cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
STAD	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	25.34	7.37e-81	3.7e-73	0.95	0.81	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	24.69	2.58e-78	6.49e-71	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	23.82	6.16e-75	1.03e-67	0.97	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
STAD	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	23.36	4.05e-73	3.39e-66	0.93	0.78	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	23.21	1.6e-72	1.15e-65	0.93	0.78	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	22.79	7.39e-71	1.69e-64	0.96	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
STAD	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	22.52	8.98e-70	1.46e-63	0.92	0.77	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	21.96	1.51e-67	1.51e-61	0.94	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
STAD	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-21.17	2.1e-64	1.09e-58	-0.89	-0.75	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-21.17	2.1e-64	1.09e-58	-0.89	-0.75	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	21.07	5.26e-64	2.54e-58	0.88	0.75	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	21.03	7.86e-64	3.49e-58	0.88	0.75	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	21.03	7.86e-64	3.49e-58	0.88	0.75	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	21.03	7.86e-64	3.49e-58	0.88	0.75	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	21.02	8.21e-64	3.52e-58	0.88	0.75	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-21.02	8.68e-64	3.66e-58	-0.88	-0.75	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-21.02	8.68e-64	3.66e-58	-0.88	-0.75	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-20.86	3.62e-63	1.39e-57	-0.88	-0.75	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	20.69	1.75e-62	5.44e-57	0.87	0.74	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-20.63	3.04e-62	9.03e-57	-0.88	-0.74	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	20.5	1.1e-61	3.11e-56	0.87	0.74	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	20.46	1.56e-61	4.35e-56	0.87	0.74	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-20.46	1.56e-61	4.35e-56	-0.87	-0.74	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
STAD	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	20.38	3.29e-61	8.98e-56	0.93	0.74	Shingles;	chr7:38346957	chr7:38343894~38350022:-
STAD	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-20.24	1.15e-60	3.04e-55	-0.87	-0.74	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	20.23	1.29e-60	3.39e-55	0.87	0.74	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	20.16	2.46e-60	6.3e-55	0.86	0.73	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	20.13	3.34e-60	8.53e-55	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	20.11	3.79e-60	9.62e-55	0.9	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	20.03	8.28e-60	2.06e-54	0.9	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	19.87	3.57e-59	8.51e-54	0.9	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
STAD	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	19.83	5.35e-59	1.27e-53	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	19.8	6.98e-59	1.64e-53	0.86	0.73	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	19.8	6.98e-59	1.64e-53	0.86	0.73	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
STAD	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	19.78	8.21e-59	1.92e-53	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	19.7	1.75e-58	4.03e-53	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	19.7	1.75e-58	4.03e-53	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	19.68	2.27e-58	5.2e-53	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	19.61	4.12e-58	9.27e-53	0.85	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
STAD	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	19.55	7.07e-58	1.56e-52	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	19.51	1.04e-57	2.26e-52	0.84	0.72	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
STAD	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	19.48	1.37e-57	2.96e-52	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	19.39	3.12e-57	6.69e-52	1.28	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
STAD	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	19.37	3.89e-57	8.29e-52	1.29	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
STAD	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	19.3	7.8e-57	1.65e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	19.26	1.04e-56	2.12e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	19.26	1.04e-56	2.12e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	19.26	1.04e-56	2.12e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	19.26	1.04e-56	2.12e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	19.23	1.45e-56	2.85e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	19.23	1.45e-56	2.85e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	19.23	1.45e-56	2.85e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	19.23	1.45e-56	2.85e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	19.23	1.45e-56	2.85e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	19.2	1.89e-56	3.7e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	19.2	1.91e-56	3.74e-51	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	19.2	1.93e-56	3.75e-51	0.83	0.72	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
STAD	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	19.15	3.02e-56	5.72e-51	1.26	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
STAD	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	19.15	3.02e-56	5.72e-51	1.26	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
STAD	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	19.15	3.05e-56	5.76e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-19.1	4.71e-56	8.82e-51	-0.85	-0.72	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
STAD	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	19.1	4.83e-56	8.82e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	19.1	4.83e-56	8.82e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	19.1	4.83e-56	8.82e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	19.1	4.83e-56	8.82e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	19.1	4.83e-56	8.82e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	19.1	4.83e-56	8.82e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	19.1	4.83e-56	8.82e-51	0.81	0.72	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	19.06	6.94e-56	1.25e-50	0.83	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
STAD	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-19	1.22e-55	2.18e-50	-0.78	-0.71	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
STAD	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-19	1.24e-55	2.19e-50	-0.78	-0.71	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
STAD	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-19	1.24e-55	2.19e-50	-0.78	-0.71	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
STAD	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	18.99	1.29e-55	2.25e-50	0.82	0.71	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	18.97	1.56e-55	2.71e-50	0.88	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	18.97	1.58e-55	2.73e-50	0.88	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
STAD	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	18.97	1.65e-55	2.84e-50	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	18.95	2.03e-55	3.48e-50	0.88	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
STAD	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-18.93	2.3e-55	3.89e-50	-0.81	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	18.91	2.83e-55	4.74e-50	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
STAD	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	18.9	3e-55	5e-50	1.27	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
STAD	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	18.88	3.79e-55	6.26e-50	1.27	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
STAD	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	18.84	5.32e-55	8.71e-50	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-18.83	6.22e-55	1.01e-49	-0.85	-0.71	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	18.8	7.93e-55	1.28e-49	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
STAD	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	18.77	1e-54	1.59e-49	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	18.77	1e-54	1.59e-49	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-18.76	1.18e-54	1.86e-49	-0.82	-0.71	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
STAD	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	18.73	1.59e-54	2.5e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-18.7	1.96e-54	3.06e-49	-0.8	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	18.67	2.59e-54	4.01e-49	0.89	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	18.67	2.77e-54	4.29e-49	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
STAD	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	18.66	2.86e-54	4.41e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	18.65	3.05e-54	4.69e-49	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
STAD	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	18.65	3.17e-54	4.83e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	18.65	3.2e-54	4.83e-49	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	18.65	3.2e-54	4.83e-49	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	18.65	3.2e-54	4.83e-49	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	18.65	3.2e-54	4.83e-49	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	18.64	3.63e-54	5.45e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
STAD	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	18.63	3.76e-54	5.56e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
STAD	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	18.63	3.76e-54	5.56e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	18.63	3.78e-54	5.56e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	18.63	3.78e-54	5.56e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	18.63	3.78e-54	5.56e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	18.63	3.78e-54	5.56e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	18.63	3.86e-54	5.63e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	18.63	3.86e-54	5.63e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	18.63	3.88e-54	5.63e-49	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
STAD	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	18.62	4.26e-54	6.13e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	18.62	4.26e-54	6.13e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	18.61	4.55e-54	6.54e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-18.61	4.77e-54	6.83e-49	-0.76	-0.71	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
STAD	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	18.6	4.89e-54	6.96e-49	1.25	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
STAD	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	18.6	4.89e-54	6.96e-49	1.25	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
STAD	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-18.6	5.09e-54	7.2e-49	-0.76	-0.71	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
STAD	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	18.59	5.67e-54	8e-49	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	18.59	5.72e-54	8.05e-49	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
STAD	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-18.57	6.6e-54	9.23e-49	-0.76	-0.71	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
STAD	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	18.55	8.34e-54	1.16e-48	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	18.52	1.03e-53	1.43e-48	1.25	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
STAD	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	18.52	1.08e-53	1.5e-48	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	18.52	1.1e-53	1.51e-48	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	18.51	1.15e-53	1.57e-48	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	18.49	1.37e-53	1.87e-48	0.8	0.71	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
STAD	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	18.49	1.37e-53	1.87e-48	0.79	0.71	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-18.45	2.13e-53	2.88e-48	-0.76	-0.7	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-18.45	2.15e-53	2.9e-48	-0.87	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
STAD	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	18.44	2.34e-53	3.15e-48	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	18.41	3.03e-53	4.04e-48	0.78	0.7	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	18.41	3.03e-53	4.04e-48	0.78	0.7	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
STAD	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	18.41	3.07e-53	4.08e-48	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
STAD	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	18.41	3.12e-53	4.14e-48	0.83	0.7	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-18.4	3.15e-53	4.17e-48	-0.87	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
STAD	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	18.4	3.24e-53	4.27e-48	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-18.39	3.55e-53	4.65e-48	-0.85	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
STAD	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	18.38	3.94e-53	5.09e-48	0.82	0.7	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
STAD	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-18.38	4.15e-53	5.35e-48	-0.76	-0.7	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
STAD	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-18.37	4.23e-53	5.44e-48	-0.77	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	18.36	4.59e-53	5.85e-48	0.88	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
STAD	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-18.34	5.8e-53	7.38e-48	-0.79	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	18.32	6.92e-53	8.77e-48	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
STAD	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-18.3	8.75e-53	1.1e-47	-0.79	-0.7	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
STAD	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	18.29	9.26e-53	1.17e-47	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
STAD	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	18.26	1.22e-52	1.51e-47	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	18.26	1.26e-52	1.56e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
STAD	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-18.26	1.27e-52	1.57e-47	-0.79	-0.7	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
STAD	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	18.25	1.3e-52	1.6e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	18.25	1.3e-52	1.6e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	18.25	1.35e-52	1.64e-47	0.81	0.7	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
STAD	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	18.25	1.36e-52	1.65e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	18.25	1.36e-52	1.65e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	18.24	1.41e-52	1.7e-47	0.89	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	18.24	1.43e-52	1.72e-47	0.88	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
STAD	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	18.23	1.62e-52	1.94e-47	1.22	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	18.21	1.95e-52	2.34e-47	0.88	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
STAD	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	18.19	2.44e-52	2.9e-47	0.76	0.7	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	18.17	2.82e-52	3.35e-47	0.89	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	18.16	2.95e-52	3.49e-47	0.86	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
STAD	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	18.16	3.11e-52	3.66e-47	0.91	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	18.15	3.48e-52	4.05e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	18.15	3.48e-52	4.05e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	18.15	3.48e-52	4.05e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	18.15	3.48e-52	4.05e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	18.13	3.92e-52	4.51e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	18.13	4.2e-52	4.81e-47	1.19	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
STAD	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	18.12	4.3e-52	4.91e-47	1.17	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
STAD	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	18.12	4.43e-52	5.03e-47	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	18.12	4.44e-52	5.03e-47	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
STAD	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	18.12	4.53e-52	5.11e-47	1.19	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-18.11	4.73e-52	5.33e-47	-0.86	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
STAD	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-18.1	5.28e-52	5.87e-47	-0.77	-0.7	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
STAD	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	18.09	5.97e-52	6.61e-47	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-18.09	6.03e-52	6.66e-47	-0.9	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-18.07	7.1e-52	7.8e-47	-0.91	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
STAD	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	18.06	7.82e-52	8.5e-47	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	18.06	7.82e-52	8.5e-47	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	18.06	7.82e-52	8.5e-47	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	18.06	7.82e-52	8.5e-47	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	18.06	7.82e-52	8.5e-47	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	18.03	1e-51	1.09e-46	1.23	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
STAD	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-18.03	1.05e-51	1.12e-46	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-18.03	1.05e-51	1.12e-46	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-18.03	1.05e-51	1.12e-46	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-18.03	1.05e-51	1.12e-46	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	18.03	1.05e-51	1.12e-46	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	18.03	1.06e-51	1.13e-46	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	18.02	1.14e-51	1.21e-46	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
STAD	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	18.02	1.14e-51	1.21e-46	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-18.02	1.15e-51	1.21e-46	-0.91	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-18.01	1.21e-51	1.27e-46	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-18.01	1.21e-51	1.27e-46	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-18.01	1.21e-51	1.27e-46	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-18.01	1.23e-51	1.29e-46	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
STAD	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	18.01	1.24e-51	1.29e-46	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
STAD	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	18.01	1.26e-51	1.31e-46	0.79	0.7	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-18	1.38e-51	1.42e-46	-0.9	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
STAD	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	18	1.41e-51	1.45e-46	1.18	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
STAD	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	18	1.41e-51	1.45e-46	1.18	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-17.99	1.56e-51	1.59e-46	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-17.98	1.59e-51	1.61e-46	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-17.98	1.61e-51	1.63e-46	-0.91	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-17.98	1.61e-51	1.63e-46	-0.91	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
STAD	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	17.98	1.72e-51	1.74e-46	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-17.97	1.77e-51	1.76e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-17.97	1.77e-51	1.76e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-17.97	1.78e-51	1.76e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-17.97	1.81e-51	1.76e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-17.96	1.93e-51	1.87e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-17.95	2.12e-51	2.02e-46	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-17.95	2.12e-51	2.02e-46	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-17.95	2.12e-51	2.02e-46	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-17.95	2.12e-51	2.02e-46	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-17.95	2.12e-51	2.02e-46	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-17.95	2.12e-51	2.02e-46	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-17.95	2.12e-51	2.02e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-17.94	2.3e-51	2.18e-46	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
STAD	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	17.94	2.34e-51	2.22e-46	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-17.94	2.44e-51	2.31e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
STAD	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	17.94	2.45e-51	2.31e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	17.94	2.46e-51	2.32e-46	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-17.93	2.59e-51	2.4e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-17.93	2.59e-51	2.4e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-17.93	2.59e-51	2.4e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-17.93	2.59e-51	2.4e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-17.93	2.69e-51	2.48e-46	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-17.93	2.69e-51	2.48e-46	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-17.92	2.83e-51	2.6e-46	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-17.92	2.83e-51	2.6e-46	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-17.92	3.01e-51	2.76e-46	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
STAD	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	17.91	3.19e-51	2.91e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-17.91	3.22e-51	2.91e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-17.91	3.22e-51	2.91e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	17.91	3.22e-51	2.91e-46	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	17.91	3.22e-51	2.91e-46	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	17.91	3.22e-51	2.91e-46	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	17.91	3.3e-51	2.94e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	17.91	3.3e-51	2.94e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	17.91	3.3e-51	2.94e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
STAD	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	17.91	3.3e-51	2.94e-46	0.79	0.69	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	17.91	3.3e-51	2.94e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	17.91	3.3e-51	2.94e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
STAD	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	17.91	3.3e-51	2.94e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	17.9	3.47e-51	3.08e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-17.9	3.57e-51	3.15e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-17.9	3.57e-51	3.15e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-17.9	3.57e-51	3.15e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-17.9	3.62e-51	3.19e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-17.9	3.62e-51	3.19e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
STAD	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	17.88	4.02e-51	3.52e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	17.88	4.02e-51	3.52e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-17.88	4.08e-51	3.56e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-17.88	4.09e-51	3.57e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-17.87	4.43e-51	3.8e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-17.87	4.43e-51	3.8e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-17.87	4.43e-51	3.8e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-17.87	4.43e-51	3.8e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-17.87	4.52e-51	3.87e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
STAD	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-17.87	4.67e-51	3.99e-46	-0.78	-0.69	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
STAD	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	17.87	4.77e-51	4.06e-46	1.17	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
STAD	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	17.87	4.77e-51	4.06e-46	1.17	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	17.86	5.07e-51	4.29e-46	0.85	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
STAD	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	17.86	5.12e-51	4.33e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-17.84	6.27e-51	5.25e-46	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-17.83	6.41e-51	5.35e-46	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	17.83	6.6e-51	5.5e-46	0.83	0.69	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	17.83	6.89e-51	5.73e-46	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	17.82	7.31e-51	6.05e-46	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
STAD	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	17.82	7.61e-51	6.28e-46	0.78	0.69	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-17.81	8.19e-51	6.73e-46	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-17.81	8.19e-51	6.73e-46	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-17.81	8.23e-51	6.75e-46	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	17.8	8.83e-51	7.23e-46	0.86	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
STAD	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	17.79	1e-50	8.18e-46	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
STAD	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-17.78	1.04e-50	8.46e-46	-0.78	-0.69	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
STAD	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	17.78	1.07e-50	8.7e-46	1.22	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
STAD	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	17.77	1.14e-50	9.18e-46	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-17.75	1.4e-50	1.12e-45	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
STAD	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-17.75	1.47e-50	1.18e-45	-0.73	-0.69	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
STAD	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	17.74	1.53e-50	1.23e-45	1.18	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-17.74	1.59e-50	1.27e-45	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	17.73	1.69e-50	1.34e-45	0.9	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-17.73	1.69e-50	1.34e-45	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-17.73	1.69e-50	1.34e-45	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-17.73	1.69e-50	1.34e-45	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
STAD	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	17.73	1.72e-50	1.36e-45	0.78	0.69	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
STAD	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	17.71	1.96e-50	1.55e-45	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
STAD	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	17.71	1.97e-50	1.55e-45	0.75	0.69	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
STAD	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-17.71	2.06e-50	1.62e-45	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-17.71	2.09e-50	1.64e-45	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	17.7	2.28e-50	1.78e-45	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	17.7	2.28e-50	1.78e-45	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-17.69	2.37e-50	1.85e-45	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
STAD	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	17.69	2.43e-50	1.9e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-17.69	2.46e-50	1.91e-45	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-17.69	2.48e-50	1.92e-45	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-17.68	2.61e-50	2.02e-45	-0.83	-0.69	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
STAD	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-17.68	2.74e-50	2.12e-45	-0.74	-0.69	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	17.67	2.99e-50	2.31e-45	0.88	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
STAD	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	17.65	3.69e-50	2.82e-45	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
STAD	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	17.64	3.8e-50	2.9e-45	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	17.64	3.83e-50	2.92e-45	0.75	0.69	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
STAD	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	17.61	5.26e-50	3.94e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	17.61	5.26e-50	3.94e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	17.61	5.26e-50	3.94e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	17.61	5.26e-50	3.94e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	17.6	5.56e-50	4.15e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	17.6	5.56e-50	4.15e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-17.6	5.59e-50	4.17e-45	-0.73	-0.69	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
STAD	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	17.59	6.26e-50	4.64e-45	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-17.59	6.53e-50	4.79e-45	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-17.59	6.53e-50	4.79e-45	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-17.57	7.5e-50	5.49e-45	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-17.55	8.73e-50	6.35e-45	-0.79	-0.69	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-17.55	8.89e-50	6.45e-45	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	17.55	9.01e-50	6.53e-45	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
STAD	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	17.55	9.09e-50	6.57e-45	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-17.55	9.1e-50	6.57e-45	-0.9	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
STAD	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	17.53	1.06e-49	7.59e-45	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	17.53	1.09e-49	7.8e-45	0.79	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-17.53	1.14e-49	8.1e-45	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-17.51	1.3e-49	9.24e-45	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-17.51	1.31e-49	9.28e-45	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	17.51	1.31e-49	9.28e-45	0.82	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
STAD	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-17.5	1.4e-49	9.81e-45	-0.72	-0.69	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
STAD	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	17.5	1.41e-49	9.83e-45	0.89	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	17.49	1.52e-49	1.06e-44	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	17.49	1.52e-49	1.06e-44	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
STAD	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	17.49	1.52e-49	1.06e-44	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
STAD	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	17.49	1.52e-49	1.06e-44	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	17.49	1.54e-49	1.07e-44	1.17	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
STAD	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	17.49	1.61e-49	1.12e-44	1.19	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
STAD	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	17.49	1.64e-49	1.13e-44	0.79	0.68	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	17.48	1.7e-49	1.17e-44	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	17.48	1.72e-49	1.19e-44	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
STAD	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-17.47	1.84e-49	1.26e-44	-0.76	-0.68	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
STAD	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	17.47	1.97e-49	1.35e-44	1.16	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
STAD	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	17.47	1.97e-49	1.35e-44	1.16	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
STAD	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-17.44	2.59e-49	1.77e-44	-0.77	-0.68	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
STAD	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-17.43	2.75e-49	1.87e-44	-0.78	-0.68	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	17.43	2.77e-49	1.88e-44	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-17.43	2.89e-49	1.96e-44	-0.82	-0.68	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-17.4	3.59e-49	2.42e-44	-0.78	-0.68	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
STAD	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	17.4	3.71e-49	2.5e-44	1.16	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
STAD	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	17.4	3.74e-49	2.52e-44	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-17.4	3.81e-49	2.56e-44	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-17.4	3.81e-49	2.56e-44	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
STAD	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-17.4	3.84e-49	2.57e-44	-0.77	-0.68	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
STAD	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	17.39	4.15e-49	2.77e-44	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-17.38	4.42e-49	2.95e-44	-0.9	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	17.37	4.88e-49	3.24e-44	0.78	0.68	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-17.37	4.91e-49	3.26e-44	-0.88	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	17.37	5.07e-49	3.36e-44	0.89	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	17.36	5.21e-49	3.44e-44	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
STAD	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	17.35	5.85e-49	3.85e-44	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	17.35	6.1e-49	4e-44	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	17.35	6.12e-49	4.01e-44	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	17.34	6.73e-49	4.4e-44	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
STAD	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	17.33	7.02e-49	4.56e-44	1.16	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	17.32	7.49e-49	4.86e-44	0.81	0.68	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-17.32	7.78e-49	5.03e-44	-0.77	-0.68	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
STAD	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	17.32	8.09e-49	5.22e-44	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-17.31	8.22e-49	5.3e-44	-0.77	-0.68	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-17.3	9.3e-49	5.9e-44	-0.77	-0.68	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-17.3	9.3e-49	5.9e-44	-0.77	-0.68	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
STAD	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	17.28	1.13e-48	7.12e-44	1.21	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
STAD	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	17.28	1.13e-48	7.12e-44	1.21	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	17.27	1.2e-48	7.54e-44	0.81	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	17.27	1.29e-48	8.03e-44	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
STAD	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	17.26	1.39e-48	8.59e-44	0.79	0.68	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-17.23	1.72e-48	1.05e-43	-0.76	-0.68	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-17.23	1.72e-48	1.05e-43	-0.76	-0.68	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	17.21	2.09e-48	1.27e-43	0.88	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
STAD	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	17.21	2.22e-48	1.34e-43	0.78	0.68	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	17.21	2.22e-48	1.34e-43	0.78	0.68	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-17.21	2.25e-48	1.36e-43	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
STAD	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	17.2	2.42e-48	1.46e-43	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-17.19	2.66e-48	1.6e-43	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-17.17	3.09e-48	1.85e-43	-0.9	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
STAD	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	17.17	3.21e-48	1.92e-43	1.13	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
STAD	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	17.16	3.32e-48	1.98e-43	0.74	0.68	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-17.16	3.41e-48	2.03e-43	-0.78	-0.68	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-17.15	3.89e-48	2.31e-43	-0.76	-0.68	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-17.14	4.1e-48	2.42e-43	-0.76	-0.68	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
STAD	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-17.14	4.11e-48	2.43e-43	-0.9	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
STAD	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-17.14	4.17e-48	2.45e-43	-0.76	-0.68	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-17.14	4.17e-48	2.45e-43	-0.76	-0.68	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	17.12	4.94e-48	2.88e-43	0.77	0.68	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	17.11	5.41e-48	3.12e-43	0.78	0.68	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	17.11	5.41e-48	3.12e-43	0.78	0.68	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	17.1	6.2e-48	3.57e-43	0.81	0.68	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-17.09	6.62e-48	3.8e-43	-0.74	-0.68	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
STAD	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-17.07	7.58e-48	4.33e-43	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-17.06	8.43e-48	4.8e-43	-0.77	-0.68	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-17.05	9.41e-48	5.35e-43	-0.76	-0.68	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
STAD	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	17.04	1.07e-47	6.09e-43	0.89	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	17.04	1.08e-47	6.1e-43	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
STAD	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-17.03	1.18e-47	6.68e-43	-0.77	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	17.01	1.41e-47	7.89e-43	0.8	0.67	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	16.99	1.68e-47	9.38e-43	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	16.98	1.75e-47	9.71e-43	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
STAD	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-16.96	2.31e-47	1.28e-42	-0.79	-0.67	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	16.95	2.46e-47	1.36e-42	0.78	0.67	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	16.94	2.6e-47	1.43e-42	0.78	0.67	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
STAD	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	16.94	2.76e-47	1.51e-42	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
STAD	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-16.92	3.27e-47	1.79e-42	-1.07	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
STAD	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	16.92	3.33e-47	1.82e-42	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
STAD	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	16.87	5.21e-47	2.82e-42	1.14	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	16.85	5.93e-47	3.2e-42	0.78	0.67	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-16.85	5.98e-47	3.22e-42	-0.77	-0.67	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-16.82	8.42e-47	4.5e-42	-0.75	-0.67	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
STAD	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-16.8	9.48e-47	5.05e-42	-1.12	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	16.8	9.87e-47	5.25e-42	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
STAD	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-16.77	1.27e-46	6.74e-42	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-16.77	1.34e-46	7.08e-42	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
STAD	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	16.76	1.47e-46	7.69e-42	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
STAD	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	16.76	1.47e-46	7.69e-42	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
STAD	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	16.76	1.47e-46	7.69e-42	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	16.75	1.58e-46	8.29e-42	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	16.74	1.69e-46	8.84e-42	0.77	0.67	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
STAD	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	16.72	1.96e-46	1.01e-41	1.13	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-16.72	2.08e-46	1.07e-41	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	16.7	2.42e-46	1.23e-41	0.77	0.67	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-16.7	2.47e-46	1.26e-41	-0.87	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
STAD	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	16.7	2.5e-46	1.27e-41	1.18	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
STAD	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-16.7	2.54e-46	1.28e-41	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-16.7	2.54e-46	1.28e-41	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-16.69	2.61e-46	1.31e-41	-0.77	-0.67	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	16.69	2.65e-46	1.33e-41	0.76	0.67	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	16.69	2.65e-46	1.33e-41	0.76	0.67	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	16.69	2.65e-46	1.33e-41	0.76	0.67	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	16.69	2.7e-46	1.35e-41	0.76	0.67	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	16.69	2.7e-46	1.35e-41	0.76	0.67	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	16.69	2.7e-46	1.35e-41	0.76	0.67	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	16.69	2.7e-46	1.35e-41	0.76	0.67	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	16.69	2.7e-46	1.35e-41	0.76	0.67	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-16.68	3.04e-46	1.51e-41	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-16.67	3.32e-46	1.64e-41	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-16.65	3.76e-46	1.85e-41	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-16.65	4.04e-46	1.97e-41	-0.88	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-16.63	4.7e-46	2.28e-41	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-16.62	5.28e-46	2.56e-41	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-16.61	5.77e-46	2.75e-41	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-16.61	5.77e-46	2.75e-41	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
STAD	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	16.57	7.96e-46	3.77e-41	0.82	0.67	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	16.57	8.29e-46	3.92e-41	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	16.57	8.29e-46	3.92e-41	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	16.57	8.29e-46	3.92e-41	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-16.55	1.01e-45	4.73e-41	-0.79	-0.66	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-16.55	1.03e-45	4.84e-41	-0.85	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-16.54	1.12e-45	5.24e-41	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-16.53	1.16e-45	5.42e-41	-0.85	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	16.53	1.21e-45	5.62e-41	0.77	0.66	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-16.51	1.4e-45	6.53e-41	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-16.5	1.55e-45	7.2e-41	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-16.5	1.57e-45	7.29e-41	-0.84	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	16.49	1.74e-45	8.02e-41	0.77	0.66	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
STAD	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	16.47	2.02e-45	9.28e-41	1.11	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-16.45	2.4e-45	1.1e-40	-0.84	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
STAD	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	16.44	2.63e-45	1.2e-40	0.82	0.66	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
STAD	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	16.42	3.21e-45	1.45e-40	0.75	0.66	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	16.42	3.21e-45	1.45e-40	0.75	0.66	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	16.42	3.21e-45	1.45e-40	0.75	0.66	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-16.42	3.21e-45	1.45e-40	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-16.42	3.21e-45	1.45e-40	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-16.42	3.21e-45	1.45e-40	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	16.42	3.23e-45	1.45e-40	0.75	0.66	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
STAD	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-16.41	3.77e-45	1.69e-40	-1.1	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	16.39	4.21e-45	1.88e-40	0.79	0.66	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-16.39	4.21e-45	1.88e-40	-0.88	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-16.38	4.61e-45	2.06e-40	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-16.36	5.57e-45	2.47e-40	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-16.36	5.57e-45	2.47e-40	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-16.36	5.57e-45	2.47e-40	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-16.36	5.57e-45	2.47e-40	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-16.36	5.67e-45	2.51e-40	-0.85	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	16.36	5.78e-45	2.56e-40	0.78	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	16.36	5.87e-45	2.6e-40	0.84	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-16.35	6.11e-45	2.7e-40	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	16.35	6.11e-45	2.7e-40	0.76	0.66	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	16.34	6.7e-45	2.95e-40	0.75	0.66	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	16.34	6.75e-45	2.97e-40	0.76	0.66	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	16.34	6.75e-45	2.97e-40	0.76	0.66	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	16.34	6.9e-45	3.03e-40	0.88	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-16.32	8.51e-45	3.71e-40	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-16.32	8.51e-45	3.71e-40	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-16.32	8.51e-45	3.71e-40	-0.79	-0.66	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-16.31	9.05e-45	3.9e-40	-1.15	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
STAD	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-16.21	2.25e-44	9.53e-40	-0.78	-0.66	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
STAD	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	16.21	2.41e-44	1.02e-39	0.82	0.66	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-16.2	2.64e-44	1.11e-39	-0.75	-0.66	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-16.18	2.96e-44	1.24e-39	-0.75	-0.66	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	16.15	3.94e-44	1.64e-39	0.85	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	16.13	4.69e-44	1.96e-39	0.76	0.66	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
STAD	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-16.12	5.49e-44	2.29e-39	-1.04	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-16.11	5.62e-44	2.29e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-16.11	5.77e-44	2.35e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-16.11	5.77e-44	2.35e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	16.11	6.05e-44	2.45e-39	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
STAD	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-16.09	7.17e-44	2.9e-39	-1.09	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
STAD	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	16.07	8.3e-44	3.35e-39	0.84	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-16.07	8.76e-44	3.54e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-16.05	1e-43	4.04e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-16.05	1e-43	4.04e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-16.05	1e-43	4.04e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	16.03	1.23e-43	4.93e-39	0.75	0.65	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-16.02	1.38e-43	5.5e-39	-0.75	-0.65	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-16	1.57e-43	6.21e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-16	1.68e-43	6.63e-39	-1.08	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
STAD	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-16	1.68e-43	6.63e-39	-1.08	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
STAD	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-16	1.68e-43	6.63e-39	-1.08	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
STAD	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-16	1.68e-43	6.63e-39	-1.08	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
STAD	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-16	1.68e-43	6.63e-39	-1.08	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
STAD	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-15.99	1.75e-43	6.88e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
STAD	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	15.98	1.87e-43	7.36e-39	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-15.98	1.92e-43	7.55e-39	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	15.97	2.21e-43	8.65e-39	0.88	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	15.93	3.13e-43	1.22e-38	0.84	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	15.93	3.13e-43	1.22e-38	0.84	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	15.93	3.13e-43	1.22e-38	0.84	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	15.88	4.76e-43	1.85e-38	0.75	0.65	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	15.88	4.85e-43	1.88e-38	0.87	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	15.88	4.93e-43	1.91e-38	0.76	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
STAD	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-15.88	5.06e-43	1.93e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	15.87	5.58e-43	2.13e-38	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
STAD	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-15.85	6.36e-43	2.42e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-15.83	7.49e-43	2.85e-38	-1.08	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
STAD	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-15.83	7.49e-43	2.85e-38	-1.08	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	15.83	7.58e-43	2.88e-38	0.79	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
STAD	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-15.82	8.76e-43	3.31e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-15.82	8.76e-43	3.31e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-15.82	8.76e-43	3.31e-38	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	15.8	9.83e-43	3.7e-38	0.88	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	15.8	9.93e-43	3.74e-38	0.74	0.65	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-15.78	1.17e-42	4.4e-38	-1.07	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	15.76	1.52e-42	5.66e-38	0.76	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
STAD	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-15.75	1.66e-42	6.14e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-15.75	1.66e-42	6.14e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-15.75	1.66e-42	6.14e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-15.75	1.66e-42	6.14e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-15.75	1.66e-42	6.14e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-15.74	1.7e-42	6.31e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-15.74	1.74e-42	6.42e-38	-0.87	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-15.74	1.78e-42	6.59e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	15.74	1.83e-42	6.74e-38	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
STAD	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-15.73	1.94e-42	7.14e-38	-0.77	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-15.73	1.94e-42	7.16e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	15.71	2.23e-42	8.19e-38	0.81	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-15.71	2.4e-42	8.69e-38	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-15.7	2.54e-42	9.21e-38	-0.76	-0.65	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
STAD	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-15.7	2.58e-42	9.35e-38	-1.11	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
STAD	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	15.66	3.53e-42	1.27e-37	0.73	0.64	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
STAD	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-15.66	3.57e-42	1.28e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-15.66	3.57e-42	1.28e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-15.66	3.57e-42	1.28e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-15.66	3.57e-42	1.28e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-15.66	3.57e-42	1.28e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-15.66	3.57e-42	1.28e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-15.66	3.57e-42	1.28e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-15.66	3.61e-42	1.29e-37	-0.77	-0.64	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-15.65	3.99e-42	1.42e-37	-0.77	-0.64	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	15.64	4.25e-42	1.51e-37	0.73	0.64	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
STAD	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	15.64	4.36e-42	1.55e-37	1.08	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
STAD	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	15.6	6.57e-42	2.32e-37	0.87	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	15.59	7.17e-42	2.52e-37	0.86	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
STAD	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	15.56	9.32e-42	3.27e-37	1.13	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
STAD	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-15.56	9.68e-42	3.4e-37	-0.75	-0.64	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
STAD	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	15.53	1.17e-41	4.09e-37	1.03	0.64	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
STAD	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-15.52	1.37e-41	4.77e-37	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	15.52	1.39e-41	4.85e-37	0.72	0.64	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	15.51	1.41e-41	4.89e-37	0.86	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	15.51	1.51e-41	5.25e-37	0.87	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
STAD	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-15.46	2.4e-41	8.25e-37	-1.06	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	15.45	2.57e-41	8.82e-37	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
STAD	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.45	2.64e-41	9.03e-37	0.73	0.64	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-15.44	2.83e-41	9.66e-37	-1.11	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
STAD	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	15.43	3.03e-41	1.03e-36	1.07	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
STAD	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-15.41	3.56e-41	1.2e-36	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	15.41	3.57e-41	1.2e-36	0.72	0.64	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-15.41	3.57e-41	1.2e-36	-1.1	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
STAD	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-15.41	3.57e-41	1.2e-36	-1.1	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
STAD	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-15.41	3.57e-41	1.2e-36	-1.1	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
STAD	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-15.41	3.57e-41	1.2e-36	-1.1	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
STAD	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-15.41	3.57e-41	1.2e-36	-1.1	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
STAD	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	15.41	3.69e-41	1.24e-36	1.01	0.64	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
STAD	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-15.4	4.1e-41	1.38e-36	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	15.38	4.66e-41	1.57e-36	0.75	0.64	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-15.38	4.94e-41	1.66e-36	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-15.38	4.94e-41	1.66e-36	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-15.37	5.33e-41	1.79e-36	-0.87	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-15.35	6.26e-41	2.09e-36	-0.82	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	15.35	6.44e-41	2.15e-36	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
STAD	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	15.34	6.81e-41	2.27e-36	1.02	0.64	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
STAD	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	15.3	9.86e-41	3.27e-36	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
STAD	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	15.28	1.19e-40	3.95e-36	1.03	0.63	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
STAD	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	15.28	1.21e-40	4e-36	0.86	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	15.27	1.29e-40	4.26e-36	0.86	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
STAD	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-15.27	1.35e-40	4.44e-36	-1.1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
STAD	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-15.27	1.35e-40	4.44e-36	-1.1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	15.24	1.67e-40	5.47e-36	0.82	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	15.24	1.75e-40	5.73e-36	0.77	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	15.24	1.75e-40	5.75e-36	0.82	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
STAD	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	15.22	2.06e-40	6.74e-36	0.79	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	15.22	2.07e-40	6.78e-36	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	15.22	2.17e-40	7.09e-36	0.82	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
STAD	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-15.21	2.32e-40	7.58e-36	-0.75	-0.63	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	15.21	2.33e-40	7.62e-36	0.87	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	15.19	2.78e-40	9.03e-36	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
STAD	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	15.19	2.8e-40	9.11e-36	0.75	0.63	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-15.19	2.81e-40	9.11e-36	-0.75	-0.63	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
STAD	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	15.18	3.07e-40	9.95e-36	1.01	0.63	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	15.17	3.36e-40	1.09e-35	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
STAD	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	15.16	3.78e-40	1.22e-35	0.72	0.63	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	15.16	3.78e-40	1.22e-35	0.72	0.63	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	15.15	3.99e-40	1.28e-35	0.83	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	15.11	5.8e-40	1.86e-35	0.82	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
STAD	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	15.1	6.31e-40	2.02e-35	1.02	0.63	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	15.09	6.65e-40	2.13e-35	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-15.09	6.71e-40	2.15e-35	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
STAD	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-15.08	7.33e-40	2.34e-35	-0.75	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
STAD	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	15.08	7.42e-40	2.37e-35	0.75	0.63	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
STAD	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	15.08	7.86e-40	2.51e-35	0.72	0.63	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	15.07	8.05e-40	2.56e-35	0.72	0.63	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	15.07	8.05e-40	2.56e-35	0.72	0.63	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	15.07	8.08e-40	2.57e-35	0.74	0.63	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	15.07	8.17e-40	2.6e-35	0.72	0.63	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	15.05	1.01e-39	3.19e-35	0.76	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
STAD	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	15.04	1.06e-39	3.36e-35	0.74	0.63	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-15.04	1.07e-39	3.38e-35	-1.09	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
STAD	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	15.03	1.14e-39	3.61e-35	0.72	0.63	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
STAD	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-15	1.56e-39	4.9e-35	-0.7	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	14.98	1.84e-39	5.78e-35	0.82	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
STAD	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	14.98	1.86e-39	5.82e-35	0.71	0.63	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
STAD	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	14.98	1.86e-39	5.83e-35	1.04	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
STAD	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	14.98	1.86e-39	5.83e-35	1.04	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
STAD	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	14.98	1.94e-39	6.07e-35	0.73	0.63	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
STAD	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	14.96	2.16e-39	6.72e-35	1.01	0.63	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
STAD	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	14.95	2.46e-39	7.66e-35	0.71	0.63	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	14.95	2.46e-39	7.66e-35	0.71	0.63	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	14.95	2.46e-39	7.66e-35	0.71	0.63	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	14.94	2.83e-39	8.78e-35	0.71	0.63	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-14.93	3.08e-39	9.54e-35	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	14.92	3.32e-39	1.03e-34	0.83	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	14.92	3.38e-39	1.05e-34	0.86	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
STAD	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	14.9	3.76e-39	1.16e-34	0.73	0.63	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-14.89	4.35e-39	1.34e-34	-0.73	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	14.89	4.41e-39	1.36e-34	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	14.88	4.7e-39	1.45e-34	0.71	0.62	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	14.88	4.86e-39	1.5e-34	0.7	0.62	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	14.87	4.93e-39	1.51e-34	0.71	0.62	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	14.87	4.93e-39	1.51e-34	0.71	0.62	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	14.87	4.93e-39	1.51e-34	0.71	0.62	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	14.87	4.98e-39	1.53e-34	0.71	0.62	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
STAD	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	14.87	5.02e-39	1.54e-34	1.04	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	14.87	5.19e-39	1.59e-34	0.8	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
STAD	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	14.87	5.26e-39	1.61e-34	0.71	0.62	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	14.87	5.26e-39	1.61e-34	0.71	0.62	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
STAD	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	14.86	5.6e-39	1.71e-34	1.01	0.62	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
STAD	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-14.86	5.62e-39	1.72e-34	-0.71	-0.62	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	14.85	5.98e-39	1.82e-34	0.83	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
STAD	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	14.85	6.03e-39	1.84e-34	0.71	0.62	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	14.85	6.18e-39	1.88e-34	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	14.85	6.21e-39	1.89e-34	0.71	0.62	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-14.84	6.87e-39	2.08e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	14.83	7.28e-39	2.21e-34	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	14.83	7.31e-39	2.21e-34	0.79	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
STAD	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-14.83	7.42e-39	2.24e-34	-0.71	-0.62	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
STAD	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-14.83	7.42e-39	2.24e-34	-0.71	-0.62	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
STAD	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-14.83	7.56e-39	2.27e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-14.83	7.56e-39	2.27e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-14.83	7.56e-39	2.27e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-14.83	7.56e-39	2.27e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-14.83	7.56e-39	2.27e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-14.83	7.71e-39	2.32e-34	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	14.82	7.78e-39	2.34e-34	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	14.82	7.84e-39	2.35e-34	0.85	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	14.82	8.13e-39	2.44e-34	0.71	0.62	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-14.82	8.17e-39	2.45e-34	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	14.81	8.67e-39	2.59e-34	0.74	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-14.8	9.97e-39	2.97e-34	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	14.8	9.97e-39	2.97e-34	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	14.8	9.97e-39	2.97e-34	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
STAD	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	14.8	1.01e-38	3.01e-34	1.04	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
STAD	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-14.79	1.05e-38	3.12e-34	-0.69	-0.62	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
STAD	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-14.79	1.05e-38	3.12e-34	-0.69	-0.62	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
STAD	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	14.78	1.17e-38	3.44e-34	0.71	0.62	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
STAD	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	14.77	1.28e-38	3.72e-34	1.04	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
STAD	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-14.76	1.34e-38	3.88e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-14.76	1.34e-38	3.88e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-14.76	1.35e-38	3.91e-34	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-14.76	1.36e-38	3.94e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
STAD	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-14.76	1.38e-38	3.97e-34	-0.69	-0.62	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
STAD	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	14.76	1.45e-38	4.17e-34	0.71	0.62	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	14.75	1.48e-38	4.26e-34	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	14.74	1.67e-38	4.8e-34	0.7	0.62	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	14.73	1.77e-38	5.05e-34	0.7	0.62	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	14.73	1.77e-38	5.05e-34	0.7	0.62	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	14.73	1.77e-38	5.05e-34	0.7	0.62	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	14.73	1.82e-38	5.18e-34	0.85	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	14.72	1.97e-38	5.61e-34	0.7	0.62	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	14.72	2.04e-38	5.82e-34	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	14.72	2.06e-38	5.85e-34	0.74	0.62	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
STAD	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	14.71	2.18e-38	6.17e-34	0.95	0.62	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
STAD	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-14.71	2.2e-38	6.22e-34	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-14.71	2.27e-38	6.43e-34	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
STAD	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	14.71	2.3e-38	6.49e-34	0.7	0.62	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	14.7	2.32e-38	6.55e-34	0.83	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-14.7	2.35e-38	6.59e-34	-0.74	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	14.7	2.39e-38	6.68e-34	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-14.7	2.4e-38	6.71e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-14.7	2.42e-38	6.75e-34	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
STAD	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	14.69	2.61e-38	7.26e-34	1.02	0.62	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
STAD	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	14.69	2.61e-38	7.26e-34	1.02	0.62	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
STAD	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	14.69	2.61e-38	7.26e-34	1.02	0.62	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
STAD	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-14.68	2.78e-38	7.72e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-14.68	2.78e-38	7.72e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-14.68	2.78e-38	7.72e-34	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	14.68	2.79e-38	7.75e-34	0.8	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-14.68	2.79e-38	7.76e-34	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	14.68	2.96e-38	8.21e-34	0.71	0.62	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-14.67	3.17e-38	8.78e-34	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
STAD	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-14.67	3.22e-38	8.91e-34	-0.7	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	14.66	3.48e-38	9.6e-34	0.83	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	14.66	3.48e-38	9.6e-34	0.83	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-14.66	3.48e-38	9.6e-34	-0.83	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-14.66	3.48e-38	9.6e-34	-0.83	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	14.65	3.68e-38	1.02e-33	0.72	0.62	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	14.65	3.76e-38	1.04e-33	0.82	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-14.65	3.81e-38	1.05e-33	-0.74	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	14.64	4.09e-38	1.12e-33	0.85	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
STAD	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	14.63	4.44e-38	1.22e-33	1.01	0.62	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
STAD	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-14.62	4.8e-38	1.32e-33	-0.7	-0.62	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
STAD	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-14.61	5.31e-38	1.46e-33	-0.83	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	14.61	5.31e-38	1.46e-33	0.7	0.62	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	14.61	5.48e-38	1.5e-33	0.7	0.62	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	14.61	5.6e-38	1.53e-33	0.71	0.62	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-14.61	5.63e-38	1.54e-33	-0.85	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	14.6	5.85e-38	1.6e-33	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	14.6	5.9e-38	1.61e-33	0.7	0.62	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	14.6	6.18e-38	1.68e-33	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	14.59	6.31e-38	1.72e-33	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	14.59	6.31e-38	1.72e-33	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	14.59	6.41e-38	1.74e-33	0.7	0.62	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	14.58	6.88e-38	1.87e-33	0.82	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
STAD	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	14.58	6.97e-38	1.89e-33	0.7	0.62	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	14.58	7.11e-38	1.92e-33	0.71	0.62	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	14.58	7.11e-38	1.92e-33	0.71	0.62	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	14.58	7.34e-38	1.98e-33	0.7	0.62	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	14.57	7.56e-38	2.04e-33	0.7	0.62	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	14.57	7.61e-38	2.05e-33	0.71	0.62	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	14.57	7.69e-38	2.07e-33	0.71	0.62	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	14.57	7.9e-38	2.12e-33	0.71	0.62	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	14.55	9.04e-38	2.42e-33	0.71	0.62	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	14.55	9.35e-38	2.5e-33	0.71	0.62	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
STAD	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-14.54	1.06e-37	2.83e-33	-1.02	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
STAD	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-14.54	1.07e-37	2.87e-33	-0.71	-0.62	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
STAD	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	14.53	1.11e-37	2.96e-33	0.7	0.62	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	14.53	1.14e-37	3.04e-33	0.7	0.62	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	14.53	1.18e-37	3.14e-33	0.73	0.62	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	14.52	1.19e-37	3.17e-33	0.76	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
STAD	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	14.52	1.2e-37	3.2e-33	0.74	0.62	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
STAD	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-14.52	1.25e-37	3.32e-33	-0.7	-0.62	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
STAD	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-14.52	1.25e-37	3.33e-33	-0.69	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	14.5	1.41e-37	3.75e-33	0.86	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	14.5	1.45e-37	3.84e-33	0.81	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
STAD	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	14.5	1.45e-37	3.84e-33	0.71	0.61	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	14.5	1.45e-37	3.84e-33	0.71	0.61	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	14.5	1.48e-37	3.91e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	14.5	1.48e-37	3.91e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	14.5	1.48e-37	3.91e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	14.5	1.48e-37	3.91e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	14.5	1.48e-37	3.91e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	14.5	1.48e-37	3.92e-33	0.71	0.61	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	14.5	1.55e-37	4.08e-33	0.84	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	14.5	1.55e-37	4.08e-33	0.84	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	14.49	1.6e-37	4.23e-33	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
STAD	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	14.49	1.65e-37	4.36e-33	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
STAD	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	14.48	1.81e-37	4.76e-33	0.71	0.61	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	14.48	1.81e-37	4.76e-33	0.71	0.61	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	14.47	1.87e-37	4.92e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	14.47	1.87e-37	4.92e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	14.47	1.87e-37	4.92e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	14.47	1.87e-37	4.92e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
STAD	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	14.47	1.87e-37	4.92e-33	1.01	0.61	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
STAD	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	14.47	1.9e-37	4.98e-33	0.69	0.61	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
STAD	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	14.47	1.95e-37	5.1e-33	0.71	0.61	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	14.45	2.31e-37	6.04e-33	0.7	0.61	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
STAD	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	14.44	2.46e-37	6.41e-33	0.69	0.61	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
STAD	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	14.44	2.48e-37	6.46e-33	1.01	0.61	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
STAD	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-14.44	2.48e-37	6.46e-33	-0.76	-0.61	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	14.43	2.78e-37	7.24e-33	0.7	0.61	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
STAD	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	14.43	2.83e-37	7.34e-33	0.75	0.61	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
STAD	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	14.42	2.92e-37	7.58e-33	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	14.42	2.94e-37	7.64e-33	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
STAD	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	14.42	3.07e-37	7.97e-33	1	0.61	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
STAD	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-14.4	3.52e-37	9.11e-33	-0.7	-0.61	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	14.4	3.64e-37	9.41e-33	0.7	0.61	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	14.4	3.73e-37	9.65e-33	0.85	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
STAD	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-14.39	3.91e-37	1.01e-32	-0.71	-0.61	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
STAD	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-14.38	4.23e-37	1.09e-32	-0.68	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	14.38	4.42e-37	1.14e-32	0.75	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	14.38	4.45e-37	1.15e-32	0.82	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	14.37	4.73e-37	1.21e-32	0.8	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	14.37	4.88e-37	1.25e-32	0.79	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
STAD	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	14.36	5.27e-37	1.35e-32	0.7	0.61	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	14.36	5.38e-37	1.37e-32	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
STAD	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	14.35	5.57e-37	1.42e-32	0.73	0.61	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
STAD	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	14.35	5.71e-37	1.46e-32	0.71	0.61	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	14.35	5.79e-37	1.48e-32	0.7	0.61	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	14.33	6.81e-37	1.73e-32	0.71	0.61	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	14.33	7.06e-37	1.8e-32	0.74	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	14.32	7.48e-37	1.9e-32	0.77	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
STAD	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	14.32	7.6e-37	1.93e-32	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	14.32	7.82e-37	1.99e-32	0.79	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
STAD	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-14.31	8.29e-37	2.09e-32	-0.7	-0.61	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
STAD	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	14.31	8.49e-37	2.14e-32	1	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
STAD	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	14.3	8.85e-37	2.23e-32	0.7	0.61	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
STAD	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	14.3	9.16e-37	2.31e-32	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	14.3	9.27e-37	2.34e-32	0.69	0.61	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-14.29	9.49e-37	2.39e-32	-0.77	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
STAD	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	14.29	9.54e-37	2.4e-32	0.69	0.61	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
STAD	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-14.29	9.66e-37	2.43e-32	-0.7	-0.61	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-14.28	1.05e-36	2.63e-32	-0.79	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
STAD	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	14.28	1.09e-36	2.73e-32	0.83	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	14.28	1.1e-36	2.76e-32	0.74	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
STAD	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	14.28	1.12e-36	2.82e-32	0.88	0.61	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
STAD	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	14.27	1.14e-36	2.86e-32	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
STAD	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-14.27	1.17e-36	2.93e-32	-0.72	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
STAD	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	14.27	1.19e-36	2.98e-32	0.68	0.61	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
STAD	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-14.27	1.23e-36	3.07e-32	-0.7	-0.61	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
STAD	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	14.27	1.24e-36	3.09e-32	0.94	0.61	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
STAD	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	14.26	1.28e-36	3.2e-32	0.69	0.61	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
STAD	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-14.26	1.34e-36	3.33e-32	-0.7	-0.61	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
STAD	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	14.26	1.35e-36	3.35e-32	0.7	0.61	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
STAD	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	14.24	1.53e-36	3.8e-32	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	14.23	1.74e-36	4.31e-32	0.75	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
STAD	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-14.22	1.83e-36	4.55e-32	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	14.22	1.92e-36	4.74e-32	0.7	0.61	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-14.21	2.1e-36	5.18e-32	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	14.2	2.21e-36	5.45e-32	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	14.2	2.25e-36	5.55e-32	0.85	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	14.19	2.35e-36	5.8e-32	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
STAD	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	14.19	2.46e-36	6.05e-32	0.84	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
STAD	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	14.19	2.49e-36	6.13e-32	0.9	0.61	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
STAD	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-14.19	2.52e-36	6.21e-32	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	14.17	2.9e-36	7.12e-32	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	14.16	3.17e-36	7.77e-32	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
STAD	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	14.16	3.22e-36	7.89e-32	0.98	0.61	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
STAD	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	14.15	3.45e-36	8.45e-32	0.85	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-14.14	3.66e-36	8.96e-32	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-14.14	3.7e-36	9.07e-32	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-14.13	4.01e-36	9.78e-32	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
STAD	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-14.12	4.48e-36	1.09e-31	-0.7	-0.6	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
STAD	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-14.12	4.62e-36	1.12e-31	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
STAD	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-14.11	4.87e-36	1.18e-31	-0.73	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
STAD	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-14.1	5.46e-36	1.32e-31	-0.69	-0.6	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
STAD	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	14.09	5.94e-36	1.44e-31	0.73	0.6	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
STAD	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	14.09	6.02e-36	1.46e-31	0.8	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-14.09	6.02e-36	1.46e-31	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	14.09	6.1e-36	1.48e-31	0.8	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	14.08	6.56e-36	1.59e-31	0.8	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-14.08	6.83e-36	1.65e-31	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
STAD	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	14.07	7.37e-36	1.78e-31	1	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
STAD	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	14.07	7.37e-36	1.78e-31	1	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
STAD	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-14.06	7.83e-36	1.89e-31	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-14.06	7.83e-36	1.89e-31	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-14.06	7.94e-36	1.91e-31	-0.78	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
STAD	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	14.05	8.24e-36	1.98e-31	0.91	0.6	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
STAD	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	14.05	8.53e-36	2.05e-31	0.86	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	14.05	8.74e-36	2.1e-31	0.72	0.6	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-14.04	9.07e-36	2.18e-31	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
STAD	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	14.04	9.48e-36	2.27e-31	0.76	0.6	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-14.02	1.16e-35	2.76e-31	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
STAD	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	14.01	1.18e-35	2.82e-31	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
STAD	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	14.01	1.18e-35	2.82e-31	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	14.01	1.18e-35	2.82e-31	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
STAD	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-13.99	1.42e-35	3.39e-31	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	13.99	1.46e-35	3.49e-31	0.86	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
STAD	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	13.99	1.54e-35	3.66e-31	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
STAD	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	13.97	1.8e-35	4.29e-31	0.72	0.6	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
STAD	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-13.96	1.91e-35	4.53e-31	-0.71	-0.6	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	13.96	1.94e-35	4.62e-31	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
STAD	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-13.95	2.07e-35	4.92e-31	-0.71	-0.6	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-13.95	2.07e-35	4.92e-31	-0.71	-0.6	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-13.95	2.16e-35	5.11e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
STAD	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
STAD	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
STAD	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
STAD	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
STAD	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-13.94	2.22e-35	5.21e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-13.94	2.35e-35	5.53e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
STAD	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-13.93	2.41e-35	5.65e-31	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-13.93	2.41e-35	5.65e-31	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-13.93	2.41e-35	5.65e-31	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	13.92	2.65e-35	6.21e-31	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
STAD	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-13.92	2.81e-35	6.58e-31	-0.72	-0.6	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	13.92	2.84e-35	6.65e-31	0.74	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
STAD	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	13.91	3.03e-35	7.06e-31	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
STAD	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	13.91	3.03e-35	7.06e-31	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-13.9	3.27e-35	7.6e-31	-0.73	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
STAD	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-13.89	3.47e-35	8.04e-31	-0.7	-0.6	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
STAD	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-13.89	3.64e-35	8.41e-31	-0.82	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
STAD	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	13.89	3.66e-35	8.47e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-13.89	3.73e-35	8.61e-31	-0.76	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
STAD	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	13.88	4e-35	9.24e-31	0.68	0.6	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	13.88	4.13e-35	9.53e-31	0.72	0.6	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-13.87	4.28e-35	9.87e-31	-0.78	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
STAD	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	13.87	4.46e-35	1.03e-30	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-13.86	4.54e-35	1.05e-30	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
STAD	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-13.86	4.72e-35	1.09e-30	-0.7	-0.6	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
STAD	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-13.86	4.72e-35	1.09e-30	-0.7	-0.6	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
STAD	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-13.86	4.92e-35	1.13e-30	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-13.84	5.55e-35	1.27e-30	-0.71	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
STAD	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-13.82	6.48e-35	1.47e-30	-0.71	-0.6	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	13.82	6.57e-35	1.49e-30	0.72	0.6	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
STAD	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	13.82	6.65e-35	1.51e-30	0.99	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
STAD	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	13.82	6.65e-35	1.51e-30	0.99	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	13.82	7.03e-35	1.59e-30	0.71	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
STAD	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	13.8	7.88e-35	1.78e-30	0.8	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-13.79	8.6e-35	1.94e-30	-0.71	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
STAD	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	13.79	9.19e-35	2.08e-30	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
STAD	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	13.77	1.1e-34	2.48e-30	0.72	0.59	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	13.77	1.1e-34	2.48e-30	0.72	0.59	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
STAD	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-13.76	1.15e-34	2.6e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-13.76	1.15e-34	2.6e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-13.76	1.15e-34	2.6e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-13.76	1.15e-34	2.6e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	13.75	1.24e-34	2.78e-30	0.66	0.59	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
STAD	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-13.73	1.55e-34	3.48e-30	-0.72	-0.59	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-13.73	1.58e-34	3.54e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
STAD	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	13.72	1.65e-34	3.69e-30	0.89	0.59	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
STAD	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-13.71	1.74e-34	3.88e-30	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-13.71	1.74e-34	3.88e-30	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-13.71	1.74e-34	3.88e-30	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-13.71	1.74e-34	3.88e-30	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-13.71	1.74e-34	3.88e-30	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-13.71	1.74e-34	3.88e-30	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-13.71	1.74e-34	3.88e-30	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
STAD	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	13.71	1.76e-34	3.93e-30	0.99	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
STAD	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	13.71	1.82e-34	4.05e-30	0.98	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
STAD	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	13.7	1.97e-34	4.37e-30	0.73	0.59	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
STAD	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-13.7	2.04e-34	4.54e-30	-0.71	-0.59	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
STAD	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-13.69	2.24e-34	4.99e-30	-0.66	-0.59	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
STAD	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-13.68	2.26e-34	5.02e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
STAD	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	13.66	2.76e-34	6.11e-30	0.68	0.59	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	13.65	3.15e-34	6.96e-30	0.97	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
STAD	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	13.65	3.18e-34	7e-30	0.73	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
STAD	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-13.64	3.26e-34	7.19e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-13.64	3.37e-34	7.41e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-13.64	3.37e-34	7.41e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-13.63	3.71e-34	8.14e-30	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
STAD	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	13.62	3.86e-34	8.47e-30	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
STAD	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-13.62	4.02e-34	8.8e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-13.62	4.02e-34	8.8e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-13.62	4.02e-34	8.8e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-13.62	4.02e-34	8.8e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-13.62	4.02e-34	8.8e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-13.62	4.16e-34	9.08e-30	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	13.61	4.56e-34	9.97e-30	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
STAD	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-13.6	4.83e-34	1.05e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-13.6	4.83e-34	1.05e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-13.6	4.83e-34	1.05e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-13.6	4.83e-34	1.05e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-13.6	4.83e-34	1.05e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-13.6	4.83e-34	1.05e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-13.6	5.03e-34	1.09e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	13.59	5.45e-34	1.18e-29	0.71	0.59	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	13.59	5.48e-34	1.19e-29	0.72	0.59	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
STAD	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	13.58	5.54e-34	1.2e-29	0.73	0.59	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-13.58	5.84e-34	1.26e-29	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-13.57	6.24e-34	1.34e-29	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
STAD	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-13.57	6.48e-34	1.39e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	13.56	6.65e-34	1.43e-29	0.71	0.59	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-13.56	7.01e-34	1.5e-29	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
STAD	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	13.55	7.23e-34	1.55e-29	0.71	0.59	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	13.55	7.23e-34	1.55e-29	0.71	0.59	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	13.55	7.23e-34	1.55e-29	0.71	0.59	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	13.55	7.23e-34	1.55e-29	0.71	0.59	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
STAD	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-13.55	7.81e-34	1.67e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-13.55	7.83e-34	1.67e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-13.55	7.83e-34	1.67e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-13.55	7.83e-34	1.67e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	13.53	8.75e-34	1.86e-29	0.71	0.59	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
STAD	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	13.52	9.69e-34	2.06e-29	0.71	0.59	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
STAD	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-13.52	1.02e-33	2.16e-29	-0.72	-0.59	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-13.52	1.02e-33	2.16e-29	-0.72	-0.59	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-13.52	1.02e-33	2.16e-29	-0.72	-0.59	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-13.5	1.16e-33	2.47e-29	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
STAD	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	13.5	1.19e-33	2.52e-29	0.97	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
STAD	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-13.49	1.24e-33	2.62e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-13.49	1.24e-33	2.62e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-13.49	1.24e-33	2.62e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-13.49	1.24e-33	2.62e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-13.49	1.24e-33	2.62e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-13.49	1.24e-33	2.62e-29	-0.7	-0.59	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-13.49	1.26e-33	2.65e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-13.49	1.26e-33	2.65e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-13.49	1.26e-33	2.65e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-13.49	1.33e-33	2.81e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	13.46	1.64e-33	3.45e-29	0.8	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	13.46	1.67e-33	3.5e-29	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
STAD	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	13.45	1.76e-33	3.69e-29	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
STAD	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-13.45	1.8e-33	3.77e-29	-0.71	-0.59	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
STAD	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	13.45	1.81e-33	3.79e-29	0.81	0.59	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
STAD	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-13.44	1.99e-33	4.16e-29	-0.89	-0.59	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-13.41	2.59e-33	5.41e-29	-0.79	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-13.41	2.62e-33	5.47e-29	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
STAD	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	13.41	2.66e-33	5.54e-29	0.69	0.58	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-13.39	3.08e-33	6.33e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-13.38	3.26e-33	6.7e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
STAD	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	13.38	3.55e-33	7.3e-29	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
STAD	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-13.37	3.61e-33	7.42e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-13.37	3.71e-33	7.6e-29	-0.71	-0.58	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
STAD	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-13.37	3.87e-33	7.92e-29	-0.71	-0.58	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
STAD	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-13.36	4.13e-33	8.44e-29	-0.7	-0.58	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
STAD	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	13.36	4.16e-33	8.51e-29	0.66	0.58	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
STAD	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	13.35	4.55e-33	9.29e-29	0.71	0.58	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
STAD	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	13.34	4.87e-33	9.94e-29	0.97	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
STAD	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-13.34	4.9e-33	1e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-13.33	5.2e-33	1.06e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-13.33	5.2e-33	1.06e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-13.33	5.2e-33	1.06e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-13.33	5.2e-33	1.06e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
STAD	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	13.33	5.51e-33	1.12e-28	0.95	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
STAD	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	13.33	5.54e-33	1.13e-28	0.71	0.58	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
STAD	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-13.32	5.62e-33	1.14e-28	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-13.32	5.62e-33	1.14e-28	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-13.32	5.62e-33	1.14e-28	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	13.31	6.15e-33	1.24e-28	0.79	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
STAD	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-13.3	7.02e-33	1.42e-28	-0.69	-0.58	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	13.29	7.45e-33	1.51e-28	0.66	0.58	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
STAD	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	13.29	7.9e-33	1.6e-28	0.97	0.58	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
STAD	cis	rs858239	0.669	rs56400441	ENSG00000230658.1	KLHL7-AS1	13.28	7.91e-33	1.6e-28	0.66	0.58	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-13.27	8.88e-33	1.79e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
STAD	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	13.27	9e-33	1.82e-28	0.71	0.58	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	13.26	9.53e-33	1.92e-28	0.67	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
STAD	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	13.26	9.88e-33	1.99e-28	0.72	0.58	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
STAD	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	13.26	9.95e-33	2e-28	0.65	0.58	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-13.25	1.03e-32	2.08e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-13.25	1.06e-32	2.14e-28	-0.71	-0.58	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-13.24	1.18e-32	2.38e-28	-0.69	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-13.24	1.19e-32	2.38e-28	-0.69	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
STAD	cis	rs858239	0.614	rs2014816	ENSG00000230658.1	KLHL7-AS1	13.24	1.21e-32	2.43e-28	0.66	0.58	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-13.23	1.26e-32	2.54e-28	-0.69	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-13.23	1.3e-32	2.61e-28	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
STAD	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-13.22	1.35e-32	2.71e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-13.22	1.35e-32	2.71e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-13.22	1.35e-32	2.71e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-13.22	1.35e-32	2.71e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-13.22	1.37e-32	2.74e-28	-0.69	-0.58	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-13.22	1.4e-32	2.8e-28	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
STAD	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-13.22	1.44e-32	2.87e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-13.21	1.52e-32	3.03e-28	-0.72	-0.58	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-13.21	1.52e-32	3.04e-28	-0.7	-0.58	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
STAD	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	13.21	1.56e-32	3.1e-28	0.78	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
STAD	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	13.2	1.69e-32	3.36e-28	0.95	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-13.2	1.74e-32	3.45e-28	-0.69	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	13.18	1.96e-32	3.88e-28	0.68	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	13.18	1.96e-32	3.88e-28	0.68	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
STAD	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	13.18	2e-32	3.95e-28	0.66	0.58	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
STAD	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-13.18	2.05e-32	4.05e-28	-0.69	-0.58	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-13.17	2.26e-32	4.46e-28	-0.69	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
STAD	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	13.13	3.1e-32	6.1e-28	0.7	0.58	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-13.13	3.24e-32	6.37e-28	-0.69	-0.58	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
STAD	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	13.12	3.33e-32	6.55e-28	0.72	0.58	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
STAD	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	13.12	3.36e-32	6.59e-28	0.79	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
STAD	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-13.12	3.45e-32	6.77e-28	-0.69	-0.58	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
STAD	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-13.09	4.38e-32	8.54e-28	-0.6	-0.58	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
STAD	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	13.08	4.65e-32	9.06e-28	0.66	0.58	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
STAD	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-13.08	4.74e-32	9.22e-28	-0.69	-0.58	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
STAD	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	13.08	4.75e-32	9.24e-28	0.7	0.58	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
STAD	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	13.08	4.97e-32	9.65e-28	0.8	0.58	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
STAD	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	13.07	5.09e-32	9.89e-28	0.65	0.58	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
STAD	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-13.07	5.11e-32	9.91e-28	-0.7	-0.58	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
STAD	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	13.07	5.14e-32	9.96e-28	0.87	0.58	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
STAD	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-13.07	5.31e-32	1.03e-27	-0.67	-0.57	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
STAD	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-13.06	5.97e-32	1.15e-27	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-13.06	5.97e-32	1.15e-27	-0.7	-0.57	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
STAD	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	13.04	6.73e-32	1.29e-27	0.71	0.57	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	13.04	6.73e-32	1.29e-27	0.71	0.57	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	13.04	6.73e-32	1.29e-27	0.71	0.57	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	13.04	6.73e-32	1.29e-27	0.71	0.57	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	13.04	6.73e-32	1.29e-27	0.71	0.57	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	13.04	6.73e-32	1.29e-27	0.71	0.57	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
STAD	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-13.04	6.78e-32	1.3e-27	-0.68	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
STAD	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	13.03	7.59e-32	1.46e-27	0.68	0.57	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-13.03	7.64e-32	1.47e-27	-0.69	-0.57	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-12.99	1.05e-31	2e-27	-0.69	-0.57	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
STAD	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-12.97	1.31e-31	2.48e-27	-0.62	-0.57	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
STAD	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	12.94	1.65e-31	3.13e-27	0.66	0.57	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
STAD	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-12.94	1.7e-31	3.22e-27	-0.69	-0.57	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	12.93	1.84e-31	3.47e-27	0.76	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
STAD	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	12.92	2e-31	3.77e-27	0.79	0.57	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
STAD	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-12.92	2.04e-31	3.86e-27	-0.66	-0.57	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
STAD	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-12.91	2.16e-31	4.07e-27	-0.69	-0.57	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-12.91	2.16e-31	4.07e-27	-0.69	-0.57	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-12.91	2.19e-31	4.13e-27	-0.67	-0.57	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	12.89	2.5e-31	4.7e-27	0.58	0.57	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	12.89	2.56e-31	4.81e-27	0.66	0.57	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-12.88	2.77e-31	5.2e-27	-0.68	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
STAD	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	12.86	3.2e-31	6.01e-27	0.66	0.57	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-12.85	3.55e-31	6.66e-27	-0.69	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
STAD	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-12.85	3.63e-31	6.79e-27	-0.69	-0.57	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-12.85	3.7e-31	6.92e-27	-0.66	-0.57	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	12.83	4.15e-31	7.75e-27	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
STAD	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	12.83	4.16e-31	7.78e-27	0.66	0.57	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
STAD	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-12.81	5.15e-31	9.61e-27	-0.67	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
STAD	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-12.81	5.34e-31	9.95e-27	-0.62	-0.57	Breast cancer;	chr11:743813	chr11:779617~780755:+
STAD	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-12.8	5.71e-31	1.06e-26	-0.67	-0.57	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
STAD	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	12.78	6.5e-31	1.21e-26	0.67	0.57	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
STAD	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-12.77	7.15e-31	1.33e-26	-0.69	-0.57	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	12.77	7.46e-31	1.38e-26	0.67	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-12.76	7.69e-31	1.42e-26	-0.75	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	12.76	7.94e-31	1.47e-26	0.67	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
STAD	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-12.75	8.36e-31	1.55e-26	-0.66	-0.57	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
STAD	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-12.75	8.86e-31	1.64e-26	-0.66	-0.57	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
STAD	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-12.74	9.22e-31	1.7e-26	-0.62	-0.57	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
STAD	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-12.74	9.48e-31	1.75e-26	-0.66	-0.57	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-12.74	9.67e-31	1.78e-26	-0.67	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
STAD	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-12.72	1.1e-30	2.03e-26	-0.66	-0.56	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
STAD	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	12.72	1.11e-30	2.04e-26	0.63	0.56	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-12.72	1.16e-30	2.13e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-12.7	1.31e-30	2.4e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-12.7	1.31e-30	2.4e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-12.7	1.38e-30	2.52e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-12.69	1.51e-30	2.75e-26	-0.71	-0.56	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-12.69	1.53e-30	2.8e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
STAD	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	12.68	1.6e-30	2.93e-26	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-12.67	1.72e-30	3.14e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-12.67	1.72e-30	3.14e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-12.66	1.86e-30	3.38e-26	-0.69	-0.56	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
STAD	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-12.66	1.9e-30	3.46e-26	-0.71	-0.56	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-12.66	1.96e-30	3.56e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-12.66	1.96e-30	3.56e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
STAD	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-12.66	1.97e-30	3.58e-26	-0.89	-0.56	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
STAD	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-12.64	2.19e-30	3.98e-26	-0.92	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
STAD	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-12.64	2.36e-30	4.27e-26	-0.65	-0.56	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-12.64	2.36e-30	4.27e-26	-0.65	-0.56	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-12.64	2.36e-30	4.27e-26	-0.65	-0.56	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-12.64	2.36e-30	4.27e-26	-0.65	-0.56	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-12.64	2.36e-30	4.27e-26	-0.65	-0.56	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-12.63	2.43e-30	4.38e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-12.63	2.45e-30	4.42e-26	-0.66	-0.56	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
STAD	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	12.63	2.52e-30	4.54e-26	0.62	0.56	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
STAD	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	12.62	2.61e-30	4.7e-26	0.69	0.56	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	12.62	2.61e-30	4.7e-26	0.69	0.56	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	12.62	2.61e-30	4.7e-26	0.69	0.56	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
STAD	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-12.62	2.77e-30	4.98e-26	-0.62	-0.56	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
STAD	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-12.61	2.9e-30	5.2e-26	-0.58	-0.56	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
STAD	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	12.61	3.06e-30	5.49e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	12.61	3.06e-30	5.49e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	12.61	3.06e-30	5.49e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	12.61	3.06e-30	5.49e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	12.61	3.06e-30	5.49e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	12.61	3.06e-30	5.49e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	12.61	3.06e-30	5.49e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	12.57	4.04e-30	7.2e-26	0.64	0.56	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
STAD	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-12.57	4.15e-30	7.39e-26	-0.61	-0.56	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
STAD	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	12.57	4.18e-30	7.44e-26	0.61	0.56	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
STAD	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	12.57	4.28e-30	7.6e-26	0.67	0.56	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	12.57	4.28e-30	7.6e-26	0.67	0.56	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	12.57	4.28e-30	7.6e-26	0.67	0.56	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	12.57	4.28e-30	7.6e-26	0.67	0.56	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
STAD	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	12.57	4.29e-30	7.62e-26	0.65	0.56	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
STAD	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-12.56	4.62e-30	8.19e-26	-0.58	-0.56	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
STAD	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	12.55	5.01e-30	8.88e-26	0.62	0.56	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
STAD	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-12.55	5.01e-30	8.88e-26	-0.64	-0.56	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
STAD	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-12.54	5.25e-30	9.28e-26	-0.65	-0.56	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
STAD	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-12.54	5.46e-30	9.63e-26	-0.57	-0.56	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
STAD	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	12.54	5.5e-30	9.71e-26	0.64	0.56	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
STAD	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	12.53	5.88e-30	1.04e-25	0.64	0.56	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
STAD	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	12.53	5.94e-30	1.05e-25	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
STAD	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	12.53	6.15e-30	1.08e-25	0.61	0.56	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	12.52	6.24e-30	1.1e-25	0.59	0.56	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
STAD	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-12.52	6.38e-30	1.12e-25	-0.63	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
STAD	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	12.52	6.65e-30	1.17e-25	0.59	0.56	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
STAD	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	12.5	7.63e-30	1.33e-25	0.64	0.56	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	12.5	7.63e-30	1.33e-25	0.64	0.56	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
STAD	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	12.49	8.55e-30	1.49e-25	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-12.47	9.72e-30	1.69e-25	-0.67	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
STAD	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	12.46	1.07e-29	1.87e-25	0.64	0.56	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
STAD	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-12.46	1.09e-29	1.89e-25	-0.56	-0.56	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
STAD	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	12.46	1.1e-29	1.9e-25	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
STAD	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	12.46	1.1e-29	1.91e-25	0.64	0.56	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
STAD	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	12.45	1.13e-29	1.96e-25	0.69	0.56	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-12.45	1.21e-29	2.1e-25	-0.66	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
STAD	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	12.44	1.28e-29	2.22e-25	0.58	0.56	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	12.44	1.34e-29	2.31e-25	0.66	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
STAD	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-12.43	1.35e-29	2.33e-25	-0.58	-0.56	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
STAD	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	12.43	1.37e-29	2.37e-25	0.74	0.56	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
STAD	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	12.43	1.39e-29	2.39e-25	0.64	0.56	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
STAD	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	12.43	1.41e-29	2.43e-25	0.84	0.56	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
STAD	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	12.42	1.47e-29	2.53e-25	0.67	0.56	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
STAD	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	12.42	1.56e-29	2.67e-25	0.61	0.56	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	12.42	1.56e-29	2.67e-25	0.61	0.56	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	12.41	1.67e-29	2.86e-25	0.6	0.55	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	12.41	1.71e-29	2.93e-25	0.59	0.55	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
STAD	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-12.4	1.78e-29	3.05e-25	-0.64	-0.55	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
STAD	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	12.4	1.81e-29	3.1e-25	0.66	0.55	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	12.4	1.81e-29	3.1e-25	0.66	0.55	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	12.4	1.81e-29	3.1e-25	0.66	0.55	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
STAD	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	12.4	1.83e-29	3.12e-25	0.75	0.55	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
STAD	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	12.4	1.89e-29	3.22e-25	0.61	0.55	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	12.4	1.89e-29	3.22e-25	0.61	0.55	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	12.4	1.89e-29	3.22e-25	0.61	0.55	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	12.4	1.89e-29	3.22e-25	0.61	0.55	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	12.4	1.89e-29	3.22e-25	0.61	0.55	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	12.4	1.89e-29	3.22e-25	0.61	0.55	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	12.39	1.95e-29	3.31e-25	0.58	0.55	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
STAD	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	12.39	2e-29	3.4e-25	0.62	0.55	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
STAD	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	12.38	2.14e-29	3.63e-25	0.73	0.55	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
STAD	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	12.38	2.14e-29	3.63e-25	0.73	0.55	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
STAD	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	12.37	2.28e-29	3.85e-25	0.83	0.55	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
STAD	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-12.37	2.28e-29	3.85e-25	-0.73	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
STAD	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-12.37	2.37e-29	3.99e-25	-0.65	-0.55	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
STAD	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-12.37	2.37e-29	4e-25	-0.64	-0.55	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
STAD	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	12.37	2.38e-29	4.02e-25	0.74	0.55	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
STAD	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-12.37	2.42e-29	4.08e-25	-0.67	-0.55	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
STAD	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	12.36	2.52e-29	4.23e-25	0.6	0.55	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	12.36	2.52e-29	4.23e-25	0.6	0.55	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
STAD	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	12.35	2.74e-29	4.6e-25	0.67	0.55	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	12.35	2.77e-29	4.64e-25	0.66	0.55	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
STAD	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	12.35	2.84e-29	4.77e-25	0.6	0.55	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
STAD	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	12.35	2.87e-29	4.8e-25	0.6	0.55	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
STAD	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-12.35	2.89e-29	4.83e-25	-0.57	-0.55	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
STAD	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	12.34	3.04e-29	5.08e-25	0.66	0.55	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
STAD	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	12.34	3.12e-29	5.2e-25	0.6	0.55	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	12.34	3.12e-29	5.2e-25	0.6	0.55	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
STAD	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	12.34	3.12e-29	5.2e-25	0.6	0.55	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
STAD	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-12.34	3.17e-29	5.28e-25	-0.61	-0.55	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	12.33	3.22e-29	5.36e-25	0.6	0.55	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	12.33	3.22e-29	5.36e-25	0.6	0.55	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-12.33	3.31e-29	5.51e-25	-0.67	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
STAD	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
STAD	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
STAD	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
STAD	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
STAD	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
STAD	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	12.33	3.38e-29	5.59e-25	0.6	0.55	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
STAD	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-12.33	3.41e-29	5.65e-25	-0.67	-0.55	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	12.33	3.43e-29	5.67e-25	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
STAD	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	12.32	3.68e-29	6.08e-25	0.74	0.55	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
STAD	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	12.32	3.78e-29	6.24e-25	0.6	0.55	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	12.31	3.81e-29	6.27e-25	0.59	0.55	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	12.31	3.81e-29	6.27e-25	0.59	0.55	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	12.31	3.81e-29	6.27e-25	0.59	0.55	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	12.3	4.22e-29	6.93e-25	0.6	0.55	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
STAD	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	12.29	4.64e-29	7.62e-25	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
STAD	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	12.29	4.73e-29	7.76e-25	0.74	0.55	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
STAD	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	12.29	4.73e-29	7.76e-25	0.74	0.55	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
STAD	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-12.29	4.89e-29	8.01e-25	-0.61	-0.55	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-12.29	4.9e-29	8.02e-25	-0.66	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
STAD	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	12.28	5e-29	8.18e-25	0.6	0.55	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
STAD	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	12.28	5.01e-29	8.19e-25	0.62	0.55	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
STAD	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	12.28	5.26e-29	8.58e-25	0.6	0.55	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	12.28	5.26e-29	8.58e-25	0.6	0.55	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	12.28	5.26e-29	8.58e-25	0.6	0.55	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
STAD	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-12.27	5.82e-29	9.48e-25	-0.64	-0.55	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
STAD	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	12.25	6.35e-29	1.03e-24	0.6	0.55	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	12.25	6.61e-29	1.07e-24	0.61	0.55	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-12.25	6.64e-29	1.07e-24	-0.65	-0.55	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-12.25	6.64e-29	1.07e-24	-0.65	-0.55	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	12.24	7.37e-29	1.19e-24	0.6	0.55	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	12.23	7.71e-29	1.24e-24	0.59	0.55	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-12.22	8.36e-29	1.35e-24	-0.65	-0.55	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-12.22	8.36e-29	1.35e-24	-0.65	-0.55	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
STAD	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-12.22	8.55e-29	1.38e-24	-0.89	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
STAD	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-12.21	9.01e-29	1.45e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
STAD	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	12.2	9.97e-29	1.6e-24	0.73	0.55	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
STAD	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-12.2	9.98e-29	1.6e-24	-0.6	-0.55	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-12.2	9.98e-29	1.6e-24	-0.6	-0.55	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-12.2	9.98e-29	1.6e-24	-0.6	-0.55	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-12.2	9.98e-29	1.6e-24	-0.6	-0.55	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
STAD	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	12.2	1.01e-28	1.62e-24	0.66	0.55	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
STAD	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	12.2	1.02e-28	1.63e-24	0.64	0.55	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
STAD	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-12.2	1.02e-28	1.64e-24	-0.6	-0.55	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-12.2	1.06e-28	1.7e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-12.2	1.06e-28	1.7e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
STAD	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-12.19	1.06e-28	1.7e-24	-0.6	-0.55	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-12.19	1.06e-28	1.7e-24	-0.6	-0.55	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
STAD	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-12.19	1.06e-28	1.7e-24	-0.6	-0.55	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-12.19	1.06e-28	1.7e-24	-0.6	-0.55	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-12.19	1.06e-28	1.7e-24	-0.6	-0.55	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-12.19	1.06e-28	1.7e-24	-0.6	-0.55	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
STAD	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-12.19	1.06e-28	1.7e-24	-0.6	-0.55	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
STAD	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	12.19	1.07e-28	1.7e-24	0.68	0.55	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
STAD	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-12.19	1.08e-28	1.72e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-12.19	1.08e-28	1.72e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-12.19	1.08e-28	1.72e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-12.19	1.08e-28	1.72e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-12.19	1.08e-28	1.72e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-12.19	1.09e-28	1.74e-24	-0.67	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
STAD	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	12.19	1.12e-28	1.78e-24	0.6	0.55	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	12.19	1.12e-28	1.78e-24	0.6	0.55	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
STAD	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	12.19	1.12e-28	1.78e-24	0.6	0.55	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
STAD	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-12.19	1.13e-28	1.8e-24	-0.6	-0.55	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-12.19	1.16e-28	1.84e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
STAD	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-12.18	1.17e-28	1.86e-24	-0.71	-0.55	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
STAD	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-12.18	1.19e-28	1.89e-24	-0.6	-0.55	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-12.18	1.23e-28	1.95e-24	-0.6	-0.55	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
STAD	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-12.18	1.23e-28	1.95e-24	-0.6	-0.55	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
STAD	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	12.17	1.27e-28	2.01e-24	0.6	0.55	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	12.17	1.27e-28	2.01e-24	0.6	0.55	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
STAD	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	12.17	1.33e-28	2.1e-24	0.59	0.55	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
STAD	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	12.17	1.33e-28	2.1e-24	0.59	0.55	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
STAD	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	12.16	1.38e-28	2.18e-24	0.64	0.55	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	12.16	1.38e-28	2.18e-24	0.64	0.55	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
STAD	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	12.16	1.38e-28	2.18e-24	0.64	0.55	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
STAD	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	12.16	1.42e-28	2.23e-24	0.63	0.55	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	12.16	1.42e-28	2.23e-24	0.63	0.55	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
STAD	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	12.16	1.44e-28	2.27e-24	0.66	0.55	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
STAD	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	12.16	1.44e-28	2.27e-24	0.66	0.55	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
STAD	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	12.16	1.46e-28	2.29e-24	0.73	0.55	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
STAD	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	12.16	1.5e-28	2.35e-24	0.68	0.55	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
STAD	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-12.15	1.58e-28	2.48e-24	-0.6	-0.55	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-12.15	1.58e-28	2.48e-24	-0.6	-0.55	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
STAD	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-12.15	1.61e-28	2.51e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-12.15	1.61e-28	2.51e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
STAD	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-12.15	1.61e-28	2.51e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
STAD	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	12.14	1.67e-28	2.61e-24	0.67	0.55	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
STAD	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
STAD	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-12.14	1.68e-28	2.61e-24	-0.6	-0.55	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	12.14	1.69e-28	2.62e-24	0.6	0.55	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	12.14	1.69e-28	2.62e-24	0.6	0.55	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	12.14	1.69e-28	2.62e-24	0.6	0.55	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-12.14	1.7e-28	2.63e-24	-0.6	-0.55	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
STAD	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	12.14	1.78e-28	2.75e-24	0.6	0.55	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	12.14	1.78e-28	2.75e-24	0.6	0.55	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-12.13	1.87e-28	2.89e-24	-0.6	-0.55	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-12.13	1.87e-28	2.89e-24	-0.6	-0.55	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-12.13	1.87e-28	2.89e-24	-0.6	-0.55	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-12.13	1.87e-28	2.89e-24	-0.6	-0.55	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	12.12	1.94e-28	3e-24	0.6	0.55	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
STAD	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-12.12	1.97e-28	3.03e-24	-0.59	-0.55	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-12.12	1.98e-28	3.04e-24	-0.67	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
STAD	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	12.12	2.05e-28	3.16e-24	0.59	0.55	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	12.12	2.05e-28	3.16e-24	0.59	0.55	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
STAD	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-12.12	2.11e-28	3.23e-24	-0.6	-0.55	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-12.12	2.11e-28	3.23e-24	-0.6	-0.55	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
STAD	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-12.12	2.11e-28	3.23e-24	-0.6	-0.55	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-12.12	2.11e-28	3.23e-24	-0.6	-0.55	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
STAD	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-12.11	2.13e-28	3.27e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
STAD	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-12.11	2.13e-28	3.27e-24	-0.6	-0.55	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-12.11	2.15e-28	3.3e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
STAD	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	12.11	2.23e-28	3.41e-24	0.65	0.55	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
STAD	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	12.11	2.26e-28	3.45e-24	0.68	0.55	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
STAD	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	12.11	2.29e-28	3.5e-24	0.6	0.55	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-12.11	2.29e-28	3.5e-24	-0.63	-0.55	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-12.11	2.29e-28	3.5e-24	-0.63	-0.55	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
STAD	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
STAD	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
STAD	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
STAD	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
STAD	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-12.1	2.35e-28	3.57e-24	-0.64	-0.55	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
STAD	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	12.1	2.37e-28	3.6e-24	0.61	0.55	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
STAD	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-12.1	2.37e-28	3.6e-24	-0.6	-0.55	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-12.1	2.41e-28	3.66e-24	-0.6	-0.55	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-12.1	2.43e-28	3.69e-24	-0.6	-0.55	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-12.1	2.43e-28	3.69e-24	-0.6	-0.55	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	12.09	2.59e-28	3.91e-24	0.68	0.55	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	12.09	2.59e-28	3.91e-24	0.68	0.55	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	12.09	2.59e-28	3.91e-24	0.68	0.55	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	12.09	2.59e-28	3.91e-24	0.68	0.55	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
STAD	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	12.09	2.59e-28	3.91e-24	0.78	0.55	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
STAD	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-12.09	2.64e-28	3.99e-24	-0.63	-0.54	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
STAD	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-12.09	2.68e-28	4.04e-24	-0.64	-0.54	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
STAD	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-12.08	2.79e-28	4.21e-24	-0.6	-0.54	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-12.08	2.79e-28	4.21e-24	-0.6	-0.54	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
STAD	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	12.08	2.83e-28	4.27e-24	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
STAD	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
STAD	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-12.08	2.91e-28	4.38e-24	-0.6	-0.54	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
STAD	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	12.07	3.12e-28	4.68e-24	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
STAD	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	12.07	3.13e-28	4.7e-24	0.59	0.54	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
STAD	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	12.07	3.19e-28	4.79e-24	0.6	0.54	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-12.06	3.28e-28	4.92e-24	-0.67	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
STAD	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
STAD	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
STAD	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-12.06	3.34e-28	4.99e-24	-0.6	-0.54	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
STAD	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	12.06	3.5e-28	5.22e-24	0.69	0.54	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
STAD	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	12.06	3.51e-28	5.23e-24	0.68	0.54	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
STAD	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-12.05	3.57e-28	5.32e-24	-0.64	-0.54	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-12.05	3.57e-28	5.32e-24	-0.64	-0.54	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
STAD	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-12.04	3.9e-28	5.79e-24	-0.58	-0.54	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
STAD	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-12.04	3.93e-28	5.82e-24	-0.61	-0.54	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
STAD	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-12.04	3.96e-28	5.87e-24	-0.8	-0.54	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
STAD	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	12.04	4.1e-28	6.07e-24	0.62	0.54	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
STAD	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-12.04	4.17e-28	6.17e-24	-0.69	-0.54	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
STAD	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-12.03	4.43e-28	6.55e-24	-0.64	-0.54	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
STAD	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-12.03	4.5e-28	6.65e-24	-0.59	-0.54	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
STAD	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	12.02	4.59e-28	6.79e-24	0.58	0.54	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-12.02	4.66e-28	6.87e-24	-0.74	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
STAD	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	12.02	4.87e-28	7.18e-24	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
STAD	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	12.02	4.93e-28	7.26e-24	0.68	0.54	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	12.02	4.93e-28	7.26e-24	0.68	0.54	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
STAD	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	12.02	4.93e-28	7.26e-24	0.68	0.54	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	12.02	4.93e-28	7.26e-24	0.68	0.54	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
STAD	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-12.01	5.17e-28	7.61e-24	-0.59	-0.54	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
STAD	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-12	5.58e-28	8.2e-24	-0.63	-0.54	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
STAD	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-12	5.58e-28	8.2e-24	-0.63	-0.54	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
STAD	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-11.99	5.96e-28	8.75e-24	-0.6	-0.54	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	11.99	5.99e-28	8.8e-24	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
STAD	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-11.99	6.06e-28	8.9e-24	-0.6	-0.54	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
STAD	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-11.98	6.41e-28	9.4e-24	-0.7	-0.54	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
STAD	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-11.98	6.69e-28	9.79e-24	-0.6	-0.54	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-11.97	7.04e-28	1.03e-23	-0.67	-0.54	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-11.97	7.04e-28	1.03e-23	-0.67	-0.54	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-11.97	7.04e-28	1.03e-23	-0.67	-0.54	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
STAD	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-11.96	7.71e-28	1.12e-23	-0.59	-0.54	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-11.96	7.94e-28	1.16e-23	-0.63	-0.54	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-11.96	7.94e-28	1.16e-23	-0.63	-0.54	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
STAD	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-11.96	7.94e-28	1.16e-23	-0.63	-0.54	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
STAD	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-11.96	8.06e-28	1.17e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
STAD	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-11.96	8.06e-28	1.17e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
STAD	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-11.96	8.06e-28	1.17e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
STAD	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-11.96	8.06e-28	1.17e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
STAD	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-11.96	8.06e-28	1.17e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
STAD	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-11.95	8.36e-28	1.21e-23	-0.71	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
STAD	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-11.94	9.54e-28	1.38e-23	-0.65	-0.54	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
STAD	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	11.93	9.96e-28	1.44e-23	0.59	0.54	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
STAD	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	11.93	1.05e-27	1.51e-23	0.84	0.54	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
STAD	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-11.93	1.06e-27	1.54e-23	-0.58	-0.54	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-11.92	1.14e-27	1.64e-23	-0.57	-0.54	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-11.92	1.14e-27	1.64e-23	-0.57	-0.54	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-11.92	1.14e-27	1.64e-23	-0.57	-0.54	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
STAD	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	11.92	1.14e-27	1.64e-23	0.66	0.54	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	11.91	1.23e-27	1.76e-23	0.64	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
STAD	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-11.9	1.33e-27	1.89e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
STAD	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	11.9	1.34e-27	1.91e-23	0.59	0.54	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
STAD	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	11.9	1.34e-27	1.91e-23	0.59	0.54	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-11.89	1.41e-27	2e-23	-0.65	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
STAD	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-11.89	1.48e-27	2.1e-23	-0.68	-0.54	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
STAD	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	11.89	1.49e-27	2.11e-23	0.62	0.54	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
STAD	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-11.88	1.53e-27	2.16e-23	-0.68	-0.54	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
STAD	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-11.88	1.58e-27	2.24e-23	-0.63	-0.54	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
STAD	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-11.88	1.59e-27	2.24e-23	-0.64	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
STAD	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-11.88	1.62e-27	2.28e-23	-0.7	-0.54	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
STAD	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-11.87	1.68e-27	2.37e-23	-0.67	-0.54	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-11.87	1.68e-27	2.37e-23	-0.67	-0.54	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	11.87	1.76e-27	2.47e-23	0.67	0.54	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
STAD	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-11.87	1.77e-27	2.49e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
STAD	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-11.87	1.77e-27	2.49e-23	-0.88	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
STAD	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	11.86	1.91e-27	2.68e-23	0.58	0.54	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
STAD	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-11.85	1.96e-27	2.75e-23	-0.63	-0.54	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
STAD	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	11.85	2.05e-27	2.87e-23	0.65	0.54	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
STAD	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-11.84	2.2e-27	3.07e-23	-0.61	-0.54	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	11.84	2.28e-27	3.17e-23	0.58	0.54	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
STAD	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-11.83	2.43e-27	3.38e-23	-0.69	-0.54	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
STAD	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-11.83	2.44e-27	3.39e-23	-0.67	-0.54	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
STAD	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-11.83	2.49e-27	3.45e-23	-0.61	-0.54	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
STAD	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-11.82	2.5e-27	3.48e-23	-0.57	-0.54	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
STAD	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	11.82	2.53e-27	3.51e-23	0.58	0.54	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
STAD	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-11.82	2.54e-27	3.52e-23	-0.58	-0.54	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-11.82	2.54e-27	3.52e-23	-0.58	-0.54	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
STAD	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	11.82	2.66e-27	3.67e-23	0.57	0.54	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	11.82	2.66e-27	3.67e-23	0.57	0.54	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	11.82	2.66e-27	3.67e-23	0.57	0.54	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
STAD	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	11.82	2.66e-27	3.67e-23	0.57	0.54	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
STAD	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	11.82	2.66e-27	3.67e-23	0.57	0.54	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	11.82	2.66e-27	3.67e-23	0.57	0.54	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
STAD	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-11.81	2.87e-27	3.96e-23	-0.57	-0.54	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
STAD	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	11.81	2.87e-27	3.97e-23	0.64	0.54	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	11.8	2.97e-27	4.1e-23	0.57	0.54	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
STAD	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	11.8	3.13e-27	4.31e-23	0.7	0.54	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
STAD	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-11.79	3.3e-27	4.54e-23	-0.67	-0.54	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
STAD	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	11.79	3.32e-27	4.56e-23	0.57	0.54	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	11.79	3.32e-27	4.56e-23	0.57	0.54	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	11.79	3.32e-27	4.56e-23	0.57	0.54	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	11.79	3.32e-27	4.56e-23	0.57	0.54	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
STAD	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-11.77	3.82e-27	5.25e-23	-0.57	-0.53	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
STAD	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-11.77	3.89e-27	5.33e-23	-0.66	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
STAD	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	11.77	4.02e-27	5.51e-23	0.66	0.53	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
STAD	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-11.77	4.04e-27	5.53e-23	-0.83	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
STAD	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	11.77	4.14e-27	5.66e-23	0.59	0.53	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
STAD	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	11.77	4.14e-27	5.66e-23	0.59	0.53	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-11.76	4.17e-27	5.7e-23	-0.67	-0.53	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
STAD	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	11.76	4.24e-27	5.79e-23	0.59	0.53	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	11.76	4.33e-27	5.92e-23	0.57	0.53	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
STAD	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	11.76	4.38e-27	5.98e-23	0.75	0.53	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
STAD	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	11.76	4.5e-27	6.14e-23	0.65	0.53	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	11.75	4.54e-27	6.19e-23	0.65	0.53	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	11.75	4.54e-27	6.19e-23	0.65	0.53	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	11.75	4.54e-27	6.19e-23	0.65	0.53	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
STAD	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	11.75	4.81e-27	6.54e-23	0.58	0.53	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
STAD	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	11.75	4.9e-27	6.66e-23	0.58	0.53	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	11.75	4.91e-27	6.66e-23	0.59	0.53	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	11.74	5e-27	6.79e-23	0.59	0.53	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-11.74	5.08e-27	6.89e-23	-0.67	-0.53	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-11.74	5.24e-27	7.1e-23	-0.67	-0.53	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
STAD	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-11.74	5.3e-27	7.18e-23	-0.71	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
STAD	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-11.73	5.56e-27	7.52e-23	-0.57	-0.53	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
STAD	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	11.73	5.61e-27	7.57e-23	0.58	0.53	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	11.73	5.61e-27	7.57e-23	0.58	0.53	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	11.73	5.61e-27	7.57e-23	0.58	0.53	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	11.73	5.61e-27	7.57e-23	0.58	0.53	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-11.73	5.69e-27	7.67e-23	-0.67	-0.53	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
STAD	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	11.72	5.95e-27	7.99e-23	0.69	0.53	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
STAD	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	11.72	6e-27	8.07e-23	0.72	0.53	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	11.72	6.19e-27	8.31e-23	0.72	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
STAD	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	11.71	6.51e-27	8.73e-23	0.65	0.53	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
STAD	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-11.7	6.99e-27	9.33e-23	-0.57	-0.53	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-11.7	6.99e-27	9.33e-23	-0.57	-0.53	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-11.7	6.99e-27	9.33e-23	-0.57	-0.53	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-11.7	7.4e-27	9.86e-23	-0.66	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
STAD	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	11.69	7.84e-27	1.04e-22	0.68	0.53	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
STAD	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-11.69	8.07e-27	1.07e-22	-0.6	-0.53	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
STAD	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-11.69	8.11e-27	1.08e-22	-0.61	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
STAD	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-11.68	8.27e-27	1.1e-22	-0.56	-0.53	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-11.68	8.27e-27	1.1e-22	-0.56	-0.53	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
STAD	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	11.68	8.8e-27	1.17e-22	0.67	0.53	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
STAD	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	11.68	8.89e-27	1.18e-22	0.59	0.53	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
STAD	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-11.67	8.98e-27	1.19e-22	-0.62	-0.53	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-11.67	8.98e-27	1.19e-22	-0.62	-0.53	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
STAD	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-11.67	9.22e-27	1.22e-22	-0.61	-0.53	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
STAD	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	11.66	9.69e-27	1.28e-22	0.7	0.53	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
STAD	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-11.66	9.71e-27	1.28e-22	-0.57	-0.53	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
STAD	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-11.66	1e-26	1.32e-22	-0.58	-0.53	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	11.66	1.03e-26	1.36e-22	0.59	0.53	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
STAD	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-11.66	1.04e-26	1.37e-22	-0.56	-0.53	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-11.66	1.04e-26	1.37e-22	-0.56	-0.53	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
STAD	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-11.66	1.04e-26	1.37e-22	-0.57	-0.53	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	11.66	1.04e-26	1.37e-22	0.59	0.53	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	11.66	1.05e-26	1.38e-22	0.59	0.53	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-11.65	1.05e-26	1.38e-22	-0.57	-0.53	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-11.65	1.05e-26	1.38e-22	-0.57	-0.53	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-11.65	1.05e-26	1.38e-22	-0.57	-0.53	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-11.65	1.05e-26	1.38e-22	-0.57	-0.53	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-11.65	1.05e-26	1.38e-22	-0.57	-0.53	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-11.65	1.1e-26	1.44e-22	-0.66	-0.53	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-11.65	1.1e-26	1.44e-22	-0.66	-0.53	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
STAD	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	11.64	1.15e-26	1.51e-22	0.65	0.53	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
STAD	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-11.64	1.16e-26	1.52e-22	-0.56	-0.53	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
STAD	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	11.63	1.25e-26	1.63e-22	0.64	0.53	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
STAD	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-11.63	1.33e-26	1.73e-22	-0.57	-0.53	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
STAD	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-11.62	1.38e-26	1.79e-22	-0.56	-0.53	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
STAD	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-11.62	1.38e-26	1.8e-22	-0.57	-0.53	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-11.62	1.38e-26	1.8e-22	-0.57	-0.53	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-11.62	1.38e-26	1.8e-22	-0.57	-0.53	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-11.62	1.38e-26	1.8e-22	-0.57	-0.53	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-11.62	1.38e-26	1.8e-22	-0.57	-0.53	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-11.62	1.38e-26	1.8e-22	-0.57	-0.53	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	11.62	1.44e-26	1.87e-22	0.57	0.53	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
STAD	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	11.6	1.64e-26	2.12e-22	0.57	0.53	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	11.6	1.64e-26	2.12e-22	0.57	0.53	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	11.6	1.64e-26	2.12e-22	0.57	0.53	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	11.6	1.64e-26	2.12e-22	0.57	0.53	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
STAD	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	11.6	1.68e-26	2.17e-22	0.68	0.53	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
STAD	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	11.6	1.68e-26	2.17e-22	0.68	0.53	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
STAD	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-11.6	1.69e-26	2.18e-22	-0.57	-0.53	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
STAD	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	11.6	1.7e-26	2.19e-22	0.6	0.53	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
STAD	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-11.6	1.72e-26	2.22e-22	-0.57	-0.53	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-11.6	1.73e-26	2.23e-22	-0.57	-0.53	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
STAD	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-11.59	1.81e-26	2.33e-22	-0.61	-0.53	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
STAD	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-11.59	1.87e-26	2.41e-22	-0.57	-0.53	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	11.58	1.91e-26	2.45e-22	0.57	0.53	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
STAD	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	11.58	1.92e-26	2.46e-22	0.57	0.53	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
STAD	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	11.58	1.92e-26	2.46e-22	0.57	0.53	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	11.58	1.92e-26	2.46e-22	0.57	0.53	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	11.58	1.92e-26	2.46e-22	0.57	0.53	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	11.58	1.93e-26	2.48e-22	0.58	0.53	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
STAD	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-11.58	1.95e-26	2.5e-22	-0.56	-0.53	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
STAD	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	11.58	1.98e-26	2.53e-22	0.58	0.53	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	11.58	1.98e-26	2.53e-22	0.58	0.53	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
STAD	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-11.58	1.99e-26	2.55e-22	-0.57	-0.53	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-11.58	1.99e-26	2.55e-22	-0.57	-0.53	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
STAD	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-11.58	1.99e-26	2.55e-22	-0.57	-0.53	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	11.56	2.25e-26	2.88e-22	0.57	0.53	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
STAD	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-11.56	2.26e-26	2.89e-22	-0.65	-0.53	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
STAD	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-11.56	2.37e-26	3.03e-22	-0.58	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
STAD	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	11.56	2.4e-26	3.06e-22	0.63	0.53	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	11.56	2.4e-26	3.06e-22	0.63	0.53	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
STAD	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	11.55	2.5e-26	3.18e-22	0.68	0.53	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	11.55	2.59e-26	3.3e-22	0.65	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
STAD	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-11.54	2.81e-26	3.58e-22	-0.62	-0.53	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
STAD	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	11.54	2.84e-26	3.62e-22	0.57	0.53	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
STAD	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	11.53	2.93e-26	3.72e-22	0.58	0.53	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
STAD	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	11.53	2.93e-26	3.72e-22	0.58	0.53	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	11.53	2.99e-26	3.8e-22	0.7	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
STAD	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-11.53	3e-26	3.81e-22	-0.57	-0.53	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
STAD	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-11.53	3e-26	3.81e-22	-0.57	-0.53	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
STAD	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	11.53	3.04e-26	3.85e-22	0.62	0.53	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
STAD	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-11.53	3.06e-26	3.88e-22	-0.57	-0.53	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-11.51	3.46e-26	4.38e-22	-0.6	-0.53	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
STAD	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	11.51	3.57e-26	4.51e-22	0.56	0.53	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
STAD	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-11.51	3.59e-26	4.53e-22	-0.61	-0.53	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
STAD	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-11.51	3.64e-26	4.6e-22	-0.56	-0.53	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
STAD	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	11.51	3.69e-26	4.66e-22	0.83	0.53	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
STAD	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	11.51	3.7e-26	4.67e-22	0.58	0.53	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
STAD	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	11.51	3.7e-26	4.67e-22	0.58	0.53	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-11.5	3.85e-26	4.86e-22	-0.7	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
STAD	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-11.5	3.94e-26	4.96e-22	-0.59	-0.53	Height;	chr11:118703185	chr11:118704607~118750263:+
STAD	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-11.5	3.94e-26	4.96e-22	-0.59	-0.53	Height;	chr11:118703207	chr11:118704607~118750263:+
STAD	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-11.5	3.94e-26	4.96e-22	-0.59	-0.53	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
STAD	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-11.5	3.94e-26	4.96e-22	-0.59	-0.53	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
STAD	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-11.49	4.07e-26	5.12e-22	-0.63	-0.53	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
STAD	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	11.47	4.79e-26	6.01e-22	0.63	0.53	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
STAD	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-11.47	4.87e-26	6.08e-22	-0.6	-0.52	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-11.47	4.87e-26	6.08e-22	-0.6	-0.52	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
STAD	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-11.47	4.87e-26	6.08e-22	-0.6	-0.52	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
STAD	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	11.47	4.98e-26	6.22e-22	0.57	0.52	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
STAD	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	11.47	5.12e-26	6.38e-22	0.57	0.52	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	11.47	5.12e-26	6.38e-22	0.57	0.52	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	11.47	5.19e-26	6.47e-22	0.58	0.52	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	11.47	5.19e-26	6.47e-22	0.58	0.52	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
STAD	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-11.46	5.24e-26	6.53e-22	-0.6	-0.52	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
STAD	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	11.46	5.36e-26	6.67e-22	0.58	0.52	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
STAD	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	11.46	5.39e-26	6.7e-22	0.57	0.52	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
STAD	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-11.46	5.64e-26	6.99e-22	-0.6	-0.52	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
STAD	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	11.45	5.71e-26	7.09e-22	0.66	0.52	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
STAD	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-11.45	5.85e-26	7.26e-22	-0.57	-0.52	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
STAD	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	11.45	5.91e-26	7.32e-22	0.62	0.52	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-11.45	6.1e-26	7.55e-22	-0.65	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
STAD	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	11.44	6.23e-26	7.71e-22	0.84	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
STAD	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	11.44	6.56e-26	8.1e-22	0.57	0.52	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
STAD	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-11.43	6.68e-26	8.25e-22	-0.66	-0.52	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
STAD	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-11.43	6.78e-26	8.37e-22	-0.6	-0.52	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-11.43	6.96e-26	8.58e-22	-0.63	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
STAD	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	11.43	7e-26	8.63e-22	0.65	0.52	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
STAD	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-11.42	7.28e-26	8.98e-22	-0.56	-0.52	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
STAD	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	11.42	7.34e-26	9.04e-22	0.57	0.52	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
STAD	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-11.41	8.28e-26	1.02e-21	-0.85	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
STAD	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-11.41	8.54e-26	1.05e-21	-0.56	-0.52	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
STAD	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
STAD	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
STAD	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
STAD	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
STAD	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
STAD	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
STAD	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
STAD	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
STAD	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
STAD	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
STAD	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	11.4	8.92e-26	1.09e-21	0.57	0.52	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
STAD	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	11.4	8.95e-26	1.09e-21	0.58	0.52	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
STAD	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	11.4	9.04e-26	1.1e-21	0.58	0.52	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
STAD	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-11.36	1.23e-25	1.49e-21	-0.58	-0.52	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
STAD	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-11.35	1.31e-25	1.59e-21	-0.56	-0.52	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-11.35	1.31e-25	1.59e-21	-0.56	-0.52	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	11.35	1.38e-25	1.66e-21	0.57	0.52	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
STAD	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-11.35	1.38e-25	1.66e-21	-0.67	-0.52	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
STAD	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-11.35	1.4e-25	1.69e-21	-0.68	-0.52	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
STAD	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	11.35	1.4e-25	1.69e-21	0.81	0.52	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	11.34	1.46e-25	1.76e-21	0.81	0.52	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
STAD	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	11.34	1.46e-25	1.77e-21	0.58	0.52	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
STAD	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	11.34	1.47e-25	1.77e-21	0.57	0.52	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
STAD	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	11.34	1.5e-25	1.81e-21	0.62	0.52	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
STAD	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	11.34	1.53e-25	1.84e-21	0.81	0.52	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
STAD	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	11.34	1.53e-25	1.85e-21	0.58	0.52	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
STAD	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	11.33	1.59e-25	1.91e-21	0.67	0.52	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
STAD	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	11.33	1.64e-25	1.97e-21	0.63	0.52	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
STAD	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-11.32	1.67e-25	2.01e-21	-0.61	-0.52	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
STAD	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-11.32	1.69e-25	2.03e-21	-0.81	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
STAD	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-11.32	1.75e-25	2.1e-21	-0.59	-0.52	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
STAD	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	11.32	1.79e-25	2.15e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
STAD	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	11.31	1.9e-25	2.27e-21	0.58	0.52	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
STAD	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	11.3	2.01e-25	2.4e-21	0.65	0.52	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
STAD	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-11.3	2.06e-25	2.45e-21	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
STAD	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-11.29	2.16e-25	2.58e-21	-0.67	-0.52	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
STAD	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-11.29	2.21e-25	2.63e-21	-0.66	-0.52	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
STAD	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	11.28	2.48e-25	2.94e-21	0.58	0.52	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
STAD	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-11.28	2.49e-25	2.95e-21	-0.74	-0.52	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
STAD	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	11.28	2.49e-25	2.96e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	11.28	2.49e-25	2.96e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.8	0.52	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	11.27	2.58e-25	3.05e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
STAD	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-11.27	2.71e-25	3.2e-21	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
STAD	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	11.27	2.75e-25	3.24e-21	0.57	0.52	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
STAD	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-11.26	2.75e-25	3.25e-21	-0.67	-0.52	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
STAD	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	11.26	2.84e-25	3.35e-21	0.56	0.52	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
STAD	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	11.25	3.06e-25	3.6e-21	0.58	0.52	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
STAD	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	11.25	3.06e-25	3.6e-21	0.58	0.52	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
STAD	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-11.25	3.06e-25	3.6e-21	-0.55	-0.52	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
STAD	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-11.25	3.13e-25	3.68e-21	-0.61	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
STAD	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	11.25	3.16e-25	3.72e-21	0.58	0.52	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
STAD	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	11.25	3.2e-25	3.75e-21	0.66	0.52	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
STAD	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	11.24	3.29e-25	3.86e-21	0.82	0.52	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
STAD	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-11.24	3.4e-25	3.99e-21	-0.66	-0.52	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
STAD	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-11.23	3.69e-25	4.32e-21	-0.58	-0.52	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
STAD	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	11.22	4.05e-25	4.73e-21	0.49	0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
STAD	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	11.22	4.05e-25	4.73e-21	0.62	0.52	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
STAD	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	11.22	4.06e-25	4.74e-21	0.67	0.52	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
STAD	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	11.22	4.06e-25	4.74e-21	0.67	0.52	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
STAD	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-11.22	4.15e-25	4.84e-21	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
STAD	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	11.2	4.72e-25	5.48e-21	0.56	0.52	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	11.2	4.72e-25	5.48e-21	0.56	0.52	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
STAD	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-11.2	4.85e-25	5.63e-21	-0.59	-0.52	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
STAD	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	11.19	4.93e-25	5.71e-21	0.81	0.52	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
STAD	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-11.19	4.94e-25	5.73e-21	-0.65	-0.52	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
STAD	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-11.19	5.01e-25	5.8e-21	-0.59	-0.52	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
STAD	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-11.19	5.11e-25	5.91e-21	-0.56	-0.52	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
STAD	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-11.19	5.29e-25	6.11e-21	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-11.19	5.29e-25	6.11e-21	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
STAD	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	11.18	5.4e-25	6.23e-21	0.64	0.52	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
STAD	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	11.18	5.61e-25	6.48e-21	0.57	0.52	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
STAD	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-11.18	5.62e-25	6.48e-21	-0.58	-0.52	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
STAD	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	11.18	5.68e-25	6.55e-21	0.84	0.52	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
STAD	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-11.18	5.77e-25	6.65e-21	-0.57	-0.52	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
STAD	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	11.18	5.77e-25	6.65e-21	0.56	0.52	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
STAD	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	11.17	5.85e-25	6.74e-21	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
STAD	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-11.17	6.16e-25	7.09e-21	-0.64	-0.51	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
STAD	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	11.16	6.3e-25	7.25e-21	0.6	0.51	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	11.16	6.71e-25	7.7e-21	0.6	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
STAD	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-11.15	6.91e-25	7.92e-21	-0.48	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
STAD	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-11.15	7.03e-25	8.05e-21	-0.61	-0.51	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
STAD	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-11.15	7.05e-25	8.07e-21	-0.59	-0.51	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-11.14	7.5e-25	8.58e-21	-0.6	-0.51	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
STAD	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	11.14	7.54e-25	8.61e-21	0.82	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
STAD	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	11.14	7.57e-25	8.64e-21	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	11.14	7.57e-25	8.64e-21	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	11.14	7.57e-25	8.64e-21	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
STAD	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-11.14	7.83e-25	8.93e-21	-0.55	-0.51	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
STAD	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	11.13	8.67e-25	9.87e-21	0.63	0.51	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
STAD	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-11.12	9.13e-25	1.04e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
STAD	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	11.12	9.13e-25	1.04e-20	0.79	0.51	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
STAD	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	11.12	9.22e-25	1.05e-20	0.6	0.51	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
STAD	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-11.11	9.65e-25	1.09e-20	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
STAD	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	11.11	9.99e-25	1.13e-20	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	11.11	9.99e-25	1.13e-20	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	11.11	9.99e-25	1.13e-20	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	11.11	9.99e-25	1.13e-20	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	11.11	9.99e-25	1.13e-20	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	11.11	9.99e-25	1.13e-20	0.82	0.51	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
STAD	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-11.1	1.04e-24	1.17e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-11.1	1.04e-24	1.17e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-11.1	1.07e-24	1.21e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
STAD	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	11.1	1.07e-24	1.21e-20	0.8	0.51	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
STAD	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-11.1	1.09e-24	1.23e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
STAD	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-11.1	1.1e-24	1.24e-20	-0.57	-0.51	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
STAD	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-11.1	1.12e-24	1.26e-20	-0.57	-0.51	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
STAD	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	11.09	1.21e-24	1.36e-20	0.56	0.51	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	11.09	1.21e-24	1.36e-20	0.56	0.51	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
STAD	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	11.08	1.24e-24	1.39e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
STAD	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	11.08	1.26e-24	1.41e-20	0.56	0.51	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
STAD	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	11.08	1.26e-24	1.41e-20	0.56	0.51	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	11.08	1.26e-24	1.41e-20	0.56	0.51	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	11.08	1.26e-24	1.41e-20	0.56	0.51	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
STAD	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	11.08	1.3e-24	1.45e-20	0.68	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
STAD	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-11.08	1.3e-24	1.46e-20	-0.54	-0.51	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-11.07	1.35e-24	1.5e-20	-0.55	-0.51	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
STAD	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	11.07	1.35e-24	1.5e-20	0.56	0.51	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
STAD	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	11.07	1.39e-24	1.55e-20	0.71	0.51	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
STAD	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-11.07	1.39e-24	1.55e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-11.07	1.39e-24	1.55e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-11.07	1.39e-24	1.55e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-11.07	1.39e-24	1.55e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
STAD	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-11.07	1.4e-24	1.56e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
STAD	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-11.07	1.4e-24	1.56e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
STAD	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	11.07	1.4e-24	1.56e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	11.07	1.4e-24	1.56e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	11.07	1.4e-24	1.56e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	11.07	1.4e-24	1.56e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
STAD	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	11.07	1.41e-24	1.57e-20	0.56	0.51	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
STAD	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	11.07	1.43e-24	1.59e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
STAD	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-11.06	1.44e-24	1.6e-20	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
STAD	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	11.06	1.49e-24	1.65e-20	0.56	0.51	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	11.06	1.49e-24	1.65e-20	0.56	0.51	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	11.06	1.5e-24	1.66e-20	0.56	0.51	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
STAD	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	11.06	1.5e-24	1.66e-20	0.68	0.51	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
STAD	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-11.06	1.53e-24	1.69e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-11.06	1.53e-24	1.7e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-11.06	1.53e-24	1.7e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-11.06	1.53e-24	1.7e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-11.06	1.55e-24	1.71e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
STAD	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-11.05	1.64e-24	1.8e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
STAD	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	11.05	1.68e-24	1.85e-20	0.47	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
STAD	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	11.05	1.68e-24	1.85e-20	0.79	0.51	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
STAD	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-11.04	1.71e-24	1.88e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
STAD	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	11.04	1.71e-24	1.88e-20	0.79	0.51	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
STAD	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-11.04	1.75e-24	1.92e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-11.04	1.75e-24	1.92e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-11.04	1.75e-24	1.92e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
STAD	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	11.04	1.78e-24	1.95e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
STAD	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-11.04	1.8e-24	1.97e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
STAD	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	11.04	1.81e-24	1.98e-20	0.74	0.51	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
STAD	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-11.04	1.83e-24	1.99e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-11.04	1.83e-24	1.99e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-11.04	1.83e-24	1.99e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
STAD	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-11.03	1.84e-24	2.01e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
STAD	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	11.03	1.88e-24	2.05e-20	0.8	0.51	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
STAD	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-11.03	1.9e-24	2.07e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
STAD	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	11.03	1.94e-24	2.11e-20	0.63	0.51	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
STAD	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-11.03	1.96e-24	2.13e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-11.03	1.96e-24	2.13e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
STAD	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-11.03	1.96e-24	2.13e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
STAD	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	11.02	2.08e-24	2.26e-20	0.57	0.51	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
STAD	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-11.02	2.1e-24	2.27e-20	-0.59	-0.51	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
STAD	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	11.02	2.11e-24	2.29e-20	0.56	0.51	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
STAD	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	11.02	2.12e-24	2.29e-20	0.67	0.51	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
STAD	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	11.02	2.15e-24	2.32e-20	0.56	0.51	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
STAD	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	11.01	2.18e-24	2.34e-20	0.59	0.51	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
STAD	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-11.01	2.19e-24	2.35e-20	-0.55	-0.51	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
STAD	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-11.01	2.21e-24	2.37e-20	-0.66	-0.51	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-11.01	2.24e-24	2.41e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-11.01	2.24e-24	2.41e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-11.01	2.3e-24	2.45e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-11.01	2.3e-24	2.45e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-11.01	2.3e-24	2.45e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-11.01	2.3e-24	2.45e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-11	2.43e-24	2.58e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
STAD	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-11	2.46e-24	2.62e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-11	2.5e-24	2.66e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-11	2.5e-24	2.66e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-11	2.5e-24	2.66e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
STAD	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	11	2.51e-24	2.66e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
STAD	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-11	2.52e-24	2.68e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-11	2.52e-24	2.68e-20	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
STAD	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-10.99	2.57e-24	2.73e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
STAD	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-10.99	2.57e-24	2.73e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-10.99	2.57e-24	2.73e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
STAD	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-10.99	2.71e-24	2.87e-20	-0.54	-0.51	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
STAD	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-10.99	2.75e-24	2.9e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-10.99	2.77e-24	2.93e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
STAD	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	10.98	2.8e-24	2.97e-20	0.59	0.51	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
STAD	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-10.98	2.85e-24	3.01e-20	-0.58	-0.51	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
STAD	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-10.98	2.9e-24	3.06e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
STAD	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-10.98	2.9e-24	3.06e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
STAD	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-10.98	2.9e-24	3.06e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-10.98	2.9e-24	3.06e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-10.98	2.9e-24	3.06e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-10.98	2.9e-24	3.06e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-10.98	2.9e-24	3.06e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
STAD	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	10.97	3.16e-24	3.33e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
STAD	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-10.97	3.16e-24	3.33e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
STAD	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-10.97	3.16e-24	3.33e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-10.97	3.17e-24	3.34e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-10.97	3.17e-24	3.34e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
STAD	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-10.97	3.19e-24	3.35e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
STAD	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	10.97	3.25e-24	3.41e-20	0.55	0.51	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
STAD	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-10.97	3.26e-24	3.42e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
STAD	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-10.96	3.29e-24	3.45e-20	-0.63	-0.51	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
STAD	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-10.96	3.33e-24	3.48e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
STAD	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-10.96	3.33e-24	3.48e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
STAD	cis	rs9457247	0.905	rs444210	ENSG00000265828.1	MIR3939	-10.96	3.34e-24	3.49e-20	-0.58	-0.51	Crohn's disease;	chr6:166976754	chr6:166997807~166997912:-
STAD	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-10.96	3.46e-24	3.61e-20	-0.58	-0.51	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
STAD	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-10.96	3.49e-24	3.63e-20	-0.83	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
STAD	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-10.96	3.5e-24	3.64e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-10.96	3.55e-24	3.7e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
STAD	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	10.96	3.55e-24	3.7e-20	0.55	0.51	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
STAD	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-10.95	3.61e-24	3.75e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-10.95	3.61e-24	3.75e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-10.95	3.61e-24	3.75e-20	-0.6	-0.51	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
STAD	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-10.95	3.67e-24	3.81e-20	-0.58	-0.51	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
STAD	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	10.95	3.69e-24	3.82e-20	0.65	0.51	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
STAD	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	10.95	3.77e-24	3.91e-20	0.58	0.51	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
STAD	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-10.95	3.85e-24	3.99e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-10.94	3.96e-24	4.09e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-10.94	3.96e-24	4.09e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
STAD	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	10.94	3.98e-24	4.11e-20	0.67	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
STAD	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-10.94	4.04e-24	4.17e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-10.94	4.04e-24	4.17e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-10.94	4.04e-24	4.17e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-10.94	4.11e-24	4.24e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-10.94	4.12e-24	4.25e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-10.93	4.19e-24	4.32e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
STAD	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	10.93	4.2e-24	4.33e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
STAD	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-10.93	4.21e-24	4.33e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	10.93	4.22e-24	4.34e-20	0.64	0.51	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-10.93	4.33e-24	4.44e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
STAD	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-10.93	4.33e-24	4.44e-20	-0.58	-0.51	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-10.93	4.33e-24	4.44e-20	-0.58	-0.51	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
STAD	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-10.93	4.39e-24	4.48e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
STAD	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-10.93	4.39e-24	4.48e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-10.92	4.55e-24	4.63e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
STAD	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-10.92	4.64e-24	4.73e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
STAD	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	10.92	4.71e-24	4.79e-20	0.67	0.51	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
STAD	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-10.92	4.72e-24	4.81e-20	-0.54	-0.51	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
STAD	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-10.92	4.77e-24	4.85e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-10.92	4.77e-24	4.85e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-10.92	4.77e-24	4.85e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-10.92	4.77e-24	4.85e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
STAD	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-10.92	4.79e-24	4.87e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-10.92	4.79e-24	4.87e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-10.92	4.79e-24	4.87e-20	-0.64	-0.51	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
STAD	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-10.92	4.89e-24	4.95e-20	-0.63	-0.51	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
STAD	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-10.92	4.89e-24	4.95e-20	-0.63	-0.51	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
STAD	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	10.91	4.96e-24	5.02e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	10.91	4.96e-24	5.02e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	10.91	4.96e-24	5.02e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	10.91	4.96e-24	5.02e-20	0.81	0.51	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
STAD	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-10.9	5.37e-24	5.44e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
STAD	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-10.9	5.56e-24	5.62e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-10.9	5.56e-24	5.62e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-10.9	5.56e-24	5.62e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
STAD	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-10.9	5.56e-24	5.62e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
STAD	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-10.9	5.56e-24	5.62e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
STAD	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-10.9	5.56e-24	5.62e-20	-0.58	-0.51	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
STAD	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-10.9	5.67e-24	5.72e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
STAD	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	10.9	5.71e-24	5.76e-20	0.73	0.51	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
STAD	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	10.9	5.77e-24	5.81e-20	0.55	0.51	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	10.89	5.87e-24	5.92e-20	0.55	0.51	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
STAD	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-10.89	5.91e-24	5.95e-20	-0.63	-0.51	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
STAD	cis	rs9457247	1	rs386548	ENSG00000265828.1	MIR3939	10.89	6.13e-24	6.17e-20	0.58	0.51	Crohn's disease;	chr6:166972045	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	10.89	6.24e-24	6.28e-20	0.56	0.51	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
STAD	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-10.89	6.28e-24	6.31e-20	-0.65	-0.51	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-10.88	6.43e-24	6.46e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-10.88	6.52e-24	6.55e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-10.88	6.52e-24	6.55e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-10.88	6.58e-24	6.6e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-10.88	6.58e-24	6.6e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-10.88	6.58e-24	6.6e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-10.88	6.58e-24	6.6e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
STAD	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-10.88	6.58e-24	6.6e-20	-0.69	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
STAD	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-10.87	7.28e-24	7.29e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-10.87	7.31e-24	7.32e-20	-0.65	-0.5	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
STAD	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-10.87	7.31e-24	7.32e-20	-0.65	-0.5	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
STAD	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-10.87	7.31e-24	7.32e-20	-0.65	-0.5	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
STAD	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-10.87	7.31e-24	7.32e-20	-0.65	-0.5	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-10.87	7.37e-24	7.38e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
STAD	cis	rs10256972	0.616	rs3802141	ENSG00000229043.2	AC091729.9	-10.87	7.4e-24	7.4e-20	-0.59	-0.5	Endometriosis;Longevity;	chr7:1091720	chr7:1160374~1165267:+
STAD	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	10.86	7.73e-24	7.71e-20	0.55	0.5	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
STAD	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-10.86	8.01e-24	7.97e-20	-0.62	-0.5	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
STAD	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-10.86	8.01e-24	7.97e-20	-0.57	-0.5	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
STAD	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-10.85	8.13e-24	8.06e-20	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
STAD	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-10.85	8.32e-24	8.22e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-10.85	8.32e-24	8.22e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-10.85	8.32e-24	8.22e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-10.85	8.32e-24	8.22e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
STAD	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-10.85	8.37e-24	8.27e-20	-0.62	-0.5	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
STAD	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	10.85	8.5e-24	8.39e-20	0.56	0.5	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	10.85	8.5e-24	8.39e-20	0.56	0.5	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
STAD	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-10.85	8.57e-24	8.45e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-10.85	8.69e-24	8.56e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-10.85	8.69e-24	8.56e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-10.85	8.69e-24	8.56e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
STAD	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-10.84	8.93e-24	8.79e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
STAD	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-10.84	8.99e-24	8.82e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-10.84	9.05e-24	8.89e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
STAD	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	10.84	9.14e-24	8.96e-20	0.67	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
STAD	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	10.84	9.14e-24	8.96e-20	0.67	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
STAD	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-10.84	9.17e-24	8.99e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
STAD	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-10.84	9.2e-24	9.02e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
STAD	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	10.84	9.4e-24	9.2e-20	0.67	0.5	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
STAD	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-10.84	9.44e-24	9.24e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-10.83	9.54e-24	9.31e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-10.83	9.54e-24	9.31e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-10.83	9.54e-24	9.31e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-10.83	9.54e-24	9.31e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
STAD	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	10.83	9.56e-24	9.32e-20	0.64	0.5	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
STAD	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	10.83	9.56e-24	9.32e-20	0.64	0.5	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-10.83	9.76e-24	9.52e-20	-0.65	-0.5	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-10.83	9.78e-24	9.53e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-10.83	9.78e-24	9.53e-20	-0.64	-0.5	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-10.83	9.92e-24	9.65e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-10.83	9.92e-24	9.65e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
STAD	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-10.83	1.01e-23	9.8e-20	-0.64	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
STAD	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-10.83	1.01e-23	9.84e-20	-0.59	-0.5	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
STAD	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-10.82	1.03e-23	1e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
STAD	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	10.82	1.05e-23	1.02e-19	0.61	0.5	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
STAD	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-10.82	1.11e-23	1.08e-19	-0.57	-0.5	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
STAD	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-10.82	1.11e-23	1.08e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-10.81	1.12e-23	1.09e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-10.81	1.16e-23	1.12e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
STAD	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	10.81	1.18e-23	1.14e-19	0.55	0.5	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
STAD	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-10.81	1.18e-23	1.14e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-10.81	1.18e-23	1.14e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
STAD	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	10.81	1.2e-23	1.16e-19	0.67	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
STAD	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-10.8	1.21e-23	1.17e-19	-0.62	-0.5	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
STAD	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-10.8	1.23e-23	1.18e-19	-0.66	-0.5	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
STAD	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-10.8	1.26e-23	1.21e-19	-0.65	-0.5	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-10.8	1.27e-23	1.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-10.8	1.28e-23	1.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-10.8	1.28e-23	1.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-10.8	1.28e-23	1.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-10.8	1.28e-23	1.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-10.8	1.28e-23	1.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-10.8	1.28e-23	1.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
STAD	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	10.8	1.29e-23	1.23e-19	0.8	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
STAD	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-10.8	1.29e-23	1.24e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-10.79	1.31e-23	1.26e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-10.79	1.31e-23	1.26e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-10.79	1.31e-23	1.26e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
STAD	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-10.79	1.32e-23	1.26e-19	-0.66	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
STAD	cis	rs9457247	0.902	rs34560498	ENSG00000265828.1	MIR3939	-10.79	1.35e-23	1.29e-19	-0.58	-0.5	Crohn's disease;	chr6:166982374	chr6:166997807~166997912:-
STAD	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-10.79	1.41e-23	1.35e-19	-0.65	-0.5	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
STAD	cis	rs9457247	1	rs2769347	ENSG00000265828.1	MIR3939	10.78	1.43e-23	1.36e-19	0.59	0.5	Crohn's disease;	chr6:166958249	chr6:166997807~166997912:-
STAD	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-10.78	1.44e-23	1.38e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
STAD	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-10.78	1.45e-23	1.38e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-10.78	1.45e-23	1.38e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
STAD	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-10.78	1.48e-23	1.41e-19	-0.67	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
STAD	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-10.78	1.48e-23	1.41e-19	-0.67	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
STAD	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-10.78	1.51e-23	1.44e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
STAD	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-10.78	1.52e-23	1.45e-19	-0.54	-0.5	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
STAD	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-10.78	1.53e-23	1.46e-19	-0.62	-0.5	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
STAD	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-10.77	1.57e-23	1.49e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
STAD	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-10.77	1.6e-23	1.52e-19	-0.54	-0.5	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
STAD	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	10.77	1.6e-23	1.52e-19	0.63	0.5	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
STAD	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	10.77	1.6e-23	1.52e-19	0.63	0.5	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
STAD	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	10.77	1.6e-23	1.52e-19	0.63	0.5	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
STAD	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	10.77	1.65e-23	1.57e-19	0.66	0.5	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
STAD	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-10.76	1.68e-23	1.59e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
STAD	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-10.76	1.68e-23	1.59e-19	-0.54	-0.5	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
STAD	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-10.76	1.68e-23	1.6e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-10.76	1.68e-23	1.6e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-10.76	1.68e-23	1.6e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
STAD	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-10.76	1.69e-23	1.6e-19	-0.67	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
STAD	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-10.76	1.72e-23	1.63e-19	-0.54	-0.5	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
STAD	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-10.76	1.74e-23	1.64e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
STAD	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-10.76	1.76e-23	1.66e-19	-0.77	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
STAD	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-10.76	1.76e-23	1.66e-19	-0.54	-0.5	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
STAD	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-10.76	1.76e-23	1.66e-19	-0.62	-0.5	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
STAD	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	10.76	1.76e-23	1.67e-19	0.64	0.5	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
STAD	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	10.76	1.79e-23	1.69e-19	0.66	0.5	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
STAD	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-10.76	1.79e-23	1.69e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
STAD	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-10.76	1.79e-23	1.69e-19	-0.54	-0.5	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
STAD	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-10.75	1.83e-23	1.73e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
STAD	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-10.75	1.84e-23	1.73e-19	-0.6	-0.5	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
STAD	cis	rs9457247	0.967	rs2149092	ENSG00000265828.1	MIR3939	10.75	1.85e-23	1.75e-19	0.58	0.5	Crohn's disease;	chr6:166959490	chr6:166997807~166997912:-
STAD	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-10.75	1.87e-23	1.76e-19	-0.54	-0.5	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-10.75	1.94e-23	1.82e-19	-0.54	-0.5	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
STAD	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-10.74	2.04e-23	1.91e-19	-0.54	-0.5	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
STAD	cis	rs9457247	1	rs398278	ENSG00000265828.1	MIR3939	-10.74	2.05e-23	1.92e-19	-0.59	-0.5	Crohn's disease;	chr6:166974681	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs444988	ENSG00000265828.1	MIR3939	-10.74	2.05e-23	1.92e-19	-0.59	-0.5	Crohn's disease;	chr6:166976186	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs408080	ENSG00000265828.1	MIR3939	-10.74	2.05e-23	1.92e-19	-0.59	-0.5	Crohn's disease;	chr6:166979034	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-10.74	2.1e-23	1.97e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-10.74	2.1e-23	1.97e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
STAD	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-10.74	2.13e-23	1.99e-19	-0.64	-0.5	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-10.74	2.13e-23	1.99e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
STAD	cis	rs9457247	0.967	rs443570	ENSG00000265828.1	MIR3939	-10.73	2.15e-23	2.01e-19	-0.57	-0.5	Crohn's disease;	chr6:166976437	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-10.73	2.15e-23	2.01e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	10.73	2.22e-23	2.07e-19	0.55	0.5	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	10.73	2.22e-23	2.07e-19	0.55	0.5	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	10.73	2.22e-23	2.07e-19	0.55	0.5	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
STAD	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-10.73	2.26e-23	2.11e-19	-0.56	-0.5	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
STAD	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-10.73	2.27e-23	2.11e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-10.73	2.27e-23	2.11e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-10.73	2.27e-23	2.11e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-10.73	2.27e-23	2.11e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-10.73	2.27e-23	2.11e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
STAD	cis	rs9457247	1	rs416131	ENSG00000265828.1	MIR3939	10.73	2.28e-23	2.12e-19	0.57	0.5	Crohn's disease;	chr6:166993056	chr6:166997807~166997912:-
STAD	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-10.73	2.3e-23	2.14e-19	-0.6	-0.5	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
STAD	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-10.73	2.31e-23	2.14e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
STAD	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-10.73	2.31e-23	2.14e-19	-0.54	-0.5	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
STAD	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-10.72	2.32e-23	2.16e-19	-0.82	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
STAD	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-10.72	2.35e-23	2.18e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
STAD	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-10.72	2.39e-23	2.22e-19	-0.57	-0.5	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
STAD	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-10.72	2.4e-23	2.22e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
STAD	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	10.72	2.42e-23	2.24e-19	0.67	0.5	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
STAD	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	10.72	2.44e-23	2.27e-19	0.64	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
STAD	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	10.72	2.48e-23	2.29e-19	0.63	0.5	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
STAD	cis	rs9457247	1	rs402749	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166972616	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs385863	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166973127	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs397713	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166973226	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.905	rs453184	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166973916	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs436707	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166975355	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs377753	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166976008	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs430477	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166976363	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs376574	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166976468	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs439237	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166977904	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs9457247	ENSG00000265828.1	MIR3939	-10.72	2.5e-23	2.31e-19	-0.57	-0.5	Crohn's disease;	chr6:166978686	chr6:166997807~166997912:-
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	10.72	2.51e-23	2.32e-19	0.57	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
STAD	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-10.71	2.58e-23	2.37e-19	-0.62	-0.5	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
STAD	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-10.71	2.7e-23	2.48e-19	-0.6	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
STAD	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	10.71	2.72e-23	2.49e-19	0.54	0.5	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
STAD	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-10.7	2.78e-23	2.55e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
STAD	cis	rs9457247	1	rs2149090	ENSG00000265828.1	MIR3939	10.7	2.8e-23	2.57e-19	0.58	0.5	Crohn's disease;	chr6:166959276	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs2149091	ENSG00000265828.1	MIR3939	10.7	2.8e-23	2.57e-19	0.58	0.5	Crohn's disease;	chr6:166959298	chr6:166997807~166997912:-
STAD	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-10.7	2.85e-23	2.61e-19	-0.55	-0.5	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
STAD	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	10.7	2.93e-23	2.68e-19	0.62	0.5	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
STAD	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	10.7	2.93e-23	2.68e-19	0.62	0.5	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	10.7	2.93e-23	2.68e-19	0.62	0.5	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
STAD	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	10.7	2.93e-23	2.68e-19	0.62	0.5	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
STAD	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-10.7	2.94e-23	2.69e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-10.69	3e-23	2.74e-19	-0.62	-0.5	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
STAD	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-10.69	3.08e-23	2.81e-19	-0.55	-0.5	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
STAD	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-10.69	3.09e-23	2.82e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-10.69	3.09e-23	2.82e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
STAD	cis	rs9457247	1	rs400063	ENSG00000265828.1	MIR3939	-10.69	3.2e-23	2.92e-19	-0.57	-0.5	Crohn's disease;	chr6:166973104	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs439553	ENSG00000265828.1	MIR3939	-10.69	3.2e-23	2.92e-19	-0.57	-0.5	Crohn's disease;	chr6:166977724	chr6:166997807~166997912:-
STAD	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-10.68	3.27e-23	2.98e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-10.68	3.29e-23	3e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
STAD	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	10.68	3.33e-23	3.03e-19	0.7	0.5	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
STAD	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	10.68	3.4e-23	3.09e-19	0.66	0.5	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	10.68	3.4e-23	3.09e-19	0.66	0.5	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
STAD	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-10.67	3.49e-23	3.17e-19	-0.66	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
STAD	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-10.67	3.59e-23	3.25e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-10.67	3.62e-23	3.28e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-10.67	3.65e-23	3.3e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-10.67	3.65e-23	3.3e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-10.67	3.65e-23	3.3e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
STAD	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	10.67	3.67e-23	3.31e-19	0.62	0.5	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
STAD	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	10.67	3.73e-23	3.37e-19	0.66	0.5	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
STAD	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-10.66	3.79e-23	3.42e-19	-0.61	-0.5	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
STAD	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-10.66	3.8e-23	3.43e-19	-0.62	-0.5	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
STAD	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-10.66	3.81e-23	3.44e-19	-0.52	-0.5	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
STAD	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	10.66	3.82e-23	3.44e-19	0.54	0.5	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
STAD	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	10.66	3.82e-23	3.45e-19	0.66	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
STAD	cis	rs9457247	1	rs415890	ENSG00000265828.1	MIR3939	10.66	3.83e-23	3.45e-19	0.57	0.5	Crohn's disease;	chr6:166993145	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-10.66	3.83e-23	3.45e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-10.66	3.83e-23	3.45e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-10.66	3.83e-23	3.45e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-10.66	3.83e-23	3.45e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
STAD	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-10.66	3.84e-23	3.45e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
STAD	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	10.66	3.86e-23	3.48e-19	0.7	0.5	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
STAD	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-10.66	3.9e-23	3.51e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-10.66	3.9e-23	3.51e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
STAD	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	10.66	3.98e-23	3.57e-19	0.58	0.5	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
STAD	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-10.66	4.03e-23	3.62e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-10.66	4.05e-23	3.64e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
STAD	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	10.66	4.07e-23	3.65e-19	0.71	0.5	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
STAD	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-10.65	4.11e-23	3.69e-19	-0.53	-0.5	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
STAD	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-10.65	4.18e-23	3.74e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-10.65	4.18e-23	3.74e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-10.65	4.18e-23	3.74e-19	-0.59	-0.5	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	10.65	4.21e-23	3.77e-19	0.55	0.5	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
STAD	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	10.65	4.22e-23	3.77e-19	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
STAD	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-10.65	4.42e-23	3.95e-19	-0.58	-0.5	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
STAD	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	10.65	4.43e-23	3.95e-19	0.54	0.5	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
STAD	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	10.65	4.43e-23	3.95e-19	0.54	0.5	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
STAD	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	10.64	4.49e-23	4.01e-19	0.54	0.5	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
STAD	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-10.64	4.63e-23	4.13e-19	-0.62	-0.5	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-10.64	4.63e-23	4.13e-19	-0.62	-0.5	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-10.63	4.9e-23	4.35e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
STAD	cis	rs9457247	0.967	rs1794696	ENSG00000265828.1	MIR3939	-10.63	4.98e-23	4.42e-19	-0.59	-0.5	Crohn's disease;	chr6:166982686	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.935	rs427824	ENSG00000265828.1	MIR3939	-10.63	5.04e-23	4.47e-19	-0.59	-0.5	Crohn's disease;	chr6:166990430	chr6:166997807~166997912:-
STAD	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-10.63	5.05e-23	4.47e-19	-0.52	-0.5	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
STAD	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	10.63	5.13e-23	4.54e-19	0.63	0.5	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-10.63	5.2e-23	4.6e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
STAD	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	10.62	5.43e-23	4.8e-19	0.66	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
STAD	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-10.62	5.51e-23	4.86e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
STAD	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-10.62	5.51e-23	4.86e-19	-0.63	-0.5	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
STAD	cis	rs9457247	1	rs422562	ENSG00000265828.1	MIR3939	-10.62	5.51e-23	4.87e-19	-0.57	-0.5	Crohn's disease;	chr6:166992830	chr6:166997807~166997912:-
STAD	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	10.62	5.55e-23	4.89e-19	0.65	0.5	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
STAD	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	10.62	5.55e-23	4.89e-19	0.65	0.5	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
STAD	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	10.61	5.73e-23	5.05e-19	0.63	0.5	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	10.61	5.75e-23	5.06e-19	0.53	0.5	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	10.61	5.75e-23	5.06e-19	0.53	0.5	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	10.61	5.75e-23	5.06e-19	0.53	0.5	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	10.61	5.75e-23	5.06e-19	0.53	0.5	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
STAD	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	10.61	5.84e-23	5.14e-19	0.6	0.5	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
STAD	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	10.61	5.85e-23	5.14e-19	0.6	0.5	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
STAD	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	10.61	5.97e-23	5.25e-19	0.62	0.5	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-10.61	6.04e-23	5.3e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
STAD	cis	rs9457247	1	rs405553	ENSG00000265828.1	MIR3939	-10.6	6.14e-23	5.38e-19	-0.57	-0.5	Crohn's disease;	chr6:166981570	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.935	rs1794697	ENSG00000265828.1	MIR3939	-10.6	6.14e-23	5.38e-19	-0.57	-0.5	Crohn's disease;	chr6:166981922	chr6:166997807~166997912:-
STAD	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-10.6	6.29e-23	5.5e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
STAD	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-10.6	6.33e-23	5.53e-19	-0.61	-0.5	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
STAD	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	10.6	6.37e-23	5.57e-19	0.53	0.5	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
STAD	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-10.6	6.43e-23	5.62e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
STAD	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	10.6	6.45e-23	5.63e-19	0.62	0.5	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
STAD	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-10.6	6.6e-23	5.77e-19	-0.64	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
STAD	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-10.6	6.61e-23	5.77e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
STAD	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-10.59	6.74e-23	5.87e-19	-0.59	-0.49	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
STAD	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	10.59	6.75e-23	5.88e-19	0.62	0.49	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
STAD	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	10.59	6.75e-23	5.88e-19	0.62	0.49	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
STAD	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	10.59	6.75e-23	5.88e-19	0.62	0.49	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
STAD	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	10.59	6.75e-23	5.88e-19	0.62	0.49	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
STAD	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-10.59	6.78e-23	5.9e-19	-0.58	-0.49	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-10.59	6.85e-23	5.96e-19	-0.58	-0.49	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-10.59	6.86e-23	5.96e-19	-0.56	-0.49	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-10.59	7.06e-23	6.13e-19	-0.6	-0.49	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	10.58	7.28e-23	6.32e-19	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
STAD	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	10.58	7.45e-23	6.46e-19	0.61	0.49	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
STAD	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	10.58	7.55e-23	6.53e-19	0.79	0.49	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	10.58	7.55e-23	6.53e-19	0.79	0.49	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
STAD	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	10.58	7.69e-23	6.65e-19	0.53	0.49	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
STAD	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-10.58	7.69e-23	6.65e-19	-0.59	-0.49	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
STAD	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	10.58	7.7e-23	6.66e-19	0.62	0.49	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	10.58	7.7e-23	6.66e-19	0.62	0.49	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
STAD	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	10.58	7.74e-23	6.69e-19	0.65	0.49	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
STAD	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	10.57	7.91e-23	6.83e-19	0.65	0.49	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
STAD	cis	rs9457247	0.935	rs2149093	ENSG00000265828.1	MIR3939	10.57	7.94e-23	6.86e-19	0.59	0.49	Crohn's disease;	chr6:166959557	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs404222	ENSG00000265828.1	MIR3939	-10.57	8.37e-23	7.21e-19	-0.59	-0.49	Crohn's disease;	chr6:166988662	chr6:166997807~166997912:-
STAD	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	10.57	8.41e-23	7.24e-19	0.65	0.49	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
STAD	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	10.57	8.45e-23	7.28e-19	0.57	0.49	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
STAD	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-10.56	8.57e-23	7.38e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
STAD	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	10.56	8.63e-23	7.42e-19	0.61	0.49	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
STAD	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-10.56	8.66e-23	7.45e-19	-0.59	-0.49	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
STAD	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	10.55	9.32e-23	8.01e-19	0.65	0.49	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
STAD	cis	rs9457247	1	rs2013815	ENSG00000265828.1	MIR3939	10.55	9.41e-23	8.07e-19	0.57	0.49	Crohn's disease;	chr6:166960324	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs4710147	ENSG00000265828.1	MIR3939	10.55	9.41e-23	8.07e-19	0.57	0.49	Crohn's disease;	chr6:166960751	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.935	rs2757046	ENSG00000265828.1	MIR3939	10.55	9.41e-23	8.07e-19	0.57	0.49	Crohn's disease;	chr6:166960865	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs2757047	ENSG00000265828.1	MIR3939	10.55	9.41e-23	8.07e-19	0.57	0.49	Crohn's disease;	chr6:166961001	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs389946	ENSG00000265828.1	MIR3939	-10.55	9.58e-23	8.22e-19	-0.57	-0.49	Crohn's disease;	chr6:166993780	chr6:166997807~166997912:-
STAD	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-10.55	9.62e-23	8.25e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
STAD	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	10.54	1.01e-22	8.66e-19	0.62	0.49	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
STAD	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-10.54	1.03e-22	8.77e-19	-0.59	-0.49	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
STAD	cis	rs9457247	0.967	rs385460	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166990400	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs385113	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166990483	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs932644	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166990699	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs10946198	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166990944	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs10946199	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166991004	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs1794694	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166991263	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs430293	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166991470	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs430097	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166991585	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs409356	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166991738	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs447042	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166991947	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs402191	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166992065	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs1794693	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166992182	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.935	rs401260	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166992400	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs422694	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166992586	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs422780	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166992721	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs400176	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166992750	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs415842	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166993193	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs389956	ENSG00000265828.1	MIR3939	-10.54	1.03e-22	8.77e-19	-0.57	-0.49	Crohn's disease;	chr6:166993766	chr6:166997807~166997912:-
STAD	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-10.54	1.06e-22	9.03e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
STAD	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-10.54	1.08e-22	9.16e-19	-0.61	-0.49	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
STAD	cis	rs9457247	1	rs1819333	ENSG00000265828.1	MIR3939	-10.53	1.08e-22	9.19e-19	-0.57	-0.49	Crohn's disease;	chr6:166960059	chr6:166997807~166997912:-
STAD	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	10.53	1.09e-22	9.23e-19	0.53	0.49	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
STAD	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-10.53	1.09e-22	9.26e-19	-0.58	-0.49	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
STAD	cis	rs9457247	0.902	rs366938	ENSG00000265828.1	MIR3939	-10.53	1.11e-22	9.46e-19	-0.56	-0.49	Crohn's disease;	chr6:166990050	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.871	rs1811121	ENSG00000265828.1	MIR3939	-10.53	1.11e-22	9.46e-19	-0.56	-0.49	Crohn's disease;	chr6:166990051	chr6:166997807~166997912:-
STAD	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-10.53	1.12e-22	9.52e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
STAD	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-10.53	1.13e-22	9.59e-19	-0.64	-0.49	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
STAD	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-10.53	1.13e-22	9.59e-19	-0.64	-0.49	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
STAD	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-10.53	1.14e-22	9.65e-19	-0.59	-0.49	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
STAD	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-10.53	1.14e-22	9.65e-19	-0.58	-0.49	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-10.53	1.14e-22	9.65e-19	-0.58	-0.49	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
STAD	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-10.53	1.16e-22	9.82e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
STAD	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-10.53	1.17e-22	9.88e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
STAD	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-10.52	1.17e-22	9.93e-19	-0.62	-0.49	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	10.52	1.18e-22	9.96e-19	0.64	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
STAD	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	10.52	1.18e-22	9.98e-19	0.53	0.49	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
STAD	cis	rs9457247	1	rs364451	ENSG00000265828.1	MIR3939	-10.52	1.18e-22	9.99e-19	-0.59	-0.49	Crohn's disease;	chr6:166971268	chr6:166997807~166997912:-
STAD	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-10.52	1.19e-22	1e-18	-0.59	-0.49	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
STAD	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	10.52	1.21e-22	1.02e-18	0.53	0.49	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
STAD	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-10.52	1.22e-22	1.03e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-10.52	1.22e-22	1.03e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
STAD	cis	rs9457247	1	rs421214	ENSG00000265828.1	MIR3939	-10.52	1.24e-22	1.05e-18	-0.57	-0.49	Crohn's disease;	chr6:166983141	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-10.52	1.24e-22	1.05e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
STAD	cis	rs9457247	1	rs422094	ENSG00000265828.1	MIR3939	-10.52	1.24e-22	1.05e-18	-0.57	-0.49	Crohn's disease;	chr6:166983545	chr6:166997807~166997912:-
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	10.51	1.29e-22	1.08e-18	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
STAD	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	10.51	1.29e-22	1.09e-18	0.53	0.49	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
STAD	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	10.51	1.29e-22	1.09e-18	0.53	0.49	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
STAD	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	10.51	1.29e-22	1.09e-18	0.53	0.49	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
STAD	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	10.51	1.29e-22	1.09e-18	0.53	0.49	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	10.51	1.29e-22	1.09e-18	0.53	0.49	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
STAD	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	10.51	1.29e-22	1.09e-18	0.53	0.49	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	10.51	1.3e-22	1.09e-18	0.53	0.49	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
STAD	cis	rs9457247	1	rs2769352	ENSG00000265828.1	MIR3939	10.51	1.33e-22	1.12e-18	0.59	0.49	Crohn's disease;	chr6:166965131	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs2149083	ENSG00000265828.1	MIR3939	10.51	1.36e-22	1.14e-18	0.57	0.49	Crohn's disease;	chr6:166957483	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs2149084	ENSG00000265828.1	MIR3939	10.51	1.36e-22	1.14e-18	0.57	0.49	Crohn's disease;	chr6:166957500	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs2769346	ENSG00000265828.1	MIR3939	10.51	1.36e-22	1.14e-18	0.57	0.49	Crohn's disease;	chr6:166957511	chr6:166997807~166997912:-
STAD	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	10.51	1.37e-22	1.15e-18	0.65	0.49	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
STAD	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-10.5	1.37e-22	1.15e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
STAD	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-10.5	1.37e-22	1.15e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
STAD	cis	rs9457247	1	rs2149085	ENSG00000265828.1	MIR3939	10.5	1.37e-22	1.15e-18	0.57	0.49	Crohn's disease;	chr6:166957622	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs2015864	ENSG00000265828.1	MIR3939	10.5	1.37e-22	1.15e-18	0.57	0.49	Crohn's disease;	chr6:166967988	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs1211447	ENSG00000265828.1	MIR3939	-10.5	1.37e-22	1.15e-18	-0.57	-0.49	Crohn's disease;	chr6:166968491	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs1187532	ENSG00000265828.1	MIR3939	-10.5	1.37e-22	1.15e-18	-0.57	-0.49	Crohn's disease;	chr6:166968532	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs448060	ENSG00000265828.1	MIR3939	-10.5	1.37e-22	1.15e-18	-0.57	-0.49	Crohn's disease;	chr6:166969134	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs364283	ENSG00000265828.1	MIR3939	-10.5	1.37e-22	1.15e-18	-0.57	-0.49	Crohn's disease;	chr6:166970262	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs429083	ENSG00000265828.1	MIR3939	-10.5	1.37e-22	1.15e-18	-0.57	-0.49	Crohn's disease;	chr6:166970484	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs365189	ENSG00000265828.1	MIR3939	-10.5	1.37e-22	1.15e-18	-0.57	-0.49	Crohn's disease;	chr6:166971057	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs376551	ENSG00000265828.1	MIR3939	-10.5	1.37e-22	1.15e-18	-0.57	-0.49	Crohn's disease;	chr6:166971435	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.935	rs9348211	ENSG00000265828.1	MIR3939	10.5	1.38e-22	1.15e-18	0.59	0.49	Crohn's disease;	chr6:166961685	chr6:166997807~166997912:-
STAD	cis	rs6920364	1	rs6920364	ENSG00000265828.1	MIR3939	10.5	1.38e-22	1.15e-18	0.59	0.49	Lung cancer;	chr6:166962978	chr6:166997807~166997912:-
STAD	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-10.5	1.4e-22	1.17e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
STAD	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-10.5	1.4e-22	1.17e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
STAD	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	10.5	1.4e-22	1.17e-18	0.57	0.49	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
STAD	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-10.5	1.42e-22	1.19e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	10.5	1.43e-22	1.2e-18	0.53	0.49	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	10.5	1.43e-22	1.2e-18	0.53	0.49	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
STAD	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-10.5	1.46e-22	1.22e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
STAD	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-10.5	1.47e-22	1.23e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
STAD	cis	rs9457247	0.967	rs1590257	ENSG00000265828.1	MIR3939	10.49	1.49e-22	1.24e-18	0.57	0.49	Crohn's disease;	chr6:166964294	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs2769354	ENSG00000265828.1	MIR3939	10.49	1.49e-22	1.24e-18	0.57	0.49	Crohn's disease;	chr6:166966283	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.846	rs2757052	ENSG00000265828.1	MIR3939	10.49	1.49e-22	1.24e-18	0.57	0.49	Crohn's disease;	chr6:166966686	chr6:166997807~166997912:-
STAD	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-10.49	1.49e-22	1.25e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
STAD	cis	rs9457247	0.935	rs1187530	ENSG00000265828.1	MIR3939	10.49	1.52e-22	1.26e-18	0.57	0.49	Crohn's disease;	chr6:166963324	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.935	rs2757050	ENSG00000265828.1	MIR3939	10.49	1.52e-22	1.26e-18	0.57	0.49	Crohn's disease;	chr6:166963677	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs393558	ENSG00000265828.1	MIR3939	-10.49	1.57e-22	1.3e-18	-0.56	-0.49	Crohn's disease;	chr6:166984262	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs394522	ENSG00000265828.1	MIR3939	-10.49	1.57e-22	1.3e-18	-0.56	-0.49	Crohn's disease;	chr6:166984583	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs393727	ENSG00000265828.1	MIR3939	-10.49	1.57e-22	1.3e-18	-0.56	-0.49	Crohn's disease;	chr6:166985144	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs408040	ENSG00000265828.1	MIR3939	-10.49	1.57e-22	1.3e-18	-0.56	-0.49	Crohn's disease;	chr6:166985415	chr6:166997807~166997912:-
STAD	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	10.49	1.57e-22	1.3e-18	0.53	0.49	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
STAD	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-10.49	1.57e-22	1.31e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
STAD	cis	rs9457247	0.935	rs1044059	ENSG00000265828.1	MIR3939	10.49	1.58e-22	1.32e-18	0.57	0.49	Crohn's disease;	chr6:166956409	chr6:166997807~166997912:-
STAD	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-10.49	1.59e-22	1.32e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
STAD	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-10.49	1.59e-22	1.32e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
STAD	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	10.49	1.6e-22	1.33e-18	0.59	0.49	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
STAD	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-10.49	1.6e-22	1.33e-18	-0.6	-0.49	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
STAD	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-10.49	1.61e-22	1.33e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
STAD	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	10.48	1.64e-22	1.36e-18	0.79	0.49	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	10.48	1.64e-22	1.36e-18	0.79	0.49	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
STAD	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-10.48	1.64e-22	1.36e-18	-0.54	-0.49	Breast cancer;	chr11:825777	chr11:779617~780755:+
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-10.48	1.64e-22	1.36e-18	-0.6	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
STAD	cis	rs9457247	0.967	rs2769355	ENSG00000265828.1	MIR3939	10.48	1.65e-22	1.36e-18	0.57	0.49	Crohn's disease;	chr6:166967005	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs2757054	ENSG00000265828.1	MIR3939	10.48	1.65e-22	1.36e-18	0.57	0.49	Crohn's disease;	chr6:166967013	chr6:166997807~166997912:-
STAD	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-10.48	1.66e-22	1.37e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-10.48	1.66e-22	1.37e-18	-0.57	-0.49	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
STAD	cis	rs9457247	1	rs413232	ENSG00000265828.1	MIR3939	-10.48	1.66e-22	1.37e-18	-0.56	-0.49	Crohn's disease;	chr6:166987484	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs86755	ENSG00000265828.1	MIR3939	-10.48	1.66e-22	1.37e-18	-0.56	-0.49	Crohn's disease;	chr6:166989620	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs382009	ENSG00000265828.1	MIR3939	-10.48	1.66e-22	1.37e-18	-0.56	-0.49	Crohn's disease;	chr6:166989633	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs428805	ENSG00000265828.1	MIR3939	-10.48	1.66e-22	1.37e-18	-0.56	-0.49	Crohn's disease;	chr6:166989644	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.934	rs2345571	ENSG00000265828.1	MIR3939	-10.48	1.66e-22	1.37e-18	-0.56	-0.49	Crohn's disease;	chr6:166989912	chr6:166997807~166997912:-
STAD	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-10.48	1.67e-22	1.38e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-10.48	1.67e-22	1.38e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
STAD	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	10.48	1.68e-22	1.38e-18	0.53	0.49	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
STAD	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	10.48	1.68e-22	1.38e-18	0.66	0.49	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
STAD	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-10.48	1.7e-22	1.4e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-10.48	1.7e-22	1.4e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-10.48	1.7e-22	1.4e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-10.48	1.7e-22	1.4e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	10.47	1.76e-22	1.45e-18	0.57	0.49	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
STAD	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	10.47	1.76e-22	1.45e-18	0.53	0.49	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
STAD	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-10.47	1.79e-22	1.47e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-10.47	1.79e-22	1.47e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
STAD	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-10.47	1.82e-22	1.5e-18	-0.59	-0.49	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
STAD	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	10.47	1.84e-22	1.51e-18	0.53	0.49	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
STAD	cis	rs9457247	1	rs239935	ENSG00000265828.1	MIR3939	-10.47	1.87e-22	1.53e-18	-0.58	-0.49	Crohn's disease;	chr6:166998300	chr6:166997807~166997912:-
STAD	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-10.47	1.89e-22	1.55e-18	-0.61	-0.49	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
STAD	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	10.46	1.91e-22	1.57e-18	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
STAD	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	10.46	1.92e-22	1.58e-18	0.53	0.49	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
STAD	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-10.46	1.95e-22	1.6e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
STAD	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-10.46	1.95e-22	1.6e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
STAD	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-10.46	1.95e-22	1.6e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
STAD	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-10.46	1.95e-22	1.6e-18	-0.62	-0.49	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
STAD	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	10.46	1.96e-22	1.61e-18	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
STAD	cis	rs9457247	1	rs408087	ENSG00000265828.1	MIR3939	-10.46	1.97e-22	1.61e-18	-0.56	-0.49	Crohn's disease;	chr6:166985464	chr6:166997807~166997912:-
STAD	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-10.46	2e-22	1.64e-18	-0.6	-0.49	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
STAD	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-10.46	2e-22	1.64e-18	-0.6	-0.49	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
STAD	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-10.46	2e-22	1.64e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-10.46	2.04e-22	1.67e-18	-0.53	-0.49	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-10.46	2.04e-22	1.67e-18	-0.53	-0.49	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-10.46	2.04e-22	1.67e-18	-0.53	-0.49	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-10.46	2.04e-22	1.67e-18	-0.53	-0.49	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-10.46	2.04e-22	1.67e-18	-0.53	-0.49	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-10.46	2.04e-22	1.67e-18	-0.53	-0.49	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
STAD	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-10.45	2.12e-22	1.72e-18	-0.52	-0.49	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
STAD	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
STAD	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	10.45	2.12e-22	1.72e-18	0.52	0.49	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
STAD	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-10.45	2.12e-22	1.72e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-10.45	2.13e-22	1.73e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-10.45	2.14e-22	1.74e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
STAD	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-10.45	2.16e-22	1.75e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
STAD	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-10.45	2.16e-22	1.75e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-10.45	2.2e-22	1.79e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
STAD	cis	rs9457247	0.756	rs2345572	ENSG00000265828.1	MIR3939	-10.44	2.22e-22	1.8e-18	-0.58	-0.49	Crohn's disease;	chr6:166989953	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.663	rs6456143	ENSG00000265828.1	MIR3939	-10.44	2.32e-22	1.87e-18	-0.53	-0.49	Crohn's disease;	chr6:167001952	chr6:166997807~166997912:-
STAD	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-10.44	2.35e-22	1.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
STAD	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	10.44	2.35e-22	1.9e-18	0.52	0.49	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	10.44	2.35e-22	1.9e-18	0.52	0.49	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	10.44	2.35e-22	1.9e-18	0.52	0.49	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
STAD	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	10.44	2.35e-22	1.9e-18	0.52	0.49	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	10.44	2.35e-22	1.9e-18	0.52	0.49	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	10.44	2.35e-22	1.9e-18	0.52	0.49	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
STAD	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-10.44	2.35e-22	1.9e-18	-0.65	-0.49	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
STAD	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	10.43	2.45e-22	1.98e-18	0.59	0.49	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
STAD	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-10.43	2.51e-22	2.03e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
STAD	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-10.43	2.54e-22	2.05e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
STAD	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	10.42	2.77e-22	2.23e-18	0.55	0.49	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-10.41	2.82e-22	2.26e-18	-0.63	-0.49	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
STAD	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-10.41	2.93e-22	2.35e-18	-0.59	-0.49	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
STAD	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-10.41	2.95e-22	2.36e-18	-0.61	-0.49	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
STAD	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	10.41	2.97e-22	2.37e-18	0.52	0.49	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
STAD	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-10.4	3.06e-22	2.44e-18	-0.59	-0.49	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
STAD	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-10.4	3.06e-22	2.44e-18	-0.59	-0.49	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
STAD	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-10.4	3.09e-22	2.47e-18	-0.59	-0.49	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
STAD	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-10.4	3.09e-22	2.47e-18	-0.59	-0.49	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
STAD	cis	rs9457247	1	rs408918	ENSG00000265828.1	MIR3939	-10.4	3.19e-22	2.54e-18	-0.56	-0.49	Crohn's disease;	chr6:166985794	chr6:166997807~166997912:-
STAD	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-10.4	3.2e-22	2.55e-18	-0.59	-0.49	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
STAD	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-10.4	3.2e-22	2.55e-18	-0.59	-0.49	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
STAD	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-10.4	3.2e-22	2.55e-18	-0.59	-0.49	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
STAD	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-10.4	3.2e-22	2.55e-18	-0.59	-0.49	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
STAD	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-10.4	3.2e-22	2.55e-18	-0.59	-0.49	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-10.4	3.2e-22	2.55e-18	-0.59	-0.49	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
STAD	cis	rs9457247	1	rs407515	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166994056	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs406095	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166995599	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.646	rs4710160	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166995753	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs430145	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166996881	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs425039	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166997039	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs376097	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166997390	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs424185	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166997419	chr6:166997807~166997912:-
STAD	cis	rs9457247	1	rs400837	ENSG00000265828.1	MIR3939	-10.4	3.2e-22	2.55e-18	-0.56	-0.49	Crohn's disease;	chr6:166997520	chr6:166997807~166997912:-
STAD	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-10.4	3.25e-22	2.58e-18	-0.54	-0.49	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
STAD	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	10.4	3.28e-22	2.61e-18	0.52	0.49	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
STAD	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-10.39	3.33e-22	2.64e-18	-0.54	-0.49	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-10.39	3.33e-22	2.64e-18	-0.54	-0.49	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
STAD	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-10.39	3.33e-22	2.64e-18	-0.65	-0.49	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
STAD	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	10.39	3.36e-22	2.66e-18	0.45	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
STAD	cis	rs9457247	0.967	rs388406	ENSG00000265828.1	MIR3939	-10.39	3.37e-22	2.67e-18	-0.56	-0.49	Crohn's disease;	chr6:166996074	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs433191	ENSG00000265828.1	MIR3939	-10.39	3.37e-22	2.67e-18	-0.56	-0.49	Crohn's disease;	chr6:166996174	chr6:166997807~166997912:-
STAD	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-10.39	3.39e-22	2.69e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-10.39	3.47e-22	2.75e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
STAD	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-10.39	3.47e-22	2.75e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
STAD	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-10.39	3.51e-22	2.78e-18	-0.62	-0.49	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	10.38	3.6e-22	2.84e-18	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
STAD	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-10.38	3.69e-22	2.9e-18	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
STAD	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-10.38	3.82e-22	3e-18	-0.8	-0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
STAD	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-10.38	3.84e-22	3.01e-18	-0.52	-0.49	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-10.37	3.96e-22	3.11e-18	-0.54	-0.49	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
STAD	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	10.37	4.03e-22	3.16e-18	0.55	0.49	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
STAD	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-10.37	4.06e-22	3.18e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-10.37	4.06e-22	3.18e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-10.37	4.06e-22	3.18e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-10.37	4.06e-22	3.18e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
STAD	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-10.37	4.06e-22	3.18e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-10.37	4.06e-22	3.18e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-10.37	4.06e-22	3.18e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
STAD	cis	rs9457247	0.756	rs1811123	ENSG00000265828.1	MIR3939	-10.37	4.08e-22	3.2e-18	-0.56	-0.49	Crohn's disease;	chr6:166989955	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.663	rs9459835	ENSG00000265828.1	MIR3939	-10.37	4.2e-22	3.28e-18	-0.53	-0.49	Crohn's disease;	chr6:167004063	chr6:166997807~166997912:-
STAD	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-10.37	4.2e-22	3.29e-18	-0.58	-0.49	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
STAD	cis	rs9457247	0.905	rs377232	ENSG00000265828.1	MIR3939	-10.36	4.22e-22	3.3e-18	-0.55	-0.49	Crohn's disease;	chr6:166996150	chr6:166997807~166997912:-
STAD	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-10.36	4.24e-22	3.31e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-10.36	4.26e-22	3.33e-18	-0.58	-0.49	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	10.36	4.27e-22	3.33e-18	0.52	0.49	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	10.36	4.27e-22	3.33e-18	0.52	0.49	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
STAD	cis	rs9457247	0.646	rs239934	ENSG00000265828.1	MIR3939	-10.36	4.33e-22	3.38e-18	-0.58	-0.49	Crohn's disease;	chr6:166998560	chr6:166997807~166997912:-
STAD	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	10.36	4.38e-22	3.42e-18	0.78	0.49	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	10.36	4.38e-22	3.42e-18	0.78	0.49	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	10.36	4.38e-22	3.42e-18	0.78	0.49	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
STAD	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	10.36	4.47e-22	3.48e-18	0.57	0.49	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
STAD	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-10.35	4.64e-22	3.62e-18	-0.62	-0.49	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
STAD	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	10.35	4.65e-22	3.62e-18	0.78	0.49	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	10.35	4.65e-22	3.62e-18	0.78	0.49	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
STAD	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	10.35	4.65e-22	3.62e-18	0.78	0.49	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
STAD	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	10.35	4.83e-22	3.76e-18	0.55	0.49	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
STAD	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-10.35	4.87e-22	3.78e-18	-0.59	-0.49	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
STAD	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	10.35	4.87e-22	3.78e-18	0.65	0.49	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
STAD	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	10.35	4.9e-22	3.81e-18	0.52	0.49	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
STAD	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-10.35	4.91e-22	3.81e-18	-0.52	-0.49	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
STAD	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	10.35	4.93e-22	3.82e-18	0.6	0.49	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
STAD	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-10.35	4.93e-22	3.83e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	10.34	4.95e-22	3.83e-18	0.52	0.49	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	10.34	4.95e-22	3.83e-18	0.52	0.49	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	10.34	4.95e-22	3.83e-18	0.52	0.49	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	10.34	4.95e-22	3.83e-18	0.52	0.49	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
STAD	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	10.34	4.95e-22	3.83e-18	0.52	0.49	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
STAD	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	10.34	4.95e-22	3.83e-18	0.52	0.49	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	10.34	4.95e-22	3.83e-18	0.52	0.49	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
STAD	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	10.34	5.04e-22	3.9e-18	0.45	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
STAD	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-10.34	5.06e-22	3.91e-18	-0.52	-0.49	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
STAD	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	10.34	5.17e-22	4e-18	0.44	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
STAD	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-10.34	5.33e-22	4.12e-18	-0.59	-0.49	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
STAD	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	10.34	5.34e-22	4.13e-18	0.44	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
STAD	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	10.33	5.49e-22	4.24e-18	0.57	0.49	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
STAD	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-10.33	5.51e-22	4.25e-18	-0.55	-0.49	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
STAD	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-10.33	5.61e-22	4.33e-18	-0.59	-0.49	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
STAD	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-10.33	5.69e-22	4.39e-18	-0.54	-0.49	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
STAD	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-10.33	5.73e-22	4.42e-18	-0.53	-0.49	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
STAD	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	10.33	5.74e-22	4.42e-18	0.52	0.49	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	10.33	5.74e-22	4.42e-18	0.52	0.49	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	10.33	5.74e-22	4.42e-18	0.52	0.49	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	10.33	5.74e-22	4.42e-18	0.52	0.49	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	10.33	5.74e-22	4.42e-18	0.52	0.49	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	10.33	5.74e-22	4.42e-18	0.52	0.49	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
STAD	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-10.32	5.79e-22	4.46e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-10.32	5.94e-22	4.55e-18	-0.51	-0.49	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
STAD	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-10.32	6.03e-22	4.61e-18	-0.58	-0.49	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
STAD	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-10.32	6.03e-22	4.61e-18	-0.58	-0.49	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-10.32	6.03e-22	4.61e-18	-0.58	-0.49	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
STAD	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-10.32	6.07e-22	4.64e-18	-0.61	-0.49	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-10.32	6.11e-22	4.67e-18	-0.5	-0.49	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
STAD	cis	rs9457247	1	rs2757042	ENSG00000265828.1	MIR3939	10.32	6.16e-22	4.7e-18	0.58	0.49	Crohn's disease;	chr6:166957746	chr6:166997807~166997912:-
STAD	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-10.32	6.18e-22	4.72e-18	-0.81	-0.49	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
STAD	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	10.32	6.19e-22	4.72e-18	0.57	0.49	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
STAD	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-10.31	6.28e-22	4.79e-18	-0.62	-0.48	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
STAD	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-10.31	6.45e-22	4.92e-18	-0.54	-0.48	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
STAD	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	10.31	6.6e-22	5.02e-18	0.65	0.48	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
STAD	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-10.31	6.67e-22	5.08e-18	-0.55	-0.48	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
STAD	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-10.3	7.28e-22	5.53e-18	-0.84	-0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
STAD	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-10.29	7.42e-22	5.63e-18	-0.52	-0.48	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
STAD	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-10.29	7.42e-22	5.63e-18	-0.52	-0.48	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-10.29	7.42e-22	5.63e-18	-0.52	-0.48	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
STAD	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	10.29	7.69e-22	5.84e-18	0.6	0.48	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
STAD	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	10.29	7.78e-22	5.9e-18	0.65	0.48	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	10.29	7.78e-22	5.9e-18	0.65	0.48	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
STAD	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-10.29	7.81e-22	5.92e-18	-0.62	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
STAD	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-10.29	7.82e-22	5.93e-18	-0.57	-0.48	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
STAD	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-10.29	7.94e-22	6.01e-18	-0.55	-0.48	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
STAD	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	10.29	7.96e-22	6.03e-18	0.63	0.48	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
STAD	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-10.28	7.98e-22	6.05e-18	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
STAD	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-10.28	7.99e-22	6.05e-18	-0.6	-0.48	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
STAD	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	10.28	8.04e-22	6.08e-18	0.59	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
STAD	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-10.28	8.14e-22	6.15e-18	-0.63	-0.48	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
STAD	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-10.28	8.24e-22	6.22e-18	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
STAD	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-10.28	8.37e-22	6.31e-18	-0.55	-0.48	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
STAD	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	10.28	8.42e-22	6.35e-18	0.65	0.48	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
STAD	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-10.28	8.42e-22	6.35e-18	-0.6	-0.48	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
STAD	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	10.27	8.63e-22	6.5e-18	0.53	0.48	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
STAD	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-10.27	8.63e-22	6.5e-18	-0.59	-0.48	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
STAD	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	10.27	8.73e-22	6.57e-18	0.5	0.48	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.663	rs10946205	ENSG00000265828.1	MIR3939	-10.27	8.91e-22	6.71e-18	-0.52	-0.48	Crohn's disease;	chr6:167037823	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.967	rs387733	ENSG00000265828.1	MIR3939	10.27	9.15e-22	6.88e-18	0.55	0.48	Crohn's disease;	chr6:166996283	chr6:166997807~166997912:-
STAD	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	10.27	9.24e-22	6.95e-18	0.64	0.48	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
STAD	cis	rs9457247	0.663	rs9457258	ENSG00000265828.1	MIR3939	-10.27	9.25e-22	6.96e-18	-0.52	-0.48	Crohn's disease;	chr6:167030766	chr6:166997807~166997912:-
STAD	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	10.27	9.3e-22	7e-18	0.59	0.48	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
STAD	cis	rs9457247	0.663	rs2282861	ENSG00000265828.1	MIR3939	-10.26	9.51e-22	7.14e-18	-0.52	-0.48	Crohn's disease;	chr6:167026640	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.663	rs2282860	ENSG00000265828.1	MIR3939	-10.26	9.51e-22	7.14e-18	-0.52	-0.48	Crohn's disease;	chr6:167026756	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.579	rs2181059	ENSG00000265828.1	MIR3939	-10.26	9.51e-22	7.14e-18	-0.52	-0.48	Crohn's disease;	chr6:167028136	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	10.26	9.54e-22	7.17e-18	0.5	0.48	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	10.26	9.6e-22	7.21e-18	0.62	0.48	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	10.26	9.6e-22	7.21e-18	0.62	0.48	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
STAD	cis	rs9457247	0.663	rs2237277	ENSG00000265828.1	MIR3939	-10.26	9.77e-22	7.34e-18	-0.52	-0.48	Crohn's disease;	chr6:167028619	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	10.26	9.94e-22	7.46e-18	0.5	0.48	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-10.26	9.94e-22	7.46e-18	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-10.26	9.94e-22	7.46e-18	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
STAD	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	10.26	1e-21	7.5e-18	0.5	0.48	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
STAD	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	10.25	1.01e-21	7.58e-18	0.52	0.48	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
STAD	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-10.25	1.02e-21	7.65e-18	-0.56	-0.48	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
STAD	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	10.25	1.03e-21	7.68e-18	0.6	0.48	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
STAD	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	10.25	1.04e-21	7.82e-18	0.5	0.48	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-10.25	1.05e-21	7.88e-18	-0.54	-0.48	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
STAD	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-10.25	1.06e-21	7.9e-18	-0.61	-0.48	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	10.25	1.06e-21	7.95e-18	0.5	0.48	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-10.25	1.07e-21	8.02e-18	-0.58	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
STAD	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	10.25	1.08e-21	8.08e-18	0.5	0.48	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-10.24	1.1e-21	8.22e-18	-0.64	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
STAD	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-10.24	1.12e-21	8.34e-18	-0.59	-0.48	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
STAD	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	10.24	1.12e-21	8.4e-18	0.55	0.48	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
STAD	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-10.23	1.19e-21	8.84e-18	-0.61	-0.48	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-10.23	1.2e-21	8.94e-18	-0.52	-0.48	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	10.23	1.23e-21	9.15e-18	0.5	0.48	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
STAD	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	10.23	1.23e-21	9.15e-18	0.5	0.48	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	10.23	1.23e-21	9.15e-18	0.5	0.48	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	10.23	1.23e-21	9.15e-18	0.5	0.48	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
STAD	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	10.23	1.23e-21	9.18e-18	0.58	0.48	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
STAD	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-10.23	1.26e-21	9.36e-18	-0.56	-0.48	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-10.23	1.26e-21	9.36e-18	-0.56	-0.48	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
STAD	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	10.23	1.26e-21	9.38e-18	0.65	0.48	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
STAD	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-10.23	1.26e-21	9.38e-18	-0.56	-0.48	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
STAD	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-10.23	1.27e-21	9.45e-18	-0.52	-0.48	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
STAD	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-10.22	1.29e-21	9.58e-18	-0.6	-0.48	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
STAD	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-10.22	1.29e-21	9.6e-18	-0.54	-0.48	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
STAD	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	10.22	1.31e-21	9.74e-18	0.52	0.48	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	10.22	1.31e-21	9.74e-18	0.52	0.48	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
STAD	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	10.22	1.32e-21	9.81e-18	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
STAD	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	10.22	1.33e-21	9.87e-18	0.5	0.48	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
STAD	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-10.21	1.4e-21	1.03e-17	-0.78	-0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
STAD	cis	rs9457247	0.765	rs1060404	ENSG00000265828.1	MIR3939	-10.21	1.45e-21	1.07e-17	-0.55	-0.48	Crohn's disease;	chr6:167015979	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.765	rs9457252	ENSG00000265828.1	MIR3939	10.2	1.51e-21	1.11e-17	0.55	0.48	Crohn's disease;	chr6:167020437	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-10.2	1.54e-21	1.14e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-10.2	1.54e-21	1.14e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-10.2	1.54e-21	1.14e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	10.2	1.57e-21	1.16e-17	0.49	0.48	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	10.2	1.57e-21	1.16e-17	0.49	0.48	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
STAD	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-10.2	1.58e-21	1.16e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
STAD	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-10.2	1.61e-21	1.19e-17	-0.61	-0.48	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
STAD	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-10.19	1.65e-21	1.22e-17	-0.57	-0.48	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
STAD	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	10.19	1.66e-21	1.22e-17	0.5	0.48	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
STAD	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-10.19	1.69e-21	1.24e-17	-0.59	-0.48	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
STAD	cis	rs9457247	0.765	rs4710171	ENSG00000265828.1	MIR3939	-10.19	1.72e-21	1.27e-17	-0.55	-0.48	Crohn's disease;	chr6:167016698	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-10.19	1.73e-21	1.27e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-10.19	1.73e-21	1.27e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	10.18	1.78e-21	1.31e-17	0.48	0.48	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-10.18	1.78e-21	1.31e-17	-0.54	-0.48	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
STAD	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-10.18	1.79e-21	1.31e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-10.18	1.79e-21	1.31e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-10.18	1.79e-21	1.31e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-10.18	1.79e-21	1.31e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	10.18	1.8e-21	1.32e-17	0.51	0.48	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
STAD	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-10.18	1.81e-21	1.32e-17	-0.6	-0.48	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
STAD	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-10.18	1.86e-21	1.36e-17	-0.61	-0.48	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
STAD	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	10.18	1.89e-21	1.39e-17	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
STAD	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	10.17	1.94e-21	1.42e-17	0.64	0.48	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
STAD	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-10.17	1.95e-21	1.42e-17	-0.6	-0.48	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
STAD	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-10.17	1.97e-21	1.44e-17	-0.6	-0.48	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
STAD	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-10.17	1.97e-21	1.44e-17	-0.6	-0.48	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
STAD	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-10.17	1.98e-21	1.45e-17	-0.54	-0.48	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
STAD	cis	rs9457247	0.765	rs12212247	ENSG00000265828.1	MIR3939	-10.17	2.04e-21	1.49e-17	-0.55	-0.48	Crohn's disease;	chr6:167000051	chr6:166997807~166997912:-
STAD	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-10.16	2.07e-21	1.51e-17	-0.58	-0.48	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
STAD	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-10.16	2.07e-21	1.51e-17	-0.58	-0.48	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
STAD	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	10.16	2.07e-21	1.51e-17	0.58	0.48	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
STAD	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-10.16	2.11e-21	1.53e-17	-0.58	-0.48	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
STAD	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	10.16	2.17e-21	1.58e-17	0.58	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
STAD	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-10.15	2.25e-21	1.63e-17	-0.6	-0.48	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
STAD	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-10.15	2.33e-21	1.69e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-10.15	2.33e-21	1.69e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
STAD	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-10.15	2.35e-21	1.7e-17	-0.64	-0.48	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
STAD	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	10.15	2.36e-21	1.71e-17	0.76	0.48	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
STAD	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-10.14	2.43e-21	1.76e-17	-0.49	-0.48	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
STAD	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-10.14	2.45e-21	1.78e-17	-0.6	-0.48	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
STAD	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-10.14	2.49e-21	1.8e-17	-0.63	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
STAD	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-10.14	2.55e-21	1.84e-17	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
STAD	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	10.14	2.57e-21	1.86e-17	0.5	0.48	Height;	chr11:118703185	chr11:118688039~118690600:-
STAD	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	10.14	2.57e-21	1.86e-17	0.5	0.48	Height;	chr11:118703207	chr11:118688039~118690600:-
STAD	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	10.14	2.57e-21	1.86e-17	0.5	0.48	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
STAD	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	10.14	2.57e-21	1.86e-17	0.5	0.48	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
STAD	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-10.13	2.62e-21	1.89e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-10.13	2.62e-21	1.89e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-10.13	2.62e-21	1.89e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-10.13	2.62e-21	1.89e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-10.13	2.62e-21	1.89e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
STAD	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	10.13	2.67e-21	1.92e-17	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
STAD	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	10.13	2.67e-21	1.92e-17	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
STAD	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	10.13	2.68e-21	1.93e-17	0.56	0.48	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
STAD	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	10.13	2.72e-21	1.96e-17	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
STAD	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-10.13	2.73e-21	1.96e-17	-0.57	-0.48	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
STAD	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-10.13	2.81e-21	2.02e-17	-0.58	-0.48	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
STAD	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	10.12	2.9e-21	2.08e-17	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
STAD	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	10.12	3.01e-21	2.16e-17	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
STAD	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-10.11	3.14e-21	2.25e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
STAD	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	10.11	3.19e-21	2.29e-17	0.45	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
STAD	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-10.11	3.22e-21	2.31e-17	-0.5	-0.48	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
STAD	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	10.11	3.25e-21	2.33e-17	0.59	0.48	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
STAD	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-10.11	3.26e-21	2.33e-17	-0.49	-0.48	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-10.11	3.26e-21	2.33e-17	-0.49	-0.48	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-10.11	3.26e-21	2.33e-17	-0.49	-0.48	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-10.11	3.26e-21	2.33e-17	-0.49	-0.48	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
STAD	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-10.11	3.27e-21	2.34e-17	-0.66	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
STAD	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-10.1	3.52e-21	2.52e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
STAD	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	10.09	3.6e-21	2.57e-17	0.49	0.48	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
STAD	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-10.09	3.62e-21	2.58e-17	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
STAD	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-10.09	3.62e-21	2.58e-17	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
STAD	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	10.09	3.65e-21	2.6e-17	0.8	0.48	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
STAD	cis	rs9457247	0.663	rs12526548	ENSG00000265828.1	MIR3939	-10.09	3.69e-21	2.63e-17	-0.53	-0.48	Crohn's disease;	chr6:167017659	chr6:166997807~166997912:-
STAD	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-10.09	3.74e-21	2.66e-17	-0.65	-0.48	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
STAD	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-10.09	3.8e-21	2.7e-17	-0.54	-0.48	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
STAD	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	10.09	3.8e-21	2.71e-17	0.49	0.48	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
STAD	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-10.09	3.82e-21	2.71e-17	-0.58	-0.48	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
STAD	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-10.09	3.82e-21	2.72e-17	-0.57	-0.48	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
STAD	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	10.09	3.86e-21	2.75e-17	0.8	0.48	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
STAD	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	10.08	3.97e-21	2.82e-17	0.54	0.48	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	10.08	4.05e-21	2.87e-17	0.56	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
STAD	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	10.08	4.12e-21	2.91e-17	0.64	0.48	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
STAD	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	10.08	4.18e-21	2.95e-17	0.52	0.48	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
STAD	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	10.07	4.25e-21	3e-17	0.81	0.48	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
STAD	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-10.07	4.26e-21	3.01e-17	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
STAD	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-10.07	4.35e-21	3.07e-17	-0.68	-0.48	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
STAD	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	10.07	4.41e-21	3.11e-17	0.57	0.48	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
STAD	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-10.07	4.43e-21	3.12e-17	-0.66	-0.48	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
STAD	cis	rs16828019	0.704	rs12743340	ENSG00000235358.1	RP11-399E6.1	10.07	4.44e-21	3.13e-17	0.75	0.48	Intelligence (multi-trait analysis);	chr1:40990360	chr1:41242373~41284861:+
STAD	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-10.07	4.47e-21	3.15e-17	-0.64	-0.48	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
STAD	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-10.07	4.49e-21	3.16e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-10.07	4.5e-21	3.17e-17	-0.55	-0.48	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
STAD	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-10.06	4.53e-21	3.19e-17	-0.61	-0.48	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
STAD	cis	rs9457247	0.663	rs1894603	ENSG00000265828.1	MIR3939	10.06	4.57e-21	3.21e-17	0.52	0.48	Crohn's disease;	chr6:167021198	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-10.06	4.59e-21	3.23e-17	-0.51	-0.48	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
STAD	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-10.06	4.6e-21	3.23e-17	-0.54	-0.48	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
STAD	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-10.06	4.64e-21	3.26e-17	-0.59	-0.48	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
STAD	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-10.06	4.64e-21	3.26e-17	-0.59	-0.48	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
STAD	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-10.06	4.68e-21	3.28e-17	-0.49	-0.48	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
STAD	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-10.06	4.68e-21	3.28e-17	-0.49	-0.48	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-10.06	4.72e-21	3.31e-17	-0.53	-0.48	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
STAD	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-10.06	4.76e-21	3.34e-17	-0.6	-0.48	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
STAD	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	10.06	4.85e-21	3.39e-17	0.52	0.48	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-10.06	4.86e-21	3.4e-17	-0.5	-0.48	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
STAD	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	10.06	4.88e-21	3.41e-17	0.46	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
STAD	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	10.05	5e-21	3.49e-17	0.8	0.48	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	10.05	5.02e-21	3.5e-17	0.56	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
STAD	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	10.05	5.02e-21	3.5e-17	0.49	0.48	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	10.05	5.02e-21	3.5e-17	0.49	0.48	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	10.05	5.02e-21	3.5e-17	0.49	0.48	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-10.05	5.17e-21	3.6e-17	-0.48	-0.48	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.765	rs9459836	ENSG00000265828.1	MIR3939	-10.05	5.19e-21	3.61e-17	-0.55	-0.48	Crohn's disease;	chr6:167005617	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.765	rs9459838	ENSG00000265828.1	MIR3939	-10.05	5.19e-21	3.61e-17	-0.55	-0.48	Crohn's disease;	chr6:167013111	chr6:166997807~166997912:-
STAD	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-10.05	5.22e-21	3.63e-17	-0.49	-0.48	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
STAD	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-10.05	5.26e-21	3.66e-17	-0.59	-0.48	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
STAD	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-10.04	5.34e-21	3.71e-17	-0.49	-0.48	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
STAD	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	10.04	5.38e-21	3.74e-17	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
STAD	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-10.04	5.4e-21	3.75e-17	-0.6	-0.48	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
STAD	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	10.04	5.46e-21	3.78e-17	0.49	0.48	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	10.04	5.46e-21	3.78e-17	0.49	0.48	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
STAD	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-10.04	5.46e-21	3.78e-17	-0.66	-0.48	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
STAD	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	10.04	5.47e-21	3.79e-17	0.52	0.48	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	10.04	5.47e-21	3.79e-17	0.52	0.48	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	10.04	5.47e-21	3.79e-17	0.52	0.48	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-10.04	5.65e-21	3.91e-17	-0.49	-0.47	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-10.04	5.65e-21	3.91e-17	-0.49	-0.47	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
STAD	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	10.04	5.7e-21	3.94e-17	0.56	0.47	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
STAD	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-10.03	5.88e-21	4.06e-17	-0.56	-0.47	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-10.03	5.88e-21	4.06e-17	-0.56	-0.47	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
STAD	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-10.03	5.91e-21	4.08e-17	-0.58	-0.47	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	10.03	6.03e-21	4.16e-17	0.61	0.47	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
STAD	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-10.03	6.07e-21	4.18e-17	-0.66	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
STAD	cis	rs9457247	0.811	rs239936	ENSG00000265828.1	MIR3939	-10.03	6.07e-21	4.18e-17	-0.56	-0.47	Crohn's disease;	chr6:166998128	chr6:166997807~166997912:-
STAD	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	10.03	6.08e-21	4.19e-17	0.59	0.47	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
STAD	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	10.02	6.44e-21	4.42e-17	0.57	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
STAD	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	10.02	6.44e-21	4.42e-17	0.48	0.47	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	10.02	6.44e-21	4.42e-17	0.48	0.47	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	10.02	6.44e-21	4.42e-17	0.48	0.47	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	10.02	6.44e-21	4.42e-17	0.48	0.47	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
STAD	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	10.02	6.44e-21	4.42e-17	0.49	0.47	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
STAD	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-10.02	6.47e-21	4.43e-17	-0.59	-0.47	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
STAD	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	10.02	6.47e-21	4.43e-17	0.56	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
STAD	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-10.02	6.48e-21	4.44e-17	-0.48	-0.47	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-10.02	6.56e-21	4.49e-17	-0.49	-0.47	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	10.02	6.56e-21	4.49e-17	0.61	0.47	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
STAD	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-10.02	6.62e-21	4.53e-17	-0.56	-0.47	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
STAD	cis	rs9457247	0.638	rs239933	ENSG00000265828.1	MIR3939	-10.01	6.76e-21	4.62e-17	-0.52	-0.47	Crohn's disease;	chr6:166999742	chr6:166997807~166997912:-
STAD	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	10.01	6.79e-21	4.64e-17	0.66	0.47	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
STAD	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-10.01	7.18e-21	4.9e-17	-0.54	-0.47	Height;	chr11:118737823	chr11:118704607~118750263:+
STAD	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	10	7.35e-21	5.01e-17	0.49	0.47	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
STAD	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-10	7.83e-21	5.33e-17	-0.56	-0.47	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-10	7.83e-21	5.33e-17	-0.56	-0.47	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-10	7.83e-21	5.33e-17	-0.56	-0.47	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
STAD	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	9.99	8.03e-21	5.46e-17	0.49	0.47	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	9.99	8.03e-21	5.46e-17	0.49	0.47	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	9.99	8.03e-21	5.46e-17	0.49	0.47	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
STAD	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	9.99	8.06e-21	5.48e-17	0.6	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
STAD	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	9.99	8.1e-21	5.5e-17	0.49	0.47	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
STAD	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-9.99	8.12e-21	5.51e-17	-0.55	-0.47	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
STAD	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-9.99	8.25e-21	5.6e-17	-0.66	-0.47	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
STAD	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	9.98	8.69e-21	5.89e-17	0.6	0.47	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
STAD	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-9.98	8.91e-21	6.04e-17	-0.54	-0.47	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
STAD	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	9.98	8.92e-21	6.05e-17	0.6	0.47	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
STAD	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	9.97	9.74e-21	6.58e-17	0.48	0.47	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	9.97	9.74e-21	6.58e-17	0.48	0.47	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	9.97	9.74e-21	6.58e-17	0.48	0.47	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	9.97	9.74e-21	6.58e-17	0.48	0.47	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
STAD	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-9.96	9.93e-21	6.7e-17	-0.58	-0.47	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
STAD	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-9.96	9.94e-21	6.7e-17	-0.49	-0.47	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-9.96	1.02e-20	6.89e-17	-0.51	-0.47	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
STAD	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	9.96	1.03e-20	6.97e-17	0.6	0.47	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
STAD	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	9.96	1.04e-20	7e-17	0.48	0.47	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
STAD	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	9.96	1.04e-20	7e-17	0.48	0.47	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	9.96	1.04e-20	7e-17	0.48	0.47	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	9.96	1.04e-20	7e-17	0.48	0.47	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-9.96	1.05e-20	7.06e-17	-0.51	-0.47	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-9.96	1.05e-20	7.06e-17	-0.51	-0.47	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-9.96	1.05e-20	7.06e-17	-0.51	-0.47	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
STAD	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-9.96	1.05e-20	7.06e-17	-0.51	-0.47	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-9.96	1.05e-20	7.06e-17	-0.51	-0.47	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
STAD	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-9.96	1.05e-20	7.06e-17	-0.51	-0.47	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
STAD	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-9.96	1.06e-20	7.12e-17	-0.55	-0.47	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-9.96	1.06e-20	7.14e-17	-0.55	-0.47	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
STAD	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-9.96	1.06e-20	7.14e-17	-0.55	-0.47	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-9.95	1.08e-20	7.25e-17	-0.68	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
STAD	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	9.95	1.1e-20	7.37e-17	0.48	0.47	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-9.95	1.12e-20	7.47e-17	-0.51	-0.47	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-9.95	1.12e-20	7.47e-17	-0.51	-0.47	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
STAD	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-9.95	1.12e-20	7.47e-17	-0.51	-0.47	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
STAD	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-9.95	1.12e-20	7.48e-17	-0.54	-0.47	Height;	chr11:118737916	chr11:118704607~118750263:+
STAD	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	9.95	1.14e-20	7.65e-17	0.44	0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
STAD	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	9.95	1.15e-20	7.67e-17	0.43	0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
STAD	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-9.95	1.16e-20	7.74e-17	-0.51	-0.47	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	9.95	1.16e-20	7.74e-17	0.48	0.47	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-9.94	1.17e-20	7.84e-17	-0.47	-0.47	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
STAD	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-9.94	1.18e-20	7.89e-17	-0.56	-0.47	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
STAD	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-9.94	1.18e-20	7.9e-17	-0.51	-0.47	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	9.94	1.2e-20	7.99e-17	0.57	0.47	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	9.94	1.21e-20	8.04e-17	0.54	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
STAD	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-9.94	1.21e-20	8.06e-17	-0.56	-0.47	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
STAD	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-9.94	1.22e-20	8.11e-17	-0.5	-0.47	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
STAD	cis	rs9457247	0.765	rs6904946	ENSG00000265828.1	MIR3939	9.94	1.22e-20	8.12e-17	0.54	0.47	Crohn's disease;	chr6:167020460	chr6:166997807~166997912:-
STAD	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
STAD	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-9.94	1.23e-20	8.21e-17	-0.48	-0.47	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-9.94	1.24e-20	8.22e-17	-0.51	-0.47	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
STAD	cis	rs1799949	0.832	rs2070835	ENSG00000198496.9	NBR2	-9.94	1.24e-20	8.22e-17	-0.57	-0.47	Menopause (age at onset);	chr17:43022008	chr17:43125610~43153671:+
STAD	cis	rs9457247	0.74	rs10946204	ENSG00000265828.1	MIR3939	-9.93	1.31e-20	8.7e-17	-0.54	-0.47	Crohn's disease;	chr6:167037641	chr6:166997807~166997912:-
STAD	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	9.93	1.32e-20	8.76e-17	0.48	0.47	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-9.93	1.34e-20	8.83e-17	-0.49	-0.47	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-9.93	1.34e-20	8.83e-17	-0.49	-0.47	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.765	rs10455982	ENSG00000265828.1	MIR3939	-9.92	1.37e-20	9.08e-17	-0.54	-0.47	Crohn's disease;	chr6:167035240	chr6:166997807~166997912:-
STAD	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	9.92	1.4e-20	9.24e-17	0.62	0.47	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
STAD	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	9.92	1.41e-20	9.3e-17	0.58	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
STAD	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	9.92	1.41e-20	9.31e-17	0.53	0.47	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
STAD	cis	rs9457247	0.765	rs9457251	ENSG00000265828.1	MIR3939	-9.92	1.43e-20	9.46e-17	-0.54	-0.47	Crohn's disease;	chr6:167013219	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-9.92	1.44e-20	9.52e-17	-0.49	-0.47	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.765	rs9459849	ENSG00000265828.1	MIR3939	-9.92	1.45e-20	9.6e-17	-0.54	-0.47	Crohn's disease;	chr6:167030672	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.765	rs9457259	ENSG00000265828.1	MIR3939	-9.92	1.45e-20	9.6e-17	-0.54	-0.47	Crohn's disease;	chr6:167030793	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.765	rs10946203	ENSG00000265828.1	MIR3939	-9.92	1.45e-20	9.6e-17	-0.54	-0.47	Crohn's disease;	chr6:167033247	chr6:166997807~166997912:-
STAD	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-9.92	1.46e-20	9.63e-17	-0.48	-0.47	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	9.91	1.49e-20	9.81e-17	0.48	0.47	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-9.91	1.51e-20	9.94e-17	-0.55	-0.47	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
STAD	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-9.91	1.51e-20	9.97e-17	-0.5	-0.47	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-9.91	1.52e-20	1e-16	-0.49	-0.47	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
STAD	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	9.91	1.54e-20	1.01e-16	0.43	0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
STAD	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-9.91	1.55e-20	1.02e-16	-0.5	-0.47	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
STAD	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
STAD	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
STAD	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
STAD	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-9.91	1.56e-20	1.02e-16	-0.48	-0.47	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
STAD	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	9.91	1.57e-20	1.03e-16	0.48	0.47	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
STAD	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	9.91	1.58e-20	1.03e-16	0.57	0.47	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	9.91	1.58e-20	1.03e-16	0.57	0.47	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
STAD	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-9.91	1.58e-20	1.04e-16	-0.54	-0.47	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
STAD	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-9.91	1.59e-20	1.04e-16	-0.49	-0.47	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-9.91	1.59e-20	1.04e-16	-0.49	-0.47	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-9.91	1.59e-20	1.04e-16	-0.49	-0.47	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-9.91	1.59e-20	1.04e-16	-0.49	-0.47	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
STAD	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-9.9	1.6e-20	1.05e-16	-0.65	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
STAD	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	9.9	1.63e-20	1.07e-16	0.49	0.47	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
STAD	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	9.9	1.65e-20	1.08e-16	0.63	0.47	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
STAD	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	9.9	1.65e-20	1.08e-16	0.63	0.47	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
STAD	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	9.9	1.65e-20	1.08e-16	0.63	0.47	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
STAD	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	9.9	1.71e-20	1.12e-16	0.48	0.47	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.765	rs1322077	ENSG00000265828.1	MIR3939	-9.89	1.72e-20	1.13e-16	-0.54	-0.47	Crohn's disease;	chr6:167010805	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.765	rs9457249	ENSG00000265828.1	MIR3939	-9.89	1.72e-20	1.13e-16	-0.54	-0.47	Crohn's disease;	chr6:167012950	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	9.89	1.75e-20	1.14e-16	0.48	0.47	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	9.89	1.75e-20	1.14e-16	0.48	0.47	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-9.89	1.77e-20	1.16e-16	-0.48	-0.47	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	9.89	1.78e-20	1.16e-16	0.52	0.47	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	9.89	1.79e-20	1.17e-16	0.54	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
STAD	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	9.89	1.8e-20	1.17e-16	0.47	0.47	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
STAD	cis	rs9457247	0.765	rs9457256	ENSG00000265828.1	MIR3939	-9.89	1.81e-20	1.18e-16	-0.54	-0.47	Crohn's disease;	chr6:167022973	chr6:166997807~166997912:-
STAD	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-9.89	1.83e-20	1.19e-16	-0.51	-0.47	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
STAD	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-9.89	1.84e-20	1.19e-16	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-9.89	1.84e-20	1.19e-16	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
STAD	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	9.88	1.88e-20	1.22e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
STAD	cis	rs9457247	0.663	rs9459839	ENSG00000265828.1	MIR3939	-9.88	1.92e-20	1.24e-16	-0.52	-0.47	Crohn's disease;	chr6:167018341	chr6:166997807~166997912:-
STAD	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-9.88	1.96e-20	1.27e-16	-0.48	-0.47	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
STAD	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	9.88	1.97e-20	1.28e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	9.88	1.98e-20	1.28e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
STAD	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-9.88	1.98e-20	1.28e-16	-0.51	-0.47	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
STAD	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-9.87	2.05e-20	1.33e-16	-0.53	-0.47	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
STAD	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-9.87	2.05e-20	1.33e-16	-0.5	-0.47	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-9.87	2.05e-20	1.33e-16	-0.5	-0.47	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
STAD	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	9.87	2.06e-20	1.33e-16	0.47	0.47	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
STAD	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	9.87	2.07e-20	1.34e-16	0.48	0.47	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
STAD	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-9.87	2.08e-20	1.35e-16	-0.48	-0.47	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-9.87	2.08e-20	1.35e-16	-0.48	-0.47	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-9.87	2.08e-20	1.35e-16	-0.48	-0.47	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-9.87	2.08e-20	1.35e-16	-0.48	-0.47	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
STAD	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	9.87	2.08e-20	1.35e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
STAD	cis	rs9457247	0.765	rs3752520	ENSG00000265828.1	MIR3939	-9.87	2.15e-20	1.39e-16	-0.54	-0.47	Crohn's disease;	chr6:167022671	chr6:166997807~166997912:-
STAD	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-9.87	2.16e-20	1.4e-16	-0.48	-0.47	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-9.87	2.16e-20	1.4e-16	-0.48	-0.47	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
STAD	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-9.87	2.16e-20	1.4e-16	-0.48	-0.47	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-9.87	2.16e-20	1.4e-16	-0.48	-0.47	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-9.87	2.16e-20	1.4e-16	-0.48	-0.47	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-9.87	2.16e-20	1.4e-16	-0.48	-0.47	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
STAD	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-9.87	2.16e-20	1.4e-16	-0.48	-0.47	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-9.86	2.18e-20	1.41e-16	-0.58	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
STAD	cis	rs9457247	0.612	rs2237273	ENSG00000265828.1	MIR3939	-9.86	2.19e-20	1.42e-16	-0.52	-0.47	Crohn's disease;	chr6:167029529	chr6:166997807~166997912:-
STAD	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	9.86	2.22e-20	1.43e-16	0.51	0.47	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-9.86	2.25e-20	1.45e-16	-0.49	-0.47	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
STAD	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	9.86	2.25e-20	1.45e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
STAD	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	9.86	2.31e-20	1.49e-16	0.6	0.47	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
STAD	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	9.86	2.32e-20	1.5e-16	0.48	0.47	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
STAD	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	9.86	2.32e-20	1.5e-16	0.48	0.47	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-9.85	2.37e-20	1.52e-16	-0.47	-0.47	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.663	rs9295384	ENSG00000265828.1	MIR3939	-9.85	2.37e-20	1.53e-16	-0.52	-0.47	Crohn's disease;	chr6:167034625	chr6:166997807~166997912:-
STAD	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	9.85	2.37e-20	1.53e-16	0.48	0.47	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-9.85	2.37e-20	1.53e-16	-0.54	-0.47	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	9.85	2.38e-20	1.53e-16	0.48	0.47	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
STAD	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	9.85	2.41e-20	1.55e-16	0.48	0.47	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	9.85	2.41e-20	1.55e-16	0.48	0.47	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-9.85	2.42e-20	1.56e-16	-0.47	-0.47	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
STAD	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	9.85	2.42e-20	1.56e-16	0.48	0.47	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-9.85	2.45e-20	1.57e-16	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-9.85	2.45e-20	1.57e-16	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
STAD	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	9.85	2.46e-20	1.58e-16	0.6	0.47	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
STAD	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	9.85	2.47e-20	1.59e-16	0.78	0.47	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
STAD	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-9.85	2.47e-20	1.59e-16	-0.48	-0.47	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-9.85	2.47e-20	1.59e-16	-0.48	-0.47	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
STAD	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-9.85	2.47e-20	1.59e-16	-0.48	-0.47	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-9.85	2.47e-20	1.59e-16	-0.48	-0.47	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	9.85	2.49e-20	1.6e-16	0.48	0.47	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	9.85	2.49e-20	1.6e-16	0.48	0.47	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-9.84	2.58e-20	1.65e-16	-0.48	-0.47	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
STAD	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-9.84	2.6e-20	1.66e-16	-0.57	-0.47	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
STAD	cis	rs9457247	0.663	rs2237274	ENSG00000265828.1	MIR3939	-9.84	2.6e-20	1.67e-16	-0.51	-0.47	Crohn's disease;	chr6:167029507	chr6:166997807~166997912:-
STAD	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-9.84	2.61e-20	1.67e-16	-0.53	-0.47	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
STAD	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	9.84	2.62e-20	1.68e-16	0.49	0.47	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.663	rs9459845	ENSG00000265828.1	MIR3939	-9.84	2.64e-20	1.68e-16	-0.51	-0.47	Crohn's disease;	chr6:167027013	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.663	rs9457257	ENSG00000265828.1	MIR3939	-9.84	2.64e-20	1.68e-16	-0.51	-0.47	Crohn's disease;	chr6:167027248	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.637	rs9459846	ENSG00000265828.1	MIR3939	-9.84	2.64e-20	1.68e-16	-0.51	-0.47	Crohn's disease;	chr6:167027535	chr6:166997807~166997912:-
STAD	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-9.84	2.71e-20	1.73e-16	-0.47	-0.47	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-9.84	2.71e-20	1.73e-16	-0.47	-0.47	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
STAD	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-9.84	2.71e-20	1.73e-16	-0.47	-0.47	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	9.84	2.73e-20	1.74e-16	0.6	0.47	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
STAD	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-9.83	2.78e-20	1.78e-16	-0.48	-0.47	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-9.83	2.82e-20	1.8e-16	-0.53	-0.47	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-9.83	2.83e-20	1.8e-16	-0.54	-0.47	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
STAD	cis	rs9457247	0.765	rs6900701	ENSG00000265828.1	MIR3939	-9.83	2.92e-20	1.86e-16	-0.53	-0.47	Crohn's disease;	chr6:167020624	chr6:166997807~166997912:-
STAD	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-9.83	2.92e-20	1.86e-16	-0.47	-0.47	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-9.83	2.92e-20	1.86e-16	-0.47	-0.47	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-9.83	2.92e-20	1.86e-16	-0.47	-0.47	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-9.83	2.92e-20	1.86e-16	-0.47	-0.47	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-9.83	2.92e-20	1.86e-16	-0.47	-0.47	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
STAD	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	9.83	2.93e-20	1.87e-16	0.57	0.47	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-9.83	2.94e-20	1.87e-16	-0.56	-0.47	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
STAD	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	9.83	2.95e-20	1.87e-16	0.63	0.47	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
STAD	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	9.83	2.95e-20	1.87e-16	0.63	0.47	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
STAD	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	9.83	2.95e-20	1.87e-16	0.63	0.47	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
STAD	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-9.82	3e-20	1.91e-16	-0.5	-0.47	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
STAD	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-9.82	3.02e-20	1.92e-16	-0.48	-0.47	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-9.82	3.04e-20	1.94e-16	-0.59	-0.47	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
STAD	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	9.82	3.1e-20	1.97e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
STAD	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	9.82	3.13e-20	1.99e-16	0.61	0.47	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
STAD	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-9.82	3.16e-20	2.01e-16	-0.56	-0.47	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-9.81	3.32e-20	2.11e-16	-0.56	-0.47	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-9.81	3.32e-20	2.11e-16	-0.56	-0.47	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-9.81	3.32e-20	2.11e-16	-0.56	-0.47	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	9.81	3.35e-20	2.13e-16	0.6	0.47	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
STAD	cis	rs9457247	0.588	rs35171809	ENSG00000265828.1	MIR3939	-9.81	3.44e-20	2.17e-16	-0.51	-0.47	Crohn's disease;	chr6:167019278	chr6:166997807~166997912:-
STAD	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-9.8	3.49e-20	2.21e-16	-0.52	-0.47	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
STAD	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	9.8	3.53e-20	2.23e-16	0.56	0.47	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
STAD	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-9.8	3.62e-20	2.29e-16	-0.49	-0.47	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
STAD	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	9.8	3.63e-20	2.29e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	9.8	3.63e-20	2.29e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	9.8	3.63e-20	2.29e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	9.8	3.63e-20	2.29e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	9.8	3.63e-20	2.29e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
STAD	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	9.8	3.65e-20	2.3e-16	0.53	0.47	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
STAD	cis	rs9457247	0.73	rs9459841	ENSG00000265828.1	MIR3939	-9.8	3.65e-20	2.3e-16	-0.53	-0.47	Crohn's disease;	chr6:167018461	chr6:166997807~166997912:-
STAD	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	9.8	3.68e-20	2.32e-16	0.56	0.47	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
STAD	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	9.79	3.73e-20	2.35e-16	0.58	0.47	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
STAD	cis	rs9457247	0.765	rs10484531	ENSG00000265828.1	MIR3939	-9.79	3.77e-20	2.37e-16	-0.53	-0.47	Crohn's disease;	chr6:167040946	chr6:166997807~166997912:-
STAD	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	9.79	3.81e-20	2.4e-16	0.56	0.47	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	9.79	3.81e-20	2.4e-16	0.56	0.47	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	9.79	3.81e-20	2.4e-16	0.56	0.47	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-9.79	3.81e-20	2.4e-16	-0.56	-0.47	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-9.79	3.81e-20	2.4e-16	-0.56	-0.47	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-9.79	3.81e-20	2.4e-16	-0.56	-0.47	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-9.79	3.81e-20	2.4e-16	-0.56	-0.47	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
STAD	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-9.79	3.83e-20	2.41e-16	-0.58	-0.47	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
STAD	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-9.79	4e-20	2.51e-16	-0.48	-0.47	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	9.79	4.01e-20	2.52e-16	0.59	0.47	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
STAD	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	9.79	4.01e-20	2.52e-16	0.48	0.47	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	9.79	4.01e-20	2.52e-16	0.48	0.47	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
STAD	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-9.78	4.03e-20	2.53e-16	-0.48	-0.47	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
STAD	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-9.78	4.08e-20	2.56e-16	-0.6	-0.47	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
STAD	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-9.78	4.08e-20	2.56e-16	-0.6	-0.47	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
STAD	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-9.78	4.08e-20	2.56e-16	-0.6	-0.47	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
STAD	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	9.78	4.08e-20	2.56e-16	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
STAD	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	9.78	4.08e-20	2.56e-16	0.57	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	9.78	4.17e-20	2.61e-16	0.59	0.47	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
STAD	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-9.78	4.19e-20	2.63e-16	-0.55	-0.47	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
STAD	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-9.78	4.26e-20	2.67e-16	-0.56	-0.47	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
STAD	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	9.78	4.27e-20	2.68e-16	0.47	0.47	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-9.78	4.29e-20	2.69e-16	-0.54	-0.47	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
STAD	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-9.77	4.43e-20	2.77e-16	-0.53	-0.47	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-9.77	4.43e-20	2.77e-16	-0.53	-0.47	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
STAD	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-9.77	4.43e-20	2.77e-16	-0.49	-0.47	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
STAD	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-9.77	4.43e-20	2.77e-16	-0.49	-0.47	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
STAD	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	9.77	4.47e-20	2.79e-16	0.56	0.47	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
STAD	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-9.77	4.5e-20	2.81e-16	-0.5	-0.47	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
STAD	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-9.77	4.64e-20	2.9e-16	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
STAD	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-9.76	4.7e-20	2.93e-16	-0.56	-0.46	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
STAD	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-9.76	4.84e-20	3.01e-16	-0.53	-0.46	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
STAD	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-9.76	4.99e-20	3.1e-16	-0.53	-0.46	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
STAD	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	9.76	5e-20	3.11e-16	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	9.76	5e-20	3.11e-16	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	9.76	5e-20	3.11e-16	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	9.76	5e-20	3.11e-16	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
STAD	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	9.76	5.05e-20	3.13e-16	0.48	0.46	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
STAD	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	9.75	5.16e-20	3.2e-16	0.49	0.46	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	9.75	5.16e-20	3.2e-16	0.49	0.46	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	9.75	5.16e-20	3.2e-16	0.49	0.46	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-9.75	5.22e-20	3.23e-16	-0.48	-0.46	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-9.75	5.22e-20	3.23e-16	-0.48	-0.46	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	9.75	5.22e-20	3.23e-16	0.52	0.46	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
STAD	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-9.75	5.31e-20	3.29e-16	-0.6	-0.46	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
STAD	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-9.75	5.31e-20	3.29e-16	-0.53	-0.46	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
STAD	cis	rs9457247	0.663	rs2301436	ENSG00000265828.1	MIR3939	-9.75	5.44e-20	3.37e-16	-0.51	-0.46	Crohn's disease;	chr6:167024500	chr6:166997807~166997912:-
STAD	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-9.75	5.47e-20	3.38e-16	-0.55	-0.46	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
STAD	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-9.75	5.48e-20	3.39e-16	-0.62	-0.46	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
STAD	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	9.74	5.5e-20	3.4e-16	0.48	0.46	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
STAD	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-9.74	5.6e-20	3.46e-16	-0.48	-0.46	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
STAD	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	9.74	5.62e-20	3.47e-16	0.46	0.46	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
STAD	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	9.74	5.67e-20	3.5e-16	0.48	0.46	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.765	rs2237276	ENSG00000265828.1	MIR3939	-9.74	5.7e-20	3.51e-16	-0.52	-0.46	Crohn's disease;	chr6:167028627	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	9.74	5.74e-20	3.54e-16	0.48	0.46	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
STAD	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	9.74	5.83e-20	3.59e-16	0.42	0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
STAD	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	9.74	5.84e-20	3.6e-16	0.6	0.46	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	9.74	5.84e-20	3.6e-16	0.6	0.46	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
STAD	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	9.74	5.87e-20	3.61e-16	0.61	0.46	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
STAD	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	9.74	5.87e-20	3.61e-16	0.61	0.46	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
STAD	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	9.74	5.88e-20	3.62e-16	0.76	0.46	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
STAD	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-9.73	6.03e-20	3.71e-16	-0.57	-0.46	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
STAD	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-9.73	6.03e-20	3.71e-16	-0.57	-0.46	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
STAD	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-9.73	6.03e-20	3.71e-16	-0.57	-0.46	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
STAD	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-9.73	6.03e-20	3.71e-16	-0.57	-0.46	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
STAD	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-9.73	6.06e-20	3.73e-16	-0.49	-0.46	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	9.73	6.15e-20	3.78e-16	0.47	0.46	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
STAD	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-9.73	6.19e-20	3.79e-16	-0.5	-0.46	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
STAD	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-9.73	6.19e-20	3.79e-16	-0.5	-0.46	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-9.73	6.19e-20	3.79e-16	-0.5	-0.46	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-9.73	6.19e-20	3.79e-16	-0.5	-0.46	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-9.73	6.19e-20	3.79e-16	-0.5	-0.46	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-9.73	6.19e-20	3.79e-16	-0.5	-0.46	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-9.73	6.19e-20	3.79e-16	-0.5	-0.46	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
STAD	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	9.73	6.28e-20	3.85e-16	0.48	0.46	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
STAD	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-9.73	6.3e-20	3.86e-16	-0.46	-0.46	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
STAD	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-9.73	6.3e-20	3.86e-16	-0.55	-0.46	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
STAD	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-9.73	6.32e-20	3.87e-16	-0.49	-0.46	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-9.73	6.32e-20	3.87e-16	-0.49	-0.46	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-9.73	6.32e-20	3.87e-16	-0.49	-0.46	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
STAD	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	9.72	6.46e-20	3.96e-16	0.57	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	9.72	6.52e-20	3.99e-16	0.6	0.46	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
STAD	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	9.72	6.62e-20	4.05e-16	0.63	0.46	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
STAD	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-9.72	6.65e-20	4.06e-16	-0.46	-0.46	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-9.72	6.65e-20	4.06e-16	-0.46	-0.46	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-9.72	6.65e-20	4.06e-16	-0.46	-0.46	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-9.72	6.65e-20	4.06e-16	-0.46	-0.46	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-9.72	6.65e-20	4.06e-16	-0.46	-0.46	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-9.72	6.65e-20	4.06e-16	-0.46	-0.46	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
STAD	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-9.72	6.79e-20	4.14e-16	-0.63	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
STAD	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-9.72	6.79e-20	4.14e-16	-0.63	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-9.72	6.85e-20	4.17e-16	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
STAD	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	9.72	6.89e-20	4.2e-16	0.57	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
STAD	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-9.71	7.19e-20	4.37e-16	-0.6	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
STAD	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-9.71	7.19e-20	4.37e-16	-0.6	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
STAD	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-9.71	7.24e-20	4.4e-16	-0.55	-0.46	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
STAD	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	9.71	7.27e-20	4.42e-16	0.49	0.46	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	9.71	7.39e-20	4.49e-16	0.59	0.46	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	9.71	7.46e-20	4.53e-16	0.59	0.46	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	9.71	7.46e-20	4.53e-16	0.59	0.46	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	9.7	7.48e-20	4.55e-16	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
STAD	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-9.7	7.53e-20	4.57e-16	-0.79	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
STAD	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	9.7	7.54e-20	4.58e-16	0.59	0.46	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
STAD	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-9.7	7.59e-20	4.61e-16	-0.49	-0.46	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-9.7	7.59e-20	4.61e-16	-0.49	-0.46	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	9.7	7.85e-20	4.76e-16	0.55	0.46	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
STAD	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	9.7	7.92e-20	4.8e-16	0.59	0.46	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
STAD	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	9.7	7.97e-20	4.83e-16	0.56	0.46	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	9.7	7.97e-20	4.83e-16	0.56	0.46	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
STAD	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	9.7	8.06e-20	4.88e-16	0.53	0.46	Height;	chr11:118758322	chr11:118704607~118750263:+
STAD	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-9.69	8.44e-20	5.11e-16	-0.49	-0.46	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
STAD	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	9.69	8.47e-20	5.12e-16	0.47	0.46	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	9.69	8.58e-20	5.19e-16	0.46	0.46	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
STAD	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-9.68	8.91e-20	5.38e-16	-0.49	-0.46	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
STAD	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	9.68	9.04e-20	5.46e-16	0.49	0.46	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
STAD	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	9.68	9.04e-20	5.46e-16	0.49	0.46	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	9.68	9.04e-20	5.46e-16	0.49	0.46	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
STAD	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	9.68	9.16e-20	5.53e-16	0.55	0.46	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
STAD	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	9.68	9.35e-20	5.64e-16	0.47	0.46	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
STAD	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-9.67	9.45e-20	5.7e-16	-0.7	-0.46	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
STAD	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	9.67	9.47e-20	5.71e-16	0.56	0.46	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
STAD	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	9.67	9.55e-20	5.76e-16	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
STAD	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	9.67	9.65e-20	5.82e-16	0.54	0.46	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
STAD	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	9.67	9.87e-20	5.94e-16	0.49	0.46	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
STAD	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
STAD	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
STAD	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-9.67	9.87e-20	5.94e-16	-0.49	-0.46	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
STAD	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	9.67	9.98e-20	6e-16	0.49	0.46	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
STAD	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-9.66	1.04e-19	6.25e-16	-0.49	-0.46	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	9.66	1.04e-19	6.26e-16	0.58	0.46	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
STAD	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	9.66	1.05e-19	6.29e-16	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
STAD	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	9.66	1.06e-19	6.35e-16	0.49	0.46	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
STAD	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-9.66	1.06e-19	6.35e-16	-0.49	-0.46	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-9.66	1.06e-19	6.35e-16	-0.49	-0.46	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
STAD	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	9.66	1.07e-19	6.4e-16	0.51	0.46	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
STAD	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	9.66	1.07e-19	6.43e-16	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
STAD	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	9.66	1.07e-19	6.44e-16	0.51	0.46	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
STAD	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	9.66	1.09e-19	6.51e-16	0.78	0.46	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
STAD	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-9.65	1.11e-19	6.64e-16	-0.46	-0.46	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	9.65	1.11e-19	6.64e-16	0.54	0.46	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
STAD	cis	rs9457247	0.715	rs6923582	ENSG00000265828.1	MIR3939	-9.65	1.11e-19	6.67e-16	-0.52	-0.46	Crohn's disease;	chr6:167023674	chr6:166997807~166997912:-
STAD	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-9.65	1.14e-19	6.83e-16	-0.54	-0.46	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
STAD	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	9.65	1.15e-19	6.9e-16	0.58	0.46	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
STAD	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-9.65	1.15e-19	6.9e-16	-0.56	-0.46	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	9.65	1.16e-19	6.93e-16	0.58	0.46	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
STAD	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	9.64	1.19e-19	7.09e-16	0.49	0.46	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
STAD	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-9.64	1.2e-19	7.18e-16	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
STAD	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-9.64	1.21e-19	7.23e-16	-0.49	-0.46	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
STAD	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-9.64	1.21e-19	7.23e-16	-0.49	-0.46	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-9.64	1.21e-19	7.24e-16	-0.48	-0.46	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
STAD	cis	rs9457247	0.74	rs13195812	ENSG00000265828.1	MIR3939	-9.64	1.26e-19	7.5e-16	-0.52	-0.46	Crohn's disease;	chr6:167030414	chr6:166997807~166997912:-
STAD	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	9.64	1.26e-19	7.51e-16	0.58	0.46	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	9.64	1.26e-19	7.53e-16	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
STAD	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	9.64	1.27e-19	7.56e-16	0.59	0.46	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	9.64	1.28e-19	7.61e-16	0.6	0.46	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
STAD	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-9.63	1.29e-19	7.67e-16	-0.56	-0.46	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
STAD	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-9.63	1.3e-19	7.72e-16	-0.49	-0.46	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
STAD	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-9.63	1.3e-19	7.73e-16	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-9.63	1.3e-19	7.73e-16	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
STAD	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	9.63	1.31e-19	7.79e-16	0.56	0.46	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
STAD	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	9.63	1.32e-19	7.81e-16	0.38	0.46	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
STAD	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	9.63	1.32e-19	7.85e-16	0.56	0.46	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
STAD	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	9.63	1.33e-19	7.87e-16	0.76	0.46	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
STAD	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-9.63	1.34e-19	7.95e-16	-0.49	-0.46	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
STAD	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-9.63	1.35e-19	8.01e-16	-0.48	-0.46	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
STAD	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	9.63	1.36e-19	8.05e-16	0.47	0.46	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	9.63	1.36e-19	8.05e-16	0.47	0.46	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	9.63	1.36e-19	8.05e-16	0.47	0.46	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
STAD	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-9.63	1.37e-19	8.14e-16	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-9.62	1.38e-19	8.2e-16	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
STAD	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-9.62	1.39e-19	8.26e-16	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-9.62	1.4e-19	8.29e-16	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
STAD	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-9.62	1.4e-19	8.29e-16	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
STAD	cis	rs380904	0.572	rs2060967	ENSG00000254859.1	RP11-661A12.5	-9.62	1.42e-19	8.42e-16	-0.68	-0.46	Venous thromboembolism (SNP x SNP interaction);	chr8:143521427	chr8:143541973~143549729:-
STAD	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	9.62	1.43e-19	8.45e-16	0.56	0.46	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	9.62	1.43e-19	8.45e-16	0.56	0.46	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
STAD	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	9.62	1.47e-19	8.69e-16	0.54	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
STAD	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-9.62	1.49e-19	8.8e-16	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
STAD	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	9.61	1.5e-19	8.86e-16	0.46	0.46	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
STAD	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-9.61	1.5e-19	8.88e-16	-0.56	-0.46	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
STAD	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-9.61	1.5e-19	8.89e-16	-0.47	-0.46	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
STAD	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	9.61	1.51e-19	8.91e-16	0.48	0.46	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
STAD	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-9.61	1.51e-19	8.92e-16	-0.6	-0.46	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
STAD	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	9.61	1.52e-19	8.98e-16	0.59	0.46	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	9.61	1.54e-19	9.1e-16	0.58	0.46	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
STAD	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	9.61	1.55e-19	9.13e-16	0.59	0.46	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
STAD	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-9.61	1.58e-19	9.31e-16	-0.65	-0.46	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
STAD	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-9.6	1.63e-19	9.58e-16	-0.64	-0.46	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	9.6	1.64e-19	9.66e-16	0.59	0.46	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	9.6	1.64e-19	9.66e-16	0.59	0.46	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
STAD	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	9.6	1.65e-19	9.72e-16	0.75	0.46	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
STAD	cis	rs10129255	0.5	rs1974468	ENSG00000280411.1	IGHV1-69-2	-9.6	1.67e-19	9.83e-16	-0.37	-0.46	Kawasaki disease;	chr14:106686149	chr14:106762092~106762588:-
STAD	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	9.6	1.67e-19	9.83e-16	0.64	0.46	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
STAD	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-9.6	1.71e-19	1e-15	-0.49	-0.46	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
STAD	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	9.6	1.71e-19	1e-15	0.53	0.46	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
STAD	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	9.6	1.72e-19	1.01e-15	0.59	0.46	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
STAD	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-9.59	1.75e-19	1.03e-15	-0.55	-0.46	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
STAD	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	9.59	1.79e-19	1.05e-15	0.59	0.46	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
STAD	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-9.59	1.82e-19	1.07e-15	-0.41	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
STAD	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	9.58	1.88e-19	1.1e-15	0.48	0.46	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
STAD	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	9.58	1.89e-19	1.11e-15	0.58	0.46	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
STAD	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	9.58	1.89e-19	1.11e-15	0.48	0.46	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
STAD	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	9.58	1.89e-19	1.11e-15	0.49	0.46	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
STAD	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-9.58	1.9e-19	1.11e-15	-0.53	-0.46	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	9.58	1.9e-19	1.11e-15	0.47	0.46	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
STAD	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-9.58	1.91e-19	1.11e-15	-0.55	-0.46	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	9.58	1.91e-19	1.12e-15	0.6	0.46	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
STAD	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-9.58	1.92e-19	1.13e-15	-0.64	-0.46	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
STAD	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-9.58	1.93e-19	1.13e-15	-0.49	-0.46	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
STAD	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-9.58	1.95e-19	1.14e-15	-0.48	-0.46	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
STAD	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-9.58	2e-19	1.17e-15	-0.55	-0.46	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-9.58	2e-19	1.17e-15	-0.55	-0.46	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-9.58	2e-19	1.17e-15	-0.55	-0.46	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
STAD	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-9.58	2e-19	1.17e-15	-0.55	-0.46	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
STAD	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-9.58	2e-19	1.17e-15	-0.55	-0.46	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
STAD	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	9.58	2.02e-19	1.18e-15	0.49	0.46	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
STAD	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	9.58	2.02e-19	1.18e-15	0.49	0.46	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
STAD	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-9.58	2.02e-19	1.18e-15	-0.55	-0.46	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
STAD	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-9.57	2.05e-19	1.2e-15	-0.53	-0.46	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
STAD	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-9.57	2.07e-19	1.21e-15	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
STAD	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	9.57	2.07e-19	1.21e-15	0.58	0.46	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	9.57	2.13e-19	1.24e-15	0.59	0.46	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
STAD	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	9.57	2.14e-19	1.24e-15	0.79	0.46	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
STAD	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	9.57	2.18e-19	1.27e-15	0.48	0.46	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
STAD	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	9.57	2.18e-19	1.27e-15	0.76	0.46	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
STAD	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	9.56	2.2e-19	1.28e-15	0.59	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
STAD	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-9.56	2.22e-19	1.29e-15	-0.49	-0.46	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
STAD	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-9.56	2.26e-19	1.31e-15	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
STAD	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-9.56	2.29e-19	1.33e-15	-0.58	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	9.56	2.3e-19	1.33e-15	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
STAD	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	9.56	2.32e-19	1.35e-15	0.58	0.46	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
STAD	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	9.56	2.33e-19	1.35e-15	0.49	0.46	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
STAD	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-9.56	2.34e-19	1.36e-15	-0.48	-0.46	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
STAD	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-9.55	2.37e-19	1.37e-15	-0.55	-0.46	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
STAD	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-9.55	2.38e-19	1.38e-15	-0.49	-0.46	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-9.55	2.38e-19	1.38e-15	-0.49	-0.46	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
STAD	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-9.55	2.41e-19	1.39e-15	-0.54	-0.46	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
STAD	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	9.55	2.43e-19	1.4e-15	0.54	0.46	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	9.55	2.43e-19	1.4e-15	0.54	0.46	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	9.55	2.43e-19	1.4e-15	0.54	0.46	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
STAD	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	9.55	2.44e-19	1.41e-15	0.53	0.46	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
STAD	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-9.55	2.52e-19	1.45e-15	-0.55	-0.46	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-9.55	2.52e-19	1.45e-15	-0.55	-0.46	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
STAD	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-9.55	2.53e-19	1.46e-15	-0.49	-0.46	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
STAD	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-9.55	2.55e-19	1.47e-15	-0.55	-0.46	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
STAD	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	9.54	2.56e-19	1.48e-15	0.55	0.46	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
STAD	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	9.54	2.57e-19	1.48e-15	0.48	0.46	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
STAD	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-9.54	2.59e-19	1.5e-15	-0.55	-0.46	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
STAD	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	9.54	2.65e-19	1.53e-15	0.54	0.46	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
STAD	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	9.54	2.65e-19	1.53e-15	0.46	0.46	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	9.54	2.67e-19	1.54e-15	0.58	0.46	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
STAD	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-9.53	2.77e-19	1.6e-15	-0.55	-0.46	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	9.53	2.78e-19	1.6e-15	0.58	0.46	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
STAD	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-9.53	2.8e-19	1.62e-15	-0.55	-0.46	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
STAD	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-9.53	2.91e-19	1.67e-15	-0.57	-0.46	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
STAD	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	9.53	2.91e-19	1.67e-15	0.48	0.46	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	9.53	2.91e-19	1.67e-15	0.48	0.46	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	9.53	2.91e-19	1.67e-15	0.48	0.46	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
STAD	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-9.53	2.95e-19	1.69e-15	-0.52	-0.46	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
STAD	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	9.52	2.98e-19	1.71e-15	0.58	0.46	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	9.52	2.98e-19	1.71e-15	0.58	0.46	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
STAD	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-9.52	2.99e-19	1.72e-15	-0.52	-0.46	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
STAD	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	9.52	3.01e-19	1.73e-15	0.58	0.46	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	9.52	3.01e-19	1.73e-15	0.58	0.46	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	9.52	3.01e-19	1.73e-15	0.58	0.46	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
STAD	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-9.52	3.03e-19	1.74e-15	-0.49	-0.46	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	9.52	3.03e-19	1.74e-15	0.48	0.46	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	9.52	3.03e-19	1.74e-15	0.48	0.46	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
STAD	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-9.52	3.08e-19	1.76e-15	-0.49	-0.46	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
STAD	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-9.52	3.09e-19	1.77e-15	-0.49	-0.46	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
STAD	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-9.52	3.09e-19	1.77e-15	-0.51	-0.46	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
STAD	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	9.52	3.12e-19	1.78e-15	0.55	0.46	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
STAD	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-9.52	3.16e-19	1.81e-15	-0.6	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
STAD	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	9.51	3.23e-19	1.85e-15	0.5	0.46	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
STAD	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	9.51	3.23e-19	1.85e-15	0.5	0.46	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
STAD	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	9.51	3.28e-19	1.88e-15	0.59	0.46	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
STAD	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-9.51	3.29e-19	1.88e-15	-0.55	-0.46	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
STAD	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	9.51	3.3e-19	1.88e-15	0.49	0.46	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
STAD	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-9.51	3.33e-19	1.9e-15	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
STAD	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-9.51	3.33e-19	1.9e-15	-0.54	-0.46	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
STAD	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	9.51	3.34e-19	1.91e-15	0.52	0.46	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
STAD	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	9.51	3.38e-19	1.93e-15	0.45	0.46	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
STAD	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	9.51	3.43e-19	1.96e-15	0.49	0.46	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
STAD	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-9.5	3.49e-19	1.99e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
STAD	cis	rs748404	0.578	rs2584701	ENSG00000249839.1	AC011330.5	-9.5	3.54e-19	2.02e-15	-0.55	-0.45	Lung cancer;	chr15:43392741	chr15:43663654~43684339:-
STAD	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-9.5	3.55e-19	2.02e-15	-0.55	-0.45	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-9.5	3.55e-19	2.02e-15	-0.55	-0.45	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
STAD	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	9.5	3.55e-19	2.03e-15	0.59	0.45	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
STAD	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	9.5	3.62e-19	2.06e-15	0.59	0.45	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
STAD	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-9.5	3.64e-19	2.07e-15	-0.47	-0.45	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
STAD	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	9.5	3.65e-19	2.08e-15	0.58	0.45	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	9.5	3.65e-19	2.08e-15	0.58	0.45	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
STAD	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	9.49	3.79e-19	2.16e-15	0.46	0.45	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	9.49	3.81e-19	2.17e-15	0.48	0.45	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
STAD	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	9.49	3.81e-19	2.17e-15	0.48	0.45	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
STAD	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	9.49	3.88e-19	2.21e-15	0.64	0.45	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
STAD	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-9.49	4.02e-19	2.29e-15	-0.61	-0.45	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
STAD	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	9.48	4.15e-19	2.36e-15	0.55	0.45	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
STAD	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	9.48	4.15e-19	2.36e-15	0.55	0.45	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
STAD	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-9.48	4.18e-19	2.37e-15	-0.41	-0.45	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
STAD	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	9.48	4.18e-19	2.38e-15	0.46	0.45	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
STAD	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-9.48	4.2e-19	2.38e-15	-0.53	-0.45	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	9.48	4.27e-19	2.42e-15	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
STAD	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	9.47	4.48e-19	2.53e-15	0.48	0.45	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
STAD	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-9.47	4.52e-19	2.56e-15	-0.59	-0.45	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
STAD	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	9.47	4.54e-19	2.57e-15	0.58	0.45	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
STAD	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	9.47	4.54e-19	2.57e-15	0.55	0.45	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
STAD	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	9.47	4.54e-19	2.57e-15	0.48	0.45	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
STAD	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-9.47	4.6e-19	2.6e-15	-0.49	-0.45	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
STAD	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	9.47	4.68e-19	2.65e-15	0.59	0.45	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	9.47	4.69e-19	2.65e-15	0.58	0.45	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	9.46	4.76e-19	2.69e-15	0.58	0.45	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
STAD	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	9.46	4.77e-19	2.69e-15	0.48	0.45	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
STAD	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	9.46	4.77e-19	2.69e-15	0.48	0.45	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	9.46	4.98e-19	2.81e-15	0.58	0.45	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	9.46	4.98e-19	2.81e-15	0.58	0.45	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
STAD	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-9.46	5.03e-19	2.84e-15	-0.53	-0.45	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	9.46	5.04e-19	2.84e-15	0.58	0.45	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
STAD	cis	rs2658782	0.547	rs10741464	ENSG00000279684.1	RP11-755E23.2	-9.45	5.15e-19	2.9e-15	-0.58	-0.45	Pulmonary function decline;	chr11:93457586	chr11:93286629~93288903:-
STAD	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	9.45	5.32e-19	2.99e-15	0.47	0.45	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
STAD	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	9.45	5.36e-19	3.01e-15	0.89	0.45	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
STAD	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	9.44	5.48e-19	3.08e-15	0.76	0.45	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
STAD	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-9.44	5.48e-19	3.08e-15	-0.52	-0.45	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
STAD	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	9.44	5.49e-19	3.08e-15	0.59	0.45	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
STAD	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-9.44	5.66e-19	3.18e-15	-0.37	-0.45	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-9.44	5.66e-19	3.18e-15	-0.37	-0.45	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
STAD	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	9.44	5.76e-19	3.23e-15	0.48	0.45	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	9.44	5.88e-19	3.3e-15	0.45	0.45	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	9.43	5.92e-19	3.31e-15	0.45	0.45	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	9.43	5.92e-19	3.31e-15	0.45	0.45	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	9.43	5.92e-19	3.31e-15	0.45	0.45	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	9.43	5.92e-19	3.31e-15	0.45	0.45	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
STAD	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	9.43	5.92e-19	3.31e-15	0.45	0.45	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
STAD	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	9.43	5.92e-19	3.31e-15	0.45	0.45	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	9.43	5.92e-19	3.31e-15	0.45	0.45	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-9.43	6.04e-19	3.38e-15	-0.48	-0.45	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-9.43	6.04e-19	3.38e-15	-0.48	-0.45	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	9.43	6.04e-19	3.38e-15	0.48	0.45	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
STAD	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	9.43	6.04e-19	3.38e-15	0.48	0.45	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
STAD	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-9.43	6.05e-19	3.38e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
STAD	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-9.43	6.12e-19	3.42e-15	-0.48	-0.45	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.663	rs7749278	ENSG00000265828.1	MIR3939	9.43	6.2e-19	3.47e-15	0.5	0.45	Crohn's disease;	chr6:167021837	chr6:166997807~166997912:-
STAD	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	9.42	6.38e-19	3.57e-15	0.55	0.45	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
STAD	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	9.42	6.66e-19	3.72e-15	0.57	0.45	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	9.42	6.66e-19	3.72e-15	0.57	0.45	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	9.42	6.66e-19	3.72e-15	0.57	0.45	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
STAD	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-9.42	6.75e-19	3.77e-15	-0.46	-0.45	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	9.42	6.82e-19	3.81e-15	0.57	0.45	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
STAD	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	9.41	6.86e-19	3.82e-15	0.46	0.45	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
STAD	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-9.41	6.94e-19	3.87e-15	-0.51	-0.45	Height;	chr11:118742526	chr11:118704607~118750263:+
STAD	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	9.41	6.98e-19	3.89e-15	0.57	0.45	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
STAD	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-9.41	7.22e-19	4.02e-15	-0.48	-0.45	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-9.41	7.24e-19	4.03e-15	-0.51	-0.45	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
STAD	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	9.41	7.25e-19	4.03e-15	0.46	0.45	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
STAD	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	9.41	7.25e-19	4.03e-15	0.77	0.45	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
STAD	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	9.4	7.54e-19	4.19e-15	0.53	0.45	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
STAD	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	9.4	7.61e-19	4.23e-15	0.48	0.45	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	9.4	7.61e-19	4.23e-15	0.48	0.45	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
STAD	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-9.4	7.67e-19	4.26e-15	-0.52	-0.45	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
STAD	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	9.4	7.67e-19	4.26e-15	0.52	0.45	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
STAD	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-9.4	7.78e-19	4.31e-15	-0.62	-0.45	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
STAD	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-9.4	7.81e-19	4.33e-15	-0.48	-0.45	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
STAD	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-9.4	7.81e-19	4.33e-15	-0.48	-0.45	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-9.4	7.81e-19	4.33e-15	-0.48	-0.45	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
STAD	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-9.39	7.98e-19	4.42e-15	-0.47	-0.45	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
STAD	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	9.39	8.03e-19	4.45e-15	0.58	0.45	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
STAD	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	9.39	8.04e-19	4.45e-15	0.58	0.45	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
STAD	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-9.39	8.04e-19	4.45e-15	-0.48	-0.45	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	9.39	8.05e-19	4.46e-15	0.36	0.45	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
STAD	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	9.39	8.09e-19	4.48e-15	0.46	0.45	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	9.39	8.09e-19	4.48e-15	0.46	0.45	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	9.39	8.09e-19	4.48e-15	0.46	0.45	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	9.39	8.09e-19	4.48e-15	0.46	0.45	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.602	rs2157388	ENSG00000265828.1	MIR3939	-9.39	8.12e-19	4.49e-15	-0.52	-0.45	Crohn's disease;	chr6:167068424	chr6:166997807~166997912:-
STAD	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-9.39	8.15e-19	4.51e-15	-0.46	-0.45	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	9.39	8.17e-19	4.52e-15	0.57	0.45	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	9.39	8.17e-19	4.52e-15	0.57	0.45	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	9.39	8.17e-19	4.52e-15	0.57	0.45	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
STAD	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-9.39	8.27e-19	4.57e-15	-0.48	-0.45	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-9.39	8.27e-19	4.57e-15	-0.48	-0.45	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
STAD	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-9.39	8.36e-19	4.62e-15	-0.51	-0.45	Height;	chr11:118746590	chr11:118704607~118750263:+
STAD	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-9.39	8.38e-19	4.63e-15	-0.52	-0.45	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
STAD	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	9.39	8.38e-19	4.63e-15	0.49	0.45	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
STAD	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	9.39	8.58e-19	4.73e-15	0.76	0.45	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	9.39	8.58e-19	4.73e-15	0.76	0.45	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
STAD	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	9.39	8.6e-19	4.74e-15	0.72	0.45	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
STAD	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	9.39	8.6e-19	4.74e-15	0.72	0.45	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
STAD	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	9.38	8.8e-19	4.85e-15	0.56	0.45	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
STAD	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	9.38	8.9e-19	4.9e-15	0.48	0.45	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
STAD	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	9.38	8.9e-19	4.9e-15	0.48	0.45	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	9.38	8.9e-19	4.9e-15	0.48	0.45	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	9.38	8.9e-19	4.9e-15	0.48	0.45	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
STAD	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	9.38	8.9e-19	4.9e-15	0.48	0.45	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	9.38	8.9e-19	4.9e-15	0.48	0.45	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-9.38	8.91e-19	4.9e-15	-0.48	-0.45	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
STAD	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-9.38	8.91e-19	4.9e-15	-0.48	-0.45	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-9.38	8.91e-19	4.9e-15	-0.48	-0.45	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-9.38	8.91e-19	4.9e-15	-0.48	-0.45	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-9.38	8.91e-19	4.9e-15	-0.48	-0.45	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	9.38	8.95e-19	4.92e-15	0.48	0.45	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
STAD	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	9.38	9.15e-19	5.03e-15	0.72	0.45	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
STAD	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	9.38	9.23e-19	5.07e-15	0.48	0.45	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
STAD	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	9.38	9.25e-19	5.08e-15	0.47	0.45	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
STAD	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-9.37	9.34e-19	5.13e-15	-0.48	-0.45	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-9.37	9.34e-19	5.13e-15	-0.52	-0.45	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
STAD	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	9.37	9.38e-19	5.15e-15	0.57	0.45	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	9.37	9.38e-19	5.15e-15	0.57	0.45	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	9.37	9.39e-19	5.15e-15	0.57	0.45	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
STAD	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-9.37	9.43e-19	5.17e-15	-0.56	-0.45	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
STAD	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-9.37	9.58e-19	5.25e-15	-0.47	-0.45	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
STAD	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	9.37	9.63e-19	5.28e-15	0.46	0.45	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	9.37	9.83e-19	5.38e-15	0.57	0.45	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
STAD	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-9.37	9.86e-19	5.4e-15	-0.55	-0.45	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
STAD	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	9.36	1e-18	5.48e-15	0.48	0.45	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	9.36	1e-18	5.48e-15	0.46	0.45	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	9.36	1.01e-18	5.52e-15	0.36	0.45	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-9.36	1.03e-18	5.6e-15	-0.36	-0.45	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
STAD	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-9.36	1.03e-18	5.64e-15	-0.46	-0.45	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
STAD	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	9.36	1.04e-18	5.69e-15	0.48	0.45	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	9.36	1.06e-18	5.81e-15	0.46	0.45	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
STAD	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-9.36	1.07e-18	5.86e-15	-0.54	-0.45	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
STAD	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-9.35	1.1e-18	6.02e-15	-0.49	-0.45	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
STAD	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	9.35	1.11e-18	6.07e-15	0.48	0.45	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
STAD	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-9.35	1.12e-18	6.12e-15	-0.5	-0.45	Height;	chr11:118749988	chr11:118704607~118750263:+
STAD	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	9.35	1.13e-18	6.14e-15	0.72	0.45	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
STAD	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	9.34	1.18e-18	6.41e-15	0.53	0.45	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
STAD	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	9.34	1.19e-18	6.45e-15	0.48	0.45	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
STAD	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-9.34	1.2e-18	6.53e-15	-0.53	-0.45	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-9.34	1.23e-18	6.68e-15	-0.52	-0.45	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-9.34	1.23e-18	6.68e-15	-0.52	-0.45	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
STAD	cis	rs9457247	0.565	rs12178491	ENSG00000265828.1	MIR3939	-9.34	1.24e-18	6.76e-15	-0.5	-0.45	Crohn's disease;	chr6:167098986	chr6:166997807~166997912:-
STAD	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-9.33	1.25e-18	6.81e-15	-0.47	-0.45	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
STAD	cis	rs2301436	0.512	rs6925969	ENSG00000265828.1	MIR3939	-9.33	1.26e-18	6.83e-15	-0.5	-0.45	Crohn's disease;	chr6:167088250	chr6:166997807~166997912:-
STAD	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	9.33	1.26e-18	6.86e-15	0.57	0.45	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
STAD	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	9.33	1.28e-18	6.95e-15	0.54	0.45	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
STAD	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-9.33	1.3e-18	7.03e-15	-0.68	-0.45	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
STAD	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	9.33	1.3e-18	7.04e-15	0.46	0.45	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	9.33	1.3e-18	7.04e-15	0.46	0.45	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	9.33	1.3e-18	7.04e-15	0.46	0.45	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-9.33	1.33e-18	7.19e-15	-0.51	-0.45	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
STAD	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	9.33	1.34e-18	7.26e-15	0.55	0.45	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
STAD	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-9.33	1.35e-18	7.31e-15	-0.36	-0.45	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
STAD	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	9.32	1.37e-18	7.4e-15	0.49	0.45	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
STAD	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	9.32	1.37e-18	7.41e-15	0.72	0.45	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
STAD	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	9.32	1.38e-18	7.48e-15	0.58	0.45	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
STAD	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-9.32	1.4e-18	7.55e-15	-0.56	-0.45	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
STAD	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-9.32	1.4e-18	7.59e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
STAD	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	9.32	1.41e-18	7.62e-15	0.54	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
STAD	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-9.32	1.44e-18	7.75e-15	-0.45	-0.45	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
STAD	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	9.32	1.46e-18	7.87e-15	0.6	0.45	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
STAD	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.46e-18	7.88e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.46e-18	7.88e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
STAD	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-9.31	1.47e-18	7.96e-15	-0.53	-0.45	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
STAD	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
STAD	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
STAD	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
STAD	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
STAD	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.48e-18	7.98e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
STAD	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-9.31	1.49e-18	8e-15	-0.54	-0.45	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
STAD	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-9.31	1.51e-18	8.12e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
STAD	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	9.31	1.52e-18	8.21e-15	0.57	0.45	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	9.31	1.52e-18	8.21e-15	0.57	0.45	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	9.31	1.52e-18	8.21e-15	0.57	0.45	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	9.31	1.52e-18	8.21e-15	0.57	0.45	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	9.31	1.52e-18	8.21e-15	0.57	0.45	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
STAD	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-9.31	1.54e-18	8.31e-15	-0.36	-0.45	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
STAD	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	9.31	1.55e-18	8.35e-15	0.78	0.45	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
STAD	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	9.31	1.56e-18	8.37e-15	0.57	0.45	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-9.31	1.56e-18	8.38e-15	-0.36	-0.45	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-9.31	1.56e-18	8.38e-15	-0.36	-0.45	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
STAD	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-9.31	1.56e-18	8.39e-15	-0.5	-0.45	Height;	chr11:118781100	chr11:118704607~118750263:+
STAD	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-9.31	1.57e-18	8.41e-15	-0.53	-0.45	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-9.31	1.57e-18	8.41e-15	-0.53	-0.45	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
STAD	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-9.3	1.58e-18	8.47e-15	-0.5	-0.45	Height;	chr11:118761813	chr11:118704607~118750263:+
STAD	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	9.3	1.6e-18	8.58e-15	0.45	0.45	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	9.3	1.68e-18	9.02e-15	0.57	0.45	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
STAD	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-9.29	1.7e-18	9.11e-15	-0.36	-0.45	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
STAD	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-9.29	1.72e-18	9.2e-15	-0.57	-0.45	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
STAD	cis	rs6456156	0.586	rs10946209	ENSG00000265828.1	MIR3939	-9.29	1.74e-18	9.32e-15	-0.5	-0.45	Primary biliary cholangitis;	chr6:167067503	chr6:166997807~166997912:-
STAD	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-9.29	1.74e-18	9.34e-15	-0.5	-0.45	Height;	chr11:118764443	chr11:118704607~118750263:+
STAD	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-9.29	1.75e-18	9.38e-15	-0.5	-0.45	Height;	chr11:118760944	chr11:118704607~118750263:+
STAD	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-9.29	1.78e-18	9.53e-15	-0.47	-0.45	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.565	rs2038580	ENSG00000265828.1	MIR3939	-9.29	1.83e-18	9.78e-15	-0.51	-0.45	Crohn's disease;	chr6:167043002	chr6:166997807~166997912:-
STAD	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-9.28	1.86e-18	9.93e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-9.28	1.86e-18	9.93e-15	-0.48	-0.45	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
STAD	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	9.28	1.87e-18	1e-14	0.76	0.45	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
STAD	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	9.28	1.88e-18	1.01e-14	0.69	0.45	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
STAD	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-9.28	1.88e-18	1.01e-14	-0.47	-0.45	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	9.28	1.89e-18	1.01e-14	0.45	0.45	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
STAD	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	9.28	1.89e-18	1.01e-14	0.45	0.45	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
STAD	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	9.28	1.89e-18	1.01e-14	0.45	0.45	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
STAD	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	9.28	1.89e-18	1.01e-14	0.45	0.45	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	9.28	1.89e-18	1.01e-14	0.45	0.45	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
STAD	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	9.28	1.89e-18	1.01e-14	0.45	0.45	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
STAD	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-9.28	1.93e-18	1.03e-14	-0.5	-0.45	Height;	chr11:118773873	chr11:118704607~118750263:+
STAD	cis	rs9457247	0.602	rs4710175	ENSG00000265828.1	MIR3939	-9.28	1.94e-18	1.03e-14	-0.51	-0.45	Crohn's disease;	chr6:167054312	chr6:166997807~166997912:-
STAD	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	9.28	1.94e-18	1.03e-14	0.45	0.45	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.586	rs12198816	ENSG00000265828.1	MIR3939	-9.28	1.95e-18	1.04e-14	-0.5	-0.45	Primary biliary cholangitis;	chr6:167070058	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs2001114	ENSG00000265828.1	MIR3939	-9.28	1.95e-18	1.04e-14	-0.5	-0.45	Primary biliary cholangitis;	chr6:167073090	chr6:166997807~166997912:-
STAD	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	9.27	1.98e-18	1.06e-14	0.57	0.45	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
STAD	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	9.27	2e-18	1.07e-14	0.46	0.45	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
STAD	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-9.27	2.01e-18	1.07e-14	-0.66	-0.45	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
STAD	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	9.27	2.03e-18	1.08e-14	0.57	0.45	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	9.27	2.03e-18	1.08e-14	0.57	0.45	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	9.27	2.03e-18	1.08e-14	0.57	0.45	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
STAD	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	9.27	2.04e-18	1.08e-14	0.77	0.45	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
STAD	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	9.27	2.05e-18	1.09e-14	0.57	0.45	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
STAD	cis	rs6456156	0.586	rs1358883	ENSG00000265828.1	MIR3939	9.27	2.06e-18	1.1e-14	0.49	0.45	Primary biliary cholangitis;	chr6:167053945	chr6:166997807~166997912:-
STAD	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	9.27	2.08e-18	1.1e-14	0.57	0.45	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	9.27	2.08e-18	1.1e-14	0.57	0.45	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
STAD	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-9.27	2.09e-18	1.11e-14	-0.48	-0.45	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-9.27	2.09e-18	1.11e-14	-0.48	-0.45	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-9.27	2.09e-18	1.11e-14	-0.48	-0.45	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-9.27	2.09e-18	1.11e-14	-0.48	-0.45	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
STAD	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	9.27	2.1e-18	1.12e-14	0.54	0.45	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
STAD	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	9.27	2.11e-18	1.12e-14	0.5	0.45	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
STAD	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	9.26	2.13e-18	1.13e-14	0.47	0.45	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	9.26	2.13e-18	1.13e-14	0.58	0.45	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-9.26	2.15e-18	1.14e-14	-0.51	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
STAD	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	9.26	2.16e-18	1.15e-14	0.56	0.45	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
STAD	cis	rs6456156	0.586	rs4710176	ENSG00000265828.1	MIR3939	-9.26	2.17e-18	1.15e-14	-0.5	-0.45	Primary biliary cholangitis;	chr6:167078151	chr6:166997807~166997912:-
STAD	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	9.26	2.23e-18	1.18e-14	0.47	0.45	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
STAD	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	9.26	2.29e-18	1.21e-14	0.45	0.45	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
STAD	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	9.25	2.3e-18	1.22e-14	0.46	0.45	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	9.25	2.31e-18	1.22e-14	0.45	0.45	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
STAD	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-9.25	2.35e-18	1.24e-14	-0.47	-0.45	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
STAD	cis	rs6456156	0.528	rs6936261	ENSG00000265828.1	MIR3939	-9.25	2.36e-18	1.25e-14	-0.48	-0.45	Primary biliary cholangitis;	chr6:167056188	chr6:166997807~166997912:-
STAD	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-9.25	2.37e-18	1.25e-14	-0.4	-0.45	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
STAD	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-9.25	2.37e-18	1.25e-14	-0.51	-0.45	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
STAD	cis	rs6456156	0.586	rs12525855	ENSG00000265828.1	MIR3939	-9.25	2.39e-18	1.26e-14	-0.5	-0.45	Primary biliary cholangitis;	chr6:167066525	chr6:166997807~166997912:-
STAD	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-9.24	2.5e-18	1.32e-14	-0.36	-0.45	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
STAD	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-9.24	2.51e-18	1.32e-14	-0.48	-0.44	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-9.24	2.51e-18	1.32e-14	-0.48	-0.44	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
STAD	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	9.24	2.52e-18	1.33e-14	0.53	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
STAD	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	9.24	2.53e-18	1.33e-14	0.55	0.44	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
STAD	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-9.24	2.53e-18	1.34e-14	-0.45	-0.44	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
STAD	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	9.24	2.56e-18	1.35e-14	0.48	0.44	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
STAD	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	9.24	2.58e-18	1.36e-14	0.46	0.44	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
STAD	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	9.24	2.58e-18	1.36e-14	0.46	0.44	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
STAD	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-9.24	2.58e-18	1.36e-14	-0.4	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
STAD	cis	rs9457247	0.602	rs12209395	ENSG00000265828.1	MIR3939	-9.24	2.64e-18	1.39e-14	-0.5	-0.44	Crohn's disease;	chr6:167050426	chr6:166997807~166997912:-
STAD	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	9.23	2.67e-18	1.41e-14	0.45	0.44	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-9.23	2.67e-18	1.41e-14	-0.36	-0.44	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
STAD	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	9.23	2.74e-18	1.44e-14	0.46	0.44	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-9.23	2.76e-18	1.45e-14	-0.5	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
STAD	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-9.23	2.77e-18	1.46e-14	-0.39	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
STAD	cis	rs9457247	0.561	rs916331	ENSG00000265828.1	MIR3939	-9.23	2.79e-18	1.46e-14	-0.51	-0.44	Crohn's disease;	chr6:167057071	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.602	rs13204839	ENSG00000265828.1	MIR3939	-9.23	2.79e-18	1.46e-14	-0.51	-0.44	Crohn's disease;	chr6:167057631	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.602	rs6456152	ENSG00000265828.1	MIR3939	-9.23	2.79e-18	1.46e-14	-0.51	-0.44	Crohn's disease;	chr6:167058574	chr6:166997807~166997912:-
STAD	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	9.23	2.79e-18	1.47e-14	0.77	0.44	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
STAD	cis	rs9457247	0.602	rs10484530	ENSG00000265828.1	MIR3939	-9.23	2.8e-18	1.47e-14	-0.51	-0.44	Crohn's disease;	chr6:167048074	chr6:166997807~166997912:-
STAD	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-9.23	2.82e-18	1.48e-14	-0.46	-0.44	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
STAD	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-9.23	2.83e-18	1.49e-14	-0.46	-0.44	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-9.23	2.83e-18	1.49e-14	-0.46	-0.44	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
STAD	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	9.22	2.87e-18	1.51e-14	0.75	0.44	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
STAD	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-9.22	2.88e-18	1.51e-14	-0.47	-0.44	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
STAD	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	9.22	2.89e-18	1.52e-14	0.48	0.44	Temperament;	chr17:14068990	chr17:14024514~14025488:+
STAD	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-9.22	2.98e-18	1.57e-14	-0.65	-0.44	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-9.22	2.99e-18	1.57e-14	-0.57	-0.44	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
STAD	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-9.22	3.08e-18	1.61e-14	-0.46	-0.44	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
STAD	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-9.21	3.09e-18	1.62e-14	-0.5	-0.44	Height;	chr11:118747911	chr11:118704607~118750263:+
STAD	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	9.21	3.1e-18	1.62e-14	0.6	0.44	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
STAD	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-9.21	3.1e-18	1.62e-14	-0.36	-0.44	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
STAD	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-9.21	3.1e-18	1.62e-14	-0.52	-0.44	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
STAD	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-9.21	3.11e-18	1.63e-14	-0.36	-0.44	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
STAD	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-9.21	3.12e-18	1.64e-14	-0.47	-0.44	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.586	rs10946208	ENSG00000265828.1	MIR3939	-9.21	3.15e-18	1.65e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167046108	chr6:166997807~166997912:-
STAD	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	9.21	3.16e-18	1.65e-14	0.48	0.44	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
STAD	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	9.21	3.16e-18	1.65e-14	0.48	0.44	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
STAD	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	9.21	3.16e-18	1.65e-14	0.48	0.44	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-9.21	3.17e-18	1.66e-14	-0.36	-0.44	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-9.21	3.17e-18	1.66e-14	-0.36	-0.44	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-9.21	3.18e-18	1.66e-14	-0.36	-0.44	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-9.21	3.18e-18	1.66e-14	-0.36	-0.44	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
STAD	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-9.21	3.22e-18	1.68e-14	-0.53	-0.44	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
STAD	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-9.21	3.22e-18	1.68e-14	-0.46	-0.44	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-9.21	3.28e-18	1.72e-14	-0.57	-0.44	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	9.21	3.3e-18	1.72e-14	0.57	0.44	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	9.21	3.3e-18	1.72e-14	0.55	0.44	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
STAD	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	9.2	3.35e-18	1.75e-14	0.45	0.44	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
STAD	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-9.2	3.4e-18	1.77e-14	-0.45	-0.44	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
STAD	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-9.2	3.46e-18	1.8e-14	-0.48	-0.44	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
STAD	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-9.2	3.47e-18	1.81e-14	-0.36	-0.44	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
STAD	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-9.2	3.54e-18	1.84e-14	-0.45	-0.44	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
STAD	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	9.19	3.62e-18	1.89e-14	0.55	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
STAD	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	9.19	3.63e-18	1.89e-14	0.52	0.44	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
STAD	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	9.19	3.63e-18	1.89e-14	0.46	0.44	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
STAD	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	9.19	3.65e-18	1.9e-14	0.56	0.44	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
STAD	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-9.19	3.67e-18	1.91e-14	-0.46	-0.44	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-9.19	3.68e-18	1.92e-14	-0.36	-0.44	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
STAD	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	9.19	3.69e-18	1.92e-14	0.45	0.44	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.582	rs9459855	ENSG00000265828.1	MIR3939	-9.19	3.75e-18	1.95e-14	-0.51	-0.44	Crohn's disease;	chr6:167052662	chr6:166997807~166997912:-
STAD	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-9.19	3.82e-18	1.98e-14	-0.36	-0.44	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
STAD	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-9.19	3.83e-18	1.99e-14	-0.45	-0.44	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
STAD	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-9.19	3.84e-18	1.99e-14	-0.51	-0.44	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
STAD	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-9.19	3.86e-18	2e-14	-0.45	-0.44	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.586	rs9459853	ENSG00000265828.1	MIR3939	-9.18	3.88e-18	2.01e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167052286	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.583	rs7748224	ENSG00000265828.1	MIR3939	-9.18	3.89e-18	2.02e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167043372	chr6:166997807~166997912:-
STAD	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-9.18	3.9e-18	2.02e-14	-0.47	-0.44	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
STAD	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-9.18	3.94e-18	2.04e-14	-0.45	-0.44	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	9.18	3.97e-18	2.06e-14	0.58	0.44	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
STAD	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-9.18	3.98e-18	2.06e-14	-0.5	-0.44	Height;	chr11:118786602	chr11:118704607~118750263:+
STAD	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	9.18	4e-18	2.07e-14	0.65	0.44	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
STAD	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-9.18	4e-18	2.07e-14	-0.45	-0.44	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-9.18	4.02e-18	2.08e-14	-0.44	-0.44	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
STAD	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-9.18	4.03e-18	2.09e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-9.18	4.03e-18	2.09e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
STAD	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-9.18	4.05e-18	2.09e-14	-0.36	-0.44	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-9.18	4.05e-18	2.09e-14	-0.36	-0.44	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-9.18	4.05e-18	2.09e-14	-0.36	-0.44	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
STAD	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	9.18	4.06e-18	2.1e-14	0.45	0.44	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
STAD	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-9.18	4.06e-18	2.1e-14	-0.52	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
STAD	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	9.18	4.09e-18	2.11e-14	0.56	0.44	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
STAD	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-9.18	4.09e-18	2.11e-14	-0.46	-0.44	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
STAD	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-9.18	4.09e-18	2.11e-14	-0.46	-0.44	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
STAD	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-9.18	4.1e-18	2.12e-14	-0.51	-0.44	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
STAD	cis	rs9457247	0.602	rs12208359	ENSG00000265828.1	MIR3939	-9.18	4.15e-18	2.14e-14	-0.51	-0.44	Crohn's disease;	chr6:167044967	chr6:166997807~166997912:-
STAD	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	9.18	4.15e-18	2.15e-14	0.44	0.44	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
STAD	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	9.18	4.16e-18	2.15e-14	0.45	0.44	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
STAD	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-9.17	4.17e-18	2.15e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-9.17	4.2e-18	2.17e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-9.17	4.2e-18	2.17e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-9.17	4.2e-18	2.17e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
STAD	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-9.17	4.2e-18	2.17e-14	-0.45	-0.44	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
STAD	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	9.17	4.22e-18	2.17e-14	0.45	0.44	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
STAD	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	9.17	4.22e-18	2.17e-14	0.45	0.44	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
STAD	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	9.17	4.22e-18	2.17e-14	0.45	0.44	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
STAD	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	9.17	4.22e-18	2.17e-14	0.45	0.44	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-9.17	4.25e-18	2.19e-14	-0.36	-0.44	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
STAD	cis	rs9457247	0.624	rs17524252	ENSG00000265828.1	MIR3939	-9.17	4.3e-18	2.21e-14	-0.51	-0.44	Crohn's disease;	chr6:167053490	chr6:166997807~166997912:-
STAD	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	9.17	4.32e-18	2.22e-14	0.38	0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
STAD	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-9.17	4.32e-18	2.23e-14	-0.44	-0.44	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-9.17	4.35e-18	2.24e-14	-0.5	-0.44	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
STAD	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	9.17	4.36e-18	2.24e-14	0.54	0.44	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
STAD	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-9.17	4.38e-18	2.25e-14	-0.36	-0.44	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
STAD	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	9.17	4.38e-18	2.26e-14	0.75	0.44	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
STAD	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	9.17	4.48e-18	2.3e-14	0.46	0.44	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
STAD	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	9.17	4.48e-18	2.3e-14	0.46	0.44	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
STAD	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-9.16	4.54e-18	2.33e-14	-0.54	-0.44	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	9.16	4.57e-18	2.35e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
STAD	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-9.16	4.58e-18	2.35e-14	-0.45	-0.44	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
STAD	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-9.16	4.58e-18	2.35e-14	-0.55	-0.44	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
STAD	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	9.16	4.58e-18	2.35e-14	0.55	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
STAD	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	9.16	4.58e-18	2.35e-14	0.55	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
STAD	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-9.16	4.58e-18	2.35e-14	-0.36	-0.44	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
STAD	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-9.16	4.62e-18	2.37e-14	-0.46	-0.44	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
STAD	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-9.16	4.62e-18	2.37e-14	-0.46	-0.44	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
STAD	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-9.16	4.62e-18	2.37e-14	-0.46	-0.44	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
STAD	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-9.16	4.65e-18	2.38e-14	-0.53	-0.44	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
STAD	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-9.16	4.69e-18	2.4e-14	-0.45	-0.44	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
STAD	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	9.16	4.74e-18	2.43e-14	0.42	0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
STAD	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-9.16	4.75e-18	2.43e-14	-0.49	-0.44	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
STAD	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	9.16	4.76e-18	2.44e-14	0.53	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
STAD	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	9.16	4.84e-18	2.47e-14	0.47	0.44	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
STAD	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-9.15	4.88e-18	2.5e-14	-0.45	-0.44	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
STAD	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	9.15	4.9e-18	2.51e-14	0.46	0.44	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	9.15	4.9e-18	2.51e-14	0.46	0.44	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
STAD	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	9.15	4.92e-18	2.52e-14	0.44	0.44	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
STAD	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-9.15	4.93e-18	2.52e-14	-0.46	-0.44	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	9.15	4.93e-18	2.52e-14	0.45	0.44	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	9.15	4.93e-18	2.52e-14	0.45	0.44	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
STAD	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	9.15	4.96e-18	2.53e-14	0.55	0.44	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
STAD	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-9.15	4.96e-18	2.53e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
STAD	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-9.15	4.96e-18	2.53e-14	-0.47	-0.44	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
STAD	cis	rs6456156	0.586	rs13195158	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167067904	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs9457266	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167069067	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.565	rs7750209	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167069407	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs7746628	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167069747	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs2345753	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167070856	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.603	rs2345754	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167070873	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs7761977	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167072190	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs7742305	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167072235	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs7762156	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167072343	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs2001115	ENSG00000265828.1	MIR3939	-9.15	5e-18	2.55e-14	-0.49	-0.44	Primary biliary cholangitis;	chr6:167072730	chr6:166997807~166997912:-
STAD	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	9.15	5.06e-18	2.58e-14	0.47	0.44	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
STAD	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	9.15	5.08e-18	2.59e-14	0.48	0.44	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
STAD	cis	rs9457247	0.602	rs2239827	ENSG00000265828.1	MIR3939	-9.14	5.23e-18	2.66e-14	-0.51	-0.44	Crohn's disease;	chr6:167077457	chr6:166997807~166997912:-
STAD	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	9.14	5.25e-18	2.67e-14	0.55	0.44	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
STAD	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-9.14	5.32e-18	2.71e-14	-0.68	-0.44	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
STAD	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-9.14	5.4e-18	2.75e-14	-0.48	-0.44	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
STAD	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	9.14	5.41e-18	2.75e-14	0.52	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
STAD	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	9.14	5.44e-18	2.77e-14	0.48	0.44	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
STAD	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-9.14	5.46e-18	2.78e-14	-0.48	-0.44	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
STAD	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-9.14	5.53e-18	2.81e-14	-0.52	-0.44	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
STAD	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	9.14	5.55e-18	2.82e-14	0.48	0.44	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
STAD	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	9.13	5.62e-18	2.85e-14	0.45	0.44	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
STAD	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-9.13	5.66e-18	2.87e-14	-0.55	-0.44	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-9.13	5.66e-18	2.87e-14	-0.55	-0.44	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
STAD	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	9.13	5.67e-18	2.88e-14	0.7	0.44	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
STAD	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-9.13	5.67e-18	2.88e-14	-0.56	-0.44	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
STAD	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-9.13	5.7e-18	2.89e-14	-0.67	-0.44	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
STAD	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-9.13	5.73e-18	2.91e-14	-0.49	-0.44	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
STAD	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-9.13	5.76e-18	2.92e-14	-0.46	-0.44	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-9.13	5.76e-18	2.92e-14	-0.47	-0.44	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.534	rs933243	ENSG00000265828.1	MIR3939	-9.13	5.81e-18	2.94e-14	-0.5	-0.44	Crohn's disease;	chr6:166990385	chr6:166997807~166997912:-
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	9.13	5.84e-18	2.96e-14	0.5	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
STAD	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-9.13	5.9e-18	2.99e-14	-0.47	-0.44	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
STAD	cis	rs6456156	0.586	rs13210649	ENSG00000265828.1	MIR3939	-9.13	5.93e-18	3e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167059705	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs12213801	ENSG00000265828.1	MIR3939	-9.13	5.93e-18	3e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167060596	chr6:166997807~166997912:-
STAD	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	9.13	5.96e-18	3.02e-14	0.57	0.44	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
STAD	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-9.13	5.99e-18	3.03e-14	-0.46	-0.44	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
STAD	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-9.13	5.99e-18	3.03e-14	-0.46	-0.44	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.792	rs4710183	ENSG00000265828.1	MIR3939	9.13	5.99e-18	3.03e-14	0.48	0.44	Primary biliary cholangitis;	chr6:167100595	chr6:166997807~166997912:-
STAD	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	9.13	6.05e-18	3.06e-14	0.48	0.44	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
STAD	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-9.12	6.17e-18	3.11e-14	-0.46	-0.44	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
STAD	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-9.12	6.17e-18	3.11e-14	-0.46	-0.44	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
STAD	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-9.12	6.19e-18	3.12e-14	-0.47	-0.44	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-9.12	6.19e-18	3.12e-14	-0.47	-0.44	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-9.12	6.19e-18	3.12e-14	-0.47	-0.44	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
STAD	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	9.12	6.24e-18	3.15e-14	0.77	0.44	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	9.12	6.24e-18	3.15e-14	0.77	0.44	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
STAD	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-9.12	6.29e-18	3.17e-14	-0.55	-0.44	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
STAD	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-9.12	6.3e-18	3.17e-14	-0.48	-0.44	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
STAD	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-9.12	6.31e-18	3.18e-14	-0.49	-0.44	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
STAD	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-9.12	6.31e-18	3.18e-14	-0.49	-0.44	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
STAD	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-9.12	6.31e-18	3.18e-14	-0.55	-0.44	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-9.12	6.31e-18	3.18e-14	-0.55	-0.44	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-9.12	6.31e-18	3.18e-14	-0.55	-0.44	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
STAD	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	9.12	6.47e-18	3.26e-14	0.52	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
STAD	cis	rs9457247	0.544	rs6920858	ENSG00000265828.1	MIR3939	-9.12	6.47e-18	3.26e-14	-0.5	-0.44	Crohn's disease;	chr6:167051142	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.602	rs9459854	ENSG00000265828.1	MIR3939	-9.12	6.47e-18	3.26e-14	-0.5	-0.44	Crohn's disease;	chr6:167052394	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.624	rs9457260	ENSG00000265828.1	MIR3939	-9.12	6.47e-18	3.26e-14	-0.5	-0.44	Crohn's disease;	chr6:167053177	chr6:166997807~166997912:-
STAD	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-9.12	6.47e-18	3.26e-14	-0.47	-0.44	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
STAD	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-9.11	6.55e-18	3.29e-14	-0.54	-0.44	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
STAD	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-9.11	6.59e-18	3.31e-14	-0.44	-0.44	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
STAD	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-9.11	6.61e-18	3.32e-14	-0.48	-0.44	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-9.11	6.61e-18	3.32e-14	-0.48	-0.44	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-9.11	6.61e-18	3.32e-14	-0.48	-0.44	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
STAD	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	9.11	6.67e-18	3.35e-14	0.44	0.44	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	9.11	6.67e-18	3.35e-14	0.44	0.44	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	9.11	6.68e-18	3.35e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
STAD	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-9.11	6.69e-18	3.36e-14	-0.46	-0.44	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
STAD	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-9.11	6.69e-18	3.36e-14	-0.46	-0.44	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
STAD	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-9.11	6.69e-18	3.36e-14	-0.46	-0.44	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	9.11	6.7e-18	3.36e-14	0.56	0.44	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
STAD	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-9.11	6.79e-18	3.4e-14	-0.48	-0.44	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-9.11	6.79e-18	3.4e-14	-0.48	-0.44	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-9.11	6.79e-18	3.4e-14	-0.48	-0.44	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-9.11	6.79e-18	3.4e-14	-0.48	-0.44	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-9.11	6.79e-18	3.4e-14	-0.48	-0.44	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-9.11	6.79e-18	3.4e-14	-0.48	-0.44	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
STAD	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	9.11	6.85e-18	3.43e-14	0.44	0.44	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
STAD	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	9.11	7e-18	3.51e-14	0.47	0.44	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
STAD	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-9.11	7.01e-18	3.51e-14	-0.48	-0.44	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
STAD	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-9.1	7.06e-18	3.53e-14	-0.44	-0.44	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.566	rs10946207	ENSG00000265828.1	MIR3939	-9.1	7.07e-18	3.53e-14	-0.51	-0.44	Crohn's disease;	chr6:167042548	chr6:166997807~166997912:-
STAD	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	9.1	7.37e-18	3.68e-14	0.48	0.44	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
STAD	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-9.09	7.6e-18	3.79e-14	-0.44	-0.44	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
STAD	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-9.09	7.6e-18	3.79e-14	-0.44	-0.44	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-9.09	7.6e-18	3.79e-14	-0.44	-0.44	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
STAD	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	9.09	7.62e-18	3.79e-14	0.55	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
STAD	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-9.09	7.63e-18	3.8e-14	-0.67	-0.44	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-9.09	7.63e-18	3.8e-14	-0.67	-0.44	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
STAD	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-9.09	7.71e-18	3.84e-14	-0.46	-0.44	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
STAD	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-9.09	7.71e-18	3.84e-14	-0.46	-0.44	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
STAD	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	9.09	7.85e-18	3.9e-14	0.46	0.44	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.602	rs9457262	ENSG00000265828.1	MIR3939	-9.09	7.85e-18	3.9e-14	-0.5	-0.44	Crohn's disease;	chr6:167060197	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.534	rs9347170	ENSG00000265828.1	MIR3939	9.09	7.89e-18	3.92e-14	0.51	0.44	Crohn's disease;	chr6:166991699	chr6:166997807~166997912:-
STAD	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	9.09	7.97e-18	3.96e-14	0.44	0.44	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	9.09	7.97e-18	3.96e-14	0.44	0.44	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	9.09	7.97e-18	3.96e-14	0.44	0.44	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
STAD	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	9.09	7.97e-18	3.96e-14	0.44	0.44	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	9.09	7.97e-18	3.96e-14	0.44	0.44	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	9.09	7.97e-18	3.96e-14	0.44	0.44	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-9.09	8.01e-18	3.98e-14	-0.36	-0.44	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
STAD	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-9.09	8.05e-18	3.99e-14	-0.47	-0.44	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
STAD	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	9.09	8.06e-18	3.99e-14	0.46	0.44	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
STAD	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-9.08	8.23e-18	4.08e-14	-0.46	-0.44	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	9.08	8.3e-18	4.11e-14	0.56	0.44	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
STAD	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-9.08	8.48e-18	4.2e-14	-0.48	-0.44	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
STAD	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-9.08	8.48e-18	4.2e-14	-0.48	-0.44	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
STAD	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-9.08	8.48e-18	4.2e-14	-0.48	-0.44	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
STAD	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-9.08	8.67e-18	4.29e-14	-0.55	-0.44	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
STAD	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-9.07	8.96e-18	4.43e-14	-0.52	-0.44	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
STAD	cis	rs9457247	0.534	rs9366078	ENSG00000265828.1	MIR3939	9.07	9.04e-18	4.47e-14	0.5	0.44	Crohn's disease;	chr6:166986024	chr6:166997807~166997912:-
STAD	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-9.07	9.1e-18	4.49e-14	-0.48	-0.44	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
STAD	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	9.07	9.11e-18	4.5e-14	0.71	0.44	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
STAD	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-9.07	9.15e-18	4.52e-14	-0.48	-0.44	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
STAD	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-9.07	9.19e-18	4.54e-14	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
STAD	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-9.07	9.21e-18	4.54e-14	-0.56	-0.44	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
STAD	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	9.07	9.3e-18	4.59e-14	0.67	0.44	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
STAD	cis	rs6456156	0.586	rs6909180	ENSG00000265828.1	MIR3939	-9.07	9.42e-18	4.64e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167047049	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs12213683	ENSG00000265828.1	MIR3939	-9.07	9.42e-18	4.64e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167047230	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs12529876	ENSG00000265828.1	MIR3939	-9.07	9.42e-18	4.64e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167048013	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs12528323	ENSG00000265828.1	MIR3939	-9.07	9.42e-18	4.64e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167048157	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs12528689	ENSG00000265828.1	MIR3939	-9.07	9.42e-18	4.64e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167048258	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs13208636	ENSG00000265828.1	MIR3939	-9.07	9.42e-18	4.64e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167048477	chr6:166997807~166997912:-
STAD	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-9.07	9.42e-18	4.64e-14	-0.54	-0.44	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-9.07	9.42e-18	4.64e-14	-0.54	-0.44	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-9.07	9.42e-18	4.64e-14	-0.54	-0.44	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-9.07	9.42e-18	4.64e-14	-0.54	-0.44	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
STAD	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	9.06	9.48e-18	4.67e-14	0.52	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
STAD	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-9.06	9.49e-18	4.67e-14	-0.54	-0.44	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-9.06	9.49e-18	4.67e-14	-0.54	-0.44	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-9.06	9.49e-18	4.67e-14	-0.54	-0.44	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-9.06	9.49e-18	4.67e-14	-0.54	-0.44	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-9.06	9.49e-18	4.67e-14	-0.54	-0.44	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
STAD	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-9.06	9.64e-18	4.74e-14	-0.52	-0.44	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-9.06	9.64e-18	4.74e-14	-0.52	-0.44	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
STAD	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-9.06	9.84e-18	4.84e-14	-0.54	-0.44	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-9.06	9.85e-18	4.84e-14	-0.54	-0.44	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
STAD	cis	rs6456156	0.586	rs1407315	ENSG00000265828.1	MIR3939	-9.06	9.97e-18	4.9e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167055171	chr6:166997807~166997912:-
STAD	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	9.06	1e-17	4.92e-14	0.48	0.44	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
STAD	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	9.06	1.01e-17	4.95e-14	0.52	0.44	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
STAD	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	9.05	1.02e-17	5.02e-14	0.66	0.44	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
STAD	cis	rs6456156	0.586	rs6456150	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167055434	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs12527827	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167055783	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.565	rs12529959	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167055804	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs911632	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167057973	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs2017338	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167058226	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.51	rs6456151	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Crohn's disease;	chr6:167058363	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.565	rs6456153	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167058679	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs6456154	ENSG00000265828.1	MIR3939	-9.05	1.02e-17	5.02e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167058768	chr6:166997807~166997912:-
STAD	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	9.05	1.03e-17	5.05e-14	0.52	0.44	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
STAD	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	9.05	1.06e-17	5.21e-14	0.52	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
STAD	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.26e-14	-0.54	-0.44	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.26e-14	-0.54	-0.44	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
STAD	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.26e-14	-0.54	-0.44	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.26e-14	-0.54	-0.44	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.26e-14	-0.54	-0.44	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.26e-14	-0.54	-0.44	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.26e-14	-0.54	-0.44	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-9.05	1.08e-17	5.27e-14	-0.54	-0.44	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
STAD	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-9.05	1.09e-17	5.33e-14	-0.39	-0.44	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
STAD	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	9.04	1.1e-17	5.36e-14	0.46	0.44	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
STAD	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	9.04	1.1e-17	5.39e-14	0.58	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
STAD	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	9.04	1.11e-17	5.44e-14	0.65	0.44	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
STAD	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	9.04	1.12e-17	5.45e-14	0.46	0.44	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
STAD	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	9.04	1.12e-17	5.49e-14	0.45	0.44	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.534	rs9356551	ENSG00000265828.1	MIR3939	9.04	1.16e-17	5.64e-14	0.5	0.44	Crohn's disease;	chr6:166986857	chr6:166997807~166997912:-
STAD	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	9.03	1.18e-17	5.77e-14	0.52	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
STAD	cis	rs6456156	0.586	rs1358882	ENSG00000265828.1	MIR3939	-9.03	1.19e-17	5.8e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167053613	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.586	rs9457261	ENSG00000265828.1	MIR3939	-9.03	1.19e-17	5.8e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167054191	chr6:166997807~166997912:-
STAD	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-9.03	1.19e-17	5.8e-14	-0.47	-0.44	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
STAD	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-9.03	1.19e-17	5.81e-14	-0.54	-0.44	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
STAD	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-9.03	1.2e-17	5.87e-14	-0.44	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
STAD	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	9.03	1.23e-17	5.97e-14	0.56	0.44	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	9.03	1.23e-17	5.97e-14	0.56	0.44	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
STAD	cis	rs9457247	0.534	rs4710149	ENSG00000265828.1	MIR3939	9.03	1.23e-17	6e-14	0.5	0.44	Crohn's disease;	chr6:166972858	chr6:166997807~166997912:-
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000280411.1	IGHV1-69-2	-9.03	1.24e-17	6.06e-14	-0.36	-0.44	Kawasaki disease;	chr14:106767802	chr14:106762092~106762588:-
STAD	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	9.03	1.27e-17	6.17e-14	0.47	0.44	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
STAD	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	9.02	1.3e-17	6.32e-14	0.52	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	9.02	1.3e-17	6.34e-14	0.53	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
STAD	cis	rs10129255	0.5	rs7159033	ENSG00000280411.1	IGHV1-69-2	-9.02	1.31e-17	6.37e-14	-0.36	-0.44	Kawasaki disease;	chr14:106701709	chr14:106762092~106762588:-
STAD	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	9.02	1.31e-17	6.38e-14	0.53	0.44	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
STAD	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-9.02	1.32e-17	6.39e-14	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
STAD	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	9.02	1.33e-17	6.44e-14	0.5	0.44	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
STAD	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-9.02	1.34e-17	6.51e-14	-0.51	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
STAD	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-9.02	1.34e-17	6.51e-14	-0.52	-0.44	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-9.02	1.34e-17	6.51e-14	-0.52	-0.44	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
STAD	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-9.02	1.34e-17	6.51e-14	-0.52	-0.44	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
STAD	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-9.02	1.34e-17	6.52e-14	-0.47	-0.44	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.692	rs9457270	ENSG00000265828.1	MIR3939	-9.02	1.36e-17	6.6e-14	-0.48	-0.44	Primary biliary cholangitis;	chr6:167099440	chr6:166997807~166997912:-
STAD	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-9.01	1.38e-17	6.69e-14	-0.55	-0.44	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-9.01	1.39e-17	6.75e-14	-0.36	-0.44	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
STAD	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-9.01	1.4e-17	6.8e-14	-0.52	-0.44	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
STAD	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-9.01	1.41e-17	6.82e-14	-0.53	-0.44	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
STAD	cis	rs9457247	0.565	rs2239823	ENSG00000265828.1	MIR3939	-9.01	1.41e-17	6.84e-14	-0.49	-0.44	Crohn's disease;	chr6:167098643	chr6:166997807~166997912:-
STAD	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	9.01	1.42e-17	6.9e-14	0.6	0.44	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
STAD	cis	rs3093024	0.595	rs4412174	ENSG00000265828.1	MIR3939	-9.01	1.43e-17	6.95e-14	-0.5	-0.44	Rheumatoid arthritis;	chr6:167062578	chr6:166997807~166997912:-
STAD	cis	rs3093024	0.595	rs4458654	ENSG00000265828.1	MIR3939	-9.01	1.43e-17	6.95e-14	-0.5	-0.44	Rheumatoid arthritis;	chr6:167062580	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	9.01	1.44e-17	6.97e-14	0.53	0.44	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
STAD	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	9.01	1.46e-17	7.06e-14	0.53	0.44	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
STAD	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-9.01	1.46e-17	7.07e-14	-0.45	-0.44	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-9.01	1.46e-17	7.07e-14	-0.44	-0.44	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-9.01	1.46e-17	7.07e-14	-0.44	-0.44	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-9.01	1.46e-17	7.07e-14	-0.44	-0.44	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
STAD	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-9.01	1.46e-17	7.07e-14	-0.44	-0.44	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-9.01	1.46e-17	7.07e-14	-0.44	-0.44	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
STAD	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-9.01	1.46e-17	7.07e-14	-0.44	-0.44	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
STAD	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	9	1.47e-17	7.12e-14	0.57	0.44	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
STAD	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-9	1.49e-17	7.18e-14	-0.63	-0.44	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-9	1.5e-17	7.23e-14	-0.55	-0.44	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
STAD	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-9	1.5e-17	7.24e-14	-0.53	-0.44	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
STAD	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-9	1.51e-17	7.3e-14	-0.44	-0.44	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
STAD	cis	rs11089937	0.963	rs5757078	ENSG00000211639.2	IGLV4-60	9	1.52e-17	7.32e-14	0.44	0.44	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22162199~22162681:+
STAD	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-9	1.52e-17	7.33e-14	-0.65	-0.44	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
STAD	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
STAD	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-9	1.56e-17	7.51e-14	-0.43	-0.44	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
STAD	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-9	1.57e-17	7.54e-14	-0.53	-0.44	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
STAD	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	8.99	1.61e-17	7.74e-14	0.46	0.44	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
STAD	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	8.99	1.61e-17	7.74e-14	0.46	0.44	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
STAD	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-8.99	1.63e-17	7.81e-14	-0.54	-0.44	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-8.99	1.63e-17	7.81e-14	-0.35	-0.44	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-8.99	1.63e-17	7.81e-14	-0.35	-0.44	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
STAD	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-8.99	1.64e-17	7.87e-14	-0.54	-0.44	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
STAD	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	8.99	1.65e-17	7.88e-14	0.56	0.44	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
STAD	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-8.99	1.65e-17	7.91e-14	-0.54	-0.44	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
STAD	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	8.99	1.69e-17	8.11e-14	0.56	0.43	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	8.99	1.69e-17	8.11e-14	0.56	0.43	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
STAD	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-8.99	1.7e-17	8.11e-14	-0.44	-0.43	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-8.99	1.7e-17	8.11e-14	-0.44	-0.43	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-8.99	1.7e-17	8.11e-14	-0.44	-0.43	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-8.99	1.7e-17	8.11e-14	-0.44	-0.43	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-8.99	1.7e-17	8.11e-14	-0.44	-0.43	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-8.99	1.7e-17	8.11e-14	-0.44	-0.43	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
STAD	cis	rs1577917	0.687	rs13197828	ENSG00000203875.9	SNHG5	-8.99	1.7e-17	8.13e-14	-0.58	-0.43	Response to antipsychotic treatment;	chr6:86095912	chr6:85660950~85678736:-
STAD	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-8.98	1.71e-17	8.19e-14	-0.44	-0.43	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
STAD	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-8.98	1.71e-17	8.19e-14	-0.44	-0.43	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
STAD	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-8.98	1.71e-17	8.19e-14	-0.44	-0.43	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	8.98	1.73e-17	8.27e-14	0.53	0.43	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
STAD	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	8.98	1.74e-17	8.32e-14	0.44	0.43	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
STAD	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	8.98	1.78e-17	8.49e-14	0.44	0.43	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	8.98	1.78e-17	8.49e-14	0.44	0.43	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	8.98	1.78e-17	8.49e-14	0.44	0.43	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
STAD	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	8.98	1.78e-17	8.49e-14	0.44	0.43	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	8.98	1.78e-17	8.49e-14	0.44	0.43	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	8.98	1.78e-17	8.49e-14	0.44	0.43	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
STAD	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-8.98	1.81e-17	8.61e-14	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
STAD	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	8.98	1.81e-17	8.64e-14	0.6	0.43	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
STAD	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-8.98	1.82e-17	8.66e-14	-0.53	-0.43	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
STAD	cis	rs916888	0.61	rs199436	ENSG00000262500.1	RP11-259G18.2	-8.98	1.82e-17	8.69e-14	-0.54	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46243606~46245044:+
STAD	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-8.97	1.84e-17	8.76e-14	-0.44	-0.43	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.565	rs6921588	ENSG00000265828.1	MIR3939	-8.97	1.84e-17	8.78e-14	-0.48	-0.43	Primary biliary cholangitis;	chr6:167080909	chr6:166997807~166997912:-
STAD	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-8.97	1.85e-17	8.79e-14	-0.44	-0.43	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
STAD	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-8.97	1.85e-17	8.81e-14	-0.54	-0.43	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-8.97	1.85e-17	8.81e-14	-0.54	-0.43	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
STAD	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	8.97	1.87e-17	8.89e-14	0.72	0.43	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
STAD	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	8.97	1.87e-17	8.9e-14	0.55	0.43	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
STAD	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-8.97	1.88e-17	8.94e-14	-0.43	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
STAD	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-8.97	1.89e-17	8.98e-14	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
STAD	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	8.97	1.92e-17	9.12e-14	0.49	0.43	Breast cancer;	chr11:750849	chr11:779617~780755:+
STAD	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-8.97	1.95e-17	9.25e-14	-0.53	-0.43	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
STAD	cis	rs6456156	0.565	rs2181058	ENSG00000265828.1	MIR3939	-8.97	1.95e-17	9.27e-14	-0.48	-0.43	Primary biliary cholangitis;	chr6:167051842	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.565	rs12529238	ENSG00000265828.1	MIR3939	-8.97	1.95e-17	9.27e-14	-0.48	-0.43	Primary biliary cholangitis;	chr6:167052088	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.524	rs6932740	ENSG00000265828.1	MIR3939	-8.97	1.95e-17	9.27e-14	-0.48	-0.43	Primary biliary cholangitis;	chr6:167052951	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.524	rs6934043	ENSG00000265828.1	MIR3939	-8.97	1.95e-17	9.27e-14	-0.48	-0.43	Primary biliary cholangitis;	chr6:167052961	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	8.97	1.96e-17	9.31e-14	0.52	0.43	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
STAD	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-8.97	1.97e-17	9.34e-14	-0.44	-0.43	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
STAD	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
STAD	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	8.97	1.97e-17	9.34e-14	0.44	0.43	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
STAD	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-8.96	2e-17	9.46e-14	-0.54	-0.43	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
STAD	cis	rs6456156	0.586	rs6456149	ENSG00000265828.1	MIR3939	-8.96	2.03e-17	9.61e-14	-0.48	-0.43	Primary biliary cholangitis;	chr6:167050414	chr6:166997807~166997912:-
STAD	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-8.96	2.04e-17	9.64e-14	-0.47	-0.43	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
STAD	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-8.96	2.04e-17	9.65e-14	-0.52	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
STAD	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-8.96	2.05e-17	9.69e-14	-0.52	-0.43	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
STAD	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-8.96	2.05e-17	9.72e-14	-0.54	-0.43	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-8.96	2.06e-17	9.74e-14	-0.54	-0.43	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
STAD	cis	rs9457247	0.624	rs2239826	ENSG00000265828.1	MIR3939	-8.96	2.06e-17	9.76e-14	-0.5	-0.43	Crohn's disease;	chr6:167091392	chr6:166997807~166997912:-
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	8.96	2.07e-17	9.79e-14	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
STAD	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	8.96	2.09e-17	9.89e-14	0.52	0.43	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
STAD	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	8.95	2.16e-17	1.02e-13	0.66	0.43	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
STAD	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	8.95	2.17e-17	1.02e-13	0.47	0.43	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
STAD	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-8.95	2.2e-17	1.04e-13	-0.46	-0.43	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
STAD	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	8.95	2.2e-17	1.04e-13	0.56	0.43	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	8.95	2.25e-17	1.06e-13	0.56	0.43	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
STAD	cis	rs9457247	0.602	rs17615336	ENSG00000265828.1	MIR3939	-8.95	2.25e-17	1.06e-13	-0.5	-0.43	Crohn's disease;	chr6:167093246	chr6:166997807~166997912:-
STAD	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-8.95	2.29e-17	1.08e-13	-0.54	-0.43	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-8.95	2.29e-17	1.08e-13	-0.54	-0.43	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-8.95	2.29e-17	1.08e-13	-0.54	-0.43	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-8.95	2.29e-17	1.08e-13	-0.54	-0.43	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-8.95	2.29e-17	1.08e-13	-0.54	-0.43	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-8.95	2.29e-17	1.08e-13	-0.54	-0.43	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-8.95	2.29e-17	1.08e-13	-0.54	-0.43	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
STAD	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	8.94	2.31e-17	1.09e-13	0.46	0.43	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.792	rs4710181	ENSG00000265828.1	MIR3939	-8.94	2.31e-17	1.09e-13	-0.48	-0.43	Primary biliary cholangitis;	chr6:167100510	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.755	rs4710182	ENSG00000265828.1	MIR3939	-8.94	2.31e-17	1.09e-13	-0.48	-0.43	Primary biliary cholangitis;	chr6:167100573	chr6:166997807~166997912:-
STAD	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	8.94	2.41e-17	1.13e-13	0.52	0.43	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
STAD	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	8.94	2.42e-17	1.14e-13	0.43	0.43	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
STAD	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-8.94	2.43e-17	1.14e-13	-0.53	-0.43	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
STAD	cis	rs9457247	0.565	rs12193698	ENSG00000265828.1	MIR3939	-8.94	2.45e-17	1.15e-13	-0.49	-0.43	Crohn's disease;	chr6:167098585	chr6:166997807~166997912:-
STAD	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-8.94	2.45e-17	1.15e-13	-0.54	-0.43	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
STAD	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	8.94	2.45e-17	1.15e-13	0.69	0.43	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
STAD	cis	rs6456156	0.565	rs12525345	ENSG00000265828.1	MIR3939	-8.93	2.49e-17	1.17e-13	-0.48	-0.43	Primary biliary cholangitis;	chr6:167065387	chr6:166997807~166997912:-
STAD	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	8.93	2.56e-17	1.2e-13	0.46	0.43	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
STAD	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-8.93	2.56e-17	1.2e-13	-0.51	-0.43	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
STAD	cis	rs6456156	0.792	rs4710178	ENSG00000265828.1	MIR3939	-8.93	2.61e-17	1.22e-13	-0.48	-0.43	Primary biliary cholangitis;	chr6:167100044	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.792	rs4710179	ENSG00000265828.1	MIR3939	-8.93	2.61e-17	1.22e-13	-0.48	-0.43	Primary biliary cholangitis;	chr6:167100204	chr6:166997807~166997912:-
STAD	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-8.93	2.62e-17	1.23e-13	-0.44	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
STAD	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	8.92	2.67e-17	1.25e-13	0.54	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
STAD	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-8.92	2.68e-17	1.26e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
STAD	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-8.92	2.73e-17	1.28e-13	-0.53	-0.43	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
STAD	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	8.92	2.73e-17	1.28e-13	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	8.92	2.73e-17	1.28e-13	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
STAD	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-8.92	2.74e-17	1.28e-13	-0.5	-0.43	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
STAD	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
STAD	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	8.92	2.77e-17	1.29e-13	0.52	0.43	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
STAD	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	8.92	2.78e-17	1.29e-13	0.56	0.43	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
STAD	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-8.92	2.8e-17	1.3e-13	-0.44	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-8.92	2.8e-17	1.3e-13	-0.44	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-8.92	2.82e-17	1.31e-13	-0.43	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-8.92	2.82e-17	1.31e-13	-0.43	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-8.92	2.82e-17	1.31e-13	-0.43	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
STAD	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-8.92	2.82e-17	1.31e-13	-0.54	-0.43	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-8.92	2.82e-17	1.31e-13	-0.54	-0.43	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
STAD	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	8.92	2.83e-17	1.32e-13	0.45	0.43	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
STAD	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-8.92	2.84e-17	1.32e-13	-0.64	-0.43	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
STAD	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-8.91	2.87e-17	1.33e-13	-0.53	-0.43	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-8.91	2.87e-17	1.33e-13	-0.53	-0.43	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-8.91	2.87e-17	1.33e-13	-0.53	-0.43	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-8.91	2.87e-17	1.33e-13	-0.53	-0.43	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-8.91	2.87e-17	1.33e-13	-0.53	-0.43	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-8.91	2.87e-17	1.33e-13	-0.53	-0.43	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
STAD	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-8.91	2.9e-17	1.35e-13	-0.54	-0.43	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
STAD	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	8.91	2.9e-17	1.35e-13	0.69	0.43	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
STAD	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-8.91	2.91e-17	1.35e-13	-0.52	-0.43	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
STAD	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-8.91	2.94e-17	1.37e-13	-0.44	-0.43	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
STAD	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	8.91	3e-17	1.39e-13	0.52	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
STAD	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-8.91	3.03e-17	1.41e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
STAD	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-8.91	3.04e-17	1.41e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
STAD	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	8.9	3.09e-17	1.43e-13	0.46	0.43	Height;	chr11:118737823	chr11:118688039~118690600:-
STAD	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.12e-17	1.44e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.12e-17	1.44e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.12e-17	1.44e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.12e-17	1.44e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.12e-17	1.44e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.12e-17	1.44e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.12e-17	1.44e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
STAD	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-8.9	3.13e-17	1.45e-13	-0.49	-0.43	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
STAD	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-8.9	3.14e-17	1.45e-13	-0.48	-0.43	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
STAD	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	8.9	3.15e-17	1.46e-13	0.51	0.43	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
STAD	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.17e-17	1.47e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.17e-17	1.47e-13	-0.48	-0.43	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
STAD	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	8.9	3.27e-17	1.51e-13	0.68	0.43	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
STAD	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-8.89	3.35e-17	1.55e-13	-0.5	-0.43	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
STAD	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-8.89	3.38e-17	1.56e-13	-0.52	-0.43	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
STAD	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	8.89	3.4e-17	1.57e-13	0.52	0.43	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
STAD	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-8.89	3.42e-17	1.58e-13	-0.65	-0.43	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
STAD	cis	rs9457247	0.765	rs9295385	ENSG00000265828.1	MIR3939	-8.89	3.43e-17	1.58e-13	-0.52	-0.43	Crohn's disease;	chr6:167034693	chr6:166997807~166997912:-
STAD	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-8.89	3.51e-17	1.62e-13	-0.54	-0.43	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
STAD	cis	rs9457247	0.565	rs2239824	ENSG00000265828.1	MIR3939	-8.88	3.62e-17	1.67e-13	-0.49	-0.43	Crohn's disease;	chr6:167098311	chr6:166997807~166997912:-
STAD	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	8.88	3.65e-17	1.68e-13	0.47	0.43	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
STAD	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	8.88	3.65e-17	1.68e-13	0.56	0.43	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-8.88	3.66e-17	1.69e-13	-0.35	-0.43	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-8.88	3.66e-17	1.69e-13	-0.35	-0.43	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
STAD	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	8.88	3.69e-17	1.7e-13	0.56	0.43	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
STAD	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-8.88	3.69e-17	1.7e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
STAD	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	8.88	3.72e-17	1.71e-13	0.56	0.43	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	8.88	3.73e-17	1.71e-13	0.55	0.43	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	8.88	3.73e-17	1.71e-13	0.55	0.43	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
STAD	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-8.88	3.73e-17	1.71e-13	-0.53	-0.43	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-8.88	3.73e-17	1.71e-13	-0.53	-0.43	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-8.88	3.73e-17	1.71e-13	-0.53	-0.43	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-8.88	3.73e-17	1.71e-13	-0.53	-0.43	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-8.88	3.73e-17	1.71e-13	-0.53	-0.43	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	8.88	3.75e-17	1.72e-13	0.5	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
STAD	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	8.88	3.79e-17	1.74e-13	0.52	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
STAD	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	8.87	3.91e-17	1.79e-13	0.56	0.43	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	8.87	3.91e-17	1.79e-13	0.56	0.43	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	8.87	3.91e-17	1.79e-13	0.56	0.43	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
STAD	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-8.87	3.92e-17	1.8e-13	-0.49	-0.43	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
STAD	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-8.87	3.93e-17	1.8e-13	-0.35	-0.43	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
STAD	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-8.87	3.95e-17	1.81e-13	-0.5	-0.43	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
STAD	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-8.87	3.99e-17	1.82e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-8.87	3.99e-17	1.83e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
STAD	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-8.87	4.02e-17	1.84e-13	-0.46	-0.43	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
STAD	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-8.87	4.05e-17	1.85e-13	-0.49	-0.43	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
STAD	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	8.87	4.06e-17	1.85e-13	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
STAD	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-8.86	4.15e-17	1.9e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
STAD	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-8.86	4.17e-17	1.9e-13	-0.52	-0.43	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
STAD	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-8.86	4.2e-17	1.92e-13	-0.5	-0.43	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
STAD	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	8.86	4.21e-17	1.92e-13	0.66	0.43	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
STAD	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-8.86	4.26e-17	1.94e-13	-0.52	-0.43	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
STAD	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-8.86	4.26e-17	1.94e-13	-0.5	-0.43	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
STAD	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-8.86	4.32e-17	1.97e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
STAD	cis	rs6456156	0.792	rs10946213	ENSG00000265828.1	MIR3939	8.86	4.35e-17	1.98e-13	0.47	0.43	Primary biliary cholangitis;	chr6:167102607	chr6:166997807~166997912:-
STAD	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	8.86	4.35e-17	1.98e-13	0.66	0.43	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
STAD	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	8.86	4.42e-17	2.01e-13	0.68	0.43	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	8.86	4.42e-17	2.01e-13	0.68	0.43	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
STAD	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-8.85	4.44e-17	2.02e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
STAD	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	8.85	4.45e-17	2.02e-13	0.49	0.43	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
STAD	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-8.85	4.45e-17	2.02e-13	-0.55	-0.43	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
STAD	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-8.85	4.48e-17	2.04e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
STAD	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	8.85	4.48e-17	2.04e-13	0.45	0.43	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.534	rs2757053	ENSG00000265828.1	MIR3939	8.85	4.49e-17	2.04e-13	0.5	0.43	Crohn's disease;	chr6:166966850	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	8.85	4.5e-17	2.04e-13	0.53	0.43	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
STAD	cis	rs9457247	0.534	rs4710154	ENSG00000265828.1	MIR3939	8.85	4.53e-17	2.06e-13	0.5	0.43	Crohn's disease;	chr6:166981146	chr6:166997807~166997912:-
STAD	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	8.85	4.53e-17	2.06e-13	0.68	0.43	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
STAD	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-8.85	4.54e-17	2.06e-13	-0.51	-0.43	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
STAD	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-8.85	4.6e-17	2.09e-13	-0.41	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
STAD	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	8.85	4.63e-17	2.1e-13	0.45	0.43	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
STAD	cis	rs9457247	0.515	rs1951459	ENSG00000265828.1	MIR3939	8.85	4.64e-17	2.1e-13	0.49	0.43	Crohn's disease;	chr6:166989048	chr6:166997807~166997912:-
STAD	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-8.85	4.67e-17	2.12e-13	-0.53	-0.43	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
STAD	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-8.85	4.68e-17	2.12e-13	-0.53	-0.43	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	8.85	4.71e-17	2.14e-13	0.52	0.43	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
STAD	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-8.84	4.79e-17	2.17e-13	-0.47	-0.43	Temperament;	chr17:14075460	chr17:14024514~14025488:+
STAD	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-8.84	4.82e-17	2.18e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-8.84	4.82e-17	2.18e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
STAD	cis	rs9457247	0.534	rs7750593	ENSG00000265828.1	MIR3939	8.84	4.98e-17	2.25e-13	0.49	0.43	Crohn's disease;	chr6:166973871	chr6:166997807~166997912:-
STAD	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-8.84	5.02e-17	2.27e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
STAD	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	8.84	5.06e-17	2.29e-13	0.7	0.43	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
STAD	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-8.84	5.09e-17	2.3e-13	-0.53	-0.43	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-8.84	5.09e-17	2.3e-13	-0.53	-0.43	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-8.84	5.09e-17	2.3e-13	-0.53	-0.43	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-8.84	5.09e-17	2.3e-13	-0.53	-0.43	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-8.84	5.09e-17	2.3e-13	-0.53	-0.43	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-8.84	5.09e-17	2.3e-13	-0.53	-0.43	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-8.84	5.09e-17	2.3e-13	-0.53	-0.43	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
STAD	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	8.84	5.09e-17	2.3e-13	0.7	0.43	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
STAD	cis	rs916888	0.61	rs199438	ENSG00000262500.1	RP11-259G18.2	8.84	5.12e-17	2.31e-13	0.53	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46243606~46245044:+
STAD	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-8.83	5.14e-17	2.32e-13	-0.64	-0.43	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
STAD	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-8.83	5.2e-17	2.35e-13	-0.52	-0.43	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
STAD	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-8.83	5.21e-17	2.35e-13	-0.35	-0.43	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
STAD	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-8.83	5.25e-17	2.36e-13	-0.52	-0.43	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-8.83	5.25e-17	2.36e-13	-0.52	-0.43	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
STAD	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-8.83	5.25e-17	2.36e-13	-0.46	-0.43	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
STAD	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-8.83	5.25e-17	2.36e-13	-0.46	-0.43	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
STAD	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-8.83	5.25e-17	2.37e-13	-0.54	-0.43	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
STAD	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	8.83	5.26e-17	2.37e-13	0.52	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
STAD	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-8.83	5.28e-17	2.38e-13	-0.63	-0.43	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
STAD	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-8.83	5.29e-17	2.38e-13	-0.45	-0.43	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
STAD	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-8.83	5.29e-17	2.38e-13	-0.45	-0.43	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
STAD	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-8.83	5.31e-17	2.39e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-8.83	5.31e-17	2.39e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
STAD	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	8.83	5.34e-17	2.4e-13	0.62	0.43	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
STAD	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-8.83	5.35e-17	2.4e-13	-0.43	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
STAD	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-8.83	5.37e-17	2.41e-13	-0.53	-0.43	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
STAD	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	8.83	5.4e-17	2.43e-13	0.51	0.43	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	8.83	5.4e-17	2.43e-13	0.51	0.43	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	8.83	5.4e-17	2.43e-13	0.51	0.43	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	8.83	5.4e-17	2.43e-13	0.51	0.43	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	8.83	5.4e-17	2.43e-13	0.51	0.43	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	8.83	5.4e-17	2.43e-13	0.51	0.43	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	8.83	5.4e-17	2.43e-13	0.51	0.43	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
STAD	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	8.83	5.41e-17	2.43e-13	0.72	0.43	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
STAD	cis	rs748404	0.697	rs546722	ENSG00000249839.1	AC011330.5	-8.83	5.45e-17	2.45e-13	-0.53	-0.43	Lung cancer;	chr15:43288621	chr15:43663654~43684339:-
STAD	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	8.83	5.45e-17	2.45e-13	0.55	0.43	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
STAD	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	8.83	5.45e-17	2.45e-13	0.55	0.43	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
STAD	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-8.83	5.48e-17	2.46e-13	-0.53	-0.43	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
STAD	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	8.83	5.48e-17	2.46e-13	0.43	0.43	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
STAD	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-8.83	5.51e-17	2.47e-13	-0.53	-0.43	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-8.82	5.6e-17	2.51e-13	-0.53	-0.43	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
STAD	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	8.82	5.66e-17	2.54e-13	0.5	0.43	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
STAD	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-8.82	5.67e-17	2.54e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
STAD	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	8.82	5.68e-17	2.54e-13	0.52	0.43	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	8.82	5.73e-17	2.57e-13	0.5	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
STAD	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-8.82	5.78e-17	2.59e-13	-0.35	-0.43	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	8.82	5.79e-17	2.59e-13	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
STAD	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-8.82	5.81e-17	2.6e-13	-0.53	-0.43	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
STAD	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-8.82	5.85e-17	2.62e-13	-0.6	-0.43	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
STAD	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-8.82	5.93e-17	2.65e-13	-0.52	-0.43	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
STAD	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-8.81	5.95e-17	2.66e-13	-0.52	-0.43	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
STAD	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	8.81	6.04e-17	2.7e-13	0.45	0.43	Height;	chr11:118737916	chr11:118688039~118690600:-
STAD	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	8.81	6.08e-17	2.72e-13	0.53	0.43	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
STAD	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-8.81	6.08e-17	2.72e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-8.81	6.29e-17	2.81e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
STAD	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-8.81	6.3e-17	2.81e-13	-0.53	-0.43	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-8.81	6.31e-17	2.82e-13	-0.53	-0.43	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-8.8	6.42e-17	2.86e-13	-0.35	-0.43	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-8.8	6.43e-17	2.87e-13	-0.35	-0.43	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-8.8	6.43e-17	2.87e-13	-0.35	-0.43	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
STAD	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	8.8	6.5e-17	2.9e-13	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
STAD	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-8.8	6.52e-17	2.91e-13	-0.66	-0.43	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
STAD	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	8.8	6.52e-17	2.91e-13	0.7	0.43	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
STAD	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	8.8	6.52e-17	2.91e-13	0.7	0.43	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
STAD	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-8.8	6.54e-17	2.91e-13	-0.51	-0.43	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-8.8	6.54e-17	2.91e-13	-0.35	-0.43	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-8.8	6.54e-17	2.91e-13	-0.35	-0.43	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
STAD	cis	rs16828019	0.568	rs2236129	ENSG00000235358.1	RP11-399E6.1	8.8	6.58e-17	2.93e-13	0.84	0.43	Intelligence (multi-trait analysis);	chr1:41152242	chr1:41242373~41284861:+
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	8.8	6.66e-17	2.97e-13	0.49	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
STAD	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-8.8	6.69e-17	2.98e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
STAD	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-8.8	6.82e-17	3.03e-13	-0.5	-0.43	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
STAD	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-8.8	6.84e-17	3.05e-13	-0.54	-0.43	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
STAD	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-8.79	6.9e-17	3.07e-13	-0.45	-0.43	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
STAD	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-8.79	6.93e-17	3.09e-13	-0.5	-0.43	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
STAD	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-8.79	6.97e-17	3.1e-13	-0.53	-0.43	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-8.79	6.97e-17	3.1e-13	-0.53	-0.43	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-8.79	7.02e-17	3.12e-13	-0.53	-0.43	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
STAD	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	8.79	7.07e-17	3.14e-13	0.52	0.43	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
STAD	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	8.79	7.08e-17	3.15e-13	0.61	0.43	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	8.79	7.12e-17	3.17e-13	0.51	0.43	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	8.79	7.16e-17	3.18e-13	0.5	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
STAD	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	8.79	7.25e-17	3.22e-13	0.49	0.43	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-8.79	7.26e-17	3.22e-13	-0.35	-0.43	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-8.79	7.26e-17	3.22e-13	-0.35	-0.43	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
STAD	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-8.79	7.28e-17	3.23e-13	-0.53	-0.43	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-8.79	7.28e-17	3.23e-13	-0.53	-0.43	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
STAD	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-8.79	7.33e-17	3.25e-13	-0.52	-0.43	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-8.79	7.33e-17	3.25e-13	-0.52	-0.43	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	8.79	7.33e-17	3.25e-13	0.52	0.43	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
STAD	cis	rs916888	0.61	rs142167	ENSG00000262500.1	RP11-259G18.2	-8.78	7.4e-17	3.28e-13	-0.53	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46243606~46245044:+
STAD	cis	rs9457247	0.534	rs1130033	ENSG00000265828.1	MIR3939	-8.78	7.47e-17	3.31e-13	-0.5	-0.43	Crohn's disease;	chr6:166972135	chr6:166997807~166997912:-
STAD	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-8.78	7.5e-17	3.33e-13	-0.47	-0.43	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
STAD	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-8.78	7.5e-17	3.33e-13	-0.47	-0.43	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-8.78	7.51e-17	3.33e-13	-0.47	-0.43	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
STAD	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-8.78	7.51e-17	3.33e-13	-0.47	-0.43	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
STAD	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-8.78	7.63e-17	3.38e-13	-0.47	-0.43	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
STAD	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	8.78	7.66e-17	3.39e-13	0.7	0.43	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
STAD	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-8.78	7.74e-17	3.43e-13	-0.52	-0.43	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
STAD	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-8.78	7.74e-17	3.43e-13	-0.52	-0.43	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
STAD	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	8.78	7.76e-17	3.44e-13	0.53	0.43	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	8.78	7.77e-17	3.44e-13	0.53	0.43	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
STAD	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-8.78	7.78e-17	3.44e-13	-0.42	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
STAD	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	8.78	7.78e-17	3.44e-13	0.51	0.43	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
STAD	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-8.78	7.8e-17	3.45e-13	-0.46	-0.43	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
STAD	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	8.78	7.81e-17	3.46e-13	0.51	0.43	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	8.78	7.81e-17	3.46e-13	0.51	0.43	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
STAD	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	8.78	7.87e-17	3.48e-13	0.68	0.43	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
STAD	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	8.78	7.87e-17	3.48e-13	0.56	0.43	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
STAD	cis	rs3136516	0.772	rs7947747	ENSG00000271350.1	CTD-2384B9.1	-8.78	7.89e-17	3.49e-13	-0.47	-0.43	Venous thromboembolism;	chr11:46831288	chr11:47041027~47041945:-
STAD	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-8.77	7.95e-17	3.51e-13	-0.47	-0.43	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
STAD	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	8.77	7.96e-17	3.51e-13	0.72	0.43	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
STAD	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-8.77	7.96e-17	3.52e-13	-0.51	-0.43	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
STAD	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	8.77	7.98e-17	3.53e-13	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
STAD	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-8.77	8.08e-17	3.57e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
STAD	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	8.77	8.15e-17	3.59e-13	0.72	0.43	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	8.77	8.15e-17	3.59e-13	0.72	0.43	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
STAD	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	8.77	8.21e-17	3.62e-13	0.61	0.43	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
STAD	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	8.77	8.21e-17	3.62e-13	0.61	0.43	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
STAD	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-8.77	8.22e-17	3.62e-13	-0.48	-0.43	Height;	chr11:118791319	chr11:118704607~118750263:+
STAD	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	8.77	8.25e-17	3.64e-13	0.52	0.43	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
STAD	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	8.77	8.26e-17	3.64e-13	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
STAD	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-8.77	8.29e-17	3.65e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
STAD	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-8.77	8.3e-17	3.66e-13	-0.42	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
STAD	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	8.77	8.31e-17	3.66e-13	0.49	0.43	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
STAD	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-8.77	8.39e-17	3.7e-13	-0.53	-0.43	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
STAD	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-8.77	8.4e-17	3.7e-13	-0.53	-0.43	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
STAD	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	8.77	8.41e-17	3.7e-13	0.53	0.43	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	8.77	8.41e-17	3.7e-13	0.53	0.43	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	8.77	8.41e-17	3.7e-13	0.53	0.43	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
STAD	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-8.77	8.43e-17	3.71e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
STAD	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	8.77	8.43e-17	3.71e-13	0.43	0.43	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	8.77	8.43e-17	3.71e-13	0.43	0.43	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
STAD	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-8.77	8.44e-17	3.71e-13	-0.51	-0.43	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
STAD	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-8.76	8.57e-17	3.77e-13	-0.47	-0.43	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
STAD	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	8.76	8.6e-17	3.78e-13	0.53	0.43	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
STAD	cis	rs2581828	0.618	rs6777975	ENSG00000242142.1	SERBP1P3	-8.76	8.61e-17	3.78e-13	-0.47	-0.43	Crohn's disease;	chr3:53132119	chr3:53064283~53065091:-
STAD	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-8.76	8.61e-17	3.79e-13	-0.51	-0.43	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-8.76	8.64e-17	3.8e-13	-0.51	-0.43	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-8.76	8.64e-17	3.8e-13	-0.51	-0.43	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-8.76	8.64e-17	3.8e-13	-0.51	-0.43	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-8.76	8.64e-17	3.8e-13	-0.51	-0.43	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-8.76	8.64e-17	3.8e-13	-0.51	-0.43	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-8.76	8.64e-17	3.8e-13	-0.51	-0.43	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	8.76	8.68e-17	3.81e-13	0.52	0.43	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
STAD	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	8.76	8.71e-17	3.83e-13	0.62	0.43	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
STAD	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-8.76	8.74e-17	3.84e-13	-0.52	-0.43	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
STAD	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-8.76	8.75e-17	3.84e-13	-0.48	-0.43	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
STAD	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-8.76	8.93e-17	3.92e-13	-0.51	-0.43	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	8.76	8.98e-17	3.94e-13	0.52	0.43	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
STAD	cis	rs916888	0.531	rs183211	ENSG00000262500.1	RP11-259G18.2	8.76	8.98e-17	3.94e-13	0.53	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46243606~46245044:+
STAD	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-8.76	9.15e-17	4.01e-13	-0.64	-0.43	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
STAD	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-8.75	9.21e-17	4.03e-13	-0.42	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-8.75	9.21e-17	4.03e-13	-0.42	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
STAD	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-8.75	9.33e-17	4.08e-13	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
STAD	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-8.75	9.35e-17	4.09e-13	-0.63	-0.43	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-8.75	9.45e-17	4.13e-13	-0.35	-0.43	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
STAD	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-8.75	9.54e-17	4.17e-13	-0.51	-0.43	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	8.75	9.61e-17	4.2e-13	0.54	0.43	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
STAD	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-8.75	9.65e-17	4.21e-13	-0.52	-0.43	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
STAD	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-8.75	9.68e-17	4.23e-13	-0.5	-0.43	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
STAD	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-8.75	9.74e-17	4.25e-13	-0.52	-0.43	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
STAD	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-8.75	9.74e-17	4.25e-13	-0.52	-0.43	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-8.75	9.74e-17	4.25e-13	-0.52	-0.43	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-8.75	9.74e-17	4.25e-13	-0.52	-0.43	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-8.75	9.74e-17	4.25e-13	-0.52	-0.43	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
STAD	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-8.75	9.75e-17	4.25e-13	-0.65	-0.43	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-8.74	9.93e-17	4.32e-13	-0.64	-0.43	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
STAD	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-8.74	9.94e-17	4.32e-13	-0.51	-0.43	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
STAD	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	8.74	9.94e-17	4.32e-13	0.55	0.43	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
STAD	cis	rs6456156	0.792	rs9366089	ENSG00000265828.1	MIR3939	-8.74	9.98e-17	4.34e-13	-0.47	-0.43	Primary biliary cholangitis;	chr6:167099408	chr6:166997807~166997912:-
STAD	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-8.74	1e-16	4.35e-13	-0.66	-0.43	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
STAD	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	8.74	1e-16	4.35e-13	0.53	0.43	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
STAD	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	8.74	1.02e-16	4.43e-13	0.51	0.43	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
STAD	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	8.74	1.03e-16	4.46e-13	0.52	0.43	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
STAD	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	8.74	1.03e-16	4.46e-13	0.52	0.43	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
STAD	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	8.74	1.04e-16	4.5e-13	0.5	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
STAD	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	8.74	1.04e-16	4.51e-13	0.65	0.43	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
STAD	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	8.74	1.04e-16	4.51e-13	0.65	0.43	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
STAD	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	8.74	1.05e-16	4.57e-13	0.52	0.43	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	8.74	1.05e-16	4.57e-13	0.52	0.43	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
STAD	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-8.74	1.05e-16	4.57e-13	-0.37	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
STAD	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	8.74	1.06e-16	4.59e-13	0.45	0.43	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
STAD	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	8.74	1.06e-16	4.59e-13	0.45	0.43	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	8.73	1.07e-16	4.64e-13	0.52	0.43	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	8.73	1.07e-16	4.64e-13	0.52	0.43	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	8.73	1.07e-16	4.64e-13	0.52	0.43	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
STAD	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	8.73	1.07e-16	4.64e-13	0.5	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
STAD	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	8.73	1.08e-16	4.66e-13	0.44	0.42	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
STAD	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-8.73	1.08e-16	4.68e-13	-0.35	-0.42	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
STAD	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-8.73	1.09e-16	4.72e-13	-0.49	-0.42	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
STAD	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	8.73	1.11e-16	4.78e-13	0.52	0.42	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	8.73	1.11e-16	4.78e-13	0.52	0.42	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	8.73	1.12e-16	4.85e-13	0.52	0.42	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	8.73	1.12e-16	4.85e-13	0.51	0.42	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
STAD	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	8.73	1.13e-16	4.88e-13	0.51	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-8.73	1.13e-16	4.89e-13	-0.35	-0.42	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-8.73	1.13e-16	4.89e-13	-0.35	-0.42	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
STAD	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	8.72	1.14e-16	4.93e-13	0.65	0.42	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
STAD	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-8.72	1.14e-16	4.93e-13	-0.61	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
STAD	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	8.72	1.15e-16	4.95e-13	0.6	0.42	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	8.72	1.15e-16	4.97e-13	0.53	0.42	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	8.72	1.15e-16	4.97e-13	0.53	0.42	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	8.72	1.15e-16	4.97e-13	0.53	0.42	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	8.72	1.15e-16	4.97e-13	0.53	0.42	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
STAD	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	8.72	1.16e-16	5e-13	0.45	0.42	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	8.72	1.17e-16	5.04e-13	0.52	0.42	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	8.72	1.17e-16	5.04e-13	0.52	0.42	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
STAD	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	8.72	1.17e-16	5.04e-13	0.51	0.42	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-8.72	1.18e-16	5.06e-13	-0.54	-0.42	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
STAD	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-8.72	1.18e-16	5.08e-13	-0.63	-0.42	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
STAD	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	8.72	1.19e-16	5.13e-13	0.38	0.42	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
STAD	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	8.72	1.2e-16	5.15e-13	0.51	0.42	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	8.72	1.21e-16	5.2e-13	0.52	0.42	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	8.72	1.21e-16	5.2e-13	0.52	0.42	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
STAD	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-8.72	1.21e-16	5.21e-13	-0.63	-0.42	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
STAD	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-8.72	1.21e-16	5.21e-13	-0.61	-0.42	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
STAD	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-8.72	1.22e-16	5.22e-13	-0.51	-0.42	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-8.72	1.22e-16	5.23e-13	-0.52	-0.42	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
STAD	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-8.72	1.22e-16	5.23e-13	-0.5	-0.42	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
STAD	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-8.72	1.22e-16	5.24e-13	-0.47	-0.42	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
STAD	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-8.72	1.22e-16	5.24e-13	-0.47	-0.42	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
STAD	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-8.71	1.23e-16	5.28e-13	-0.52	-0.42	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-8.71	1.23e-16	5.28e-13	-0.52	-0.42	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-8.71	1.25e-16	5.34e-13	-0.35	-0.42	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
STAD	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-8.71	1.26e-16	5.4e-13	-0.51	-0.42	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-8.71	1.26e-16	5.4e-13	-0.51	-0.42	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-8.71	1.27e-16	5.43e-13	-0.51	-0.42	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	8.71	1.27e-16	5.45e-13	0.49	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
STAD	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	8.71	1.28e-16	5.47e-13	0.52	0.42	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
STAD	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-8.71	1.29e-16	5.5e-13	-0.45	-0.42	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	8.71	1.3e-16	5.57e-13	0.53	0.42	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	8.71	1.31e-16	5.58e-13	0.51	0.42	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	8.71	1.31e-16	5.58e-13	0.51	0.42	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	8.71	1.31e-16	5.58e-13	0.51	0.42	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	8.71	1.31e-16	5.58e-13	0.51	0.42	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	8.71	1.31e-16	5.58e-13	0.51	0.42	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	8.71	1.31e-16	5.58e-13	0.51	0.42	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
STAD	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-8.71	1.31e-16	5.61e-13	-0.42	-0.42	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
STAD	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	8.7	1.32e-16	5.64e-13	0.52	0.42	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	8.7	1.32e-16	5.65e-13	0.51	0.42	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	8.7	1.32e-16	5.65e-13	0.51	0.42	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	8.7	1.32e-16	5.65e-13	0.51	0.42	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	8.7	1.32e-16	5.65e-13	0.51	0.42	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	8.7	1.32e-16	5.65e-13	0.51	0.42	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	8.7	1.33e-16	5.67e-13	0.51	0.42	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
STAD	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	8.7	1.33e-16	5.68e-13	0.44	0.42	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	8.7	1.34e-16	5.71e-13	0.53	0.42	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
STAD	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	8.7	1.35e-16	5.74e-13	0.66	0.42	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
STAD	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-8.7	1.36e-16	5.8e-13	-0.43	-0.42	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
STAD	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-8.7	1.36e-16	5.8e-13	-0.63	-0.42	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
STAD	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	8.7	1.37e-16	5.82e-13	0.51	0.42	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
STAD	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-8.7	1.38e-16	5.88e-13	-0.64	-0.42	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
STAD	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	8.7	1.41e-16	5.98e-13	0.52	0.42	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	8.7	1.41e-16	5.98e-13	0.51	0.42	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
STAD	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-8.7	1.41e-16	5.99e-13	-0.45	-0.42	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
STAD	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	8.7	1.41e-16	6.01e-13	0.44	0.42	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
STAD	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-8.69	1.43e-16	6.06e-13	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-8.69	1.44e-16	6.1e-13	-0.5	-0.42	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
STAD	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	8.69	1.46e-16	6.19e-13	0.69	0.42	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
STAD	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	8.69	1.46e-16	6.19e-13	0.52	0.42	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	8.69	1.46e-16	6.19e-13	0.52	0.42	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
STAD	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	8.69	1.48e-16	6.26e-13	0.38	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
STAD	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	8.69	1.48e-16	6.28e-13	0.52	0.42	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.69	1.49e-16	6.33e-13	0.51	0.42	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
STAD	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	8.69	1.51e-16	6.41e-13	0.51	0.42	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
STAD	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-8.68	1.52e-16	6.45e-13	-0.47	-0.42	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
STAD	cis	rs6456156	0.792	rs10946214	ENSG00000265828.1	MIR3939	-8.68	1.53e-16	6.47e-13	-0.47	-0.42	Primary biliary cholangitis;	chr6:167102634	chr6:166997807~166997912:-
STAD	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-8.68	1.55e-16	6.54e-13	-0.5	-0.42	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
STAD	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-8.68	1.56e-16	6.61e-13	-0.52	-0.42	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
STAD	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-8.68	1.56e-16	6.61e-13	-0.5	-0.42	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	8.68	1.56e-16	6.62e-13	0.52	0.42	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
STAD	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	8.68	1.58e-16	6.67e-13	0.44	0.42	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.766	rs150112	ENSG00000265828.1	MIR3939	8.68	1.58e-16	6.67e-13	0.45	0.42	Primary biliary cholangitis;	chr6:167096390	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	8.68	1.58e-16	6.68e-13	0.51	0.42	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	8.68	1.58e-16	6.68e-13	0.51	0.42	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	8.68	1.59e-16	6.74e-13	0.52	0.42	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
STAD	cis	rs6456156	0.792	rs10946212	ENSG00000265828.1	MIR3939	-8.68	1.61e-16	6.79e-13	-0.47	-0.42	Primary biliary cholangitis;	chr6:167102459	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.792	rs2039321	ENSG00000265828.1	MIR3939	-8.68	1.61e-16	6.81e-13	-0.47	-0.42	Primary biliary cholangitis;	chr6:167102811	chr6:166997807~166997912:-
STAD	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	8.67	1.64e-16	6.94e-13	0.67	0.42	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
STAD	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-8.67	1.65e-16	6.96e-13	-0.52	-0.42	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-8.67	1.65e-16	6.96e-13	-0.52	-0.42	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs11767262	ENSG00000222364.1	RNU6-96P	-8.67	1.65e-16	6.96e-13	-0.52	-0.42	Aortic root size;	chr7:66302237	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs66594357	ENSG00000222364.1	RNU6-96P	-8.67	1.65e-16	6.96e-13	-0.52	-0.42	Aortic root size;	chr7:66327797	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs10950036	ENSG00000222364.1	RNU6-96P	-8.67	1.67e-16	7.03e-13	-0.52	-0.42	Aortic root size;	chr7:66353241	chr7:66395191~66395286:+
STAD	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	8.67	1.67e-16	7.04e-13	0.45	0.42	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	8.67	1.69e-16	7.08e-13	0.52	0.42	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
STAD	cis	rs875971	0.545	rs75840613	ENSG00000222364.1	RNU6-96P	-8.67	1.69e-16	7.08e-13	-0.52	-0.42	Aortic root size;	chr7:66376399	chr7:66395191~66395286:+
STAD	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-8.67	1.69e-16	7.09e-13	-0.64	-0.42	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-8.67	1.69e-16	7.09e-13	-0.64	-0.42	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
STAD	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	8.67	1.7e-16	7.1e-13	0.52	0.42	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
STAD	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	8.67	1.76e-16	7.35e-13	0.45	0.42	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	8.66	1.78e-16	7.44e-13	0.52	0.42	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
STAD	cis	rs9355610	0.727	rs2247315	ENSG00000265828.1	MIR3939	8.66	1.79e-16	7.46e-13	0.49	0.42	Graves' disease;	chr6:166956723	chr6:166997807~166997912:-
STAD	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-8.66	1.79e-16	7.47e-13	-0.67	-0.42	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
STAD	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	8.66	1.79e-16	7.48e-13	0.51	0.42	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	8.66	1.79e-16	7.48e-13	0.51	0.42	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	8.66	1.79e-16	7.48e-13	0.51	0.42	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	8.66	1.79e-16	7.48e-13	0.51	0.42	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
STAD	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-8.66	1.79e-16	7.48e-13	-0.53	-0.42	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
STAD	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	8.66	1.8e-16	7.51e-13	0.38	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
STAD	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	8.66	1.82e-16	7.6e-13	0.45	0.42	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
STAD	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	8.66	1.84e-16	7.68e-13	0.48	0.42	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
STAD	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	8.66	1.85e-16	7.72e-13	0.52	0.42	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
STAD	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-8.66	1.86e-16	7.73e-13	-0.51	-0.42	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-8.66	1.86e-16	7.73e-13	-0.51	-0.42	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
STAD	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	8.66	1.87e-16	7.79e-13	0.73	0.42	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
STAD	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-8.66	1.88e-16	7.81e-13	-0.51	-0.42	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
STAD	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-8.66	1.88e-16	7.84e-13	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
STAD	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	8.66	1.89e-16	7.86e-13	0.45	0.42	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
STAD	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	8.65	1.91e-16	7.95e-13	0.44	0.42	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
STAD	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	8.65	1.91e-16	7.96e-13	0.5	0.42	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
STAD	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-8.65	1.92e-16	7.98e-13	-0.52	-0.42	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-8.65	1.92e-16	7.98e-13	-0.52	-0.42	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-8.65	1.92e-16	7.98e-13	-0.52	-0.42	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
STAD	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	8.65	1.94e-16	8.07e-13	0.52	0.42	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
STAD	cis	rs6456156	0.586	rs12203510	ENSG00000265828.1	MIR3939	-8.65	1.97e-16	8.2e-13	-0.46	-0.42	Primary biliary cholangitis;	chr6:167059518	chr6:166997807~166997912:-
STAD	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-8.65	2.02e-16	8.39e-13	-0.5	-0.42	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	8.65	2.03e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	8.64	2.04e-16	8.4e-13	0.52	0.42	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
STAD	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-8.64	2.04e-16	8.41e-13	-0.52	-0.42	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-8.64	2.04e-16	8.41e-13	-0.52	-0.42	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
STAD	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	8.64	2.05e-16	8.45e-13	0.71	0.42	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
STAD	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	8.64	2.05e-16	8.46e-13	0.51	0.42	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
STAD	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-8.64	2.07e-16	8.52e-13	-0.5	-0.42	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-8.64	2.07e-16	8.52e-13	-0.5	-0.42	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-8.64	2.07e-16	8.52e-13	-0.5	-0.42	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-8.64	2.07e-16	8.52e-13	-0.5	-0.42	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-8.64	2.07e-16	8.52e-13	-0.5	-0.42	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-8.64	2.07e-16	8.52e-13	-0.5	-0.42	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	8.64	2.08e-16	8.55e-13	0.52	0.42	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
STAD	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-8.64	2.09e-16	8.59e-13	-0.52	-0.42	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
STAD	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-8.64	2.1e-16	8.64e-13	-0.5	-0.42	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
STAD	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-8.64	2.1e-16	8.65e-13	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-8.64	2.1e-16	8.65e-13	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
STAD	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	8.64	2.13e-16	8.78e-13	0.67	0.42	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
STAD	cis	rs875971	0.545	rs1638724	ENSG00000222364.1	RNU6-96P	8.64	2.18e-16	8.97e-13	0.51	0.42	Aortic root size;	chr7:66575494	chr7:66395191~66395286:+
STAD	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-8.63	2.23e-16	9.16e-13	-0.45	-0.42	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
STAD	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-8.63	2.25e-16	9.22e-13	-0.52	-0.42	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
STAD	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	8.63	2.27e-16	9.29e-13	0.52	0.42	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	8.63	2.27e-16	9.29e-13	0.52	0.42	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	8.63	2.27e-16	9.29e-13	0.52	0.42	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	8.63	2.27e-16	9.29e-13	0.52	0.42	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	8.63	2.27e-16	9.29e-13	0.52	0.42	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
STAD	cis	rs6456156	0.586	rs720325	ENSG00000265828.1	MIR3939	-8.63	2.27e-16	9.3e-13	-0.46	-0.42	Primary biliary cholangitis;	chr6:167053861	chr6:166997807~166997912:-
STAD	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	8.63	2.31e-16	9.45e-13	0.45	0.42	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-8.63	2.31e-16	9.46e-13	-0.42	-0.42	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
STAD	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	8.63	2.32e-16	9.49e-13	0.56	0.42	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
STAD	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	8.63	2.32e-16	9.49e-13	0.52	0.42	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	8.63	2.33e-16	9.52e-13	0.52	0.42	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
STAD	cis	rs875971	0.545	rs73148639	ENSG00000222364.1	RNU6-96P	-8.63	2.33e-16	9.52e-13	-0.51	-0.42	Aortic root size;	chr7:66390342	chr7:66395191~66395286:+
STAD	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	8.63	2.33e-16	9.53e-13	0.5	0.42	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-8.62	2.35e-16	9.59e-13	-0.52	-0.42	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-8.62	2.35e-16	9.6e-13	-0.34	-0.42	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
STAD	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	8.62	2.38e-16	9.7e-13	0.71	0.42	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
STAD	cis	rs9457247	0.668	rs2236313	ENSG00000265828.1	MIR3939	-8.62	2.38e-16	9.7e-13	-0.48	-0.42	Crohn's disease;	chr6:166946901	chr6:166997807~166997912:-
STAD	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-8.62	2.38e-16	9.71e-13	-0.47	-0.42	Height;	chr11:118809363	chr11:118704607~118750263:+
STAD	cis	rs11089937	0.926	rs5750601	ENSG00000211639.2	IGLV4-60	8.62	2.39e-16	9.74e-13	0.43	0.42	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22162199~22162681:+
STAD	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	8.62	2.39e-16	9.74e-13	0.39	0.42	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
STAD	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-8.62	2.42e-16	9.87e-13	-0.5	-0.42	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
STAD	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	8.62	2.42e-16	9.87e-13	0.5	0.42	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-8.62	2.43e-16	9.89e-13	-0.5	-0.42	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-8.62	2.43e-16	9.89e-13	-0.5	-0.42	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-8.62	2.43e-16	9.89e-13	-0.5	-0.42	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	8.62	2.44e-16	9.92e-13	0.5	0.42	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	8.62	2.44e-16	9.92e-13	0.5	0.42	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	8.62	2.44e-16	9.92e-13	0.5	0.42	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	8.62	2.45e-16	9.95e-13	0.5	0.42	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	8.62	2.45e-16	9.96e-13	0.5	0.42	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
STAD	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	8.62	2.45e-16	9.98e-13	0.65	0.42	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
STAD	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	8.62	2.46e-16	9.99e-13	0.51	0.42	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	8.62	2.47e-16	1.01e-12	0.52	0.42	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-8.62	2.48e-16	1.01e-12	-0.5	-0.42	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
STAD	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-8.61	2.53e-16	1.03e-12	-0.51	-0.42	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-8.61	2.53e-16	1.03e-12	-0.51	-0.42	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	8.61	2.55e-16	1.04e-12	0.51	0.42	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
STAD	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	8.61	2.61e-16	1.06e-12	0.45	0.42	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs73152714	ENSG00000222364.1	RNU6-96P	-8.61	2.61e-16	1.06e-12	-0.51	-0.42	Aortic root size;	chr7:66534641	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs4718364	ENSG00000222364.1	RNU6-96P	-8.61	2.61e-16	1.06e-12	-0.51	-0.42	Aortic root size;	chr7:66536353	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs6961853	ENSG00000222364.1	RNU6-96P	-8.61	2.61e-16	1.06e-12	-0.51	-0.42	Aortic root size;	chr7:66537035	chr7:66395191~66395286:+
STAD	cis	rs875971	0.528	rs801213	ENSG00000222364.1	RNU6-96P	8.61	2.61e-16	1.06e-12	0.51	0.42	Aortic root size;	chr7:66549931	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs801212	ENSG00000222364.1	RNU6-96P	8.61	2.61e-16	1.06e-12	0.51	0.42	Aortic root size;	chr7:66550643	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs801199	ENSG00000222364.1	RNU6-96P	8.61	2.61e-16	1.06e-12	0.51	0.42	Aortic root size;	chr7:66560286	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs1267814	ENSG00000222364.1	RNU6-96P	8.61	2.61e-16	1.06e-12	0.51	0.42	Aortic root size;	chr7:66579422	chr7:66395191~66395286:+
STAD	cis	rs6456156	0.792	rs7775443	ENSG00000265828.1	MIR3939	8.61	2.67e-16	1.08e-12	0.46	0.42	Primary biliary cholangitis;	chr6:167099764	chr6:166997807~166997912:-
STAD	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	8.61	2.68e-16	1.08e-12	0.58	0.42	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
STAD	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	8.61	2.7e-16	1.09e-12	0.66	0.42	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
STAD	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	8.61	2.7e-16	1.09e-12	0.52	0.42	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
STAD	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-8.6	2.74e-16	1.11e-12	-0.48	-0.42	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
STAD	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-8.6	2.75e-16	1.11e-12	-0.51	-0.42	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
STAD	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-8.6	2.77e-16	1.12e-12	-0.53	-0.42	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-8.6	2.77e-16	1.12e-12	-0.53	-0.42	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-8.6	2.77e-16	1.12e-12	-0.53	-0.42	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-8.6	2.77e-16	1.12e-12	-0.53	-0.42	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-8.6	2.77e-16	1.12e-12	-0.53	-0.42	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-8.6	2.77e-16	1.12e-12	-0.53	-0.42	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-8.6	2.77e-16	1.12e-12	-0.53	-0.42	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-8.6	2.79e-16	1.13e-12	-0.53	-0.42	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
STAD	cis	rs9355610	0.892	rs2247314	ENSG00000265828.1	MIR3939	8.6	2.81e-16	1.13e-12	0.49	0.42	Graves' disease;	chr6:166956742	chr6:166997807~166997912:-
STAD	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-8.6	2.84e-16	1.14e-12	-0.52	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
STAD	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-8.6	2.84e-16	1.14e-12	-0.52	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
STAD	cis	rs9457247	0.534	rs12055488	ENSG00000265828.1	MIR3939	8.6	2.84e-16	1.14e-12	0.49	0.42	Crohn's disease;	chr6:166966082	chr6:166997807~166997912:-
STAD	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-8.6	2.84e-16	1.14e-12	-0.5	-0.42	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-8.6	2.85e-16	1.15e-12	-0.5	-0.42	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
STAD	cis	rs6456156	0.792	rs10946215	ENSG00000265828.1	MIR3939	8.6	2.87e-16	1.16e-12	0.46	0.42	Primary biliary cholangitis;	chr6:167102693	chr6:166997807~166997912:-
STAD	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	8.6	2.88e-16	1.16e-12	0.48	0.42	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
STAD	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	8.6	2.91e-16	1.17e-12	0.52	0.42	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
STAD	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	8.59	2.92e-16	1.17e-12	0.65	0.42	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
STAD	cis	rs875971	0.545	rs13311962	ENSG00000222364.1	RNU6-96P	8.59	2.92e-16	1.17e-12	0.51	0.42	Aortic root size;	chr7:66603142	chr7:66395191~66395286:+
STAD	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-8.59	2.93e-16	1.18e-12	-0.47	-0.42	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
STAD	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-8.59	2.96e-16	1.19e-12	-0.45	-0.42	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
STAD	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-8.59	2.98e-16	1.2e-12	-0.5	-0.42	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
STAD	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-8.59	2.99e-16	1.2e-12	-0.45	-0.42	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
STAD	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	8.59	3e-16	1.2e-12	0.52	0.42	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-8.59	3.02e-16	1.21e-12	-0.5	-0.42	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	8.59	3.03e-16	1.22e-12	0.51	0.42	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
STAD	cis	rs875971	0.545	rs6950988	ENSG00000222364.1	RNU6-96P	-8.59	3.06e-16	1.23e-12	-0.51	-0.42	Aortic root size;	chr7:66511428	chr7:66395191~66395286:+
STAD	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-8.59	3.08e-16	1.24e-12	-0.51	-0.42	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
STAD	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-8.59	3.09e-16	1.24e-12	-0.48	-0.42	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
STAD	cis	rs875971	0.545	rs1638735	ENSG00000222364.1	RNU6-96P	-8.59	3.1e-16	1.24e-12	-0.5	-0.42	Aortic root size;	chr7:66630751	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	8.58	3.16e-16	1.27e-12	0.51	0.42	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	8.58	3.16e-16	1.27e-12	0.51	0.42	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	8.58	3.16e-16	1.27e-12	0.51	0.42	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	8.58	3.16e-16	1.27e-12	0.51	0.42	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	8.58	3.16e-16	1.27e-12	0.51	0.42	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	8.58	3.18e-16	1.27e-12	0.52	0.42	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	8.58	3.18e-16	1.27e-12	0.52	0.42	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	8.58	3.24e-16	1.3e-12	0.52	0.42	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
STAD	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-8.58	3.27e-16	1.31e-12	-0.47	-0.42	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
STAD	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	8.58	3.31e-16	1.32e-12	0.56	0.42	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
STAD	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	8.58	3.31e-16	1.32e-12	0.56	0.42	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
STAD	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	8.58	3.32e-16	1.32e-12	0.5	0.42	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
STAD	cis	rs875971	0.545	rs6460298	ENSG00000222364.1	RNU6-96P	-8.57	3.39e-16	1.35e-12	-0.51	-0.42	Aortic root size;	chr7:66442783	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs75577046	ENSG00000222364.1	RNU6-96P	-8.57	3.39e-16	1.35e-12	-0.51	-0.42	Aortic root size;	chr7:66493729	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs3735147	ENSG00000222364.1	RNU6-96P	-8.57	3.39e-16	1.35e-12	-0.51	-0.42	Aortic root size;	chr7:66505541	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	8.57	3.39e-16	1.35e-12	0.52	0.42	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	8.57	3.39e-16	1.35e-12	0.52	0.42	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
STAD	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-8.57	3.41e-16	1.36e-12	-0.51	-0.42	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-8.57	3.41e-16	1.36e-12	-0.51	-0.42	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
STAD	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	8.57	3.42e-16	1.36e-12	0.5	0.42	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-8.57	3.42e-16	1.36e-12	-0.34	-0.42	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
STAD	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	8.57	3.45e-16	1.37e-12	0.52	0.42	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
STAD	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-8.57	3.46e-16	1.38e-12	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
STAD	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	8.57	3.49e-16	1.39e-12	0.51	0.42	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	8.57	3.5e-16	1.39e-12	0.52	0.42	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	8.57	3.5e-16	1.39e-12	0.52	0.42	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
STAD	cis	rs9457247	0.515	rs2757039	ENSG00000265828.1	MIR3939	8.57	3.6e-16	1.43e-12	0.49	0.42	Crohn's disease;	chr6:166956865	chr6:166997807~166997912:-
STAD	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-8.56	3.65e-16	1.45e-12	-0.5	-0.42	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
STAD	cis	rs9457247	0.534	rs9355610	ENSG00000265828.1	MIR3939	8.56	3.66e-16	1.46e-12	0.49	0.42	Crohn's disease;	chr6:166969587	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	8.56	3.67e-16	1.46e-12	0.51	0.42	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-8.56	3.68e-16	1.46e-12	-0.5	-0.42	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
STAD	cis	rs875971	0.502	rs1796227	ENSG00000222364.1	RNU6-96P	8.56	3.69e-16	1.47e-12	0.51	0.42	Aortic root size;	chr7:66622032	chr7:66395191~66395286:+
STAD	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-8.56	3.71e-16	1.47e-12	-0.63	-0.42	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
STAD	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-8.56	3.73e-16	1.48e-12	-0.52	-0.42	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
STAD	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-8.56	3.75e-16	1.49e-12	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	8.56	3.77e-16	1.5e-12	0.52	0.42	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	8.56	3.82e-16	1.51e-12	0.5	0.42	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	8.56	3.82e-16	1.51e-12	0.5	0.42	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	8.56	3.82e-16	1.51e-12	0.5	0.42	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-8.56	3.83e-16	1.52e-12	-0.5	-0.42	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
STAD	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	8.56	3.83e-16	1.52e-12	0.64	0.42	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
STAD	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-8.55	3.93e-16	1.56e-12	-0.36	-0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
STAD	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	8.55	3.94e-16	1.56e-12	0.5	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
STAD	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.55	3.95e-16	1.56e-12	0.5	0.42	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.55	3.95e-16	1.56e-12	0.5	0.42	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
STAD	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-8.55	3.96e-16	1.57e-12	-0.44	-0.42	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-8.55	4e-16	1.58e-12	-0.41	-0.42	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
STAD	cis	rs6456156	0.819	rs7765739	ENSG00000265828.1	MIR3939	-8.55	4.04e-16	1.6e-12	-0.46	-0.42	Primary biliary cholangitis;	chr6:167104984	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.846	rs7774396	ENSG00000265828.1	MIR3939	-8.55	4.04e-16	1.6e-12	-0.46	-0.42	Primary biliary cholangitis;	chr6:167106298	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	8.55	4.08e-16	1.61e-12	0.51	0.42	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	8.55	4.08e-16	1.61e-12	0.51	0.42	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	8.55	4.08e-16	1.61e-12	0.51	0.42	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
STAD	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	8.55	4.09e-16	1.62e-12	0.59	0.42	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
STAD	cis	rs875971	0.545	rs35459055	ENSG00000222364.1	RNU6-96P	-8.55	4.09e-16	1.62e-12	-0.51	-0.42	Aortic root size;	chr7:66479399	chr7:66395191~66395286:+
STAD	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	8.54	4.18e-16	1.65e-12	0.74	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
STAD	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	8.54	4.18e-16	1.65e-12	0.74	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
STAD	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-8.54	4.27e-16	1.68e-12	-0.43	-0.42	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	8.54	4.31e-16	1.7e-12	0.52	0.42	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
STAD	cis	rs6456156	0.819	rs9457273	ENSG00000265828.1	MIR3939	8.54	4.34e-16	1.71e-12	0.46	0.42	Primary biliary cholangitis;	chr6:167107261	chr6:166997807~166997912:-
STAD	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-8.54	4.35e-16	1.71e-12	-0.52	-0.42	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-8.54	4.35e-16	1.71e-12	-0.52	-0.42	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
STAD	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	8.54	4.36e-16	1.72e-12	0.5	0.42	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	8.54	4.37e-16	1.72e-12	0.5	0.42	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	8.54	4.38e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	8.54	4.38e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	8.54	4.38e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
STAD	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	8.54	4.39e-16	1.73e-12	0.57	0.42	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
STAD	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	8.54	4.4e-16	1.73e-12	0.5	0.42	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
STAD	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	8.54	4.44e-16	1.74e-12	0.47	0.42	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
STAD	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	8.54	4.45e-16	1.75e-12	0.52	0.42	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	8.54	4.45e-16	1.75e-12	0.52	0.42	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	8.54	4.45e-16	1.75e-12	0.52	0.42	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
STAD	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-8.53	4.5e-16	1.76e-12	-0.5	-0.42	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
STAD	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	8.53	4.53e-16	1.78e-12	0.45	0.42	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
STAD	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	8.53	4.53e-16	1.78e-12	0.45	0.42	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
STAD	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-8.53	4.54e-16	1.78e-12	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	8.53	4.58e-16	1.8e-12	0.52	0.42	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
STAD	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-8.53	4.58e-16	1.8e-12	-0.63	-0.42	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
STAD	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	8.53	4.62e-16	1.81e-12	0.74	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
STAD	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	8.53	4.71e-16	1.84e-12	0.49	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
STAD	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-8.53	4.71e-16	1.85e-12	-0.47	-0.42	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
STAD	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-8.53	4.72e-16	1.85e-12	-0.47	-0.42	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
STAD	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-8.53	4.72e-16	1.85e-12	-0.47	-0.42	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
STAD	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	8.53	4.75e-16	1.86e-12	0.48	0.42	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
STAD	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-8.53	4.76e-16	1.86e-12	-0.5	-0.42	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
STAD	cis	rs2581828	0.58	rs4687570	ENSG00000242142.1	SERBP1P3	8.53	4.79e-16	1.87e-12	0.46	0.42	Crohn's disease;	chr3:53136484	chr3:53064283~53065091:-
STAD	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-8.52	4.81e-16	1.88e-12	-0.61	-0.42	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
STAD	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	8.52	4.86e-16	1.9e-12	0.44	0.42	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
STAD	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	8.52	4.86e-16	1.9e-12	0.44	0.42	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
STAD	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	8.52	4.87e-16	1.9e-12	0.49	0.42	Temperament;	chr17:13996939	chr17:14024514~14025488:+
STAD	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	8.52	4.91e-16	1.92e-12	0.61	0.42	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-8.52	4.94e-16	1.93e-12	-0.34	-0.42	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
STAD	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-8.52	4.95e-16	1.93e-12	-0.47	-0.42	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
STAD	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	8.52	4.97e-16	1.94e-12	0.8	0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
STAD	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	8.52	4.98e-16	1.94e-12	0.51	0.42	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
STAD	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	8.52	4.98e-16	1.95e-12	0.51	0.42	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
STAD	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	8.52	4.98e-16	1.95e-12	0.5	0.42	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	8.52	5.02e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	8.52	5.03e-16	1.96e-12	0.5	0.42	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	8.52	5.05e-16	1.97e-12	0.5	0.42	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	8.52	5.05e-16	1.97e-12	0.5	0.42	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
STAD	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	8.52	5.05e-16	1.97e-12	0.56	0.42	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
STAD	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	8.52	5.13e-16	2e-12	0.64	0.42	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
STAD	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	8.52	5.15e-16	2e-12	0.5	0.42	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
STAD	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-8.52	5.16e-16	2.01e-12	-0.53	-0.42	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
STAD	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	8.51	5.19e-16	2.02e-12	0.51	0.42	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
STAD	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-8.51	5.2e-16	2.02e-12	-0.51	-0.42	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	8.51	5.24e-16	2.03e-12	0.51	0.42	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
STAD	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	8.51	5.26e-16	2.05e-12	0.44	0.42	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
STAD	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	8.51	5.26e-16	2.05e-12	0.44	0.42	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
STAD	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-8.51	5.27e-16	2.05e-12	-0.5	-0.42	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
STAD	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-8.51	5.29e-16	2.05e-12	-0.52	-0.42	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
STAD	cis	rs1426063	0.8	rs28861517	ENSG00000249717.1	RP11-44F21.3	8.51	5.33e-16	2.07e-12	0.59	0.42	QT interval;	chr4:75092995	chr4:74955974~74970362:-
STAD	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-8.51	5.39e-16	2.09e-12	-0.5	-0.42	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	8.51	5.42e-16	2.1e-12	0.51	0.42	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
STAD	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	8.51	5.45e-16	2.11e-12	0.47	0.42	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
STAD	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-8.51	5.46e-16	2.11e-12	-0.5	-0.42	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-8.51	5.46e-16	2.11e-12	-0.5	-0.42	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-8.51	5.46e-16	2.11e-12	-0.5	-0.42	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-8.51	5.46e-16	2.11e-12	-0.5	-0.42	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-8.51	5.46e-16	2.11e-12	-0.5	-0.42	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-8.51	5.46e-16	2.11e-12	-0.5	-0.42	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-8.51	5.46e-16	2.11e-12	-0.5	-0.42	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.51	5.5e-16	2.13e-12	0.5	0.42	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
STAD	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-8.51	5.54e-16	2.14e-12	-0.34	-0.42	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
STAD	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-8.5	5.6e-16	2.16e-12	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	8.5	5.62e-16	2.17e-12	0.51	0.42	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	8.5	5.64e-16	2.18e-12	0.49	0.42	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	8.5	5.64e-16	2.18e-12	0.49	0.42	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	8.5	5.64e-16	2.18e-12	0.49	0.42	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	8.5	5.64e-16	2.18e-12	0.49	0.42	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	8.5	5.64e-16	2.18e-12	0.49	0.42	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	8.5	5.64e-16	2.18e-12	0.49	0.42	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
STAD	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-8.5	5.66e-16	2.19e-12	-0.48	-0.42	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
STAD	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	8.5	5.68e-16	2.2e-12	0.44	0.42	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	8.5	5.68e-16	2.2e-12	0.44	0.42	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
STAD	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-8.5	5.68e-16	2.2e-12	-0.52	-0.42	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
STAD	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	8.5	5.74e-16	2.22e-12	0.52	0.42	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	8.5	5.74e-16	2.22e-12	0.52	0.42	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
STAD	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	8.5	5.79e-16	2.23e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	8.5	5.79e-16	2.23e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	8.5	5.79e-16	2.23e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	8.5	5.79e-16	2.23e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	8.5	5.79e-16	2.23e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
STAD	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	8.5	5.8e-16	2.24e-12	0.51	0.42	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
STAD	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-8.5	5.82e-16	2.24e-12	-0.48	-0.42	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
STAD	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-8.5	5.92e-16	2.28e-12	-0.47	-0.42	Height;	chr11:118808920	chr11:118704607~118750263:+
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-8.49	6.03e-16	2.32e-12	-0.34	-0.42	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
STAD	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-8.49	6.06e-16	2.33e-12	-0.5	-0.42	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
STAD	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	8.49	6.08e-16	2.34e-12	0.47	0.42	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	8.49	6.08e-16	2.34e-12	0.47	0.42	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	8.49	6.08e-16	2.34e-12	0.47	0.42	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
STAD	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-8.49	6.1e-16	2.35e-12	-0.52	-0.42	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
STAD	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-8.49	6.12e-16	2.35e-12	-0.5	-0.42	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
STAD	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	8.49	6.14e-16	2.36e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	8.49	6.14e-16	2.36e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	8.49	6.14e-16	2.36e-12	0.47	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
STAD	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-8.49	6.15e-16	2.36e-12	-0.5	-0.42	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
STAD	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-8.49	6.18e-16	2.37e-12	-0.48	-0.42	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
STAD	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-8.49	6.18e-16	2.37e-12	-0.48	-0.42	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
STAD	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-8.49	6.2e-16	2.38e-12	-0.5	-0.42	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-8.49	6.2e-16	2.38e-12	-0.5	-0.42	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-8.49	6.2e-16	2.38e-12	-0.5	-0.42	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-8.49	6.2e-16	2.38e-12	-0.5	-0.42	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-8.49	6.2e-16	2.38e-12	-0.5	-0.42	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
STAD	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-8.49	6.31e-16	2.42e-12	-0.51	-0.42	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
STAD	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	8.49	6.34e-16	2.43e-12	0.49	0.42	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	8.49	6.34e-16	2.43e-12	0.49	0.42	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	8.49	6.34e-16	2.43e-12	0.49	0.42	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	8.49	6.34e-16	2.43e-12	0.49	0.42	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	8.49	6.34e-16	2.43e-12	0.49	0.42	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	8.49	6.34e-16	2.43e-12	0.49	0.42	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
STAD	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	8.48	6.4e-16	2.45e-12	0.7	0.42	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
STAD	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	8.48	6.5e-16	2.49e-12	0.4	0.41	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
STAD	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-8.48	6.52e-16	2.49e-12	-0.44	-0.41	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	8.48	6.63e-16	2.54e-12	0.51	0.41	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	8.48	6.63e-16	2.54e-12	0.51	0.41	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	8.48	6.63e-16	2.54e-12	0.51	0.41	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	8.48	6.63e-16	2.54e-12	0.51	0.41	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	8.48	6.63e-16	2.54e-12	0.51	0.41	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
STAD	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-8.48	6.75e-16	2.58e-12	-0.48	-0.41	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
STAD	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-8.48	6.75e-16	2.58e-12	-0.48	-0.41	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
STAD	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-8.48	6.75e-16	2.58e-12	-0.48	-0.41	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
STAD	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-8.48	6.75e-16	2.58e-12	-0.48	-0.41	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
STAD	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-8.48	6.83e-16	2.61e-12	-0.49	-0.41	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
STAD	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	8.47	6.89e-16	2.63e-12	0.43	0.41	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
STAD	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	8.47	6.96e-16	2.66e-12	0.44	0.41	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
STAD	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-8.47	6.97e-16	2.66e-12	-0.47	-0.41	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
STAD	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	8.47	7.04e-16	2.68e-12	0.44	0.41	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs1909508	ENSG00000222364.1	RNU6-96P	-8.47	7.04e-16	2.69e-12	-0.5	-0.41	Aortic root size;	chr7:66301366	chr7:66395191~66395286:+
STAD	cis	rs916888	0.779	rs199498	ENSG00000262500.1	RP11-259G18.2	8.47	7.11e-16	2.71e-12	0.52	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46243606~46245044:+
STAD	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	8.47	7.22e-16	2.75e-12	0.44	0.41	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
STAD	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	8.47	7.22e-16	2.75e-12	0.44	0.41	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
STAD	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	8.47	7.35e-16	2.79e-12	0.64	0.41	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	8.46	7.39e-16	2.81e-12	0.59	0.41	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
STAD	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	8.46	7.4e-16	2.81e-12	0.51	0.41	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.46	7.41e-16	2.82e-12	0.5	0.41	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.46	7.41e-16	2.82e-12	0.5	0.41	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.46	7.41e-16	2.82e-12	0.5	0.41	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
STAD	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-8.46	7.48e-16	2.84e-12	-0.74	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	8.46	7.6e-16	2.89e-12	0.48	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
STAD	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	8.46	7.61e-16	2.89e-12	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
STAD	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-8.46	7.64e-16	2.9e-12	-0.45	-0.41	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
STAD	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-8.46	7.64e-16	2.9e-12	-0.34	-0.41	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
STAD	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-8.46	7.64e-16	2.9e-12	-0.35	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
STAD	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	8.46	7.67e-16	2.91e-12	0.51	0.41	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	8.46	7.67e-16	2.91e-12	0.51	0.41	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	8.46	7.67e-16	2.91e-12	0.51	0.41	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
STAD	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-8.46	7.68e-16	2.92e-12	-0.49	-0.41	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-8.46	7.68e-16	2.92e-12	-0.49	-0.41	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
STAD	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	8.46	7.91e-16	3e-12	0.51	0.41	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
STAD	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	8.45	7.96e-16	3.02e-12	0.49	0.41	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
STAD	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	8.45	7.96e-16	3.02e-12	0.44	0.41	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
STAD	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-8.45	8.04e-16	3.04e-12	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
STAD	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-8.45	8.04e-16	3.05e-12	-0.4	-0.41	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
STAD	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.45	8.16e-16	3.09e-12	0.5	0.41	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.45	8.16e-16	3.09e-12	0.5	0.41	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	8.45	8.16e-16	3.09e-12	0.5	0.41	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
STAD	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	8.45	8.38e-16	3.17e-12	0.51	0.41	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	8.45	8.44e-16	3.19e-12	0.51	0.41	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	8.45	8.44e-16	3.19e-12	0.51	0.41	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	8.45	8.44e-16	3.19e-12	0.51	0.41	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	8.45	8.44e-16	3.19e-12	0.51	0.41	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
STAD	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-8.45	8.45e-16	3.19e-12	-0.52	-0.41	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
STAD	cis	rs875971	0.545	rs1796222	ENSG00000222364.1	RNU6-96P	8.44	8.51e-16	3.22e-12	0.5	0.41	Aortic root size;	chr7:66592167	chr7:66395191~66395286:+
STAD	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-8.44	8.59e-16	3.24e-12	-0.48	-0.41	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
STAD	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	8.44	8.69e-16	3.28e-12	0.43	0.41	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
STAD	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-8.44	8.74e-16	3.3e-12	-0.47	-0.41	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
STAD	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	8.44	8.76e-16	3.3e-12	0.56	0.41	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
STAD	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-8.44	8.83e-16	3.33e-12	-0.52	-0.41	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	8.44	8.9e-16	3.35e-12	0.49	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
STAD	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-8.44	8.91e-16	3.36e-12	-0.5	-0.41	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
STAD	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	8.44	8.91e-16	3.36e-12	0.48	0.41	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
STAD	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	8.44	8.92e-16	3.36e-12	0.47	0.41	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
STAD	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-8.44	8.95e-16	3.37e-12	-0.62	-0.41	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-8.44	8.95e-16	3.37e-12	-0.62	-0.41	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
STAD	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-8.44	8.97e-16	3.38e-12	-0.51	-0.41	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-8.44	8.97e-16	3.38e-12	-0.51	-0.41	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
STAD	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	8.44	8.98e-16	3.38e-12	0.57	0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
STAD	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-8.44	8.99e-16	3.38e-12	-0.47	-0.41	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
STAD	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	8.44	9.11e-16	3.43e-12	0.51	0.41	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
STAD	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-8.43	9.29e-16	3.49e-12	-0.41	-0.41	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
STAD	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	8.43	9.34e-16	3.51e-12	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	8.43	9.34e-16	3.51e-12	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
STAD	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	8.43	9.48e-16	3.55e-12	0.73	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
STAD	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	8.43	9.64e-16	3.61e-12	0.51	0.41	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	8.43	9.64e-16	3.61e-12	0.51	0.41	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	8.43	9.64e-16	3.61e-12	0.51	0.41	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	8.43	9.64e-16	3.61e-12	0.51	0.41	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
STAD	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-8.43	9.66e-16	3.62e-12	-0.53	-0.41	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
STAD	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	8.42	9.8e-16	3.67e-12	0.54	0.41	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
STAD	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	8.42	9.81e-16	3.67e-12	0.44	0.41	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
STAD	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-8.42	9.91e-16	3.71e-12	-0.34	-0.41	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
STAD	cis	rs6456156	0.875	rs55802221	ENSG00000265828.1	MIR3939	8.42	9.96e-16	3.72e-12	0.44	0.41	Primary biliary cholangitis;	chr6:167103832	chr6:166997807~166997912:-
STAD	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	8.42	9.99e-16	3.74e-12	0.47	0.41	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
STAD	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-8.42	1e-15	3.75e-12	-0.62	-0.41	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
STAD	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-8.42	1.02e-15	3.8e-12	-0.44	-0.41	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	8.42	1.02e-15	3.81e-12	0.51	0.41	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
STAD	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	8.42	1.03e-15	3.83e-12	0.44	0.41	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-8.42	1.03e-15	3.83e-12	-0.51	-0.41	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
STAD	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-8.42	1.03e-15	3.84e-12	-0.47	-0.41	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
STAD	cis	rs9457247	0.529	rs6907666	ENSG00000265828.1	MIR3939	8.42	1.04e-15	3.88e-12	0.45	0.41	Crohn's disease;	chr6:167109907	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	8.42	1.05e-15	3.91e-12	0.5	0.41	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
STAD	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-8.41	1.06e-15	3.95e-12	-0.49	-0.41	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
STAD	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-8.41	1.06e-15	3.97e-12	-0.47	-0.41	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
STAD	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	8.41	1.09e-15	4.08e-12	0.49	0.41	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
STAD	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	8.41	1.1e-15	4.11e-12	0.44	0.41	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
STAD	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-8.41	1.1e-15	4.11e-12	-0.49	-0.41	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
STAD	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-8.41	1.11e-15	4.15e-12	-0.43	-0.41	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
STAD	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	8.41	1.12e-15	4.17e-12	0.51	0.41	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
STAD	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	8.41	1.12e-15	4.17e-12	0.51	0.41	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
STAD	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-8.4	1.13e-15	4.2e-12	-0.49	-0.41	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
STAD	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-8.4	1.14e-15	4.22e-12	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
STAD	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-8.4	1.14e-15	4.22e-12	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
STAD	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-8.4	1.14e-15	4.24e-12	-0.49	-0.41	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-8.4	1.14e-15	4.24e-12	-0.49	-0.41	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
STAD	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-8.4	1.14e-15	4.24e-12	-0.49	-0.41	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
STAD	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-8.4	1.14e-15	4.25e-12	-0.48	-0.41	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
STAD	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-8.4	1.15e-15	4.26e-12	-0.47	-0.41	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-8.4	1.15e-15	4.27e-12	-0.47	-0.41	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-8.4	1.15e-15	4.27e-12	-0.47	-0.41	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-8.4	1.15e-15	4.27e-12	-0.47	-0.41	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
STAD	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-8.4	1.16e-15	4.31e-12	-0.49	-0.41	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
STAD	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-8.4	1.17e-15	4.33e-12	-0.48	-0.41	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-8.4	1.17e-15	4.33e-12	-0.48	-0.41	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
STAD	cis	rs3136516	0.696	rs10838611	ENSG00000271350.1	CTD-2384B9.1	-8.4	1.17e-15	4.34e-12	-0.47	-0.41	Venous thromboembolism;	chr11:46675649	chr11:47041027~47041945:-
STAD	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	8.39	1.26e-15	4.68e-12	0.44	0.41	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
STAD	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	8.39	1.3e-15	4.8e-12	0.49	0.41	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
STAD	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-8.38	1.31e-15	4.83e-12	-0.51	-0.41	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
STAD	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	8.38	1.32e-15	4.89e-12	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
STAD	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-8.38	1.33e-15	4.92e-12	-0.47	-0.41	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
STAD	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-8.38	1.33e-15	4.92e-12	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
STAD	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-8.38	1.34e-15	4.94e-12	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
STAD	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	8.38	1.34e-15	4.94e-12	0.45	0.41	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-8.38	1.34e-15	4.95e-12	-0.51	-0.41	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
STAD	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-8.38	1.37e-15	5.04e-12	-0.51	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
STAD	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	8.38	1.37e-15	5.04e-12	0.46	0.41	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
STAD	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-8.38	1.37e-15	5.04e-12	-0.46	-0.41	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
STAD	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-8.38	1.37e-15	5.04e-12	-0.46	-0.41	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
STAD	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-8.38	1.38e-15	5.09e-12	-0.45	-0.41	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
STAD	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-8.37	1.42e-15	5.22e-12	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
STAD	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	8.37	1.43e-15	5.26e-12	0.48	0.41	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
STAD	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-8.37	1.43e-15	5.27e-12	-0.36	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
STAD	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	8.37	1.44e-15	5.28e-12	0.44	0.41	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
STAD	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	8.37	1.44e-15	5.28e-12	0.44	0.41	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
STAD	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	8.37	1.44e-15	5.28e-12	0.44	0.41	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
STAD	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	8.37	1.44e-15	5.28e-12	0.44	0.41	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
STAD	cis	rs875971	0.597	rs11763224	ENSG00000222364.1	RNU6-96P	-8.37	1.45e-15	5.33e-12	-0.52	-0.41	Aortic root size;	chr7:66518628	chr7:66395191~66395286:+
STAD	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-8.37	1.46e-15	5.36e-12	-0.45	-0.41	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
STAD	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-8.37	1.46e-15	5.36e-12	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-8.37	1.46e-15	5.36e-12	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-8.37	1.46e-15	5.36e-12	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
STAD	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-8.37	1.48e-15	5.45e-12	-0.4	-0.41	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000224205.1	AP000351.4	8.36	1.52e-15	5.6e-12	0.47	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23987320~23991421:-
STAD	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-8.36	1.55e-15	5.69e-12	-0.49	-0.41	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
STAD	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	8.36	1.57e-15	5.76e-12	0.49	0.41	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
STAD	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-8.36	1.6e-15	5.85e-12	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000224205.1	AP000351.4	-8.35	1.61e-15	5.89e-12	-0.47	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23987320~23991421:-
STAD	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	8.35	1.63e-15	5.96e-12	0.53	0.41	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
STAD	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-8.35	1.63e-15	5.99e-12	-0.4	-0.41	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-8.35	1.64e-15	6e-12	-0.4	-0.41	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-8.35	1.65e-15	6.04e-12	-0.4	-0.41	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
STAD	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	8.35	1.67e-15	6.1e-12	0.5	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
STAD	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	8.35	1.67e-15	6.1e-12	0.5	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
STAD	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-8.35	1.68e-15	6.16e-12	-0.46	-0.41	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-8.35	1.68e-15	6.16e-12	-0.46	-0.41	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-8.35	1.68e-15	6.16e-12	-0.46	-0.41	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-8.35	1.68e-15	6.16e-12	-0.46	-0.41	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-8.35	1.68e-15	6.16e-12	-0.46	-0.41	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-8.35	1.68e-15	6.16e-12	-0.46	-0.41	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	8.35	1.69e-15	6.16e-12	0.5	0.41	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-8.35	1.7e-15	6.2e-12	-0.51	-0.41	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
STAD	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-8.35	1.71e-15	6.23e-12	-0.57	-0.41	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
STAD	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-8.34	1.73e-15	6.3e-12	-0.44	-0.41	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
STAD	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-8.34	1.73e-15	6.3e-12	-0.44	-0.41	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
STAD	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	8.34	1.74e-15	6.34e-12	0.56	0.41	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
STAD	cis	rs875971	0.502	rs6460311	ENSG00000222364.1	RNU6-96P	8.34	1.8e-15	6.58e-12	0.5	0.41	Aortic root size;	chr7:66646886	chr7:66395191~66395286:+
STAD	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-8.34	1.81e-15	6.62e-12	-0.38	-0.41	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
STAD	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-8.34	1.83e-15	6.66e-12	-0.48	-0.41	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
STAD	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-8.34	1.83e-15	6.67e-12	-0.44	-0.41	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
STAD	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	8.34	1.84e-15	6.69e-12	0.56	0.41	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
STAD	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-8.33	1.85e-15	6.75e-12	-0.42	-0.41	Height;	chr3:53085518	chr3:53064283~53065091:-
STAD	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	8.33	1.86e-15	6.79e-12	0.49	0.41	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
STAD	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-8.33	1.9e-15	6.91e-12	-0.43	-0.41	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
STAD	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	8.33	1.91e-15	6.94e-12	0.57	0.41	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
STAD	cis	rs9506514	0.722	rs11147813	ENSG00000238286.1	SLC35E1P1	8.33	1.91e-15	6.96e-12	0.46	0.41	Coronary artery calcification;	chr13:20684419	chr13:20607268~20608131:+
STAD	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	8.33	1.92e-15	6.99e-12	0.49	0.41	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
STAD	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-8.33	1.93e-15	7e-12	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	8.33	1.93e-15	7.02e-12	0.51	0.41	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
STAD	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-8.33	1.93e-15	7.03e-12	-0.46	-0.41	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
STAD	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-8.33	1.94e-15	7.04e-12	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
STAD	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	8.33	1.95e-15	7.07e-12	0.45	0.41	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
STAD	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	8.33	1.97e-15	7.16e-12	0.49	0.41	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	8.32	2.09e-15	7.56e-12	0.46	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
STAD	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-8.32	2.1e-15	7.6e-12	-0.61	-0.41	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
STAD	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	8.32	2.11e-15	7.63e-12	0.51	0.41	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
STAD	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	8.32	2.11e-15	7.64e-12	0.73	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
STAD	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	8.32	2.13e-15	7.7e-12	0.48	0.41	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
STAD	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-8.31	2.14e-15	7.73e-12	-0.41	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
STAD	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-8.31	2.14e-15	7.74e-12	-0.47	-0.41	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
STAD	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	8.31	2.14e-15	7.75e-12	0.51	0.41	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
STAD	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-8.31	2.16e-15	7.82e-12	-0.46	-0.41	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
STAD	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-8.31	2.17e-15	7.84e-12	-0.48	-0.41	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
STAD	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.31	2.2e-15	7.95e-12	-0.49	-0.41	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
STAD	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-8.31	2.22e-15	8.01e-12	-0.4	-0.41	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
STAD	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	8.31	2.23e-15	8.06e-12	0.48	0.41	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
STAD	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-8.31	2.23e-15	8.06e-12	-0.4	-0.41	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-8.31	2.25e-15	8.1e-12	-0.4	-0.41	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-8.31	2.25e-15	8.1e-12	-0.4	-0.41	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-8.31	2.25e-15	8.1e-12	-0.4	-0.41	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-8.31	2.25e-15	8.1e-12	-0.4	-0.41	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
STAD	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-8.31	2.25e-15	8.11e-12	-0.48	-0.41	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
STAD	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-8.31	2.27e-15	8.18e-12	-0.4	-0.41	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-8.31	2.27e-15	8.18e-12	-0.4	-0.41	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
STAD	cis	rs11098499	0.821	rs56155624	ENSG00000248280.1	RP11-33B1.2	8.3	2.29e-15	8.26e-12	0.51	0.41	Corneal astigmatism;	chr4:119369871	chr4:119440561~119450157:-
STAD	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	8.3	2.31e-15	8.31e-12	0.44	0.41	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
STAD	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-8.3	2.31e-15	8.33e-12	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
STAD	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	8.3	2.32e-15	8.37e-12	0.5	0.41	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
STAD	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	8.3	2.33e-15	8.39e-12	0.5	0.41	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
STAD	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-8.3	2.33e-15	8.39e-12	-0.4	-0.41	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-8.3	2.33e-15	8.39e-12	-0.4	-0.41	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
STAD	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-8.3	2.34e-15	8.4e-12	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
STAD	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-8.3	2.34e-15	8.41e-12	-0.45	-0.41	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
STAD	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.3	2.37e-15	8.52e-12	-0.49	-0.41	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
STAD	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	8.3	2.38e-15	8.55e-12	0.73	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
STAD	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-8.3	2.4e-15	8.63e-12	-0.4	-0.41	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
STAD	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	8.29	2.47e-15	8.85e-12	0.47	0.41	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
STAD	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-8.29	2.48e-15	8.88e-12	-0.46	-0.41	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-8.29	2.48e-15	8.89e-12	-0.46	-0.41	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-8.29	2.48e-15	8.89e-12	-0.46	-0.41	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-8.29	2.48e-15	8.89e-12	-0.46	-0.41	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
STAD	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-8.29	2.48e-15	8.89e-12	-0.46	-0.41	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-8.29	2.48e-15	8.89e-12	-0.46	-0.41	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
STAD	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-8.29	2.5e-15	8.94e-12	-0.48	-0.41	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
STAD	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	8.29	2.5e-15	8.96e-12	0.44	0.41	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
STAD	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	8.29	2.5e-15	8.96e-12	0.44	0.41	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
STAD	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	8.29	2.51e-15	8.99e-12	0.72	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
STAD	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	8.29	2.51e-15	8.99e-12	0.72	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
STAD	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-8.29	2.52e-15	9.02e-12	-0.48	-0.41	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
STAD	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-8.29	2.52e-15	9.02e-12	-0.48	-0.41	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
STAD	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-8.29	2.52e-15	9.02e-12	-0.48	-0.41	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
STAD	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-8.29	2.52e-15	9.02e-12	-0.48	-0.41	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
STAD	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-8.29	2.52e-15	9.02e-12	-0.48	-0.41	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
STAD	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-8.29	2.53e-15	9.06e-12	-0.46	-0.41	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
STAD	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-8.29	2.54e-15	9.07e-12	-0.51	-0.41	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
STAD	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	8.29	2.54e-15	9.07e-12	0.42	0.41	Height;	chr3:53091453	chr3:53064283~53065091:-
STAD	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	8.29	2.55e-15	9.12e-12	0.51	0.41	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
STAD	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-8.29	2.57e-15	9.19e-12	-0.35	-0.41	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
STAD	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-8.28	2.66e-15	9.47e-12	-0.48	-0.41	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
STAD	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	8.28	2.66e-15	9.48e-12	0.39	0.41	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
STAD	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-8.28	2.67e-15	9.51e-12	-0.44	-0.41	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
STAD	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-8.28	2.67e-15	9.51e-12	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
STAD	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-8.28	2.69e-15	9.57e-12	-0.39	-0.41	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-8.28	2.69e-15	9.57e-12	-0.39	-0.41	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-8.28	2.69e-15	9.57e-12	-0.39	-0.41	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-8.28	2.69e-15	9.57e-12	-0.39	-0.41	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-8.28	2.69e-15	9.57e-12	-0.39	-0.41	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-8.28	2.69e-15	9.57e-12	-0.39	-0.41	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-8.28	2.69e-15	9.57e-12	-0.39	-0.41	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
STAD	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	8.28	2.72e-15	9.66e-12	0.44	0.41	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
STAD	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	8.28	2.72e-15	9.66e-12	0.44	0.41	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
STAD	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	8.28	2.73e-15	9.72e-12	0.44	0.41	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
STAD	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	8.28	2.76e-15	9.82e-12	0.44	0.41	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
STAD	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	8.28	2.79e-15	9.91e-12	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
STAD	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-8.28	2.79e-15	9.91e-12	-0.39	-0.41	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
STAD	cis	rs875971	0.545	rs316328	ENSG00000222364.1	RNU6-96P	8.28	2.79e-15	9.91e-12	0.49	0.41	Aortic root size;	chr7:66143851	chr7:66395191~66395286:+
STAD	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-8.28	2.79e-15	9.92e-12	-0.57	-0.41	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
STAD	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-8.28	2.81e-15	9.97e-12	-0.4	-0.41	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-8.28	2.81e-15	9.97e-12	-0.4	-0.41	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
STAD	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	8.28	2.81e-15	9.97e-12	0.44	0.41	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
STAD	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	8.28	2.81e-15	9.97e-12	0.44	0.41	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
STAD	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	8.28	2.81e-15	9.97e-12	0.44	0.41	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
STAD	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	8.27	2.82e-15	1e-11	0.43	0.41	Height;	chr3:53073584	chr3:53064283~53065091:-
STAD	cis	rs916888	0.647	rs199524	ENSG00000262500.1	RP11-259G18.2	-8.27	2.83e-15	1e-11	-0.52	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46243606~46245044:+
STAD	cis	rs916888	0.647	rs199523	ENSG00000262500.1	RP11-259G18.2	-8.27	2.83e-15	1e-11	-0.52	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46243606~46245044:+
STAD	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-8.27	2.84e-15	1.01e-11	-0.4	-0.41	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
STAD	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-8.27	2.85e-15	1.01e-11	-0.46	-0.41	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
STAD	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-8.27	2.87e-15	1.02e-11	-0.46	-0.41	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-8.27	2.87e-15	1.02e-11	-0.46	-0.41	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
STAD	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-8.27	2.87e-15	1.02e-11	-0.46	-0.41	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
STAD	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	8.27	2.91e-15	1.03e-11	0.46	0.41	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
STAD	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	8.27	2.96e-15	1.05e-11	0.56	0.41	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	8.27	2.96e-15	1.05e-11	0.56	0.41	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	8.27	2.96e-15	1.05e-11	0.56	0.41	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	8.27	2.96e-15	1.05e-11	0.56	0.41	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
STAD	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-8.27	3e-15	1.06e-11	-0.47	-0.41	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
STAD	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-8.27	3.01e-15	1.07e-11	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
STAD	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	8.26	3.04e-15	1.08e-11	0.33	0.41	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
STAD	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	8.26	3.08e-15	1.09e-11	0.5	0.41	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	8.26	3.08e-15	1.09e-11	0.5	0.41	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
STAD	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	8.26	3.12e-15	1.1e-11	0.46	0.41	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
STAD	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-8.26	3.17e-15	1.12e-11	-0.43	-0.41	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
STAD	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	8.26	3.18e-15	1.12e-11	0.44	0.41	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
STAD	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-8.26	3.2e-15	1.13e-11	-0.45	-0.41	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
STAD	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	8.26	3.21e-15	1.13e-11	0.5	0.41	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
STAD	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	8.26	3.22e-15	1.14e-11	0.48	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
STAD	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	8.26	3.24e-15	1.14e-11	0.47	0.41	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
STAD	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	8.25	3.31e-15	1.16e-11	0.5	0.41	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
STAD	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-8.25	3.31e-15	1.16e-11	-0.5	-0.41	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
STAD	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	8.25	3.33e-15	1.17e-11	0.49	0.41	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
STAD	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-8.25	3.39e-15	1.19e-11	-0.46	-0.41	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
STAD	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-8.25	3.43e-15	1.2e-11	-0.46	-0.41	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
STAD	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	8.25	3.45e-15	1.21e-11	0.5	0.41	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
STAD	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-8.25	3.45e-15	1.21e-11	-0.67	-0.41	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
STAD	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-8.25	3.46e-15	1.22e-11	-0.59	-0.41	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
STAD	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	8.24	3.54e-15	1.24e-11	0.38	0.41	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
STAD	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-8.24	3.57e-15	1.25e-11	-0.4	-0.41	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
STAD	cis	rs875971	0.545	rs6969224	ENSG00000222364.1	RNU6-96P	-8.24	3.57e-15	1.25e-11	-0.5	-0.41	Aortic root size;	chr7:66370011	chr7:66395191~66395286:+
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	8.24	3.61e-15	1.26e-11	0.46	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
STAD	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-8.24	3.61e-15	1.26e-11	-0.4	-0.41	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-8.24	3.64e-15	1.27e-11	-0.4	-0.4	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
STAD	cis	rs875971	0.545	rs12670811	ENSG00000222364.1	RNU6-96P	-8.24	3.65e-15	1.28e-11	-0.5	-0.4	Aortic root size;	chr7:66358032	chr7:66395191~66395286:+
STAD	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-8.24	3.66e-15	1.28e-11	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
STAD	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-8.24	3.67e-15	1.28e-11	-0.4	-0.4	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-8.24	3.67e-15	1.28e-11	-0.4	-0.4	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
STAD	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	8.24	3.67e-15	1.28e-11	0.48	0.4	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
STAD	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	8.24	3.67e-15	1.28e-11	0.48	0.4	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
STAD	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	8.24	3.67e-15	1.28e-11	0.43	0.4	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
STAD	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-8.24	3.7e-15	1.29e-11	-0.46	-0.4	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
STAD	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-8.23	3.78e-15	1.32e-11	-0.44	-0.4	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
STAD	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	8.23	3.94e-15	1.37e-11	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
STAD	cis	rs9506514	0.712	rs11838795	ENSG00000238286.1	SLC35E1P1	8.23	3.94e-15	1.37e-11	0.46	0.4	Coronary artery calcification;	chr13:20684189	chr13:20607268~20608131:+
STAD	cis	rs9506514	0.722	rs10400670	ENSG00000238286.1	SLC35E1P1	8.22	4e-15	1.39e-11	0.46	0.4	Coronary artery calcification;	chr13:20679350	chr13:20607268~20608131:+
STAD	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-8.22	4.01e-15	1.39e-11	-0.47	-0.4	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
STAD	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	8.22	4.07e-15	1.41e-11	0.49	0.4	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
STAD	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-8.22	4.1e-15	1.42e-11	-0.4	-0.4	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-8.22	4.1e-15	1.42e-11	-0.4	-0.4	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-8.22	4.1e-15	1.42e-11	-0.4	-0.4	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-8.22	4.1e-15	1.42e-11	-0.4	-0.4	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-8.22	4.1e-15	1.42e-11	-0.4	-0.4	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-8.22	4.1e-15	1.42e-11	-0.4	-0.4	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
STAD	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-8.22	4.11e-15	1.43e-11	-0.46	-0.4	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
STAD	cis	rs9506514	0.722	rs11147813	ENSG00000222726.1	RNU2-7P	8.22	4.14e-15	1.44e-11	0.47	0.4	Coronary artery calcification;	chr13:20684419	chr13:20612161~20612338:+
STAD	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-8.22	4.2e-15	1.45e-11	-0.39	-0.4	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-8.22	4.21e-15	1.46e-11	-0.39	-0.4	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-8.22	4.21e-15	1.46e-11	-0.39	-0.4	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-8.22	4.21e-15	1.46e-11	-0.39	-0.4	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-8.22	4.21e-15	1.46e-11	-0.39	-0.4	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-8.22	4.23e-15	1.46e-11	-0.39	-0.4	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-8.22	4.26e-15	1.47e-11	-0.4	-0.4	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-8.22	4.26e-15	1.47e-11	-0.39	-0.4	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	8.21	4.3e-15	1.49e-11	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
STAD	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	8.21	4.31e-15	1.49e-11	0.5	0.4	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	8.21	4.31e-15	1.49e-11	0.5	0.4	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
STAD	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-8.21	4.32e-15	1.49e-11	-0.4	-0.4	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
STAD	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	8.21	4.32e-15	1.49e-11	0.54	0.4	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
STAD	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-8.21	4.38e-15	1.51e-11	-0.43	-0.4	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
STAD	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-8.21	4.39e-15	1.52e-11	-0.39	-0.4	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
STAD	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-8.21	4.48e-15	1.55e-11	-0.46	-0.4	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
STAD	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-8.21	4.5e-15	1.55e-11	-0.41	-0.4	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
STAD	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-8.21	4.52e-15	1.56e-11	-0.46	-0.4	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
STAD	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-8.2	4.6e-15	1.59e-11	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	8.2	4.6e-15	1.59e-11	0.46	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
STAD	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	8.2	4.61e-15	1.59e-11	0.61	0.4	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
STAD	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	8.2	4.61e-15	1.59e-11	0.56	0.4	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
STAD	cis	rs875971	0.545	rs2420612	ENSG00000222364.1	RNU6-96P	-8.2	4.62e-15	1.59e-11	-0.5	-0.4	Aortic root size;	chr7:66536825	chr7:66395191~66395286:+
STAD	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	8.2	4.63e-15	1.6e-11	0.44	0.4	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
STAD	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-8.2	4.64e-15	1.6e-11	-0.47	-0.4	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
STAD	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	8.2	4.64e-15	1.6e-11	0.47	0.4	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
STAD	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	8.2	4.64e-15	1.6e-11	0.5	0.4	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	8.2	4.64e-15	1.6e-11	0.5	0.4	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	8.2	4.64e-15	1.6e-11	0.5	0.4	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	8.2	4.64e-15	1.6e-11	0.5	0.4	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	8.2	4.64e-15	1.6e-11	0.5	0.4	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
STAD	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-8.2	4.65e-15	1.6e-11	-0.33	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
STAD	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-8.2	4.65e-15	1.6e-11	-0.33	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
STAD	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-8.2	4.72e-15	1.63e-11	-0.41	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
STAD	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-8.2	4.72e-15	1.63e-11	-0.49	-0.4	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
STAD	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	8.2	4.75e-15	1.64e-11	0.66	0.4	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
STAD	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	8.2	4.76e-15	1.64e-11	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	8.2	4.76e-15	1.64e-11	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
STAD	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	8.2	4.76e-15	1.64e-11	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	8.2	4.76e-15	1.64e-11	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	8.2	4.76e-15	1.64e-11	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
STAD	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	8.2	4.78e-15	1.64e-11	0.43	0.4	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	8.2	4.78e-15	1.64e-11	0.5	0.4	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
STAD	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-8.2	4.89e-15	1.67e-11	-0.5	-0.4	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
STAD	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-8.19	4.95e-15	1.69e-11	-0.49	-0.4	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
STAD	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-8.19	5.01e-15	1.71e-11	-0.39	-0.4	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-8.19	5.01e-15	1.71e-11	-0.39	-0.4	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-8.19	5.01e-15	1.71e-11	-0.39	-0.4	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
STAD	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	8.19	5.1e-15	1.74e-11	0.43	0.4	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
STAD	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	8.19	5.1e-15	1.74e-11	0.43	0.4	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
STAD	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-8.19	5.22e-15	1.78e-11	-0.39	-0.4	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-8.19	5.22e-15	1.78e-11	-0.39	-0.4	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-8.19	5.22e-15	1.78e-11	-0.39	-0.4	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-8.19	5.22e-15	1.78e-11	-0.39	-0.4	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-8.19	5.22e-15	1.78e-11	-0.39	-0.4	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
STAD	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	8.19	5.22e-15	1.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
STAD	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-8.18	5.29e-15	1.81e-11	-0.47	-0.4	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
STAD	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-8.18	5.37e-15	1.83e-11	-0.42	-0.4	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	8.18	5.48e-15	1.87e-11	0.51	0.4	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	8.18	5.48e-15	1.87e-11	0.51	0.4	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
STAD	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-8.18	5.5e-15	1.87e-11	-0.46	-0.4	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-8.18	5.5e-15	1.87e-11	-0.46	-0.4	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
STAD	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	8.18	5.6e-15	1.91e-11	0.58	0.4	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
STAD	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-8.17	5.67e-15	1.93e-11	-0.46	-0.4	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
STAD	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-8.17	5.7e-15	1.94e-11	-0.44	-0.4	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
STAD	cis	rs11089937	1	rs6001121	ENSG00000211639.2	IGLV4-60	8.17	5.79e-15	1.97e-11	0.4	0.4	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22162199~22162681:+
STAD	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	8.17	5.82e-15	1.98e-11	0.57	0.4	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
STAD	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	8.17	5.87e-15	1.99e-11	0.5	0.4	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000224205.1	AP000351.4	8.17	5.88e-15	2e-11	0.47	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23987320~23991421:-
STAD	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	8.17	5.93e-15	2.01e-11	0.44	0.4	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
STAD	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	8.17	5.94e-15	2.02e-11	0.43	0.4	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
STAD	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	8.17	5.94e-15	2.02e-11	0.43	0.4	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
STAD	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	8.17	5.94e-15	2.02e-11	0.43	0.4	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
STAD	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	8.17	5.94e-15	2.02e-11	0.72	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
STAD	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	8.17	5.95e-15	2.02e-11	0.48	0.4	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
STAD	cis	rs875971	0.545	rs2279757	ENSG00000222364.1	RNU6-96P	-8.17	5.96e-15	2.02e-11	-0.5	-0.4	Aortic root size;	chr7:66363676	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs11766183	ENSG00000222364.1	RNU6-96P	-8.17	5.96e-15	2.02e-11	-0.5	-0.4	Aortic root size;	chr7:66374173	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs1065265	ENSG00000222364.1	RNU6-96P	-8.17	5.96e-15	2.02e-11	-0.5	-0.4	Aortic root size;	chr7:66376216	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs73146609	ENSG00000222364.1	RNU6-96P	-8.17	5.98e-15	2.03e-11	-0.5	-0.4	Aortic root size;	chr7:66302477	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs2173571	ENSG00000222364.1	RNU6-96P	-8.17	5.98e-15	2.03e-11	-0.5	-0.4	Aortic root size;	chr7:66305392	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs11770063	ENSG00000222364.1	RNU6-96P	-8.17	5.98e-15	2.03e-11	-0.5	-0.4	Aortic root size;	chr7:66318029	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs3936065	ENSG00000222364.1	RNU6-96P	-8.17	5.98e-15	2.03e-11	-0.5	-0.4	Aortic root size;	chr7:66325577	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs4718335	ENSG00000222364.1	RNU6-96P	-8.17	5.98e-15	2.03e-11	-0.5	-0.4	Aortic root size;	chr7:66339619	chr7:66395191~66395286:+
STAD	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-8.17	6.03e-15	2.04e-11	-0.41	-0.4	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
STAD	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	8.16	6.13e-15	2.07e-11	0.45	0.4	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
STAD	cis	rs748404	0.578	rs2584701	ENSG00000205771.5	CATSPER2P1	-8.16	6.2e-15	2.1e-11	-0.46	-0.4	Lung cancer;	chr15:43392741	chr15:43726918~43747094:-
STAD	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-8.16	6.22e-15	2.1e-11	-0.57	-0.4	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
STAD	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-8.16	6.3e-15	2.13e-11	-0.43	-0.4	Height;	chr11:118758322	chr11:118688039~118690600:-
STAD	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-8.16	6.31e-15	2.13e-11	-0.47	-0.4	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
STAD	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	8.16	6.33e-15	2.14e-11	0.59	0.4	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
STAD	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-8.16	6.46e-15	2.18e-11	-0.49	-0.4	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-8.16	6.46e-15	2.18e-11	-0.49	-0.4	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-8.16	6.46e-15	2.18e-11	-0.49	-0.4	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
STAD	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-8.16	6.49e-15	2.19e-11	-0.5	-0.4	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
STAD	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-8.15	6.51e-15	2.19e-11	-0.43	-0.4	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
STAD	cis	rs875971	0.502	rs11769702	ENSG00000222364.1	RNU6-96P	-8.15	6.69e-15	2.26e-11	-0.5	-0.4	Aortic root size;	chr7:66255529	chr7:66395191~66395286:+
STAD	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-8.15	6.74e-15	2.27e-11	-0.39	-0.4	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-8.15	6.74e-15	2.27e-11	-0.39	-0.4	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
STAD	cis	rs9506514	0.722	rs4769124	ENSG00000238286.1	SLC35E1P1	8.15	6.85e-15	2.31e-11	0.46	0.4	Coronary artery calcification;	chr13:20652706	chr13:20607268~20608131:+
STAD	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-8.14	7.13e-15	2.4e-11	-0.47	-0.4	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
STAD	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	8.14	7.25e-15	2.44e-11	0.44	0.4	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
STAD	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	8.14	7.25e-15	2.44e-11	0.44	0.4	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
STAD	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	8.14	7.25e-15	2.44e-11	0.44	0.4	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
STAD	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-8.14	7.37e-15	2.47e-11	-0.47	-0.4	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
STAD	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-8.14	7.42e-15	2.49e-11	-0.49	-0.4	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
STAD	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-8.14	7.42e-15	2.49e-11	-0.49	-0.4	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-8.14	7.42e-15	2.49e-11	-0.49	-0.4	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-8.14	7.42e-15	2.49e-11	-0.49	-0.4	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-8.14	7.42e-15	2.49e-11	-0.49	-0.4	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
STAD	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	8.14	7.45e-15	2.5e-11	0.46	0.4	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
STAD	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-8.13	7.59e-15	2.54e-11	-0.37	-0.4	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
STAD	cis	rs6456156	0.716	rs6905876	ENSG00000265828.1	MIR3939	-8.13	7.63e-15	2.56e-11	-0.44	-0.4	Primary biliary cholangitis;	chr6:167108074	chr6:166997807~166997912:-
STAD	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	8.13	7.71e-15	2.58e-11	0.49	0.4	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
STAD	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-8.13	7.73e-15	2.58e-11	-0.48	-0.4	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
STAD	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-8.13	7.75e-15	2.59e-11	-0.47	-0.4	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-8.13	7.75e-15	2.59e-11	-0.47	-0.4	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
STAD	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-8.13	7.88e-15	2.64e-11	-0.45	-0.4	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
STAD	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-8.13	7.89e-15	2.64e-11	-0.47	-0.4	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-8.13	7.89e-15	2.64e-11	-0.47	-0.4	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-8.13	7.89e-15	2.64e-11	-0.47	-0.4	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
STAD	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-8.13	7.92e-15	2.65e-11	-0.43	-0.4	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
STAD	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	8.13	7.98e-15	2.66e-11	0.5	0.4	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	8.13	7.98e-15	2.66e-11	0.5	0.4	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	8.13	7.98e-15	2.66e-11	0.5	0.4	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-8.13	8e-15	2.67e-11	-0.49	-0.4	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
STAD	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	8.12	8.06e-15	2.69e-11	0.59	0.4	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
STAD	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	8.12	8.15e-15	2.72e-11	0.49	0.4	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	8.12	8.15e-15	2.72e-11	0.49	0.4	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
STAD	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-8.12	8.17e-15	2.72e-11	-0.38	-0.4	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
STAD	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	8.12	8.19e-15	2.72e-11	0.67	0.4	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
STAD	cis	rs875971	0.545	rs7811204	ENSG00000222364.1	RNU6-96P	-8.12	8.24e-15	2.74e-11	-0.49	-0.4	Aortic root size;	chr7:66387213	chr7:66395191~66395286:+
STAD	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	8.12	8.32e-15	2.76e-11	0.55	0.4	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
STAD	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	8.12	8.34e-15	2.77e-11	0.76	0.4	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
STAD	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	8.12	8.35e-15	2.77e-11	0.5	0.4	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	8.12	8.35e-15	2.77e-11	0.5	0.4	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	8.12	8.35e-15	2.77e-11	0.5	0.4	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	8.12	8.35e-15	2.77e-11	0.5	0.4	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	8.12	8.35e-15	2.77e-11	0.5	0.4	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
STAD	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	8.12	8.36e-15	2.77e-11	0.51	0.4	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	8.12	8.4e-15	2.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	8.12	8.4e-15	2.78e-11	0.5	0.4	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
STAD	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	8.12	8.55e-15	2.83e-11	0.51	0.4	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
STAD	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-8.12	8.56e-15	2.83e-11	-0.45	-0.4	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
STAD	cis	rs875971	0.545	rs4441996	ENSG00000222364.1	RNU6-96P	8.12	8.56e-15	2.83e-11	0.5	0.4	Aortic root size;	chr7:66123233	chr7:66395191~66395286:+
STAD	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-8.12	8.58e-15	2.84e-11	-0.45	-0.4	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-8.12	8.58e-15	2.84e-11	-0.45	-0.4	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
STAD	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-8.12	8.58e-15	2.84e-11	-0.45	-0.4	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
STAD	cis	rs875971	0.545	rs4718348	ENSG00000222364.1	RNU6-96P	-8.11	8.65e-15	2.86e-11	-0.49	-0.4	Aortic root size;	chr7:66441589	chr7:66395191~66395286:+
STAD	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	8.11	8.8e-15	2.91e-11	0.47	0.4	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	8.11	8.8e-15	2.91e-11	0.47	0.4	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	8.11	8.8e-15	2.91e-11	0.47	0.4	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	8.11	8.8e-15	2.91e-11	0.47	0.4	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
STAD	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	8.11	9.01e-15	2.98e-11	0.51	0.4	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
STAD	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-8.11	9.05e-15	2.99e-11	-0.49	-0.4	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
STAD	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	8.11	9.18e-15	3.02e-11	0.46	0.4	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
STAD	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	8.11	9.18e-15	3.02e-11	0.5	0.4	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
STAD	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-8.1	9.23e-15	3.04e-11	-0.49	-0.4	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
STAD	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	8.1	9.28e-15	3.05e-11	0.43	0.4	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
STAD	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-8.1	9.28e-15	3.05e-11	-0.5	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
STAD	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-8.1	9.33e-15	3.07e-11	-0.4	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
STAD	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-8.1	9.38e-15	3.08e-11	-0.46	-0.4	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
STAD	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	8.1	9.45e-15	3.1e-11	0.5	0.4	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
STAD	cis	rs875971	0.545	rs10950029	ENSG00000222364.1	RNU6-96P	-8.1	9.55e-15	3.14e-11	-0.48	-0.4	Aortic root size;	chr7:66169334	chr7:66395191~66395286:+
STAD	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-8.1	9.71e-15	3.18e-11	-0.39	-0.4	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
STAD	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-8.1	9.76e-15	3.2e-11	-0.5	-0.4	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-8.1	9.79e-15	3.21e-11	-0.5	-0.4	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
STAD	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-8.1	9.85e-15	3.23e-11	-0.4	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
STAD	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-8.09	9.9e-15	3.25e-11	-0.4	-0.4	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
STAD	cis	rs9457247	0.555	rs2247325	ENSG00000265828.1	MIR3939	8.09	9.91e-15	3.25e-11	0.48	0.4	Crohn's disease;	chr6:166956504	chr6:166997807~166997912:-
STAD	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	8.09	9.92e-15	3.25e-11	0.56	0.4	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
STAD	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-8.09	9.98e-15	3.27e-11	-0.49	-0.4	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
STAD	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-8.09	1.01e-14	3.31e-11	-0.39	-0.4	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-8.09	1.01e-14	3.31e-11	-0.39	-0.4	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
STAD	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	8.09	1.02e-14	3.33e-11	0.54	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	8.09	1.02e-14	3.33e-11	0.5	0.4	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
STAD	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-8.09	1.03e-14	3.38e-11	-0.47	-0.4	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
STAD	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-8.09	1.04e-14	3.4e-11	-0.4	-0.4	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
STAD	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	8.09	1.04e-14	3.41e-11	0.5	0.4	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
STAD	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-8.09	1.05e-14	3.42e-11	-0.49	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
STAD	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-8.09	1.05e-14	3.43e-11	-0.49	-0.4	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
STAD	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	8.09	1.05e-14	3.43e-11	0.67	0.4	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
STAD	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	8.08	1.07e-14	3.49e-11	0.5	0.4	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	8.08	1.07e-14	3.49e-11	0.5	0.4	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
STAD	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-8.08	1.07e-14	3.49e-11	-0.44	-0.4	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
STAD	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-8.08	1.1e-14	3.59e-11	-0.45	-0.4	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
STAD	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	8.08	1.11e-14	3.61e-11	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
STAD	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-8.08	1.11e-14	3.63e-11	-0.47	-0.4	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-8.08	1.11e-14	3.63e-11	-0.47	-0.4	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-8.08	1.11e-14	3.63e-11	-0.47	-0.4	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-8.08	1.11e-14	3.63e-11	-0.47	-0.4	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-8.08	1.11e-14	3.63e-11	-0.47	-0.4	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-8.08	1.11e-14	3.63e-11	-0.47	-0.4	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
STAD	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	8.08	1.12e-14	3.63e-11	0.5	0.4	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
STAD	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	8.08	1.12e-14	3.66e-11	0.57	0.4	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
STAD	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-8.07	1.14e-14	3.71e-11	-0.44	-0.4	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
STAD	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-8.07	1.14e-14	3.72e-11	-0.45	-0.4	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
STAD	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	8.07	1.18e-14	3.82e-11	0.42	0.4	Height;	chr11:118749988	chr11:118688039~118690600:-
STAD	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	8.07	1.18e-14	3.84e-11	0.49	0.4	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	8.07	1.18e-14	3.84e-11	0.49	0.4	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	8.07	1.18e-14	3.85e-11	0.49	0.4	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
STAD	cis	rs875971	0.571	rs78668714	ENSG00000222364.1	RNU6-96P	-8.07	1.2e-14	3.91e-11	-0.49	-0.4	Aortic root size;	chr7:66474464	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs73150604	ENSG00000222364.1	RNU6-96P	-8.07	1.2e-14	3.91e-11	-0.49	-0.4	Aortic root size;	chr7:66480545	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs7810213	ENSG00000222364.1	RNU6-96P	-8.07	1.2e-14	3.91e-11	-0.49	-0.4	Aortic root size;	chr7:66481592	chr7:66395191~66395286:+
STAD	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	8.07	1.21e-14	3.92e-11	0.75	0.4	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
STAD	cis	rs875971	0.545	rs73376394	ENSG00000222364.1	RNU6-96P	-8.06	1.22e-14	3.96e-11	-0.48	-0.4	Aortic root size;	chr7:66172694	chr7:66395191~66395286:+
STAD	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-8.06	1.23e-14	3.99e-11	-0.46	-0.4	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
STAD	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-8.06	1.24e-14	4.02e-11	-0.41	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
STAD	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-8.06	1.26e-14	4.07e-11	-0.52	-0.4	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
STAD	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-8.06	1.28e-14	4.14e-11	-0.46	-0.4	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
STAD	cis	rs6456156	0.586	rs9459862	ENSG00000265828.1	MIR3939	8.06	1.29e-14	4.16e-11	0.44	0.4	Primary biliary cholangitis;	chr6:167073523	chr6:166997807~166997912:-
STAD	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	8.06	1.29e-14	4.18e-11	0.49	0.4	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
STAD	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	8.06	1.29e-14	4.18e-11	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	8.06	1.29e-14	4.18e-11	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	8.06	1.29e-14	4.18e-11	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	8.06	1.29e-14	4.18e-11	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
STAD	cis	rs875971	0.545	rs6970498	ENSG00000222364.1	RNU6-96P	-8.05	1.32e-14	4.26e-11	-0.5	-0.4	Aortic root size;	chr7:66275908	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-8.05	1.33e-14	4.28e-11	-0.5	-0.4	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
STAD	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-8.05	1.33e-14	4.3e-11	-0.46	-0.4	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-8.05	1.33e-14	4.3e-11	-0.46	-0.4	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-8.05	1.33e-14	4.3e-11	-0.46	-0.4	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-8.05	1.33e-14	4.3e-11	-0.46	-0.4	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-8.05	1.33e-14	4.3e-11	-0.46	-0.4	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
STAD	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-8.05	1.34e-14	4.32e-11	-0.48	-0.4	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
STAD	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-8.05	1.35e-14	4.34e-11	-0.38	-0.4	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
STAD	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	8.05	1.35e-14	4.34e-11	0.38	0.4	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
STAD	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	8.05	1.35e-14	4.37e-11	0.49	0.4	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
STAD	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-8.05	1.37e-14	4.41e-11	-0.43	-0.4	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
STAD	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-8.05	1.37e-14	4.42e-11	-0.46	-0.4	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
STAD	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	8.04	1.4e-14	4.52e-11	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	8.04	1.4e-14	4.52e-11	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	8.04	1.4e-14	4.52e-11	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
STAD	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-8.04	1.42e-14	4.58e-11	-0.49	-0.4	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
STAD	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-8.04	1.44e-14	4.63e-11	-0.45	-0.4	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
STAD	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	8.04	1.44e-14	4.64e-11	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
STAD	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-8.04	1.45e-14	4.68e-11	-0.34	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
STAD	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-8.04	1.46e-14	4.69e-11	-0.43	-0.4	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
STAD	cis	rs9506514	0.712	rs11838795	ENSG00000222726.1	RNU2-7P	8.04	1.47e-14	4.72e-11	0.47	0.4	Coronary artery calcification;	chr13:20684189	chr13:20612161~20612338:+
STAD	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	8.04	1.47e-14	4.74e-11	0.48	0.4	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
STAD	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	8.04	1.48e-14	4.75e-11	0.49	0.4	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	8.03	1.51e-14	4.85e-11	0.49	0.4	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
STAD	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	8.03	1.51e-14	4.86e-11	0.42	0.4	Height;	chr11:118746590	chr11:118688039~118690600:-
STAD	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	8.03	1.53e-14	4.91e-11	0.7	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
STAD	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	8.03	1.53e-14	4.91e-11	0.7	0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
STAD	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-8.03	1.54e-14	4.93e-11	-0.46	-0.4	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
STAD	cis	rs9506514	0.722	rs10400670	ENSG00000222726.1	RNU2-7P	8.03	1.56e-14	4.99e-11	0.46	0.4	Coronary artery calcification;	chr13:20679350	chr13:20612161~20612338:+
STAD	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	8.03	1.58e-14	5.07e-11	0.42	0.4	Height;	chr11:118747911	chr11:118688039~118690600:-
STAD	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-8.02	1.6e-14	5.12e-11	-0.46	-0.4	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
STAD	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	8.02	1.61e-14	5.15e-11	0.57	0.4	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	8.02	1.61e-14	5.15e-11	0.57	0.4	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
STAD	cis	rs944002	1	rs72706640	ENSG00000259444.1	RP11-736N17.8	8.02	1.62e-14	5.2e-11	0.54	0.4	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103103411	chr14:103094723~103098885:+
STAD	cis	rs944002	0.857	rs77071436	ENSG00000259444.1	RP11-736N17.8	8.02	1.63e-14	5.2e-11	0.53	0.4	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103102644	chr14:103094723~103098885:+
STAD	cis	rs10129255	0.843	rs7142649	ENSG00000211970.3	IGHV4-61	-8.02	1.63e-14	5.21e-11	-0.34	-0.4	Kawasaki disease;	chr14:106708870	chr14:106639119~106639657:-
STAD	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	8.02	1.64e-14	5.23e-11	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	8.02	1.64e-14	5.23e-11	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
STAD	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-8.02	1.67e-14	5.33e-11	-0.34	-0.4	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
STAD	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	8.02	1.68e-14	5.36e-11	0.48	0.4	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	8.01	1.72e-14	5.48e-11	0.49	0.4	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	8.01	1.72e-14	5.48e-11	0.49	0.4	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	8.01	1.72e-14	5.48e-11	0.49	0.4	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	8.01	1.72e-14	5.48e-11	0.49	0.4	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
STAD	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	8.01	1.75e-14	5.58e-11	0.5	0.4	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
STAD	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	8.01	1.76e-14	5.59e-11	0.42	0.4	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
STAD	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	8.01	1.76e-14	5.59e-11	0.55	0.4	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	8.01	1.76e-14	5.59e-11	0.55	0.4	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	8.01	1.76e-14	5.59e-11	0.55	0.4	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	8.01	1.76e-14	5.59e-11	0.55	0.4	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
STAD	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-8.01	1.79e-14	5.68e-11	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-8.01	1.79e-14	5.68e-11	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-8.01	1.79e-14	5.68e-11	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-8.01	1.79e-14	5.68e-11	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-8.01	1.79e-14	5.68e-11	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-8.01	1.79e-14	5.68e-11	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
STAD	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	8.01	1.8e-14	5.72e-11	0.56	0.4	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
STAD	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	8.01	1.8e-14	5.73e-11	0.54	0.4	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
STAD	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-8.01	1.81e-14	5.74e-11	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
STAD	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-8.01	1.81e-14	5.75e-11	-0.46	-0.4	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
STAD	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	8.01	1.82e-14	5.77e-11	0.75	0.4	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	8.01	1.82e-14	5.77e-11	0.75	0.4	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
STAD	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-8.01	1.82e-14	5.79e-11	-0.66	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
STAD	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	8.01	1.83e-14	5.8e-11	0.4	0.4	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
STAD	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-8	1.87e-14	5.94e-11	-0.4	-0.4	Height;	chr3:53084188	chr3:53064283~53065091:-
STAD	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-8	1.91e-14	6.05e-11	-0.4	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-8	1.91e-14	6.05e-11	-0.4	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
STAD	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-8	1.91e-14	6.05e-11	-0.39	-0.4	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
STAD	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-8	1.91e-14	6.05e-11	-0.39	-0.4	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
STAD	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	8	1.92e-14	6.09e-11	0.7	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
STAD	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	8	1.94e-14	6.15e-11	0.7	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
STAD	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-8	1.95e-14	6.15e-11	-0.69	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
STAD	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-8	1.95e-14	6.16e-11	-0.48	-0.39	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
STAD	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	7.99	1.97e-14	6.23e-11	0.41	0.39	Height;	chr11:118764443	chr11:118688039~118690600:-
STAD	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-7.99	1.98e-14	6.27e-11	-0.46	-0.39	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-7.99	1.98e-14	6.27e-11	-0.46	-0.39	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-7.99	1.98e-14	6.27e-11	-0.46	-0.39	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-7.99	1.98e-14	6.27e-11	-0.46	-0.39	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-7.99	1.98e-14	6.27e-11	-0.46	-0.39	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
STAD	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-7.99	1.98e-14	6.27e-11	-0.34	-0.39	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
STAD	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	7.99	1.99e-14	6.29e-11	0.56	0.39	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
STAD	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	7.99	2e-14	6.32e-11	0.41	0.39	Height;	chr11:118773873	chr11:118688039~118690600:-
STAD	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	7.99	2.01e-14	6.33e-11	0.55	0.39	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
STAD	cis	rs875971	0.571	rs160641	ENSG00000222364.1	RNU6-96P	7.99	2.02e-14	6.37e-11	0.5	0.39	Aortic root size;	chr7:66112359	chr7:66395191~66395286:+
STAD	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-7.99	2.02e-14	6.38e-11	-0.53	-0.39	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
STAD	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	7.99	2.03e-14	6.39e-11	0.41	0.39	Height;	chr11:118760944	chr11:118688039~118690600:-
STAD	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	7.99	2.06e-14	6.48e-11	0.49	0.39	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
STAD	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	7.99	2.06e-14	6.49e-11	0.52	0.39	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
STAD	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	7.99	2.09e-14	6.59e-11	0.42	0.39	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
STAD	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-7.98	2.14e-14	6.73e-11	-0.4	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
STAD	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	7.98	2.14e-14	6.73e-11	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
STAD	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	7.98	2.15e-14	6.75e-11	0.55	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
STAD	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	7.98	2.16e-14	6.78e-11	0.44	0.39	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
STAD	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	7.98	2.16e-14	6.78e-11	0.44	0.39	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
STAD	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	7.98	2.17e-14	6.81e-11	0.56	0.39	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	7.98	2.17e-14	6.81e-11	0.56	0.39	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	7.98	2.17e-14	6.81e-11	0.56	0.39	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	7.98	2.17e-14	6.81e-11	0.56	0.39	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
STAD	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	7.98	2.24e-14	7.03e-11	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
STAD	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-7.97	2.26e-14	7.08e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
STAD	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-7.97	2.26e-14	7.1e-11	-0.49	-0.39	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
STAD	cis	rs944002	1	rs2297067	ENSG00000259444.1	RP11-736N17.8	-7.97	2.28e-14	7.14e-11	-0.52	-0.39	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100448	chr14:103094723~103098885:+
STAD	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	7.97	2.31e-14	7.25e-11	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
STAD	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	7.97	2.35e-14	7.36e-11	0.54	0.39	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
STAD	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-7.97	2.35e-14	7.37e-11	-0.43	-0.39	Temperament;	chr17:14003617	chr17:14024514~14025488:+
STAD	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	7.97	2.36e-14	7.39e-11	0.53	0.39	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
STAD	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-7.97	2.37e-14	7.42e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-7.97	2.4e-14	7.51e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
STAD	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	7.97	2.4e-14	7.52e-11	0.41	0.39	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	7.97	2.4e-14	7.52e-11	0.41	0.39	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
STAD	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	7.96	2.42e-14	7.57e-11	0.55	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
STAD	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-7.96	2.43e-14	7.59e-11	-0.49	-0.39	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
STAD	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-7.96	2.46e-14	7.68e-11	-0.52	-0.39	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
STAD	cis	rs2439831	0.867	rs2260160	ENSG00000205771.5	CATSPER2P1	-7.96	2.46e-14	7.68e-11	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43603445	chr15:43726918~43747094:-
STAD	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-7.96	2.48e-14	7.74e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
STAD	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	7.96	2.52e-14	7.87e-11	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
STAD	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-7.96	2.53e-14	7.89e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-7.96	2.53e-14	7.89e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-7.96	2.53e-14	7.89e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-7.96	2.53e-14	7.89e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-7.96	2.53e-14	7.89e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
STAD	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-7.96	2.54e-14	7.91e-11	-0.46	-0.39	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
STAD	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	7.96	2.54e-14	7.91e-11	0.54	0.39	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
STAD	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	7.96	2.54e-14	7.93e-11	0.45	0.39	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-7.96	2.54e-14	7.93e-11	-0.45	-0.39	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
STAD	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-7.96	2.54e-14	7.93e-11	-0.45	-0.39	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
STAD	cis	rs875971	0.545	rs1796219	ENSG00000222364.1	RNU6-96P	7.96	2.57e-14	8.01e-11	0.49	0.39	Aortic root size;	chr7:66645977	chr7:66395191~66395286:+
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-7.96	2.58e-14	8.02e-11	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
STAD	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-7.95	2.58e-14	8.04e-11	-0.49	-0.39	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-7.95	2.59e-14	8.07e-11	-0.48	-0.39	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
STAD	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-7.95	2.64e-14	8.22e-11	-0.52	-0.39	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
STAD	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-7.95	2.65e-14	8.22e-11	-0.45	-0.39	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
STAD	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	7.95	2.65e-14	8.24e-11	0.49	0.39	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	7.95	2.65e-14	8.24e-11	0.49	0.39	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
STAD	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	7.95	2.65e-14	8.24e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
STAD	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	7.95	2.67e-14	8.29e-11	0.42	0.39	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs6979636	ENSG00000222364.1	RNU6-96P	-7.95	2.71e-14	8.43e-11	-0.48	-0.39	Aortic root size;	chr7:66276638	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs17138149	ENSG00000222364.1	RNU6-96P	-7.95	2.72e-14	8.44e-11	-0.48	-0.39	Aortic root size;	chr7:66228193	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	7.95	2.72e-14	8.45e-11	0.49	0.39	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
STAD	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-7.95	2.74e-14	8.5e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
STAD	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-7.94	2.76e-14	8.57e-11	-0.45	-0.39	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
STAD	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	7.94	2.76e-14	8.57e-11	0.42	0.39	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
STAD	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	7.94	2.77e-14	8.6e-11	0.49	0.39	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
STAD	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-7.94	2.79e-14	8.63e-11	-0.41	-0.39	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-7.94	2.81e-14	8.7e-11	-0.46	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
STAD	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	7.94	2.81e-14	8.71e-11	0.46	0.39	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
STAD	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-7.94	2.81e-14	8.72e-11	-0.42	-0.39	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
STAD	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-7.94	2.83e-14	8.76e-11	-0.46	-0.39	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-7.94	2.83e-14	8.76e-11	-0.46	-0.39	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-7.94	2.83e-14	8.76e-11	-0.46	-0.39	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-7.94	2.83e-14	8.76e-11	-0.46	-0.39	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-7.94	2.83e-14	8.76e-11	-0.46	-0.39	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-7.94	2.83e-14	8.76e-11	-0.46	-0.39	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
STAD	cis	rs4927850	1	rs6799572	ENSG00000231464.1	AC024937.4	7.94	2.89e-14	8.93e-11	0.43	0.39	Pancreatic cancer;	chr3:196013537	chr3:195996738~195998233:+
STAD	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-7.94	2.93e-14	9.07e-11	-0.52	-0.39	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
STAD	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	7.94	2.95e-14	9.11e-11	0.54	0.39	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
STAD	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	7.93	2.97e-14	9.18e-11	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	7.93	2.97e-14	9.18e-11	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	7.93	2.97e-14	9.18e-11	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	7.93	3e-14	9.27e-11	0.49	0.39	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
STAD	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	7.93	3.01e-14	9.29e-11	0.41	0.39	Height;	chr11:118742526	chr11:118688039~118690600:-
STAD	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-7.93	3.01e-14	9.31e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-7.93	3.01e-14	9.31e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-7.93	3.02e-14	9.31e-11	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
STAD	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	7.93	3.03e-14	9.36e-11	0.54	0.39	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	7.93	3.03e-14	9.36e-11	0.54	0.39	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
STAD	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-7.93	3.03e-14	9.36e-11	-0.52	-0.39	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
STAD	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-7.93	3.03e-14	9.36e-11	-0.46	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
STAD	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	7.93	3.04e-14	9.38e-11	0.45	0.39	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
STAD	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-7.93	3.07e-14	9.46e-11	-0.48	-0.39	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
STAD	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	7.93	3.09e-14	9.52e-11	0.57	0.39	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
STAD	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	7.93	3.09e-14	9.52e-11	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
STAD	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-7.92	3.17e-14	9.73e-11	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-7.92	3.17e-14	9.73e-11	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
STAD	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	7.92	3.24e-14	9.95e-11	0.55	0.39	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
STAD	cis	rs2108622	0.545	rs59140933	ENSG00000267453.5	AC004791.2	-7.92	3.28e-14	1.01e-10	-0.44	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15851993~15864904:-
STAD	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-7.92	3.32e-14	1.02e-10	-0.43	-0.39	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
STAD	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	7.92	3.32e-14	1.02e-10	0.41	0.39	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
STAD	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	7.92	3.32e-14	1.02e-10	0.55	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	7.92	3.32e-14	1.02e-10	0.55	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
STAD	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	7.92	3.34e-14	1.02e-10	0.53	0.39	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
STAD	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-7.92	3.35e-14	1.02e-10	-0.46	-0.39	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
STAD	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-7.92	3.35e-14	1.02e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	7.92	3.35e-14	1.02e-10	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	7.92	3.35e-14	1.02e-10	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	7.92	3.35e-14	1.02e-10	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	7.92	3.35e-14	1.02e-10	0.37	0.39	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-7.92	3.37e-14	1.03e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
STAD	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	7.92	3.38e-14	1.03e-10	0.41	0.39	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	7.92	3.38e-14	1.03e-10	0.41	0.39	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
STAD	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-7.91	3.4e-14	1.04e-10	-0.5	-0.39	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
STAD	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-7.91	3.4e-14	1.04e-10	-0.5	-0.39	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
STAD	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	7.91	3.41e-14	1.04e-10	0.45	0.39	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
STAD	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	7.91	3.41e-14	1.04e-10	0.69	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
STAD	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-7.91	3.44e-14	1.05e-10	-0.47	-0.39	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
STAD	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	7.91	3.45e-14	1.05e-10	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
STAD	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-7.91	3.46e-14	1.06e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-7.91	3.48e-14	1.06e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-7.91	3.51e-14	1.07e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-7.91	3.51e-14	1.07e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
STAD	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-7.91	3.51e-14	1.07e-10	-0.37	-0.39	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
STAD	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-7.91	3.54e-14	1.08e-10	-0.45	-0.39	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
STAD	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	7.91	3.56e-14	1.09e-10	0.49	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
STAD	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-7.91	3.6e-14	1.1e-10	-0.41	-0.39	Height;	chr3:53069965	chr3:53064283~53065091:-
STAD	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-7.9	3.73e-14	1.14e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
STAD	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	7.9	3.74e-14	1.14e-10	0.5	0.39	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
STAD	cis	rs9368481	0.546	rs12664610	ENSG00000243307.2	POM121L6P	7.9	3.75e-14	1.14e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26896952~26898777:+
STAD	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-7.9	3.77e-14	1.15e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-7.9	3.77e-14	1.15e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-7.9	3.77e-14	1.15e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-7.9	3.77e-14	1.15e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
STAD	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	7.9	3.82e-14	1.16e-10	0.53	0.39	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
STAD	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	7.9	3.85e-14	1.17e-10	0.49	0.39	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
STAD	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-7.89	3.89e-14	1.18e-10	-0.45	-0.39	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
STAD	cis	rs944002	1	rs10131298	ENSG00000259444.1	RP11-736N17.8	7.89	3.9e-14	1.18e-10	0.52	0.39	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103102277	chr14:103094723~103098885:+
STAD	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-7.89	3.9e-14	1.19e-10	-0.39	-0.39	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
STAD	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	7.89	3.96e-14	1.2e-10	0.75	0.39	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
STAD	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-7.89	3.99e-14	1.21e-10	-0.49	-0.39	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	7.89	3.99e-14	1.21e-10	0.49	0.39	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
STAD	cis	rs9506514	0.722	rs4769124	ENSG00000222726.1	RNU2-7P	7.89	4e-14	1.21e-10	0.46	0.39	Coronary artery calcification;	chr13:20652706	chr13:20612161~20612338:+
STAD	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	7.89	4.02e-14	1.22e-10	0.54	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
STAD	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	7.89	4.03e-14	1.22e-10	0.59	0.39	Migraine;	chr16:75350086	chr16:75379818~75381260:-
STAD	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	7.89	4.03e-14	1.22e-10	0.5	0.39	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
STAD	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	7.89	4.05e-14	1.23e-10	0.75	0.39	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
STAD	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	7.89	4.06e-14	1.23e-10	0.54	0.39	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
STAD	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-7.89	4.09e-14	1.24e-10	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-7.89	4.09e-14	1.24e-10	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-7.89	4.09e-14	1.24e-10	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
STAD	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-7.89	4.12e-14	1.25e-10	-0.42	-0.39	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
STAD	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	7.88	4.18e-14	1.26e-10	0.41	0.39	Height;	chr3:53085313	chr3:53064283~53065091:-
STAD	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	7.88	4.2e-14	1.27e-10	0.6	0.39	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
STAD	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-7.88	4.21e-14	1.27e-10	-0.46	-0.39	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
STAD	cis	rs944002	1	rs62006947	ENSG00000259444.1	RP11-736N17.8	7.88	4.24e-14	1.28e-10	0.52	0.39	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103099033	chr14:103094723~103098885:+
STAD	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	7.88	4.27e-14	1.29e-10	0.47	0.39	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
STAD	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-7.88	4.32e-14	1.3e-10	-0.47	-0.39	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
STAD	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-7.88	4.38e-14	1.32e-10	-0.46	-0.39	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
STAD	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-7.88	4.39e-14	1.33e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-7.88	4.39e-14	1.33e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
STAD	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-7.88	4.42e-14	1.33e-10	-0.46	-0.39	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
STAD	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	7.88	4.42e-14	1.33e-10	0.41	0.39	Height;	chr11:118781100	chr11:118688039~118690600:-
STAD	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-7.87	4.52e-14	1.36e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
STAD	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-7.87	4.53e-14	1.36e-10	-0.52	-0.39	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-7.87	4.53e-14	1.36e-10	-0.52	-0.39	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
STAD	cis	rs6456156	0.716	rs6905911	ENSG00000265828.1	MIR3939	-7.87	4.6e-14	1.38e-10	-0.43	-0.39	Primary biliary cholangitis;	chr6:167108136	chr6:166997807~166997912:-
STAD	cis	rs9368481	0.524	rs9393768	ENSG00000243307.2	POM121L6P	7.87	4.66e-14	1.4e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26896952~26898777:+
STAD	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	7.87	4.67e-14	1.4e-10	0.51	0.39	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	7.87	4.69e-14	1.41e-10	0.45	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
STAD	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-7.86	4.85e-14	1.46e-10	-0.42	-0.39	Temperament;	chr17:14007232	chr17:14024514~14025488:+
STAD	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-7.86	4.85e-14	1.46e-10	-0.68	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
STAD	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-7.86	4.87e-14	1.46e-10	-0.48	-0.39	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
STAD	cis	rs9368481	0.569	rs10946868	ENSG00000243307.2	POM121L6P	7.86	4.88e-14	1.46e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26896952~26898777:+
STAD	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	7.86	4.9e-14	1.47e-10	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
STAD	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	7.86	4.91e-14	1.47e-10	0.44	0.39	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
STAD	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-7.86	4.95e-14	1.48e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
STAD	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	7.86	5.03e-14	1.51e-10	0.55	0.39	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	7.86	5.03e-14	1.51e-10	0.55	0.39	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	7.86	5.03e-14	1.51e-10	0.55	0.39	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
STAD	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	7.85	5.1e-14	1.53e-10	0.69	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
STAD	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	7.85	5.14e-14	1.54e-10	0.54	0.39	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	7.85	5.14e-14	1.54e-10	0.54	0.39	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	7.85	5.14e-14	1.54e-10	0.54	0.39	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
STAD	cis	rs9368481	0.569	rs6907403	ENSG00000243307.2	POM121L6P	7.85	5.15e-14	1.54e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26896952~26898777:+
STAD	cis	rs9368481	0.502	rs3933232	ENSG00000243307.2	POM121L6P	7.85	5.15e-14	1.54e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26896952~26898777:+
STAD	cis	rs9368481	0.524	rs12530345	ENSG00000243307.2	POM121L6P	7.85	5.15e-14	1.54e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26896952~26898777:+
STAD	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-7.85	5.2e-14	1.55e-10	-0.39	-0.39	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
STAD	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	7.85	5.22e-14	1.56e-10	0.49	0.39	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
STAD	cis	rs9368481	0.594	rs7768643	ENSG00000243307.2	POM121L6P	7.85	5.28e-14	1.57e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26896952~26898777:+
STAD	cis	rs9368481	0.594	rs7768814	ENSG00000243307.2	POM121L6P	7.85	5.28e-14	1.57e-10	0.41	0.39	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26896952~26898777:+
STAD	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	7.85	5.28e-14	1.57e-10	0.47	0.39	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
STAD	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.29e-14	1.58e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
STAD	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-7.85	5.32e-14	1.58e-10	-0.45	-0.39	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
STAD	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-7.85	5.34e-14	1.59e-10	-0.68	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
STAD	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-7.85	5.34e-14	1.59e-10	-0.68	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
STAD	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-7.85	5.34e-14	1.59e-10	-0.68	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
STAD	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-7.85	5.34e-14	1.59e-10	-0.68	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
STAD	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-7.85	5.34e-14	1.59e-10	-0.68	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
STAD	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-7.85	5.34e-14	1.59e-10	-0.65	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
STAD	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	7.85	5.35e-14	1.59e-10	0.62	0.39	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
STAD	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	7.84	5.45e-14	1.62e-10	0.41	0.39	Height;	chr11:118761813	chr11:118688039~118690600:-
STAD	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	7.84	5.48e-14	1.63e-10	0.42	0.39	Height;	chr3:53072864	chr3:53064283~53065091:-
STAD	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-7.84	5.48e-14	1.63e-10	-0.4	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
STAD	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	7.84	5.5e-14	1.64e-10	0.51	0.39	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
STAD	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	7.84	5.5e-14	1.64e-10	0.41	0.39	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
STAD	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	7.84	5.51e-14	1.64e-10	0.75	0.39	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	7.84	5.51e-14	1.64e-10	0.75	0.39	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
STAD	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	7.84	5.53e-14	1.64e-10	0.56	0.39	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
STAD	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	7.84	5.53e-14	1.64e-10	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
STAD	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	7.84	5.82e-14	1.73e-10	0.43	0.39	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
STAD	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	7.84	5.82e-14	1.73e-10	0.43	0.39	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
STAD	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	7.84	5.82e-14	1.73e-10	0.43	0.39	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
STAD	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-7.83	5.89e-14	1.75e-10	-0.46	-0.39	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
STAD	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-7.83	5.9e-14	1.75e-10	-0.4	-0.39	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
STAD	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	7.83	5.94e-14	1.76e-10	0.33	0.39	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
STAD	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	7.83	6.01e-14	1.78e-10	0.54	0.39	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
STAD	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	7.83	6.03e-14	1.79e-10	0.73	0.39	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
STAD	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	7.83	6.05e-14	1.79e-10	0.46	0.39	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
STAD	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	7.83	6.1e-14	1.81e-10	0.38	0.39	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
STAD	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-7.83	6.23e-14	1.84e-10	-0.51	-0.39	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
STAD	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	7.82	6.24e-14	1.85e-10	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
STAD	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-7.82	6.27e-14	1.85e-10	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
STAD	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	7.82	6.28e-14	1.86e-10	0.39	0.39	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
STAD	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	7.82	6.29e-14	1.86e-10	0.56	0.39	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
STAD	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-7.82	6.33e-14	1.87e-10	-0.45	-0.39	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
STAD	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	7.82	6.43e-14	1.9e-10	0.54	0.39	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
STAD	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-7.82	6.45e-14	1.9e-10	-0.51	-0.39	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
STAD	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-7.82	6.49e-14	1.91e-10	-0.39	-0.39	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
STAD	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-7.82	6.52e-14	1.92e-10	-0.5	-0.39	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
STAD	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-7.82	6.52e-14	1.92e-10	-0.5	-0.39	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
STAD	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-7.82	6.52e-14	1.92e-10	-0.5	-0.39	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
STAD	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-7.82	6.55e-14	1.93e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
STAD	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-7.82	6.59e-14	1.94e-10	-0.45	-0.39	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
STAD	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	7.82	6.59e-14	1.94e-10	0.51	0.39	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
STAD	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	7.82	6.61e-14	1.95e-10	0.39	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
STAD	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	7.82	6.61e-14	1.95e-10	0.41	0.39	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	7.82	6.61e-14	1.95e-10	0.41	0.39	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
STAD	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-7.82	6.63e-14	1.95e-10	-0.44	-0.39	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
STAD	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-7.81	6.79e-14	2e-10	-0.5	-0.39	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-7.81	6.79e-14	2e-10	-0.5	-0.39	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-7.81	6.79e-14	2e-10	-0.5	-0.39	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-7.81	6.79e-14	2e-10	-0.5	-0.39	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-7.81	6.79e-14	2e-10	-0.5	-0.39	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-7.81	6.79e-14	2e-10	-0.5	-0.39	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-7.81	6.79e-14	2e-10	-0.5	-0.39	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
STAD	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-7.81	6.82e-14	2.01e-10	-0.36	-0.39	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
STAD	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-7.81	6.9e-14	2.03e-10	-0.67	-0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
STAD	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-7.81	6.92e-14	2.04e-10	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
STAD	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	7.81	6.98e-14	2.05e-10	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
STAD	cis	rs4927850	1	rs4927704	ENSG00000231464.1	AC024937.4	7.81	7.02e-14	2.06e-10	0.43	0.39	Pancreatic cancer;	chr3:196011357	chr3:195996738~195998233:+
STAD	cis	rs4927850	1	rs4927848	ENSG00000231464.1	AC024937.4	7.81	7.02e-14	2.06e-10	0.43	0.39	Pancreatic cancer;	chr3:196011535	chr3:195996738~195998233:+
STAD	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	7.81	7.04e-14	2.07e-10	0.47	0.39	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
STAD	cis	rs11903757	1	rs6731095	ENSG00000281467.1	Clostridiales-1	7.8	7.13e-14	2.1e-10	0.62	0.39	Colorectal cancer;	chr2:191724716	chr2:191699476~191699631:-
STAD	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	7.8	7.32e-14	2.15e-10	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	7.8	7.32e-14	2.15e-10	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	7.8	7.32e-14	2.15e-10	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
STAD	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	7.8	7.34e-14	2.16e-10	0.4	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
STAD	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-7.8	7.35e-14	2.16e-10	-0.45	-0.39	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
STAD	cis	rs12922317	0.681	rs2869492	ENSG00000260224.1	UBL5P4	7.8	7.36e-14	2.16e-10	0.41	0.39	Schizophrenia;	chr16:11977484	chr16:11968508~11968743:-
STAD	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	7.8	7.47e-14	2.19e-10	0.36	0.39	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
STAD	cis	rs944002	1	rs2297066	ENSG00000259444.1	RP11-736N17.8	7.8	7.57e-14	2.22e-10	0.52	0.39	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100498	chr14:103094723~103098885:+
STAD	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-7.79	7.76e-14	2.27e-10	-0.45	-0.39	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
STAD	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	7.79	7.79e-14	2.28e-10	0.48	0.39	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	7.79	7.81e-14	2.29e-10	0.43	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
STAD	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-7.79	7.83e-14	2.29e-10	-0.44	-0.39	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
STAD	cis	rs944002	1	rs56956502	ENSG00000259444.1	RP11-736N17.8	7.79	7.88e-14	2.31e-10	0.51	0.39	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098707	chr14:103094723~103098885:+
STAD	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-7.79	7.92e-14	2.32e-10	-0.42	-0.39	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	7.79	7.92e-14	2.32e-10	0.55	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
STAD	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-7.79	8.02e-14	2.35e-10	-0.48	-0.39	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
STAD	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	7.79	8.06e-14	2.36e-10	0.46	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
STAD	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	7.79	8.07e-14	2.36e-10	0.55	0.39	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	7.79	8.07e-14	2.36e-10	0.55	0.39	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
STAD	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-7.79	8.1e-14	2.37e-10	-0.44	-0.39	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
STAD	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-7.79	8.15e-14	2.38e-10	-0.48	-0.39	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-7.79	8.15e-14	2.38e-10	-0.48	-0.39	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
STAD	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-7.78	8.16e-14	2.38e-10	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
STAD	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	7.78	8.19e-14	2.39e-10	0.43	0.39	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
STAD	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	7.78	8.31e-14	2.42e-10	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
STAD	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-7.78	8.33e-14	2.43e-10	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
STAD	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-7.78	8.45e-14	2.46e-10	-0.37	-0.39	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
STAD	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	7.78	8.49e-14	2.47e-10	0.49	0.39	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
STAD	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-7.78	8.52e-14	2.48e-10	-0.42	-0.39	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
STAD	cis	rs4927850	0.958	rs2044599	ENSG00000231464.1	AC024937.4	7.78	8.58e-14	2.5e-10	0.43	0.39	Pancreatic cancer;	chr3:196009869	chr3:195996738~195998233:+
STAD	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-7.78	8.62e-14	2.51e-10	-0.42	-0.39	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
STAD	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	7.78	8.63e-14	2.51e-10	0.47	0.39	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
STAD	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	7.78	8.65e-14	2.52e-10	0.44	0.39	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
STAD	cis	rs11903757	1	rs4425034	ENSG00000281467.1	Clostridiales-1	-7.77	8.75e-14	2.55e-10	-0.61	-0.39	Colorectal cancer;	chr2:191715885	chr2:191699476~191699631:-
STAD	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-7.77	8.85e-14	2.57e-10	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
STAD	cis	rs944002	1	rs36027406	ENSG00000259444.1	RP11-736N17.8	7.77	8.91e-14	2.59e-10	0.51	0.39	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098743	chr14:103094723~103098885:+
STAD	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	7.77	8.96e-14	2.6e-10	0.45	0.39	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
STAD	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-7.77	8.98e-14	2.61e-10	-0.51	-0.39	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
STAD	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	7.77	9.02e-14	2.62e-10	0.38	0.39	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
STAD	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	7.77	9.04e-14	2.63e-10	0.45	0.39	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
STAD	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-7.77	9.13e-14	2.65e-10	-0.4	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
STAD	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	7.77	9.16e-14	2.66e-10	0.54	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
STAD	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	7.77	9.22e-14	2.67e-10	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	7.77	9.22e-14	2.67e-10	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
STAD	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-7.77	9.23e-14	2.68e-10	-0.44	-0.39	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
STAD	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-7.77	9.27e-14	2.69e-10	-0.4	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
STAD	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-7.77	9.33e-14	2.71e-10	-0.42	-0.39	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
STAD	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	7.76	9.37e-14	2.72e-10	0.38	0.39	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
STAD	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-7.76	9.38e-14	2.72e-10	-0.33	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
STAD	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	7.76	9.39e-14	2.72e-10	0.4	0.39	Height;	chr11:118786602	chr11:118688039~118690600:-
STAD	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	7.76	9.41e-14	2.73e-10	0.38	0.39	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
STAD	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	7.76	9.42e-14	2.73e-10	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
STAD	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-7.76	9.43e-14	2.73e-10	-0.4	-0.39	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	7.76	9.46e-14	2.74e-10	0.41	0.39	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
STAD	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	7.76	9.49e-14	2.75e-10	0.44	0.39	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
STAD	cis	rs9368481	0.547	rs2093303	ENSG00000243307.2	POM121L6P	7.76	9.51e-14	2.76e-10	0.4	0.39	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26896952~26898777:+
STAD	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-7.76	9.52e-14	2.76e-10	-0.48	-0.39	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
STAD	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	7.76	9.52e-14	2.76e-10	0.54	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	7.76	9.52e-14	2.76e-10	0.54	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	7.76	9.52e-14	2.76e-10	0.54	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-7.76	9.58e-14	2.77e-10	-0.45	-0.39	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
STAD	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-7.76	9.59e-14	2.78e-10	-0.45	-0.39	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
STAD	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	7.76	9.64e-14	2.79e-10	0.55	0.39	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
STAD	cis	rs944002	1	rs59643720	ENSG00000259444.1	RP11-736N17.8	7.76	9.71e-14	2.81e-10	0.51	0.38	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098470	chr14:103094723~103098885:+
STAD	cis	rs944002	1	rs61462345	ENSG00000259444.1	RP11-736N17.8	7.76	9.71e-14	2.81e-10	0.51	0.38	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098598	chr14:103094723~103098885:+
STAD	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-7.76	9.72e-14	2.81e-10	-0.46	-0.38	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
STAD	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	7.76	9.74e-14	2.82e-10	0.4	0.38	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
STAD	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	7.76	9.75e-14	2.82e-10	0.38	0.38	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
STAD	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-7.76	9.81e-14	2.83e-10	-0.5	-0.38	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
STAD	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-7.76	9.94e-14	2.87e-10	-0.44	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
STAD	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	7.75	1.01e-13	2.92e-10	0.42	0.38	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
STAD	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	7.75	1.02e-13	2.95e-10	0.55	0.38	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
STAD	cis	rs875971	0.545	rs12671152	ENSG00000222364.1	RNU6-96P	-7.75	1.03e-13	2.98e-10	-0.49	-0.38	Aortic root size;	chr7:66311140	chr7:66395191~66395286:+
STAD	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	7.75	1.04e-13	2.99e-10	0.55	0.38	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	7.75	1.04e-13	2.99e-10	0.55	0.38	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
STAD	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-7.75	1.06e-13	3.06e-10	-0.4	-0.38	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
STAD	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-7.75	1.06e-13	3.06e-10	-0.4	-0.38	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
STAD	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-7.75	1.06e-13	3.06e-10	-0.4	-0.38	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
STAD	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-7.75	1.06e-13	3.06e-10	-0.4	-0.38	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-7.75	1.06e-13	3.06e-10	-0.52	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-7.75	1.06e-13	3.06e-10	-0.52	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
STAD	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-7.74	1.07e-13	3.08e-10	-0.38	-0.38	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
STAD	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-7.74	1.07e-13	3.09e-10	-0.44	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
STAD	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	7.74	1.08e-13	3.1e-10	0.38	0.38	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
STAD	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-7.74	1.08e-13	3.11e-10	-0.54	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
STAD	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	7.74	1.08e-13	3.11e-10	0.47	0.38	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
STAD	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-7.74	1.1e-13	3.16e-10	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-7.74	1.1e-13	3.16e-10	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-7.74	1.1e-13	3.16e-10	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
STAD	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	7.74	1.11e-13	3.18e-10	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	7.74	1.11e-13	3.18e-10	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	7.74	1.11e-13	3.18e-10	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
STAD	cis	rs944002	0.951	rs7151779	ENSG00000259444.1	RP11-736N17.8	7.74	1.11e-13	3.18e-10	0.52	0.38	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103099825	chr14:103094723~103098885:+
STAD	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	7.74	1.11e-13	3.19e-10	0.41	0.38	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
STAD	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	7.74	1.11e-13	3.19e-10	0.6	0.38	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
STAD	cis	rs11903757	1	rs75823023	ENSG00000281467.1	Clostridiales-1	-7.74	1.13e-13	3.25e-10	-0.61	-0.38	Colorectal cancer;	chr2:191712122	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs80201920	ENSG00000281467.1	Clostridiales-1	-7.74	1.13e-13	3.25e-10	-0.61	-0.38	Colorectal cancer;	chr2:191712510	chr2:191699476~191699631:-
STAD	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	7.73	1.15e-13	3.29e-10	0.5	0.38	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
STAD	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-7.73	1.17e-13	3.35e-10	-0.42	-0.38	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
STAD	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-7.73	1.18e-13	3.37e-10	-0.67	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
STAD	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-7.73	1.18e-13	3.37e-10	-0.67	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
STAD	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	7.73	1.19e-13	3.39e-10	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
STAD	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-7.73	1.19e-13	3.4e-10	-0.59	-0.38	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
STAD	cis	rs944002	1	rs17101241	ENSG00000259444.1	RP11-736N17.8	7.73	1.19e-13	3.41e-10	0.51	0.38	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098483	chr14:103094723~103098885:+
STAD	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-7.73	1.2e-13	3.43e-10	-0.45	-0.38	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
STAD	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	7.73	1.2e-13	3.43e-10	0.53	0.38	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
STAD	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	7.73	1.21e-13	3.47e-10	0.47	0.38	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
STAD	cis	rs11903757	1	rs78894429	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191702130	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs80113293	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191703011	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs12469001	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191703205	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs77674344	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191704157	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs75225465	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191704615	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs77866902	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191705588	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs77827994	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191707401	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs6730901	ENSG00000281467.1	Clostridiales-1	-7.73	1.22e-13	3.48e-10	-0.61	-0.38	Colorectal cancer;	chr2:191708079	chr2:191699476~191699631:-
STAD	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	7.72	1.22e-13	3.49e-10	0.41	0.38	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
STAD	cis	rs11903757	0.945	rs77282295	ENSG00000281467.1	Clostridiales-1	-7.72	1.24e-13	3.54e-10	-0.61	-0.38	Colorectal cancer;	chr2:191709580	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs74747990	ENSG00000281467.1	Clostridiales-1	-7.72	1.24e-13	3.54e-10	-0.61	-0.38	Colorectal cancer;	chr2:191709742	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs75226604	ENSG00000281467.1	Clostridiales-1	-7.72	1.24e-13	3.54e-10	-0.61	-0.38	Colorectal cancer;	chr2:191709807	chr2:191699476~191699631:-
STAD	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	7.72	1.24e-13	3.55e-10	0.68	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
STAD	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-7.72	1.25e-13	3.57e-10	-0.51	-0.38	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
STAD	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-7.72	1.25e-13	3.57e-10	-0.4	-0.38	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
STAD	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-7.72	1.27e-13	3.62e-10	-0.49	-0.38	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
STAD	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-7.72	1.28e-13	3.64e-10	-0.41	-0.38	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
STAD	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	7.72	1.28e-13	3.64e-10	0.54	0.38	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
STAD	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	7.72	1.28e-13	3.66e-10	0.38	0.38	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
STAD	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	7.72	1.29e-13	3.68e-10	0.41	0.38	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
STAD	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	7.71	1.31e-13	3.72e-10	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
STAD	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-7.71	1.32e-13	3.76e-10	-0.44	-0.38	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
STAD	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	7.71	1.35e-13	3.83e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	7.71	1.35e-13	3.83e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	7.71	1.35e-13	3.83e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	7.71	1.35e-13	3.83e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	7.71	1.35e-13	3.83e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
STAD	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-7.71	1.35e-13	3.83e-10	-0.4	-0.38	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
STAD	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	7.71	1.35e-13	3.85e-10	0.48	0.38	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
STAD	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	7.71	1.36e-13	3.87e-10	0.55	0.38	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
STAD	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-7.71	1.38e-13	3.91e-10	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-7.71	1.38e-13	3.91e-10	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-7.71	1.38e-13	3.91e-10	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
STAD	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-7.71	1.38e-13	3.92e-10	-0.41	-0.38	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
STAD	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-7.71	1.38e-13	3.92e-10	-0.41	-0.38	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
STAD	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-7.71	1.38e-13	3.92e-10	-0.41	-0.38	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
STAD	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	7.71	1.39e-13	3.95e-10	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
STAD	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	7.7	1.4e-13	3.98e-10	0.54	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
STAD	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-7.7	1.4e-13	3.98e-10	-0.48	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
STAD	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	7.7	1.4e-13	3.99e-10	0.54	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
STAD	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	7.7	1.41e-13	4e-10	0.46	0.38	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
STAD	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-7.7	1.42e-13	4.03e-10	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
STAD	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	7.7	1.43e-13	4.05e-10	0.41	0.38	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
STAD	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	7.7	1.43e-13	4.06e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	7.7	1.43e-13	4.06e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	7.7	1.43e-13	4.06e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
STAD	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-7.7	1.45e-13	4.11e-10	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
STAD	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	7.7	1.46e-13	4.12e-10	0.42	0.38	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
STAD	cis	rs11903757	1	rs11888351	ENSG00000281467.1	Clostridiales-1	-7.7	1.47e-13	4.15e-10	-0.61	-0.38	Colorectal cancer;	chr2:191704936	chr2:191699476~191699631:-
STAD	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	7.7	1.47e-13	4.16e-10	0.38	0.38	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	7.7	1.47e-13	4.16e-10	0.38	0.38	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
STAD	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-7.7	1.48e-13	4.2e-10	-0.47	-0.38	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-7.7	1.48e-13	4.2e-10	-0.47	-0.38	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-7.7	1.48e-13	4.2e-10	-0.47	-0.38	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
STAD	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	7.69	1.51e-13	4.27e-10	0.46	0.38	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	7.69	1.51e-13	4.27e-10	0.46	0.38	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
STAD	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	7.69	1.51e-13	4.27e-10	0.46	0.38	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
STAD	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	7.69	1.52e-13	4.29e-10	0.47	0.38	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
STAD	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-7.69	1.52e-13	4.29e-10	-0.41	-0.38	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
STAD	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-7.69	1.52e-13	4.29e-10	-0.41	-0.38	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	7.69	1.54e-13	4.34e-10	0.46	0.38	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	7.69	1.54e-13	4.34e-10	0.46	0.38	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
STAD	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-7.69	1.54e-13	4.36e-10	-0.48	-0.38	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
STAD	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	7.69	1.55e-13	4.37e-10	0.47	0.38	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	7.69	1.55e-13	4.37e-10	0.46	0.38	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	7.69	1.55e-13	4.37e-10	0.46	0.38	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	7.69	1.55e-13	4.37e-10	0.46	0.38	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
STAD	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-7.69	1.56e-13	4.41e-10	-0.49	-0.38	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
STAD	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	7.69	1.57e-13	4.42e-10	0.52	0.38	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
STAD	cis	rs11903757	1	rs4477849	ENSG00000281467.1	Clostridiales-1	7.69	1.57e-13	4.43e-10	0.61	0.38	Colorectal cancer;	chr2:191716203	chr2:191699476~191699631:-
STAD	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-7.69	1.57e-13	4.44e-10	-0.44	-0.38	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-7.69	1.57e-13	4.44e-10	-0.44	-0.38	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
STAD	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	7.69	1.58e-13	4.45e-10	0.41	0.38	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
STAD	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	7.69	1.58e-13	4.45e-10	0.41	0.38	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
STAD	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-7.69	1.58e-13	4.45e-10	-0.41	-0.38	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
STAD	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-7.69	1.58e-13	4.45e-10	-0.41	-0.38	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
STAD	cis	rs944002	1	rs61418148	ENSG00000259444.1	RP11-736N17.8	7.68	1.6e-13	4.5e-10	0.51	0.38	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100683	chr14:103094723~103098885:+
STAD	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	7.68	1.62e-13	4.56e-10	0.49	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
STAD	cis	rs875971	0.545	rs4718325	ENSG00000222364.1	RNU6-96P	-7.68	1.64e-13	4.62e-10	-0.48	-0.38	Aortic root size;	chr7:66215323	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	7.68	1.64e-13	4.62e-10	0.46	0.38	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	7.68	1.64e-13	4.62e-10	0.46	0.38	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	7.68	1.64e-13	4.62e-10	0.46	0.38	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
STAD	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-7.68	1.65e-13	4.64e-10	-0.54	-0.38	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
STAD	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-7.68	1.66e-13	4.68e-10	-0.4	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
STAD	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	7.68	1.67e-13	4.68e-10	0.41	0.38	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
STAD	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	7.68	1.67e-13	4.69e-10	0.44	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
STAD	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	7.68	1.69e-13	4.74e-10	0.47	0.38	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	7.68	1.69e-13	4.76e-10	0.47	0.38	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
STAD	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	7.68	1.7e-13	4.77e-10	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
STAD	cis	rs11903757	1	rs12464838	ENSG00000281467.1	Clostridiales-1	-7.68	1.7e-13	4.77e-10	-0.6	-0.38	Colorectal cancer;	chr2:191703186	chr2:191699476~191699631:-
STAD	cis	rs10129255	0.879	rs7160512	ENSG00000211970.3	IGHV4-61	-7.67	1.71e-13	4.8e-10	-0.32	-0.38	Kawasaki disease;	chr14:106694574	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.879	rs7159157	ENSG00000211970.3	IGHV4-61	-7.67	1.71e-13	4.8e-10	-0.32	-0.38	Kawasaki disease;	chr14:106694578	chr14:106639119~106639657:-
STAD	cis	rs732716	0.752	rs11085072	ENSG00000267769.1	CTB-50L17.9	-7.67	1.71e-13	4.8e-10	-0.6	-0.38	Mean corpuscular volume;	chr19:4368145	chr19:4454014~4455286:+
STAD	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	7.67	1.73e-13	4.86e-10	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
STAD	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	7.67	1.76e-13	4.93e-10	0.36	0.38	Depression;	chr6:28240757	chr6:28176188~28176674:+
STAD	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	7.67	1.76e-13	4.93e-10	0.44	0.38	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
STAD	cis	rs3136516	0.503	rs17787966	ENSG00000271350.1	CTD-2384B9.1	7.67	1.76e-13	4.94e-10	0.43	0.38	Venous thromboembolism;	chr11:47048874	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	7.67	1.76e-13	4.95e-10	0.44	0.38	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
STAD	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-7.67	1.77e-13	4.97e-10	-0.48	-0.38	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
STAD	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	7.67	1.77e-13	4.98e-10	0.54	0.38	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
STAD	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-7.67	1.78e-13	4.98e-10	-0.49	-0.38	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-7.67	1.78e-13	4.98e-10	-0.49	-0.38	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
STAD	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	7.67	1.78e-13	5e-10	0.46	0.38	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
STAD	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-7.67	1.78e-13	5e-10	-0.41	-0.38	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
STAD	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-7.67	1.78e-13	5e-10	-0.41	-0.38	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
STAD	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-7.67	1.78e-13	5e-10	-0.41	-0.38	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
STAD	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-7.67	1.78e-13	5e-10	-0.41	-0.38	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
STAD	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-7.67	1.78e-13	5e-10	-0.41	-0.38	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
STAD	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-7.67	1.78e-13	5e-10	-0.41	-0.38	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
STAD	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	7.67	1.8e-13	5.03e-10	0.55	0.38	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
STAD	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	7.67	1.8e-13	5.04e-10	0.41	0.38	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
STAD	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	7.67	1.82e-13	5.08e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
STAD	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-7.66	1.84e-13	5.13e-10	-0.42	-0.38	Height;	chr3:53094335	chr3:53064283~53065091:-
STAD	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	7.66	1.87e-13	5.22e-10	0.38	0.38	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
STAD	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-7.66	1.88e-13	5.25e-10	-0.44	-0.38	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
STAD	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	7.66	1.88e-13	5.26e-10	0.55	0.38	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	7.66	1.88e-13	5.26e-10	0.55	0.38	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	7.66	1.89e-13	5.28e-10	0.54	0.38	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
STAD	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-7.66	1.9e-13	5.29e-10	-0.42	-0.38	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
STAD	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-7.66	1.9e-13	5.3e-10	-0.41	-0.38	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
STAD	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	7.66	1.94e-13	5.39e-10	0.54	0.38	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
STAD	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-7.65	1.95e-13	5.43e-10	-0.4	-0.38	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
STAD	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	7.65	1.95e-13	5.43e-10	0.46	0.38	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	7.65	1.95e-13	5.43e-10	0.46	0.38	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
STAD	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	7.65	1.95e-13	5.43e-10	0.46	0.38	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
STAD	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	7.65	1.95e-13	5.43e-10	0.46	0.38	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	7.65	1.95e-13	5.43e-10	0.47	0.38	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
STAD	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-7.65	1.96e-13	5.46e-10	-0.54	-0.38	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
STAD	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-7.65	1.97e-13	5.48e-10	-0.41	-0.38	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	7.65	1.98e-13	5.51e-10	0.43	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
STAD	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	7.65	2e-13	5.55e-10	0.47	0.38	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
STAD	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-7.65	2.02e-13	5.62e-10	-0.52	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
STAD	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-7.65	2.02e-13	5.63e-10	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
STAD	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	7.65	2.03e-13	5.63e-10	0.44	0.38	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	7.65	2.03e-13	5.63e-10	0.44	0.38	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	7.65	2.03e-13	5.63e-10	0.44	0.38	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	7.65	2.03e-13	5.63e-10	0.44	0.38	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	7.65	2.03e-13	5.63e-10	0.44	0.38	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
STAD	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	7.65	2.03e-13	5.63e-10	0.44	0.38	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	7.65	2.03e-13	5.63e-10	0.44	0.38	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
STAD	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	7.65	2.04e-13	5.67e-10	0.37	0.38	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
STAD	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	7.65	2.06e-13	5.73e-10	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	7.65	2.06e-13	5.73e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	7.65	2.06e-13	5.73e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
STAD	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	7.65	2.07e-13	5.73e-10	0.39	0.38	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.872	rs10133674	ENSG00000211970.3	IGHV4-61	-7.64	2.1e-13	5.82e-10	-0.33	-0.38	Kawasaki disease;	chr14:106692788	chr14:106639119~106639657:-
STAD	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-7.64	2.11e-13	5.84e-10	-0.32	-0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
STAD	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	7.64	2.11e-13	5.84e-10	0.38	0.38	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
STAD	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	7.64	2.11e-13	5.85e-10	0.55	0.38	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
STAD	cis	rs11903757	1	rs77399531	ENSG00000281467.1	Clostridiales-1	-7.64	2.12e-13	5.88e-10	-0.61	-0.38	Colorectal cancer;	chr2:191724338	chr2:191699476~191699631:-
STAD	cis	rs875971	0.545	rs73142233	ENSG00000222364.1	RNU6-96P	-7.64	2.13e-13	5.89e-10	-0.47	-0.38	Aortic root size;	chr7:66221293	chr7:66395191~66395286:+
STAD	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-7.64	2.13e-13	5.89e-10	-0.44	-0.38	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
STAD	cis	rs875971	0.545	rs73142245	ENSG00000222364.1	RNU6-96P	-7.64	2.13e-13	5.92e-10	-0.47	-0.38	Aortic root size;	chr7:66226662	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	7.64	2.19e-13	6.05e-10	0.48	0.38	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	7.64	2.19e-13	6.05e-10	0.46	0.38	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
STAD	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-7.64	2.19e-13	6.06e-10	-0.44	-0.38	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
STAD	cis	rs7615952	0.543	rs4645102	ENSG00000272840.1	RP11-379B18.6	7.64	2.19e-13	6.06e-10	0.59	0.38	Blood pressure (smoking interaction);	chr3:125705597	chr3:125774714~125797953:+
STAD	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	7.64	2.2e-13	6.07e-10	0.53	0.38	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
STAD	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	7.64	2.21e-13	6.1e-10	0.41	0.38	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
STAD	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-7.64	2.21e-13	6.11e-10	-0.38	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-7.64	2.21e-13	6.11e-10	-0.38	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
STAD	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	7.64	2.21e-13	6.11e-10	0.47	0.38	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
STAD	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	7.64	2.21e-13	6.12e-10	0.49	0.38	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
STAD	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	7.63	2.23e-13	6.15e-10	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
STAD	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	7.63	2.24e-13	6.2e-10	0.37	0.38	Depression;	chr6:28301886	chr6:28176188~28176674:+
STAD	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-7.63	2.25e-13	6.22e-10	-0.36	-0.38	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
STAD	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	7.63	2.27e-13	6.25e-10	0.66	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
STAD	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-7.63	2.27e-13	6.26e-10	-0.37	-0.38	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
STAD	cis	rs11903757	1	rs79858889	ENSG00000281467.1	Clostridiales-1	-7.63	2.28e-13	6.3e-10	-0.62	-0.38	Colorectal cancer;	chr2:191724366	chr2:191699476~191699631:-
STAD	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	7.63	2.29e-13	6.32e-10	0.33	0.38	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
STAD	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-7.63	2.31e-13	6.36e-10	-0.44	-0.38	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
STAD	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	7.63	2.32e-13	6.37e-10	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
STAD	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-7.63	2.32e-13	6.39e-10	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
STAD	cis	rs11903757	1	rs6717663	ENSG00000281467.1	Clostridiales-1	-7.63	2.33e-13	6.4e-10	-0.61	-0.38	Colorectal cancer;	chr2:191724659	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs6717668	ENSG00000281467.1	Clostridiales-1	-7.63	2.33e-13	6.4e-10	-0.61	-0.38	Colorectal cancer;	chr2:191724673	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs6759665	ENSG00000281467.1	Clostridiales-1	-7.63	2.33e-13	6.4e-10	-0.61	-0.38	Colorectal cancer;	chr2:191724728	chr2:191699476~191699631:-
STAD	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-7.63	2.34e-13	6.44e-10	-0.41	-0.38	Height;	chr3:53080524	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	7.63	2.35e-13	6.47e-10	0.37	0.38	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
STAD	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	7.63	2.35e-13	6.48e-10	0.54	0.38	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
STAD	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	7.63	2.36e-13	6.5e-10	0.51	0.38	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
STAD	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-7.63	2.37e-13	6.53e-10	-0.47	-0.38	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
STAD	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	7.62	2.38e-13	6.56e-10	0.44	0.38	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	7.62	2.38e-13	6.56e-10	0.44	0.38	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
STAD	cis	rs875971	0.545	rs73142265	ENSG00000222364.1	RNU6-96P	-7.62	2.4e-13	6.61e-10	-0.47	-0.38	Aortic root size;	chr7:66234510	chr7:66395191~66395286:+
STAD	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	7.62	2.42e-13	6.64e-10	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
STAD	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	7.62	2.43e-13	6.68e-10	0.51	0.38	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
STAD	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-7.62	2.48e-13	6.81e-10	-0.41	-0.38	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	7.62	2.49e-13	6.82e-10	0.44	0.38	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
STAD	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	7.62	2.49e-13	6.85e-10	0.34	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
STAD	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-7.62	2.5e-13	6.85e-10	-0.46	-0.38	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	7.62	2.5e-13	6.85e-10	0.46	0.38	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	7.62	2.5e-13	6.85e-10	0.46	0.38	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	7.62	2.5e-13	6.85e-10	0.46	0.38	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
STAD	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	7.62	2.52e-13	6.92e-10	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
STAD	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-7.62	2.53e-13	6.93e-10	-0.46	-0.38	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
STAD	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	7.61	2.57e-13	7.04e-10	0.44	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
STAD	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	7.61	2.61e-13	7.14e-10	0.47	0.38	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
STAD	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	7.61	2.61e-13	7.14e-10	0.44	0.38	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
STAD	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	7.61	2.61e-13	7.15e-10	0.48	0.38	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
STAD	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-7.61	2.62e-13	7.16e-10	-0.43	-0.38	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
STAD	cis	rs11903757	1	rs12463776	ENSG00000281467.1	Clostridiales-1	-7.61	2.62e-13	7.17e-10	-0.61	-0.38	Colorectal cancer;	chr2:191723608	chr2:191699476~191699631:-
STAD	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	7.61	2.63e-13	7.19e-10	0.4	0.38	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
STAD	cis	rs9368481	0.729	rs10946881	ENSG00000243307.2	POM121L6P	7.61	2.63e-13	7.2e-10	0.39	0.38	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26896952~26898777:+
STAD	cis	rs62402013	1	rs62402013	ENSG00000243307.2	POM121L6P	7.61	2.63e-13	7.2e-10	0.39	0.38	Schizophrenia;	chr6:26947221	chr6:26896952~26898777:+
STAD	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	7.61	2.64e-13	7.21e-10	0.74	0.38	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
STAD	cis	rs11903757	1	rs12470148	ENSG00000281467.1	Clostridiales-1	-7.61	2.65e-13	7.23e-10	-0.6	-0.38	Colorectal cancer;	chr2:191706143	chr2:191699476~191699631:-
STAD	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-7.61	2.65e-13	7.24e-10	-0.39	-0.38	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
STAD	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-7.61	2.66e-13	7.25e-10	-0.36	-0.38	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
STAD	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-7.61	2.66e-13	7.25e-10	-0.36	-0.38	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
STAD	cis	rs11903757	1	rs78893166	ENSG00000281467.1	Clostridiales-1	-7.61	2.66e-13	7.27e-10	-0.6	-0.38	Colorectal cancer;	chr2:191713930	chr2:191699476~191699631:-
STAD	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	7.61	2.67e-13	7.29e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
STAD	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-7.61	2.67e-13	7.29e-10	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
STAD	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-7.61	2.67e-13	7.29e-10	-0.4	-0.38	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
STAD	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	7.61	2.67e-13	7.29e-10	0.32	0.38	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
STAD	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-7.61	2.68e-13	7.3e-10	-0.4	-0.38	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
STAD	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-7.61	2.68e-13	7.31e-10	-0.46	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
STAD	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	7.61	2.68e-13	7.33e-10	0.4	0.38	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
STAD	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	7.61	2.69e-13	7.34e-10	0.47	0.38	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
STAD	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-7.61	2.71e-13	7.4e-10	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
STAD	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	7.6	2.73e-13	7.44e-10	0.76	0.38	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
STAD	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-7.6	2.77e-13	7.54e-10	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
STAD	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-7.6	2.79e-13	7.6e-10	-0.47	-0.38	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
STAD	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	7.6	2.8e-13	7.61e-10	0.36	0.38	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	7.6	2.8e-13	7.61e-10	0.36	0.38	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
STAD	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	7.6	2.8e-13	7.62e-10	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
STAD	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-7.6	2.83e-13	7.68e-10	-0.35	-0.38	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
STAD	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	7.6	2.84e-13	7.73e-10	0.53	0.38	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	7.6	2.84e-13	7.73e-10	0.53	0.38	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	7.6	2.86e-13	7.77e-10	0.54	0.38	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
STAD	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	7.6	2.88e-13	7.82e-10	0.54	0.38	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
STAD	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-7.59	2.9e-13	7.89e-10	-0.41	-0.38	Height;	chr3:53064759	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	7.59	2.91e-13	7.91e-10	0.37	0.38	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
STAD	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-7.59	2.93e-13	7.96e-10	-0.42	-0.38	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
STAD	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-7.59	2.99e-13	8.11e-10	-0.44	-0.38	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
STAD	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	7.59	3.03e-13	8.21e-10	0.44	0.38	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
STAD	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-7.59	3.07e-13	8.3e-10	-0.47	-0.38	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
STAD	cis	rs5760092	0.618	rs4461358	ENSG00000099984.9	GSTT2	7.59	3.07e-13	8.31e-10	0.48	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23980123~23983911:+
STAD	cis	rs11903757	1	rs4299283	ENSG00000281467.1	Clostridiales-1	-7.59	3.09e-13	8.38e-10	-0.6	-0.38	Colorectal cancer;	chr2:191716161	chr2:191699476~191699631:-
STAD	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	7.58	3.16e-13	8.55e-10	0.33	0.38	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
STAD	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	7.58	3.17e-13	8.58e-10	0.46	0.38	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
STAD	cis	rs611744	0.967	rs673015	ENSG00000253754.1	RP11-35G22.1	-7.58	3.18e-13	8.62e-10	-0.33	-0.38	Dupuytren's disease;	chr8:108179440	chr8:108226200~108227544:+
STAD	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	7.58	3.21e-13	8.68e-10	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-7.58	3.21e-13	8.68e-10	-0.44	-0.38	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
STAD	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-7.58	3.21e-13	8.68e-10	-0.5	-0.38	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
STAD	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	7.58	3.22e-13	8.7e-10	0.38	0.38	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
STAD	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	7.58	3.22e-13	8.72e-10	0.45	0.38	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
STAD	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	7.58	3.26e-13	8.81e-10	0.47	0.38	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	7.57	3.33e-13	8.99e-10	0.44	0.38	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	7.57	3.33e-13	8.99e-10	0.44	0.38	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	7.57	3.33e-13	8.99e-10	0.44	0.38	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	7.57	3.33e-13	8.99e-10	0.44	0.38	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	7.57	3.33e-13	8.99e-10	0.44	0.38	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
STAD	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-7.57	3.33e-13	9e-10	-0.45	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
STAD	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-7.57	3.41e-13	9.2e-10	-0.46	-0.38	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
STAD	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-7.57	3.43e-13	9.24e-10	-0.52	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
STAD	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-7.57	3.43e-13	9.24e-10	-0.56	-0.38	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
STAD	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-7.57	3.45e-13	9.31e-10	-0.35	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
STAD	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	7.57	3.45e-13	9.31e-10	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	7.57	3.46e-13	9.32e-10	0.54	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
STAD	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-7.57	3.48e-13	9.37e-10	-0.54	-0.38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
STAD	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	7.57	3.48e-13	9.37e-10	0.54	0.38	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	7.57	3.48e-13	9.37e-10	0.54	0.38	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	7.57	3.48e-13	9.37e-10	0.54	0.38	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
STAD	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-7.57	3.5e-13	9.42e-10	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
STAD	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-7.57	3.5e-13	9.44e-10	-0.41	-0.38	Height;	chr3:53070344	chr3:53064283~53065091:-
STAD	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	7.57	3.5e-13	9.44e-10	0.33	0.38	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
STAD	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	7.57	3.52e-13	9.47e-10	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-7.57	3.52e-13	9.47e-10	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
STAD	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-7.56	3.55e-13	9.57e-10	-0.41	-0.38	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
STAD	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	7.56	3.57e-13	9.6e-10	0.46	0.38	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
STAD	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	7.56	3.58e-13	9.64e-10	0.44	0.38	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
STAD	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	7.56	3.59e-13	9.66e-10	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	7.56	3.59e-13	9.66e-10	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	7.56	3.59e-13	9.66e-10	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
STAD	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-7.56	3.6e-13	9.68e-10	-0.41	-0.38	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
STAD	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-7.56	3.61e-13	9.71e-10	-0.44	-0.38	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
STAD	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-7.56	3.62e-13	9.74e-10	-0.41	-0.38	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
STAD	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	7.56	3.63e-13	9.74e-10	0.47	0.38	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
STAD	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	7.56	3.63e-13	9.74e-10	0.47	0.38	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
STAD	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-7.56	3.64e-13	9.79e-10	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
STAD	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	7.56	3.65e-13	9.81e-10	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
STAD	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	7.56	3.68e-13	9.87e-10	0.34	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	7.56	3.68e-13	9.87e-10	0.34	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
STAD	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-7.56	3.68e-13	9.88e-10	-0.4	-0.38	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
STAD	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-7.56	3.69e-13	9.91e-10	-0.39	-0.38	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
STAD	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	7.56	3.74e-13	1e-09	0.41	0.38	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
STAD	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-7.56	3.77e-13	1.01e-09	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
STAD	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	7.55	3.79e-13	1.02e-09	0.53	0.38	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
STAD	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	7.55	3.83e-13	1.02e-09	0.43	0.38	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	7.55	3.83e-13	1.02e-09	0.43	0.38	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
STAD	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	7.55	3.85e-13	1.03e-09	0.46	0.38	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
STAD	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	7.55	3.87e-13	1.04e-09	0.42	0.38	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
STAD	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-7.55	3.9e-13	1.04e-09	-0.53	-0.38	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
STAD	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-7.55	3.91e-13	1.05e-09	-0.39	-0.38	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
STAD	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	7.55	3.94e-13	1.05e-09	0.47	0.38	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
STAD	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	7.55	3.97e-13	1.06e-09	0.43	0.38	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	7.55	3.97e-13	1.06e-09	0.43	0.38	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
STAD	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	7.55	3.97e-13	1.06e-09	0.36	0.38	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
STAD	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	7.55	3.98e-13	1.06e-09	0.36	0.38	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
STAD	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-7.55	3.98e-13	1.06e-09	-0.39	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
STAD	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	7.55	4e-13	1.07e-09	0.39	0.38	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
STAD	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	7.55	4e-13	1.07e-09	0.47	0.38	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
STAD	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	7.55	4e-13	1.07e-09	0.47	0.38	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
STAD	cis	rs2283792	0.566	rs1005579	ENSG00000228050.1	TOP3BP1	7.55	4.02e-13	1.07e-09	0.44	0.38	Multiple sclerosis;	chr22:21946569	chr22:22223187~22224566:-
STAD	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	7.55	4.03e-13	1.08e-09	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
STAD	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-7.54	4.04e-13	1.08e-09	-0.39	-0.38	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
STAD	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	7.54	4.04e-13	1.08e-09	0.48	0.38	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
STAD	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	7.54	4.04e-13	1.08e-09	0.37	0.38	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	7.54	4.04e-13	1.08e-09	0.37	0.38	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
STAD	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-7.54	4.05e-13	1.08e-09	-0.39	-0.38	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
STAD	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	7.54	4.05e-13	1.08e-09	0.51	0.38	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
STAD	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-7.54	4.05e-13	1.08e-09	-0.54	-0.38	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
STAD	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	7.54	4.06e-13	1.08e-09	0.34	0.38	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
STAD	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-7.54	4.09e-13	1.09e-09	-0.36	-0.38	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
STAD	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	7.54	4.1e-13	1.09e-09	0.55	0.38	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	7.54	4.1e-13	1.09e-09	0.55	0.38	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
STAD	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	7.54	4.1e-13	1.09e-09	0.51	0.38	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	7.54	4.1e-13	1.09e-09	0.51	0.38	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	7.54	4.11e-13	1.09e-09	0.51	0.38	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	7.54	4.11e-13	1.09e-09	0.51	0.38	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	7.54	4.11e-13	1.09e-09	0.51	0.38	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
STAD	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	7.54	4.12e-13	1.1e-09	0.45	0.38	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
STAD	cis	rs9457247	0.508	rs7760495	ENSG00000265828.1	MIR3939	-7.54	4.12e-13	1.1e-09	-0.43	-0.38	Crohn's disease;	chr6:167093307	chr6:166997807~166997912:-
STAD	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	7.54	4.13e-13	1.1e-09	0.47	0.38	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
STAD	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-7.54	4.14e-13	1.1e-09	-0.44	-0.38	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
STAD	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	7.54	4.19e-13	1.11e-09	0.53	0.38	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	7.54	4.19e-13	1.11e-09	0.53	0.38	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
STAD	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	7.54	4.19e-13	1.11e-09	0.53	0.38	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
STAD	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	7.54	4.19e-13	1.12e-09	0.37	0.38	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
STAD	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-7.54	4.2e-13	1.12e-09	-0.4	-0.38	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
STAD	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-7.54	4.26e-13	1.13e-09	-0.37	-0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
STAD	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-7.54	4.27e-13	1.14e-09	-0.39	-0.38	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-7.54	4.29e-13	1.14e-09	-0.43	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
STAD	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-7.54	4.3e-13	1.14e-09	-0.44	-0.38	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
STAD	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	7.53	4.32e-13	1.15e-09	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	7.53	4.32e-13	1.15e-09	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
STAD	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	7.53	4.35e-13	1.15e-09	0.46	0.38	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
STAD	cis	rs1426063	0.8	rs28861517	ENSG00000248165.1	RP11-44F21.2	7.53	4.35e-13	1.16e-09	0.53	0.38	QT interval;	chr4:75092995	chr4:74993877~75034824:-
STAD	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	7.53	4.36e-13	1.16e-09	0.36	0.38	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
STAD	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-7.53	4.39e-13	1.17e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-7.53	4.4e-13	1.17e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-7.53	4.4e-13	1.17e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
STAD	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	7.53	4.41e-13	1.17e-09	0.53	0.38	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
STAD	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-7.53	4.44e-13	1.18e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-7.53	4.44e-13	1.18e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-7.53	4.44e-13	1.18e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-7.53	4.44e-13	1.18e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-7.53	4.44e-13	1.18e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-7.53	4.44e-13	1.18e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-7.53	4.44e-13	1.18e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
STAD	cis	rs11039131	0.929	rs1685404	ENSG00000271350.1	CTD-2384B9.1	-7.53	4.45e-13	1.18e-09	-0.43	-0.38	Schizophrenia;	chr11:47222114	chr11:47041027~47041945:-
STAD	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-7.53	4.48e-13	1.19e-09	-0.38	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
STAD	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	7.53	4.49e-13	1.19e-09	0.41	0.38	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	7.53	4.49e-13	1.19e-09	0.41	0.38	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	7.53	4.49e-13	1.19e-09	0.41	0.38	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	7.53	4.49e-13	1.19e-09	0.41	0.38	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
STAD	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-7.53	4.54e-13	1.2e-09	-0.5	-0.38	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-7.53	4.54e-13	1.2e-09	-0.5	-0.38	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
STAD	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	7.53	4.55e-13	1.21e-09	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
STAD	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	7.53	4.57e-13	1.21e-09	0.37	0.38	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	7.53	4.57e-13	1.21e-09	0.37	0.38	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
STAD	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-7.53	4.57e-13	1.21e-09	-0.43	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
STAD	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	7.53	4.58e-13	1.21e-09	0.45	0.38	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
STAD	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	7.53	4.6e-13	1.22e-09	0.41	0.38	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
STAD	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	7.52	4.61e-13	1.22e-09	0.58	0.38	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
STAD	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-7.52	4.62e-13	1.22e-09	-0.4	-0.38	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
STAD	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-7.52	4.62e-13	1.22e-09	-0.48	-0.37	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
STAD	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	7.52	4.62e-13	1.22e-09	0.39	0.37	Height;	chr11:118791319	chr11:118688039~118690600:-
STAD	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	7.52	4.66e-13	1.23e-09	0.36	0.37	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
STAD	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	7.52	4.66e-13	1.23e-09	0.36	0.37	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
STAD	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-7.52	4.67e-13	1.23e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-7.52	4.67e-13	1.23e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-7.52	4.67e-13	1.23e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-7.52	4.67e-13	1.23e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-7.52	4.67e-13	1.23e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-7.52	4.67e-13	1.23e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
STAD	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-7.52	4.75e-13	1.26e-09	-0.53	-0.37	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
STAD	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	7.52	4.8e-13	1.27e-09	0.4	0.37	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
STAD	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	7.52	4.83e-13	1.28e-09	0.45	0.37	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	7.52	4.86e-13	1.28e-09	0.44	0.37	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	7.52	4.86e-13	1.28e-09	0.44	0.37	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	7.52	4.86e-13	1.28e-09	0.44	0.37	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
STAD	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	7.52	4.89e-13	1.29e-09	0.46	0.37	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
STAD	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	7.52	4.89e-13	1.29e-09	0.51	0.37	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	7.52	4.89e-13	1.29e-09	0.51	0.37	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	7.52	4.89e-13	1.29e-09	0.51	0.37	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
STAD	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-7.51	4.95e-13	1.3e-09	-0.43	-0.37	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
STAD	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	7.51	4.96e-13	1.31e-09	0.44	0.37	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
STAD	cis	rs9368481	0.761	rs4713062	ENSG00000243307.2	POM121L6P	-7.51	4.98e-13	1.31e-09	-0.38	-0.37	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26896952~26898777:+
STAD	cis	rs12468226	0.938	rs55668474	ENSG00000273456.1	RP11-686O6.2	7.51	4.99e-13	1.31e-09	0.5	0.37	Urate levels;	chr2:202265559	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs13392645	ENSG00000273456.1	RP11-686O6.2	7.51	4.99e-13	1.31e-09	0.5	0.37	Urate levels;	chr2:202270116	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs6753044	ENSG00000273456.1	RP11-686O6.2	7.51	4.99e-13	1.31e-09	0.5	0.37	Urate levels;	chr2:202300710	chr2:202374932~202375604:-
STAD	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	7.51	5.01e-13	1.32e-09	0.38	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
STAD	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	7.51	5.03e-13	1.32e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	7.51	5.03e-13	1.32e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
STAD	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-7.51	5.07e-13	1.33e-09	-0.43	-0.37	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
STAD	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	7.51	5.1e-13	1.34e-09	0.39	0.37	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
STAD	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-7.51	5.16e-13	1.36e-09	-0.41	-0.37	Height;	chr3:53093751	chr3:53064283~53065091:-
STAD	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	7.51	5.17e-13	1.36e-09	0.45	0.37	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
STAD	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	7.51	5.18e-13	1.36e-09	0.53	0.37	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
STAD	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	7.5	5.27e-13	1.38e-09	0.4	0.37	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	7.5	5.27e-13	1.38e-09	0.4	0.37	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
STAD	cis	rs1426063	0.614	rs76325897	ENSG00000248165.1	RP11-44F21.2	7.5	5.29e-13	1.39e-09	0.84	0.37	QT interval;	chr4:75084747	chr4:74993877~75034824:-
STAD	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	7.5	5.34e-13	1.4e-09	0.53	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-7.5	5.34e-13	1.4e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-7.5	5.34e-13	1.4e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-7.5	5.34e-13	1.4e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-7.5	5.34e-13	1.4e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-7.5	5.34e-13	1.4e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	7.5	5.35e-13	1.4e-09	0.45	0.37	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
STAD	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-7.5	5.35e-13	1.4e-09	-0.4	-0.37	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	7.5	5.36e-13	1.4e-09	0.41	0.37	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-7.5	5.37e-13	1.41e-09	-0.4	-0.37	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
STAD	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-7.5	5.38e-13	1.41e-09	-0.31	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
STAD	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	7.5	5.39e-13	1.41e-09	0.43	0.37	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
STAD	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-7.5	5.4e-13	1.41e-09	-0.47	-0.37	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
STAD	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-7.5	5.41e-13	1.42e-09	-0.41	-0.37	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
STAD	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-7.5	5.43e-13	1.42e-09	-0.44	-0.37	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
STAD	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	7.5	5.43e-13	1.42e-09	0.53	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
STAD	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-7.5	5.43e-13	1.42e-09	-0.39	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-7.5	5.43e-13	1.42e-09	-0.39	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-7.5	5.43e-13	1.42e-09	-0.39	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-7.5	5.43e-13	1.42e-09	-0.39	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-7.5	5.43e-13	1.42e-09	-0.39	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
STAD	cis	rs12468226	0.938	rs7568159	ENSG00000273456.1	RP11-686O6.2	7.5	5.49e-13	1.44e-09	0.5	0.37	Urate levels;	chr2:202286226	chr2:202374932~202375604:-
STAD	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	7.5	5.52e-13	1.44e-09	0.36	0.37	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
STAD	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	7.5	5.53e-13	1.45e-09	0.47	0.37	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
STAD	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	7.5	5.54e-13	1.45e-09	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
STAD	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	7.5	5.56e-13	1.45e-09	0.53	0.37	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
STAD	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-7.49	5.66e-13	1.48e-09	-0.44	-0.37	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
STAD	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-7.49	5.71e-13	1.49e-09	-0.36	-0.37	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
STAD	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-7.49	5.72e-13	1.49e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
STAD	cis	rs12468226	0.938	rs55681656	ENSG00000273456.1	RP11-686O6.2	7.49	5.74e-13	1.5e-09	0.5	0.37	Urate levels;	chr2:202319041	chr2:202374932~202375604:-
STAD	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-7.49	5.74e-13	1.5e-09	-0.41	-0.37	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
STAD	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	7.49	5.77e-13	1.51e-09	0.42	0.37	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	7.49	5.77e-13	1.51e-09	0.42	0.37	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
STAD	cis	rs10935480	0.577	rs10804683	ENSG00000239445.4	ST3GAL6-AS1	-7.49	5.78e-13	1.51e-09	-0.43	-0.37	Blood protein levels;	chr3:98661882	chr3:98714330~98732651:-
STAD	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-7.49	5.78e-13	1.51e-09	-0.42	-0.37	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
STAD	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-7.49	5.78e-13	1.51e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
STAD	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	7.49	5.79e-13	1.51e-09	0.41	0.37	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
STAD	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-7.49	5.8e-13	1.51e-09	-0.47	-0.37	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
STAD	cis	rs9457247	0.508	rs9457268	ENSG00000265828.1	MIR3939	-7.49	5.8e-13	1.51e-09	-0.42	-0.37	Crohn's disease;	chr6:167090151	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.508	rs6902119	ENSG00000265828.1	MIR3939	-7.49	5.8e-13	1.51e-09	-0.42	-0.37	Crohn's disease;	chr6:167092303	chr6:166997807~166997912:-
STAD	cis	rs9457247	0.508	rs6918286	ENSG00000265828.1	MIR3939	-7.49	5.8e-13	1.51e-09	-0.42	-0.37	Crohn's disease;	chr6:167092341	chr6:166997807~166997912:-
STAD	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	7.49	5.81e-13	1.51e-09	0.41	0.37	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	7.49	5.81e-13	1.51e-09	0.41	0.37	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	7.49	5.81e-13	1.51e-09	0.41	0.37	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
STAD	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	7.49	5.83e-13	1.52e-09	0.4	0.37	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
STAD	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	7.49	5.85e-13	1.52e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
STAD	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	7.49	5.86e-13	1.53e-09	0.36	0.37	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
STAD	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	7.49	5.88e-13	1.53e-09	0.4	0.37	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
STAD	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-7.49	5.92e-13	1.54e-09	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
STAD	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	7.49	5.92e-13	1.54e-09	0.51	0.37	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
STAD	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	7.49	5.98e-13	1.56e-09	0.43	0.37	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
STAD	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-7.48	6.03e-13	1.57e-09	-0.4	-0.37	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
STAD	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	7.48	6.03e-13	1.57e-09	0.4	0.37	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	7.48	6.03e-13	1.57e-09	0.4	0.37	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
STAD	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	7.48	6.03e-13	1.57e-09	0.36	0.37	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
STAD	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	7.48	6.03e-13	1.57e-09	0.36	0.37	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
STAD	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-7.48	6.05e-13	1.57e-09	-0.38	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
STAD	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	7.48	6.05e-13	1.57e-09	0.36	0.37	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
STAD	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-7.48	6.08e-13	1.58e-09	-0.57	-0.37	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
STAD	cis	rs11903757	1	rs10202549	ENSG00000281467.1	Clostridiales-1	-7.48	6.08e-13	1.58e-09	-0.6	-0.37	Colorectal cancer;	chr2:191720289	chr2:191699476~191699631:-
STAD	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	7.48	6.09e-13	1.58e-09	0.44	0.37	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
STAD	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	7.48	6.12e-13	1.59e-09	0.47	0.37	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
STAD	cis	rs1426063	0.614	rs115690958	ENSG00000248165.1	RP11-44F21.2	7.48	6.13e-13	1.59e-09	0.84	0.37	QT interval;	chr4:75078364	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs78681370	ENSG00000248165.1	RP11-44F21.2	7.48	6.13e-13	1.59e-09	0.84	0.37	QT interval;	chr4:75081556	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs17000212	ENSG00000248165.1	RP11-44F21.2	7.48	6.13e-13	1.59e-09	0.84	0.37	QT interval;	chr4:75081611	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs77018380	ENSG00000248165.1	RP11-44F21.2	7.48	6.13e-13	1.59e-09	0.84	0.37	QT interval;	chr4:75081621	chr4:74993877~75034824:-
STAD	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	7.48	6.16e-13	1.6e-09	0.4	0.37	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
STAD	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	7.48	6.22e-13	1.61e-09	0.52	0.37	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
STAD	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	7.48	6.24e-13	1.62e-09	0.44	0.37	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
STAD	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-7.48	6.25e-13	1.62e-09	-0.45	-0.37	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
STAD	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-7.48	6.3e-13	1.63e-09	-0.65	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
STAD	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-7.47	6.4e-13	1.66e-09	-0.38	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
STAD	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	7.47	6.4e-13	1.66e-09	0.4	0.37	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
STAD	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	7.47	6.4e-13	1.66e-09	0.4	0.37	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	7.47	6.4e-13	1.66e-09	0.4	0.37	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	7.47	6.4e-13	1.66e-09	0.4	0.37	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	7.47	6.4e-13	1.66e-09	0.4	0.37	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
STAD	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-7.47	6.43e-13	1.66e-09	-0.39	-0.37	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
STAD	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-7.47	6.43e-13	1.66e-09	-0.39	-0.37	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
STAD	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-7.47	6.48e-13	1.68e-09	-0.4	-0.37	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
STAD	cis	rs611744	0.934	rs624311	ENSG00000253754.1	RP11-35G22.1	-7.47	6.49e-13	1.68e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108192208	chr8:108226200~108227544:+
STAD	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	7.47	6.52e-13	1.69e-09	0.36	0.37	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
STAD	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-7.47	6.53e-13	1.69e-09	-0.57	-0.37	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-7.47	6.53e-13	1.69e-09	-0.57	-0.37	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
STAD	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	7.47	6.53e-13	1.69e-09	0.47	0.37	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
STAD	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-7.47	6.6e-13	1.7e-09	-0.39	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
STAD	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	7.47	6.6e-13	1.71e-09	0.44	0.37	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	7.47	6.6e-13	1.71e-09	0.44	0.37	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
STAD	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	7.47	6.61e-13	1.71e-09	0.4	0.37	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	7.47	6.61e-13	1.71e-09	0.4	0.37	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-7.47	6.61e-13	1.71e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-7.47	6.63e-13	1.71e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-7.47	6.63e-13	1.71e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-7.47	6.63e-13	1.71e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
STAD	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-7.47	6.64e-13	1.71e-09	-0.38	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-7.47	6.64e-13	1.71e-09	-0.38	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-7.47	6.64e-13	1.71e-09	-0.38	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
STAD	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	7.47	6.67e-13	1.72e-09	0.36	0.37	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	7.47	6.68e-13	1.72e-09	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
STAD	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	7.47	6.68e-13	1.72e-09	0.32	0.37	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
STAD	cis	rs11903757	1	rs11903675	ENSG00000281467.1	Clostridiales-1	-7.47	6.69e-13	1.73e-09	-0.61	-0.37	Colorectal cancer;	chr2:191722329	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs11903757	ENSG00000281467.1	Clostridiales-1	-7.47	6.69e-13	1.73e-09	-0.61	-0.37	Colorectal cancer;	chr2:191722478	chr2:191699476~191699631:-
STAD	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	7.47	6.73e-13	1.74e-09	0.37	0.37	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
STAD	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-7.47	6.74e-13	1.74e-09	-0.4	-0.37	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
STAD	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-7.47	6.76e-13	1.74e-09	-0.41	-0.37	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
STAD	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	7.47	6.77e-13	1.75e-09	0.53	0.37	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
STAD	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	7.47	6.79e-13	1.75e-09	0.4	0.37	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	7.47	6.79e-13	1.75e-09	0.4	0.37	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
STAD	cis	rs1426063	0.614	rs75846524	ENSG00000248165.1	RP11-44F21.2	7.47	6.8e-13	1.75e-09	0.85	0.37	QT interval;	chr4:75083172	chr4:74993877~75034824:-
STAD	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	7.47	6.81e-13	1.75e-09	0.33	0.37	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
STAD	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	7.47	6.81e-13	1.75e-09	0.5	0.37	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
STAD	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-7.46	6.83e-13	1.76e-09	-0.48	-0.37	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-7.46	6.83e-13	1.76e-09	-0.48	-0.37	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
STAD	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	7.46	6.83e-13	1.76e-09	0.4	0.37	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
STAD	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-7.46	6.88e-13	1.77e-09	-0.4	-0.37	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
STAD	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-7.46	6.88e-13	1.77e-09	-0.4	-0.37	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
STAD	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	7.46	6.92e-13	1.78e-09	0.52	0.37	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
STAD	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	7.46	6.93e-13	1.78e-09	0.46	0.37	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
STAD	cis	rs9368481	0.645	rs10456350	ENSG00000243307.2	POM121L6P	7.46	6.93e-13	1.78e-09	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26896952~26898777:+
STAD	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	7.46	6.96e-13	1.79e-09	0.35	0.37	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
STAD	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	7.46	6.99e-13	1.8e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	7.46	6.99e-13	1.8e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	7.46	6.99e-13	1.8e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
STAD	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
STAD	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
STAD	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
STAD	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	7.46	7.03e-13	1.81e-09	0.52	0.37	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
STAD	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-7.46	7.05e-13	1.81e-09	-0.44	-0.37	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
STAD	cis	rs12468226	0.938	rs58834901	ENSG00000273456.1	RP11-686O6.2	7.46	7.17e-13	1.84e-09	0.5	0.37	Urate levels;	chr2:202288169	chr2:202374932~202375604:-
STAD	cis	rs9457247	0.508	rs6941355	ENSG00000265828.1	MIR3939	-7.46	7.2e-13	1.85e-09	-0.41	-0.37	Crohn's disease;	chr6:167092750	chr6:166997807~166997912:-
STAD	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	7.46	7.24e-13	1.86e-09	0.37	0.37	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
STAD	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	7.46	7.25e-13	1.86e-09	0.43	0.37	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
STAD	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-7.45	7.3e-13	1.87e-09	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
STAD	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	7.45	7.34e-13	1.88e-09	0.44	0.37	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
STAD	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-7.45	7.37e-13	1.89e-09	-0.49	-0.37	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
STAD	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-7.45	7.49e-13	1.92e-09	-0.51	-0.37	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
STAD	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-7.45	7.52e-13	1.93e-09	-0.69	-0.37	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
STAD	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	7.45	7.72e-13	1.97e-09	0.35	0.37	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
STAD	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-7.45	7.76e-13	1.98e-09	-0.4	-0.37	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
STAD	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-7.44	7.78e-13	1.98e-09	-0.48	-0.37	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
STAD	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	7.44	7.78e-13	1.99e-09	0.47	0.37	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	7.44	7.79e-13	1.99e-09	0.44	0.37	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
STAD	cis	rs9368481	0.7	rs6911401	ENSG00000243307.2	POM121L6P	7.44	7.85e-13	2e-09	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26896952~26898777:+
STAD	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-7.44	7.85e-13	2e-09	-0.54	-0.37	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
STAD	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	7.44	7.86e-13	2e-09	0.46	0.37	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
STAD	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	7.44	7.9e-13	2.01e-09	0.57	0.37	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-7.44	8.04e-13	2.05e-09	-0.43	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
STAD	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-7.44	8.05e-13	2.05e-09	-0.55	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
STAD	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	7.44	8.08e-13	2.06e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	7.44	8.08e-13	2.06e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	7.44	8.08e-13	2.06e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
STAD	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-7.44	8.13e-13	2.07e-09	-0.51	-0.37	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
STAD	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	7.44	8.18e-13	2.08e-09	0.36	0.37	Depression;	chr6:28314871	chr6:28176188~28176674:+
STAD	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	7.44	8.18e-13	2.08e-09	0.4	0.37	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
STAD	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	7.44	8.24e-13	2.1e-09	0.54	0.37	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
STAD	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	7.44	8.25e-13	2.1e-09	0.36	0.37	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
STAD	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	7.44	8.28e-13	2.1e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
STAD	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	7.43	8.32e-13	2.11e-09	0.4	0.37	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
STAD	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	7.43	8.32e-13	2.11e-09	0.4	0.37	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	7.43	8.32e-13	2.11e-09	0.4	0.37	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	7.43	8.34e-13	2.12e-09	0.44	0.37	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	7.43	8.34e-13	2.12e-09	0.44	0.37	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
STAD	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	7.43	8.35e-13	2.12e-09	0.41	0.37	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
STAD	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-7.43	8.36e-13	2.12e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
STAD	cis	rs9368481	0.678	rs62402024	ENSG00000243307.2	POM121L6P	7.43	8.39e-13	2.13e-09	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26896952~26898777:+
STAD	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	7.43	8.44e-13	2.14e-09	0.52	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
STAD	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	7.43	8.5e-13	2.16e-09	0.4	0.37	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	7.43	8.5e-13	2.16e-09	0.4	0.37	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
STAD	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	7.43	8.54e-13	2.17e-09	0.47	0.37	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
STAD	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-7.43	8.56e-13	2.17e-09	-0.35	-0.37	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
STAD	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	7.43	8.59e-13	2.18e-09	0.7	0.37	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
STAD	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	7.43	8.68e-13	2.2e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	7.43	8.68e-13	2.2e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	7.43	8.68e-13	2.2e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	7.43	8.68e-13	2.2e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
STAD	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	7.43	8.69e-13	2.2e-09	0.45	0.37	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	7.43	8.76e-13	2.22e-09	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
STAD	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-7.43	8.85e-13	2.24e-09	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
STAD	cis	rs9368481	0.672	rs3931463	ENSG00000243307.2	POM121L6P	7.42	8.89e-13	2.25e-09	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26896952~26898777:+
STAD	cis	rs9368481	0.761	rs3931464	ENSG00000243307.2	POM121L6P	7.42	8.89e-13	2.25e-09	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26896952~26898777:+
STAD	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-7.42	8.9e-13	2.25e-09	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
STAD	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	7.42	8.91e-13	2.25e-09	0.52	0.37	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
STAD	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-7.42	8.92e-13	2.26e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
STAD	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	7.42	8.98e-13	2.27e-09	0.43	0.37	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
STAD	cis	rs611744	0.967	rs677288	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108165310	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs677330	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108165343	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs660816	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108165819	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs584716	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108166405	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs673356	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108172930	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs689256	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108174169	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs597649	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108175489	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs598022	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108175530	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs598477	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108175645	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs610452	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108176034	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs612265	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108176421	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs613644	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108176765	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs628340	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108177196	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs627604	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108177590	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs631031	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108177803	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs641820	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108178488	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs645241	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108178734	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs671139	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108179031	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs1668178	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108179471	chr8:108226200~108227544:+
STAD	cis	rs611744	0.901	rs673981	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108179688	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs660065	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108179703	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs685690	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108179916	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs686584	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108180128	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs672591	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108180224	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs594405	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108181378	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs595266	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108181555	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs597992	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108181579	chr8:108226200~108227544:+
STAD	cis	rs611744	0.901	rs599357	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108181931	chr8:108226200~108227544:+
STAD	cis	rs611744	0.868	rs612722	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108182621	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs628843	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108183886	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs653633	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108183922	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs651814	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108184342	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs650401	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108184625	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs635624	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108185570	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs2600614	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108185850	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs2848619	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108185956	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs2212704	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108186186	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs686251	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108186678	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs684093	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108187126	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs684904	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108187188	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs686265	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108187534	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs591792	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108188217	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs2600615	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108188941	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs638905	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108191177	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs666821	ENSG00000253754.1	RP11-35G22.1	-7.42	8.99e-13	2.27e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108192084	chr8:108226200~108227544:+
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	7.42	9.01e-13	2.27e-09	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
STAD	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-7.42	9.03e-13	2.28e-09	-0.52	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
STAD	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-7.42	9.08e-13	2.29e-09	-0.5	-0.37	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
STAD	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-7.42	9.13e-13	2.3e-09	-0.45	-0.37	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
STAD	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	7.42	9.13e-13	2.3e-09	0.38	0.37	Height;	chr11:118809363	chr11:118688039~118690600:-
STAD	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-7.42	9.17e-13	2.31e-09	-0.47	-0.37	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	7.42	9.22e-13	2.32e-09	0.44	0.37	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	7.42	9.22e-13	2.32e-09	0.44	0.37	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	7.42	9.22e-13	2.32e-09	0.44	0.37	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	7.42	9.22e-13	2.32e-09	0.44	0.37	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	7.42	9.22e-13	2.32e-09	0.44	0.37	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
STAD	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	7.42	9.22e-13	2.32e-09	0.43	0.37	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	7.42	9.22e-13	2.32e-09	0.42	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
STAD	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	7.42	9.29e-13	2.34e-09	0.51	0.37	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
STAD	cis	rs611744	0.967	rs637358	ENSG00000253754.1	RP11-35G22.1	-7.42	9.37e-13	2.36e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108185225	chr8:108226200~108227544:+
STAD	cis	rs611744	0.901	rs655320	ENSG00000253754.1	RP11-35G22.1	-7.42	9.37e-13	2.36e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108185253	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs655707	ENSG00000253754.1	RP11-35G22.1	-7.42	9.37e-13	2.36e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108185301	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs636904	ENSG00000253754.1	RP11-35G22.1	-7.42	9.37e-13	2.36e-09	-0.33	-0.37	Dupuytren's disease;	chr8:108185336	chr8:108226200~108227544:+
STAD	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	7.42	9.37e-13	2.36e-09	0.48	0.37	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
STAD	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	7.42	9.41e-13	2.37e-09	0.36	0.37	Depression;	chr6:28303421	chr6:28176188~28176674:+
STAD	cis	rs611744	0.87	rs429315	ENSG00000253754.1	RP11-35G22.1	7.41	9.6e-13	2.41e-09	0.31	0.37	Dupuytren's disease;	chr8:108081840	chr8:108226200~108227544:+
STAD	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-7.41	9.63e-13	2.42e-09	-0.55	-0.37	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
STAD	cis	rs11903757	1	rs75610640	ENSG00000281467.1	Clostridiales-1	-7.41	9.63e-13	2.42e-09	-0.59	-0.37	Colorectal cancer;	chr2:191698038	chr2:191699476~191699631:-
STAD	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	7.41	9.7e-13	2.44e-09	0.43	0.37	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	7.41	9.7e-13	2.44e-09	0.43	0.37	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
STAD	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	7.41	9.74e-13	2.44e-09	0.52	0.37	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
STAD	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	7.41	9.75e-13	2.45e-09	0.36	0.37	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
STAD	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	7.41	9.76e-13	2.45e-09	0.45	0.37	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
STAD	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	7.41	9.85e-13	2.47e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
STAD	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
STAD	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
STAD	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	7.41	9.9e-13	2.48e-09	0.44	0.37	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
STAD	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-7.41	9.92e-13	2.48e-09	-0.47	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
STAD	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-7.41	9.92e-13	2.48e-09	-0.47	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
STAD	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-7.41	1e-12	2.5e-09	-0.4	-0.37	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
STAD	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-7.41	1.01e-12	2.51e-09	-0.41	-0.37	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
STAD	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-7.41	1.01e-12	2.52e-09	-0.39	-0.37	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
STAD	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-7.41	1.01e-12	2.52e-09	-0.39	-0.37	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
STAD	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	7.4	1.01e-12	2.52e-09	0.51	0.37	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
STAD	cis	rs11098499	0.913	rs12186259	ENSG00000248280.1	RP11-33B1.2	7.4	1.01e-12	2.52e-09	0.47	0.37	Corneal astigmatism;	chr4:119230884	chr4:119440561~119450157:-
STAD	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-7.4	1.01e-12	2.53e-09	-0.38	-0.37	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
STAD	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-7.4	1.02e-12	2.56e-09	-0.45	-0.37	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
STAD	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-7.4	1.03e-12	2.58e-09	-0.44	-0.37	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
STAD	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	7.4	1.04e-12	2.59e-09	0.51	0.37	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
STAD	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-7.4	1.06e-12	2.63e-09	-0.54	-0.37	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-7.4	1.06e-12	2.63e-09	-0.54	-0.37	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-7.4	1.06e-12	2.63e-09	-0.54	-0.37	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-7.4	1.06e-12	2.63e-09	-0.54	-0.37	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-7.4	1.06e-12	2.63e-09	-0.54	-0.37	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-7.4	1.06e-12	2.63e-09	-0.54	-0.37	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
STAD	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-7.4	1.06e-12	2.64e-09	-0.48	-0.37	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
STAD	cis	rs11903757	1	rs78771268	ENSG00000281467.1	Clostridiales-1	-7.4	1.06e-12	2.65e-09	-0.59	-0.37	Colorectal cancer;	chr2:191699167	chr2:191699476~191699631:-
STAD	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	7.4	1.06e-12	2.65e-09	0.52	0.37	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
STAD	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-7.39	1.08e-12	2.69e-09	-0.4	-0.37	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
STAD	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-7.39	1.08e-12	2.69e-09	-0.4	-0.37	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-7.39	1.08e-12	2.69e-09	-0.4	-0.37	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
STAD	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-7.39	1.08e-12	2.7e-09	-0.41	-0.37	Height;	chr3:53047596	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	7.39	1.09e-12	2.72e-09	0.36	0.37	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
STAD	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	7.39	1.1e-12	2.75e-09	0.52	0.37	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
STAD	cis	rs9368481	0.729	rs9379948	ENSG00000243307.2	POM121L6P	7.39	1.11e-12	2.75e-09	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26896952~26898777:+
STAD	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-7.39	1.11e-12	2.77e-09	-0.39	-0.37	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
STAD	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-7.39	1.11e-12	2.77e-09	-0.39	-0.37	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
STAD	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-7.39	1.11e-12	2.77e-09	-0.39	-0.37	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
STAD	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-7.39	1.11e-12	2.77e-09	-0.39	-0.37	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
STAD	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-7.39	1.11e-12	2.77e-09	-0.39	-0.37	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
STAD	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-7.39	1.11e-12	2.77e-09	-0.39	-0.37	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
STAD	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	7.39	1.11e-12	2.77e-09	0.44	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	7.39	1.13e-12	2.8e-09	0.43	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	7.39	1.13e-12	2.8e-09	0.43	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
STAD	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	7.39	1.13e-12	2.8e-09	0.43	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
STAD	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-7.39	1.13e-12	2.8e-09	-0.34	-0.37	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
STAD	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-7.39	1.13e-12	2.8e-09	-0.4	-0.37	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
STAD	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	7.39	1.14e-12	2.83e-09	0.38	0.37	Height;	chr11:118808920	chr11:118688039~118690600:-
STAD	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	7.39	1.15e-12	2.84e-09	0.52	0.37	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	7.39	1.15e-12	2.84e-09	0.52	0.37	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	7.39	1.15e-12	2.84e-09	0.52	0.37	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
STAD	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	7.38	1.16e-12	2.86e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	7.38	1.16e-12	2.86e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	7.38	1.16e-12	2.86e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	7.38	1.16e-12	2.86e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	7.38	1.16e-12	2.86e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	7.38	1.16e-12	2.86e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
STAD	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	7.38	1.16e-12	2.86e-09	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
STAD	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-7.38	1.16e-12	2.88e-09	-0.43	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
STAD	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-7.38	1.17e-12	2.9e-09	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
STAD	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-7.38	1.18e-12	2.92e-09	-0.54	-0.37	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
STAD	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	7.38	1.18e-12	2.92e-09	0.44	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	7.38	1.18e-12	2.92e-09	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
STAD	cis	rs611744	0.967	rs630492	ENSG00000253754.1	RP11-35G22.1	7.38	1.19e-12	2.95e-09	0.31	0.37	Dupuytren's disease;	chr8:108203139	chr8:108226200~108227544:+
STAD	cis	rs2412819	0.559	rs8040336	ENSG00000249839.1	AC011330.5	-7.38	1.2e-12	2.97e-09	-0.43	-0.37	Lung cancer;	chr15:43761419	chr15:43663654~43684339:-
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	7.38	1.21e-12	2.99e-09	0.42	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
STAD	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-7.37	1.23e-12	3.04e-09	-0.42	-0.37	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
STAD	cis	rs6456156	0.967	rs150108	ENSG00000265828.1	MIR3939	-7.37	1.23e-12	3.04e-09	-0.41	-0.37	Primary biliary cholangitis;	chr6:167099665	chr6:166997807~166997912:-
STAD	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-7.37	1.25e-12	3.07e-09	-0.35	-0.37	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
STAD	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	7.37	1.26e-12	3.1e-09	0.44	0.37	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
STAD	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	7.37	1.26e-12	3.11e-09	0.52	0.37	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
STAD	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	7.37	1.26e-12	3.12e-09	0.49	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
STAD	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-7.37	1.27e-12	3.12e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-7.37	1.27e-12	3.12e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-7.37	1.27e-12	3.12e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-7.37	1.27e-12	3.12e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-7.37	1.27e-12	3.12e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-7.37	1.27e-12	3.12e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.917	rs7155356	ENSG00000211970.3	IGHV4-61	-7.37	1.27e-12	3.13e-09	-0.32	-0.37	Kawasaki disease;	chr14:106697376	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.917	rs10137601	ENSG00000211970.3	IGHV4-61	-7.37	1.27e-12	3.13e-09	-0.32	-0.37	Kawasaki disease;	chr14:106697476	chr14:106639119~106639657:-
STAD	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	7.37	1.28e-12	3.15e-09	0.42	0.37	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
STAD	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	7.37	1.28e-12	3.15e-09	0.42	0.37	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
STAD	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-7.37	1.29e-12	3.19e-09	-0.52	-0.37	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
STAD	cis	rs1426063	0.614	rs77625282	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75089646	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs75112697	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75089725	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs7684790	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75090873	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs78046076	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75091818	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs74670563	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75094656	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs115338890	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75094719	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.541	rs116304289	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75095072	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs76204704	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75097804	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs80030693	ENSG00000248165.1	RP11-44F21.2	7.37	1.3e-12	3.19e-09	0.83	0.37	QT interval;	chr4:75099929	chr4:74993877~75034824:-
STAD	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-7.37	1.3e-12	3.21e-09	-0.41	-0.37	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
STAD	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-7.36	1.31e-12	3.22e-09	-0.45	-0.37	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
STAD	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-7.36	1.32e-12	3.23e-09	-0.42	-0.37	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	7.36	1.32e-12	3.25e-09	0.44	0.37	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	7.36	1.32e-12	3.25e-09	0.44	0.37	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
STAD	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-7.36	1.32e-12	3.25e-09	-0.42	-0.37	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
STAD	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	7.36	1.32e-12	3.25e-09	0.56	0.37	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
STAD	cis	rs9368481	0.761	rs4358615	ENSG00000243307.2	POM121L6P	7.36	1.34e-12	3.3e-09	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26896952~26898777:+
STAD	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	7.36	1.35e-12	3.31e-09	0.47	0.37	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
STAD	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-7.36	1.35e-12	3.32e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
STAD	cis	rs1426063	0.614	rs76093954	ENSG00000248165.1	RP11-44F21.2	7.36	1.35e-12	3.32e-09	0.84	0.37	QT interval;	chr4:75087994	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs114977200	ENSG00000248165.1	RP11-44F21.2	7.36	1.35e-12	3.32e-09	0.84	0.37	QT interval;	chr4:75088736	chr4:74993877~75034824:-
STAD	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	7.36	1.36e-12	3.33e-09	0.47	0.37	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
STAD	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-7.36	1.36e-12	3.34e-09	-0.55	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
STAD	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-7.36	1.36e-12	3.34e-09	-0.46	-0.37	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
STAD	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-7.36	1.37e-12	3.36e-09	-0.39	-0.37	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
STAD	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	7.36	1.38e-12	3.38e-09	0.4	0.37	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
STAD	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	7.36	1.39e-12	3.4e-09	0.52	0.37	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
STAD	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-7.35	1.4e-12	3.43e-09	-0.47	-0.37	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-7.35	1.4e-12	3.43e-09	-0.47	-0.37	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
STAD	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-7.35	1.4e-12	3.43e-09	-0.47	-0.37	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-7.35	1.4e-12	3.43e-09	-0.47	-0.37	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-7.35	1.4e-12	3.43e-09	-0.47	-0.37	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-7.35	1.4e-12	3.43e-09	-0.47	-0.37	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
STAD	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-7.35	1.4e-12	3.43e-09	-0.47	-0.37	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	7.35	1.4e-12	3.43e-09	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
STAD	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	7.35	1.42e-12	3.49e-09	0.49	0.37	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
STAD	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	7.35	1.43e-12	3.5e-09	0.42	0.37	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
STAD	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-7.35	1.43e-12	3.5e-09	-0.53	-0.37	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
STAD	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	7.35	1.44e-12	3.52e-09	0.44	0.37	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
STAD	cis	rs3093024	1	rs3093023	ENSG00000265828.1	MIR3939	7.35	1.44e-12	3.52e-09	0.4	0.37	Rheumatoid arthritis;	chr6:167120802	chr6:166997807~166997912:-
STAD	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	7.35	1.44e-12	3.52e-09	0.39	0.37	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
STAD	cis	rs1426063	0.614	rs7671634	ENSG00000248165.1	RP11-44F21.2	7.35	1.44e-12	3.53e-09	0.84	0.37	QT interval;	chr4:75090883	chr4:74993877~75034824:-
STAD	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	7.35	1.44e-12	3.53e-09	0.35	0.37	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
STAD	cis	rs1426063	0.541	rs58959724	ENSG00000248165.1	RP11-44F21.2	7.35	1.45e-12	3.54e-09	0.83	0.37	QT interval;	chr4:75073543	chr4:74993877~75034824:-
STAD	cis	rs11903757	1	rs13416906	ENSG00000281467.1	Clostridiales-1	-7.35	1.45e-12	3.54e-09	-0.6	-0.37	Colorectal cancer;	chr2:191722103	chr2:191699476~191699631:-
STAD	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	7.35	1.45e-12	3.55e-09	0.44	0.37	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
STAD	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-7.35	1.45e-12	3.55e-09	-0.43	-0.37	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
STAD	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	7.35	1.45e-12	3.55e-09	0.44	0.37	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
STAD	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	7.35	1.46e-12	3.57e-09	0.53	0.37	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
STAD	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	7.35	1.47e-12	3.6e-09	0.73	0.37	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	7.35	1.47e-12	3.6e-09	0.73	0.37	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
STAD	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-7.35	1.49e-12	3.63e-09	-0.51	-0.37	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
STAD	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	7.34	1.49e-12	3.64e-09	0.44	0.37	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
STAD	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	7.34	1.49e-12	3.64e-09	0.42	0.37	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
STAD	cis	rs10129255	0.917	rs11625208	ENSG00000211970.3	IGHV4-61	-7.34	1.5e-12	3.66e-09	-0.32	-0.37	Kawasaki disease;	chr14:106698757	chr14:106639119~106639657:-
STAD	cis	rs611744	0.87	rs2212703	ENSG00000253754.1	RP11-35G22.1	-7.34	1.51e-12	3.68e-09	-0.32	-0.37	Dupuytren's disease;	chr8:108186172	chr8:108226200~108227544:+
STAD	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	7.34	1.51e-12	3.68e-09	0.32	0.37	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
STAD	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	7.34	1.52e-12	3.71e-09	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
STAD	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-7.34	1.52e-12	3.71e-09	-0.36	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
STAD	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	7.34	1.53e-12	3.72e-09	0.32	0.37	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
STAD	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-7.34	1.53e-12	3.74e-09	-0.53	-0.37	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
STAD	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-7.34	1.55e-12	3.77e-09	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
STAD	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	7.34	1.55e-12	3.78e-09	0.54	0.37	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
STAD	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	7.34	1.55e-12	3.78e-09	0.41	0.37	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
STAD	cis	rs9467773	0.511	rs11755443	ENSG00000243307.2	POM121L6P	7.34	1.56e-12	3.79e-09	0.36	0.37	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26896952~26898777:+
STAD	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-7.34	1.56e-12	3.8e-09	-0.41	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
STAD	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-7.34	1.56e-12	3.8e-09	-0.4	-0.37	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-7.34	1.57e-12	3.82e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-7.34	1.57e-12	3.82e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-7.34	1.57e-12	3.82e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-7.34	1.57e-12	3.82e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
STAD	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-7.34	1.58e-12	3.83e-09	-0.43	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
STAD	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-7.34	1.58e-12	3.83e-09	-0.43	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
STAD	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-7.34	1.58e-12	3.83e-09	-0.43	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
STAD	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-7.34	1.58e-12	3.84e-09	-0.41	-0.37	Height;	chr3:53052712	chr3:53064283~53065091:-
STAD	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-7.34	1.59e-12	3.86e-09	-0.45	-0.37	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
STAD	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	7.33	1.59e-12	3.87e-09	0.46	0.37	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
STAD	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-7.33	1.59e-12	3.87e-09	-0.56	-0.37	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
STAD	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-7.33	1.59e-12	3.88e-09	-0.46	-0.37	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
STAD	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	7.33	1.59e-12	3.88e-09	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
STAD	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	7.33	1.6e-12	3.89e-09	0.47	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
STAD	cis	rs611744	0.905	rs421695	ENSG00000253754.1	RP11-35G22.1	-7.33	1.61e-12	3.91e-09	-0.32	-0.37	Dupuytren's disease;	chr8:108105175	chr8:108226200~108227544:+
STAD	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-7.33	1.62e-12	3.93e-09	-0.55	-0.37	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
STAD	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.33	1.64e-12	3.98e-09	-0.36	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
STAD	cis	rs1426063	0.614	rs6534447	ENSG00000248165.1	RP11-44F21.2	-7.33	1.65e-12	4e-09	-0.79	-0.37	QT interval;	chr4:75080682	chr4:74993877~75034824:-
STAD	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-7.33	1.65e-12	4e-09	-0.39	-0.37	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
STAD	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	7.33	1.65e-12	4.02e-09	0.4	0.37	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
STAD	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	7.33	1.67e-12	4.06e-09	0.55	0.37	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
STAD	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-7.33	1.69e-12	4.11e-09	-0.43	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
STAD	cis	rs2108622	0.64	rs58858790	ENSG00000267453.5	AC004791.2	-7.33	1.69e-12	4.11e-09	-0.42	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15863463	chr19:15851993~15864904:-
STAD	cis	rs2439831	0.85	rs3097773	ENSG00000249839.1	AC011330.5	7.32	1.7e-12	4.13e-09	0.54	0.37	Lung cancer in ever smokers;	chr15:43600874	chr15:43663654~43684339:-
STAD	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	7.32	1.71e-12	4.15e-09	0.48	0.37	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
STAD	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-7.32	1.72e-12	4.17e-09	-0.35	-0.37	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
STAD	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	7.32	1.76e-12	4.27e-09	0.41	0.37	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
STAD	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	7.32	1.76e-12	4.27e-09	0.45	0.37	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
STAD	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	7.32	1.77e-12	4.28e-09	0.5	0.37	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
STAD	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	7.32	1.78e-12	4.32e-09	0.44	0.37	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
STAD	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	7.32	1.78e-12	4.32e-09	0.52	0.37	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	7.32	1.78e-12	4.32e-09	0.52	0.37	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	7.32	1.78e-12	4.32e-09	0.52	0.37	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	7.32	1.78e-12	4.32e-09	0.52	0.37	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
STAD	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-7.32	1.8e-12	4.36e-09	-0.47	-0.37	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
STAD	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-7.32	1.81e-12	4.37e-09	-0.56	-0.37	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
STAD	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-7.31	1.83e-12	4.42e-09	-0.56	-0.37	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
STAD	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-7.31	1.84e-12	4.46e-09	-0.39	-0.37	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
STAD	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	7.31	1.85e-12	4.47e-09	0.46	0.37	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
STAD	cis	rs10885997	0.626	rs4751995	ENSG00000266200.5	PNLIPRP2	7.31	1.88e-12	4.53e-09	0.44	0.37	Phospholipid levels (plasma);	chr10:116638373	chr10:116620953~116645143:+
STAD	cis	rs10885997	0.626	rs4751996	ENSG00000266200.5	PNLIPRP2	7.31	1.88e-12	4.53e-09	0.44	0.37	Phospholipid levels (plasma);	chr10:116638383	chr10:116620953~116645143:+
STAD	cis	rs10885997	0.626	rs7910135	ENSG00000266200.5	PNLIPRP2	7.31	1.88e-12	4.53e-09	0.44	0.37	Phospholipid levels (plasma);	chr10:116638535	chr10:116620953~116645143:+
STAD	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-7.31	1.88e-12	4.55e-09	-0.47	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
STAD	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-7.31	1.88e-12	4.55e-09	-0.47	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
STAD	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	7.31	1.9e-12	4.58e-09	0.43	0.37	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
STAD	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	7.31	1.9e-12	4.58e-09	0.43	0.37	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	7.31	1.92e-12	4.63e-09	0.39	0.37	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
STAD	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	7.31	1.92e-12	4.64e-09	0.4	0.37	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
STAD	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	7.31	1.92e-12	4.64e-09	0.4	0.37	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
STAD	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.3	1.94e-12	4.67e-09	-0.35	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	7.3	1.94e-12	4.68e-09	0.42	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
STAD	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	7.3	1.94e-12	4.68e-09	0.51	0.37	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
STAD	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	7.3	1.95e-12	4.71e-09	0.35	0.37	Depression;	chr6:28317705	chr6:28176188~28176674:+
STAD	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	7.3	1.95e-12	4.71e-09	0.38	0.37	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
STAD	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	7.3	1.95e-12	4.71e-09	0.47	0.37	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
STAD	cis	rs801193	1	rs2659909	ENSG00000222364.1	RNU6-96P	-7.3	1.98e-12	4.78e-09	-0.41	-0.37	Aortic root size;	chr7:66695292	chr7:66395191~66395286:+
STAD	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-7.3	1.98e-12	4.78e-09	-0.31	-0.37	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
STAD	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-7.3	1.99e-12	4.78e-09	-0.39	-0.37	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-7.3	1.99e-12	4.78e-09	-0.39	-0.37	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
STAD	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-7.3	1.99e-12	4.78e-09	-0.39	-0.37	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-7.3	1.99e-12	4.78e-09	-0.51	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
STAD	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	7.3	1.99e-12	4.79e-09	0.32	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
STAD	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-7.3	1.99e-12	4.8e-09	-0.56	-0.37	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
STAD	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-7.3	2e-12	4.8e-09	-0.45	-0.37	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	7.3	2e-12	4.81e-09	0.42	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
STAD	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-7.3	2.02e-12	4.86e-09	-0.42	-0.37	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
STAD	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	7.3	2.02e-12	4.87e-09	0.52	0.37	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
STAD	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	7.3	2.04e-12	4.9e-09	0.44	0.37	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
STAD	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-7.3	2.04e-12	4.9e-09	-0.4	-0.37	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
STAD	cis	rs12922317	0.556	rs8062691	ENSG00000260224.1	UBL5P4	-7.3	2.05e-12	4.93e-09	-0.38	-0.37	Schizophrenia;	chr16:11997972	chr16:11968508~11968743:-
STAD	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-7.3	2.05e-12	4.93e-09	-0.53	-0.37	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
STAD	cis	rs611744	0.967	rs645070	ENSG00000253754.1	RP11-35G22.1	-7.29	2.06e-12	4.94e-09	-0.32	-0.37	Dupuytren's disease;	chr8:108204116	chr8:108226200~108227544:+
STAD	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-7.29	2.06e-12	4.94e-09	-0.47	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
STAD	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-7.29	2.06e-12	4.94e-09	-0.45	-0.37	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
STAD	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	7.29	2.06e-12	4.95e-09	0.52	0.37	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
STAD	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	7.29	2.06e-12	4.95e-09	0.4	0.37	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-7.29	2.06e-12	4.95e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-7.29	2.06e-12	4.95e-09	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
STAD	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	7.29	2.08e-12	4.99e-09	0.37	0.37	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
STAD	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	7.29	2.09e-12	5.01e-09	0.42	0.37	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
STAD	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-7.29	2.1e-12	5.03e-09	-0.51	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
STAD	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
STAD	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
STAD	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	7.29	2.1e-12	5.03e-09	0.51	0.36	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
STAD	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	7.29	2.15e-12	5.13e-09	0.4	0.36	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
STAD	cis	rs611744	0.967	rs688746	ENSG00000253754.1	RP11-35G22.1	-7.29	2.15e-12	5.13e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108213496	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs609102	ENSG00000253754.1	RP11-35G22.1	-7.29	2.15e-12	5.13e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108215177	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs859788	ENSG00000253754.1	RP11-35G22.1	-7.29	2.15e-12	5.13e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108215341	chr8:108226200~108227544:+
STAD	cis	rs611744	1	rs611744	ENSG00000253754.1	RP11-35G22.1	-7.29	2.15e-12	5.13e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108215779	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs635219	ENSG00000253754.1	RP11-35G22.1	-7.29	2.15e-12	5.13e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108217014	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs608115	ENSG00000253754.1	RP11-35G22.1	-7.29	2.15e-12	5.13e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108219719	chr8:108226200~108227544:+
STAD	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	7.29	2.15e-12	5.13e-09	0.4	0.36	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
STAD	cis	rs611744	0.967	rs475865	ENSG00000253754.1	RP11-35G22.1	-7.29	2.15e-12	5.14e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108223629	chr8:108226200~108227544:+
STAD	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-7.29	2.16e-12	5.16e-09	-0.51	-0.36	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
STAD	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-7.29	2.16e-12	5.16e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
STAD	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	7.29	2.16e-12	5.16e-09	0.4	0.36	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
STAD	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-7.29	2.17e-12	5.18e-09	-0.51	-0.36	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
STAD	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	7.28	2.2e-12	5.25e-09	0.52	0.36	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
STAD	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	7.28	2.2e-12	5.25e-09	0.4	0.36	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
STAD	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-7.28	2.2e-12	5.26e-09	-0.43	-0.36	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
STAD	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-7.28	2.21e-12	5.28e-09	-0.35	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
STAD	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-7.28	2.22e-12	5.29e-09	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-7.28	2.22e-12	5.29e-09	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
STAD	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-7.28	2.22e-12	5.3e-09	-0.43	-0.36	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
STAD	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	7.28	2.24e-12	5.34e-09	0.51	0.36	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
STAD	cis	rs611744	0.934	rs1452021	ENSG00000253754.1	RP11-35G22.1	-7.28	2.25e-12	5.36e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108195657	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs682007	ENSG00000253754.1	RP11-35G22.1	-7.28	2.25e-12	5.36e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108198097	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs682954	ENSG00000253754.1	RP11-35G22.1	-7.28	2.25e-12	5.36e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108198330	chr8:108226200~108227544:+
STAD	cis	rs611744	0.836	rs684412	ENSG00000253754.1	RP11-35G22.1	-7.28	2.25e-12	5.36e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108198676	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs650437	ENSG00000253754.1	RP11-35G22.1	-7.28	2.25e-12	5.36e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108198698	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs650968	ENSG00000253754.1	RP11-35G22.1	-7.28	2.25e-12	5.36e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108198826	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs603571	ENSG00000253754.1	RP11-35G22.1	-7.28	2.25e-12	5.36e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108201664	chr8:108226200~108227544:+
STAD	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-7.28	2.25e-12	5.37e-09	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
STAD	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-7.28	2.26e-12	5.39e-09	-0.43	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
STAD	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	7.28	2.28e-12	5.43e-09	0.41	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	7.28	2.28e-12	5.43e-09	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
STAD	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-7.28	2.3e-12	5.47e-09	-0.39	-0.36	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
STAD	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-7.28	2.32e-12	5.52e-09	-0.42	-0.36	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
STAD	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	7.28	2.33e-12	5.54e-09	0.44	0.36	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
STAD	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	7.27	2.34e-12	5.56e-09	0.49	0.36	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
STAD	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	7.27	2.35e-12	5.59e-09	0.43	0.36	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
STAD	cis	rs6456156	1	rs6911766	ENSG00000265828.1	MIR3939	7.27	2.35e-12	5.59e-09	0.4	0.36	Primary biliary cholangitis;	chr6:167109682	chr6:166997807~166997912:-
STAD	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	7.27	2.36e-12	5.6e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	7.27	2.36e-12	5.6e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
STAD	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	7.27	2.39e-12	5.68e-09	0.43	0.36	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
STAD	cis	rs611744	0.967	rs702802	ENSG00000253754.1	RP11-35G22.1	-7.27	2.4e-12	5.7e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108206009	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs681099	ENSG00000253754.1	RP11-35G22.1	-7.27	2.4e-12	5.7e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108206663	chr8:108226200~108227544:+
STAD	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-7.27	2.41e-12	5.72e-09	-0.4	-0.36	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
STAD	cis	rs8040855	0.965	rs11073990	ENSG00000229212.6	RP11-561C5.4	7.27	2.43e-12	5.75e-09	0.49	0.36	Bulimia nervosa;	chr15:85168070	chr15:85205440~85234795:-
STAD	cis	rs611744	0.967	rs2597654	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108208861	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs662714	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108209430	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs627019	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108210315	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs603889	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108212003	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs672408	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108212161	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs641721	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108217911	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs653081	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108218154	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs536860	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.79e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108218493	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs686630	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108221010	chr8:108226200~108227544:+
STAD	cis	rs611744	0.752	rs609197	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108221806	chr8:108226200~108227544:+
STAD	cis	rs611744	0.901	rs639746	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108222596	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs636399	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108223340	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs637626	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108223556	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs702805	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108223700	chr8:108226200~108227544:+
STAD	cis	rs611744	0.934	rs604698	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108226492	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs569701	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108226978	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs695028	ENSG00000253754.1	RP11-35G22.1	-7.27	2.45e-12	5.8e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108227095	chr8:108226200~108227544:+
STAD	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-7.27	2.45e-12	5.8e-09	-0.4	-0.36	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
STAD	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-7.27	2.47e-12	5.84e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
STAD	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	7.27	2.49e-12	5.89e-09	0.53	0.36	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	7.27	2.49e-12	5.89e-09	0.53	0.36	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	7.27	2.49e-12	5.89e-09	0.53	0.36	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
STAD	cis	rs611744	0.967	rs639059	ENSG00000253754.1	RP11-35G22.1	-7.26	2.51e-12	5.92e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108223890	chr8:108226200~108227544:+
STAD	cis	rs611744	0.846	rs405534	ENSG00000253754.1	RP11-35G22.1	-7.26	2.51e-12	5.93e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108142180	chr8:108226200~108227544:+
STAD	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	7.26	2.51e-12	5.94e-09	0.38	0.36	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
STAD	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-7.26	2.53e-12	5.98e-09	-0.39	-0.36	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
STAD	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.26	2.53e-12	5.99e-09	0.36	0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
STAD	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-7.26	2.54e-12	6e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
STAD	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	7.26	2.55e-12	6.01e-09	0.42	0.36	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
STAD	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	7.26	2.55e-12	6.03e-09	0.4	0.36	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
STAD	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	7.26	2.55e-12	6.03e-09	0.4	0.36	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
STAD	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-7.26	2.56e-12	6.04e-09	-0.44	-0.36	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
STAD	cis	rs2143950	0.765	rs17113838	ENSG00000241052.1	RP11-173D9.1	-7.26	2.56e-12	6.04e-09	-0.47	-0.36	Atopic dermatitis;	chr14:35235461	chr14:35144021~35144480:-
STAD	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	7.26	2.56e-12	6.04e-09	0.47	0.36	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
STAD	cis	rs611744	0.967	rs662591	ENSG00000253754.1	RP11-35G22.1	-7.26	2.56e-12	6.04e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108199129	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs702801	ENSG00000253754.1	RP11-35G22.1	-7.26	2.56e-12	6.04e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108199573	chr8:108226200~108227544:+
STAD	cis	rs611744	0.967	rs677842	ENSG00000253754.1	RP11-35G22.1	-7.26	2.56e-12	6.04e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108200239	chr8:108226200~108227544:+
STAD	cis	rs611744	0.935	rs661036	ENSG00000253754.1	RP11-35G22.1	-7.26	2.56e-12	6.04e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108200859	chr8:108226200~108227544:+
STAD	cis	rs11089937	0.626	rs5757017	ENSG00000211639.2	IGLV4-60	7.26	2.58e-12	6.08e-09	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.568	rs59356111	ENSG00000211639.2	IGLV4-60	7.26	2.58e-12	6.08e-09	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs5757019	ENSG00000211639.2	IGLV4-60	7.26	2.58e-12	6.08e-09	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22162199~22162681:+
STAD	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	7.26	2.58e-12	6.09e-09	0.49	0.36	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
STAD	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	7.26	2.59e-12	6.1e-09	0.4	0.36	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
STAD	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	7.26	2.59e-12	6.11e-09	0.47	0.36	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
STAD	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	7.26	2.6e-12	6.13e-09	0.47	0.36	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
STAD	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	7.26	2.61e-12	6.15e-09	0.4	0.36	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
STAD	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	7.26	2.61e-12	6.15e-09	0.48	0.36	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
STAD	cis	rs11903757	1	rs78345298	ENSG00000281467.1	Clostridiales-1	-7.26	2.61e-12	6.16e-09	-0.58	-0.36	Colorectal cancer;	chr2:191700286	chr2:191699476~191699631:-
STAD	cis	rs11903757	1	rs77127860	ENSG00000281467.1	Clostridiales-1	-7.26	2.61e-12	6.16e-09	-0.58	-0.36	Colorectal cancer;	chr2:191700674	chr2:191699476~191699631:-
STAD	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	7.26	2.61e-12	6.16e-09	0.49	0.36	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
STAD	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	7.26	2.62e-12	6.17e-09	0.43	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
STAD	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	7.26	2.62e-12	6.18e-09	0.52	0.36	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
STAD	cis	rs13217239	0.646	rs7451149	ENSG00000243307.2	POM121L6P	-7.26	2.63e-12	6.2e-09	-0.35	-0.36	Schizophrenia;	chr6:27089739	chr6:26896952~26898777:+
STAD	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	7.26	2.63e-12	6.2e-09	0.53	0.36	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	7.26	2.63e-12	6.2e-09	0.53	0.36	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	7.26	2.63e-12	6.2e-09	0.53	0.36	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
STAD	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	7.26	2.63e-12	6.2e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	7.26	2.63e-12	6.2e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
STAD	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	7.26	2.64e-12	6.22e-09	0.45	0.36	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
STAD	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-7.25	2.66e-12	6.27e-09	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
STAD	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	7.25	2.67e-12	6.27e-09	0.51	0.36	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	7.25	2.67e-12	6.27e-09	0.51	0.36	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
STAD	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-7.25	2.68e-12	6.31e-09	-0.4	-0.36	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
STAD	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	7.25	2.68e-12	6.32e-09	0.35	0.36	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
STAD	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	7.25	2.68e-12	6.32e-09	0.35	0.36	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
STAD	cis	rs801193	1	rs2420824	ENSG00000222364.1	RNU6-96P	7.25	2.7e-12	6.35e-09	0.41	0.36	Aortic root size;	chr7:66666129	chr7:66395191~66395286:+
STAD	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	7.25	2.7e-12	6.36e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	7.25	2.7e-12	6.36e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
STAD	cis	rs2439831	0.867	rs2260160	ENSG00000249839.1	AC011330.5	-7.25	2.71e-12	6.36e-09	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43603445	chr15:43663654~43684339:-
STAD	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-7.25	2.71e-12	6.37e-09	-0.39	-0.36	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
STAD	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	7.25	2.71e-12	6.37e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
STAD	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-7.25	2.73e-12	6.41e-09	-0.51	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-7.25	2.73e-12	6.41e-09	-0.51	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
STAD	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-7.25	2.73e-12	6.41e-09	-0.37	-0.36	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
STAD	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	7.25	2.73e-12	6.42e-09	0.31	0.36	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
STAD	cis	rs611744	0.816	rs626211	ENSG00000253754.1	RP11-35G22.1	-7.25	2.75e-12	6.47e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108177219	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs650925	ENSG00000253754.1	RP11-35G22.1	-7.25	2.75e-12	6.47e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108184496	chr8:108226200~108227544:+
STAD	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-7.25	2.76e-12	6.48e-09	-0.55	-0.36	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
STAD	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	7.25	2.77e-12	6.52e-09	0.28	0.36	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
STAD	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	7.25	2.78e-12	6.52e-09	0.43	0.36	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	7.25	2.78e-12	6.52e-09	0.43	0.36	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	7.25	2.78e-12	6.52e-09	0.43	0.36	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
STAD	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-7.25	2.81e-12	6.58e-09	-0.43	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
STAD	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-7.25	2.81e-12	6.59e-09	-0.43	-0.36	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
STAD	cis	rs11903757	1	rs78934362	ENSG00000281467.1	Clostridiales-1	-7.25	2.81e-12	6.59e-09	-0.58	-0.36	Colorectal cancer;	chr2:191701161	chr2:191699476~191699631:-
STAD	cis	rs611744	0.686	rs424976	ENSG00000253754.1	RP11-35G22.1	-7.25	2.81e-12	6.59e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108108592	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs416611	ENSG00000253754.1	RP11-35G22.1	-7.25	2.81e-12	6.59e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108112365	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs371878	ENSG00000253754.1	RP11-35G22.1	-7.25	2.81e-12	6.59e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108118392	chr8:108226200~108227544:+
STAD	cis	rs611744	0.805	rs453634	ENSG00000253754.1	RP11-35G22.1	-7.25	2.81e-12	6.59e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108122873	chr8:108226200~108227544:+
STAD	cis	rs611744	0.659	rs669584	ENSG00000253754.1	RP11-35G22.1	-7.25	2.81e-12	6.59e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108125879	chr8:108226200~108227544:+
STAD	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	7.24	2.84e-12	6.66e-09	0.58	0.36	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
STAD	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-7.24	2.85e-12	6.67e-09	-0.4	-0.36	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
STAD	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	7.24	2.86e-12	6.71e-09	0.44	0.36	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
STAD	cis	rs9457247	0.508	rs9459874	ENSG00000265828.1	MIR3939	7.24	2.87e-12	6.73e-09	0.41	0.36	Crohn's disease;	chr6:167090639	chr6:166997807~166997912:-
STAD	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-7.24	2.88e-12	6.73e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
STAD	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	7.24	2.89e-12	6.76e-09	0.48	0.36	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
STAD	cis	rs2143950	0.749	rs57275892	ENSG00000241052.1	RP11-173D9.1	-7.24	2.9e-12	6.78e-09	-0.46	-0.36	Atopic dermatitis;	chr14:35278065	chr14:35144021~35144480:-
STAD	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	7.24	2.9e-12	6.79e-09	0.28	0.36	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	7.24	2.9e-12	6.79e-09	0.28	0.36	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	7.24	2.9e-12	6.79e-09	0.28	0.36	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
STAD	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	7.24	2.91e-12	6.81e-09	0.35	0.36	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
STAD	cis	rs611744	0.967	rs584555	ENSG00000253754.1	RP11-35G22.1	-7.24	2.93e-12	6.85e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108206383	chr8:108226200~108227544:+
STAD	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-7.24	2.93e-12	6.86e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-7.24	2.93e-12	6.86e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-7.24	2.93e-12	6.86e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-7.24	2.93e-12	6.86e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-7.24	2.93e-12	6.86e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-7.24	2.93e-12	6.86e-09	-0.41	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
STAD	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-7.24	2.97e-12	6.94e-09	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
STAD	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-7.24	2.98e-12	6.96e-09	-0.41	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
STAD	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	7.24	2.98e-12	6.96e-09	0.35	0.36	Depression;	chr6:28323463	chr6:28176188~28176674:+
STAD	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	7.24	2.99e-12	6.98e-09	0.53	0.36	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	7.24	2.99e-12	6.98e-09	0.53	0.36	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
STAD	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-7.24	2.99e-12	6.98e-09	-0.42	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
STAD	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-7.24	2.99e-12	6.98e-09	-0.42	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
STAD	cis	rs611744	0.935	rs679077	ENSG00000253754.1	RP11-35G22.1	-7.24	2.99e-12	6.99e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108232513	chr8:108226200~108227544:+
STAD	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	7.23	3.04e-12	7.1e-09	0.43	0.36	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
STAD	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-7.23	3.05e-12	7.12e-09	-0.44	-0.36	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
STAD	cis	rs611744	0.905	rs677031	ENSG00000253754.1	RP11-35G22.1	-7.23	3.07e-12	7.16e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108139840	chr8:108226200~108227544:+
STAD	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-7.23	3.08e-12	7.2e-09	-0.54	-0.36	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
STAD	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	7.23	3.11e-12	7.24e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	7.23	3.11e-12	7.24e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	7.23	3.11e-12	7.24e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	7.23	3.11e-12	7.24e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
STAD	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	7.23	3.11e-12	7.24e-09	0.51	0.36	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
STAD	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	7.23	3.12e-12	7.27e-09	0.47	0.36	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
STAD	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-7.23	3.12e-12	7.27e-09	-0.41	-0.36	Height;	chr3:53097932	chr3:53064283~53065091:-
STAD	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	7.23	3.13e-12	7.29e-09	0.43	0.36	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	7.23	3.14e-12	7.31e-09	0.42	0.36	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
STAD	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	7.23	3.14e-12	7.31e-09	0.39	0.36	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-7.23	3.16e-12	7.35e-09	-0.47	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
STAD	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	7.23	3.17e-12	7.37e-09	0.43	0.36	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
STAD	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	7.23	3.17e-12	7.39e-09	0.41	0.36	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
STAD	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	7.23	3.18e-12	7.4e-09	0.51	0.36	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
STAD	cis	rs2283792	0.792	rs151680	ENSG00000228050.1	TOP3BP1	7.23	3.19e-12	7.43e-09	0.4	0.36	Multiple sclerosis;	chr22:21918869	chr22:22223187~22224566:-
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-7.23	3.2e-12	7.46e-09	-0.41	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
STAD	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	7.23	3.21e-12	7.47e-09	0.5	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
STAD	cis	rs611744	0.967	rs678387	ENSG00000253754.1	RP11-35G22.1	-7.22	3.25e-12	7.55e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108230501	chr8:108226200~108227544:+
STAD	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	7.22	3.27e-12	7.61e-09	0.28	0.36	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
STAD	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	7.22	3.29e-12	7.66e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
STAD	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	7.22	3.32e-12	7.72e-09	0.5	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
STAD	cis	rs611744	0.81	rs619227	ENSG00000253754.1	RP11-35G22.1	-7.22	3.33e-12	7.74e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108202871	chr8:108226200~108227544:+
STAD	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	7.22	3.35e-12	7.8e-09	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
STAD	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-7.22	3.37e-12	7.82e-09	-0.46	-0.36	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
STAD	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-7.22	3.37e-12	7.83e-09	-0.42	-0.36	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
STAD	cis	rs611744	0.967	rs652485	ENSG00000253754.1	RP11-35G22.1	-7.22	3.39e-12	7.86e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108190467	chr8:108226200~108227544:+
STAD	cis	rs11903757	0.945	rs76571691	ENSG00000281467.1	Clostridiales-1	-7.22	3.39e-12	7.87e-09	-0.59	-0.36	Colorectal cancer;	chr2:191693665	chr2:191699476~191699631:-
STAD	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	7.22	3.4e-12	7.89e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
STAD	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	7.22	3.4e-12	7.89e-09	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
STAD	cis	rs9467773	0.511	rs17278688	ENSG00000243307.2	POM121L6P	7.22	3.41e-12	7.92e-09	0.35	0.36	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26896952~26898777:+
STAD	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-7.22	3.41e-12	7.92e-09	-0.43	-0.36	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
STAD	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	7.21	3.47e-12	8.05e-09	0.37	0.36	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
STAD	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	7.21	3.49e-12	8.09e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
STAD	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	7.21	3.49e-12	8.09e-09	0.42	0.36	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
STAD	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-7.21	3.5e-12	8.11e-09	-0.41	-0.36	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
STAD	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	7.21	3.54e-12	8.19e-09	0.37	0.36	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
STAD	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	7.21	3.57e-12	8.26e-09	0.41	0.36	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
STAD	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	7.21	3.58e-12	8.29e-09	0.46	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
STAD	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	7.21	3.58e-12	8.3e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
STAD	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	7.21	3.61e-12	8.36e-09	0.41	0.36	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	7.21	3.62e-12	8.37e-09	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
STAD	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-7.21	3.63e-12	8.39e-09	-0.41	-0.36	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
STAD	cis	rs7714584	0.793	rs11949375	ENSG00000197083.10	ZNF300P1	7.2	3.69e-12	8.53e-09	0.51	0.36	Crohn's disease;	chr5:150823418	chr5:150930645~150946289:-
STAD	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	7.2	3.7e-12	8.56e-09	0.4	0.36	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
STAD	cis	rs11089937	0.597	rs5750579	ENSG00000211639.2	IGLV4-60	7.2	3.72e-12	8.6e-09	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.597	rs11089925	ENSG00000211639.2	IGLV4-60	7.2	3.72e-12	8.6e-09	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22162199~22162681:+
STAD	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	7.2	3.73e-12	8.63e-09	0.43	0.36	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	7.2	3.73e-12	8.63e-09	0.43	0.36	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
STAD	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-7.2	3.74e-12	8.65e-09	-0.5	-0.36	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
STAD	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	7.2	3.78e-12	8.73e-09	0.45	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
STAD	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-7.2	3.78e-12	8.73e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
STAD	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-7.2	3.8e-12	8.77e-09	-0.41	-0.36	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
STAD	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-7.2	3.82e-12	8.82e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
STAD	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	7.2	3.84e-12	8.86e-09	0.49	0.36	Cancer;	chr7:142407435	chr7:142554836~142555318:+
STAD	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-7.2	3.89e-12	8.96e-09	-0.55	-0.36	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
STAD	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	7.2	3.89e-12	8.96e-09	0.45	0.36	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
STAD	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	7.2	3.9e-12	8.99e-09	0.46	0.36	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
STAD	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-7.2	3.9e-12	8.99e-09	-0.54	-0.36	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
STAD	cis	rs611744	0.967	rs602384	ENSG00000253754.1	RP11-35G22.1	-7.19	3.93e-12	9.05e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108175956	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs57723916	ENSG00000253754.1	RP11-35G22.1	-7.19	3.93e-12	9.05e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108179204	chr8:108226200~108227544:+
STAD	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-7.19	3.96e-12	9.11e-09	-0.38	-0.36	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
STAD	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-7.19	3.96e-12	9.12e-09	-0.42	-0.36	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
STAD	cis	rs611744	0.87	rs635941	ENSG00000253754.1	RP11-35G22.1	-7.19	3.97e-12	9.15e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108223228	chr8:108226200~108227544:+
STAD	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.19	3.99e-12	9.2e-09	-0.35	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
STAD	cis	rs611744	0.87	rs685358	ENSG00000253754.1	RP11-35G22.1	-7.19	4.02e-12	9.26e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108149184	chr8:108226200~108227544:+
STAD	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-7.19	4.09e-12	9.4e-09	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
STAD	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	7.19	4.1e-12	9.42e-09	0.47	0.36	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
STAD	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	7.19	4.11e-12	9.44e-09	0.34	0.36	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
STAD	cis	rs11089937	0.626	rs5757011	ENSG00000211639.2	IGLV4-60	7.19	4.11e-12	9.44e-09	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22162199~22162681:+
STAD	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	7.19	4.11e-12	9.45e-09	0.37	0.36	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
STAD	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	7.19	4.13e-12	9.48e-09	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
STAD	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.19	4.13e-12	9.49e-09	-0.35	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
STAD	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-7.19	4.15e-12	9.53e-09	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
STAD	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	7.18	4.17e-12	9.56e-09	0.39	0.36	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
STAD	cis	rs11089937	0.597	rs9619793	ENSG00000211639.2	IGLV4-60	7.18	4.17e-12	9.58e-09	0.39	0.36	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.568	rs5756988	ENSG00000211639.2	IGLV4-60	-7.18	4.18e-12	9.59e-09	-0.39	-0.36	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22162199~22162681:+
STAD	cis	rs611744	0.967	rs673854	ENSG00000253754.1	RP11-35G22.1	-7.18	4.19e-12	9.6e-09	-0.32	-0.36	Dupuytren's disease;	chr8:108179609	chr8:108226200~108227544:+
STAD	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-7.18	4.21e-12	9.66e-09	-0.41	-0.36	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
STAD	cis	rs11089937	0.597	rs4821772	ENSG00000211639.2	IGLV4-60	-7.18	4.23e-12	9.69e-09	-0.39	-0.36	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22162199~22162681:+
STAD	cis	rs611744	0.805	rs396149	ENSG00000253754.1	RP11-35G22.1	-7.18	4.23e-12	9.7e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108096512	chr8:108226200~108227544:+
STAD	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-7.18	4.25e-12	9.75e-09	-0.37	-0.36	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
STAD	cis	rs58873874	0.522	rs6875379	ENSG00000251405.2	CTB-109A12.1	7.18	4.3e-12	9.84e-09	0.54	0.36	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157362615~157460078:-
STAD	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	7.18	4.3e-12	9.86e-09	0.36	0.36	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
STAD	cis	rs611744	0.87	rs429884	ENSG00000253754.1	RP11-35G22.1	-7.18	4.3e-12	9.86e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108102894	chr8:108226200~108227544:+
STAD	cis	rs611744	0.837	rs438191	ENSG00000253754.1	RP11-35G22.1	-7.18	4.3e-12	9.86e-09	-0.31	-0.36	Dupuytren's disease;	chr8:108111994	chr8:108226200~108227544:+
STAD	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-7.18	4.33e-12	9.91e-09	-0.44	-0.36	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
STAD	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-7.18	4.37e-12	1e-08	-0.45	-0.36	Height;	chr6:109531713	chr6:109382795~109383666:+
STAD	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	7.18	4.38e-12	1e-08	0.3	0.36	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
STAD	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-7.18	4.4e-12	1.01e-08	-0.61	-0.36	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
STAD	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-7.18	4.4e-12	1.01e-08	-0.61	-0.36	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
STAD	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-7.17	4.55e-12	1.04e-08	-0.51	-0.36	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
STAD	cis	rs13217239	0.572	rs9379958	ENSG00000243307.2	POM121L6P	-7.17	4.59e-12	1.05e-08	-0.35	-0.36	Schizophrenia;	chr6:27098384	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs9393789	ENSG00000243307.2	POM121L6P	-7.17	4.59e-12	1.05e-08	-0.35	-0.36	Schizophrenia;	chr6:27099249	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs6456767	ENSG00000243307.2	POM121L6P	-7.17	4.59e-12	1.05e-08	-0.35	-0.36	Schizophrenia;	chr6:27102764	chr6:26896952~26898777:+
STAD	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-7.17	4.66e-12	1.06e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
STAD	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	7.17	4.7e-12	1.07e-08	0.41	0.36	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
STAD	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	7.17	4.7e-12	1.07e-08	0.41	0.36	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
STAD	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	7.17	4.7e-12	1.07e-08	0.41	0.36	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
STAD	cis	rs11089937	0.626	rs5757013	ENSG00000211639.2	IGLV4-60	7.17	4.71e-12	1.07e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs5757014	ENSG00000211639.2	IGLV4-60	7.17	4.71e-12	1.07e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22162199~22162681:+
STAD	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-7.17	4.71e-12	1.07e-08	-0.35	-0.36	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-7.17	4.71e-12	1.07e-08	-0.35	-0.36	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
STAD	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	7.16	4.72e-12	1.08e-08	0.44	0.36	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
STAD	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	7.16	4.73e-12	1.08e-08	0.36	0.36	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	7.16	4.73e-12	1.08e-08	0.36	0.36	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	7.16	4.73e-12	1.08e-08	0.36	0.36	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	7.16	4.73e-12	1.08e-08	0.36	0.36	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
STAD	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	7.16	4.74e-12	1.08e-08	0.34	0.36	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
STAD	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-7.16	4.75e-12	1.08e-08	-0.53	-0.36	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	7.16	4.76e-12	1.08e-08	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
STAD	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	7.16	4.77e-12	1.09e-08	0.41	0.36	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
STAD	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	7.16	4.78e-12	1.09e-08	0.36	0.36	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	7.16	4.78e-12	1.09e-08	0.36	0.36	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
STAD	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	7.16	4.78e-12	1.09e-08	0.36	0.36	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
STAD	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	7.16	4.79e-12	1.09e-08	0.45	0.36	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
STAD	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-7.16	4.8e-12	1.09e-08	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-7.16	4.8e-12	1.09e-08	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-7.16	4.8e-12	1.09e-08	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
STAD	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	7.16	4.81e-12	1.09e-08	0.39	0.36	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
STAD	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	7.16	4.81e-12	1.09e-08	0.36	0.36	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
STAD	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-7.16	4.82e-12	1.1e-08	-0.4	-0.36	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
STAD	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.16	4.82e-12	1.1e-08	-0.35	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
STAD	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	7.16	4.83e-12	1.1e-08	0.47	0.36	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
STAD	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-7.16	4.85e-12	1.1e-08	-0.41	-0.36	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-7.16	4.85e-12	1.1e-08	-0.41	-0.36	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
STAD	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	7.16	4.87e-12	1.11e-08	0.39	0.36	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
STAD	cis	rs2221894	0.922	rs4407834	ENSG00000273710.1	Metazoa_SRP	-7.16	4.87e-12	1.11e-08	-0.39	-0.36	Obesity-related traits;	chr8:28984304	chr8:28915579~28915864:-
STAD	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-7.16	4.89e-12	1.11e-08	-0.35	-0.36	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
STAD	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	7.16	4.89e-12	1.11e-08	0.45	0.36	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
STAD	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-7.16	4.9e-12	1.11e-08	-0.43	-0.36	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
STAD	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-7.16	4.9e-12	1.11e-08	-0.44	-0.36	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
STAD	cis	rs11903757	1	rs75521628	ENSG00000281467.1	Clostridiales-1	-7.16	4.91e-12	1.12e-08	-0.59	-0.36	Colorectal cancer;	chr2:191717363	chr2:191699476~191699631:-
STAD	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-7.16	4.94e-12	1.12e-08	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
STAD	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	7.16	4.97e-12	1.13e-08	0.46	0.36	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
STAD	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	7.16	5.02e-12	1.14e-08	0.37	0.36	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
STAD	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-7.16	5.02e-12	1.14e-08	-0.4	-0.36	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
STAD	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-7.15	5.03e-12	1.14e-08	-0.56	-0.36	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
STAD	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	7.15	5.04e-12	1.14e-08	0.41	0.36	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
STAD	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-7.15	5.04e-12	1.14e-08	-0.3	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
STAD	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	7.15	5.04e-12	1.14e-08	0.43	0.36	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	7.15	5.04e-12	1.14e-08	0.43	0.36	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	7.15	5.04e-12	1.14e-08	0.43	0.36	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
STAD	cis	rs6558530	0.698	rs7015858	ENSG00000253982.1	CTD-2336O2.1	7.15	5.06e-12	1.15e-08	0.37	0.36	Systolic blood pressure;	chr8:1776141	chr8:1761990~1764502:-
STAD	cis	rs9457247	0.508	rs2285147	ENSG00000265828.1	MIR3939	-7.15	5.08e-12	1.15e-08	-0.4	-0.36	Crohn's disease;	chr6:167092060	chr6:166997807~166997912:-
STAD	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	7.15	5.08e-12	1.15e-08	0.39	0.36	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
STAD	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-7.15	5.12e-12	1.16e-08	-0.38	-0.36	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
STAD	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	7.15	5.13e-12	1.16e-08	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	7.15	5.13e-12	1.16e-08	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	7.15	5.13e-12	1.16e-08	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
STAD	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	7.15	5.14e-12	1.17e-08	0.34	0.36	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
STAD	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	7.15	5.17e-12	1.17e-08	0.38	0.36	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
STAD	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-7.15	5.2e-12	1.18e-08	-0.41	-0.36	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
STAD	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	7.15	5.24e-12	1.19e-08	0.34	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
STAD	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	7.15	5.24e-12	1.19e-08	0.42	0.36	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	7.15	5.24e-12	1.19e-08	0.42	0.36	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	7.15	5.24e-12	1.19e-08	0.42	0.36	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
STAD	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-7.15	5.24e-12	1.19e-08	-0.42	-0.36	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-7.15	5.24e-12	1.19e-08	-0.42	-0.36	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-7.15	5.24e-12	1.19e-08	-0.42	-0.36	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-7.15	5.24e-12	1.19e-08	-0.42	-0.36	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
STAD	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	7.15	5.25e-12	1.19e-08	0.46	0.36	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
STAD	cis	rs9506514	0.509	rs9506515	ENSG00000238286.1	SLC35E1P1	-7.15	5.25e-12	1.19e-08	-0.4	-0.36	Coronary artery calcification;	chr13:20557870	chr13:20607268~20608131:+
STAD	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-7.15	5.26e-12	1.19e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
STAD	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	7.15	5.27e-12	1.19e-08	0.56	0.36	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
STAD	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	7.15	5.28e-12	1.19e-08	0.27	0.36	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	7.15	5.28e-12	1.19e-08	0.27	0.36	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
STAD	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-7.15	5.29e-12	1.2e-08	-0.51	-0.36	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
STAD	cis	rs11089937	0.597	rs5757007	ENSG00000211639.2	IGLV4-60	7.15	5.3e-12	1.2e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22162199~22162681:+
STAD	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-7.15	5.32e-12	1.2e-08	-0.52	-0.36	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
STAD	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	7.14	5.36e-12	1.21e-08	0.42	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
STAD	cis	rs611744	0.967	rs596245	ENSG00000253754.1	RP11-35G22.1	-7.14	5.37e-12	1.21e-08	-0.32	-0.36	Dupuytren's disease;	chr8:108228593	chr8:108226200~108227544:+
STAD	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-7.14	5.38e-12	1.22e-08	-0.57	-0.36	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
STAD	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	7.14	5.4e-12	1.22e-08	0.41	0.36	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
STAD	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	7.14	5.4e-12	1.22e-08	0.41	0.36	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
STAD	cis	rs611744	0.901	rs2348801	ENSG00000253754.1	RP11-35G22.1	-7.14	5.42e-12	1.22e-08	-0.32	-0.36	Dupuytren's disease;	chr8:108155108	chr8:108226200~108227544:+
STAD	cis	rs12468226	0.938	rs1474002	ENSG00000273456.1	RP11-686O6.2	7.14	5.42e-12	1.22e-08	0.49	0.36	Urate levels;	chr2:202290195	chr2:202374932~202375604:-
STAD	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-7.14	5.46e-12	1.23e-08	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
STAD	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	7.14	5.46e-12	1.23e-08	0.33	0.36	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
STAD	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	7.14	5.47e-12	1.23e-08	0.43	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
STAD	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	7.14	5.48e-12	1.24e-08	0.27	0.36	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
STAD	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	7.14	5.49e-12	1.24e-08	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	7.14	5.49e-12	1.24e-08	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
STAD	cis	rs875971	0.66	rs2013222	ENSG00000222364.1	RNU6-96P	7.14	5.5e-12	1.24e-08	0.4	0.36	Aortic root size;	chr7:66570949	chr7:66395191~66395286:+
STAD	cis	rs611744	0.87	rs596703	ENSG00000253754.1	RP11-35G22.1	7.14	5.5e-12	1.24e-08	0.31	0.36	Dupuytren's disease;	chr8:108147917	chr8:108226200~108227544:+
STAD	cis	rs9355610	0.609	rs7772112	ENSG00000265828.1	MIR3939	7.14	5.55e-12	1.25e-08	0.45	0.36	Graves' disease;	chr6:166995408	chr6:166997807~166997912:-
STAD	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	7.14	5.55e-12	1.25e-08	0.27	0.36	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
STAD	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-7.14	5.63e-12	1.27e-08	-0.46	-0.36	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
STAD	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	7.14	5.69e-12	1.28e-08	0.42	0.36	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	7.14	5.69e-12	1.28e-08	0.42	0.36	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	7.14	5.69e-12	1.28e-08	0.42	0.36	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
STAD	cis	rs1426063	0.748	rs7654088	ENSG00000248165.1	RP11-44F21.2	-7.14	5.71e-12	1.28e-08	-0.47	-0.36	QT interval;	chr4:75107103	chr4:74993877~75034824:-
STAD	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-7.13	5.71e-12	1.29e-08	-0.4	-0.36	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
STAD	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-7.13	5.71e-12	1.29e-08	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-7.13	5.71e-12	1.29e-08	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
STAD	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	7.13	5.75e-12	1.29e-08	0.42	0.36	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	7.13	5.75e-12	1.29e-08	0.42	0.36	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	7.13	5.75e-12	1.29e-08	0.42	0.36	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	7.13	5.75e-12	1.29e-08	0.42	0.36	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
STAD	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-7.13	5.78e-12	1.3e-08	-0.41	-0.36	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
STAD	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-7.13	5.78e-12	1.3e-08	-0.4	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
STAD	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	7.13	5.78e-12	1.3e-08	0.34	0.36	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
STAD	cis	rs13217239	0.646	rs35691005	ENSG00000243307.2	POM121L6P	7.13	5.79e-12	1.3e-08	0.34	0.36	Schizophrenia;	chr6:27004291	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs10946891	ENSG00000243307.2	POM121L6P	7.13	5.79e-12	1.3e-08	0.34	0.36	Schizophrenia;	chr6:27005436	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs12201393	ENSG00000243307.2	POM121L6P	7.13	5.79e-12	1.3e-08	0.34	0.36	Schizophrenia;	chr6:27007911	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs12209886	ENSG00000243307.2	POM121L6P	7.13	5.79e-12	1.3e-08	0.34	0.36	Schizophrenia;	chr6:27016978	chr6:26896952~26898777:+
STAD	cis	rs6940638	0.531	rs12211984	ENSG00000243307.2	POM121L6P	7.13	5.79e-12	1.3e-08	0.34	0.36	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs10456351	ENSG00000243307.2	POM121L6P	7.13	5.79e-12	1.3e-08	0.34	0.36	Schizophrenia;	chr6:27019013	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs10456352	ENSG00000243307.2	POM121L6P	7.13	5.79e-12	1.3e-08	0.34	0.36	Schizophrenia;	chr6:27022579	chr6:26896952~26898777:+
STAD	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-7.13	5.82e-12	1.31e-08	-0.27	-0.36	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
STAD	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	7.13	5.83e-12	1.31e-08	0.4	0.36	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
STAD	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	7.13	5.83e-12	1.31e-08	0.48	0.36	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
STAD	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	7.13	5.84e-12	1.31e-08	0.34	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
STAD	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-7.13	5.84e-12	1.31e-08	-0.44	-0.36	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
STAD	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	7.13	5.85e-12	1.31e-08	0.42	0.36	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
STAD	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	7.13	5.91e-12	1.33e-08	0.42	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	7.13	5.91e-12	1.33e-08	0.42	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
STAD	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	7.13	5.92e-12	1.33e-08	0.42	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
STAD	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	7.13	5.93e-12	1.33e-08	0.42	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
STAD	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-7.13	5.94e-12	1.33e-08	-0.39	-0.36	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
STAD	cis	rs12468226	0.938	rs16824590	ENSG00000273456.1	RP11-686O6.2	7.13	5.99e-12	1.34e-08	0.49	0.36	Urate levels;	chr2:202272624	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs77018809	ENSG00000273456.1	RP11-686O6.2	7.13	5.99e-12	1.34e-08	0.49	0.36	Urate levels;	chr2:202273166	chr2:202374932~202375604:-
STAD	cis	rs12468226	0.938	rs7585867	ENSG00000273456.1	RP11-686O6.2	7.13	5.99e-12	1.34e-08	0.49	0.36	Urate levels;	chr2:202287040	chr2:202374932~202375604:-
STAD	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	7.13	6.04e-12	1.35e-08	0.39	0.36	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
STAD	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-7.13	6.05e-12	1.35e-08	-0.37	-0.36	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
STAD	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	7.13	6.05e-12	1.36e-08	0.42	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
STAD	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-7.13	6.05e-12	1.36e-08	-0.43	-0.36	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
STAD	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-7.13	6.07e-12	1.36e-08	-0.42	-0.36	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
STAD	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-7.12	6.09e-12	1.36e-08	-0.54	-0.36	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
STAD	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	7.12	6.11e-12	1.37e-08	0.49	0.36	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
STAD	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.12	6.12e-12	1.37e-08	-0.35	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
STAD	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	7.12	6.12e-12	1.37e-08	0.34	0.36	Depression;	chr6:28327262	chr6:28176188~28176674:+
STAD	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	7.12	6.13e-12	1.37e-08	0.44	0.36	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
STAD	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-7.12	6.16e-12	1.38e-08	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-7.12	6.16e-12	1.38e-08	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
STAD	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	7.12	6.22e-12	1.39e-08	0.49	0.36	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	7.12	6.22e-12	1.39e-08	0.49	0.36	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
STAD	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	7.12	6.22e-12	1.39e-08	0.42	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
STAD	cis	rs496547	0.719	rs472641	ENSG00000255422.1	AP002954.4	-7.12	6.24e-12	1.39e-08	-0.42	-0.36	Hip minimal joint space width;	chr11:118746835	chr11:118704607~118750263:+
STAD	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-7.12	6.26e-12	1.4e-08	-0.43	-0.36	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
STAD	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-7.12	6.27e-12	1.4e-08	-0.41	-0.36	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
STAD	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	7.12	6.29e-12	1.4e-08	0.48	0.36	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
STAD	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	7.12	6.3e-12	1.4e-08	0.4	0.36	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
STAD	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	7.12	6.38e-12	1.42e-08	0.27	0.36	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
STAD	cis	rs13217239	0.646	rs10946888	ENSG00000243307.2	POM121L6P	7.12	6.4e-12	1.43e-08	0.34	0.36	Schizophrenia;	chr6:26983899	chr6:26896952~26898777:+
STAD	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	7.12	6.41e-12	1.43e-08	0.47	0.36	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
STAD	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	7.12	6.42e-12	1.43e-08	0.42	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
STAD	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	7.12	6.42e-12	1.43e-08	0.4	0.36	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
STAD	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	7.12	6.43e-12	1.43e-08	0.47	0.36	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
STAD	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-7.12	6.43e-12	1.43e-08	-0.41	-0.36	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
STAD	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-7.12	6.44e-12	1.44e-08	-0.53	-0.36	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
STAD	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	7.11	6.53e-12	1.45e-08	0.34	0.36	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
STAD	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	7.11	6.53e-12	1.45e-08	0.42	0.36	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
STAD	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	7.11	6.58e-12	1.46e-08	0.41	0.36	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
STAD	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-7.11	6.58e-12	1.46e-08	-0.4	-0.36	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-7.11	6.58e-12	1.46e-08	-0.4	-0.36	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
STAD	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	7.11	6.61e-12	1.47e-08	0.34	0.36	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
STAD	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-7.11	6.61e-12	1.47e-08	-0.4	-0.36	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
STAD	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-7.11	6.61e-12	1.47e-08	-0.4	-0.36	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
STAD	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-7.11	6.64e-12	1.48e-08	-0.51	-0.36	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
STAD	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	7.11	6.69e-12	1.49e-08	0.45	0.36	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000099984.9	GSTT2	7.11	6.69e-12	1.49e-08	0.48	0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23980123~23983911:+
STAD	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	7.11	6.69e-12	1.49e-08	0.26	0.36	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
STAD	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	7.11	6.71e-12	1.49e-08	0.36	0.36	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	7.11	6.71e-12	1.49e-08	0.36	0.36	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	7.11	6.71e-12	1.49e-08	0.36	0.36	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	7.11	6.71e-12	1.49e-08	0.36	0.36	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	7.11	6.71e-12	1.49e-08	0.36	0.36	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	7.11	6.71e-12	1.49e-08	0.36	0.36	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
STAD	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-7.11	6.75e-12	1.5e-08	-0.51	-0.36	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
STAD	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	7.11	6.76e-12	1.5e-08	0.6	0.36	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
STAD	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	7.11	6.76e-12	1.5e-08	0.48	0.36	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
STAD	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-7.11	6.78e-12	1.51e-08	-0.48	-0.36	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
STAD	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-7.11	6.79e-12	1.51e-08	-0.41	-0.36	Height;	chr11:118856460	chr11:118704607~118750263:+
STAD	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-7.11	6.79e-12	1.51e-08	-0.41	-0.36	Height;	chr11:118856623	chr11:118704607~118750263:+
STAD	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	7.11	6.8e-12	1.51e-08	0.43	0.36	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
STAD	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-7.11	6.84e-12	1.52e-08	-0.3	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
STAD	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	7.11	6.87e-12	1.52e-08	0.5	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-7.11	6.87e-12	1.52e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-7.11	6.87e-12	1.52e-08	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
STAD	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	7.11	6.9e-12	1.53e-08	0.37	0.36	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
STAD	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	7.1	6.92e-12	1.53e-08	0.49	0.36	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
STAD	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	7.1	6.92e-12	1.53e-08	0.49	0.36	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
STAD	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-7.1	6.92e-12	1.53e-08	-0.4	-0.36	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
STAD	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	7.1	7.01e-12	1.55e-08	0.39	0.36	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
STAD	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	7.1	7.01e-12	1.55e-08	0.39	0.36	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
STAD	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	7.1	7.04e-12	1.56e-08	0.42	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
STAD	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	7.1	7.04e-12	1.56e-08	0.38	0.36	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
STAD	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	7.1	7.05e-12	1.56e-08	0.36	0.36	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
STAD	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	7.1	7.05e-12	1.56e-08	0.4	0.36	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
STAD	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	7.1	7.11e-12	1.57e-08	0.39	0.36	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
STAD	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	7.1	7.12e-12	1.57e-08	0.39	0.36	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
STAD	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	7.1	7.13e-12	1.58e-08	0.46	0.36	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
STAD	cis	rs2143950	0.765	rs75359261	ENSG00000241052.1	RP11-173D9.1	-7.1	7.13e-12	1.58e-08	-0.46	-0.36	Atopic dermatitis;	chr14:35235851	chr14:35144021~35144480:-
STAD	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	7.1	7.18e-12	1.59e-08	0.27	0.36	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
STAD	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-7.1	7.24e-12	1.6e-08	-0.42	-0.36	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
STAD	cis	rs611744	0.81	rs672161	ENSG00000253754.1	RP11-35G22.1	-7.1	7.27e-12	1.61e-08	-0.31	-0.36	Dupuytren's disease;	chr8:108151953	chr8:108226200~108227544:+
STAD	cis	rs611744	0.839	rs672552	ENSG00000253754.1	RP11-35G22.1	-7.1	7.27e-12	1.61e-08	-0.31	-0.36	Dupuytren's disease;	chr8:108151994	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs613261	ENSG00000253754.1	RP11-35G22.1	-7.1	7.27e-12	1.61e-08	-0.31	-0.36	Dupuytren's disease;	chr8:108153720	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs613179	ENSG00000253754.1	RP11-35G22.1	-7.1	7.27e-12	1.61e-08	-0.31	-0.36	Dupuytren's disease;	chr8:108153777	chr8:108226200~108227544:+
STAD	cis	rs611744	0.839	rs638238	ENSG00000253754.1	RP11-35G22.1	-7.1	7.27e-12	1.61e-08	-0.31	-0.36	Dupuytren's disease;	chr8:108156923	chr8:108226200~108227544:+
STAD	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	7.1	7.27e-12	1.61e-08	0.36	0.36	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
STAD	cis	rs11089937	0.597	rs5757005	ENSG00000211639.2	IGLV4-60	7.1	7.29e-12	1.61e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22162199~22162681:+
STAD	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	7.1	7.29e-12	1.61e-08	0.38	0.36	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
STAD	cis	rs3093024	0.839	rs968334	ENSG00000265828.1	MIR3939	7.1	7.3e-12	1.61e-08	0.39	0.36	Rheumatoid arthritis;	chr6:167112608	chr6:166997807~166997912:-
STAD	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	7.1	7.31e-12	1.61e-08	0.4	0.36	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
STAD	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-7.1	7.31e-12	1.61e-08	-0.4	-0.36	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-7.1	7.31e-12	1.61e-08	-0.4	-0.36	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
STAD	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	7.1	7.33e-12	1.62e-08	0.34	0.36	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
STAD	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	7.1	7.33e-12	1.62e-08	0.34	0.36	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
STAD	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	7.09	7.38e-12	1.63e-08	0.41	0.36	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
STAD	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	7.09	7.43e-12	1.64e-08	0.63	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
STAD	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-7.09	7.46e-12	1.64e-08	-0.4	-0.36	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
STAD	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	7.09	7.5e-12	1.65e-08	0.44	0.36	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
STAD	cis	rs6456156	0.846	rs204293	ENSG00000265828.1	MIR3939	-7.09	7.53e-12	1.66e-08	-0.39	-0.36	Primary biliary cholangitis;	chr6:167100993	chr6:166997807~166997912:-
STAD	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-7.09	7.53e-12	1.66e-08	-0.42	-0.36	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-7.09	7.53e-12	1.66e-08	-0.42	-0.36	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
STAD	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	7.09	7.56e-12	1.67e-08	0.42	0.36	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
STAD	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	7.09	7.59e-12	1.67e-08	0.4	0.36	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
STAD	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-7.09	7.62e-12	1.68e-08	-0.38	-0.36	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
STAD	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-7.09	7.64e-12	1.68e-08	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-7.09	7.64e-12	1.68e-08	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-7.09	7.64e-12	1.68e-08	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-7.09	7.64e-12	1.68e-08	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-7.09	7.64e-12	1.68e-08	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
STAD	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-7.09	7.67e-12	1.69e-08	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
STAD	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	7.09	7.67e-12	1.69e-08	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
STAD	cis	rs2221894	0.853	rs1976610	ENSG00000273710.1	Metazoa_SRP	-7.09	7.69e-12	1.69e-08	-0.39	-0.36	Obesity-related traits;	chr8:28926498	chr8:28915579~28915864:-
STAD	cis	rs11089937	0.597	rs6001072	ENSG00000211639.2	IGLV4-60	7.09	7.7e-12	1.7e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.512	rs6001073	ENSG00000211639.2	IGLV4-60	7.09	7.7e-12	1.7e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22162199~22162681:+
STAD	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-7.09	7.73e-12	1.7e-08	-0.39	-0.36	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
STAD	cis	rs611744	0.87	rs672243	ENSG00000253754.1	RP11-35G22.1	-7.09	7.77e-12	1.71e-08	-0.3	-0.36	Dupuytren's disease;	chr8:108086514	chr8:108226200~108227544:+
STAD	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	7.09	7.77e-12	1.71e-08	0.41	0.36	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	7.09	7.79e-12	1.71e-08	0.26	0.36	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
STAD	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	7.08	7.89e-12	1.73e-08	0.34	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
STAD	cis	rs6456156	0.526	rs3093025	ENSG00000265828.1	MIR3939	7.08	7.9e-12	1.74e-08	0.38	0.36	Primary biliary cholangitis;	chr6:167119243	chr6:166997807~166997912:-
STAD	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	7.08	7.91e-12	1.74e-08	0.36	0.36	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
STAD	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	7.08	7.95e-12	1.75e-08	0.41	0.36	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
STAD	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-7.08	7.96e-12	1.75e-08	-0.4	-0.36	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
STAD	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	7.08	8e-12	1.76e-08	0.46	0.36	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	7.08	8.04e-12	1.76e-08	0.27	0.36	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
STAD	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	7.08	8.09e-12	1.78e-08	0.49	0.36	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	7.08	8.11e-12	1.78e-08	0.48	0.36	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
STAD	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-7.08	8.13e-12	1.78e-08	-0.26	-0.36	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
STAD	cis	rs11089937	0.597	rs6001076	ENSG00000211639.2	IGLV4-60	7.08	8.14e-12	1.78e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.597	rs5995560	ENSG00000211639.2	IGLV4-60	7.08	8.14e-12	1.78e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.568	rs6001078	ENSG00000211639.2	IGLV4-60	7.08	8.14e-12	1.78e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22162199~22162681:+
STAD	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	7.08	8.15e-12	1.79e-08	0.34	0.36	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
STAD	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-7.08	8.16e-12	1.79e-08	-0.37	-0.36	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
STAD	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	7.08	8.18e-12	1.79e-08	0.48	0.36	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
STAD	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	7.08	8.19e-12	1.79e-08	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
STAD	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-7.08	8.22e-12	1.8e-08	-0.42	-0.36	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
STAD	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	7.08	8.24e-12	1.8e-08	0.36	0.36	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
STAD	cis	rs7826238	0.594	rs2948285	ENSG00000173295.6	FAM86B3P	7.08	8.26e-12	1.81e-08	0.4	0.36	Systolic blood pressure;	chr8:8273016	chr8:8228595~8244865:+
STAD	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	7.08	8.27e-12	1.81e-08	0.42	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	7.08	8.27e-12	1.81e-08	0.42	0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
STAD	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	7.08	8.27e-12	1.81e-08	0.42	0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
STAD	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	7.08	8.28e-12	1.81e-08	0.59	0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
STAD	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-7.07	8.43e-12	1.84e-08	-0.41	-0.36	Height;	chr11:118854014	chr11:118704607~118750263:+
STAD	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-7.07	8.43e-12	1.84e-08	-0.41	-0.36	Height;	chr11:118855233	chr11:118704607~118750263:+
STAD	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-7.07	8.43e-12	1.84e-08	-0.41	-0.36	Height;	chr11:118855938	chr11:118704607~118750263:+
STAD	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-7.07	8.44e-12	1.85e-08	-0.34	-0.36	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
STAD	cis	rs7615952	0.609	rs13088451	ENSG00000272840.1	RP11-379B18.6	7.07	8.48e-12	1.85e-08	0.52	0.36	Blood pressure (smoking interaction);	chr3:125834656	chr3:125774714~125797953:+
STAD	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	7.07	8.5e-12	1.86e-08	0.27	0.36	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
STAD	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-7.07	8.5e-12	1.86e-08	-0.41	-0.36	Height;	chr11:118860890	chr11:118704607~118750263:+
STAD	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-7.07	8.5e-12	1.86e-08	-0.41	-0.36	Height;	chr11:118861053	chr11:118704607~118750263:+
STAD	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	7.07	8.5e-12	1.86e-08	0.5	0.36	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
STAD	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	7.07	8.51e-12	1.86e-08	0.4	0.36	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
STAD	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-7.07	8.58e-12	1.87e-08	-0.41	-0.36	Height;	chr11:118859432	chr11:118704607~118750263:+
STAD	cis	rs11089937	0.539	rs6001075	ENSG00000211639.2	IGLV4-60	7.07	8.59e-12	1.88e-08	0.38	0.36	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22162199~22162681:+
STAD	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	7.07	8.59e-12	1.88e-08	0.42	0.36	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
STAD	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	7.07	8.6e-12	1.88e-08	0.4	0.36	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
STAD	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	7.07	8.61e-12	1.88e-08	0.42	0.36	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
STAD	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	7.07	8.62e-12	1.88e-08	0.52	0.36	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
STAD	cis	rs6456156	0.773	rs6456159	ENSG00000265828.1	MIR3939	7.07	8.67e-12	1.89e-08	0.39	0.36	Primary biliary cholangitis;	chr6:167115784	chr6:166997807~166997912:-
STAD	cis	rs2221894	0.922	rs11136055	ENSG00000273710.1	Metazoa_SRP	-7.07	8.69e-12	1.9e-08	-0.38	-0.36	Obesity-related traits;	chr8:28998009	chr8:28915579~28915864:-
STAD	cis	rs875971	0.642	rs35526611	ENSG00000222364.1	RNU6-96P	7.07	8.72e-12	1.9e-08	0.4	0.36	Aortic root size;	chr7:66629021	chr7:66395191~66395286:+
STAD	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	7.07	8.72e-12	1.9e-08	0.42	0.36	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
STAD	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	7.07	8.72e-12	1.9e-08	0.4	0.36	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
STAD	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	7.07	8.73e-12	1.9e-08	0.37	0.36	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
STAD	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.07	8.8e-12	1.92e-08	-0.43	-0.36	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
STAD	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-7.07	8.87e-12	1.93e-08	-0.41	-0.36	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	7.07	8.88e-12	1.94e-08	0.41	0.36	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	7.06	8.91e-12	1.94e-08	0.41	0.36	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
STAD	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-7.06	8.93e-12	1.95e-08	-0.56	-0.36	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
STAD	cis	rs611744	0.87	rs381742	ENSG00000253754.1	RP11-35G22.1	-7.06	8.98e-12	1.96e-08	-0.31	-0.35	Dupuytren's disease;	chr8:108129851	chr8:108226200~108227544:+
STAD	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	7.06	9e-12	1.96e-08	0.48	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
STAD	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	7.06	9.01e-12	1.96e-08	0.4	0.35	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
STAD	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	7.06	9.01e-12	1.96e-08	0.4	0.35	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	7.06	9.01e-12	1.96e-08	0.4	0.35	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
STAD	cis	rs611744	0.781	rs656406	ENSG00000253754.1	RP11-35G22.1	-7.06	9.08e-12	1.98e-08	-0.31	-0.35	Dupuytren's disease;	chr8:108161614	chr8:108226200~108227544:+
STAD	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	7.06	9.09e-12	1.98e-08	0.46	0.35	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
STAD	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-7.06	9.11e-12	1.98e-08	-0.42	-0.35	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
STAD	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-7.06	9.14e-12	1.99e-08	-0.39	-0.35	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
STAD	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	7.06	9.18e-12	2e-08	0.5	0.35	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
STAD	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-7.06	9.34e-12	2.03e-08	-0.42	-0.35	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-7.06	9.34e-12	2.03e-08	-0.42	-0.35	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
STAD	cis	rs496547	0.719	rs1790189	ENSG00000255422.1	AP002954.4	-7.06	9.4e-12	2.04e-08	-0.42	-0.35	Hip minimal joint space width;	chr11:118781617	chr11:118704607~118750263:+
STAD	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	7.05	9.48e-12	2.06e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
STAD	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	7.05	9.52e-12	2.07e-08	0.34	0.35	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
STAD	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	7.05	9.52e-12	2.07e-08	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
STAD	cis	rs12922317	0.927	rs12923439	ENSG00000260224.1	UBL5P4	7.05	9.53e-12	2.07e-08	0.37	0.35	Schizophrenia;	chr16:11980101	chr16:11968508~11968743:-
STAD	cis	rs10885997	0.626	rs2286779	ENSG00000266200.5	PNLIPRP2	7.05	9.53e-12	2.07e-08	0.42	0.35	Phospholipid levels (plasma);	chr10:116635040	chr10:116620953~116645143:+
STAD	cis	rs6456156	0.806	rs11967165	ENSG00000265828.1	MIR3939	7.05	9.58e-12	2.08e-08	0.39	0.35	Primary biliary cholangitis;	chr6:167116448	chr6:166997807~166997912:-
STAD	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	7.05	9.58e-12	2.08e-08	0.42	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
STAD	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-7.05	9.6e-12	2.08e-08	-0.41	-0.35	Height;	chr11:118857611	chr11:118704607~118750263:+
STAD	cis	rs11089937	0.597	rs9619794	ENSG00000211639.2	IGLV4-60	7.05	9.6e-12	2.08e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22162199~22162681:+
STAD	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-7.05	9.6e-12	2.08e-08	-0.57	-0.35	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-7.05	9.62e-12	2.09e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
STAD	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-7.05	9.69e-12	2.1e-08	-0.41	-0.35	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
STAD	cis	rs611744	0.87	rs633794	ENSG00000253754.1	RP11-35G22.1	-7.05	9.7e-12	2.1e-08	-0.31	-0.35	Dupuytren's disease;	chr8:108162473	chr8:108226200~108227544:+
STAD	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-7.05	9.76e-12	2.12e-08	-0.4	-0.35	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
STAD	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	7.05	9.77e-12	2.12e-08	0.39	0.35	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
STAD	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	7.05	9.9e-12	2.15e-08	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
STAD	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-7.05	9.91e-12	2.15e-08	-0.49	-0.35	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
STAD	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	7.05	9.96e-12	2.16e-08	0.49	0.35	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	7.05	9.96e-12	2.16e-08	0.49	0.35	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
STAD	cis	rs2439831	0.867	rs2447208	ENSG00000249839.1	AC011330.5	-7.05	9.97e-12	2.16e-08	-0.55	-0.35	Lung cancer in ever smokers;	chr15:43641697	chr15:43663654~43684339:-
STAD	cis	rs6456156	1	rs9457274	ENSG00000265828.1	MIR3939	-7.05	1e-11	2.17e-08	-0.39	-0.35	Primary biliary cholangitis;	chr6:167107377	chr6:166997807~166997912:-
STAD	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-7.05	1e-11	2.17e-08	-0.4	-0.35	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
STAD	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	7.05	1e-11	2.18e-08	0.4	0.35	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
STAD	cis	rs9506514	0.509	rs9506515	ENSG00000222726.1	RNU2-7P	-7.05	1.01e-11	2.18e-08	-0.41	-0.35	Coronary artery calcification;	chr13:20557870	chr13:20612161~20612338:+
STAD	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-7.05	1.01e-11	2.18e-08	-0.41	-0.35	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
STAD	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	7.04	1.01e-11	2.19e-08	0.38	0.35	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
STAD	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-7.04	1.02e-11	2.21e-08	-0.51	-0.35	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
STAD	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	7.04	1.02e-11	2.21e-08	0.4	0.35	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
STAD	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-7.04	1.03e-11	2.22e-08	-0.48	-0.35	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
STAD	cis	rs611744	0.806	rs374810	ENSG00000253754.1	RP11-35G22.1	-7.04	1.03e-11	2.22e-08	-0.3	-0.35	Dupuytren's disease;	chr8:108083801	chr8:108226200~108227544:+
STAD	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-7.04	1.03e-11	2.22e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-7.04	1.03e-11	2.22e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
STAD	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-7.04	1.03e-11	2.22e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-7.04	1.03e-11	2.22e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-7.04	1.03e-11	2.22e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-7.04	1.03e-11	2.22e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
STAD	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	7.04	1.03e-11	2.22e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
STAD	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	7.04	1.03e-11	2.23e-08	0.31	0.35	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
STAD	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	7.04	1.03e-11	2.23e-08	0.31	0.35	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
STAD	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-7.04	1.04e-11	2.24e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
STAD	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	7.04	1.04e-11	2.24e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
STAD	cis	rs6456156	1	rs6456156	ENSG00000265828.1	MIR3939	-7.04	1.04e-11	2.24e-08	-0.4	-0.35	Primary biliary cholangitis;	chr6:167108812	chr6:166997807~166997912:-
STAD	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	7.04	1.04e-11	2.25e-08	0.39	0.35	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
STAD	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	7.04	1.04e-11	2.25e-08	0.31	0.35	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
STAD	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	7.04	1.05e-11	2.26e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	7.04	1.05e-11	2.26e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	7.04	1.05e-11	2.26e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	7.04	1.05e-11	2.26e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	7.04	1.05e-11	2.26e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	7.04	1.05e-11	2.26e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	7.04	1.05e-11	2.26e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
STAD	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-7.04	1.05e-11	2.26e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
STAD	cis	rs6456156	1	rs7761159	ENSG00000265828.1	MIR3939	-7.04	1.05e-11	2.26e-08	-0.39	-0.35	Primary biliary cholangitis;	chr6:167106419	chr6:166997807~166997912:-
STAD	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-7.04	1.05e-11	2.27e-08	-0.52	-0.35	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
STAD	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-7.04	1.06e-11	2.28e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
STAD	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	7.04	1.06e-11	2.29e-08	0.38	0.35	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
STAD	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-7.04	1.07e-11	2.3e-08	-0.46	-0.35	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
STAD	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-7.04	1.07e-11	2.3e-08	-0.39	-0.35	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
STAD	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-7.04	1.07e-11	2.3e-08	-0.39	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
STAD	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-7.04	1.07e-11	2.31e-08	-0.47	-0.35	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
STAD	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	7.03	1.07e-11	2.31e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
STAD	cis	rs611744	0.837	rs399131	ENSG00000253754.1	RP11-35G22.1	7.03	1.08e-11	2.32e-08	0.3	0.35	Dupuytren's disease;	chr8:108093057	chr8:108226200~108227544:+
STAD	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	7.03	1.08e-11	2.32e-08	0.55	0.35	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
STAD	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	7.03	1.08e-11	2.32e-08	0.41	0.35	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
STAD	cis	rs2436845	0.531	rs1806299	ENSG00000253385.1	KB-1254G8.1	7.03	1.08e-11	2.33e-08	0.36	0.35	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102886303	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.554	rs10104704	ENSG00000253385.1	KB-1254G8.1	7.03	1.08e-11	2.33e-08	0.36	0.35	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102888657	chr8:102854455~102856075:+
STAD	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-7.03	1.08e-11	2.33e-08	-0.39	-0.35	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
STAD	cis	rs8040855	0.794	rs4843024	ENSG00000229212.6	RP11-561C5.4	-7.03	1.08e-11	2.33e-08	-0.51	-0.35	Bulimia nervosa;	chr15:85162669	chr15:85205440~85234795:-
STAD	cis	rs2439831	0.867	rs2447196	ENSG00000249839.1	AC011330.5	7.03	1.09e-11	2.35e-08	0.53	0.35	Lung cancer in ever smokers;	chr15:43601620	chr15:43663654~43684339:-
STAD	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	7.03	1.09e-11	2.35e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
STAD	cis	rs9368481	0.761	rs6918835	ENSG00000243307.2	POM121L6P	-7.03	1.11e-11	2.38e-08	-0.37	-0.35	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26896952~26898777:+
STAD	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-7.03	1.11e-11	2.39e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
STAD	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	7.03	1.11e-11	2.39e-08	0.41	0.35	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
STAD	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	7.03	1.11e-11	2.39e-08	0.31	0.35	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
STAD	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	7.03	1.11e-11	2.39e-08	0.41	0.35	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
STAD	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	7.03	1.11e-11	2.39e-08	0.41	0.35	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	7.03	1.11e-11	2.39e-08	0.41	0.35	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	7.03	1.11e-11	2.39e-08	0.41	0.35	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	7.03	1.11e-11	2.39e-08	0.41	0.35	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
STAD	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-7.03	1.12e-11	2.4e-08	-0.35	-0.35	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
STAD	cis	rs875971	0.66	rs801193	ENSG00000222364.1	RNU6-96P	7.03	1.12e-11	2.41e-08	0.4	0.35	Aortic root size;	chr7:66565625	chr7:66395191~66395286:+
STAD	cis	rs11148252	0.512	rs9526950	ENSG00000235660.1	LINC00345	-7.03	1.12e-11	2.41e-08	-0.41	-0.35	Lewy body disease;	chr13:52600328	chr13:52484161~52484680:-
STAD	cis	rs732716	0.752	rs11085072	ENSG00000267980.1	AC007292.6	-7.03	1.12e-11	2.41e-08	-0.53	-0.35	Mean corpuscular volume;	chr19:4368145	chr19:4363789~4364640:+
STAD	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	7.03	1.12e-11	2.41e-08	0.41	0.35	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
STAD	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-7.03	1.13e-11	2.42e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
STAD	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	7.03	1.13e-11	2.42e-08	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
STAD	cis	rs2221894	0.922	rs1858462	ENSG00000273710.1	Metazoa_SRP	-7.03	1.13e-11	2.43e-08	-0.39	-0.35	Obesity-related traits;	chr8:28903220	chr8:28915579~28915864:-
STAD	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	7.03	1.14e-11	2.44e-08	0.31	0.35	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
STAD	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	7.03	1.14e-11	2.44e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	7.03	1.14e-11	2.44e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
STAD	cis	rs6456156	0.904	rs2021033	ENSG00000265828.1	MIR3939	7.03	1.14e-11	2.45e-08	0.38	0.35	Primary biliary cholangitis;	chr6:167110751	chr6:166997807~166997912:-
STAD	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-7.02	1.15e-11	2.46e-08	-0.35	-0.35	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
STAD	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-7.02	1.15e-11	2.47e-08	-0.44	-0.35	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
STAD	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
STAD	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	7.02	1.16e-11	2.47e-08	0.5	0.35	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
STAD	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	7.02	1.16e-11	2.47e-08	0.41	0.35	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
STAD	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	7.02	1.17e-11	2.5e-08	0.42	0.35	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	7.02	1.17e-11	2.5e-08	0.42	0.35	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	7.02	1.17e-11	2.5e-08	0.42	0.35	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	7.02	1.17e-11	2.5e-08	0.42	0.35	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	7.02	1.17e-11	2.5e-08	0.42	0.35	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
STAD	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	7.02	1.17e-11	2.5e-08	0.42	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	7.02	1.17e-11	2.5e-08	0.42	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
STAD	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-7.02	1.17e-11	2.51e-08	-0.34	-0.35	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
STAD	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-7.02	1.17e-11	2.51e-08	-0.5	-0.35	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
STAD	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	7.02	1.17e-11	2.51e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	7.02	1.17e-11	2.51e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
STAD	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	7.02	1.18e-11	2.52e-08	0.27	0.35	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
STAD	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	7.02	1.18e-11	2.52e-08	0.5	0.35	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
STAD	cis	rs2221894	0.853	rs11781448	ENSG00000273710.1	Metazoa_SRP	-7.02	1.18e-11	2.52e-08	-0.39	-0.35	Obesity-related traits;	chr8:28936410	chr8:28915579~28915864:-
STAD	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	7.02	1.18e-11	2.53e-08	0.42	0.35	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	7.02	1.18e-11	2.53e-08	0.42	0.35	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	7.02	1.18e-11	2.53e-08	0.42	0.35	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
STAD	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	7.02	1.19e-11	2.53e-08	0.4	0.35	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	7.02	1.19e-11	2.53e-08	0.4	0.35	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	7.02	1.19e-11	2.53e-08	0.4	0.35	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
STAD	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	7.02	1.19e-11	2.54e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	7.02	1.19e-11	2.54e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
STAD	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	7.02	1.19e-11	2.54e-08	0.4	0.35	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
STAD	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	7.02	1.19e-11	2.54e-08	0.4	0.35	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-7.02	1.19e-11	2.54e-08	-0.4	-0.35	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-7.02	1.19e-11	2.54e-08	-0.4	-0.35	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
STAD	cis	rs611744	0.87	rs634216	ENSG00000253754.1	RP11-35G22.1	-7.02	1.2e-11	2.56e-08	-0.31	-0.35	Dupuytren's disease;	chr8:108162574	chr8:108226200~108227544:+
STAD	cis	rs611744	0.87	rs640068	ENSG00000253754.1	RP11-35G22.1	-7.02	1.21e-11	2.58e-08	-0.3	-0.35	Dupuytren's disease;	chr8:108145773	chr8:108226200~108227544:+
STAD	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	7.02	1.21e-11	2.58e-08	0.37	0.35	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
STAD	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	7.02	1.22e-11	2.59e-08	0.26	0.35	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-7.02	1.22e-11	2.59e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-7.02	1.22e-11	2.59e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-7.02	1.22e-11	2.59e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-7.02	1.22e-11	2.59e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-7.02	1.22e-11	2.59e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-7.02	1.22e-11	2.59e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-7.02	1.22e-11	2.59e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
STAD	cis	rs11089937	0.626	rs9622955	ENSG00000211639.2	IGLV4-60	7.01	1.22e-11	2.6e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs4821781	ENSG00000211639.2	IGLV4-60	7.01	1.22e-11	2.6e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs5750589	ENSG00000211639.2	IGLV4-60	7.01	1.22e-11	2.6e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs5757038	ENSG00000211639.2	IGLV4-60	7.01	1.22e-11	2.6e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22162199~22162681:+
STAD	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-7.01	1.22e-11	2.6e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-7.01	1.22e-11	2.6e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-7.01	1.22e-11	2.6e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-7.01	1.22e-11	2.6e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-7.01	1.22e-11	2.6e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-7.01	1.22e-11	2.6e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
STAD	cis	rs6456156	0.742	rs3093026	ENSG00000265828.1	MIR3939	-7.01	1.22e-11	2.6e-08	-0.39	-0.35	Primary biliary cholangitis;	chr6:167119202	chr6:166997807~166997912:-
STAD	cis	rs496547	0.756	rs562059	ENSG00000255422.1	AP002954.4	-7.01	1.23e-11	2.61e-08	-0.42	-0.35	Hip minimal joint space width;	chr11:118731349	chr11:118704607~118750263:+
STAD	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-7.01	1.23e-11	2.61e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-7.01	1.23e-11	2.61e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-7.01	1.23e-11	2.61e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-7.01	1.23e-11	2.61e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-7.01	1.23e-11	2.61e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-7.01	1.23e-11	2.61e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
STAD	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-7.01	1.23e-11	2.61e-08	-0.39	-0.35	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
STAD	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	7.01	1.23e-11	2.61e-08	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
STAD	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-7.01	1.24e-11	2.63e-08	-0.41	-0.35	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
STAD	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	7.01	1.26e-11	2.67e-08	0.49	0.35	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
STAD	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	7.01	1.26e-11	2.67e-08	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
STAD	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	7.01	1.26e-11	2.68e-08	0.4	0.35	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
STAD	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	7.01	1.26e-11	2.68e-08	0.4	0.35	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
STAD	cis	rs11089937	0.597	rs5757027	ENSG00000211639.2	IGLV4-60	7.01	1.27e-11	2.68e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22162199~22162681:+
STAD	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-7.01	1.27e-11	2.69e-08	-0.47	-0.35	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-7.01	1.27e-11	2.69e-08	-0.47	-0.35	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
STAD	cis	rs611744	0.805	rs378515	ENSG00000253754.1	RP11-35G22.1	-7.01	1.28e-11	2.71e-08	-0.31	-0.35	Dupuytren's disease;	chr8:108092677	chr8:108226200~108227544:+
STAD	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	7.01	1.28e-11	2.71e-08	0.53	0.35	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
STAD	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	7.01	1.28e-11	2.72e-08	0.27	0.35	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
STAD	cis	rs611744	0.837	rs403200	ENSG00000253754.1	RP11-35G22.1	-7.01	1.28e-11	2.72e-08	-0.31	-0.35	Dupuytren's disease;	chr8:108091147	chr8:108226200~108227544:+
STAD	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-7.01	1.29e-11	2.72e-08	-0.43	-0.35	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
STAD	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-7.01	1.29e-11	2.72e-08	-0.4	-0.35	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
STAD	cis	rs7615952	0.546	rs2976733	ENSG00000272840.1	RP11-379B18.6	7.01	1.29e-11	2.72e-08	0.54	0.35	Blood pressure (smoking interaction);	chr3:125695294	chr3:125774714~125797953:+
STAD	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-7.01	1.29e-11	2.73e-08	-0.37	-0.35	Height;	chr3:52972039	chr3:53064283~53065091:-
STAD	cis	rs11603023	0.569	rs573905	ENSG00000255422.1	AP002954.4	-7.01	1.29e-11	2.73e-08	-0.42	-0.35	Cholesterol, total;	chr11:118701558	chr11:118704607~118750263:+
STAD	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-7.01	1.29e-11	2.74e-08	-0.5	-0.35	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
STAD	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	7	1.29e-11	2.74e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
STAD	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	7	1.3e-11	2.74e-08	0.49	0.35	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
STAD	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	7	1.3e-11	2.75e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
STAD	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	7	1.3e-11	2.76e-08	0.4	0.35	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	7	1.31e-11	2.76e-08	0.42	0.35	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
STAD	cis	rs611744	0.905	rs408506	ENSG00000253754.1	RP11-35G22.1	7	1.31e-11	2.76e-08	0.3	0.35	Dupuytren's disease;	chr8:108142005	chr8:108226200~108227544:+
STAD	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	7	1.31e-11	2.76e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
STAD	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	7	1.31e-11	2.76e-08	0.31	0.35	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
STAD	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-7	1.32e-11	2.78e-08	-0.35	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
STAD	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-7	1.32e-11	2.79e-08	-0.39	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
STAD	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-7	1.32e-11	2.79e-08	-0.39	-0.35	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
STAD	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	7	1.32e-11	2.79e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	7	1.32e-11	2.79e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	7	1.32e-11	2.79e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	7	1.32e-11	2.79e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	7	1.32e-11	2.79e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
STAD	cis	rs7580658	0.864	rs4150441	ENSG00000200250.1	RNU6-1147P	7	1.32e-11	2.79e-08	0.34	0.35	Protein C levels;	chr2:127283339	chr2:127316873~127316979:+
STAD	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	7	1.32e-11	2.8e-08	0.37	0.35	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
STAD	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-7	1.33e-11	2.8e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
STAD	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	7	1.33e-11	2.81e-08	0.41	0.35	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
STAD	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	7	1.33e-11	2.81e-08	0.41	0.35	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
STAD	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-7	1.33e-11	2.81e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
STAD	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-7	1.34e-11	2.83e-08	-0.41	-0.35	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	7	1.34e-11	2.83e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	7	1.34e-11	2.83e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
STAD	cis	rs2436845	0.554	rs667927	ENSG00000253385.1	KB-1254G8.1	7	1.34e-11	2.83e-08	0.36	0.35	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102900186	chr8:102854455~102856075:+
STAD	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	7	1.34e-11	2.83e-08	0.43	0.35	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
STAD	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	7	1.34e-11	2.83e-08	0.38	0.35	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
STAD	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	7	1.34e-11	2.83e-08	0.38	0.35	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
STAD	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	7	1.35e-11	2.84e-08	0.44	0.35	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
STAD	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-7	1.35e-11	2.85e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-7	1.35e-11	2.85e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
STAD	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	7	1.36e-11	2.86e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	7	1.36e-11	2.86e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
STAD	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	7	1.36e-11	2.87e-08	0.41	0.35	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	7	1.36e-11	2.87e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
STAD	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-7	1.36e-11	2.87e-08	-0.44	-0.35	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
STAD	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	7	1.36e-11	2.87e-08	0.4	0.35	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
STAD	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	7	1.36e-11	2.87e-08	0.4	0.35	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	7	1.36e-11	2.87e-08	0.4	0.35	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	7	1.36e-11	2.87e-08	0.4	0.35	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
STAD	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	7	1.36e-11	2.87e-08	0.4	0.35	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	7	1.36e-11	2.87e-08	0.4	0.35	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
STAD	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	7	1.37e-11	2.87e-08	0.34	0.35	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
STAD	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	7	1.37e-11	2.88e-08	0.34	0.35	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
STAD	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-7	1.37e-11	2.88e-08	-0.42	-0.35	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
STAD	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
STAD	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
STAD	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
STAD	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-7	1.37e-11	2.89e-08	-0.43	-0.35	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
STAD	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	6.99	1.38e-11	2.91e-08	0.37	0.35	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
STAD	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	6.99	1.39e-11	2.91e-08	0.32	0.35	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
STAD	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-6.99	1.39e-11	2.91e-08	-0.5	-0.35	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
STAD	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	6.99	1.39e-11	2.92e-08	0.5	0.35	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
STAD	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-6.99	1.39e-11	2.92e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
STAD	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-6.99	1.39e-11	2.92e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
STAD	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-6.99	1.4e-11	2.93e-08	-0.4	-0.35	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
STAD	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-6.99	1.4e-11	2.95e-08	-0.34	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
STAD	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-6.99	1.41e-11	2.95e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-6.99	1.41e-11	2.95e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-6.99	1.41e-11	2.95e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-6.99	1.41e-11	2.95e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-6.99	1.41e-11	2.95e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-6.99	1.41e-11	2.95e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
STAD	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	6.99	1.41e-11	2.95e-08	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
STAD	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	6.99	1.41e-11	2.96e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
STAD	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	6.99	1.41e-11	2.96e-08	0.4	0.35	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
STAD	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	6.99	1.41e-11	2.96e-08	0.27	0.35	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
STAD	cis	rs2436845	0.554	rs491770	ENSG00000253385.1	KB-1254G8.1	6.99	1.42e-11	2.97e-08	0.36	0.35	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102895800	chr8:102854455~102856075:+
STAD	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	6.99	1.42e-11	2.97e-08	0.42	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
STAD	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	6.99	1.42e-11	2.98e-08	0.29	0.35	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
STAD	cis	rs11089937	0.54	rs5756992	ENSG00000211639.2	IGLV4-60	6.99	1.42e-11	2.98e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.597	rs9622919	ENSG00000211639.2	IGLV4-60	6.99	1.42e-11	2.98e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22162199~22162681:+
STAD	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-6.99	1.42e-11	2.98e-08	-0.35	-0.35	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
STAD	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-6.99	1.42e-11	2.98e-08	-0.35	-0.35	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
STAD	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	6.99	1.42e-11	2.98e-08	0.46	0.35	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
STAD	cis	rs2221894	0.922	rs9792190	ENSG00000273710.1	Metazoa_SRP	-6.99	1.42e-11	2.99e-08	-0.38	-0.35	Obesity-related traits;	chr8:28970874	chr8:28915579~28915864:-
STAD	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-6.99	1.43e-11	3e-08	-0.34	-0.35	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
STAD	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	6.99	1.43e-11	3.01e-08	0.35	0.35	Height;	chr3:53082835	chr3:53064283~53065091:-
STAD	cis	rs11089937	0.597	rs5756991	ENSG00000211639.2	IGLV4-60	6.99	1.44e-11	3.01e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22162199~22162681:+
STAD	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-6.99	1.44e-11	3.02e-08	-0.43	-0.35	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
STAD	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	6.99	1.44e-11	3.02e-08	0.34	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
STAD	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-6.99	1.45e-11	3.03e-08	-0.4	-0.35	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
STAD	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	6.99	1.45e-11	3.03e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
STAD	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	6.99	1.46e-11	3.05e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	6.99	1.46e-11	3.05e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	6.99	1.46e-11	3.05e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	6.99	1.46e-11	3.05e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
STAD	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-6.99	1.46e-11	3.05e-08	-0.52	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	6.99	1.46e-11	3.06e-08	0.27	0.35	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	6.99	1.46e-11	3.06e-08	0.27	0.35	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	6.99	1.46e-11	3.06e-08	0.27	0.35	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	6.99	1.46e-11	3.06e-08	0.27	0.35	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
STAD	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	6.99	1.47e-11	3.07e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
STAD	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-6.99	1.47e-11	3.07e-08	-0.44	-0.35	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
STAD	cis	rs12922317	0.538	rs442234	ENSG00000260224.1	UBL5P4	6.98	1.47e-11	3.08e-08	0.37	0.35	Schizophrenia;	chr16:11978304	chr16:11968508~11968743:-
STAD	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	6.98	1.47e-11	3.08e-08	0.47	0.35	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
STAD	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	6.98	1.48e-11	3.09e-08	0.51	0.35	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
STAD	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-6.98	1.48e-11	3.09e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-6.98	1.48e-11	3.11e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
STAD	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	6.98	1.48e-11	3.11e-08	0.4	0.35	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
STAD	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	6.98	1.49e-11	3.11e-08	0.29	0.35	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
STAD	cis	rs7580658	0.929	rs4150477	ENSG00000200250.1	RNU6-1147P	-6.98	1.49e-11	3.11e-08	-0.34	-0.35	Protein C levels;	chr2:127274970	chr2:127316873~127316979:+
STAD	cis	rs2221894	0.922	rs11136054	ENSG00000273710.1	Metazoa_SRP	-6.98	1.49e-11	3.12e-08	-0.38	-0.35	Obesity-related traits;	chr8:28997585	chr8:28915579~28915864:-
STAD	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	6.98	1.5e-11	3.13e-08	0.55	0.35	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	6.98	1.5e-11	3.14e-08	0.27	0.35	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
STAD	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-6.98	1.52e-11	3.17e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
STAD	cis	rs1426063	0.748	rs10005117	ENSG00000249717.1	RP11-44F21.3	6.98	1.52e-11	3.17e-08	0.46	0.35	QT interval;	chr4:75108281	chr4:74955974~74970362:-
STAD	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	6.98	1.52e-11	3.17e-08	0.41	0.35	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
STAD	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	6.98	1.52e-11	3.17e-08	0.5	0.35	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
STAD	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-6.98	1.53e-11	3.19e-08	-0.43	-0.35	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-6.98	1.53e-11	3.19e-08	-0.43	-0.35	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-6.98	1.53e-11	3.19e-08	-0.43	-0.35	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-6.98	1.53e-11	3.19e-08	-0.43	-0.35	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-6.98	1.53e-11	3.19e-08	-0.43	-0.35	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-6.98	1.53e-11	3.19e-08	-0.43	-0.35	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
STAD	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-6.98	1.53e-11	3.19e-08	-0.43	-0.35	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
STAD	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-6.98	1.53e-11	3.2e-08	-0.54	-0.35	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
STAD	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	6.98	1.55e-11	3.22e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
STAD	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	6.98	1.55e-11	3.23e-08	0.41	0.35	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
STAD	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	6.98	1.55e-11	3.23e-08	0.41	0.35	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
STAD	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	6.98	1.55e-11	3.24e-08	0.39	0.35	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
STAD	cis	rs2221894	0.922	rs2203209	ENSG00000273710.1	Metazoa_SRP	-6.97	1.57e-11	3.27e-08	-0.38	-0.35	Obesity-related traits;	chr8:28930516	chr8:28915579~28915864:-
STAD	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	6.97	1.57e-11	3.28e-08	0.41	0.35	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
STAD	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-6.97	1.58e-11	3.28e-08	-0.39	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
STAD	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-6.97	1.59e-11	3.31e-08	-0.39	-0.35	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
STAD	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-6.97	1.59e-11	3.32e-08	-0.39	-0.35	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
STAD	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	6.97	1.6e-11	3.32e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
STAD	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-6.97	1.61e-11	3.34e-08	-0.39	-0.35	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
STAD	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-6.97	1.61e-11	3.35e-08	-0.52	-0.35	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
STAD	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	6.97	1.61e-11	3.35e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
STAD	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-6.97	1.61e-11	3.36e-08	-0.42	-0.35	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
STAD	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	6.97	1.62e-11	3.36e-08	0.5	0.35	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
STAD	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	6.97	1.63e-11	3.38e-08	0.3	0.35	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
STAD	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	6.97	1.63e-11	3.38e-08	0.42	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
STAD	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-6.97	1.63e-11	3.38e-08	-0.45	-0.35	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
STAD	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	6.97	1.63e-11	3.39e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
STAD	cis	rs6456156	0.774	rs2022001	ENSG00000265828.1	MIR3939	6.97	1.64e-11	3.4e-08	0.39	0.35	Primary biliary cholangitis;	chr6:167116021	chr6:166997807~166997912:-
STAD	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-6.97	1.64e-11	3.4e-08	-0.38	-0.35	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
STAD	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-6.97	1.64e-11	3.41e-08	-0.35	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
STAD	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-6.97	1.64e-11	3.41e-08	-0.4	-0.35	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
STAD	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	6.97	1.64e-11	3.41e-08	0.27	0.35	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
STAD	cis	rs2221894	0.922	rs4732894	ENSG00000273710.1	Metazoa_SRP	-6.97	1.65e-11	3.41e-08	-0.38	-0.35	Obesity-related traits;	chr8:28965534	chr8:28915579~28915864:-
STAD	cis	rs11089937	0.568	rs35626600	ENSG00000211639.2	IGLV4-60	6.97	1.65e-11	3.42e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.539	rs34228957	ENSG00000211639.2	IGLV4-60	6.97	1.65e-11	3.42e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22162199~22162681:+
STAD	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-6.97	1.65e-11	3.42e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
STAD	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-6.97	1.65e-11	3.43e-08	-0.44	-0.35	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
STAD	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	6.97	1.66e-11	3.44e-08	0.27	0.35	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
STAD	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	6.96	1.66e-11	3.45e-08	0.44	0.35	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
STAD	cis	rs13217239	0.621	rs12527231	ENSG00000243307.2	POM121L6P	6.96	1.66e-11	3.45e-08	0.33	0.35	Schizophrenia;	chr6:27033509	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs12523820	ENSG00000243307.2	POM121L6P	6.96	1.66e-11	3.45e-08	0.33	0.35	Schizophrenia;	chr6:27033723	chr6:26896952~26898777:+
STAD	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	6.96	1.67e-11	3.45e-08	0.36	0.35	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	6.96	1.67e-11	3.45e-08	0.36	0.35	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	6.96	1.67e-11	3.45e-08	0.36	0.35	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	6.96	1.67e-11	3.45e-08	0.36	0.35	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	6.96	1.67e-11	3.45e-08	0.36	0.35	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	6.96	1.67e-11	3.45e-08	0.36	0.35	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	6.96	1.67e-11	3.45e-08	0.36	0.35	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
STAD	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-6.96	1.67e-11	3.46e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-6.96	1.67e-11	3.46e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-6.96	1.67e-11	3.46e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-6.96	1.67e-11	3.46e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-6.96	1.67e-11	3.46e-08	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
STAD	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	6.96	1.68e-11	3.47e-08	0.4	0.35	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
STAD	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	6.96	1.68e-11	3.47e-08	0.4	0.35	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
STAD	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	6.96	1.68e-11	3.47e-08	0.4	0.35	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
STAD	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-6.96	1.68e-11	3.48e-08	-0.41	-0.35	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
STAD	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-6.96	1.68e-11	3.49e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
STAD	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-6.96	1.68e-11	3.49e-08	-0.36	-0.35	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
STAD	cis	rs13217239	0.646	rs4583981	ENSG00000243307.2	POM121L6P	6.96	1.69e-11	3.5e-08	0.33	0.35	Schizophrenia;	chr6:27024244	chr6:26896952~26898777:+
STAD	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-6.96	1.7e-11	3.52e-08	-0.4	-0.35	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
STAD	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	6.96	1.71e-11	3.53e-08	0.35	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
STAD	cis	rs11089937	0.597	rs5757024	ENSG00000211639.2	IGLV4-60	6.96	1.71e-11	3.54e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.597	rs5757026	ENSG00000211639.2	IGLV4-60	6.96	1.71e-11	3.54e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.597	rs5750582	ENSG00000211639.2	IGLV4-60	6.96	1.71e-11	3.54e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs5757028	ENSG00000211639.2	IGLV4-60	6.96	1.71e-11	3.54e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.597	rs2213156	ENSG00000211639.2	IGLV4-60	6.96	1.71e-11	3.54e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs2213157	ENSG00000211639.2	IGLV4-60	6.96	1.71e-11	3.54e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22162199~22162681:+
STAD	cis	rs11903757	1	rs12475675	ENSG00000281467.1	Clostridiales-1	-6.96	1.71e-11	3.54e-08	-0.52	-0.35	Colorectal cancer;	chr2:191723588	chr2:191699476~191699631:-
STAD	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-6.96	1.71e-11	3.55e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
STAD	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	6.96	1.71e-11	3.55e-08	0.5	0.35	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	6.96	1.71e-11	3.55e-08	0.5	0.35	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
STAD	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-6.96	1.72e-11	3.55e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
STAD	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-6.96	1.72e-11	3.55e-08	-0.42	-0.35	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
STAD	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	6.96	1.72e-11	3.56e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
STAD	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	6.96	1.72e-11	3.56e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
STAD	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	6.96	1.72e-11	3.56e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
STAD	cis	rs13217239	0.646	rs11756275	ENSG00000243307.2	POM121L6P	-6.96	1.72e-11	3.56e-08	-0.33	-0.35	Schizophrenia;	chr6:27039334	chr6:26896952~26898777:+
STAD	cis	rs11089937	0.512	rs13054756	ENSG00000211639.2	IGLV4-60	6.96	1.72e-11	3.56e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22162199~22162681:+
STAD	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-6.96	1.73e-11	3.57e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
STAD	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-6.96	1.73e-11	3.57e-08	-0.44	-0.35	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
STAD	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	6.96	1.73e-11	3.58e-08	0.41	0.35	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
STAD	cis	rs6456156	0.774	rs2021999	ENSG00000265828.1	MIR3939	6.96	1.73e-11	3.58e-08	0.39	0.35	Primary biliary cholangitis;	chr6:167116278	chr6:166997807~166997912:-
STAD	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-6.96	1.74e-11	3.59e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
STAD	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	6.96	1.74e-11	3.59e-08	0.41	0.35	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
STAD	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-6.96	1.74e-11	3.6e-08	-0.34	-0.35	Height;	chr11:118808920	chr11:118791254~118793137:+
STAD	cis	rs12922317	0.964	rs12930612	ENSG00000260224.1	UBL5P4	6.96	1.75e-11	3.6e-08	0.36	0.35	Schizophrenia;	chr16:11978346	chr16:11968508~11968743:-
STAD	cis	rs6456156	0.742	rs2022000	ENSG00000265828.1	MIR3939	6.96	1.75e-11	3.61e-08	0.39	0.35	Primary biliary cholangitis;	chr6:167116123	chr6:166997807~166997912:-
STAD	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	6.96	1.75e-11	3.61e-08	0.41	0.35	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	6.96	1.75e-11	3.61e-08	0.41	0.35	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	6.96	1.75e-11	3.61e-08	0.41	0.35	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	6.96	1.75e-11	3.61e-08	0.42	0.35	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	6.96	1.75e-11	3.61e-08	0.42	0.35	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	6.96	1.75e-11	3.61e-08	0.42	0.35	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
STAD	cis	rs13217239	0.646	rs10946897	ENSG00000243307.2	POM121L6P	6.96	1.75e-11	3.62e-08	0.33	0.35	Schizophrenia;	chr6:27027472	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs6937880	ENSG00000243307.2	POM121L6P	6.96	1.75e-11	3.62e-08	0.33	0.35	Schizophrenia;	chr6:27032457	chr6:26896952~26898777:+
STAD	cis	rs10129255	0.5	rs7159033	ENSG00000223648.3	IGHV3-64	6.96	1.76e-11	3.62e-08	0.27	0.35	Kawasaki disease;	chr14:106701709	chr14:106643132~106658258:-
STAD	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-6.96	1.76e-11	3.63e-08	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
STAD	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-6.96	1.76e-11	3.64e-08	-0.27	-0.35	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
STAD	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-6.95	1.77e-11	3.65e-08	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
STAD	cis	rs11089937	0.54	rs9622920	ENSG00000211639.2	IGLV4-60	-6.95	1.77e-11	3.65e-08	-0.36	-0.35	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22162199~22162681:+
STAD	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	6.95	1.77e-11	3.65e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
STAD	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	6.95	1.77e-11	3.66e-08	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
STAD	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	6.95	1.79e-11	3.7e-08	0.34	0.35	Height;	chr3:53073764	chr3:53064283~53065091:-
STAD	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	6.95	1.8e-11	3.7e-08	0.27	0.35	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
STAD	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	6.95	1.8e-11	3.71e-08	0.41	0.35	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
STAD	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	6.95	1.81e-11	3.72e-08	0.44	0.35	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
STAD	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	6.95	1.81e-11	3.72e-08	0.26	0.35	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
STAD	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-6.95	1.81e-11	3.73e-08	-0.49	-0.35	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
STAD	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-6.95	1.81e-11	3.73e-08	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
STAD	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	6.95	1.81e-11	3.73e-08	0.47	0.35	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
STAD	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	6.95	1.82e-11	3.74e-08	0.49	0.35	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
STAD	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	6.95	1.82e-11	3.75e-08	0.4	0.35	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	6.95	1.83e-11	3.76e-08	0.39	0.35	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	6.95	1.83e-11	3.76e-08	0.39	0.35	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
STAD	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	6.95	1.83e-11	3.76e-08	0.39	0.35	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	6.95	1.84e-11	3.79e-08	0.37	0.35	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
STAD	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	6.95	1.84e-11	3.79e-08	0.48	0.35	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
STAD	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	6.95	1.87e-11	3.84e-08	0.47	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
STAD	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-6.95	1.87e-11	3.84e-08	-0.4	-0.35	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
STAD	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-6.95	1.87e-11	3.84e-08	-0.4	-0.35	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
STAD	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-6.95	1.87e-11	3.84e-08	-0.43	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
STAD	cis	rs2945232	1	rs2945232	ENSG00000173295.6	FAM86B3P	6.95	1.87e-11	3.85e-08	0.4	0.35	Schizophrenia;	chr8:8240516	chr8:8228595~8244865:+
STAD	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	6.95	1.88e-11	3.85e-08	0.4	0.35	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
STAD	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	6.94	1.88e-11	3.87e-08	0.42	0.35	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	6.94	1.89e-11	3.88e-08	0.4	0.35	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	6.94	1.89e-11	3.89e-08	0.42	0.35	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
STAD	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	6.94	1.9e-11	3.9e-08	0.44	0.35	Height;	chr6:109518783	chr6:109382795~109383666:+
STAD	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	6.94	1.9e-11	3.91e-08	0.43	0.35	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
STAD	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	6.94	1.91e-11	3.92e-08	0.39	0.35	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
STAD	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	6.94	1.91e-11	3.92e-08	0.39	0.35	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
STAD	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	6.94	1.92e-11	3.93e-08	0.54	0.35	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
STAD	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	6.94	1.92e-11	3.95e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	6.94	1.92e-11	3.95e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
STAD	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	6.94	1.93e-11	3.95e-08	0.47	0.35	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	6.94	1.93e-11	3.95e-08	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
STAD	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	6.94	1.93e-11	3.96e-08	0.44	0.35	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
STAD	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-6.94	1.93e-11	3.96e-08	-0.35	-0.35	Height;	chr11:118742526	chr11:118791254~118793137:+
STAD	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-6.94	1.94e-11	3.97e-08	-0.39	-0.35	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
STAD	cis	rs11089937	0.568	rs5756989	ENSG00000211639.2	IGLV4-60	6.94	1.94e-11	3.98e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22162199~22162681:+
STAD	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-6.94	1.94e-11	3.98e-08	-0.37	-0.35	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-6.94	1.94e-11	3.98e-08	-0.37	-0.35	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-6.94	1.94e-11	3.98e-08	-0.37	-0.35	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
STAD	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	6.94	1.95e-11	3.99e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
STAD	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-6.94	1.95e-11	4e-08	-0.39	-0.35	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
STAD	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-6.94	1.96e-11	4.01e-08	-0.37	-0.35	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
STAD	cis	rs3093024	1	rs3093024	ENSG00000265828.1	MIR3939	-6.94	1.96e-11	4.01e-08	-0.37	-0.35	Rheumatoid arthritis;	chr6:167119305	chr6:166997807~166997912:-
STAD	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	6.94	1.96e-11	4.01e-08	0.5	0.35	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
STAD	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	6.94	1.96e-11	4.01e-08	0.5	0.35	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
STAD	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	6.94	1.97e-11	4.03e-08	0.26	0.35	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
STAD	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-6.94	1.97e-11	4.04e-08	-0.41	-0.35	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
STAD	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	6.94	1.97e-11	4.04e-08	0.34	0.35	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
STAD	cis	rs2404602	0.655	rs10444809	ENSG00000259422.1	RP11-593F23.1	-6.94	1.97e-11	4.04e-08	-0.35	-0.35	Blood metabolite levels;	chr15:76832195	chr15:76174891~76181486:-
STAD	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	6.94	1.97e-11	4.04e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
STAD	cis	rs6456156	0.774	rs6456158	ENSG00000265828.1	MIR3939	-6.94	1.98e-11	4.04e-08	-0.39	-0.35	Primary biliary cholangitis;	chr6:167114544	chr6:166997807~166997912:-
STAD	cis	rs2221894	0.922	rs11136056	ENSG00000273710.1	Metazoa_SRP	-6.94	1.98e-11	4.04e-08	-0.38	-0.35	Obesity-related traits;	chr8:29006558	chr8:28915579~28915864:-
STAD	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	6.94	1.98e-11	4.05e-08	0.41	0.35	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	6.94	1.98e-11	4.05e-08	0.41	0.35	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
STAD	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	6.94	1.98e-11	4.05e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
STAD	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	6.94	1.99e-11	4.07e-08	0.27	0.35	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
STAD	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	6.94	2e-11	4.08e-08	0.4	0.35	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-6.93	2.01e-11	4.1e-08	-0.38	-0.35	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
STAD	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-6.93	2.01e-11	4.11e-08	-0.38	-0.35	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
STAD	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-6.93	2.02e-11	4.12e-08	-0.41	-0.35	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
STAD	cis	rs10129255	0.517	rs11625572	ENSG00000280411.1	IGHV1-69-2	-6.93	2.02e-11	4.12e-08	-0.33	-0.35	Kawasaki disease;	chr14:106656426	chr14:106762092~106762588:-
STAD	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-6.93	2.02e-11	4.12e-08	-0.35	-0.35	Height;	chr11:118737823	chr11:118791254~118793137:+
STAD	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-6.93	2.02e-11	4.13e-08	-0.49	-0.35	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
STAD	cis	rs6452524	0.868	rs1011981	ENSG00000243385.2	CTD-2110K23.1	6.93	2.02e-11	4.13e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.868	rs17284218	ENSG00000243385.2	CTD-2110K23.1	6.93	2.02e-11	4.13e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83201229~83202141:+
STAD	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-6.93	2.03e-11	4.13e-08	-0.51	-0.35	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
STAD	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	6.93	2.03e-11	4.14e-08	0.38	0.35	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
STAD	cis	rs11089937	0.597	rs4821773	ENSG00000211639.2	IGLV4-60	6.93	2.03e-11	4.15e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22162199~22162681:+
STAD	cis	rs6456156	0.846	rs10946211	ENSG00000265828.1	MIR3939	6.93	2.03e-11	4.15e-08	0.38	0.35	Primary biliary cholangitis;	chr6:167102001	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.846	rs7749827	ENSG00000265828.1	MIR3939	6.93	2.03e-11	4.15e-08	0.38	0.35	Primary biliary cholangitis;	chr6:167102136	chr6:166997807~166997912:-
STAD	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	6.93	2.04e-11	4.17e-08	0.37	0.35	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
STAD	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	6.93	2.04e-11	4.17e-08	0.37	0.35	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
STAD	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	6.93	2.05e-11	4.17e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
STAD	cis	rs875971	0.545	rs10261710	ENSG00000222364.1	RNU6-96P	-6.93	2.05e-11	4.18e-08	-0.44	-0.35	Aortic root size;	chr7:66249202	chr7:66395191~66395286:+
STAD	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-6.93	2.05e-11	4.18e-08	-0.41	-0.35	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
STAD	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	6.93	2.05e-11	4.18e-08	0.29	0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
STAD	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	6.93	2.05e-11	4.18e-08	0.38	0.35	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
STAD	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	6.93	2.05e-11	4.18e-08	0.38	0.35	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
STAD	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	6.93	2.05e-11	4.18e-08	0.37	0.35	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
STAD	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	6.93	2.06e-11	4.2e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
STAD	cis	rs7615952	0.512	rs4234285	ENSG00000272840.1	RP11-379B18.6	6.93	2.06e-11	4.2e-08	0.53	0.35	Blood pressure (smoking interaction);	chr3:125685633	chr3:125774714~125797953:+
STAD	cis	rs6782228	0.675	rs6806687	ENSG00000277250.1	Metazoa_SRP	6.93	2.06e-11	4.2e-08	0.34	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128673681~128674021:-
STAD	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-6.93	2.07e-11	4.22e-08	-0.46	-0.35	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
STAD	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-6.93	2.08e-11	4.23e-08	-0.49	-0.35	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
STAD	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	6.93	2.08e-11	4.23e-08	0.31	0.35	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
STAD	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	6.93	2.08e-11	4.24e-08	0.4	0.35	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
STAD	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	6.93	2.09e-11	4.25e-08	0.37	0.35	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	6.93	2.09e-11	4.25e-08	0.37	0.35	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	6.93	2.09e-11	4.25e-08	0.37	0.35	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	6.93	2.09e-11	4.25e-08	0.37	0.35	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
STAD	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-6.93	2.09e-11	4.26e-08	-0.33	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
STAD	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-6.93	2.1e-11	4.27e-08	-0.47	-0.35	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
STAD	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	6.93	2.1e-11	4.27e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	6.93	2.1e-11	4.27e-08	0.26	0.35	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	6.93	2.1e-11	4.27e-08	0.26	0.35	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
STAD	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	6.93	2.1e-11	4.28e-08	0.44	0.35	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
STAD	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-6.93	2.1e-11	4.28e-08	-0.51	-0.35	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
STAD	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	6.93	2.12e-11	4.31e-08	0.4	0.35	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
STAD	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-6.93	2.12e-11	4.31e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
STAD	cis	rs11089937	0.597	rs4821768	ENSG00000211639.2	IGLV4-60	6.92	2.14e-11	4.35e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.597	rs4821770	ENSG00000211639.2	IGLV4-60	6.92	2.14e-11	4.35e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.568	rs4821771	ENSG00000211639.2	IGLV4-60	6.92	2.14e-11	4.35e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22162199~22162681:+
STAD	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-6.92	2.14e-11	4.35e-08	-0.51	-0.35	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
STAD	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-6.92	2.14e-11	4.35e-08	-0.3	-0.35	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
STAD	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-6.92	2.15e-11	4.37e-08	-0.45	-0.35	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
STAD	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	6.92	2.15e-11	4.38e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	6.92	2.15e-11	4.38e-08	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
STAD	cis	rs801193	1	rs17566701	ENSG00000222364.1	RNU6-96P	-6.92	2.16e-11	4.39e-08	-0.4	-0.35	Aortic root size;	chr7:66728196	chr7:66395191~66395286:+
STAD	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	6.92	2.16e-11	4.39e-08	0.47	0.35	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
STAD	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-6.92	2.16e-11	4.39e-08	-0.4	-0.35	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
STAD	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-6.92	2.17e-11	4.4e-08	-0.42	-0.35	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
STAD	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-6.92	2.17e-11	4.41e-08	-0.34	-0.35	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
STAD	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	6.92	2.17e-11	4.41e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
STAD	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	6.92	2.18e-11	4.42e-08	0.41	0.35	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
STAD	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	6.92	2.18e-11	4.43e-08	0.53	0.35	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
STAD	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	6.92	2.19e-11	4.44e-08	0.29	0.35	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
STAD	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	6.92	2.19e-11	4.44e-08	0.29	0.35	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
STAD	cis	rs7580658	0.864	rs4150454	ENSG00000200250.1	RNU6-1147P	6.92	2.2e-11	4.46e-08	0.34	0.35	Protein C levels;	chr2:127280968	chr2:127316873~127316979:+
STAD	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	6.92	2.2e-11	4.46e-08	0.37	0.35	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
STAD	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	6.92	2.2e-11	4.47e-08	0.33	0.35	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
STAD	cis	rs11098499	0.954	rs11098524	ENSG00000248280.1	RP11-33B1.2	6.92	2.21e-11	4.48e-08	0.42	0.35	Corneal astigmatism;	chr4:119468877	chr4:119440561~119450157:-
STAD	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	6.92	2.21e-11	4.48e-08	0.44	0.35	Height;	chr6:109533040	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	6.92	2.21e-11	4.48e-08	0.44	0.35	Height;	chr6:109534269	chr6:109382795~109383666:+
STAD	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-6.92	2.21e-11	4.48e-08	-0.44	-0.35	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
STAD	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	6.92	2.22e-11	4.5e-08	0.48	0.35	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
STAD	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	6.92	2.22e-11	4.5e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
STAD	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	6.92	2.22e-11	4.5e-08	0.43	0.35	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
STAD	cis	rs12922317	0.538	rs446289	ENSG00000260224.1	UBL5P4	-6.92	2.22e-11	4.5e-08	-0.37	-0.35	Schizophrenia;	chr16:11976629	chr16:11968508~11968743:-
STAD	cis	rs2436845	0.521	rs1714399	ENSG00000253385.1	KB-1254G8.1	6.92	2.22e-11	4.5e-08	0.36	0.35	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102892525	chr8:102854455~102856075:+
STAD	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-6.92	2.22e-11	4.5e-08	-0.47	-0.35	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
STAD	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	6.92	2.22e-11	4.51e-08	0.36	0.35	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
STAD	cis	rs2283792	0.846	rs240053	ENSG00000228050.1	TOP3BP1	6.92	2.22e-11	4.51e-08	0.39	0.35	Multiple sclerosis;	chr22:21911000	chr22:22223187~22224566:-
STAD	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-6.92	2.23e-11	4.53e-08	-0.4	-0.35	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
STAD	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-6.92	2.23e-11	4.53e-08	-0.4	-0.35	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
STAD	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-6.92	2.23e-11	4.53e-08	-0.4	-0.35	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
STAD	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	6.92	2.24e-11	4.53e-08	0.45	0.35	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
STAD	cis	rs2436845	0.521	rs7833202	ENSG00000253385.1	KB-1254G8.1	6.92	2.25e-11	4.55e-08	0.35	0.35	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102909325	chr8:102854455~102856075:+
STAD	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-6.92	2.25e-11	4.56e-08	-0.51	-0.35	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
STAD	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	6.92	2.26e-11	4.57e-08	0.54	0.35	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
STAD	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	6.92	2.26e-11	4.58e-08	0.42	0.35	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
STAD	cis	rs11089937	0.597	rs4821774	ENSG00000211639.2	IGLV4-60	6.92	2.26e-11	4.58e-08	0.38	0.35	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22162199~22162681:+
STAD	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-6.92	2.26e-11	4.58e-08	-0.44	-0.35	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
STAD	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	6.92	2.26e-11	4.58e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
STAD	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-6.92	2.27e-11	4.59e-08	-0.34	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
STAD	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	6.91	2.27e-11	4.59e-08	0.36	0.35	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
STAD	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-6.91	2.27e-11	4.6e-08	-0.53	-0.35	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	6.91	2.27e-11	4.6e-08	0.27	0.35	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
STAD	cis	rs6452524	1	rs10080123	ENSG00000243385.2	CTD-2110K23.1	-6.91	2.28e-11	4.61e-08	-0.4	-0.35	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83201229~83202141:+
STAD	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	6.91	2.28e-11	4.61e-08	0.46	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
STAD	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-6.91	2.28e-11	4.61e-08	-0.35	-0.35	Height;	chr11:118737916	chr11:118791254~118793137:+
STAD	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	6.91	2.28e-11	4.61e-08	0.41	0.35	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
STAD	cis	rs11089937	0.626	rs5757056	ENSG00000211639.2	IGLV4-60	6.91	2.28e-11	4.62e-08	0.36	0.35	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22162199~22162681:+
STAD	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-6.91	2.29e-11	4.62e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-6.91	2.29e-11	4.62e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-6.91	2.29e-11	4.62e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
STAD	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-6.91	2.29e-11	4.62e-08	-0.56	-0.35	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
STAD	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-6.91	2.29e-11	4.62e-08	-0.31	-0.35	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
STAD	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-6.91	2.29e-11	4.63e-08	-0.42	-0.35	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-6.91	2.29e-11	4.63e-08	-0.42	-0.35	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-6.91	2.29e-11	4.63e-08	-0.42	-0.35	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
STAD	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-6.91	2.29e-11	4.63e-08	-0.4	-0.35	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
STAD	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	6.91	2.3e-11	4.65e-08	0.44	0.35	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
STAD	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-6.91	2.3e-11	4.65e-08	-0.33	-0.35	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
STAD	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-6.91	2.32e-11	4.68e-08	-0.43	-0.35	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
STAD	cis	rs7580658	0.891	rs3768866	ENSG00000200250.1	RNU6-1147P	6.91	2.33e-11	4.7e-08	0.34	0.35	Protein C levels;	chr2:127287839	chr2:127316873~127316979:+
STAD	cis	rs2221894	0.922	rs7837237	ENSG00000273710.1	Metazoa_SRP	6.91	2.33e-11	4.71e-08	0.38	0.35	Obesity-related traits;	chr8:29018704	chr8:28915579~28915864:-
STAD	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	6.91	2.34e-11	4.71e-08	0.4	0.35	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
STAD	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-6.91	2.34e-11	4.73e-08	-0.35	-0.35	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
STAD	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-6.91	2.35e-11	4.74e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
STAD	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-6.91	2.35e-11	4.75e-08	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
STAD	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	6.91	2.35e-11	4.75e-08	0.33	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
STAD	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-6.91	2.35e-11	4.75e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-6.91	2.35e-11	4.75e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-6.91	2.35e-11	4.75e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-6.91	2.35e-11	4.75e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-6.91	2.35e-11	4.75e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-6.91	2.36e-11	4.75e-08	-0.49	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
STAD	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-6.91	2.36e-11	4.76e-08	-0.45	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
STAD	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	6.91	2.36e-11	4.76e-08	0.41	0.35	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
STAD	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	6.91	2.37e-11	4.78e-08	0.3	0.35	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
STAD	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	6.91	2.37e-11	4.78e-08	0.35	0.35	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	6.91	2.37e-11	4.78e-08	0.35	0.35	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	6.91	2.37e-11	4.78e-08	0.35	0.35	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	6.91	2.37e-11	4.78e-08	0.35	0.35	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	6.91	2.37e-11	4.78e-08	0.35	0.35	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
STAD	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	6.91	2.37e-11	4.79e-08	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	6.91	2.37e-11	4.79e-08	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
STAD	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-6.91	2.38e-11	4.79e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
STAD	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	6.91	2.38e-11	4.8e-08	0.35	0.35	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
STAD	cis	rs2221894	0.96	rs1877501	ENSG00000273710.1	Metazoa_SRP	-6.91	2.38e-11	4.8e-08	-0.38	-0.35	Obesity-related traits;	chr8:28952434	chr8:28915579~28915864:-
STAD	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	6.91	2.39e-11	4.82e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-6.91	2.39e-11	4.82e-08	-0.47	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
STAD	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	6.91	2.39e-11	4.82e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
STAD	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	6.91	2.39e-11	4.82e-08	0.44	0.35	Height;	chr6:109571489	chr6:109382795~109383666:+
STAD	cis	rs6452524	0.836	rs62372713	ENSG00000243385.2	CTD-2110K23.1	6.91	2.4e-11	4.82e-08	0.42	0.35	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83201229~83202141:+
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-6.91	2.4e-11	4.83e-08	-0.39	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
STAD	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-6.91	2.4e-11	4.84e-08	-0.33	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
STAD	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	6.91	2.4e-11	4.84e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
STAD	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-6.91	2.4e-11	4.84e-08	-0.4	-0.35	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
STAD	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	6.91	2.41e-11	4.85e-08	0.44	0.35	Height;	chr6:109586733	chr6:109382795~109383666:+
STAD	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-6.9	2.42e-11	4.86e-08	-0.39	-0.35	Height;	chr3:53034139	chr3:53064283~53065091:-
STAD	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-6.9	2.42e-11	4.87e-08	-0.43	-0.35	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
STAD	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	6.9	2.43e-11	4.88e-08	0.47	0.35	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
STAD	cis	rs496547	0.686	rs524590	ENSG00000255422.1	AP002954.4	-6.9	2.43e-11	4.89e-08	-0.41	-0.35	Hip minimal joint space width;	chr11:118769354	chr11:118704607~118750263:+
STAD	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-6.9	2.43e-11	4.89e-08	-0.41	-0.35	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
STAD	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	6.9	2.44e-11	4.89e-08	0.41	0.35	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
STAD	cis	rs875971	0.66	rs7807930	ENSG00000222364.1	RNU6-96P	6.9	2.44e-11	4.91e-08	0.39	0.35	Aortic root size;	chr7:66622178	chr7:66395191~66395286:+
STAD	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	6.9	2.45e-11	4.92e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
STAD	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	6.9	2.45e-11	4.92e-08	0.39	0.35	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
STAD	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	6.9	2.45e-11	4.92e-08	0.33	0.35	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
STAD	cis	rs2833693	0.572	rs4816428	ENSG00000261610.1	AP000265.1	6.9	2.45e-11	4.93e-08	0.39	0.35	Temperament;	chr21:32232689	chr21:32259804~32261585:-
STAD	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-6.9	2.46e-11	4.93e-08	-0.45	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
STAD	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	6.9	2.46e-11	4.94e-08	0.37	0.35	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
STAD	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	6.9	2.46e-11	4.95e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
STAD	cis	rs2283792	0.812	rs94194	ENSG00000228050.1	TOP3BP1	6.9	2.46e-11	4.95e-08	0.39	0.35	Multiple sclerosis;	chr22:21933937	chr22:22223187~22224566:-
STAD	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	6.9	2.47e-11	4.95e-08	0.46	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	6.9	2.48e-11	4.97e-08	0.26	0.35	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
STAD	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-6.9	2.48e-11	4.98e-08	-0.35	-0.35	Height;	chr11:118746590	chr11:118791254~118793137:+
STAD	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-6.9	2.49e-11	4.99e-08	-0.47	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
STAD	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	6.9	2.5e-11	5.02e-08	0.47	0.35	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
STAD	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	6.9	2.51e-11	5.04e-08	0.33	0.35	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
STAD	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-6.9	2.51e-11	5.04e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
STAD	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-6.9	2.51e-11	5.04e-08	-0.41	-0.35	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	6.9	2.51e-11	5.05e-08	0.27	0.35	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
STAD	cis	rs496547	0.686	rs540180	ENSG00000255422.1	AP002954.4	-6.9	2.52e-11	5.06e-08	-0.41	-0.35	Hip minimal joint space width;	chr11:118782920	chr11:118704607~118750263:+
STAD	cis	rs496547	0.686	rs2508916	ENSG00000255422.1	AP002954.4	-6.9	2.52e-11	5.06e-08	-0.41	-0.35	Hip minimal joint space width;	chr11:118783942	chr11:118704607~118750263:+
STAD	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-6.9	2.53e-11	5.07e-08	-0.4	-0.35	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
STAD	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-6.9	2.54e-11	5.09e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-6.9	2.54e-11	5.09e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
STAD	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-6.9	2.54e-11	5.09e-08	-0.42	-0.35	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-6.9	2.54e-11	5.09e-08	-0.42	-0.35	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
STAD	cis	rs496547	0.686	rs487728	ENSG00000255422.1	AP002954.4	-6.9	2.54e-11	5.1e-08	-0.41	-0.35	Hip minimal joint space width;	chr11:118750785	chr11:118704607~118750263:+
STAD	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-6.9	2.55e-11	5.11e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
STAD	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	6.9	2.55e-11	5.11e-08	0.48	0.35	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
STAD	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-6.9	2.55e-11	5.11e-08	-0.48	-0.35	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
STAD	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-6.9	2.55e-11	5.11e-08	-0.48	-0.35	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
STAD	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-6.9	2.55e-11	5.11e-08	-0.48	-0.35	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
STAD	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	6.9	2.55e-11	5.11e-08	0.37	0.35	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
STAD	cis	rs2436845	0.554	rs647313	ENSG00000253385.1	KB-1254G8.1	6.9	2.56e-11	5.12e-08	0.35	0.35	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102904426	chr8:102854455~102856075:+
STAD	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	6.89	2.57e-11	5.15e-08	0.36	0.35	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
STAD	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.4	-0.35	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-6.89	2.58e-11	5.16e-08	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
STAD	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-6.89	2.59e-11	5.17e-08	-0.32	-0.35	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
STAD	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-6.89	2.59e-11	5.17e-08	-0.32	-0.35	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
STAD	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-6.89	2.6e-11	5.19e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
STAD	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	6.89	2.6e-11	5.19e-08	0.33	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
STAD	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-6.89	2.61e-11	5.21e-08	-0.4	-0.35	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
STAD	cis	rs7849270	0.84	rs3118639	ENSG00000268707.1	RP11-247A12.7	6.89	2.62e-11	5.23e-08	0.45	0.35	Blood metabolite ratios;	chr9:129093324	chr9:129170434~129170940:+
STAD	cis	rs6456156	0.774	rs9347175	ENSG00000265828.1	MIR3939	6.89	2.64e-11	5.27e-08	0.39	0.35	Primary biliary cholangitis;	chr6:167114156	chr6:166997807~166997912:-
STAD	cis	rs6456156	0.742	rs6456157	ENSG00000265828.1	MIR3939	6.89	2.64e-11	5.27e-08	0.39	0.35	Primary biliary cholangitis;	chr6:167114330	chr6:166997807~166997912:-
STAD	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-6.89	2.64e-11	5.27e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-6.89	2.64e-11	5.27e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
STAD	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-6.89	2.64e-11	5.28e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-6.89	2.64e-11	5.28e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
STAD	cis	rs494459	0.536	rs7103067	ENSG00000255422.1	AP002954.4	-6.89	2.65e-11	5.29e-08	-0.41	-0.35	Height;	chr11:118852670	chr11:118704607~118750263:+
STAD	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	6.89	2.65e-11	5.3e-08	0.39	0.35	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
STAD	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-6.89	2.65e-11	5.3e-08	-0.34	-0.35	Height;	chr11:118791319	chr11:118791254~118793137:+
STAD	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-6.89	2.67e-11	5.32e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-6.89	2.67e-11	5.32e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
STAD	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-6.89	2.67e-11	5.33e-08	-0.52	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
STAD	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	6.89	2.67e-11	5.34e-08	0.43	0.35	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
STAD	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	6.89	2.68e-11	5.34e-08	0.44	0.35	Height;	chr6:109546439	chr6:109382795~109383666:+
STAD	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	6.89	2.68e-11	5.34e-08	0.44	0.35	Height;	chr6:109551060	chr6:109382795~109383666:+
STAD	cis	rs17361889	0.752	rs6956986	ENSG00000224683.1	RPL36AP29	-6.89	2.68e-11	5.34e-08	-0.38	-0.35	Pediatric bone mineral content (hip);	chr7:16230707	chr7:16208945~16209265:+
STAD	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-6.89	2.68e-11	5.34e-08	-0.32	-0.35	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
STAD	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	6.89	2.68e-11	5.34e-08	0.32	0.35	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
STAD	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	6.89	2.68e-11	5.35e-08	0.36	0.35	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
STAD	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	6.89	2.68e-11	5.35e-08	0.42	0.35	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
STAD	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	6.89	2.69e-11	5.36e-08	0.54	0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
STAD	cis	rs11089937	0.609	rs2213158	ENSG00000211639.2	IGLV4-60	6.89	2.69e-11	5.36e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.637	rs2213159	ENSG00000211639.2	IGLV4-60	6.89	2.69e-11	5.36e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22162199~22162681:+
STAD	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	6.89	2.69e-11	5.37e-08	0.4	0.35	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
STAD	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	6.89	2.7e-11	5.38e-08	0.29	0.35	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
STAD	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-6.89	2.7e-11	5.38e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
STAD	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	6.89	2.72e-11	5.42e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
STAD	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	6.89	2.72e-11	5.43e-08	0.4	0.35	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
STAD	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-6.89	2.73e-11	5.43e-08	-0.34	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
STAD	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-6.89	2.73e-11	5.43e-08	-0.34	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
STAD	cis	rs858239	0.669	rs1618339	ENSG00000226816.2	AC005082.12	6.88	2.74e-11	5.46e-08	0.41	0.35	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23206013~23208045:+
STAD	cis	rs13217239	0.646	rs7768407	ENSG00000243307.2	POM121L6P	6.88	2.74e-11	5.46e-08	0.34	0.35	Schizophrenia;	chr6:27049016	chr6:26896952~26898777:+
STAD	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	6.88	2.74e-11	5.46e-08	0.44	0.35	Height;	chr6:109490935	chr6:109382795~109383666:+
STAD	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-6.88	2.75e-11	5.47e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
STAD	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-6.88	2.75e-11	5.47e-08	-0.36	-0.35	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
STAD	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	6.88	2.76e-11	5.5e-08	0.3	0.35	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
STAD	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-6.88	2.77e-11	5.51e-08	-0.4	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
STAD	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
STAD	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
STAD	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	6.88	2.77e-11	5.51e-08	0.36	0.35	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.868	rs10057303	ENSG00000243385.2	CTD-2110K23.1	6.88	2.78e-11	5.54e-08	0.42	0.35	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.868	rs2386235	ENSG00000243385.2	CTD-2110K23.1	6.88	2.78e-11	5.54e-08	0.42	0.35	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83201229~83202141:+
STAD	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-6.88	2.79e-11	5.55e-08	-0.36	-0.35	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
STAD	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	6.88	2.79e-11	5.56e-08	0.37	0.35	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
STAD	cis	rs6456156	0.846	rs9364891	ENSG00000265828.1	MIR3939	6.88	2.8e-11	5.57e-08	0.38	0.35	Primary biliary cholangitis;	chr6:167102831	chr6:166997807~166997912:-
STAD	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	6.88	2.81e-11	5.58e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
STAD	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	6.88	2.81e-11	5.58e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
STAD	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-6.88	2.81e-11	5.59e-08	-0.43	-0.35	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
STAD	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	6.88	2.82e-11	5.6e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	6.88	2.82e-11	5.6e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
STAD	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	6.88	2.83e-11	5.61e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	6.88	2.84e-11	5.63e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
STAD	cis	rs9506514	0.76	rs9506518	ENSG00000238286.1	SLC35E1P1	-6.88	2.84e-11	5.63e-08	-0.4	-0.35	Coronary artery calcification;	chr13:20560843	chr13:20607268~20608131:+
STAD	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	6.88	2.84e-11	5.63e-08	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
STAD	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	6.88	2.84e-11	5.63e-08	0.45	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	6.88	2.84e-11	5.63e-08	0.45	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
STAD	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	6.88	2.84e-11	5.63e-08	0.3	0.35	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
STAD	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	6.88	2.84e-11	5.64e-08	0.29	0.35	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
STAD	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	6.88	2.84e-11	5.64e-08	0.29	0.35	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	6.88	2.84e-11	5.64e-08	0.26	0.35	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	6.88	2.84e-11	5.64e-08	0.26	0.35	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
STAD	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-6.88	2.85e-11	5.65e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
STAD	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-6.88	2.85e-11	5.65e-08	-0.34	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
STAD	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	6.88	2.86e-11	5.67e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	6.88	2.86e-11	5.68e-08	0.45	0.35	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
STAD	cis	rs4568518	0.53	rs12699921	ENSG00000279048.1	RP11-511H23.2	6.88	2.87e-11	5.69e-08	0.32	0.35	Measles;	chr7:17954871	chr7:17940503~17942922:+
STAD	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-6.88	2.87e-11	5.69e-08	-0.51	-0.35	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
STAD	cis	rs2273156	0.57	rs7144423	ENSG00000241052.1	RP11-173D9.1	-6.88	2.87e-11	5.69e-08	-0.42	-0.35	Immunoglobulin light chain (AL) amyloidosis;	chr14:35103341	chr14:35144021~35144480:-
STAD	cis	rs2221894	1	rs10111019	ENSG00000273710.1	Metazoa_SRP	-6.88	2.88e-11	5.7e-08	-0.38	-0.35	Obesity-related traits;	chr8:28972783	chr8:28915579~28915864:-
STAD	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-6.88	2.88e-11	5.7e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-6.88	2.88e-11	5.7e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-6.88	2.88e-11	5.7e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-6.88	2.88e-11	5.7e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
STAD	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	6.88	2.88e-11	5.71e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-6.88	2.88e-11	5.71e-08	-0.47	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
STAD	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-6.88	2.89e-11	5.72e-08	-0.39	-0.35	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
STAD	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-6.88	2.9e-11	5.73e-08	-0.48	-0.35	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
STAD	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	6.87	2.91e-11	5.75e-08	0.36	0.35	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
STAD	cis	rs9355610	0.609	rs62436424	ENSG00000265828.1	MIR3939	6.87	2.91e-11	5.77e-08	0.43	0.35	Graves' disease;	chr6:166960770	chr6:166997807~166997912:-
STAD	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	6.87	2.92e-11	5.78e-08	0.39	0.35	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
STAD	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-6.87	2.93e-11	5.8e-08	-0.36	-0.35	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-6.87	2.93e-11	5.8e-08	-0.36	-0.35	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
STAD	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-6.87	2.94e-11	5.81e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	6.87	2.95e-11	5.84e-08	0.26	0.35	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
STAD	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-6.87	2.95e-11	5.84e-08	-0.36	-0.35	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
STAD	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-6.87	2.95e-11	5.84e-08	-0.36	-0.35	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-6.87	2.95e-11	5.84e-08	-0.36	-0.35	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-6.87	2.95e-11	5.84e-08	-0.36	-0.35	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
STAD	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	6.87	2.97e-11	5.86e-08	0.37	0.35	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
STAD	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-6.87	2.97e-11	5.87e-08	-0.4	-0.35	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-6.87	2.97e-11	5.87e-08	-0.4	-0.35	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-6.87	2.97e-11	5.87e-08	-0.4	-0.35	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-6.87	2.97e-11	5.87e-08	-0.4	-0.35	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-6.87	2.97e-11	5.87e-08	-0.4	-0.35	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
STAD	cis	rs12922317	0.535	rs8051349	ENSG00000260224.1	UBL5P4	-6.87	2.97e-11	5.87e-08	-0.35	-0.35	Schizophrenia;	chr16:12011666	chr16:11968508~11968743:-
STAD	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	6.87	2.97e-11	5.87e-08	0.35	0.35	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
STAD	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	6.87	2.98e-11	5.88e-08	0.32	0.35	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
STAD	cis	rs8040855	0.599	rs2342123	ENSG00000229212.6	RP11-561C5.4	6.87	2.99e-11	5.9e-08	0.45	0.35	Bulimia nervosa;	chr15:85181918	chr15:85205440~85234795:-
STAD	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	6.87	3e-11	5.92e-08	0.42	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
STAD	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-6.87	3e-11	5.92e-08	-0.39	-0.35	Height;	chr3:53029908	chr3:53064283~53065091:-
STAD	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-6.87	3e-11	5.93e-08	-0.51	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
STAD	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	6.87	3.01e-11	5.94e-08	0.44	0.35	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
STAD	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-6.87	3.03e-11	5.97e-08	-0.33	-0.35	Height;	chr3:53074760	chr3:53064283~53065091:-
STAD	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-6.87	3.03e-11	5.98e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
STAD	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-6.87	3.03e-11	5.98e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
STAD	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-6.87	3.03e-11	5.98e-08	-0.4	-0.35	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
STAD	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-6.87	3.04e-11	5.99e-08	-0.38	-0.35	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
STAD	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	6.87	3.05e-11	6.02e-08	0.35	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
STAD	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	6.87	3.05e-11	6.02e-08	0.41	0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
STAD	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-6.87	3.06e-11	6.03e-08	-0.5	-0.35	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
STAD	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	6.87	3.06e-11	6.03e-08	0.3	0.35	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
STAD	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	6.87	3.06e-11	6.03e-08	0.4	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
STAD	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-6.87	3.06e-11	6.03e-08	-0.44	-0.35	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
STAD	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-6.87	3.06e-11	6.04e-08	-0.45	-0.35	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
STAD	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	6.87	3.06e-11	6.04e-08	0.3	0.35	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
STAD	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
STAD	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	6.87	3.07e-11	6.04e-08	0.36	0.35	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
STAD	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-6.87	3.07e-11	6.05e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
STAD	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	6.87	3.07e-11	6.05e-08	0.41	0.35	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
STAD	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	6.87	3.08e-11	6.06e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	6.87	3.08e-11	6.06e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	6.87	3.08e-11	6.06e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	6.87	3.08e-11	6.06e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	6.87	3.08e-11	6.06e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	6.87	3.08e-11	6.06e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	6.87	3.08e-11	6.06e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
STAD	cis	rs2221894	0.881	rs6994074	ENSG00000273710.1	Metazoa_SRP	6.87	3.08e-11	6.06e-08	0.37	0.35	Obesity-related traits;	chr8:29035376	chr8:28915579~28915864:-
STAD	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	6.87	3.08e-11	6.06e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	6.87	3.08e-11	6.06e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	6.87	3.08e-11	6.06e-08	0.41	0.35	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	6.87	3.08e-11	6.06e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	6.87	3.08e-11	6.06e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	6.87	3.08e-11	6.06e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
STAD	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	6.86	3.09e-11	6.08e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
STAD	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	6.86	3.09e-11	6.08e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-6.86	3.1e-11	6.09e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-6.86	3.1e-11	6.09e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-6.86	3.1e-11	6.09e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-6.86	3.1e-11	6.09e-08	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
STAD	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-6.86	3.1e-11	6.1e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-6.86	3.1e-11	6.1e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-6.86	3.1e-11	6.1e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-6.86	3.1e-11	6.1e-08	-0.55	-0.35	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
STAD	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	6.86	3.11e-11	6.11e-08	0.33	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
STAD	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-6.86	3.11e-11	6.12e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
STAD	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	6.86	3.11e-11	6.12e-08	0.36	0.35	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	6.86	3.11e-11	6.12e-08	0.36	0.35	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
STAD	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	6.86	3.11e-11	6.12e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
STAD	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-6.86	3.12e-11	6.12e-08	-0.41	-0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
STAD	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	6.86	3.12e-11	6.14e-08	0.4	0.35	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
STAD	cis	rs11089937	0.512	rs34963809	ENSG00000211639.2	IGLV4-60	6.86	3.13e-11	6.15e-08	0.37	0.35	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22162199~22162681:+
STAD	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	6.86	3.13e-11	6.15e-08	0.44	0.35	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
STAD	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-6.86	3.14e-11	6.16e-08	-0.44	-0.35	Height;	chr6:109731677	chr6:109382795~109383666:+
STAD	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-6.86	3.14e-11	6.16e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
STAD	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	6.86	3.14e-11	6.17e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
STAD	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-6.86	3.15e-11	6.19e-08	-0.39	-0.35	Height;	chr3:53027969	chr3:53064283~53065091:-
STAD	cis	rs7829975	0.511	rs1543238	ENSG00000173295.6	FAM86B3P	6.86	3.16e-11	6.21e-08	0.39	0.35	Mood instability;	chr8:8277287	chr8:8228595~8244865:+
STAD	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	6.86	3.16e-11	6.21e-08	0.35	0.35	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	6.86	3.17e-11	6.22e-08	0.36	0.35	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
STAD	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-6.86	3.18e-11	6.23e-08	-0.59	-0.35	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
STAD	cis	rs9355610	0.609	rs9366076	ENSG00000265828.1	MIR3939	6.86	3.18e-11	6.25e-08	0.43	0.35	Graves' disease;	chr6:166960220	chr6:166997807~166997912:-
STAD	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-6.86	3.19e-11	6.27e-08	-0.51	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
STAD	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	6.86	3.2e-11	6.28e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
STAD	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	6.86	3.22e-11	6.32e-08	0.35	0.35	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	6.86	3.23e-11	6.32e-08	0.35	0.35	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
STAD	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	6.86	3.24e-11	6.35e-08	0.43	0.35	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
STAD	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-6.86	3.24e-11	6.35e-08	-0.38	-0.35	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	6.86	3.24e-11	6.35e-08	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	6.86	3.25e-11	6.37e-08	0.27	0.35	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
STAD	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	6.86	3.25e-11	6.37e-08	0.33	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
STAD	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	6.86	3.25e-11	6.37e-08	0.33	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
STAD	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-6.86	3.25e-11	6.37e-08	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-6.86	3.25e-11	6.37e-08	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-6.86	3.25e-11	6.37e-08	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-6.86	3.25e-11	6.37e-08	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
STAD	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-6.86	3.26e-11	6.38e-08	-0.36	-0.35	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
STAD	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	6.86	3.27e-11	6.41e-08	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
STAD	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
STAD	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-6.86	3.27e-11	6.41e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
STAD	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	6.86	3.28e-11	6.42e-08	0.44	0.35	Height;	chr6:109715504	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	6.86	3.28e-11	6.42e-08	0.44	0.35	Height;	chr6:109715560	chr6:109382795~109383666:+
STAD	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-6.86	3.28e-11	6.42e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-6.86	3.28e-11	6.42e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
STAD	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	6.86	3.28e-11	6.42e-08	0.4	0.35	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
STAD	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	6.85	3.29e-11	6.43e-08	0.35	0.35	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	6.85	3.29e-11	6.43e-08	0.35	0.35	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
STAD	cis	rs17361889	0.752	rs34750529	ENSG00000224683.1	RPL36AP29	6.85	3.29e-11	6.43e-08	0.39	0.35	Pediatric bone mineral content (hip);	chr7:16236950	chr7:16208945~16209265:+
STAD	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	6.85	3.29e-11	6.43e-08	0.46	0.35	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
STAD	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	6.85	3.29e-11	6.44e-08	0.32	0.35	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
STAD	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	6.85	3.29e-11	6.44e-08	0.41	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
STAD	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	6.85	3.3e-11	6.45e-08	0.41	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
STAD	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	6.85	3.31e-11	6.47e-08	0.36	0.35	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
STAD	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	6.85	3.31e-11	6.47e-08	0.36	0.35	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
STAD	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	6.85	3.31e-11	6.47e-08	0.44	0.35	Height;	chr6:109558247	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	6.85	3.31e-11	6.47e-08	0.44	0.35	Height;	chr6:109564443	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	6.85	3.31e-11	6.47e-08	0.44	0.35	Height;	chr6:109576414	chr6:109382795~109383666:+
STAD	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-6.85	3.31e-11	6.47e-08	-0.36	-0.35	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
STAD	cis	rs11903757	1	rs10190843	ENSG00000281467.1	Clostridiales-1	6.85	3.32e-11	6.48e-08	0.54	0.35	Colorectal cancer;	chr2:191714957	chr2:191699476~191699631:-
STAD	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-6.85	3.32e-11	6.49e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
STAD	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	6.85	3.32e-11	6.49e-08	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	6.85	3.32e-11	6.49e-08	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
STAD	cis	rs13217239	0.646	rs10946898	ENSG00000243307.2	POM121L6P	6.85	3.32e-11	6.49e-08	0.33	0.35	Schizophrenia;	chr6:27036105	chr6:26896952~26898777:+
STAD	cis	rs875971	0.638	rs6960778	ENSG00000222364.1	RNU6-96P	6.85	3.34e-11	6.53e-08	0.39	0.35	Aortic root size;	chr7:66606610	chr7:66395191~66395286:+
STAD	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-6.85	3.35e-11	6.55e-08	-0.47	-0.35	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
STAD	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	6.85	3.36e-11	6.55e-08	0.4	0.35	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	6.85	3.36e-11	6.56e-08	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-6.85	3.36e-11	6.56e-08	-0.4	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
STAD	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	6.85	3.36e-11	6.56e-08	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
STAD	cis	rs8040855	0.599	rs8037195	ENSG00000229212.6	RP11-561C5.4	-6.85	3.37e-11	6.57e-08	-0.45	-0.35	Bulimia nervosa;	chr15:85181455	chr15:85205440~85234795:-
STAD	cis	rs10129255	0.5	rs7159033	ENSG00000211972.2	IGHV3-66	6.85	3.37e-11	6.57e-08	0.25	0.35	Kawasaki disease;	chr14:106701709	chr14:106675017~106675544:-
STAD	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	6.85	3.39e-11	6.6e-08	0.35	0.35	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	6.85	3.39e-11	6.6e-08	0.35	0.35	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	6.85	3.39e-11	6.6e-08	0.35	0.35	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	6.85	3.39e-11	6.6e-08	0.35	0.35	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	6.85	3.39e-11	6.6e-08	0.35	0.35	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
STAD	cis	rs611744	0.905	rs610891	ENSG00000253754.1	RP11-35G22.1	6.85	3.39e-11	6.61e-08	0.3	0.35	Dupuytren's disease;	chr8:108148774	chr8:108226200~108227544:+
STAD	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	6.85	3.4e-11	6.63e-08	0.27	0.35	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
STAD	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-6.85	3.41e-11	6.64e-08	-0.5	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
STAD	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-6.85	3.41e-11	6.64e-08	-0.54	-0.35	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
STAD	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-6.85	3.41e-11	6.65e-08	-0.42	-0.35	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
STAD	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-6.85	3.41e-11	6.65e-08	-0.42	-0.35	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
STAD	cis	rs6456156	0.711	rs1855025	ENSG00000265828.1	MIR3939	6.85	3.42e-11	6.65e-08	0.38	0.35	Primary biliary cholangitis;	chr6:167124106	chr6:166997807~166997912:-
STAD	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-6.85	3.42e-11	6.65e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
STAD	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	6.85	3.43e-11	6.67e-08	0.44	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
STAD	cis	rs9355610	0.609	rs3756838	ENSG00000265828.1	MIR3939	6.85	3.43e-11	6.68e-08	0.43	0.35	Graves' disease;	chr6:166957763	chr6:166997807~166997912:-
STAD	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-6.85	3.44e-11	6.69e-08	-0.4	-0.35	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
STAD	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	6.85	3.48e-11	6.76e-08	0.42	0.35	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	6.85	3.48e-11	6.76e-08	0.42	0.35	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
STAD	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	6.85	3.48e-11	6.76e-08	0.37	0.35	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
STAD	cis	rs11903757	1	rs4076769	ENSG00000281467.1	Clostridiales-1	6.85	3.48e-11	6.77e-08	0.57	0.35	Colorectal cancer;	chr2:191719480	chr2:191699476~191699631:-
STAD	cis	rs11089937	0.626	rs5757051	ENSG00000211639.2	IGLV4-60	-6.84	3.5e-11	6.8e-08	-0.36	-0.35	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22162199~22162681:+
STAD	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-6.84	3.53e-11	6.85e-08	-0.47	-0.35	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
STAD	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	6.84	3.53e-11	6.85e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	6.84	3.53e-11	6.85e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	6.84	3.53e-11	6.85e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	6.84	3.53e-11	6.86e-08	0.4	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
STAD	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	6.84	3.53e-11	6.86e-08	0.38	0.35	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
STAD	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	6.84	3.53e-11	6.86e-08	0.36	0.35	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
STAD	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-6.84	3.54e-11	6.87e-08	-0.33	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
STAD	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	6.84	3.55e-11	6.88e-08	0.38	0.35	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	6.84	3.55e-11	6.88e-08	0.38	0.35	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
STAD	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	6.84	3.56e-11	6.9e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	6.84	3.57e-11	6.93e-08	0.26	0.35	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	6.84	3.57e-11	6.93e-08	0.26	0.35	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
STAD	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-6.84	3.58e-11	6.94e-08	-0.53	-0.35	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
STAD	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	6.84	3.59e-11	6.96e-08	0.38	0.35	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
STAD	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	6.84	3.59e-11	6.97e-08	0.41	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
STAD	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	6.84	3.59e-11	6.97e-08	0.3	0.35	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
STAD	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-6.84	3.61e-11	6.99e-08	-0.61	-0.35	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	6.84	3.61e-11	7e-08	0.43	0.35	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-6.84	3.62e-11	7.01e-08	-0.36	-0.35	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
STAD	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-6.84	3.64e-11	7.05e-08	-0.42	-0.35	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-6.84	3.64e-11	7.05e-08	-0.42	-0.35	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
STAD	cis	rs7580658	0.891	rs55998967	ENSG00000200250.1	RNU6-1147P	6.84	3.64e-11	7.05e-08	0.33	0.35	Protein C levels;	chr2:127291098	chr2:127316873~127316979:+
STAD	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-6.84	3.65e-11	7.07e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
STAD	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-6.84	3.65e-11	7.08e-08	-0.36	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
STAD	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-6.84	3.66e-11	7.08e-08	-0.4	-0.35	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
STAD	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-6.84	3.66e-11	7.08e-08	-0.4	-0.35	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
STAD	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	6.84	3.67e-11	7.1e-08	0.43	0.34	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
STAD	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-6.84	3.68e-11	7.13e-08	-0.37	-0.34	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
STAD	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	6.84	3.69e-11	7.13e-08	0.41	0.34	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
STAD	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	6.84	3.69e-11	7.14e-08	0.36	0.34	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
STAD	cis	rs6452524	1	rs10474093	ENSG00000243385.2	CTD-2110K23.1	6.84	3.69e-11	7.14e-08	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs10473868	ENSG00000243385.2	CTD-2110K23.1	6.84	3.69e-11	7.14e-08	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83201229~83202141:+
STAD	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	6.84	3.7e-11	7.17e-08	0.4	0.34	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
STAD	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-6.84	3.71e-11	7.17e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
STAD	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.84	3.71e-11	7.17e-08	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
STAD	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-6.84	3.71e-11	7.18e-08	-0.38	-0.34	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
STAD	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	6.83	3.73e-11	7.22e-08	0.41	0.34	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
STAD	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	6.83	3.74e-11	7.24e-08	0.66	0.34	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
STAD	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	6.83	3.74e-11	7.24e-08	0.58	0.34	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
STAD	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-6.83	3.75e-11	7.25e-08	-0.34	-0.34	Height;	chr11:118760944	chr11:118791254~118793137:+
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	6.83	3.76e-11	7.27e-08	0.39	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
STAD	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	6.83	3.77e-11	7.28e-08	0.51	0.34	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	6.83	3.78e-11	7.31e-08	0.26	0.34	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	6.83	3.78e-11	7.31e-08	0.26	0.34	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
STAD	cis	rs2221894	0.922	rs11136052	ENSG00000273710.1	Metazoa_SRP	-6.83	3.78e-11	7.31e-08	-0.38	-0.34	Obesity-related traits;	chr8:28945558	chr8:28915579~28915864:-
STAD	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	6.83	3.79e-11	7.33e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
STAD	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-6.83	3.81e-11	7.35e-08	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-6.83	3.81e-11	7.35e-08	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
STAD	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-6.83	3.82e-11	7.37e-08	-0.34	-0.34	Height;	chr11:118773873	chr11:118791254~118793137:+
STAD	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-6.83	3.82e-11	7.37e-08	-0.54	-0.34	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
STAD	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	6.83	3.82e-11	7.38e-08	0.41	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	6.83	3.82e-11	7.38e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	6.83	3.82e-11	7.38e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	6.83	3.82e-11	7.38e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
STAD	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-6.83	3.83e-11	7.4e-08	-0.4	-0.34	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
STAD	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-6.83	3.83e-11	7.4e-08	-0.4	-0.34	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
STAD	cis	rs875971	0.66	rs1860468	ENSG00000222364.1	RNU6-96P	6.83	3.83e-11	7.4e-08	0.39	0.34	Aortic root size;	chr7:66642265	chr7:66395191~66395286:+
STAD	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	6.83	3.84e-11	7.42e-08	0.37	0.34	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
STAD	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-6.83	3.85e-11	7.43e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
STAD	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-6.83	3.86e-11	7.45e-08	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-6.83	3.87e-11	7.47e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-6.83	3.87e-11	7.47e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
STAD	cis	rs801193	1	rs2055682	ENSG00000222364.1	RNU6-96P	-6.83	3.87e-11	7.47e-08	-0.39	-0.34	Aortic root size;	chr7:66795302	chr7:66395191~66395286:+
STAD	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	6.83	3.89e-11	7.49e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
STAD	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	6.83	3.89e-11	7.49e-08	0.39	0.34	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
STAD	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	6.83	3.89e-11	7.5e-08	0.36	0.34	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
STAD	cis	rs9549260	0.755	rs9549252	ENSG00000229456.1	RLIMP1	6.83	3.9e-11	7.51e-08	0.31	0.34	Red blood cell count;	chr13:40656004	chr13:40618738~40621348:+
STAD	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	6.83	3.9e-11	7.52e-08	0.44	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
STAD	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	6.83	3.91e-11	7.53e-08	0.33	0.34	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
STAD	cis	rs2221894	0.922	rs7018244	ENSG00000273710.1	Metazoa_SRP	6.83	3.91e-11	7.53e-08	0.37	0.34	Obesity-related traits;	chr8:29037474	chr8:28915579~28915864:-
STAD	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	6.83	3.92e-11	7.55e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
STAD	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	6.83	3.93e-11	7.58e-08	0.41	0.34	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
STAD	cis	rs7580658	0.864	rs10928761	ENSG00000200250.1	RNU6-1147P	6.83	3.94e-11	7.58e-08	0.34	0.34	Protein C levels;	chr2:127245671	chr2:127316873~127316979:+
STAD	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-6.83	3.94e-11	7.59e-08	-0.54	-0.34	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-6.83	3.94e-11	7.59e-08	-0.54	-0.34	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-6.83	3.94e-11	7.59e-08	-0.54	-0.34	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
STAD	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-6.82	3.95e-11	7.61e-08	-0.4	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
STAD	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-6.82	3.96e-11	7.63e-08	-0.34	-0.34	Height;	chr11:118747911	chr11:118791254~118793137:+
STAD	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	6.82	3.97e-11	7.64e-08	0.42	0.34	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
STAD	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-6.82	3.97e-11	7.64e-08	-0.43	-0.34	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
STAD	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-6.82	3.97e-11	7.64e-08	-0.43	-0.34	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
STAD	cis	rs1426063	0.668	rs6534595	ENSG00000249717.1	RP11-44F21.3	6.82	3.98e-11	7.66e-08	0.45	0.34	QT interval;	chr4:75104432	chr4:74955974~74970362:-
STAD	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-6.82	3.98e-11	7.67e-08	-0.34	-0.34	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
STAD	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-6.82	3.99e-11	7.68e-08	-0.39	-0.34	Height;	chr3:53027361	chr3:53064283~53065091:-
STAD	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	6.82	3.99e-11	7.68e-08	0.51	0.34	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
STAD	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-6.82	4e-11	7.69e-08	-0.48	-0.34	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
STAD	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	6.82	4e-11	7.7e-08	0.44	0.34	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	6.82	4e-11	7.7e-08	0.26	0.34	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
STAD	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	6.82	4.01e-11	7.71e-08	0.36	0.34	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
STAD	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	6.82	4.01e-11	7.71e-08	0.36	0.34	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
STAD	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-6.82	4.01e-11	7.71e-08	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
STAD	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
STAD	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	6.82	4.03e-11	7.74e-08	0.36	0.34	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
STAD	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	6.82	4.04e-11	7.75e-08	0.34	0.34	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
STAD	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-6.82	4.04e-11	7.76e-08	-0.41	-0.34	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
STAD	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	6.82	4.04e-11	7.77e-08	0.26	0.34	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
STAD	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	6.82	4.05e-11	7.79e-08	0.36	0.34	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	6.82	4.05e-11	7.79e-08	0.36	0.34	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
STAD	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	6.82	4.06e-11	7.79e-08	0.44	0.34	Height;	chr6:109494237	chr6:109382795~109383666:+
STAD	cis	rs2221894	0.922	rs4732890	ENSG00000273710.1	Metazoa_SRP	-6.82	4.06e-11	7.79e-08	-0.38	-0.34	Obesity-related traits;	chr8:28893864	chr8:28915579~28915864:-
STAD	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	6.82	4.07e-11	7.81e-08	0.34	0.34	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	6.82	4.07e-11	7.81e-08	0.34	0.34	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
STAD	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-6.82	4.07e-11	7.81e-08	-0.45	-0.34	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	6.82	4.07e-11	7.82e-08	0.26	0.34	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	6.82	4.07e-11	7.82e-08	0.26	0.34	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
STAD	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	6.82	4.08e-11	7.83e-08	0.47	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-6.82	4.09e-11	7.84e-08	-0.37	-0.34	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
STAD	cis	rs2833693	0.572	rs4817477	ENSG00000261610.1	AP000265.1	6.82	4.09e-11	7.85e-08	0.39	0.34	Temperament;	chr21:32213799	chr21:32259804~32261585:-
STAD	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-6.82	4.09e-11	7.85e-08	-0.33	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
STAD	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	6.82	4.13e-11	7.92e-08	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	6.82	4.13e-11	7.92e-08	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
STAD	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	6.82	4.14e-11	7.94e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
STAD	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	6.82	4.14e-11	7.94e-08	0.35	0.34	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
STAD	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	6.82	4.14e-11	7.95e-08	0.36	0.34	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
STAD	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-6.82	4.15e-11	7.95e-08	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-6.82	4.15e-11	7.95e-08	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
STAD	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-6.82	4.15e-11	7.95e-08	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
STAD	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	6.82	4.15e-11	7.95e-08	0.43	0.34	Height;	chr6:109676091	chr6:109382795~109383666:+
STAD	cis	rs6452524	0.935	rs6896953	ENSG00000243385.2	CTD-2110K23.1	-6.82	4.15e-11	7.96e-08	-0.37	-0.34	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83201229~83202141:+
STAD	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-6.82	4.16e-11	7.96e-08	-0.47	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
STAD	cis	rs2221894	1	rs4732896	ENSG00000273710.1	Metazoa_SRP	-6.82	4.16e-11	7.97e-08	-0.38	-0.34	Obesity-related traits;	chr8:28967957	chr8:28915579~28915864:-
STAD	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-6.82	4.18e-11	8.01e-08	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
STAD	cis	rs181553	0.504	rs7237062	ENSG00000266696.1	RP11-30L3.2	6.82	4.19e-11	8.03e-08	0.35	0.34	Hip circumference adjusted for BMI;	chr18:49200883	chr18:49205912~49208781:+
STAD	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-6.82	4.19e-11	8.03e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
STAD	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	6.81	4.21e-11	8.05e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
STAD	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-6.81	4.21e-11	8.05e-08	-0.55	-0.34	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
STAD	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-6.81	4.21e-11	8.05e-08	-0.55	-0.34	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
STAD	cis	rs7301826	0.627	rs7315707	ENSG00000256299.1	RP11-989F5.3	6.81	4.21e-11	8.05e-08	0.49	0.34	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810821~130812622:-
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	6.81	4.21e-11	8.06e-08	0.26	0.34	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	6.81	4.21e-11	8.06e-08	0.26	0.34	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
STAD	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-6.81	4.21e-11	8.06e-08	-0.48	-0.34	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
STAD	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-6.81	4.23e-11	8.09e-08	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
STAD	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-6.81	4.23e-11	8.09e-08	-0.5	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
STAD	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-6.81	4.24e-11	8.11e-08	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
STAD	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-6.81	4.25e-11	8.12e-08	-0.54	-0.34	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
STAD	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-6.81	4.25e-11	8.12e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	6.81	4.25e-11	8.12e-08	0.26	0.34	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	6.81	4.25e-11	8.12e-08	0.26	0.34	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
STAD	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	6.81	4.27e-11	8.16e-08	0.43	0.34	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
STAD	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-6.81	4.27e-11	8.16e-08	-0.44	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
STAD	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-6.81	4.28e-11	8.18e-08	-0.3	-0.34	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
STAD	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-6.81	4.28e-11	8.18e-08	-0.3	-0.34	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
STAD	cis	rs62130978	0.55	rs56153949	ENSG00000267769.1	CTB-50L17.9	-6.81	4.28e-11	8.18e-08	-0.51	-0.34	Red cell distribution width;	chr19:4457521	chr19:4454014~4455286:+
STAD	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-6.81	4.29e-11	8.19e-08	-0.34	-0.34	Height;	chr11:118749988	chr11:118791254~118793137:+
STAD	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-6.81	4.29e-11	8.19e-08	-0.4	-0.34	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
STAD	cis	rs9368481	0.729	rs9379950	ENSG00000243307.2	POM121L6P	-6.81	4.3e-11	8.22e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26896952~26898777:+
STAD	cis	rs9368481	1	rs9368481	ENSG00000243307.2	POM121L6P	-6.81	4.3e-11	8.22e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26896952~26898777:+
STAD	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	6.81	4.31e-11	8.23e-08	0.41	0.34	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
STAD	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	6.81	4.31e-11	8.23e-08	0.4	0.34	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
STAD	cis	rs1862618	0.853	rs1833896	ENSG00000271828.1	CTD-2310F14.1	6.81	4.31e-11	8.24e-08	0.44	0.34	Initial pursuit acceleration;	chr5:56801842	chr5:56927874~56929573:+
STAD	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	6.81	4.32e-11	8.25e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	6.81	4.32e-11	8.25e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	6.81	4.32e-11	8.25e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
STAD	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-6.81	4.32e-11	8.26e-08	-0.26	-0.34	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
STAD	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	6.81	4.33e-11	8.26e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
STAD	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-6.81	4.38e-11	8.34e-08	-0.33	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
STAD	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-6.81	4.38e-11	8.35e-08	-0.39	-0.34	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
STAD	cis	rs7580658	0.929	rs2276583	ENSG00000200250.1	RNU6-1147P	6.81	4.38e-11	8.35e-08	0.33	0.34	Protein C levels;	chr2:127257108	chr2:127316873~127316979:+
STAD	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	6.81	4.39e-11	8.37e-08	0.36	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
STAD	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-6.81	4.4e-11	8.37e-08	-0.41	-0.34	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
STAD	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	6.81	4.4e-11	8.38e-08	0.36	0.34	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
STAD	cis	rs9368481	0.761	rs9348746	ENSG00000243307.2	POM121L6P	-6.81	4.4e-11	8.39e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26896952~26898777:+
STAD	cis	rs9368481	0.761	rs9357030	ENSG00000243307.2	POM121L6P	-6.81	4.4e-11	8.39e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26896952~26898777:+
STAD	cis	rs9368481	0.761	rs9379952	ENSG00000243307.2	POM121L6P	-6.81	4.4e-11	8.39e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26896952~26898777:+
STAD	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	6.81	4.41e-11	8.39e-08	0.5	0.34	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	6.81	4.41e-11	8.39e-08	0.5	0.34	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	6.81	4.41e-11	8.39e-08	0.5	0.34	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	6.81	4.41e-11	8.39e-08	0.5	0.34	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
STAD	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-6.81	4.41e-11	8.39e-08	-0.61	-0.34	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
STAD	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	6.81	4.42e-11	8.41e-08	0.42	0.34	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
STAD	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-6.81	4.45e-11	8.47e-08	-0.55	-0.34	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
STAD	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-6.81	4.45e-11	8.47e-08	-0.4	-0.34	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-6.81	4.45e-11	8.47e-08	-0.4	-0.34	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
STAD	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-6.81	4.46e-11	8.49e-08	-0.36	-0.34	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
STAD	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	6.81	4.46e-11	8.49e-08	0.43	0.34	Height;	chr6:109672088	chr6:109382795~109383666:+
STAD	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-6.8	4.47e-11	8.49e-08	-0.39	-0.34	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-6.8	4.47e-11	8.49e-08	-0.39	-0.34	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
STAD	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-6.8	4.47e-11	8.51e-08	-0.4	-0.34	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	6.8	4.48e-11	8.51e-08	0.39	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
STAD	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	6.8	4.48e-11	8.52e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	6.8	4.48e-11	8.52e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
STAD	cis	rs7829975	0.511	rs1401390	ENSG00000173295.6	FAM86B3P	6.8	4.49e-11	8.54e-08	0.39	0.34	Mood instability;	chr8:8278888	chr8:8228595~8244865:+
STAD	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-6.8	4.5e-11	8.55e-08	-0.48	-0.34	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
STAD	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-6.8	4.5e-11	8.55e-08	-0.48	-0.34	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
STAD	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-6.8	4.5e-11	8.55e-08	-0.48	-0.34	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
STAD	cis	rs9368481	0.554	rs2754603	ENSG00000243307.2	POM121L6P	-6.8	4.51e-11	8.56e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26896952~26898777:+
STAD	cis	rs9368481	0.761	rs9357028	ENSG00000243307.2	POM121L6P	-6.8	4.51e-11	8.56e-08	-0.36	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26896952~26898777:+
STAD	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	6.8	4.52e-11	8.59e-08	0.34	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
STAD	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-6.8	4.52e-11	8.59e-08	-0.39	-0.34	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
STAD	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	6.8	4.53e-11	8.6e-08	0.34	0.34	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
STAD	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	6.8	4.55e-11	8.64e-08	0.44	0.34	Height;	chr6:109706514	chr6:109382795~109383666:+
STAD	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-6.8	4.57e-11	8.68e-08	-0.33	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
STAD	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	6.8	4.57e-11	8.68e-08	0.36	0.34	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
STAD	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-6.8	4.57e-11	8.68e-08	-0.54	-0.34	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
STAD	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	6.8	4.58e-11	8.69e-08	0.25	0.34	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
STAD	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	6.8	4.58e-11	8.69e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
STAD	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-6.8	4.58e-11	8.69e-08	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	6.8	4.58e-11	8.69e-08	0.25	0.34	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	6.8	4.58e-11	8.69e-08	0.25	0.34	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-6.8	4.58e-11	8.7e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
STAD	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	6.8	4.59e-11	8.72e-08	0.59	0.34	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-6.8	4.59e-11	8.72e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
STAD	cis	rs2221894	0.881	rs2035644	ENSG00000273710.1	Metazoa_SRP	6.8	4.6e-11	8.73e-08	0.37	0.34	Obesity-related traits;	chr8:29042180	chr8:28915579~28915864:-
STAD	cis	rs2221894	0.881	rs1948132	ENSG00000273710.1	Metazoa_SRP	6.8	4.6e-11	8.73e-08	0.37	0.34	Obesity-related traits;	chr8:29042570	chr8:28915579~28915864:-
STAD	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-6.8	4.6e-11	8.73e-08	-0.55	-0.34	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-6.8	4.6e-11	8.73e-08	-0.55	-0.34	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-6.8	4.6e-11	8.73e-08	-0.55	-0.34	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
STAD	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	6.8	4.61e-11	8.75e-08	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
STAD	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	6.8	4.61e-11	8.75e-08	0.26	0.34	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
STAD	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	6.8	4.62e-11	8.75e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
STAD	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-6.8	4.62e-11	8.76e-08	-0.39	-0.34	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
STAD	cis	rs13217239	0.646	rs4269366	ENSG00000243307.2	POM121L6P	6.8	4.64e-11	8.79e-08	0.33	0.34	Schizophrenia;	chr6:27048634	chr6:26896952~26898777:+
STAD	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-6.8	4.65e-11	8.81e-08	-0.38	-0.34	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	6.8	4.67e-11	8.84e-08	0.4	0.34	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
STAD	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	6.8	4.67e-11	8.85e-08	0.35	0.34	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	6.8	4.67e-11	8.85e-08	0.35	0.34	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	6.8	4.67e-11	8.85e-08	0.35	0.34	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	6.8	4.67e-11	8.85e-08	0.35	0.34	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
STAD	cis	rs11089937	0.626	rs11704092	ENSG00000211639.2	IGLV4-60	6.8	4.69e-11	8.88e-08	0.38	0.34	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22162199~22162681:+
STAD	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	6.8	4.7e-11	8.89e-08	0.42	0.34	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	6.8	4.7e-11	8.89e-08	0.42	0.34	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	6.8	4.7e-11	8.89e-08	0.42	0.34	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	6.8	4.7e-11	8.89e-08	0.42	0.34	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	6.8	4.7e-11	8.89e-08	0.42	0.34	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
STAD	cis	rs9506514	0.76	rs9506518	ENSG00000222726.1	RNU2-7P	-6.8	4.7e-11	8.9e-08	-0.41	-0.34	Coronary artery calcification;	chr13:20560843	chr13:20612161~20612338:+
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	6.8	4.71e-11	8.9e-08	0.26	0.34	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
STAD	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	6.8	4.71e-11	8.91e-08	0.43	0.34	Height;	chr6:109526846	chr6:109382795~109383666:+
STAD	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	6.8	4.75e-11	8.98e-08	0.32	0.34	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
STAD	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	6.79	4.75e-11	8.98e-08	0.29	0.34	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
STAD	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	6.79	4.75e-11	8.98e-08	0.29	0.34	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
STAD	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-6.79	4.75e-11	8.98e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-6.79	4.75e-11	8.98e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-6.79	4.75e-11	8.98e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-6.79	4.75e-11	8.98e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-6.79	4.75e-11	8.98e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-6.79	4.75e-11	8.98e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	6.79	4.75e-11	8.99e-08	0.26	0.34	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
STAD	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-6.79	4.76e-11	9e-08	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
STAD	cis	rs6452524	0.967	rs4541638	ENSG00000243385.2	CTD-2110K23.1	6.79	4.76e-11	9.01e-08	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83201229~83202141:+
STAD	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
STAD	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
STAD	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	6.79	4.77e-11	9.01e-08	0.36	0.34	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
STAD	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-6.79	4.77e-11	9.01e-08	-0.34	-0.34	Height;	chr11:118764443	chr11:118791254~118793137:+
STAD	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	6.79	4.78e-11	9.03e-08	0.36	0.34	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
STAD	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	6.79	4.81e-11	9.08e-08	0.44	0.34	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
STAD	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-6.79	4.82e-11	9.1e-08	-0.32	-0.34	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
STAD	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	6.79	4.82e-11	9.1e-08	0.4	0.34	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
STAD	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-6.79	4.85e-11	9.15e-08	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
STAD	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-6.79	4.86e-11	9.17e-08	-0.36	-0.34	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-6.79	4.87e-11	9.18e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
STAD	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-6.79	4.87e-11	9.18e-08	-0.42	-0.34	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
STAD	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	6.79	4.87e-11	9.2e-08	0.41	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	6.79	4.87e-11	9.2e-08	0.41	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	6.79	4.89e-11	9.21e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
STAD	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	6.79	4.89e-11	9.22e-08	0.36	0.34	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
STAD	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-6.79	4.91e-11	9.25e-08	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
STAD	cis	rs2273156	0.57	rs79436302	ENSG00000241052.1	RP11-173D9.1	-6.79	4.92e-11	9.27e-08	-0.41	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35109591	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.57	rs79199019	ENSG00000241052.1	RP11-173D9.1	-6.79	4.92e-11	9.27e-08	-0.41	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35111919	chr14:35144021~35144480:-
STAD	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	6.79	4.92e-11	9.28e-08	0.42	0.34	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
STAD	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-6.79	4.94e-11	9.3e-08	-0.4	-0.34	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
STAD	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	6.79	4.95e-11	9.32e-08	0.43	0.34	Height;	chr6:109584789	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	6.79	4.95e-11	9.32e-08	0.43	0.34	Height;	chr6:109588639	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	6.79	4.95e-11	9.32e-08	0.43	0.34	Height;	chr6:109589051	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	6.79	4.95e-11	9.32e-08	0.43	0.34	Height;	chr6:109592105	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	6.79	4.95e-11	9.32e-08	0.43	0.34	Height;	chr6:109608105	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	6.79	4.95e-11	9.32e-08	0.43	0.34	Height;	chr6:109618620	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	6.79	4.95e-11	9.32e-08	0.43	0.34	Height;	chr6:109620772	chr6:109382795~109383666:+
STAD	cis	rs9368481	0.761	rs12661756	ENSG00000243307.2	POM121L6P	6.79	4.97e-11	9.36e-08	0.36	0.34	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26896952~26898777:+
STAD	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	6.79	4.99e-11	9.39e-08	0.41	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	6.79	4.99e-11	9.39e-08	0.41	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
STAD	cis	rs6452524	0.868	rs62372714	ENSG00000243385.2	CTD-2110K23.1	6.79	5e-11	9.41e-08	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83201229~83202141:+
STAD	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	6.79	5e-11	9.42e-08	0.36	0.34	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-6.79	5.01e-11	9.42e-08	-0.36	-0.34	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
STAD	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	6.79	5.02e-11	9.42e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	6.79	5.02e-11	9.42e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
STAD	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	6.79	5.02e-11	9.42e-08	0.32	0.34	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
STAD	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	6.79	5.04e-11	9.45e-08	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
STAD	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-6.78	5.05e-11	9.47e-08	-0.39	-0.34	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
STAD	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	6.78	5.05e-11	9.47e-08	0.36	0.34	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
STAD	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	6.78	5.05e-11	9.48e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
STAD	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-6.78	5.09e-11	9.55e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-6.78	5.09e-11	9.55e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-6.78	5.09e-11	9.55e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-6.78	5.09e-11	9.55e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-6.78	5.09e-11	9.55e-08	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
STAD	cis	rs2436845	0.521	rs601588	ENSG00000253385.1	KB-1254G8.1	6.78	5.09e-11	9.55e-08	0.35	0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102902518	chr8:102854455~102856075:+
STAD	cis	rs6452524	1	rs6452524	ENSG00000243385.2	CTD-2110K23.1	-6.78	5.1e-11	9.55e-08	-0.37	-0.34	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83201229~83202141:+
STAD	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	6.78	5.1e-11	9.57e-08	0.36	0.34	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	6.78	5.11e-11	9.59e-08	0.36	0.34	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
STAD	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	6.78	5.12e-11	9.6e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	6.78	5.12e-11	9.6e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
STAD	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	6.78	5.13e-11	9.6e-08	0.45	0.34	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
STAD	cis	rs2273156	0.57	rs57075379	ENSG00000241052.1	RP11-173D9.1	-6.78	5.14e-11	9.63e-08	-0.42	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35108595	chr14:35144021~35144480:-
STAD	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-6.78	5.15e-11	9.65e-08	-0.34	-0.34	Height;	chr11:118786602	chr11:118791254~118793137:+
STAD	cis	rs1426063	0.748	rs7654088	ENSG00000249717.1	RP11-44F21.3	-6.78	5.16e-11	9.66e-08	-0.45	-0.34	QT interval;	chr4:75107103	chr4:74955974~74970362:-
STAD	cis	rs2273156	0.57	rs2143950	ENSG00000241052.1	RP11-173D9.1	-6.78	5.17e-11	9.68e-08	-0.42	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35103151	chr14:35144021~35144480:-
STAD	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	6.78	5.18e-11	9.69e-08	0.36	0.34	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	6.78	5.18e-11	9.69e-08	0.36	0.34	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
STAD	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	6.78	5.18e-11	9.7e-08	0.39	0.34	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
STAD	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	6.78	5.18e-11	9.7e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	6.78	5.18e-11	9.7e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
STAD	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-6.78	5.18e-11	9.7e-08	-0.39	-0.34	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	6.78	5.19e-11	9.7e-08	0.25	0.34	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	6.78	5.19e-11	9.7e-08	0.25	0.34	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
STAD	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	6.78	5.19e-11	9.71e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	6.78	5.2e-11	9.73e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	6.78	5.2e-11	9.73e-08	0.41	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	6.78	5.21e-11	9.74e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
STAD	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	6.78	5.22e-11	9.77e-08	0.45	0.34	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	6.78	5.22e-11	9.77e-08	0.45	0.34	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
STAD	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	6.78	5.22e-11	9.77e-08	0.4	0.34	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
STAD	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	6.78	5.23e-11	9.78e-08	0.4	0.34	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	6.78	5.24e-11	9.79e-08	0.4	0.34	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
STAD	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	6.78	5.24e-11	9.8e-08	0.34	0.34	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
STAD	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	6.78	5.25e-11	9.81e-08	0.4	0.34	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	6.78	5.25e-11	9.81e-08	0.4	0.34	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
STAD	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	6.78	5.25e-11	9.82e-08	0.41	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
STAD	cis	rs10028773	0.632	rs34481394	ENSG00000248280.1	RP11-33B1.2	6.78	5.26e-11	9.83e-08	0.42	0.34	Educational attainment;	chr4:119327219	chr4:119440561~119450157:-
STAD	cis	rs10028773	0.666	rs35231872	ENSG00000248280.1	RP11-33B1.2	6.78	5.26e-11	9.83e-08	0.42	0.34	Educational attainment;	chr4:119327221	chr4:119440561~119450157:-
STAD	cis	rs10028773	0.7	rs35653026	ENSG00000248280.1	RP11-33B1.2	6.78	5.26e-11	9.83e-08	0.42	0.34	Educational attainment;	chr4:119327223	chr4:119440561~119450157:-
STAD	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-6.78	5.26e-11	9.83e-08	-0.4	-0.34	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
STAD	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	6.78	5.26e-11	9.83e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
STAD	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	6.78	5.26e-11	9.84e-08	0.42	0.34	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	6.78	5.26e-11	9.84e-08	0.42	0.34	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	6.78	5.26e-11	9.84e-08	0.42	0.34	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
STAD	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	6.78	5.27e-11	9.84e-08	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
STAD	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-6.78	5.28e-11	9.87e-08	-0.36	-0.34	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
STAD	cis	rs13217239	0.646	rs4403259	ENSG00000243307.2	POM121L6P	6.78	5.29e-11	9.88e-08	0.33	0.34	Schizophrenia;	chr6:27029838	chr6:26896952~26898777:+
STAD	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-6.78	5.3e-11	9.89e-08	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-6.78	5.3e-11	9.89e-08	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-6.78	5.3e-11	9.89e-08	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-6.78	5.3e-11	9.89e-08	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-6.78	5.3e-11	9.89e-08	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-6.78	5.3e-11	9.89e-08	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
STAD	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	6.78	5.3e-11	9.89e-08	0.34	0.34	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
STAD	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-6.78	5.32e-11	9.93e-08	-0.53	-0.34	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
STAD	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	6.78	5.32e-11	9.93e-08	0.4	0.34	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
STAD	cis	rs1862618	0.853	rs1862619	ENSG00000271828.1	CTD-2310F14.1	6.78	5.34e-11	9.96e-08	0.44	0.34	Initial pursuit acceleration;	chr5:56802429	chr5:56927874~56929573:+
STAD	cis	rs2221894	0.922	rs4732657	ENSG00000273710.1	Metazoa_SRP	-6.78	5.36e-11	1e-07	-0.37	-0.34	Obesity-related traits;	chr8:28898471	chr8:28915579~28915864:-
STAD	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	6.77	5.37e-11	1e-07	0.33	0.34	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
STAD	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-6.77	5.37e-11	1e-07	-0.42	-0.34	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
STAD	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-6.77	5.37e-11	1e-07	-0.42	-0.34	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
STAD	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-6.77	5.38e-11	1e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-6.77	5.38e-11	1e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
STAD	cis	rs2273156	0.57	rs114200987	ENSG00000241052.1	RP11-173D9.1	-6.77	5.38e-11	1e-07	-0.41	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35117710	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.57	rs28365850	ENSG00000241052.1	RP11-173D9.1	-6.77	5.38e-11	1e-07	-0.41	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35122110	chr14:35144021~35144480:-
STAD	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	6.77	5.39e-11	1e-07	0.36	0.34	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.967	rs11949474	ENSG00000243385.2	CTD-2110K23.1	6.77	5.4e-11	1.01e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83201229~83202141:+
STAD	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	6.77	5.43e-11	1.01e-07	0.39	0.34	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
STAD	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-6.77	5.43e-11	1.01e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-6.77	5.43e-11	1.01e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-6.77	5.43e-11	1.01e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
STAD	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-6.77	5.44e-11	1.01e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-6.77	5.44e-11	1.01e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-6.77	5.44e-11	1.01e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-6.77	5.44e-11	1.01e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-6.77	5.44e-11	1.01e-07	-0.3	-0.34	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
STAD	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-6.77	5.45e-11	1.01e-07	-0.39	-0.34	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
STAD	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-6.77	5.45e-11	1.02e-07	-0.48	-0.34	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
STAD	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-6.77	5.46e-11	1.02e-07	-0.26	-0.34	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
STAD	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-6.77	5.47e-11	1.02e-07	-0.33	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000211972.2	IGHV3-66	6.77	5.49e-11	1.02e-07	0.25	0.34	Kawasaki disease;	chr14:106767802	chr14:106675017~106675544:-
STAD	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	6.77	5.49e-11	1.02e-07	0.33	0.34	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
STAD	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-6.77	5.51e-11	1.03e-07	-0.4	-0.34	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	6.77	5.51e-11	1.03e-07	0.25	0.34	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
STAD	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-6.77	5.53e-11	1.03e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
STAD	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	6.77	5.53e-11	1.03e-07	0.45	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
STAD	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	6.77	5.55e-11	1.03e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	6.77	5.55e-11	1.03e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
STAD	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-6.77	5.55e-11	1.03e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
STAD	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	6.77	5.55e-11	1.03e-07	0.45	0.34	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
STAD	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	6.77	5.58e-11	1.04e-07	0.48	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
STAD	cis	rs611744	0.837	rs422847	ENSG00000253754.1	RP11-35G22.1	6.77	5.6e-11	1.04e-07	0.29	0.34	Dupuytren's disease;	chr8:108091046	chr8:108226200~108227544:+
STAD	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-6.77	5.6e-11	1.04e-07	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
STAD	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-6.77	5.61e-11	1.04e-07	-0.39	-0.34	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
STAD	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-6.77	5.62e-11	1.04e-07	-0.4	-0.34	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
STAD	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-6.77	5.62e-11	1.04e-07	-0.4	-0.34	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
STAD	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	6.77	5.64e-11	1.05e-07	0.57	0.34	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
STAD	cis	rs6452524	0.904	rs10473867	ENSG00000243385.2	CTD-2110K23.1	6.77	5.64e-11	1.05e-07	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83201229~83202141:+
STAD	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-6.77	5.64e-11	1.05e-07	-0.36	-0.34	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
STAD	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	6.77	5.65e-11	1.05e-07	0.35	0.34	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	6.77	5.65e-11	1.05e-07	0.38	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
STAD	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-6.77	5.66e-11	1.05e-07	-0.53	-0.34	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
STAD	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-6.77	5.69e-11	1.05e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.868	rs17205699	ENSG00000243385.2	CTD-2110K23.1	6.77	5.69e-11	1.06e-07	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83201229~83202141:+
STAD	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-6.77	5.7e-11	1.06e-07	-0.32	-0.34	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
STAD	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-6.77	5.7e-11	1.06e-07	-0.32	-0.34	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
STAD	cis	rs6452524	1	rs4590162	ENSG00000243385.2	CTD-2110K23.1	6.76	5.7e-11	1.06e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83201229~83202141:+
STAD	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	6.76	5.72e-11	1.06e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
STAD	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-6.76	5.72e-11	1.06e-07	-0.35	-0.34	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-6.76	5.72e-11	1.06e-07	-0.39	-0.34	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
STAD	cis	rs2436845	0.521	rs2570948	ENSG00000253385.1	KB-1254G8.1	6.76	5.73e-11	1.06e-07	0.35	0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102870430	chr8:102854455~102856075:+
STAD	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-6.76	5.75e-11	1.07e-07	-0.37	-0.34	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
STAD	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	6.76	5.77e-11	1.07e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
STAD	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	6.76	5.77e-11	1.07e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
STAD	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	6.76	5.77e-11	1.07e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
STAD	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	6.76	5.77e-11	1.07e-07	0.47	0.34	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
STAD	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	6.76	5.78e-11	1.07e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	6.76	5.78e-11	1.07e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	6.76	5.78e-11	1.07e-07	0.4	0.34	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	6.76	5.78e-11	1.07e-07	0.4	0.34	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	6.76	5.78e-11	1.07e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
STAD	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-6.76	5.84e-11	1.08e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
STAD	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	6.76	5.84e-11	1.08e-07	0.41	0.34	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
STAD	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	6.76	5.85e-11	1.08e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	6.76	5.85e-11	1.08e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
STAD	cis	rs2221894	0.922	rs983365	ENSG00000273710.1	Metazoa_SRP	-6.76	5.87e-11	1.09e-07	-0.37	-0.34	Obesity-related traits;	chr8:28892912	chr8:28915579~28915864:-
STAD	cis	rs801193	0.967	rs2420827	ENSG00000222364.1	RNU6-96P	6.76	5.87e-11	1.09e-07	0.39	0.34	Aortic root size;	chr7:66682114	chr7:66395191~66395286:+
STAD	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	6.76	5.88e-11	1.09e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	6.76	5.89e-11	1.09e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
STAD	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-6.76	5.89e-11	1.09e-07	-0.39	-0.34	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
STAD	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-6.76	5.89e-11	1.09e-07	-0.39	-0.34	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-6.76	5.89e-11	1.09e-07	-0.39	-0.34	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-6.76	5.89e-11	1.09e-07	-0.39	-0.34	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-6.76	5.89e-11	1.09e-07	-0.39	-0.34	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
STAD	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	6.76	5.9e-11	1.09e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
STAD	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-6.76	5.91e-11	1.09e-07	-0.35	-0.34	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
STAD	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	6.76	5.91e-11	1.09e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
STAD	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	6.76	5.91e-11	1.09e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
STAD	cis	rs6452524	0.935	rs6880566	ENSG00000243385.2	CTD-2110K23.1	6.76	5.93e-11	1.09e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.905	rs6884981	ENSG00000243385.2	CTD-2110K23.1	6.76	5.93e-11	1.09e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83201229~83202141:+
STAD	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-6.76	5.94e-11	1.1e-07	-0.39	-0.34	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-6.76	5.94e-11	1.1e-07	-0.39	-0.34	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
STAD	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	6.76	5.96e-11	1.1e-07	0.59	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
STAD	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	6.76	5.97e-11	1.1e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
STAD	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-6.76	5.98e-11	1.1e-07	-0.49	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
STAD	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-6.76	5.98e-11	1.1e-07	-0.38	-0.34	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
STAD	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	6.76	5.99e-11	1.1e-07	0.38	0.34	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
STAD	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-6.76	5.99e-11	1.1e-07	-0.42	-0.34	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
STAD	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-6.76	5.99e-11	1.1e-07	-0.48	-0.34	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
STAD	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	6.76	6e-11	1.11e-07	0.41	0.34	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
STAD	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	6.76	6e-11	1.11e-07	0.3	0.34	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
STAD	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-6.76	6.02e-11	1.11e-07	-0.4	-0.34	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
STAD	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-6.76	6.02e-11	1.11e-07	-0.43	-0.34	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
STAD	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-6.76	6.05e-11	1.12e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-6.76	6.05e-11	1.12e-07	-0.51	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
STAD	cis	rs11039131	0.787	rs326217	ENSG00000271350.1	CTD-2384B9.1	-6.76	6.06e-11	1.12e-07	-0.4	-0.34	Schizophrenia;	chr11:47281724	chr11:47041027~47041945:-
STAD	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	6.75	6.07e-11	1.12e-07	0.4	0.34	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	6.75	6.1e-11	1.12e-07	0.25	0.34	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-6.75	6.11e-11	1.13e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
STAD	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-6.75	6.11e-11	1.13e-07	-0.39	-0.34	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-6.75	6.11e-11	1.13e-07	-0.39	-0.34	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-6.75	6.11e-11	1.13e-07	-0.39	-0.34	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
STAD	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-6.75	6.13e-11	1.13e-07	-0.39	-0.34	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
STAD	cis	rs7580658	0.929	rs4150496	ENSG00000200250.1	RNU6-1147P	6.75	6.13e-11	1.13e-07	0.33	0.34	Protein C levels;	chr2:127271927	chr2:127316873~127316979:+
STAD	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	6.75	6.15e-11	1.13e-07	0.39	0.34	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
STAD	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	6.75	6.18e-11	1.14e-07	0.35	0.34	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	6.75	6.18e-11	1.14e-07	0.35	0.34	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
STAD	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-6.75	6.19e-11	1.14e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	6.75	6.2e-11	1.14e-07	0.38	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
STAD	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	6.75	6.23e-11	1.15e-07	0.49	0.34	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
STAD	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-6.75	6.24e-11	1.15e-07	-0.34	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
STAD	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-6.75	6.25e-11	1.15e-07	-0.47	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
STAD	cis	rs66823261	0.778	rs2906332	ENSG00000253166.2	RP11-585F1.6	-6.75	6.26e-11	1.15e-07	-0.49	-0.34	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:202660~202897:-
STAD	cis	rs6452524	0.868	rs11746977	ENSG00000243385.2	CTD-2110K23.1	6.75	6.26e-11	1.15e-07	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83201229~83202141:+
STAD	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	6.75	6.27e-11	1.15e-07	0.36	0.34	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
STAD	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-6.75	6.31e-11	1.16e-07	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
STAD	cis	rs7580658	0.929	rs4662575	ENSG00000200250.1	RNU6-1147P	6.75	6.33e-11	1.16e-07	0.33	0.34	Protein C levels;	chr2:127264639	chr2:127316873~127316979:+
STAD	cis	rs10129255	0.642	rs11624918	ENSG00000280411.1	IGHV1-69-2	-6.75	6.33e-11	1.16e-07	-0.33	-0.34	Kawasaki disease;	chr14:106664672	chr14:106762092~106762588:-
STAD	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-6.75	6.34e-11	1.16e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
STAD	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-6.75	6.35e-11	1.17e-07	-0.42	-0.34	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
STAD	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-6.75	6.35e-11	1.17e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
STAD	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	6.75	6.41e-11	1.18e-07	0.41	0.34	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
STAD	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-6.75	6.42e-11	1.18e-07	-0.57	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
STAD	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	6.75	6.43e-11	1.18e-07	0.26	0.34	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
STAD	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-6.74	6.45e-11	1.18e-07	-0.37	-0.34	Height;	chr3:53009621	chr3:53064283~53065091:-
STAD	cis	rs1862618	0.853	rs6450409	ENSG00000271828.1	CTD-2310F14.1	6.74	6.48e-11	1.19e-07	0.44	0.34	Initial pursuit acceleration;	chr5:56805572	chr5:56927874~56929573:+
STAD	cis	rs2739330	0.791	rs4822458	ENSG00000224205.1	AP000351.4	6.74	6.49e-11	1.19e-07	0.39	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23987320~23991421:-
STAD	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	6.74	6.5e-11	1.19e-07	0.43	0.34	Height;	chr6:109634150	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	6.74	6.5e-11	1.19e-07	0.43	0.34	Height;	chr6:109640141	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	6.74	6.5e-11	1.19e-07	0.43	0.34	Height;	chr6:109642186	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	6.74	6.5e-11	1.19e-07	0.43	0.34	Height;	chr6:109646187	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	6.74	6.5e-11	1.19e-07	0.43	0.34	Height;	chr6:109652694	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	6.74	6.5e-11	1.19e-07	0.43	0.34	Height;	chr6:109655791	chr6:109382795~109383666:+
STAD	cis	rs7580658	0.864	rs1566823	ENSG00000200250.1	RNU6-1147P	6.74	6.5e-11	1.19e-07	0.33	0.34	Protein C levels;	chr2:127260616	chr2:127316873~127316979:+
STAD	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-6.74	6.53e-11	1.2e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
STAD	cis	rs7580658	0.929	rs11886231	ENSG00000200250.1	RNU6-1147P	6.74	6.54e-11	1.2e-07	0.33	0.34	Protein C levels;	chr2:127270554	chr2:127316873~127316979:+
STAD	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	6.74	6.55e-11	1.2e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
STAD	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-6.74	6.55e-11	1.2e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
STAD	cis	rs10885997	0.626	rs2301179	ENSG00000266200.5	PNLIPRP2	-6.74	6.56e-11	1.2e-07	-0.4	-0.34	Phospholipid levels (plasma);	chr10:116645109	chr10:116620953~116645143:+
STAD	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-6.74	6.56e-11	1.2e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-6.74	6.56e-11	1.2e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-6.74	6.56e-11	1.2e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-6.74	6.57e-11	1.2e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-6.74	6.58e-11	1.2e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-6.74	6.58e-11	1.2e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
STAD	cis	rs6452524	1	rs7716962	ENSG00000243385.2	CTD-2110K23.1	6.74	6.6e-11	1.21e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs6882179	ENSG00000243385.2	CTD-2110K23.1	6.74	6.6e-11	1.21e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs6863300	ENSG00000243385.2	CTD-2110K23.1	6.74	6.6e-11	1.21e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83201229~83202141:+
STAD	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-6.74	6.6e-11	1.21e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
STAD	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	6.74	6.65e-11	1.22e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	6.74	6.65e-11	1.22e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	6.74	6.65e-11	1.22e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
STAD	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	6.74	6.66e-11	1.22e-07	0.49	0.34	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
STAD	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-6.74	6.66e-11	1.22e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-6.74	6.66e-11	1.22e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-6.74	6.66e-11	1.22e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-6.74	6.66e-11	1.22e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-6.74	6.66e-11	1.22e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
STAD	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	6.74	6.67e-11	1.22e-07	0.3	0.34	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
STAD	cis	rs6452524	0.868	rs1564379	ENSG00000243385.2	CTD-2110K23.1	6.74	6.67e-11	1.22e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83201229~83202141:+
STAD	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	6.74	6.67e-11	1.22e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
STAD	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-6.74	6.69e-11	1.22e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
STAD	cis	rs2221894	0.881	rs2693	ENSG00000273710.1	Metazoa_SRP	6.74	6.69e-11	1.22e-07	0.35	0.34	Obesity-related traits;	chr8:29067341	chr8:28915579~28915864:-
STAD	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-6.74	6.72e-11	1.23e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-6.74	6.72e-11	1.23e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
STAD	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-6.74	6.72e-11	1.23e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-6.74	6.72e-11	1.23e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-6.74	6.72e-11	1.23e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-6.74	6.72e-11	1.23e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-6.74	6.72e-11	1.23e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
STAD	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	6.74	6.72e-11	1.23e-07	0.46	0.34	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
STAD	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	6.74	6.73e-11	1.23e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	6.74	6.75e-11	1.23e-07	0.36	0.34	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
STAD	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	6.74	6.75e-11	1.23e-07	0.41	0.34	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
STAD	cis	rs4568518	0.53	rs6967917	ENSG00000279048.1	RP11-511H23.2	6.74	6.77e-11	1.24e-07	0.31	0.34	Measles;	chr7:17944674	chr7:17940503~17942922:+
STAD	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	6.74	6.77e-11	1.24e-07	0.33	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
STAD	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-6.74	6.77e-11	1.24e-07	-0.39	-0.34	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
STAD	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-6.74	6.77e-11	1.24e-07	-0.39	-0.34	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-6.74	6.77e-11	1.24e-07	-0.39	-0.34	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
STAD	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-6.74	6.79e-11	1.24e-07	-0.41	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
STAD	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-6.74	6.79e-11	1.24e-07	-0.38	-0.34	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
STAD	cis	rs2074038	1	rs2074038	ENSG00000255165.1	CTD-2609K8.3	6.74	6.79e-11	1.24e-07	0.55	0.34	IgA nephropathy;	chr11:44066439	chr11:44071462~44072403:+
STAD	cis	rs4568518	0.53	rs4721672	ENSG00000279048.1	RP11-511H23.2	6.74	6.79e-11	1.24e-07	0.31	0.34	Measles;	chr7:17946475	chr7:17940503~17942922:+
STAD	cis	rs2833693	0.572	rs11088213	ENSG00000261610.1	AP000265.1	6.74	6.79e-11	1.24e-07	0.39	0.34	Temperament;	chr21:32241398	chr21:32259804~32261585:-
STAD	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	6.74	6.79e-11	1.24e-07	0.39	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
STAD	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-6.74	6.81e-11	1.24e-07	-0.39	-0.34	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-6.74	6.81e-11	1.24e-07	-0.39	-0.34	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
STAD	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	6.74	6.81e-11	1.24e-07	0.3	0.34	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
STAD	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	6.74	6.81e-11	1.24e-07	0.26	0.34	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
STAD	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-6.74	6.83e-11	1.24e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
STAD	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-6.74	6.83e-11	1.25e-07	-0.49	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
STAD	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	6.74	6.84e-11	1.25e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
STAD	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-6.73	6.85e-11	1.25e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
STAD	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-6.73	6.88e-11	1.25e-07	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-6.73	6.88e-11	1.25e-07	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
STAD	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-6.73	6.88e-11	1.25e-07	-0.4	-0.34	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
STAD	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-6.73	6.9e-11	1.26e-07	-0.32	-0.34	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
STAD	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	6.73	6.93e-11	1.26e-07	0.35	0.34	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-6.73	6.93e-11	1.26e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
STAD	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-6.73	6.95e-11	1.27e-07	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-6.73	6.95e-11	1.27e-07	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-6.73	6.95e-11	1.27e-07	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-6.73	6.95e-11	1.27e-07	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
STAD	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	6.73	6.96e-11	1.27e-07	0.4	0.34	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
STAD	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	6.73	6.96e-11	1.27e-07	0.43	0.34	Height;	chr6:109503623	chr6:109382795~109383666:+
STAD	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	6.73	6.96e-11	1.27e-07	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	6.73	6.96e-11	1.27e-07	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
STAD	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-6.73	6.96e-11	1.27e-07	-0.39	-0.34	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-6.73	6.96e-11	1.27e-07	-0.39	-0.34	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
STAD	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-6.73	6.98e-11	1.27e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
STAD	cis	rs13217239	0.646	rs12527111	ENSG00000243307.2	POM121L6P	6.73	6.99e-11	1.27e-07	0.32	0.34	Schizophrenia;	chr6:27038696	chr6:26896952~26898777:+
STAD	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-6.73	7.02e-11	1.28e-07	-0.4	-0.34	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
STAD	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-6.73	7.02e-11	1.28e-07	-0.43	-0.34	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
STAD	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	6.73	7.02e-11	1.28e-07	0.26	0.34	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
STAD	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	6.73	7.05e-11	1.28e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	6.73	7.05e-11	1.28e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	6.73	7.05e-11	1.28e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	6.73	7.05e-11	1.28e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	6.73	7.05e-11	1.28e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	6.73	7.05e-11	1.28e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	6.73	7.05e-11	1.28e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
STAD	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	6.73	7.05e-11	1.28e-07	0.35	0.34	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
STAD	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	6.73	7.06e-11	1.28e-07	0.32	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
STAD	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-6.73	7.07e-11	1.29e-07	-0.47	-0.34	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
STAD	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-6.73	7.07e-11	1.29e-07	-0.42	-0.34	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
STAD	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	6.73	7.07e-11	1.29e-07	0.41	0.34	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
STAD	cis	rs6456156	0.742	rs1331299	ENSG00000265828.1	MIR3939	-6.73	7.08e-11	1.29e-07	-0.37	-0.34	Primary biliary cholangitis;	chr6:167119979	chr6:166997807~166997912:-
STAD	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	6.73	7.08e-11	1.29e-07	0.4	0.34	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	6.73	7.11e-11	1.29e-07	0.25	0.34	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-6.73	7.15e-11	1.3e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-6.73	7.15e-11	1.3e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-6.73	7.15e-11	1.3e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-6.73	7.15e-11	1.3e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	6.73	7.19e-11	1.31e-07	0.38	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
STAD	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	6.73	7.2e-11	1.31e-07	0.4	0.34	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
STAD	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	6.73	7.21e-11	1.31e-07	0.43	0.34	Height;	chr6:109501402	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	6.73	7.21e-11	1.31e-07	0.43	0.34	Height;	chr6:109501429	chr6:109382795~109383666:+
STAD	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-6.73	7.21e-11	1.31e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-6.73	7.21e-11	1.31e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
STAD	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	6.73	7.22e-11	1.31e-07	0.31	0.34	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
STAD	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-6.73	7.22e-11	1.31e-07	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
STAD	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-6.73	7.22e-11	1.31e-07	-0.36	-0.34	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
STAD	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	6.73	7.22e-11	1.31e-07	0.4	0.34	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
STAD	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	6.73	7.23e-11	1.31e-07	0.43	0.34	Height;	chr6:109498586	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	6.73	7.23e-11	1.31e-07	0.43	0.34	Height;	chr6:109499759	chr6:109382795~109383666:+
STAD	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	6.73	7.23e-11	1.31e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
STAD	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	6.73	7.24e-11	1.31e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
STAD	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	6.73	7.25e-11	1.32e-07	0.35	0.34	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	6.73	7.26e-11	1.32e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
STAD	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	6.73	7.27e-11	1.32e-07	0.38	0.34	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
STAD	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	6.72	7.28e-11	1.32e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	6.72	7.28e-11	1.32e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	6.72	7.28e-11	1.32e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
STAD	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-6.72	7.28e-11	1.32e-07	-0.37	-0.34	Height;	chr3:53007328	chr3:53064283~53065091:-
STAD	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-6.72	7.29e-11	1.32e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
STAD	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	6.72	7.3e-11	1.32e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	6.72	7.3e-11	1.32e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
STAD	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	6.72	7.3e-11	1.32e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	6.72	7.3e-11	1.32e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	6.72	7.3e-11	1.32e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
STAD	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	6.72	7.31e-11	1.32e-07	0.4	0.34	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
STAD	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	6.72	7.34e-11	1.33e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
STAD	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	6.72	7.35e-11	1.33e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
STAD	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-6.72	7.36e-11	1.33e-07	-0.42	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
STAD	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-6.72	7.37e-11	1.33e-07	-0.39	-0.34	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
STAD	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-6.72	7.47e-11	1.35e-07	-0.3	-0.34	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-6.72	7.5e-11	1.36e-07	-0.26	-0.34	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
STAD	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-6.72	7.51e-11	1.36e-07	-0.47	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
STAD	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	6.72	7.52e-11	1.36e-07	0.45	0.34	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
STAD	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-6.72	7.52e-11	1.36e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-6.72	7.52e-11	1.36e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-6.72	7.52e-11	1.36e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
STAD	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	6.72	7.58e-11	1.37e-07	0.3	0.34	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
STAD	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-6.72	7.6e-11	1.37e-07	-0.57	-0.34	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
STAD	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-6.72	7.62e-11	1.38e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
STAD	cis	rs1426063	0.748	rs10005117	ENSG00000248165.1	RP11-44F21.2	6.72	7.62e-11	1.38e-07	0.45	0.34	QT interval;	chr4:75108281	chr4:74993877~75034824:-
STAD	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-6.72	7.64e-11	1.38e-07	-0.47	-0.34	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
STAD	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-6.72	7.64e-11	1.38e-07	-0.39	-0.34	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
STAD	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-6.72	7.67e-11	1.38e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-6.72	7.67e-11	1.38e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-6.72	7.67e-11	1.38e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-6.72	7.67e-11	1.38e-07	-0.51	-0.34	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
STAD	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-6.72	7.68e-11	1.39e-07	-0.41	-0.34	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
STAD	cis	rs2221894	0.922	rs2323134	ENSG00000273710.1	Metazoa_SRP	-6.72	7.68e-11	1.39e-07	-0.38	-0.34	Obesity-related traits;	chr8:28982405	chr8:28915579~28915864:-
STAD	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	6.72	7.7e-11	1.39e-07	0.36	0.34	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
STAD	cis	rs7927771	0.864	rs755555	ENSG00000280615.1	Y_RNA	-6.72	7.7e-11	1.39e-07	-0.36	-0.34	Subjective well-being;	chr11:47410415	chr11:47614898~47614994:-
STAD	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	6.72	7.71e-11	1.39e-07	0.44	0.34	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
STAD	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	6.72	7.72e-11	1.39e-07	0.35	0.34	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	6.71	7.73e-11	1.4e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-6.71	7.73e-11	1.4e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
STAD	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	6.71	7.8e-11	1.41e-07	0.36	0.34	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	6.71	7.8e-11	1.41e-07	0.36	0.34	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
STAD	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	6.71	7.8e-11	1.41e-07	0.36	0.34	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
STAD	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	6.71	7.8e-11	1.41e-07	0.36	0.34	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
STAD	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-6.71	7.81e-11	1.41e-07	-0.58	-0.34	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
STAD	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	6.71	7.81e-11	1.41e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
STAD	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	6.71	7.81e-11	1.41e-07	0.35	0.34	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
STAD	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-6.71	7.82e-11	1.41e-07	-0.37	-0.34	Height;	chr3:53015087	chr3:53064283~53065091:-
STAD	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-6.71	7.85e-11	1.42e-07	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	6.71	7.85e-11	1.42e-07	0.25	0.34	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	6.71	7.85e-11	1.42e-07	0.25	0.34	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	6.71	7.85e-11	1.42e-07	0.25	0.34	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	6.71	7.85e-11	1.42e-07	0.25	0.34	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
STAD	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	6.71	7.85e-11	1.42e-07	0.33	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
STAD	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-6.71	7.86e-11	1.42e-07	-0.36	-0.34	Height;	chr3:52971094	chr3:53064283~53065091:-
STAD	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	6.71	7.87e-11	1.42e-07	0.39	0.34	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
STAD	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	6.71	7.9e-11	1.42e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	6.71	7.9e-11	1.42e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	6.71	7.9e-11	1.42e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
STAD	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	6.71	7.91e-11	1.43e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
STAD	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-6.71	7.92e-11	1.43e-07	-0.36	-0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
STAD	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	6.71	7.94e-11	1.43e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	6.71	7.94e-11	1.43e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	6.71	7.94e-11	1.43e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
STAD	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	6.71	7.94e-11	1.43e-07	0.43	0.34	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
STAD	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-6.71	7.95e-11	1.43e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
STAD	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	6.71	7.95e-11	1.43e-07	0.28	0.34	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
STAD	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-6.71	7.96e-11	1.43e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
STAD	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-6.71	7.97e-11	1.43e-07	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
STAD	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	6.71	7.99e-11	1.44e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	6.71	7.99e-11	1.44e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	6.71	7.99e-11	1.44e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	6.71	7.99e-11	1.44e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
STAD	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-6.71	8e-11	1.44e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
STAD	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	6.71	8e-11	1.44e-07	0.35	0.34	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
STAD	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-6.71	8.01e-11	1.44e-07	-0.52	-0.34	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
STAD	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-6.71	8.01e-11	1.44e-07	-0.39	-0.34	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
STAD	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-6.71	8.06e-11	1.45e-07	-0.48	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	6.71	8.08e-11	1.45e-07	0.26	0.34	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
STAD	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	6.71	8.09e-11	1.45e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	6.71	8.09e-11	1.45e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	6.71	8.09e-11	1.45e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
STAD	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	6.71	8.09e-11	1.45e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	6.71	8.09e-11	1.45e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
STAD	cis	rs6452524	1	rs7732092	ENSG00000243385.2	CTD-2110K23.1	6.71	8.09e-11	1.45e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83201229~83202141:+
STAD	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-6.71	8.11e-11	1.46e-07	-0.38	-0.34	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
STAD	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	6.71	8.11e-11	1.46e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
STAD	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-6.71	8.13e-11	1.46e-07	-0.39	-0.34	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-6.71	8.13e-11	1.46e-07	-0.39	-0.34	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-6.71	8.13e-11	1.46e-07	-0.39	-0.34	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-6.71	8.13e-11	1.46e-07	-0.39	-0.34	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
STAD	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-6.71	8.13e-11	1.46e-07	-0.35	-0.34	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
STAD	cis	rs7580658	0.857	rs2896980	ENSG00000200250.1	RNU6-1147P	6.71	8.15e-11	1.46e-07	0.33	0.34	Protein C levels;	chr2:127382383	chr2:127316873~127316979:+
STAD	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	6.71	8.17e-11	1.47e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
STAD	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	6.71	8.17e-11	1.47e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
STAD	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	6.71	8.21e-11	1.47e-07	0.36	0.34	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
STAD	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-6.7	8.23e-11	1.48e-07	-0.48	-0.34	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
STAD	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	6.7	8.24e-11	1.48e-07	0.37	0.34	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
STAD	cis	rs9368481	0.743	rs9368480	ENSG00000243307.2	POM121L6P	6.7	8.26e-11	1.48e-07	0.36	0.34	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26896952~26898777:+
STAD	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	6.7	8.28e-11	1.49e-07	0.36	0.34	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.967	rs4616871	ENSG00000243385.2	CTD-2110K23.1	6.7	8.29e-11	1.49e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83201229~83202141:+
STAD	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	6.7	8.29e-11	1.49e-07	0.4	0.34	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	6.7	8.31e-11	1.49e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
STAD	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-6.7	8.33e-11	1.49e-07	-0.41	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-6.7	8.33e-11	1.49e-07	-0.41	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	6.7	8.35e-11	1.5e-07	0.25	0.34	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
STAD	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-6.7	8.35e-11	1.5e-07	-0.36	-0.34	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
STAD	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	6.7	8.35e-11	1.5e-07	0.49	0.34	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
STAD	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-6.7	8.36e-11	1.5e-07	-0.36	-0.34	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-6.7	8.36e-11	1.5e-07	-0.36	-0.34	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
STAD	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	6.7	8.39e-11	1.5e-07	0.33	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
STAD	cis	rs7829975	0.511	rs2980426	ENSG00000173295.6	FAM86B3P	6.7	8.39e-11	1.5e-07	0.38	0.34	Mood instability;	chr8:8288087	chr8:8228595~8244865:+
STAD	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	6.7	8.41e-11	1.51e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	6.7	8.41e-11	1.51e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	6.7	8.41e-11	1.51e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
STAD	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	6.7	8.42e-11	1.51e-07	0.36	0.34	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
STAD	cis	rs2833693	0.572	rs9982765	ENSG00000261610.1	AP000265.1	6.7	8.44e-11	1.51e-07	0.39	0.34	Temperament;	chr21:32204315	chr21:32259804~32261585:-
STAD	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	6.7	8.45e-11	1.51e-07	0.4	0.34	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
STAD	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	6.7	8.45e-11	1.51e-07	0.35	0.34	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
STAD	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-6.7	8.49e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
STAD	cis	rs6452524	1	rs6452519	ENSG00000243385.2	CTD-2110K23.1	6.7	8.5e-11	1.52e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83201229~83202141:+
STAD	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-6.7	8.52e-11	1.52e-07	-0.32	-0.34	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
STAD	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-6.7	8.52e-11	1.52e-07	-0.41	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
STAD	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
STAD	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
STAD	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
STAD	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
STAD	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
STAD	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
STAD	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-6.7	8.53e-11	1.52e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
STAD	cis	rs2412819	0.571	rs8030536	ENSG00000249839.1	AC011330.5	-6.7	8.53e-11	1.53e-07	-0.61	-0.34	Lung cancer;	chr15:43627365	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	6.7	8.54e-11	1.53e-07	0.25	0.34	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
STAD	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	6.7	8.55e-11	1.53e-07	0.4	0.34	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
STAD	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	6.7	8.56e-11	1.53e-07	0.32	0.34	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	6.7	8.56e-11	1.53e-07	0.32	0.34	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	6.7	8.56e-11	1.53e-07	0.32	0.34	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	6.7	8.56e-11	1.53e-07	0.32	0.34	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	6.7	8.56e-11	1.53e-07	0.32	0.34	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
STAD	cis	rs1426063	0.748	rs6534607	ENSG00000249717.1	RP11-44F21.3	6.7	8.59e-11	1.53e-07	0.44	0.34	QT interval;	chr4:75106366	chr4:74955974~74970362:-
STAD	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-6.7	8.64e-11	1.54e-07	-0.49	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
STAD	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	6.7	8.66e-11	1.55e-07	0.35	0.34	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-6.7	8.68e-11	1.55e-07	-0.35	-0.34	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
STAD	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-6.7	8.71e-11	1.55e-07	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-6.7	8.72e-11	1.56e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-6.7	8.72e-11	1.56e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-6.7	8.72e-11	1.56e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-6.7	8.72e-11	1.56e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
STAD	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-6.69	8.73e-11	1.56e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-6.69	8.73e-11	1.56e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-6.69	8.73e-11	1.56e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-6.69	8.73e-11	1.56e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-6.69	8.73e-11	1.56e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
STAD	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	6.69	8.74e-11	1.56e-07	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
STAD	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-6.69	8.76e-11	1.56e-07	-0.42	-0.34	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
STAD	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	6.69	8.77e-11	1.56e-07	0.5	0.34	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	6.69	8.77e-11	1.56e-07	0.5	0.34	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	6.69	8.77e-11	1.56e-07	0.5	0.34	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
STAD	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	6.69	8.81e-11	1.57e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	6.69	8.82e-11	1.57e-07	0.25	0.34	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
STAD	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	6.69	8.82e-11	1.57e-07	0.36	0.34	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
STAD	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-6.69	8.83e-11	1.57e-07	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
STAD	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	6.69	8.85e-11	1.58e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
STAD	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	6.69	8.85e-11	1.58e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	6.69	8.85e-11	1.58e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
STAD	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	6.69	8.85e-11	1.58e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-6.69	8.91e-11	1.59e-07	-0.47	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
STAD	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-6.69	8.93e-11	1.59e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
STAD	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	6.69	8.95e-11	1.59e-07	0.45	0.34	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
STAD	cis	rs987724	0.551	rs1835372	ENSG00000240875.4	LINC00886	-6.69	8.96e-11	1.6e-07	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156801238	chr3:156747346~156817062:-
STAD	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-6.69	8.97e-11	1.6e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
STAD	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-6.69	8.98e-11	1.6e-07	-0.36	-0.34	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-6.69	8.98e-11	1.6e-07	-0.36	-0.34	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
STAD	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	6.69	9e-11	1.6e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
STAD	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-6.69	9.01e-11	1.6e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-6.69	9.01e-11	1.6e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
STAD	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	6.69	9.03e-11	1.61e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
STAD	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	6.69	9.06e-11	1.61e-07	0.38	0.34	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
STAD	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	6.69	9.07e-11	1.61e-07	0.42	0.34	Height;	chr6:109507271	chr6:109382795~109383666:+
STAD	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-6.69	9.09e-11	1.62e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
STAD	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	6.69	9.09e-11	1.62e-07	0.57	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
STAD	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	6.69	9.09e-11	1.62e-07	0.57	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
STAD	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	6.69	9.1e-11	1.62e-07	0.41	0.34	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	6.69	9.1e-11	1.62e-07	0.41	0.34	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
STAD	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	6.69	9.1e-11	1.62e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
STAD	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-6.69	9.11e-11	1.62e-07	-0.33	-0.34	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
STAD	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-6.69	9.11e-11	1.62e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
STAD	cis	rs2833693	0.572	rs2040106	ENSG00000261610.1	AP000265.1	6.69	9.11e-11	1.62e-07	0.38	0.34	Temperament;	chr21:32242397	chr21:32259804~32261585:-
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	6.69	9.19e-11	1.63e-07	0.25	0.34	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	6.69	9.19e-11	1.63e-07	0.25	0.34	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
STAD	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-6.69	9.2e-11	1.63e-07	-0.5	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
STAD	cis	rs7580658	0.963	rs12463451	ENSG00000200250.1	RNU6-1147P	6.69	9.21e-11	1.64e-07	0.33	0.34	Protein C levels;	chr2:127296307	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.963	rs4233584	ENSG00000200250.1	RNU6-1147P	6.69	9.21e-11	1.64e-07	0.33	0.34	Protein C levels;	chr2:127302587	chr2:127316873~127316979:+
STAD	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-6.69	9.23e-11	1.64e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
STAD	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-6.69	9.23e-11	1.64e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
STAD	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-6.68	9.29e-11	1.65e-07	-0.37	-0.34	Height;	chr3:53029854	chr3:53064283~53065091:-
STAD	cis	rs7580658	0.895	rs9636237	ENSG00000200250.1	RNU6-1147P	6.68	9.3e-11	1.65e-07	0.33	0.34	Protein C levels;	chr2:127318446	chr2:127316873~127316979:+
STAD	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-6.68	9.32e-11	1.66e-07	-0.28	-0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
STAD	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	6.68	9.32e-11	1.66e-07	0.4	0.34	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-6.68	9.33e-11	1.66e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-6.68	9.33e-11	1.66e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-6.68	9.33e-11	1.66e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-6.68	9.33e-11	1.66e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-6.68	9.33e-11	1.66e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
STAD	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-6.68	9.34e-11	1.66e-07	-0.5	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-6.68	9.34e-11	1.66e-07	-0.5	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-6.68	9.34e-11	1.66e-07	-0.5	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-6.68	9.34e-11	1.66e-07	-0.5	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
STAD	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	6.68	9.34e-11	1.66e-07	0.46	0.34	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
STAD	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-6.68	9.37e-11	1.66e-07	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-6.68	9.39e-11	1.67e-07	-0.34	-0.34	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
STAD	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	6.68	9.41e-11	1.67e-07	0.39	0.34	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-6.68	9.41e-11	1.67e-07	-0.39	-0.34	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-6.68	9.41e-11	1.67e-07	-0.39	-0.34	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
STAD	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	6.68	9.42e-11	1.67e-07	0.43	0.34	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
STAD	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-6.68	9.46e-11	1.68e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
STAD	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-6.68	9.47e-11	1.68e-07	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
STAD	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-6.68	9.47e-11	1.68e-07	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
STAD	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	6.68	9.47e-11	1.68e-07	0.35	0.34	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
STAD	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	6.68	9.48e-11	1.68e-07	0.4	0.34	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
STAD	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-6.68	9.48e-11	1.68e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
STAD	cis	rs6452524	0.935	rs1017794	ENSG00000243385.2	CTD-2110K23.1	6.68	9.49e-11	1.68e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.905	rs6896548	ENSG00000243385.2	CTD-2110K23.1	6.68	9.49e-11	1.68e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs1580311	ENSG00000243385.2	CTD-2110K23.1	6.68	9.49e-11	1.68e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83201229~83202141:+
STAD	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	6.68	9.49e-11	1.68e-07	0.41	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
STAD	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-6.68	9.5e-11	1.68e-07	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
STAD	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-6.68	9.5e-11	1.68e-07	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
STAD	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-6.68	9.5e-11	1.68e-07	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
STAD	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-6.68	9.5e-11	1.68e-07	-0.41	-0.34	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
STAD	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-6.68	9.5e-11	1.68e-07	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
STAD	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-6.68	9.5e-11	1.68e-07	-0.4	-0.34	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	6.68	9.52e-11	1.69e-07	0.25	0.34	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
STAD	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-6.68	9.52e-11	1.69e-07	-0.54	-0.34	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
STAD	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	6.68	9.54e-11	1.69e-07	0.41	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
STAD	cis	rs2221894	1	rs12674777	ENSG00000273710.1	Metazoa_SRP	-6.68	9.54e-11	1.69e-07	-0.37	-0.34	Obesity-related traits;	chr8:28986204	chr8:28915579~28915864:-
STAD	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-6.68	9.55e-11	1.69e-07	-0.41	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
STAD	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-6.68	9.55e-11	1.69e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
STAD	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	6.68	9.59e-11	1.7e-07	0.4	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
STAD	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	6.68	9.59e-11	1.7e-07	0.43	0.34	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
STAD	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	6.68	9.59e-11	1.7e-07	0.43	0.34	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
STAD	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	6.68	9.67e-11	1.71e-07	0.28	0.34	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
STAD	cis	rs2412819	0.571	rs66903736	ENSG00000249839.1	AC011330.5	-6.68	9.68e-11	1.71e-07	-0.61	-0.34	Lung cancer;	chr15:43619435	chr15:43663654~43684339:-
STAD	cis	rs2412819	0.571	rs66749753	ENSG00000249839.1	AC011330.5	-6.68	9.68e-11	1.71e-07	-0.61	-0.34	Lung cancer;	chr15:43619601	chr15:43663654~43684339:-
STAD	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	6.68	9.69e-11	1.71e-07	0.38	0.34	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
STAD	cis	rs7580658	0.895	rs62157549	ENSG00000200250.1	RNU6-1147P	6.68	9.72e-11	1.72e-07	0.33	0.34	Protein C levels;	chr2:127308431	chr2:127316873~127316979:+
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	6.68	9.72e-11	1.72e-07	0.25	0.34	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	6.68	9.72e-11	1.72e-07	0.25	0.34	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
STAD	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-6.68	9.75e-11	1.72e-07	-0.38	-0.34	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
STAD	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-6.68	9.75e-11	1.72e-07	-0.34	-0.34	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
STAD	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	6.68	9.75e-11	1.72e-07	0.43	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
STAD	cis	rs2283792	0.812	rs5995269	ENSG00000228050.1	TOP3BP1	6.68	9.76e-11	1.72e-07	0.38	0.34	Multiple sclerosis;	chr22:21935025	chr22:22223187~22224566:-
STAD	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	6.68	9.77e-11	1.73e-07	0.41	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
STAD	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-6.68	9.78e-11	1.73e-07	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-6.68	9.81e-11	1.73e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
STAD	cis	rs6558530	0.863	rs4595147	ENSG00000253982.1	CTD-2336O2.1	6.68	9.82e-11	1.74e-07	0.36	0.34	Systolic blood pressure;	chr8:1755403	chr8:1761990~1764502:-
STAD	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	6.67	9.86e-11	1.74e-07	0.4	0.34	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
STAD	cis	rs4568518	0.53	rs10950690	ENSG00000279048.1	RP11-511H23.2	6.67	9.86e-11	1.74e-07	0.31	0.34	Measles;	chr7:17941687	chr7:17940503~17942922:+
STAD	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-6.67	9.87e-11	1.74e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
STAD	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-6.67	9.88e-11	1.74e-07	-0.5	-0.34	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
STAD	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-6.67	9.88e-11	1.75e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
STAD	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	6.67	9.9e-11	1.75e-07	0.32	0.34	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	6.67	9.9e-11	1.75e-07	0.32	0.34	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	6.67	9.9e-11	1.75e-07	0.32	0.34	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	6.67	9.9e-11	1.75e-07	0.32	0.34	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
STAD	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	6.67	9.9e-11	1.75e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
STAD	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-6.67	9.94e-11	1.75e-07	-0.36	-0.34	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
STAD	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-6.67	9.94e-11	1.75e-07	-0.35	-0.34	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
STAD	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	6.67	9.97e-11	1.76e-07	0.32	0.34	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
STAD	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	6.67	1e-10	1.77e-07	0.41	0.34	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
STAD	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-6.67	1e-10	1.77e-07	-0.35	-0.34	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
STAD	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	6.67	1e-10	1.77e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	6.67	1e-10	1.77e-07	0.25	0.34	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
STAD	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	6.67	1e-10	1.77e-07	0.41	0.34	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
STAD	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-6.67	1.01e-10	1.77e-07	-0.35	-0.34	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-6.67	1.01e-10	1.77e-07	-0.35	-0.34	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
STAD	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-6.67	1.01e-10	1.77e-07	-0.47	-0.34	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
STAD	cis	rs6456156	0.819	rs4709148	ENSG00000265828.1	MIR3939	-6.67	1.02e-10	1.79e-07	-0.37	-0.34	Primary biliary cholangitis;	chr6:167108188	chr6:166997807~166997912:-
STAD	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-6.67	1.02e-10	1.79e-07	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
STAD	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-6.67	1.02e-10	1.79e-07	-0.39	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
STAD	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-6.67	1.02e-10	1.8e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
STAD	cis	rs2436845	0.521	rs2679742	ENSG00000253385.1	KB-1254G8.1	6.67	1.02e-10	1.8e-07	0.36	0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102867569	chr8:102854455~102856075:+
STAD	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-6.67	1.02e-10	1.8e-07	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
STAD	cis	rs2221894	1	rs7842492	ENSG00000273710.1	Metazoa_SRP	-6.67	1.02e-10	1.8e-07	-0.37	-0.34	Obesity-related traits;	chr8:29012120	chr8:28915579~28915864:-
STAD	cis	rs11089937	0.568	rs2876996	ENSG00000211639.2	IGLV4-60	6.67	1.02e-10	1.8e-07	0.37	0.34	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22162199~22162681:+
STAD	cis	rs1862618	0.853	rs1423620	ENSG00000271828.1	CTD-2310F14.1	6.67	1.02e-10	1.8e-07	0.43	0.34	Initial pursuit acceleration;	chr5:56805169	chr5:56927874~56929573:+
STAD	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-6.67	1.02e-10	1.8e-07	-0.55	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
STAD	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	6.67	1.03e-10	1.81e-07	0.4	0.34	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-6.67	1.03e-10	1.81e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.967	rs62374399	ENSG00000243385.2	CTD-2110K23.1	6.67	1.03e-10	1.81e-07	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs62374401	ENSG00000243385.2	CTD-2110K23.1	6.67	1.03e-10	1.81e-07	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83201229~83202141:+
STAD	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	6.67	1.03e-10	1.81e-07	0.36	0.34	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
STAD	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	6.67	1.04e-10	1.82e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
STAD	cis	rs78579487	1	rs78579487	ENSG00000240875.4	LINC00886	-6.67	1.04e-10	1.83e-07	-0.41	-0.34	Breast cancer;	chr3:156800879	chr3:156747346~156817062:-
STAD	cis	rs6452524	0.967	rs2974443	ENSG00000243385.2	CTD-2110K23.1	6.67	1.04e-10	1.83e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2974441	ENSG00000243385.2	CTD-2110K23.1	6.67	1.04e-10	1.83e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83201229~83202141:+
STAD	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-6.67	1.04e-10	1.83e-07	-0.31	-0.34	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
STAD	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-6.67	1.04e-10	1.83e-07	-0.38	-0.34	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
STAD	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-6.67	1.04e-10	1.83e-07	-0.43	-0.34	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
STAD	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-6.67	1.04e-10	1.83e-07	-0.34	-0.34	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
STAD	cis	rs6452524	0.967	rs28360104	ENSG00000243385.2	CTD-2110K23.1	6.67	1.04e-10	1.83e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83201229~83202141:+
STAD	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	6.67	1.04e-10	1.83e-07	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
STAD	cis	rs6456156	0.904	rs2023305	ENSG00000265828.1	MIR3939	-6.67	1.04e-10	1.83e-07	-0.37	-0.34	Primary biliary cholangitis;	chr6:167111410	chr6:166997807~166997912:-
STAD	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-6.67	1.04e-10	1.84e-07	-0.4	-0.34	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
STAD	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	6.67	1.05e-10	1.84e-07	0.41	0.34	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
STAD	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	6.66	1.05e-10	1.84e-07	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
STAD	cis	rs2221894	1	rs6985217	ENSG00000273710.1	Metazoa_SRP	-6.66	1.05e-10	1.84e-07	-0.38	-0.34	Obesity-related traits;	chr8:28955638	chr8:28915579~28915864:-
STAD	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-6.66	1.05e-10	1.84e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
STAD	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	6.66	1.05e-10	1.85e-07	0.41	0.34	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
STAD	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	6.66	1.05e-10	1.85e-07	0.3	0.34	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
STAD	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-6.66	1.05e-10	1.85e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-6.66	1.05e-10	1.85e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
STAD	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	6.66	1.06e-10	1.85e-07	0.36	0.34	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	6.66	1.06e-10	1.86e-07	0.42	0.34	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
STAD	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-6.66	1.06e-10	1.86e-07	-0.42	-0.34	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
STAD	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-6.66	1.06e-10	1.86e-07	-0.33	-0.34	Height;	chr11:118781100	chr11:118791254~118793137:+
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-6.66	1.06e-10	1.86e-07	-0.38	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
STAD	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-6.66	1.06e-10	1.86e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
STAD	cis	rs4568518	0.53	rs4493811	ENSG00000279048.1	RP11-511H23.2	6.66	1.06e-10	1.86e-07	0.31	0.34	Measles;	chr7:17943746	chr7:17940503~17942922:+
STAD	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-6.66	1.06e-10	1.87e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
STAD	cis	rs210138	0.882	rs407710	ENSG00000197251.3	LINC00336	6.66	1.06e-10	1.87e-07	0.44	0.34	Testicular germ cell tumor;	chr6:33586480	chr6:33586106~33593338:-
STAD	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-6.66	1.07e-10	1.87e-07	-0.4	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
STAD	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	6.66	1.07e-10	1.87e-07	0.43	0.34	Height;	chr6:109738751	chr6:109382795~109383666:+
STAD	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-6.66	1.07e-10	1.88e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-6.66	1.07e-10	1.88e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-6.66	1.07e-10	1.88e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-6.66	1.07e-10	1.88e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-6.66	1.07e-10	1.88e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-6.66	1.07e-10	1.88e-07	-0.39	-0.34	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
STAD	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	6.66	1.07e-10	1.88e-07	0.39	0.34	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
STAD	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-6.66	1.08e-10	1.89e-07	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-6.66	1.08e-10	1.89e-07	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
STAD	cis	rs2439831	0.867	rs3101443	ENSG00000249839.1	AC011330.5	-6.66	1.08e-10	1.89e-07	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43620174	chr15:43663654~43684339:-
STAD	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-6.66	1.09e-10	1.91e-07	-0.35	-0.34	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
STAD	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-6.66	1.09e-10	1.91e-07	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-6.66	1.09e-10	1.91e-07	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
STAD	cis	rs13217239	0.646	rs62401067	ENSG00000243307.2	POM121L6P	6.66	1.09e-10	1.91e-07	0.32	0.34	Schizophrenia;	chr6:27050322	chr6:26896952~26898777:+
STAD	cis	rs7580658	0.963	rs12991768	ENSG00000200250.1	RNU6-1147P	6.66	1.09e-10	1.91e-07	0.33	0.34	Protein C levels;	chr2:127388669	chr2:127316873~127316979:+
STAD	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-6.66	1.09e-10	1.91e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
STAD	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-6.66	1.09e-10	1.91e-07	-0.35	-0.34	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
STAD	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	6.66	1.09e-10	1.91e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	6.66	1.09e-10	1.91e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	6.66	1.09e-10	1.91e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	6.66	1.09e-10	1.91e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	6.66	1.09e-10	1.91e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	6.66	1.09e-10	1.91e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	6.66	1.09e-10	1.92e-07	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	6.66	1.09e-10	1.92e-07	0.45	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
STAD	cis	rs1005277	0.602	rs1831315	ENSG00000099251.13	HSD17B7P2	6.66	1.09e-10	1.92e-07	0.37	0.34	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38356380~38378505:+
STAD	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	6.66	1.09e-10	1.92e-07	0.38	0.34	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
STAD	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	6.66	1.1e-10	1.92e-07	0.43	0.34	Height;	chr6:109738307	chr6:109382795~109383666:+
STAD	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-6.66	1.1e-10	1.92e-07	-0.49	-0.34	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
STAD	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-6.66	1.11e-10	1.93e-07	-0.35	-0.34	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-6.66	1.11e-10	1.94e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-6.66	1.11e-10	1.94e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
STAD	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-6.66	1.11e-10	1.94e-07	-0.43	-0.34	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
STAD	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-6.65	1.11e-10	1.95e-07	-0.3	-0.34	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
STAD	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	6.65	1.12e-10	1.95e-07	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
STAD	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	6.65	1.12e-10	1.95e-07	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
STAD	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-6.65	1.12e-10	1.95e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
STAD	cis	rs6452524	1	rs10077862	ENSG00000243385.2	CTD-2110K23.1	6.65	1.12e-10	1.95e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83201229~83202141:+
STAD	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-6.65	1.12e-10	1.95e-07	-0.32	-0.34	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
STAD	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	6.65	1.12e-10	1.96e-07	0.31	0.34	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	6.65	1.12e-10	1.96e-07	0.31	0.34	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
STAD	cis	rs11089937	0.553	rs35336247	ENSG00000211639.2	IGLV4-60	6.65	1.12e-10	1.96e-07	0.37	0.34	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.553	rs34088081	ENSG00000211639.2	IGLV4-60	6.65	1.12e-10	1.96e-07	0.37	0.34	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.568	rs12160317	ENSG00000211639.2	IGLV4-60	6.65	1.12e-10	1.96e-07	0.37	0.34	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.568	rs12160318	ENSG00000211639.2	IGLV4-60	6.65	1.12e-10	1.96e-07	0.37	0.34	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22162199~22162681:+
STAD	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-6.65	1.12e-10	1.96e-07	-0.53	-0.34	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
STAD	cis	rs13217239	0.608	rs6930508	ENSG00000243307.2	POM121L6P	-6.65	1.13e-10	1.96e-07	-0.32	-0.34	Schizophrenia;	chr6:27085363	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs2142685	ENSG00000243307.2	POM121L6P	-6.65	1.13e-10	1.96e-07	-0.32	-0.34	Schizophrenia;	chr6:27086718	chr6:26896952~26898777:+
STAD	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	6.65	1.13e-10	1.97e-07	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
STAD	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	6.65	1.13e-10	1.97e-07	0.4	0.34	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
STAD	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-6.65	1.14e-10	1.98e-07	-0.49	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
STAD	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	6.65	1.14e-10	1.98e-07	0.24	0.34	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
STAD	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	6.65	1.14e-10	1.98e-07	0.41	0.34	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
STAD	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	6.65	1.14e-10	1.98e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
STAD	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-6.65	1.14e-10	1.98e-07	-0.46	-0.34	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
STAD	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-6.65	1.14e-10	1.98e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
STAD	cis	rs7580658	0.857	rs17015199	ENSG00000200250.1	RNU6-1147P	6.65	1.14e-10	1.98e-07	0.33	0.34	Protein C levels;	chr2:127336477	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.895	rs4662722	ENSG00000200250.1	RNU6-1147P	6.65	1.14e-10	1.98e-07	0.33	0.34	Protein C levels;	chr2:127344993	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.895	rs4662580	ENSG00000200250.1	RNU6-1147P	6.65	1.14e-10	1.98e-07	0.33	0.34	Protein C levels;	chr2:127345230	chr2:127316873~127316979:+
STAD	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	6.65	1.14e-10	1.99e-07	0.41	0.34	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
STAD	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	6.65	1.14e-10	1.99e-07	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
STAD	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-6.65	1.14e-10	1.99e-07	-0.42	-0.34	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
STAD	cis	rs13217239	0.646	rs9379956	ENSG00000243307.2	POM121L6P	-6.65	1.14e-10	1.99e-07	-0.32	-0.34	Schizophrenia;	chr6:27065956	chr6:26896952~26898777:+
STAD	cis	rs13217239	0.646	rs7747454	ENSG00000243307.2	POM121L6P	-6.65	1.14e-10	1.99e-07	-0.32	-0.34	Schizophrenia;	chr6:27066474	chr6:26896952~26898777:+
STAD	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	6.65	1.15e-10	2e-07	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
STAD	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	6.65	1.15e-10	2e-07	0.4	0.34	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
STAD	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	6.65	1.15e-10	2e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	6.65	1.15e-10	2e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
STAD	cis	rs496547	0.719	rs598373	ENSG00000255422.1	AP002954.4	-6.65	1.15e-10	2e-07	-0.4	-0.34	Hip minimal joint space width;	chr11:118793668	chr11:118704607~118750263:+
STAD	cis	rs6452524	0.967	rs11741420	ENSG00000243385.2	CTD-2110K23.1	6.65	1.15e-10	2e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs4401555	ENSG00000243385.2	CTD-2110K23.1	6.65	1.15e-10	2e-07	0.37	0.34	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83201229~83202141:+
STAD	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-6.65	1.15e-10	2e-07	-0.4	-0.34	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
STAD	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-6.65	1.15e-10	2.01e-07	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-6.65	1.15e-10	2.01e-07	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-6.65	1.15e-10	2.01e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
STAD	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	6.65	1.16e-10	2.01e-07	0.4	0.34	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	6.65	1.16e-10	2.01e-07	0.24	0.34	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
STAD	cis	rs611744	0.967	rs655722	ENSG00000253754.1	RP11-35G22.1	-6.65	1.16e-10	2.01e-07	-0.28	-0.34	Dupuytren's disease;	chr8:108185312	chr8:108226200~108227544:+
STAD	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	6.65	1.16e-10	2.01e-07	0.24	0.34	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
STAD	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	6.65	1.16e-10	2.01e-07	0.4	0.34	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	6.65	1.16e-10	2.01e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	6.65	1.16e-10	2.02e-07	0.38	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
STAD	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	6.65	1.16e-10	2.02e-07	0.24	0.34	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
STAD	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-6.65	1.17e-10	2.02e-07	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-6.65	1.17e-10	2.02e-07	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
STAD	cis	rs9506514	0.509	rs9509279	ENSG00000222726.1	RNU2-7P	6.65	1.17e-10	2.03e-07	0.39	0.34	Coronary artery calcification;	chr13:20559580	chr13:20612161~20612338:+
STAD	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-6.65	1.17e-10	2.03e-07	-0.37	-0.34	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
STAD	cis	rs8040855	0.965	rs1961276	ENSG00000229212.6	RP11-561C5.4	6.65	1.17e-10	2.03e-07	0.45	0.34	Bulimia nervosa;	chr15:85170986	chr15:85205440~85234795:-
STAD	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	6.65	1.17e-10	2.04e-07	0.35	0.34	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
STAD	cis	rs2436845	0.627	rs1055376	ENSG00000253385.1	KB-1254G8.1	6.65	1.18e-10	2.04e-07	0.36	0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102865206	chr8:102854455~102856075:+
STAD	cis	rs1426063	0.668	rs6534595	ENSG00000248165.1	RP11-44F21.2	6.64	1.18e-10	2.05e-07	0.44	0.34	QT interval;	chr4:75104432	chr4:74993877~75034824:-
STAD	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	6.64	1.18e-10	2.05e-07	0.35	0.34	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	6.64	1.19e-10	2.06e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	6.64	1.19e-10	2.06e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	6.64	1.19e-10	2.06e-07	0.38	0.34	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs62374373	ENSG00000243385.2	CTD-2110K23.1	6.64	1.19e-10	2.06e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs10043018	ENSG00000243385.2	CTD-2110K23.1	6.64	1.19e-10	2.06e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs10037501	ENSG00000243385.2	CTD-2110K23.1	6.64	1.19e-10	2.06e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.904	rs6452525	ENSG00000243385.2	CTD-2110K23.1	6.64	1.19e-10	2.06e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs7716931	ENSG00000243385.2	CTD-2110K23.1	6.64	1.19e-10	2.06e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs7721416	ENSG00000243385.2	CTD-2110K23.1	6.64	1.19e-10	2.06e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs6882220	ENSG00000243385.2	CTD-2110K23.1	6.64	1.19e-10	2.06e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83201229~83202141:+
STAD	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-6.64	1.19e-10	2.06e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
STAD	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	6.64	1.19e-10	2.06e-07	0.39	0.34	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
STAD	cis	rs2273156	0.57	rs77477310	ENSG00000241052.1	RP11-173D9.1	-6.64	1.2e-10	2.07e-07	-0.4	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35146587	chr14:35144021~35144480:-
STAD	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-6.64	1.2e-10	2.07e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
STAD	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-6.64	1.2e-10	2.07e-07	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
STAD	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	6.64	1.2e-10	2.08e-07	0.44	0.34	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
STAD	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	6.64	1.2e-10	2.08e-07	0.47	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-6.64	1.21e-10	2.08e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-6.64	1.21e-10	2.08e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-6.64	1.21e-10	2.08e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-6.64	1.21e-10	2.08e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-6.64	1.21e-10	2.08e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-6.64	1.21e-10	2.09e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
STAD	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	6.64	1.21e-10	2.09e-07	0.41	0.34	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
STAD	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-6.64	1.21e-10	2.09e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
STAD	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-6.64	1.21e-10	2.09e-07	-0.39	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
STAD	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-6.64	1.21e-10	2.09e-07	-0.38	-0.34	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
STAD	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-6.64	1.21e-10	2.09e-07	-0.38	-0.34	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
STAD	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-6.64	1.21e-10	2.09e-07	-0.38	-0.34	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
STAD	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-6.64	1.21e-10	2.09e-07	-0.38	-0.34	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
STAD	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-6.64	1.21e-10	2.09e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-6.64	1.21e-10	2.09e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
STAD	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	6.64	1.22e-10	2.1e-07	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
STAD	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	6.64	1.22e-10	2.1e-07	0.39	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
STAD	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	6.64	1.22e-10	2.1e-07	0.33	0.34	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
STAD	cis	rs2412819	0.571	rs8038068	ENSG00000249839.1	AC011330.5	-6.64	1.22e-10	2.11e-07	-0.61	-0.34	Lung cancer;	chr15:43622175	chr15:43663654~43684339:-
STAD	cis	rs2412819	0.571	rs56246169	ENSG00000249839.1	AC011330.5	-6.64	1.22e-10	2.11e-07	-0.61	-0.34	Lung cancer;	chr15:43628358	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-6.64	1.22e-10	2.11e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-6.64	1.22e-10	2.11e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
STAD	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	6.64	1.22e-10	2.11e-07	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
STAD	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	6.64	1.22e-10	2.11e-07	0.38	0.34	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
STAD	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-6.64	1.23e-10	2.12e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-6.64	1.23e-10	2.12e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-6.64	1.23e-10	2.12e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
STAD	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	6.64	1.23e-10	2.12e-07	0.39	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
STAD	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-6.64	1.23e-10	2.12e-07	-0.49	-0.34	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
STAD	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-6.64	1.23e-10	2.12e-07	-0.35	-0.34	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
STAD	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-6.64	1.23e-10	2.12e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
STAD	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	6.64	1.24e-10	2.13e-07	0.4	0.34	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
STAD	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-6.64	1.24e-10	2.13e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-6.64	1.24e-10	2.13e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
STAD	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-6.64	1.24e-10	2.13e-07	-0.34	-0.34	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-6.64	1.24e-10	2.13e-07	-0.34	-0.34	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
STAD	cis	rs2439831	1	rs1814538	ENSG00000249839.1	AC011330.5	6.64	1.24e-10	2.14e-07	0.47	0.34	Lung cancer in ever smokers;	chr15:43467576	chr15:43663654~43684339:-
STAD	cis	rs7580658	0.926	rs79789049	ENSG00000200250.1	RNU6-1147P	6.64	1.24e-10	2.14e-07	0.33	0.34	Protein C levels;	chr2:127387896	chr2:127316873~127316979:+
STAD	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-6.64	1.24e-10	2.14e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
STAD	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-6.64	1.24e-10	2.14e-07	-0.4	-0.34	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.967	rs2974444	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2940542	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.934	rs2940543	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2974450	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2974449	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2662241	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2731861	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs2940544	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2731865	ENSG00000243385.2	CTD-2110K23.1	6.64	1.24e-10	2.14e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs6452526	ENSG00000243385.2	CTD-2110K23.1	6.64	1.25e-10	2.15e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs6452527	ENSG00000243385.2	CTD-2110K23.1	6.64	1.25e-10	2.15e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs10055844	ENSG00000243385.2	CTD-2110K23.1	6.64	1.25e-10	2.15e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83201229~83202141:+
STAD	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-6.64	1.25e-10	2.15e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-6.64	1.25e-10	2.15e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-6.64	1.25e-10	2.15e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-6.64	1.25e-10	2.15e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-6.64	1.25e-10	2.15e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	6.64	1.25e-10	2.15e-07	0.25	0.34	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	6.64	1.25e-10	2.15e-07	0.25	0.34	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
STAD	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	6.64	1.25e-10	2.15e-07	0.4	0.34	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
STAD	cis	rs6452524	1	rs6452531	ENSG00000243385.2	CTD-2110K23.1	6.64	1.25e-10	2.15e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83201229~83202141:+
STAD	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	6.64	1.25e-10	2.15e-07	0.39	0.34	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
STAD	cis	rs3136516	0.696	rs4752926	ENSG00000271350.1	CTD-2384B9.1	-6.63	1.25e-10	2.16e-07	-0.37	-0.34	Venous thromboembolism;	chr11:46671320	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-6.63	1.26e-10	2.16e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
STAD	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-6.63	1.26e-10	2.16e-07	-0.32	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
STAD	cis	rs11089937	0.54	rs2329931	ENSG00000211639.2	IGLV4-60	6.63	1.26e-10	2.16e-07	0.36	0.34	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22162199~22162681:+
STAD	cis	rs2221894	1	rs4559202	ENSG00000273710.1	Metazoa_SRP	-6.63	1.26e-10	2.16e-07	-0.38	-0.34	Obesity-related traits;	chr8:28959335	chr8:28915579~28915864:-
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	6.63	1.26e-10	2.16e-07	0.25	0.34	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-6.63	1.26e-10	2.17e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-6.63	1.26e-10	2.17e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	6.63	1.27e-10	2.18e-07	0.24	0.34	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	6.63	1.27e-10	2.18e-07	0.24	0.34	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
STAD	cis	rs7580658	0.857	rs11890187	ENSG00000200250.1	RNU6-1147P	6.63	1.27e-10	2.18e-07	0.33	0.34	Protein C levels;	chr2:127326162	chr2:127316873~127316979:+
STAD	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	6.63	1.28e-10	2.19e-07	0.42	0.34	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	6.63	1.28e-10	2.19e-07	0.42	0.34	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
STAD	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	6.63	1.28e-10	2.19e-07	0.42	0.34	Height;	chr6:109496073	chr6:109382795~109383666:+
STAD	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-6.63	1.28e-10	2.19e-07	-0.37	-0.34	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
STAD	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-6.63	1.28e-10	2.19e-07	-0.37	-0.34	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
STAD	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-6.63	1.28e-10	2.19e-07	-0.37	-0.34	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
STAD	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-6.63	1.28e-10	2.2e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-6.63	1.28e-10	2.2e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-6.63	1.28e-10	2.2e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
STAD	cis	rs801193	0.967	rs3800823	ENSG00000222364.1	RNU6-96P	6.63	1.28e-10	2.2e-07	0.38	0.34	Aortic root size;	chr7:66682123	chr7:66395191~66395286:+
STAD	cis	rs6452524	1	rs10055948	ENSG00000243385.2	CTD-2110K23.1	6.63	1.28e-10	2.2e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83201229~83202141:+
STAD	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-6.63	1.28e-10	2.2e-07	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
STAD	cis	rs7580658	0.926	rs4662725	ENSG00000200250.1	RNU6-1147P	6.63	1.28e-10	2.2e-07	0.33	0.34	Protein C levels;	chr2:127383744	chr2:127316873~127316979:+
STAD	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	6.63	1.29e-10	2.21e-07	0.35	0.34	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
STAD	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-6.63	1.29e-10	2.22e-07	-0.32	-0.34	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
STAD	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-6.63	1.3e-10	2.22e-07	-0.39	-0.34	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-6.63	1.3e-10	2.22e-07	-0.39	-0.34	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
STAD	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-6.63	1.3e-10	2.23e-07	-0.39	-0.34	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
STAD	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-6.63	1.3e-10	2.23e-07	-0.39	-0.34	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
STAD	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-6.63	1.3e-10	2.23e-07	-0.3	-0.34	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
STAD	cis	rs7580658	0.864	rs34832797	ENSG00000200250.1	RNU6-1147P	6.63	1.3e-10	2.23e-07	0.33	0.34	Protein C levels;	chr2:127361865	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.895	rs7589451	ENSG00000200250.1	RNU6-1147P	6.63	1.3e-10	2.23e-07	0.33	0.34	Protein C levels;	chr2:127371199	chr2:127316873~127316979:+
STAD	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-6.63	1.31e-10	2.25e-07	-0.38	-0.34	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
STAD	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-6.63	1.31e-10	2.25e-07	-0.32	-0.34	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
STAD	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	6.63	1.31e-10	2.25e-07	0.42	0.34	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
STAD	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-6.63	1.32e-10	2.25e-07	-0.35	-0.34	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-6.63	1.32e-10	2.25e-07	-0.35	-0.34	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
STAD	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	6.63	1.32e-10	2.25e-07	0.4	0.34	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	6.63	1.32e-10	2.25e-07	0.4	0.34	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
STAD	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-6.63	1.32e-10	2.25e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-6.63	1.32e-10	2.26e-07	-0.38	-0.34	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
STAD	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	6.63	1.32e-10	2.26e-07	0.43	0.34	Height;	chr6:109706740	chr6:109382795~109383666:+
STAD	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	6.63	1.32e-10	2.26e-07	0.47	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
STAD	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	6.63	1.32e-10	2.26e-07	0.34	0.34	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
STAD	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	6.63	1.32e-10	2.26e-07	0.34	0.34	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
STAD	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	6.63	1.32e-10	2.26e-07	0.34	0.34	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	6.63	1.32e-10	2.26e-07	0.34	0.34	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	6.63	1.32e-10	2.26e-07	0.34	0.34	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	6.63	1.32e-10	2.26e-07	0.34	0.34	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	6.63	1.32e-10	2.26e-07	0.25	0.34	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-6.63	1.33e-10	2.27e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000223648.3	IGHV3-64	6.63	1.33e-10	2.27e-07	0.26	0.34	Kawasaki disease;	chr14:106767802	chr14:106643132~106658258:-
STAD	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-6.62	1.33e-10	2.28e-07	-0.35	-0.34	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
STAD	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	6.62	1.34e-10	2.28e-07	0.38	0.34	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
STAD	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	6.62	1.34e-10	2.29e-07	0.4	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
STAD	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	6.62	1.34e-10	2.29e-07	0.38	0.34	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
STAD	cis	rs6456156	0.774	rs6908364	ENSG00000265828.1	MIR3939	6.62	1.34e-10	2.29e-07	0.37	0.34	Primary biliary cholangitis;	chr6:167113808	chr6:166997807~166997912:-
STAD	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-6.62	1.34e-10	2.29e-07	-0.35	-0.34	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
STAD	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-6.62	1.34e-10	2.29e-07	-0.35	-0.34	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
STAD	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-6.62	1.34e-10	2.29e-07	-0.4	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-6.62	1.34e-10	2.29e-07	-0.4	-0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
STAD	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-6.62	1.34e-10	2.29e-07	-0.34	-0.34	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
STAD	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-6.62	1.34e-10	2.29e-07	-0.34	-0.34	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
STAD	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-6.62	1.35e-10	2.31e-07	-0.34	-0.34	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
STAD	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	6.62	1.35e-10	2.31e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
STAD	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	6.62	1.36e-10	2.31e-07	0.43	0.34	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	6.62	1.36e-10	2.31e-07	0.43	0.34	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
STAD	cis	rs7580658	0.963	rs12052483	ENSG00000200250.1	RNU6-1147P	6.62	1.36e-10	2.32e-07	0.33	0.34	Protein C levels;	chr2:127379244	chr2:127316873~127316979:+
STAD	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	6.62	1.36e-10	2.32e-07	0.34	0.34	Height;	chr11:118758322	chr11:118791254~118793137:+
STAD	cis	rs2436845	0.589	rs2570950	ENSG00000253385.1	KB-1254G8.1	6.62	1.36e-10	2.32e-07	0.36	0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102871637	chr8:102854455~102856075:+
STAD	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-6.62	1.36e-10	2.32e-07	-0.36	-0.34	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
STAD	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	6.62	1.36e-10	2.32e-07	0.45	0.34	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
STAD	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	6.62	1.36e-10	2.32e-07	0.33	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
STAD	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	6.62	1.36e-10	2.33e-07	0.43	0.34	Height;	chr6:109739615	chr6:109382795~109383666:+
STAD	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-6.62	1.36e-10	2.33e-07	-0.38	-0.34	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
STAD	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-6.62	1.37e-10	2.33e-07	-0.42	-0.34	Height;	chr6:109501793	chr6:109382795~109383666:+
STAD	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-6.62	1.37e-10	2.33e-07	-0.39	-0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
STAD	cis	rs7580658	0.963	rs867304	ENSG00000200250.1	RNU6-1147P	6.62	1.37e-10	2.33e-07	0.33	0.34	Protein C levels;	chr2:127320912	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.963	rs12622436	ENSG00000200250.1	RNU6-1147P	6.62	1.37e-10	2.33e-07	0.33	0.34	Protein C levels;	chr2:127324106	chr2:127316873~127316979:+
STAD	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-6.62	1.37e-10	2.33e-07	-0.39	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	6.62	1.37e-10	2.33e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	6.62	1.37e-10	2.33e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	6.62	1.37e-10	2.33e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	6.62	1.37e-10	2.33e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	6.62	1.37e-10	2.33e-07	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
STAD	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	6.62	1.37e-10	2.34e-07	0.43	0.34	Height;	chr6:109690255	chr6:109382795~109383666:+
STAD	cis	rs6452524	1	rs17284288	ENSG00000243385.2	CTD-2110K23.1	6.62	1.38e-10	2.35e-07	0.36	0.34	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83201229~83202141:+
STAD	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-6.62	1.38e-10	2.35e-07	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
STAD	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	6.62	1.38e-10	2.35e-07	0.4	0.34	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
STAD	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	6.62	1.38e-10	2.36e-07	0.31	0.34	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
STAD	cis	rs8040855	0.557	rs9744503	ENSG00000229212.6	RP11-561C5.4	-6.62	1.39e-10	2.36e-07	-0.44	-0.34	Bulimia nervosa;	chr15:85180986	chr15:85205440~85234795:-
STAD	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	6.62	1.39e-10	2.36e-07	0.43	0.34	Height;	chr6:109732518	chr6:109382795~109383666:+
STAD	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-6.62	1.39e-10	2.37e-07	-0.38	-0.34	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
STAD	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	6.62	1.39e-10	2.37e-07	0.3	0.34	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
STAD	cis	rs7580658	0.963	rs10803585	ENSG00000200250.1	RNU6-1147P	6.62	1.4e-10	2.37e-07	0.33	0.34	Protein C levels;	chr2:127372532	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.963	rs2090574	ENSG00000200250.1	RNU6-1147P	6.62	1.4e-10	2.37e-07	0.33	0.34	Protein C levels;	chr2:127373815	chr2:127316873~127316979:+
STAD	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	6.62	1.4e-10	2.39e-07	0.3	0.34	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
STAD	cis	rs2436845	0.554	rs567395	ENSG00000253385.1	KB-1254G8.1	6.62	1.4e-10	2.39e-07	0.35	0.34	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102902262	chr8:102854455~102856075:+
STAD	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-6.62	1.41e-10	2.4e-07	-0.33	-0.34	Height;	chr11:118761813	chr11:118791254~118793137:+
STAD	cis	rs6452524	1	rs7349753	ENSG00000243385.2	CTD-2110K23.1	6.62	1.41e-10	2.4e-07	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83201229~83202141:+
STAD	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-6.62	1.41e-10	2.4e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-6.62	1.41e-10	2.4e-07	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-6.61	1.42e-10	2.41e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-6.61	1.42e-10	2.41e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
STAD	cis	rs9828933	0.701	rs7621544	ENSG00000280620.1	SCAANT1	6.61	1.42e-10	2.41e-07	0.53	0.34	Type 2 diabetes;	chr3:63943005	chr3:63911518~63911772:-
STAD	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	6.61	1.42e-10	2.41e-07	0.48	0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
STAD	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-6.61	1.42e-10	2.42e-07	-0.35	-0.34	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
STAD	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	6.61	1.42e-10	2.42e-07	0.58	0.34	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
STAD	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-6.61	1.43e-10	2.42e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	6.61	1.43e-10	2.43e-07	0.24	0.33	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	6.61	1.43e-10	2.43e-07	0.24	0.33	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
STAD	cis	rs611744	0.87	rs423940	ENSG00000253754.1	RP11-35G22.1	-6.61	1.43e-10	2.43e-07	-0.29	-0.33	Dupuytren's disease;	chr8:108081350	chr8:108226200~108227544:+
STAD	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	6.61	1.43e-10	2.43e-07	0.42	0.33	Height;	chr6:109494148	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	6.61	1.43e-10	2.43e-07	0.42	0.33	Height;	chr6:109494760	chr6:109382795~109383666:+
STAD	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	6.61	1.43e-10	2.43e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
STAD	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-6.61	1.44e-10	2.44e-07	-0.38	-0.33	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
STAD	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-6.61	1.44e-10	2.44e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-6.61	1.44e-10	2.44e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
STAD	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-6.61	1.44e-10	2.45e-07	-0.52	-0.33	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
STAD	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	6.61	1.45e-10	2.45e-07	0.4	0.33	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
STAD	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-6.61	1.45e-10	2.45e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-6.61	1.45e-10	2.45e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
STAD	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-6.61	1.45e-10	2.46e-07	-0.42	-0.33	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
STAD	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-6.61	1.45e-10	2.46e-07	-0.32	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
STAD	cis	rs2439831	1	rs690436	ENSG00000249839.1	AC011330.5	-6.61	1.45e-10	2.46e-07	-0.47	-0.33	Lung cancer in ever smokers;	chr15:43469007	chr15:43663654~43684339:-
STAD	cis	rs2439831	1	rs2264239	ENSG00000249839.1	AC011330.5	-6.61	1.45e-10	2.46e-07	-0.47	-0.33	Lung cancer in ever smokers;	chr15:43473335	chr15:43663654~43684339:-
STAD	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-6.61	1.45e-10	2.47e-07	-0.34	-0.33	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	6.61	1.46e-10	2.47e-07	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
STAD	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-6.61	1.46e-10	2.47e-07	-0.34	-0.33	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
STAD	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	6.61	1.46e-10	2.47e-07	0.43	0.33	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-6.61	1.46e-10	2.47e-07	-0.43	-0.33	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
STAD	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-6.61	1.46e-10	2.47e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-6.61	1.46e-10	2.47e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-6.61	1.46e-10	2.47e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-6.61	1.46e-10	2.47e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-6.61	1.46e-10	2.47e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-6.61	1.46e-10	2.47e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
STAD	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-6.61	1.46e-10	2.48e-07	-0.38	-0.33	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	6.61	1.47e-10	2.49e-07	0.38	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
STAD	cis	rs9549260	0.755	rs2297627	ENSG00000229456.1	RLIMP1	6.61	1.47e-10	2.49e-07	0.31	0.33	Red blood cell count;	chr13:40659794	chr13:40618738~40621348:+
STAD	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-6.61	1.47e-10	2.49e-07	-0.33	-0.33	Height;	chr11:118809363	chr11:118791254~118793137:+
STAD	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	6.61	1.47e-10	2.5e-07	0.37	0.33	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
STAD	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.61	1.48e-10	2.5e-07	0.38	0.33	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-6.61	1.48e-10	2.51e-07	-0.34	-0.33	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
STAD	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-6.61	1.48e-10	2.51e-07	-0.34	-0.33	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
STAD	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-6.61	1.48e-10	2.51e-07	-0.34	-0.33	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
STAD	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-6.61	1.48e-10	2.51e-07	-0.34	-0.33	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-6.61	1.48e-10	2.51e-07	-0.34	-0.33	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
STAD	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-6.61	1.48e-10	2.51e-07	-0.34	-0.33	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
STAD	cis	rs240993	0.715	rs9400483	ENSG00000230177.1	RP5-1112D6.4	6.61	1.48e-10	2.51e-07	0.34	0.33	Inflammatory skin disease;Psoriasis;	chr6:111535073	chr6:111277932~111278742:+
STAD	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-6.61	1.49e-10	2.53e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
STAD	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	6.61	1.49e-10	2.53e-07	0.34	0.33	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
STAD	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	6.61	1.5e-10	2.53e-07	0.34	0.33	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	6.61	1.5e-10	2.53e-07	0.34	0.33	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	6.61	1.5e-10	2.53e-07	0.34	0.33	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
STAD	cis	rs801193	0.773	rs801207	ENSG00000222364.1	RNU6-96P	6.61	1.5e-10	2.53e-07	0.37	0.33	Aortic root size;	chr7:66555603	chr7:66395191~66395286:+
STAD	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	6.61	1.5e-10	2.53e-07	0.43	0.33	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
STAD	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-6.6	1.5e-10	2.54e-07	-0.53	-0.33	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
STAD	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-6.6	1.5e-10	2.54e-07	-0.51	-0.33	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
STAD	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-6.6	1.5e-10	2.54e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
STAD	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	6.6	1.5e-10	2.54e-07	0.39	0.33	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
STAD	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-6.6	1.51e-10	2.55e-07	-0.52	-0.33	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
STAD	cis	rs6452524	1	rs10037872	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs62374374	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs1382372	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs1382371	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs2386240	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs9986131	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs11740478	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs4591730	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs1031902	ENSG00000243385.2	CTD-2110K23.1	6.6	1.51e-10	2.55e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83201229~83202141:+
STAD	cis	rs7580658	0.817	rs6761447	ENSG00000200250.1	RNU6-1147P	6.6	1.51e-10	2.56e-07	0.33	0.33	Protein C levels;	chr2:127316997	chr2:127316873~127316979:+
STAD	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	6.6	1.51e-10	2.56e-07	0.32	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
STAD	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-6.6	1.51e-10	2.56e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
STAD	cis	rs7580658	0.963	rs4233583	ENSG00000200250.1	RNU6-1147P	6.6	1.51e-10	2.56e-07	0.33	0.33	Protein C levels;	chr2:127302492	chr2:127316873~127316979:+
STAD	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	6.6	1.52e-10	2.56e-07	0.3	0.33	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
STAD	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-6.6	1.52e-10	2.57e-07	-0.35	-0.33	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
STAD	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-6.6	1.53e-10	2.58e-07	-0.34	-0.33	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
STAD	cis	rs6452524	0.905	rs10040244	ENSG00000243385.2	CTD-2110K23.1	6.6	1.53e-10	2.58e-07	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83201229~83202141:+
STAD	cis	rs875971	0.508	rs10258739	ENSG00000222364.1	RNU6-96P	6.6	1.53e-10	2.59e-07	0.37	0.33	Aortic root size;	chr7:66597948	chr7:66395191~66395286:+
STAD	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-6.6	1.54e-10	2.59e-07	-0.34	-0.33	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
STAD	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	6.6	1.54e-10	2.6e-07	0.34	0.33	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
STAD	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	6.6	1.54e-10	2.6e-07	0.39	0.33	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
STAD	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	6.6	1.54e-10	2.6e-07	0.42	0.33	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
STAD	cis	rs11089937	0.568	rs12159174	ENSG00000211639.2	IGLV4-60	6.6	1.54e-10	2.6e-07	0.36	0.33	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.568	rs11089919	ENSG00000211639.2	IGLV4-60	6.6	1.54e-10	2.6e-07	0.36	0.33	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22162199~22162681:+
STAD	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-6.6	1.54e-10	2.6e-07	-0.36	-0.33	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
STAD	cis	rs11089937	0.597	rs4145535	ENSG00000211639.2	IGLV4-60	6.6	1.54e-10	2.6e-07	0.36	0.33	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22162199~22162681:+
STAD	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-6.6	1.54e-10	2.61e-07	-0.38	-0.33	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-6.6	1.54e-10	2.61e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-6.6	1.54e-10	2.61e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
STAD	cis	rs1426063	0.614	rs17199779	ENSG00000248165.1	RP11-44F21.2	-6.6	1.54e-10	2.61e-07	-0.64	-0.33	QT interval;	chr4:75105647	chr4:74993877~75034824:-
STAD	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	6.6	1.54e-10	2.61e-07	0.39	0.33	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
STAD	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	6.6	1.55e-10	2.61e-07	0.35	0.33	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
STAD	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	6.6	1.55e-10	2.61e-07	0.34	0.33	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
STAD	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
STAD	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-6.6	1.55e-10	2.61e-07	-0.34	-0.33	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
STAD	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-6.6	1.55e-10	2.62e-07	-0.39	-0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
STAD	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	6.6	1.57e-10	2.64e-07	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
STAD	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	6.6	1.57e-10	2.64e-07	0.38	0.33	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
STAD	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	6.6	1.57e-10	2.64e-07	0.45	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
STAD	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-6.6	1.57e-10	2.64e-07	-0.35	-0.33	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
STAD	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	6.6	1.57e-10	2.64e-07	0.37	0.33	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
STAD	cis	rs875971	0.543	rs801191	ENSG00000222364.1	RNU6-96P	6.6	1.58e-10	2.66e-07	0.37	0.33	Aortic root size;	chr7:66567968	chr7:66395191~66395286:+
STAD	cis	rs875971	0.508	rs6947808	ENSG00000222364.1	RNU6-96P	6.6	1.58e-10	2.66e-07	0.37	0.33	Aortic root size;	chr7:66580095	chr7:66395191~66395286:+
STAD	cis	rs875971	0.508	rs10242423	ENSG00000222364.1	RNU6-96P	6.6	1.58e-10	2.66e-07	0.37	0.33	Aortic root size;	chr7:66594188	chr7:66395191~66395286:+
STAD	cis	rs875971	0.508	rs10253883	ENSG00000222364.1	RNU6-96P	6.6	1.58e-10	2.66e-07	0.37	0.33	Aortic root size;	chr7:66596151	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	6.6	1.58e-10	2.66e-07	0.35	0.33	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
STAD	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	6.6	1.58e-10	2.66e-07	0.36	0.33	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
STAD	cis	rs2283792	0.687	rs381849	ENSG00000228050.1	TOP3BP1	6.6	1.58e-10	2.66e-07	0.38	0.33	Multiple sclerosis;	chr22:21951341	chr22:22223187~22224566:-
STAD	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-6.6	1.58e-10	2.66e-07	-0.35	-0.33	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-6.6	1.58e-10	2.66e-07	-0.35	-0.33	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-6.6	1.58e-10	2.66e-07	-0.35	-0.33	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-6.6	1.58e-10	2.66e-07	-0.35	-0.33	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
STAD	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-6.6	1.58e-10	2.66e-07	-0.38	-0.33	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
STAD	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-6.6	1.58e-10	2.66e-07	-0.38	-0.33	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
STAD	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-6.6	1.59e-10	2.67e-07	-0.37	-0.33	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
STAD	cis	rs7487075	0.754	rs10880962	ENSG00000272369.1	RP11-446N19.1	6.6	1.59e-10	2.67e-07	0.39	0.33	Itch intensity from mosquito bite;	chr12:46379661	chr12:46537502~46652550:+
STAD	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-6.6	1.59e-10	2.67e-07	-0.32	-0.33	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
STAD	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-6.6	1.59e-10	2.67e-07	-0.34	-0.33	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
STAD	cis	rs13631	0.728	rs7848423	ENSG00000268996.3	MAN1B1-AS1	6.6	1.59e-10	2.68e-07	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr9:137093304	chr9:137084946~137086817:-
STAD	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-6.6	1.59e-10	2.68e-07	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	6.6	1.59e-10	2.68e-07	0.44	0.33	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	6.6	1.59e-10	2.68e-07	0.44	0.33	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	6.6	1.59e-10	2.68e-07	0.44	0.33	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
STAD	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-6.59	1.6e-10	2.69e-07	-0.54	-0.33	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
STAD	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-6.59	1.6e-10	2.69e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-6.59	1.6e-10	2.69e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
STAD	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	6.59	1.6e-10	2.7e-07	0.55	0.33	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
STAD	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-6.59	1.61e-10	2.7e-07	-0.35	-0.33	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
STAD	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-6.59	1.61e-10	2.7e-07	-0.37	-0.33	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
STAD	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-6.59	1.61e-10	2.7e-07	-0.37	-0.33	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
STAD	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-6.59	1.61e-10	2.7e-07	-0.37	-0.33	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
STAD	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-6.59	1.61e-10	2.7e-07	-0.58	-0.33	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
STAD	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	6.59	1.61e-10	2.7e-07	0.47	0.33	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
STAD	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-6.59	1.62e-10	2.71e-07	-0.34	-0.33	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-6.59	1.62e-10	2.71e-07	-0.34	-0.33	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-6.59	1.62e-10	2.71e-07	-0.34	-0.33	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
STAD	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-6.59	1.62e-10	2.71e-07	-0.34	-0.33	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-6.59	1.62e-10	2.71e-07	-0.34	-0.33	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-6.59	1.62e-10	2.71e-07	-0.34	-0.33	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
STAD	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	6.59	1.62e-10	2.72e-07	0.31	0.33	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
STAD	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-6.59	1.62e-10	2.73e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-6.59	1.62e-10	2.73e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-6.59	1.62e-10	2.73e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
STAD	cis	rs875971	0.577	rs35072105	ENSG00000222364.1	RNU6-96P	6.59	1.63e-10	2.73e-07	0.37	0.33	Aortic root size;	chr7:66144830	chr7:66395191~66395286:+
STAD	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-6.59	1.63e-10	2.73e-07	-0.32	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
STAD	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	6.59	1.63e-10	2.73e-07	0.31	0.33	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	6.59	1.63e-10	2.73e-07	0.31	0.33	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
STAD	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-6.59	1.63e-10	2.74e-07	-0.35	-0.33	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
STAD	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-6.59	1.63e-10	2.74e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
STAD	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-6.59	1.63e-10	2.74e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
STAD	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	6.59	1.64e-10	2.75e-07	0.31	0.33	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
STAD	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	6.59	1.64e-10	2.75e-07	0.43	0.33	Height;	chr6:109740895	chr6:109382795~109383666:+
STAD	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	6.59	1.64e-10	2.75e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
STAD	cis	rs801193	0.904	rs4718405	ENSG00000222364.1	RNU6-96P	-6.59	1.64e-10	2.76e-07	-0.38	-0.33	Aortic root size;	chr7:66789659	chr7:66395191~66395286:+
STAD	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-6.59	1.64e-10	2.76e-07	-0.47	-0.33	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
STAD	cis	rs2221894	0.959	rs6558089	ENSG00000273710.1	Metazoa_SRP	6.59	1.65e-10	2.76e-07	0.37	0.33	Obesity-related traits;	chr8:29036720	chr8:28915579~28915864:-
STAD	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-6.59	1.65e-10	2.76e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
STAD	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	6.59	1.65e-10	2.76e-07	0.34	0.33	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	6.59	1.65e-10	2.76e-07	0.34	0.33	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	6.59	1.65e-10	2.76e-07	0.34	0.33	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	6.59	1.65e-10	2.76e-07	0.34	0.33	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	6.59	1.65e-10	2.76e-07	0.34	0.33	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	6.59	1.65e-10	2.76e-07	0.34	0.33	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
STAD	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-6.59	1.65e-10	2.76e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-6.59	1.65e-10	2.76e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-6.59	1.65e-10	2.76e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-6.59	1.65e-10	2.76e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-6.59	1.65e-10	2.76e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	6.59	1.65e-10	2.77e-07	0.4	0.33	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
STAD	cis	rs2283792	0.812	rs240066	ENSG00000228050.1	TOP3BP1	-6.59	1.66e-10	2.78e-07	-0.4	-0.33	Multiple sclerosis;	chr22:21938623	chr22:22223187~22224566:-
STAD	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-6.59	1.66e-10	2.79e-07	-0.38	-0.33	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
STAD	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.8e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.8e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
STAD	cis	rs2658782	0.704	rs2605614	ENSG00000279684.1	RP11-755E23.2	-6.59	1.68e-10	2.81e-07	-0.48	-0.33	Pulmonary function decline;	chr11:93499579	chr11:93286629~93288903:-
STAD	cis	rs2658782	0.615	rs2605615	ENSG00000279684.1	RP11-755E23.2	-6.59	1.68e-10	2.81e-07	-0.48	-0.33	Pulmonary function decline;	chr11:93499902	chr11:93286629~93288903:-
STAD	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-6.59	1.68e-10	2.81e-07	-0.31	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
STAD	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-6.59	1.68e-10	2.82e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-6.59	1.68e-10	2.82e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
STAD	cis	rs6452524	1	rs10068099	ENSG00000243385.2	CTD-2110K23.1	6.58	1.69e-10	2.83e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83201229~83202141:+
STAD	cis	rs6456156	0.774	rs6931530	ENSG00000265828.1	MIR3939	6.58	1.69e-10	2.83e-07	0.37	0.33	Primary biliary cholangitis;	chr6:167113712	chr6:166997807~166997912:-
STAD	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	6.58	1.69e-10	2.83e-07	0.38	0.33	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
STAD	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	6.58	1.69e-10	2.83e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	6.58	1.69e-10	2.83e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	6.58	1.69e-10	2.83e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	6.58	1.69e-10	2.83e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-6.58	1.7e-10	2.83e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
STAD	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-6.58	1.7e-10	2.84e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
STAD	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-6.58	1.7e-10	2.84e-07	-0.42	-0.33	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-6.58	1.7e-10	2.84e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
STAD	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	6.58	1.7e-10	2.84e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
STAD	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	6.58	1.7e-10	2.84e-07	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
STAD	cis	rs801193	0.844	rs732465	ENSG00000222364.1	RNU6-96P	-6.58	1.7e-10	2.84e-07	-0.37	-0.33	Aortic root size;	chr7:66533463	chr7:66395191~66395286:+
STAD	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-6.58	1.7e-10	2.84e-07	-0.35	-0.33	Height;	chr3:52967831	chr3:53064283~53065091:-
STAD	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-6.58	1.71e-10	2.85e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
STAD	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-6.58	1.71e-10	2.85e-07	-0.32	-0.33	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-6.58	1.71e-10	2.85e-07	-0.32	-0.33	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
STAD	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	6.58	1.71e-10	2.85e-07	0.34	0.33	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
STAD	cis	rs7580658	0.963	rs9789510	ENSG00000200250.1	RNU6-1147P	6.58	1.71e-10	2.86e-07	0.32	0.33	Protein C levels;	chr2:127379436	chr2:127316873~127316979:+
STAD	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-6.58	1.71e-10	2.86e-07	-0.36	-0.33	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
STAD	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-6.58	1.72e-10	2.87e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
STAD	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	6.58	1.72e-10	2.87e-07	0.34	0.33	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
STAD	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	6.58	1.72e-10	2.87e-07	0.34	0.33	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
STAD	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-6.58	1.72e-10	2.87e-07	-0.35	-0.33	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
STAD	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-6.58	1.73e-10	2.88e-07	-0.47	-0.33	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
STAD	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-6.58	1.73e-10	2.89e-07	-0.32	-0.33	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
STAD	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-6.58	1.74e-10	2.9e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-6.58	1.74e-10	2.9e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-6.58	1.74e-10	2.9e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-6.58	1.74e-10	2.9e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
STAD	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	6.58	1.74e-10	2.9e-07	0.34	0.33	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
STAD	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	6.58	1.74e-10	2.9e-07	0.33	0.33	Myopia;	chr6:28302807	chr6:28176188~28176674:+
STAD	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	6.58	1.74e-10	2.9e-07	0.39	0.33	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	6.58	1.74e-10	2.9e-07	0.39	0.33	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	6.58	1.74e-10	2.9e-07	0.39	0.33	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
STAD	cis	rs7580658	0.929	rs13029237	ENSG00000200250.1	RNU6-1147P	6.58	1.74e-10	2.9e-07	0.33	0.33	Protein C levels;	chr2:127390278	chr2:127316873~127316979:+
STAD	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-6.58	1.74e-10	2.91e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
STAD	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-6.58	1.75e-10	2.92e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-6.58	1.75e-10	2.92e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	6.58	1.76e-10	2.94e-07	0.24	0.33	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	6.58	1.76e-10	2.94e-07	0.24	0.33	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
STAD	cis	rs611744	0.819	rs424012	ENSG00000253754.1	RP11-35G22.1	-6.58	1.76e-10	2.94e-07	-0.29	-0.33	Dupuytren's disease;	chr8:108142424	chr8:108226200~108227544:+
STAD	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	6.58	1.77e-10	2.94e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
STAD	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-6.58	1.77e-10	2.94e-07	-0.34	-0.33	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
STAD	cis	rs11098499	1	rs1011054	ENSG00000248280.1	RP11-33B1.2	-6.58	1.77e-10	2.95e-07	-0.41	-0.33	Corneal astigmatism;	chr4:119281232	chr4:119440561~119450157:-
STAD	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	6.58	1.77e-10	2.95e-07	0.31	0.33	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
STAD	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-6.58	1.77e-10	2.95e-07	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
STAD	cis	rs2221894	0.96	rs1487970	ENSG00000273710.1	Metazoa_SRP	6.58	1.78e-10	2.96e-07	0.37	0.33	Obesity-related traits;	chr8:29031649	chr8:28915579~28915864:-
STAD	cis	rs7927771	0.826	rs2293578	ENSG00000280615.1	Y_RNA	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Subjective well-being;	chr11:47415852	chr11:47614898~47614994:-
STAD	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-6.58	1.78e-10	2.96e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.901	rs4571449	ENSG00000243385.2	CTD-2110K23.1	6.58	1.78e-10	2.96e-07	0.4	0.33	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83201229~83202141:+
STAD	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-6.58	1.78e-10	2.96e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-6.58	1.78e-10	2.96e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-6.58	1.78e-10	2.96e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-6.58	1.78e-10	2.96e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
STAD	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-6.58	1.78e-10	2.96e-07	-0.39	-0.33	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
STAD	cis	rs6452524	1	rs9293334	ENSG00000243385.2	CTD-2110K23.1	6.58	1.78e-10	2.97e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83201229~83202141:+
STAD	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-6.58	1.79e-10	2.97e-07	-0.37	-0.33	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
STAD	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	6.58	1.79e-10	2.97e-07	0.45	0.33	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
STAD	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	6.58	1.79e-10	2.97e-07	0.39	0.33	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-6.58	1.79e-10	2.98e-07	-0.4	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
STAD	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	6.58	1.79e-10	2.98e-07	0.38	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
STAD	cis	rs875971	0.54	rs35510581	ENSG00000222364.1	RNU6-96P	6.58	1.79e-10	2.98e-07	0.37	0.33	Aortic root size;	chr7:66113790	chr7:66395191~66395286:+
STAD	cis	rs2833693	0.524	rs8129993	ENSG00000261610.1	AP000265.1	6.57	1.8e-10	2.99e-07	0.38	0.33	Temperament;	chr21:32268841	chr21:32259804~32261585:-
STAD	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-6.57	1.8e-10	2.99e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
STAD	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-6.57	1.8e-10	2.99e-07	-0.41	-0.33	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
STAD	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-6.57	1.8e-10	2.99e-07	-0.38	-0.33	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-6.57	1.8e-10	2.99e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-6.57	1.8e-10	2.99e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-6.57	1.8e-10	2.99e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-6.57	1.8e-10	2.99e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
STAD	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	6.57	1.8e-10	2.99e-07	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
STAD	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	6.57	1.8e-10	2.99e-07	0.31	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
STAD	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	6.57	1.8e-10	2.99e-07	0.4	0.33	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
STAD	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	6.57	1.8e-10	2.99e-07	0.4	0.33	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
STAD	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-6.57	1.8e-10	3e-07	-0.37	-0.33	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
STAD	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-6.57	1.81e-10	3e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
STAD	cis	rs7580658	0.963	rs62157555	ENSG00000200250.1	RNU6-1147P	6.57	1.81e-10	3e-07	0.32	0.33	Protein C levels;	chr2:127349600	chr2:127316873~127316979:+
STAD	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-6.57	1.81e-10	3e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-6.57	1.81e-10	3e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-6.57	1.81e-10	3e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-6.57	1.81e-10	3e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-6.57	1.81e-10	3e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-6.57	1.81e-10	3e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
STAD	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-6.57	1.81e-10	3e-07	-0.45	-0.33	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-6.57	1.81e-10	3e-07	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
STAD	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	6.57	1.81e-10	3e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	6.57	1.81e-10	3e-07	0.39	0.33	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	6.57	1.81e-10	3e-07	0.39	0.33	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	6.57	1.81e-10	3e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	6.57	1.81e-10	3e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	6.57	1.81e-10	3e-07	0.39	0.33	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
STAD	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-6.57	1.81e-10	3.01e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-6.57	1.81e-10	3.01e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
STAD	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-6.57	1.81e-10	3.01e-07	-0.39	-0.33	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
STAD	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	6.57	1.82e-10	3.01e-07	0.43	0.33	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
STAD	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-6.57	1.82e-10	3.02e-07	-0.32	-0.33	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	6.57	1.82e-10	3.02e-07	0.24	0.33	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	6.57	1.82e-10	3.02e-07	0.41	0.33	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
STAD	cis	rs210138	0.832	rs375555	ENSG00000197251.3	LINC00336	6.57	1.83e-10	3.03e-07	0.45	0.33	Testicular germ cell tumor;	chr6:33589964	chr6:33586106~33593338:-
STAD	cis	rs6452524	1	rs2126990	ENSG00000243385.2	CTD-2110K23.1	6.57	1.83e-10	3.03e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83201229~83202141:+
STAD	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	6.57	1.83e-10	3.04e-07	0.54	0.33	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
STAD	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	6.57	1.84e-10	3.04e-07	0.38	0.33	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
STAD	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-6.57	1.84e-10	3.05e-07	-0.33	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
STAD	cis	rs1862618	0.853	rs1559282	ENSG00000271828.1	CTD-2310F14.1	6.57	1.84e-10	3.05e-07	0.43	0.33	Initial pursuit acceleration;	chr5:56803548	chr5:56927874~56929573:+
STAD	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	6.57	1.84e-10	3.05e-07	0.39	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
STAD	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	6.57	1.85e-10	3.06e-07	0.39	0.33	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	6.57	1.85e-10	3.06e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
STAD	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-6.57	1.85e-10	3.06e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	6.57	1.85e-10	3.06e-07	0.36	0.33	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
STAD	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	6.57	1.86e-10	3.07e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
STAD	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-6.57	1.86e-10	3.07e-07	-0.47	-0.33	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
STAD	cis	rs858239	0.863	rs274054	ENSG00000226816.2	AC005082.12	6.57	1.86e-10	3.07e-07	0.4	0.33	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23206013~23208045:+
STAD	cis	rs6452524	1	rs6452528	ENSG00000243385.2	CTD-2110K23.1	6.57	1.86e-10	3.08e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83201229~83202141:+
STAD	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-6.57	1.86e-10	3.08e-07	-0.3	-0.33	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
STAD	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	6.57	1.86e-10	3.08e-07	0.45	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
STAD	cis	rs6452524	0.967	rs10042018	ENSG00000243385.2	CTD-2110K23.1	6.57	1.86e-10	3.08e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs10036418	ENSG00000243385.2	CTD-2110K23.1	6.57	1.86e-10	3.08e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83201229~83202141:+
STAD	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-6.57	1.86e-10	3.08e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-6.57	1.86e-10	3.08e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-6.57	1.86e-10	3.08e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-6.57	1.86e-10	3.08e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
STAD	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	6.57	1.87e-10	3.08e-07	0.45	0.33	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	6.57	1.87e-10	3.08e-07	0.45	0.33	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
STAD	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-6.57	1.87e-10	3.09e-07	-0.53	-0.33	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
STAD	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	6.57	1.87e-10	3.1e-07	0.31	0.33	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
STAD	cis	rs7580658	0.963	rs6732279	ENSG00000200250.1	RNU6-1147P	6.57	1.87e-10	3.1e-07	0.32	0.33	Protein C levels;	chr2:127331964	chr2:127316873~127316979:+
STAD	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-6.57	1.88e-10	3.1e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
STAD	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	6.57	1.88e-10	3.11e-07	0.31	0.33	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	6.57	1.88e-10	3.11e-07	0.31	0.33	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	6.57	1.88e-10	3.11e-07	0.31	0.33	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	6.57	1.88e-10	3.11e-07	0.31	0.33	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
STAD	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-6.57	1.88e-10	3.11e-07	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-6.57	1.88e-10	3.11e-07	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
STAD	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-6.57	1.88e-10	3.11e-07	-0.44	-0.33	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
STAD	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
STAD	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-6.57	1.89e-10	3.11e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
STAD	cis	rs7617773	0.962	rs6797587	ENSG00000229759.1	MRPS18AP1	-6.57	1.89e-10	3.12e-07	-0.37	-0.33	Coronary artery disease;	chr3:48156124	chr3:48256350~48256938:-
STAD	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-6.57	1.89e-10	3.12e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
STAD	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	6.57	1.89e-10	3.12e-07	0.34	0.33	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	6.57	1.89e-10	3.12e-07	0.34	0.33	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	6.57	1.89e-10	3.12e-07	0.34	0.33	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	6.57	1.89e-10	3.12e-07	0.34	0.33	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	6.57	1.89e-10	3.12e-07	0.34	0.33	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	6.57	1.89e-10	3.12e-07	0.34	0.33	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
STAD	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	6.57	1.89e-10	3.12e-07	0.31	0.33	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	6.57	1.89e-10	3.12e-07	0.31	0.33	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
STAD	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-6.57	1.89e-10	3.12e-07	-0.37	-0.33	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
STAD	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-6.57	1.9e-10	3.13e-07	-0.38	-0.33	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.867	rs11856184	ENSG00000249839.1	AC011330.5	-6.57	1.9e-10	3.13e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43626964	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.867	rs2927072	ENSG00000249839.1	AC011330.5	-6.57	1.9e-10	3.13e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43630200	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.867	rs2920781	ENSG00000249839.1	AC011330.5	-6.57	1.9e-10	3.13e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43632484	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.764	rs2447193	ENSG00000249839.1	AC011330.5	-6.57	1.9e-10	3.13e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43637535	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.867	rs2447211	ENSG00000249839.1	AC011330.5	-6.57	1.9e-10	3.13e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43644153	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.571	rs2470121	ENSG00000249839.1	AC011330.5	-6.57	1.9e-10	3.13e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43645420	chr15:43663654~43684339:-
STAD	cis	rs11089937	0.626	rs9619800	ENSG00000211639.2	IGLV4-60	6.57	1.9e-10	3.13e-07	0.36	0.33	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22162199~22162681:+
STAD	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-6.57	1.9e-10	3.13e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
STAD	cis	rs2221894	0.96	rs7837112	ENSG00000273710.1	Metazoa_SRP	-6.57	1.9e-10	3.13e-07	-0.38	-0.33	Obesity-related traits;	chr8:28907976	chr8:28915579~28915864:-
STAD	cis	rs12550612	0.567	rs7834950	ENSG00000253616.4	RP11-875O11.3	6.57	1.91e-10	3.14e-07	0.52	0.33	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084305	chr8:23071377~23074488:-
STAD	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-6.56	1.91e-10	3.14e-07	-0.56	-0.33	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
STAD	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-6.56	1.91e-10	3.14e-07	-0.38	-0.33	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
STAD	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-6.56	1.92e-10	3.15e-07	-0.34	-0.33	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
STAD	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	6.56	1.92e-10	3.16e-07	0.4	0.33	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	6.56	1.92e-10	3.16e-07	0.4	0.33	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
STAD	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-6.56	1.92e-10	3.16e-07	-0.47	-0.33	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
STAD	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-6.56	1.92e-10	3.16e-07	-0.39	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
STAD	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-6.56	1.92e-10	3.17e-07	-0.59	-0.33	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
STAD	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-6.56	1.93e-10	3.17e-07	-0.59	-0.33	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
STAD	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-6.56	1.93e-10	3.17e-07	-0.59	-0.33	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
STAD	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-6.56	1.93e-10	3.17e-07	-0.59	-0.33	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
STAD	cis	rs875971	0.508	rs10950045	ENSG00000222364.1	RNU6-96P	6.56	1.93e-10	3.17e-07	0.36	0.33	Aortic root size;	chr7:66601386	chr7:66395191~66395286:+
STAD	cis	rs801193	0.839	rs6968619	ENSG00000222364.1	RNU6-96P	6.56	1.93e-10	3.17e-07	0.36	0.33	Aortic root size;	chr7:66603880	chr7:66395191~66395286:+
STAD	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	6.56	1.93e-10	3.17e-07	0.46	0.33	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	6.56	1.93e-10	3.17e-07	0.46	0.33	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	6.56	1.93e-10	3.17e-07	0.46	0.33	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	6.56	1.93e-10	3.17e-07	0.46	0.33	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	6.56	1.93e-10	3.17e-07	0.46	0.33	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	6.56	1.93e-10	3.17e-07	0.46	0.33	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	6.56	1.93e-10	3.17e-07	0.46	0.33	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
STAD	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	6.56	1.93e-10	3.18e-07	0.34	0.33	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
STAD	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	6.56	1.93e-10	3.18e-07	0.31	0.33	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
STAD	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-6.56	1.94e-10	3.19e-07	-0.37	-0.33	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
STAD	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	6.56	1.95e-10	3.2e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
STAD	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	6.56	1.95e-10	3.2e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
STAD	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	6.56	1.96e-10	3.21e-07	0.35	0.33	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
STAD	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-6.56	1.96e-10	3.22e-07	-0.42	-0.33	Height;	chr6:109636120	chr6:109382795~109383666:+
STAD	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
STAD	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	6.56	1.96e-10	3.22e-07	0.34	0.33	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-6.56	1.96e-10	3.23e-07	-0.34	-0.33	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-6.56	1.96e-10	3.23e-07	-0.34	-0.33	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
STAD	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	6.56	1.97e-10	3.23e-07	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
STAD	cis	rs6452524	0.967	rs62374400	ENSG00000243385.2	CTD-2110K23.1	6.56	1.97e-10	3.23e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs10040363	ENSG00000243385.2	CTD-2110K23.1	6.56	1.97e-10	3.23e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83201229~83202141:+
STAD	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-6.56	1.97e-10	3.23e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-6.56	1.97e-10	3.23e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
STAD	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	6.56	1.97e-10	3.23e-07	0.38	0.33	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
STAD	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-6.56	1.97e-10	3.24e-07	-0.34	-0.33	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
STAD	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-6.56	1.97e-10	3.24e-07	-0.37	-0.33	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-6.56	1.97e-10	3.24e-07	-0.37	-0.33	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
STAD	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	6.56	1.97e-10	3.24e-07	0.4	0.33	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	6.56	1.97e-10	3.24e-07	0.4	0.33	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
STAD	cis	rs6452524	1	rs6868817	ENSG00000243385.2	CTD-2110K23.1	6.56	1.98e-10	3.24e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83201229~83202141:+
STAD	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-6.56	1.98e-10	3.25e-07	-0.39	-0.33	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
STAD	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-6.56	1.99e-10	3.25e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
STAD	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-6.56	1.99e-10	3.25e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
STAD	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-6.56	1.99e-10	3.25e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
STAD	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	6.56	1.99e-10	3.26e-07	0.34	0.33	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
STAD	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	6.56	1.99e-10	3.26e-07	0.31	0.33	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
STAD	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-6.56	1.99e-10	3.26e-07	-0.37	-0.33	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
STAD	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-6.56	1.99e-10	3.26e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
STAD	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-6.56	2e-10	3.27e-07	-0.39	-0.33	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
STAD	cis	rs7615952	0.512	rs34085484	ENSG00000272840.1	RP11-379B18.6	6.56	2e-10	3.27e-07	0.48	0.33	Blood pressure (smoking interaction);	chr3:125825343	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.608	rs35668111	ENSG00000272840.1	RP11-379B18.6	6.56	2e-10	3.27e-07	0.48	0.33	Blood pressure (smoking interaction);	chr3:125825792	chr3:125774714~125797953:+
STAD	cis	rs6452524	1	rs1382368	ENSG00000243385.2	CTD-2110K23.1	6.56	2e-10	3.27e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs1382366	ENSG00000243385.2	CTD-2110K23.1	6.56	2e-10	3.27e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs1382364	ENSG00000243385.2	CTD-2110K23.1	6.56	2e-10	3.27e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs1382363	ENSG00000243385.2	CTD-2110K23.1	6.56	2e-10	3.27e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs11741897	ENSG00000243385.2	CTD-2110K23.1	6.56	2e-10	3.27e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs13358361	ENSG00000243385.2	CTD-2110K23.1	6.56	2e-10	3.27e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs10076000	ENSG00000243385.2	CTD-2110K23.1	6.56	2e-10	3.27e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83201229~83202141:+
STAD	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	6.56	2e-10	3.28e-07	0.38	0.33	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
STAD	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	6.56	2.01e-10	3.28e-07	0.4	0.33	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
STAD	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-6.56	2.01e-10	3.3e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
STAD	cis	rs1005277	0.579	rs1780130	ENSG00000099251.13	HSD17B7P2	6.56	2.02e-10	3.3e-07	0.37	0.33	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38356380~38378505:+
STAD	cis	rs6452524	1	rs7710900	ENSG00000243385.2	CTD-2110K23.1	6.56	2.02e-10	3.3e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83201229~83202141:+
STAD	cis	rs7487075	0.79	rs4074773	ENSG00000257261.4	RP11-96H19.1	-6.56	2.02e-10	3.31e-07	-0.38	-0.33	Itch intensity from mosquito bite;	chr12:46525398	chr12:46383679~46876159:+
STAD	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-6.55	2.02e-10	3.31e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
STAD	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	6.55	2.02e-10	3.31e-07	0.47	0.33	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
STAD	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-6.55	2.03e-10	3.32e-07	-0.31	-0.33	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
STAD	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-6.55	2.03e-10	3.32e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
STAD	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-6.55	2.04e-10	3.33e-07	-0.47	-0.33	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
STAD	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	6.55	2.05e-10	3.35e-07	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
STAD	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-6.55	2.06e-10	3.36e-07	-0.39	-0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
STAD	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	6.55	2.06e-10	3.36e-07	0.24	0.33	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
STAD	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	6.55	2.06e-10	3.37e-07	0.37	0.33	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
STAD	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	6.55	2.06e-10	3.37e-07	0.34	0.33	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
STAD	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	6.55	2.06e-10	3.37e-07	0.42	0.33	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
STAD	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	6.55	2.07e-10	3.38e-07	0.4	0.33	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
STAD	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	6.55	2.07e-10	3.38e-07	0.34	0.33	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	6.55	2.07e-10	3.38e-07	0.34	0.33	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	6.55	2.07e-10	3.38e-07	0.34	0.33	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	6.55	2.07e-10	3.38e-07	0.34	0.33	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
STAD	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	6.55	2.07e-10	3.38e-07	0.4	0.33	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
STAD	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-6.55	2.07e-10	3.38e-07	-0.46	-0.33	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
STAD	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-6.55	2.07e-10	3.38e-07	-0.46	-0.33	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
STAD	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-6.55	2.07e-10	3.39e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
STAD	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	6.55	2.07e-10	3.39e-07	0.43	0.33	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
STAD	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-6.55	2.08e-10	3.39e-07	-0.53	-0.33	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
STAD	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-6.55	2.08e-10	3.4e-07	-0.35	-0.33	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.879	rs7160512	ENSG00000280411.1	IGHV1-69-2	-6.55	2.08e-10	3.4e-07	-0.3	-0.33	Kawasaki disease;	chr14:106694574	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.879	rs7159157	ENSG00000280411.1	IGHV1-69-2	-6.55	2.08e-10	3.4e-07	-0.3	-0.33	Kawasaki disease;	chr14:106694578	chr14:106762092~106762588:-
STAD	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	6.55	2.09e-10	3.4e-07	0.47	0.33	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
STAD	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-6.55	2.09e-10	3.41e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-6.55	2.09e-10	3.41e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-6.55	2.09e-10	3.41e-07	-0.44	-0.33	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
STAD	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	6.55	2.09e-10	3.42e-07	0.35	0.33	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
STAD	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-6.55	2.09e-10	3.42e-07	-0.37	-0.33	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
STAD	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-6.55	2.09e-10	3.42e-07	-0.43	-0.33	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
STAD	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	6.55	2.1e-10	3.42e-07	0.4	0.33	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
STAD	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	6.55	2.1e-10	3.42e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
STAD	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	6.55	2.1e-10	3.43e-07	0.34	0.33	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
STAD	cis	rs6452524	0.967	rs10051542	ENSG00000243385.2	CTD-2110K23.1	6.55	2.1e-10	3.43e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs10051557	ENSG00000243385.2	CTD-2110K23.1	6.55	2.1e-10	3.43e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83201229~83202141:+
STAD	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-6.55	2.1e-10	3.43e-07	-0.38	-0.33	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-6.55	2.11e-10	3.43e-07	-0.56	-0.33	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	6.55	2.12e-10	3.45e-07	0.28	0.33	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
STAD	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-6.55	2.12e-10	3.46e-07	-0.53	-0.33	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
STAD	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	6.55	2.13e-10	3.47e-07	0.34	0.33	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
STAD	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	6.55	2.13e-10	3.47e-07	0.3	0.33	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
STAD	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	6.55	2.13e-10	3.48e-07	0.45	0.33	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
STAD	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-6.55	2.13e-10	3.48e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
STAD	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	6.55	2.14e-10	3.48e-07	0.31	0.33	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	6.55	2.14e-10	3.48e-07	0.31	0.33	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
STAD	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	6.55	2.14e-10	3.48e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
STAD	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-6.55	2.14e-10	3.49e-07	-0.32	-0.33	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
STAD	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-6.55	2.14e-10	3.49e-07	-0.34	-0.33	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
STAD	cis	rs801193	0.839	rs12534943	ENSG00000222364.1	RNU6-96P	6.55	2.14e-10	3.49e-07	0.36	0.33	Aortic root size;	chr7:66605533	chr7:66395191~66395286:+
STAD	cis	rs801193	0.805	rs12532355	ENSG00000222364.1	RNU6-96P	6.55	2.14e-10	3.49e-07	0.36	0.33	Aortic root size;	chr7:66605597	chr7:66395191~66395286:+
STAD	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-6.55	2.14e-10	3.49e-07	-0.38	-0.33	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-6.55	2.14e-10	3.49e-07	-0.38	-0.33	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-6.54	2.15e-10	3.5e-07	-0.38	-0.33	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-6.54	2.15e-10	3.5e-07	-0.38	-0.33	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
STAD	cis	rs6452524	1	rs10474094	ENSG00000243385.2	CTD-2110K23.1	6.54	2.16e-10	3.51e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83201229~83202141:+
STAD	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-6.54	2.16e-10	3.51e-07	-0.5	-0.33	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
STAD	cis	rs9549260	0.785	rs6563842	ENSG00000229456.1	RLIMP1	6.54	2.17e-10	3.52e-07	0.3	0.33	Red blood cell count;	chr13:40670160	chr13:40618738~40621348:+
STAD	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-6.54	2.17e-10	3.53e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.935	rs1382376	ENSG00000243385.2	CTD-2110K23.1	6.54	2.17e-10	3.54e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs12109517	ENSG00000243385.2	CTD-2110K23.1	6.54	2.17e-10	3.54e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs12109514	ENSG00000243385.2	CTD-2110K23.1	6.54	2.17e-10	3.54e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.901	rs17284211	ENSG00000243385.2	CTD-2110K23.1	6.54	2.17e-10	3.54e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs1382374	ENSG00000243385.2	CTD-2110K23.1	6.54	2.17e-10	3.54e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83201229~83202141:+
STAD	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	6.54	2.17e-10	3.54e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
STAD	cis	rs7580658	0.963	rs12479003	ENSG00000200250.1	RNU6-1147P	6.54	2.18e-10	3.54e-07	0.32	0.33	Protein C levels;	chr2:127360977	chr2:127316873~127316979:+
STAD	cis	rs6456156	0.526	rs1854853	ENSG00000265828.1	MIR3939	6.54	2.18e-10	3.55e-07	0.35	0.33	Primary biliary cholangitis;	chr6:167119574	chr6:166997807~166997912:-
STAD	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-6.54	2.18e-10	3.55e-07	-0.47	-0.33	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
STAD	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-6.54	2.19e-10	3.56e-07	-0.28	-0.33	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
STAD	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	6.54	2.19e-10	3.56e-07	0.43	0.33	Height;	chr6:109694672	chr6:109382795~109383666:+
STAD	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-6.54	2.19e-10	3.56e-07	-0.39	-0.33	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-6.54	2.19e-10	3.56e-07	-0.39	-0.33	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
STAD	cis	rs9549260	0.755	rs59308928	ENSG00000229456.1	RLIMP1	6.54	2.2e-10	3.57e-07	0.3	0.33	Red blood cell count;	chr13:40670942	chr13:40618738~40621348:+
STAD	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	6.54	2.2e-10	3.57e-07	0.4	0.33	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
STAD	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-6.54	2.2e-10	3.57e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
STAD	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-6.54	2.2e-10	3.58e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-6.54	2.2e-10	3.58e-07	-0.46	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	6.54	2.21e-10	3.59e-07	0.41	0.33	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
STAD	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-6.54	2.21e-10	3.59e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
STAD	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-6.54	2.21e-10	3.59e-07	-0.48	-0.33	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
STAD	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	6.54	2.21e-10	3.59e-07	0.31	0.33	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
STAD	cis	rs6452524	1	rs1382369	ENSG00000243385.2	CTD-2110K23.1	6.54	2.22e-10	3.6e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83201229~83202141:+
STAD	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	6.54	2.22e-10	3.61e-07	0.39	0.33	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
STAD	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	6.54	2.23e-10	3.61e-07	0.43	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
STAD	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-6.54	2.23e-10	3.62e-07	-0.34	-0.33	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
STAD	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-6.54	2.23e-10	3.62e-07	-0.38	-0.33	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
STAD	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	6.54	2.23e-10	3.63e-07	0.45	0.33	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	6.54	2.23e-10	3.63e-07	0.45	0.33	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	6.54	2.23e-10	3.63e-07	0.45	0.33	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	6.54	2.23e-10	3.63e-07	0.45	0.33	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	6.54	2.23e-10	3.63e-07	0.45	0.33	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
STAD	cis	rs1426063	0.61	rs72862239	ENSG00000248165.1	RP11-44F21.2	6.54	2.24e-10	3.64e-07	0.7	0.33	QT interval;	chr4:75071967	chr4:74993877~75034824:-
STAD	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-6.54	2.24e-10	3.64e-07	-0.34	-0.33	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-6.54	2.24e-10	3.64e-07	-0.34	-0.33	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-6.54	2.24e-10	3.64e-07	-0.34	-0.33	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-6.54	2.24e-10	3.64e-07	-0.34	-0.33	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
STAD	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	6.54	2.24e-10	3.64e-07	0.45	0.33	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
STAD	cis	rs6452524	1	rs9293332	ENSG00000243385.2	CTD-2110K23.1	6.54	2.25e-10	3.64e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83201229~83202141:+
STAD	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-6.54	2.25e-10	3.65e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-6.54	2.25e-10	3.65e-07	-0.36	-0.33	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
STAD	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-6.54	2.25e-10	3.65e-07	-0.27	-0.33	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
STAD	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-6.54	2.25e-10	3.65e-07	-0.47	-0.33	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
STAD	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	6.54	2.26e-10	3.66e-07	0.34	0.33	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
STAD	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-6.54	2.26e-10	3.66e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
STAD	cis	rs6452524	1	rs67683443	ENSG00000243385.2	CTD-2110K23.1	6.54	2.26e-10	3.66e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83201229~83202141:+
STAD	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-6.54	2.26e-10	3.66e-07	-0.31	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-6.54	2.26e-10	3.66e-07	-0.31	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-6.54	2.26e-10	3.66e-07	-0.31	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
STAD	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	6.54	2.26e-10	3.67e-07	0.46	0.33	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
STAD	cis	rs1426063	0.614	rs115279737	ENSG00000248165.1	RP11-44F21.2	6.54	2.26e-10	3.67e-07	0.7	0.33	QT interval;	chr4:75107557	chr4:74993877~75034824:-
STAD	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	6.54	2.27e-10	3.68e-07	0.34	0.33	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
STAD	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	6.54	2.27e-10	3.68e-07	0.39	0.33	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
STAD	cis	rs6452524	0.935	rs5000997	ENSG00000243385.2	CTD-2110K23.1	6.53	2.29e-10	3.7e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs6887915	ENSG00000243385.2	CTD-2110K23.1	6.53	2.29e-10	3.7e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83201229~83202141:+
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	6.53	2.29e-10	3.71e-07	0.37	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
STAD	cis	rs6452524	0.901	rs1600362	ENSG00000243385.2	CTD-2110K23.1	6.53	2.29e-10	3.71e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs1580310	ENSG00000243385.2	CTD-2110K23.1	6.53	2.29e-10	3.71e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83201229~83202141:+
STAD	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-6.53	2.3e-10	3.71e-07	-0.39	-0.33	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-6.53	2.3e-10	3.71e-07	-0.39	-0.33	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
STAD	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-6.53	2.3e-10	3.71e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
STAD	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-6.53	2.3e-10	3.71e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
STAD	cis	rs2221894	1	rs2292478	ENSG00000273710.1	Metazoa_SRP	-6.53	2.3e-10	3.71e-07	-0.37	-0.33	Obesity-related traits;	chr8:28949839	chr8:28915579~28915864:-
STAD	cis	rs2221894	1	rs13280242	ENSG00000273710.1	Metazoa_SRP	-6.53	2.3e-10	3.71e-07	-0.38	-0.33	Obesity-related traits;	chr8:28899221	chr8:28915579~28915864:-
STAD	cis	rs2221894	1	rs6558084	ENSG00000273710.1	Metazoa_SRP	-6.53	2.3e-10	3.71e-07	-0.38	-0.33	Obesity-related traits;	chr8:28900115	chr8:28915579~28915864:-
STAD	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	6.53	2.3e-10	3.71e-07	0.24	0.33	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
STAD	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-6.53	2.3e-10	3.72e-07	-0.49	-0.33	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
STAD	cis	rs6452524	0.967	rs4290995	ENSG00000243385.2	CTD-2110K23.1	6.53	2.3e-10	3.72e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83201229~83202141:+
STAD	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-6.53	2.31e-10	3.73e-07	-0.34	-0.33	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
STAD	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-6.53	2.31e-10	3.73e-07	-0.38	-0.33	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
STAD	cis	rs7615952	0.688	rs9754526	ENSG00000272840.1	RP11-379B18.6	6.53	2.32e-10	3.74e-07	0.48	0.33	Blood pressure (smoking interaction);	chr3:125824023	chr3:125774714~125797953:+
STAD	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-6.53	2.32e-10	3.75e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	6.53	2.32e-10	3.75e-07	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
STAD	cis	rs6456156	0.811	rs975822	ENSG00000265828.1	MIR3939	6.53	2.33e-10	3.76e-07	0.36	0.33	Primary biliary cholangitis;	chr6:167102970	chr6:166997807~166997912:-
STAD	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-6.53	2.33e-10	3.76e-07	-0.37	-0.33	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
STAD	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-6.53	2.33e-10	3.76e-07	-0.37	-0.33	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
STAD	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-6.53	2.33e-10	3.76e-07	-0.37	-0.33	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
STAD	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-6.53	2.33e-10	3.76e-07	-0.31	-0.33	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
STAD	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-6.53	2.34e-10	3.77e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
STAD	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	6.53	2.34e-10	3.77e-07	0.34	0.33	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
STAD	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-6.53	2.35e-10	3.79e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-6.53	2.35e-10	3.79e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
STAD	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	6.53	2.35e-10	3.79e-07	0.32	0.33	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
STAD	cis	rs2283792	0.718	rs239918	ENSG00000228050.1	TOP3BP1	6.53	2.36e-10	3.8e-07	0.37	0.33	Multiple sclerosis;	chr22:21959457	chr22:22223187~22224566:-
STAD	cis	rs6452524	0.967	rs62372752	ENSG00000243385.2	CTD-2110K23.1	6.53	2.36e-10	3.8e-07	0.37	0.33	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83201229~83202141:+
STAD	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	6.53	2.36e-10	3.8e-07	0.34	0.33	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
STAD	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-6.53	2.37e-10	3.81e-07	-0.38	-0.33	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
STAD	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-6.53	2.37e-10	3.81e-07	-0.41	-0.33	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
STAD	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	6.53	2.37e-10	3.82e-07	0.41	0.33	Height;	chr6:109497088	chr6:109382795~109383666:+
STAD	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	6.53	2.37e-10	3.82e-07	0.38	0.33	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
STAD	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	6.53	2.38e-10	3.84e-07	0.38	0.33	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
STAD	cis	rs6452524	0.967	rs965674	ENSG00000243385.2	CTD-2110K23.1	6.53	2.39e-10	3.84e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2662242	ENSG00000243385.2	CTD-2110K23.1	6.53	2.39e-10	3.84e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs2731844	ENSG00000243385.2	CTD-2110K23.1	6.53	2.39e-10	3.84e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.901	rs2940540	ENSG00000243385.2	CTD-2110K23.1	6.53	2.39e-10	3.84e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83201229~83202141:+
STAD	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-6.53	2.4e-10	3.86e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-6.53	2.4e-10	3.86e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-6.53	2.4e-10	3.86e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
STAD	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	6.53	2.41e-10	3.87e-07	0.41	0.33	Height;	chr6:109500687	chr6:109382795~109383666:+
STAD	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	6.53	2.41e-10	3.87e-07	0.37	0.33	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	6.53	2.41e-10	3.87e-07	0.37	0.33	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
STAD	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	6.53	2.41e-10	3.87e-07	0.41	0.33	Height;	chr6:109498751	chr6:109382795~109383666:+
STAD	cis	rs6452524	0.935	rs72767160	ENSG00000243385.2	CTD-2110K23.1	6.53	2.41e-10	3.88e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83201229~83202141:+
STAD	cis	rs9326248	0.53	rs2471884	ENSG00000280143.1	AP000892.6	6.53	2.41e-10	3.88e-07	0.34	0.33	Blood protein levels;	chr11:117139604	chr11:117204967~117210292:+
STAD	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-6.52	2.42e-10	3.89e-07	-0.52	-0.33	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
STAD	cis	rs453301	0.624	rs330049	ENSG00000254340.1	RP11-10A14.3	6.52	2.42e-10	3.89e-07	0.39	0.33	Joint mobility (Beighton score);	chr8:9229789	chr8:9141424~9145435:+
STAD	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	6.52	2.42e-10	3.89e-07	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	6.52	2.42e-10	3.89e-07	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
STAD	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	6.52	2.42e-10	3.9e-07	0.45	0.33	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
STAD	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	6.52	2.42e-10	3.9e-07	0.38	0.33	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
STAD	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	6.52	2.43e-10	3.9e-07	0.42	0.33	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
STAD	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	6.52	2.43e-10	3.91e-07	0.38	0.33	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
STAD	cis	rs11089937	0.667	rs78549985	ENSG00000211639.2	IGLV4-60	6.52	2.44e-10	3.91e-07	0.36	0.33	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22162199~22162681:+
STAD	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	6.52	2.44e-10	3.93e-07	0.38	0.33	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
STAD	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	6.52	2.45e-10	3.93e-07	0.31	0.33	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
STAD	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	6.52	2.45e-10	3.94e-07	0.46	0.33	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
STAD	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-6.52	2.46e-10	3.95e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-6.52	2.46e-10	3.95e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
STAD	cis	rs2221894	1	rs2221894	ENSG00000273710.1	Metazoa_SRP	-6.52	2.46e-10	3.95e-07	-0.37	-0.33	Obesity-related traits;	chr8:28933642	chr8:28915579~28915864:-
STAD	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	6.52	2.46e-10	3.95e-07	0.39	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
STAD	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-6.52	2.46e-10	3.95e-07	-0.34	-0.33	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
STAD	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-6.52	2.46e-10	3.95e-07	-0.37	-0.33	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
STAD	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	6.52	2.46e-10	3.96e-07	0.43	0.33	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
STAD	cis	rs7487075	0.797	rs10785630	ENSG00000257261.4	RP11-96H19.1	6.52	2.47e-10	3.97e-07	0.39	0.33	Itch intensity from mosquito bite;	chr12:46486597	chr12:46383679~46876159:+
STAD	cis	rs611744	0.934	rs1989388	ENSG00000253754.1	RP11-35G22.1	-6.52	2.48e-10	3.97e-07	-0.28	-0.33	Dupuytren's disease;	chr8:108208040	chr8:108226200~108227544:+
STAD	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-6.52	2.48e-10	3.97e-07	-0.38	-0.33	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
STAD	cis	rs2221894	0.96	rs4732893	ENSG00000273710.1	Metazoa_SRP	6.52	2.48e-10	3.98e-07	0.37	0.33	Obesity-related traits;	chr8:28937161	chr8:28915579~28915864:-
STAD	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	6.52	2.49e-10	4e-07	0.32	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
STAD	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-6.52	2.49e-10	4e-07	-0.37	-0.33	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
STAD	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-6.52	2.49e-10	4e-07	-0.37	-0.33	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-6.52	2.5e-10	4e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
STAD	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-6.52	2.5e-10	4e-07	-0.34	-0.33	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
STAD	cis	rs4568518	0.53	rs7802064	ENSG00000279048.1	RP11-511H23.2	6.52	2.5e-10	4.01e-07	0.3	0.33	Measles;	chr7:17955230	chr7:17940503~17942922:+
STAD	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	6.52	2.5e-10	4.01e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	6.52	2.5e-10	4.01e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
STAD	cis	rs2273156	0.57	rs79702597	ENSG00000241052.1	RP11-173D9.1	-6.52	2.5e-10	4.01e-07	-0.4	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:35089650	chr14:35144021~35144480:-
STAD	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	6.52	2.51e-10	4.02e-07	0.35	0.33	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
STAD	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	6.52	2.51e-10	4.02e-07	0.34	0.33	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
STAD	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	6.52	2.51e-10	4.03e-07	0.39	0.33	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
STAD	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	6.52	2.51e-10	4.03e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
STAD	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	6.52	2.52e-10	4.04e-07	0.51	0.33	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
STAD	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	6.52	2.52e-10	4.04e-07	0.31	0.33	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
STAD	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	6.52	2.53e-10	4.05e-07	0.34	0.33	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	6.52	2.53e-10	4.05e-07	0.34	0.33	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
STAD	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	6.52	2.53e-10	4.05e-07	0.34	0.33	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
STAD	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-6.52	2.53e-10	4.05e-07	-0.32	-0.33	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
STAD	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	6.52	2.53e-10	4.05e-07	0.28	0.33	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
STAD	cis	rs7615952	0.575	rs35949599	ENSG00000272840.1	RP11-379B18.6	6.52	2.54e-10	4.06e-07	0.48	0.33	Blood pressure (smoking interaction);	chr3:125825359	chr3:125774714~125797953:+
STAD	cis	rs4568518	0.53	rs6970593	ENSG00000279048.1	RP11-511H23.2	-6.52	2.54e-10	4.07e-07	-0.3	-0.33	Measles;	chr7:17949736	chr7:17940503~17942922:+
STAD	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	6.52	2.55e-10	4.08e-07	0.41	0.33	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	6.52	2.55e-10	4.08e-07	0.41	0.33	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	6.52	2.55e-10	4.08e-07	0.41	0.33	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	6.52	2.55e-10	4.08e-07	0.41	0.33	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	6.52	2.55e-10	4.08e-07	0.41	0.33	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
STAD	cis	rs12922317	0.556	rs11648938	ENSG00000260224.1	UBL5P4	6.52	2.55e-10	4.08e-07	0.34	0.33	Schizophrenia;	chr16:12000292	chr16:11968508~11968743:-
STAD	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-6.52	2.56e-10	4.1e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
STAD	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	6.52	2.56e-10	4.1e-07	0.43	0.33	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
STAD	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-6.52	2.56e-10	4.1e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-6.52	2.56e-10	4.1e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
STAD	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-6.52	2.56e-10	4.1e-07	-0.34	-0.33	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
STAD	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-6.52	2.56e-10	4.1e-07	-0.34	-0.33	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-6.52	2.56e-10	4.1e-07	-0.34	-0.33	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-6.52	2.56e-10	4.1e-07	-0.34	-0.33	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-6.52	2.56e-10	4.1e-07	-0.36	-0.33	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
STAD	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	6.51	2.57e-10	4.11e-07	0.34	0.33	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-6.51	2.57e-10	4.11e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
STAD	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-6.51	2.57e-10	4.11e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
STAD	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-6.51	2.57e-10	4.11e-07	-0.38	-0.33	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-6.51	2.57e-10	4.11e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-6.51	2.57e-10	4.11e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-6.51	2.57e-10	4.11e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-6.51	2.57e-10	4.11e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-6.51	2.57e-10	4.11e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
STAD	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-6.51	2.58e-10	4.12e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
STAD	cis	rs11235843	0.602	rs7106773	ENSG00000255928.1	RP11-456I15.2	-6.51	2.58e-10	4.12e-07	-0.45	-0.33	Hand grip strength;	chr11:73672129	chr11:73722349~73722694:+
STAD	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	6.51	2.58e-10	4.12e-07	0.41	0.33	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	6.51	2.58e-10	4.12e-07	0.41	0.33	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
STAD	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	6.51	2.58e-10	4.13e-07	0.34	0.33	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
STAD	cis	rs6452524	0.967	rs2974445	ENSG00000243385.2	CTD-2110K23.1	-6.51	2.58e-10	4.13e-07	-0.35	-0.33	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83201229~83202141:+
STAD	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-6.51	2.58e-10	4.13e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
STAD	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-6.51	2.6e-10	4.15e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-6.51	2.6e-10	4.15e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-6.51	2.6e-10	4.15e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-6.51	2.6e-10	4.15e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
STAD	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-6.51	2.6e-10	4.15e-07	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
STAD	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-6.51	2.6e-10	4.16e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-6.51	2.6e-10	4.16e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-6.51	2.6e-10	4.16e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
STAD	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	6.51	2.61e-10	4.16e-07	0.4	0.33	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
STAD	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-6.51	2.61e-10	4.17e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-6.51	2.61e-10	4.17e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-6.51	2.61e-10	4.17e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
STAD	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	6.51	2.61e-10	4.17e-07	0.31	0.33	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
STAD	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	6.51	2.61e-10	4.17e-07	0.34	0.33	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	6.51	2.61e-10	4.17e-07	0.34	0.33	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	6.51	2.61e-10	4.17e-07	0.34	0.33	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	6.51	2.61e-10	4.17e-07	0.34	0.33	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	6.51	2.61e-10	4.17e-07	0.34	0.33	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000224205.1	AP000351.4	6.51	2.61e-10	4.17e-07	0.38	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23987320~23991421:-
STAD	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-6.51	2.61e-10	4.17e-07	-0.34	-0.33	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
STAD	cis	rs11235843	0.565	rs1723840	ENSG00000255928.1	RP11-456I15.2	6.51	2.62e-10	4.17e-07	0.45	0.33	Hand grip strength;	chr11:73762840	chr11:73722349~73722694:+
STAD	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-6.51	2.62e-10	4.18e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-6.51	2.62e-10	4.18e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-6.51	2.62e-10	4.18e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-6.51	2.62e-10	4.18e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-6.51	2.62e-10	4.18e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
STAD	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	6.51	2.62e-10	4.18e-07	0.43	0.33	Height;	chr6:109693890	chr6:109382795~109383666:+
STAD	cis	rs9549260	0.753	rs10507486	ENSG00000229456.1	RLIMP1	-6.51	2.62e-10	4.18e-07	-0.37	-0.33	Red blood cell count;	chr13:40612364	chr13:40618738~40621348:+
STAD	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	6.51	2.62e-10	4.19e-07	0.4	0.33	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
STAD	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-6.51	2.63e-10	4.2e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
STAD	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	6.51	2.64e-10	4.2e-07	0.46	0.33	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
STAD	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	6.51	2.65e-10	4.22e-07	0.49	0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
STAD	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	6.51	2.65e-10	4.22e-07	0.47	0.33	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
STAD	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	6.51	2.67e-10	4.25e-07	0.4	0.33	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	6.51	2.67e-10	4.25e-07	0.41	0.33	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	6.51	2.67e-10	4.25e-07	0.41	0.33	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-6.51	2.67e-10	4.25e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
STAD	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-6.51	2.68e-10	4.27e-07	-0.39	-0.33	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
STAD	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	6.51	2.68e-10	4.27e-07	0.34	0.33	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
STAD	cis	rs7615952	0.512	rs2979351	ENSG00000272840.1	RP11-379B18.6	6.51	2.69e-10	4.27e-07	0.52	0.33	Blood pressure (smoking interaction);	chr3:125644755	chr3:125774714~125797953:+
STAD	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-6.51	2.7e-10	4.29e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	6.51	2.7e-10	4.3e-07	0.35	0.33	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-6.51	2.72e-10	4.33e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
STAD	cis	rs9549260	0.755	rs2151785	ENSG00000229456.1	RLIMP1	6.5	2.72e-10	4.33e-07	0.3	0.33	Red blood cell count;	chr13:40669523	chr13:40618738~40621348:+
STAD	cis	rs7927771	1	rs12419692	ENSG00000280615.1	Y_RNA	6.5	2.74e-10	4.35e-07	0.33	0.33	Subjective well-being;	chr11:47603162	chr11:47614898~47614994:-
STAD	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-6.5	2.75e-10	4.38e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-6.5	2.75e-10	4.38e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-6.5	2.75e-10	4.38e-07	-0.28	-0.33	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
STAD	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	6.5	2.76e-10	4.38e-07	0.47	0.33	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
STAD	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	6.5	2.76e-10	4.39e-07	0.37	0.33	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
STAD	cis	rs4568518	0.502	rs4543441	ENSG00000279048.1	RP11-511H23.2	6.5	2.76e-10	4.39e-07	0.29	0.33	Measles;	chr7:17943674	chr7:17940503~17942922:+
STAD	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-6.5	2.77e-10	4.39e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
STAD	cis	rs2980439	0.818	rs2948300	ENSG00000173295.6	FAM86B3P	6.5	2.77e-10	4.4e-07	0.37	0.33	Neuroticism;	chr8:8248986	chr8:8228595~8244865:+
STAD	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-6.5	2.77e-10	4.4e-07	-0.48	-0.33	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
STAD	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-6.5	2.77e-10	4.4e-07	-0.48	-0.33	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
STAD	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-6.5	2.77e-10	4.4e-07	-0.48	-0.33	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
STAD	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-6.5	2.77e-10	4.4e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-6.5	2.77e-10	4.4e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
STAD	cis	rs858239	0.863	rs274058	ENSG00000226816.2	AC005082.12	6.5	2.77e-10	4.4e-07	0.41	0.33	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23206013~23208045:+
STAD	cis	rs2221894	1	rs2137471	ENSG00000273710.1	Metazoa_SRP	-6.5	2.77e-10	4.4e-07	-0.37	-0.33	Obesity-related traits;	chr8:28948132	chr8:28915579~28915864:-
STAD	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-6.5	2.78e-10	4.41e-07	-0.33	-0.33	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
STAD	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-6.5	2.78e-10	4.41e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-6.5	2.79e-10	4.43e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
STAD	cis	rs17361889	0.727	rs62440406	ENSG00000224683.1	RPL36AP29	6.5	2.79e-10	4.43e-07	0.37	0.33	Pediatric bone mineral content (hip);	chr7:16245394	chr7:16208945~16209265:+
STAD	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	6.5	2.8e-10	4.44e-07	0.44	0.33	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	6.5	2.8e-10	4.44e-07	0.44	0.33	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
STAD	cis	rs2404602	0.583	rs4381566	ENSG00000259422.1	RP11-593F23.1	6.5	2.8e-10	4.45e-07	0.35	0.33	Blood metabolite levels;	chr15:76296921	chr15:76174891~76181486:-
STAD	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-6.5	2.81e-10	4.45e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
STAD	cis	rs1862618	0.853	rs1423621	ENSG00000271828.1	CTD-2310F14.1	6.5	2.81e-10	4.46e-07	0.42	0.33	Initial pursuit acceleration;	chr5:56805208	chr5:56927874~56929573:+
STAD	cis	rs11098499	0.71	rs4145952	ENSG00000248280.1	RP11-33B1.2	6.5	2.82e-10	4.46e-07	0.4	0.33	Corneal astigmatism;	chr4:119234651	chr4:119440561~119450157:-
STAD	cis	rs11235843	0.636	rs2140892	ENSG00000255928.1	RP11-456I15.2	-6.5	2.82e-10	4.47e-07	-0.45	-0.33	Hand grip strength;	chr11:73711834	chr11:73722349~73722694:+
STAD	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-6.5	2.82e-10	4.47e-07	-0.37	-0.33	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
STAD	cis	rs6782228	0.675	rs9813845	ENSG00000277250.1	Metazoa_SRP	-6.5	2.82e-10	4.47e-07	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128673681~128674021:-
STAD	cis	rs2404602	0.583	rs3759853	ENSG00000259422.1	RP11-593F23.1	6.5	2.83e-10	4.48e-07	0.35	0.33	Blood metabolite levels;	chr15:76295436	chr15:76174891~76181486:-
STAD	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	6.5	2.84e-10	4.5e-07	0.36	0.33	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
STAD	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	6.5	2.84e-10	4.5e-07	0.4	0.33	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	6.5	2.84e-10	4.5e-07	0.4	0.33	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	6.5	2.84e-10	4.5e-07	0.37	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
STAD	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-6.5	2.84e-10	4.5e-07	-0.38	-0.33	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
STAD	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	6.5	2.84e-10	4.5e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
STAD	cis	rs6452524	1	rs6864479	ENSG00000243385.2	CTD-2110K23.1	6.5	2.85e-10	4.51e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs13436667	ENSG00000243385.2	CTD-2110K23.1	6.5	2.85e-10	4.51e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs7726564	ENSG00000243385.2	CTD-2110K23.1	6.5	2.85e-10	4.51e-07	0.36	0.33	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83201229~83202141:+
STAD	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-6.5	2.85e-10	4.51e-07	-0.38	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
STAD	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	6.5	2.85e-10	4.52e-07	0.31	0.33	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
STAD	cis	rs11089937	0.667	rs9622981	ENSG00000211639.2	IGLV4-60	6.5	2.86e-10	4.53e-07	0.36	0.33	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22162199~22162681:+
STAD	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.5	2.87e-10	4.54e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
STAD	cis	rs2833693	0.572	rs2833711	ENSG00000261610.1	AP000265.1	6.5	2.87e-10	4.55e-07	0.37	0.33	Temperament;	chr21:32191022	chr21:32259804~32261585:-
STAD	cis	rs2439831	0.717	rs28495368	ENSG00000249839.1	AC011330.5	-6.5	2.88e-10	4.55e-07	-0.52	-0.33	Lung cancer in ever smokers;	chr15:43603444	chr15:43663654~43684339:-
STAD	cis	rs611744	0.905	rs640950	ENSG00000253754.1	RP11-35G22.1	-6.5	2.88e-10	4.56e-07	-0.29	-0.33	Dupuytren's disease;	chr8:108145590	chr8:108226200~108227544:+
STAD	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-6.49	2.89e-10	4.57e-07	-0.37	-0.33	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
STAD	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	6.49	2.89e-10	4.57e-07	0.38	0.33	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	6.49	2.89e-10	4.57e-07	0.38	0.33	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
STAD	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	6.49	2.89e-10	4.57e-07	0.46	0.33	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	6.49	2.89e-10	4.57e-07	0.46	0.33	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
STAD	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-6.49	2.89e-10	4.58e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
STAD	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	6.49	2.89e-10	4.58e-07	0.35	0.33	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
STAD	cis	rs1426063	0.614	rs78784058	ENSG00000248165.1	RP11-44F21.2	6.49	2.9e-10	4.58e-07	0.68	0.33	QT interval;	chr4:75108738	chr4:74993877~75034824:-
STAD	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	6.49	2.9e-10	4.58e-07	0.35	0.33	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
STAD	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	6.49	2.9e-10	4.59e-07	0.31	0.33	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
STAD	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	6.49	2.91e-10	4.6e-07	0.26	0.33	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
STAD	cis	rs12699921	0.935	rs6461363	ENSG00000279048.1	RP11-511H23.2	6.49	2.92e-10	4.62e-07	0.3	0.33	Fibrinogen levels;	chr7:17952527	chr7:17940503~17942922:+
STAD	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	6.49	2.92e-10	4.62e-07	0.44	0.33	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
STAD	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	6.49	2.93e-10	4.63e-07	0.37	0.33	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
STAD	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	6.49	2.93e-10	4.63e-07	0.38	0.33	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
STAD	cis	rs4568518	0.53	rs7802331	ENSG00000279048.1	RP11-511H23.2	6.49	2.93e-10	4.63e-07	0.3	0.33	Measles;	chr7:17955352	chr7:17940503~17942922:+
STAD	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-6.49	2.94e-10	4.64e-07	-0.36	-0.33	Height;	chr3:52977358	chr3:53064283~53065091:-
STAD	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	6.49	2.95e-10	4.65e-07	0.4	0.33	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
STAD	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-6.49	2.95e-10	4.66e-07	-0.37	-0.33	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
STAD	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-6.49	2.97e-10	4.68e-07	-0.47	-0.33	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
STAD	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-6.49	2.97e-10	4.68e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	6.49	2.97e-10	4.68e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	6.49	2.97e-10	4.68e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
STAD	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	6.49	2.97e-10	4.68e-07	0.34	0.33	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
STAD	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	6.49	2.98e-10	4.69e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
STAD	cis	rs2833693	0.615	rs9974274	ENSG00000261610.1	AP000265.1	6.49	2.98e-10	4.69e-07	0.38	0.33	Temperament;	chr21:32196563	chr21:32259804~32261585:-
STAD	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-6.49	2.99e-10	4.71e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
STAD	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-6.49	2.99e-10	4.71e-07	-0.35	-0.33	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-6.49	2.99e-10	4.71e-07	-0.35	-0.33	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-6.49	2.99e-10	4.71e-07	-0.35	-0.33	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
STAD	cis	rs2273156	0.517	rs7159324	ENSG00000241052.1	RP11-173D9.1	6.49	3.01e-10	4.74e-07	0.38	0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:35157791	chr14:35144021~35144480:-
STAD	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	6.49	3.01e-10	4.74e-07	0.31	0.33	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	6.49	3.01e-10	4.74e-07	0.31	0.33	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	6.49	3.01e-10	4.74e-07	0.31	0.33	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
STAD	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	6.49	3.01e-10	4.74e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
STAD	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-6.49	3.01e-10	4.74e-07	-0.37	-0.33	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
STAD	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	6.49	3.01e-10	4.74e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
STAD	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	6.49	3.02e-10	4.75e-07	0.38	0.33	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	6.49	3.02e-10	4.75e-07	0.38	0.33	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
STAD	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-6.49	3.02e-10	4.75e-07	-0.35	-0.33	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
STAD	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	6.49	3.02e-10	4.75e-07	0.31	0.33	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	6.49	3.02e-10	4.75e-07	0.31	0.33	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
STAD	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-6.49	3.02e-10	4.75e-07	-0.35	-0.33	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
STAD	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-6.49	3.02e-10	4.75e-07	-0.35	-0.33	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
STAD	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	6.49	3.02e-10	4.75e-07	0.45	0.33	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
STAD	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-6.49	3.02e-10	4.76e-07	-0.33	-0.33	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
STAD	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	6.49	3.03e-10	4.76e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
STAD	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-6.49	3.03e-10	4.77e-07	-0.34	-0.33	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
STAD	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	6.49	3.04e-10	4.78e-07	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
STAD	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	6.49	3.05e-10	4.79e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
STAD	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	6.49	3.05e-10	4.79e-07	0.38	0.33	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	6.49	3.05e-10	4.79e-07	0.38	0.33	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
STAD	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	6.49	3.05e-10	4.8e-07	0.47	0.33	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
STAD	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	6.49	3.05e-10	4.8e-07	0.37	0.33	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
STAD	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	6.49	3.06e-10	4.82e-07	0.42	0.33	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
STAD	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-6.48	3.08e-10	4.84e-07	-0.34	-0.33	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
STAD	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	6.48	3.08e-10	4.84e-07	0.34	0.33	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
STAD	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	6.48	3.08e-10	4.84e-07	0.41	0.33	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
STAD	cis	rs748404	0.601	rs502157	ENSG00000249839.1	AC011330.5	6.48	3.08e-10	4.84e-07	0.39	0.33	Lung cancer;	chr15:43236375	chr15:43663654~43684339:-
STAD	cis	rs6456156	0.774	rs6930998	ENSG00000265828.1	MIR3939	6.48	3.09e-10	4.85e-07	0.37	0.33	Primary biliary cholangitis;	chr6:167113452	chr6:166997807~166997912:-
STAD	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-6.48	3.09e-10	4.86e-07	-0.46	-0.33	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
STAD	cis	rs11235843	0.602	rs1830069	ENSG00000255928.1	RP11-456I15.2	-6.48	3.09e-10	4.86e-07	-0.44	-0.33	Hand grip strength;	chr11:73722184	chr11:73722349~73722694:+
STAD	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-6.48	3.09e-10	4.86e-07	-0.39	-0.33	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-6.48	3.09e-10	4.86e-07	-0.39	-0.33	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
STAD	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-6.48	3.1e-10	4.86e-07	-0.33	-0.33	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	6.48	3.1e-10	4.86e-07	0.34	0.33	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
STAD	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-6.48	3.11e-10	4.88e-07	-0.38	-0.33	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
STAD	cis	rs6456156	0.774	rs1012656	ENSG00000265828.1	MIR3939	6.48	3.11e-10	4.89e-07	0.36	0.33	Primary biliary cholangitis;	chr6:167111815	chr6:166997807~166997912:-
STAD	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-6.48	3.12e-10	4.89e-07	-0.39	-0.33	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
STAD	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	6.48	3.12e-10	4.89e-07	0.58	0.33	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
STAD	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-6.48	3.14e-10	4.93e-07	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
STAD	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-6.48	3.15e-10	4.94e-07	-0.47	-0.33	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	6.48	3.16e-10	4.96e-07	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
STAD	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-6.48	3.16e-10	4.96e-07	-0.42	-0.33	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
STAD	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-6.48	3.16e-10	4.96e-07	-0.35	-0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
STAD	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-6.48	3.16e-10	4.96e-07	-0.38	-0.33	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-6.48	3.17e-10	4.97e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-6.48	3.17e-10	4.97e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-6.48	3.17e-10	4.97e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
STAD	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	6.48	3.17e-10	4.98e-07	0.46	0.33	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	6.48	3.17e-10	4.98e-07	0.46	0.33	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	6.48	3.17e-10	4.98e-07	0.46	0.33	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
STAD	cis	rs875971	0.577	rs34888281	ENSG00000222364.1	RNU6-96P	6.48	3.18e-10	4.99e-07	0.37	0.33	Aortic root size;	chr7:66120784	chr7:66395191~66395286:+
STAD	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-6.48	3.19e-10	5e-07	-0.37	-0.33	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
STAD	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	6.48	3.2e-10	5.02e-07	0.38	0.33	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
STAD	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	6.48	3.21e-10	5.03e-07	0.27	0.33	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
STAD	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	6.48	3.21e-10	5.03e-07	0.27	0.33	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
STAD	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	6.48	3.22e-10	5.03e-07	0.46	0.33	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
STAD	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	6.48	3.22e-10	5.04e-07	0.43	0.33	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	6.48	3.22e-10	5.04e-07	0.43	0.33	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	6.48	3.22e-10	5.04e-07	0.43	0.33	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
STAD	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	6.48	3.22e-10	5.04e-07	0.43	0.33	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
STAD	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-6.48	3.23e-10	5.05e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-6.48	3.23e-10	5.05e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-6.48	3.23e-10	5.05e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-6.48	3.23e-10	5.05e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
STAD	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	6.48	3.23e-10	5.06e-07	0.6	0.33	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
STAD	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-6.48	3.24e-10	5.07e-07	-0.27	-0.33	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
STAD	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-6.48	3.24e-10	5.07e-07	-0.27	-0.33	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
STAD	cis	rs4568518	0.501	rs12699920	ENSG00000279048.1	RP11-511H23.2	6.48	3.24e-10	5.07e-07	0.3	0.33	Measles;	chr7:17953326	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.53	rs4721674	ENSG00000279048.1	RP11-511H23.2	6.48	3.24e-10	5.07e-07	0.3	0.33	Measles;	chr7:17953754	chr7:17940503~17942922:+
STAD	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-6.48	3.24e-10	5.08e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
STAD	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-6.47	3.26e-10	5.09e-07	-0.37	-0.33	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
STAD	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-6.47	3.26e-10	5.09e-07	-0.37	-0.33	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
STAD	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-6.47	3.26e-10	5.11e-07	-0.38	-0.33	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
STAD	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-6.47	3.27e-10	5.11e-07	-0.39	-0.33	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-6.47	3.27e-10	5.11e-07	-0.39	-0.33	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-6.47	3.27e-10	5.11e-07	-0.39	-0.33	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-6.47	3.27e-10	5.11e-07	-0.39	-0.33	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-6.47	3.27e-10	5.11e-07	-0.39	-0.33	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-6.47	3.27e-10	5.11e-07	-0.39	-0.33	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
STAD	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	6.47	3.28e-10	5.12e-07	0.4	0.33	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	6.47	3.28e-10	5.12e-07	0.4	0.33	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	6.47	3.28e-10	5.13e-07	0.37	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
STAD	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-6.47	3.29e-10	5.13e-07	-0.31	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
STAD	cis	rs1005277	0.579	rs2749612	ENSG00000099251.13	HSD17B7P2	6.47	3.29e-10	5.14e-07	0.36	0.33	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38356380~38378505:+
STAD	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-6.47	3.29e-10	5.14e-07	-0.42	-0.33	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
STAD	cis	rs6452524	0.904	rs10474095	ENSG00000243385.2	CTD-2110K23.1	6.47	3.3e-10	5.15e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83201229~83202141:+
STAD	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	6.47	3.3e-10	5.15e-07	0.33	0.33	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
STAD	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-6.47	3.3e-10	5.16e-07	-0.48	-0.33	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
STAD	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-6.47	3.31e-10	5.16e-07	-0.35	-0.33	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
STAD	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-6.47	3.31e-10	5.16e-07	-0.35	-0.33	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
STAD	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	6.47	3.31e-10	5.17e-07	0.31	0.33	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	6.47	3.31e-10	5.17e-07	0.31	0.33	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
STAD	cis	rs496547	0.654	rs688161	ENSG00000255422.1	AP002954.4	-6.47	3.31e-10	5.17e-07	-0.38	-0.33	Hip minimal joint space width;	chr11:118807001	chr11:118704607~118750263:+
STAD	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	6.47	3.32e-10	5.18e-07	0.39	0.33	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
STAD	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-6.47	3.32e-10	5.19e-07	-0.41	-0.33	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
STAD	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-6.47	3.32e-10	5.19e-07	-0.33	-0.33	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
STAD	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-6.47	3.33e-10	5.19e-07	-0.42	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
STAD	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	6.47	3.33e-10	5.19e-07	0.38	0.33	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
STAD	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-6.47	3.33e-10	5.2e-07	-0.5	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
STAD	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	6.47	3.34e-10	5.21e-07	0.43	0.33	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
STAD	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	6.47	3.34e-10	5.21e-07	0.43	0.33	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
STAD	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	6.47	3.34e-10	5.22e-07	0.45	0.33	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	6.47	3.34e-10	5.22e-07	0.45	0.33	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
STAD	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-6.47	3.34e-10	5.22e-07	-0.45	-0.33	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
STAD	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-6.47	3.35e-10	5.22e-07	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
STAD	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-6.47	3.35e-10	5.22e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
STAD	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-6.47	3.35e-10	5.22e-07	-0.39	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
STAD	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-6.47	3.36e-10	5.24e-07	-0.35	-0.33	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
STAD	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-6.47	3.36e-10	5.24e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
STAD	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-6.47	3.4e-10	5.3e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
STAD	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-6.47	3.41e-10	5.31e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-6.47	3.41e-10	5.31e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-6.47	3.41e-10	5.31e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-6.47	3.41e-10	5.31e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-6.47	3.41e-10	5.31e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
STAD	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	6.47	3.42e-10	5.33e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
STAD	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-6.47	3.43e-10	5.35e-07	-0.31	-0.33	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
STAD	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	6.47	3.44e-10	5.36e-07	0.38	0.33	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
STAD	cis	rs17361889	0.634	rs6954901	ENSG00000224683.1	RPL36AP29	-6.47	3.44e-10	5.36e-07	-0.34	-0.33	Pediatric bone mineral content (hip);	chr7:16267078	chr7:16208945~16209265:+
STAD	cis	rs2273156	0.57	rs941653	ENSG00000241052.1	RP11-173D9.1	-6.47	3.45e-10	5.36e-07	-0.39	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:35123332	chr14:35144021~35144480:-
STAD	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	6.47	3.45e-10	5.37e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
STAD	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	6.46	3.45e-10	5.37e-07	0.45	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
STAD	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	6.46	3.45e-10	5.38e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
STAD	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-6.46	3.46e-10	5.38e-07	-0.28	-0.33	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
STAD	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	6.46	3.46e-10	5.39e-07	0.31	0.33	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
STAD	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	6.46	3.47e-10	5.39e-07	0.37	0.33	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
STAD	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-6.46	3.47e-10	5.4e-07	-0.31	-0.33	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
STAD	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-6.46	3.47e-10	5.4e-07	-0.31	-0.33	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	6.46	3.48e-10	5.41e-07	0.24	0.33	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	6.46	3.48e-10	5.41e-07	0.24	0.33	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
STAD	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	6.46	3.49e-10	5.43e-07	0.31	0.33	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
STAD	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-6.46	3.49e-10	5.43e-07	-0.39	-0.33	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
STAD	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	6.46	3.49e-10	5.43e-07	0.31	0.33	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
STAD	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	6.46	3.5e-10	5.44e-07	0.34	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
STAD	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	6.46	3.51e-10	5.45e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	6.46	3.51e-10	5.45e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	6.46	3.51e-10	5.45e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	6.46	3.51e-10	5.45e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	6.46	3.51e-10	5.45e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	6.46	3.51e-10	5.45e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
STAD	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-6.46	3.51e-10	5.46e-07	-0.34	-0.33	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
STAD	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-6.46	3.52e-10	5.46e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
STAD	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	6.46	3.52e-10	5.47e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
STAD	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-6.46	3.53e-10	5.48e-07	-0.3	-0.33	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
STAD	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-6.46	3.53e-10	5.48e-07	-0.43	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
STAD	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-6.46	3.53e-10	5.48e-07	-0.43	-0.33	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
STAD	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-6.46	3.53e-10	5.48e-07	-0.37	-0.33	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
STAD	cis	rs10885997	0.967	rs11197775	ENSG00000266200.5	PNLIPRP2	-6.46	3.53e-10	5.49e-07	-0.39	-0.33	Phospholipid levels (plasma);	chr10:116636627	chr10:116620953~116645143:+
STAD	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	6.46	3.54e-10	5.49e-07	0.41	0.33	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
STAD	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-6.46	3.55e-10	5.5e-07	-0.45	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
STAD	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	6.46	3.55e-10	5.5e-07	0.49	0.33	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
STAD	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-6.46	3.56e-10	5.52e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
STAD	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	6.46	3.57e-10	5.53e-07	0.37	0.33	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	6.46	3.57e-10	5.53e-07	0.37	0.33	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
STAD	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-6.46	3.57e-10	5.54e-07	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
STAD	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-6.46	3.57e-10	5.54e-07	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
STAD	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-6.46	3.58e-10	5.55e-07	-0.34	-0.33	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-6.46	3.58e-10	5.55e-07	-0.34	-0.33	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-6.46	3.58e-10	5.55e-07	-0.34	-0.33	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-6.46	3.58e-10	5.55e-07	-0.34	-0.33	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-6.46	3.58e-10	5.55e-07	-0.34	-0.33	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
STAD	cis	rs2221894	1	rs6558085	ENSG00000273710.1	Metazoa_SRP	-6.46	3.58e-10	5.55e-07	-0.37	-0.33	Obesity-related traits;	chr8:28945415	chr8:28915579~28915864:-
STAD	cis	rs2833693	0.572	rs8130652	ENSG00000261610.1	AP000265.1	6.46	3.59e-10	5.57e-07	0.38	0.33	Temperament;	chr21:32189593	chr21:32259804~32261585:-
STAD	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	6.46	3.6e-10	5.57e-07	0.33	0.33	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
STAD	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	6.46	3.6e-10	5.57e-07	0.33	0.33	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	6.46	3.6e-10	5.57e-07	0.33	0.33	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.739	rs10031033	ENSG00000248280.1	RP11-33B1.2	6.46	3.61e-10	5.59e-07	0.4	0.33	Corneal astigmatism;	chr4:119230297	chr4:119440561~119450157:-
STAD	cis	rs2945232	1	rs2945232	ENSG00000253981.4	ALG1L13P	6.46	3.61e-10	5.59e-07	0.39	0.33	Schizophrenia;	chr8:8240516	chr8:8236003~8244667:-
STAD	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-6.46	3.61e-10	5.6e-07	-0.39	-0.33	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
STAD	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-6.46	3.62e-10	5.6e-07	-0.28	-0.33	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
STAD	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	6.46	3.62e-10	5.6e-07	0.34	0.33	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
STAD	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-6.46	3.62e-10	5.6e-07	-0.35	-0.33	Height;	chr3:52975027	chr3:53064283~53065091:-
STAD	cis	rs748404	0.601	rs489964	ENSG00000249839.1	AC011330.5	6.46	3.62e-10	5.61e-07	0.39	0.33	Lung cancer;	chr15:43225356	chr15:43663654~43684339:-
STAD	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	6.46	3.62e-10	5.61e-07	0.41	0.33	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
STAD	cis	rs6452524	0.935	rs10474081	ENSG00000243385.2	CTD-2110K23.1	6.46	3.62e-10	5.61e-07	0.37	0.33	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83201229~83202141:+
STAD	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-6.46	3.63e-10	5.62e-07	-0.39	-0.33	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
STAD	cis	rs6452524	1	rs6887846	ENSG00000243385.2	CTD-2110K23.1	-6.46	3.63e-10	5.62e-07	-0.35	-0.33	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83201229~83202141:+
STAD	cis	rs7615952	0.688	rs17334074	ENSG00000272840.1	RP11-379B18.6	-6.46	3.63e-10	5.63e-07	-0.45	-0.33	Blood pressure (smoking interaction);	chr3:125821617	chr3:125774714~125797953:+
STAD	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-6.46	3.65e-10	5.65e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
STAD	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-6.46	3.65e-10	5.65e-07	-0.34	-0.33	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
STAD	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	6.46	3.65e-10	5.65e-07	0.41	0.33	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	6.46	3.65e-10	5.65e-07	0.41	0.33	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	6.46	3.65e-10	5.65e-07	0.41	0.33	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
STAD	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-6.46	3.65e-10	5.65e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-6.46	3.65e-10	5.65e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-6.46	3.65e-10	5.65e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	6.46	3.65e-10	5.65e-07	0.34	0.33	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
STAD	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	6.46	3.66e-10	5.66e-07	0.41	0.33	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	6.46	3.66e-10	5.66e-07	0.41	0.33	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	6.46	3.66e-10	5.66e-07	0.41	0.33	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	6.46	3.66e-10	5.66e-07	0.41	0.33	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	6.46	3.66e-10	5.66e-07	0.41	0.33	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
STAD	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	6.45	3.66e-10	5.66e-07	0.31	0.33	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	6.45	3.66e-10	5.66e-07	0.31	0.33	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	6.45	3.66e-10	5.66e-07	0.31	0.33	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	6.45	3.66e-10	5.66e-07	0.31	0.33	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	6.45	3.66e-10	5.66e-07	0.31	0.33	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	6.45	3.66e-10	5.66e-07	0.31	0.33	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
STAD	cis	rs7829975	0.511	rs2948286	ENSG00000253981.4	ALG1L13P	6.45	3.67e-10	5.67e-07	0.39	0.33	Mood instability;	chr8:8272638	chr8:8236003~8244667:-
STAD	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	6.45	3.67e-10	5.67e-07	0.55	0.33	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
STAD	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-6.45	3.67e-10	5.68e-07	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
STAD	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	6.45	3.67e-10	5.68e-07	0.41	0.33	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
STAD	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	6.45	3.68e-10	5.68e-07	0.34	0.33	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
STAD	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-6.45	3.68e-10	5.69e-07	-0.57	-0.33	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
STAD	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	6.45	3.68e-10	5.69e-07	0.32	0.33	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
STAD	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-6.45	3.69e-10	5.7e-07	-0.34	-0.33	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
STAD	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	6.45	3.7e-10	5.71e-07	0.37	0.33	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
STAD	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	6.45	3.71e-10	5.73e-07	0.31	0.33	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
STAD	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	6.45	3.73e-10	5.75e-07	0.43	0.33	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	6.45	3.73e-10	5.75e-07	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
STAD	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
STAD	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
STAD	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
STAD	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-6.45	3.73e-10	5.76e-07	-0.34	-0.33	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
STAD	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	6.45	3.74e-10	5.77e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
STAD	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	6.45	3.76e-10	5.79e-07	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
STAD	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-6.45	3.76e-10	5.8e-07	-0.31	-0.33	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
STAD	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	6.45	3.78e-10	5.82e-07	0.39	0.33	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
STAD	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	6.45	3.78e-10	5.82e-07	0.51	0.33	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
STAD	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-6.45	3.78e-10	5.84e-07	-0.39	-0.33	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
STAD	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-6.45	3.78e-10	5.84e-07	-0.35	-0.33	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.87	rs2174976	ENSG00000243385.2	CTD-2110K23.1	6.45	3.78e-10	5.84e-07	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83201229~83202141:+
STAD	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-6.45	3.79e-10	5.84e-07	-0.34	-0.33	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-6.45	3.79e-10	5.84e-07	-0.34	-0.33	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-6.45	3.79e-10	5.84e-07	-0.34	-0.33	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
STAD	cis	rs6452524	0.935	rs10043698	ENSG00000243385.2	CTD-2110K23.1	6.45	3.81e-10	5.87e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83201229~83202141:+
STAD	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	6.45	3.81e-10	5.88e-07	0.34	0.33	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
STAD	cis	rs1426063	0.614	rs114761716	ENSG00000248165.1	RP11-44F21.2	6.45	3.81e-10	5.88e-07	0.69	0.33	QT interval;	chr4:75107209	chr4:74993877~75034824:-
STAD	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-6.45	3.83e-10	5.89e-07	-0.38	-0.33	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
STAD	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	6.45	3.84e-10	5.92e-07	0.44	0.33	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
STAD	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-6.45	3.84e-10	5.92e-07	-0.34	-0.33	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
STAD	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-6.45	3.86e-10	5.95e-07	-0.39	-0.33	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
STAD	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	6.45	3.87e-10	5.96e-07	0.32	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
STAD	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-6.45	3.87e-10	5.96e-07	-0.28	-0.33	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
STAD	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-6.45	3.88e-10	5.97e-07	-0.32	-0.33	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	6.44	3.88e-10	5.98e-07	0.37	0.33	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
STAD	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	6.44	3.89e-10	5.99e-07	0.42	0.33	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
STAD	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-6.44	3.9e-10	6e-07	-0.41	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
STAD	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	6.44	3.91e-10	6.01e-07	0.26	0.33	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
STAD	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	6.44	3.91e-10	6.02e-07	0.33	0.33	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
STAD	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-6.44	3.91e-10	6.02e-07	-0.5	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
STAD	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-6.44	3.92e-10	6.03e-07	-0.32	-0.33	Height;	chr11:118703185	chr11:118791254~118793137:+
STAD	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-6.44	3.92e-10	6.03e-07	-0.32	-0.33	Height;	chr11:118703207	chr11:118791254~118793137:+
STAD	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-6.44	3.92e-10	6.03e-07	-0.32	-0.33	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
STAD	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-6.44	3.92e-10	6.03e-07	-0.32	-0.33	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
STAD	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-6.44	3.94e-10	6.05e-07	-0.33	-0.33	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
STAD	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	6.44	3.94e-10	6.05e-07	0.38	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
STAD	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	6.44	3.94e-10	6.05e-07	0.55	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
STAD	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	6.44	3.94e-10	6.06e-07	0.33	0.33	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
STAD	cis	rs2273156	0.57	rs11156875	ENSG00000241052.1	RP11-173D9.1	-6.44	3.95e-10	6.07e-07	-0.38	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:35150610	chr14:35144021~35144480:-
STAD	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	6.44	3.96e-10	6.09e-07	0.4	0.33	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
STAD	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	6.44	3.97e-10	6.1e-07	0.38	0.33	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	6.44	3.97e-10	6.1e-07	0.4	0.33	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
STAD	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-6.44	3.97e-10	6.1e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-6.44	3.97e-10	6.1e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-6.44	3.97e-10	6.1e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-6.44	3.97e-10	6.1e-07	-0.44	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
STAD	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-6.44	3.98e-10	6.1e-07	-0.44	-0.33	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-6.44	3.98e-10	6.1e-07	-0.44	-0.33	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
STAD	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-6.44	3.98e-10	6.1e-07	-0.44	-0.33	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
STAD	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-6.44	3.98e-10	6.1e-07	-0.34	-0.33	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
STAD	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-6.44	3.99e-10	6.12e-07	-0.43	-0.33	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
STAD	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-6.44	3.99e-10	6.13e-07	-0.39	-0.33	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
STAD	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	6.44	4e-10	6.13e-07	0.4	0.33	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
STAD	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	6.44	4e-10	6.13e-07	0.41	0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
STAD	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	6.44	4e-10	6.13e-07	0.37	0.33	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
STAD	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	6.44	4e-10	6.13e-07	0.37	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
STAD	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-6.44	4e-10	6.13e-07	-0.34	-0.33	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
STAD	cis	rs6452524	0.869	rs10051155	ENSG00000243385.2	CTD-2110K23.1	6.44	4.01e-10	6.14e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83201229~83202141:+
STAD	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-6.44	4.01e-10	6.14e-07	-0.42	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
STAD	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	6.44	4.02e-10	6.15e-07	0.45	0.33	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
STAD	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	6.44	4.04e-10	6.19e-07	0.34	0.33	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
STAD	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-6.44	4.05e-10	6.19e-07	-0.38	-0.33	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-6.44	4.05e-10	6.19e-07	-0.38	-0.33	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-6.44	4.05e-10	6.19e-07	-0.38	-0.33	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	6.44	4.05e-10	6.2e-07	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
STAD	cis	rs2221894	0.96	rs10093622	ENSG00000273710.1	Metazoa_SRP	-6.44	4.05e-10	6.2e-07	-0.36	-0.33	Obesity-related traits;	chr8:29005420	chr8:28915579~28915864:-
STAD	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-6.44	4.06e-10	6.21e-07	-0.24	-0.33	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
STAD	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-6.44	4.06e-10	6.22e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-6.44	4.06e-10	6.22e-07	-0.4	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
STAD	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-6.44	4.06e-10	6.22e-07	-0.48	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
STAD	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-6.44	4.07e-10	6.22e-07	-0.39	-0.33	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
STAD	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-6.44	4.07e-10	6.23e-07	-0.34	-0.33	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-6.44	4.07e-10	6.23e-07	-0.34	-0.33	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
STAD	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-6.44	4.07e-10	6.23e-07	-0.31	-0.33	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
STAD	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	6.44	4.08e-10	6.24e-07	0.41	0.33	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
STAD	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	6.44	4.08e-10	6.24e-07	0.41	0.33	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
STAD	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	6.44	4.09e-10	6.25e-07	0.4	0.33	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
STAD	cis	rs2439831	0.85	rs2957637	ENSG00000249839.1	AC011330.5	-6.44	4.09e-10	6.26e-07	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43658920	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-6.44	4.1e-10	6.26e-07	-0.28	-0.33	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-6.44	4.1e-10	6.26e-07	-0.28	-0.33	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000224205.1	AP000351.4	-6.44	4.1e-10	6.26e-07	-0.38	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23987320~23991421:-
STAD	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-6.44	4.1e-10	6.27e-07	-0.46	-0.33	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
STAD	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	6.44	4.1e-10	6.27e-07	0.4	0.33	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
STAD	cis	rs7927771	0.698	rs34467936	ENSG00000280615.1	Y_RNA	-6.44	4.1e-10	6.27e-07	-0.34	-0.33	Subjective well-being;	chr11:47893747	chr11:47614898~47614994:-
STAD	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	6.44	4.12e-10	6.29e-07	0.38	0.33	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
STAD	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-6.43	4.12e-10	6.3e-07	-0.37	-0.33	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
STAD	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-6.43	4.13e-10	6.31e-07	-0.36	-0.33	Height;	chr3:52992698	chr3:53064283~53065091:-
STAD	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	6.43	4.14e-10	6.33e-07	0.37	0.33	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
STAD	cis	rs1426063	0.614	rs17000262	ENSG00000248165.1	RP11-44F21.2	6.43	4.16e-10	6.35e-07	0.63	0.33	QT interval;	chr4:75108836	chr4:74993877~75034824:-
STAD	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	6.43	4.16e-10	6.35e-07	0.44	0.33	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
STAD	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	6.43	4.16e-10	6.36e-07	0.41	0.33	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
STAD	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-6.43	4.17e-10	6.37e-07	-0.36	-0.33	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-6.43	4.17e-10	6.37e-07	-0.36	-0.33	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
STAD	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-6.43	4.17e-10	6.37e-07	-0.28	-0.33	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-6.43	4.18e-10	6.38e-07	-0.36	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
STAD	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	6.43	4.18e-10	6.38e-07	0.41	0.33	Height;	chr6:109507364	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	6.43	4.18e-10	6.38e-07	0.41	0.33	Height;	chr6:109507366	chr6:109382795~109383666:+
STAD	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-6.43	4.19e-10	6.39e-07	-0.46	-0.33	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
STAD	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-6.43	4.19e-10	6.39e-07	-0.4	-0.33	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-6.43	4.19e-10	6.39e-07	-0.4	-0.33	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
STAD	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	6.43	4.19e-10	6.39e-07	0.39	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
STAD	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	6.43	4.19e-10	6.4e-07	0.38	0.33	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
STAD	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-6.43	4.2e-10	6.41e-07	-0.4	-0.33	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
STAD	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-6.43	4.2e-10	6.41e-07	-0.39	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
STAD	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-6.43	4.21e-10	6.41e-07	-0.44	-0.33	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
STAD	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	6.43	4.21e-10	6.41e-07	0.34	0.33	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	6.43	4.21e-10	6.41e-07	0.34	0.33	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	6.43	4.21e-10	6.41e-07	0.34	0.33	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
STAD	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	6.43	4.21e-10	6.41e-07	0.34	0.33	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	6.43	4.21e-10	6.41e-07	0.34	0.33	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
STAD	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	6.43	4.21e-10	6.41e-07	0.34	0.33	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
STAD	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	6.43	4.21e-10	6.41e-07	0.4	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
STAD	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	6.43	4.21e-10	6.42e-07	0.41	0.33	Height;	chr6:109495102	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	6.43	4.21e-10	6.42e-07	0.41	0.33	Height;	chr6:109496680	chr6:109382795~109383666:+
STAD	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-6.43	4.23e-10	6.44e-07	-0.34	-0.33	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
STAD	cis	rs228614	0.509	rs223486	ENSG00000230069.3	LRRC37A15P	-6.43	4.23e-10	6.44e-07	-0.34	-0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102727274~102730721:-
STAD	cis	rs732716	0.853	rs72990643	ENSG00000267980.1	AC007292.6	-6.43	4.23e-10	6.44e-07	-0.44	-0.33	Mean corpuscular volume;	chr19:4454739	chr19:4363789~4364640:+
STAD	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-6.43	4.23e-10	6.45e-07	-0.28	-0.33	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
STAD	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-6.43	4.25e-10	6.47e-07	-0.34	-0.33	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
STAD	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-6.43	4.25e-10	6.48e-07	-0.41	-0.33	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
STAD	cis	rs9368481	0.761	rs7775041	ENSG00000243307.2	POM121L6P	-6.43	4.25e-10	6.48e-07	-0.34	-0.33	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26896952~26898777:+
STAD	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-6.43	4.27e-10	6.5e-07	-0.38	-0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
STAD	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-6.43	4.28e-10	6.5e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-6.43	4.28e-10	6.5e-07	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
STAD	cis	rs6452524	0.836	rs62374402	ENSG00000243385.2	CTD-2110K23.1	6.43	4.29e-10	6.52e-07	0.39	0.33	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.804	rs2048215	ENSG00000243385.2	CTD-2110K23.1	-6.43	4.29e-10	6.52e-07	-0.39	-0.33	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.836	rs11949301	ENSG00000243385.2	CTD-2110K23.1	-6.43	4.29e-10	6.52e-07	-0.39	-0.33	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83201229~83202141:+
STAD	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	6.43	4.29e-10	6.53e-07	0.42	0.33	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
STAD	cis	rs611744	0.806	rs2514846	ENSG00000253754.1	RP11-35G22.1	-6.43	4.29e-10	6.53e-07	-0.29	-0.33	Dupuytren's disease;	chr8:108054877	chr8:108226200~108227544:+
STAD	cis	rs13217239	0.574	rs9366680	ENSG00000243307.2	POM121L6P	6.43	4.3e-10	6.54e-07	0.31	0.33	Schizophrenia;	chr6:27038344	chr6:26896952~26898777:+
STAD	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-6.43	4.3e-10	6.54e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
STAD	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-6.43	4.33e-10	6.59e-07	-0.29	-0.33	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
STAD	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	6.43	4.35e-10	6.62e-07	0.28	0.33	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
STAD	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-6.43	4.36e-10	6.62e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
STAD	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-6.43	4.36e-10	6.62e-07	-0.36	-0.33	Height;	chr3:52991821	chr3:53064283~53065091:-
STAD	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-6.43	4.36e-10	6.63e-07	-0.33	-0.33	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
STAD	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	6.42	4.37e-10	6.64e-07	0.37	0.33	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	6.42	4.37e-10	6.64e-07	0.37	0.33	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
STAD	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-6.42	4.37e-10	6.64e-07	-0.34	-0.33	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
STAD	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-6.42	4.38e-10	6.65e-07	-0.42	-0.33	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-6.42	4.38e-10	6.65e-07	-0.42	-0.33	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-6.42	4.38e-10	6.65e-07	-0.42	-0.33	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
STAD	cis	rs6452524	0.905	rs7736289	ENSG00000243385.2	CTD-2110K23.1	6.42	4.39e-10	6.67e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83201229~83202141:+
STAD	cis	rs9549260	0.755	rs8001443	ENSG00000229456.1	RLIMP1	-6.42	4.4e-10	6.68e-07	-0.29	-0.33	Red blood cell count;	chr13:40642509	chr13:40618738~40621348:+
STAD	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-6.42	4.4e-10	6.68e-07	-0.43	-0.33	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
STAD	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-6.42	4.42e-10	6.7e-07	-0.29	-0.33	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
STAD	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-6.42	4.42e-10	6.71e-07	-0.34	-0.33	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-6.42	4.42e-10	6.71e-07	-0.34	-0.33	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
STAD	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-6.42	4.42e-10	6.71e-07	-0.36	-0.33	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
STAD	cis	rs11235843	0.636	rs10736793	ENSG00000255928.1	RP11-456I15.2	-6.42	4.43e-10	6.73e-07	-0.44	-0.33	Hand grip strength;	chr11:73691531	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.636	rs1464908	ENSG00000255928.1	RP11-456I15.2	-6.42	4.43e-10	6.73e-07	-0.44	-0.33	Hand grip strength;	chr11:73691634	chr11:73722349~73722694:+
STAD	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	6.42	4.43e-10	6.73e-07	0.37	0.33	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
STAD	cis	rs875971	0.666	rs13242072	ENSG00000222364.1	RNU6-96P	6.42	4.45e-10	6.75e-07	0.37	0.33	Aortic root size;	chr7:66301001	chr7:66395191~66395286:+
STAD	cis	rs1005277	0.563	rs2505215	ENSG00000099251.13	HSD17B7P2	6.42	4.46e-10	6.76e-07	0.36	0.33	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.563	rs2505216	ENSG00000099251.13	HSD17B7P2	6.42	4.46e-10	6.76e-07	0.36	0.33	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.563	rs2800550	ENSG00000099251.13	HSD17B7P2	6.42	4.46e-10	6.76e-07	0.36	0.33	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38356380~38378505:+
STAD	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	6.42	4.46e-10	6.77e-07	0.28	0.33	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-6.42	4.47e-10	6.78e-07	-0.28	-0.33	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
STAD	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	6.42	4.47e-10	6.78e-07	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
STAD	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	6.42	4.47e-10	6.78e-07	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
STAD	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-6.42	4.49e-10	6.81e-07	-0.36	-0.33	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
STAD	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-6.42	4.49e-10	6.81e-07	-0.34	-0.33	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-6.42	4.49e-10	6.81e-07	-0.34	-0.33	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
STAD	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	6.42	4.5e-10	6.82e-07	0.39	0.33	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
STAD	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-6.42	4.51e-10	6.84e-07	-0.33	-0.33	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-6.42	4.51e-10	6.84e-07	-0.33	-0.33	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-6.42	4.51e-10	6.84e-07	-0.33	-0.33	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-6.42	4.51e-10	6.84e-07	-0.33	-0.33	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-6.42	4.51e-10	6.84e-07	-0.33	-0.33	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-6.42	4.51e-10	6.84e-07	-0.33	-0.33	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
STAD	cis	rs66823261	0.741	rs7841786	ENSG00000253166.2	RP11-585F1.6	-6.42	4.51e-10	6.84e-07	-0.47	-0.33	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:202660~202897:-
STAD	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-6.42	4.51e-10	6.84e-07	-0.31	-0.33	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
STAD	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	6.42	4.52e-10	6.85e-07	0.33	0.33	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
STAD	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-6.42	4.54e-10	6.88e-07	-0.48	-0.33	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
STAD	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-6.42	4.57e-10	6.92e-07	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
STAD	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	6.42	4.58e-10	6.93e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
STAD	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-6.42	4.58e-10	6.94e-07	-0.35	-0.33	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
STAD	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	6.42	4.59e-10	6.95e-07	0.34	0.33	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
STAD	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	6.42	4.59e-10	6.95e-07	0.34	0.33	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
STAD	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	6.42	4.59e-10	6.95e-07	0.34	0.33	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
STAD	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-6.42	4.62e-10	6.98e-07	-0.29	-0.33	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	6.42	4.62e-10	6.99e-07	0.37	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
STAD	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-6.42	4.62e-10	6.99e-07	-0.34	-0.33	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
STAD	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	6.41	4.64e-10	7.01e-07	0.37	0.33	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	6.41	4.64e-10	7.01e-07	0.37	0.33	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-6.41	4.64e-10	7.01e-07	-0.37	-0.33	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
STAD	cis	rs2273156	0.5	rs17103104	ENSG00000241052.1	RP11-173D9.1	-6.41	4.64e-10	7.02e-07	-0.49	-0.33	Immunoglobulin light chain (AL) amyloidosis;	chr14:35221772	chr14:35144021~35144480:-
STAD	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	6.41	4.66e-10	7.04e-07	0.51	0.33	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
STAD	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	6.41	4.66e-10	7.05e-07	0.42	0.33	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
STAD	cis	rs11089937	0.524	rs2877021	ENSG00000211639.2	IGLV4-60	6.41	4.7e-10	7.1e-07	0.34	0.33	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22162199~22162681:+
STAD	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	6.41	4.7e-10	7.1e-07	0.4	0.33	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
STAD	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-6.41	4.71e-10	7.11e-07	-0.34	-0.33	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
STAD	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	6.41	4.72e-10	7.12e-07	0.42	0.33	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
STAD	cis	rs7615952	0.512	rs4679430	ENSG00000272840.1	RP11-379B18.6	6.41	4.73e-10	7.13e-07	0.51	0.33	Blood pressure (smoking interaction);	chr3:125639049	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.512	rs34651730	ENSG00000272840.1	RP11-379B18.6	6.41	4.73e-10	7.13e-07	0.51	0.33	Blood pressure (smoking interaction);	chr3:125639796	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.512	rs11929125	ENSG00000272840.1	RP11-379B18.6	6.41	4.73e-10	7.13e-07	0.51	0.33	Blood pressure (smoking interaction);	chr3:125640599	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.512	rs2922175	ENSG00000272840.1	RP11-379B18.6	6.41	4.73e-10	7.13e-07	0.51	0.33	Blood pressure (smoking interaction);	chr3:125642516	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.512	rs2979336	ENSG00000272840.1	RP11-379B18.6	6.41	4.73e-10	7.14e-07	0.51	0.33	Blood pressure (smoking interaction);	chr3:125638626	chr3:125774714~125797953:+
STAD	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-6.41	4.73e-10	7.14e-07	-0.38	-0.33	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
STAD	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-6.41	4.76e-10	7.18e-07	-0.34	-0.33	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-6.41	4.8e-10	7.25e-07	-0.24	-0.33	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	6.41	4.81e-10	7.26e-07	0.4	0.33	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	6.41	4.81e-10	7.26e-07	0.4	0.33	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
STAD	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-6.41	4.82e-10	7.27e-07	-0.34	-0.33	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
STAD	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-6.41	4.86e-10	7.32e-07	-0.33	-0.33	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
STAD	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	6.41	4.86e-10	7.32e-07	0.41	0.33	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
STAD	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	6.41	4.88e-10	7.35e-07	0.43	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
STAD	cis	rs10461617	0.617	rs1423623	ENSG00000271828.1	CTD-2310F14.1	-6.41	4.9e-10	7.38e-07	-0.37	-0.33	Type 2 diabetes;	chr5:56769748	chr5:56927874~56929573:+
STAD	cis	rs6452524	1	rs7733151	ENSG00000243385.2	CTD-2110K23.1	6.41	4.91e-10	7.39e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs7733330	ENSG00000243385.2	CTD-2110K23.1	6.41	4.91e-10	7.39e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs7733354	ENSG00000243385.2	CTD-2110K23.1	6.41	4.91e-10	7.39e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs4634330	ENSG00000243385.2	CTD-2110K23.1	6.41	4.91e-10	7.39e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs2386238	ENSG00000243385.2	CTD-2110K23.1	6.41	4.91e-10	7.39e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs2386239	ENSG00000243385.2	CTD-2110K23.1	6.41	4.91e-10	7.39e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83201229~83202141:+
STAD	cis	rs7826238	0.594	rs2948285	ENSG00000253981.4	ALG1L13P	6.4	4.91e-10	7.4e-07	0.39	0.33	Systolic blood pressure;	chr8:8273016	chr8:8236003~8244667:-
STAD	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	6.4	4.92e-10	7.42e-07	0.44	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
STAD	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	6.4	4.93e-10	7.42e-07	0.33	0.33	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
STAD	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-6.4	4.93e-10	7.42e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
STAD	cis	rs2221894	0.959	rs28679662	ENSG00000273710.1	Metazoa_SRP	6.4	4.93e-10	7.43e-07	0.36	0.33	Obesity-related traits;	chr8:29033270	chr8:28915579~28915864:-
STAD	cis	rs9549260	0.651	rs9549251	ENSG00000229456.1	RLIMP1	6.4	4.94e-10	7.44e-07	0.29	0.33	Red blood cell count;	chr13:40654513	chr13:40618738~40621348:+
STAD	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-6.4	4.96e-10	7.47e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
STAD	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	6.4	4.96e-10	7.47e-07	0.39	0.33	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
STAD	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	6.4	4.97e-10	7.48e-07	0.46	0.33	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	6.4	4.97e-10	7.48e-07	0.46	0.33	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
STAD	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-6.4	4.98e-10	7.49e-07	-0.38	-0.33	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
STAD	cis	rs2833693	0.656	rs2833697	ENSG00000261610.1	AP000265.1	6.4	4.99e-10	7.5e-07	0.37	0.33	Temperament;	chr21:32183825	chr21:32259804~32261585:-
STAD	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-6.4	5e-10	7.51e-07	-0.42	-0.33	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
STAD	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-6.4	5.01e-10	7.53e-07	-0.36	-0.33	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
STAD	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-6.4	5.02e-10	7.54e-07	-0.31	-0.33	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-6.4	5.02e-10	7.54e-07	-0.31	-0.33	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
STAD	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-6.4	5.02e-10	7.55e-07	-0.33	-0.33	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
STAD	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	6.4	5.04e-10	7.58e-07	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
STAD	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-6.4	5.04e-10	7.58e-07	-0.33	-0.33	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
STAD	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-6.4	5.04e-10	7.58e-07	-0.34	-0.33	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.934	rs7700253	ENSG00000243385.2	CTD-2110K23.1	6.4	5.04e-10	7.58e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83201229~83202141:+
STAD	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-6.4	5.05e-10	7.6e-07	-0.43	-0.33	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
STAD	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-6.4	5.06e-10	7.6e-07	-0.31	-0.33	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
STAD	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	6.4	5.09e-10	7.64e-07	0.31	0.33	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
STAD	cis	rs7615952	0.558	rs17334039	ENSG00000272840.1	RP11-379B18.6	6.4	5.1e-10	7.65e-07	0.45	0.33	Blood pressure (smoking interaction);	chr3:125821465	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.688	rs12638240	ENSG00000272840.1	RP11-379B18.6	6.4	5.1e-10	7.65e-07	0.45	0.33	Blood pressure (smoking interaction);	chr3:125822395	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.688	rs12638224	ENSG00000272840.1	RP11-379B18.6	6.4	5.1e-10	7.65e-07	0.45	0.33	Blood pressure (smoking interaction);	chr3:125822477	chr3:125774714~125797953:+
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	6.4	5.1e-10	7.66e-07	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
STAD	cis	rs11089937	0.559	rs2330014	ENSG00000211639.2	IGLV4-60	6.4	5.11e-10	7.67e-07	0.35	0.33	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22162199~22162681:+
STAD	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	6.4	5.11e-10	7.67e-07	0.4	0.33	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	6.4	5.11e-10	7.67e-07	0.4	0.33	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
STAD	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	6.4	5.11e-10	7.67e-07	0.4	0.33	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
STAD	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-6.4	5.12e-10	7.68e-07	-0.39	-0.33	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
STAD	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-6.4	5.14e-10	7.71e-07	-0.32	-0.33	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
STAD	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-6.4	5.15e-10	7.73e-07	-0.35	-0.33	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
STAD	cis	rs6452524	0.935	rs1011979	ENSG00000243385.2	CTD-2110K23.1	6.4	5.15e-10	7.74e-07	0.35	0.33	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83201229~83202141:+
STAD	cis	rs7487075	0.578	rs4768118	ENSG00000272369.1	RP11-446N19.1	6.4	5.17e-10	7.75e-07	0.41	0.33	Itch intensity from mosquito bite;	chr12:46390961	chr12:46537502~46652550:+
STAD	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	6.4	5.18e-10	7.76e-07	0.39	0.33	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
STAD	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-6.4	5.19e-10	7.79e-07	-0.34	-0.33	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
STAD	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	6.4	5.2e-10	7.79e-07	0.37	0.33	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
STAD	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-6.4	5.2e-10	7.8e-07	-0.41	-0.33	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
STAD	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-6.4	5.2e-10	7.8e-07	-0.37	-0.33	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
STAD	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	6.4	5.2e-10	7.8e-07	0.4	0.33	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
STAD	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	6.39	5.21e-10	7.81e-07	0.49	0.33	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
STAD	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	6.39	5.21e-10	7.81e-07	0.49	0.33	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
STAD	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-6.39	5.21e-10	7.82e-07	-0.34	-0.33	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
STAD	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-6.39	5.21e-10	7.82e-07	-0.34	-0.33	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
STAD	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	6.39	5.22e-10	7.83e-07	0.33	0.33	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
STAD	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-6.39	5.22e-10	7.83e-07	-0.34	-0.33	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
STAD	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-6.39	5.22e-10	7.83e-07	-0.37	-0.33	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
STAD	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	6.39	5.23e-10	7.83e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
STAD	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	6.39	5.23e-10	7.83e-07	0.43	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
STAD	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	6.39	5.23e-10	7.84e-07	0.29	0.33	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
STAD	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	6.39	5.24e-10	7.85e-07	0.37	0.33	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
STAD	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	6.39	5.24e-10	7.86e-07	0.24	0.33	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
STAD	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-6.39	5.24e-10	7.86e-07	-0.33	-0.33	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
STAD	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	6.39	5.25e-10	7.86e-07	0.37	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
STAD	cis	rs10885997	1	rs10885997	ENSG00000266200.5	PNLIPRP2	6.39	5.25e-10	7.87e-07	0.4	0.33	Phospholipid levels (plasma);	chr10:116638460	chr10:116620953~116645143:+
STAD	cis	rs7487075	0.78	rs1873793	ENSG00000272369.1	RP11-446N19.1	-6.39	5.25e-10	7.87e-07	-0.38	-0.33	Itch intensity from mosquito bite;	chr12:46367541	chr12:46537502~46652550:+
STAD	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	6.39	5.26e-10	7.87e-07	0.38	0.33	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
STAD	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	6.39	5.27e-10	7.89e-07	0.42	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	6.39	5.27e-10	7.89e-07	0.42	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	6.39	5.27e-10	7.89e-07	0.42	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
STAD	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	6.39	5.28e-10	7.9e-07	0.36	0.33	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
STAD	cis	rs6452524	0.935	rs6868416	ENSG00000243385.2	CTD-2110K23.1	6.39	5.29e-10	7.92e-07	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs1478485	ENSG00000243385.2	CTD-2110K23.1	6.39	5.29e-10	7.92e-07	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83201229~83202141:+
STAD	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-6.39	5.29e-10	7.92e-07	-0.34	-0.32	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
STAD	cis	rs881375	0.967	rs3761849	ENSG00000226752.6	PSMD5-AS1	-6.39	5.29e-10	7.92e-07	-0.38	-0.32	Rheumatoid arthritis;	chr9:120928679	chr9:120824828~120854385:+
STAD	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	6.39	5.3e-10	7.93e-07	0.37	0.32	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
STAD	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-6.39	5.31e-10	7.94e-07	-0.35	-0.32	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-6.39	5.31e-10	7.94e-07	-0.35	-0.32	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
STAD	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	6.39	5.31e-10	7.95e-07	0.39	0.32	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
STAD	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	6.39	5.31e-10	7.95e-07	0.39	0.32	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
STAD	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-6.39	5.32e-10	7.95e-07	-0.31	-0.32	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
STAD	cis	rs10885997	0.967	rs4751994	ENSG00000266200.5	PNLIPRP2	6.39	5.32e-10	7.96e-07	0.4	0.32	Phospholipid levels (plasma);	chr10:116638048	chr10:116620953~116645143:+
STAD	cis	rs7580658	0.68	rs6710535	ENSG00000200250.1	RNU6-1147P	-6.39	5.32e-10	7.96e-07	-0.31	-0.32	Protein C levels;	chr2:127433384	chr2:127316873~127316979:+
STAD	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	6.39	5.33e-10	7.97e-07	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
STAD	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-6.39	5.35e-10	8e-07	-0.33	-0.32	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-6.39	5.35e-10	8e-07	-0.33	-0.32	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-6.39	5.35e-10	8e-07	-0.33	-0.32	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
STAD	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-6.39	5.37e-10	8.03e-07	-0.36	-0.32	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
STAD	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-6.39	5.37e-10	8.03e-07	-0.55	-0.32	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-6.39	5.39e-10	8.05e-07	-0.28	-0.32	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
STAD	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-6.39	5.41e-10	8.08e-07	-0.32	-0.32	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
STAD	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-6.39	5.44e-10	8.12e-07	-0.52	-0.32	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
STAD	cis	rs2221894	0.959	rs2129784	ENSG00000273710.1	Metazoa_SRP	6.39	5.44e-10	8.13e-07	0.36	0.32	Obesity-related traits;	chr8:29042480	chr8:28915579~28915864:-
STAD	cis	rs6456156	0.805	rs6909252	ENSG00000265828.1	MIR3939	6.39	5.45e-10	8.15e-07	0.36	0.32	Primary biliary cholangitis;	chr6:167113609	chr6:166997807~166997912:-
STAD	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	6.39	5.45e-10	8.15e-07	0.4	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
STAD	cis	rs992157	1	rs992157	ENSG00000237281.1	CATIP-AS2	6.39	5.46e-10	8.16e-07	0.33	0.32	Colorectal cancer;	chr2:218290058	chr2:218326889~218357966:-
STAD	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-6.39	5.46e-10	8.16e-07	-0.34	-0.32	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
STAD	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	6.39	5.47e-10	8.17e-07	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	6.39	5.47e-10	8.17e-07	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	6.39	5.47e-10	8.17e-07	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
STAD	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	6.39	5.48e-10	8.18e-07	0.37	0.32	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
STAD	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	6.39	5.49e-10	8.19e-07	0.38	0.32	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
STAD	cis	rs11089937	0.589	rs4239891	ENSG00000211639.2	IGLV4-60	6.39	5.49e-10	8.19e-07	0.34	0.32	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22162199~22162681:+
STAD	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-6.39	5.49e-10	8.19e-07	-0.33	-0.32	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
STAD	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-6.39	5.5e-10	8.2e-07	-0.34	-0.32	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
STAD	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-6.39	5.5e-10	8.21e-07	-0.38	-0.32	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
STAD	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-6.39	5.5e-10	8.21e-07	-0.38	-0.32	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-6.39	5.5e-10	8.21e-07	-0.38	-0.32	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
STAD	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	6.39	5.5e-10	8.22e-07	0.3	0.32	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
STAD	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	6.38	5.54e-10	8.26e-07	0.34	0.32	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-6.38	5.54e-10	8.26e-07	-0.29	-0.32	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
STAD	cis	rs8040855	0.825	rs3964197	ENSG00000229212.6	RP11-561C5.4	6.38	5.54e-10	8.26e-07	0.45	0.32	Bulimia nervosa;	chr15:85178681	chr15:85205440~85234795:-
STAD	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-6.38	5.55e-10	8.27e-07	-0.44	-0.32	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
STAD	cis	rs11089937	0.626	rs9622968	ENSG00000211639.2	IGLV4-60	6.38	5.55e-10	8.27e-07	0.35	0.32	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22162199~22162681:+
STAD	cis	rs6452524	1	rs10069402	ENSG00000243385.2	CTD-2110K23.1	6.38	5.55e-10	8.27e-07	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83201229~83202141:+
STAD	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	6.38	5.56e-10	8.29e-07	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	6.38	5.56e-10	8.29e-07	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	6.38	5.56e-10	8.29e-07	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	6.38	5.56e-10	8.29e-07	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
STAD	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-6.38	5.58e-10	8.32e-07	-0.33	-0.32	Asthma;	chr2:102394777	chr2:102438713~102440475:+
STAD	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	6.38	5.59e-10	8.33e-07	0.3	0.32	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	6.38	5.59e-10	8.33e-07	0.3	0.32	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	6.38	5.59e-10	8.33e-07	0.3	0.32	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	6.38	5.59e-10	8.33e-07	0.3	0.32	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	6.38	5.59e-10	8.33e-07	0.3	0.32	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	6.38	5.59e-10	8.33e-07	0.3	0.32	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	6.38	5.59e-10	8.33e-07	0.3	0.32	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
STAD	cis	rs2273156	0.5	rs17103120	ENSG00000241052.1	RP11-173D9.1	6.38	5.59e-10	8.33e-07	0.49	0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:35234633	chr14:35144021~35144480:-
STAD	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	6.38	5.63e-10	8.38e-07	0.34	0.32	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
STAD	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	6.38	5.64e-10	8.39e-07	0.38	0.32	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
STAD	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	6.38	5.64e-10	8.4e-07	0.43	0.32	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
STAD	cis	rs6452524	1	rs10067439	ENSG00000243385.2	CTD-2110K23.1	6.38	5.66e-10	8.42e-07	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83201229~83202141:+
STAD	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	6.38	5.66e-10	8.42e-07	0.47	0.32	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	6.38	5.66e-10	8.42e-07	0.47	0.32	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	6.38	5.66e-10	8.42e-07	0.47	0.32	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	6.38	5.66e-10	8.42e-07	0.47	0.32	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	6.38	5.66e-10	8.42e-07	0.47	0.32	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
STAD	cis	rs4568518	0.501	rs6966247	ENSG00000279048.1	RP11-511H23.2	6.38	5.7e-10	8.47e-07	0.29	0.32	Measles;	chr7:17949624	chr7:17940503~17942922:+
STAD	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	6.38	5.7e-10	8.48e-07	0.42	0.32	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
STAD	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	6.38	5.72e-10	8.5e-07	0.34	0.32	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	6.38	5.72e-10	8.5e-07	0.34	0.32	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
STAD	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-6.38	5.72e-10	8.5e-07	-0.34	-0.32	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-6.38	5.72e-10	8.5e-07	-0.34	-0.32	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
STAD	cis	rs1426063	0.748	rs6534607	ENSG00000248165.1	RP11-44F21.2	6.38	5.72e-10	8.51e-07	0.43	0.32	QT interval;	chr4:75106366	chr4:74993877~75034824:-
STAD	cis	rs875971	0.558	rs4433015	ENSG00000222364.1	RNU6-96P	6.38	5.74e-10	8.52e-07	0.36	0.32	Aortic root size;	chr7:66174736	chr7:66395191~66395286:+
STAD	cis	rs6452524	0.78	rs2386237	ENSG00000243385.2	CTD-2110K23.1	6.38	5.74e-10	8.53e-07	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83201229~83202141:+
STAD	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	6.38	5.75e-10	8.54e-07	0.48	0.32	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
STAD	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-6.38	5.76e-10	8.56e-07	-0.34	-0.32	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
STAD	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-6.38	5.78e-10	8.58e-07	-0.34	-0.32	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
STAD	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-6.38	5.78e-10	8.58e-07	-0.38	-0.32	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
STAD	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-6.38	5.78e-10	8.58e-07	-0.41	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
STAD	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-6.38	5.79e-10	8.6e-07	-0.29	-0.32	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
STAD	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	6.38	5.81e-10	8.62e-07	0.52	0.32	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
STAD	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-6.38	5.82e-10	8.63e-07	-0.32	-0.32	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
STAD	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	6.37	5.85e-10	8.68e-07	0.52	0.32	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	6.37	5.85e-10	8.68e-07	0.52	0.32	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
STAD	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-6.37	5.86e-10	8.68e-07	-0.5	-0.32	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
STAD	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-6.37	5.86e-10	8.69e-07	-0.36	-0.32	Height;	chr3:52989619	chr3:53064283~53065091:-
STAD	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	6.37	5.86e-10	8.69e-07	0.4	0.32	Height;	chr6:109407238	chr6:109382795~109383666:+
STAD	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-6.37	5.9e-10	8.73e-07	-0.34	-0.32	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
STAD	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-6.37	5.9e-10	8.74e-07	-0.36	-0.32	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
STAD	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	6.37	5.91e-10	8.76e-07	0.3	0.32	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
STAD	cis	rs11079159	0.606	rs876720	ENSG00000263096.1	RP11-515O17.2	-6.37	5.91e-10	8.76e-07	-0.39	-0.32	QRS duration;	chr17:55289154	chr17:55271504~55273653:-
STAD	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	6.37	5.91e-10	8.76e-07	0.42	0.32	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
STAD	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	6.37	5.91e-10	8.76e-07	0.44	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
STAD	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	6.37	5.93e-10	8.78e-07	0.38	0.32	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
STAD	cis	rs748404	0.736	rs542036	ENSG00000249839.1	AC011330.5	6.37	5.94e-10	8.79e-07	0.44	0.32	Lung cancer;	chr15:43248941	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	6.37	5.95e-10	8.81e-07	0.39	0.32	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
STAD	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-6.37	6.03e-10	8.92e-07	-0.33	-0.32	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-6.37	6.03e-10	8.92e-07	-0.33	-0.32	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-6.37	6.03e-10	8.92e-07	-0.33	-0.32	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-6.37	6.03e-10	8.92e-07	-0.33	-0.32	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
STAD	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	6.37	6.03e-10	8.92e-07	0.4	0.32	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
STAD	cis	rs4568518	0.502	rs4544985	ENSG00000279048.1	RP11-511H23.2	6.37	6.07e-10	8.97e-07	0.29	0.32	Measles;	chr7:17944184	chr7:17940503~17942922:+
STAD	cis	rs1005277	0.579	rs1780137	ENSG00000099251.13	HSD17B7P2	6.37	6.07e-10	8.97e-07	0.36	0.32	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38356380~38378505:+
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-6.37	6.07e-10	8.98e-07	-0.41	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
STAD	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	6.37	6.1e-10	9.02e-07	0.31	0.32	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
STAD	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	6.37	6.1e-10	9.02e-07	0.31	0.32	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
STAD	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	6.37	6.11e-10	9.03e-07	0.37	0.32	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
STAD	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-6.37	6.11e-10	9.03e-07	-0.41	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
STAD	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-6.37	6.13e-10	9.06e-07	-0.28	-0.32	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
STAD	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	6.37	6.14e-10	9.07e-07	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
STAD	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-6.37	6.15e-10	9.09e-07	-0.46	-0.32	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
STAD	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-6.37	6.17e-10	9.12e-07	-0.33	-0.32	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
STAD	cis	rs732716	0.853	rs12459922	ENSG00000267980.1	AC007292.6	-6.37	6.18e-10	9.12e-07	-0.44	-0.32	Mean corpuscular volume;	chr19:4455865	chr19:4363789~4364640:+
STAD	cis	rs7927771	0.832	rs10838704	ENSG00000280615.1	Y_RNA	-6.37	6.19e-10	9.13e-07	-0.34	-0.32	Subjective well-being;	chr11:47403166	chr11:47614898~47614994:-
STAD	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-6.36	6.21e-10	9.17e-07	-0.31	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
STAD	cis	rs453301	0.624	rs2915251	ENSG00000254340.1	RP11-10A14.3	6.36	6.21e-10	9.17e-07	0.39	0.32	Joint mobility (Beighton score);	chr8:9009901	chr8:9141424~9145435:+
STAD	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	6.36	6.22e-10	9.18e-07	0.43	0.32	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
STAD	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-6.36	6.23e-10	9.19e-07	-0.38	-0.32	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
STAD	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	6.36	6.23e-10	9.2e-07	0.34	0.32	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
STAD	cis	rs2833693	0.572	rs2833715	ENSG00000261610.1	AP000265.1	6.36	6.25e-10	9.22e-07	0.37	0.32	Temperament;	chr21:32192268	chr21:32259804~32261585:-
STAD	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-6.36	6.28e-10	9.26e-07	-0.33	-0.32	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
STAD	cis	rs3758911	0.894	rs10749902	ENSG00000261098.1	RP11-819C21.1	-6.36	6.29e-10	9.28e-07	-0.31	-0.32	Coronary artery disease;	chr11:107324855	chr11:107312132~107316271:-
STAD	cis	rs4568518	0.53	rs10226084	ENSG00000279048.1	RP11-511H23.2	6.36	6.31e-10	9.31e-07	0.3	0.32	Measles;	chr7:17957989	chr7:17940503~17942922:+
STAD	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	6.36	6.31e-10	9.31e-07	0.51	0.32	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
STAD	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	6.36	6.32e-10	9.32e-07	0.28	0.32	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
STAD	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-6.36	6.33e-10	9.33e-07	-0.31	-0.32	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
STAD	cis	rs6782228	0.628	rs7641584	ENSG00000277250.1	Metazoa_SRP	-6.36	6.33e-10	9.33e-07	-0.33	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128673681~128674021:-
STAD	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	6.36	6.33e-10	9.33e-07	0.4	0.32	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	6.36	6.33e-10	9.33e-07	0.4	0.32	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	6.36	6.33e-10	9.33e-07	0.4	0.32	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	6.36	6.33e-10	9.33e-07	0.4	0.32	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
STAD	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	6.36	6.33e-10	9.33e-07	0.28	0.32	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
STAD	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	6.36	6.33e-10	9.33e-07	0.39	0.32	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
STAD	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-6.36	6.35e-10	9.36e-07	-0.33	-0.32	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
STAD	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	6.36	6.35e-10	9.37e-07	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
STAD	cis	rs9549260	0.755	rs4943800	ENSG00000229456.1	RLIMP1	6.36	6.36e-10	9.37e-07	0.29	0.32	Red blood cell count;	chr13:40642694	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.816	rs7334318	ENSG00000229456.1	RLIMP1	6.36	6.36e-10	9.37e-07	0.29	0.32	Red blood cell count;	chr13:40643273	chr13:40618738~40621348:+
STAD	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	6.36	6.38e-10	9.4e-07	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
STAD	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	6.36	6.38e-10	9.4e-07	0.28	0.32	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
STAD	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	6.36	6.39e-10	9.41e-07	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	6.36	6.39e-10	9.41e-07	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
STAD	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	6.36	6.4e-10	9.43e-07	0.3	0.32	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
STAD	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-6.36	6.41e-10	9.44e-07	-0.28	-0.32	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
STAD	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-6.36	6.41e-10	9.45e-07	-0.37	-0.32	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
STAD	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-6.36	6.42e-10	9.45e-07	-0.39	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
STAD	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-6.36	6.42e-10	9.45e-07	-0.39	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
STAD	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-6.36	6.42e-10	9.45e-07	-0.39	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
STAD	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	6.36	6.42e-10	9.45e-07	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
STAD	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-6.36	6.43e-10	9.46e-07	-0.37	-0.32	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
STAD	cis	rs7580658	0.68	rs2069931	ENSG00000200250.1	RNU6-1147P	6.36	6.43e-10	9.47e-07	0.31	0.32	Protein C levels;	chr2:127427993	chr2:127316873~127316979:+
STAD	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-6.36	6.44e-10	9.48e-07	-0.34	-0.32	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
STAD	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-6.36	6.44e-10	9.48e-07	-0.33	-0.32	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
STAD	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-6.36	6.44e-10	9.48e-07	-0.33	-0.32	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
STAD	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-6.36	6.44e-10	9.48e-07	-0.31	-0.32	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
STAD	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	6.36	6.46e-10	9.5e-07	0.43	0.32	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
STAD	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-6.36	6.46e-10	9.5e-07	-0.34	-0.32	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
STAD	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-6.36	6.47e-10	9.52e-07	-0.33	-0.32	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
STAD	cis	rs9549260	0.755	rs7317254	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40643712	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.785	rs10507484	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40643997	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.709	rs9549247	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40646640	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs55920113	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40647975	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs12585277	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40650676	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.664	rs9532575	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40651224	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs58919811	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40652348	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.651	rs57735994	ENSG00000229456.1	RLIMP1	6.36	6.47e-10	9.52e-07	0.29	0.32	Red blood cell count;	chr13:40652424	chr13:40618738~40621348:+
STAD	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	6.36	6.48e-10	9.53e-07	0.32	0.32	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
STAD	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	6.36	6.49e-10	9.54e-07	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
STAD	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-6.36	6.49e-10	9.54e-07	-0.48	-0.32	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
STAD	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	6.36	6.5e-10	9.56e-07	0.37	0.32	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
STAD	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-6.36	6.5e-10	9.56e-07	-0.41	-0.32	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
STAD	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	6.36	6.51e-10	9.57e-07	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
STAD	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-6.36	6.53e-10	9.59e-07	-0.35	-0.32	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
STAD	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	6.36	6.55e-10	9.62e-07	0.43	0.32	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
STAD	cis	rs7615952	0.512	rs2979334	ENSG00000272840.1	RP11-379B18.6	6.36	6.55e-10	9.62e-07	0.5	0.32	Blood pressure (smoking interaction);	chr3:125639980	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.512	rs11921452	ENSG00000272840.1	RP11-379B18.6	6.36	6.55e-10	9.62e-07	0.5	0.32	Blood pressure (smoking interaction);	chr3:125640906	chr3:125774714~125797953:+
STAD	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-6.36	6.55e-10	9.63e-07	-0.38	-0.32	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-6.36	6.55e-10	9.63e-07	-0.38	-0.32	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
STAD	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-6.36	6.57e-10	9.64e-07	-0.31	-0.32	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
STAD	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	6.36	6.57e-10	9.65e-07	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
STAD	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-6.35	6.59e-10	9.67e-07	-0.31	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
STAD	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-6.35	6.59e-10	9.68e-07	-0.34	-0.32	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-6.35	6.59e-10	9.68e-07	-0.34	-0.32	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
STAD	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	6.35	6.6e-10	9.68e-07	0.37	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
STAD	cis	rs496547	0.686	rs477014	ENSG00000255422.1	AP002954.4	-6.35	6.6e-10	9.68e-07	-0.37	-0.32	Hip minimal joint space width;	chr11:118808277	chr11:118704607~118750263:+
STAD	cis	rs496547	0.557	rs516719	ENSG00000255422.1	AP002954.4	-6.35	6.6e-10	9.68e-07	-0.37	-0.32	Hip minimal joint space width;	chr11:118808736	chr11:118704607~118750263:+
STAD	cis	rs7927771	0.864	rs11604680	ENSG00000280615.1	Y_RNA	-6.35	6.61e-10	9.69e-07	-0.33	-0.32	Subjective well-being;	chr11:47435988	chr11:47614898~47614994:-
STAD	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-6.35	6.62e-10	9.71e-07	-0.33	-0.32	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
STAD	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	6.35	6.63e-10	9.71e-07	0.3	0.32	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
STAD	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-6.35	6.63e-10	9.71e-07	-0.34	-0.32	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
STAD	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-6.35	6.65e-10	9.75e-07	-0.34	-0.32	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
STAD	cis	rs9326248	0.53	rs1242229	ENSG00000280143.1	AP000892.6	6.35	6.65e-10	9.75e-07	0.33	0.32	Blood protein levels;	chr11:117191654	chr11:117204967~117210292:+
STAD	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	6.35	6.67e-10	9.77e-07	0.41	0.32	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
STAD	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	6.35	6.67e-10	9.78e-07	0.34	0.32	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
STAD	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-6.35	6.68e-10	9.79e-07	-0.33	-0.32	Height;	chr5:36861889	chr5:36666214~36725195:-
STAD	cis	rs7176527	0.784	rs62021162	ENSG00000188388.10	GOLGA6L3	6.35	6.69e-10	9.8e-07	0.44	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85240472~85247170:+
STAD	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-6.35	6.7e-10	9.82e-07	-0.29	-0.32	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
STAD	cis	rs6452524	1	rs2126988	ENSG00000243385.2	CTD-2110K23.1	6.35	6.71e-10	9.82e-07	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83201229~83202141:+
STAD	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-6.35	6.71e-10	9.83e-07	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
STAD	cis	rs6452524	0.901	rs1580309	ENSG00000243385.2	CTD-2110K23.1	6.35	6.72e-10	9.84e-07	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83201229~83202141:+
STAD	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	6.35	6.74e-10	9.86e-07	0.3	0.32	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
STAD	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	6.35	6.76e-10	9.89e-07	0.39	0.32	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
STAD	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	6.35	6.76e-10	9.9e-07	0.28	0.32	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
STAD	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	6.35	6.77e-10	9.91e-07	0.36	0.32	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
STAD	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-6.35	6.8e-10	9.95e-07	-0.36	-0.32	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
STAD	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	6.35	6.8e-10	9.96e-07	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
STAD	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	6.35	6.81e-10	9.96e-07	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
STAD	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	6.35	6.83e-10	1e-06	0.37	0.32	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
STAD	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	6.35	6.85e-10	1e-06	0.38	0.32	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
STAD	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-6.35	6.85e-10	1e-06	-0.34	-0.32	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.934	rs10473870	ENSG00000243385.2	CTD-2110K23.1	6.35	6.87e-10	1e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83201229~83202141:+
STAD	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	6.35	6.89e-10	1.01e-06	0.41	0.32	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
STAD	cis	rs2273156	0.57	rs28399702	ENSG00000241052.1	RP11-173D9.1	-6.35	6.9e-10	1.01e-06	-0.37	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:35156011	chr14:35144021~35144480:-
STAD	cis	rs240993	0.715	rs7776346	ENSG00000230177.1	RP5-1112D6.4	6.35	6.9e-10	1.01e-06	0.32	0.32	Inflammatory skin disease;Psoriasis;	chr6:111540162	chr6:111277932~111278742:+
STAD	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	6.35	6.91e-10	1.01e-06	0.4	0.32	Height;	chr6:109374782	chr6:109382795~109383666:+
STAD	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	6.35	6.91e-10	1.01e-06	0.33	0.32	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
STAD	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-6.35	6.91e-10	1.01e-06	-0.39	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
STAD	cis	rs9395066	0.545	rs4714828	ENSG00000219384.1	RP11-491H9.3	-6.35	6.92e-10	1.01e-06	-0.31	-0.32	Height;	chr6:44878271	chr6:45158870~45159511:+
STAD	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-6.35	6.92e-10	1.01e-06	-0.56	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
STAD	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-6.35	6.92e-10	1.01e-06	-0.38	-0.32	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
STAD	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-6.35	6.92e-10	1.01e-06	-0.33	-0.32	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-6.35	6.92e-10	1.01e-06	-0.33	-0.32	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-6.35	6.92e-10	1.01e-06	-0.33	-0.32	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-6.35	6.92e-10	1.01e-06	-0.33	-0.32	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
STAD	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-6.35	6.95e-10	1.02e-06	-0.55	-0.32	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
STAD	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-6.35	6.95e-10	1.02e-06	-0.55	-0.32	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
STAD	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-6.35	6.96e-10	1.02e-06	-0.34	-0.32	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
STAD	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	6.35	6.96e-10	1.02e-06	0.3	0.32	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
STAD	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-6.35	6.96e-10	1.02e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-6.35	6.96e-10	1.02e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-6.35	6.96e-10	1.02e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
STAD	cis	rs4639966	0.569	rs603486	ENSG00000255239.1	AP002954.6	6.34	6.98e-10	1.02e-06	0.35	0.32	Systemic lupus erythematosus;	chr11:118716638	chr11:118688039~118690600:-
STAD	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	6.34	6.98e-10	1.02e-06	0.37	0.32	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
STAD	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	6.34	6.98e-10	1.02e-06	0.37	0.32	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
STAD	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-6.34	6.99e-10	1.02e-06	-0.33	-0.32	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
STAD	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-6.34	7e-10	1.02e-06	-0.33	-0.32	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
STAD	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-6.34	7.01e-10	1.02e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
STAD	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	6.34	7.02e-10	1.02e-06	0.51	0.32	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
STAD	cis	rs748404	0.723	rs512431	ENSG00000205771.5	CATSPER2P1	6.34	7.04e-10	1.03e-06	0.37	0.32	Lung cancer;	chr15:43249741	chr15:43726918~43747094:-
STAD	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-6.34	7.05e-10	1.03e-06	-0.29	-0.32	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
STAD	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	6.34	7.07e-10	1.03e-06	0.38	0.32	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
STAD	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	6.34	7.09e-10	1.03e-06	0.3	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
STAD	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	6.34	7.1e-10	1.03e-06	0.38	0.32	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
STAD	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	6.34	7.1e-10	1.04e-06	0.36	0.32	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
STAD	cis	rs858239	0.73	rs858279	ENSG00000226816.2	AC005082.12	6.34	7.11e-10	1.04e-06	0.38	0.32	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23206013~23208045:+
STAD	cis	rs1426063	0.614	rs74949513	ENSG00000248165.1	RP11-44F21.2	6.34	7.13e-10	1.04e-06	0.68	0.32	QT interval;	chr4:75124631	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs77982391	ENSG00000248165.1	RP11-44F21.2	6.34	7.13e-10	1.04e-06	0.68	0.32	QT interval;	chr4:75125224	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.541	rs116664844	ENSG00000248165.1	RP11-44F21.2	6.34	7.13e-10	1.04e-06	0.68	0.32	QT interval;	chr4:75125677	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.541	rs114162294	ENSG00000248165.1	RP11-44F21.2	6.34	7.13e-10	1.04e-06	0.68	0.32	QT interval;	chr4:75125682	chr4:74993877~75034824:-
STAD	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-6.34	7.14e-10	1.04e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
STAD	cis	rs6452524	1	rs10076271	ENSG00000243385.2	CTD-2110K23.1	6.34	7.14e-10	1.04e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs10076274	ENSG00000243385.2	CTD-2110K23.1	6.34	7.14e-10	1.04e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs10061521	ENSG00000243385.2	CTD-2110K23.1	6.34	7.14e-10	1.04e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83201229~83202141:+
STAD	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-6.34	7.15e-10	1.04e-06	-0.41	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
STAD	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-6.34	7.16e-10	1.04e-06	-0.33	-0.32	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
STAD	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-6.34	7.16e-10	1.04e-06	-0.33	-0.32	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
STAD	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-6.34	7.17e-10	1.04e-06	-0.31	-0.32	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
STAD	cis	rs611744	0.743	rs2514843	ENSG00000253754.1	RP11-35G22.1	-6.34	7.17e-10	1.04e-06	-0.28	-0.32	Dupuytren's disease;	chr8:108051206	chr8:108226200~108227544:+
STAD	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	6.34	7.18e-10	1.04e-06	0.49	0.32	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
STAD	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	6.34	7.18e-10	1.04e-06	0.49	0.32	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
STAD	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	6.34	7.18e-10	1.04e-06	0.49	0.32	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
STAD	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	6.34	7.18e-10	1.04e-06	0.49	0.32	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
STAD	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-6.34	7.19e-10	1.05e-06	-0.38	-0.32	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
STAD	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	6.34	7.19e-10	1.05e-06	0.39	0.32	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
STAD	cis	rs801193	0.901	rs4273746	ENSG00000222364.1	RNU6-96P	6.34	7.19e-10	1.05e-06	0.37	0.32	Aortic root size;	chr7:66836124	chr7:66395191~66395286:+
STAD	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	6.34	7.2e-10	1.05e-06	0.52	0.32	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
STAD	cis	rs1005277	0.579	rs1740737	ENSG00000099251.13	HSD17B7P2	6.34	7.21e-10	1.05e-06	0.36	0.32	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38356380~38378505:+
STAD	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	6.34	7.22e-10	1.05e-06	0.35	0.32	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
STAD	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	6.34	7.22e-10	1.05e-06	0.49	0.32	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
STAD	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-6.34	7.24e-10	1.05e-06	-0.46	-0.32	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
STAD	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	6.34	7.25e-10	1.05e-06	0.4	0.32	Height;	chr6:109405536	chr6:109382795~109383666:+
STAD	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	6.34	7.25e-10	1.05e-06	0.39	0.32	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	6.34	7.25e-10	1.05e-06	0.39	0.32	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
STAD	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	6.34	7.27e-10	1.06e-06	0.46	0.32	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
STAD	cis	rs5760092	0.618	rs4461358	ENSG00000231271.1	AP000350.8	-6.34	7.27e-10	1.06e-06	-0.4	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23949918~23954042:+
STAD	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-6.34	7.28e-10	1.06e-06	-0.29	-0.32	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-6.34	7.28e-10	1.06e-06	-0.29	-0.32	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
STAD	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	6.34	7.28e-10	1.06e-06	0.34	0.32	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.912	rs61996059	ENSG00000211970.3	IGHV4-61	-6.34	7.29e-10	1.06e-06	-0.29	-0.32	Kawasaki disease;	chr14:106716897	chr14:106639119~106639657:-
STAD	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-6.34	7.3e-10	1.06e-06	-0.38	-0.32	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-6.34	7.3e-10	1.06e-06	-0.38	-0.32	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-6.34	7.3e-10	1.06e-06	-0.38	-0.32	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
STAD	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	6.34	7.3e-10	1.06e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	6.34	7.3e-10	1.06e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	6.34	7.3e-10	1.06e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	6.34	7.3e-10	1.06e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	6.34	7.3e-10	1.06e-06	0.43	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
STAD	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	6.34	7.32e-10	1.06e-06	0.47	0.32	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	6.34	7.32e-10	1.06e-06	0.47	0.32	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
STAD	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-6.34	7.33e-10	1.07e-06	-0.29	-0.32	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
STAD	cis	rs7924176	0.54	rs61866073	ENSG00000236900.1	TIMM9P1	-6.34	7.35e-10	1.07e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74344550~74344805:-
STAD	cis	rs7924176	0.521	rs10509347	ENSG00000236900.1	TIMM9P1	-6.34	7.36e-10	1.07e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74344550~74344805:-
STAD	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	6.34	7.37e-10	1.07e-06	0.28	0.32	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
STAD	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	6.34	7.37e-10	1.07e-06	0.39	0.32	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
STAD	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	6.33	7.39e-10	1.07e-06	0.32	0.32	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
STAD	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	6.33	7.39e-10	1.07e-06	0.38	0.32	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
STAD	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-6.33	7.4e-10	1.08e-06	-0.39	-0.32	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
STAD	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	6.33	7.43e-10	1.08e-06	0.4	0.32	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
STAD	cis	rs7924176	0.521	rs11516630	ENSG00000236900.1	TIMM9P1	-6.33	7.43e-10	1.08e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74344550~74344805:-
STAD	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	6.33	7.44e-10	1.08e-06	0.38	0.32	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
STAD	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-6.33	7.46e-10	1.08e-06	-0.37	-0.32	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
STAD	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-6.33	7.47e-10	1.08e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-6.33	7.47e-10	1.08e-06	-0.44	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
STAD	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-6.33	7.48e-10	1.08e-06	-0.55	-0.32	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-6.33	7.48e-10	1.08e-06	-0.55	-0.32	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
STAD	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-6.33	7.49e-10	1.09e-06	-0.3	-0.32	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
STAD	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-6.33	7.49e-10	1.09e-06	-0.3	-0.32	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
STAD	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-6.33	7.51e-10	1.09e-06	-0.3	-0.32	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
STAD	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-6.33	7.51e-10	1.09e-06	-0.39	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
STAD	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-6.33	7.53e-10	1.09e-06	-0.37	-0.32	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
STAD	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	6.33	7.55e-10	1.09e-06	0.29	0.32	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
STAD	cis	rs9549260	0.62	rs4325427	ENSG00000229456.1	RLIMP1	6.33	7.58e-10	1.1e-06	0.3	0.32	Red blood cell count;	chr13:40642397	chr13:40618738~40621348:+
STAD	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-6.33	7.6e-10	1.1e-06	-0.37	-0.32	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
STAD	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	6.33	7.61e-10	1.1e-06	0.38	0.32	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
STAD	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	6.33	7.62e-10	1.1e-06	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	6.33	7.62e-10	1.1e-06	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
STAD	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	6.33	7.63e-10	1.11e-06	0.38	0.32	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
STAD	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	6.33	7.63e-10	1.11e-06	0.38	0.32	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
STAD	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-6.33	7.64e-10	1.11e-06	-0.41	-0.32	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
STAD	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-6.33	7.67e-10	1.11e-06	-0.33	-0.32	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
STAD	cis	rs6452524	0.935	rs7714710	ENSG00000243385.2	CTD-2110K23.1	6.33	7.67e-10	1.11e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83201229~83202141:+
STAD	cis	rs11089937	0.667	rs5757081	ENSG00000211639.2	IGLV4-60	6.33	7.68e-10	1.11e-06	0.35	0.32	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22162199~22162681:+
STAD	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	6.33	7.69e-10	1.11e-06	0.43	0.32	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
STAD	cis	rs9549260	0.709	rs9549240	ENSG00000229456.1	RLIMP1	6.33	7.69e-10	1.11e-06	0.29	0.32	Red blood cell count;	chr13:40612507	chr13:40618738~40621348:+
STAD	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	6.33	7.69e-10	1.11e-06	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
STAD	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-6.33	7.69e-10	1.11e-06	-0.41	-0.32	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
STAD	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	6.33	7.69e-10	1.11e-06	0.3	0.32	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
STAD	cis	rs10129255	0.843	rs7142649	ENSG00000280411.1	IGHV1-69-2	-6.33	7.7e-10	1.11e-06	-0.29	-0.32	Kawasaki disease;	chr14:106708870	chr14:106762092~106762588:-
STAD	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	6.33	7.7e-10	1.11e-06	0.51	0.32	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
STAD	cis	rs11089937	0.597	rs9619812	ENSG00000211639.2	IGLV4-60	6.33	7.71e-10	1.12e-06	0.36	0.32	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22162199~22162681:+
STAD	cis	rs732716	0.853	rs1127888	ENSG00000267980.1	AC007292.6	-6.33	7.72e-10	1.12e-06	-0.44	-0.32	Mean corpuscular volume;	chr19:4454086	chr19:4363789~4364640:+
STAD	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-6.33	7.72e-10	1.12e-06	-0.56	-0.32	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
STAD	cis	rs6452524	1	rs6452520	ENSG00000243385.2	CTD-2110K23.1	6.33	7.75e-10	1.12e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs6452521	ENSG00000243385.2	CTD-2110K23.1	6.33	7.75e-10	1.12e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs6452522	ENSG00000243385.2	CTD-2110K23.1	6.33	7.75e-10	1.12e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83201229~83202141:+
STAD	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	6.33	7.76e-10	1.12e-06	0.28	0.32	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
STAD	cis	rs9549260	0.755	rs17061503	ENSG00000229456.1	RLIMP1	-6.33	7.78e-10	1.13e-06	-0.29	-0.32	Red blood cell count;	chr13:40672621	chr13:40618738~40621348:+
STAD	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-6.33	7.79e-10	1.13e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
STAD	cis	rs10129255	0.642	rs11624918	ENSG00000223648.3	IGHV3-64	6.33	7.79e-10	1.13e-06	0.29	0.32	Kawasaki disease;	chr14:106664672	chr14:106643132~106658258:-
STAD	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-6.32	7.84e-10	1.13e-06	-0.33	-0.32	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
STAD	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	6.32	7.84e-10	1.13e-06	0.4	0.32	Height;	chr6:109367528	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	6.32	7.84e-10	1.13e-06	0.4	0.32	Height;	chr6:109368704	chr6:109382795~109383666:+
STAD	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	6.32	7.85e-10	1.13e-06	0.37	0.32	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
STAD	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-6.32	7.89e-10	1.14e-06	-0.42	-0.32	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
STAD	cis	rs6452524	0.836	rs1478484	ENSG00000243385.2	CTD-2110K23.1	6.32	7.89e-10	1.14e-06	0.35	0.32	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83201229~83202141:+
STAD	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-6.32	7.89e-10	1.14e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
STAD	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-6.32	7.91e-10	1.14e-06	-0.38	-0.32	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-6.32	7.92e-10	1.14e-06	-0.33	-0.32	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
STAD	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	6.32	7.92e-10	1.14e-06	0.26	0.32	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
STAD	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	6.32	7.92e-10	1.14e-06	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
STAD	cis	rs6452524	0.569	rs7720588	ENSG00000243385.2	CTD-2110K23.1	6.32	7.95e-10	1.15e-06	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83201229~83202141:+
STAD	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	6.32	7.97e-10	1.15e-06	0.31	0.32	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
STAD	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	6.32	7.97e-10	1.15e-06	0.39	0.32	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
STAD	cis	rs7829975	0.511	rs1401390	ENSG00000253981.4	ALG1L13P	6.32	7.98e-10	1.15e-06	0.39	0.32	Mood instability;	chr8:8278888	chr8:8236003~8244667:-
STAD	cis	rs7487075	0.797	rs10785630	ENSG00000272369.1	RP11-446N19.1	6.32	7.99e-10	1.15e-06	0.38	0.32	Itch intensity from mosquito bite;	chr12:46486597	chr12:46537502~46652550:+
STAD	cis	rs1005277	0.579	rs1780146	ENSG00000099251.13	HSD17B7P2	6.32	8.01e-10	1.16e-06	0.35	0.32	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38356380~38378505:+
STAD	cis	rs9549260	0.755	rs9532571	ENSG00000229456.1	RLIMP1	6.32	8.03e-10	1.16e-06	0.3	0.32	Red blood cell count;	chr13:40644533	chr13:40618738~40621348:+
STAD	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-6.32	8.04e-10	1.16e-06	-0.36	-0.32	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
STAD	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-6.32	8.04e-10	1.16e-06	-0.33	-0.32	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
STAD	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-6.32	8.1e-10	1.17e-06	-0.3	-0.32	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
STAD	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	6.32	8.1e-10	1.17e-06	0.36	0.32	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
STAD	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	6.32	8.11e-10	1.17e-06	0.42	0.32	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
STAD	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	6.32	8.11e-10	1.17e-06	0.38	0.32	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
STAD	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	6.32	8.11e-10	1.17e-06	0.4	0.32	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
STAD	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	6.32	8.13e-10	1.17e-06	0.39	0.32	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
STAD	cis	rs11235843	0.636	rs6592531	ENSG00000255928.1	RP11-456I15.2	-6.32	8.14e-10	1.17e-06	-0.43	-0.32	Hand grip strength;	chr11:73701309	chr11:73722349~73722694:+
STAD	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-6.32	8.15e-10	1.17e-06	-0.37	-0.32	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-6.32	8.15e-10	1.17e-06	-0.37	-0.32	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
STAD	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	6.32	8.17e-10	1.18e-06	0.38	0.32	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
STAD	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-6.32	8.18e-10	1.18e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
STAD	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-6.32	8.19e-10	1.18e-06	-0.31	-0.32	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
STAD	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	6.32	8.22e-10	1.18e-06	0.39	0.32	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
STAD	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-6.32	8.23e-10	1.19e-06	-0.45	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
STAD	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	6.32	8.26e-10	1.19e-06	0.31	0.32	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
STAD	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	6.32	8.26e-10	1.19e-06	0.38	0.32	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
STAD	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-6.32	8.26e-10	1.19e-06	-0.45	-0.32	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
STAD	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-6.32	8.27e-10	1.19e-06	-0.36	-0.32	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
STAD	cis	rs496547	0.721	rs2508570	ENSG00000255422.1	AP002954.4	-6.32	8.28e-10	1.19e-06	-0.37	-0.32	Hip minimal joint space width;	chr11:118807900	chr11:118704607~118750263:+
STAD	cis	rs496547	0.686	rs591756	ENSG00000255422.1	AP002954.4	-6.32	8.28e-10	1.19e-06	-0.37	-0.32	Hip minimal joint space width;	chr11:118808172	chr11:118704607~118750263:+
STAD	cis	rs227275	0.554	rs223424	ENSG00000230069.3	LRRC37A15P	-6.32	8.29e-10	1.19e-06	-0.35	-0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102727274~102730721:-
STAD	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	6.31	8.31e-10	1.2e-06	0.33	0.32	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
STAD	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	6.31	8.32e-10	1.2e-06	0.33	0.32	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
STAD	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-6.31	8.36e-10	1.2e-06	-0.33	-0.32	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-6.31	8.36e-10	1.2e-06	-0.33	-0.32	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-6.31	8.36e-10	1.2e-06	-0.33	-0.32	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-6.31	8.36e-10	1.2e-06	-0.33	-0.32	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-6.31	8.36e-10	1.2e-06	-0.33	-0.32	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-6.31	8.36e-10	1.2e-06	-0.33	-0.32	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
STAD	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-6.31	8.36e-10	1.2e-06	-0.33	-0.32	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
STAD	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	6.31	8.38e-10	1.21e-06	0.45	0.32	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
STAD	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	6.31	8.39e-10	1.21e-06	0.4	0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
STAD	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-6.31	8.4e-10	1.21e-06	-0.45	-0.32	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
STAD	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-6.31	8.41e-10	1.21e-06	-0.29	-0.32	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
STAD	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-6.31	8.41e-10	1.21e-06	-0.29	-0.32	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
STAD	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-6.31	8.41e-10	1.21e-06	-0.29	-0.32	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-6.31	8.41e-10	1.21e-06	-0.29	-0.32	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
STAD	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-6.31	8.41e-10	1.21e-06	-0.37	-0.32	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-6.31	8.42e-10	1.21e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
STAD	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-6.31	8.43e-10	1.21e-06	-0.34	-0.32	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
STAD	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	6.31	8.43e-10	1.21e-06	0.38	0.32	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
STAD	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	6.31	8.43e-10	1.21e-06	0.39	0.32	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
STAD	cis	rs2143950	0.831	rs80031420	ENSG00000241052.1	RP11-173D9.1	-6.31	8.45e-10	1.21e-06	-0.38	-0.32	Atopic dermatitis;	chr14:35086915	chr14:35144021~35144480:-
STAD	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-6.31	8.47e-10	1.22e-06	-0.39	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000224205.1	AP000351.4	6.31	8.48e-10	1.22e-06	0.37	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23987320~23991421:-
STAD	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	6.31	8.51e-10	1.22e-06	0.38	0.32	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
STAD	cis	rs1005277	0.579	rs1614236	ENSG00000099251.13	HSD17B7P2	6.31	8.54e-10	1.23e-06	0.35	0.32	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2749616	ENSG00000099251.13	HSD17B7P2	6.31	8.54e-10	1.23e-06	0.35	0.32	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38356380~38378505:+
STAD	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-6.31	8.58e-10	1.23e-06	-0.28	-0.32	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
STAD	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-6.31	8.6e-10	1.23e-06	-0.34	-0.32	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
STAD	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-6.31	8.61e-10	1.24e-06	-0.36	-0.32	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-6.31	8.61e-10	1.24e-06	-0.36	-0.32	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
STAD	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	6.31	8.61e-10	1.24e-06	0.47	0.32	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
STAD	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	6.31	8.62e-10	1.24e-06	0.36	0.32	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	6.31	8.62e-10	1.24e-06	0.36	0.32	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
STAD	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	6.31	8.62e-10	1.24e-06	0.24	0.32	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
STAD	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-6.31	8.63e-10	1.24e-06	-0.34	-0.32	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
STAD	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-6.31	8.65e-10	1.24e-06	-0.31	-0.32	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
STAD	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-6.31	8.67e-10	1.24e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
STAD	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-6.31	8.67e-10	1.24e-06	-0.36	-0.32	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
STAD	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.31	8.69e-10	1.25e-06	-0.4	-0.32	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
STAD	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-6.31	8.7e-10	1.25e-06	-0.57	-0.32	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
STAD	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-6.31	8.71e-10	1.25e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-6.31	8.71e-10	1.25e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-6.31	8.71e-10	1.25e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-6.31	8.71e-10	1.25e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-6.31	8.71e-10	1.25e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
STAD	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	6.31	8.72e-10	1.25e-06	0.33	0.32	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
STAD	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	6.31	8.72e-10	1.25e-06	0.33	0.32	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
STAD	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	6.31	8.72e-10	1.25e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	6.31	8.72e-10	1.25e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
STAD	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	6.31	8.78e-10	1.26e-06	0.36	0.32	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
STAD	cis	rs9395066	0.545	rs10456119	ENSG00000219384.1	RP11-491H9.3	-6.31	8.79e-10	1.26e-06	-0.31	-0.32	Height;	chr6:44921308	chr6:45158870~45159511:+
STAD	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	6.3	8.8e-10	1.26e-06	0.37	0.32	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
STAD	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-6.3	8.8e-10	1.26e-06	-0.29	-0.32	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
STAD	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-6.3	8.81e-10	1.26e-06	-0.38	-0.32	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
STAD	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	6.3	8.81e-10	1.26e-06	0.33	0.32	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	6.3	8.81e-10	1.26e-06	0.33	0.32	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
STAD	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	6.3	8.81e-10	1.26e-06	0.28	0.32	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
STAD	cis	rs9813712	0.596	rs2587988	ENSG00000253540.4	FAM86HP	-6.3	8.81e-10	1.26e-06	-0.34	-0.32	Response to amphetamines;	chr3:130201415	chr3:130099092~130111472:-
STAD	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-6.3	8.83e-10	1.26e-06	-0.33	-0.32	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
STAD	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	6.3	8.84e-10	1.26e-06	0.23	0.32	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
STAD	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	6.3	8.86e-10	1.27e-06	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
STAD	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-6.3	8.88e-10	1.27e-06	-0.33	-0.32	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
STAD	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	6.3	8.93e-10	1.28e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	6.3	8.93e-10	1.28e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
STAD	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	6.3	8.96e-10	1.28e-06	0.31	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
STAD	cis	rs7487075	0.619	rs11183483	ENSG00000272369.1	RP11-446N19.1	6.3	8.97e-10	1.28e-06	0.43	0.32	Itch intensity from mosquito bite;	chr12:46432698	chr12:46537502~46652550:+
STAD	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	6.3	8.98e-10	1.28e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
STAD	cis	rs6452524	0.935	rs7736296	ENSG00000243385.2	CTD-2110K23.1	-6.3	8.98e-10	1.28e-06	-0.34	-0.32	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83201229~83202141:+
STAD	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	6.3	8.99e-10	1.28e-06	0.39	0.32	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
STAD	cis	rs9549260	0.755	rs7338669	ENSG00000229456.1	RLIMP1	-6.3	8.99e-10	1.28e-06	-0.29	-0.32	Red blood cell count;	chr13:40625954	chr13:40618738~40621348:+
STAD	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	6.3	9e-10	1.29e-06	0.37	0.32	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
STAD	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	6.3	9.08e-10	1.3e-06	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
STAD	cis	rs7927771	0.931	rs12361256	ENSG00000280615.1	Y_RNA	-6.3	9.08e-10	1.3e-06	-0.33	-0.32	Subjective well-being;	chr11:47889271	chr11:47614898~47614994:-
STAD	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-6.3	9.09e-10	1.3e-06	-0.37	-0.32	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
STAD	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-6.3	9.09e-10	1.3e-06	-0.37	-0.32	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-6.3	9.09e-10	1.3e-06	-0.37	-0.32	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-6.3	9.09e-10	1.3e-06	-0.37	-0.32	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
STAD	cis	rs7487075	0.619	rs1472178	ENSG00000272369.1	RP11-446N19.1	6.3	9.15e-10	1.3e-06	0.43	0.32	Itch intensity from mosquito bite;	chr12:46410392	chr12:46537502~46652550:+
STAD	cis	rs2404602	0.608	rs12911035	ENSG00000259422.1	RP11-593F23.1	6.3	9.15e-10	1.3e-06	0.34	0.32	Blood metabolite levels;	chr15:76314250	chr15:76174891~76181486:-
STAD	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	6.3	9.15e-10	1.31e-06	0.37	0.32	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
STAD	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-6.3	9.16e-10	1.31e-06	-0.29	-0.32	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
STAD	cis	rs9395066	0.545	rs35357222	ENSG00000219384.1	RP11-491H9.3	-6.3	9.17e-10	1.31e-06	-0.32	-0.32	Height;	chr6:44972815	chr6:45158870~45159511:+
STAD	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-6.3	9.18e-10	1.31e-06	-0.26	-0.32	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
STAD	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-6.3	9.2e-10	1.31e-06	-0.28	-0.32	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
STAD	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-6.3	9.23e-10	1.32e-06	-0.33	-0.32	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
STAD	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	6.3	9.24e-10	1.32e-06	0.37	0.32	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
STAD	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	6.3	9.28e-10	1.32e-06	0.4	0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
STAD	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	6.3	9.29e-10	1.32e-06	0.39	0.32	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
STAD	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	6.3	9.3e-10	1.32e-06	0.37	0.32	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
STAD	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	6.3	9.3e-10	1.32e-06	0.35	0.32	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
STAD	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	6.29	9.31e-10	1.33e-06	0.36	0.32	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	6.29	9.31e-10	1.33e-06	0.36	0.32	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
STAD	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	6.29	9.34e-10	1.33e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
STAD	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	6.29	9.37e-10	1.33e-06	0.44	0.32	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
STAD	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	6.29	9.4e-10	1.34e-06	0.36	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
STAD	cis	rs7487075	0.93	rs11183468	ENSG00000272369.1	RP11-446N19.1	6.29	9.41e-10	1.34e-06	0.38	0.32	Itch intensity from mosquito bite;	chr12:46412478	chr12:46537502~46652550:+
STAD	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-6.29	9.42e-10	1.34e-06	-0.36	-0.32	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
STAD	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	6.29	9.44e-10	1.34e-06	0.28	0.32	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.517	rs11625572	ENSG00000223648.3	IGHV3-64	6.29	9.46e-10	1.35e-06	0.28	0.32	Kawasaki disease;	chr14:106656426	chr14:106643132~106658258:-
STAD	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-6.29	9.48e-10	1.35e-06	-0.38	-0.32	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
STAD	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-6.29	9.48e-10	1.35e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
STAD	cis	rs9326248	0.53	rs7123517	ENSG00000280143.1	AP000892.6	6.29	9.49e-10	1.35e-06	0.33	0.32	Blood protein levels;	chr11:117157039	chr11:117204967~117210292:+
STAD	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-6.29	9.53e-10	1.36e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-6.29	9.54e-10	1.36e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
STAD	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	6.29	9.55e-10	1.36e-06	0.28	0.32	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-6.29	9.57e-10	1.36e-06	-0.29	-0.32	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
STAD	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-6.29	9.62e-10	1.37e-06	-0.38	-0.32	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
STAD	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	6.29	9.63e-10	1.37e-06	0.48	0.32	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
STAD	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	6.29	9.66e-10	1.37e-06	0.4	0.32	Height;	chr6:109357369	chr6:109382795~109383666:+
STAD	cis	rs6456156	0.774	rs1556413	ENSG00000265828.1	MIR3939	6.29	9.66e-10	1.37e-06	0.35	0.32	Primary biliary cholangitis;	chr6:167111255	chr6:166997807~166997912:-
STAD	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-6.29	9.67e-10	1.37e-06	-0.33	-0.32	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
STAD	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	6.29	9.69e-10	1.38e-06	0.28	0.32	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
STAD	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-6.29	9.69e-10	1.38e-06	-0.42	-0.32	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
STAD	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	6.29	9.71e-10	1.38e-06	0.41	0.32	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
STAD	cis	rs7945705	0.967	rs10840147	ENSG00000254860.4	TMEM9B-AS1	-6.29	9.72e-10	1.38e-06	-0.35	-0.32	Hemoglobin concentration;	chr11:8899157	chr11:8964675~8977527:+
STAD	cis	rs6452524	0.868	rs10045104	ENSG00000243385.2	CTD-2110K23.1	6.29	9.72e-10	1.38e-06	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83201229~83202141:+
STAD	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-6.29	9.72e-10	1.38e-06	-0.36	-0.32	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
STAD	cis	rs11089937	0.626	rs737840	ENSG00000211639.2	IGLV4-60	6.29	9.73e-10	1.38e-06	0.37	0.32	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.626	rs737841	ENSG00000211639.2	IGLV4-60	6.29	9.73e-10	1.38e-06	0.37	0.32	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22162199~22162681:+
STAD	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	6.29	9.73e-10	1.38e-06	0.36	0.32	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	6.29	9.73e-10	1.38e-06	0.36	0.32	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
STAD	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-6.29	9.74e-10	1.38e-06	-0.48	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
STAD	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	6.29	9.74e-10	1.38e-06	0.24	0.32	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	6.29	9.75e-10	1.39e-06	0.27	0.32	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
STAD	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-6.29	9.76e-10	1.39e-06	-0.33	-0.32	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
STAD	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	6.29	9.77e-10	1.39e-06	0.36	0.32	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
STAD	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	6.29	9.78e-10	1.39e-06	0.23	0.32	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	6.29	9.78e-10	1.39e-06	0.23	0.32	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
STAD	cis	rs9549260	0.755	rs1413482	ENSG00000229456.1	RLIMP1	6.29	9.79e-10	1.39e-06	0.29	0.32	Red blood cell count;	chr13:40644314	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs7993233	ENSG00000229456.1	RLIMP1	6.29	9.79e-10	1.39e-06	0.29	0.32	Red blood cell count;	chr13:40645297	chr13:40618738~40621348:+
STAD	cis	rs71718386	1	rs71718386	ENSG00000229456.1	RLIMP1	6.29	9.79e-10	1.39e-06	0.29	0.32	Eosinophil counts;	chr13:40650154	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.664	rs1360719	ENSG00000229456.1	RLIMP1	6.29	9.79e-10	1.39e-06	0.29	0.32	Red blood cell count;	chr13:40651737	chr13:40618738~40621348:+
STAD	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	6.29	9.8e-10	1.39e-06	0.39	0.32	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
STAD	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	6.29	9.8e-10	1.39e-06	0.38	0.32	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
STAD	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-6.29	9.81e-10	1.39e-06	-0.4	-0.32	Height;	chr6:109497253	chr6:109382795~109383666:+
STAD	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	6.28	9.87e-10	1.4e-06	0.38	0.32	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
STAD	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	6.28	9.9e-10	1.4e-06	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
STAD	cis	rs2273156	0.57	rs2010648	ENSG00000241052.1	RP11-173D9.1	-6.28	9.9e-10	1.4e-06	-0.38	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:35135686	chr14:35144021~35144480:-
STAD	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-6.28	9.9e-10	1.4e-06	-0.38	-0.32	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
STAD	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	6.28	9.91e-10	1.41e-06	0.3	0.32	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
STAD	cis	rs6452524	1	rs11958314	ENSG00000243385.2	CTD-2110K23.1	6.28	9.93e-10	1.41e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.686	rs6452517	ENSG00000243385.2	CTD-2110K23.1	6.28	9.93e-10	1.41e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.686	rs6452518	ENSG00000243385.2	CTD-2110K23.1	6.28	9.93e-10	1.41e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83201229~83202141:+
STAD	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	6.28	9.95e-10	1.41e-06	0.31	0.32	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
STAD	cis	rs6782228	0.606	rs7613073	ENSG00000277250.1	Metazoa_SRP	-6.28	9.95e-10	1.41e-06	-0.33	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128673681~128674021:-
STAD	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	6.28	9.97e-10	1.41e-06	0.33	0.32	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	6.28	9.97e-10	1.41e-06	0.33	0.32	Asthma;	chr2:102388870	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	6.28	9.97e-10	1.41e-06	0.33	0.32	Asthma;	chr2:102389644	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	6.28	9.97e-10	1.41e-06	0.33	0.32	Asthma;	chr2:102389988	chr2:102438713~102440475:+
STAD	cis	rs4604732	0.536	rs12049066	ENSG00000227135.1	GCSAML-AS1	-6.28	9.98e-10	1.41e-06	-0.44	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247479353	chr1:247524679~247526752:-
STAD	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	6.28	9.98e-10	1.41e-06	0.36	0.32	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
STAD	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-6.28	1e-09	1.42e-06	-0.31	-0.32	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
STAD	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-6.28	1e-09	1.42e-06	-0.28	-0.32	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-6.28	1e-09	1.42e-06	-0.28	-0.32	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
STAD	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	6.28	1e-09	1.42e-06	0.36	0.32	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
STAD	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	6.28	1e-09	1.42e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
STAD	cis	rs2221894	0.959	rs8180944	ENSG00000273710.1	Metazoa_SRP	6.28	1e-09	1.42e-06	0.36	0.32	Obesity-related traits;	chr8:29046569	chr8:28915579~28915864:-
STAD	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	6.28	1e-09	1.42e-06	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	6.28	1e-09	1.42e-06	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
STAD	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	6.28	1.01e-09	1.42e-06	0.4	0.32	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
STAD	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	6.28	1.01e-09	1.42e-06	0.4	0.32	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
STAD	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-6.28	1.01e-09	1.42e-06	-0.34	-0.32	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-6.28	1.01e-09	1.42e-06	-0.34	-0.32	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-6.28	1.01e-09	1.43e-06	-0.39	-0.32	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	6.28	1.01e-09	1.43e-06	0.39	0.32	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
STAD	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	6.28	1.01e-09	1.43e-06	0.45	0.32	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
STAD	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-6.28	1.01e-09	1.43e-06	-0.31	-0.32	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
STAD	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-6.28	1.01e-09	1.43e-06	-0.33	-0.32	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
STAD	cis	rs9532580	0.71	rs9577090	ENSG00000229456.1	RLIMP1	6.28	1.01e-09	1.43e-06	0.29	0.32	Mean corpuscular hemoglobin;	chr13:40651091	chr13:40618738~40621348:+
STAD	cis	rs9532580	0.553	rs9549250	ENSG00000229456.1	RLIMP1	6.28	1.01e-09	1.43e-06	0.29	0.32	Mean corpuscular hemoglobin;	chr13:40651092	chr13:40618738~40621348:+
STAD	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-6.28	1.01e-09	1.43e-06	-0.31	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
STAD	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	6.28	1.01e-09	1.44e-06	0.44	0.32	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
STAD	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	6.28	1.02e-09	1.44e-06	0.38	0.32	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	6.28	1.02e-09	1.44e-06	0.38	0.32	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
STAD	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-6.28	1.02e-09	1.44e-06	-0.34	-0.32	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
STAD	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	6.28	1.02e-09	1.44e-06	0.3	0.32	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
STAD	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	6.28	1.02e-09	1.44e-06	0.36	0.32	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	6.28	1.02e-09	1.44e-06	0.36	0.32	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	6.28	1.02e-09	1.44e-06	0.36	0.32	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
STAD	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	6.28	1.02e-09	1.44e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	6.28	1.02e-09	1.44e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-6.28	1.02e-09	1.45e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
STAD	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	6.28	1.02e-09	1.45e-06	0.38	0.32	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
STAD	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	6.28	1.02e-09	1.45e-06	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
STAD	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-6.28	1.03e-09	1.45e-06	-0.57	-0.32	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
STAD	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-6.28	1.03e-09	1.45e-06	-0.31	-0.32	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
STAD	cis	rs9326248	0.53	rs7122944	ENSG00000280143.1	AP000892.6	6.28	1.03e-09	1.45e-06	0.33	0.32	Blood protein levels;	chr11:117163903	chr11:117204967~117210292:+
STAD	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	6.28	1.03e-09	1.45e-06	0.36	0.32	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
STAD	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	6.28	1.03e-09	1.45e-06	0.35	0.32	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
STAD	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	6.28	1.03e-09	1.46e-06	0.45	0.32	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
STAD	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-6.28	1.03e-09	1.46e-06	-0.3	-0.32	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
STAD	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-6.28	1.04e-09	1.47e-06	-0.3	-0.32	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
STAD	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-6.28	1.04e-09	1.47e-06	-0.38	-0.32	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-6.28	1.04e-09	1.47e-06	-0.38	-0.32	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-6.28	1.04e-09	1.47e-06	-0.38	-0.32	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-6.28	1.04e-09	1.47e-06	-0.38	-0.32	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-6.28	1.04e-09	1.47e-06	-0.38	-0.32	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-6.28	1.04e-09	1.47e-06	-0.38	-0.32	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
STAD	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	6.28	1.04e-09	1.47e-06	0.4	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
STAD	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-6.28	1.04e-09	1.47e-06	-0.35	-0.32	Height;	chr3:52989412	chr3:53064283~53065091:-
STAD	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-6.28	1.04e-09	1.47e-06	-0.35	-0.32	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
STAD	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-6.28	1.04e-09	1.47e-06	-0.34	-0.32	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
STAD	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-6.27	1.05e-09	1.48e-06	-0.31	-0.32	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
STAD	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-6.27	1.05e-09	1.48e-06	-0.36	-0.32	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
STAD	cis	rs7924176	0.521	rs12359775	ENSG00000236900.1	TIMM9P1	-6.27	1.05e-09	1.48e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74344550~74344805:-
STAD	cis	rs8141529	0.778	rs7287806	ENSG00000226471.5	CTA-292E10.6	-6.27	1.05e-09	1.48e-06	-0.37	-0.32	Lymphocyte counts;	chr22:28817023	chr22:28800683~28848559:+
STAD	cis	rs7487075	0.79	rs4074773	ENSG00000272369.1	RP11-446N19.1	-6.27	1.05e-09	1.48e-06	-0.37	-0.32	Itch intensity from mosquito bite;	chr12:46525398	chr12:46537502~46652550:+
STAD	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	6.27	1.05e-09	1.48e-06	0.35	0.32	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
STAD	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	6.27	1.05e-09	1.48e-06	0.35	0.32	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
STAD	cis	rs7924176	0.521	rs11000999	ENSG00000236900.1	TIMM9P1	-6.27	1.05e-09	1.48e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74344550~74344805:-
STAD	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-6.27	1.05e-09	1.48e-06	-0.32	-0.32	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	6.27	1.06e-09	1.49e-06	0.39	0.32	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
STAD	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	6.27	1.06e-09	1.49e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
STAD	cis	rs7924176	0.521	rs10762599	ENSG00000236900.1	TIMM9P1	-6.27	1.06e-09	1.5e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74344550~74344805:-
STAD	cis	rs6452524	0.967	rs2974448	ENSG00000243385.2	CTD-2110K23.1	6.27	1.06e-09	1.5e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83201229~83202141:+
STAD	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	6.27	1.06e-09	1.5e-06	0.4	0.32	Height;	chr6:109424139	chr6:109382795~109383666:+
STAD	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	6.27	1.07e-09	1.5e-06	0.29	0.32	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
STAD	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	6.27	1.07e-09	1.5e-06	0.29	0.32	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
STAD	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	6.27	1.07e-09	1.5e-06	0.33	0.32	Asthma;	chr2:102446466	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	6.27	1.07e-09	1.5e-06	0.33	0.32	Asthma;	chr2:102446780	chr2:102438713~102440475:+
STAD	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-6.27	1.07e-09	1.51e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
STAD	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	6.27	1.07e-09	1.51e-06	0.33	0.32	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
STAD	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	6.27	1.07e-09	1.51e-06	0.33	0.32	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	6.27	1.07e-09	1.51e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
STAD	cis	rs2404602	0.583	rs12898415	ENSG00000259422.1	RP11-593F23.1	6.27	1.08e-09	1.51e-06	0.34	0.32	Blood metabolite levels;	chr15:76281891	chr15:76174891~76181486:-
STAD	cis	rs10461617	0.541	rs860581	ENSG00000271828.1	CTD-2310F14.1	6.27	1.08e-09	1.52e-06	0.45	0.32	Type 2 diabetes;	chr5:56854710	chr5:56927874~56929573:+
STAD	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	6.27	1.08e-09	1.52e-06	0.38	0.32	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
STAD	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	6.27	1.08e-09	1.52e-06	0.37	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
STAD	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	6.27	1.08e-09	1.52e-06	0.37	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
STAD	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	6.27	1.08e-09	1.52e-06	0.37	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
STAD	cis	rs9395066	0.527	rs12524069	ENSG00000219384.1	RP11-491H9.3	-6.27	1.08e-09	1.52e-06	-0.31	-0.32	Height;	chr6:44930236	chr6:45158870~45159511:+
STAD	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	6.27	1.08e-09	1.52e-06	0.44	0.32	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
STAD	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-6.27	1.08e-09	1.52e-06	-0.32	-0.32	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
STAD	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.27	1.08e-09	1.52e-06	-0.4	-0.32	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
STAD	cis	rs7924176	0.521	rs11000986	ENSG00000236900.1	TIMM9P1	-6.27	1.08e-09	1.52e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74344550~74344805:-
STAD	cis	rs7924176	0.521	rs10824147	ENSG00000236900.1	TIMM9P1	-6.27	1.08e-09	1.52e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74344550~74344805:-
STAD	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	6.27	1.08e-09	1.52e-06	0.23	0.32	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
STAD	cis	rs2833693	0.533	rs2833746	ENSG00000261610.1	AP000265.1	6.27	1.09e-09	1.53e-06	0.36	0.32	Temperament;	chr21:32252556	chr21:32259804~32261585:-
STAD	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	6.27	1.09e-09	1.53e-06	0.38	0.32	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
STAD	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	6.27	1.09e-09	1.53e-06	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
STAD	cis	rs11098499	0.874	rs28452522	ENSG00000248280.1	RP11-33B1.2	6.27	1.09e-09	1.53e-06	0.4	0.32	Corneal astigmatism;	chr4:119189629	chr4:119440561~119450157:-
STAD	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-6.27	1.09e-09	1.53e-06	-0.28	-0.32	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
STAD	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	6.27	1.09e-09	1.53e-06	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
STAD	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-6.27	1.09e-09	1.53e-06	-0.28	-0.32	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
STAD	cis	rs1005277	0.579	rs1780116	ENSG00000099251.13	HSD17B7P2	6.27	1.09e-09	1.53e-06	0.35	0.32	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1780121	ENSG00000099251.13	HSD17B7P2	6.27	1.09e-09	1.53e-06	0.35	0.32	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1780122	ENSG00000099251.13	HSD17B7P2	6.27	1.09e-09	1.53e-06	0.35	0.32	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1780145	ENSG00000099251.13	HSD17B7P2	6.27	1.09e-09	1.53e-06	0.35	0.32	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38356380~38378505:+
STAD	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	6.27	1.09e-09	1.53e-06	0.36	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
STAD	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	6.27	1.09e-09	1.53e-06	0.38	0.32	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	6.27	1.09e-09	1.53e-06	0.38	0.32	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
STAD	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-6.27	1.09e-09	1.54e-06	-0.33	-0.32	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
STAD	cis	rs2439831	0.717	rs2447198	ENSG00000249839.1	AC011330.5	-6.27	1.1e-09	1.54e-06	-0.51	-0.32	Lung cancer in ever smokers;	chr15:43602920	chr15:43663654~43684339:-
STAD	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	6.27	1.1e-09	1.54e-06	0.34	0.32	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
STAD	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	6.27	1.1e-09	1.54e-06	0.47	0.32	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
STAD	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	6.27	1.1e-09	1.54e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	6.27	1.1e-09	1.54e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
STAD	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-6.27	1.1e-09	1.54e-06	-0.54	-0.32	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
STAD	cis	rs6782228	0.675	rs56141228	ENSG00000277250.1	Metazoa_SRP	-6.27	1.1e-09	1.54e-06	-0.33	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.651	rs9852825	ENSG00000277250.1	Metazoa_SRP	-6.27	1.1e-09	1.54e-06	-0.33	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.651	rs9289332	ENSG00000277250.1	Metazoa_SRP	-6.27	1.1e-09	1.54e-06	-0.33	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128673681~128674021:-
STAD	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	6.27	1.1e-09	1.54e-06	0.56	0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
STAD	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	6.27	1.1e-09	1.55e-06	0.38	0.32	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
STAD	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-6.27	1.1e-09	1.55e-06	-0.34	-0.32	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
STAD	cis	rs10129255	0.957	rs67625077	ENSG00000223648.3	IGHV3-64	6.27	1.1e-09	1.55e-06	0.28	0.32	Kawasaki disease;	chr14:106715436	chr14:106643132~106658258:-
STAD	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-6.27	1.1e-09	1.55e-06	-0.33	-0.32	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-6.27	1.1e-09	1.55e-06	-0.33	-0.32	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.901	rs1842020	ENSG00000243385.2	CTD-2110K23.1	6.27	1.1e-09	1.55e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83201229~83202141:+
STAD	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-6.27	1.11e-09	1.55e-06	-0.31	-0.32	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
STAD	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-6.26	1.11e-09	1.56e-06	-0.37	-0.32	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
STAD	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-6.26	1.11e-09	1.56e-06	-0.32	-0.32	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
STAD	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-6.26	1.11e-09	1.56e-06	-0.3	-0.32	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
STAD	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-6.26	1.12e-09	1.57e-06	-0.38	-0.32	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
STAD	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	6.26	1.12e-09	1.57e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	6.26	1.12e-09	1.57e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	6.26	1.12e-09	1.57e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
STAD	cis	rs9601248	0.711	rs9530937	ENSG00000227354.5	RBM26-AS1	-6.26	1.12e-09	1.57e-06	-0.36	-0.32	Major depressive disorder;	chr13:79603701	chr13:79406309~79424328:+
STAD	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-6.26	1.12e-09	1.57e-06	-0.32	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
STAD	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	6.26	1.12e-09	1.57e-06	0.55	0.32	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
STAD	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-6.26	1.12e-09	1.57e-06	-0.36	-0.32	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
STAD	cis	rs7924176	0.521	rs1904062	ENSG00000236900.1	TIMM9P1	-6.26	1.12e-09	1.58e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74344550~74344805:-
STAD	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-6.26	1.13e-09	1.58e-06	-0.28	-0.32	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-6.26	1.13e-09	1.58e-06	-0.28	-0.32	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
STAD	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-6.26	1.13e-09	1.58e-06	-0.33	-0.32	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
STAD	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-6.26	1.13e-09	1.58e-06	-0.3	-0.32	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
STAD	cis	rs6456156	0.774	rs1012657	ENSG00000265828.1	MIR3939	6.26	1.13e-09	1.59e-06	0.35	0.32	Primary biliary cholangitis;	chr6:167111654	chr6:166997807~166997912:-
STAD	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-6.26	1.13e-09	1.59e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-6.26	1.13e-09	1.59e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
STAD	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-6.26	1.14e-09	1.6e-06	-0.41	-0.32	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
STAD	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-6.26	1.14e-09	1.6e-06	-0.41	-0.32	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
STAD	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-6.26	1.14e-09	1.6e-06	-0.34	-0.32	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
STAD	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-6.26	1.14e-09	1.6e-06	-0.34	-0.32	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
STAD	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-6.26	1.14e-09	1.6e-06	-0.34	-0.32	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
STAD	cis	rs801193	0.844	rs2244022	ENSG00000222364.1	RNU6-96P	-6.26	1.15e-09	1.6e-06	-0.35	-0.32	Aortic root size;	chr7:66737443	chr7:66395191~66395286:+
STAD	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-6.26	1.15e-09	1.6e-06	-0.33	-0.32	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
STAD	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	6.26	1.15e-09	1.61e-06	0.33	0.32	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
STAD	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	6.26	1.15e-09	1.61e-06	0.41	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
STAD	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	6.26	1.15e-09	1.61e-06	0.32	0.32	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	6.26	1.15e-09	1.61e-06	0.32	0.32	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
STAD	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-6.26	1.15e-09	1.61e-06	-0.38	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
STAD	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	6.26	1.15e-09	1.61e-06	0.32	0.32	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
STAD	cis	rs7195287	0.591	rs63744561	ENSG00000276791.1	CTD-2270P14.5	6.26	1.15e-09	1.61e-06	0.41	0.32	Eosinophil counts;	chr16:2778171	chr16:2777319~2780568:+
STAD	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	6.26	1.15e-09	1.61e-06	0.46	0.32	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
STAD	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-6.26	1.15e-09	1.61e-06	-0.34	-0.32	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
STAD	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-6.26	1.15e-09	1.61e-06	-0.36	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
STAD	cis	rs8005677	0.851	rs8010804	ENSG00000257285.4	RP11-298I3.1	6.26	1.15e-09	1.61e-06	0.4	0.32	Cognitive ability (multi-trait analysis);	chr14:22927271	chr14:22929609~22955562:+
STAD	cis	rs9395066	0.545	rs10948185	ENSG00000219384.1	RP11-491H9.3	-6.26	1.16e-09	1.62e-06	-0.31	-0.32	Height;	chr6:44933990	chr6:45158870~45159511:+
STAD	cis	rs11722779	0.81	rs223417	ENSG00000230069.3	LRRC37A15P	-6.26	1.16e-09	1.62e-06	-0.34	-0.32	Schizophrenia;	chr4:102810568	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.805	rs223416	ENSG00000230069.3	LRRC37A15P	-6.26	1.16e-09	1.62e-06	-0.34	-0.32	Schizophrenia;	chr4:102810580	chr4:102727274~102730721:-
STAD	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-6.26	1.16e-09	1.62e-06	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
STAD	cis	rs9549260	0.755	rs3892360	ENSG00000229456.1	RLIMP1	6.26	1.16e-09	1.62e-06	0.29	0.32	Red blood cell count;	chr13:40609941	chr13:40618738~40621348:+
STAD	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	6.26	1.16e-09	1.62e-06	0.43	0.32	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
STAD	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	6.26	1.16e-09	1.62e-06	0.38	0.32	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
STAD	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-6.26	1.16e-09	1.62e-06	-0.28	-0.32	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
STAD	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	6.26	1.17e-09	1.63e-06	0.34	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
STAD	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	6.26	1.17e-09	1.63e-06	0.34	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
STAD	cis	rs11039131	0.629	rs67871383	ENSG00000271350.1	CTD-2384B9.1	-6.26	1.17e-09	1.63e-06	-0.36	-0.32	Schizophrenia;	chr11:47314287	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	6.26	1.17e-09	1.63e-06	0.39	0.32	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
STAD	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-6.26	1.17e-09	1.63e-06	-0.57	-0.32	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
STAD	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	6.25	1.18e-09	1.64e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
STAD	cis	rs875971	0.628	rs6974355	ENSG00000222364.1	RNU6-96P	-6.25	1.18e-09	1.64e-06	-0.36	-0.32	Aortic root size;	chr7:66376994	chr7:66395191~66395286:+
STAD	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	6.25	1.18e-09	1.64e-06	0.39	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
STAD	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	6.25	1.18e-09	1.64e-06	0.36	0.32	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
STAD	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-6.25	1.18e-09	1.65e-06	-0.37	-0.32	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
STAD	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	6.25	1.18e-09	1.65e-06	0.33	0.32	Asthma;	chr2:102394452	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	6.25	1.18e-09	1.65e-06	0.33	0.32	Asthma;	chr2:102399227	chr2:102438713~102440475:+
STAD	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	6.25	1.18e-09	1.65e-06	0.42	0.32	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
STAD	cis	rs227275	0.524	rs150894	ENSG00000230069.3	LRRC37A15P	-6.25	1.18e-09	1.65e-06	-0.34	-0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102727274~102730721:-
STAD	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	6.25	1.18e-09	1.65e-06	0.48	0.32	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	6.25	1.18e-09	1.65e-06	0.48	0.32	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	6.25	1.18e-09	1.65e-06	0.48	0.32	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
STAD	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	6.25	1.18e-09	1.65e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
STAD	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-6.25	1.19e-09	1.65e-06	-0.45	-0.32	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
STAD	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-6.25	1.19e-09	1.66e-06	-0.36	-0.32	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
STAD	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	6.25	1.19e-09	1.66e-06	0.33	0.32	Asthma;	chr2:102379885	chr2:102438713~102440475:+
STAD	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	6.25	1.19e-09	1.66e-06	0.48	0.32	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
STAD	cis	rs11722779	0.692	rs223414	ENSG00000230069.3	LRRC37A15P	-6.25	1.19e-09	1.66e-06	-0.34	-0.32	Schizophrenia;	chr4:102811688	chr4:102727274~102730721:-
STAD	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-6.25	1.19e-09	1.66e-06	-0.3	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
STAD	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-6.25	1.19e-09	1.66e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-6.25	1.19e-09	1.66e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
STAD	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	6.25	1.19e-09	1.66e-06	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	6.25	1.19e-09	1.66e-06	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	6.25	1.19e-09	1.66e-06	0.46	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
STAD	cis	rs227275	0.554	rs223422	ENSG00000230069.3	LRRC37A15P	-6.25	1.2e-09	1.67e-06	-0.34	-0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223421	ENSG00000230069.3	LRRC37A15P	-6.25	1.2e-09	1.67e-06	-0.34	-0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102727274~102730721:-
STAD	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	6.25	1.2e-09	1.67e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	6.25	1.2e-09	1.67e-06	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs7718472	ENSG00000243385.2	CTD-2110K23.1	6.25	1.2e-09	1.67e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83201229~83202141:+
STAD	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-6.25	1.2e-09	1.67e-06	-0.34	-0.32	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
STAD	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-6.25	1.2e-09	1.67e-06	-0.33	-0.32	Asthma;	chr2:102377873	chr2:102438713~102440475:+
STAD	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-6.25	1.2e-09	1.67e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
STAD	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	6.25	1.2e-09	1.67e-06	0.34	0.32	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
STAD	cis	rs453301	0.598	rs2921383	ENSG00000254340.1	RP11-10A14.3	6.25	1.2e-09	1.68e-06	0.39	0.32	Joint mobility (Beighton score);	chr8:9034711	chr8:9141424~9145435:+
STAD	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-6.25	1.21e-09	1.68e-06	-0.53	-0.32	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
STAD	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-6.25	1.21e-09	1.68e-06	-0.34	-0.32	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
STAD	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-6.25	1.21e-09	1.68e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
STAD	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	6.25	1.21e-09	1.68e-06	0.37	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
STAD	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	6.25	1.21e-09	1.69e-06	0.38	0.32	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	6.25	1.21e-09	1.69e-06	0.38	0.32	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	6.25	1.21e-09	1.69e-06	0.38	0.32	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
STAD	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-6.25	1.21e-09	1.69e-06	-0.34	-0.32	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	6.25	1.22e-09	1.69e-06	0.23	0.32	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
STAD	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-6.25	1.22e-09	1.7e-06	-0.32	-0.32	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
STAD	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	6.25	1.22e-09	1.7e-06	0.33	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
STAD	cis	rs611744	0.806	rs2440387	ENSG00000253754.1	RP11-35G22.1	-6.25	1.22e-09	1.7e-06	-0.28	-0.32	Dupuytren's disease;	chr8:108054850	chr8:108226200~108227544:+
STAD	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-6.25	1.22e-09	1.7e-06	-0.46	-0.32	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
STAD	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	6.25	1.22e-09	1.7e-06	0.36	0.32	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	6.25	1.22e-09	1.7e-06	0.36	0.32	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
STAD	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	6.25	1.22e-09	1.7e-06	0.35	0.32	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
STAD	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-6.25	1.23e-09	1.71e-06	-0.28	-0.32	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-6.25	1.23e-09	1.71e-06	-0.28	-0.32	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
STAD	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	6.25	1.23e-09	1.71e-06	0.33	0.32	Asthma;	chr2:102412435	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	6.25	1.23e-09	1.71e-06	0.33	0.32	Asthma;	chr2:102412461	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	6.25	1.23e-09	1.71e-06	0.33	0.32	Asthma;	chr2:102412524	chr2:102438713~102440475:+
STAD	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	6.25	1.23e-09	1.71e-06	0.36	0.32	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
STAD	cis	rs227275	0.554	rs223409	ENSG00000230069.3	LRRC37A15P	-6.25	1.24e-09	1.72e-06	-0.34	-0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223404	ENSG00000230069.3	LRRC37A15P	-6.25	1.24e-09	1.72e-06	-0.34	-0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102727274~102730721:-
STAD	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-6.25	1.24e-09	1.72e-06	-0.3	-0.32	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
STAD	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-6.25	1.24e-09	1.72e-06	-0.37	-0.32	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-6.25	1.24e-09	1.72e-06	-0.37	-0.32	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-6.25	1.24e-09	1.72e-06	-0.37	-0.32	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-6.25	1.24e-09	1.72e-06	-0.37	-0.32	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
STAD	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-6.25	1.24e-09	1.72e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
STAD	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	6.24	1.24e-09	1.73e-06	0.44	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	6.24	1.24e-09	1.73e-06	0.44	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
STAD	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	6.24	1.24e-09	1.73e-06	0.3	0.32	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
STAD	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-6.24	1.24e-09	1.73e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
STAD	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	6.24	1.24e-09	1.73e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
STAD	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	6.24	1.25e-09	1.73e-06	0.38	0.32	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
STAD	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	6.24	1.25e-09	1.73e-06	0.32	0.32	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	6.24	1.25e-09	1.73e-06	0.32	0.32	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
STAD	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	6.24	1.25e-09	1.73e-06	0.42	0.32	Height;	chr6:109486036	chr6:109382795~109383666:+
STAD	cis	rs62130978	0.55	rs56153949	ENSG00000267980.1	AC007292.6	-6.24	1.25e-09	1.73e-06	-0.46	-0.32	Red cell distribution width;	chr19:4457521	chr19:4363789~4364640:+
STAD	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-6.24	1.25e-09	1.74e-06	-0.31	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
STAD	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-6.24	1.25e-09	1.74e-06	-0.28	-0.32	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.957	rs61997760	ENSG00000223648.3	IGHV3-64	6.24	1.26e-09	1.74e-06	0.28	0.32	Kawasaki disease;	chr14:106716993	chr14:106643132~106658258:-
STAD	cis	rs6452524	0.935	rs11750799	ENSG00000243385.2	CTD-2110K23.1	6.24	1.26e-09	1.75e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs10942321	ENSG00000243385.2	CTD-2110K23.1	6.24	1.26e-09	1.75e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83201229~83202141:+
STAD	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	6.24	1.26e-09	1.75e-06	0.41	0.32	Height;	chr6:109747119	chr6:109382795~109383666:+
STAD	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-6.24	1.27e-09	1.76e-06	-0.4	-0.32	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
STAD	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	6.24	1.27e-09	1.76e-06	0.32	0.32	Asthma;	chr2:102418659	chr2:102438713~102440475:+
STAD	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	6.24	1.27e-09	1.76e-06	0.51	0.32	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
STAD	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	6.24	1.27e-09	1.76e-06	0.33	0.32	Asthma;	chr2:102381819	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	6.24	1.27e-09	1.76e-06	0.33	0.32	Asthma;	chr2:102382514	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	6.24	1.27e-09	1.76e-06	0.33	0.32	Asthma;	chr2:102382943	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	6.24	1.27e-09	1.76e-06	0.33	0.32	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	6.24	1.27e-09	1.76e-06	0.33	0.32	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
STAD	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-6.24	1.27e-09	1.77e-06	-0.3	-0.32	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
STAD	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	6.24	1.27e-09	1.77e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
STAD	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-6.24	1.28e-09	1.77e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
STAD	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	6.24	1.28e-09	1.77e-06	0.34	0.32	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
STAD	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	6.24	1.28e-09	1.77e-06	0.36	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
STAD	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.24	1.28e-09	1.77e-06	-0.33	-0.32	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
STAD	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	6.24	1.28e-09	1.78e-06	0.39	0.32	Height;	chr6:109391084	chr6:109382795~109383666:+
STAD	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-6.24	1.28e-09	1.78e-06	-0.44	-0.32	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
STAD	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	6.24	1.29e-09	1.78e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	6.24	1.29e-09	1.78e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
STAD	cis	rs2335455	1	rs2335455	ENSG00000276791.1	CTD-2270P14.5	6.24	1.29e-09	1.78e-06	0.41	0.32	Sum eosinophil basophil counts;	chr16:2778172	chr16:2777319~2780568:+
STAD	cis	rs228614	0.51	rs150893	ENSG00000230069.3	LRRC37A15P	6.24	1.29e-09	1.79e-06	0.34	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102727274~102730721:-
STAD	cis	rs7924176	0.521	rs11001022	ENSG00000236900.1	TIMM9P1	-6.24	1.29e-09	1.79e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74344550~74344805:-
STAD	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-6.24	1.29e-09	1.79e-06	-0.45	-0.32	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
STAD	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-6.24	1.3e-09	1.8e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
STAD	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	6.24	1.3e-09	1.8e-06	0.37	0.32	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
STAD	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-6.24	1.3e-09	1.8e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
STAD	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	6.24	1.31e-09	1.81e-06	0.25	0.32	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
STAD	cis	rs9549260	0.755	rs9549244	ENSG00000229456.1	RLIMP1	6.24	1.31e-09	1.81e-06	0.29	0.32	Red blood cell count;	chr13:40644548	chr13:40618738~40621348:+
STAD	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-6.24	1.31e-09	1.81e-06	-0.5	-0.32	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
STAD	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	6.24	1.31e-09	1.81e-06	0.38	0.32	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
STAD	cis	rs6782228	0.527	rs7426806	ENSG00000277250.1	Metazoa_SRP	-6.24	1.31e-09	1.81e-06	-0.32	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128673681~128674021:-
STAD	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	6.23	1.32e-09	1.82e-06	0.39	0.32	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
STAD	cis	rs67180937	0.882	rs17163313	ENSG00000272750.1	RP11-378J18.8	-6.23	1.32e-09	1.82e-06	-0.31	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222626283	chr1:222658867~222661512:-
STAD	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	6.23	1.32e-09	1.82e-06	0.38	0.32	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
STAD	cis	rs8141529	0.778	rs763073	ENSG00000226471.5	CTA-292E10.6	-6.23	1.32e-09	1.82e-06	-0.37	-0.32	Lymphocyte counts;	chr22:28819554	chr22:28800683~28848559:+
STAD	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	6.23	1.32e-09	1.83e-06	0.45	0.32	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	6.23	1.32e-09	1.83e-06	0.45	0.32	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	6.23	1.32e-09	1.83e-06	0.45	0.32	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
STAD	cis	rs748404	1	rs12909095	ENSG00000249839.1	AC011330.5	-6.23	1.32e-09	1.83e-06	-0.5	-0.32	Lung cancer;	chr15:43265944	chr15:43663654~43684339:-
STAD	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-6.23	1.32e-09	1.83e-06	-0.29	-0.32	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
STAD	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	6.23	1.32e-09	1.83e-06	0.34	0.32	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
STAD	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-6.23	1.33e-09	1.83e-06	-0.37	-0.32	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
STAD	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-6.23	1.33e-09	1.84e-06	-0.33	-0.32	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
STAD	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-6.23	1.33e-09	1.84e-06	-0.39	-0.32	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
STAD	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-6.23	1.33e-09	1.84e-06	-0.35	-0.32	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
STAD	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-6.23	1.33e-09	1.84e-06	-0.32	-0.32	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
STAD	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-6.23	1.33e-09	1.84e-06	-0.38	-0.32	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
STAD	cis	rs9326248	0.569	rs4938315	ENSG00000280143.1	AP000892.6	6.23	1.33e-09	1.84e-06	0.33	0.32	Blood protein levels;	chr11:116860489	chr11:117204967~117210292:+
STAD	cis	rs9395066	0.545	rs12209076	ENSG00000219384.1	RP11-491H9.3	-6.23	1.34e-09	1.85e-06	-0.31	-0.32	Height;	chr6:44865686	chr6:45158870~45159511:+
STAD	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	6.23	1.34e-09	1.85e-06	0.29	0.32	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
STAD	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-6.23	1.34e-09	1.85e-06	-0.45	-0.32	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
STAD	cis	rs2273156	0.57	rs7156322	ENSG00000241052.1	RP11-173D9.1	-6.23	1.34e-09	1.85e-06	-0.38	-0.32	Immunoglobulin light chain (AL) amyloidosis;	chr14:35075124	chr14:35144021~35144480:-
STAD	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	6.23	1.34e-09	1.85e-06	0.38	0.32	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	6.23	1.34e-09	1.85e-06	0.38	0.32	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	6.23	1.34e-09	1.85e-06	0.38	0.32	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	6.23	1.34e-09	1.85e-06	0.38	0.32	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	6.23	1.34e-09	1.85e-06	0.38	0.32	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
STAD	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	6.23	1.34e-09	1.85e-06	0.3	0.32	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
STAD	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-6.23	1.34e-09	1.85e-06	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-6.23	1.34e-09	1.85e-06	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
STAD	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-6.23	1.35e-09	1.86e-06	-0.53	-0.32	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
STAD	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-6.23	1.35e-09	1.87e-06	-0.3	-0.32	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
STAD	cis	rs6452524	0.901	rs12188673	ENSG00000243385.2	CTD-2110K23.1	6.23	1.35e-09	1.87e-06	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83201229~83202141:+
STAD	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-6.23	1.36e-09	1.87e-06	-0.54	-0.32	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-6.23	1.36e-09	1.87e-06	-0.54	-0.32	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
STAD	cis	rs10129255	0.957	rs1056705	ENSG00000223648.3	IGHV3-64	6.23	1.36e-09	1.87e-06	0.28	0.32	Kawasaki disease;	chr14:106714323	chr14:106643132~106658258:-
STAD	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-6.23	1.36e-09	1.87e-06	-0.3	-0.32	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
STAD	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	6.23	1.36e-09	1.88e-06	0.37	0.32	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
STAD	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-6.23	1.36e-09	1.88e-06	-0.37	-0.32	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
STAD	cis	rs10461617	0.617	rs6874733	ENSG00000271828.1	CTD-2310F14.1	6.23	1.36e-09	1.88e-06	0.38	0.32	Type 2 diabetes;	chr5:56773773	chr5:56927874~56929573:+
STAD	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	6.23	1.36e-09	1.88e-06	0.47	0.32	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
STAD	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-6.23	1.36e-09	1.88e-06	-0.32	-0.32	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-6.23	1.36e-09	1.88e-06	-0.33	-0.32	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
STAD	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-6.23	1.37e-09	1.89e-06	-0.33	-0.32	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-6.23	1.37e-09	1.89e-06	-0.33	-0.32	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
STAD	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-6.23	1.37e-09	1.89e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
STAD	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	6.23	1.37e-09	1.89e-06	0.38	0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
STAD	cis	rs6452524	0.901	rs1039786	ENSG00000243385.2	CTD-2110K23.1	6.23	1.38e-09	1.9e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83201229~83202141:+
STAD	cis	rs9395066	0.545	rs10948192	ENSG00000219384.1	RP11-491H9.3	-6.23	1.38e-09	1.9e-06	-0.31	-0.32	Height;	chr6:44979584	chr6:45158870~45159511:+
STAD	cis	rs9549260	0.755	rs17061491	ENSG00000229456.1	RLIMP1	6.23	1.38e-09	1.9e-06	0.29	0.32	Red blood cell count;	chr13:40654073	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs9532577	ENSG00000229456.1	RLIMP1	6.23	1.38e-09	1.9e-06	0.29	0.32	Red blood cell count;	chr13:40657405	chr13:40618738~40621348:+
STAD	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-6.23	1.38e-09	1.9e-06	-0.37	-0.32	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
STAD	cis	rs9549260	0.62	rs12583418	ENSG00000229456.1	RLIMP1	6.23	1.38e-09	1.9e-06	0.29	0.32	Red blood cell count;	chr13:40621274	chr13:40618738~40621348:+
STAD	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	6.23	1.39e-09	1.91e-06	0.51	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
STAD	cis	rs1400745	0.756	rs799683	ENSG00000258738.1	RP11-73E17.2	6.23	1.39e-09	1.91e-06	0.39	0.32	Monocyte count;	chr14:34880030	chr14:34874343~34876459:+
STAD	cis	rs1400745	0.756	rs799682	ENSG00000258738.1	RP11-73E17.2	6.23	1.39e-09	1.91e-06	0.39	0.32	Monocyte count;	chr14:34880778	chr14:34874343~34876459:+
STAD	cis	rs1400745	0.718	rs799681	ENSG00000258738.1	RP11-73E17.2	6.23	1.39e-09	1.91e-06	0.39	0.32	Monocyte count;	chr14:34881373	chr14:34874343~34876459:+
STAD	cis	rs3806843	0.735	rs801183	ENSG00000202111.1	VTRNA1-2	-6.23	1.39e-09	1.92e-06	-0.31	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr5:140718925~140719013:+
STAD	cis	rs9549260	0.755	rs9566553	ENSG00000229456.1	RLIMP1	6.22	1.4e-09	1.92e-06	0.29	0.32	Red blood cell count;	chr13:40600094	chr13:40618738~40621348:+
STAD	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-6.22	1.4e-09	1.92e-06	-0.37	-0.32	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
STAD	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	6.22	1.4e-09	1.92e-06	0.32	0.32	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
STAD	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	6.22	1.4e-09	1.92e-06	0.33	0.32	Asthma;	chr2:102381261	chr2:102438713~102440475:+
STAD	cis	rs7487075	0.619	rs4427617	ENSG00000272369.1	RP11-446N19.1	6.22	1.4e-09	1.93e-06	0.43	0.32	Itch intensity from mosquito bite;	chr12:46400719	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs2131371	ENSG00000272369.1	RP11-446N19.1	6.22	1.4e-09	1.93e-06	0.43	0.32	Itch intensity from mosquito bite;	chr12:46402739	chr12:46537502~46652550:+
STAD	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-6.22	1.4e-09	1.93e-06	-0.45	-0.32	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
STAD	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-6.22	1.4e-09	1.93e-06	-0.45	-0.32	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
STAD	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	6.22	1.41e-09	1.93e-06	0.38	0.32	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
STAD	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-6.22	1.41e-09	1.93e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
STAD	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	6.22	1.41e-09	1.94e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
STAD	cis	rs13276960	0.553	rs58867349	ENSG00000253385.1	KB-1254G8.1	6.22	1.41e-09	1.94e-06	0.35	0.32	Schizophrenia;	chr8:102915932	chr8:102854455~102856075:+
STAD	cis	rs9549260	0.709	rs4943795	ENSG00000229456.1	RLIMP1	-6.22	1.41e-09	1.94e-06	-0.28	-0.32	Red blood cell count;	chr13:40599296	chr13:40618738~40621348:+
STAD	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	6.22	1.41e-09	1.94e-06	0.39	0.32	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
STAD	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-6.22	1.41e-09	1.94e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-6.22	1.41e-09	1.94e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-6.22	1.41e-09	1.94e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
STAD	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-6.22	1.41e-09	1.94e-06	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-6.22	1.41e-09	1.94e-06	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-6.22	1.41e-09	1.94e-06	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-6.22	1.41e-09	1.94e-06	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-6.22	1.41e-09	1.94e-06	-0.39	-0.32	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
STAD	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-6.22	1.42e-09	1.94e-06	-0.3	-0.32	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
STAD	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	6.22	1.42e-09	1.95e-06	0.36	0.32	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	6.22	1.42e-09	1.95e-06	0.36	0.32	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
STAD	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-6.22	1.42e-09	1.95e-06	-0.31	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
STAD	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	6.22	1.42e-09	1.95e-06	0.37	0.32	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
STAD	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	6.22	1.42e-09	1.95e-06	0.34	0.32	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
STAD	cis	rs7487075	0.538	rs1125909	ENSG00000272369.1	RP11-446N19.1	6.22	1.42e-09	1.95e-06	0.43	0.32	Itch intensity from mosquito bite;	chr12:46392611	chr12:46537502~46652550:+
STAD	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	6.22	1.42e-09	1.95e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
STAD	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	6.22	1.42e-09	1.95e-06	0.55	0.32	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
STAD	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	6.22	1.42e-09	1.95e-06	0.55	0.32	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
STAD	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	6.22	1.42e-09	1.95e-06	0.55	0.32	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
STAD	cis	rs496547	0.588	rs473298	ENSG00000255422.1	AP002954.4	-6.22	1.42e-09	1.95e-06	-0.36	-0.32	Hip minimal joint space width;	chr11:118808678	chr11:118704607~118750263:+
STAD	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	6.22	1.42e-09	1.95e-06	0.4	0.32	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
STAD	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	6.22	1.42e-09	1.95e-06	0.4	0.32	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
STAD	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	6.22	1.42e-09	1.96e-06	0.32	0.32	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
STAD	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	6.22	1.43e-09	1.96e-06	0.36	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
STAD	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	6.22	1.43e-09	1.97e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
STAD	cis	rs9549260	0.755	rs7333037	ENSG00000229456.1	RLIMP1	6.22	1.43e-09	1.97e-06	0.29	0.32	Red blood cell count;	chr13:40641119	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs7989711	ENSG00000229456.1	RLIMP1	6.22	1.43e-09	1.97e-06	0.29	0.32	Red blood cell count;	chr13:40641559	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs7988604	ENSG00000229456.1	RLIMP1	6.22	1.43e-09	1.97e-06	0.29	0.32	Red blood cell count;	chr13:40641665	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs7990923	ENSG00000229456.1	RLIMP1	6.22	1.43e-09	1.97e-06	0.29	0.32	Red blood cell count;	chr13:40641835	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs4325426	ENSG00000229456.1	RLIMP1	6.22	1.43e-09	1.97e-06	0.29	0.32	Red blood cell count;	chr13:40642300	chr13:40618738~40621348:+
STAD	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	6.22	1.44e-09	1.97e-06	0.4	0.32	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
STAD	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	6.22	1.44e-09	1.97e-06	0.33	0.32	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
STAD	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	6.22	1.44e-09	1.98e-06	0.38	0.32	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
STAD	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.22	1.44e-09	1.98e-06	-0.33	-0.32	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
STAD	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	6.22	1.44e-09	1.98e-06	0.35	0.32	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	6.22	1.44e-09	1.98e-06	0.35	0.32	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	6.22	1.44e-09	1.98e-06	0.35	0.32	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	6.22	1.44e-09	1.98e-06	0.35	0.32	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
STAD	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-6.22	1.45e-09	1.98e-06	-0.5	-0.32	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.867	rs2614811	ENSG00000249839.1	AC011330.5	-6.22	1.45e-09	1.98e-06	-0.52	-0.32	Lung cancer in ever smokers;	chr15:43621289	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-6.22	1.45e-09	1.99e-06	-0.29	-0.32	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
STAD	cis	rs9368481	0.594	rs2636425	ENSG00000243307.2	POM121L6P	6.22	1.45e-09	1.99e-06	0.33	0.32	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26896952~26898777:+
STAD	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	6.22	1.45e-09	1.99e-06	0.46	0.32	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
STAD	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	6.22	1.46e-09	2e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
STAD	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	6.22	1.46e-09	2e-06	0.35	0.32	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
STAD	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	6.22	1.46e-09	2e-06	0.44	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
STAD	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	6.22	1.46e-09	2e-06	0.29	0.32	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
STAD	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	6.22	1.46e-09	2e-06	0.27	0.32	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	6.22	1.46e-09	2e-06	0.27	0.32	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
STAD	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-6.22	1.46e-09	2.01e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
STAD	cis	rs8067354	0.574	rs1295923	ENSG00000266701.1	AC005702.4	6.22	1.46e-09	2.01e-06	0.46	0.32	Hemoglobin concentration;	chr17:59883075	chr17:60042546~60042627:-
STAD	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	6.22	1.47e-09	2.01e-06	0.38	0.32	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
STAD	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	6.22	1.47e-09	2.01e-06	0.5	0.32	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
STAD	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	6.22	1.47e-09	2.01e-06	0.33	0.32	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
STAD	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	6.22	1.47e-09	2.02e-06	0.38	0.32	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	6.22	1.47e-09	2.02e-06	0.38	0.32	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	6.22	1.47e-09	2.02e-06	0.38	0.32	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
STAD	cis	rs9549260	0.755	rs2721066	ENSG00000229456.1	RLIMP1	-6.22	1.47e-09	2.02e-06	-0.29	-0.32	Red blood cell count;	chr13:40582051	chr13:40618738~40621348:+
STAD	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-6.22	1.48e-09	2.02e-06	-0.43	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
STAD	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	6.21	1.48e-09	2.02e-06	0.33	0.32	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
STAD	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	6.21	1.48e-09	2.02e-06	0.28	0.32	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
STAD	cis	rs9467773	0.534	rs34453863	ENSG00000243307.2	POM121L6P	6.21	1.48e-09	2.03e-06	0.31	0.32	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26896952~26898777:+
STAD	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	6.21	1.48e-09	2.03e-06	0.38	0.32	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
STAD	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-6.21	1.48e-09	2.03e-06	-0.4	-0.32	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
STAD	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-6.21	1.49e-09	2.03e-06	-0.34	-0.32	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-6.21	1.49e-09	2.03e-06	-0.34	-0.32	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-6.21	1.49e-09	2.03e-06	-0.34	-0.32	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
STAD	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	6.21	1.49e-09	2.04e-06	0.38	0.32	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
STAD	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-6.21	1.49e-09	2.04e-06	-0.41	-0.32	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
STAD	cis	rs2221894	0.959	rs1487969	ENSG00000273710.1	Metazoa_SRP	6.21	1.5e-09	2.05e-06	0.34	0.32	Obesity-related traits;	chr8:29028144	chr8:28915579~28915864:-
STAD	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-6.21	1.5e-09	2.05e-06	-0.28	-0.32	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
STAD	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-6.21	1.51e-09	2.06e-06	-0.32	-0.32	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
STAD	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	6.21	1.51e-09	2.06e-06	0.33	0.32	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
STAD	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	6.21	1.51e-09	2.06e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
STAD	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-6.21	1.51e-09	2.07e-06	-0.36	-0.32	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
STAD	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-6.21	1.52e-09	2.07e-06	-0.28	-0.32	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
STAD	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	6.21	1.52e-09	2.07e-06	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
STAD	cis	rs992157	1	rs4791	ENSG00000237281.1	CATIP-AS2	-6.21	1.52e-09	2.07e-06	-0.33	-0.32	Colorectal cancer;	chr2:218274217	chr2:218326889~218357966:-
STAD	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-6.21	1.52e-09	2.08e-06	-0.3	-0.32	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
STAD	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-6.21	1.53e-09	2.09e-06	-0.54	-0.32	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-6.21	1.53e-09	2.09e-06	-0.54	-0.32	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
STAD	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	6.21	1.53e-09	2.09e-06	0.32	0.32	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
STAD	cis	rs11903757	0.738	rs10931515	ENSG00000281467.1	Clostridiales-1	-6.21	1.53e-09	2.09e-06	-0.43	-0.32	Colorectal cancer;	chr2:191710385	chr2:191699476~191699631:-
STAD	cis	rs453301	0.686	rs6601280	ENSG00000254340.1	RP11-10A14.3	6.21	1.53e-09	2.09e-06	0.42	0.32	Joint mobility (Beighton score);	chr8:9051726	chr8:9141424~9145435:+
STAD	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	6.21	1.54e-09	2.1e-06	0.36	0.32	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
STAD	cis	rs6993244	1	rs6993244	ENSG00000254340.1	RP11-10A14.3	6.21	1.54e-09	2.1e-06	0.38	0.32	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9141424~9145435:+
STAD	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	6.21	1.54e-09	2.1e-06	0.32	0.32	Asthma;	chr2:102411180	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	6.21	1.54e-09	2.1e-06	0.32	0.32	Asthma;	chr2:102411191	chr2:102438713~102440475:+
STAD	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	6.21	1.55e-09	2.11e-06	0.41	0.32	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
STAD	cis	rs11089937	0.667	rs10483108	ENSG00000211639.2	IGLV4-60	6.21	1.55e-09	2.11e-06	0.36	0.32	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22162199~22162681:+
STAD	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	6.21	1.55e-09	2.11e-06	0.38	0.32	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
STAD	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	6.21	1.55e-09	2.12e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
STAD	cis	rs7924176	0.521	rs61863363	ENSG00000236900.1	TIMM9P1	-6.21	1.56e-09	2.13e-06	-0.33	-0.32	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74344550~74344805:-
STAD	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	6.2	1.56e-09	2.13e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
STAD	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	6.2	1.57e-09	2.14e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
STAD	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	6.2	1.57e-09	2.14e-06	0.33	0.32	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
STAD	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	6.2	1.57e-09	2.14e-06	0.36	0.32	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	6.2	1.57e-09	2.14e-06	0.36	0.32	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
STAD	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	6.2	1.57e-09	2.14e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
STAD	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	6.2	1.57e-09	2.14e-06	0.28	0.32	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
STAD	cis	rs6452524	0.901	rs2662238	ENSG00000243385.2	CTD-2110K23.1	6.2	1.57e-09	2.14e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83201229~83202141:+
STAD	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-6.2	1.57e-09	2.14e-06	-0.37	-0.32	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
STAD	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-6.2	1.57e-09	2.14e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
STAD	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-6.2	1.58e-09	2.15e-06	-0.54	-0.32	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
STAD	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-6.2	1.58e-09	2.15e-06	-0.34	-0.32	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
STAD	cis	rs9549260	0.755	rs4941987	ENSG00000229456.1	RLIMP1	6.2	1.58e-09	2.15e-06	0.29	0.32	Red blood cell count;	chr13:40621855	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.683	rs4941988	ENSG00000229456.1	RLIMP1	6.2	1.58e-09	2.15e-06	0.29	0.32	Red blood cell count;	chr13:40621869	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.64	rs4943796	ENSG00000229456.1	RLIMP1	6.2	1.58e-09	2.15e-06	0.29	0.32	Red blood cell count;	chr13:40621879	chr13:40618738~40621348:+
STAD	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	6.2	1.58e-09	2.15e-06	0.37	0.32	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
STAD	cis	rs9395066	0.545	rs10484627	ENSG00000219384.1	RP11-491H9.3	-6.2	1.58e-09	2.15e-06	-0.31	-0.32	Height;	chr6:44916530	chr6:45158870~45159511:+
STAD	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	6.2	1.59e-09	2.17e-06	0.32	0.32	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
STAD	cis	rs711244	0.783	rs2252032	ENSG00000252756.1	RNU6-577P	-6.2	1.59e-09	2.17e-06	-0.35	-0.32	Mean platelet volume;	chr2:36872196	chr2:36867398~36867495:-
STAD	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	6.2	1.59e-09	2.17e-06	0.32	0.32	Asthma;	chr2:102402540	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	6.2	1.59e-09	2.17e-06	0.32	0.32	Asthma;	chr2:102402571	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	6.2	1.59e-09	2.17e-06	0.32	0.32	Asthma;	chr2:102403325	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	6.2	1.59e-09	2.17e-06	0.32	0.32	Asthma;	chr2:102403679	chr2:102438713~102440475:+
STAD	cis	rs10129255	0.869	rs72690553	ENSG00000223648.3	IGHV3-64	6.2	1.6e-09	2.17e-06	0.28	0.32	Kawasaki disease;	chr14:106715491	chr14:106643132~106658258:-
STAD	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	6.2	1.6e-09	2.17e-06	0.26	0.32	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
STAD	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-6.2	1.6e-09	2.18e-06	-0.27	-0.32	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
STAD	cis	rs9395066	0.545	rs4714830	ENSG00000219384.1	RP11-491H9.3	-6.2	1.6e-09	2.18e-06	-0.31	-0.32	Height;	chr6:44987791	chr6:45158870~45159511:+
STAD	cis	rs9395066	0.527	rs55893720	ENSG00000219384.1	RP11-491H9.3	-6.2	1.6e-09	2.18e-06	-0.31	-0.32	Height;	chr6:44987979	chr6:45158870~45159511:+
STAD	cis	rs9395066	0.545	rs35813980	ENSG00000219384.1	RP11-491H9.3	-6.2	1.6e-09	2.18e-06	-0.31	-0.32	Height;	chr6:44988271	chr6:45158870~45159511:+
STAD	cis	rs9395066	0.509	rs11967188	ENSG00000219384.1	RP11-491H9.3	-6.2	1.6e-09	2.18e-06	-0.31	-0.32	Height;	chr6:44989188	chr6:45158870~45159511:+
STAD	cis	rs11089937	0.667	rs10483107	ENSG00000211639.2	IGLV4-60	6.2	1.6e-09	2.18e-06	0.36	0.32	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22162199~22162681:+
STAD	cis	rs9309711	0.621	rs11127428	ENSG00000225234.1	TRAPPC12-AS1	-6.2	1.6e-09	2.18e-06	-0.36	-0.32	Neurofibrillary tangles;	chr2:3467375	chr2:3481242~3482409:-
STAD	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-6.2	1.6e-09	2.18e-06	-0.33	-0.32	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
STAD	cis	rs9395066	0.545	rs10948193	ENSG00000219384.1	RP11-491H9.3	-6.2	1.61e-09	2.18e-06	-0.31	-0.32	Height;	chr6:44981439	chr6:45158870~45159511:+
STAD	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-6.2	1.61e-09	2.18e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
STAD	cis	rs9549260	0.755	rs17061450	ENSG00000229456.1	RLIMP1	6.2	1.61e-09	2.18e-06	0.29	0.32	Red blood cell count;	chr13:40609579	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs4429172	ENSG00000229456.1	RLIMP1	6.2	1.61e-09	2.18e-06	0.29	0.32	Red blood cell count;	chr13:40615006	chr13:40618738~40621348:+
STAD	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-6.2	1.61e-09	2.19e-06	-0.43	-0.32	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
STAD	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	6.2	1.61e-09	2.19e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	6.2	1.61e-09	2.19e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
STAD	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-6.2	1.61e-09	2.19e-06	-0.34	-0.32	Height;	chr2:231516587	chr2:231501990~231502201:-
STAD	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-6.2	1.61e-09	2.19e-06	-0.3	-0.32	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
STAD	cis	rs12699921	0.933	rs6942635	ENSG00000279048.1	RP11-511H23.2	6.2	1.61e-09	2.19e-06	0.28	0.32	Fibrinogen levels;	chr7:17948242	chr7:17940503~17942922:+
STAD	cis	rs9549260	0.755	rs12585875	ENSG00000229456.1	RLIMP1	6.2	1.61e-09	2.19e-06	0.28	0.32	Red blood cell count;	chr13:40625394	chr13:40618738~40621348:+
STAD	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-6.2	1.61e-09	2.19e-06	-0.42	-0.32	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
STAD	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.2	1.62e-09	2.19e-06	-0.33	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
STAD	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	6.2	1.62e-09	2.2e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	6.2	1.62e-09	2.2e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
STAD	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	6.2	1.62e-09	2.2e-06	0.32	0.32	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
STAD	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-6.2	1.62e-09	2.2e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	6.2	1.62e-09	2.2e-06	0.37	0.32	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	6.2	1.62e-09	2.2e-06	0.41	0.32	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
STAD	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	6.2	1.63e-09	2.21e-06	0.32	0.32	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
STAD	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	6.2	1.63e-09	2.21e-06	0.3	0.32	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
STAD	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	6.2	1.63e-09	2.21e-06	0.44	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	6.2	1.63e-09	2.21e-06	0.44	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
STAD	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	6.2	1.63e-09	2.21e-06	0.37	0.32	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
STAD	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	6.2	1.63e-09	2.21e-06	0.37	0.32	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
STAD	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	6.2	1.63e-09	2.21e-06	0.34	0.32	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
STAD	cis	rs992157	1	rs736730	ENSG00000237281.1	CATIP-AS2	-6.2	1.63e-09	2.22e-06	-0.32	-0.32	Colorectal cancer;	chr2:218255532	chr2:218326889~218357966:-
STAD	cis	rs992157	1	rs736731	ENSG00000237281.1	CATIP-AS2	-6.2	1.63e-09	2.22e-06	-0.32	-0.32	Colorectal cancer;	chr2:218255865	chr2:218326889~218357966:-
STAD	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	6.2	1.64e-09	2.22e-06	0.32	0.32	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	6.2	1.64e-09	2.22e-06	0.32	0.32	Asthma;	chr2:102415109	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	6.2	1.64e-09	2.22e-06	0.32	0.32	Asthma;	chr2:102415289	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	6.2	1.64e-09	2.22e-06	0.32	0.32	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	6.2	1.64e-09	2.22e-06	0.32	0.32	Asthma;	chr2:102417501	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	6.2	1.64e-09	2.22e-06	0.32	0.32	Asthma;	chr2:102418383	chr2:102438713~102440475:+
STAD	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	6.2	1.64e-09	2.22e-06	0.23	0.32	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
STAD	cis	rs7487075	0.93	rs11183468	ENSG00000257261.4	RP11-96H19.1	6.2	1.64e-09	2.22e-06	0.37	0.32	Itch intensity from mosquito bite;	chr12:46412478	chr12:46383679~46876159:+
STAD	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	6.2	1.64e-09	2.23e-06	0.4	0.32	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
STAD	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	6.2	1.64e-09	2.23e-06	0.3	0.32	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
STAD	cis	rs9395066	0.545	rs3799977	ENSG00000219384.1	RP11-491H9.3	6.2	1.64e-09	2.23e-06	0.31	0.32	Height;	chr6:44869619	chr6:45158870~45159511:+
STAD	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	6.2	1.65e-09	2.23e-06	0.39	0.32	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
STAD	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	6.2	1.65e-09	2.24e-06	0.49	0.32	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
STAD	cis	rs6452524	0.775	rs10071579	ENSG00000243385.2	CTD-2110K23.1	6.2	1.65e-09	2.24e-06	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83201229~83202141:+
STAD	cis	rs875971	0.522	rs781144	ENSG00000222364.1	RNU6-96P	-6.2	1.65e-09	2.24e-06	-0.36	-0.32	Aortic root size;	chr7:65975357	chr7:66395191~66395286:+
STAD	cis	rs1426063	0.614	rs75345649	ENSG00000248165.1	RP11-44F21.2	6.2	1.65e-09	2.24e-06	0.66	0.32	QT interval;	chr4:75100963	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs77333523	ENSG00000248165.1	RP11-44F21.2	6.2	1.65e-09	2.24e-06	0.66	0.32	QT interval;	chr4:75101024	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs17199632	ENSG00000248165.1	RP11-44F21.2	6.2	1.65e-09	2.24e-06	0.66	0.32	QT interval;	chr4:75103663	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.614	rs76931926	ENSG00000248165.1	RP11-44F21.2	6.2	1.65e-09	2.24e-06	0.66	0.32	QT interval;	chr4:75106902	chr4:74993877~75034824:-
STAD	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-6.19	1.66e-09	2.24e-06	-0.3	-0.32	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
STAD	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	6.19	1.66e-09	2.25e-06	0.3	0.32	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
STAD	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-6.19	1.66e-09	2.25e-06	-0.33	-0.32	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
STAD	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-6.19	1.66e-09	2.25e-06	-0.31	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
STAD	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-6.19	1.67e-09	2.25e-06	-0.27	-0.32	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
STAD	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	6.19	1.67e-09	2.26e-06	0.38	0.32	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
STAD	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-6.19	1.67e-09	2.26e-06	-0.4	-0.32	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
STAD	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-6.19	1.67e-09	2.26e-06	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.719	rs7156660	ENSG00000280411.1	IGHV1-69-2	-6.19	1.68e-09	2.27e-06	-0.29	-0.32	Kawasaki disease;	chr14:106673171	chr14:106762092~106762588:-
STAD	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-6.19	1.69e-09	2.28e-06	-0.34	-0.32	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-6.19	1.69e-09	2.28e-06	-0.34	-0.32	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-6.19	1.69e-09	2.28e-06	-0.34	-0.32	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
STAD	cis	rs10129255	1	rs10137758	ENSG00000211970.3	IGHV4-61	-6.19	1.69e-09	2.28e-06	-0.28	-0.32	Kawasaki disease;	chr14:106697673	chr14:106639119~106639657:-
STAD	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	6.19	1.69e-09	2.28e-06	0.32	0.32	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
STAD	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	6.19	1.69e-09	2.28e-06	0.32	0.32	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
STAD	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-6.19	1.69e-09	2.29e-06	-0.33	-0.32	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
STAD	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	6.19	1.69e-09	2.29e-06	0.41	0.32	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
STAD	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-6.19	1.69e-09	2.29e-06	-0.32	-0.32	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
STAD	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	6.19	1.7e-09	2.3e-06	0.32	0.32	Asthma;	chr2:102404807	chr2:102438713~102440475:+
STAD	cis	rs9389248	0.623	rs2142725	ENSG00000232876.1	CTA-212D2.2	6.19	1.7e-09	2.3e-06	0.4	0.32	High light scatter reticulocyte percentage of red cells;	chr6:134937804	chr6:135055033~135060550:+
STAD	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	6.19	1.7e-09	2.3e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	6.19	1.7e-09	2.3e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	6.19	1.7e-09	2.3e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	6.19	1.7e-09	2.3e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
STAD	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-6.19	1.7e-09	2.3e-06	-0.34	-0.32	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
STAD	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	6.19	1.71e-09	2.31e-06	0.33	0.32	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
STAD	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	6.19	1.71e-09	2.31e-06	0.41	0.32	Height;	chr6:109747411	chr6:109382795~109383666:+
STAD	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	6.19	1.71e-09	2.31e-06	0.41	0.32	Height;	chr6:109748819	chr6:109382795~109383666:+
STAD	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	6.19	1.71e-09	2.31e-06	0.41	0.32	Height;	chr6:109749564	chr6:109382795~109383666:+
STAD	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	6.19	1.71e-09	2.31e-06	0.41	0.32	Height;	chr6:109763331	chr6:109382795~109383666:+
STAD	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-6.19	1.71e-09	2.31e-06	-0.5	-0.32	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
STAD	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	6.19	1.71e-09	2.31e-06	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
STAD	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-6.19	1.72e-09	2.32e-06	-0.39	-0.32	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
STAD	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	6.19	1.72e-09	2.32e-06	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
STAD	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-6.19	1.72e-09	2.32e-06	-0.39	-0.32	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
STAD	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
STAD	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-6.19	1.72e-09	2.32e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
STAD	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	6.19	1.72e-09	2.32e-06	0.36	0.32	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
STAD	cis	rs992157	1	rs10932766	ENSG00000237281.1	CATIP-AS2	-6.19	1.72e-09	2.32e-06	-0.32	-0.32	Colorectal cancer;	chr2:218257367	chr2:218326889~218357966:-
STAD	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	6.19	1.73e-09	2.33e-06	0.28	0.32	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
STAD	cis	rs9395066	0.545	rs3799976	ENSG00000219384.1	RP11-491H9.3	-6.19	1.73e-09	2.33e-06	-0.31	-0.32	Height;	chr6:44867885	chr6:45158870~45159511:+
STAD	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-6.19	1.73e-09	2.33e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
STAD	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	6.19	1.73e-09	2.33e-06	0.32	0.32	Asthma;	chr2:102407218	chr2:102438713~102440475:+
STAD	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-6.19	1.73e-09	2.34e-06	-0.34	-0.32	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
STAD	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
STAD	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
STAD	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
STAD	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
STAD	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
STAD	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
STAD	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
STAD	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
STAD	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
STAD	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
STAD	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-6.19	1.73e-09	2.34e-06	-0.33	-0.32	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
STAD	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	6.19	1.73e-09	2.34e-06	0.41	0.32	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
STAD	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-6.19	1.74e-09	2.35e-06	-0.28	-0.32	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
STAD	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-6.19	1.74e-09	2.35e-06	-0.41	-0.32	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
STAD	cis	rs9549260	0.816	rs7337995	ENSG00000229456.1	RLIMP1	6.19	1.74e-09	2.35e-06	0.29	0.32	Red blood cell count;	chr13:40674903	chr13:40618738~40621348:+
STAD	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	6.19	1.74e-09	2.35e-06	0.32	0.32	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
STAD	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	6.19	1.75e-09	2.35e-06	0.34	0.32	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	6.19	1.75e-09	2.35e-06	0.34	0.32	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	6.19	1.75e-09	2.35e-06	0.34	0.32	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
STAD	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-6.19	1.75e-09	2.35e-06	-0.39	-0.32	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-6.19	1.75e-09	2.35e-06	-0.39	-0.32	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-6.19	1.75e-09	2.35e-06	-0.39	-0.32	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-6.19	1.75e-09	2.35e-06	-0.39	-0.32	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-6.19	1.75e-09	2.35e-06	-0.39	-0.32	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-6.19	1.75e-09	2.35e-06	-0.39	-0.32	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-6.19	1.75e-09	2.35e-06	-0.39	-0.32	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
STAD	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-6.19	1.75e-09	2.36e-06	-0.31	-0.32	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
STAD	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	6.19	1.75e-09	2.36e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
STAD	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-6.19	1.75e-09	2.36e-06	-0.53	-0.32	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
STAD	cis	rs9549260	0.753	rs9549254	ENSG00000229456.1	RLIMP1	6.18	1.75e-09	2.36e-06	0.36	0.32	Red blood cell count;	chr13:40660626	chr13:40618738~40621348:+
STAD	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-6.18	1.75e-09	2.36e-06	-0.39	-0.32	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
STAD	cis	rs8005677	0.611	rs11624528	ENSG00000257285.4	RP11-298I3.1	6.18	1.76e-09	2.36e-06	0.39	0.32	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:22929609~22955562:+
STAD	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-6.18	1.76e-09	2.37e-06	-0.36	-0.32	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
STAD	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	6.18	1.76e-09	2.37e-06	0.27	0.32	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
STAD	cis	rs801193	1	rs10252765	ENSG00000222364.1	RNU6-96P	-6.18	1.76e-09	2.37e-06	-0.36	-0.32	Aortic root size;	chr7:66763745	chr7:66395191~66395286:+
STAD	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	6.18	1.76e-09	2.37e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
STAD	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	6.18	1.76e-09	2.38e-06	0.38	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
STAD	cis	rs6940638	0.513	rs4424065	ENSG00000243307.2	POM121L6P	-6.18	1.77e-09	2.38e-06	-0.3	-0.32	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26896952~26898777:+
STAD	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	6.18	1.77e-09	2.38e-06	0.42	0.32	Height;	chr6:109482392	chr6:109382795~109383666:+
STAD	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-6.18	1.77e-09	2.39e-06	-0.33	-0.32	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
STAD	cis	rs9549260	0.755	rs2721044	ENSG00000229456.1	RLIMP1	6.18	1.78e-09	2.39e-06	0.28	0.32	Red blood cell count;	chr13:40588088	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs2721045	ENSG00000229456.1	RLIMP1	6.18	1.78e-09	2.39e-06	0.28	0.32	Red blood cell count;	chr13:40588495	chr13:40618738~40621348:+
STAD	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-6.18	1.78e-09	2.39e-06	-0.39	-0.32	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
STAD	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-6.18	1.78e-09	2.39e-06	-0.31	-0.32	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-6.18	1.78e-09	2.39e-06	-0.31	-0.32	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-6.18	1.78e-09	2.39e-06	-0.31	-0.32	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-6.18	1.78e-09	2.39e-06	-0.31	-0.32	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-6.18	1.78e-09	2.39e-06	-0.31	-0.32	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
STAD	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-6.18	1.78e-09	2.39e-06	-0.31	-0.32	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-6.18	1.78e-09	2.39e-06	-0.31	-0.32	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
STAD	cis	rs711244	0.777	rs12476515	ENSG00000252756.1	RNU6-577P	6.18	1.78e-09	2.4e-06	0.35	0.32	Mean platelet volume;	chr2:36875477	chr2:36867398~36867495:-
STAD	cis	rs6452524	0.967	rs7718278	ENSG00000243385.2	CTD-2110K23.1	6.18	1.78e-09	2.4e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.934	rs1120476	ENSG00000243385.2	CTD-2110K23.1	6.18	1.78e-09	2.4e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.934	rs6452510	ENSG00000243385.2	CTD-2110K23.1	6.18	1.78e-09	2.4e-06	0.36	0.32	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83201229~83202141:+
STAD	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-6.18	1.78e-09	2.4e-06	-0.3	-0.32	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
STAD	cis	rs7927771	0.864	rs10838724	ENSG00000280615.1	Y_RNA	-6.18	1.78e-09	2.4e-06	-0.32	-0.32	Subjective well-being;	chr11:47505500	chr11:47614898~47614994:-
STAD	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	6.18	1.78e-09	2.4e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
STAD	cis	rs2404602	0.608	rs12439484	ENSG00000259422.1	RP11-593F23.1	6.18	1.78e-09	2.4e-06	0.34	0.32	Blood metabolite levels;	chr15:76310596	chr15:76174891~76181486:-
STAD	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-6.18	1.79e-09	2.4e-06	-0.39	-0.32	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
STAD	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-6.18	1.79e-09	2.41e-06	-0.32	-0.32	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
STAD	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-6.18	1.8e-09	2.41e-06	-0.3	-0.32	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
STAD	cis	rs10129255	1	rs10129255	ENSG00000280411.1	IGHV1-69-2	6.18	1.8e-09	2.42e-06	0.3	0.32	Kawasaki disease;	chr14:106767970	chr14:106762092~106762588:-
STAD	cis	rs9549260	0.632	rs7323267	ENSG00000229456.1	RLIMP1	6.18	1.8e-09	2.42e-06	0.37	0.32	Red blood cell count;	chr13:40629878	chr13:40618738~40621348:+
STAD	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	6.18	1.8e-09	2.42e-06	0.38	0.32	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
STAD	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.18	1.81e-09	2.42e-06	-0.4	-0.32	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
STAD	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	6.18	1.81e-09	2.43e-06	0.51	0.32	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
STAD	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-6.18	1.81e-09	2.43e-06	-0.27	-0.32	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
STAD	cis	rs2439831	0.85	rs3097773	ENSG00000205771.5	CATSPER2P1	6.18	1.81e-09	2.43e-06	0.44	0.32	Lung cancer in ever smokers;	chr15:43600874	chr15:43726918~43747094:-
STAD	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.18	1.81e-09	2.43e-06	-0.33	-0.32	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
STAD	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-6.18	1.81e-09	2.43e-06	-0.32	-0.32	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
STAD	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	6.18	1.81e-09	2.43e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	6.18	1.81e-09	2.43e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
STAD	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	6.18	1.82e-09	2.44e-06	0.38	0.32	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	6.18	1.82e-09	2.44e-06	0.38	0.32	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
STAD	cis	rs6452524	0.901	rs10079680	ENSG00000243385.2	CTD-2110K23.1	6.18	1.82e-09	2.44e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83201229~83202141:+
STAD	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	6.18	1.82e-09	2.44e-06	0.38	0.32	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
STAD	cis	rs6452524	0.71	rs7708124	ENSG00000243385.2	CTD-2110K23.1	6.18	1.82e-09	2.44e-06	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83201229~83202141:+
STAD	cis	rs9549260	0.753	rs1986649	ENSG00000229456.1	RLIMP1	6.18	1.82e-09	2.45e-06	0.36	0.32	Red blood cell count;	chr13:40604687	chr13:40618738~40621348:+
STAD	cis	rs6452524	0.87	rs6452511	ENSG00000243385.2	CTD-2110K23.1	6.18	1.82e-09	2.45e-06	0.38	0.32	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83201229~83202141:+
STAD	cis	rs10129255	0.957	rs17113284	ENSG00000280411.1	IGHV1-69-2	6.18	1.83e-09	2.45e-06	0.29	0.32	Kawasaki disease;	chr14:106684476	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	6.18	1.83e-09	2.45e-06	0.23	0.32	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
STAD	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-6.18	1.83e-09	2.45e-06	-0.42	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
STAD	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-6.18	1.83e-09	2.46e-06	-0.49	-0.32	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
STAD	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	6.18	1.84e-09	2.47e-06	0.32	0.32	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
STAD	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	6.18	1.84e-09	2.47e-06	0.38	0.32	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
STAD	cis	rs453301	0.624	rs2288671	ENSG00000254340.1	RP11-10A14.3	6.18	1.84e-09	2.47e-06	0.38	0.32	Joint mobility (Beighton score);	chr8:9003384	chr8:9141424~9145435:+
STAD	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	6.18	1.85e-09	2.48e-06	0.32	0.32	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
STAD	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	6.18	1.85e-09	2.48e-06	0.32	0.32	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
STAD	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	6.18	1.85e-09	2.48e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	6.18	1.85e-09	2.48e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	6.18	1.85e-09	2.48e-06	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
STAD	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
STAD	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
STAD	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
STAD	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
STAD	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
STAD	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	6.18	1.85e-09	2.48e-06	0.48	0.32	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
STAD	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	6.18	1.85e-09	2.48e-06	0.36	0.32	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
STAD	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	6.17	1.86e-09	2.49e-06	0.36	0.32	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
STAD	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	6.17	1.86e-09	2.49e-06	0.32	0.32	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
STAD	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	6.17	1.86e-09	2.5e-06	0.25	0.32	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
STAD	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	6.17	1.87e-09	2.5e-06	0.38	0.32	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
STAD	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-6.17	1.87e-09	2.5e-06	-0.3	-0.32	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
STAD	cis	rs9549260	0.755	rs9549255	ENSG00000229456.1	RLIMP1	6.17	1.87e-09	2.5e-06	0.29	0.32	Red blood cell count;	chr13:40661076	chr13:40618738~40621348:+
STAD	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	6.17	1.87e-09	2.5e-06	0.39	0.31	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
STAD	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-6.17	1.87e-09	2.5e-06	-0.26	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
STAD	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	6.17	1.87e-09	2.51e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
STAD	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	6.17	1.88e-09	2.51e-06	0.34	0.31	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
STAD	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	6.17	1.88e-09	2.52e-06	0.34	0.31	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
STAD	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	6.17	1.88e-09	2.52e-06	0.34	0.31	Height;	chr11:118856460	chr11:118688039~118690600:-
STAD	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	6.17	1.88e-09	2.52e-06	0.34	0.31	Height;	chr11:118856623	chr11:118688039~118690600:-
STAD	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-6.17	1.89e-09	2.52e-06	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
STAD	cis	rs8067354	0.574	rs9789060	ENSG00000266701.1	AC005702.4	6.17	1.89e-09	2.52e-06	0.47	0.31	Hemoglobin concentration;	chr17:59941209	chr17:60042546~60042627:-
STAD	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	6.17	1.89e-09	2.53e-06	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
STAD	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	6.17	1.89e-09	2.53e-06	0.34	0.31	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-6.17	1.89e-09	2.53e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	6.17	1.89e-09	2.53e-06	0.38	0.31	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
STAD	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-6.17	1.89e-09	2.53e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
STAD	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-6.17	1.9e-09	2.54e-06	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
STAD	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	6.17	1.9e-09	2.54e-06	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
STAD	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-6.17	1.9e-09	2.54e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
STAD	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-6.17	1.91e-09	2.55e-06	-0.33	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
STAD	cis	rs10129255	0.872	rs10133674	ENSG00000280411.1	IGHV1-69-2	-6.17	1.91e-09	2.55e-06	-0.29	-0.31	Kawasaki disease;	chr14:106692788	chr14:106762092~106762588:-
STAD	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	6.17	1.92e-09	2.56e-06	0.51	0.31	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
STAD	cis	rs4568518	0.53	rs11764965	ENSG00000279048.1	RP11-511H23.2	6.17	1.92e-09	2.56e-06	0.29	0.31	Measles;	chr7:17959127	chr7:17940503~17942922:+
STAD	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-6.17	1.93e-09	2.57e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
STAD	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	6.17	1.93e-09	2.57e-06	0.36	0.31	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
STAD	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	6.17	1.93e-09	2.57e-06	0.27	0.31	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
STAD	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	6.17	1.93e-09	2.57e-06	0.32	0.31	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
STAD	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	6.17	1.93e-09	2.57e-06	0.32	0.31	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
STAD	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	6.17	1.93e-09	2.57e-06	0.32	0.31	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
STAD	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	6.17	1.93e-09	2.58e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	6.17	1.93e-09	2.58e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	6.17	1.93e-09	2.58e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	6.17	1.93e-09	2.58e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	6.17	1.93e-09	2.58e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
STAD	cis	rs227275	0.524	rs223423	ENSG00000230069.3	LRRC37A15P	-6.17	1.94e-09	2.59e-06	-0.34	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102727274~102730721:-
STAD	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	6.17	1.94e-09	2.59e-06	0.37	0.31	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
STAD	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-6.17	1.95e-09	2.6e-06	-0.41	-0.31	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
STAD	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	6.17	1.95e-09	2.6e-06	0.34	0.31	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
STAD	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-6.17	1.95e-09	2.6e-06	-0.39	-0.31	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-6.17	1.95e-09	2.6e-06	-0.39	-0.31	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-6.17	1.95e-09	2.6e-06	-0.39	-0.31	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
STAD	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	6.17	1.95e-09	2.6e-06	0.38	0.31	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
STAD	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	6.17	1.95e-09	2.6e-06	0.38	0.31	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
STAD	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	6.17	1.95e-09	2.6e-06	0.38	0.31	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
STAD	cis	rs9549260	0.755	rs9577091	ENSG00000229456.1	RLIMP1	6.16	1.96e-09	2.62e-06	0.29	0.31	Red blood cell count;	chr13:40653728	chr13:40618738~40621348:+
STAD	cis	rs875971	0.522	rs1880556	ENSG00000222364.1	RNU6-96P	-6.16	1.97e-09	2.62e-06	-0.35	-0.31	Aortic root size;	chr7:65967557	chr7:66395191~66395286:+
STAD	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	6.16	1.98e-09	2.64e-06	0.28	0.31	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
STAD	cis	rs1400745	0.729	rs1741196	ENSG00000258738.1	RP11-73E17.2	6.16	1.98e-09	2.64e-06	0.38	0.31	Monocyte count;	chr14:34877814	chr14:34874343~34876459:+
STAD	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	6.16	1.99e-09	2.65e-06	0.38	0.31	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
STAD	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	6.16	1.99e-09	2.65e-06	0.32	0.31	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
STAD	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	6.16	2e-09	2.66e-06	0.46	0.31	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
STAD	cis	rs7580658	0.613	rs6754999	ENSG00000200250.1	RNU6-1147P	6.16	2e-09	2.66e-06	0.3	0.31	Protein C levels;	chr2:127437811	chr2:127316873~127316979:+
STAD	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-6.16	2e-09	2.66e-06	-0.36	-0.31	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
STAD	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	6.16	2e-09	2.66e-06	0.36	0.31	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
STAD	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-6.16	2e-09	2.67e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
STAD	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	6.16	2.01e-09	2.67e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	6.16	2.01e-09	2.67e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	6.16	2.01e-09	2.67e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
STAD	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	6.16	2.01e-09	2.67e-06	0.38	0.31	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	6.16	2.01e-09	2.67e-06	0.38	0.31	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	6.16	2.01e-09	2.67e-06	0.38	0.31	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
STAD	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	6.16	2.01e-09	2.67e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	6.16	2.01e-09	2.67e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	6.16	2.01e-09	2.67e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	6.16	2.01e-09	2.67e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
STAD	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	6.16	2.01e-09	2.67e-06	0.44	0.31	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
STAD	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	6.16	2.01e-09	2.67e-06	0.36	0.31	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
STAD	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	6.16	2.01e-09	2.68e-06	0.34	0.31	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
STAD	cis	rs9395066	0.545	rs12526711	ENSG00000219384.1	RP11-491H9.3	-6.16	2.01e-09	2.68e-06	-0.3	-0.31	Height;	chr6:44916136	chr6:45158870~45159511:+
STAD	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	6.16	2.02e-09	2.68e-06	0.35	0.31	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
STAD	cis	rs9549260	0.755	rs7986407	ENSG00000229456.1	RLIMP1	6.16	2.02e-09	2.68e-06	0.28	0.31	Red blood cell count;	chr13:40605661	chr13:40618738~40621348:+
STAD	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	6.16	2.02e-09	2.68e-06	0.38	0.31	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
STAD	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	6.16	2.02e-09	2.68e-06	0.33	0.31	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
STAD	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	6.16	2.02e-09	2.69e-06	0.5	0.31	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
STAD	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	6.16	2.02e-09	2.69e-06	0.36	0.31	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
STAD	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-6.16	2.03e-09	2.7e-06	-0.32	-0.31	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
STAD	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-6.16	2.04e-09	2.7e-06	-0.32	-0.31	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
STAD	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-6.16	2.04e-09	2.7e-06	-0.32	-0.31	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
STAD	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	6.16	2.04e-09	2.71e-06	0.31	0.31	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
STAD	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-6.16	2.04e-09	2.71e-06	-0.36	-0.31	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	6.16	2.04e-09	2.71e-06	0.34	0.31	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
STAD	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	6.16	2.05e-09	2.72e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
STAD	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-6.16	2.05e-09	2.72e-06	-0.4	-0.31	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
STAD	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	6.16	2.05e-09	2.73e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	6.16	2.05e-09	2.73e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	6.16	2.05e-09	2.73e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	6.16	2.05e-09	2.73e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	6.16	2.05e-09	2.73e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	6.16	2.05e-09	2.73e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	6.16	2.05e-09	2.73e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
STAD	cis	rs8005677	0.741	rs1043675	ENSG00000257285.4	RP11-298I3.1	-6.16	2.06e-09	2.73e-06	-0.39	-0.31	Cognitive ability (multi-trait analysis);	chr14:22987106	chr14:22929609~22955562:+
STAD	cis	rs9549260	0.755	rs7328677	ENSG00000229456.1	RLIMP1	6.16	2.06e-09	2.73e-06	0.29	0.31	Red blood cell count;	chr13:40655768	chr13:40618738~40621348:+
STAD	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	6.16	2.06e-09	2.73e-06	0.33	0.31	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
STAD	cis	rs6452524	0.836	rs2731852	ENSG00000243385.2	CTD-2110K23.1	-6.16	2.06e-09	2.73e-06	-0.38	-0.31	Hypertension (SNP x SNP interaction);	chr5:83212591	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.805	rs2731850	ENSG00000243385.2	CTD-2110K23.1	-6.16	2.06e-09	2.73e-06	-0.38	-0.31	Hypertension (SNP x SNP interaction);	chr5:83213024	chr5:83201229~83202141:+
STAD	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	6.16	2.07e-09	2.74e-06	0.35	0.31	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
STAD	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	6.16	2.07e-09	2.75e-06	0.33	0.31	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
STAD	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	6.16	2.07e-09	2.75e-06	0.47	0.31	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
STAD	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-6.16	2.08e-09	2.75e-06	-0.37	-0.31	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
STAD	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	6.16	2.08e-09	2.75e-06	0.28	0.31	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
STAD	cis	rs875971	0.706	rs1643374	ENSG00000222364.1	RNU6-96P	-6.16	2.08e-09	2.75e-06	-0.36	-0.31	Aortic root size;	chr7:66407695	chr7:66395191~66395286:+
STAD	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	6.15	2.08e-09	2.76e-06	0.32	0.31	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
STAD	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	6.15	2.09e-09	2.76e-06	0.33	0.31	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
STAD	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-6.15	2.1e-09	2.78e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-6.15	2.1e-09	2.78e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
STAD	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-6.15	2.1e-09	2.78e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
STAD	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-6.15	2.1e-09	2.78e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
STAD	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	6.15	2.1e-09	2.79e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	6.15	2.1e-09	2.79e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	6.15	2.1e-09	2.79e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	6.15	2.1e-09	2.79e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	6.15	2.1e-09	2.79e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	6.15	2.1e-09	2.79e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	6.15	2.1e-09	2.79e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
STAD	cis	rs748404	0.556	rs574856	ENSG00000249839.1	AC011330.5	6.15	2.11e-09	2.8e-06	0.38	0.31	Lung cancer;	chr15:43168636	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	6.15	2.13e-09	2.81e-06	0.38	0.31	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
STAD	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	6.15	2.13e-09	2.82e-06	0.32	0.31	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
STAD	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	6.15	2.13e-09	2.82e-06	0.32	0.31	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
STAD	cis	rs7176527	0.579	rs366717	ENSG00000188388.10	GOLGA6L3	6.15	2.13e-09	2.82e-06	0.42	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85240472~85247170:+
STAD	cis	rs6558530	0.692	rs6981804	ENSG00000253982.1	CTD-2336O2.1	6.15	2.13e-09	2.82e-06	0.35	0.31	Systolic blood pressure;	chr8:1752118	chr8:1761990~1764502:-
STAD	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-6.15	2.13e-09	2.82e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-6.15	2.13e-09	2.82e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
STAD	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-6.15	2.13e-09	2.82e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
STAD	cis	rs228614	0.536	rs223478	ENSG00000230069.3	LRRC37A15P	-6.15	2.14e-09	2.83e-06	-0.33	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102727274~102730721:-
STAD	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-6.15	2.14e-09	2.83e-06	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
STAD	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-6.15	2.14e-09	2.83e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-6.15	2.14e-09	2.83e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
STAD	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	6.15	2.14e-09	2.83e-06	0.28	0.31	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
STAD	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-6.15	2.14e-09	2.83e-06	-0.32	-0.31	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
STAD	cis	rs9326248	0.53	rs2000614	ENSG00000280143.1	AP000892.6	6.15	2.15e-09	2.84e-06	0.32	0.31	Blood protein levels;	chr11:117045026	chr11:117204967~117210292:+
STAD	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	6.15	2.15e-09	2.85e-06	0.32	0.31	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
STAD	cis	rs7924176	0.521	rs7098200	ENSG00000236900.1	TIMM9P1	6.15	2.15e-09	2.85e-06	0.32	0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74344550~74344805:-
STAD	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-6.15	2.16e-09	2.85e-06	-0.31	-0.31	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
STAD	cis	rs2439831	1	rs690436	ENSG00000205771.5	CATSPER2P1	-6.15	2.16e-09	2.85e-06	-0.42	-0.31	Lung cancer in ever smokers;	chr15:43469007	chr15:43726918~43747094:-
STAD	cis	rs2439831	1	rs2264239	ENSG00000205771.5	CATSPER2P1	-6.15	2.16e-09	2.85e-06	-0.42	-0.31	Lung cancer in ever smokers;	chr15:43473335	chr15:43726918~43747094:-
STAD	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	6.15	2.16e-09	2.85e-06	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	6.15	2.16e-09	2.85e-06	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	6.15	2.16e-09	2.85e-06	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
STAD	cis	rs11089937	0.609	rs9622980	ENSG00000211639.2	IGLV4-60	6.15	2.16e-09	2.86e-06	0.35	0.31	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.667	rs11704024	ENSG00000211639.2	IGLV4-60	6.15	2.16e-09	2.86e-06	0.35	0.31	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22162199~22162681:+
STAD	cis	rs2439831	0.85	rs28413881	ENSG00000249839.1	AC011330.5	-6.15	2.16e-09	2.86e-06	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43881901	chr15:43663654~43684339:-
STAD	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	6.15	2.16e-09	2.86e-06	0.52	0.31	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
STAD	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-6.15	2.17e-09	2.86e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
STAD	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	6.15	2.17e-09	2.86e-06	0.36	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
STAD	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	6.15	2.17e-09	2.87e-06	0.46	0.31	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
STAD	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	6.15	2.17e-09	2.87e-06	0.34	0.31	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
STAD	cis	rs228614	0.536	rs150898	ENSG00000230069.3	LRRC37A15P	-6.15	2.17e-09	2.87e-06	-0.33	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102727274~102730721:-
STAD	cis	rs228614	0.509	rs223476	ENSG00000230069.3	LRRC37A15P	-6.15	2.17e-09	2.87e-06	-0.33	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102727274~102730721:-
STAD	cis	rs228614	0.509	rs150896	ENSG00000230069.3	LRRC37A15P	-6.15	2.17e-09	2.87e-06	-0.33	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102727274~102730721:-
STAD	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-6.15	2.18e-09	2.88e-06	-0.33	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
STAD	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-6.15	2.18e-09	2.88e-06	-0.33	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
STAD	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	6.15	2.18e-09	2.88e-06	0.36	0.31	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
STAD	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	6.15	2.18e-09	2.88e-06	0.32	0.31	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
STAD	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-6.15	2.19e-09	2.89e-06	-0.47	-0.31	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
STAD	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	6.15	2.19e-09	2.9e-06	0.41	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
STAD	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-6.15	2.2e-09	2.9e-06	-0.41	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
STAD	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-6.15	2.2e-09	2.9e-06	-0.29	-0.31	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
STAD	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-6.14	2.2e-09	2.91e-06	-0.35	-0.31	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
STAD	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-6.14	2.2e-09	2.91e-06	-0.35	-0.31	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
STAD	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-6.14	2.21e-09	2.91e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
STAD	cis	rs6452524	0.901	rs72767146	ENSG00000243385.2	CTD-2110K23.1	6.14	2.21e-09	2.91e-06	0.38	0.31	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83201229~83202141:+
STAD	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	6.14	2.21e-09	2.92e-06	0.32	0.31	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
STAD	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	6.14	2.21e-09	2.92e-06	0.36	0.31	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	6.14	2.21e-09	2.92e-06	0.36	0.31	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	6.14	2.21e-09	2.92e-06	0.36	0.31	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
STAD	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-6.14	2.22e-09	2.92e-06	-0.32	-0.31	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
STAD	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-6.14	2.22e-09	2.93e-06	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
STAD	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	6.14	2.23e-09	2.93e-06	0.34	0.31	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
STAD	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	6.14	2.23e-09	2.93e-06	0.34	0.31	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	6.14	2.23e-09	2.93e-06	0.34	0.31	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	6.14	2.23e-09	2.93e-06	0.34	0.31	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	6.14	2.23e-09	2.93e-06	0.34	0.31	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
STAD	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-6.14	2.23e-09	2.94e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
STAD	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	6.14	2.23e-09	2.94e-06	0.38	0.31	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
STAD	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	6.14	2.24e-09	2.95e-06	0.44	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
STAD	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-6.14	2.24e-09	2.95e-06	-0.29	-0.31	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
STAD	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	6.14	2.24e-09	2.95e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
STAD	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-6.14	2.24e-09	2.95e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
STAD	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-6.14	2.24e-09	2.96e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-6.14	2.24e-09	2.96e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
STAD	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.14	2.25e-09	2.96e-06	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
STAD	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	6.14	2.25e-09	2.96e-06	0.28	0.31	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
STAD	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	6.14	2.25e-09	2.96e-06	0.52	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
STAD	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	6.14	2.25e-09	2.96e-06	0.31	0.31	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
STAD	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-6.14	2.25e-09	2.96e-06	-0.35	-0.31	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
STAD	cis	rs4604732	0.631	rs12091081	ENSG00000227135.1	GCSAML-AS1	-6.14	2.25e-09	2.96e-06	-0.44	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459762	chr1:247524679~247526752:-
STAD	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-6.14	2.25e-09	2.96e-06	-0.39	-0.31	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
STAD	cis	rs6452524	0.804	rs1478481	ENSG00000243385.2	CTD-2110K23.1	6.14	2.25e-09	2.97e-06	0.38	0.31	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83201229~83202141:+
STAD	cis	rs7487075	0.619	rs4768709	ENSG00000272369.1	RP11-446N19.1	6.14	2.26e-09	2.97e-06	0.42	0.31	Itch intensity from mosquito bite;	chr12:46411982	chr12:46537502~46652550:+
STAD	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-6.14	2.26e-09	2.98e-06	-0.43	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
STAD	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	6.14	2.27e-09	2.98e-06	0.36	0.31	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
STAD	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-6.14	2.27e-09	2.99e-06	-0.32	-0.31	Asthma;	chr2:102392894	chr2:102438713~102440475:+
STAD	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	6.14	2.28e-09	2.99e-06	0.32	0.31	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
STAD	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	6.14	2.28e-09	3e-06	0.4	0.31	Height;	chr6:109741670	chr6:109382795~109383666:+
STAD	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-6.14	2.28e-09	3e-06	-0.27	-0.31	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
STAD	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-6.14	2.28e-09	3e-06	-0.36	-0.31	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
STAD	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	6.14	2.28e-09	3e-06	0.39	0.31	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
STAD	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	6.14	2.28e-09	3e-06	0.38	0.31	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
STAD	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	6.14	2.29e-09	3.01e-06	0.36	0.31	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
STAD	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	6.14	2.29e-09	3.01e-06	0.36	0.31	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
STAD	cis	rs3806843	0.735	rs2530242	ENSG00000202111.1	VTRNA1-2	6.14	2.29e-09	3.01e-06	0.31	0.31	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr5:140718925~140719013:+
STAD	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-6.14	2.29e-09	3.01e-06	-0.35	-0.31	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
STAD	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-6.14	2.29e-09	3.01e-06	-0.35	-0.31	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
STAD	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-6.14	2.29e-09	3.01e-06	-0.35	-0.31	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
STAD	cis	rs1426063	0.614	rs76087197	ENSG00000248165.1	RP11-44F21.2	6.14	2.29e-09	3.01e-06	0.66	0.31	QT interval;	chr4:75134108	chr4:74993877~75034824:-
STAD	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	6.14	2.3e-09	3.02e-06	0.32	0.31	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
STAD	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-6.14	2.3e-09	3.03e-06	-0.27	-0.31	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
STAD	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	6.14	2.3e-09	3.03e-06	0.39	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
STAD	cis	rs2404602	0.716	rs67418609	ENSG00000259422.1	RP11-593F23.1	6.14	2.31e-09	3.03e-06	0.34	0.31	Blood metabolite levels;	chr15:76334748	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs12440815	ENSG00000259422.1	RP11-593F23.1	6.14	2.31e-09	3.03e-06	0.34	0.31	Blood metabolite levels;	chr15:76334987	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs3866543	ENSG00000259422.1	RP11-593F23.1	6.14	2.31e-09	3.03e-06	0.34	0.31	Blood metabolite levels;	chr15:76337268	chr15:76174891~76181486:-
STAD	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-6.14	2.32e-09	3.04e-06	-0.53	-0.31	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
STAD	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	6.14	2.32e-09	3.05e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
STAD	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	6.14	2.32e-09	3.05e-06	0.34	0.31	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	6.14	2.32e-09	3.05e-06	0.34	0.31	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
STAD	cis	rs6782228	0.527	rs6767383	ENSG00000277250.1	Metazoa_SRP	-6.14	2.32e-09	3.05e-06	-0.32	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.509	rs6780447	ENSG00000277250.1	Metazoa_SRP	-6.14	2.32e-09	3.05e-06	-0.32	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128673681~128674021:-
STAD	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	6.14	2.32e-09	3.05e-06	0.39	0.31	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
STAD	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-6.14	2.32e-09	3.05e-06	-0.37	-0.31	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
STAD	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	6.14	2.33e-09	3.05e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
STAD	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	6.13	2.33e-09	3.06e-06	0.38	0.31	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
STAD	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-6.13	2.33e-09	3.06e-06	-0.52	-0.31	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
STAD	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-6.13	2.34e-09	3.07e-06	-0.36	-0.31	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-6.13	2.34e-09	3.07e-06	-0.36	-0.31	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-6.13	2.34e-09	3.07e-06	-0.36	-0.31	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
STAD	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	6.13	2.34e-09	3.07e-06	0.36	0.31	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	6.13	2.34e-09	3.07e-06	0.36	0.31	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	6.13	2.34e-09	3.07e-06	0.36	0.31	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	6.13	2.34e-09	3.07e-06	0.36	0.31	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
STAD	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	6.13	2.34e-09	3.07e-06	0.32	0.31	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	6.13	2.34e-09	3.07e-06	0.32	0.31	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
STAD	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	6.13	2.34e-09	3.07e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
STAD	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	6.13	2.34e-09	3.07e-06	0.36	0.31	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
STAD	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	6.13	2.34e-09	3.08e-06	0.38	0.31	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
STAD	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-6.13	2.35e-09	3.09e-06	-0.35	-0.31	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
STAD	cis	rs2440129	0.611	rs1042356	ENSG00000215067.8	ALOX12-AS1	6.13	2.35e-09	3.09e-06	0.32	0.31	Tonsillectomy;	chr17:6999424	chr17:6876635~7012349:-
STAD	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	6.13	2.35e-09	3.09e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
STAD	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-6.13	2.36e-09	3.09e-06	-0.53	-0.31	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
STAD	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	6.13	2.36e-09	3.09e-06	0.29	0.31	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
STAD	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-6.13	2.36e-09	3.09e-06	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
STAD	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	6.13	2.37e-09	3.11e-06	0.46	0.31	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
STAD	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	6.13	2.37e-09	3.11e-06	0.38	0.31	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
STAD	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	6.13	2.38e-09	3.11e-06	0.37	0.31	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	6.13	2.38e-09	3.11e-06	0.37	0.31	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
STAD	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	6.13	2.38e-09	3.11e-06	0.33	0.31	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
STAD	cis	rs9549260	0.753	rs9549243	ENSG00000229456.1	RLIMP1	6.13	2.38e-09	3.12e-06	0.35	0.31	Red blood cell count;	chr13:40643068	chr13:40618738~40621348:+
STAD	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-6.13	2.38e-09	3.12e-06	-0.34	-0.31	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
STAD	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	6.13	2.38e-09	3.12e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
STAD	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-6.13	2.38e-09	3.12e-06	-0.29	-0.31	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-6.13	2.38e-09	3.12e-06	-0.29	-0.31	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
STAD	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	6.13	2.39e-09	3.12e-06	0.5	0.31	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
STAD	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	6.13	2.39e-09	3.13e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	6.13	2.39e-09	3.13e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	6.13	2.39e-09	3.13e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
STAD	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-6.13	2.39e-09	3.13e-06	-0.36	-0.31	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-6.13	2.4e-09	3.14e-06	-0.28	-0.31	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
STAD	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-6.13	2.41e-09	3.15e-06	-0.47	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
STAD	cis	rs1400745	0.812	rs72678789	ENSG00000258738.1	RP11-73E17.2	-6.13	2.41e-09	3.15e-06	-0.38	-0.31	Monocyte count;	chr14:34878995	chr14:34874343~34876459:+
STAD	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-6.13	2.41e-09	3.15e-06	-0.3	-0.31	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
STAD	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-6.13	2.41e-09	3.15e-06	-0.3	-0.31	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
STAD	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	6.13	2.41e-09	3.16e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	6.13	2.41e-09	3.16e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-6.13	2.42e-09	3.16e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	6.13	2.42e-09	3.16e-06	0.27	0.31	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
STAD	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-6.13	2.42e-09	3.17e-06	-0.38	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
STAD	cis	rs240993	0.715	rs4947122	ENSG00000230177.1	RP5-1112D6.4	-6.13	2.42e-09	3.17e-06	-0.31	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111548887	chr6:111277932~111278742:+
STAD	cis	rs9549260	0.739	rs7330614	ENSG00000229456.1	RLIMP1	6.13	2.42e-09	3.17e-06	0.29	0.31	Red blood cell count;	chr13:40625284	chr13:40618738~40621348:+
STAD	cis	rs7924176	0.521	rs7899920	ENSG00000236900.1	TIMM9P1	6.13	2.42e-09	3.17e-06	0.33	0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74344550~74344805:-
STAD	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	6.13	2.42e-09	3.17e-06	0.38	0.31	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
STAD	cis	rs227275	0.554	rs223395	ENSG00000230069.3	LRRC37A15P	-6.13	2.42e-09	3.17e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223388	ENSG00000230069.3	LRRC37A15P	-6.13	2.42e-09	3.17e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223386	ENSG00000230069.3	LRRC37A15P	-6.13	2.42e-09	3.17e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223385	ENSG00000230069.3	LRRC37A15P	-6.13	2.42e-09	3.17e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102727274~102730721:-
STAD	cis	rs10129255	1	rs10129407	ENSG00000280411.1	IGHV1-69-2	-6.13	2.43e-09	3.17e-06	-0.29	-0.31	Kawasaki disease;	chr14:106767956	chr14:106762092~106762588:-
STAD	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	6.13	2.43e-09	3.18e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
STAD	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-6.13	2.43e-09	3.18e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	6.13	2.44e-09	3.19e-06	0.27	0.31	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
STAD	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-6.13	2.44e-09	3.19e-06	-0.39	-0.31	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-6.13	2.44e-09	3.19e-06	-0.39	-0.31	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
STAD	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-6.13	2.44e-09	3.19e-06	-0.39	-0.31	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
STAD	cis	rs7849270	0.84	rs12346996	ENSG00000268707.1	RP11-247A12.7	-6.13	2.44e-09	3.19e-06	-0.41	-0.31	Blood metabolite ratios;	chr9:129078577	chr9:129170434~129170940:+
STAD	cis	rs8141529	0.732	rs6005881	ENSG00000226471.5	CTA-292E10.6	-6.13	2.44e-09	3.19e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28787145	chr22:28800683~28848559:+
STAD	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-6.13	2.44e-09	3.19e-06	-0.27	-0.31	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
STAD	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	6.13	2.44e-09	3.19e-06	0.33	0.31	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
STAD	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	6.13	2.44e-09	3.19e-06	0.33	0.31	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
STAD	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	6.13	2.45e-09	3.19e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
STAD	cis	rs992157	1	rs6736362	ENSG00000237281.1	CATIP-AS2	-6.13	2.45e-09	3.2e-06	-0.32	-0.31	Colorectal cancer;	chr2:218250385	chr2:218326889~218357966:-
STAD	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	6.13	2.45e-09	3.2e-06	0.36	0.31	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
STAD	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	6.13	2.45e-09	3.2e-06	0.33	0.31	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
STAD	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	6.13	2.46e-09	3.21e-06	0.36	0.31	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
STAD	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	6.12	2.47e-09	3.22e-06	0.36	0.31	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
STAD	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.22e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
STAD	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-6.12	2.47e-09	3.22e-06	-0.42	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
STAD	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	6.12	2.47e-09	3.22e-06	0.37	0.31	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
STAD	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	6.12	2.47e-09	3.23e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
STAD	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-6.12	2.47e-09	3.23e-06	-0.34	-0.31	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
STAD	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	6.12	2.48e-09	3.23e-06	0.38	0.31	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
STAD	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-6.12	2.48e-09	3.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-6.12	2.48e-09	3.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-6.12	2.48e-09	3.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
STAD	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-6.12	2.48e-09	3.24e-06	-0.32	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
STAD	cis	rs7487075	0.78	rs12307969	ENSG00000272369.1	RP11-446N19.1	6.12	2.49e-09	3.24e-06	0.36	0.31	Itch intensity from mosquito bite;	chr12:46365274	chr12:46537502~46652550:+
STAD	cis	rs9549260	0.755	rs2755219	ENSG00000229456.1	RLIMP1	6.12	2.49e-09	3.24e-06	0.28	0.31	Red blood cell count;	chr13:40595488	chr13:40618738~40621348:+
STAD	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	6.12	2.49e-09	3.24e-06	0.35	0.31	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
STAD	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	6.12	2.49e-09	3.25e-06	0.35	0.31	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
STAD	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-6.12	2.49e-09	3.25e-06	-0.39	-0.31	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
STAD	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	6.12	2.5e-09	3.25e-06	0.35	0.31	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
STAD	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	6.12	2.5e-09	3.25e-06	0.37	0.31	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
STAD	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	6.12	2.5e-09	3.25e-06	0.27	0.31	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
STAD	cis	rs7487075	0.619	rs9669404	ENSG00000272369.1	RP11-446N19.1	-6.12	2.5e-09	3.26e-06	-0.38	-0.31	Itch intensity from mosquito bite;	chr12:46405180	chr12:46537502~46652550:+
STAD	cis	rs11079159	0.606	rs4239192	ENSG00000263096.1	RP11-515O17.2	6.12	2.5e-09	3.26e-06	0.39	0.31	QRS duration;	chr17:55299143	chr17:55271504~55273653:-
STAD	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-6.12	2.51e-09	3.26e-06	-0.35	-0.31	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
STAD	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	6.12	2.51e-09	3.27e-06	0.39	0.31	Height;	chr6:109506513	chr6:109382795~109383666:+
STAD	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	6.12	2.51e-09	3.27e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	6.12	2.51e-09	3.27e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	6.12	2.51e-09	3.27e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
STAD	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-6.12	2.51e-09	3.27e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
STAD	cis	rs992157	0.798	rs4996257	ENSG00000237281.1	CATIP-AS2	-6.12	2.52e-09	3.28e-06	-0.32	-0.31	Colorectal cancer;	chr2:218298113	chr2:218326889~218357966:-
STAD	cis	rs9532580	0.778	rs34373380	ENSG00000229456.1	RLIMP1	6.12	2.52e-09	3.28e-06	0.29	0.31	Mean corpuscular hemoglobin;	chr13:40670080	chr13:40618738~40621348:+
STAD	cis	rs9532580	0.778	rs61963319	ENSG00000229456.1	RLIMP1	6.12	2.52e-09	3.28e-06	0.29	0.31	Mean corpuscular hemoglobin;	chr13:40670083	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.599	rs12870023	ENSG00000229456.1	RLIMP1	6.12	2.52e-09	3.28e-06	0.29	0.31	Red blood cell count;	chr13:40670085	chr13:40618738~40621348:+
STAD	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	6.12	2.52e-09	3.28e-06	0.37	0.31	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
STAD	cis	rs11146838	1	rs11146838	ENSG00000099251.13	HSD17B7P2	6.12	2.52e-09	3.28e-06	0.34	0.31	Breast cancer;	chr10:38856846	chr10:38356380~38378505:+
STAD	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	6.12	2.52e-09	3.28e-06	0.36	0.31	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
STAD	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-6.12	2.52e-09	3.28e-06	-0.45	-0.31	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
STAD	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	6.12	2.52e-09	3.28e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
STAD	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	6.12	2.53e-09	3.28e-06	0.55	0.31	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
STAD	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-6.12	2.53e-09	3.29e-06	-0.36	-0.31	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
STAD	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	6.12	2.53e-09	3.29e-06	0.42	0.31	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
STAD	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	6.12	2.53e-09	3.29e-06	0.43	0.31	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
STAD	cis	rs8067354	0.574	rs2526353	ENSG00000266701.1	AC005702.4	6.12	2.54e-09	3.29e-06	0.46	0.31	Hemoglobin concentration;	chr17:59911246	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.574	rs1292035	ENSG00000266701.1	AC005702.4	6.12	2.54e-09	3.29e-06	0.46	0.31	Hemoglobin concentration;	chr17:59912196	chr17:60042546~60042627:-
STAD	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	6.12	2.54e-09	3.3e-06	0.38	0.31	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
STAD	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-6.12	2.54e-09	3.31e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.957	rs61997760	ENSG00000211970.3	IGHV4-61	-6.12	2.55e-09	3.31e-06	-0.27	-0.31	Kawasaki disease;	chr14:106716993	chr14:106639119~106639657:-
STAD	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-6.12	2.55e-09	3.31e-06	-0.32	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
STAD	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-6.12	2.55e-09	3.31e-06	-0.32	-0.31	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
STAD	cis	rs6452524	0.836	rs1015440	ENSG00000243385.2	CTD-2110K23.1	6.12	2.55e-09	3.31e-06	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83201229~83202141:+
STAD	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	6.12	2.55e-09	3.31e-06	0.31	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
STAD	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-6.12	2.55e-09	3.31e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-6.12	2.55e-09	3.31e-06	-0.27	-0.31	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
STAD	cis	rs12699921	0.632	rs1524777	ENSG00000279048.1	RP11-511H23.2	-6.12	2.57e-09	3.33e-06	-0.28	-0.31	Fibrinogen levels;	chr7:17799986	chr7:17940503~17942922:+
STAD	cis	rs3806843	0.766	rs801176	ENSG00000202111.1	VTRNA1-2	-6.12	2.57e-09	3.33e-06	-0.3	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140707425	chr5:140718925~140719013:+
STAD	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-6.12	2.57e-09	3.33e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
STAD	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-6.12	2.58e-09	3.34e-06	-0.41	-0.31	Height;	chr6:109485060	chr6:109382795~109383666:+
STAD	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	6.12	2.58e-09	3.35e-06	0.33	0.31	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
STAD	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-6.12	2.6e-09	3.37e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	6.12	2.6e-09	3.37e-06	0.37	0.31	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
STAD	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	6.11	2.61e-09	3.38e-06	0.25	0.31	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
STAD	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-6.11	2.61e-09	3.38e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	6.11	2.62e-09	3.39e-06	0.27	0.31	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
STAD	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-6.11	2.62e-09	3.4e-06	-0.37	-0.31	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-6.11	2.62e-09	3.4e-06	-0.37	-0.31	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-6.11	2.62e-09	3.4e-06	-0.37	-0.31	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-6.11	2.62e-09	3.4e-06	-0.37	-0.31	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-6.11	2.62e-09	3.4e-06	-0.37	-0.31	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
STAD	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	6.11	2.62e-09	3.4e-06	0.38	0.31	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
STAD	cis	rs11089937	0.626	rs11089933	ENSG00000211639.2	IGLV4-60	6.11	2.63e-09	3.4e-06	0.36	0.31	Periodontitis (PAL4Q3);	chr22:22145708	chr22:22162199~22162681:+
STAD	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	6.11	2.63e-09	3.41e-06	0.27	0.31	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
STAD	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	6.11	2.63e-09	3.41e-06	0.32	0.31	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
STAD	cis	rs227275	0.554	rs149576	ENSG00000230069.3	LRRC37A15P	-6.11	2.63e-09	3.41e-06	-0.34	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102727274~102730721:-
STAD	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	6.11	2.64e-09	3.41e-06	0.32	0.31	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
STAD	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	6.11	2.64e-09	3.41e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	6.11	2.64e-09	3.41e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	6.11	2.64e-09	3.41e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	6.11	2.64e-09	3.41e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	6.11	2.64e-09	3.41e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	6.11	2.64e-09	3.41e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	6.11	2.64e-09	3.41e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
STAD	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-6.11	2.64e-09	3.42e-06	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
STAD	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	6.11	2.64e-09	3.42e-06	0.38	0.31	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
STAD	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-6.11	2.64e-09	3.42e-06	-0.35	-0.31	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
STAD	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	6.11	2.64e-09	3.42e-06	0.32	0.31	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
STAD	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	6.11	2.64e-09	3.42e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
STAD	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	6.11	2.65e-09	3.42e-06	0.37	0.31	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
STAD	cis	rs6452524	0.967	rs12153441	ENSG00000243385.2	CTD-2110K23.1	6.11	2.65e-09	3.43e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs12152891	ENSG00000243385.2	CTD-2110K23.1	6.11	2.65e-09	3.43e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83201229~83202141:+
STAD	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-6.11	2.66e-09	3.44e-06	-0.41	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
STAD	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	6.11	2.66e-09	3.45e-06	0.64	0.31	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
STAD	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	6.11	2.67e-09	3.45e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
STAD	cis	rs12550612	0.614	rs6983885	ENSG00000253616.4	RP11-875O11.3	6.11	2.68e-09	3.46e-06	0.48	0.31	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23087574	chr8:23071377~23074488:-
STAD	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	6.11	2.68e-09	3.46e-06	0.33	0.31	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
STAD	cis	rs6452524	0.537	rs1583	ENSG00000243385.2	CTD-2110K23.1	6.11	2.68e-09	3.46e-06	0.38	0.31	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83201229~83202141:+
STAD	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-6.11	2.68e-09	3.46e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
STAD	cis	rs831571	0.955	rs35837	ENSG00000280620.1	SCAANT1	6.11	2.68e-09	3.46e-06	0.47	0.31	Type 2 diabetes;	chr3:64027573	chr3:63911518~63911772:-
STAD	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	6.11	2.68e-09	3.47e-06	0.36	0.31	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
STAD	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	6.11	2.68e-09	3.47e-06	0.36	0.31	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
STAD	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	6.11	2.68e-09	3.47e-06	0.88	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
STAD	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	6.11	2.68e-09	3.47e-06	0.88	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
STAD	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	6.11	2.68e-09	3.47e-06	0.88	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
STAD	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-6.11	2.7e-09	3.48e-06	-0.54	-0.31	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
STAD	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	6.11	2.7e-09	3.49e-06	0.44	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
STAD	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-6.11	2.72e-09	3.51e-06	-0.3	-0.31	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
STAD	cis	rs2440129	0.611	rs1126667	ENSG00000215067.8	ALOX12-AS1	-6.11	2.72e-09	3.51e-06	-0.32	-0.31	Tonsillectomy;	chr17:6999441	chr17:6876635~7012349:-
STAD	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-6.11	2.72e-09	3.52e-06	-0.26	-0.31	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
STAD	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	6.11	2.73e-09	3.52e-06	0.47	0.31	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
STAD	cis	rs3806843	0.735	rs2563335	ENSG00000202111.1	VTRNA1-2	-6.11	2.73e-09	3.52e-06	-0.3	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr5:140718925~140719013:+
STAD	cis	rs11089937	0.626	rs4821784	ENSG00000211639.2	IGLV4-60	6.11	2.73e-09	3.53e-06	0.36	0.31	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22162199~22162681:+
STAD	cis	rs9549260	0.755	rs3900833	ENSG00000229456.1	RLIMP1	6.11	2.73e-09	3.53e-06	0.28	0.31	Red blood cell count;	chr13:40614155	chr13:40618738~40621348:+
STAD	cis	rs13113518	0.812	rs2048564	ENSG00000272969.1	RP11-528I4.2	6.11	2.73e-09	3.53e-06	0.4	0.31	Height;	chr4:55407965	chr4:55547112~55547889:+
STAD	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-6.11	2.74e-09	3.53e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
STAD	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	6.11	2.74e-09	3.53e-06	0.31	0.31	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
STAD	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-6.11	2.74e-09	3.54e-06	-0.32	-0.31	Asthma;	chr2:102374328	chr2:102438713~102440475:+
STAD	cis	rs7487075	0.78	rs12307969	ENSG00000257261.4	RP11-96H19.1	6.11	2.75e-09	3.54e-06	0.36	0.31	Itch intensity from mosquito bite;	chr12:46365274	chr12:46383679~46876159:+
STAD	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-6.11	2.75e-09	3.54e-06	-0.47	-0.31	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
STAD	cis	rs11603023	0.569	rs573905	ENSG00000255239.1	AP002954.6	6.11	2.75e-09	3.55e-06	0.35	0.31	Cholesterol, total;	chr11:118701558	chr11:118688039~118690600:-
STAD	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-6.11	2.76e-09	3.56e-06	-0.33	-0.31	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
STAD	cis	rs9549260	0.755	rs9532579	ENSG00000229456.1	RLIMP1	6.1	2.76e-09	3.56e-06	0.29	0.31	Red blood cell count;	chr13:40669321	chr13:40618738~40621348:+
STAD	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	6.1	2.76e-09	3.56e-06	0.37	0.31	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
STAD	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-6.1	2.76e-09	3.56e-06	-0.33	-0.31	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-6.1	2.76e-09	3.56e-06	-0.33	-0.31	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
STAD	cis	rs10129255	0.869	rs72690553	ENSG00000211970.3	IGHV4-61	-6.1	2.77e-09	3.57e-06	-0.28	-0.31	Kawasaki disease;	chr14:106715491	chr14:106639119~106639657:-
STAD	cis	rs7487075	0.78	rs1873793	ENSG00000257261.4	RP11-96H19.1	-6.1	2.77e-09	3.57e-06	-0.36	-0.31	Itch intensity from mosquito bite;	chr12:46367541	chr12:46383679~46876159:+
STAD	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	6.1	2.77e-09	3.57e-06	0.39	0.31	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
STAD	cis	rs10853057	0.541	rs62065481	ENSG00000214174.7	AMZ2P1	6.1	2.78e-09	3.58e-06	0.57	0.31	White matter microstructure (global fractional anisotropy);	chr17:65008273	chr17:64966550~64975576:-
STAD	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-6.1	2.78e-09	3.58e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
STAD	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	6.1	2.78e-09	3.58e-06	0.41	0.31	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
STAD	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	6.1	2.78e-09	3.58e-06	0.39	0.31	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
STAD	cis	rs10129255	0.701	rs2005643	ENSG00000280411.1	IGHV1-69-2	-6.1	2.78e-09	3.59e-06	-0.28	-0.31	Kawasaki disease;	chr14:106676288	chr14:106762092~106762588:-
STAD	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-6.1	2.78e-09	3.59e-06	-0.32	-0.31	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
STAD	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	6.1	2.78e-09	3.59e-06	0.34	0.31	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	6.1	2.78e-09	3.59e-06	0.34	0.31	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
STAD	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	6.1	2.79e-09	3.59e-06	0.39	0.31	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
STAD	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	6.1	2.79e-09	3.59e-06	0.36	0.31	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
STAD	cis	rs875971	0.505	rs2462573	ENSG00000222364.1	RNU6-96P	6.1	2.79e-09	3.6e-06	0.35	0.31	Aortic root size;	chr7:66042405	chr7:66395191~66395286:+
STAD	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-6.1	2.79e-09	3.6e-06	-0.45	-0.31	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
STAD	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-6.1	2.79e-09	3.6e-06	-0.45	-0.31	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
STAD	cis	rs4639966	0.589	rs480958	ENSG00000255239.1	AP002954.6	6.1	2.8e-09	3.6e-06	0.34	0.31	Systemic lupus erythematosus;	chr11:118707281	chr11:118688039~118690600:-
STAD	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-6.1	2.8e-09	3.6e-06	-0.26	-0.31	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
STAD	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-6.1	2.8e-09	3.6e-06	-0.26	-0.31	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
STAD	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-6.1	2.8e-09	3.6e-06	-0.26	-0.31	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
STAD	cis	rs7487075	0.619	rs12314541	ENSG00000272369.1	RP11-446N19.1	6.1	2.8e-09	3.61e-06	0.38	0.31	Itch intensity from mosquito bite;	chr12:46400983	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs2408498	ENSG00000272369.1	RP11-446N19.1	6.1	2.8e-09	3.61e-06	0.38	0.31	Itch intensity from mosquito bite;	chr12:46403117	chr12:46537502~46652550:+
STAD	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-6.1	2.8e-09	3.61e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-6.1	2.8e-09	3.61e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
STAD	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	6.1	2.81e-09	3.62e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
STAD	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-6.1	2.81e-09	3.62e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-6.1	2.81e-09	3.62e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-6.1	2.81e-09	3.62e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
STAD	cis	rs227275	0.554	rs223466	ENSG00000230069.3	LRRC37A15P	-6.1	2.81e-09	3.62e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102727274~102730721:-
STAD	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	6.1	2.81e-09	3.62e-06	0.32	0.31	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
STAD	cis	rs9326248	0.53	rs1351452	ENSG00000280143.1	AP000892.6	-6.1	2.82e-09	3.63e-06	-0.32	-0.31	Blood protein levels;	chr11:117072638	chr11:117204967~117210292:+
STAD	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	6.1	2.82e-09	3.63e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
STAD	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-6.1	2.82e-09	3.63e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-6.1	2.83e-09	3.64e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
STAD	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	6.1	2.83e-09	3.64e-06	0.37	0.31	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
STAD	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	6.1	2.83e-09	3.64e-06	0.37	0.31	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	6.1	2.83e-09	3.64e-06	0.37	0.31	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
STAD	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	6.1	2.84e-09	3.65e-06	0.37	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
STAD	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-6.1	2.84e-09	3.66e-06	-0.39	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
STAD	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	6.1	2.85e-09	3.66e-06	0.38	0.31	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
STAD	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	6.1	2.85e-09	3.66e-06	0.38	0.31	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
STAD	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	6.1	2.85e-09	3.66e-06	0.38	0.31	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
STAD	cis	rs9549260	0.564	rs9646110	ENSG00000229456.1	RLIMP1	-6.1	2.85e-09	3.67e-06	-0.27	-0.31	Red blood cell count;	chr13:40734165	chr13:40618738~40621348:+
STAD	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	6.1	2.86e-09	3.68e-06	0.53	0.31	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
STAD	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	6.1	2.87e-09	3.68e-06	0.27	0.31	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
STAD	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	6.1	2.87e-09	3.68e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
STAD	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	6.1	2.87e-09	3.68e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
STAD	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	6.1	2.87e-09	3.69e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
STAD	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-6.1	2.87e-09	3.69e-06	-0.34	-0.31	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
STAD	cis	rs453301	0.653	rs7016139	ENSG00000254340.1	RP11-10A14.3	-6.1	2.89e-09	3.71e-06	-0.38	-0.31	Joint mobility (Beighton score);	chr8:9037960	chr8:9141424~9145435:+
STAD	cis	rs8141529	0.732	rs5997408	ENSG00000226471.5	CTA-292E10.6	-6.1	2.89e-09	3.71e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28811927	chr22:28800683~28848559:+
STAD	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	6.1	2.89e-09	3.71e-06	0.34	0.31	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
STAD	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	6.1	2.89e-09	3.71e-06	0.34	0.31	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	6.1	2.89e-09	3.71e-06	0.34	0.31	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-6.1	2.89e-09	3.71e-06	-0.27	-0.31	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
STAD	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-6.1	2.89e-09	3.71e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
STAD	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-6.1	2.9e-09	3.72e-06	-0.27	-0.31	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
STAD	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	6.1	2.91e-09	3.73e-06	0.38	0.31	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
STAD	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.1	2.91e-09	3.73e-06	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
STAD	cis	rs6452524	0.934	rs12153179	ENSG00000243385.2	CTD-2110K23.1	6.1	2.91e-09	3.73e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83201229~83202141:+
STAD	cis	rs875971	0.54	rs781152	ENSG00000222364.1	RNU6-96P	-6.1	2.91e-09	3.73e-06	-0.35	-0.31	Aortic root size;	chr7:66014585	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.727	rs781151	ENSG00000222364.1	RNU6-96P	-6.1	2.91e-09	3.73e-06	-0.35	-0.31	Calcium levels;	chr7:66014891	chr7:66395191~66395286:+
STAD	cis	rs3806843	0.766	rs6848	ENSG00000202111.1	VTRNA1-2	6.1	2.92e-09	3.74e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr5:140718925~140719013:+
STAD	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	6.09	2.92e-09	3.75e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	6.09	2.92e-09	3.75e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
STAD	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	6.09	2.92e-09	3.75e-06	0.37	0.31	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
STAD	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	6.09	2.92e-09	3.75e-06	0.4	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
STAD	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	6.09	2.94e-09	3.76e-06	0.35	0.31	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
STAD	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	6.09	2.94e-09	3.76e-06	0.3	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
STAD	cis	rs1426063	0.614	rs17000260	ENSG00000248165.1	RP11-44F21.2	6.09	2.94e-09	3.77e-06	0.66	0.31	QT interval;	chr4:75108576	chr4:74993877~75034824:-
STAD	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	6.09	2.95e-09	3.78e-06	0.35	0.31	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
STAD	cis	rs9549260	0.712	rs1334241	ENSG00000229456.1	RLIMP1	6.09	2.95e-09	3.78e-06	0.35	0.31	Red blood cell count;	chr13:40648973	chr13:40618738~40621348:+
STAD	cis	rs5769707	0.967	rs5769698	ENSG00000280224.1	CTA-722E9.1	-6.09	2.95e-09	3.79e-06	-0.32	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49500568~49501585:+
STAD	cis	rs6452524	0.967	rs6897075	ENSG00000243385.2	CTD-2110K23.1	6.09	2.96e-09	3.79e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs10065973	ENSG00000243385.2	CTD-2110K23.1	6.09	2.96e-09	3.79e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83201229~83202141:+
STAD	cis	rs227275	0.554	rs223439	ENSG00000230069.3	LRRC37A15P	-6.09	2.96e-09	3.79e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223436	ENSG00000230069.3	LRRC37A15P	-6.09	2.96e-09	3.79e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102727274~102730721:-
STAD	cis	rs9467773	0.935	rs1884947	ENSG00000243307.2	POM121L6P	6.09	2.96e-09	3.79e-06	0.3	0.31	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26896952~26898777:+
STAD	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	6.09	2.96e-09	3.79e-06	0.34	0.31	Height;	chr11:118857611	chr11:118688039~118690600:-
STAD	cis	rs9549260	0.709	rs4581585	ENSG00000229456.1	RLIMP1	6.09	2.97e-09	3.8e-06	0.28	0.31	Red blood cell count;	chr13:40629768	chr13:40618738~40621348:+
STAD	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-6.09	2.97e-09	3.8e-06	-0.42	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-6.09	2.97e-09	3.8e-06	-0.42	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
STAD	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	6.09	2.97e-09	3.8e-06	0.35	0.31	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
STAD	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	6.09	2.97e-09	3.8e-06	0.35	0.31	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
STAD	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	6.09	2.97e-09	3.8e-06	0.35	0.31	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
STAD	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	6.09	2.98e-09	3.81e-06	0.35	0.31	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
STAD	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-6.09	2.98e-09	3.81e-06	-0.29	-0.31	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
STAD	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	6.09	2.99e-09	3.82e-06	0.37	0.31	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
STAD	cis	rs11089937	0.626	rs9619811	ENSG00000211639.2	IGLV4-60	6.09	2.99e-09	3.82e-06	0.34	0.31	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22162199~22162681:+
STAD	cis	rs7487075	0.619	rs10748448	ENSG00000272369.1	RP11-446N19.1	6.09	2.99e-09	3.83e-06	0.38	0.31	Itch intensity from mosquito bite;	chr12:46409555	chr12:46537502~46652550:+
STAD	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	6.09	2.99e-09	3.83e-06	0.36	0.31	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	6.09	2.99e-09	3.83e-06	0.36	0.31	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
STAD	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-6.09	3e-09	3.83e-06	-0.31	-0.31	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
STAD	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	6.09	3e-09	3.83e-06	0.31	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
STAD	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	6.09	3e-09	3.84e-06	0.44	0.31	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
STAD	cis	rs728616	0.614	rs55720611	ENSG00000225484.5	NUTM2B-AS1	-6.09	3e-09	3.84e-06	-0.59	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030543	chr10:79663088~79826594:-
STAD	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.09	3.01e-09	3.84e-06	-0.36	-0.31	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
STAD	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	6.09	3.01e-09	3.85e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
STAD	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	6.09	3.01e-09	3.85e-06	0.39	0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
STAD	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	6.09	3.02e-09	3.86e-06	0.34	0.31	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	6.09	3.02e-09	3.86e-06	0.34	0.31	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
STAD	cis	rs9463078	0.565	rs3799973	ENSG00000219384.1	RP11-491H9.3	-6.09	3.02e-09	3.86e-06	-0.3	-0.31	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44855990	chr6:45158870~45159511:+
STAD	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	6.09	3.02e-09	3.86e-06	0.36	0.31	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
STAD	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	6.09	3.03e-09	3.87e-06	0.35	0.31	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
STAD	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	6.09	3.04e-09	3.88e-06	0.41	0.31	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
STAD	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	6.09	3.04e-09	3.89e-06	0.32	0.31	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
STAD	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	6.09	3.05e-09	3.89e-06	0.34	0.31	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
STAD	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-6.09	3.05e-09	3.89e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
STAD	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-6.09	3.05e-09	3.89e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
STAD	cis	rs858239	0.539	rs6975852	ENSG00000226816.2	AC005082.12	6.09	3.05e-09	3.89e-06	0.39	0.31	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23206013~23208045:+
STAD	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-6.09	3.05e-09	3.9e-06	-0.38	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-6.09	3.05e-09	3.9e-06	-0.38	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
STAD	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-6.09	3.05e-09	3.9e-06	-0.38	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
STAD	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	6.09	3.05e-09	3.9e-06	0.37	0.31	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	6.09	3.05e-09	3.9e-06	0.37	0.31	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
STAD	cis	rs9467773	0.935	rs11752946	ENSG00000243307.2	POM121L6P	6.09	3.05e-09	3.9e-06	0.3	0.31	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26896952~26898777:+
STAD	cis	rs10129255	0.957	rs67625077	ENSG00000211970.3	IGHV4-61	-6.09	3.06e-09	3.9e-06	-0.28	-0.31	Kawasaki disease;	chr14:106715436	chr14:106639119~106639657:-
STAD	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	6.09	3.06e-09	3.91e-06	0.36	0.31	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
STAD	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-6.09	3.06e-09	3.91e-06	-0.27	-0.31	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
STAD	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-6.09	3.06e-09	3.91e-06	-0.33	-0.31	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
STAD	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-6.09	3.08e-09	3.92e-06	-0.41	-0.31	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
STAD	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-6.09	3.08e-09	3.92e-06	-0.4	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
STAD	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	6.09	3.08e-09	3.93e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
STAD	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	6.09	3.08e-09	3.93e-06	0.35	0.31	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
STAD	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	6.09	3.09e-09	3.94e-06	0.51	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
STAD	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-6.09	3.09e-09	3.94e-06	-0.32	-0.31	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
STAD	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-6.09	3.09e-09	3.94e-06	-0.32	-0.31	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
STAD	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-6.08	3.09e-09	3.94e-06	-0.26	-0.31	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
STAD	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	6.08	3.1e-09	3.96e-06	0.51	0.31	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
STAD	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-6.08	3.11e-09	3.96e-06	-0.28	-0.31	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
STAD	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-6.08	3.11e-09	3.97e-06	-0.32	-0.31	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
STAD	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-6.08	3.11e-09	3.97e-06	-0.32	-0.31	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
STAD	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	6.08	3.11e-09	3.97e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
STAD	cis	rs6558530	0.653	rs7001282	ENSG00000253982.1	CTD-2336O2.1	6.08	3.12e-09	3.97e-06	0.35	0.31	Systolic blood pressure;	chr8:1752022	chr8:1761990~1764502:-
STAD	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-6.08	3.12e-09	3.97e-06	-0.29	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
STAD	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-6.08	3.12e-09	3.98e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
STAD	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	6.08	3.12e-09	3.98e-06	0.37	0.31	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	6.08	3.12e-09	3.98e-06	0.37	0.31	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	6.08	3.12e-09	3.98e-06	0.37	0.31	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
STAD	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-6.08	3.13e-09	3.99e-06	-0.28	-0.31	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	6.08	3.14e-09	3.99e-06	0.27	0.31	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	6.08	3.14e-09	3.99e-06	0.27	0.31	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
STAD	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.08	3.14e-09	4e-06	-0.36	-0.31	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000211970.3	IGHV4-61	-6.08	3.14e-09	4e-06	-0.26	-0.31	Kawasaki disease;	chr14:106799309	chr14:106639119~106639657:-
STAD	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	6.08	3.14e-09	4e-06	0.36	0.31	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
STAD	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.08	3.14e-09	4e-06	-0.29	-0.31	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
STAD	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-6.08	3.14e-09	4e-06	-0.29	-0.31	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
STAD	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-6.08	3.14e-09	4e-06	-0.27	-0.31	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
STAD	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	6.08	3.15e-09	4.01e-06	0.46	0.31	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	6.08	3.15e-09	4.01e-06	0.46	0.31	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
STAD	cis	rs10129255	0.957	rs10137980	ENSG00000280411.1	IGHV1-69-2	-6.08	3.16e-09	4.02e-06	-0.28	-0.31	Kawasaki disease;	chr14:106775735	chr14:106762092~106762588:-
STAD	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-6.08	3.16e-09	4.02e-06	-0.34	-0.31	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
STAD	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	6.08	3.16e-09	4.02e-06	0.42	0.31	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
STAD	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-6.08	3.16e-09	4.02e-06	-0.31	-0.31	Asthma;	chr2:102438096	chr2:102438713~102440475:+
STAD	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-6.08	3.17e-09	4.03e-06	-0.3	-0.31	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
STAD	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-6.08	3.17e-09	4.03e-06	-0.3	-0.31	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
STAD	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-6.08	3.18e-09	4.04e-06	-0.35	-0.31	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
STAD	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-6.08	3.18e-09	4.04e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
STAD	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	6.08	3.18e-09	4.05e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	6.08	3.18e-09	4.05e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
STAD	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-6.08	3.19e-09	4.05e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
STAD	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	6.08	3.19e-09	4.06e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
STAD	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	6.08	3.2e-09	4.07e-06	0.35	0.31	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	6.08	3.2e-09	4.07e-06	0.35	0.31	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
STAD	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	6.08	3.2e-09	4.07e-06	0.51	0.31	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
STAD	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-6.08	3.21e-09	4.08e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	6.08	3.21e-09	4.09e-06	0.37	0.31	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
STAD	cis	rs9549260	0.816	rs964901	ENSG00000229456.1	RLIMP1	6.08	3.22e-09	4.09e-06	0.28	0.31	Red blood cell count;	chr13:40674561	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.709	rs12585870	ENSG00000229456.1	RLIMP1	6.08	3.22e-09	4.09e-06	0.28	0.31	Red blood cell count;	chr13:40625350	chr13:40618738~40621348:+
STAD	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-6.08	3.22e-09	4.09e-06	-0.33	-0.31	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
STAD	cis	rs13113518	1	rs4865013	ENSG00000272969.1	RP11-528I4.2	6.08	3.23e-09	4.1e-06	0.4	0.31	Height;	chr4:55559957	chr4:55547112~55547889:+
STAD	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	6.08	3.23e-09	4.1e-06	0.36	0.31	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	6.08	3.23e-09	4.1e-06	0.36	0.31	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
STAD	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	6.08	3.23e-09	4.11e-06	0.32	0.31	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
STAD	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	6.08	3.23e-09	4.11e-06	0.47	0.31	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
STAD	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	6.08	3.23e-09	4.11e-06	0.47	0.31	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
STAD	cis	rs11089937	0.626	rs2213161	ENSG00000211639.2	IGLV4-60	6.08	3.24e-09	4.11e-06	0.35	0.31	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22162199~22162681:+
STAD	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	6.08	3.25e-09	4.12e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	6.08	3.25e-09	4.12e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
STAD	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-6.08	3.25e-09	4.13e-06	-0.35	-0.31	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-6.08	3.25e-09	4.13e-06	-0.35	-0.31	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-6.08	3.25e-09	4.13e-06	-0.35	-0.31	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
STAD	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	6.08	3.25e-09	4.13e-06	0.35	0.31	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
STAD	cis	rs13113518	1	rs3762837	ENSG00000272969.1	RP11-528I4.2	6.08	3.25e-09	4.13e-06	0.39	0.31	Height;	chr4:55511198	chr4:55547112~55547889:+
STAD	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	6.08	3.25e-09	4.13e-06	0.34	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
STAD	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-6.08	3.26e-09	4.14e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-6.08	3.26e-09	4.14e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-6.08	3.26e-09	4.14e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-6.08	3.26e-09	4.14e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
STAD	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-6.08	3.26e-09	4.14e-06	-0.35	-0.31	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-6.08	3.26e-09	4.14e-06	-0.35	-0.31	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-6.08	3.26e-09	4.14e-06	-0.35	-0.31	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
STAD	cis	rs6452524	0.967	rs6452507	ENSG00000243385.2	CTD-2110K23.1	6.08	3.26e-09	4.14e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs6452508	ENSG00000243385.2	CTD-2110K23.1	6.08	3.26e-09	4.14e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83201229~83202141:+
STAD	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-6.08	3.26e-09	4.14e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
STAD	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	6.08	3.27e-09	4.14e-06	0.33	0.31	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
STAD	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-6.07	3.27e-09	4.15e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-6.07	3.27e-09	4.15e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
STAD	cis	rs875971	0.505	rs1167386	ENSG00000222364.1	RNU6-96P	6.07	3.27e-09	4.15e-06	0.35	0.31	Aortic root size;	chr7:66048109	chr7:66395191~66395286:+
STAD	cis	rs875971	0.505	rs1167385	ENSG00000222364.1	RNU6-96P	6.07	3.27e-09	4.15e-06	0.35	0.31	Aortic root size;	chr7:66048321	chr7:66395191~66395286:+
STAD	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	6.07	3.28e-09	4.16e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
STAD	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	6.07	3.28e-09	4.16e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
STAD	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	6.07	3.28e-09	4.16e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
STAD	cis	rs7487075	0.619	rs2220727	ENSG00000272369.1	RP11-446N19.1	6.07	3.29e-09	4.17e-06	0.38	0.31	Itch intensity from mosquito bite;	chr12:46411286	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs6582645	ENSG00000272369.1	RP11-446N19.1	6.07	3.29e-09	4.17e-06	0.38	0.31	Itch intensity from mosquito bite;	chr12:46411361	chr12:46537502~46652550:+
STAD	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	6.07	3.29e-09	4.17e-06	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
STAD	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	6.07	3.29e-09	4.17e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	6.07	3.29e-09	4.17e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	6.07	3.29e-09	4.17e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	6.07	3.29e-09	4.17e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	6.07	3.29e-09	4.17e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	6.07	3.29e-09	4.17e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
STAD	cis	rs11603023	1	rs11603023	ENSG00000255239.1	AP002954.6	6.07	3.29e-09	4.18e-06	0.35	0.31	Cholesterol, total;	chr11:118615352	chr11:118688039~118690600:-
STAD	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	6.07	3.3e-09	4.18e-06	0.48	0.31	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
STAD	cis	rs2337406	0.714	rs8022729	ENSG00000274576.2	IGHV2-70	6.07	3.3e-09	4.18e-06	0.35	0.31	Alzheimer's disease (late onset);	chr14:106816928	chr14:106770577~106771020:-
STAD	cis	rs748404	0.556	rs7166467	ENSG00000249839.1	AC011330.5	6.07	3.3e-09	4.18e-06	0.38	0.31	Lung cancer;	chr15:43148324	chr15:43663654~43684339:-
STAD	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	6.07	3.3e-09	4.18e-06	0.37	0.31	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
STAD	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-6.07	3.31e-09	4.19e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
STAD	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	6.07	3.34e-09	4.23e-06	0.36	0.31	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
STAD	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-6.07	3.34e-09	4.23e-06	-0.32	-0.31	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
STAD	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-6.07	3.34e-09	4.23e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
STAD	cis	rs227275	0.554	rs223399	ENSG00000230069.3	LRRC37A15P	-6.07	3.35e-09	4.23e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102727274~102730721:-
STAD	cis	rs9549260	0.753	rs9549246	ENSG00000229456.1	RLIMP1	6.07	3.35e-09	4.24e-06	0.36	0.31	Red blood cell count;	chr13:40646618	chr13:40618738~40621348:+
STAD	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	6.07	3.35e-09	4.24e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
STAD	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-6.07	3.35e-09	4.24e-06	-0.36	-0.31	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
STAD	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	6.07	3.35e-09	4.24e-06	0.41	0.31	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
STAD	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-6.07	3.36e-09	4.25e-06	-0.3	-0.31	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
STAD	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-6.07	3.36e-09	4.26e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
STAD	cis	rs9549260	0.564	rs9577110	ENSG00000229456.1	RLIMP1	6.07	3.36e-09	4.26e-06	0.28	0.31	Red blood cell count;	chr13:40697742	chr13:40618738~40621348:+
STAD	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-6.07	3.37e-09	4.26e-06	-0.53	-0.31	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
STAD	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-6.07	3.37e-09	4.26e-06	-0.35	-0.31	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-6.07	3.37e-09	4.26e-06	-0.35	-0.31	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
STAD	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-6.07	3.37e-09	4.26e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
STAD	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	6.07	3.37e-09	4.26e-06	0.49	0.31	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
STAD	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	6.07	3.38e-09	4.28e-06	0.36	0.31	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
STAD	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-6.07	3.39e-09	4.29e-06	-0.39	-0.31	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
STAD	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	6.07	3.39e-09	4.29e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	6.07	3.39e-09	4.29e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	6.07	3.39e-09	4.29e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
STAD	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-6.07	3.39e-09	4.29e-06	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-6.07	3.39e-09	4.29e-06	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
STAD	cis	rs6452524	0.868	rs10079372	ENSG00000243385.2	CTD-2110K23.1	6.07	3.41e-09	4.3e-06	0.38	0.31	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83201229~83202141:+
STAD	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	6.07	3.41e-09	4.3e-06	0.28	0.31	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
STAD	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	6.07	3.41e-09	4.3e-06	0.28	0.31	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
STAD	cis	rs10129255	1	rs10134517	ENSG00000280411.1	IGHV1-69-2	-6.07	3.41e-09	4.31e-06	-0.29	-0.31	Kawasaki disease;	chr14:106718498	chr14:106762092~106762588:-
STAD	cis	rs2440129	0.611	rs10852889	ENSG00000215067.8	ALOX12-AS1	6.07	3.41e-09	4.31e-06	0.32	0.31	Tonsillectomy;	chr17:6997526	chr17:6876635~7012349:-
STAD	cis	rs4604732	0.536	rs12058821	ENSG00000227135.1	GCSAML-AS1	-6.07	3.42e-09	4.32e-06	-0.43	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247486349	chr1:247524679~247526752:-
STAD	cis	rs711244	0.756	rs2372786	ENSG00000252756.1	RNU6-577P	-6.07	3.43e-09	4.33e-06	-0.34	-0.31	Mean platelet volume;	chr2:36932656	chr2:36867398~36867495:-
STAD	cis	rs7927771	0.839	rs3817334	ENSG00000280615.1	Y_RNA	-6.07	3.43e-09	4.33e-06	-0.31	-0.31	Subjective well-being;	chr11:47629441	chr11:47614898~47614994:-
STAD	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	6.07	3.43e-09	4.34e-06	0.38	0.31	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	6.07	3.43e-09	4.34e-06	0.38	0.31	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
STAD	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-6.07	3.44e-09	4.35e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
STAD	cis	rs6452524	0.904	rs10076056	ENSG00000243385.2	CTD-2110K23.1	-6.07	3.45e-09	4.36e-06	-0.37	-0.31	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83201229~83202141:+
STAD	cis	rs2273156	0.57	rs7154306	ENSG00000241052.1	RP11-173D9.1	-6.07	3.45e-09	4.36e-06	-0.37	-0.31	Immunoglobulin light chain (AL) amyloidosis;	chr14:35071293	chr14:35144021~35144480:-
STAD	cis	rs2143950	0.831	rs12589079	ENSG00000241052.1	RP11-173D9.1	-6.07	3.45e-09	4.36e-06	-0.37	-0.31	Atopic dermatitis;	chr14:35073287	chr14:35144021~35144480:-
STAD	cis	rs12699921	0.566	rs2691586	ENSG00000279048.1	RP11-511H23.2	-6.07	3.45e-09	4.36e-06	-0.29	-0.31	Fibrinogen levels;	chr7:17798236	chr7:17940503~17942922:+
STAD	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	6.07	3.45e-09	4.36e-06	0.35	0.31	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
STAD	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	6.07	3.46e-09	4.36e-06	0.5	0.31	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
STAD	cis	rs9549260	0.755	rs4943798	ENSG00000229456.1	RLIMP1	6.06	3.46e-09	4.36e-06	0.28	0.31	Red blood cell count;	chr13:40628811	chr13:40618738~40621348:+
STAD	cis	rs8067354	0.574	rs2531898	ENSG00000266701.1	AC005702.4	6.06	3.46e-09	4.36e-06	0.45	0.31	Hemoglobin concentration;	chr17:59934990	chr17:60042546~60042627:-
STAD	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-6.06	3.46e-09	4.37e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
STAD	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	6.06	3.46e-09	4.37e-06	0.37	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
STAD	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-6.06	3.46e-09	4.37e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-6.06	3.46e-09	4.37e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
STAD	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-6.06	3.47e-09	4.37e-06	-0.36	-0.31	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-6.06	3.47e-09	4.37e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
STAD	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-6.06	3.47e-09	4.37e-06	-0.31	-0.31	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
STAD	cis	rs6558530	0.692	rs12335115	ENSG00000253982.1	CTD-2336O2.1	6.06	3.47e-09	4.37e-06	0.35	0.31	Systolic blood pressure;	chr8:1751686	chr8:1761990~1764502:-
STAD	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-6.06	3.47e-09	4.37e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-6.06	3.47e-09	4.37e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-6.06	3.47e-09	4.38e-06	-0.28	-0.31	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
STAD	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-6.06	3.48e-09	4.39e-06	-0.37	-0.31	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
STAD	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	6.06	3.48e-09	4.39e-06	0.54	0.31	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
STAD	cis	rs8005677	0.649	rs11629120	ENSG00000257285.4	RP11-298I3.1	-6.06	3.51e-09	4.42e-06	-0.39	-0.31	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:22929609~22955562:+
STAD	cis	rs10129255	1	rs10129319	ENSG00000280411.1	IGHV1-69-2	-6.06	3.51e-09	4.42e-06	-0.29	-0.31	Kawasaki disease;	chr14:106767996	chr14:106762092~106762588:-
STAD	cis	rs227275	0.586	rs223448	ENSG00000230069.3	LRRC37A15P	-6.06	3.51e-09	4.42e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102727274~102730721:-
STAD	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-6.06	3.51e-09	4.42e-06	-0.39	-0.31	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
STAD	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-6.06	3.51e-09	4.43e-06	-0.27	-0.31	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
STAD	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	6.06	3.51e-09	4.43e-06	0.39	0.31	Height;	chr6:109358227	chr6:109382795~109383666:+
STAD	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-6.06	3.52e-09	4.44e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
STAD	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	6.06	3.52e-09	4.44e-06	0.36	0.31	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-6.06	3.53e-09	4.44e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
STAD	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	6.06	3.53e-09	4.45e-06	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
STAD	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-6.06	3.53e-09	4.45e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-6.06	3.53e-09	4.45e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-6.06	3.53e-09	4.45e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
STAD	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	6.06	3.54e-09	4.45e-06	0.36	0.31	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
STAD	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-6.06	3.54e-09	4.46e-06	-0.3	-0.31	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-6.06	3.54e-09	4.46e-06	-0.3	-0.31	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
STAD	cis	rs227275	0.554	rs223382	ENSG00000230069.3	LRRC37A15P	-6.06	3.54e-09	4.46e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102727274~102730721:-
STAD	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	6.06	3.55e-09	4.46e-06	0.35	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
STAD	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	6.06	3.55e-09	4.47e-06	0.32	0.31	Asthma;	chr2:102374753	chr2:102438713~102440475:+
STAD	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-6.06	3.55e-09	4.47e-06	-0.5	-0.31	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
STAD	cis	rs2980439	0.818	rs2948300	ENSG00000253981.4	ALG1L13P	6.06	3.55e-09	4.47e-06	0.37	0.31	Neuroticism;	chr8:8248986	chr8:8236003~8244667:-
STAD	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	6.06	3.55e-09	4.47e-06	0.27	0.31	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
STAD	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-6.06	3.56e-09	4.48e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
STAD	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-6.06	3.58e-09	4.5e-06	-0.35	-0.31	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
STAD	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-6.06	3.58e-09	4.51e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-6.06	3.59e-09	4.52e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-6.06	3.59e-09	4.52e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-6.06	3.59e-09	4.52e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-6.06	3.59e-09	4.52e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-6.06	3.59e-09	4.52e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
STAD	cis	rs11722779	0.873	rs223384	ENSG00000230069.3	LRRC37A15P	-6.06	3.59e-09	4.52e-06	-0.33	-0.31	Schizophrenia;	chr4:102829976	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223383	ENSG00000230069.3	LRRC37A15P	-6.06	3.59e-09	4.52e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102727274~102730721:-
STAD	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-6.06	3.6e-09	4.53e-06	-0.33	-0.31	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-6.06	3.6e-09	4.53e-06	-0.33	-0.31	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
STAD	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-6.06	3.6e-09	4.53e-06	-0.34	-0.31	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
STAD	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	6.06	3.6e-09	4.53e-06	0.32	0.31	Asthma;	chr2:102437614	chr2:102438713~102440475:+
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-6.06	3.6e-09	4.53e-06	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
STAD	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-6.06	3.61e-09	4.54e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
STAD	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	6.06	3.62e-09	4.55e-06	0.32	0.31	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
STAD	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	6.06	3.63e-09	4.56e-06	0.32	0.31	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
STAD	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	6.06	3.63e-09	4.56e-06	0.39	0.31	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
STAD	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-6.06	3.65e-09	4.58e-06	-0.32	-0.31	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
STAD	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	6.06	3.65e-09	4.58e-06	0.35	0.31	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
STAD	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	6.06	3.65e-09	4.58e-06	0.4	0.31	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
STAD	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	6.06	3.65e-09	4.58e-06	0.32	0.31	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
STAD	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	6.06	3.66e-09	4.59e-06	0.3	0.31	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
STAD	cis	rs4568518	0.557	rs13224298	ENSG00000279048.1	RP11-511H23.2	6.05	3.66e-09	4.59e-06	0.29	0.31	Measles;	chr7:17962503	chr7:17940503~17942922:+
STAD	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	6.05	3.67e-09	4.6e-06	0.32	0.31	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
STAD	cis	rs2337406	0.714	rs2337463	ENSG00000274576.2	IGHV2-70	-6.05	3.67e-09	4.61e-06	-0.35	-0.31	Alzheimer's disease (late onset);	chr14:106816066	chr14:106770577~106771020:-
STAD	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	6.05	3.7e-09	4.63e-06	0.36	0.31	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
STAD	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	6.05	3.7e-09	4.64e-06	0.38	0.31	Height;	chr6:109354092	chr6:109382795~109383666:+
STAD	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	6.05	3.7e-09	4.64e-06	0.33	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
STAD	cis	rs3806843	0.735	rs6849	ENSG00000202111.1	VTRNA1-2	6.05	3.7e-09	4.64e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.735	rs702394	ENSG00000202111.1	VTRNA1-2	6.05	3.7e-09	4.64e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr5:140718925~140719013:+
STAD	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	6.05	3.71e-09	4.65e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
STAD	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-6.05	3.71e-09	4.65e-06	-0.44	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
STAD	cis	rs8141529	0.778	rs5762795	ENSG00000226471.5	CTA-292E10.6	-6.05	3.72e-09	4.65e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28786512	chr22:28800683~28848559:+
STAD	cis	rs2337406	0.714	rs7145254	ENSG00000274576.2	IGHV2-70	-6.05	3.72e-09	4.66e-06	-0.35	-0.31	Alzheimer's disease (late onset);	chr14:106817783	chr14:106770577~106771020:-
STAD	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	6.05	3.72e-09	4.66e-06	0.31	0.31	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
STAD	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-6.05	3.72e-09	4.66e-06	-0.42	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
STAD	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	6.05	3.73e-09	4.67e-06	0.31	0.31	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
STAD	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	6.05	3.73e-09	4.67e-06	0.38	0.31	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
STAD	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
STAD	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
STAD	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-6.05	3.73e-09	4.67e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
STAD	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	6.05	3.74e-09	4.67e-06	0.39	0.31	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
STAD	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	6.05	3.75e-09	4.69e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
STAD	cis	rs7924176	0.521	rs10824137	ENSG00000236900.1	TIMM9P1	6.05	3.76e-09	4.7e-06	0.32	0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74344550~74344805:-
STAD	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-6.05	3.76e-09	4.7e-06	-0.37	-0.31	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
STAD	cis	rs11763147	1	rs11763147	ENSG00000222364.1	RNU6-96P	6.05	3.77e-09	4.71e-06	0.34	0.31	Corneal structure;	chr7:65861834	chr7:66395191~66395286:+
STAD	cis	rs2283792	0.905	rs5755694	ENSG00000228050.1	TOP3BP1	6.05	3.78e-09	4.72e-06	0.34	0.31	Multiple sclerosis;	chr22:21846241	chr22:22223187~22224566:-
STAD	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-6.05	3.78e-09	4.73e-06	-0.46	-0.31	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
STAD	cis	rs5769707	0.967	rs5770585	ENSG00000280224.1	CTA-722E9.1	-6.05	3.78e-09	4.73e-06	-0.32	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49500568~49501585:+
STAD	cis	rs12802244	1	rs12802244	ENSG00000280615.1	Y_RNA	-6.05	3.79e-09	4.73e-06	-0.32	-0.31	Neuroticism;	chr11:47911114	chr11:47614898~47614994:-
STAD	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-6.05	3.8e-09	4.74e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
STAD	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-6.05	3.81e-09	4.75e-06	-0.4	-0.31	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
STAD	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	6.05	3.81e-09	4.75e-06	0.36	0.31	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
STAD	cis	rs721917	0.506	rs2819102	ENSG00000225484.5	NUTM2B-AS1	-6.05	3.81e-09	4.75e-06	-0.4	-0.31	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79663088~79826594:-
STAD	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-6.05	3.81e-09	4.76e-06	-0.36	-0.31	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
STAD	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-6.05	3.82e-09	4.76e-06	-0.54	-0.31	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
STAD	cis	rs9549260	0.577	rs6563841	ENSG00000229456.1	RLIMP1	6.05	3.82e-09	4.76e-06	0.29	0.31	Red blood cell count;	chr13:40665041	chr13:40618738~40621348:+
STAD	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	6.05	3.82e-09	4.77e-06	0.38	0.31	Height;	chr6:109360263	chr6:109382795~109383666:+
STAD	cis	rs516805	0.706	rs1267943	ENSG00000279453.1	RP3-425C14.4	-6.05	3.83e-09	4.78e-06	-0.42	-0.31	Lymphocyte counts;	chr6:122462498	chr6:122436789~122439223:-
STAD	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-6.05	3.83e-09	4.78e-06	-0.42	-0.31	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-6.05	3.83e-09	4.78e-06	-0.42	-0.31	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
STAD	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-6.05	3.85e-09	4.81e-06	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
STAD	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	6.05	3.86e-09	4.81e-06	0.49	0.31	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
STAD	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-6.05	3.86e-09	4.81e-06	-0.35	-0.31	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-6.05	3.86e-09	4.81e-06	-0.35	-0.31	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-6.05	3.86e-09	4.81e-06	-0.35	-0.31	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
STAD	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-6.05	3.86e-09	4.81e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
STAD	cis	rs721917	0.506	rs1923540	ENSG00000225484.5	NUTM2B-AS1	-6.05	3.86e-09	4.82e-06	-0.4	-0.31	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79663088~79826594:-
STAD	cis	rs7849270	0.879	rs2229419	ENSG00000268707.1	RP11-247A12.7	6.05	3.87e-09	4.82e-06	0.36	0.31	Blood metabolite ratios;	chr9:129095351	chr9:129170434~129170940:+
STAD	cis	rs516805	0.781	rs574462	ENSG00000279453.1	RP3-425C14.4	-6.04	3.87e-09	4.83e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122404863	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs512063	ENSG00000279453.1	RP3-425C14.4	-6.04	3.87e-09	4.83e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122409206	chr6:122436789~122439223:-
STAD	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-6.04	3.88e-09	4.83e-06	-0.33	-0.31	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
STAD	cis	rs5769707	0.967	rs763127	ENSG00000280224.1	CTA-722E9.1	-6.04	3.88e-09	4.83e-06	-0.32	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49500568~49501585:+
STAD	cis	rs10129255	0.957	rs2013423	ENSG00000280411.1	IGHV1-69-2	-6.04	3.88e-09	4.84e-06	-0.29	-0.31	Kawasaki disease;	chr14:106690675	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.957	rs10132367	ENSG00000280411.1	IGHV1-69-2	-6.04	3.88e-09	4.84e-06	-0.29	-0.31	Kawasaki disease;	chr14:106690981	chr14:106762092~106762588:-
STAD	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	6.04	3.9e-09	4.85e-06	0.37	0.31	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	6.04	3.9e-09	4.85e-06	0.37	0.31	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
STAD	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	6.04	3.9e-09	4.85e-06	0.29	0.31	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
STAD	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-6.04	3.9e-09	4.86e-06	-0.37	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
STAD	cis	rs858239	0.669	rs56400441	ENSG00000226816.2	AC005082.12	6.04	3.91e-09	4.87e-06	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23206013~23208045:+
STAD	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	6.04	3.91e-09	4.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
STAD	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	6.04	3.91e-09	4.87e-06	0.5	0.31	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
STAD	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	6.04	3.91e-09	4.87e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
STAD	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	6.04	3.91e-09	4.87e-06	0.33	0.31	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
STAD	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	6.04	3.93e-09	4.89e-06	0.36	0.31	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
STAD	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-6.04	3.94e-09	4.9e-06	-0.41	-0.31	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
STAD	cis	rs3806843	0.735	rs809635	ENSG00000202111.1	VTRNA1-2	6.04	3.94e-09	4.9e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.648	rs2530233	ENSG00000202111.1	VTRNA1-2	6.04	3.94e-09	4.9e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr5:140718925~140719013:+
STAD	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-6.04	3.95e-09	4.91e-06	-0.31	-0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
STAD	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-6.04	3.95e-09	4.92e-06	-0.34	-0.31	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
STAD	cis	rs11603023	0.569	rs573905	ENSG00000278376.1	RP11-158I9.8	-6.04	3.96e-09	4.92e-06	-0.33	-0.31	Cholesterol, total;	chr11:118701558	chr11:118791254~118793137:+
STAD	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	6.04	3.96e-09	4.92e-06	0.35	0.31	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
STAD	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	6.04	3.96e-09	4.92e-06	0.32	0.31	Asthma;	chr2:102440033	chr2:102438713~102440475:+
STAD	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	6.04	3.96e-09	4.93e-06	0.36	0.31	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
STAD	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	6.04	3.96e-09	4.93e-06	0.35	0.31	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	6.04	3.96e-09	4.93e-06	0.35	0.31	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
STAD	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	6.04	3.97e-09	4.93e-06	0.32	0.31	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
STAD	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-6.04	3.97e-09	4.94e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
STAD	cis	rs10129255	0.957	rs10141009	ENSG00000280411.1	IGHV1-69-2	-6.04	3.98e-09	4.94e-06	-0.28	-0.31	Kawasaki disease;	chr14:106776695	chr14:106762092~106762588:-
STAD	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	6.04	3.98e-09	4.95e-06	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
STAD	cis	rs453301	0.606	rs7462373	ENSG00000254340.1	RP11-10A14.3	-6.04	3.99e-09	4.96e-06	-0.39	-0.31	Joint mobility (Beighton score);	chr8:9041808	chr8:9141424~9145435:+
STAD	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	6.04	4e-09	4.97e-06	0.3	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
STAD	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	6.04	4e-09	4.97e-06	0.29	0.31	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
STAD	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-6.04	4e-09	4.97e-06	-0.32	-0.31	Asthma;	chr2:102374909	chr2:102438713~102440475:+
STAD	cis	rs10129255	0.957	rs8014696	ENSG00000280411.1	IGHV1-69-2	6.04	4e-09	4.97e-06	0.28	0.31	Kawasaki disease;	chr14:106769752	chr14:106762092~106762588:-
STAD	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-6.04	4e-09	4.97e-06	-0.49	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
STAD	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-6.04	4.01e-09	4.98e-06	-0.32	-0.31	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
STAD	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-6.04	4.01e-09	4.98e-06	-0.45	-0.31	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
STAD	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	6.04	4.01e-09	4.98e-06	0.36	0.31	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
STAD	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-6.04	4.01e-09	4.98e-06	-0.33	-0.31	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
STAD	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-6.04	4.02e-09	4.99e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
STAD	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-6.04	4.03e-09	5e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
STAD	cis	rs7829975	0.711	rs1039916	ENSG00000254340.1	RP11-10A14.3	6.04	4.03e-09	5e-06	0.37	0.31	Mood instability;	chr8:8828344	chr8:9141424~9145435:+
STAD	cis	rs12699921	0.572	rs2030725	ENSG00000279048.1	RP11-511H23.2	-6.04	4.04e-09	5.01e-06	-0.29	-0.31	Fibrinogen levels;	chr7:17828708	chr7:17940503~17942922:+
STAD	cis	rs6668108	1	rs6668108	ENSG00000224358.1	RP11-466F5.8	-6.04	4.04e-09	5.02e-06	-0.52	-0.31	Intraocular pressure;	chr1:165722083	chr1:165768929~165775176:+
STAD	cis	rs6558530	0.615	rs12674711	ENSG00000253982.1	CTD-2336O2.1	6.04	4.05e-09	5.03e-06	0.35	0.31	Systolic blood pressure;	chr8:1751442	chr8:1761990~1764502:-
STAD	cis	rs227275	0.554	rs150895	ENSG00000230069.3	LRRC37A15P	-6.04	4.05e-09	5.03e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223442	ENSG00000230069.3	LRRC37A15P	-6.04	4.05e-09	5.03e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223441	ENSG00000230069.3	LRRC37A15P	-6.04	4.05e-09	5.03e-06	-0.33	-0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102727274~102730721:-
STAD	cis	rs13113518	1	rs4864542	ENSG00000272969.1	RP11-528I4.2	-6.04	4.06e-09	5.03e-06	-0.39	-0.31	Height;	chr4:55487920	chr4:55547112~55547889:+
STAD	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-6.04	4.06e-09	5.04e-06	-0.29	-0.31	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
STAD	cis	rs732716	0.813	rs760369	ENSG00000267980.1	AC007292.6	6.04	4.06e-09	5.04e-06	0.4	0.31	Mean corpuscular volume;	chr19:4449290	chr19:4363789~4364640:+
STAD	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-6.04	4.06e-09	5.04e-06	-0.29	-0.31	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
STAD	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	6.04	4.07e-09	5.05e-06	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
STAD	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-6.04	4.09e-09	5.07e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
STAD	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	6.04	4.09e-09	5.07e-06	0.36	0.31	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
STAD	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	6.04	4.09e-09	5.07e-06	0.45	0.31	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
STAD	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	6.04	4.09e-09	5.07e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
STAD	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-6.04	4.09e-09	5.07e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
STAD	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-6.03	4.1e-09	5.08e-06	-0.35	-0.31	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
STAD	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	6.03	4.1e-09	5.08e-06	0.33	0.31	Height;	chr11:118860890	chr11:118688039~118690600:-
STAD	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	6.03	4.1e-09	5.08e-06	0.33	0.31	Height;	chr11:118861053	chr11:118688039~118690600:-
STAD	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-6.03	4.11e-09	5.09e-06	-0.43	-0.31	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
STAD	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	6.03	4.11e-09	5.09e-06	0.38	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
STAD	cis	rs11098499	0.913	rs12186259	ENSG00000245958.5	RP11-33B1.1	-6.03	4.11e-09	5.1e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119230884	chr4:119454791~119552025:+
STAD	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	6.03	4.12e-09	5.1e-06	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
STAD	cis	rs6452524	0.836	rs4343818	ENSG00000249664.1	CTD-2227C6.2	6.03	4.12e-09	5.11e-06	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83012285~83013109:-
STAD	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	6.03	4.13e-09	5.12e-06	0.29	0.31	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
STAD	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-6.03	4.13e-09	5.12e-06	-0.35	-0.31	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
STAD	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-6.03	4.14e-09	5.12e-06	-0.52	-0.31	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
STAD	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	6.03	4.15e-09	5.13e-06	0.29	0.31	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
STAD	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	6.03	4.15e-09	5.14e-06	0.32	0.31	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
STAD	cis	rs8040855	0.627	rs4843019	ENSG00000229212.6	RP11-561C5.4	-6.03	4.15e-09	5.14e-06	-0.45	-0.31	Bulimia nervosa;	chr15:85101228	chr15:85205440~85234795:-
STAD	cis	rs10129255	0.912	rs6576227	ENSG00000280411.1	IGHV1-69-2	-6.03	4.16e-09	5.15e-06	-0.28	-0.31	Kawasaki disease;	chr14:106778202	chr14:106762092~106762588:-
STAD	cis	rs453301	0.658	rs9329175	ENSG00000254340.1	RP11-10A14.3	-6.03	4.17e-09	5.16e-06	-0.4	-0.31	Joint mobility (Beighton score);	chr8:9009151	chr8:9141424~9145435:+
STAD	cis	rs11089937	0.597	rs11704434	ENSG00000211639.2	IGLV4-60	6.03	4.18e-09	5.17e-06	0.36	0.31	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22162199~22162681:+
STAD	cis	rs1426063	0.614	rs17000264	ENSG00000248165.1	RP11-44F21.2	6.03	4.18e-09	5.17e-06	0.64	0.31	QT interval;	chr4:75108962	chr4:74993877~75034824:-
STAD	cis	rs950027	0.549	rs11636114	ENSG00000259433.2	CTD-2651B20.4	-6.03	4.18e-09	5.17e-06	-0.33	-0.31	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45330209~45332634:-
STAD	cis	rs11603023	1	rs11603023	ENSG00000255422.1	AP002954.4	-6.03	4.19e-09	5.18e-06	-0.37	-0.31	Cholesterol, total;	chr11:118615352	chr11:118704607~118750263:+
STAD	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-6.03	4.19e-09	5.18e-06	-0.26	-0.31	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
STAD	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	6.03	4.2e-09	5.19e-06	0.39	0.31	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
STAD	cis	rs875971	0.545	rs10950029	ENSG00000224316.1	RP11-479O9.2	6.03	4.21e-09	5.2e-06	0.33	0.31	Aortic root size;	chr7:66169334	chr7:65773620~65802067:+
STAD	cis	rs453301	0.653	rs7853	ENSG00000254340.1	RP11-10A14.3	6.03	4.21e-09	5.21e-06	0.37	0.31	Joint mobility (Beighton score);	chr8:9033304	chr8:9141424~9145435:+
STAD	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-6.03	4.22e-09	5.21e-06	-0.42	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
STAD	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-6.03	4.24e-09	5.24e-06	-0.53	-0.31	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
STAD	cis	rs11089937	0.637	rs988200	ENSG00000211639.2	IGLV4-60	6.03	4.24e-09	5.24e-06	0.35	0.31	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22162199~22162681:+
STAD	cis	rs9467773	0.572	rs62394558	ENSG00000243307.2	POM121L6P	6.03	4.25e-09	5.25e-06	0.3	0.31	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26896952~26898777:+
STAD	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	6.03	4.25e-09	5.25e-06	0.31	0.31	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
STAD	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	6.03	4.26e-09	5.26e-06	0.33	0.31	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
STAD	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	6.03	4.26e-09	5.26e-06	0.53	0.31	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
STAD	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-6.03	4.26e-09	5.27e-06	-0.53	-0.31	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
STAD	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	6.03	4.28e-09	5.29e-06	0.33	0.31	Height;	chr11:118854014	chr11:118688039~118690600:-
STAD	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	6.03	4.28e-09	5.29e-06	0.33	0.31	Height;	chr11:118855233	chr11:118688039~118690600:-
STAD	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	6.03	4.28e-09	5.29e-06	0.33	0.31	Height;	chr11:118855938	chr11:118688039~118690600:-
STAD	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-6.03	4.28e-09	5.29e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-6.03	4.28e-09	5.29e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
STAD	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-6.03	4.28e-09	5.29e-06	-0.27	-0.31	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
STAD	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	6.03	4.29e-09	5.29e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	6.03	4.29e-09	5.29e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	6.03	4.29e-09	5.29e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
STAD	cis	rs9549260	0.755	rs7335520	ENSG00000229456.1	RLIMP1	6.03	4.29e-09	5.3e-06	0.28	0.31	Red blood cell count;	chr13:40622270	chr13:40618738~40621348:+
STAD	cis	rs721917	0.506	rs2758556	ENSG00000225484.5	NUTM2B-AS1	6.03	4.29e-09	5.3e-06	0.4	0.31	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79663088~79826594:-
STAD	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-6.03	4.3e-09	5.3e-06	-0.32	-0.31	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
STAD	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-6.03	4.3e-09	5.3e-06	-0.36	-0.31	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
STAD	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-6.03	4.3e-09	5.3e-06	-0.36	-0.31	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
STAD	cis	rs875971	0.505	rs1723275	ENSG00000222364.1	RNU6-96P	6.03	4.3e-09	5.31e-06	0.35	0.31	Aortic root size;	chr7:66039646	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-6.03	4.3e-09	5.31e-06	-0.36	-0.31	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-6.03	4.3e-09	5.31e-06	-0.36	-0.31	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-6.03	4.3e-09	5.31e-06	-0.36	-0.31	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
STAD	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-6.03	4.3e-09	5.31e-06	-0.32	-0.31	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
STAD	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-6.03	4.31e-09	5.31e-06	-0.36	-0.31	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
STAD	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-6.03	4.31e-09	5.31e-06	-0.35	-0.31	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
STAD	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-6.03	4.31e-09	5.31e-06	-0.35	-0.31	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-6.03	4.31e-09	5.32e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
STAD	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-6.03	4.32e-09	5.33e-06	-0.35	-0.31	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-6.03	4.33e-09	5.33e-06	-0.36	-0.31	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
STAD	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-6.03	4.33e-09	5.33e-06	-0.34	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
STAD	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-6.02	4.33e-09	5.34e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-6.02	4.33e-09	5.34e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
STAD	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-6.02	4.34e-09	5.34e-06	-0.32	-0.31	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-6.02	4.34e-09	5.34e-06	-0.32	-0.31	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
STAD	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	6.02	4.35e-09	5.36e-06	0.32	0.31	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
STAD	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	6.02	4.35e-09	5.36e-06	0.38	0.31	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
STAD	cis	rs2739330	0.731	rs4822450	ENSG00000224205.1	AP000351.4	6.02	4.35e-09	5.36e-06	0.36	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23987320~23991421:-
STAD	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-6.02	4.36e-09	5.37e-06	-0.33	-0.31	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
STAD	cis	rs7927771	0.832	rs56030824	ENSG00000280615.1	Y_RNA	-6.02	4.36e-09	5.37e-06	-0.32	-0.31	Subjective well-being;	chr11:47375802	chr11:47614898~47614994:-
STAD	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	6.02	4.36e-09	5.37e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
STAD	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	6.02	4.38e-09	5.39e-06	0.32	0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
STAD	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	6.02	4.39e-09	5.4e-06	0.32	0.31	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
STAD	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-6.02	4.39e-09	5.41e-06	-0.45	-0.31	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
STAD	cis	rs12699921	0.566	rs2723515	ENSG00000279048.1	RP11-511H23.2	-6.02	4.4e-09	5.41e-06	-0.28	-0.31	Fibrinogen levels;	chr7:17815843	chr7:17940503~17942922:+
STAD	cis	rs13113518	1	rs4864549	ENSG00000272969.1	RP11-528I4.2	6.02	4.4e-09	5.41e-06	0.39	0.31	Height;	chr4:55554380	chr4:55547112~55547889:+
STAD	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	6.02	4.41e-09	5.42e-06	0.37	0.31	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
STAD	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-6.02	4.41e-09	5.43e-06	-0.37	-0.31	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
STAD	cis	rs992157	0.835	rs7559416	ENSG00000237281.1	CATIP-AS2	6.02	4.41e-09	5.43e-06	0.31	0.31	Colorectal cancer;	chr2:218285488	chr2:218326889~218357966:-
STAD	cis	rs3806843	0.705	rs2530230	ENSG00000202111.1	VTRNA1-2	6.02	4.42e-09	5.44e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr5:140718925~140719013:+
STAD	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-6.02	4.43e-09	5.45e-06	-0.38	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
STAD	cis	rs9549260	0.753	rs2297628	ENSG00000229456.1	RLIMP1	6.02	4.43e-09	5.45e-06	0.35	0.31	Red blood cell count;	chr13:40659768	chr13:40618738~40621348:+
STAD	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-6.02	4.44e-09	5.46e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-6.02	4.44e-09	5.46e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
STAD	cis	rs13113518	1	rs13115828	ENSG00000272969.1	RP11-528I4.2	6.02	4.44e-09	5.46e-06	0.39	0.31	Height;	chr4:55551447	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11934897	ENSG00000272969.1	RP11-528I4.2	6.02	4.44e-09	5.46e-06	0.39	0.31	Height;	chr4:55553396	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.934	rs11932293	ENSG00000272969.1	RP11-528I4.2	6.02	4.44e-09	5.46e-06	0.39	0.31	Height;	chr4:55554025	chr4:55547112~55547889:+
STAD	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-6.02	4.45e-09	5.47e-06	-0.43	-0.31	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
STAD	cis	rs6782228	1	rs12495411	ENSG00000277250.1	Metazoa_SRP	6.02	4.45e-09	5.48e-06	0.36	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128673681~128674021:-
STAD	cis	rs6452524	0.506	rs7891	ENSG00000243385.2	CTD-2110K23.1	6.02	4.46e-09	5.49e-06	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83201229~83202141:+
STAD	cis	rs13113518	1	rs10462032	ENSG00000272969.1	RP11-528I4.2	6.02	4.47e-09	5.49e-06	0.39	0.31	Height;	chr4:55479069	chr4:55547112~55547889:+
STAD	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-6.02	4.47e-09	5.5e-06	-0.34	-0.31	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
STAD	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-6.02	4.48e-09	5.5e-06	-0.32	-0.31	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
STAD	cis	rs10129255	0.957	rs56134540	ENSG00000280411.1	IGHV1-69-2	-6.02	4.48e-09	5.51e-06	-0.29	-0.31	Kawasaki disease;	chr14:106691290	chr14:106762092~106762588:-
STAD	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	6.02	4.48e-09	5.51e-06	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
STAD	cis	rs2439831	0.85	rs7181039	ENSG00000249839.1	AC011330.5	-6.02	4.49e-09	5.52e-06	-0.56	-0.31	Lung cancer in ever smokers;	chr15:43886914	chr15:43663654~43684339:-
STAD	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	6.02	4.49e-09	5.52e-06	0.42	0.31	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
STAD	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	6.02	4.49e-09	5.52e-06	0.26	0.31	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
STAD	cis	rs3806843	0.766	rs801399	ENSG00000202111.1	VTRNA1-2	6.02	4.5e-09	5.53e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr5:140718925~140719013:+
STAD	cis	rs453301	0.682	rs2929451	ENSG00000254340.1	RP11-10A14.3	6.02	4.5e-09	5.53e-06	0.38	0.31	Joint mobility (Beighton score);	chr8:9227785	chr8:9141424~9145435:+
STAD	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-6.02	4.5e-09	5.53e-06	-0.35	-0.31	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
STAD	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	6.02	4.5e-09	5.53e-06	0.54	0.31	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
STAD	cis	rs10461617	0.592	rs6450403	ENSG00000271828.1	CTD-2310F14.1	6.02	4.52e-09	5.55e-06	0.36	0.31	Type 2 diabetes;	chr5:56766910	chr5:56927874~56929573:+
STAD	cis	rs453301	0.658	rs3855900	ENSG00000254340.1	RP11-10A14.3	-6.02	4.52e-09	5.55e-06	-0.39	-0.31	Joint mobility (Beighton score);	chr8:9044411	chr8:9141424~9145435:+
STAD	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	6.02	4.52e-09	5.55e-06	0.38	0.31	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
STAD	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	6.02	4.53e-09	5.57e-06	0.33	0.31	Height;	chr11:118859432	chr11:118688039~118690600:-
STAD	cis	rs10461617	0.541	rs832575	ENSG00000271828.1	CTD-2310F14.1	6.02	4.54e-09	5.58e-06	0.42	0.31	Type 2 diabetes;	chr5:56865960	chr5:56927874~56929573:+
STAD	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-6.02	4.54e-09	5.58e-06	-0.3	-0.31	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-6.02	4.54e-09	5.58e-06	-0.3	-0.31	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
STAD	cis	rs9549260	0.755	rs9549241	ENSG00000229456.1	RLIMP1	6.02	4.55e-09	5.58e-06	0.28	0.31	Red blood cell count;	chr13:40635904	chr13:40618738~40621348:+
STAD	cis	rs6452524	0.507	rs28592576	ENSG00000243385.2	CTD-2110K23.1	6.02	4.56e-09	5.59e-06	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.534	rs7727691	ENSG00000243385.2	CTD-2110K23.1	6.02	4.56e-09	5.59e-06	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.562	rs10474080	ENSG00000243385.2	CTD-2110K23.1	6.02	4.56e-09	5.59e-06	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83201229~83202141:+
STAD	cis	rs7487075	0.619	rs7959731	ENSG00000272369.1	RP11-446N19.1	-6.02	4.57e-09	5.6e-06	-0.38	-0.31	Itch intensity from mosquito bite;	chr12:46445874	chr12:46537502~46652550:+
STAD	cis	rs6452524	0.836	rs4343818	ENSG00000243385.2	CTD-2110K23.1	6.02	4.57e-09	5.61e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83201229~83202141:+
STAD	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-6.02	4.57e-09	5.61e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
STAD	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	6.02	4.58e-09	5.62e-06	0.35	0.31	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
STAD	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	6.01	4.58e-09	5.62e-06	0.29	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
STAD	cis	rs1400745	0.756	rs3783316	ENSG00000258738.1	RP11-73E17.2	6.01	4.58e-09	5.62e-06	0.37	0.31	Monocyte count;	chr14:34867986	chr14:34874343~34876459:+
STAD	cis	rs1400745	0.756	rs3783314	ENSG00000258738.1	RP11-73E17.2	6.01	4.58e-09	5.62e-06	0.37	0.31	Monocyte count;	chr14:34868178	chr14:34874343~34876459:+
STAD	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-6.01	4.58e-09	5.62e-06	-0.35	-0.31	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
STAD	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	6.01	4.58e-09	5.62e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
STAD	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	6.01	4.59e-09	5.63e-06	0.38	0.31	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
STAD	cis	rs721917	0.525	rs2819106	ENSG00000225484.5	NUTM2B-AS1	-6.01	4.59e-09	5.63e-06	-0.4	-0.31	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79663088~79826594:-
STAD	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	6.01	4.59e-09	5.63e-06	0.32	0.31	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
STAD	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-6.01	4.6e-09	5.64e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
STAD	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	6.01	4.61e-09	5.65e-06	0.35	0.31	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
STAD	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	6.01	4.61e-09	5.66e-06	0.29	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	6.01	4.61e-09	5.66e-06	0.29	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
STAD	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-6.01	4.62e-09	5.66e-06	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
STAD	cis	rs13113518	1	rs13136282	ENSG00000272969.1	RP11-528I4.2	6.01	4.62e-09	5.66e-06	0.39	0.31	Height;	chr4:55551845	chr4:55547112~55547889:+
STAD	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-6.01	4.62e-09	5.67e-06	-0.35	-0.31	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
STAD	cis	rs6452524	0.935	rs7703318	ENSG00000243385.2	CTD-2110K23.1	6.01	4.63e-09	5.67e-06	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83201229~83202141:+
STAD	cis	rs3806843	0.735	rs801180	ENSG00000202111.1	VTRNA1-2	6.01	4.63e-09	5.68e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr5:140718925~140719013:+
STAD	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-6.01	4.64e-09	5.68e-06	-0.38	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
STAD	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	6.01	4.64e-09	5.68e-06	0.35	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
STAD	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	6.01	4.64e-09	5.68e-06	0.35	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
STAD	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-6.01	4.64e-09	5.68e-06	-0.32	-0.31	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
STAD	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-6.01	4.64e-09	5.68e-06	-0.29	-0.31	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
STAD	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	6.01	4.64e-09	5.68e-06	0.33	0.31	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
STAD	cis	rs7849270	0.879	rs7046990	ENSG00000268707.1	RP11-247A12.7	-6.01	4.64e-09	5.69e-06	-0.36	-0.31	Blood metabolite ratios;	chr9:129093859	chr9:129170434~129170940:+
STAD	cis	rs10129255	0.912	rs61996059	ENSG00000280411.1	IGHV1-69-2	-6.01	4.65e-09	5.7e-06	-0.29	-0.31	Kawasaki disease;	chr14:106716897	chr14:106762092~106762588:-
STAD	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	6.01	4.65e-09	5.7e-06	0.32	0.31	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
STAD	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	6.01	4.66e-09	5.71e-06	0.35	0.31	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
STAD	cis	rs728616	0.764	rs79529820	ENSG00000225484.5	NUTM2B-AS1	-6.01	4.67e-09	5.72e-06	-0.61	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060773	chr10:79663088~79826594:-
STAD	cis	rs13113518	1	rs7675109	ENSG00000272969.1	RP11-528I4.2	6.01	4.68e-09	5.73e-06	0.38	0.31	Height;	chr4:55525589	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs4865005	ENSG00000272969.1	RP11-528I4.2	6.01	4.68e-09	5.73e-06	0.38	0.31	Height;	chr4:55525781	chr4:55547112~55547889:+
STAD	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-6.01	4.68e-09	5.74e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
STAD	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-6.01	4.69e-09	5.74e-06	-0.39	-0.31	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
STAD	cis	rs6496044	0.507	rs410522	ENSG00000259407.1	RP11-158M2.3	6.01	4.71e-09	5.77e-06	0.33	0.31	Interstitial lung disease;	chr15:85663813	chr15:85744109~85750281:-
STAD	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	6.01	4.71e-09	5.77e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
STAD	cis	rs13113518	1	rs4865011	ENSG00000272969.1	RP11-528I4.2	6.01	4.72e-09	5.78e-06	0.39	0.31	Height;	chr4:55554456	chr4:55547112~55547889:+
STAD	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-6.01	4.72e-09	5.78e-06	-0.46	-0.31	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
STAD	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-6.01	4.73e-09	5.78e-06	-0.31	-0.31	Asthma;	chr2:102399682	chr2:102438713~102440475:+
STAD	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	6.01	4.73e-09	5.78e-06	0.33	0.31	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
STAD	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-6.01	4.73e-09	5.79e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-6.01	4.73e-09	5.79e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-6.01	4.73e-09	5.79e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
STAD	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	6.01	4.74e-09	5.8e-06	0.35	0.31	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
STAD	cis	rs9549260	0.753	rs4943794	ENSG00000229456.1	RLIMP1	6.01	4.76e-09	5.82e-06	0.35	0.31	Red blood cell count;	chr13:40599271	chr13:40618738~40621348:+
STAD	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-6.01	4.76e-09	5.82e-06	-0.37	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
STAD	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-6.01	4.76e-09	5.82e-06	-0.47	-0.31	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
STAD	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-6.01	4.76e-09	5.82e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-6.01	4.76e-09	5.82e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-6.01	4.76e-09	5.82e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
STAD	cis	rs9400467	0.528	rs457492	ENSG00000230177.1	RP5-1112D6.4	-6.01	4.76e-09	5.82e-06	-0.28	-0.31	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111277932~111278742:+
STAD	cis	rs858239	0.601	rs10239760	ENSG00000226816.2	AC005082.12	6.01	4.77e-09	5.83e-06	0.39	0.31	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23206013~23208045:+
STAD	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	6.01	4.79e-09	5.86e-06	0.32	0.31	Asthma;	chr2:102410644	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-6.01	4.8e-09	5.86e-06	-0.32	-0.31	Asthma;	chr2:102401592	chr2:102438713~102440475:+
STAD	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-6.01	4.8e-09	5.86e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	6.01	4.8e-09	5.87e-06	0.3	0.31	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
STAD	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	6.01	4.81e-09	5.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	6.01	4.81e-09	5.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	6.01	4.81e-09	5.87e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
STAD	cis	rs8141529	0.753	rs5752813	ENSG00000226471.5	CTA-292E10.6	-6.01	4.81e-09	5.88e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28830582	chr22:28800683~28848559:+
STAD	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	6.01	4.82e-09	5.89e-06	0.38	0.31	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
STAD	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-6.01	4.82e-09	5.89e-06	-0.52	-0.31	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
STAD	cis	rs12699921	0.632	rs2691585	ENSG00000279048.1	RP11-511H23.2	-6.01	4.84e-09	5.9e-06	-0.28	-0.31	Fibrinogen levels;	chr7:17798064	chr7:17940503~17942922:+
STAD	cis	rs13113518	1	rs11726198	ENSG00000272969.1	RP11-528I4.2	6.01	4.84e-09	5.9e-06	0.38	0.31	Height;	chr4:55523835	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs11133396	ENSG00000272969.1	RP11-528I4.2	6.01	4.84e-09	5.9e-06	0.38	0.31	Height;	chr4:55524246	chr4:55547112~55547889:+
STAD	cis	rs10129255	1	rs4612959	ENSG00000280411.1	IGHV1-69-2	-6	4.86e-09	5.92e-06	-0.28	-0.31	Kawasaki disease;	chr14:106767055	chr14:106762092~106762588:-
STAD	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	6	4.88e-09	5.95e-06	0.32	0.31	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
STAD	cis	rs10129255	0.957	rs1056705	ENSG00000211970.3	IGHV4-61	-6	4.88e-09	5.95e-06	-0.27	-0.31	Kawasaki disease;	chr14:106714323	chr14:106639119~106639657:-
STAD	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-6	4.89e-09	5.96e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-6	4.89e-09	5.96e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-6	4.89e-09	5.96e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-6	4.89e-09	5.96e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-6	4.89e-09	5.96e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
STAD	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-6	4.89e-09	5.96e-06	-0.32	-0.31	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
STAD	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-6	4.89e-09	5.96e-06	-0.32	-0.31	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
STAD	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-6	4.89e-09	5.96e-06	-0.32	-0.31	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
STAD	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-6	4.89e-09	5.96e-06	-0.32	-0.31	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
STAD	cis	rs9549260	0.755	rs2701863	ENSG00000229456.1	RLIMP1	6	4.89e-09	5.96e-06	0.28	0.31	Red blood cell count;	chr13:40596003	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs7985364	ENSG00000229456.1	RLIMP1	6	4.89e-09	5.96e-06	0.28	0.31	Red blood cell count;	chr13:40605443	chr13:40618738~40621348:+
STAD	cis	rs13113518	1	rs6847529	ENSG00000272969.1	RP11-528I4.2	6	4.89e-09	5.96e-06	0.38	0.31	Height;	chr4:55518776	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs6822740	ENSG00000272969.1	RP11-528I4.2	6	4.89e-09	5.96e-06	0.38	0.31	Height;	chr4:55518922	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs13108409	ENSG00000272969.1	RP11-528I4.2	6	4.89e-09	5.96e-06	0.38	0.31	Height;	chr4:55520278	chr4:55547112~55547889:+
STAD	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	6	4.89e-09	5.96e-06	0.35	0.31	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
STAD	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	6	4.9e-09	5.97e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
STAD	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-6	4.9e-09	5.98e-06	-0.33	-0.31	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
STAD	cis	rs3806843	0.733	rs801181	ENSG00000202111.1	VTRNA1-2	6	4.91e-09	5.98e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr5:140718925~140719013:+
STAD	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-6	4.91e-09	5.99e-06	-0.39	-0.31	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
STAD	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-6	4.92e-09	5.99e-06	-0.38	-0.31	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
STAD	cis	rs6452524	0.868	rs10071617	ENSG00000243385.2	CTD-2110K23.1	6	4.92e-09	5.99e-06	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83201229~83202141:+
STAD	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	6	4.93e-09	6.01e-06	0.38	0.31	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	6	4.93e-09	6.01e-06	0.38	0.31	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
STAD	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	6	4.94e-09	6.01e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
STAD	cis	rs7849270	0.879	rs7042928	ENSG00000268707.1	RP11-247A12.7	6	4.94e-09	6.02e-06	0.36	0.31	Blood metabolite ratios;	chr9:129092996	chr9:129170434~129170940:+
STAD	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6	4.95e-09	6.03e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
STAD	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	6	4.96e-09	6.04e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	6	4.96e-09	6.04e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	6	4.96e-09	6.04e-06	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
STAD	cis	rs7580658	0.613	rs12478656	ENSG00000200250.1	RNU6-1147P	6	4.96e-09	6.04e-06	0.29	0.31	Protein C levels;	chr2:127438944	chr2:127316873~127316979:+
STAD	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	6	4.96e-09	6.04e-06	0.3	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
STAD	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-6	4.97e-09	6.04e-06	-0.35	-0.31	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
STAD	cis	rs10129255	0.957	rs61997760	ENSG00000280411.1	IGHV1-69-2	-6	4.98e-09	6.06e-06	-0.29	-0.31	Kawasaki disease;	chr14:106716993	chr14:106762092~106762588:-
STAD	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-6	4.98e-09	6.06e-06	-0.3	-0.31	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
STAD	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-6	4.98e-09	6.06e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-6	4.99e-09	6.07e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
STAD	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-6	4.99e-09	6.07e-06	-0.34	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
STAD	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-6	4.99e-09	6.07e-06	-0.34	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
STAD	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-6	4.99e-09	6.07e-06	-0.34	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
STAD	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-6	5e-09	6.08e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
STAD	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-6	5.02e-09	6.11e-06	-0.26	-0.31	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
STAD	cis	rs8067354	0.54	rs1051424	ENSG00000266701.1	AC005702.4	6	5.02e-09	6.11e-06	0.46	0.31	Hemoglobin concentration;	chr17:59946963	chr17:60042546~60042627:-
STAD	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-6	5.03e-09	6.12e-06	-0.34	-0.31	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
STAD	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	6	5.04e-09	6.12e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
STAD	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-6	5.05e-09	6.14e-06	-0.38	-0.31	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-6	5.06e-09	6.16e-06	-0.22	-0.31	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
STAD	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-6	5.07e-09	6.16e-06	-0.38	-0.31	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
STAD	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	6	5.07e-09	6.17e-06	0.32	0.31	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	6	5.07e-09	6.17e-06	0.32	0.31	Asthma;	chr2:102423587	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	6	5.07e-09	6.17e-06	0.32	0.31	Asthma;	chr2:102423717	chr2:102438713~102440475:+
STAD	cis	rs516805	0.748	rs1267941	ENSG00000279453.1	RP3-425C14.4	-6	5.07e-09	6.17e-06	-0.42	-0.31	Lymphocyte counts;	chr6:122471888	chr6:122436789~122439223:-
STAD	cis	rs6452524	0.967	rs7717964	ENSG00000243385.2	CTD-2110K23.1	6	5.09e-09	6.18e-06	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83201229~83202141:+
STAD	cis	rs516805	0.665	rs517427	ENSG00000279453.1	RP3-425C14.4	-6	5.09e-09	6.18e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122291180	chr6:122436789~122439223:-
STAD	cis	rs5769707	0.681	rs135879	ENSG00000280224.1	CTA-722E9.1	-6	5.09e-09	6.18e-06	-0.34	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.642	rs135880	ENSG00000280224.1	CTA-722E9.1	-6	5.09e-09	6.18e-06	-0.34	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49500568~49501585:+
STAD	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-6	5.09e-09	6.18e-06	-0.32	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
STAD	cis	rs3136516	0.504	rs10838610	ENSG00000271350.1	CTD-2384B9.1	-6	5.1e-09	6.19e-06	-0.39	-0.31	Venous thromboembolism;	chr11:46664710	chr11:47041027~47041945:-
STAD	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	6	5.1e-09	6.2e-06	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
STAD	cis	rs3806843	0.735	rs2530241	ENSG00000202111.1	VTRNA1-2	6	5.1e-09	6.2e-06	0.3	0.31	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr5:140718925~140719013:+
STAD	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	6	5.11e-09	6.21e-06	0.56	0.31	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
STAD	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	6	5.11e-09	6.21e-06	0.32	0.31	Asthma;	chr2:102426252	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	6	5.11e-09	6.21e-06	0.32	0.31	Asthma;	chr2:102427407	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	6	5.11e-09	6.21e-06	0.32	0.31	Asthma;	chr2:102427715	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	6	5.11e-09	6.21e-06	0.32	0.31	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	6	5.11e-09	6.21e-06	0.32	0.31	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
STAD	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-5.99	5.12e-09	6.22e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-5.99	5.12e-09	6.22e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
STAD	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	5.99	5.13e-09	6.22e-06	0.29	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
STAD	cis	rs10129255	0.785	rs10150044	ENSG00000280411.1	IGHV1-69-2	-5.99	5.15e-09	6.25e-06	-0.28	-0.31	Kawasaki disease;	chr14:106775695	chr14:106762092~106762588:-
STAD	cis	rs1005277	0.579	rs2474568	ENSG00000099251.13	HSD17B7P2	5.99	5.16e-09	6.26e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38356380~38378505:+
STAD	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-5.99	5.16e-09	6.26e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-5.99	5.16e-09	6.26e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-5.99	5.16e-09	6.26e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
STAD	cis	rs7487075	0.656	rs3936214	ENSG00000272369.1	RP11-446N19.1	5.99	5.17e-09	6.27e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46432029	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs10880969	ENSG00000272369.1	RP11-446N19.1	5.99	5.17e-09	6.27e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46433240	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs7489242	ENSG00000272369.1	RP11-446N19.1	5.99	5.17e-09	6.27e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46434848	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs7485599	ENSG00000272369.1	RP11-446N19.1	5.99	5.17e-09	6.27e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46436696	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs12832777	ENSG00000272369.1	RP11-446N19.1	5.99	5.17e-09	6.27e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46437346	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.578	rs4768716	ENSG00000272369.1	RP11-446N19.1	5.99	5.17e-09	6.27e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46437375	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.578	rs4768122	ENSG00000272369.1	RP11-446N19.1	5.99	5.17e-09	6.27e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46438551	chr12:46537502~46652550:+
STAD	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	5.99	5.17e-09	6.28e-06	0.5	0.31	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	5.99	5.17e-09	6.28e-06	0.5	0.31	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
STAD	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	5.99	5.18e-09	6.28e-06	0.24	0.31	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
STAD	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-5.99	5.19e-09	6.29e-06	-0.35	-0.31	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
STAD	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-5.99	5.19e-09	6.3e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
STAD	cis	rs721917	0.506	rs2758555	ENSG00000225484.5	NUTM2B-AS1	-5.99	5.2e-09	6.3e-06	-0.4	-0.31	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79663088~79826594:-
STAD	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	5.99	5.21e-09	6.31e-06	0.37	0.31	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
STAD	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	5.99	5.21e-09	6.31e-06	0.31	0.31	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
STAD	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	5.99	5.21e-09	6.31e-06	0.31	0.31	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
STAD	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	5.99	5.21e-09	6.31e-06	0.31	0.31	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
STAD	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-5.99	5.23e-09	6.34e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
STAD	cis	rs6452524	0.934	rs1120477	ENSG00000243385.2	CTD-2110K23.1	5.99	5.24e-09	6.35e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.934	rs1120478	ENSG00000243385.2	CTD-2110K23.1	5.99	5.24e-09	6.35e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.934	rs6452512	ENSG00000243385.2	CTD-2110K23.1	5.99	5.24e-09	6.35e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.967	rs6452514	ENSG00000243385.2	CTD-2110K23.1	5.99	5.24e-09	6.35e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs6884543	ENSG00000243385.2	CTD-2110K23.1	5.99	5.24e-09	6.35e-06	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83201229~83202141:+
STAD	cis	rs12699921	0.632	rs4316058	ENSG00000279048.1	RP11-511H23.2	-5.99	5.24e-09	6.35e-06	-0.28	-0.31	Fibrinogen levels;	chr7:17795103	chr7:17940503~17942922:+
STAD	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	5.99	5.26e-09	6.37e-06	0.34	0.31	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	5.99	5.26e-09	6.37e-06	0.34	0.31	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	5.99	5.26e-09	6.37e-06	0.34	0.31	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
STAD	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-5.99	5.28e-09	6.39e-06	-0.3	-0.31	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
STAD	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	5.99	5.28e-09	6.39e-06	0.35	0.31	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
STAD	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-5.99	5.28e-09	6.4e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
STAD	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-5.99	5.3e-09	6.42e-06	-0.33	-0.31	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
STAD	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	5.99	5.3e-09	6.42e-06	0.33	0.31	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	5.99	5.3e-09	6.42e-06	0.33	0.31	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
STAD	cis	rs858239	0.669	rs1990365	ENSG00000226816.2	AC005082.12	5.99	5.31e-09	6.43e-06	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23206013~23208045:+
STAD	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-5.99	5.31e-09	6.43e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-5.99	5.32e-09	6.43e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
STAD	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	5.99	5.32e-09	6.44e-06	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
STAD	cis	rs17361889	0.634	rs7799150	ENSG00000224683.1	RPL36AP29	5.99	5.34e-09	6.46e-06	0.32	0.31	Pediatric bone mineral content (hip);	chr7:16258813	chr7:16208945~16209265:+
STAD	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	5.99	5.35e-09	6.47e-06	0.49	0.31	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
STAD	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-5.99	5.35e-09	6.47e-06	-0.33	-0.31	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
STAD	cis	rs7487075	0.93	rs4076248	ENSG00000272369.1	RP11-446N19.1	5.99	5.36e-09	6.49e-06	0.36	0.31	Itch intensity from mosquito bite;	chr12:46439822	chr12:46537502~46652550:+
STAD	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	5.99	5.38e-09	6.5e-06	0.35	0.31	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
STAD	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	5.99	5.39e-09	6.52e-06	0.35	0.31	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
STAD	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	5.99	5.4e-09	6.52e-06	0.4	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
STAD	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	5.99	5.4e-09	6.52e-06	0.4	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
STAD	cis	rs8067354	0.527	rs1292039	ENSG00000266701.1	AC005702.4	5.99	5.4e-09	6.53e-06	0.45	0.31	Hemoglobin concentration;	chr17:59897552	chr17:60042546~60042627:-
STAD	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-5.99	5.41e-09	6.53e-06	-0.42	-0.31	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
STAD	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-5.98	5.41e-09	6.54e-06	-0.33	-0.31	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
STAD	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	5.98	5.42e-09	6.54e-06	0.48	0.31	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
STAD	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-5.98	5.42e-09	6.55e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
STAD	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-5.98	5.43e-09	6.56e-06	-0.52	-0.31	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
STAD	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-5.98	5.43e-09	6.56e-06	-0.52	-0.31	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
STAD	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-5.98	5.43e-09	6.56e-06	-0.52	-0.31	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
STAD	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-5.98	5.43e-09	6.56e-06	-0.52	-0.31	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
STAD	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-5.98	5.43e-09	6.56e-06	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
STAD	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	5.98	5.44e-09	6.57e-06	0.38	0.31	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
STAD	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	5.98	5.44e-09	6.57e-06	0.31	0.31	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
STAD	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	5.98	5.44e-09	6.57e-06	0.29	0.31	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
STAD	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-5.98	5.44e-09	6.57e-06	-0.52	-0.31	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
STAD	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-5.98	5.44e-09	6.57e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
STAD	cis	rs2739330	0.627	rs9608219	ENSG00000224205.1	AP000351.4	5.98	5.45e-09	6.58e-06	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23987320~23991421:-
STAD	cis	rs8141529	0.764	rs5762824	ENSG00000226471.5	CTA-292E10.6	-5.98	5.45e-09	6.58e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28826942	chr22:28800683~28848559:+
STAD	cis	rs9549260	0.753	rs61963266	ENSG00000229456.1	RLIMP1	5.98	5.45e-09	6.58e-06	0.35	0.31	Red blood cell count;	chr13:40596899	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.753	rs9549238	ENSG00000229456.1	RLIMP1	5.98	5.45e-09	6.58e-06	0.35	0.31	Red blood cell count;	chr13:40605184	chr13:40618738~40621348:+
STAD	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	5.98	5.46e-09	6.59e-06	0.38	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
STAD	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	5.98	5.46e-09	6.59e-06	0.37	0.31	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
STAD	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	5.98	5.46e-09	6.59e-06	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	5.98	5.46e-09	6.59e-06	0.29	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
STAD	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	5.98	5.5e-09	6.64e-06	0.32	0.31	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	5.98	5.5e-09	6.64e-06	0.32	0.31	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	5.98	5.5e-09	6.64e-06	0.32	0.31	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
STAD	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	5.98	5.51e-09	6.64e-06	0.38	0.31	Height;	chr6:109351795	chr6:109382795~109383666:+
STAD	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	5.98	5.52e-09	6.65e-06	0.33	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
STAD	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-5.98	5.52e-09	6.66e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-5.98	5.52e-09	6.66e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
STAD	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	5.98	5.52e-09	6.66e-06	0.36	0.31	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
STAD	cis	rs8098244	0.597	rs12958312	ENSG00000267301.1	RPL23AP77	5.98	5.53e-09	6.67e-06	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23784372	chr18:23709825~23710287:-
STAD	cis	rs4568518	0.74	rs12699925	ENSG00000279048.1	RP11-511H23.2	5.98	5.53e-09	6.67e-06	0.28	0.31	Measles;	chr7:17971039	chr7:17940503~17942922:+
STAD	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	5.98	5.53e-09	6.67e-06	0.36	0.31	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
STAD	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	5.98	5.54e-09	6.67e-06	0.34	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
STAD	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-5.98	5.54e-09	6.67e-06	-0.32	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
STAD	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	5.98	5.54e-09	6.68e-06	0.35	0.31	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
STAD	cis	rs10129255	0.957	rs10141052	ENSG00000280411.1	IGHV1-69-2	-5.98	5.55e-09	6.68e-06	-0.28	-0.31	Kawasaki disease;	chr14:106776528	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.957	rs6576228	ENSG00000280411.1	IGHV1-69-2	-5.98	5.55e-09	6.68e-06	-0.28	-0.31	Kawasaki disease;	chr14:106778401	chr14:106762092~106762588:-
STAD	cis	rs13113518	0.966	rs4864544	ENSG00000272969.1	RP11-528I4.2	5.98	5.55e-09	6.69e-06	0.38	0.31	Height;	chr4:55515292	chr4:55547112~55547889:+
STAD	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	5.98	5.55e-09	6.69e-06	0.33	0.31	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
STAD	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	5.98	5.55e-09	6.69e-06	0.33	0.31	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
STAD	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-5.98	5.55e-09	6.69e-06	-0.33	-0.31	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
STAD	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-5.98	5.55e-09	6.69e-06	-0.33	-0.31	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
STAD	cis	rs8141529	0.719	rs5762825	ENSG00000226471.5	CTA-292E10.6	-5.98	5.56e-09	6.7e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28827654	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.764	rs5752809	ENSG00000226471.5	CTA-292E10.6	-5.98	5.56e-09	6.7e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28829512	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.764	rs5752812	ENSG00000226471.5	CTA-292E10.6	-5.98	5.56e-09	6.7e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28829615	chr22:28800683~28848559:+
STAD	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-5.98	5.56e-09	6.7e-06	-0.32	-0.31	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
STAD	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-5.98	5.57e-09	6.71e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
STAD	cis	rs228614	0.51	rs223377	ENSG00000230069.3	LRRC37A15P	-5.98	5.57e-09	6.71e-06	-0.33	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102727274~102730721:-
STAD	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	5.98	5.57e-09	6.71e-06	0.38	0.31	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	5.98	5.57e-09	6.71e-06	0.38	0.31	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
STAD	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	5.98	5.58e-09	6.71e-06	0.33	0.31	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	5.98	5.58e-09	6.71e-06	0.33	0.31	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
STAD	cis	rs13113518	1	rs13146987	ENSG00000272969.1	RP11-528I4.2	5.98	5.58e-09	6.72e-06	0.38	0.31	Height;	chr4:55491628	chr4:55547112~55547889:+
STAD	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	5.98	5.58e-09	6.72e-06	0.26	0.31	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
STAD	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-5.98	5.59e-09	6.72e-06	-0.34	-0.31	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-5.98	5.59e-09	6.72e-06	-0.34	-0.31	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
STAD	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-5.98	5.6e-09	6.73e-06	-0.34	-0.31	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
STAD	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-5.98	5.6e-09	6.73e-06	-0.34	-0.31	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
STAD	cis	rs801193	1	rs17566701	ENSG00000224316.1	RP11-479O9.2	5.98	5.6e-09	6.74e-06	0.32	0.31	Aortic root size;	chr7:66728196	chr7:65773620~65802067:+
STAD	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	5.98	5.6e-09	6.74e-06	0.34	0.31	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
STAD	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-5.98	5.6e-09	6.74e-06	-0.33	-0.31	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
STAD	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-5.98	5.63e-09	6.77e-06	-0.26	-0.31	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
STAD	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	5.98	5.64e-09	6.78e-06	0.35	0.31	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
STAD	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-5.98	5.64e-09	6.79e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-5.98	5.64e-09	6.79e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-5.98	5.64e-09	6.79e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-5.98	5.64e-09	6.79e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-5.98	5.64e-09	6.79e-06	-0.37	-0.31	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-5.98	5.64e-09	6.79e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-5.98	5.64e-09	6.79e-06	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
STAD	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-5.98	5.66e-09	6.8e-06	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
STAD	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	5.98	5.66e-09	6.81e-06	0.31	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
STAD	cis	rs8141529	0.732	rs2239815	ENSG00000226471.5	CTA-292E10.6	5.98	5.67e-09	6.81e-06	0.35	0.31	Lymphocyte counts;	chr22:28796682	chr22:28800683~28848559:+
STAD	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-5.98	5.67e-09	6.81e-06	-0.37	-0.31	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
STAD	cis	rs11079159	0.5	rs7223165	ENSG00000263096.1	RP11-515O17.2	5.98	5.67e-09	6.81e-06	0.38	0.31	QRS duration;	chr17:55286477	chr17:55271504~55273653:-
STAD	cis	rs13113518	0.967	rs4340844	ENSG00000272969.1	RP11-528I4.2	5.98	5.67e-09	6.82e-06	0.38	0.31	Height;	chr4:55462689	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs1522112	ENSG00000272969.1	RP11-528I4.2	5.98	5.67e-09	6.82e-06	0.38	0.31	Height;	chr4:55463606	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs4864997	ENSG00000272969.1	RP11-528I4.2	5.98	5.67e-09	6.82e-06	0.38	0.31	Height;	chr4:55466010	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs960152	ENSG00000272969.1	RP11-528I4.2	5.98	5.67e-09	6.82e-06	0.38	0.31	Height;	chr4:55467308	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.967	rs12644948	ENSG00000272969.1	RP11-528I4.2	5.98	5.67e-09	6.82e-06	0.38	0.31	Height;	chr4:55470266	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs3805151	ENSG00000272969.1	RP11-528I4.2	5.98	5.67e-09	6.82e-06	0.38	0.31	Height;	chr4:55470874	chr4:55547112~55547889:+
STAD	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	5.98	5.68e-09	6.83e-06	0.34	0.31	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
STAD	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	5.98	5.68e-09	6.83e-06	0.33	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
STAD	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-5.98	5.68e-09	6.83e-06	-0.27	-0.31	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
STAD	cis	rs9549260	0.683	rs35594717	ENSG00000229456.1	RLIMP1	5.98	5.69e-09	6.84e-06	0.35	0.31	Red blood cell count;	chr13:40666646	chr13:40618738~40621348:+
STAD	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-5.98	5.72e-09	6.87e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-5.98	5.72e-09	6.87e-06	-0.33	-0.31	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
STAD	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	5.97	5.72e-09	6.87e-06	0.33	0.31	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
STAD	cis	rs8141529	0.732	rs2269577	ENSG00000226471.5	CTA-292E10.6	-5.97	5.73e-09	6.88e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28800769	chr22:28800683~28848559:+
STAD	cis	rs516805	0.59	rs13371	ENSG00000279453.1	RP3-425C14.4	-5.97	5.73e-09	6.89e-06	-0.42	-0.31	Lymphocyte counts;	chr6:122443881	chr6:122436789~122439223:-
STAD	cis	rs7849270	0.837	rs4642748	ENSG00000268707.1	RP11-247A12.7	-5.97	5.74e-09	6.89e-06	-0.36	-0.31	Blood metabolite ratios;	chr9:129092668	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.692	rs4397510	ENSG00000268707.1	RP11-247A12.7	-5.97	5.74e-09	6.89e-06	-0.36	-0.31	Blood metabolite ratios;	chr9:129092671	chr9:129170434~129170940:+
STAD	cis	rs7849270	0.879	rs10739741	ENSG00000268707.1	RP11-247A12.7	-5.97	5.74e-09	6.89e-06	-0.36	-0.31	Blood metabolite ratios;	chr9:129092881	chr9:129170434~129170940:+
STAD	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	5.97	5.74e-09	6.89e-06	0.35	0.31	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	5.97	5.74e-09	6.89e-06	0.35	0.31	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
STAD	cis	rs13113518	1	rs13118237	ENSG00000272969.1	RP11-528I4.2	5.97	5.74e-09	6.9e-06	0.38	0.31	Height;	chr4:55474259	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs11133387	ENSG00000272969.1	RP11-528I4.2	5.97	5.74e-09	6.9e-06	0.38	0.31	Height;	chr4:55475130	chr4:55547112~55547889:+
STAD	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	5.97	5.75e-09	6.9e-06	0.37	0.31	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
STAD	cis	rs13113518	1	rs55699500	ENSG00000272969.1	RP11-528I4.2	5.97	5.75e-09	6.9e-06	0.38	0.31	Height;	chr4:55540912	chr4:55547112~55547889:+
STAD	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	5.97	5.77e-09	6.92e-06	0.39	0.31	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
STAD	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-5.97	5.78e-09	6.94e-06	-0.39	-0.31	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
STAD	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-5.97	5.79e-09	6.94e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
STAD	cis	rs6782228	0.606	rs4857919	ENSG00000277250.1	Metazoa_SRP	-5.97	5.79e-09	6.95e-06	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128673681~128674021:-
STAD	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-5.97	5.81e-09	6.97e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	5.97	5.81e-09	6.97e-06	0.37	0.31	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
STAD	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	5.97	5.82e-09	6.98e-06	0.35	0.31	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
STAD	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	5.97	5.82e-09	6.98e-06	0.35	0.31	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
STAD	cis	rs721917	0.525	rs2246111	ENSG00000225484.5	NUTM2B-AS1	-5.97	5.82e-09	6.98e-06	-0.4	-0.31	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79663088~79826594:-
STAD	cis	rs7927771	0.864	rs2053979	ENSG00000280615.1	Y_RNA	-5.97	5.83e-09	6.99e-06	-0.31	-0.31	Subjective well-being;	chr11:47417893	chr11:47614898~47614994:-
STAD	cis	rs8141529	0.764	rs5752807	ENSG00000226471.5	CTA-292E10.6	-5.97	5.83e-09	6.99e-06	-0.36	-0.31	Lymphocyte counts;	chr22:28827181	chr22:28800683~28848559:+
STAD	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-5.97	5.84e-09	7e-06	-0.25	-0.31	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
STAD	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	5.97	5.84e-09	7e-06	0.33	0.31	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
STAD	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	5.97	5.85e-09	7.01e-06	0.31	0.31	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
STAD	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	5.97	5.85e-09	7.01e-06	0.31	0.31	Asthma;	chr2:102419319	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	5.97	5.85e-09	7.01e-06	0.31	0.31	Asthma;	chr2:102419875	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	5.97	5.85e-09	7.01e-06	0.31	0.31	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	5.97	5.85e-09	7.01e-06	0.31	0.31	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
STAD	cis	rs4604732	0.578	rs12040725	ENSG00000227135.1	GCSAML-AS1	-5.97	5.86e-09	7.02e-06	-0.42	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247481395	chr1:247524679~247526752:-
STAD	cis	rs13113518	1	rs7677085	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55495801	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs12510681	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55496737	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs12500162	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55496933	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.934	rs3805155	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55497842	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs7686261	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55500224	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11729220	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55501629	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11133390	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55501726	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11133391	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55501788	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs13133484	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55504176	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.934	rs13127906	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55504201	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs6849433	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55506498	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs12501327	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55507248	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11133392	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55507729	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs6838305	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55508587	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.902	rs12503578	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55509367	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs3828480	ENSG00000272969.1	RP11-528I4.2	5.97	5.86e-09	7.02e-06	0.38	0.31	Height;	chr4:55510352	chr4:55547112~55547889:+
STAD	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	5.97	5.86e-09	7.02e-06	0.35	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
STAD	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	5.97	5.86e-09	7.02e-06	0.35	0.31	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
STAD	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-5.97	5.87e-09	7.03e-06	-0.26	-0.31	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
STAD	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-5.97	5.87e-09	7.03e-06	-0.33	-0.31	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
STAD	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	5.97	5.89e-09	7.05e-06	0.33	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	5.97	5.89e-09	7.05e-06	0.33	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	5.97	5.89e-09	7.05e-06	0.33	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
STAD	cis	rs711244	0.748	rs10193295	ENSG00000252756.1	RNU6-577P	-5.97	5.89e-09	7.06e-06	-0.34	-0.31	Mean platelet volume;	chr2:36941906	chr2:36867398~36867495:-
STAD	cis	rs8098244	0.557	rs11659490	ENSG00000267301.1	RPL23AP77	5.97	5.91e-09	7.07e-06	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722343	chr18:23709825~23710287:-
STAD	cis	rs516805	0.748	rs492250	ENSG00000279453.1	RP3-425C14.4	-5.97	5.91e-09	7.07e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122421808	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs9320872	ENSG00000279453.1	RP3-425C14.4	-5.97	5.91e-09	7.07e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122425438	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs505749	ENSG00000279453.1	RP3-425C14.4	-5.97	5.91e-09	7.07e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122425751	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs502252	ENSG00000279453.1	RP3-425C14.4	-5.97	5.91e-09	7.07e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122436330	chr6:122436789~122439223:-
STAD	cis	rs516805	0.706	rs577049	ENSG00000279453.1	RP3-425C14.4	-5.97	5.91e-09	7.07e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122438204	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs577838	ENSG00000279453.1	RP3-425C14.4	-5.97	5.91e-09	7.07e-06	-0.43	-0.31	Lymphocyte counts;	chr6:122438270	chr6:122436789~122439223:-
STAD	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	5.97	5.91e-09	7.07e-06	0.4	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
STAD	cis	rs6452524	1	rs10042854	ENSG00000243385.2	CTD-2110K23.1	-5.97	5.92e-09	7.08e-06	-0.33	-0.31	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83201229~83202141:+
STAD	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	5.97	5.92e-09	7.08e-06	0.37	0.31	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
STAD	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-5.97	5.92e-09	7.08e-06	-0.26	-0.31	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
STAD	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-5.97	5.92e-09	7.09e-06	-0.33	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
STAD	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	5.97	5.93e-09	7.09e-06	0.36	0.31	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
STAD	cis	rs4604732	0.536	rs4433437	ENSG00000227135.1	GCSAML-AS1	-5.97	5.93e-09	7.09e-06	-0.43	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473278	chr1:247524679~247526752:-
STAD	cis	rs10129255	0.957	rs10140904	ENSG00000280411.1	IGHV1-69-2	-5.97	5.93e-09	7.09e-06	-0.28	-0.31	Kawasaki disease;	chr14:106776558	chr14:106762092~106762588:-
STAD	cis	rs9549260	0.755	rs2755216	ENSG00000229456.1	RLIMP1	5.97	5.93e-09	7.1e-06	0.28	0.31	Red blood cell count;	chr13:40582801	chr13:40618738~40621348:+
STAD	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-5.97	5.93e-09	7.1e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
STAD	cis	rs5769707	0.967	rs2187891	ENSG00000280224.1	CTA-722E9.1	-5.97	5.94e-09	7.11e-06	-0.31	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49500568~49501585:+
STAD	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.97	5.95e-09	7.11e-06	-0.35	-0.31	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
STAD	cis	rs2439831	0.867	rs12443102	ENSG00000249839.1	AC011330.5	-5.97	5.96e-09	7.12e-06	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43639905	chr15:43663654~43684339:-
STAD	cis	rs1005277	0.579	rs2474587	ENSG00000099251.13	HSD17B7P2	5.97	5.96e-09	7.12e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474588	ENSG00000099251.13	HSD17B7P2	5.97	5.96e-09	7.12e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38356380~38378505:+
STAD	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	5.97	5.96e-09	7.13e-06	0.33	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
STAD	cis	rs6782228	0.606	rs6775270	ENSG00000277250.1	Metazoa_SRP	-5.97	5.97e-09	7.14e-06	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs6807019	ENSG00000277250.1	Metazoa_SRP	-5.97	5.97e-09	7.14e-06	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128673681~128674021:-
STAD	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-5.97	5.98e-09	7.15e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-5.97	5.98e-09	7.15e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
STAD	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	5.97	5.99e-09	7.16e-06	0.31	0.31	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
STAD	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	5.97	5.99e-09	7.16e-06	0.48	0.31	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
STAD	cis	rs9467773	0.572	rs13213953	ENSG00000243307.2	POM121L6P	5.97	5.99e-09	7.16e-06	0.3	0.31	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26896952~26898777:+
STAD	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-5.97	6e-09	7.17e-06	-0.36	-0.31	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
STAD	cis	rs13113518	0.966	rs12506788	ENSG00000272969.1	RP11-528I4.2	5.97	6e-09	7.17e-06	0.38	0.31	Height;	chr4:55477426	chr4:55547112~55547889:+
STAD	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	5.97	6.02e-09	7.19e-06	0.38	0.31	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
STAD	cis	rs7487075	0.578	rs4768119	ENSG00000272369.1	RP11-446N19.1	5.97	6.03e-09	7.2e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46414119	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.578	rs4258438	ENSG00000272369.1	RP11-446N19.1	5.97	6.03e-09	7.2e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46415343	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.55	rs1472179	ENSG00000272369.1	RP11-446N19.1	5.97	6.03e-09	7.2e-06	0.41	0.31	Itch intensity from mosquito bite;	chr12:46416731	chr12:46537502~46652550:+
STAD	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-5.97	6.04e-09	7.21e-06	-0.38	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
STAD	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	5.96	6.05e-09	7.22e-06	0.38	0.31	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
STAD	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	5.96	6.05e-09	7.22e-06	0.32	0.31	Asthma;	chr2:102431747	chr2:102438713~102440475:+
STAD	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	5.96	6.05e-09	7.22e-06	0.32	0.31	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	5.96	6.05e-09	7.22e-06	0.32	0.31	Asthma;	chr2:102432120	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	5.96	6.05e-09	7.22e-06	0.32	0.31	Asthma;	chr2:102432614	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	5.96	6.05e-09	7.22e-06	0.32	0.31	Asthma;	chr2:102433405	chr2:102438713~102440475:+
STAD	cis	rs1005277	0.579	rs2505237	ENSG00000099251.13	HSD17B7P2	5.96	6.06e-09	7.23e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474599	ENSG00000099251.13	HSD17B7P2	5.96	6.06e-09	7.23e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38356380~38378505:+
STAD	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	5.96	6.07e-09	7.24e-06	0.37	0.31	Height;	chr6:109358652	chr6:109382795~109383666:+
STAD	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	5.96	6.09e-09	7.26e-06	0.34	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
STAD	cis	rs7829975	0.681	rs2271342	ENSG00000254340.1	RP11-10A14.3	5.96	6.09e-09	7.26e-06	0.36	0.31	Mood instability;	chr8:8786428	chr8:9141424~9145435:+
STAD	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	5.96	6.09e-09	7.26e-06	0.46	0.31	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	5.96	6.09e-09	7.26e-06	0.46	0.31	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
STAD	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-5.96	6.1e-09	7.27e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
STAD	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-5.96	6.1e-09	7.27e-06	-0.25	-0.31	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
STAD	cis	rs453301	0.624	rs4841083	ENSG00000254340.1	RP11-10A14.3	5.96	6.12e-09	7.3e-06	0.37	0.31	Joint mobility (Beighton score);	chr8:9012918	chr8:9141424~9145435:+
STAD	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	5.96	6.13e-09	7.3e-06	0.37	0.31	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
STAD	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-5.96	6.13e-09	7.31e-06	-0.43	-0.31	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
STAD	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-5.96	6.13e-09	7.31e-06	-0.49	-0.31	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
STAD	cis	rs7829975	0.51	rs332037	ENSG00000254340.1	RP11-10A14.3	5.96	6.14e-09	7.31e-06	0.36	0.31	Mood instability;	chr8:8865165	chr8:9141424~9145435:+
STAD	cis	rs13113518	1	rs9312661	ENSG00000272969.1	RP11-528I4.2	5.96	6.16e-09	7.33e-06	0.38	0.31	Height;	chr4:55476159	chr4:55547112~55547889:+
STAD	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	5.96	6.17e-09	7.34e-06	0.27	0.31	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
STAD	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-5.96	6.18e-09	7.36e-06	-0.38	-0.31	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
STAD	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-5.96	6.18e-09	7.36e-06	-0.32	-0.31	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
STAD	cis	rs12699921	0.632	rs2691594	ENSG00000279048.1	RP11-511H23.2	-5.96	6.2e-09	7.38e-06	-0.28	-0.31	Fibrinogen levels;	chr7:17825193	chr7:17940503~17942922:+
STAD	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-5.96	6.2e-09	7.38e-06	-0.32	-0.31	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
STAD	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	5.96	6.2e-09	7.38e-06	0.45	0.31	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
STAD	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-5.96	6.21e-09	7.39e-06	-0.33	-0.31	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
STAD	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	5.96	6.21e-09	7.39e-06	0.35	0.31	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	5.96	6.21e-09	7.39e-06	0.35	0.31	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
STAD	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-5.96	6.21e-09	7.39e-06	-0.33	-0.31	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
STAD	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-5.96	6.21e-09	7.39e-06	-0.33	-0.31	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
STAD	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-5.96	6.21e-09	7.39e-06	-0.33	-0.31	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
STAD	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	5.96	6.22e-09	7.4e-06	0.33	0.31	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
STAD	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-5.96	6.23e-09	7.41e-06	-0.34	-0.31	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
STAD	cis	rs1005277	0.579	rs2474608	ENSG00000099251.13	HSD17B7P2	5.96	6.24e-09	7.42e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.603	rs1998062	ENSG00000099251.13	HSD17B7P2	5.96	6.24e-09	7.42e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38356380~38378505:+
STAD	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-5.96	6.24e-09	7.42e-06	-0.33	-0.31	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
STAD	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	5.96	6.25e-09	7.43e-06	0.31	0.31	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
STAD	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	5.96	6.25e-09	7.44e-06	0.31	0.31	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
STAD	cis	rs6782228	0.606	rs4857861	ENSG00000277250.1	Metazoa_SRP	-5.96	6.26e-09	7.44e-06	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128673681~128674021:-
STAD	cis	rs8067354	0.574	rs1296279	ENSG00000266701.1	AC005702.4	5.96	6.26e-09	7.44e-06	0.45	0.31	Hemoglobin concentration;	chr17:59888370	chr17:60042546~60042627:-
STAD	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	5.96	6.26e-09	7.45e-06	0.44	0.31	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
STAD	cis	rs13113518	1	rs13133579	ENSG00000272969.1	RP11-528I4.2	5.96	6.26e-09	7.45e-06	0.38	0.31	Height;	chr4:55459921	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.902	rs11133386	ENSG00000272969.1	RP11-528I4.2	5.96	6.26e-09	7.45e-06	0.38	0.31	Height;	chr4:55461320	chr4:55547112~55547889:+
STAD	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-5.96	6.27e-09	7.45e-06	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
STAD	cis	rs875971	0.522	rs2949690	ENSG00000222364.1	RNU6-96P	5.96	6.27e-09	7.46e-06	0.34	0.31	Aortic root size;	chr7:66018255	chr7:66395191~66395286:+
STAD	cis	rs1005277	0.579	rs1740732	ENSG00000099251.13	HSD17B7P2	5.96	6.28e-09	7.47e-06	0.34	0.31	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38356380~38378505:+
STAD	cis	rs7176527	0.579	rs366717	ENSG00000229212.6	RP11-561C5.4	5.96	6.29e-09	7.47e-06	0.43	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85205440~85234795:-
STAD	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	5.96	6.29e-09	7.47e-06	0.35	0.31	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
STAD	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	5.96	6.29e-09	7.48e-06	0.38	0.31	Height;	chr6:109347707	chr6:109382795~109383666:+
STAD	cis	rs7829975	0.626	rs332040	ENSG00000254340.1	RP11-10A14.3	5.96	6.29e-09	7.48e-06	0.37	0.31	Mood instability;	chr8:8872978	chr8:9141424~9145435:+
STAD	cis	rs13113518	0.902	rs12642716	ENSG00000272969.1	RP11-528I4.2	5.96	6.31e-09	7.49e-06	0.38	0.31	Height;	chr4:55479996	chr4:55547112~55547889:+
STAD	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-5.96	6.31e-09	7.5e-06	-0.31	-0.31	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
STAD	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	5.96	6.32e-09	7.51e-06	0.36	0.3	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
STAD	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-5.96	6.34e-09	7.53e-06	-0.52	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
STAD	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-5.96	6.34e-09	7.53e-06	-0.33	-0.3	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
STAD	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-5.96	6.34e-09	7.53e-06	-0.33	-0.3	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
STAD	cis	rs13113518	1	rs4864999	ENSG00000272969.1	RP11-528I4.2	5.96	6.34e-09	7.53e-06	0.38	0.3	Height;	chr4:55476736	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs10517344	ENSG00000272969.1	RP11-528I4.2	5.96	6.34e-09	7.53e-06	0.38	0.3	Height;	chr4:55477545	chr4:55547112~55547889:+
STAD	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-5.96	6.35e-09	7.54e-06	-0.34	-0.3	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
STAD	cis	rs6452524	0.935	rs10045744	ENSG00000243385.2	CTD-2110K23.1	5.96	6.35e-09	7.54e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83201229~83202141:+
STAD	cis	rs9549260	0.609	rs9315780	ENSG00000229456.1	RLIMP1	5.96	6.36e-09	7.54e-06	0.28	0.3	Red blood cell count;	chr13:40689824	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.609	rs9315781	ENSG00000229456.1	RLIMP1	5.96	6.36e-09	7.54e-06	0.28	0.3	Red blood cell count;	chr13:40689917	chr13:40618738~40621348:+
STAD	cis	rs1005277	0.579	rs2103938	ENSG00000099251.13	HSD17B7P2	5.96	6.36e-09	7.54e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38356380~38378505:+
STAD	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	5.96	6.36e-09	7.55e-06	0.32	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
STAD	cis	rs875971	0.522	rs709604	ENSG00000222364.1	RNU6-96P	5.96	6.37e-09	7.56e-06	0.34	0.3	Aortic root size;	chr7:66032447	chr7:66395191~66395286:+
STAD	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-5.96	6.37e-09	7.56e-06	-0.34	-0.3	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
STAD	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-5.96	6.37e-09	7.56e-06	-0.33	-0.3	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
STAD	cis	rs13113518	1	rs12501636	ENSG00000272969.1	RP11-528I4.2	5.96	6.37e-09	7.56e-06	0.38	0.3	Height;	chr4:55482317	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs6858803	ENSG00000272969.1	RP11-528I4.2	5.96	6.37e-09	7.56e-06	0.38	0.3	Height;	chr4:55484534	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs13114841	ENSG00000272969.1	RP11-528I4.2	5.96	6.37e-09	7.56e-06	0.38	0.3	Height;	chr4:55485974	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs939823	ENSG00000272969.1	RP11-528I4.2	5.96	6.37e-09	7.56e-06	0.38	0.3	Height;	chr4:55487368	chr4:55547112~55547889:+
STAD	cis	rs228614	0.51	rs223438	ENSG00000230069.3	LRRC37A15P	5.95	6.4e-09	7.59e-06	0.33	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102727274~102730721:-
STAD	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	5.95	6.41e-09	7.6e-06	0.31	0.3	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
STAD	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	5.95	6.41e-09	7.6e-06	0.31	0.3	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
STAD	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-5.95	6.41e-09	7.6e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-5.95	6.41e-09	7.6e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
STAD	cis	rs227275	0.554	rs223457	ENSG00000230069.3	LRRC37A15P	-5.95	6.42e-09	7.61e-06	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102727274~102730721:-
STAD	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	5.95	6.42e-09	7.61e-06	0.39	0.3	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
STAD	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	5.95	6.43e-09	7.62e-06	0.38	0.3	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
STAD	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-5.95	6.43e-09	7.62e-06	-0.46	-0.3	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
STAD	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	5.95	6.43e-09	7.62e-06	0.26	0.3	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
STAD	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-5.95	6.46e-09	7.65e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
STAD	cis	rs6452524	0.534	rs72765386	ENSG00000243385.2	CTD-2110K23.1	5.95	6.48e-09	7.67e-06	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.534	rs9293328	ENSG00000243385.2	CTD-2110K23.1	5.95	6.48e-09	7.67e-06	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.534	rs11746747	ENSG00000243385.2	CTD-2110K23.1	5.95	6.48e-09	7.67e-06	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83201229~83202141:+
STAD	cis	rs992157	0.731	rs1399132	ENSG00000237281.1	CATIP-AS2	-5.95	6.48e-09	7.67e-06	-0.31	-0.3	Colorectal cancer;	chr2:218295047	chr2:218326889~218357966:-
STAD	cis	rs992157	0.796	rs55680399	ENSG00000237281.1	CATIP-AS2	-5.95	6.48e-09	7.67e-06	-0.31	-0.3	Colorectal cancer;	chr2:218295898	chr2:218326889~218357966:-
STAD	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	5.95	6.48e-09	7.68e-06	0.27	0.3	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
STAD	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-5.95	6.49e-09	7.68e-06	-0.51	-0.3	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
STAD	cis	rs7615952	0.546	rs2979333	ENSG00000272840.1	RP11-379B18.6	5.95	6.49e-09	7.69e-06	0.52	0.3	Blood pressure (smoking interaction);	chr3:125641499	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.546	rs111812401	ENSG00000272840.1	RP11-379B18.6	5.95	6.49e-09	7.69e-06	0.52	0.3	Blood pressure (smoking interaction);	chr3:125642651	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.546	rs2979350	ENSG00000272840.1	RP11-379B18.6	5.95	6.49e-09	7.69e-06	0.52	0.3	Blood pressure (smoking interaction);	chr3:125643371	chr3:125774714~125797953:+
STAD	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	5.95	6.5e-09	7.69e-06	0.55	0.3	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
STAD	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-5.95	6.5e-09	7.7e-06	-0.3	-0.3	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-5.95	6.5e-09	7.7e-06	-0.3	-0.3	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
STAD	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-5.95	6.52e-09	7.72e-06	-0.35	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
STAD	cis	rs858239	0.614	rs2014816	ENSG00000226816.2	AC005082.12	5.95	6.52e-09	7.72e-06	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23206013~23208045:+
STAD	cis	rs13113518	1	rs6838882	ENSG00000272969.1	RP11-528I4.2	5.95	6.55e-09	7.75e-06	0.38	0.3	Height;	chr4:55489310	chr4:55547112~55547889:+
STAD	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-5.95	6.55e-09	7.75e-06	-0.29	-0.3	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
STAD	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-5.95	6.56e-09	7.76e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
STAD	cis	rs12699921	0.658	rs1404422	ENSG00000279048.1	RP11-511H23.2	-5.95	6.56e-09	7.76e-06	-0.27	-0.3	Fibrinogen levels;	chr7:17795362	chr7:17940503~17942922:+
STAD	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-5.95	6.56e-09	7.76e-06	-0.34	-0.3	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
STAD	cis	rs13113518	0.966	rs13144598	ENSG00000272969.1	RP11-528I4.2	5.95	6.57e-09	7.77e-06	0.39	0.3	Height;	chr4:55570311	chr4:55547112~55547889:+
STAD	cis	rs728616	0.867	rs118134654	ENSG00000225484.5	NUTM2B-AS1	-5.95	6.57e-09	7.77e-06	-0.66	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79663088~79826594:-
STAD	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	5.95	6.57e-09	7.77e-06	0.33	0.3	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
STAD	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	5.95	6.57e-09	7.78e-06	0.37	0.3	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
STAD	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	5.95	6.58e-09	7.78e-06	0.39	0.3	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
STAD	cis	rs12699921	0.632	rs2691597	ENSG00000279048.1	RP11-511H23.2	-5.95	6.58e-09	7.78e-06	-0.28	-0.3	Fibrinogen levels;	chr7:17830717	chr7:17940503~17942922:+
STAD	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-5.95	6.59e-09	7.8e-06	-0.34	-0.3	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
STAD	cis	rs228614	0.51	rs223397	ENSG00000230069.3	LRRC37A15P	-5.95	6.6e-09	7.8e-06	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102727274~102730721:-
STAD	cis	rs2273156	0.587	rs7145474	ENSG00000241052.1	RP11-173D9.1	-5.95	6.6e-09	7.81e-06	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35067909	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.57	rs75889859	ENSG00000241052.1	RP11-173D9.1	-5.95	6.6e-09	7.81e-06	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35069848	chr14:35144021~35144480:-
STAD	cis	rs79403677	1	rs79403677	ENSG00000241052.1	RP11-173D9.1	-5.95	6.6e-09	7.81e-06	-0.37	-0.3	Bipolar disorder lithium response (continuous) or schizophrenia;	chr14:35069925	chr14:35144021~35144480:-
STAD	cis	rs2739330	0.791	rs9612520	ENSG00000224205.1	AP000351.4	5.95	6.61e-09	7.81e-06	0.35	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23987320~23991421:-
STAD	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	5.95	6.62e-09	7.82e-06	0.31	0.3	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
STAD	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	5.95	6.62e-09	7.82e-06	0.45	0.3	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
STAD	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	5.95	6.63e-09	7.83e-06	0.38	0.3	Height;	chr6:109346560	chr6:109382795~109383666:+
STAD	cis	rs2439831	0.85	rs67541383	ENSG00000249839.1	AC011330.5	-5.95	6.63e-09	7.84e-06	-0.56	-0.3	Lung cancer in ever smokers;	chr15:43880350	chr15:43663654~43684339:-
STAD	cis	rs6496044	0.507	rs2467096	ENSG00000259407.1	RP11-158M2.3	5.95	6.63e-09	7.84e-06	0.32	0.3	Interstitial lung disease;	chr15:85667447	chr15:85744109~85750281:-
STAD	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	5.95	6.64e-09	7.84e-06	0.29	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
STAD	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-5.95	6.64e-09	7.84e-06	-0.35	-0.3	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
STAD	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-5.95	6.65e-09	7.85e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
STAD	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-5.95	6.65e-09	7.86e-06	-0.33	-0.3	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
STAD	cis	rs2283792	0.765	rs34550586	ENSG00000228050.1	TOP3BP1	5.95	6.66e-09	7.86e-06	0.34	0.3	Multiple sclerosis;	chr22:21791345	chr22:22223187~22224566:-
STAD	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	5.95	6.66e-09	7.87e-06	0.3	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
STAD	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-5.95	6.67e-09	7.87e-06	-0.34	-0.3	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
STAD	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-5.95	6.69e-09	7.89e-06	-0.32	-0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
STAD	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	5.95	6.7e-09	7.9e-06	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
STAD	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	5.95	6.7e-09	7.9e-06	0.33	0.3	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	5.95	6.7e-09	7.9e-06	0.33	0.3	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
STAD	cis	rs5769707	0.681	rs9616329	ENSG00000280224.1	CTA-722E9.1	-5.95	6.71e-09	7.91e-06	-0.34	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49500568~49501585:+
STAD	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	5.95	6.71e-09	7.92e-06	0.32	0.3	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
STAD	cis	rs3806843	0.735	rs2563314	ENSG00000202111.1	VTRNA1-2	5.95	6.71e-09	7.92e-06	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr5:140718925~140719013:+
STAD	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	5.95	6.72e-09	7.93e-06	0.38	0.3	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
STAD	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-5.95	6.72e-09	7.93e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
STAD	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	5.95	6.74e-09	7.95e-06	0.31	0.3	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
STAD	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-5.95	6.75e-09	7.95e-06	-0.5	-0.3	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
STAD	cis	rs1005277	0.579	rs2474567	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2472175	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2472176	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2983343	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474569	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2504143	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.602	rs2504142	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474571	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2472181	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474574	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2504140	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474575	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2472182	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.541	rs2263163	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2021649	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2505197	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2505196	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.541	rs2505193	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474580	ENSG00000099251.13	HSD17B7P2	5.95	6.75e-09	7.95e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2505248	ENSG00000099251.13	HSD17B7P2	5.94	6.76e-09	7.96e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2504148	ENSG00000099251.13	HSD17B7P2	5.94	6.76e-09	7.96e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs176886	ENSG00000099251.13	HSD17B7P2	5.94	6.76e-09	7.96e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.557	rs176887	ENSG00000099251.13	HSD17B7P2	5.94	6.76e-09	7.96e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38356380~38378505:+
STAD	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	5.94	6.76e-09	7.96e-06	0.34	0.3	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
STAD	cis	rs17361889	0.613	rs62440449	ENSG00000224683.1	RPL36AP29	5.94	6.76e-09	7.96e-06	0.32	0.3	Pediatric bone mineral content (hip);	chr7:16257180	chr7:16208945~16209265:+
STAD	cis	rs10129255	0.957	rs8005468	ENSG00000280411.1	IGHV1-69-2	-5.94	6.79e-09	7.99e-06	-0.29	-0.3	Kawasaki disease;	chr14:106686431	chr14:106762092~106762588:-
STAD	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	5.94	6.79e-09	7.99e-06	0.34	0.3	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
STAD	cis	rs2440129	0.611	rs11571335	ENSG00000215067.8	ALOX12-AS1	5.94	6.8e-09	8.01e-06	0.31	0.3	Tonsillectomy;	chr17:7000944	chr17:6876635~7012349:-
STAD	cis	rs516805	0.706	rs572674	ENSG00000279453.1	RP3-425C14.4	-5.94	6.81e-09	8.01e-06	-0.42	-0.3	Lymphocyte counts;	chr6:122411239	chr6:122436789~122439223:-
STAD	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-5.94	6.81e-09	8.02e-06	-0.53	-0.3	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
STAD	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	5.94	6.82e-09	8.02e-06	0.37	0.3	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	5.94	6.82e-09	8.02e-06	0.37	0.3	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
STAD	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	5.94	6.83e-09	8.04e-06	0.33	0.3	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
STAD	cis	rs8141529	0.732	rs5762815	ENSG00000226471.5	CTA-292E10.6	-5.94	6.84e-09	8.04e-06	-0.36	-0.3	Lymphocyte counts;	chr22:28809088	chr22:28800683~28848559:+
STAD	cis	rs13113518	1	rs13141049	ENSG00000272969.1	RP11-528I4.2	5.94	6.85e-09	8.05e-06	0.38	0.3	Height;	chr4:55535489	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.967	rs12507722	ENSG00000272969.1	RP11-528I4.2	5.94	6.85e-09	8.05e-06	0.38	0.3	Height;	chr4:55536421	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.967	rs7696832	ENSG00000272969.1	RP11-528I4.2	5.94	6.85e-09	8.05e-06	0.38	0.3	Height;	chr4:55537080	chr4:55547112~55547889:+
STAD	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-5.94	6.85e-09	8.05e-06	-0.3	-0.3	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
STAD	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	5.94	6.85e-09	8.05e-06	0.31	0.3	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	5.94	6.85e-09	8.05e-06	0.31	0.3	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	5.94	6.85e-09	8.05e-06	0.31	0.3	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	5.94	6.85e-09	8.05e-06	0.31	0.3	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	5.94	6.85e-09	8.05e-06	0.31	0.3	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
STAD	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	5.94	6.87e-09	8.06e-06	0.35	0.3	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
STAD	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-5.94	6.87e-09	8.06e-06	-0.32	-0.3	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
STAD	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-5.94	6.87e-09	8.07e-06	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
STAD	cis	rs7487075	0.619	rs7486495	ENSG00000272369.1	RP11-446N19.1	5.94	6.87e-09	8.07e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46432553	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs7485580	ENSG00000272369.1	RP11-446N19.1	5.94	6.87e-09	8.07e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46436591	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs10880970	ENSG00000272369.1	RP11-446N19.1	5.94	6.87e-09	8.07e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46436637	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs7311504	ENSG00000272369.1	RP11-446N19.1	5.94	6.87e-09	8.07e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46436993	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs4768717	ENSG00000272369.1	RP11-446N19.1	5.94	6.87e-09	8.07e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46437778	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs4076247	ENSG00000272369.1	RP11-446N19.1	5.94	6.87e-09	8.07e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46439667	chr12:46537502~46652550:+
STAD	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-5.94	6.88e-09	8.08e-06	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-5.94	6.88e-09	8.08e-06	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-5.94	6.88e-09	8.08e-06	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-5.94	6.9e-09	8.09e-06	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
STAD	cis	rs13113518	1	rs56362210	ENSG00000272969.1	RP11-528I4.2	5.94	6.9e-09	8.1e-06	0.38	0.3	Height;	chr4:55540972	chr4:55547112~55547889:+
STAD	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	5.94	6.91e-09	8.1e-06	0.47	0.3	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
STAD	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	5.94	6.91e-09	8.1e-06	0.47	0.3	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
STAD	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	5.94	6.91e-09	8.11e-06	0.26	0.3	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	5.94	6.91e-09	8.11e-06	0.26	0.3	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
STAD	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	5.94	6.92e-09	8.12e-06	0.5	0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
STAD	cis	rs801193	1	rs13239306	ENSG00000222364.1	RNU6-96P	5.94	6.93e-09	8.12e-06	0.34	0.3	Aortic root size;	chr7:66671030	chr7:66395191~66395286:+
STAD	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-5.94	6.93e-09	8.13e-06	-0.49	-0.3	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
STAD	cis	rs8141529	0.644	rs5752795	ENSG00000226471.5	CTA-292E10.6	-5.94	6.94e-09	8.13e-06	-0.35	-0.3	Lymphocyte counts;	chr22:28782832	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.732	rs2347447	ENSG00000226471.5	CTA-292E10.6	-5.94	6.94e-09	8.13e-06	-0.35	-0.3	Lymphocyte counts;	chr22:28783751	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.732	rs5752798	ENSG00000226471.5	CTA-292E10.6	-5.94	6.94e-09	8.13e-06	-0.35	-0.3	Lymphocyte counts;	chr22:28785880	chr22:28800683~28848559:+
STAD	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-5.94	6.94e-09	8.13e-06	-0.32	-0.3	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-5.94	6.94e-09	8.13e-06	-0.32	-0.3	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
STAD	cis	rs2739330	0.703	rs5760112	ENSG00000224205.1	AP000351.4	5.94	6.94e-09	8.13e-06	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23987320~23991421:-
STAD	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-5.94	6.94e-09	8.13e-06	-0.39	-0.3	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
STAD	cis	rs13113518	0.934	rs11133397	ENSG00000272969.1	RP11-528I4.2	5.94	6.95e-09	8.15e-06	0.38	0.3	Height;	chr4:55534166	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.934	rs11133398	ENSG00000272969.1	RP11-528I4.2	5.94	6.95e-09	8.15e-06	0.38	0.3	Height;	chr4:55534180	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs13152173	ENSG00000272969.1	RP11-528I4.2	5.94	6.95e-09	8.15e-06	0.38	0.3	Height;	chr4:55534788	chr4:55547112~55547889:+
STAD	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	5.94	6.96e-09	8.15e-06	0.35	0.3	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
STAD	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	5.94	6.98e-09	8.17e-06	0.33	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
STAD	cis	rs9395066	0.545	rs2396372	ENSG00000219384.1	RP11-491H9.3	-5.94	6.98e-09	8.18e-06	-0.3	-0.3	Height;	chr6:44999130	chr6:45158870~45159511:+
STAD	cis	rs227275	0.525	rs223461	ENSG00000230069.3	LRRC37A15P	-5.94	7e-09	8.19e-06	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102727274~102730721:-
STAD	cis	rs6452524	0.935	rs10076059	ENSG00000243385.2	CTD-2110K23.1	5.94	7e-09	8.19e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs7736783	ENSG00000243385.2	CTD-2110K23.1	5.94	7e-09	8.19e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs11951257	ENSG00000243385.2	CTD-2110K23.1	5.94	7e-09	8.19e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs767771	ENSG00000243385.2	CTD-2110K23.1	5.94	7e-09	8.19e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.905	rs1478482	ENSG00000243385.2	CTD-2110K23.1	5.94	7e-09	8.19e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs1542539	ENSG00000243385.2	CTD-2110K23.1	5.94	7e-09	8.19e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.935	rs1543847	ENSG00000243385.2	CTD-2110K23.1	5.94	7e-09	8.19e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83201229~83202141:+
STAD	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	5.94	7.01e-09	8.21e-06	0.38	0.3	Height;	chr6:109332929	chr6:109382795~109383666:+
STAD	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	5.94	7.01e-09	8.21e-06	0.25	0.3	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
STAD	cis	rs13113518	1	rs13122619	ENSG00000272969.1	RP11-528I4.2	5.94	7.02e-09	8.22e-06	0.39	0.3	Height;	chr4:55479339	chr4:55547112~55547889:+
STAD	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-5.94	7.02e-09	8.22e-06	-0.34	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	5.94	7.02e-09	8.22e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
STAD	cis	rs7487075	0.567	rs7486580	ENSG00000272369.1	RP11-446N19.1	5.94	7.04e-09	8.24e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46434565	chr12:46537502~46652550:+
STAD	cis	rs3806843	0.766	rs2251860	ENSG00000202111.1	VTRNA1-2	5.94	7.04e-09	8.24e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.766	rs702397	ENSG00000202111.1	VTRNA1-2	5.94	7.04e-09	8.24e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.735	rs2530240	ENSG00000202111.1	VTRNA1-2	5.94	7.05e-09	8.24e-06	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.735	rs801189	ENSG00000202111.1	VTRNA1-2	5.94	7.05e-09	8.24e-06	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.706	rs1089305	ENSG00000202111.1	VTRNA1-2	5.94	7.05e-09	8.24e-06	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr5:140718925~140719013:+
STAD	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-5.94	7.05e-09	8.25e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
STAD	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-5.94	7.06e-09	8.26e-06	-0.35	-0.3	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
STAD	cis	rs7487075	0.619	rs7488450	ENSG00000272369.1	RP11-446N19.1	5.94	7.07e-09	8.26e-06	0.41	0.3	Itch intensity from mosquito bite;	chr12:46427255	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs11183479	ENSG00000272369.1	RP11-446N19.1	5.94	7.07e-09	8.26e-06	0.41	0.3	Itch intensity from mosquito bite;	chr12:46430381	chr12:46537502~46652550:+
STAD	cis	rs3806843	0.735	rs801185	ENSG00000202111.1	VTRNA1-2	5.94	7.07e-09	8.26e-06	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.676	rs2563304	ENSG00000202111.1	VTRNA1-2	5.94	7.07e-09	8.26e-06	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.735	rs3776129	ENSG00000202111.1	VTRNA1-2	5.94	7.07e-09	8.26e-06	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr5:140718925~140719013:+
STAD	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-5.94	7.09e-09	8.29e-06	-0.49	-0.3	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
STAD	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	5.94	7.09e-09	8.29e-06	0.38	0.3	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
STAD	cis	rs7927771	0.864	rs3781625	ENSG00000280615.1	Y_RNA	-5.94	7.09e-09	8.29e-06	-0.31	-0.3	Subjective well-being;	chr11:47421529	chr11:47614898~47614994:-
STAD	cis	rs858239	0.863	rs466225	ENSG00000226816.2	AC005082.12	5.94	7.1e-09	8.3e-06	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23206013~23208045:+
STAD	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-5.94	7.1e-09	8.3e-06	-0.44	-0.3	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	5.94	7.12e-09	8.32e-06	0.46	0.3	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
STAD	cis	rs10129255	0.917	rs7142373	ENSG00000223648.3	IGHV3-64	5.93	7.14e-09	8.35e-06	0.27	0.3	Kawasaki disease;	chr14:106708947	chr14:106643132~106658258:-
STAD	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	5.93	7.15e-09	8.35e-06	0.31	0.3	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
STAD	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-5.93	7.15e-09	8.35e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
STAD	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	5.93	7.16e-09	8.36e-06	0.48	0.3	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
STAD	cis	rs10129255	0.957	rs1056705	ENSG00000280411.1	IGHV1-69-2	-5.93	7.16e-09	8.36e-06	-0.28	-0.3	Kawasaki disease;	chr14:106714323	chr14:106762092~106762588:-
STAD	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-5.93	7.17e-09	8.37e-06	-0.42	-0.3	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	5.93	7.17e-09	8.37e-06	0.5	0.3	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
STAD	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	5.93	7.19e-09	8.4e-06	0.29	0.3	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
STAD	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-5.93	7.21e-09	8.41e-06	-0.34	-0.3	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
STAD	cis	rs12699921	0.599	rs4721661	ENSG00000279048.1	RP11-511H23.2	-5.93	7.22e-09	8.43e-06	-0.28	-0.3	Fibrinogen levels;	chr7:17834677	chr7:17940503~17942922:+
STAD	cis	rs3806843	0.735	rs801167	ENSG00000202111.1	VTRNA1-2	-5.93	7.22e-09	8.43e-06	-0.29	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr5:140718925~140719013:+
STAD	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-5.93	7.22e-09	8.43e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-5.93	7.22e-09	8.43e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-5.93	7.22e-09	8.43e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
STAD	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	5.93	7.23e-09	8.44e-06	0.37	0.3	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
STAD	cis	rs1005277	0.54	rs2474598	ENSG00000099251.13	HSD17B7P2	-5.93	7.23e-09	8.44e-06	-0.33	-0.3	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38356380~38378505:+
STAD	cis	rs10129255	0.828	rs10140989	ENSG00000280411.1	IGHV1-69-2	-5.93	7.23e-09	8.44e-06	-0.29	-0.3	Kawasaki disease;	chr14:106668657	chr14:106762092~106762588:-
STAD	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	5.93	7.24e-09	8.45e-06	0.31	0.3	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
STAD	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-5.93	7.25e-09	8.46e-06	-0.32	-0.3	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
STAD	cis	rs9395066	0.545	rs12525009	ENSG00000219384.1	RP11-491H9.3	-5.93	7.25e-09	8.46e-06	-0.29	-0.3	Height;	chr6:44908106	chr6:45158870~45159511:+
STAD	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	5.93	7.26e-09	8.48e-06	0.37	0.3	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
STAD	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	5.93	7.28e-09	8.49e-06	0.37	0.3	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
STAD	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	5.93	7.28e-09	8.49e-06	0.37	0.3	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
STAD	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	5.93	7.28e-09	8.5e-06	0.3	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
STAD	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	5.93	7.29e-09	8.5e-06	0.31	0.3	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
STAD	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-5.93	7.3e-09	8.51e-06	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-5.93	7.3e-09	8.51e-06	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
STAD	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	5.93	7.33e-09	8.54e-06	0.3	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
STAD	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	5.93	7.33e-09	8.54e-06	0.35	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
STAD	cis	rs3806843	0.766	rs2530239	ENSG00000202111.1	VTRNA1-2	5.93	7.33e-09	8.54e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr5:140718925~140719013:+
STAD	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-5.93	7.33e-09	8.55e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
STAD	cis	rs858239	0.665	rs6964665	ENSG00000226816.2	AC005082.12	5.93	7.35e-09	8.57e-06	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23206013~23208045:+
STAD	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-5.93	7.36e-09	8.58e-06	-0.42	-0.3	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
STAD	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	5.93	7.38e-09	8.6e-06	0.38	0.3	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
STAD	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-5.93	7.39e-09	8.61e-06	-0.29	-0.3	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
STAD	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	5.93	7.39e-09	8.61e-06	0.32	0.3	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
STAD	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	5.93	7.4e-09	8.62e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
STAD	cis	rs6452524	0.534	rs10037377	ENSG00000243385.2	CTD-2110K23.1	5.93	7.4e-09	8.62e-06	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83201229~83202141:+
STAD	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-5.93	7.43e-09	8.65e-06	-0.35	-0.3	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
STAD	cis	rs2283792	0.764	rs2298432	ENSG00000228050.1	TOP3BP1	5.93	7.44e-09	8.67e-06	0.35	0.3	Multiple sclerosis;	chr22:21768900	chr22:22223187~22224566:-
STAD	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	5.93	7.45e-09	8.67e-06	0.31	0.3	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
STAD	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-5.93	7.45e-09	8.67e-06	-0.33	-0.3	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
STAD	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-5.93	7.45e-09	8.67e-06	-0.33	-0.3	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
STAD	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-5.93	7.45e-09	8.67e-06	-0.33	-0.3	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
STAD	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-5.93	7.45e-09	8.67e-06	-0.33	-0.3	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
STAD	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-5.93	7.45e-09	8.67e-06	-0.33	-0.3	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
STAD	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-5.93	7.45e-09	8.67e-06	-0.33	-0.3	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
STAD	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-5.93	7.46e-09	8.68e-06	-0.53	-0.3	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
STAD	cis	rs10129255	0.957	rs11846893	ENSG00000280411.1	IGHV1-69-2	-5.93	7.47e-09	8.7e-06	-0.28	-0.3	Kawasaki disease;	chr14:106779068	chr14:106762092~106762588:-
STAD	cis	rs240993	0.909	rs240991	ENSG00000230177.1	RP5-1112D6.4	-5.93	7.48e-09	8.7e-06	-0.29	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111277932~111278742:+
STAD	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-5.93	7.48e-09	8.7e-06	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
STAD	cis	rs3806843	0.706	rs2563302	ENSG00000202111.1	VTRNA1-2	5.93	7.49e-09	8.72e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr5:140718925~140719013:+
STAD	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-5.93	7.49e-09	8.72e-06	-0.29	-0.3	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-5.93	7.49e-09	8.72e-06	-0.29	-0.3	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
STAD	cis	rs7487075	0.619	rs9971879	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46412990	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs4768710	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46414321	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.578	rs1492895	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46414972	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.578	rs2897951	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46415423	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.567	rs4768712	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46417738	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.578	rs10880967	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46418240	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.578	rs4768713	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46420264	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.606	rs4768714	ENSG00000272369.1	RP11-446N19.1	5.93	7.5e-09	8.73e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46420462	chr12:46537502~46652550:+
STAD	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	5.93	7.51e-09	8.74e-06	0.3	0.3	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
STAD	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	5.93	7.52e-09	8.75e-06	0.43	0.3	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
STAD	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-5.93	7.52e-09	8.75e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
STAD	cis	rs1005277	0.565	rs2474565	ENSG00000099251.13	HSD17B7P2	5.93	7.52e-09	8.75e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38356380~38378505:+
STAD	cis	rs9549260	0.755	rs4943797	ENSG00000229456.1	RLIMP1	-5.93	7.53e-09	8.75e-06	-0.27	-0.3	Red blood cell count;	chr13:40627496	chr13:40618738~40621348:+
STAD	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-5.93	7.53e-09	8.75e-06	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
STAD	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	5.93	7.53e-09	8.76e-06	0.27	0.3	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
STAD	cis	rs992157	0.661	rs10171839	ENSG00000237281.1	CATIP-AS2	-5.92	7.55e-09	8.77e-06	-0.29	-0.3	Colorectal cancer;	chr2:218186591	chr2:218326889~218357966:-
STAD	cis	rs7487075	0.619	rs4077707	ENSG00000272369.1	RP11-446N19.1	5.92	7.55e-09	8.77e-06	0.39	0.3	Itch intensity from mosquito bite;	chr12:46464715	chr12:46537502~46652550:+
STAD	cis	rs13113518	1	rs4864547	ENSG00000272969.1	RP11-528I4.2	5.92	7.55e-09	8.78e-06	0.38	0.3	Height;	chr4:55538228	chr4:55547112~55547889:+
STAD	cis	rs6452524	0.935	rs9293330	ENSG00000243385.2	CTD-2110K23.1	5.92	7.56e-09	8.78e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83201229~83202141:+
STAD	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-5.92	7.56e-09	8.78e-06	-0.36	-0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-5.92	7.56e-09	8.78e-06	-0.36	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
STAD	cis	rs10129255	0.879	rs7160512	ENSG00000223648.3	IGHV3-64	5.92	7.56e-09	8.78e-06	0.26	0.3	Kawasaki disease;	chr14:106694574	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.879	rs7159157	ENSG00000223648.3	IGHV3-64	5.92	7.56e-09	8.78e-06	0.26	0.3	Kawasaki disease;	chr14:106694578	chr14:106643132~106658258:-
STAD	cis	rs875971	0.54	rs1723268	ENSG00000222364.1	RNU6-96P	-5.92	7.57e-09	8.79e-06	-0.34	-0.3	Aortic root size;	chr7:66008093	chr7:66395191~66395286:+
STAD	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-5.92	7.57e-09	8.79e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-5.92	7.57e-09	8.79e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
STAD	cis	rs8141529	0.732	rs5762788	ENSG00000226471.5	CTA-292E10.6	-5.92	7.59e-09	8.81e-06	-0.36	-0.3	Lymphocyte counts;	chr22:28778782	chr22:28800683~28848559:+
STAD	cis	rs1005277	0.579	rs2023351	ENSG00000099251.13	HSD17B7P2	5.92	7.6e-09	8.82e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38356380~38378505:+
STAD	cis	rs7487075	1	rs7487075	ENSG00000272369.1	RP11-446N19.1	5.92	7.62e-09	8.85e-06	0.36	0.3	Itch intensity from mosquito bite;	chr12:46435135	chr12:46537502~46652550:+
STAD	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-5.92	7.63e-09	8.86e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
STAD	cis	rs7487075	0.619	rs7968897	ENSG00000272369.1	RP11-446N19.1	5.92	7.63e-09	8.86e-06	0.41	0.3	Itch intensity from mosquito bite;	chr12:46420041	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs6582646	ENSG00000272369.1	RP11-446N19.1	5.92	7.63e-09	8.86e-06	0.41	0.3	Itch intensity from mosquito bite;	chr12:46420074	chr12:46537502~46652550:+
STAD	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-5.92	7.66e-09	8.88e-06	-0.37	-0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
STAD	cis	rs8098244	0.565	rs11664777	ENSG00000267301.1	RPL23AP77	-5.92	7.66e-09	8.88e-06	-0.35	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23731793	chr18:23709825~23710287:-
STAD	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	5.92	7.68e-09	8.91e-06	0.36	0.3	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	5.92	7.68e-09	8.91e-06	0.36	0.3	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
STAD	cis	rs13113518	0.966	rs11942472	ENSG00000272969.1	RP11-528I4.2	5.92	7.68e-09	8.91e-06	0.39	0.3	Height;	chr4:55574959	chr4:55547112~55547889:+
STAD	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	5.92	7.69e-09	8.91e-06	0.26	0.3	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
STAD	cis	rs13113518	0.902	rs12505266	ENSG00000272969.1	RP11-528I4.2	5.92	7.69e-09	8.92e-06	0.38	0.3	Height;	chr4:55546002	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs56154935	ENSG00000272969.1	RP11-528I4.2	5.92	7.69e-09	8.92e-06	0.38	0.3	Height;	chr4:55546378	chr4:55547112~55547889:+
STAD	cis	rs6782228	1	rs6775011	ENSG00000277250.1	Metazoa_SRP	5.92	7.69e-09	8.92e-06	0.36	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128673681~128674021:-
STAD	cis	rs748404	1	rs748404	ENSG00000249839.1	AC011330.5	-5.92	7.69e-09	8.92e-06	-0.49	-0.3	Lung cancer;	chr15:43267033	chr15:43663654~43684339:-
STAD	cis	rs748404	1	rs12911132	ENSG00000249839.1	AC011330.5	-5.92	7.69e-09	8.92e-06	-0.49	-0.3	Lung cancer;	chr15:43268238	chr15:43663654~43684339:-
STAD	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	5.92	7.71e-09	8.94e-06	0.34	0.3	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
STAD	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-5.92	7.72e-09	8.95e-06	-0.42	-0.3	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
STAD	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	5.92	7.74e-09	8.97e-06	0.32	0.3	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
STAD	cis	rs6452524	0.967	rs1564211	ENSG00000243385.2	CTD-2110K23.1	5.92	7.75e-09	8.98e-06	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83201229~83202141:+
STAD	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-5.92	7.75e-09	8.98e-06	-0.43	-0.3	QT interval;	chr16:28857143	chr16:28700294~28701540:-
STAD	cis	rs12699921	0.632	rs11768866	ENSG00000279048.1	RP11-511H23.2	-5.92	7.75e-09	8.99e-06	-0.27	-0.3	Fibrinogen levels;	chr7:17925956	chr7:17940503~17942922:+
STAD	cis	rs9395066	0.527	rs1590864	ENSG00000219384.1	RP11-491H9.3	-5.92	7.77e-09	9e-06	-0.29	-0.3	Height;	chr6:44938414	chr6:45158870~45159511:+
STAD	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-5.92	7.77e-09	9e-06	-0.42	-0.3	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-5.92	7.77e-09	9e-06	-0.42	-0.3	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-5.92	7.77e-09	9e-06	-0.42	-0.3	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
STAD	cis	rs8141529	0.732	rs6005872	ENSG00000226471.5	CTA-292E10.6	-5.92	7.78e-09	9.01e-06	-0.36	-0.3	Lymphocyte counts;	chr22:28776910	chr22:28800683~28848559:+
STAD	cis	rs7487075	0.78	rs12296120	ENSG00000272369.1	RP11-446N19.1	5.92	7.78e-09	9.01e-06	0.35	0.3	Itch intensity from mosquito bite;	chr12:46343808	chr12:46537502~46652550:+
STAD	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	5.92	7.81e-09	9.05e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	5.92	7.81e-09	9.05e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	5.92	7.81e-09	9.05e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	5.92	7.81e-09	9.05e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	5.92	7.81e-09	9.05e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	5.92	7.81e-09	9.05e-06	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	5.92	7.82e-09	9.06e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
STAD	cis	rs3806843	0.705	rs35614340	ENSG00000202111.1	VTRNA1-2	5.92	7.83e-09	9.07e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr5:140718925~140719013:+
STAD	cis	rs858239	0.508	rs2390754	ENSG00000226816.2	AC005082.12	5.92	7.84e-09	9.07e-06	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23206013~23208045:+
STAD	cis	rs6563842	0.572	rs9549263	ENSG00000229456.1	RLIMP1	5.92	7.84e-09	9.08e-06	0.28	0.3	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr13:40690648	chr13:40618738~40621348:+
STAD	cis	rs7487075	0.93	rs4076484	ENSG00000257261.4	RP11-96H19.1	5.92	7.85e-09	9.08e-06	0.35	0.3	Itch intensity from mosquito bite;	chr12:46440129	chr12:46383679~46876159:+
STAD	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-5.92	7.85e-09	9.08e-06	-0.35	-0.3	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
STAD	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-5.92	7.85e-09	9.08e-06	-0.35	-0.3	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-5.92	7.85e-09	9.08e-06	-0.35	-0.3	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-5.92	7.85e-09	9.08e-06	-0.35	-0.3	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-5.92	7.85e-09	9.08e-06	-0.35	-0.3	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
STAD	cis	rs453301	0.571	rs2929456	ENSG00000254340.1	RP11-10A14.3	-5.92	7.85e-09	9.08e-06	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9225906	chr8:9141424~9145435:+
STAD	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-5.92	7.86e-09	9.08e-06	-0.36	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
STAD	cis	rs7487075	0.619	rs7312259	ENSG00000272369.1	RP11-446N19.1	5.92	7.86e-09	9.09e-06	0.42	0.3	Itch intensity from mosquito bite;	chr12:46397751	chr12:46537502~46652550:+
STAD	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	5.92	7.89e-09	9.12e-06	0.26	0.3	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
STAD	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-5.92	7.89e-09	9.12e-06	-0.31	-0.3	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-5.92	7.89e-09	9.12e-06	-0.31	-0.3	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-5.92	7.89e-09	9.12e-06	-0.31	-0.3	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
STAD	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	5.92	7.9e-09	9.12e-06	0.34	0.3	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	5.92	7.9e-09	9.12e-06	0.34	0.3	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	5.92	7.9e-09	9.12e-06	0.34	0.3	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	5.92	7.9e-09	9.12e-06	0.34	0.3	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
STAD	cis	rs9549260	0.785	rs2253001	ENSG00000229456.1	RLIMP1	5.92	7.9e-09	9.13e-06	0.28	0.3	Red blood cell count;	chr13:40571193	chr13:40618738~40621348:+
STAD	cis	rs748404	1	rs17779494	ENSG00000249839.1	AC011330.5	5.92	7.91e-09	9.13e-06	0.5	0.3	Lung cancer;	chr15:43287025	chr15:43663654~43684339:-
STAD	cis	rs13113518	1	rs13132420	ENSG00000272969.1	RP11-528I4.2	-5.92	7.92e-09	9.14e-06	-0.37	-0.3	Height;	chr4:55526646	chr4:55547112~55547889:+
STAD	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-5.92	7.93e-09	9.15e-06	-0.35	-0.3	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-5.92	7.93e-09	9.15e-06	-0.35	-0.3	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
STAD	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-5.92	7.97e-09	9.19e-06	-0.33	-0.3	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
STAD	cis	rs13113518	1	rs7662966	ENSG00000272969.1	RP11-528I4.2	5.91	7.98e-09	9.21e-06	0.38	0.3	Height;	chr4:55548261	chr4:55547112~55547889:+
STAD	cis	rs7924176	0.521	rs10824142	ENSG00000236900.1	TIMM9P1	-5.91	8e-09	9.23e-06	-0.31	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74344550~74344805:-
STAD	cis	rs7924176	0.521	rs11000965	ENSG00000236900.1	TIMM9P1	-5.91	8e-09	9.23e-06	-0.31	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74344550~74344805:-
STAD	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	5.91	8.02e-09	9.25e-06	0.32	0.3	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
STAD	cis	rs4568518	0.619	rs9648238	ENSG00000279048.1	RP11-511H23.2	5.91	8.02e-09	9.25e-06	0.27	0.3	Measles;	chr7:17965614	chr7:17940503~17942922:+
STAD	cis	rs2273156	0.587	rs76767804	ENSG00000241052.1	RP11-173D9.1	-5.91	8.02e-09	9.26e-06	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35050161	chr14:35144021~35144480:-
STAD	cis	rs2337406	0.85	rs11849578	ENSG00000211972.2	IGHV3-66	5.91	8.03e-09	9.26e-06	0.34	0.3	Alzheimer's disease (late onset);	chr14:106670302	chr14:106675017~106675544:-
STAD	cis	rs7924176	0.502	rs10824134	ENSG00000236900.1	TIMM9P1	-5.91	8.03e-09	9.27e-06	-0.31	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74261866	chr10:74344550~74344805:-
STAD	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-5.91	8.04e-09	9.27e-06	-0.33	-0.3	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
STAD	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-5.91	8.04e-09	9.27e-06	-0.33	-0.3	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
STAD	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	5.91	8.06e-09	9.29e-06	0.44	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
STAD	cis	rs3806843	0.735	rs2563306	ENSG00000202111.1	VTRNA1-2	5.91	8.07e-09	9.3e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.735	rs813897	ENSG00000202111.1	VTRNA1-2	5.91	8.07e-09	9.3e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr5:140718925~140719013:+
STAD	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-5.91	8.08e-09	9.31e-06	-0.35	-0.3	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
STAD	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	5.91	8.08e-09	9.32e-06	0.31	0.3	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
STAD	cis	rs13113518	1	rs34648901	ENSG00000272969.1	RP11-528I4.2	5.91	8.09e-09	9.33e-06	0.38	0.3	Height;	chr4:55541259	chr4:55547112~55547889:+
STAD	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-5.91	8.1e-09	9.33e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
STAD	cis	rs240993	0.812	rs9400481	ENSG00000230177.1	RP5-1112D6.4	5.91	8.1e-09	9.34e-06	0.32	0.3	Inflammatory skin disease;Psoriasis;	chr6:111529539	chr6:111277932~111278742:+
STAD	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	5.91	8.1e-09	9.34e-06	0.29	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
STAD	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-5.91	8.11e-09	9.34e-06	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
STAD	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-5.91	8.11e-09	9.34e-06	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
STAD	cis	rs2404602	0.669	rs1875885	ENSG00000259422.1	RP11-593F23.1	5.91	8.11e-09	9.34e-06	0.33	0.3	Blood metabolite levels;	chr15:76345740	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.669	rs1875884	ENSG00000259422.1	RP11-593F23.1	5.91	8.11e-09	9.34e-06	0.33	0.3	Blood metabolite levels;	chr15:76345820	chr15:76174891~76181486:-
STAD	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	5.91	8.12e-09	9.35e-06	0.38	0.3	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
STAD	cis	rs453301	0.571	rs2929454	ENSG00000254340.1	RP11-10A14.3	-5.91	8.13e-09	9.37e-06	-0.38	-0.3	Joint mobility (Beighton score);	chr8:9226344	chr8:9141424~9145435:+
STAD	cis	rs1005277	0.579	rs2505257	ENSG00000099251.13	HSD17B7P2	5.91	8.14e-09	9.38e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2472173	ENSG00000099251.13	HSD17B7P2	5.91	8.14e-09	9.38e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2472174	ENSG00000099251.13	HSD17B7P2	5.91	8.14e-09	9.38e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474563	ENSG00000099251.13	HSD17B7P2	5.91	8.14e-09	9.38e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs9418322	ENSG00000099251.13	HSD17B7P2	5.91	8.14e-09	9.38e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs9299760	ENSG00000099251.13	HSD17B7P2	5.91	8.14e-09	9.38e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38356380~38378505:+
STAD	cis	rs7924176	0.521	rs11000960	ENSG00000236900.1	TIMM9P1	-5.91	8.14e-09	9.38e-06	-0.31	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74344550~74344805:-
STAD	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-5.91	8.16e-09	9.39e-06	-0.32	-0.3	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-5.91	8.16e-09	9.39e-06	-0.32	-0.3	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
STAD	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	5.91	8.17e-09	9.4e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	5.91	8.17e-09	9.4e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	5.91	8.17e-09	9.4e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	5.91	8.17e-09	9.4e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	5.91	8.17e-09	9.4e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	5.91	8.17e-09	9.4e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	5.91	8.17e-09	9.4e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
STAD	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	5.91	8.17e-09	9.41e-06	0.27	0.3	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
STAD	cis	rs3806843	0.735	rs778596	ENSG00000202111.1	VTRNA1-2	5.91	8.18e-09	9.41e-06	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr5:140718925~140719013:+
STAD	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	5.91	8.19e-09	9.42e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
STAD	cis	rs1426063	0.541	rs58959724	ENSG00000249717.1	RP11-44F21.3	5.91	8.21e-09	9.44e-06	0.68	0.3	QT interval;	chr4:75073543	chr4:74955974~74970362:-
STAD	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	5.91	8.27e-09	9.51e-06	0.46	0.3	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
STAD	cis	rs8067354	0.54	rs12600680	ENSG00000266701.1	AC005702.4	5.91	8.27e-09	9.51e-06	0.45	0.3	Hemoglobin concentration;	chr17:59960013	chr17:60042546~60042627:-
STAD	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	5.91	8.27e-09	9.51e-06	0.29	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
STAD	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	5.91	8.28e-09	9.52e-06	0.35	0.3	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
STAD	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	5.91	8.28e-09	9.52e-06	0.35	0.3	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
STAD	cis	rs7924176	0.521	rs7477710	ENSG00000236900.1	TIMM9P1	-5.91	8.28e-09	9.52e-06	-0.31	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74344550~74344805:-
STAD	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-5.91	8.29e-09	9.53e-06	-0.32	-0.3	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
STAD	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	5.91	8.29e-09	9.53e-06	0.27	0.3	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
STAD	cis	rs2283792	0.967	rs5749998	ENSG00000228050.1	TOP3BP1	5.91	8.29e-09	9.53e-06	0.33	0.3	Multiple sclerosis;	chr22:21808085	chr22:22223187~22224566:-
STAD	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	5.91	8.3e-09	9.54e-06	0.32	0.3	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
STAD	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-5.91	8.32e-09	9.56e-06	-0.35	-0.3	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-5.91	8.32e-09	9.56e-06	-0.35	-0.3	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-5.91	8.32e-09	9.56e-06	-0.35	-0.3	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
STAD	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-5.91	8.32e-09	9.57e-06	-0.28	-0.3	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
STAD	cis	rs7487075	0.619	rs4768718	ENSG00000272369.1	RP11-446N19.1	5.91	8.33e-09	9.58e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46440553	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs12822345	ENSG00000272369.1	RP11-446N19.1	5.91	8.33e-09	9.58e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46440894	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs12824565	ENSG00000272369.1	RP11-446N19.1	5.91	8.33e-09	9.58e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46440910	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs67249026	ENSG00000272369.1	RP11-446N19.1	5.91	8.33e-09	9.58e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46441985	chr12:46537502~46652550:+
STAD	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	5.91	8.34e-09	9.58e-06	0.35	0.3	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
STAD	cis	rs10849893	0.538	rs10744762	ENSG00000258435.1	RP11-711D18.2	5.91	8.36e-09	9.6e-06	0.32	0.3	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121401898	chr12:121391962~121399859:+
STAD	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	5.91	8.36e-09	9.6e-06	0.36	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
STAD	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	5.91	8.37e-09	9.61e-06	0.48	0.3	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
STAD	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	5.91	8.37e-09	9.61e-06	0.32	0.3	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
STAD	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-5.91	8.37e-09	9.61e-06	-0.29	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
STAD	cis	rs7924176	0.668	rs7895133	ENSG00000236900.1	TIMM9P1	-5.91	8.37e-09	9.62e-06	-0.31	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74344550~74344805:-
STAD	cis	rs7487075	0.619	rs10880968	ENSG00000272369.1	RP11-446N19.1	5.91	8.37e-09	9.62e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46429177	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs10785627	ENSG00000272369.1	RP11-446N19.1	5.91	8.37e-09	9.62e-06	0.37	0.3	Itch intensity from mosquito bite;	chr12:46430446	chr12:46537502~46652550:+
STAD	cis	rs2283792	1	rs3788332	ENSG00000228050.1	TOP3BP1	5.91	8.38e-09	9.62e-06	0.33	0.3	Multiple sclerosis;	chr22:21817278	chr22:22223187~22224566:-
STAD	cis	rs7927771	0.864	rs55927797	ENSG00000280615.1	Y_RNA	-5.91	8.39e-09	9.63e-06	-0.31	-0.3	Subjective well-being;	chr11:47424741	chr11:47614898~47614994:-
STAD	cis	rs11098499	0.739	rs9996382	ENSG00000248280.1	RP11-33B1.2	5.91	8.4e-09	9.64e-06	0.36	0.3	Corneal astigmatism;	chr4:119229857	chr4:119440561~119450157:-
STAD	cis	rs1005277	0.579	rs2472183	ENSG00000099251.13	HSD17B7P2	5.91	8.41e-09	9.65e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38356380~38378505:+
STAD	cis	rs12699921	0.632	rs2723553	ENSG00000279048.1	RP11-511H23.2	-5.9	8.43e-09	9.67e-06	-0.27	-0.3	Fibrinogen levels;	chr7:17799715	chr7:17940503~17942922:+
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000224205.1	AP000351.4	-5.9	8.44e-09	9.68e-06	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23987320~23991421:-
STAD	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-5.9	8.44e-09	9.68e-06	-0.32	-0.3	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
STAD	cis	rs7083	0.716	rs687740	ENSG00000254851.1	RP11-109L13.1	-5.9	8.44e-09	9.69e-06	-0.35	-0.3	Blood protein levels;	chr11:117306887	chr11:117135528~117138582:+
STAD	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-5.9	8.44e-09	9.69e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.957	rs2007467	ENSG00000280411.1	IGHV1-69-2	5.9	8.45e-09	9.69e-06	0.28	0.3	Kawasaki disease;	chr14:106771605	chr14:106762092~106762588:-
STAD	cis	rs2283792	1	rs9607287	ENSG00000228050.1	TOP3BP1	5.9	8.45e-09	9.69e-06	0.33	0.3	Multiple sclerosis;	chr22:21809136	chr22:22223187~22224566:-
STAD	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-5.9	8.46e-09	9.71e-06	-0.33	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
STAD	cis	rs1005277	0.579	rs1621040	ENSG00000099251.13	HSD17B7P2	5.9	8.46e-09	9.71e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38356380~38378505:+
STAD	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-5.9	8.49e-09	9.74e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-5.9	8.49e-09	9.74e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
STAD	cis	rs7580658	0.724	rs71414745	ENSG00000200250.1	RNU6-1147P	5.9	8.5e-09	9.75e-06	0.29	0.3	Protein C levels;	chr2:127235012	chr2:127316873~127316979:+
STAD	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	5.9	8.51e-09	9.75e-06	0.52	0.3	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	5.9	8.51e-09	9.75e-06	0.52	0.3	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
STAD	cis	rs453301	0.571	rs330048	ENSG00000254340.1	RP11-10A14.3	-5.9	8.53e-09	9.78e-06	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9229768	chr8:9141424~9145435:+
STAD	cis	rs4604732	0.536	rs61184655	ENSG00000227135.1	GCSAML-AS1	-5.9	8.59e-09	9.85e-06	-0.41	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247488040	chr1:247524679~247526752:-
STAD	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	5.9	8.61e-09	9.86e-06	0.38	0.3	Depression;	chr6:28303421	chr6:28943877~28944537:+
STAD	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-5.9	8.62e-09	9.87e-06	-0.24	-0.3	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
STAD	cis	rs10129255	0.957	rs10136781	ENSG00000280411.1	IGHV1-69-2	-5.9	8.62e-09	9.88e-06	-0.28	-0.3	Kawasaki disease;	chr14:106780451	chr14:106762092~106762588:-
STAD	cis	rs11148252	0.532	rs9526975	ENSG00000235660.1	LINC00345	-5.9	8.63e-09	9.88e-06	-0.34	-0.3	Lewy body disease;	chr13:52681669	chr13:52484161~52484680:-
STAD	cis	rs721917	0.586	rs2758550	ENSG00000225484.5	NUTM2B-AS1	-5.9	8.64e-09	9.89e-06	-0.39	-0.3	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79663088~79826594:-
STAD	cis	rs1005277	0.579	rs2474594	ENSG00000099251.13	HSD17B7P2	5.9	8.64e-09	9.9e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs11011461	ENSG00000099251.13	HSD17B7P2	5.9	8.64e-09	9.9e-06	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38356380~38378505:+
STAD	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	5.9	8.65e-09	9.9e-06	0.32	0.3	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	5.9	8.66e-09	9.92e-06	0.27	0.3	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
STAD	cis	rs9549260	0.755	rs2755214	ENSG00000229456.1	RLIMP1	5.9	8.67e-09	9.93e-06	0.27	0.3	Red blood cell count;	chr13:40575208	chr13:40618738~40621348:+
STAD	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	5.9	8.68e-09	9.94e-06	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
STAD	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-5.9	8.69e-09	9.95e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-5.9	8.71e-09	9.97e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-5.9	8.71e-09	9.97e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-5.9	8.71e-09	9.97e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-5.9	8.71e-09	9.97e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-5.9	8.71e-09	9.97e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-5.9	8.71e-09	9.97e-06	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
STAD	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-5.9	8.72e-09	9.98e-06	-0.46	-0.3	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
STAD	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-5.9	8.73e-09	9.99e-06	-0.36	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
STAD	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	5.9	8.73e-09	9.99e-06	0.48	0.3	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
STAD	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	5.9	8.73e-09	9.99e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	5.9	8.73e-09	9.99e-06	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
STAD	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	5.9	8.74e-09	9.99e-06	0.36	0.3	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
STAD	cis	rs875971	0.522	rs2008188	ENSG00000222364.1	RNU6-96P	-5.9	8.74e-09	1e-05	-0.34	-0.3	Aortic root size;	chr7:65964026	chr7:66395191~66395286:+
STAD	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-5.9	8.74e-09	1e-05	-0.35	-0.3	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
STAD	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-5.9	8.75e-09	1e-05	-0.33	-0.3	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
STAD	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-5.9	8.77e-09	1e-05	-0.25	-0.3	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
STAD	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	5.9	8.78e-09	1e-05	0.32	0.3	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
STAD	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	5.9	8.78e-09	1e-05	0.34	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
STAD	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-5.9	8.78e-09	1e-05	-0.35	-0.3	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
STAD	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	5.9	8.8e-09	1.01e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
STAD	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	5.9	8.8e-09	1.01e-05	0.5	0.3	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
STAD	cis	rs11722779	0.869	rs223350	ENSG00000230069.3	LRRC37A15P	-5.9	8.82e-09	1.01e-05	-0.33	-0.3	Schizophrenia;	chr4:102856899	chr4:102727274~102730721:-
STAD	cis	rs858239	0.699	rs858260	ENSG00000226816.2	AC005082.12	5.9	8.83e-09	1.01e-05	0.39	0.3	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23206013~23208045:+
STAD	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	5.9	8.85e-09	1.01e-05	0.33	0.3	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	5.9	8.85e-09	1.01e-05	0.33	0.3	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
STAD	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	5.9	8.85e-09	1.01e-05	0.35	0.3	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
STAD	cis	rs9395066	0.545	rs7749865	ENSG00000219384.1	RP11-491H9.3	-5.9	8.86e-09	1.01e-05	-0.29	-0.3	Height;	chr6:44950669	chr6:45158870~45159511:+
STAD	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	5.9	8.86e-09	1.01e-05	0.79	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
STAD	cis	rs7580658	0.676	rs4150407	ENSG00000200250.1	RNU6-1147P	-5.9	8.86e-09	1.01e-05	-0.29	-0.3	Protein C levels;	chr2:127292055	chr2:127316873~127316979:+
STAD	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	5.9	8.89e-09	1.02e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
STAD	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-5.9	8.9e-09	1.02e-05	-0.52	-0.3	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
STAD	cis	rs7615952	0.546	rs11718647	ENSG00000272840.1	RP11-379B18.6	5.9	8.9e-09	1.02e-05	0.5	0.3	Blood pressure (smoking interaction);	chr3:125633178	chr3:125774714~125797953:+
STAD	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-5.89	8.91e-09	1.02e-05	-0.47	-0.3	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
STAD	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	5.89	8.93e-09	1.02e-05	0.27	0.3	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
STAD	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-5.89	8.93e-09	1.02e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
STAD	cis	rs1707322	0.928	rs925524	ENSG00000280836.1	AL355480.1	5.89	8.93e-09	1.02e-05	0.41	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46031037	chr1:45581219~45581321:-
STAD	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-5.89	8.95e-09	1.02e-05	-0.35	-0.3	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-5.89	8.95e-09	1.02e-05	-0.35	-0.3	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-5.89	8.95e-09	1.02e-05	-0.35	-0.3	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
STAD	cis	rs9549260	0.755	rs2721071	ENSG00000229456.1	RLIMP1	5.89	8.96e-09	1.02e-05	0.27	0.3	Red blood cell count;	chr13:40570370	chr13:40618738~40621348:+
STAD	cis	rs12699921	0.598	rs1524774	ENSG00000279048.1	RP11-511H23.2	-5.89	8.96e-09	1.02e-05	-0.28	-0.3	Fibrinogen levels;	chr7:17827352	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.589	rs2723556	ENSG00000279048.1	RP11-511H23.2	-5.89	8.96e-09	1.02e-05	-0.28	-0.3	Fibrinogen levels;	chr7:17827972	chr7:17940503~17942922:+
STAD	cis	rs13113518	1	rs4865004	ENSG00000272969.1	RP11-528I4.2	5.89	8.96e-09	1.02e-05	0.38	0.3	Height;	chr4:55515118	chr4:55547112~55547889:+
STAD	cis	rs8141529	0.584	rs58004020	ENSG00000226471.5	CTA-292E10.6	-5.89	8.99e-09	1.03e-05	-0.36	-0.3	Lymphocyte counts;	chr22:28861062	chr22:28800683~28848559:+
STAD	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-5.89	9e-09	1.03e-05	-0.25	-0.3	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
STAD	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-5.89	9.01e-09	1.03e-05	-0.32	-0.3	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.957	rs12590799	ENSG00000280411.1	IGHV1-69-2	-5.89	9.01e-09	1.03e-05	-0.28	-0.3	Kawasaki disease;	chr14:106779713	chr14:106762092~106762588:-
STAD	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	5.89	9.02e-09	1.03e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
STAD	cis	rs10461617	0.535	rs7709874	ENSG00000271828.1	CTD-2310F14.1	5.89	9.04e-09	1.03e-05	0.37	0.3	Type 2 diabetes;	chr5:56751624	chr5:56927874~56929573:+
STAD	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-5.89	9.04e-09	1.03e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-5.89	9.04e-09	1.03e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
STAD	cis	rs9549260	0.753	rs9532562	ENSG00000229456.1	RLIMP1	5.89	9.04e-09	1.03e-05	0.34	0.3	Red blood cell count;	chr13:40579448	chr13:40618738~40621348:+
STAD	cis	rs240993	0.812	rs6929024	ENSG00000230177.1	RP5-1112D6.4	5.89	9.05e-09	1.03e-05	0.31	0.3	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111277932~111278742:+
STAD	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-5.89	9.05e-09	1.03e-05	-0.29	-0.3	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
STAD	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	5.89	9.09e-09	1.04e-05	0.38	0.3	Depression;	chr6:28301886	chr6:28943877~28944537:+
STAD	cis	rs1005277	0.579	rs1985707	ENSG00000099251.13	HSD17B7P2	5.89	9.09e-09	1.04e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.557	rs1854563	ENSG00000099251.13	HSD17B7P2	5.89	9.09e-09	1.04e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2505240	ENSG00000099251.13	HSD17B7P2	5.89	9.09e-09	1.04e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2505241	ENSG00000099251.13	HSD17B7P2	5.89	9.09e-09	1.04e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.54	rs2224248	ENSG00000099251.13	HSD17B7P2	5.89	9.09e-09	1.04e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38356380~38378505:+
STAD	cis	rs6496044	0.507	rs7175731	ENSG00000259407.1	RP11-158M2.3	5.89	9.1e-09	1.04e-05	0.33	0.3	Interstitial lung disease;	chr15:85611115	chr15:85744109~85750281:-
STAD	cis	rs6496044	0.507	rs1471455	ENSG00000259407.1	RP11-158M2.3	5.89	9.1e-09	1.04e-05	0.33	0.3	Interstitial lung disease;	chr15:85611496	chr15:85744109~85750281:-
STAD	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	5.89	9.1e-09	1.04e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	5.89	9.1e-09	1.04e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	5.89	9.1e-09	1.04e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	5.89	9.1e-09	1.04e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	5.89	9.1e-09	1.04e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-5.89	9.1e-09	1.04e-05	-0.33	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
STAD	cis	rs9425766	0.679	rs6681618	ENSG00000227373.4	RP11-160H22.5	-5.89	9.1e-09	1.04e-05	-0.35	-0.3	Life satisfaction;	chr1:174201203	chr1:174115300~174160004:-
STAD	cis	rs1426063	0.858	rs6823982	ENSG00000248165.1	RP11-44F21.2	5.89	9.11e-09	1.04e-05	0.52	0.3	QT interval;	chr4:75084961	chr4:74993877~75034824:-
STAD	cis	rs7829975	0.627	rs2979172	ENSG00000254340.1	RP11-10A14.3	5.89	9.12e-09	1.04e-05	0.37	0.3	Mood instability;	chr8:8452998	chr8:9141424~9145435:+
STAD	cis	rs13113518	1	rs7691799	ENSG00000272969.1	RP11-528I4.2	5.89	9.13e-09	1.04e-05	0.38	0.3	Height;	chr4:55545574	chr4:55547112~55547889:+
STAD	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	5.89	9.14e-09	1.04e-05	0.29	0.3	Depression;	chr6:28273215	chr6:28176188~28176674:+
STAD	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	5.89	9.15e-09	1.04e-05	0.34	0.3	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	5.89	9.15e-09	1.04e-05	0.34	0.3	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
STAD	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-5.89	9.15e-09	1.04e-05	-0.35	-0.3	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
STAD	cis	rs8141529	0.732	rs3788409	ENSG00000226471.5	CTA-292E10.6	-5.89	9.2e-09	1.05e-05	-0.35	-0.3	Lymphocyte counts;	chr22:28802163	chr22:28800683~28848559:+
STAD	cis	rs992157	0.932	rs56109829	ENSG00000237281.1	CATIP-AS2	-5.89	9.21e-09	1.05e-05	-0.31	-0.3	Colorectal cancer;	chr2:218285017	chr2:218326889~218357966:-
STAD	cis	rs1075265	0.588	rs1477258	ENSG00000235937.1	AC008280.1	5.89	9.22e-09	1.05e-05	0.27	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54029552~54030682:-
STAD	cis	rs6452524	0.967	rs1031901	ENSG00000243385.2	CTD-2110K23.1	5.89	9.23e-09	1.05e-05	0.32	0.3	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83201229~83202141:+
STAD	cis	rs858239	0.601	rs12539331	ENSG00000226816.2	AC005082.12	5.89	9.25e-09	1.05e-05	0.39	0.3	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23206013~23208045:+
STAD	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	5.89	9.25e-09	1.05e-05	0.35	0.3	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
STAD	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-5.89	9.26e-09	1.05e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-5.89	9.26e-09	1.05e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
STAD	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-5.89	9.27e-09	1.05e-05	-0.45	-0.3	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
STAD	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	5.89	9.28e-09	1.06e-05	0.45	0.3	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
STAD	cis	rs992157	0.687	rs35271699	ENSG00000237281.1	CATIP-AS2	-5.89	9.29e-09	1.06e-05	-0.3	-0.3	Colorectal cancer;	chr2:218252759	chr2:218326889~218357966:-
STAD	cis	rs9395066	0.545	rs4711805	ENSG00000219384.1	RP11-491H9.3	-5.89	9.31e-09	1.06e-05	-0.29	-0.3	Height;	chr6:44902365	chr6:45158870~45159511:+
STAD	cis	rs2273156	0.587	rs8014377	ENSG00000241052.1	RP11-173D9.1	-5.89	9.32e-09	1.06e-05	-0.36	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35061851	chr14:35144021~35144480:-
STAD	cis	rs9549260	0.709	rs2721072	ENSG00000229456.1	RLIMP1	5.89	9.32e-09	1.06e-05	0.27	0.3	Red blood cell count;	chr13:40570782	chr13:40618738~40621348:+
STAD	cis	rs4604732	0.536	rs10925056	ENSG00000227135.1	GCSAML-AS1	-5.89	9.33e-09	1.06e-05	-0.42	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247487170	chr1:247524679~247526752:-
STAD	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	5.89	9.33e-09	1.06e-05	0.29	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	5.89	9.33e-09	1.06e-05	0.29	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
STAD	cis	rs13113518	1	rs11724094	ENSG00000272969.1	RP11-528I4.2	5.89	9.33e-09	1.06e-05	0.38	0.3	Height;	chr4:55501479	chr4:55547112~55547889:+
STAD	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-5.89	9.35e-09	1.06e-05	-0.28	-0.3	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
STAD	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	5.89	9.35e-09	1.06e-05	0.51	0.3	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
STAD	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	5.89	9.35e-09	1.06e-05	0.25	0.3	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
STAD	cis	rs6452524	0.534	rs7724935	ENSG00000243385.2	CTD-2110K23.1	5.89	9.36e-09	1.06e-05	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.506	rs7707143	ENSG00000243385.2	CTD-2110K23.1	5.89	9.36e-09	1.06e-05	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.563	rs10473863	ENSG00000243385.2	CTD-2110K23.1	5.89	9.36e-09	1.06e-05	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83201229~83202141:+
STAD	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-5.89	9.37e-09	1.07e-05	-0.44	-0.3	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
STAD	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	5.89	9.38e-09	1.07e-05	0.33	0.3	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
STAD	cis	rs9395066	0.545	rs4711807	ENSG00000219384.1	RP11-491H9.3	-5.89	9.4e-09	1.07e-05	-0.29	-0.3	Height;	chr6:44943915	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.528	rs13211229	ENSG00000219384.1	RP11-491H9.3	-5.89	9.4e-09	1.07e-05	-0.29	-0.3	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44944725	chr6:45158870~45159511:+
STAD	cis	rs10129255	0.957	rs10150241	ENSG00000280411.1	IGHV1-69-2	5.88	9.41e-09	1.07e-05	0.28	0.3	Kawasaki disease;	chr14:106775945	chr14:106762092~106762588:-
STAD	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-5.88	9.42e-09	1.07e-05	-0.44	-0.3	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
STAD	cis	rs8098244	0.541	rs1711445	ENSG00000267301.1	RPL23AP77	-5.88	9.42e-09	1.07e-05	-0.35	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23673901	chr18:23709825~23710287:-
STAD	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	5.88	9.43e-09	1.07e-05	0.34	0.3	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
STAD	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	5.88	9.43e-09	1.07e-05	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
STAD	cis	rs1005277	0.579	rs1548255	ENSG00000099251.13	HSD17B7P2	5.88	9.44e-09	1.07e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474586	ENSG00000099251.13	HSD17B7P2	5.88	9.44e-09	1.07e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38356380~38378505:+
STAD	cis	rs2273156	0.517	rs8007274	ENSG00000241052.1	RP11-173D9.1	-5.88	9.47e-09	1.08e-05	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043012	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.706	rs8009093	ENSG00000241052.1	RP11-173D9.1	-5.88	9.47e-09	1.08e-05	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043497	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.57	rs1028449	ENSG00000241052.1	RP11-173D9.1	-5.88	9.47e-09	1.08e-05	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043789	chr14:35144021~35144480:-
STAD	cis	rs1426063	0.614	rs79750906	ENSG00000248165.1	RP11-44F21.2	5.88	9.48e-09	1.08e-05	0.63	0.3	QT interval;	chr4:75139193	chr4:74993877~75034824:-
STAD	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	5.88	9.5e-09	1.08e-05	0.31	0.3	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
STAD	cis	rs2283792	0.935	rs5750113	ENSG00000228050.1	TOP3BP1	5.88	9.51e-09	1.08e-05	0.35	0.3	Multiple sclerosis;	chr22:21865784	chr22:22223187~22224566:-
STAD	cis	rs7829975	0.591	rs12677543	ENSG00000254340.1	RP11-10A14.3	5.88	9.53e-09	1.08e-05	0.36	0.3	Mood instability;	chr8:8786764	chr8:9141424~9145435:+
STAD	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-5.88	9.53e-09	1.08e-05	-0.26	-0.3	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
STAD	cis	rs3806843	0.735	rs801188	ENSG00000202111.1	VTRNA1-2	5.88	9.53e-09	1.08e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr5:140718925~140719013:+
STAD	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-5.88	9.54e-09	1.08e-05	-0.27	-0.3	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-5.88	9.54e-09	1.08e-05	-0.27	-0.3	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-5.88	9.54e-09	1.08e-05	-0.27	-0.3	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
STAD	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	5.88	9.55e-09	1.08e-05	0.45	0.3	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
STAD	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	5.88	9.57e-09	1.09e-05	0.32	0.3	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
STAD	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	5.88	9.58e-09	1.09e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	5.88	9.58e-09	1.09e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
STAD	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-5.88	9.58e-09	1.09e-05	-0.34	-0.3	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
STAD	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	5.88	9.59e-09	1.09e-05	0.37	0.3	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
STAD	cis	rs9860428	0.844	rs16860225	ENSG00000240057.4	RP11-572M11.4	5.88	9.6e-09	1.09e-05	0.28	0.3	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904882	chr3:113019532~113183301:+
STAD	cis	rs2273156	0.57	rs8013540	ENSG00000241052.1	RP11-173D9.1	-5.88	9.6e-09	1.09e-05	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35044554	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.57	rs60693825	ENSG00000241052.1	RP11-173D9.1	-5.88	9.6e-09	1.09e-05	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045250	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.587	rs3809449	ENSG00000241052.1	RP11-173D9.1	-5.88	9.6e-09	1.09e-05	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045751	chr14:35144021~35144480:-
STAD	cis	rs1005277	0.579	rs2474584	ENSG00000099251.13	HSD17B7P2	5.88	9.62e-09	1.09e-05	0.34	0.3	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38356380~38378505:+
STAD	cis	rs7927771	0.839	rs59360790	ENSG00000280615.1	Y_RNA	-5.88	9.63e-09	1.09e-05	-0.3	-0.3	Subjective well-being;	chr11:47647623	chr11:47614898~47614994:-
STAD	cis	rs992157	1	rs2292553	ENSG00000237281.1	CATIP-AS2	-5.88	9.64e-09	1.09e-05	-0.31	-0.3	Colorectal cancer;	chr2:218282080	chr2:218326889~218357966:-
STAD	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	5.88	9.64e-09	1.09e-05	0.32	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
STAD	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	5.88	9.65e-09	1.09e-05	0.32	0.3	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
STAD	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	5.88	9.66e-09	1.09e-05	0.35	0.3	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
STAD	cis	rs6452524	0.534	rs17284134	ENSG00000243385.2	CTD-2110K23.1	-5.88	9.66e-09	1.09e-05	-0.36	-0.3	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83201229~83202141:+
STAD	cis	rs6782228	0.675	rs4857918	ENSG00000277250.1	Metazoa_SRP	-5.88	9.68e-09	1.1e-05	-0.31	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128673681~128674021:-
STAD	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-5.88	9.68e-09	1.1e-05	-0.39	-0.3	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
STAD	cis	rs858239	0.537	rs6942981	ENSG00000226816.2	AC005082.12	5.88	9.69e-09	1.1e-05	0.39	0.3	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23206013~23208045:+
STAD	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-5.88	9.69e-09	1.1e-05	-0.45	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
STAD	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	5.88	9.7e-09	1.1e-05	0.37	0.3	Height;	chr6:109383848	chr6:109382795~109383666:+
STAD	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	5.88	9.7e-09	1.1e-05	0.25	0.3	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
STAD	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	5.88	9.7e-09	1.1e-05	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
STAD	cis	rs10849893	0.576	rs889970	ENSG00000258435.1	RP11-711D18.2	-5.88	9.7e-09	1.1e-05	-0.33	-0.3	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121418414	chr12:121391962~121399859:+
STAD	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-5.88	9.72e-09	1.1e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
STAD	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	5.88	9.72e-09	1.1e-05	0.34	0.3	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
STAD	cis	rs3806843	0.735	rs801168	ENSG00000202111.1	VTRNA1-2	5.88	9.72e-09	1.1e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr5:140718925~140719013:+
STAD	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-5.88	9.73e-09	1.1e-05	-0.29	-0.3	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
STAD	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	5.88	9.73e-09	1.1e-05	0.37	0.3	Height;	chr6:109382188	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	5.88	9.73e-09	1.1e-05	0.37	0.3	Height;	chr6:109383239	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	5.88	9.73e-09	1.1e-05	0.37	0.3	Height;	chr6:109383248	chr6:109382795~109383666:+
STAD	cis	rs3806843	0.676	rs2245643	ENSG00000202111.1	VTRNA1-2	5.88	9.73e-09	1.1e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr5:140718925~140719013:+
STAD	cis	rs992157	0.798	rs1017698	ENSG00000237281.1	CATIP-AS2	5.88	9.74e-09	1.1e-05	0.3	0.3	Colorectal cancer;	chr2:218305802	chr2:218326889~218357966:-
STAD	cis	rs453301	0.682	rs2929308	ENSG00000254340.1	RP11-10A14.3	-5.88	9.74e-09	1.1e-05	-0.38	-0.3	Joint mobility (Beighton score);	chr8:9226611	chr8:9141424~9145435:+
STAD	cis	rs73219805	0.554	rs13266943	ENSG00000228451.3	SDAD1P1	-5.88	9.77e-09	1.11e-05	-0.42	-0.3	Schizophrenia;	chr8:26336629	chr8:26379259~26382953:-
STAD	cis	rs7927771	0.864	rs755554	ENSG00000280615.1	Y_RNA	5.88	9.8e-09	1.11e-05	0.31	0.3	Subjective well-being;	chr11:47410483	chr11:47614898~47614994:-
STAD	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	5.88	9.8e-09	1.11e-05	0.5	0.3	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000224205.1	AP000351.4	5.88	9.81e-09	1.11e-05	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23987320~23991421:-
STAD	cis	rs7580658	0.613	rs12463538	ENSG00000200250.1	RNU6-1147P	5.88	9.82e-09	1.11e-05	0.29	0.3	Protein C levels;	chr2:127439278	chr2:127316873~127316979:+
STAD	cis	rs227275	0.525	rs2086499	ENSG00000230069.3	LRRC37A15P	-5.88	9.83e-09	1.11e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102727274~102730721:-
STAD	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	5.88	9.83e-09	1.11e-05	0.26	0.3	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	5.88	9.83e-09	1.11e-05	0.26	0.3	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
STAD	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-5.88	9.83e-09	1.11e-05	-0.35	-0.3	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
STAD	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-5.88	9.86e-09	1.12e-05	-0.3	-0.3	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
STAD	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-5.88	9.87e-09	1.12e-05	-0.41	-0.3	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
STAD	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	5.88	9.87e-09	1.12e-05	0.32	0.3	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	5.88	9.87e-09	1.12e-05	0.32	0.3	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
STAD	cis	rs9400467	0.528	rs456865	ENSG00000230177.1	RP5-1112D6.4	-5.88	9.88e-09	1.12e-05	-0.27	-0.3	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111277932~111278742:+
STAD	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-5.88	9.88e-09	1.12e-05	-0.31	-0.3	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
STAD	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	5.88	9.89e-09	1.12e-05	0.35	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
STAD	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	5.88	9.89e-09	1.12e-05	0.33	0.3	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
STAD	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	5.88	9.9e-09	1.12e-05	0.4	0.3	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
STAD	cis	rs8098244	0.603	rs2337186	ENSG00000267301.1	RPL23AP77	-5.88	9.91e-09	1.12e-05	-0.35	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732088	chr18:23709825~23710287:-
STAD	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	5.88	9.91e-09	1.12e-05	0.35	0.3	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
STAD	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-5.88	9.93e-09	1.12e-05	-0.35	-0.3	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
STAD	cis	rs858239	0.539	rs10247268	ENSG00000226816.2	AC005082.12	5.88	9.93e-09	1.12e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs6461694	ENSG00000226816.2	AC005082.12	5.88	9.93e-09	1.12e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23206013~23208045:+
STAD	cis	rs858239	0.508	rs7805071	ENSG00000226816.2	AC005082.12	5.88	9.93e-09	1.12e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23206013~23208045:+
STAD	cis	rs858239	0.508	rs7805085	ENSG00000226816.2	AC005082.12	5.88	9.93e-09	1.12e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23206013~23208045:+
STAD	cis	rs2439831	0.681	rs478104	ENSG00000205771.5	CATSPER2P1	-5.87	9.94e-09	1.12e-05	-0.4	-0.3	Lung cancer in ever smokers;	chr15:43302702	chr15:43726918~43747094:-
STAD	cis	rs9549260	0.753	rs9532578	ENSG00000229456.1	RLIMP1	5.87	9.96e-09	1.12e-05	0.35	0.3	Red blood cell count;	chr13:40662270	chr13:40618738~40621348:+
STAD	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	5.87	9.96e-09	1.12e-05	0.34	0.3	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
STAD	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	5.87	9.96e-09	1.13e-05	0.51	0.3	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
STAD	cis	rs1729407	0.814	rs2071521	ENSG00000280143.1	AP000892.6	-5.87	9.97e-09	1.13e-05	-0.22	-0.3	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117204967~117210292:+
STAD	cis	rs7924176	0.521	rs12415957	ENSG00000236900.1	TIMM9P1	5.87	9.99e-09	1.13e-05	0.31	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74344550~74344805:-
STAD	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	5.87	9.99e-09	1.13e-05	0.38	0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
STAD	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-5.87	1e-08	1.13e-05	-0.43	-0.3	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
STAD	cis	rs7487075	0.93	rs4076484	ENSG00000272369.1	RP11-446N19.1	5.87	1e-08	1.13e-05	0.35	0.3	Itch intensity from mosquito bite;	chr12:46440129	chr12:46537502~46652550:+
STAD	cis	rs7829975	0.659	rs4382480	ENSG00000254340.1	RP11-10A14.3	5.87	1e-08	1.13e-05	0.36	0.3	Mood instability;	chr8:8863963	chr8:9141424~9145435:+
STAD	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-5.87	1e-08	1.13e-05	-0.25	-0.3	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
STAD	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	5.87	1e-08	1.13e-05	0.36	0.3	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
STAD	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	5.87	1.01e-08	1.13e-05	0.37	0.3	Height;	chr6:109384807	chr6:109382795~109383666:+
STAD	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-5.87	1.01e-08	1.14e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
STAD	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	5.87	1.01e-08	1.14e-05	0.33	0.3	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
STAD	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-5.87	1.01e-08	1.14e-05	-0.32	-0.3	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
STAD	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-5.87	1.01e-08	1.14e-05	-0.37	-0.3	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
STAD	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-5.87	1.01e-08	1.14e-05	-0.29	-0.3	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
STAD	cis	rs7555523	0.887	rs12691499	ENSG00000224358.1	RP11-466F5.8	-5.87	1.01e-08	1.14e-05	-0.51	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718428	chr1:165768929~165775176:+
STAD	cis	rs7555523	0.83	rs12691500	ENSG00000224358.1	RP11-466F5.8	-5.87	1.01e-08	1.14e-05	-0.51	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718524	chr1:165768929~165775176:+
STAD	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	5.87	1.01e-08	1.14e-05	0.35	0.3	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	5.87	1.01e-08	1.14e-05	0.35	0.3	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	5.87	1.01e-08	1.14e-05	0.35	0.3	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	5.87	1.01e-08	1.14e-05	0.35	0.3	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
STAD	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	5.87	1.01e-08	1.14e-05	0.32	0.3	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
STAD	cis	rs875971	0.522	rs1701760	ENSG00000222364.1	RNU6-96P	-5.87	1.01e-08	1.14e-05	-0.34	-0.3	Aortic root size;	chr7:66008701	chr7:66395191~66395286:+
STAD	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	5.87	1.01e-08	1.14e-05	0.79	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
STAD	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	5.87	1.01e-08	1.14e-05	0.31	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
STAD	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	5.87	1.01e-08	1.14e-05	0.31	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
STAD	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	5.87	1.01e-08	1.14e-05	0.3	0.3	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	5.87	1.01e-08	1.14e-05	0.3	0.3	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
STAD	cis	rs7555523	0.887	rs4657475	ENSG00000224358.1	RP11-466F5.8	-5.87	1.01e-08	1.14e-05	-0.51	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717938	chr1:165768929~165775176:+
STAD	cis	rs7555523	0.887	rs4656461	ENSG00000224358.1	RP11-466F5.8	-5.87	1.01e-08	1.14e-05	-0.51	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717968	chr1:165768929~165775176:+
STAD	cis	rs8067354	0.574	rs7219089	ENSG00000266701.1	AC005702.4	5.87	1.01e-08	1.14e-05	0.45	0.3	Hemoglobin concentration;	chr17:59955504	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.54	rs7221472	ENSG00000266701.1	AC005702.4	5.87	1.01e-08	1.14e-05	0.45	0.3	Hemoglobin concentration;	chr17:59959376	chr17:60042546~60042627:-
STAD	cis	rs6496044	0.507	rs8034676	ENSG00000259407.1	RP11-158M2.3	-5.87	1.02e-08	1.15e-05	-0.32	-0.3	Interstitial lung disease;	chr15:85616031	chr15:85744109~85750281:-
STAD	cis	rs10129255	0.912	rs61996059	ENSG00000223648.3	IGHV3-64	5.87	1.02e-08	1.15e-05	0.27	0.3	Kawasaki disease;	chr14:106716897	chr14:106643132~106658258:-
STAD	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-5.87	1.02e-08	1.15e-05	-0.33	-0.3	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
STAD	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-5.87	1.02e-08	1.15e-05	-0.33	-0.3	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-5.87	1.02e-08	1.15e-05	-0.33	-0.3	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
STAD	cis	rs2239557	1	rs2358633	ENSG00000259065.1	RP5-1021I20.1	5.87	1.02e-08	1.15e-05	0.36	0.3	Common traits (Other);	chr14:74180715	chr14:73787360~73803270:+
STAD	cis	rs6452524	0.532	rs27363	ENSG00000243385.2	CTD-2110K23.1	5.87	1.03e-08	1.16e-05	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83201229~83202141:+
STAD	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	5.87	1.03e-08	1.16e-05	0.35	0.3	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
STAD	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-5.87	1.03e-08	1.16e-05	-0.37	-0.3	Height;	chr6:109360458	chr6:109382795~109383666:+
STAD	cis	rs9395066	0.545	rs1831310	ENSG00000219384.1	RP11-491H9.3	-5.87	1.03e-08	1.16e-05	-0.29	-0.3	Height;	chr6:45008988	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.51	rs4714832	ENSG00000219384.1	RP11-491H9.3	-5.87	1.03e-08	1.16e-05	-0.29	-0.3	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45010446	chr6:45158870~45159511:+
STAD	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	5.87	1.03e-08	1.16e-05	0.39	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
STAD	cis	rs3806843	0.735	rs2530235	ENSG00000202111.1	VTRNA1-2	5.87	1.03e-08	1.16e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr5:140718925~140719013:+
STAD	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	5.87	1.03e-08	1.16e-05	0.29	0.3	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
STAD	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-5.87	1.03e-08	1.16e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
STAD	cis	rs7927771	0.839	rs7124681	ENSG00000280615.1	Y_RNA	-5.87	1.03e-08	1.16e-05	-0.3	-0.3	Subjective well-being;	chr11:47508395	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.801	rs12798028	ENSG00000280615.1	Y_RNA	-5.87	1.03e-08	1.16e-05	-0.3	-0.3	Subjective well-being;	chr11:47583087	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.839	rs11039308	ENSG00000280615.1	Y_RNA	-5.87	1.03e-08	1.16e-05	-0.3	-0.3	Subjective well-being;	chr11:47600860	chr11:47614898~47614994:-
STAD	cis	rs1005277	0.579	rs2505194	ENSG00000099251.13	HSD17B7P2	5.87	1.03e-08	1.16e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38356380~38378505:+
STAD	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	5.87	1.03e-08	1.16e-05	0.48	0.3	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
STAD	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-5.87	1.03e-08	1.16e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-5.87	1.03e-08	1.16e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
STAD	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-5.87	1.03e-08	1.16e-05	-0.44	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
STAD	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-5.87	1.03e-08	1.16e-05	-0.29	-0.3	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
STAD	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-5.87	1.04e-08	1.16e-05	-0.33	-0.3	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
STAD	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-5.87	1.04e-08	1.17e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-5.87	1.04e-08	1.17e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
STAD	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	5.87	1.04e-08	1.17e-05	0.48	0.3	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
STAD	cis	rs728616	0.867	rs56198874	ENSG00000225484.5	NUTM2B-AS1	-5.87	1.04e-08	1.17e-05	-0.65	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs17884637	ENSG00000225484.5	NUTM2B-AS1	-5.87	1.04e-08	1.17e-05	-0.65	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:79663088~79826594:-
STAD	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-5.87	1.04e-08	1.17e-05	-0.42	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
STAD	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	5.87	1.04e-08	1.17e-05	0.35	0.3	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
STAD	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-5.87	1.04e-08	1.18e-05	-0.35	-0.3	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
STAD	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-5.87	1.04e-08	1.18e-05	-0.32	-0.3	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
STAD	cis	rs11079159	0.606	rs4239193	ENSG00000263096.1	RP11-515O17.2	5.87	1.05e-08	1.18e-05	0.37	0.3	QRS duration;	chr17:55299163	chr17:55271504~55273653:-
STAD	cis	rs9549260	0.816	rs7328594	ENSG00000229456.1	RLIMP1	5.87	1.05e-08	1.18e-05	0.28	0.3	Red blood cell count;	chr13:40679627	chr13:40618738~40621348:+
STAD	cis	rs7924176	0.521	rs12357370	ENSG00000236900.1	TIMM9P1	-5.87	1.05e-08	1.18e-05	-0.31	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74344550~74344805:-
STAD	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	5.87	1.05e-08	1.18e-05	0.46	0.3	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
STAD	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	5.87	1.05e-08	1.18e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
STAD	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-5.86	1.05e-08	1.18e-05	-0.41	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
STAD	cis	rs711244	0.748	rs11124555	ENSG00000252756.1	RNU6-577P	-5.86	1.05e-08	1.18e-05	-0.33	-0.3	Mean platelet volume;	chr2:36949070	chr2:36867398~36867495:-
STAD	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-5.86	1.05e-08	1.18e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
STAD	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-5.86	1.05e-08	1.18e-05	-0.33	-0.3	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
STAD	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-5.86	1.05e-08	1.18e-05	-0.32	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
STAD	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	5.86	1.05e-08	1.18e-05	0.38	0.3	Depression;	chr6:28323463	chr6:28943877~28944537:+
STAD	cis	rs2439831	1	rs527921	ENSG00000249839.1	AC011330.5	5.86	1.05e-08	1.18e-05	0.45	0.3	Lung cancer in ever smokers;	chr15:43478218	chr15:43663654~43684339:-
STAD	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-5.86	1.06e-08	1.19e-05	-0.33	-0.3	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
STAD	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	5.86	1.06e-08	1.19e-05	0.39	0.3	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
STAD	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-5.86	1.06e-08	1.19e-05	-0.26	-0.3	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
STAD	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	5.86	1.06e-08	1.19e-05	0.33	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
STAD	cis	rs13113518	0.966	rs7677952	ENSG00000272969.1	RP11-528I4.2	5.86	1.06e-08	1.19e-05	0.38	0.3	Height;	chr4:55425312	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs1047354	ENSG00000272969.1	RP11-528I4.2	5.86	1.06e-08	1.19e-05	0.38	0.3	Height;	chr4:55429416	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs1056547	ENSG00000272969.1	RP11-528I4.2	5.86	1.06e-08	1.19e-05	0.38	0.3	Height;	chr4:55430596	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs1056545	ENSG00000272969.1	RP11-528I4.2	5.86	1.06e-08	1.19e-05	0.38	0.3	Height;	chr4:55430730	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs5863	ENSG00000272969.1	RP11-528I4.2	5.86	1.06e-08	1.19e-05	0.38	0.3	Height;	chr4:55430740	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs6828570	ENSG00000272969.1	RP11-528I4.2	5.86	1.06e-08	1.19e-05	0.38	0.3	Height;	chr4:55431595	chr4:55547112~55547889:+
STAD	cis	rs2273156	0.587	rs61125355	ENSG00000241052.1	RP11-173D9.1	-5.86	1.06e-08	1.19e-05	-0.36	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35065995	chr14:35144021~35144480:-
STAD	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	5.86	1.06e-08	1.19e-05	0.31	0.3	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
STAD	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-5.86	1.06e-08	1.19e-05	-0.35	-0.3	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
STAD	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	5.86	1.06e-08	1.19e-05	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
STAD	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	5.86	1.06e-08	1.2e-05	0.37	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
STAD	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	5.86	1.06e-08	1.2e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
STAD	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	5.86	1.07e-08	1.2e-05	0.35	0.3	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
STAD	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-5.86	1.07e-08	1.2e-05	-0.42	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
STAD	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	5.86	1.07e-08	1.2e-05	0.3	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
STAD	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-5.86	1.07e-08	1.2e-05	-0.44	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
STAD	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-5.86	1.07e-08	1.2e-05	-0.31	-0.3	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
STAD	cis	rs3806843	0.735	rs778595	ENSG00000202111.1	VTRNA1-2	5.86	1.07e-08	1.2e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr5:140718925~140719013:+
STAD	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-5.86	1.07e-08	1.2e-05	-0.37	-0.3	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
STAD	cis	rs7829975	0.84	rs572366	ENSG00000253981.4	ALG1L13P	5.86	1.07e-08	1.21e-05	0.35	0.3	Mood instability;	chr8:8721284	chr8:8236003~8244667:-
STAD	cis	rs10129255	0.957	rs8009464	ENSG00000280411.1	IGHV1-69-2	-5.86	1.07e-08	1.21e-05	-0.28	-0.3	Kawasaki disease;	chr14:106777611	chr14:106762092~106762588:-
STAD	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	5.86	1.07e-08	1.21e-05	0.29	0.3	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
STAD	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	5.86	1.08e-08	1.21e-05	0.32	0.3	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
STAD	cis	rs6452524	0.534	rs10061690	ENSG00000243385.2	CTD-2110K23.1	5.86	1.08e-08	1.21e-05	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83201229~83202141:+
STAD	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	5.86	1.08e-08	1.21e-05	0.38	0.3	Height;	chr6:109471826	chr6:109382795~109383666:+
STAD	cis	rs992157	0.798	rs10932772	ENSG00000237281.1	CATIP-AS2	-5.86	1.08e-08	1.21e-05	-0.3	-0.3	Colorectal cancer;	chr2:218312425	chr2:218326889~218357966:-
STAD	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	5.86	1.08e-08	1.21e-05	0.34	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
STAD	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	5.86	1.09e-08	1.22e-05	0.48	0.3	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
STAD	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-5.86	1.09e-08	1.22e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
STAD	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	5.86	1.09e-08	1.22e-05	0.34	0.3	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
STAD	cis	rs2921036	0.505	rs35190619	ENSG00000254340.1	RP11-10A14.3	-5.86	1.09e-08	1.22e-05	-0.45	-0.3	Neuroticism;	chr8:8504313	chr8:9141424~9145435:+
STAD	cis	rs3806843	0.657	rs2563283	ENSG00000202111.1	VTRNA1-2	5.86	1.09e-08	1.22e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.771	rs2563336	ENSG00000202111.1	VTRNA1-2	5.86	1.09e-08	1.22e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr5:140718925~140719013:+
STAD	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	5.86	1.09e-08	1.22e-05	0.37	0.3	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
STAD	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-5.86	1.09e-08	1.22e-05	-0.4	-0.3	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
STAD	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-5.86	1.1e-08	1.23e-05	-0.36	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	5.86	1.1e-08	1.23e-05	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
STAD	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	5.86	1.1e-08	1.23e-05	0.31	0.3	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
STAD	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	5.86	1.1e-08	1.23e-05	0.31	0.3	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
STAD	cis	rs8141529	0.719	rs2097461	ENSG00000226471.5	CTA-292E10.6	-5.86	1.1e-08	1.23e-05	-0.35	-0.3	Lymphocyte counts;	chr22:28795891	chr22:28800683~28848559:+
STAD	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-5.86	1.1e-08	1.23e-05	-0.51	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
STAD	cis	rs10129255	1	rs11621409	ENSG00000280411.1	IGHV1-69-2	-5.86	1.1e-08	1.23e-05	-0.29	-0.3	Kawasaki disease;	chr14:106695603	chr14:106762092~106762588:-
STAD	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-5.86	1.1e-08	1.24e-05	-0.33	-0.3	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
STAD	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	5.86	1.11e-08	1.24e-05	0.31	0.3	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
STAD	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-5.86	1.11e-08	1.24e-05	-0.28	-0.3	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-5.86	1.11e-08	1.24e-05	-0.28	-0.3	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-5.86	1.11e-08	1.24e-05	-0.28	-0.3	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
STAD	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-5.85	1.11e-08	1.24e-05	-0.42	-0.3	QT interval;	chr16:28877088	chr16:28700294~28701540:-
STAD	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-5.85	1.11e-08	1.24e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
STAD	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-5.85	1.11e-08	1.24e-05	-0.49	-0.3	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
STAD	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-5.85	1.12e-08	1.25e-05	-0.51	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
STAD	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-5.85	1.12e-08	1.25e-05	-0.51	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
STAD	cis	rs748404	1	rs66651343	ENSG00000249839.1	AC011330.5	-5.85	1.12e-08	1.25e-05	-0.48	-0.3	Lung cancer;	chr15:43265806	chr15:43663654~43684339:-
STAD	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-5.85	1.12e-08	1.25e-05	-0.31	-0.3	Asthma;	chr2:102393077	chr2:102438713~102440475:+
STAD	cis	rs7829975	0.627	rs876954	ENSG00000254340.1	RP11-10A14.3	5.85	1.13e-08	1.26e-05	0.37	0.3	Mood instability;	chr8:8453413	chr8:9141424~9145435:+
STAD	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-5.85	1.13e-08	1.26e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-5.85	1.13e-08	1.26e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
STAD	cis	rs7826238	0.517	rs35144760	ENSG00000254340.1	RP11-10A14.3	-5.85	1.13e-08	1.26e-05	-0.45	-0.3	Systolic blood pressure;	chr8:8504213	chr8:9141424~9145435:+
STAD	cis	rs7580658	0.68	rs12468304	ENSG00000200250.1	RNU6-1147P	-5.85	1.13e-08	1.26e-05	-0.29	-0.3	Protein C levels;	chr2:127436236	chr2:127316873~127316979:+
STAD	cis	rs12699921	0.632	rs2691595	ENSG00000279048.1	RP11-511H23.2	-5.85	1.13e-08	1.26e-05	-0.28	-0.3	Fibrinogen levels;	chr7:17780421	chr7:17940503~17942922:+
STAD	cis	rs9549260	0.848	rs966968	ENSG00000229456.1	RLIMP1	-5.85	1.13e-08	1.26e-05	-0.27	-0.3	Red blood cell count;	chr13:40673900	chr13:40618738~40621348:+
STAD	cis	rs4604732	0.631	rs60311891	ENSG00000227135.1	GCSAML-AS1	-5.85	1.13e-08	1.26e-05	-0.41	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459825	chr1:247524679~247526752:-
STAD	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	5.85	1.13e-08	1.27e-05	0.32	0.3	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
STAD	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-5.85	1.13e-08	1.27e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-5.85	1.13e-08	1.27e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-5.85	1.13e-08	1.27e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
STAD	cis	rs228614	0.51	rs223412	ENSG00000230069.3	LRRC37A15P	-5.85	1.14e-08	1.27e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102727274~102730721:-
STAD	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	5.85	1.14e-08	1.27e-05	0.79	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
STAD	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-5.85	1.14e-08	1.27e-05	-0.29	-0.3	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-5.85	1.14e-08	1.27e-05	-0.29	-0.3	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
STAD	cis	rs9549260	0.727	rs4603422	ENSG00000229456.1	RLIMP1	5.85	1.14e-08	1.27e-05	0.27	0.3	Red blood cell count;	chr13:40574216	chr13:40618738~40621348:+
STAD	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	5.85	1.14e-08	1.27e-05	0.36	0.3	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
STAD	cis	rs728616	0.867	rs12413715	ENSG00000225484.5	NUTM2B-AS1	-5.85	1.14e-08	1.27e-05	-0.64	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:79663088~79826594:-
STAD	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	5.85	1.14e-08	1.27e-05	0.33	0.3	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
STAD	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	5.85	1.14e-08	1.28e-05	0.32	0.3	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
STAD	cis	rs3806843	0.712	rs2530244	ENSG00000202111.1	VTRNA1-2	5.85	1.14e-08	1.28e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140729570	chr5:140718925~140719013:+
STAD	cis	rs2337406	1	rs17095456	ENSG00000211972.2	IGHV3-66	5.85	1.14e-08	1.28e-05	0.34	0.3	Alzheimer's disease (late onset);	chr14:106676559	chr14:106675017~106675544:-
STAD	cis	rs6782228	0.606	rs2811488	ENSG00000277250.1	Metazoa_SRP	-5.85	1.15e-08	1.28e-05	-0.31	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128673681~128674021:-
STAD	cis	rs13113518	1	rs13116194	ENSG00000272969.1	RP11-528I4.2	5.85	1.15e-08	1.28e-05	0.37	0.3	Height;	chr4:55531150	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs13117836	ENSG00000272969.1	RP11-528I4.2	5.85	1.15e-08	1.28e-05	0.37	0.3	Height;	chr4:55531218	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs7668429	ENSG00000272969.1	RP11-528I4.2	5.85	1.15e-08	1.28e-05	0.37	0.3	Height;	chr4:55531811	chr4:55547112~55547889:+
STAD	cis	rs7927771	0.864	rs3781626	ENSG00000280615.1	Y_RNA	-5.85	1.15e-08	1.28e-05	-0.31	-0.3	Subjective well-being;	chr11:47421342	chr11:47614898~47614994:-
STAD	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-5.85	1.15e-08	1.28e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
STAD	cis	rs2337406	1	rs11850600	ENSG00000211972.2	IGHV3-66	5.85	1.15e-08	1.28e-05	0.34	0.3	Alzheimer's disease (late onset);	chr14:106670765	chr14:106675017~106675544:-
STAD	cis	rs9400467	0.508	rs1676863	ENSG00000230177.1	RP5-1112D6.4	-5.85	1.15e-08	1.28e-05	-0.27	-0.3	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111277932~111278742:+
STAD	cis	rs858239	0.508	rs10242104	ENSG00000226816.2	AC005082.12	5.85	1.15e-08	1.29e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23206013~23208045:+
STAD	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-5.85	1.15e-08	1.29e-05	-0.32	-0.3	Breast cancer;	chr11:743813	chr11:777578~784297:+
STAD	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-5.85	1.15e-08	1.29e-05	-0.31	-0.3	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-5.85	1.15e-08	1.29e-05	-0.31	-0.3	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
STAD	cis	rs858239	0.539	rs4377861	ENSG00000226816.2	AC005082.12	5.85	1.16e-08	1.29e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23206013~23208045:+
STAD	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	5.85	1.16e-08	1.29e-05	0.42	0.3	QT interval;	chr16:28860645	chr16:28700294~28701540:-
STAD	cis	rs3758911	0.828	rs11212207	ENSG00000261098.1	RP11-819C21.1	5.85	1.16e-08	1.29e-05	0.27	0.3	Coronary artery disease;	chr11:107404796	chr11:107312132~107316271:-
STAD	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	5.85	1.16e-08	1.29e-05	0.31	0.3	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
STAD	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	5.85	1.16e-08	1.29e-05	0.33	0.3	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
STAD	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	5.85	1.16e-08	1.3e-05	0.29	0.3	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
STAD	cis	rs7487075	1	rs7487075	ENSG00000257261.4	RP11-96H19.1	5.85	1.16e-08	1.3e-05	0.35	0.3	Itch intensity from mosquito bite;	chr12:46435135	chr12:46383679~46876159:+
STAD	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-5.85	1.16e-08	1.3e-05	-0.26	-0.3	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.957	rs8009638	ENSG00000223648.3	IGHV3-64	5.85	1.16e-08	1.3e-05	0.26	0.3	Kawasaki disease;	chr14:106777570	chr14:106643132~106658258:-
STAD	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-5.85	1.16e-08	1.3e-05	-0.32	-0.3	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
STAD	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-5.85	1.17e-08	1.3e-05	-0.29	-0.3	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
STAD	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-5.85	1.17e-08	1.3e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
STAD	cis	rs721917	0.526	rs2256574	ENSG00000225484.5	NUTM2B-AS1	-5.85	1.17e-08	1.3e-05	-0.39	-0.3	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79663088~79826594:-
STAD	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	5.85	1.17e-08	1.3e-05	0.35	0.3	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
STAD	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-5.85	1.17e-08	1.3e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
STAD	cis	rs2273156	0.517	rs77803033	ENSG00000241052.1	RP11-173D9.1	-5.84	1.17e-08	1.3e-05	-0.37	-0.3	Immunoglobulin light chain (AL) amyloidosis;	chr14:35042646	chr14:35144021~35144480:-
STAD	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	5.84	1.18e-08	1.31e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	5.84	1.18e-08	1.31e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
STAD	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-5.84	1.18e-08	1.31e-05	-0.29	-0.3	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-5.84	1.18e-08	1.31e-05	-0.29	-0.3	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-5.84	1.18e-08	1.31e-05	-0.29	-0.3	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
STAD	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	5.84	1.18e-08	1.31e-05	0.32	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
STAD	cis	rs7487075	0.78	rs12320197	ENSG00000272369.1	RP11-446N19.1	5.84	1.18e-08	1.31e-05	0.34	0.3	Itch intensity from mosquito bite;	chr12:46345100	chr12:46537502~46652550:+
STAD	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	5.84	1.18e-08	1.31e-05	0.27	0.3	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
STAD	cis	rs4568518	0.587	rs4576329	ENSG00000279048.1	RP11-511H23.2	5.84	1.18e-08	1.31e-05	0.27	0.3	Measles;	chr7:17967529	chr7:17940503~17942922:+
STAD	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-5.84	1.18e-08	1.32e-05	-0.33	-0.3	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
STAD	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-5.84	1.18e-08	1.32e-05	-0.36	-0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
STAD	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-5.84	1.18e-08	1.32e-05	-0.36	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
STAD	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	5.84	1.18e-08	1.32e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
STAD	cis	rs227275	0.525	rs4698874	ENSG00000230069.3	LRRC37A15P	-5.84	1.19e-08	1.32e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102727274~102730721:-
STAD	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-5.84	1.19e-08	1.32e-05	-0.31	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
STAD	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	5.84	1.19e-08	1.32e-05	0.32	0.3	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
STAD	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	5.84	1.19e-08	1.32e-05	0.35	0.3	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	5.84	1.19e-08	1.32e-05	0.35	0.3	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	5.84	1.19e-08	1.32e-05	0.35	0.3	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
STAD	cis	rs9549260	0.816	rs9532582	ENSG00000229456.1	RLIMP1	5.84	1.19e-08	1.32e-05	0.28	0.3	Red blood cell count;	chr13:40677070	chr13:40618738~40621348:+
STAD	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-5.84	1.19e-08	1.33e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
STAD	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-5.84	1.19e-08	1.33e-05	-0.28	-0.3	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
STAD	cis	rs7927771	0.864	rs11600581	ENSG00000280615.1	Y_RNA	-5.84	1.19e-08	1.33e-05	-0.3	-0.3	Subjective well-being;	chr11:47426946	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.864	rs60075622	ENSG00000280615.1	Y_RNA	-5.84	1.19e-08	1.33e-05	-0.3	-0.3	Subjective well-being;	chr11:47427550	chr11:47614898~47614994:-
STAD	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	5.84	1.19e-08	1.33e-05	0.3	0.3	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
STAD	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-5.84	1.19e-08	1.33e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
STAD	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	5.84	1.2e-08	1.33e-05	0.27	0.3	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
STAD	cis	rs453301	0.686	rs6601281	ENSG00000254340.1	RP11-10A14.3	-5.84	1.2e-08	1.33e-05	-0.39	-0.3	Joint mobility (Beighton score);	chr8:9053494	chr8:9141424~9145435:+
STAD	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	5.84	1.2e-08	1.33e-05	0.31	0.3	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
STAD	cis	rs992157	0.764	rs4672886	ENSG00000237281.1	CATIP-AS2	5.84	1.2e-08	1.33e-05	0.31	0.3	Colorectal cancer;	chr2:218320822	chr2:218326889~218357966:-
STAD	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-5.84	1.2e-08	1.33e-05	-0.38	-0.3	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
STAD	cis	rs240993	0.812	rs2025269	ENSG00000230177.1	RP5-1112D6.4	-5.84	1.2e-08	1.33e-05	-0.3	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111489237	chr6:111277932~111278742:+
STAD	cis	rs227275	0.554	rs223339	ENSG00000230069.3	LRRC37A15P	-5.84	1.2e-08	1.33e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223333	ENSG00000230069.3	LRRC37A15P	-5.84	1.2e-08	1.33e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223328	ENSG00000230069.3	LRRC37A15P	-5.84	1.2e-08	1.33e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102727274~102730721:-
STAD	cis	rs228614	0.536	rs223325	ENSG00000230069.3	LRRC37A15P	-5.84	1.2e-08	1.33e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102727274~102730721:-
STAD	cis	rs3806843	0.838	rs2337514	ENSG00000202111.1	VTRNA1-2	5.84	1.2e-08	1.33e-05	0.3	0.3	Depressive symptoms (multi-trait analysis);	chr5:140753147	chr5:140718925~140719013:+
STAD	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	5.84	1.2e-08	1.33e-05	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
STAD	cis	rs4568518	0.619	rs13238312	ENSG00000279048.1	RP11-511H23.2	5.84	1.2e-08	1.33e-05	0.26	0.3	Measles;	chr7:17968821	chr7:17940503~17942922:+
STAD	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	5.84	1.2e-08	1.33e-05	0.48	0.3	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
STAD	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	5.84	1.21e-08	1.34e-05	0.36	0.3	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
STAD	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	5.84	1.21e-08	1.34e-05	0.48	0.3	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	5.84	1.21e-08	1.34e-05	0.48	0.3	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	5.84	1.21e-08	1.34e-05	0.48	0.3	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	5.84	1.21e-08	1.34e-05	0.48	0.3	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
STAD	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	5.84	1.21e-08	1.34e-05	0.48	0.3	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
STAD	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-5.84	1.21e-08	1.34e-05	-0.38	-0.3	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
STAD	cis	rs10129255	1	rs10141557	ENSG00000280411.1	IGHV1-69-2	-5.84	1.21e-08	1.34e-05	-0.28	-0.3	Kawasaki disease;	chr14:106767990	chr14:106762092~106762588:-
STAD	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	5.84	1.21e-08	1.34e-05	0.23	0.3	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
STAD	cis	rs10461617	0.512	rs7715746	ENSG00000271828.1	CTD-2310F14.1	5.84	1.21e-08	1.34e-05	0.37	0.3	Type 2 diabetes;	chr5:56753010	chr5:56927874~56929573:+
STAD	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-5.84	1.21e-08	1.35e-05	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
STAD	cis	rs13113518	0.702	rs78829811	ENSG00000272969.1	RP11-528I4.2	5.84	1.21e-08	1.35e-05	0.39	0.3	Height;	chr4:55558258	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.702	rs75801206	ENSG00000272969.1	RP11-528I4.2	5.84	1.21e-08	1.35e-05	0.39	0.3	Height;	chr4:55558259	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.702	rs34658078	ENSG00000272969.1	RP11-528I4.2	5.84	1.21e-08	1.35e-05	0.39	0.3	Height;	chr4:55558261	chr4:55547112~55547889:+
STAD	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	5.84	1.21e-08	1.35e-05	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
STAD	cis	rs8098244	0.617	rs34511347	ENSG00000267301.1	RPL23AP77	-5.84	1.22e-08	1.35e-05	-0.34	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23822920	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.617	rs11872810	ENSG00000267301.1	RPL23AP77	-5.84	1.22e-08	1.35e-05	-0.34	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23823416	chr18:23709825~23710287:-
STAD	cis	rs12699921	0.632	rs2723506	ENSG00000279048.1	RP11-511H23.2	-5.84	1.22e-08	1.35e-05	-0.28	-0.3	Fibrinogen levels;	chr7:17780675	chr7:17940503~17942922:+
STAD	cis	rs11079159	0.606	rs1114603	ENSG00000263096.1	RP11-515O17.2	5.84	1.22e-08	1.35e-05	0.37	0.3	QRS duration;	chr17:55291706	chr17:55271504~55273653:-
STAD	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	5.84	1.22e-08	1.35e-05	0.3	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
STAD	cis	rs13113518	1	rs13108499	ENSG00000272969.1	RP11-528I4.2	5.84	1.22e-08	1.35e-05	0.37	0.3	Height;	chr4:55526514	chr4:55547112~55547889:+
STAD	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-5.84	1.22e-08	1.35e-05	-0.32	-0.3	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-5.84	1.22e-08	1.35e-05	-0.32	-0.3	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
STAD	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-5.84	1.22e-08	1.35e-05	-0.39	-0.3	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
STAD	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-5.84	1.22e-08	1.35e-05	-0.45	-0.3	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
STAD	cis	rs516805	0.563	rs571706	ENSG00000279453.1	RP3-425C14.4	-5.84	1.22e-08	1.35e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122393787	chr6:122436789~122439223:-
STAD	cis	rs10129255	0.957	rs8009073	ENSG00000280411.1	IGHV1-69-2	-5.84	1.22e-08	1.36e-05	-0.28	-0.3	Kawasaki disease;	chr14:106777278	chr14:106762092~106762588:-
STAD	cis	rs7924176	0.564	rs12359146	ENSG00000236900.1	TIMM9P1	-5.84	1.22e-08	1.36e-05	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74205914	chr10:74344550~74344805:-
STAD	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	5.84	1.23e-08	1.36e-05	0.26	0.3	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
STAD	cis	rs4604732	0.631	rs4411161	ENSG00000227135.1	GCSAML-AS1	-5.84	1.23e-08	1.36e-05	-0.42	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469072	chr1:247524679~247526752:-
STAD	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	5.84	1.23e-08	1.36e-05	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	5.84	1.23e-08	1.36e-05	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	5.84	1.23e-08	1.36e-05	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
STAD	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-5.84	1.23e-08	1.36e-05	-0.36	-0.3	Height;	chr6:109432968	chr6:109382795~109383666:+
STAD	cis	rs7487075	0.578	rs11183486	ENSG00000272369.1	RP11-446N19.1	5.84	1.23e-08	1.36e-05	0.37	0.3	Itch intensity from mosquito bite;	chr12:46443921	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs4768724	ENSG00000272369.1	RP11-446N19.1	5.84	1.23e-08	1.36e-05	0.37	0.3	Itch intensity from mosquito bite;	chr12:46454633	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs4768725	ENSG00000272369.1	RP11-446N19.1	5.84	1.23e-08	1.36e-05	0.37	0.3	Itch intensity from mosquito bite;	chr12:46454695	chr12:46537502~46652550:+
STAD	cis	rs7487075	1	rs10880966	ENSG00000272369.1	RP11-446N19.1	5.84	1.23e-08	1.36e-05	0.36	0.3	Itch intensity from mosquito bite;	chr12:46407999	chr12:46537502~46652550:+
STAD	cis	rs453301	0.653	rs1562211	ENSG00000254340.1	RP11-10A14.3	-5.84	1.23e-08	1.36e-05	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9044914	chr8:9141424~9145435:+
STAD	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	5.84	1.23e-08	1.37e-05	0.37	0.3	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
STAD	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-5.84	1.24e-08	1.37e-05	-0.28	-0.3	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
STAD	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	5.83	1.24e-08	1.37e-05	0.37	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
STAD	cis	rs10853057	0.85	rs62065479	ENSG00000214174.7	AMZ2P1	5.83	1.24e-08	1.37e-05	0.64	0.3	White matter microstructure (global fractional anisotropy);	chr17:65002593	chr17:64966550~64975576:-
STAD	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-5.83	1.24e-08	1.37e-05	-0.32	-0.3	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
STAD	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-5.83	1.24e-08	1.37e-05	-0.41	-0.3	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
STAD	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-5.83	1.24e-08	1.38e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
STAD	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	5.83	1.25e-08	1.38e-05	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	5.83	1.25e-08	1.38e-05	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
STAD	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	5.83	1.25e-08	1.38e-05	0.3	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
STAD	cis	rs9395066	0.545	rs17424547	ENSG00000219384.1	RP11-491H9.3	-5.83	1.25e-08	1.38e-05	-0.29	-0.3	Height;	chr6:45021233	chr6:45158870~45159511:+
STAD	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-5.83	1.25e-08	1.38e-05	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
STAD	cis	rs7580658	0.676	rs4662717	ENSG00000200250.1	RNU6-1147P	5.83	1.25e-08	1.38e-05	0.29	0.3	Protein C levels;	chr2:127255928	chr2:127316873~127316979:+
STAD	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	5.83	1.25e-08	1.38e-05	0.39	0.3	Height;	chr6:109640682	chr6:109382795~109383666:+
STAD	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	5.83	1.25e-08	1.39e-05	0.38	0.3	Depression;	chr6:28317705	chr6:28943877~28944537:+
STAD	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	5.83	1.25e-08	1.39e-05	0.35	0.3	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
STAD	cis	rs12699921	0.632	rs2691600	ENSG00000279048.1	RP11-511H23.2	-5.83	1.25e-08	1.39e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17833542	chr7:17940503~17942922:+
STAD	cis	rs3758911	0.765	rs609821	ENSG00000261098.1	RP11-819C21.1	5.83	1.26e-08	1.39e-05	0.27	0.3	Coronary artery disease;	chr11:107468429	chr11:107312132~107316271:-
STAD	cis	rs12699921	0.632	rs1524776	ENSG00000279048.1	RP11-511H23.2	-5.83	1.26e-08	1.39e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17832470	chr7:17940503~17942922:+
STAD	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-5.83	1.26e-08	1.39e-05	-0.29	-0.3	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
STAD	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-5.83	1.26e-08	1.39e-05	-0.31	-0.3	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
STAD	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-5.83	1.26e-08	1.39e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
STAD	cis	rs992157	0.965	rs62182826	ENSG00000237281.1	CATIP-AS2	-5.83	1.26e-08	1.4e-05	-0.3	-0.3	Colorectal cancer;	chr2:218284000	chr2:218326889~218357966:-
STAD	cis	rs10129255	0.913	rs28861466	ENSG00000280411.1	IGHV1-69-2	-5.83	1.26e-08	1.4e-05	-0.28	-0.3	Kawasaki disease;	chr14:106718572	chr14:106762092~106762588:-
STAD	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-5.83	1.26e-08	1.4e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
STAD	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	5.83	1.26e-08	1.4e-05	0.44	0.3	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	5.83	1.26e-08	1.4e-05	0.44	0.3	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-5.83	1.26e-08	1.4e-05	-0.44	-0.3	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
STAD	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	5.83	1.26e-08	1.4e-05	0.35	0.3	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
STAD	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-5.83	1.26e-08	1.4e-05	-0.31	-0.3	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
STAD	cis	rs2439831	0.681	rs484846	ENSG00000205771.5	CATSPER2P1	-5.83	1.27e-08	1.4e-05	-0.4	-0.3	Lung cancer in ever smokers;	chr15:43308605	chr15:43726918~43747094:-
STAD	cis	rs2439831	0.681	rs540388	ENSG00000205771.5	CATSPER2P1	-5.83	1.27e-08	1.4e-05	-0.4	-0.3	Lung cancer in ever smokers;	chr15:43314296	chr15:43726918~43747094:-
STAD	cis	rs7924176	0.58	rs12360119	ENSG00000236900.1	TIMM9P1	-5.83	1.27e-08	1.4e-05	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74344550~74344805:-
STAD	cis	rs11038871	0.746	rs10769204	ENSG00000271350.1	CTD-2384B9.1	-5.83	1.27e-08	1.4e-05	-0.38	-0.3	Immunoglobulin A;	chr11:46654807	chr11:47041027~47041945:-
STAD	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	5.83	1.27e-08	1.4e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
STAD	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	5.83	1.27e-08	1.4e-05	0.3	0.3	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	5.83	1.27e-08	1.4e-05	0.3	0.3	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	5.83	1.27e-08	1.4e-05	0.3	0.3	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
STAD	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	5.83	1.27e-08	1.4e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
STAD	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	5.83	1.27e-08	1.41e-05	0.35	0.3	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
STAD	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	5.83	1.27e-08	1.41e-05	0.35	0.3	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
STAD	cis	rs6782228	0.606	rs10048945	ENSG00000277250.1	Metazoa_SRP	-5.83	1.27e-08	1.41e-05	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128673681~128674021:-
STAD	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	5.83	1.28e-08	1.41e-05	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
STAD	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	5.83	1.28e-08	1.41e-05	0.32	0.3	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
STAD	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	5.83	1.28e-08	1.41e-05	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
STAD	cis	rs7829975	0.742	rs1533059	ENSG00000254340.1	RP11-10A14.3	-5.83	1.28e-08	1.41e-05	-0.34	-0.3	Mood instability;	chr8:8827443	chr8:9141424~9145435:+
STAD	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	5.83	1.28e-08	1.41e-05	0.48	0.3	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
STAD	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-5.83	1.28e-08	1.41e-05	-0.45	-0.3	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-5.83	1.28e-08	1.41e-05	-0.45	-0.3	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
STAD	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-5.83	1.28e-08	1.41e-05	-0.25	-0.3	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
STAD	cis	rs858239	0.539	rs4559148	ENSG00000226816.2	AC005082.12	5.83	1.28e-08	1.41e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23206013~23208045:+
STAD	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-5.83	1.28e-08	1.42e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
STAD	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-5.83	1.28e-08	1.42e-05	-0.33	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
STAD	cis	rs1005277	0.579	rs1740735	ENSG00000099251.13	HSD17B7P2	5.83	1.28e-08	1.42e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38356380~38378505:+
STAD	cis	rs3806843	0.741	rs4912597	ENSG00000202111.1	VTRNA1-2	5.83	1.29e-08	1.42e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.771	rs2563334	ENSG00000202111.1	VTRNA1-2	5.83	1.29e-08	1.42e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr5:140718925~140719013:+
STAD	cis	rs8098244	0.617	rs7244406	ENSG00000267301.1	RPL23AP77	-5.83	1.29e-08	1.42e-05	-0.35	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23820041	chr18:23709825~23710287:-
STAD	cis	rs227275	0.554	rs223467	ENSG00000230069.3	LRRC37A15P	-5.83	1.29e-08	1.42e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102727274~102730721:-
STAD	cis	rs13113518	1	rs3805148	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55440643	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11133380	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55441110	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs12510110	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55441567	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs12510990	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55441907	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs3805149	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55442184	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11945370	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55442875	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs12647677	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55444253	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.902	rs3805150	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55446869	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs4864990	ENSG00000272969.1	RP11-528I4.2	5.83	1.29e-08	1.42e-05	0.37	0.3	Height;	chr4:55447523	chr4:55547112~55547889:+
STAD	cis	rs9395066	0.545	rs10948197	ENSG00000219384.1	RP11-491H9.3	5.83	1.29e-08	1.42e-05	0.29	0.3	Height;	chr6:44999753	chr6:45158870~45159511:+
STAD	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-5.83	1.29e-08	1.42e-05	-0.45	-0.3	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
STAD	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-5.83	1.29e-08	1.42e-05	-0.45	-0.3	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
STAD	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-5.83	1.29e-08	1.42e-05	-0.45	-0.3	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
STAD	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-5.83	1.3e-08	1.43e-05	-0.43	-0.3	QT interval;	chr16:28824579	chr16:28700294~28701540:-
STAD	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-5.83	1.3e-08	1.43e-05	-0.32	-0.3	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
STAD	cis	rs1426063	0.614	rs76512224	ENSG00000248165.1	RP11-44F21.2	5.83	1.3e-08	1.43e-05	0.63	0.3	QT interval;	chr4:75144808	chr4:74993877~75034824:-
STAD	cis	rs1005277	0.502	rs2800484	ENSG00000099251.13	HSD17B7P2	5.83	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38356380~38378505:+
STAD	cis	rs227275	0.555	rs223403	ENSG00000230069.3	LRRC37A15P	-5.82	1.31e-08	1.44e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102727274~102730721:-
STAD	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	5.82	1.31e-08	1.44e-05	0.27	0.3	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
STAD	cis	rs3806843	0.741	rs2563293	ENSG00000202111.1	VTRNA1-2	5.82	1.31e-08	1.44e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr5:140718925~140719013:+
STAD	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	5.82	1.31e-08	1.44e-05	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
STAD	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-5.82	1.31e-08	1.44e-05	-0.29	-0.3	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-5.82	1.31e-08	1.44e-05	-0.29	-0.3	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-5.82	1.31e-08	1.44e-05	-0.29	-0.3	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-5.82	1.31e-08	1.44e-05	-0.29	-0.3	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
STAD	cis	rs9549260	0.755	rs2721069	ENSG00000229456.1	RLIMP1	5.82	1.31e-08	1.44e-05	0.27	0.3	Red blood cell count;	chr13:40569583	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.755	rs1923249	ENSG00000229456.1	RLIMP1	5.82	1.31e-08	1.44e-05	0.27	0.3	Red blood cell count;	chr13:40569744	chr13:40618738~40621348:+
STAD	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-5.82	1.31e-08	1.44e-05	-0.32	-0.3	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
STAD	cis	rs12699921	0.568	rs2691605	ENSG00000279048.1	RP11-511H23.2	-5.82	1.31e-08	1.44e-05	-0.28	-0.3	Fibrinogen levels;	chr7:17837825	chr7:17940503~17942922:+
STAD	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-5.82	1.31e-08	1.44e-05	-0.32	-0.3	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
STAD	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-5.82	1.31e-08	1.44e-05	-0.32	-0.3	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
STAD	cis	rs1005277	0.541	rs1740741	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.528	rs2057228	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1740742	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.602	rs1740743	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1740745	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1740747	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1740749	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1780115	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.529	rs1780125	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2800485	ENSG00000099251.13	HSD17B7P2	5.82	1.31e-08	1.44e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38356380~38378505:+
STAD	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	5.82	1.32e-08	1.45e-05	0.31	0.3	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
STAD	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	5.82	1.32e-08	1.45e-05	0.36	0.3	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
STAD	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	5.82	1.32e-08	1.45e-05	0.25	0.3	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
STAD	cis	rs1563304	1	rs1563304	ENSG00000262500.1	RP11-259G18.2	5.82	1.32e-08	1.45e-05	0.53	0.3	Neuroticism;	chr17:46797087	chr17:46243606~46245044:+
STAD	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	5.82	1.32e-08	1.45e-05	0.38	0.3	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
STAD	cis	rs227275	0.525	rs28778380	ENSG00000230069.3	LRRC37A15P	-5.82	1.32e-08	1.45e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102727274~102730721:-
STAD	cis	rs12699921	0.632	rs2723552	ENSG00000279048.1	RP11-511H23.2	-5.82	1.32e-08	1.45e-05	-0.28	-0.3	Fibrinogen levels;	chr7:17821038	chr7:17940503~17942922:+
STAD	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	5.82	1.32e-08	1.45e-05	0.4	0.3	Height;	chr6:109429207	chr6:109382795~109383666:+
STAD	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-5.82	1.32e-08	1.45e-05	-0.45	-0.3	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
STAD	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	5.82	1.33e-08	1.46e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
STAD	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-5.82	1.33e-08	1.46e-05	-0.29	-0.3	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
STAD	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	5.82	1.33e-08	1.46e-05	0.79	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
STAD	cis	rs875971	0.545	rs2460427	ENSG00000224316.1	RP11-479O9.2	-5.82	1.33e-08	1.46e-05	-0.33	-0.3	Aortic root size;	chr7:66154218	chr7:65773620~65802067:+
STAD	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-5.82	1.33e-08	1.46e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
STAD	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-5.82	1.33e-08	1.46e-05	-0.31	-0.3	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
STAD	cis	rs606458	0.764	rs483962	ENSG00000269038.1	AP001462.6	-5.82	1.33e-08	1.46e-05	-0.38	-0.3	Urate levels;	chr11:64760279	chr11:64778954~64779405:+
STAD	cis	rs858239	0.539	rs2390757	ENSG00000226816.2	AC005082.12	5.82	1.34e-08	1.47e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23206013~23208045:+
STAD	cis	rs9400467	0.528	rs465796	ENSG00000230177.1	RP5-1112D6.4	-5.82	1.34e-08	1.47e-05	-0.27	-0.3	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111277932~111278742:+
STAD	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	5.82	1.34e-08	1.47e-05	0.36	0.3	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
STAD	cis	rs227275	0.525	rs4699046	ENSG00000230069.3	LRRC37A15P	-5.82	1.34e-08	1.47e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs4699047	ENSG00000230069.3	LRRC37A15P	-5.82	1.34e-08	1.47e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102727274~102730721:-
STAD	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	5.82	1.34e-08	1.47e-05	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
STAD	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-5.82	1.34e-08	1.47e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
STAD	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	5.82	1.34e-08	1.47e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
STAD	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-5.82	1.35e-08	1.48e-05	-0.45	-0.3	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
STAD	cis	rs13113518	1	rs11133388	ENSG00000272969.1	RP11-528I4.2	-5.82	1.35e-08	1.48e-05	-0.38	-0.3	Height;	chr4:55477866	chr4:55547112~55547889:+
STAD	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	5.82	1.35e-08	1.48e-05	0.37	0.3	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
STAD	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-5.82	1.35e-08	1.48e-05	-0.32	-0.3	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-5.82	1.35e-08	1.48e-05	-0.32	-0.3	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
STAD	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-5.82	1.35e-08	1.48e-05	-0.32	-0.3	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.917	rs7155356	ENSG00000223648.3	IGHV3-64	5.82	1.35e-08	1.48e-05	0.26	0.3	Kawasaki disease;	chr14:106697376	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.917	rs10137601	ENSG00000223648.3	IGHV3-64	5.82	1.35e-08	1.48e-05	0.26	0.3	Kawasaki disease;	chr14:106697476	chr14:106643132~106658258:-
STAD	cis	rs12699921	0.632	rs2691601	ENSG00000279048.1	RP11-511H23.2	-5.82	1.35e-08	1.48e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17835808	chr7:17940503~17942922:+
STAD	cis	rs728616	0.867	rs34870056	ENSG00000225484.5	NUTM2B-AS1	-5.82	1.35e-08	1.48e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79663088~79826594:-
STAD	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-5.82	1.35e-08	1.48e-05	-0.31	-0.3	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
STAD	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-5.82	1.35e-08	1.48e-05	-0.31	-0.3	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
STAD	cis	rs2283792	0.967	rs5755099	ENSG00000228050.1	TOP3BP1	5.82	1.35e-08	1.48e-05	0.33	0.3	Multiple sclerosis;	chr22:21770751	chr22:22223187~22224566:-
STAD	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-5.82	1.35e-08	1.48e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
STAD	cis	rs4568518	0.616	rs4721675	ENSG00000279048.1	RP11-511H23.2	5.82	1.36e-08	1.49e-05	0.27	0.3	Measles;	chr7:17965079	chr7:17940503~17942922:+
STAD	cis	rs8141529	0.764	rs8137969	ENSG00000226471.5	CTA-292E10.6	-5.82	1.36e-08	1.49e-05	-0.35	-0.3	Lymphocyte counts;	chr22:28832496	chr22:28800683~28848559:+
STAD	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	5.82	1.36e-08	1.49e-05	0.39	0.3	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
STAD	cis	rs13113518	0.783	rs34534635	ENSG00000272969.1	RP11-528I4.2	5.82	1.36e-08	1.49e-05	0.39	0.3	Height;	chr4:55573424	chr4:55547112~55547889:+
STAD	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	5.82	1.36e-08	1.49e-05	0.3	0.3	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	5.82	1.36e-08	1.49e-05	0.3	0.3	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	5.82	1.36e-08	1.49e-05	0.3	0.3	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
STAD	cis	rs3806843	0.735	rs2563333	ENSG00000202111.1	VTRNA1-2	5.82	1.36e-08	1.49e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140672686	chr5:140718925~140719013:+
STAD	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	5.82	1.37e-08	1.5e-05	0.32	0.3	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
STAD	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	5.82	1.37e-08	1.5e-05	0.31	0.3	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
STAD	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	5.82	1.37e-08	1.5e-05	0.3	0.3	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
STAD	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-5.82	1.37e-08	1.5e-05	-0.34	-0.3	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
STAD	cis	rs1005277	0.579	rs1780133	ENSG00000099251.13	HSD17B7P2	5.82	1.37e-08	1.5e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1780136	ENSG00000099251.13	HSD17B7P2	5.82	1.37e-08	1.5e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1780138	ENSG00000099251.13	HSD17B7P2	5.82	1.37e-08	1.5e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs1780139	ENSG00000099251.13	HSD17B7P2	5.82	1.37e-08	1.5e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.602	rs1780141	ENSG00000099251.13	HSD17B7P2	5.82	1.37e-08	1.5e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38356380~38378505:+
STAD	cis	rs228614	0.536	rs223484	ENSG00000230069.3	LRRC37A15P	-5.82	1.37e-08	1.5e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102727274~102730721:-
STAD	cis	rs3806843	0.966	rs10036519	ENSG00000202111.1	VTRNA1-2	5.82	1.37e-08	1.5e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140772116	chr5:140718925~140719013:+
STAD	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-5.82	1.37e-08	1.5e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-5.82	1.37e-08	1.5e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
STAD	cis	rs5760092	0.618	rs4461358	ENSG00000250470.1	AP000351.3	-5.82	1.37e-08	1.5e-05	-0.36	-0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23976904~23977585:-
STAD	cis	rs453301	0.686	rs11787026	ENSG00000254340.1	RP11-10A14.3	5.82	1.37e-08	1.5e-05	0.38	0.3	Joint mobility (Beighton score);	chr8:9044861	chr8:9141424~9145435:+
STAD	cis	rs858239	0.601	rs73272053	ENSG00000226816.2	AC005082.12	5.82	1.37e-08	1.5e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23206013~23208045:+
STAD	cis	rs7487075	0.619	rs6582657	ENSG00000272369.1	RP11-446N19.1	5.82	1.37e-08	1.5e-05	0.36	0.3	Itch intensity from mosquito bite;	chr12:46462236	chr12:46537502~46652550:+
STAD	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	5.82	1.38e-08	1.5e-05	0.32	0.3	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
STAD	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	5.82	1.38e-08	1.5e-05	0.26	0.3	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
STAD	cis	rs210138	1	rs210144	ENSG00000197251.3	LINC00336	5.82	1.38e-08	1.51e-05	0.38	0.3	Testicular germ cell tumor;	chr6:33579653	chr6:33586106~33593338:-
STAD	cis	rs453301	0.538	rs7830804	ENSG00000254340.1	RP11-10A14.3	-5.82	1.38e-08	1.51e-05	-0.38	-0.3	Joint mobility (Beighton score);	chr8:9113252	chr8:9141424~9145435:+
STAD	cis	rs453301	0.624	rs2979256	ENSG00000254340.1	RP11-10A14.3	5.82	1.38e-08	1.51e-05	0.37	0.3	Joint mobility (Beighton score);	chr8:9014200	chr8:9141424~9145435:+
STAD	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-5.81	1.38e-08	1.51e-05	-0.35	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-5.81	1.38e-08	1.51e-05	-0.35	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
STAD	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-5.81	1.38e-08	1.51e-05	-0.34	-0.3	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
STAD	cis	rs13113518	1	rs4865007	ENSG00000272969.1	RP11-528I4.2	-5.81	1.38e-08	1.51e-05	-0.37	-0.3	Height;	chr4:55537550	chr4:55547112~55547889:+
STAD	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	5.81	1.38e-08	1.51e-05	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
STAD	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-5.81	1.38e-08	1.51e-05	-0.37	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
STAD	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-5.81	1.39e-08	1.51e-05	-0.31	-0.3	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
STAD	cis	rs240993	0.812	rs9481160	ENSG00000230177.1	RP5-1112D6.4	5.81	1.39e-08	1.51e-05	0.31	0.3	Inflammatory skin disease;Psoriasis;	chr6:111517317	chr6:111277932~111278742:+
STAD	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.39e-08	1.52e-05	-0.29	-0.3	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
STAD	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-5.81	1.39e-08	1.52e-05	-0.32	-0.3	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
STAD	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-5.81	1.39e-08	1.52e-05	-0.36	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
STAD	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-5.81	1.39e-08	1.52e-05	-0.5	-0.3	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
STAD	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	5.81	1.4e-08	1.52e-05	0.36	0.3	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
STAD	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-5.81	1.4e-08	1.53e-05	-0.32	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
STAD	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	5.81	1.4e-08	1.53e-05	0.4	0.3	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
STAD	cis	rs7924176	0.564	rs2270551	ENSG00000236900.1	TIMM9P1	-5.81	1.4e-08	1.53e-05	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74109307	chr10:74344550~74344805:-
STAD	cis	rs17301013	0.932	rs1653632	ENSG00000227373.4	RP11-160H22.5	-5.81	1.4e-08	1.53e-05	-0.34	-0.3	Systemic lupus erythematosus;	chr1:174786459	chr1:174115300~174160004:-
STAD	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-5.81	1.4e-08	1.53e-05	-0.25	-0.3	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
STAD	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-5.81	1.41e-08	1.54e-05	-0.35	-0.3	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
STAD	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	5.81	1.41e-08	1.54e-05	0.29	0.3	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
STAD	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	5.81	1.41e-08	1.54e-05	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
STAD	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	5.81	1.42e-08	1.54e-05	0.3	0.3	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
STAD	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-5.81	1.42e-08	1.54e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
STAD	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-5.81	1.42e-08	1.54e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-5.81	1.42e-08	1.54e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-5.81	1.42e-08	1.54e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-5.81	1.42e-08	1.54e-05	-0.35	-0.3	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
STAD	cis	rs858239	0.539	rs10254544	ENSG00000226816.2	AC005082.12	5.81	1.42e-08	1.54e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23206013~23208045:+
STAD	cis	rs453301	0.571	rs2929452	ENSG00000254340.1	RP11-10A14.3	-5.81	1.42e-08	1.54e-05	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9226955	chr8:9141424~9145435:+
STAD	cis	rs453301	0.507	rs2929306	ENSG00000254340.1	RP11-10A14.3	-5.81	1.42e-08	1.54e-05	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9227399	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.917	rs11625208	ENSG00000280411.1	IGHV1-69-2	-5.81	1.42e-08	1.54e-05	-0.27	-0.3	Kawasaki disease;	chr14:106698757	chr14:106762092~106762588:-
STAD	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-5.81	1.42e-08	1.55e-05	-0.28	-0.3	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
STAD	cis	rs7829975	0.617	rs4841071	ENSG00000254340.1	RP11-10A14.3	5.81	1.42e-08	1.55e-05	0.35	0.3	Mood instability;	chr8:8933634	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	5.81	1.43e-08	1.55e-05	0.27	0.3	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
STAD	cis	rs1005277	0.579	rs176880	ENSG00000099251.13	HSD17B7P2	-5.81	1.43e-08	1.55e-05	-0.33	-0.3	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38356380~38378505:+
STAD	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	5.81	1.43e-08	1.56e-05	0.36	0.3	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
STAD	cis	rs1816752	0.905	rs8002309	ENSG00000273628.1	RP11-756A22.7	5.81	1.43e-08	1.56e-05	0.37	0.3	Obesity-related traits;	chr13:24402217	chr13:24933006~24936796:+
STAD	cis	rs858239	0.539	rs6461695	ENSG00000226816.2	AC005082.12	5.81	1.43e-08	1.56e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23206013~23208045:+
STAD	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	5.81	1.43e-08	1.56e-05	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
STAD	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	5.81	1.43e-08	1.56e-05	0.29	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
STAD	cis	rs228614	0.51	rs223405	ENSG00000230069.3	LRRC37A15P	-5.81	1.43e-08	1.56e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102727274~102730721:-
STAD	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	5.81	1.44e-08	1.57e-05	0.26	0.3	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
STAD	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	5.81	1.44e-08	1.57e-05	0.8	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
STAD	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	5.81	1.44e-08	1.57e-05	0.8	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
STAD	cis	rs1150668	0.768	rs1233713	ENSG00000220721.1	OR1F12	5.81	1.44e-08	1.57e-05	0.29	0.3	Pubertal anthropometrics;	chr6:28230503	chr6:28073316~28074233:+
STAD	cis	rs12699921	0.607	rs1051603	ENSG00000279048.1	RP11-511H23.2	-5.81	1.44e-08	1.57e-05	-0.28	-0.3	Fibrinogen levels;	chr7:17822402	chr7:17940503~17942922:+
STAD	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	5.81	1.44e-08	1.57e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
STAD	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	5.81	1.45e-08	1.58e-05	0.47	0.3	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
STAD	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-5.81	1.45e-08	1.58e-05	-0.41	-0.3	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
STAD	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-5.81	1.45e-08	1.58e-05	-0.4	-0.3	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
STAD	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-5.81	1.45e-08	1.58e-05	-0.32	-0.3	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	5.81	1.45e-08	1.58e-05	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
STAD	cis	rs1005277	0.579	rs2474595	ENSG00000099251.13	HSD17B7P2	-5.81	1.46e-08	1.58e-05	-0.33	-0.3	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38356380~38378505:+
STAD	cis	rs8098244	0.603	rs2960580	ENSG00000267301.1	RPL23AP77	-5.81	1.46e-08	1.58e-05	-0.34	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23712058	chr18:23709825~23710287:-
STAD	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	5.8	1.46e-08	1.59e-05	0.37	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
STAD	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-5.8	1.46e-08	1.59e-05	-0.44	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
STAD	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	5.8	1.46e-08	1.59e-05	0.45	0.3	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
STAD	cis	rs7487075	0.78	rs10785620	ENSG00000272369.1	RP11-446N19.1	5.8	1.47e-08	1.59e-05	0.37	0.3	Itch intensity from mosquito bite;	chr12:46343469	chr12:46537502~46652550:+
STAD	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-5.8	1.47e-08	1.59e-05	-0.8	-0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
STAD	cis	rs10129255	0.957	rs4387509	ENSG00000280411.1	IGHV1-69-2	-5.8	1.47e-08	1.59e-05	-0.28	-0.3	Kawasaki disease;	chr14:106704386	chr14:106762092~106762588:-
STAD	cis	rs3806843	0.676	rs1583005	ENSG00000202111.1	VTRNA1-2	5.8	1.47e-08	1.6e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr5:140718925~140719013:+
STAD	cis	rs228614	0.51	rs223452	ENSG00000230069.3	LRRC37A15P	-5.8	1.47e-08	1.6e-05	-0.33	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102727274~102730721:-
STAD	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	5.8	1.47e-08	1.6e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
STAD	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-5.8	1.47e-08	1.6e-05	-0.32	-0.3	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
STAD	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-5.8	1.48e-08	1.6e-05	-0.32	-0.3	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
STAD	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	5.8	1.48e-08	1.6e-05	0.27	0.3	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
STAD	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	5.8	1.48e-08	1.6e-05	0.38	0.3	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
STAD	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-5.8	1.48e-08	1.6e-05	-0.4	-0.3	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
STAD	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	5.8	1.48e-08	1.6e-05	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
STAD	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-5.8	1.48e-08	1.6e-05	-0.32	-0.3	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
STAD	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	5.8	1.48e-08	1.61e-05	0.36	0.3	Height;	chr6:109392096	chr6:109382795~109383666:+
STAD	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-5.8	1.48e-08	1.61e-05	-0.36	-0.3	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
STAD	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	5.8	1.48e-08	1.61e-05	0.36	0.3	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
STAD	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	5.8	1.49e-08	1.61e-05	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
STAD	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-5.8	1.49e-08	1.61e-05	-0.29	-0.3	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
STAD	cis	rs6452524	0.806	rs10078084	ENSG00000243385.2	CTD-2110K23.1	5.8	1.49e-08	1.61e-05	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.868	rs11750836	ENSG00000243385.2	CTD-2110K23.1	5.8	1.49e-08	1.61e-05	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83201229~83202141:+
STAD	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	5.8	1.49e-08	1.61e-05	0.32	0.3	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
STAD	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	5.8	1.49e-08	1.62e-05	0.42	0.3	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
STAD	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	5.8	1.49e-08	1.62e-05	0.34	0.3	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
STAD	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-5.8	1.49e-08	1.62e-05	-0.31	-0.3	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
STAD	cis	rs10129255	1	rs10137758	ENSG00000223648.3	IGHV3-64	5.8	1.49e-08	1.62e-05	0.26	0.3	Kawasaki disease;	chr14:106697673	chr14:106643132~106658258:-
STAD	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	5.8	1.49e-08	1.62e-05	0.31	0.3	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
STAD	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
STAD	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-5.8	1.5e-08	1.62e-05	-0.28	-0.3	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
STAD	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	5.8	1.5e-08	1.62e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
STAD	cis	rs10129255	0.913	rs10140943	ENSG00000280411.1	IGHV1-69-2	-5.8	1.5e-08	1.62e-05	-0.28	-0.3	Kawasaki disease;	chr14:106767441	chr14:106762092~106762588:-
STAD	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	5.8	1.5e-08	1.63e-05	0.34	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
STAD	cis	rs516805	0.748	rs155460	ENSG00000279453.1	RP3-425C14.4	-5.8	1.51e-08	1.63e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122499180	chr6:122436789~122439223:-
STAD	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	5.8	1.51e-08	1.63e-05	0.31	0.3	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
STAD	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	5.8	1.51e-08	1.63e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	5.8	1.51e-08	1.63e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	5.8	1.51e-08	1.63e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	5.8	1.51e-08	1.63e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	5.8	1.51e-08	1.63e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
STAD	cis	rs9395066	0.545	rs3799979	ENSG00000219384.1	RP11-491H9.3	-5.8	1.51e-08	1.63e-05	-0.29	-0.3	Height;	chr6:44877777	chr6:45158870~45159511:+
STAD	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-5.8	1.51e-08	1.63e-05	-0.3	-0.3	Height;	chr11:118857611	chr11:118791254~118793137:+
STAD	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	5.8	1.51e-08	1.64e-05	0.43	0.3	Height;	chr6:109573151	chr6:109382795~109383666:+
STAD	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-5.8	1.51e-08	1.64e-05	-0.25	-0.3	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
STAD	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	5.8	1.51e-08	1.64e-05	0.37	0.3	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
STAD	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-5.8	1.52e-08	1.64e-05	-0.28	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
STAD	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-5.8	1.52e-08	1.64e-05	-0.35	-0.3	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
STAD	cis	rs7951870	0.504	rs7484125	ENSG00000271350.1	CTD-2384B9.1	5.8	1.52e-08	1.64e-05	0.37	0.3	Schizophrenia;	chr11:46566717	chr11:47041027~47041945:-
STAD	cis	rs8067354	0.574	rs2531899	ENSG00000266701.1	AC005702.4	-5.8	1.52e-08	1.64e-05	-0.43	-0.3	Hemoglobin concentration;	chr17:59929832	chr17:60042546~60042627:-
STAD	cis	rs7487075	0.93	rs6582656	ENSG00000272369.1	RP11-446N19.1	5.8	1.52e-08	1.65e-05	0.35	0.3	Itch intensity from mosquito bite;	chr12:46449633	chr12:46537502~46652550:+
STAD	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-5.8	1.53e-08	1.65e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
STAD	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-5.8	1.53e-08	1.65e-05	-0.31	-0.3	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
STAD	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	5.8	1.53e-08	1.65e-05	0.4	0.3	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
STAD	cis	rs7927771	0.864	rs2868459	ENSG00000280615.1	Y_RNA	-5.8	1.53e-08	1.65e-05	-0.3	-0.3	Subjective well-being;	chr11:47433421	chr11:47614898~47614994:-
STAD	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	5.8	1.53e-08	1.65e-05	0.26	0.3	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
STAD	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	5.8	1.53e-08	1.65e-05	0.36	0.3	Height;	chr6:109409679	chr6:109382795~109383666:+
STAD	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	5.8	1.53e-08	1.65e-05	0.36	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
STAD	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	5.8	1.53e-08	1.65e-05	0.31	0.3	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
STAD	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	5.8	1.53e-08	1.66e-05	0.59	0.3	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
STAD	cis	rs7927771	0.826	rs7925389	ENSG00000280615.1	Y_RNA	-5.8	1.54e-08	1.66e-05	-0.3	-0.3	Subjective well-being;	chr11:47445238	chr11:47614898~47614994:-
STAD	cis	rs728616	0.717	rs12412999	ENSG00000225484.5	NUTM2B-AS1	-5.79	1.54e-08	1.66e-05	-0.66	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:79663088~79826594:-
STAD	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-5.79	1.54e-08	1.66e-05	-0.32	-0.3	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
STAD	cis	rs728616	0.867	rs4633405	ENSG00000225484.5	NUTM2B-AS1	-5.79	1.55e-08	1.67e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860034	ENSG00000225484.5	NUTM2B-AS1	-5.79	1.55e-08	1.67e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79663088~79826594:-
STAD	cis	rs210138	1	rs210138	ENSG00000197251.3	LINC00336	-5.79	1.55e-08	1.67e-05	-0.37	-0.3	Testicular germ cell tumor;	chr6:33574761	chr6:33586106~33593338:-
STAD	cis	rs7927771	0.864	rs7937331	ENSG00000280615.1	Y_RNA	5.79	1.55e-08	1.67e-05	0.3	0.3	Subjective well-being;	chr11:47408907	chr11:47614898~47614994:-
STAD	cis	rs75045569	1	rs75045569	ENSG00000229153.4	EPHA1-AS1	5.79	1.55e-08	1.68e-05	0.56	0.3	Alzheimer's disease in APOE e4- carriers;	chr7:143412115	chr7:143407813~143523449:+
STAD	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-5.79	1.56e-08	1.68e-05	-0.37	-0.3	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
STAD	cis	rs7927771	0.697	rs11039307	ENSG00000280615.1	Y_RNA	-5.79	1.56e-08	1.68e-05	-0.3	-0.3	Subjective well-being;	chr11:47589600	chr11:47614898~47614994:-
STAD	cis	rs12699921	0.632	rs2723501	ENSG00000279048.1	RP11-511H23.2	5.79	1.56e-08	1.68e-05	0.27	0.3	Fibrinogen levels;	chr7:17814909	chr7:17940503~17942922:+
STAD	cis	rs7829975	0.711	rs4841051	ENSG00000254340.1	RP11-10A14.3	-5.79	1.56e-08	1.68e-05	-0.35	-0.3	Mood instability;	chr8:8828136	chr8:9141424~9145435:+
STAD	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-5.79	1.56e-08	1.68e-05	-0.43	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
STAD	cis	rs10129255	0.872	rs10133674	ENSG00000223648.3	IGHV3-64	5.79	1.56e-08	1.69e-05	0.26	0.3	Kawasaki disease;	chr14:106692788	chr14:106643132~106658258:-
STAD	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	5.79	1.57e-08	1.69e-05	0.32	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
STAD	cis	rs1816752	0.905	rs4769348	ENSG00000273628.1	RP11-756A22.7	5.79	1.57e-08	1.69e-05	0.36	0.3	Obesity-related traits;	chr13:24400975	chr13:24933006~24936796:+
STAD	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	5.79	1.57e-08	1.69e-05	0.26	0.3	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
STAD	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	5.79	1.57e-08	1.69e-05	0.46	0.3	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
STAD	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-5.79	1.57e-08	1.69e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
STAD	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	5.79	1.57e-08	1.69e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
STAD	cis	rs1799949	1	rs8070085	ENSG00000236383.6	LINC00854	5.79	1.57e-08	1.69e-05	0.24	0.3	Menopause (age at onset);	chr17:43189967	chr17:43216941~43305976:-
STAD	cis	rs60065504	1	rs60065504	ENSG00000251022.5	THAP9-AS1	-5.79	1.57e-08	1.7e-05	-0.29	-0.3	Lymphocyte percentage of white cells;	chr4:82964057	chr4:82893009~82900960:-
STAD	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	5.79	1.57e-08	1.7e-05	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
STAD	cis	rs875971	0.545	rs73376394	ENSG00000224316.1	RP11-479O9.2	5.79	1.58e-08	1.7e-05	0.33	0.3	Aortic root size;	chr7:66172694	chr7:65773620~65802067:+
STAD	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	5.79	1.58e-08	1.7e-05	0.33	0.3	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
STAD	cis	rs7580658	0.75	rs6731176	ENSG00000200250.1	RNU6-1147P	5.79	1.58e-08	1.7e-05	0.28	0.3	Protein C levels;	chr2:127313427	chr2:127316873~127316979:+
STAD	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	5.79	1.58e-08	1.7e-05	0.3	0.3	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
STAD	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	5.79	1.58e-08	1.7e-05	0.36	0.3	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
STAD	cis	rs7487075	0.823	rs34472481	ENSG00000257261.4	RP11-96H19.1	5.79	1.58e-08	1.7e-05	0.35	0.3	Itch intensity from mosquito bite;	chr12:46442565	chr12:46383679~46876159:+
STAD	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-5.79	1.58e-08	1.7e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-5.79	1.58e-08	1.7e-05	-0.31	-0.3	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
STAD	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	5.79	1.58e-08	1.7e-05	0.3	0.3	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	5.79	1.58e-08	1.7e-05	0.3	0.3	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
STAD	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-5.79	1.58e-08	1.7e-05	-0.31	-0.3	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-5.79	1.58e-08	1.7e-05	-0.31	-0.3	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
STAD	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-5.79	1.58e-08	1.7e-05	-0.31	-0.3	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
STAD	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-5.79	1.58e-08	1.7e-05	-0.44	-0.3	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
STAD	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-5.79	1.58e-08	1.7e-05	-0.4	-0.3	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
STAD	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-5.79	1.58e-08	1.7e-05	-0.31	-0.3	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
STAD	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	5.79	1.58e-08	1.71e-05	0.33	0.3	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
STAD	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	5.79	1.58e-08	1.71e-05	0.37	0.3	Depression;	chr6:28327262	chr6:28943877~28944537:+
STAD	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-5.79	1.59e-08	1.71e-05	-0.4	-0.3	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
STAD	cis	rs858239	0.799	rs10279941	ENSG00000226816.2	AC005082.12	5.79	1.6e-08	1.72e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23206013~23208045:+
STAD	cis	rs1075265	0.61	rs6746965	ENSG00000235937.1	AC008280.1	5.79	1.6e-08	1.72e-05	0.27	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54029552~54030682:-
STAD	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	5.79	1.6e-08	1.72e-05	0.44	0.3	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
STAD	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-5.79	1.6e-08	1.72e-05	-0.39	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
STAD	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-5.79	1.6e-08	1.72e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
STAD	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	5.79	1.6e-08	1.72e-05	0.27	0.3	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
STAD	cis	rs7487075	1	rs7976280	ENSG00000272369.1	RP11-446N19.1	5.79	1.6e-08	1.72e-05	0.36	0.3	Itch intensity from mosquito bite;	chr12:46407042	chr12:46537502~46652550:+
STAD	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	5.79	1.6e-08	1.72e-05	0.28	0.3	Depression;	chr6:28273214	chr6:28176188~28176674:+
STAD	cis	rs3806843	0.9	rs2262576	ENSG00000202111.1	VTRNA1-2	5.79	1.6e-08	1.72e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140755951	chr5:140718925~140719013:+
STAD	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	5.79	1.61e-08	1.73e-05	0.31	0.3	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
STAD	cis	rs916888	0.647	rs199524	ENSG00000261575.2	RP11-259G18.1	-5.79	1.61e-08	1.73e-05	-0.41	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46267037~46268694:+
STAD	cis	rs916888	0.647	rs199523	ENSG00000261575.2	RP11-259G18.1	-5.79	1.61e-08	1.73e-05	-0.41	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46267037~46268694:+
STAD	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-5.79	1.61e-08	1.73e-05	-0.31	-0.3	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
STAD	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	5.79	1.62e-08	1.74e-05	0.47	0.3	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
STAD	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-5.79	1.62e-08	1.74e-05	-0.44	-0.3	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
STAD	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	5.79	1.62e-08	1.74e-05	0.37	0.3	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
STAD	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-5.79	1.62e-08	1.74e-05	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
STAD	cis	rs494459	0.536	rs7103067	ENSG00000278376.1	RP11-158I9.8	-5.79	1.62e-08	1.74e-05	-0.31	-0.3	Height;	chr11:118852670	chr11:118791254~118793137:+
STAD	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-5.79	1.62e-08	1.74e-05	-0.29	-0.3	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
STAD	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-5.78	1.63e-08	1.75e-05	-0.36	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
STAD	cis	rs10129255	0.957	rs67625077	ENSG00000280411.1	IGHV1-69-2	-5.78	1.63e-08	1.75e-05	-0.28	-0.3	Kawasaki disease;	chr14:106715436	chr14:106762092~106762588:-
STAD	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	5.78	1.63e-08	1.75e-05	0.3	0.3	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
STAD	cis	rs1400745	0.756	rs10136352	ENSG00000258738.1	RP11-73E17.2	5.78	1.63e-08	1.75e-05	0.35	0.3	Monocyte count;	chr14:34865349	chr14:34874343~34876459:+
STAD	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	5.78	1.63e-08	1.75e-05	0.37	0.3	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
STAD	cis	rs7555523	0.83	rs1547725	ENSG00000224358.1	RP11-466F5.8	-5.78	1.63e-08	1.75e-05	-0.54	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165701721	chr1:165768929~165775176:+
STAD	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-5.78	1.63e-08	1.75e-05	-0.32	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
STAD	cis	rs10129255	0.744	rs28517388	ENSG00000280411.1	IGHV1-69-2	-5.78	1.63e-08	1.75e-05	-0.28	-0.3	Kawasaki disease;	chr14:106704323	chr14:106762092~106762588:-
STAD	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-5.78	1.64e-08	1.76e-05	-0.31	-0.3	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	5.78	1.64e-08	1.76e-05	0.26	0.3	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
STAD	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-5.78	1.64e-08	1.76e-05	-0.32	-0.3	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
STAD	cis	rs7487075	0.754	rs10880962	ENSG00000257261.4	RP11-96H19.1	5.78	1.64e-08	1.76e-05	0.35	0.3	Itch intensity from mosquito bite;	chr12:46379661	chr12:46383679~46876159:+
STAD	cis	rs728616	0.867	rs61860039	ENSG00000225484.5	NUTM2B-AS1	-5.78	1.64e-08	1.76e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860041	ENSG00000225484.5	NUTM2B-AS1	-5.78	1.64e-08	1.76e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860042	ENSG00000225484.5	NUTM2B-AS1	-5.78	1.64e-08	1.76e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860043	ENSG00000225484.5	NUTM2B-AS1	-5.78	1.64e-08	1.76e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860044	ENSG00000225484.5	NUTM2B-AS1	-5.78	1.64e-08	1.76e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs12415870	ENSG00000225484.5	NUTM2B-AS1	-5.78	1.64e-08	1.76e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs12414521	ENSG00000225484.5	NUTM2B-AS1	-5.78	1.64e-08	1.76e-05	-0.67	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79663088~79826594:-
STAD	cis	rs67180937	0.677	rs17011666	ENSG00000272750.1	RP11-378J18.8	-5.78	1.65e-08	1.77e-05	-0.3	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222625623	chr1:222658867~222661512:-
STAD	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	5.78	1.65e-08	1.77e-05	0.43	0.3	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
STAD	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	5.78	1.65e-08	1.77e-05	0.31	0.3	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
STAD	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	5.78	1.65e-08	1.77e-05	0.3	0.3	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
STAD	cis	rs1426063	0.858	rs6823982	ENSG00000249717.1	RP11-44F21.3	5.78	1.65e-08	1.77e-05	0.52	0.3	QT interval;	chr4:75084961	chr4:74955974~74970362:-
STAD	cis	rs1400745	0.729	rs28472856	ENSG00000258738.1	RP11-73E17.2	5.78	1.66e-08	1.77e-05	0.36	0.3	Monocyte count;	chr14:34862951	chr14:34874343~34876459:+
STAD	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	5.78	1.66e-08	1.78e-05	0.47	0.3	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	5.78	1.66e-08	1.78e-05	0.47	0.3	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
STAD	cis	rs12699921	0.632	rs2723502	ENSG00000279048.1	RP11-511H23.2	-5.78	1.66e-08	1.78e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17814993	chr7:17940503~17942922:+
STAD	cis	rs992157	0.735	rs13430006	ENSG00000237281.1	CATIP-AS2	5.78	1.66e-08	1.78e-05	0.3	0.3	Colorectal cancer;	chr2:218248366	chr2:218326889~218357966:-
STAD	cis	rs8141529	0.719	rs6005916	ENSG00000226471.5	CTA-292E10.6	-5.78	1.66e-08	1.78e-05	-0.34	-0.3	Lymphocyte counts;	chr22:28837354	chr22:28800683~28848559:+
STAD	cis	rs1005277	0.557	rs2983338	ENSG00000099251.13	HSD17B7P2	5.78	1.66e-08	1.78e-05	0.33	0.3	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38356380~38378505:+
STAD	cis	rs7487075	0.964	rs2408497	ENSG00000272369.1	RP11-446N19.1	5.78	1.66e-08	1.78e-05	0.36	0.3	Itch intensity from mosquito bite;	chr12:46402968	chr12:46537502~46652550:+
STAD	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-5.78	1.66e-08	1.78e-05	-0.34	-0.3	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
STAD	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	5.78	1.66e-08	1.78e-05	0.38	0.3	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
STAD	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-5.78	1.67e-08	1.79e-05	-0.33	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	5.78	1.67e-08	1.79e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	5.78	1.67e-08	1.79e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	5.78	1.67e-08	1.79e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	5.78	1.67e-08	1.79e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	5.78	1.67e-08	1.79e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
STAD	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	5.78	1.67e-08	1.79e-05	0.36	0.3	Height;	chr6:109424305	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	5.78	1.67e-08	1.79e-05	0.36	0.3	Height;	chr6:109425054	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	5.78	1.67e-08	1.79e-05	0.36	0.3	Height;	chr6:109426518	chr6:109382795~109383666:+
STAD	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-5.78	1.67e-08	1.79e-05	-0.33	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
STAD	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-5.78	1.67e-08	1.79e-05	-0.31	-0.3	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-5.78	1.67e-08	1.79e-05	-0.31	-0.3	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
STAD	cis	rs12699921	0.598	rs1404421	ENSG00000279048.1	RP11-511H23.2	-5.78	1.67e-08	1.79e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17777807	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2723508	ENSG00000279048.1	RP11-511H23.2	-5.78	1.67e-08	1.79e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17778440	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.658	rs2691592	ENSG00000279048.1	RP11-511H23.2	-5.78	1.67e-08	1.79e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17779817	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.598	rs2691593	ENSG00000279048.1	RP11-511H23.2	-5.78	1.67e-08	1.79e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17780032	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2723507	ENSG00000279048.1	RP11-511H23.2	-5.78	1.67e-08	1.79e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17780305	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2691596	ENSG00000279048.1	RP11-511H23.2	-5.78	1.67e-08	1.79e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17780460	chr7:17940503~17942922:+
STAD	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	5.78	1.68e-08	1.79e-05	0.36	0.3	Height;	chr6:109370741	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	5.78	1.68e-08	1.79e-05	0.36	0.3	Height;	chr6:109371524	chr6:109382795~109383666:+
STAD	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	5.78	1.68e-08	1.8e-05	0.32	0.3	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
STAD	cis	rs7580658	0.724	rs4662711	ENSG00000200250.1	RNU6-1147P	5.78	1.68e-08	1.8e-05	0.28	0.3	Protein C levels;	chr2:127233264	chr2:127316873~127316979:+
STAD	cis	rs228614	0.51	rs223415	ENSG00000230069.3	LRRC37A15P	-5.78	1.68e-08	1.8e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102727274~102730721:-
STAD	cis	rs7927771	0.8	rs12146565	ENSG00000280615.1	Y_RNA	-5.78	1.68e-08	1.8e-05	-0.31	-0.3	Subjective well-being;	chr11:47377412	chr11:47614898~47614994:-
STAD	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	5.78	1.68e-08	1.8e-05	0.36	0.3	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	5.78	1.68e-08	1.8e-05	0.36	0.3	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
STAD	cis	rs17301013	0.93	rs6425279	ENSG00000227373.4	RP11-160H22.5	-5.78	1.69e-08	1.8e-05	-0.34	-0.3	Systemic lupus erythematosus;	chr1:174418717	chr1:174115300~174160004:-
STAD	cis	rs12699921	0.598	rs1965534	ENSG00000279048.1	RP11-511H23.2	-5.78	1.69e-08	1.8e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17790488	chr7:17940503~17942922:+
STAD	cis	rs228614	0.536	rs223419	ENSG00000230069.3	LRRC37A15P	-5.78	1.69e-08	1.8e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102727274~102730721:-
STAD	cis	rs228614	0.536	rs223418	ENSG00000230069.3	LRRC37A15P	-5.78	1.69e-08	1.8e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102727274~102730721:-
STAD	cis	rs7487075	0.619	rs10748450	ENSG00000272369.1	RP11-446N19.1	5.78	1.69e-08	1.81e-05	0.37	0.3	Itch intensity from mosquito bite;	chr12:46463319	chr12:46537502~46652550:+
STAD	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	5.78	1.69e-08	1.81e-05	0.43	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
STAD	cis	rs858239	0.537	rs2286272	ENSG00000226816.2	AC005082.12	5.78	1.69e-08	1.81e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23206013~23208045:+
STAD	cis	rs858239	0.537	rs6955115	ENSG00000226816.2	AC005082.12	5.78	1.69e-08	1.81e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23206013~23208045:+
STAD	cis	rs858239	0.537	rs10279691	ENSG00000226816.2	AC005082.12	5.78	1.69e-08	1.81e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23206013~23208045:+
STAD	cis	rs228614	0.536	rs223420	ENSG00000230069.3	LRRC37A15P	-5.78	1.69e-08	1.81e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102727274~102730721:-
STAD	cis	rs11038871	0.815	rs6485686	ENSG00000271350.1	CTD-2384B9.1	5.78	1.69e-08	1.81e-05	0.37	0.3	Immunoglobulin A;	chr11:46635880	chr11:47041027~47041945:-
STAD	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-5.78	1.69e-08	1.81e-05	-0.31	-0.3	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
STAD	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	5.78	1.7e-08	1.81e-05	0.38	0.3	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
STAD	cis	rs3770081	1	rs17027011	ENSG00000273080.1	RP11-301O19.1	-5.78	1.7e-08	1.81e-05	-0.65	-0.3	Facial emotion recognition (sad faces);	chr2:86179433	chr2:86195590~86196049:+
STAD	cis	rs228614	0.51	rs65671	ENSG00000230069.3	LRRC37A15P	-5.78	1.7e-08	1.82e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102727274~102730721:-
STAD	cis	rs4568518	0.616	rs10950691	ENSG00000279048.1	RP11-511H23.2	5.78	1.7e-08	1.82e-05	0.27	0.3	Measles;	chr7:17966511	chr7:17940503~17942922:+
STAD	cis	rs11722779	0.844	rs223345	ENSG00000230069.3	LRRC37A15P	-5.78	1.7e-08	1.82e-05	-0.32	-0.3	Schizophrenia;	chr4:102859366	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.873	rs223344	ENSG00000230069.3	LRRC37A15P	-5.78	1.7e-08	1.82e-05	-0.32	-0.3	Schizophrenia;	chr4:102859765	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.775	rs223341	ENSG00000230069.3	LRRC37A15P	-5.78	1.7e-08	1.82e-05	-0.32	-0.3	Schizophrenia;	chr4:102862343	chr4:102727274~102730721:-
STAD	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-5.78	1.7e-08	1.82e-05	-0.4	-0.3	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-5.78	1.7e-08	1.82e-05	-0.4	-0.3	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-5.78	1.7e-08	1.82e-05	-0.4	-0.3	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-5.78	1.7e-08	1.82e-05	-0.4	-0.3	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-5.78	1.7e-08	1.82e-05	-0.4	-0.3	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-5.78	1.7e-08	1.82e-05	-0.4	-0.3	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
STAD	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-5.78	1.7e-08	1.82e-05	-0.4	-0.3	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
STAD	cis	rs9549260	0.816	rs7324090	ENSG00000229456.1	RLIMP1	5.78	1.7e-08	1.82e-05	0.27	0.3	Red blood cell count;	chr13:40679821	chr13:40618738~40621348:+
STAD	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	5.78	1.71e-08	1.82e-05	0.36	0.3	Height;	chr6:109368228	chr6:109382795~109383666:+
STAD	cis	rs10129255	0.917	rs11625208	ENSG00000223648.3	IGHV3-64	5.78	1.71e-08	1.82e-05	0.25	0.3	Kawasaki disease;	chr14:106698757	chr14:106643132~106658258:-
STAD	cis	rs17301013	0.932	rs7555533	ENSG00000227373.4	RP11-160H22.5	5.78	1.71e-08	1.82e-05	0.35	0.3	Systemic lupus erythematosus;	chr1:174589983	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.861	rs6672148	ENSG00000227373.4	RP11-160H22.5	5.78	1.71e-08	1.82e-05	0.35	0.3	Systemic lupus erythematosus;	chr1:174604016	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs10912813	ENSG00000227373.4	RP11-160H22.5	5.78	1.71e-08	1.82e-05	0.35	0.3	Systemic lupus erythematosus;	chr1:174607342	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs67967476	ENSG00000227373.4	RP11-160H22.5	5.78	1.71e-08	1.82e-05	0.35	0.3	Systemic lupus erythematosus;	chr1:174616119	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs6683602	ENSG00000227373.4	RP11-160H22.5	5.78	1.71e-08	1.82e-05	0.35	0.3	Systemic lupus erythematosus;	chr1:174617615	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs6696197	ENSG00000227373.4	RP11-160H22.5	5.78	1.71e-08	1.82e-05	0.35	0.3	Systemic lupus erythematosus;	chr1:174617860	chr1:174115300~174160004:-
STAD	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	5.78	1.71e-08	1.82e-05	0.31	0.3	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
STAD	cis	rs4927850	1	rs6799572	ENSG00000185485.13	SDHAP1	5.78	1.71e-08	1.82e-05	0.3	0.3	Pancreatic cancer;	chr3:196013537	chr3:195959748~195990318:-
STAD	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	5.78	1.71e-08	1.82e-05	0.31	0.3	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
STAD	cis	rs227275	0.555	rs223402	ENSG00000230069.3	LRRC37A15P	-5.78	1.71e-08	1.82e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223410	ENSG00000230069.3	LRRC37A15P	-5.78	1.71e-08	1.83e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102727274~102730721:-
STAD	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-5.78	1.71e-08	1.83e-05	-0.41	-0.3	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
STAD	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	5.77	1.71e-08	1.83e-05	0.36	0.3	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
STAD	cis	rs11038871	1	rs3802890	ENSG00000271350.1	CTD-2384B9.1	5.77	1.72e-08	1.83e-05	0.37	0.3	Immunoglobulin A;	chr11:46512996	chr11:47041027~47041945:-
STAD	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-5.77	1.72e-08	1.83e-05	-0.36	-0.3	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
STAD	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	5.77	1.72e-08	1.83e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	5.77	1.72e-08	1.83e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
STAD	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-5.77	1.72e-08	1.83e-05	-0.35	-0.3	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
STAD	cis	rs6456156	0.774	rs968333	ENSG00000265828.1	MIR3939	-5.77	1.72e-08	1.83e-05	-0.32	-0.3	Primary biliary cholangitis;	chr6:167112710	chr6:166997807~166997912:-
STAD	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	5.77	1.72e-08	1.83e-05	0.32	0.3	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
STAD	cis	rs8098244	0.603	rs1711460	ENSG00000267301.1	RPL23AP77	-5.77	1.72e-08	1.83e-05	-0.34	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23711441	chr18:23709825~23710287:-
STAD	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	5.77	1.72e-08	1.84e-05	0.4	0.3	Height;	chr6:109430398	chr6:109382795~109383666:+
STAD	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	5.77	1.72e-08	1.84e-05	0.46	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
STAD	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	5.77	1.72e-08	1.84e-05	0.36	0.3	Height;	chr6:109402736	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	5.77	1.72e-08	1.84e-05	0.36	0.3	Height;	chr6:109403734	chr6:109382795~109383666:+
STAD	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	5.77	1.73e-08	1.84e-05	0.39	0.3	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
STAD	cis	rs11079159	0.628	rs884303	ENSG00000263096.1	RP11-515O17.2	5.77	1.73e-08	1.84e-05	0.37	0.3	QRS duration;	chr17:55289939	chr17:55271504~55273653:-
STAD	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-5.77	1.73e-08	1.84e-05	-0.32	-0.3	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
STAD	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-5.77	1.73e-08	1.84e-05	-0.32	-0.3	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
STAD	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	5.77	1.73e-08	1.84e-05	0.31	0.3	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
STAD	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	5.77	1.73e-08	1.84e-05	0.31	0.3	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
STAD	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	5.77	1.73e-08	1.84e-05	0.34	0.3	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
STAD	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	5.77	1.73e-08	1.84e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	5.77	1.73e-08	1.84e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	5.77	1.73e-08	1.84e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	5.77	1.73e-08	1.84e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	5.77	1.73e-08	1.84e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
STAD	cis	rs11079159	0.628	rs884301	ENSG00000263096.1	RP11-515O17.2	5.77	1.73e-08	1.84e-05	0.37	0.3	QRS duration;	chr17:55290103	chr17:55271504~55273653:-
STAD	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	5.77	1.73e-08	1.84e-05	0.36	0.3	Height;	chr6:109397362	chr6:109382795~109383666:+
STAD	cis	rs7927771	0.864	rs755553	ENSG00000280615.1	Y_RNA	5.77	1.73e-08	1.84e-05	0.3	0.3	Subjective well-being;	chr11:47410752	chr11:47614898~47614994:-
STAD	cis	rs875971	0.545	rs17138149	ENSG00000224316.1	RP11-479O9.2	5.77	1.73e-08	1.85e-05	0.33	0.3	Aortic root size;	chr7:66228193	chr7:65773620~65802067:+
STAD	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	5.77	1.74e-08	1.85e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	5.77	1.74e-08	1.85e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	5.77	1.74e-08	1.85e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
STAD	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	5.77	1.74e-08	1.85e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	5.77	1.74e-08	1.85e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
STAD	cis	rs17301013	0.932	rs10753086	ENSG00000227373.4	RP11-160H22.5	5.77	1.74e-08	1.85e-05	0.35	0.3	Systemic lupus erythematosus;	chr1:174580802	chr1:174115300~174160004:-
STAD	cis	rs12699921	0.632	rs2691581	ENSG00000279048.1	RP11-511H23.2	-5.77	1.74e-08	1.86e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17789568	chr7:17940503~17942922:+
STAD	cis	rs7555523	0.83	rs4656460	ENSG00000224358.1	RP11-466F5.8	-5.77	1.75e-08	1.86e-05	-0.54	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165703130	chr1:165768929~165775176:+
STAD	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	5.77	1.75e-08	1.87e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
STAD	cis	rs1426063	0.614	rs76325897	ENSG00000249717.1	RP11-44F21.3	5.77	1.75e-08	1.87e-05	0.67	0.3	QT interval;	chr4:75084747	chr4:74955974~74970362:-
STAD	cis	rs7555523	0.83	rs6426936	ENSG00000224358.1	RP11-466F5.8	5.77	1.76e-08	1.87e-05	0.52	0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165715470	chr1:165768929~165775176:+
STAD	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	5.77	1.76e-08	1.87e-05	0.3	0.3	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	5.77	1.76e-08	1.87e-05	0.3	0.3	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	5.77	1.76e-08	1.87e-05	0.3	0.3	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	5.77	1.76e-08	1.87e-05	0.3	0.3	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	5.77	1.76e-08	1.87e-05	0.3	0.3	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	5.77	1.76e-08	1.87e-05	0.3	0.3	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	5.77	1.76e-08	1.87e-05	0.3	0.3	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
STAD	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	5.77	1.76e-08	1.87e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
STAD	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-5.77	1.77e-08	1.88e-05	-0.3	-0.3	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
STAD	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-5.77	1.77e-08	1.88e-05	-0.36	-0.3	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
STAD	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	5.77	1.77e-08	1.88e-05	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	5.77	1.77e-08	1.88e-05	0.37	0.3	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
STAD	cis	rs992157	0.735	rs2271541	ENSG00000237281.1	CATIP-AS2	-5.77	1.77e-08	1.88e-05	-0.3	-0.3	Colorectal cancer;	chr2:218217396	chr2:218326889~218357966:-
STAD	cis	rs992157	0.71	rs12694432	ENSG00000237281.1	CATIP-AS2	-5.77	1.77e-08	1.88e-05	-0.3	-0.3	Colorectal cancer;	chr2:218217607	chr2:218326889~218357966:-
STAD	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	5.77	1.77e-08	1.88e-05	0.29	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
STAD	cis	rs2439831	0.867	rs2447196	ENSG00000275601.1	AC011330.13	5.77	1.78e-08	1.89e-05	0.39	0.3	Lung cancer in ever smokers;	chr15:43601620	chr15:43642389~43643023:-
STAD	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	5.77	1.78e-08	1.89e-05	0.32	0.3	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
STAD	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	5.77	1.78e-08	1.89e-05	0.37	0.3	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
STAD	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-5.77	1.78e-08	1.89e-05	-0.32	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
STAD	cis	rs9549260	0.564	rs6563844	ENSG00000229456.1	RLIMP1	5.77	1.78e-08	1.9e-05	0.26	0.3	Red blood cell count;	chr13:40724054	chr13:40618738~40621348:+
STAD	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-5.77	1.79e-08	1.9e-05	-0.56	-0.3	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
STAD	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	5.77	1.79e-08	1.9e-05	0.4	0.3	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
STAD	cis	rs2337406	0.714	rs7150993	ENSG00000274576.2	IGHV2-70	-5.77	1.79e-08	1.9e-05	-0.35	-0.3	Alzheimer's disease (late onset);	chr14:106818515	chr14:106770577~106771020:-
STAD	cis	rs13113518	1	rs3749474	ENSG00000272969.1	RP11-528I4.2	5.77	1.79e-08	1.9e-05	0.37	0.3	Height;	chr4:55434518	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.966	rs1474271	ENSG00000272969.1	RP11-528I4.2	5.77	1.79e-08	1.9e-05	0.37	0.3	Height;	chr4:55435912	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11937487	ENSG00000272969.1	RP11-528I4.2	5.77	1.79e-08	1.9e-05	0.37	0.3	Height;	chr4:55436576	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs3805146	ENSG00000272969.1	RP11-528I4.2	5.77	1.79e-08	1.9e-05	0.37	0.3	Height;	chr4:55436985	chr4:55547112~55547889:+
STAD	cis	rs240993	0.761	rs9400480	ENSG00000230177.1	RP5-1112D6.4	5.77	1.79e-08	1.9e-05	0.3	0.3	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111277932~111278742:+
STAD	cis	rs3806843	0.864	rs2531343	ENSG00000202111.1	VTRNA1-2	5.77	1.8e-08	1.91e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.9	rs2531341	ENSG00000202111.1	VTRNA1-2	5.77	1.8e-08	1.91e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751309	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.9	rs2531340	ENSG00000202111.1	VTRNA1-2	5.77	1.8e-08	1.91e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751461	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.868	rs2563281	ENSG00000202111.1	VTRNA1-2	5.77	1.8e-08	1.91e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751634	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.9	rs2563280	ENSG00000202111.1	VTRNA1-2	5.77	1.8e-08	1.91e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751945	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.838	rs2262567	ENSG00000202111.1	VTRNA1-2	5.77	1.8e-08	1.91e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr5:140718925~140719013:+
STAD	cis	rs13113518	0.783	rs11943206	ENSG00000272969.1	RP11-528I4.2	5.77	1.8e-08	1.91e-05	0.38	0.3	Height;	chr4:55570843	chr4:55547112~55547889:+
STAD	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-5.77	1.8e-08	1.91e-05	-0.27	-0.3	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
STAD	cis	rs453301	0.571	rs2929305	ENSG00000254340.1	RP11-10A14.3	-5.77	1.8e-08	1.91e-05	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9227707	chr8:9141424~9145435:+
STAD	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	5.77	1.81e-08	1.92e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
STAD	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-5.77	1.81e-08	1.92e-05	-0.28	-0.3	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
STAD	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-5.76	1.81e-08	1.92e-05	-0.31	-0.3	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
STAD	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	5.76	1.81e-08	1.92e-05	0.34	0.3	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
STAD	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	5.76	1.81e-08	1.92e-05	0.34	0.3	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
STAD	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-5.76	1.81e-08	1.92e-05	-0.34	-0.3	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
STAD	cis	rs2283792	0.776	rs9610458	ENSG00000228050.1	TOP3BP1	5.76	1.81e-08	1.92e-05	0.33	0.3	Multiple sclerosis;	chr22:21851064	chr22:22223187~22224566:-
STAD	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	5.76	1.82e-08	1.93e-05	0.3	0.3	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
STAD	cis	rs453301	0.571	rs2929453	ENSG00000254340.1	RP11-10A14.3	-5.76	1.82e-08	1.93e-05	-0.37	-0.3	Joint mobility (Beighton score);	chr8:9226831	chr8:9141424~9145435:+
STAD	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	5.76	1.82e-08	1.93e-05	0.48	0.3	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
STAD	cis	rs992157	0.735	rs10932765	ENSG00000237281.1	CATIP-AS2	-5.76	1.82e-08	1.93e-05	-0.3	-0.3	Colorectal cancer;	chr2:218234761	chr2:218326889~218357966:-
STAD	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	5.76	1.82e-08	1.93e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
STAD	cis	rs7927771	0.756	rs10742803	ENSG00000280615.1	Y_RNA	5.76	1.82e-08	1.93e-05	0.3	0.3	Subjective well-being;	chr11:47418387	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.864	rs2293580	ENSG00000280615.1	Y_RNA	5.76	1.82e-08	1.93e-05	0.3	0.3	Subjective well-being;	chr11:47418732	chr11:47614898~47614994:-
STAD	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-5.76	1.82e-08	1.93e-05	-0.32	-0.3	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
STAD	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-5.76	1.82e-08	1.93e-05	-0.42	-0.3	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
STAD	cis	rs516805	0.748	rs647178	ENSG00000279453.1	RP3-425C14.4	-5.76	1.83e-08	1.94e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122543602	chr6:122436789~122439223:-
STAD	cis	rs516805	0.667	rs197679	ENSG00000279453.1	RP3-425C14.4	-5.76	1.83e-08	1.94e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122548188	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs197681	ENSG00000279453.1	RP3-425C14.4	-5.76	1.83e-08	1.94e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122551788	chr6:122436789~122439223:-
STAD	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	5.76	1.83e-08	1.94e-05	0.32	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
STAD	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-5.76	1.83e-08	1.94e-05	-0.45	-0.3	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
STAD	cis	rs8040855	0.658	rs4842864	ENSG00000229212.6	RP11-561C5.4	5.76	1.83e-08	1.94e-05	0.41	0.3	Bulimia nervosa;	chr15:85101315	chr15:85205440~85234795:-
STAD	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	5.76	1.83e-08	1.94e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
STAD	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	5.76	1.83e-08	1.94e-05	0.31	0.3	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
STAD	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-5.76	1.84e-08	1.94e-05	-0.28	-0.3	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
STAD	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	5.76	1.84e-08	1.95e-05	0.31	0.3	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
STAD	cis	rs7927771	0.864	rs2293577	ENSG00000280615.1	Y_RNA	5.76	1.84e-08	1.95e-05	0.3	0.3	Subjective well-being;	chr11:47415651	chr11:47614898~47614994:-
STAD	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	5.76	1.84e-08	1.95e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	5.76	1.84e-08	1.95e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
STAD	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	5.76	1.84e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
STAD	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	5.76	1.84e-08	1.95e-05	0.47	0.3	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
STAD	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	5.76	1.84e-08	1.95e-05	0.3	0.3	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
STAD	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-5.76	1.84e-08	1.95e-05	-0.38	-0.3	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
STAD	cis	rs227275	0.525	rs7685399	ENSG00000230069.3	LRRC37A15P	-5.76	1.84e-08	1.95e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs2866417	ENSG00000230069.3	LRRC37A15P	-5.76	1.84e-08	1.95e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs1383733	ENSG00000230069.3	LRRC37A15P	-5.76	1.84e-08	1.95e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102727274~102730721:-
STAD	cis	rs17138358	0.515	rs2691610	ENSG00000279048.1	RP11-511H23.2	-5.76	1.84e-08	1.95e-05	-0.28	-0.3	HDL cholesterol levels;	chr7:17781815	chr7:17940503~17942922:+
STAD	cis	rs9549260	0.755	rs2721067	ENSG00000229456.1	RLIMP1	5.76	1.84e-08	1.95e-05	0.27	0.3	Red blood cell count;	chr13:40582571	chr13:40618738~40621348:+
STAD	cis	rs7924176	0.564	rs12569971	ENSG00000236900.1	TIMM9P1	-5.76	1.85e-08	1.95e-05	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74194617	chr10:74344550~74344805:-
STAD	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	5.76	1.85e-08	1.95e-05	0.5	0.3	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
STAD	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-5.76	1.85e-08	1.95e-05	-0.25	-0.3	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
STAD	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-5.76	1.85e-08	1.95e-05	-0.25	-0.3	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
STAD	cis	rs516805	0.715	rs197691	ENSG00000279453.1	RP3-425C14.4	-5.76	1.85e-08	1.95e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122513394	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs197692	ENSG00000279453.1	RP3-425C14.4	-5.76	1.85e-08	1.95e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122515260	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs197693	ENSG00000279453.1	RP3-425C14.4	-5.76	1.85e-08	1.95e-05	-0.42	-0.3	Lymphocyte counts;	chr6:122521294	chr6:122436789~122439223:-
STAD	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	5.76	1.85e-08	1.95e-05	0.31	0.3	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
STAD	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	5.76	1.85e-08	1.95e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
STAD	cis	rs7829975	0.742	rs1533058	ENSG00000254340.1	RP11-10A14.3	5.76	1.85e-08	1.95e-05	0.33	0.3	Mood instability;	chr8:8827680	chr8:9141424~9145435:+
STAD	cis	rs7487075	0.647	rs4077708	ENSG00000272369.1	RP11-446N19.1	5.76	1.85e-08	1.95e-05	0.41	0.3	Itch intensity from mosquito bite;	chr12:46463590	chr12:46537502~46652550:+
STAD	cis	rs3806843	0.568	rs2530232	ENSG00000202111.1	VTRNA1-2	5.76	1.86e-08	1.97e-05	0.29	0.3	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr5:140718925~140719013:+
STAD	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	5.76	1.87e-08	1.97e-05	0.4	0.3	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
STAD	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	5.76	1.87e-08	1.97e-05	0.43	0.3	Height;	chr6:109427303	chr6:109382795~109383666:+
STAD	cis	rs12699921	0.632	rs2723572	ENSG00000279048.1	RP11-511H23.2	-5.76	1.87e-08	1.97e-05	-0.27	-0.3	Fibrinogen levels;	chr7:17848964	chr7:17940503~17942922:+
STAD	cis	rs4927850	1	rs7630875	ENSG00000185485.13	SDHAP1	5.76	1.87e-08	1.97e-05	0.29	0.3	Pancreatic cancer;	chr3:196026895	chr3:195959748~195990318:-
STAD	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-5.76	1.87e-08	1.97e-05	-0.41	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
STAD	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	5.76	1.87e-08	1.97e-05	0.34	0.3	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
STAD	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-5.76	1.88e-08	1.98e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
STAD	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-5.76	1.88e-08	1.98e-05	-0.32	-0.3	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
STAD	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-5.76	1.88e-08	1.98e-05	-0.36	-0.3	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
STAD	cis	rs227275	0.524	rs223337	ENSG00000230069.3	LRRC37A15P	-5.76	1.88e-08	1.98e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223357	ENSG00000230069.3	LRRC37A15P	-5.76	1.89e-08	1.99e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102727274~102730721:-
STAD	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	5.76	1.89e-08	1.99e-05	0.32	0.3	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
STAD	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	5.76	1.89e-08	1.99e-05	0.43	0.3	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
STAD	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	5.76	1.89e-08	1.99e-05	0.43	0.3	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
STAD	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	5.76	1.89e-08	1.99e-05	0.31	0.3	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
STAD	cis	rs7927771	0.69	rs35496532	ENSG00000280615.1	Y_RNA	-5.76	1.9e-08	2e-05	-0.3	-0.3	Subjective well-being;	chr11:47428787	chr11:47614898~47614994:-
STAD	cis	rs7924176	0.601	rs10824071	ENSG00000236900.1	TIMM9P1	-5.76	1.9e-08	2e-05	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74344550~74344805:-
STAD	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	5.76	1.9e-08	2e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	5.76	1.9e-08	2e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
STAD	cis	rs13113518	1	rs11133378	ENSG00000272969.1	RP11-528I4.2	5.76	1.9e-08	2e-05	0.37	0.3	Height;	chr4:55439472	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11942279	ENSG00000272969.1	RP11-528I4.2	5.76	1.9e-08	2e-05	0.37	0.3	Height;	chr4:55439652	chr4:55547112~55547889:+
STAD	cis	rs2948294	0.588	rs12544596	ENSG00000253981.4	ALG1L13P	5.76	1.9e-08	2e-05	0.36	0.3	Red cell distribution width;	chr8:8258824	chr8:8236003~8244667:-
STAD	cis	rs10129255	0.826	rs7150693	ENSG00000280411.1	IGHV1-69-2	-5.76	1.9e-08	2e-05	-0.28	-0.3	Kawasaki disease;	chr14:106705382	chr14:106762092~106762588:-
STAD	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-5.76	1.9e-08	2e-05	-0.32	-0.3	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-5.76	1.9e-08	2e-05	-0.32	-0.3	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
STAD	cis	rs7487075	0.823	rs34472481	ENSG00000272369.1	RP11-446N19.1	5.76	1.91e-08	2.01e-05	0.35	0.3	Itch intensity from mosquito bite;	chr12:46442565	chr12:46537502~46652550:+
STAD	cis	rs992157	0.71	rs12996912	ENSG00000237281.1	CATIP-AS2	-5.76	1.91e-08	2.01e-05	-0.3	-0.3	Colorectal cancer;	chr2:218245832	chr2:218326889~218357966:-
STAD	cis	rs992157	0.687	rs10206984	ENSG00000237281.1	CATIP-AS2	-5.76	1.91e-08	2.01e-05	-0.29	-0.3	Colorectal cancer;	chr2:218202257	chr2:218326889~218357966:-
STAD	cis	rs992157	0.697	rs13384682	ENSG00000237281.1	CATIP-AS2	-5.76	1.91e-08	2.01e-05	-0.29	-0.3	Colorectal cancer;	chr2:218204414	chr2:218326889~218357966:-
STAD	cis	rs992157	0.71	rs7569907	ENSG00000237281.1	CATIP-AS2	-5.76	1.91e-08	2.01e-05	-0.29	-0.3	Colorectal cancer;	chr2:218205828	chr2:218326889~218357966:-
STAD	cis	rs992157	0.735	rs13393821	ENSG00000237281.1	CATIP-AS2	-5.76	1.91e-08	2.01e-05	-0.29	-0.3	Colorectal cancer;	chr2:218212019	chr2:218326889~218357966:-
STAD	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	5.76	1.91e-08	2.01e-05	0.31	0.3	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
STAD	cis	rs875971	0.545	rs10950025	ENSG00000224316.1	RP11-479O9.2	5.76	1.91e-08	2.01e-05	0.33	0.3	Aortic root size;	chr7:66158946	chr7:65773620~65802067:+
STAD	cis	rs875971	0.52	rs12666485	ENSG00000224316.1	RP11-479O9.2	5.76	1.91e-08	2.01e-05	0.33	0.3	Aortic root size;	chr7:66160135	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs67688847	ENSG00000224316.1	RP11-479O9.2	5.76	1.91e-08	2.01e-05	0.33	0.3	Aortic root size;	chr7:66161064	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs7787063	ENSG00000224316.1	RP11-479O9.2	5.76	1.91e-08	2.01e-05	0.33	0.3	Aortic root size;	chr7:66164012	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs12673308	ENSG00000224316.1	RP11-479O9.2	5.76	1.91e-08	2.01e-05	0.33	0.3	Aortic root size;	chr7:66166374	chr7:65773620~65802067:+
STAD	cis	rs228614	0.536	rs150897	ENSG00000230069.3	LRRC37A15P	-5.75	1.91e-08	2.01e-05	-0.32	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102727274~102730721:-
STAD	cis	rs1075265	0.633	rs28653587	ENSG00000235937.1	AC008280.1	5.75	1.91e-08	2.01e-05	0.26	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.633	rs7564912	ENSG00000235937.1	AC008280.1	5.75	1.91e-08	2.01e-05	0.26	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54029552~54030682:-
STAD	cis	rs992157	0.735	rs12990082	ENSG00000237281.1	CATIP-AS2	-5.75	1.91e-08	2.01e-05	-0.3	-0.3	Colorectal cancer;	chr2:218237609	chr2:218326889~218357966:-
STAD	cis	rs992157	0.661	rs17653757	ENSG00000237281.1	CATIP-AS2	-5.75	1.91e-08	2.01e-05	-0.3	-0.3	Colorectal cancer;	chr2:218244641	chr2:218326889~218357966:-
STAD	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-5.75	1.91e-08	2.01e-05	-0.3	-0.3	Height;	chr11:118856460	chr11:118791254~118793137:+
STAD	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-5.75	1.91e-08	2.01e-05	-0.3	-0.3	Height;	chr11:118856623	chr11:118791254~118793137:+
STAD	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-5.75	1.91e-08	2.01e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
STAD	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	5.75	1.92e-08	2.01e-05	0.36	0.3	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
STAD	cis	rs6782228	0.675	rs9841987	ENSG00000277250.1	Metazoa_SRP	-5.75	1.92e-08	2.01e-05	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128673681~128674021:-
STAD	cis	rs8040855	0.627	rs12909971	ENSG00000229212.6	RP11-561C5.4	5.75	1.92e-08	2.02e-05	0.42	0.3	Bulimia nervosa;	chr15:85045767	chr15:85205440~85234795:-
STAD	cis	rs7927771	0.864	rs4752838	ENSG00000280615.1	Y_RNA	-5.75	1.92e-08	2.02e-05	-0.3	-0.3	Subjective well-being;	chr11:47444454	chr11:47614898~47614994:-
STAD	cis	rs6496044	0.507	rs62022863	ENSG00000259407.1	RP11-158M2.3	5.75	1.92e-08	2.02e-05	0.32	0.3	Interstitial lung disease;	chr15:85618822	chr15:85744109~85750281:-
STAD	cis	rs7083	0.875	rs536648	ENSG00000254851.1	RP11-109L13.1	5.75	1.92e-08	2.02e-05	0.33	0.3	Blood protein levels;	chr11:117272469	chr11:117135528~117138582:+
STAD	cis	rs7555523	0.832	rs7524755	ENSG00000224358.1	RP11-466F5.8	-5.75	1.93e-08	2.02e-05	-0.48	-0.3	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165725660	chr1:165768929~165775176:+
STAD	cis	rs10129255	0.917	rs8022493	ENSG00000280411.1	IGHV1-69-2	-5.75	1.93e-08	2.03e-05	-0.27	-0.3	Kawasaki disease;	chr14:106781820	chr14:106762092~106762588:-
STAD	cis	rs227275	0.554	rs223359	ENSG00000230069.3	LRRC37A15P	-5.75	1.93e-08	2.03e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102727274~102730721:-
STAD	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-5.75	1.93e-08	2.03e-05	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
STAD	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-5.75	1.93e-08	2.03e-05	-0.35	-0.3	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
STAD	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-5.75	1.93e-08	2.03e-05	-0.33	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
STAD	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-5.75	1.93e-08	2.03e-05	-0.45	-0.3	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
STAD	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	5.75	1.94e-08	2.04e-05	0.31	0.3	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	5.75	1.94e-08	2.04e-05	0.31	0.3	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	5.75	1.94e-08	2.04e-05	0.31	0.3	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	5.75	1.94e-08	2.04e-05	0.31	0.3	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
STAD	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	5.75	1.94e-08	2.04e-05	0.35	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
STAD	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	5.75	1.94e-08	2.04e-05	0.44	0.3	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
STAD	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	5.75	1.94e-08	2.04e-05	0.3	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
STAD	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	5.75	1.94e-08	2.04e-05	0.34	0.3	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	5.75	1.94e-08	2.04e-05	0.34	0.3	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	5.75	1.94e-08	2.04e-05	0.34	0.3	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
STAD	cis	rs858239	0.601	rs6461702	ENSG00000226816.2	AC005082.12	5.75	1.94e-08	2.04e-05	0.38	0.3	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23206013~23208045:+
STAD	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	5.75	1.94e-08	2.04e-05	0.32	0.3	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
STAD	cis	rs227275	0.525	rs10029073	ENSG00000230069.3	LRRC37A15P	-5.75	1.94e-08	2.04e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102727274~102730721:-
STAD	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-5.75	1.94e-08	2.04e-05	-0.36	-0.3	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
STAD	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	5.75	1.95e-08	2.04e-05	0.31	0.3	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
STAD	cis	rs2337406	0.925	rs10131226	ENSG00000211972.2	IGHV3-66	5.75	1.95e-08	2.04e-05	0.32	0.3	Alzheimer's disease (late onset);	chr14:106665764	chr14:106675017~106675544:-
STAD	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	5.75	1.95e-08	2.05e-05	0.31	0.3	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	5.75	1.95e-08	2.05e-05	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
STAD	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	5.75	1.96e-08	2.06e-05	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
STAD	cis	rs7924176	0.601	rs2131957	ENSG00000236900.1	TIMM9P1	-5.75	1.96e-08	2.06e-05	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74344550~74344805:-
STAD	cis	rs11722779	0.935	rs7676736	ENSG00000230069.3	LRRC37A15P	-5.75	1.96e-08	2.06e-05	-0.31	-0.3	Schizophrenia;	chr4:103016729	chr4:102727274~102730721:-
STAD	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	5.75	1.97e-08	2.06e-05	0.29	0.3	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
STAD	cis	rs6452524	0.532	rs26263	ENSG00000243385.2	CTD-2110K23.1	5.75	1.97e-08	2.06e-05	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83201229~83202141:+
STAD	cis	rs227275	0.525	rs11097796	ENSG00000230069.3	LRRC37A15P	-5.75	1.97e-08	2.06e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs11097797	ENSG00000230069.3	LRRC37A15P	-5.75	1.97e-08	2.06e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs13117110	ENSG00000230069.3	LRRC37A15P	-5.75	1.97e-08	2.06e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs13144033	ENSG00000230069.3	LRRC37A15P	-5.75	1.97e-08	2.06e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102727274~102730721:-
STAD	cis	rs10853057	0.541	rs8082708	ENSG00000214174.7	AMZ2P1	-5.75	1.97e-08	2.07e-05	-0.5	-0.3	White matter microstructure (global fractional anisotropy);	chr17:65046182	chr17:64966550~64975576:-
STAD	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	5.75	1.97e-08	2.07e-05	0.36	0.3	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
STAD	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	5.75	1.97e-08	2.07e-05	0.36	0.3	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
STAD	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	5.75	1.97e-08	2.07e-05	0.36	0.3	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	5.75	1.97e-08	2.07e-05	0.36	0.3	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	5.75	1.97e-08	2.07e-05	0.36	0.3	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
STAD	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	5.75	1.98e-08	2.07e-05	0.31	0.3	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	5.75	1.98e-08	2.07e-05	0.31	0.3	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	5.75	1.98e-08	2.07e-05	0.31	0.3	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
STAD	cis	rs1153858	1	rs4775911	ENSG00000259433.2	CTD-2651B20.4	5.75	1.98e-08	2.07e-05	0.32	0.3	Homoarginine levels;	chr15:45357589	chr15:45330209~45332634:-
STAD	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	5.75	1.98e-08	2.07e-05	0.33	0.3	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
STAD	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	5.75	1.98e-08	2.08e-05	0.34	0.3	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
STAD	cis	rs7924176	0.564	rs34868542	ENSG00000236900.1	TIMM9P1	-5.75	1.98e-08	2.08e-05	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226399	chr10:74344550~74344805:-
STAD	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	5.75	1.98e-08	2.08e-05	0.27	0.3	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
STAD	cis	rs992157	0.835	rs11677953	ENSG00000237281.1	CATIP-AS2	5.75	1.98e-08	2.08e-05	0.3	0.3	Colorectal cancer;	chr2:218256940	chr2:218326889~218357966:-
STAD	cis	rs227275	0.525	rs13150426	ENSG00000230069.3	LRRC37A15P	-5.75	1.99e-08	2.08e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102727274~102730721:-
STAD	cis	rs9549260	0.564	rs4943805	ENSG00000229456.1	RLIMP1	5.75	1.99e-08	2.08e-05	0.26	0.3	Red blood cell count;	chr13:40695944	chr13:40618738~40621348:+
STAD	cis	rs875971	0.502	rs2465121	ENSG00000224316.1	RP11-479O9.2	-5.75	1.99e-08	2.08e-05	-0.33	-0.3	Aortic root size;	chr7:66156017	chr7:65773620~65802067:+
STAD	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	5.75	1.99e-08	2.09e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	5.75	1.99e-08	2.09e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
STAD	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	5.75	1.99e-08	2.09e-05	0.25	0.3	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
STAD	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	5.75	1.99e-08	2.09e-05	0.36	0.3	Height;	chr6:109375548	chr6:109382795~109383666:+
STAD	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-5.75	2e-08	2.09e-05	-0.32	-0.3	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
STAD	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	5.75	2e-08	2.09e-05	0.32	0.3	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
STAD	cis	rs10504130	0.569	rs9650179	ENSG00000272024.1	RP11-546K22.3	-5.75	2e-08	2.09e-05	-0.41	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51950284~51950690:+
STAD	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	5.75	2e-08	2.09e-05	0.36	0.3	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
STAD	cis	rs227275	0.554	rs223367	ENSG00000230069.3	LRRC37A15P	-5.75	2e-08	2.1e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102727274~102730721:-
STAD	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-5.75	2e-08	2.1e-05	-0.31	-0.3	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
STAD	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-5.75	2e-08	2.1e-05	-0.29	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
STAD	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-5.75	2e-08	2.1e-05	-0.41	-0.3	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-5.75	2e-08	2.1e-05	-0.41	-0.3	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-5.75	2e-08	2.1e-05	-0.41	-0.3	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-5.75	2e-08	2.1e-05	-0.41	-0.3	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-5.75	2e-08	2.1e-05	-0.41	-0.3	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-5.75	2e-08	2.1e-05	-0.41	-0.3	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
STAD	cis	rs9400467	0.528	rs10872066	ENSG00000230177.1	RP5-1112D6.4	-5.75	2.01e-08	2.1e-05	-0.27	-0.3	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111277932~111278742:+
STAD	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-5.75	2.01e-08	2.1e-05	-0.28	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
STAD	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	5.75	2.01e-08	2.11e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
STAD	cis	rs12682352	0.715	rs332039	ENSG00000254340.1	RP11-10A14.3	5.75	2.02e-08	2.11e-05	0.35	0.3	Neuroticism;	chr8:8866141	chr8:9141424~9145435:+
STAD	cis	rs516805	0.748	rs563084	ENSG00000279453.1	RP3-425C14.4	5.74	2.02e-08	2.11e-05	0.41	0.3	Lymphocyte counts;	chr6:122397105	chr6:122436789~122439223:-
STAD	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	5.74	2.02e-08	2.11e-05	0.28	0.3	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
STAD	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-5.74	2.02e-08	2.11e-05	-0.36	-0.3	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-5.74	2.02e-08	2.11e-05	-0.36	-0.3	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
STAD	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	5.74	2.02e-08	2.11e-05	0.32	0.3	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
STAD	cis	rs9395066	0.525	rs1971482	ENSG00000219384.1	RP11-491H9.3	-5.74	2.02e-08	2.11e-05	-0.29	-0.3	Height;	chr6:45023376	chr6:45158870~45159511:+
STAD	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	5.74	2.02e-08	2.12e-05	0.35	0.3	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
STAD	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	5.74	2.02e-08	2.12e-05	0.3	0.3	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	5.74	2.02e-08	2.12e-05	0.3	0.3	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	5.74	2.02e-08	2.12e-05	0.3	0.3	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	5.74	2.02e-08	2.12e-05	0.3	0.3	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	5.74	2.02e-08	2.12e-05	0.3	0.3	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
STAD	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	5.74	2.02e-08	2.12e-05	0.37	0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
STAD	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	5.74	2.03e-08	2.12e-05	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
STAD	cis	rs227275	0.525	rs17215211	ENSG00000230069.3	LRRC37A15P	-5.74	2.03e-08	2.12e-05	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102727274~102730721:-
STAD	cis	rs7924176	0.601	rs10824073	ENSG00000236900.1	TIMM9P1	-5.74	2.03e-08	2.12e-05	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74344550~74344805:-
STAD	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	5.74	2.03e-08	2.13e-05	0.31	0.3	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
STAD	cis	rs1816752	0.905	rs7571	ENSG00000273628.1	RP11-756A22.7	5.74	2.04e-08	2.13e-05	0.36	0.3	Obesity-related traits;	chr13:24426479	chr13:24933006~24936796:+
STAD	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-5.74	2.04e-08	2.13e-05	-0.38	-0.29	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
STAD	cis	rs17138358	0.515	rs1357796	ENSG00000279048.1	RP11-511H23.2	-5.74	2.05e-08	2.14e-05	-0.26	-0.29	HDL cholesterol levels;	chr7:17833852	chr7:17940503~17942922:+
STAD	cis	rs7829975	0.606	rs6601274	ENSG00000254340.1	RP11-10A14.3	-5.74	2.05e-08	2.14e-05	-0.37	-0.29	Mood instability;	chr8:8941549	chr8:9141424~9145435:+
STAD	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-5.74	2.05e-08	2.14e-05	-0.35	-0.29	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
STAD	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-5.74	2.05e-08	2.14e-05	-0.35	-0.29	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
STAD	cis	rs5769707	0.839	rs73176988	ENSG00000280224.1	CTA-722E9.1	-5.74	2.05e-08	2.14e-05	-0.3	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49500568~49501585:+
STAD	cis	rs10129255	0.957	rs8022165	ENSG00000280411.1	IGHV1-69-2	-5.74	2.05e-08	2.14e-05	-0.27	-0.29	Kawasaki disease;	chr14:106781682	chr14:106762092~106762588:-
STAD	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	5.74	2.06e-08	2.15e-05	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
STAD	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	5.74	2.06e-08	2.15e-05	0.31	0.29	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
STAD	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-5.74	2.06e-08	2.15e-05	-0.31	-0.29	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.869	rs72690553	ENSG00000280411.1	IGHV1-69-2	-5.74	2.06e-08	2.15e-05	-0.28	-0.29	Kawasaki disease;	chr14:106715491	chr14:106762092~106762588:-
STAD	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	5.74	2.06e-08	2.15e-05	0.54	0.29	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
STAD	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	5.74	2.06e-08	2.15e-05	0.28	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
STAD	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-5.74	2.06e-08	2.15e-05	-0.31	-0.29	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
STAD	cis	rs606458	0.92	rs637332	ENSG00000269038.1	AP001462.6	-5.74	2.07e-08	2.16e-05	-0.37	-0.29	Urate levels;	chr11:64761278	chr11:64778954~64779405:+
STAD	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	5.74	2.07e-08	2.16e-05	0.36	0.29	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
STAD	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	5.74	2.07e-08	2.16e-05	0.36	0.29	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
STAD	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	5.74	2.07e-08	2.16e-05	0.36	0.29	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
STAD	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-5.74	2.08e-08	2.16e-05	-0.34	-0.29	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
STAD	cis	rs992157	0.71	rs10169718	ENSG00000237281.1	CATIP-AS2	5.74	2.08e-08	2.16e-05	0.29	0.29	Colorectal cancer;	chr2:218238857	chr2:218326889~218357966:-
STAD	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	5.74	2.08e-08	2.17e-05	0.3	0.29	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	5.74	2.08e-08	2.17e-05	0.3	0.29	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
STAD	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	5.74	2.09e-08	2.17e-05	0.33	0.29	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
STAD	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-5.74	2.09e-08	2.18e-05	-0.31	-0.29	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
STAD	cis	rs7487075	0.578	rs12319162	ENSG00000272369.1	RP11-446N19.1	5.74	2.09e-08	2.18e-05	0.36	0.29	Itch intensity from mosquito bite;	chr12:46444131	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs7134289	ENSG00000272369.1	RP11-446N19.1	5.74	2.09e-08	2.18e-05	0.36	0.29	Itch intensity from mosquito bite;	chr12:46444553	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs10880973	ENSG00000272369.1	RP11-446N19.1	5.74	2.09e-08	2.18e-05	0.36	0.29	Itch intensity from mosquito bite;	chr12:46459426	chr12:46537502~46652550:+
STAD	cis	rs4604732	0.527	rs60444724	ENSG00000227135.1	GCSAML-AS1	-5.74	2.09e-08	2.18e-05	-0.4	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459862	chr1:247524679~247526752:-
STAD	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	5.74	2.09e-08	2.18e-05	0.26	0.29	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
STAD	cis	rs721917	0.506	rs1923538	ENSG00000225484.5	NUTM2B-AS1	-5.74	2.1e-08	2.18e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79663088~79826594:-
STAD	cis	rs721917	0.507	rs2819101	ENSG00000225484.5	NUTM2B-AS1	-5.74	2.1e-08	2.18e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2819100	ENSG00000225484.5	NUTM2B-AS1	-5.74	2.1e-08	2.18e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2758547	ENSG00000225484.5	NUTM2B-AS1	-5.74	2.1e-08	2.18e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79663088~79826594:-
STAD	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-5.74	2.1e-08	2.18e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
STAD	cis	rs7083	0.935	rs523366	ENSG00000254851.1	RP11-109L13.1	5.74	2.1e-08	2.19e-05	0.34	0.29	Blood protein levels;	chr11:117248836	chr11:117135528~117138582:+
STAD	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	5.74	2.1e-08	2.19e-05	0.37	0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
STAD	cis	rs10129255	0.83	rs61997609	ENSG00000280411.1	IGHV1-69-2	-5.74	2.1e-08	2.19e-05	-0.28	-0.29	Kawasaki disease;	chr14:106692376	chr14:106762092~106762588:-
STAD	cis	rs2729354	0.779	rs2511984	ENSG00000265566.2	RN7SL605P	-5.74	2.1e-08	2.19e-05	-0.47	-0.29	Blood protein levels;	chr11:57511260	chr11:57528085~57528365:-
STAD	cis	rs516805	0.667	rs197676	ENSG00000279453.1	RP3-425C14.4	-5.74	2.1e-08	2.19e-05	-0.42	-0.29	Lymphocyte counts;	chr6:122532410	chr6:122436789~122439223:-
STAD	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-5.74	2.11e-08	2.2e-05	-0.34	-0.29	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
STAD	cis	rs7829975	0.755	rs3789849	ENSG00000254340.1	RP11-10A14.3	5.74	2.11e-08	2.2e-05	0.34	0.29	Mood instability;	chr8:8829544	chr8:9141424~9145435:+
STAD	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	5.74	2.11e-08	2.2e-05	0.4	0.29	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
STAD	cis	rs228614	0.534	rs223387	ENSG00000230069.3	LRRC37A15P	-5.74	2.12e-08	2.2e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102727274~102730721:-
STAD	cis	rs875971	0.545	rs316305	ENSG00000224316.1	RP11-479O9.2	-5.74	2.12e-08	2.2e-05	-0.33	-0.29	Aortic root size;	chr7:66152984	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs316306	ENSG00000224316.1	RP11-479O9.2	-5.74	2.12e-08	2.2e-05	-0.33	-0.29	Aortic root size;	chr7:66153687	chr7:65773620~65802067:+
STAD	cis	rs6452524	0.561	rs4331874	ENSG00000243385.2	CTD-2110K23.1	5.74	2.12e-08	2.2e-05	0.36	0.29	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83201229~83202141:+
STAD	cis	rs8005677	0.828	rs12589539	ENSG00000257285.4	RP11-298I3.1	5.74	2.12e-08	2.21e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:22929609~22955562:+
STAD	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	5.74	2.12e-08	2.21e-05	0.32	0.29	Height;	chr11:118852670	chr11:118688039~118690600:-
STAD	cis	rs12699921	0.599	rs2691583	ENSG00000279048.1	RP11-511H23.2	-5.74	2.12e-08	2.21e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17792182	chr7:17940503~17942922:+
STAD	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-5.74	2.12e-08	2.21e-05	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
STAD	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	5.74	2.12e-08	2.21e-05	0.37	0.29	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
STAD	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-5.74	2.12e-08	2.21e-05	-0.42	-0.29	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
STAD	cis	rs9549260	0.755	rs2701869	ENSG00000229456.1	RLIMP1	5.74	2.12e-08	2.21e-05	0.27	0.29	Red blood cell count;	chr13:40583235	chr13:40618738~40621348:+
STAD	cis	rs2337406	0.778	rs56965016	ENSG00000211972.2	IGHV3-66	5.73	2.13e-08	2.22e-05	0.32	0.29	Alzheimer's disease (late onset);	chr14:106656649	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.778	rs56658355	ENSG00000211972.2	IGHV3-66	5.73	2.13e-08	2.22e-05	0.32	0.29	Alzheimer's disease (late onset);	chr14:106662151	chr14:106675017~106675544:-
STAD	cis	rs748404	0.626	rs57938858	ENSG00000249839.1	AC011330.5	-5.73	2.13e-08	2.22e-05	-0.51	-0.29	Lung cancer;	chr15:43520259	chr15:43663654~43684339:-
STAD	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	5.73	2.14e-08	2.22e-05	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
STAD	cis	rs453301	0.624	rs2979265	ENSG00000254340.1	RP11-10A14.3	5.73	2.14e-08	2.22e-05	0.36	0.29	Joint mobility (Beighton score);	chr8:9001207	chr8:9141424~9145435:+
STAD	cis	rs1707322	0.613	rs1473840	ENSG00000280836.1	AL355480.1	5.73	2.14e-08	2.22e-05	0.39	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr1:45581219~45581321:-
STAD	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	5.73	2.14e-08	2.22e-05	0.46	0.29	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	5.73	2.14e-08	2.22e-05	0.46	0.29	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	5.73	2.14e-08	2.22e-05	0.46	0.29	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
STAD	cis	rs1426063	0.614	rs115690958	ENSG00000249717.1	RP11-44F21.3	5.73	2.14e-08	2.22e-05	0.67	0.29	QT interval;	chr4:75078364	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs78681370	ENSG00000249717.1	RP11-44F21.3	5.73	2.14e-08	2.22e-05	0.67	0.29	QT interval;	chr4:75081556	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs17000212	ENSG00000249717.1	RP11-44F21.3	5.73	2.14e-08	2.22e-05	0.67	0.29	QT interval;	chr4:75081611	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs77018380	ENSG00000249717.1	RP11-44F21.3	5.73	2.14e-08	2.22e-05	0.67	0.29	QT interval;	chr4:75081621	chr4:74955974~74970362:-
STAD	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	5.73	2.14e-08	2.23e-05	0.51	0.29	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
STAD	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	5.73	2.14e-08	2.23e-05	0.41	0.29	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
STAD	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	5.73	2.15e-08	2.23e-05	0.4	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	5.73	2.15e-08	2.23e-05	0.4	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	5.73	2.15e-08	2.23e-05	0.4	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
STAD	cis	rs7760535	0.831	rs62420437	ENSG00000230177.1	RP5-1112D6.4	-5.73	2.15e-08	2.23e-05	-0.27	-0.29	Metabolic traits;	chr6:111427577	chr6:111277932~111278742:+
STAD	cis	rs7760535	0.757	rs10456875	ENSG00000230177.1	RP5-1112D6.4	-5.73	2.15e-08	2.23e-05	-0.27	-0.29	Metabolic traits;	chr6:111428522	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs4276544	ENSG00000230177.1	RP5-1112D6.4	-5.73	2.15e-08	2.23e-05	-0.27	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111277932~111278742:+
STAD	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-5.73	2.15e-08	2.23e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
STAD	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	5.73	2.15e-08	2.23e-05	0.79	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
STAD	cis	rs62432291	0.681	rs2932987	ENSG00000235086.1	FNDC1-IT1	5.73	2.15e-08	2.24e-05	0.44	0.29	Joint mobility (Beighton score);	chr6:159234641	chr6:159240786~159243329:+
STAD	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-5.73	2.15e-08	2.24e-05	-0.25	-0.29	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
STAD	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-5.73	2.16e-08	2.25e-05	-0.31	-0.29	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
STAD	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	5.73	2.17e-08	2.25e-05	0.4	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
STAD	cis	rs10129255	0.917	rs7155356	ENSG00000280411.1	IGHV1-69-2	-5.73	2.17e-08	2.25e-05	-0.27	-0.29	Kawasaki disease;	chr14:106697376	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.917	rs10137601	ENSG00000280411.1	IGHV1-69-2	-5.73	2.17e-08	2.25e-05	-0.27	-0.29	Kawasaki disease;	chr14:106697476	chr14:106762092~106762588:-
STAD	cis	rs1075265	0.633	rs10183655	ENSG00000235937.1	AC008280.1	5.73	2.17e-08	2.26e-05	0.26	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54029552~54030682:-
STAD	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	5.73	2.17e-08	2.26e-05	0.36	0.29	Height;	chr6:109390116	chr6:109382795~109383666:+
STAD	cis	rs7487075	0.578	rs4072304	ENSG00000272369.1	RP11-446N19.1	5.73	2.18e-08	2.26e-05	0.4	0.29	Itch intensity from mosquito bite;	chr12:46432404	chr12:46537502~46652550:+
STAD	cis	rs2283792	1	rs2006893	ENSG00000228050.1	TOP3BP1	5.73	2.18e-08	2.26e-05	0.33	0.29	Multiple sclerosis;	chr22:21774389	chr22:22223187~22224566:-
STAD	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	5.73	2.18e-08	2.26e-05	0.32	0.29	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
STAD	cis	rs67180937	0.631	rs1909195	ENSG00000272750.1	RP11-378J18.8	-5.73	2.18e-08	2.26e-05	-0.3	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623985	chr1:222658867~222661512:-
STAD	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	5.73	2.18e-08	2.26e-05	0.35	0.29	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
STAD	cis	rs7487075	0.619	rs10785629	ENSG00000272369.1	RP11-446N19.1	5.73	2.18e-08	2.26e-05	0.36	0.29	Itch intensity from mosquito bite;	chr12:46460944	chr12:46537502~46652550:+
STAD	cis	rs11098499	0.739	rs2203039	ENSG00000248280.1	RP11-33B1.2	-5.73	2.19e-08	2.27e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119211192	chr4:119440561~119450157:-
STAD	cis	rs7487075	0.93	rs4768121	ENSG00000272369.1	RP11-446N19.1	5.73	2.19e-08	2.27e-05	0.36	0.29	Itch intensity from mosquito bite;	chr12:46436069	chr12:46537502~46652550:+
STAD	cis	rs7924176	0.601	rs3180427	ENSG00000236900.1	TIMM9P1	-5.73	2.19e-08	2.27e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74344550~74344805:-
STAD	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	5.73	2.19e-08	2.28e-05	0.45	0.29	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
STAD	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	5.73	2.19e-08	2.28e-05	0.38	0.29	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
STAD	cis	rs1056107	0.931	rs7871559	ENSG00000225513.1	RP11-165N19.2	-5.73	2.2e-08	2.28e-05	-0.34	-0.29	Colorectal cancer;	chr9:112225574	chr9:112173522~112173971:-
STAD	cis	rs12744310	1	rs12035913	ENSG00000235358.1	RP11-399E6.1	-5.73	2.2e-08	2.28e-05	-0.37	-0.29	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291385	chr1:41242373~41284861:+
STAD	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	5.73	2.2e-08	2.28e-05	0.36	0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
STAD	cis	rs227275	0.554	rs223454	ENSG00000230069.3	LRRC37A15P	-5.73	2.21e-08	2.29e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102727274~102730721:-
STAD	cis	rs453301	0.658	rs6983877	ENSG00000254340.1	RP11-10A14.3	-5.73	2.21e-08	2.29e-05	-0.38	-0.29	Joint mobility (Beighton score);	chr8:9047129	chr8:9141424~9145435:+
STAD	cis	rs453301	0.658	rs12114954	ENSG00000254340.1	RP11-10A14.3	-5.73	2.21e-08	2.29e-05	-0.38	-0.29	Joint mobility (Beighton score);	chr8:9047352	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.774	rs1703982	ENSG00000253981.4	ALG1L13P	-5.73	2.21e-08	2.29e-05	-0.34	-0.29	Mood instability;	chr8:8740878	chr8:8236003~8244667:-
STAD	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	5.73	2.21e-08	2.29e-05	0.45	0.29	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	5.73	2.21e-08	2.29e-05	0.45	0.29	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	5.73	2.21e-08	2.29e-05	0.45	0.29	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
STAD	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	5.73	2.21e-08	2.29e-05	0.31	0.29	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
STAD	cis	rs12699921	0.598	rs2691602	ENSG00000279048.1	RP11-511H23.2	-5.73	2.21e-08	2.29e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17836153	chr7:17940503~17942922:+
STAD	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-5.73	2.21e-08	2.29e-05	-0.5	-0.29	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
STAD	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	5.73	2.21e-08	2.29e-05	0.31	0.29	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
STAD	cis	rs2221894	0.6	rs76071566	ENSG00000273710.1	Metazoa_SRP	5.73	2.22e-08	2.3e-05	0.37	0.29	Obesity-related traits;	chr8:28928468	chr8:28915579~28915864:-
STAD	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-5.73	2.22e-08	2.3e-05	-0.31	-0.29	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
STAD	cis	rs12699921	0.598	rs2723504	ENSG00000279048.1	RP11-511H23.2	-5.73	2.22e-08	2.3e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17815210	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.598	rs2723505	ENSG00000279048.1	RP11-511H23.2	-5.73	2.22e-08	2.3e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17815226	chr7:17940503~17942922:+
STAD	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	5.73	2.22e-08	2.3e-05	0.36	0.29	Height;	chr6:109390638	chr6:109382795~109383666:+
STAD	cis	rs12130219	0.543	rs11204988	ENSG00000237975.5	FLG-AS1	5.73	2.22e-08	2.3e-05	0.4	0.29	Inflammatory skin disease;	chr1:152371417	chr1:152168125~152445456:+
STAD	cis	rs8098244	0.565	rs1711446	ENSG00000267301.1	RPL23AP77	-5.73	2.22e-08	2.3e-05	-0.35	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23674776	chr18:23709825~23710287:-
STAD	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	5.73	2.22e-08	2.3e-05	0.36	0.29	Height;	chr6:109391534	chr6:109382795~109383666:+
STAD	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	5.73	2.22e-08	2.3e-05	0.38	0.29	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	5.73	2.22e-08	2.3e-05	0.38	0.29	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	5.73	2.22e-08	2.3e-05	0.38	0.29	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
STAD	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-5.73	2.22e-08	2.3e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
STAD	cis	rs516805	0.748	rs155467	ENSG00000279453.1	RP3-425C14.4	-5.73	2.23e-08	2.31e-05	-0.41	-0.29	Lymphocyte counts;	chr6:122512451	chr6:122436789~122439223:-
STAD	cis	rs13113518	1	rs13113518	ENSG00000272969.1	RP11-528I4.2	5.73	2.23e-08	2.31e-05	0.36	0.29	Height;	chr4:55533481	chr4:55547112~55547889:+
STAD	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	5.73	2.23e-08	2.31e-05	0.54	0.29	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
STAD	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-5.73	2.23e-08	2.31e-05	-0.32	-0.29	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
STAD	cis	rs7924176	0.564	rs6480727	ENSG00000236900.1	TIMM9P1	-5.73	2.24e-08	2.31e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74344550~74344805:-
STAD	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-5.73	2.24e-08	2.32e-05	-0.3	-0.29	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
STAD	cis	rs516805	0.781	rs477425	ENSG00000279453.1	RP3-425C14.4	-5.73	2.24e-08	2.32e-05	-0.41	-0.29	Lymphocyte counts;	chr6:122393627	chr6:122436789~122439223:-
STAD	cis	rs7178615	1	rs7178615	ENSG00000259471.1	LINC01169	5.73	2.24e-08	2.32e-05	0.37	0.29	Diastolic blood pressure;	chr15:66576734	chr15:66582190~66685794:+
STAD	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	5.73	2.24e-08	2.32e-05	0.3	0.29	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	5.73	2.24e-08	2.32e-05	0.3	0.29	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	5.73	2.24e-08	2.32e-05	0.3	0.29	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
STAD	cis	rs3806843	0.676	rs2569159	ENSG00000202111.1	VTRNA1-2	5.73	2.24e-08	2.32e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr5:140718925~140719013:+
STAD	cis	rs992157	0.764	rs10932774	ENSG00000237281.1	CATIP-AS2	-5.72	2.25e-08	2.32e-05	-0.31	-0.29	Colorectal cancer;	chr2:218326846	chr2:218326889~218357966:-
STAD	cis	rs853679	0.517	rs9380052	ENSG00000220721.1	OR1F12	5.72	2.25e-08	2.32e-05	0.33	0.29	Depression;	chr6:28096845	chr6:28073316~28074233:+
STAD	cis	rs12699921	0.568	rs67452591	ENSG00000279048.1	RP11-511H23.2	-5.72	2.25e-08	2.33e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17876573	chr7:17940503~17942922:+
STAD	cis	rs12922317	0.823	rs350222	ENSG00000260224.1	UBL5P4	-5.72	2.25e-08	2.33e-05	-0.31	-0.29	Schizophrenia;	chr16:12027722	chr16:11968508~11968743:-
STAD	cis	rs1426063	0.614	rs75846524	ENSG00000249717.1	RP11-44F21.3	5.72	2.25e-08	2.33e-05	0.67	0.29	QT interval;	chr4:75083172	chr4:74955974~74970362:-
STAD	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-5.72	2.25e-08	2.33e-05	-0.3	-0.29	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
STAD	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	5.72	2.25e-08	2.33e-05	0.3	0.29	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	5.72	2.25e-08	2.33e-05	0.3	0.29	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
STAD	cis	rs2980439	0.846	rs2980437	ENSG00000254340.1	RP11-10A14.3	-5.72	2.25e-08	2.33e-05	-0.34	-0.29	Neuroticism;	chr8:8237241	chr8:9141424~9145435:+
STAD	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	5.72	2.25e-08	2.33e-05	0.33	0.29	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
STAD	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-5.72	2.26e-08	2.33e-05	-0.3	-0.29	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
STAD	cis	rs2948294	0.588	rs7011221	ENSG00000253981.4	ALG1L13P	5.72	2.26e-08	2.33e-05	0.36	0.29	Red cell distribution width;	chr8:8256724	chr8:8236003~8244667:-
STAD	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-5.72	2.26e-08	2.34e-05	-0.32	-0.29	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
STAD	cis	rs1799949	0.965	rs4239149	ENSG00000236383.6	LINC00854	5.72	2.26e-08	2.34e-05	0.23	0.29	Menopause (age at onset);	chr17:43176078	chr17:43216941~43305976:-
STAD	cis	rs7927771	0.864	rs4752999	ENSG00000280615.1	Y_RNA	-5.72	2.26e-08	2.34e-05	-0.3	-0.29	Subjective well-being;	chr11:47407014	chr11:47614898~47614994:-
STAD	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	5.72	2.27e-08	2.35e-05	0.3	0.29	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-5.72	2.27e-08	2.35e-05	-0.3	-0.29	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
STAD	cis	rs858239	0.539	rs2103281	ENSG00000226816.2	AC005082.12	5.72	2.27e-08	2.35e-05	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23206013~23208045:+
STAD	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	5.72	2.27e-08	2.35e-05	0.26	0.29	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
STAD	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-5.72	2.28e-08	2.35e-05	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
STAD	cis	rs62432291	0.681	rs435521	ENSG00000235086.1	FNDC1-IT1	5.72	2.28e-08	2.36e-05	0.44	0.29	Joint mobility (Beighton score);	chr6:159241606	chr6:159240786~159243329:+
STAD	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-5.72	2.28e-08	2.36e-05	-0.39	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
STAD	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-5.72	2.28e-08	2.36e-05	-0.39	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
STAD	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	5.72	2.28e-08	2.36e-05	0.35	0.29	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
STAD	cis	rs11098499	0.739	rs9884728	ENSG00000248280.1	RP11-33B1.2	-5.72	2.29e-08	2.37e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119205924	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.739	rs6534130	ENSG00000248280.1	RP11-33B1.2	-5.72	2.29e-08	2.37e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119210184	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.739	rs7441137	ENSG00000248280.1	RP11-33B1.2	-5.72	2.29e-08	2.37e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119212066	chr4:119440561~119450157:-
STAD	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-5.72	2.29e-08	2.37e-05	-0.33	-0.29	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
STAD	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	5.72	2.29e-08	2.37e-05	0.31	0.29	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
STAD	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-5.72	2.3e-08	2.37e-05	-0.3	-0.29	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
STAD	cis	rs2239557	0.961	rs10133356	ENSG00000259065.1	RP5-1021I20.1	5.72	2.3e-08	2.37e-05	0.35	0.29	Common traits (Other);	chr14:74181056	chr14:73787360~73803270:+
STAD	cis	rs2239557	1	rs10144220	ENSG00000259065.1	RP5-1021I20.1	5.72	2.3e-08	2.37e-05	0.35	0.29	Common traits (Other);	chr14:74181201	chr14:73787360~73803270:+
STAD	cis	rs2239557	0.961	rs10135858	ENSG00000259065.1	RP5-1021I20.1	5.72	2.3e-08	2.37e-05	0.35	0.29	Common traits (Other);	chr14:74181259	chr14:73787360~73803270:+
STAD	cis	rs7487075	0.619	rs6582658	ENSG00000272369.1	RP11-446N19.1	5.72	2.3e-08	2.37e-05	0.36	0.29	Itch intensity from mosquito bite;	chr12:46462312	chr12:46537502~46652550:+
STAD	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-5.72	2.3e-08	2.38e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
STAD	cis	rs2439831	0.681	rs524527	ENSG00000205771.5	CATSPER2P1	5.72	2.3e-08	2.38e-05	0.39	0.29	Lung cancer in ever smokers;	chr15:43306918	chr15:43726918~43747094:-
STAD	cis	rs7487075	0.93	rs4076248	ENSG00000257261.4	RP11-96H19.1	5.72	2.3e-08	2.38e-05	0.34	0.29	Itch intensity from mosquito bite;	chr12:46439822	chr12:46383679~46876159:+
STAD	cis	rs7580658	0.676	rs58475809	ENSG00000200250.1	RNU6-1147P	5.72	2.31e-08	2.38e-05	0.28	0.29	Protein C levels;	chr2:127245074	chr2:127316873~127316979:+
STAD	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	5.72	2.31e-08	2.38e-05	0.36	0.29	Height;	chr6:109393881	chr6:109382795~109383666:+
STAD	cis	rs8005677	0.828	rs4981451	ENSG00000257285.4	RP11-298I3.1	5.72	2.31e-08	2.38e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:22929609~22955562:+
STAD	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	5.72	2.31e-08	2.39e-05	0.34	0.29	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
STAD	cis	rs1816752	0.905	rs9511242	ENSG00000273628.1	RP11-756A22.7	5.72	2.32e-08	2.4e-05	0.36	0.29	Obesity-related traits;	chr13:24419261	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs7317850	ENSG00000273628.1	RP11-756A22.7	5.72	2.32e-08	2.4e-05	0.36	0.29	Obesity-related traits;	chr13:24419899	chr13:24933006~24936796:+
STAD	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	5.72	2.32e-08	2.4e-05	0.3	0.29	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
STAD	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	5.72	2.33e-08	2.4e-05	0.3	0.29	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
STAD	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	5.72	2.33e-08	2.4e-05	0.34	0.29	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
STAD	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	5.72	2.33e-08	2.41e-05	0.29	0.29	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
STAD	cis	rs227275	0.525	rs4623004	ENSG00000230069.3	LRRC37A15P	-5.72	2.34e-08	2.41e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102727274~102730721:-
STAD	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-5.72	2.34e-08	2.41e-05	-0.29	-0.29	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
STAD	cis	rs210138	1	rs210137	ENSG00000197251.3	LINC00336	5.72	2.34e-08	2.41e-05	0.38	0.29	Testicular germ cell tumor;	chr6:33574701	chr6:33586106~33593338:-
STAD	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-5.72	2.35e-08	2.42e-05	-0.41	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
STAD	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	5.72	2.35e-08	2.42e-05	0.31	0.29	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
STAD	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	5.72	2.35e-08	2.42e-05	0.31	0.29	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
STAD	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-5.72	2.35e-08	2.42e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-5.72	2.35e-08	2.42e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
STAD	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-5.72	2.35e-08	2.42e-05	-0.46	-0.29	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
STAD	cis	rs12699921	0.632	rs2691616	ENSG00000279048.1	RP11-511H23.2	-5.72	2.36e-08	2.43e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17782557	chr7:17940503~17942922:+
STAD	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	5.72	2.36e-08	2.43e-05	0.35	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
STAD	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-5.72	2.36e-08	2.43e-05	-0.31	-0.29	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
STAD	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	5.72	2.37e-08	2.44e-05	0.3	0.29	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	5.72	2.37e-08	2.44e-05	0.3	0.29	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
STAD	cis	rs8067354	0.507	rs2645478	ENSG00000266701.1	AC005702.4	5.71	2.37e-08	2.44e-05	0.43	0.29	Hemoglobin concentration;	chr17:59937351	chr17:60042546~60042627:-
STAD	cis	rs10129255	0.869	rs7150549	ENSG00000223648.3	IGHV3-64	5.71	2.37e-08	2.44e-05	0.26	0.29	Kawasaki disease;	chr14:106705441	chr14:106643132~106658258:-
STAD	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-5.71	2.38e-08	2.45e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-5.71	2.38e-08	2.45e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
STAD	cis	rs10129255	0.826	rs7150693	ENSG00000223648.3	IGHV3-64	5.71	2.38e-08	2.45e-05	0.26	0.29	Kawasaki disease;	chr14:106705382	chr14:106643132~106658258:-
STAD	cis	rs17301013	0.896	rs6425292	ENSG00000227373.4	RP11-160H22.5	5.71	2.38e-08	2.45e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174618364	chr1:174115300~174160004:-
STAD	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-5.71	2.38e-08	2.45e-05	-0.33	-0.29	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
STAD	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	5.71	2.38e-08	2.45e-05	0.3	0.29	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
STAD	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	5.71	2.38e-08	2.45e-05	0.35	0.29	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
STAD	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	5.71	2.38e-08	2.45e-05	0.31	0.29	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
STAD	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-5.71	2.38e-08	2.45e-05	-0.32	-0.29	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
STAD	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	5.71	2.38e-08	2.45e-05	0.32	0.29	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
STAD	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-5.71	2.39e-08	2.46e-05	-0.25	-0.29	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
STAD	cis	rs13113518	0.841	rs11133400	ENSG00000272969.1	RP11-528I4.2	5.71	2.4e-08	2.46e-05	0.38	0.29	Height;	chr4:55578787	chr4:55547112~55547889:+
STAD	cis	rs1056107	0.931	rs10759540	ENSG00000225513.1	RP11-165N19.2	-5.71	2.4e-08	2.46e-05	-0.34	-0.29	Colorectal cancer;	chr9:112239394	chr9:112173522~112173971:-
STAD	cis	rs2948294	0.545	rs11776397	ENSG00000253981.4	ALG1L13P	5.71	2.4e-08	2.47e-05	0.36	0.29	Red cell distribution width;	chr8:8257639	chr8:8236003~8244667:-
STAD	cis	rs728616	0.558	rs61859793	ENSG00000225484.5	NUTM2B-AS1	-5.71	2.4e-08	2.47e-05	-0.54	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79663088~79826594:-
STAD	cis	rs12699921	0.599	rs2723554	ENSG00000279048.1	RP11-511H23.2	-5.71	2.41e-08	2.47e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17802029	chr7:17940503~17942922:+
STAD	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-5.71	2.41e-08	2.47e-05	-0.3	-0.29	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
STAD	cis	rs728616	0.867	rs55666905	ENSG00000225484.5	NUTM2B-AS1	-5.71	2.41e-08	2.48e-05	-0.69	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs56008106	ENSG00000225484.5	NUTM2B-AS1	-5.71	2.41e-08	2.48e-05	-0.69	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:79663088~79826594:-
STAD	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	5.71	2.41e-08	2.48e-05	0.3	0.29	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	5.71	2.41e-08	2.48e-05	0.3	0.29	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
STAD	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	5.71	2.41e-08	2.48e-05	0.32	0.29	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
STAD	cis	rs721917	0.506	rs2475756	ENSG00000225484.5	NUTM2B-AS1	-5.71	2.42e-08	2.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79663088~79826594:-
STAD	cis	rs55894132	1	rs55894132	ENSG00000257285.4	RP11-298I3.1	5.71	2.42e-08	2.49e-05	0.36	0.29	Intelligence (multi-trait analysis);	chr14:22939628	chr14:22929609~22955562:+
STAD	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-5.71	2.43e-08	2.49e-05	-0.28	-0.29	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
STAD	cis	rs7829975	0.626	rs907183	ENSG00000254340.1	RP11-10A14.3	-5.71	2.43e-08	2.49e-05	-0.35	-0.29	Mood instability;	chr8:8872251	chr8:9141424~9145435:+
STAD	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	5.71	2.43e-08	2.49e-05	0.3	0.29	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
STAD	cis	rs9400467	0.528	rs11153280	ENSG00000230177.1	RP5-1112D6.4	-5.71	2.43e-08	2.5e-05	-0.27	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111277932~111278742:+
STAD	cis	rs992157	0.965	rs13427681	ENSG00000237281.1	CATIP-AS2	-5.71	2.43e-08	2.5e-05	-0.3	-0.29	Colorectal cancer;	chr2:218302840	chr2:218326889~218357966:-
STAD	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-5.71	2.43e-08	2.5e-05	-0.25	-0.29	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
STAD	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	5.71	2.43e-08	2.5e-05	0.37	0.29	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
STAD	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	5.71	2.44e-08	2.5e-05	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000223648.3	IGHV3-64	5.71	2.44e-08	2.5e-05	0.25	0.29	Kawasaki disease;	chr14:106799309	chr14:106643132~106658258:-
STAD	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	5.71	2.44e-08	2.51e-05	0.38	0.29	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
STAD	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	5.71	2.44e-08	2.51e-05	0.34	0.29	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
STAD	cis	rs13113518	1	rs2279458	ENSG00000272969.1	RP11-528I4.2	5.71	2.44e-08	2.51e-05	0.38	0.29	Height;	chr4:55562653	chr4:55547112~55547889:+
STAD	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-5.71	2.45e-08	2.51e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
STAD	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	5.71	2.45e-08	2.52e-05	0.39	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
STAD	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	5.71	2.45e-08	2.52e-05	0.43	0.29	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
STAD	cis	rs3806843	0.868	rs2531342	ENSG00000202111.1	VTRNA1-2	5.71	2.46e-08	2.52e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.9	rs2563279	ENSG00000202111.1	VTRNA1-2	5.71	2.46e-08	2.52e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr5:140718925~140719013:+
STAD	cis	rs12699921	0.632	rs1404414	ENSG00000279048.1	RP11-511H23.2	5.71	2.46e-08	2.52e-05	0.26	0.29	Fibrinogen levels;	chr7:17826764	chr7:17940503~17942922:+
STAD	cis	rs10129255	0.917	rs7142373	ENSG00000280411.1	IGHV1-69-2	-5.71	2.46e-08	2.52e-05	-0.28	-0.29	Kawasaki disease;	chr14:106708947	chr14:106762092~106762588:-
STAD	cis	rs11694172	0.874	rs12466268	ENSG00000273456.1	RP11-686O6.2	5.71	2.46e-08	2.52e-05	0.34	0.29	Cholesterol, total;	chr2:202646848	chr2:202374932~202375604:-
STAD	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-5.71	2.47e-08	2.53e-05	-0.31	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
STAD	cis	rs12922317	0.856	rs1641835	ENSG00000260224.1	UBL5P4	-5.71	2.47e-08	2.53e-05	-0.3	-0.29	Schizophrenia;	chr16:12042727	chr16:11968508~11968743:-
STAD	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-5.71	2.47e-08	2.53e-05	-0.3	-0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
STAD	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	5.71	2.47e-08	2.53e-05	0.35	0.29	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	5.71	2.47e-08	2.53e-05	0.35	0.29	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
STAD	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-5.71	2.47e-08	2.54e-05	-0.51	-0.29	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
STAD	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	5.71	2.48e-08	2.54e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
STAD	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	5.71	2.48e-08	2.54e-05	0.37	0.29	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
STAD	cis	rs7487075	0.619	rs4768719	ENSG00000272369.1	RP11-446N19.1	5.71	2.48e-08	2.55e-05	0.4	0.29	Itch intensity from mosquito bite;	chr12:46447055	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs4768123	ENSG00000272369.1	RP11-446N19.1	5.71	2.48e-08	2.55e-05	0.4	0.29	Itch intensity from mosquito bite;	chr12:46458310	chr12:46537502~46652550:+
STAD	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	5.71	2.48e-08	2.55e-05	0.26	0.29	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	5.71	2.48e-08	2.55e-05	0.26	0.29	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
STAD	cis	rs1816752	0.905	rs4770666	ENSG00000273628.1	RP11-756A22.7	5.71	2.49e-08	2.55e-05	0.36	0.29	Obesity-related traits;	chr13:24414891	chr13:24933006~24936796:+
STAD	cis	rs7829975	0.742	rs12547493	ENSG00000254340.1	RP11-10A14.3	-5.71	2.49e-08	2.55e-05	-0.35	-0.29	Mood instability;	chr8:8804024	chr8:9141424~9145435:+
STAD	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-5.71	2.49e-08	2.56e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-5.71	2.49e-08	2.56e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
STAD	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	5.71	2.5e-08	2.56e-05	0.31	0.29	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	5.71	2.5e-08	2.56e-05	0.31	0.29	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	5.71	2.5e-08	2.56e-05	0.31	0.29	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	5.71	2.5e-08	2.56e-05	0.31	0.29	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
STAD	cis	rs8141529	0.778	rs9625566	ENSG00000226471.5	CTA-292E10.6	-5.71	2.5e-08	2.56e-05	-0.34	-0.29	Lymphocyte counts;	chr22:28766518	chr22:28800683~28848559:+
STAD	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-5.71	2.5e-08	2.56e-05	-0.3	-0.29	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
STAD	cis	rs516805	0.748	rs1989254	ENSG00000279453.1	RP3-425C14.4	-5.7	2.5e-08	2.56e-05	-0.42	-0.29	Lymphocyte counts;	chr6:122556317	chr6:122436789~122439223:-
STAD	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-5.7	2.5e-08	2.56e-05	-0.31	-0.29	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
STAD	cis	rs4568518	0.74	rs10428925	ENSG00000279048.1	RP11-511H23.2	5.7	2.5e-08	2.56e-05	0.27	0.29	Measles;	chr7:17969582	chr7:17940503~17942922:+
STAD	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-5.7	2.5e-08	2.57e-05	-0.28	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
STAD	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	5.7	2.51e-08	2.57e-05	0.3	0.29	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
STAD	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	5.7	2.51e-08	2.57e-05	0.3	0.29	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	5.7	2.51e-08	2.57e-05	0.3	0.29	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	5.7	2.51e-08	2.57e-05	0.3	0.29	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	5.7	2.51e-08	2.57e-05	0.3	0.29	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
STAD	cis	rs3806843	0.868	rs2262574	ENSG00000202111.1	VTRNA1-2	5.7	2.51e-08	2.57e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr5:140718925~140719013:+
STAD	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	5.7	2.51e-08	2.57e-05	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
STAD	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	5.7	2.51e-08	2.57e-05	0.36	0.29	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
STAD	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-5.7	2.51e-08	2.57e-05	-0.33	-0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
STAD	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	5.7	2.52e-08	2.58e-05	0.29	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
STAD	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-5.7	2.52e-08	2.58e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
STAD	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	5.7	2.53e-08	2.59e-05	0.47	0.29	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
STAD	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-5.7	2.53e-08	2.59e-05	-0.4	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
STAD	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-5.7	2.53e-08	2.59e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
STAD	cis	rs3806843	0.801	rs801170	ENSG00000202111.1	VTRNA1-2	5.7	2.53e-08	2.59e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140735758	chr5:140718925~140719013:+
STAD	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	5.7	2.54e-08	2.6e-05	0.28	0.29	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
STAD	cis	rs6782228	0.585	rs2811492	ENSG00000277250.1	Metazoa_SRP	-5.7	2.54e-08	2.6e-05	-0.31	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128673681~128674021:-
STAD	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	5.7	2.54e-08	2.6e-05	0.3	0.29	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
STAD	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	5.7	2.54e-08	2.6e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
STAD	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-5.7	2.55e-08	2.61e-05	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
STAD	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-5.7	2.55e-08	2.61e-05	-0.25	-0.29	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
STAD	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-5.7	2.55e-08	2.61e-05	-0.35	-0.29	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
STAD	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.7	2.56e-08	2.62e-05	-0.38	-0.29	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
STAD	cis	rs8005677	0.828	rs35085068	ENSG00000257285.4	RP11-298I3.1	5.7	2.56e-08	2.62e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.828	rs57822749	ENSG00000257285.4	RP11-298I3.1	5.7	2.56e-08	2.62e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.798	rs4536383	ENSG00000257285.4	RP11-298I3.1	5.7	2.56e-08	2.62e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.828	rs34584578	ENSG00000257285.4	RP11-298I3.1	5.7	2.56e-08	2.62e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.828	rs8016027	ENSG00000257285.4	RP11-298I3.1	5.7	2.56e-08	2.62e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:22929609~22955562:+
STAD	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-5.7	2.56e-08	2.62e-05	-0.28	-0.29	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
STAD	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-5.7	2.57e-08	2.63e-05	-0.32	-0.29	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
STAD	cis	rs3806843	0.801	rs801171	ENSG00000202111.1	VTRNA1-2	5.7	2.57e-08	2.63e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140735718	chr5:140718925~140719013:+
STAD	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	5.7	2.57e-08	2.63e-05	0.3	0.29	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	5.7	2.57e-08	2.63e-05	0.3	0.29	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
STAD	cis	rs2115536	0.692	rs6495450	ENSG00000278600.1	RP11-81A1.6	-5.7	2.57e-08	2.63e-05	-0.24	-0.29	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79870157	chr15:79920195~79922455:-
STAD	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	5.7	2.57e-08	2.63e-05	0.36	0.29	Height;	chr6:109424122	chr6:109382795~109383666:+
STAD	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-5.7	2.57e-08	2.63e-05	-0.35	-0.29	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	5.7	2.58e-08	2.63e-05	0.34	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
STAD	cis	rs227275	0.556	rs223426	ENSG00000230069.3	LRRC37A15P	-5.7	2.58e-08	2.64e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223425	ENSG00000230069.3	LRRC37A15P	-5.7	2.58e-08	2.64e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102727274~102730721:-
STAD	cis	rs1816752	0.905	rs13428	ENSG00000273628.1	RP11-756A22.7	5.7	2.58e-08	2.64e-05	0.36	0.29	Obesity-related traits;	chr13:24435303	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs8000215	ENSG00000273628.1	RP11-756A22.7	5.7	2.58e-08	2.64e-05	0.36	0.29	Obesity-related traits;	chr13:24435648	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs11839006	ENSG00000273628.1	RP11-756A22.7	5.7	2.58e-08	2.64e-05	0.36	0.29	Obesity-related traits;	chr13:24435893	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs2033955	ENSG00000273628.1	RP11-756A22.7	5.7	2.58e-08	2.64e-05	0.36	0.29	Obesity-related traits;	chr13:24436406	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs2033954	ENSG00000273628.1	RP11-756A22.7	5.7	2.58e-08	2.64e-05	0.36	0.29	Obesity-related traits;	chr13:24436429	chr13:24933006~24936796:+
STAD	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	5.7	2.58e-08	2.64e-05	0.38	0.29	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	5.7	2.58e-08	2.64e-05	0.38	0.29	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	5.7	2.58e-08	2.64e-05	0.38	0.29	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	5.7	2.58e-08	2.64e-05	0.38	0.29	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	5.7	2.58e-08	2.64e-05	0.38	0.29	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
STAD	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-5.7	2.58e-08	2.64e-05	-0.25	-0.29	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
STAD	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-5.7	2.58e-08	2.64e-05	-0.33	-0.29	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
STAD	cis	rs720064	0.586	rs2241643	ENSG00000267301.1	RPL23AP77	-5.7	2.59e-08	2.64e-05	-0.35	-0.29	Strep throat;	chr18:23949758	chr18:23709825~23710287:-
STAD	cis	rs5769707	0.967	rs763126	ENSG00000280224.1	CTA-722E9.1	5.7	2.59e-08	2.64e-05	0.3	0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49500568~49501585:+
STAD	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-5.7	2.59e-08	2.64e-05	-0.41	-0.29	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
STAD	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	5.7	2.59e-08	2.65e-05	0.36	0.29	Height;	chr6:109427644	chr6:109382795~109383666:+
STAD	cis	rs6782228	0.606	rs2811489	ENSG00000277250.1	Metazoa_SRP	5.7	2.59e-08	2.65e-05	0.3	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128673681~128674021:-
STAD	cis	rs7829975	0.84	rs555617	ENSG00000253981.4	ALG1L13P	-5.7	2.59e-08	2.65e-05	-0.35	-0.29	Mood instability;	chr8:8735335	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.711	rs4481596	ENSG00000254340.1	RP11-10A14.3	5.7	2.6e-08	2.65e-05	0.35	0.29	Mood instability;	chr8:8846820	chr8:9141424~9145435:+
STAD	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	5.7	2.61e-08	2.66e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
STAD	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	5.7	2.61e-08	2.66e-05	0.31	0.29	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
STAD	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-5.7	2.61e-08	2.66e-05	-0.28	-0.29	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
STAD	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	5.7	2.61e-08	2.67e-05	0.3	0.29	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	5.7	2.61e-08	2.67e-05	0.3	0.29	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
STAD	cis	rs1075265	0.527	rs10167891	ENSG00000235937.1	AC008280.1	5.7	2.61e-08	2.67e-05	0.26	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54029552~54030682:-
STAD	cis	rs2933343	0.679	rs789254	ENSG00000231305.3	RP11-723O4.2	5.7	2.61e-08	2.67e-05	0.31	0.29	IgG glycosylation;	chr3:128855750	chr3:128861313~128871540:-
STAD	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	5.7	2.61e-08	2.67e-05	0.26	0.29	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
STAD	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	5.7	2.61e-08	2.67e-05	0.3	0.29	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
STAD	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-5.7	2.62e-08	2.68e-05	-0.46	-0.29	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
STAD	cis	rs7580658	0.724	rs12623948	ENSG00000200250.1	RNU6-1147P	5.7	2.63e-08	2.68e-05	0.28	0.29	Protein C levels;	chr2:127243766	chr2:127316873~127316979:+
STAD	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-5.7	2.63e-08	2.68e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-5.7	2.63e-08	2.68e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-5.7	2.63e-08	2.68e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-5.7	2.63e-08	2.68e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
STAD	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-5.7	2.64e-08	2.69e-05	-0.45	-0.29	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
STAD	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	5.69	2.64e-08	2.7e-05	0.33	0.29	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
STAD	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	5.69	2.64e-08	2.7e-05	0.36	0.29	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
STAD	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	5.69	2.65e-08	2.7e-05	0.29	0.29	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	5.69	2.65e-08	2.7e-05	0.29	0.29	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	5.69	2.65e-08	2.7e-05	0.29	0.29	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	5.69	2.65e-08	2.7e-05	0.29	0.29	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
STAD	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	5.69	2.65e-08	2.7e-05	0.29	0.29	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	5.69	2.65e-08	2.7e-05	0.29	0.29	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	5.69	2.65e-08	2.7e-05	0.29	0.29	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
STAD	cis	rs1961102	0.521	rs613559	ENSG00000253385.1	KB-1254G8.1	5.69	2.65e-08	2.7e-05	0.29	0.29	QT interval;	chr8:102918952	chr8:102854455~102856075:+
STAD	cis	rs9425766	0.679	rs10912761	ENSG00000227373.4	RP11-160H22.5	5.69	2.65e-08	2.7e-05	0.34	0.29	Life satisfaction;	chr1:174312466	chr1:174115300~174160004:-
STAD	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	5.69	2.65e-08	2.7e-05	0.29	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
STAD	cis	rs227275	0.554	rs223319	ENSG00000230069.3	LRRC37A15P	-5.69	2.65e-08	2.7e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102727274~102730721:-
STAD	cis	rs228614	0.509	rs223318	ENSG00000230069.3	LRRC37A15P	-5.69	2.65e-08	2.7e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102727274~102730721:-
STAD	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	5.69	2.66e-08	2.71e-05	0.29	0.29	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
STAD	cis	rs3806843	0.9	rs2563287	ENSG00000202111.1	VTRNA1-2	-5.69	2.66e-08	2.71e-05	-0.29	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr5:140718925~140719013:+
STAD	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	5.69	2.67e-08	2.72e-05	0.43	0.29	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
STAD	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	5.69	2.67e-08	2.72e-05	0.37	0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
STAD	cis	rs8098244	0.565	rs2850205	ENSG00000267301.1	RPL23AP77	-5.69	2.67e-08	2.72e-05	-0.33	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677531	chr18:23709825~23710287:-
STAD	cis	rs9549260	0.564	rs7997896	ENSG00000229456.1	RLIMP1	5.69	2.67e-08	2.72e-05	0.26	0.29	Red blood cell count;	chr13:40694687	chr13:40618738~40621348:+
STAD	cis	rs12699921	0.632	rs2691618	ENSG00000279048.1	RP11-511H23.2	-5.69	2.67e-08	2.72e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17850572	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.594	rs2691620	ENSG00000279048.1	RP11-511H23.2	-5.69	2.67e-08	2.72e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17851213	chr7:17940503~17942922:+
STAD	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	5.69	2.67e-08	2.72e-05	0.35	0.29	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	5.69	2.67e-08	2.72e-05	0.32	0.29	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
STAD	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-5.69	2.67e-08	2.72e-05	-0.35	-0.29	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
STAD	cis	rs2440129	0.632	rs2292353	ENSG00000215067.8	ALOX12-AS1	5.69	2.68e-08	2.73e-05	0.3	0.29	Tonsillectomy;	chr17:7000218	chr17:6876635~7012349:-
STAD	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-5.69	2.68e-08	2.73e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
STAD	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-5.69	2.68e-08	2.73e-05	-0.35	-0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
STAD	cis	rs228614	0.51	rs223434	ENSG00000230069.3	LRRC37A15P	-5.69	2.68e-08	2.73e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs3886723	ENSG00000230069.3	LRRC37A15P	-5.69	2.68e-08	2.73e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102727274~102730721:-
STAD	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	5.69	2.68e-08	2.73e-05	0.36	0.29	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
STAD	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	5.69	2.69e-08	2.74e-05	0.32	0.29	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
STAD	cis	rs1816752	0.719	rs11841989	ENSG00000273628.1	RP11-756A22.7	5.69	2.69e-08	2.74e-05	0.36	0.29	Obesity-related traits;	chr13:24423560	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs9581026	ENSG00000273628.1	RP11-756A22.7	5.69	2.69e-08	2.74e-05	0.36	0.29	Obesity-related traits;	chr13:24423788	chr13:24933006~24936796:+
STAD	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	5.69	2.69e-08	2.74e-05	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
STAD	cis	rs227275	0.525	rs11737544	ENSG00000230069.3	LRRC37A15P	-5.69	2.7e-08	2.75e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs7672319	ENSG00000230069.3	LRRC37A15P	-5.69	2.7e-08	2.75e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs6533051	ENSG00000230069.3	LRRC37A15P	-5.69	2.7e-08	2.75e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs6533052	ENSG00000230069.3	LRRC37A15P	-5.69	2.7e-08	2.75e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs3974485	ENSG00000230069.3	LRRC37A15P	-5.69	2.7e-08	2.75e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs7688940	ENSG00000230069.3	LRRC37A15P	-5.69	2.7e-08	2.75e-05	-0.32	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102727274~102730721:-
STAD	cis	rs1816752	0.905	rs1348110	ENSG00000273628.1	RP11-756A22.7	5.69	2.71e-08	2.76e-05	0.36	0.29	Obesity-related traits;	chr13:24406537	chr13:24933006~24936796:+
STAD	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	5.69	2.71e-08	2.76e-05	0.45	0.29	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
STAD	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-5.69	2.71e-08	2.76e-05	-0.3	-0.29	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
STAD	cis	rs1816752	0.905	rs9511260	ENSG00000273628.1	RP11-756A22.7	5.69	2.71e-08	2.76e-05	0.36	0.29	Obesity-related traits;	chr13:24437038	chr13:24933006~24936796:+
STAD	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	5.69	2.71e-08	2.76e-05	0.31	0.29	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
STAD	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-5.69	2.72e-08	2.76e-05	-0.41	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
STAD	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-5.69	2.72e-08	2.76e-05	-0.41	-0.29	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
STAD	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	5.69	2.72e-08	2.76e-05	0.36	0.29	Height;	chr6:109430292	chr6:109382795~109383666:+
STAD	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	5.69	2.72e-08	2.77e-05	0.34	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
STAD	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	5.69	2.73e-08	2.77e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
STAD	cis	rs1816752	0.905	rs8002215	ENSG00000273628.1	RP11-756A22.7	5.69	2.73e-08	2.77e-05	0.36	0.29	Obesity-related traits;	chr13:24416229	chr13:24933006~24936796:+
STAD	cis	rs2239557	1	rs10150201	ENSG00000259065.1	RP5-1021I20.1	5.69	2.73e-08	2.77e-05	0.35	0.29	Common traits (Other);	chr14:74182454	chr14:73787360~73803270:+
STAD	cis	rs1729407	0.814	rs2542051	ENSG00000280143.1	AP000892.6	-5.69	2.73e-08	2.77e-05	-0.21	-0.29	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117204967~117210292:+
STAD	cis	rs13113518	1	rs4864546	ENSG00000272969.1	RP11-528I4.2	5.69	2.73e-08	2.77e-05	0.36	0.29	Height;	chr4:55537960	chr4:55547112~55547889:+
STAD	cis	rs875971	0.545	rs67397473	ENSG00000224316.1	RP11-479O9.2	5.69	2.73e-08	2.78e-05	0.33	0.29	Aortic root size;	chr7:66168318	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs10950027	ENSG00000224316.1	RP11-479O9.2	5.69	2.73e-08	2.78e-05	0.33	0.29	Aortic root size;	chr7:66169164	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs73376401	ENSG00000224316.1	RP11-479O9.2	5.69	2.73e-08	2.78e-05	0.33	0.29	Aortic root size;	chr7:66174841	chr7:65773620~65802067:+
STAD	cis	rs7580658	0.724	rs7568261	ENSG00000200250.1	RNU6-1147P	5.69	2.73e-08	2.78e-05	0.28	0.29	Protein C levels;	chr2:127359748	chr2:127316873~127316979:+
STAD	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	5.69	2.74e-08	2.78e-05	0.34	0.29	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	5.69	2.74e-08	2.78e-05	0.34	0.29	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
STAD	cis	rs7829975	0.774	rs11249893	ENSG00000254340.1	RP11-10A14.3	5.69	2.74e-08	2.78e-05	0.35	0.29	Mood instability;	chr8:8843341	chr8:9141424~9145435:+
STAD	cis	rs3806843	0.771	rs801174	ENSG00000202111.1	VTRNA1-2	5.69	2.74e-08	2.78e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr5:140718925~140719013:+
STAD	cis	rs6452524	0.967	rs2662243	ENSG00000243385.2	CTD-2110K23.1	5.69	2.74e-08	2.78e-05	0.31	0.29	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83201229~83202141:+
STAD	cis	rs2239557	1	rs7153587	ENSG00000259065.1	RP5-1021I20.1	-5.69	2.74e-08	2.79e-05	-0.35	-0.29	Common traits (Other);	chr14:74042957	chr14:73787360~73803270:+
STAD	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	5.69	2.75e-08	2.79e-05	0.36	0.29	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
STAD	cis	rs1426063	0.614	rs77625282	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75089646	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs75112697	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75089725	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs7684790	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75090873	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs78046076	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75091818	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs74670563	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75094656	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs115338890	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75094719	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.541	rs116304289	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75095072	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs76204704	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75097804	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs80030693	ENSG00000249717.1	RP11-44F21.3	5.69	2.75e-08	2.79e-05	0.66	0.29	QT interval;	chr4:75099929	chr4:74955974~74970362:-
STAD	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	5.69	2.75e-08	2.79e-05	0.37	0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
STAD	cis	rs992157	0.732	rs10932771	ENSG00000237281.1	CATIP-AS2	-5.69	2.75e-08	2.79e-05	-0.29	-0.29	Colorectal cancer;	chr2:218305513	chr2:218326889~218357966:-
STAD	cis	rs721917	0.506	rs2758539	ENSG00000225484.5	NUTM2B-AS1	-5.69	2.75e-08	2.79e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79663088~79826594:-
STAD	cis	rs12699921	0.632	rs10264355	ENSG00000279048.1	RP11-511H23.2	5.69	2.76e-08	2.8e-05	0.27	0.29	Fibrinogen levels;	chr7:17782391	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs10264445	ENSG00000279048.1	RP11-511H23.2	5.69	2.76e-08	2.8e-05	0.27	0.29	Fibrinogen levels;	chr7:17782425	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.607	rs10264447	ENSG00000279048.1	RP11-511H23.2	5.69	2.76e-08	2.8e-05	0.27	0.29	Fibrinogen levels;	chr7:17782430	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs10249221	ENSG00000279048.1	RP11-511H23.2	5.69	2.76e-08	2.8e-05	0.27	0.29	Fibrinogen levels;	chr7:17782436	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2691604	ENSG00000279048.1	RP11-511H23.2	-5.69	2.76e-08	2.8e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17781389	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2723503	ENSG00000279048.1	RP11-511H23.2	-5.69	2.76e-08	2.8e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17782012	chr7:17940503~17942922:+
STAD	cis	rs228614	0.536	rs223475	ENSG00000230069.3	LRRC37A15P	-5.69	2.76e-08	2.8e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102727274~102730721:-
STAD	cis	rs228614	0.536	rs223474	ENSG00000230069.3	LRRC37A15P	-5.69	2.76e-08	2.8e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102727274~102730721:-
STAD	cis	rs228614	0.509	rs223480	ENSG00000230069.3	LRRC37A15P	-5.69	2.76e-08	2.8e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102727274~102730721:-
STAD	cis	rs7924176	0.601	rs767809	ENSG00000236900.1	TIMM9P1	-5.69	2.77e-08	2.81e-05	-0.3	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74105307	chr10:74344550~74344805:-
STAD	cis	rs12699921	0.632	rs2723571	ENSG00000279048.1	RP11-511H23.2	-5.69	2.77e-08	2.81e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17851591	chr7:17940503~17942922:+
STAD	cis	rs228614	0.51	rs223470	ENSG00000230069.3	LRRC37A15P	-5.69	2.77e-08	2.81e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223468	ENSG00000230069.3	LRRC37A15P	-5.69	2.77e-08	2.81e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102727274~102730721:-
STAD	cis	rs7924176	0.601	rs10824107	ENSG00000236900.1	TIMM9P1	-5.68	2.79e-08	2.83e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74344550~74344805:-
STAD	cis	rs7924176	0.564	rs11000920	ENSG00000236900.1	TIMM9P1	-5.68	2.79e-08	2.83e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74344550~74344805:-
STAD	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	5.68	2.79e-08	2.83e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
STAD	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-5.68	2.79e-08	2.83e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-5.68	2.79e-08	2.83e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
STAD	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-5.68	2.8e-08	2.83e-05	-0.35	-0.29	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
STAD	cis	rs6142102	0.961	rs2284387	ENSG00000275784.1	RP5-1125A11.6	-5.68	2.8e-08	2.83e-05	-0.3	-0.29	Skin pigmentation;	chr20:34056782	chr20:33989480~33991818:-
STAD	cis	rs228614	0.51	rs223465	ENSG00000230069.3	LRRC37A15P	-5.68	2.8e-08	2.84e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223464	ENSG00000230069.3	LRRC37A15P	-5.68	2.8e-08	2.84e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102727274~102730721:-
STAD	cis	rs7580658	0.676	rs12465955	ENSG00000200250.1	RNU6-1147P	5.68	2.8e-08	2.84e-05	0.28	0.29	Protein C levels;	chr2:127249498	chr2:127316873~127316979:+
STAD	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-5.68	2.81e-08	2.84e-05	-0.32	-0.29	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
STAD	cis	rs1816752	0.905	rs2000153	ENSG00000273628.1	RP11-756A22.7	5.68	2.81e-08	2.84e-05	0.36	0.29	Obesity-related traits;	chr13:24405752	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs7400631	ENSG00000273628.1	RP11-756A22.7	5.68	2.81e-08	2.85e-05	0.35	0.29	Obesity-related traits;	chr13:24415927	chr13:24933006~24936796:+
STAD	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-5.68	2.81e-08	2.85e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.956	rs10137268	ENSG00000280411.1	IGHV1-69-2	-5.68	2.81e-08	2.85e-05	-0.27	-0.29	Kawasaki disease;	chr14:106697402	chr14:106762092~106762588:-
STAD	cis	rs5769707	0.935	rs1109320	ENSG00000280224.1	CTA-722E9.1	-5.68	2.81e-08	2.85e-05	-0.3	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49500568~49501585:+
STAD	cis	rs721917	0.525	rs2758545	ENSG00000225484.5	NUTM2B-AS1	-5.68	2.81e-08	2.85e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79663088~79826594:-
STAD	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-5.68	2.81e-08	2.85e-05	-0.28	-0.29	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-5.68	2.81e-08	2.85e-05	-0.28	-0.29	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
STAD	cis	rs7760535	0.763	rs10457241	ENSG00000230177.1	RP5-1112D6.4	-5.68	2.82e-08	2.85e-05	-0.27	-0.29	Metabolic traits;	chr6:111527831	chr6:111277932~111278742:+
STAD	cis	rs13113518	0.783	rs7690837	ENSG00000272969.1	RP11-528I4.2	5.68	2.82e-08	2.85e-05	0.38	0.29	Height;	chr4:55575856	chr4:55547112~55547889:+
STAD	cis	rs7924176	0.564	rs10762588	ENSG00000236900.1	TIMM9P1	-5.68	2.82e-08	2.86e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74344550~74344805:-
STAD	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	5.68	2.83e-08	2.86e-05	0.35	0.29	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
STAD	cis	rs7924176	0.601	rs10824072	ENSG00000236900.1	TIMM9P1	-5.68	2.83e-08	2.86e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74344550~74344805:-
STAD	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-5.68	2.83e-08	2.86e-05	-0.51	-0.29	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
STAD	cis	rs8098244	0.58	rs1620152	ENSG00000267301.1	RPL23AP77	-5.68	2.83e-08	2.87e-05	-0.35	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23678335	chr18:23709825~23710287:-
STAD	cis	rs7945705	1	rs7937298	ENSG00000254860.4	TMEM9B-AS1	-5.68	2.83e-08	2.87e-05	-0.32	-0.29	Hemoglobin concentration;	chr11:8845962	chr11:8964675~8977527:+
STAD	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-5.68	2.83e-08	2.87e-05	-0.28	-0.29	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
STAD	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-5.68	2.83e-08	2.87e-05	-0.45	-0.29	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-5.68	2.83e-08	2.87e-05	-0.45	-0.29	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-5.68	2.83e-08	2.87e-05	-0.45	-0.29	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-5.68	2.83e-08	2.87e-05	-0.45	-0.29	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-5.68	2.83e-08	2.87e-05	-0.45	-0.29	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
STAD	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	5.68	2.83e-08	2.87e-05	0.34	0.29	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
STAD	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-5.68	2.84e-08	2.87e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
STAD	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-5.68	2.85e-08	2.88e-05	-0.42	-0.29	QT interval;	chr16:28884339	chr16:28700294~28701540:-
STAD	cis	rs916888	0.61	rs199530	ENSG00000261575.2	RP11-259G18.1	-5.68	2.85e-08	2.88e-05	-0.39	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46267037~46268694:+
STAD	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	5.68	2.85e-08	2.88e-05	0.39	0.29	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
STAD	cis	rs748404	0.589	rs62020616	ENSG00000249839.1	AC011330.5	-5.68	2.85e-08	2.88e-05	-0.51	-0.29	Lung cancer;	chr15:43558554	chr15:43663654~43684339:-
STAD	cis	rs748404	0.626	rs60367691	ENSG00000249839.1	AC011330.5	-5.68	2.85e-08	2.88e-05	-0.51	-0.29	Lung cancer;	chr15:43559201	chr15:43663654~43684339:-
STAD	cis	rs3806843	0.801	rs2531358	ENSG00000202111.1	VTRNA1-2	5.68	2.86e-08	2.89e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr5:140718925~140719013:+
STAD	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	5.68	2.86e-08	2.89e-05	0.23	0.29	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
STAD	cis	rs453301	0.598	rs10104303	ENSG00000254340.1	RP11-10A14.3	5.68	2.86e-08	2.89e-05	0.35	0.29	Joint mobility (Beighton score);	chr8:8977018	chr8:9141424~9145435:+
STAD	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	5.68	2.86e-08	2.89e-05	0.34	0.29	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
STAD	cis	rs12699921	0.632	rs4543433	ENSG00000279048.1	RP11-511H23.2	-5.68	2.86e-08	2.89e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17926529	chr7:17940503~17942922:+
STAD	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	5.68	2.86e-08	2.89e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
STAD	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	5.68	2.86e-08	2.89e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
STAD	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	5.68	2.86e-08	2.89e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
STAD	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	5.68	2.86e-08	2.89e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
STAD	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	5.68	2.86e-08	2.89e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
STAD	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	5.68	2.86e-08	2.89e-05	0.38	0.29	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
STAD	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	5.68	2.87e-08	2.9e-05	0.37	0.29	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
STAD	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	5.68	2.88e-08	2.91e-05	0.39	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
STAD	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	5.68	2.88e-08	2.91e-05	0.33	0.29	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
STAD	cis	rs987724	0.727	rs6776157	ENSG00000240875.4	LINC00886	-5.68	2.88e-08	2.91e-05	-0.36	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156825693	chr3:156747346~156817062:-
STAD	cis	rs9545047	0.604	rs1324868	ENSG00000227676.3	LINC01068	-5.68	2.89e-08	2.91e-05	-0.42	-0.29	Schizophrenia;	chr13:79380040	chr13:79566727~79571436:+
STAD	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	5.68	2.89e-08	2.91e-05	0.35	0.29	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
STAD	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	5.68	2.89e-08	2.91e-05	0.3	0.29	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
STAD	cis	rs516805	0.748	rs72962455	ENSG00000279453.1	RP3-425C14.4	5.68	2.89e-08	2.91e-05	0.42	0.29	Lymphocyte counts;	chr6:122563378	chr6:122436789~122439223:-
STAD	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	5.68	2.89e-08	2.92e-05	0.34	0.29	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	5.68	2.89e-08	2.92e-05	0.34	0.29	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
STAD	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-5.68	2.9e-08	2.92e-05	-0.41	-0.29	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
STAD	cis	rs228614	0.536	rs223477	ENSG00000230069.3	LRRC37A15P	-5.68	2.9e-08	2.92e-05	-0.32	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102727274~102730721:-
STAD	cis	rs1426063	0.614	rs7671634	ENSG00000249717.1	RP11-44F21.3	5.68	2.9e-08	2.93e-05	0.66	0.29	QT interval;	chr4:75090883	chr4:74955974~74970362:-
STAD	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-5.68	2.9e-08	2.93e-05	-0.31	-0.29	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
STAD	cis	rs7924176	0.564	rs4564273	ENSG00000236900.1	TIMM9P1	-5.68	2.9e-08	2.93e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74344550~74344805:-
STAD	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-5.68	2.91e-08	2.93e-05	-0.43	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
STAD	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-5.68	2.91e-08	2.94e-05	-0.45	-0.29	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
STAD	cis	rs12699921	0.607	rs1404425	ENSG00000279048.1	RP11-511H23.2	-5.68	2.91e-08	2.94e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17788034	chr7:17940503~17942922:+
STAD	cis	rs10129255	1	rs8010605	ENSG00000280411.1	IGHV1-69-2	-5.68	2.91e-08	2.94e-05	-0.27	-0.29	Kawasaki disease;	chr14:106678742	chr14:106762092~106762588:-
STAD	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-5.68	2.91e-08	2.94e-05	-0.4	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
STAD	cis	rs12699921	0.599	rs2462512	ENSG00000279048.1	RP11-511H23.2	-5.68	2.92e-08	2.94e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17808215	chr7:17940503~17942922:+
STAD	cis	rs7829975	0.871	rs572307	ENSG00000253981.4	ALG1L13P	-5.68	2.92e-08	2.94e-05	-0.34	-0.29	Mood instability;	chr8:8721301	chr8:8236003~8244667:-
STAD	cis	rs7487075	0.619	rs11183478	ENSG00000272369.1	RP11-446N19.1	5.68	2.92e-08	2.94e-05	0.39	0.29	Itch intensity from mosquito bite;	chr12:46430283	chr12:46537502~46652550:+
STAD	cis	rs606458	0.92	rs620006	ENSG00000269038.1	AP001462.6	5.68	2.92e-08	2.94e-05	0.37	0.29	Urate levels;	chr11:64762959	chr11:64778954~64779405:+
STAD	cis	rs721917	0.506	rs2819098	ENSG00000225484.5	NUTM2B-AS1	-5.68	2.93e-08	2.95e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79663088~79826594:-
STAD	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	5.68	2.93e-08	2.95e-05	0.26	0.29	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
STAD	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	5.67	2.94e-08	2.96e-05	0.31	0.29	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
STAD	cis	rs7924176	0.601	rs12414280	ENSG00000236900.1	TIMM9P1	-5.67	2.94e-08	2.96e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74344550~74344805:-
STAD	cis	rs2439831	1	rs7173487	ENSG00000249839.1	AC011330.5	-5.67	2.94e-08	2.96e-05	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43458041	chr15:43663654~43684339:-
STAD	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	5.67	2.95e-08	2.97e-05	0.37	0.29	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
STAD	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	5.67	2.96e-08	2.98e-05	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
STAD	cis	rs1056107	0.931	rs7041185	ENSG00000225513.1	RP11-165N19.2	-5.67	2.96e-08	2.98e-05	-0.34	-0.29	Colorectal cancer;	chr9:112225084	chr9:112173522~112173971:-
STAD	cis	rs6782228	0.606	rs2001703	ENSG00000277250.1	Metazoa_SRP	-5.67	2.97e-08	2.99e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128673681~128674021:-
STAD	cis	rs8098244	0.576	rs11082762	ENSG00000267301.1	RPL23AP77	-5.67	2.97e-08	2.99e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23785889	chr18:23709825~23710287:-
STAD	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-5.67	2.98e-08	3e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
STAD	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	5.67	2.98e-08	3e-05	0.52	0.29	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
STAD	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	5.67	2.98e-08	3e-05	0.5	0.29	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
STAD	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-5.67	2.98e-08	3e-05	-0.3	-0.29	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	5.67	2.98e-08	3e-05	0.26	0.29	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
STAD	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-5.67	2.99e-08	3.01e-05	-0.29	-0.29	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
STAD	cis	rs1056107	0.898	rs3736985	ENSG00000225513.1	RP11-165N19.2	-5.67	2.99e-08	3.01e-05	-0.34	-0.29	Colorectal cancer;	chr9:112228093	chr9:112173522~112173971:-
STAD	cis	rs11098499	0.739	rs4833612	ENSG00000248280.1	RP11-33B1.2	-5.67	3e-08	3.02e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119226441	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.739	rs10013032	ENSG00000248280.1	RP11-33B1.2	-5.67	3e-08	3.02e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119228264	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.739	rs951570	ENSG00000248280.1	RP11-33B1.2	-5.67	3e-08	3.02e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119229312	chr4:119440561~119450157:-
STAD	cis	rs992157	1	rs4674280	ENSG00000237281.1	CATIP-AS2	5.67	3e-08	3.02e-05	0.3	0.29	Colorectal cancer;	chr2:218276735	chr2:218326889~218357966:-
STAD	cis	rs12699921	0.598	rs2723567	ENSG00000279048.1	RP11-511H23.2	-5.67	3e-08	3.02e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17858856	chr7:17940503~17942922:+
STAD	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	5.67	3.01e-08	3.03e-05	0.26	0.29	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
STAD	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	5.67	3.01e-08	3.03e-05	0.32	0.29	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
STAD	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	5.67	3.02e-08	3.04e-05	0.3	0.29	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
STAD	cis	rs1426063	0.614	rs76093954	ENSG00000249717.1	RP11-44F21.3	5.67	3.02e-08	3.04e-05	0.66	0.29	QT interval;	chr4:75087994	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs114977200	ENSG00000249717.1	RP11-44F21.3	5.67	3.02e-08	3.04e-05	0.66	0.29	QT interval;	chr4:75088736	chr4:74955974~74970362:-
STAD	cis	rs992157	0.804	rs6758540	ENSG00000237281.1	CATIP-AS2	5.67	3.03e-08	3.04e-05	0.3	0.29	Colorectal cancer;	chr2:218273902	chr2:218326889~218357966:-
STAD	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-5.67	3.03e-08	3.05e-05	-0.31	-0.29	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
STAD	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	5.67	3.03e-08	3.05e-05	0.29	0.29	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
STAD	cis	rs227275	0.525	rs28445579	ENSG00000230069.3	LRRC37A15P	-5.67	3.03e-08	3.05e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102727274~102730721:-
STAD	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-5.67	3.03e-08	3.05e-05	-0.31	-0.29	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
STAD	cis	rs13113518	0.812	rs13116035	ENSG00000272969.1	RP11-528I4.2	5.67	3.03e-08	3.05e-05	0.38	0.29	Height;	chr4:55561218	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.783	rs2171618	ENSG00000272969.1	RP11-528I4.2	5.67	3.03e-08	3.05e-05	0.38	0.29	Height;	chr4:55564241	chr4:55547112~55547889:+
STAD	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	5.67	3.04e-08	3.05e-05	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	5.67	3.04e-08	3.06e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	5.67	3.04e-08	3.06e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
STAD	cis	rs8067354	0.574	rs1292033	ENSG00000266701.1	AC005702.4	5.67	3.04e-08	3.06e-05	0.42	0.29	Hemoglobin concentration;	chr17:59913236	chr17:60042546~60042627:-
STAD	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-5.67	3.05e-08	3.07e-05	-0.3	-0.29	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
STAD	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	5.67	3.06e-08	3.07e-05	0.52	0.29	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
STAD	cis	rs227275	0.554	rs223381	ENSG00000230069.3	LRRC37A15P	-5.67	3.06e-08	3.07e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102727274~102730721:-
STAD	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-5.67	3.06e-08	3.08e-05	-0.39	-0.29	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
STAD	cis	rs10129255	0.833	rs61997797	ENSG00000280411.1	IGHV1-69-2	-5.67	3.06e-08	3.08e-05	-0.27	-0.29	Kawasaki disease;	chr14:106815190	chr14:106762092~106762588:-
STAD	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-5.67	3.07e-08	3.08e-05	-0.31	-0.29	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
STAD	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	5.67	3.07e-08	3.09e-05	0.31	0.29	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
STAD	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-5.67	3.08e-08	3.09e-05	-0.24	-0.29	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-5.67	3.08e-08	3.09e-05	-0.24	-0.29	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
STAD	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-5.67	3.08e-08	3.09e-05	-0.24	-0.29	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-5.67	3.08e-08	3.09e-05	-0.24	-0.29	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-5.67	3.08e-08	3.09e-05	-0.24	-0.29	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
STAD	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-5.67	3.08e-08	3.09e-05	-0.24	-0.29	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
STAD	cis	rs7580658	0.724	rs6712446	ENSG00000200250.1	RNU6-1147P	5.67	3.08e-08	3.1e-05	0.28	0.29	Protein C levels;	chr2:127240823	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.724	rs6712551	ENSG00000200250.1	RNU6-1147P	5.67	3.08e-08	3.1e-05	0.28	0.29	Protein C levels;	chr2:127240909	chr2:127316873~127316979:+
STAD	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	5.67	3.09e-08	3.1e-05	0.31	0.29	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
STAD	cis	rs17301013	0.896	rs332773	ENSG00000227373.4	RP11-160H22.5	5.66	3.1e-08	3.11e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174695711	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.896	rs332791	ENSG00000227373.4	RP11-160H22.5	5.66	3.1e-08	3.11e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174709784	chr1:174115300~174160004:-
STAD	cis	rs7924176	0.521	rs11000959	ENSG00000236900.1	TIMM9P1	-5.66	3.1e-08	3.11e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74287053	chr10:74344550~74344805:-
STAD	cis	rs9425766	0.64	rs17301013	ENSG00000227373.4	RP11-160H22.5	5.66	3.1e-08	3.11e-05	0.33	0.29	Life satisfaction;	chr1:174343675	chr1:174115300~174160004:-
STAD	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	5.66	3.11e-08	3.12e-05	0.36	0.29	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
STAD	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	5.66	3.11e-08	3.12e-05	0.34	0.29	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
STAD	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-5.66	3.12e-08	3.13e-05	-0.33	-0.29	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
STAD	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	5.66	3.12e-08	3.13e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	5.66	3.12e-08	3.13e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	5.66	3.12e-08	3.13e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	5.66	3.12e-08	3.13e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	5.66	3.12e-08	3.13e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
STAD	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	5.66	3.12e-08	3.13e-05	0.32	0.29	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
STAD	cis	rs9425766	0.679	rs4652234	ENSG00000227373.4	RP11-160H22.5	5.66	3.12e-08	3.13e-05	0.34	0.29	Life satisfaction;	chr1:174181712	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.732	rs6658543	ENSG00000227373.4	RP11-160H22.5	5.66	3.12e-08	3.13e-05	0.34	0.29	Life satisfaction;	chr1:174183338	chr1:174115300~174160004:-
STAD	cis	rs556990	0.574	rs473598	ENSG00000269125.1	RP11-98F14.11	-5.66	3.12e-08	3.13e-05	-0.35	-0.29	Blood protein levels;	chr13:113146875	chr13:113165002~113165183:-
STAD	cis	rs228614	0.51	rs223392	ENSG00000230069.3	LRRC37A15P	-5.66	3.12e-08	3.13e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223390	ENSG00000230069.3	LRRC37A15P	-5.66	3.12e-08	3.13e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102727274~102730721:-
STAD	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-5.66	3.12e-08	3.13e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
STAD	cis	rs453301	0.686	rs7017868	ENSG00000254340.1	RP11-10A14.3	-5.66	3.12e-08	3.13e-05	-0.38	-0.29	Joint mobility (Beighton score);	chr8:9015783	chr8:9141424~9145435:+
STAD	cis	rs453301	0.686	rs3895823	ENSG00000254340.1	RP11-10A14.3	-5.66	3.12e-08	3.13e-05	-0.38	-0.29	Joint mobility (Beighton score);	chr8:9016136	chr8:9141424~9145435:+
STAD	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	5.66	3.13e-08	3.14e-05	0.37	0.29	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
STAD	cis	rs17301013	0.73	rs12060177	ENSG00000227373.4	RP11-160H22.5	5.66	3.13e-08	3.14e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174618545	chr1:174115300~174160004:-
STAD	cis	rs35934224	0.891	rs13054713	ENSG00000232926.1	AC000078.5	5.66	3.13e-08	3.14e-05	0.41	0.29	Glaucoma (primary open-angle);	chr22:19880391	chr22:19887289~19887970:+
STAD	cis	rs7760535	0.826	rs3851229	ENSG00000230177.1	RP5-1112D6.4	-5.66	3.14e-08	3.15e-05	-0.27	-0.29	Metabolic traits;	chr6:111533457	chr6:111277932~111278742:+
STAD	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-5.66	3.15e-08	3.15e-05	-0.3	-0.29	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
STAD	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-5.66	3.15e-08	3.15e-05	-0.3	-0.29	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
STAD	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-5.66	3.15e-08	3.15e-05	-0.3	-0.29	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
STAD	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-5.66	3.15e-08	3.15e-05	-0.3	-0.29	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
STAD	cis	rs8141529	0.764	rs5762854	ENSG00000226471.5	CTA-292E10.6	-5.66	3.15e-08	3.15e-05	-0.34	-0.29	Lymphocyte counts;	chr22:28850290	chr22:28800683~28848559:+
STAD	cis	rs228614	0.51	rs223472	ENSG00000230069.3	LRRC37A15P	-5.66	3.15e-08	3.15e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102727274~102730721:-
STAD	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-5.66	3.15e-08	3.16e-05	-0.3	-0.29	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
STAD	cis	rs1400745	0.718	rs1200414	ENSG00000258738.1	RP11-73E17.2	5.66	3.15e-08	3.16e-05	0.35	0.29	Monocyte count;	chr14:34861687	chr14:34874343~34876459:+
STAD	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	5.66	3.16e-08	3.16e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
STAD	cis	rs4568518	0.74	rs12699927	ENSG00000279048.1	RP11-511H23.2	5.66	3.16e-08	3.16e-05	0.26	0.29	Measles;	chr7:17972129	chr7:17940503~17942922:+
STAD	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	5.66	3.17e-08	3.17e-05	0.31	0.29	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
STAD	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	5.66	3.17e-08	3.17e-05	0.31	0.29	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
STAD	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-5.66	3.17e-08	3.17e-05	-0.28	-0.29	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
STAD	cis	rs992157	0.735	rs13388024	ENSG00000237281.1	CATIP-AS2	-5.66	3.17e-08	3.17e-05	-0.29	-0.29	Colorectal cancer;	chr2:218233050	chr2:218326889~218357966:-
STAD	cis	rs2486288	0.656	rs7167146	ENSG00000259433.2	CTD-2651B20.4	-5.66	3.17e-08	3.18e-05	-0.32	-0.29	Glomerular filtration rate;	chr15:45279188	chr15:45330209~45332634:-
STAD	cis	rs748404	0.589	rs3862138	ENSG00000249839.1	AC011330.5	-5.66	3.17e-08	3.18e-05	-0.5	-0.29	Lung cancer;	chr15:43523801	chr15:43663654~43684339:-
STAD	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-5.66	3.17e-08	3.18e-05	-0.35	-0.29	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
STAD	cis	rs1075265	0.554	rs10168293	ENSG00000235937.1	AC008280.1	5.66	3.17e-08	3.18e-05	0.26	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.567	rs66773232	ENSG00000235937.1	AC008280.1	5.66	3.17e-08	3.18e-05	0.26	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54029552~54030682:-
STAD	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-5.66	3.18e-08	3.18e-05	-0.35	-0.29	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
STAD	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-5.66	3.18e-08	3.18e-05	-0.35	-0.29	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
STAD	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-5.66	3.18e-08	3.18e-05	-0.35	-0.29	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
STAD	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	5.66	3.18e-08	3.18e-05	0.45	0.29	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
STAD	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-5.66	3.18e-08	3.18e-05	-0.46	-0.29	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
STAD	cis	rs875971	0.545	rs10261710	ENSG00000224316.1	RP11-479O9.2	5.66	3.18e-08	3.18e-05	0.34	0.29	Aortic root size;	chr7:66249202	chr7:65773620~65802067:+
STAD	cis	rs227275	0.525	rs724446	ENSG00000230069.3	LRRC37A15P	-5.66	3.19e-08	3.19e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102727274~102730721:-
STAD	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	5.66	3.19e-08	3.19e-05	0.43	0.29	Height;	chr6:109737797	chr6:109382795~109383666:+
STAD	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	5.66	3.19e-08	3.2e-05	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
STAD	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-5.66	3.2e-08	3.2e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
STAD	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-5.66	3.2e-08	3.2e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
STAD	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	5.66	3.2e-08	3.2e-05	0.3	0.29	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	5.66	3.2e-08	3.2e-05	0.3	0.29	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
STAD	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-5.66	3.2e-08	3.2e-05	-0.3	-0.29	Height;	chr11:118860890	chr11:118791254~118793137:+
STAD	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-5.66	3.2e-08	3.2e-05	-0.3	-0.29	Height;	chr11:118861053	chr11:118791254~118793137:+
STAD	cis	rs13113518	0.812	rs12500456	ENSG00000272969.1	RP11-528I4.2	5.66	3.21e-08	3.21e-05	0.38	0.29	Height;	chr4:55561053	chr4:55547112~55547889:+
STAD	cis	rs875971	0.545	rs316324	ENSG00000224316.1	RP11-479O9.2	-5.66	3.21e-08	3.21e-05	-0.32	-0.29	Aortic root size;	chr7:66145627	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs316323	ENSG00000224316.1	RP11-479O9.2	-5.66	3.21e-08	3.21e-05	-0.32	-0.29	Aortic root size;	chr7:66146002	chr7:65773620~65802067:+
STAD	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-5.66	3.21e-08	3.21e-05	-0.31	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
STAD	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	5.66	3.22e-08	3.22e-05	0.51	0.29	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
STAD	cis	rs4568518	0.74	rs11535159	ENSG00000279048.1	RP11-511H23.2	5.66	3.22e-08	3.22e-05	0.26	0.29	Measles;	chr7:17970686	chr7:17940503~17942922:+
STAD	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-5.66	3.22e-08	3.22e-05	-0.3	-0.29	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
STAD	cis	rs8005677	0.798	rs61977741	ENSG00000257285.4	RP11-298I3.1	5.66	3.23e-08	3.22e-05	0.35	0.29	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.798	rs4982713	ENSG00000257285.4	RP11-298I3.1	5.66	3.23e-08	3.22e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.798	rs35615180	ENSG00000257285.4	RP11-298I3.1	5.66	3.23e-08	3.22e-05	0.36	0.29	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:22929609~22955562:+
STAD	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	5.66	3.23e-08	3.23e-05	0.43	0.29	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
STAD	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	5.66	3.23e-08	3.23e-05	0.43	0.29	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
STAD	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	5.66	3.23e-08	3.23e-05	0.43	0.29	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
STAD	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	5.66	3.23e-08	3.23e-05	0.43	0.29	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
STAD	cis	rs6782228	0.606	rs58977394	ENSG00000277250.1	Metazoa_SRP	-5.66	3.23e-08	3.23e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs2712381	ENSG00000277250.1	Metazoa_SRP	-5.66	3.23e-08	3.23e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs1127030	ENSG00000277250.1	Metazoa_SRP	-5.66	3.23e-08	3.23e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128673681~128674021:-
STAD	cis	rs3806843	0.735	rs778597	ENSG00000202111.1	VTRNA1-2	-5.66	3.24e-08	3.23e-05	-0.28	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr5:140718925~140719013:+
STAD	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-5.66	3.24e-08	3.24e-05	-0.28	-0.29	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
STAD	cis	rs2439831	0.681	rs956391	ENSG00000249839.1	AC011330.5	5.66	3.24e-08	3.24e-05	0.41	0.29	Lung cancer in ever smokers;	chr15:43325295	chr15:43663654~43684339:-
STAD	cis	rs7924176	0.601	rs11000882	ENSG00000236900.1	TIMM9P1	-5.66	3.24e-08	3.24e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74130145	chr10:74344550~74344805:-
STAD	cis	rs2143950	0.607	rs58770366	ENSG00000241052.1	RP11-173D9.1	-5.66	3.25e-08	3.24e-05	-0.33	-0.29	Atopic dermatitis;	chr14:35058817	chr14:35144021~35144480:-
STAD	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	5.66	3.26e-08	3.25e-05	0.39	0.29	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
STAD	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	5.66	3.26e-08	3.25e-05	0.36	0.29	Height;	chr6:109361200	chr6:109382795~109383666:+
STAD	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-5.66	3.26e-08	3.26e-05	-0.31	-0.29	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
STAD	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-5.66	3.26e-08	3.26e-05	-0.28	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
STAD	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-5.66	3.27e-08	3.26e-05	-0.34	-0.29	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
STAD	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	5.65	3.27e-08	3.27e-05	0.28	0.29	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
STAD	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	5.65	3.27e-08	3.27e-05	0.3	0.29	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
STAD	cis	rs13113518	1	rs4864994	ENSG00000272969.1	RP11-528I4.2	5.65	3.28e-08	3.27e-05	0.36	0.29	Height;	chr4:55451955	chr4:55547112~55547889:+
STAD	cis	rs7924176	0.601	rs10824091	ENSG00000236900.1	TIMM9P1	-5.65	3.28e-08	3.28e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74169750	chr10:74344550~74344805:-
STAD	cis	rs1426063	0.614	rs17000261	ENSG00000248165.1	RP11-44F21.2	5.65	3.29e-08	3.28e-05	0.58	0.29	QT interval;	chr4:75108766	chr4:74993877~75034824:-
STAD	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	5.65	3.29e-08	3.29e-05	0.46	0.29	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
STAD	cis	rs12699921	0.632	rs949451	ENSG00000279048.1	RP11-511H23.2	-5.65	3.29e-08	3.29e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17818931	chr7:17940503~17942922:+
STAD	cis	rs2436845	0.934	rs892486	ENSG00000253385.1	KB-1254G8.1	5.65	3.3e-08	3.29e-05	0.3	0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862401	chr8:102854455~102856075:+
STAD	cis	rs721917	0.525	rs2250652	ENSG00000225484.5	NUTM2B-AS1	-5.65	3.3e-08	3.29e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79663088~79826594:-
STAD	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-5.65	3.3e-08	3.3e-05	-0.31	-0.29	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
STAD	cis	rs916888	0.61	rs199454	ENSG00000261575.2	RP11-259G18.1	-5.65	3.3e-08	3.3e-05	-0.39	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46267037~46268694:+
STAD	cis	rs6782228	0.565	rs12695509	ENSG00000277250.1	Metazoa_SRP	-5.65	3.3e-08	3.3e-05	-0.29	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128673681~128674021:-
STAD	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-5.65	3.31e-08	3.3e-05	-0.3	-0.29	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
STAD	cis	rs12699921	0.537	rs2691582	ENSG00000279048.1	RP11-511H23.2	-5.65	3.31e-08	3.31e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17789623	chr7:17940503~17942922:+
STAD	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	5.65	3.32e-08	3.31e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
STAD	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-5.65	3.33e-08	3.32e-05	-0.32	-0.29	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
STAD	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	5.65	3.33e-08	3.33e-05	0.44	0.29	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
STAD	cis	rs2239557	1	rs11628710	ENSG00000259065.1	RP5-1021I20.1	-5.65	3.34e-08	3.33e-05	-0.35	-0.29	Common traits (Other);	chr14:74182577	chr14:73787360~73803270:+
STAD	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	5.65	3.35e-08	3.34e-05	0.32	0.29	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
STAD	cis	rs7924176	0.564	rs12572820	ENSG00000236900.1	TIMM9P1	-5.65	3.35e-08	3.34e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74344550~74344805:-
STAD	cis	rs7924176	0.601	rs7099026	ENSG00000236900.1	TIMM9P1	-5.65	3.35e-08	3.34e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74344550~74344805:-
STAD	cis	rs12682352	0.652	rs3789843	ENSG00000254340.1	RP11-10A14.3	5.65	3.35e-08	3.34e-05	0.35	0.29	Neuroticism;	chr8:8866747	chr8:9141424~9145435:+
STAD	cis	rs12682352	0.652	rs3827806	ENSG00000254340.1	RP11-10A14.3	5.65	3.35e-08	3.34e-05	0.35	0.29	Neuroticism;	chr8:8866766	chr8:9141424~9145435:+
STAD	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	5.65	3.35e-08	3.34e-05	0.38	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
STAD	cis	rs7849270	0.879	rs10988200	ENSG00000268707.1	RP11-247A12.7	-5.65	3.35e-08	3.34e-05	-0.34	-0.29	Blood metabolite ratios;	chr9:129094306	chr9:129170434~129170940:+
STAD	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-5.65	3.35e-08	3.34e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
STAD	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-5.65	3.35e-08	3.34e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
STAD	cis	rs3806843	0.868	rs2531349	ENSG00000202111.1	VTRNA1-2	5.65	3.35e-08	3.34e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr5:140718925~140719013:+
STAD	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	5.65	3.36e-08	3.35e-05	0.4	0.29	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
STAD	cis	rs12699921	0.632	rs2723569	ENSG00000279048.1	RP11-511H23.2	-5.65	3.36e-08	3.35e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17854048	chr7:17940503~17942922:+
STAD	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	5.65	3.36e-08	3.35e-05	0.3	0.29	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
STAD	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	5.65	3.36e-08	3.35e-05	0.29	0.29	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
STAD	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	5.65	3.36e-08	3.35e-05	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
STAD	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	5.65	3.37e-08	3.35e-05	0.36	0.29	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
STAD	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	5.65	3.37e-08	3.35e-05	0.36	0.29	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
STAD	cis	rs10129255	0.957	rs12590667	ENSG00000280411.1	IGHV1-69-2	5.65	3.37e-08	3.35e-05	0.26	0.29	Kawasaki disease;	chr14:106779223	chr14:106762092~106762588:-
STAD	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	5.65	3.37e-08	3.36e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
STAD	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	5.65	3.37e-08	3.36e-05	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
STAD	cis	rs4927850	1	rs6799572	ENSG00000207650.1	MIR570	5.65	3.38e-08	3.36e-05	0.28	0.29	Pancreatic cancer;	chr3:196013537	chr3:195699401~195699497:+
STAD	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	5.65	3.38e-08	3.37e-05	0.29	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
STAD	cis	rs992157	0.71	rs56364928	ENSG00000237281.1	CATIP-AS2	-5.65	3.38e-08	3.37e-05	-0.29	-0.29	Colorectal cancer;	chr2:218194335	chr2:218326889~218357966:-
STAD	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	5.65	3.39e-08	3.37e-05	0.36	0.29	Height;	chr6:109634847	chr6:109382795~109383666:+
STAD	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	5.65	3.4e-08	3.38e-05	0.28	0.29	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
STAD	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-5.65	3.4e-08	3.39e-05	-0.31	-0.29	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
STAD	cis	rs9425766	0.679	rs4650989	ENSG00000227373.4	RP11-160H22.5	5.65	3.4e-08	3.39e-05	0.34	0.29	Life satisfaction;	chr1:174289739	chr1:174115300~174160004:-
STAD	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-5.65	3.41e-08	3.39e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
STAD	cis	rs875971	0.545	rs67775320	ENSG00000224316.1	RP11-479O9.2	5.65	3.41e-08	3.39e-05	0.32	0.29	Aortic root size;	chr7:66193792	chr7:65773620~65802067:+
STAD	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-5.65	3.41e-08	3.39e-05	-0.24	-0.29	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
STAD	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-5.65	3.42e-08	3.4e-05	-0.3	-0.29	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
STAD	cis	rs7487075	0.619	rs10785628	ENSG00000272369.1	RP11-446N19.1	5.65	3.43e-08	3.41e-05	0.39	0.29	Itch intensity from mosquito bite;	chr12:46460893	chr12:46537502~46652550:+
STAD	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-5.65	3.44e-08	3.42e-05	-0.34	-0.29	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
STAD	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	5.65	3.44e-08	3.42e-05	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
STAD	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	5.65	3.44e-08	3.42e-05	0.43	0.29	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
STAD	cis	rs11098499	0.71	rs6851130	ENSG00000248280.1	RP11-33B1.2	-5.65	3.44e-08	3.42e-05	-0.35	-0.29	Corneal astigmatism;	chr4:119212557	chr4:119440561~119450157:-
STAD	cis	rs1056107	0.931	rs7847972	ENSG00000225513.1	RP11-165N19.2	5.65	3.44e-08	3.42e-05	0.34	0.29	Colorectal cancer;	chr9:112214590	chr9:112173522~112173971:-
STAD	cis	rs3806843	0.808	rs6893708	ENSG00000202111.1	VTRNA1-2	5.65	3.44e-08	3.42e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140746337	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.9	rs2563286	ENSG00000202111.1	VTRNA1-2	5.64	3.45e-08	3.43e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140745614	chr5:140718925~140719013:+
STAD	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	5.64	3.45e-08	3.43e-05	0.35	0.29	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
STAD	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	5.64	3.45e-08	3.43e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
STAD	cis	rs2439831	1	rs1814538	ENSG00000275601.1	AC011330.13	5.64	3.45e-08	3.43e-05	0.35	0.29	Lung cancer in ever smokers;	chr15:43467576	chr15:43642389~43643023:-
STAD	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-5.64	3.45e-08	3.43e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
STAD	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	5.64	3.46e-08	3.44e-05	0.37	0.29	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
STAD	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	5.64	3.46e-08	3.44e-05	0.32	0.29	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
STAD	cis	rs3806843	0.868	rs2262573	ENSG00000202111.1	VTRNA1-2	5.64	3.46e-08	3.44e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr5:140718925~140719013:+
STAD	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	5.64	3.47e-08	3.44e-05	0.33	0.29	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
STAD	cis	rs875971	0.545	rs6460276	ENSG00000224316.1	RP11-479O9.2	5.64	3.47e-08	3.45e-05	0.32	0.29	Aortic root size;	chr7:66182290	chr7:65773620~65802067:+
STAD	cis	rs516805	0.748	rs197682	ENSG00000279453.1	RP3-425C14.4	-5.64	3.48e-08	3.45e-05	-0.42	-0.29	Lymphocyte counts;	chr6:122551848	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs197683	ENSG00000279453.1	RP3-425C14.4	-5.64	3.48e-08	3.45e-05	-0.42	-0.29	Lymphocyte counts;	chr6:122552277	chr6:122436789~122439223:-
STAD	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-5.64	3.48e-08	3.46e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-5.64	3.48e-08	3.46e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
STAD	cis	rs2221894	0.632	rs10503835	ENSG00000273710.1	Metazoa_SRP	-5.64	3.48e-08	3.46e-05	-0.36	-0.29	Obesity-related traits;	chr8:28965578	chr8:28915579~28915864:-
STAD	cis	rs12699921	0.632	rs2723494	ENSG00000279048.1	RP11-511H23.2	-5.64	3.48e-08	3.46e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17814360	chr7:17940503~17942922:+
STAD	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	5.64	3.48e-08	3.46e-05	0.36	0.29	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
STAD	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	5.64	3.49e-08	3.46e-05	0.33	0.29	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
STAD	cis	rs10461617	0.541	rs7715822	ENSG00000271828.1	CTD-2310F14.1	5.64	3.49e-08	3.46e-05	0.45	0.29	Type 2 diabetes;	chr5:56747773	chr5:56927874~56929573:+
STAD	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-5.64	3.5e-08	3.47e-05	-0.4	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
STAD	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	5.64	3.5e-08	3.48e-05	0.38	0.29	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
STAD	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	5.64	3.5e-08	3.48e-05	0.28	0.29	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
STAD	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-5.64	3.51e-08	3.48e-05	-0.42	-0.29	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
STAD	cis	rs4568518	0.74	rs11543650	ENSG00000279048.1	RP11-511H23.2	5.64	3.51e-08	3.48e-05	0.26	0.29	Measles;	chr7:17970257	chr7:17940503~17942922:+
STAD	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-5.64	3.52e-08	3.49e-05	-0.31	-0.29	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
STAD	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-5.64	3.52e-08	3.49e-05	-0.31	-0.29	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
STAD	cis	rs721917	0.506	rs2493722	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79663088~79826594:-
STAD	cis	rs721917	0.545	rs2758542	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs7914360	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2493725	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2254025	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79663088~79826594:-
STAD	cis	rs721917	0.525	rs2254017	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2254013	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2253875	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79663088~79826594:-
STAD	cis	rs721917	0.544	rs9325567	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2758543	ENSG00000225484.5	NUTM2B-AS1	-5.64	3.52e-08	3.49e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79663088~79826594:-
STAD	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-5.64	3.52e-08	3.49e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
STAD	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	5.64	3.53e-08	3.5e-05	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
STAD	cis	rs3806843	0.676	rs778591	ENSG00000202111.1	VTRNA1-2	5.64	3.53e-08	3.5e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140645899	chr5:140718925~140719013:+
STAD	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-5.64	3.54e-08	3.5e-05	-0.34	-0.29	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-5.64	3.54e-08	3.5e-05	-0.34	-0.29	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
STAD	cis	rs7924176	0.601	rs7896660	ENSG00000236900.1	TIMM9P1	-5.64	3.54e-08	3.51e-05	-0.3	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74344550~74344805:-
STAD	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-5.64	3.54e-08	3.51e-05	-0.32	-0.29	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
STAD	cis	rs6782228	0.675	rs4443194	ENSG00000277250.1	Metazoa_SRP	-5.64	3.54e-08	3.51e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128673681~128674021:-
STAD	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-5.64	3.54e-08	3.51e-05	-0.34	-0.29	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
STAD	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	5.64	3.55e-08	3.51e-05	0.34	0.29	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	5.64	3.55e-08	3.51e-05	0.34	0.29	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	5.64	3.55e-08	3.51e-05	0.34	0.29	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
STAD	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	5.64	3.56e-08	3.52e-05	0.42	0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
STAD	cis	rs228614	0.51	rs223463	ENSG00000230069.3	LRRC37A15P	-5.64	3.56e-08	3.52e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102727274~102730721:-
STAD	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-5.64	3.56e-08	3.52e-05	-0.3	-0.29	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
STAD	cis	rs4604732	0.536	rs4925674	ENSG00000227135.1	GCSAML-AS1	-5.64	3.56e-08	3.53e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473604	chr1:247524679~247526752:-
STAD	cis	rs13113518	1	rs11133381	ENSG00000272969.1	RP11-528I4.2	5.64	3.56e-08	3.53e-05	0.36	0.29	Height;	chr4:55450812	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs4864995	ENSG00000272969.1	RP11-528I4.2	5.64	3.56e-08	3.53e-05	0.36	0.29	Height;	chr4:55452853	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs12651640	ENSG00000272969.1	RP11-528I4.2	5.64	3.56e-08	3.53e-05	0.36	0.29	Height;	chr4:55454154	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs1554483	ENSG00000272969.1	RP11-528I4.2	5.64	3.56e-08	3.53e-05	0.36	0.29	Height;	chr4:55455650	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs1464490	ENSG00000272969.1	RP11-528I4.2	5.64	3.56e-08	3.53e-05	0.36	0.29	Height;	chr4:55456620	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs10517346	ENSG00000272969.1	RP11-528I4.2	5.64	3.56e-08	3.53e-05	0.36	0.29	Height;	chr4:55457027	chr4:55547112~55547889:+
STAD	cis	rs13113518	1	rs11133384	ENSG00000272969.1	RP11-528I4.2	5.64	3.56e-08	3.53e-05	0.36	0.29	Height;	chr4:55457086	chr4:55547112~55547889:+
STAD	cis	rs992157	0.735	rs13392177	ENSG00000237281.1	CATIP-AS2	5.64	3.56e-08	3.53e-05	0.29	0.29	Colorectal cancer;	chr2:218248233	chr2:218326889~218357966:-
STAD	cis	rs12699921	0.632	rs2691621	ENSG00000279048.1	RP11-511H23.2	-5.64	3.57e-08	3.53e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17782826	chr7:17940503~17942922:+
STAD	cis	rs6452524	0.534	rs10514246	ENSG00000243385.2	CTD-2110K23.1	5.64	3.57e-08	3.53e-05	0.35	0.29	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83201229~83202141:+
STAD	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	5.64	3.57e-08	3.54e-05	0.34	0.29	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
STAD	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-5.64	3.58e-08	3.54e-05	-0.31	-0.29	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
STAD	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-5.64	3.58e-08	3.54e-05	-0.3	-0.29	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
STAD	cis	rs7487075	0.93	rs6582656	ENSG00000257261.4	RP11-96H19.1	5.64	3.58e-08	3.54e-05	0.34	0.29	Itch intensity from mosquito bite;	chr12:46449633	chr12:46383679~46876159:+
STAD	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	5.64	3.58e-08	3.54e-05	0.37	0.29	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
STAD	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-5.64	3.58e-08	3.54e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
STAD	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	5.64	3.58e-08	3.55e-05	0.34	0.29	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
STAD	cis	rs7927771	0.832	rs7924485	ENSG00000280615.1	Y_RNA	5.64	3.59e-08	3.55e-05	0.29	0.29	Subjective well-being;	chr11:47397578	chr11:47614898~47614994:-
STAD	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-5.64	3.59e-08	3.55e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
STAD	cis	rs2239557	1	rs75824542	ENSG00000259065.1	RP5-1021I20.1	-5.64	3.59e-08	3.55e-05	-0.35	-0.29	Common traits (Other);	chr14:74056344	chr14:73787360~73803270:+
STAD	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	5.64	3.6e-08	3.56e-05	0.33	0.29	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
STAD	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	5.64	3.6e-08	3.56e-05	0.3	0.29	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
STAD	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-5.64	3.6e-08	3.56e-05	-0.24	-0.29	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
STAD	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	5.64	3.6e-08	3.56e-05	0.33	0.29	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
STAD	cis	rs62432291	0.681	rs420054	ENSG00000235086.1	FNDC1-IT1	-5.64	3.6e-08	3.56e-05	-0.43	-0.29	Joint mobility (Beighton score);	chr6:159234052	chr6:159240786~159243329:+
STAD	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-5.64	3.61e-08	3.56e-05	-0.3	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
STAD	cis	rs13113518	1	rs4864993	ENSG00000272969.1	RP11-528I4.2	5.64	3.61e-08	3.57e-05	0.36	0.29	Height;	chr4:55450662	chr4:55547112~55547889:+
STAD	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	5.64	3.61e-08	3.57e-05	0.43	0.29	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
STAD	cis	rs3806843	0.778	rs2531346	ENSG00000202111.1	VTRNA1-2	5.64	3.61e-08	3.57e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140746554	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.868	rs2531345	ENSG00000202111.1	VTRNA1-2	5.64	3.61e-08	3.57e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140747196	chr5:140718925~140719013:+
STAD	cis	rs9549260	0.62	rs9532580	ENSG00000229456.1	RLIMP1	5.64	3.62e-08	3.57e-05	0.29	0.29	Red blood cell count;	chr13:40670123	chr13:40618738~40621348:+
STAD	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	5.64	3.62e-08	3.57e-05	0.4	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
STAD	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-5.64	3.62e-08	3.57e-05	-0.3	-0.29	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
STAD	cis	rs8098244	0.603	rs4800507	ENSG00000267301.1	RPL23AP77	-5.64	3.62e-08	3.57e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23726168	chr18:23709825~23710287:-
STAD	cis	rs516805	0.748	rs155463	ENSG00000279453.1	RP3-425C14.4	-5.64	3.62e-08	3.58e-05	-0.41	-0.29	Lymphocyte counts;	chr6:122501474	chr6:122436789~122439223:-
STAD	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	5.64	3.63e-08	3.58e-05	0.28	0.29	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	5.64	3.63e-08	3.58e-05	0.28	0.29	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
STAD	cis	rs7487075	0.554	rs7967629	ENSG00000257261.4	RP11-96H19.1	5.64	3.63e-08	3.58e-05	0.35	0.29	Itch intensity from mosquito bite;	chr12:46234824	chr12:46383679~46876159:+
STAD	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	5.64	3.63e-08	3.58e-05	0.28	0.29	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
STAD	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	5.64	3.63e-08	3.58e-05	0.28	0.29	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
STAD	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	5.64	3.63e-08	3.58e-05	0.28	0.29	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
STAD	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-5.63	3.63e-08	3.59e-05	-0.3	-0.29	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
STAD	cis	rs11722779	0.815	rs223347	ENSG00000230069.3	LRRC37A15P	-5.63	3.64e-08	3.59e-05	-0.31	-0.29	Schizophrenia;	chr4:102858815	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.873	rs223346	ENSG00000230069.3	LRRC37A15P	-5.63	3.64e-08	3.59e-05	-0.31	-0.29	Schizophrenia;	chr4:102859339	chr4:102727274~102730721:-
STAD	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	5.63	3.64e-08	3.59e-05	0.37	0.29	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
STAD	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	5.63	3.64e-08	3.59e-05	0.36	0.29	Height;	chr6:109367335	chr6:109382795~109383666:+
STAD	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-5.63	3.65e-08	3.6e-05	-0.3	-0.29	Height;	chr11:118859432	chr11:118791254~118793137:+
STAD	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	5.63	3.65e-08	3.6e-05	0.34	0.29	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
STAD	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	5.63	3.65e-08	3.6e-05	0.39	0.29	Height;	chr6:109582583	chr6:109382795~109383666:+
STAD	cis	rs1799949	1	rs8074136	ENSG00000236383.6	LINC00854	-5.63	3.65e-08	3.6e-05	-0.23	-0.29	Menopause (age at onset);	chr17:43190296	chr17:43216941~43305976:-
STAD	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	5.63	3.66e-08	3.6e-05	0.33	0.29	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	5.63	3.66e-08	3.6e-05	0.33	0.29	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
STAD	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-5.63	3.66e-08	3.61e-05	-0.35	-0.29	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
STAD	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-5.63	3.66e-08	3.61e-05	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
STAD	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	5.63	3.66e-08	3.61e-05	0.29	0.29	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	5.63	3.66e-08	3.61e-05	0.29	0.29	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	5.63	3.66e-08	3.61e-05	0.29	0.29	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	5.63	3.66e-08	3.61e-05	0.29	0.29	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
STAD	cis	rs8098244	0.603	rs1711456	ENSG00000267301.1	RPL23AP77	-5.63	3.67e-08	3.61e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23697390	chr18:23709825~23710287:-
STAD	cis	rs3806843	0.676	rs2245640	ENSG00000202111.1	VTRNA1-2	5.63	3.67e-08	3.61e-05	0.28	0.29	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr5:140718925~140719013:+
STAD	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	5.63	3.67e-08	3.62e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
STAD	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-5.63	3.67e-08	3.62e-05	-0.32	-0.29	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
STAD	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-5.63	3.67e-08	3.62e-05	-0.3	-0.29	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
STAD	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-5.63	3.67e-08	3.62e-05	-0.26	-0.29	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
STAD	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	5.63	3.68e-08	3.62e-05	0.36	0.29	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
STAD	cis	rs8098244	0.603	rs1711457	ENSG00000267301.1	RPL23AP77	-5.63	3.68e-08	3.62e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699494	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.603	rs1788813	ENSG00000267301.1	RPL23AP77	-5.63	3.68e-08	3.62e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701204	chr18:23709825~23710287:-
STAD	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-5.63	3.68e-08	3.62e-05	-0.34	-0.29	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
STAD	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	5.63	3.68e-08	3.62e-05	0.28	0.29	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
STAD	cis	rs4568518	0.616	rs13223642	ENSG00000279048.1	RP11-511H23.2	5.63	3.68e-08	3.63e-05	0.26	0.29	Measles;	chr7:17965352	chr7:17940503~17942922:+
STAD	cis	rs875971	0.862	rs1860469	ENSG00000236529.1	RP13-254B10.1	-5.63	3.68e-08	3.63e-05	-0.3	-0.29	Aortic root size;	chr7:66641888	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs4718383	ENSG00000236529.1	RP13-254B10.1	-5.63	3.68e-08	3.63e-05	-0.3	-0.29	Aortic root size;	chr7:66643422	chr7:65840212~65840596:+
STAD	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-5.63	3.68e-08	3.63e-05	-0.24	-0.29	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
STAD	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-5.63	3.7e-08	3.64e-05	-0.29	-0.29	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
STAD	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	5.63	3.7e-08	3.64e-05	0.3	0.29	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
STAD	cis	rs4568518	0.74	rs10429191	ENSG00000279048.1	RP11-511H23.2	5.63	3.7e-08	3.65e-05	0.26	0.29	Measles;	chr7:17969474	chr7:17940503~17942922:+
STAD	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-5.63	3.7e-08	3.65e-05	-0.32	-0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
STAD	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	5.63	3.71e-08	3.65e-05	0.53	0.29	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
STAD	cis	rs6782228	0.527	rs2811491	ENSG00000277250.1	Metazoa_SRP	-5.63	3.71e-08	3.65e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128673681~128674021:-
STAD	cis	rs10504130	0.569	rs9650305	ENSG00000272024.1	RP11-546K22.3	-5.63	3.71e-08	3.65e-05	-0.4	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs9650180	ENSG00000272024.1	RP11-546K22.3	-5.63	3.71e-08	3.65e-05	-0.4	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51950284~51950690:+
STAD	cis	rs74225573	1	rs74225573	ENSG00000230337.1	RP4-635E18.6	-5.63	3.72e-08	3.66e-05	-0.64	-0.29	Corneal curvature;	chr1:11220937	chr1:11099675~11102100:+
STAD	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-5.63	3.72e-08	3.66e-05	-0.41	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
STAD	cis	rs7927771	0.864	rs112060627	ENSG00000280615.1	Y_RNA	-5.63	3.72e-08	3.66e-05	-0.29	-0.29	Subjective well-being;	chr11:47405405	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.864	rs7107726	ENSG00000280615.1	Y_RNA	-5.63	3.72e-08	3.66e-05	-0.29	-0.29	Subjective well-being;	chr11:47407694	chr11:47614898~47614994:-
STAD	cis	rs8040855	0.657	rs6496733	ENSG00000229212.6	RP11-561C5.4	-5.63	3.72e-08	3.67e-05	-0.41	-0.29	Bulimia nervosa;	chr15:85129945	chr15:85205440~85234795:-
STAD	cis	rs7829975	0.6	rs1719381	ENSG00000253981.4	ALG1L13P	-5.63	3.72e-08	3.67e-05	-0.34	-0.29	Mood instability;	chr8:8744834	chr8:8236003~8244667:-
STAD	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-5.63	3.73e-08	3.67e-05	-0.39	-0.29	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
STAD	cis	rs7760535	0.826	rs7753887	ENSG00000230177.1	RP5-1112D6.4	-5.63	3.73e-08	3.67e-05	-0.26	-0.29	Metabolic traits;	chr6:111533904	chr6:111277932~111278742:+
STAD	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-5.63	3.73e-08	3.67e-05	-0.32	-0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
STAD	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	5.63	3.73e-08	3.67e-05	0.33	0.29	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
STAD	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	5.63	3.73e-08	3.67e-05	0.3	0.29	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
STAD	cis	rs3806843	0.832	rs2531360	ENSG00000202111.1	VTRNA1-2	5.63	3.74e-08	3.68e-05	0.28	0.29	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr5:140718925~140719013:+
STAD	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-5.63	3.74e-08	3.68e-05	-0.4	-0.29	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
STAD	cis	rs1799949	1	rs4793231	ENSG00000279602.1	CTD-3014M21.1	5.63	3.74e-08	3.68e-05	0.36	0.29	Menopause (age at onset);	chr17:43350101	chr17:43360041~43361361:-
STAD	cis	rs12699921	0.598	rs2691607	ENSG00000279048.1	RP11-511H23.2	-5.63	3.74e-08	3.68e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17839480	chr7:17940503~17942922:+
STAD	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	5.63	3.75e-08	3.68e-05	0.25	0.29	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
STAD	cis	rs7580658	0.724	rs6712213	ENSG00000200250.1	RNU6-1147P	5.63	3.75e-08	3.69e-05	0.28	0.29	Protein C levels;	chr2:127240654	chr2:127316873~127316979:+
STAD	cis	rs4927850	1	rs4927850	ENSG00000185485.13	SDHAP1	-5.63	3.75e-08	3.69e-05	-0.28	-0.29	Pancreatic cancer;	chr3:196024759	chr3:195959748~195990318:-
STAD	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-5.63	3.76e-08	3.69e-05	-0.3	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
STAD	cis	rs10129255	0.833	rs7156689	ENSG00000280411.1	IGHV1-69-2	-5.63	3.76e-08	3.69e-05	-0.27	-0.29	Kawasaki disease;	chr14:106816039	chr14:106762092~106762588:-
STAD	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	5.63	3.77e-08	3.7e-05	0.3	0.29	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
STAD	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	5.63	3.77e-08	3.71e-05	0.32	0.29	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
STAD	cis	rs7083	0.716	rs574603	ENSG00000254851.1	RP11-109L13.1	5.63	3.78e-08	3.71e-05	0.34	0.29	Blood protein levels;	chr11:117307025	chr11:117135528~117138582:+
STAD	cis	rs1799949	0.965	rs4793230	ENSG00000236383.6	LINC00854	-5.63	3.78e-08	3.71e-05	-0.23	-0.29	Menopause (age at onset);	chr17:43350035	chr17:43216941~43305976:-
STAD	cis	rs12699921	0.632	rs2691552	ENSG00000279048.1	RP11-511H23.2	-5.63	3.78e-08	3.72e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17884121	chr7:17940503~17942922:+
STAD	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-5.63	3.78e-08	3.72e-05	-0.41	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
STAD	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-5.63	3.78e-08	3.72e-05	-0.41	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
STAD	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	5.63	3.79e-08	3.72e-05	0.3	0.29	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
STAD	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	5.63	3.79e-08	3.72e-05	0.28	0.29	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	5.63	3.79e-08	3.72e-05	0.28	0.29	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
STAD	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-5.63	3.79e-08	3.72e-05	-0.27	-0.29	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
STAD	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-5.63	3.79e-08	3.72e-05	-0.27	-0.29	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
STAD	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-5.63	3.79e-08	3.72e-05	-0.27	-0.29	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-5.63	3.79e-08	3.72e-05	-0.27	-0.29	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
STAD	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-5.63	3.79e-08	3.73e-05	-0.24	-0.29	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
STAD	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-5.63	3.79e-08	3.73e-05	-0.35	-0.29	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
STAD	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	5.63	3.8e-08	3.73e-05	0.31	0.29	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
STAD	cis	rs12130219	0.588	rs2282302	ENSG00000237975.5	FLG-AS1	5.63	3.8e-08	3.73e-05	0.39	0.29	Inflammatory skin disease;	chr1:152356893	chr1:152168125~152445456:+
STAD	cis	rs12699921	0.632	rs2691613	ENSG00000279048.1	RP11-511H23.2	-5.63	3.8e-08	3.73e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17844358	chr7:17940503~17942922:+
STAD	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	5.63	3.8e-08	3.73e-05	0.32	0.29	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	5.63	3.8e-08	3.73e-05	0.32	0.29	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
STAD	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-5.63	3.81e-08	3.74e-05	-0.29	-0.29	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-5.63	3.81e-08	3.74e-05	-0.29	-0.29	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
STAD	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-5.63	3.81e-08	3.74e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
STAD	cis	rs3806843	0.838	rs2563289	ENSG00000202111.1	VTRNA1-2	5.63	3.82e-08	3.75e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140743181	chr5:140718925~140719013:+
STAD	cis	rs7487075	0.859	rs7968283	ENSG00000272369.1	RP11-446N19.1	5.63	3.82e-08	3.75e-05	0.37	0.29	Itch intensity from mosquito bite;	chr12:46365353	chr12:46537502~46652550:+
STAD	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	5.63	3.82e-08	3.75e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
STAD	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-5.63	3.83e-08	3.76e-05	-0.33	-0.29	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
STAD	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	5.63	3.83e-08	3.76e-05	0.31	0.29	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
STAD	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-5.62	3.83e-08	3.76e-05	-0.3	-0.29	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
STAD	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	5.62	3.84e-08	3.77e-05	0.32	0.29	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	5.62	3.84e-08	3.77e-05	0.32	0.29	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
STAD	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	5.62	3.85e-08	3.77e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	5.62	3.85e-08	3.77e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	5.62	3.85e-08	3.77e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
STAD	cis	rs7924176	0.601	rs4638254	ENSG00000236900.1	TIMM9P1	-5.62	3.85e-08	3.77e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74344550~74344805:-
STAD	cis	rs3806843	0.966	rs7737424	ENSG00000202111.1	VTRNA1-2	-5.62	3.85e-08	3.77e-05	-0.29	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140766760	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.966	rs12659129	ENSG00000202111.1	VTRNA1-2	-5.62	3.85e-08	3.77e-05	-0.29	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140767663	chr5:140718925~140719013:+
STAD	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	5.62	3.85e-08	3.78e-05	0.32	0.29	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
STAD	cis	rs1862618	0.671	rs2591961	ENSG00000271828.1	CTD-2310F14.1	-5.62	3.86e-08	3.78e-05	-0.35	-0.29	Initial pursuit acceleration;	chr5:56942770	chr5:56927874~56929573:+
STAD	cis	rs875971	0.545	rs73142233	ENSG00000224316.1	RP11-479O9.2	5.62	3.86e-08	3.78e-05	0.33	0.29	Aortic root size;	chr7:66221293	chr7:65773620~65802067:+
STAD	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	5.62	3.87e-08	3.79e-05	0.33	0.29	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
STAD	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	5.62	3.87e-08	3.79e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	5.62	3.87e-08	3.79e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
STAD	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-5.62	3.87e-08	3.79e-05	-0.3	-0.29	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	5.62	3.88e-08	3.8e-05	0.3	0.29	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-5.62	3.88e-08	3.8e-05	-0.27	-0.29	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
STAD	cis	rs516805	0.781	rs560717	ENSG00000279453.1	RP3-425C14.4	-5.62	3.88e-08	3.8e-05	-0.42	-0.29	Lymphocyte counts;	chr6:122482909	chr6:122436789~122439223:-
STAD	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	5.62	3.89e-08	3.81e-05	0.25	0.29	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
STAD	cis	rs721917	0.525	rs2758541	ENSG00000225484.5	NUTM2B-AS1	-5.62	3.9e-08	3.82e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs927452	ENSG00000225484.5	NUTM2B-AS1	-5.62	3.9e-08	3.82e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79663088~79826594:-
STAD	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	5.62	3.91e-08	3.83e-05	0.29	0.29	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
STAD	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-5.62	3.91e-08	3.83e-05	-0.36	-0.29	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
STAD	cis	rs2237234	0.58	rs7763910	ENSG00000243307.2	POM121L6P	-5.62	3.92e-08	3.83e-05	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26472427	chr6:26896952~26898777:+
STAD	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-5.62	3.92e-08	3.83e-05	-0.42	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
STAD	cis	rs494459	0.536	rs57719838	ENSG00000278376.1	RP11-158I9.8	-5.62	3.93e-08	3.84e-05	-0.3	-0.29	Height;	chr11:118854014	chr11:118791254~118793137:+
STAD	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-5.62	3.93e-08	3.84e-05	-0.3	-0.29	Height;	chr11:118855233	chr11:118791254~118793137:+
STAD	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-5.62	3.93e-08	3.84e-05	-0.3	-0.29	Height;	chr11:118855938	chr11:118791254~118793137:+
STAD	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-5.62	3.93e-08	3.84e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
STAD	cis	rs17301013	0.932	rs11804941	ENSG00000227373.4	RP11-160H22.5	-5.62	3.93e-08	3.84e-05	-0.34	-0.29	Systemic lupus erythematosus;	chr1:174624074	chr1:174115300~174160004:-
STAD	cis	rs1150668	0.799	rs1150707	ENSG00000220721.1	OR1F12	5.62	3.93e-08	3.85e-05	0.28	0.29	Pubertal anthropometrics;	chr6:28229827	chr6:28073316~28074233:+
STAD	cis	rs9425766	0.679	rs7555067	ENSG00000227373.4	RP11-160H22.5	5.62	3.94e-08	3.85e-05	0.33	0.29	Life satisfaction;	chr1:174297504	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs6695636	ENSG00000227373.4	RP11-160H22.5	5.62	3.94e-08	3.85e-05	0.33	0.29	Life satisfaction;	chr1:174303087	chr1:174115300~174160004:-
STAD	cis	rs875971	0.545	rs73142245	ENSG00000224316.1	RP11-479O9.2	5.62	3.94e-08	3.85e-05	0.33	0.29	Aortic root size;	chr7:66226662	chr7:65773620~65802067:+
STAD	cis	rs3806843	0.932	rs2563256	ENSG00000202111.1	VTRNA1-2	5.62	3.95e-08	3.86e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140762194	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.966	rs2563255	ENSG00000202111.1	VTRNA1-2	5.62	3.95e-08	3.86e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140762962	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.9	rs2563254	ENSG00000202111.1	VTRNA1-2	5.62	3.95e-08	3.86e-05	0.29	0.29	Depressive symptoms (multi-trait analysis);	chr5:140763116	chr5:140718925~140719013:+
STAD	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-5.62	3.95e-08	3.86e-05	-0.32	-0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
STAD	cis	rs721917	0.525	rs2250473	ENSG00000225484.5	NUTM2B-AS1	-5.62	3.95e-08	3.86e-05	-0.37	-0.29	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79663088~79826594:-
STAD	cis	rs17301013	0.612	rs56199565	ENSG00000227373.4	RP11-160H22.5	5.62	3.95e-08	3.86e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174640992	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.861	rs34819375	ENSG00000227373.4	RP11-160H22.5	5.62	3.95e-08	3.86e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174654958	chr1:174115300~174160004:-
STAD	cis	rs12699921	0.632	rs2691557	ENSG00000279048.1	RP11-511H23.2	-5.62	3.96e-08	3.87e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17902974	chr7:17940503~17942922:+
STAD	cis	rs1961102	0.521	rs644299	ENSG00000253385.1	KB-1254G8.1	5.62	3.96e-08	3.87e-05	0.29	0.29	QT interval;	chr8:102918016	chr8:102854455~102856075:+
STAD	cis	rs7580658	0.55	rs62160290	ENSG00000200250.1	RNU6-1147P	5.62	3.96e-08	3.87e-05	0.28	0.29	Protein C levels;	chr2:127443119	chr2:127316873~127316979:+
STAD	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-5.62	3.96e-08	3.87e-05	-0.4	-0.29	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
STAD	cis	rs228614	0.517	rs3886722	ENSG00000230069.3	LRRC37A15P	-5.62	3.97e-08	3.88e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102727274~102730721:-
STAD	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	5.62	3.97e-08	3.89e-05	0.39	0.29	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
STAD	cis	rs721917	0.506	rs7073842	ENSG00000225484.5	NUTM2B-AS1	-5.62	3.98e-08	3.89e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79663088~79826594:-
STAD	cis	rs2980439	0.807	rs2980438	ENSG00000173295.6	FAM86B3P	5.62	3.99e-08	3.9e-05	0.33	0.29	Neuroticism;	chr8:8237303	chr8:8228595~8244865:+
STAD	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	5.62	3.99e-08	3.9e-05	0.3	0.29	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
STAD	cis	rs1816752	0.87	rs7320102	ENSG00000273628.1	RP11-756A22.7	5.62	3.99e-08	3.9e-05	0.35	0.29	Obesity-related traits;	chr13:24437435	chr13:24933006~24936796:+
STAD	cis	rs10129255	0.872	rs8015406	ENSG00000280411.1	IGHV1-69-2	-5.62	3.99e-08	3.9e-05	-0.27	-0.29	Kawasaki disease;	chr14:106670611	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.957	rs12590735	ENSG00000280411.1	IGHV1-69-2	-5.62	4e-08	3.91e-05	-0.27	-0.29	Kawasaki disease;	chr14:106779660	chr14:106762092~106762588:-
STAD	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	5.62	4e-08	3.91e-05	0.28	0.29	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
STAD	cis	rs720064	0.586	rs8099403	ENSG00000267301.1	RPL23AP77	5.62	4e-08	3.91e-05	0.35	0.29	Strep throat;	chr18:23933031	chr18:23709825~23710287:-
STAD	cis	rs1056107	0.966	rs4979094	ENSG00000225513.1	RP11-165N19.2	-5.62	4.01e-08	3.91e-05	-0.33	-0.29	Colorectal cancer;	chr9:112283837	chr9:112173522~112173971:-
STAD	cis	rs6782228	0.606	rs2712419	ENSG00000277250.1	Metazoa_SRP	-5.62	4.01e-08	3.91e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128673681~128674021:-
STAD	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	5.62	4.01e-08	3.92e-05	0.78	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
STAD	cis	rs9549260	0.753	rs9532563	ENSG00000229456.1	RLIMP1	5.62	4.02e-08	3.92e-05	0.32	0.29	Red blood cell count;	chr13:40586133	chr13:40618738~40621348:+
STAD	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	5.62	4.02e-08	3.92e-05	0.34	0.29	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
STAD	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-5.62	4.02e-08	3.92e-05	-0.29	-0.29	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-5.62	4.02e-08	3.92e-05	-0.29	-0.29	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
STAD	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	5.62	4.02e-08	3.93e-05	0.41	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	5.62	4.02e-08	3.93e-05	0.41	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	5.62	4.02e-08	3.93e-05	0.41	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
STAD	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	5.62	4.03e-08	3.93e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	5.62	4.03e-08	3.93e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	5.62	4.03e-08	3.93e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	5.62	4.03e-08	3.93e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	5.62	4.03e-08	3.93e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
STAD	cis	rs13113518	0.812	rs6830409	ENSG00000272969.1	RP11-528I4.2	5.62	4.03e-08	3.93e-05	0.37	0.29	Height;	chr4:55522229	chr4:55547112~55547889:+
STAD	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-5.62	4.03e-08	3.93e-05	-0.3	-0.29	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
STAD	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-5.62	4.03e-08	3.93e-05	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
STAD	cis	rs4927850	1	rs7627706	ENSG00000185485.13	SDHAP1	5.62	4.03e-08	3.94e-05	0.29	0.29	Pancreatic cancer;	chr3:196026482	chr3:195959748~195990318:-
STAD	cis	rs4927850	0.881	rs7630489	ENSG00000185485.13	SDHAP1	5.62	4.03e-08	3.94e-05	0.29	0.29	Pancreatic cancer;	chr3:196026530	chr3:195959748~195990318:-
STAD	cis	rs4927850	1	rs7627868	ENSG00000185485.13	SDHAP1	5.62	4.03e-08	3.94e-05	0.29	0.29	Pancreatic cancer;	chr3:196026602	chr3:195959748~195990318:-
STAD	cis	rs5769707	0.706	rs763128	ENSG00000280224.1	CTA-722E9.1	-5.62	4.03e-08	3.94e-05	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.568	rs2011097	ENSG00000280224.1	CTA-722E9.1	-5.62	4.03e-08	3.94e-05	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49500568~49501585:+
STAD	cis	rs7487075	0.619	rs11183488	ENSG00000272369.1	RP11-446N19.1	5.62	4.04e-08	3.94e-05	0.39	0.29	Itch intensity from mosquito bite;	chr12:46448053	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs7486532	ENSG00000272369.1	RP11-446N19.1	5.62	4.04e-08	3.94e-05	0.39	0.29	Itch intensity from mosquito bite;	chr12:46449472	chr12:46537502~46652550:+
STAD	cis	rs12699921	0.558	rs2691559	ENSG00000279048.1	RP11-511H23.2	-5.61	4.04e-08	3.94e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17905636	chr7:17940503~17942922:+
STAD	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-5.61	4.04e-08	3.94e-05	-0.28	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
STAD	cis	rs228614	0.536	rs223437	ENSG00000230069.3	LRRC37A15P	-5.61	4.04e-08	3.94e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102727274~102730721:-
STAD	cis	rs9425766	0.679	rs7552830	ENSG00000227373.4	RP11-160H22.5	5.61	4.04e-08	3.94e-05	0.33	0.29	Life satisfaction;	chr1:174321643	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs7523938	ENSG00000227373.4	RP11-160H22.5	5.61	4.04e-08	3.94e-05	0.33	0.29	Life satisfaction;	chr1:174327373	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.64	rs6681780	ENSG00000227373.4	RP11-160H22.5	5.61	4.04e-08	3.94e-05	0.33	0.29	Life satisfaction;	chr1:174328980	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.55	rs57366619	ENSG00000227373.4	RP11-160H22.5	5.61	4.04e-08	3.94e-05	0.33	0.29	Life satisfaction;	chr1:174334929	chr1:174115300~174160004:-
STAD	cis	rs9463078	0.546	rs10948191	ENSG00000219384.1	RP11-491H9.3	-5.61	4.05e-08	3.95e-05	-0.28	-0.29	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44979544	chr6:45158870~45159511:+
STAD	cis	rs950027	0.787	rs1153845	ENSG00000259433.2	CTD-2651B20.4	5.61	4.06e-08	3.96e-05	0.31	0.29	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45330209~45332634:-
STAD	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	5.61	4.06e-08	3.96e-05	0.26	0.29	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
STAD	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	5.61	4.06e-08	3.96e-05	0.26	0.29	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
STAD	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	5.61	4.06e-08	3.96e-05	0.26	0.29	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
STAD	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	5.61	4.06e-08	3.96e-05	0.26	0.29	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
STAD	cis	rs35934224	0.891	rs33997573	ENSG00000232926.1	AC000078.5	5.61	4.06e-08	3.96e-05	0.41	0.29	Glaucoma (primary open-angle);	chr22:19881428	chr22:19887289~19887970:+
STAD	cis	rs875971	0.545	rs1638724	ENSG00000224316.1	RP11-479O9.2	-5.61	4.06e-08	3.96e-05	-0.32	-0.29	Aortic root size;	chr7:66575494	chr7:65773620~65802067:+
STAD	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-5.61	4.06e-08	3.96e-05	-0.3	-0.29	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
STAD	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	5.61	4.06e-08	3.96e-05	0.36	0.29	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
STAD	cis	rs7487075	0.93	rs7308910	ENSG00000272369.1	RP11-446N19.1	5.61	4.07e-08	3.97e-05	0.34	0.29	Itch intensity from mosquito bite;	chr12:46444459	chr12:46537502~46652550:+
STAD	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	5.61	4.07e-08	3.97e-05	0.35	0.29	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
STAD	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-5.61	4.09e-08	3.98e-05	-0.28	-0.29	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
STAD	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	5.61	4.09e-08	3.98e-05	0.31	0.29	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
STAD	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-5.61	4.09e-08	3.98e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
STAD	cis	rs7927771	0.832	rs4752994	ENSG00000280615.1	Y_RNA	5.61	4.09e-08	3.99e-05	0.29	0.29	Subjective well-being;	chr11:47389514	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.832	rs10769262	ENSG00000280615.1	Y_RNA	5.61	4.09e-08	3.99e-05	0.29	0.29	Subjective well-being;	chr11:47390030	chr11:47614898~47614994:-
STAD	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	5.61	4.09e-08	3.99e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
STAD	cis	rs7176527	1	rs7176527	ENSG00000188388.10	GOLGA6L3	5.61	4.09e-08	3.99e-05	0.4	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85240472~85247170:+
STAD	cis	rs2712381	0.797	rs62270806	ENSG00000277250.1	Metazoa_SRP	-5.61	4.1e-08	3.99e-05	-0.3	-0.29	Monocyte count;	chr3:128657426	chr3:128673681~128674021:-
STAD	cis	rs17301013	0.9	rs56347239	ENSG00000227373.4	RP11-160H22.5	5.61	4.1e-08	3.99e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174564476	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs7542389	ENSG00000227373.4	RP11-160H22.5	5.61	4.1e-08	3.99e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174565104	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs12074753	ENSG00000227373.4	RP11-160H22.5	5.61	4.1e-08	3.99e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174565768	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs1016466	ENSG00000227373.4	RP11-160H22.5	5.61	4.1e-08	3.99e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174570652	chr1:174115300~174160004:-
STAD	cis	rs228614	0.51	rs223435	ENSG00000230069.3	LRRC37A15P	-5.61	4.11e-08	4e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs6533050	ENSG00000230069.3	LRRC37A15P	-5.61	4.11e-08	4e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs10032234	ENSG00000230069.3	LRRC37A15P	-5.61	4.11e-08	4e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs28845922	ENSG00000230069.3	LRRC37A15P	-5.61	4.11e-08	4e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102727274~102730721:-
STAD	cis	rs1816752	0.875	rs1050110	ENSG00000273628.1	RP11-756A22.7	5.61	4.11e-08	4.01e-05	0.36	0.29	Obesity-related traits;	chr13:24435347	chr13:24933006~24936796:+
STAD	cis	rs6782228	0.585	rs6774515	ENSG00000277250.1	Metazoa_SRP	-5.61	4.11e-08	4.01e-05	-0.29	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128673681~128674021:-
STAD	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	5.61	4.12e-08	4.02e-05	0.35	0.29	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
STAD	cis	rs7487075	0.79	rs11183527	ENSG00000272369.1	RP11-446N19.1	5.61	4.13e-08	4.02e-05	0.34	0.29	Itch intensity from mosquito bite;	chr12:46552580	chr12:46537502~46652550:+
STAD	cis	rs2439831	0.681	rs956391	ENSG00000205771.5	CATSPER2P1	5.61	4.13e-08	4.02e-05	0.38	0.29	Lung cancer in ever smokers;	chr15:43325295	chr15:43726918~43747094:-
STAD	cis	rs1816752	0.905	rs7339140	ENSG00000273628.1	RP11-756A22.7	5.61	4.13e-08	4.02e-05	0.35	0.29	Obesity-related traits;	chr13:24437764	chr13:24933006~24936796:+
STAD	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	5.61	4.13e-08	4.02e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
STAD	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-5.61	4.13e-08	4.02e-05	-0.33	-0.29	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
STAD	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-5.61	4.13e-08	4.02e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
STAD	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-5.61	4.13e-08	4.02e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
STAD	cis	rs1707322	0.638	rs1416706	ENSG00000280836.1	AL355480.1	5.61	4.13e-08	4.02e-05	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.957	rs11847726	ENSG00000280411.1	IGHV1-69-2	-5.61	4.13e-08	4.02e-05	-0.27	-0.29	Kawasaki disease;	chr14:106779116	chr14:106762092~106762588:-
STAD	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	5.61	4.14e-08	4.02e-05	0.33	0.29	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
STAD	cis	rs7927771	0.524	rs7929014	ENSG00000280615.1	Y_RNA	5.61	4.14e-08	4.03e-05	0.29	0.29	Subjective well-being;	chr11:47754731	chr11:47614898~47614994:-
STAD	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	5.61	4.14e-08	4.03e-05	0.32	0.29	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
STAD	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	5.61	4.14e-08	4.03e-05	0.24	0.29	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
STAD	cis	rs7615952	0.688	rs7624806	ENSG00000272840.1	RP11-379B18.6	5.61	4.15e-08	4.03e-05	0.52	0.29	Blood pressure (smoking interaction);	chr3:125880231	chr3:125774714~125797953:+
STAD	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-5.61	4.15e-08	4.04e-05	-0.42	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
STAD	cis	rs9425766	0.64	rs6693423	ENSG00000227373.4	RP11-160H22.5	5.61	4.15e-08	4.04e-05	0.33	0.29	Life satisfaction;	chr1:174364680	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs60363188	ENSG00000227373.4	RP11-160H22.5	5.61	4.15e-08	4.04e-05	0.33	0.29	Life satisfaction;	chr1:174375959	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs12084119	ENSG00000227373.4	RP11-160H22.5	5.61	4.15e-08	4.04e-05	0.33	0.29	Life satisfaction;	chr1:174377138	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.965	rs7548540	ENSG00000227373.4	RP11-160H22.5	5.61	4.15e-08	4.04e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174411672	chr1:174115300~174160004:-
STAD	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	5.61	4.15e-08	4.04e-05	0.34	0.29	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
STAD	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	5.61	4.17e-08	4.05e-05	0.38	0.29	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
STAD	cis	rs7829975	0.542	rs7844374	ENSG00000254340.1	RP11-10A14.3	-5.61	4.17e-08	4.06e-05	-0.36	-0.29	Mood instability;	chr8:8941174	chr8:9141424~9145435:+
STAD	cis	rs17301013	0.932	rs444678	ENSG00000227373.4	RP11-160H22.5	5.61	4.17e-08	4.06e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174706080	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs332795	ENSG00000227373.4	RP11-160H22.5	5.61	4.17e-08	4.06e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174726785	chr1:174115300~174160004:-
STAD	cis	rs721917	0.506	rs2758561	ENSG00000225484.5	NUTM2B-AS1	-5.61	4.18e-08	4.06e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79663088~79826594:-
STAD	cis	rs1961102	0.521	rs657000	ENSG00000253385.1	KB-1254G8.1	5.61	4.18e-08	4.07e-05	0.29	0.29	QT interval;	chr8:102917514	chr8:102854455~102856075:+
STAD	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	5.61	4.18e-08	4.07e-05	0.31	0.29	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
STAD	cis	rs12699921	0.632	rs2691617	ENSG00000279048.1	RP11-511H23.2	-5.61	4.19e-08	4.07e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17782704	chr7:17940503~17942922:+
STAD	cis	rs7396835	0.866	rs6589571	ENSG00000280143.1	AP000892.6	5.61	4.19e-08	4.07e-05	0.29	0.29	Quantitative traits;	chr11:116809702	chr11:117204967~117210292:+
STAD	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-5.61	4.19e-08	4.08e-05	-0.37	-0.29	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
STAD	cis	rs992157	1	rs2168704	ENSG00000237281.1	CATIP-AS2	-5.61	4.2e-08	4.08e-05	-0.29	-0.29	Colorectal cancer;	chr2:218277769	chr2:218326889~218357966:-
STAD	cis	rs992157	1	rs13429408	ENSG00000237281.1	CATIP-AS2	-5.61	4.2e-08	4.08e-05	-0.29	-0.29	Colorectal cancer;	chr2:218278137	chr2:218326889~218357966:-
STAD	cis	rs7487075	0.78	rs12296120	ENSG00000257261.4	RP11-96H19.1	5.61	4.2e-08	4.08e-05	0.34	0.29	Itch intensity from mosquito bite;	chr12:46343808	chr12:46383679~46876159:+
STAD	cis	rs12530	0.715	rs5749428	ENSG00000230736.2	RP1-149A16.3	-5.61	4.2e-08	4.08e-05	-0.38	-0.29	IgG glycosylation;	chr22:32403709	chr22:32376664~32384343:+
STAD	cis	rs12530	0.715	rs5998475	ENSG00000230736.2	RP1-149A16.3	-5.61	4.2e-08	4.08e-05	-0.38	-0.29	IgG glycosylation;	chr22:32405345	chr22:32376664~32384343:+
STAD	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-5.61	4.2e-08	4.08e-05	-0.24	-0.29	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
STAD	cis	rs9425766	0.679	rs6670617	ENSG00000227373.4	RP11-160H22.5	5.61	4.2e-08	4.08e-05	0.33	0.29	Life satisfaction;	chr1:174277574	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs4650990	ENSG00000227373.4	RP11-160H22.5	5.61	4.2e-08	4.08e-05	0.33	0.29	Life satisfaction;	chr1:174289943	chr1:174115300~174160004:-
STAD	cis	rs4568518	0.619	rs34058374	ENSG00000279048.1	RP11-511H23.2	5.61	4.2e-08	4.09e-05	0.26	0.29	Measles;	chr7:17968959	chr7:17940503~17942922:+
STAD	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	5.61	4.21e-08	4.09e-05	0.29	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
STAD	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	5.61	4.21e-08	4.09e-05	0.29	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
STAD	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	5.61	4.21e-08	4.09e-05	0.29	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
STAD	cis	rs4604732	0.631	rs12031721	ENSG00000227135.1	GCSAML-AS1	-5.61	4.22e-08	4.1e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460471	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.578	rs12038656	ENSG00000227135.1	GCSAML-AS1	-5.61	4.22e-08	4.1e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460514	chr1:247524679~247526752:-
STAD	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	5.61	4.22e-08	4.1e-05	0.33	0.29	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
STAD	cis	rs721917	0.506	rs2819097	ENSG00000225484.5	NUTM2B-AS1	-5.61	4.22e-08	4.1e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2254016	ENSG00000225484.5	NUTM2B-AS1	-5.61	4.24e-08	4.12e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79663088~79826594:-
STAD	cis	rs1799949	0.965	rs11080034	ENSG00000236383.6	LINC00854	-5.61	4.24e-08	4.12e-05	-0.23	-0.29	Menopause (age at onset);	chr17:43365646	chr17:43216941~43305976:-
STAD	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-5.61	4.24e-08	4.12e-05	-0.41	-0.29	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
STAD	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	5.61	4.25e-08	4.13e-05	0.31	0.29	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
STAD	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-5.6	4.26e-08	4.14e-05	-0.41	-0.29	QT interval;	chr16:28845498	chr16:28700294~28701540:-
STAD	cis	rs4604732	0.588	rs6677477	ENSG00000227135.1	GCSAML-AS1	-5.6	4.26e-08	4.14e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466109	chr1:247524679~247526752:-
STAD	cis	rs875971	0.571	rs160641	ENSG00000224316.1	RP11-479O9.2	-5.6	4.26e-08	4.14e-05	-0.33	-0.29	Aortic root size;	chr7:66112359	chr7:65773620~65802067:+
STAD	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	5.6	4.27e-08	4.14e-05	0.43	0.29	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
STAD	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	5.6	4.27e-08	4.14e-05	0.43	0.29	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
STAD	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	5.6	4.27e-08	4.14e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
STAD	cis	rs9549260	0.617	rs9549266	ENSG00000229456.1	RLIMP1	5.6	4.28e-08	4.15e-05	0.34	0.29	Red blood cell count;	chr13:40704273	chr13:40618738~40621348:+
STAD	cis	rs6782228	1	rs11711038	ENSG00000277250.1	Metazoa_SRP	5.6	4.28e-08	4.15e-05	0.34	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128673681~128674021:-
STAD	cis	rs7829975	0.559	rs4841025	ENSG00000253981.4	ALG1L13P	-5.6	4.28e-08	4.15e-05	-0.34	-0.29	Mood instability;	chr8:8745650	chr8:8236003~8244667:-
STAD	cis	rs17301013	0.932	rs332771	ENSG00000227373.4	RP11-160H22.5	5.6	4.28e-08	4.16e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174704141	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.861	rs332789	ENSG00000227373.4	RP11-160H22.5	5.6	4.28e-08	4.16e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174735754	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs461910	ENSG00000227373.4	RP11-160H22.5	5.6	4.28e-08	4.16e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174736351	chr1:174115300~174160004:-
STAD	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-5.6	4.29e-08	4.16e-05	-0.24	-0.29	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
STAD	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-5.6	4.29e-08	4.16e-05	-0.24	-0.29	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
STAD	cis	rs875971	0.545	rs73142265	ENSG00000224316.1	RP11-479O9.2	5.6	4.3e-08	4.17e-05	0.33	0.29	Aortic root size;	chr7:66234510	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs1638735	ENSG00000224316.1	RP11-479O9.2	5.6	4.3e-08	4.17e-05	0.31	0.29	Aortic root size;	chr7:66630751	chr7:65773620~65802067:+
STAD	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	5.6	4.3e-08	4.17e-05	0.3	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
STAD	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	5.6	4.3e-08	4.17e-05	0.34	0.29	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
STAD	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	5.6	4.31e-08	4.18e-05	0.31	0.29	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
STAD	cis	rs1056107	0.966	rs7041688	ENSG00000225513.1	RP11-165N19.2	-5.6	4.31e-08	4.18e-05	-0.34	-0.29	Colorectal cancer;	chr9:112272619	chr9:112173522~112173971:-
STAD	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-5.6	4.31e-08	4.18e-05	-0.36	-0.29	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
STAD	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-5.6	4.32e-08	4.18e-05	-0.42	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
STAD	cis	rs7487075	0.786	rs7980775	ENSG00000272369.1	RP11-446N19.1	5.6	4.32e-08	4.19e-05	0.37	0.29	Itch intensity from mosquito bite;	chr12:46281090	chr12:46537502~46652550:+
STAD	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-5.6	4.32e-08	4.19e-05	-0.31	-0.29	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
STAD	cis	rs8067354	0.54	rs72840315	ENSG00000266701.1	AC005702.4	5.6	4.32e-08	4.19e-05	0.42	0.29	Hemoglobin concentration;	chr17:59940781	chr17:60042546~60042627:-
STAD	cis	rs11722779	0.873	rs6533041	ENSG00000230069.3	LRRC37A15P	-5.6	4.33e-08	4.19e-05	-0.31	-0.29	Schizophrenia;	chr4:102951615	chr4:102727274~102730721:-
STAD	cis	rs858239	0.601	rs10224327	ENSG00000226816.2	AC005082.12	5.6	4.33e-08	4.2e-05	0.36	0.29	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23206013~23208045:+
STAD	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-5.6	4.34e-08	4.21e-05	-0.36	-0.29	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
STAD	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	5.6	4.34e-08	4.21e-05	0.49	0.29	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
STAD	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	5.6	4.34e-08	4.21e-05	0.33	0.29	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
STAD	cis	rs4698412	0.531	rs6852450	ENSG00000214846.4	RP11-115L11.1	-5.6	4.35e-08	4.21e-05	-0.33	-0.29	Parkinson's disease;	chr4:15741363	chr4:15730962~15731627:-
STAD	cis	rs8098244	0.597	rs12960583	ENSG00000267301.1	RPL23AP77	-5.6	4.35e-08	4.21e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23772629	chr18:23709825~23710287:-
STAD	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	5.6	4.36e-08	4.22e-05	0.25	0.29	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
STAD	cis	rs992157	0.835	rs2292550	ENSG00000237281.1	CATIP-AS2	5.6	4.36e-08	4.22e-05	0.3	0.29	Colorectal cancer;	chr2:218275565	chr2:218326889~218357966:-
STAD	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-5.6	4.36e-08	4.22e-05	-0.45	-0.29	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-5.6	4.36e-08	4.22e-05	-0.45	-0.29	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
STAD	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	5.6	4.36e-08	4.22e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
STAD	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-5.6	4.38e-08	4.24e-05	-0.41	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
STAD	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-5.6	4.38e-08	4.24e-05	-0.28	-0.29	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
STAD	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	5.6	4.38e-08	4.24e-05	0.31	0.29	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
STAD	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-5.6	4.39e-08	4.24e-05	-0.31	-0.29	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
STAD	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	5.6	4.39e-08	4.24e-05	0.38	0.29	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
STAD	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-5.6	4.39e-08	4.25e-05	-0.4	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
STAD	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-5.6	4.39e-08	4.25e-05	-0.3	-0.29	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
STAD	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-5.6	4.39e-08	4.25e-05	-0.3	-0.29	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
STAD	cis	rs453301	0.686	rs28482034	ENSG00000254340.1	RP11-10A14.3	-5.6	4.39e-08	4.25e-05	-0.38	-0.29	Joint mobility (Beighton score);	chr8:9012154	chr8:9141424~9145435:+
STAD	cis	rs748404	0.533	rs2139651	ENSG00000249839.1	AC011330.5	5.6	4.4e-08	4.26e-05	0.34	0.29	Lung cancer;	chr15:43126560	chr15:43663654~43684339:-
STAD	cis	rs228614	0.51	rs223400	ENSG00000230069.3	LRRC37A15P	-5.6	4.4e-08	4.26e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102727274~102730721:-
STAD	cis	rs8005677	0.798	rs4982711	ENSG00000257285.4	RP11-298I3.1	5.6	4.41e-08	4.26e-05	0.35	0.29	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:22929609~22955562:+
STAD	cis	rs13113518	0.783	rs6843722	ENSG00000272969.1	RP11-528I4.2	5.6	4.41e-08	4.26e-05	0.37	0.29	Height;	chr4:55465165	chr4:55547112~55547889:+
STAD	cis	rs240993	0.715	rs7752418	ENSG00000230177.1	RP5-1112D6.4	5.6	4.41e-08	4.27e-05	0.29	0.29	Inflammatory skin disease;Psoriasis;	chr6:111466682	chr6:111277932~111278742:+
STAD	cis	rs2980439	0.818	rs2945249	ENSG00000254340.1	RP11-10A14.3	5.6	4.42e-08	4.27e-05	0.34	0.29	Neuroticism;	chr8:8237204	chr8:9141424~9145435:+
STAD	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-5.6	4.42e-08	4.27e-05	-0.39	-0.29	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
STAD	cis	rs11722779	0.935	rs3857199	ENSG00000230069.3	LRRC37A15P	-5.6	4.42e-08	4.27e-05	-0.31	-0.29	Schizophrenia;	chr4:102957991	chr4:102727274~102730721:-
STAD	cis	rs7580658	0.676	rs2174270	ENSG00000200250.1	RNU6-1147P	5.6	4.42e-08	4.27e-05	0.28	0.29	Protein C levels;	chr2:127248502	chr2:127316873~127316979:+
STAD	cis	rs11722779	0.935	rs3974481	ENSG00000230069.3	LRRC37A15P	-5.6	4.42e-08	4.28e-05	-0.31	-0.29	Schizophrenia;	chr4:102956834	chr4:102727274~102730721:-
STAD	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	5.6	4.43e-08	4.28e-05	0.31	0.29	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	5.6	4.43e-08	4.28e-05	0.31	0.29	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
STAD	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	5.6	4.43e-08	4.28e-05	0.3	0.29	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
STAD	cis	rs9463078	0.546	rs1285026	ENSG00000219384.1	RP11-491H9.3	5.6	4.44e-08	4.29e-05	0.28	0.29	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45153097	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.565	rs1284980	ENSG00000219384.1	RP11-491H9.3	5.6	4.44e-08	4.29e-05	0.28	0.29	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45113691	chr6:45158870~45159511:+
STAD	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	5.6	4.44e-08	4.29e-05	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	5.6	4.44e-08	4.29e-05	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	5.6	4.44e-08	4.29e-05	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
STAD	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-5.6	4.44e-08	4.29e-05	-0.3	-0.29	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
STAD	cis	rs227275	0.527	rs223308	ENSG00000230069.3	LRRC37A15P	-5.6	4.44e-08	4.3e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102727274~102730721:-
STAD	cis	rs227275	0.554	rs223315	ENSG00000230069.3	LRRC37A15P	-5.6	4.44e-08	4.3e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102727274~102730721:-
STAD	cis	rs12744310	0.887	rs2363810	ENSG00000235358.1	RP11-399E6.1	5.6	4.45e-08	4.3e-05	0.35	0.29	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318201	chr1:41242373~41284861:+
STAD	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-5.6	4.45e-08	4.3e-05	-0.34	-0.29	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
STAD	cis	rs9425766	0.679	rs6656188	ENSG00000227373.4	RP11-160H22.5	5.6	4.45e-08	4.3e-05	0.33	0.29	Life satisfaction;	chr1:174183550	chr1:174115300~174160004:-
STAD	cis	rs4568518	0.561	rs4579426	ENSG00000279048.1	RP11-511H23.2	5.6	4.45e-08	4.3e-05	0.25	0.29	Measles;	chr7:17968636	chr7:17940503~17942922:+
STAD	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-5.6	4.46e-08	4.31e-05	-0.33	-0.29	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
STAD	cis	rs1816752	0.905	rs1050112	ENSG00000273628.1	RP11-756A22.7	5.6	4.46e-08	4.31e-05	0.35	0.29	Obesity-related traits;	chr13:24435159	chr13:24933006~24936796:+
STAD	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-5.6	4.46e-08	4.31e-05	-0.3	-0.29	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
STAD	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	5.6	4.46e-08	4.31e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
STAD	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	5.6	4.47e-08	4.31e-05	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	5.6	4.47e-08	4.31e-05	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	5.6	4.47e-08	4.31e-05	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
STAD	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	5.6	4.47e-08	4.32e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
STAD	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	5.6	4.47e-08	4.32e-05	0.44	0.29	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
STAD	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	5.6	4.48e-08	4.33e-05	0.35	0.29	Height;	chr6:109470427	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	5.6	4.48e-08	4.33e-05	0.35	0.29	Height;	chr6:109470900	chr6:109382795~109383666:+
STAD	cis	rs9425766	0.679	rs12087441	ENSG00000227373.4	RP11-160H22.5	5.6	4.49e-08	4.33e-05	0.33	0.29	Life satisfaction;	chr1:174188696	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs4652237	ENSG00000227373.4	RP11-160H22.5	5.6	4.49e-08	4.33e-05	0.33	0.29	Life satisfaction;	chr1:174189718	chr1:174115300~174160004:-
STAD	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	5.6	4.49e-08	4.33e-05	0.35	0.29	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
STAD	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-5.6	4.49e-08	4.33e-05	-0.31	-0.29	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-5.6	4.49e-08	4.33e-05	-0.31	-0.29	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
STAD	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-5.6	4.49e-08	4.33e-05	-0.3	-0.29	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
STAD	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	5.59	4.49e-08	4.34e-05	0.42	0.29	Height;	chr6:109436760	chr6:109382795~109383666:+
STAD	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-5.59	4.5e-08	4.34e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
STAD	cis	rs12699921	0.632	rs2723570	ENSG00000279048.1	RP11-511H23.2	-5.59	4.5e-08	4.35e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17853533	chr7:17940503~17942922:+
STAD	cis	rs8067354	0.574	rs1292042	ENSG00000266701.1	AC005702.4	5.59	4.51e-08	4.35e-05	0.42	0.29	Hemoglobin concentration;	chr17:59857634	chr17:60042546~60042627:-
STAD	cis	rs8141529	0.732	rs5762784	ENSG00000226471.5	CTA-292E10.6	-5.59	4.51e-08	4.35e-05	-0.34	-0.29	Lymphocyte counts;	chr22:28775310	chr22:28800683~28848559:+
STAD	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-5.59	4.51e-08	4.35e-05	-0.42	-0.29	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
STAD	cis	rs13113518	0.934	rs10866425	ENSG00000272969.1	RP11-528I4.2	5.59	4.53e-08	4.37e-05	0.37	0.29	Height;	chr4:55582068	chr4:55547112~55547889:+
STAD	cis	rs875971	0.545	rs6460281	ENSG00000224316.1	RP11-479O9.2	5.59	4.53e-08	4.37e-05	0.32	0.29	Aortic root size;	chr7:66216128	chr7:65773620~65802067:+
STAD	cis	rs7487075	0.619	rs4768723	ENSG00000272369.1	RP11-446N19.1	5.59	4.53e-08	4.37e-05	0.39	0.29	Itch intensity from mosquito bite;	chr12:46451941	chr12:46537502~46652550:+
STAD	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-5.59	4.53e-08	4.37e-05	-0.36	-0.29	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
STAD	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-5.59	4.53e-08	4.37e-05	-0.27	-0.29	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
STAD	cis	rs6782228	0.606	rs6439135	ENSG00000277250.1	Metazoa_SRP	-5.59	4.53e-08	4.37e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.509	rs2811495	ENSG00000277250.1	Metazoa_SRP	-5.59	4.53e-08	4.37e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.565	rs2811496	ENSG00000277250.1	Metazoa_SRP	-5.59	4.53e-08	4.37e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128673681~128674021:-
STAD	cis	rs10129255	1	rs10137758	ENSG00000280411.1	IGHV1-69-2	-5.59	4.53e-08	4.37e-05	-0.27	-0.29	Kawasaki disease;	chr14:106697673	chr14:106762092~106762588:-
STAD	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-5.59	4.53e-08	4.37e-05	-0.44	-0.29	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
STAD	cis	rs228614	0.51	rs50034	ENSG00000230069.3	LRRC37A15P	-5.59	4.53e-08	4.37e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102727274~102730721:-
STAD	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-5.59	4.54e-08	4.37e-05	-0.27	-0.29	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-5.59	4.54e-08	4.37e-05	-0.27	-0.29	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
STAD	cis	rs7487075	0.79	rs11183527	ENSG00000257261.4	RP11-96H19.1	5.59	4.54e-08	4.38e-05	0.34	0.29	Itch intensity from mosquito bite;	chr12:46552580	chr12:46383679~46876159:+
STAD	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-5.59	4.54e-08	4.38e-05	-0.31	-0.29	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
STAD	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	5.59	4.54e-08	4.38e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	5.59	4.54e-08	4.38e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
STAD	cis	rs2945232	1	rs2945232	ENSG00000254340.1	RP11-10A14.3	5.59	4.55e-08	4.38e-05	0.34	0.29	Schizophrenia;	chr8:8240516	chr8:9141424~9145435:+
STAD	cis	rs2239557	1	rs11159067	ENSG00000259065.1	RP5-1021I20.1	-5.59	4.55e-08	4.38e-05	-0.35	-0.29	Common traits (Other);	chr14:74170741	chr14:73787360~73803270:+
STAD	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	5.59	4.56e-08	4.39e-05	0.43	0.29	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
STAD	cis	rs12699921	0.632	rs2691615	ENSG00000279048.1	RP11-511H23.2	-5.59	4.56e-08	4.4e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17847557	chr7:17940503~17942922:+
STAD	cis	rs721917	0.525	rs2258874	ENSG00000225484.5	NUTM2B-AS1	-5.59	4.56e-08	4.4e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79663088~79826594:-
STAD	cis	rs6782228	0.509	rs4481172	ENSG00000277250.1	Metazoa_SRP	-5.59	4.56e-08	4.4e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128673681~128674021:-
STAD	cis	rs1426063	0.614	rs6534447	ENSG00000249717.1	RP11-44F21.3	-5.59	4.57e-08	4.4e-05	-0.62	-0.29	QT interval;	chr4:75080682	chr4:74955974~74970362:-
STAD	cis	rs2980439	0.818	rs2948294	ENSG00000254340.1	RP11-10A14.3	5.59	4.57e-08	4.4e-05	0.33	0.29	Neuroticism;	chr8:8237439	chr8:9141424~9145435:+
STAD	cis	rs5769707	0.933	rs2157444	ENSG00000280224.1	CTA-722E9.1	-5.59	4.57e-08	4.4e-05	-0.3	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49500568~49501585:+
STAD	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-5.59	4.57e-08	4.4e-05	-0.34	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
STAD	cis	rs9463078	0.528	rs12524323	ENSG00000219384.1	RP11-491H9.3	-5.59	4.57e-08	4.4e-05	-0.28	-0.29	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45336116	chr6:45158870~45159511:+
STAD	cis	rs2239557	1	rs2072293	ENSG00000259065.1	RP5-1021I20.1	-5.59	4.58e-08	4.41e-05	-0.35	-0.29	Common traits (Other);	chr14:74071182	chr14:73787360~73803270:+
STAD	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-5.59	4.58e-08	4.42e-05	-0.43	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-5.59	4.58e-08	4.42e-05	-0.43	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
STAD	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-5.59	4.59e-08	4.42e-05	-0.34	-0.29	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
STAD	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	5.59	4.59e-08	4.42e-05	0.34	0.29	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
STAD	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-5.59	4.59e-08	4.42e-05	-0.28	-0.29	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
STAD	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	5.59	4.59e-08	4.42e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
STAD	cis	rs9395066	0.529	rs12529490	ENSG00000219384.1	RP11-491H9.3	-5.59	4.59e-08	4.42e-05	-0.28	-0.29	Height;	chr6:45050514	chr6:45158870~45159511:+
STAD	cis	rs4568518	0.619	rs4470902	ENSG00000279048.1	RP11-511H23.2	-5.59	4.59e-08	4.42e-05	-0.25	-0.29	Measles;	chr7:17968687	chr7:17940503~17942922:+
STAD	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-5.59	4.59e-08	4.42e-05	-0.3	-0.29	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
STAD	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-5.59	4.61e-08	4.43e-05	-0.33	-0.29	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
STAD	cis	rs9400467	0.528	rs6933627	ENSG00000230177.1	RP5-1112D6.4	-5.59	4.62e-08	4.45e-05	-0.26	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111277932~111278742:+
STAD	cis	rs875971	0.862	rs6944374	ENSG00000236529.1	RP13-254B10.1	-5.59	4.62e-08	4.45e-05	-0.3	-0.29	Aortic root size;	chr7:66221942	chr7:65840212~65840596:+
STAD	cis	rs4927850	0.957	rs4927851	ENSG00000185485.13	SDHAP1	5.59	4.63e-08	4.46e-05	0.29	0.29	Pancreatic cancer;	chr3:196024982	chr3:195959748~195990318:-
STAD	cis	rs4927850	0.918	rs4361313	ENSG00000185485.13	SDHAP1	5.59	4.63e-08	4.46e-05	0.29	0.29	Pancreatic cancer;	chr3:196025389	chr3:195959748~195990318:-
STAD	cis	rs2446066	0.799	rs76805893	ENSG00000257379.1	RP11-793H13.8	5.59	4.63e-08	4.46e-05	0.47	0.29	Red blood cell count;	chr12:53436335	chr12:53441741~53467528:+
STAD	cis	rs2858942	0.575	rs2858011	ENSG00000268836.1	LA16c-OS12.2	5.59	4.64e-08	4.47e-05	0.32	0.29	Mean corpuscular hemoglobin;	chr16:197939	chr16:185748~186294:-
STAD	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-5.59	4.64e-08	4.47e-05	-0.43	-0.29	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
STAD	cis	rs2436845	1	rs2679756	ENSG00000253385.1	KB-1254G8.1	5.59	4.65e-08	4.47e-05	0.31	0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858241	chr8:102854455~102856075:+
STAD	cis	rs2436845	1	rs2679757	ENSG00000253385.1	KB-1254G8.1	5.59	4.65e-08	4.47e-05	0.31	0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858590	chr8:102854455~102856075:+
STAD	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	5.59	4.65e-08	4.47e-05	0.37	0.29	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
STAD	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-5.59	4.67e-08	4.49e-05	-0.28	-0.29	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
STAD	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	5.59	4.67e-08	4.49e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
STAD	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-5.59	4.68e-08	4.5e-05	-0.42	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
STAD	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	5.59	4.68e-08	4.5e-05	0.26	0.29	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
STAD	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.59	4.69e-08	4.5e-05	0.34	0.29	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
STAD	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	5.59	4.69e-08	4.5e-05	0.33	0.29	Depression;	chr6:28074687	chr6:28073316~28074233:+
STAD	cis	rs2286503	1	rs17724311	ENSG00000228649.7	AC005682.5	5.59	4.69e-08	4.5e-05	0.34	0.29	Fibrinogen;	chr7:22837174	chr7:22854178~22861579:+
STAD	cis	rs1816752	0.638	rs9578730	ENSG00000273628.1	RP11-756A22.7	5.59	4.69e-08	4.51e-05	0.35	0.29	Obesity-related traits;	chr13:24425545	chr13:24933006~24936796:+
STAD	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-5.59	4.7e-08	4.51e-05	-0.3	-0.29	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
STAD	cis	rs227275	0.554	rs223371	ENSG00000230069.3	LRRC37A15P	-5.59	4.7e-08	4.52e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102727274~102730721:-
STAD	cis	rs7924176	0.502	rs12784355	ENSG00000236900.1	TIMM9P1	-5.59	4.71e-08	4.53e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74344550~74344805:-
STAD	cis	rs858239	0.601	rs28673077	ENSG00000226816.2	AC005082.12	5.59	4.72e-08	4.53e-05	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23206013~23208045:+
STAD	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	5.59	4.72e-08	4.53e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	5.59	4.72e-08	4.53e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	5.59	4.72e-08	4.53e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	5.59	4.72e-08	4.53e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
STAD	cis	rs17301013	0.932	rs10912804	ENSG00000227373.4	RP11-160H22.5	5.59	4.72e-08	4.54e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174527412	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.9	rs12088073	ENSG00000227373.4	RP11-160H22.5	5.59	4.72e-08	4.54e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174528504	chr1:174115300~174160004:-
STAD	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-5.59	4.73e-08	4.54e-05	-0.34	-0.29	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
STAD	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-5.58	4.74e-08	4.56e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
STAD	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-5.58	4.74e-08	4.56e-05	-0.48	-0.29	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
STAD	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	5.58	4.75e-08	4.56e-05	0.33	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
STAD	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	5.58	4.75e-08	4.56e-05	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
STAD	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	5.58	4.75e-08	4.56e-05	0.49	0.29	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
STAD	cis	rs875971	0.545	rs1796222	ENSG00000224316.1	RP11-479O9.2	-5.58	4.76e-08	4.56e-05	-0.32	-0.29	Aortic root size;	chr7:66592167	chr7:65773620~65802067:+
STAD	cis	rs12699921	0.632	rs1404424	ENSG00000279048.1	RP11-511H23.2	-5.58	4.76e-08	4.56e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17906981	chr7:17940503~17942922:+
STAD	cis	rs875971	0.502	rs6460311	ENSG00000224316.1	RP11-479O9.2	-5.58	4.76e-08	4.57e-05	-0.32	-0.29	Aortic root size;	chr7:66646886	chr7:65773620~65802067:+
STAD	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	5.58	4.76e-08	4.57e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
STAD	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	5.58	4.77e-08	4.57e-05	0.3	0.29	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
STAD	cis	rs6782228	0.527	rs2712371	ENSG00000277250.1	Metazoa_SRP	-5.58	4.77e-08	4.57e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128673681~128674021:-
STAD	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	5.58	4.77e-08	4.58e-05	0.42	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
STAD	cis	rs516805	0.748	rs197684	ENSG00000279453.1	RP3-425C14.4	-5.58	4.77e-08	4.58e-05	-0.41	-0.29	Lymphocyte counts;	chr6:122553697	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs197685	ENSG00000279453.1	RP3-425C14.4	-5.58	4.77e-08	4.58e-05	-0.41	-0.29	Lymphocyte counts;	chr6:122554622	chr6:122436789~122439223:-
STAD	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.78e-08	4.58e-05	-0.27	-0.29	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.78e-08	4.58e-05	-0.27	-0.29	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
STAD	cis	rs12699921	0.632	rs2691627	ENSG00000279048.1	RP11-511H23.2	-5.58	4.78e-08	4.59e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17784627	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2691628	ENSG00000279048.1	RP11-511H23.2	-5.58	4.78e-08	4.59e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17784732	chr7:17940503~17942922:+
STAD	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-5.58	4.79e-08	4.6e-05	-0.31	-0.29	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
STAD	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	5.58	4.79e-08	4.6e-05	0.44	0.29	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
STAD	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	5.58	4.79e-08	4.6e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	5.58	4.79e-08	4.6e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	5.58	4.79e-08	4.6e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
STAD	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-5.58	4.8e-08	4.6e-05	-0.32	-0.29	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
STAD	cis	rs8005677	0.828	rs4981450	ENSG00000257285.4	RP11-298I3.1	5.58	4.8e-08	4.6e-05	0.35	0.29	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:22929609~22955562:+
STAD	cis	rs875971	0.545	rs73152714	ENSG00000224316.1	RP11-479O9.2	5.58	4.8e-08	4.6e-05	0.32	0.29	Aortic root size;	chr7:66534641	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs4718364	ENSG00000224316.1	RP11-479O9.2	5.58	4.8e-08	4.6e-05	0.32	0.29	Aortic root size;	chr7:66536353	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs6961853	ENSG00000224316.1	RP11-479O9.2	5.58	4.8e-08	4.6e-05	0.32	0.29	Aortic root size;	chr7:66537035	chr7:65773620~65802067:+
STAD	cis	rs875971	0.528	rs801213	ENSG00000224316.1	RP11-479O9.2	-5.58	4.8e-08	4.6e-05	-0.32	-0.29	Aortic root size;	chr7:66549931	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs801212	ENSG00000224316.1	RP11-479O9.2	-5.58	4.8e-08	4.6e-05	-0.32	-0.29	Aortic root size;	chr7:66550643	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs801199	ENSG00000224316.1	RP11-479O9.2	-5.58	4.8e-08	4.6e-05	-0.32	-0.29	Aortic root size;	chr7:66560286	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs1267814	ENSG00000224316.1	RP11-479O9.2	-5.58	4.8e-08	4.6e-05	-0.32	-0.29	Aortic root size;	chr7:66579422	chr7:65773620~65802067:+
STAD	cis	rs858239	0.568	rs6970694	ENSG00000226816.2	AC005082.12	5.58	4.81e-08	4.61e-05	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23206013~23208045:+
STAD	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-5.58	4.82e-08	4.62e-05	-0.31	-0.29	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
STAD	cis	rs1799949	0.965	rs9646418	ENSG00000236383.6	LINC00854	-5.58	4.82e-08	4.62e-05	-0.23	-0.29	Menopause (age at onset);	chr17:43348533	chr17:43216941~43305976:-
STAD	cis	rs1056107	0.931	rs7869523	ENSG00000225513.1	RP11-165N19.2	-5.58	4.82e-08	4.62e-05	-0.34	-0.29	Colorectal cancer;	chr9:112220269	chr9:112173522~112173971:-
STAD	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	5.58	4.83e-08	4.63e-05	0.42	0.29	Height;	chr6:109415050	chr6:109382795~109383666:+
STAD	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	5.58	4.83e-08	4.63e-05	0.3	0.29	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
STAD	cis	rs6782228	0.606	rs2712417	ENSG00000277250.1	Metazoa_SRP	-5.58	4.83e-08	4.63e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128673681~128674021:-
STAD	cis	rs875971	0.545	rs17138156	ENSG00000224316.1	RP11-479O9.2	5.58	4.84e-08	4.63e-05	0.32	0.29	Aortic root size;	chr7:66249708	chr7:65773620~65802067:+
STAD	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-5.58	4.84e-08	4.64e-05	-0.33	-0.29	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
STAD	cis	rs5769707	0.609	rs2071890	ENSG00000280224.1	CTA-722E9.1	-5.58	4.84e-08	4.64e-05	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49500568~49501585:+
STAD	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-5.58	4.84e-08	4.64e-05	-0.33	-0.29	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
STAD	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	5.58	4.85e-08	4.64e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
STAD	cis	rs7927771	0.507	rs1483988	ENSG00000280615.1	Y_RNA	5.58	4.86e-08	4.65e-05	0.29	0.29	Subjective well-being;	chr11:47877478	chr11:47614898~47614994:-
STAD	cis	rs227275	0.554	rs223363	ENSG00000230069.3	LRRC37A15P	-5.58	4.86e-08	4.65e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102727274~102730721:-
STAD	cis	rs6782228	0.565	rs11719239	ENSG00000277250.1	Metazoa_SRP	-5.58	4.86e-08	4.66e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs2001950	ENSG00000277250.1	Metazoa_SRP	-5.58	4.86e-08	4.66e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128673681~128674021:-
STAD	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.86e-08	4.66e-05	-0.27	-0.29	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
STAD	cis	rs1153858	1	rs4395020	ENSG00000259433.2	CTD-2651B20.4	-5.58	4.87e-08	4.66e-05	-0.31	-0.29	Homoarginine levels;	chr15:45360691	chr15:45330209~45332634:-
STAD	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	5.58	4.88e-08	4.67e-05	0.31	0.29	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
STAD	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-5.58	4.88e-08	4.68e-05	-0.3	-0.29	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
STAD	cis	rs7829975	0.536	rs2980439	ENSG00000254340.1	RP11-10A14.3	5.58	4.88e-08	4.68e-05	0.33	0.29	Mood instability;	chr8:8237348	chr8:9141424~9145435:+
STAD	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	5.58	4.89e-08	4.68e-05	0.35	0.29	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
STAD	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	5.58	4.89e-08	4.68e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
STAD	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-5.58	4.89e-08	4.68e-05	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
STAD	cis	rs1707322	0.638	rs1707302	ENSG00000280836.1	AL355480.1	5.58	4.9e-08	4.69e-05	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr1:45581219~45581321:-
STAD	cis	rs12699921	0.566	rs1997019	ENSG00000279048.1	RP11-511H23.2	-5.58	4.9e-08	4.69e-05	-0.27	-0.29	Fibrinogen levels;	chr7:17787856	chr7:17940503~17942922:+
STAD	cis	rs17301013	0.932	rs10912807	ENSG00000227373.4	RP11-160H22.5	5.58	4.9e-08	4.69e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174547228	chr1:174115300~174160004:-
STAD	cis	rs228614	0.51	rs223447	ENSG00000230069.3	LRRC37A15P	-5.58	4.91e-08	4.7e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102727274~102730721:-
STAD	cis	rs13113518	0.812	rs4865003	ENSG00000272969.1	RP11-528I4.2	5.58	4.91e-08	4.7e-05	0.37	0.29	Height;	chr4:55514802	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.756	rs12510275	ENSG00000272969.1	RP11-528I4.2	5.58	4.91e-08	4.7e-05	0.37	0.29	Height;	chr4:55516548	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs12510327	ENSG00000272969.1	RP11-528I4.2	5.58	4.91e-08	4.7e-05	0.37	0.29	Height;	chr4:55516744	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs11939580	ENSG00000272969.1	RP11-528I4.2	5.58	4.91e-08	4.7e-05	0.37	0.29	Height;	chr4:55517185	chr4:55547112~55547889:+
STAD	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	5.58	4.91e-08	4.7e-05	0.43	0.29	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
STAD	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	5.58	4.91e-08	4.7e-05	0.38	0.29	Height;	chr6:109655182	chr6:109382795~109383666:+
STAD	cis	rs4927850	1	rs7625570	ENSG00000185485.13	SDHAP1	5.58	4.91e-08	4.7e-05	0.28	0.29	Pancreatic cancer;	chr3:196020527	chr3:195959748~195990318:-
STAD	cis	rs4927850	0.881	rs7624638	ENSG00000185485.13	SDHAP1	5.58	4.91e-08	4.7e-05	0.28	0.29	Pancreatic cancer;	chr3:196021858	chr3:195959748~195990318:-
STAD	cis	rs4927850	1	rs10881564	ENSG00000185485.13	SDHAP1	5.58	4.91e-08	4.7e-05	0.28	0.29	Pancreatic cancer;	chr3:196023455	chr3:195959748~195990318:-
STAD	cis	rs9400467	0.508	rs61269242	ENSG00000230177.1	RP5-1112D6.4	-5.58	4.91e-08	4.7e-05	-0.26	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111277932~111278742:+
STAD	cis	rs875971	0.545	rs316316	ENSG00000224316.1	RP11-479O9.2	-5.58	4.92e-08	4.71e-05	-0.32	-0.29	Aortic root size;	chr7:66149270	chr7:65773620~65802067:+
STAD	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	5.58	4.92e-08	4.71e-05	0.34	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
STAD	cis	rs2446066	0.872	rs17099205	ENSG00000257379.1	RP11-793H13.8	5.58	4.93e-08	4.71e-05	0.47	0.29	Red blood cell count;	chr12:53430798	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.872	rs12368222	ENSG00000257379.1	RP11-793H13.8	5.58	4.93e-08	4.71e-05	0.47	0.29	Red blood cell count;	chr12:53430960	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.872	rs7309494	ENSG00000257379.1	RP11-793H13.8	5.58	4.93e-08	4.71e-05	0.47	0.29	Red blood cell count;	chr12:53432209	chr12:53441741~53467528:+
STAD	cis	rs1799949	0.965	rs8176198	ENSG00000236383.6	LINC00854	-5.58	4.93e-08	4.71e-05	-0.22	-0.29	Menopause (age at onset);	chr17:43078520	chr17:43216941~43305976:-
STAD	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-5.58	4.93e-08	4.71e-05	-0.29	-0.29	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
STAD	cis	rs7924176	0.549	rs2395076	ENSG00000236900.1	TIMM9P1	-5.58	4.93e-08	4.72e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74344550~74344805:-
STAD	cis	rs7924176	0.601	rs7089391	ENSG00000236900.1	TIMM9P1	-5.58	4.93e-08	4.72e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74344550~74344805:-
STAD	cis	rs7924176	0.601	rs7093532	ENSG00000236900.1	TIMM9P1	-5.58	4.93e-08	4.72e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74344550~74344805:-
STAD	cis	rs4568518	0.74	rs12699924	ENSG00000279048.1	RP11-511H23.2	5.58	4.94e-08	4.72e-05	0.26	0.29	Measles;	chr7:17970768	chr7:17940503~17942922:+
STAD	cis	rs8067354	0.574	rs2526358	ENSG00000266701.1	AC005702.4	5.58	4.94e-08	4.72e-05	0.42	0.29	Hemoglobin concentration;	chr17:59865224	chr17:60042546~60042627:-
STAD	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	5.58	4.94e-08	4.73e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
STAD	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	5.58	4.95e-08	4.73e-05	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
STAD	cis	rs453301	0.686	rs3989373	ENSG00000254340.1	RP11-10A14.3	-5.58	4.95e-08	4.73e-05	-0.37	-0.29	Joint mobility (Beighton score);	chr8:9053798	chr8:9141424~9145435:+
STAD	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-5.58	4.95e-08	4.73e-05	-0.27	-0.29	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
STAD	cis	rs6782228	0.606	rs7627549	ENSG00000277250.1	Metazoa_SRP	-5.58	4.95e-08	4.73e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs1697	ENSG00000277250.1	Metazoa_SRP	-5.58	4.95e-08	4.73e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.585	rs3122175	ENSG00000277250.1	Metazoa_SRP	-5.58	4.95e-08	4.73e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs2811497	ENSG00000277250.1	Metazoa_SRP	-5.58	4.95e-08	4.73e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs2811500	ENSG00000277250.1	Metazoa_SRP	-5.58	4.95e-08	4.73e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128673681~128674021:-
STAD	cis	rs7927771	0.832	rs10838698	ENSG00000280615.1	Y_RNA	5.58	4.95e-08	4.73e-05	0.29	0.29	Subjective well-being;	chr11:47364372	chr11:47614898~47614994:-
STAD	cis	rs875971	0.545	rs4718325	ENSG00000224316.1	RP11-479O9.2	5.58	4.96e-08	4.74e-05	0.33	0.29	Aortic root size;	chr7:66215323	chr7:65773620~65802067:+
STAD	cis	rs10129255	0.957	rs10136817	ENSG00000280411.1	IGHV1-69-2	-5.58	4.97e-08	4.75e-05	-0.27	-0.29	Kawasaki disease;	chr14:106787730	chr14:106762092~106762588:-
STAD	cis	rs7580658	0.75	rs4497825	ENSG00000200250.1	RNU6-1147P	5.58	4.97e-08	4.75e-05	0.27	0.29	Protein C levels;	chr2:127303477	chr2:127316873~127316979:+
STAD	cis	rs1056107	0.931	rs7855745	ENSG00000225513.1	RP11-165N19.2	-5.58	4.97e-08	4.75e-05	-0.33	-0.29	Colorectal cancer;	chr9:112220183	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs7859107	ENSG00000225513.1	RP11-165N19.2	-5.58	4.97e-08	4.75e-05	-0.33	-0.29	Colorectal cancer;	chr9:112220518	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs7025680	ENSG00000225513.1	RP11-165N19.2	-5.58	4.97e-08	4.75e-05	-0.33	-0.29	Colorectal cancer;	chr9:112224434	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.872	rs3780514	ENSG00000225513.1	RP11-165N19.2	-5.58	4.97e-08	4.75e-05	-0.33	-0.29	Colorectal cancer;	chr9:112226051	chr9:112173522~112173971:-
STAD	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-5.58	4.98e-08	4.76e-05	-0.3	-0.29	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
STAD	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	5.58	4.99e-08	4.77e-05	0.34	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
STAD	cis	rs9601248	0.627	rs9545151	ENSG00000227354.5	RBM26-AS1	-5.57	5e-08	4.77e-05	-0.36	-0.29	Major depressive disorder;	chr13:79608400	chr13:79406309~79424328:+
STAD	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-5.57	5e-08	4.77e-05	-0.32	-0.29	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
STAD	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	5.57	5e-08	4.77e-05	0.41	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	5.57	5e-08	4.77e-05	0.41	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
STAD	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	5.57	5e-08	4.78e-05	0.39	0.29	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
STAD	cis	rs4604732	0.588	rs12045675	ENSG00000227135.1	GCSAML-AS1	-5.57	5.01e-08	4.78e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460613	chr1:247524679~247526752:-
STAD	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-5.57	5.02e-08	4.79e-05	-0.32	-0.29	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
STAD	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	5.57	5.02e-08	4.79e-05	0.31	0.29	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
STAD	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-5.57	5.02e-08	4.79e-05	-0.27	-0.29	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
STAD	cis	rs8098244	0.515	rs4387667	ENSG00000267301.1	RPL23AP77	-5.57	5.02e-08	4.8e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716161	chr18:23709825~23710287:-
STAD	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	5.57	5.03e-08	4.8e-05	0.3	0.29	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
STAD	cis	rs12699921	0.598	rs2691611	ENSG00000279048.1	RP11-511H23.2	-5.57	5.04e-08	4.81e-05	-0.25	-0.29	Fibrinogen levels;	chr7:17843804	chr7:17940503~17942922:+
STAD	cis	rs4604732	0.631	rs12080860	ENSG00000227135.1	GCSAML-AS1	-5.57	5.06e-08	4.83e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459751	chr1:247524679~247526752:-
STAD	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	5.57	5.06e-08	4.83e-05	0.34	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
STAD	cis	rs13113518	0.812	rs11133385	ENSG00000272969.1	RP11-528I4.2	5.57	5.06e-08	4.83e-05	0.36	0.29	Height;	chr4:55460485	chr4:55547112~55547889:+
STAD	cis	rs7829975	0.517	rs12542733	ENSG00000254340.1	RP11-10A14.3	-5.57	5.06e-08	4.83e-05	-0.35	-0.29	Mood instability;	chr8:8967348	chr8:9141424~9145435:+
STAD	cis	rs2283792	0.967	rs743409	ENSG00000228050.1	TOP3BP1	5.57	5.08e-08	4.84e-05	0.33	0.29	Multiple sclerosis;	chr22:21774926	chr22:22223187~22224566:-
STAD	cis	rs8098244	0.557	rs2226835	ENSG00000267301.1	RPL23AP77	-5.57	5.08e-08	4.84e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23715912	chr18:23709825~23710287:-
STAD	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	5.57	5.08e-08	4.84e-05	0.35	0.29	Height;	chr6:109440234	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	5.57	5.08e-08	4.84e-05	0.35	0.29	Height;	chr6:109443332	chr6:109382795~109383666:+
STAD	cis	rs1816752	0.905	rs9511266	ENSG00000273628.1	RP11-756A22.7	5.57	5.09e-08	4.86e-05	0.35	0.29	Obesity-related traits;	chr13:24438366	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.817	rs7985394	ENSG00000273628.1	RP11-756A22.7	5.57	5.09e-08	4.86e-05	0.35	0.29	Obesity-related traits;	chr13:24438714	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.789	rs7986037	ENSG00000273628.1	RP11-756A22.7	5.57	5.09e-08	4.86e-05	0.35	0.29	Obesity-related traits;	chr13:24438715	chr13:24933006~24936796:+
STAD	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	5.57	5.09e-08	4.86e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
STAD	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	5.57	5.12e-08	4.88e-05	0.41	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	5.57	5.12e-08	4.88e-05	0.41	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
STAD	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	5.57	5.12e-08	4.88e-05	0.28	0.29	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
STAD	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	5.57	5.13e-08	4.89e-05	0.33	0.29	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
STAD	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-5.57	5.13e-08	4.89e-05	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
STAD	cis	rs9425766	0.64	rs7512930	ENSG00000227373.4	RP11-160H22.5	5.57	5.13e-08	4.89e-05	0.33	0.29	Life satisfaction;	chr1:174319464	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs7523460	ENSG00000227373.4	RP11-160H22.5	5.57	5.13e-08	4.89e-05	0.33	0.29	Life satisfaction;	chr1:174319664	chr1:174115300~174160004:-
STAD	cis	rs9400467	0.508	rs11153283	ENSG00000230177.1	RP5-1112D6.4	-5.57	5.13e-08	4.89e-05	-0.26	-0.29	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111277932~111278742:+
STAD	cis	rs4927850	1	rs4927704	ENSG00000207650.1	MIR570	5.57	5.14e-08	4.9e-05	0.28	0.29	Pancreatic cancer;	chr3:196011357	chr3:195699401~195699497:+
STAD	cis	rs4927850	1	rs4927848	ENSG00000207650.1	MIR570	5.57	5.14e-08	4.9e-05	0.28	0.29	Pancreatic cancer;	chr3:196011535	chr3:195699401~195699497:+
STAD	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-5.57	5.14e-08	4.9e-05	-0.31	-0.29	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
STAD	cis	rs9549260	0.592	rs9315783	ENSG00000229456.1	RLIMP1	5.57	5.15e-08	4.9e-05	0.26	0.29	Red blood cell count;	chr13:40715028	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.564	rs9315784	ENSG00000229456.1	RLIMP1	5.57	5.15e-08	4.9e-05	0.26	0.29	Red blood cell count;	chr13:40715030	chr13:40618738~40621348:+
STAD	cis	rs957448	0.848	rs113630732	ENSG00000253704.1	RP11-267M23.4	5.57	5.15e-08	4.9e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94483802	chr8:94553722~94569745:+
STAD	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-5.57	5.16e-08	4.92e-05	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
STAD	cis	rs2337406	0.85	rs10131280	ENSG00000211972.2	IGHV3-66	5.57	5.16e-08	4.92e-05	0.31	0.29	Alzheimer's disease (late onset);	chr14:106665591	chr14:106675017~106675544:-
STAD	cis	rs1816752	0.905	rs4769352	ENSG00000273628.1	RP11-756A22.7	5.57	5.18e-08	4.93e-05	0.35	0.29	Obesity-related traits;	chr13:24426237	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.805	rs4769353	ENSG00000273628.1	RP11-756A22.7	5.57	5.18e-08	4.93e-05	0.35	0.29	Obesity-related traits;	chr13:24426318	chr13:24933006~24936796:+
STAD	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-5.57	5.19e-08	4.94e-05	-0.3	-0.29	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
STAD	cis	rs10129255	0.869	rs7150549	ENSG00000280411.1	IGHV1-69-2	-5.57	5.19e-08	4.94e-05	-0.27	-0.29	Kawasaki disease;	chr14:106705441	chr14:106762092~106762588:-
STAD	cis	rs4927850	0.958	rs2044599	ENSG00000207650.1	MIR570	5.57	5.19e-08	4.94e-05	0.28	0.29	Pancreatic cancer;	chr3:196009869	chr3:195699401~195699497:+
STAD	cis	rs7487075	1	rs12813763	ENSG00000272369.1	RP11-446N19.1	-5.57	5.19e-08	4.94e-05	-0.35	-0.29	Itch intensity from mosquito bite;	chr12:46429121	chr12:46537502~46652550:+
STAD	cis	rs10759883	0.612	rs2943532	ENSG00000175611.10	LINC00476	5.57	5.19e-08	4.94e-05	0.29	0.29	Nicotine dependence;	chr9:96024975	chr9:95759231~95875977:-
STAD	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	5.57	5.2e-08	4.95e-05	0.37	0.29	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
STAD	cis	rs3136516	0.504	rs11038910	ENSG00000271350.1	CTD-2384B9.1	5.57	5.2e-08	4.95e-05	0.36	0.29	Venous thromboembolism;	chr11:46521974	chr11:47041027~47041945:-
STAD	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-5.57	5.21e-08	4.96e-05	-0.37	-0.29	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
STAD	cis	rs2933343	0.7	rs1680779	ENSG00000231305.3	RP11-723O4.2	5.57	5.21e-08	4.96e-05	0.3	0.29	IgG glycosylation;	chr3:128895927	chr3:128861313~128871540:-
STAD	cis	rs2436845	1	rs2164061	ENSG00000253385.1	KB-1254G8.1	-5.57	5.22e-08	4.97e-05	-0.31	-0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102852245	chr8:102854455~102856075:+
STAD	cis	rs13113518	0.841	rs7699867	ENSG00000272969.1	RP11-528I4.2	5.57	5.23e-08	4.98e-05	0.36	0.29	Height;	chr4:55483718	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.783	rs11133389	ENSG00000272969.1	RP11-528I4.2	5.57	5.23e-08	4.98e-05	0.36	0.29	Height;	chr4:55486718	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs4865001	ENSG00000272969.1	RP11-528I4.2	5.57	5.23e-08	4.98e-05	0.36	0.29	Height;	chr4:55490176	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs4864543	ENSG00000272969.1	RP11-528I4.2	5.57	5.23e-08	4.98e-05	0.36	0.29	Height;	chr4:55490228	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs6825774	ENSG00000272969.1	RP11-528I4.2	5.57	5.23e-08	4.98e-05	0.36	0.29	Height;	chr4:55491150	chr4:55547112~55547889:+
STAD	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	5.57	5.24e-08	4.99e-05	0.36	0.29	Depression;	chr6:28314871	chr6:28943877~28944537:+
STAD	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-5.57	5.24e-08	4.99e-05	-0.47	-0.29	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
STAD	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-5.57	5.24e-08	4.99e-05	-0.47	-0.29	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
STAD	cis	rs1816752	0.87	rs9318529	ENSG00000273628.1	RP11-756A22.7	5.57	5.24e-08	4.99e-05	0.35	0.29	Obesity-related traits;	chr13:24424190	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs9511249	ENSG00000273628.1	RP11-756A22.7	5.57	5.24e-08	4.99e-05	0.35	0.29	Obesity-related traits;	chr13:24425457	chr13:24933006~24936796:+
STAD	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-5.57	5.25e-08	4.99e-05	-0.27	-0.29	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-5.57	5.25e-08	4.99e-05	-0.27	-0.29	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-5.57	5.25e-08	4.99e-05	-0.27	-0.29	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-5.57	5.25e-08	4.99e-05	-0.27	-0.29	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
STAD	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-5.57	5.25e-08	5e-05	-0.29	-0.29	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
STAD	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-5.57	5.25e-08	5e-05	-0.29	-0.29	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-5.57	5.25e-08	5e-05	-0.29	-0.29	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
STAD	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	5.57	5.26e-08	5e-05	0.38	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	5.57	5.26e-08	5e-05	0.38	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	5.57	5.26e-08	5e-05	0.38	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
STAD	cis	rs1816752	0.837	rs7324645	ENSG00000273628.1	RP11-756A22.7	5.57	5.26e-08	5e-05	0.35	0.29	Obesity-related traits;	chr13:24426717	chr13:24933006~24936796:+
STAD	cis	rs10504130	0.569	rs34372756	ENSG00000272024.1	RP11-546K22.3	-5.56	5.26e-08	5e-05	-0.4	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs35032384	ENSG00000272024.1	RP11-546K22.3	-5.56	5.26e-08	5e-05	-0.4	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:51910524	chr8:51950284~51950690:+
STAD	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	5.56	5.28e-08	5.02e-05	0.28	0.29	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
STAD	cis	rs2436845	1	rs892484	ENSG00000253385.1	KB-1254G8.1	-5.56	5.28e-08	5.02e-05	-0.3	-0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862333	chr8:102854455~102856075:+
STAD	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	5.56	5.28e-08	5.02e-05	0.42	0.29	Height;	chr6:109339681	chr6:109382795~109383666:+
STAD	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	5.56	5.28e-08	5.02e-05	0.34	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
STAD	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	5.56	5.29e-08	5.02e-05	0.39	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	5.56	5.29e-08	5.02e-05	0.39	0.29	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	5.56	5.29e-08	5.02e-05	0.39	0.29	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	5.56	5.29e-08	5.02e-05	0.39	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	5.56	5.29e-08	5.02e-05	0.39	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	5.56	5.29e-08	5.02e-05	0.39	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	5.56	5.29e-08	5.02e-05	0.39	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
STAD	cis	rs516805	0.706	rs1034060	ENSG00000279453.1	RP3-425C14.4	5.56	5.29e-08	5.02e-05	0.38	0.29	Lymphocyte counts;	chr6:122319181	chr6:122436789~122439223:-
STAD	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	5.56	5.29e-08	5.03e-05	0.35	0.29	Height;	chr6:109476101	chr6:109382795~109383666:+
STAD	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-5.56	5.29e-08	5.03e-05	-0.33	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
STAD	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	5.56	5.29e-08	5.03e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
STAD	cis	rs8098244	0.617	rs12957168	ENSG00000267301.1	RPL23AP77	5.56	5.3e-08	5.04e-05	0.33	0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23821960	chr18:23709825~23710287:-
STAD	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	5.56	5.31e-08	5.04e-05	0.35	0.29	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
STAD	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	5.56	5.31e-08	5.04e-05	0.3	0.29	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
STAD	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	5.56	5.31e-08	5.04e-05	0.35	0.29	Height;	chr6:109454233	chr6:109382795~109383666:+
STAD	cis	rs13113518	0.756	rs7658446	ENSG00000272969.1	RP11-528I4.2	5.56	5.31e-08	5.04e-05	0.36	0.29	Height;	chr4:55495262	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.776	rs13124436	ENSG00000272969.1	RP11-528I4.2	5.56	5.31e-08	5.04e-05	0.36	0.29	Height;	chr4:55502504	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.783	rs6843997	ENSG00000272969.1	RP11-528I4.2	5.56	5.31e-08	5.04e-05	0.36	0.29	Height;	chr4:55508982	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.783	rs12508367	ENSG00000272969.1	RP11-528I4.2	5.56	5.31e-08	5.04e-05	0.36	0.29	Height;	chr4:55509442	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs2272073	ENSG00000272969.1	RP11-528I4.2	5.56	5.31e-08	5.04e-05	0.36	0.29	Height;	chr4:55510177	chr4:55547112~55547889:+
STAD	cis	rs17301013	0.761	rs332805	ENSG00000227373.4	RP11-160H22.5	5.56	5.31e-08	5.04e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174652487	chr1:174115300~174160004:-
STAD	cis	rs516805	0.923	rs491171	ENSG00000279453.1	RP3-425C14.4	-5.56	5.31e-08	5.04e-05	-0.31	-0.29	Lymphocyte counts;	chr6:122408021	chr6:122436789~122439223:-
STAD	cis	rs516805	0.923	rs556675	ENSG00000279453.1	RP3-425C14.4	-5.56	5.31e-08	5.04e-05	-0.31	-0.29	Lymphocyte counts;	chr6:122408083	chr6:122436789~122439223:-
STAD	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	5.56	5.32e-08	5.05e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	5.56	5.32e-08	5.05e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	5.56	5.32e-08	5.05e-05	0.45	0.29	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
STAD	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	5.56	5.32e-08	5.05e-05	0.28	0.29	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
STAD	cis	rs13113518	0.934	rs11935823	ENSG00000272969.1	RP11-528I4.2	5.56	5.32e-08	5.05e-05	0.37	0.29	Height;	chr4:55589624	chr4:55547112~55547889:+
STAD	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	5.56	5.32e-08	5.05e-05	0.35	0.29	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
STAD	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-5.56	5.32e-08	5.05e-05	-0.32	-0.29	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
STAD	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-5.56	5.32e-08	5.05e-05	-0.33	-0.29	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
STAD	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	5.56	5.32e-08	5.05e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
STAD	cis	rs8098244	0.557	rs7229859	ENSG00000267301.1	RPL23AP77	-5.56	5.32e-08	5.05e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716812	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.557	rs12957301	ENSG00000267301.1	RPL23AP77	-5.56	5.32e-08	5.05e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23717906	chr18:23709825~23710287:-
STAD	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	5.56	5.33e-08	5.06e-05	0.31	0.29	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
STAD	cis	rs7665090	0.51	rs223498	ENSG00000230069.3	LRRC37A15P	5.56	5.33e-08	5.06e-05	0.31	0.29	Primary biliary cholangitis;	chr4:102730805	chr4:102727274~102730721:-
STAD	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-5.56	5.34e-08	5.06e-05	-0.27	-0.29	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
STAD	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	5.56	5.34e-08	5.06e-05	0.42	0.29	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
STAD	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	5.56	5.34e-08	5.06e-05	0.5	0.29	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
STAD	cis	rs3806843	0.868	rs2531352	ENSG00000202111.1	VTRNA1-2	5.56	5.34e-08	5.07e-05	0.28	0.29	Depressive symptoms (multi-trait analysis);	chr5:140739949	chr5:140718925~140719013:+
STAD	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	5.56	5.34e-08	5.07e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
STAD	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	5.56	5.35e-08	5.07e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	5.56	5.35e-08	5.07e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
STAD	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	5.56	5.35e-08	5.07e-05	0.36	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
STAD	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	5.56	5.36e-08	5.08e-05	0.35	0.29	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
STAD	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	5.56	5.36e-08	5.08e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	5.56	5.36e-08	5.08e-05	0.43	0.29	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
STAD	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	5.56	5.36e-08	5.08e-05	0.35	0.29	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
STAD	cis	rs17301013	0.794	rs6425283	ENSG00000227373.4	RP11-160H22.5	5.56	5.36e-08	5.08e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174499853	chr1:174115300~174160004:-
STAD	cis	rs7487075	1	rs12832425	ENSG00000272369.1	RP11-446N19.1	5.56	5.37e-08	5.09e-05	0.35	0.29	Itch intensity from mosquito bite;	chr12:46429035	chr12:46537502~46652550:+
STAD	cis	rs7487075	1	rs12814341	ENSG00000272369.1	RP11-446N19.1	5.56	5.37e-08	5.09e-05	0.35	0.29	Itch intensity from mosquito bite;	chr12:46429489	chr12:46537502~46652550:+
STAD	cis	rs7487075	1	rs7301001	ENSG00000272369.1	RP11-446N19.1	5.56	5.37e-08	5.09e-05	0.35	0.29	Itch intensity from mosquito bite;	chr12:46437058	chr12:46537502~46652550:+
STAD	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-5.56	5.37e-08	5.09e-05	-0.33	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	5.56	5.37e-08	5.09e-05	0.33	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
STAD	cis	rs7927771	0.832	rs7105851	ENSG00000280615.1	Y_RNA	5.56	5.39e-08	5.1e-05	0.29	0.29	Subjective well-being;	chr11:47361724	chr11:47614898~47614994:-
STAD	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-5.56	5.39e-08	5.11e-05	-0.28	-0.29	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
STAD	cis	rs17301013	0.932	rs2072760	ENSG00000227373.4	RP11-160H22.5	5.56	5.4e-08	5.11e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174510186	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs10912797	ENSG00000227373.4	RP11-160H22.5	5.56	5.4e-08	5.11e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174511225	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs6668053	ENSG00000227373.4	RP11-160H22.5	5.56	5.4e-08	5.11e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174515139	chr1:174115300~174160004:-
STAD	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	5.56	5.4e-08	5.12e-05	0.28	0.29	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
STAD	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-5.56	5.41e-08	5.12e-05	-0.29	-0.29	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
STAD	cis	rs17301013	0.861	rs332770	ENSG00000227373.4	RP11-160H22.5	5.56	5.41e-08	5.12e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174681511	chr1:174115300~174160004:-
STAD	cis	rs12699921	0.599	rs4721665	ENSG00000279048.1	RP11-511H23.2	-5.56	5.41e-08	5.13e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17876696	chr7:17940503~17942922:+
STAD	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-5.56	5.41e-08	5.13e-05	-0.3	-0.29	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
STAD	cis	rs8040855	0.52	rs11629963	ENSG00000229212.6	RP11-561C5.4	-5.56	5.41e-08	5.13e-05	-0.41	-0.29	Bulimia nervosa;	chr15:84986808	chr15:85205440~85234795:-
STAD	cis	rs5769707	0.732	rs135865	ENSG00000280224.1	CTA-722E9.1	-5.56	5.42e-08	5.13e-05	-0.32	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49500568~49501585:+
STAD	cis	rs227275	0.525	rs4699037	ENSG00000230069.3	LRRC37A15P	-5.56	5.42e-08	5.13e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs3857198	ENSG00000230069.3	LRRC37A15P	-5.56	5.42e-08	5.13e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102727274~102730721:-
STAD	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-5.56	5.42e-08	5.14e-05	-0.34	-0.29	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
STAD	cis	rs2436845	1	rs1138	ENSG00000253385.1	KB-1254G8.1	5.56	5.43e-08	5.14e-05	0.3	0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102856258	chr8:102854455~102856075:+
STAD	cis	rs1816752	0.905	rs7991450	ENSG00000273628.1	RP11-756A22.7	5.56	5.43e-08	5.14e-05	0.35	0.29	Obesity-related traits;	chr13:24425898	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.774	rs7986162	ENSG00000273628.1	RP11-756A22.7	5.56	5.43e-08	5.14e-05	0.35	0.29	Obesity-related traits;	chr13:24425941	chr13:24933006~24936796:+
STAD	cis	rs227275	0.525	rs3974608	ENSG00000230069.3	LRRC37A15P	-5.56	5.43e-08	5.14e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102727274~102730721:-
STAD	cis	rs2283792	0.935	rs2283794	ENSG00000228050.1	TOP3BP1	5.56	5.43e-08	5.14e-05	0.33	0.29	Multiple sclerosis;	chr22:21858180	chr22:22223187~22224566:-
STAD	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	5.56	5.43e-08	5.14e-05	0.28	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
STAD	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	5.56	5.43e-08	5.14e-05	0.3	0.29	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
STAD	cis	rs11722779	0.838	rs4533776	ENSG00000230069.3	LRRC37A15P	-5.56	5.43e-08	5.14e-05	-0.31	-0.29	Schizophrenia;	chr4:102912732	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs10028116	ENSG00000230069.3	LRRC37A15P	-5.56	5.43e-08	5.14e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102727274~102730721:-
STAD	cis	rs2980436	1	rs2980436	ENSG00000254340.1	RP11-10A14.3	-5.56	5.43e-08	5.14e-05	-0.33	-0.29	Schizophrenia;	chr8:8234503	chr8:9141424~9145435:+
STAD	cis	rs13113518	0.812	rs56055342	ENSG00000272969.1	RP11-528I4.2	5.56	5.43e-08	5.14e-05	0.36	0.29	Height;	chr4:55540928	chr4:55547112~55547889:+
STAD	cis	rs17301013	0.965	rs2179214	ENSG00000227373.4	RP11-160H22.5	5.56	5.43e-08	5.14e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174413954	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.93	rs7523263	ENSG00000227373.4	RP11-160H22.5	5.56	5.43e-08	5.14e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174414542	chr1:174115300~174160004:-
STAD	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-5.56	5.43e-08	5.14e-05	-0.28	-0.29	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
STAD	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	5.56	5.44e-08	5.14e-05	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
STAD	cis	rs11148252	0.553	rs9536236	ENSG00000235660.1	LINC00345	-5.56	5.44e-08	5.15e-05	-0.32	-0.29	Lewy body disease;	chr13:52680877	chr13:52484161~52484680:-
STAD	cis	rs13113518	1	rs4864548	ENSG00000272969.1	RP11-528I4.2	-5.56	5.45e-08	5.15e-05	-0.36	-0.29	Height;	chr4:55547636	chr4:55547112~55547889:+
STAD	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	5.56	5.45e-08	5.15e-05	0.33	0.29	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
STAD	cis	rs17301013	0.932	rs6689170	ENSG00000227373.4	RP11-160H22.5	5.56	5.45e-08	5.16e-05	0.34	0.29	Systemic lupus erythematosus;	chr1:174639596	chr1:174115300~174160004:-
STAD	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	5.56	5.45e-08	5.16e-05	0.29	0.29	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
STAD	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	5.56	5.45e-08	5.16e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
STAD	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-5.56	5.47e-08	5.17e-05	-0.29	-0.29	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
STAD	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	5.56	5.47e-08	5.18e-05	0.3	0.29	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
STAD	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	5.56	5.48e-08	5.18e-05	0.76	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
STAD	cis	rs992157	0.798	rs2382817	ENSG00000237281.1	CATIP-AS2	-5.56	5.48e-08	5.19e-05	-0.29	-0.29	Colorectal cancer;	chr2:218286495	chr2:218326889~218357966:-
STAD	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	5.56	5.49e-08	5.19e-05	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
STAD	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	5.56	5.49e-08	5.19e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	5.56	5.49e-08	5.19e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	5.56	5.49e-08	5.19e-05	0.27	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
STAD	cis	rs228614	0.514	rs59550147	ENSG00000230069.3	LRRC37A15P	-5.56	5.5e-08	5.2e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102727274~102730721:-
STAD	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	5.56	5.5e-08	5.2e-05	0.35	0.29	Height;	chr6:109462738	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	5.56	5.5e-08	5.2e-05	0.35	0.29	Height;	chr6:109464011	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	5.56	5.5e-08	5.2e-05	0.35	0.29	Height;	chr6:109465777	chr6:109382795~109383666:+
STAD	cis	rs227275	0.556	rs6821173	ENSG00000230069.3	LRRC37A15P	-5.56	5.51e-08	5.2e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102727274~102730721:-
STAD	cis	rs10129255	0.784	rs7147210	ENSG00000280411.1	IGHV1-69-2	-5.56	5.51e-08	5.2e-05	-0.27	-0.29	Kawasaki disease;	chr14:106705271	chr14:106762092~106762588:-
STAD	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.56	5.51e-08	5.2e-05	0.39	0.29	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
STAD	cis	rs12699921	0.632	rs2691609	ENSG00000279048.1	RP11-511H23.2	-5.56	5.51e-08	5.2e-05	-0.25	-0.29	Fibrinogen levels;	chr7:17841539	chr7:17940503~17942922:+
STAD	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	5.56	5.51e-08	5.21e-05	0.44	0.29	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
STAD	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-5.56	5.51e-08	5.21e-05	-0.31	-0.29	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
STAD	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-5.56	5.51e-08	5.21e-05	-0.31	-0.29	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
STAD	cis	rs950027	0.787	rs1547487	ENSG00000259433.2	CTD-2651B20.4	-5.56	5.51e-08	5.21e-05	-0.3	-0.29	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45330209~45332634:-
STAD	cis	rs227275	0.556	rs223449	ENSG00000230069.3	LRRC37A15P	-5.56	5.52e-08	5.22e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223446	ENSG00000230069.3	LRRC37A15P	-5.56	5.52e-08	5.22e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223445	ENSG00000230069.3	LRRC37A15P	-5.56	5.52e-08	5.22e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223443	ENSG00000230069.3	LRRC37A15P	-5.56	5.52e-08	5.22e-05	-0.31	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102727274~102730721:-
STAD	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	5.56	5.52e-08	5.22e-05	0.48	0.29	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
STAD	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	5.56	5.53e-08	5.22e-05	0.36	0.29	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
STAD	cis	rs7927771	0.832	rs4992357	ENSG00000280615.1	Y_RNA	-5.56	5.54e-08	5.23e-05	-0.29	-0.29	Subjective well-being;	chr11:47372087	chr11:47614898~47614994:-
STAD	cis	rs2283792	0.967	rs5999823	ENSG00000228050.1	TOP3BP1	5.55	5.55e-08	5.24e-05	0.33	0.29	Multiple sclerosis;	chr22:21856587	chr22:22223187~22224566:-
STAD	cis	rs1816752	0.87	rs9581025	ENSG00000273628.1	RP11-756A22.7	5.55	5.55e-08	5.24e-05	0.35	0.29	Obesity-related traits;	chr13:24423687	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs9581027	ENSG00000273628.1	RP11-756A22.7	5.55	5.55e-08	5.24e-05	0.35	0.29	Obesity-related traits;	chr13:24423790	chr13:24933006~24936796:+
STAD	cis	rs12699921	0.632	rs2723545	ENSG00000279048.1	RP11-511H23.2	-5.55	5.56e-08	5.25e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17820068	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2691612	ENSG00000279048.1	RP11-511H23.2	-5.55	5.57e-08	5.25e-05	-0.25	-0.29	Fibrinogen levels;	chr7:17844293	chr7:17940503~17942922:+
STAD	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	5.55	5.58e-08	5.26e-05	0.33	0.29	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
STAD	cis	rs721917	0.525	rs1054053	ENSG00000225484.5	NUTM2B-AS1	-5.55	5.58e-08	5.27e-05	-0.38	-0.29	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79663088~79826594:-
STAD	cis	rs7924176	0.58	rs7912162	ENSG00000236900.1	TIMM9P1	-5.55	5.58e-08	5.27e-05	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74344550~74344805:-
STAD	cis	rs227275	0.525	rs4699039	ENSG00000230069.3	LRRC37A15P	-5.55	5.58e-08	5.27e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102727274~102730721:-
STAD	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	5.55	5.59e-08	5.27e-05	0.46	0.29	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
STAD	cis	rs6504622	0.728	rs7222781	ENSG00000262879.4	RP11-156P1.3	-5.55	5.59e-08	5.28e-05	-0.24	-0.29	Orofacial clefts;	chr17:47100059	chr17:46984045~47100323:-
STAD	cis	rs4568518	0.71	rs12699929	ENSG00000279048.1	RP11-511H23.2	5.55	5.59e-08	5.28e-05	0.26	0.29	Measles;	chr7:17972634	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.71	rs12699930	ENSG00000279048.1	RP11-511H23.2	5.55	5.59e-08	5.28e-05	0.26	0.29	Measles;	chr7:17972635	chr7:17940503~17942922:+
STAD	cis	rs4604732	0.631	rs76761880	ENSG00000227135.1	GCSAML-AS1	-5.55	5.6e-08	5.29e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463075	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.536	rs78019731	ENSG00000227135.1	GCSAML-AS1	-5.55	5.6e-08	5.29e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463128	chr1:247524679~247526752:-
STAD	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	5.55	5.6e-08	5.29e-05	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
STAD	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	5.55	5.61e-08	5.29e-05	0.29	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
STAD	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	5.55	5.61e-08	5.29e-05	0.29	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
STAD	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-5.55	5.61e-08	5.29e-05	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
STAD	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	5.55	5.62e-08	5.3e-05	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
STAD	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-5.55	5.62e-08	5.3e-05	-0.31	-0.29	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
STAD	cis	rs227275	0.556	rs223398	ENSG00000230069.3	LRRC37A15P	-5.55	5.63e-08	5.31e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102727274~102730721:-
STAD	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-5.55	5.63e-08	5.31e-05	-0.33	-0.29	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
STAD	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-5.55	5.63e-08	5.31e-05	-0.28	-0.29	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
STAD	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-5.55	5.63e-08	5.31e-05	-0.28	-0.29	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
STAD	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-5.55	5.63e-08	5.31e-05	-0.28	-0.29	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
STAD	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-5.55	5.63e-08	5.31e-05	-0.28	-0.29	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
STAD	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-5.55	5.64e-08	5.32e-05	-0.33	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
STAD	cis	rs453301	0.606	rs6601279	ENSG00000254340.1	RP11-10A14.3	-5.55	5.65e-08	5.33e-05	-0.38	-0.29	Joint mobility (Beighton score);	chr8:9050721	chr8:9141424~9145435:+
STAD	cis	rs453301	0.606	rs6981060	ENSG00000254340.1	RP11-10A14.3	-5.55	5.65e-08	5.33e-05	-0.38	-0.29	Joint mobility (Beighton score);	chr8:9050725	chr8:9141424~9145435:+
STAD	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	5.55	5.65e-08	5.33e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	5.55	5.65e-08	5.33e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	5.55	5.65e-08	5.33e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
STAD	cis	rs240993	0.812	rs9374262	ENSG00000230177.1	RP5-1112D6.4	5.55	5.65e-08	5.33e-05	0.29	0.29	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111277932~111278742:+
STAD	cis	rs3806843	0.966	rs6891559	ENSG00000202111.1	VTRNA1-2	-5.55	5.66e-08	5.34e-05	-0.28	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.966	rs11741994	ENSG00000202111.1	VTRNA1-2	-5.55	5.66e-08	5.34e-05	-0.28	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr5:140718925~140719013:+
STAD	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-5.55	5.66e-08	5.34e-05	-0.34	-0.29	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
STAD	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-5.55	5.66e-08	5.34e-05	-0.34	-0.29	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
STAD	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-5.55	5.66e-08	5.34e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
STAD	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-5.55	5.66e-08	5.34e-05	-0.34	-0.29	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
STAD	cis	rs62432291	0.681	rs2932988	ENSG00000235086.1	FNDC1-IT1	-5.55	5.66e-08	5.34e-05	-0.43	-0.29	Joint mobility (Beighton score);	chr6:159234370	chr6:159240786~159243329:+
STAD	cis	rs6782228	0.606	rs6787559	ENSG00000277250.1	Metazoa_SRP	-5.55	5.67e-08	5.34e-05	-0.3	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128673681~128674021:-
STAD	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	5.55	5.67e-08	5.34e-05	0.29	0.29	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
STAD	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-5.55	5.68e-08	5.35e-05	-0.27	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
STAD	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	5.55	5.68e-08	5.36e-05	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
STAD	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	5.55	5.69e-08	5.36e-05	0.28	0.29	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
STAD	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	5.55	5.69e-08	5.36e-05	0.28	0.29	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
STAD	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	5.55	5.69e-08	5.36e-05	0.37	0.29	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
STAD	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-5.55	5.69e-08	5.36e-05	-0.36	-0.29	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
STAD	cis	rs720064	0.586	rs11661565	ENSG00000267301.1	RPL23AP77	-5.55	5.69e-08	5.36e-05	-0.33	-0.29	Strep throat;	chr18:23673187	chr18:23709825~23710287:-
STAD	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-5.55	5.7e-08	5.37e-05	-0.37	-0.29	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
STAD	cis	rs950169	0.922	rs12910334	ENSG00000259295.5	CSPG4P12	5.55	5.7e-08	5.37e-05	0.43	0.29	Schizophrenia;	chr15:84403620	chr15:85191438~85213905:+
STAD	cis	rs1799949	0.965	rs6503727	ENSG00000236383.6	LINC00854	-5.55	5.7e-08	5.37e-05	-0.23	-0.29	Menopause (age at onset);	chr17:43160842	chr17:43216941~43305976:-
STAD	cis	rs17301013	0.896	rs6425287	ENSG00000227373.4	RP11-160H22.5	5.55	5.71e-08	5.37e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174566264	chr1:174115300~174160004:-
STAD	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	5.55	5.71e-08	5.38e-05	0.34	0.29	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
STAD	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-5.55	5.72e-08	5.38e-05	-0.29	-0.29	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
STAD	cis	rs6782228	0.606	rs2712404	ENSG00000277250.1	Metazoa_SRP	5.55	5.72e-08	5.38e-05	0.29	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128673681~128674021:-
STAD	cis	rs2446066	0.872	rs11170555	ENSG00000257379.1	RP11-793H13.8	5.55	5.72e-08	5.39e-05	0.47	0.29	Red blood cell count;	chr12:53430359	chr12:53441741~53467528:+
STAD	cis	rs10129255	0.912	rs35468694	ENSG00000280411.1	IGHV1-69-2	-5.55	5.73e-08	5.39e-05	-0.27	-0.29	Kawasaki disease;	chr14:106784199	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.957	rs8019272	ENSG00000280411.1	IGHV1-69-2	-5.55	5.73e-08	5.39e-05	-0.27	-0.29	Kawasaki disease;	chr14:106784709	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.957	rs10142918	ENSG00000280411.1	IGHV1-69-2	-5.55	5.73e-08	5.4e-05	-0.27	-0.29	Kawasaki disease;	chr14:106782206	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.957	rs10142859	ENSG00000280411.1	IGHV1-69-2	-5.55	5.73e-08	5.4e-05	-0.27	-0.29	Kawasaki disease;	chr14:106782238	chr14:106762092~106762588:-
STAD	cis	rs2980439	0.807	rs2980438	ENSG00000253981.4	ALG1L13P	5.55	5.74e-08	5.4e-05	0.35	0.29	Neuroticism;	chr8:8237303	chr8:8236003~8244667:-
STAD	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-5.55	5.74e-08	5.4e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
STAD	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	5.55	5.75e-08	5.41e-05	0.46	0.29	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	5.55	5.75e-08	5.41e-05	0.46	0.29	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
STAD	cis	rs227275	0.531	rs223460	ENSG00000230069.3	LRRC37A15P	-5.55	5.75e-08	5.41e-05	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102727274~102730721:-
STAD	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-5.55	5.75e-08	5.41e-05	-0.28	-0.29	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
STAD	cis	rs4713118	0.587	rs61471148	ENSG00000220721.1	OR1F12	5.55	5.75e-08	5.41e-05	0.34	0.29	Parkinson's disease;	chr6:28069254	chr6:28073316~28074233:+
STAD	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-5.55	5.75e-08	5.41e-05	-0.27	-0.29	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
STAD	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	5.55	5.75e-08	5.41e-05	0.33	0.29	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
STAD	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-5.55	5.76e-08	5.41e-05	-0.41	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
STAD	cis	rs7083	0.967	rs558590	ENSG00000254851.1	RP11-109L13.1	5.55	5.76e-08	5.42e-05	0.32	0.29	Blood protein levels;	chr11:117268405	chr11:117135528~117138582:+
STAD	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	5.55	5.77e-08	5.42e-05	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
STAD	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	5.55	5.77e-08	5.43e-05	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
STAD	cis	rs858239	0.829	rs2268744	ENSG00000226816.2	AC005082.12	5.55	5.77e-08	5.43e-05	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23206013~23208045:+
STAD	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-5.55	5.77e-08	5.43e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
STAD	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-5.55	5.78e-08	5.43e-05	-0.29	-0.29	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
STAD	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-5.55	5.78e-08	5.43e-05	-0.37	-0.29	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
STAD	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	5.55	5.78e-08	5.44e-05	0.33	0.29	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	5.55	5.78e-08	5.44e-05	0.33	0.29	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
STAD	cis	rs9549260	0.564	rs9549271	ENSG00000229456.1	RLIMP1	5.55	5.79e-08	5.44e-05	0.25	0.29	Red blood cell count;	chr13:40721341	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.592	rs9532588	ENSG00000229456.1	RLIMP1	5.55	5.79e-08	5.44e-05	0.25	0.29	Red blood cell count;	chr13:40728777	chr13:40618738~40621348:+
STAD	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-5.55	5.79e-08	5.44e-05	-0.33	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
STAD	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-5.55	5.79e-08	5.44e-05	-0.28	-0.29	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-5.55	5.79e-08	5.44e-05	-0.28	-0.29	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
STAD	cis	rs62432291	0.681	rs1699442	ENSG00000235086.1	FNDC1-IT1	5.55	5.81e-08	5.46e-05	0.43	0.29	Joint mobility (Beighton score);	chr6:159234886	chr6:159240786~159243329:+
STAD	cis	rs17301013	0.932	rs6671824	ENSG00000227373.4	RP11-160H22.5	5.55	5.83e-08	5.47e-05	0.33	0.29	Systemic lupus erythematosus;	chr1:174603721	chr1:174115300~174160004:-
STAD	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-5.55	5.83e-08	5.48e-05	-0.4	-0.29	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
STAD	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-5.54	5.85e-08	5.49e-05	-0.36	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
STAD	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-5.54	5.85e-08	5.49e-05	-0.24	-0.29	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
STAD	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-5.54	5.85e-08	5.49e-05	-0.37	-0.29	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
STAD	cis	rs7927771	0.832	rs10838699	ENSG00000280615.1	Y_RNA	5.54	5.86e-08	5.5e-05	0.29	0.29	Subjective well-being;	chr11:47364522	chr11:47614898~47614994:-
STAD	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	5.54	5.88e-08	5.52e-05	0.33	0.29	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
STAD	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	5.54	5.88e-08	5.52e-05	0.33	0.29	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
STAD	cis	rs9425766	0.655	rs6666767	ENSG00000227373.4	RP11-160H22.5	5.54	5.88e-08	5.52e-05	0.33	0.29	Life satisfaction;	chr1:174357564	chr1:174115300~174160004:-
STAD	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	5.54	5.89e-08	5.52e-05	0.33	0.29	Depression;	chr6:28070115	chr6:28073316~28074233:+
STAD	cis	rs516805	0.748	rs12211993	ENSG00000279453.1	RP3-425C14.4	5.54	5.9e-08	5.53e-05	0.41	0.29	Lymphocyte counts;	chr6:122570216	chr6:122436789~122439223:-
STAD	cis	rs12699921	0.632	rs2714877	ENSG00000279048.1	RP11-511H23.2	-5.54	5.9e-08	5.54e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17888027	chr7:17940503~17942922:+
STAD	cis	rs2283792	1	rs6518986	ENSG00000228050.1	TOP3BP1	5.54	5.91e-08	5.55e-05	0.32	0.29	Multiple sclerosis;	chr22:21831058	chr22:22223187~22224566:-
STAD	cis	rs2283792	1	rs1892846	ENSG00000228050.1	TOP3BP1	5.54	5.91e-08	5.55e-05	0.32	0.29	Multiple sclerosis;	chr22:21832190	chr22:22223187~22224566:-
STAD	cis	rs2283792	1	rs1892848	ENSG00000228050.1	TOP3BP1	5.54	5.91e-08	5.55e-05	0.32	0.29	Multiple sclerosis;	chr22:21832273	chr22:22223187~22224566:-
STAD	cis	rs2283792	1	rs5999750	ENSG00000228050.1	TOP3BP1	5.54	5.91e-08	5.55e-05	0.32	0.29	Multiple sclerosis;	chr22:21833720	chr22:22223187~22224566:-
STAD	cis	rs853679	0.55	rs34477097	ENSG00000220721.1	OR1F12	5.54	5.91e-08	5.55e-05	0.32	0.29	Depression;	chr6:28229408	chr6:28073316~28074233:+
STAD	cis	rs7083	1	rs512188	ENSG00000254851.1	RP11-109L13.1	-5.54	5.92e-08	5.55e-05	-0.32	-0.29	Blood protein levels;	chr11:117255994	chr11:117135528~117138582:+
STAD	cis	rs875971	0.545	rs13311962	ENSG00000224316.1	RP11-479O9.2	-5.54	5.92e-08	5.55e-05	-0.32	-0.29	Aortic root size;	chr7:66603142	chr7:65773620~65802067:+
STAD	cis	rs4927850	0.958	rs1975582	ENSG00000185485.13	SDHAP1	5.54	5.93e-08	5.56e-05	0.28	0.29	Pancreatic cancer;	chr3:196024568	chr3:195959748~195990318:-
STAD	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-5.54	5.93e-08	5.56e-05	-0.29	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
STAD	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-5.54	5.93e-08	5.56e-05	-0.29	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
STAD	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	5.54	5.93e-08	5.56e-05	0.31	0.29	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
STAD	cis	rs2283792	0.935	rs8141851	ENSG00000228050.1	TOP3BP1	5.54	5.94e-08	5.56e-05	0.32	0.29	Multiple sclerosis;	chr22:21812161	chr22:22223187~22224566:-
STAD	cis	rs10978777	0.805	rs7031904	ENSG00000276883.1	AL137852.1	-5.54	5.94e-08	5.57e-05	-0.28	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107287195	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.805	rs7031906	ENSG00000276883.1	AL137852.1	-5.54	5.94e-08	5.57e-05	-0.28	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107287196	chr9:107292369~107292456:-
STAD	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	5.54	5.95e-08	5.58e-05	0.31	0.29	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
STAD	cis	rs9425766	0.692	rs4652294	ENSG00000227373.4	RP11-160H22.5	5.54	5.95e-08	5.58e-05	0.33	0.29	Life satisfaction;	chr1:174272027	chr1:174115300~174160004:-
STAD	cis	rs3806843	0.75	rs2563285	ENSG00000202111.1	VTRNA1-2	5.54	5.96e-08	5.58e-05	0.28	0.29	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr5:140718925~140719013:+
STAD	cis	rs7487075	0.859	rs4768698	ENSG00000272369.1	RP11-446N19.1	-5.54	5.96e-08	5.59e-05	-0.34	-0.29	Itch intensity from mosquito bite;	chr12:46355305	chr12:46537502~46652550:+
STAD	cis	rs228614	0.51	rs223453	ENSG00000230069.3	LRRC37A15P	-5.54	5.96e-08	5.59e-05	-0.3	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102727274~102730721:-
STAD	cis	rs875971	0.545	rs4441996	ENSG00000224316.1	RP11-479O9.2	-5.54	5.97e-08	5.6e-05	-0.32	-0.29	Aortic root size;	chr7:66123233	chr7:65773620~65802067:+
STAD	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	5.54	5.97e-08	5.6e-05	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
STAD	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	5.54	5.98e-08	5.6e-05	0.33	0.29	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
STAD	cis	rs8098244	0.557	rs10445487	ENSG00000267301.1	RPL23AP77	-5.54	5.99e-08	5.61e-05	-0.34	-0.29	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23723728	chr18:23709825~23710287:-
STAD	cis	rs3806843	0.966	rs2337516	ENSG00000202111.1	VTRNA1-2	5.54	6e-08	5.62e-05	0.28	0.29	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr5:140718925~140719013:+
STAD	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	5.54	6.01e-08	5.63e-05	0.33	0.29	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
STAD	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-5.54	6.01e-08	5.63e-05	-0.29	-0.29	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
STAD	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	5.54	6.02e-08	5.63e-05	0.42	0.29	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
STAD	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-5.54	6.02e-08	5.63e-05	-0.36	-0.29	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
STAD	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	5.54	6.03e-08	5.64e-05	0.29	0.29	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-5.54	6.03e-08	5.65e-05	-0.28	-0.29	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
STAD	cis	rs2239557	0.961	rs11159061	ENSG00000259065.1	RP5-1021I20.1	-5.54	6.03e-08	5.65e-05	-0.35	-0.29	Common traits (Other);	chr14:74089560	chr14:73787360~73803270:+
STAD	cis	rs2239557	1	rs17096228	ENSG00000259065.1	RP5-1021I20.1	-5.54	6.03e-08	5.65e-05	-0.35	-0.29	Common traits (Other);	chr14:74091966	chr14:73787360~73803270:+
STAD	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	5.54	6.03e-08	5.65e-05	0.32	0.29	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
STAD	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-5.54	6.04e-08	5.65e-05	-0.32	-0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
STAD	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-5.54	6.04e-08	5.65e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-5.54	6.04e-08	5.65e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-5.54	6.04e-08	5.65e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-5.54	6.04e-08	5.65e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-5.54	6.04e-08	5.65e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
STAD	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	5.54	6.06e-08	5.67e-05	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
STAD	cis	rs6452524	1	rs7738033	ENSG00000243385.2	CTD-2110K23.1	5.54	6.06e-08	5.67e-05	0.3	0.29	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83201229~83202141:+
STAD	cis	rs6452524	1	rs6860239	ENSG00000243385.2	CTD-2110K23.1	5.54	6.06e-08	5.67e-05	0.3	0.29	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83201229~83202141:+
STAD	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	5.54	6.06e-08	5.67e-05	0.3	0.29	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.957	rs12589190	ENSG00000280411.1	IGHV1-69-2	-5.54	6.07e-08	5.67e-05	-0.27	-0.29	Kawasaki disease;	chr14:106783079	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.957	rs7493713	ENSG00000280411.1	IGHV1-69-2	-5.54	6.07e-08	5.67e-05	-0.27	-0.29	Kawasaki disease;	chr14:106783685	chr14:106762092~106762588:-
STAD	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-5.54	6.08e-08	5.68e-05	-0.4	-0.29	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
STAD	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	5.54	6.09e-08	5.69e-05	0.37	0.29	Height;	chr6:109415411	chr6:109382795~109383666:+
STAD	cis	rs606458	0.92	rs474707	ENSG00000269038.1	AP001462.6	-5.54	6.09e-08	5.69e-05	-0.37	-0.29	Urate levels;	chr11:64776663	chr11:64778954~64779405:+
STAD	cis	rs13113518	0.812	rs7667741	ENSG00000272969.1	RP11-528I4.2	5.54	6.09e-08	5.69e-05	0.37	0.29	Height;	chr4:55544621	chr4:55547112~55547889:+
STAD	cis	rs10129255	0.957	rs1024349	ENSG00000280411.1	IGHV1-69-2	-5.54	6.1e-08	5.7e-05	-0.27	-0.29	Kawasaki disease;	chr14:106689997	chr14:106762092~106762588:-
STAD	cis	rs2439831	1	rs2256764	ENSG00000205771.5	CATSPER2P1	-5.54	6.11e-08	5.71e-05	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43443565	chr15:43726918~43747094:-
STAD	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	5.54	6.11e-08	5.71e-05	0.34	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
STAD	cis	rs875971	0.545	rs6950988	ENSG00000224316.1	RP11-479O9.2	5.54	6.12e-08	5.72e-05	0.32	0.29	Aortic root size;	chr7:66511428	chr7:65773620~65802067:+
STAD	cis	rs12699921	0.565	rs2714876	ENSG00000279048.1	RP11-511H23.2	-5.54	6.13e-08	5.73e-05	-0.26	-0.29	Fibrinogen levels;	chr7:17887983	chr7:17940503~17942922:+
STAD	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-5.54	6.15e-08	5.74e-05	-0.3	-0.29	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
STAD	cis	rs748404	0.589	rs62020612	ENSG00000249839.1	AC011330.5	-5.53	6.16e-08	5.75e-05	-0.5	-0.29	Lung cancer;	chr15:43525881	chr15:43663654~43684339:-
STAD	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	5.53	6.17e-08	5.77e-05	0.31	0.29	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
STAD	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	5.53	6.18e-08	5.77e-05	0.31	0.29	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
STAD	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	5.53	6.19e-08	5.78e-05	0.37	0.29	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
STAD	cis	rs3806843	0.676	rs778593	ENSG00000202111.1	VTRNA1-2	5.53	6.2e-08	5.78e-05	0.28	0.29	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.676	rs778594	ENSG00000202111.1	VTRNA1-2	5.53	6.2e-08	5.78e-05	0.28	0.29	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr5:140718925~140719013:+
STAD	cis	rs2436845	0.934	rs2679758	ENSG00000253385.1	KB-1254G8.1	5.53	6.2e-08	5.78e-05	0.3	0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858978	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.934	rs892485	ENSG00000253385.1	KB-1254G8.1	5.53	6.2e-08	5.78e-05	0.3	0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862394	chr8:102854455~102856075:+
STAD	cis	rs62432291	0.681	rs445957	ENSG00000235086.1	FNDC1-IT1	-5.53	6.2e-08	5.78e-05	-0.42	-0.29	Joint mobility (Beighton score);	chr6:159241032	chr6:159240786~159243329:+
STAD	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-5.53	6.2e-08	5.79e-05	-0.31	-0.29	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
STAD	cis	rs992157	0.71	rs12612347	ENSG00000237281.1	CATIP-AS2	5.53	6.2e-08	5.79e-05	0.28	0.29	Colorectal cancer;	chr2:218192615	chr2:218326889~218357966:-
STAD	cis	rs2283792	1	rs5999521	ENSG00000228050.1	TOP3BP1	5.53	6.21e-08	5.79e-05	0.32	0.29	Multiple sclerosis;	chr22:21792110	chr22:22223187~22224566:-
STAD	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-5.53	6.21e-08	5.79e-05	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000228039.3	KB-1125A3.10	5.53	6.21e-08	5.79e-05	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23963780~23964374:+
STAD	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	5.53	6.21e-08	5.8e-05	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	5.53	6.21e-08	5.8e-05	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
STAD	cis	rs227275	0.554	rs9307281	ENSG00000230069.3	LRRC37A15P	-5.53	6.22e-08	5.8e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.903	rs6533037	ENSG00000230069.3	LRRC37A15P	-5.53	6.22e-08	5.8e-05	-0.31	-0.29	Schizophrenia;	chr4:102935865	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.903	rs4530634	ENSG00000230069.3	LRRC37A15P	-5.53	6.22e-08	5.8e-05	-0.31	-0.29	Schizophrenia;	chr4:102937924	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs7676943	ENSG00000230069.3	LRRC37A15P	-5.53	6.22e-08	5.8e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs6419160	ENSG00000230069.3	LRRC37A15P	-5.53	6.22e-08	5.8e-05	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.838	rs3974494	ENSG00000230069.3	LRRC37A15P	-5.53	6.22e-08	5.8e-05	-0.31	-0.29	Schizophrenia;	chr4:102945323	chr4:102727274~102730721:-
STAD	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-5.53	6.22e-08	5.8e-05	-0.3	-0.29	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
STAD	cis	rs7927771	0.524	rs10838784	ENSG00000280615.1	Y_RNA	5.53	6.23e-08	5.81e-05	0.29	0.29	Subjective well-being;	chr11:47860789	chr11:47614898~47614994:-
STAD	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	5.53	6.23e-08	5.81e-05	0.25	0.29	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
STAD	cis	rs4639966	0.836	rs7943039	ENSG00000255239.1	AP002954.6	-5.53	6.24e-08	5.81e-05	-0.36	-0.29	Systemic lupus erythematosus;	chr11:118732321	chr11:118688039~118690600:-
STAD	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	5.53	6.24e-08	5.82e-05	0.37	0.29	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
STAD	cis	rs4604732	0.588	rs9943231	ENSG00000227135.1	GCSAML-AS1	-5.53	6.25e-08	5.83e-05	-0.39	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466527	chr1:247524679~247526752:-
STAD	cis	rs4568518	0.619	rs6946266	ENSG00000279048.1	RP11-511H23.2	5.53	6.25e-08	5.83e-05	0.25	0.29	Measles;	chr7:17967965	chr7:17940503~17942922:+
STAD	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	5.53	6.27e-08	5.84e-05	0.43	0.29	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
STAD	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-5.53	6.28e-08	5.85e-05	-0.34	-0.29	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
STAD	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-5.53	6.28e-08	5.85e-05	-0.3	-0.29	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
STAD	cis	rs2933343	0.621	rs4927921	ENSG00000231305.3	RP11-723O4.2	-5.53	6.28e-08	5.85e-05	-0.3	-0.29	IgG glycosylation;	chr3:128850025	chr3:128861313~128871540:-
STAD	cis	rs453301	0.686	rs11785819	ENSG00000254340.1	RP11-10A14.3	-5.53	6.29e-08	5.86e-05	-0.37	-0.29	Joint mobility (Beighton score);	chr8:9012868	chr8:9141424~9145435:+
STAD	cis	rs1799949	1	rs9646412	ENSG00000279602.1	CTD-3014M21.1	5.53	6.29e-08	5.86e-05	0.36	0.29	Menopause (age at onset);	chr17:43348525	chr17:43360041~43361361:-
STAD	cis	rs992157	0.835	rs2292555	ENSG00000237281.1	CATIP-AS2	5.53	6.29e-08	5.86e-05	0.29	0.29	Colorectal cancer;	chr2:218282159	chr2:218326889~218357966:-
STAD	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-5.53	6.3e-08	5.87e-05	-0.27	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
STAD	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-5.53	6.31e-08	5.87e-05	-0.34	-0.28	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
STAD	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-5.53	6.31e-08	5.88e-05	-0.3	-0.28	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
STAD	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-5.53	6.32e-08	5.88e-05	-0.27	-0.28	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
STAD	cis	rs228614	0.51	rs3774987	ENSG00000230069.3	LRRC37A15P	-5.53	6.33e-08	5.89e-05	-0.31	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102727274~102730721:-
STAD	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	5.53	6.34e-08	5.9e-05	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
STAD	cis	rs3806843	0.576	rs251370	ENSG00000202111.1	VTRNA1-2	5.53	6.36e-08	5.92e-05	0.29	0.28	Depressive symptoms (multi-trait analysis);	chr5:140866702	chr5:140718925~140719013:+
STAD	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-5.53	6.37e-08	5.93e-05	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
STAD	cis	rs2239557	1	rs2239557	ENSG00000259065.1	RP5-1021I20.1	-5.53	6.38e-08	5.93e-05	-0.35	-0.28	Common traits (Other);	chr14:74085267	chr14:73787360~73803270:+
STAD	cis	rs9425766	0.679	rs2143114	ENSG00000227373.4	RP11-160H22.5	5.53	6.38e-08	5.93e-05	0.33	0.28	Life satisfaction;	chr1:174192292	chr1:174115300~174160004:-
STAD	cis	rs2337406	1	rs78631692	ENSG00000211972.2	IGHV3-66	5.53	6.38e-08	5.94e-05	0.33	0.28	Alzheimer's disease (late onset);	chr14:106709371	chr14:106675017~106675544:-
STAD	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	5.53	6.39e-08	5.94e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	5.53	6.39e-08	5.94e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	5.53	6.39e-08	5.94e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	5.53	6.39e-08	5.94e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	5.53	6.39e-08	5.94e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	5.53	6.39e-08	5.94e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
STAD	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-5.53	6.39e-08	5.94e-05	-0.42	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
STAD	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	5.53	6.39e-08	5.94e-05	0.33	0.28	Depression;	chr6:28071237	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	5.53	6.39e-08	5.94e-05	0.33	0.28	Depression;	chr6:28076559	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	5.53	6.39e-08	5.94e-05	0.33	0.28	Depression;	chr6:28078391	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	5.53	6.39e-08	5.94e-05	0.33	0.28	Depression;	chr6:28080757	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	5.53	6.39e-08	5.94e-05	0.33	0.28	Depression;	chr6:28080760	chr6:28073316~28074233:+
STAD	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	5.53	6.39e-08	5.94e-05	0.35	0.28	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
STAD	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-5.53	6.39e-08	5.95e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
STAD	cis	rs875971	0.545	rs316328	ENSG00000224316.1	RP11-479O9.2	-5.53	6.39e-08	5.95e-05	-0.31	-0.28	Aortic root size;	chr7:66143851	chr7:65773620~65802067:+
STAD	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-5.53	6.4e-08	5.95e-05	-0.47	-0.28	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
STAD	cis	rs17301013	0.932	rs1793297	ENSG00000227373.4	RP11-160H22.5	-5.53	6.4e-08	5.95e-05	-0.33	-0.28	Systemic lupus erythematosus;	chr1:174784411	chr1:174115300~174160004:-
STAD	cis	rs7829975	0.606	rs7819827	ENSG00000254340.1	RP11-10A14.3	-5.53	6.41e-08	5.96e-05	-0.35	-0.28	Mood instability;	chr8:8939545	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.573	rs7842359	ENSG00000254340.1	RP11-10A14.3	-5.53	6.41e-08	5.96e-05	-0.35	-0.28	Mood instability;	chr8:8939568	chr8:9141424~9145435:+
STAD	cis	rs4713118	0.868	rs10484401	ENSG00000280107.1	AL022393.9	5.53	6.42e-08	5.97e-05	0.4	0.28	Parkinson's disease;	chr6:27778811	chr6:28170845~28172521:+
STAD	cis	rs8098244	0.579	rs1788798	ENSG00000267301.1	RPL23AP77	-5.53	6.42e-08	5.97e-05	-0.34	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23687281	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.557	rs1788797	ENSG00000267301.1	RPL23AP77	-5.53	6.42e-08	5.97e-05	-0.34	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23687416	chr18:23709825~23710287:-
STAD	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	5.53	6.42e-08	5.97e-05	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	5.53	6.42e-08	5.97e-05	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
STAD	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	5.53	6.42e-08	5.97e-05	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
STAD	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-5.53	6.43e-08	5.98e-05	-0.29	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
STAD	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-5.53	6.44e-08	5.98e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
STAD	cis	rs721917	0.506	rs2244451	ENSG00000225484.5	NUTM2B-AS1	-5.53	6.46e-08	6e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2265961	ENSG00000225484.5	NUTM2B-AS1	-5.53	6.46e-08	6e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs7088752	ENSG00000225484.5	NUTM2B-AS1	-5.53	6.46e-08	6e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs7078242	ENSG00000225484.5	NUTM2B-AS1	-5.53	6.46e-08	6e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79663088~79826594:-
STAD	cis	rs721917	0.525	rs2244001	ENSG00000225484.5	NUTM2B-AS1	-5.53	6.46e-08	6e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs1811886	ENSG00000225484.5	NUTM2B-AS1	-5.53	6.46e-08	6e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs2819113	ENSG00000225484.5	NUTM2B-AS1	-5.53	6.46e-08	6e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79663088~79826594:-
STAD	cis	rs10978777	0.805	rs10739234	ENSG00000276883.1	AL137852.1	-5.53	6.47e-08	6e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107285035	chr9:107292369~107292456:-
STAD	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	5.53	6.47e-08	6e-05	0.28	0.28	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
STAD	cis	rs8067354	0.574	rs1291947	ENSG00000266701.1	AC005702.4	5.53	6.47e-08	6.01e-05	0.41	0.28	Hemoglobin concentration;	chr17:59918975	chr17:60042546~60042627:-
STAD	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	5.53	6.47e-08	6.01e-05	0.3	0.28	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
STAD	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	5.53	6.47e-08	6.01e-05	0.3	0.28	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
STAD	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	5.53	6.48e-08	6.02e-05	0.4	0.28	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
STAD	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-5.52	6.5e-08	6.03e-05	-0.36	-0.28	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
STAD	cis	rs1816752	0.87	rs9511261	ENSG00000273628.1	RP11-756A22.7	5.52	6.52e-08	6.04e-05	0.35	0.28	Obesity-related traits;	chr13:24437880	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs9511262	ENSG00000273628.1	RP11-756A22.7	5.52	6.52e-08	6.04e-05	0.35	0.28	Obesity-related traits;	chr13:24437885	chr13:24933006~24936796:+
STAD	cis	rs2439831	1	rs690436	ENSG00000275601.1	AC011330.13	-5.52	6.53e-08	6.06e-05	-0.35	-0.28	Lung cancer in ever smokers;	chr15:43469007	chr15:43642389~43643023:-
STAD	cis	rs2439831	1	rs2264239	ENSG00000275601.1	AC011330.13	-5.52	6.53e-08	6.06e-05	-0.35	-0.28	Lung cancer in ever smokers;	chr15:43473335	chr15:43642389~43643023:-
STAD	cis	rs721917	0.506	rs2758558	ENSG00000225484.5	NUTM2B-AS1	-5.52	6.54e-08	6.06e-05	-0.37	-0.28	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79663088~79826594:-
STAD	cis	rs1816752	0.87	rs73469543	ENSG00000273628.1	RP11-756A22.7	5.52	6.54e-08	6.06e-05	0.35	0.28	Obesity-related traits;	chr13:24424832	chr13:24933006~24936796:+
STAD	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-5.52	6.55e-08	6.07e-05	-0.44	-0.28	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
STAD	cis	rs12530	0.715	rs2294314	ENSG00000230736.2	RP1-149A16.3	-5.52	6.55e-08	6.08e-05	-0.37	-0.28	IgG glycosylation;	chr22:32398616	chr22:32376664~32384343:+
STAD	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	5.52	6.56e-08	6.08e-05	0.41	0.28	Height;	chr6:109416945	chr6:109382795~109383666:+
STAD	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-5.52	6.57e-08	6.09e-05	-0.47	-0.28	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
STAD	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-5.52	6.57e-08	6.09e-05	-0.28	-0.28	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs73148639	ENSG00000224316.1	RP11-479O9.2	5.52	6.57e-08	6.09e-05	0.32	0.28	Aortic root size;	chr7:66390342	chr7:65773620~65802067:+
STAD	cis	rs8005677	0.77	rs56180741	ENSG00000257285.4	RP11-298I3.1	5.52	6.57e-08	6.09e-05	0.35	0.28	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:22929609~22955562:+
STAD	cis	rs8005677	0.828	rs3794452	ENSG00000257285.4	RP11-298I3.1	5.52	6.57e-08	6.09e-05	0.35	0.28	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:22929609~22955562:+
STAD	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	5.52	6.57e-08	6.09e-05	0.43	0.28	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
STAD	cis	rs12744310	1	rs55707527	ENSG00000235358.1	RP11-399E6.1	5.52	6.58e-08	6.1e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303441	chr1:41242373~41284861:+
STAD	cis	rs2404602	0.735	rs4886800	ENSG00000259422.1	RP11-593F23.1	-5.52	6.58e-08	6.1e-05	-0.3	-0.28	Blood metabolite levels;	chr15:76386351	chr15:76174891~76181486:-
STAD	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	5.52	6.59e-08	6.11e-05	0.35	0.28	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
STAD	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-5.52	6.59e-08	6.11e-05	-0.38	-0.28	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
STAD	cis	rs992157	0.56	rs6436048	ENSG00000237281.1	CATIP-AS2	-5.52	6.6e-08	6.11e-05	-0.28	-0.28	Colorectal cancer;	chr2:218244310	chr2:218326889~218357966:-
STAD	cis	rs6452524	0.935	rs2386241	ENSG00000243385.2	CTD-2110K23.1	-5.52	6.61e-08	6.12e-05	-0.34	-0.28	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83201229~83202141:+
STAD	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	5.52	6.61e-08	6.12e-05	0.42	0.28	Height;	chr6:109333018	chr6:109382795~109383666:+
STAD	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-5.52	6.61e-08	6.12e-05	-0.31	-0.28	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
STAD	cis	rs1005277	0.691	rs2474558	ENSG00000099251.13	HSD17B7P2	-5.52	6.62e-08	6.13e-05	-0.33	-0.28	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38356380~38378505:+
STAD	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-5.52	6.62e-08	6.13e-05	-0.27	-0.28	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	5.52	6.63e-08	6.14e-05	0.29	0.28	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
STAD	cis	rs12699921	0.607	rs35819944	ENSG00000279048.1	RP11-511H23.2	5.52	6.64e-08	6.14e-05	0.26	0.28	Fibrinogen levels;	chr7:17928168	chr7:17940503~17942922:+
STAD	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	5.52	6.64e-08	6.15e-05	0.29	0.28	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
STAD	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-5.52	6.66e-08	6.16e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-5.52	6.66e-08	6.16e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-5.52	6.66e-08	6.16e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-5.52	6.66e-08	6.16e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
STAD	cis	rs62432291	0.681	rs404435	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159233455	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.614	rs370434	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159233519	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs402388	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159233962	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.764	rs436743	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159234070	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs3003174	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159234294	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs2501176	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159234351	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs2501177	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159234561	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs431205	ENSG00000235086.1	FNDC1-IT1	-5.52	6.66e-08	6.16e-05	-0.43	-0.28	Joint mobility (Beighton score);	chr6:159241467	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs7757530	ENSG00000235086.1	FNDC1-IT1	5.52	6.66e-08	6.16e-05	0.43	0.28	Joint mobility (Beighton score);	chr6:159226897	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs418859	ENSG00000235086.1	FNDC1-IT1	5.52	6.66e-08	6.16e-05	0.43	0.28	Joint mobility (Beighton score);	chr6:159228663	chr6:159240786~159243329:+
STAD	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-5.52	6.66e-08	6.17e-05	-0.41	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
STAD	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-5.52	6.67e-08	6.17e-05	-0.33	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
STAD	cis	rs11722779	0.935	rs3857200	ENSG00000230069.3	LRRC37A15P	-5.52	6.67e-08	6.18e-05	-0.31	-0.28	Schizophrenia;	chr4:103001864	chr4:102727274~102730721:-
STAD	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	5.52	6.68e-08	6.18e-05	0.3	0.28	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
STAD	cis	rs13113518	0.812	rs13140590	ENSG00000272969.1	RP11-528I4.2	5.52	6.68e-08	6.18e-05	0.36	0.28	Height;	chr4:55548666	chr4:55547112~55547889:+
STAD	cis	rs728616	0.867	rs55690691	ENSG00000225484.5	NUTM2B-AS1	-5.52	6.69e-08	6.19e-05	-0.68	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs1983775	ENSG00000225484.5	NUTM2B-AS1	-5.52	6.69e-08	6.19e-05	-0.68	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs1983776	ENSG00000225484.5	NUTM2B-AS1	-5.52	6.69e-08	6.19e-05	-0.68	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:79663088~79826594:-
STAD	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	5.52	6.69e-08	6.19e-05	0.31	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
STAD	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	5.52	6.71e-08	6.2e-05	0.39	0.28	Height;	chr6:109465229	chr6:109382795~109383666:+
STAD	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	5.52	6.75e-08	6.24e-05	0.33	0.28	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
STAD	cis	rs4912314	1	rs7515808	ENSG00000236776.1	RPL21P23	-5.52	6.75e-08	6.24e-05	-0.36	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr1:56506728	chr1:56538452~56538911:+
STAD	cis	rs10849893	0.576	rs7296507	ENSG00000258435.1	RP11-711D18.2	-5.52	6.75e-08	6.24e-05	-0.31	-0.28	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121409332	chr12:121391962~121399859:+
STAD	cis	rs2273156	0.501	rs5014384	ENSG00000241052.1	RP11-173D9.1	-5.52	6.76e-08	6.24e-05	-0.35	-0.28	Immunoglobulin light chain (AL) amyloidosis;	chr14:35038468	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.57	rs4594164	ENSG00000241052.1	RP11-173D9.1	-5.52	6.76e-08	6.24e-05	-0.35	-0.28	Immunoglobulin light chain (AL) amyloidosis;	chr14:35040365	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.57	rs79888893	ENSG00000241052.1	RP11-173D9.1	-5.52	6.76e-08	6.24e-05	-0.35	-0.28	Immunoglobulin light chain (AL) amyloidosis;	chr14:35041470	chr14:35144021~35144480:-
STAD	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	5.52	6.76e-08	6.24e-05	0.33	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
STAD	cis	rs1862618	0.671	rs2591956	ENSG00000271828.1	CTD-2310F14.1	-5.52	6.77e-08	6.25e-05	-0.35	-0.28	Initial pursuit acceleration;	chr5:56948777	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.671	rs2591955	ENSG00000271828.1	CTD-2310F14.1	-5.52	6.77e-08	6.25e-05	-0.35	-0.28	Initial pursuit acceleration;	chr5:56949121	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.641	rs2591954	ENSG00000271828.1	CTD-2310F14.1	-5.52	6.77e-08	6.25e-05	-0.35	-0.28	Initial pursuit acceleration;	chr5:56949217	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.671	rs906631	ENSG00000271828.1	CTD-2310F14.1	-5.52	6.77e-08	6.25e-05	-0.35	-0.28	Initial pursuit acceleration;	chr5:56949976	chr5:56927874~56929573:+
STAD	cis	rs1816752	1	rs7999554	ENSG00000273628.1	RP11-756A22.7	5.52	6.77e-08	6.25e-05	0.35	0.28	Obesity-related traits;	chr13:24435631	chr13:24933006~24936796:+
STAD	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-5.52	6.77e-08	6.25e-05	-0.24	-0.28	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
STAD	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-5.52	6.77e-08	6.26e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
STAD	cis	rs2283792	1	rs6928	ENSG00000228050.1	TOP3BP1	5.52	6.79e-08	6.27e-05	0.31	0.28	Multiple sclerosis;	chr22:21760715	chr22:22223187~22224566:-
STAD	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-5.52	6.79e-08	6.27e-05	-0.49	-0.28	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
STAD	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-5.52	6.8e-08	6.27e-05	-0.29	-0.28	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
STAD	cis	rs7927771	0.832	rs10769258	ENSG00000280615.1	Y_RNA	5.52	6.8e-08	6.28e-05	0.29	0.28	Subjective well-being;	chr11:47369488	chr11:47614898~47614994:-
STAD	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	5.52	6.82e-08	6.29e-05	0.33	0.28	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
STAD	cis	rs516805	0.667	rs7752093	ENSG00000279453.1	RP3-425C14.4	5.52	6.83e-08	6.3e-05	0.39	0.28	Lymphocyte counts;	chr6:122301265	chr6:122436789~122439223:-
STAD	cis	rs8067354	0.574	rs1292050	ENSG00000266701.1	AC005702.4	5.52	6.83e-08	6.3e-05	0.41	0.28	Hemoglobin concentration;	chr17:59887808	chr17:60042546~60042627:-
STAD	cis	rs875971	0.545	rs7811204	ENSG00000224316.1	RP11-479O9.2	5.52	6.83e-08	6.3e-05	0.32	0.28	Aortic root size;	chr7:66387213	chr7:65773620~65802067:+
STAD	cis	rs1153858	1	rs11070453	ENSG00000259433.2	CTD-2651B20.4	-5.51	6.84e-08	6.31e-05	-0.31	-0.28	Homoarginine levels;	chr15:45352956	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs12593230	ENSG00000259433.2	CTD-2651B20.4	-5.51	6.84e-08	6.31e-05	-0.31	-0.28	Homoarginine levels;	chr15:45354770	chr15:45330209~45332634:-
STAD	cis	rs7927771	0.832	rs896816	ENSG00000280615.1	Y_RNA	5.51	6.85e-08	6.32e-05	0.29	0.28	Subjective well-being;	chr11:47372787	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.832	rs7940536	ENSG00000280615.1	Y_RNA	5.51	6.85e-08	6.32e-05	0.29	0.28	Subjective well-being;	chr11:47373689	chr11:47614898~47614994:-
STAD	cis	rs3758911	0.828	rs1490946	ENSG00000261098.1	RP11-819C21.1	-5.51	6.85e-08	6.32e-05	-0.25	-0.28	Coronary artery disease;	chr11:107325374	chr11:107312132~107316271:-
STAD	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	5.51	6.86e-08	6.32e-05	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
STAD	cis	rs12699921	0.599	rs2723540	ENSG00000279048.1	RP11-511H23.2	-5.51	6.86e-08	6.32e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17866067	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.616	rs11766489	ENSG00000279048.1	RP11-511H23.2	5.51	6.87e-08	6.34e-05	0.25	0.28	Measles;	chr7:17964047	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.616	rs11766586	ENSG00000279048.1	RP11-511H23.2	5.51	6.87e-08	6.34e-05	0.25	0.28	Measles;	chr7:17964342	chr7:17940503~17942922:+
STAD	cis	rs62432291	0.681	rs385438	ENSG00000235086.1	FNDC1-IT1	-5.51	6.89e-08	6.36e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159235181	chr6:159240786~159243329:+
STAD	cis	rs1426063	0.61	rs72862239	ENSG00000249717.1	RP11-44F21.3	5.51	6.89e-08	6.36e-05	0.6	0.28	QT interval;	chr4:75071967	chr4:74955974~74970362:-
STAD	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	5.51	6.91e-08	6.37e-05	0.37	0.28	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
STAD	cis	rs11722779	0.838	rs6821247	ENSG00000230069.3	LRRC37A15P	-5.51	6.92e-08	6.37e-05	-0.31	-0.28	Schizophrenia;	chr4:102913483	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs9917919	ENSG00000230069.3	LRRC37A15P	-5.51	6.92e-08	6.37e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs11731885	ENSG00000230069.3	LRRC37A15P	-5.51	6.92e-08	6.38e-05	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102727274~102730721:-
STAD	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	5.51	6.93e-08	6.38e-05	0.33	0.28	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
STAD	cis	rs12744310	1	rs12030762	ENSG00000235358.1	RP11-399E6.1	5.51	6.93e-08	6.39e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301089	chr1:41242373~41284861:+
STAD	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	5.51	6.94e-08	6.39e-05	0.34	0.28	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
STAD	cis	rs7927771	0.524	rs10838771	ENSG00000280615.1	Y_RNA	-5.51	6.96e-08	6.41e-05	-0.29	-0.28	Subjective well-being;	chr11:47809780	chr11:47614898~47614994:-
STAD	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	5.51	6.96e-08	6.41e-05	0.36	0.28	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
STAD	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	5.51	6.96e-08	6.41e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
STAD	cis	rs1322639	0.592	rs7743597	ENSG00000261039.2	RP11-417E7.2	-5.51	6.96e-08	6.41e-05	-0.34	-0.28	Pulse pressure;	chr6:169191583	chr6:169175304~169182740:-
STAD	cis	rs606458	0.92	rs523200	ENSG00000269038.1	AP001462.6	5.51	6.96e-08	6.41e-05	0.36	0.28	Urate levels;	chr11:64765107	chr11:64778954~64779405:+
STAD	cis	rs8098244	0.536	rs10445488	ENSG00000267301.1	RPL23AP77	-5.51	6.97e-08	6.41e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23725402	chr18:23709825~23710287:-
STAD	cis	rs858239	0.601	rs987257	ENSG00000226816.2	AC005082.12	5.51	6.97e-08	6.41e-05	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23206013~23208045:+
STAD	cis	rs17592366	0.517	rs4981250	ENSG00000251726.1	RNU7-41P	-5.51	6.97e-08	6.42e-05	-0.26	-0.28	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34785267	chr14:34845300~34845360:-
STAD	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	5.51	6.98e-08	6.42e-05	0.25	0.28	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
STAD	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-5.51	6.98e-08	6.43e-05	-0.4	-0.28	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
STAD	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	5.51	6.99e-08	6.43e-05	0.29	0.28	Height;	chr2:231516534	chr2:231508426~231514339:-
STAD	cis	rs7829975	0.509	rs7838674	ENSG00000254340.1	RP11-10A14.3	-5.51	6.99e-08	6.43e-05	-0.35	-0.28	Mood instability;	chr8:8939563	chr8:9141424~9145435:+
STAD	cis	rs1816752	0.935	rs4770676	ENSG00000273628.1	RP11-756A22.7	5.51	7e-08	6.44e-05	0.35	0.28	Obesity-related traits;	chr13:24429745	chr13:24933006~24936796:+
STAD	cis	rs1816752	1	rs7326932	ENSG00000273628.1	RP11-756A22.7	5.51	7e-08	6.44e-05	0.35	0.28	Obesity-related traits;	chr13:24430355	chr13:24933006~24936796:+
STAD	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	5.51	7.01e-08	6.45e-05	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
STAD	cis	rs9425766	0.679	rs2901785	ENSG00000227373.4	RP11-160H22.5	5.51	7.02e-08	6.45e-05	0.33	0.28	Life satisfaction;	chr1:174135605	chr1:174115300~174160004:-
STAD	cis	rs7927771	0.542	rs3886262	ENSG00000280615.1	Y_RNA	5.51	7.03e-08	6.46e-05	0.29	0.28	Subjective well-being;	chr11:47795458	chr11:47614898~47614994:-
STAD	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-5.51	7.03e-08	6.47e-05	-0.29	-0.28	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
STAD	cis	rs228614	0.536	rs223375	ENSG00000230069.3	LRRC37A15P	-5.51	7.04e-08	6.47e-05	-0.31	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102727274~102730721:-
STAD	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	5.51	7.04e-08	6.48e-05	0.3	0.28	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
STAD	cis	rs453301	0.658	rs6986044	ENSG00000254340.1	RP11-10A14.3	-5.51	7.06e-08	6.49e-05	-0.37	-0.28	Joint mobility (Beighton score);	chr8:9017276	chr8:9141424~9145435:+
STAD	cis	rs228614	0.51	rs170565	ENSG00000230069.3	LRRC37A15P	-5.51	7.06e-08	6.49e-05	-0.31	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102727274~102730721:-
STAD	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-5.51	7.07e-08	6.5e-05	-0.3	-0.28	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
STAD	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-5.51	7.08e-08	6.5e-05	-0.28	-0.28	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
STAD	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-5.51	7.08e-08	6.5e-05	-0.28	-0.28	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
STAD	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-5.51	7.1e-08	6.52e-05	-0.29	-0.28	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
STAD	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	5.51	7.1e-08	6.52e-05	0.33	0.28	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
STAD	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-5.51	7.1e-08	6.52e-05	-0.36	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
STAD	cis	rs516805	0.706	rs1339533	ENSG00000279453.1	RP3-425C14.4	-5.51	7.1e-08	6.52e-05	-0.37	-0.28	Lymphocyte counts;	chr6:122348687	chr6:122436789~122439223:-
STAD	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	5.51	7.11e-08	6.52e-05	0.35	0.28	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
STAD	cis	rs9463078	0.51	rs1329714	ENSG00000219384.1	RP11-491H9.3	-5.51	7.11e-08	6.52e-05	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45035598	chr6:45158870~45159511:+
STAD	cis	rs9549260	0.712	rs9532564	ENSG00000229456.1	RLIMP1	5.51	7.11e-08	6.53e-05	0.34	0.28	Red blood cell count;	chr13:40586442	chr13:40618738~40621348:+
STAD	cis	rs858239	0.601	rs6969733	ENSG00000226816.2	AC005082.12	5.51	7.11e-08	6.53e-05	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs4440529	ENSG00000226816.2	AC005082.12	5.51	7.11e-08	6.53e-05	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23206013~23208045:+
STAD	cis	rs4604732	0.588	rs7549495	ENSG00000227135.1	GCSAML-AS1	-5.51	7.12e-08	6.53e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464504	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.536	rs76191272	ENSG00000227135.1	GCSAML-AS1	-5.51	7.12e-08	6.53e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464753	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.536	rs7528219	ENSG00000227135.1	GCSAML-AS1	-5.51	7.12e-08	6.53e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465005	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.588	rs7549955	ENSG00000227135.1	GCSAML-AS1	-5.51	7.12e-08	6.53e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465019	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.588	rs7552443	ENSG00000227135.1	GCSAML-AS1	-5.51	7.12e-08	6.53e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465281	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.588	rs7552461	ENSG00000227135.1	GCSAML-AS1	-5.51	7.12e-08	6.53e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465342	chr1:247524679~247526752:-
STAD	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-5.51	7.12e-08	6.53e-05	-0.33	-0.28	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
STAD	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-5.51	7.12e-08	6.53e-05	-0.31	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
STAD	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-5.51	7.12e-08	6.53e-05	-0.37	-0.28	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000228039.3	KB-1125A3.10	5.51	7.14e-08	6.55e-05	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23963780~23964374:+
STAD	cis	rs227275	0.556	rs223380	ENSG00000230069.3	LRRC37A15P	-5.51	7.14e-08	6.55e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs223379	ENSG00000230069.3	LRRC37A15P	-5.51	7.14e-08	6.55e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102727274~102730721:-
STAD	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-5.51	7.15e-08	6.56e-05	-0.26	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
STAD	cis	rs8040855	0.52	rs11629962	ENSG00000229212.6	RP11-561C5.4	5.51	7.18e-08	6.58e-05	0.42	0.28	Bulimia nervosa;	chr15:84986797	chr15:85205440~85234795:-
STAD	cis	rs858239	0.57	rs10235467	ENSG00000226816.2	AC005082.12	5.51	7.18e-08	6.58e-05	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23206013~23208045:+
STAD	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-5.51	7.2e-08	6.6e-05	-0.29	-0.28	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-5.51	7.2e-08	6.6e-05	-0.29	-0.28	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-5.5	7.21e-08	6.61e-05	-0.3	-0.28	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-5.5	7.21e-08	6.61e-05	-0.3	-0.28	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-5.5	7.21e-08	6.61e-05	-0.3	-0.28	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-5.5	7.21e-08	6.61e-05	-0.3	-0.28	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
STAD	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-5.5	7.23e-08	6.62e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-5.5	7.23e-08	6.62e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
STAD	cis	rs12744310	0.83	rs12028010	ENSG00000235358.1	RP11-399E6.1	5.5	7.23e-08	6.62e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298799	chr1:41242373~41284861:+
STAD	cis	rs7829975	0.509	rs2945269	ENSG00000253981.4	ALG1L13P	5.5	7.23e-08	6.62e-05	0.35	0.28	Mood instability;	chr8:8258056	chr8:8236003~8244667:-
STAD	cis	rs7487075	0.619	rs10880971	ENSG00000272369.1	RP11-446N19.1	5.5	7.24e-08	6.63e-05	0.38	0.28	Itch intensity from mosquito bite;	chr12:46445715	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs10467214	ENSG00000272369.1	RP11-446N19.1	5.5	7.24e-08	6.63e-05	0.38	0.28	Itch intensity from mosquito bite;	chr12:46447427	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.619	rs12298616	ENSG00000272369.1	RP11-446N19.1	5.5	7.24e-08	6.63e-05	0.38	0.28	Itch intensity from mosquito bite;	chr12:46448389	chr12:46537502~46652550:+
STAD	cis	rs2436845	1	rs2679755	ENSG00000253385.1	KB-1254G8.1	5.5	7.24e-08	6.63e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102856682	chr8:102854455~102856075:+
STAD	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-5.5	7.26e-08	6.65e-05	-0.3	-0.28	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
STAD	cis	rs1816752	0.905	rs7995909	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24439159	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs6490927	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24439802	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs6490928	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24439921	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs6490929	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24440114	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs3825449	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24440303	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs7998797	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24440850	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs7981337	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24440915	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.87	rs7981480	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24440966	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.837	rs4769355	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24441059	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.905	rs4770680	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24441110	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.805	rs61614647	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24441829	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.774	rs55888616	ENSG00000273628.1	RP11-756A22.7	5.5	7.29e-08	6.67e-05	0.34	0.28	Obesity-related traits;	chr13:24441954	chr13:24933006~24936796:+
STAD	cis	rs3806843	0.931	rs13168670	ENSG00000202111.1	VTRNA1-2	-5.5	7.3e-08	6.67e-05	-0.28	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr5:140718925~140719013:+
STAD	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-5.5	7.31e-08	6.69e-05	-0.29	-0.28	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
STAD	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	5.5	7.32e-08	6.69e-05	0.5	0.28	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
STAD	cis	rs516805	0.715	rs11154087	ENSG00000279453.1	RP3-425C14.4	5.5	7.33e-08	6.7e-05	0.41	0.28	Lymphocyte counts;	chr6:122575484	chr6:122436789~122439223:-
STAD	cis	rs875971	0.545	rs2707851	ENSG00000224316.1	RP11-479O9.2	-5.5	7.33e-08	6.7e-05	-0.31	-0.28	Aortic root size;	chr7:66624178	chr7:65773620~65802067:+
STAD	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	5.5	7.33e-08	6.7e-05	0.38	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
STAD	cis	rs7487075	0.897	rs7979418	ENSG00000272369.1	RP11-446N19.1	5.5	7.34e-08	6.71e-05	0.36	0.28	Itch intensity from mosquito bite;	chr12:46380988	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.93	rs7308910	ENSG00000257261.4	RP11-96H19.1	5.5	7.35e-08	6.71e-05	0.34	0.28	Itch intensity from mosquito bite;	chr12:46444459	chr12:46383679~46876159:+
STAD	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	5.5	7.35e-08	6.72e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
STAD	cis	rs8098244	0.603	rs3017550	ENSG00000267301.1	RPL23AP77	-5.5	7.36e-08	6.73e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696510	chr18:23709825~23710287:-
STAD	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	5.5	7.37e-08	6.73e-05	0.33	0.28	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
STAD	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	5.5	7.37e-08	6.73e-05	0.33	0.28	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
STAD	cis	rs6452524	0.836	rs2731852	ENSG00000249664.1	CTD-2227C6.2	-5.5	7.38e-08	6.74e-05	-0.36	-0.28	Hypertension (SNP x SNP interaction);	chr5:83212591	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.805	rs2731850	ENSG00000249664.1	CTD-2227C6.2	-5.5	7.38e-08	6.74e-05	-0.36	-0.28	Hypertension (SNP x SNP interaction);	chr5:83213024	chr5:83012285~83013109:-
STAD	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	5.5	7.38e-08	6.75e-05	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	5.5	7.4e-08	6.76e-05	0.29	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
STAD	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	5.5	7.4e-08	6.76e-05	0.36	0.28	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
STAD	cis	rs992157	0.56	rs6436047	ENSG00000237281.1	CATIP-AS2	-5.5	7.41e-08	6.77e-05	-0.27	-0.28	Colorectal cancer;	chr2:218244190	chr2:218326889~218357966:-
STAD	cis	rs1816752	0.837	rs7139748	ENSG00000273628.1	RP11-756A22.7	5.5	7.41e-08	6.77e-05	0.35	0.28	Obesity-related traits;	chr13:24411531	chr13:24933006~24936796:+
STAD	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	5.5	7.42e-08	6.78e-05	0.35	0.28	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
STAD	cis	rs1816752	1	rs1816752	ENSG00000273628.1	RP11-756A22.7	5.5	7.42e-08	6.78e-05	0.35	0.28	Obesity-related traits;	chr13:24406811	chr13:24933006~24936796:+
STAD	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	5.5	7.42e-08	6.78e-05	0.36	0.28	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
STAD	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-5.5	7.42e-08	6.78e-05	-0.29	-0.28	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
STAD	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	5.5	7.43e-08	6.78e-05	0.44	0.28	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
STAD	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	5.5	7.43e-08	6.79e-05	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
STAD	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-5.5	7.43e-08	6.79e-05	-0.24	-0.28	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
STAD	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	5.5	7.44e-08	6.79e-05	0.32	0.28	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	5.5	7.44e-08	6.79e-05	0.32	0.28	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
STAD	cis	rs240993	0.812	rs458806	ENSG00000230177.1	RP5-1112D6.4	-5.5	7.45e-08	6.8e-05	-0.3	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111354825	chr6:111277932~111278742:+
STAD	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	5.5	7.46e-08	6.81e-05	0.43	0.28	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
STAD	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	5.5	7.47e-08	6.81e-05	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
STAD	cis	rs1426063	0.858	rs11936768	ENSG00000248165.1	RP11-44F21.2	5.5	7.49e-08	6.83e-05	0.49	0.28	QT interval;	chr4:75084506	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.858	rs72662426	ENSG00000248165.1	RP11-44F21.2	5.5	7.49e-08	6.83e-05	0.49	0.28	QT interval;	chr4:75084828	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.858	rs6837969	ENSG00000248165.1	RP11-44F21.2	5.5	7.49e-08	6.83e-05	0.49	0.28	QT interval;	chr4:75085005	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.858	rs6843217	ENSG00000248165.1	RP11-44F21.2	5.5	7.49e-08	6.83e-05	0.49	0.28	QT interval;	chr4:75085201	chr4:74993877~75034824:-
STAD	cis	rs9907295	0.818	rs9303692	ENSG00000270894.1	AC015849.13	5.5	7.49e-08	6.83e-05	0.28	0.28	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35818399~35823713:+
STAD	cis	rs7829975	0.684	rs546603	ENSG00000253981.4	ALG1L13P	-5.5	7.49e-08	6.83e-05	-0.33	-0.28	Mood instability;	chr8:8738328	chr8:8236003~8244667:-
STAD	cis	rs9425766	0.54	rs2294492	ENSG00000227373.4	RP11-160H22.5	5.5	7.51e-08	6.85e-05	0.33	0.28	Life satisfaction;	chr1:174157884	chr1:174115300~174160004:-
STAD	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-5.5	7.52e-08	6.85e-05	-0.25	-0.28	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
STAD	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	5.5	7.52e-08	6.85e-05	0.33	0.28	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
STAD	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-5.5	7.52e-08	6.85e-05	-0.33	-0.28	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-5.5	7.54e-08	6.87e-05	-0.34	-0.28	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
STAD	cis	rs1056107	0.931	rs6575	ENSG00000225513.1	RP11-165N19.2	-5.5	7.54e-08	6.87e-05	-0.32	-0.28	Colorectal cancer;	chr9:112218687	chr9:112173522~112173971:-
STAD	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-5.5	7.54e-08	6.87e-05	-0.27	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
STAD	cis	rs858239	0.712	rs199650	ENSG00000226816.2	AC005082.12	-5.5	7.55e-08	6.88e-05	-0.35	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23206013~23208045:+
STAD	cis	rs453301	0.522	rs2929455	ENSG00000254340.1	RP11-10A14.3	-5.5	7.56e-08	6.89e-05	-0.36	-0.28	Joint mobility (Beighton score);	chr8:9225923	chr8:9141424~9145435:+
STAD	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-5.49	7.59e-08	6.92e-05	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
STAD	cis	rs9425766	0.64	rs10912734	ENSG00000227373.4	RP11-160H22.5	5.49	7.6e-08	6.92e-05	0.33	0.28	Life satisfaction;	chr1:174141977	chr1:174115300~174160004:-
STAD	cis	rs7487075	0.786	rs12298619	ENSG00000272369.1	RP11-446N19.1	5.49	7.61e-08	6.93e-05	0.37	0.28	Itch intensity from mosquito bite;	chr12:46279718	chr12:46537502~46652550:+
STAD	cis	rs875971	0.545	rs6979636	ENSG00000224316.1	RP11-479O9.2	5.49	7.61e-08	6.93e-05	0.32	0.28	Aortic root size;	chr7:66276638	chr7:65773620~65802067:+
STAD	cis	rs12699921	0.632	rs2140710	ENSG00000279048.1	RP11-511H23.2	-5.49	7.61e-08	6.93e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17855952	chr7:17940503~17942922:+
STAD	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	5.49	7.62e-08	6.94e-05	0.38	0.28	Height;	chr6:109469907	chr6:109382795~109383666:+
STAD	cis	rs950169	0.724	rs11632668	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84393989	chr15:85191438~85213905:+
STAD	cis	rs950169	0.881	rs34591918	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84396135	chr15:85191438~85213905:+
STAD	cis	rs950169	0.887	rs12903946	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84399732	chr15:85191438~85213905:+
STAD	cis	rs950169	0.887	rs62029593	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84400482	chr15:85191438~85213905:+
STAD	cis	rs950169	0.81	rs62029594	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84400554	chr15:85191438~85213905:+
STAD	cis	rs950169	0.881	rs62029596	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84400736	chr15:85191438~85213905:+
STAD	cis	rs950169	0.881	rs4081123	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84401537	chr15:85191438~85213905:+
STAD	cis	rs950169	0.881	rs62029599	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84401867	chr15:85191438~85213905:+
STAD	cis	rs950169	0.8	rs4099846	ENSG00000259295.5	CSPG4P12	5.49	7.63e-08	6.94e-05	0.42	0.28	Schizophrenia;	chr15:84402196	chr15:85191438~85213905:+
STAD	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	5.49	7.63e-08	6.95e-05	0.4	0.28	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
STAD	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-5.49	7.64e-08	6.96e-05	-0.33	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
STAD	cis	rs7487075	0.859	rs7974529	ENSG00000272369.1	RP11-446N19.1	5.49	7.65e-08	6.96e-05	0.34	0.28	Itch intensity from mosquito bite;	chr12:46357605	chr12:46537502~46652550:+
STAD	cis	rs7927771	0.524	rs1563821	ENSG00000280615.1	Y_RNA	5.49	7.65e-08	6.96e-05	0.29	0.28	Subjective well-being;	chr11:47735016	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs6485773	ENSG00000280615.1	Y_RNA	5.49	7.65e-08	6.96e-05	0.29	0.28	Subjective well-being;	chr11:47741957	chr11:47614898~47614994:-
STAD	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	5.49	7.66e-08	6.97e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	5.49	7.66e-08	6.97e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	5.49	7.66e-08	6.97e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	5.49	7.66e-08	6.97e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
STAD	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	5.49	7.66e-08	6.97e-05	0.23	0.28	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
STAD	cis	rs7124681	0.565	rs2904127	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47795738	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs11039402	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47804538	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs6485786	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47815856	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs11039415	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47824262	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7110300	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47826890	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7932703	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47748384	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10838758	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47749924	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.542	rs7108479	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47759908	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10838760	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47764862	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7111576	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47765893	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.507	rs7111606	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47765986	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs61895760	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47772986	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10838763	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47773250	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7114813	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47779549	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs12226431	ENSG00000280615.1	Y_RNA	5.49	7.66e-08	6.97e-05	0.29	0.28	Subjective well-being;	chr11:47784304	chr11:47614898~47614994:-
STAD	cis	rs10129255	0.957	rs10138532	ENSG00000280411.1	IGHV1-69-2	-5.49	7.68e-08	6.98e-05	-0.27	-0.28	Kawasaki disease;	chr14:106803901	chr14:106762092~106762588:-
STAD	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	5.49	7.68e-08	6.98e-05	0.33	0.28	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
STAD	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	5.49	7.68e-08	6.98e-05	0.33	0.28	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
STAD	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	5.49	7.68e-08	6.98e-05	0.29	0.28	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
STAD	cis	rs6782228	0.606	rs7650156	ENSG00000277250.1	Metazoa_SRP	-5.49	7.69e-08	6.99e-05	-0.3	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128673681~128674021:-
STAD	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-5.49	7.69e-08	6.99e-05	-0.29	-0.28	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
STAD	cis	rs516805	0.748	rs510471	ENSG00000279453.1	RP3-425C14.4	-5.49	7.7e-08	6.99e-05	-0.4	-0.28	Lymphocyte counts;	chr6:122391714	chr6:122436789~122439223:-
STAD	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-5.49	7.71e-08	7e-05	-0.36	-0.28	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
STAD	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	5.49	7.71e-08	7e-05	0.46	0.28	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
STAD	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	5.49	7.71e-08	7e-05	0.31	0.28	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
STAD	cis	rs6452524	0.935	rs7718284	ENSG00000243385.2	CTD-2110K23.1	-5.49	7.72e-08	7.01e-05	-0.31	-0.28	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83201229~83202141:+
STAD	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	5.49	7.72e-08	7.01e-05	0.36	0.28	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	5.49	7.72e-08	7.01e-05	0.36	0.28	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
STAD	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-5.49	7.74e-08	7.03e-05	-0.41	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
STAD	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	5.49	7.74e-08	7.03e-05	0.41	0.28	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
STAD	cis	rs7927771	0.542	rs7102205	ENSG00000280615.1	Y_RNA	5.49	7.75e-08	7.04e-05	0.29	0.28	Subjective well-being;	chr11:47723822	chr11:47614898~47614994:-
STAD	cis	rs12699921	0.632	rs2723497	ENSG00000279048.1	RP11-511H23.2	-5.49	7.76e-08	7.04e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17786204	chr7:17940503~17942922:+
STAD	cis	rs11638352	1	rs2412854	ENSG00000205771.5	CATSPER2P1	5.49	7.77e-08	7.05e-05	0.57	0.28	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44002274	chr15:43726918~43747094:-
STAD	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	5.49	7.77e-08	7.05e-05	0.35	0.28	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
STAD	cis	rs227275	0.525	rs7698608	ENSG00000230069.3	LRRC37A15P	-5.49	7.77e-08	7.05e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102727274~102730721:-
STAD	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	5.49	7.79e-08	7.07e-05	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
STAD	cis	rs12530	0.715	rs2294311	ENSG00000230736.2	RP1-149A16.3	-5.49	7.79e-08	7.07e-05	-0.37	-0.28	IgG glycosylation;	chr22:32397282	chr22:32376664~32384343:+
STAD	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	5.49	7.79e-08	7.07e-05	0.27	0.28	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
STAD	cis	rs7662987	0.793	rs28730602	ENSG00000272777.1	RP11-571L19.8	5.49	7.81e-08	7.08e-05	0.53	0.28	Smoking initiation;	chr4:99080531	chr4:99067256~99068125:-
STAD	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	5.49	7.81e-08	7.08e-05	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
STAD	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	5.49	7.81e-08	7.08e-05	0.28	0.28	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
STAD	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	5.49	7.81e-08	7.09e-05	0.28	0.28	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
STAD	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-5.49	7.83e-08	7.1e-05	-0.34	-0.28	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
STAD	cis	rs2337406	0.925	rs34064152	ENSG00000274576.2	IGHV2-70	-5.49	7.83e-08	7.1e-05	-0.39	-0.28	Alzheimer's disease (late onset);	chr14:106700364	chr14:106770577~106771020:-
STAD	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	5.49	7.83e-08	7.1e-05	0.41	0.28	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
STAD	cis	rs10978777	0.805	rs7035611	ENSG00000276883.1	AL137852.1	-5.49	7.83e-08	7.1e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107287547	chr9:107292369~107292456:-
STAD	cis	rs453301	0.686	rs7814328	ENSG00000254340.1	RP11-10A14.3	-5.49	7.83e-08	7.1e-05	-0.36	-0.28	Joint mobility (Beighton score);	chr8:9018719	chr8:9141424~9145435:+
STAD	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-5.49	7.84e-08	7.11e-05	-0.32	-0.28	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
STAD	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	5.49	7.85e-08	7.11e-05	0.29	0.28	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
STAD	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	5.49	7.85e-08	7.12e-05	0.35	0.28	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
STAD	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-5.49	7.86e-08	7.12e-05	-0.33	-0.28	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
STAD	cis	rs8040855	0.52	rs67613323	ENSG00000229212.6	RP11-561C5.4	5.49	7.86e-08	7.13e-05	0.42	0.28	Bulimia nervosa;	chr15:84986541	chr15:85205440~85234795:-
STAD	cis	rs1075265	0.597	rs11694711	ENSG00000235937.1	AC008280.1	5.49	7.86e-08	7.13e-05	0.25	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54029552~54030682:-
STAD	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	5.49	7.87e-08	7.13e-05	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
STAD	cis	rs3806843	0.966	rs2563262	ENSG00000202111.1	VTRNA1-2	5.49	7.87e-08	7.13e-05	0.28	0.28	Depressive symptoms (multi-trait analysis);	chr5:140758127	chr5:140718925~140719013:+
STAD	cis	rs7927771	0.524	rs12785949	ENSG00000280615.1	Y_RNA	5.49	7.88e-08	7.14e-05	0.29	0.28	Subjective well-being;	chr11:47708218	chr11:47614898~47614994:-
STAD	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-5.49	7.88e-08	7.14e-05	-0.29	-0.28	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-5.49	7.88e-08	7.14e-05	-0.29	-0.28	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
STAD	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-5.49	7.88e-08	7.14e-05	-0.29	-0.28	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	5.49	7.89e-08	7.15e-05	0.29	0.28	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
STAD	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	5.49	7.89e-08	7.15e-05	0.33	0.28	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
STAD	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	5.49	7.9e-08	7.15e-05	0.34	0.28	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
STAD	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-5.49	7.9e-08	7.15e-05	-0.32	-0.28	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
STAD	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	5.49	7.91e-08	7.17e-05	0.42	0.28	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
STAD	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	5.49	7.92e-08	7.17e-05	0.34	0.28	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
STAD	cis	rs11722779	0.901	rs28674656	ENSG00000230069.3	LRRC37A15P	-5.49	7.92e-08	7.17e-05	-0.31	-0.28	Schizophrenia;	chr4:102944396	chr4:102727274~102730721:-
STAD	cis	rs7083	0.653	rs573442	ENSG00000254851.1	RP11-109L13.1	5.49	7.93e-08	7.18e-05	0.33	0.28	Blood protein levels;	chr11:117307204	chr11:117135528~117138582:+
STAD	cis	rs4243830	0.85	rs6679649	ENSG00000229519.2	RP11-58A11.2	-5.49	7.93e-08	7.18e-05	-0.29	-0.28	Body mass index;	chr1:6546548	chr1:6547905~6548619:+
STAD	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	5.49	7.93e-08	7.18e-05	0.35	0.28	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
STAD	cis	rs12530	0.715	rs2294313	ENSG00000230736.2	RP1-149A16.3	-5.49	7.93e-08	7.18e-05	-0.37	-0.28	IgG glycosylation;	chr22:32398452	chr22:32376664~32384343:+
STAD	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	5.49	7.93e-08	7.18e-05	0.34	0.28	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
STAD	cis	rs9463078	0.546	rs9369529	ENSG00000219384.1	RP11-491H9.3	-5.49	7.94e-08	7.19e-05	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45036796	chr6:45158870~45159511:+
STAD	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	5.49	7.94e-08	7.19e-05	0.26	0.28	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
STAD	cis	rs10129255	0.957	rs10136560	ENSG00000280411.1	IGHV1-69-2	-5.49	7.96e-08	7.2e-05	-0.26	-0.28	Kawasaki disease;	chr14:106787630	chr14:106762092~106762588:-
STAD	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	5.49	7.96e-08	7.2e-05	0.3	0.28	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
STAD	cis	rs17301013	0.932	rs6425280	ENSG00000227373.4	RP11-160H22.5	5.49	7.97e-08	7.21e-05	0.33	0.28	Systemic lupus erythematosus;	chr1:174422186	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.932	rs6664764	ENSG00000227373.4	RP11-160H22.5	5.49	7.97e-08	7.21e-05	0.33	0.28	Systemic lupus erythematosus;	chr1:174443402	chr1:174115300~174160004:-
STAD	cis	rs12699921	0.632	rs4532510	ENSG00000279048.1	RP11-511H23.2	5.49	7.97e-08	7.21e-05	0.26	0.28	Fibrinogen levels;	chr7:17931601	chr7:17940503~17942922:+
STAD	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	5.49	7.97e-08	7.21e-05	0.38	0.28	Height;	chr6:109480428	chr6:109382795~109383666:+
STAD	cis	rs2980439	0.783	rs2955587	ENSG00000254340.1	RP11-10A14.3	5.49	7.98e-08	7.22e-05	0.34	0.28	Neuroticism;	chr8:8240557	chr8:9141424~9145435:+
STAD	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-5.49	7.99e-08	7.23e-05	-0.3	-0.28	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
STAD	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	5.48	8e-08	7.23e-05	0.49	0.28	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
STAD	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	5.48	8e-08	7.24e-05	0.31	0.28	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
STAD	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	5.48	8.01e-08	7.24e-05	0.36	0.28	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
STAD	cis	rs2412819	0.571	rs4644832	ENSG00000249839.1	AC011330.5	5.48	8.01e-08	7.24e-05	0.5	0.28	Lung cancer;	chr15:43792507	chr15:43663654~43684339:-
STAD	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-5.48	8.01e-08	7.24e-05	-0.6	-0.28	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
STAD	cis	rs228614	0.51	rs223451	ENSG00000230069.3	LRRC37A15P	-5.48	8.01e-08	7.25e-05	-0.31	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223450	ENSG00000230069.3	LRRC37A15P	-5.48	8.01e-08	7.25e-05	-0.31	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102727274~102730721:-
STAD	cis	rs1816752	0.819	rs6490917	ENSG00000273628.1	RP11-756A22.7	5.48	8.02e-08	7.25e-05	0.34	0.28	Obesity-related traits;	chr13:24423119	chr13:24933006~24936796:+
STAD	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	5.48	8.02e-08	7.25e-05	0.27	0.28	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
STAD	cis	rs227275	0.525	rs5028609	ENSG00000230069.3	LRRC37A15P	-5.48	8.03e-08	7.26e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs6815540	ENSG00000230069.3	LRRC37A15P	-5.48	8.03e-08	7.26e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs4698867	ENSG00000230069.3	LRRC37A15P	-5.48	8.03e-08	7.26e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102727274~102730721:-
STAD	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-5.48	8.04e-08	7.27e-05	-0.29	-0.28	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
STAD	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-5.48	8.05e-08	7.28e-05	-0.29	-0.28	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
STAD	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-5.48	8.05e-08	7.28e-05	-0.29	-0.28	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	5.48	8.05e-08	7.28e-05	0.29	0.28	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	5.48	8.05e-08	7.28e-05	0.29	0.28	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
STAD	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-5.48	8.06e-08	7.28e-05	-0.33	-0.28	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
STAD	cis	rs2439831	0.867	rs2470134	ENSG00000249839.1	AC011330.5	5.48	8.08e-08	7.3e-05	0.45	0.28	Lung cancer in ever smokers;	chr15:43557688	chr15:43663654~43684339:-
STAD	cis	rs7580658	0.637	rs3902960	ENSG00000200250.1	RNU6-1147P	5.48	8.09e-08	7.31e-05	0.27	0.28	Protein C levels;	chr2:127230666	chr2:127316873~127316979:+
STAD	cis	rs7924176	0.601	rs17676126	ENSG00000236900.1	TIMM9P1	-5.48	8.11e-08	7.32e-05	-0.29	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74145440	chr10:74344550~74344805:-
STAD	cis	rs2980439	0.607	rs2980419	ENSG00000173295.6	FAM86B3P	5.48	8.11e-08	7.32e-05	0.32	0.28	Neuroticism;	chr8:8256619	chr8:8228595~8244865:+
STAD	cis	rs611744	0.506	rs13280454	ENSG00000253754.1	RP11-35G22.1	-5.48	8.11e-08	7.32e-05	-0.25	-0.28	Dupuytren's disease;	chr8:108251011	chr8:108226200~108227544:+
STAD	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-5.48	8.11e-08	7.33e-05	-0.29	-0.28	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
STAD	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-5.48	8.11e-08	7.33e-05	-0.29	-0.28	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
STAD	cis	rs227275	0.525	rs7663876	ENSG00000230069.3	LRRC37A15P	-5.48	8.12e-08	7.33e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102727274~102730721:-
STAD	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	5.48	8.12e-08	7.33e-05	0.33	0.28	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
STAD	cis	rs4912314	0.903	rs1418978	ENSG00000236776.1	RPL21P23	-5.48	8.13e-08	7.34e-05	-0.35	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr1:56506052	chr1:56538452~56538911:+
STAD	cis	rs66887589	0.592	rs11731571	ENSG00000249244.1	RP11-548H18.2	5.48	8.14e-08	7.35e-05	0.35	0.28	Diastolic blood pressure;	chr4:119300030	chr4:119391831~119395335:-
STAD	cis	rs7829975	0.806	rs2428	ENSG00000254340.1	RP11-10A14.3	5.48	8.15e-08	7.35e-05	0.34	0.28	Mood instability;	chr8:8783635	chr8:9141424~9145435:+
STAD	cis	rs9463078	0.546	rs1284982	ENSG00000219384.1	RP11-491H9.3	5.48	8.17e-08	7.37e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45114084	chr6:45158870~45159511:+
STAD	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-5.48	8.18e-08	7.38e-05	-0.33	-0.28	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
STAD	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-5.48	8.18e-08	7.38e-05	-0.33	-0.28	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
STAD	cis	rs875971	0.545	rs1796217	ENSG00000224316.1	RP11-479O9.2	-5.48	8.18e-08	7.38e-05	-0.31	-0.28	Aortic root size;	chr7:66620931	chr7:65773620~65802067:+
STAD	cis	rs227275	0.525	rs1080081	ENSG00000230069.3	LRRC37A15P	-5.48	8.18e-08	7.38e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs4699049	ENSG00000230069.3	LRRC37A15P	-5.48	8.18e-08	7.38e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102727274~102730721:-
STAD	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28082231	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28082261	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28082984	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28083994	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28084025	chr6:28073316~28074233:+
STAD	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28085319	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28089816	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28090857	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28091439	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28091659	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28092227	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28093966	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28094014	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28096077	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	5.48	8.2e-08	7.4e-05	0.33	0.28	Depression;	chr6:28096855	chr6:28073316~28074233:+
STAD	cis	rs2436845	1	rs974759	ENSG00000253385.1	KB-1254G8.1	5.48	8.21e-08	7.41e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102825684	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.934	rs2256440	ENSG00000253385.1	KB-1254G8.1	5.48	8.21e-08	7.41e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102836035	chr8:102854455~102856075:+
STAD	cis	rs2436845	1	rs2436844	ENSG00000253385.1	KB-1254G8.1	5.48	8.21e-08	7.41e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102837864	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.966	rs2513898	ENSG00000253385.1	KB-1254G8.1	5.48	8.21e-08	7.41e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102838004	chr8:102854455~102856075:+
STAD	cis	rs17301013	0.932	rs2987869	ENSG00000227373.4	RP11-160H22.5	-5.48	8.22e-08	7.41e-05	-0.33	-0.28	Systemic lupus erythematosus;	chr1:174820269	chr1:174115300~174160004:-
STAD	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	5.48	8.22e-08	7.42e-05	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
STAD	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	5.48	8.24e-08	7.42e-05	0.28	0.28	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	5.48	8.24e-08	7.42e-05	0.28	0.28	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	5.48	8.24e-08	7.42e-05	0.28	0.28	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
STAD	cis	rs12922317	0.856	rs1703492	ENSG00000260224.1	UBL5P4	-5.48	8.24e-08	7.43e-05	-0.3	-0.28	Schizophrenia;	chr16:12043097	chr16:11968508~11968743:-
STAD	cis	rs8098244	0.638	rs1941516	ENSG00000267301.1	RPL23AP77	-5.48	8.25e-08	7.43e-05	-0.34	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23812603	chr18:23709825~23710287:-
STAD	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-5.48	8.26e-08	7.45e-05	-0.32	-0.28	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
STAD	cis	rs13113518	0.812	rs13107810	ENSG00000272969.1	RP11-528I4.2	5.48	8.27e-08	7.45e-05	0.36	0.28	Height;	chr4:55542243	chr4:55547112~55547889:+
STAD	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-5.48	8.28e-08	7.46e-05	-0.51	-0.28	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
STAD	cis	rs1799949	0.894	rs36062488	ENSG00000236383.6	LINC00854	5.48	8.28e-08	7.46e-05	0.22	0.28	Menopause (age at onset);	chr17:43185455	chr17:43216941~43305976:-
STAD	cis	rs9463078	0.546	rs4714836	ENSG00000219384.1	RP11-491H9.3	5.48	8.29e-08	7.47e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45052040	chr6:45158870~45159511:+
STAD	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-5.48	8.29e-08	7.47e-05	-0.29	-0.28	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
STAD	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	5.48	8.3e-08	7.47e-05	0.43	0.28	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
STAD	cis	rs12699921	0.632	rs2691629	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17785007	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2723500	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17785111	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2691630	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17785163	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2723499	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17785261	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2723498	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17785362	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2254176	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17785981	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2723496	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17786367	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.632	rs2691553	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17786658	chr7:17940503~17942922:+
STAD	cis	rs12699921	0.598	rs1852010	ENSG00000279048.1	RP11-511H23.2	-5.48	8.3e-08	7.48e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17786744	chr7:17940503~17942922:+
STAD	cis	rs8098244	0.756	rs1154229	ENSG00000267301.1	RPL23AP77	5.48	8.3e-08	7.48e-05	0.34	0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23902252	chr18:23709825~23710287:-
STAD	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-5.48	8.31e-08	7.48e-05	-0.29	-0.28	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
STAD	cis	rs17361889	0.613	rs4721484	ENSG00000224683.1	RPL36AP29	5.48	8.31e-08	7.48e-05	0.31	0.28	Pediatric bone mineral content (hip);	chr7:16242778	chr7:16208945~16209265:+
STAD	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	5.48	8.31e-08	7.49e-05	0.37	0.28	Height;	chr6:109581800	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	5.48	8.31e-08	7.49e-05	0.37	0.28	Height;	chr6:109613205	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	5.48	8.31e-08	7.49e-05	0.37	0.28	Height;	chr6:109617741	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	5.48	8.31e-08	7.49e-05	0.37	0.28	Height;	chr6:109619295	chr6:109382795~109383666:+
STAD	cis	rs12744310	1	rs12031169	ENSG00000235358.1	RP11-399E6.1	5.48	8.32e-08	7.49e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302579	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs35502198	ENSG00000235358.1	RP11-399E6.1	5.48	8.32e-08	7.49e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302869	chr1:41242373~41284861:+
STAD	cis	rs227275	0.525	rs223462	ENSG00000230069.3	LRRC37A15P	-5.48	8.32e-08	7.49e-05	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223459	ENSG00000230069.3	LRRC37A15P	-5.48	8.32e-08	7.49e-05	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102727274~102730721:-
STAD	cis	rs227275	0.588	rs223458	ENSG00000230069.3	LRRC37A15P	-5.48	8.32e-08	7.49e-05	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102727274~102730721:-
STAD	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-5.48	8.33e-08	7.5e-05	-0.24	-0.28	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
STAD	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-5.48	8.35e-08	7.51e-05	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
STAD	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	5.48	8.36e-08	7.52e-05	0.34	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
STAD	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	5.48	8.37e-08	7.52e-05	0.3	0.28	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
STAD	cis	rs875971	0.545	rs1796226	ENSG00000224316.1	RP11-479O9.2	5.48	8.37e-08	7.53e-05	0.31	0.28	Aortic root size;	chr7:66622723	chr7:65773620~65802067:+
STAD	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	5.48	8.38e-08	7.53e-05	0.32	0.28	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
STAD	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	5.48	8.38e-08	7.54e-05	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	5.48	8.38e-08	7.54e-05	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
STAD	cis	rs875971	0.545	rs1796219	ENSG00000224316.1	RP11-479O9.2	-5.48	8.39e-08	7.54e-05	-0.32	-0.28	Aortic root size;	chr7:66645977	chr7:65773620~65802067:+
STAD	cis	rs9307551	0.817	rs12500146	ENSG00000250334.4	LINC00989	-5.48	8.39e-08	7.54e-05	-0.34	-0.28	Refractive error;	chr4:79580002	chr4:79492416~79576460:+
STAD	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-5.48	8.4e-08	7.55e-05	-0.3	-0.28	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
STAD	cis	rs8005677	0.828	rs2295682	ENSG00000257285.4	RP11-298I3.1	5.48	8.4e-08	7.55e-05	0.34	0.28	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:22929609~22955562:+
STAD	cis	rs8040855	0.627	rs11637512	ENSG00000229212.6	RP11-561C5.4	5.48	8.41e-08	7.56e-05	0.41	0.28	Bulimia nervosa;	chr15:85105528	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.627	rs17541051	ENSG00000229212.6	RP11-561C5.4	5.48	8.41e-08	7.56e-05	0.41	0.28	Bulimia nervosa;	chr15:85106122	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.627	rs35668291	ENSG00000229212.6	RP11-561C5.4	5.48	8.41e-08	7.56e-05	0.41	0.28	Bulimia nervosa;	chr15:85109582	chr15:85205440~85234795:-
STAD	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-5.48	8.41e-08	7.56e-05	-0.29	-0.28	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-5.48	8.41e-08	7.56e-05	-0.29	-0.28	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-5.48	8.41e-08	7.56e-05	-0.29	-0.28	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
STAD	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	5.47	8.44e-08	7.58e-05	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
STAD	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-5.47	8.45e-08	7.59e-05	-0.29	-0.28	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
STAD	cis	rs7924176	0.502	rs1874151	ENSG00000236900.1	TIMM9P1	-5.47	8.45e-08	7.59e-05	-0.28	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74344550~74344805:-
STAD	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-5.47	8.46e-08	7.6e-05	-0.33	-0.28	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
STAD	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	5.47	8.46e-08	7.6e-05	0.33	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
STAD	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-5.47	8.47e-08	7.6e-05	-0.38	-0.28	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
STAD	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-5.47	8.47e-08	7.6e-05	-0.38	-0.28	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
STAD	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-5.47	8.47e-08	7.61e-05	-0.29	-0.28	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
STAD	cis	rs2412819	0.571	rs4923965	ENSG00000249839.1	AC011330.5	5.47	8.47e-08	7.61e-05	0.51	0.28	Lung cancer;	chr15:43790232	chr15:43663654~43684339:-
STAD	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-5.47	8.48e-08	7.61e-05	-0.43	-0.28	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
STAD	cis	rs7927771	0.832	rs11605672	ENSG00000280615.1	Y_RNA	-5.47	8.48e-08	7.61e-05	-0.28	-0.28	Subjective well-being;	chr11:47392182	chr11:47614898~47614994:-
STAD	cis	rs6452524	0.618	rs1478487	ENSG00000243385.2	CTD-2110K23.1	5.47	8.49e-08	7.62e-05	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83201229~83202141:+
STAD	cis	rs12744310	0.832	rs12027990	ENSG00000235358.1	RP11-399E6.1	5.47	8.49e-08	7.62e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298765	chr1:41242373~41284861:+
STAD	cis	rs4604732	0.678	rs74154674	ENSG00000227135.1	GCSAML-AS1	-5.47	8.49e-08	7.62e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462383	chr1:247524679~247526752:-
STAD	cis	rs17138358	0.506	rs2691623	ENSG00000279048.1	RP11-511H23.2	-5.47	8.5e-08	7.63e-05	-0.25	-0.28	HDL cholesterol levels;	chr7:17853953	chr7:17940503~17942922:+
STAD	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-5.47	8.5e-08	7.63e-05	-0.29	-0.28	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
STAD	cis	rs6782228	0.606	rs2811490	ENSG00000277250.1	Metazoa_SRP	-5.47	8.52e-08	7.64e-05	-0.29	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128673681~128674021:-
STAD	cis	rs7124681	0.584	rs4752792	ENSG00000280615.1	Y_RNA	-5.47	8.52e-08	7.65e-05	-0.28	-0.28	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47794150	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10838769	ENSG00000280615.1	Y_RNA	-5.47	8.52e-08	7.65e-05	-0.28	-0.28	Subjective well-being;	chr11:47803781	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs1563820	ENSG00000280615.1	Y_RNA	-5.47	8.52e-08	7.65e-05	-0.28	-0.28	Subjective well-being;	chr11:47811846	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs4752796	ENSG00000280615.1	Y_RNA	-5.47	8.52e-08	7.65e-05	-0.28	-0.28	Subjective well-being;	chr11:47820310	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7122182	ENSG00000280615.1	Y_RNA	-5.47	8.52e-08	7.65e-05	-0.28	-0.28	Subjective well-being;	chr11:47821581	chr11:47614898~47614994:-
STAD	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	5.47	8.52e-08	7.65e-05	0.41	0.28	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
STAD	cis	rs8040855	0.627	rs11632658	ENSG00000229212.6	RP11-561C5.4	-5.47	8.54e-08	7.66e-05	-0.41	-0.28	Bulimia nervosa;	chr15:85062982	chr15:85205440~85234795:-
STAD	cis	rs4713118	0.868	rs742047	ENSG00000280107.1	AL022393.9	-5.47	8.54e-08	7.66e-05	-0.39	-0.28	Parkinson's disease;	chr6:27771601	chr6:28170845~28172521:+
STAD	cis	rs516805	0.667	rs9482234	ENSG00000279453.1	RP3-425C14.4	5.47	8.55e-08	7.67e-05	0.38	0.28	Lymphocyte counts;	chr6:122313998	chr6:122436789~122439223:-
STAD	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-5.47	8.56e-08	7.68e-05	-0.54	-0.28	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
STAD	cis	rs2436845	0.9	rs2436857	ENSG00000253385.1	KB-1254G8.1	5.47	8.56e-08	7.68e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813236	chr8:102854455~102856075:+
STAD	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	5.47	8.58e-08	7.69e-05	0.32	0.28	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
STAD	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-5.47	8.58e-08	7.7e-05	-0.24	-0.28	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
STAD	cis	rs228614	0.51	rs223455	ENSG00000230069.3	LRRC37A15P	-5.47	8.59e-08	7.7e-05	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102727274~102730721:-
STAD	cis	rs10504130	0.569	rs10958305	ENSG00000272024.1	RP11-546K22.3	-5.47	8.59e-08	7.7e-05	-0.39	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs11784869	ENSG00000272024.1	RP11-546K22.3	-5.47	8.59e-08	7.7e-05	-0.39	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51950284~51950690:+
STAD	cis	rs12699921	0.599	rs998342	ENSG00000279048.1	RP11-511H23.2	-5.47	8.59e-08	7.7e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17785965	chr7:17940503~17942922:+
STAD	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	5.47	8.59e-08	7.7e-05	0.41	0.28	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
STAD	cis	rs1426063	0.858	rs10004802	ENSG00000248165.1	RP11-44F21.2	5.47	8.59e-08	7.71e-05	0.49	0.28	QT interval;	chr4:75084413	chr4:74993877~75034824:-
STAD	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-5.47	8.6e-08	7.71e-05	-0.33	-0.28	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
STAD	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-5.47	8.6e-08	7.71e-05	-0.33	-0.28	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
STAD	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-5.47	8.61e-08	7.71e-05	-0.29	-0.28	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
STAD	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-5.47	8.61e-08	7.71e-05	-0.29	-0.28	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-5.47	8.61e-08	7.71e-05	-0.29	-0.28	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-5.47	8.61e-08	7.71e-05	-0.29	-0.28	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
STAD	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-5.47	8.61e-08	7.71e-05	-0.29	-0.28	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
STAD	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-5.47	8.61e-08	7.71e-05	-0.29	-0.28	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
STAD	cis	rs12699921	0.598	rs1524775	ENSG00000279048.1	RP11-511H23.2	-5.47	8.61e-08	7.72e-05	-0.26	-0.28	Fibrinogen levels;	chr7:17896742	chr7:17940503~17942922:+
STAD	cis	rs2436845	1	rs2513935	ENSG00000253385.1	KB-1254G8.1	5.47	8.62e-08	7.72e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102832620	chr8:102854455~102856075:+
STAD	cis	rs611744	0.647	rs7016198	ENSG00000253754.1	RP11-35G22.1	-5.47	8.64e-08	7.74e-05	-0.25	-0.28	Dupuytren's disease;	chr8:108250523	chr8:108226200~108227544:+
STAD	cis	rs611744	0.529	rs13282825	ENSG00000253754.1	RP11-35G22.1	-5.47	8.64e-08	7.74e-05	-0.25	-0.28	Dupuytren's disease;	chr8:108251008	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs1584373	ENSG00000253754.1	RP11-35G22.1	-5.47	8.64e-08	7.74e-05	-0.25	-0.28	Dupuytren's disease;	chr8:108251170	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs2859813	ENSG00000253754.1	RP11-35G22.1	-5.47	8.64e-08	7.74e-05	-0.25	-0.28	Dupuytren's disease;	chr8:108251268	chr8:108226200~108227544:+
STAD	cis	rs2237234	0.542	rs7755997	ENSG00000243307.2	POM121L6P	5.47	8.65e-08	7.75e-05	0.27	0.28	Autism spectrum disorder or schizophrenia;	chr6:26482820	chr6:26896952~26898777:+
STAD	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	5.47	8.65e-08	7.75e-05	0.75	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
STAD	cis	rs1816752	0.905	rs7995492	ENSG00000273628.1	RP11-756A22.7	5.47	8.66e-08	7.75e-05	0.34	0.28	Obesity-related traits;	chr13:24438885	chr13:24933006~24936796:+
STAD	cis	rs7487075	0.718	rs4768735	ENSG00000272369.1	RP11-446N19.1	-5.47	8.66e-08	7.75e-05	-0.34	-0.28	Itch intensity from mosquito bite;	chr12:46550351	chr12:46537502~46652550:+
STAD	cis	rs3758911	0.894	rs10890717	ENSG00000261098.1	RP11-819C21.1	-5.47	8.68e-08	7.78e-05	-0.26	-0.28	Coronary artery disease;	chr11:107324666	chr11:107312132~107316271:-
STAD	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-5.47	8.69e-08	7.78e-05	-0.35	-0.28	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
STAD	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	5.47	8.69e-08	7.78e-05	0.35	0.28	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
STAD	cis	rs7474896	0.616	rs2474561	ENSG00000099251.13	HSD17B7P2	5.47	8.71e-08	7.79e-05	0.37	0.28	Obesity (extreme);	chr10:38084616	chr10:38356380~38378505:+
STAD	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	5.47	8.71e-08	7.8e-05	0.3	0.28	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
STAD	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	5.47	8.71e-08	7.8e-05	0.31	0.28	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
STAD	cis	rs4604732	0.631	rs7546720	ENSG00000227135.1	GCSAML-AS1	-5.47	8.71e-08	7.8e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463927	chr1:247524679~247526752:-
STAD	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-5.47	8.72e-08	7.81e-05	-0.33	-0.28	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
STAD	cis	rs9307551	0.817	rs11098764	ENSG00000250334.4	LINC00989	-5.47	8.73e-08	7.82e-05	-0.34	-0.28	Refractive error;	chr4:79578860	chr4:79492416~79576460:+
STAD	cis	rs2436845	1	rs2570942	ENSG00000253385.1	KB-1254G8.1	5.47	8.73e-08	7.82e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848812	chr8:102854455~102856075:+
STAD	cis	rs950169	0.84	rs62029595	ENSG00000259295.5	CSPG4P12	5.47	8.74e-08	7.82e-05	0.42	0.28	Schizophrenia;	chr15:84400603	chr15:85191438~85213905:+
STAD	cis	rs606458	0.92	rs477549	ENSG00000269038.1	AP001462.6	-5.47	8.74e-08	7.82e-05	-0.36	-0.28	Urate levels;	chr11:64759608	chr11:64778954~64779405:+
STAD	cis	rs3806843	0.868	rs2563291	ENSG00000202111.1	VTRNA1-2	5.47	8.75e-08	7.83e-05	0.28	0.28	Depressive symptoms (multi-trait analysis);	chr5:140740014	chr5:140718925~140719013:+
STAD	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	5.47	8.75e-08	7.83e-05	0.32	0.28	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
STAD	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	5.47	8.76e-08	7.83e-05	0.38	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
STAD	cis	rs992157	0.866	rs2292554	ENSG00000237281.1	CATIP-AS2	5.47	8.77e-08	7.84e-05	0.29	0.28	Colorectal cancer;	chr2:218282145	chr2:218326889~218357966:-
STAD	cis	rs12744310	1	rs12035012	ENSG00000235358.1	RP11-399E6.1	5.47	8.77e-08	7.84e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41284976	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs1343775	ENSG00000235358.1	RP11-399E6.1	5.47	8.77e-08	7.84e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292321	chr1:41242373~41284861:+
STAD	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	5.47	8.77e-08	7.85e-05	0.29	0.28	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
STAD	cis	rs7083	1	rs588763	ENSG00000254851.1	RP11-109L13.1	5.47	8.79e-08	7.86e-05	0.32	0.28	Blood protein levels;	chr11:117246065	chr11:117135528~117138582:+
STAD	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	5.47	8.79e-08	7.86e-05	0.33	0.28	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	5.47	8.79e-08	7.86e-05	0.33	0.28	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
STAD	cis	rs1426063	0.858	rs11931653	ENSG00000248165.1	RP11-44F21.2	5.47	8.79e-08	7.86e-05	0.49	0.28	QT interval;	chr4:75080856	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.858	rs55775471	ENSG00000248165.1	RP11-44F21.2	5.47	8.79e-08	7.86e-05	0.49	0.28	QT interval;	chr4:75081074	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.858	rs9990627	ENSG00000248165.1	RP11-44F21.2	5.47	8.79e-08	7.86e-05	0.49	0.28	QT interval;	chr4:75081244	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.858	rs10026994	ENSG00000248165.1	RP11-44F21.2	5.47	8.79e-08	7.86e-05	0.49	0.28	QT interval;	chr4:75081551	chr4:74993877~75034824:-
STAD	cis	rs1426063	0.858	rs6830936	ENSG00000248165.1	RP11-44F21.2	5.47	8.79e-08	7.86e-05	0.49	0.28	QT interval;	chr4:75083952	chr4:74993877~75034824:-
STAD	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-5.47	8.8e-08	7.87e-05	-0.3	-0.28	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
STAD	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-5.47	8.8e-08	7.87e-05	-0.3	-0.28	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
STAD	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	5.47	8.81e-08	7.88e-05	0.31	0.28	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
STAD	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	5.47	8.82e-08	7.88e-05	0.48	0.28	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
STAD	cis	rs2439831	0.867	rs2260160	ENSG00000275601.1	AC011330.13	-5.47	8.83e-08	7.89e-05	-0.37	-0.28	Lung cancer in ever smokers;	chr15:43603445	chr15:43642389~43643023:-
STAD	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	5.47	8.84e-08	7.9e-05	0.37	0.28	Height;	chr6:109530435	chr6:109382795~109383666:+
STAD	cis	rs9425766	0.679	rs2064149	ENSG00000227373.4	RP11-160H22.5	5.47	8.84e-08	7.9e-05	0.33	0.28	Life satisfaction;	chr1:174255856	chr1:174115300~174160004:-
STAD	cis	rs9307551	0.817	rs11098766	ENSG00000250334.4	LINC00989	-5.47	8.85e-08	7.91e-05	-0.33	-0.28	Refractive error;	chr4:79579266	chr4:79492416~79576460:+
STAD	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-5.47	8.85e-08	7.91e-05	-0.34	-0.28	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
STAD	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-5.47	8.86e-08	7.91e-05	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.925	rs11851094	ENSG00000211972.2	IGHV3-66	5.47	8.87e-08	7.92e-05	0.3	0.28	Alzheimer's disease (late onset);	chr14:106688967	chr14:106675017~106675544:-
STAD	cis	rs7932354	0.682	rs7118404	ENSG00000271350.1	CTD-2384B9.1	-5.47	8.87e-08	7.92e-05	-0.34	-0.28	Bone mineral density (hip);Bone mineral density;	chr11:46887179	chr11:47041027~47041945:-
STAD	cis	rs1153858	1	rs11858495	ENSG00000259433.2	CTD-2651B20.4	5.46	8.88e-08	7.92e-05	0.32	0.28	Homoarginine levels;	chr15:45345464	chr15:45330209~45332634:-
STAD	cis	rs3806843	0.648	rs702399	ENSG00000202111.1	VTRNA1-2	5.46	8.88e-08	7.93e-05	0.28	0.28	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr5:140718925~140719013:+
STAD	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	5.46	8.89e-08	7.93e-05	0.29	0.28	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	5.46	8.89e-08	7.93e-05	0.29	0.28	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
STAD	cis	rs728616	0.614	rs35193855	ENSG00000225484.5	NUTM2B-AS1	-5.46	8.9e-08	7.94e-05	-0.54	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028739	chr10:79663088~79826594:-
STAD	cis	rs1799949	0.93	rs34210004	ENSG00000236383.6	LINC00854	-5.46	8.9e-08	7.94e-05	-0.23	-0.28	Menopause (age at onset);	chr17:43218318	chr17:43216941~43305976:-
STAD	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	5.46	8.91e-08	7.95e-05	0.3	0.28	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
STAD	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-5.46	8.92e-08	7.95e-05	-0.4	-0.28	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
STAD	cis	rs7637701	0.818	rs10936038	ENSG00000240875.4	LINC00886	-5.46	8.92e-08	7.95e-05	-0.34	-0.28	Breast cancer;	chr3:156814877	chr3:156747346~156817062:-
STAD	cis	rs7637701	0.818	rs11711674	ENSG00000240875.4	LINC00886	-5.46	8.92e-08	7.95e-05	-0.34	-0.28	Breast cancer;	chr3:156815164	chr3:156747346~156817062:-
STAD	cis	rs7637701	0.818	rs1560415	ENSG00000240875.4	LINC00886	-5.46	8.92e-08	7.95e-05	-0.34	-0.28	Breast cancer;	chr3:156819569	chr3:156747346~156817062:-
STAD	cis	rs7637701	0.818	rs1560416	ENSG00000240875.4	LINC00886	-5.46	8.92e-08	7.95e-05	-0.34	-0.28	Breast cancer;	chr3:156819630	chr3:156747346~156817062:-
STAD	cis	rs7637701	0.818	rs9837271	ENSG00000240875.4	LINC00886	-5.46	8.92e-08	7.95e-05	-0.34	-0.28	Breast cancer;	chr3:156820949	chr3:156747346~156817062:-
STAD	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-5.46	8.92e-08	7.95e-05	-0.28	-0.28	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
STAD	cis	rs7829975	0.777	rs486781	ENSG00000254340.1	RP11-10A14.3	-5.46	8.93e-08	7.96e-05	-0.33	-0.28	Mood instability;	chr8:8782230	chr8:9141424~9145435:+
STAD	cis	rs13113518	0.812	rs3805153	ENSG00000272969.1	RP11-528I4.2	5.46	8.93e-08	7.96e-05	0.36	0.28	Height;	chr4:55493557	chr4:55547112~55547889:+
STAD	cis	rs7829975	0.582	rs448231	ENSG00000254340.1	RP11-10A14.3	-5.46	8.94e-08	7.97e-05	-0.34	-0.28	Mood instability;	chr8:8932549	chr8:9141424~9145435:+
STAD	cis	rs2948294	0.524	rs13270062	ENSG00000253981.4	ALG1L13P	5.46	8.94e-08	7.97e-05	0.35	0.28	Red cell distribution width;	chr8:8255128	chr8:8236003~8244667:-
STAD	cis	rs7107356	1	rs7107356	ENSG00000280615.1	Y_RNA	5.46	8.96e-08	7.98e-05	0.28	0.28	Neuroticism (multi-trait analysis);Neuroticism;	chr11:47654618	chr11:47614898~47614994:-
STAD	cis	rs4604732	0.527	rs7539082	ENSG00000227135.1	GCSAML-AS1	-5.46	8.96e-08	7.99e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463958	chr1:247524679~247526752:-
STAD	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-5.46	8.96e-08	7.99e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
STAD	cis	rs8040855	0.547	rs17611171	ENSG00000229212.6	RP11-561C5.4	5.46	8.96e-08	7.99e-05	0.42	0.28	Bulimia nervosa;	chr15:85029468	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.575	rs12912860	ENSG00000229212.6	RP11-561C5.4	5.46	8.96e-08	7.99e-05	0.42	0.28	Bulimia nervosa;	chr15:85030267	chr15:85205440~85234795:-
STAD	cis	rs9326248	0.53	rs6589576	ENSG00000280143.1	AP000892.6	-5.46	8.97e-08	7.99e-05	-0.29	-0.28	Blood protein levels;	chr11:116865072	chr11:117204967~117210292:+
STAD	cis	rs9425766	0.679	rs9787001	ENSG00000227373.4	RP11-160H22.5	5.46	8.97e-08	8e-05	0.33	0.28	Life satisfaction;	chr1:174222556	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs972361	ENSG00000227373.4	RP11-160H22.5	5.46	8.97e-08	8e-05	0.33	0.28	Life satisfaction;	chr1:174228270	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs6667267	ENSG00000227373.4	RP11-160H22.5	5.46	8.97e-08	8e-05	0.33	0.28	Life satisfaction;	chr1:174243623	chr1:174115300~174160004:-
STAD	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	5.46	8.98e-08	8e-05	0.4	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
STAD	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-5.46	8.99e-08	8.01e-05	-0.41	-0.28	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
STAD	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	5.46	9.01e-08	8.02e-05	0.4	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
STAD	cis	rs6142102	0.923	rs6057961	ENSG00000275784.1	RP5-1125A11.6	-5.46	9.02e-08	8.03e-05	-0.29	-0.28	Skin pigmentation;	chr20:33986005	chr20:33989480~33991818:-
STAD	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-5.46	9.02e-08	8.03e-05	-0.31	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
STAD	cis	rs7487075	0.786	rs2172398	ENSG00000272369.1	RP11-446N19.1	5.46	9.02e-08	8.04e-05	0.34	0.28	Itch intensity from mosquito bite;	chr12:46278788	chr12:46537502~46652550:+
STAD	cis	rs7760535	0.794	rs3851225	ENSG00000230177.1	RP5-1112D6.4	-5.46	9.02e-08	8.04e-05	-0.26	-0.28	Metabolic traits;	chr6:111503929	chr6:111277932~111278742:+
STAD	cis	rs2436845	1	rs2436845	ENSG00000253385.1	KB-1254G8.1	5.46	9.03e-08	8.04e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102840179	chr8:102854455~102856075:+
STAD	cis	rs2436845	1	rs2436846	ENSG00000253385.1	KB-1254G8.1	5.46	9.03e-08	8.04e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102840181	chr8:102854455~102856075:+
STAD	cis	rs2436845	1	rs2513913	ENSG00000253385.1	KB-1254G8.1	5.46	9.03e-08	8.04e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102842878	chr8:102854455~102856075:+
STAD	cis	rs2436845	1	rs2513921	ENSG00000253385.1	KB-1254G8.1	5.46	9.04e-08	8.05e-05	0.3	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102818167	chr8:102854455~102856075:+
STAD	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-5.46	9.05e-08	8.06e-05	-0.29	-0.28	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
STAD	cis	rs11722779	0.658	rs6533044	ENSG00000230069.3	LRRC37A15P	-5.46	9.05e-08	8.06e-05	-0.31	-0.28	Schizophrenia;	chr4:102965261	chr4:102727274~102730721:-
STAD	cis	rs240993	0.812	rs9487668	ENSG00000230177.1	RP5-1112D6.4	5.46	9.06e-08	8.07e-05	0.29	0.28	Inflammatory skin disease;Psoriasis;	chr6:111553466	chr6:111277932~111278742:+
STAD	cis	rs12699921	0.632	rs2103144	ENSG00000279048.1	RP11-511H23.2	-5.46	9.07e-08	8.07e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17900529	chr7:17940503~17942922:+
STAD	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	5.46	9.08e-08	8.08e-05	0.35	0.28	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
STAD	cis	rs1816752	1	rs9511265	ENSG00000273628.1	RP11-756A22.7	5.46	9.09e-08	8.08e-05	0.35	0.28	Obesity-related traits;	chr13:24438221	chr13:24933006~24936796:+
STAD	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-5.46	9.09e-08	8.09e-05	-0.29	-0.28	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
STAD	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-5.46	9.1e-08	8.09e-05	-0.35	-0.28	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
STAD	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-5.46	9.1e-08	8.09e-05	-0.35	-0.28	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
STAD	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-5.46	9.1e-08	8.09e-05	-0.33	-0.28	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
STAD	cis	rs1816752	0.905	rs9511264	ENSG00000273628.1	RP11-756A22.7	-5.46	9.1e-08	8.09e-05	-0.34	-0.28	Obesity-related traits;	chr13:24438079	chr13:24933006~24936796:+
STAD	cis	rs12699921	0.632	rs2691555	ENSG00000279048.1	RP11-511H23.2	-5.46	9.14e-08	8.12e-05	-0.25	-0.28	Fibrinogen levels;	chr7:17898660	chr7:17940503~17942922:+
STAD	cis	rs7829975	0.567	rs6601273	ENSG00000254340.1	RP11-10A14.3	-5.46	9.15e-08	8.12e-05	-0.35	-0.28	Mood instability;	chr8:8939009	chr8:9141424~9145435:+
STAD	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	5.46	9.15e-08	8.13e-05	0.43	0.28	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
STAD	cis	rs9425766	0.679	rs12079062	ENSG00000227373.4	RP11-160H22.5	5.46	9.15e-08	8.13e-05	0.33	0.28	Life satisfaction;	chr1:174110446	chr1:174115300~174160004:-
STAD	cis	rs721917	0.811	rs2256462	ENSG00000225484.5	NUTM2B-AS1	-5.46	9.17e-08	8.14e-05	-0.34	-0.28	Chronic obstructive pulmonary disease;	chr10:79925837	chr10:79663088~79826594:-
STAD	cis	rs7487075	0.751	rs7310869	ENSG00000272369.1	RP11-446N19.1	5.46	9.17e-08	8.14e-05	0.34	0.28	Itch intensity from mosquito bite;	chr12:46271603	chr12:46537502~46652550:+
STAD	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	5.46	9.18e-08	8.15e-05	0.31	0.28	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
STAD	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	5.46	9.19e-08	8.16e-05	0.36	0.28	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
STAD	cis	rs9463078	0.546	rs1284973	ENSG00000219384.1	RP11-491H9.3	5.46	9.19e-08	8.16e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45110426	chr6:45158870~45159511:+
STAD	cis	rs2283792	0.871	rs8136867	ENSG00000228050.1	TOP3BP1	5.46	9.2e-08	8.16e-05	0.32	0.28	Multiple sclerosis;	chr22:21850504	chr22:22223187~22224566:-
STAD	cis	rs1799949	0.93	rs35292991	ENSG00000236383.6	LINC00854	-5.46	9.21e-08	8.17e-05	-0.23	-0.28	Menopause (age at onset);	chr17:43181999	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs11658499	ENSG00000236383.6	LINC00854	-5.46	9.21e-08	8.17e-05	-0.23	-0.28	Menopause (age at onset);	chr17:43182732	chr17:43216941~43305976:-
STAD	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-5.46	9.22e-08	8.18e-05	-0.3	-0.28	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
STAD	cis	rs3136516	0.504	rs7925678	ENSG00000271350.1	CTD-2384B9.1	-5.46	9.23e-08	8.19e-05	-0.34	-0.28	Venous thromboembolism;	chr11:46549309	chr11:47041027~47041945:-
STAD	cis	rs556990	0.57	rs5960	ENSG00000269125.1	RP11-98F14.11	5.46	9.24e-08	8.19e-05	0.35	0.28	Blood protein levels;	chr13:113147423	chr13:113165002~113165183:-
STAD	cis	rs2283792	0.967	rs5999550	ENSG00000228050.1	TOP3BP1	5.46	9.25e-08	8.2e-05	0.32	0.28	Multiple sclerosis;	chr22:21796997	chr22:22223187~22224566:-
STAD	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	5.46	9.26e-08	8.21e-05	0.32	0.28	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
STAD	cis	rs4927850	1	rs10881563	ENSG00000185485.13	SDHAP1	5.46	9.26e-08	8.21e-05	0.28	0.28	Pancreatic cancer;	chr3:196023354	chr3:195959748~195990318:-
STAD	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-5.46	9.27e-08	8.22e-05	-0.41	-0.28	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
STAD	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	5.46	9.27e-08	8.22e-05	0.36	0.28	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
STAD	cis	rs7487075	0.558	rs7959095	ENSG00000257261.4	RP11-96H19.1	5.46	9.27e-08	8.22e-05	0.34	0.28	Itch intensity from mosquito bite;	chr12:46239545	chr12:46383679~46876159:+
STAD	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-5.46	9.28e-08	8.23e-05	-0.24	-0.28	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
STAD	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	5.46	9.29e-08	8.24e-05	0.29	0.28	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
STAD	cis	rs606458	1	rs606458	ENSG00000269038.1	AP001462.6	5.46	9.3e-08	8.24e-05	0.37	0.28	Urate levels;	chr11:64778919	chr11:64778954~64779405:+
STAD	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	5.46	9.3e-08	8.24e-05	0.43	0.28	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
STAD	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	5.46	9.3e-08	8.24e-05	0.43	0.28	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
STAD	cis	rs6452524	0.618	rs4266384	ENSG00000243385.2	CTD-2110K23.1	5.46	9.3e-08	8.24e-05	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83201229~83202141:+
STAD	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	5.46	9.31e-08	8.25e-05	0.34	0.28	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
STAD	cis	rs875971	0.862	rs9791712	ENSG00000236529.1	RP13-254B10.1	-5.46	9.31e-08	8.25e-05	-0.29	-0.28	Aortic root size;	chr7:66640176	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs9791713	ENSG00000236529.1	RP13-254B10.1	-5.46	9.31e-08	8.25e-05	-0.29	-0.28	Aortic root size;	chr7:66640211	chr7:65840212~65840596:+
STAD	cis	rs9425766	0.679	rs2860846	ENSG00000227373.4	RP11-160H22.5	5.46	9.31e-08	8.25e-05	0.33	0.28	Life satisfaction;	chr1:174106786	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs2860847	ENSG00000227373.4	RP11-160H22.5	5.46	9.31e-08	8.25e-05	0.33	0.28	Life satisfaction;	chr1:174106787	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs6672986	ENSG00000227373.4	RP11-160H22.5	5.46	9.31e-08	8.25e-05	0.33	0.28	Life satisfaction;	chr1:174107726	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs7533430	ENSG00000227373.4	RP11-160H22.5	5.46	9.31e-08	8.25e-05	0.33	0.28	Life satisfaction;	chr1:174109279	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs7526024	ENSG00000227373.4	RP11-160H22.5	5.46	9.31e-08	8.25e-05	0.33	0.28	Life satisfaction;	chr1:174109722	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs12079063	ENSG00000227373.4	RP11-160H22.5	5.46	9.31e-08	8.25e-05	0.33	0.28	Life satisfaction;	chr1:174110447	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs12094341	ENSG00000227373.4	RP11-160H22.5	5.46	9.31e-08	8.25e-05	0.33	0.28	Life satisfaction;	chr1:174110562	chr1:174115300~174160004:-
STAD	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-5.46	9.32e-08	8.25e-05	-0.29	-0.28	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
STAD	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	5.46	9.32e-08	8.26e-05	0.43	0.28	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
STAD	cis	rs6142102	0.923	rs2268078	ENSG00000275784.1	RP5-1125A11.6	-5.46	9.33e-08	8.26e-05	-0.29	-0.28	Skin pigmentation;	chr20:34008898	chr20:33989480~33991818:-
STAD	cis	rs1426063	0.858	rs10004802	ENSG00000249717.1	RP11-44F21.3	5.46	9.33e-08	8.26e-05	0.49	0.28	QT interval;	chr4:75084413	chr4:74955974~74970362:-
STAD	cis	rs2436845	0.934	rs6921	ENSG00000253385.1	KB-1254G8.1	5.45	9.34e-08	8.27e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102826648	chr8:102854455~102856075:+
STAD	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-5.45	9.35e-08	8.28e-05	-0.29	-0.28	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
STAD	cis	rs1862618	0.671	rs2591968	ENSG00000271828.1	CTD-2310F14.1	5.45	9.35e-08	8.28e-05	0.34	0.28	Initial pursuit acceleration;	chr5:56937714	chr5:56927874~56929573:+
STAD	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-5.45	9.35e-08	8.28e-05	-0.31	-0.28	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
STAD	cis	rs1426063	0.858	rs11936768	ENSG00000249717.1	RP11-44F21.3	5.45	9.36e-08	8.29e-05	0.49	0.28	QT interval;	chr4:75084506	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.858	rs72662426	ENSG00000249717.1	RP11-44F21.3	5.45	9.36e-08	8.29e-05	0.49	0.28	QT interval;	chr4:75084828	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.858	rs6837969	ENSG00000249717.1	RP11-44F21.3	5.45	9.36e-08	8.29e-05	0.49	0.28	QT interval;	chr4:75085005	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.858	rs6843217	ENSG00000249717.1	RP11-44F21.3	5.45	9.36e-08	8.29e-05	0.49	0.28	QT interval;	chr4:75085201	chr4:74955974~74970362:-
STAD	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-5.45	9.36e-08	8.29e-05	-0.37	-0.28	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
STAD	cis	rs12699921	0.632	rs1830006	ENSG00000279048.1	RP11-511H23.2	-5.45	9.38e-08	8.3e-05	-0.26	-0.28	Fibrinogen levels;	chr7:17788261	chr7:17940503~17942922:+
STAD	cis	rs240993	0.812	rs9387013	ENSG00000230177.1	RP5-1112D6.4	5.45	9.38e-08	8.3e-05	0.29	0.28	Inflammatory skin disease;Psoriasis;	chr6:111512517	chr6:111277932~111278742:+
STAD	cis	rs8067354	0.609	rs1292066	ENSG00000266701.1	AC005702.4	5.45	9.38e-08	8.3e-05	0.39	0.28	Hemoglobin concentration;	chr17:59854953	chr17:60042546~60042627:-
STAD	cis	rs9467773	0.935	rs4573	ENSG00000243307.2	POM121L6P	5.45	9.39e-08	8.31e-05	0.27	0.28	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26896952~26898777:+
STAD	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	5.45	9.41e-08	8.32e-05	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
STAD	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	5.45	9.42e-08	8.33e-05	0.43	0.28	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
STAD	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-5.45	9.43e-08	8.34e-05	-0.27	-0.28	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
STAD	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	5.45	9.43e-08	8.34e-05	0.35	0.28	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
STAD	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-5.45	9.44e-08	8.35e-05	-0.3	-0.28	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
STAD	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	5.45	9.44e-08	8.35e-05	0.37	0.28	Height;	chr6:109656105	chr6:109382795~109383666:+
STAD	cis	rs9425766	0.679	rs57919173	ENSG00000227373.4	RP11-160H22.5	5.45	9.44e-08	8.35e-05	0.33	0.28	Life satisfaction;	chr1:174159856	chr1:174115300~174160004:-
STAD	cis	rs4604732	0.578	rs12036417	ENSG00000227135.1	GCSAML-AS1	-5.45	9.46e-08	8.37e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461503	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs12039642	ENSG00000227135.1	GCSAML-AS1	-5.45	9.46e-08	8.37e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461596	chr1:247524679~247526752:-
STAD	cis	rs1729407	0.649	rs2849176	ENSG00000280143.1	AP000892.6	-5.45	9.46e-08	8.37e-05	-0.2	-0.28	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117204967~117210292:+
STAD	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-5.45	9.47e-08	8.37e-05	-0.28	-0.28	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-5.45	9.47e-08	8.37e-05	-0.28	-0.28	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
STAD	cis	rs728616	0.764	rs12413678	ENSG00000225484.5	NUTM2B-AS1	-5.45	9.49e-08	8.39e-05	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927343	chr10:79663088~79826594:-
STAD	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-5.45	9.52e-08	8.41e-05	-0.28	-0.28	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
STAD	cis	rs13113518	0.812	rs1522114	ENSG00000272969.1	RP11-528I4.2	5.45	9.53e-08	8.42e-05	0.36	0.28	Height;	chr4:55489895	chr4:55547112~55547889:+
STAD	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	5.45	9.53e-08	8.43e-05	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
STAD	cis	rs1075265	0.633	rs7591431	ENSG00000235937.1	AC008280.1	5.45	9.54e-08	8.43e-05	0.26	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54029552~54030682:-
STAD	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-5.45	9.54e-08	8.43e-05	-0.34	-0.28	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
STAD	cis	rs7733403	1	rs7733403	ENSG00000202111.1	VTRNA1-2	-5.45	9.54e-08	8.43e-05	-0.28	-0.28	Schizophrenia;	chr5:140774630	chr5:140718925~140719013:+
STAD	cis	rs2436845	0.934	rs1991927	ENSG00000253385.1	KB-1254G8.1	5.45	9.57e-08	8.46e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102846520	chr8:102854455~102856075:+
STAD	cis	rs6686842	0.689	rs2885697	ENSG00000235358.1	RP11-399E6.1	-5.45	9.58e-08	8.46e-05	-0.32	-0.28	Height;	chr1:41078607	chr1:41242373~41284861:+
STAD	cis	rs2337406	1	rs11849532	ENSG00000211972.2	IGHV3-66	5.45	9.6e-08	8.48e-05	0.31	0.28	Alzheimer's disease (late onset);	chr14:106669877	chr14:106675017~106675544:-
STAD	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	5.45	9.6e-08	8.48e-05	0.31	0.28	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
STAD	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	5.45	9.61e-08	8.49e-05	0.36	0.28	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	5.45	9.61e-08	8.49e-05	0.36	0.28	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	5.45	9.61e-08	8.49e-05	0.36	0.28	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
STAD	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-5.45	9.62e-08	8.49e-05	-0.4	-0.28	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
STAD	cis	rs7927771	0.524	rs7942074	ENSG00000280615.1	Y_RNA	5.45	9.63e-08	8.5e-05	0.29	0.28	Subjective well-being;	chr11:47698957	chr11:47614898~47614994:-
STAD	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-5.45	9.65e-08	8.52e-05	-0.3	-0.28	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
STAD	cis	rs67311347	0.635	rs62261855	ENSG00000223797.4	ENTPD3-AS1	5.45	9.66e-08	8.52e-05	0.33	0.28	Renal cell carcinoma;	chr3:40253447	chr3:40313802~40453329:-
STAD	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-5.45	9.66e-08	8.53e-05	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
STAD	cis	rs9860428	0.844	rs12490586	ENSG00000240057.4	RP11-572M11.4	-5.45	9.66e-08	8.53e-05	-0.27	-0.28	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904386	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs12487198	ENSG00000240057.4	RP11-572M11.4	-5.45	9.66e-08	8.53e-05	-0.27	-0.28	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904423	chr3:113019532~113183301:+
STAD	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	5.45	9.67e-08	8.53e-05	0.29	0.28	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
STAD	cis	rs2283792	1	rs5749986	ENSG00000228050.1	TOP3BP1	-5.45	9.67e-08	8.54e-05	-0.32	-0.28	Multiple sclerosis;	chr22:21803372	chr22:22223187~22224566:-
STAD	cis	rs1153858	1	rs4774577	ENSG00000259433.2	CTD-2651B20.4	-5.45	9.69e-08	8.55e-05	-0.31	-0.28	Homoarginine levels;	chr15:45352487	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs4774578	ENSG00000259433.2	CTD-2651B20.4	-5.45	9.69e-08	8.55e-05	-0.31	-0.28	Homoarginine levels;	chr15:45353853	chr15:45330209~45332634:-
STAD	cis	rs61524473	1	rs61524473	ENSG00000259433.2	CTD-2651B20.4	-5.45	9.69e-08	8.55e-05	-0.31	-0.28	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs10444821	ENSG00000259433.2	CTD-2651B20.4	-5.45	9.69e-08	8.55e-05	-0.31	-0.28	Homoarginine levels;	chr15:45355038	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs72623915	ENSG00000259433.2	CTD-2651B20.4	-5.45	9.69e-08	8.55e-05	-0.31	-0.28	Homoarginine levels;	chr15:45355235	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs66714503	ENSG00000259433.2	CTD-2651B20.4	-5.45	9.69e-08	8.55e-05	-0.31	-0.28	Homoarginine levels;	chr15:45355840	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs2066090	ENSG00000259433.2	CTD-2651B20.4	-5.45	9.69e-08	8.55e-05	-0.31	-0.28	Homoarginine levels;	chr15:45357820	chr15:45330209~45332634:-
STAD	cis	rs4604732	0.631	rs74154672	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462323	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs74154673	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462327	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs11490198	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462401	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs11490199	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462435	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs74154675	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462534	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs74154676	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462592	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs11490200	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462613	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs56704806	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462846	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.588	rs74154678	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462900	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs11490201	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462960	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.589	rs78689516	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462972	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.527	rs77361748	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463173	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.527	rs79329288	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463211	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.578	rs79203328	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463279	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs75320597	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463449	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs35046441	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463510	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs80319072	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463533	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs34330532	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463542	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs34924545	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463590	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs34443739	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463611	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs12036460	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463626	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs10925043	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463699	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs10802509	ENSG00000227135.1	GCSAML-AS1	-5.45	9.7e-08	8.55e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463856	chr1:247524679~247526752:-
STAD	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	5.45	9.71e-08	8.56e-05	0.4	0.28	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
STAD	cis	rs1056107	0.931	rs3849123	ENSG00000225513.1	RP11-165N19.2	-5.45	9.72e-08	8.57e-05	-0.33	-0.28	Colorectal cancer;	chr9:112215901	chr9:112173522~112173971:-
STAD	cis	rs7829975	0.902	rs777707	ENSG00000254340.1	RP11-10A14.3	5.45	9.75e-08	8.59e-05	0.33	0.28	Mood instability;	chr8:8726834	chr8:9141424~9145435:+
STAD	cis	rs7580658	0.545	rs885275	ENSG00000200250.1	RNU6-1147P	5.45	9.75e-08	8.59e-05	0.27	0.28	Protein C levels;	chr2:127193519	chr2:127316873~127316979:+
STAD	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	5.45	9.75e-08	8.6e-05	0.48	0.28	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
STAD	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-5.45	9.77e-08	8.61e-05	-0.29	-0.28	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
STAD	cis	rs227275	0.554	rs6810668	ENSG00000230069.3	LRRC37A15P	-5.45	9.79e-08	8.63e-05	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.869	rs223323	ENSG00000230069.3	LRRC37A15P	-5.45	9.81e-08	8.64e-05	-0.3	-0.28	Schizophrenia;	chr4:102878412	chr4:102727274~102730721:-
STAD	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-5.45	9.82e-08	8.65e-05	-0.33	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
STAD	cis	rs7487075	0.82	rs7976362	ENSG00000272369.1	RP11-446N19.1	5.45	9.82e-08	8.65e-05	0.35	0.28	Itch intensity from mosquito bite;	chr12:46315779	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.786	rs59919892	ENSG00000272369.1	RP11-446N19.1	5.45	9.82e-08	8.65e-05	0.35	0.28	Itch intensity from mosquito bite;	chr12:46318447	chr12:46537502~46652550:+
STAD	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	5.45	9.83e-08	8.66e-05	0.41	0.28	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
STAD	cis	rs9400467	0.509	rs11153287	ENSG00000230177.1	RP5-1112D6.4	-5.45	9.83e-08	8.66e-05	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111277932~111278742:+
STAD	cis	rs9463078	0.546	rs1284987	ENSG00000219384.1	RP11-491H9.3	5.45	9.84e-08	8.66e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45095984	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs1284988	ENSG00000219384.1	RP11-491H9.3	5.45	9.84e-08	8.66e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45097035	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.528	rs1284992	ENSG00000219384.1	RP11-491H9.3	5.45	9.84e-08	8.66e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45103407	chr6:45158870~45159511:+
STAD	cis	rs9395066	0.56	rs9395065	ENSG00000219384.1	RP11-491H9.3	5.45	9.84e-08	8.66e-05	0.27	0.28	Height;	chr6:45106655	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs1324532	ENSG00000219384.1	RP11-491H9.3	5.45	9.84e-08	8.66e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45108058	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs1284972	ENSG00000219384.1	RP11-491H9.3	5.45	9.84e-08	8.66e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45109661	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs1284975	ENSG00000219384.1	RP11-491H9.3	5.45	9.84e-08	8.66e-05	0.27	0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45111608	chr6:45158870~45159511:+
STAD	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	5.44	9.85e-08	8.67e-05	0.34	0.28	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
STAD	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	5.44	9.89e-08	8.71e-05	0.33	0.28	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
STAD	cis	rs11722779	0.903	rs13130741	ENSG00000230069.3	LRRC37A15P	-5.44	9.9e-08	8.71e-05	-0.31	-0.28	Schizophrenia;	chr4:103035799	chr4:102727274~102730721:-
STAD	cis	rs8141529	0.687	rs6005867	ENSG00000226471.5	CTA-292E10.6	-5.44	9.9e-08	8.71e-05	-0.33	-0.28	Lymphocyte counts;	chr22:28769132	chr22:28800683~28848559:+
STAD	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-5.44	9.92e-08	8.73e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
STAD	cis	rs240993	0.812	rs7764543	ENSG00000230177.1	RP5-1112D6.4	-5.44	9.92e-08	8.73e-05	-0.29	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111277932~111278742:+
STAD	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	5.44	9.92e-08	8.73e-05	0.3	0.28	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
STAD	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-5.44	9.93e-08	8.74e-05	-0.23	-0.28	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
STAD	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	5.44	9.94e-08	8.75e-05	0.31	0.28	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	5.44	9.94e-08	8.75e-05	0.31	0.28	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
STAD	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-5.44	9.95e-08	8.75e-05	-0.34	-0.28	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
STAD	cis	rs992157	0.71	rs13026485	ENSG00000237281.1	CATIP-AS2	5.44	9.95e-08	8.76e-05	0.27	0.28	Colorectal cancer;	chr2:218193261	chr2:218326889~218357966:-
STAD	cis	rs875971	0.545	rs6460298	ENSG00000224316.1	RP11-479O9.2	5.44	9.95e-08	8.76e-05	0.31	0.28	Aortic root size;	chr7:66442783	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs75577046	ENSG00000224316.1	RP11-479O9.2	5.44	9.95e-08	8.76e-05	0.31	0.28	Aortic root size;	chr7:66493729	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs3735147	ENSG00000224316.1	RP11-479O9.2	5.44	9.95e-08	8.76e-05	0.31	0.28	Aortic root size;	chr7:66505541	chr7:65773620~65802067:+
STAD	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-5.44	9.95e-08	8.76e-05	-0.31	-0.28	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
STAD	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-5.44	9.97e-08	8.77e-05	-0.29	-0.28	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
STAD	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	5.44	9.98e-08	8.78e-05	0.27	0.28	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
STAD	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-5.44	9.98e-08	8.78e-05	-0.31	-0.28	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
STAD	cis	rs227275	0.556	rs6842179	ENSG00000230069.3	LRRC37A15P	-5.44	9.99e-08	8.79e-05	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102727274~102730721:-
STAD	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-5.44	9.99e-08	8.79e-05	-0.33	-0.28	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
STAD	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-5.44	1e-07	8.79e-05	-0.36	-0.28	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
STAD	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-5.44	1e-07	8.81e-05	-0.29	-0.28	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
STAD	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-5.44	1e-07	8.81e-05	-0.38	-0.28	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
STAD	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	5.44	1e-07	8.81e-05	0.4	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
STAD	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	5.44	1e-07	8.81e-05	0.39	0.28	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	5.44	1e-07	8.81e-05	0.39	0.28	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	5.44	1e-07	8.81e-05	0.39	0.28	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	5.44	1e-07	8.81e-05	0.39	0.28	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
STAD	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	5.44	1e-07	8.81e-05	0.3	0.28	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
STAD	cis	rs7829975	0.774	rs57312668	ENSG00000254340.1	RP11-10A14.3	5.44	1e-07	8.81e-05	0.32	0.28	Mood instability;	chr8:8822967	chr8:9141424~9145435:+
STAD	cis	rs992157	0.643	rs10191283	ENSG00000237281.1	CATIP-AS2	-5.44	1e-07	8.83e-05	-0.28	-0.28	Colorectal cancer;	chr2:218192032	chr2:218326889~218357966:-
STAD	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-5.44	1e-07	8.84e-05	-0.3	-0.28	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
STAD	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-5.44	1.01e-07	8.84e-05	-0.4	-0.28	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
STAD	cis	rs1005277	0.579	rs2008449	ENSG00000099251.13	HSD17B7P2	-5.44	1.01e-07	8.84e-05	-0.32	-0.28	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38356380~38378505:+
STAD	cis	rs2436845	1	rs1434235	ENSG00000253385.1	KB-1254G8.1	5.44	1.01e-07	8.84e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102830804	chr8:102854455~102856075:+
STAD	cis	rs2436845	1	rs34655485	ENSG00000253385.1	KB-1254G8.1	5.44	1.01e-07	8.84e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102832474	chr8:102854455~102856075:+
STAD	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	5.44	1.01e-07	8.85e-05	0.33	0.28	Depression;	chr6:28076704	chr6:28073316~28074233:+
STAD	cis	rs8040855	0.627	rs4980357	ENSG00000229212.6	RP11-561C5.4	5.44	1.01e-07	8.86e-05	0.41	0.28	Bulimia nervosa;	chr15:85064878	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.627	rs4980356	ENSG00000229212.6	RP11-561C5.4	5.44	1.01e-07	8.86e-05	0.41	0.28	Bulimia nervosa;	chr15:85064901	chr15:85205440~85234795:-
STAD	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-5.44	1.01e-07	8.86e-05	-0.33	-0.28	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
STAD	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-5.44	1.01e-07	8.87e-05	-0.33	-0.28	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
STAD	cis	rs7927771	0.832	rs1317164	ENSG00000280615.1	Y_RNA	-5.44	1.01e-07	8.87e-05	-0.29	-0.28	Subjective well-being;	chr11:47398206	chr11:47614898~47614994:-
STAD	cis	rs1799949	0.93	rs4445938	ENSG00000236383.6	LINC00854	-5.44	1.01e-07	8.87e-05	-0.23	-0.28	Menopause (age at onset);	chr17:43185883	chr17:43216941~43305976:-
STAD	cis	rs9463078	0.528	rs12214778	ENSG00000219384.1	RP11-491H9.3	-5.44	1.01e-07	8.87e-05	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44956675	chr6:45158870~45159511:+
STAD	cis	rs8098244	0.706	rs1154227	ENSG00000267301.1	RPL23AP77	5.44	1.01e-07	8.87e-05	0.33	0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23901376	chr18:23709825~23710287:-
STAD	cis	rs9549260	0.604	rs56302456	ENSG00000229456.1	RLIMP1	5.44	1.01e-07	8.88e-05	0.33	0.28	Red blood cell count;	chr13:40721751	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.534	rs4943809	ENSG00000229456.1	RLIMP1	5.44	1.01e-07	8.88e-05	0.33	0.28	Red blood cell count;	chr13:40723268	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.534	rs4943810	ENSG00000229456.1	RLIMP1	5.44	1.01e-07	8.88e-05	0.33	0.28	Red blood cell count;	chr13:40723269	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.604	rs9532587	ENSG00000229456.1	RLIMP1	5.44	1.01e-07	8.88e-05	0.33	0.28	Red blood cell count;	chr13:40728558	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.569	rs73174811	ENSG00000229456.1	RLIMP1	5.44	1.01e-07	8.88e-05	0.33	0.28	Red blood cell count;	chr13:40741862	chr13:40618738~40621348:+
STAD	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	5.44	1.01e-07	8.89e-05	0.43	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
STAD	cis	rs4568518	0.71	rs13230836	ENSG00000279048.1	RP11-511H23.2	5.44	1.01e-07	8.9e-05	0.26	0.28	Measles;	chr7:17974272	chr7:17940503~17942922:+
STAD	cis	rs7829975	0.744	rs2409092	ENSG00000254340.1	RP11-10A14.3	5.44	1.01e-07	8.9e-05	0.32	0.28	Mood instability;	chr8:8824682	chr8:9141424~9145435:+
STAD	cis	rs7927771	0.725	rs11570094	ENSG00000271350.1	CTD-2384B9.1	5.44	1.01e-07	8.91e-05	0.32	0.28	Subjective well-being;	chr11:47338155	chr11:47041027~47041945:-
STAD	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-5.44	1.02e-07	8.92e-05	-0.3	-0.28	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
STAD	cis	rs6452524	0.618	rs6452501	ENSG00000243385.2	CTD-2110K23.1	5.44	1.02e-07	8.92e-05	0.3	0.28	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83201229~83202141:+
STAD	cis	rs858239	0.601	rs3735228	ENSG00000226816.2	AC005082.12	5.44	1.02e-07	8.92e-05	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23206013~23208045:+
STAD	cis	rs4927850	1	rs4927704	ENSG00000185485.13	SDHAP1	5.44	1.02e-07	8.93e-05	0.28	0.28	Pancreatic cancer;	chr3:196011357	chr3:195959748~195990318:-
STAD	cis	rs4927850	1	rs4927848	ENSG00000185485.13	SDHAP1	5.44	1.02e-07	8.93e-05	0.28	0.28	Pancreatic cancer;	chr3:196011535	chr3:195959748~195990318:-
STAD	cis	rs7487075	0.786	rs7966288	ENSG00000272369.1	RP11-446N19.1	5.44	1.02e-07	8.94e-05	0.36	0.28	Itch intensity from mosquito bite;	chr12:46281187	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.786	rs7965629	ENSG00000272369.1	RP11-446N19.1	5.44	1.02e-07	8.94e-05	0.36	0.28	Itch intensity from mosquito bite;	chr12:46281283	chr12:46537502~46652550:+
STAD	cis	rs71327718	1	rs71327718	ENSG00000272840.1	RP11-379B18.6	5.44	1.02e-07	8.94e-05	0.57	0.28	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125774714~125797953:+
STAD	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	5.44	1.02e-07	8.97e-05	0.4	0.28	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
STAD	cis	rs240993	0.715	rs240995	ENSG00000230177.1	RP5-1112D6.4	-5.44	1.02e-07	8.98e-05	-0.29	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111355310	chr6:111277932~111278742:+
STAD	cis	rs1816752	0.819	rs7985478	ENSG00000273628.1	RP11-756A22.7	5.44	1.02e-07	8.98e-05	0.34	0.28	Obesity-related traits;	chr13:24417135	chr13:24933006~24936796:+
STAD	cis	rs611744	0.608	rs612744	ENSG00000253754.1	RP11-35G22.1	-5.44	1.02e-07	8.98e-05	-0.25	-0.28	Dupuytren's disease;	chr8:108233762	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs587340	ENSG00000253754.1	RP11-35G22.1	-5.44	1.02e-07	8.98e-05	-0.25	-0.28	Dupuytren's disease;	chr8:108233803	chr8:108226200~108227544:+
STAD	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	5.44	1.02e-07	8.98e-05	0.36	0.28	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
STAD	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	5.44	1.02e-07	8.99e-05	0.29	0.28	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
STAD	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	5.44	1.03e-07	9.02e-05	0.42	0.28	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
STAD	cis	rs2439831	0.85	rs2957637	ENSG00000275601.1	AC011330.13	-5.44	1.03e-07	9.02e-05	-0.4	-0.28	Lung cancer in ever smokers;	chr15:43658920	chr15:43642389~43643023:-
STAD	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	5.44	1.03e-07	9.03e-05	0.32	0.28	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
STAD	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	5.44	1.03e-07	9.03e-05	0.29	0.28	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	5.44	1.03e-07	9.03e-05	0.29	0.28	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	5.44	1.03e-07	9.03e-05	0.29	0.28	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
STAD	cis	rs10129255	0.843	rs7142649	ENSG00000223648.3	IGHV3-64	5.44	1.03e-07	9.03e-05	0.24	0.28	Kawasaki disease;	chr14:106708870	chr14:106643132~106658258:-
STAD	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-5.44	1.03e-07	9.03e-05	-0.23	-0.28	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
STAD	cis	rs720064	0.655	rs12964862	ENSG00000267301.1	RPL23AP77	-5.44	1.03e-07	9.03e-05	-0.33	-0.28	Strep throat;	chr18:23700711	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.536	rs12955616	ENSG00000267301.1	RPL23AP77	-5.44	1.03e-07	9.03e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701097	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.557	rs8089282	ENSG00000267301.1	RPL23AP77	-5.44	1.03e-07	9.03e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23708402	chr18:23709825~23710287:-
STAD	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-5.44	1.03e-07	9.03e-05	-0.43	-0.28	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-5.44	1.03e-07	9.03e-05	-0.43	-0.28	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
STAD	cis	rs13113518	0.756	rs11939652	ENSG00000272969.1	RP11-528I4.2	5.44	1.03e-07	9.03e-05	0.36	0.28	Height;	chr4:55532542	chr4:55547112~55547889:+
STAD	cis	rs4604732	0.631	rs1106721	ENSG00000227135.1	GCSAML-AS1	-5.44	1.03e-07	9.04e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461374	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.631	rs1106720	ENSG00000227135.1	GCSAML-AS1	-5.44	1.03e-07	9.04e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461379	chr1:247524679~247526752:-
STAD	cis	rs2412819	0.597	rs2412821	ENSG00000249839.1	AC011330.5	-5.44	1.03e-07	9.04e-05	-0.5	-0.28	Lung cancer;	chr15:43864966	chr15:43663654~43684339:-
STAD	cis	rs9549260	0.753	rs61963264	ENSG00000229456.1	RLIMP1	5.44	1.03e-07	9.04e-05	0.32	0.28	Red blood cell count;	chr13:40580655	chr13:40618738~40621348:+
STAD	cis	rs875971	0.545	rs12670811	ENSG00000224316.1	RP11-479O9.2	5.44	1.03e-07	9.04e-05	0.31	0.28	Aortic root size;	chr7:66358032	chr7:65773620~65802067:+
STAD	cis	rs8098244	0.557	rs10853571	ENSG00000267301.1	RPL23AP77	-5.44	1.03e-07	9.05e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710723	chr18:23709825~23710287:-
STAD	cis	rs13113518	0.812	rs13140173	ENSG00000272969.1	RP11-528I4.2	5.44	1.03e-07	9.06e-05	0.36	0.28	Height;	chr4:55527164	chr4:55547112~55547889:+
STAD	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-5.44	1.03e-07	9.06e-05	-0.33	-0.28	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
STAD	cis	rs12744310	1	rs12034357	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302557	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs7553908	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302569	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12041533	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302599	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs34862272	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302981	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs34796305	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303373	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs35972058	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303474	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs12032906	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303486	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs34315814	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303500	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12032191	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303546	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12032215	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303662	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12035353	ENSG00000235358.1	RP11-399E6.1	5.44	1.03e-07	9.07e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303665	chr1:41242373~41284861:+
STAD	cis	rs6782228	0.675	rs2253151	ENSG00000277250.1	Metazoa_SRP	-5.43	1.04e-07	9.08e-05	-0.29	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128673681~128674021:-
STAD	cis	rs62432291	0.681	rs439126	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159235600	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.614	rs420339	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159236163	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs425906	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159236543	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs388001	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159237427	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs447637	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159237694	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs378339	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159237820	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs419836	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159238449	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs450538	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159238491	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.764	rs433256	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159239073	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs429339	ENSG00000235086.1	FNDC1-IT1	-5.43	1.04e-07	9.08e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159239116	chr6:159240786~159243329:+
STAD	cis	rs12744310	0.887	rs6660265	ENSG00000235358.1	RP11-399E6.1	-5.43	1.04e-07	9.08e-05	-0.34	-0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41353004	chr1:41242373~41284861:+
STAD	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-5.43	1.04e-07	9.1e-05	-0.3	-0.28	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
STAD	cis	rs711244	0.532	rs4670181	ENSG00000252756.1	RNU6-577P	-5.43	1.04e-07	9.11e-05	-0.32	-0.28	Mean platelet volume;	chr2:36999760	chr2:36867398~36867495:-
STAD	cis	rs7487075	0.93	rs12814298	ENSG00000272369.1	RP11-446N19.1	5.43	1.04e-07	9.12e-05	0.34	0.28	Itch intensity from mosquito bite;	chr12:46443841	chr12:46537502~46652550:+
STAD	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	5.43	1.04e-07	9.13e-05	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
STAD	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-5.43	1.04e-07	9.13e-05	-0.46	-0.28	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
STAD	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-5.43	1.04e-07	9.14e-05	-0.47	-0.28	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
STAD	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-5.43	1.04e-07	9.14e-05	-0.47	-0.28	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
STAD	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	5.43	1.05e-07	9.15e-05	0.34	0.28	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
STAD	cis	rs7487075	0.78	rs10785620	ENSG00000257261.4	RP11-96H19.1	5.43	1.05e-07	9.15e-05	0.35	0.28	Itch intensity from mosquito bite;	chr12:46343469	chr12:46383679~46876159:+
STAD	cis	rs2436845	1	rs2513919	ENSG00000253385.1	KB-1254G8.1	5.43	1.05e-07	9.16e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102819526	chr8:102854455~102856075:+
STAD	cis	rs2436845	1	rs972142	ENSG00000253385.1	KB-1254G8.1	5.43	1.05e-07	9.16e-05	0.31	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102824025	chr8:102854455~102856075:+
STAD	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-5.43	1.05e-07	9.17e-05	-0.39	-0.28	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
STAD	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	5.43	1.05e-07	9.17e-05	0.28	0.28	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
STAD	cis	rs516805	0.667	rs1339532	ENSG00000279453.1	RP3-425C14.4	5.43	1.05e-07	9.17e-05	0.37	0.28	Lymphocyte counts;	chr6:122345249	chr6:122436789~122439223:-
STAD	cis	rs9400467	0.528	rs459403	ENSG00000230177.1	RP5-1112D6.4	-5.43	1.05e-07	9.18e-05	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111277932~111278742:+
STAD	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	5.43	1.05e-07	9.18e-05	0.27	0.28	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
STAD	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-5.43	1.05e-07	9.19e-05	-0.29	-0.28	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
STAD	cis	rs875971	0.571	rs78668714	ENSG00000224316.1	RP11-479O9.2	5.43	1.05e-07	9.19e-05	0.32	0.28	Aortic root size;	chr7:66474464	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs73150604	ENSG00000224316.1	RP11-479O9.2	5.43	1.05e-07	9.19e-05	0.32	0.28	Aortic root size;	chr7:66480545	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs7810213	ENSG00000224316.1	RP11-479O9.2	5.43	1.05e-07	9.19e-05	0.32	0.28	Aortic root size;	chr7:66481592	chr7:65773620~65802067:+
STAD	cis	rs9425766	0.628	rs6425274	ENSG00000227373.4	RP11-160H22.5	5.43	1.05e-07	9.19e-05	0.33	0.28	Life satisfaction;	chr1:174144270	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.566	rs6696076	ENSG00000227373.4	RP11-160H22.5	5.43	1.05e-07	9.19e-05	0.33	0.28	Life satisfaction;	chr1:174149900	chr1:174115300~174160004:-
STAD	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-5.43	1.05e-07	9.2e-05	-0.34	-0.28	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
STAD	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-5.43	1.05e-07	9.21e-05	-0.29	-0.28	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
STAD	cis	rs8098244	0.536	rs7232217	ENSG00000267301.1	RPL23AP77	-5.43	1.06e-07	9.22e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699115	chr18:23709825~23710287:-
STAD	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-5.43	1.06e-07	9.23e-05	-0.34	-0.28	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
STAD	cis	rs58873874	0.737	rs10515750	ENSG00000251405.2	CTB-109A12.1	5.43	1.06e-07	9.23e-05	0.47	0.28	Bipolar disorder (body mass index interaction);	chr5:157383064	chr5:157362615~157460078:-
STAD	cis	rs240993	0.812	rs118203	ENSG00000230177.1	RP5-1112D6.4	-5.43	1.06e-07	9.23e-05	-0.28	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111277932~111278742:+
STAD	cis	rs8098244	0.557	rs11662031	ENSG00000267301.1	RPL23AP77	-5.43	1.06e-07	9.24e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707799	chr18:23709825~23710287:-
STAD	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	5.43	1.06e-07	9.24e-05	0.31	0.28	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
STAD	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-5.43	1.06e-07	9.25e-05	-0.27	-0.28	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
STAD	cis	rs1799949	1	rs8176126	ENSG00000236383.6	LINC00854	5.43	1.06e-07	9.26e-05	0.23	0.28	Menopause (age at onset);	chr17:43107032	chr17:43216941~43305976:-
STAD	cis	rs11038871	1	rs7949371	ENSG00000271350.1	CTD-2384B9.1	5.43	1.06e-07	9.26e-05	0.35	0.28	Immunoglobulin A;	chr11:46500754	chr11:47041027~47041945:-
STAD	cis	rs11038871	1	rs7949282	ENSG00000271350.1	CTD-2384B9.1	5.43	1.06e-07	9.26e-05	0.35	0.28	Immunoglobulin A;	chr11:46500756	chr11:47041027~47041945:-
STAD	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	5.43	1.06e-07	9.27e-05	0.36	0.28	Height;	chr6:109421257	chr6:109382795~109383666:+
STAD	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	5.43	1.06e-07	9.27e-05	0.25	0.28	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
STAD	cis	rs1799949	0.965	rs1842147	ENSG00000279602.1	CTD-3014M21.1	5.43	1.06e-07	9.28e-05	0.36	0.28	Menopause (age at onset);	chr17:43357824	chr17:43360041~43361361:-
STAD	cis	rs8040855	0.597	rs12902942	ENSG00000229212.6	RP11-561C5.4	5.43	1.06e-07	9.28e-05	0.41	0.28	Bulimia nervosa;	chr15:85041573	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.627	rs12909130	ENSG00000229212.6	RP11-561C5.4	5.43	1.06e-07	9.28e-05	0.41	0.28	Bulimia nervosa;	chr15:85047270	chr15:85205440~85234795:-
STAD	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	5.43	1.06e-07	9.29e-05	0.32	0.28	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
STAD	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-5.43	1.06e-07	9.3e-05	-0.4	-0.28	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
STAD	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	5.43	1.07e-07	9.3e-05	0.34	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
STAD	cis	rs853679	0.517	rs3757187	ENSG00000220721.1	OR1F12	5.43	1.07e-07	9.32e-05	0.33	0.28	Depression;	chr6:28139876	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs3757185	ENSG00000220721.1	OR1F12	5.43	1.07e-07	9.32e-05	0.33	0.28	Depression;	chr6:28139998	chr6:28073316~28074233:+
STAD	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	5.43	1.07e-07	9.33e-05	0.31	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
STAD	cis	rs7829975	0.774	rs1039915	ENSG00000254340.1	RP11-10A14.3	5.43	1.07e-07	9.34e-05	0.32	0.28	Mood instability;	chr8:8822104	chr8:9141424~9145435:+
STAD	cis	rs1056107	0.931	rs11792718	ENSG00000225513.1	RP11-165N19.2	-5.43	1.07e-07	9.34e-05	-0.33	-0.28	Colorectal cancer;	chr9:112253684	chr9:112173522~112173971:-
STAD	cis	rs6142102	0.961	rs4911385	ENSG00000275784.1	RP5-1125A11.6	-5.43	1.07e-07	9.34e-05	-0.29	-0.28	Skin pigmentation;	chr20:33970787	chr20:33989480~33991818:-
STAD	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-5.43	1.07e-07	9.36e-05	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
STAD	cis	rs7927771	0.524	rs2290851	ENSG00000280615.1	Y_RNA	-5.43	1.07e-07	9.36e-05	-0.28	-0.28	Subjective well-being;	chr11:47731818	chr11:47614898~47614994:-
STAD	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	5.43	1.07e-07	9.36e-05	0.47	0.28	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
STAD	cis	rs7674212	0.581	rs13150953	ENSG00000230069.3	LRRC37A15P	-5.43	1.07e-07	9.37e-05	-0.33	-0.28	Type 2 diabetes;	chr4:103021341	chr4:102727274~102730721:-
STAD	cis	rs7674212	0.556	rs13151569	ENSG00000230069.3	LRRC37A15P	-5.43	1.07e-07	9.37e-05	-0.33	-0.28	Type 2 diabetes;	chr4:103021633	chr4:102727274~102730721:-
STAD	cis	rs1799949	1	rs2271573	ENSG00000236383.6	LINC00854	-5.43	1.07e-07	9.37e-05	-0.23	-0.28	Menopause (age at onset);	chr17:43175604	chr17:43216941~43305976:-
STAD	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-5.43	1.07e-07	9.37e-05	-0.31	-0.28	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
STAD	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	5.43	1.08e-07	9.38e-05	0.29	0.28	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
STAD	cis	rs1005277	0.579	rs932538	ENSG00000099251.13	HSD17B7P2	5.43	1.08e-07	9.38e-05	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.541	rs2472177	ENSG00000099251.13	HSD17B7P2	5.43	1.08e-07	9.38e-05	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2472178	ENSG00000099251.13	HSD17B7P2	5.43	1.08e-07	9.38e-05	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2474572	ENSG00000099251.13	HSD17B7P2	5.43	1.08e-07	9.38e-05	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.579	rs2505198	ENSG00000099251.13	HSD17B7P2	5.43	1.08e-07	9.38e-05	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38356380~38378505:+
STAD	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	5.43	1.08e-07	9.38e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	5.43	1.08e-07	9.38e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
STAD	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-5.43	1.08e-07	9.39e-05	-0.36	-0.28	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
STAD	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	5.43	1.08e-07	9.39e-05	0.41	0.28	Height;	chr6:109441837	chr6:109382795~109383666:+
STAD	cis	rs7829975	0.84	rs572366	ENSG00000254340.1	RP11-10A14.3	5.43	1.08e-07	9.39e-05	0.33	0.28	Mood instability;	chr8:8721284	chr8:9141424~9145435:+
STAD	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-5.43	1.08e-07	9.4e-05	-0.29	-0.28	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
STAD	cis	rs7487075	0.859	rs956910	ENSG00000272369.1	RP11-446N19.1	5.43	1.08e-07	9.41e-05	0.34	0.28	Itch intensity from mosquito bite;	chr12:46366005	chr12:46537502~46652550:+
STAD	cis	rs240993	0.812	rs6942129	ENSG00000230177.1	RP5-1112D6.4	-5.43	1.08e-07	9.42e-05	-0.3	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111442417	chr6:111277932~111278742:+
STAD	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-5.43	1.08e-07	9.44e-05	-0.3	-0.28	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
STAD	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	5.43	1.08e-07	9.44e-05	0.5	0.28	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
STAD	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-5.43	1.08e-07	9.44e-05	-0.3	-0.28	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
STAD	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	5.43	1.09e-07	9.46e-05	0.41	0.28	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
STAD	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	5.43	1.09e-07	9.46e-05	0.3	0.28	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
STAD	cis	rs6714710	0.535	rs13033383	ENSG00000235833.1	AC159540.14	-5.43	1.09e-07	9.47e-05	-0.34	-0.28	Posterior cortical atrophy and Alzheimer's disease;	chr2:97723050	chr2:97523949~97524976:-
STAD	cis	rs6782228	0.606	rs9828893	ENSG00000277250.1	Metazoa_SRP	-5.43	1.09e-07	9.47e-05	-0.29	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128673681~128674021:-
STAD	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	5.43	1.09e-07	9.47e-05	0.34	0.28	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
STAD	cis	rs62432291	0.681	rs420137	ENSG00000235086.1	FNDC1-IT1	-5.43	1.09e-07	9.47e-05	-0.41	-0.28	Joint mobility (Beighton score);	chr6:159231899	chr6:159240786~159243329:+
STAD	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-5.43	1.09e-07	9.48e-05	-0.42	-0.28	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
STAD	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-5.43	1.09e-07	9.48e-05	-0.29	-0.28	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-5.43	1.09e-07	9.48e-05	-0.29	-0.28	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
STAD	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	5.43	1.09e-07	9.49e-05	0.35	0.28	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
STAD	cis	rs12744310	1	rs12029950	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41287493	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs35318047	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289494	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs35493284	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289517	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs12027685	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290626	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12024413	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290744	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs34027267	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291005	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12025254	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291234	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12722758	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291343	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12723893	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291368	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.945	rs1343776	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292046	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs60552457	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41293827	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12739950	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294219	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.945	rs12740093	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294329	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12038894	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294535	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12038924	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294645	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12032514	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294890	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12039767	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295188	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12731400	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295680	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12032756	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295757	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs55859000	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295769	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12030372	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41296357	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12032162	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297263	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12031417	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297356	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12037588	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298283	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12037657	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298503	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs34190295	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300207	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.945	rs34961305	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300272	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs35812095	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300402	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs35529558	ENSG00000235358.1	RP11-399E6.1	5.43	1.09e-07	9.5e-05	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301350	chr1:41242373~41284861:+
STAD	cis	rs4984778	0.717	rs2738892	ENSG00000260182.1	RP11-616M22.5	5.42	1.09e-07	9.52e-05	0.38	0.28	Blood protein levels;	chr16:1218758	chr16:1257339~1258074:+
STAD	cis	rs2439831	0.85	rs694985	ENSG00000275601.1	AC011330.13	-5.42	1.09e-07	9.52e-05	-0.36	-0.28	Lung cancer in ever smokers;	chr15:43521189	chr15:43642389~43643023:-
STAD	cis	rs17301013	0.827	rs1793309	ENSG00000227373.4	RP11-160H22.5	-5.42	1.09e-07	9.53e-05	-0.33	-0.28	Systemic lupus erythematosus;	chr1:174826199	chr1:174115300~174160004:-
STAD	cis	rs611744	0.647	rs9969614	ENSG00000253754.1	RP11-35G22.1	-5.42	1.09e-07	9.53e-05	-0.24	-0.28	Dupuytren's disease;	chr8:108248352	chr8:108226200~108227544:+
STAD	cis	rs6782228	1	rs11718130	ENSG00000277250.1	Metazoa_SRP	5.42	1.1e-07	9.54e-05	0.37	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128673681~128674021:-
STAD	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-5.42	1.1e-07	9.54e-05	-0.3	-0.28	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
STAD	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-5.42	1.1e-07	9.54e-05	-0.3	-0.28	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
STAD	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-5.42	1.1e-07	9.54e-05	-0.3	-0.28	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
STAD	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-5.42	1.1e-07	9.54e-05	-0.3	-0.28	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
STAD	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	5.42	1.1e-07	9.54e-05	0.43	0.28	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
STAD	cis	rs1862618	0.671	rs28397234	ENSG00000271828.1	CTD-2310F14.1	-5.42	1.1e-07	9.55e-05	-0.35	-0.28	Initial pursuit acceleration;	chr5:56952601	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.641	rs170733	ENSG00000271828.1	CTD-2310F14.1	-5.42	1.1e-07	9.55e-05	-0.35	-0.28	Initial pursuit acceleration;	chr5:56953424	chr5:56927874~56929573:+
STAD	cis	rs1005277	0.579	rs176838	ENSG00000099251.13	HSD17B7P2	-5.42	1.1e-07	9.55e-05	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38356380~38378505:+
STAD	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-5.42	1.1e-07	9.55e-05	-0.29	-0.28	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
STAD	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-5.42	1.1e-07	9.56e-05	-0.33	-0.28	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
STAD	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-5.42	1.1e-07	9.57e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
STAD	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	5.42	1.1e-07	9.57e-05	0.38	0.28	Height;	chr6:109479396	chr6:109382795~109383666:+
STAD	cis	rs62432291	0.614	rs452112	ENSG00000235086.1	FNDC1-IT1	-5.42	1.1e-07	9.57e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159236996	chr6:159240786~159243329:+
STAD	cis	rs62432291	0.681	rs417719	ENSG00000235086.1	FNDC1-IT1	-5.42	1.1e-07	9.57e-05	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159237010	chr6:159240786~159243329:+
STAD	cis	rs4604732	0.578	rs7525209	ENSG00000227135.1	GCSAML-AS1	-5.42	1.1e-07	9.58e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464102	chr1:247524679~247526752:-
STAD	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-5.42	1.1e-07	9.58e-05	-0.29	-0.28	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
STAD	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	5.42	1.1e-07	9.59e-05	0.36	0.28	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
STAD	cis	rs2436845	0.934	rs2304346	ENSG00000253385.1	KB-1254G8.1	5.42	1.1e-07	9.59e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102829633	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.934	rs2679746	ENSG00000253385.1	KB-1254G8.1	5.42	1.1e-07	9.59e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102844547	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.834	rs2570939	ENSG00000253385.1	KB-1254G8.1	5.42	1.1e-07	9.59e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102844814	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.934	rs2679748	ENSG00000253385.1	KB-1254G8.1	5.42	1.1e-07	9.59e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102846080	chr8:102854455~102856075:+
STAD	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-5.42	1.1e-07	9.6e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-5.42	1.1e-07	9.6e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
STAD	cis	rs2436845	0.934	rs10808382	ENSG00000253385.1	KB-1254G8.1	5.42	1.1e-07	9.6e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102822364	chr8:102854455~102856075:+
STAD	cis	rs2436845	0.934	rs2117313	ENSG00000253385.1	KB-1254G8.1	5.42	1.1e-07	9.6e-05	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102822826	chr8:102854455~102856075:+
STAD	cis	rs8098244	0.597	rs12964391	ENSG00000267301.1	RPL23AP77	-5.42	1.1e-07	9.6e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23734541	chr18:23709825~23710287:-
STAD	cis	rs17301013	0.932	rs12077622	ENSG00000227373.4	RP11-160H22.5	5.42	1.11e-07	9.61e-05	0.33	0.28	Systemic lupus erythematosus;	chr1:174442507	chr1:174115300~174160004:-
STAD	cis	rs747650	0.504	rs4548577	ENSG00000271350.1	CTD-2384B9.1	5.42	1.11e-07	9.62e-05	0.36	0.28	Acne (severe);	chr11:46976961	chr11:47041027~47041945:-
STAD	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	5.42	1.11e-07	9.62e-05	0.34	0.28	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
STAD	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	5.42	1.11e-07	9.62e-05	0.34	0.28	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
STAD	cis	rs3806843	0.966	rs2563260	ENSG00000202111.1	VTRNA1-2	5.42	1.11e-07	9.62e-05	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr5:140718925~140719013:+
STAD	cis	rs2337406	0.714	rs7152055	ENSG00000280411.1	IGHV1-69-2	-5.42	1.11e-07	9.62e-05	-0.33	-0.28	Alzheimer's disease (late onset);	chr14:106818996	chr14:106762092~106762588:-
STAD	cis	rs2980439	0.607	rs2980419	ENSG00000253981.4	ALG1L13P	5.42	1.11e-07	9.62e-05	0.34	0.28	Neuroticism;	chr8:8256619	chr8:8236003~8244667:-
STAD	cis	rs3806843	0.932	rs2563269	ENSG00000202111.1	VTRNA1-2	5.42	1.11e-07	9.62e-05	0.28	0.28	Depressive symptoms (multi-trait analysis);	chr5:140756883	chr5:140718925~140719013:+
STAD	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.42	1.11e-07	9.62e-05	0.33	0.28	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
STAD	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	5.42	1.11e-07	9.63e-05	0.35	0.28	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
STAD	cis	rs2337406	1	rs11849532	ENSG00000274576.2	IGHV2-70	-5.42	1.11e-07	9.63e-05	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106669877	chr14:106770577~106771020:-
STAD	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-5.42	1.11e-07	9.63e-05	-0.32	-0.28	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
STAD	cis	rs4604732	0.574	rs111928142	ENSG00000227135.1	GCSAML-AS1	-5.42	1.11e-07	9.64e-05	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461927	chr1:247524679~247526752:-
STAD	cis	rs9860428	0.844	rs9863580	ENSG00000240057.4	RP11-572M11.4	-5.42	1.11e-07	9.65e-05	-0.27	-0.28	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905883	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs9877803	ENSG00000240057.4	RP11-572M11.4	-5.42	1.11e-07	9.65e-05	-0.27	-0.28	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112906290	chr3:113019532~113183301:+
STAD	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	5.42	1.11e-07	9.66e-05	0.46	0.28	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
STAD	cis	rs1799949	0.965	rs35954893	ENSG00000236383.6	LINC00854	-5.42	1.11e-07	9.66e-05	-0.23	-0.28	Menopause (age at onset);	chr17:43181769	chr17:43216941~43305976:-
STAD	cis	rs516805	0.923	rs487487	ENSG00000279453.1	RP3-425C14.4	-5.42	1.11e-07	9.66e-05	-0.3	-0.28	Lymphocyte counts;	chr6:122422357	chr6:122436789~122439223:-
STAD	cis	rs516805	0.961	rs556439	ENSG00000279453.1	RP3-425C14.4	-5.42	1.11e-07	9.66e-05	-0.3	-0.28	Lymphocyte counts;	chr6:122423864	chr6:122436789~122439223:-
STAD	cis	rs516805	0.961	rs572632	ENSG00000279453.1	RP3-425C14.4	-5.42	1.11e-07	9.66e-05	-0.3	-0.28	Lymphocyte counts;	chr6:122437753	chr6:122436789~122439223:-
STAD	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	5.42	1.11e-07	9.67e-05	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
STAD	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	5.42	1.11e-07	9.68e-05	0.29	0.28	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
STAD	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-5.42	1.11e-07	9.68e-05	-0.26	-0.28	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
STAD	cis	rs875971	0.798	rs12698522	ENSG00000236529.1	RP13-254B10.1	5.42	1.12e-07	9.68e-05	0.28	0.28	Aortic root size;	chr7:66502354	chr7:65840212~65840596:+
STAD	cis	rs875971	0.83	rs28714531	ENSG00000236529.1	RP13-254B10.1	5.42	1.12e-07	9.68e-05	0.28	0.28	Aortic root size;	chr7:66503250	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs12698526	ENSG00000236529.1	RP13-254B10.1	5.42	1.12e-07	9.68e-05	0.28	0.28	Aortic root size;	chr7:66504118	chr7:65840212~65840596:+
STAD	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-5.42	1.12e-07	9.69e-05	-0.32	-0.28	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
STAD	cis	rs992157	0.775	rs7559428	ENSG00000237281.1	CATIP-AS2	5.42	1.12e-07	9.69e-05	0.28	0.28	Colorectal cancer;	chr2:218285515	chr2:218326889~218357966:-
STAD	cis	rs7829975	0.633	rs2979181	ENSG00000254340.1	RP11-10A14.3	5.42	1.12e-07	9.69e-05	0.34	0.28	Mood instability;	chr8:8465578	chr8:9141424~9145435:+
STAD	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	5.42	1.12e-07	9.71e-05	0.34	0.28	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
STAD	cis	rs13113518	0.812	rs2035692	ENSG00000272969.1	RP11-528I4.2	5.42	1.12e-07	9.72e-05	0.35	0.28	Height;	chr4:55528801	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs4507426	ENSG00000272969.1	RP11-528I4.2	5.42	1.12e-07	9.72e-05	0.35	0.28	Height;	chr4:55529387	chr4:55547112~55547889:+
STAD	cis	rs2439831	0.85	rs544122	ENSG00000249839.1	AC011330.5	-5.42	1.12e-07	9.72e-05	-0.43	-0.28	Lung cancer in ever smokers;	chr15:43483534	chr15:43663654~43684339:-
STAD	cis	rs6584283	0.766	rs7911680	ENSG00000228778.1	RP11-129J12.1	-5.42	1.12e-07	9.73e-05	-0.32	-0.28	Ulcerative colitis;	chr10:99533711	chr10:99527081~99528261:+
STAD	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-5.42	1.12e-07	9.74e-05	-0.29	-0.28	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
STAD	cis	rs10978777	0.737	rs1535765	ENSG00000276883.1	AL137852.1	-5.42	1.12e-07	9.74e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107291226	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.664	rs7029997	ENSG00000276883.1	AL137852.1	-5.42	1.12e-07	9.74e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107291456	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.616	rs7030631	ENSG00000276883.1	AL137852.1	-5.42	1.12e-07	9.74e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107291959	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.677	rs2147071	ENSG00000276883.1	AL137852.1	-5.42	1.12e-07	9.74e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107292418	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.737	rs7038737	ENSG00000276883.1	AL137852.1	-5.42	1.12e-07	9.74e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107293740	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.737	rs7039041	ENSG00000276883.1	AL137852.1	-5.42	1.12e-07	9.74e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107293985	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.706	rs10739238	ENSG00000276883.1	AL137852.1	-5.42	1.12e-07	9.74e-05	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107295525	chr9:107292369~107292456:-
STAD	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-5.42	1.12e-07	9.75e-05	-0.29	-0.28	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
STAD	cis	rs10504130	0.569	rs11775611	ENSG00000272024.1	RP11-546K22.3	-5.42	1.12e-07	9.75e-05	-0.38	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51950284~51950690:+
STAD	cis	rs3806843	0.932	rs2563257	ENSG00000202111.1	VTRNA1-2	5.42	1.12e-07	9.75e-05	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140760944	chr5:140718925~140719013:+
STAD	cis	rs10129255	0.912	rs8009135	ENSG00000280411.1	IGHV1-69-2	-5.42	1.13e-07	9.78e-05	-0.26	-0.28	Kawasaki disease;	chr14:106777528	chr14:106762092~106762588:-
STAD	cis	rs8098244	0.58	rs12970254	ENSG00000267301.1	RPL23AP77	-5.42	1.13e-07	9.78e-05	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23735733	chr18:23709825~23710287:-
STAD	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	5.42	1.13e-07	9.78e-05	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
STAD	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-5.42	1.13e-07	9.79e-05	-0.23	-0.28	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
STAD	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	5.42	1.13e-07	9.79e-05	0.32	0.28	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
STAD	cis	rs992157	0.835	rs6729058	ENSG00000237281.1	CATIP-AS2	5.42	1.13e-07	9.82e-05	0.28	0.28	Colorectal cancer;	chr2:218283646	chr2:218326889~218357966:-
STAD	cis	rs2273156	0.57	rs78207779	ENSG00000241052.1	RP11-173D9.1	-5.42	1.13e-07	9.83e-05	-0.34	-0.28	Immunoglobulin light chain (AL) amyloidosis;	chr14:35037181	chr14:35144021~35144480:-
STAD	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	5.42	1.14e-07	9.84e-05	0.44	0.28	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
STAD	cis	rs7083	1	rs664011	ENSG00000254851.1	RP11-109L13.1	5.42	1.14e-07	9.84e-05	0.32	0.28	Blood protein levels;	chr11:117237602	chr11:117135528~117138582:+
STAD	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-5.42	1.14e-07	9.85e-05	-0.34	-0.28	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-5.42	1.14e-07	9.85e-05	-0.34	-0.28	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-5.42	1.14e-07	9.85e-05	-0.34	-0.28	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-5.42	1.14e-07	9.85e-05	-0.34	-0.28	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-5.42	1.14e-07	9.85e-05	-0.34	-0.28	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-5.42	1.14e-07	9.85e-05	-0.34	-0.28	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-5.42	1.14e-07	9.85e-05	-0.34	-0.28	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
STAD	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-5.42	1.14e-07	9.86e-05	-0.32	-0.28	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
STAD	cis	rs17301013	0.932	rs1653627	ENSG00000227373.4	RP11-160H22.5	-5.42	1.14e-07	9.88e-05	-0.33	-0.28	Systemic lupus erythematosus;	chr1:174771879	chr1:174115300~174160004:-
STAD	cis	rs1961102	0.521	rs613049	ENSG00000253385.1	KB-1254G8.1	5.42	1.14e-07	9.88e-05	0.28	0.28	QT interval;	chr8:102919081	chr8:102854455~102856075:+
STAD	cis	rs240993	0.672	rs6922226	ENSG00000230177.1	RP5-1112D6.4	-5.42	1.14e-07	9.89e-05	-0.29	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111277932~111278742:+
STAD	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-5.42	1.14e-07	9.89e-05	-0.29	-0.28	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
STAD	cis	rs7829975	0.902	rs777707	ENSG00000253981.4	ALG1L13P	5.42	1.14e-07	9.89e-05	0.33	0.28	Mood instability;	chr8:8726834	chr8:8236003~8244667:-
STAD	cis	rs6452524	0.967	rs12186460	ENSG00000243385.2	CTD-2110K23.1	5.42	1.14e-07	9.91e-05	0.29	0.28	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83201229~83202141:+
STAD	cis	rs8067354	0.645	rs2645492	ENSG00000266701.1	AC005702.4	-5.42	1.14e-07	9.91e-05	-0.38	-0.28	Hemoglobin concentration;	chr17:59798193	chr17:60042546~60042627:-
STAD	cis	rs3806843	0.966	rs2563264	ENSG00000202111.1	VTRNA1-2	5.42	1.15e-07	9.92e-05	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140757918	chr5:140718925~140719013:+
STAD	cis	rs58873874	0.737	rs10061544	ENSG00000251405.2	CTB-109A12.1	5.42	1.15e-07	9.92e-05	0.47	0.28	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.737	rs10078836	ENSG00000251405.2	CTB-109A12.1	5.42	1.15e-07	9.92e-05	0.47	0.28	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157362615~157460078:-
STAD	cis	rs992157	0.804	rs7559525	ENSG00000237281.1	CATIP-AS2	5.42	1.15e-07	9.93e-05	0.28	0.28	Colorectal cancer;	chr2:218285584	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs13005100	ENSG00000237281.1	CATIP-AS2	5.42	1.15e-07	9.93e-05	0.28	0.28	Colorectal cancer;	chr2:218287044	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs13031757	ENSG00000237281.1	CATIP-AS2	5.42	1.15e-07	9.93e-05	0.28	0.28	Colorectal cancer;	chr2:218287203	chr2:218326889~218357966:-
STAD	cis	rs7829975	0.684	rs474892	ENSG00000253981.4	ALG1L13P	-5.42	1.15e-07	9.94e-05	-0.33	-0.28	Mood instability;	chr8:8739221	chr8:8236003~8244667:-
STAD	cis	rs2108622	0.628	rs11086005	ENSG00000267453.5	AC004791.2	-5.42	1.15e-07	9.94e-05	-0.32	-0.28	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864286	chr19:15851993~15864904:-
STAD	cis	rs7396835	1	rs7396835	ENSG00000280143.1	AP000892.6	5.42	1.15e-07	9.94e-05	0.27	0.28	Quantitative traits;	chr11:116813312	chr11:117204967~117210292:+
STAD	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-5.42	1.15e-07	9.94e-05	-0.31	-0.28	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
STAD	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-5.41	1.15e-07	9.94e-05	-0.31	-0.28	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
STAD	cis	rs7487075	0.718	rs4768735	ENSG00000257261.4	RP11-96H19.1	-5.41	1.15e-07	9.94e-05	-0.33	-0.28	Itch intensity from mosquito bite;	chr12:46550351	chr12:46383679~46876159:+
STAD	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	5.41	1.15e-07	9.95e-05	0.39	0.28	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	5.41	1.15e-07	9.95e-05	0.39	0.28	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
STAD	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	5.41	1.15e-07	9.95e-05	0.39	0.28	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	5.41	1.15e-07	9.95e-05	0.39	0.28	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	5.41	1.15e-07	9.95e-05	0.39	0.28	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
STAD	cis	rs17301013	0.932	rs727279	ENSG00000227373.4	RP11-160H22.5	5.41	1.15e-07	9.95e-05	0.33	0.28	Systemic lupus erythematosus;	chr1:174496026	chr1:174115300~174160004:-
STAD	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	5.41	1.15e-07	9.95e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	5.41	1.15e-07	9.95e-05	0.44	0.28	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
STAD	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	5.41	1.15e-07	9.95e-05	0.35	0.28	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
STAD	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-5.41	1.15e-07	9.96e-05	-0.24	-0.28	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
STAD	cis	rs737008	0.5	rs7189239	ENSG00000262703.1	RP11-485G7.6	5.41	1.15e-07	9.97e-05	0.26	0.28	Obesity-related traits;	chr16:11308658	chr16:11348143~11349321:-
STAD	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-5.41	1.15e-07	9.97e-05	-0.29	-0.28	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
STAD	cis	rs10849893	0.595	rs7980819	ENSG00000258435.1	RP11-711D18.2	-5.41	1.15e-07	9.98e-05	-0.3	-0.28	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121449391	chr12:121391962~121399859:+
STAD	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	5.41	1.15e-07	9.98e-05	0.4	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
STAD	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-5.41	1.16e-07	9.99e-05	-0.4	-0.28	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
STAD	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	5.41	1.16e-07	1e-04	0.32	0.28	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
STAD	cis	rs12699921	0.632	rs12699918	ENSG00000279048.1	RP11-511H23.2	5.41	1.16e-07	1e-04	0.25	0.28	Fibrinogen levels;	chr7:17930277	chr7:17940503~17942922:+
STAD	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	5.41	1.16e-07	1e-04	0.3	0.28	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
STAD	cis	rs17301013	0.896	rs13375788	ENSG00000227373.4	RP11-160H22.5	5.41	1.16e-07	1e-04	0.33	0.28	Systemic lupus erythematosus;	chr1:174524207	chr1:174115300~174160004:-
STAD	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-5.41	1.16e-07	1e-04	-0.36	-0.28	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-5.41	1.16e-07	1e-04	-0.36	-0.28	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-5.41	1.16e-07	1e-04	-0.36	-0.28	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
STAD	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-5.41	1.16e-07	1e-04	-0.26	-0.28	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
STAD	cis	rs4604732	0.631	rs12039596	ENSG00000227135.1	GCSAML-AS1	-5.41	1.16e-07	1e-04	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461464	chr1:247524679~247526752:-
STAD	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-5.41	1.16e-07	0.000101	-0.35	-0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
STAD	cis	rs10129255	0.957	rs28887506	ENSG00000280411.1	IGHV1-69-2	-5.41	1.16e-07	0.000101	-0.27	-0.28	Kawasaki disease;	chr14:106785589	chr14:106762092~106762588:-
STAD	cis	rs9549260	0.604	rs13508	ENSG00000229456.1	RLIMP1	5.41	1.16e-07	0.000101	0.33	0.28	Red blood cell count;	chr13:40749261	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.604	rs9549281	ENSG00000229456.1	RLIMP1	5.41	1.16e-07	0.000101	0.33	0.28	Red blood cell count;	chr13:40756035	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.568	rs8002412	ENSG00000229456.1	RLIMP1	5.41	1.16e-07	0.000101	0.33	0.28	Red blood cell count;	chr13:40757361	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.569	rs9549285	ENSG00000229456.1	RLIMP1	5.41	1.16e-07	0.000101	0.33	0.28	Red blood cell count;	chr13:40767283	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.534	rs3812891	ENSG00000229456.1	RLIMP1	5.41	1.16e-07	0.000101	0.33	0.28	Red blood cell count;	chr13:40771315	chr13:40618738~40621348:+
STAD	cis	rs13113518	0.812	rs2035691	ENSG00000272969.1	RP11-528I4.2	5.41	1.17e-07	0.000101	0.35	0.28	Height;	chr4:55529786	chr4:55547112~55547889:+
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000228039.3	KB-1125A3.10	5.41	1.17e-07	0.000101	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23963780~23964374:+
STAD	cis	rs3806843	0.966	rs2563261	ENSG00000202111.1	VTRNA1-2	5.41	1.17e-07	0.000101	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr5:140718925~140719013:+
STAD	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-5.41	1.17e-07	0.000101	-0.3	-0.28	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
STAD	cis	rs950169	0.887	rs35986397	ENSG00000259295.5	CSPG4P12	5.41	1.17e-07	0.000101	0.42	0.28	Schizophrenia;	chr15:84400409	chr15:85191438~85213905:+
STAD	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-5.41	1.17e-07	0.000101	-0.29	-0.28	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
STAD	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-5.41	1.17e-07	0.000101	-0.38	-0.28	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
STAD	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	5.41	1.17e-07	0.000101	0.4	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	5.41	1.17e-07	0.000101	0.4	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	5.41	1.17e-07	0.000101	0.4	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
STAD	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-5.41	1.17e-07	0.000101	-0.31	-0.28	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
STAD	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-5.41	1.17e-07	0.000101	-0.35	-0.28	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
STAD	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-5.41	1.17e-07	0.000101	-0.35	-0.28	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
STAD	cis	rs516805	0.667	rs17729938	ENSG00000279453.1	RP3-425C14.4	5.41	1.18e-07	0.000101	0.36	0.28	Lymphocyte counts;	chr6:122340364	chr6:122436789~122439223:-
STAD	cis	rs875971	0.545	rs35459055	ENSG00000224316.1	RP11-479O9.2	5.41	1.18e-07	0.000101	0.31	0.28	Aortic root size;	chr7:66479399	chr7:65773620~65802067:+
STAD	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-5.41	1.18e-07	0.000102	-0.23	-0.28	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
STAD	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	5.41	1.18e-07	0.000102	0.41	0.28	Height;	chr6:109372084	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	5.41	1.18e-07	0.000102	0.41	0.28	Height;	chr6:109375848	chr6:109382795~109383666:+
STAD	cis	rs950169	0.84	rs72748702	ENSG00000259295.5	CSPG4P12	5.41	1.19e-07	0.000102	0.41	0.28	Schizophrenia;	chr15:84246494	chr15:85191438~85213905:+
STAD	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-5.41	1.19e-07	0.000102	-0.3	-0.28	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
STAD	cis	rs1150668	0.799	rs1150705	ENSG00000220721.1	OR1F12	5.41	1.19e-07	0.000102	0.27	0.28	Pubertal anthropometrics;	chr6:28226008	chr6:28073316~28074233:+
STAD	cis	rs4604732	0.631	rs10925044	ENSG00000227135.1	GCSAML-AS1	-5.41	1.19e-07	0.000102	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463769	chr1:247524679~247526752:-
STAD	cis	rs9860428	0.844	rs9819621	ENSG00000240057.4	RP11-572M11.4	-5.41	1.19e-07	0.000102	-0.27	-0.28	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904219	chr3:113019532~113183301:+
STAD	cis	rs2115536	0.692	rs6495451	ENSG00000278600.1	RP11-81A1.6	-5.41	1.19e-07	0.000103	-0.23	-0.28	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79871711	chr15:79920195~79922455:-
STAD	cis	rs7927771	0.524	rs10838777	ENSG00000280615.1	Y_RNA	5.41	1.19e-07	0.000103	0.28	0.28	Subjective well-being;	chr11:47839402	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10458915	ENSG00000280615.1	Y_RNA	5.41	1.19e-07	0.000103	0.28	0.28	Subjective well-being;	chr11:47842840	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10742824	ENSG00000280615.1	Y_RNA	5.41	1.19e-07	0.000103	0.28	0.28	Subjective well-being;	chr11:47843290	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.542	rs10769300	ENSG00000280615.1	Y_RNA	5.41	1.19e-07	0.000103	0.28	0.28	Subjective well-being;	chr11:47844008	chr11:47614898~47614994:-
STAD	cis	rs17301013	0.932	rs6664864	ENSG00000227373.4	RP11-160H22.5	5.41	1.19e-07	0.000103	0.32	0.28	Systemic lupus erythematosus;	chr1:174622912	chr1:174115300~174160004:-
STAD	cis	rs13113518	0.812	rs11945371	ENSG00000272969.1	RP11-528I4.2	5.41	1.19e-07	0.000103	0.35	0.28	Height;	chr4:55409063	chr4:55547112~55547889:+
STAD	cis	rs227275	0.556	rs10015289	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	0.000103	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs6852141	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	0.000103	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs9999303	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	0.000103	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102727274~102730721:-
STAD	cis	rs228614	0.509	rs4455415	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	0.000103	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102727274~102730721:-
STAD	cis	rs227275	0.525	rs6853193	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	0.000103	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102727274~102730721:-
STAD	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	5.41	1.19e-07	0.000103	0.43	0.28	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
STAD	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-5.41	1.19e-07	0.000103	-0.29	-0.28	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
STAD	cis	rs7487075	0.554	rs12229299	ENSG00000257261.4	RP11-96H19.1	5.41	1.19e-07	0.000103	0.33	0.28	Itch intensity from mosquito bite;	chr12:46691110	chr12:46383679~46876159:+
STAD	cis	rs227275	0.556	rs12508069	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	0.000103	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102727274~102730721:-
STAD	cis	rs227275	0.527	rs12500379	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	0.000103	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102727274~102730721:-
STAD	cis	rs7580658	0.637	rs1566822	ENSG00000200250.1	RNU6-1147P	5.41	1.2e-07	0.000103	0.26	0.28	Protein C levels;	chr2:127229815	chr2:127316873~127316979:+
STAD	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	5.41	1.2e-07	0.000103	0.44	0.28	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
STAD	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-5.41	1.2e-07	0.000103	-0.37	-0.28	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
STAD	cis	rs7829975	0.777	rs560544	ENSG00000254340.1	RP11-10A14.3	-5.41	1.2e-07	0.000103	-0.34	-0.28	Mood instability;	chr8:8779919	chr8:9141424~9145435:+
STAD	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-5.41	1.2e-07	0.000103	-0.3	-0.28	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
STAD	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	5.41	1.2e-07	0.000103	0.44	0.28	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
STAD	cis	rs9463078	0.507	rs1023089	ENSG00000219384.1	RP11-491H9.3	-5.41	1.2e-07	0.000103	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45044609	chr6:45158870~45159511:+
STAD	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-5.41	1.2e-07	0.000103	-0.3	-0.28	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
STAD	cis	rs1056107	0.933	rs4978481	ENSG00000225513.1	RP11-165N19.2	-5.41	1.2e-07	0.000104	-0.34	-0.28	Colorectal cancer;	chr9:112309164	chr9:112173522~112173971:-
STAD	cis	rs2337406	0.925	rs873533	ENSG00000211972.2	IGHV3-66	5.41	1.2e-07	0.000104	0.31	0.28	Alzheimer's disease (late onset);	chr14:106667442	chr14:106675017~106675544:-
STAD	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	5.41	1.2e-07	0.000104	0.3	0.28	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
STAD	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-5.41	1.2e-07	0.000104	-0.45	-0.28	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
STAD	cis	rs992157	0.717	rs11692780	ENSG00000237281.1	CATIP-AS2	5.41	1.2e-07	0.000104	0.28	0.28	Colorectal cancer;	chr2:218284440	chr2:218326889~218357966:-
STAD	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-5.41	1.2e-07	0.000104	-0.39	-0.28	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
STAD	cis	rs1816752	0.819	rs4770664	ENSG00000273628.1	RP11-756A22.7	5.41	1.21e-07	0.000104	0.34	0.28	Obesity-related traits;	chr13:24414695	chr13:24933006~24936796:+
STAD	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-5.41	1.21e-07	0.000104	-0.23	-0.28	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
STAD	cis	rs7829975	0.509	rs2945269	ENSG00000173295.6	FAM86B3P	5.41	1.21e-07	0.000104	0.33	0.28	Mood instability;	chr8:8258056	chr8:8228595~8244865:+
STAD	cis	rs6142102	0.812	rs6059558	ENSG00000275784.1	RP5-1125A11.6	-5.41	1.21e-07	0.000104	-0.3	-0.28	Skin pigmentation;	chr20:33929024	chr20:33989480~33991818:-
STAD	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-5.41	1.21e-07	0.000104	-0.47	-0.28	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-5.41	1.21e-07	0.000104	-0.47	-0.28	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
STAD	cis	rs3806843	0.676	rs753280	ENSG00000202111.1	VTRNA1-2	-5.41	1.21e-07	0.000104	-0.28	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140644457	chr5:140718925~140719013:+
STAD	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-5.4	1.21e-07	0.000104	-0.29	-0.28	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
STAD	cis	rs7829975	0.711	rs12682352	ENSG00000254340.1	RP11-10A14.3	5.4	1.21e-07	0.000104	0.33	0.28	Mood instability;	chr8:8788736	chr8:9141424~9145435:+
STAD	cis	rs11694172	1	rs55866932	ENSG00000273456.1	RP11-686O6.2	5.4	1.21e-07	0.000104	0.32	0.28	Cholesterol, total;	chr2:202658319	chr2:202374932~202375604:-
STAD	cis	rs2283792	1	rs3810610	ENSG00000228050.1	TOP3BP1	5.4	1.21e-07	0.000104	0.31	0.28	Multiple sclerosis;	chr22:21761209	chr22:22223187~22224566:-
STAD	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	5.4	1.21e-07	0.000104	0.28	0.28	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
STAD	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	5.4	1.22e-07	0.000105	0.3	0.28	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
STAD	cis	rs992157	0.835	rs34353396	ENSG00000237281.1	CATIP-AS2	5.4	1.22e-07	0.000105	0.28	0.28	Colorectal cancer;	chr2:218289259	chr2:218326889~218357966:-
STAD	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-5.4	1.22e-07	0.000105	-0.33	-0.28	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
STAD	cis	rs17301013	0.932	rs6425282	ENSG00000227373.4	RP11-160H22.5	5.4	1.22e-07	0.000105	0.33	0.28	Systemic lupus erythematosus;	chr1:174493387	chr1:174115300~174160004:-
STAD	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	5.4	1.22e-07	0.000105	0.32	0.28	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
STAD	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	5.4	1.22e-07	0.000105	0.44	0.28	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
STAD	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-5.4	1.22e-07	0.000105	-0.3	-0.28	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
STAD	cis	rs516805	0.961	rs9385248	ENSG00000279453.1	RP3-425C14.4	-5.4	1.22e-07	0.000105	-0.3	-0.28	Lymphocyte counts;	chr6:122490982	chr6:122436789~122439223:-
STAD	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	5.4	1.22e-07	0.000105	0.35	0.28	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
STAD	cis	rs987724	0.519	rs9820830	ENSG00000240875.4	LINC00886	-5.4	1.22e-07	0.000105	-0.34	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824915	chr3:156747346~156817062:-
STAD	cis	rs7124681	0.546	rs7941399	ENSG00000280615.1	Y_RNA	5.4	1.22e-07	0.000105	0.28	0.28	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47868869	chr11:47614898~47614994:-
STAD	cis	rs721917	0.506	rs4320898	ENSG00000225484.5	NUTM2B-AS1	-5.4	1.22e-07	0.000105	-0.36	-0.28	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79663088~79826594:-
STAD	cis	rs721917	0.506	rs4322333	ENSG00000225484.5	NUTM2B-AS1	-5.4	1.22e-07	0.000105	-0.36	-0.28	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79663088~79826594:-
STAD	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	5.4	1.22e-07	0.000105	0.51	0.28	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
STAD	cis	rs7487075	0.619	rs12314541	ENSG00000257261.4	RP11-96H19.1	5.4	1.22e-07	0.000105	0.34	0.28	Itch intensity from mosquito bite;	chr12:46400983	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs2408498	ENSG00000257261.4	RP11-96H19.1	5.4	1.22e-07	0.000105	0.34	0.28	Itch intensity from mosquito bite;	chr12:46403117	chr12:46383679~46876159:+
STAD	cis	rs4713118	0.911	rs9461406	ENSG00000280107.1	AL022393.9	5.4	1.22e-07	0.000105	0.39	0.28	Parkinson's disease;	chr6:27751985	chr6:28170845~28172521:+
STAD	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	5.4	1.22e-07	0.000105	0.29	0.28	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	5.4	1.22e-07	0.000105	0.29	0.28	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
STAD	cis	rs2439831	0.717	rs2447198	ENSG00000275601.1	AC011330.13	-5.4	1.22e-07	0.000105	-0.38	-0.28	Lung cancer in ever smokers;	chr15:43602920	chr15:43642389~43643023:-
STAD	cis	rs9467773	1	rs12526680	ENSG00000243307.2	POM121L6P	5.4	1.23e-07	0.000105	0.27	0.28	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26896952~26898777:+
STAD	cis	rs13113518	0.812	rs12649507	ENSG00000272969.1	RP11-528I4.2	-5.4	1.23e-07	0.000105	-0.35	-0.28	Height;	chr4:55514317	chr4:55547112~55547889:+
STAD	cis	rs992157	0.798	rs2382818	ENSG00000237281.1	CATIP-AS2	5.4	1.23e-07	0.000106	0.29	0.28	Colorectal cancer;	chr2:218291184	chr2:218326889~218357966:-
STAD	cis	rs992157	0.798	rs2382819	ENSG00000237281.1	CATIP-AS2	5.4	1.23e-07	0.000106	0.29	0.28	Colorectal cancer;	chr2:218291186	chr2:218326889~218357966:-
STAD	cis	rs4698412	0.646	rs4698120	ENSG00000214846.4	RP11-115L11.1	-5.4	1.23e-07	0.000106	-0.32	-0.28	Parkinson's disease;	chr4:15741709	chr4:15730962~15731627:-
STAD	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	5.4	1.23e-07	0.000106	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
STAD	cis	rs3758911	0.861	rs11212163	ENSG00000261098.1	RP11-819C21.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Coronary artery disease;	chr11:107328005	chr11:107312132~107316271:-
STAD	cis	rs7760535	0.763	rs10457240	ENSG00000230177.1	RP5-1112D6.4	-5.4	1.23e-07	0.000106	-0.25	-0.28	Metabolic traits;	chr6:111527671	chr6:111277932~111278742:+
STAD	cis	rs1426063	0.858	rs11931653	ENSG00000249717.1	RP11-44F21.3	5.4	1.23e-07	0.000106	0.49	0.28	QT interval;	chr4:75080856	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.858	rs55775471	ENSG00000249717.1	RP11-44F21.3	5.4	1.23e-07	0.000106	0.49	0.28	QT interval;	chr4:75081074	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.858	rs9990627	ENSG00000249717.1	RP11-44F21.3	5.4	1.23e-07	0.000106	0.49	0.28	QT interval;	chr4:75081244	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.858	rs10026994	ENSG00000249717.1	RP11-44F21.3	5.4	1.23e-07	0.000106	0.49	0.28	QT interval;	chr4:75081551	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.858	rs6830936	ENSG00000249717.1	RP11-44F21.3	5.4	1.23e-07	0.000106	0.49	0.28	QT interval;	chr4:75083952	chr4:74955974~74970362:-
STAD	cis	rs17301013	0.932	rs3737651	ENSG00000227373.4	RP11-160H22.5	-5.4	1.23e-07	0.000106	-0.33	-0.28	Systemic lupus erythematosus;	chr1:174475414	chr1:174115300~174160004:-
STAD	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-5.4	1.23e-07	0.000106	-0.43	-0.28	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
STAD	cis	rs611744	0.647	rs615126	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108235390	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs647907	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108239145	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs631775	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108240517	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs589347	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108241700	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs615233	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108242033	chr8:108226200~108227544:+
STAD	cis	rs611744	0.631	rs627392	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108242448	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs579162	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108242613	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs2597658	ENSG00000253754.1	RP11-35G22.1	-5.4	1.23e-07	0.000106	-0.25	-0.28	Dupuytren's disease;	chr8:108243785	chr8:108226200~108227544:+
STAD	cis	rs7487075	0.554	rs7960819	ENSG00000257261.4	RP11-96H19.1	5.4	1.24e-07	0.000106	0.33	0.28	Itch intensity from mosquito bite;	chr12:46234999	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.554	rs7957777	ENSG00000257261.4	RP11-96H19.1	5.4	1.24e-07	0.000106	0.33	0.28	Itch intensity from mosquito bite;	chr12:46235006	chr12:46383679~46876159:+
STAD	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-5.4	1.24e-07	0.000106	-0.29	-0.28	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
STAD	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	5.4	1.24e-07	0.000106	0.28	0.28	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
STAD	cis	rs8067354	0.574	rs2250526	ENSG00000266701.1	AC005702.4	5.4	1.24e-07	0.000106	0.4	0.28	Hemoglobin concentration;	chr17:59874612	chr17:60042546~60042627:-
STAD	cis	rs3806843	0.966	rs3806842	ENSG00000202111.1	VTRNA1-2	-5.4	1.24e-07	0.000107	-0.27	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140833091	chr5:140718925~140719013:+
STAD	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	5.4	1.24e-07	0.000107	0.41	0.28	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
STAD	cis	rs853679	0.517	rs4713145	ENSG00000220721.1	OR1F12	5.4	1.24e-07	0.000107	0.33	0.28	Depression;	chr6:28139049	chr6:28073316~28074233:+
STAD	cis	rs3758911	0.765	rs687991	ENSG00000261098.1	RP11-819C21.1	5.4	1.25e-07	0.000107	0.26	0.28	Coronary artery disease;	chr11:107449918	chr11:107312132~107316271:-
STAD	cis	rs7927771	0.524	rs754434	ENSG00000280615.1	Y_RNA	5.4	1.25e-07	0.000107	0.28	0.28	Subjective well-being;	chr11:47792728	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.507	rs12366244	ENSG00000280615.1	Y_RNA	5.4	1.25e-07	0.000107	0.28	0.28	Subjective well-being;	chr11:47860578	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7933896	ENSG00000280615.1	Y_RNA	5.4	1.25e-07	0.000107	0.28	0.28	Subjective well-being;	chr11:47861230	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7943464	ENSG00000280615.1	Y_RNA	5.4	1.25e-07	0.000107	0.28	0.28	Subjective well-being;	chr11:47865087	chr11:47614898~47614994:-
STAD	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-5.4	1.25e-07	0.000107	-0.28	-0.28	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
STAD	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-5.4	1.25e-07	0.000107	-0.26	-0.28	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
STAD	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	5.4	1.25e-07	0.000107	0.29	0.28	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
STAD	cis	rs992157	0.798	rs7557709	ENSG00000237281.1	CATIP-AS2	-5.4	1.25e-07	0.000107	-0.28	-0.28	Colorectal cancer;	chr2:218302806	chr2:218326889~218357966:-
STAD	cis	rs2337406	0.714	rs7152055	ENSG00000274576.2	IGHV2-70	-5.4	1.25e-07	0.000107	-0.34	-0.28	Alzheimer's disease (late onset);	chr14:106818996	chr14:106770577~106771020:-
STAD	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	5.4	1.26e-07	0.000108	0.3	0.28	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	5.4	1.26e-07	0.000108	0.3	0.28	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	5.4	1.26e-07	0.000108	0.3	0.28	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	5.4	1.26e-07	0.000108	0.3	0.28	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	5.4	1.26e-07	0.000108	0.3	0.28	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
STAD	cis	rs748404	0.666	rs514438	ENSG00000249839.1	AC011330.5	-5.4	1.26e-07	0.000108	-0.45	-0.28	Lung cancer;	chr15:43328245	chr15:43663654~43684339:-
STAD	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	5.4	1.26e-07	0.000108	0.34	0.28	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
STAD	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-5.4	1.26e-07	0.000108	-0.37	-0.28	Height;	chr6:109380015	chr6:109382795~109383666:+
STAD	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-5.4	1.26e-07	0.000108	-0.26	-0.28	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
STAD	cis	rs611744	0.647	rs4735053	ENSG00000253754.1	RP11-35G22.1	-5.4	1.26e-07	0.000108	-0.25	-0.28	Dupuytren's disease;	chr8:108248547	chr8:108226200~108227544:+
STAD	cis	rs7555523	0.779	rs2790049	ENSG00000224358.1	RP11-466F5.8	-5.4	1.26e-07	0.000108	-0.5	-0.28	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165774286	chr1:165768929~165775176:+
STAD	cis	rs950027	0.787	rs2433616	ENSG00000259433.2	CTD-2651B20.4	-5.4	1.26e-07	0.000108	-0.29	-0.28	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45330209~45332634:-
STAD	cis	rs8098244	0.557	rs11082712	ENSG00000267301.1	RPL23AP77	-5.4	1.26e-07	0.000108	-0.32	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23718286	chr18:23709825~23710287:-
STAD	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-5.4	1.26e-07	0.000108	-0.28	-0.28	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
STAD	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-5.4	1.26e-07	0.000108	-0.32	-0.28	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
STAD	cis	rs11098499	0.687	rs71610270	ENSG00000260091.1	RP11-33B1.4	5.4	1.26e-07	0.000108	0.27	0.28	Corneal astigmatism;	chr4:119366281	chr4:119409333~119410233:+
STAD	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-5.4	1.27e-07	0.000108	-0.28	-0.28	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
STAD	cis	rs2404602	0.692	rs66866130	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76836233	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs35170561	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76838354	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs12904198	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76854637	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs2137307	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76856679	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs12437733	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76863221	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.669	rs17367297	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76865685	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs12594556	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76873022	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs12595586	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76879869	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs58889902	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76880729	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs4360890	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76880954	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.669	rs12916324	ENSG00000259422.1	RP11-593F23.1	5.4	1.27e-07	0.000108	0.29	0.28	Blood metabolite levels;	chr15:76887262	chr15:76174891~76181486:-
STAD	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	5.4	1.27e-07	0.000108	0.33	0.28	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
STAD	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	5.4	1.27e-07	0.000109	0.34	0.28	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
STAD	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	5.4	1.27e-07	0.000109	0.34	0.28	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
STAD	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-5.4	1.27e-07	0.000109	-0.39	-0.28	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
STAD	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-5.4	1.27e-07	0.000109	-0.39	-0.28	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
STAD	cis	rs9307551	0.817	rs6852514	ENSG00000250334.4	LINC00989	-5.4	1.27e-07	0.000109	-0.33	-0.28	Refractive error;	chr4:79580759	chr4:79492416~79576460:+
STAD	cis	rs1799949	1	rs11653231	ENSG00000236383.6	LINC00854	-5.4	1.27e-07	0.000109	-0.23	-0.28	Menopause (age at onset);	chr17:43179443	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs1399323	ENSG00000236383.6	LINC00854	-5.4	1.27e-07	0.000109	-0.23	-0.28	Menopause (age at onset);	chr17:43180313	chr17:43216941~43305976:-
STAD	cis	rs1961102	0.521	rs599777	ENSG00000253385.1	KB-1254G8.1	5.4	1.27e-07	0.000109	0.28	0.28	QT interval;	chr8:102919710	chr8:102854455~102856075:+
STAD	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	5.39	1.27e-07	0.000109	0.27	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
STAD	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	5.39	1.27e-07	0.000109	0.34	0.28	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
STAD	cis	rs7829975	0.582	rs6982832	ENSG00000254340.1	RP11-10A14.3	-5.39	1.28e-07	0.000109	-0.35	-0.28	Mood instability;	chr8:8934707	chr8:9141424~9145435:+
STAD	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	5.39	1.28e-07	0.000109	0.29	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
STAD	cis	rs2404602	0.692	rs12913810	ENSG00000259422.1	RP11-593F23.1	5.39	1.28e-07	0.000109	0.29	0.28	Blood metabolite levels;	chr15:76874334	chr15:76174891~76181486:-
STAD	cis	rs7829975	0.582	rs6983150	ENSG00000254340.1	RP11-10A14.3	-5.39	1.28e-07	0.000109	-0.35	-0.28	Mood instability;	chr8:8934916	chr8:9141424~9145435:+
STAD	cis	rs1799949	1	rs2271574	ENSG00000236383.6	LINC00854	-5.39	1.28e-07	0.00011	-0.23	-0.28	Menopause (age at onset);	chr17:43175631	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs33994002	ENSG00000236383.6	LINC00854	-5.39	1.28e-07	0.00011	-0.23	-0.28	Menopause (age at onset);	chr17:43176801	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs33920795	ENSG00000236383.6	LINC00854	-5.39	1.28e-07	0.00011	-0.23	-0.28	Menopause (age at onset);	chr17:43176993	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs33918839	ENSG00000236383.6	LINC00854	-5.39	1.28e-07	0.00011	-0.23	-0.28	Menopause (age at onset);	chr17:43177155	chr17:43216941~43305976:-
STAD	cis	rs227275	0.525	rs223332	ENSG00000230069.3	LRRC37A15P	-5.39	1.28e-07	0.00011	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102727274~102730721:-
STAD	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-5.39	1.28e-07	0.00011	-0.34	-0.28	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
STAD	cis	rs7662987	0.793	rs28730632	ENSG00000272777.1	RP11-571L19.8	5.39	1.28e-07	0.00011	0.51	0.28	Smoking initiation;	chr4:99074552	chr4:99067256~99068125:-
STAD	cis	rs7662987	0.793	rs4699700	ENSG00000272777.1	RP11-571L19.8	5.39	1.28e-07	0.00011	0.51	0.28	Smoking initiation;	chr4:99077184	chr4:99067256~99068125:-
STAD	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-5.39	1.28e-07	0.00011	-0.29	-0.28	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
STAD	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-5.39	1.28e-07	0.00011	-0.39	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
STAD	cis	rs12744310	1	rs36143444	ENSG00000235358.1	RP11-399E6.1	5.39	1.29e-07	0.00011	0.36	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298638	chr1:41242373~41284861:+
STAD	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-5.39	1.29e-07	0.00011	-0.34	-0.28	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
STAD	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	5.39	1.29e-07	0.00011	0.34	0.28	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
STAD	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
STAD	cis	rs7826238	0.509	rs2948288	ENSG00000173295.6	FAM86B3P	5.39	1.29e-07	0.00011	0.32	0.28	Systolic blood pressure;	chr8:8257782	chr8:8228595~8244865:+
STAD	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-5.39	1.29e-07	0.00011	-0.46	-0.28	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
STAD	cis	rs1799949	1	rs12944430	ENSG00000236383.6	LINC00854	-5.39	1.29e-07	0.00011	-0.23	-0.28	Menopause (age at onset);	chr17:43178803	chr17:43216941~43305976:-
STAD	cis	rs1426063	1	rs10030850	ENSG00000248165.1	RP11-44F21.2	5.39	1.29e-07	0.00011	0.5	0.28	QT interval;	chr4:75099199	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs9993589	ENSG00000248165.1	RP11-44F21.2	5.39	1.29e-07	0.00011	0.5	0.28	QT interval;	chr4:75099556	chr4:74993877~75034824:-
STAD	cis	rs35934224	0.783	rs16984299	ENSG00000232926.1	AC000078.5	-5.39	1.29e-07	0.00011	-0.36	-0.28	Glaucoma (primary open-angle);	chr22:19876070	chr22:19887289~19887970:+
STAD	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	5.39	1.29e-07	0.00011	0.42	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
STAD	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	5.39	1.29e-07	0.00011	0.29	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
STAD	cis	rs9425766	0.679	rs6681390	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.32	0.28	Life satisfaction;	chr1:174261331	chr1:174115300~174160004:-
STAD	cis	rs9463078	0.528	rs12208023	ENSG00000219384.1	RP11-491H9.3	-5.39	1.29e-07	0.00011	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45056950	chr6:45158870~45159511:+
STAD	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	0.00011	0.4	0.28	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
STAD	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-5.39	1.3e-07	0.000111	-0.27	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
STAD	cis	rs9395066	0.545	rs66604011	ENSG00000219384.1	RP11-491H9.3	-5.39	1.3e-07	0.000111	-0.27	-0.28	Height;	chr6:45085322	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.528	rs11966936	ENSG00000219384.1	RP11-491H9.3	-5.39	1.3e-07	0.000111	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45085935	chr6:45158870~45159511:+
STAD	cis	rs9395066	0.509	rs6922772	ENSG00000219384.1	RP11-491H9.3	-5.39	1.3e-07	0.000111	-0.27	-0.28	Height;	chr6:45091847	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs6458418	ENSG00000219384.1	RP11-491H9.3	-5.39	1.3e-07	0.000111	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45047260	chr6:45158870~45159511:+
STAD	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-5.39	1.3e-07	0.000111	-0.36	-0.28	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-5.39	1.3e-07	0.000111	-0.36	-0.28	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-5.39	1.3e-07	0.000111	-0.36	-0.28	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
STAD	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-5.39	1.3e-07	0.000111	-0.3	-0.28	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
STAD	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-5.39	1.3e-07	0.000111	-0.28	-0.28	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
STAD	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-5.39	1.3e-07	0.000111	-0.28	-0.28	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
STAD	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-5.39	1.3e-07	0.000111	-0.28	-0.28	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
STAD	cis	rs507080	1	rs507080	ENSG00000278376.1	RP11-158I9.8	-5.39	1.3e-07	0.000111	-0.28	-0.28	Serum metabolite levels;	chr11:118678873	chr11:118791254~118793137:+
STAD	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-5.39	1.3e-07	0.000111	-0.28	-0.28	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
STAD	cis	rs507080	0.961	rs543413	ENSG00000278376.1	RP11-158I9.8	-5.39	1.3e-07	0.000111	-0.28	-0.28	Serum metabolite levels;	chr11:118679308	chr11:118791254~118793137:+
STAD	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	5.39	1.3e-07	0.000111	0.35	0.28	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	5.39	1.3e-07	0.000111	0.35	0.28	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
STAD	cis	rs748404	0.511	rs12442190	ENSG00000249839.1	AC011330.5	5.39	1.31e-07	0.000111	0.34	0.28	Lung cancer;	chr15:43153107	chr15:43663654~43684339:-
STAD	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	5.39	1.31e-07	0.000111	0.34	0.28	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
STAD	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-5.39	1.31e-07	0.000111	-0.4	-0.28	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
STAD	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	5.39	1.31e-07	0.000111	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
STAD	cis	rs611744	0.647	rs628206	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108235644	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs864166	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108237071	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs2848620	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108237322	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs702808	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108240325	chr8:108226200~108227544:+
STAD	cis	rs611744	0.608	rs667742	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108241774	chr8:108226200~108227544:+
STAD	cis	rs611744	0.631	rs681963	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108242803	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs2594357	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108243760	chr8:108226200~108227544:+
STAD	cis	rs611744	0.669	rs13251024	ENSG00000253754.1	RP11-35G22.1	-5.39	1.31e-07	0.000111	-0.25	-0.28	Dupuytren's disease;	chr8:108246104	chr8:108226200~108227544:+
STAD	cis	rs8141529	0.632	rs5762803	ENSG00000226471.5	CTA-292E10.6	-5.39	1.31e-07	0.000111	-0.35	-0.28	Lymphocyte counts;	chr22:28797650	chr22:28800683~28848559:+
STAD	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	5.39	1.31e-07	0.000112	0.3	0.28	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
STAD	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-5.39	1.31e-07	0.000112	-0.29	-0.28	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
STAD	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-5.39	1.31e-07	0.000112	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
STAD	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	5.39	1.31e-07	0.000112	0.41	0.28	Height;	chr6:109351533	chr6:109382795~109383666:+
STAD	cis	rs3806843	0.966	rs2563267	ENSG00000202111.1	VTRNA1-2	5.39	1.31e-07	0.000112	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.966	rs2563266	ENSG00000202111.1	VTRNA1-2	5.39	1.31e-07	0.000112	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr5:140718925~140719013:+
STAD	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-5.39	1.31e-07	0.000112	-0.3	-0.28	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
STAD	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	5.39	1.31e-07	0.000112	0.42	0.28	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
STAD	cis	rs7932354	0.528	rs10838654	ENSG00000271350.1	CTD-2384B9.1	-5.39	1.31e-07	0.000112	-0.34	-0.28	Bone mineral density (hip);Bone mineral density;	chr11:47073960	chr11:47041027~47041945:-
STAD	cis	rs2404602	0.692	rs12911174	ENSG00000259422.1	RP11-593F23.1	5.39	1.31e-07	0.000112	0.29	0.28	Blood metabolite levels;	chr15:76857602	chr15:76174891~76181486:-
STAD	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	5.39	1.32e-07	0.000112	0.29	0.28	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	5.39	1.32e-07	0.000112	0.29	0.28	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
STAD	cis	rs7083	0.935	rs529470	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117262092	chr11:117135528~117138582:+
STAD	cis	rs7083	0.935	rs529471	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117262093	chr11:117135528~117138582:+
STAD	cis	rs7083	0.935	rs7111678	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117265090	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs2509210	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117265354	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs507880	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117266539	chr11:117135528~117138582:+
STAD	cis	rs7083	0.935	rs2509211	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117266917	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs524085	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117266931	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs673738	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117272865	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs495438	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117274011	chr11:117135528~117138582:+
STAD	cis	rs7083	0.935	rs492151	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117275099	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs7083	ENSG00000254851.1	RP11-109L13.1	5.39	1.32e-07	0.000112	0.31	0.28	Blood protein levels;	chr11:117285836	chr11:117135528~117138582:+
STAD	cis	rs2283792	0.967	rs11704205	ENSG00000228050.1	TOP3BP1	5.39	1.32e-07	0.000112	0.31	0.28	Multiple sclerosis;	chr22:21790964	chr22:22223187~22224566:-
STAD	cis	rs7760535	0.763	rs9487666	ENSG00000230177.1	RP5-1112D6.4	-5.39	1.32e-07	0.000112	-0.25	-0.28	Metabolic traits;	chr6:111547821	chr6:111277932~111278742:+
STAD	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-5.39	1.32e-07	0.000112	-0.28	-0.28	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
STAD	cis	rs62432291	0.681	rs386818	ENSG00000235086.1	FNDC1-IT1	-5.39	1.32e-07	0.000112	-0.42	-0.28	Joint mobility (Beighton score);	chr6:159239223	chr6:159240786~159243329:+
STAD	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	5.39	1.32e-07	0.000112	0.41	0.28	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	5.39	1.32e-07	0.000112	0.41	0.28	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	5.39	1.32e-07	0.000112	0.41	0.28	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
STAD	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-5.39	1.32e-07	0.000112	-0.29	-0.28	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
STAD	cis	rs1799949	0.794	rs116409325	ENSG00000236383.6	LINC00854	-5.39	1.32e-07	0.000113	-0.23	-0.28	Menopause (age at onset);	chr17:43368092	chr17:43216941~43305976:-
STAD	cis	rs1862618	0.671	rs2591958	ENSG00000271828.1	CTD-2310F14.1	-5.39	1.33e-07	0.000113	-0.34	-0.28	Initial pursuit acceleration;	chr5:56943542	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.671	rs72644088	ENSG00000271828.1	CTD-2310F14.1	-5.39	1.33e-07	0.000113	-0.34	-0.28	Initial pursuit acceleration;	chr5:56945192	chr5:56927874~56929573:+
STAD	cis	rs1799949	0.965	rs9897425	ENSG00000236383.6	LINC00854	-5.39	1.33e-07	0.000113	-0.22	-0.28	Menopause (age at onset);	chr17:43352811	chr17:43216941~43305976:-
STAD	cis	rs7487075	0.82	rs7314069	ENSG00000272369.1	RP11-446N19.1	5.39	1.33e-07	0.000113	0.34	0.28	Itch intensity from mosquito bite;	chr12:46314954	chr12:46537502~46652550:+
STAD	cis	rs7932354	0.528	rs7121418	ENSG00000271350.1	CTD-2384B9.1	-5.39	1.33e-07	0.000113	-0.33	-0.28	Bone mineral density (hip);Bone mineral density;	chr11:47143555	chr11:47041027~47041945:-
STAD	cis	rs7829975	0.714	rs11784052	ENSG00000254340.1	RP11-10A14.3	5.39	1.33e-07	0.000113	0.32	0.28	Mood instability;	chr8:8814452	chr8:9141424~9145435:+
STAD	cis	rs1862618	0.671	rs2255726	ENSG00000271828.1	CTD-2310F14.1	-5.39	1.33e-07	0.000113	-0.34	-0.28	Initial pursuit acceleration;	chr5:56947301	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.671	rs2591957	ENSG00000271828.1	CTD-2310F14.1	-5.39	1.33e-07	0.000113	-0.34	-0.28	Initial pursuit acceleration;	chr5:56947319	chr5:56927874~56929573:+
STAD	cis	rs875971	0.522	rs1617484	ENSG00000222364.1	RNU6-96P	-5.39	1.33e-07	0.000113	-0.31	-0.28	Aortic root size;	chr7:65998108	chr7:66395191~66395286:+
STAD	cis	rs3806843	0.9	rs3756334	ENSG00000202111.1	VTRNA1-2	-5.39	1.33e-07	0.000113	-0.28	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140834211	chr5:140718925~140719013:+
STAD	cis	rs13113518	0.812	rs11932712	ENSG00000272969.1	RP11-528I4.2	5.39	1.33e-07	0.000113	0.35	0.28	Height;	chr4:55436423	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs12501746	ENSG00000272969.1	RP11-528I4.2	5.39	1.33e-07	0.000113	0.35	0.28	Height;	chr4:55437438	chr4:55547112~55547889:+
STAD	cis	rs2404602	0.692	rs12910734	ENSG00000259422.1	RP11-593F23.1	5.39	1.33e-07	0.000113	0.29	0.28	Blood metabolite levels;	chr15:76857590	chr15:76174891~76181486:-
STAD	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	5.39	1.33e-07	0.000113	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
STAD	cis	rs6142102	0.961	rs1007090	ENSG00000275784.1	RP5-1125A11.6	-5.39	1.34e-07	0.000114	-0.29	-0.28	Skin pigmentation;	chr20:33995065	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.923	rs2284377	ENSG00000275784.1	RP5-1125A11.6	-5.39	1.34e-07	0.000114	-0.29	-0.28	Skin pigmentation;	chr20:33998876	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs2284378	ENSG00000275784.1	RP5-1125A11.6	-5.39	1.34e-07	0.000114	-0.29	-0.28	Skin pigmentation;	chr20:34000289	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs2268080	ENSG00000275784.1	RP5-1125A11.6	-5.39	1.34e-07	0.000114	-0.29	-0.28	Skin pigmentation;	chr20:34009910	chr20:33989480~33991818:-
STAD	cis	rs875971	0.825	rs28480509	ENSG00000236529.1	RP13-254B10.1	-5.39	1.34e-07	0.000114	-0.28	-0.28	Aortic root size;	chr7:66634237	chr7:65840212~65840596:+
STAD	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	5.39	1.34e-07	0.000114	0.34	0.28	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
STAD	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	5.39	1.34e-07	0.000114	0.34	0.28	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	5.39	1.34e-07	0.000114	0.34	0.28	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
STAD	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	5.39	1.34e-07	0.000114	0.34	0.28	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
STAD	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	5.39	1.34e-07	0.000114	0.41	0.28	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
STAD	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	5.38	1.34e-07	0.000114	0.48	0.28	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
STAD	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-5.38	1.34e-07	0.000114	-0.28	-0.28	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
STAD	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	5.38	1.34e-07	0.000114	0.27	0.28	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
STAD	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	5.38	1.34e-07	0.000114	0.27	0.28	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
STAD	cis	rs7927771	0.832	rs11601173	ENSG00000280615.1	Y_RNA	-5.38	1.34e-07	0.000114	-0.28	-0.28	Subjective well-being;	chr11:47379507	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.832	rs11607981	ENSG00000280615.1	Y_RNA	-5.38	1.34e-07	0.000114	-0.28	-0.28	Subjective well-being;	chr11:47379509	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.832	rs11601603	ENSG00000280615.1	Y_RNA	-5.38	1.34e-07	0.000114	-0.28	-0.28	Subjective well-being;	chr11:47379620	chr11:47614898~47614994:-
STAD	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-5.38	1.34e-07	0.000114	-0.32	-0.28	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
STAD	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	5.38	1.34e-07	0.000114	0.32	0.28	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
STAD	cis	rs13113518	0.783	rs13111128	ENSG00000272969.1	RP11-528I4.2	5.38	1.34e-07	0.000114	0.36	0.28	Height;	chr4:55578154	chr4:55547112~55547889:+
STAD	cis	rs853679	0.517	rs4713141	ENSG00000220721.1	OR1F12	5.38	1.35e-07	0.000114	0.33	0.28	Depression;	chr6:28133900	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380056	ENSG00000220721.1	OR1F12	5.38	1.35e-07	0.000114	0.33	0.28	Depression;	chr6:28136698	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380057	ENSG00000220721.1	OR1F12	5.38	1.35e-07	0.000114	0.33	0.28	Depression;	chr6:28136856	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs6941992	ENSG00000220721.1	OR1F12	5.38	1.35e-07	0.000114	0.33	0.28	Depression;	chr6:28138363	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.516	rs4713142	ENSG00000220721.1	OR1F12	5.38	1.35e-07	0.000114	0.33	0.28	Parkinson's disease;	chr6:28138569	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs4713143	ENSG00000220721.1	OR1F12	5.38	1.35e-07	0.000114	0.33	0.28	Depression;	chr6:28138981	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs4713144	ENSG00000220721.1	OR1F12	5.38	1.35e-07	0.000114	0.33	0.28	Depression;	chr6:28139012	chr6:28073316~28074233:+
STAD	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	5.38	1.35e-07	0.000114	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
STAD	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	5.38	1.35e-07	0.000114	0.3	0.28	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
STAD	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	5.38	1.35e-07	0.000114	0.3	0.28	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
STAD	cis	rs9463078	0.546	rs10948198	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000114	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45041427	chr6:45158870~45159511:+
STAD	cis	rs3806843	0.897	rs2531338	ENSG00000202111.1	VTRNA1-2	5.38	1.35e-07	0.000114	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140757372	chr5:140718925~140719013:+
STAD	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	5.38	1.35e-07	0.000114	0.33	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
STAD	cis	rs1799949	0.93	rs3092987	ENSG00000279602.1	CTD-3014M21.1	5.38	1.35e-07	0.000114	0.35	0.28	Menopause (age at onset);	chr17:43070706	chr17:43360041~43361361:-
STAD	cis	rs4604732	0.631	rs12038793	ENSG00000227135.1	GCSAML-AS1	5.38	1.35e-07	0.000114	0.37	0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460960	chr1:247524679~247526752:-
STAD	cis	rs611744	0.647	rs585077	ENSG00000253754.1	RP11-35G22.1	-5.38	1.35e-07	0.000115	-0.25	-0.28	Dupuytren's disease;	chr8:108233268	chr8:108226200~108227544:+
STAD	cis	rs2439831	0.85	rs544122	ENSG00000275601.1	AC011330.13	-5.38	1.35e-07	0.000115	-0.37	-0.28	Lung cancer in ever smokers;	chr15:43483534	chr15:43642389~43643023:-
STAD	cis	rs2283792	1	rs2266967	ENSG00000228050.1	TOP3BP1	5.38	1.35e-07	0.000115	0.31	0.28	Multiple sclerosis;	chr22:21802500	chr22:22223187~22224566:-
STAD	cis	rs7487075	0.859	rs3782904	ENSG00000272369.1	RP11-446N19.1	5.38	1.35e-07	0.000115	0.33	0.28	Itch intensity from mosquito bite;	chr12:46364202	chr12:46537502~46652550:+
STAD	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	5.38	1.35e-07	0.000115	0.34	0.28	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
STAD	cis	rs9463078	0.546	rs13207575	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45053103	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs969211	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45054641	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs4412189	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45055489	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs2186062	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45055995	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs7758031	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45058099	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs12190261	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45061282	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs11968042	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45078998	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs1937046	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45080506	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.546	rs1937047	ENSG00000219384.1	RP11-491H9.3	-5.38	1.35e-07	0.000115	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45080517	chr6:45158870~45159511:+
STAD	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-5.38	1.36e-07	0.000115	-0.24	-0.28	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
STAD	cis	rs7665090	0.728	rs228617	ENSG00000248971.2	KRT8P46	5.38	1.36e-07	0.000115	0.29	0.28	Primary biliary cholangitis;	chr4:102659631	chr4:102728746~102730171:-
STAD	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-5.38	1.36e-07	0.000115	-0.35	-0.28	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
STAD	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-5.38	1.36e-07	0.000115	-0.26	-0.28	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
STAD	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-5.38	1.36e-07	0.000115	-0.32	-0.28	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
STAD	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-5.38	1.36e-07	0.000115	-0.24	-0.28	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
STAD	cis	rs516805	0.924	rs809770	ENSG00000279453.1	RP3-425C14.4	-5.38	1.36e-07	0.000115	-0.3	-0.28	Lymphocyte counts;	chr6:122440061	chr6:122436789~122439223:-
STAD	cis	rs516805	0.924	rs476215	ENSG00000279453.1	RP3-425C14.4	-5.38	1.36e-07	0.000115	-0.3	-0.28	Lymphocyte counts;	chr6:122440739	chr6:122436789~122439223:-
STAD	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-5.38	1.36e-07	0.000116	-0.35	-0.28	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
STAD	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	5.38	1.37e-07	0.000116	0.31	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
STAD	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-5.38	1.37e-07	0.000116	-0.3	-0.28	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
STAD	cis	rs2221894	0.665	rs10111109	ENSG00000273710.1	Metazoa_SRP	-5.38	1.37e-07	0.000116	-0.29	-0.28	Obesity-related traits;	chr8:29078274	chr8:28915579~28915864:-
STAD	cis	rs516805	0.748	rs11968579	ENSG00000279453.1	RP3-425C14.4	5.38	1.37e-07	0.000116	0.4	0.28	Lymphocyte counts;	chr6:122575950	chr6:122436789~122439223:-
STAD	cis	rs853679	0.517	rs35193936	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28108492	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs36078605	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28110254	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393891	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28111382	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9468286	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28111650	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.516	rs7739216	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Parkinson's disease;	chr6:28112168	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs35512245	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28112175	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380055	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28113851	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368553	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28114487	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368554	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28114933	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs4713137	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28115743	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9348793	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28116411	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.586	rs6905516	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Parkinson's disease;	chr6:28118700	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.586	rs6905522	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Parkinson's disease;	chr6:28118701	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.586	rs9468290	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Parkinson's disease;	chr6:28119896	chr6:28073316~28074233:+
STAD	cis	rs853679	0.542	rs6934769	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28123153	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs17711801	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28124529	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.527	rs9461433	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Parkinson's disease;	chr6:28127394	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9468292	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28127577	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs1947863	ENSG00000220721.1	OR1F12	5.38	1.37e-07	0.000116	0.33	0.28	Depression;	chr6:28131566	chr6:28073316~28074233:+
STAD	cis	rs7927771	0.832	rs4752993	ENSG00000280615.1	Y_RNA	5.38	1.37e-07	0.000116	0.28	0.28	Subjective well-being;	chr11:47389400	chr11:47614898~47614994:-
STAD	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	5.38	1.37e-07	0.000116	0.31	0.28	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
STAD	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	5.38	1.37e-07	0.000116	0.31	0.28	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
STAD	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-5.38	1.37e-07	0.000116	-0.42	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
STAD	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	5.38	1.37e-07	0.000116	0.3	0.28	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
STAD	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-5.38	1.37e-07	0.000116	-0.28	-0.28	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
STAD	cis	rs66887589	0.616	rs11098497	ENSG00000249244.1	RP11-548H18.2	5.38	1.37e-07	0.000116	0.34	0.28	Diastolic blood pressure;	chr4:119265913	chr4:119391831~119395335:-
STAD	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	5.38	1.38e-07	0.000116	0.37	0.28	Height;	chr6:109407148	chr6:109382795~109383666:+
STAD	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-5.38	1.38e-07	0.000116	-0.29	-0.28	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
STAD	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-5.38	1.38e-07	0.000116	-0.31	-0.28	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
STAD	cis	rs8040855	0.627	rs12904238	ENSG00000229212.6	RP11-561C5.4	5.38	1.38e-07	0.000116	0.39	0.28	Bulimia nervosa;	chr15:85096610	chr15:85205440~85234795:-
STAD	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	5.38	1.38e-07	0.000116	0.3	0.28	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
STAD	cis	rs8098244	0.52	rs12955456	ENSG00000267301.1	RPL23AP77	-5.38	1.38e-07	0.000116	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677624	chr18:23709825~23710287:-
STAD	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-5.38	1.38e-07	0.000117	-0.36	-0.28	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
STAD	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	5.38	1.38e-07	0.000117	0.43	0.28	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
STAD	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-5.38	1.38e-07	0.000117	-0.29	-0.28	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
STAD	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-5.38	1.38e-07	0.000117	-0.35	-0.28	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
STAD	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	5.38	1.38e-07	0.000117	0.37	0.28	Height;	chr6:109423238	chr6:109382795~109383666:+
STAD	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-5.38	1.38e-07	0.000117	-0.26	-0.28	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-5.38	1.38e-07	0.000117	-0.26	-0.28	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
STAD	cis	rs4927850	0.958	rs2044599	ENSG00000185485.13	SDHAP1	5.38	1.39e-07	0.000117	0.28	0.28	Pancreatic cancer;	chr3:196009869	chr3:195959748~195990318:-
STAD	cis	rs2439831	0.681	rs478104	ENSG00000249839.1	AC011330.5	-5.38	1.39e-07	0.000117	-0.4	-0.28	Lung cancer in ever smokers;	chr15:43302702	chr15:43663654~43684339:-
STAD	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	5.38	1.39e-07	0.000117	0.37	0.28	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
STAD	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.38	1.39e-07	0.000117	-0.38	-0.28	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
STAD	cis	rs1729407	0.625	rs2727789	ENSG00000280143.1	AP000892.6	5.38	1.39e-07	0.000117	0.2	0.28	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117204967~117210292:+
STAD	cis	rs1729407	0.659	rs2542050	ENSG00000280143.1	AP000892.6	5.38	1.39e-07	0.000117	0.2	0.28	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117204967~117210292:+
STAD	cis	rs1729407	0.565	rs2849173	ENSG00000280143.1	AP000892.6	5.38	1.39e-07	0.000117	0.2	0.28	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117204967~117210292:+
STAD	cis	rs7829975	0.742	rs882462	ENSG00000254340.1	RP11-10A14.3	5.38	1.39e-07	0.000117	0.32	0.28	Mood instability;	chr8:8821020	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.774	rs11775523	ENSG00000254340.1	RP11-10A14.3	5.38	1.39e-07	0.000117	0.32	0.28	Mood instability;	chr8:8821666	chr8:9141424~9145435:+
STAD	cis	rs7927771	0.524	rs9633830	ENSG00000280615.1	Y_RNA	5.38	1.39e-07	0.000118	0.28	0.28	Subjective well-being;	chr11:47827918	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs11039419	ENSG00000280615.1	Y_RNA	5.38	1.39e-07	0.000118	0.28	0.28	Subjective well-being;	chr11:47829802	chr11:47614898~47614994:-
STAD	cis	rs6142102	0.961	rs4911390	ENSG00000275784.1	RP5-1125A11.6	-5.38	1.39e-07	0.000118	-0.29	-0.28	Skin pigmentation;	chr20:33977401	chr20:33989480~33991818:-
STAD	cis	rs4604732	0.527	rs12031949	ENSG00000227135.1	GCSAML-AS1	-5.38	1.39e-07	0.000118	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461161	chr1:247524679~247526752:-
STAD	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	5.38	1.39e-07	0.000118	0.32	0.28	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
STAD	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-5.38	1.39e-07	0.000118	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-5.38	1.39e-07	0.000118	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
STAD	cis	rs950169	0.8	rs4842847	ENSG00000259295.5	CSPG4P12	5.38	1.39e-07	0.000118	0.42	0.28	Schizophrenia;	chr15:84262447	chr15:85191438~85213905:+
STAD	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-5.38	1.4e-07	0.000118	-0.43	-0.28	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
STAD	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-5.38	1.4e-07	0.000118	-0.43	-0.28	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
STAD	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	5.38	1.4e-07	0.000118	0.34	0.28	Height;	chr6:109446727	chr6:109382795~109383666:+
STAD	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	5.38	1.4e-07	0.000118	0.31	0.28	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
STAD	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	5.38	1.4e-07	0.000118	0.42	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	5.38	1.4e-07	0.000118	0.42	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	5.38	1.4e-07	0.000118	0.42	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	5.38	1.4e-07	0.000118	0.42	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
STAD	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	5.38	1.4e-07	0.000118	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
STAD	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-5.38	1.4e-07	0.000118	-0.32	-0.28	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
STAD	cis	rs875971	0.83	rs778711	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66386670	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs1083554	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66387354	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs778707	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66392040	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs778705	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66396128	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs778697	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66405439	chr7:65840212~65840596:+
STAD	cis	rs875971	0.798	rs7789615	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66413674	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6978028	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66421313	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6947339	ENSG00000236529.1	RP13-254B10.1	5.38	1.4e-07	0.000118	0.28	0.28	Aortic root size;	chr7:66423483	chr7:65840212~65840596:+
STAD	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	5.38	1.4e-07	0.000118	0.37	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
STAD	cis	rs8098244	0.619	rs1009588	ENSG00000267301.1	RPL23AP77	5.38	1.4e-07	0.000118	0.32	0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23741751	chr18:23709825~23710287:-
STAD	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	5.38	1.4e-07	0.000118	0.3	0.28	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
STAD	cis	rs8098244	0.638	rs3745027	ENSG00000267301.1	RPL23AP77	-5.38	1.4e-07	0.000118	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23893999	chr18:23709825~23710287:-
STAD	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	5.38	1.41e-07	0.000119	0.27	0.28	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
STAD	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	5.38	1.41e-07	0.000119	0.27	0.28	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
STAD	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	5.38	1.41e-07	0.000119	0.27	0.28	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
STAD	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-5.38	1.41e-07	0.000119	-0.34	-0.28	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
STAD	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-5.38	1.41e-07	0.000119	-0.34	-0.28	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
STAD	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-5.38	1.41e-07	0.000119	-0.29	-0.28	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
STAD	cis	rs1816752	0.749	rs77832754	ENSG00000273628.1	RP11-756A22.7	5.37	1.41e-07	0.000119	0.34	0.28	Obesity-related traits;	chr13:24416016	chr13:24933006~24936796:+
STAD	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-5.37	1.41e-07	0.000119	-0.25	-0.28	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
STAD	cis	rs2688482	0.557	rs2550236	ENSG00000185485.13	SDHAP1	5.37	1.42e-07	0.000119	0.36	0.28	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195959748~195990318:-
STAD	cis	rs228614	0.543	rs223330	ENSG00000230069.3	LRRC37A15P	-5.37	1.42e-07	0.000119	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223329	ENSG00000230069.3	LRRC37A15P	-5.37	1.42e-07	0.000119	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102727274~102730721:-
STAD	cis	rs228614	0.536	rs223327	ENSG00000230069.3	LRRC37A15P	-5.37	1.42e-07	0.000119	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223326	ENSG00000230069.3	LRRC37A15P	-5.37	1.42e-07	0.000119	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223324	ENSG00000230069.3	LRRC37A15P	-5.37	1.42e-07	0.000119	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102727274~102730721:-
STAD	cis	rs950169	0.922	rs62028133	ENSG00000259295.5	CSPG4P12	5.37	1.42e-07	0.000119	0.41	0.28	Schizophrenia;	chr15:84250623	chr15:85191438~85213905:+
STAD	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	5.37	1.42e-07	0.000119	0.35	0.28	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
STAD	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-5.37	1.42e-07	0.000119	-0.39	-0.28	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
STAD	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	5.37	1.42e-07	0.00012	0.47	0.28	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
STAD	cis	rs1056107	0.931	rs10981332	ENSG00000225513.1	RP11-165N19.2	-5.37	1.42e-07	0.00012	-0.32	-0.28	Colorectal cancer;	chr9:112254003	chr9:112173522~112173971:-
STAD	cis	rs227275	0.527	rs223338	ENSG00000230069.3	LRRC37A15P	-5.37	1.42e-07	0.00012	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102727274~102730721:-
STAD	cis	rs9549260	0.561	rs9549297	ENSG00000229456.1	RLIMP1	5.37	1.42e-07	0.00012	0.33	0.28	Red blood cell count;	chr13:40823346	chr13:40618738~40621348:+
STAD	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	5.37	1.42e-07	0.00012	0.3	0.28	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
STAD	cis	rs875971	0.502	rs1796227	ENSG00000224316.1	RP11-479O9.2	-5.37	1.42e-07	0.00012	-0.31	-0.28	Aortic root size;	chr7:66622032	chr7:65773620~65802067:+
STAD	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-5.37	1.42e-07	0.00012	-0.29	-0.28	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
STAD	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-5.37	1.42e-07	0.00012	-0.32	-0.28	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-5.37	1.42e-07	0.00012	-0.32	-0.28	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
STAD	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	5.37	1.42e-07	0.00012	0.43	0.28	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
STAD	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-5.37	1.42e-07	0.00012	-0.29	-0.28	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
STAD	cis	rs9400467	0.528	rs56827	ENSG00000230177.1	RP5-1112D6.4	-5.37	1.42e-07	0.00012	-0.24	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111277932~111278742:+
STAD	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	5.37	1.42e-07	0.00012	0.38	0.28	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
STAD	cis	rs10504130	0.569	rs13265006	ENSG00000272024.1	RP11-546K22.3	-5.37	1.43e-07	0.00012	-0.39	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.597	rs34058697	ENSG00000272024.1	RP11-546K22.3	-5.37	1.43e-07	0.00012	-0.39	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51950284~51950690:+
STAD	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	5.37	1.43e-07	0.00012	0.4	0.28	Height;	chr6:109331033	chr6:109382795~109383666:+
STAD	cis	rs6714710	0.627	rs11680883	ENSG00000235833.1	AC159540.14	-5.37	1.43e-07	0.00012	-0.33	-0.28	Posterior cortical atrophy and Alzheimer's disease;	chr2:97856147	chr2:97523949~97524976:-
STAD	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	5.37	1.43e-07	0.000121	0.39	0.28	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
STAD	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-5.37	1.43e-07	0.000121	-0.29	-0.28	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
STAD	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	5.37	1.44e-07	0.000121	0.32	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
STAD	cis	rs992157	0.56	rs6738394	ENSG00000237281.1	CATIP-AS2	5.37	1.44e-07	0.000121	0.27	0.28	Colorectal cancer;	chr2:218245902	chr2:218326889~218357966:-
STAD	cis	rs2436845	0.966	rs3018956	ENSG00000253385.1	KB-1254G8.1	5.37	1.44e-07	0.000121	0.3	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102835367	chr8:102854455~102856075:+
STAD	cis	rs1799949	0.894	rs71367985	ENSG00000236383.6	LINC00854	-5.37	1.44e-07	0.000121	-0.22	-0.28	Menopause (age at onset);	chr17:43222443	chr17:43216941~43305976:-
STAD	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	5.37	1.44e-07	0.000121	0.37	0.28	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
STAD	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-5.37	1.44e-07	0.000121	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
STAD	cis	rs875971	0.545	rs2420612	ENSG00000224316.1	RP11-479O9.2	5.37	1.44e-07	0.000121	0.31	0.28	Aortic root size;	chr7:66536825	chr7:65773620~65802067:+
STAD	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	5.37	1.44e-07	0.000121	0.34	0.28	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
STAD	cis	rs992157	0.835	rs12987180	ENSG00000237281.1	CATIP-AS2	5.37	1.44e-07	0.000121	0.28	0.28	Colorectal cancer;	chr2:218279366	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs12987219	ENSG00000237281.1	CATIP-AS2	5.37	1.44e-07	0.000121	0.28	0.28	Colorectal cancer;	chr2:218279426	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs4674283	ENSG00000237281.1	CATIP-AS2	5.37	1.44e-07	0.000121	0.28	0.28	Colorectal cancer;	chr2:218279531	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs10932768	ENSG00000237281.1	CATIP-AS2	5.37	1.44e-07	0.000121	0.28	0.28	Colorectal cancer;	chr2:218281476	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs7585702	ENSG00000237281.1	CATIP-AS2	5.37	1.44e-07	0.000121	0.28	0.28	Colorectal cancer;	chr2:218281884	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs10932769	ENSG00000237281.1	CATIP-AS2	5.37	1.44e-07	0.000121	0.28	0.28	Colorectal cancer;	chr2:218282522	chr2:218326889~218357966:-
STAD	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	5.37	1.44e-07	0.000121	0.34	0.28	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
STAD	cis	rs1799949	0.965	rs11650132	ENSG00000236383.6	LINC00854	-5.37	1.44e-07	0.000121	-0.23	-0.28	Menopause (age at onset);	chr17:43174070	chr17:43216941~43305976:-
STAD	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	5.37	1.44e-07	0.000121	0.46	0.28	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
STAD	cis	rs611744	0.573	rs674580	ENSG00000253754.1	RP11-35G22.1	-5.37	1.44e-07	0.000121	-0.24	-0.28	Dupuytren's disease;	chr8:108239461	chr8:108226200~108227544:+
STAD	cis	rs611744	0.573	rs629996	ENSG00000253754.1	RP11-35G22.1	-5.37	1.44e-07	0.000121	-0.24	-0.28	Dupuytren's disease;	chr8:108242977	chr8:108226200~108227544:+
STAD	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	5.37	1.45e-07	0.000122	0.3	0.28	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-5.37	1.45e-07	0.000122	-0.29	-0.28	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-5.37	1.45e-07	0.000122	-0.29	-0.28	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
STAD	cis	rs9400467	0.528	rs462432	ENSG00000230177.1	RP5-1112D6.4	-5.37	1.45e-07	0.000122	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111277932~111278742:+
STAD	cis	rs7760535	0.931	rs466923	ENSG00000230177.1	RP5-1112D6.4	-5.37	1.45e-07	0.000122	-0.25	-0.28	Metabolic traits;	chr6:111341774	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs1623806	ENSG00000230177.1	RP5-1112D6.4	-5.37	1.45e-07	0.000122	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111277932~111278742:+
STAD	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-5.37	1.45e-07	0.000122	-0.26	-0.28	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
STAD	cis	rs7927771	0.8	rs35996350	ENSG00000280615.1	Y_RNA	-5.37	1.45e-07	0.000122	-0.28	-0.28	Subjective well-being;	chr11:47367672	chr11:47614898~47614994:-
STAD	cis	rs3806843	0.898	rs3756335	ENSG00000202111.1	VTRNA1-2	-5.37	1.46e-07	0.000122	-0.28	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140833925	chr5:140718925~140719013:+
STAD	cis	rs1056107	0.931	rs2274519	ENSG00000225513.1	RP11-165N19.2	-5.37	1.46e-07	0.000122	-0.32	-0.28	Colorectal cancer;	chr9:112235008	chr9:112173522~112173971:-
STAD	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-5.37	1.46e-07	0.000122	-0.52	-0.28	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
STAD	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-5.37	1.46e-07	0.000122	-0.32	-0.28	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
STAD	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	5.37	1.46e-07	0.000123	0.4	0.28	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
STAD	cis	rs9463078	0.546	rs7763450	ENSG00000219384.1	RP11-491H9.3	-5.37	1.46e-07	0.000123	-0.27	-0.28	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45062159	chr6:45158870~45159511:+
STAD	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-5.37	1.46e-07	0.000123	-0.29	-0.28	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
STAD	cis	rs2404602	0.692	rs7169663	ENSG00000259422.1	RP11-593F23.1	5.37	1.46e-07	0.000123	0.29	0.28	Blood metabolite levels;	chr15:76900502	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs35999717	ENSG00000259422.1	RP11-593F23.1	5.37	1.46e-07	0.000123	0.29	0.28	Blood metabolite levels;	chr15:76901026	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-5.37	1.46e-07	0.000123	-0.25	-0.28	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
STAD	cis	rs507080	0.883	rs656575	ENSG00000278376.1	RP11-158I9.8	-5.37	1.46e-07	0.000123	-0.28	-0.28	Serum metabolite levels;	chr11:118679199	chr11:118791254~118793137:+
STAD	cis	rs507080	0.961	rs656505	ENSG00000278376.1	RP11-158I9.8	-5.37	1.46e-07	0.000123	-0.28	-0.28	Serum metabolite levels;	chr11:118679245	chr11:118791254~118793137:+
STAD	cis	rs507080	0.961	rs660489	ENSG00000278376.1	RP11-158I9.8	-5.37	1.46e-07	0.000123	-0.28	-0.28	Serum metabolite levels;	chr11:118679255	chr11:118791254~118793137:+
STAD	cis	rs507080	0.961	rs543327	ENSG00000278376.1	RP11-158I9.8	-5.37	1.46e-07	0.000123	-0.28	-0.28	Serum metabolite levels;	chr11:118679276	chr11:118791254~118793137:+
STAD	cis	rs1816752	0.819	rs4770665	ENSG00000273628.1	RP11-756A22.7	5.37	1.46e-07	0.000123	0.34	0.28	Obesity-related traits;	chr13:24414810	chr13:24933006~24936796:+
STAD	cis	rs2337406	1	rs10459466	ENSG00000211972.2	IGHV3-66	5.37	1.46e-07	0.000123	0.33	0.28	Alzheimer's disease (late onset);	chr14:106689255	chr14:106675017~106675544:-
STAD	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-5.37	1.47e-07	0.000123	-0.29	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
STAD	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-5.37	1.47e-07	0.000123	-0.38	-0.28	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
STAD	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-5.37	1.47e-07	0.000123	-0.26	-0.28	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
STAD	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	5.37	1.47e-07	0.000123	0.4	0.28	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
STAD	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	5.37	1.47e-07	0.000123	0.38	0.28	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
STAD	cis	rs7927771	0.524	rs7118747	ENSG00000280615.1	Y_RNA	-5.37	1.47e-07	0.000123	-0.28	-0.28	Subjective well-being;	chr11:47867993	chr11:47614898~47614994:-
STAD	cis	rs17301013	0.932	rs2987874	ENSG00000227373.4	RP11-160H22.5	-5.37	1.47e-07	0.000123	-0.32	-0.28	Systemic lupus erythematosus;	chr1:174801053	chr1:174115300~174160004:-
STAD	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	5.37	1.47e-07	0.000123	0.31	0.28	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
STAD	cis	rs7580658	0.864	rs3088374	ENSG00000200250.1	RNU6-1147P	5.37	1.47e-07	0.000124	0.28	0.28	Protein C levels;	chr2:127304472	chr2:127316873~127316979:+
STAD	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	5.37	1.48e-07	0.000124	0.33	0.28	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
STAD	cis	rs228614	0.51	rs223362	ENSG00000230069.3	LRRC37A15P	-5.37	1.48e-07	0.000124	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102727274~102730721:-
STAD	cis	rs17301013	0.932	rs6425281	ENSG00000227373.4	RP11-160H22.5	5.37	1.48e-07	0.000124	0.32	0.28	Systemic lupus erythematosus;	chr1:174449784	chr1:174115300~174160004:-
STAD	cis	rs7829975	0.627	rs2979172	ENSG00000253893.2	FAM85B	-5.37	1.48e-07	0.000124	-0.34	-0.28	Mood instability;	chr8:8452998	chr8:8167819~8226614:-
STAD	cis	rs5769707	0.605	rs9616702	ENSG00000280224.1	CTA-722E9.1	-5.37	1.48e-07	0.000124	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49500568~49501585:+
STAD	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-5.37	1.48e-07	0.000124	-0.35	-0.28	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
STAD	cis	rs2221894	0.632	rs11785025	ENSG00000273710.1	Metazoa_SRP	5.37	1.48e-07	0.000124	0.35	0.28	Obesity-related traits;	chr8:28988482	chr8:28915579~28915864:-
STAD	cis	rs4713118	0.866	rs9468217	ENSG00000280107.1	AL022393.9	-5.37	1.48e-07	0.000124	-0.38	-0.28	Parkinson's disease;	chr6:27758688	chr6:28170845~28172521:+
STAD	cis	rs2948294	0.566	rs13274039	ENSG00000253981.4	ALG1L13P	5.36	1.49e-07	0.000124	0.33	0.28	Red cell distribution width;	chr8:8254137	chr8:8236003~8244667:-
STAD	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	5.36	1.49e-07	0.000124	0.4	0.28	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	5.36	1.49e-07	0.000124	0.4	0.28	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
STAD	cis	rs9400467	0.528	rs455247	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111277932~111278742:+
STAD	cis	rs7760535	0.811	rs464401	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Metabolic traits;	chr6:111347804	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.509	rs463854	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.509	rs463853	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs456569	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs455335	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs465795	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs110732	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.592	rs462493	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.508	rs456871	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.49e-07	0.000125	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111277932~111278742:+
STAD	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	5.36	1.49e-07	0.000125	0.34	0.28	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
STAD	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	5.36	1.49e-07	0.000125	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
STAD	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-5.36	1.49e-07	0.000125	-0.27	-0.28	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
STAD	cis	rs3806843	0.966	rs10060640	ENSG00000202111.1	VTRNA1-2	-5.36	1.49e-07	0.000125	-0.27	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr5:140718925~140719013:+
STAD	cis	rs7083	0.967	rs477269	ENSG00000254851.1	RP11-109L13.1	5.36	1.49e-07	0.000125	0.31	0.28	Blood protein levels;	chr11:117267575	chr11:117135528~117138582:+
STAD	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-5.36	1.49e-07	0.000125	-0.3	-0.28	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-5.36	1.49e-07	0.000125	-0.3	-0.28	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
STAD	cis	rs875971	0.545	rs10950036	ENSG00000224316.1	RP11-479O9.2	5.36	1.5e-07	0.000125	0.31	0.28	Aortic root size;	chr7:66353241	chr7:65773620~65802067:+
STAD	cis	rs7927771	0.524	rs4752798	ENSG00000280615.1	Y_RNA	-5.36	1.5e-07	0.000125	-0.28	-0.28	Subjective well-being;	chr11:47864812	chr11:47614898~47614994:-
STAD	cis	rs9601248	0.627	rs2876741	ENSG00000227354.5	RBM26-AS1	-5.36	1.5e-07	0.000126	-0.35	-0.28	Major depressive disorder;	chr13:79612577	chr13:79406309~79424328:+
STAD	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	5.36	1.5e-07	0.000126	0.3	0.28	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
STAD	cis	rs2436845	1	rs2513922	ENSG00000253385.1	KB-1254G8.1	5.36	1.5e-07	0.000126	0.29	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102817960	chr8:102854455~102856075:+
STAD	cis	rs2404602	0.669	rs12441484	ENSG00000259422.1	RP11-593F23.1	5.36	1.51e-07	0.000126	0.29	0.28	Blood metabolite levels;	chr15:76817534	chr15:76174891~76181486:-
STAD	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	5.36	1.51e-07	0.000126	0.29	0.28	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
STAD	cis	rs611744	0.658	rs2443775	ENSG00000253754.1	RP11-35G22.1	5.36	1.51e-07	0.000126	0.25	0.28	Dupuytren's disease;	chr8:108050253	chr8:108226200~108227544:+
STAD	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	5.36	1.51e-07	0.000126	0.39	0.28	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
STAD	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	5.36	1.51e-07	0.000126	0.31	0.28	Height;	chr4:55489895	chr4:55540502~55540835:-
STAD	cis	rs228614	0.51	rs4699033	ENSG00000230069.3	LRRC37A15P	-5.36	1.51e-07	0.000126	-0.3	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102727274~102730721:-
STAD	cis	rs7078219	0.505	rs10883371	ENSG00000228778.1	RP11-129J12.1	-5.36	1.51e-07	0.000126	-0.32	-0.28	Dental caries;	chr10:99532698	chr10:99527081~99528261:+
STAD	cis	rs7927771	0.524	rs7116346	ENSG00000280615.1	Y_RNA	-5.36	1.51e-07	0.000126	-0.28	-0.28	Subjective well-being;	chr11:47862328	chr11:47614898~47614994:-
STAD	cis	rs66887589	0.616	rs10032299	ENSG00000249244.1	RP11-548H18.2	5.36	1.51e-07	0.000127	0.35	0.28	Diastolic blood pressure;	chr4:119285264	chr4:119391831~119395335:-
STAD	cis	rs1799949	0.965	rs799917	ENSG00000236383.6	LINC00854	-5.36	1.52e-07	0.000127	-0.22	-0.28	Menopause (age at onset);	chr17:43092919	chr17:43216941~43305976:-
STAD	cis	rs2980439	0.525	rs2980508	ENSG00000173295.6	FAM86B3P	5.36	1.52e-07	0.000127	0.29	0.28	Neuroticism;	chr8:8314210	chr8:8228595~8244865:+
STAD	cis	rs3806843	0.966	rs11953833	ENSG00000202111.1	VTRNA1-2	-5.36	1.52e-07	0.000127	-0.27	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140775538	chr5:140718925~140719013:+
STAD	cis	rs4604732	0.536	rs12074913	ENSG00000227135.1	GCSAML-AS1	-5.36	1.52e-07	0.000127	-0.38	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468305	chr1:247524679~247526752:-
STAD	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-5.36	1.52e-07	0.000127	-0.31	-0.28	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
STAD	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	5.36	1.52e-07	0.000127	0.3	0.28	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
STAD	cis	rs7927771	0.832	rs6485753	ENSG00000280615.1	Y_RNA	5.36	1.53e-07	0.000127	0.28	0.28	Subjective well-being;	chr11:47388649	chr11:47614898~47614994:-
STAD	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	5.36	1.53e-07	0.000127	0.37	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
STAD	cis	rs9646944	0.519	rs1041973	ENSG00000234389.1	AC007278.3	-5.36	1.53e-07	0.000128	-0.31	-0.28	Blood protein levels;	chr2:102339008	chr2:102438713~102440475:+
STAD	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-5.36	1.53e-07	0.000128	-0.25	-0.28	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
STAD	cis	rs4713118	0.868	rs760587	ENSG00000280107.1	AL022393.9	-5.36	1.53e-07	0.000128	-0.39	-0.28	Parkinson's disease;	chr6:27772521	chr6:28170845~28172521:+
STAD	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-5.36	1.53e-07	0.000128	-0.45	-0.28	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
STAD	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	5.36	1.54e-07	0.000128	0.35	0.28	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
STAD	cis	rs1056107	0.931	rs7048773	ENSG00000225513.1	RP11-165N19.2	-5.36	1.54e-07	0.000128	-0.34	-0.28	Colorectal cancer;	chr9:112226388	chr9:112173522~112173971:-
STAD	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	5.36	1.54e-07	0.000129	0.43	0.28	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
STAD	cis	rs728616	0.867	rs12414877	ENSG00000225484.5	NUTM2B-AS1	-5.36	1.54e-07	0.000129	-0.62	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:79663088~79826594:-
STAD	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	5.36	1.54e-07	0.000129	0.34	0.28	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
STAD	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	0.000129	0.4	0.28	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
STAD	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	5.36	1.55e-07	0.000129	0.29	0.28	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
STAD	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	5.36	1.55e-07	0.000129	0.29	0.28	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
STAD	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	5.36	1.55e-07	0.000129	0.29	0.28	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
STAD	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	5.36	1.55e-07	0.000129	0.33	0.28	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
STAD	cis	rs904251	0.523	rs9349039	ENSG00000204110.6	RP1-153P14.8	-5.36	1.55e-07	0.00013	-0.29	-0.28	Cognitive performance;	chr6:37512616	chr6:37507348~37535616:+
STAD	cis	rs904251	0.523	rs9366935	ENSG00000204110.6	RP1-153P14.8	-5.36	1.55e-07	0.00013	-0.29	-0.28	Cognitive performance;	chr6:37512628	chr6:37507348~37535616:+
STAD	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	5.36	1.56e-07	0.00013	0.29	0.28	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
STAD	cis	rs8098244	0.619	rs1316950	ENSG00000267301.1	RPL23AP77	-5.36	1.56e-07	0.00013	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23744102	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.619	rs12955853	ENSG00000267301.1	RPL23AP77	-5.36	1.56e-07	0.00013	-0.33	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23745274	chr18:23709825~23710287:-
STAD	cis	rs673078	0.66	rs61943365	ENSG00000275409.1	RP11-131L12.4	-5.36	1.56e-07	0.00013	-0.35	-0.28	Glucose homeostasis traits;	chr12:118339166	chr12:118430147~118430699:+
STAD	cis	rs11098499	0.73	rs78971550	ENSG00000260091.1	RP11-33B1.4	5.36	1.56e-07	0.00013	0.27	0.28	Corneal astigmatism;	chr4:119359886	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.645	rs78422072	ENSG00000260091.1	RP11-33B1.4	5.36	1.56e-07	0.00013	0.27	0.28	Corneal astigmatism;	chr4:119359887	chr4:119409333~119410233:+
STAD	cis	rs9400467	0.528	rs455726	ENSG00000230177.1	RP5-1112D6.4	-5.36	1.56e-07	0.00013	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111277932~111278742:+
STAD	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-5.36	1.56e-07	0.00013	-0.29	-0.28	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
STAD	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	5.36	1.56e-07	0.00013	0.28	0.28	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	5.36	1.56e-07	0.00013	0.28	0.28	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
STAD	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-5.36	1.56e-07	0.00013	-0.32	-0.28	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
STAD	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	5.35	1.56e-07	0.00013	0.42	0.28	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
STAD	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-5.35	1.56e-07	0.00013	-0.31	-0.28	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
STAD	cis	rs2239557	0.961	rs8003212	ENSG00000259065.1	RP5-1021I20.1	5.35	1.56e-07	0.00013	0.33	0.28	Common traits (Other);	chr14:74158260	chr14:73787360~73803270:+
STAD	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	5.35	1.57e-07	0.000131	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	5.35	1.57e-07	0.000131	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	5.35	1.57e-07	0.000131	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	5.35	1.57e-07	0.000131	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	5.35	1.57e-07	0.000131	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
STAD	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	5.35	1.57e-07	0.000131	0.49	0.28	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
STAD	cis	rs4604732	0.578	rs112449432	ENSG00000227135.1	GCSAML-AS1	-5.35	1.57e-07	0.000131	-0.37	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460878	chr1:247524679~247526752:-
STAD	cis	rs7662987	0.793	rs12106	ENSG00000272777.1	RP11-571L19.8	5.35	1.57e-07	0.000131	0.51	0.28	Smoking initiation;	chr4:99072199	chr4:99067256~99068125:-
STAD	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	5.35	1.57e-07	0.000131	0.4	0.28	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.631	rs10158289	ENSG00000227373.4	RP11-160H22.5	5.35	1.57e-07	0.000131	0.32	0.28	Life satisfaction;	chr1:174081529	chr1:174115300~174160004:-
STAD	cis	rs13113518	0.678	rs7663650	ENSG00000272969.1	RP11-528I4.2	-5.35	1.58e-07	0.000131	-0.35	-0.28	Height;	chr4:55364952	chr4:55547112~55547889:+
STAD	cis	rs7083	1	rs655023	ENSG00000254851.1	RP11-109L13.1	5.35	1.58e-07	0.000131	0.31	0.28	Blood protein levels;	chr11:117256904	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs505045	ENSG00000254851.1	RP11-109L13.1	5.35	1.58e-07	0.000131	0.31	0.28	Blood protein levels;	chr11:117281824	chr11:117135528~117138582:+
STAD	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	5.35	1.58e-07	0.000131	0.36	0.28	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
STAD	cis	rs611744	0.647	rs2594358	ENSG00000253754.1	RP11-35G22.1	-5.35	1.58e-07	0.000131	-0.24	-0.28	Dupuytren's disease;	chr8:108243789	chr8:108226200~108227544:+
STAD	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-5.35	1.58e-07	0.000132	-0.37	-0.28	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
STAD	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-5.35	1.58e-07	0.000132	-0.44	-0.28	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
STAD	cis	rs3806843	0.521	rs192231	ENSG00000202111.1	VTRNA1-2	5.35	1.58e-07	0.000132	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140868954	chr5:140718925~140719013:+
STAD	cis	rs2933343	0.7	rs1683779	ENSG00000231305.3	RP11-723O4.2	5.35	1.58e-07	0.000132	0.3	0.28	IgG glycosylation;	chr3:128923205	chr3:128861313~128871540:-
STAD	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	5.35	1.58e-07	0.000132	0.35	0.28	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
STAD	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	5.35	1.59e-07	0.000132	0.27	0.28	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
STAD	cis	rs7927771	0.507	rs10838754	ENSG00000280615.1	Y_RNA	5.35	1.59e-07	0.000132	0.28	0.28	Subjective well-being;	chr11:47736980	chr11:47614898~47614994:-
STAD	cis	rs9425766	0.655	rs4652169	ENSG00000227373.4	RP11-160H22.5	5.35	1.59e-07	0.000132	0.32	0.28	Life satisfaction;	chr1:174095343	chr1:174115300~174160004:-
STAD	cis	rs1799949	1	rs11651341	ENSG00000236383.6	LINC00854	-5.35	1.59e-07	0.000132	-0.22	-0.28	Menopause (age at onset);	chr17:43350693	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs34572725	ENSG00000236383.6	LINC00854	-5.35	1.59e-07	0.000132	-0.22	-0.28	Menopause (age at onset);	chr17:43351298	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs4534897	ENSG00000236383.6	LINC00854	-5.35	1.59e-07	0.000132	-0.22	-0.28	Menopause (age at onset);	chr17:43354440	chr17:43216941~43305976:-
STAD	cis	rs7927771	0.507	rs10838759	ENSG00000280615.1	Y_RNA	5.35	1.59e-07	0.000132	0.28	0.28	Subjective well-being;	chr11:47763795	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7101597	ENSG00000280615.1	Y_RNA	5.35	1.59e-07	0.000132	0.28	0.28	Subjective well-being;	chr11:47776365	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs11039392	ENSG00000280615.1	Y_RNA	5.35	1.59e-07	0.000132	0.28	0.28	Subjective well-being;	chr11:47777201	chr11:47614898~47614994:-
STAD	cis	rs7396835	0.866	rs7927820	ENSG00000280143.1	AP000892.6	5.35	1.59e-07	0.000132	0.26	0.28	Quantitative traits;	chr11:116811440	chr11:117204967~117210292:+
STAD	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	5.35	1.59e-07	0.000132	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
STAD	cis	rs1707322	0.685	rs11211177	ENSG00000225447.1	RPS15AP10	5.35	1.59e-07	0.000132	0.22	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45645816~45646197:-
STAD	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-5.35	1.59e-07	0.000132	-0.26	-0.28	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-5.35	1.59e-07	0.000132	-0.26	-0.28	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
STAD	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	5.35	1.59e-07	0.000132	0.42	0.28	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
STAD	cis	rs3806843	0.966	rs2563265	ENSG00000202111.1	VTRNA1-2	5.35	1.59e-07	0.000132	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr5:140718925~140719013:+
STAD	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-5.35	1.59e-07	0.000132	-0.29	-0.28	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
STAD	cis	rs9425766	0.679	rs6691711	ENSG00000227373.4	RP11-160H22.5	5.35	1.59e-07	0.000132	0.32	0.28	Life satisfaction;	chr1:174100283	chr1:174115300~174160004:-
STAD	cis	rs11992186	0.505	rs7845203	ENSG00000254340.1	RP11-10A14.3	5.35	1.6e-07	0.000133	0.33	0.28	Neuroticism;	chr8:8287918	chr8:9141424~9145435:+
STAD	cis	rs4604732	0.631	rs4436425	ENSG00000227135.1	GCSAML-AS1	-5.35	1.6e-07	0.000133	-0.38	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469021	chr1:247524679~247526752:-
STAD	cis	rs11098499	0.738	rs28687057	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119359657	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.775	rs67281037	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119360002	chr4:119409333~119410233:+
STAD	cis	rs10028773	0.506	rs12374346	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Educational attainment;	chr4:119360550	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs12374244	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119360817	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs12374352	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119360822	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs6857892	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119361541	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs28581362	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119362393	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.82	rs12503082	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119363162	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs12499602	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119363232	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.774	rs11098505	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119363472	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs13105020	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119364533	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs6824111	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119364813	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.779	rs10857066	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119365441	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.775	rs10029303	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119365600	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs9995136	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119365690	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs13125526	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119366864	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs12513310	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119366884	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.564	rs11098507	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119367131	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs12510451	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119367988	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.774	rs73842616	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119369528	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.645	rs72676059	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119369673	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.569	rs55845118	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119369758	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs7677068	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119370549	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs9991221	ENSG00000260091.1	RP11-33B1.4	5.35	1.6e-07	0.000133	0.26	0.28	Corneal astigmatism;	chr4:119370952	chr4:119409333~119410233:+
STAD	cis	rs7580658	0.545	rs12477559	ENSG00000200250.1	RNU6-1147P	5.35	1.6e-07	0.000133	0.26	0.28	Protein C levels;	chr2:127194221	chr2:127316873~127316979:+
STAD	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	5.35	1.6e-07	0.000133	0.32	0.28	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
STAD	cis	rs6844153	0.887	rs62302533	ENSG00000240005.4	RP11-293A21.1	-5.35	1.6e-07	0.000133	-0.42	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955309	chr4:26859806~26860599:-
STAD	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	5.35	1.6e-07	0.000133	0.32	0.28	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
STAD	cis	rs453301	0.522	rs2929309	ENSG00000254340.1	RP11-10A14.3	-5.35	1.6e-07	0.000133	-0.35	-0.28	Joint mobility (Beighton score);	chr8:9226261	chr8:9141424~9145435:+
STAD	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	5.35	1.61e-07	0.000133	0.29	0.28	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
STAD	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-5.35	1.61e-07	0.000133	-0.25	-0.28	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-5.35	1.61e-07	0.000133	-0.25	-0.28	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-5.35	1.61e-07	0.000133	-0.25	-0.28	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
STAD	cis	rs7927771	0.832	rs4752990	ENSG00000280615.1	Y_RNA	-5.35	1.61e-07	0.000133	-0.28	-0.28	Subjective well-being;	chr11:47388842	chr11:47614898~47614994:-
STAD	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	5.35	1.61e-07	0.000133	0.37	0.28	Height;	chr6:109428824	chr6:109382795~109383666:+
STAD	cis	rs728616	0.867	rs7893241	ENSG00000225484.5	NUTM2B-AS1	-5.35	1.61e-07	0.000133	-0.6	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194582	chr10:79663088~79826594:-
STAD	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	5.35	1.61e-07	0.000133	0.31	0.28	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
STAD	cis	rs728616	0.867	rs726289	ENSG00000225484.5	NUTM2B-AS1	-5.35	1.61e-07	0.000134	-0.6	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79663088~79826594:-
STAD	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-5.35	1.61e-07	0.000134	-0.29	-0.28	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
STAD	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-5.35	1.61e-07	0.000134	-0.43	-0.28	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-5.35	1.61e-07	0.000134	-0.43	-0.28	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-5.35	1.61e-07	0.000134	-0.43	-0.28	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
STAD	cis	rs1799949	1	rs33946455	ENSG00000236383.6	LINC00854	-5.35	1.62e-07	0.000134	-0.23	-0.28	Menopause (age at onset);	chr17:43169829	chr17:43216941~43305976:-
STAD	cis	rs7951870	0.504	rs3740973	ENSG00000271350.1	CTD-2384B9.1	5.35	1.62e-07	0.000134	0.35	0.28	Schizophrenia;	chr11:46400687	chr11:47041027~47041945:-
STAD	cis	rs7927771	0.524	rs3758655	ENSG00000280615.1	Y_RNA	5.35	1.62e-07	0.000134	0.28	0.28	Subjective well-being;	chr11:47682391	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7936948	ENSG00000280615.1	Y_RNA	5.35	1.62e-07	0.000134	0.28	0.28	Subjective well-being;	chr11:47682648	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10838746	ENSG00000280615.1	Y_RNA	5.35	1.62e-07	0.000134	0.28	0.28	Subjective well-being;	chr11:47684739	chr11:47614898~47614994:-
STAD	cis	rs7124681	0.584	rs10769285	ENSG00000280615.1	Y_RNA	5.35	1.62e-07	0.000134	0.28	0.28	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47687660	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7943213	ENSG00000280615.1	Y_RNA	5.35	1.62e-07	0.000134	0.28	0.28	Subjective well-being;	chr11:47693972	chr11:47614898~47614994:-
STAD	cis	rs10504130	0.569	rs60153173	ENSG00000272024.1	RP11-546K22.3	-5.35	1.62e-07	0.000134	-0.39	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51950284~51950690:+
STAD	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	5.35	1.62e-07	0.000134	0.31	0.28	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
STAD	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	5.35	1.62e-07	0.000134	0.29	0.28	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
STAD	cis	rs66887589	0.616	rs7659403	ENSG00000249244.1	RP11-548H18.2	5.35	1.62e-07	0.000134	0.34	0.28	Diastolic blood pressure;	chr4:119286099	chr4:119391831~119395335:-
STAD	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	5.35	1.62e-07	0.000134	0.33	0.28	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	5.35	1.62e-07	0.000134	0.33	0.28	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
STAD	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-5.35	1.62e-07	0.000135	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
STAD	cis	rs992157	0.835	rs4674282	ENSG00000237281.1	CATIP-AS2	5.35	1.62e-07	0.000135	0.28	0.28	Colorectal cancer;	chr2:218279507	chr2:218326889~218357966:-
STAD	cis	rs7247513	1	rs12459123	ENSG00000230310.1	CTD-2192J16.11	-5.35	1.63e-07	0.000135	-0.36	-0.28	Bipolar disorder;	chr19:12578927	chr19:12552597~12553644:+
STAD	cis	rs11169552	1	rs11169552	ENSG00000200183.1	RNU6-238P	-5.35	1.63e-07	0.000135	-0.27	-0.28	Colorectal cancer;	chr12:50761880	chr12:50656973~50657078:+
STAD	cis	rs11169552	1	rs12424860	ENSG00000200183.1	RNU6-238P	-5.35	1.63e-07	0.000135	-0.27	-0.28	Colorectal cancer;	chr12:50765357	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.943	rs4768921	ENSG00000200183.1	RNU6-238P	-5.35	1.63e-07	0.000135	-0.27	-0.28	Colorectal cancer;	chr12:50772825	chr12:50656973~50657078:+
STAD	cis	rs7637701	0.818	rs4680305	ENSG00000240875.4	LINC00886	-5.35	1.63e-07	0.000135	-0.33	-0.28	Breast cancer;	chr3:156815614	chr3:156747346~156817062:-
STAD	cis	rs240993	0.812	rs6568677	ENSG00000230177.1	RP5-1112D6.4	-5.35	1.63e-07	0.000135	-0.27	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111392099	chr6:111277932~111278742:+
STAD	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-5.35	1.63e-07	0.000135	-0.36	-0.28	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
STAD	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	5.35	1.63e-07	0.000135	0.31	0.28	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
STAD	cis	rs611744	0.625	rs6469168	ENSG00000253754.1	RP11-35G22.1	-5.35	1.64e-07	0.000135	-0.24	-0.28	Dupuytren's disease;	chr8:108276170	chr8:108226200~108227544:+
STAD	cis	rs1056107	0.897	rs7867328	ENSG00000225513.1	RP11-165N19.2	-5.35	1.64e-07	0.000136	-0.32	-0.28	Colorectal cancer;	chr9:112196925	chr9:112173522~112173971:-
STAD	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	5.35	1.64e-07	0.000136	0.29	0.28	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	5.35	1.64e-07	0.000136	0.29	0.28	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	5.35	1.64e-07	0.000136	0.29	0.28	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	5.35	1.64e-07	0.000136	0.29	0.28	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
STAD	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-5.35	1.64e-07	0.000136	-0.28	-0.28	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
STAD	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-5.35	1.64e-07	0.000136	-0.39	-0.28	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
STAD	cis	rs747650	0.532	rs4587689	ENSG00000271350.1	CTD-2384B9.1	5.35	1.64e-07	0.000136	0.35	0.28	Acne (severe);	chr11:47108303	chr11:47041027~47041945:-
STAD	cis	rs5769707	0.681	rs4824068	ENSG00000280224.1	CTA-722E9.1	-5.35	1.64e-07	0.000136	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.605	rs6009791	ENSG00000280224.1	CTA-722E9.1	-5.35	1.64e-07	0.000136	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49500568~49501585:+
STAD	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-5.34	1.65e-07	0.000136	-0.27	-0.28	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
STAD	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	5.34	1.65e-07	0.000136	0.35	0.28	Height;	chr6:109355573	chr6:109382795~109383666:+
STAD	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-5.34	1.65e-07	0.000136	-0.29	-0.28	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
STAD	cis	rs611744	0.647	rs633901	ENSG00000253754.1	RP11-35G22.1	-5.34	1.65e-07	0.000136	-0.24	-0.28	Dupuytren's disease;	chr8:108230752	chr8:108226200~108227544:+
STAD	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	5.34	1.65e-07	0.000136	0.37	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
STAD	cis	rs7927771	0.524	rs7939420	ENSG00000280615.1	Y_RNA	-5.34	1.65e-07	0.000137	-0.28	-0.28	Subjective well-being;	chr11:47702386	chr11:47614898~47614994:-
STAD	cis	rs7083	1	rs644215	ENSG00000254851.1	RP11-109L13.1	5.34	1.65e-07	0.000137	0.31	0.28	Blood protein levels;	chr11:117275202	chr11:117135528~117138582:+
STAD	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	5.34	1.65e-07	0.000137	0.27	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
STAD	cis	rs7932354	0.55	rs12807111	ENSG00000271350.1	CTD-2384B9.1	-5.34	1.66e-07	0.000137	-0.33	-0.28	Bone mineral density (hip);Bone mineral density;	chr11:46902623	chr11:47041027~47041945:-
STAD	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-5.34	1.66e-07	0.000137	-0.29	-0.28	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
STAD	cis	rs11846409	0.587	rs1806881	ENSG00000211972.2	IGHV3-66	-5.34	1.66e-07	0.000137	-0.29	-0.28	Rheumatic heart disease;	chr14:106650770	chr14:106675017~106675544:-
STAD	cis	rs992157	0.835	rs2045434	ENSG00000237281.1	CATIP-AS2	5.34	1.66e-07	0.000137	0.28	0.28	Colorectal cancer;	chr2:218279775	chr2:218326889~218357966:-
STAD	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	5.34	1.66e-07	0.000137	0.34	0.28	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
STAD	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	5.34	1.66e-07	0.000137	0.38	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
STAD	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	5.34	1.66e-07	0.000137	0.41	0.28	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	5.34	1.66e-07	0.000137	0.41	0.28	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	5.34	1.66e-07	0.000137	0.41	0.28	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
STAD	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	5.34	1.66e-07	0.000137	0.41	0.28	Height;	chr6:109712525	chr6:109382795~109383666:+
STAD	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-5.34	1.66e-07	0.000137	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
STAD	cis	rs1729407	0.709	rs2098453	ENSG00000280143.1	AP000892.6	5.34	1.66e-07	0.000137	0.2	0.28	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117204967~117210292:+
STAD	cis	rs611744	0.647	rs11785776	ENSG00000253754.1	RP11-35G22.1	-5.34	1.67e-07	0.000138	-0.25	-0.28	Dupuytren's disease;	chr8:108252704	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs6981420	ENSG00000253754.1	RP11-35G22.1	-5.34	1.67e-07	0.000138	-0.25	-0.28	Dupuytren's disease;	chr8:108254465	chr8:108226200~108227544:+
STAD	cis	rs2739330	0.685	rs4822453	ENSG00000224205.1	AP000351.4	5.34	1.67e-07	0.000138	0.31	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23987320~23991421:-
STAD	cis	rs6142102	0.961	rs2284379	ENSG00000275784.1	RP5-1125A11.6	-5.34	1.67e-07	0.000138	-0.29	-0.28	Skin pigmentation;	chr20:34006836	chr20:33989480~33991818:-
STAD	cis	rs858239	0.601	rs11984129	ENSG00000226816.2	AC005082.12	5.34	1.68e-07	0.000138	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23206013~23208045:+
STAD	cis	rs2404602	0.692	rs3110382	ENSG00000259422.1	RP11-593F23.1	-5.34	1.68e-07	0.000138	-0.29	-0.28	Blood metabolite levels;	chr15:76856347	chr15:76174891~76181486:-
STAD	cis	rs3758911	0.894	rs12286915	ENSG00000261098.1	RP11-819C21.1	-5.34	1.68e-07	0.000138	-0.25	-0.28	Coronary artery disease;	chr11:107340608	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.894	rs10890723	ENSG00000261098.1	RP11-819C21.1	-5.34	1.68e-07	0.000138	-0.25	-0.28	Coronary artery disease;	chr11:107342510	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.894	rs7350479	ENSG00000261098.1	RP11-819C21.1	-5.34	1.68e-07	0.000138	-0.25	-0.28	Coronary artery disease;	chr11:107342553	chr11:107312132~107316271:-
STAD	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	5.34	1.68e-07	0.000138	0.46	0.28	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	5.34	1.68e-07	0.000138	0.46	0.28	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
STAD	cis	rs1799949	0.859	rs11657004	ENSG00000236383.6	LINC00854	-5.34	1.68e-07	0.000139	-0.22	-0.28	Menopause (age at onset);	chr17:43365383	chr17:43216941~43305976:-
STAD	cis	rs1318937	1	rs3821639	ENSG00000224660.1	SH3BP5-AS1	5.34	1.68e-07	0.000139	0.28	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264159	chr3:15254184~15264493:+
STAD	cis	rs1816752	0.633	rs8002387	ENSG00000273628.1	RP11-756A22.7	5.34	1.68e-07	0.000139	0.33	0.28	Obesity-related traits;	chr13:24416306	chr13:24933006~24936796:+
STAD	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-5.34	1.68e-07	0.000139	-0.32	-0.28	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
STAD	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-5.34	1.68e-07	0.000139	-0.34	-0.28	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
STAD	cis	rs3758911	0.894	rs1490947	ENSG00000261098.1	RP11-819C21.1	-5.34	1.69e-07	0.000139	-0.25	-0.28	Coronary artery disease;	chr11:107325294	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.894	rs10789620	ENSG00000261098.1	RP11-819C21.1	-5.34	1.69e-07	0.00014	-0.25	-0.28	Coronary artery disease;	chr11:107334700	chr11:107312132~107316271:-
STAD	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	5.34	1.69e-07	0.00014	0.31	0.28	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
STAD	cis	rs11098499	0.775	rs10021601	ENSG00000260091.1	RP11-33B1.4	5.34	1.69e-07	0.00014	0.26	0.28	Corneal astigmatism;	chr4:119361408	chr4:119409333~119410233:+
STAD	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	5.34	1.7e-07	0.00014	0.3	0.28	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
STAD	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	5.34	1.7e-07	0.00014	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
STAD	cis	rs7396835	0.741	rs7396851	ENSG00000280143.1	AP000892.6	-5.34	1.7e-07	0.00014	-0.26	-0.28	Quantitative traits;	chr11:116813448	chr11:117204967~117210292:+
STAD	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-5.34	1.7e-07	0.00014	-0.34	-0.28	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
STAD	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-5.34	1.7e-07	0.00014	-0.39	-0.28	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
STAD	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-5.34	1.7e-07	0.00014	-0.39	-0.28	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
STAD	cis	rs1799949	0.965	rs34633610	ENSG00000279602.1	CTD-3014M21.1	5.34	1.71e-07	0.00014	0.35	0.28	Menopause (age at onset);	chr17:43342017	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs11654051	ENSG00000279602.1	CTD-3014M21.1	5.34	1.71e-07	0.00014	0.35	0.28	Menopause (age at onset);	chr17:43342288	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.93	rs56729776	ENSG00000279602.1	CTD-3014M21.1	5.34	1.71e-07	0.00014	0.35	0.28	Menopause (age at onset);	chr17:43344763	chr17:43360041~43361361:-
STAD	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-5.34	1.71e-07	0.000141	-0.28	-0.28	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
STAD	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-5.34	1.71e-07	0.000141	-0.39	-0.28	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
STAD	cis	rs2948294	0.566	rs13261997	ENSG00000253981.4	ALG1L13P	5.34	1.71e-07	0.000141	0.34	0.28	Red cell distribution width;	chr8:8254773	chr8:8236003~8244667:-
STAD	cis	rs7487075	0.82	rs1586905	ENSG00000272369.1	RP11-446N19.1	5.34	1.71e-07	0.000141	0.34	0.28	Itch intensity from mosquito bite;	chr12:46313835	chr12:46537502~46652550:+
STAD	cis	rs7829975	0.742	rs7832968	ENSG00000254340.1	RP11-10A14.3	5.34	1.71e-07	0.000141	0.33	0.28	Mood instability;	chr8:8795379	chr8:9141424~9145435:+
STAD	cis	rs1816752	0.87	rs9581029	ENSG00000273628.1	RP11-756A22.7	5.34	1.71e-07	0.000141	0.34	0.28	Obesity-related traits;	chr13:24425147	chr13:24933006~24936796:+
STAD	cis	rs7688014	1	rs7688014	ENSG00000230069.3	LRRC37A15P	-5.34	1.71e-07	0.000141	-0.3	-0.28	Schizophrenia;	chr4:103053903	chr4:102727274~102730721:-
STAD	cis	rs7474896	0.507	rs2474555	ENSG00000099251.13	HSD17B7P2	5.34	1.71e-07	0.000141	0.37	0.28	Obesity (extreme);	chr10:38176292	chr10:38356380~38378505:+
STAD	cis	rs3806843	0.966	rs3806844	ENSG00000202111.1	VTRNA1-2	-5.34	1.71e-07	0.000141	-0.27	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr5:140718925~140719013:+
STAD	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	5.34	1.71e-07	0.000141	0.28	0.28	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
STAD	cis	rs1729407	0.774	rs2849167	ENSG00000280143.1	AP000892.6	-5.34	1.71e-07	0.000141	-0.21	-0.28	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117204967~117210292:+
STAD	cis	rs10266483	0.515	rs6949304	ENSG00000271550.1	BNIP3P11	-5.34	1.72e-07	0.000141	-0.38	-0.28	Response to statin therapy;	chr7:64257903	chr7:64678954~64687393:-
STAD	cis	rs10266483	0.545	rs73132069	ENSG00000271550.1	BNIP3P11	-5.34	1.72e-07	0.000141	-0.38	-0.28	Response to statin therapy;	chr7:64258440	chr7:64678954~64687393:-
STAD	cis	rs10266483	0.545	rs114664455	ENSG00000271550.1	BNIP3P11	-5.34	1.72e-07	0.000141	-0.38	-0.28	Response to statin therapy;	chr7:64263634	chr7:64678954~64687393:-
STAD	cis	rs611744	0.647	rs1457211	ENSG00000253754.1	RP11-35G22.1	5.34	1.72e-07	0.000141	0.24	0.28	Dupuytren's disease;	chr8:108249089	chr8:108226200~108227544:+
STAD	cis	rs556990	0.76	rs3024739	ENSG00000269125.1	RP11-98F14.11	-5.34	1.72e-07	0.000141	-0.35	-0.28	Blood protein levels;	chr13:113165634	chr13:113165002~113165183:-
STAD	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	5.34	1.72e-07	0.000141	0.3	0.28	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
STAD	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	5.34	1.72e-07	0.000141	0.3	0.28	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
STAD	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	5.34	1.72e-07	0.000141	0.37	0.28	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
STAD	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-5.34	1.72e-07	0.000142	-0.34	-0.28	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
STAD	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-5.34	1.72e-07	0.000142	-0.27	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
STAD	cis	rs7487075	0.786	rs11504511	ENSG00000272369.1	RP11-446N19.1	5.34	1.72e-07	0.000142	0.33	0.28	Itch intensity from mosquito bite;	chr12:46283261	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.786	rs7316773	ENSG00000272369.1	RP11-446N19.1	5.34	1.72e-07	0.000142	0.33	0.28	Itch intensity from mosquito bite;	chr12:46290664	chr12:46537502~46652550:+
STAD	cis	rs853679	0.517	rs6922063	ENSG00000220721.1	OR1F12	5.34	1.72e-07	0.000142	0.33	0.28	Depression;	chr6:28126588	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs2275508	ENSG00000220721.1	OR1F12	5.34	1.72e-07	0.000142	0.33	0.28	Depression;	chr6:28126953	chr6:28073316~28074233:+
STAD	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	5.34	1.72e-07	0.000142	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	5.34	1.72e-07	0.000142	0.26	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
STAD	cis	rs2439831	0.867	rs12443102	ENSG00000275601.1	AC011330.13	-5.34	1.72e-07	0.000142	-0.39	-0.28	Lung cancer in ever smokers;	chr15:43639905	chr15:43642389~43643023:-
STAD	cis	rs9400467	0.528	rs9689727	ENSG00000230177.1	RP5-1112D6.4	-5.34	1.72e-07	0.000142	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs12214380	ENSG00000230177.1	RP5-1112D6.4	-5.34	1.72e-07	0.000142	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111277932~111278742:+
STAD	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	5.34	1.73e-07	0.000142	0.37	0.28	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
STAD	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-5.34	1.73e-07	0.000142	-0.35	-0.28	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
STAD	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-5.34	1.73e-07	0.000142	-0.31	-0.28	Migraine;	chr4:56937339	chr4:56960927~56961373:-
STAD	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	5.34	1.73e-07	0.000142	0.29	0.28	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
STAD	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	5.34	1.73e-07	0.000142	0.44	0.28	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
STAD	cis	rs8098244	0.557	rs11662720	ENSG00000267301.1	RPL23AP77	5.34	1.73e-07	0.000142	0.31	0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722127	chr18:23709825~23710287:-
STAD	cis	rs748404	0.533	rs11632120	ENSG00000249839.1	AC011330.5	5.34	1.73e-07	0.000142	0.33	0.28	Lung cancer;	chr15:43123175	chr15:43663654~43684339:-
STAD	cis	rs7487075	0.619	rs9669404	ENSG00000257261.4	RP11-96H19.1	-5.33	1.73e-07	0.000142	-0.34	-0.28	Itch intensity from mosquito bite;	chr12:46405180	chr12:46383679~46876159:+
STAD	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-5.33	1.74e-07	0.000143	-0.44	-0.28	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
STAD	cis	rs189798	0.592	rs10111263	ENSG00000253981.4	ALG1L13P	-5.33	1.74e-07	0.000143	-0.34	-0.28	Myopia (pathological);	chr8:9111923	chr8:8236003~8244667:-
STAD	cis	rs7927771	0.793	rs12803525	ENSG00000280615.1	Y_RNA	-5.33	1.74e-07	0.000143	-0.28	-0.28	Subjective well-being;	chr11:47391924	chr11:47614898~47614994:-
STAD	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-5.33	1.74e-07	0.000143	-0.3	-0.28	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
STAD	cis	rs58873874	0.737	rs11134766	ENSG00000251405.2	CTB-109A12.1	5.33	1.74e-07	0.000143	0.49	0.28	Bipolar disorder (body mass index interaction);	chr5:157481309	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.737	rs11134767	ENSG00000251405.2	CTB-109A12.1	5.33	1.74e-07	0.000143	0.49	0.28	Bipolar disorder (body mass index interaction);	chr5:157481645	chr5:157362615~157460078:-
STAD	cis	rs4604732	0.631	rs75600450	ENSG00000227135.1	GCSAML-AS1	-5.33	1.74e-07	0.000143	-0.38	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462190	chr1:247524679~247526752:-
STAD	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	5.33	1.74e-07	0.000143	0.34	0.28	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	5.33	1.74e-07	0.000143	0.34	0.28	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
STAD	cis	rs13113518	0.783	rs12510400	ENSG00000272969.1	RP11-528I4.2	5.33	1.74e-07	0.000143	0.36	0.28	Height;	chr4:55577294	chr4:55547112~55547889:+
STAD	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	5.33	1.74e-07	0.000143	0.34	0.28	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
STAD	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	5.33	1.74e-07	0.000143	0.34	0.28	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
STAD	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-5.33	1.74e-07	0.000143	-0.33	-0.28	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
STAD	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	5.33	1.74e-07	0.000143	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
STAD	cis	rs7083	0.905	rs11216338	ENSG00000254851.1	RP11-109L13.1	5.33	1.75e-07	0.000144	0.31	0.28	Blood protein levels;	chr11:117261003	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs619772	ENSG00000254851.1	RP11-109L13.1	5.33	1.75e-07	0.000144	0.31	0.28	Blood protein levels;	chr11:117268120	chr11:117135528~117138582:+
STAD	cis	rs7083	1	rs493139	ENSG00000254851.1	RP11-109L13.1	5.33	1.75e-07	0.000144	0.31	0.28	Blood protein levels;	chr11:117275233	chr11:117135528~117138582:+
STAD	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-5.33	1.75e-07	0.000144	-0.29	-0.28	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
STAD	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	5.33	1.75e-07	0.000144	0.3	0.28	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
STAD	cis	rs1799949	0.931	rs34474989	ENSG00000236383.6	LINC00854	-5.33	1.75e-07	0.000144	-0.22	-0.28	Menopause (age at onset);	chr17:43368042	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs11656945	ENSG00000236383.6	LINC00854	-5.33	1.75e-07	0.000144	-0.23	-0.28	Menopause (age at onset);	chr17:43178248	chr17:43216941~43305976:-
STAD	cis	rs9400467	0.528	rs7752361	ENSG00000230177.1	RP5-1112D6.4	-5.33	1.75e-07	0.000144	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111277932~111278742:+
STAD	cis	rs7760535	0.811	rs7764591	ENSG00000230177.1	RP5-1112D6.4	-5.33	1.75e-07	0.000144	-0.25	-0.28	Metabolic traits;	chr6:111462211	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs7750792	ENSG00000230177.1	RP5-1112D6.4	-5.33	1.75e-07	0.000144	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111277932~111278742:+
STAD	cis	rs3758911	0.894	rs12285491	ENSG00000261098.1	RP11-819C21.1	-5.33	1.75e-07	0.000144	-0.25	-0.28	Coronary artery disease;	chr11:107340319	chr11:107312132~107316271:-
STAD	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-5.33	1.75e-07	0.000144	-0.42	-0.28	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
STAD	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	5.33	1.76e-07	0.000144	0.23	0.28	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
STAD	cis	rs992157	0.835	rs6707559	ENSG00000237281.1	CATIP-AS2	-5.33	1.76e-07	0.000144	-0.28	-0.28	Colorectal cancer;	chr2:218278050	chr2:218326889~218357966:-
STAD	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	5.33	1.76e-07	0.000144	0.43	0.28	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
STAD	cis	rs7927771	0.524	rs3816605	ENSG00000280615.1	Y_RNA	5.33	1.76e-07	0.000145	0.28	0.28	Subjective well-being;	chr11:47835701	chr11:47614898~47614994:-
STAD	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-5.33	1.76e-07	0.000145	-0.34	-0.28	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
STAD	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-5.33	1.76e-07	0.000145	-0.34	-0.28	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
STAD	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	5.33	1.76e-07	0.000145	0.33	0.28	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
STAD	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	5.33	1.77e-07	0.000145	0.43	0.28	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
STAD	cis	rs58873874	0.737	rs76634949	ENSG00000251405.2	CTB-109A12.1	5.33	1.77e-07	0.000145	0.48	0.28	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.737	rs79339674	ENSG00000251405.2	CTB-109A12.1	5.33	1.77e-07	0.000145	0.48	0.28	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157362615~157460078:-
STAD	cis	rs9549260	1	rs9549260	ENSG00000229456.1	RLIMP1	5.33	1.77e-07	0.000145	0.27	0.28	Red blood cell count;	chr13:40679967	chr13:40618738~40621348:+
STAD	cis	rs950169	0.881	rs4842852	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84387263	chr15:85191438~85213905:+
STAD	cis	rs950169	0.84	rs4842853	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84387606	chr15:85191438~85213905:+
STAD	cis	rs950169	0.922	rs4842946	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84387633	chr15:85191438~85213905:+
STAD	cis	rs950169	0.84	rs4842854	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84387641	chr15:85191438~85213905:+
STAD	cis	rs950169	0.84	rs2896002	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84390423	chr15:85191438~85213905:+
STAD	cis	rs950169	0.887	rs3860265	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84390487	chr15:85191438~85213905:+
STAD	cis	rs950169	0.723	rs17589320	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84251244	chr15:85191438~85213905:+
STAD	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	5.33	1.77e-07	0.000145	0.41	0.28	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
STAD	cis	rs9400467	0.528	rs7451051	ENSG00000230177.1	RP5-1112D6.4	-5.33	1.77e-07	0.000145	-0.25	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111277932~111278742:+
STAD	cis	rs7474896	0.616	rs1985260	ENSG00000099251.13	HSD17B7P2	5.33	1.77e-07	0.000145	0.38	0.28	Obesity (extreme);	chr10:38145162	chr10:38356380~38378505:+
STAD	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	5.33	1.77e-07	0.000145	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
STAD	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	5.33	1.78e-07	0.000145	0.36	0.28	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	5.33	1.78e-07	0.000145	0.36	0.28	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	5.33	1.78e-07	0.000145	0.36	0.28	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
STAD	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-5.33	1.78e-07	0.000146	-0.33	-0.28	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
STAD	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.33	1.78e-07	0.000146	0.42	0.28	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
STAD	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-5.33	1.78e-07	0.000146	-0.28	-0.28	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
STAD	cis	rs1799949	1	rs4793236	ENSG00000236383.6	LINC00854	-5.33	1.78e-07	0.000146	-0.23	-0.28	Menopause (age at onset);	chr17:43359072	chr17:43216941~43305976:-
STAD	cis	rs9425766	0.523	rs6668959	ENSG00000227373.4	RP11-160H22.5	5.33	1.78e-07	0.000146	0.32	0.28	Life satisfaction;	chr1:174088488	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.665	rs7553788	ENSG00000227373.4	RP11-160H22.5	5.33	1.78e-07	0.000146	0.32	0.28	Life satisfaction;	chr1:174093773	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs6682017	ENSG00000227373.4	RP11-160H22.5	5.33	1.78e-07	0.000146	0.32	0.28	Life satisfaction;	chr1:174097809	chr1:174115300~174160004:-
STAD	cis	rs2300206	1	rs2300206	ENSG00000275784.1	RP5-1125A11.6	-5.33	1.78e-07	0.000146	-0.29	-0.28	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33989480~33991818:-
STAD	cis	rs7487075	1	rs12827740	ENSG00000272369.1	RP11-446N19.1	5.33	1.78e-07	0.000146	0.33	0.28	Itch intensity from mosquito bite;	chr12:46454332	chr12:46537502~46652550:+
STAD	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-5.33	1.78e-07	0.000146	-0.28	-0.28	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
STAD	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	5.33	1.78e-07	0.000146	0.32	0.28	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
STAD	cis	rs2412819	0.571	rs6493090	ENSG00000249839.1	AC011330.5	5.33	1.78e-07	0.000146	0.5	0.28	Lung cancer;	chr15:43792084	chr15:43663654~43684339:-
STAD	cis	rs606458	0.92	rs680273	ENSG00000269038.1	AP001462.6	-5.33	1.79e-07	0.000146	-0.35	-0.28	Urate levels;	chr11:64772163	chr11:64778954~64779405:+
STAD	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	5.33	1.79e-07	0.000146	0.41	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
STAD	cis	rs9425766	0.655	rs2145376	ENSG00000227373.4	RP11-160H22.5	5.33	1.79e-07	0.000146	0.32	0.28	Life satisfaction;	chr1:174098911	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.679	rs6663794	ENSG00000227373.4	RP11-160H22.5	5.33	1.79e-07	0.000146	0.32	0.28	Life satisfaction;	chr1:174099791	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.64	rs6658769	ENSG00000227373.4	RP11-160H22.5	5.33	1.79e-07	0.000146	0.32	0.28	Life satisfaction;	chr1:174100843	chr1:174115300~174160004:-
STAD	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-5.33	1.79e-07	0.000146	-0.28	-0.28	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
STAD	cis	rs6504622	0.755	rs12939753	ENSG00000262879.4	RP11-156P1.3	-5.33	1.79e-07	0.000147	-0.23	-0.28	Orofacial clefts;	chr17:47104133	chr17:46984045~47100323:-
STAD	cis	rs6142102	0.659	rs6057945	ENSG00000275784.1	RP5-1125A11.6	-5.33	1.79e-07	0.000147	-0.29	-0.28	Skin pigmentation;	chr20:33929374	chr20:33989480~33991818:-
STAD	cis	rs11169552	0.943	rs3809319	ENSG00000200183.1	RNU6-238P	-5.33	1.79e-07	0.000147	-0.27	-0.28	Colorectal cancer;	chr12:50779950	chr12:50656973~50657078:+
STAD	cis	rs11722779	0.935	rs7681629	ENSG00000230069.3	LRRC37A15P	-5.33	1.79e-07	0.000147	-0.3	-0.28	Schizophrenia;	chr4:102974407	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.844	rs17033381	ENSG00000230069.3	LRRC37A15P	-5.33	1.79e-07	0.000147	-0.3	-0.28	Schizophrenia;	chr4:102974952	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs4699045	ENSG00000230069.3	LRRC37A15P	-5.33	1.79e-07	0.000147	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102727274~102730721:-
STAD	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	5.33	1.8e-07	0.000147	0.3	0.28	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
STAD	cis	rs7487075	0.893	rs4768115	ENSG00000272369.1	RP11-446N19.1	5.33	1.8e-07	0.000147	0.33	0.28	Itch intensity from mosquito bite;	chr12:46338736	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.893	rs4547171	ENSG00000272369.1	RP11-446N19.1	5.33	1.8e-07	0.000147	0.33	0.28	Itch intensity from mosquito bite;	chr12:46339609	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.828	rs2169030	ENSG00000272369.1	RP11-446N19.1	5.33	1.8e-07	0.000147	0.33	0.28	Itch intensity from mosquito bite;	chr12:46341273	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.893	rs12317787	ENSG00000272369.1	RP11-446N19.1	5.33	1.8e-07	0.000147	0.33	0.28	Itch intensity from mosquito bite;	chr12:46342946	chr12:46537502~46652550:+
STAD	cis	rs227275	0.556	rs4455413	ENSG00000230069.3	LRRC37A15P	-5.33	1.8e-07	0.000147	-0.3	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102727274~102730721:-
STAD	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-5.33	1.8e-07	0.000147	-0.27	-0.28	Height;	chr2:231516587	chr2:231508426~231514339:-
STAD	cis	rs1292059	1	rs1292059	ENSG00000266701.1	AC005702.4	5.33	1.8e-07	0.000147	0.39	0.28	Eosinophil percentage of granulocytes;	chr17:59880527	chr17:60042546~60042627:-
STAD	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-5.33	1.8e-07	0.000147	-0.32	-0.28	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
STAD	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-5.33	1.8e-07	0.000147	-0.32	-0.28	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
STAD	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-5.33	1.8e-07	0.000147	-0.29	-0.28	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
STAD	cis	rs4950322	0.57	rs72692917	ENSG00000278811.3	LINC00624	5.33	1.8e-07	0.000147	0.29	0.28	Protein quantitative trait loci;	chr1:147304389	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692920	ENSG00000278811.3	LINC00624	5.33	1.8e-07	0.000147	0.29	0.28	Protein quantitative trait loci;	chr1:147308501	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs66580541	ENSG00000278811.3	LINC00624	5.33	1.8e-07	0.000147	0.29	0.28	Protein quantitative trait loci;	chr1:147308828	chr1:147258885~147517875:-
STAD	cis	rs10978777	0.765	rs7043962	ENSG00000276883.1	AL137852.1	-5.33	1.8e-07	0.000147	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107310320	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.805	rs7856227	ENSG00000276883.1	AL137852.1	-5.33	1.8e-07	0.000147	-0.28	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107310714	chr9:107292369~107292456:-
STAD	cis	rs12682352	0.652	rs1567398	ENSG00000254340.1	RP11-10A14.3	-5.33	1.81e-07	0.000148	-0.32	-0.28	Neuroticism;	chr8:8869294	chr8:9141424~9145435:+
STAD	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	5.33	1.81e-07	0.000148	0.31	0.28	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
STAD	cis	rs7083	1	rs678837	ENSG00000254851.1	RP11-109L13.1	5.33	1.81e-07	0.000148	0.31	0.28	Blood protein levels;	chr11:117238554	chr11:117135528~117138582:+
STAD	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-5.33	1.81e-07	0.000148	-0.28	-0.28	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
STAD	cis	rs2337406	0.5	rs57619050	ENSG00000280411.1	IGHV1-69-2	-5.33	1.81e-07	0.000148	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106820074	chr14:106762092~106762588:-
STAD	cis	rs2933343	0.7	rs2249514	ENSG00000231305.3	RP11-723O4.2	5.33	1.81e-07	0.000148	0.3	0.28	IgG glycosylation;	chr3:128924969	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.7	rs2630257	ENSG00000231305.3	RP11-723O4.2	5.33	1.81e-07	0.000148	0.3	0.28	IgG glycosylation;	chr3:128925172	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.729	rs1680785	ENSG00000231305.3	RP11-723O4.2	5.33	1.81e-07	0.000148	0.3	0.28	IgG glycosylation;	chr3:128925973	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.729	rs1680786	ENSG00000231305.3	RP11-723O4.2	5.33	1.81e-07	0.000148	0.3	0.28	IgG glycosylation;	chr3:128925997	chr3:128861313~128871540:-
STAD	cis	rs7829975	0.774	rs1703982	ENSG00000254340.1	RP11-10A14.3	-5.33	1.82e-07	0.000148	-0.32	-0.28	Mood instability;	chr8:8740878	chr8:9141424~9145435:+
STAD	cis	rs611744	0.647	rs689275	ENSG00000253754.1	RP11-35G22.1	-5.33	1.82e-07	0.000148	-0.24	-0.28	Dupuytren's disease;	chr8:108229593	chr8:108226200~108227544:+
STAD	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	5.33	1.82e-07	0.000149	0.28	0.28	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
STAD	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-5.33	1.82e-07	0.000149	-0.22	-0.28	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-5.33	1.82e-07	0.000149	-0.22	-0.28	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
STAD	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-5.33	1.82e-07	0.000149	-0.22	-0.28	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
STAD	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-5.33	1.82e-07	0.000149	-0.22	-0.28	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
STAD	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	5.33	1.82e-07	0.000149	0.44	0.28	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
STAD	cis	rs853679	0.517	rs1947862	ENSG00000220721.1	OR1F12	5.32	1.82e-07	0.000149	0.33	0.28	Depression;	chr6:28137418	chr6:28073316~28074233:+
STAD	cis	rs7487075	0.786	rs4768110	ENSG00000272369.1	RP11-446N19.1	5.32	1.82e-07	0.000149	0.34	0.28	Itch intensity from mosquito bite;	chr12:46283678	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.786	rs4768694	ENSG00000272369.1	RP11-446N19.1	5.32	1.82e-07	0.000149	0.34	0.28	Itch intensity from mosquito bite;	chr12:46283875	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.786	rs2242355	ENSG00000272369.1	RP11-446N19.1	5.32	1.82e-07	0.000149	0.33	0.28	Itch intensity from mosquito bite;	chr12:46268702	chr12:46537502~46652550:+
STAD	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	5.32	1.82e-07	0.000149	0.29	0.28	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	5.32	1.82e-07	0.000149	0.29	0.28	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	5.32	1.82e-07	0.000149	0.29	0.28	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	5.32	1.82e-07	0.000149	0.29	0.28	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
STAD	cis	rs1799949	0.965	rs4793233	ENSG00000236383.6	LINC00854	-5.32	1.82e-07	0.000149	-0.23	-0.28	Menopause (age at onset);	chr17:43358069	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.864	rs60309406	ENSG00000236383.6	LINC00854	-5.32	1.82e-07	0.000149	-0.23	-0.28	Menopause (age at onset);	chr17:43358297	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs4793234	ENSG00000236383.6	LINC00854	-5.32	1.82e-07	0.000149	-0.23	-0.28	Menopause (age at onset);	chr17:43358815	chr17:43216941~43305976:-
STAD	cis	rs8097348	0.817	rs9960142	ENSG00000266602.1	RP11-476K15.1	-5.32	1.83e-07	0.000149	-0.34	-0.28	Exercise (leisure time);	chr18:1623614	chr18:1509183~1647097:+
STAD	cis	rs3770081	1	rs2303340	ENSG00000273080.1	RP11-301O19.1	-5.32	1.83e-07	0.00015	-0.6	-0.28	Facial emotion recognition (sad faces);	chr2:86106070	chr2:86195590~86196049:+
STAD	cis	rs11169552	1	rs11169554	ENSG00000200183.1	RNU6-238P	-5.32	1.83e-07	0.00015	-0.27	-0.28	Colorectal cancer;	chr12:50766424	chr12:50656973~50657078:+
STAD	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-5.32	1.84e-07	0.00015	-0.36	-0.28	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-5.32	1.84e-07	0.00015	-0.36	-0.28	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
STAD	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-5.32	1.84e-07	0.00015	-0.29	-0.28	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
STAD	cis	rs240993	0.812	rs28770304	ENSG00000230177.1	RP5-1112D6.4	5.32	1.84e-07	0.00015	0.29	0.28	Inflammatory skin disease;Psoriasis;	chr6:111461586	chr6:111277932~111278742:+
STAD	cis	rs8040855	0.576	rs62022527	ENSG00000229212.6	RP11-561C5.4	5.32	1.84e-07	0.00015	0.41	0.28	Bulimia nervosa;	chr15:84988022	chr15:85205440~85234795:-
STAD	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-5.32	1.84e-07	0.00015	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
STAD	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-5.32	1.84e-07	0.00015	-0.3	-0.28	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
STAD	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-5.32	1.84e-07	0.00015	-0.29	-0.28	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
STAD	cis	rs728616	0.867	rs17879726	ENSG00000225484.5	NUTM2B-AS1	-5.32	1.84e-07	0.000151	-0.61	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:79663088~79826594:-
STAD	cis	rs950169	0.922	rs2033284	ENSG00000259295.5	CSPG4P12	5.32	1.85e-07	0.000151	0.41	0.28	Schizophrenia;	chr15:84391575	chr15:85191438~85213905:+
STAD	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-5.32	1.85e-07	0.000151	-0.38	-0.28	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
STAD	cis	rs58873874	0.737	rs11739062	ENSG00000251405.2	CTB-109A12.1	5.32	1.85e-07	0.000151	0.48	0.28	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157362615~157460078:-
STAD	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	5.32	1.85e-07	0.000151	0.3	0.28	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
STAD	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	5.32	1.85e-07	0.000151	0.3	0.28	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
STAD	cis	rs7829975	0.617	rs4841072	ENSG00000254340.1	RP11-10A14.3	-5.32	1.85e-07	0.000151	-0.33	-0.28	Mood instability;	chr8:8933743	chr8:9141424~9145435:+
STAD	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-5.32	1.85e-07	0.000151	-0.26	-0.28	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
STAD	cis	rs7760535	0.826	rs10872068	ENSG00000230177.1	RP5-1112D6.4	5.32	1.86e-07	0.000151	0.24	0.28	Metabolic traits;	chr6:111528657	chr6:111277932~111278742:+
STAD	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	5.32	1.86e-07	0.000151	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
STAD	cis	rs8098244	0.537	rs11877880	ENSG00000267301.1	RPL23AP77	-5.32	1.86e-07	0.000151	-0.32	-0.28	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716401	chr18:23709825~23710287:-
STAD	cis	rs1799949	1	rs11654731	ENSG00000236383.6	LINC00854	-5.32	1.86e-07	0.000152	-0.23	-0.28	Menopause (age at onset);	chr17:43174923	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs11651623	ENSG00000236383.6	LINC00854	-5.32	1.86e-07	0.000152	-0.23	-0.28	Menopause (age at onset);	chr17:43177830	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs11657883	ENSG00000236383.6	LINC00854	-5.32	1.86e-07	0.000152	-0.23	-0.28	Menopause (age at onset);	chr17:43178007	chr17:43216941~43305976:-
STAD	cis	rs3806843	1	rs10072015	ENSG00000202111.1	VTRNA1-2	5.32	1.86e-07	0.000152	0.27	0.28	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr5:140718925~140719013:+
STAD	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	5.32	1.86e-07	0.000152	0.32	0.28	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
STAD	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	5.32	1.86e-07	0.000152	0.41	0.28	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
STAD	cis	rs1799949	1	rs35070007	ENSG00000236383.6	LINC00854	5.32	1.86e-07	0.000152	0.22	0.28	Menopause (age at onset);	chr17:43164730	chr17:43216941~43305976:-
STAD	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	5.32	1.86e-07	0.000152	0.32	0.28	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
STAD	cis	rs9400467	0.528	rs11153288	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.86e-07	0.000152	-0.25	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs11153290	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.86e-07	0.000152	-0.25	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs11153291	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.86e-07	0.000152	-0.25	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs11153292	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.86e-07	0.000152	-0.25	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs12190634	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.86e-07	0.000152	-0.25	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.508	rs11153294	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.86e-07	0.000152	-0.25	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111277932~111278742:+
STAD	cis	rs7474896	0.616	rs2505239	ENSG00000099251.13	HSD17B7P2	5.32	1.86e-07	0.000152	0.37	0.27	Obesity (extreme);	chr10:38151837	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.561	rs2474603	ENSG00000099251.13	HSD17B7P2	5.32	1.86e-07	0.000152	0.37	0.27	Obesity (extreme);	chr10:38156754	chr10:38356380~38378505:+
STAD	cis	rs10853057	0.541	rs4239089	ENSG00000214174.7	AMZ2P1	-5.32	1.87e-07	0.000152	-0.48	-0.27	White matter microstructure (global fractional anisotropy);	chr17:65005864	chr17:64966550~64975576:-
STAD	cis	rs9463078	0.528	rs12196818	ENSG00000219384.1	RP11-491H9.3	-5.32	1.87e-07	0.000152	-0.27	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44943677	chr6:45158870~45159511:+
STAD	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	5.32	1.87e-07	0.000152	0.3	0.27	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
STAD	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-5.32	1.87e-07	0.000152	-0.32	-0.27	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
STAD	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	5.32	1.87e-07	0.000152	0.29	0.27	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
STAD	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	5.32	1.87e-07	0.000152	0.44	0.27	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
STAD	cis	rs7829975	0.564	rs2976855	ENSG00000254340.1	RP11-10A14.3	5.32	1.88e-07	0.000153	0.33	0.27	Mood instability;	chr8:8444284	chr8:9141424~9145435:+
STAD	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-5.32	1.88e-07	0.000153	-0.27	-0.27	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
STAD	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-5.32	1.88e-07	0.000153	-0.27	-0.27	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
STAD	cis	rs7760535	0.811	rs1002475	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.88e-07	0.000153	-0.25	-0.27	Metabolic traits;	chr6:111388386	chr6:111277932~111278742:+
STAD	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-5.32	1.88e-07	0.000153	-0.28	-0.27	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
STAD	cis	rs8098244	0.557	rs12954712	ENSG00000267301.1	RPL23AP77	-5.32	1.88e-07	0.000153	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707144	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.557	rs4347707	ENSG00000267301.1	RPL23AP77	-5.32	1.88e-07	0.000153	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710362	chr18:23709825~23710287:-
STAD	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-5.32	1.88e-07	0.000153	-0.46	-0.27	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
STAD	cis	rs2439831	1	rs527921	ENSG00000275601.1	AC011330.13	5.32	1.88e-07	0.000153	0.36	0.27	Lung cancer in ever smokers;	chr15:43478218	chr15:43642389~43643023:-
STAD	cis	rs4604732	0.536	rs12037221	ENSG00000227135.1	GCSAML-AS1	-5.32	1.88e-07	0.000153	-0.38	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247467910	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.588	rs4925551	ENSG00000227135.1	GCSAML-AS1	-5.32	1.88e-07	0.000153	-0.38	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468422	chr1:247524679~247526752:-
STAD	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	5.32	1.89e-07	0.000153	0.4	0.27	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
STAD	cis	rs7760535	0.811	rs455732	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.89e-07	0.000154	-0.25	-0.27	Metabolic traits;	chr6:111374065	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs458486	ENSG00000230177.1	RP5-1112D6.4	-5.32	1.89e-07	0.000154	-0.25	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111277932~111278742:+
STAD	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	5.32	1.89e-07	0.000154	0.3	0.27	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
STAD	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	5.32	1.89e-07	0.000154	0.3	0.27	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
STAD	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	5.32	1.89e-07	0.000154	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
STAD	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	5.32	1.89e-07	0.000154	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
STAD	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	5.32	1.89e-07	0.000154	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
STAD	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	5.32	1.89e-07	0.000154	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
STAD	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	5.32	1.89e-07	0.000154	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
STAD	cis	rs8040855	0.658	rs11634877	ENSG00000229212.6	RP11-561C5.4	5.32	1.89e-07	0.000154	0.4	0.27	Bulimia nervosa;	chr15:85068246	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.627	rs11632175	ENSG00000229212.6	RP11-561C5.4	5.32	1.89e-07	0.000154	0.4	0.27	Bulimia nervosa;	chr15:85068449	chr15:85205440~85234795:-
STAD	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	5.32	1.89e-07	0.000154	0.38	0.27	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
STAD	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-5.32	1.9e-07	0.000154	-0.35	-0.27	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
STAD	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-5.32	1.9e-07	0.000154	-0.35	-0.27	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
STAD	cis	rs4927850	1	rs7614767	ENSG00000185485.13	SDHAP1	5.32	1.9e-07	0.000154	0.27	0.27	Pancreatic cancer;	chr3:196026580	chr3:195959748~195990318:-
STAD	cis	rs3758911	0.796	rs11602033	ENSG00000261098.1	RP11-819C21.1	-5.32	1.9e-07	0.000154	-0.25	-0.27	Coronary artery disease;	chr11:107380986	chr11:107312132~107316271:-
STAD	cis	rs7078219	0.523	rs4129134	ENSG00000228778.1	RP11-129J12.1	-5.32	1.9e-07	0.000154	-0.31	-0.27	Dental caries;	chr10:99524588	chr10:99527081~99528261:+
STAD	cis	rs2283792	1	rs13943	ENSG00000228050.1	TOP3BP1	5.32	1.9e-07	0.000155	0.31	0.27	Multiple sclerosis;	chr22:21761913	chr22:22223187~22224566:-
STAD	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-5.32	1.9e-07	0.000155	-0.37	-0.27	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
STAD	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	5.32	1.9e-07	0.000155	0.27	0.27	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	5.32	1.91e-07	0.000155	0.28	0.27	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
STAD	cis	rs8098244	0.683	rs10853591	ENSG00000267301.1	RPL23AP77	-5.32	1.91e-07	0.000155	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23845888	chr18:23709825~23710287:-
STAD	cis	rs7826238	0.653	rs2979202	ENSG00000173295.6	FAM86B3P	5.32	1.91e-07	0.000155	0.31	0.27	Systolic blood pressure;	chr8:8486617	chr8:8228595~8244865:+
STAD	cis	rs6142102	0.961	rs4911144	ENSG00000275784.1	RP5-1125A11.6	-5.32	1.91e-07	0.000155	-0.28	-0.27	Skin pigmentation;	chr20:34026565	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-5.31	1.92e-07	0.000156	-0.29	-0.27	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
STAD	cis	rs950169	0.922	rs4338765	ENSG00000259295.5	CSPG4P12	5.31	1.92e-07	0.000156	0.41	0.27	Schizophrenia;	chr15:84248084	chr15:85191438~85213905:+
STAD	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	5.31	1.92e-07	0.000156	0.4	0.27	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	5.31	1.92e-07	0.000156	0.4	0.27	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
STAD	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-5.31	1.92e-07	0.000156	-0.35	-0.27	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
STAD	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-5.31	1.92e-07	0.000156	-0.28	-0.27	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
STAD	cis	rs6142102	0.961	rs2056990	ENSG00000275784.1	RP5-1125A11.6	-5.31	1.92e-07	0.000156	-0.28	-0.27	Skin pigmentation;	chr20:34035658	chr20:33989480~33991818:-
STAD	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-5.31	1.92e-07	0.000156	-0.35	-0.27	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
STAD	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-5.31	1.92e-07	0.000156	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
STAD	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-5.31	1.92e-07	0.000156	-0.36	-0.27	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
STAD	cis	rs6782228	0.883	rs11712115	ENSG00000277250.1	Metazoa_SRP	5.31	1.93e-07	0.000156	0.32	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128673681~128674021:-
STAD	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-5.31	1.93e-07	0.000157	-0.29	-0.27	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
STAD	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	5.31	1.93e-07	0.000157	0.43	0.27	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	5.31	1.93e-07	0.000157	0.43	0.27	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
STAD	cis	rs1816752	0.712	rs2862898	ENSG00000273628.1	RP11-756A22.7	5.31	1.93e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24414323	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.652	rs2902356	ENSG00000273628.1	RP11-756A22.7	5.31	1.93e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24414333	chr13:24933006~24936796:+
STAD	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	5.31	1.93e-07	0.000157	0.32	0.27	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
STAD	cis	rs9601248	0.756	rs7997134	ENSG00000227354.5	RBM26-AS1	-5.31	1.93e-07	0.000157	-0.33	-0.27	Major depressive disorder;	chr13:79619594	chr13:79406309~79424328:+
STAD	cis	rs7487075	0.786	rs7316127	ENSG00000272369.1	RP11-446N19.1	5.31	1.93e-07	0.000157	0.35	0.27	Itch intensity from mosquito bite;	chr12:46280466	chr12:46537502~46652550:+
STAD	cis	rs1799949	0.929	rs799905	ENSG00000236383.6	LINC00854	-5.31	1.94e-07	0.000157	-0.22	-0.27	Menopause (age at onset);	chr17:43125170	chr17:43216941~43305976:-
STAD	cis	rs2436845	1	rs2679749	ENSG00000253385.1	KB-1254G8.1	5.31	1.94e-07	0.000157	0.29	0.27	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102846260	chr8:102854455~102856075:+
STAD	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	5.31	1.94e-07	0.000157	0.3	0.27	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
STAD	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	5.31	1.94e-07	0.000157	0.35	0.27	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
STAD	cis	rs1816752	0.806	rs3816218	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24443033	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.666	rs7994022	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24443092	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.776	rs7998843	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24443147	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.712	rs6490932	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24443313	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.713	rs7336357	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24443452	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.683	rs7330532	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24443453	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.59	rs61947036	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24443544	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.746	rs9511270	ENSG00000273628.1	RP11-756A22.7	5.31	1.94e-07	0.000157	0.34	0.27	Obesity-related traits;	chr13:24444542	chr13:24933006~24936796:+
STAD	cis	rs6782228	0.848	rs6439140	ENSG00000277250.1	Metazoa_SRP	5.31	1.94e-07	0.000157	0.33	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128673681~128674021:-
STAD	cis	rs4713118	0.955	rs9468203	ENSG00000280107.1	AL022393.9	-5.31	1.94e-07	0.000158	-0.35	-0.27	Parkinson's disease;	chr6:27720888	chr6:28170845~28172521:+
STAD	cis	rs7927771	0.507	rs11039432	ENSG00000280615.1	Y_RNA	5.31	1.94e-07	0.000158	0.28	0.27	Subjective well-being;	chr11:47851775	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs2170815	ENSG00000280615.1	Y_RNA	5.31	1.94e-07	0.000158	0.28	0.27	Subjective well-being;	chr11:47854358	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7929725	ENSG00000280615.1	Y_RNA	5.31	1.94e-07	0.000158	0.28	0.27	Subjective well-being;	chr11:47860188	chr11:47614898~47614994:-
STAD	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	5.31	1.95e-07	0.000158	0.31	0.27	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
STAD	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	5.31	1.95e-07	0.000158	0.29	0.27	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
STAD	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	5.31	1.95e-07	0.000158	0.29	0.27	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
STAD	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	5.31	1.95e-07	0.000158	0.4	0.27	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
STAD	cis	rs992157	0.56	rs7578940	ENSG00000237281.1	CATIP-AS2	5.31	1.95e-07	0.000158	0.28	0.27	Colorectal cancer;	chr2:218218595	chr2:218326889~218357966:-
STAD	cis	rs8098244	0.683	rs4334381	ENSG00000267301.1	RPL23AP77	-5.31	1.95e-07	0.000158	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852485	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.683	rs4488534	ENSG00000267301.1	RPL23AP77	-5.31	1.95e-07	0.000158	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852486	chr18:23709825~23710287:-
STAD	cis	rs507080	0.922	rs12577485	ENSG00000278376.1	RP11-158I9.8	-5.31	1.95e-07	0.000158	-0.28	-0.27	Serum metabolite levels;	chr11:118676793	chr11:118791254~118793137:+
STAD	cis	rs62432291	0.681	rs433786	ENSG00000235086.1	FNDC1-IT1	-5.31	1.95e-07	0.000158	-0.43	-0.27	Joint mobility (Beighton score);	chr6:159244914	chr6:159240786~159243329:+
STAD	cis	rs7662987	0.793	rs7684735	ENSG00000272777.1	RP11-571L19.8	5.31	1.95e-07	0.000158	0.51	0.27	Smoking initiation;	chr4:99070355	chr4:99067256~99068125:-
STAD	cis	rs7662987	0.793	rs7669660	ENSG00000272777.1	RP11-571L19.8	5.31	1.95e-07	0.000158	0.51	0.27	Smoking initiation;	chr4:99071451	chr4:99067256~99068125:-
STAD	cis	rs992157	0.798	rs7587220	ENSG00000237281.1	CATIP-AS2	5.31	1.95e-07	0.000158	0.28	0.27	Colorectal cancer;	chr2:218296141	chr2:218326889~218357966:-
STAD	cis	rs992157	0.798	rs4674284	ENSG00000237281.1	CATIP-AS2	5.31	1.95e-07	0.000158	0.28	0.27	Colorectal cancer;	chr2:218296518	chr2:218326889~218357966:-
STAD	cis	rs228614	0.51	rs223349	ENSG00000230069.3	LRRC37A15P	-5.31	1.95e-07	0.000158	-0.3	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102727274~102730721:-
STAD	cis	rs17301013	0.896	rs3118980	ENSG00000227373.4	RP11-160H22.5	-5.31	1.95e-07	0.000158	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174793701	chr1:174115300~174160004:-
STAD	cis	rs11169552	0.709	rs4768924	ENSG00000200183.1	RNU6-238P	5.31	1.96e-07	0.000159	0.27	0.27	Colorectal cancer;	chr12:50824331	chr12:50656973~50657078:+
STAD	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	5.31	1.96e-07	0.000159	0.35	0.27	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	5.31	1.96e-07	0.000159	0.35	0.27	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
STAD	cis	rs2921073	0.51	rs2976945	ENSG00000173295.6	FAM86B3P	5.31	1.96e-07	0.000159	0.3	0.27	Parkinson's disease;	chr8:8413361	chr8:8228595~8244865:+
STAD	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	5.31	1.96e-07	0.000159	0.36	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
STAD	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-5.31	1.96e-07	0.000159	-0.28	-0.27	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
STAD	cis	rs17301013	0.869	rs3133270	ENSG00000227373.4	RP11-160H22.5	-5.31	1.96e-07	0.000159	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174819547	chr1:174115300~174160004:-
STAD	cis	rs2404602	0.655	rs3829489	ENSG00000259422.1	RP11-593F23.1	5.31	1.96e-07	0.000159	0.3	0.27	Blood metabolite levels;	chr15:76930915	chr15:76174891~76181486:-
STAD	cis	rs6782228	1	rs35604103	ENSG00000277250.1	Metazoa_SRP	5.31	1.96e-07	0.000159	0.33	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128673681~128674021:-
STAD	cis	rs7927771	0.524	rs11039345	ENSG00000280615.1	Y_RNA	5.31	1.97e-07	0.000159	0.28	0.27	Subjective well-being;	chr11:47698676	chr11:47614898~47614994:-
STAD	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-5.31	1.97e-07	0.000159	-0.32	-0.27	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
STAD	cis	rs7927771	0.524	rs11039431	ENSG00000280615.1	Y_RNA	5.31	1.97e-07	0.000159	0.28	0.27	Subjective well-being;	chr11:47850460	chr11:47614898~47614994:-
STAD	cis	rs7580658	0.637	rs9636235	ENSG00000200250.1	RNU6-1147P	5.31	1.97e-07	0.00016	0.26	0.27	Protein C levels;	chr2:127223975	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.637	rs9636236	ENSG00000200250.1	RNU6-1147P	5.31	1.97e-07	0.00016	0.26	0.27	Protein C levels;	chr2:127225365	chr2:127316873~127316979:+
STAD	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-5.31	1.97e-07	0.00016	-0.43	-0.27	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
STAD	cis	rs6142102	0.778	rs4911374	ENSG00000275784.1	RP5-1125A11.6	-5.31	1.98e-07	0.00016	-0.29	-0.27	Skin pigmentation;	chr20:33928195	chr20:33989480~33991818:-
STAD	cis	rs507080	0.961	rs600969	ENSG00000278376.1	RP11-158I9.8	-5.31	1.98e-07	0.00016	-0.28	-0.27	Serum metabolite levels;	chr11:118675087	chr11:118791254~118793137:+
STAD	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	5.31	1.98e-07	0.00016	0.27	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
STAD	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.31	1.98e-07	0.00016	0.31	0.27	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
STAD	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	5.31	1.98e-07	0.00016	0.34	0.27	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000224205.1	AP000351.4	5.31	1.98e-07	0.00016	0.31	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23987320~23991421:-
STAD	cis	rs6142102	0.923	rs4911394	ENSG00000275784.1	RP5-1125A11.6	-5.31	1.98e-07	0.00016	-0.29	-0.27	Skin pigmentation;	chr20:33989521	chr20:33989480~33991818:-
STAD	cis	rs7665090	0.87	rs228627	ENSG00000246560.2	RP11-10L12.4	-5.31	1.98e-07	0.00016	-0.33	-0.27	Primary biliary cholangitis;	chr4:102651925	chr4:102828055~102844075:+
STAD	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-5.31	1.99e-07	0.000161	-0.3	-0.27	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
STAD	cis	rs7078219	0.505	rs11190140	ENSG00000228778.1	RP11-129J12.1	-5.31	1.99e-07	0.000161	-0.32	-0.27	Dental caries;	chr10:99531836	chr10:99527081~99528261:+
STAD	cis	rs2404602	0.632	rs34338978	ENSG00000259422.1	RP11-593F23.1	5.31	1.99e-07	0.000161	0.3	0.27	Blood metabolite levels;	chr15:76934464	chr15:76174891~76181486:-
STAD	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	5.31	1.99e-07	0.000161	0.3	0.27	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
STAD	cis	rs2412819	0.571	rs514255	ENSG00000249839.1	AC011330.5	-5.31	1.99e-07	0.000161	-0.49	-0.27	Lung cancer;	chr15:43893134	chr15:43663654~43684339:-
STAD	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	5.31	2e-07	0.000161	0.4	0.27	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
STAD	cis	rs853679	0.542	rs9393892	ENSG00000220721.1	OR1F12	5.31	2e-07	0.000161	0.33	0.27	Depression;	chr6:28113616	chr6:28073316~28074233:+
STAD	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-5.31	2e-07	0.000162	-0.43	-0.27	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
STAD	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	5.31	2e-07	0.000162	0.43	0.27	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
STAD	cis	rs10504130	0.597	rs4598243	ENSG00000272024.1	RP11-546K22.3	-5.31	2e-07	0.000162	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51950284~51950690:+
STAD	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	5.31	2e-07	0.000162	0.4	0.27	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
STAD	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-5.31	2e-07	0.000162	-0.34	-0.27	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
STAD	cis	rs748404	0.626	rs17780920	ENSG00000249839.1	AC011330.5	-5.31	2.01e-07	0.000162	-0.46	-0.27	Lung cancer;	chr15:43370164	chr15:43663654~43684339:-
STAD	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-5.31	2.01e-07	0.000162	-0.29	-0.27	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
STAD	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	5.31	2.01e-07	0.000162	0.32	0.27	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
STAD	cis	rs10849893	0.576	rs10849886	ENSG00000258435.1	RP11-711D18.2	-5.31	2.01e-07	0.000162	-0.3	-0.27	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121449118	chr12:121391962~121399859:+
STAD	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	5.31	2.01e-07	0.000162	0.43	0.27	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
STAD	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-5.31	2.01e-07	0.000163	-0.31	-0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
STAD	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	5.31	2.01e-07	0.000163	0.34	0.27	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
STAD	cis	rs516805	0.748	rs572261	ENSG00000279453.1	RP3-425C14.4	-5.3	2.02e-07	0.000163	-0.45	-0.27	Lymphocyte counts;	chr6:122408877	chr6:122436789~122439223:-
STAD	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-5.3	2.02e-07	0.000163	-0.29	-0.27	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
STAD	cis	rs3758911	0.861	rs1388170	ENSG00000261098.1	RP11-819C21.1	-5.3	2.02e-07	0.000163	-0.25	-0.27	Coronary artery disease;	chr11:107272130	chr11:107312132~107316271:-
STAD	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-5.3	2.02e-07	0.000163	-0.44	-0.27	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
STAD	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	5.3	2.02e-07	0.000163	0.37	0.27	Height;	chr6:109352730	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	5.3	2.02e-07	0.000163	0.37	0.27	Height;	chr6:109353355	chr6:109382795~109383666:+
STAD	cis	rs3758911	0.894	rs56393657	ENSG00000261098.1	RP11-819C21.1	-5.3	2.02e-07	0.000163	-0.25	-0.27	Coronary artery disease;	chr11:107342902	chr11:107312132~107316271:-
STAD	cis	rs1322639	0.614	rs9689800	ENSG00000261039.2	RP11-417E7.2	5.3	2.02e-07	0.000163	0.3	0.27	Pulse pressure;	chr6:169172850	chr6:169175304~169182740:-
STAD	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	5.3	2.02e-07	0.000163	0.27	0.27	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
STAD	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-5.3	2.03e-07	0.000164	-0.29	-0.27	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
STAD	cis	rs7680126	0.53	rs11721682	ENSG00000250613.1	RP11-136I13.1	-5.3	2.03e-07	0.000164	-0.34	-0.27	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10149523	chr4:10410996~10411644:+
STAD	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	5.3	2.03e-07	0.000164	0.27	0.27	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
STAD	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	5.3	2.03e-07	0.000164	0.24	0.27	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
STAD	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	5.3	2.03e-07	0.000164	0.34	0.27	Height;	chr6:109447092	chr6:109382795~109383666:+
STAD	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-5.3	2.04e-07	0.000165	-0.26	-0.27	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
STAD	cis	rs516805	0.667	rs2606609	ENSG00000279453.1	RP3-425C14.4	5.3	2.04e-07	0.000165	0.38	0.27	Lymphocyte counts;	chr6:122190346	chr6:122436789~122439223:-
STAD	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-5.3	2.04e-07	0.000165	-0.32	-0.27	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
STAD	cis	rs17301013	0.9	rs1754351	ENSG00000227373.4	RP11-160H22.5	-5.3	2.04e-07	0.000165	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174762458	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.9	rs1793300	ENSG00000227373.4	RP11-160H22.5	-5.3	2.04e-07	0.000165	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174768559	chr1:174115300~174160004:-
STAD	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-5.3	2.04e-07	0.000165	-0.32	-0.27	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
STAD	cis	rs7829975	0.522	rs6601689	ENSG00000254340.1	RP11-10A14.3	5.3	2.05e-07	0.000165	0.34	0.27	Mood instability;	chr8:8314761	chr8:9141424~9145435:+
STAD	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-5.3	2.05e-07	0.000165	-0.34	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
STAD	cis	rs12744310	0.83	rs12045184	ENSG00000235358.1	RP11-399E6.1	5.3	2.05e-07	0.000165	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333939	chr1:41242373~41284861:+
STAD	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	5.3	2.05e-07	0.000165	0.27	0.27	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
STAD	cis	rs7927771	0.77	rs11039203	ENSG00000280615.1	Y_RNA	-5.3	2.05e-07	0.000165	-0.28	-0.27	Subjective well-being;	chr11:47363046	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.832	rs67116452	ENSG00000280615.1	Y_RNA	-5.3	2.05e-07	0.000165	-0.28	-0.27	Subjective well-being;	chr11:47363643	chr11:47614898~47614994:-
STAD	cis	rs7124681	0.585	rs10838773	ENSG00000280615.1	Y_RNA	5.3	2.05e-07	0.000165	0.28	0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47812794	chr11:47614898~47614994:-
STAD	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	5.3	2.05e-07	0.000165	0.26	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
STAD	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-5.3	2.05e-07	0.000166	-0.22	-0.27	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
STAD	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	5.3	2.06e-07	0.000166	0.3	0.27	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	5.3	2.06e-07	0.000166	0.3	0.27	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
STAD	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-5.3	2.06e-07	0.000166	-0.34	-0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
STAD	cis	rs10504130	0.569	rs12681734	ENSG00000272024.1	RP11-546K22.3	-5.3	2.06e-07	0.000166	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51893635	chr8:51950284~51950690:+
STAD	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-5.3	2.07e-07	0.000167	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
STAD	cis	rs875971	0.862	rs11765791	ENSG00000236529.1	RP13-254B10.1	5.3	2.07e-07	0.000167	0.28	0.27	Aortic root size;	chr7:66471587	chr7:65840212~65840596:+
STAD	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-5.3	2.07e-07	0.000167	-0.23	-0.27	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
STAD	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	5.3	2.07e-07	0.000167	0.4	0.27	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
STAD	cis	rs7927771	0.832	rs55677087	ENSG00000280615.1	Y_RNA	-5.3	2.07e-07	0.000167	-0.28	-0.27	Subjective well-being;	chr11:47376163	chr11:47614898~47614994:-
STAD	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-5.3	2.07e-07	0.000167	-0.28	-0.27	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
STAD	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	5.3	2.07e-07	0.000167	0.27	0.27	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
STAD	cis	rs227275	0.525	rs3974604	ENSG00000230069.3	LRRC37A15P	-5.3	2.07e-07	0.000167	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102727274~102730721:-
STAD	cis	rs7487075	0.786	rs1492892	ENSG00000272369.1	RP11-446N19.1	5.3	2.07e-07	0.000167	0.33	0.27	Itch intensity from mosquito bite;	chr12:46297704	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs35497251	ENSG00000272369.1	RP11-446N19.1	5.3	2.07e-07	0.000167	0.33	0.27	Itch intensity from mosquito bite;	chr12:46298698	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs7967669	ENSG00000272369.1	RP11-446N19.1	5.3	2.07e-07	0.000167	0.33	0.27	Itch intensity from mosquito bite;	chr12:46299208	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs2018424	ENSG00000272369.1	RP11-446N19.1	5.3	2.07e-07	0.000167	0.33	0.27	Itch intensity from mosquito bite;	chr12:46300874	chr12:46537502~46652550:+
STAD	cis	rs1799949	0.501	rs2343819	ENSG00000236383.6	LINC00854	-5.3	2.07e-07	0.000167	-0.22	-0.27	Menopause (age at onset);	chr17:43332285	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.501	rs35399157	ENSG00000236383.6	LINC00854	-5.3	2.07e-07	0.000167	-0.22	-0.27	Menopause (age at onset);	chr17:43334234	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.602	rs4600503	ENSG00000236383.6	LINC00854	-5.3	2.07e-07	0.000167	-0.22	-0.27	Menopause (age at onset);	chr17:43336956	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.501	rs9675035	ENSG00000236383.6	LINC00854	-5.3	2.07e-07	0.000167	-0.22	-0.27	Menopause (age at onset);	chr17:43337648	chr17:43216941~43305976:-
STAD	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-5.3	2.08e-07	0.000167	-0.33	-0.27	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
STAD	cis	rs516805	0.706	rs9490427	ENSG00000279453.1	RP3-425C14.4	5.3	2.08e-07	0.000167	0.37	0.27	Lymphocyte counts;	chr6:122353084	chr6:122436789~122439223:-
STAD	cis	rs17301013	0.932	rs1754349	ENSG00000227373.4	RP11-160H22.5	-5.3	2.08e-07	0.000167	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174837663	chr1:174115300~174160004:-
STAD	cis	rs2933343	0.7	rs883602	ENSG00000231305.3	RP11-723O4.2	5.3	2.08e-07	0.000167	0.29	0.27	IgG glycosylation;	chr3:128935109	chr3:128861313~128871540:-
STAD	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-5.3	2.08e-07	0.000167	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
STAD	cis	rs611744	0.647	rs674391	ENSG00000253754.1	RP11-35G22.1	-5.3	2.08e-07	0.000167	-0.24	-0.27	Dupuytren's disease;	chr8:108230574	chr8:108226200~108227544:+
STAD	cis	rs516805	0.748	rs11154072	ENSG00000279453.1	RP3-425C14.4	5.3	2.08e-07	0.000167	0.38	0.27	Lymphocyte counts;	chr6:122374632	chr6:122436789~122439223:-
STAD	cis	rs516805	0.748	rs12189881	ENSG00000279453.1	RP3-425C14.4	5.3	2.08e-07	0.000167	0.38	0.27	Lymphocyte counts;	chr6:122375109	chr6:122436789~122439223:-
STAD	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	5.3	2.08e-07	0.000168	0.35	0.27	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
STAD	cis	rs3806843	1	rs7732179	ENSG00000202111.1	VTRNA1-2	-5.3	2.08e-07	0.000168	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140819454	chr5:140718925~140719013:+
STAD	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-5.3	2.08e-07	0.000168	-0.32	-0.27	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
STAD	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	5.3	2.08e-07	0.000168	0.33	0.27	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
STAD	cis	rs1056107	0.966	rs7869209	ENSG00000225513.1	RP11-165N19.2	-5.3	2.08e-07	0.000168	-0.32	-0.27	Colorectal cancer;	chr9:112301133	chr9:112173522~112173971:-
STAD	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	5.3	2.08e-07	0.000168	0.33	0.27	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
STAD	cis	rs1056107	0.872	rs7865097	ENSG00000225513.1	RP11-165N19.2	-5.3	2.09e-07	0.000168	-0.32	-0.27	Colorectal cancer;	chr9:112272079	chr9:112173522~112173971:-
STAD	cis	rs7487075	0.808	rs10880961	ENSG00000272369.1	RP11-446N19.1	5.3	2.09e-07	0.000168	0.36	0.27	Itch intensity from mosquito bite;	chr12:46371445	chr12:46537502~46652550:+
STAD	cis	rs6782228	0.848	rs3935016	ENSG00000277250.1	Metazoa_SRP	5.3	2.09e-07	0.000168	0.32	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.848	rs6439141	ENSG00000277250.1	Metazoa_SRP	5.3	2.09e-07	0.000168	0.32	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.883	rs6439142	ENSG00000277250.1	Metazoa_SRP	5.3	2.09e-07	0.000168	0.32	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128673681~128674021:-
STAD	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-5.3	2.09e-07	0.000168	-0.3	-0.27	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
STAD	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-5.3	2.09e-07	0.000168	-0.3	-0.27	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
STAD	cis	rs992157	0.798	rs10193383	ENSG00000237281.1	CATIP-AS2	-5.3	2.09e-07	0.000168	-0.28	-0.27	Colorectal cancer;	chr2:218292969	chr2:218326889~218357966:-
STAD	cis	rs992157	0.798	rs10206064	ENSG00000237281.1	CATIP-AS2	-5.3	2.09e-07	0.000168	-0.28	-0.27	Colorectal cancer;	chr2:218293236	chr2:218326889~218357966:-
STAD	cis	rs992157	0.7	rs10165153	ENSG00000237281.1	CATIP-AS2	-5.3	2.09e-07	0.000168	-0.28	-0.27	Colorectal cancer;	chr2:218294906	chr2:218326889~218357966:-
STAD	cis	rs1056107	0.966	rs1538770	ENSG00000225513.1	RP11-165N19.2	-5.3	2.09e-07	0.000168	-0.32	-0.27	Colorectal cancer;	chr9:112300069	chr9:112173522~112173971:-
STAD	cis	rs7829975	0.572	rs28446104	ENSG00000254340.1	RP11-10A14.3	-5.3	2.09e-07	0.000168	-0.34	-0.27	Mood instability;	chr8:8938391	chr8:9141424~9145435:+
STAD	cis	rs992157	0.798	rs12053514	ENSG00000237281.1	CATIP-AS2	5.3	2.09e-07	0.000168	0.28	0.27	Colorectal cancer;	chr2:218303242	chr2:218326889~218357966:-
STAD	cis	rs2933343	0.621	rs883843	ENSG00000231305.3	RP11-723O4.2	-5.3	2.1e-07	0.000169	-0.29	-0.27	IgG glycosylation;	chr3:128848540	chr3:128861313~128871540:-
STAD	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	5.3	2.1e-07	0.000169	0.38	0.27	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
STAD	cis	rs4713118	0.868	rs7756968	ENSG00000280107.1	AL022393.9	-5.3	2.1e-07	0.000169	-0.38	-0.27	Parkinson's disease;	chr6:27767175	chr6:28170845~28172521:+
STAD	cis	rs10129255	0.912	rs61997792	ENSG00000280411.1	IGHV1-69-2	-5.3	2.1e-07	0.000169	-0.26	-0.27	Kawasaki disease;	chr14:106799304	chr14:106762092~106762588:-
STAD	cis	rs875971	0.597	rs11763224	ENSG00000224316.1	RP11-479O9.2	5.3	2.1e-07	0.000169	0.31	0.27	Aortic root size;	chr7:66518628	chr7:65773620~65802067:+
STAD	cis	rs12091564	1	rs12091564	ENSG00000233396.6	RP11-458D21.1	5.3	2.1e-07	0.000169	0.56	0.27	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr1:146052566~146061948:+
STAD	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-5.3	2.1e-07	0.000169	-0.33	-0.27	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
STAD	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-5.3	2.1e-07	0.000169	-0.32	-0.27	Depression;	chr6:28086929	chr6:28073316~28074233:+
STAD	cis	rs516805	0.886	rs557528	ENSG00000279453.1	RP3-425C14.4	-5.3	2.11e-07	0.000169	-0.3	-0.27	Lymphocyte counts;	chr6:122482793	chr6:122436789~122439223:-
STAD	cis	rs516805	0.961	rs559721	ENSG00000279453.1	RP3-425C14.4	-5.3	2.11e-07	0.000169	-0.3	-0.27	Lymphocyte counts;	chr6:122482796	chr6:122436789~122439223:-
STAD	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	5.3	2.11e-07	0.000169	0.48	0.27	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
STAD	cis	rs8040855	0.627	rs11630697	ENSG00000229212.6	RP11-561C5.4	5.3	2.11e-07	0.000169	0.4	0.27	Bulimia nervosa;	chr15:85063214	chr15:85205440~85234795:-
STAD	cis	rs875971	0.571	rs160641	ENSG00000236529.1	RP13-254B10.1	-5.3	2.11e-07	0.000169	-0.33	-0.27	Aortic root size;	chr7:66112359	chr7:65840212~65840596:+
STAD	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	5.3	2.11e-07	0.00017	0.27	0.27	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
STAD	cis	rs7487075	0.82	rs7953659	ENSG00000272369.1	RP11-446N19.1	5.3	2.11e-07	0.00017	0.33	0.27	Itch intensity from mosquito bite;	chr12:46304900	chr12:46537502~46652550:+
STAD	cis	rs7124681	0.584	rs1471712	ENSG00000280615.1	Y_RNA	-5.3	2.11e-07	0.00017	-0.27	-0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47890598	chr11:47614898~47614994:-
STAD	cis	rs12699921	0.632	rs1852011	ENSG00000279048.1	RP11-511H23.2	-5.3	2.11e-07	0.00017	-0.24	-0.27	Fibrinogen levels;	chr7:17787004	chr7:17940503~17942922:+
STAD	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	5.3	2.12e-07	0.00017	0.42	0.27	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
STAD	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	5.3	2.12e-07	0.00017	0.29	0.27	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	5.3	2.12e-07	0.00017	0.29	0.27	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	5.3	2.12e-07	0.00017	0.29	0.27	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
STAD	cis	rs7927771	0.8	rs55876153	ENSG00000280615.1	Y_RNA	-5.3	2.12e-07	0.00017	-0.27	-0.27	Subjective well-being;	chr11:47395085	chr11:47614898~47614994:-
STAD	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-5.3	2.12e-07	0.00017	-0.37	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
STAD	cis	rs7927771	0.542	rs7122217	ENSG00000280615.1	Y_RNA	-5.29	2.12e-07	0.00017	-0.27	-0.27	Subjective well-being;	chr11:47756368	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs12421563	ENSG00000280615.1	Y_RNA	-5.29	2.12e-07	0.00017	-0.27	-0.27	Subjective well-being;	chr11:47758670	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10742820	ENSG00000280615.1	Y_RNA	-5.29	2.12e-07	0.00017	-0.27	-0.27	Subjective well-being;	chr11:47759505	chr11:47614898~47614994:-
STAD	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-5.29	2.13e-07	0.000171	-0.3	-0.27	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
STAD	cis	rs728616	0.867	rs3088308	ENSG00000225484.5	NUTM2B-AS1	-5.29	2.13e-07	0.000171	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:79663088~79826594:-
STAD	cis	rs4713118	0.911	rs9295746	ENSG00000280107.1	AL022393.9	-5.29	2.13e-07	0.000171	-0.38	-0.27	Parkinson's disease;	chr6:27762285	chr6:28170845~28172521:+
STAD	cis	rs6714710	0.603	rs7421146	ENSG00000235833.1	AC159540.14	-5.29	2.13e-07	0.000171	-0.32	-0.27	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935808	chr2:97523949~97524976:-
STAD	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	5.29	2.13e-07	0.000171	0.33	0.27	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
STAD	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-5.29	2.13e-07	0.000171	-0.38	-0.27	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
STAD	cis	rs7487075	0.722	rs4768111	ENSG00000272369.1	RP11-446N19.1	5.29	2.13e-07	0.000171	0.34	0.27	Itch intensity from mosquito bite;	chr12:46311978	chr12:46537502~46652550:+
STAD	cis	rs1153858	1	rs1153858	ENSG00000259433.2	CTD-2651B20.4	5.29	2.13e-07	0.000171	0.31	0.27	Homoarginine levels;	chr15:45360505	chr15:45330209~45332634:-
STAD	cis	rs10129255	0.872	rs1858683	ENSG00000280411.1	IGHV1-69-2	-5.29	2.14e-07	0.000171	-0.26	-0.27	Kawasaki disease;	chr14:106670217	chr14:106762092~106762588:-
STAD	cis	rs3806843	1	rs7710794	ENSG00000202111.1	VTRNA1-2	-5.29	2.14e-07	0.000171	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140829882	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs10038174	ENSG00000202111.1	VTRNA1-2	-5.29	2.14e-07	0.000171	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140831031	chr5:140718925~140719013:+
STAD	cis	rs9907295	1	rs11868244	ENSG00000270894.1	AC015849.13	-5.29	2.14e-07	0.000172	-0.3	-0.27	Fibroblast growth factor basic levels;	chr17:35916339	chr17:35818399~35823713:+
STAD	cis	rs7829975	0.658	rs907181	ENSG00000254340.1	RP11-10A14.3	5.29	2.14e-07	0.000172	0.31	0.27	Mood instability;	chr8:8845365	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.688	rs7827182	ENSG00000254340.1	RP11-10A14.3	5.29	2.15e-07	0.000172	0.33	0.27	Mood instability;	chr8:8522961	chr8:9141424~9145435:+
STAD	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	5.29	2.15e-07	0.000172	0.32	0.27	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
STAD	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	5.29	2.15e-07	0.000172	0.28	0.27	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
STAD	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	5.29	2.15e-07	0.000172	0.28	0.27	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
STAD	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	5.29	2.15e-07	0.000173	0.4	0.27	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
STAD	cis	rs516805	0.667	rs7767993	ENSG00000279453.1	RP3-425C14.4	5.29	2.16e-07	0.000173	0.37	0.27	Lymphocyte counts;	chr6:122343192	chr6:122436789~122439223:-
STAD	cis	rs516805	0.667	rs10457432	ENSG00000279453.1	RP3-425C14.4	5.29	2.16e-07	0.000173	0.37	0.27	Lymphocyte counts;	chr6:122344699	chr6:122436789~122439223:-
STAD	cis	rs516805	0.673	rs12201010	ENSG00000279453.1	RP3-425C14.4	5.29	2.16e-07	0.000173	0.37	0.27	Lymphocyte counts;	chr6:122345675	chr6:122436789~122439223:-
STAD	cis	rs516805	0.64	rs12208084	ENSG00000279453.1	RP3-425C14.4	5.29	2.16e-07	0.000173	0.37	0.27	Lymphocyte counts;	chr6:122345745	chr6:122436789~122439223:-
STAD	cis	rs516805	0.706	rs17662514	ENSG00000279453.1	RP3-425C14.4	5.29	2.16e-07	0.000173	0.37	0.27	Lymphocyte counts;	chr6:122346013	chr6:122436789~122439223:-
STAD	cis	rs516805	0.706	rs9320863	ENSG00000279453.1	RP3-425C14.4	5.29	2.16e-07	0.000173	0.37	0.27	Lymphocyte counts;	chr6:122347086	chr6:122436789~122439223:-
STAD	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-5.29	2.16e-07	0.000173	-0.26	-0.27	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
STAD	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-5.29	2.16e-07	0.000173	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
STAD	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	5.29	2.16e-07	0.000173	0.29	0.27	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
STAD	cis	rs9307551	0.817	rs13127970	ENSG00000250334.4	LINC00989	-5.29	2.16e-07	0.000173	-0.33	-0.27	Refractive error;	chr4:79581236	chr4:79492416~79576460:+
STAD	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-5.29	2.16e-07	0.000173	-0.32	-0.27	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
STAD	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	5.29	2.16e-07	0.000173	0.29	0.27	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
STAD	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-5.29	2.16e-07	0.000173	-0.29	-0.27	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
STAD	cis	rs6142102	0.778	rs6059555	ENSG00000275784.1	RP5-1125A11.6	-5.29	2.17e-07	0.000174	-0.29	-0.27	Skin pigmentation;	chr20:33926518	chr20:33989480~33991818:-
STAD	cis	rs9463078	0.585	rs7754378	ENSG00000219384.1	RP11-491H9.3	-5.29	2.17e-07	0.000174	-0.26	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44895369	chr6:45158870~45159511:+
STAD	cis	rs1729407	0.786	rs5100	ENSG00000280143.1	AP000892.6	5.29	2.17e-07	0.000174	0.2	0.27	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117204967~117210292:+
STAD	cis	rs7083	1	rs535602	ENSG00000254851.1	RP11-109L13.1	5.29	2.17e-07	0.000174	0.31	0.27	Blood protein levels;	chr11:117237059	chr11:117135528~117138582:+
STAD	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	5.29	2.17e-07	0.000174	0.33	0.27	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
STAD	cis	rs875971	0.767	rs12668005	ENSG00000236529.1	RP13-254B10.1	5.29	2.17e-07	0.000174	0.28	0.27	Aortic root size;	chr7:66444034	chr7:65840212~65840596:+
STAD	cis	rs58873874	0.737	rs11466784	ENSG00000251405.2	CTB-109A12.1	5.29	2.17e-07	0.000174	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157494643	chr5:157362615~157460078:-
STAD	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	5.29	2.17e-07	0.000174	0.34	0.27	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
STAD	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-5.29	2.18e-07	0.000174	-0.28	-0.27	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
STAD	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-5.29	2.18e-07	0.000174	-0.28	-0.27	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
STAD	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	5.29	2.18e-07	0.000174	0.38	0.27	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
STAD	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-5.29	2.18e-07	0.000174	-0.29	-0.27	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
STAD	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	5.29	2.18e-07	0.000175	0.29	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
STAD	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	5.29	2.18e-07	0.000175	0.34	0.27	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	5.29	2.18e-07	0.000175	0.34	0.27	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
STAD	cis	rs1056107	0.931	rs10981316	ENSG00000225513.1	RP11-165N19.2	-5.29	2.19e-07	0.000175	-0.32	-0.27	Colorectal cancer;	chr9:112211522	chr9:112173522~112173971:-
STAD	cis	rs7662987	0.793	rs78790289	ENSG00000272777.1	RP11-571L19.8	5.29	2.19e-07	0.000175	0.5	0.27	Smoking initiation;	chr4:99066736	chr4:99067256~99068125:-
STAD	cis	rs2404602	0.692	rs35557205	ENSG00000259422.1	RP11-593F23.1	5.29	2.19e-07	0.000175	0.29	0.27	Blood metabolite levels;	chr15:76838370	chr15:76174891~76181486:-
STAD	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	5.29	2.19e-07	0.000175	0.4	0.27	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	5.29	2.19e-07	0.000175	0.4	0.27	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
STAD	cis	rs2933343	0.7	rs1683787	ENSG00000261159.1	RP11-723O4.9	-5.29	2.19e-07	0.000176	-0.34	-0.27	IgG glycosylation;	chr3:128908178	chr3:128859716~128860526:-
STAD	cis	rs1799949	1	rs35956818	ENSG00000236383.6	LINC00854	-5.29	2.2e-07	0.000176	-0.22	-0.27	Menopause (age at onset);	chr17:43345617	chr17:43216941~43305976:-
STAD	cis	rs8098244	0.638	rs9948008	ENSG00000267301.1	RPL23AP77	-5.29	2.2e-07	0.000176	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23906049	chr18:23709825~23710287:-
STAD	cis	rs66887589	0.616	rs11098498	ENSG00000249244.1	RP11-548H18.2	5.29	2.2e-07	0.000176	0.34	0.27	Diastolic blood pressure;	chr4:119265964	chr4:119391831~119395335:-
STAD	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-5.29	2.2e-07	0.000176	-0.28	-0.27	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
STAD	cis	rs7932354	0.517	rs7940441	ENSG00000271350.1	CTD-2384B9.1	-5.29	2.2e-07	0.000176	-0.34	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:46917476	chr11:47041027~47041945:-
STAD	cis	rs11169552	0.943	rs73096846	ENSG00000200183.1	RNU6-238P	-5.29	2.2e-07	0.000176	-0.27	-0.27	Colorectal cancer;	chr12:50780946	chr12:50656973~50657078:+
STAD	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-5.29	2.21e-07	0.000176	-0.45	-0.27	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
STAD	cis	rs1153858	1	rs4775909	ENSG00000259433.2	CTD-2651B20.4	-5.29	2.21e-07	0.000177	-0.3	-0.27	Homoarginine levels;	chr15:45350844	chr15:45330209~45332634:-
STAD	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-5.29	2.21e-07	0.000177	-0.43	-0.27	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
STAD	cis	rs9860428	0.815	rs9825873	ENSG00000240057.4	RP11-572M11.4	-5.29	2.21e-07	0.000177	-0.26	-0.27	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905547	chr3:113019532~113183301:+
STAD	cis	rs228614	0.51	rs223356	ENSG00000230069.3	LRRC37A15P	-5.29	2.21e-07	0.000177	-0.3	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223353	ENSG00000230069.3	LRRC37A15P	-5.29	2.21e-07	0.000177	-0.3	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223352	ENSG00000230069.3	LRRC37A15P	-5.29	2.21e-07	0.000177	-0.3	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs223358	ENSG00000230069.3	LRRC37A15P	-5.29	2.21e-07	0.000177	-0.3	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102727274~102730721:-
STAD	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-5.29	2.22e-07	0.000177	-0.22	-0.27	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
STAD	cis	rs227275	0.556	rs7676765	ENSG00000230069.3	LRRC37A15P	5.29	2.22e-07	0.000177	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102727274~102730721:-
STAD	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	5.29	2.22e-07	0.000177	0.28	0.27	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
STAD	cis	rs9860428	0.844	rs9845041	ENSG00000240057.4	RP11-572M11.4	-5.29	2.22e-07	0.000178	-0.26	-0.27	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905212	chr3:113019532~113183301:+
STAD	cis	rs916888	0.61	rs142167	ENSG00000261575.2	RP11-259G18.1	-5.29	2.22e-07	0.000178	-0.37	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46267037~46268694:+
STAD	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	5.29	2.23e-07	0.000178	0.32	0.27	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
STAD	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	5.29	2.23e-07	0.000178	0.32	0.27	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
STAD	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-5.28	2.23e-07	0.000178	-0.29	-0.27	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
STAD	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-5.28	2.23e-07	0.000178	-0.32	-0.27	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
STAD	cis	rs7927771	0.524	rs4752865	ENSG00000280615.1	Y_RNA	-5.28	2.23e-07	0.000179	-0.27	-0.27	Subjective well-being;	chr11:47738289	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs7124396	ENSG00000280615.1	Y_RNA	-5.28	2.23e-07	0.000179	-0.27	-0.27	Subjective well-being;	chr11:47765882	chr11:47614898~47614994:-
STAD	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	5.28	2.24e-07	0.000179	0.26	0.27	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
STAD	cis	rs1799949	0.965	rs799910	ENSG00000236383.6	LINC00854	-5.28	2.24e-07	0.000179	-0.22	-0.27	Menopause (age at onset);	chr17:43127544	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs4793231	ENSG00000236383.6	LINC00854	-5.28	2.24e-07	0.000179	-0.22	-0.27	Menopause (age at onset);	chr17:43350101	chr17:43216941~43305976:-
STAD	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-5.28	2.24e-07	0.000179	-0.36	-0.27	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
STAD	cis	rs1799949	1	rs11649954	ENSG00000236383.6	LINC00854	-5.28	2.24e-07	0.000179	-0.22	-0.27	Menopause (age at onset);	chr17:43342667	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs1824889	ENSG00000236383.6	LINC00854	-5.28	2.24e-07	0.000179	-0.22	-0.27	Menopause (age at onset);	chr17:43344508	chr17:43216941~43305976:-
STAD	cis	rs1816752	0.721	rs7399656	ENSG00000273628.1	RP11-756A22.7	5.28	2.24e-07	0.000179	0.33	0.27	Obesity-related traits;	chr13:24415708	chr13:24933006~24936796:+
STAD	cis	rs3758911	1	rs2046903	ENSG00000261098.1	RP11-819C21.1	-5.28	2.25e-07	0.000179	-0.24	-0.27	Coronary artery disease;	chr11:107315208	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10890705	ENSG00000261098.1	RP11-819C21.1	-5.28	2.25e-07	0.000179	-0.24	-0.27	Coronary artery disease;	chr11:107315308	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs4387327	ENSG00000261098.1	RP11-819C21.1	-5.28	2.25e-07	0.000179	-0.24	-0.27	Coronary artery disease;	chr11:107315334	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs12286342	ENSG00000261098.1	RP11-819C21.1	-5.28	2.25e-07	0.000179	-0.24	-0.27	Coronary artery disease;	chr11:107315568	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs12273125	ENSG00000261098.1	RP11-819C21.1	-5.28	2.25e-07	0.000179	-0.24	-0.27	Coronary artery disease;	chr11:107315602	chr11:107312132~107316271:-
STAD	cis	rs1075265	0.548	rs805448	ENSG00000235937.1	AC008280.1	5.28	2.25e-07	0.000179	0.26	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54029552~54030682:-
STAD	cis	rs711244	0.935	rs2110942	ENSG00000252756.1	RNU6-577P	-5.28	2.25e-07	0.000179	-0.3	-0.27	Mean platelet volume;	chr2:36869866	chr2:36867398~36867495:-
STAD	cis	rs10504130	0.569	rs35509250	ENSG00000272024.1	RP11-546K22.3	-5.28	2.25e-07	0.000179	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51774993	chr8:51950284~51950690:+
STAD	cis	rs4568518	0.616	rs17661083	ENSG00000279048.1	RP11-511H23.2	5.28	2.25e-07	0.00018	0.24	0.27	Measles;	chr7:17965230	chr7:17940503~17942922:+
STAD	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	5.28	2.25e-07	0.00018	0.42	0.27	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
STAD	cis	rs1816752	0.875	rs8001187	ENSG00000273628.1	RP11-756A22.7	5.28	2.25e-07	0.00018	0.33	0.27	Obesity-related traits;	chr13:24402276	chr13:24933006~24936796:+
STAD	cis	rs9425766	0.679	rs7537517	ENSG00000227373.4	RP11-160H22.5	5.28	2.25e-07	0.00018	0.32	0.27	Life satisfaction;	chr1:174207225	chr1:174115300~174160004:-
STAD	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	5.28	2.25e-07	0.00018	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
STAD	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	5.28	2.26e-07	0.00018	0.3	0.27	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
STAD	cis	rs2436845	1	rs2679754	ENSG00000253385.1	KB-1254G8.1	5.28	2.26e-07	0.00018	0.3	0.27	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855772	chr8:102854455~102856075:+
STAD	cis	rs507080	0.961	rs34413584	ENSG00000278376.1	RP11-158I9.8	-5.28	2.26e-07	0.00018	-0.28	-0.27	Serum metabolite levels;	chr11:118675072	chr11:118791254~118793137:+
STAD	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-5.28	2.26e-07	0.00018	-0.34	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
STAD	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-5.28	2.26e-07	0.00018	-0.28	-0.27	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
STAD	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-5.28	2.26e-07	0.00018	-0.28	-0.27	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
STAD	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-5.28	2.26e-07	0.00018	-0.31	-0.27	Migraine;	chr4:56940917	chr4:56960927~56961373:-
STAD	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-5.28	2.26e-07	0.00018	-0.31	-0.27	Migraine;	chr4:56943905	chr4:56960927~56961373:-
STAD	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	5.28	2.26e-07	0.00018	0.28	0.27	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
STAD	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-5.28	2.27e-07	0.000181	-0.28	-0.27	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
STAD	cis	rs875971	0.545	rs6970498	ENSG00000224316.1	RP11-479O9.2	5.28	2.27e-07	0.000181	0.31	0.27	Aortic root size;	chr7:66275908	chr7:65773620~65802067:+
STAD	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	5.28	2.27e-07	0.000181	0.46	0.27	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
STAD	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-5.28	2.27e-07	0.000181	-0.29	-0.27	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	5.28	2.27e-07	0.000181	0.3	0.27	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	5.28	2.27e-07	0.000181	0.3	0.27	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
STAD	cis	rs2143950	0.564	rs58872167	ENSG00000241052.1	RP11-173D9.1	-5.28	2.27e-07	0.000181	-0.32	-0.27	Atopic dermatitis;	chr14:35364151	chr14:35144021~35144480:-
STAD	cis	rs2143950	0.564	rs59618010	ENSG00000241052.1	RP11-173D9.1	-5.28	2.27e-07	0.000181	-0.32	-0.27	Atopic dermatitis;	chr14:35364152	chr14:35144021~35144480:-
STAD	cis	rs9425766	0.679	rs4650945	ENSG00000227373.4	RP11-160H22.5	-5.28	2.27e-07	0.000181	-0.32	-0.27	Life satisfaction;	chr1:174114966	chr1:174115300~174160004:-
STAD	cis	rs2283792	0.967	rs3810609	ENSG00000228050.1	TOP3BP1	5.28	2.28e-07	0.000181	0.31	0.27	Multiple sclerosis;	chr22:21758513	chr22:22223187~22224566:-
STAD	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	5.28	2.28e-07	0.000181	0.28	0.27	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
STAD	cis	rs2446066	0.872	rs3741664	ENSG00000257379.1	RP11-793H13.8	5.28	2.28e-07	0.000181	0.45	0.27	Red blood cell count;	chr12:53428886	chr12:53441741~53467528:+
STAD	cis	rs8177876	0.749	rs10459872	ENSG00000261061.1	RP11-303E16.2	5.28	2.28e-07	0.000181	0.41	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81030770~81031485:+
STAD	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	5.28	2.28e-07	0.000181	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
STAD	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-5.28	2.28e-07	0.000182	-0.26	-0.27	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
STAD	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-5.28	2.28e-07	0.000182	-0.28	-0.27	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
STAD	cis	rs875971	0.545	rs75840613	ENSG00000224316.1	RP11-479O9.2	5.28	2.28e-07	0.000182	0.3	0.27	Aortic root size;	chr7:66376399	chr7:65773620~65802067:+
STAD	cis	rs3806843	1	rs10477033	ENSG00000202111.1	VTRNA1-2	-5.28	2.28e-07	0.000182	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140790018	chr5:140718925~140719013:+
STAD	cis	rs8098244	0.617	rs12969388	ENSG00000267301.1	RPL23AP77	-5.28	2.28e-07	0.000182	-0.33	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23907089	chr18:23709825~23710287:-
STAD	cis	rs1150668	0.799	rs1736891	ENSG00000220721.1	OR1F12	5.28	2.28e-07	0.000182	0.27	0.27	Pubertal anthropometrics;	chr6:28219323	chr6:28073316~28074233:+
STAD	cis	rs1862618	0.62	rs2591967	ENSG00000271828.1	CTD-2310F14.1	-5.28	2.29e-07	0.000182	-0.34	-0.27	Initial pursuit acceleration;	chr5:56937724	chr5:56927874~56929573:+
STAD	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-5.28	2.29e-07	0.000182	-0.3	-0.27	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-5.28	2.29e-07	0.000182	-0.3	-0.27	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
STAD	cis	rs8098244	0.516	rs7236486	ENSG00000267301.1	RPL23AP77	-5.28	2.29e-07	0.000182	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23685001	chr18:23709825~23710287:-
STAD	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	5.28	2.29e-07	0.000183	0.34	0.27	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
STAD	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-5.28	2.29e-07	0.000183	-0.34	-0.27	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
STAD	cis	rs3806843	1	rs11167609	ENSG00000202111.1	VTRNA1-2	-5.28	2.3e-07	0.000183	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140820841	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs6885319	ENSG00000202111.1	VTRNA1-2	-5.28	2.3e-07	0.000183	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140821026	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs4151682	ENSG00000202111.1	VTRNA1-2	-5.28	2.3e-07	0.000183	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140821679	chr5:140718925~140719013:+
STAD	cis	rs58873874	0.737	rs11744671	ENSG00000251405.2	CTB-109A12.1	5.28	2.3e-07	0.000183	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157494223	chr5:157362615~157460078:-
STAD	cis	rs9307551	0.817	rs1975399	ENSG00000250334.4	LINC00989	-5.28	2.31e-07	0.000183	-0.33	-0.27	Refractive error;	chr4:79582612	chr4:79492416~79576460:+
STAD	cis	rs11992186	0.505	rs7845203	ENSG00000253981.4	ALG1L13P	5.28	2.31e-07	0.000183	0.33	0.27	Neuroticism;	chr8:8287918	chr8:8236003~8244667:-
STAD	cis	rs992157	0.56	rs1514132	ENSG00000237281.1	CATIP-AS2	5.28	2.31e-07	0.000184	0.27	0.27	Colorectal cancer;	chr2:218219359	chr2:218326889~218357966:-
STAD	cis	rs992157	0.56	rs10932763	ENSG00000237281.1	CATIP-AS2	5.28	2.31e-07	0.000184	0.27	0.27	Colorectal cancer;	chr2:218221140	chr2:218326889~218357966:-
STAD	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	5.28	2.31e-07	0.000184	0.4	0.27	Height;	chr6:109403951	chr6:109382795~109383666:+
STAD	cis	rs58873874	0.737	rs11745566	ENSG00000251405.2	CTB-109A12.1	5.28	2.31e-07	0.000184	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157362615~157460078:-
STAD	cis	rs35934224	0.783	rs7289343	ENSG00000232926.1	AC000078.5	5.28	2.31e-07	0.000184	0.37	0.27	Glaucoma (primary open-angle);	chr22:19873467	chr22:19887289~19887970:+
STAD	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-5.28	2.31e-07	0.000184	-0.45	-0.27	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-5.28	2.31e-07	0.000184	-0.45	-0.27	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-5.28	2.31e-07	0.000184	-0.45	-0.27	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-5.28	2.31e-07	0.000184	-0.45	-0.27	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-5.28	2.31e-07	0.000184	-0.45	-0.27	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-5.28	2.31e-07	0.000184	-0.45	-0.27	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-5.28	2.31e-07	0.000184	-0.45	-0.27	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
STAD	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	5.28	2.31e-07	0.000184	0.3	0.27	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
STAD	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-5.28	2.32e-07	0.000184	-0.22	-0.27	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
STAD	cis	rs35955747	0.633	rs5998002	ENSG00000236132.1	CTA-440B3.1	5.28	2.32e-07	0.000184	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485183	chr22:31816379~31817491:-
STAD	cis	rs611744	0.55	rs57045491	ENSG00000253754.1	RP11-35G22.1	-5.28	2.32e-07	0.000184	-0.24	-0.27	Dupuytren's disease;	chr8:108266891	chr8:108226200~108227544:+
STAD	cis	rs1799949	0.536	rs4793227	ENSG00000236383.6	LINC00854	-5.28	2.32e-07	0.000184	-0.22	-0.27	Menopause (age at onset);	chr17:43334882	chr17:43216941~43305976:-
STAD	cis	rs8005677	0.828	rs12437151	ENSG00000257285.4	RP11-298I3.1	5.28	2.32e-07	0.000184	0.33	0.27	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:22929609~22955562:+
STAD	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	5.28	2.32e-07	0.000184	0.3	0.27	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
STAD	cis	rs1799949	1	rs11653460	ENSG00000236383.6	LINC00854	-5.28	2.32e-07	0.000185	-0.22	-0.27	Menopause (age at onset);	chr17:43179289	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs11650913	ENSG00000236383.6	LINC00854	-5.28	2.32e-07	0.000185	-0.22	-0.27	Menopause (age at onset);	chr17:43179580	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs12936831	ENSG00000236383.6	LINC00854	-5.28	2.32e-07	0.000185	-0.22	-0.27	Menopause (age at onset);	chr17:43179799	chr17:43216941~43305976:-
STAD	cis	rs9549260	0.604	rs61963351	ENSG00000229456.1	RLIMP1	5.28	2.32e-07	0.000185	0.33	0.27	Red blood cell count;	chr13:40744686	chr13:40618738~40621348:+
STAD	cis	rs2933343	0.672	rs1872545	ENSG00000231305.3	RP11-723O4.2	5.28	2.33e-07	0.000185	0.29	0.27	IgG glycosylation;	chr3:128926196	chr3:128861313~128871540:-
STAD	cis	rs7927771	0.524	rs10838774	ENSG00000280615.1	Y_RNA	5.28	2.33e-07	0.000185	0.28	0.27	Subjective well-being;	chr11:47834562	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs11039377	ENSG00000280615.1	Y_RNA	5.28	2.33e-07	0.000185	0.27	0.27	Subjective well-being;	chr11:47768224	chr11:47614898~47614994:-
STAD	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	5.28	2.33e-07	0.000185	0.29	0.27	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
STAD	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	5.28	2.33e-07	0.000185	0.34	0.27	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
STAD	cis	rs1729407	0.786	rs5096	ENSG00000280143.1	AP000892.6	5.28	2.33e-07	0.000185	0.2	0.27	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117204967~117210292:+
STAD	cis	rs7932354	0.71	rs6485702	ENSG00000271350.1	CTD-2384B9.1	-5.28	2.33e-07	0.000185	-0.32	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:46877220	chr11:47041027~47041945:-
STAD	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-5.28	2.34e-07	0.000186	-0.31	-0.27	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
STAD	cis	rs13113518	0.812	rs12505880	ENSG00000272969.1	RP11-528I4.2	5.28	2.34e-07	0.000186	0.34	0.27	Height;	chr4:55440988	chr4:55547112~55547889:+
STAD	cis	rs2439831	0.681	rs484846	ENSG00000249839.1	AC011330.5	-5.28	2.34e-07	0.000186	-0.39	-0.27	Lung cancer in ever smokers;	chr15:43308605	chr15:43663654~43684339:-
STAD	cis	rs2439831	0.681	rs540388	ENSG00000249839.1	AC011330.5	-5.28	2.34e-07	0.000186	-0.39	-0.27	Lung cancer in ever smokers;	chr15:43314296	chr15:43663654~43684339:-
STAD	cis	rs4568518	0.71	rs6966083	ENSG00000279048.1	RP11-511H23.2	5.28	2.34e-07	0.000186	0.25	0.27	Measles;	chr7:17976921	chr7:17940503~17942922:+
STAD	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-5.28	2.34e-07	0.000186	-0.28	-0.27	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
STAD	cis	rs8098244	0.557	rs12185288	ENSG00000267301.1	RPL23AP77	-5.28	2.35e-07	0.000186	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732782	chr18:23709825~23710287:-
STAD	cis	rs3806843	0.9	rs2337984	ENSG00000202111.1	VTRNA1-2	5.28	2.35e-07	0.000186	0.27	0.27	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr5:140718925~140719013:+
STAD	cis	rs58873874	0.737	rs10476052	ENSG00000251405.2	CTB-109A12.1	5.27	2.35e-07	0.000186	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.737	rs78832945	ENSG00000251405.2	CTB-109A12.1	5.27	2.35e-07	0.000186	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157362615~157460078:-
STAD	cis	rs7829975	0.627	rs876954	ENSG00000253893.2	FAM85B	-5.27	2.35e-07	0.000186	-0.34	-0.27	Mood instability;	chr8:8453413	chr8:8167819~8226614:-
STAD	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	5.27	2.35e-07	0.000187	0.3	0.27	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
STAD	cis	rs7396835	0.8	rs6589572	ENSG00000280143.1	AP000892.6	5.27	2.35e-07	0.000187	0.26	0.27	Quantitative traits;	chr11:116810847	chr11:117204967~117210292:+
STAD	cis	rs1799949	0.93	rs4584865	ENSG00000236383.6	LINC00854	-5.27	2.35e-07	0.000187	-0.22	-0.27	Menopause (age at onset);	chr17:43347551	chr17:43216941~43305976:-
STAD	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-5.27	2.36e-07	0.000187	-0.33	-0.27	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
STAD	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-5.27	2.36e-07	0.000187	-0.23	-0.27	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
STAD	cis	rs4713118	0.869	rs4713121	ENSG00000280107.1	AL022393.9	-5.27	2.36e-07	0.000187	-0.37	-0.27	Parkinson's disease;	chr6:27754285	chr6:28170845~28172521:+
STAD	cis	rs10504130	0.569	rs34364864	ENSG00000272024.1	RP11-546K22.3	-5.27	2.36e-07	0.000187	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51950284~51950690:+
STAD	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	5.27	2.36e-07	0.000187	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
STAD	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-5.27	2.36e-07	0.000187	-0.39	-0.27	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
STAD	cis	rs13113518	0.783	rs1586555	ENSG00000272969.1	RP11-528I4.2	5.27	2.36e-07	0.000187	0.36	0.27	Height;	chr4:55587104	chr4:55547112~55547889:+
STAD	cis	rs992157	0.71	rs6752254	ENSG00000237281.1	CATIP-AS2	-5.27	2.36e-07	0.000187	-0.27	-0.27	Colorectal cancer;	chr2:218194020	chr2:218326889~218357966:-
STAD	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	5.27	2.37e-07	0.000188	0.29	0.27	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
STAD	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	5.27	2.37e-07	0.000188	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
STAD	cis	rs1799949	0.773	rs2137990	ENSG00000236383.6	LINC00854	5.27	2.37e-07	0.000188	0.22	0.27	Menopause (age at onset);	chr17:43165879	chr17:43216941~43305976:-
STAD	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-5.27	2.37e-07	0.000188	-0.28	-0.27	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
STAD	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000188	-0.3	-0.27	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
STAD	cis	rs2688482	0.512	rs3103953	ENSG00000185485.13	SDHAP1	-5.27	2.37e-07	0.000188	-0.35	-0.27	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195959748~195990318:-
STAD	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-5.27	2.37e-07	0.000188	-0.35	-0.27	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
STAD	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-5.27	2.37e-07	0.000188	-0.35	-0.27	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
STAD	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	5.27	2.37e-07	0.000188	0.41	0.27	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
STAD	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	5.27	2.37e-07	0.000188	0.32	0.27	Depression;	chr6:28099759	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	5.27	2.37e-07	0.000188	0.32	0.27	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	5.27	2.37e-07	0.000188	0.32	0.27	Depression;	chr6:28100648	chr6:28073316~28074233:+
STAD	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	5.27	2.37e-07	0.000188	0.32	0.27	Depression;	chr6:28107222	chr6:28073316~28074233:+
STAD	cis	rs516805	0.923	rs538457	ENSG00000279453.1	RP3-425C14.4	-5.27	2.37e-07	0.000188	-0.3	-0.27	Lymphocyte counts;	chr6:122485610	chr6:122436789~122439223:-
STAD	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	5.27	2.37e-07	0.000188	0.36	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
STAD	cis	rs11169552	0.883	rs10876095	ENSG00000200183.1	RNU6-238P	-5.27	2.37e-07	0.000188	-0.27	-0.27	Colorectal cancer;	chr12:50809079	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.943	rs4026593	ENSG00000200183.1	RNU6-238P	-5.27	2.37e-07	0.000188	-0.27	-0.27	Colorectal cancer;	chr12:50814692	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.943	rs10876097	ENSG00000200183.1	RNU6-238P	-5.27	2.37e-07	0.000188	-0.27	-0.27	Colorectal cancer;	chr12:50815853	chr12:50656973~50657078:+
STAD	cis	rs13113518	0.738	rs6849883	ENSG00000272969.1	RP11-528I4.2	5.27	2.38e-07	0.000188	0.34	0.27	Height;	chr4:55387515	chr4:55547112~55547889:+
STAD	cis	rs611744	0.647	rs7015513	ENSG00000253754.1	RP11-35G22.1	-5.27	2.38e-07	0.000188	-0.24	-0.27	Dupuytren's disease;	chr8:108250341	chr8:108226200~108227544:+
STAD	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	5.27	2.38e-07	0.000188	0.23	0.27	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
STAD	cis	rs11676348	0.755	rs1008562	ENSG00000237281.1	CATIP-AS2	-5.27	2.38e-07	0.000188	-0.28	-0.27	Ulcerative colitis;	chr2:218162249	chr2:218326889~218357966:-
STAD	cis	rs1322639	0.571	rs13204417	ENSG00000261039.2	RP11-417E7.2	5.27	2.38e-07	0.000188	0.3	0.27	Pulse pressure;	chr6:169175260	chr6:169175304~169182740:-
STAD	cis	rs858239	0.536	rs6961109	ENSG00000226816.2	AC005082.12	5.27	2.38e-07	0.000189	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23206013~23208045:+
STAD	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	5.27	2.38e-07	0.000189	0.44	0.27	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
STAD	cis	rs1816752	0.719	rs11843470	ENSG00000273628.1	RP11-756A22.7	5.27	2.38e-07	0.000189	0.34	0.27	Obesity-related traits;	chr13:24423561	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.783	rs9507333	ENSG00000273628.1	RP11-756A22.7	5.27	2.38e-07	0.000189	0.33	0.27	Obesity-related traits;	chr13:24404172	chr13:24933006~24936796:+
STAD	cis	rs2404602	0.655	rs4886507	ENSG00000259422.1	RP11-593F23.1	5.27	2.38e-07	0.000189	0.29	0.27	Blood metabolite levels;	chr15:76917353	chr15:76174891~76181486:-
STAD	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-5.27	2.39e-07	0.000189	-0.45	-0.27	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-5.27	2.39e-07	0.000189	-0.45	-0.27	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
STAD	cis	rs2404602	0.655	rs34748201	ENSG00000259422.1	RP11-593F23.1	5.27	2.39e-07	0.000189	0.29	0.27	Blood metabolite levels;	chr15:76929189	chr15:76174891~76181486:-
STAD	cis	rs611744	0.56	rs58605513	ENSG00000253754.1	RP11-35G22.1	-5.27	2.39e-07	0.000189	-0.24	-0.27	Dupuytren's disease;	chr8:108266893	chr8:108226200~108227544:+
STAD	cis	rs875971	0.545	rs6969224	ENSG00000224316.1	RP11-479O9.2	5.27	2.39e-07	0.000189	0.31	0.27	Aortic root size;	chr7:66370011	chr7:65773620~65802067:+
STAD	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	5.27	2.39e-07	0.000189	0.39	0.27	Height;	chr6:109359125	chr6:109382795~109383666:+
STAD	cis	rs3806843	1	rs10053586	ENSG00000202111.1	VTRNA1-2	-5.27	2.39e-07	0.000189	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr5:140718925~140719013:+
STAD	cis	rs1056107	0.931	rs4979089	ENSG00000225513.1	RP11-165N19.2	-5.27	2.39e-07	0.000189	-0.31	-0.27	Colorectal cancer;	chr9:112236816	chr9:112173522~112173971:-
STAD	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	5.27	2.39e-07	0.000189	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
STAD	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	5.27	2.39e-07	0.000189	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
STAD	cis	rs11722779	0.935	rs11938650	ENSG00000230069.3	LRRC37A15P	-5.27	2.39e-07	0.000189	-0.29	-0.27	Schizophrenia;	chr4:103021639	chr4:102727274~102730721:-
STAD	cis	rs875971	0.545	rs2279757	ENSG00000224316.1	RP11-479O9.2	5.27	2.39e-07	0.000189	0.31	0.27	Aortic root size;	chr7:66363676	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs11766183	ENSG00000224316.1	RP11-479O9.2	5.27	2.39e-07	0.000189	0.31	0.27	Aortic root size;	chr7:66374173	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs1065265	ENSG00000224316.1	RP11-479O9.2	5.27	2.39e-07	0.000189	0.31	0.27	Aortic root size;	chr7:66376216	chr7:65773620~65802067:+
STAD	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	5.27	2.39e-07	0.000189	0.37	0.27	Height;	chr6:109347085	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	5.27	2.39e-07	0.000189	0.37	0.27	Height;	chr6:109347277	chr6:109382795~109383666:+
STAD	cis	rs2948294	0.545	rs11776397	ENSG00000254340.1	RP11-10A14.3	5.27	2.4e-07	0.00019	0.33	0.27	Red cell distribution width;	chr8:8257639	chr8:9141424~9145435:+
STAD	cis	rs13113518	0.812	rs4864996	ENSG00000272969.1	RP11-528I4.2	5.27	2.4e-07	0.00019	0.34	0.27	Height;	chr4:55452921	chr4:55547112~55547889:+
STAD	cis	rs1056107	0.931	rs2027384	ENSG00000225513.1	RP11-165N19.2	-5.27	2.4e-07	0.00019	-0.31	-0.27	Colorectal cancer;	chr9:112237954	chr9:112173522~112173971:-
STAD	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-5.27	2.4e-07	0.00019	-0.28	-0.27	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
STAD	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	5.27	2.4e-07	0.00019	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
STAD	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	5.27	2.41e-07	0.00019	0.29	0.27	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
STAD	cis	rs2283792	1	rs2283792	ENSG00000228050.1	TOP3BP1	5.27	2.41e-07	0.00019	0.31	0.27	Multiple sclerosis;	chr22:21776836	chr22:22223187~22224566:-
STAD	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-5.27	2.41e-07	0.000191	-0.36	-0.27	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
STAD	cis	rs11169552	1	rs4768866	ENSG00000200183.1	RNU6-238P	-5.27	2.41e-07	0.000191	-0.27	-0.27	Colorectal cancer;	chr12:50762797	chr12:50656973~50657078:+
STAD	cis	rs7674212	0.556	rs34475639	ENSG00000230069.3	LRRC37A15P	-5.27	2.41e-07	0.000191	-0.32	-0.27	Type 2 diabetes;	chr4:103033694	chr4:102727274~102730721:-
STAD	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	5.27	2.41e-07	0.000191	0.34	0.27	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
STAD	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	5.27	2.41e-07	0.000191	0.39	0.27	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	5.27	2.41e-07	0.000191	0.39	0.27	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	5.27	2.41e-07	0.000191	0.39	0.27	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	5.27	2.41e-07	0.000191	0.39	0.27	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	5.27	2.41e-07	0.000191	0.39	0.27	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	5.27	2.41e-07	0.000191	0.39	0.27	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	5.27	2.41e-07	0.000191	0.39	0.27	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
STAD	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	5.27	2.41e-07	0.000191	0.3	0.27	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	5.27	2.41e-07	0.000191	0.3	0.27	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
STAD	cis	rs7932354	0.528	rs1872896	ENSG00000271350.1	CTD-2384B9.1	-5.27	2.42e-07	0.000191	-0.32	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:47139072	chr11:47041027~47041945:-
STAD	cis	rs9549260	0.876	rs9549258	ENSG00000229456.1	RLIMP1	5.27	2.42e-07	0.000191	0.31	0.27	Red blood cell count;	chr13:40673889	chr13:40618738~40621348:+
STAD	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-5.27	2.42e-07	0.000191	-0.35	-0.27	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
STAD	cis	rs9400467	0.528	rs445349	ENSG00000230177.1	RP5-1112D6.4	5.27	2.42e-07	0.000191	0.25	0.27	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111277932~111278742:+
STAD	cis	rs3806843	0.966	rs4141841	ENSG00000202111.1	VTRNA1-2	-5.27	2.42e-07	0.000191	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs10050455	ENSG00000202111.1	VTRNA1-2	-5.27	2.42e-07	0.000191	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr5:140718925~140719013:+
STAD	cis	rs58873874	0.737	rs75022277	ENSG00000251405.2	CTB-109A12.1	5.27	2.42e-07	0.000191	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157362615~157460078:-
STAD	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	5.27	2.42e-07	0.000191	0.38	0.27	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
STAD	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-5.27	2.42e-07	0.000191	-0.28	-0.27	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
STAD	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	5.27	2.42e-07	0.000191	0.34	0.27	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
STAD	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	5.27	2.42e-07	0.000191	0.33	0.27	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
STAD	cis	rs3770081	1	rs17584578	ENSG00000273080.1	RP11-301O19.1	5.27	2.42e-07	0.000191	0.61	0.27	Facial emotion recognition (sad faces);	chr2:86080501	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs78032828	ENSG00000273080.1	RP11-301O19.1	-5.27	2.42e-07	0.000191	-0.61	-0.27	Facial emotion recognition (sad faces);	chr2:86081909	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs56104203	ENSG00000273080.1	RP11-301O19.1	-5.27	2.42e-07	0.000191	-0.61	-0.27	Facial emotion recognition (sad faces);	chr2:86109133	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs12620810	ENSG00000273080.1	RP11-301O19.1	-5.27	2.42e-07	0.000191	-0.61	-0.27	Facial emotion recognition (sad faces);	chr2:86164358	chr2:86195590~86196049:+
STAD	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	5.27	2.43e-07	0.000192	0.28	0.27	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
STAD	cis	rs747650	0.504	rs11600292	ENSG00000271350.1	CTD-2384B9.1	5.27	2.43e-07	0.000192	0.35	0.27	Acne (severe);	chr11:46937147	chr11:47041027~47041945:-
STAD	cis	rs1320333	0.772	rs35181861	ENSG00000233296.1	AC092159.2	5.27	2.43e-07	0.000192	0.56	0.27	Obesity-related traits;	chr2:679483	chr2:677186~697371:+
STAD	cis	rs7927771	0.524	rs10769299	ENSG00000280615.1	Y_RNA	5.27	2.43e-07	0.000192	0.28	0.27	Subjective well-being;	chr11:47843608	chr11:47614898~47614994:-
STAD	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	5.27	2.43e-07	0.000192	0.26	0.27	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
STAD	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-5.27	2.43e-07	0.000192	-0.24	-0.27	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
STAD	cis	rs7849270	0.842	rs12237274	ENSG00000268707.1	RP11-247A12.7	-5.27	2.43e-07	0.000192	-0.3	-0.27	Blood metabolite ratios;	chr9:129169441	chr9:129170434~129170940:+
STAD	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	5.27	2.43e-07	0.000192	0.31	0.27	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
STAD	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-5.27	2.43e-07	0.000192	-0.25	-0.27	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-5.27	2.43e-07	0.000192	-0.25	-0.27	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
STAD	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	5.27	2.43e-07	0.000192	0.3	0.27	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
STAD	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	5.27	2.43e-07	0.000192	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
STAD	cis	rs2115536	0.692	rs8036559	ENSG00000278600.1	RP11-81A1.6	-5.27	2.44e-07	0.000192	-0.23	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79878221	chr15:79920195~79922455:-
STAD	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	5.27	2.44e-07	0.000193	0.29	0.27	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
STAD	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	5.27	2.45e-07	0.000193	0.36	0.27	Height;	chr6:109354040	chr6:109382795~109383666:+
STAD	cis	rs9463078	0.585	rs988147	ENSG00000219384.1	RP11-491H9.3	-5.27	2.45e-07	0.000193	-0.27	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45206643	chr6:45158870~45159511:+
STAD	cis	rs1153858	0.943	rs28605551	ENSG00000259433.2	CTD-2651B20.4	-5.27	2.45e-07	0.000193	-0.3	-0.27	Homoarginine levels;	chr15:45349522	chr15:45330209~45332634:-
STAD	cis	rs1056107	0.797	rs4979087	ENSG00000225513.1	RP11-165N19.2	-5.27	2.45e-07	0.000193	-0.32	-0.27	Colorectal cancer;	chr9:112179920	chr9:112173522~112173971:-
STAD	cis	rs5758659	1	rs5751255	ENSG00000182057.4	OGFRP1	5.27	2.45e-07	0.000193	0.28	0.27	Cognitive function;	chr22:42252402	chr22:42269753~42275196:+
STAD	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	5.27	2.45e-07	0.000193	0.29	0.27	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
STAD	cis	rs1056107	0.931	rs10817295	ENSG00000225513.1	RP11-165N19.2	-5.27	2.45e-07	0.000193	-0.31	-0.27	Colorectal cancer;	chr9:112235310	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs10118422	ENSG00000225513.1	RP11-165N19.2	-5.27	2.45e-07	0.000193	-0.31	-0.27	Colorectal cancer;	chr9:112236116	chr9:112173522~112173971:-
STAD	cis	rs73219805	1	rs73219805	ENSG00000228451.3	SDAD1P1	-5.27	2.45e-07	0.000193	-0.35	-0.27	Schizophrenia;	chr8:26415252	chr8:26379259~26382953:-
STAD	cis	rs1799949	1	rs4793229	ENSG00000236383.6	LINC00854	5.27	2.45e-07	0.000193	0.22	0.27	Menopause (age at onset);	chr17:43340966	chr17:43216941~43305976:-
STAD	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-5.27	2.45e-07	0.000194	-0.32	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
STAD	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-5.27	2.45e-07	0.000194	-0.32	-0.27	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
STAD	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	5.27	2.46e-07	0.000194	0.34	0.27	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
STAD	cis	rs516805	0.667	rs2606598	ENSG00000279453.1	RP3-425C14.4	5.27	2.46e-07	0.000194	0.41	0.27	Lymphocyte counts;	chr6:122206501	chr6:122436789~122439223:-
STAD	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	5.27	2.46e-07	0.000194	0.28	0.27	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
STAD	cis	rs1075265	0.633	rs3731967	ENSG00000235937.1	AC008280.1	-5.27	2.46e-07	0.000194	-0.24	-0.27	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54029552~54030682:-
STAD	cis	rs12744310	1	rs68132196	ENSG00000235358.1	RP11-399E6.1	5.27	2.46e-07	0.000194	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41304948	chr1:41242373~41284861:+
STAD	cis	rs4713118	0.516	rs6931858	ENSG00000220721.1	OR1F12	5.27	2.46e-07	0.000194	0.32	0.27	Parkinson's disease;	chr6:28110633	chr6:28073316~28074233:+
STAD	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.26	2.47e-07	0.000194	0.31	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
STAD	cis	rs3806843	0.933	rs2337987	ENSG00000202111.1	VTRNA1-2	-5.26	2.47e-07	0.000195	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140808798	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.933	rs2879087	ENSG00000202111.1	VTRNA1-2	-5.26	2.47e-07	0.000195	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140808990	chr5:140718925~140719013:+
STAD	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-5.26	2.47e-07	0.000195	-0.29	-0.27	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
STAD	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-5.26	2.47e-07	0.000195	-0.26	-0.27	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
STAD	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	5.26	2.47e-07	0.000195	0.28	0.27	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
STAD	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-5.26	2.47e-07	0.000195	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
STAD	cis	rs13113518	0.812	rs6849474	ENSG00000272969.1	RP11-528I4.2	5.26	2.47e-07	0.000195	0.34	0.27	Height;	chr4:55452295	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs2412648	ENSG00000272969.1	RP11-528I4.2	5.26	2.47e-07	0.000195	0.34	0.27	Height;	chr4:55454900	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs12512737	ENSG00000272969.1	RP11-528I4.2	5.26	2.47e-07	0.000195	0.34	0.27	Height;	chr4:55454938	chr4:55547112~55547889:+
STAD	cis	rs13113518	0.812	rs13125984	ENSG00000272969.1	RP11-528I4.2	5.26	2.47e-07	0.000195	0.34	0.27	Height;	chr4:55455102	chr4:55547112~55547889:+
STAD	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	5.26	2.47e-07	0.000195	0.27	0.27	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
STAD	cis	rs7487075	0.786	rs4768696	ENSG00000272369.1	RP11-446N19.1	5.26	2.47e-07	0.000195	0.36	0.27	Itch intensity from mosquito bite;	chr12:46332593	chr12:46537502~46652550:+
STAD	cis	rs9463078	0.546	rs1284983	ENSG00000219384.1	RP11-491H9.3	5.26	2.47e-07	0.000195	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45114179	chr6:45158870~45159511:+
STAD	cis	rs12744310	0.887	rs72667608	ENSG00000235358.1	RP11-399E6.1	5.26	2.48e-07	0.000195	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329101	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs35410722	ENSG00000235358.1	RP11-399E6.1	5.26	2.48e-07	0.000195	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41330592	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs34539673	ENSG00000235358.1	RP11-399E6.1	5.26	2.48e-07	0.000195	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331145	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs35690915	ENSG00000235358.1	RP11-399E6.1	5.26	2.48e-07	0.000195	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332327	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12728217	ENSG00000235358.1	RP11-399E6.1	5.26	2.48e-07	0.000195	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332597	chr1:41242373~41284861:+
STAD	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-5.26	2.48e-07	0.000195	-0.29	-0.27	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
STAD	cis	rs10971721	0.631	rs10971945	ENSG00000260947.1	RP11-384P7.7	5.26	2.48e-07	0.000195	0.39	0.27	Body mass index;	chr9:34129397	chr9:33697459~33700986:+
STAD	cis	rs2948294	0.524	rs13270062	ENSG00000254340.1	RP11-10A14.3	5.26	2.48e-07	0.000195	0.34	0.27	Red cell distribution width;	chr8:8255128	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.902	rs485107	ENSG00000254340.1	RP11-10A14.3	-5.26	2.48e-07	0.000195	-0.32	-0.27	Mood instability;	chr8:8723898	chr8:9141424~9145435:+
STAD	cis	rs2404602	0.655	rs8028294	ENSG00000259422.1	RP11-593F23.1	5.26	2.48e-07	0.000196	0.29	0.27	Blood metabolite levels;	chr15:76792536	chr15:76174891~76181486:-
STAD	cis	rs7829975	0.84	rs555617	ENSG00000254340.1	RP11-10A14.3	-5.26	2.48e-07	0.000196	-0.32	-0.27	Mood instability;	chr8:8735335	chr8:9141424~9145435:+
STAD	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	5.26	2.48e-07	0.000196	0.3	0.27	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-5.26	2.48e-07	0.000196	-0.3	-0.27	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-5.26	2.48e-07	0.000196	-0.3	-0.27	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-5.26	2.48e-07	0.000196	-0.3	-0.27	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-5.26	2.48e-07	0.000196	-0.3	-0.27	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-5.26	2.48e-07	0.000196	-0.3	-0.27	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-5.26	2.48e-07	0.000196	-0.3	-0.27	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-5.26	2.48e-07	0.000196	-0.3	-0.27	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
STAD	cis	rs9307551	0.744	rs968176	ENSG00000250334.4	LINC00989	-5.26	2.49e-07	0.000196	-0.33	-0.27	Refractive error;	chr4:79585080	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs1440852	ENSG00000250334.4	LINC00989	-5.26	2.49e-07	0.000196	-0.33	-0.27	Refractive error;	chr4:79585435	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.779	rs1440854	ENSG00000250334.4	LINC00989	-5.26	2.49e-07	0.000196	-0.33	-0.27	Refractive error;	chr4:79585580	chr4:79492416~79576460:+
STAD	cis	rs13129838	1	rs13129838	ENSG00000250334.4	LINC00989	-5.26	2.49e-07	0.000196	-0.33	-0.27	Myopia;	chr4:79587634	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs12643976	ENSG00000250334.4	LINC00989	-5.26	2.49e-07	0.000196	-0.33	-0.27	Refractive error;	chr4:79589616	chr4:79492416~79576460:+
STAD	cis	rs1056107	0.966	rs10981338	ENSG00000225513.1	RP11-165N19.2	-5.26	2.49e-07	0.000196	-0.31	-0.27	Colorectal cancer;	chr9:112273741	chr9:112173522~112173971:-
STAD	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	5.26	2.49e-07	0.000196	0.34	0.27	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
STAD	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	5.26	2.49e-07	0.000196	0.34	0.27	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
STAD	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-5.26	2.49e-07	0.000196	-0.29	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
STAD	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-5.26	2.49e-07	0.000196	-0.29	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
STAD	cis	rs3806843	0.9	rs2261651	ENSG00000202111.1	VTRNA1-2	5.26	2.5e-07	0.000196	0.27	0.27	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.9	rs2337983	ENSG00000202111.1	VTRNA1-2	5.26	2.5e-07	0.000196	0.27	0.27	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr5:140718925~140719013:+
STAD	cis	rs728616	0.702	rs78734698	ENSG00000225484.5	NUTM2B-AS1	-5.26	2.5e-07	0.000196	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79663088~79826594:-
STAD	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	5.26	2.5e-07	0.000197	0.3	0.27	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
STAD	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	5.26	2.5e-07	0.000197	0.39	0.27	Height;	chr6:109382480	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	5.26	2.5e-07	0.000197	0.39	0.27	Height;	chr6:109387972	chr6:109382795~109383666:+
STAD	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	5.26	2.5e-07	0.000197	0.43	0.27	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
STAD	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	5.26	2.5e-07	0.000197	0.34	0.27	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
STAD	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-5.26	2.5e-07	0.000197	-0.3	-0.27	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
STAD	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-5.26	2.5e-07	0.000197	-0.29	-0.27	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
STAD	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-5.26	2.5e-07	0.000197	-0.35	-0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
STAD	cis	rs7932354	0.528	rs12224096	ENSG00000271350.1	CTD-2384B9.1	5.26	2.51e-07	0.000197	0.33	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47152810	chr11:47041027~47041945:-
STAD	cis	rs9425766	0.64	rs6685314	ENSG00000227373.4	RP11-160H22.5	5.26	2.51e-07	0.000197	0.32	0.27	Life satisfaction;	chr1:174089905	chr1:174115300~174160004:-
STAD	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-5.26	2.51e-07	0.000197	-0.22	-0.27	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
STAD	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-5.26	2.51e-07	0.000197	-0.22	-0.27	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
STAD	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	5.26	2.51e-07	0.000197	0.33	0.27	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
STAD	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-5.26	2.51e-07	0.000197	-0.28	-0.27	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
STAD	cis	rs1056107	0.931	rs3908938	ENSG00000225513.1	RP11-165N19.2	-5.26	2.51e-07	0.000197	-0.31	-0.27	Colorectal cancer;	chr9:112228940	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.898	rs1417111	ENSG00000225513.1	RP11-165N19.2	-5.26	2.51e-07	0.000197	-0.31	-0.27	Colorectal cancer;	chr9:112229033	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs3908939	ENSG00000225513.1	RP11-165N19.2	-5.26	2.51e-07	0.000197	-0.31	-0.27	Colorectal cancer;	chr9:112229058	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs10759536	ENSG00000225513.1	RP11-165N19.2	-5.26	2.51e-07	0.000197	-0.31	-0.27	Colorectal cancer;	chr9:112229222	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.898	rs10733586	ENSG00000225513.1	RP11-165N19.2	-5.26	2.51e-07	0.000197	-0.31	-0.27	Colorectal cancer;	chr9:112229903	chr9:112173522~112173971:-
STAD	cis	rs9859260	0.744	rs539816	ENSG00000207650.1	MIR570	-5.26	2.51e-07	0.000197	-0.27	-0.27	Mean corpuscular volume;	chr3:196057205	chr3:195699401~195699497:+
STAD	cis	rs9859260	0.744	rs492349	ENSG00000207650.1	MIR570	-5.26	2.51e-07	0.000197	-0.27	-0.27	Mean corpuscular volume;	chr3:196057321	chr3:195699401~195699497:+
STAD	cis	rs9859260	0.744	rs492288	ENSG00000207650.1	MIR570	-5.26	2.51e-07	0.000197	-0.27	-0.27	Mean corpuscular volume;	chr3:196057339	chr3:195699401~195699497:+
STAD	cis	rs3806843	0.576	rs251368	ENSG00000202111.1	VTRNA1-2	5.26	2.51e-07	0.000197	0.28	0.27	Depressive symptoms (multi-trait analysis);	chr5:140861442	chr5:140718925~140719013:+
STAD	cis	rs2337406	0.5	rs57619050	ENSG00000274576.2	IGHV2-70	-5.26	2.52e-07	0.000198	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106820074	chr14:106770577~106771020:-
STAD	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	5.26	2.52e-07	0.000198	0.34	0.27	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
STAD	cis	rs1799949	0.965	rs6503726	ENSG00000236383.6	LINC00854	-5.26	2.52e-07	0.000198	-0.22	-0.27	Menopause (age at onset);	chr17:43132725	chr17:43216941~43305976:-
STAD	cis	rs992157	0.56	rs12992937	ENSG00000237281.1	CATIP-AS2	5.26	2.52e-07	0.000198	0.27	0.27	Colorectal cancer;	chr2:218222349	chr2:218326889~218357966:-
STAD	cis	rs992157	0.56	rs4674274	ENSG00000237281.1	CATIP-AS2	5.26	2.52e-07	0.000198	0.27	0.27	Colorectal cancer;	chr2:218224408	chr2:218326889~218357966:-
STAD	cis	rs2382817	0.58	rs6756265	ENSG00000237281.1	CATIP-AS2	5.26	2.52e-07	0.000198	0.27	0.27	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218326889~218357966:-
STAD	cis	rs992157	0.56	rs4674275	ENSG00000237281.1	CATIP-AS2	5.26	2.52e-07	0.000198	0.27	0.27	Colorectal cancer;	chr2:218233015	chr2:218326889~218357966:-
STAD	cis	rs992157	0.585	rs62182795	ENSG00000237281.1	CATIP-AS2	5.26	2.52e-07	0.000198	0.27	0.27	Colorectal cancer;	chr2:218235479	chr2:218326889~218357966:-
STAD	cis	rs992157	0.56	rs12987130	ENSG00000237281.1	CATIP-AS2	5.26	2.52e-07	0.000198	0.27	0.27	Colorectal cancer;	chr2:218240267	chr2:218326889~218357966:-
STAD	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-5.26	2.52e-07	0.000198	-0.31	-0.27	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
STAD	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-5.26	2.52e-07	0.000198	-0.29	-0.27	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
STAD	cis	rs17036350	1	rs17036350	ENSG00000230337.1	RP4-635E18.6	-5.26	2.53e-07	0.000199	-0.57	-0.27	Corneal curvature;	chr1:11111169	chr1:11099675~11102100:+
STAD	cis	rs875971	0.545	rs2420456	ENSG00000224316.1	RP11-479O9.2	5.26	2.53e-07	0.000199	0.3	0.27	Aortic root size;	chr7:66280619	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs7783889	ENSG00000224316.1	RP11-479O9.2	5.26	2.53e-07	0.000199	0.3	0.27	Aortic root size;	chr7:66283366	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs11767262	ENSG00000224316.1	RP11-479O9.2	5.26	2.53e-07	0.000199	0.3	0.27	Aortic root size;	chr7:66302237	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs66594357	ENSG00000224316.1	RP11-479O9.2	5.26	2.53e-07	0.000199	0.3	0.27	Aortic root size;	chr7:66327797	chr7:65773620~65802067:+
STAD	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-5.26	2.54e-07	2e-04	-0.31	-0.27	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
STAD	cis	rs1056107	0.898	rs943620	ENSG00000225513.1	RP11-165N19.2	-5.26	2.54e-07	2e-04	-0.31	-0.27	Colorectal cancer;	chr9:112231228	chr9:112173522~112173971:-
STAD	cis	rs227275	0.554	rs223316	ENSG00000230069.3	LRRC37A15P	-5.26	2.55e-07	2e-04	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102727274~102730721:-
STAD	cis	rs35955747	0.659	rs11704494	ENSG00000236132.1	CTA-440B3.1	5.26	2.55e-07	2e-04	0.3	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31517285	chr22:31816379~31817491:-
STAD	cis	rs7829975	0.871	rs7829826	ENSG00000253981.4	ALG1L13P	-5.26	2.55e-07	2e-04	-0.32	-0.27	Mood instability;	chr8:8720610	chr8:8236003~8244667:-
STAD	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	5.26	2.55e-07	2e-04	0.52	0.27	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
STAD	cis	rs2436845	0.934	rs2916564	ENSG00000253385.1	KB-1254G8.1	5.26	2.55e-07	2e-04	0.29	0.27	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102811112	chr8:102854455~102856075:+
STAD	cis	rs728616	0.867	rs61859763	ENSG00000225484.5	NUTM2B-AS1	-5.26	2.56e-07	0.000201	-0.65	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:79663088~79826594:-
STAD	cis	rs1056107	0.897	rs10817298	ENSG00000225513.1	RP11-165N19.2	-5.26	2.56e-07	0.000201	-0.31	-0.27	Colorectal cancer;	chr9:112244396	chr9:112173522~112173971:-
STAD	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-5.26	2.56e-07	0.000201	-0.32	-0.27	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
STAD	cis	rs8098244	0.66	rs12970745	ENSG00000267301.1	RPL23AP77	-5.26	2.56e-07	0.000201	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23908142	chr18:23709825~23710287:-
STAD	cis	rs7927771	0.524	rs7933184	ENSG00000280615.1	Y_RNA	5.26	2.57e-07	0.000201	0.27	0.27	Subjective well-being;	chr11:47660850	chr11:47614898~47614994:-
STAD	cis	rs7487075	0.856	rs1079780	ENSG00000272369.1	RP11-446N19.1	5.26	2.57e-07	0.000201	0.36	0.27	Itch intensity from mosquito bite;	chr12:46342240	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.797	rs12816358	ENSG00000272369.1	RP11-446N19.1	5.26	2.57e-07	0.000201	0.36	0.27	Itch intensity from mosquito bite;	chr12:46342863	chr12:46537502~46652550:+
STAD	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-5.26	2.57e-07	0.000202	-0.28	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
STAD	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-5.26	2.57e-07	0.000202	-0.28	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
STAD	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-5.26	2.57e-07	0.000202	-0.28	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
STAD	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-5.26	2.58e-07	0.000202	-0.34	-0.27	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
STAD	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	5.26	2.58e-07	0.000202	0.48	0.27	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
STAD	cis	rs7487075	0.897	rs10880960	ENSG00000272369.1	RP11-446N19.1	5.26	2.58e-07	0.000202	0.35	0.27	Itch intensity from mosquito bite;	chr12:46368046	chr12:46537502~46652550:+
STAD	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	5.26	2.58e-07	0.000202	0.35	0.27	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	5.26	2.58e-07	0.000202	0.35	0.27	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	5.26	2.58e-07	0.000202	0.35	0.27	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
STAD	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-5.26	2.58e-07	0.000202	-0.41	-0.27	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
STAD	cis	rs4713118	0.826	rs2893929	ENSG00000280107.1	AL022393.9	-5.26	2.58e-07	0.000202	-0.39	-0.27	Parkinson's disease;	chr6:27770953	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.666	rs4140646	ENSG00000280107.1	AL022393.9	-5.26	2.58e-07	0.000202	-0.39	-0.27	Parkinson's disease;	chr6:27771022	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.666	rs2893930	ENSG00000280107.1	AL022393.9	-5.26	2.58e-07	0.000202	-0.39	-0.27	Parkinson's disease;	chr6:27771027	chr6:28170845~28172521:+
STAD	cis	rs1816752	0.819	rs7400583	ENSG00000273628.1	RP11-756A22.7	5.26	2.58e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24415916	chr13:24933006~24936796:+
STAD	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-5.26	2.58e-07	0.000203	-0.36	-0.27	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
STAD	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-5.26	2.58e-07	0.000203	-0.35	-0.27	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
STAD	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	5.26	2.59e-07	0.000203	0.38	0.27	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	5.26	2.59e-07	0.000203	0.38	0.27	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
STAD	cis	rs12744310	0.887	rs12732820	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333101	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12724690	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41334585	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs35464028	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41334802	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs34152153	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335736	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs36040148	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335776	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs35807669	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335980	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12026404	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41336240	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12047272	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41336271	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12047161	ENSG00000235358.1	RP11-399E6.1	5.26	2.59e-07	0.000203	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41341856	chr1:41242373~41284861:+
STAD	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-5.26	2.59e-07	0.000203	-0.34	-0.27	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
STAD	cis	rs8067354	0.645	rs2645489	ENSG00000266701.1	AC005702.4	5.26	2.59e-07	0.000203	0.37	0.27	Hemoglobin concentration;	chr17:59806010	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs2645486	ENSG00000266701.1	AC005702.4	5.26	2.59e-07	0.000203	0.37	0.27	Hemoglobin concentration;	chr17:59808540	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs2645487	ENSG00000266701.1	AC005702.4	5.26	2.59e-07	0.000203	0.37	0.27	Hemoglobin concentration;	chr17:59808764	chr17:60042546~60042627:-
STAD	cis	rs1051424	0.642	rs115869798	ENSG00000266701.1	AC005702.4	5.26	2.59e-07	0.000203	0.37	0.27	Obesity-related traits;	chr17:59815468	chr17:60042546~60042627:-
STAD	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	5.26	2.59e-07	0.000203	0.29	0.27	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	5.26	2.59e-07	0.000203	0.29	0.27	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000280411.1	IGHV1-69-2	-5.26	2.59e-07	0.000203	-0.25	-0.27	Kawasaki disease;	chr14:106799309	chr14:106762092~106762588:-
STAD	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	5.25	2.59e-07	0.000203	0.28	0.27	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
STAD	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	5.25	2.59e-07	0.000203	0.29	0.27	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
STAD	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	5.25	2.6e-07	0.000203	0.3	0.27	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	5.25	2.6e-07	0.000203	0.3	0.27	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
STAD	cis	rs1816752	0.783	rs7317439	ENSG00000273628.1	RP11-756A22.7	5.25	2.6e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24410939	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.783	rs7139527	ENSG00000273628.1	RP11-756A22.7	5.25	2.6e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24411374	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.819	rs9511240	ENSG00000273628.1	RP11-756A22.7	5.25	2.6e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24411768	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.819	rs7988388	ENSG00000273628.1	RP11-756A22.7	5.25	2.6e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24412675	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.875	rs7993132	ENSG00000273628.1	RP11-756A22.7	5.25	2.6e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24412903	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.792	rs7330956	ENSG00000273628.1	RP11-756A22.7	5.25	2.6e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24413174	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.777	rs6490915	ENSG00000273628.1	RP11-756A22.7	5.25	2.6e-07	0.000203	0.33	0.27	Obesity-related traits;	chr13:24413724	chr13:24933006~24936796:+
STAD	cis	rs7932354	0.528	rs10838660	ENSG00000271350.1	CTD-2384B9.1	-5.25	2.6e-07	0.000204	-0.33	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:47130722	chr11:47041027~47041945:-
STAD	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	5.25	2.6e-07	0.000204	0.37	0.27	Height;	chr6:109416225	chr6:109382795~109383666:+
STAD	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	5.25	2.6e-07	0.000204	0.38	0.27	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
STAD	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	5.25	2.6e-07	0.000204	0.3	0.27	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
STAD	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	5.25	2.6e-07	0.000204	0.39	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
STAD	cis	rs12744310	0.887	rs12045979	ENSG00000235358.1	RP11-399E6.1	5.25	2.6e-07	0.000204	0.34	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343805	chr1:41242373~41284861:+
STAD	cis	rs75426604	0.527	rs76124244	ENSG00000241052.1	RP11-173D9.1	-5.25	2.61e-07	0.000204	-0.37	-0.27	Eotaxin levels;	chr14:35370321	chr14:35144021~35144480:-
STAD	cis	rs75426604	0.527	rs4272943	ENSG00000241052.1	RP11-173D9.1	-5.25	2.61e-07	0.000204	-0.37	-0.27	Eotaxin levels;	chr14:35371472	chr14:35144021~35144480:-
STAD	cis	rs7580658	0.545	rs885276	ENSG00000200250.1	RNU6-1147P	5.25	2.61e-07	0.000204	0.26	0.27	Protein C levels;	chr2:127193328	chr2:127316873~127316979:+
STAD	cis	rs7115242	0.858	rs6589592	ENSG00000280143.1	AP000892.6	5.25	2.61e-07	0.000205	0.34	0.27	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117204967~117210292:+
STAD	cis	rs6142102	0.812	rs4911375	ENSG00000275784.1	RP5-1125A11.6	-5.25	2.62e-07	0.000205	-0.28	-0.27	Skin pigmentation;	chr20:33928216	chr20:33989480~33991818:-
STAD	cis	rs11846409	0.86	rs61686131	ENSG00000211972.2	IGHV3-66	5.25	2.62e-07	0.000205	0.29	0.27	Rheumatic heart disease;	chr14:106631568	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs10151046	ENSG00000211972.2	IGHV3-66	5.25	2.62e-07	0.000205	0.29	0.27	Rheumatic heart disease;	chr14:106633095	chr14:106675017~106675544:-
STAD	cis	rs4604732	0.588	rs4356092	ENSG00000227135.1	GCSAML-AS1	-5.25	2.62e-07	0.000205	-0.37	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469366	chr1:247524679~247526752:-
STAD	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	5.25	2.62e-07	0.000205	0.3	0.27	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
STAD	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	5.25	2.62e-07	0.000205	0.3	0.27	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
STAD	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-5.25	2.62e-07	0.000205	-0.27	-0.27	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
STAD	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	5.25	2.62e-07	0.000205	0.34	0.27	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
STAD	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-5.25	2.62e-07	0.000205	-0.29	-0.27	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
STAD	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-5.25	2.62e-07	0.000205	-0.29	-0.27	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
STAD	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-5.25	2.62e-07	0.000205	-0.29	-0.27	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
STAD	cis	rs7615952	0.558	rs7641353	ENSG00000272840.1	RP11-379B18.6	5.25	2.62e-07	0.000205	0.42	0.27	Blood pressure (smoking interaction);	chr3:125621035	chr3:125774714~125797953:+
STAD	cis	rs2833693	0.574	rs9653707	ENSG00000261610.1	AP000265.1	5.25	2.63e-07	0.000205	0.3	0.27	Temperament;	chr21:32179462	chr21:32259804~32261585:-
STAD	cis	rs2833693	0.574	rs11088205	ENSG00000261610.1	AP000265.1	5.25	2.63e-07	0.000205	0.3	0.27	Temperament;	chr21:32179989	chr21:32259804~32261585:-
STAD	cis	rs9307551	0.779	rs13124357	ENSG00000250334.4	LINC00989	-5.25	2.63e-07	0.000205	-0.32	-0.27	Refractive error;	chr4:79591148	chr4:79492416~79576460:+
STAD	cis	rs801193	0.569	rs7800620	ENSG00000236529.1	RP13-254B10.1	5.25	2.63e-07	0.000206	0.28	0.27	Aortic root size;	chr7:66758701	chr7:65840212~65840596:+
STAD	cis	rs17301013	0.932	rs1754355	ENSG00000227373.4	RP11-160H22.5	-5.25	2.63e-07	0.000206	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174807407	chr1:174115300~174160004:-
STAD	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	5.25	2.63e-07	0.000206	0.33	0.27	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
STAD	cis	rs6782228	0.585	rs9841161	ENSG00000277250.1	Metazoa_SRP	-5.25	2.63e-07	0.000206	-0.28	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128673681~128674021:-
STAD	cis	rs6782228	0.606	rs2712405	ENSG00000277250.1	Metazoa_SRP	-5.25	2.63e-07	0.000206	-0.28	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128673681~128674021:-
STAD	cis	rs6142102	0.961	rs1555075	ENSG00000275784.1	RP5-1125A11.6	-5.25	2.63e-07	0.000206	-0.28	-0.27	Skin pigmentation;	chr20:34022595	chr20:33989480~33991818:-
STAD	cis	rs10504130	0.569	rs2069119	ENSG00000272024.1	RP11-546K22.3	-5.25	2.64e-07	0.000206	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51773876	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs35603537	ENSG00000272024.1	RP11-546K22.3	-5.25	2.64e-07	0.000206	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51773899	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.502	rs71513552	ENSG00000272024.1	RP11-546K22.3	-5.25	2.64e-07	0.000206	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs34073804	ENSG00000272024.1	RP11-546K22.3	-5.25	2.64e-07	0.000206	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs34319820	ENSG00000272024.1	RP11-546K22.3	-5.25	2.64e-07	0.000206	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51950284~51950690:+
STAD	cis	rs11169552	0.943	rs4768922	ENSG00000200183.1	RNU6-238P	-5.25	2.64e-07	0.000206	-0.27	-0.27	Colorectal cancer;	chr12:50785557	chr12:50656973~50657078:+
STAD	cis	rs1056107	0.866	rs10817308	ENSG00000225513.1	RP11-165N19.2	-5.25	2.64e-07	0.000206	-0.31	-0.27	Colorectal cancer;	chr9:112273585	chr9:112173522~112173971:-
STAD	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	5.25	2.64e-07	0.000206	0.39	0.27	Height;	chr6:109365409	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	5.25	2.64e-07	0.000206	0.39	0.27	Height;	chr6:109373851	chr6:109382795~109383666:+
STAD	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	5.25	2.64e-07	0.000206	0.37	0.27	Height;	chr6:109414295	chr6:109382795~109383666:+
STAD	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-5.25	2.64e-07	0.000206	-0.3	-0.27	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
STAD	cis	rs6714710	0.535	rs3192177	ENSG00000235833.1	AC159540.14	-5.25	2.64e-07	0.000207	-0.33	-0.27	Posterior cortical atrophy and Alzheimer's disease;	chr2:97738048	chr2:97523949~97524976:-
STAD	cis	rs7487075	0.893	rs2408508	ENSG00000272369.1	RP11-446N19.1	5.25	2.64e-07	0.000207	0.32	0.27	Itch intensity from mosquito bite;	chr12:46336817	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.828	rs7132228	ENSG00000272369.1	RP11-446N19.1	5.25	2.64e-07	0.000207	0.32	0.27	Itch intensity from mosquito bite;	chr12:46338178	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.893	rs4768116	ENSG00000272369.1	RP11-446N19.1	5.25	2.64e-07	0.000207	0.32	0.27	Itch intensity from mosquito bite;	chr12:46339247	chr12:46537502~46652550:+
STAD	cis	rs1799949	0.965	rs35521261	ENSG00000236383.6	LINC00854	-5.25	2.65e-07	0.000207	-0.22	-0.27	Menopause (age at onset);	chr17:43161595	chr17:43216941~43305976:-
STAD	cis	rs875971	0.862	rs801194	ENSG00000236529.1	RP13-254B10.1	-5.25	2.65e-07	0.000207	-0.28	-0.27	Aortic root size;	chr7:66563508	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs2024192	ENSG00000236529.1	RP13-254B10.1	-5.25	2.65e-07	0.000207	-0.28	-0.27	Aortic root size;	chr7:66576460	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6955837	ENSG00000236529.1	RP13-254B10.1	-5.25	2.65e-07	0.000207	-0.28	-0.27	Aortic root size;	chr7:66578155	chr7:65840212~65840596:+
STAD	cis	rs875971	0.825	rs10281499	ENSG00000236529.1	RP13-254B10.1	-5.25	2.65e-07	0.000207	-0.28	-0.27	Aortic root size;	chr7:66583979	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs4718377	ENSG00000236529.1	RP13-254B10.1	-5.25	2.65e-07	0.000207	-0.28	-0.27	Aortic root size;	chr7:66584691	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10278014	ENSG00000236529.1	RP13-254B10.1	-5.25	2.65e-07	0.000207	-0.28	-0.27	Aortic root size;	chr7:66586277	chr7:65840212~65840596:+
STAD	cis	rs1799949	0.794	rs116409325	ENSG00000279602.1	CTD-3014M21.1	5.25	2.65e-07	0.000207	0.34	0.27	Menopause (age at onset);	chr17:43368092	chr17:43360041~43361361:-
STAD	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-5.25	2.65e-07	0.000207	-0.25	-0.27	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
STAD	cis	rs711244	0.967	rs17496249	ENSG00000252756.1	RNU6-577P	-5.25	2.65e-07	0.000207	-0.3	-0.27	Mean platelet volume;	chr2:36875106	chr2:36867398~36867495:-
STAD	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-5.25	2.66e-07	0.000207	-0.34	-0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
STAD	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-5.25	2.66e-07	0.000207	-0.26	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
STAD	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	5.25	2.66e-07	0.000208	0.31	0.27	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
STAD	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	5.25	2.66e-07	0.000208	0.29	0.27	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
STAD	cis	rs2948294	0.588	rs12544596	ENSG00000254340.1	RP11-10A14.3	5.25	2.66e-07	0.000208	0.33	0.27	Red cell distribution width;	chr8:8258824	chr8:9141424~9145435:+
STAD	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	5.25	2.66e-07	0.000208	0.39	0.27	Height;	chr6:109360679	chr6:109382795~109383666:+
STAD	cis	rs11169552	0.943	rs4768923	ENSG00000200183.1	RNU6-238P	-5.25	2.67e-07	0.000208	-0.27	-0.27	Colorectal cancer;	chr12:50800926	chr12:50656973~50657078:+
STAD	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-5.25	2.67e-07	0.000208	-0.28	-0.27	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
STAD	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	5.25	2.67e-07	0.000208	0.3	0.27	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
STAD	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	5.25	2.67e-07	0.000208	0.28	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
STAD	cis	rs57339844	1	rs57339844	ENSG00000273080.1	RP11-301O19.1	-5.25	2.67e-07	0.000208	-0.33	-0.27	Mean platelet volume;	chr2:85891155	chr2:86195590~86196049:+
STAD	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-5.25	2.67e-07	0.000208	-0.32	-0.27	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
STAD	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	5.25	2.67e-07	0.000208	0.47	0.27	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
STAD	cis	rs728616	0.867	rs61860420	ENSG00000225484.5	NUTM2B-AS1	-5.25	2.67e-07	0.000208	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs75447386	ENSG00000225484.5	NUTM2B-AS1	-5.25	2.67e-07	0.000208	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs4520539	ENSG00000225484.5	NUTM2B-AS1	-5.25	2.67e-07	0.000208	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860421	ENSG00000225484.5	NUTM2B-AS1	-5.25	2.67e-07	0.000208	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79663088~79826594:-
STAD	cis	rs9307551	0.817	rs11098762	ENSG00000250334.4	LINC00989	-5.25	2.67e-07	0.000209	-0.33	-0.27	Refractive error;	chr4:79575097	chr4:79492416~79576460:+
STAD	cis	rs1799949	0.55	rs2343818	ENSG00000279602.1	CTD-3014M21.1	5.25	2.68e-07	0.000209	0.34	0.27	Menopause (age at onset);	chr17:43332406	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.526	rs4352088	ENSG00000279602.1	CTD-3014M21.1	5.25	2.68e-07	0.000209	0.34	0.27	Menopause (age at onset);	chr17:43337311	chr17:43360041~43361361:-
STAD	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-5.25	2.68e-07	0.000209	-0.29	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
STAD	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-5.25	2.68e-07	0.000209	-0.29	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
STAD	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	5.25	2.68e-07	0.000209	0.36	0.27	Height;	chr6:109371573	chr6:109382795~109383666:+
STAD	cis	rs2436845	1	rs2679752	ENSG00000253385.1	KB-1254G8.1	5.25	2.69e-07	0.00021	0.29	0.27	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102851890	chr8:102854455~102856075:+
STAD	cis	rs875971	0.545	rs73146609	ENSG00000224316.1	RP11-479O9.2	5.25	2.7e-07	0.000211	0.31	0.27	Aortic root size;	chr7:66302477	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs2173571	ENSG00000224316.1	RP11-479O9.2	5.25	2.7e-07	0.000211	0.31	0.27	Aortic root size;	chr7:66305392	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs11770063	ENSG00000224316.1	RP11-479O9.2	5.25	2.7e-07	0.000211	0.31	0.27	Aortic root size;	chr7:66318029	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs3936065	ENSG00000224316.1	RP11-479O9.2	5.25	2.7e-07	0.000211	0.31	0.27	Aortic root size;	chr7:66325577	chr7:65773620~65802067:+
STAD	cis	rs875971	0.545	rs4718335	ENSG00000224316.1	RP11-479O9.2	5.25	2.7e-07	0.000211	0.31	0.27	Aortic root size;	chr7:66339619	chr7:65773620~65802067:+
STAD	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	5.25	2.7e-07	0.000211	0.27	0.27	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
STAD	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-5.25	2.7e-07	0.000211	-0.22	-0.27	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
STAD	cis	rs8098244	0.638	rs1109949	ENSG00000267301.1	RPL23AP77	-5.25	2.7e-07	0.000211	-0.31	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23834136	chr18:23709825~23710287:-
STAD	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-5.25	2.7e-07	0.000211	-0.29	-0.27	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
STAD	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-5.25	2.7e-07	0.000211	-0.29	-0.27	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
STAD	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-5.25	2.7e-07	0.000211	-0.29	-0.27	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
STAD	cis	rs8098244	0.557	rs11082724	ENSG00000267301.1	RPL23AP77	-5.25	2.7e-07	0.000211	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732544	chr18:23709825~23710287:-
STAD	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-5.25	2.7e-07	0.000211	-0.48	-0.27	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
STAD	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-5.25	2.7e-07	0.000211	-0.38	-0.27	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
STAD	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-5.25	2.7e-07	0.000211	-0.38	-0.27	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
STAD	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-5.25	2.7e-07	0.000211	-0.38	-0.27	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
STAD	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-5.25	2.7e-07	0.000211	-0.38	-0.27	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
STAD	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-5.25	2.7e-07	0.000211	-0.38	-0.27	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
STAD	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-5.25	2.7e-07	0.000211	-0.38	-0.27	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
STAD	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.25	2.7e-07	0.000211	-0.49	-0.27	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
STAD	cis	rs3758911	0.861	rs12287772	ENSG00000261098.1	RP11-819C21.1	-5.25	2.7e-07	0.000211	-0.25	-0.27	Coronary artery disease;	chr11:107271121	chr11:107312132~107316271:-
STAD	cis	rs8097348	0.724	rs8099579	ENSG00000266602.1	RP11-476K15.1	-5.25	2.7e-07	0.000211	-0.34	-0.27	Exercise (leisure time);	chr18:1623184	chr18:1509183~1647097:+
STAD	cis	rs1322639	0.531	rs11751421	ENSG00000261039.2	RP11-417E7.2	5.25	2.71e-07	0.000211	0.3	0.27	Pulse pressure;	chr6:169174898	chr6:169175304~169182740:-
STAD	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	5.25	2.71e-07	0.000211	0.31	0.27	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
STAD	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	5.25	2.71e-07	0.000211	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
STAD	cis	rs853679	0.517	rs868987	ENSG00000220721.1	OR1F12	-5.25	2.71e-07	0.000211	-0.32	-0.27	Depression;	chr6:28142370	chr6:28073316~28074233:+
STAD	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	5.25	2.71e-07	0.000211	0.25	0.27	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
STAD	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	5.25	2.71e-07	0.000211	0.38	0.27	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
STAD	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-5.25	2.71e-07	0.000211	-0.36	-0.27	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
STAD	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	5.25	2.72e-07	0.000212	0.42	0.27	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
STAD	cis	rs10510102	0.872	rs12264952	ENSG00000226864.1	ATE1-AS1	5.25	2.72e-07	0.000212	0.44	0.27	Breast cancer;	chr10:121885673	chr10:121928312~121951965:+
STAD	cis	rs4713118	0.868	rs2893928	ENSG00000280107.1	AL022393.9	-5.25	2.72e-07	0.000212	-0.38	-0.27	Parkinson's disease;	chr6:27770651	chr6:28170845~28172521:+
STAD	cis	rs801193	0.569	rs2659907	ENSG00000236529.1	RP13-254B10.1	5.25	2.72e-07	0.000212	0.28	0.27	Aortic root size;	chr7:66699045	chr7:65840212~65840596:+
STAD	cis	rs2404602	0.692	rs4641709	ENSG00000259422.1	RP11-593F23.1	-5.25	2.72e-07	0.000212	-0.28	-0.27	Blood metabolite levels;	chr15:76755395	chr15:76174891~76181486:-
STAD	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	5.25	2.72e-07	0.000212	0.27	0.27	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	5.25	2.72e-07	0.000212	0.27	0.27	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
STAD	cis	rs10978777	0.805	rs4978844	ENSG00000276883.1	AL137852.1	-5.25	2.73e-07	0.000212	-0.27	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107308902	chr9:107292369~107292456:-
STAD	cis	rs7927771	0.524	rs4752860	ENSG00000280615.1	Y_RNA	-5.24	2.73e-07	0.000212	-0.27	-0.27	Subjective well-being;	chr11:47683463	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.542	rs11039336	ENSG00000280615.1	Y_RNA	-5.24	2.73e-07	0.000212	-0.27	-0.27	Subjective well-being;	chr11:47684589	chr11:47614898~47614994:-
STAD	cis	rs1056107	1	rs58632972	ENSG00000225513.1	RP11-165N19.2	-5.24	2.73e-07	0.000212	-0.34	-0.27	Colorectal cancer;	chr9:112324639	chr9:112173522~112173971:-
STAD	cis	rs1799949	0.896	rs33933393	ENSG00000236383.6	LINC00854	-5.24	2.73e-07	0.000212	-0.22	-0.27	Menopause (age at onset);	chr17:43165415	chr17:43216941~43305976:-
STAD	cis	rs7829975	0.902	rs485107	ENSG00000253981.4	ALG1L13P	-5.24	2.73e-07	0.000213	-0.32	-0.27	Mood instability;	chr8:8723898	chr8:8236003~8244667:-
STAD	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-5.24	2.73e-07	0.000213	-0.29	-0.27	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
STAD	cis	rs1799949	0.965	rs799912	ENSG00000236383.6	LINC00854	-5.24	2.73e-07	0.000213	-0.22	-0.27	Menopause (age at onset);	chr17:43105117	chr17:43216941~43305976:-
STAD	cis	rs728616	0.614	rs56147535	ENSG00000225484.5	NUTM2B-AS1	-5.24	2.73e-07	0.000213	-0.54	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80267869	chr10:79663088~79826594:-
STAD	cis	rs2283792	1	rs5749806	ENSG00000228050.1	TOP3BP1	5.24	2.73e-07	0.000213	0.31	0.27	Multiple sclerosis;	chr22:21752329	chr22:22223187~22224566:-
STAD	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	5.24	2.74e-07	0.000213	0.39	0.27	Height;	chr6:109381443	chr6:109382795~109383666:+
STAD	cis	rs858239	0.536	rs6956974	ENSG00000226816.2	AC005082.12	-5.24	2.74e-07	0.000213	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23206013~23208045:+
STAD	cis	rs240993	0.812	rs9487644	ENSG00000230177.1	RP5-1112D6.4	-5.24	2.74e-07	0.000213	-0.29	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111443064	chr6:111277932~111278742:+
STAD	cis	rs240993	0.761	rs9487645	ENSG00000230177.1	RP5-1112D6.4	-5.24	2.74e-07	0.000213	-0.29	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111443065	chr6:111277932~111278742:+
STAD	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-5.24	2.74e-07	0.000213	-0.29	-0.27	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
STAD	cis	rs6142102	0.961	rs2235597	ENSG00000275784.1	RP5-1125A11.6	-5.24	2.74e-07	0.000213	-0.28	-0.27	Skin pigmentation;	chr20:34077808	chr20:33989480~33991818:-
STAD	cis	rs1799949	0.859	rs11657004	ENSG00000279602.1	CTD-3014M21.1	5.24	2.75e-07	0.000213	0.33	0.27	Menopause (age at onset);	chr17:43365383	chr17:43360041~43361361:-
STAD	cis	rs2404602	0.692	rs55864032	ENSG00000259422.1	RP11-593F23.1	5.24	2.75e-07	0.000213	0.29	0.27	Blood metabolite levels;	chr15:76830207	chr15:76174891~76181486:-
STAD	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	5.24	2.75e-07	0.000214	0.3	0.27	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
STAD	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	5.24	2.75e-07	0.000214	0.27	0.27	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
STAD	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-5.24	2.75e-07	0.000214	-0.35	-0.27	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
STAD	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-5.24	2.75e-07	0.000214	-0.35	-0.27	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
STAD	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	5.24	2.76e-07	0.000214	0.26	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	5.24	2.76e-07	0.000214	0.26	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
STAD	cis	rs7078219	0.505	rs7908704	ENSG00000228778.1	RP11-129J12.1	-5.24	2.76e-07	0.000214	-0.32	-0.27	Dental caries;	chr10:99533561	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.505	rs7893840	ENSG00000228778.1	RP11-129J12.1	-5.24	2.76e-07	0.000214	-0.32	-0.27	Dental caries;	chr10:99533584	chr10:99527081~99528261:+
STAD	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-5.24	2.76e-07	0.000214	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-5.24	2.76e-07	0.000214	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-5.24	2.76e-07	0.000214	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-5.24	2.76e-07	0.000214	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-5.24	2.76e-07	0.000214	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
STAD	cis	rs17301013	0.932	rs1653626	ENSG00000227373.4	RP11-160H22.5	-5.24	2.76e-07	0.000214	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174770348	chr1:174115300~174160004:-
STAD	cis	rs9813712	0.574	rs11718032	ENSG00000253540.4	FAM86HP	5.24	2.76e-07	0.000215	0.29	0.27	Response to amphetamines;	chr3:130257749	chr3:130099092~130111472:-
STAD	cis	rs9860428	0.808	rs34147006	ENSG00000240057.4	RP11-572M11.4	-5.24	2.77e-07	0.000215	-0.26	-0.27	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112903063	chr3:113019532~113183301:+
STAD	cis	rs875971	0.862	rs13232191	ENSG00000236529.1	RP13-254B10.1	5.24	2.77e-07	0.000215	0.28	0.27	Aortic root size;	chr7:66521661	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs35378740	ENSG00000236529.1	RP13-254B10.1	5.24	2.77e-07	0.000215	0.28	0.27	Aortic root size;	chr7:66522725	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10950043	ENSG00000236529.1	RP13-254B10.1	5.24	2.77e-07	0.000215	0.28	0.27	Aortic root size;	chr7:66523623	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs17747530	ENSG00000236529.1	RP13-254B10.1	5.24	2.77e-07	0.000215	0.28	0.27	Aortic root size;	chr7:66529742	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs13226170	ENSG00000236529.1	RP13-254B10.1	5.24	2.77e-07	0.000215	0.28	0.27	Aortic root size;	chr7:66534311	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs2420611	ENSG00000236529.1	RP13-254B10.1	5.24	2.77e-07	0.000215	0.28	0.27	Aortic root size;	chr7:66534333	chr7:65840212~65840596:+
STAD	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	5.24	2.77e-07	0.000215	0.29	0.27	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
STAD	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-5.24	2.77e-07	0.000215	-0.28	-0.27	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
STAD	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-5.24	2.78e-07	0.000216	-0.27	-0.27	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
STAD	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	5.24	2.78e-07	0.000216	0.4	0.27	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	5.24	2.78e-07	0.000216	0.4	0.27	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
STAD	cis	rs7829975	0.684	rs488904	ENSG00000253981.4	ALG1L13P	-5.24	2.78e-07	0.000216	-0.32	-0.27	Mood instability;	chr8:8730061	chr8:8236003~8244667:-
STAD	cis	rs7078219	0.505	rs41290504	ENSG00000228778.1	RP11-129J12.1	-5.24	2.78e-07	0.000216	-0.32	-0.27	Dental caries;	chr10:99533278	chr10:99527081~99528261:+
STAD	cis	rs13113518	0.729	rs11133377	ENSG00000272969.1	RP11-528I4.2	5.24	2.78e-07	0.000216	0.36	0.27	Height;	chr4:55413708	chr4:55547112~55547889:+
STAD	cis	rs728616	0.717	rs111403425	ENSG00000225484.5	NUTM2B-AS1	-5.24	2.78e-07	0.000216	-0.58	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs78131725	ENSG00000225484.5	NUTM2B-AS1	-5.24	2.78e-07	0.000216	-0.58	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:79663088~79826594:-
STAD	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	5.24	2.78e-07	0.000216	0.28	0.27	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
STAD	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	5.24	2.78e-07	0.000216	0.32	0.27	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
STAD	cis	rs1799949	1	rs9646412	ENSG00000236383.6	LINC00854	-5.24	2.79e-07	0.000216	-0.22	-0.27	Menopause (age at onset);	chr17:43348525	chr17:43216941~43305976:-
STAD	cis	rs611744	0.647	rs10106246	ENSG00000253754.1	RP11-35G22.1	-5.24	2.79e-07	0.000216	-0.24	-0.27	Dupuytren's disease;	chr8:108256481	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs12675265	ENSG00000253754.1	RP11-35G22.1	-5.24	2.79e-07	0.000216	-0.24	-0.27	Dupuytren's disease;	chr8:108256576	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs1609472	ENSG00000253754.1	RP11-35G22.1	-5.24	2.79e-07	0.000216	-0.24	-0.27	Dupuytren's disease;	chr8:108257003	chr8:108226200~108227544:+
STAD	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	5.24	2.79e-07	0.000216	0.28	0.27	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
STAD	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	5.24	2.79e-07	0.000216	0.28	0.27	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
STAD	cis	rs2440129	0.611	rs11571335	ENSG00000262089.1	RP11-589P10.5	5.24	2.79e-07	0.000216	0.31	0.27	Tonsillectomy;	chr17:7000944	chr17:6994642~6995189:-
STAD	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	5.24	2.79e-07	0.000216	0.31	0.27	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
STAD	cis	rs673078	0.66	rs11068910	ENSG00000275409.1	RP11-131L12.4	-5.24	2.8e-07	0.000217	-0.34	-0.27	Glucose homeostasis traits;	chr12:118336076	chr12:118430147~118430699:+
STAD	cis	rs8098244	0.597	rs10775488	ENSG00000267301.1	RPL23AP77	-5.24	2.8e-07	0.000217	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23743203	chr18:23709825~23710287:-
STAD	cis	rs7580658	0.545	rs13006847	ENSG00000200250.1	RNU6-1147P	-5.24	2.8e-07	0.000217	-0.26	-0.27	Protein C levels;	chr2:127194687	chr2:127316873~127316979:+
STAD	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-5.24	2.8e-07	0.000217	-0.26	-0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
STAD	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-5.24	2.8e-07	0.000217	-0.33	-0.27	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
STAD	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	5.24	2.8e-07	0.000217	0.27	0.27	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
STAD	cis	rs3806843	1	rs10223116	ENSG00000202111.1	VTRNA1-2	-5.24	2.8e-07	0.000217	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140813058	chr5:140718925~140719013:+
STAD	cis	rs9425766	0.679	rs12563301	ENSG00000227373.4	RP11-160H22.5	5.24	2.8e-07	0.000217	0.32	0.27	Life satisfaction;	chr1:174090924	chr1:174115300~174160004:-
STAD	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-5.24	2.81e-07	0.000218	-0.69	-0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
STAD	cis	rs858239	0.601	rs4140959	ENSG00000226816.2	AC005082.12	5.24	2.81e-07	0.000218	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23206013~23208045:+
STAD	cis	rs2404602	0.716	rs1125932	ENSG00000259422.1	RP11-593F23.1	5.24	2.81e-07	0.000218	0.28	0.27	Blood metabolite levels;	chr15:76528199	chr15:76174891~76181486:-
STAD	cis	rs35934224	0.783	rs34462686	ENSG00000232926.1	AC000078.5	5.24	2.81e-07	0.000218	0.36	0.27	Glaucoma (primary open-angle);	chr22:19872394	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs34143881	ENSG00000232926.1	AC000078.5	5.24	2.81e-07	0.000218	0.36	0.27	Glaucoma (primary open-angle);	chr22:19872570	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs35969236	ENSG00000232926.1	AC000078.5	5.24	2.81e-07	0.000218	0.36	0.27	Glaucoma (primary open-angle);	chr22:19872832	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs12159647	ENSG00000232926.1	AC000078.5	5.24	2.81e-07	0.000218	0.36	0.27	Glaucoma (primary open-angle);	chr22:19873052	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs7285948	ENSG00000232926.1	AC000078.5	5.24	2.81e-07	0.000218	0.36	0.27	Glaucoma (primary open-angle);	chr22:19873604	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs7286104	ENSG00000232926.1	AC000078.5	5.24	2.81e-07	0.000218	0.36	0.27	Glaucoma (primary open-angle);	chr22:19873703	chr22:19887289~19887970:+
STAD	cis	rs7927771	0.524	rs10838739	ENSG00000280615.1	Y_RNA	-5.24	2.81e-07	0.000218	-0.27	-0.27	Subjective well-being;	chr11:47651191	chr11:47614898~47614994:-
STAD	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-5.24	2.81e-07	0.000218	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
STAD	cis	rs7927771	0.524	rs7123952	ENSG00000280615.1	Y_RNA	5.24	2.81e-07	0.000218	0.27	0.27	Subjective well-being;	chr11:47830505	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10838775	ENSG00000280615.1	Y_RNA	5.24	2.81e-07	0.000218	0.27	0.27	Subjective well-being;	chr11:47834830	chr11:47614898~47614994:-
STAD	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	5.24	2.82e-07	0.000218	0.4	0.27	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
STAD	cis	rs58873874	0.737	rs78565801	ENSG00000251405.2	CTB-109A12.1	5.24	2.82e-07	0.000218	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.737	rs79951742	ENSG00000251405.2	CTB-109A12.1	5.24	2.82e-07	0.000218	0.48	0.27	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157362615~157460078:-
STAD	cis	rs1979398	1	rs1979398	ENSG00000251237.1	B3GNTL1P1	5.24	2.82e-07	0.000218	0.29	0.27	Attention deficit hyperactivity disorder;	chr5:52898497	chr5:52889666~52889954:+
STAD	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-5.24	2.82e-07	0.000218	-0.32	-0.27	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
STAD	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-5.24	2.82e-07	0.000218	-0.28	-0.27	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
STAD	cis	rs11098499	0.722	rs1814814	ENSG00000260091.1	RP11-33B1.4	5.24	2.82e-07	0.000218	0.25	0.27	Corneal astigmatism;	chr4:119336969	chr4:119409333~119410233:+
STAD	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-5.24	2.82e-07	0.000219	-0.29	-0.27	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
STAD	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	5.24	2.82e-07	0.000219	0.32	0.27	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
STAD	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-5.24	2.82e-07	0.000219	-0.31	-0.27	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
STAD	cis	rs728616	0.681	rs56184245	ENSG00000225484.5	NUTM2B-AS1	-5.24	2.82e-07	0.000219	-0.54	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80258800	chr10:79663088~79826594:-
STAD	cis	rs3806843	1	rs2879089	ENSG00000202111.1	VTRNA1-2	-5.24	2.83e-07	0.000219	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140812308	chr5:140718925~140719013:+
STAD	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-5.24	2.83e-07	0.000219	-0.33	-0.27	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-5.24	2.83e-07	0.000219	-0.33	-0.27	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-5.24	2.83e-07	0.000219	-0.33	-0.27	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-5.24	2.83e-07	0.000219	-0.33	-0.27	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
STAD	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-5.24	2.83e-07	0.000219	-0.28	-0.27	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
STAD	cis	rs11169552	0.943	rs11169561	ENSG00000200183.1	RNU6-238P	-5.24	2.83e-07	0.000219	-0.27	-0.27	Colorectal cancer;	chr12:50792167	chr12:50656973~50657078:+
STAD	cis	rs1056107	0.933	rs10116045	ENSG00000225513.1	RP11-165N19.2	-5.24	2.83e-07	0.000219	-0.32	-0.27	Colorectal cancer;	chr9:112285580	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs6477908	ENSG00000225513.1	RP11-165N19.2	-5.24	2.83e-07	0.000219	-0.32	-0.27	Colorectal cancer;	chr9:112285627	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs4979095	ENSG00000225513.1	RP11-165N19.2	-5.24	2.83e-07	0.000219	-0.32	-0.27	Colorectal cancer;	chr9:112286527	chr9:112173522~112173971:-
STAD	cis	rs1153858	1	rs2056493	ENSG00000259433.2	CTD-2651B20.4	-5.24	2.84e-07	0.00022	-0.29	-0.27	Homoarginine levels;	chr15:45356074	chr15:45330209~45332634:-
STAD	cis	rs992157	0.698	rs6746089	ENSG00000237281.1	CATIP-AS2	-5.24	2.84e-07	0.00022	-0.27	-0.27	Colorectal cancer;	chr2:218305654	chr2:218326889~218357966:-
STAD	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	5.24	2.84e-07	0.00022	0.34	0.27	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
STAD	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-5.24	2.85e-07	0.00022	-0.24	-0.27	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
STAD	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	5.24	2.85e-07	0.00022	0.31	0.27	Depression;	chr6:28079011	chr6:28073316~28074233:+
STAD	cis	rs7829975	0.688	rs6995407	ENSG00000254340.1	RP11-10A14.3	5.24	2.85e-07	0.00022	0.33	0.27	Mood instability;	chr8:8527137	chr8:9141424~9145435:+
STAD	cis	rs9859260	0.71	rs41298097	ENSG00000207650.1	MIR570	-5.24	2.85e-07	0.000221	-0.27	-0.27	Mean corpuscular volume;	chr3:196052284	chr3:195699401~195699497:+
STAD	cis	rs9859260	0.71	rs34906439	ENSG00000207650.1	MIR570	-5.24	2.85e-07	0.000221	-0.27	-0.27	Mean corpuscular volume;	chr3:196052835	chr3:195699401~195699497:+
STAD	cis	rs9859260	0.744	rs557527	ENSG00000207650.1	MIR570	-5.24	2.85e-07	0.000221	-0.27	-0.27	Mean corpuscular volume;	chr3:196053838	chr3:195699401~195699497:+
STAD	cis	rs12744310	1	rs12756822	ENSG00000235358.1	RP11-399E6.1	5.24	2.85e-07	0.000221	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311655	chr1:41242373~41284861:+
STAD	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-5.24	2.85e-07	0.000221	-0.28	-0.27	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
STAD	cis	rs7927771	0.524	rs10838740	ENSG00000280615.1	Y_RNA	5.24	2.85e-07	0.000221	0.27	0.27	Subjective well-being;	chr11:47658428	chr11:47614898~47614994:-
STAD	cis	rs728616	0.681	rs3862518	ENSG00000225484.5	NUTM2B-AS1	-5.24	2.86e-07	0.000221	-0.49	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158201	chr10:79663088~79826594:-
STAD	cis	rs35955747	0.533	rs5998004	ENSG00000236132.1	CTA-440B3.1	5.24	2.86e-07	0.000221	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485843	chr22:31816379~31817491:-
STAD	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-5.24	2.86e-07	0.000221	-0.34	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
STAD	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-5.24	2.86e-07	0.000221	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
STAD	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-5.24	2.86e-07	0.000221	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
STAD	cis	rs7078219	0.505	rs10883372	ENSG00000228778.1	RP11-129J12.1	-5.24	2.86e-07	0.000221	-0.31	-0.27	Dental caries;	chr10:99532726	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.505	rs10883373	ENSG00000228778.1	RP11-129J12.1	-5.24	2.86e-07	0.000221	-0.31	-0.27	Dental caries;	chr10:99532727	chr10:99527081~99528261:+
STAD	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-5.24	2.86e-07	0.000221	-0.28	-0.27	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
STAD	cis	rs35955747	0.633	rs5998012	ENSG00000236132.1	CTA-440B3.1	5.23	2.87e-07	0.000222	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31493858	chr22:31816379~31817491:-
STAD	cis	rs7932354	0.528	rs7125807	ENSG00000271350.1	CTD-2384B9.1	5.23	2.87e-07	0.000222	0.32	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47019612	chr11:47041027~47041945:-
STAD	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	5.23	2.87e-07	0.000222	0.33	0.27	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
STAD	cis	rs1862618	0.671	rs2034244	ENSG00000271828.1	CTD-2310F14.1	-5.23	2.87e-07	0.000222	-0.33	-0.27	Initial pursuit acceleration;	chr5:56946947	chr5:56927874~56929573:+
STAD	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-5.23	2.87e-07	0.000222	-0.31	-0.27	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
STAD	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-5.23	2.87e-07	0.000222	-0.42	-0.27	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
STAD	cis	rs3806843	0.518	rs2563310	ENSG00000202111.1	VTRNA1-2	5.23	2.88e-07	0.000223	0.26	0.27	Depressive symptoms (multi-trait analysis);	chr5:140636156	chr5:140718925~140719013:+
STAD	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-5.23	2.88e-07	0.000223	-0.36	-0.27	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
STAD	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	5.23	2.88e-07	0.000223	0.42	0.27	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
STAD	cis	rs1056107	0.933	rs7047691	ENSG00000225513.1	RP11-165N19.2	-5.23	2.88e-07	0.000223	-0.31	-0.27	Colorectal cancer;	chr9:112289887	chr9:112173522~112173971:-
STAD	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	5.23	2.89e-07	0.000223	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
STAD	cis	rs875971	0.545	rs1547529	ENSG00000224316.1	RP11-479O9.2	5.23	2.89e-07	0.000223	0.3	0.27	Aortic root size;	chr7:66258859	chr7:65773620~65802067:+
STAD	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	5.23	2.89e-07	0.000224	0.32	0.27	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
STAD	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	5.23	2.9e-07	0.000224	0.37	0.27	Height;	chr6:109694120	chr6:109382795~109383666:+
STAD	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	5.23	2.9e-07	0.000224	0.42	0.27	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
STAD	cis	rs7124681	0.584	rs11039448	ENSG00000280615.1	Y_RNA	-5.23	2.9e-07	0.000224	-0.27	-0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47896864	chr11:47614898~47614994:-
STAD	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-5.23	2.91e-07	0.000224	-0.25	-0.27	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
STAD	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-5.23	2.91e-07	0.000225	-0.28	-0.27	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
STAD	cis	rs7927771	0.524	rs4539273	ENSG00000280615.1	Y_RNA	-5.23	2.92e-07	0.000225	-0.27	-0.27	Subjective well-being;	chr11:47673147	chr11:47614898~47614994:-
STAD	cis	rs875971	0.545	rs10261710	ENSG00000236529.1	RP13-254B10.1	5.23	2.92e-07	0.000225	0.33	0.27	Aortic root size;	chr7:66249202	chr7:65840212~65840596:+
STAD	cis	rs12744310	0.887	rs12043581	ENSG00000235358.1	RP11-399E6.1	5.23	2.92e-07	0.000225	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41322593	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12046670	ENSG00000235358.1	RP11-399E6.1	5.23	2.92e-07	0.000225	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343640	chr1:41242373~41284861:+
STAD	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	5.23	2.92e-07	0.000225	0.26	0.27	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
STAD	cis	rs3806843	0.619	rs2569160	ENSG00000202111.1	VTRNA1-2	5.23	2.92e-07	0.000225	0.27	0.27	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr5:140718925~140719013:+
STAD	cis	rs507080	0.961	rs673770	ENSG00000278376.1	RP11-158I9.8	-5.23	2.92e-07	0.000225	-0.28	-0.27	Serum metabolite levels;	chr11:118679892	chr11:118791254~118793137:+
STAD	cis	rs728616	0.867	rs1923534	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs12414096	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:79663088~79826594:-
STAD	cis	rs728616	0.557	rs17107449	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs76239460	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860400	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61860412	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs12412257	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs117139504	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs12412226	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs4387301	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79663088~79826594:-
STAD	cis	rs728616	0.764	rs117833443	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs116994688	ENSG00000225484.5	NUTM2B-AS1	-5.23	2.92e-07	0.000225	-0.61	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79663088~79826594:-
STAD	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	5.23	2.92e-07	0.000226	0.32	0.27	Depression;	chr6:28071808	chr6:28073316~28074233:+
STAD	cis	rs9910055	0.571	rs10208	ENSG00000260793.2	RP5-882C2.2	-5.23	2.93e-07	0.000226	-0.3	-0.27	Total body bone mineral density;	chr17:44222910	chr17:44221401~44223710:+
STAD	cis	rs875971	0.545	rs10950029	ENSG00000236529.1	RP13-254B10.1	5.23	2.93e-07	0.000226	0.31	0.27	Aortic root size;	chr7:66169334	chr7:65840212~65840596:+
STAD	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	5.23	2.93e-07	0.000226	0.35	0.27	Height;	chr6:109416903	chr6:109382795~109383666:+
STAD	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	5.23	2.93e-07	0.000226	0.35	0.27	Height;	chr6:109417941	chr6:109382795~109383666:+
STAD	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	5.23	2.93e-07	0.000226	0.35	0.27	Height;	chr6:109420812	chr6:109382795~109383666:+
STAD	cis	rs11169552	0.943	rs10783389	ENSG00000200183.1	RNU6-238P	-5.23	2.93e-07	0.000226	-0.27	-0.27	Colorectal cancer;	chr12:50796823	chr12:50656973~50657078:+
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-5.23	2.93e-07	0.000226	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
STAD	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-5.23	2.93e-07	0.000226	-0.25	-0.27	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
STAD	cis	rs1007738	0.58	rs10501319	ENSG00000271350.1	CTD-2384B9.1	5.23	2.93e-07	0.000226	0.35	0.27	Bone mineral density (hip);	chr11:47152511	chr11:47041027~47041945:-
STAD	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	5.23	2.93e-07	0.000226	0.36	0.27	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
STAD	cis	rs7927771	0.524	rs10838782	ENSG00000280615.1	Y_RNA	5.23	2.94e-07	0.000226	0.27	0.27	Subjective well-being;	chr11:47856248	chr11:47614898~47614994:-
STAD	cis	rs875971	0.756	rs2901210	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66552518	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs13536	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66554203	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs801209	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66554403	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs801206	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66556979	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs801204	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66557934	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs801203	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66558025	chr7:65840212~65840596:+
STAD	cis	rs875971	0.825	rs801202	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66558942	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs801195	ENSG00000236529.1	RP13-254B10.1	-5.23	2.94e-07	0.000227	-0.28	-0.27	Aortic root size;	chr7:66561128	chr7:65840212~65840596:+
STAD	cis	rs875971	0.767	rs61348003	ENSG00000236529.1	RP13-254B10.1	5.23	2.94e-07	0.000227	0.28	0.27	Aortic root size;	chr7:66540947	chr7:65840212~65840596:+
STAD	cis	rs747650	0.504	rs4315028	ENSG00000271350.1	CTD-2384B9.1	5.23	2.94e-07	0.000227	0.35	0.27	Acne (severe);	chr11:47077574	chr11:47041027~47041945:-
STAD	cis	rs10504130	0.569	rs12676345	ENSG00000272024.1	RP11-546K22.3	-5.23	2.94e-07	0.000227	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51950284~51950690:+
STAD	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-5.23	2.95e-07	0.000227	-0.29	-0.27	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
STAD	cis	rs1056107	0.866	rs4979093	ENSG00000225513.1	RP11-165N19.2	-5.23	2.95e-07	0.000227	-0.31	-0.27	Colorectal cancer;	chr9:112275820	chr9:112173522~112173971:-
STAD	cis	rs1799949	0.55	rs2343818	ENSG00000236383.6	LINC00854	-5.23	2.95e-07	0.000227	-0.22	-0.27	Menopause (age at onset);	chr17:43332406	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.526	rs4352088	ENSG00000236383.6	LINC00854	-5.23	2.95e-07	0.000227	-0.22	-0.27	Menopause (age at onset);	chr17:43337311	chr17:43216941~43305976:-
STAD	cis	rs7932354	0.71	rs2306032	ENSG00000271350.1	CTD-2384B9.1	-5.23	2.95e-07	0.000227	-0.32	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:46875702	chr11:47041027~47041945:-
STAD	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	5.23	2.95e-07	0.000227	0.29	0.27	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
STAD	cis	rs11098499	0.78	rs10013652	ENSG00000260091.1	RP11-33B1.4	5.23	2.95e-07	0.000227	0.26	0.27	Corneal astigmatism;	chr4:119371101	chr4:119409333~119410233:+
STAD	cis	rs728616	0.717	rs17098169	ENSG00000225484.5	NUTM2B-AS1	5.23	2.95e-07	0.000227	0.56	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:79663088~79826594:-
STAD	cis	rs13113518	1	rs7660980	ENSG00000272969.1	RP11-528I4.2	-5.23	2.95e-07	0.000227	-0.35	-0.27	Height;	chr4:55542948	chr4:55547112~55547889:+
STAD	cis	rs9463078	0.605	rs7763421	ENSG00000219384.1	RP11-491H9.3	-5.23	2.96e-07	0.000228	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44909576	chr6:45158870~45159511:+
STAD	cis	rs8098244	0.516	rs1711451	ENSG00000267301.1	RPL23AP77	-5.23	2.96e-07	0.000228	-0.33	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690470	chr18:23709825~23710287:-
STAD	cis	rs10971721	0.584	rs72731217	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34119555	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.584	rs72731218	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34119678	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.584	rs72731221	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34122376	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.584	rs72731222	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34122864	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.584	rs10971939	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34123437	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.584	rs10971940	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34127213	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.584	rs72731226	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34128832	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.584	rs10971944	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34129008	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.631	rs74450404	ENSG00000260947.1	RP11-384P7.7	5.23	2.97e-07	0.000228	0.39	0.27	Body mass index;	chr9:34134666	chr9:33697459~33700986:+
STAD	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	5.23	2.97e-07	0.000229	0.33	0.27	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
STAD	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	5.23	2.97e-07	0.000229	0.31	0.27	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
STAD	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-5.23	2.97e-07	0.000229	-0.29	-0.27	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
STAD	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	5.23	2.97e-07	0.000229	0.45	0.27	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
STAD	cis	rs6142102	0.961	rs4911389	ENSG00000275784.1	RP5-1125A11.6	-5.23	2.98e-07	0.000229	-0.28	-0.27	Skin pigmentation;	chr20:33977235	chr20:33989480~33991818:-
STAD	cis	rs8141529	0.732	rs11556025	ENSG00000226471.5	CTA-292E10.6	-5.23	2.98e-07	0.000229	-0.32	-0.27	Lymphocyte counts;	chr22:28772767	chr22:28800683~28848559:+
STAD	cis	rs2440129	0.611	rs1042356	ENSG00000262089.1	RP11-589P10.5	5.23	2.98e-07	0.000229	0.3	0.27	Tonsillectomy;	chr17:6999424	chr17:6994642~6995189:-
STAD	cis	rs12699921	0.599	rs6973480	ENSG00000279048.1	RP11-511H23.2	5.23	2.99e-07	0.00023	0.25	0.27	Fibrinogen levels;	chr7:17938506	chr7:17940503~17942922:+
STAD	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	5.23	2.99e-07	0.00023	0.41	0.27	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
STAD	cis	rs611744	0.647	rs676654	ENSG00000253754.1	RP11-35G22.1	-5.23	2.99e-07	0.00023	-0.24	-0.27	Dupuytren's disease;	chr8:108230074	chr8:108226200~108227544:+
STAD	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-5.23	2.99e-07	0.00023	-0.38	-0.27	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
STAD	cis	rs3806843	0.569	rs753279	ENSG00000202111.1	VTRNA1-2	5.23	2.99e-07	0.00023	0.27	0.27	Depressive symptoms (multi-trait analysis);	chr5:140644233	chr5:140718925~140719013:+
STAD	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	5.23	2.99e-07	0.00023	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
STAD	cis	rs516805	0.633	rs9490414	ENSG00000279453.1	RP3-425C14.4	5.23	2.99e-07	0.00023	0.37	0.27	Lymphocyte counts;	chr6:122245612	chr6:122436789~122439223:-
STAD	cis	rs516805	0.667	rs9632500	ENSG00000279453.1	RP3-425C14.4	5.23	2.99e-07	0.00023	0.37	0.27	Lymphocyte counts;	chr6:122251472	chr6:122436789~122439223:-
STAD	cis	rs7927771	0.832	rs935914	ENSG00000280615.1	Y_RNA	5.23	3e-07	0.00023	0.28	0.27	Subjective well-being;	chr11:47366048	chr11:47614898~47614994:-
STAD	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-5.23	3e-07	0.00023	-0.32	-0.27	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
STAD	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	5.23	3e-07	0.000231	0.36	0.27	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
STAD	cis	rs516805	0.748	rs72974455	ENSG00000279453.1	RP3-425C14.4	5.23	3e-07	0.000231	0.37	0.27	Lymphocyte counts;	chr6:122377134	chr6:122436789~122439223:-
STAD	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	5.23	3e-07	0.000231	0.3	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
STAD	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-5.23	3e-07	0.000231	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-5.23	3e-07	0.000231	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-5.23	3e-07	0.000231	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
STAD	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
STAD	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
STAD	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-5.23	3e-07	0.000231	-0.22	-0.27	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
STAD	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	5.23	3.01e-07	0.000231	0.36	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
STAD	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	5.23	3.01e-07	0.000231	0.33	0.27	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
STAD	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	5.23	3.01e-07	0.000231	0.32	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
STAD	cis	rs10504130	0.53	rs4292674	ENSG00000272024.1	RP11-546K22.3	-5.23	3.01e-07	0.000231	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs4292675	ENSG00000272024.1	RP11-546K22.3	-5.23	3.01e-07	0.000231	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs76746661	ENSG00000272024.1	RP11-546K22.3	-5.23	3.01e-07	0.000231	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs71513549	ENSG00000272024.1	RP11-546K22.3	-5.23	3.01e-07	0.000231	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.502	rs4321994	ENSG00000272024.1	RP11-546K22.3	-5.23	3.01e-07	0.000231	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.66	rs79691523	ENSG00000272024.1	RP11-546K22.3	-5.23	3.01e-07	0.000231	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51950284~51950690:+
STAD	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	5.23	3.01e-07	0.000231	0.29	0.27	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
STAD	cis	rs7829975	0.624	rs7823056	ENSG00000254340.1	RP11-10A14.3	5.23	3.01e-07	0.000231	0.32	0.27	Mood instability;	chr8:8525195	chr8:9141424~9145435:+
STAD	cis	rs611744	0.624	rs2514844	ENSG00000253754.1	RP11-35G22.1	-5.23	3.01e-07	0.000231	-0.24	-0.27	Dupuytren's disease;	chr8:108052581	chr8:108226200~108227544:+
STAD	cis	rs611744	0.658	rs2443774	ENSG00000253754.1	RP11-35G22.1	-5.23	3.01e-07	0.000231	-0.24	-0.27	Dupuytren's disease;	chr8:108052729	chr8:108226200~108227544:+
STAD	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-5.23	3.01e-07	0.000232	-0.42	-0.27	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
STAD	cis	rs1318937	0.516	rs73023424	ENSG00000224660.1	SH3BP5-AS1	5.23	3.01e-07	0.000232	0.28	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15201995	chr3:15254184~15264493:+
STAD	cis	rs1056107	0.933	rs2418201	ENSG00000225513.1	RP11-165N19.2	-5.22	3.02e-07	0.000232	-0.32	-0.27	Colorectal cancer;	chr9:112271580	chr9:112173522~112173971:-
STAD	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-5.22	3.02e-07	0.000232	-0.26	-0.27	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
STAD	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-5.22	3.02e-07	0.000232	-0.33	-0.27	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
STAD	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	5.22	3.02e-07	0.000232	0.4	0.27	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
STAD	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-5.22	3.03e-07	0.000233	-0.33	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
STAD	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	5.22	3.03e-07	0.000233	0.35	0.27	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
STAD	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-5.22	3.03e-07	0.000233	-0.3	-0.27	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
STAD	cis	rs875971	0.755	rs76288834	ENSG00000236529.1	RP13-254B10.1	-5.22	3.03e-07	0.000233	-0.28	-0.27	Aortic root size;	chr7:66604815	chr7:65840212~65840596:+
STAD	cis	rs2404602	0.692	rs7174673	ENSG00000259422.1	RP11-593F23.1	5.22	3.04e-07	0.000233	0.28	0.27	Blood metabolite levels;	chr15:76779657	chr15:76174891~76181486:-
STAD	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-5.22	3.04e-07	0.000233	-0.34	-0.27	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
STAD	cis	rs7829975	0.511	rs2976906	ENSG00000254340.1	RP11-10A14.3	5.22	3.04e-07	0.000233	0.32	0.27	Mood instability;	chr8:8484905	chr8:9141424~9145435:+
STAD	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-5.22	3.04e-07	0.000233	-0.36	-0.27	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
STAD	cis	rs950169	0.922	rs12906983	ENSG00000259295.5	CSPG4P12	5.22	3.04e-07	0.000233	0.41	0.27	Schizophrenia;	chr15:84262270	chr15:85191438~85213905:+
STAD	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-5.22	3.04e-07	0.000233	-0.41	-0.27	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
STAD	cis	rs2933343	0.7	rs6787833	ENSG00000231305.3	RP11-723O4.2	5.22	3.05e-07	0.000234	0.28	0.27	IgG glycosylation;	chr3:128937341	chr3:128861313~128871540:-
STAD	cis	rs6452524	0.648	rs27364	ENSG00000243385.2	CTD-2110K23.1	5.22	3.05e-07	0.000234	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83201229~83202141:+
STAD	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	5.22	3.05e-07	0.000234	0.3	0.27	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
STAD	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-5.22	3.05e-07	0.000234	-0.28	-0.27	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
STAD	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-5.22	3.05e-07	0.000234	-0.28	-0.27	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
STAD	cis	rs611744	0.647	rs13280487	ENSG00000253754.1	RP11-35G22.1	-5.22	3.06e-07	0.000234	-0.24	-0.27	Dupuytren's disease;	chr8:108258034	chr8:108226200~108227544:+
STAD	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	5.22	3.06e-07	0.000234	0.32	0.27	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
STAD	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	5.22	3.06e-07	0.000234	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
STAD	cis	rs6142102	0.961	rs4911401	ENSG00000275784.1	RP5-1125A11.6	-5.22	3.06e-07	0.000235	-0.28	-0.27	Skin pigmentation;	chr20:34066756	chr20:33989480~33991818:-
STAD	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	5.22	3.06e-07	0.000235	0.42	0.27	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
STAD	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-5.22	3.07e-07	0.000235	-0.26	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-5.22	3.07e-07	0.000235	-0.26	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
STAD	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-5.22	3.07e-07	0.000235	-0.29	-0.27	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
STAD	cis	rs1816752	0.716	rs9553289	ENSG00000273628.1	RP11-756A22.7	-5.22	3.07e-07	0.000235	-0.32	-0.27	Obesity-related traits;	chr13:24400640	chr13:24933006~24936796:+
STAD	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-5.22	3.07e-07	0.000235	-0.28	-0.27	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
STAD	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	5.22	3.07e-07	0.000235	0.29	0.27	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
STAD	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	5.22	3.07e-07	0.000236	0.27	0.27	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
STAD	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-5.22	3.08e-07	0.000236	-0.23	-0.27	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
STAD	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	5.22	3.08e-07	0.000236	0.36	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
STAD	cis	rs1799949	1	rs9646417	ENSG00000279602.1	CTD-3014M21.1	5.22	3.08e-07	0.000236	0.34	0.27	Menopause (age at onset);	chr17:43346885	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs1545764	ENSG00000279602.1	CTD-3014M21.1	5.22	3.08e-07	0.000236	0.34	0.27	Menopause (age at onset);	chr17:43347197	chr17:43360041~43361361:-
STAD	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-5.22	3.08e-07	0.000236	-0.36	-0.27	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
STAD	cis	rs1153858	0.725	rs74572151	ENSG00000259433.2	CTD-2651B20.4	-5.22	3.08e-07	0.000236	-0.3	-0.27	Homoarginine levels;	chr15:45355328	chr15:45330209~45332634:-
STAD	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-5.22	3.08e-07	0.000236	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
STAD	cis	rs747650	0.798	rs11039086	ENSG00000271350.1	CTD-2384B9.1	-5.22	3.08e-07	0.000236	-0.32	-0.27	Acne (severe);	chr11:47094482	chr11:47041027~47041945:-
STAD	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	5.22	3.09e-07	0.000236	0.27	0.27	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
STAD	cis	rs1426063	1	rs11941556	ENSG00000248165.1	RP11-44F21.2	5.22	3.09e-07	0.000236	0.48	0.27	QT interval;	chr4:75093825	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs10022814	ENSG00000248165.1	RP11-44F21.2	5.22	3.09e-07	0.000236	0.48	0.27	QT interval;	chr4:75094704	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs10029141	ENSG00000248165.1	RP11-44F21.2	5.22	3.09e-07	0.000236	0.48	0.27	QT interval;	chr4:75097437	chr4:74993877~75034824:-
STAD	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-5.22	3.09e-07	0.000237	-0.22	-0.27	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
STAD	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-5.22	3.09e-07	0.000237	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
STAD	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-5.22	3.09e-07	0.000237	-0.29	-0.27	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
STAD	cis	rs453301	0.686	rs10217044	ENSG00000254340.1	RP11-10A14.3	-5.22	3.09e-07	0.000237	-0.36	-0.27	Joint mobility (Beighton score);	chr8:9037242	chr8:9141424~9145435:+
STAD	cis	rs1051424	0.651	rs1292063	ENSG00000266701.1	AC005702.4	-5.22	3.1e-07	0.000237	-0.37	-0.27	Obesity-related traits;	chr17:59830407	chr17:60042546~60042627:-
STAD	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	5.22	3.1e-07	0.000237	0.3	0.27	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
STAD	cis	rs3758911	0.861	rs11212117	ENSG00000261098.1	RP11-819C21.1	-5.22	3.11e-07	0.000238	-0.25	-0.27	Coronary artery disease;	chr11:107276757	chr11:107312132~107316271:-
STAD	cis	rs858239	0.539	rs6945510	ENSG00000226816.2	AC005082.12	5.22	3.11e-07	0.000238	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23206013~23208045:+
STAD	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-5.22	3.11e-07	0.000238	-0.42	-0.27	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
STAD	cis	rs8040855	0.627	rs62019482	ENSG00000229212.6	RP11-561C5.4	5.22	3.11e-07	0.000238	0.39	0.27	Bulimia nervosa;	chr15:85071796	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.627	rs11631548	ENSG00000229212.6	RP11-561C5.4	5.22	3.11e-07	0.000238	0.39	0.27	Bulimia nervosa;	chr15:85076017	chr15:85205440~85234795:-
STAD	cis	rs8040855	0.627	rs1532776	ENSG00000229212.6	RP11-561C5.4	5.22	3.11e-07	0.000238	0.39	0.27	Bulimia nervosa;	chr15:85081383	chr15:85205440~85234795:-
STAD	cis	rs1056107	0.931	rs7855376	ENSG00000225513.1	RP11-165N19.2	5.22	3.11e-07	0.000238	0.31	0.27	Colorectal cancer;	chr9:112251851	chr9:112173522~112173971:-
STAD	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	5.22	3.11e-07	0.000238	0.35	0.27	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
STAD	cis	rs58873874	0.737	rs11749762	ENSG00000251405.2	CTB-109A12.1	5.22	3.11e-07	0.000238	0.46	0.27	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157362615~157460078:-
STAD	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-5.22	3.11e-07	0.000238	-0.26	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-5.22	3.11e-07	0.000238	-0.26	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
STAD	cis	rs10129255	0.957	rs6576233	ENSG00000280411.1	IGHV1-69-2	-5.22	3.12e-07	0.000238	-0.24	-0.27	Kawasaki disease;	chr14:106787239	chr14:106762092~106762588:-
STAD	cis	rs9463078	0.605	rs17422760	ENSG00000219384.1	RP11-491H9.3	-5.22	3.12e-07	0.000239	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44917551	chr6:45158870~45159511:+
STAD	cis	rs5769707	0.667	rs4824069	ENSG00000280224.1	CTA-722E9.1	-5.22	3.12e-07	0.000239	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49500568~49501585:+
STAD	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	5.22	3.12e-07	0.000239	0.37	0.27	Height;	chr6:109352852	chr6:109382795~109383666:+
STAD	cis	rs8098244	0.683	rs1941524	ENSG00000267301.1	RPL23AP77	5.22	3.13e-07	0.000239	0.31	0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23865299	chr18:23709825~23710287:-
STAD	cis	rs728616	0.614	rs10887199	ENSG00000225484.5	NUTM2B-AS1	-5.22	3.13e-07	0.000239	-0.42	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79943078	chr10:79663088~79826594:-
STAD	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-5.22	3.13e-07	0.000239	-0.28	-0.27	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
STAD	cis	rs673078	0.66	rs73205551	ENSG00000275409.1	RP11-131L12.4	-5.22	3.13e-07	0.000239	-0.34	-0.27	Glucose homeostasis traits;	chr12:118330808	chr12:118430147~118430699:+
STAD	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-5.22	3.13e-07	0.000239	-0.34	-0.27	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-5.22	3.13e-07	0.000239	-0.34	-0.27	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
STAD	cis	rs8098244	0.537	rs7236794	ENSG00000267301.1	RPL23AP77	-5.22	3.13e-07	0.000239	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23697706	chr18:23709825~23710287:-
STAD	cis	rs6452524	0.836	rs10041617	ENSG00000243385.2	CTD-2110K23.1	5.22	3.13e-07	0.000239	0.28	0.27	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83201229~83202141:+
STAD	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-5.22	3.14e-07	0.00024	-0.42	-0.27	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
STAD	cis	rs728616	0.614	rs55768100	ENSG00000225484.5	NUTM2B-AS1	-5.22	3.14e-07	0.00024	-0.43	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79663088~79826594:-
STAD	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	5.22	3.14e-07	0.00024	0.38	0.27	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	5.22	3.14e-07	0.00024	0.38	0.27	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	5.22	3.14e-07	0.00024	0.38	0.27	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
STAD	cis	rs801193	0.569	rs11772819	ENSG00000236529.1	RP13-254B10.1	5.22	3.14e-07	0.00024	0.28	0.27	Aortic root size;	chr7:66752983	chr7:65840212~65840596:+
STAD	cis	rs2404602	0.669	rs9788684	ENSG00000259422.1	RP11-593F23.1	5.22	3.14e-07	0.00024	0.28	0.27	Blood metabolite levels;	chr15:76902497	chr15:76174891~76181486:-
STAD	cis	rs4604732	0.588	rs4925552	ENSG00000227135.1	GCSAML-AS1	-5.22	3.15e-07	0.00024	-0.37	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468447	chr1:247524679~247526752:-
STAD	cis	rs238295	0.766	rs6085197	ENSG00000230563.2	RP5-828H9.1	5.22	3.15e-07	0.00024	0.31	0.27	Occipital cortical area (total cortical area interaction);	chr20:5530364	chr20:5471207~5475182:+
STAD	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-5.22	3.15e-07	0.00024	-0.42	-0.27	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
STAD	cis	rs1799949	0.965	rs8176310	ENSG00000236383.6	LINC00854	-5.22	3.15e-07	0.000241	-0.21	-0.27	Menopause (age at onset);	chr17:43047896	chr17:43216941~43305976:-
STAD	cis	rs2404602	0.692	rs12910382	ENSG00000259422.1	RP11-593F23.1	5.22	3.15e-07	0.000241	0.28	0.27	Blood metabolite levels;	chr15:76761101	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs12911902	ENSG00000259422.1	RP11-593F23.1	5.22	3.15e-07	0.000241	0.28	0.27	Blood metabolite levels;	chr15:76761234	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs4383105	ENSG00000259422.1	RP11-593F23.1	5.22	3.15e-07	0.000241	0.28	0.27	Blood metabolite levels;	chr15:76763169	chr15:76174891~76181486:-
STAD	cis	rs10504130	0.569	rs34004633	ENSG00000272024.1	RP11-546K22.3	-5.22	3.15e-07	0.000241	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51950284~51950690:+
STAD	cis	rs62432291	0.681	rs423533	ENSG00000235086.1	FNDC1-IT1	-5.22	3.16e-07	0.000241	-0.42	-0.27	Joint mobility (Beighton score);	chr6:159243484	chr6:159240786~159243329:+
STAD	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-5.22	3.16e-07	0.000241	-0.23	-0.27	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
STAD	cis	rs1426063	0.858	rs7666182	ENSG00000249717.1	RP11-44F21.3	5.22	3.16e-07	0.000241	0.46	0.27	QT interval;	chr4:75090989	chr4:74955974~74970362:-
STAD	cis	rs11169552	0.882	rs1344958	ENSG00000200183.1	RNU6-238P	-5.22	3.16e-07	0.000241	-0.27	-0.27	Colorectal cancer;	chr12:50803934	chr12:50656973~50657078:+
STAD	cis	rs875971	0.502	rs11769702	ENSG00000224316.1	RP11-479O9.2	5.22	3.16e-07	0.000241	0.31	0.27	Aortic root size;	chr7:66255529	chr7:65773620~65802067:+
STAD	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	5.22	3.16e-07	0.000241	0.3	0.27	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
STAD	cis	rs1799949	0.965	rs8071278	ENSG00000236383.6	LINC00854	-5.21	3.17e-07	0.000242	-0.22	-0.27	Menopause (age at onset);	chr17:43041893	chr17:43216941~43305976:-
STAD	cis	rs58873874	0.737	rs11466807	ENSG00000251405.2	CTB-109A12.1	5.21	3.17e-07	0.000242	0.49	0.27	Bipolar disorder (body mass index interaction);	chr5:157487920	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.737	rs77273565	ENSG00000251405.2	CTB-109A12.1	5.21	3.17e-07	0.000242	0.49	0.27	Bipolar disorder (body mass index interaction);	chr5:157489547	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.737	rs111759027	ENSG00000251405.2	CTB-109A12.1	5.21	3.17e-07	0.000242	0.49	0.27	Bipolar disorder (body mass index interaction);	chr5:157489628	chr5:157362615~157460078:-
STAD	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	5.21	3.18e-07	0.000242	0.44	0.27	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
STAD	cis	rs1799949	0.965	rs34633610	ENSG00000236383.6	LINC00854	-5.21	3.18e-07	0.000242	-0.22	-0.27	Menopause (age at onset);	chr17:43342017	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs11654051	ENSG00000236383.6	LINC00854	-5.21	3.18e-07	0.000242	-0.22	-0.27	Menopause (age at onset);	chr17:43342288	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.93	rs56729776	ENSG00000236383.6	LINC00854	-5.21	3.18e-07	0.000242	-0.22	-0.27	Menopause (age at onset);	chr17:43344763	chr17:43216941~43305976:-
STAD	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-5.21	3.18e-07	0.000242	-0.29	-0.27	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-5.21	3.18e-07	0.000242	-0.29	-0.27	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-5.21	3.18e-07	0.000242	-0.29	-0.27	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
STAD	cis	rs516805	0.706	rs9490431	ENSG00000279453.1	RP3-425C14.4	5.21	3.18e-07	0.000243	0.38	0.27	Lymphocyte counts;	chr6:122361132	chr6:122436789~122439223:-
STAD	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-5.21	3.18e-07	0.000243	-0.25	-0.27	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
STAD	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-5.21	3.18e-07	0.000243	-0.33	-0.27	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
STAD	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	5.21	3.18e-07	0.000243	0.36	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
STAD	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	5.21	3.18e-07	0.000243	0.36	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
STAD	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	5.21	3.18e-07	0.000243	0.36	0.27	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
STAD	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-5.21	3.18e-07	0.000243	-0.34	-0.27	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
STAD	cis	rs2006771	0.846	rs6518754	ENSG00000236132.1	CTA-440B3.1	-5.21	3.19e-07	0.000243	-0.27	-0.27	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:31816379~31817491:-
STAD	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	5.21	3.19e-07	0.000243	0.41	0.27	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
STAD	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-5.21	3.19e-07	0.000243	-0.42	-0.27	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
STAD	cis	rs7927771	0.832	rs10838697	ENSG00000280615.1	Y_RNA	-5.21	3.19e-07	0.000243	-0.27	-0.27	Subjective well-being;	chr11:47362933	chr11:47614898~47614994:-
STAD	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-5.21	3.19e-07	0.000243	-0.28	-0.27	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-5.21	3.19e-07	0.000243	-0.28	-0.27	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
STAD	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	5.21	3.2e-07	0.000244	0.28	0.27	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
STAD	cis	rs1799949	1	rs4340367	ENSG00000236383.6	LINC00854	-5.21	3.2e-07	0.000244	-0.22	-0.27	Menopause (age at onset);	chr17:43155755	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs4792981	ENSG00000236383.6	LINC00854	-5.21	3.2e-07	0.000244	-0.22	-0.27	Menopause (age at onset);	chr17:43156257	chr17:43216941~43305976:-
STAD	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	5.21	3.2e-07	0.000244	0.32	0.27	Depression;	chr6:28104824	chr6:28073316~28074233:+
STAD	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-5.21	3.21e-07	0.000245	-0.23	-0.27	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
STAD	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	5.21	3.21e-07	0.000245	0.28	0.27	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
STAD	cis	rs7829975	0.502	rs7820738	ENSG00000254340.1	RP11-10A14.3	-5.21	3.22e-07	0.000245	-0.31	-0.27	Mood instability;	chr8:8845097	chr8:9141424~9145435:+
STAD	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-5.21	3.22e-07	0.000245	-0.28	-0.27	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
STAD	cis	rs12744310	0.887	rs72667610	ENSG00000235358.1	RP11-399E6.1	5.21	3.22e-07	0.000245	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329138	chr1:41242373~41284861:+
STAD	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	5.21	3.22e-07	0.000245	0.48	0.27	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
STAD	cis	rs227275	0.556	rs4699044	ENSG00000230069.3	LRRC37A15P	-5.21	3.23e-07	0.000246	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102727274~102730721:-
STAD	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-5.21	3.23e-07	0.000246	-0.29	-0.27	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
STAD	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-5.21	3.23e-07	0.000246	-0.35	-0.27	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
STAD	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-5.21	3.23e-07	0.000246	-0.35	-0.27	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
STAD	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	5.21	3.23e-07	0.000246	0.29	0.27	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
STAD	cis	rs516805	0.748	rs6912610	ENSG00000279453.1	RP3-425C14.4	5.21	3.23e-07	0.000246	0.36	0.27	Lymphocyte counts;	chr6:122379961	chr6:122436789~122439223:-
STAD	cis	rs12744310	1	rs56409354	ENSG00000235358.1	RP11-399E6.1	5.21	3.24e-07	0.000247	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307299	chr1:41242373~41284861:+
STAD	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	5.21	3.24e-07	0.000247	0.3	0.27	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
STAD	cis	rs1056107	0.931	rs7019056	ENSG00000225513.1	RP11-165N19.2	-5.21	3.25e-07	0.000247	-0.31	-0.27	Colorectal cancer;	chr9:112248160	chr9:112173522~112173971:-
STAD	cis	rs7487075	0.893	rs1471223	ENSG00000272369.1	RP11-446N19.1	-5.21	3.25e-07	0.000247	-0.32	-0.27	Itch intensity from mosquito bite;	chr12:46333987	chr12:46537502~46652550:+
STAD	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	5.21	3.25e-07	0.000248	0.29	0.27	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
STAD	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-5.21	3.25e-07	0.000248	-0.35	-0.27	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
STAD	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-5.21	3.26e-07	0.000248	-0.27	-0.27	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
STAD	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-5.21	3.26e-07	0.000248	-0.35	-0.27	Height;	chr20:49235382	chr20:49280319~49280409:+
STAD	cis	rs62432291	0.681	rs3003173	ENSG00000235086.1	FNDC1-IT1	-5.21	3.26e-07	0.000248	-0.42	-0.27	Joint mobility (Beighton score);	chr6:159244660	chr6:159240786~159243329:+
STAD	cis	rs4308124	0.708	rs2137168	ENSG00000230499.1	AC108463.1	-5.21	3.26e-07	0.000248	-0.39	-0.27	Vitiligo;	chr2:111228932	chr2:111195963~111206494:+
STAD	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-5.21	3.26e-07	0.000248	-0.26	-0.27	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
STAD	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-5.21	3.26e-07	0.000248	-0.26	-0.27	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
STAD	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-5.21	3.26e-07	0.000248	-0.35	-0.27	Height;	chr20:49227804	chr20:49280319~49280409:+
STAD	cis	rs453301	0.657	rs36056437	ENSG00000254340.1	RP11-10A14.3	-5.21	3.27e-07	0.000249	-0.35	-0.27	Joint mobility (Beighton score);	chr8:8935355	chr8:9141424~9145435:+
STAD	cis	rs516805	0.748	rs12211888	ENSG00000279453.1	RP3-425C14.4	5.21	3.27e-07	0.000249	0.36	0.27	Lymphocyte counts;	chr6:122384621	chr6:122436789~122439223:-
STAD	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-5.21	3.27e-07	0.000249	-0.28	-0.27	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
STAD	cis	rs992157	0.767	rs2382822	ENSG00000237281.1	CATIP-AS2	5.21	3.27e-07	0.000249	0.28	0.27	Colorectal cancer;	chr2:218308604	chr2:218326889~218357966:-
STAD	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-5.21	3.28e-07	0.000249	-0.29	-0.27	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
STAD	cis	rs3806843	0.966	rs10053945	ENSG00000202111.1	VTRNA1-2	-5.21	3.28e-07	0.000249	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140780542	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs1548700	ENSG00000202111.1	VTRNA1-2	-5.21	3.28e-07	0.000249	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140785304	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs1548699	ENSG00000202111.1	VTRNA1-2	-5.21	3.28e-07	0.000249	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140785333	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs12055222	ENSG00000202111.1	VTRNA1-2	-5.21	3.28e-07	0.000249	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140785983	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs6898939	ENSG00000202111.1	VTRNA1-2	-5.21	3.28e-07	0.000249	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140789770	chr5:140718925~140719013:+
STAD	cis	rs748404	0.666	rs12906481	ENSG00000249839.1	AC011330.5	-5.21	3.28e-07	0.000249	-0.46	-0.27	Lung cancer;	chr15:43467356	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs35958032	ENSG00000249839.1	AC011330.5	-5.21	3.28e-07	0.000249	-0.46	-0.27	Lung cancer;	chr15:43494397	chr15:43663654~43684339:-
STAD	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	5.21	3.28e-07	0.000249	0.31	0.27	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
STAD	cis	rs7615952	0.673	rs115942855	ENSG00000272840.1	RP11-379B18.6	5.21	3.28e-07	0.000249	0.58	0.27	Blood pressure (smoking interaction);	chr3:125883117	chr3:125774714~125797953:+
STAD	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	5.21	3.28e-07	0.00025	0.26	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
STAD	cis	rs875971	0.861	rs801215	ENSG00000236529.1	RP13-254B10.1	-5.21	3.29e-07	0.00025	-0.28	-0.27	Aortic root size;	chr7:66546951	chr7:65840212~65840596:+
STAD	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	5.21	3.29e-07	0.00025	0.31	0.27	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
STAD	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-5.21	3.29e-07	0.00025	-0.36	-0.27	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
STAD	cis	rs6584283	0.846	rs10883370	ENSG00000228778.1	RP11-129J12.1	-5.21	3.29e-07	0.00025	-0.31	-0.27	Ulcerative colitis;	chr10:99531715	chr10:99527081~99528261:+
STAD	cis	rs7927771	0.524	rs12286721	ENSG00000280615.1	Y_RNA	-5.21	3.29e-07	0.00025	-0.27	-0.27	Subjective well-being;	chr11:47679976	chr11:47614898~47614994:-
STAD	cis	rs10504130	0.569	rs4534123	ENSG00000272024.1	RP11-546K22.3	5.21	3.29e-07	0.00025	0.38	0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51765297	chr8:51950284~51950690:+
STAD	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	5.21	3.29e-07	0.00025	0.38	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
STAD	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	5.21	3.3e-07	0.000251	0.36	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
STAD	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	5.21	3.3e-07	0.000251	0.39	0.27	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
STAD	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-5.21	3.3e-07	0.000251	-0.28	-0.27	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
STAD	cis	rs3806843	0.966	rs2240693	ENSG00000202111.1	VTRNA1-2	-5.21	3.3e-07	0.000251	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140803740	chr5:140718925~140719013:+
STAD	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-5.21	3.3e-07	0.000251	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
STAD	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-5.21	3.3e-07	0.000251	-0.42	-0.27	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
STAD	cis	rs8098244	0.706	rs6508004	ENSG00000267301.1	RPL23AP77	-5.21	3.3e-07	0.000251	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23884153	chr18:23709825~23710287:-
STAD	cis	rs1056107	0.898	rs7021564	ENSG00000225513.1	RP11-165N19.2	-5.21	3.3e-07	0.000251	-0.31	-0.27	Colorectal cancer;	chr9:112240034	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.897	rs1887518	ENSG00000225513.1	RP11-165N19.2	5.21	3.3e-07	0.000251	0.31	0.27	Colorectal cancer;	chr9:112195177	chr9:112173522~112173971:-
STAD	cis	rs516805	0.706	rs9490430	ENSG00000279453.1	RP3-425C14.4	5.21	3.31e-07	0.000251	0.38	0.27	Lymphocyte counts;	chr6:122360951	chr6:122436789~122439223:-
STAD	cis	rs7078219	0.543	rs7096296	ENSG00000228778.1	RP11-129J12.1	5.21	3.31e-07	0.000251	0.32	0.27	Dental caries;	chr10:99518059	chr10:99527081~99528261:+
STAD	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.21	3.31e-07	0.000252	0.3	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
STAD	cis	rs8100891	0.665	rs7259259	ENSG00000267213.4	AC007773.2	-5.21	3.31e-07	0.000252	-0.32	-0.27	Neuroticism;	chr19:32328935	chr19:32390050~32405560:-
STAD	cis	rs1029738	0.659	rs1608553	ENSG00000228649.7	AC005682.5	5.21	3.32e-07	0.000252	0.32	0.27	Fibrinogen levels;	chr7:22856612	chr7:22854178~22861579:+
STAD	cis	rs1056107	0.931	rs10817304	ENSG00000225513.1	RP11-165N19.2	-5.21	3.32e-07	0.000252	-0.31	-0.27	Colorectal cancer;	chr9:112259006	chr9:112173522~112173971:-
STAD	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	5.21	3.32e-07	0.000252	0.4	0.27	Height;	chr6:109708527	chr6:109382795~109383666:+
STAD	cis	rs6452524	0.618	rs7722924	ENSG00000243385.2	CTD-2110K23.1	5.21	3.32e-07	0.000252	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83201229~83202141:+
STAD	cis	rs10849893	0.595	rs10444490	ENSG00000258435.1	RP11-711D18.2	-5.21	3.32e-07	0.000252	-0.29	-0.27	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121438582	chr12:121391962~121399859:+
STAD	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-5.21	3.32e-07	0.000252	-0.32	-0.27	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-5.21	3.32e-07	0.000252	-0.32	-0.27	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-5.21	3.32e-07	0.000252	-0.32	-0.27	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
STAD	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-5.21	3.32e-07	0.000252	-0.25	-0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
STAD	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	5.21	3.32e-07	0.000252	0.29	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
STAD	cis	rs858239	0.539	rs10279194	ENSG00000226816.2	AC005082.12	5.21	3.32e-07	0.000252	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs3950345	ENSG00000226816.2	AC005082.12	5.21	3.32e-07	0.000252	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23206013~23208045:+
STAD	cis	rs1729407	0.933	rs1729405	ENSG00000280143.1	AP000892.6	5.21	3.32e-07	0.000253	0.2	0.27	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117204967~117210292:+
STAD	cis	rs7487075	0.797	rs10880959	ENSG00000272369.1	RP11-446N19.1	5.21	3.32e-07	0.000253	0.35	0.27	Itch intensity from mosquito bite;	chr12:46367344	chr12:46537502~46652550:+
STAD	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-5.21	3.32e-07	0.000253	-0.35	-0.27	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
STAD	cis	rs7580658	0.534	rs2089109	ENSG00000200250.1	RNU6-1147P	5.21	3.33e-07	0.000253	0.26	0.27	Protein C levels;	chr2:127193882	chr2:127316873~127316979:+
STAD	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-5.21	3.33e-07	0.000253	-0.28	-0.27	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
STAD	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-5.21	3.33e-07	0.000253	-0.28	-0.27	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
STAD	cis	rs172166	0.543	rs1150691	ENSG00000220721.1	OR1F12	5.21	3.33e-07	0.000253	0.27	0.27	Cardiac Troponin-T levels;	chr6:28200255	chr6:28073316~28074233:+
STAD	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	5.2	3.33e-07	0.000253	0.3	0.27	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	5.2	3.33e-07	0.000253	0.3	0.27	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	5.2	3.33e-07	0.000253	0.3	0.27	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
STAD	cis	rs875971	0.545	rs73378304	ENSG00000224316.1	RP11-479O9.2	5.2	3.33e-07	0.000253	0.29	0.27	Aortic root size;	chr7:66175760	chr7:65773620~65802067:+
STAD	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-5.2	3.34e-07	0.000253	-0.3	-0.27	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
STAD	cis	rs1816752	0.633	rs9578729	ENSG00000273628.1	RP11-756A22.7	5.2	3.34e-07	0.000253	0.33	0.27	Obesity-related traits;	chr13:24425106	chr13:24933006~24936796:+
STAD	cis	rs3758911	0.894	rs11212166	ENSG00000261098.1	RP11-819C21.1	-5.2	3.34e-07	0.000254	-0.25	-0.27	Coronary artery disease;	chr11:107331878	chr11:107312132~107316271:-
STAD	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-5.2	3.34e-07	0.000254	-0.35	-0.27	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
STAD	cis	rs7487075	0.619	rs2220727	ENSG00000257261.4	RP11-96H19.1	5.2	3.34e-07	0.000254	0.33	0.27	Itch intensity from mosquito bite;	chr12:46411286	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs6582645	ENSG00000257261.4	RP11-96H19.1	5.2	3.34e-07	0.000254	0.33	0.27	Itch intensity from mosquito bite;	chr12:46411361	chr12:46383679~46876159:+
STAD	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-5.2	3.34e-07	0.000254	-0.39	-0.27	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
STAD	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-5.2	3.34e-07	0.000254	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-5.2	3.34e-07	0.000254	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
STAD	cis	rs7927771	0.542	rs6485775	ENSG00000280615.1	Y_RNA	-5.2	3.34e-07	0.000254	-0.27	-0.27	Subjective well-being;	chr11:47751966	chr11:47614898~47614994:-
STAD	cis	rs7487075	0.554	rs7967629	ENSG00000272369.1	RP11-446N19.1	5.2	3.35e-07	0.000254	0.33	0.27	Itch intensity from mosquito bite;	chr12:46234824	chr12:46537502~46652550:+
STAD	cis	rs6452524	0.618	rs10051445	ENSG00000243385.2	CTD-2110K23.1	5.2	3.35e-07	0.000254	0.3	0.27	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83201229~83202141:+
STAD	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	5.2	3.35e-07	0.000254	0.41	0.27	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
STAD	cis	rs875971	0.862	rs1968126	ENSG00000236529.1	RP13-254B10.1	-5.2	3.35e-07	0.000254	-0.28	-0.27	Aortic root size;	chr7:66592017	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6460306	ENSG00000236529.1	RP13-254B10.1	-5.2	3.35e-07	0.000254	-0.28	-0.27	Aortic root size;	chr7:66595806	chr7:65840212~65840596:+
STAD	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	5.2	3.35e-07	0.000254	0.32	0.27	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
STAD	cis	rs3806843	0.966	rs11958868	ENSG00000202111.1	VTRNA1-2	-5.2	3.35e-07	0.000254	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140821835	chr5:140718925~140719013:+
STAD	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	5.2	3.35e-07	0.000254	0.48	0.27	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
STAD	cis	rs4713118	0.868	rs35069907	ENSG00000280107.1	AL022393.9	-5.2	3.35e-07	0.000254	-0.39	-0.27	Parkinson's disease;	chr6:27778913	chr6:28170845~28172521:+
STAD	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-5.2	3.36e-07	0.000255	-0.3	-0.27	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-5.2	3.36e-07	0.000255	-0.3	-0.27	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-5.2	3.36e-07	0.000255	-0.3	-0.27	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
STAD	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	5.2	3.36e-07	0.000255	0.34	0.27	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
STAD	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	5.2	3.36e-07	0.000255	0.39	0.27	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
STAD	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-5.2	3.36e-07	0.000255	-0.27	-0.27	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
STAD	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-5.2	3.37e-07	0.000255	-0.27	-0.27	Breast cancer;	chr11:825777	chr11:781645~782105:+
STAD	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-5.2	3.37e-07	0.000255	-0.22	-0.27	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
STAD	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-5.2	3.37e-07	0.000255	-0.22	-0.27	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
STAD	cis	rs516805	0.64	rs55768410	ENSG00000279453.1	RP3-425C14.4	5.2	3.37e-07	0.000255	0.38	0.27	Lymphocyte counts;	chr6:122358588	chr6:122436789~122439223:-
STAD	cis	rs516805	0.667	rs928011	ENSG00000279453.1	RP3-425C14.4	5.2	3.37e-07	0.000255	0.36	0.27	Lymphocyte counts;	chr6:122248991	chr6:122436789~122439223:-
STAD	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-5.2	3.37e-07	0.000255	-0.31	-0.27	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
STAD	cis	rs1799949	1	rs9646417	ENSG00000236383.6	LINC00854	-5.2	3.37e-07	0.000255	-0.22	-0.27	Menopause (age at onset);	chr17:43346885	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs1545764	ENSG00000236383.6	LINC00854	-5.2	3.37e-07	0.000255	-0.22	-0.27	Menopause (age at onset);	chr17:43347197	chr17:43216941~43305976:-
STAD	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	5.2	3.37e-07	0.000256	0.34	0.27	Height;	chr6:109422189	chr6:109382795~109383666:+
STAD	cis	rs1799949	0.965	rs12950779	ENSG00000236383.6	LINC00854	-5.2	3.37e-07	0.000256	-0.22	-0.27	Menopause (age at onset);	chr17:43154506	chr17:43216941~43305976:-
STAD	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	5.2	3.37e-07	0.000256	0.3	0.27	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
STAD	cis	rs3758911	0.894	rs7358308	ENSG00000261098.1	RP11-819C21.1	-5.2	3.37e-07	0.000256	-0.25	-0.27	Coronary artery disease;	chr11:107333178	chr11:107312132~107316271:-
STAD	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	5.2	3.37e-07	0.000256	0.34	0.27	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
STAD	cis	rs11098499	0.731	rs6846966	ENSG00000260091.1	RP11-33B1.4	5.2	3.38e-07	0.000256	0.26	0.27	Corneal astigmatism;	chr4:119372053	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.866	rs6847778	ENSG00000260091.1	RP11-33B1.4	5.2	3.38e-07	0.000256	0.26	0.27	Corneal astigmatism;	chr4:119372427	chr4:119409333~119410233:+
STAD	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-5.2	3.38e-07	0.000256	-0.41	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
STAD	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	5.2	3.38e-07	0.000256	0.27	0.27	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
STAD	cis	rs2143950	0.621	rs17103226	ENSG00000241052.1	RP11-173D9.1	-5.2	3.38e-07	0.000256	-0.36	-0.27	Atopic dermatitis;	chr14:35353633	chr14:35144021~35144480:-
STAD	cis	rs516805	0.667	rs7771090	ENSG00000279453.1	RP3-425C14.4	-5.2	3.38e-07	0.000256	-0.35	-0.27	Lymphocyte counts;	chr6:122339732	chr6:122436789~122439223:-
STAD	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	5.2	3.38e-07	0.000256	0.34	0.27	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
STAD	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-5.2	3.39e-07	0.000257	-0.31	-0.27	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
STAD	cis	rs1816752	0.935	rs3816219	ENSG00000273628.1	RP11-756A22.7	5.2	3.39e-07	0.000257	0.34	0.27	Obesity-related traits;	chr13:24442995	chr13:24933006~24936796:+
STAD	cis	rs1816752	1	rs7988810	ENSG00000273628.1	RP11-756A22.7	5.2	3.39e-07	0.000257	0.34	0.27	Obesity-related traits;	chr13:24444958	chr13:24933006~24936796:+
STAD	cis	rs4308124	0.708	rs28766030	ENSG00000230499.1	AC108463.1	-5.2	3.39e-07	0.000257	-0.38	-0.27	Vitiligo;	chr2:111204852	chr2:111195963~111206494:+
STAD	cis	rs9921338	0.54	rs2868409	ENSG00000263080.1	RP11-485G7.5	5.2	3.4e-07	0.000258	0.31	0.27	Vein graft stenosis in coronary artery bypass grafting;	chr16:11323512	chr16:11341809~11345211:-
STAD	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-5.2	3.4e-07	0.000258	-0.23	-0.27	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
STAD	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-5.2	3.4e-07	0.000258	-0.26	-0.27	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-5.2	3.4e-07	0.000258	-0.26	-0.27	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
STAD	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	5.2	3.4e-07	0.000258	0.3	0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
STAD	cis	rs11722779	0.903	rs6830193	ENSG00000230069.3	LRRC37A15P	-5.2	3.41e-07	0.000258	-0.29	-0.27	Schizophrenia;	chr4:102955457	chr4:102727274~102730721:-
STAD	cis	rs8098244	0.597	rs883083	ENSG00000267301.1	RPL23AP77	-5.2	3.41e-07	0.000258	-0.31	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23856448	chr18:23709825~23710287:-
STAD	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-5.2	3.41e-07	0.000258	-0.24	-0.27	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
STAD	cis	rs748404	0.666	rs7183708	ENSG00000249839.1	AC011330.5	-5.2	3.41e-07	0.000258	-0.46	-0.27	Lung cancer;	chr15:43355226	chr15:43663654~43684339:-
STAD	cis	rs11722779	0.844	rs10003326	ENSG00000230069.3	LRRC37A15P	-5.2	3.41e-07	0.000258	-0.29	-0.27	Schizophrenia;	chr4:102948193	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.787	rs6533040	ENSG00000230069.3	LRRC37A15P	-5.2	3.41e-07	0.000258	-0.29	-0.27	Schizophrenia;	chr4:102951421	chr4:102727274~102730721:-
STAD	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-5.2	3.42e-07	0.000259	-0.36	-0.27	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
STAD	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-5.2	3.42e-07	0.000259	-0.41	-0.27	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
STAD	cis	rs10978777	0.921	rs817841	ENSG00000276883.1	AL137852.1	5.2	3.42e-07	0.000259	0.27	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107337971	chr9:107292369~107292456:-
STAD	cis	rs10504130	0.569	rs12679983	ENSG00000272024.1	RP11-546K22.3	-5.2	3.42e-07	0.000259	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs12680128	ENSG00000272024.1	RP11-546K22.3	-5.2	3.42e-07	0.000259	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51950284~51950690:+
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000224205.1	AP000351.4	5.2	3.42e-07	0.000259	0.3	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23987320~23991421:-
STAD	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-5.2	3.42e-07	0.000259	-0.34	-0.27	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
STAD	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	5.2	3.42e-07	0.000259	0.35	0.27	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
STAD	cis	rs12744310	0.887	rs35021924	ENSG00000235358.1	RP11-399E6.1	5.2	3.42e-07	0.000259	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321235	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs35592291	ENSG00000235358.1	RP11-399E6.1	5.2	3.42e-07	0.000259	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41325599	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs2363811	ENSG00000235358.1	RP11-399E6.1	5.2	3.42e-07	0.000259	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326193	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12026778	ENSG00000235358.1	RP11-399E6.1	5.2	3.42e-07	0.000259	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326602	chr1:41242373~41284861:+
STAD	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	5.2	3.43e-07	0.000259	0.4	0.27	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
STAD	cis	rs3758911	0.828	rs10890684	ENSG00000261098.1	RP11-819C21.1	-5.2	3.43e-07	0.00026	-0.25	-0.27	Coronary artery disease;	chr11:107266325	chr11:107312132~107316271:-
STAD	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	5.2	3.43e-07	0.00026	0.41	0.27	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
STAD	cis	rs295490	0.688	rs184157	ENSG00000272656.1	RP11-219D15.3	5.2	3.44e-07	0.00026	0.44	0.27	PR interval in Tripanosoma cruzi seropositivity;	chr3:139523324	chr3:139349024~139349371:-
STAD	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-5.2	3.44e-07	0.00026	-0.45	-0.27	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
STAD	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-5.2	3.44e-07	0.00026	-0.45	-0.27	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
STAD	cis	rs8098244	0.617	rs12969104	ENSG00000267301.1	RPL23AP77	-5.2	3.44e-07	0.00026	-0.31	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23832275	chr18:23709825~23710287:-
STAD	cis	rs6142102	0.961	rs6088360	ENSG00000275784.1	RP5-1125A11.6	-5.2	3.45e-07	0.000261	-0.28	-0.27	Skin pigmentation;	chr20:33969383	chr20:33989480~33991818:-
STAD	cis	rs3758911	0.861	rs10890688	ENSG00000261098.1	RP11-819C21.1	-5.2	3.45e-07	0.000261	-0.25	-0.27	Coronary artery disease;	chr11:107272020	chr11:107312132~107316271:-
STAD	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-5.2	3.45e-07	0.000261	-0.37	-0.27	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
STAD	cis	rs9859260	0.744	rs3933	ENSG00000207650.1	MIR570	-5.2	3.45e-07	0.000261	-0.26	-0.27	Mean corpuscular volume;	chr3:196058126	chr3:195699401~195699497:+
STAD	cis	rs2439831	0.85	rs3097773	ENSG00000275601.1	AC011330.13	5.2	3.46e-07	0.000261	0.34	0.27	Lung cancer in ever smokers;	chr15:43600874	chr15:43642389~43643023:-
STAD	cis	rs6452524	0.618	rs6867727	ENSG00000243385.2	CTD-2110K23.1	5.2	3.46e-07	0.000261	0.29	0.27	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83201229~83202141:+
STAD	cis	rs2404602	0.692	rs34181263	ENSG00000259422.1	RP11-593F23.1	5.2	3.46e-07	0.000261	0.28	0.27	Blood metabolite levels;	chr15:76773047	chr15:76174891~76181486:-
STAD	cis	rs3758911	0.964	rs10789607	ENSG00000261098.1	RP11-819C21.1	-5.2	3.46e-07	0.000261	-0.24	-0.27	Coronary artery disease;	chr11:107314128	chr11:107312132~107316271:-
STAD	cis	rs11722779	0.935	rs6533046	ENSG00000230069.3	LRRC37A15P	-5.2	3.46e-07	0.000261	-0.29	-0.27	Schizophrenia;	chr4:102965917	chr4:102727274~102730721:-
STAD	cis	rs6951245	0.554	rs2070118	ENSG00000229043.2	AC091729.9	-5.2	3.46e-07	0.000261	-0.37	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092869	chr7:1160374~1165267:+
STAD	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	5.2	3.46e-07	0.000262	0.3	0.27	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-5.2	3.47e-07	0.000262	-0.29	-0.27	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
STAD	cis	rs7487075	0.897	rs2897968	ENSG00000272369.1	RP11-446N19.1	5.2	3.47e-07	0.000262	0.35	0.27	Itch intensity from mosquito bite;	chr12:46369903	chr12:46537502~46652550:+
STAD	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-5.2	3.47e-07	0.000262	-0.22	-0.27	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
STAD	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	5.2	3.47e-07	0.000262	0.33	0.27	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
STAD	cis	rs66887589	0.592	rs62320740	ENSG00000249244.1	RP11-548H18.2	5.2	3.47e-07	0.000262	0.33	0.27	Diastolic blood pressure;	chr4:119358331	chr4:119391831~119395335:-
STAD	cis	rs7124681	0.528	rs74608150	ENSG00000280615.1	Y_RNA	5.2	3.47e-07	0.000262	0.27	0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47674662	chr11:47614898~47614994:-
STAD	cis	rs516805	0.667	rs225080	ENSG00000279453.1	RP3-425C14.4	-5.2	3.48e-07	0.000263	-0.36	-0.27	Lymphocyte counts;	chr6:122295949	chr6:122436789~122439223:-
STAD	cis	rs2404602	0.71	rs2469541	ENSG00000196274.5	Metazoa_SRP	-5.2	3.48e-07	0.000263	-0.23	-0.27	Blood metabolite levels;	chr15:76269777	chr15:76230048~76230390:-
STAD	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	5.2	3.48e-07	0.000263	0.29	0.27	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
STAD	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	5.2	3.48e-07	0.000263	0.29	0.27	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
STAD	cis	rs516805	0.748	rs6930548	ENSG00000279453.1	RP3-425C14.4	-5.2	3.48e-07	0.000263	-0.36	-0.27	Lymphocyte counts;	chr6:122375807	chr6:122436789~122439223:-
STAD	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	5.2	3.48e-07	0.000263	0.42	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
STAD	cis	rs1056107	0.898	rs940592	ENSG00000225513.1	RP11-165N19.2	-5.2	3.48e-07	0.000263	-0.31	-0.27	Colorectal cancer;	chr9:112255785	chr9:112173522~112173971:-
STAD	cis	rs7665090	0.743	rs228626	ENSG00000246560.2	RP11-10L12.4	-5.2	3.48e-07	0.000263	-0.32	-0.27	Primary biliary cholangitis;	chr4:102651789	chr4:102828055~102844075:+
STAD	cis	rs516805	0.706	rs11752939	ENSG00000279453.1	RP3-425C14.4	5.2	3.48e-07	0.000263	0.37	0.27	Lymphocyte counts;	chr6:122350062	chr6:122436789~122439223:-
STAD	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-5.2	3.49e-07	0.000263	-0.22	-0.27	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
STAD	cis	rs62432291	0.681	rs404461	ENSG00000235086.1	FNDC1-IT1	5.2	3.49e-07	0.000263	0.4	0.27	Joint mobility (Beighton score);	chr6:159219677	chr6:159240786~159243329:+
STAD	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	5.2	3.49e-07	0.000263	0.27	0.27	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
STAD	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-5.2	3.49e-07	0.000263	-0.34	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
STAD	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	5.2	3.49e-07	0.000263	0.33	0.27	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
STAD	cis	rs11722779	0.844	rs3974602	ENSG00000230069.3	LRRC37A15P	-5.2	3.49e-07	0.000263	-0.29	-0.27	Schizophrenia;	chr4:102928840	chr4:102727274~102730721:-
STAD	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-5.2	3.49e-07	0.000264	-0.32	-0.27	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
STAD	cis	rs7829975	0.774	rs1703982	ENSG00000173295.6	FAM86B3P	-5.2	3.5e-07	0.000264	-0.3	-0.27	Mood instability;	chr8:8740878	chr8:8228595~8244865:+
STAD	cis	rs516805	0.748	rs55863504	ENSG00000279453.1	RP3-425C14.4	5.2	3.5e-07	0.000264	0.35	0.27	Lymphocyte counts;	chr6:122376339	chr6:122436789~122439223:-
STAD	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-5.2	3.5e-07	0.000264	-0.23	-0.27	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
STAD	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	5.2	3.5e-07	0.000264	0.34	0.27	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
STAD	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	5.2	3.5e-07	0.000264	0.26	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
STAD	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	5.2	3.5e-07	0.000264	0.4	0.27	Height;	chr6:109713188	chr6:109382795~109383666:+
STAD	cis	rs1799949	0.965	rs8070179	ENSG00000236383.6	LINC00854	-5.19	3.5e-07	0.000264	-0.21	-0.27	Menopause (age at onset);	chr17:43050671	chr17:43216941~43305976:-
STAD	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	5.19	3.51e-07	0.000264	0.48	0.27	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
STAD	cis	rs1075265	0.73	rs11893270	ENSG00000235937.1	AC008280.1	5.19	3.51e-07	0.000264	0.24	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54029552~54030682:-
STAD	cis	rs4308124	0.708	rs7585313	ENSG00000230499.1	AC108463.1	-5.19	3.51e-07	0.000265	-0.39	-0.27	Vitiligo;	chr2:111217626	chr2:111195963~111206494:+
STAD	cis	rs6095360	0.727	rs13044004	ENSG00000222365.1	SNORD12B	-5.19	3.51e-07	0.000265	-0.34	-0.27	Intelligence (multi-trait analysis);	chr20:49101834	chr20:49280319~49280409:+
STAD	cis	rs6142102	0.961	rs4911407	ENSG00000275784.1	RP5-1125A11.6	-5.19	3.51e-07	0.000265	-0.28	-0.27	Skin pigmentation;	chr20:34095759	chr20:33989480~33991818:-
STAD	cis	rs2833693	0.574	rs4143359	ENSG00000261610.1	AP000265.1	5.19	3.51e-07	0.000265	0.3	0.27	Temperament;	chr21:32179062	chr21:32259804~32261585:-
STAD	cis	rs4950322	0.57	rs945742	ENSG00000278811.3	LINC00624	5.19	3.52e-07	0.000265	0.28	0.27	Protein quantitative trait loci;	chr1:147313437	chr1:147258885~147517875:-
STAD	cis	rs711244	0.532	rs12104444	ENSG00000252756.1	RNU6-577P	-5.19	3.52e-07	0.000265	-0.31	-0.27	Mean platelet volume;	chr2:37026290	chr2:36867398~36867495:-
STAD	cis	rs12744310	0.887	rs12028244	ENSG00000235358.1	RP11-399E6.1	5.19	3.52e-07	0.000265	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343490	chr1:41242373~41284861:+
STAD	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	5.19	3.53e-07	0.000266	0.3	0.27	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
STAD	cis	rs858239	0.57	rs6968242	ENSG00000226816.2	AC005082.12	5.19	3.53e-07	0.000266	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs1981665	ENSG00000226816.2	AC005082.12	5.19	3.53e-07	0.000266	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23206013~23208045:+
STAD	cis	rs6142102	0.961	rs2284388	ENSG00000275784.1	RP5-1125A11.6	-5.19	3.53e-07	0.000266	-0.28	-0.27	Skin pigmentation;	chr20:34067935	chr20:33989480~33991818:-
STAD	cis	rs2948294	0.588	rs7011221	ENSG00000254340.1	RP11-10A14.3	5.19	3.54e-07	0.000266	0.33	0.27	Red cell distribution width;	chr8:8256724	chr8:9141424~9145435:+
STAD	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	5.19	3.54e-07	0.000267	0.29	0.27	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
STAD	cis	rs1153858	1	rs16942000	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.54e-07	0.000267	-0.29	-0.27	Homoarginine levels;	chr15:45340805	chr15:45330209~45332634:-
STAD	cis	rs1153858	0.945	rs7182300	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.54e-07	0.000267	-0.29	-0.27	Homoarginine levels;	chr15:45342730	chr15:45330209~45332634:-
STAD	cis	rs1153858	0.887	rs7171163	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.54e-07	0.000267	-0.29	-0.27	Homoarginine levels;	chr15:45344197	chr15:45330209~45332634:-
STAD	cis	rs5758659	0.904	rs5758653	ENSG00000182057.4	OGFRP1	5.19	3.54e-07	0.000267	0.28	0.27	Cognitive function;	chr22:42217479	chr22:42269753~42275196:+
STAD	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	5.19	3.54e-07	0.000267	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
STAD	cis	rs10510102	0.872	rs78369301	ENSG00000226864.1	ATE1-AS1	5.19	3.54e-07	0.000267	0.42	0.27	Breast cancer;	chr10:121858527	chr10:121928312~121951965:+
STAD	cis	rs2239557	0.645	rs3742810	ENSG00000259065.1	RP5-1021I20.1	5.19	3.55e-07	0.000267	0.35	0.27	Common traits (Other);	chr14:74010785	chr14:73787360~73803270:+
STAD	cis	rs9307551	0.948	rs2165386	ENSG00000250334.4	LINC00989	-5.19	3.55e-07	0.000267	-0.34	-0.27	Refractive error;	chr4:79582248	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.948	rs1440853	ENSG00000250334.4	LINC00989	-5.19	3.55e-07	0.000267	-0.34	-0.27	Refractive error;	chr4:79585493	chr4:79492416~79576460:+
STAD	cis	rs1799949	0.965	rs9897425	ENSG00000279602.1	CTD-3014M21.1	5.19	3.55e-07	0.000267	0.32	0.27	Menopause (age at onset);	chr17:43352811	chr17:43360041~43361361:-
STAD	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-5.19	3.55e-07	0.000267	-0.32	-0.27	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
STAD	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	5.19	3.55e-07	0.000267	0.45	0.27	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
STAD	cis	rs1056107	0.931	rs10759538	ENSG00000225513.1	RP11-165N19.2	-5.19	3.55e-07	0.000267	-0.3	-0.27	Colorectal cancer;	chr9:112234047	chr9:112173522~112173971:-
STAD	cis	rs4308124	0.708	rs6716091	ENSG00000230499.1	AC108463.1	-5.19	3.55e-07	0.000267	-0.39	-0.27	Vitiligo;	chr2:111233556	chr2:111195963~111206494:+
STAD	cis	rs240993	0.812	rs9387012	ENSG00000230177.1	RP5-1112D6.4	5.19	3.55e-07	0.000268	0.28	0.27	Inflammatory skin disease;Psoriasis;	chr6:111465824	chr6:111277932~111278742:+
STAD	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-5.19	3.56e-07	0.000268	-0.42	-0.27	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
STAD	cis	rs2412819	0.571	rs678084	ENSG00000249839.1	AC011330.5	5.19	3.56e-07	0.000268	0.48	0.27	Lung cancer;	chr15:43828361	chr15:43663654~43684339:-
STAD	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	5.19	3.56e-07	0.000268	0.29	0.27	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
STAD	cis	rs227275	0.556	rs4235407	ENSG00000230069.3	LRRC37A15P	-5.19	3.56e-07	0.000268	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102727274~102730721:-
STAD	cis	rs801193	0.569	rs13226966	ENSG00000236529.1	RP13-254B10.1	5.19	3.56e-07	0.000268	0.27	0.27	Aortic root size;	chr7:66768636	chr7:65840212~65840596:+
STAD	cis	rs1056107	0.897	rs7026917	ENSG00000225513.1	RP11-165N19.2	-5.19	3.56e-07	0.000268	-0.31	-0.27	Colorectal cancer;	chr9:112228592	chr9:112173522~112173971:-
STAD	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	5.19	3.57e-07	0.000269	0.28	0.27	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
STAD	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-5.19	3.57e-07	0.000269	-0.28	-0.27	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
STAD	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	5.19	3.57e-07	0.000269	0.31	0.27	Depression;	chr6:28091242	chr6:28073316~28074233:+
STAD	cis	rs3806843	1	rs2240692	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140804000	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs6579987	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140804074	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.966	rs1030163	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140805547	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs1030164	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140805687	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs1030165	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140805863	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.966	rs1030166	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140805888	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs4151680	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140807072	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs3822346	ENSG00000202111.1	VTRNA1-2	-5.19	3.57e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140807737	chr5:140718925~140719013:+
STAD	cis	rs9463078	0.605	rs3799981	ENSG00000219384.1	RP11-491H9.3	-5.19	3.57e-07	0.000269	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44914643	chr6:45158870~45159511:+
STAD	cis	rs7487075	0.619	rs10748448	ENSG00000257261.4	RP11-96H19.1	5.19	3.57e-07	0.000269	0.33	0.27	Itch intensity from mosquito bite;	chr12:46409555	chr12:46383679~46876159:+
STAD	cis	rs3806843	1	rs4404730	ENSG00000202111.1	VTRNA1-2	-5.19	3.58e-07	0.000269	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr5:140718925~140719013:+
STAD	cis	rs1153858	1	rs56669689	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.58e-07	0.000269	-0.29	-0.27	Homoarginine levels;	chr15:45345531	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs56806728	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.58e-07	0.000269	-0.29	-0.27	Homoarginine levels;	chr15:45345616	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs4775906	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.58e-07	0.000269	-0.29	-0.27	Homoarginine levels;	chr15:45346096	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs7179743	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.58e-07	0.000269	-0.29	-0.27	Homoarginine levels;	chr15:45346133	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs4775907	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.58e-07	0.000269	-0.29	-0.27	Homoarginine levels;	chr15:45346449	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs7163720	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.58e-07	0.000269	-0.29	-0.27	Homoarginine levels;	chr15:45347176	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs7167900	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.58e-07	0.000269	-0.29	-0.27	Homoarginine levels;	chr15:45347273	chr15:45330209~45332634:-
STAD	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	5.19	3.58e-07	0.000269	0.44	0.27	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
STAD	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	5.19	3.58e-07	0.000269	0.44	0.27	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
STAD	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-5.19	3.58e-07	0.000269	-0.33	-0.27	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
STAD	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	5.19	3.58e-07	0.000269	0.5	0.27	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
STAD	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-5.19	3.58e-07	0.000269	-0.23	-0.27	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
STAD	cis	rs3806843	0.966	rs2337986	ENSG00000202111.1	VTRNA1-2	-5.19	3.59e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs1548701	ENSG00000202111.1	VTRNA1-2	-5.19	3.59e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs3756342	ENSG00000202111.1	VTRNA1-2	-5.19	3.59e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.933	rs2240696	ENSG00000202111.1	VTRNA1-2	-5.19	3.59e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.966	rs6579965	ENSG00000202111.1	VTRNA1-2	-5.19	3.59e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs6898906	ENSG00000202111.1	VTRNA1-2	-5.19	3.59e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr5:140718925~140719013:+
STAD	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	5.19	3.59e-07	0.00027	0.35	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
STAD	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	5.19	3.59e-07	0.00027	0.36	0.27	Height;	chr6:109380457	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	5.19	3.59e-07	0.00027	0.4	0.27	Height;	chr6:109764163	chr6:109382795~109383666:+
STAD	cis	rs7829975	0.511	rs2921028	ENSG00000254340.1	RP11-10A14.3	5.19	3.59e-07	0.00027	0.32	0.27	Mood instability;	chr8:8482967	chr8:9141424~9145435:+
STAD	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-5.19	3.59e-07	0.00027	-0.42	-0.27	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
STAD	cis	rs7487075	0.82	rs4238102	ENSG00000272369.1	RP11-446N19.1	5.19	3.6e-07	0.00027	0.33	0.27	Itch intensity from mosquito bite;	chr12:46332713	chr12:46537502~46652550:+
STAD	cis	rs3806843	1	rs2337985	ENSG00000202111.1	VTRNA1-2	-5.19	3.6e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs10073974	ENSG00000202111.1	VTRNA1-2	-5.19	3.6e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs2240695	ENSG00000202111.1	VTRNA1-2	-5.19	3.6e-07	0.00027	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr5:140718925~140719013:+
STAD	cis	rs2921073	0.51	rs2976945	ENSG00000253981.4	ALG1L13P	5.19	3.6e-07	0.00027	0.31	0.27	Parkinson's disease;	chr8:8413361	chr8:8236003~8244667:-
STAD	cis	rs1799949	1	rs4793215	ENSG00000236383.6	LINC00854	-5.19	3.61e-07	0.000271	-0.22	-0.27	Menopause (age at onset);	chr17:43166915	chr17:43216941~43305976:-
STAD	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-5.19	3.61e-07	0.000271	-0.22	-0.27	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
STAD	cis	rs1862618	0.671	rs2591964	ENSG00000271828.1	CTD-2310F14.1	-5.19	3.61e-07	0.000271	-0.33	-0.27	Initial pursuit acceleration;	chr5:56941073	chr5:56927874~56929573:+
STAD	cis	rs1153858	1	rs12591058	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.61e-07	0.000271	-0.29	-0.27	Homoarginine levels;	chr15:45347974	chr15:45330209~45332634:-
STAD	cis	rs1153858	1	rs7169587	ENSG00000259433.2	CTD-2651B20.4	-5.19	3.61e-07	0.000271	-0.29	-0.27	Homoarginine levels;	chr15:45348181	chr15:45330209~45332634:-
STAD	cis	rs516805	0.63	rs2606641	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122103704	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2606643	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122104352	chr6:122436789~122439223:-
STAD	cis	rs516805	0.596	rs2606644	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122104734	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2816077	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122105669	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2816075	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122106110	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2816073	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122106794	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2816072	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122106871	chr6:122436789~122439223:-
STAD	cis	rs516805	0.666	rs2816071	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122106995	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs720205	ENSG00000279453.1	RP3-425C14.4	-5.19	3.62e-07	0.000272	-0.37	-0.27	Lymphocyte counts;	chr6:122107329	chr6:122436789~122439223:-
STAD	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	5.19	3.62e-07	0.000272	0.35	0.27	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
STAD	cis	rs875971	0.862	rs3893216	ENSG00000236529.1	RP13-254B10.1	-5.19	3.62e-07	0.000272	-0.27	-0.27	Aortic root size;	chr7:66325720	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6958294	ENSG00000236529.1	RP13-254B10.1	-5.19	3.62e-07	0.000272	-0.27	-0.27	Aortic root size;	chr7:66329809	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs2088655	ENSG00000236529.1	RP13-254B10.1	-5.19	3.62e-07	0.000272	-0.27	-0.27	Aortic root size;	chr7:66330724	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs10447522	ENSG00000236529.1	RP13-254B10.1	-5.19	3.62e-07	0.000272	-0.27	-0.27	Aortic root size;	chr7:66331087	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs2088653	ENSG00000236529.1	RP13-254B10.1	-5.19	3.62e-07	0.000272	-0.27	-0.27	Aortic root size;	chr7:66343621	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6460293	ENSG00000236529.1	RP13-254B10.1	-5.19	3.62e-07	0.000272	-0.27	-0.27	Aortic root size;	chr7:66345205	chr7:65840212~65840596:+
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	5.19	3.62e-07	0.000272	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
STAD	cis	rs1056107	0.931	rs7040713	ENSG00000225513.1	RP11-165N19.2	-5.19	3.62e-07	0.000272	-0.31	-0.27	Colorectal cancer;	chr9:112255041	chr9:112173522~112173971:-
STAD	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-5.19	3.63e-07	0.000272	-0.32	-0.27	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
STAD	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-5.19	3.63e-07	0.000272	-0.29	-0.27	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
STAD	cis	rs3806843	0.518	rs2569191	ENSG00000202111.1	VTRNA1-2	5.19	3.64e-07	0.000273	0.26	0.27	Depressive symptoms (multi-trait analysis);	chr5:140634318	chr5:140718925~140719013:+
STAD	cis	rs516805	0.748	rs577744	ENSG00000279453.1	RP3-425C14.4	-5.19	3.64e-07	0.000273	-0.39	-0.27	Lymphocyte counts;	chr6:122447712	chr6:122436789~122439223:-
STAD	cis	rs7829975	0.667	rs1877119	ENSG00000254340.1	RP11-10A14.3	5.19	3.65e-07	0.000274	0.3	0.27	Mood instability;	chr8:8849687	chr8:9141424~9145435:+
STAD	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	5.19	3.65e-07	0.000274	0.39	0.27	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
STAD	cis	rs9307551	1	rs6855486	ENSG00000250334.4	LINC00989	5.19	3.65e-07	0.000274	0.33	0.27	Refractive error;	chr4:79612886	chr4:79492416~79576460:+
STAD	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-5.19	3.66e-07	0.000274	-0.31	-0.27	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
STAD	cis	rs1056107	0.931	rs7863117	ENSG00000225513.1	RP11-165N19.2	-5.19	3.66e-07	0.000274	-0.31	-0.27	Colorectal cancer;	chr9:112253559	chr9:112173522~112173971:-
STAD	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	5.19	3.66e-07	0.000274	0.28	0.27	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
STAD	cis	rs11169552	0.943	rs10876096	ENSG00000200183.1	RNU6-238P	5.19	3.66e-07	0.000275	0.26	0.27	Colorectal cancer;	chr12:50810170	chr12:50656973~50657078:+
STAD	cis	rs9549367	0.713	rs3024757	ENSG00000269125.1	RP11-98F14.11	-5.19	3.66e-07	0.000275	-0.34	-0.27	Platelet distribution width;	chr13:113168872	chr13:113165002~113165183:-
STAD	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	5.19	3.66e-07	0.000275	0.29	0.27	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
STAD	cis	rs3806843	0.966	rs7710380	ENSG00000202111.1	VTRNA1-2	-5.19	3.66e-07	0.000275	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr5:140718925~140719013:+
STAD	cis	rs7665090	0.728	rs228617	ENSG00000246560.2	RP11-10L12.4	-5.19	3.66e-07	0.000275	-0.32	-0.27	Primary biliary cholangitis;	chr4:102659631	chr4:102828055~102844075:+
STAD	cis	rs1150668	0.745	rs213238	ENSG00000220721.1	OR1F12	5.19	3.66e-07	0.000275	0.26	0.27	Pubertal anthropometrics;	chr6:28354216	chr6:28073316~28074233:+
STAD	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-5.19	3.67e-07	0.000275	-0.28	-0.27	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-5.19	3.67e-07	0.000275	-0.28	-0.27	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
STAD	cis	rs3806843	1	rs10477034	ENSG00000202111.1	VTRNA1-2	-5.19	3.67e-07	0.000275	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr5:140718925~140719013:+
STAD	cis	rs7932354	0.655	rs6485690	ENSG00000271350.1	CTD-2384B9.1	-5.19	3.67e-07	0.000275	-0.31	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:46777081	chr11:47041027~47041945:-
STAD	cis	rs6142102	0.961	rs2268088	ENSG00000275784.1	RP5-1125A11.6	-5.19	3.67e-07	0.000275	-0.28	-0.27	Skin pigmentation;	chr20:34061258	chr20:33989480~33991818:-
STAD	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	5.19	3.67e-07	0.000275	0.36	0.27	Height;	chr6:109382524	chr6:109382795~109383666:+
STAD	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-5.19	3.67e-07	0.000275	-0.21	-0.27	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
STAD	cis	rs6452524	0.618	rs1871203	ENSG00000243385.2	CTD-2110K23.1	5.19	3.67e-07	0.000275	0.29	0.27	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83201229~83202141:+
STAD	cis	rs13631	1	rs13631	ENSG00000268996.3	MAN1B1-AS1	5.19	3.67e-07	0.000275	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr9:137111750	chr9:137084946~137086817:-
STAD	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	5.19	3.68e-07	0.000276	0.29	0.27	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
STAD	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-5.19	3.68e-07	0.000276	-0.29	-0.27	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
STAD	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	5.18	3.68e-07	0.000276	0.36	0.27	Height;	chr6:109380990	chr6:109382795~109383666:+
STAD	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	5.18	3.69e-07	0.000276	0.43	0.27	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
STAD	cis	rs7829975	0.509	rs2945269	ENSG00000254340.1	RP11-10A14.3	5.18	3.69e-07	0.000276	0.33	0.27	Mood instability;	chr8:8258056	chr8:9141424~9145435:+
STAD	cis	rs748404	0.666	rs12899865	ENSG00000249839.1	AC011330.5	-5.18	3.69e-07	0.000276	-0.45	-0.27	Lung cancer;	chr15:43448819	chr15:43663654~43684339:-
STAD	cis	rs1007738	0.597	rs10838635	ENSG00000271350.1	CTD-2384B9.1	-5.18	3.69e-07	0.000276	-0.34	-0.27	Bone mineral density (hip);	chr11:46923676	chr11:47041027~47041945:-
STAD	cis	rs8098244	0.617	rs12965616	ENSG00000267301.1	RPL23AP77	-5.18	3.69e-07	0.000277	-0.31	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23831262	chr18:23709825~23710287:-
STAD	cis	rs10510102	0.872	rs12259144	ENSG00000226864.1	ATE1-AS1	5.18	3.7e-07	0.000277	0.44	0.27	Breast cancer;	chr10:121965433	chr10:121928312~121951965:+
STAD	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-5.18	3.7e-07	0.000277	-0.3	-0.27	Migraine;	chr4:56956882	chr4:56960927~56961373:-
STAD	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-5.18	3.7e-07	0.000277	-0.3	-0.27	Migraine;	chr4:56957291	chr4:56960927~56961373:-
STAD	cis	rs8040855	0.627	rs12900012	ENSG00000229212.6	RP11-561C5.4	5.18	3.7e-07	0.000277	0.39	0.27	Bulimia nervosa;	chr15:85046955	chr15:85205440~85234795:-
STAD	cis	rs9859260	0.614	rs493661	ENSG00000207650.1	MIR570	-5.18	3.71e-07	0.000278	-0.26	-0.27	Mean corpuscular volume;	chr3:196059618	chr3:195699401~195699497:+
STAD	cis	rs748404	0.666	rs12906017	ENSG00000249839.1	AC011330.5	-5.18	3.71e-07	0.000278	-0.48	-0.27	Lung cancer;	chr15:43504710	chr15:43663654~43684339:-
STAD	cis	rs3806843	0.966	rs2563263	ENSG00000202111.1	VTRNA1-2	-5.18	3.72e-07	0.000278	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr5:140718925~140719013:+
STAD	cis	rs858239	0.601	rs929507	ENSG00000226816.2	AC005082.12	5.18	3.72e-07	0.000278	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs929508	ENSG00000226816.2	AC005082.12	5.18	3.72e-07	0.000278	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs4599714	ENSG00000226816.2	AC005082.12	5.18	3.72e-07	0.000278	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23206013~23208045:+
STAD	cis	rs858239	0.601	rs10278776	ENSG00000226816.2	AC005082.12	5.18	3.72e-07	0.000278	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23206013~23208045:+
STAD	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	5.18	3.72e-07	0.000278	0.33	0.27	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
STAD	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	5.18	3.72e-07	0.000279	0.3	0.27	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
STAD	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	5.18	3.72e-07	0.000279	0.35	0.27	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
STAD	cis	rs7932354	0.583	rs10838629	ENSG00000271350.1	CTD-2384B9.1	-5.18	3.73e-07	0.000279	-0.32	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:46885294	chr11:47041027~47041945:-
STAD	cis	rs240993	0.812	rs9400476	ENSG00000230177.1	RP5-1112D6.4	5.18	3.73e-07	0.000279	0.27	0.27	Inflammatory skin disease;Psoriasis;	chr6:111463172	chr6:111277932~111278742:+
STAD	cis	rs858239	0.539	rs6965833	ENSG00000226816.2	AC005082.12	5.18	3.73e-07	0.000279	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs6949363	ENSG00000226816.2	AC005082.12	5.18	3.73e-07	0.000279	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23206013~23208045:+
STAD	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-5.18	3.74e-07	0.000279	-0.25	-0.27	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
STAD	cis	rs2337406	0.714	rs7150993	ENSG00000280411.1	IGHV1-69-2	-5.18	3.74e-07	0.00028	-0.3	-0.27	Alzheimer's disease (late onset);	chr14:106818515	chr14:106762092~106762588:-
STAD	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	5.18	3.74e-07	0.00028	0.28	0.27	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	5.18	3.74e-07	0.00028	0.28	0.27	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	5.18	3.74e-07	0.00028	0.28	0.27	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
STAD	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	5.18	3.74e-07	0.00028	0.28	0.27	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
STAD	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-5.18	3.74e-07	0.00028	-0.37	-0.27	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
STAD	cis	rs11148252	0.595	rs4884522	ENSG00000235660.1	LINC00345	-5.18	3.74e-07	0.00028	-0.3	-0.27	Lewy body disease;	chr13:52479633	chr13:52484161~52484680:-
STAD	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-5.18	3.74e-07	0.00028	-0.33	-0.27	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
STAD	cis	rs950169	0.922	rs62029585	ENSG00000259295.5	CSPG4P12	5.18	3.75e-07	0.00028	0.41	0.27	Schizophrenia;	chr15:84397176	chr15:85191438~85213905:+
STAD	cis	rs7487075	0.78	rs12320197	ENSG00000257261.4	RP11-96H19.1	5.18	3.75e-07	0.00028	0.31	0.27	Itch intensity from mosquito bite;	chr12:46345100	chr12:46383679~46876159:+
STAD	cis	rs728616	0.681	rs55855057	ENSG00000225484.5	NUTM2B-AS1	-5.18	3.76e-07	0.000281	-0.52	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80274973	chr10:79663088~79826594:-
STAD	cis	rs7932354	0.528	rs4752952	ENSG00000271350.1	CTD-2384B9.1	-5.18	3.76e-07	0.000281	-0.33	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:47061307	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.528	rs7946709	ENSG00000271350.1	CTD-2384B9.1	-5.18	3.76e-07	0.000281	-0.33	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:47079245	chr11:47041027~47041945:-
STAD	cis	rs13113518	1	rs13132420	ENSG00000223305.1	RN7SKP30	-5.18	3.77e-07	0.000281	-0.29	-0.27	Height;	chr4:55526646	chr4:55540502~55540835:-
STAD	cis	rs1056107	0.931	rs6477903	ENSG00000225513.1	RP11-165N19.2	-5.18	3.77e-07	0.000281	-0.31	-0.27	Colorectal cancer;	chr9:112254581	chr9:112173522~112173971:-
STAD	cis	rs7429990	0.833	rs1486915	ENSG00000224895.1	VPS26BP1	5.18	3.77e-07	0.000282	0.26	0.27	Educational attainment (years of education);	chr3:47781053	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.828	rs6792350	ENSG00000224895.1	VPS26BP1	5.18	3.77e-07	0.000282	0.26	0.27	Educational attainment (years of education);	chr3:47797451	chr3:47960327~47961081:-
STAD	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-5.18	3.77e-07	0.000282	-0.29	-0.27	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
STAD	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	5.18	3.77e-07	0.000282	0.34	0.27	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
STAD	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-5.18	3.78e-07	0.000282	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-5.18	3.78e-07	0.000282	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-5.18	3.78e-07	0.000282	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-5.18	3.78e-07	0.000282	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-5.18	3.78e-07	0.000282	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-5.18	3.78e-07	0.000282	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
STAD	cis	rs3806843	0.966	rs3756338	ENSG00000202111.1	VTRNA1-2	-5.18	3.78e-07	0.000282	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140800976	chr5:140718925~140719013:+
STAD	cis	rs10510102	0.935	rs12244866	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121886013	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12266597	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121886062	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12245018	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121886195	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200217	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121886372	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200218	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121886410	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs10887008	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121886714	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12268872	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121887426	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs9630107	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121887713	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs10887010	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121888542	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12251175	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121889015	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11200220	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121889949	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200221	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121890134	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs10887011	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121890203	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs10887012	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121890454	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11200222	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121891177	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200223	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121891416	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs10887013	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121891546	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11200225	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121891948	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200226	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000282	0.43	0.27	Breast cancer;	chr10:121891988	chr10:121928312~121951965:+
STAD	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-5.18	3.79e-07	0.000283	-0.32	-0.27	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-5.18	3.79e-07	0.000283	-0.32	-0.27	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-5.18	3.79e-07	0.000283	-0.32	-0.27	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
STAD	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	5.18	3.79e-07	0.000283	0.34	0.27	Height;	chr6:109370985	chr6:109382795~109383666:+
STAD	cis	rs4568518	0.742	rs13245422	ENSG00000279048.1	RP11-511H23.2	5.18	3.8e-07	0.000283	0.24	0.27	Measles;	chr7:17976352	chr7:17940503~17942922:+
STAD	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	5.18	3.8e-07	0.000283	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
STAD	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	5.18	3.81e-07	0.000284	0.35	0.27	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
STAD	cis	rs9601248	0.756	rs2146592	ENSG00000227354.5	RBM26-AS1	-5.18	3.81e-07	0.000284	-0.32	-0.27	Major depressive disorder;	chr13:79606146	chr13:79406309~79424328:+
STAD	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	5.18	3.81e-07	0.000284	0.35	0.27	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
STAD	cis	rs611744	0.55	rs1448154	ENSG00000253754.1	RP11-35G22.1	-5.18	3.81e-07	0.000284	-0.24	-0.27	Dupuytren's disease;	chr8:108268824	chr8:108226200~108227544:+
STAD	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-5.18	3.81e-07	0.000284	-0.37	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
STAD	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	5.18	3.82e-07	0.000284	0.34	0.27	Height;	chr6:109415123	chr6:109382795~109383666:+
STAD	cis	rs858239	0.601	rs1034963	ENSG00000226816.2	AC005082.12	5.18	3.82e-07	0.000284	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23206013~23208045:+
STAD	cis	rs58873874	0.737	rs11746314	ENSG00000251405.2	CTB-109A12.1	5.18	3.82e-07	0.000285	0.51	0.27	Bipolar disorder (body mass index interaction);	chr5:157325949	chr5:157362615~157460078:-
STAD	cis	rs9400467	0.508	rs12211763	ENSG00000230177.1	RP5-1112D6.4	-5.18	3.82e-07	0.000285	-0.24	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.528	rs10872067	ENSG00000230177.1	RP5-1112D6.4	-5.18	3.82e-07	0.000285	-0.24	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111277932~111278742:+
STAD	cis	rs7829975	0.606	rs6422352	ENSG00000254340.1	RP11-10A14.3	-5.18	3.82e-07	0.000285	-0.33	-0.27	Mood instability;	chr8:8936683	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.606	rs891570	ENSG00000254340.1	RP11-10A14.3	-5.18	3.82e-07	0.000285	-0.33	-0.27	Mood instability;	chr8:8936944	chr8:9141424~9145435:+
STAD	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-5.18	3.82e-07	0.000285	-0.34	-0.27	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
STAD	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-5.18	3.82e-07	0.000285	-0.34	-0.27	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
STAD	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-5.18	3.82e-07	0.000285	-0.31	-0.27	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
STAD	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-5.18	3.83e-07	0.000286	-0.34	-0.27	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-5.18	3.83e-07	0.000286	-0.34	-0.27	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-5.18	3.83e-07	0.000286	-0.34	-0.27	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-5.18	3.83e-07	0.000286	-0.34	-0.27	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
STAD	cis	rs9859260	0.744	rs406271	ENSG00000207650.1	MIR570	-5.18	3.83e-07	0.000286	-0.26	-0.27	Mean corpuscular volume;	chr3:196050105	chr3:195699401~195699497:+
STAD	cis	rs9859260	0.71	rs419068	ENSG00000207650.1	MIR570	-5.18	3.83e-07	0.000286	-0.26	-0.27	Mean corpuscular volume;	chr3:196055305	chr3:195699401~195699497:+
STAD	cis	rs9859260	0.71	rs366268	ENSG00000207650.1	MIR570	-5.18	3.83e-07	0.000286	-0.26	-0.27	Mean corpuscular volume;	chr3:196055306	chr3:195699401~195699497:+
STAD	cis	rs9859260	0.744	rs419059	ENSG00000207650.1	MIR570	-5.18	3.83e-07	0.000286	-0.26	-0.27	Mean corpuscular volume;	chr3:196055313	chr3:195699401~195699497:+
STAD	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	5.18	3.84e-07	0.000286	0.37	0.27	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	5.18	3.84e-07	0.000286	0.37	0.27	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	5.18	3.84e-07	0.000286	0.37	0.27	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	5.18	3.84e-07	0.000286	0.37	0.27	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	5.18	3.84e-07	0.000286	0.37	0.27	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
STAD	cis	rs9309473	0.513	rs62149782	ENSG00000163016.8	ALMS1P	5.18	3.84e-07	0.000286	0.41	0.27	Metabolite levels;	chr2:73591901	chr2:73644919~73685576:+
STAD	cis	rs858239	0.539	rs4365988	ENSG00000226816.2	AC005082.12	5.18	3.84e-07	0.000286	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs2178139	ENSG00000226816.2	AC005082.12	5.18	3.84e-07	0.000286	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs2141306	ENSG00000226816.2	AC005082.12	5.18	3.84e-07	0.000286	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs2141305	ENSG00000226816.2	AC005082.12	5.18	3.84e-07	0.000286	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23206013~23208045:+
STAD	cis	rs1816752	0.774	rs2862895	ENSG00000273628.1	RP11-756A22.7	5.18	3.84e-07	0.000286	0.33	0.27	Obesity-related traits;	chr13:24410328	chr13:24933006~24936796:+
STAD	cis	rs7487075	0.558	rs4768692	ENSG00000257261.4	RP11-96H19.1	5.18	3.84e-07	0.000286	0.32	0.27	Itch intensity from mosquito bite;	chr12:46245852	chr12:46383679~46876159:+
STAD	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-5.18	3.85e-07	0.000286	-0.22	-0.27	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
STAD	cis	rs3806843	1	rs3756340	ENSG00000202111.1	VTRNA1-2	-5.18	3.85e-07	0.000286	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140800866	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs7701755	ENSG00000202111.1	VTRNA1-2	-5.18	3.85e-07	0.000286	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140802516	chr5:140718925~140719013:+
STAD	cis	rs2833693	0.586	rs76801162	ENSG00000261610.1	AP000265.1	5.18	3.85e-07	0.000286	0.34	0.27	Temperament;	chr21:32196289	chr21:32259804~32261585:-
STAD	cis	rs3758911	0.964	rs10749896	ENSG00000261098.1	RP11-819C21.1	-5.18	3.85e-07	0.000286	-0.24	-0.27	Coronary artery disease;	chr11:107314102	chr11:107312132~107316271:-
STAD	cis	rs8098244	0.58	rs1711452	ENSG00000267301.1	RPL23AP77	-5.18	3.85e-07	0.000286	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692607	chr18:23709825~23710287:-
STAD	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-5.18	3.85e-07	0.000287	-0.29	-0.27	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
STAD	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-5.18	3.85e-07	0.000287	-0.34	-0.27	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000211973.2	IGHV1-69	5.18	3.85e-07	0.000287	0.23	0.27	Kawasaki disease;	chr14:106792798	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000211973.2	IGHV1-69	5.18	3.85e-07	0.000287	0.23	0.27	Kawasaki disease;	chr14:106800208	chr14:106714684~106715181:-
STAD	cis	rs7932354	0.528	rs12796744	ENSG00000271350.1	CTD-2384B9.1	5.18	3.85e-07	0.000287	0.33	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47111173	chr11:47041027~47041945:-
STAD	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	5.18	3.85e-07	0.000287	0.35	0.27	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
STAD	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-5.18	3.86e-07	0.000287	-0.28	-0.27	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
STAD	cis	rs7474896	0.616	rs2474561	ENSG00000120555.12	SEPT7P9	5.18	3.86e-07	0.000287	0.33	0.27	Obesity (extreme);	chr10:38084616	chr10:38383069~38402916:-
STAD	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	5.18	3.86e-07	0.000287	0.42	0.27	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
STAD	cis	rs7932354	0.528	rs6485739	ENSG00000271350.1	CTD-2384B9.1	-5.18	3.86e-07	0.000287	-0.32	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:47123521	chr11:47041027~47041945:-
STAD	cis	rs747650	0.926	rs10838659	ENSG00000271350.1	CTD-2384B9.1	-5.18	3.86e-07	0.000287	-0.32	-0.27	Acne (severe);	chr11:47126659	chr11:47041027~47041945:-
STAD	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	5.18	3.86e-07	0.000287	0.29	0.27	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
STAD	cis	rs12744310	0.945	rs72665696	ENSG00000235358.1	RP11-399E6.1	5.18	3.86e-07	0.000287	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309757	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs12751511	ENSG00000235358.1	RP11-399E6.1	5.18	3.86e-07	0.000287	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41310731	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs34073585	ENSG00000235358.1	RP11-399E6.1	5.18	3.86e-07	0.000287	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311527	chr1:41242373~41284861:+
STAD	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-5.18	3.86e-07	0.000287	-0.35	-0.27	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
STAD	cis	rs9463078	0.585	rs718112	ENSG00000219384.1	RP11-491H9.3	-5.18	3.86e-07	0.000288	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44891714	chr6:45158870~45159511:+
STAD	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-5.18	3.87e-07	0.000288	-0.37	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
STAD	cis	rs6142102	0.961	rs6059596	ENSG00000275784.1	RP5-1125A11.6	-5.17	3.87e-07	0.000288	-0.28	-0.27	Skin pigmentation;	chr20:33969313	chr20:33989480~33991818:-
STAD	cis	rs7829975	0.807	rs519019	ENSG00000253981.4	ALG1L13P	-5.17	3.87e-07	0.000288	-0.32	-0.27	Mood instability;	chr8:8737594	chr8:8236003~8244667:-
STAD	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	5.17	3.87e-07	0.000288	0.31	0.27	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
STAD	cis	rs58873874	0.737	rs75326191	ENSG00000251405.2	CTB-109A12.1	5.17	3.88e-07	0.000288	0.46	0.27	Bipolar disorder (body mass index interaction);	chr5:157445797	chr5:157362615~157460078:-
STAD	cis	rs62432291	0.681	rs294912	ENSG00000235086.1	FNDC1-IT1	-5.17	3.88e-07	0.000289	-0.42	-0.27	Joint mobility (Beighton score);	chr6:159246305	chr6:159240786~159243329:+
STAD	cis	rs1799949	0.929	rs12937015	ENSG00000236383.6	LINC00854	-5.17	3.88e-07	0.000289	-0.22	-0.27	Menopause (age at onset);	chr17:43155456	chr17:43216941~43305976:-
STAD	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-5.17	3.88e-07	0.000289	-0.4	-0.27	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
STAD	cis	rs11169552	0.943	rs11169560	ENSG00000200183.1	RNU6-238P	-5.17	3.89e-07	0.000289	-0.27	-0.27	Colorectal cancer;	chr12:50791981	chr12:50656973~50657078:+
STAD	cis	rs858239	0.539	rs2178140	ENSG00000226816.2	AC005082.12	5.17	3.89e-07	0.000289	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23206013~23208045:+
STAD	cis	rs957448	0.507	rs1984711	ENSG00000253704.1	RP11-267M23.4	5.17	3.89e-07	0.000289	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94553722~94569745:+
STAD	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-5.17	3.89e-07	0.000289	-0.31	-0.27	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
STAD	cis	rs875971	0.862	rs2909688	ENSG00000236529.1	RP13-254B10.1	5.17	3.89e-07	0.000289	0.27	0.27	Aortic root size;	chr7:66376625	chr7:65840212~65840596:+
STAD	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-5.17	3.89e-07	0.000289	-0.32	-0.27	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
STAD	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-5.17	3.89e-07	0.00029	-0.3	-0.27	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
STAD	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-5.17	3.9e-07	0.00029	-0.42	-0.27	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
STAD	cis	rs17592366	0.517	rs1967722	ENSG00000251726.1	RNU7-41P	-5.17	3.9e-07	0.00029	-0.24	-0.27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34816068	chr14:34845300~34845360:-
STAD	cis	rs17592366	0.517	rs4982219	ENSG00000251726.1	RNU7-41P	-5.17	3.9e-07	0.00029	-0.24	-0.27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34817277	chr14:34845300~34845360:-
STAD	cis	rs1322639	1	rs1322639	ENSG00000261039.2	RP11-417E7.2	5.17	3.9e-07	0.00029	0.34	0.27	Pulse pressure;	chr6:169187008	chr6:169175304~169182740:-
STAD	cis	rs10028773	0.632	rs34481394	ENSG00000245958.5	RP11-33B1.1	-5.17	3.9e-07	0.00029	-0.28	-0.27	Educational attainment;	chr4:119327219	chr4:119454791~119552025:+
STAD	cis	rs10028773	0.666	rs35231872	ENSG00000245958.5	RP11-33B1.1	-5.17	3.9e-07	0.00029	-0.28	-0.27	Educational attainment;	chr4:119327221	chr4:119454791~119552025:+
STAD	cis	rs10028773	0.7	rs35653026	ENSG00000245958.5	RP11-33B1.1	-5.17	3.9e-07	0.00029	-0.28	-0.27	Educational attainment;	chr4:119327223	chr4:119454791~119552025:+
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000211973.2	IGHV1-69	5.17	3.91e-07	0.00029	0.23	0.27	Kawasaki disease;	chr14:106807157	chr14:106714684~106715181:-
STAD	cis	rs728616	0.681	rs12769764	ENSG00000225484.5	NUTM2B-AS1	-5.17	3.91e-07	0.00029	-0.35	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80157357	chr10:79663088~79826594:-
STAD	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	5.17	3.91e-07	0.00029	0.29	0.27	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
STAD	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	5.17	3.92e-07	0.000291	0.28	0.27	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
STAD	cis	rs6142102	0.961	rs6059649	ENSG00000275784.1	RP5-1125A11.6	-5.17	3.92e-07	0.000291	-0.28	-0.27	Skin pigmentation;	chr20:34056071	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs6059651	ENSG00000275784.1	RP5-1125A11.6	-5.17	3.92e-07	0.000291	-0.28	-0.27	Skin pigmentation;	chr20:34057246	chr20:33989480~33991818:-
STAD	cis	rs2933343	0.7	rs2624910	ENSG00000231305.3	RP11-723O4.2	5.17	3.92e-07	0.000291	0.28	0.27	IgG glycosylation;	chr3:128931432	chr3:128861313~128871540:-
STAD	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	5.17	3.92e-07	0.000291	0.3	0.27	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
STAD	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-5.17	3.92e-07	0.000291	-0.32	-0.27	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-5.17	3.92e-07	0.000291	-0.32	-0.27	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
STAD	cis	rs2337406	0.587	rs2583291	ENSG00000211972.2	IGHV3-66	-5.17	3.92e-07	0.000292	-0.28	-0.27	Alzheimer's disease (late onset);	chr14:106649293	chr14:106675017~106675544:-
STAD	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-5.17	3.93e-07	0.000292	-0.28	-0.27	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
STAD	cis	rs10853057	0.618	rs12947222	ENSG00000214174.7	AMZ2P1	5.17	3.93e-07	0.000292	0.47	0.27	White matter microstructure (global fractional anisotropy);	chr17:65005160	chr17:64966550~64975576:-
STAD	cis	rs10853057	0.618	rs34476326	ENSG00000214174.7	AMZ2P1	5.17	3.93e-07	0.000292	0.47	0.27	White matter microstructure (global fractional anisotropy);	chr17:65005296	chr17:64966550~64975576:-
STAD	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-5.17	3.93e-07	0.000292	-0.34	-0.27	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
STAD	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	5.17	3.93e-07	0.000292	0.38	0.27	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
STAD	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	5.17	3.93e-07	0.000292	0.38	0.27	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
STAD	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	5.17	3.93e-07	0.000292	0.39	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
STAD	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	5.17	3.93e-07	0.000292	0.39	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
STAD	cis	rs10504130	0.569	rs11785467	ENSG00000272024.1	RP11-546K22.3	-5.17	3.93e-07	0.000292	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51950284~51950690:+
STAD	cis	rs1799949	0.931	rs34410138	ENSG00000236383.6	LINC00854	-5.17	3.93e-07	0.000292	-0.22	-0.27	Menopause (age at onset);	chr17:43127753	chr17:43216941~43305976:-
STAD	cis	rs7124681	0.584	rs7950674	ENSG00000280615.1	Y_RNA	5.17	3.93e-07	0.000292	0.27	0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47849465	chr11:47614898~47614994:-
STAD	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-5.17	3.94e-07	0.000292	-0.31	-0.27	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
STAD	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-5.17	3.94e-07	0.000293	-0.36	-0.27	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
STAD	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	5.17	3.94e-07	0.000293	0.32	0.27	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
STAD	cis	rs1056107	0.897	rs7851034	ENSG00000225513.1	RP11-165N19.2	-5.17	3.94e-07	0.000293	-0.31	-0.27	Colorectal cancer;	chr9:112193100	chr9:112173522~112173971:-
STAD	cis	rs10978777	0.676	rs4625087	ENSG00000276883.1	AL137852.1	-5.17	3.94e-07	0.000293	-0.27	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107298562	chr9:107292369~107292456:-
STAD	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-5.17	3.95e-07	0.000293	-0.3	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
STAD	cis	rs2404602	0.716	rs67204011	ENSG00000259422.1	RP11-593F23.1	5.17	3.95e-07	0.000293	0.28	0.27	Blood metabolite levels;	chr15:76554214	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs12902174	ENSG00000259422.1	RP11-593F23.1	5.17	3.95e-07	0.000293	0.28	0.27	Blood metabolite levels;	chr15:76571199	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs12438077	ENSG00000259422.1	RP11-593F23.1	5.17	3.95e-07	0.000293	0.28	0.27	Blood metabolite levels;	chr15:76571260	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs12441550	ENSG00000259422.1	RP11-593F23.1	5.17	3.95e-07	0.000293	0.28	0.27	Blood metabolite levels;	chr15:76571341	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs1874944	ENSG00000259422.1	RP11-593F23.1	5.17	3.95e-07	0.000293	0.28	0.27	Blood metabolite levels;	chr15:76571587	chr15:76174891~76181486:-
STAD	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-5.17	3.95e-07	0.000293	-0.32	-0.27	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-5.17	3.95e-07	0.000293	-0.32	-0.27	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
STAD	cis	rs858239	0.676	rs3807459	ENSG00000226816.2	AC005082.12	5.17	3.95e-07	0.000293	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23206013~23208045:+
STAD	cis	rs8028182	0.501	rs7166281	ENSG00000260269.4	CTD-2323K18.1	5.17	3.95e-07	0.000293	0.34	0.27	Sudden cardiac arrest;	chr15:75635851	chr15:75527150~75601205:-
STAD	cis	rs11169552	1	rs11169544	ENSG00000200183.1	RNU6-238P	5.17	3.96e-07	0.000294	0.26	0.27	Colorectal cancer;	chr12:50750966	chr12:50656973~50657078:+
STAD	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	5.17	3.97e-07	0.000294	0.36	0.27	Height;	chr6:109454855	chr6:109382795~109383666:+
STAD	cis	rs611744	0.647	rs7015240	ENSG00000253754.1	RP11-35G22.1	-5.17	3.97e-07	0.000294	-0.24	-0.27	Dupuytren's disease;	chr8:108249975	chr8:108226200~108227544:+
STAD	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	5.17	3.97e-07	0.000295	0.36	0.27	Height;	chr6:109384228	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	5.17	3.97e-07	0.000295	0.36	0.27	Height;	chr6:109385087	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	5.17	3.97e-07	0.000295	0.36	0.27	Height;	chr6:109388256	chr6:109382795~109383666:+
STAD	cis	rs4308124	0.708	rs6749633	ENSG00000230499.1	AC108463.1	5.17	3.97e-07	0.000295	0.38	0.27	Vitiligo;	chr2:111230439	chr2:111195963~111206494:+
STAD	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	5.17	3.97e-07	0.000295	0.39	0.27	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
STAD	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-5.17	3.98e-07	0.000295	-0.42	-0.27	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
STAD	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-5.17	3.98e-07	0.000295	-0.33	-0.27	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
STAD	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	5.17	3.98e-07	0.000295	0.37	0.27	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	5.17	3.98e-07	0.000295	0.37	0.27	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	5.17	3.98e-07	0.000295	0.37	0.27	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	5.17	3.98e-07	0.000295	0.37	0.27	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
STAD	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-5.17	3.99e-07	0.000296	-0.35	-0.27	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
STAD	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-5.17	3.99e-07	0.000296	-0.35	-0.27	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
STAD	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-5.17	3.99e-07	0.000296	-0.35	-0.27	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
STAD	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-5.17	3.99e-07	0.000296	-0.31	-0.27	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
STAD	cis	rs2436845	0.934	rs2436865	ENSG00000253385.1	KB-1254G8.1	5.17	3.99e-07	0.000296	0.29	0.27	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102806542	chr8:102854455~102856075:+
STAD	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-5.17	4e-07	0.000296	-0.29	-0.27	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
STAD	cis	rs17592366	0.517	rs11845027	ENSG00000251726.1	RNU7-41P	-5.17	4e-07	0.000296	-0.24	-0.27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34846368	chr14:34845300~34845360:-
STAD	cis	rs2404602	0.716	rs2404737	ENSG00000259422.1	RP11-593F23.1	5.17	4.02e-07	0.000298	0.28	0.27	Blood metabolite levels;	chr15:76579876	chr15:76174891~76181486:-
STAD	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-5.17	4.02e-07	0.000298	-0.36	-0.27	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
STAD	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	5.17	4.02e-07	0.000298	0.38	0.27	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	5.17	4.02e-07	0.000298	0.38	0.27	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
STAD	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-5.17	4.02e-07	0.000298	-0.3	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
STAD	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-5.17	4.02e-07	0.000298	-0.37	-0.27	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
STAD	cis	rs12744310	0.887	rs4453028	ENSG00000235358.1	RP11-399E6.1	5.17	4.03e-07	0.000298	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326851	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.83	rs4406620	ENSG00000235358.1	RP11-399E6.1	5.17	4.03e-07	0.000298	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327093	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs35436312	ENSG00000235358.1	RP11-399E6.1	5.17	4.03e-07	0.000298	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327686	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs1316274	ENSG00000235358.1	RP11-399E6.1	5.17	4.03e-07	0.000298	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327986	chr1:41242373~41284861:+
STAD	cis	rs9425766	0.679	rs2049992	ENSG00000227373.4	RP11-160H22.5	5.17	4.03e-07	0.000298	0.3	0.27	Life satisfaction;	chr1:174356554	chr1:174115300~174160004:-
STAD	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-5.17	4.03e-07	0.000299	-0.39	-0.27	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
STAD	cis	rs7182621	0.883	rs10468181	ENSG00000259363.4	CTD-2054N24.2	-5.17	4.04e-07	0.000299	-0.27	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99885244	chr15:99807023~99877148:+
STAD	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-5.17	4.05e-07	3e-04	-0.33	-0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
STAD	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-5.17	4.05e-07	3e-04	-0.33	-0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
STAD	cis	rs10504130	0.569	rs13275967	ENSG00000272024.1	RP11-546K22.3	-5.17	4.05e-07	3e-04	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs13274159	ENSG00000272024.1	RP11-546K22.3	-5.17	4.05e-07	3e-04	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs4436115	ENSG00000272024.1	RP11-546K22.3	-5.17	4.05e-07	3e-04	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs4573262	ENSG00000272024.1	RP11-546K22.3	-5.17	4.05e-07	3e-04	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51950284~51950690:+
STAD	cis	rs801193	0.569	rs7782587	ENSG00000236529.1	RP13-254B10.1	5.17	4.05e-07	3e-04	0.27	0.27	Aortic root size;	chr7:66701485	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs4717315	ENSG00000236529.1	RP13-254B10.1	5.17	4.05e-07	3e-04	0.27	0.27	Aortic root size;	chr7:66713338	chr7:65840212~65840596:+
STAD	cis	rs801193	0.527	rs2707837	ENSG00000236529.1	RP13-254B10.1	5.17	4.05e-07	3e-04	0.27	0.27	Aortic root size;	chr7:66716086	chr7:65840212~65840596:+
STAD	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-5.17	4.05e-07	3e-04	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
STAD	cis	rs8098244	0.638	rs12953820	ENSG00000267301.1	RPL23AP77	-5.17	4.05e-07	3e-04	-0.31	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23878760	chr18:23709825~23710287:-
STAD	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-5.17	4.06e-07	3e-04	-0.22	-0.27	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
STAD	cis	rs11169552	0.58	rs4768913	ENSG00000200183.1	RNU6-238P	-5.17	4.06e-07	0.000301	-0.26	-0.27	Colorectal cancer;	chr12:50742173	chr12:50656973~50657078:+
STAD	cis	rs2833693	0.574	rs2211675	ENSG00000261610.1	AP000265.1	-5.17	4.06e-07	0.000301	-0.29	-0.27	Temperament;	chr21:32180793	chr21:32259804~32261585:-
STAD	cis	rs2404602	0.692	rs4886503	ENSG00000259422.1	RP11-593F23.1	-5.17	4.07e-07	0.000301	-0.28	-0.27	Blood metabolite levels;	chr15:76816533	chr15:76174891~76181486:-
STAD	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	5.17	4.07e-07	0.000301	0.46	0.27	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
STAD	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	5.17	4.07e-07	0.000301	0.29	0.27	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
STAD	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-5.16	4.07e-07	0.000301	-0.29	-0.27	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
STAD	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	5.16	4.07e-07	0.000301	0.34	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
STAD	cis	rs9393777	0.546	rs9366673	ENSG00000224843.5	LINC00240	5.16	4.08e-07	0.000302	0.39	0.27	Intelligence (multi-trait analysis);	chr6:26925550	chr6:26956992~27023924:+
STAD	cis	rs748404	0.626	rs35992154	ENSG00000249839.1	AC011330.5	-5.16	4.08e-07	0.000302	-0.46	-0.27	Lung cancer;	chr15:43345669	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs17780417	ENSG00000249839.1	AC011330.5	-5.16	4.08e-07	0.000302	-0.46	-0.27	Lung cancer;	chr15:43347264	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs7181634	ENSG00000249839.1	AC011330.5	-5.16	4.08e-07	0.000302	-0.46	-0.27	Lung cancer;	chr15:43351703	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs55748552	ENSG00000249839.1	AC011330.5	-5.16	4.08e-07	0.000302	-0.46	-0.27	Lung cancer;	chr15:43359428	chr15:43663654~43684339:-
STAD	cis	rs748404	0.63	rs35278805	ENSG00000249839.1	AC011330.5	-5.16	4.08e-07	0.000302	-0.46	-0.27	Lung cancer;	chr15:43361124	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs35160541	ENSG00000249839.1	AC011330.5	-5.16	4.08e-07	0.000302	-0.46	-0.27	Lung cancer;	chr15:43365601	chr15:43663654~43684339:-
STAD	cis	rs1799949	1	rs8176202	ENSG00000279602.1	CTD-3014M21.1	5.16	4.08e-07	0.000302	0.34	0.27	Menopause (age at onset);	chr17:43078211	chr17:43360041~43361361:-
STAD	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	5.16	4.08e-07	0.000302	0.31	0.27	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
STAD	cis	rs227275	0.554	rs223314	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000302	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs7254	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000302	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.566	rs6822658	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000302	-0.29	-0.27	Schizophrenia;	chr4:102891964	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs6823625	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000302	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs6846762	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000302	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102727274~102730721:-
STAD	cis	rs228614	0.51	rs4699032	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000302	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102727274~102730721:-
STAD	cis	rs3806843	1	rs10037757	ENSG00000202111.1	VTRNA1-2	-5.16	4.09e-07	0.000302	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140817637	chr5:140718925~140719013:+
STAD	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-5.16	4.09e-07	0.000302	-0.34	-0.27	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
STAD	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-5.16	4.09e-07	0.000302	-0.31	-0.27	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
STAD	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-5.16	4.09e-07	0.000303	-0.32	-0.27	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
STAD	cis	rs228614	0.51	rs223311	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000303	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102727274~102730721:-
STAD	cis	rs9463078	0.565	rs10948183	ENSG00000219384.1	RP11-491H9.3	-5.16	4.1e-07	0.000303	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44913144	chr6:45158870~45159511:+
STAD	cis	rs227275	0.525	rs13113923	ENSG00000230069.3	LRRC37A15P	-5.16	4.11e-07	0.000303	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102727274~102730721:-
STAD	cis	rs12744310	1	rs34008156	ENSG00000235358.1	RP11-399E6.1	5.16	4.11e-07	0.000303	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307510	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12744310	ENSG00000235358.1	RP11-399E6.1	5.16	4.11e-07	0.000303	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307830	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs56077539	ENSG00000235358.1	RP11-399E6.1	5.16	4.11e-07	0.000303	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308270	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs55892603	ENSG00000235358.1	RP11-399E6.1	5.16	4.11e-07	0.000303	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308322	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs34759578	ENSG00000235358.1	RP11-399E6.1	5.16	4.11e-07	0.000303	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308678	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.945	rs72665690	ENSG00000235358.1	RP11-399E6.1	5.16	4.11e-07	0.000303	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309564	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.945	rs72665691	ENSG00000235358.1	RP11-399E6.1	5.16	4.11e-07	0.000303	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309573	chr1:41242373~41284861:+
STAD	cis	rs1799949	0.965	rs8067269	ENSG00000236383.6	LINC00854	-5.16	4.11e-07	0.000303	-0.21	-0.27	Menopause (age at onset);	chr17:43083782	chr17:43216941~43305976:-
STAD	cis	rs1153858	1	rs67831559	ENSG00000259433.2	CTD-2651B20.4	-5.16	4.11e-07	0.000303	-0.29	-0.27	Homoarginine levels;	chr15:45357109	chr15:45330209~45332634:-
STAD	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	5.16	4.11e-07	0.000303	0.28	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
STAD	cis	rs11722779	0.935	rs6856176	ENSG00000230069.3	LRRC37A15P	-5.16	4.11e-07	0.000304	-0.29	-0.27	Schizophrenia;	chr4:102902574	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs11722779	ENSG00000230069.3	LRRC37A15P	-5.16	4.11e-07	0.000304	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102727274~102730721:-
STAD	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	5.16	4.11e-07	0.000304	0.3	0.27	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
STAD	cis	rs12744310	1	rs56381773	ENSG00000235358.1	RP11-399E6.1	5.16	4.12e-07	0.000304	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305046	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs56096486	ENSG00000235358.1	RP11-399E6.1	5.16	4.12e-07	0.000304	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305558	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs60825180	ENSG00000235358.1	RP11-399E6.1	5.16	4.12e-07	0.000304	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306072	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.778	rs61477144	ENSG00000235358.1	RP11-399E6.1	5.16	4.12e-07	0.000304	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306121	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.943	rs7521544	ENSG00000235358.1	RP11-399E6.1	5.16	4.12e-07	0.000304	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306454	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs7513682	ENSG00000235358.1	RP11-399E6.1	5.16	4.12e-07	0.000304	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306495	chr1:41242373~41284861:+
STAD	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-5.16	4.12e-07	0.000304	-0.27	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
STAD	cis	rs1816752	0.819	rs7317504	ENSG00000273628.1	RP11-756A22.7	5.16	4.12e-07	0.000304	0.32	0.27	Obesity-related traits;	chr13:24411287	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.783	rs7317712	ENSG00000273628.1	RP11-756A22.7	5.16	4.12e-07	0.000304	0.32	0.27	Obesity-related traits;	chr13:24411365	chr13:24933006~24936796:+
STAD	cis	rs3858145	0.5	rs4633337	ENSG00000233590.1	RP11-153K11.3	5.16	4.12e-07	0.000304	0.34	0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68233251~68242379:-
STAD	cis	rs7429990	0.864	rs3888	ENSG00000224895.1	VPS26BP1	5.16	4.12e-07	0.000304	0.26	0.27	Educational attainment (years of education);	chr3:47816085	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs4858860	ENSG00000224895.1	VPS26BP1	5.16	4.12e-07	0.000304	0.26	0.27	Educational attainment (years of education);	chr3:47817344	chr3:47960327~47961081:-
STAD	cis	rs1816752	0.819	rs7316961	ENSG00000273628.1	RP11-756A22.7	5.16	4.12e-07	0.000304	0.32	0.27	Obesity-related traits;	chr13:24411039	chr13:24933006~24936796:+
STAD	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	5.16	4.13e-07	0.000305	0.38	0.27	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
STAD	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	5.16	4.13e-07	0.000305	0.32	0.27	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
STAD	cis	rs172166	0.516	rs2791333	ENSG00000220721.1	OR1F12	5.16	4.13e-07	0.000305	0.26	0.27	Cardiac Troponin-T levels;	chr6:28143336	chr6:28073316~28074233:+
STAD	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	5.16	4.13e-07	0.000305	0.31	0.27	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
STAD	cis	rs3758911	0.788	rs10890704	ENSG00000261098.1	RP11-819C21.1	-5.16	4.13e-07	0.000305	-0.24	-0.27	Coronary artery disease;	chr11:107312779	chr11:107312132~107316271:-
STAD	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-5.16	4.14e-07	0.000305	-0.33	-0.27	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
STAD	cis	rs3758911	0.796	rs56753250	ENSG00000261098.1	RP11-819C21.1	-5.16	4.14e-07	0.000305	-0.24	-0.27	Coronary artery disease;	chr11:107338499	chr11:107312132~107316271:-
STAD	cis	rs1150668	0.699	rs13408	ENSG00000220721.1	OR1F12	5.16	4.14e-07	0.000306	0.26	0.27	Pubertal anthropometrics;	chr6:28244970	chr6:28073316~28074233:+
STAD	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-5.16	4.15e-07	0.000306	-0.42	-0.27	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
STAD	cis	rs66887589	0.72	rs2036858	ENSG00000249244.1	RP11-548H18.2	5.16	4.15e-07	0.000306	0.33	0.27	Diastolic blood pressure;	chr4:119328082	chr4:119391831~119395335:-
STAD	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	5.16	4.15e-07	0.000306	0.36	0.27	Height;	chr6:109357908	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	5.16	4.15e-07	0.000306	0.36	0.27	Height;	chr6:109359747	chr6:109382795~109383666:+
STAD	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	5.16	4.16e-07	0.000307	0.28	0.27	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
STAD	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-5.16	4.17e-07	0.000307	-0.3	-0.27	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
STAD	cis	rs801193	0.569	rs11761542	ENSG00000236529.1	RP13-254B10.1	5.16	4.17e-07	0.000307	0.27	0.27	Aortic root size;	chr7:66753209	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs4718348	ENSG00000224316.1	RP11-479O9.2	5.16	4.17e-07	0.000307	0.3	0.27	Aortic root size;	chr7:66441589	chr7:65773620~65802067:+
STAD	cis	rs3806843	1	rs991918	ENSG00000202111.1	VTRNA1-2	-5.16	4.17e-07	0.000308	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140815273	chr5:140718925~140719013:+
STAD	cis	rs7031325	0.962	rs2578283	ENSG00000229611.1	RP11-390F4.10	-5.16	4.17e-07	0.000308	-0.27	-0.27	Systemic lupus erythematosus;	chr9:6652997	chr9:6704471~6707780:+
STAD	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	5.16	4.18e-07	0.000308	0.34	0.27	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
STAD	cis	rs8067354	0.645	rs2102507	ENSG00000266701.1	AC005702.4	5.16	4.18e-07	0.000308	0.37	0.27	Hemoglobin concentration;	chr17:59798546	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs2645491	ENSG00000266701.1	AC005702.4	5.16	4.18e-07	0.000308	0.37	0.27	Hemoglobin concentration;	chr17:59799688	chr17:60042546~60042627:-
STAD	cis	rs728616	0.867	rs17886286	ENSG00000225484.5	NUTM2B-AS1	-5.16	4.18e-07	0.000308	-0.62	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944096	chr10:79663088~79826594:-
STAD	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	5.16	4.18e-07	0.000308	0.38	0.27	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
STAD	cis	rs3758911	0.796	rs59525924	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000308	-0.25	-0.27	Coronary artery disease;	chr11:107339286	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10789611	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107316810	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10789612	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107316931	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10890707	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107317153	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10890708	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107317315	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs10890709	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107317378	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs10890711	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107317424	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs12290112	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107317487	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs12270655	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107317507	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs10890712	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107317583	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs10789614	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107318047	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10789615	ENSG00000261098.1	RP11-819C21.1	-5.16	4.19e-07	0.000309	-0.23	-0.27	Coronary artery disease;	chr11:107318088	chr11:107312132~107316271:-
STAD	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-5.16	4.19e-07	0.000309	-0.32	-0.27	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-5.16	4.19e-07	0.000309	-0.32	-0.27	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-5.16	4.19e-07	0.000309	-0.32	-0.27	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
STAD	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-5.16	4.19e-07	0.000309	-0.48	-0.27	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
STAD	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	5.16	4.19e-07	0.000309	0.32	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
STAD	cis	rs66887589	0.616	rs13113885	ENSG00000249244.1	RP11-548H18.2	5.16	4.2e-07	0.000309	0.33	0.27	Diastolic blood pressure;	chr4:119300021	chr4:119391831~119395335:-
STAD	cis	rs7580658	0.637	rs4560059	ENSG00000200250.1	RNU6-1147P	5.16	4.2e-07	0.000309	0.25	0.27	Protein C levels;	chr2:127214652	chr2:127316873~127316979:+
STAD	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	5.16	4.2e-07	0.000309	0.3	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
STAD	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	5.16	4.2e-07	0.000309	0.34	0.27	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
STAD	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	5.16	4.2e-07	0.00031	0.38	0.27	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
STAD	cis	rs2980439	0.525	rs2980508	ENSG00000253981.4	ALG1L13P	5.16	4.21e-07	0.00031	0.3	0.27	Neuroticism;	chr8:8314210	chr8:8236003~8244667:-
STAD	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-5.16	4.21e-07	0.00031	-0.28	-0.27	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
STAD	cis	rs1056107	0.931	rs2418199	ENSG00000225513.1	RP11-165N19.2	-5.16	4.21e-07	0.00031	-0.31	-0.27	Colorectal cancer;	chr9:112242888	chr9:112173522~112173971:-
STAD	cis	rs2337406	0.925	rs2011167	ENSG00000211972.2	IGHV3-66	5.16	4.22e-07	0.00031	0.29	0.27	Alzheimer's disease (late onset);	chr14:106680831	chr14:106675017~106675544:-
STAD	cis	rs1056107	0.931	rs1359878	ENSG00000225513.1	RP11-165N19.2	-5.16	4.22e-07	0.000311	-0.31	-0.27	Colorectal cancer;	chr9:112249037	chr9:112173522~112173971:-
STAD	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	5.16	4.22e-07	0.000311	0.38	0.27	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
STAD	cis	rs3806843	0.966	rs3756341	ENSG00000202111.1	VTRNA1-2	-5.16	4.22e-07	0.000311	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr5:140718925~140719013:+
STAD	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	5.16	4.22e-07	0.000311	0.28	0.27	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
STAD	cis	rs853679	0.517	rs4711164	ENSG00000220721.1	OR1F12	5.16	4.23e-07	0.000311	0.32	0.27	Depression;	chr6:28147378	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs4711165	ENSG00000220721.1	OR1F12	5.16	4.23e-07	0.000311	0.32	0.27	Depression;	chr6:28147406	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs4713148	ENSG00000220721.1	OR1F12	5.16	4.23e-07	0.000311	0.32	0.27	Depression;	chr6:28148143	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9348794	ENSG00000220721.1	OR1F12	5.16	4.23e-07	0.000311	0.32	0.27	Depression;	chr6:28149979	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9468297	ENSG00000220721.1	OR1F12	5.16	4.23e-07	0.000311	0.32	0.27	Depression;	chr6:28151096	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9295758	ENSG00000220721.1	OR1F12	5.16	4.23e-07	0.000311	0.32	0.27	Depression;	chr6:28152885	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs17774663	ENSG00000220721.1	OR1F12	5.16	4.23e-07	0.000311	0.32	0.27	Depression;	chr6:28153120	chr6:28073316~28074233:+
STAD	cis	rs4308124	0.708	rs28871990	ENSG00000230499.1	AC108463.1	-5.16	4.23e-07	0.000311	-0.38	-0.27	Vitiligo;	chr2:111204864	chr2:111195963~111206494:+
STAD	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-5.16	4.23e-07	0.000311	-0.42	-0.27	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
STAD	cis	rs4308124	0.708	rs10178095	ENSG00000230499.1	AC108463.1	-5.16	4.23e-07	0.000311	-0.38	-0.27	Vitiligo;	chr2:111214939	chr2:111195963~111206494:+
STAD	cis	rs1056107	0.866	rs12351043	ENSG00000225513.1	RP11-165N19.2	-5.16	4.23e-07	0.000311	-0.31	-0.27	Colorectal cancer;	chr9:112241012	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs7864927	ENSG00000225513.1	RP11-165N19.2	-5.16	4.23e-07	0.000311	-0.31	-0.27	Colorectal cancer;	chr9:112241713	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs10759541	ENSG00000225513.1	RP11-165N19.2	-5.16	4.23e-07	0.000311	-0.31	-0.27	Colorectal cancer;	chr9:112243277	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs7032120	ENSG00000225513.1	RP11-165N19.2	-5.16	4.23e-07	0.000311	-0.31	-0.27	Colorectal cancer;	chr9:112243865	chr9:112173522~112173971:-
STAD	cis	rs3806843	1	rs13157397	ENSG00000202111.1	VTRNA1-2	-5.16	4.24e-07	0.000312	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr5:140718925~140719013:+
STAD	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-5.16	4.25e-07	0.000312	-0.42	-0.27	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
STAD	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-5.16	4.25e-07	0.000313	-0.32	-0.27	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
STAD	cis	rs3806843	1	rs10057161	ENSG00000202111.1	VTRNA1-2	-5.16	4.25e-07	0.000313	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr5:140718925~140719013:+
STAD	cis	rs6782228	0.565	rs67445542	ENSG00000277250.1	Metazoa_SRP	-5.16	4.25e-07	0.000313	-0.28	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128673681~128674021:-
STAD	cis	rs801193	0.569	rs2659908	ENSG00000236529.1	RP13-254B10.1	5.16	4.26e-07	0.000313	0.27	0.27	Aortic root size;	chr7:66695835	chr7:65840212~65840596:+
STAD	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	5.16	4.26e-07	0.000313	0.32	0.27	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
STAD	cis	rs12744310	0.887	rs67483852	ENSG00000235358.1	RP11-399E6.1	5.16	4.26e-07	0.000313	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318793	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs36015391	ENSG00000235358.1	RP11-399E6.1	5.16	4.26e-07	0.000313	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319133	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs28399806	ENSG00000235358.1	RP11-399E6.1	5.16	4.26e-07	0.000313	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319299	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12047875	ENSG00000235358.1	RP11-399E6.1	5.16	4.26e-07	0.000313	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319504	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs35932978	ENSG00000235358.1	RP11-399E6.1	5.16	4.26e-07	0.000313	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319773	chr1:41242373~41284861:+
STAD	cis	rs875971	0.755	rs10228885	ENSG00000236529.1	RP13-254B10.1	-5.16	4.26e-07	0.000313	-0.27	-0.27	Aortic root size;	chr7:66315542	chr7:65840212~65840596:+
STAD	cis	rs737008	0.959	rs11865598	ENSG00000262703.1	RP11-485G7.6	5.16	4.26e-07	0.000313	0.26	0.27	Obesity-related traits;	chr16:11309575	chr16:11348143~11349321:-
STAD	cis	rs801193	0.569	rs2707824	ENSG00000236529.1	RP13-254B10.1	5.16	4.26e-07	0.000313	0.27	0.27	Aortic root size;	chr7:66724256	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs2659893	ENSG00000236529.1	RP13-254B10.1	5.16	4.26e-07	0.000313	0.27	0.27	Aortic root size;	chr7:66735006	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs2659892	ENSG00000236529.1	RP13-254B10.1	5.16	4.26e-07	0.000313	0.27	0.27	Aortic root size;	chr7:66735318	chr7:65840212~65840596:+
STAD	cis	rs801193	0.548	rs2659891	ENSG00000236529.1	RP13-254B10.1	5.16	4.26e-07	0.000313	0.27	0.27	Aortic root size;	chr7:66736127	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs2707847	ENSG00000236529.1	RP13-254B10.1	5.16	4.26e-07	0.000313	0.27	0.27	Aortic root size;	chr7:66737884	chr7:65840212~65840596:+
STAD	cis	rs801193	0.548	rs7805152	ENSG00000236529.1	RP13-254B10.1	5.16	4.26e-07	0.000313	0.27	0.27	Aortic root size;	chr7:66744266	chr7:65840212~65840596:+
STAD	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-5.16	4.26e-07	0.000313	-0.3	-0.27	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
STAD	cis	rs2446066	0.872	rs10876454	ENSG00000257379.1	RP11-793H13.8	5.16	4.26e-07	0.000313	0.44	0.27	Red blood cell count;	chr12:53427758	chr12:53441741~53467528:+
STAD	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	5.16	4.27e-07	0.000314	0.33	0.27	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
STAD	cis	rs6095360	0.727	rs35334143	ENSG00000222365.1	SNORD12B	-5.16	4.27e-07	0.000314	-0.36	-0.27	Intelligence (multi-trait analysis);	chr20:48914171	chr20:49280319~49280409:+
STAD	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-5.16	4.27e-07	0.000314	-0.33	-0.27	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-5.16	4.27e-07	0.000314	-0.33	-0.27	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
STAD	cis	rs516805	0.665	rs225077	ENSG00000279453.1	RP3-425C14.4	-5.16	4.27e-07	0.000314	-0.36	-0.27	Lymphocyte counts;	chr6:122269794	chr6:122436789~122439223:-
STAD	cis	rs611744	0.538	rs59930666	ENSG00000253754.1	RP11-35G22.1	-5.15	4.28e-07	0.000314	-0.24	-0.27	Dupuytren's disease;	chr8:108250067	chr8:108226200~108227544:+
STAD	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-5.15	4.28e-07	0.000314	-0.32	-0.27	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
STAD	cis	rs6714710	0.603	rs11681535	ENSG00000235833.1	AC159540.14	-5.15	4.28e-07	0.000314	-0.29	-0.27	Posterior cortical atrophy and Alzheimer's disease;	chr2:97872486	chr2:97523949~97524976:-
STAD	cis	rs2933343	0.621	rs6764682	ENSG00000231305.3	RP11-723O4.2	-5.15	4.28e-07	0.000314	-0.28	-0.27	IgG glycosylation;	chr3:128849540	chr3:128861313~128871540:-
STAD	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-5.15	4.28e-07	0.000315	-0.4	-0.27	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
STAD	cis	rs9463078	0.585	rs1284965	ENSG00000219384.1	RP11-491H9.3	5.15	4.28e-07	0.000315	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45209174	chr6:45158870~45159511:+
STAD	cis	rs516805	0.667	rs225074	ENSG00000279453.1	RP3-425C14.4	-5.15	4.29e-07	0.000315	-0.36	-0.27	Lymphocyte counts;	chr6:122265102	chr6:122436789~122439223:-
STAD	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-5.15	4.29e-07	0.000315	-0.3	-0.27	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
STAD	cis	rs748404	0.666	rs35326382	ENSG00000249839.1	AC011330.5	-5.15	4.29e-07	0.000315	-0.46	-0.27	Lung cancer;	chr15:43338686	chr15:43663654~43684339:-
STAD	cis	rs858239	0.509	rs57611130	ENSG00000226816.2	AC005082.12	5.15	4.29e-07	0.000315	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23206013~23208045:+
STAD	cis	rs1707322	0.638	rs9429095	ENSG00000280836.1	AL355480.1	5.15	4.29e-07	0.000315	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45581219~45581321:-
STAD	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-5.15	4.29e-07	0.000315	-0.44	-0.27	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
STAD	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-5.15	4.29e-07	0.000315	-0.34	-0.27	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
STAD	cis	rs7665090	1	rs2125211	ENSG00000230069.3	LRRC37A15P	5.15	4.29e-07	0.000315	0.31	0.27	Primary biliary cholangitis;	chr4:102638719	chr4:102727274~102730721:-
STAD	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-5.15	4.3e-07	0.000316	-0.42	-0.27	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
STAD	cis	rs750460	1	rs12441130	ENSG00000261801.4	LOXL1-AS1	-5.15	4.3e-07	0.000316	-0.32	-0.27	Height;	chr15:73942561	chr15:73908071~73928248:-
STAD	cis	rs3758911	1	rs10890716	ENSG00000261098.1	RP11-819C21.1	-5.15	4.3e-07	0.000316	-0.24	-0.27	Coronary artery disease;	chr11:107324310	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10789619	ENSG00000261098.1	RP11-819C21.1	-5.15	4.3e-07	0.000316	-0.24	-0.27	Coronary artery disease;	chr11:107324570	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs11212157	ENSG00000261098.1	RP11-819C21.1	-5.15	4.3e-07	0.000316	-0.24	-0.27	Coronary artery disease;	chr11:107324572	chr11:107312132~107316271:-
STAD	cis	rs1816752	0.74	rs6490924	ENSG00000273628.1	RP11-756A22.7	-5.15	4.3e-07	0.000316	-0.32	-0.27	Obesity-related traits;	chr13:24432914	chr13:24933006~24936796:+
STAD	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	5.15	4.31e-07	0.000316	0.28	0.27	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
STAD	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	5.15	4.31e-07	0.000316	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
STAD	cis	rs3806843	1	rs11167600	ENSG00000202111.1	VTRNA1-2	-5.15	4.31e-07	0.000316	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140795280	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs3806845	ENSG00000202111.1	VTRNA1-2	-5.15	4.31e-07	0.000316	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140801152	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs3733707	ENSG00000202111.1	VTRNA1-2	-5.15	4.31e-07	0.000316	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140802307	chr5:140718925~140719013:+
STAD	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	5.15	4.31e-07	0.000316	0.43	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
STAD	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	5.15	4.31e-07	0.000316	0.38	0.27	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
STAD	cis	rs1729407	0.741	rs1263177	ENSG00000280143.1	AP000892.6	5.15	4.31e-07	0.000317	0.19	0.27	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117204967~117210292:+
STAD	cis	rs3806843	1	rs6870764	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs6891995	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs13184940	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs1476768	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs9686540	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs3756339	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs3733708	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr5:140718925~140719013:+
STAD	cis	rs3806843	1	rs2240694	ENSG00000202111.1	VTRNA1-2	-5.15	4.32e-07	0.000317	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr5:140718925~140719013:+
STAD	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-5.15	4.32e-07	0.000317	-0.22	-0.27	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
STAD	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-5.15	4.33e-07	0.000317	-0.34	-0.27	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
STAD	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-5.15	4.33e-07	0.000318	-0.36	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
STAD	cis	rs516805	0.63	rs4245520	ENSG00000279453.1	RP3-425C14.4	-5.15	4.35e-07	0.000319	-0.38	-0.27	Lymphocyte counts;	chr6:122106477	chr6:122436789~122439223:-
STAD	cis	rs858239	1	rs156425	ENSG00000230042.1	AK3P3	5.15	4.35e-07	0.000319	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23129178~23129841:+
STAD	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	5.15	4.36e-07	0.00032	0.33	0.27	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
STAD	cis	rs9400467	0.528	rs1989574	ENSG00000230177.1	RP5-1112D6.4	-5.15	4.36e-07	0.00032	-0.24	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111277932~111278742:+
STAD	cis	rs4713118	0.869	rs6901520	ENSG00000280107.1	AL022393.9	-5.15	4.36e-07	0.00032	-0.35	-0.27	Parkinson's disease;	chr6:27746796	chr6:28170845~28172521:+
STAD	cis	rs875971	0.862	rs6460282	ENSG00000236529.1	RP13-254B10.1	-5.15	4.36e-07	0.00032	-0.28	-0.27	Aortic root size;	chr7:66226259	chr7:65840212~65840596:+
STAD	cis	rs516805	0.568	rs56290570	ENSG00000279453.1	RP3-425C14.4	5.15	4.36e-07	0.00032	0.36	0.27	Lymphocyte counts;	chr6:122240177	chr6:122436789~122439223:-
STAD	cis	rs1426063	1	rs10030850	ENSG00000249717.1	RP11-44F21.3	5.15	4.37e-07	0.000321	0.48	0.27	QT interval;	chr4:75099199	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs9993589	ENSG00000249717.1	RP11-44F21.3	5.15	4.37e-07	0.000321	0.48	0.27	QT interval;	chr4:75099556	chr4:74955974~74970362:-
STAD	cis	rs3758911	0.796	rs10890720	ENSG00000261098.1	RP11-819C21.1	5.15	4.37e-07	0.000321	0.24	0.27	Coronary artery disease;	chr11:107335292	chr11:107312132~107316271:-
STAD	cis	rs1816752	0.583	rs6490918	ENSG00000273628.1	RP11-756A22.7	-5.15	4.38e-07	0.000321	-0.32	-0.27	Obesity-related traits;	chr13:24427977	chr13:24933006~24936796:+
STAD	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	5.15	4.38e-07	0.000321	0.3	0.27	QT interval;	chr12:29304617	chr12:29280418~29317848:-
STAD	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-5.15	4.38e-07	0.000321	-0.39	-0.27	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
STAD	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	5.15	4.38e-07	0.000321	0.37	0.27	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
STAD	cis	rs1862618	0.671	rs832531	ENSG00000271828.1	CTD-2310F14.1	5.15	4.39e-07	0.000321	0.33	0.27	Initial pursuit acceleration;	chr5:56932574	chr5:56927874~56929573:+
STAD	cis	rs1799949	1	rs11653460	ENSG00000279602.1	CTD-3014M21.1	5.15	4.39e-07	0.000322	0.33	0.27	Menopause (age at onset);	chr17:43179289	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs11650913	ENSG00000279602.1	CTD-3014M21.1	5.15	4.39e-07	0.000322	0.33	0.27	Menopause (age at onset);	chr17:43179580	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs12936831	ENSG00000279602.1	CTD-3014M21.1	5.15	4.39e-07	0.000322	0.33	0.27	Menopause (age at onset);	chr17:43179799	chr17:43360041~43361361:-
STAD	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-5.15	4.39e-07	0.000322	-0.37	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
STAD	cis	rs227275	0.556	rs724447	ENSG00000230069.3	LRRC37A15P	5.15	4.4e-07	0.000322	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102727274~102730721:-
STAD	cis	rs13113518	0.683	rs9761521	ENSG00000272969.1	RP11-528I4.2	5.15	4.4e-07	0.000322	0.34	0.27	Height;	chr4:55363436	chr4:55547112~55547889:+
STAD	cis	rs9307551	0.711	rs11098774	ENSG00000250334.4	LINC00989	5.15	4.4e-07	0.000322	0.32	0.27	Refractive error;	chr4:79615697	chr4:79492416~79576460:+
STAD	cis	rs6142102	0.961	rs909884	ENSG00000275784.1	RP5-1125A11.6	-5.15	4.4e-07	0.000323	-0.28	-0.27	Skin pigmentation;	chr20:34058257	chr20:33989480~33991818:-
STAD	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	5.15	4.41e-07	0.000323	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
STAD	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-5.15	4.41e-07	0.000323	-0.33	-0.27	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
STAD	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	5.15	4.41e-07	0.000323	0.3	0.27	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
STAD	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	5.15	4.41e-07	0.000323	0.29	0.27	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
STAD	cis	rs3758911	0.765	rs588921	ENSG00000261098.1	RP11-819C21.1	5.15	4.41e-07	0.000323	0.25	0.27	Coronary artery disease;	chr11:107415274	chr11:107312132~107316271:-
STAD	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-5.15	4.42e-07	0.000323	-0.36	-0.27	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
STAD	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-5.15	4.42e-07	0.000324	-0.22	-0.27	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
STAD	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-5.15	4.42e-07	0.000324	-0.22	-0.27	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
STAD	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	5.15	4.42e-07	0.000324	0.27	0.27	Depression;	chr6:28363475	chr6:28176188~28176674:+
STAD	cis	rs1056107	0.863	rs7041663	ENSG00000225513.1	RP11-165N19.2	-5.15	4.42e-07	0.000324	-0.31	-0.27	Colorectal cancer;	chr9:112240538	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.898	rs1831118	ENSG00000225513.1	RP11-165N19.2	-5.15	4.42e-07	0.000324	-0.31	-0.27	Colorectal cancer;	chr9:112240552	chr9:112173522~112173971:-
STAD	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	5.15	4.42e-07	0.000324	0.41	0.27	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
STAD	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-5.15	4.43e-07	0.000324	-0.27	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
STAD	cis	rs10266483	0.576	rs2863327	ENSG00000271550.1	BNIP3P11	-5.15	4.43e-07	0.000324	-0.37	-0.27	Response to statin therapy;	chr7:64268698	chr7:64678954~64687393:-
STAD	cis	rs2439831	0.681	rs524527	ENSG00000249839.1	AC011330.5	5.15	4.43e-07	0.000325	0.38	0.27	Lung cancer in ever smokers;	chr15:43306918	chr15:43663654~43684339:-
STAD	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-5.15	4.43e-07	0.000325	-0.35	-0.27	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
STAD	cis	rs992157	0.835	rs2271543	ENSG00000237281.1	CATIP-AS2	5.15	4.44e-07	0.000325	0.27	0.27	Colorectal cancer;	chr2:218277768	chr2:218326889~218357966:-
STAD	cis	rs992157	0.717	rs3817266	ENSG00000237281.1	CATIP-AS2	5.15	4.44e-07	0.000325	0.27	0.27	Colorectal cancer;	chr2:218277871	chr2:218326889~218357966:-
STAD	cis	rs992157	0.835	rs2292551	ENSG00000237281.1	CATIP-AS2	5.15	4.44e-07	0.000325	0.27	0.27	Colorectal cancer;	chr2:218278506	chr2:218326889~218357966:-
STAD	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-5.15	4.44e-07	0.000325	-0.35	-0.27	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-5.15	4.44e-07	0.000325	-0.35	-0.27	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
STAD	cis	rs6714710	0.603	rs956039	ENSG00000235833.1	AC159540.14	-5.15	4.44e-07	0.000325	-0.31	-0.27	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800385	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs717417	ENSG00000235833.1	AC159540.14	-5.15	4.44e-07	0.000325	-0.31	-0.27	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800387	chr2:97523949~97524976:-
STAD	cis	rs13113518	0.729	rs12641881	ENSG00000272969.1	RP11-528I4.2	5.15	4.45e-07	0.000325	0.35	0.27	Height;	chr4:55401306	chr4:55547112~55547889:+
STAD	cis	rs7829975	0.871	rs777709	ENSG00000254340.1	RP11-10A14.3	-5.15	4.45e-07	0.000325	-0.31	-0.27	Mood instability;	chr8:8726362	chr8:9141424~9145435:+
STAD	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	5.15	4.45e-07	0.000325	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
STAD	cis	rs228614	0.51	rs223313	ENSG00000230069.3	LRRC37A15P	-5.15	4.45e-07	0.000326	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102727274~102730721:-
STAD	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-5.15	4.45e-07	0.000326	-0.33	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
STAD	cis	rs875971	0.545	rs6979636	ENSG00000236529.1	RP13-254B10.1	5.15	4.45e-07	0.000326	0.31	0.27	Aortic root size;	chr7:66276638	chr7:65840212~65840596:+
STAD	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	5.15	4.46e-07	0.000326	0.34	0.27	Height;	chr6:109423330	chr6:109382795~109383666:+
STAD	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	5.15	4.46e-07	0.000326	0.34	0.27	Height;	chr6:109423487	chr6:109382795~109383666:+
STAD	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	5.15	4.47e-07	0.000327	0.27	0.27	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs6088361	ENSG00000275784.1	RP5-1125A11.6	-5.15	4.47e-07	0.000327	-0.28	-0.27	Skin pigmentation;	chr20:33969520	chr20:33989480~33991818:-
STAD	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	5.15	4.47e-07	0.000327	0.27	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
STAD	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-5.15	4.47e-07	0.000327	-0.39	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
STAD	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-5.15	4.48e-07	0.000327	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
STAD	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	5.15	4.48e-07	0.000327	0.38	0.27	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
STAD	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-5.15	4.48e-07	0.000328	-0.24	-0.27	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
STAD	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	5.15	4.49e-07	0.000328	0.41	0.27	Height;	chr6:109455700	chr6:109382795~109383666:+
STAD	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	5.15	4.49e-07	0.000328	0.35	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
STAD	cis	rs7580658	0.637	rs4580338	ENSG00000200250.1	RNU6-1147P	5.15	4.49e-07	0.000328	0.25	0.27	Protein C levels;	chr2:127217361	chr2:127316873~127316979:+
STAD	cis	rs516805	0.63	rs1379098	ENSG00000279453.1	RP3-425C14.4	-5.15	4.49e-07	0.000328	-0.37	-0.27	Lymphocyte counts;	chr6:122121672	chr6:122436789~122439223:-
STAD	cis	rs516805	0.634	rs2816159	ENSG00000279453.1	RP3-425C14.4	-5.15	4.49e-07	0.000328	-0.37	-0.27	Lymphocyte counts;	chr6:122121982	chr6:122436789~122439223:-
STAD	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	5.14	4.49e-07	0.000328	0.29	0.27	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
STAD	cis	rs728616	1	rs12414891	ENSG00000225484.5	NUTM2B-AS1	-5.14	4.49e-07	0.000328	-0.59	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:79663088~79826594:-
STAD	cis	rs7829975	0.688	rs6601703	ENSG00000254340.1	RP11-10A14.3	5.14	4.49e-07	0.000328	0.32	0.27	Mood instability;	chr8:8522714	chr8:9141424~9145435:+
STAD	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-5.14	4.51e-07	0.00033	-0.29	-0.27	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
STAD	cis	rs11169552	1	rs10876080	ENSG00000200183.1	RNU6-238P	-5.14	4.51e-07	0.00033	-0.26	-0.27	Colorectal cancer;	chr12:50761411	chr12:50656973~50657078:+
STAD	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-5.14	4.51e-07	0.00033	-0.28	-0.27	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
STAD	cis	rs875971	0.862	rs6971059	ENSG00000236529.1	RP13-254B10.1	-5.14	4.51e-07	0.00033	-0.27	-0.27	Aortic root size;	chr7:66602045	chr7:65840212~65840596:+
STAD	cis	rs875971	0.789	rs7808013	ENSG00000236529.1	RP13-254B10.1	-5.14	4.51e-07	0.00033	-0.27	-0.27	Aortic root size;	chr7:66606209	chr7:65840212~65840596:+
STAD	cis	rs875971	0.825	rs7384021	ENSG00000236529.1	RP13-254B10.1	-5.14	4.51e-07	0.00033	-0.27	-0.27	Aortic root size;	chr7:66612917	chr7:65840212~65840596:+
STAD	cis	rs875971	0.825	rs66981195	ENSG00000236529.1	RP13-254B10.1	-5.14	4.51e-07	0.00033	-0.27	-0.27	Aortic root size;	chr7:66614048	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs3926380	ENSG00000236529.1	RP13-254B10.1	-5.14	4.51e-07	0.00033	-0.27	-0.27	Aortic root size;	chr7:66615658	chr7:65840212~65840596:+
STAD	cis	rs875971	0.825	rs1860472	ENSG00000236529.1	RP13-254B10.1	-5.14	4.51e-07	0.00033	-0.27	-0.27	Aortic root size;	chr7:66617736	chr7:65840212~65840596:+
STAD	cis	rs7665090	0.905	rs2866410	ENSG00000248971.2	KRT8P46	-5.14	4.52e-07	0.00033	-0.28	-0.27	Primary biliary cholangitis;	chr4:102633178	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.936	rs2866411	ENSG00000248971.2	KRT8P46	-5.14	4.52e-07	0.00033	-0.28	-0.27	Primary biliary cholangitis;	chr4:102633183	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.936	rs2866412	ENSG00000248971.2	KRT8P46	-5.14	4.52e-07	0.00033	-0.28	-0.27	Primary biliary cholangitis;	chr4:102633193	chr4:102728746~102730171:-
STAD	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-5.14	4.52e-07	0.00033	-0.36	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
STAD	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	5.14	4.52e-07	0.00033	0.33	0.27	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
STAD	cis	rs172166	0.516	rs1150670	ENSG00000220721.1	OR1F12	5.14	4.52e-07	0.00033	0.26	0.27	Cardiac Troponin-T levels;	chr6:28162781	chr6:28073316~28074233:+
STAD	cis	rs172166	0.516	rs2021826	ENSG00000220721.1	OR1F12	5.14	4.52e-07	0.00033	0.26	0.27	Cardiac Troponin-T levels;	chr6:28164978	chr6:28073316~28074233:+
STAD	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-5.14	4.52e-07	0.00033	-0.22	-0.27	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
STAD	cis	rs1799949	1	rs1973646	ENSG00000236383.6	LINC00854	-5.14	4.53e-07	0.000331	-0.22	-0.27	Menopause (age at onset);	chr17:43158478	chr17:43216941~43305976:-
STAD	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-5.14	4.53e-07	0.000331	-0.29	-0.27	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-5.14	4.53e-07	0.000331	-0.29	-0.27	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-5.14	4.53e-07	0.000331	-0.29	-0.27	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-5.14	4.53e-07	0.000331	-0.29	-0.27	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-5.14	4.53e-07	0.000331	-0.29	-0.27	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-5.14	4.53e-07	0.000331	-0.29	-0.27	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
STAD	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-5.14	4.53e-07	0.000331	-0.36	-0.27	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
STAD	cis	rs189798	0.592	rs10111263	ENSG00000173295.6	FAM86B3P	-5.14	4.54e-07	0.000331	-0.31	-0.27	Myopia (pathological);	chr8:9111923	chr8:8228595~8244865:+
STAD	cis	rs7927771	0.507	rs7119517	ENSG00000280615.1	Y_RNA	5.14	4.54e-07	0.000331	0.27	0.27	Subjective well-being;	chr11:47653764	chr11:47614898~47614994:-
STAD	cis	rs748404	0.666	rs12907870	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43453971	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs72709850	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43462486	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs34633582	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43462683	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs36078097	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43466209	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs7181783	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43469723	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs35903301	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43472332	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs34002293	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43472401	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs34181131	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43478527	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs7173383	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43480838	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs55801120	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43495042	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs12911740	ENSG00000249839.1	AC011330.5	-5.14	4.54e-07	0.000331	-0.44	-0.27	Lung cancer;	chr15:43498254	chr15:43663654~43684339:-
STAD	cis	rs8098244	0.516	rs2960586	ENSG00000267301.1	RPL23AP77	-5.14	4.54e-07	0.000331	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690207	chr18:23709825~23710287:-
STAD	cis	rs35955747	0.633	rs4541328	ENSG00000236132.1	CTA-440B3.1	5.14	4.54e-07	0.000331	0.29	0.27	Neutrophil count;Sum basophil neutrophil counts;	chr22:31500186	chr22:31816379~31817491:-
STAD	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	5.14	4.55e-07	0.000332	0.29	0.27	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	5.14	4.55e-07	0.000332	0.29	0.27	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
STAD	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	5.14	4.55e-07	0.000332	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	5.14	4.55e-07	0.000332	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs57864591	ENSG00000226816.2	AC005082.12	5.14	4.56e-07	0.000332	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23206013~23208045:+
STAD	cis	rs9307551	1	rs3943669	ENSG00000250334.4	LINC00989	-5.14	4.56e-07	0.000333	-0.34	-0.27	Refractive error;	chr4:79595389	chr4:79492416~79576460:+
STAD	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-5.14	4.57e-07	0.000333	-0.33	-0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
STAD	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	5.14	4.57e-07	0.000333	0.27	0.27	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
STAD	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	5.14	4.57e-07	0.000333	0.3	0.27	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	5.14	4.57e-07	0.000333	0.3	0.27	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
STAD	cis	rs240993	0.812	rs9398272	ENSG00000230177.1	RP5-1112D6.4	5.14	4.58e-07	0.000334	0.27	0.27	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:111277932~111278742:+
STAD	cis	rs11169552	0.51	rs4768912	ENSG00000200183.1	RNU6-238P	-5.14	4.58e-07	0.000334	-0.26	-0.27	Colorectal cancer;	chr12:50742157	chr12:50656973~50657078:+
STAD	cis	rs8067354	0.645	rs11079389	ENSG00000266701.1	AC005702.4	5.14	4.59e-07	0.000334	0.37	0.27	Hemoglobin concentration;	chr17:59810591	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs2665403	ENSG00000266701.1	AC005702.4	5.14	4.59e-07	0.000334	0.37	0.27	Hemoglobin concentration;	chr17:59812624	chr17:60042546~60042627:-
STAD	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	5.14	4.59e-07	0.000334	0.36	0.27	Height;	chr6:109387685	chr6:109382795~109383666:+
STAD	cis	rs2446066	0.659	rs34109204	ENSG00000257379.1	RP11-793H13.8	5.14	4.59e-07	0.000334	0.51	0.27	Red blood cell count;	chr12:53478499	chr12:53441741~53467528:+
STAD	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	5.14	4.59e-07	0.000335	0.33	0.27	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
STAD	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-5.14	4.6e-07	0.000335	-0.31	-0.27	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
STAD	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-5.14	4.6e-07	0.000335	-0.35	-0.27	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
STAD	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-5.14	4.6e-07	0.000335	-0.22	-0.27	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
STAD	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	5.14	4.6e-07	0.000335	0.3	0.27	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
STAD	cis	rs728616	0.867	rs61860417	ENSG00000225484.5	NUTM2B-AS1	-5.14	4.6e-07	0.000335	-0.58	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79663088~79826594:-
STAD	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	5.14	4.61e-07	0.000336	0.4	0.27	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
STAD	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	5.14	4.61e-07	0.000336	0.28	0.27	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
STAD	cis	rs240993	0.812	rs10214442	ENSG00000230177.1	RP5-1112D6.4	-5.14	4.61e-07	0.000336	-0.27	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111277932~111278742:+
STAD	cis	rs747650	0.504	rs7126005	ENSG00000271350.1	CTD-2384B9.1	-5.14	4.61e-07	0.000336	-0.34	-0.27	Acne (severe);	chr11:47019514	chr11:47041027~47041945:-
STAD	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	5.14	4.61e-07	0.000336	0.3	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
STAD	cis	rs7927771	0.524	rs7107922	ENSG00000280615.1	Y_RNA	5.14	4.62e-07	0.000337	0.27	0.27	Subjective well-being;	chr11:47647737	chr11:47614898~47614994:-
STAD	cis	rs12744310	0.887	rs12757611	ENSG00000235358.1	RP11-399E6.1	5.14	4.62e-07	0.000337	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343300	chr1:41242373~41284861:+
STAD	cis	rs1799949	0.931	rs34474989	ENSG00000279602.1	CTD-3014M21.1	5.14	4.62e-07	0.000337	0.32	0.27	Menopause (age at onset);	chr17:43368042	chr17:43360041~43361361:-
STAD	cis	rs9467773	0.869	rs742090	ENSG00000243307.2	POM121L6P	-5.14	4.63e-07	0.000337	-0.25	-0.27	Intelligence (multi-trait analysis);	chr6:26415409	chr6:26896952~26898777:+
STAD	cis	rs1799949	0.965	rs1842147	ENSG00000236383.6	LINC00854	-5.14	4.64e-07	0.000337	-0.22	-0.27	Menopause (age at onset);	chr17:43357824	chr17:43216941~43305976:-
STAD	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-5.14	4.64e-07	0.000338	-0.35	-0.27	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
STAD	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	5.14	4.64e-07	0.000338	0.38	0.27	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
STAD	cis	rs1799949	1	rs11651341	ENSG00000279602.1	CTD-3014M21.1	5.14	4.64e-07	0.000338	0.33	0.27	Menopause (age at onset);	chr17:43350693	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs34572725	ENSG00000279602.1	CTD-3014M21.1	5.14	4.64e-07	0.000338	0.33	0.27	Menopause (age at onset);	chr17:43351298	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs4534897	ENSG00000279602.1	CTD-3014M21.1	5.14	4.64e-07	0.000338	0.33	0.27	Menopause (age at onset);	chr17:43354440	chr17:43360041~43361361:-
STAD	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-5.14	4.64e-07	0.000338	-0.33	-0.27	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
STAD	cis	rs7487075	0.786	rs12302984	ENSG00000272369.1	RP11-446N19.1	5.14	4.65e-07	0.000338	0.32	0.27	Itch intensity from mosquito bite;	chr12:46290287	chr12:46537502~46652550:+
STAD	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-5.14	4.65e-07	0.000338	-0.42	-0.27	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
STAD	cis	rs1426063	1	rs11941556	ENSG00000249717.1	RP11-44F21.3	5.14	4.65e-07	0.000338	0.47	0.27	QT interval;	chr4:75093825	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs10022814	ENSG00000249717.1	RP11-44F21.3	5.14	4.65e-07	0.000338	0.47	0.27	QT interval;	chr4:75094704	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs10029141	ENSG00000249717.1	RP11-44F21.3	5.14	4.65e-07	0.000338	0.47	0.27	QT interval;	chr4:75097437	chr4:74955974~74970362:-
STAD	cis	rs7932354	0.528	rs4752967	ENSG00000271350.1	CTD-2384B9.1	5.14	4.65e-07	0.000339	0.32	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47147825	chr11:47041027~47041945:-
STAD	cis	rs5758659	1	rs134882	ENSG00000182057.4	OGFRP1	5.14	4.65e-07	0.000339	0.27	0.27	Cognitive function;	chr22:42274959	chr22:42269753~42275196:+
STAD	cis	rs1799949	0.965	rs11080034	ENSG00000279602.1	CTD-3014M21.1	5.14	4.66e-07	0.000339	0.32	0.27	Menopause (age at onset);	chr17:43365646	chr17:43360041~43361361:-
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000224205.1	AP000351.4	5.14	4.66e-07	0.000339	0.3	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23987320~23991421:-
STAD	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-5.14	4.66e-07	0.000339	-0.3	-0.27	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
STAD	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-5.14	4.66e-07	0.000339	-0.32	-0.27	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
STAD	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-5.14	4.66e-07	0.000339	-0.29	-0.27	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
STAD	cis	rs6142102	0.812	rs725478	ENSG00000275784.1	RP5-1125A11.6	5.14	4.66e-07	0.000339	0.28	0.27	Skin pigmentation;	chr20:33930548	chr20:33989480~33991818:-
STAD	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-5.14	4.67e-07	0.00034	-0.31	-0.27	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
STAD	cis	rs8067354	0.645	rs2665400	ENSG00000266701.1	AC005702.4	5.14	4.67e-07	0.00034	0.37	0.27	Hemoglobin concentration;	chr17:59802840	chr17:60042546~60042627:-
STAD	cis	rs9549260	0.56	rs61963353	ENSG00000229456.1	RLIMP1	5.14	4.67e-07	0.00034	0.32	0.27	Red blood cell count;	chr13:40753165	chr13:40618738~40621348:+
STAD	cis	rs9549260	0.569	rs7328453	ENSG00000229456.1	RLIMP1	5.14	4.67e-07	0.00034	0.32	0.27	Red blood cell count;	chr13:40760191	chr13:40618738~40621348:+
STAD	cis	rs516805	0.667	rs2606651	ENSG00000279453.1	RP3-425C14.4	-5.14	4.67e-07	0.00034	-0.38	-0.27	Lymphocyte counts;	chr6:122136475	chr6:122436789~122439223:-
STAD	cis	rs7115242	0.925	rs7925256	ENSG00000280143.1	AP000892.6	5.14	4.68e-07	0.00034	0.35	0.27	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117204967~117210292:+
STAD	cis	rs7487075	0.751	rs10880947	ENSG00000272369.1	RP11-446N19.1	-5.14	4.68e-07	0.00034	-0.34	-0.27	Itch intensity from mosquito bite;	chr12:46283501	chr12:46537502~46652550:+
STAD	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-5.14	4.68e-07	0.00034	-0.31	-0.27	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
STAD	cis	rs8098244	0.617	rs35943794	ENSG00000267301.1	RPL23AP77	-5.14	4.68e-07	0.000341	-0.31	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23826485	chr18:23709825~23710287:-
STAD	cis	rs3758911	0.796	rs2356280	ENSG00000261098.1	RP11-819C21.1	-5.14	4.69e-07	0.000341	-0.25	-0.27	Coronary artery disease;	chr11:107356230	chr11:107312132~107316271:-
STAD	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	5.14	4.69e-07	0.000341	0.36	0.27	Height;	chr6:109366911	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	5.14	4.69e-07	0.000341	0.36	0.27	Height;	chr6:109375003	chr6:109382795~109383666:+
STAD	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	5.14	4.69e-07	0.000341	0.31	0.27	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
STAD	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	5.14	4.7e-07	0.000341	0.41	0.27	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
STAD	cis	rs875971	0.862	rs7783779	ENSG00000236529.1	RP13-254B10.1	-5.14	4.7e-07	0.000342	-0.27	-0.27	Aortic root size;	chr7:66331639	chr7:65840212~65840596:+
STAD	cis	rs3758911	0.796	rs4576794	ENSG00000261098.1	RP11-819C21.1	-5.14	4.7e-07	0.000342	-0.25	-0.27	Coronary artery disease;	chr11:107353499	chr11:107312132~107316271:-
STAD	cis	rs7580658	0.637	rs4662710	ENSG00000200250.1	RNU6-1147P	5.14	4.71e-07	0.000342	0.25	0.27	Protein C levels;	chr2:127219241	chr2:127316873~127316979:+
STAD	cis	rs17592366	0.517	rs60007157	ENSG00000251726.1	RNU7-41P	-5.14	4.71e-07	0.000343	-0.24	-0.27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34843066	chr14:34845300~34845360:-
STAD	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-5.14	4.72e-07	0.000343	-0.28	-0.27	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
STAD	cis	rs11846409	0.872	rs74091715	ENSG00000211972.2	IGHV3-66	5.13	4.72e-07	0.000343	0.28	0.27	Rheumatic heart disease;	chr14:106637731	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs74091721	ENSG00000211972.2	IGHV3-66	5.13	4.72e-07	0.000343	0.28	0.27	Rheumatic heart disease;	chr14:106638262	chr14:106675017~106675544:-
STAD	cis	rs12744310	1	rs57529969	ENSG00000235358.1	RP11-399E6.1	5.13	4.72e-07	0.000343	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306011	chr1:41242373~41284861:+
STAD	cis	rs6095360	0.727	rs755588	ENSG00000222365.1	SNORD12B	-5.13	4.73e-07	0.000343	-0.34	-0.27	Intelligence (multi-trait analysis);	chr20:49104491	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs13040292	ENSG00000222365.1	SNORD12B	-5.13	4.73e-07	0.000343	-0.34	-0.27	Intelligence (multi-trait analysis);	chr20:49105045	chr20:49280319~49280409:+
STAD	cis	rs11148252	0.532	rs9536262	ENSG00000235660.1	LINC00345	5.13	4.73e-07	0.000344	0.29	0.27	Lewy body disease;	chr13:52728939	chr13:52484161~52484680:-
STAD	cis	rs747650	0.504	rs7935346	ENSG00000271350.1	CTD-2384B9.1	-5.13	4.73e-07	0.000344	-0.33	-0.27	Acne (severe);	chr11:46986828	chr11:47041027~47041945:-
STAD	cis	rs957448	0.561	rs34471170	ENSG00000253704.1	RP11-267M23.4	5.13	4.74e-07	0.000345	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94553722~94569745:+
STAD	cis	rs957448	0.561	rs9642927	ENSG00000253704.1	RP11-267M23.4	5.13	4.74e-07	0.000345	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94553722~94569745:+
STAD	cis	rs957448	0.529	rs9642928	ENSG00000253704.1	RP11-267M23.4	5.13	4.74e-07	0.000345	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94553722~94569745:+
STAD	cis	rs957448	0.561	rs1808488	ENSG00000253704.1	RP11-267M23.4	5.13	4.74e-07	0.000345	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94553722~94569745:+
STAD	cis	rs957448	0.583	rs754275	ENSG00000253704.1	RP11-267M23.4	5.13	4.74e-07	0.000345	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94553722~94569745:+
STAD	cis	rs957448	0.561	rs1426172	ENSG00000253704.1	RP11-267M23.4	5.13	4.74e-07	0.000345	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94553722~94569745:+
STAD	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	5.13	4.74e-07	0.000345	0.32	0.27	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
STAD	cis	rs3758911	0.964	rs10789608	ENSG00000261098.1	RP11-819C21.1	-5.13	4.75e-07	0.000345	-0.24	-0.27	Coronary artery disease;	chr11:107314132	chr11:107312132~107316271:-
STAD	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	5.13	4.75e-07	0.000345	0.29	0.27	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	5.13	4.75e-07	0.000345	0.29	0.27	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
STAD	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	5.13	4.75e-07	0.000345	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
STAD	cis	rs6584283	0.846	rs7917446	ENSG00000228778.1	RP11-129J12.1	-5.13	4.75e-07	0.000345	-0.3	-0.27	Ulcerative colitis;	chr10:99526450	chr10:99527081~99528261:+
STAD	cis	rs10504130	0.696	rs113323463	ENSG00000272024.1	RP11-546K22.3	-5.13	4.76e-07	0.000345	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs111926180	ENSG00000272024.1	RP11-546K22.3	-5.13	4.76e-07	0.000345	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs78238505	ENSG00000272024.1	RP11-546K22.3	-5.13	4.76e-07	0.000345	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs76649327	ENSG00000272024.1	RP11-546K22.3	-5.13	4.76e-07	0.000345	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs76717135	ENSG00000272024.1	RP11-546K22.3	-5.13	4.76e-07	0.000345	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51950284~51950690:+
STAD	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	5.13	4.76e-07	0.000346	0.41	0.27	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
STAD	cis	rs7760535	0.93	rs10872069	ENSG00000230177.1	RP5-1112D6.4	-5.13	4.76e-07	0.000346	-0.25	-0.27	Metabolic traits;	chr6:111540523	chr6:111277932~111278742:+
STAD	cis	rs611744	0.523	rs13253581	ENSG00000253754.1	RP11-35G22.1	-5.13	4.77e-07	0.000346	-0.24	-0.27	Dupuytren's disease;	chr8:108330876	chr8:108226200~108227544:+
STAD	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-5.13	4.77e-07	0.000346	-0.31	-0.27	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
STAD	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	5.13	4.77e-07	0.000346	0.28	0.27	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
STAD	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	5.13	4.77e-07	0.000346	0.32	0.27	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
STAD	cis	rs12744310	1	rs55929643	ENSG00000235358.1	RP11-399E6.1	5.13	4.77e-07	0.000346	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308540	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.945	rs72665692	ENSG00000235358.1	RP11-399E6.1	5.13	4.77e-07	0.000346	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309707	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs72665694	ENSG00000235358.1	RP11-399E6.1	5.13	4.77e-07	0.000346	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309712	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12036554	ENSG00000235358.1	RP11-399E6.1	5.13	4.77e-07	0.000346	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312317	chr1:41242373~41284861:+
STAD	cis	rs12744310	1	rs12036555	ENSG00000235358.1	RP11-399E6.1	5.13	4.77e-07	0.000346	0.35	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312318	chr1:41242373~41284861:+
STAD	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-5.13	4.77e-07	0.000347	-0.39	-0.27	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
STAD	cis	rs3758911	0.861	rs10890689	ENSG00000261098.1	RP11-819C21.1	-5.13	4.77e-07	0.000347	-0.24	-0.27	Coronary artery disease;	chr11:107275626	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs10890690	ENSG00000261098.1	RP11-819C21.1	-5.13	4.77e-07	0.000347	-0.24	-0.27	Coronary artery disease;	chr11:107276174	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs11212116	ENSG00000261098.1	RP11-819C21.1	-5.13	4.77e-07	0.000347	-0.24	-0.27	Coronary artery disease;	chr11:107276621	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs10890692	ENSG00000261098.1	RP11-819C21.1	-5.13	4.77e-07	0.000347	-0.24	-0.27	Coronary artery disease;	chr11:107277053	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs10749890	ENSG00000261098.1	RP11-819C21.1	-5.13	4.77e-07	0.000347	-0.24	-0.27	Coronary artery disease;	chr11:107278357	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs10454489	ENSG00000261098.1	RP11-819C21.1	-5.13	4.77e-07	0.000347	-0.24	-0.27	Coronary artery disease;	chr11:107279206	chr11:107312132~107316271:-
STAD	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	5.13	4.78e-07	0.000347	0.36	0.27	Height;	chr6:109361318	chr6:109382795~109383666:+
STAD	cis	rs7932354	0.528	rs1965952	ENSG00000271350.1	CTD-2384B9.1	5.13	4.79e-07	0.000348	0.32	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47159489	chr11:47041027~47041945:-
STAD	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-5.13	4.8e-07	0.000348	-0.3	-0.27	Migraine;	chr4:56950140	chr4:56960927~56961373:-
STAD	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	5.13	4.8e-07	0.000349	0.38	0.27	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
STAD	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	5.13	4.82e-07	0.000349	0.35	0.27	Height;	chr6:109395761	chr6:109382795~109383666:+
STAD	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-5.13	4.82e-07	0.000349	-0.32	-0.27	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
STAD	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	5.13	4.82e-07	0.00035	0.29	0.27	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
STAD	cis	rs987710	1	rs987710	ENSG00000211639.2	IGLV4-60	-5.13	4.83e-07	0.00035	-0.27	-0.27	Iron status biomarkers;Iron deficiency;	chr22:22158022	chr22:22162199~22162681:+
STAD	cis	rs1799949	0.683	rs55737636	ENSG00000236383.6	LINC00854	-5.13	4.83e-07	0.00035	-0.21	-0.27	Menopause (age at onset);	chr17:43112722	chr17:43216941~43305976:-
STAD	cis	rs6714710	0.603	rs34503448	ENSG00000235833.1	AC159540.14	-5.13	4.83e-07	0.00035	-0.31	-0.27	Posterior cortical atrophy and Alzheimer's disease;	chr2:97970825	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs953320	ENSG00000235833.1	AC159540.14	-5.13	4.83e-07	0.00035	-0.31	-0.27	Posterior cortical atrophy and Alzheimer's disease;	chr2:97990307	chr2:97523949~97524976:-
STAD	cis	rs8098244	0.603	rs1788787	ENSG00000267301.1	RPL23AP77	-5.13	4.83e-07	0.00035	-0.31	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23694775	chr18:23709825~23710287:-
STAD	cis	rs875971	0.895	rs6460278	ENSG00000236529.1	RP13-254B10.1	-5.13	4.83e-07	0.00035	-0.28	-0.27	Aortic root size;	chr7:66197749	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6460279	ENSG00000236529.1	RP13-254B10.1	-5.13	4.83e-07	0.00035	-0.28	-0.27	Aortic root size;	chr7:66197774	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs28491091	ENSG00000236529.1	RP13-254B10.1	-5.13	4.83e-07	0.00035	-0.28	-0.27	Aortic root size;	chr7:66204077	chr7:65840212~65840596:+
STAD	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	5.13	4.83e-07	0.00035	0.31	0.27	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
STAD	cis	rs10853057	0.85	rs8076385	ENSG00000214174.7	AMZ2P1	5.13	4.83e-07	0.00035	0.53	0.27	White matter microstructure (global fractional anisotropy);	chr17:65002369	chr17:64966550~64975576:-
STAD	cis	rs9463078	0.585	rs964452	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45161005	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs1748231	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45165617	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs1748234	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45173116	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs1748235	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45173624	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs9463075	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45181913	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.565	rs1797161	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45182484	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs1284969	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45186144	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.565	rs1797145	ENSG00000219384.1	RP11-491H9.3	5.13	4.84e-07	0.000351	0.26	0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45188045	chr6:45158870~45159511:+
STAD	cis	rs1816752	0.776	rs9511268	ENSG00000273628.1	RP11-756A22.7	5.13	4.84e-07	0.000351	0.33	0.27	Obesity-related traits;	chr13:24444182	chr13:24933006~24936796:+
STAD	cis	rs858239	0.601	rs73272048	ENSG00000226816.2	AC005082.12	5.13	4.84e-07	0.000351	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23206013~23208045:+
STAD	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-5.13	4.84e-07	0.000351	-0.3	-0.27	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
STAD	cis	rs9463078	0.605	rs9472416	ENSG00000219384.1	RP11-491H9.3	-5.13	4.84e-07	0.000351	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44983226	chr6:45158870~45159511:+
STAD	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-5.13	4.84e-07	0.000351	-0.28	-0.27	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
STAD	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-5.13	4.84e-07	0.000351	-0.28	-0.27	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
STAD	cis	rs858239	0.571	rs2390755	ENSG00000226816.2	AC005082.12	5.13	4.85e-07	0.000351	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23206013~23208045:+
STAD	cis	rs453301	0.686	rs13252797	ENSG00000254340.1	RP11-10A14.3	5.13	4.85e-07	0.000351	0.35	0.27	Joint mobility (Beighton score);	chr8:9003920	chr8:9141424~9145435:+
STAD	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-5.13	4.85e-07	0.000351	-0.35	-0.27	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
STAD	cis	rs611744	0.506	rs4735054	ENSG00000253754.1	RP11-35G22.1	5.13	4.85e-07	0.000351	0.23	0.27	Dupuytren's disease;	chr8:108249551	chr8:108226200~108227544:+
STAD	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-5.13	4.85e-07	0.000352	-0.33	-0.27	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
STAD	cis	rs1799949	0.93	rs8176194	ENSG00000279602.1	CTD-3014M21.1	5.13	4.85e-07	0.000352	0.33	0.27	Menopause (age at onset);	chr17:43079204	chr17:43360041~43361361:-
STAD	cis	rs6095360	0.727	rs35989889	ENSG00000222365.1	SNORD12B	-5.13	4.85e-07	0.000352	-0.34	-0.27	Intelligence (multi-trait analysis);	chr20:49100816	chr20:49280319~49280409:+
STAD	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	5.13	4.86e-07	0.000352	0.37	0.27	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	5.13	4.86e-07	0.000352	0.37	0.27	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	5.13	4.86e-07	0.000352	0.37	0.27	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	5.13	4.86e-07	0.000352	0.37	0.27	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
STAD	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	5.13	4.86e-07	0.000352	0.37	0.27	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
STAD	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	5.13	4.86e-07	0.000352	0.32	0.27	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
STAD	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-5.13	4.86e-07	0.000352	-0.37	-0.27	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
STAD	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-5.13	4.86e-07	0.000352	-0.37	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
STAD	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	5.13	4.86e-07	0.000352	0.35	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
STAD	cis	rs10510102	0.872	rs10887003	ENSG00000226864.1	ATE1-AS1	5.13	4.86e-07	0.000352	0.42	0.27	Breast cancer;	chr10:121864660	chr10:121928312~121951965:+
STAD	cis	rs611744	0.583	rs1448148	ENSG00000253754.1	RP11-35G22.1	-5.13	4.87e-07	0.000353	-0.24	-0.27	Dupuytren's disease;	chr8:108320845	chr8:108226200~108227544:+
STAD	cis	rs7176527	1	rs3762169	ENSG00000188388.10	GOLGA6L3	5.13	4.87e-07	0.000353	0.37	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85240472~85247170:+
STAD	cis	rs9907295	0.818	rs9889874	ENSG00000270894.1	AC015849.13	-5.13	4.87e-07	0.000353	-0.28	-0.27	Fibroblast growth factor basic levels;	chr17:35875293	chr17:35818399~35823713:+
STAD	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-5.13	4.87e-07	0.000353	-0.35	-0.27	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000211973.2	IGHV1-69	5.13	4.88e-07	0.000353	0.22	0.27	Kawasaki disease;	chr14:106782523	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000211973.2	IGHV1-69	5.13	4.88e-07	0.000353	0.22	0.27	Kawasaki disease;	chr14:106782559	chr14:106714684~106715181:-
STAD	cis	rs8062405	0.69	rs6498089	ENSG00000278665.1	RP11-666O2.4	-5.13	4.88e-07	0.000353	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28599241~28601881:-
STAD	cis	rs1799949	0.931	rs9912203	ENSG00000236383.6	LINC00854	5.13	4.88e-07	0.000353	0.21	0.27	Menopause (age at onset);	chr17:43367777	chr17:43216941~43305976:-
STAD	cis	rs3806843	1	rs3733710	ENSG00000202111.1	VTRNA1-2	-5.13	4.88e-07	0.000353	-0.26	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr5:140718925~140719013:+
STAD	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	5.13	4.89e-07	0.000354	0.38	0.27	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	5.13	4.89e-07	0.000354	0.38	0.27	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
STAD	cis	rs7927771	0.524	rs2869024	ENSG00000280615.1	Y_RNA	-5.13	4.89e-07	0.000354	-0.27	-0.27	Subjective well-being;	chr11:47652549	chr11:47614898~47614994:-
STAD	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-5.13	4.89e-07	0.000354	-0.34	-0.27	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
STAD	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-5.13	4.89e-07	0.000354	-0.22	-0.27	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
STAD	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-5.13	4.89e-07	0.000354	-0.27	-0.27	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
STAD	cis	rs516805	0.63	rs696650	ENSG00000279453.1	RP3-425C14.4	-5.13	4.9e-07	0.000355	-0.35	-0.27	Lymphocyte counts;	chr6:122261316	chr6:122436789~122439223:-
STAD	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-5.13	4.9e-07	0.000355	-0.22	-0.27	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
STAD	cis	rs2404602	0.692	rs1116535	ENSG00000259422.1	RP11-593F23.1	-5.13	4.91e-07	0.000355	-0.28	-0.27	Blood metabolite levels;	chr15:76717173	chr15:76174891~76181486:-
STAD	cis	rs6782228	1	rs35871360	ENSG00000277250.1	Metazoa_SRP	5.13	4.91e-07	0.000355	0.32	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128673681~128674021:-
STAD	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-5.13	4.91e-07	0.000356	-0.31	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
STAD	cis	rs2980439	0.807	rs2980438	ENSG00000254340.1	RP11-10A14.3	5.13	4.92e-07	0.000356	0.32	0.27	Neuroticism;	chr8:8237303	chr8:9141424~9145435:+
STAD	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-5.13	4.93e-07	0.000356	-0.24	-0.27	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
STAD	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	5.13	4.93e-07	0.000357	0.43	0.27	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
STAD	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-5.13	4.93e-07	0.000357	-0.31	-0.27	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-5.13	4.93e-07	0.000357	-0.31	-0.27	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
STAD	cis	rs7829975	0.511	rs2976902	ENSG00000254340.1	RP11-10A14.3	5.13	4.93e-07	0.000357	0.32	0.27	Mood instability;	chr8:8483595	chr8:9141424~9145435:+
STAD	cis	rs747650	0.504	rs6485715	ENSG00000271350.1	CTD-2384B9.1	5.13	4.93e-07	0.000357	0.33	0.27	Acne (severe);	chr11:46953574	chr11:47041027~47041945:-
STAD	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	5.13	4.93e-07	0.000357	0.31	0.27	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
STAD	cis	rs11676348	0.755	rs62183956	ENSG00000237281.1	CATIP-AS2	-5.13	4.93e-07	0.000357	-0.27	-0.27	Ulcerative colitis;	chr2:218181399	chr2:218326889~218357966:-
STAD	cis	rs748404	0.666	rs12913977	ENSG00000249839.1	AC011330.5	-5.13	4.93e-07	0.000357	-0.44	-0.27	Lung cancer;	chr15:43438913	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs12914122	ENSG00000249839.1	AC011330.5	-5.13	4.93e-07	0.000357	-0.44	-0.27	Lung cancer;	chr15:43438956	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs34697113	ENSG00000249839.1	AC011330.5	-5.13	4.93e-07	0.000357	-0.44	-0.27	Lung cancer;	chr15:43442041	chr15:43663654~43684339:-
STAD	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-5.13	4.93e-07	0.000357	-0.44	-0.27	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
STAD	cis	rs6584283	0.846	rs10883370	ENSG00000257582.4	LINC01475	-5.13	4.95e-07	0.000358	-0.3	-0.27	Ulcerative colitis;	chr10:99531715	chr10:99526350~99531177:-
STAD	cis	rs957448	0.539	rs9643346	ENSG00000253704.1	RP11-267M23.4	5.13	4.95e-07	0.000358	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94553722~94569745:+
STAD	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	5.13	4.95e-07	0.000358	0.31	0.27	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
STAD	cis	rs853679	0.517	rs9393894	ENSG00000220721.1	OR1F12	5.13	4.96e-07	0.000358	0.32	0.27	Depression;	chr6:28144784	chr6:28073316~28074233:+
STAD	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-5.12	4.96e-07	0.000359	-0.31	-0.27	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
STAD	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	5.12	4.96e-07	0.000359	0.38	0.27	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
STAD	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	5.12	4.97e-07	0.000359	0.43	0.27	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
STAD	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	5.12	4.97e-07	0.000359	0.29	0.27	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
STAD	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-5.12	4.97e-07	0.000359	-0.34	-0.27	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
STAD	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-5.12	4.97e-07	0.000359	-0.34	-0.27	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
STAD	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-5.12	4.97e-07	0.000359	-0.34	-0.27	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
STAD	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	5.12	4.98e-07	0.000359	0.42	0.27	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
STAD	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-5.12	4.98e-07	0.00036	-0.27	-0.27	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
STAD	cis	rs7487075	0.688	rs12227156	ENSG00000257261.4	RP11-96H19.1	5.12	4.99e-07	0.00036	0.31	0.27	Itch intensity from mosquito bite;	chr12:46615645	chr12:46383679~46876159:+
STAD	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	5.12	4.99e-07	0.00036	0.42	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
STAD	cis	rs10466239	0.614	rs56214316	ENSG00000230555.2	RP11-517P14.2	5.12	4.99e-07	0.00036	0.35	0.27	Telomere length;	chr10:43365658	chr10:43420738~43422100:+
STAD	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-5.12	4.99e-07	0.00036	-0.4	-0.27	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
STAD	cis	rs3758911	0.796	rs112617433	ENSG00000261098.1	RP11-819C21.1	-5.12	4.99e-07	0.00036	-0.25	-0.27	Coronary artery disease;	chr11:107282855	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs7929343	ENSG00000261098.1	RP11-819C21.1	-5.12	4.99e-07	0.00036	-0.25	-0.27	Coronary artery disease;	chr11:107285183	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs7929345	ENSG00000261098.1	RP11-819C21.1	-5.12	4.99e-07	0.00036	-0.25	-0.27	Coronary artery disease;	chr11:107285185	chr11:107312132~107316271:-
STAD	cis	rs2221894	0.665	rs6999630	ENSG00000273710.1	Metazoa_SRP	-5.12	5e-07	0.000361	-0.27	-0.27	Obesity-related traits;	chr8:29077484	chr8:28915579~28915864:-
STAD	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-5.12	5e-07	0.000361	-0.41	-0.27	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
STAD	cis	rs611744	0.647	rs11774904	ENSG00000253754.1	RP11-35G22.1	-5.12	5.01e-07	0.000361	-0.23	-0.27	Dupuytren's disease;	chr8:108261206	chr8:108226200~108227544:+
STAD	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-5.12	5.01e-07	0.000362	-0.27	-0.27	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
STAD	cis	rs3806843	0.933	rs10069930	ENSG00000202111.1	VTRNA1-2	-5.12	5.01e-07	0.000362	-0.27	-0.27	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr5:140718925~140719013:+
STAD	cis	rs9400467	0.528	rs6913769	ENSG00000230177.1	RP5-1112D6.4	-5.12	5.02e-07	0.000362	-0.24	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111277932~111278742:+
STAD	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-5.12	5.02e-07	0.000362	-0.29	-0.27	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-5.12	5.02e-07	0.000362	-0.29	-0.27	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-5.12	5.02e-07	0.000362	-0.29	-0.27	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
STAD	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-5.12	5.03e-07	0.000363	-0.29	-0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
STAD	cis	rs12744310	0.887	rs12047439	ENSG00000235358.1	RP11-399E6.1	5.12	5.03e-07	0.000363	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343968	chr1:41242373~41284861:+
STAD	cis	rs11098499	0.754	rs1814813	ENSG00000260091.1	RP11-33B1.4	-5.12	5.03e-07	0.000363	-0.26	-0.27	Corneal astigmatism;	chr4:119337052	chr4:119409333~119410233:+
STAD	cis	rs228614	0.51	rs6830407	ENSG00000230069.3	LRRC37A15P	-5.12	5.04e-07	0.000363	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102727274~102730721:-
STAD	cis	rs4604732	0.631	rs12038880	ENSG00000227135.1	GCSAML-AS1	-5.12	5.04e-07	0.000364	-0.39	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461301	chr1:247524679~247526752:-
STAD	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-5.12	5.05e-07	0.000364	-0.25	-0.27	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
STAD	cis	rs7927771	0.524	rs12362318	ENSG00000280615.1	Y_RNA	5.12	5.05e-07	0.000364	0.27	0.27	Subjective well-being;	chr11:47661119	chr11:47614898~47614994:-
STAD	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	5.12	5.05e-07	0.000364	0.29	0.27	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
STAD	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	5.12	5.05e-07	0.000364	0.29	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
STAD	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	5.12	5.05e-07	0.000364	0.3	0.27	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	5.12	5.05e-07	0.000364	0.3	0.27	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
STAD	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	5.12	5.05e-07	0.000364	0.3	0.27	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
STAD	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	5.12	5.05e-07	0.000364	0.35	0.27	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	5.12	5.05e-07	0.000364	0.35	0.27	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	5.12	5.05e-07	0.000364	0.35	0.27	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	5.12	5.05e-07	0.000364	0.35	0.27	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	5.12	5.05e-07	0.000364	0.35	0.27	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	5.12	5.05e-07	0.000364	0.35	0.27	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	5.12	5.05e-07	0.000364	0.35	0.27	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
STAD	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-5.12	5.06e-07	0.000365	-0.32	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
STAD	cis	rs747650	0.504	rs923324	ENSG00000271350.1	CTD-2384B9.1	-5.12	5.06e-07	0.000365	-0.35	-0.27	Acne (severe);	chr11:47142657	chr11:47041027~47041945:-
STAD	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	5.12	5.06e-07	0.000365	0.27	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
STAD	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-5.12	5.07e-07	0.000366	-0.35	-0.27	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
STAD	cis	rs9463078	0.605	rs3799984	ENSG00000219384.1	RP11-491H9.3	-5.12	5.08e-07	0.000366	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44925903	chr6:45158870~45159511:+
STAD	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	5.12	5.08e-07	0.000366	0.29	0.27	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
STAD	cis	rs227275	0.554	rs149576	ENSG00000248971.2	KRT8P46	-5.12	5.08e-07	0.000366	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102728746~102730171:-
STAD	cis	rs3758911	0.765	rs10789592	ENSG00000261098.1	RP11-819C21.1	-5.12	5.08e-07	0.000366	-0.24	-0.27	Coronary artery disease;	chr11:107283589	chr11:107312132~107316271:-
STAD	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-5.12	5.09e-07	0.000367	-0.23	-0.27	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
STAD	cis	rs721917	0.506	rs2758538	ENSG00000225484.5	NUTM2B-AS1	-5.12	5.09e-07	0.000367	-0.34	-0.27	Chronic obstructive pulmonary disease;	chr10:79893047	chr10:79663088~79826594:-
STAD	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-5.12	5.09e-07	0.000367	-0.34	-0.27	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
STAD	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-5.12	5.09e-07	0.000367	-0.36	-0.27	Height;	chr6:109405874	chr6:109382795~109383666:+
STAD	cis	rs8067354	0.574	rs1292043	ENSG00000266701.1	AC005702.4	5.12	5.1e-07	0.000367	0.38	0.27	Hemoglobin concentration;	chr17:59856808	chr17:60042546~60042627:-
STAD	cis	rs7487075	0.82	rs10880953	ENSG00000272369.1	RP11-446N19.1	5.12	5.1e-07	0.000367	0.32	0.27	Itch intensity from mosquito bite;	chr12:46332086	chr12:46537502~46652550:+
STAD	cis	rs875971	0.862	rs778736	ENSG00000236529.1	RP13-254B10.1	5.12	5.1e-07	0.000367	0.27	0.27	Aortic root size;	chr7:66348861	chr7:65840212~65840596:+
STAD	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-5.12	5.1e-07	0.000367	-0.32	-0.27	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-5.12	5.1e-07	0.000367	-0.32	-0.27	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
STAD	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-5.12	5.1e-07	0.000367	-0.32	-0.27	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
STAD	cis	rs35934224	0.504	rs10372	ENSG00000232926.1	AC000078.5	5.12	5.1e-07	0.000367	0.38	0.27	Glaucoma (primary open-angle);	chr22:19849775	chr22:19887289~19887970:+
STAD	cis	rs748404	0.666	rs72709879	ENSG00000249839.1	AC011330.5	-5.12	5.1e-07	0.000368	-0.46	-0.27	Lung cancer;	chr15:43507777	chr15:43663654~43684339:-
STAD	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	5.12	5.11e-07	0.000368	0.38	0.27	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
STAD	cis	rs35934224	0.504	rs11704009	ENSG00000232926.1	AC000078.5	5.12	5.11e-07	0.000368	0.38	0.27	Glaucoma (primary open-angle);	chr22:19852600	chr22:19887289~19887970:+
STAD	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	5.12	5.11e-07	0.000368	0.3	0.27	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
STAD	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-5.12	5.11e-07	0.000368	-0.32	-0.27	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
STAD	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	5.12	5.12e-07	0.000368	0.4	0.27	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
STAD	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-5.12	5.12e-07	0.000368	-0.3	-0.27	QT interval;	chr12:29303562	chr12:29280418~29317848:-
STAD	cis	rs1799949	0.965	rs9646413	ENSG00000236383.6	LINC00854	-5.12	5.12e-07	0.000369	-0.21	-0.27	Menopause (age at onset);	chr17:43348789	chr17:43216941~43305976:-
STAD	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	5.12	5.14e-07	0.00037	0.43	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
STAD	cis	rs4604732	0.631	rs1106719	ENSG00000227135.1	GCSAML-AS1	5.12	5.14e-07	0.00037	0.37	0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461411	chr1:247524679~247526752:-
STAD	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-5.12	5.14e-07	0.00037	-0.29	-0.27	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
STAD	cis	rs9463078	0.605	rs17339124	ENSG00000219384.1	RP11-491H9.3	-5.12	5.14e-07	0.00037	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44974840	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.605	rs9472411	ENSG00000219384.1	RP11-491H9.3	-5.12	5.14e-07	0.00037	-0.25	-0.27	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44975446	chr6:45158870~45159511:+
STAD	cis	rs2006771	0.836	rs7285777	ENSG00000236132.1	CTA-440B3.1	5.12	5.15e-07	0.00037	0.29	0.27	Nonsyndromic cleft lip with cleft palate;	chr22:31586255	chr22:31816379~31817491:-
STAD	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	5.12	5.15e-07	0.000371	0.39	0.27	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
STAD	cis	rs7932354	0.554	rs6485721	ENSG00000271350.1	CTD-2384B9.1	-5.12	5.15e-07	0.000371	-0.32	-0.27	Bone mineral density (hip);Bone mineral density;	chr11:47019303	chr11:47041027~47041945:-
STAD	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-5.12	5.16e-07	0.000371	-0.37	-0.27	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
STAD	cis	rs5769707	0.616	rs6009786	ENSG00000280224.1	CTA-722E9.1	-5.12	5.16e-07	0.000371	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49500568~49501585:+
STAD	cis	rs728616	0.717	rs12415523	ENSG00000225484.5	NUTM2B-AS1	-5.12	5.17e-07	0.000372	-0.59	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:79663088~79826594:-
STAD	cis	rs728616	0.764	rs75385771	ENSG00000225484.5	NUTM2B-AS1	-5.12	5.17e-07	0.000372	-0.59	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs17883671	ENSG00000225484.5	NUTM2B-AS1	-5.12	5.17e-07	0.000372	-0.59	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs17885031	ENSG00000225484.5	NUTM2B-AS1	-5.12	5.17e-07	0.000372	-0.59	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:79663088~79826594:-
STAD	cis	rs858239	0.539	rs10280815	ENSG00000226816.2	AC005082.12	5.12	5.17e-07	0.000372	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs10225608	ENSG00000226816.2	AC005082.12	5.12	5.17e-07	0.000372	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs28624974	ENSG00000226816.2	AC005082.12	5.12	5.17e-07	0.000372	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23206013~23208045:+
STAD	cis	rs5850	0.557	rs10270788	ENSG00000226816.2	AC005082.12	5.12	5.17e-07	0.000372	0.31	0.27	Blood protein levels;	chr7:23149381	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs28716381	ENSG00000226816.2	AC005082.12	5.12	5.17e-07	0.000372	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs1358442	ENSG00000226816.2	AC005082.12	5.12	5.17e-07	0.000372	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23206013~23208045:+
STAD	cis	rs11846409	0.818	rs2516909	ENSG00000211972.2	IGHV3-66	-5.12	5.18e-07	0.000372	-0.29	-0.27	Rheumatic heart disease;	chr14:106630317	chr14:106675017~106675544:-
STAD	cis	rs58873874	0.737	rs10476050	ENSG00000251405.2	CTB-109A12.1	5.12	5.18e-07	0.000372	0.45	0.27	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157362615~157460078:-
STAD	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-5.12	5.18e-07	0.000372	-0.35	-0.27	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-5.12	5.18e-07	0.000372	-0.35	-0.27	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
STAD	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-5.12	5.18e-07	0.000373	-0.35	-0.27	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
STAD	cis	rs11694172	1	rs62194137	ENSG00000273456.1	RP11-686O6.2	5.12	5.19e-07	0.000373	0.3	0.27	Cholesterol, total;	chr2:202686822	chr2:202374932~202375604:-
STAD	cis	rs875971	0.502	rs2465121	ENSG00000236529.1	RP13-254B10.1	-5.12	5.19e-07	0.000373	-0.31	-0.27	Aortic root size;	chr7:66156017	chr7:65840212~65840596:+
STAD	cis	rs9400467	0.508	rs11153293	ENSG00000230177.1	RP5-1112D6.4	-5.12	5.19e-07	0.000373	-0.24	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111277932~111278742:+
STAD	cis	rs9400467	0.508	rs11756643	ENSG00000230177.1	RP5-1112D6.4	-5.12	5.19e-07	0.000373	-0.24	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111277932~111278742:+
STAD	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-5.12	5.19e-07	0.000373	-0.3	-0.27	QT interval;	chr12:29343291	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-5.12	5.19e-07	0.000373	-0.3	-0.27	QT interval;	chr12:29344573	chr12:29280418~29317848:-
STAD	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	5.12	5.2e-07	0.000374	0.43	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
STAD	cis	rs8098244	0.66	rs1560281	ENSG00000267301.1	RPL23AP77	5.12	5.2e-07	0.000374	0.31	0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23913711	chr18:23709825~23710287:-
STAD	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-5.12	5.21e-07	0.000374	-0.27	-0.27	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
STAD	cis	rs10510102	0.935	rs10466217	ENSG00000226864.1	ATE1-AS1	5.12	5.21e-07	0.000374	0.42	0.27	Breast cancer;	chr10:121860362	chr10:121928312~121951965:+
STAD	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	5.11	5.21e-07	0.000374	0.27	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
STAD	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-5.11	5.21e-07	0.000374	-0.28	-0.27	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
STAD	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	5.11	5.21e-07	0.000374	0.41	0.27	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
STAD	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	5.11	5.21e-07	0.000374	0.33	0.27	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
STAD	cis	rs240993	0.812	rs9487632	ENSG00000230177.1	RP5-1112D6.4	-5.11	5.21e-07	0.000375	-0.27	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs11153295	ENSG00000230177.1	RP5-1112D6.4	-5.11	5.21e-07	0.000375	-0.27	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs6915753	ENSG00000230177.1	RP5-1112D6.4	-5.11	5.21e-07	0.000375	-0.27	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs4620159	ENSG00000230177.1	RP5-1112D6.4	-5.11	5.21e-07	0.000375	-0.27	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111277932~111278742:+
STAD	cis	rs7191700	0.673	rs12325495	ENSG00000262703.1	RP11-485G7.6	5.11	5.22e-07	0.000375	0.24	0.27	Multiple sclerosis;	chr16:11324471	chr16:11348143~11349321:-
STAD	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-5.11	5.22e-07	0.000375	-0.36	-0.27	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
STAD	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-5.11	5.22e-07	0.000375	-0.36	-0.27	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
STAD	cis	rs17592366	0.517	rs7147621	ENSG00000251726.1	RNU7-41P	-5.11	5.22e-07	0.000375	-0.24	-0.27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34806498	chr14:34845300~34845360:-
STAD	cis	rs17592366	0.517	rs10145350	ENSG00000251726.1	RNU7-41P	-5.11	5.22e-07	0.000375	-0.24	-0.27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34809903	chr14:34845300~34845360:-
STAD	cis	rs17592366	0.517	rs10148967	ENSG00000251726.1	RNU7-41P	-5.11	5.22e-07	0.000375	-0.24	-0.27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34814538	chr14:34845300~34845360:-
STAD	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	5.11	5.23e-07	0.000376	0.32	0.27	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
STAD	cis	rs7927771	0.56	rs4752858	ENSG00000280615.1	Y_RNA	-5.11	5.23e-07	0.000376	-0.26	-0.27	Subjective well-being;	chr11:47664277	chr11:47614898~47614994:-
STAD	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-5.11	5.23e-07	0.000376	-0.29	-0.27	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
STAD	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-5.11	5.23e-07	0.000376	-0.29	-0.27	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
STAD	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-5.11	5.23e-07	0.000376	-0.34	-0.27	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
STAD	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	5.11	5.23e-07	0.000376	0.38	0.27	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
STAD	cis	rs12744310	0.887	rs12041352	ENSG00000235358.1	RP11-399E6.1	5.11	5.24e-07	0.000376	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317109	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs28566545	ENSG00000235358.1	RP11-399E6.1	5.11	5.24e-07	0.000376	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317561	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs16828067	ENSG00000235358.1	RP11-399E6.1	5.11	5.24e-07	0.000376	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317880	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs16828071	ENSG00000235358.1	RP11-399E6.1	5.11	5.24e-07	0.000376	0.33	0.27	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317931	chr1:41242373~41284861:+
STAD	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	5.11	5.24e-07	0.000376	0.34	0.27	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
STAD	cis	rs6142102	0.923	rs4911383	ENSG00000275784.1	RP5-1125A11.6	-5.11	5.25e-07	0.000377	-0.28	-0.27	Skin pigmentation;	chr20:33967973	chr20:33989480~33991818:-
STAD	cis	rs7927771	0.832	rs11039212	ENSG00000280615.1	Y_RNA	5.11	5.25e-07	0.000377	0.27	0.27	Subjective well-being;	chr11:47371752	chr11:47614898~47614994:-
STAD	cis	rs1799949	0.827	rs74252763	ENSG00000267681.1	CTD-3199J23.6	-5.11	5.25e-07	0.000377	-0.32	-0.27	Menopause (age at onset);	chr17:43324652	chr17:43144956~43145255:+
STAD	cis	rs7487075	0.82	rs12311507	ENSG00000272369.1	RP11-446N19.1	5.11	5.25e-07	0.000377	0.32	0.27	Itch intensity from mosquito bite;	chr12:46329407	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs12816413	ENSG00000272369.1	RP11-446N19.1	5.11	5.25e-07	0.000377	0.32	0.27	Itch intensity from mosquito bite;	chr12:46329506	chr12:46537502~46652550:+
STAD	cis	rs6142102	0.961	rs973409	ENSG00000275784.1	RP5-1125A11.6	-5.11	5.25e-07	0.000377	-0.28	-0.27	Skin pigmentation;	chr20:33948558	chr20:33989480~33991818:-
STAD	cis	rs7487075	0.893	rs1492894	ENSG00000272369.1	RP11-446N19.1	5.11	5.26e-07	0.000377	0.32	0.27	Itch intensity from mosquito bite;	chr12:46334885	chr12:46537502~46652550:+
STAD	cis	rs11846409	0.799	rs10467899	ENSG00000211972.2	IGHV3-66	5.11	5.27e-07	0.000378	0.28	0.27	Rheumatic heart disease;	chr14:106644012	chr14:106675017~106675544:-
STAD	cis	rs8098244	0.557	rs11660632	ENSG00000267301.1	RPL23AP77	-5.11	5.27e-07	0.000378	-0.32	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696084	chr18:23709825~23710287:-
STAD	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-5.11	5.27e-07	0.000378	-0.36	-0.27	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
STAD	cis	rs875971	0.862	rs6952182	ENSG00000236529.1	RP13-254B10.1	-5.11	5.28e-07	0.000379	-0.27	-0.27	Aortic root size;	chr7:66218330	chr7:65840212~65840596:+
STAD	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-5.11	5.28e-07	0.000379	-0.41	-0.27	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
STAD	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-5.11	5.28e-07	0.000379	-0.27	-0.27	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
STAD	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	5.11	5.28e-07	0.000379	0.41	0.27	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
STAD	cis	rs8040855	0.627	rs11632899	ENSG00000229212.6	RP11-561C5.4	5.11	5.28e-07	0.000379	0.37	0.27	Bulimia nervosa;	chr15:85057609	chr15:85205440~85234795:-
STAD	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	5.11	5.28e-07	0.000379	0.32	0.26	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
STAD	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-5.11	5.29e-07	0.000379	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
STAD	cis	rs2439831	0.867	rs2470134	ENSG00000275601.1	AC011330.13	5.11	5.29e-07	0.000379	0.37	0.26	Lung cancer in ever smokers;	chr15:43557688	chr15:43642389~43643023:-
STAD	cis	rs875971	0.545	rs17138149	ENSG00000236529.1	RP13-254B10.1	5.11	5.29e-07	0.000379	0.31	0.26	Aortic root size;	chr7:66228193	chr7:65840212~65840596:+
STAD	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-5.11	5.29e-07	0.000379	-0.28	-0.26	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
STAD	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-5.11	5.3e-07	0.00038	-0.37	-0.26	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
STAD	cis	rs2337406	1	rs74090714	ENSG00000211972.2	IGHV3-66	5.11	5.3e-07	0.00038	0.31	0.26	Alzheimer's disease (late onset);	chr14:106691225	chr14:106675017~106675544:-
STAD	cis	rs853679	0.517	rs4713146	ENSG00000220721.1	OR1F12	5.11	5.3e-07	0.00038	0.31	0.26	Depression;	chr6:28143758	chr6:28073316~28074233:+
STAD	cis	rs611744	0.647	rs1448150	ENSG00000253754.1	RP11-35G22.1	-5.11	5.31e-07	0.00038	-0.23	-0.26	Dupuytren's disease;	chr8:108263932	chr8:108226200~108227544:+
STAD	cis	rs611744	0.647	rs1448151	ENSG00000253754.1	RP11-35G22.1	-5.11	5.31e-07	0.00038	-0.23	-0.26	Dupuytren's disease;	chr8:108264054	chr8:108226200~108227544:+
STAD	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	5.11	5.31e-07	0.000381	0.37	0.26	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
STAD	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	5.11	5.31e-07	0.000381	0.37	0.26	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
STAD	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-5.11	5.32e-07	0.000381	-0.34	-0.26	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
STAD	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	5.11	5.32e-07	0.000381	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
STAD	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	5.11	5.32e-07	0.000382	0.29	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
STAD	cis	rs1799949	0.965	rs4793230	ENSG00000279602.1	CTD-3014M21.1	5.11	5.32e-07	0.000382	0.32	0.26	Menopause (age at onset);	chr17:43350035	chr17:43360041~43361361:-
STAD	cis	rs7927771	0.524	rs11039329	ENSG00000280615.1	Y_RNA	5.11	5.32e-07	0.000382	0.27	0.26	Subjective well-being;	chr11:47663356	chr11:47614898~47614994:-
STAD	cis	rs747650	0.504	rs7108822	ENSG00000271350.1	CTD-2384B9.1	-5.11	5.32e-07	0.000382	-0.34	-0.26	Acne (severe);	chr11:47022804	chr11:47041027~47041945:-
STAD	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	5.11	5.33e-07	0.000382	0.42	0.26	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
STAD	cis	rs8067354	0.645	rs9901606	ENSG00000266701.1	AC005702.4	5.11	5.33e-07	0.000382	0.37	0.26	Hemoglobin concentration;	chr17:59734046	chr17:60042546~60042627:-
STAD	cis	rs2446066	0.872	rs12811015	ENSG00000257379.1	RP11-793H13.8	5.11	5.33e-07	0.000382	0.44	0.26	Red blood cell count;	chr12:53426941	chr12:53441741~53467528:+
STAD	cis	rs11694172	0.955	rs62194149	ENSG00000273456.1	RP11-686O6.2	5.11	5.33e-07	0.000382	0.29	0.26	Cholesterol, total;	chr2:202721036	chr2:202374932~202375604:-
STAD	cis	rs6714710	0.603	rs13034929	ENSG00000235833.1	AC159540.14	-5.11	5.33e-07	0.000382	-0.31	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786309	chr2:97523949~97524976:-
STAD	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	5.11	5.33e-07	0.000382	0.39	0.26	Height;	chr6:109564272	chr6:109382795~109383666:+
STAD	cis	rs7474896	0.583	rs10740950	ENSG00000120555.12	SEPT7P9	5.11	5.34e-07	0.000382	0.32	0.26	Obesity (extreme);	chr10:37714568	chr10:38383069~38402916:-
STAD	cis	rs12699921	0.599	rs9942602	ENSG00000279048.1	RP11-511H23.2	5.11	5.34e-07	0.000383	0.24	0.26	Fibrinogen levels;	chr7:17937431	chr7:17940503~17942922:+
STAD	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-5.11	5.34e-07	0.000383	-0.34	-0.26	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
STAD	cis	rs1729407	0.706	rs1268354	ENSG00000280143.1	AP000892.6	5.11	5.35e-07	0.000383	0.19	0.26	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117204967~117210292:+
STAD	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-5.11	5.35e-07	0.000383	-0.27	-0.26	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
STAD	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	5.11	5.35e-07	0.000383	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
STAD	cis	rs10851478	0.515	rs12439429	ENSG00000259545.2	RP11-325E5.4	5.11	5.35e-07	0.000384	0.28	0.26	Oral cavity cancer;	chr15:49442437	chr15:49177610~49178741:-
STAD	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	5.11	5.36e-07	0.000384	0.32	0.26	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
STAD	cis	rs1056107	0.931	rs7033486	ENSG00000225513.1	RP11-165N19.2	5.11	5.36e-07	0.000384	0.3	0.26	Colorectal cancer;	chr9:112248027	chr9:112173522~112173971:-
STAD	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-5.11	5.36e-07	0.000384	-0.32	-0.26	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
STAD	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-5.11	5.36e-07	0.000384	-0.31	-0.26	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
STAD	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-5.11	5.37e-07	0.000385	-0.34	-0.26	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
STAD	cis	rs6432852	0.516	rs2304002	ENSG00000229195.1	AC009495.4	5.11	5.37e-07	0.000385	0.29	0.26	Diabetic kidney disease;	chr2:165857585	chr2:165794857~165846091:-
STAD	cis	rs7487075	0.964	rs2408497	ENSG00000257261.4	RP11-96H19.1	5.11	5.38e-07	0.000385	0.32	0.26	Itch intensity from mosquito bite;	chr12:46402968	chr12:46383679~46876159:+
STAD	cis	rs875971	0.862	rs6964437	ENSG00000236529.1	RP13-254B10.1	-5.11	5.38e-07	0.000385	-0.27	-0.26	Aortic root size;	chr7:66221457	chr7:65840212~65840596:+
STAD	cis	rs2404602	0.692	rs60658665	ENSG00000259422.1	RP11-593F23.1	5.11	5.38e-07	0.000385	0.28	0.26	Blood metabolite levels;	chr15:76750167	chr15:76174891~76181486:-
STAD	cis	rs453301	0.686	rs6987107	ENSG00000254340.1	RP11-10A14.3	-5.11	5.38e-07	0.000386	-0.35	-0.26	Joint mobility (Beighton score);	chr8:9036071	chr8:9141424~9145435:+
STAD	cis	rs7950696	1	rs7950696	ENSG00000280615.1	Y_RNA	5.11	5.39e-07	0.000386	0.27	0.26	Platelet count;	chr11:47459981	chr11:47614898~47614994:-
STAD	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-5.11	5.39e-07	0.000386	-0.29	-0.26	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
STAD	cis	rs9307551	0.817	rs1031004	ENSG00000250334.4	LINC00989	-5.11	5.39e-07	0.000386	-0.32	-0.26	Refractive error;	chr4:79595695	chr4:79492416~79576460:+
STAD	cis	rs172166	0.516	rs2622322	ENSG00000220721.1	OR1F12	5.11	5.39e-07	0.000386	0.26	0.26	Cardiac Troponin-T levels;	chr6:28149665	chr6:28073316~28074233:+
STAD	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	5.11	5.39e-07	0.000386	0.28	0.26	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
STAD	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	5.11	5.39e-07	0.000386	0.28	0.26	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
STAD	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-5.11	5.39e-07	0.000386	-0.27	-0.26	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
STAD	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	5.11	5.39e-07	0.000386	0.37	0.26	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
STAD	cis	rs516805	0.667	rs2045354	ENSG00000279453.1	RP3-425C14.4	-5.11	5.4e-07	0.000387	-0.37	-0.26	Lymphocyte counts;	chr6:122209244	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2606596	ENSG00000279453.1	RP3-425C14.4	-5.11	5.4e-07	0.000387	-0.37	-0.26	Lymphocyte counts;	chr6:122211597	chr6:122436789~122439223:-
STAD	cis	rs1594829	0.535	rs17055121	ENSG00000228451.3	SDAD1P1	5.11	5.41e-07	0.000387	0.28	0.26	Height;	chr8:26313459	chr8:26379259~26382953:-
STAD	cis	rs875971	0.545	rs2460427	ENSG00000236529.1	RP13-254B10.1	-5.11	5.41e-07	0.000387	-0.31	-0.26	Aortic root size;	chr7:66154218	chr7:65840212~65840596:+
STAD	cis	rs853679	0.517	rs1904840	ENSG00000220721.1	OR1F12	5.11	5.42e-07	0.000388	0.32	0.26	Depression;	chr6:28140454	chr6:28073316~28074233:+
STAD	cis	rs7927771	0.524	rs2242081	ENSG00000280615.1	Y_RNA	5.11	5.42e-07	0.000388	0.27	0.26	Subjective well-being;	chr11:47478715	chr11:47614898~47614994:-
STAD	cis	rs7665090	0.87	rs228613	ENSG00000248971.2	KRT8P46	5.11	5.42e-07	0.000388	0.28	0.26	Primary biliary cholangitis;	chr4:102656308	chr4:102728746~102730171:-
STAD	cis	rs7487075	0.558	rs56988021	ENSG00000257261.4	RP11-96H19.1	5.11	5.42e-07	0.000388	0.32	0.26	Itch intensity from mosquito bite;	chr12:46243568	chr12:46383679~46876159:+
STAD	cis	rs10510102	0.935	rs75339296	ENSG00000226864.1	ATE1-AS1	5.11	5.43e-07	0.000389	0.42	0.26	Breast cancer;	chr10:121859895	chr10:121928312~121951965:+
STAD	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-5.11	5.43e-07	0.000389	-0.36	-0.26	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
STAD	cis	rs9467773	0.935	rs1056668	ENSG00000243307.2	POM121L6P	5.11	5.43e-07	0.000389	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26896952~26898777:+
STAD	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-5.11	5.43e-07	0.000389	-0.29	-0.26	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
STAD	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-5.11	5.43e-07	0.000389	-0.37	-0.26	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
STAD	cis	rs1056107	0.83	rs10739340	ENSG00000225513.1	RP11-165N19.2	-5.11	5.43e-07	0.000389	-0.31	-0.26	Colorectal cancer;	chr9:112295272	chr9:112173522~112173971:-
STAD	cis	rs2337406	0.789	rs112027230	ENSG00000280411.1	IGHV1-69-2	-5.11	5.44e-07	0.000389	-0.32	-0.26	Alzheimer's disease (late onset);	chr14:106810329	chr14:106762092~106762588:-
STAD	cis	rs7487075	0.786	rs898242	ENSG00000272369.1	RP11-446N19.1	5.11	5.44e-07	0.000389	0.33	0.26	Itch intensity from mosquito bite;	chr12:46327036	chr12:46537502~46652550:+
STAD	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-5.11	5.44e-07	0.000389	-0.37	-0.26	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
STAD	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	5.11	5.45e-07	0.00039	0.57	0.26	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
STAD	cis	rs112744032	1	rs112744032	ENSG00000240350.2	AC017002.1	-5.11	5.45e-07	0.00039	-0.47	-0.26	Mean corpuscular hemoglobin;	chr2:111521757	chr2:111491273~111570974:+
STAD	cis	rs62162297	1	rs62162297	ENSG00000240350.2	AC017002.1	-5.11	5.45e-07	0.00039	-0.47	-0.26	Red blood cell count;	chr2:111521758	chr2:111491273~111570974:+
STAD	cis	rs831571	0.915	rs6797912	ENSG00000280620.1	SCAANT1	-5.11	5.45e-07	0.00039	-0.38	-0.26	Type 2 diabetes;	chr3:64072564	chr3:63911518~63911772:-
STAD	cis	rs6714710	0.603	rs1470483	ENSG00000235833.1	AC159540.14	-5.11	5.45e-07	0.00039	-0.31	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97777431	chr2:97523949~97524976:-
STAD	cis	rs12744310	1	rs72665698	ENSG00000235358.1	RP11-399E6.1	5.11	5.46e-07	0.000391	0.35	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309917	chr1:41242373~41284861:+
STAD	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-5.11	5.46e-07	0.000391	-0.33	-0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
STAD	cis	rs858239	0.539	rs7791200	ENSG00000226816.2	AC005082.12	5.11	5.47e-07	0.000391	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23206013~23208045:+
STAD	cis	rs9307551	0.817	rs12507160	ENSG00000250334.4	LINC00989	-5.11	5.47e-07	0.000391	-0.32	-0.26	Refractive error;	chr4:79573647	chr4:79492416~79576460:+
STAD	cis	rs7927771	0.524	rs10742817	ENSG00000280615.1	Y_RNA	-5.11	5.47e-07	0.000391	-0.26	-0.26	Subjective well-being;	chr11:47667791	chr11:47614898~47614994:-
STAD	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-5.1	5.47e-07	0.000391	-0.25	-0.26	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
STAD	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-5.1	5.47e-07	0.000391	-0.25	-0.26	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
STAD	cis	rs7829975	0.871	rs572307	ENSG00000254340.1	RP11-10A14.3	-5.1	5.48e-07	0.000392	-0.3	-0.26	Mood instability;	chr8:8721301	chr8:9141424~9145435:+
STAD	cis	rs7247513	1	rs7247513	ENSG00000230310.1	CTD-2192J16.11	-5.1	5.49e-07	0.000393	-0.34	-0.26	Bipolar disorder;	chr19:12580371	chr19:12552597~12553644:+
STAD	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	5.1	5.5e-07	0.000393	0.43	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
STAD	cis	rs7429990	0.965	rs9854454	ENSG00000224895.1	VPS26BP1	5.1	5.5e-07	0.000393	0.26	0.26	Educational attainment (years of education);	chr3:47971307	chr3:47960327~47961081:-
STAD	cis	rs11098499	0.866	rs12501602	ENSG00000260091.1	RP11-33B1.4	5.1	5.5e-07	0.000393	0.25	0.26	Corneal astigmatism;	chr4:119366780	chr4:119409333~119410233:+
STAD	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	5.1	5.5e-07	0.000393	0.29	0.26	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	5.1	5.5e-07	0.000393	0.29	0.26	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	5.1	5.5e-07	0.000393	0.29	0.26	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
STAD	cis	rs10510102	0.872	rs12246728	ENSG00000226864.1	ATE1-AS1	5.1	5.51e-07	0.000394	0.43	0.26	Breast cancer;	chr10:121966618	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12261371	ENSG00000226864.1	ATE1-AS1	5.1	5.51e-07	0.000394	0.43	0.26	Breast cancer;	chr10:121966686	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11200292	ENSG00000226864.1	ATE1-AS1	5.1	5.51e-07	0.000394	0.43	0.26	Breast cancer;	chr10:121967383	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.808	rs17102804	ENSG00000226864.1	ATE1-AS1	5.1	5.51e-07	0.000394	0.43	0.26	Breast cancer;	chr10:121968365	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12265369	ENSG00000226864.1	ATE1-AS1	5.1	5.51e-07	0.000394	0.43	0.26	Breast cancer;	chr10:121968455	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12265542	ENSG00000226864.1	ATE1-AS1	5.1	5.51e-07	0.000394	0.43	0.26	Breast cancer;	chr10:121968740	chr10:121928312~121951965:+
STAD	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-5.1	5.52e-07	0.000394	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
STAD	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	5.1	5.52e-07	0.000394	0.3	0.26	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
STAD	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-5.1	5.52e-07	0.000394	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
STAD	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-5.1	5.52e-07	0.000394	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
STAD	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-5.1	5.52e-07	0.000394	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
STAD	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-5.1	5.52e-07	0.000394	-0.39	-0.26	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
STAD	cis	rs11694172	1	rs72928921	ENSG00000273456.1	RP11-686O6.2	5.1	5.53e-07	0.000395	0.3	0.26	Cholesterol, total;	chr2:202685302	chr2:202374932~202375604:-
STAD	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	5.1	5.54e-07	0.000395	0.26	0.26	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
STAD	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	5.1	5.54e-07	0.000396	0.37	0.26	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
STAD	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	5.1	5.54e-07	0.000396	0.33	0.26	Height;	chr6:109458989	chr6:109382795~109383666:+
STAD	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	5.1	5.55e-07	0.000396	0.26	0.26	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
STAD	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-5.1	5.55e-07	0.000396	-0.39	-0.26	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
STAD	cis	rs5769707	0.656	rs135875	ENSG00000280224.1	CTA-722E9.1	-5.1	5.55e-07	0.000396	-0.32	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49500568~49501585:+
STAD	cis	rs4568518	0.535	rs4404818	ENSG00000279048.1	RP11-511H23.2	5.1	5.55e-07	0.000397	0.25	0.26	Measles;	chr7:18021068	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.535	rs12699954	ENSG00000279048.1	RP11-511H23.2	5.1	5.55e-07	0.000397	0.25	0.26	Measles;	chr7:18021586	chr7:17940503~17942922:+
STAD	cis	rs6142102	0.886	rs6059583	ENSG00000275784.1	RP5-1125A11.6	-5.1	5.55e-07	0.000397	-0.28	-0.26	Skin pigmentation;	chr20:33944308	chr20:33989480~33991818:-
STAD	cis	rs240993	0.812	rs7751272	ENSG00000230177.1	RP5-1112D6.4	-5.1	5.56e-07	0.000397	-0.28	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111419068	chr6:111277932~111278742:+
STAD	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-5.1	5.56e-07	0.000397	-0.31	-0.26	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
STAD	cis	rs9463078	0.585	rs1290386	ENSG00000219384.1	RP11-491H9.3	5.1	5.56e-07	0.000397	0.26	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45201016	chr6:45158870~45159511:+
STAD	cis	rs875971	0.545	rs73376394	ENSG00000236529.1	RP13-254B10.1	5.1	5.57e-07	0.000397	0.31	0.26	Aortic root size;	chr7:66172694	chr7:65840212~65840596:+
STAD	cis	rs10510102	0.935	rs12266380	ENSG00000226864.1	ATE1-AS1	5.1	5.57e-07	0.000398	0.43	0.26	Breast cancer;	chr10:121882559	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200212	ENSG00000226864.1	ATE1-AS1	5.1	5.57e-07	0.000398	0.43	0.26	Breast cancer;	chr10:121883145	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200213	ENSG00000226864.1	ATE1-AS1	5.1	5.57e-07	0.000398	0.43	0.26	Breast cancer;	chr10:121883228	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12247749	ENSG00000226864.1	ATE1-AS1	5.1	5.57e-07	0.000398	0.43	0.26	Breast cancer;	chr10:121884196	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12262776	ENSG00000226864.1	ATE1-AS1	5.1	5.57e-07	0.000398	0.43	0.26	Breast cancer;	chr10:121884532	chr10:121928312~121951965:+
STAD	cis	rs875971	0.862	rs1612452	ENSG00000236529.1	RP13-254B10.1	-5.1	5.58e-07	0.000398	-0.28	-0.26	Aortic root size;	chr7:66108909	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs1167390	ENSG00000236529.1	RP13-254B10.1	-5.1	5.58e-07	0.000398	-0.28	-0.26	Aortic root size;	chr7:66110906	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs35034167	ENSG00000236529.1	RP13-254B10.1	-5.1	5.58e-07	0.000398	-0.28	-0.26	Aortic root size;	chr7:66115179	chr7:65840212~65840596:+
STAD	cis	rs10510102	0.935	rs7083278	ENSG00000226864.1	ATE1-AS1	5.1	5.58e-07	0.000398	0.41	0.26	Breast cancer;	chr10:121853758	chr10:121928312~121951965:+
STAD	cis	rs7580658	0.509	rs12477653	ENSG00000200250.1	RNU6-1147P	5.1	5.58e-07	0.000398	0.25	0.26	Protein C levels;	chr2:127194505	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.545	rs13001179	ENSG00000200250.1	RNU6-1147P	5.1	5.58e-07	0.000398	0.25	0.26	Protein C levels;	chr2:127194617	chr2:127316873~127316979:+
STAD	cis	rs7580658	0.545	rs13001184	ENSG00000200250.1	RNU6-1147P	5.1	5.58e-07	0.000398	0.25	0.26	Protein C levels;	chr2:127194630	chr2:127316873~127316979:+
STAD	cis	rs7829975	0.714	rs60315134	ENSG00000254340.1	RP11-10A14.3	5.1	5.58e-07	0.000398	0.31	0.26	Mood instability;	chr8:8813089	chr8:9141424~9145435:+
STAD	cis	rs7932354	0.798	rs2282686	ENSG00000271350.1	CTD-2384B9.1	5.1	5.59e-07	0.000399	0.32	0.26	Bone mineral density (hip);Bone mineral density;	chr11:46729088	chr11:47041027~47041945:-
STAD	cis	rs3736858	0.825	rs3759445	ENSG00000261105.4	LMO7-AS1	-5.1	5.59e-07	0.000399	-0.42	-0.26	Interleukin-9 levels;	chr13:75816090	chr13:75604700~75635994:-
STAD	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	5.1	5.59e-07	0.000399	0.27	0.26	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
STAD	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	5.1	5.59e-07	0.000399	0.27	0.26	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
STAD	cis	rs9307551	1	rs1031005	ENSG00000250334.4	LINC00989	-5.1	5.59e-07	0.000399	-0.33	-0.26	Refractive error;	chr4:79595750	chr4:79492416~79576460:+
STAD	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-5.1	5.59e-07	0.000399	-0.29	-0.26	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
STAD	cis	rs1056107	0.931	rs1969946	ENSG00000225513.1	RP11-165N19.2	-5.1	5.6e-07	4e-04	-0.31	-0.26	Colorectal cancer;	chr9:112269241	chr9:112173522~112173971:-
STAD	cis	rs3758911	1	rs10789618	ENSG00000261098.1	RP11-819C21.1	-5.1	5.6e-07	4e-04	-0.23	-0.26	Coronary artery disease;	chr11:107319003	chr11:107312132~107316271:-
STAD	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	5.1	5.61e-07	4e-04	0.39	0.26	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
STAD	cis	rs1318937	0.764	rs60977744	ENSG00000224660.1	SH3BP5-AS1	5.1	5.61e-07	4e-04	0.27	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198464	chr3:15254184~15264493:+
STAD	cis	rs1318937	0.764	rs58837640	ENSG00000224660.1	SH3BP5-AS1	5.1	5.61e-07	4e-04	0.27	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15199139	chr3:15254184~15264493:+
STAD	cis	rs1318937	0.764	rs66813829	ENSG00000224660.1	SH3BP5-AS1	5.1	5.61e-07	4e-04	0.27	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15202214	chr3:15254184~15264493:+
STAD	cis	rs748404	0.626	rs72707530	ENSG00000249839.1	AC011330.5	-5.1	5.61e-07	4e-04	-0.45	-0.26	Lung cancer;	chr15:43353622	chr15:43663654~43684339:-
STAD	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	5.1	5.61e-07	4e-04	0.35	0.26	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
STAD	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-5.1	5.61e-07	4e-04	-0.32	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
STAD	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	5.1	5.62e-07	0.000401	0.29	0.26	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
STAD	cis	rs2688608	0.592	rs7080579	ENSG00000271816.1	BMS1P4	5.1	5.63e-07	0.000401	0.29	0.26	Inflammatory bowel disease;	chr10:73744271	chr10:73699151~73730487:-
STAD	cis	rs7078219	0.543	rs7095491	ENSG00000228778.1	RP11-129J12.1	-5.1	5.64e-07	0.000402	-0.31	-0.26	Dental caries;	chr10:99514301	chr10:99527081~99528261:+
STAD	cis	rs6095360	0.727	rs13037063	ENSG00000222365.1	SNORD12B	-5.1	5.65e-07	0.000402	-0.36	-0.26	Intelligence (multi-trait analysis);	chr20:48909128	chr20:49280319~49280409:+
STAD	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	5.1	5.65e-07	0.000403	0.43	0.26	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
STAD	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-5.1	5.66e-07	0.000403	-0.32	-0.26	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
STAD	cis	rs611744	0.625	rs11991891	ENSG00000253754.1	RP11-35G22.1	-5.1	5.67e-07	0.000404	-0.23	-0.26	Dupuytren's disease;	chr8:108282629	chr8:108226200~108227544:+
STAD	cis	rs606458	0.841	rs489192	ENSG00000269038.1	AP001462.6	-5.1	5.67e-07	0.000404	-0.35	-0.26	Urate levels;	chr11:64758172	chr11:64778954~64779405:+
STAD	cis	rs10510102	1	rs6585764	ENSG00000226864.1	ATE1-AS1	5.1	5.67e-07	0.000404	0.4	0.26	Breast cancer;	chr10:121837308	chr10:121928312~121951965:+
STAD	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-5.1	5.67e-07	0.000404	-0.43	-0.26	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
STAD	cis	rs7829975	1	rs7829975	ENSG00000254340.1	RP11-10A14.3	-5.1	5.69e-07	0.000405	-0.32	-0.26	Mood instability;	chr8:8690607	chr8:9141424~9145435:+
STAD	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-5.1	5.69e-07	0.000405	-0.3	-0.26	QT interval;	chr12:29306357	chr12:29280418~29317848:-
STAD	cis	rs2337406	0.81	rs7161739	ENSG00000211972.2	IGHV3-66	5.1	5.69e-07	0.000405	0.28	0.26	Alzheimer's disease (late onset);	chr14:106776118	chr14:106675017~106675544:-
STAD	cis	rs2440129	0.611	rs1126667	ENSG00000262089.1	RP11-589P10.5	-5.1	5.7e-07	0.000405	-0.29	-0.26	Tonsillectomy;	chr17:6999441	chr17:6994642~6995189:-
STAD	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	5.1	5.7e-07	0.000406	0.28	0.26	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
STAD	cis	rs9601248	0.711	rs9530937	ENSG00000227676.3	LINC01068	-5.1	5.71e-07	0.000406	-0.3	-0.26	Major depressive disorder;	chr13:79603701	chr13:79566727~79571436:+
STAD	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	5.1	5.71e-07	0.000406	0.32	0.26	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
STAD	cis	rs516805	0.63	rs2606656	ENSG00000279453.1	RP3-425C14.4	-5.1	5.71e-07	0.000406	-0.39	-0.26	Lymphocyte counts;	chr6:122153088	chr6:122436789~122439223:-
STAD	cis	rs1816752	0.679	rs7999480	ENSG00000273628.1	RP11-756A22.7	-5.1	5.71e-07	0.000407	-0.31	-0.26	Obesity-related traits;	chr13:24397865	chr13:24933006~24936796:+
STAD	cis	rs172166	0.694	rs203884	ENSG00000220721.1	OR1F12	5.1	5.72e-07	0.000407	0.28	0.26	Cardiac Troponin-T levels;	chr6:28109596	chr6:28073316~28074233:+
STAD	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	5.1	5.72e-07	0.000407	0.4	0.26	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	5.1	5.72e-07	0.000407	0.4	0.26	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	5.1	5.72e-07	0.000407	0.4	0.26	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	5.1	5.72e-07	0.000407	0.4	0.26	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
STAD	cis	rs2933343	0.7	rs1680779	ENSG00000261159.1	RP11-723O4.9	5.1	5.72e-07	0.000407	0.32	0.26	IgG glycosylation;	chr3:128895927	chr3:128859716~128860526:-
STAD	cis	rs3806843	0.518	rs2569188	ENSG00000202111.1	VTRNA1-2	5.1	5.73e-07	0.000407	0.25	0.26	Depressive symptoms (multi-trait analysis);	chr5:140628834	chr5:140718925~140719013:+
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000211973.2	IGHV1-69	5.1	5.74e-07	0.000408	0.22	0.26	Kawasaki disease;	chr14:106786292	chr14:106714684~106715181:-
STAD	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-5.1	5.74e-07	0.000408	-0.28	-0.26	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
STAD	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	5.1	5.74e-07	0.000408	0.4	0.26	Height;	chr6:109548647	chr6:109382795~109383666:+
STAD	cis	rs2688608	0.592	rs10762560	ENSG00000271816.1	BMS1P4	5.09	5.75e-07	0.000409	0.28	0.26	Inflammatory bowel disease;	chr10:73735647	chr10:73699151~73730487:-
STAD	cis	rs12744310	0.887	rs1892420	ENSG00000235358.1	RP11-399E6.1	5.09	5.75e-07	0.000409	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315738	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs28541673	ENSG00000235358.1	RP11-399E6.1	5.09	5.75e-07	0.000409	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316322	chr1:41242373~41284861:+
STAD	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-5.09	5.75e-07	0.000409	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
STAD	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-5.09	5.75e-07	0.000409	-0.26	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
STAD	cis	rs858239	0.6	rs6461692	ENSG00000226816.2	AC005082.12	5.09	5.75e-07	0.000409	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23206013~23208045:+
STAD	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	5.09	5.75e-07	0.000409	0.32	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
STAD	cis	rs3758911	0.964	rs10890715	ENSG00000261098.1	RP11-819C21.1	-5.09	5.75e-07	0.000409	-0.23	-0.26	Coronary artery disease;	chr11:107322457	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs12146472	ENSG00000261098.1	RP11-819C21.1	-5.09	5.75e-07	0.000409	-0.23	-0.26	Coronary artery disease;	chr11:107323450	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs12146473	ENSG00000261098.1	RP11-819C21.1	-5.09	5.75e-07	0.000409	-0.23	-0.26	Coronary artery disease;	chr11:107323540	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.929	rs55837508	ENSG00000261098.1	RP11-819C21.1	-5.09	5.75e-07	0.000409	-0.23	-0.26	Coronary artery disease;	chr11:107323756	chr11:107312132~107316271:-
STAD	cis	rs6142102	0.812	rs6059578	ENSG00000275784.1	RP5-1125A11.6	-5.09	5.76e-07	0.000409	-0.28	-0.26	Skin pigmentation;	chr20:33939900	chr20:33989480~33991818:-
STAD	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-5.09	5.76e-07	0.000409	-0.37	-0.26	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
STAD	cis	rs853679	0.513	rs9468296	ENSG00000220721.1	OR1F12	5.09	5.77e-07	0.00041	0.31	0.26	Depression;	chr6:28145952	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.955	rs9468204	ENSG00000280107.1	AL022393.9	-5.09	5.77e-07	0.00041	-0.35	-0.26	Parkinson's disease;	chr6:27721030	chr6:28170845~28172521:+
STAD	cis	rs4308124	0.708	rs61358692	ENSG00000230499.1	AC108463.1	-5.09	5.77e-07	0.00041	-0.38	-0.26	Vitiligo;	chr2:111207582	chr2:111195963~111206494:+
STAD	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-5.09	5.77e-07	0.00041	-0.3	-0.26	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
STAD	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	5.09	5.78e-07	0.000411	0.27	0.26	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
STAD	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-5.09	5.78e-07	0.000411	-0.35	-0.26	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
STAD	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-5.09	5.79e-07	0.000411	-0.37	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
STAD	cis	rs4308124	0.708	rs67816163	ENSG00000230499.1	AC108463.1	-5.09	5.79e-07	0.000412	-0.37	-0.26	Vitiligo;	chr2:111205733	chr2:111195963~111206494:+
STAD	cis	rs4308124	0.679	rs7600458	ENSG00000230499.1	AC108463.1	-5.09	5.79e-07	0.000412	-0.37	-0.26	Vitiligo;	chr2:111206013	chr2:111195963~111206494:+
STAD	cis	rs1075265	0.73	rs7597189	ENSG00000235937.1	AC008280.1	5.09	5.79e-07	0.000412	0.24	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54029552~54030682:-
STAD	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	5.09	5.79e-07	0.000412	0.29	0.26	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
STAD	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	5.09	5.79e-07	0.000412	0.28	0.26	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	5.09	5.79e-07	0.000412	0.28	0.26	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
STAD	cis	rs11694172	1	rs72928909	ENSG00000273456.1	RP11-686O6.2	5.09	5.8e-07	0.000412	0.29	0.26	Cholesterol, total;	chr2:202676931	chr2:202374932~202375604:-
STAD	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-5.09	5.81e-07	0.000413	-0.43	-0.26	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
STAD	cis	rs75426604	0.568	rs17103242	ENSG00000241052.1	RP11-173D9.1	-5.09	5.81e-07	0.000413	-0.35	-0.26	Eotaxin levels;	chr14:35363631	chr14:35144021~35144480:-
STAD	cis	rs7487075	1	rs10880966	ENSG00000257261.4	RP11-96H19.1	5.09	5.81e-07	0.000413	0.32	0.26	Itch intensity from mosquito bite;	chr12:46407999	chr12:46383679~46876159:+
STAD	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	5.09	5.82e-07	0.000414	0.33	0.26	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
STAD	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	5.09	5.82e-07	0.000414	0.33	0.26	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
STAD	cis	rs853679	0.517	rs9283884	ENSG00000220721.1	OR1F12	-5.09	5.82e-07	0.000414	-0.31	-0.26	Depression;	chr6:28167882	chr6:28073316~28074233:+
STAD	cis	rs12744310	0.887	rs12032040	ENSG00000235358.1	RP11-399E6.1	5.09	5.82e-07	0.000414	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41352635	chr1:41242373~41284861:+
STAD	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-5.09	5.83e-07	0.000414	-0.28	-0.26	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
STAD	cis	rs7615952	0.8	rs11915699	ENSG00000272840.1	RP11-379B18.6	5.09	5.83e-07	0.000414	0.48	0.26	Blood pressure (smoking interaction);	chr3:125913841	chr3:125774714~125797953:+
STAD	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-5.09	5.83e-07	0.000414	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
STAD	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	5.09	5.84e-07	0.000415	0.35	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
STAD	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	5.09	5.84e-07	0.000415	0.46	0.26	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
STAD	cis	rs10851478	0.515	rs28375625	ENSG00000259545.2	RP11-325E5.4	5.09	5.84e-07	0.000415	0.28	0.26	Oral cavity cancer;	chr15:49450297	chr15:49177610~49178741:-
STAD	cis	rs8067354	0.681	rs9907923	ENSG00000266701.1	AC005702.4	5.09	5.84e-07	0.000415	0.36	0.26	Hemoglobin concentration;	chr17:59747566	chr17:60042546~60042627:-
STAD	cis	rs9307551	0.817	rs13146986	ENSG00000250334.4	LINC00989	-5.09	5.84e-07	0.000415	-0.31	-0.26	Refractive error;	chr4:79591074	chr4:79492416~79576460:+
STAD	cis	rs11694172	1	rs55669835	ENSG00000273456.1	RP11-686O6.2	5.09	5.84e-07	0.000415	0.3	0.26	Cholesterol, total;	chr2:202661245	chr2:202374932~202375604:-
STAD	cis	rs7487075	0.619	rs7959731	ENSG00000257261.4	RP11-96H19.1	-5.09	5.84e-07	0.000415	-0.32	-0.26	Itch intensity from mosquito bite;	chr12:46445874	chr12:46383679~46876159:+
STAD	cis	rs4589258	1	rs7937113	ENSG00000280367.1	RP11-121L10.2	5.09	5.84e-07	0.000415	0.28	0.26	Intelligence (multi-trait analysis);	chr11:90733217	chr11:90223153~90226538:+
STAD	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-5.09	5.85e-07	0.000415	-0.42	-0.26	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
STAD	cis	rs992157	0.71	rs10167446	ENSG00000237281.1	CATIP-AS2	-5.09	5.85e-07	0.000415	-0.26	-0.26	Colorectal cancer;	chr2:218192143	chr2:218326889~218357966:-
STAD	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	5.09	5.87e-07	0.000416	0.42	0.26	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
STAD	cis	rs1816752	0.748	rs6490912	ENSG00000273628.1	RP11-756A22.7	5.09	5.87e-07	0.000417	0.32	0.26	Obesity-related traits;	chr13:24408941	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.819	rs1981276	ENSG00000273628.1	RP11-756A22.7	5.09	5.87e-07	0.000417	0.32	0.26	Obesity-related traits;	chr13:24409361	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.837	rs57052031	ENSG00000273628.1	RP11-756A22.7	5.09	5.87e-07	0.000417	0.32	0.26	Obesity-related traits;	chr13:24409730	chr13:24933006~24936796:+
STAD	cis	rs453301	0.719	rs34004903	ENSG00000254340.1	RP11-10A14.3	-5.09	5.88e-07	0.000417	-0.35	-0.26	Joint mobility (Beighton score);	chr8:9035094	chr8:9141424~9145435:+
STAD	cis	rs747650	0.532	rs7128650	ENSG00000271350.1	CTD-2384B9.1	-5.09	5.89e-07	0.000418	-0.34	-0.26	Acne (severe);	chr11:47025508	chr11:47041027~47041945:-
STAD	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-5.09	5.89e-07	0.000418	-0.22	-0.26	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
STAD	cis	rs3758911	1	rs10789616	ENSG00000261098.1	RP11-819C21.1	-5.09	5.89e-07	0.000418	-0.23	-0.26	Coronary artery disease;	chr11:107318365	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs10789617	ENSG00000261098.1	RP11-819C21.1	-5.09	5.89e-07	0.000418	-0.23	-0.26	Coronary artery disease;	chr11:107318968	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs11212153	ENSG00000261098.1	RP11-819C21.1	-5.09	5.89e-07	0.000418	-0.23	-0.26	Coronary artery disease;	chr11:107319234	chr11:107312132~107316271:-
STAD	cis	rs4950322	0.57	rs7554833	ENSG00000278811.3	LINC00624	-5.09	5.89e-07	0.000418	-0.28	-0.26	Protein quantitative trait loci;	chr1:147289362	chr1:147258885~147517875:-
STAD	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-5.09	5.9e-07	0.000418	-0.29	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
STAD	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	5.09	5.9e-07	0.000418	0.43	0.26	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
STAD	cis	rs2337406	0.866	rs2301535	ENSG00000280411.1	IGHV1-69-2	-5.09	5.9e-07	0.000418	-0.32	-0.26	Alzheimer's disease (late onset);	chr14:106790663	chr14:106762092~106762588:-
STAD	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-5.09	5.9e-07	0.000419	-0.42	-0.26	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
STAD	cis	rs2221894	0.616	rs7817447	ENSG00000273710.1	Metazoa_SRP	-5.09	5.9e-07	0.000419	-0.27	-0.26	Obesity-related traits;	chr8:29089252	chr8:28915579~28915864:-
STAD	cis	rs9463078	0.51	rs11964325	ENSG00000219384.1	RP11-491H9.3	-5.09	5.91e-07	0.000419	-0.26	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45085880	chr6:45158870~45159511:+
STAD	cis	rs7829975	0.508	rs1594437	ENSG00000254340.1	RP11-10A14.3	5.09	5.91e-07	0.000419	0.34	0.26	Mood instability;	chr8:8968365	chr8:9141424~9145435:+
STAD	cis	rs748404	0.666	rs34515241	ENSG00000249839.1	AC011330.5	-5.09	5.91e-07	0.000419	-0.45	-0.26	Lung cancer;	chr15:43342011	chr15:43663654~43684339:-
STAD	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	5.09	5.91e-07	0.000419	0.3	0.26	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
STAD	cis	rs9307551	0.744	rs10004226	ENSG00000250334.4	LINC00989	-5.09	5.91e-07	0.000419	-0.32	-0.26	Refractive error;	chr4:79569654	chr4:79492416~79576460:+
STAD	cis	rs6430585	0.528	rs12476127	ENSG00000231890.6	DARS-AS1	-5.09	5.92e-07	0.00042	-0.3	-0.26	Corneal structure;	chr2:136005672	chr2:135985176~136022593:+
STAD	cis	rs4713118	0.869	rs6914924	ENSG00000280107.1	AL022393.9	-5.09	5.92e-07	0.00042	-0.35	-0.26	Parkinson's disease;	chr6:27743751	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs6930992	ENSG00000280107.1	AL022393.9	-5.09	5.92e-07	0.00042	-0.35	-0.26	Parkinson's disease;	chr6:27744341	chr6:28170845~28172521:+
STAD	cis	rs7829975	0.807	rs519019	ENSG00000254340.1	RP11-10A14.3	-5.09	5.92e-07	0.00042	-0.31	-0.26	Mood instability;	chr8:8737594	chr8:9141424~9145435:+
STAD	cis	rs2404602	0.692	rs1471780	ENSG00000259422.1	RP11-593F23.1	5.09	5.92e-07	0.00042	0.28	0.26	Blood metabolite levels;	chr15:76734185	chr15:76174891~76181486:-
STAD	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-5.09	5.93e-07	0.00042	-0.38	-0.26	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-5.09	5.93e-07	0.00042	-0.38	-0.26	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-5.09	5.93e-07	0.00042	-0.38	-0.26	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-5.09	5.93e-07	0.00042	-0.38	-0.26	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
STAD	cis	rs611744	0.517	rs62537573	ENSG00000253754.1	RP11-35G22.1	-5.09	5.93e-07	0.00042	-0.23	-0.26	Dupuytren's disease;	chr8:108257052	chr8:108226200~108227544:+
STAD	cis	rs7078219	0.505	rs4409764	ENSG00000228778.1	RP11-129J12.1	-5.09	5.93e-07	0.000421	-0.3	-0.26	Dental caries;	chr10:99524480	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.505	rs4129133	ENSG00000228778.1	RP11-129J12.1	-5.09	5.93e-07	0.000421	-0.3	-0.26	Dental caries;	chr10:99524813	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.505	rs4129132	ENSG00000228778.1	RP11-129J12.1	-5.09	5.93e-07	0.000421	-0.3	-0.26	Dental caries;	chr10:99524880	chr10:99527081~99528261:+
STAD	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	5.09	5.93e-07	0.000421	0.31	0.26	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
STAD	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	5.09	5.94e-07	0.000421	0.38	0.26	Height;	chr6:109732047	chr6:109382795~109383666:+
STAD	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	5.09	5.94e-07	0.000421	0.39	0.26	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
STAD	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-5.09	5.94e-07	0.000421	-0.3	-0.26	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-5.09	5.94e-07	0.000421	-0.3	-0.26	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
STAD	cis	rs1799949	1	rs12944430	ENSG00000279602.1	CTD-3014M21.1	5.09	5.94e-07	0.000421	0.33	0.26	Menopause (age at onset);	chr17:43178803	chr17:43360041~43361361:-
STAD	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	5.09	5.94e-07	0.000421	0.29	0.26	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
STAD	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-5.09	5.95e-07	0.000421	-0.41	-0.26	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
STAD	cis	rs516805	0.596	rs4326267	ENSG00000279453.1	RP3-425C14.4	-5.09	5.95e-07	0.000421	-0.38	-0.26	Lymphocyte counts;	chr6:122106476	chr6:122436789~122439223:-
STAD	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	5.09	5.95e-07	0.000421	0.32	0.26	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
STAD	cis	rs728616	0.558	rs17616958	ENSG00000225484.5	NUTM2B-AS1	-5.09	5.96e-07	0.000422	-0.52	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr10:79663088~79826594:-
STAD	cis	rs728616	0.558	rs17616964	ENSG00000225484.5	NUTM2B-AS1	-5.09	5.96e-07	0.000422	-0.52	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr10:79663088~79826594:-
STAD	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	5.09	5.96e-07	0.000422	0.31	0.26	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
STAD	cis	rs240993	0.812	rs9487626	ENSG00000230177.1	RP5-1112D6.4	-5.09	5.96e-07	0.000422	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111277932~111278742:+
STAD	cis	rs240993	0.715	rs9487627	ENSG00000230177.1	RP5-1112D6.4	-5.09	5.96e-07	0.000422	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111277932~111278742:+
STAD	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-5.09	5.96e-07	0.000422	-0.33	-0.26	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
STAD	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	5.09	5.97e-07	0.000423	0.42	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
STAD	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	5.09	5.98e-07	0.000423	0.38	0.26	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
STAD	cis	rs9860428	0.808	rs6805341	ENSG00000240057.4	RP11-572M11.4	-5.09	5.98e-07	0.000423	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899471	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.808	rs9868922	ENSG00000240057.4	RP11-572M11.4	-5.09	5.98e-07	0.000423	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899503	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs2399437	ENSG00000240057.4	RP11-572M11.4	-5.09	5.98e-07	0.000423	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112900369	chr3:113019532~113183301:+
STAD	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-5.09	5.98e-07	0.000423	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-5.09	5.98e-07	0.000423	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
STAD	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-5.09	5.98e-07	0.000423	-0.27	-0.26	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-5.09	5.98e-07	0.000423	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-5.09	5.98e-07	0.000423	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-5.09	5.98e-07	0.000423	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-5.09	5.98e-07	0.000423	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
STAD	cis	rs748404	0.666	rs16957715	ENSG00000249839.1	AC011330.5	-5.09	5.98e-07	0.000423	-0.44	-0.26	Lung cancer;	chr15:43416539	chr15:43663654~43684339:-
STAD	cis	rs728616	0.614	rs17678737	ENSG00000225484.5	NUTM2B-AS1	-5.09	5.98e-07	0.000423	-0.52	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79663088~79826594:-
STAD	cis	rs801193	0.591	rs4506088	ENSG00000236529.1	RP13-254B10.1	-5.09	5.99e-07	0.000424	-0.27	-0.26	Aortic root size;	chr7:66670470	chr7:65840212~65840596:+
STAD	cis	rs3758911	0.765	rs72990438	ENSG00000261098.1	RP11-819C21.1	-5.09	5.99e-07	0.000424	-0.24	-0.26	Coronary artery disease;	chr11:107345678	chr11:107312132~107316271:-
STAD	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	5.09	6e-07	0.000425	0.37	0.26	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
STAD	cis	rs516805	0.748	rs11154077	ENSG00000279453.1	RP3-425C14.4	5.09	6.01e-07	0.000425	0.35	0.26	Lymphocyte counts;	chr6:122386994	chr6:122436789~122439223:-
STAD	cis	rs7247513	1	rs2042947	ENSG00000230310.1	CTD-2192J16.11	-5.09	6.01e-07	0.000426	-0.34	-0.26	Bipolar disorder;	chr19:12582289	chr19:12552597~12553644:+
STAD	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	5.09	6.01e-07	0.000426	0.49	0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
STAD	cis	rs1345301	1	rs12475055	ENSG00000234389.1	AC007278.3	5.09	6.02e-07	0.000426	0.26	0.26	Waist circumference;	chr2:102262431	chr2:102438713~102440475:+
STAD	cis	rs7951870	0.645	rs2070852	ENSG00000271350.1	CTD-2384B9.1	-5.09	6.03e-07	0.000427	-0.31	-0.26	Schizophrenia;	chr11:46723375	chr11:47041027~47041945:-
STAD	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	5.09	6.03e-07	0.000427	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
STAD	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-5.09	6.03e-07	0.000427	-0.33	-0.26	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
STAD	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-5.08	6.04e-07	0.000427	-0.3	-0.26	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
STAD	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-5.08	6.04e-07	0.000427	-0.29	-0.26	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-5.08	6.04e-07	0.000427	-0.29	-0.26	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	5.08	6.04e-07	0.000427	0.29	0.26	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
STAD	cis	rs8040855	0.627	rs72757059	ENSG00000229212.6	RP11-561C5.4	5.08	6.05e-07	0.000428	0.39	0.26	Bulimia nervosa;	chr15:85059918	chr15:85205440~85234795:-
STAD	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	5.08	6.05e-07	0.000428	0.29	0.26	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
STAD	cis	rs1729407	0.695	rs1263176	ENSG00000280143.1	AP000892.6	5.08	6.05e-07	0.000428	0.19	0.26	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117204967~117210292:+
STAD	cis	rs728616	0.614	rs61860413	ENSG00000225484.5	NUTM2B-AS1	-5.08	6.05e-07	0.000428	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79663088~79826594:-
STAD	cis	rs728616	0.614	rs61860414	ENSG00000225484.5	NUTM2B-AS1	-5.08	6.05e-07	0.000428	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79663088~79826594:-
STAD	cis	rs2221894	0.665	rs6558093	ENSG00000273710.1	Metazoa_SRP	-5.08	6.06e-07	0.000428	-0.27	-0.26	Obesity-related traits;	chr8:29088603	chr8:28915579~28915864:-
STAD	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	5.08	6.06e-07	0.000428	0.26	0.26	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
STAD	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	5.08	6.06e-07	0.000429	0.34	0.26	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
STAD	cis	rs7598759	0.527	rs7571691	ENSG00000223198.1	RNU2-22P	-5.08	6.06e-07	0.000429	-0.3	-0.26	Noise-induced hearing loss;	chr2:231504690	chr2:231501990~231502201:-
STAD	cis	rs6142102	0.812	rs2377955	ENSG00000275784.1	RP5-1125A11.6	-5.08	6.07e-07	0.000429	-0.27	-0.26	Skin pigmentation;	chr20:33937564	chr20:33989480~33991818:-
STAD	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	5.08	6.07e-07	0.000429	0.25	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
STAD	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	5.08	6.07e-07	0.000429	0.39	0.26	Height;	chr6:109618283	chr6:109382795~109383666:+
STAD	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-5.08	6.07e-07	0.000429	-0.38	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-5.08	6.07e-07	0.000429	-0.38	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-5.08	6.07e-07	0.000429	-0.38	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
STAD	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	5.08	6.07e-07	0.000429	0.32	0.26	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
STAD	cis	rs2404602	0.692	rs59088060	ENSG00000259422.1	RP11-593F23.1	5.08	6.07e-07	0.000429	0.28	0.26	Blood metabolite levels;	chr15:76567633	chr15:76174891~76181486:-
STAD	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-5.08	6.07e-07	0.000429	-0.31	-0.26	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
STAD	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	5.08	6.08e-07	0.00043	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
STAD	cis	rs1150668	0.796	rs1005125	ENSG00000220721.1	OR1F12	5.08	6.1e-07	0.000431	0.26	0.26	Pubertal anthropometrics;	chr6:28399578	chr6:28073316~28074233:+
STAD	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-5.08	6.1e-07	0.000431	-0.31	-0.26	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
STAD	cis	rs6430585	0.528	rs7573555	ENSG00000231890.6	DARS-AS1	5.08	6.1e-07	0.000431	0.29	0.26	Corneal structure;	chr2:135937335	chr2:135985176~136022593:+
STAD	cis	rs7826238	0.653	rs2979202	ENSG00000253981.4	ALG1L13P	5.08	6.1e-07	0.000431	0.31	0.26	Systolic blood pressure;	chr8:8486617	chr8:8236003~8244667:-
STAD	cis	rs3758911	0.929	rs10749895	ENSG00000261098.1	RP11-819C21.1	-5.08	6.11e-07	0.000432	-0.24	-0.26	Coronary artery disease;	chr11:107310855	chr11:107312132~107316271:-
STAD	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-5.08	6.11e-07	0.000432	-0.3	-0.26	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
STAD	cis	rs9307551	1	rs9307545	ENSG00000250334.4	LINC00989	-5.08	6.12e-07	0.000432	-0.33	-0.26	Refractive error;	chr4:79595417	chr4:79492416~79576460:+
STAD	cis	rs747650	0.504	rs7124648	ENSG00000271350.1	CTD-2384B9.1	-5.08	6.12e-07	0.000432	-0.34	-0.26	Acne (severe);	chr11:47022698	chr11:47041027~47041945:-
STAD	cis	rs1056107	0.933	rs7866603	ENSG00000225513.1	RP11-165N19.2	-5.08	6.12e-07	0.000432	-0.3	-0.26	Colorectal cancer;	chr9:112202052	chr9:112173522~112173971:-
STAD	cis	rs58873874	0.737	rs112160357	ENSG00000251405.2	CTB-109A12.1	5.08	6.12e-07	0.000433	0.46	0.26	Bipolar disorder (body mass index interaction);	chr5:157501696	chr5:157362615~157460078:-
STAD	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-5.08	6.13e-07	0.000433	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
STAD	cis	rs8067354	0.645	rs72840522	ENSG00000266701.1	AC005702.4	5.08	6.13e-07	0.000433	0.36	0.26	Hemoglobin concentration;	chr17:59752631	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs9899611	ENSG00000266701.1	AC005702.4	5.08	6.13e-07	0.000433	0.36	0.26	Hemoglobin concentration;	chr17:59754829	chr17:60042546~60042627:-
STAD	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	5.08	6.14e-07	0.000433	0.38	0.26	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
STAD	cis	rs9601248	0.756	rs928640	ENSG00000227354.5	RBM26-AS1	-5.08	6.14e-07	0.000434	-0.32	-0.26	Major depressive disorder;	chr13:79603348	chr13:79406309~79424328:+
STAD	cis	rs747650	0.884	rs7128325	ENSG00000271350.1	CTD-2384B9.1	-5.08	6.15e-07	0.000434	-0.32	-0.26	Acne (severe);	chr11:47025003	chr11:47041027~47041945:-
STAD	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	5.08	6.15e-07	0.000435	0.35	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
STAD	cis	rs9860428	0.76	rs9823692	ENSG00000240057.4	RP11-572M11.4	-5.08	6.16e-07	0.000435	-0.26	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112910375	chr3:113019532~113183301:+
STAD	cis	rs611744	0.604	rs6469170	ENSG00000253754.1	RP11-35G22.1	-5.08	6.16e-07	0.000435	-0.23	-0.26	Dupuytren's disease;	chr8:108293048	chr8:108226200~108227544:+
STAD	cis	rs7665090	0.87	rs228616	ENSG00000248971.2	KRT8P46	5.08	6.17e-07	0.000435	0.27	0.26	Primary biliary cholangitis;	chr4:102658534	chr4:102728746~102730171:-
STAD	cis	rs237743	1	rs35759030	ENSG00000222365.1	SNORD12B	-5.08	6.17e-07	0.000435	-0.35	-0.26	Height;	chr20:49241753	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs6512577	ENSG00000222365.1	SNORD12B	-5.08	6.17e-07	0.000435	-0.35	-0.26	Height;	chr20:49249247	chr20:49280319~49280409:+
STAD	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	5.08	6.17e-07	0.000436	0.4	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
STAD	cis	rs879620	1	rs2531995	ENSG00000262185.1	RP11-462G12.1	-5.08	6.17e-07	0.000436	-0.25	-0.26	Hip circumference;Body mass index;	chr16:3963466	chr16:3947609~3950444:-
STAD	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	5.08	6.18e-07	0.000436	0.29	0.26	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
STAD	cis	rs944990	0.576	rs3901421	ENSG00000227603.1	RP11-165J3.6	5.08	6.18e-07	0.000436	0.29	0.26	Body mass index;	chr9:93442256	chr9:93435332~93437121:-
STAD	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	5.08	6.18e-07	0.000436	0.39	0.26	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
STAD	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-5.08	6.19e-07	0.000437	-0.33	-0.26	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
STAD	cis	rs7665090	0.87	rs228613	ENSG00000246560.2	RP11-10L12.4	-5.08	6.19e-07	0.000437	-0.31	-0.26	Primary biliary cholangitis;	chr4:102656308	chr4:102828055~102844075:+
STAD	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-5.08	6.19e-07	0.000437	-0.33	-0.26	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
STAD	cis	rs1056107	0.931	rs10981334	ENSG00000225513.1	RP11-165N19.2	-5.08	6.19e-07	0.000437	-0.31	-0.26	Colorectal cancer;	chr9:112262415	chr9:112173522~112173971:-
STAD	cis	rs6142102	0.812	rs761236	ENSG00000275784.1	RP5-1125A11.6	-5.08	6.19e-07	0.000437	-0.27	-0.26	Skin pigmentation;	chr20:33932245	chr20:33989480~33991818:-
STAD	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-5.08	6.19e-07	0.000437	-0.35	-0.26	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-5.08	6.19e-07	0.000437	-0.35	-0.26	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	5.08	6.2e-07	0.000437	0.38	0.26	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
STAD	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-5.08	6.2e-07	0.000438	-0.34	-0.26	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
STAD	cis	rs1799949	0.965	rs2236762	ENSG00000236383.6	LINC00854	-5.08	6.2e-07	0.000438	-0.21	-0.26	Menopause (age at onset);	chr17:43074658	chr17:43216941~43305976:-
STAD	cis	rs227275	0.556	rs6815526	ENSG00000230069.3	LRRC37A15P	-5.08	6.21e-07	0.000438	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102727274~102730721:-
STAD	cis	rs227275	0.556	rs6824070	ENSG00000230069.3	LRRC37A15P	-5.08	6.21e-07	0.000438	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102727274~102730721:-
STAD	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	5.08	6.21e-07	0.000438	0.39	0.26	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
STAD	cis	rs66887589	0.72	rs11724758	ENSG00000249244.1	RP11-548H18.2	5.08	6.21e-07	0.000438	0.32	0.26	Diastolic blood pressure;	chr4:119318723	chr4:119391831~119395335:-
STAD	cis	rs2688608	0.56	rs10128354	ENSG00000271816.1	BMS1P4	5.08	6.22e-07	0.000438	0.29	0.26	Inflammatory bowel disease;	chr10:73710287	chr10:73699151~73730487:-
STAD	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-5.08	6.22e-07	0.000439	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
STAD	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-5.08	6.22e-07	0.000439	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
STAD	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-5.08	6.22e-07	0.000439	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
STAD	cis	rs919433	0.929	rs1366836	ENSG00000231621.1	AC013264.2	5.08	6.22e-07	0.000439	0.22	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197307424	chr2:197197991~197199273:+
STAD	cis	rs919433	1	rs112572902	ENSG00000231621.1	AC013264.2	5.08	6.22e-07	0.000439	0.22	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310455	chr2:197197991~197199273:+
STAD	cis	rs2404602	0.716	rs66754747	ENSG00000259422.1	RP11-593F23.1	5.08	6.23e-07	0.000439	0.27	0.26	Blood metabolite levels;	chr15:76536227	chr15:76174891~76181486:-
STAD	cis	rs240993	0.812	rs118202	ENSG00000230177.1	RP5-1112D6.4	-5.08	6.23e-07	0.000439	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111337168	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs240955	ENSG00000230177.1	RP5-1112D6.4	-5.08	6.23e-07	0.000439	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111339440	chr6:111277932~111278742:+
STAD	cis	rs240993	0.761	rs453776	ENSG00000230177.1	RP5-1112D6.4	-5.08	6.23e-07	0.000439	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111342260	chr6:111277932~111278742:+
STAD	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-5.08	6.24e-07	0.00044	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
STAD	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-5.08	6.24e-07	0.00044	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
STAD	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-5.08	6.24e-07	0.00044	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
STAD	cis	rs4243830	0.85	rs12410405	ENSG00000229519.2	RP11-58A11.2	-5.08	6.24e-07	0.00044	-0.29	-0.26	Body mass index;	chr1:6521223	chr1:6547905~6548619:+
STAD	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-5.08	6.25e-07	0.00044	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-5.08	6.25e-07	0.00044	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
STAD	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	5.08	6.25e-07	0.00044	0.29	0.26	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	5.08	6.25e-07	0.00044	0.29	0.26	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	5.08	6.25e-07	0.00044	0.29	0.26	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	5.08	6.25e-07	0.00044	0.29	0.26	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	5.08	6.25e-07	0.00044	0.29	0.26	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	5.08	6.25e-07	0.00044	0.29	0.26	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
STAD	cis	rs7932354	0.583	rs2306027	ENSG00000271350.1	CTD-2384B9.1	-5.08	6.26e-07	0.000441	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:46886276	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.617	rs7118170	ENSG00000271350.1	CTD-2384B9.1	-5.08	6.26e-07	0.000441	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:46887170	chr11:47041027~47041945:-
STAD	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-5.08	6.26e-07	0.000441	-0.38	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-5.08	6.26e-07	0.000441	-0.38	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
STAD	cis	rs1056107	0.931	rs940593	ENSG00000225513.1	RP11-165N19.2	-5.08	6.27e-07	0.000442	-0.31	-0.26	Colorectal cancer;	chr9:112255380	chr9:112173522~112173971:-
STAD	cis	rs1029738	0.615	rs3757447	ENSG00000228649.7	AC005682.5	5.08	6.27e-07	0.000442	0.31	0.26	Fibrinogen levels;	chr7:22855116	chr7:22854178~22861579:+
STAD	cis	rs673078	0.607	rs7294498	ENSG00000275409.1	RP11-131L12.4	-5.08	6.27e-07	0.000442	-0.33	-0.26	Glucose homeostasis traits;	chr12:118321680	chr12:118430147~118430699:+
STAD	cis	rs2337406	0.866	rs7153964	ENSG00000211972.2	IGHV3-66	5.08	6.27e-07	0.000442	0.28	0.26	Alzheimer's disease (late onset);	chr14:106790480	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs2301536	ENSG00000211972.2	IGHV3-66	5.08	6.27e-07	0.000442	0.28	0.26	Alzheimer's disease (late onset);	chr14:106790636	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs7144369	ENSG00000211972.2	IGHV3-66	5.08	6.27e-07	0.000442	0.28	0.26	Alzheimer's disease (late onset);	chr14:106793065	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs78525520	ENSG00000211972.2	IGHV3-66	5.08	6.27e-07	0.000442	0.28	0.26	Alzheimer's disease (late onset);	chr14:106795643	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000211972.2	IGHV3-66	5.08	6.27e-07	0.000442	0.28	0.26	Kawasaki disease;	chr14:106799309	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs76871148	ENSG00000211972.2	IGHV3-66	5.08	6.27e-07	0.000442	0.28	0.26	Alzheimer's disease (late onset);	chr14:106799722	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs61521632	ENSG00000211972.2	IGHV3-66	5.08	6.27e-07	0.000442	0.28	0.26	Alzheimer's disease (late onset);	chr14:106801091	chr14:106675017~106675544:-
STAD	cis	rs516805	0.667	rs1456706	ENSG00000279453.1	RP3-425C14.4	-5.08	6.28e-07	0.000442	-0.38	-0.26	Lymphocyte counts;	chr6:122134801	chr6:122436789~122439223:-
STAD	cis	rs240993	0.812	rs240990	ENSG00000230177.1	RP5-1112D6.4	-5.08	6.29e-07	0.000443	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111343820	chr6:111277932~111278742:+
STAD	cis	rs1799949	0.965	rs799916	ENSG00000236383.6	LINC00854	5.08	6.29e-07	0.000443	0.21	0.26	Menopause (age at onset);	chr17:43091173	chr17:43216941~43305976:-
STAD	cis	rs10510102	0.872	rs11200293	ENSG00000226864.1	ATE1-AS1	5.08	6.29e-07	0.000443	0.43	0.26	Breast cancer;	chr10:121969195	chr10:121928312~121951965:+
STAD	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	5.08	6.29e-07	0.000443	0.41	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
STAD	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	5.08	6.29e-07	0.000443	0.41	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
STAD	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	5.08	6.29e-07	0.000443	0.41	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
STAD	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-5.08	6.3e-07	0.000444	-0.36	-0.26	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
STAD	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	5.08	6.3e-07	0.000444	0.34	0.26	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
STAD	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	5.08	6.3e-07	0.000444	0.28	0.26	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	5.08	6.3e-07	0.000444	0.28	0.26	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
STAD	cis	rs7078219	0.505	rs7916751	ENSG00000228778.1	RP11-129J12.1	-5.08	6.31e-07	0.000444	-0.3	-0.26	Dental caries;	chr10:99525893	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.505	rs6584281	ENSG00000228778.1	RP11-129J12.1	-5.08	6.31e-07	0.000444	-0.3	-0.26	Dental caries;	chr10:99526723	chr10:99527081~99528261:+
STAD	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-5.08	6.31e-07	0.000444	-0.3	-0.26	QT interval;	chr12:29310155	chr12:29280418~29317848:-
STAD	cis	rs10510102	0.748	rs11200297	ENSG00000226864.1	ATE1-AS1	5.08	6.31e-07	0.000444	0.45	0.26	Breast cancer;	chr10:121972916	chr10:121928312~121951965:+
STAD	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	5.08	6.31e-07	0.000444	0.28	0.26	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
STAD	cis	rs9467773	0.901	rs1407045	ENSG00000243307.2	POM121L6P	5.08	6.32e-07	0.000445	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26475927	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9295743	ENSG00000280107.1	AL022393.9	-5.08	6.33e-07	0.000445	-0.35	-0.26	Parkinson's disease;	chr6:27747323	chr6:28170845~28172521:+
STAD	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	5.08	6.33e-07	0.000445	0.39	0.26	Height;	chr6:109762861	chr6:109382795~109383666:+
STAD	cis	rs1056107	0.897	rs4979090	ENSG00000225513.1	RP11-165N19.2	-5.08	6.33e-07	0.000446	-0.3	-0.26	Colorectal cancer;	chr9:112257991	chr9:112173522~112173971:-
STAD	cis	rs8040855	0.627	rs17540307	ENSG00000229212.6	RP11-561C5.4	5.08	6.33e-07	0.000446	0.38	0.26	Bulimia nervosa;	chr15:85090614	chr15:85205440~85234795:-
STAD	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-5.08	6.34e-07	0.000446	-0.34	-0.26	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
STAD	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-5.08	6.34e-07	0.000446	-0.26	-0.26	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
STAD	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-5.08	6.34e-07	0.000446	-0.43	-0.26	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
STAD	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	5.07	6.34e-07	0.000446	0.39	0.26	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
STAD	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-5.07	6.35e-07	0.000446	-0.33	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
STAD	cis	rs7665090	1	rs2125211	ENSG00000248971.2	KRT8P46	5.07	6.35e-07	0.000447	0.29	0.26	Primary biliary cholangitis;	chr4:102638719	chr4:102728746~102730171:-
STAD	cis	rs7829975	0.846	rs6601724	ENSG00000253981.4	ALG1L13P	-5.07	6.36e-07	0.000447	-0.31	-0.26	Mood instability;	chr8:8687362	chr8:8236003~8244667:-
STAD	cis	rs2384207	0.818	rs7955036	ENSG00000277566.1	RP11-545P7.9	-5.07	6.36e-07	0.000447	-0.36	-0.26	Response to fenofibrate (adiponectin levels);	chr12:113277446	chr12:113249466~113250042:+
STAD	cis	rs9463078	0.585	rs1285019	ENSG00000219384.1	RP11-491H9.3	5.07	6.36e-07	0.000447	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45199935	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.605	rs927658	ENSG00000219384.1	RP11-491H9.3	5.07	6.36e-07	0.000447	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45200316	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs6905396	ENSG00000219384.1	RP11-491H9.3	5.07	6.36e-07	0.000447	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45201428	chr6:45158870~45159511:+
STAD	cis	rs7760535	0.794	rs12529158	ENSG00000230177.1	RP5-1112D6.4	5.07	6.36e-07	0.000447	0.24	0.26	Metabolic traits;	chr6:111501244	chr6:111277932~111278742:+
STAD	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-5.07	6.36e-07	0.000447	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
STAD	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-5.07	6.38e-07	0.000449	-0.42	-0.26	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
STAD	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	5.07	6.38e-07	0.000449	0.33	0.26	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
STAD	cis	rs6452524	0.618	rs10462394	ENSG00000243385.2	CTD-2110K23.1	5.07	6.38e-07	0.000449	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83201229~83202141:+
STAD	cis	rs8099594	0.524	rs12961303	ENSG00000266696.1	RP11-30L3.2	5.07	6.38e-07	0.000449	0.24	0.26	Height;	chr18:49212678	chr18:49205912~49208781:+
STAD	cis	rs6452524	0.56	rs6895174	ENSG00000243385.2	CTD-2110K23.1	5.07	6.39e-07	0.000449	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83201229~83202141:+
STAD	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	5.07	6.39e-07	0.000449	0.35	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
STAD	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	5.07	6.4e-07	0.00045	0.27	0.26	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
STAD	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-5.07	6.4e-07	0.00045	-0.33	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
STAD	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-5.07	6.4e-07	0.00045	-0.33	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
STAD	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-5.07	6.4e-07	0.00045	-0.24	-0.26	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
STAD	cis	rs919433	0.929	rs4850788	ENSG00000231621.1	AC013264.2	5.07	6.4e-07	0.00045	0.22	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318216	chr2:197197991~197199273:+
STAD	cis	rs6714710	0.603	rs10432626	ENSG00000235833.1	AC159540.14	-5.07	6.4e-07	0.00045	-0.29	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97944690	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs1875699	ENSG00000235833.1	AC159540.14	-5.07	6.4e-07	0.00045	-0.29	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97964261	chr2:97523949~97524976:-
STAD	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	5.07	6.4e-07	0.00045	0.29	0.26	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
STAD	cis	rs10510102	0.872	rs12244199	ENSG00000226864.1	ATE1-AS1	5.07	6.41e-07	0.00045	0.43	0.26	Breast cancer;	chr10:121965117	chr10:121928312~121951965:+
STAD	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-5.07	6.42e-07	0.000451	-0.26	-0.26	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
STAD	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	5.07	6.42e-07	0.000451	0.37	0.26	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
STAD	cis	rs611744	0.538	rs2298605	ENSG00000253754.1	RP11-35G22.1	-5.07	6.42e-07	0.000451	-0.23	-0.26	Dupuytren's disease;	chr8:108259777	chr8:108226200~108227544:+
STAD	cis	rs6714710	0.603	rs17488897	ENSG00000235833.1	AC159540.14	-5.07	6.43e-07	0.000451	-0.31	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97748701	chr2:97523949~97524976:-
STAD	cis	rs8099594	0.565	rs4939849	ENSG00000266696.1	RP11-30L3.2	-5.07	6.43e-07	0.000452	-0.24	-0.26	Height;	chr18:49201252	chr18:49205912~49208781:+
STAD	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-5.07	6.43e-07	0.000452	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
STAD	cis	rs58873874	0.737	rs80320835	ENSG00000251405.2	CTB-109A12.1	5.07	6.43e-07	0.000452	0.49	0.26	Bipolar disorder (body mass index interaction);	chr5:157389887	chr5:157362615~157460078:-
STAD	cis	rs747650	0.504	rs10838641	ENSG00000271350.1	CTD-2384B9.1	-5.07	6.43e-07	0.000452	-0.33	-0.26	Acne (severe);	chr11:46981753	chr11:47041027~47041945:-
STAD	cis	rs11694172	0.908	rs12464670	ENSG00000273456.1	RP11-686O6.2	5.07	6.44e-07	0.000452	0.3	0.26	Cholesterol, total;	chr2:202708432	chr2:202374932~202375604:-
STAD	cis	rs11694172	0.955	rs35581848	ENSG00000273456.1	RP11-686O6.2	5.07	6.44e-07	0.000452	0.3	0.26	Cholesterol, total;	chr2:202718673	chr2:202374932~202375604:-
STAD	cis	rs11694172	0.955	rs62194147	ENSG00000273456.1	RP11-686O6.2	5.07	6.44e-07	0.000452	0.3	0.26	Cholesterol, total;	chr2:202720225	chr2:202374932~202375604:-
STAD	cis	rs17630293	0.737	rs78412932	ENSG00000201649.1	RNY4P34	-5.07	6.44e-07	0.000452	-0.39	-0.26	Schizophrenia;	chr2:200364340	chr2:200373175~200373269:+
STAD	cis	rs6142102	0.961	rs4911405	ENSG00000275784.1	RP5-1125A11.6	-5.07	6.44e-07	0.000452	-0.27	-0.26	Skin pigmentation;	chr20:34087161	chr20:33989480~33991818:-
STAD	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-5.07	6.44e-07	0.000452	-0.27	-0.26	Height;	chr5:36941456	chr5:36666214~36725195:-
STAD	cis	rs748404	0.666	rs34591748	ENSG00000249839.1	AC011330.5	-5.07	6.45e-07	0.000453	-0.45	-0.26	Lung cancer;	chr15:43334917	chr15:43663654~43684339:-
STAD	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-5.07	6.46e-07	0.000453	-0.21	-0.26	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
STAD	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-5.07	6.46e-07	0.000453	-0.21	-0.26	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
STAD	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-5.07	6.46e-07	0.000453	-0.21	-0.26	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
STAD	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-5.07	6.46e-07	0.000453	-0.21	-0.26	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
STAD	cis	rs957448	0.561	rs4734282	ENSG00000253704.1	RP11-267M23.4	5.07	6.46e-07	0.000453	0.31	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94553722~94569745:+
STAD	cis	rs11694172	1	rs11675723	ENSG00000273456.1	RP11-686O6.2	5.07	6.46e-07	0.000453	0.29	0.26	Cholesterol, total;	chr2:202682150	chr2:202374932~202375604:-
STAD	cis	rs6142102	0.961	rs761235	ENSG00000275784.1	RP5-1125A11.6	-5.07	6.46e-07	0.000454	-0.27	-0.26	Skin pigmentation;	chr20:33946602	chr20:33989480~33991818:-
STAD	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-5.07	6.47e-07	0.000454	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-5.07	6.47e-07	0.000454	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-5.07	6.47e-07	0.000454	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-5.07	6.47e-07	0.000454	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-5.07	6.47e-07	0.000454	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-5.07	6.47e-07	0.000454	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
STAD	cis	rs10266483	0.545	rs1812912	ENSG00000271550.1	BNIP3P11	-5.07	6.47e-07	0.000454	-0.36	-0.26	Response to statin therapy;	chr7:64282891	chr7:64678954~64687393:-
STAD	cis	rs2337406	0.866	rs4774019	ENSG00000211972.2	IGHV3-66	5.07	6.47e-07	0.000454	0.28	0.26	Alzheimer's disease (late onset);	chr14:106805386	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs58850145	ENSG00000211972.2	IGHV3-66	5.07	6.47e-07	0.000454	0.28	0.26	Alzheimer's disease (late onset);	chr14:106806185	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs2027901	ENSG00000211972.2	IGHV3-66	5.07	6.47e-07	0.000454	0.28	0.26	Alzheimer's disease (late onset);	chr14:106807164	chr14:106675017~106675544:-
STAD	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-5.07	6.48e-07	0.000454	-0.34	-0.26	Height;	chr20:49254902	chr20:49280319~49280409:+
STAD	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-5.07	6.48e-07	0.000455	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-5.07	6.48e-07	0.000455	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-5.07	6.48e-07	0.000455	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-5.07	6.48e-07	0.000455	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-5.07	6.48e-07	0.000455	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-5.07	6.48e-07	0.000455	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-5.07	6.48e-07	0.000455	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
STAD	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-5.07	6.48e-07	0.000455	-0.33	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
STAD	cis	rs4950322	0.947	rs72694723	ENSG00000278811.3	LINC00624	5.07	6.48e-07	0.000455	0.3	0.26	Protein quantitative trait loci;	chr1:147373174	chr1:147258885~147517875:-
STAD	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-5.07	6.49e-07	0.000455	-0.31	-0.26	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
STAD	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	5.07	6.49e-07	0.000455	0.38	0.26	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
STAD	cis	rs3758911	0.964	rs7358296	ENSG00000261098.1	RP11-819C21.1	-5.07	6.5e-07	0.000456	-0.23	-0.26	Coronary artery disease;	chr11:107403212	chr11:107312132~107316271:-
STAD	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-5.07	6.5e-07	0.000456	-0.27	-0.26	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
STAD	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-5.07	6.5e-07	0.000456	-0.25	-0.26	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
STAD	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	5.07	6.5e-07	0.000456	0.37	0.26	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
STAD	cis	rs9902453	0.542	rs3809789	ENSG00000240074.1	RPL9P30	5.07	6.5e-07	0.000456	0.23	0.26	Coffee consumption (cups per day);	chr17:29628743	chr17:29855759~29856332:+
STAD	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	5.07	6.51e-07	0.000457	0.27	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
STAD	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-5.07	6.51e-07	0.000457	-0.29	-0.26	QT interval;	chr12:29306799	chr12:29280418~29317848:-
STAD	cis	rs7615952	0.932	rs13065725	ENSG00000272840.1	RP11-379B18.6	5.07	6.51e-07	0.000457	0.48	0.26	Blood pressure (smoking interaction);	chr3:125913446	chr3:125774714~125797953:+
STAD	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-5.07	6.52e-07	0.000457	-0.3	-0.26	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
STAD	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	5.07	6.52e-07	0.000457	0.38	0.26	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
STAD	cis	rs11098499	0.863	rs1552095	ENSG00000260091.1	RP11-33B1.4	5.07	6.52e-07	0.000457	0.26	0.26	Corneal astigmatism;	chr4:119539151	chr4:119409333~119410233:+
STAD	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	5.07	6.54e-07	0.000458	0.31	0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
STAD	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	5.07	6.54e-07	0.000458	0.32	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
STAD	cis	rs240993	0.812	rs460594	ENSG00000230177.1	RP5-1112D6.4	-5.07	6.54e-07	0.000459	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111348602	chr6:111277932~111278742:+
STAD	cis	rs240993	0.761	rs462832	ENSG00000230177.1	RP5-1112D6.4	-5.07	6.54e-07	0.000459	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111365088	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs459147	ENSG00000230177.1	RP5-1112D6.4	-5.07	6.54e-07	0.000459	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111370285	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs455650	ENSG00000230177.1	RP5-1112D6.4	-5.07	6.54e-07	0.000459	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111370320	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs455645	ENSG00000230177.1	RP5-1112D6.4	-5.07	6.54e-07	0.000459	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111373870	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs462779	ENSG00000230177.1	RP5-1112D6.4	-5.07	6.54e-07	0.000459	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111374684	chr6:111277932~111278742:+
STAD	cis	rs240993	0.812	rs461646	ENSG00000230177.1	RP5-1112D6.4	-5.07	6.54e-07	0.000459	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111375054	chr6:111277932~111278742:+
STAD	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-5.07	6.54e-07	0.000459	-0.31	-0.26	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
STAD	cis	rs516805	0.961	rs544099	ENSG00000279453.1	RP3-425C14.4	5.07	6.55e-07	0.000459	0.28	0.26	Lymphocyte counts;	chr6:122479837	chr6:122436789~122439223:-
STAD	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	5.07	6.55e-07	0.000459	0.38	0.26	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
STAD	cis	rs10129255	0.642	rs11624918	ENSG00000224373.3	IGHV4-59	5.07	6.56e-07	0.000459	0.22	0.26	Kawasaki disease;	chr14:106664672	chr14:106627249~106627825:-
STAD	cis	rs7487075	0.567	rs7486580	ENSG00000257261.4	RP11-96H19.1	5.07	6.56e-07	0.000459	0.32	0.26	Itch intensity from mosquito bite;	chr12:46434565	chr12:46383679~46876159:+
STAD	cis	rs7829975	0.51	rs332037	ENSG00000253981.4	ALG1L13P	5.07	6.56e-07	0.000459	0.31	0.26	Mood instability;	chr8:8865165	chr8:8236003~8244667:-
STAD	cis	rs516805	0.63	rs2315816	ENSG00000279453.1	RP3-425C14.4	-5.07	6.56e-07	0.000459	-0.36	-0.26	Lymphocyte counts;	chr6:122102793	chr6:122436789~122439223:-
STAD	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	5.07	6.56e-07	0.000459	0.38	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
STAD	cis	rs6452524	0.935	rs1478480	ENSG00000243385.2	CTD-2110K23.1	5.07	6.56e-07	0.000459	0.27	0.26	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83201229~83202141:+
STAD	cis	rs2833693	1	rs2833696	ENSG00000261610.1	AP000265.1	-5.07	6.57e-07	0.00046	-0.3	-0.26	Temperament;	chr21:32182271	chr21:32259804~32261585:-
STAD	cis	rs8098244	0.638	rs12373237	ENSG00000267301.1	RPL23AP77	5.07	6.57e-07	0.00046	0.3	0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23845972	chr18:23709825~23710287:-
STAD	cis	rs12744310	0.887	rs12024263	ENSG00000235358.1	RP11-399E6.1	5.07	6.57e-07	0.00046	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41355277	chr1:41242373~41284861:+
STAD	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-5.07	6.58e-07	0.000461	-0.25	-0.26	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
STAD	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-5.07	6.58e-07	0.000461	-0.29	-0.26	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
STAD	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-5.07	6.59e-07	0.000461	-0.29	-0.26	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
STAD	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-5.07	6.6e-07	0.000462	-0.37	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
STAD	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	-5.07	6.6e-07	0.000462	-0.29	-0.26	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
STAD	cis	rs6452524	0.618	rs6452503	ENSG00000243385.2	CTD-2110K23.1	5.07	6.6e-07	0.000462	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.618	rs6452504	ENSG00000243385.2	CTD-2110K23.1	5.07	6.6e-07	0.000462	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.618	rs6452506	ENSG00000243385.2	CTD-2110K23.1	5.07	6.6e-07	0.000462	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.618	rs1993948	ENSG00000243385.2	CTD-2110K23.1	5.07	6.6e-07	0.000462	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83201229~83202141:+
STAD	cis	rs4589258	0.564	rs10734135	ENSG00000280367.1	RP11-121L10.2	5.07	6.6e-07	0.000462	0.25	0.26	Intelligence (multi-trait analysis);	chr11:90739807	chr11:90223153~90226538:+
STAD	cis	rs4713118	0.869	rs9283880	ENSG00000280107.1	AL022393.9	-5.07	6.6e-07	0.000462	-0.35	-0.26	Parkinson's disease;	chr6:27747464	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs9283881	ENSG00000280107.1	AL022393.9	-5.07	6.6e-07	0.000462	-0.35	-0.26	Parkinson's disease;	chr6:27747476	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs9283882	ENSG00000280107.1	AL022393.9	-5.07	6.6e-07	0.000462	-0.35	-0.26	Parkinson's disease;	chr6:27747479	chr6:28170845~28172521:+
STAD	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	5.07	6.6e-07	0.000462	0.3	0.26	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
STAD	cis	rs4834770	0.746	rs2389747	ENSG00000248280.1	RP11-33B1.2	5.07	6.6e-07	0.000462	0.31	0.26	Blood protein levels;	chr4:119314947	chr4:119440561~119450157:-
STAD	cis	rs4834770	0.717	rs1022146	ENSG00000248280.1	RP11-33B1.2	5.07	6.6e-07	0.000462	0.31	0.26	Blood protein levels;	chr4:119314948	chr4:119440561~119450157:-
STAD	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	5.07	6.61e-07	0.000462	0.32	0.26	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
STAD	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-5.07	6.61e-07	0.000463	-0.31	-0.26	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
STAD	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	5.07	6.61e-07	0.000463	0.42	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
STAD	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-5.07	6.63e-07	0.000463	-0.28	-0.26	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
STAD	cis	rs6840360	0.642	rs2724577	ENSG00000270265.1	RP11-731D1.4	-5.07	6.63e-07	0.000464	-0.33	-0.26	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151333775~151353224:-
STAD	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	5.07	6.63e-07	0.000464	0.41	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
STAD	cis	rs1862618	0.671	rs2591965	ENSG00000271828.1	CTD-2310F14.1	-5.07	6.64e-07	0.000465	-0.32	-0.26	Initial pursuit acceleration;	chr5:56940349	chr5:56927874~56929573:+
STAD	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-5.07	6.65e-07	0.000465	-0.41	-0.26	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
STAD	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-5.07	6.65e-07	0.000465	-0.3	-0.26	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
STAD	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	5.06	6.66e-07	0.000465	0.41	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
STAD	cis	rs227275	0.556	rs28367331	ENSG00000230069.3	LRRC37A15P	-5.06	6.66e-07	0.000465	-0.29	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102727274~102730721:-
STAD	cis	rs944990	0.64	rs10821131	ENSG00000227603.1	RP11-165J3.6	5.06	6.66e-07	0.000466	0.29	0.26	Body mass index;	chr9:93466540	chr9:93435332~93437121:-
STAD	cis	rs8040855	0.624	rs12903975	ENSG00000229212.6	RP11-561C5.4	5.06	6.66e-07	0.000466	0.36	0.26	Bulimia nervosa;	chr15:85006004	chr15:85205440~85234795:-
STAD	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	5.06	6.67e-07	0.000466	0.29	0.26	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
STAD	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	5.06	6.67e-07	0.000466	0.37	0.26	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
STAD	cis	rs2337406	0.866	rs78462736	ENSG00000211972.2	IGHV3-66	5.06	6.67e-07	0.000466	0.28	0.26	Alzheimer's disease (late onset);	chr14:106779942	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs8016203	ENSG00000211972.2	IGHV3-66	5.06	6.67e-07	0.000466	0.28	0.26	Alzheimer's disease (late onset);	chr14:106780575	chr14:106675017~106675544:-
STAD	cis	rs1056107	0.933	rs12376681	ENSG00000225513.1	RP11-165N19.2	-5.06	6.68e-07	0.000467	-0.31	-0.26	Colorectal cancer;	chr9:112297115	chr9:112173522~112173971:-
STAD	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	5.06	6.68e-07	0.000467	0.26	0.26	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
STAD	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	5.06	6.69e-07	0.000467	0.35	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
STAD	cis	rs1345301	1	rs1345302	ENSG00000234389.1	AC007278.3	-5.06	6.69e-07	0.000467	-0.27	-0.26	Waist circumference;	chr2:102256909	chr2:102438713~102440475:+
STAD	cis	rs747650	0.504	rs7111270	ENSG00000271350.1	CTD-2384B9.1	-5.06	6.69e-07	0.000467	-0.34	-0.26	Acne (severe);	chr11:46998226	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs10838644	ENSG00000271350.1	CTD-2384B9.1	-5.06	6.69e-07	0.000467	-0.34	-0.26	Acne (severe);	chr11:47014210	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs10838646	ENSG00000271350.1	CTD-2384B9.1	-5.06	6.69e-07	0.000467	-0.34	-0.26	Acne (severe);	chr11:47015243	chr11:47041027~47041945:-
STAD	cis	rs7760535	0.93	rs7742244	ENSG00000230177.1	RP5-1112D6.4	-5.06	6.69e-07	0.000467	-0.24	-0.26	Metabolic traits;	chr6:111531459	chr6:111277932~111278742:+
STAD	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-5.06	6.69e-07	0.000468	-0.28	-0.26	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
STAD	cis	rs747650	0.504	rs7130947	ENSG00000271350.1	CTD-2384B9.1	-5.06	6.69e-07	0.000468	-0.33	-0.26	Acne (severe);	chr11:46980454	chr11:47041027~47041945:-
STAD	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	5.06	6.7e-07	0.000468	0.39	0.26	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	5.06	6.7e-07	0.000468	0.39	0.26	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	5.06	6.7e-07	0.000468	0.39	0.26	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	5.06	6.7e-07	0.000468	0.39	0.26	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	5.06	6.7e-07	0.000468	0.39	0.26	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	5.06	6.7e-07	0.000468	0.39	0.26	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	5.06	6.7e-07	0.000468	0.39	0.26	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
STAD	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-5.06	6.7e-07	0.000468	-0.31	-0.26	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
STAD	cis	rs992157	0.767	rs2014615	ENSG00000237281.1	CATIP-AS2	-5.06	6.7e-07	0.000468	-0.26	-0.26	Colorectal cancer;	chr2:218306468	chr2:218326889~218357966:-
STAD	cis	rs1318937	0.764	rs58768954	ENSG00000224660.1	SH3BP5-AS1	5.06	6.72e-07	0.000469	0.27	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198798	chr3:15254184~15264493:+
STAD	cis	rs58873874	0.737	rs11746837	ENSG00000251405.2	CTB-109A12.1	5.06	6.72e-07	0.000469	0.47	0.26	Bipolar disorder (body mass index interaction);	chr5:157491138	chr5:157362615~157460078:-
STAD	cis	rs10129255	0.957	rs8009638	ENSG00000280411.1	IGHV1-69-2	-5.06	6.72e-07	0.000469	-0.25	-0.26	Kawasaki disease;	chr14:106777570	chr14:106762092~106762588:-
STAD	cis	rs747650	0.504	rs10769227	ENSG00000271350.1	CTD-2384B9.1	-5.06	6.72e-07	0.000469	-0.34	-0.26	Acne (severe);	chr11:46981063	chr11:47041027~47041945:-
STAD	cis	rs9463078	0.585	rs1284961	ENSG00000219384.1	RP11-491H9.3	5.06	6.73e-07	0.00047	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45204884	chr6:45158870~45159511:+
STAD	cis	rs1729407	0.647	rs2727791	ENSG00000280143.1	AP000892.6	5.06	6.73e-07	0.00047	0.19	0.26	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117204967~117210292:+
STAD	cis	rs853679	0.517	rs1904841	ENSG00000220721.1	OR1F12	5.06	6.73e-07	0.00047	0.31	0.26	Depression;	chr6:28140307	chr6:28073316~28074233:+
STAD	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	5.06	6.73e-07	0.00047	0.31	0.26	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
STAD	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	5.06	6.73e-07	0.00047	0.31	0.26	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
STAD	cis	rs35934224	0.783	rs34675706	ENSG00000232926.1	AC000078.5	5.06	6.74e-07	0.00047	0.35	0.26	Glaucoma (primary open-angle);	chr22:19860095	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs9754418	ENSG00000232926.1	AC000078.5	5.06	6.74e-07	0.00047	0.35	0.26	Glaucoma (primary open-angle);	chr22:19867210	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs28360650	ENSG00000232926.1	AC000078.5	5.06	6.74e-07	0.00047	0.35	0.26	Glaucoma (primary open-angle);	chr22:19869538	chr22:19887289~19887970:+
STAD	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-5.06	6.74e-07	0.00047	-0.42	-0.26	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
STAD	cis	rs3736858	0.8	rs12427729	ENSG00000261105.4	LMO7-AS1	-5.06	6.74e-07	0.00047	-0.46	-0.26	Interleukin-9 levels;	chr13:75870254	chr13:75604700~75635994:-
STAD	cis	rs9487094	1	rs17070580	ENSG00000260273.1	RP11-425D10.10	-5.06	6.75e-07	0.000471	-0.34	-0.26	Height;	chr6:109417511	chr6:109382795~109383666:+
STAD	cis	rs58873874	0.737	rs78738433	ENSG00000251405.2	CTB-109A12.1	5.06	6.76e-07	0.000471	0.47	0.26	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157362615~157460078:-
STAD	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-5.06	6.76e-07	0.000472	-0.27	-0.26	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
STAD	cis	rs13113518	0.812	rs12500601	ENSG00000272969.1	RP11-528I4.2	5.06	6.77e-07	0.000472	0.33	0.26	Height;	chr4:55451489	chr4:55547112~55547889:+
STAD	cis	rs9860428	1	rs10934197	ENSG00000240057.4	RP11-572M11.4	-5.06	6.77e-07	0.000472	-0.24	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112861621	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.815	rs11720045	ENSG00000240057.4	RP11-572M11.4	-5.06	6.77e-07	0.000472	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112906315	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs9813901	ENSG00000240057.4	RP11-572M11.4	-5.06	6.77e-07	0.000472	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112908718	chr3:113019532~113183301:+
STAD	cis	rs10510102	0.935	rs11818001	ENSG00000226864.1	ATE1-AS1	-5.06	6.77e-07	0.000473	-0.42	-0.26	Breast cancer;	chr10:121884830	chr10:121928312~121951965:+
STAD	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-5.06	6.78e-07	0.000473	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-5.06	6.78e-07	0.000473	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-5.06	6.78e-07	0.000473	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-5.06	6.78e-07	0.000473	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-5.06	6.78e-07	0.000473	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
STAD	cis	rs748404	0.666	rs16957730	ENSG00000249839.1	AC011330.5	-5.06	6.79e-07	0.000474	-0.44	-0.26	Lung cancer;	chr15:43438288	chr15:43663654~43684339:-
STAD	cis	rs8067354	0.645	rs9910518	ENSG00000266701.1	AC005702.4	5.06	6.79e-07	0.000474	0.36	0.26	Hemoglobin concentration;	chr17:59734706	chr17:60042546~60042627:-
STAD	cis	rs10849893	0.554	rs10849888	ENSG00000258435.1	RP11-711D18.2	-5.06	6.79e-07	0.000474	-0.29	-0.26	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121454983	chr12:121391962~121399859:+
STAD	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-5.06	6.79e-07	0.000474	-0.47	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
STAD	cis	rs561341	0.883	rs6505274	ENSG00000265798.5	RP11-271K11.5	5.06	6.79e-07	0.000474	0.33	0.26	Hip circumference adjusted for BMI;	chr17:32017562	chr17:31038575~31059121:-
STAD	cis	rs853679	0.517	rs9368555	ENSG00000220721.1	OR1F12	5.06	6.8e-07	0.000474	0.31	0.26	Depression;	chr6:28141189	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393893	ENSG00000220721.1	OR1F12	5.06	6.8e-07	0.000474	0.31	0.26	Depression;	chr6:28141484	chr6:28073316~28074233:+
STAD	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-5.06	6.8e-07	0.000474	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
STAD	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-5.06	6.8e-07	0.000474	-0.31	-0.26	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
STAD	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-5.06	6.8e-07	0.000474	-0.42	-0.26	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
STAD	cis	rs12744310	0.887	rs12724625	ENSG00000235358.1	RP11-399E6.1	5.06	6.81e-07	0.000475	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316598	chr1:41242373~41284861:+
STAD	cis	rs1426063	0.858	rs7666182	ENSG00000248165.1	RP11-44F21.2	5.06	6.82e-07	0.000476	0.45	0.26	QT interval;	chr4:75090989	chr4:74993877~75034824:-
STAD	cis	rs4568518	0.71	rs6955337	ENSG00000279048.1	RP11-511H23.2	-5.06	6.83e-07	0.000476	-0.24	-0.26	Measles;	chr7:17974951	chr7:17940503~17942922:+
STAD	cis	rs2337406	0.925	rs76288499	ENSG00000211972.2	IGHV3-66	5.06	6.83e-07	0.000476	0.29	0.26	Alzheimer's disease (late onset);	chr14:106686309	chr14:106675017~106675544:-
STAD	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	5.06	6.84e-07	0.000476	0.34	0.26	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
STAD	cis	rs919433	0.929	rs7592511	ENSG00000231621.1	AC013264.2	5.06	6.85e-07	0.000477	0.22	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313250	chr2:197197991~197199273:+
STAD	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	5.06	6.85e-07	0.000477	0.32	0.26	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-5.06	6.85e-07	0.000477	-0.32	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
STAD	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	5.06	6.85e-07	0.000477	0.27	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
STAD	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	5.06	6.86e-07	0.000478	0.37	0.26	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	5.06	6.86e-07	0.000478	0.37	0.26	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
STAD	cis	rs1816752	1	rs9507341	ENSG00000273628.1	RP11-756A22.7	-5.06	6.86e-07	0.000478	-0.32	-0.26	Obesity-related traits;	chr13:24432440	chr13:24933006~24936796:+
STAD	cis	rs1799949	1	rs1060915	ENSG00000236383.6	LINC00854	-5.06	6.86e-07	0.000478	-0.22	-0.26	Menopause (age at onset);	chr17:43082453	chr17:43216941~43305976:-
STAD	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	5.06	6.86e-07	0.000478	0.43	0.26	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
STAD	cis	rs7665090	0.87	rs228615	ENSG00000248971.2	KRT8P46	5.06	6.87e-07	0.000478	0.27	0.26	Primary biliary cholangitis;	chr4:102658303	chr4:102728746~102730171:-
STAD	cis	rs4568518	0.502	rs10950696	ENSG00000279048.1	RP11-511H23.2	5.06	6.87e-07	0.000478	0.25	0.26	Measles;	chr7:18002636	chr7:17940503~17942922:+
STAD	cis	rs2439831	1	rs2256764	ENSG00000275601.1	AC011330.13	-5.06	6.87e-07	0.000478	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43443565	chr15:43642389~43643023:-
STAD	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-5.06	6.88e-07	0.000479	-0.33	-0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
STAD	cis	rs7487075	0.502	rs12299843	ENSG00000257261.4	RP11-96H19.1	5.06	6.88e-07	0.000479	0.32	0.26	Itch intensity from mosquito bite;	chr12:46242227	chr12:46383679~46876159:+
STAD	cis	rs875971	0.789	rs10260426	ENSG00000236529.1	RP13-254B10.1	-5.06	6.88e-07	0.000479	-0.27	-0.26	Aortic root size;	chr7:66271055	chr7:65840212~65840596:+
STAD	cis	rs6584283	0.656	rs7080361	ENSG00000228778.1	RP11-129J12.1	-5.06	6.89e-07	0.000479	-0.31	-0.26	Ulcerative colitis;	chr10:99518015	chr10:99527081~99528261:+
STAD	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-5.06	6.9e-07	0.00048	-0.24	-0.26	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
STAD	cis	rs8059260	0.673	rs8056854	ENSG00000274038.1	RP11-66H6.4	-5.06	6.9e-07	0.00048	-0.43	-0.26	Alcohol consumption over the past year;	chr16:10947858	chr16:11056556~11057034:+
STAD	cis	rs516805	0.63	rs2606642	ENSG00000279453.1	RP3-425C14.4	5.06	6.9e-07	0.00048	0.35	0.26	Lymphocyte counts;	chr6:122103758	chr6:122436789~122439223:-
STAD	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-5.06	6.91e-07	0.000481	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
STAD	cis	rs2440129	0.611	rs10852889	ENSG00000262089.1	RP11-589P10.5	5.06	6.91e-07	0.000481	0.3	0.26	Tonsillectomy;	chr17:6997526	chr17:6994642~6995189:-
STAD	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	5.06	6.92e-07	0.000481	0.37	0.26	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
STAD	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	5.06	6.93e-07	0.000482	0.33	0.26	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
STAD	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-5.06	6.93e-07	0.000482	-0.27	-0.26	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
STAD	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-5.06	6.93e-07	0.000482	-0.42	-0.26	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
STAD	cis	rs240993	0.812	rs459809	ENSG00000230177.1	RP5-1112D6.4	-5.06	6.93e-07	0.000482	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111277932~111278742:+
STAD	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	5.06	6.93e-07	0.000482	0.41	0.26	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
STAD	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-5.06	6.94e-07	0.000483	-0.3	-0.26	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
STAD	cis	rs9463078	0.585	rs7757282	ENSG00000219384.1	RP11-491H9.3	-5.06	6.94e-07	0.000483	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45334917	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.605	rs2396504	ENSG00000219384.1	RP11-491H9.3	-5.06	6.94e-07	0.000483	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45348465	chr6:45158870~45159511:+
STAD	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-5.06	6.94e-07	0.000483	-0.32	-0.26	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
STAD	cis	rs1150668	0.799	rs7206	ENSG00000220721.1	OR1F12	5.06	6.95e-07	0.000483	0.26	0.26	Pubertal anthropometrics;	chr6:28233360	chr6:28073316~28074233:+
STAD	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	5.06	6.95e-07	0.000483	0.3	0.26	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
STAD	cis	rs2688608	0.587	rs2894040	ENSG00000271816.1	BMS1P4	5.06	6.95e-07	0.000483	0.28	0.26	Inflammatory bowel disease;	chr10:73718401	chr10:73699151~73730487:-
STAD	cis	rs2688608	0.592	rs3849967	ENSG00000271816.1	BMS1P4	5.06	6.95e-07	0.000483	0.28	0.26	Inflammatory bowel disease;	chr10:73723608	chr10:73699151~73730487:-
STAD	cis	rs35934224	0.771	rs34820460	ENSG00000232926.1	AC000078.5	5.06	6.96e-07	0.000484	0.35	0.26	Glaucoma (primary open-angle);	chr22:19881687	chr22:19887289~19887970:+
STAD	cis	rs7916697	0.593	rs10762198	ENSG00000233590.1	RP11-153K11.3	5.06	6.96e-07	0.000484	0.3	0.26	Optic disc area;	chr10:68263296	chr10:68233251~68242379:-
STAD	cis	rs35934224	0.783	rs6518585	ENSG00000232926.1	AC000078.5	5.06	6.97e-07	0.000484	0.34	0.26	Glaucoma (primary open-angle);	chr22:19861978	chr22:19887289~19887970:+
STAD	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	5.06	6.97e-07	0.000484	0.29	0.26	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
STAD	cis	rs240993	0.761	rs6920014	ENSG00000230177.1	RP5-1112D6.4	-5.06	6.97e-07	0.000485	-0.27	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111385198	chr6:111277932~111278742:+
STAD	cis	rs8067354	0.645	rs28516945	ENSG00000266701.1	AC005702.4	5.06	6.98e-07	0.000485	0.36	0.26	Hemoglobin concentration;	chr17:59739217	chr17:60042546~60042627:-
STAD	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	5.06	6.98e-07	0.000485	0.35	0.26	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
STAD	cis	rs7429990	0.866	rs3732529	ENSG00000224895.1	VPS26BP1	-5.06	6.98e-07	0.000485	-0.26	-0.26	Educational attainment (years of education);	chr3:47928619	chr3:47960327~47961081:-
STAD	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-5.06	6.98e-07	0.000485	-0.36	-0.26	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
STAD	cis	rs11676348	0.846	rs13009946	ENSG00000237281.1	CATIP-AS2	5.06	6.99e-07	0.000485	0.25	0.26	Ulcerative colitis;	chr2:218143029	chr2:218326889~218357966:-
STAD	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-5.06	6.99e-07	0.000485	-0.32	-0.26	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
STAD	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-5.05	6.99e-07	0.000486	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
STAD	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	5.05	6.99e-07	0.000486	0.27	0.26	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
STAD	cis	rs516805	0.63	rs696651	ENSG00000279453.1	RP3-425C14.4	-5.05	6.99e-07	0.000486	-0.35	-0.26	Lymphocyte counts;	chr6:122280069	chr6:122436789~122439223:-
STAD	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-5.05	7e-07	0.000486	-0.34	-0.26	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-5.05	7e-07	0.000486	-0.34	-0.26	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
STAD	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	5.05	7e-07	0.000486	0.29	0.26	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	5.05	7e-07	0.000486	0.29	0.26	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	5.05	7e-07	0.000486	0.29	0.26	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
STAD	cis	rs879620	1	rs879620	ENSG00000262185.1	RP11-462G12.1	5.05	7e-07	0.000486	0.25	0.26	Hip circumference;Body mass index;	chr16:3965728	chr16:3947609~3950444:-
STAD	cis	rs7674212	0.865	rs13149311	ENSG00000230069.3	LRRC37A15P	-5.05	7e-07	0.000487	-0.3	-0.26	Type 2 diabetes;	chr4:103056543	chr4:102727274~102730721:-
STAD	cis	rs720064	0.537	rs2676106	ENSG00000267301.1	RPL23AP77	-5.05	7.01e-07	0.000487	-0.31	-0.26	Strep throat;	chr18:23685075	chr18:23709825~23710287:-
STAD	cis	rs7665090	0.743	rs228626	ENSG00000248971.2	KRT8P46	5.05	7.01e-07	0.000487	0.27	0.26	Primary biliary cholangitis;	chr4:102651789	chr4:102728746~102730171:-
STAD	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	5.05	7.01e-07	0.000487	0.29	0.26	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
STAD	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	5.05	7.02e-07	0.000487	0.26	0.26	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
STAD	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-5.05	7.04e-07	0.000489	-0.29	-0.26	QT interval;	chr12:29314736	chr12:29280418~29317848:-
STAD	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-5.05	7.04e-07	0.000489	-0.27	-0.26	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
STAD	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	5.05	7.05e-07	0.000489	0.37	0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
STAD	cis	rs8040855	0.627	rs11634975	ENSG00000229212.6	RP11-561C5.4	5.05	7.05e-07	0.00049	0.38	0.26	Bulimia nervosa;	chr15:85063247	chr15:85205440~85234795:-
STAD	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	5.05	7.05e-07	0.00049	0.29	0.26	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
STAD	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-5.05	7.05e-07	0.00049	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
STAD	cis	rs7829975	0.514	rs2976926	ENSG00000253981.4	ALG1L13P	5.05	7.06e-07	0.00049	0.3	0.26	Mood instability;	chr8:8404114	chr8:8236003~8244667:-
STAD	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	5.05	7.06e-07	0.00049	0.26	0.26	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
STAD	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-5.05	7.06e-07	0.00049	-0.41	-0.26	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
STAD	cis	rs7829975	0.714	rs6994038	ENSG00000254340.1	RP11-10A14.3	5.05	7.07e-07	0.000491	0.31	0.26	Mood instability;	chr8:8803028	chr8:9141424~9145435:+
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000224205.1	AP000351.4	5.05	7.07e-07	0.000491	0.29	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23987320~23991421:-
STAD	cis	rs507080	0.769	rs570836	ENSG00000278376.1	RP11-158I9.8	-5.05	7.08e-07	0.000491	-0.28	-0.26	Serum metabolite levels;	chr11:118641444	chr11:118791254~118793137:+
STAD	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-5.05	7.08e-07	0.000491	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
STAD	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-5.05	7.08e-07	0.000491	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
STAD	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	5.05	7.08e-07	0.000491	0.2	0.26	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
STAD	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	5.05	7.08e-07	0.000491	0.4	0.26	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
STAD	cis	rs7829975	0.711	rs4481596	ENSG00000253981.4	ALG1L13P	5.05	7.08e-07	0.000492	0.31	0.26	Mood instability;	chr8:8846820	chr8:8236003~8244667:-
STAD	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	5.05	7.09e-07	0.000492	0.35	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
STAD	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	5.05	7.1e-07	0.000492	0.49	0.26	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
STAD	cis	rs858239	0.899	rs5850	ENSG00000226816.2	AC005082.12	5.05	7.1e-07	0.000493	0.33	0.26	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23206013~23208045:+
STAD	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-5.05	7.11e-07	0.000493	-0.28	-0.26	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
STAD	cis	rs3758911	0.929	rs1843	ENSG00000261098.1	RP11-819C21.1	-5.05	7.11e-07	0.000493	-0.24	-0.26	Coronary artery disease;	chr11:107312219	chr11:107312132~107316271:-
STAD	cis	rs2337406	0.925	rs873534	ENSG00000211972.2	IGHV3-66	5.05	7.11e-07	0.000493	0.29	0.26	Alzheimer's disease (late onset);	chr14:106667423	chr14:106675017~106675544:-
STAD	cis	rs7078219	0.543	rs10786556	ENSG00000228778.1	RP11-129J12.1	-5.05	7.12e-07	0.000494	-0.3	-0.26	Dental caries;	chr10:99518567	chr10:99527081~99528261:+
STAD	cis	rs2337406	0.866	rs78462736	ENSG00000280411.1	IGHV1-69-2	-5.05	7.12e-07	0.000494	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106779942	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs8016203	ENSG00000280411.1	IGHV1-69-2	-5.05	7.12e-07	0.000494	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106780575	chr14:106762092~106762588:-
STAD	cis	rs858239	0.899	rs7794684	ENSG00000226816.2	AC005082.12	5.05	7.12e-07	0.000494	0.33	0.26	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23206013~23208045:+
STAD	cis	rs11694172	0.955	rs56074256	ENSG00000273456.1	RP11-686O6.2	5.05	7.12e-07	0.000494	0.29	0.26	Cholesterol, total;	chr2:202710383	chr2:202374932~202375604:-
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000211973.2	IGHV1-69	5.05	7.13e-07	0.000495	0.22	0.26	Kawasaki disease;	chr14:106784065	chr14:106714684~106715181:-
STAD	cis	rs11169552	0.51	rs10747587	ENSG00000200183.1	RNU6-238P	-5.05	7.13e-07	0.000495	-0.25	-0.26	Colorectal cancer;	chr12:50711517	chr12:50656973~50657078:+
STAD	cis	rs7932354	0.528	rs7479189	ENSG00000271350.1	CTD-2384B9.1	-5.05	7.14e-07	0.000495	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:47035458	chr11:47041027~47041945:-
STAD	cis	rs7829975	0.688	rs7837587	ENSG00000254340.1	RP11-10A14.3	5.05	7.14e-07	0.000495	0.32	0.26	Mood instability;	chr8:8521482	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.688	rs7826654	ENSG00000254340.1	RP11-10A14.3	5.05	7.14e-07	0.000495	0.32	0.26	Mood instability;	chr8:8521596	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.688	rs7826660	ENSG00000254340.1	RP11-10A14.3	5.05	7.14e-07	0.000495	0.32	0.26	Mood instability;	chr8:8521597	chr8:9141424~9145435:+
STAD	cis	rs9307551	0.817	rs1440864	ENSG00000250334.4	LINC00989	-5.05	7.15e-07	0.000495	-0.32	-0.26	Refractive error;	chr4:79571830	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs12507375	ENSG00000250334.4	LINC00989	-5.05	7.15e-07	0.000495	-0.32	-0.26	Refractive error;	chr4:79575206	chr4:79492416~79576460:+
STAD	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	5.05	7.15e-07	0.000495	0.38	0.26	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
STAD	cis	rs957448	0.561	rs71532325	ENSG00000253704.1	RP11-267M23.4	5.05	7.15e-07	0.000495	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94553722~94569745:+
STAD	cis	rs1816752	0.755	rs1981277	ENSG00000273628.1	RP11-756A22.7	5.05	7.15e-07	0.000496	0.32	0.26	Obesity-related traits;	chr13:24409375	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.712	rs9507335	ENSG00000273628.1	RP11-756A22.7	5.05	7.15e-07	0.000496	0.32	0.26	Obesity-related traits;	chr13:24409766	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.811	rs9507337	ENSG00000273628.1	RP11-756A22.7	5.05	7.15e-07	0.000496	0.32	0.26	Obesity-related traits;	chr13:24410807	chr13:24933006~24936796:+
STAD	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	5.05	7.15e-07	0.000496	0.28	0.26	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
STAD	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-5.05	7.16e-07	0.000496	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
STAD	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-5.05	7.16e-07	0.000496	-0.27	-0.26	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
STAD	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-5.05	7.16e-07	0.000496	-0.33	-0.26	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
STAD	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-5.05	7.16e-07	0.000496	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
STAD	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-5.05	7.16e-07	0.000496	-0.28	-0.26	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
STAD	cis	rs1318937	1	rs3773469	ENSG00000224660.1	SH3BP5-AS1	5.05	7.17e-07	0.000496	0.25	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15266733	chr3:15254184~15264493:+
STAD	cis	rs12530	0.651	rs2072816	ENSG00000230736.2	RP1-149A16.3	-5.05	7.17e-07	0.000497	-0.35	-0.26	IgG glycosylation;	chr22:32394411	chr22:32376664~32384343:+
STAD	cis	rs7932354	0.55	rs2035068	ENSG00000271350.1	CTD-2384B9.1	-5.05	7.17e-07	0.000497	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:46894442	chr11:47041027~47041945:-
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000224205.1	AP000351.4	-5.05	7.17e-07	0.000497	-0.29	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23987320~23991421:-
STAD	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	5.05	7.18e-07	0.000497	0.26	0.26	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
STAD	cis	rs7829975	0.774	rs11249893	ENSG00000253981.4	ALG1L13P	5.05	7.18e-07	0.000497	0.31	0.26	Mood instability;	chr8:8843341	chr8:8236003~8244667:-
STAD	cis	rs13113518	1	rs11133388	ENSG00000223305.1	RN7SKP30	-5.05	7.18e-07	0.000498	-0.29	-0.26	Height;	chr4:55477866	chr4:55540502~55540835:-
STAD	cis	rs6452524	0.711	rs1478486	ENSG00000243385.2	CTD-2110K23.1	5.05	7.19e-07	0.000498	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83201229~83202141:+
STAD	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-5.05	7.19e-07	0.000498	-0.26	-0.26	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
STAD	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	5.05	7.19e-07	0.000498	0.27	0.26	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
STAD	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-5.05	7.19e-07	0.000498	-0.33	-0.26	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
STAD	cis	rs4308124	0.708	rs56693625	ENSG00000230499.1	AC108463.1	-5.05	7.19e-07	0.000498	-0.37	-0.26	Vitiligo;	chr2:111207578	chr2:111195963~111206494:+
STAD	cis	rs2980439	0.818	rs2948300	ENSG00000254340.1	RP11-10A14.3	5.05	7.21e-07	0.000499	0.31	0.26	Neuroticism;	chr8:8248986	chr8:9141424~9145435:+
STAD	cis	rs6061231	0.675	rs755726	ENSG00000275437.1	RP5-908M14.10	5.05	7.21e-07	0.000499	0.24	0.26	Colorectal cancer;	chr20:62387568	chr20:62402236~62405935:-
STAD	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	5.05	7.22e-07	5e-04	0.32	0.26	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
STAD	cis	rs7665090	0.87	rs228615	ENSG00000246560.2	RP11-10L12.4	-5.05	7.23e-07	5e-04	-0.31	-0.26	Primary biliary cholangitis;	chr4:102658303	chr4:102828055~102844075:+
STAD	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	5.05	7.23e-07	5e-04	0.33	0.26	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
STAD	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	5.05	7.23e-07	0.000501	0.32	0.26	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
STAD	cis	rs7829975	0.84	rs555617	ENSG00000173295.6	FAM86B3P	-5.05	7.24e-07	0.000501	-0.29	-0.26	Mood instability;	chr8:8735335	chr8:8228595~8244865:+
STAD	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-5.05	7.24e-07	0.000501	-0.25	-0.26	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
STAD	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	5.05	7.24e-07	0.000501	0.3	0.26	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
STAD	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-5.05	7.24e-07	0.000501	-0.28	-0.26	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
STAD	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-5.05	7.24e-07	0.000501	-0.27	-0.26	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
STAD	cis	rs11098499	0.821	rs56155624	ENSG00000260091.1	RP11-33B1.4	5.05	7.25e-07	0.000502	0.26	0.26	Corneal astigmatism;	chr4:119369871	chr4:119409333~119410233:+
STAD	cis	rs9463078	0.585	rs1285013	ENSG00000219384.1	RP11-491H9.3	-5.05	7.25e-07	0.000502	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45197471	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs1285014	ENSG00000219384.1	RP11-491H9.3	-5.05	7.25e-07	0.000502	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45197488	chr6:45158870~45159511:+
STAD	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	5.05	7.26e-07	0.000502	0.28	0.26	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
STAD	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	5.05	7.27e-07	0.000503	0.27	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
STAD	cis	rs9733	0.536	rs10888385	ENSG00000274963.1	Metazoa_SRP	-5.05	7.27e-07	0.000503	-0.21	-0.26	Tonsillectomy;	chr1:150601826	chr1:150568971~150569269:-
STAD	cis	rs9307551	0.901	rs6850999	ENSG00000250334.4	LINC00989	-5.05	7.27e-07	0.000503	-0.33	-0.26	Refractive error;	chr4:79580784	chr4:79492416~79576460:+
STAD	cis	rs10504130	0.569	rs34213209	ENSG00000272024.1	RP11-546K22.3	-5.05	7.27e-07	0.000503	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51950284~51950690:+
STAD	cis	rs17592366	0.54	rs3818801	ENSG00000251726.1	RNU7-41P	-5.05	7.28e-07	0.000504	-0.24	-0.26	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34773494	chr14:34845300~34845360:-
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000211973.2	IGHV1-69	5.05	7.28e-07	0.000504	0.22	0.26	Kawasaki disease;	chr14:106785926	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000211973.2	IGHV1-69	5.05	7.28e-07	0.000504	0.22	0.26	Kawasaki disease;	chr14:106787090	chr14:106714684~106715181:-
STAD	cis	rs2688608	0.588	rs10128205	ENSG00000271816.1	BMS1P4	5.05	7.29e-07	0.000504	0.29	0.26	Inflammatory bowel disease;	chr10:73709890	chr10:73699151~73730487:-
STAD	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	5.05	7.29e-07	0.000504	0.23	0.26	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
STAD	cis	rs875971	0.545	rs316305	ENSG00000236529.1	RP13-254B10.1	-5.05	7.3e-07	0.000505	-0.31	-0.26	Aortic root size;	chr7:66152984	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs316306	ENSG00000236529.1	RP13-254B10.1	-5.05	7.3e-07	0.000505	-0.31	-0.26	Aortic root size;	chr7:66153687	chr7:65840212~65840596:+
STAD	cis	rs9860428	0.844	rs7609699	ENSG00000240057.4	RP11-572M11.4	-5.05	7.3e-07	0.000505	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112902758	chr3:113019532~113183301:+
STAD	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-5.05	7.3e-07	0.000505	-0.36	-0.26	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
STAD	cis	rs6430585	0.583	rs7581814	ENSG00000231890.6	DARS-AS1	5.05	7.31e-07	0.000505	0.29	0.26	Corneal structure;	chr2:135884023	chr2:135985176~136022593:+
STAD	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-5.05	7.31e-07	0.000505	-0.31	-0.26	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-5.05	7.31e-07	0.000505	-0.31	-0.26	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-5.05	7.31e-07	0.000505	-0.31	-0.26	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
STAD	cis	rs9987353	0.522	rs2929466	ENSG00000254340.1	RP11-10A14.3	-5.05	7.32e-07	0.000506	-0.35	-0.26	Recombination measurement;	chr8:9206389	chr8:9141424~9145435:+
STAD	cis	rs8098244	0.638	rs867448	ENSG00000267301.1	RPL23AP77	-5.05	7.32e-07	0.000506	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23857757	chr18:23709825~23710287:-
STAD	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-5.05	7.32e-07	0.000506	-0.27	-0.26	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
STAD	cis	rs12744310	1	rs2364535	ENSG00000235358.1	RP11-399E6.1	5.05	7.32e-07	0.000506	0.33	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300564	chr1:41242373~41284861:+
STAD	cis	rs7665090	0.806	rs434644	ENSG00000248971.2	KRT8P46	5.05	7.33e-07	0.000506	0.27	0.26	Primary biliary cholangitis;	chr4:102662032	chr4:102728746~102730171:-
STAD	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-5.05	7.33e-07	0.000507	-0.31	-0.26	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
STAD	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-5.05	7.33e-07	0.000507	-0.31	-0.26	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
STAD	cis	rs944990	0.597	rs11789176	ENSG00000227603.1	RP11-165J3.6	5.05	7.33e-07	0.000507	0.29	0.26	Body mass index;	chr9:93433884	chr9:93435332~93437121:-
STAD	cis	rs237743	1	rs3021	ENSG00000222365.1	SNORD12B	-5.04	7.34e-07	0.000507	-0.36	-0.26	Height;	chr20:49257468	chr20:49280319~49280409:+
STAD	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	5.04	7.35e-07	0.000508	0.38	0.26	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
STAD	cis	rs10504130	0.569	rs11775587	ENSG00000272024.1	RP11-546K22.3	5.04	7.35e-07	0.000508	0.36	0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51907605	chr8:51950284~51950690:+
STAD	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	5.04	7.35e-07	0.000508	0.31	0.26	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
STAD	cis	rs516805	0.667	rs2606650	ENSG00000279453.1	RP3-425C14.4	-5.04	7.35e-07	0.000508	-0.36	-0.26	Lymphocyte counts;	chr6:122123443	chr6:122436789~122439223:-
STAD	cis	rs801193	0.548	rs6975044	ENSG00000236529.1	RP13-254B10.1	5.04	7.35e-07	0.000508	0.27	0.26	Aortic root size;	chr7:66762495	chr7:65840212~65840596:+
STAD	cis	rs7429990	0.965	rs796566	ENSG00000224895.1	VPS26BP1	-5.04	7.35e-07	0.000508	-0.26	-0.26	Educational attainment (years of education);	chr3:47896864	chr3:47960327~47961081:-
STAD	cis	rs11846409	0.86	rs73378154	ENSG00000211972.2	IGHV3-66	5.04	7.35e-07	0.000508	0.27	0.26	Rheumatic heart disease;	chr14:106637687	chr14:106675017~106675544:-
STAD	cis	rs3758911	0.894	rs10890698	ENSG00000261098.1	RP11-819C21.1	-5.04	7.36e-07	0.000508	-0.24	-0.26	Coronary artery disease;	chr11:107308080	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.929	rs10890700	ENSG00000261098.1	RP11-819C21.1	-5.04	7.36e-07	0.000508	-0.24	-0.26	Coronary artery disease;	chr11:107308243	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.964	rs10789599	ENSG00000261098.1	RP11-819C21.1	-5.04	7.36e-07	0.000508	-0.24	-0.26	Coronary artery disease;	chr11:107309145	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.929	rs10749894	ENSG00000261098.1	RP11-819C21.1	-5.04	7.36e-07	0.000508	-0.24	-0.26	Coronary artery disease;	chr11:107309586	chr11:107312132~107316271:-
STAD	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	5.04	7.37e-07	0.000509	0.3	0.26	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
STAD	cis	rs748404	0.666	rs12905220	ENSG00000249839.1	AC011330.5	-5.04	7.37e-07	0.000509	-0.44	-0.26	Lung cancer;	chr15:43465641	chr15:43663654~43684339:-
STAD	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-5.04	7.37e-07	0.000509	-0.26	-0.26	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
STAD	cis	rs3758911	0.964	rs10890702	ENSG00000261098.1	RP11-819C21.1	5.04	7.38e-07	0.000509	0.23	0.26	Coronary artery disease;	chr11:107310159	chr11:107312132~107316271:-
STAD	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-5.04	7.39e-07	0.00051	-0.41	-0.26	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
STAD	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	5.04	7.4e-07	0.000511	0.42	0.26	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
STAD	cis	rs858239	0.539	rs4295546	ENSG00000226816.2	AC005082.12	5.04	7.4e-07	0.000511	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23206013~23208045:+
STAD	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	5.04	7.4e-07	0.000511	0.29	0.26	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
STAD	cis	rs6714710	0.603	rs12995673	ENSG00000235833.1	AC159540.14	-5.04	7.42e-07	0.000512	-0.3	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97792583	chr2:97523949~97524976:-
STAD	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-5.04	7.42e-07	0.000512	-0.27	-0.26	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
STAD	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	5.04	7.42e-07	0.000512	0.41	0.26	Height;	chr6:109409645	chr6:109382795~109383666:+
STAD	cis	rs7826238	0.601	rs2976907	ENSG00000253981.4	ALG1L13P	5.04	7.43e-07	0.000512	0.31	0.26	Systolic blood pressure;	chr8:8487658	chr8:8236003~8244667:-
STAD	cis	rs6452524	0.618	rs7723639	ENSG00000243385.2	CTD-2110K23.1	5.04	7.43e-07	0.000512	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.618	rs2306336	ENSG00000243385.2	CTD-2110K23.1	5.04	7.43e-07	0.000512	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.589	rs6882386	ENSG00000243385.2	CTD-2110K23.1	5.04	7.43e-07	0.000512	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.618	rs6860752	ENSG00000243385.2	CTD-2110K23.1	5.04	7.43e-07	0.000512	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83201229~83202141:+
STAD	cis	rs6452524	0.618	rs3899556	ENSG00000243385.2	CTD-2110K23.1	5.04	7.43e-07	0.000512	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83201229~83202141:+
STAD	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-5.04	7.44e-07	0.000513	-0.4	-0.26	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
STAD	cis	rs9860428	0.787	rs9815002	ENSG00000240057.4	RP11-572M11.4	-5.04	7.44e-07	0.000514	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112903419	chr3:113019532~113183301:+
STAD	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	5.04	7.45e-07	0.000514	0.26	0.26	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
STAD	cis	rs8067354	0.645	rs56236317	ENSG00000266701.1	AC005702.4	5.04	7.45e-07	0.000514	0.36	0.26	Hemoglobin concentration;	chr17:59744764	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs7215180	ENSG00000266701.1	AC005702.4	5.04	7.45e-07	0.000514	0.36	0.26	Hemoglobin concentration;	chr17:59744993	chr17:60042546~60042627:-
STAD	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	5.04	7.46e-07	0.000514	0.42	0.26	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
STAD	cis	rs801193	0.569	rs35070132	ENSG00000236529.1	RP13-254B10.1	5.04	7.46e-07	0.000514	0.27	0.26	Aortic root size;	chr7:66773096	chr7:65840212~65840596:+
STAD	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	5.04	7.46e-07	0.000515	0.28	0.26	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
STAD	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	5.04	7.46e-07	0.000515	0.28	0.26	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
STAD	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-5.04	7.47e-07	0.000515	-0.26	-0.26	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
STAD	cis	rs858239	0.509	rs6975524	ENSG00000226816.2	AC005082.12	5.04	7.47e-07	0.000515	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs6955726	ENSG00000226816.2	AC005082.12	5.04	7.47e-07	0.000515	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs6976957	ENSG00000226816.2	AC005082.12	5.04	7.47e-07	0.000515	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs6956828	ENSG00000226816.2	AC005082.12	5.04	7.47e-07	0.000515	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23206013~23208045:+
STAD	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-5.04	7.48e-07	0.000516	-0.33	-0.26	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
STAD	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	5.04	7.49e-07	0.000516	0.38	0.26	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
STAD	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	5.04	7.49e-07	0.000516	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
STAD	cis	rs73219805	0.793	rs3808573	ENSG00000228451.3	SDAD1P1	-5.04	7.49e-07	0.000516	-0.34	-0.26	Schizophrenia;	chr8:26339117	chr8:26379259~26382953:-
STAD	cis	rs7580658	0.521	rs2404535	ENSG00000200250.1	RNU6-1147P	-5.04	7.49e-07	0.000517	-0.25	-0.26	Protein C levels;	chr2:127190133	chr2:127316873~127316979:+
STAD	cis	rs6432852	0.516	rs2304002	ENSG00000232411.1	AC009495.3	5.04	7.5e-07	0.000517	0.27	0.26	Diabetic kidney disease;	chr2:165857585	chr2:165833048~165839098:-
STAD	cis	rs11992186	0.505	rs7845203	ENSG00000173295.6	FAM86B3P	5.04	7.5e-07	0.000517	0.3	0.26	Neuroticism;	chr8:8287918	chr8:8228595~8244865:+
STAD	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	5.04	7.5e-07	0.000517	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
STAD	cis	rs2286503	0.839	rs1054471	ENSG00000228649.7	AC005682.5	5.04	7.51e-07	0.000518	0.31	0.26	Fibrinogen;	chr7:22813024	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.839	rs2240726	ENSG00000228649.7	AC005682.5	5.04	7.51e-07	0.000518	0.31	0.26	Fibrinogen;	chr7:22813516	chr7:22854178~22861579:+
STAD	cis	rs7829975	0.714	rs11777085	ENSG00000254340.1	RP11-10A14.3	5.04	7.52e-07	0.000518	0.3	0.26	Mood instability;	chr8:8814919	chr8:9141424~9145435:+
STAD	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	5.04	7.52e-07	0.000518	0.27	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
STAD	cis	rs35955747	0.633	rs7287937	ENSG00000236132.1	CTA-440B3.1	5.04	7.52e-07	0.000518	0.28	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31624759	chr22:31816379~31817491:-
STAD	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-5.04	7.52e-07	0.000518	-0.39	-0.26	Height;	chr6:109625358	chr6:109382795~109383666:+
STAD	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-5.04	7.53e-07	0.000519	-0.38	-0.26	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
STAD	cis	rs9463078	0.585	rs1629542	ENSG00000219384.1	RP11-491H9.3	5.04	7.53e-07	0.000519	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45190748	chr6:45158870~45159511:+
STAD	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-5.04	7.54e-07	0.00052	-0.25	-0.26	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
STAD	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	5.04	7.54e-07	0.00052	0.32	0.26	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
STAD	cis	rs875971	0.545	rs10950025	ENSG00000236529.1	RP13-254B10.1	5.04	7.55e-07	0.00052	0.31	0.26	Aortic root size;	chr7:66158946	chr7:65840212~65840596:+
STAD	cis	rs875971	0.52	rs12666485	ENSG00000236529.1	RP13-254B10.1	5.04	7.55e-07	0.00052	0.31	0.26	Aortic root size;	chr7:66160135	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs67688847	ENSG00000236529.1	RP13-254B10.1	5.04	7.55e-07	0.00052	0.31	0.26	Aortic root size;	chr7:66161064	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs7787063	ENSG00000236529.1	RP13-254B10.1	5.04	7.55e-07	0.00052	0.31	0.26	Aortic root size;	chr7:66164012	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs12673308	ENSG00000236529.1	RP13-254B10.1	5.04	7.55e-07	0.00052	0.31	0.26	Aortic root size;	chr7:66166374	chr7:65840212~65840596:+
STAD	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-5.04	7.55e-07	0.00052	-0.24	-0.26	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
STAD	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-5.04	7.55e-07	0.00052	-0.29	-0.26	QT interval;	chr12:29331030	chr12:29280418~29317848:-
STAD	cis	rs1056107	0.931	rs7867823	ENSG00000225513.1	RP11-165N19.2	-5.04	7.55e-07	0.00052	-0.3	-0.26	Colorectal cancer;	chr9:112245813	chr9:112173522~112173971:-
STAD	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	5.04	7.56e-07	0.000521	0.26	0.26	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
STAD	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-5.04	7.57e-07	0.000521	-0.33	-0.26	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
STAD	cis	rs11694172	0.955	rs12476638	ENSG00000273456.1	RP11-686O6.2	5.04	7.59e-07	0.000523	0.29	0.26	Cholesterol, total;	chr2:202708665	chr2:202374932~202375604:-
STAD	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	5.04	7.59e-07	0.000523	0.28	0.26	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
STAD	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	5.04	7.59e-07	0.000523	0.28	0.26	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
STAD	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	5.04	7.59e-07	0.000523	0.28	0.26	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
STAD	cis	rs1153858	1	rs9783731	ENSG00000259433.2	CTD-2651B20.4	5.04	7.59e-07	0.000523	0.29	0.26	Homoarginine levels;	chr15:45350686	chr15:45330209~45332634:-
STAD	cis	rs453301	0.538	rs7830804	ENSG00000253981.4	ALG1L13P	-5.04	7.6e-07	0.000523	-0.33	-0.26	Joint mobility (Beighton score);	chr8:9113252	chr8:8236003~8244667:-
STAD	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-5.04	7.6e-07	0.000523	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-5.04	7.6e-07	0.000523	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-5.04	7.6e-07	0.000523	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-5.04	7.6e-07	0.000523	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
STAD	cis	rs1816752	1	rs9511272	ENSG00000273628.1	RP11-756A22.7	5.04	7.6e-07	0.000523	0.33	0.26	Obesity-related traits;	chr13:24446495	chr13:24933006~24936796:+
STAD	cis	rs747650	0.504	rs11039080	ENSG00000271350.1	CTD-2384B9.1	5.04	7.6e-07	0.000523	0.34	0.26	Acne (severe);	chr11:47071533	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs11039081	ENSG00000271350.1	CTD-2384B9.1	5.04	7.6e-07	0.000523	0.34	0.26	Acne (severe);	chr11:47071914	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs7127741	ENSG00000271350.1	CTD-2384B9.1	-5.04	7.6e-07	0.000523	-0.34	-0.26	Acne (severe);	chr11:47052928	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs6485726	ENSG00000271350.1	CTD-2384B9.1	-5.04	7.6e-07	0.000523	-0.34	-0.26	Acne (severe);	chr11:47060571	chr11:47041027~47041945:-
STAD	cis	rs10510102	0.935	rs12245528	ENSG00000226864.1	ATE1-AS1	-5.04	7.62e-07	0.000524	-0.41	-0.26	Breast cancer;	chr10:121881006	chr10:121928312~121951965:+
STAD	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-5.04	7.62e-07	0.000524	-0.29	-0.26	QT interval;	chr12:29319943	chr12:29280418~29317848:-
STAD	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.04	7.62e-07	0.000524	0.29	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
STAD	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-5.04	7.63e-07	0.000525	-0.41	-0.26	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
STAD	cis	rs6452524	0.618	rs255561	ENSG00000243385.2	CTD-2110K23.1	5.04	7.63e-07	0.000525	0.28	0.26	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83201229~83202141:+
STAD	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-5.04	7.63e-07	0.000525	-0.28	-0.26	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-5.04	7.63e-07	0.000525	-0.28	-0.26	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-5.04	7.63e-07	0.000525	-0.28	-0.26	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
STAD	cis	rs875971	0.862	rs10274883	ENSG00000236529.1	RP13-254B10.1	-5.04	7.64e-07	0.000525	-0.27	-0.26	Aortic root size;	chr7:66651104	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs881285	ENSG00000236529.1	RP13-254B10.1	-5.04	7.64e-07	0.000525	-0.27	-0.26	Aortic root size;	chr7:66654433	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs3846973	ENSG00000236529.1	RP13-254B10.1	-5.04	7.64e-07	0.000525	-0.27	-0.26	Aortic root size;	chr7:66655048	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs2013908	ENSG00000236529.1	RP13-254B10.1	-5.04	7.64e-07	0.000525	-0.27	-0.26	Aortic root size;	chr7:66656082	chr7:65840212~65840596:+
STAD	cis	rs801193	0.548	rs2109297	ENSG00000236529.1	RP13-254B10.1	-5.04	7.64e-07	0.000525	-0.27	-0.26	Aortic root size;	chr7:66657397	chr7:65840212~65840596:+
STAD	cis	rs801193	0.591	rs721717	ENSG00000236529.1	RP13-254B10.1	-5.04	7.64e-07	0.000525	-0.27	-0.26	Aortic root size;	chr7:66665305	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs6951302	ENSG00000236529.1	RP13-254B10.1	-5.04	7.64e-07	0.000525	-0.27	-0.26	Aortic root size;	chr7:66667525	chr7:65840212~65840596:+
STAD	cis	rs3758911	0.751	rs590699	ENSG00000261098.1	RP11-819C21.1	5.04	7.64e-07	0.000525	0.24	0.26	Coronary artery disease;	chr11:107447553	chr11:107312132~107316271:-
STAD	cis	rs858239	0.509	rs6962213	ENSG00000226816.2	AC005082.12	5.04	7.64e-07	0.000525	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23206013~23208045:+
STAD	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	5.04	7.64e-07	0.000525	0.3	0.26	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
STAD	cis	rs1075265	0.73	rs7597188	ENSG00000235937.1	AC008280.1	5.04	7.64e-07	0.000525	0.23	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.73	rs6711105	ENSG00000235937.1	AC008280.1	5.04	7.64e-07	0.000525	0.23	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.704	rs6711217	ENSG00000235937.1	AC008280.1	5.04	7.64e-07	0.000525	0.23	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54029552~54030682:-
STAD	cis	rs1322639	0.806	rs1322640	ENSG00000261039.2	RP11-417E7.2	5.04	7.64e-07	0.000526	0.33	0.26	Pulse pressure;	chr6:169186792	chr6:169175304~169182740:-
STAD	cis	rs7487075	0.619	rs7486495	ENSG00000257261.4	RP11-96H19.1	5.04	7.64e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46432553	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs7485580	ENSG00000257261.4	RP11-96H19.1	5.04	7.64e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46436591	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs10880970	ENSG00000257261.4	RP11-96H19.1	5.04	7.64e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46436637	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs7311504	ENSG00000257261.4	RP11-96H19.1	5.04	7.64e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46436993	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs4768717	ENSG00000257261.4	RP11-96H19.1	5.04	7.64e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46437778	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs4076247	ENSG00000257261.4	RP11-96H19.1	5.04	7.64e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46439667	chr12:46383679~46876159:+
STAD	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-5.04	7.65e-07	0.000526	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-5.04	7.65e-07	0.000526	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
STAD	cis	rs172166	0.516	rs1225618	ENSG00000220721.1	OR1F12	5.04	7.65e-07	0.000526	0.26	0.26	Cardiac Troponin-T levels;	chr6:28161935	chr6:28073316~28074233:+
STAD	cis	rs1862618	0.613	rs252889	ENSG00000271828.1	CTD-2310F14.1	5.04	7.65e-07	0.000526	0.32	0.26	Initial pursuit acceleration;	chr5:56931242	chr5:56927874~56929573:+
STAD	cis	rs7487075	0.82	rs7134855	ENSG00000272369.1	RP11-446N19.1	5.04	7.65e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46317527	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.637	rs4438106	ENSG00000272369.1	RP11-446N19.1	5.04	7.65e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46321745	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.786	rs11183441	ENSG00000272369.1	RP11-446N19.1	5.04	7.65e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46322137	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs2408505	ENSG00000272369.1	RP11-446N19.1	5.04	7.65e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46324041	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs7967549	ENSG00000272369.1	RP11-446N19.1	5.04	7.65e-07	0.000526	0.32	0.26	Itch intensity from mosquito bite;	chr12:46329909	chr12:46537502~46652550:+
STAD	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	5.04	7.66e-07	0.000526	0.28	0.26	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
STAD	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	5.04	7.66e-07	0.000526	0.28	0.26	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
STAD	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	5.04	7.66e-07	0.000526	0.28	0.26	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
STAD	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-5.04	7.66e-07	0.000526	-0.36	-0.26	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
STAD	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-5.04	7.67e-07	0.000527	-0.35	-0.26	Height;	chr6:109444615	chr6:109382795~109383666:+
STAD	cis	rs11694172	0.955	rs62194152	ENSG00000273456.1	RP11-686O6.2	5.04	7.67e-07	0.000527	0.29	0.26	Cholesterol, total;	chr2:202730647	chr2:202374932~202375604:-
STAD	cis	rs8098244	0.638	rs9958787	ENSG00000267301.1	RPL23AP77	-5.04	7.68e-07	0.000527	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23870461	chr18:23709825~23710287:-
STAD	cis	rs7826238	0.601	rs2979206	ENSG00000253981.4	ALG1L13P	5.04	7.68e-07	0.000528	0.31	0.26	Systolic blood pressure;	chr8:8488071	chr8:8236003~8244667:-
STAD	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-5.04	7.68e-07	0.000528	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-5.04	7.68e-07	0.000528	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-5.04	7.68e-07	0.000528	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
STAD	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-5.04	7.68e-07	0.000528	-0.27	-0.26	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-5.04	7.68e-07	0.000528	-0.27	-0.26	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
STAD	cis	rs9907295	0.901	rs4795096	ENSG00000270894.1	AC015849.13	-5.04	7.69e-07	0.000528	-0.27	-0.26	Fibroblast growth factor basic levels;	chr17:35888821	chr17:35818399~35823713:+
STAD	cis	rs4950322	1	rs72694715	ENSG00000278811.3	LINC00624	5.04	7.69e-07	0.000528	0.29	0.26	Protein quantitative trait loci;	chr1:147368468	chr1:147258885~147517875:-
STAD	cis	rs4950322	1	rs72694720	ENSG00000278811.3	LINC00624	5.04	7.69e-07	0.000528	0.29	0.26	Protein quantitative trait loci;	chr1:147371939	chr1:147258885~147517875:-
STAD	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	5.04	7.69e-07	0.000529	0.27	0.26	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
STAD	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	5.04	7.69e-07	0.000529	0.27	0.26	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
STAD	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	5.04	7.7e-07	0.000529	0.36	0.26	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
STAD	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-5.04	7.7e-07	0.000529	-0.31	-0.26	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
STAD	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-5.04	7.7e-07	0.000529	-0.35	-0.26	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
STAD	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	5.03	7.71e-07	0.00053	0.28	0.26	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
STAD	cis	rs858239	0.738	rs13225593	ENSG00000226816.2	AC005082.12	5.03	7.71e-07	0.00053	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23206013~23208045:+
STAD	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	5.03	7.71e-07	0.00053	0.32	0.26	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
STAD	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	5.03	7.72e-07	0.00053	0.29	0.26	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
STAD	cis	rs4713118	0.869	rs9366700	ENSG00000280107.1	AL022393.9	-5.03	7.73e-07	0.000531	-0.35	-0.26	Parkinson's disease;	chr6:27729172	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs6456802	ENSG00000280107.1	AL022393.9	-5.03	7.73e-07	0.000531	-0.35	-0.26	Parkinson's disease;	chr6:27730576	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs9393851	ENSG00000280107.1	AL022393.9	-5.03	7.73e-07	0.000531	-0.35	-0.26	Parkinson's disease;	chr6:27731802	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs9461400	ENSG00000280107.1	AL022393.9	-5.03	7.73e-07	0.000531	-0.35	-0.26	Parkinson's disease;	chr6:27732780	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs9295742	ENSG00000280107.1	AL022393.9	-5.03	7.73e-07	0.000531	-0.35	-0.26	Parkinson's disease;	chr6:27735053	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs9461401	ENSG00000280107.1	AL022393.9	-5.03	7.73e-07	0.000531	-0.35	-0.26	Parkinson's disease;	chr6:27735512	chr6:28170845~28172521:+
STAD	cis	rs9463078	0.509	rs1300126	ENSG00000219384.1	RP11-491H9.3	5.03	7.73e-07	0.000531	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45117124	chr6:45158870~45159511:+
STAD	cis	rs1816752	0.837	rs9318530	ENSG00000273628.1	RP11-756A22.7	-5.03	7.74e-07	0.000532	-0.31	-0.26	Obesity-related traits;	chr13:24424419	chr13:24933006~24936796:+
STAD	cis	rs11694172	0.821	rs36126443	ENSG00000273456.1	RP11-686O6.2	5.03	7.75e-07	0.000532	0.29	0.26	Cholesterol, total;	chr2:202693808	chr2:202374932~202375604:-
STAD	cis	rs9463078	0.585	rs10807320	ENSG00000219384.1	RP11-491H9.3	-5.03	7.75e-07	0.000532	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45270705	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs4352679	ENSG00000219384.1	RP11-491H9.3	-5.03	7.75e-07	0.000532	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45271921	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs12205274	ENSG00000219384.1	RP11-491H9.3	-5.03	7.75e-07	0.000532	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45277289	chr6:45158870~45159511:+
STAD	cis	rs2337406	0.636	rs74090069	ENSG00000280411.1	IGHV1-69-2	-5.03	7.76e-07	0.000533	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106777532	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74090071	ENSG00000280411.1	IGHV1-69-2	-5.03	7.76e-07	0.000533	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106777533	chr14:106762092~106762588:-
STAD	cis	rs1799949	0.93	rs1554063	ENSG00000236383.6	LINC00854	-5.03	7.77e-07	0.000533	-0.21	-0.26	Menopause (age at onset);	chr17:43135128	chr17:43216941~43305976:-
STAD	cis	rs12744310	0.887	rs1892419	ENSG00000235358.1	RP11-399E6.1	5.03	7.77e-07	0.000533	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315479	chr1:41242373~41284861:+
STAD	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-5.03	7.77e-07	0.000533	-0.22	-0.26	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
STAD	cis	rs801193	0.569	rs13242290	ENSG00000236529.1	RP13-254B10.1	-5.03	7.78e-07	0.000534	-0.27	-0.26	Aortic root size;	chr7:66656898	chr7:65840212~65840596:+
STAD	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-5.03	7.78e-07	0.000534	-0.29	-0.26	QT interval;	chr12:29300845	chr12:29280418~29317848:-
STAD	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	5.03	7.78e-07	0.000534	0.3	0.26	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
STAD	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	5.03	7.79e-07	0.000534	0.31	0.26	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
STAD	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	5.03	7.79e-07	0.000534	0.29	0.26	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
STAD	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	5.03	7.79e-07	0.000534	0.5	0.26	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
STAD	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-5.03	7.81e-07	0.000536	-0.42	-0.26	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
STAD	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-5.03	7.81e-07	0.000536	-0.29	-0.26	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
STAD	cis	rs9860428	0.844	rs7641119	ENSG00000240057.4	RP11-572M11.4	-5.03	7.81e-07	0.000536	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112891978	chr3:113019532~113183301:+
STAD	cis	rs7829975	0.686	rs907180	ENSG00000254340.1	RP11-10A14.3	5.03	7.82e-07	0.000536	0.3	0.26	Mood instability;	chr8:8845317	chr8:9141424~9145435:+
STAD	cis	rs2337406	0.866	rs7153964	ENSG00000280411.1	IGHV1-69-2	-5.03	7.82e-07	0.000536	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106790480	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs2301536	ENSG00000280411.1	IGHV1-69-2	-5.03	7.82e-07	0.000536	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106790636	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs7144369	ENSG00000280411.1	IGHV1-69-2	-5.03	7.82e-07	0.000536	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106793065	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs78525520	ENSG00000280411.1	IGHV1-69-2	-5.03	7.82e-07	0.000536	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106795643	chr14:106762092~106762588:-
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000280411.1	IGHV1-69-2	-5.03	7.82e-07	0.000536	-0.31	-0.26	Kawasaki disease;	chr14:106799309	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs76871148	ENSG00000280411.1	IGHV1-69-2	-5.03	7.82e-07	0.000536	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106799722	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs61521632	ENSG00000280411.1	IGHV1-69-2	-5.03	7.82e-07	0.000536	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106801091	chr14:106762092~106762588:-
STAD	cis	rs8098244	0.638	rs12965685	ENSG00000267301.1	RPL23AP77	-5.03	7.82e-07	0.000536	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23861753	chr18:23709825~23710287:-
STAD	cis	rs2337406	0.866	rs7140974	ENSG00000280411.1	IGHV1-69-2	-5.03	7.83e-07	0.000537	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106795976	chr14:106762092~106762588:-
STAD	cis	rs4912314	1	rs4912314	ENSG00000236776.1	RPL21P23	-5.03	7.83e-07	0.000537	-0.32	-0.26	Waist-to-hip ratio adjusted for body mass index;	chr1:56502805	chr1:56538452~56538911:+
STAD	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-5.03	7.83e-07	0.000537	-0.31	-0.26	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
STAD	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-5.03	7.83e-07	0.000537	-0.31	-0.26	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
STAD	cis	rs853679	0.517	rs6932109	ENSG00000220721.1	OR1F12	-5.03	7.83e-07	0.000537	-0.3	-0.26	Depression;	chr6:28110525	chr6:28073316~28074233:+
STAD	cis	rs2833693	0.574	rs9978000	ENSG00000261610.1	AP000265.1	5.03	7.84e-07	0.000537	0.29	0.26	Temperament;	chr21:32176510	chr21:32259804~32261585:-
STAD	cis	rs2337406	0.866	rs7140974	ENSG00000211972.2	IGHV3-66	5.03	7.84e-07	0.000538	0.28	0.26	Alzheimer's disease (late onset);	chr14:106795976	chr14:106675017~106675544:-
STAD	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-5.03	7.84e-07	0.000538	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-5.03	7.84e-07	0.000538	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-5.03	7.84e-07	0.000538	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
STAD	cis	rs3758911	1	rs11212164	ENSG00000261098.1	RP11-819C21.1	-5.03	7.85e-07	0.000538	-0.24	-0.26	Coronary artery disease;	chr11:107328113	chr11:107312132~107316271:-
STAD	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	5.03	7.87e-07	0.000539	0.26	0.26	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
STAD	cis	rs6061231	0.701	rs6061505	ENSG00000275437.1	RP5-908M14.10	5.03	7.87e-07	0.000539	0.24	0.26	Colorectal cancer;	chr20:62385155	chr20:62402236~62405935:-
STAD	cis	rs3758911	0.964	rs10789602	ENSG00000261098.1	RP11-819C21.1	-5.03	7.87e-07	0.000539	-0.23	-0.26	Coronary artery disease;	chr11:107310729	chr11:107312132~107316271:-
STAD	cis	rs875971	0.545	rs1796219	ENSG00000236529.1	RP13-254B10.1	-5.03	7.88e-07	0.000539	-0.31	-0.26	Aortic root size;	chr7:66645977	chr7:65840212~65840596:+
STAD	cis	rs2836950	0.565	rs7278297	ENSG00000238141.2	BRWD1-AS1	-5.03	7.9e-07	0.000541	-0.26	-0.26	Menarche (age at onset);	chr21:39253826	chr21:39315707~39323218:+
STAD	cis	rs721917	0.506	rs1923538	ENSG00000244733.5	RP11-506M13.3	-5.03	7.9e-07	0.000541	-0.32	-0.26	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79660891~79677996:+
STAD	cis	rs721917	0.507	rs2819101	ENSG00000244733.5	RP11-506M13.3	-5.03	7.9e-07	0.000541	-0.32	-0.26	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2819100	ENSG00000244733.5	RP11-506M13.3	-5.03	7.9e-07	0.000541	-0.32	-0.26	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2758547	ENSG00000244733.5	RP11-506M13.3	-5.03	7.9e-07	0.000541	-0.32	-0.26	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79660891~79677996:+
STAD	cis	rs7078219	0.505	rs11190140	ENSG00000257582.4	LINC01475	-5.03	7.91e-07	0.000541	-0.3	-0.26	Dental caries;	chr10:99531836	chr10:99526350~99531177:-
STAD	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	5.03	7.91e-07	0.000541	0.4	0.26	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
STAD	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	5.03	7.91e-07	0.000542	0.26	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
STAD	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-5.03	7.92e-07	0.000542	-0.33	-0.26	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
STAD	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.03	7.92e-07	0.000542	-0.29	-0.26	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.03	7.92e-07	0.000542	-0.29	-0.26	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-5.03	7.92e-07	0.000542	-0.29	-0.26	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
STAD	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-5.03	7.92e-07	0.000542	-0.29	-0.26	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
STAD	cis	rs875971	0.862	rs7798630	ENSG00000236529.1	RP13-254B10.1	-5.03	7.92e-07	0.000542	-0.27	-0.26	Aortic root size;	chr7:66306492	chr7:65840212~65840596:+
STAD	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-5.03	7.92e-07	0.000542	-0.37	-0.26	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
STAD	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-5.03	7.93e-07	0.000543	-0.32	-0.26	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
STAD	cis	rs3758911	0.861	rs11212197	ENSG00000261098.1	RP11-819C21.1	-5.03	7.94e-07	0.000543	-0.24	-0.26	Coronary artery disease;	chr11:107391784	chr11:107312132~107316271:-
STAD	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	5.03	7.94e-07	0.000543	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
STAD	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	5.03	7.94e-07	0.000543	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
STAD	cis	rs6142102	0.886	rs4911147	ENSG00000275784.1	RP5-1125A11.6	-5.03	7.94e-07	0.000543	-0.27	-0.26	Skin pigmentation;	chr20:34079801	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs8123521	ENSG00000275784.1	RP5-1125A11.6	-5.03	7.94e-07	0.000543	-0.27	-0.26	Skin pigmentation;	chr20:34081079	chr20:33989480~33991818:-
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000211973.2	IGHV1-69	5.03	7.94e-07	0.000544	0.22	0.26	Kawasaki disease;	chr14:106804049	chr14:106714684~106715181:-
STAD	cis	rs2404602	0.716	rs67920045	ENSG00000259422.1	RP11-593F23.1	5.03	7.95e-07	0.000544	0.27	0.26	Blood metabolite levels;	chr15:76507743	chr15:76174891~76181486:-
STAD	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	5.03	7.95e-07	0.000544	0.28	0.26	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
STAD	cis	rs992157	0.56	rs7605980	ENSG00000237281.1	CATIP-AS2	-5.03	7.95e-07	0.000544	-0.26	-0.26	Colorectal cancer;	chr2:218236146	chr2:218326889~218357966:-
STAD	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-5.03	7.96e-07	0.000544	-0.27	-0.26	Height;	chr5:36925633	chr5:36666214~36725195:-
STAD	cis	rs875971	0.545	rs7811204	ENSG00000236529.1	RP13-254B10.1	5.03	7.96e-07	0.000544	0.31	0.26	Aortic root size;	chr7:66387213	chr7:65840212~65840596:+
STAD	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-5.03	7.97e-07	0.000545	-0.25	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
STAD	cis	rs7829975	0.514	rs2945873	ENSG00000253981.4	ALG1L13P	5.03	7.97e-07	0.000545	0.3	0.26	Mood instability;	chr8:8402935	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-5.03	7.97e-07	0.000545	-0.33	-0.26	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
STAD	cis	rs721917	0.586	rs2758550	ENSG00000244733.5	RP11-506M13.3	-5.03	7.98e-07	0.000545	-0.32	-0.26	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79660891~79677996:+
STAD	cis	rs3758911	1	rs11212159	ENSG00000261098.1	RP11-819C21.1	-5.03	7.98e-07	0.000545	-0.24	-0.26	Coronary artery disease;	chr11:107326003	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs11212160	ENSG00000261098.1	RP11-819C21.1	-5.03	7.98e-07	0.000545	-0.24	-0.26	Coronary artery disease;	chr11:107326192	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs1046095	ENSG00000261098.1	RP11-819C21.1	-5.03	7.98e-07	0.000545	-0.24	-0.26	Coronary artery disease;	chr11:107326509	chr11:107312132~107316271:-
STAD	cis	rs3758911	1	rs3758911	ENSG00000261098.1	RP11-819C21.1	-5.03	7.98e-07	0.000545	-0.24	-0.26	Coronary artery disease;	chr11:107326914	chr11:107312132~107316271:-
STAD	cis	rs858239	0.899	rs2268747	ENSG00000226816.2	AC005082.12	5.03	7.98e-07	0.000545	0.33	0.26	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23206013~23208045:+
STAD	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	5.03	7.98e-07	0.000545	0.31	0.26	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
STAD	cis	rs8040855	0.658	rs12909111	ENSG00000229212.6	RP11-561C5.4	5.03	7.98e-07	0.000546	0.36	0.26	Bulimia nervosa;	chr15:85061095	chr15:85205440~85234795:-
STAD	cis	rs28602288	1	rs28602288	ENSG00000237118.2	CYP2F2P	5.03	7.99e-07	0.000546	0.29	0.26	Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr19:40882835	chr19:40818721~40826772:-
STAD	cis	rs1799949	1	rs33926631	ENSG00000236383.6	LINC00854	-5.03	7.99e-07	0.000546	-0.21	-0.26	Menopause (age at onset);	chr17:43152446	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs1960605	ENSG00000236383.6	LINC00854	-5.03	7.99e-07	0.000546	-0.21	-0.26	Menopause (age at onset);	chr17:43153380	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs2037076	ENSG00000236383.6	LINC00854	-5.03	7.99e-07	0.000546	-0.21	-0.26	Menopause (age at onset);	chr17:43153866	chr17:43216941~43305976:-
STAD	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-5.03	8e-07	0.000546	-0.41	-0.26	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
STAD	cis	rs6452524	0.618	rs2075685	ENSG00000243385.2	CTD-2110K23.1	5.03	8e-07	0.000547	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83201229~83202141:+
STAD	cis	rs9549260	0.604	rs9549273	ENSG00000229456.1	RLIMP1	-5.03	8e-07	0.000547	-0.29	-0.26	Red blood cell count;	chr13:40728011	chr13:40618738~40621348:+
STAD	cis	rs5769707	0.632	rs6009782	ENSG00000280224.1	CTA-722E9.1	-5.03	8e-07	0.000547	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49500568~49501585:+
STAD	cis	rs17301013	0.932	rs4233195	ENSG00000227373.4	RP11-160H22.5	-5.03	8.01e-07	0.000547	-0.3	-0.26	Systemic lupus erythematosus;	chr1:174806736	chr1:174115300~174160004:-
STAD	cis	rs6584283	0.846	rs11190135	ENSG00000228778.1	RP11-129J12.1	-5.03	8.01e-07	0.000547	-0.29	-0.26	Ulcerative colitis;	chr10:99527091	chr10:99527081~99528261:+
STAD	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-5.03	8.01e-07	0.000547	-0.34	-0.26	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-5.03	8.01e-07	0.000547	-0.34	-0.26	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-5.03	8.01e-07	0.000547	-0.34	-0.26	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-5.03	8.01e-07	0.000547	-0.34	-0.26	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
STAD	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-5.03	8.01e-07	0.000547	-0.25	-0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
STAD	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-5.03	8.02e-07	0.000548	-0.29	-0.26	QT interval;	chr12:29319476	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-5.03	8.02e-07	0.000548	-0.29	-0.26	QT interval;	chr12:29320175	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-5.03	8.02e-07	0.000548	-0.29	-0.26	QT interval;	chr12:29321177	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-5.03	8.02e-07	0.000548	-0.29	-0.26	QT interval;	chr12:29321323	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-5.03	8.02e-07	0.000548	-0.29	-0.26	QT interval;	chr12:29322770	chr12:29280418~29317848:-
STAD	cis	rs2404602	0.679	rs12900494	ENSG00000259422.1	RP11-593F23.1	5.03	8.03e-07	0.000548	0.27	0.26	Blood metabolite levels;	chr15:76620163	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.716	rs7169394	ENSG00000259422.1	RP11-593F23.1	5.03	8.03e-07	0.000548	0.27	0.26	Blood metabolite levels;	chr15:76620933	chr15:76174891~76181486:-
STAD	cis	rs1056107	0.931	rs7875843	ENSG00000225513.1	RP11-165N19.2	-5.03	8.04e-07	0.000549	-0.3	-0.26	Colorectal cancer;	chr9:112256675	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.866	rs10817305	ENSG00000225513.1	RP11-165N19.2	-5.03	8.04e-07	0.000549	-0.3	-0.26	Colorectal cancer;	chr9:112259120	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs3849126	ENSG00000225513.1	RP11-165N19.2	-5.03	8.04e-07	0.000549	-0.3	-0.26	Colorectal cancer;	chr9:112261060	chr9:112173522~112173971:-
STAD	cis	rs1799949	0.929	rs799906	ENSG00000236383.6	LINC00854	-5.03	8.04e-07	0.000549	-0.21	-0.26	Menopause (age at onset);	chr17:43126099	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs799908	ENSG00000236383.6	LINC00854	-5.03	8.04e-07	0.000549	-0.21	-0.26	Menopause (age at onset);	chr17:43126899	chr17:43216941~43305976:-
STAD	cis	rs12030196	0.536	rs2716130	ENSG00000230812.4	LINC01358	5.03	8.04e-07	0.000549	0.28	0.26	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59021456	chr1:59020387~59044614:+
STAD	cis	rs875971	0.545	rs1796226	ENSG00000236529.1	RP13-254B10.1	5.03	8.05e-07	0.000549	0.3	0.26	Aortic root size;	chr7:66622723	chr7:65840212~65840596:+
STAD	cis	rs13113518	1	rs7660980	ENSG00000223305.1	RN7SKP30	-5.03	8.06e-07	0.00055	-0.29	-0.26	Height;	chr4:55542948	chr4:55540502~55540835:-
STAD	cis	rs1707322	0.717	rs3014237	ENSG00000225447.1	RPS15AP10	-5.03	8.06e-07	0.00055	-0.21	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45645816~45646197:-
STAD	cis	rs9860428	0.844	rs9820561	ENSG00000240057.4	RP11-572M11.4	-5.03	8.06e-07	0.00055	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897693	chr3:113019532~113183301:+
STAD	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-5.03	8.07e-07	0.000551	-0.34	-0.26	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
STAD	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	5.03	8.07e-07	0.000551	0.28	0.26	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
STAD	cis	rs858239	0.539	rs6955969	ENSG00000226816.2	AC005082.12	5.03	8.08e-07	0.000552	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23206013~23208045:+
STAD	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	5.03	8.09e-07	0.000552	0.28	0.26	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
STAD	cis	rs7247513	0.897	rs12972944	ENSG00000230310.1	CTD-2192J16.11	-5.03	8.09e-07	0.000552	-0.33	-0.26	Bipolar disorder;	chr19:12602994	chr19:12552597~12553644:+
STAD	cis	rs801193	0.569	rs6978178	ENSG00000236529.1	RP13-254B10.1	-5.02	8.09e-07	0.000552	-0.27	-0.26	Aortic root size;	chr7:66658097	chr7:65840212~65840596:+
STAD	cis	rs453301	0.686	rs6748	ENSG00000254340.1	RP11-10A14.3	-5.02	8.09e-07	0.000552	-0.34	-0.26	Joint mobility (Beighton score);	chr8:9033292	chr8:9141424~9145435:+
STAD	cis	rs1045529	0.524	rs34251783	ENSG00000254340.1	RP11-10A14.3	-5.02	8.09e-07	0.000552	-0.34	-0.26	Myopia (pathological);Myopia;	chr8:9033866	chr8:9141424~9145435:+
STAD	cis	rs747650	0.504	rs4394802	ENSG00000271350.1	CTD-2384B9.1	-5.02	8.09e-07	0.000552	-0.33	-0.26	Acne (severe);	chr11:46969036	chr11:47041027~47041945:-
STAD	cis	rs7826238	0.509	rs2948288	ENSG00000254340.1	RP11-10A14.3	5.02	8.1e-07	0.000552	0.32	0.26	Systolic blood pressure;	chr8:8257782	chr8:9141424~9145435:+
STAD	cis	rs9307551	0.857	rs2165387	ENSG00000250334.4	LINC00989	-5.02	8.1e-07	0.000552	-0.31	-0.26	Refractive error;	chr4:79570666	chr4:79492416~79576460:+
STAD	cis	rs11846409	0.521	rs10143547	ENSG00000211972.2	IGHV3-66	5.02	8.1e-07	0.000553	0.27	0.26	Rheumatic heart disease;	chr14:106644638	chr14:106675017~106675544:-
STAD	cis	rs2239557	0.614	rs73303112	ENSG00000259065.1	RP5-1021I20.1	-5.02	8.1e-07	0.000553	-0.34	-0.26	Common traits (Other);	chr14:74013433	chr14:73787360~73803270:+
STAD	cis	rs747650	0.504	rs4269876	ENSG00000271350.1	CTD-2384B9.1	5.02	8.11e-07	0.000553	0.34	0.26	Acne (severe);	chr11:47087912	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs61896133	ENSG00000271350.1	CTD-2384B9.1	5.02	8.11e-07	0.000553	0.34	0.26	Acne (severe);	chr11:47094168	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs7112854	ENSG00000271350.1	CTD-2384B9.1	5.02	8.11e-07	0.000553	0.34	0.26	Acne (severe);	chr11:47095272	chr11:47041027~47041945:-
STAD	cis	rs1007738	0.579	rs61896136	ENSG00000271350.1	CTD-2384B9.1	5.02	8.11e-07	0.000553	0.34	0.26	Bone mineral density (hip);	chr11:47098748	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs12417519	ENSG00000271350.1	CTD-2384B9.1	5.02	8.11e-07	0.000553	0.34	0.26	Acne (severe);	chr11:47107846	chr11:47041027~47041945:-
STAD	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	5.02	8.12e-07	0.000554	0.29	0.26	Height;	chr4:55465165	chr4:55540502~55540835:-
STAD	cis	rs9601248	0.756	rs9601251	ENSG00000227354.5	RBM26-AS1	-5.02	8.13e-07	0.000554	-0.31	-0.26	Major depressive disorder;	chr13:79615582	chr13:79406309~79424328:+
STAD	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	5.02	8.14e-07	0.000555	0.4	0.26	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	5.02	8.14e-07	0.000555	0.4	0.26	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
STAD	cis	rs2115536	0.64	rs934134	ENSG00000278600.1	RP11-81A1.6	-5.02	8.14e-07	0.000555	-0.22	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79875876	chr15:79920195~79922455:-
STAD	cis	rs3806843	1	rs12717860	ENSG00000202111.1	VTRNA1-2	-5.02	8.14e-07	0.000555	-0.26	-0.26	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr5:140718925~140719013:+
STAD	cis	rs9549260	0.561	rs2297014	ENSG00000229456.1	RLIMP1	5.02	8.14e-07	0.000555	0.31	0.26	Red blood cell count;	chr13:40798824	chr13:40618738~40621348:+
STAD	cis	rs17592366	0.517	rs4982222	ENSG00000251726.1	RNU7-41P	-5.02	8.15e-07	0.000555	-0.23	-0.26	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34832791	chr14:34845300~34845360:-
STAD	cis	rs6142102	0.961	rs4911146	ENSG00000275784.1	RP5-1125A11.6	-5.02	8.16e-07	0.000556	-0.27	-0.26	Skin pigmentation;	chr20:34052241	chr20:33989480~33991818:-
STAD	cis	rs3758911	0.828	rs10789605	ENSG00000261098.1	RP11-819C21.1	-5.02	8.16e-07	0.000556	-0.24	-0.26	Coronary artery disease;	chr11:107313859	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.828	rs10789606	ENSG00000261098.1	RP11-819C21.1	-5.02	8.16e-07	0.000556	-0.24	-0.26	Coronary artery disease;	chr11:107313862	chr11:107312132~107316271:-
STAD	cis	rs3806843	1	rs4451093	ENSG00000202111.1	VTRNA1-2	5.02	8.17e-07	0.000557	0.26	0.26	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr5:140718925~140719013:+
STAD	cis	rs61542988	1	rs61542988	ENSG00000228649.7	AC005682.5	5.02	8.17e-07	0.000557	0.32	0.26	Fibrinogen levels;	chr7:22842672	chr7:22854178~22861579:+
STAD	cis	rs7191700	0.674	rs12597893	ENSG00000262703.1	RP11-485G7.6	5.02	8.17e-07	0.000557	0.24	0.26	Multiple sclerosis;	chr16:11332474	chr16:11348143~11349321:-
STAD	cis	rs4713118	0.824	rs2179095	ENSG00000280107.1	AL022393.9	5.02	8.18e-07	0.000557	0.34	0.26	Parkinson's disease;	chr6:27783079	chr6:28170845~28172521:+
STAD	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-5.02	8.18e-07	0.000557	-0.27	-0.26	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-5.02	8.18e-07	0.000557	-0.27	-0.26	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
STAD	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	5.02	8.18e-07	0.000557	0.33	0.26	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
STAD	cis	rs61841072	0.714	rs2907192	ENSG00000253326.2	RP11-261C10.7	-5.02	8.19e-07	0.000558	-0.32	-0.26	Schizophrenia;	chr1:242974088	chr1:243054861~243056394:-
STAD	cis	rs1153858	1	rs11852800	ENSG00000259433.2	CTD-2651B20.4	5.02	8.19e-07	0.000558	0.28	0.26	Homoarginine levels;	chr15:45346933	chr15:45330209~45332634:-
STAD	cis	rs11676348	0.808	rs1008563	ENSG00000237281.1	CATIP-AS2	5.02	8.22e-07	0.000559	0.26	0.26	Ulcerative colitis;	chr2:218162165	chr2:218326889~218357966:-
STAD	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	5.02	8.22e-07	0.00056	0.28	0.26	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
STAD	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	5.02	8.23e-07	0.00056	0.37	0.26	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	5.02	8.23e-07	0.00056	0.37	0.26	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	5.02	8.23e-07	0.00056	0.37	0.26	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	5.02	8.23e-07	0.00056	0.37	0.26	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	5.02	8.23e-07	0.00056	0.37	0.26	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971788	ENSG00000260947.1	RP11-384P7.7	5.02	8.23e-07	0.00056	0.37	0.26	Body mass index;	chr9:33915087	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	5.02	8.23e-07	0.00056	0.37	0.26	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
STAD	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-5.02	8.24e-07	0.000561	-0.29	-0.26	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
STAD	cis	rs516805	0.667	rs9320856	ENSG00000279453.1	RP3-425C14.4	-5.02	8.25e-07	0.000561	-0.36	-0.26	Lymphocyte counts;	chr6:122219888	chr6:122436789~122439223:-
STAD	cis	rs6782228	1	rs6782407	ENSG00000277250.1	Metazoa_SRP	5.02	8.25e-07	0.000561	0.32	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128673681~128674021:-
STAD	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	5.02	8.25e-07	0.000561	0.2	0.26	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
STAD	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	5.02	8.25e-07	0.000561	0.39	0.26	Height;	chr6:109645257	chr6:109382795~109383666:+
STAD	cis	rs891378	1	rs12095015	ENSG00000274245.1	RP11-357P18.2	5.02	8.25e-07	0.000561	0.32	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207283129	chr1:207372559~207373252:+
STAD	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-5.02	8.25e-07	0.000561	-0.41	-0.26	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
STAD	cis	rs875971	0.545	rs73142265	ENSG00000236529.1	RP13-254B10.1	5.02	8.26e-07	0.000562	0.31	0.26	Aortic root size;	chr7:66234510	chr7:65840212~65840596:+
STAD	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	5.02	8.26e-07	0.000562	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
STAD	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	5.02	8.26e-07	0.000562	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
STAD	cis	rs611744	0.608	rs1448152	ENSG00000253754.1	RP11-35G22.1	-5.02	8.26e-07	0.000562	-0.23	-0.26	Dupuytren's disease;	chr8:108266020	chr8:108226200~108227544:+
STAD	cis	rs611744	0.625	rs11779824	ENSG00000253754.1	RP11-35G22.1	-5.02	8.26e-07	0.000562	-0.23	-0.26	Dupuytren's disease;	chr8:108266460	chr8:108226200~108227544:+
STAD	cis	rs9860428	1	rs9860428	ENSG00000240057.4	RP11-572M11.4	-5.02	8.27e-07	0.000562	-0.24	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112852072	chr3:113019532~113183301:+
STAD	cis	rs9813712	0.571	rs9824426	ENSG00000253540.4	FAM86HP	-5.02	8.28e-07	0.000563	-0.29	-0.26	Response to amphetamines;	chr3:130226115	chr3:130099092~130111472:-
STAD	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	5.02	8.28e-07	0.000563	0.49	0.26	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
STAD	cis	rs12906542	0.507	rs4395040	ENSG00000259792.1	RP11-114H24.6	-5.02	8.3e-07	0.000564	-0.38	-0.26	Breast cancer;	chr15:77990191	chr15:77993405~77995289:+
STAD	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-5.02	8.31e-07	0.000565	-0.26	-0.26	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
STAD	cis	rs7487075	0.578	rs4768118	ENSG00000257261.4	RP11-96H19.1	5.02	8.31e-07	0.000565	0.32	0.26	Itch intensity from mosquito bite;	chr12:46390961	chr12:46383679~46876159:+
STAD	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-5.02	8.32e-07	0.000566	-0.28	-0.26	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
STAD	cis	rs6142102	0.778	rs6059581	ENSG00000275784.1	RP5-1125A11.6	-5.02	8.32e-07	0.000566	-0.27	-0.26	Skin pigmentation;	chr20:33940582	chr20:33989480~33991818:-
STAD	cis	rs10510102	0.935	rs12253283	ENSG00000226864.1	ATE1-AS1	-5.02	8.33e-07	0.000566	-0.41	-0.26	Breast cancer;	chr10:121909740	chr10:121928312~121951965:+
STAD	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	5.02	8.34e-07	0.000566	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
STAD	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-5.02	8.34e-07	0.000567	-0.29	-0.26	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-5.02	8.34e-07	0.000567	-0.29	-0.26	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
STAD	cis	rs6095360	0.727	rs34841991	ENSG00000222365.1	SNORD12B	-5.02	8.34e-07	0.000567	-0.34	-0.26	Intelligence (multi-trait analysis);	chr20:49130437	chr20:49280319~49280409:+
STAD	cis	rs5769707	0.592	rs6009783	ENSG00000280224.1	CTA-722E9.1	-5.02	8.35e-07	0.000567	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49500568~49501585:+
STAD	cis	rs891378	1	rs6703857	ENSG00000274245.1	RP11-357P18.2	-5.02	8.36e-07	0.000568	-0.33	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270208	chr1:207372559~207373252:+
STAD	cis	rs2933343	0.7	rs789240	ENSG00000261159.1	RP11-723O4.9	5.02	8.36e-07	0.000568	0.32	0.26	IgG glycosylation;	chr3:128911792	chr3:128859716~128860526:-
STAD	cis	rs875971	0.825	rs1129531	ENSG00000236529.1	RP13-254B10.1	-5.02	8.37e-07	0.000568	-0.27	-0.26	Aortic root size;	chr7:66154117	chr7:65840212~65840596:+
STAD	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-5.02	8.37e-07	0.000569	-0.35	-0.26	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
STAD	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	5.02	8.38e-07	0.000569	0.27	0.26	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
STAD	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	5.02	8.39e-07	0.000569	0.26	0.26	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
STAD	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-5.02	8.4e-07	0.00057	-0.24	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
STAD	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-5.02	8.4e-07	0.00057	-0.3	-0.26	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
STAD	cis	rs747650	0.504	rs34340483	ENSG00000271350.1	CTD-2384B9.1	-5.02	8.4e-07	0.00057	-0.32	-0.26	Acne (severe);	chr11:46931603	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs7945558	ENSG00000271350.1	CTD-2384B9.1	-5.02	8.4e-07	0.00057	-0.32	-0.26	Acne (severe);	chr11:46936257	chr11:47041027~47041945:-
STAD	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	5.02	8.41e-07	0.000571	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
STAD	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-5.02	8.41e-07	0.000571	-0.35	-0.26	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
STAD	cis	rs6095360	0.727	rs13037942	ENSG00000222365.1	SNORD12B	-5.02	8.42e-07	0.000571	-0.34	-0.26	Intelligence (multi-trait analysis);	chr20:48909134	chr20:49280319~49280409:+
STAD	cis	rs7487075	1	rs7976280	ENSG00000257261.4	RP11-96H19.1	5.02	8.42e-07	0.000572	0.32	0.26	Itch intensity from mosquito bite;	chr12:46407042	chr12:46383679~46876159:+
STAD	cis	rs516805	0.667	rs2045352	ENSG00000279453.1	RP3-425C14.4	-5.02	8.42e-07	0.000572	-0.36	-0.26	Lymphocyte counts;	chr6:122119694	chr6:122436789~122439223:-
STAD	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-5.02	8.43e-07	0.000572	-0.27	-0.26	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
STAD	cis	rs13113518	0.812	rs6830409	ENSG00000223305.1	RN7SKP30	5.02	8.43e-07	0.000572	0.29	0.26	Height;	chr4:55522229	chr4:55540502~55540835:-
STAD	cis	rs2404602	0.669	rs12148877	ENSG00000259422.1	RP11-593F23.1	5.02	8.44e-07	0.000573	0.27	0.26	Blood metabolite levels;	chr15:76627618	chr15:76174891~76181486:-
STAD	cis	rs1426063	0.748	rs6534607	ENSG00000260265.1	RP11-44F21.5	5.02	8.45e-07	0.000573	0.36	0.26	QT interval;	chr4:75106366	chr4:75081702~75084717:-
STAD	cis	rs747650	0.504	rs2087215	ENSG00000271350.1	CTD-2384B9.1	5.02	8.45e-07	0.000573	0.34	0.26	Acne (severe);	chr11:47122991	chr11:47041027~47041945:-
STAD	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	5.02	8.45e-07	0.000573	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	5.02	8.45e-07	0.000573	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
STAD	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	5.02	8.45e-07	0.000573	0.4	0.26	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
STAD	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	5.02	8.45e-07	0.000573	0.38	0.26	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	5.02	8.45e-07	0.000573	0.38	0.26	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	5.02	8.45e-07	0.000573	0.38	0.26	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	5.02	8.45e-07	0.000573	0.38	0.26	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
STAD	cis	rs9425766	0.679	rs12085290	ENSG00000227373.4	RP11-160H22.5	-5.02	8.47e-07	0.000574	-0.3	-0.26	Life satisfaction;	chr1:174124699	chr1:174115300~174160004:-
STAD	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	5.02	8.47e-07	0.000574	0.31	0.26	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	5.02	8.47e-07	0.000574	0.31	0.26	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
STAD	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	5.02	8.48e-07	0.000575	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
STAD	cis	rs4568518	0.535	rs7781217	ENSG00000279048.1	RP11-511H23.2	5.02	8.48e-07	0.000575	0.24	0.26	Measles;	chr7:18023173	chr7:17940503~17942922:+
STAD	cis	rs875971	1	rs7792762	ENSG00000236529.1	RP13-254B10.1	5.02	8.48e-07	0.000575	0.27	0.26	Aortic root size;	chr7:66539151	chr7:65840212~65840596:+
STAD	cis	rs301901	0.897	rs12657771	ENSG00000250155.1	CTD-2353F22.1	-5.02	8.49e-07	0.000575	-0.27	-0.26	Height;	chr5:36787860	chr5:36666214~36725195:-
STAD	cis	rs9307551	0.817	rs7667469	ENSG00000250334.4	LINC00989	-5.02	8.49e-07	0.000575	-0.31	-0.26	Refractive error;	chr4:79576538	chr4:79492416~79576460:+
STAD	cis	rs13113518	0.783	rs13111128	ENSG00000223305.1	RN7SKP30	5.01	8.49e-07	0.000575	0.3	0.26	Height;	chr4:55578154	chr4:55540502~55540835:-
STAD	cis	rs858239	0.6	rs7776649	ENSG00000226816.2	AC005082.12	5.01	8.49e-07	0.000575	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23206013~23208045:+
STAD	cis	rs4950322	0.57	rs72691093	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147297977	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs76236344	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147297989	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691095	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147298305	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691097	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147299711	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691098	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147300142	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691102	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147301189	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692904	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147301437	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692905	ENSG00000278811.3	LINC00624	5.01	8.5e-07	0.000576	0.28	0.26	Protein quantitative trait loci;	chr1:147301560	chr1:147258885~147517875:-
STAD	cis	rs9463078	0.565	rs4714845	ENSG00000219384.1	RP11-491H9.3	-5.01	8.51e-07	0.000576	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45262684	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs4714847	ENSG00000219384.1	RP11-491H9.3	-5.01	8.51e-07	0.000576	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45263337	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs4714848	ENSG00000219384.1	RP11-491H9.3	-5.01	8.51e-07	0.000576	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45263398	chr6:45158870~45159511:+
STAD	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-5.01	8.52e-07	0.000577	-0.29	-0.26	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.514	rs2920983	ENSG00000253981.4	ALG1L13P	5.01	8.52e-07	0.000577	0.3	0.26	Mood instability;	chr8:8410553	chr8:8236003~8244667:-
STAD	cis	rs2933343	0.729	rs1680794	ENSG00000261159.1	RP11-723O4.9	5.01	8.52e-07	0.000577	0.32	0.26	IgG glycosylation;	chr3:128901547	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.7	rs1683777	ENSG00000261159.1	RP11-723O4.9	5.01	8.52e-07	0.000577	0.32	0.26	IgG glycosylation;	chr3:128906037	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.7	rs1680788	ENSG00000261159.1	RP11-723O4.9	5.01	8.52e-07	0.000577	0.32	0.26	IgG glycosylation;	chr3:128906475	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.7	rs789239	ENSG00000261159.1	RP11-723O4.9	5.01	8.52e-07	0.000577	0.32	0.26	IgG glycosylation;	chr3:128914965	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.7	rs789238	ENSG00000261159.1	RP11-723O4.9	5.01	8.52e-07	0.000577	0.32	0.26	IgG glycosylation;	chr3:128917872	chr3:128859716~128860526:-
STAD	cis	rs711244	0.532	rs2540998	ENSG00000252756.1	RNU6-577P	-5.01	8.52e-07	0.000577	-0.29	-0.26	Mean platelet volume;	chr2:37027872	chr2:36867398~36867495:-
STAD	cis	rs9733	0.593	rs10888384	ENSG00000274963.1	Metazoa_SRP	-5.01	8.52e-07	0.000577	-0.21	-0.26	Tonsillectomy;	chr1:150601780	chr1:150568971~150569269:-
STAD	cis	rs7124681	0.565	rs2203712	ENSG00000280615.1	Y_RNA	5.01	8.52e-07	0.000577	0.26	0.26	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47513412	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs10838732	ENSG00000280615.1	Y_RNA	5.01	8.52e-07	0.000577	0.26	0.26	Subjective well-being;	chr11:47586388	chr11:47614898~47614994:-
STAD	cis	rs7927771	0.524	rs6485763	ENSG00000280615.1	Y_RNA	5.01	8.52e-07	0.000577	0.26	0.26	Subjective well-being;	chr11:47605750	chr11:47614898~47614994:-
STAD	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-5.01	8.53e-07	0.000577	-0.33	-0.26	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
STAD	cis	rs1729407	0.632	rs2071523	ENSG00000280143.1	AP000892.6	5.01	8.53e-07	0.000577	0.19	0.26	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117204967~117210292:+
STAD	cis	rs30380	0.69	rs2042381	ENSG00000248734.2	CTD-2260A17.1	5.01	8.53e-07	0.000577	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96784777~96785999:+
STAD	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-5.01	8.53e-07	0.000578	-0.32	-0.26	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
STAD	cis	rs1075265	0.704	rs9631059	ENSG00000235937.1	AC008280.1	5.01	8.54e-07	0.000578	0.23	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54029552~54030682:-
STAD	cis	rs748404	0.666	rs7177146	ENSG00000249839.1	AC011330.5	-5.01	8.55e-07	0.000578	-0.46	-0.26	Lung cancer;	chr15:43506110	chr15:43663654~43684339:-
STAD	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	5.01	8.55e-07	0.000579	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
STAD	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-5.01	8.55e-07	0.000579	-0.28	-0.26	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
STAD	cis	rs1056107	0.966	rs7043856	ENSG00000225513.1	RP11-165N19.2	-5.01	8.56e-07	0.000579	-0.31	-0.26	Colorectal cancer;	chr9:112325876	chr9:112173522~112173971:-
STAD	cis	rs1056107	1	rs4363271	ENSG00000225513.1	RP11-165N19.2	-5.01	8.56e-07	0.000579	-0.31	-0.26	Colorectal cancer;	chr9:112326251	chr9:112173522~112173971:-
STAD	cis	rs1150668	0.83	rs213240	ENSG00000220721.1	OR1F12	5.01	8.56e-07	0.000579	0.25	0.26	Pubertal anthropometrics;	chr6:28348098	chr6:28073316~28074233:+
STAD	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	5.01	8.56e-07	0.000579	0.24	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
STAD	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	5.01	8.56e-07	0.000579	0.38	0.26	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
STAD	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	5.01	8.56e-07	0.000579	0.38	0.26	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
STAD	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-5.01	8.56e-07	0.000579	-0.27	-0.26	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
STAD	cis	rs858239	0.539	rs4294098	ENSG00000226816.2	AC005082.12	5.01	8.56e-07	0.000579	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23206013~23208045:+
STAD	cis	rs858239	0.539	rs4504540	ENSG00000226816.2	AC005082.12	5.01	8.56e-07	0.000579	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23206013~23208045:+
STAD	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-5.01	8.57e-07	0.00058	-0.33	-0.26	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-5.01	8.57e-07	0.00058	-0.33	-0.26	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	5.01	8.57e-07	0.00058	0.33	0.26	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
STAD	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-5.01	8.57e-07	0.00058	-0.36	-0.26	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
STAD	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-5.01	8.57e-07	0.00058	-0.36	-0.26	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
STAD	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-5.01	8.57e-07	0.00058	-0.36	-0.26	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
STAD	cis	rs516805	0.667	rs2606624	ENSG00000279453.1	RP3-425C14.4	-5.01	8.59e-07	0.000581	-0.37	-0.26	Lymphocyte counts;	chr6:122168693	chr6:122436789~122439223:-
STAD	cis	rs516805	0.667	rs2606617	ENSG00000279453.1	RP3-425C14.4	-5.01	8.59e-07	0.000581	-0.37	-0.26	Lymphocyte counts;	chr6:122182619	chr6:122436789~122439223:-
STAD	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	5.01	8.59e-07	0.000581	0.31	0.26	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	5.01	8.59e-07	0.000581	0.31	0.26	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	5.01	8.59e-07	0.000581	0.31	0.26	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	5.01	8.59e-07	0.000581	0.31	0.26	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
STAD	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	5.01	8.59e-07	0.000581	0.43	0.26	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
STAD	cis	rs11098499	0.526	rs10026625	ENSG00000249244.1	RP11-548H18.2	5.01	8.62e-07	0.000583	0.32	0.26	Corneal astigmatism;	chr4:119358981	chr4:119391831~119395335:-
STAD	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-5.01	8.62e-07	0.000583	-0.31	-0.26	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
STAD	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-5.01	8.62e-07	0.000583	-0.31	-0.26	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
STAD	cis	rs9902453	0.584	rs3809790	ENSG00000240074.1	RPL9P30	-5.01	8.62e-07	0.000583	-0.23	-0.26	Coffee consumption (cups per day);	chr17:29628522	chr17:29855759~29856332:+
STAD	cis	rs453301	0.624	rs7014430	ENSG00000254340.1	RP11-10A14.3	5.01	8.63e-07	0.000584	0.34	0.26	Joint mobility (Beighton score);	chr8:8970227	chr8:9141424~9145435:+
STAD	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	5.01	8.65e-07	0.000585	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
STAD	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-5.01	8.66e-07	0.000585	-0.34	-0.26	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
STAD	cis	rs9910055	0.509	rs9916444	ENSG00000260793.2	RP5-882C2.2	-5.01	8.66e-07	0.000585	-0.28	-0.26	Total body bone mineral density;	chr17:44236144	chr17:44221401~44223710:+
STAD	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	5.01	8.66e-07	0.000586	0.29	0.26	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
STAD	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	5.01	8.67e-07	0.000586	0.24	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
STAD	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	5.01	8.67e-07	0.000586	0.28	0.26	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
STAD	cis	rs8097348	0.817	rs28867755	ENSG00000266602.1	RP11-476K15.1	-5.01	8.67e-07	0.000586	-0.3	-0.26	Exercise (leisure time);	chr18:1630503	chr18:1509183~1647097:+
STAD	cis	rs11676348	0.811	rs13027120	ENSG00000237281.1	CATIP-AS2	-5.01	8.67e-07	0.000586	-0.26	-0.26	Ulcerative colitis;	chr2:218156191	chr2:218326889~218357966:-
STAD	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-5.01	8.68e-07	0.000587	-0.36	-0.26	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
STAD	cis	rs7932354	0.528	rs11039097	ENSG00000271350.1	CTD-2384B9.1	-5.01	8.68e-07	0.000587	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:47110330	chr11:47041027~47041945:-
STAD	cis	rs916888	0.61	rs199438	ENSG00000261575.2	RP11-259G18.1	5.01	8.69e-07	0.000587	0.35	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46267037~46268694:+
STAD	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-5.01	8.7e-07	0.000588	-0.36	-0.26	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
STAD	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	5.01	8.71e-07	0.000588	0.35	0.26	Height;	chr6:109446728	chr6:109382795~109383666:+
STAD	cis	rs7487075	0.82	rs7315493	ENSG00000272369.1	RP11-446N19.1	5.01	8.71e-07	0.000588	0.34	0.26	Itch intensity from mosquito bite;	chr12:46295644	chr12:46537502~46652550:+
STAD	cis	rs606458	0.841	rs523752	ENSG00000269038.1	AP001462.6	-5.01	8.71e-07	0.000589	-0.33	-0.26	Urate levels;	chr11:64781112	chr11:64778954~64779405:+
STAD	cis	rs1862618	0.641	rs252893	ENSG00000271828.1	CTD-2310F14.1	5.01	8.72e-07	0.000589	0.32	0.26	Initial pursuit acceleration;	chr5:56928887	chr5:56927874~56929573:+
STAD	cis	rs1862618	0.671	rs173763	ENSG00000271828.1	CTD-2310F14.1	5.01	8.72e-07	0.000589	0.32	0.26	Initial pursuit acceleration;	chr5:56929591	chr5:56927874~56929573:+
STAD	cis	rs2446066	0.659	rs3816806	ENSG00000257379.1	RP11-793H13.8	5.01	8.73e-07	0.000589	0.5	0.26	Red blood cell count;	chr12:53486338	chr12:53441741~53467528:+
STAD	cis	rs2404602	0.536	rs1587381	ENSG00000259422.1	RP11-593F23.1	5.01	8.73e-07	0.00059	0.27	0.26	Blood metabolite levels;	chr15:76477279	chr15:76174891~76181486:-
STAD	cis	rs516805	0.748	rs11154078	ENSG00000279453.1	RP3-425C14.4	5.01	8.73e-07	0.00059	0.34	0.26	Lymphocyte counts;	chr6:122387058	chr6:122436789~122439223:-
STAD	cis	rs875971	0.895	rs12531677	ENSG00000236529.1	RP13-254B10.1	-5.01	8.74e-07	0.00059	-0.27	-0.26	Aortic root size;	chr7:66304099	chr7:65840212~65840596:+
STAD	cis	rs2404602	0.563	rs12914005	ENSG00000259422.1	RP11-593F23.1	5.01	8.74e-07	0.00059	0.27	0.26	Blood metabolite levels;	chr15:76473326	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.536	rs7163946	ENSG00000259422.1	RP11-593F23.1	5.01	8.74e-07	0.00059	0.27	0.26	Blood metabolite levels;	chr15:76473708	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.536	rs7165025	ENSG00000259422.1	RP11-593F23.1	5.01	8.74e-07	0.00059	0.27	0.26	Blood metabolite levels;	chr15:76474093	chr15:76174891~76181486:-
STAD	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-5.01	8.74e-07	0.00059	-0.29	-0.26	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
STAD	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-5.01	8.74e-07	0.00059	-0.3	-0.26	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
STAD	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	5.01	8.74e-07	0.00059	0.28	0.26	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
STAD	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-5.01	8.74e-07	0.00059	-0.32	-0.26	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
STAD	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-5.01	8.74e-07	0.00059	-0.27	-0.26	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
STAD	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-5.01	8.75e-07	0.000591	-0.31	-0.26	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
STAD	cis	rs6430585	0.528	rs6750549	ENSG00000231890.6	DARS-AS1	-5.01	8.76e-07	0.000591	-0.29	-0.26	Corneal structure;	chr2:135949910	chr2:135985176~136022593:+
STAD	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-5.01	8.76e-07	0.000591	-0.27	-0.26	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
STAD	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-5.01	8.76e-07	0.000591	-0.25	-0.26	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
STAD	cis	rs2337406	0.866	rs4774019	ENSG00000280411.1	IGHV1-69-2	-5.01	8.77e-07	0.000592	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106805386	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs58850145	ENSG00000280411.1	IGHV1-69-2	-5.01	8.77e-07	0.000592	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106806185	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs2027901	ENSG00000280411.1	IGHV1-69-2	-5.01	8.77e-07	0.000592	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106807164	chr14:106762092~106762588:-
STAD	cis	rs4237845	0.586	rs4760174	ENSG00000273805.1	RP11-620J15.4	-5.01	8.77e-07	0.000592	-0.3	-0.26	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57894232~57896846:+
STAD	cis	rs875971	0.862	rs28470208	ENSG00000236529.1	RP13-254B10.1	-5.01	8.77e-07	0.000592	-0.27	-0.26	Aortic root size;	chr7:66119713	chr7:65840212~65840596:+
STAD	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-5.01	8.78e-07	0.000592	-0.33	-0.26	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
STAD	cis	rs2404602	0.716	rs4886813	ENSG00000259422.1	RP11-593F23.1	-5.01	8.79e-07	0.000593	-0.27	-0.26	Blood metabolite levels;	chr15:76545880	chr15:76174891~76181486:-
STAD	cis	rs7580658	0.521	rs7605733	ENSG00000200250.1	RNU6-1147P	5.01	8.8e-07	0.000594	0.25	0.26	Protein C levels;	chr2:127174211	chr2:127316873~127316979:+
STAD	cis	rs1799949	0.965	rs8176193	ENSG00000236383.6	LINC00854	-5.01	8.81e-07	0.000595	-0.21	-0.26	Menopause (age at onset);	chr17:43079499	chr17:43216941~43305976:-
STAD	cis	rs2286503	0.839	rs2240728	ENSG00000228649.7	AC005682.5	5.01	8.81e-07	0.000595	0.3	0.26	Fibrinogen;	chr7:22812880	chr7:22854178~22861579:+
STAD	cis	rs611744	0.647	rs1379336	ENSG00000253754.1	RP11-35G22.1	-5.01	8.81e-07	0.000595	-0.23	-0.26	Dupuytren's disease;	chr8:108264377	chr8:108226200~108227544:+
STAD	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-5.01	8.81e-07	0.000595	-0.39	-0.26	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-5.01	8.81e-07	0.000595	-0.39	-0.26	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-5.01	8.81e-07	0.000595	-0.39	-0.26	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
STAD	cis	rs606458	0.841	rs1633462	ENSG00000269038.1	AP001462.6	-5.01	8.82e-07	0.000595	-0.36	-0.26	Urate levels;	chr11:64778785	chr11:64778954~64779405:+
STAD	cis	rs606458	0.92	rs487105	ENSG00000269038.1	AP001462.6	-5.01	8.82e-07	0.000595	-0.36	-0.26	Urate levels;	chr11:64779419	chr11:64778954~64779405:+
STAD	cis	rs606458	0.92	rs593394	ENSG00000269038.1	AP001462.6	-5.01	8.82e-07	0.000595	-0.36	-0.26	Urate levels;	chr11:64779519	chr11:64778954~64779405:+
STAD	cis	rs10504130	0.569	rs4418329	ENSG00000272024.1	RP11-546K22.3	-5.01	8.83e-07	0.000595	-0.38	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51758554	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs4442134	ENSG00000272024.1	RP11-546K22.3	-5.01	8.83e-07	0.000595	-0.38	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51758584	chr8:51950284~51950690:+
STAD	cis	rs6714710	0.603	rs11678591	ENSG00000235833.1	AC159540.14	-5.01	8.83e-07	0.000596	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97924538	chr2:97523949~97524976:-
STAD	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	5.01	8.84e-07	0.000596	0.28	0.26	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
STAD	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-5.01	8.84e-07	0.000596	-0.31	-0.26	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
STAD	cis	rs7124681	0.584	rs12226590	ENSG00000280615.1	Y_RNA	5.01	8.84e-07	0.000596	0.26	0.26	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47550256	chr11:47614898~47614994:-
STAD	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	5.01	8.85e-07	0.000597	0.37	0.26	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
STAD	cis	rs8098244	0.638	rs17797660	ENSG00000267301.1	RPL23AP77	-5.01	8.85e-07	0.000597	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23853074	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.638	rs12955347	ENSG00000267301.1	RPL23AP77	-5.01	8.85e-07	0.000597	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23853232	chr18:23709825~23710287:-
STAD	cis	rs6430585	0.528	rs309162	ENSG00000231890.6	DARS-AS1	-5.01	8.89e-07	0.000599	-0.29	-0.26	Corneal structure;	chr2:135933213	chr2:135985176~136022593:+
STAD	cis	rs9467773	0.62	rs1027203	ENSG00000243307.2	POM121L6P	5.01	8.89e-07	0.000599	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.595	rs2172007	ENSG00000243307.2	POM121L6P	5.01	8.89e-07	0.000599	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26896952~26898777:+
STAD	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-5.01	8.9e-07	6e-04	-0.21	-0.26	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
STAD	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	5.01	8.9e-07	6e-04	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
STAD	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-5.01	8.9e-07	6e-04	-0.33	-0.26	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-5.01	8.9e-07	6e-04	-0.33	-0.26	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-5.01	8.9e-07	6e-04	-0.33	-0.26	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
STAD	cis	rs7927771	0.524	rs7107792	ENSG00000280615.1	Y_RNA	5.01	8.9e-07	6e-04	0.26	0.26	Subjective well-being;	chr11:47647697	chr11:47614898~47614994:-
STAD	cis	rs7015630	0.618	rs28405481	ENSG00000251136.7	RP11-37B2.1	-5.01	8.9e-07	6e-04	-0.36	-0.26	Inflammatory bowel disease;Crohn's disease;	chr8:89807501	chr8:89609409~89757727:-
STAD	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-5	8.91e-07	6e-04	-0.29	-0.26	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
STAD	cis	rs516805	0.597	rs2816157	ENSG00000279453.1	RP3-425C14.4	-5	8.91e-07	6e-04	-0.36	-0.26	Lymphocyte counts;	chr6:122124400	chr6:122436789~122439223:-
STAD	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-5	8.92e-07	0.000601	-0.41	-0.26	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
STAD	cis	rs611744	0.604	rs13248461	ENSG00000253754.1	RP11-35G22.1	-5	8.92e-07	0.000601	-0.23	-0.26	Dupuytren's disease;	chr8:108273604	chr8:108226200~108227544:+
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000211973.2	IGHV1-69	5	8.92e-07	0.000601	0.22	0.26	Kawasaki disease;	chr14:106802182	chr14:106714684~106715181:-
STAD	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-5	8.92e-07	0.000601	-0.33	-0.26	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
STAD	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-5	8.93e-07	0.000602	-0.41	-0.26	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
STAD	cis	rs2524005	1	rs2524005	ENSG00000231130.1	HLA-T	-5	8.93e-07	0.000602	-0.38	-0.26	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29896654~29897786:+
STAD	cis	rs747650	0.504	rs7938169	ENSG00000271350.1	CTD-2384B9.1	-5	8.94e-07	0.000602	-0.32	-0.26	Acne (severe);	chr11:46949988	chr11:47041027~47041945:-
STAD	cis	rs606458	0.92	rs3741398	ENSG00000269038.1	AP001462.6	-5	8.95e-07	0.000603	-0.36	-0.26	Urate levels;	chr11:64778634	chr11:64778954~64779405:+
STAD	cis	rs10504130	0.696	rs17212214	ENSG00000272024.1	RP11-546K22.3	5	8.96e-07	0.000603	0.36	0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51950284~51950690:+
STAD	cis	rs875971	0.545	rs316324	ENSG00000236529.1	RP13-254B10.1	-5	8.96e-07	0.000603	-0.3	-0.26	Aortic root size;	chr7:66145627	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs316323	ENSG00000236529.1	RP13-254B10.1	-5	8.96e-07	0.000603	-0.3	-0.26	Aortic root size;	chr7:66146002	chr7:65840212~65840596:+
STAD	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-5	8.97e-07	0.000604	-0.39	-0.26	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
STAD	cis	rs747650	0.504	rs10838640	ENSG00000271350.1	CTD-2384B9.1	-5	8.97e-07	0.000604	-0.33	-0.26	Acne (severe);	chr11:46963078	chr11:47041027~47041945:-
STAD	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-5	8.97e-07	0.000604	-0.31	-0.26	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
STAD	cis	rs1862618	0.62	rs189695	ENSG00000271828.1	CTD-2310F14.1	5	8.97e-07	0.000604	0.32	0.26	Initial pursuit acceleration;	chr5:56929942	chr5:56927874~56929573:+
STAD	cis	rs2283792	1	rs5999515	ENSG00000228050.1	TOP3BP1	-5	8.97e-07	0.000604	-0.29	-0.26	Multiple sclerosis;	chr22:21790812	chr22:22223187~22224566:-
STAD	cis	rs728616	0.867	rs723191	ENSG00000225484.5	NUTM2B-AS1	-5	8.98e-07	0.000605	-0.57	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs723193	ENSG00000225484.5	NUTM2B-AS1	-5	8.98e-07	0.000605	-0.57	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79663088~79826594:-
STAD	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-5	8.99e-07	0.000605	-0.38	-0.26	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
STAD	cis	rs2933343	0.7	rs1680778	ENSG00000261159.1	RP11-723O4.9	5	8.99e-07	0.000605	0.32	0.26	IgG glycosylation;	chr3:128895342	chr3:128859716~128860526:-
STAD	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	5	8.99e-07	0.000605	0.27	0.26	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
STAD	cis	rs516805	0.63	rs2816082	ENSG00000279453.1	RP3-425C14.4	-5	9e-07	0.000606	-0.36	-0.26	Lymphocyte counts;	chr6:122102489	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2315814	ENSG00000279453.1	RP3-425C14.4	-5	9e-07	0.000606	-0.36	-0.26	Lymphocyte counts;	chr6:122102712	chr6:122436789~122439223:-
STAD	cis	rs516805	0.596	rs2606640	ENSG00000279453.1	RP3-425C14.4	-5	9e-07	0.000606	-0.36	-0.26	Lymphocyte counts;	chr6:122102901	chr6:122436789~122439223:-
STAD	cis	rs516805	0.63	rs2262318	ENSG00000279453.1	RP3-425C14.4	-5	9e-07	0.000606	-0.36	-0.26	Lymphocyte counts;	chr6:122102980	chr6:122436789~122439223:-
STAD	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	5	9e-07	0.000606	0.26	0.26	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
STAD	cis	rs7665090	0.87	rs228627	ENSG00000248971.2	KRT8P46	5	9.01e-07	0.000606	0.27	0.26	Primary biliary cholangitis;	chr4:102651925	chr4:102728746~102730171:-
STAD	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-5	9.01e-07	0.000606	-0.39	-0.26	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
STAD	cis	rs3758911	0.894	rs999985	ENSG00000261098.1	RP11-819C21.1	-5	9.01e-07	0.000606	-0.24	-0.26	Coronary artery disease;	chr11:107321531	chr11:107312132~107316271:-
STAD	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-5	9.01e-07	0.000607	-0.29	-0.26	QT interval;	chr12:29309811	chr12:29280418~29317848:-
STAD	cis	rs516805	0.665	rs2606648	ENSG00000279453.1	RP3-425C14.4	-5	9.02e-07	0.000607	-0.36	-0.26	Lymphocyte counts;	chr6:122119554	chr6:122436789~122439223:-
STAD	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	5	9.03e-07	0.000607	0.26	0.26	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
STAD	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	5	9.03e-07	0.000607	0.26	0.26	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
STAD	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	5	9.03e-07	0.000607	0.26	0.26	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
STAD	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	5	9.03e-07	0.000607	0.26	0.26	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
STAD	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-5	9.03e-07	0.000607	-0.26	-0.26	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
STAD	cis	rs6452524	0.618	rs6452502	ENSG00000243385.2	CTD-2110K23.1	5	9.03e-07	0.000607	0.29	0.26	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83201229~83202141:+
STAD	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-5	9.03e-07	0.000607	-0.3	-0.26	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
STAD	cis	rs1056107	0.933	rs6477891	ENSG00000225513.1	RP11-165N19.2	-5	9.03e-07	0.000608	-0.3	-0.26	Colorectal cancer;	chr9:112200029	chr9:112173522~112173971:-
STAD	cis	rs13113518	0.812	rs11133385	ENSG00000223305.1	RN7SKP30	5	9.04e-07	0.000608	0.29	0.26	Height;	chr4:55460485	chr4:55540502~55540835:-
STAD	cis	rs3736858	0.736	rs9544056	ENSG00000261105.4	LMO7-AS1	-5	9.05e-07	0.000608	-0.45	-0.26	Interleukin-9 levels;	chr13:75869711	chr13:75604700~75635994:-
STAD	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	5	9.06e-07	0.000609	0.34	0.26	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
STAD	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-5	9.06e-07	0.000609	-0.32	-0.26	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
STAD	cis	rs7487075	0.504	rs7312682	ENSG00000257261.4	RP11-96H19.1	5	9.06e-07	0.00061	0.31	0.26	Itch intensity from mosquito bite;	chr12:46254215	chr12:46383679~46876159:+
STAD	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-5	9.06e-07	0.00061	-0.38	-0.26	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
STAD	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	5	9.07e-07	0.00061	0.27	0.26	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	5	9.07e-07	0.00061	0.27	0.26	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
STAD	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	5	9.08e-07	0.00061	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
STAD	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	5	9.08e-07	0.00061	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
STAD	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	5	9.08e-07	0.00061	0.35	0.26	Height;	chr6:109438349	chr6:109382795~109383666:+
STAD	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	5	9.08e-07	0.00061	0.35	0.26	Height;	chr6:109441033	chr6:109382795~109383666:+
STAD	cis	rs7247513	0.964	rs8100964	ENSG00000230310.1	CTD-2192J16.11	-5	9.08e-07	0.00061	-0.33	-0.26	Bipolar disorder;	chr19:12609817	chr19:12552597~12553644:+
STAD	cis	rs7829975	0.593	rs2921051	ENSG00000254340.1	RP11-10A14.3	5	9.08e-07	0.00061	0.31	0.26	Mood instability;	chr8:8462594	chr8:9141424~9145435:+
STAD	cis	rs1322639	1	rs9689079	ENSG00000261039.2	RP11-417E7.2	5	9.09e-07	0.000611	0.33	0.26	Pulse pressure;	chr6:169187053	chr6:169175304~169182740:-
STAD	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-5	9.1e-07	0.000611	-0.32	-0.26	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
STAD	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	5	9.1e-07	0.000611	0.37	0.26	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
STAD	cis	rs875971	0.893	rs62465470	ENSG00000236529.1	RP13-254B10.1	-5	9.1e-07	0.000611	-0.27	-0.26	Aortic root size;	chr7:66136231	chr7:65840212~65840596:+
STAD	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	5	9.1e-07	0.000612	0.33	0.26	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
STAD	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	5	9.1e-07	0.000612	0.32	0.26	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
STAD	cis	rs7115242	0.844	rs645258	ENSG00000280143.1	AP000892.6	5	9.11e-07	0.000612	0.33	0.26	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117204967~117210292:+
STAD	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-5	9.11e-07	0.000612	-0.27	-0.26	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
STAD	cis	rs1799949	1	rs4793229	ENSG00000279602.1	CTD-3014M21.1	-5	9.11e-07	0.000612	-0.33	-0.26	Menopause (age at onset);	chr17:43340966	chr17:43360041~43361361:-
STAD	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-5	9.11e-07	0.000612	-0.26	-0.26	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
STAD	cis	rs1799949	0.965	rs11656945	ENSG00000279602.1	CTD-3014M21.1	5	9.12e-07	0.000613	0.33	0.26	Menopause (age at onset);	chr17:43178248	chr17:43360041~43361361:-
STAD	cis	rs7031325	0.819	rs10758801	ENSG00000229611.1	RP11-390F4.10	5	9.12e-07	0.000613	0.27	0.26	Systemic lupus erythematosus;	chr9:6657192	chr9:6704471~6707780:+
STAD	cis	rs875971	0.862	rs10250544	ENSG00000236529.1	RP13-254B10.1	-5	9.13e-07	0.000613	-0.27	-0.26	Aortic root size;	chr7:66301574	chr7:65840212~65840596:+
STAD	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-5	9.14e-07	0.000614	-0.42	-0.26	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
STAD	cis	rs1681630	0.545	rs12790666	ENSG00000280615.1	Y_RNA	-5	9.15e-07	0.000614	-0.27	-0.26	Height;	chr11:47961925	chr11:47614898~47614994:-
STAD	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	5	9.15e-07	0.000615	0.32	0.26	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
STAD	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-5	9.15e-07	0.000615	-0.41	-0.26	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
STAD	cis	rs516805	0.631	rs2606647	ENSG00000279453.1	RP3-425C14.4	-5	9.15e-07	0.000615	-0.36	-0.26	Lymphocyte counts;	chr6:122118967	chr6:122436789~122439223:-
STAD	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-5	9.16e-07	0.000615	-0.33	-0.26	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
STAD	cis	rs1707322	0.717	rs1972410	ENSG00000225447.1	RPS15AP10	5	9.17e-07	0.000616	0.21	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45645816~45646197:-
STAD	cis	rs7829975	0.606	rs11776838	ENSG00000254340.1	RP11-10A14.3	-5	9.17e-07	0.000616	-0.31	-0.26	Mood instability;	chr8:8937291	chr8:9141424~9145435:+
STAD	cis	rs7487075	0.558	rs3847985	ENSG00000257261.4	RP11-96H19.1	5	9.17e-07	0.000616	0.31	0.26	Itch intensity from mosquito bite;	chr12:46261504	chr12:46383679~46876159:+
STAD	cis	rs8040855	0.597	rs994989	ENSG00000229212.6	RP11-561C5.4	5	9.17e-07	0.000616	0.38	0.26	Bulimia nervosa;	chr15:85117485	chr15:85205440~85234795:-
STAD	cis	rs875971	0.545	rs73142245	ENSG00000236529.1	RP13-254B10.1	5	9.17e-07	0.000616	0.31	0.26	Aortic root size;	chr7:66226662	chr7:65840212~65840596:+
STAD	cis	rs2688608	0.592	rs11000758	ENSG00000271816.1	BMS1P4	5	9.18e-07	0.000616	0.28	0.26	Inflammatory bowel disease;	chr10:73733852	chr10:73699151~73730487:-
STAD	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-5	9.19e-07	0.000617	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
STAD	cis	rs13113518	0.756	rs7658446	ENSG00000223305.1	RN7SKP30	5	9.21e-07	0.000618	0.29	0.26	Height;	chr4:55495262	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.776	rs13124436	ENSG00000223305.1	RN7SKP30	5	9.21e-07	0.000618	0.29	0.26	Height;	chr4:55502504	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.783	rs6843997	ENSG00000223305.1	RN7SKP30	5	9.21e-07	0.000618	0.29	0.26	Height;	chr4:55508982	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.783	rs12508367	ENSG00000223305.1	RN7SKP30	5	9.21e-07	0.000618	0.29	0.26	Height;	chr4:55509442	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs2272073	ENSG00000223305.1	RN7SKP30	5	9.21e-07	0.000618	0.29	0.26	Height;	chr4:55510177	chr4:55540502~55540835:-
STAD	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-5	9.21e-07	0.000618	-0.3	-0.26	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
STAD	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	5	9.21e-07	0.000619	0.34	0.26	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
STAD	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-5	9.22e-07	0.000619	-0.31	-0.26	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
STAD	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-5	9.23e-07	0.000619	-0.33	-0.26	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-5	9.23e-07	0.000619	-0.33	-0.26	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-5	9.23e-07	0.000619	-0.33	-0.26	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
STAD	cis	rs13113518	0.812	rs4865003	ENSG00000223305.1	RN7SKP30	5	9.23e-07	0.000619	0.29	0.26	Height;	chr4:55514802	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.756	rs12510275	ENSG00000223305.1	RN7SKP30	5	9.23e-07	0.000619	0.29	0.26	Height;	chr4:55516548	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs12510327	ENSG00000223305.1	RN7SKP30	5	9.23e-07	0.000619	0.29	0.26	Height;	chr4:55516744	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs11939580	ENSG00000223305.1	RN7SKP30	5	9.23e-07	0.000619	0.29	0.26	Height;	chr4:55517185	chr4:55540502~55540835:-
STAD	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	5	9.23e-07	0.00062	0.28	0.26	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
STAD	cis	rs4950322	0.57	rs72691090	ENSG00000278811.3	LINC00624	5	9.23e-07	0.00062	0.28	0.26	Protein quantitative trait loci;	chr1:147297884	chr1:147258885~147517875:-
STAD	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-5	9.24e-07	0.00062	-0.33	-0.26	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
STAD	cis	rs13113518	0.678	rs13149568	ENSG00000272969.1	RP11-528I4.2	5	9.24e-07	0.00062	0.33	0.26	Height;	chr4:55370412	chr4:55547112~55547889:+
STAD	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-5	9.24e-07	0.00062	-0.36	-0.26	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
STAD	cis	rs9549367	0.713	rs3024756	ENSG00000269125.1	RP11-98F14.11	-5	9.24e-07	0.00062	-0.32	-0.26	Platelet distribution width;	chr13:113168636	chr13:113165002~113165183:-
STAD	cis	rs4713118	0.955	rs9468206	ENSG00000280107.1	AL022393.9	-5	9.25e-07	0.000621	-0.35	-0.26	Parkinson's disease;	chr6:27722674	chr6:28170845~28172521:+
STAD	cis	rs35955747	0.601	rs5749302	ENSG00000236132.1	CTA-440B3.1	-5	9.28e-07	0.000622	-0.29	-0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31554632	chr22:31816379~31817491:-
STAD	cis	rs9463078	0.585	rs6901786	ENSG00000219384.1	RP11-491H9.3	5	9.28e-07	0.000623	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45218436	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs6899763	ENSG00000219384.1	RP11-491H9.3	5	9.28e-07	0.000623	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45221614	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs6919847	ENSG00000219384.1	RP11-491H9.3	5	9.28e-07	0.000623	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45221643	chr6:45158870~45159511:+
STAD	cis	rs7665090	0.87	rs228616	ENSG00000246560.2	RP11-10L12.4	-5	9.28e-07	0.000623	-0.31	-0.26	Primary biliary cholangitis;	chr4:102658534	chr4:102828055~102844075:+
STAD	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-5	9.29e-07	0.000623	-0.33	-0.26	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
STAD	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-5	9.29e-07	0.000623	-0.42	-0.26	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
STAD	cis	rs11169552	0.51	rs11169532	ENSG00000200183.1	RNU6-238P	-5	9.29e-07	0.000623	-0.25	-0.26	Colorectal cancer;	chr12:50726152	chr12:50656973~50657078:+
STAD	cis	rs4568518	0.535	rs10950697	ENSG00000279048.1	RP11-511H23.2	5	9.29e-07	0.000623	0.25	0.26	Measles;	chr7:18018695	chr7:17940503~17942922:+
STAD	cis	rs9463078	0.605	rs1578676	ENSG00000219384.1	RP11-491H9.3	-5	9.29e-07	0.000623	-0.24	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44939124	chr6:45158870~45159511:+
STAD	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	5	9.32e-07	0.000625	0.43	0.26	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-5	9.32e-07	0.000625	-0.31	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
STAD	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-5	9.33e-07	0.000625	-0.3	-0.26	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
STAD	cis	rs34787248	1	rs34787248	ENSG00000220721.1	OR1F12	5	9.33e-07	0.000625	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28073316~28074233:+
STAD	cis	rs1056107	0.931	rs6477904	ENSG00000225513.1	RP11-165N19.2	-5	9.33e-07	0.000626	-0.3	-0.26	Colorectal cancer;	chr9:112261254	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.931	rs6477905	ENSG00000225513.1	RP11-165N19.2	-5	9.33e-07	0.000626	-0.3	-0.26	Colorectal cancer;	chr9:112261381	chr9:112173522~112173971:-
STAD	cis	rs875971	0.571	rs78668714	ENSG00000236529.1	RP13-254B10.1	5	9.34e-07	0.000626	0.31	0.26	Aortic root size;	chr7:66474464	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs73150604	ENSG00000236529.1	RP13-254B10.1	5	9.34e-07	0.000626	0.31	0.26	Aortic root size;	chr7:66480545	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs7810213	ENSG00000236529.1	RP13-254B10.1	5	9.34e-07	0.000626	0.31	0.26	Aortic root size;	chr7:66481592	chr7:65840212~65840596:+
STAD	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	5	9.34e-07	0.000626	0.33	0.26	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
STAD	cis	rs875971	0.862	rs11984115	ENSG00000236529.1	RP13-254B10.1	-5	9.34e-07	0.000626	-0.27	-0.26	Aortic root size;	chr7:66308872	chr7:65840212~65840596:+
STAD	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	5	9.35e-07	0.000627	0.29	0.26	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
STAD	cis	rs17592366	0.517	rs7156153	ENSG00000251726.1	RNU7-41P	-5	9.35e-07	0.000627	-0.23	-0.26	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34838868	chr14:34845300~34845360:-
STAD	cis	rs2688608	0.592	rs11000760	ENSG00000271816.1	BMS1P4	4.99	9.35e-07	0.000627	0.28	0.26	Inflammatory bowel disease;	chr10:73733976	chr10:73699151~73730487:-
STAD	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-4.99	9.37e-07	0.000628	-0.29	-0.26	QT interval;	chr12:29349303	chr12:29280418~29317848:-
STAD	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-4.99	9.38e-07	0.000629	-0.31	-0.26	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
STAD	cis	rs6714710	0.603	rs6746768	ENSG00000235833.1	AC159540.14	-4.99	9.39e-07	0.000629	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97850184	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs6757357	ENSG00000235833.1	AC159540.14	-4.99	9.39e-07	0.000629	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97875287	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.58	rs55886305	ENSG00000235833.1	AC159540.14	-4.99	9.39e-07	0.000629	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97879198	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs13023980	ENSG00000235833.1	AC159540.14	-4.99	9.39e-07	0.000629	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97886524	chr2:97523949~97524976:-
STAD	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	4.99	9.39e-07	0.000629	0.32	0.26	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
STAD	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	4.99	9.39e-07	0.000629	0.41	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
STAD	cis	rs6714710	0.603	rs35505530	ENSG00000235833.1	AC159540.14	-4.99	9.4e-07	0.00063	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97890447	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.627	rs6748124	ENSG00000235833.1	AC159540.14	-4.99	9.4e-07	0.00063	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97902551	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs58546246	ENSG00000235833.1	AC159540.14	-4.99	9.4e-07	0.00063	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97905360	chr2:97523949~97524976:-
STAD	cis	rs12744310	0.887	rs12048805	ENSG00000235358.1	RP11-399E6.1	4.99	9.4e-07	0.00063	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348604	chr1:41242373~41284861:+
STAD	cis	rs12744310	0.887	rs12022655	ENSG00000235358.1	RP11-399E6.1	4.99	9.4e-07	0.00063	0.32	0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41350647	chr1:41242373~41284861:+
STAD	cis	rs1150668	0.835	rs1233696	ENSG00000220721.1	OR1F12	4.99	9.41e-07	0.00063	0.26	0.26	Pubertal anthropometrics;	chr6:28175232	chr6:28073316~28074233:+
STAD	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-4.99	9.41e-07	0.00063	-0.3	-0.26	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
STAD	cis	rs728616	0.681	rs11815284	ENSG00000225484.5	NUTM2B-AS1	-4.99	9.42e-07	0.000631	-0.47	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80263386	chr10:79663088~79826594:-
STAD	cis	rs4308124	0.708	rs6747657	ENSG00000230499.1	AC108463.1	-4.99	9.42e-07	0.000631	-0.36	-0.26	Vitiligo;	chr2:111245586	chr2:111195963~111206494:+
STAD	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	4.99	9.43e-07	0.000631	0.26	0.26	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
STAD	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-4.99	9.43e-07	0.000631	-0.31	-0.26	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
STAD	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-4.99	9.43e-07	0.000631	-0.31	-0.26	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
STAD	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-4.99	9.43e-07	0.000631	-0.33	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
STAD	cis	rs4950322	0.57	rs4950315	ENSG00000278811.3	LINC00624	-4.99	9.44e-07	0.000632	-0.28	-0.26	Protein quantitative trait loci;	chr1:147264433	chr1:147258885~147517875:-
STAD	cis	rs2688608	0.592	rs10762563	ENSG00000271816.1	BMS1P4	4.99	9.45e-07	0.000632	0.28	0.26	Inflammatory bowel disease;	chr10:73765044	chr10:73699151~73730487:-
STAD	cis	rs2688608	0.592	rs10824032	ENSG00000271816.1	BMS1P4	4.99	9.45e-07	0.000632	0.28	0.26	Inflammatory bowel disease;	chr10:73768372	chr10:73699151~73730487:-
STAD	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-4.99	9.45e-07	0.000633	-0.29	-0.26	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
STAD	cis	rs1862618	0.671	rs2591970	ENSG00000271828.1	CTD-2310F14.1	-4.99	9.45e-07	0.000633	-0.32	-0.26	Initial pursuit acceleration;	chr5:56936768	chr5:56927874~56929573:+
STAD	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-4.99	9.46e-07	0.000633	-0.33	-0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
STAD	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	4.99	9.46e-07	0.000633	0.43	0.26	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
STAD	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-4.99	9.46e-07	0.000633	-0.3	-0.26	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
STAD	cis	rs7078219	0.505	rs7077040	ENSG00000228778.1	RP11-129J12.1	-4.99	9.47e-07	0.000633	-0.3	-0.26	Dental caries;	chr10:99521257	chr10:99527081~99528261:+
STAD	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-4.99	9.47e-07	0.000634	-0.42	-0.26	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
STAD	cis	rs4568518	0.535	rs4236293	ENSG00000279048.1	RP11-511H23.2	4.99	9.48e-07	0.000634	0.24	0.26	Measles;	chr7:18022819	chr7:17940503~17942922:+
STAD	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	4.99	9.48e-07	0.000634	0.29	0.26	QT interval;	chr12:29379056	chr12:29280418~29317848:-
STAD	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	4.99	9.48e-07	0.000634	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
STAD	cis	rs6432852	0.516	rs12477613	ENSG00000229195.1	AC009495.4	4.99	9.49e-07	0.000635	0.29	0.26	Diabetic kidney disease;	chr2:165860674	chr2:165794857~165846091:-
STAD	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-4.99	9.49e-07	0.000635	-0.32	-0.26	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
STAD	cis	rs7487075	0.619	rs9971879	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46412990	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs4768710	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46414321	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.578	rs1492895	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46414972	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.578	rs2897951	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46415423	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.567	rs4768712	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46417738	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.578	rs10880967	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46418240	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.578	rs4768713	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46420264	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.606	rs4768714	ENSG00000257261.4	RP11-96H19.1	4.99	9.5e-07	0.000635	0.32	0.26	Itch intensity from mosquito bite;	chr12:46420462	chr12:46383679~46876159:+
STAD	cis	rs75426604	0.527	rs17103240	ENSG00000241052.1	RP11-173D9.1	-4.99	9.5e-07	0.000635	-0.3	-0.26	Eotaxin levels;	chr14:35362630	chr14:35144021~35144480:-
STAD	cis	rs1056107	0.898	rs7037927	ENSG00000225513.1	RP11-165N19.2	-4.99	9.5e-07	0.000635	-0.3	-0.26	Colorectal cancer;	chr9:112205143	chr9:112173522~112173971:-
STAD	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	4.99	9.52e-07	0.000636	0.28	0.26	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
STAD	cis	rs1799949	1	rs4793197	ENSG00000236383.6	LINC00854	-4.99	9.52e-07	0.000636	-0.21	-0.26	Menopause (age at onset);	chr17:43079885	chr17:43216941~43305976:-
STAD	cis	rs1345301	0.905	rs2310243	ENSG00000234389.1	AC007278.3	-4.99	9.54e-07	0.000638	-0.26	-0.26	Waist circumference;	chr2:102261100	chr2:102438713~102440475:+
STAD	cis	rs1345301	1	rs13405355	ENSG00000234389.1	AC007278.3	-4.99	9.54e-07	0.000638	-0.26	-0.26	Waist circumference;	chr2:102261746	chr2:102438713~102440475:+
STAD	cis	rs10510102	0.808	rs11200296	ENSG00000226864.1	ATE1-AS1	4.99	9.55e-07	0.000638	0.46	0.26	Breast cancer;	chr10:121971956	chr10:121928312~121951965:+
STAD	cis	rs1799949	1	rs4793236	ENSG00000267681.1	CTD-3199J23.6	-4.99	9.55e-07	0.000638	-0.3	-0.26	Menopause (age at onset);	chr17:43359072	chr17:43144956~43145255:+
STAD	cis	rs7078219	0.543	rs10786557	ENSG00000228778.1	RP11-129J12.1	-4.99	9.55e-07	0.000638	-0.3	-0.26	Dental caries;	chr10:99523571	chr10:99527081~99528261:+
STAD	cis	rs875971	0.545	rs4441996	ENSG00000236529.1	RP13-254B10.1	-4.99	9.57e-07	0.00064	-0.31	-0.26	Aortic root size;	chr7:66123233	chr7:65840212~65840596:+
STAD	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	4.99	9.57e-07	0.00064	0.35	0.26	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
STAD	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	4.99	9.58e-07	0.00064	0.44	0.26	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
STAD	cis	rs12699921	0.632	rs2691625	ENSG00000279048.1	RP11-511H23.2	-4.99	9.58e-07	0.00064	-0.24	-0.26	Fibrinogen levels;	chr7:17784000	chr7:17940503~17942922:+
STAD	cis	rs2221894	0.616	rs11776360	ENSG00000273710.1	Metazoa_SRP	-4.99	9.59e-07	0.000641	-0.27	-0.26	Obesity-related traits;	chr8:29096632	chr8:28915579~28915864:-
STAD	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-4.99	9.59e-07	0.000641	-0.27	-0.26	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
STAD	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	4.99	9.59e-07	0.000641	0.32	0.26	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
STAD	cis	rs2337406	0.539	rs2583290	ENSG00000211972.2	IGHV3-66	-4.99	9.6e-07	0.000641	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106650277	chr14:106675017~106675544:-
STAD	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-4.99	9.6e-07	0.000641	-0.36	-0.26	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
STAD	cis	rs6782228	1	rs7429360	ENSG00000277250.1	Metazoa_SRP	4.99	9.61e-07	0.000642	0.32	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128673681~128674021:-
STAD	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	4.99	9.61e-07	0.000642	0.37	0.26	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
STAD	cis	rs1345301	1	rs1345301	ENSG00000234389.1	AC007278.3	-4.99	9.61e-07	0.000642	-0.26	-0.26	Waist circumference;	chr2:102259127	chr2:102438713~102440475:+
STAD	cis	rs1345301	1	rs11686567	ENSG00000234389.1	AC007278.3	-4.99	9.61e-07	0.000642	-0.26	-0.26	Waist circumference;	chr2:102260149	chr2:102438713~102440475:+
STAD	cis	rs1345301	0.935	rs11691721	ENSG00000234389.1	AC007278.3	-4.99	9.61e-07	0.000642	-0.26	-0.26	Waist circumference;	chr2:102260219	chr2:102438713~102440475:+
STAD	cis	rs10466239	0.73	rs2245413	ENSG00000230555.2	RP11-517P14.2	-4.99	9.62e-07	0.000642	-0.34	-0.26	Telomere length;	chr10:43355120	chr10:43420738~43422100:+
STAD	cis	rs7429990	0.965	rs9846062	ENSG00000224895.1	VPS26BP1	-4.99	9.63e-07	0.000643	-0.26	-0.26	Educational attainment (years of education);	chr3:47957476	chr3:47960327~47961081:-
STAD	cis	rs6095360	0.7	rs36098998	ENSG00000222365.1	SNORD12B	-4.99	9.64e-07	0.000644	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49071572	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs8118101	ENSG00000222365.1	SNORD12B	-4.99	9.64e-07	0.000644	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49073301	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs7271812	ENSG00000222365.1	SNORD12B	-4.99	9.64e-07	0.000644	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49076496	chr20:49280319~49280409:+
STAD	cis	rs1799949	1	rs8176120	ENSG00000236383.6	LINC00854	-4.99	9.65e-07	0.000644	-0.21	-0.26	Menopause (age at onset);	chr17:43109216	chr17:43216941~43305976:-
STAD	cis	rs747650	0.504	rs7950753	ENSG00000271350.1	CTD-2384B9.1	-4.99	9.65e-07	0.000644	-0.34	-0.26	Acne (severe);	chr11:47050346	chr11:47041027~47041945:-
STAD	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	4.99	9.66e-07	0.000644	0.32	0.26	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
STAD	cis	rs35934224	0.831	rs8141610	ENSG00000232926.1	AC000078.5	-4.99	9.67e-07	0.000645	-0.36	-0.26	Glaucoma (primary open-angle);	chr22:19882624	chr22:19887289~19887970:+
STAD	cis	rs516805	0.562	rs2816156	ENSG00000279453.1	RP3-425C14.4	-4.99	9.68e-07	0.000646	-0.36	-0.26	Lymphocyte counts;	chr6:122124569	chr6:122436789~122439223:-
STAD	cis	rs2933343	0.679	rs789254	ENSG00000261159.1	RP11-723O4.9	4.99	9.69e-07	0.000646	0.32	0.26	IgG glycosylation;	chr3:128855750	chr3:128859716~128860526:-
STAD	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	4.99	9.69e-07	0.000646	0.45	0.26	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
STAD	cis	rs3736858	0.8	rs9544059	ENSG00000261105.4	LMO7-AS1	-4.99	9.69e-07	0.000647	-0.45	-0.26	Interleukin-9 levels;	chr13:75873062	chr13:75604700~75635994:-
STAD	cis	rs3736858	0.8	rs2165774	ENSG00000261105.4	LMO7-AS1	-4.99	9.69e-07	0.000647	-0.45	-0.26	Interleukin-9 levels;	chr13:75873096	chr13:75604700~75635994:-
STAD	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-4.99	9.69e-07	0.000647	-0.33	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
STAD	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-4.99	9.69e-07	0.000647	-0.33	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
STAD	cis	rs3758911	0.861	rs10890710	ENSG00000261098.1	RP11-819C21.1	-4.99	9.69e-07	0.000647	-0.23	-0.26	Coronary artery disease;	chr11:107317423	chr11:107312132~107316271:-
STAD	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-4.99	9.71e-07	0.000648	-0.28	-0.26	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
STAD	cis	rs858239	0.738	rs7807879	ENSG00000226816.2	AC005082.12	4.99	9.71e-07	0.000648	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23206013~23208045:+
STAD	cis	rs6142102	0.812	rs761238	ENSG00000275784.1	RP5-1125A11.6	4.99	9.72e-07	0.000648	0.26	0.26	Skin pigmentation;	chr20:33932182	chr20:33989480~33991818:-
STAD	cis	rs7429990	0.965	rs2166770	ENSG00000224895.1	VPS26BP1	-4.99	9.72e-07	0.000649	-0.26	-0.26	Educational attainment (years of education);	chr3:47964183	chr3:47960327~47961081:-
STAD	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	4.99	9.73e-07	0.000649	0.24	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
STAD	cis	rs7916697	0.52	rs12246624	ENSG00000233590.1	RP11-153K11.3	-4.99	9.73e-07	0.000649	-0.31	-0.26	Optic disc area;	chr10:68276805	chr10:68233251~68242379:-
STAD	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-4.99	9.73e-07	0.000649	-0.31	-0.26	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
STAD	cis	rs10466239	0.73	rs12221341	ENSG00000230555.2	RP11-517P14.2	4.99	9.73e-07	0.000649	0.34	0.26	Telomere length;	chr10:43361882	chr10:43420738~43422100:+
STAD	cis	rs516805	0.63	rs2606606	ENSG00000279453.1	RP3-425C14.4	-4.99	9.73e-07	0.000649	-0.37	-0.26	Lymphocyte counts;	chr6:122201126	chr6:122436789~122439223:-
STAD	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	4.99	9.73e-07	0.000649	0.29	0.26	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
STAD	cis	rs8097348	0.817	rs11080879	ENSG00000266602.1	RP11-476K15.1	-4.99	9.74e-07	0.000649	-0.3	-0.26	Exercise (leisure time);	chr18:1631312	chr18:1509183~1647097:+
STAD	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	4.99	9.74e-07	0.00065	0.48	0.26	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
STAD	cis	rs8098244	0.603	rs1711455	ENSG00000267301.1	RPL23AP77	-4.99	9.74e-07	0.00065	-0.3	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23695207	chr18:23709825~23710287:-
STAD	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	4.99	9.75e-07	0.00065	0.32	0.26	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
STAD	cis	rs10510102	1	rs10886994	ENSG00000226864.1	ATE1-AS1	4.99	9.75e-07	0.00065	0.4	0.26	Breast cancer;	chr10:121841075	chr10:121928312~121951965:+
STAD	cis	rs6714710	0.603	rs13020776	ENSG00000235833.1	AC159540.14	-4.99	9.76e-07	0.000651	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786290	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs34502870	ENSG00000235833.1	AC159540.14	-4.99	9.76e-07	0.000651	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789466	chr2:97523949~97524976:-
STAD	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-4.99	9.76e-07	0.000651	-0.27	-0.26	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
STAD	cis	rs858239	0.932	rs1728320	ENSG00000230042.1	AK3P3	-4.99	9.77e-07	0.000651	-0.27	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23129178~23129841:+
STAD	cis	rs4308124	0.708	rs10179596	ENSG00000230499.1	AC108463.1	-4.99	9.77e-07	0.000652	-0.37	-0.26	Vitiligo;	chr2:111212803	chr2:111195963~111206494:+
STAD	cis	rs4308124	0.708	rs6727313	ENSG00000230499.1	AC108463.1	-4.99	9.77e-07	0.000652	-0.37	-0.26	Vitiligo;	chr2:111213963	chr2:111195963~111206494:+
STAD	cis	rs7247513	0.964	rs8105902	ENSG00000230310.1	CTD-2192J16.11	-4.99	9.78e-07	0.000652	-0.33	-0.26	Bipolar disorder;	chr19:12607537	chr19:12552597~12553644:+
STAD	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-4.99	9.79e-07	0.000652	-0.27	-0.26	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-4.99	9.79e-07	0.000652	-0.27	-0.26	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
STAD	cis	rs8097348	0.67	rs79366550	ENSG00000266602.1	RP11-476K15.1	-4.99	9.8e-07	0.000653	-0.3	-0.26	Exercise (leisure time);	chr18:1629688	chr18:1509183~1647097:+
STAD	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-4.99	9.8e-07	0.000653	-0.31	-0.26	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
STAD	cis	rs4761702	0.527	rs11106988	ENSG00000257252.4	RP11-486A14.2	-4.99	9.8e-07	0.000653	-0.28	-0.26	Immature fraction of reticulocytes;	chr12:93340674	chr12:93317135~93377736:-
STAD	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-4.99	9.8e-07	0.000653	-0.31	-0.26	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-4.99	9.8e-07	0.000653	-0.31	-0.26	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-4.99	9.8e-07	0.000653	-0.31	-0.26	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-4.99	9.8e-07	0.000653	-0.31	-0.26	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-4.99	9.8e-07	0.000653	-0.31	-0.26	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
STAD	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	4.99	9.81e-07	0.000654	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
STAD	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-4.99	9.81e-07	0.000654	-0.37	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-4.99	9.81e-07	0.000654	-0.37	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
STAD	cis	rs4589258	0.603	rs10830568	ENSG00000280367.1	RP11-121L10.2	4.98	9.83e-07	0.000655	0.26	0.26	Intelligence (multi-trait analysis);	chr11:90752129	chr11:90223153~90226538:+
STAD	cis	rs6782228	0.876	rs34198449	ENSG00000277250.1	Metazoa_SRP	4.98	9.84e-07	0.000655	0.32	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128673681~128674021:-
STAD	cis	rs1056107	0.931	rs7852473	ENSG00000225513.1	RP11-165N19.2	-4.98	9.84e-07	0.000656	-0.3	-0.26	Colorectal cancer;	chr9:112245751	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs11542205	ENSG00000225513.1	RP11-165N19.2	-4.98	9.85e-07	0.000656	-0.3	-0.26	Colorectal cancer;	chr9:112221986	chr9:112173522~112173971:-
STAD	cis	rs7829975	0.774	rs13259216	ENSG00000254340.1	RP11-10A14.3	4.98	9.85e-07	0.000656	0.3	0.26	Mood instability;	chr8:8816091	chr8:9141424~9145435:+
STAD	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-4.98	9.85e-07	0.000656	-0.3	-0.26	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-4.98	9.85e-07	0.000656	-0.3	-0.26	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-4.98	9.86e-07	0.000657	-0.3	-0.26	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
STAD	cis	rs8067354	0.645	rs2173120	ENSG00000266701.1	AC005702.4	4.98	9.87e-07	0.000657	0.36	0.26	Hemoglobin concentration;	chr17:59815279	chr17:60042546~60042627:-
STAD	cis	rs3806843	0.762	rs3756337	ENSG00000202111.1	VTRNA1-2	-4.98	9.87e-07	0.000657	-0.26	-0.26	Depressive symptoms (multi-trait analysis);	chr5:140806853	chr5:140718925~140719013:+
STAD	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-4.98	9.87e-07	0.000657	-0.3	-0.26	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
STAD	cis	rs507080	0.769	rs11603616	ENSG00000278376.1	RP11-158I9.8	-4.98	9.88e-07	0.000658	-0.27	-0.26	Serum metabolite levels;	chr11:118625350	chr11:118791254~118793137:+
STAD	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-4.98	9.88e-07	0.000658	-0.36	-0.26	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
STAD	cis	rs62432291	0.681	rs294913	ENSG00000235086.1	FNDC1-IT1	-4.98	9.89e-07	0.000658	-0.41	-0.26	Joint mobility (Beighton score);	chr6:159246195	chr6:159240786~159243329:+
STAD	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-4.98	9.9e-07	0.000659	-0.3	-0.26	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
STAD	cis	rs9463078	0.585	rs1748242	ENSG00000219384.1	RP11-491H9.3	4.98	9.91e-07	0.000659	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45195613	chr6:45158870~45159511:+
STAD	cis	rs875971	0.545	rs67397473	ENSG00000236529.1	RP13-254B10.1	4.98	9.91e-07	0.00066	0.3	0.26	Aortic root size;	chr7:66168318	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs10950027	ENSG00000236529.1	RP13-254B10.1	4.98	9.91e-07	0.00066	0.3	0.26	Aortic root size;	chr7:66169164	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs73376401	ENSG00000236529.1	RP13-254B10.1	4.98	9.91e-07	0.00066	0.3	0.26	Aortic root size;	chr7:66174841	chr7:65840212~65840596:+
STAD	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-4.98	9.91e-07	0.00066	-0.29	-0.26	QT interval;	chr12:29357436	chr12:29280418~29317848:-
STAD	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	4.98	9.92e-07	0.00066	0.43	0.26	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
STAD	cis	rs10849893	0.576	rs7134248	ENSG00000258435.1	RP11-711D18.2	-4.98	9.92e-07	0.00066	-0.28	-0.26	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121459249	chr12:121391962~121399859:+
STAD	cis	rs7829975	0.51	rs2921073	ENSG00000253893.2	FAM85B	-4.98	9.92e-07	0.00066	-0.32	-0.26	Mood instability;	chr8:8450133	chr8:8167819~8226614:-
STAD	cis	rs7829975	0.51	rs2979160	ENSG00000253893.2	FAM85B	-4.98	9.92e-07	0.00066	-0.32	-0.26	Mood instability;	chr8:8450156	chr8:8167819~8226614:-
STAD	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-4.98	9.95e-07	0.000662	-0.29	-0.26	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
STAD	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	4.98	9.97e-07	0.000663	0.24	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
STAD	cis	rs7487075	0.619	rs10880968	ENSG00000257261.4	RP11-96H19.1	4.98	9.98e-07	0.000664	0.32	0.26	Itch intensity from mosquito bite;	chr12:46429177	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs10785627	ENSG00000257261.4	RP11-96H19.1	4.98	9.98e-07	0.000664	0.32	0.26	Itch intensity from mosquito bite;	chr12:46430446	chr12:46383679~46876159:+
STAD	cis	rs12699921	0.599	rs6955984	ENSG00000279048.1	RP11-511H23.2	4.98	9.98e-07	0.000664	0.24	0.26	Fibrinogen levels;	chr7:17938589	chr7:17940503~17942922:+
STAD	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	4.98	9.99e-07	0.000665	0.28	0.26	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	4.98	9.99e-07	0.000665	0.28	0.26	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
STAD	cis	rs853679	0.76	rs2299029	ENSG00000220721.1	OR1F12	4.98	1e-06	0.000665	0.3	0.26	Depression;	chr6:28231053	chr6:28073316~28074233:+
STAD	cis	rs9291683	0.527	rs3822241	ENSG00000250613.1	RP11-136I13.1	4.98	1e-06	0.000665	0.26	0.26	Bone mineral density;	chr4:10093307	chr4:10410996~10411644:+
STAD	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-4.98	1e-06	0.000666	-0.34	-0.26	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
STAD	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	4.98	1e-06	0.000667	0.29	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
STAD	cis	rs9463078	0.605	rs13216116	ENSG00000219384.1	RP11-491H9.3	-4.98	1e-06	0.000667	-0.24	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44968944	chr6:45158870~45159511:+
STAD	cis	rs858239	0.73	rs858279	ENSG00000230042.1	AK3P3	-4.98	1e-06	0.000667	-0.27	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23129178~23129841:+
STAD	cis	rs3758911	0.964	rs11212158	ENSG00000261098.1	RP11-819C21.1	-4.98	1e-06	0.000668	-0.23	-0.26	Coronary artery disease;	chr11:107325745	chr11:107312132~107316271:-
STAD	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-4.98	1e-06	0.000668	-0.3	-0.26	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
STAD	cis	rs10129255	0.517	rs11625572	ENSG00000224373.3	IGHV4-59	4.98	1e-06	0.000668	0.21	0.26	Kawasaki disease;	chr14:106656426	chr14:106627249~106627825:-
STAD	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	4.98	1e-06	0.000668	0.33	0.26	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
STAD	cis	rs13113518	0.513	rs13147861	ENSG00000272969.1	RP11-528I4.2	4.98	1.01e-06	0.000669	0.34	0.26	Height;	chr4:55611014	chr4:55547112~55547889:+
STAD	cis	rs748404	0.915	rs35535692	ENSG00000249839.1	AC011330.5	-4.98	1.01e-06	0.000669	-0.46	-0.26	Lung cancer;	chr15:43252037	chr15:43663654~43684339:-
STAD	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-4.98	1.01e-06	0.000669	-0.42	-0.26	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
STAD	cis	rs1707322	0.686	rs2275085	ENSG00000281133.1	AL355480.3	4.98	1.01e-06	0.000669	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45580892~45580996:-
STAD	cis	rs3806843	1	rs10066278	ENSG00000202111.1	VTRNA1-2	-4.98	1.01e-06	0.000669	-0.26	-0.26	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr5:140718925~140719013:+
STAD	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	4.98	1.01e-06	0.00067	0.35	0.26	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
STAD	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-4.98	1.01e-06	0.00067	-0.31	-0.26	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-4.98	1.01e-06	0.00067	-0.31	-0.26	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-4.98	1.01e-06	0.00067	-0.31	-0.26	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
STAD	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	4.98	1.01e-06	0.000671	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
STAD	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	4.98	1.01e-06	0.000671	0.37	0.26	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
STAD	cis	rs2404602	0.536	rs11072599	ENSG00000259422.1	RP11-593F23.1	4.98	1.01e-06	0.000671	0.27	0.26	Blood metabolite levels;	chr15:76482167	chr15:76174891~76181486:-
STAD	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-4.98	1.01e-06	0.000671	-0.3	-0.26	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
STAD	cis	rs6584283	0.716	rs10786558	ENSG00000228778.1	RP11-129J12.1	-4.98	1.01e-06	0.000672	-0.29	-0.26	Ulcerative colitis;	chr10:99527853	chr10:99527081~99528261:+
STAD	cis	rs1799949	1	rs8077486	ENSG00000236383.6	LINC00854	-4.98	1.01e-06	0.000672	-0.2	-0.26	Menopause (age at onset);	chr17:43060788	chr17:43216941~43305976:-
STAD	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-4.98	1.01e-06	0.000672	-0.35	-0.26	Height;	chr20:49280020	chr20:49280319~49280409:+
STAD	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	4.98	1.01e-06	0.000672	0.38	0.26	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
STAD	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-4.98	1.01e-06	0.000673	-0.24	-0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
STAD	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-4.98	1.01e-06	0.000673	-0.28	-0.26	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
STAD	cis	rs747650	0.504	rs4752815	ENSG00000271350.1	CTD-2384B9.1	-4.98	1.01e-06	0.000673	-0.34	-0.26	Acne (severe);	chr11:46957147	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs10769225	ENSG00000271350.1	CTD-2384B9.1	-4.98	1.01e-06	0.000673	-0.34	-0.26	Acne (severe);	chr11:46960930	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs10769226	ENSG00000271350.1	CTD-2384B9.1	-4.98	1.01e-06	0.000673	-0.34	-0.26	Acne (severe);	chr11:46963252	chr11:47041027~47041945:-
STAD	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-4.98	1.01e-06	0.000673	-0.34	-0.26	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-4.98	1.01e-06	0.000673	-0.34	-0.26	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-4.98	1.01e-06	0.000673	-0.34	-0.26	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-4.98	1.01e-06	0.000673	-0.34	-0.26	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-4.98	1.01e-06	0.000673	-0.34	-0.26	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-4.98	1.01e-06	0.000673	-0.34	-0.26	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-4.98	1.01e-06	0.000673	-0.34	-0.26	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
STAD	cis	rs9467773	0.595	rs12525810	ENSG00000243307.2	POM121L6P	4.98	1.01e-06	0.000673	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26896952~26898777:+
STAD	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	4.98	1.01e-06	0.000673	0.28	0.26	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
STAD	cis	rs2281636	0.723	rs11190245	ENSG00000233690.1	EBAG9P1	4.98	1.01e-06	0.000673	0.29	0.26	Obesity-related traits;	chr10:99691502	chr10:99697407~99697949:-
STAD	cis	rs6584283	0.766	rs7911680	ENSG00000257582.4	LINC01475	-4.98	1.02e-06	0.000674	-0.3	-0.26	Ulcerative colitis;	chr10:99533711	chr10:99526350~99531177:-
STAD	cis	rs13113518	0.783	rs1586555	ENSG00000223305.1	RN7SKP30	4.98	1.02e-06	0.000674	0.3	0.26	Height;	chr4:55587104	chr4:55540502~55540835:-
STAD	cis	rs7078219	0.505	rs10883362	ENSG00000228778.1	RP11-129J12.1	-4.98	1.02e-06	0.000674	-0.29	-0.26	Dental caries;	chr10:99527227	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.523	rs10883366	ENSG00000228778.1	RP11-129J12.1	-4.98	1.02e-06	0.000674	-0.29	-0.26	Dental caries;	chr10:99528028	chr10:99527081~99528261:+
STAD	cis	rs6430585	0.528	rs75753154	ENSG00000231890.6	DARS-AS1	-4.98	1.02e-06	0.000674	-0.29	-0.26	Corneal structure;	chr2:135908141	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs7606267	ENSG00000231890.6	DARS-AS1	-4.98	1.02e-06	0.000674	-0.29	-0.26	Corneal structure;	chr2:135910553	chr2:135985176~136022593:+
STAD	cis	rs1707322	0.686	rs2991977	ENSG00000281133.1	AL355480.3	4.98	1.02e-06	0.000674	0.31	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.656	rs2991981	ENSG00000281133.1	AL355480.3	4.98	1.02e-06	0.000674	0.31	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45580892~45580996:-
STAD	cis	rs12439619	0.53	rs28883606	ENSG00000255769.6	GOLGA2P10	-4.98	1.02e-06	0.000674	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472993~82513950:-
STAD	cis	rs12439619	0.693	rs28665836	ENSG00000255769.6	GOLGA2P10	-4.98	1.02e-06	0.000674	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472993~82513950:-
STAD	cis	rs9860428	0.935	rs1114404	ENSG00000240057.4	RP11-572M11.4	-4.98	1.02e-06	0.000674	-0.23	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112844072	chr3:113019532~113183301:+
STAD	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-4.98	1.02e-06	0.000674	-0.27	-0.26	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
STAD	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-4.98	1.02e-06	0.000674	-0.29	-0.26	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
STAD	cis	rs4713118	0.955	rs9393848	ENSG00000280107.1	AL022393.9	-4.98	1.02e-06	0.000674	-0.34	-0.26	Parkinson's disease;	chr6:27720590	chr6:28170845~28172521:+
STAD	cis	rs3758911	0.796	rs10890719	ENSG00000261098.1	RP11-819C21.1	-4.98	1.02e-06	0.000675	-0.24	-0.26	Coronary artery disease;	chr11:107333357	chr11:107312132~107316271:-
STAD	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-4.98	1.02e-06	0.000675	-0.29	-0.26	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
STAD	cis	rs2833693	0.513	rs2833756	ENSG00000261610.1	AP000265.1	-4.98	1.02e-06	0.000675	-0.29	-0.26	Temperament;	chr21:32298033	chr21:32259804~32261585:-
STAD	cis	rs9860428	0.844	rs9288964	ENSG00000240057.4	RP11-572M11.4	-4.98	1.02e-06	0.000676	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112874676	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.808	rs10804506	ENSG00000240057.4	RP11-572M11.4	-4.98	1.02e-06	0.000676	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112875850	chr3:113019532~113183301:+
STAD	cis	rs8097348	0.779	rs4797933	ENSG00000266602.1	RP11-476K15.1	-4.98	1.02e-06	0.000676	-0.3	-0.26	Exercise (leisure time);	chr18:1638419	chr18:1509183~1647097:+
STAD	cis	rs2115630	0.936	rs6496318	ENSG00000225151.9	GOLGA2P7	4.98	1.02e-06	0.000676	0.29	0.26	P wave terminal force;	chr15:84671998	chr15:84199311~84230136:-
STAD	cis	rs2115630	0.902	rs8023276	ENSG00000225151.9	GOLGA2P7	4.98	1.02e-06	0.000676	0.29	0.26	P wave terminal force;	chr15:84676407	chr15:84199311~84230136:-
STAD	cis	rs9463078	0.585	rs12529946	ENSG00000219384.1	RP11-491H9.3	-4.98	1.02e-06	0.000676	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45287557	chr6:45158870~45159511:+
STAD	cis	rs6142102	0.961	rs4911408	ENSG00000275784.1	RP5-1125A11.6	-4.98	1.02e-06	0.000676	-0.27	-0.26	Skin pigmentation;	chr20:34112760	chr20:33989480~33991818:-
STAD	cis	rs2404602	0.716	rs7174953	ENSG00000259422.1	RP11-593F23.1	4.98	1.02e-06	0.000676	0.27	0.26	Blood metabolite levels;	chr15:76614506	chr15:76174891~76181486:-
STAD	cis	rs11098499	0.618	rs35265692	ENSG00000260091.1	RP11-33B1.4	4.98	1.02e-06	0.000677	0.26	0.26	Corneal astigmatism;	chr4:119403980	chr4:119409333~119410233:+
STAD	cis	rs10510102	0.872	rs11200277	ENSG00000226864.1	ATE1-AS1	4.98	1.02e-06	0.000677	0.41	0.26	Breast cancer;	chr10:121944295	chr10:121928312~121951965:+
STAD	cis	rs7119038	0.818	rs2155433	ENSG00000255422.1	AP002954.4	4.98	1.02e-06	0.000677	0.33	0.26	Sjögren's syndrome;	chr11:118742212	chr11:118704607~118750263:+
STAD	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	4.98	1.02e-06	0.000677	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
STAD	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	4.98	1.02e-06	0.000677	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
STAD	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	4.98	1.02e-06	0.000677	0.3	0.26	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
STAD	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	4.98	1.02e-06	0.000677	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
STAD	cis	rs9463078	0.605	rs9472407	ENSG00000219384.1	RP11-491H9.3	-4.98	1.02e-06	0.000678	-0.24	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44941063	chr6:45158870~45159511:+
STAD	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-4.98	1.02e-06	0.000678	-0.32	-0.26	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
STAD	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	4.98	1.02e-06	0.000678	0.29	0.26	QT interval;	chr12:29284120	chr12:29280418~29317848:-
STAD	cis	rs1056107	0.933	rs943621	ENSG00000225513.1	RP11-165N19.2	-4.98	1.02e-06	0.000679	-0.29	-0.26	Colorectal cancer;	chr9:112231510	chr9:112173522~112173971:-
STAD	cis	rs35934224	0.74	rs35142928	ENSG00000232926.1	AC000078.5	4.98	1.03e-06	0.00068	0.34	0.26	Glaucoma (primary open-angle);	chr22:19860228	chr22:19887289~19887970:+
STAD	cis	rs1799949	0.965	rs8176130	ENSG00000236383.6	LINC00854	-4.98	1.03e-06	0.00068	-0.21	-0.26	Menopause (age at onset);	chr17:43106026	chr17:43216941~43305976:-
STAD	cis	rs7487075	0.558	rs12580460	ENSG00000257261.4	RP11-96H19.1	4.98	1.03e-06	0.00068	0.31	0.26	Itch intensity from mosquito bite;	chr12:46255200	chr12:46383679~46876159:+
STAD	cis	rs721917	0.506	rs2758555	ENSG00000244733.5	RP11-506M13.3	-4.98	1.03e-06	0.000681	-0.31	-0.26	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79660891~79677996:+
STAD	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-4.98	1.03e-06	0.000681	-0.27	-0.26	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	4.98	1.03e-06	0.000681	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
STAD	cis	rs7829975	0.6	rs1719381	ENSG00000173295.6	FAM86B3P	-4.98	1.03e-06	0.000681	-0.29	-0.26	Mood instability;	chr8:8744834	chr8:8228595~8244865:+
STAD	cis	rs9400467	0.528	rs6568680	ENSG00000230177.1	RP5-1112D6.4	-4.98	1.03e-06	0.000682	-0.23	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111277932~111278742:+
STAD	cis	rs9463078	0.585	rs1797147	ENSG00000219384.1	RP11-491H9.3	4.98	1.03e-06	0.000682	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45194422	chr6:45158870~45159511:+
STAD	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	4.98	1.03e-06	0.000682	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
STAD	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-4.97	1.03e-06	0.000682	-0.28	-0.26	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
STAD	cis	rs748404	0.706	rs35975365	ENSG00000249839.1	AC011330.5	-4.97	1.03e-06	0.000683	-0.47	-0.26	Lung cancer;	chr15:43379347	chr15:43663654~43684339:-
STAD	cis	rs7487075	0.859	rs7960147	ENSG00000272369.1	RP11-446N19.1	4.97	1.03e-06	0.000683	0.33	0.26	Itch intensity from mosquito bite;	chr12:46357671	chr12:46537502~46652550:+
STAD	cis	rs2688608	0.592	rs7076585	ENSG00000271816.1	BMS1P4	4.97	1.03e-06	0.000684	0.29	0.26	Inflammatory bowel disease;	chr10:73743934	chr10:73699151~73730487:-
STAD	cis	rs875971	0.545	rs73142233	ENSG00000236529.1	RP13-254B10.1	4.97	1.03e-06	0.000684	0.31	0.26	Aortic root size;	chr7:66221293	chr7:65840212~65840596:+
STAD	cis	rs1056107	0.933	rs10981311	ENSG00000225513.1	RP11-165N19.2	-4.97	1.03e-06	0.000684	-0.29	-0.26	Colorectal cancer;	chr9:112203076	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.843	rs10981312	ENSG00000225513.1	RP11-165N19.2	-4.97	1.03e-06	0.000684	-0.29	-0.26	Colorectal cancer;	chr9:112203105	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs7021460	ENSG00000225513.1	RP11-165N19.2	-4.97	1.03e-06	0.000684	-0.29	-0.26	Colorectal cancer;	chr9:112205095	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs6477896	ENSG00000225513.1	RP11-165N19.2	-4.97	1.03e-06	0.000684	-0.29	-0.26	Colorectal cancer;	chr9:112205498	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs6477897	ENSG00000225513.1	RP11-165N19.2	-4.97	1.03e-06	0.000684	-0.29	-0.26	Colorectal cancer;	chr9:112205658	chr9:112173522~112173971:-
STAD	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	4.97	1.03e-06	0.000685	0.29	0.26	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
STAD	cis	rs10466239	0.667	rs10899792	ENSG00000230555.2	RP11-517P14.2	4.97	1.03e-06	0.000685	0.34	0.26	Telomere length;	chr10:43364722	chr10:43420738~43422100:+
STAD	cis	rs3758911	0.861	rs1388171	ENSG00000261098.1	RP11-819C21.1	-4.97	1.04e-06	0.000686	-0.24	-0.26	Coronary artery disease;	chr11:107272411	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs11212112	ENSG00000261098.1	RP11-819C21.1	-4.97	1.04e-06	0.000686	-0.24	-0.26	Coronary artery disease;	chr11:107272667	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs11212113	ENSG00000261098.1	RP11-819C21.1	-4.97	1.04e-06	0.000686	-0.24	-0.26	Coronary artery disease;	chr11:107272776	chr11:107312132~107316271:-
STAD	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	4.97	1.04e-06	0.000686	0.28	0.26	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
STAD	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	4.97	1.04e-06	0.000687	0.3	0.26	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
STAD	cis	rs7829975	0.774	rs35431455	ENSG00000254340.1	RP11-10A14.3	4.97	1.04e-06	0.000687	0.3	0.26	Mood instability;	chr8:8816226	chr8:9141424~9145435:+
STAD	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	4.97	1.04e-06	0.000687	0.39	0.26	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	4.97	1.04e-06	0.000687	0.39	0.26	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	4.97	1.04e-06	0.000687	0.39	0.26	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
STAD	cis	rs453301	0.686	rs4840389	ENSG00000254340.1	RP11-10A14.3	-4.97	1.04e-06	0.000687	-0.34	-0.26	Joint mobility (Beighton score);	chr8:9026993	chr8:9141424~9145435:+
STAD	cis	rs453301	0.658	rs13271797	ENSG00000254340.1	RP11-10A14.3	-4.97	1.04e-06	0.000687	-0.34	-0.26	Joint mobility (Beighton score);	chr8:9028444	chr8:9141424~9145435:+
STAD	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	4.97	1.04e-06	0.000688	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
STAD	cis	rs3758911	1	rs10749901	ENSG00000261098.1	RP11-819C21.1	-4.97	1.04e-06	0.000688	-0.23	-0.26	Coronary artery disease;	chr11:107324776	chr11:107312132~107316271:-
STAD	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	4.97	1.04e-06	0.000689	0.26	0.26	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
STAD	cis	rs611744	0.538	rs13257548	ENSG00000253754.1	RP11-35G22.1	-4.97	1.04e-06	0.000689	-0.23	-0.26	Dupuytren's disease;	chr8:108260956	chr8:108226200~108227544:+
STAD	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-4.97	1.04e-06	0.000689	-0.47	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
STAD	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-4.97	1.04e-06	0.000689	-0.47	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
STAD	cis	rs12701220	0.503	rs12531999	ENSG00000229043.2	AC091729.9	-4.97	1.04e-06	0.00069	-0.39	-0.26	Bronchopulmonary dysplasia;	chr7:1141965	chr7:1160374~1165267:+
STAD	cis	rs13113518	0.841	rs7699867	ENSG00000223305.1	RN7SKP30	4.97	1.04e-06	0.00069	0.29	0.26	Height;	chr4:55483718	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.783	rs11133389	ENSG00000223305.1	RN7SKP30	4.97	1.04e-06	0.00069	0.29	0.26	Height;	chr4:55486718	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs4865001	ENSG00000223305.1	RN7SKP30	4.97	1.04e-06	0.00069	0.29	0.26	Height;	chr4:55490176	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs4864543	ENSG00000223305.1	RN7SKP30	4.97	1.04e-06	0.00069	0.29	0.26	Height;	chr4:55490228	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs6825774	ENSG00000223305.1	RN7SKP30	4.97	1.04e-06	0.00069	0.29	0.26	Height;	chr4:55491150	chr4:55540502~55540835:-
STAD	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	4.97	1.04e-06	0.00069	0.33	0.26	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
STAD	cis	rs1964356	0.967	rs2953802	ENSG00000254340.1	RP11-10A14.3	4.97	1.04e-06	0.00069	0.31	0.26	Mean corpuscular volume;	chr8:8994371	chr8:9141424~9145435:+
STAD	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	4.97	1.04e-06	0.000691	0.29	0.26	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
STAD	cis	rs875971	0.862	rs1875057	ENSG00000236529.1	RP13-254B10.1	-4.97	1.04e-06	0.000691	-0.26	-0.26	Aortic root size;	chr7:66266868	chr7:65840212~65840596:+
STAD	cis	rs6714710	0.535	rs13006932	ENSG00000235833.1	AC159540.14	-4.97	1.05e-06	0.000692	-0.31	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97754235	chr2:97523949~97524976:-
STAD	cis	rs11676348	0.935	rs2230054	ENSG00000237281.1	CATIP-AS2	4.97	1.05e-06	0.000692	0.26	0.26	Ulcerative colitis;	chr2:218135587	chr2:218326889~218357966:-
STAD	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	4.97	1.05e-06	0.000692	0.33	0.26	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
STAD	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-4.97	1.05e-06	0.000692	-0.29	-0.26	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
STAD	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-4.97	1.05e-06	0.000692	-0.27	-0.26	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs319692	ENSG00000224895.1	VPS26BP1	-4.97	1.05e-06	0.000693	-0.25	-0.26	Educational attainment (years of education);	chr3:47882827	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.901	rs7433678	ENSG00000224895.1	VPS26BP1	4.97	1.05e-06	0.000694	0.26	0.26	Educational attainment (years of education);	chr3:47995588	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs2166772	ENSG00000224895.1	VPS26BP1	4.97	1.05e-06	0.000694	0.26	0.26	Educational attainment (years of education);	chr3:48006384	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs4392441	ENSG00000224895.1	VPS26BP1	4.97	1.05e-06	0.000694	0.26	0.26	Educational attainment (years of education);	chr3:48036211	chr3:47960327~47961081:-
STAD	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-4.97	1.05e-06	0.000695	-0.29	-0.26	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
STAD	cis	rs1322639	0.614	rs4708414	ENSG00000261039.2	RP11-417E7.2	-4.97	1.05e-06	0.000696	-0.29	-0.26	Pulse pressure;	chr6:169174049	chr6:169175304~169182740:-
STAD	cis	rs9307551	0.817	rs12511646	ENSG00000250334.4	LINC00989	-4.97	1.05e-06	0.000696	-0.31	-0.26	Refractive error;	chr4:79578700	chr4:79492416~79576460:+
STAD	cis	rs9860428	0.844	rs9858931	ENSG00000240057.4	RP11-572M11.4	4.97	1.05e-06	0.000696	0.25	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897933	chr3:113019532~113183301:+
STAD	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-4.97	1.05e-06	0.000696	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
STAD	cis	rs891378	1	rs10864178	ENSG00000274245.1	RP11-357P18.2	-4.97	1.06e-06	0.000697	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272333	chr1:207372559~207373252:+
STAD	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-4.97	1.06e-06	0.000697	-0.31	-0.26	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
STAD	cis	rs13113518	0.812	rs2048564	ENSG00000223305.1	RN7SKP30	4.97	1.06e-06	0.000698	0.29	0.26	Height;	chr4:55407965	chr4:55540502~55540835:-
STAD	cis	rs11098499	0.865	rs11722183	ENSG00000260091.1	RP11-33B1.4	4.97	1.06e-06	0.000698	0.25	0.26	Corneal astigmatism;	chr4:119359442	chr4:119409333~119410233:+
STAD	cis	rs6430585	0.583	rs7561565	ENSG00000231890.6	DARS-AS1	-4.97	1.06e-06	0.000698	-0.29	-0.26	Corneal structure;	chr2:135883217	chr2:135985176~136022593:+
STAD	cis	rs2446066	0.872	rs11614010	ENSG00000257379.1	RP11-793H13.8	4.97	1.06e-06	0.000699	0.43	0.26	Red blood cell count;	chr12:53426253	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.872	rs10876453	ENSG00000257379.1	RP11-793H13.8	4.97	1.06e-06	0.000699	0.43	0.26	Red blood cell count;	chr12:53426404	chr12:53441741~53467528:+
STAD	cis	rs7932354	0.528	rs7947878	ENSG00000271350.1	CTD-2384B9.1	-4.97	1.06e-06	0.000699	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:47006980	chr11:47041027~47041945:-
STAD	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-4.97	1.06e-06	0.000699	-0.41	-0.26	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
STAD	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-4.97	1.06e-06	0.000699	-0.46	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
STAD	cis	rs12682352	0.652	rs1567398	ENSG00000253981.4	ALG1L13P	-4.97	1.06e-06	0.000699	-0.3	-0.26	Neuroticism;	chr8:8869294	chr8:8236003~8244667:-
STAD	cis	rs6452524	0.935	rs3901654	ENSG00000243385.2	CTD-2110K23.1	4.97	1.06e-06	0.000699	0.27	0.26	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83201229~83202141:+
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000224205.1	AP000351.4	-4.97	1.06e-06	7e-04	-0.32	-0.26	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23987320~23991421:-
STAD	cis	rs6095360	0.69	rs35888516	ENSG00000222365.1	SNORD12B	-4.97	1.06e-06	7e-04	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49147738	chr20:49280319~49280409:+
STAD	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	4.97	1.06e-06	7e-04	0.35	0.26	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
STAD	cis	rs7829975	0.811	rs7011229	ENSG00000253981.4	ALG1L13P	-4.97	1.06e-06	7e-04	-0.32	-0.26	Mood instability;	chr8:8685814	chr8:8236003~8244667:-
STAD	cis	rs12699921	0.536	rs2177652	ENSG00000279048.1	RP11-511H23.2	-4.97	1.06e-06	7e-04	-0.23	-0.26	Fibrinogen levels;	chr7:17855310	chr7:17940503~17942922:+
STAD	cis	rs721917	0.506	rs2758556	ENSG00000244733.5	RP11-506M13.3	4.97	1.06e-06	0.000701	0.31	0.26	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79660891~79677996:+
STAD	cis	rs7580658	0.545	rs67996371	ENSG00000200250.1	RNU6-1147P	4.97	1.06e-06	0.000702	0.25	0.26	Protein C levels;	chr2:127195841	chr2:127316873~127316979:+
STAD	cis	rs11169552	0.51	rs11169537	ENSG00000200183.1	RNU6-238P	-4.97	1.06e-06	0.000702	-0.25	-0.26	Colorectal cancer;	chr12:50733009	chr12:50656973~50657078:+
STAD	cis	rs728616	0.867	rs2152548	ENSG00000225484.5	NUTM2B-AS1	-4.97	1.07e-06	0.000702	-0.55	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79663088~79826594:-
STAD	cis	rs8040855	0.576	rs62022528	ENSG00000229212.6	RP11-561C5.4	4.97	1.07e-06	0.000703	0.39	0.26	Bulimia nervosa;	chr15:84992030	chr15:85205440~85234795:-
STAD	cis	rs1723838	0.826	rs2037706	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73666418	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs4944026	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73694199	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.702	rs2366944	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73694534	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.702	rs7942515	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73694843	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.609	rs4944857	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73706243	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs4944860	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73716081	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs1404975	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73722089	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.702	rs2056649	ENSG00000255928.1	RP11-456I15.2	-4.97	1.07e-06	0.000703	-0.54	-0.26	Obesity-related traits;	chr11:73730296	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs6592528	ENSG00000255928.1	RP11-456I15.2	4.97	1.07e-06	0.000703	0.54	0.26	Obesity-related traits;	chr11:73666305	chr11:73722349~73722694:+
STAD	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
STAD	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
STAD	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
STAD	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
STAD	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
STAD	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
STAD	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
STAD	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
STAD	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-4.97	1.07e-06	0.000703	-0.35	-0.26	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
STAD	cis	rs4713118	0.824	rs742046	ENSG00000280107.1	AL022393.9	-4.97	1.07e-06	0.000705	-0.34	-0.26	Parkinson's disease;	chr6:27771475	chr6:28170845~28172521:+
STAD	cis	rs507080	0.769	rs571001	ENSG00000278376.1	RP11-158I9.8	-4.97	1.07e-06	0.000705	-0.27	-0.26	Serum metabolite levels;	chr11:118629457	chr11:118791254~118793137:+
STAD	cis	rs507080	0.769	rs570952	ENSG00000278376.1	RP11-158I9.8	-4.97	1.07e-06	0.000705	-0.27	-0.26	Serum metabolite levels;	chr11:118629477	chr11:118791254~118793137:+
STAD	cis	rs6714710	0.603	rs11692010	ENSG00000235833.1	AC159540.14	-4.97	1.07e-06	0.000706	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97780838	chr2:97523949~97524976:-
STAD	cis	rs1075265	0.68	rs6715488	ENSG00000235937.1	AC008280.1	4.97	1.07e-06	0.000706	0.23	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54029552~54030682:-
STAD	cis	rs7474896	0.583	rs11011341	ENSG00000120555.12	SEPT7P9	4.97	1.07e-06	0.000707	0.31	0.26	Obesity (extreme);	chr10:37709572	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.609	rs1830612	ENSG00000120555.12	SEPT7P9	4.97	1.07e-06	0.000707	0.31	0.26	Obesity (extreme);	chr10:37710955	chr10:38383069~38402916:-
STAD	cis	rs75426604	0.568	rs17091835	ENSG00000241052.1	RP11-173D9.1	4.97	1.07e-06	0.000707	0.35	0.26	Eotaxin levels;	chr14:35376385	chr14:35144021~35144480:-
STAD	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-4.97	1.07e-06	0.000707	-0.23	-0.26	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
STAD	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-4.97	1.07e-06	0.000708	-0.29	-0.26	Depression;	chr6:28109824	chr6:28073316~28074233:+
STAD	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	4.97	1.07e-06	0.000708	0.38	0.26	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
STAD	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	4.97	1.08e-06	0.000708	0.33	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
STAD	cis	rs8098244	0.66	rs28409401	ENSG00000267301.1	RPL23AP77	-4.97	1.08e-06	0.000709	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23910400	chr18:23709825~23710287:-
STAD	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	4.97	1.08e-06	0.000709	0.31	0.26	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	4.97	1.08e-06	0.000709	0.31	0.26	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	4.97	1.08e-06	0.000709	0.31	0.26	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
STAD	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	4.97	1.08e-06	0.000709	0.28	0.26	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
STAD	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	4.97	1.08e-06	0.00071	0.37	0.26	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
STAD	cis	rs4568518	0.535	rs6956984	ENSG00000279048.1	RP11-511H23.2	4.97	1.08e-06	0.000711	0.25	0.26	Measles;	chr7:18021050	chr7:17940503~17942922:+
STAD	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	4.97	1.08e-06	0.000711	0.26	0.26	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
STAD	cis	rs75426604	0.527	rs1073597	ENSG00000241052.1	RP11-173D9.1	-4.97	1.08e-06	0.000711	-0.3	-0.26	Eotaxin levels;	chr14:35362288	chr14:35144021~35144480:-
STAD	cis	rs228614	0.51	rs223438	ENSG00000248971.2	KRT8P46	4.97	1.08e-06	0.000711	0.26	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102728746~102730171:-
STAD	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	4.97	1.08e-06	0.000711	0.3	0.26	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
STAD	cis	rs9467773	0.62	rs2504567	ENSG00000243307.2	POM121L6P	4.97	1.08e-06	0.000711	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26896952~26898777:+
STAD	cis	rs453301	0.686	rs11785634	ENSG00000254340.1	RP11-10A14.3	-4.97	1.08e-06	0.000711	-0.34	-0.26	Joint mobility (Beighton score);	chr8:9035087	chr8:9141424~9145435:+
STAD	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-4.96	1.08e-06	0.000712	-0.34	-0.26	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
STAD	cis	rs301901	0.965	rs13158310	ENSG00000250155.1	CTD-2353F22.1	4.96	1.08e-06	0.000712	0.26	0.26	Height;	chr5:36789552	chr5:36666214~36725195:-
STAD	cis	rs516805	0.748	rs11154070	ENSG00000279453.1	RP3-425C14.4	4.96	1.08e-06	0.000713	0.34	0.26	Lymphocyte counts;	chr6:122362886	chr6:122436789~122439223:-
STAD	cis	rs1799949	0.931	rs9912203	ENSG00000279602.1	CTD-3014M21.1	-4.96	1.08e-06	0.000714	-0.31	-0.26	Menopause (age at onset);	chr17:43367777	chr17:43360041~43361361:-
STAD	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-4.96	1.09e-06	0.000715	-0.39	-0.26	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-4.96	1.09e-06	0.000715	-0.39	-0.26	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-4.96	1.09e-06	0.000715	-0.39	-0.26	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-4.96	1.09e-06	0.000715	-0.39	-0.26	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
STAD	cis	rs728616	0.764	rs61859016	ENSG00000225484.5	NUTM2B-AS1	-4.96	1.09e-06	0.000715	-0.55	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61859022	ENSG00000225484.5	NUTM2B-AS1	-4.96	1.09e-06	0.000715	-0.55	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79663088~79826594:-
STAD	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	4.96	1.09e-06	0.000716	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
STAD	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-4.96	1.09e-06	0.000717	-0.26	-0.26	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
STAD	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-4.96	1.09e-06	0.000717	-0.3	-0.26	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
STAD	cis	rs853679	0.527	rs9461443	ENSG00000220721.1	OR1F12	4.96	1.09e-06	0.000718	0.29	0.26	Depression;	chr6:28226851	chr6:28073316~28074233:+
STAD	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-4.96	1.09e-06	0.000718	-0.34	-0.26	AIDS;	chr2:105300178	chr2:105324210~105330529:+
STAD	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-4.96	1.09e-06	0.000719	-0.33	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
STAD	cis	rs8098244	0.638	rs9951784	ENSG00000267301.1	RPL23AP77	-4.96	1.09e-06	0.000719	-0.3	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23882709	chr18:23709825~23710287:-
STAD	cis	rs7829975	0.871	rs777709	ENSG00000253981.4	ALG1L13P	-4.96	1.09e-06	0.000719	-0.3	-0.26	Mood instability;	chr8:8726362	chr8:8236003~8244667:-
STAD	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-4.96	1.09e-06	0.00072	-0.27	-0.26	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-4.96	1.09e-06	0.00072	-0.27	-0.26	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-4.96	1.09e-06	0.00072	-0.27	-0.26	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-4.96	1.09e-06	0.00072	-0.27	-0.26	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
STAD	cis	rs721917	0.506	rs1923540	ENSG00000244733.5	RP11-506M13.3	-4.96	1.1e-06	0.00072	-0.31	-0.26	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79660891~79677996:+
STAD	cis	rs35934224	0.724	rs35374520	ENSG00000232926.1	AC000078.5	4.96	1.1e-06	0.000721	0.34	0.26	Glaucoma (primary open-angle);	chr22:19863626	chr22:19887289~19887970:+
STAD	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	4.96	1.1e-06	0.000721	0.4	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
STAD	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-4.96	1.1e-06	0.000722	-0.29	-0.26	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
STAD	cis	rs2337406	0.866	rs112089985	ENSG00000211972.2	IGHV3-66	4.96	1.1e-06	0.000724	0.26	0.26	Alzheimer's disease (late onset);	chr14:106780074	chr14:106675017~106675544:-
STAD	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	4.96	1.1e-06	0.000725	0.29	0.26	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
STAD	cis	rs6714710	0.603	rs7583868	ENSG00000235833.1	AC159540.14	-4.96	1.1e-06	0.000725	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97971909	chr2:97523949~97524976:-
STAD	cis	rs916888	0.738	rs199515	ENSG00000232300.1	FAM215B	-4.96	1.1e-06	0.000726	-0.32	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46558830~46562795:-
STAD	cis	rs7829975	0.714	rs4841040	ENSG00000254340.1	RP11-10A14.3	4.96	1.1e-06	0.000726	0.3	0.26	Mood instability;	chr8:8797017	chr8:9141424~9145435:+
STAD	cis	rs9828933	0.808	rs3733125	ENSG00000280620.1	SCAANT1	4.96	1.1e-06	0.000726	0.51	0.26	Type 2 diabetes;	chr3:63995959	chr3:63911518~63911772:-
STAD	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-4.96	1.11e-06	0.000727	-0.27	-0.26	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
STAD	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-4.96	1.11e-06	0.000727	-0.27	-0.26	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
STAD	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-4.96	1.11e-06	0.000727	-0.34	-0.26	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
STAD	cis	rs7829975	0.514	rs2979139	ENSG00000253981.4	ALG1L13P	4.96	1.11e-06	0.000727	0.3	0.26	Mood instability;	chr8:8410803	chr8:8236003~8244667:-
STAD	cis	rs858239	0.539	rs870476	ENSG00000226816.2	AC005082.12	4.96	1.11e-06	0.000728	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23206013~23208045:+
STAD	cis	rs721917	0.506	rs2758561	ENSG00000244733.5	RP11-506M13.3	-4.96	1.11e-06	0.000728	-0.31	-0.26	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79660891~79677996:+
STAD	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-4.96	1.11e-06	0.000729	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
STAD	cis	rs7932354	0.528	rs11039107	ENSG00000271350.1	CTD-2384B9.1	4.96	1.11e-06	0.00073	0.31	0.26	Bone mineral density (hip);Bone mineral density;	chr11:47136315	chr11:47041027~47041945:-
STAD	cis	rs10510102	0.935	rs11200258	ENSG00000226864.1	ATE1-AS1	4.96	1.11e-06	0.00073	0.42	0.26	Breast cancer;	chr10:121918392	chr10:121928312~121951965:+
STAD	cis	rs7951870	0.617	rs12274785	ENSG00000271350.1	CTD-2384B9.1	4.96	1.11e-06	0.00073	0.32	0.26	Schizophrenia;	chr11:46692729	chr11:47041027~47041945:-
STAD	cis	rs13113518	0.812	rs12649507	ENSG00000223305.1	RN7SKP30	-4.96	1.11e-06	0.000731	-0.29	-0.26	Height;	chr4:55514317	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.783	rs12510400	ENSG00000223305.1	RN7SKP30	4.96	1.11e-06	0.000731	0.3	0.26	Height;	chr4:55577294	chr4:55540502~55540835:-
STAD	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-4.96	1.11e-06	0.000732	-0.3	-0.26	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
STAD	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-4.96	1.12e-06	0.000733	-0.35	-0.26	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
STAD	cis	rs4691139	0.658	rs12510282	ENSG00000248632.1	RP11-366M4.11	4.96	1.12e-06	0.000733	0.25	0.26	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003257	chr4:164968587~164970002:-
STAD	cis	rs4691139	0.658	rs12502594	ENSG00000248632.1	RP11-366M4.11	4.96	1.12e-06	0.000733	0.25	0.26	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003273	chr4:164968587~164970002:-
STAD	cis	rs4691139	0.658	rs12502595	ENSG00000248632.1	RP11-366M4.11	4.96	1.12e-06	0.000733	0.25	0.26	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003290	chr4:164968587~164970002:-
STAD	cis	rs7078219	0.543	rs7092009	ENSG00000228778.1	RP11-129J12.1	-4.96	1.12e-06	0.000733	-0.3	-0.26	Dental caries;	chr10:99517482	chr10:99527081~99528261:+
STAD	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	4.96	1.12e-06	0.000734	0.32	0.26	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
STAD	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-4.96	1.12e-06	0.000734	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
STAD	cis	rs2948294	0.588	rs4840913	ENSG00000254340.1	RP11-10A14.3	4.96	1.12e-06	0.000734	0.31	0.26	Red cell distribution width;	chr8:8259384	chr8:9141424~9145435:+
STAD	cis	rs7078219	0.524	rs6584277	ENSG00000228778.1	RP11-129J12.1	-4.96	1.12e-06	0.000734	-0.3	-0.26	Dental caries;	chr10:99518298	chr10:99527081~99528261:+
STAD	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-4.96	1.12e-06	0.000734	-0.3	-0.26	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
STAD	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-4.96	1.12e-06	0.000735	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
STAD	cis	rs6714710	0.58	rs57804205	ENSG00000235833.1	AC159540.14	-4.96	1.12e-06	0.000735	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838009	chr2:97523949~97524976:-
STAD	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-4.96	1.12e-06	0.000735	-0.25	-0.26	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
STAD	cis	rs891378	1	rs2802236	ENSG00000274245.1	RP11-357P18.2	4.96	1.12e-06	0.000735	0.32	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207298844	chr1:207372559~207373252:+
STAD	cis	rs11098499	0.909	rs28884220	ENSG00000260091.1	RP11-33B1.4	4.96	1.12e-06	0.000736	0.25	0.26	Corneal astigmatism;	chr4:119386056	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs28793658	ENSG00000260091.1	RP11-33B1.4	4.96	1.12e-06	0.000736	0.25	0.26	Corneal astigmatism;	chr4:119386059	chr4:119409333~119410233:+
STAD	cis	rs1799949	1	rs2292595	ENSG00000236383.6	LINC00854	-4.96	1.12e-06	0.000736	-0.21	-0.26	Menopause (age at onset);	chr17:43138657	chr17:43216941~43305976:-
STAD	cis	rs858239	0.601	rs10255228	ENSG00000226816.2	AC005082.12	4.96	1.12e-06	0.000736	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23206013~23208045:+
STAD	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-4.96	1.12e-06	0.000737	-0.33	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
STAD	cis	rs853679	0.517	rs9393896	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28159925	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393897	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28159932	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9468298	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28154567	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9295759	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28156691	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9348796	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28158424	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs11552219	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28159056	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393895	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28159843	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9357065	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28161802	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9357066	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28162053	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368556	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28163375	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368557	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28163759	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380059	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28164580	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380060	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28164825	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs35227624	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28164948	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380061	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28165025	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9368558	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28165528	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.587	rs9393899	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Parkinson's disease;	chr6:28165750	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs4713150	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28168434	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.527	rs4713151	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Parkinson's disease;	chr6:28168578	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393901	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28169019	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs3173443	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28169249	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs4713152	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28169676	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9348797	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28169755	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380062	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28169791	chr6:28073316~28074233:+
STAD	cis	rs853679	0.542	rs9380063	ENSG00000220721.1	OR1F12	4.96	1.12e-06	0.000737	0.3	0.26	Depression;	chr6:28170075	chr6:28073316~28074233:+
STAD	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	4.96	1.12e-06	0.000737	0.39	0.26	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	4.96	1.12e-06	0.000737	0.39	0.26	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
STAD	cis	rs891378	0.874	rs59036171	ENSG00000274245.1	RP11-357P18.2	-4.96	1.12e-06	0.000737	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207271583	chr1:207372559~207373252:+
STAD	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-4.96	1.13e-06	0.000738	-0.4	-0.26	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
STAD	cis	rs7487075	0.93	rs4768121	ENSG00000257261.4	RP11-96H19.1	4.96	1.13e-06	0.000738	0.31	0.26	Itch intensity from mosquito bite;	chr12:46436069	chr12:46383679~46876159:+
STAD	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-4.96	1.13e-06	0.000738	-0.32	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
STAD	cis	rs7665090	0.806	rs413967	ENSG00000248971.2	KRT8P46	4.96	1.13e-06	0.000738	0.26	0.26	Primary biliary cholangitis;	chr4:102662039	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.806	rs404574	ENSG00000248971.2	KRT8P46	4.96	1.13e-06	0.000738	0.26	0.26	Primary biliary cholangitis;	chr4:102662051	chr4:102728746~102730171:-
STAD	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	4.96	1.13e-06	0.000738	0.37	0.26	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
STAD	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	4.96	1.13e-06	0.000738	0.29	0.26	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
STAD	cis	rs2980439	0.525	rs2945238	ENSG00000253981.4	ALG1L13P	4.96	1.13e-06	0.000739	0.3	0.26	Neuroticism;	chr8:8312614	chr8:8236003~8244667:-
STAD	cis	rs957448	0.561	rs58663902	ENSG00000253704.1	RP11-267M23.4	4.96	1.13e-06	0.000739	0.29	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94553722~94569745:+
STAD	cis	rs1799949	0.93	rs33968979	ENSG00000236383.6	LINC00854	-4.96	1.13e-06	0.00074	-0.21	-0.26	Menopause (age at onset);	chr17:43145975	chr17:43216941~43305976:-
STAD	cis	rs10218795	1	rs10218795	ENSG00000233396.6	RP11-458D21.1	-4.96	1.13e-06	0.000741	-0.53	-0.26	Coronary heart disease (SNP X SNP interaction);	chr1:146018957	chr1:146052566~146061948:+
STAD	cis	rs875971	0.862	rs6460307	ENSG00000236529.1	RP13-254B10.1	4.96	1.13e-06	0.000741	0.26	0.26	Aortic root size;	chr7:66595884	chr7:65840212~65840596:+
STAD	cis	rs10129255	0.5	rs6576226	ENSG00000211973.2	IGHV1-69	4.96	1.13e-06	0.000741	0.22	0.26	Kawasaki disease;	chr14:106778135	chr14:106714684~106715181:-
STAD	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	4.96	1.13e-06	0.000742	0.35	0.26	Height;	chr6:109452743	chr6:109382795~109383666:+
STAD	cis	rs13020137	1	rs13020137	ENSG00000180178.9	FAR2P1	-4.96	1.13e-06	0.000743	-0.27	-0.26	Schizophrenia;	chr2:129999731	chr2:129990456~130051131:-
STAD	cis	rs875971	0.545	rs6950988	ENSG00000236529.1	RP13-254B10.1	4.95	1.13e-06	0.000743	0.3	0.26	Aortic root size;	chr7:66511428	chr7:65840212~65840596:+
STAD	cis	rs737008	0.96	rs11640295	ENSG00000262703.1	RP11-485G7.6	4.95	1.14e-06	0.000744	0.26	0.26	Obesity-related traits;	chr16:11296871	chr16:11348143~11349321:-
STAD	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-4.95	1.14e-06	0.000744	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
STAD	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-4.95	1.14e-06	0.000745	-0.33	-0.26	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
STAD	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	4.95	1.14e-06	0.000745	0.33	0.26	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
STAD	cis	rs453301	0.522	rs1964356	ENSG00000254340.1	RP11-10A14.3	4.95	1.14e-06	0.000746	0.31	0.26	Joint mobility (Beighton score);	chr8:8995760	chr8:9141424~9145435:+
STAD	cis	rs1007738	0.58	rs2279439	ENSG00000271350.1	CTD-2384B9.1	4.95	1.14e-06	0.000747	0.34	0.26	Bone mineral density (hip);	chr11:47175431	chr11:47041027~47041945:-
STAD	cis	rs10504130	0.518	rs6473654	ENSG00000272024.1	RP11-546K22.3	4.95	1.14e-06	0.000747	0.37	0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51758954	chr8:51950284~51950690:+
STAD	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-4.95	1.14e-06	0.000747	-0.3	-0.26	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
STAD	cis	rs9860428	0.774	rs13324496	ENSG00000240057.4	RP11-572M11.4	-4.95	1.14e-06	0.000748	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112883013	chr3:113019532~113183301:+
STAD	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	4.95	1.14e-06	0.000748	0.36	0.26	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	4.95	1.14e-06	0.000748	0.36	0.26	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	4.95	1.14e-06	0.000748	0.36	0.26	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	4.95	1.14e-06	0.000748	0.36	0.26	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
STAD	cis	rs7829975	0.559	rs4841025	ENSG00000173295.6	FAM86B3P	-4.95	1.14e-06	0.000748	-0.29	-0.26	Mood instability;	chr8:8745650	chr8:8228595~8244865:+
STAD	cis	rs6142102	0.812	rs6059554	ENSG00000275784.1	RP5-1125A11.6	-4.95	1.14e-06	0.000748	-0.27	-0.26	Skin pigmentation;	chr20:33926286	chr20:33989480~33991818:-
STAD	cis	rs4865169	0.934	rs12650737	ENSG00000269949.1	RP11-738E22.3	-4.95	1.14e-06	0.000748	-0.28	-0.26	Breast cancer;	chr4:57026309	chr4:56960927~56961373:-
STAD	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-4.95	1.14e-06	0.000749	-0.31	-0.26	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
STAD	cis	rs1707322	0.717	rs3014237	ENSG00000281133.1	AL355480.3	4.95	1.14e-06	0.000749	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45580892~45580996:-
STAD	cis	rs7760535	0.826	rs3777905	ENSG00000230177.1	RP5-1112D6.4	-4.95	1.14e-06	0.000749	-0.23	-0.26	Metabolic traits;	chr6:111549385	chr6:111277932~111278742:+
STAD	cis	rs507080	0.769	rs645637	ENSG00000278376.1	RP11-158I9.8	-4.95	1.14e-06	0.000749	-0.27	-0.26	Serum metabolite levels;	chr11:118634373	chr11:118791254~118793137:+
STAD	cis	rs7916697	0.593	rs3740587	ENSG00000233590.1	RP11-153K11.3	4.95	1.15e-06	0.00075	0.3	0.26	Optic disc area;	chr10:68261045	chr10:68233251~68242379:-
STAD	cis	rs1799949	1	rs4793197	ENSG00000279602.1	CTD-3014M21.1	4.95	1.15e-06	0.00075	0.32	0.26	Menopause (age at onset);	chr17:43079885	chr17:43360041~43361361:-
STAD	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	4.95	1.15e-06	0.000751	0.3	0.26	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
STAD	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-4.95	1.15e-06	0.000752	-0.46	-0.26	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
STAD	cis	rs6095360	0.674	rs7269912	ENSG00000222365.1	SNORD12B	-4.95	1.15e-06	0.000752	-0.34	-0.26	Intelligence (multi-trait analysis);	chr20:49039661	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.7	rs13042443	ENSG00000222365.1	SNORD12B	-4.95	1.15e-06	0.000752	-0.34	-0.26	Intelligence (multi-trait analysis);	chr20:49047217	chr20:49280319~49280409:+
STAD	cis	rs1056107	0.737	rs7041381	ENSG00000225513.1	RP11-165N19.2	-4.95	1.15e-06	0.000753	-0.3	-0.26	Colorectal cancer;	chr9:112309799	chr9:112173522~112173971:-
STAD	cis	rs507080	0.769	rs483283	ENSG00000278376.1	RP11-158I9.8	-4.95	1.15e-06	0.000753	-0.27	-0.26	Serum metabolite levels;	chr11:118635684	chr11:118791254~118793137:+
STAD	cis	rs8099594	0.51	rs1893528	ENSG00000266696.1	RP11-30L3.2	4.95	1.15e-06	0.000753	0.23	0.26	Height;	chr18:49169720	chr18:49205912~49208781:+
STAD	cis	rs721917	0.525	rs2250473	ENSG00000244733.5	RP11-506M13.3	-4.95	1.15e-06	0.000754	-0.31	-0.26	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79660891~79677996:+
STAD	cis	rs2436845	0.81	rs2513910	ENSG00000253385.1	KB-1254G8.1	4.95	1.15e-06	0.000754	0.26	0.26	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102804878	chr8:102854455~102856075:+
STAD	cis	rs1075265	0.704	rs10084374	ENSG00000235937.1	AC008280.1	4.95	1.15e-06	0.000754	0.23	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54029552~54030682:-
STAD	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-4.95	1.15e-06	0.000755	-0.39	-0.26	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
STAD	cis	rs858239	0.72	rs10227559	ENSG00000226816.2	AC005082.12	4.95	1.15e-06	0.000755	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23206013~23208045:+
STAD	cis	rs875971	0.862	rs6960446	ENSG00000236529.1	RP13-254B10.1	-4.95	1.16e-06	0.000756	-0.26	-0.26	Aortic root size;	chr7:66268272	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs7796162	ENSG00000236529.1	RP13-254B10.1	-4.95	1.16e-06	0.000756	-0.26	-0.26	Aortic root size;	chr7:66280771	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs2901152	ENSG00000236529.1	RP13-254B10.1	-4.95	1.16e-06	0.000756	-0.26	-0.26	Aortic root size;	chr7:66300017	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10263690	ENSG00000236529.1	RP13-254B10.1	-4.95	1.16e-06	0.000756	-0.26	-0.26	Aortic root size;	chr7:66301466	chr7:65840212~65840596:+
STAD	cis	rs1799949	1	rs11654731	ENSG00000279602.1	CTD-3014M21.1	4.95	1.16e-06	0.000756	0.32	0.26	Menopause (age at onset);	chr17:43174923	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs11651623	ENSG00000279602.1	CTD-3014M21.1	4.95	1.16e-06	0.000756	0.32	0.26	Menopause (age at onset);	chr17:43177830	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs11657883	ENSG00000279602.1	CTD-3014M21.1	4.95	1.16e-06	0.000756	0.32	0.26	Menopause (age at onset);	chr17:43178007	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs2175957	ENSG00000236383.6	LINC00854	-4.95	1.16e-06	0.000756	-0.21	-0.26	Menopause (age at onset);	chr17:43134805	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs33988650	ENSG00000236383.6	LINC00854	-4.95	1.16e-06	0.000756	-0.21	-0.26	Menopause (age at onset);	chr17:43135863	chr17:43216941~43305976:-
STAD	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-4.95	1.16e-06	0.000756	-0.26	-0.26	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
STAD	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-4.95	1.16e-06	0.000756	-0.26	-0.26	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
STAD	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	4.95	1.16e-06	0.000757	0.3	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
STAD	cis	rs1964356	0.967	rs17701675	ENSG00000254340.1	RP11-10A14.3	-4.95	1.16e-06	0.000757	-0.3	-0.26	Mean corpuscular volume;	chr8:8993123	chr8:9141424~9145435:+
STAD	cis	rs9463078	0.546	rs12205071	ENSG00000219384.1	RP11-491H9.3	-4.95	1.16e-06	0.000757	-0.24	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45053478	chr6:45158870~45159511:+
STAD	cis	rs3136516	0.504	rs17787804	ENSG00000271350.1	CTD-2384B9.1	4.95	1.16e-06	0.000757	0.32	0.26	Venous thromboembolism;	chr11:46485335	chr11:47041027~47041945:-
STAD	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-4.95	1.16e-06	0.000758	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
STAD	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-4.95	1.16e-06	0.000759	-0.36	-0.26	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
STAD	cis	rs1426063	0.668	rs6534595	ENSG00000260265.1	RP11-44F21.5	4.95	1.16e-06	0.00076	0.36	0.26	QT interval;	chr4:75104432	chr4:75081702~75084717:-
STAD	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	4.95	1.16e-06	0.00076	0.31	0.26	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
STAD	cis	rs1318937	0.764	rs9864422	ENSG00000224660.1	SH3BP5-AS1	4.95	1.16e-06	0.00076	0.26	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15185745	chr3:15254184~15264493:+
STAD	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-4.95	1.16e-06	0.000761	-0.26	-0.26	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
STAD	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-4.95	1.16e-06	0.000761	-0.33	-0.26	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
STAD	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-4.95	1.16e-06	0.000761	-0.33	-0.26	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
STAD	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	4.95	1.17e-06	0.000762	0.34	0.26	Height;	chr6:109350642	chr6:109382795~109383666:+
STAD	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-4.95	1.17e-06	0.000762	-0.36	-0.26	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
STAD	cis	rs1816752	0.905	rs3818938	ENSG00000273628.1	RP11-756A22.7	4.95	1.17e-06	0.000762	0.32	0.26	Obesity-related traits;	chr13:24454945	chr13:24933006~24936796:+
STAD	cis	rs7829975	0.714	rs7823757	ENSG00000254340.1	RP11-10A14.3	4.95	1.17e-06	0.000762	0.3	0.26	Mood instability;	chr8:8812667	chr8:9141424~9145435:+
STAD	cis	rs7665090	0.714	rs5026475	ENSG00000248971.2	KRT8P46	-4.95	1.17e-06	0.000762	-0.27	-0.26	Primary biliary cholangitis;	chr4:102633664	chr4:102728746~102730171:-
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000211973.2	IGHV1-69	4.95	1.17e-06	0.000762	0.22	0.26	Kawasaki disease;	chr14:106783414	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000211973.2	IGHV1-69	4.95	1.17e-06	0.000762	0.22	0.26	Kawasaki disease;	chr14:106783693	chr14:106714684~106715181:-
STAD	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-4.95	1.17e-06	0.000762	-0.35	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
STAD	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	4.95	1.17e-06	0.000762	0.29	0.26	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
STAD	cis	rs516805	0.63	rs699405	ENSG00000279453.1	RP3-425C14.4	-4.95	1.17e-06	0.000763	-0.34	-0.26	Lymphocyte counts;	chr6:122274145	chr6:122436789~122439223:-
STAD	cis	rs516805	0.596	rs225088	ENSG00000279453.1	RP3-425C14.4	-4.95	1.17e-06	0.000763	-0.34	-0.26	Lymphocyte counts;	chr6:122277898	chr6:122436789~122439223:-
STAD	cis	rs7932354	0.528	rs4752962	ENSG00000271350.1	CTD-2384B9.1	4.95	1.17e-06	0.000763	0.31	0.26	Bone mineral density (hip);Bone mineral density;	chr11:47120119	chr11:47041027~47041945:-
STAD	cis	rs453301	0.652	rs2043129	ENSG00000254340.1	RP11-10A14.3	4.95	1.17e-06	0.000763	0.33	0.26	Joint mobility (Beighton score);	chr8:8967994	chr8:9141424~9145435:+
STAD	cis	rs516805	0.667	rs2816139	ENSG00000279453.1	RP3-425C14.4	-4.95	1.17e-06	0.000763	-0.4	-0.26	Lymphocyte counts;	chr6:122182267	chr6:122436789~122439223:-
STAD	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	4.95	1.17e-06	0.000763	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
STAD	cis	rs7829975	0.564	rs2921057	ENSG00000253981.4	ALG1L13P	4.95	1.17e-06	0.000763	0.31	0.26	Mood instability;	chr8:8461157	chr8:8236003~8244667:-
STAD	cis	rs6782228	0.585	rs2712392	ENSG00000277250.1	Metazoa_SRP	-4.95	1.17e-06	0.000764	-0.27	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128673681~128674021:-
STAD	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-4.95	1.17e-06	0.000764	-0.3	-0.26	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000224205.1	AP000351.4	-4.95	1.17e-06	0.000764	-0.29	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23987320~23991421:-
STAD	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-4.95	1.17e-06	0.000764	-0.27	-0.26	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.618	rs28491261	ENSG00000260091.1	RP11-33B1.4	4.95	1.17e-06	0.000764	0.25	0.26	Corneal astigmatism;	chr4:119373745	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs59394118	ENSG00000260091.1	RP11-33B1.4	4.95	1.17e-06	0.000764	0.25	0.26	Corneal astigmatism;	chr4:119374396	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs9996417	ENSG00000260091.1	RP11-33B1.4	4.95	1.17e-06	0.000764	0.25	0.26	Corneal astigmatism;	chr4:119374707	chr4:119409333~119410233:+
STAD	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-4.95	1.17e-06	0.000765	-0.26	-0.26	Height;	chr5:36911514	chr5:36666214~36725195:-
STAD	cis	rs2688608	0.592	rs12253482	ENSG00000271816.1	BMS1P4	4.95	1.17e-06	0.000765	0.28	0.26	Inflammatory bowel disease;	chr10:73736372	chr10:73699151~73730487:-
STAD	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-4.95	1.17e-06	0.000766	-0.3	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
STAD	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	4.95	1.17e-06	0.000766	0.25	0.26	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
STAD	cis	rs4950322	0.857	rs72693002	ENSG00000278811.3	LINC00624	4.95	1.18e-06	0.000767	0.28	0.26	Protein quantitative trait loci;	chr1:147357593	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.857	rs72694703	ENSG00000278811.3	LINC00624	4.95	1.18e-06	0.000767	0.28	0.26	Protein quantitative trait loci;	chr1:147358427	chr1:147258885~147517875:-
STAD	cis	rs1799949	1	rs2037075	ENSG00000236383.6	LINC00854	-4.95	1.18e-06	0.000768	-0.21	-0.26	Menopause (age at onset);	chr17:43153809	chr17:43216941~43305976:-
STAD	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	4.95	1.18e-06	0.000769	0.34	0.26	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
STAD	cis	rs7474896	0.583	rs10827817	ENSG00000120555.12	SEPT7P9	4.95	1.18e-06	0.000769	0.31	0.26	Obesity (extreme);	chr10:37709046	chr10:38383069~38402916:-
STAD	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-4.95	1.18e-06	0.000769	-0.31	-0.26	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000211973.2	IGHV1-69	4.95	1.18e-06	0.000769	0.22	0.26	Kawasaki disease;	chr14:106784149	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000211973.2	IGHV1-69	4.95	1.18e-06	0.000769	0.22	0.26	Kawasaki disease;	chr14:106785139	chr14:106714684~106715181:-
STAD	cis	rs6585424	1	rs12763392	ENSG00000225484.5	NUTM2B-AS1	4.95	1.18e-06	0.000769	0.45	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175239	chr10:79663088~79826594:-
STAD	cis	rs2337406	0.85	rs10131280	ENSG00000274576.2	IGHV2-70	-4.95	1.18e-06	0.000769	-0.32	-0.26	Alzheimer's disease (late onset);	chr14:106665591	chr14:106770577~106771020:-
STAD	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-4.95	1.18e-06	0.00077	-0.27	-0.26	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-4.95	1.18e-06	0.00077	-0.27	-0.26	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
STAD	cis	rs2404602	0.692	rs12902452	ENSG00000259422.1	RP11-593F23.1	4.95	1.18e-06	0.00077	0.27	0.26	Blood metabolite levels;	chr15:76629124	chr15:76174891~76181486:-
STAD	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-4.95	1.18e-06	0.00077	-0.3	-0.26	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
STAD	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-4.95	1.18e-06	0.00077	-0.33	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
STAD	cis	rs9828933	0.577	rs832194	ENSG00000280620.1	SCAANT1	-4.95	1.18e-06	0.000771	-0.4	-0.26	Type 2 diabetes;	chr3:63871395	chr3:63911518~63911772:-
STAD	cis	rs1150668	0.799	rs9301	ENSG00000220721.1	OR1F12	4.95	1.18e-06	0.000771	0.25	0.26	Pubertal anthropometrics;	chr6:28324929	chr6:28073316~28074233:+
STAD	cis	rs1150668	0.799	rs853684	ENSG00000220721.1	OR1F12	4.95	1.18e-06	0.000771	0.25	0.26	Pubertal anthropometrics;	chr6:28326773	chr6:28073316~28074233:+
STAD	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	4.95	1.18e-06	0.000772	0.37	0.26	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	4.95	1.18e-06	0.000772	0.37	0.26	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	4.95	1.18e-06	0.000772	0.37	0.26	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	4.95	1.18e-06	0.000772	0.37	0.26	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	4.95	1.18e-06	0.000772	0.37	0.26	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	4.95	1.18e-06	0.000772	0.37	0.26	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	4.95	1.18e-06	0.000772	0.37	0.26	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
STAD	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	4.95	1.18e-06	0.000772	0.27	0.26	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
STAD	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-4.95	1.18e-06	0.000772	-0.31	-0.26	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-4.95	1.18e-06	0.000772	-0.31	-0.26	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-4.95	1.18e-06	0.000772	-0.31	-0.26	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
STAD	cis	rs1056107	0.933	rs10981354	ENSG00000225513.1	RP11-165N19.2	-4.95	1.18e-06	0.000772	-0.3	-0.26	Colorectal cancer;	chr9:112308436	chr9:112173522~112173971:-
STAD	cis	rs7829975	0.688	rs7817376	ENSG00000254340.1	RP11-10A14.3	-4.95	1.19e-06	0.000773	-0.31	-0.26	Mood instability;	chr8:8523020	chr8:9141424~9145435:+
STAD	cis	rs238295	0.628	rs6133219	ENSG00000230563.2	RP5-828H9.1	4.95	1.19e-06	0.000774	0.29	0.26	Occipital cortical area (total cortical area interaction);	chr20:5514423	chr20:5471207~5475182:+
STAD	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	4.95	1.19e-06	0.000774	0.39	0.26	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
STAD	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-4.95	1.19e-06	0.000774	-0.31	-0.26	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
STAD	cis	rs875971	1	rs6946143	ENSG00000236529.1	RP13-254B10.1	4.95	1.19e-06	0.000774	0.26	0.26	Aortic root size;	chr7:66114735	chr7:65840212~65840596:+
STAD	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	4.95	1.19e-06	0.000774	0.37	0.26	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
STAD	cis	rs12744310	0.887	rs12042464	ENSG00000235358.1	RP11-399E6.1	-4.95	1.19e-06	0.000775	-0.31	-0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321182	chr1:41242373~41284861:+
STAD	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	4.95	1.19e-06	0.000775	0.28	0.26	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
STAD	cis	rs2404602	0.716	rs2404736	ENSG00000259422.1	RP11-593F23.1	4.95	1.19e-06	0.000775	0.27	0.26	Blood metabolite levels;	chr15:76583602	chr15:76174891~76181486:-
STAD	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	4.94	1.19e-06	0.000775	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
STAD	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	4.94	1.19e-06	0.000776	0.36	0.26	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
STAD	cis	rs1799949	0.93	rs8176194	ENSG00000236383.6	LINC00854	-4.94	1.19e-06	0.000776	-0.21	-0.26	Menopause (age at onset);	chr17:43079204	chr17:43216941~43305976:-
STAD	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-4.94	1.19e-06	0.000776	-0.38	-0.26	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
STAD	cis	rs919433	0.817	rs10931780	ENSG00000231621.1	AC013264.2	4.94	1.19e-06	0.000776	0.21	0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310573	chr2:197197991~197199273:+
STAD	cis	rs13113518	1	rs3762837	ENSG00000223305.1	RN7SKP30	4.94	1.19e-06	0.000776	0.29	0.26	Height;	chr4:55511198	chr4:55540502~55540835:-
STAD	cis	rs10510102	1	rs10510102	ENSG00000226864.1	ATE1-AS1	-4.94	1.19e-06	0.000776	-0.41	-0.26	Breast cancer;	chr10:121865675	chr10:121928312~121951965:+
STAD	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	4.94	1.19e-06	0.000777	0.28	0.26	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
STAD	cis	rs7665090	1	rs5026473	ENSG00000248971.2	KRT8P46	-4.94	1.19e-06	0.000777	-0.27	-0.26	Primary biliary cholangitis;	chr4:102633636	chr4:102728746~102730171:-
STAD	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-4.94	1.19e-06	0.000777	-0.3	-0.26	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
STAD	cis	rs36423	0.528	rs1205061	ENSG00000266869.1	RP6-114E22.1	4.94	1.19e-06	0.000778	0.39	0.26	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71882819	chr14:71848606~71908430:+
STAD	cis	rs6142102	0.651	rs1015361	ENSG00000275784.1	RP5-1125A11.6	4.94	1.19e-06	0.000778	0.27	0.26	Skin pigmentation;	chr20:34150880	chr20:33989480~33991818:-
STAD	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-4.94	1.19e-06	0.000778	-0.32	-0.26	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
STAD	cis	rs875971	0.545	rs4718325	ENSG00000236529.1	RP13-254B10.1	4.94	1.2e-06	0.000779	0.31	0.26	Aortic root size;	chr7:66215323	chr7:65840212~65840596:+
STAD	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	4.94	1.2e-06	0.000779	0.28	0.26	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
STAD	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	4.94	1.2e-06	0.000779	0.31	0.26	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	4.94	1.2e-06	0.000779	0.31	0.26	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	4.94	1.2e-06	0.000779	0.31	0.26	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	4.94	1.2e-06	0.000779	0.31	0.26	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
STAD	cis	rs9860428	0.844	rs9838295	ENSG00000240057.4	RP11-572M11.4	-4.94	1.2e-06	0.00078	-0.25	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112909438	chr3:113019532~113183301:+
STAD	cis	rs4950322	0.57	rs4301678	ENSG00000278811.3	LINC00624	4.94	1.2e-06	0.000781	0.29	0.26	Protein quantitative trait loci;	chr1:147261907	chr1:147258885~147517875:-
STAD	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-4.94	1.2e-06	0.000781	-0.38	-0.26	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
STAD	cis	rs728616	0.614	rs61859198	ENSG00000225484.5	NUTM2B-AS1	-4.94	1.2e-06	0.000781	-0.5	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79663088~79826594:-
STAD	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	4.94	1.2e-06	0.000781	0.37	0.26	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
STAD	cis	rs4950322	0.634	rs7542951	ENSG00000278811.3	LINC00624	4.94	1.2e-06	0.000781	0.28	0.26	Protein quantitative trait loci;	chr1:147340308	chr1:147258885~147517875:-
STAD	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	4.94	1.2e-06	0.000781	0.28	0.26	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
STAD	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	4.94	1.2e-06	0.000781	0.28	0.26	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
STAD	cis	rs801193	0.66	rs4610622	ENSG00000236529.1	RP13-254B10.1	4.94	1.2e-06	0.000781	0.27	0.26	Aortic root size;	chr7:66759510	chr7:65840212~65840596:+
STAD	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	4.94	1.2e-06	0.000781	0.25	0.26	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
STAD	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-4.94	1.2e-06	0.000782	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
STAD	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	4.94	1.2e-06	0.000782	0.29	0.26	Height;	chr4:55544621	chr4:55540502~55540835:-
STAD	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-4.94	1.2e-06	0.000782	-0.35	-0.26	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000224205.1	AP000351.4	4.94	1.2e-06	0.000782	0.29	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23987320~23991421:-
STAD	cis	rs944990	0.576	rs6479484	ENSG00000227603.1	RP11-165J3.6	4.94	1.2e-06	0.000783	0.28	0.26	Body mass index;	chr9:93454288	chr9:93435332~93437121:-
STAD	cis	rs11098499	0.697	rs4560394	ENSG00000260091.1	RP11-33B1.4	4.94	1.2e-06	0.000783	0.25	0.26	Corneal astigmatism;	chr4:119392280	chr4:119409333~119410233:+
STAD	cis	rs875971	0.545	rs73148639	ENSG00000236529.1	RP13-254B10.1	4.94	1.2e-06	0.000783	0.3	0.26	Aortic root size;	chr7:66390342	chr7:65840212~65840596:+
STAD	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	4.94	1.2e-06	0.000783	0.31	0.26	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
STAD	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	4.94	1.2e-06	0.000784	0.34	0.26	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
STAD	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-4.94	1.21e-06	0.000784	-0.28	-0.26	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
STAD	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-4.94	1.21e-06	0.000784	-0.29	-0.26	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
STAD	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-4.94	1.21e-06	0.000784	-0.4	-0.26	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
STAD	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	4.94	1.21e-06	0.000785	0.33	0.26	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
STAD	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-4.94	1.21e-06	0.000785	-0.27	-0.26	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
STAD	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-4.94	1.21e-06	0.000786	-0.33	-0.26	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
STAD	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-4.94	1.21e-06	0.000786	-0.3	-0.26	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
STAD	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-4.94	1.21e-06	0.000786	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
STAD	cis	rs11846409	0.799	rs2583330	ENSG00000211972.2	IGHV3-66	-4.94	1.21e-06	0.000786	-0.28	-0.26	Rheumatic heart disease;	chr14:106621051	chr14:106675017~106675544:-
STAD	cis	rs1799949	0.93	rs3765640	ENSG00000236383.6	LINC00854	-4.94	1.21e-06	0.000786	-0.21	-0.26	Menopause (age at onset);	chr17:43124230	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs8176077	ENSG00000236383.6	LINC00854	-4.94	1.21e-06	0.000786	-0.21	-0.26	Menopause (age at onset);	chr17:43124331	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11655505	ENSG00000236383.6	LINC00854	-4.94	1.21e-06	0.000786	-0.21	-0.26	Menopause (age at onset);	chr17:43126360	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs4793204	ENSG00000236383.6	LINC00854	-4.94	1.21e-06	0.000786	-0.21	-0.26	Menopause (age at onset);	chr17:43127281	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs12947782	ENSG00000236383.6	LINC00854	-4.94	1.21e-06	0.000786	-0.21	-0.26	Menopause (age at onset);	chr17:43127865	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs33945274	ENSG00000236383.6	LINC00854	-4.94	1.21e-06	0.000786	-0.21	-0.26	Menopause (age at onset);	chr17:43128056	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11653069	ENSG00000236383.6	LINC00854	-4.94	1.21e-06	0.000786	-0.21	-0.26	Menopause (age at onset);	chr17:43131360	chr17:43216941~43305976:-
STAD	cis	rs2404602	0.692	rs4442773	ENSG00000259422.1	RP11-593F23.1	4.94	1.21e-06	0.000786	0.27	0.26	Blood metabolite levels;	chr15:76739292	chr15:76174891~76181486:-
STAD	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-4.94	1.21e-06	0.000787	-0.31	-0.26	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
STAD	cis	rs13113518	0.812	rs12500456	ENSG00000223305.1	RN7SKP30	4.94	1.21e-06	0.000787	0.29	0.26	Height;	chr4:55561053	chr4:55540502~55540835:-
STAD	cis	rs4713118	0.869	rs7773070	ENSG00000280107.1	AL022393.9	-4.94	1.21e-06	0.000787	-0.34	-0.26	Parkinson's disease;	chr6:27761048	chr6:28170845~28172521:+
STAD	cis	rs7429990	0.833	rs3755637	ENSG00000224895.1	VPS26BP1	4.94	1.21e-06	0.000788	0.25	0.26	Educational attainment (years of education);	chr3:47580720	chr3:47960327~47961081:-
STAD	cis	rs875971	0.862	rs4368860	ENSG00000236529.1	RP13-254B10.1	-4.94	1.21e-06	0.000788	-0.27	-0.26	Aortic root size;	chr7:66143495	chr7:65840212~65840596:+
STAD	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	4.94	1.22e-06	0.000789	0.32	0.26	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
STAD	cis	rs1799949	0.93	rs35292991	ENSG00000279602.1	CTD-3014M21.1	4.94	1.22e-06	0.000789	0.32	0.26	Menopause (age at onset);	chr17:43181999	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs11658499	ENSG00000279602.1	CTD-3014M21.1	4.94	1.22e-06	0.000789	0.32	0.26	Menopause (age at onset);	chr17:43182732	chr17:43360041~43361361:-
STAD	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-4.94	1.22e-06	0.000789	-0.28	-0.26	Breast cancer;	chr11:825777	chr11:777578~784297:+
STAD	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-4.94	1.22e-06	0.000789	-0.3	-0.26	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
STAD	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-4.94	1.22e-06	0.000789	-0.3	-0.26	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
STAD	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-4.94	1.22e-06	0.000789	-0.3	-0.26	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
STAD	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-4.94	1.22e-06	0.000789	-0.3	-0.26	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
STAD	cis	rs7487075	0.719	rs2279560	ENSG00000272369.1	RP11-446N19.1	4.94	1.22e-06	0.00079	0.34	0.26	Itch intensity from mosquito bite;	chr12:46267496	chr12:46537502~46652550:+
STAD	cis	rs7520050	0.645	rs1768809	ENSG00000280836.1	AL355480.1	4.94	1.22e-06	0.00079	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45581219~45581321:-
STAD	cis	rs7932354	0.666	rs6485696	ENSG00000271350.1	CTD-2384B9.1	-4.94	1.22e-06	0.00079	-0.3	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:46820494	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.71	rs10838621	ENSG00000271350.1	CTD-2384B9.1	-4.94	1.22e-06	0.00079	-0.3	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:46829908	chr11:47041027~47041945:-
STAD	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-4.94	1.22e-06	0.00079	-0.27	-0.26	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-4.94	1.22e-06	0.00079	-0.27	-0.26	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
STAD	cis	rs9463078	0.585	rs12208924	ENSG00000219384.1	RP11-491H9.3	-4.94	1.22e-06	0.00079	-0.25	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45374314	chr6:45158870~45159511:+
STAD	cis	rs1799949	1	rs8176145	ENSG00000236383.6	LINC00854	-4.94	1.22e-06	0.000791	-0.21	-0.26	Menopause (age at onset);	chr17:43097077	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs8176140	ENSG00000236383.6	LINC00854	-4.94	1.22e-06	0.000791	-0.21	-0.26	Menopause (age at onset);	chr17:43099629	chr17:43216941~43305976:-
STAD	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-4.94	1.22e-06	0.000791	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-4.94	1.22e-06	0.000791	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
STAD	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-4.94	1.22e-06	0.000791	-0.27	-0.26	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-4.94	1.22e-06	0.000792	-0.27	-0.26	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
STAD	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-4.94	1.22e-06	0.000792	-0.3	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
STAD	cis	rs4713118	0.955	rs9380010	ENSG00000280107.1	AL022393.9	-4.94	1.22e-06	0.000792	-0.34	-0.26	Parkinson's disease;	chr6:27715793	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.955	rs9368528	ENSG00000280107.1	AL022393.9	-4.94	1.22e-06	0.000792	-0.34	-0.26	Parkinson's disease;	chr6:27716019	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.955	rs9368529	ENSG00000280107.1	AL022393.9	-4.94	1.22e-06	0.000792	-0.34	-0.26	Parkinson's disease;	chr6:27716852	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.955	rs9380012	ENSG00000280107.1	AL022393.9	-4.94	1.22e-06	0.000792	-0.34	-0.26	Parkinson's disease;	chr6:27716875	chr6:28170845~28172521:+
STAD	cis	rs7829975	0.742	rs7832968	ENSG00000253981.4	ALG1L13P	4.94	1.22e-06	0.000793	0.31	0.26	Mood instability;	chr8:8795379	chr8:8236003~8244667:-
STAD	cis	rs11694172	1	rs11694172	ENSG00000273456.1	RP11-686O6.2	-4.94	1.22e-06	0.000793	-0.28	-0.26	Cholesterol, total;	chr2:202667581	chr2:202374932~202375604:-
STAD	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-4.94	1.22e-06	0.000793	-0.26	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
STAD	cis	rs9860428	0.868	rs9871605	ENSG00000240057.4	RP11-572M11.4	-4.94	1.22e-06	0.000793	-0.23	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112845234	chr3:113019532~113183301:+
STAD	cis	rs7487075	0.752	rs1060735	ENSG00000272369.1	RP11-446N19.1	4.94	1.22e-06	0.000793	0.34	0.26	Itch intensity from mosquito bite;	chr12:46267604	chr12:46537502~46652550:+
STAD	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-4.94	1.22e-06	0.000793	-0.35	-0.26	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
STAD	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	4.94	1.22e-06	0.000793	0.26	0.26	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
STAD	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-4.94	1.22e-06	0.000794	-0.31	-0.26	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
STAD	cis	rs2404602	0.692	rs2120108	ENSG00000259422.1	RP11-593F23.1	-4.94	1.22e-06	0.000794	-0.27	-0.26	Blood metabolite levels;	chr15:76577588	chr15:76174891~76181486:-
STAD	cis	rs1799949	1	rs8176103	ENSG00000236383.6	LINC00854	-4.94	1.23e-06	0.000794	-0.21	-0.26	Menopause (age at onset);	chr17:43115033	chr17:43216941~43305976:-
STAD	cis	rs13113518	0.812	rs13116035	ENSG00000223305.1	RN7SKP30	4.94	1.23e-06	0.000794	0.29	0.26	Height;	chr4:55561218	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.783	rs2171618	ENSG00000223305.1	RN7SKP30	4.94	1.23e-06	0.000794	0.29	0.26	Height;	chr4:55564241	chr4:55540502~55540835:-
STAD	cis	rs8097348	0.817	rs7227211	ENSG00000266602.1	RP11-476K15.1	-4.94	1.23e-06	0.000795	-0.3	-0.26	Exercise (leisure time);	chr18:1627344	chr18:1509183~1647097:+
STAD	cis	rs10129255	0.5	rs6576225	ENSG00000211973.2	IGHV1-69	4.94	1.23e-06	0.000795	0.21	0.26	Kawasaki disease;	chr14:106778120	chr14:106714684~106715181:-
STAD	cis	rs853679	0.517	rs9295761	ENSG00000220721.1	OR1F12	4.94	1.23e-06	0.000795	0.3	0.26	Depression;	chr6:28180209	chr6:28073316~28074233:+
STAD	cis	rs853679	0.76	rs9468317	ENSG00000220721.1	OR1F12	4.94	1.23e-06	0.000795	0.3	0.26	Depression;	chr6:28230678	chr6:28073316~28074233:+
STAD	cis	rs516805	0.667	rs2606610	ENSG00000279453.1	RP3-425C14.4	-4.94	1.23e-06	0.000795	-0.36	-0.26	Lymphocyte counts;	chr6:122189959	chr6:122436789~122439223:-
STAD	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	4.94	1.23e-06	0.000796	0.32	0.26	Depression;	chr6:28240757	chr6:28943877~28944537:+
STAD	cis	rs13113518	0.783	rs34534635	ENSG00000223305.1	RN7SKP30	4.94	1.23e-06	0.000796	0.29	0.26	Height;	chr4:55573424	chr4:55540502~55540835:-
STAD	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-4.94	1.23e-06	0.000796	-0.32	-0.26	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
STAD	cis	rs875971	0.793	rs460678	ENSG00000236529.1	RP13-254B10.1	4.94	1.23e-06	0.000797	0.27	0.26	Aortic root size;	chr7:66062213	chr7:65840212~65840596:+
STAD	cis	rs1862618	0.671	rs252897	ENSG00000271828.1	CTD-2310F14.1	4.94	1.23e-06	0.000797	0.32	0.26	Initial pursuit acceleration;	chr5:56927173	chr5:56927874~56929573:+
STAD	cis	rs227275	0.554	rs223409	ENSG00000248971.2	KRT8P46	-4.94	1.23e-06	0.000797	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102728746~102730171:-
STAD	cis	rs8097348	1	rs1869532	ENSG00000266602.1	RP11-476K15.1	-4.94	1.23e-06	0.000798	-0.32	-0.26	Exercise (leisure time);	chr18:1600080	chr18:1509183~1647097:+
STAD	cis	rs10504130	0.696	rs17212256	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs12676780	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs12676835	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs12677407	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs59602923	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs113096282	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.735	rs77362085	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.735	rs12681203	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.735	rs12679287	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs79069311	ENSG00000272024.1	RP11-546K22.3	-4.94	1.23e-06	0.000798	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51950284~51950690:+
STAD	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	4.94	1.23e-06	0.000798	0.37	0.26	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
STAD	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	4.94	1.23e-06	0.000799	0.3	0.26	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
STAD	cis	rs5769707	0.554	rs10854876	ENSG00000280224.1	CTA-722E9.1	-4.94	1.24e-06	0.000801	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49500568~49501585:+
STAD	cis	rs3736858	0.935	rs9530471	ENSG00000261105.4	LMO7-AS1	-4.94	1.24e-06	0.000801	-0.43	-0.26	Interleukin-9 levels;	chr13:75845638	chr13:75604700~75635994:-
STAD	cis	rs7429990	0.965	rs7426976	ENSG00000224895.1	VPS26BP1	4.94	1.24e-06	0.000802	0.26	0.26	Educational attainment (years of education);	chr3:47981083	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs1013431	ENSG00000224895.1	VPS26BP1	4.94	1.24e-06	0.000802	0.26	0.26	Educational attainment (years of education);	chr3:47987628	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs9862913	ENSG00000224895.1	VPS26BP1	-4.94	1.24e-06	0.000802	-0.26	-0.26	Educational attainment (years of education);	chr3:47974682	chr3:47960327~47961081:-
STAD	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-4.94	1.24e-06	0.000802	-0.3	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
STAD	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-4.94	1.24e-06	0.000802	-0.3	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
STAD	cis	rs11098499	0.866	rs11098506	ENSG00000260091.1	RP11-33B1.4	4.94	1.24e-06	0.000803	0.24	0.26	Corneal astigmatism;	chr4:119363816	chr4:119409333~119410233:+
STAD	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	4.94	1.24e-06	0.000803	0.33	0.26	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
STAD	cis	rs36423	0.702	rs1205076	ENSG00000266869.1	RP6-114E22.1	4.94	1.24e-06	0.000804	0.43	0.26	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71871335	chr14:71848606~71908430:+
STAD	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	4.94	1.24e-06	0.000804	0.33	0.26	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
STAD	cis	rs561341	0.943	rs508566	ENSG00000265798.5	RP11-271K11.5	4.94	1.24e-06	0.000805	0.4	0.26	Hip circumference adjusted for BMI;	chr17:31962842	chr17:31038575~31059121:-
STAD	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-4.94	1.25e-06	0.000806	-0.23	-0.26	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
STAD	cis	rs747650	0.532	rs10838658	ENSG00000271350.1	CTD-2384B9.1	4.94	1.25e-06	0.000806	0.33	0.26	Acne (severe);	chr11:47109227	chr11:47041027~47041945:-
STAD	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	4.94	1.25e-06	0.000806	0.3	0.26	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
STAD	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	4.94	1.25e-06	0.000806	0.3	0.26	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
STAD	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	4.94	1.25e-06	0.000807	0.27	0.26	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
STAD	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	4.94	1.25e-06	0.000807	0.27	0.26	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
STAD	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-4.94	1.25e-06	0.000807	-0.3	-0.26	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
STAD	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-4.94	1.25e-06	0.000807	-0.3	-0.26	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
STAD	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	4.93	1.25e-06	0.000808	0.44	0.26	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	4.93	1.25e-06	0.000808	0.44	0.26	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
STAD	cis	rs3758911	0.964	rs10789601	ENSG00000261098.1	RP11-819C21.1	-4.93	1.25e-06	0.000809	-0.23	-0.26	Coronary artery disease;	chr11:107310693	chr11:107312132~107316271:-
STAD	cis	rs4713118	0.868	rs9468220	ENSG00000280107.1	AL022393.9	4.93	1.25e-06	0.00081	0.36	0.26	Parkinson's disease;	chr6:27765197	chr6:28170845~28172521:+
STAD	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	4.93	1.26e-06	0.000812	0.28	0.26	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
STAD	cis	rs1150668	0.699	rs1736895	ENSG00000220721.1	OR1F12	4.93	1.26e-06	0.000813	0.24	0.26	Pubertal anthropometrics;	chr6:28252048	chr6:28073316~28074233:+
STAD	cis	rs1150668	0.699	rs12214383	ENSG00000220721.1	OR1F12	-4.93	1.26e-06	0.000813	-0.24	-0.26	Pubertal anthropometrics;	chr6:28255953	chr6:28073316~28074233:+
STAD	cis	rs7078219	0.714	rs11190139	ENSG00000228778.1	RP11-129J12.1	-4.93	1.26e-06	0.000813	-0.32	-0.26	Dental caries;	chr10:99528342	chr10:99527081~99528261:+
STAD	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-4.93	1.26e-06	0.000813	-0.3	-0.26	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
STAD	cis	rs7932354	0.528	rs4319472	ENSG00000271350.1	CTD-2384B9.1	4.93	1.26e-06	0.000814	0.31	0.26	Bone mineral density (hip);Bone mineral density;	chr11:47087963	chr11:47041027~47041945:-
STAD	cis	rs1799949	1	rs3950989	ENSG00000236383.6	LINC00854	-4.93	1.26e-06	0.000815	-0.21	-0.26	Menopause (age at onset);	chr17:43085936	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs8176161	ENSG00000236383.6	LINC00854	-4.93	1.26e-06	0.000815	-0.21	-0.26	Menopause (age at onset);	chr17:43089373	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.894	rs8176160	ENSG00000236383.6	LINC00854	-4.93	1.26e-06	0.000815	-0.21	-0.26	Menopause (age at onset);	chr17:43089486	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs2070834	ENSG00000236383.6	LINC00854	-4.93	1.26e-06	0.000815	-0.21	-0.26	Menopause (age at onset);	chr17:43090268	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs16942	ENSG00000236383.6	LINC00854	-4.93	1.26e-06	0.000815	-0.21	-0.26	Menopause (age at onset);	chr17:43091983	chr17:43216941~43305976:-
STAD	cis	rs17301013	0.861	rs61826916	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000815	0.32	0.26	Systemic lupus erythematosus;	chr1:174616048	chr1:174115300~174160004:-
STAD	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-4.93	1.26e-06	0.000816	-0.43	-0.26	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
STAD	cis	rs7829975	0.681	rs2271342	ENSG00000253981.4	ALG1L13P	4.93	1.26e-06	0.000817	0.3	0.26	Mood instability;	chr8:8786428	chr8:8236003~8244667:-
STAD	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-4.93	1.26e-06	0.000817	-0.27	-0.26	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
STAD	cis	rs2273156	0.636	rs12892552	ENSG00000241052.1	RP11-173D9.1	-4.93	1.26e-06	0.000817	-0.3	-0.26	Immunoglobulin light chain (AL) amyloidosis;	chr14:35036208	chr14:35144021~35144480:-
STAD	cis	rs2688608	0.592	rs3933085	ENSG00000271816.1	BMS1P4	4.93	1.27e-06	0.000817	0.28	0.26	Inflammatory bowel disease;	chr10:73723573	chr10:73699151~73730487:-
STAD	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	4.93	1.27e-06	0.000818	0.27	0.26	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
STAD	cis	rs875971	0.545	rs1638735	ENSG00000236529.1	RP13-254B10.1	4.93	1.27e-06	0.000818	0.29	0.26	Aortic root size;	chr7:66630751	chr7:65840212~65840596:+
STAD	cis	rs1056107	0.933	rs7865225	ENSG00000225513.1	RP11-165N19.2	-4.93	1.27e-06	0.000818	-0.29	-0.26	Colorectal cancer;	chr9:112211969	chr9:112173522~112173971:-
STAD	cis	rs7078219	0.543	rs4919342	ENSG00000228778.1	RP11-129J12.1	-4.93	1.27e-06	0.000819	-0.3	-0.26	Dental caries;	chr10:99522796	chr10:99527081~99528261:+
STAD	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-4.93	1.27e-06	0.000819	-0.41	-0.26	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
STAD	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	4.93	1.27e-06	0.000819	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
STAD	cis	rs1150668	0.764	rs9368565	ENSG00000220721.1	OR1F12	-4.93	1.27e-06	0.00082	-0.25	-0.26	Pubertal anthropometrics;	chr6:28377433	chr6:28073316~28074233:+
STAD	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-4.93	1.27e-06	0.00082	-0.27	-0.26	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
STAD	cis	rs875971	0.862	rs1983372	ENSG00000236529.1	RP13-254B10.1	-4.93	1.27e-06	0.000822	-0.27	-0.26	Aortic root size;	chr7:66146364	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs7809814	ENSG00000236529.1	RP13-254B10.1	-4.93	1.27e-06	0.000822	-0.27	-0.26	Aortic root size;	chr7:66150410	chr7:65840212~65840596:+
STAD	cis	rs2688608	0.592	rs7909802	ENSG00000271816.1	BMS1P4	4.93	1.27e-06	0.000822	0.28	0.26	Inflammatory bowel disease;	chr10:73724428	chr10:73699151~73730487:-
STAD	cis	rs7487075	0.82	rs4768113	ENSG00000272369.1	RP11-446N19.1	4.93	1.27e-06	0.000823	0.31	0.26	Itch intensity from mosquito bite;	chr12:46314253	chr12:46537502~46652550:+
STAD	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-4.93	1.27e-06	0.000823	-0.3	-0.26	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.896	rs35908185	ENSG00000236383.6	LINC00854	-4.93	1.27e-06	0.000823	-0.21	-0.26	Menopause (age at onset);	chr17:43103094	chr17:43216941~43305976:-
STAD	cis	rs6142102	0.961	rs1319363	ENSG00000275784.1	RP5-1125A11.6	-4.93	1.28e-06	0.000824	-0.26	-0.26	Skin pigmentation;	chr20:33954070	chr20:33989480~33991818:-
STAD	cis	rs728616	0.614	rs35395602	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.28e-06	0.000824	-0.47	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147014	chr10:79663088~79826594:-
STAD	cis	rs728616	0.681	rs36023925	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.28e-06	0.000824	-0.47	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147090	chr10:79663088~79826594:-
STAD	cis	rs7932354	0.528	rs10466478	ENSG00000271350.1	CTD-2384B9.1	-4.93	1.28e-06	0.000824	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:47141053	chr11:47041027~47041945:-
STAD	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-4.93	1.28e-06	0.000825	-0.33	-0.26	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
STAD	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-4.93	1.28e-06	0.000826	-0.27	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
STAD	cis	rs10510102	0.935	rs11200187	ENSG00000226864.1	ATE1-AS1	4.93	1.28e-06	0.000826	0.4	0.26	Breast cancer;	chr10:121843050	chr10:121928312~121951965:+
STAD	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-4.93	1.28e-06	0.000826	-0.28	-0.26	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
STAD	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-4.93	1.28e-06	0.000826	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-4.93	1.28e-06	0.000826	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
STAD	cis	rs944990	0.576	rs10821135	ENSG00000227603.1	RP11-165J3.6	4.93	1.28e-06	0.000826	0.28	0.26	Body mass index;	chr9:93476296	chr9:93435332~93437121:-
STAD	cis	rs17301013	0.803	rs2187562	ENSG00000227373.4	RP11-160H22.5	4.93	1.28e-06	0.000827	0.3	0.26	Systemic lupus erythematosus;	chr1:174842513	chr1:174115300~174160004:-
STAD	cis	rs7932354	0.528	rs11039105	ENSG00000271350.1	CTD-2384B9.1	4.93	1.28e-06	0.000827	0.31	0.26	Bone mineral density (hip);Bone mineral density;	chr11:47136126	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.69	rs34818745	ENSG00000260091.1	RP11-33B1.4	4.93	1.28e-06	0.000827	0.26	0.26	Corneal astigmatism;	chr4:119335900	chr4:119409333~119410233:+
STAD	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	4.93	1.28e-06	0.000827	0.36	0.26	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	4.93	1.28e-06	0.000827	0.36	0.26	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
STAD	cis	rs10978777	0.921	rs817845	ENSG00000276883.1	AL137852.1	4.93	1.28e-06	0.000827	0.25	0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107339429	chr9:107292369~107292456:-
STAD	cis	rs3758911	0.894	rs11212156	ENSG00000261098.1	RP11-819C21.1	-4.93	1.28e-06	0.000827	-0.23	-0.26	Coronary artery disease;	chr11:107323381	chr11:107312132~107316271:-
STAD	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	4.93	1.28e-06	0.000827	0.32	0.26	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
STAD	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-4.93	1.28e-06	0.000828	-0.33	-0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
STAD	cis	rs3770081	1	rs3770087	ENSG00000273080.1	RP11-301O19.1	-4.93	1.28e-06	0.000828	-0.56	-0.26	Facial emotion recognition (sad faces);	chr2:86039945	chr2:86195590~86196049:+
STAD	cis	rs728616	0.614	rs61859199	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.28e-06	0.000828	-0.5	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79663088~79826594:-
STAD	cis	rs728616	0.614	rs1538818	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.28e-06	0.000828	-0.5	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79663088~79826594:-
STAD	cis	rs728616	0.614	rs61859209	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.28e-06	0.000828	-0.5	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79663088~79826594:-
STAD	cis	rs728616	0.614	rs61859210	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.28e-06	0.000828	-0.5	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79663088~79826594:-
STAD	cis	rs11676348	0.846	rs4674259	ENSG00000237281.1	CATIP-AS2	4.93	1.28e-06	0.000828	0.25	0.26	Ulcerative colitis;	chr2:218126282	chr2:218326889~218357966:-
STAD	cis	rs11098499	0.909	rs10020034	ENSG00000260091.1	RP11-33B1.4	4.93	1.29e-06	0.000829	0.25	0.26	Corneal astigmatism;	chr4:119373176	chr4:119409333~119410233:+
STAD	cis	rs1056107	0.933	rs4979099	ENSG00000225513.1	RP11-165N19.2	-4.93	1.29e-06	0.00083	-0.3	-0.26	Colorectal cancer;	chr9:112319336	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs3808879	ENSG00000225513.1	RP11-165N19.2	-4.93	1.29e-06	0.000831	-0.3	-0.26	Colorectal cancer;	chr9:112299198	chr9:112173522~112173971:-
STAD	cis	rs6095360	0.727	rs13037813	ENSG00000222365.1	SNORD12B	-4.93	1.29e-06	0.000831	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49134051	chr20:49280319~49280409:+
STAD	cis	rs875971	0.79	rs10257911	ENSG00000236529.1	RP13-254B10.1	-4.93	1.29e-06	0.000831	-0.26	-0.26	Aortic root size;	chr7:66278783	chr7:65840212~65840596:+
STAD	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-4.93	1.29e-06	0.000831	-0.29	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
STAD	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-4.93	1.29e-06	0.000831	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
STAD	cis	rs2404602	0.692	rs67570291	ENSG00000259422.1	RP11-593F23.1	4.93	1.29e-06	0.000831	0.27	0.26	Blood metabolite levels;	chr15:76728161	chr15:76174891~76181486:-
STAD	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-4.93	1.29e-06	0.000831	-0.24	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
STAD	cis	rs9467773	0.933	rs2024970	ENSG00000243307.2	POM121L6P	4.93	1.29e-06	0.000832	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26497292	chr6:26896952~26898777:+
STAD	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-4.93	1.29e-06	0.000832	-0.26	-0.26	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
STAD	cis	rs2404602	0.536	rs12915248	ENSG00000259422.1	RP11-593F23.1	4.93	1.29e-06	0.000832	0.27	0.26	Blood metabolite levels;	chr15:76473274	chr15:76174891~76181486:-
STAD	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	4.93	1.29e-06	0.000832	0.34	0.26	Height;	chr6:109449796	chr6:109382795~109383666:+
STAD	cis	rs7580658	0.637	rs12463909	ENSG00000200250.1	RNU6-1147P	-4.93	1.29e-06	0.000833	-0.24	-0.26	Protein C levels;	chr2:127214162	chr2:127316873~127316979:+
STAD	cis	rs804280	0.509	rs13276433	ENSG00000255495.1	AC145124.2	4.93	1.29e-06	0.000833	0.29	0.26	Myopia (pathological);	chr8:11925527	chr8:12194467~12196280:+
STAD	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-4.93	1.3e-06	0.000835	-0.33	-0.26	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-4.93	1.3e-06	0.000835	-0.33	-0.26	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
STAD	cis	rs6714710	0.603	rs35424768	ENSG00000235833.1	AC159540.14	-4.93	1.3e-06	0.000835	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97779190	chr2:97523949~97524976:-
STAD	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-4.93	1.3e-06	0.000835	-0.3	-0.26	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
STAD	cis	rs7078219	0.505	rs6584282	ENSG00000228778.1	RP11-129J12.1	-4.93	1.3e-06	0.000835	-0.29	-0.26	Dental caries;	chr10:99526738	chr10:99527081~99528261:+
STAD	cis	rs1345301	1	rs13431601	ENSG00000234389.1	AC007278.3	-4.93	1.3e-06	0.000835	-0.26	-0.26	Waist circumference;	chr2:102257253	chr2:102438713~102440475:+
STAD	cis	rs875971	0.545	rs67775320	ENSG00000236529.1	RP13-254B10.1	4.93	1.3e-06	0.000836	0.3	0.26	Aortic root size;	chr7:66193792	chr7:65840212~65840596:+
STAD	cis	rs35934224	0.783	rs7287073	ENSG00000232926.1	AC000078.5	4.93	1.3e-06	0.000837	0.38	0.26	Glaucoma (primary open-angle);	chr22:19876812	chr22:19887289~19887970:+
STAD	cis	rs9907295	1	rs11653282	ENSG00000270894.1	AC015849.13	-4.93	1.3e-06	0.000837	-0.28	-0.26	Fibroblast growth factor basic levels;	chr17:35909742	chr17:35818399~35823713:+
STAD	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	4.93	1.3e-06	0.000838	0.36	0.26	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
STAD	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	4.93	1.3e-06	0.000838	0.25	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
STAD	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	4.93	1.3e-06	0.000838	0.38	0.26	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
STAD	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-4.93	1.3e-06	0.000838	-0.34	-0.26	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
STAD	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-4.93	1.3e-06	0.000839	-0.27	-0.26	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
STAD	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	4.93	1.3e-06	0.000839	0.41	0.26	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
STAD	cis	rs728616	0.558	rs116434658	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.3e-06	0.000839	-0.46	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79663088~79826594:-
STAD	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-4.93	1.3e-06	0.00084	-0.26	-0.26	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
STAD	cis	rs7078219	0.505	rs7085798	ENSG00000228778.1	RP11-129J12.1	-4.93	1.3e-06	0.00084	-0.29	-0.26	Dental caries;	chr10:99528590	chr10:99527081~99528261:+
STAD	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	4.93	1.31e-06	0.00084	0.3	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
STAD	cis	rs606458	0.841	rs674297	ENSG00000269038.1	AP001462.6	-4.93	1.31e-06	0.000841	-0.35	-0.26	Urate levels;	chr11:64782042	chr11:64778954~64779405:+
STAD	cis	rs950169	0.881	rs150965	ENSG00000259295.5	CSPG4P12	4.93	1.31e-06	0.000841	0.38	0.26	Schizophrenia;	chr15:84537296	chr15:85191438~85213905:+
STAD	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-4.93	1.31e-06	0.000842	-0.42	-0.26	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
STAD	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-4.92	1.31e-06	0.000843	-0.28	-0.26	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
STAD	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	4.92	1.31e-06	0.000843	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
STAD	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	4.92	1.31e-06	0.000844	0.35	0.26	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
STAD	cis	rs9467773	0.649	rs2145318	ENSG00000243307.2	POM121L6P	4.92	1.31e-06	0.000844	0.24	0.26	Intelligence (multi-trait analysis);	chr6:26496375	chr6:26896952~26898777:+
STAD	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-4.92	1.31e-06	0.000844	-0.29	-0.26	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
STAD	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-4.92	1.31e-06	0.000845	-0.26	-0.26	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
STAD	cis	rs11671005	0.651	rs55716128	ENSG00000235974.1	VN2R19P	4.92	1.31e-06	0.000845	0.36	0.26	Mean platelet volume;	chr19:58537387	chr19:58012589~58025926:-
STAD	cis	rs891378	1	rs2802238	ENSG00000274245.1	RP11-357P18.2	-4.92	1.31e-06	0.000845	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302796	chr1:207372559~207373252:+
STAD	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	4.92	1.31e-06	0.000845	0.25	0.26	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
STAD	cis	rs8177876	0.642	rs4454990	ENSG00000261061.1	RP11-303E16.2	4.92	1.32e-06	0.000846	0.4	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81030770~81031485:+
STAD	cis	rs1336900	0.544	rs10888386	ENSG00000274963.1	Metazoa_SRP	-4.92	1.32e-06	0.000847	-0.22	-0.26	Blood protein levels;	chr1:150639481	chr1:150568971~150569269:-
STAD	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-4.92	1.32e-06	0.000847	-0.3	-0.26	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
STAD	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	4.92	1.32e-06	0.000847	0.3	0.26	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
STAD	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	4.92	1.32e-06	0.000847	0.26	0.26	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
STAD	cis	rs875971	0.964	rs697969	ENSG00000236529.1	RP13-254B10.1	-4.92	1.32e-06	0.000847	-0.27	-0.26	Aortic root size;	chr7:66093491	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs1182882	ENSG00000236529.1	RP13-254B10.1	-4.92	1.32e-06	0.000847	-0.27	-0.26	Aortic root size;	chr7:66097076	chr7:65840212~65840596:+
STAD	cis	rs10504130	0.569	rs12678646	ENSG00000272024.1	RP11-546K22.3	-4.92	1.32e-06	0.000848	-0.37	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51950284~51950690:+
STAD	cis	rs7119038	0.818	rs7942535	ENSG00000255422.1	AP002954.4	-4.92	1.32e-06	0.00085	-0.33	-0.26	Sjögren's syndrome;	chr11:118810755	chr11:118704607~118750263:+
STAD	cis	rs4950322	0.748	rs56392137	ENSG00000278811.3	LINC00624	4.92	1.32e-06	0.00085	0.28	0.26	Protein quantitative trait loci;	chr1:147352450	chr1:147258885~147517875:-
STAD	cis	rs12439619	0.508	rs8032033	ENSG00000255769.6	GOLGA2P10	-4.92	1.32e-06	0.000851	-0.31	-0.26	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472993~82513950:-
STAD	cis	rs1056107	0.933	rs10981350	ENSG00000225513.1	RP11-165N19.2	-4.92	1.32e-06	0.000851	-0.3	-0.26	Colorectal cancer;	chr9:112304611	chr9:112173522~112173971:-
STAD	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	4.92	1.33e-06	0.000852	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
STAD	cis	rs10510102	0.935	rs7907871	ENSG00000226864.1	ATE1-AS1	4.92	1.33e-06	0.000852	0.4	0.26	Breast cancer;	chr10:121878185	chr10:121928312~121951965:+
STAD	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-4.92	1.33e-06	0.000852	-0.41	-0.26	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
STAD	cis	rs4950322	0.57	rs72691032	ENSG00000278811.3	LINC00624	4.92	1.33e-06	0.000853	0.29	0.26	Protein quantitative trait loci;	chr1:147261120	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691033	ENSG00000278811.3	LINC00624	4.92	1.33e-06	0.000853	0.29	0.26	Protein quantitative trait loci;	chr1:147261267	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs111370771	ENSG00000278811.3	LINC00624	4.92	1.33e-06	0.000853	0.29	0.26	Protein quantitative trait loci;	chr1:147261420	chr1:147258885~147517875:-
STAD	cis	rs721917	0.506	rs2475756	ENSG00000244733.5	RP11-506M13.3	-4.92	1.33e-06	0.000853	-0.31	-0.26	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79660891~79677996:+
STAD	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	4.92	1.33e-06	0.000853	0.3	0.26	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
STAD	cis	rs9733	0.791	rs11204693	ENSG00000274963.1	Metazoa_SRP	-4.92	1.33e-06	0.000854	-0.2	-0.26	Tonsillectomy;	chr1:150675511	chr1:150568971~150569269:-
STAD	cis	rs2337406	0.866	rs79901786	ENSG00000280411.1	IGHV1-69-2	-4.92	1.33e-06	0.000854	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106777623	chr14:106762092~106762588:-
STAD	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-4.92	1.33e-06	0.000854	-0.27	-0.26	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
STAD	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-4.92	1.33e-06	0.000854	-0.32	-0.26	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
STAD	cis	rs1799949	1	rs8176109	ENSG00000236383.6	LINC00854	-4.92	1.33e-06	0.000854	-0.21	-0.26	Menopause (age at onset);	chr17:43113759	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.896	rs8176098	ENSG00000236383.6	LINC00854	-4.92	1.33e-06	0.000854	-0.21	-0.26	Menopause (age at onset);	chr17:43116189	chr17:43216941~43305976:-
STAD	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	4.92	1.33e-06	0.000855	0.43	0.26	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
STAD	cis	rs8067354	0.645	rs2271304	ENSG00000266701.1	AC005702.4	4.92	1.33e-06	0.000856	0.36	0.26	Hemoglobin concentration;	chr17:59737280	chr17:60042546~60042627:-
STAD	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	4.92	1.33e-06	0.000856	0.25	0.26	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
STAD	cis	rs8098244	0.516	rs60464408	ENSG00000267301.1	RPL23AP77	-4.92	1.33e-06	0.000856	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692874	chr18:23709825~23710287:-
STAD	cis	rs875971	0.545	rs1909508	ENSG00000236529.1	RP13-254B10.1	4.92	1.33e-06	0.000856	0.3	0.26	Aortic root size;	chr7:66301366	chr7:65840212~65840596:+
STAD	cis	rs3858145	0.505	rs12765827	ENSG00000233590.1	RP11-153K11.3	4.92	1.33e-06	0.000856	0.33	0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68286821	chr10:68233251~68242379:-
STAD	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-4.92	1.33e-06	0.000857	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
STAD	cis	rs7474896	0.583	rs12776092	ENSG00000120555.12	SEPT7P9	4.92	1.34e-06	0.000857	0.31	0.26	Obesity (extreme);	chr10:37726867	chr10:38383069~38402916:-
STAD	cis	rs240993	0.715	rs399219	ENSG00000230177.1	RP5-1112D6.4	-4.92	1.34e-06	0.000857	-0.26	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111371880	chr6:111277932~111278742:+
STAD	cis	rs728616	0.558	rs35698456	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.34e-06	0.000857	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80381806	chr10:79663088~79826594:-
STAD	cis	rs737008	0.821	rs28671554	ENSG00000262703.1	RP11-485G7.6	4.92	1.34e-06	0.000857	0.25	0.26	Obesity-related traits;	chr16:11309896	chr16:11348143~11349321:-
STAD	cis	rs1150668	0.699	rs1531681	ENSG00000220721.1	OR1F12	4.92	1.34e-06	0.000858	0.24	0.26	Pubertal anthropometrics;	chr6:28259100	chr6:28073316~28074233:+
STAD	cis	rs728616	0.681	rs17677908	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.34e-06	0.000858	-0.5	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80289847	chr10:79663088~79826594:-
STAD	cis	rs728616	0.681	rs55899456	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.34e-06	0.000858	-0.5	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80290890	chr10:79663088~79826594:-
STAD	cis	rs9463078	0.605	rs1304168	ENSG00000219384.1	RP11-491H9.3	4.92	1.34e-06	0.000858	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45230555	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.565	rs1581777	ENSG00000219384.1	RP11-491H9.3	4.92	1.34e-06	0.000858	0.25	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45231828	chr6:45158870~45159511:+
STAD	cis	rs1799949	1	rs35668327	ENSG00000236383.6	LINC00854	-4.92	1.34e-06	0.000858	-0.21	-0.26	Menopause (age at onset);	chr17:43121078	chr17:43216941~43305976:-
STAD	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-4.92	1.34e-06	0.000858	-0.28	-0.26	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
STAD	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	4.92	1.34e-06	0.00086	0.35	0.26	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
STAD	cis	rs3758911	0.828	rs10890695	ENSG00000261098.1	RP11-819C21.1	-4.92	1.34e-06	0.000861	-0.24	-0.26	Coronary artery disease;	chr11:107294923	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs11212142	ENSG00000261098.1	RP11-819C21.1	-4.92	1.34e-06	0.000861	-0.24	-0.26	Coronary artery disease;	chr11:107302994	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs10789597	ENSG00000261098.1	RP11-819C21.1	-4.92	1.34e-06	0.000861	-0.24	-0.26	Coronary artery disease;	chr11:107304314	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs12285607	ENSG00000261098.1	RP11-819C21.1	-4.92	1.34e-06	0.000861	-0.24	-0.26	Coronary artery disease;	chr11:107304608	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs10890696	ENSG00000261098.1	RP11-819C21.1	-4.92	1.34e-06	0.000861	-0.24	-0.26	Coronary artery disease;	chr11:107306487	chr11:107312132~107316271:-
STAD	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-4.92	1.34e-06	0.000861	-0.27	-0.26	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
STAD	cis	rs7826238	0.653	rs2979202	ENSG00000254340.1	RP11-10A14.3	4.92	1.34e-06	0.000861	0.3	0.26	Systolic blood pressure;	chr8:8486617	chr8:9141424~9145435:+
STAD	cis	rs8098244	0.638	rs9962076	ENSG00000267301.1	RPL23AP77	-4.92	1.34e-06	0.000862	-0.3	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23850198	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.638	rs2001437	ENSG00000267301.1	RPL23AP77	-4.92	1.34e-06	0.000862	-0.3	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23854811	chr18:23709825~23710287:-
STAD	cis	rs7829975	0.623	rs10087493	ENSG00000254340.1	RP11-10A14.3	-4.92	1.34e-06	0.000862	-0.3	-0.26	Mood instability;	chr8:8516047	chr8:9141424~9145435:+
STAD	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-4.92	1.34e-06	0.000862	-0.37	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
STAD	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-4.92	1.35e-06	0.000863	-0.28	-0.26	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
STAD	cis	rs3758911	0.894	rs999984	ENSG00000261098.1	RP11-819C21.1	-4.92	1.35e-06	0.000863	-0.23	-0.26	Coronary artery disease;	chr11:107321266	chr11:107312132~107316271:-
STAD	cis	rs6921919	0.515	rs1339898	ENSG00000220721.1	OR1F12	4.92	1.35e-06	0.000864	0.26	0.26	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28073316~28074233:+
STAD	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	4.92	1.35e-06	0.000864	0.26	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
STAD	cis	rs172166	0.538	rs1150686	ENSG00000220721.1	OR1F12	4.92	1.35e-06	0.000866	0.25	0.26	Cardiac Troponin-T levels;	chr6:28193493	chr6:28073316~28074233:+
STAD	cis	rs1150688	1	rs1150688	ENSG00000220721.1	OR1F12	4.92	1.35e-06	0.000866	0.25	0.26	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28073316~28074233:+
STAD	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	4.92	1.35e-06	0.000866	0.41	0.26	Height;	chr6:109352277	chr6:109382795~109383666:+
STAD	cis	rs9860428	0.723	rs1354055	ENSG00000240057.4	RP11-572M11.4	-4.92	1.35e-06	0.000867	-0.24	-0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896099	chr3:113019532~113183301:+
STAD	cis	rs3747113	1	rs35303215	ENSG00000128262.7	POM121L9P	-4.92	1.35e-06	0.000867	-0.25	-0.26	Gut microbiome composition (summer);	chr22:24405567	chr22:24251828~24265525:+
STAD	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-4.92	1.35e-06	0.000867	-0.36	-0.26	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
STAD	cis	rs7932354	0.583	rs7940578	ENSG00000271350.1	CTD-2384B9.1	-4.92	1.35e-06	0.000868	-0.3	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:46790677	chr11:47041027~47041945:-
STAD	cis	rs7665090	0.714	rs5026475	ENSG00000230069.3	LRRC37A15P	-4.92	1.36e-06	0.000869	-0.29	-0.26	Primary biliary cholangitis;	chr4:102633664	chr4:102727274~102730721:-
STAD	cis	rs5758659	1	rs134900	ENSG00000182057.4	OGFRP1	4.92	1.36e-06	0.000869	0.27	0.26	Cognitive function;	chr22:42287337	chr22:42269753~42275196:+
STAD	cis	rs8028182	0.636	rs7175852	ENSG00000260269.4	CTD-2323K18.1	-4.92	1.36e-06	0.000869	-0.33	-0.26	Sudden cardiac arrest;	chr15:75402194	chr15:75527150~75601205:-
STAD	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-4.92	1.36e-06	0.000869	-0.3	-0.26	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
STAD	cis	rs7932354	0.528	rs7937950	ENSG00000271350.1	CTD-2384B9.1	-4.92	1.36e-06	0.00087	-0.31	-0.26	Bone mineral density (hip);Bone mineral density;	chr11:47076894	chr11:47041027~47041945:-
STAD	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-4.92	1.36e-06	0.000872	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
STAD	cis	rs227275	0.554	rs223422	ENSG00000248971.2	KRT8P46	-4.92	1.36e-06	0.000872	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223421	ENSG00000248971.2	KRT8P46	-4.92	1.36e-06	0.000872	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102728746~102730171:-
STAD	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.36e-06	0.000873	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
STAD	cis	rs3758911	0.861	rs2355840	ENSG00000261098.1	RP11-819C21.1	-4.92	1.36e-06	0.000873	-0.24	-0.26	Coronary artery disease;	chr11:107287251	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs11212132	ENSG00000261098.1	RP11-819C21.1	-4.92	1.36e-06	0.000873	-0.24	-0.26	Coronary artery disease;	chr11:107288576	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs10789594	ENSG00000261098.1	RP11-819C21.1	-4.92	1.36e-06	0.000873	-0.24	-0.26	Coronary artery disease;	chr11:107290391	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.828	rs11212138	ENSG00000261098.1	RP11-819C21.1	-4.92	1.36e-06	0.000873	-0.24	-0.26	Coronary artery disease;	chr11:107294553	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.828	rs11212141	ENSG00000261098.1	RP11-819C21.1	-4.92	1.36e-06	0.000873	-0.24	-0.26	Coronary artery disease;	chr11:107298200	chr11:107312132~107316271:-
STAD	cis	rs2933343	0.649	rs789216	ENSG00000261159.1	RP11-723O4.9	4.92	1.36e-06	0.000873	0.31	0.26	IgG glycosylation;	chr3:128875660	chr3:128859716~128860526:-
STAD	cis	rs8003054	0.589	rs999692	ENSG00000258515.1	RP11-203M5.7	-4.92	1.36e-06	0.000873	-0.27	-0.26	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20449506	chr14:20451305~20451918:+
STAD	cis	rs3770081	1	rs1561328	ENSG00000273080.1	RP11-301O19.1	-4.92	1.37e-06	0.000874	-0.56	-0.26	Facial emotion recognition (sad faces);	chr2:86045635	chr2:86195590~86196049:+
STAD	cis	rs7826238	0.601	rs2976907	ENSG00000254340.1	RP11-10A14.3	4.92	1.37e-06	0.000874	0.3	0.26	Systolic blood pressure;	chr8:8487658	chr8:9141424~9145435:+
STAD	cis	rs202011557	1	rs202011557	ENSG00000234389.1	AC007278.3	4.92	1.37e-06	0.000874	0.39	0.26	Asthma;	chr2:102297182	chr2:102438713~102440475:+
STAD	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-4.92	1.37e-06	0.000874	-0.29	-0.26	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
STAD	cis	rs747650	0.504	rs11601798	ENSG00000271350.1	CTD-2384B9.1	4.92	1.37e-06	0.000875	0.33	0.26	Acne (severe);	chr11:47136841	chr11:47041027~47041945:-
STAD	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-4.92	1.37e-06	0.000875	-0.27	-0.26	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-4.92	1.37e-06	0.000875	-0.27	-0.26	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
STAD	cis	rs728616	0.867	rs17606361	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.37e-06	0.000876	-0.54	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:79663088~79826594:-
STAD	cis	rs4713118	0.869	rs2056925	ENSG00000280107.1	AL022393.9	-4.92	1.37e-06	0.000876	-0.34	-0.26	Parkinson's disease;	chr6:27723126	chr6:28170845~28172521:+
STAD	cis	rs11098499	0.954	rs59866101	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119375436	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.618	rs6858383	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119375617	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.697	rs6832410	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119375645	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs1112817	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119376645	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.779	rs10016060	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119377257	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs10005644	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119377322	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.697	rs10016448	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119377690	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.657	rs9996569	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119377849	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs11723757	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119378514	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.908	rs11729050	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119378911	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs28429722	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119378938	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs10014845	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119379922	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.779	rs7674500	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119382438	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.697	rs4373140	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119386543	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs13113483	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119387884	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.542	rs10440343	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119388632	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs28668716	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119388720	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.779	rs10011097	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119389204	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.542	rs7677836	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119389483	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs10002083	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119389997	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs10024844	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119390373	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs4345162	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119391804	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.657	rs4463052	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119392103	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs13151285	ENSG00000260091.1	RP11-33B1.4	4.92	1.37e-06	0.000876	0.25	0.26	Corneal astigmatism;	chr4:119393586	chr4:119409333~119410233:+
STAD	cis	rs801193	0.569	rs10950050	ENSG00000236529.1	RP13-254B10.1	4.92	1.37e-06	0.000876	0.26	0.26	Aortic root size;	chr7:66774601	chr7:65840212~65840596:+
STAD	cis	rs6095360	0.727	rs35971376	ENSG00000222365.1	SNORD12B	-4.92	1.37e-06	0.000876	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49105171	chr20:49280319~49280409:+
STAD	cis	rs944722	0.935	rs2872753	ENSG00000266786.1	LGALS9DP	-4.92	1.37e-06	0.000876	-0.31	-0.26	Fractional exhaled nitric oxide (childhood);	chr17:27768536	chr17:27746132~27754954:+
STAD	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	4.92	1.37e-06	0.000876	0.31	0.26	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	4.92	1.37e-06	0.000876	0.31	0.26	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
STAD	cis	rs7615952	0.673	rs34209763	ENSG00000272840.1	RP11-379B18.6	4.92	1.37e-06	0.000876	0.51	0.26	Blood pressure (smoking interaction);	chr3:125880752	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.8	rs35390120	ENSG00000272840.1	RP11-379B18.6	4.92	1.37e-06	0.000876	0.51	0.26	Blood pressure (smoking interaction);	chr3:125880966	chr3:125774714~125797953:+
STAD	cis	rs2337406	0.81	rs7161739	ENSG00000280411.1	IGHV1-69-2	-4.92	1.37e-06	0.000876	-0.3	-0.26	Alzheimer's disease (late onset);	chr14:106776118	chr14:106762092~106762588:-
STAD	cis	rs35934224	0.724	rs16984286	ENSG00000232926.1	AC000078.5	4.92	1.37e-06	0.000877	0.34	0.26	Glaucoma (primary open-angle);	chr22:19870591	chr22:19887289~19887970:+
STAD	cis	rs227275	0.554	rs223404	ENSG00000248971.2	KRT8P46	-4.92	1.37e-06	0.000877	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102728746~102730171:-
STAD	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	4.91	1.37e-06	0.000879	0.4	0.26	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
STAD	cis	rs11846409	0.86	rs1974470	ENSG00000211972.2	IGHV3-66	4.91	1.37e-06	0.000879	0.28	0.26	Rheumatic heart disease;	chr14:106621300	chr14:106675017~106675544:-
STAD	cis	rs1056107	0.933	rs7861162	ENSG00000225513.1	RP11-165N19.2	-4.91	1.38e-06	0.000879	-0.29	-0.26	Colorectal cancer;	chr9:112207436	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs7861447	ENSG00000225513.1	RP11-165N19.2	-4.91	1.38e-06	0.000879	-0.29	-0.26	Colorectal cancer;	chr9:112207493	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs7861788	ENSG00000225513.1	RP11-165N19.2	-4.91	1.38e-06	0.000879	-0.29	-0.26	Colorectal cancer;	chr9:112207709	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.933	rs4644329	ENSG00000225513.1	RP11-165N19.2	-4.91	1.38e-06	0.000879	-0.29	-0.26	Colorectal cancer;	chr9:112207713	chr9:112173522~112173971:-
STAD	cis	rs9463078	0.605	rs10948188	ENSG00000219384.1	RP11-491H9.3	-4.91	1.38e-06	0.00088	-0.24	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44958475	chr6:45158870~45159511:+
STAD	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-4.91	1.38e-06	0.00088	-0.3	-0.26	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-4.91	1.38e-06	0.00088	-0.3	-0.26	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
STAD	cis	rs7932354	0.502	rs57323109	ENSG00000271350.1	CTD-2384B9.1	4.91	1.38e-06	0.00088	0.31	0.26	Bone mineral density (hip);Bone mineral density;	chr11:47171816	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.502	rs11600668	ENSG00000271350.1	CTD-2384B9.1	4.91	1.38e-06	0.00088	0.31	0.26	Bone mineral density (hip);Bone mineral density;	chr11:47172015	chr11:47041027~47041945:-
STAD	cis	rs13113518	0.812	rs3805153	ENSG00000223305.1	RN7SKP30	4.91	1.38e-06	0.00088	0.29	0.26	Height;	chr4:55493557	chr4:55540502~55540835:-
STAD	cis	rs2404602	0.716	rs4886817	ENSG00000259422.1	RP11-593F23.1	4.91	1.38e-06	0.00088	0.27	0.26	Blood metabolite levels;	chr15:76585361	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs57178708	ENSG00000259422.1	RP11-593F23.1	4.91	1.38e-06	0.00088	0.27	0.26	Blood metabolite levels;	chr15:76611728	chr15:76174891~76181486:-
STAD	cis	rs6430585	0.583	rs78364332	ENSG00000231890.6	DARS-AS1	-4.91	1.38e-06	0.000881	-0.29	-0.26	Corneal structure;	chr2:135882531	chr2:135985176~136022593:+
STAD	cis	rs747650	0.504	rs7128193	ENSG00000271350.1	CTD-2384B9.1	-4.91	1.38e-06	0.000881	-0.32	-0.26	Acne (severe);	chr11:46967432	chr11:47041027~47041945:-
STAD	cis	rs227275	0.524	rs150894	ENSG00000248971.2	KRT8P46	-4.91	1.38e-06	0.000881	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102728746~102730171:-
STAD	cis	rs35934224	0.783	rs34545894	ENSG00000232926.1	AC000078.5	4.91	1.38e-06	0.000882	0.34	0.26	Glaucoma (primary open-angle);	chr22:19870419	chr22:19887289~19887970:+
STAD	cis	rs875971	0.862	rs908915	ENSG00000236529.1	RP13-254B10.1	-4.91	1.38e-06	0.000882	-0.26	-0.26	Aortic root size;	chr7:66149664	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs316316	ENSG00000236529.1	RP13-254B10.1	-4.91	1.38e-06	0.000882	-0.3	-0.26	Aortic root size;	chr7:66149270	chr7:65840212~65840596:+
STAD	cis	rs1426063	0.614	rs115279737	ENSG00000249717.1	RP11-44F21.3	4.91	1.38e-06	0.000882	0.54	0.26	QT interval;	chr4:75107557	chr4:74955974~74970362:-
STAD	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-4.91	1.38e-06	0.000882	-0.27	-0.26	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
STAD	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-4.91	1.38e-06	0.000882	-0.29	-0.26	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
STAD	cis	rs7829975	0.51	rs332037	ENSG00000173295.6	FAM86B3P	4.91	1.38e-06	0.000883	0.29	0.26	Mood instability;	chr8:8865165	chr8:8228595~8244865:+
STAD	cis	rs853679	0.517	rs9380058	ENSG00000220721.1	OR1F12	4.91	1.38e-06	0.000883	0.3	0.26	Depression;	chr6:28159666	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9393898	ENSG00000220721.1	OR1F12	4.91	1.38e-06	0.000883	0.3	0.26	Depression;	chr6:28162598	chr6:28073316~28074233:+
STAD	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	4.91	1.38e-06	0.000884	0.31	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
STAD	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-4.91	1.38e-06	0.000885	-0.29	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
STAD	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	4.91	1.39e-06	0.000885	0.25	0.26	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
STAD	cis	rs11722779	0.692	rs223414	ENSG00000248971.2	KRT8P46	-4.91	1.39e-06	0.000886	-0.26	-0.26	Schizophrenia;	chr4:102811688	chr4:102728746~102730171:-
STAD	cis	rs4061073	1	rs4061073	ENSG00000198711.5	SSBP3-AS1	4.91	1.39e-06	0.000886	0.2	0.26	Body mass index;	chr1:54231070	chr1:54236440~54239063:+
STAD	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	4.91	1.39e-06	0.000886	0.26	0.26	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
STAD	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	4.91	1.39e-06	0.000886	0.28	0.26	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
STAD	cis	rs13113518	0.812	rs13140590	ENSG00000223305.1	RN7SKP30	4.91	1.39e-06	0.000887	0.29	0.26	Height;	chr4:55548666	chr4:55540502~55540835:-
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	4.91	1.39e-06	0.000887	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
STAD	cis	rs3758911	0.796	rs11212206	ENSG00000261098.1	RP11-819C21.1	-4.91	1.39e-06	0.000887	-0.23	-0.26	Coronary artery disease;	chr11:107404525	chr11:107312132~107316271:-
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	4.91	1.39e-06	0.000887	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
STAD	cis	rs1681630	0.545	rs1228001	ENSG00000280615.1	Y_RNA	-4.91	1.39e-06	0.000888	-0.26	-0.26	Height;	chr11:47965442	chr11:47614898~47614994:-
STAD	cis	rs9467773	0.869	rs1796521	ENSG00000243307.2	POM121L6P	-4.91	1.39e-06	0.000888	-0.24	-0.26	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26896952~26898777:+
STAD	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	4.91	1.39e-06	0.000889	0.25	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
STAD	cis	rs7829975	0.593	rs2979241	ENSG00000254340.1	RP11-10A14.3	4.91	1.39e-06	0.00089	0.31	0.26	Mood instability;	chr8:8445843	chr8:9141424~9145435:+
STAD	cis	rs4950322	0.802	rs72694705	ENSG00000278811.3	LINC00624	4.91	1.39e-06	0.00089	0.28	0.26	Protein quantitative trait loci;	chr1:147362313	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.857	rs55790545	ENSG00000278811.3	LINC00624	4.91	1.39e-06	0.00089	0.28	0.26	Protein quantitative trait loci;	chr1:147366649	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.857	rs7522219	ENSG00000278811.3	LINC00624	4.91	1.39e-06	0.00089	0.28	0.26	Protein quantitative trait loci;	chr1:147366904	chr1:147258885~147517875:-
STAD	cis	rs6584283	0.875	rs10748783	ENSG00000228778.1	RP11-129J12.1	-4.91	1.39e-06	0.00089	-0.29	-0.26	Ulcerative colitis;	chr10:99526115	chr10:99527081~99528261:+
STAD	cis	rs7927771	0.524	rs10742814	ENSG00000280615.1	Y_RNA	4.91	1.4e-06	0.000891	0.26	0.26	Subjective well-being;	chr11:47532785	chr11:47614898~47614994:-
STAD	cis	rs11098499	0.954	rs28572238	ENSG00000260091.1	RP11-33B1.4	4.91	1.4e-06	0.000891	0.25	0.26	Corneal astigmatism;	chr4:119395531	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs28714195	ENSG00000260091.1	RP11-33B1.4	4.91	1.4e-06	0.000891	0.25	0.26	Corneal astigmatism;	chr4:119395795	chr4:119409333~119410233:+
STAD	cis	rs7487075	0.647	rs12580583	ENSG00000272369.1	RP11-446N19.1	4.91	1.4e-06	0.000891	0.31	0.26	Itch intensity from mosquito bite;	chr12:46313218	chr12:46537502~46652550:+
STAD	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-4.91	1.4e-06	0.000891	-0.26	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
STAD	cis	rs3770081	1	rs2164879	ENSG00000273080.1	RP11-301O19.1	-4.91	1.4e-06	0.000892	-0.57	-0.26	Facial emotion recognition (sad faces);	chr2:86034456	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs12328085	ENSG00000273080.1	RP11-301O19.1	-4.91	1.4e-06	0.000892	-0.57	-0.26	Facial emotion recognition (sad faces);	chr2:86034886	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs3770090	ENSG00000273080.1	RP11-301O19.1	-4.91	1.4e-06	0.000892	-0.57	-0.26	Facial emotion recognition (sad faces);	chr2:86036165	chr2:86195590~86196049:+
STAD	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-4.91	1.4e-06	0.000892	-0.33	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
STAD	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-4.91	1.4e-06	0.000893	-0.3	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
STAD	cis	rs5769707	0.681	rs2319346	ENSG00000280224.1	CTA-722E9.1	-4.91	1.4e-06	0.000894	-0.3	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49500568~49501585:+
STAD	cis	rs172166	0.516	rs1225715	ENSG00000220721.1	OR1F12	-4.91	1.4e-06	0.000894	-0.25	-0.26	Cardiac Troponin-T levels;	chr6:28145595	chr6:28073316~28074233:+
STAD	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	4.91	1.4e-06	0.000894	0.25	0.26	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
STAD	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-4.91	1.4e-06	0.000895	-0.32	-0.26	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
STAD	cis	rs1707322	0.686	rs2050376	ENSG00000281133.1	AL355480.3	-4.91	1.4e-06	0.000895	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45580892~45580996:-
STAD	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	4.91	1.4e-06	0.000896	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
STAD	cis	rs516805	0.667	rs2606608	ENSG00000279453.1	RP3-425C14.4	-4.91	1.4e-06	0.000896	-0.36	-0.26	Lymphocyte counts;	chr6:122195051	chr6:122436789~122439223:-
STAD	cis	rs516805	0.667	rs2816078	ENSG00000279453.1	RP3-425C14.4	-4.91	1.4e-06	0.000896	-0.36	-0.26	Lymphocyte counts;	chr6:122201755	chr6:122436789~122439223:-
STAD	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	4.91	1.41e-06	0.000896	0.26	0.26	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000211973.2	IGHV1-69	4.91	1.41e-06	0.000896	0.22	0.26	Kawasaki disease;	chr14:106808609	chr14:106714684~106715181:-
STAD	cis	rs875971	0.545	rs6460298	ENSG00000236529.1	RP13-254B10.1	4.91	1.41e-06	0.000896	0.3	0.26	Aortic root size;	chr7:66442783	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs75577046	ENSG00000236529.1	RP13-254B10.1	4.91	1.41e-06	0.000896	0.3	0.26	Aortic root size;	chr7:66493729	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs3735147	ENSG00000236529.1	RP13-254B10.1	4.91	1.41e-06	0.000896	0.3	0.26	Aortic root size;	chr7:66505541	chr7:65840212~65840596:+
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000224205.1	AP000351.4	4.91	1.41e-06	0.000897	0.28	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23987320~23991421:-
STAD	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	4.91	1.41e-06	0.000897	0.49	0.26	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
STAD	cis	rs10510102	0.872	rs11814703	ENSG00000226864.1	ATE1-AS1	4.91	1.41e-06	0.000898	0.41	0.26	Breast cancer;	chr10:121964774	chr10:121928312~121951965:+
STAD	cis	rs1799949	1	rs8176220	ENSG00000279602.1	CTD-3014M21.1	4.91	1.41e-06	0.000898	0.32	0.26	Menopause (age at onset);	chr17:43070445	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs1799966	ENSG00000279602.1	CTD-3014M21.1	4.91	1.41e-06	0.000898	0.32	0.26	Menopause (age at onset);	chr17:43071077	chr17:43360041~43361361:-
STAD	cis	rs453301	0.686	rs1045527	ENSG00000254340.1	RP11-10A14.3	-4.91	1.41e-06	0.000898	-0.33	-0.26	Joint mobility (Beighton score);	chr8:9032531	chr8:9141424~9145435:+
STAD	cis	rs6714710	0.603	rs2278700	ENSG00000235833.1	AC159540.14	-4.91	1.41e-06	0.000898	-0.28	-0.26	Posterior cortical atrophy and Alzheimer's disease;	chr2:97810919	chr2:97523949~97524976:-
STAD	cis	rs13113518	0.783	rs7690837	ENSG00000223305.1	RN7SKP30	4.91	1.41e-06	0.000899	0.29	0.26	Height;	chr4:55575856	chr4:55540502~55540835:-
STAD	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-4.91	1.41e-06	0.000899	-0.3	-0.26	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
STAD	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-4.91	1.41e-06	0.000899	-0.2	-0.26	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
STAD	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-4.91	1.41e-06	0.000899	-0.31	-0.26	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
STAD	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	4.91	1.41e-06	9e-04	0.27	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
STAD	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	4.91	1.41e-06	9e-04	0.32	0.26	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
STAD	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	4.91	1.41e-06	9e-04	0.3	0.26	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
STAD	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	4.91	1.41e-06	9e-04	0.28	0.26	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
STAD	cis	rs13113518	0.729	rs13120134	ENSG00000272969.1	RP11-528I4.2	4.91	1.41e-06	0.000901	0.33	0.26	Height;	chr4:55415153	chr4:55547112~55547889:+
STAD	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	4.91	1.41e-06	0.000901	0.25	0.26	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
STAD	cis	rs9463078	0.625	rs12190513	ENSG00000219384.1	RP11-491H9.3	-4.91	1.41e-06	0.000901	-0.24	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44952942	chr6:45158870~45159511:+
STAD	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	4.91	1.41e-06	0.000902	0.45	0.26	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	4.91	1.41e-06	0.000902	0.45	0.26	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
STAD	cis	rs875971	1	rs1167612	ENSG00000236529.1	RP13-254B10.1	-4.91	1.42e-06	0.000902	-0.27	-0.26	Aortic root size;	chr7:66102989	chr7:65840212~65840596:+
STAD	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-4.91	1.42e-06	0.000902	-0.29	-0.26	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
STAD	cis	rs301901	1	rs6899155	ENSG00000250155.1	CTD-2353F22.1	-4.91	1.42e-06	0.000902	-0.27	-0.26	Height;	chr5:36786357	chr5:36666214~36725195:-
STAD	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	4.91	1.42e-06	0.000903	0.31	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
STAD	cis	rs8141529	0.871	rs5762877	ENSG00000226471.5	CTA-292E10.6	-4.91	1.42e-06	0.000903	-0.31	-0.26	Lymphocyte counts;	chr22:28881567	chr22:28800683~28848559:+
STAD	cis	rs6095360	0.727	rs7274221	ENSG00000222365.1	SNORD12B	-4.91	1.42e-06	0.000904	-0.34	-0.26	Intelligence (multi-trait analysis);	chr20:49006961	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs35752040	ENSG00000222365.1	SNORD12B	-4.91	1.42e-06	0.000904	-0.34	-0.26	Intelligence (multi-trait analysis);	chr20:49008063	chr20:49280319~49280409:+
STAD	cis	rs6142102	0.961	rs6057957	ENSG00000275784.1	RP5-1125A11.6	-4.91	1.42e-06	0.000904	-0.27	-0.26	Skin pigmentation;	chr20:33962052	chr20:33989480~33991818:-
STAD	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-4.91	1.42e-06	0.000904	-0.29	-0.26	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
STAD	cis	rs875971	0.545	rs1909508	ENSG00000224316.1	RP11-479O9.2	4.91	1.42e-06	0.000904	0.28	0.26	Aortic root size;	chr7:66301366	chr7:65773620~65802067:+
STAD	cis	rs7951870	0.645	rs57804402	ENSG00000271350.1	CTD-2384B9.1	4.91	1.42e-06	0.000905	0.33	0.26	Schizophrenia;	chr11:46708322	chr11:47041027~47041945:-
STAD	cis	rs6095360	0.69	rs35649484	ENSG00000222365.1	SNORD12B	-4.91	1.42e-06	0.000906	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49138625	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs35640549	ENSG00000222365.1	SNORD12B	-4.91	1.42e-06	0.000906	-0.33	-0.26	Intelligence (multi-trait analysis);	chr20:49040009	chr20:49280319~49280409:+
STAD	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-4.91	1.42e-06	0.000906	-0.32	-0.26	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
STAD	cis	rs3733585	0.604	rs73215003	ENSG00000250613.1	RP11-136I13.1	4.91	1.42e-06	0.000906	0.25	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:10124693	chr4:10410996~10411644:+
STAD	cis	rs7665090	1	rs6821119	ENSG00000230069.3	LRRC37A15P	-4.91	1.42e-06	0.000906	-0.28	-0.26	Primary biliary cholangitis;	chr4:102634076	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.934	rs6844332	ENSG00000230069.3	LRRC37A15P	-4.91	1.42e-06	0.000906	-0.28	-0.26	Primary biliary cholangitis;	chr4:102634095	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.967	rs6821133	ENSG00000230069.3	LRRC37A15P	-4.91	1.42e-06	0.000906	-0.28	-0.26	Primary biliary cholangitis;	chr4:102634096	chr4:102727274~102730721:-
STAD	cis	rs11098499	0.954	rs7437420	ENSG00000260091.1	RP11-33B1.4	4.91	1.42e-06	0.000907	0.25	0.26	Corneal astigmatism;	chr4:119391748	chr4:119409333~119410233:+
STAD	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-4.91	1.42e-06	0.000907	-0.32	-0.26	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
STAD	cis	rs10129255	0.5	rs2105989	ENSG00000211973.2	IGHV1-69	4.91	1.43e-06	0.000908	0.21	0.26	Kawasaki disease;	chr14:106682199	chr14:106714684~106715181:-
STAD	cis	rs7829975	0.51	rs2921073	ENSG00000254340.1	RP11-10A14.3	4.91	1.43e-06	0.000908	0.32	0.26	Mood instability;	chr8:8450133	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.51	rs2979160	ENSG00000254340.1	RP11-10A14.3	4.91	1.43e-06	0.000908	0.32	0.26	Mood instability;	chr8:8450156	chr8:9141424~9145435:+
STAD	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-4.91	1.43e-06	0.000908	-0.34	-0.26	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
STAD	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	4.91	1.43e-06	0.000909	0.48	0.26	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
STAD	cis	rs10978777	0.842	rs7041137	ENSG00000276883.1	AL137852.1	4.91	1.43e-06	0.000909	0.26	0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107282291	chr9:107292369~107292456:-
STAD	cis	rs35934224	0.783	rs58195087	ENSG00000232926.1	AC000078.5	4.91	1.43e-06	0.00091	0.34	0.26	Glaucoma (primary open-angle);	chr22:19871024	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs56291622	ENSG00000232926.1	AC000078.5	4.91	1.43e-06	0.00091	0.34	0.26	Glaucoma (primary open-angle);	chr22:19871211	chr22:19887289~19887970:+
STAD	cis	rs393951	1	rs392001	ENSG00000260969.1	RP11-190D6.2	-4.91	1.43e-06	0.000911	-0.31	-0.26	Childhood ear infection;	chr16:77582096	chr16:78237362~78241218:-
STAD	cis	rs393951	1	rs439920	ENSG00000260969.1	RP11-190D6.2	-4.91	1.43e-06	0.000911	-0.31	-0.26	Childhood ear infection;	chr16:77582133	chr16:78237362~78241218:-
STAD	cis	rs1799949	1	rs11656097	ENSG00000236383.6	LINC00854	-4.91	1.43e-06	0.000911	-0.21	-0.26	Menopause (age at onset);	chr17:43138596	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11658754	ENSG00000236383.6	LINC00854	-4.91	1.43e-06	0.000911	-0.21	-0.26	Menopause (age at onset);	chr17:43140722	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs12952790	ENSG00000236383.6	LINC00854	-4.91	1.43e-06	0.000911	-0.21	-0.26	Menopause (age at onset);	chr17:43147590	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs12950607	ENSG00000236383.6	LINC00854	-4.91	1.43e-06	0.000911	-0.21	-0.26	Menopause (age at onset);	chr17:43147911	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11079056	ENSG00000236383.6	LINC00854	-4.91	1.43e-06	0.000911	-0.21	-0.26	Menopause (age at onset);	chr17:43148782	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs12936816	ENSG00000236383.6	LINC00854	-4.91	1.43e-06	0.000911	-0.21	-0.26	Menopause (age at onset);	chr17:43149692	chr17:43216941~43305976:-
STAD	cis	rs2836950	0.527	rs2836958	ENSG00000238141.2	BRWD1-AS1	-4.91	1.43e-06	0.000912	-0.26	-0.26	Menarche (age at onset);	chr21:39251600	chr21:39315707~39323218:+
STAD	cis	rs9463078	0.605	rs13215618	ENSG00000219384.1	RP11-491H9.3	-4.91	1.44e-06	0.000913	-0.24	-0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44968831	chr6:45158870~45159511:+
STAD	cis	rs875971	0.545	rs6460276	ENSG00000236529.1	RP13-254B10.1	4.91	1.44e-06	0.000913	0.3	0.26	Aortic root size;	chr7:66182290	chr7:65840212~65840596:+
STAD	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-4.91	1.44e-06	0.000914	-0.24	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
STAD	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	4.91	1.44e-06	0.000916	0.25	0.25	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
STAD	cis	rs1007738	0.542	rs10838662	ENSG00000271350.1	CTD-2384B9.1	4.9	1.44e-06	0.000916	0.33	0.25	Bone mineral density (hip);	chr11:47162566	chr11:47041027~47041945:-
STAD	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	4.9	1.44e-06	0.000917	0.3	0.25	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
STAD	cis	rs10978777	0.921	rs817844	ENSG00000276883.1	AL137852.1	4.9	1.44e-06	0.000917	0.26	0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107339159	chr9:107292369~107292456:-
STAD	cis	rs875971	0.545	rs17138156	ENSG00000236529.1	RP13-254B10.1	4.9	1.44e-06	0.000917	0.3	0.25	Aortic root size;	chr7:66249708	chr7:65840212~65840596:+
STAD	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	4.9	1.44e-06	0.000917	0.36	0.25	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
STAD	cis	rs4713118	0.824	rs9468223	ENSG00000280107.1	AL022393.9	-4.9	1.44e-06	0.000917	-0.34	-0.25	Parkinson's disease;	chr6:27772887	chr6:28170845~28172521:+
STAD	cis	rs7191700	0.601	rs243329	ENSG00000262703.1	RP11-485G7.6	4.9	1.44e-06	0.000918	0.24	0.25	Multiple sclerosis;	chr16:11258456	chr16:11348143~11349321:-
STAD	cis	rs13113518	1	rs9312661	ENSG00000223305.1	RN7SKP30	4.9	1.45e-06	0.000918	0.28	0.25	Height;	chr4:55476159	chr4:55540502~55540835:-
STAD	cis	rs1799949	0.965	rs7223952	ENSG00000236383.6	LINC00854	-4.9	1.45e-06	0.000919	-0.21	-0.25	Menopause (age at onset);	chr17:43042868	chr17:43216941~43305976:-
STAD	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	4.9	1.45e-06	0.00092	0.25	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
STAD	cis	rs7474896	0.583	rs12783272	ENSG00000120555.12	SEPT7P9	4.9	1.45e-06	0.00092	0.31	0.25	Obesity (extreme);	chr10:37735957	chr10:38383069~38402916:-
STAD	cis	rs237743	1	rs56335217	ENSG00000222365.1	SNORD12B	-4.9	1.45e-06	0.00092	-0.35	-0.25	Height;	chr20:49254660	chr20:49280319~49280409:+
STAD	cis	rs17401966	0.838	rs2105212	ENSG00000199562.1	RNU6-37P	4.9	1.45e-06	0.00092	0.19	0.25	Hepatocellular carcinoma;	chr1:10220954	chr1:10298966~10299072:+
STAD	cis	rs11722779	0.81	rs223417	ENSG00000248971.2	KRT8P46	-4.9	1.45e-06	0.00092	-0.26	-0.25	Schizophrenia;	chr4:102810568	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.805	rs223416	ENSG00000248971.2	KRT8P46	-4.9	1.45e-06	0.00092	-0.26	-0.25	Schizophrenia;	chr4:102810580	chr4:102728746~102730171:-
STAD	cis	rs7429990	0.965	rs319686	ENSG00000224895.1	VPS26BP1	-4.9	1.45e-06	0.000921	-0.25	-0.25	Educational attainment (years of education);	chr3:47888930	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs4858880	ENSG00000224895.1	VPS26BP1	4.9	1.45e-06	0.000921	0.25	0.25	Educational attainment (years of education);	chr3:48062959	chr3:47960327~47961081:-
STAD	cis	rs4950322	0.57	rs72692980	ENSG00000278811.3	LINC00624	4.9	1.45e-06	0.000921	0.27	0.25	Protein quantitative trait loci;	chr1:147337830	chr1:147258885~147517875:-
STAD	cis	rs1318937	0.764	rs9853971	ENSG00000224660.1	SH3BP5-AS1	4.9	1.45e-06	0.000921	0.26	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15183840	chr3:15254184~15264493:+
STAD	cis	rs7487637	0.529	rs56389811	ENSG00000276691.1	RP5-1057I20.5	4.9	1.45e-06	0.000922	0.4	0.25	Mononucleosis;	chr12:47811575	chr12:47788426~47788971:+
STAD	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	4.9	1.45e-06	0.000922	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
STAD	cis	rs9463078	0.605	rs9472409	ENSG00000219384.1	RP11-491H9.3	-4.9	1.45e-06	0.000922	-0.24	-0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44958694	chr6:45158870~45159511:+
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	4.9	1.45e-06	0.000923	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
STAD	cis	rs891378	1	rs10864180	ENSG00000274245.1	RP11-357P18.2	-4.9	1.45e-06	0.000923	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272416	chr1:207372559~207373252:+
STAD	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-4.9	1.45e-06	0.000923	-0.41	-0.25	Gout;	chr7:66671562	chr7:66654538~66669855:+
STAD	cis	rs9467773	0.62	rs2451732	ENSG00000243307.2	POM121L6P	-4.9	1.45e-06	0.000923	-0.25	-0.25	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26896952~26898777:+
STAD	cis	rs6142102	0.527	rs1015362	ENSG00000275784.1	RP5-1125A11.6	4.9	1.45e-06	0.000924	0.26	0.25	Skin pigmentation;	chr20:34150806	chr20:33989480~33991818:-
STAD	cis	rs858239	0.57	rs10271613	ENSG00000226816.2	AC005082.12	4.9	1.46e-06	0.000924	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23206013~23208045:+
STAD	cis	rs858239	0.57	rs10242166	ENSG00000226816.2	AC005082.12	4.9	1.46e-06	0.000924	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23206013~23208045:+
STAD	cis	rs9467773	0.869	rs1796520	ENSG00000243307.2	POM121L6P	-4.9	1.46e-06	0.000924	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26410572	chr6:26896952~26898777:+
STAD	cis	rs6714710	0.58	rs57681139	ENSG00000235833.1	AC159540.14	-4.9	1.46e-06	0.000925	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838010	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.58	rs1838797	ENSG00000235833.1	AC159540.14	-4.9	1.46e-06	0.000925	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838109	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs78006955	ENSG00000235833.1	AC159540.14	-4.9	1.46e-06	0.000925	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97839047	chr2:97523949~97524976:-
STAD	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-4.9	1.46e-06	0.000925	-0.33	-0.25	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
STAD	cis	rs9463078	0.585	rs4072928	ENSG00000219384.1	RP11-491H9.3	4.9	1.46e-06	0.000927	0.25	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45323492	chr6:45158870~45159511:+
STAD	cis	rs295490	0.688	rs184156	ENSG00000272656.1	RP11-219D15.3	-4.9	1.46e-06	0.000927	-0.41	-0.25	PR interval in Tripanosoma cruzi seropositivity;	chr3:139519526	chr3:139349024~139349371:-
STAD	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-4.9	1.46e-06	0.000927	-0.3	-0.25	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
STAD	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-4.9	1.46e-06	0.000928	-0.29	-0.25	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
STAD	cis	rs5752326	0.764	rs5997093	ENSG00000261188.1	CTA-445C9.14	-4.9	1.46e-06	0.000928	-0.38	-0.25	Ischemic stroke;	chr22:26455862	chr22:26512537~26514568:+
STAD	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-4.9	1.46e-06	0.000928	-0.43	-0.25	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
STAD	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-4.9	1.46e-06	0.000929	-0.31	-0.25	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
STAD	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-4.9	1.46e-06	0.000929	-0.4	-0.25	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
STAD	cis	rs801193	0.66	rs1016265	ENSG00000236529.1	RP13-254B10.1	4.9	1.46e-06	0.000929	0.26	0.25	Aortic root size;	chr7:66749580	chr7:65840212~65840596:+
STAD	cis	rs7078219	0.505	rs1548964	ENSG00000228778.1	RP11-129J12.1	4.9	1.47e-06	0.00093	0.29	0.25	Dental caries;	chr10:99529896	chr10:99527081~99528261:+
STAD	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	4.9	1.47e-06	0.000931	0.33	0.25	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
STAD	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	4.9	1.47e-06	0.000931	0.3	0.25	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
STAD	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	4.9	1.47e-06	0.000932	0.21	0.25	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
STAD	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-4.9	1.47e-06	0.000932	-0.31	-0.25	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000224205.1	AP000351.4	-4.9	1.47e-06	0.000933	-0.29	-0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23987320~23991421:-
STAD	cis	rs1056107	0.933	rs10739341	ENSG00000225513.1	RP11-165N19.2	-4.9	1.47e-06	0.000933	-0.29	-0.25	Colorectal cancer;	chr9:112310497	chr9:112173522~112173971:-
STAD	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-4.9	1.47e-06	0.000933	-0.32	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
STAD	cis	rs7429990	0.864	rs13091913	ENSG00000224895.1	VPS26BP1	4.9	1.47e-06	0.000934	0.24	0.25	Educational attainment (years of education);	chr3:47762307	chr3:47960327~47961081:-
STAD	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-4.9	1.47e-06	0.000934	-0.3	-0.25	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
STAD	cis	rs1056107	0.933	rs12554866	ENSG00000225513.1	RP11-165N19.2	4.9	1.47e-06	0.000935	0.32	0.25	Colorectal cancer;	chr9:112201066	chr9:112173522~112173971:-
STAD	cis	rs8099594	0.565	rs1943010	ENSG00000266696.1	RP11-30L3.2	4.9	1.47e-06	0.000935	0.23	0.25	Height;	chr18:49209901	chr18:49205912~49208781:+
STAD	cis	rs8099594	0.565	rs1943009	ENSG00000266696.1	RP11-30L3.2	4.9	1.47e-06	0.000935	0.23	0.25	Height;	chr18:49209955	chr18:49205912~49208781:+
STAD	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	4.9	1.47e-06	0.000935	0.26	0.25	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
STAD	cis	rs6430585	0.528	rs6430594	ENSG00000231890.6	DARS-AS1	4.9	1.48e-06	0.000935	0.29	0.25	Corneal structure;	chr2:135961603	chr2:135985176~136022593:+
STAD	cis	rs3758911	0.894	rs10502087	ENSG00000261098.1	RP11-819C21.1	-4.9	1.48e-06	0.000937	-0.23	-0.25	Coronary artery disease;	chr11:107381482	chr11:107312132~107316271:-
STAD	cis	rs6095360	0.727	rs13036715	ENSG00000222365.1	SNORD12B	-4.9	1.48e-06	0.000937	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:49201278	chr20:49280319~49280409:+
STAD	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	4.9	1.48e-06	0.000938	0.36	0.25	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
STAD	cis	rs4722166	0.599	rs7776857	ENSG00000179428.2	AC073072.5	-4.9	1.48e-06	0.000938	-0.33	-0.25	Lung cancer;	chr7:22715149	chr7:22725395~22727620:-
STAD	cis	rs7487075	0.82	rs12310125	ENSG00000272369.1	RP11-446N19.1	4.9	1.48e-06	0.000938	0.31	0.25	Itch intensity from mosquito bite;	chr12:46299371	chr12:46537502~46652550:+
STAD	cis	rs4568518	0.535	rs3935149	ENSG00000279048.1	RP11-511H23.2	4.9	1.48e-06	0.000938	0.24	0.25	Measles;	chr7:18021306	chr7:17940503~17942922:+
STAD	cis	rs35934224	0.831	rs1044732	ENSG00000232926.1	AC000078.5	4.9	1.48e-06	0.000939	0.38	0.25	Glaucoma (primary open-angle);	chr22:19875619	chr22:19887289~19887970:+
STAD	cis	rs240993	0.812	rs9487639	ENSG00000230177.1	RP5-1112D6.4	-4.9	1.48e-06	0.000939	-0.26	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111426791	chr6:111277932~111278742:+
STAD	cis	rs6430585	0.583	rs12472293	ENSG00000231890.6	DARS-AS1	-4.9	1.48e-06	0.000939	-0.29	-0.25	Corneal structure;	chr2:135890507	chr2:135985176~136022593:+
STAD	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-4.9	1.48e-06	0.00094	-0.3	-0.25	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
STAD	cis	rs3758911	0.828	rs10890697	ENSG00000261098.1	RP11-819C21.1	-4.9	1.48e-06	0.00094	-0.23	-0.25	Coronary artery disease;	chr11:107307915	chr11:107312132~107316271:-
STAD	cis	rs1707322	0.752	rs6703748	ENSG00000225447.1	RPS15AP10	4.9	1.49e-06	0.000941	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45645816~45646197:-
STAD	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	4.9	1.49e-06	0.000941	0.25	0.25	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
STAD	cis	rs36423	0.528	rs1205063	ENSG00000266869.1	RP6-114E22.1	4.9	1.49e-06	0.000942	0.4	0.25	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71881828	chr14:71848606~71908430:+
STAD	cis	rs875971	0.798	rs6460304	ENSG00000236529.1	RP13-254B10.1	4.9	1.49e-06	0.000942	0.26	0.25	Aortic root size;	chr7:66499741	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6945775	ENSG00000236529.1	RP13-254B10.1	4.9	1.49e-06	0.000942	0.26	0.25	Aortic root size;	chr7:66503987	chr7:65840212~65840596:+
STAD	cis	rs875971	0.798	rs57739047	ENSG00000236529.1	RP13-254B10.1	4.9	1.49e-06	0.000942	0.26	0.25	Aortic root size;	chr7:66507579	chr7:65840212~65840596:+
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	4.9	1.49e-06	0.000942	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
STAD	cis	rs2117029	1	rs2293445	ENSG00000258017.1	RP11-386G11.10	-4.9	1.49e-06	0.000943	-0.26	-0.25	Intelligence (multi-trait analysis);	chr12:49005079	chr12:49127782~49147869:+
STAD	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-4.9	1.49e-06	0.000943	-0.33	-0.25	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
STAD	cis	rs55661361	0.532	rs3802902	ENSG00000245498.5	RP11-677M14.7	-4.9	1.49e-06	0.000943	-0.28	-0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124765139	chr11:124800450~124834487:+
STAD	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	4.9	1.49e-06	0.000945	0.25	0.25	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
STAD	cis	rs1799949	0.827	rs74252763	ENSG00000236383.6	LINC00854	-4.9	1.5e-06	0.000947	-0.22	-0.25	Menopause (age at onset);	chr17:43324652	chr17:43216941~43305976:-
STAD	cis	rs10266483	0.515	rs17689514	ENSG00000271550.1	BNIP3P11	-4.9	1.5e-06	0.000947	-0.35	-0.25	Response to statin therapy;	chr7:64279269	chr7:64678954~64687393:-
STAD	cis	rs7429990	0.864	rs3772399	ENSG00000224895.1	VPS26BP1	4.9	1.5e-06	0.000947	0.24	0.25	Educational attainment (years of education);	chr3:47826237	chr3:47960327~47961081:-
STAD	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	4.9	1.5e-06	0.000947	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
STAD	cis	rs7615952	0.546	rs2979340	ENSG00000272840.1	RP11-379B18.6	4.9	1.5e-06	0.000948	0.43	0.25	Blood pressure (smoking interaction);	chr3:125622540	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.546	rs2979338	ENSG00000272840.1	RP11-379B18.6	4.9	1.5e-06	0.000948	0.43	0.25	Blood pressure (smoking interaction);	chr3:125624282	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.546	rs2922171	ENSG00000272840.1	RP11-379B18.6	4.9	1.5e-06	0.000948	0.43	0.25	Blood pressure (smoking interaction);	chr3:125624349	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.546	rs112919177	ENSG00000272840.1	RP11-379B18.6	4.9	1.5e-06	0.000948	0.43	0.25	Blood pressure (smoking interaction);	chr3:125627226	chr3:125774714~125797953:+
STAD	cis	rs240993	0.812	rs383022	ENSG00000230177.1	RP5-1112D6.4	-4.9	1.5e-06	0.000948	-0.25	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111382506	chr6:111277932~111278742:+
STAD	cis	rs875971	0.83	rs6950137	ENSG00000236529.1	RP13-254B10.1	4.9	1.5e-06	0.000948	0.26	0.25	Aortic root size;	chr7:66511623	chr7:65840212~65840596:+
STAD	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-4.9	1.5e-06	0.000948	-0.26	-0.25	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
STAD	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-4.9	1.5e-06	0.000948	-0.26	-0.25	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
STAD	cis	rs9307551	0.817	rs4975057	ENSG00000250334.4	LINC00989	-4.9	1.5e-06	0.000948	-0.31	-0.25	Refractive error;	chr4:79567191	chr4:79492416~79576460:+
STAD	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-4.9	1.5e-06	0.000949	-0.31	-0.25	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
STAD	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	4.9	1.5e-06	0.000949	0.27	0.25	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
STAD	cis	rs9733	0.566	rs878471	ENSG00000274963.1	Metazoa_SRP	-4.9	1.5e-06	0.000949	-0.21	-0.25	Tonsillectomy;	chr1:150575271	chr1:150568971~150569269:-
STAD	cis	rs8097348	0.817	rs1869526	ENSG00000266602.1	RP11-476K15.1	-4.9	1.5e-06	0.00095	-0.29	-0.25	Exercise (leisure time);	chr18:1676029	chr18:1509183~1647097:+
STAD	cis	rs1799949	1	rs34534709	ENSG00000236383.6	LINC00854	-4.9	1.5e-06	0.000951	-0.21	-0.25	Menopause (age at onset);	chr17:43150923	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs34059614	ENSG00000236383.6	LINC00854	-4.9	1.5e-06	0.000951	-0.21	-0.25	Menopause (age at onset);	chr17:43151054	chr17:43216941~43305976:-
STAD	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	4.9	1.5e-06	0.000951	0.27	0.25	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
STAD	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-4.9	1.5e-06	0.000951	-0.33	-0.25	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
STAD	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	4.9	1.51e-06	0.000952	0.36	0.25	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	4.9	1.51e-06	0.000952	0.36	0.25	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
STAD	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	4.9	1.51e-06	0.000952	0.26	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
STAD	cis	rs35934224	0.891	rs5993850	ENSG00000232926.1	AC000078.5	4.9	1.51e-06	0.000953	0.34	0.25	Glaucoma (primary open-angle);	chr22:19882180	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.891	rs8141451	ENSG00000232926.1	AC000078.5	4.9	1.51e-06	0.000953	0.34	0.25	Glaucoma (primary open-angle);	chr22:19882513	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.831	rs13057374	ENSG00000232926.1	AC000078.5	4.9	1.51e-06	0.000953	0.34	0.25	Glaucoma (primary open-angle);	chr22:19883574	chr22:19887289~19887970:+
STAD	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	4.9	1.51e-06	0.000953	0.35	0.25	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
STAD	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	4.9	1.51e-06	0.000953	0.36	0.25	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
STAD	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-4.9	1.51e-06	0.000953	-0.38	-0.25	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-4.9	1.51e-06	0.000953	-0.38	-0.25	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
STAD	cis	rs2281636	0.723	rs3740078	ENSG00000233690.1	EBAG9P1	4.9	1.51e-06	0.000953	0.28	0.25	Obesity-related traits;	chr10:99685834	chr10:99697407~99697949:-
STAD	cis	rs7429990	0.864	rs11130150	ENSG00000224895.1	VPS26BP1	4.9	1.51e-06	0.000953	0.25	0.25	Educational attainment (years of education);	chr3:47832449	chr3:47960327~47961081:-
STAD	cis	rs11169552	0.766	rs4768925	ENSG00000200183.1	RNU6-238P	4.9	1.51e-06	0.000953	0.25	0.25	Colorectal cancer;	chr12:50824540	chr12:50656973~50657078:+
STAD	cis	rs875971	1	rs875971	ENSG00000236529.1	RP13-254B10.1	-4.9	1.51e-06	0.000954	-0.26	-0.25	Aortic root size;	chr7:66152608	chr7:65840212~65840596:+
STAD	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-4.9	1.51e-06	0.000954	-0.3	-0.25	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-4.9	1.51e-06	0.000954	-0.3	-0.25	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-4.9	1.51e-06	0.000954	-0.3	-0.25	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
STAD	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	4.9	1.51e-06	0.000954	0.32	0.25	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
STAD	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-4.9	1.51e-06	0.000954	-0.32	-0.25	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
STAD	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	4.89	1.51e-06	0.000956	0.26	0.25	Height;	chr5:37025769	chr5:36666214~36725195:-
STAD	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-4.89	1.51e-06	0.000956	-0.25	-0.25	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
STAD	cis	rs12744310	0.887	rs12040046	ENSG00000235358.1	RP11-399E6.1	-4.89	1.51e-06	0.000956	-0.32	-0.25	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331911	chr1:41242373~41284861:+
STAD	cis	rs7247513	0.964	rs12979795	ENSG00000230310.1	CTD-2192J16.11	4.89	1.52e-06	0.000957	0.32	0.25	Bipolar disorder;	chr19:12607033	chr19:12552597~12553644:+
STAD	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-4.89	1.52e-06	0.000957	-0.25	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
STAD	cis	rs7829975	0.682	rs7013471	ENSG00000254340.1	RP11-10A14.3	-4.89	1.52e-06	0.000958	-0.3	-0.25	Mood instability;	chr8:8829815	chr8:9141424~9145435:+
STAD	cis	rs6714710	0.603	rs2305143	ENSG00000235833.1	AC159540.14	-4.89	1.52e-06	0.000958	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97797318	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs11691494	ENSG00000235833.1	AC159540.14	-4.89	1.52e-06	0.000958	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803263	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs11684749	ENSG00000235833.1	AC159540.14	-4.89	1.52e-06	0.000958	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803679	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.58	rs17489915	ENSG00000235833.1	AC159540.14	-4.89	1.52e-06	0.000958	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803968	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs4311104	ENSG00000235833.1	AC159540.14	-4.89	1.52e-06	0.000958	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97808339	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs12104810	ENSG00000235833.1	AC159540.14	-4.89	1.52e-06	0.000958	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97827195	chr2:97523949~97524976:-
STAD	cis	rs875971	0.862	rs11763189	ENSG00000236529.1	RP13-254B10.1	4.89	1.52e-06	0.000958	0.26	0.25	Aortic root size;	chr7:66518542	chr7:65840212~65840596:+
STAD	cis	rs747650	0.504	rs4581406	ENSG00000271350.1	CTD-2384B9.1	4.89	1.52e-06	0.000958	0.33	0.25	Acne (severe);	chr11:46940900	chr11:47041027~47041945:-
STAD	cis	rs3758911	0.828	rs10789598	ENSG00000261098.1	RP11-819C21.1	-4.89	1.52e-06	0.000958	-0.24	-0.25	Coronary artery disease;	chr11:107307878	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.861	rs11212143	ENSG00000261098.1	RP11-819C21.1	-4.89	1.52e-06	0.000958	-0.24	-0.25	Coronary artery disease;	chr11:107308554	chr11:107312132~107316271:-
STAD	cis	rs7932354	0.528	rs2018527	ENSG00000271350.1	CTD-2384B9.1	4.89	1.52e-06	0.000958	0.31	0.25	Bone mineral density (hip);Bone mineral density;	chr11:47154258	chr11:47041027~47041945:-
STAD	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	4.89	1.52e-06	0.000959	0.27	0.25	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
STAD	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-4.89	1.52e-06	0.000959	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-4.89	1.52e-06	0.000959	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-4.89	1.52e-06	0.000959	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-4.89	1.52e-06	0.000959	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-4.89	1.52e-06	0.000959	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-4.89	1.52e-06	0.000959	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
STAD	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	4.89	1.52e-06	0.000959	0.34	0.25	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
STAD	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	4.89	1.52e-06	0.000959	0.34	0.25	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
STAD	cis	rs9860428	0.844	rs6795428	ENSG00000240057.4	RP11-572M11.4	-4.89	1.52e-06	0.000959	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896508	chr3:113019532~113183301:+
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000211973.2	IGHV1-69	4.89	1.52e-06	0.000959	0.21	0.25	Kawasaki disease;	chr14:106782219	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000211973.2	IGHV1-69	4.89	1.52e-06	0.000959	0.21	0.25	Kawasaki disease;	chr14:106782337	chr14:106714684~106715181:-
STAD	cis	rs858239	0.899	rs10085838	ENSG00000226816.2	AC005082.12	4.89	1.52e-06	0.000959	0.33	0.25	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23206013~23208045:+
STAD	cis	rs7487075	0.786	rs4768696	ENSG00000257261.4	RP11-96H19.1	4.89	1.52e-06	0.00096	0.34	0.25	Itch intensity from mosquito bite;	chr12:46332593	chr12:46383679~46876159:+
STAD	cis	rs7829975	0.711	rs12682352	ENSG00000173295.6	FAM86B3P	4.89	1.52e-06	0.000961	0.29	0.25	Mood instability;	chr8:8788736	chr8:8228595~8244865:+
STAD	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-4.89	1.52e-06	0.000961	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
STAD	cis	rs2980439	0.525	rs1850511	ENSG00000253981.4	ALG1L13P	4.89	1.52e-06	0.000961	0.29	0.25	Neuroticism;	chr8:8312807	chr8:8236003~8244667:-
STAD	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-4.89	1.52e-06	0.000962	-0.3	-0.25	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
STAD	cis	rs7429990	0.864	rs35698005	ENSG00000224895.1	VPS26BP1	4.89	1.53e-06	0.000963	0.25	0.25	Educational attainment (years of education);	chr3:47800558	chr3:47960327~47961081:-
STAD	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	4.89	1.53e-06	0.000963	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
STAD	cis	rs2836950	0.545	rs2836956	ENSG00000238141.2	BRWD1-AS1	4.89	1.53e-06	0.000964	0.26	0.25	Menarche (age at onset);	chr21:39251092	chr21:39315707~39323218:+
STAD	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	4.89	1.53e-06	0.000964	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
STAD	cis	rs8098244	0.52	rs12955607	ENSG00000267301.1	RPL23AP77	4.89	1.53e-06	0.000964	0.3	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677671	chr18:23709825~23710287:-
STAD	cis	rs950169	0.922	rs11635505	ENSG00000259295.5	CSPG4P12	-4.89	1.53e-06	0.000964	-0.36	-0.25	Schizophrenia;	chr15:84553803	chr15:85191438~85213905:+
STAD	cis	rs516805	0.748	rs155458	ENSG00000279453.1	RP3-425C14.4	4.89	1.53e-06	0.000965	0.36	0.25	Lymphocyte counts;	chr6:122493636	chr6:122436789~122439223:-
STAD	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-4.89	1.53e-06	0.000965	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
STAD	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-4.89	1.54e-06	0.00097	-0.29	-0.25	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-4.89	1.54e-06	0.00097	-0.29	-0.25	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-4.89	1.54e-06	0.00097	-0.29	-0.25	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-4.89	1.54e-06	0.00097	-0.29	-0.25	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
STAD	cis	rs228614	0.51	rs223405	ENSG00000248971.2	KRT8P46	-4.89	1.54e-06	0.00097	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102728746~102730171:-
STAD	cis	rs13113518	0.812	rs56055342	ENSG00000223305.1	RN7SKP30	4.89	1.54e-06	0.00097	0.28	0.25	Height;	chr4:55540928	chr4:55540502~55540835:-
STAD	cis	rs10510102	0.872	rs7907815	ENSG00000226864.1	ATE1-AS1	4.89	1.54e-06	0.00097	0.41	0.25	Breast cancer;	chr10:121965951	chr10:121928312~121951965:+
STAD	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-4.89	1.54e-06	0.000971	-0.39	-0.25	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-4.89	1.54e-06	0.000971	-0.39	-0.25	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-4.89	1.54e-06	0.000971	-0.39	-0.25	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-4.89	1.54e-06	0.000971	-0.39	-0.25	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-4.89	1.54e-06	0.000971	-0.39	-0.25	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
STAD	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-4.89	1.54e-06	0.000972	-0.31	-0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
STAD	cis	rs1707322	0.656	rs9429172	ENSG00000281133.1	AL355480.3	4.89	1.54e-06	0.000972	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.717	rs1135850	ENSG00000281133.1	AL355480.3	-4.89	1.54e-06	0.000972	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45580892~45580996:-
STAD	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	4.89	1.54e-06	0.000973	0.36	0.25	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
STAD	cis	rs858239	0.6	rs4321896	ENSG00000226816.2	AC005082.12	4.89	1.54e-06	0.000973	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs59073109	ENSG00000226816.2	AC005082.12	4.89	1.54e-06	0.000973	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs7788821	ENSG00000226816.2	AC005082.12	4.89	1.54e-06	0.000973	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs6956595	ENSG00000226816.2	AC005082.12	4.89	1.54e-06	0.000973	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23206013~23208045:+
STAD	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	4.89	1.55e-06	0.000974	0.29	0.25	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
STAD	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-4.89	1.55e-06	0.000974	-0.4	-0.25	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-4.89	1.55e-06	0.000974	-0.4	-0.25	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-4.89	1.55e-06	0.000974	-0.4	-0.25	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
STAD	cis	rs7829975	0.714	rs11784052	ENSG00000253981.4	ALG1L13P	4.89	1.55e-06	0.000974	0.29	0.25	Mood instability;	chr8:8814452	chr8:8236003~8244667:-
STAD	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	4.89	1.55e-06	0.000975	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
STAD	cis	rs1799949	0.536	rs4793227	ENSG00000279602.1	CTD-3014M21.1	4.89	1.55e-06	0.000975	0.31	0.25	Menopause (age at onset);	chr17:43334882	chr17:43360041~43361361:-
STAD	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-4.89	1.55e-06	0.000975	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-4.89	1.55e-06	0.000975	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
STAD	cis	rs10849893	0.595	rs6489811	ENSG00000258435.1	RP11-711D18.2	4.89	1.55e-06	0.000976	0.27	0.25	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121455823	chr12:121391962~121399859:+
STAD	cis	rs516805	0.63	rs170422	ENSG00000279453.1	RP3-425C14.4	-4.89	1.55e-06	0.000976	-0.33	-0.25	Lymphocyte counts;	chr6:122261422	chr6:122436789~122439223:-
STAD	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	4.89	1.55e-06	0.000977	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
STAD	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	4.89	1.55e-06	0.000977	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
STAD	cis	rs10266483	0.545	rs7777148	ENSG00000271550.1	BNIP3P11	-4.89	1.55e-06	0.000977	-0.35	-0.25	Response to statin therapy;	chr7:64285795	chr7:64678954~64687393:-
STAD	cis	rs7078219	0.965	rs11190141	ENSG00000228778.1	RP11-129J12.1	-4.89	1.55e-06	0.000977	-0.3	-0.25	Dental caries;	chr10:99532633	chr10:99527081~99528261:+
STAD	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	4.89	1.55e-06	0.000978	0.28	0.25	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
STAD	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-4.89	1.56e-06	0.000979	-0.29	-0.25	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-4.89	1.56e-06	0.000979	-0.29	-0.25	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
STAD	cis	rs10971721	0.643	rs41315997	ENSG00000281128.1	PTENP1-AS	4.89	1.56e-06	0.00098	0.45	0.25	Body mass index;	chr9:33798840	chr9:33677268~33688011:+
STAD	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-4.89	1.56e-06	0.00098	-0.35	-0.25	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
STAD	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-4.89	1.56e-06	0.00098	-0.35	-0.25	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
STAD	cis	rs7680126	0.609	rs11723742	ENSG00000250613.1	RP11-136I13.1	4.89	1.56e-06	0.000981	0.28	0.25	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10109948	chr4:10410996~10411644:+
STAD	cis	rs1056107	1	rs1056107	ENSG00000225513.1	RP11-165N19.2	-4.89	1.56e-06	0.000981	-0.3	-0.25	Colorectal cancer;	chr9:112324847	chr9:112173522~112173971:-
STAD	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-4.89	1.56e-06	0.000982	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
STAD	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-4.89	1.56e-06	0.000983	-0.34	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
STAD	cis	rs8012947	0.565	rs7151036	ENSG00000279636.2	LINC00216	4.89	1.56e-06	0.000983	0.24	0.25	Alcohol consumption in current drinkers;	chr14:58356315	chr14:58288033~58289158:+
STAD	cis	rs7474896	0.583	rs34185758	ENSG00000120555.12	SEPT7P9	4.89	1.56e-06	0.000983	0.31	0.25	Obesity (extreme);	chr10:37701926	chr10:38383069~38402916:-
STAD	cis	rs11606709	1	rs11606709	ENSG00000271350.1	CTD-2384B9.1	-4.89	1.56e-06	0.000983	-0.33	-0.25	Total body bone mineral density;	chr11:46708972	chr11:47041027~47041945:-
STAD	cis	rs4568518	0.535	rs6975848	ENSG00000279048.1	RP11-511H23.2	4.89	1.56e-06	0.000984	0.24	0.25	Measles;	chr7:18021618	chr7:17940503~17942922:+
STAD	cis	rs1799949	0.965	rs11650132	ENSG00000279602.1	CTD-3014M21.1	4.89	1.57e-06	0.000984	0.32	0.25	Menopause (age at onset);	chr17:43174070	chr17:43360041~43361361:-
STAD	cis	rs240993	0.669	rs6935759	ENSG00000230177.1	RP5-1112D6.4	-4.89	1.57e-06	0.000985	-0.26	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111457517	chr6:111277932~111278742:+
STAD	cis	rs1056107	0.902	rs2182810	ENSG00000225513.1	RP11-165N19.2	-4.89	1.57e-06	0.000985	-0.29	-0.25	Colorectal cancer;	chr9:112204169	chr9:112173522~112173971:-
STAD	cis	rs508487	0.537	rs5072	ENSG00000280143.1	AP000892.6	4.89	1.57e-06	0.000987	0.29	0.25	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117204967~117210292:+
STAD	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.89	1.57e-06	0.000988	0.24	0.25	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
STAD	cis	rs35934224	0.843	rs1139795	ENSG00000232926.1	AC000078.5	4.89	1.57e-06	0.000988	0.34	0.25	Glaucoma (primary open-angle);	chr22:19880248	chr22:19887289~19887970:+
STAD	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	4.89	1.57e-06	0.000989	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
STAD	cis	rs1150668	0.83	rs2023493	ENSG00000220721.1	OR1F12	4.89	1.57e-06	0.000989	0.25	0.25	Pubertal anthropometrics;	chr6:28432385	chr6:28073316~28074233:+
STAD	cis	rs1799949	1	rs8176242	ENSG00000279602.1	CTD-3014M21.1	4.89	1.57e-06	0.000989	0.32	0.25	Menopause (age at onset);	chr17:43065857	chr17:43360041~43361361:-
STAD	cis	rs9907295	1	rs9900563	ENSG00000270894.1	AC015849.13	-4.89	1.57e-06	0.000989	-0.27	-0.25	Fibroblast growth factor basic levels;	chr17:35908033	chr17:35818399~35823713:+
STAD	cis	rs606458	0.92	rs684720	ENSG00000269038.1	AP001462.6	-4.89	1.57e-06	0.00099	-0.35	-0.25	Urate levels;	chr11:64780957	chr11:64778954~64779405:+
STAD	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-4.89	1.57e-06	0.00099	-0.29	-0.25	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
STAD	cis	rs516805	0.748	rs155466	ENSG00000279453.1	RP3-425C14.4	-4.89	1.57e-06	0.00099	-0.44	-0.25	Lymphocyte counts;	chr6:122512286	chr6:122436789~122439223:-
STAD	cis	rs7829975	0.714	rs59046059	ENSG00000254340.1	RP11-10A14.3	4.89	1.58e-06	0.000991	0.3	0.25	Mood instability;	chr8:8813226	chr8:9141424~9145435:+
STAD	cis	rs7103648	0.603	rs3740688	ENSG00000280615.1	Y_RNA	4.89	1.58e-06	0.000991	0.26	0.25	Systolic blood pressure;Diastolic blood pressure;	chr11:47358789	chr11:47614898~47614994:-
STAD	cis	rs7674212	0.772	rs13113099	ENSG00000230069.3	LRRC37A15P	-4.89	1.58e-06	0.000991	-0.29	-0.25	Type 2 diabetes;	chr4:103052965	chr4:102727274~102730721:-
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000224205.1	AP000351.4	4.89	1.58e-06	0.000991	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23987320~23991421:-
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000211973.2	IGHV1-69	4.89	1.58e-06	0.000992	0.21	0.25	Kawasaki disease;	chr14:106807047	chr14:106714684~106715181:-
STAD	cis	rs7932354	0.528	rs1060573	ENSG00000271350.1	CTD-2384B9.1	-4.89	1.58e-06	0.000994	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47158278	chr11:47041027~47041945:-
STAD	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-4.89	1.58e-06	0.000994	-0.24	-0.25	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
STAD	cis	rs1799949	0.965	rs33961729	ENSG00000236383.6	LINC00854	-4.89	1.58e-06	0.000995	-0.21	-0.25	Menopause (age at onset);	chr17:43135907	chr17:43216941~43305976:-
STAD	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	4.89	1.58e-06	0.000995	0.39	0.25	Height;	chr6:109369898	chr6:109382795~109383666:+
STAD	cis	rs9307551	0.817	rs13142610	ENSG00000250334.4	LINC00989	-4.89	1.58e-06	0.000995	-0.3	-0.25	Refractive error;	chr4:79602297	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs17003985	ENSG00000250334.4	LINC00989	-4.89	1.58e-06	0.000995	-0.3	-0.25	Refractive error;	chr4:79602561	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs35487709	ENSG00000250334.4	LINC00989	-4.89	1.58e-06	0.000995	-0.3	-0.25	Refractive error;	chr4:79603180	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs35631270	ENSG00000250334.4	LINC00989	-4.89	1.58e-06	0.000995	-0.3	-0.25	Refractive error;	chr4:79603194	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs1348086	ENSG00000250334.4	LINC00989	-4.89	1.58e-06	0.000995	-0.3	-0.25	Refractive error;	chr4:79605078	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.817	rs2903640	ENSG00000250334.4	LINC00989	-4.89	1.58e-06	0.000995	-0.3	-0.25	Refractive error;	chr4:79610171	chr4:79492416~79576460:+
STAD	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-4.88	1.58e-06	0.000995	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
STAD	cis	rs7487075	0.619	rs4768718	ENSG00000257261.4	RP11-96H19.1	4.88	1.58e-06	0.000995	0.31	0.25	Itch intensity from mosquito bite;	chr12:46440553	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs12822345	ENSG00000257261.4	RP11-96H19.1	4.88	1.58e-06	0.000995	0.31	0.25	Itch intensity from mosquito bite;	chr12:46440894	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs12824565	ENSG00000257261.4	RP11-96H19.1	4.88	1.58e-06	0.000995	0.31	0.25	Itch intensity from mosquito bite;	chr12:46440910	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs67249026	ENSG00000257261.4	RP11-96H19.1	4.88	1.58e-06	0.000995	0.31	0.25	Itch intensity from mosquito bite;	chr12:46441985	chr12:46383679~46876159:+
STAD	cis	rs6832769	0.925	rs60992571	ENSG00000272969.1	RP11-528I4.2	-4.88	1.59e-06	0.000996	-0.33	-0.25	Personality dimensions;	chr4:55574645	chr4:55547112~55547889:+
STAD	cis	rs7487075	0.504	rs1000405	ENSG00000257261.4	RP11-96H19.1	4.88	1.59e-06	0.000996	0.32	0.25	Itch intensity from mosquito bite;	chr12:46262739	chr12:46383679~46876159:+
STAD	cis	rs1426063	0.614	rs78784058	ENSG00000249717.1	RP11-44F21.3	4.88	1.59e-06	0.000997	0.52	0.25	QT interval;	chr4:75108738	chr4:74955974~74970362:-
STAD	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-4.88	1.59e-06	0.000997	-0.25	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
STAD	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	4.88	1.59e-06	0.000997	0.33	0.25	Height;	chr6:109340338	chr6:109382795~109383666:+
STAD	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	4.88	1.59e-06	0.000998	0.32	0.25	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
STAD	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	4.88	1.59e-06	0.000998	0.25	0.25	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
STAD	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
STAD	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Depression;	chr6:28399886	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	4.88	1.59e-06	0.000998	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
STAD	cis	rs1707322	0.655	rs3014240	ENSG00000281133.1	AL355480.3	4.88	1.59e-06	0.000998	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45580892~45580996:-
STAD	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-4.88	1.59e-06	0.000998	-0.3	-0.25	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
STAD	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-4.88	1.59e-06	0.000999	-0.31	-0.25	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
STAD	cis	rs721917	0.506	rs2819098	ENSG00000244733.5	RP11-506M13.3	-4.88	1.59e-06	0.000999	-0.31	-0.25	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79660891~79677996:+
STAD	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-4.88	1.59e-06	0.000999	-0.29	-0.25	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-4.88	1.59e-06	0.000999	-0.29	-0.25	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-4.88	1.59e-06	0.000999	-0.29	-0.25	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
STAD	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	4.88	1.6e-06	0.001	0.52	0.25	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
STAD	cis	rs7615952	0.611	rs35321002	ENSG00000272840.1	RP11-379B18.6	4.88	1.6e-06	0.001	0.51	0.25	Blood pressure (smoking interaction);	chr3:125893222	chr3:125774714~125797953:+
STAD	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	4.88	1.6e-06	0.001	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
STAD	cis	rs9601248	0.756	rs9601252	ENSG00000227354.5	RBM26-AS1	-4.88	1.6e-06	0.001	-0.3	-0.25	Major depressive disorder;	chr13:79615607	chr13:79406309~79424328:+
STAD	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	4.88	1.6e-06	0.001	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
STAD	cis	rs3736858	0.825	rs9544047	ENSG00000261105.4	LMO7-AS1	-4.88	1.6e-06	0.001	-0.42	-0.25	Interleukin-9 levels;	chr13:75812019	chr13:75604700~75635994:-
STAD	cis	rs3758911	1	rs1046094	ENSG00000261098.1	RP11-819C21.1	-4.88	1.6e-06	0.001	-0.23	-0.25	Coronary artery disease;	chr11:107326530	chr11:107312132~107316271:-
STAD	cis	rs2337406	1	rs1961901	ENSG00000211972.2	IGHV3-66	4.88	1.6e-06	0.001	0.28	0.25	Alzheimer's disease (late onset);	chr14:106680856	chr14:106675017~106675544:-
STAD	cis	rs2337406	1	rs4774172	ENSG00000211972.2	IGHV3-66	4.88	1.6e-06	0.001	0.28	0.25	Alzheimer's disease (late onset);	chr14:106681320	chr14:106675017~106675544:-
STAD	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-4.88	1.6e-06	0.001	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-4.88	1.6e-06	0.001	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
STAD	cis	rs7829975	0.591	rs12677543	ENSG00000253981.4	ALG1L13P	4.88	1.6e-06	0.001	0.3	0.25	Mood instability;	chr8:8786764	chr8:8236003~8244667:-
STAD	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-4.88	1.6e-06	0.001	-0.3	-0.25	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
STAD	cis	rs13113518	1	rs7691799	ENSG00000223305.1	RN7SKP30	4.88	1.6e-06	0.00101	0.28	0.25	Height;	chr4:55545574	chr4:55540502~55540835:-
STAD	cis	rs916888	0.697	rs199516	ENSG00000232300.1	FAM215B	-4.88	1.6e-06	0.00101	-0.33	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46558830~46562795:-
STAD	cis	rs4243830	0.737	rs56036909	ENSG00000229519.2	RP11-58A11.2	-4.88	1.6e-06	0.00101	-0.28	-0.25	Body mass index;	chr1:6548443	chr1:6547905~6548619:+
STAD	cis	rs2439831	1	rs7173487	ENSG00000275601.1	AC011330.13	-4.88	1.61e-06	0.00101	-0.35	-0.25	Lung cancer in ever smokers;	chr15:43458041	chr15:43642389~43643023:-
STAD	cis	rs681383	1	rs8090276	ENSG00000266053.2	NDUFV2-AS1	4.88	1.61e-06	0.00101	0.33	0.25	Sitting height ratio;	chr18:8331235	chr18:9121265~9136645:-
STAD	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-4.88	1.61e-06	0.00101	-0.33	-0.25	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
STAD	cis	rs2404602	0.692	rs34478400	ENSG00000259422.1	RP11-593F23.1	4.88	1.61e-06	0.00101	0.27	0.25	Blood metabolite levels;	chr15:76631169	chr15:76174891~76181486:-
STAD	cis	rs3770081	1	rs12622009	ENSG00000273080.1	RP11-301O19.1	-4.88	1.61e-06	0.00101	-0.56	-0.25	Facial emotion recognition (sad faces);	chr2:86021202	chr2:86195590~86196049:+
STAD	cis	rs9860428	0.808	rs9869058	ENSG00000240057.4	RP11-572M11.4	-4.88	1.61e-06	0.00101	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899522	chr3:113019532~113183301:+
STAD	cis	rs9467773	0.511	rs11755443	ENSG00000241549.7	GUSBP2	4.88	1.61e-06	0.00101	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26871484~26956554:-
STAD	cis	rs9860428	0.815	rs10511313	ENSG00000240057.4	RP11-572M11.4	-4.88	1.61e-06	0.00101	-0.25	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112890642	chr3:113019532~113183301:+
STAD	cis	rs172166	0.561	rs149976	ENSG00000220721.1	OR1F12	-4.88	1.61e-06	0.00101	-0.25	-0.25	Cardiac Troponin-T levels;	chr6:28019998	chr6:28073316~28074233:+
STAD	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	4.88	1.61e-06	0.00101	0.25	0.25	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
STAD	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	4.88	1.62e-06	0.00101	0.3	0.25	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.967	rs5026469	ENSG00000248971.2	KRT8P46	-4.88	1.62e-06	0.00101	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633556	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.967	rs5026470	ENSG00000248971.2	KRT8P46	-4.88	1.62e-06	0.00101	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633565	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.967	rs5026471	ENSG00000248971.2	KRT8P46	-4.88	1.62e-06	0.00101	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633576	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.936	rs5026474	ENSG00000248971.2	KRT8P46	-4.88	1.62e-06	0.00101	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633653	chr4:102728746~102730171:-
STAD	cis	rs393951	1	rs393951	ENSG00000260969.1	RP11-190D6.2	-4.88	1.62e-06	0.00101	-0.31	-0.25	Childhood ear infection;	chr16:77586162	chr16:78237362~78241218:-
STAD	cis	rs393951	1	rs400226	ENSG00000260969.1	RP11-190D6.2	-4.88	1.62e-06	0.00101	-0.31	-0.25	Childhood ear infection;	chr16:77586225	chr16:78237362~78241218:-
STAD	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-4.88	1.62e-06	0.00101	-0.24	-0.25	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
STAD	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	4.88	1.62e-06	0.00101	0.37	0.25	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
STAD	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	4.88	1.62e-06	0.00101	0.31	0.25	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
STAD	cis	rs1799949	0.965	rs33925201	ENSG00000236383.6	LINC00854	-4.88	1.62e-06	0.00101	-0.21	-0.25	Menopause (age at onset);	chr17:43128665	chr17:43216941~43305976:-
STAD	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	4.88	1.62e-06	0.00101	0.31	0.25	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
STAD	cis	rs875971	1	rs10244498	ENSG00000236529.1	RP13-254B10.1	4.88	1.62e-06	0.00102	0.26	0.25	Aortic root size;	chr7:66651069	chr7:65840212~65840596:+
STAD	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-4.88	1.62e-06	0.00102	-0.27	-0.25	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
STAD	cis	rs1799949	0.965	rs9911630	ENSG00000236383.6	LINC00854	-4.88	1.62e-06	0.00102	-0.2	-0.25	Menopause (age at onset);	chr17:43036325	chr17:43216941~43305976:-
STAD	cis	rs10504130	0.569	rs6473653	ENSG00000272024.1	RP11-546K22.3	4.88	1.62e-06	0.00102	0.37	0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51757562	chr8:51950284~51950690:+
STAD	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-4.88	1.62e-06	0.00102	-0.31	-0.25	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
STAD	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	4.88	1.63e-06	0.00102	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
STAD	cis	rs7615952	0.551	rs6438945	ENSG00000272840.1	RP11-379B18.6	4.88	1.63e-06	0.00102	0.47	0.25	Blood pressure (smoking interaction);	chr3:125915630	chr3:125774714~125797953:+
STAD	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-4.88	1.63e-06	0.00102	-0.32	-0.25	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
STAD	cis	rs2337406	0.852	rs12050239	ENSG00000211972.2	IGHV3-66	4.88	1.63e-06	0.00102	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781132	chr14:106675017~106675544:-
STAD	cis	rs9860428	0.526	rs9833991	ENSG00000240057.4	RP11-572M11.4	-4.88	1.63e-06	0.00102	-0.25	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112933151	chr3:113019532~113183301:+
STAD	cis	rs2337406	1	rs17113257	ENSG00000211972.2	IGHV3-66	4.88	1.63e-06	0.00102	0.28	0.25	Alzheimer's disease (late onset);	chr14:106679574	chr14:106675017~106675544:-
STAD	cis	rs2006771	0.81	rs2006648	ENSG00000236132.1	CTA-440B3.1	4.88	1.63e-06	0.00102	0.26	0.25	Nonsyndromic cleft lip with cleft palate;	chr22:31685943	chr22:31816379~31817491:-
STAD	cis	rs1056107	0.933	rs7038215	ENSG00000225513.1	RP11-165N19.2	-4.88	1.63e-06	0.00102	-0.29	-0.25	Colorectal cancer;	chr9:112208523	chr9:112173522~112173971:-
STAD	cis	rs611744	0.625	rs4735055	ENSG00000253754.1	RP11-35G22.1	-4.88	1.63e-06	0.00102	-0.23	-0.25	Dupuytren's disease;	chr8:108274413	chr8:108226200~108227544:+
STAD	cis	rs5769707	0.609	rs135861	ENSG00000280224.1	CTA-722E9.1	-4.88	1.63e-06	0.00102	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49500568~49501585:+
STAD	cis	rs13113518	1	rs11726198	ENSG00000223305.1	RN7SKP30	4.88	1.63e-06	0.00102	0.28	0.25	Height;	chr4:55523835	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs11133396	ENSG00000223305.1	RN7SKP30	4.88	1.63e-06	0.00102	0.28	0.25	Height;	chr4:55524246	chr4:55540502~55540835:-
STAD	cis	rs35955747	0.633	rs1916	ENSG00000236132.1	CTA-440B3.1	-4.88	1.63e-06	0.00102	-0.27	-0.25	Neutrophil count;Sum basophil neutrophil counts;	chr22:31496135	chr22:31816379~31817491:-
STAD	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-4.88	1.63e-06	0.00102	-0.29	-0.25	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
STAD	cis	rs9860428	0.933	rs6808135	ENSG00000240057.4	RP11-572M11.4	-4.88	1.63e-06	0.00102	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112847301	chr3:113019532~113183301:+
STAD	cis	rs6714710	0.603	rs17489454	ENSG00000235833.1	AC159540.14	-4.88	1.64e-06	0.00102	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97790887	chr2:97523949~97524976:-
STAD	cis	rs853679	0.517	rs12332979	ENSG00000220721.1	OR1F12	4.88	1.64e-06	0.00102	0.3	0.25	Depression;	chr6:28173770	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs67878650	ENSG00000220721.1	OR1F12	4.88	1.64e-06	0.00102	0.3	0.25	Depression;	chr6:28174809	chr6:28073316~28074233:+
STAD	cis	rs853679	0.569	rs9348798	ENSG00000220721.1	OR1F12	4.88	1.64e-06	0.00102	0.3	0.25	Depression;	chr6:28175233	chr6:28073316~28074233:+
STAD	cis	rs853679	0.517	rs9380065	ENSG00000220721.1	OR1F12	4.88	1.64e-06	0.00102	0.3	0.25	Depression;	chr6:28176973	chr6:28073316~28074233:+
STAD	cis	rs875971	0.545	rs35459055	ENSG00000236529.1	RP13-254B10.1	4.88	1.64e-06	0.00102	0.29	0.25	Aortic root size;	chr7:66479399	chr7:65840212~65840596:+
STAD	cis	rs7829975	0.714	rs4841040	ENSG00000253981.4	ALG1L13P	4.88	1.64e-06	0.00102	0.3	0.25	Mood instability;	chr8:8797017	chr8:8236003~8244667:-
STAD	cis	rs9860428	1	rs11714354	ENSG00000240057.4	RP11-572M11.4	4.88	1.64e-06	0.00102	0.24	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112871706	chr3:113019532~113183301:+
STAD	cis	rs9860428	1	rs9825121	ENSG00000240057.4	RP11-572M11.4	-4.88	1.64e-06	0.00102	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112870357	chr3:113019532~113183301:+
STAD	cis	rs7474896	0.583	rs11011347	ENSG00000120555.12	SEPT7P9	4.88	1.64e-06	0.00102	0.31	0.25	Obesity (extreme);	chr10:37730336	chr10:38383069~38402916:-
STAD	cis	rs55823223	0.618	rs11867339	ENSG00000267801.1	RP11-552F3.9	4.88	1.64e-06	0.00103	0.38	0.25	Psoriasis;	chr17:75866012	chr17:75876372~75879546:+
STAD	cis	rs10751647	0.804	rs3809112	ENSG00000254910.1	RP11-326C3.7	4.88	1.64e-06	0.00103	0.29	0.25	Monocyte count;	chr11:307036	chr11:310139~311141:-
STAD	cis	rs9860428	0.844	rs6798395	ENSG00000240057.4	RP11-572M11.4	-4.88	1.64e-06	0.00103	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897190	chr3:113019532~113183301:+
STAD	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-4.88	1.64e-06	0.00103	-0.39	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
STAD	cis	rs7429990	0.864	rs883663	ENSG00000224895.1	VPS26BP1	4.88	1.64e-06	0.00103	0.24	0.25	Educational attainment (years of education);	chr3:47619306	chr3:47960327~47961081:-
STAD	cis	rs7829975	0.535	rs4841005	ENSG00000253981.4	ALG1L13P	-4.88	1.64e-06	0.00103	-0.3	-0.25	Mood instability;	chr8:8643720	chr8:8236003~8244667:-
STAD	cis	rs7429990	0.864	rs13061412	ENSG00000224895.1	VPS26BP1	4.88	1.64e-06	0.00103	0.24	0.25	Educational attainment (years of education);	chr3:47660092	chr3:47960327~47961081:-
STAD	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	4.88	1.64e-06	0.00103	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
STAD	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-4.88	1.64e-06	0.00103	-0.29	-0.25	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
STAD	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-4.88	1.64e-06	0.00103	-0.27	-0.25	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
STAD	cis	rs2933343	0.621	rs789242	ENSG00000261159.1	RP11-723O4.9	4.88	1.64e-06	0.00103	0.31	0.25	IgG glycosylation;	chr3:128866864	chr3:128859716~128860526:-
STAD	cis	rs7665090	1	rs5026472	ENSG00000248971.2	KRT8P46	-4.88	1.64e-06	0.00103	-0.26	-0.25	Primary biliary cholangitis;	chr4:102633616	chr4:102728746~102730171:-
STAD	cis	rs13113518	1	rs13118237	ENSG00000223305.1	RN7SKP30	4.88	1.64e-06	0.00103	0.28	0.25	Height;	chr4:55474259	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs11133387	ENSG00000223305.1	RN7SKP30	4.88	1.64e-06	0.00103	0.28	0.25	Height;	chr4:55475130	chr4:55540502~55540835:-
STAD	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-4.88	1.65e-06	0.00103	-0.39	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
STAD	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-4.88	1.65e-06	0.00103	-0.39	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
STAD	cis	rs721917	0.506	rs4320898	ENSG00000244733.5	RP11-506M13.3	-4.88	1.65e-06	0.00103	-0.31	-0.25	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs4322333	ENSG00000244733.5	RP11-506M13.3	-4.88	1.65e-06	0.00103	-0.31	-0.25	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79660891~79677996:+
STAD	cis	rs7015630	0.648	rs62530862	ENSG00000251136.7	RP11-37B2.1	-4.88	1.65e-06	0.00103	-0.31	-0.25	Inflammatory bowel disease;Crohn's disease;	chr8:89822659	chr8:89609409~89757727:-
STAD	cis	rs7487075	0.719	rs2408496	ENSG00000272369.1	RP11-446N19.1	4.88	1.65e-06	0.00103	0.34	0.25	Itch intensity from mosquito bite;	chr12:46256954	chr12:46537502~46652550:+
STAD	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-4.88	1.65e-06	0.00103	-0.29	-0.25	QT interval;	chr12:29302457	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-4.88	1.65e-06	0.00103	-0.29	-0.25	QT interval;	chr12:29302458	chr12:29280418~29317848:-
STAD	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	4.88	1.65e-06	0.00103	0.31	0.25	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	4.88	1.65e-06	0.00103	0.31	0.25	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
STAD	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-4.88	1.65e-06	0.00103	-0.26	-0.25	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
STAD	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-4.88	1.65e-06	0.00103	-0.3	-0.25	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
STAD	cis	rs6095360	0.7	rs2295026	ENSG00000222365.1	SNORD12B	-4.88	1.65e-06	0.00103	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:48966248	chr20:49280319~49280409:+
STAD	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-4.88	1.65e-06	0.00103	-0.29	-0.25	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	4.88	1.65e-06	0.00103	0.31	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
STAD	cis	rs11098499	0.865	rs11098513	ENSG00000260091.1	RP11-33B1.4	4.88	1.65e-06	0.00103	0.25	0.25	Corneal astigmatism;	chr4:119394920	chr4:119409333~119410233:+
STAD	cis	rs733592	0.599	rs12819124	ENSG00000258273.1	RP11-370I10.4	-4.88	1.65e-06	0.00103	-0.28	-0.25	Plateletcrit;	chr12:48015271	chr12:48333755~48333901:-
STAD	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-4.88	1.65e-06	0.00103	-0.38	-0.25	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-4.88	1.65e-06	0.00103	-0.38	-0.25	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-4.88	1.65e-06	0.00103	-0.38	-0.25	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-4.88	1.65e-06	0.00103	-0.38	-0.25	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
STAD	cis	rs1707322	0.717	rs3014246	ENSG00000281133.1	AL355480.3	4.88	1.65e-06	0.00103	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45580892~45580996:-
STAD	cis	rs3758911	0.828	rs10890701	ENSG00000261098.1	RP11-819C21.1	-4.88	1.65e-06	0.00103	-0.24	-0.25	Coronary artery disease;	chr11:107309216	chr11:107312132~107316271:-
STAD	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	4.88	1.65e-06	0.00103	0.38	0.25	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
STAD	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	4.88	1.65e-06	0.00103	0.23	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
STAD	cis	rs13113518	1	rs7675109	ENSG00000223305.1	RN7SKP30	4.88	1.66e-06	0.00103	0.28	0.25	Height;	chr4:55525589	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs4865005	ENSG00000223305.1	RN7SKP30	4.88	1.66e-06	0.00103	0.28	0.25	Height;	chr4:55525781	chr4:55540502~55540835:-
STAD	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	4.88	1.66e-06	0.00103	0.28	0.25	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
STAD	cis	rs1876905	0.539	rs240985	ENSG00000271789.1	RP5-1112D6.7	4.88	1.66e-06	0.00103	0.3	0.25	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111297126~111298510:+
STAD	cis	rs507080	0.769	rs527290	ENSG00000278376.1	RP11-158I9.8	-4.88	1.66e-06	0.00103	-0.27	-0.25	Serum metabolite levels;	chr11:118644898	chr11:118791254~118793137:+
STAD	cis	rs7176527	0.796	rs1057946	ENSG00000188388.10	GOLGA6L3	4.88	1.66e-06	0.00104	0.36	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85240472~85247170:+
STAD	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-4.87	1.66e-06	0.00104	-0.3	-0.25	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
STAD	cis	rs8067354	0.681	rs76856339	ENSG00000266701.1	AC005702.4	4.87	1.66e-06	0.00104	0.35	0.25	Hemoglobin concentration;	chr17:59723605	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.507	rs72840511	ENSG00000266701.1	AC005702.4	4.87	1.66e-06	0.00104	0.35	0.25	Hemoglobin concentration;	chr17:59728650	chr17:60042546~60042627:-
STAD	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-4.87	1.66e-06	0.00104	-0.37	-0.25	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
STAD	cis	rs1799949	1	rs16940	ENSG00000236383.6	LINC00854	-4.87	1.66e-06	0.00104	-0.21	-0.25	Menopause (age at onset);	chr17:43093220	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.93	rs66499067	ENSG00000236383.6	LINC00854	-4.87	1.66e-06	0.00104	-0.21	-0.25	Menopause (age at onset);	chr17:43096467	chr17:43216941~43305976:-
STAD	cis	rs2688608	0.592	rs11000759	ENSG00000271816.1	BMS1P4	4.87	1.66e-06	0.00104	0.28	0.25	Inflammatory bowel disease;	chr10:73733968	chr10:73699151~73730487:-
STAD	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	4.87	1.66e-06	0.00104	0.33	0.25	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
STAD	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-4.87	1.66e-06	0.00104	-0.3	-0.25	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
STAD	cis	rs10925040	0.666	rs10737808	ENSG00000227135.1	GCSAML-AS1	-4.87	1.67e-06	0.00104	-0.27	-0.25	Tumor necrosis factor beta levels;	chr1:247459638	chr1:247524679~247526752:-
STAD	cis	rs9467773	0.596	rs2451750	ENSG00000243307.2	POM121L6P	4.87	1.67e-06	0.00104	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2504600	ENSG00000243307.2	POM121L6P	4.87	1.67e-06	0.00104	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2130657	ENSG00000243307.2	POM121L6P	4.87	1.67e-06	0.00104	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2498351	ENSG00000243307.2	POM121L6P	4.87	1.67e-06	0.00104	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2504566	ENSG00000243307.2	POM121L6P	4.87	1.67e-06	0.00104	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26896952~26898777:+
STAD	cis	rs7078219	0.505	rs10883371	ENSG00000257582.4	LINC01475	-4.87	1.67e-06	0.00104	-0.29	-0.25	Dental caries;	chr10:99532698	chr10:99526350~99531177:-
STAD	cis	rs4950322	0.57	rs6703892	ENSG00000278811.3	LINC00624	4.87	1.67e-06	0.00104	0.28	0.25	Protein quantitative trait loci;	chr1:147287627	chr1:147258885~147517875:-
STAD	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-4.87	1.67e-06	0.00104	-0.28	-0.25	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
STAD	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-4.87	1.67e-06	0.00104	-0.27	-0.25	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
STAD	cis	rs9467773	0.62	rs2494716	ENSG00000243307.2	POM121L6P	4.87	1.67e-06	0.00104	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26896952~26898777:+
STAD	cis	rs1707322	0.717	rs1972410	ENSG00000281133.1	AL355480.3	-4.87	1.67e-06	0.00104	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45580892~45580996:-
STAD	cis	rs11676348	0.755	rs13410318	ENSG00000237281.1	CATIP-AS2	-4.87	1.67e-06	0.00104	-0.26	-0.25	Ulcerative colitis;	chr2:218158187	chr2:218326889~218357966:-
STAD	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	4.87	1.67e-06	0.00104	0.31	0.25	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	4.87	1.67e-06	0.00104	0.31	0.25	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
STAD	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-4.87	1.68e-06	0.00104	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
STAD	cis	rs13113518	1	rs6847529	ENSG00000223305.1	RN7SKP30	4.87	1.68e-06	0.00104	0.28	0.25	Height;	chr4:55518776	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs6822740	ENSG00000223305.1	RN7SKP30	4.87	1.68e-06	0.00104	0.28	0.25	Height;	chr4:55518922	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs13108409	ENSG00000223305.1	RN7SKP30	4.87	1.68e-06	0.00104	0.28	0.25	Height;	chr4:55520278	chr4:55540502~55540835:-
STAD	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-4.87	1.68e-06	0.00104	-0.32	-0.25	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
STAD	cis	rs7665090	0.905	rs2866410	ENSG00000230069.3	LRRC37A15P	-4.87	1.68e-06	0.00105	-0.28	-0.25	Primary biliary cholangitis;	chr4:102633178	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.936	rs2866411	ENSG00000230069.3	LRRC37A15P	-4.87	1.68e-06	0.00105	-0.28	-0.25	Primary biliary cholangitis;	chr4:102633183	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.936	rs2866412	ENSG00000230069.3	LRRC37A15P	-4.87	1.68e-06	0.00105	-0.28	-0.25	Primary biliary cholangitis;	chr4:102633193	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs909349	ENSG00000230069.3	LRRC37A15P	4.87	1.68e-06	0.00105	0.27	0.25	Primary biliary cholangitis;	chr4:102635159	chr4:102727274~102730721:-
STAD	cis	rs7615952	0.673	rs16834637	ENSG00000272840.1	RP11-379B18.6	4.87	1.68e-06	0.00105	0.51	0.25	Blood pressure (smoking interaction);	chr3:125886628	chr3:125774714~125797953:+
STAD	cis	rs2115536	0.73	rs12898642	ENSG00000278600.1	RP11-81A1.6	-4.87	1.68e-06	0.00105	-0.22	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79889708	chr15:79920195~79922455:-
STAD	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	4.87	1.68e-06	0.00105	0.29	0.25	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
STAD	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-4.87	1.68e-06	0.00105	-0.29	-0.25	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
STAD	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-4.87	1.68e-06	0.00105	-0.27	-0.25	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
STAD	cis	rs9395066	0.545	rs6925467	ENSG00000219384.1	RP11-491H9.3	-4.87	1.68e-06	0.00105	-0.24	-0.25	Height;	chr6:45030301	chr6:45158870~45159511:+
STAD	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	4.87	1.68e-06	0.00105	0.3	0.25	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
STAD	cis	rs6714710	0.603	rs895438	ENSG00000235833.1	AC159540.14	-4.87	1.68e-06	0.00105	-0.3	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97766423	chr2:97523949~97524976:-
STAD	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-4.87	1.68e-06	0.00105	-0.33	-0.25	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
STAD	cis	rs875971	0.545	rs1638724	ENSG00000236529.1	RP13-254B10.1	-4.87	1.69e-06	0.00105	-0.29	-0.25	Aortic root size;	chr7:66575494	chr7:65840212~65840596:+
STAD	cis	rs2286503	0.78	rs2240727	ENSG00000228649.7	AC005682.5	4.87	1.69e-06	0.00105	0.3	0.25	Fibrinogen;	chr7:22812893	chr7:22854178~22861579:+
STAD	cis	rs8028182	0.636	rs7166737	ENSG00000260269.4	CTD-2323K18.1	-4.87	1.69e-06	0.00105	-0.32	-0.25	Sudden cardiac arrest;	chr15:75390172	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs8028277	ENSG00000260269.4	CTD-2323K18.1	-4.87	1.69e-06	0.00105	-0.32	-0.25	Sudden cardiac arrest;	chr15:75391744	chr15:75527150~75601205:-
STAD	cis	rs2115536	1	rs11072871	ENSG00000278600.1	RP11-81A1.6	-4.87	1.69e-06	0.00105	-0.22	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79905589	chr15:79920195~79922455:-
STAD	cis	rs2306032	0.669	rs10838622	ENSG00000271350.1	CTD-2384B9.1	-4.87	1.69e-06	0.00105	-0.3	-0.25	Total body bone mineral density;	chr11:46834985	chr11:47041027~47041945:-
STAD	cis	rs13113518	1	rs11724094	ENSG00000223305.1	RN7SKP30	4.87	1.69e-06	0.00105	0.28	0.25	Height;	chr4:55501479	chr4:55540502~55540835:-
STAD	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-4.87	1.69e-06	0.00105	-0.32	-0.25	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
STAD	cis	rs801193	0.66	rs10950049	ENSG00000236529.1	RP13-254B10.1	4.87	1.69e-06	0.00105	0.26	0.25	Aortic root size;	chr7:66765873	chr7:65840212~65840596:+
STAD	cis	rs7829975	0.774	rs35039922	ENSG00000254340.1	RP11-10A14.3	4.87	1.69e-06	0.00105	0.3	0.25	Mood instability;	chr8:8817815	chr8:9141424~9145435:+
STAD	cis	rs875971	0.545	rs1796222	ENSG00000236529.1	RP13-254B10.1	-4.87	1.69e-06	0.00105	-0.29	-0.25	Aortic root size;	chr7:66592167	chr7:65840212~65840596:+
STAD	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-4.87	1.69e-06	0.00105	-0.25	-0.25	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
STAD	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-4.87	1.69e-06	0.00105	-0.32	-0.25	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
STAD	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-4.87	1.69e-06	0.00105	-0.32	-0.25	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
STAD	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-4.87	1.69e-06	0.00105	-0.32	-0.25	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
STAD	cis	rs8177876	0.658	rs2278022	ENSG00000261061.1	RP11-303E16.2	-4.87	1.69e-06	0.00105	-0.44	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81030770~81031485:+
STAD	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	4.87	1.69e-06	0.00105	0.3	0.25	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
STAD	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-4.87	1.7e-06	0.00106	-0.31	-0.25	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
STAD	cis	rs7429990	0.833	rs6442079	ENSG00000224895.1	VPS26BP1	4.87	1.7e-06	0.00106	0.24	0.25	Educational attainment (years of education);	chr3:47721044	chr3:47960327~47961081:-
STAD	cis	rs17507216	1	rs17507216	ENSG00000255769.6	GOLGA2P10	4.87	1.7e-06	0.00106	0.38	0.25	Excessive daytime sleepiness;	chr15:82558175	chr15:82472993~82513950:-
STAD	cis	rs9467773	0.836	rs1624440	ENSG00000243307.2	POM121L6P	-4.87	1.7e-06	0.00106	-0.24	-0.25	Intelligence (multi-trait analysis);	chr6:26433101	chr6:26896952~26898777:+
STAD	cis	rs6597981	0.604	rs7945912	ENSG00000255284.1	AP006621.5	4.87	1.7e-06	0.00106	0.28	0.25	Breast cancer;	chr11:750849	chr11:777578~784297:+
STAD	cis	rs7429990	0.864	rs13086149	ENSG00000224895.1	VPS26BP1	4.87	1.7e-06	0.00106	0.25	0.25	Educational attainment (years of education);	chr3:47784158	chr3:47960327~47961081:-
STAD	cis	rs3736858	0.825	rs2120061	ENSG00000261105.4	LMO7-AS1	-4.87	1.7e-06	0.00106	-0.42	-0.25	Interleukin-9 levels;	chr13:75813370	chr13:75604700~75635994:-
STAD	cis	rs8097348	0.817	rs6505943	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1640538	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.744	rs78666911	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1642655	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.744	rs2345583	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1646228	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.817	rs2881178	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1647119	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.817	rs2219123	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1647405	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.817	rs2198559	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1647552	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.744	rs2198560	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1647561	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.779	rs2198561	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1647673	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.817	rs7232582	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1648795	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.817	rs8088560	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1649141	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.817	rs6505949	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1649591	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.817	rs3859370	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1650927	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.761	rs3859373	ENSG00000266602.1	RP11-476K15.1	-4.87	1.7e-06	0.00106	-0.29	-0.25	Exercise (leisure time);	chr18:1651048	chr18:1509183~1647097:+
STAD	cis	rs2803122	0.502	rs1854552	ENSG00000273226.1	RP11-513M16.8	4.87	1.7e-06	0.00106	0.28	0.25	Pulse pressure;	chr9:19235049	chr9:19375451~19375996:+
STAD	cis	rs4713118	0.662	rs156744	ENSG00000220721.1	OR1F12	4.87	1.7e-06	0.00106	0.29	0.25	Parkinson's disease;	chr6:27999496	chr6:28073316~28074233:+
STAD	cis	rs858239	1	rs156407	ENSG00000230042.1	AK3P3	-4.87	1.71e-06	0.00106	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23129178~23129841:+
STAD	cis	rs6142102	0.961	rs6088355	ENSG00000275784.1	RP5-1125A11.6	-4.87	1.71e-06	0.00106	-0.26	-0.25	Skin pigmentation;	chr20:33958081	chr20:33989480~33991818:-
STAD	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-4.87	1.71e-06	0.00106	-0.25	-0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
STAD	cis	rs9733	0.566	rs11204675	ENSG00000274963.1	Metazoa_SRP	-4.87	1.71e-06	0.00106	-0.2	-0.25	Tonsillectomy;	chr1:150598509	chr1:150568971~150569269:-
STAD	cis	rs9467773	0.62	rs2451711	ENSG00000243307.2	POM121L6P	4.87	1.71e-06	0.00106	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26896952~26898777:+
STAD	cis	rs2273156	0.706	rs12881698	ENSG00000241052.1	RP11-173D9.1	-4.87	1.71e-06	0.00106	-0.3	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35034299	chr14:35144021~35144480:-
STAD	cis	rs7665090	0.846	rs4496586	ENSG00000248971.2	KRT8P46	-4.87	1.71e-06	0.00106	-0.26	-0.25	Primary biliary cholangitis;	chr4:102636154	chr4:102728746~102730171:-
STAD	cis	rs9307551	1	rs11098770	ENSG00000250334.4	LINC00989	-4.87	1.71e-06	0.00106	-0.32	-0.25	Refractive error;	chr4:79598850	chr4:79492416~79576460:+
STAD	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	4.87	1.71e-06	0.00106	0.34	0.25	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
STAD	cis	rs7665090	1	rs6810869	ENSG00000230069.3	LRRC37A15P	-4.87	1.71e-06	0.00106	-0.28	-0.25	Primary biliary cholangitis;	chr4:102637357	chr4:102727274~102730721:-
STAD	cis	rs7191700	0.578	rs243324	ENSG00000262703.1	RP11-485G7.6	4.87	1.71e-06	0.00106	0.24	0.25	Multiple sclerosis;	chr16:11261113	chr16:11348143~11349321:-
STAD	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	4.87	1.71e-06	0.00106	0.31	0.25	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	4.87	1.71e-06	0.00106	0.31	0.25	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	4.87	1.71e-06	0.00106	0.31	0.25	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	4.87	1.71e-06	0.00106	0.31	0.25	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
STAD	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	4.87	1.71e-06	0.00106	0.31	0.25	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
STAD	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-4.87	1.71e-06	0.00106	-0.34	-0.25	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
STAD	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	4.87	1.71e-06	0.00106	0.25	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
STAD	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	4.87	1.71e-06	0.00107	0.33	0.25	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
STAD	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-4.87	1.71e-06	0.00107	-0.3	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
STAD	cis	rs13113518	0.967	rs4340844	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55462689	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs1522112	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55463606	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs4864997	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55466010	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs960152	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55467308	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.967	rs12644948	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55470266	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs3805151	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55470874	chr4:55540502~55540835:-
STAD	cis	rs1799949	1	rs34942571	ENSG00000279602.1	CTD-3014M21.1	4.87	1.72e-06	0.00107	0.32	0.25	Menopause (age at onset);	chr17:43121362	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs4793233	ENSG00000279602.1	CTD-3014M21.1	4.87	1.72e-06	0.00107	0.32	0.25	Menopause (age at onset);	chr17:43358069	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.864	rs60309406	ENSG00000279602.1	CTD-3014M21.1	4.87	1.72e-06	0.00107	0.32	0.25	Menopause (age at onset);	chr17:43358297	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs4793234	ENSG00000279602.1	CTD-3014M21.1	4.87	1.72e-06	0.00107	0.32	0.25	Menopause (age at onset);	chr17:43358815	chr17:43360041~43361361:-
STAD	cis	rs2408955	0.715	rs1793957	ENSG00000258273.1	RP11-370I10.4	-4.87	1.72e-06	0.00107	-0.31	-0.25	Glycated hemoglobin levels;	chr12:47999041	chr12:48333755~48333901:-
STAD	cis	rs13113518	1	rs7677085	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55495801	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs12510681	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55496737	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs12500162	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55496933	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.934	rs3805155	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55497842	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs7686261	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55500224	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11729220	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55501629	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11133390	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55501726	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11133391	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55501788	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs13133484	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55504176	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.934	rs13127906	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55504201	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs6849433	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55506498	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs12501327	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55507248	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11133392	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55507729	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs6838305	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55508587	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.902	rs12503578	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55509367	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs3828480	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55510352	chr4:55540502~55540835:-
STAD	cis	rs4950322	1	rs1806618	ENSG00000278811.3	LINC00624	4.87	1.72e-06	0.00107	0.28	0.25	Protein quantitative trait loci;	chr1:147377075	chr1:147258885~147517875:-
STAD	cis	rs4950322	1	rs4448568	ENSG00000278811.3	LINC00624	4.87	1.72e-06	0.00107	0.28	0.25	Protein quantitative trait loci;	chr1:147377296	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.895	rs17356735	ENSG00000278811.3	LINC00624	4.87	1.72e-06	0.00107	0.28	0.25	Protein quantitative trait loci;	chr1:147378328	chr1:147258885~147517875:-
STAD	cis	rs6142102	0.59	rs6059691	ENSG00000275784.1	RP5-1125A11.6	4.87	1.72e-06	0.00107	0.26	0.25	Skin pigmentation;	chr20:34149161	chr20:33989480~33991818:-
STAD	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-4.87	1.72e-06	0.00107	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
STAD	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-4.87	1.72e-06	0.00107	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
STAD	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-4.87	1.72e-06	0.00107	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
STAD	cis	rs10978777	0.805	rs10816493	ENSG00000276883.1	AL137852.1	-4.87	1.72e-06	0.00107	-0.25	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107338464	chr9:107292369~107292456:-
STAD	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	4.87	1.72e-06	0.00107	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
STAD	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	4.87	1.72e-06	0.00107	0.25	0.25	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
STAD	cis	rs7429990	0.774	rs3772402	ENSG00000224895.1	VPS26BP1	4.87	1.72e-06	0.00107	0.24	0.25	Educational attainment (years of education);	chr3:47574661	chr3:47960327~47961081:-
STAD	cis	rs13113518	0.966	rs4864544	ENSG00000223305.1	RN7SKP30	4.87	1.72e-06	0.00107	0.28	0.25	Height;	chr4:55515292	chr4:55540502~55540835:-
STAD	cis	rs1707322	0.686	rs1541131	ENSG00000281133.1	AL355480.3	4.87	1.73e-06	0.00107	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.686	rs3014242	ENSG00000281133.1	AL355480.3	4.87	1.73e-06	0.00107	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.686	rs3014239	ENSG00000281133.1	AL355480.3	4.87	1.73e-06	0.00107	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45580892~45580996:-
STAD	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-4.87	1.73e-06	0.00107	-0.29	-0.25	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
STAD	cis	rs9860428	1	rs13076130	ENSG00000240057.4	RP11-572M11.4	-4.87	1.73e-06	0.00107	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112910842	chr3:113019532~113183301:+
STAD	cis	rs9907295	0.818	rs2280789	ENSG00000270894.1	AC015849.13	-4.87	1.73e-06	0.00107	-0.26	-0.25	Fibroblast growth factor basic levels;	chr17:35879999	chr17:35818399~35823713:+
STAD	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-4.87	1.73e-06	0.00107	-0.27	-0.25	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
STAD	cis	rs7396835	0.537	rs10892035	ENSG00000280143.1	AP000892.6	4.87	1.73e-06	0.00107	0.22	0.25	Quantitative traits;	chr11:116824222	chr11:117204967~117210292:+
STAD	cis	rs2337406	0.714	rs115401799	ENSG00000280411.1	IGHV1-69-2	-4.87	1.73e-06	0.00107	-0.31	-0.25	Alzheimer's disease (late onset);	chr14:106813739	chr14:106762092~106762588:-
STAD	cis	rs7674212	1	rs7674212	ENSG00000230069.3	LRRC37A15P	-4.87	1.73e-06	0.00107	-0.28	-0.25	Type 2 diabetes;	chr4:103067742	chr4:102727274~102730721:-
STAD	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	4.87	1.73e-06	0.00107	0.32	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
STAD	cis	rs7932354	0.583	rs7101374	ENSG00000271350.1	CTD-2384B9.1	-4.87	1.73e-06	0.00108	-0.31	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46802691	chr11:47041027~47041945:-
STAD	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-4.87	1.73e-06	0.00108	-0.29	-0.25	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-4.87	1.73e-06	0.00108	-0.29	-0.25	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-4.87	1.73e-06	0.00108	-0.29	-0.25	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-4.87	1.73e-06	0.00108	-0.29	-0.25	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-4.87	1.73e-06	0.00108	-0.29	-0.25	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-4.87	1.73e-06	0.00108	-0.29	-0.25	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
STAD	cis	rs7429990	0.965	rs4858881	ENSG00000224895.1	VPS26BP1	4.87	1.74e-06	0.00108	0.25	0.25	Educational attainment (years of education);	chr3:48082306	chr3:47960327~47961081:-
STAD	cis	rs7224610	0.587	rs4617927	ENSG00000263096.1	RP11-515O17.2	4.87	1.74e-06	0.00108	0.3	0.25	Urate levels;	chr17:55278765	chr17:55271504~55273653:-
STAD	cis	rs7487075	0.82	rs7488482	ENSG00000272369.1	RP11-446N19.1	4.87	1.74e-06	0.00108	0.34	0.25	Itch intensity from mosquito bite;	chr12:46331704	chr12:46537502~46652550:+
STAD	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-4.87	1.74e-06	0.00108	-0.37	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
STAD	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-4.87	1.74e-06	0.00108	-0.37	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
STAD	cis	rs10510102	1	rs7923678	ENSG00000226864.1	ATE1-AS1	4.87	1.74e-06	0.00108	0.39	0.25	Breast cancer;	chr10:121832546	chr10:121928312~121951965:+
STAD	cis	rs2446066	0.872	rs10876455	ENSG00000257379.1	RP11-793H13.8	4.87	1.74e-06	0.00108	0.43	0.25	Red blood cell count;	chr12:53431541	chr12:53441741~53467528:+
STAD	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	4.86	1.74e-06	0.00108	0.34	0.25	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
STAD	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	4.86	1.74e-06	0.00108	0.33	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
STAD	cis	rs1799949	1	rs67060599	ENSG00000236383.6	LINC00854	-4.86	1.74e-06	0.00108	-0.21	-0.25	Menopause (age at onset);	chr17:43103085	chr17:43216941~43305976:-
STAD	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	4.86	1.74e-06	0.00108	0.38	0.25	Height;	chr6:109775693	chr6:109382795~109383666:+
STAD	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-4.86	1.74e-06	0.00108	-0.25	-0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
STAD	cis	rs2337406	0.789	rs60000589	ENSG00000211972.2	IGHV3-66	4.86	1.74e-06	0.00108	0.26	0.25	Alzheimer's disease (late onset);	chr14:106782459	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs111881598	ENSG00000211972.2	IGHV3-66	4.86	1.74e-06	0.00108	0.26	0.25	Alzheimer's disease (late onset);	chr14:106783113	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs61164979	ENSG00000211972.2	IGHV3-66	4.86	1.74e-06	0.00108	0.26	0.25	Alzheimer's disease (late onset);	chr14:106783133	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs61419485	ENSG00000211972.2	IGHV3-66	4.86	1.74e-06	0.00108	0.26	0.25	Alzheimer's disease (late onset);	chr14:106783374	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74090151	ENSG00000211972.2	IGHV3-66	4.86	1.74e-06	0.00108	0.26	0.25	Alzheimer's disease (late onset);	chr14:106785377	chr14:106675017~106675544:-
STAD	cis	rs7474896	0.583	rs10827818	ENSG00000120555.12	SEPT7P9	4.86	1.74e-06	0.00108	0.3	0.25	Obesity (extreme);	chr10:37711928	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.583	rs7071147	ENSG00000120555.12	SEPT7P9	4.86	1.74e-06	0.00108	0.3	0.25	Obesity (extreme);	chr10:37714448	chr10:38383069~38402916:-
STAD	cis	rs453301	0.538	rs7830804	ENSG00000173295.6	FAM86B3P	-4.86	1.75e-06	0.00108	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9113252	chr8:8228595~8244865:+
STAD	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	4.86	1.75e-06	0.00108	0.33	0.25	Height;	chr20:49215517	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	4.86	1.75e-06	0.00108	0.33	0.25	Height;	chr20:49220589	chr20:49280319~49280409:+
STAD	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	4.86	1.75e-06	0.00108	0.34	0.25	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
STAD	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	4.86	1.75e-06	0.00108	0.34	0.25	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
STAD	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	4.86	1.75e-06	0.00108	0.34	0.25	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
STAD	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	4.86	1.75e-06	0.00108	0.34	0.25	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
STAD	cis	rs35955747	0.677	rs4820974	ENSG00000236132.1	CTA-440B3.1	4.86	1.75e-06	0.00108	0.27	0.25	Neutrophil count;Sum basophil neutrophil counts;	chr22:31473481	chr22:31816379~31817491:-
STAD	cis	rs2337406	0.778	rs56965016	ENSG00000274576.2	IGHV2-70	-4.86	1.75e-06	0.00108	-0.31	-0.25	Alzheimer's disease (late onset);	chr14:106656649	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.778	rs56658355	ENSG00000274576.2	IGHV2-70	-4.86	1.75e-06	0.00108	-0.31	-0.25	Alzheimer's disease (late onset);	chr14:106662151	chr14:106770577~106771020:-
STAD	cis	rs7615952	0.546	rs4428131	ENSG00000272840.1	RP11-379B18.6	4.86	1.75e-06	0.00108	0.43	0.25	Blood pressure (smoking interaction);	chr3:125627635	chr3:125774714~125797953:+
STAD	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	4.86	1.75e-06	0.00108	0.34	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
STAD	cis	rs6951245	0.554	rs4724294	ENSG00000229043.2	AC091729.9	-4.86	1.75e-06	0.00108	-0.34	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1160374~1165267:+
STAD	cis	rs1799949	1	rs16941	ENSG00000236383.6	LINC00854	-4.86	1.75e-06	0.00108	-0.21	-0.25	Menopause (age at onset);	chr17:43092418	chr17:43216941~43305976:-
STAD	cis	rs13113518	1	rs4864542	ENSG00000223305.1	RN7SKP30	-4.86	1.75e-06	0.00108	-0.28	-0.25	Height;	chr4:55487920	chr4:55540502~55540835:-
STAD	cis	rs4713118	0.866	rs2179094	ENSG00000280107.1	AL022393.9	-4.86	1.75e-06	0.00108	-0.34	-0.25	Parkinson's disease;	chr6:27774046	chr6:28170845~28172521:+
STAD	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	4.86	1.75e-06	0.00109	0.3	0.25	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
STAD	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	4.86	1.75e-06	0.00109	0.32	0.25	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
STAD	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-4.86	1.75e-06	0.00109	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
STAD	cis	rs7487075	0.82	rs7135897	ENSG00000272369.1	RP11-446N19.1	-4.86	1.76e-06	0.00109	-0.33	-0.25	Itch intensity from mosquito bite;	chr12:46305119	chr12:46537502~46652550:+
STAD	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	4.86	1.76e-06	0.00109	0.27	0.25	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
STAD	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	4.86	1.76e-06	0.00109	0.34	0.25	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
STAD	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	4.86	1.76e-06	0.00109	0.34	0.25	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
STAD	cis	rs7429990	0.833	rs6442072	ENSG00000224895.1	VPS26BP1	4.86	1.76e-06	0.00109	0.24	0.25	Educational attainment (years of education);	chr3:47642960	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs2882611	ENSG00000224895.1	VPS26BP1	4.86	1.76e-06	0.00109	0.24	0.25	Educational attainment (years of education);	chr3:47651532	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.803	rs6773732	ENSG00000224895.1	VPS26BP1	4.86	1.76e-06	0.00109	0.24	0.25	Educational attainment (years of education);	chr3:47677772	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs2049301	ENSG00000224895.1	VPS26BP1	4.86	1.76e-06	0.00109	0.24	0.25	Educational attainment (years of education);	chr3:47681369	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7429162	ENSG00000224895.1	VPS26BP1	4.86	1.76e-06	0.00109	0.24	0.25	Educational attainment (years of education);	chr3:47683845	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs4410463	ENSG00000224895.1	VPS26BP1	4.86	1.76e-06	0.00109	0.24	0.25	Educational attainment (years of education);	chr3:47693907	chr3:47960327~47961081:-
STAD	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	4.86	1.76e-06	0.00109	0.37	0.25	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
STAD	cis	rs875971	0.545	rs6970498	ENSG00000236529.1	RP13-254B10.1	4.86	1.76e-06	0.00109	0.3	0.25	Aortic root size;	chr7:66275908	chr7:65840212~65840596:+
STAD	cis	rs10510102	0.935	rs12240893	ENSG00000226864.1	ATE1-AS1	4.86	1.76e-06	0.00109	0.41	0.25	Breast cancer;	chr10:121870572	chr10:121928312~121951965:+
STAD	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	4.86	1.76e-06	0.00109	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	4.86	1.76e-06	0.00109	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
STAD	cis	rs13113518	1	rs4864999	ENSG00000223305.1	RN7SKP30	4.86	1.76e-06	0.00109	0.28	0.25	Height;	chr4:55476736	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs10517344	ENSG00000223305.1	RN7SKP30	4.86	1.76e-06	0.00109	0.28	0.25	Height;	chr4:55477545	chr4:55540502~55540835:-
STAD	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	4.86	1.76e-06	0.00109	0.33	0.25	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
STAD	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-4.86	1.77e-06	0.00109	-0.32	-0.25	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
STAD	cis	rs1799949	1	rs8176133	ENSG00000236383.6	LINC00854	-4.86	1.77e-06	0.00109	-0.21	-0.25	Menopause (age at onset);	chr17:43105441	chr17:43216941~43305976:-
STAD	cis	rs7932354	0.537	rs2290884	ENSG00000271350.1	CTD-2384B9.1	-4.86	1.77e-06	0.00109	-0.31	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46868837	chr11:47041027~47041945:-
STAD	cis	rs4950322	0.57	rs4593887	ENSG00000278811.3	LINC00624	4.86	1.77e-06	0.00109	0.28	0.25	Protein quantitative trait loci;	chr1:147234246	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691004	ENSG00000278811.3	LINC00624	4.86	1.77e-06	0.00109	0.28	0.25	Protein quantitative trait loci;	chr1:147234309	chr1:147258885~147517875:-
STAD	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	4.86	1.77e-06	0.00109	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	4.86	1.77e-06	0.00109	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	4.86	1.77e-06	0.00109	0.3	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
STAD	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-4.86	1.77e-06	0.00109	-0.27	-0.25	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
STAD	cis	rs611744	0.573	rs1457210	ENSG00000253754.1	RP11-35G22.1	4.86	1.77e-06	0.0011	0.22	0.25	Dupuytren's disease;	chr8:108249333	chr8:108226200~108227544:+
STAD	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	4.86	1.77e-06	0.0011	0.3	0.25	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
STAD	cis	rs992157	0.71	rs6719789	ENSG00000237281.1	CATIP-AS2	4.86	1.77e-06	0.0011	0.25	0.25	Colorectal cancer;	chr2:218193087	chr2:218326889~218357966:-
STAD	cis	rs9307551	0.948	rs4389603	ENSG00000250334.4	LINC00989	-4.86	1.77e-06	0.0011	-0.32	-0.25	Refractive error;	chr4:79567720	chr4:79492416~79576460:+
STAD	cis	rs2857078	0.72	rs9901595	ENSG00000260793.2	RP5-882C2.2	-4.86	1.77e-06	0.0011	-0.28	-0.25	Red cell distribution width;Reticulocyte count;	chr17:44228331	chr17:44221401~44223710:+
STAD	cis	rs2857078	0.72	rs9906669	ENSG00000260793.2	RP5-882C2.2	-4.86	1.77e-06	0.0011	-0.28	-0.25	Red cell distribution width;Reticulocyte count;	chr17:44228338	chr17:44221401~44223710:+
STAD	cis	rs3770081	1	rs58515922	ENSG00000273080.1	RP11-301O19.1	-4.86	1.78e-06	0.0011	-0.56	-0.25	Facial emotion recognition (sad faces);	chr2:85945914	chr2:86195590~86196049:+
STAD	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-4.86	1.78e-06	0.0011	-0.29	-0.25	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
STAD	cis	rs2337406	0.866	rs11488879	ENSG00000211972.2	IGHV3-66	4.86	1.78e-06	0.0011	0.26	0.25	Alzheimer's disease (late onset);	chr14:106786097	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs8012619	ENSG00000211972.2	IGHV3-66	4.86	1.78e-06	0.0011	0.26	0.25	Alzheimer's disease (late onset);	chr14:106793907	chr14:106675017~106675544:-
STAD	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	4.86	1.78e-06	0.0011	0.29	0.25	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
STAD	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-4.86	1.78e-06	0.0011	-0.38	-0.25	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	4.86	1.78e-06	0.0011	0.38	0.25	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	4.86	1.78e-06	0.0011	0.38	0.25	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	4.86	1.78e-06	0.0011	0.38	0.25	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	4.86	1.78e-06	0.0011	0.38	0.25	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	4.86	1.78e-06	0.0011	0.38	0.25	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
STAD	cis	rs5758659	0.967	rs5758670	ENSG00000182057.4	OGFRP1	4.86	1.78e-06	0.0011	0.26	0.25	Cognitive function;	chr22:42240681	chr22:42269753~42275196:+
STAD	cis	rs7829975	0.684	rs546603	ENSG00000173295.6	FAM86B3P	-4.86	1.78e-06	0.0011	-0.28	-0.25	Mood instability;	chr8:8738328	chr8:8228595~8244865:+
STAD	cis	rs7826238	0.564	rs2921053	ENSG00000254340.1	RP11-10A14.3	4.86	1.78e-06	0.0011	0.31	0.25	Systolic blood pressure;	chr8:8462453	chr8:9141424~9145435:+
STAD	cis	rs240993	0.809	rs11153277	ENSG00000271789.1	RP5-1112D6.7	-4.86	1.78e-06	0.0011	-0.24	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111297126~111298510:+
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000224205.1	AP000351.4	4.86	1.78e-06	0.0011	0.28	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23987320~23991421:-
STAD	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-4.86	1.78e-06	0.0011	-0.26	-0.25	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
STAD	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.0011	0.36	0.25	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
STAD	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	4.86	1.78e-06	0.0011	0.34	0.25	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
STAD	cis	rs916888	0.821	rs415430	ENSG00000232300.1	FAM215B	-4.86	1.78e-06	0.0011	-0.33	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46558830~46562795:-
STAD	cis	rs916888	0.779	rs430685	ENSG00000232300.1	FAM215B	-4.86	1.78e-06	0.0011	-0.33	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46558830~46562795:-
STAD	cis	rs4713118	0.824	rs9366702	ENSG00000280107.1	AL022393.9	-4.86	1.78e-06	0.0011	-0.33	-0.25	Parkinson's disease;	chr6:27766691	chr6:28170845~28172521:+
STAD	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-4.86	1.79e-06	0.0011	-0.39	-0.25	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
STAD	cis	rs7487075	0.82	rs10467213	ENSG00000272369.1	RP11-446N19.1	4.86	1.79e-06	0.00111	0.34	0.25	Itch intensity from mosquito bite;	chr12:46326480	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs7958774	ENSG00000272369.1	RP11-446N19.1	4.86	1.79e-06	0.00111	0.34	0.25	Itch intensity from mosquito bite;	chr12:46330885	chr12:46537502~46652550:+
STAD	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	4.86	1.79e-06	0.00111	0.38	0.25	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
STAD	cis	rs2337406	0.866	rs74092512	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106779306	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.789	rs74092514	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106779385	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74092520	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106779632	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs4583128	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106780669	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.929	rs59263250	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781183	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs58083017	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781256	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.789	rs60390024	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781327	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74092532	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781363	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74092534	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781364	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74092535	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781722	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74092537	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781883	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.81	rs74092538	ENSG00000211972.2	IGHV3-66	4.86	1.79e-06	0.00111	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781942	chr14:106675017~106675544:-
STAD	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	4.86	1.79e-06	0.00111	0.31	0.25	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
STAD	cis	rs11098499	0.954	rs4309825	ENSG00000260091.1	RP11-33B1.4	-4.86	1.79e-06	0.00111	-0.25	-0.25	Corneal astigmatism;	chr4:119393726	chr4:119409333~119410233:+
STAD	cis	rs13113518	0.513	rs13132085	ENSG00000272969.1	RP11-528I4.2	-4.86	1.8e-06	0.00111	-0.33	-0.25	Height;	chr4:55593918	chr4:55547112~55547889:+
STAD	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	4.86	1.8e-06	0.00111	0.29	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
STAD	cis	rs8141529	0.732	rs5762784	ENSG00000272858.1	CTA-292E10.8	-4.86	1.8e-06	0.00111	-0.28	-0.25	Lymphocyte counts;	chr22:28775310	chr22:28814914~28815662:+
STAD	cis	rs11676348	0.846	rs11677534	ENSG00000237281.1	CATIP-AS2	4.86	1.8e-06	0.00111	0.25	0.25	Ulcerative colitis;	chr2:218142337	chr2:218326889~218357966:-
STAD	cis	rs1318937	1	rs1318937	ENSG00000224660.1	SH3BP5-AS1	-4.86	1.8e-06	0.00111	-0.24	-0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253857	chr3:15254184~15264493:+
STAD	cis	rs9807989	0.571	rs10208293	ENSG00000234389.1	AC007278.3	4.86	1.8e-06	0.00111	0.29	0.25	Asthma;	chr2:102349850	chr2:102438713~102440475:+
STAD	cis	rs9532580	0.62	rs2701859	ENSG00000229456.1	RLIMP1	4.86	1.8e-06	0.00111	0.23	0.25	Mean corpuscular hemoglobin;	chr13:40567095	chr13:40618738~40621348:+
STAD	cis	rs9532580	0.619	rs2755211	ENSG00000229456.1	RLIMP1	4.86	1.8e-06	0.00111	0.23	0.25	Mean corpuscular hemoglobin;	chr13:40568086	chr13:40618738~40621348:+
STAD	cis	rs747650	0.892	rs7937101	ENSG00000271350.1	CTD-2384B9.1	-4.86	1.8e-06	0.00111	-0.31	-0.25	Acne (severe);	chr11:47204937	chr11:47041027~47041945:-
STAD	cis	rs13113518	1	rs13146987	ENSG00000223305.1	RN7SKP30	4.86	1.8e-06	0.00111	0.28	0.25	Height;	chr4:55491628	chr4:55540502~55540835:-
STAD	cis	rs7487075	0.859	rs7961994	ENSG00000272369.1	RP11-446N19.1	4.86	1.8e-06	0.00111	0.33	0.25	Itch intensity from mosquito bite;	chr12:46361329	chr12:46537502~46652550:+
STAD	cis	rs13113518	0.966	rs12506788	ENSG00000223305.1	RN7SKP30	4.86	1.8e-06	0.00111	0.28	0.25	Height;	chr4:55477426	chr4:55540502~55540835:-
STAD	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-4.86	1.8e-06	0.00111	-0.39	-0.25	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
STAD	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-4.86	1.8e-06	0.00111	-0.32	-0.25	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
STAD	cis	rs1426063	0.748	rs10005117	ENSG00000260265.1	RP11-44F21.5	4.86	1.8e-06	0.00111	0.35	0.25	QT interval;	chr4:75108281	chr4:75081702~75084717:-
STAD	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	4.86	1.8e-06	0.00111	0.31	0.25	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
STAD	cis	rs6832769	0.922	rs819271	ENSG00000272969.1	RP11-528I4.2	4.86	1.81e-06	0.00111	0.32	0.25	Personality dimensions;	chr4:55372680	chr4:55547112~55547889:+
STAD	cis	rs748404	0.626	rs62021176	ENSG00000249839.1	AC011330.5	-4.86	1.81e-06	0.00111	-0.43	-0.25	Lung cancer;	chr15:43388014	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs35158584	ENSG00000249839.1	AC011330.5	-4.86	1.81e-06	0.00111	-0.43	-0.25	Lung cancer;	chr15:43392876	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs16957680	ENSG00000249839.1	AC011330.5	-4.86	1.81e-06	0.00111	-0.43	-0.25	Lung cancer;	chr15:43396207	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs7180812	ENSG00000249839.1	AC011330.5	-4.86	1.81e-06	0.00111	-0.43	-0.25	Lung cancer;	chr15:43403033	chr15:43663654~43684339:-
STAD	cis	rs1263173	0.696	rs1263172	ENSG00000280143.1	AP000892.6	4.86	1.81e-06	0.00111	0.2	0.25	HDL cholesterol;	chr11:116810202	chr11:117204967~117210292:+
STAD	cis	rs4950322	0.542	rs72692942	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147318467	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs113498894	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147318880	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs4950399	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147319302	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs4950403	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147319723	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.517	rs116479391	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147320940	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692963	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147331090	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.518	rs72692965	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147332085	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.518	rs72692968	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147332884	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.518	rs72692970	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147332887	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692971	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147333088	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692973	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147333281	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692975	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147333506	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs4950409	ENSG00000278811.3	LINC00624	4.86	1.81e-06	0.00111	0.27	0.25	Protein quantitative trait loci;	chr1:147335879	chr1:147258885~147517875:-
STAD	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-4.86	1.81e-06	0.00112	-0.28	-0.25	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
STAD	cis	rs891378	0.785	rs6700846	ENSG00000274245.1	RP11-357P18.2	-4.86	1.81e-06	0.00112	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228799	chr1:207372559~207373252:+
STAD	cis	rs4243830	0.85	rs4908558	ENSG00000229519.2	RP11-58A11.2	4.86	1.81e-06	0.00112	0.28	0.25	Body mass index;	chr1:6524041	chr1:6547905~6548619:+
STAD	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	4.86	1.81e-06	0.00112	0.34	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
STAD	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-4.86	1.81e-06	0.00112	-0.26	-0.25	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-4.86	1.81e-06	0.00112	-0.26	-0.25	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-4.86	1.81e-06	0.00112	-0.26	-0.25	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-4.86	1.81e-06	0.00112	-0.26	-0.25	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-4.86	1.81e-06	0.00112	-0.26	-0.25	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-4.86	1.81e-06	0.00112	-0.26	-0.25	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-4.86	1.81e-06	0.00112	-0.26	-0.25	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
STAD	cis	rs9910055	0.55	rs113844752	ENSG00000260793.2	RP5-882C2.2	-4.86	1.81e-06	0.00112	-0.28	-0.25	Total body bone mineral density;	chr17:44220263	chr17:44221401~44223710:+
STAD	cis	rs9910055	0.593	rs58392387	ENSG00000260793.2	RP5-882C2.2	-4.86	1.81e-06	0.00112	-0.28	-0.25	Total body bone mineral density;	chr17:44220521	chr17:44221401~44223710:+
STAD	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	4.86	1.82e-06	0.00112	0.32	0.25	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
STAD	cis	rs10510102	0.872	rs11200267	ENSG00000226864.1	ATE1-AS1	4.86	1.82e-06	0.00112	0.4	0.25	Breast cancer;	chr10:121929851	chr10:121928312~121951965:+
STAD	cis	rs3770081	1	rs60981340	ENSG00000273080.1	RP11-301O19.1	-4.86	1.82e-06	0.00112	-0.51	-0.25	Facial emotion recognition (sad faces);	chr2:85949923	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs735737	ENSG00000273080.1	RP11-301O19.1	-4.86	1.82e-06	0.00112	-0.51	-0.25	Facial emotion recognition (sad faces);	chr2:85949978	chr2:86195590~86196049:+
STAD	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-4.86	1.82e-06	0.00112	-0.24	-0.25	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
STAD	cis	rs1799949	1	rs2271573	ENSG00000279602.1	CTD-3014M21.1	4.86	1.82e-06	0.00112	0.32	0.25	Menopause (age at onset);	chr17:43175604	chr17:43360041~43361361:-
STAD	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-4.86	1.82e-06	0.00112	-0.33	-0.25	AIDS;	chr2:105311539	chr2:105324210~105330529:+
STAD	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-4.86	1.82e-06	0.00112	-0.33	-0.25	AIDS;	chr2:105321650	chr2:105324210~105330529:+
STAD	cis	rs4950322	1	rs4950322	ENSG00000278811.3	LINC00624	-4.86	1.82e-06	0.00112	-0.28	-0.25	Protein quantitative trait loci;	chr1:147383114	chr1:147258885~147517875:-
STAD	cis	rs7932354	0.583	rs10769210	ENSG00000271350.1	CTD-2384B9.1	-4.86	1.82e-06	0.00112	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46850676	chr11:47041027~47041945:-
STAD	cis	rs6832769	0.961	rs28445925	ENSG00000272969.1	RP11-528I4.2	-4.85	1.83e-06	0.00113	-0.32	-0.25	Personality dimensions;	chr4:55569682	chr4:55547112~55547889:+
STAD	cis	rs875971	0.545	rs12670811	ENSG00000236529.1	RP13-254B10.1	4.85	1.83e-06	0.00113	0.3	0.25	Aortic root size;	chr7:66358032	chr7:65840212~65840596:+
STAD	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	4.85	1.83e-06	0.00113	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
STAD	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	4.85	1.83e-06	0.00113	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
STAD	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-4.85	1.83e-06	0.00113	-0.28	-0.25	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
STAD	cis	rs10741780	0.777	rs7934959	ENSG00000254544.1	PCNAP4	-4.85	1.83e-06	0.00113	-0.33	-0.25	HIV-1 susceptibility;	chr11:19593734	chr11:19274540~19275269:-
STAD	cis	rs75426604	0.527	rs11156882	ENSG00000241052.1	RP11-173D9.1	-4.85	1.83e-06	0.00113	-0.29	-0.25	Eotaxin levels;	chr14:35362964	chr14:35144021~35144480:-
STAD	cis	rs1048990	0.598	rs11156883	ENSG00000241052.1	RP11-173D9.1	-4.85	1.83e-06	0.00113	-0.29	-0.25	Allergic disease (asthma, hay fever or eczema);	chr14:35363000	chr14:35144021~35144480:-
STAD	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	4.85	1.83e-06	0.00113	0.27	0.25	Depression;	chr6:28364057	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	4.85	1.83e-06	0.00113	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
STAD	cis	rs4713118	0.628	rs9295740	ENSG00000220721.1	OR1F12	4.85	1.83e-06	0.00113	0.3	0.25	Parkinson's disease;	chr6:27721723	chr6:28073316~28074233:+
STAD	cis	rs6714710	0.603	rs13008968	ENSG00000235833.1	AC159540.14	-4.85	1.84e-06	0.00113	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97819519	chr2:97523949~97524976:-
STAD	cis	rs516805	0.564	rs2679658	ENSG00000279453.1	RP3-425C14.4	-4.85	1.84e-06	0.00113	-0.35	-0.25	Lymphocyte counts;	chr6:122109293	chr6:122436789~122439223:-
STAD	cis	rs507080	0.697	rs653008	ENSG00000278376.1	RP11-158I9.8	-4.85	1.84e-06	0.00113	-0.26	-0.25	Serum metabolite levels;	chr11:118649775	chr11:118791254~118793137:+
STAD	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	4.85	1.84e-06	0.00113	0.31	0.25	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
STAD	cis	rs1150668	0.796	rs1124132	ENSG00000220721.1	OR1F12	4.85	1.84e-06	0.00113	0.25	0.25	Pubertal anthropometrics;	chr6:28412544	chr6:28073316~28074233:+
STAD	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-4.85	1.84e-06	0.00113	-0.32	-0.25	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
STAD	cis	rs7191700	0.578	rs243327	ENSG00000262703.1	RP11-485G7.6	-4.85	1.84e-06	0.00113	-0.24	-0.25	Multiple sclerosis;	chr16:11259447	chr16:11348143~11349321:-
STAD	cis	rs875971	0.862	rs7786892	ENSG00000236529.1	RP13-254B10.1	-4.85	1.84e-06	0.00113	-0.26	-0.25	Aortic root size;	chr7:66163889	chr7:65840212~65840596:+
STAD	cis	rs13113518	1	rs13133579	ENSG00000223305.1	RN7SKP30	4.85	1.84e-06	0.00113	0.28	0.25	Height;	chr4:55459921	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.902	rs11133386	ENSG00000223305.1	RN7SKP30	4.85	1.84e-06	0.00113	0.28	0.25	Height;	chr4:55461320	chr4:55540502~55540835:-
STAD	cis	rs875971	0.502	rs6460311	ENSG00000236529.1	RP13-254B10.1	-4.85	1.84e-06	0.00113	-0.29	-0.25	Aortic root size;	chr7:66646886	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs1695820	ENSG00000236529.1	RP13-254B10.1	4.85	1.84e-06	0.00113	0.26	0.25	Aortic root size;	chr7:66379576	chr7:65840212~65840596:+
STAD	cis	rs875971	0.83	rs778715	ENSG00000236529.1	RP13-254B10.1	4.85	1.84e-06	0.00113	0.26	0.25	Aortic root size;	chr7:66384222	chr7:65840212~65840596:+
STAD	cis	rs875971	0.83	rs809025	ENSG00000236529.1	RP13-254B10.1	4.85	1.84e-06	0.00113	0.26	0.25	Aortic root size;	chr7:66384832	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs778702	ENSG00000236529.1	RP13-254B10.1	4.85	1.84e-06	0.00113	0.26	0.25	Aortic root size;	chr7:66399848	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs1643375	ENSG00000236529.1	RP13-254B10.1	4.85	1.84e-06	0.00113	0.26	0.25	Aortic root size;	chr7:66407690	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6962717	ENSG00000236529.1	RP13-254B10.1	4.85	1.84e-06	0.00113	0.26	0.25	Aortic root size;	chr7:66418748	chr7:65840212~65840596:+
STAD	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-4.85	1.84e-06	0.00113	-0.42	-0.25	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
STAD	cis	rs747650	0.961	rs7945315	ENSG00000271350.1	CTD-2384B9.1	-4.85	1.84e-06	0.00113	-0.3	-0.25	Acne (severe);	chr11:47089101	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.528	rs4752957	ENSG00000271350.1	CTD-2384B9.1	-4.85	1.84e-06	0.00113	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47104081	chr11:47041027~47041945:-
STAD	cis	rs1799949	0.965	rs2236762	ENSG00000279602.1	CTD-3014M21.1	4.85	1.84e-06	0.00113	0.31	0.25	Menopause (age at onset);	chr17:43074658	chr17:43360041~43361361:-
STAD	cis	rs12682352	0.715	rs332039	ENSG00000253981.4	ALG1L13P	4.85	1.84e-06	0.00113	0.3	0.25	Neuroticism;	chr8:8866141	chr8:8236003~8244667:-
STAD	cis	rs4950322	0.57	rs4950400	ENSG00000278811.3	LINC00624	-4.85	1.85e-06	0.00114	-0.27	-0.25	Protein quantitative trait loci;	chr1:147319383	chr1:147258885~147517875:-
STAD	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-4.85	1.85e-06	0.00114	-0.37	-0.25	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
STAD	cis	rs7429990	0.864	rs3915654	ENSG00000224895.1	VPS26BP1	4.85	1.85e-06	0.00114	0.24	0.25	Educational attainment (years of education);	chr3:47827132	chr3:47960327~47961081:-
STAD	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-4.85	1.85e-06	0.00114	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
STAD	cis	rs7004769	0.613	rs603441	ENSG00000233609.3	RP11-62H7.2	-4.85	1.85e-06	0.00114	-0.37	-0.25	Fibrinogen levels;	chr8:9310287	chr8:8961200~8979025:+
STAD	cis	rs7829975	0.572	rs7005000	ENSG00000254340.1	RP11-10A14.3	-4.85	1.85e-06	0.00114	-0.31	-0.25	Mood instability;	chr8:8939092	chr8:9141424~9145435:+
STAD	cis	rs10510102	0.872	rs12240306	ENSG00000226864.1	ATE1-AS1	4.85	1.85e-06	0.00114	0.4	0.25	Breast cancer;	chr10:121963391	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12240308	ENSG00000226864.1	ATE1-AS1	4.85	1.85e-06	0.00114	0.4	0.25	Breast cancer;	chr10:121963407	chr10:121928312~121951965:+
STAD	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-4.85	1.85e-06	0.00114	-0.39	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
STAD	cis	rs875971	1	rs1544549	ENSG00000236529.1	RP13-254B10.1	-4.85	1.85e-06	0.00114	-0.26	-0.25	Aortic root size;	chr7:66625676	chr7:65840212~65840596:+
STAD	cis	rs9467773	0.62	rs2504565	ENSG00000243307.2	POM121L6P	4.85	1.85e-06	0.00114	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26896952~26898777:+
STAD	cis	rs6496667	0.586	rs7162687	ENSG00000259262.1	NDUFA3P4	-4.85	1.85e-06	0.00114	-0.3	-0.25	Rheumatoid arthritis;	chr15:90346091	chr15:90385814~90386063:+
STAD	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	4.85	1.85e-06	0.00114	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	4.85	1.85e-06	0.00114	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
STAD	cis	rs3733585	0.605	rs7656624	ENSG00000250613.1	RP11-136I13.1	4.85	1.85e-06	0.00114	0.25	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10119473	chr4:10410996~10411644:+
STAD	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	4.85	1.85e-06	0.00114	0.31	0.25	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
STAD	cis	rs4243830	0.85	rs12030607	ENSG00000229519.2	RP11-58A11.2	-4.85	1.85e-06	0.00114	-0.27	-0.25	Body mass index;	chr1:6540947	chr1:6547905~6548619:+
STAD	cis	rs1799949	1	rs8074136	ENSG00000279602.1	CTD-3014M21.1	4.85	1.85e-06	0.00114	0.31	0.25	Menopause (age at onset);	chr17:43190296	chr17:43360041~43361361:-
STAD	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	4.85	1.85e-06	0.00114	0.26	0.25	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
STAD	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-4.85	1.85e-06	0.00114	-0.29	-0.25	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-4.85	1.85e-06	0.00114	-0.29	-0.25	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
STAD	cis	rs35955747	0.633	rs2006771	ENSG00000236132.1	CTA-440B3.1	4.85	1.85e-06	0.00114	0.27	0.25	Neutrophil count;Sum basophil neutrophil counts;	chr22:31602626	chr22:31816379~31817491:-
STAD	cis	rs4388249	0.696	rs31600	ENSG00000271849.1	CTC-332L22.1	4.85	1.85e-06	0.00114	0.38	0.25	Schizophrenia;	chr5:109670675	chr5:109687802~109688329:-
STAD	cis	rs516805	0.634	rs2816142	ENSG00000279453.1	RP3-425C14.4	4.85	1.85e-06	0.00114	0.39	0.25	Lymphocyte counts;	chr6:122177653	chr6:122436789~122439223:-
STAD	cis	rs858239	0.669	rs1618339	ENSG00000230042.1	AK3P3	-4.85	1.85e-06	0.00114	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23129178~23129841:+
STAD	cis	rs721917	0.525	rs2250652	ENSG00000244733.5	RP11-506M13.3	-4.85	1.86e-06	0.00114	-0.31	-0.25	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79660891~79677996:+
STAD	cis	rs3758911	0.861	rs7131522	ENSG00000261098.1	RP11-819C21.1	-4.85	1.86e-06	0.00114	-0.24	-0.25	Coronary artery disease;	chr11:107293773	chr11:107312132~107316271:-
STAD	cis	rs7487075	0.722	rs5016479	ENSG00000272369.1	RP11-446N19.1	4.85	1.86e-06	0.00114	0.34	0.25	Itch intensity from mosquito bite;	chr12:46319001	chr12:46537502~46652550:+
STAD	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-4.85	1.86e-06	0.00114	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
STAD	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-4.85	1.86e-06	0.00114	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
STAD	cis	rs1799949	1	rs11649954	ENSG00000279602.1	CTD-3014M21.1	4.85	1.86e-06	0.00114	0.32	0.25	Menopause (age at onset);	chr17:43342667	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs1824889	ENSG00000279602.1	CTD-3014M21.1	4.85	1.86e-06	0.00114	0.32	0.25	Menopause (age at onset);	chr17:43344508	chr17:43360041~43361361:-
STAD	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-4.85	1.86e-06	0.00114	-0.4	-0.25	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-4.85	1.86e-06	0.00114	-0.4	-0.25	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-4.85	1.86e-06	0.00114	-0.4	-0.25	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
STAD	cis	rs10510102	0.935	rs12243529	ENSG00000226864.1	ATE1-AS1	4.85	1.86e-06	0.00114	0.4	0.25	Breast cancer;	chr10:121880321	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12250677	ENSG00000226864.1	ATE1-AS1	4.85	1.86e-06	0.00114	0.4	0.25	Breast cancer;	chr10:121880575	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12243874	ENSG00000226864.1	ATE1-AS1	4.85	1.86e-06	0.00114	0.4	0.25	Breast cancer;	chr10:121880788	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs7921873	ENSG00000226864.1	ATE1-AS1	4.85	1.86e-06	0.00114	0.4	0.25	Breast cancer;	chr10:121881736	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12258426	ENSG00000226864.1	ATE1-AS1	4.85	1.86e-06	0.00114	0.4	0.25	Breast cancer;	chr10:121882189	chr10:121928312~121951965:+
STAD	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	4.85	1.86e-06	0.00114	0.34	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
STAD	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-4.85	1.86e-06	0.00114	-0.28	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
STAD	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	4.85	1.86e-06	0.00114	0.31	0.25	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
STAD	cis	rs875971	1	rs2420820	ENSG00000236529.1	RP13-254B10.1	-4.85	1.87e-06	0.00115	-0.26	-0.25	Aortic root size;	chr7:66626920	chr7:65840212~65840596:+
STAD	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	4.85	1.87e-06	0.00115	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
STAD	cis	rs1799949	0.896	rs8176086	ENSG00000236383.6	LINC00854	-4.85	1.87e-06	0.00115	-0.2	-0.25	Menopause (age at onset);	chr17:43122761	chr17:43216941~43305976:-
STAD	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-4.85	1.87e-06	0.00115	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
STAD	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-4.85	1.87e-06	0.00115	-0.29	-0.25	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
STAD	cis	rs7665090	0.846	rs4496586	ENSG00000230069.3	LRRC37A15P	-4.85	1.87e-06	0.00115	-0.28	-0.25	Primary biliary cholangitis;	chr4:102636154	chr4:102727274~102730721:-
STAD	cis	rs10466239	0.73	rs2243492	ENSG00000230555.2	RP11-517P14.2	4.85	1.87e-06	0.00115	0.33	0.25	Telomere length;	chr10:43353910	chr10:43420738~43422100:+
STAD	cis	rs748404	0.697	rs546722	ENSG00000275601.1	AC011330.13	-4.85	1.87e-06	0.00115	-0.27	-0.25	Lung cancer;	chr15:43288621	chr15:43642389~43643023:-
STAD	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-4.85	1.87e-06	0.00115	-0.29	-0.25	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
STAD	cis	rs2337406	0.929	rs12050233	ENSG00000211972.2	IGHV3-66	4.85	1.87e-06	0.00115	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781123	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.852	rs12050466	ENSG00000211972.2	IGHV3-66	4.85	1.87e-06	0.00115	0.26	0.25	Alzheimer's disease (late onset);	chr14:106781131	chr14:106675017~106675544:-
STAD	cis	rs1799949	1	rs8176269	ENSG00000279602.1	CTD-3014M21.1	4.85	1.88e-06	0.00115	0.32	0.25	Menopause (age at onset);	chr17:43061609	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs8176265	ENSG00000279602.1	CTD-3014M21.1	4.85	1.88e-06	0.00115	0.32	0.25	Menopause (age at onset);	chr17:43061979	chr17:43360041~43361361:-
STAD	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	4.85	1.88e-06	0.00115	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
STAD	cis	rs858239	0.6	rs61292332	ENSG00000226816.2	AC005082.12	4.85	1.88e-06	0.00115	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23206013~23208045:+
STAD	cis	rs9860428	0.967	rs9820264	ENSG00000240057.4	RP11-572M11.4	-4.85	1.88e-06	0.00115	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112869728	chr3:113019532~113183301:+
STAD	cis	rs1150668	0.699	rs2394049	ENSG00000220721.1	OR1F12	4.85	1.88e-06	0.00115	0.24	0.25	Pubertal anthropometrics;	chr6:28271903	chr6:28073316~28074233:+
STAD	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	4.85	1.88e-06	0.00115	0.25	0.25	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
STAD	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-4.85	1.88e-06	0.00115	-0.34	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
STAD	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-4.85	1.88e-06	0.00115	-0.34	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
STAD	cis	rs2337406	0.929	rs12050200	ENSG00000211972.2	IGHV3-66	4.85	1.88e-06	0.00115	0.26	0.25	Alzheimer's disease (late onset);	chr14:106780983	chr14:106675017~106675544:-
STAD	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-4.85	1.88e-06	0.00115	-0.32	-0.25	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
STAD	cis	rs13113518	0.812	rs13140173	ENSG00000223305.1	RN7SKP30	4.85	1.88e-06	0.00115	0.28	0.25	Height;	chr4:55527164	chr4:55540502~55540835:-
STAD	cis	rs875971	0.545	rs4718348	ENSG00000236529.1	RP13-254B10.1	4.85	1.88e-06	0.00115	0.3	0.25	Aortic root size;	chr7:66441589	chr7:65840212~65840596:+
STAD	cis	rs6095360	0.727	rs35393280	ENSG00000222365.1	SNORD12B	-4.85	1.88e-06	0.00115	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:48927097	chr20:49280319~49280409:+
STAD	cis	rs7927771	0.524	rs7129797	ENSG00000280615.1	Y_RNA	4.85	1.88e-06	0.00115	0.26	0.25	Subjective well-being;	chr11:47645615	chr11:47614898~47614994:-
STAD	cis	rs13113518	0.812	rs4864996	ENSG00000223305.1	RN7SKP30	4.85	1.88e-06	0.00115	0.28	0.25	Height;	chr4:55452921	chr4:55540502~55540835:-
STAD	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	4.85	1.88e-06	0.00116	0.25	0.25	Height;	chr5:36948260	chr5:36666214~36725195:-
STAD	cis	rs7176527	0.8	rs56747535	ENSG00000188388.10	GOLGA6L3	4.85	1.89e-06	0.00116	0.35	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85240472~85247170:+
STAD	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	4.85	1.89e-06	0.00116	0.27	0.25	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
STAD	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-4.85	1.89e-06	0.00116	-0.26	-0.25	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
STAD	cis	rs2337406	1	rs4774173	ENSG00000211972.2	IGHV3-66	4.85	1.89e-06	0.00116	0.27	0.25	Alzheimer's disease (late onset);	chr14:106682029	chr14:106675017~106675544:-
STAD	cis	rs916888	0.773	rs199448	ENSG00000232300.1	FAM215B	4.85	1.89e-06	0.00116	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46558830~46562795:-
STAD	cis	rs13392177	0.647	rs6718220	ENSG00000237281.1	CATIP-AS2	4.85	1.89e-06	0.00116	0.26	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218326889~218357966:-
STAD	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-4.85	1.89e-06	0.00116	-0.35	-0.25	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-4.85	1.89e-06	0.00116	-0.35	-0.25	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	4.85	1.89e-06	0.00116	0.3	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
STAD	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-4.85	1.89e-06	0.00116	-0.31	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
STAD	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-4.85	1.89e-06	0.00116	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
STAD	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-4.85	1.89e-06	0.00116	-0.33	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
STAD	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	4.85	1.9e-06	0.00116	0.32	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
STAD	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-4.85	1.9e-06	0.00116	-0.24	-0.25	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
STAD	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-4.85	1.9e-06	0.00116	-0.32	-0.25	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
STAD	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	4.85	1.9e-06	0.00116	0.3	0.25	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
STAD	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-4.85	1.9e-06	0.00116	-0.31	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
STAD	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	4.85	1.9e-06	0.00116	0.48	0.25	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
STAD	cis	rs7829975	0.627	rs2979172	ENSG00000173295.6	FAM86B3P	4.85	1.9e-06	0.00116	0.29	0.25	Mood instability;	chr8:8452998	chr8:8228595~8244865:+
STAD	cis	rs721917	0.506	rs2819097	ENSG00000244733.5	RP11-506M13.3	-4.85	1.9e-06	0.00116	-0.31	-0.25	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79660891~79677996:+
STAD	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	4.85	1.9e-06	0.00117	0.27	0.25	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
STAD	cis	rs4243830	0.85	rs3986417	ENSG00000229519.2	RP11-58A11.2	4.85	1.9e-06	0.00117	0.29	0.25	Body mass index;	chr1:6561951	chr1:6547905~6548619:+
STAD	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-4.85	1.9e-06	0.00117	-0.29	-0.25	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
STAD	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-4.85	1.9e-06	0.00117	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-4.85	1.9e-06	0.00117	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-4.85	1.9e-06	0.00117	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-4.85	1.9e-06	0.00117	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
STAD	cis	rs4713118	0.955	rs9393847	ENSG00000280107.1	AL022393.9	-4.85	1.91e-06	0.00117	-0.34	-0.25	Parkinson's disease;	chr6:27720194	chr6:28170845~28172521:+
STAD	cis	rs3806843	0.576	rs265316	ENSG00000202111.1	VTRNA1-2	-4.85	1.91e-06	0.00117	-0.25	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140911258	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs155358	ENSG00000202111.1	VTRNA1-2	-4.85	1.91e-06	0.00117	-0.25	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140917447	chr5:140718925~140719013:+
STAD	cis	rs10510102	0.935	rs74362676	ENSG00000226864.1	ATE1-AS1	4.85	1.91e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121898216	chr10:121928312~121951965:+
STAD	cis	rs7665090	0.967	rs6812747	ENSG00000248971.2	KRT8P46	-4.85	1.91e-06	0.00117	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634260	chr4:102728746~102730171:-
STAD	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-4.85	1.91e-06	0.00117	-0.32	-0.25	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
STAD	cis	rs7829975	0.688	rs13270194	ENSG00000254340.1	RP11-10A14.3	4.85	1.91e-06	0.00117	0.3	0.25	Mood instability;	chr8:8520592	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.556	rs8010005	ENSG00000211973.2	IGHV1-69	4.85	1.91e-06	0.00117	0.21	0.25	Kawasaki disease;	chr14:106777987	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.556	rs6576224	ENSG00000211973.2	IGHV1-69	4.85	1.91e-06	0.00117	0.21	0.25	Kawasaki disease;	chr14:106777997	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.518	rs8010020	ENSG00000211973.2	IGHV1-69	4.85	1.91e-06	0.00117	0.21	0.25	Kawasaki disease;	chr14:106778016	chr14:106714684~106715181:-
STAD	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-4.85	1.91e-06	0.00117	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
STAD	cis	rs3733585	0.657	rs62286568	ENSG00000250613.1	RP11-136I13.1	4.85	1.91e-06	0.00117	0.25	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10123265	chr4:10410996~10411644:+
STAD	cis	rs2404602	0.692	rs55676827	ENSG00000259422.1	RP11-593F23.1	4.85	1.91e-06	0.00117	0.26	0.25	Blood metabolite levels;	chr15:76669375	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs10444858	ENSG00000259422.1	RP11-593F23.1	4.85	1.91e-06	0.00117	0.26	0.25	Blood metabolite levels;	chr15:76670163	chr15:76174891~76181486:-
STAD	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-4.84	1.92e-06	0.00117	-0.34	-0.25	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
STAD	cis	rs1707322	0.717	rs3014245	ENSG00000281133.1	AL355480.3	4.84	1.92e-06	0.00117	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45580892~45580996:-
STAD	cis	rs7078219	0.524	rs1548963	ENSG00000228778.1	RP11-129J12.1	-4.84	1.92e-06	0.00117	-0.28	-0.25	Dental caries;	chr10:99529946	chr10:99527081~99528261:+
STAD	cis	rs9813712	0.597	rs62281648	ENSG00000253540.4	FAM86HP	-4.84	1.92e-06	0.00117	-0.28	-0.25	Response to amphetamines;	chr3:130244794	chr3:130099092~130111472:-
STAD	cis	rs7429990	0.727	rs319695	ENSG00000224895.1	VPS26BP1	4.84	1.92e-06	0.00117	0.26	0.25	Educational attainment (years of education);	chr3:47842749	chr3:47960327~47961081:-
STAD	cis	rs801193	0.591	rs2707839	ENSG00000236529.1	RP13-254B10.1	4.84	1.92e-06	0.00118	0.26	0.25	Aortic root size;	chr7:66728097	chr7:65840212~65840596:+
STAD	cis	rs4243830	0.85	rs57203351	ENSG00000229519.2	RP11-58A11.2	-4.84	1.92e-06	0.00118	-0.27	-0.25	Body mass index;	chr1:6541259	chr1:6547905~6548619:+
STAD	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-4.84	1.92e-06	0.00118	-0.29	-0.25	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
STAD	cis	rs801193	0.66	rs974239	ENSG00000236529.1	RP13-254B10.1	4.84	1.92e-06	0.00118	0.26	0.25	Aortic root size;	chr7:66748504	chr7:65840212~65840596:+
STAD	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	4.84	1.92e-06	0.00118	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
STAD	cis	rs1799949	0.894	rs71367985	ENSG00000279602.1	CTD-3014M21.1	4.84	1.93e-06	0.00118	0.31	0.25	Menopause (age at onset);	chr17:43222443	chr17:43360041~43361361:-
STAD	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
STAD	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-4.84	1.93e-06	0.00118	-0.32	-0.25	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
STAD	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	4.84	1.93e-06	0.00118	0.41	0.25	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
STAD	cis	rs1488193	0.826	rs1844084	ENSG00000240057.4	RP11-572M11.4	-4.84	1.93e-06	0.00118	-0.37	-0.25	Economic and political preferences;	chr3:112958191	chr3:113019532~113183301:+
STAD	cis	rs7078219	0.743	rs11190133	ENSG00000228778.1	RP11-129J12.1	-4.84	1.93e-06	0.00118	-0.32	-0.25	Dental caries;	chr10:99518968	chr10:99527081~99528261:+
STAD	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
STAD	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	4.84	1.93e-06	0.00118	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
STAD	cis	rs801193	0.636	rs10233806	ENSG00000236529.1	RP13-254B10.1	-4.84	1.93e-06	0.00118	-0.26	-0.25	Aortic root size;	chr7:66653261	chr7:65840212~65840596:+
STAD	cis	rs9467773	0.62	rs2504571	ENSG00000243307.2	POM121L6P	4.84	1.93e-06	0.00118	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26896952~26898777:+
STAD	cis	rs7078219	0.505	rs10883372	ENSG00000257582.4	LINC01475	-4.84	1.93e-06	0.00118	-0.29	-0.25	Dental caries;	chr10:99532726	chr10:99526350~99531177:-
STAD	cis	rs7078219	0.505	rs10883373	ENSG00000257582.4	LINC01475	-4.84	1.93e-06	0.00118	-0.29	-0.25	Dental caries;	chr10:99532727	chr10:99526350~99531177:-
STAD	cis	rs12906542	0.516	rs56357772	ENSG00000259792.1	RP11-114H24.6	-4.84	1.93e-06	0.00118	-0.45	-0.25	Breast cancer;	chr15:78020699	chr15:77993405~77995289:+
STAD	cis	rs12906542	0.516	rs16969422	ENSG00000259792.1	RP11-114H24.6	-4.84	1.93e-06	0.00118	-0.45	-0.25	Breast cancer;	chr15:78033857	chr15:77993405~77995289:+
STAD	cis	rs747650	0.504	rs11602250	ENSG00000271350.1	CTD-2384B9.1	4.84	1.93e-06	0.00118	0.32	0.25	Acne (severe);	chr11:46944179	chr11:47041027~47041945:-
STAD	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	4.84	1.93e-06	0.00118	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	4.84	1.93e-06	0.00118	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	4.84	1.93e-06	0.00118	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
STAD	cis	rs13113518	1	rs10462032	ENSG00000223305.1	RN7SKP30	4.84	1.93e-06	0.00118	0.28	0.25	Height;	chr4:55479069	chr4:55540502~55540835:-
STAD	cis	rs7829975	0.564	rs2921057	ENSG00000254340.1	RP11-10A14.3	4.84	1.93e-06	0.00118	0.3	0.25	Mood instability;	chr8:8461157	chr8:9141424~9145435:+
STAD	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-4.84	1.93e-06	0.00118	-0.29	-0.25	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
STAD	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	4.84	1.93e-06	0.00118	0.3	0.25	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
STAD	cis	rs747650	0.926	rs11039119	ENSG00000271350.1	CTD-2384B9.1	4.84	1.93e-06	0.00118	0.3	0.25	Acne (severe);	chr11:47180373	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.528	rs11039074	ENSG00000271350.1	CTD-2384B9.1	-4.84	1.94e-06	0.00118	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47060181	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.528	rs10769234	ENSG00000271350.1	CTD-2384B9.1	-4.84	1.94e-06	0.00118	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47062510	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.528	rs7931260	ENSG00000271350.1	CTD-2384B9.1	-4.84	1.94e-06	0.00118	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47066752	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.528	rs7108902	ENSG00000271350.1	CTD-2384B9.1	-4.84	1.94e-06	0.00118	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47070020	chr11:47041027~47041945:-
STAD	cis	rs4589258	0.788	rs7930201	ENSG00000280367.1	RP11-121L10.2	4.84	1.94e-06	0.00119	0.25	0.25	Intelligence (multi-trait analysis);	chr11:90732057	chr11:90223153~90226538:+
STAD	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	4.84	1.94e-06	0.00119	0.31	0.25	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
STAD	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	4.84	1.94e-06	0.00119	0.28	0.25	Height;	chr4:55529786	chr4:55540502~55540835:-
STAD	cis	rs1799949	1	rs8176083	ENSG00000279602.1	CTD-3014M21.1	4.84	1.95e-06	0.00119	0.32	0.25	Menopause (age at onset);	chr17:43123134	chr17:43360041~43361361:-
STAD	cis	rs4950322	0.57	rs4950401	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147319571	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs4950402	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147319684	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs4950404	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147319834	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692946	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147319966	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692948	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147320298	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692951	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147320551	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs77118461	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147320718	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs78681047	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147321013	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692953	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147321416	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs80070044	ENSG00000278811.3	LINC00624	4.84	1.95e-06	0.00119	0.27	0.25	Protein quantitative trait loci;	chr1:147330238	chr1:147258885~147517875:-
STAD	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	4.84	1.95e-06	0.00119	0.28	0.25	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
STAD	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	4.84	1.95e-06	0.00119	0.37	0.25	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
STAD	cis	rs1707322	0.686	rs3014235	ENSG00000281133.1	AL355480.3	4.84	1.95e-06	0.00119	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45580892~45580996:-
STAD	cis	rs7615952	0.611	rs9681518	ENSG00000272840.1	RP11-379B18.6	4.84	1.95e-06	0.00119	0.51	0.25	Blood pressure (smoking interaction);	chr3:125896287	chr3:125774714~125797953:+
STAD	cis	rs2404602	0.692	rs8043474	ENSG00000259422.1	RP11-593F23.1	4.84	1.95e-06	0.00119	0.26	0.25	Blood metabolite levels;	chr15:76682382	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs35138393	ENSG00000259422.1	RP11-593F23.1	4.84	1.95e-06	0.00119	0.26	0.25	Blood metabolite levels;	chr15:76685276	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.669	rs12595313	ENSG00000259422.1	RP11-593F23.1	4.84	1.95e-06	0.00119	0.26	0.25	Blood metabolite levels;	chr15:76686029	chr15:76174891~76181486:-
STAD	cis	rs801193	0.636	rs2659895	ENSG00000236529.1	RP13-254B10.1	4.84	1.95e-06	0.00119	0.26	0.25	Aortic root size;	chr7:66731484	chr7:65840212~65840596:+
STAD	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	4.84	1.95e-06	0.00119	0.3	0.25	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
STAD	cis	rs7932354	0.583	rs10769211	ENSG00000271350.1	CTD-2384B9.1	-4.84	1.95e-06	0.00119	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46851322	chr11:47041027~47041945:-
STAD	cis	rs4761702	0.527	rs12824664	ENSG00000257252.4	RP11-486A14.2	-4.84	1.95e-06	0.00119	-0.27	-0.25	Immature fraction of reticulocytes;	chr12:93343125	chr12:93317135~93377736:-
STAD	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	4.84	1.95e-06	0.00119	0.3	0.25	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
STAD	cis	rs875971	0.545	rs73152714	ENSG00000236529.1	RP13-254B10.1	4.84	1.95e-06	0.00119	0.29	0.25	Aortic root size;	chr7:66534641	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs4718364	ENSG00000236529.1	RP13-254B10.1	4.84	1.95e-06	0.00119	0.29	0.25	Aortic root size;	chr7:66536353	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs6961853	ENSG00000236529.1	RP13-254B10.1	4.84	1.95e-06	0.00119	0.29	0.25	Aortic root size;	chr7:66537035	chr7:65840212~65840596:+
STAD	cis	rs875971	0.528	rs801213	ENSG00000236529.1	RP13-254B10.1	-4.84	1.95e-06	0.00119	-0.29	-0.25	Aortic root size;	chr7:66549931	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs801212	ENSG00000236529.1	RP13-254B10.1	-4.84	1.95e-06	0.00119	-0.29	-0.25	Aortic root size;	chr7:66550643	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs801199	ENSG00000236529.1	RP13-254B10.1	-4.84	1.95e-06	0.00119	-0.29	-0.25	Aortic root size;	chr7:66560286	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs1267814	ENSG00000236529.1	RP13-254B10.1	-4.84	1.95e-06	0.00119	-0.29	-0.25	Aortic root size;	chr7:66579422	chr7:65840212~65840596:+
STAD	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	4.84	1.96e-06	0.0012	0.3	0.25	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
STAD	cis	rs9907295	0.892	rs55950249	ENSG00000270894.1	AC015849.13	-4.84	1.96e-06	0.0012	-0.27	-0.25	Fibroblast growth factor basic levels;	chr17:35903948	chr17:35818399~35823713:+
STAD	cis	rs4950322	0.57	rs72692979	ENSG00000278811.3	LINC00624	4.84	1.96e-06	0.0012	0.27	0.25	Protein quantitative trait loci;	chr1:147336094	chr1:147258885~147517875:-
STAD	cis	rs7487075	0.859	rs2307061	ENSG00000272369.1	RP11-446N19.1	4.84	1.96e-06	0.0012	0.33	0.25	Itch intensity from mosquito bite;	chr12:46364711	chr12:46537502~46652550:+
STAD	cis	rs1707322	0.717	rs2253862	ENSG00000281133.1	AL355480.3	4.84	1.96e-06	0.0012	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.717	rs2991988	ENSG00000281133.1	AL355480.3	4.84	1.96e-06	0.0012	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.717	rs2991989	ENSG00000281133.1	AL355480.3	4.84	1.96e-06	0.0012	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45580892~45580996:-
STAD	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-4.84	1.96e-06	0.0012	-0.26	-0.25	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-4.84	1.96e-06	0.0012	-0.26	-0.25	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-4.84	1.96e-06	0.0012	-0.26	-0.25	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-4.84	1.96e-06	0.0012	-0.26	-0.25	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-4.84	1.96e-06	0.0012	-0.26	-0.25	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-4.84	1.96e-06	0.0012	-0.26	-0.25	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
STAD	cis	rs2337406	0.925	rs10131226	ENSG00000274576.2	IGHV2-70	-4.84	1.96e-06	0.0012	-0.31	-0.25	Alzheimer's disease (late onset);	chr14:106665764	chr14:106770577~106771020:-
STAD	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	4.84	1.96e-06	0.0012	0.34	0.25	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
STAD	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-4.84	1.97e-06	0.0012	-0.3	-0.25	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
STAD	cis	rs858239	0.806	rs10268610	ENSG00000226816.2	AC005082.12	4.84	1.97e-06	0.0012	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23206013~23208045:+
STAD	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-4.84	1.97e-06	0.0012	-0.3	-0.25	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
STAD	cis	rs858239	0.899	rs28635122	ENSG00000226816.2	AC005082.12	4.84	1.97e-06	0.0012	0.32	0.25	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23206013~23208045:+
STAD	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	4.84	1.97e-06	0.0012	0.31	0.25	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
STAD	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-4.84	1.97e-06	0.0012	-0.41	-0.25	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
STAD	cis	rs8012947	0.545	rs1190980	ENSG00000279636.2	LINC00216	-4.84	1.97e-06	0.0012	-0.24	-0.25	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58288033~58289158:+
STAD	cis	rs4237845	0.611	rs10877036	ENSG00000273805.1	RP11-620J15.4	4.84	1.97e-06	0.0012	0.29	0.25	Intelligence (multi-trait analysis);	chr12:57927867	chr12:57894232~57896846:+
STAD	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	4.84	1.97e-06	0.0012	0.28	0.25	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
STAD	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	4.84	1.97e-06	0.0012	0.34	0.25	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
STAD	cis	rs1799949	1	rs11657835	ENSG00000236383.6	LINC00854	-4.84	1.97e-06	0.0012	-0.21	-0.25	Menopause (age at onset);	chr17:43139936	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs1135214	ENSG00000236383.6	LINC00854	-4.84	1.97e-06	0.0012	-0.21	-0.25	Menopause (age at onset);	chr17:43140306	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11652332	ENSG00000236383.6	LINC00854	-4.84	1.97e-06	0.0012	-0.21	-0.25	Menopause (age at onset);	chr17:43143472	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs4793212	ENSG00000236383.6	LINC00854	-4.84	1.97e-06	0.0012	-0.21	-0.25	Menopause (age at onset);	chr17:43150733	chr17:43216941~43305976:-
STAD	cis	rs858239	0.965	rs156429	ENSG00000230042.1	AK3P3	-4.84	1.98e-06	0.00121	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23129178~23129841:+
STAD	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	4.84	1.98e-06	0.00121	0.3	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
STAD	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-4.84	1.98e-06	0.00121	-0.38	-0.25	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
STAD	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	4.84	1.98e-06	0.00121	0.36	0.25	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
STAD	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	4.84	1.98e-06	0.00121	0.36	0.25	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
STAD	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	4.84	1.98e-06	0.00121	0.36	0.25	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
STAD	cis	rs7191700	0.511	rs243330	ENSG00000262703.1	RP11-485G7.6	4.84	1.98e-06	0.00121	0.24	0.25	Multiple sclerosis;	chr16:11257134	chr16:11348143~11349321:-
STAD	cis	rs6095360	0.615	rs2869689	ENSG00000222365.1	SNORD12B	-4.84	1.98e-06	0.00121	-0.31	-0.25	Intelligence (multi-trait analysis);	chr20:48898389	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.615	rs6019506	ENSG00000222365.1	SNORD12B	-4.84	1.98e-06	0.00121	-0.31	-0.25	Intelligence (multi-trait analysis);	chr20:48899655	chr20:49280319~49280409:+
STAD	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-4.84	1.98e-06	0.00121	-0.32	-0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
STAD	cis	rs2439831	1	rs2601014	ENSG00000249839.1	AC011330.5	-4.84	1.98e-06	0.00121	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43463815	chr15:43663654~43684339:-
STAD	cis	rs7932354	0.583	rs3829940	ENSG00000271350.1	CTD-2384B9.1	-4.84	1.98e-06	0.00121	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46858422	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.583	rs7943866	ENSG00000271350.1	CTD-2384B9.1	-4.84	1.98e-06	0.00121	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46860403	chr11:47041027~47041945:-
STAD	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	4.84	1.98e-06	0.00121	0.25	0.25	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
STAD	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	4.84	1.98e-06	0.00121	0.33	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
STAD	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-4.84	1.98e-06	0.00121	-0.26	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
STAD	cis	rs1056107	0.931	rs10481637	ENSG00000225513.1	RP11-165N19.2	-4.84	1.98e-06	0.00121	-0.3	-0.25	Colorectal cancer;	chr9:112334457	chr9:112173522~112173971:-
STAD	cis	rs4589258	0.902	rs4753295	ENSG00000280367.1	RP11-121L10.2	4.84	1.98e-06	0.00121	0.27	0.25	Intelligence (multi-trait analysis);	chr11:90735490	chr11:90223153~90226538:+
STAD	cis	rs3758911	0.964	rs10789603	ENSG00000261098.1	RP11-819C21.1	-4.84	1.99e-06	0.00121	-0.23	-0.25	Coronary artery disease;	chr11:107311050	chr11:107312132~107316271:-
STAD	cis	rs1318937	0.915	rs78365740	ENSG00000224660.1	SH3BP5-AS1	4.84	1.99e-06	0.00121	0.28	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15258339	chr3:15254184~15264493:+
STAD	cis	rs7429990	0.932	rs11130155	ENSG00000224895.1	VPS26BP1	4.84	1.99e-06	0.00121	0.25	0.25	Educational attainment (years of education);	chr3:48098938	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.901	rs6442102	ENSG00000224895.1	VPS26BP1	4.84	1.99e-06	0.00121	0.25	0.25	Educational attainment (years of education);	chr3:48111072	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.803	rs11714518	ENSG00000224895.1	VPS26BP1	4.84	1.99e-06	0.00121	0.25	0.25	Educational attainment (years of education);	chr3:48115145	chr3:47960327~47961081:-
STAD	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-4.84	1.99e-06	0.00121	-0.41	-0.25	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
STAD	cis	rs1799949	1	rs1060915	ENSG00000279602.1	CTD-3014M21.1	4.84	1.99e-06	0.00121	0.32	0.25	Menopause (age at onset);	chr17:43082453	chr17:43360041~43361361:-
STAD	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-4.84	1.99e-06	0.00121	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-4.84	1.99e-06	0.00121	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-4.84	1.99e-06	0.00121	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-4.84	1.99e-06	0.00121	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
STAD	cis	rs13113518	0.812	rs2035692	ENSG00000223305.1	RN7SKP30	4.84	1.99e-06	0.00121	0.28	0.25	Height;	chr4:55528801	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs4507426	ENSG00000223305.1	RN7SKP30	4.84	1.99e-06	0.00121	0.28	0.25	Height;	chr4:55529387	chr4:55540502~55540835:-
STAD	cis	rs17401966	0.838	rs35257796	ENSG00000199562.1	RNU6-37P	4.84	1.99e-06	0.00121	0.2	0.25	Hepatocellular carcinoma;	chr1:10207332	chr1:10298966~10299072:+
STAD	cis	rs11098499	0.865	rs4001305	ENSG00000260091.1	RP11-33B1.4	4.84	1.99e-06	0.00121	0.25	0.25	Corneal astigmatism;	chr4:119438081	chr4:119409333~119410233:+
STAD	cis	rs7665090	0.875	rs6813322	ENSG00000230069.3	LRRC37A15P	-4.84	1.99e-06	0.00121	-0.27	-0.25	Primary biliary cholangitis;	chr4:102634462	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs6839064	ENSG00000230069.3	LRRC37A15P	-4.84	1.99e-06	0.00121	-0.27	-0.25	Primary biliary cholangitis;	chr4:102634519	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs2272695	ENSG00000230069.3	LRRC37A15P	-4.84	1.99e-06	0.00121	-0.27	-0.25	Primary biliary cholangitis;	chr4:102634646	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs2272696	ENSG00000230069.3	LRRC37A15P	-4.84	1.99e-06	0.00121	-0.27	-0.25	Primary biliary cholangitis;	chr4:102634664	chr4:102727274~102730721:-
STAD	cis	rs17507216	0.667	rs72753916	ENSG00000259429.4	UBE2Q2P2	-4.84	1.99e-06	0.00121	-0.38	-0.25	Excessive daytime sleepiness;	chr15:82684001	chr15:82355142~82420075:+
STAD	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-4.84	1.99e-06	0.00122	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
STAD	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-4.84	1.99e-06	0.00122	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
STAD	cis	rs4243830	0.571	rs60256927	ENSG00000229519.2	RP11-58A11.2	-4.84	1.99e-06	0.00122	-0.28	-0.25	Body mass index;	chr1:6554687	chr1:6547905~6548619:+
STAD	cis	rs227275	0.525	rs223461	ENSG00000248971.2	KRT8P46	-4.84	2e-06	0.00122	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102728746~102730171:-
STAD	cis	rs737008	0.922	rs1559394	ENSG00000262703.1	RP11-485G7.6	-4.84	2e-06	0.00122	-0.24	-0.25	Obesity-related traits;	chr16:11275348	chr16:11348143~11349321:-
STAD	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	4.84	2e-06	0.00122	0.34	0.25	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
STAD	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	4.84	2e-06	0.00122	0.37	0.25	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
STAD	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-4.84	2e-06	0.00122	-0.24	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
STAD	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-4.84	2e-06	0.00122	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
STAD	cis	rs721917	0.525	rs2246111	ENSG00000244733.5	RP11-506M13.3	-4.84	2e-06	0.00122	-0.31	-0.25	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79660891~79677996:+
STAD	cis	rs728616	0.681	rs12413174	ENSG00000225484.5	NUTM2B-AS1	-4.84	2.01e-06	0.00122	-0.49	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80302648	chr10:79663088~79826594:-
STAD	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	4.83	2.01e-06	0.00122	0.25	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
STAD	cis	rs17401966	0.838	rs4846197	ENSG00000199562.1	RNU6-37P	4.83	2.01e-06	0.00122	0.19	0.25	Hepatocellular carcinoma;	chr1:10222108	chr1:10298966~10299072:+
STAD	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	4.83	2.01e-06	0.00122	0.32	0.25	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
STAD	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	4.83	2.01e-06	0.00122	0.32	0.25	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
STAD	cis	rs35934224	0.783	rs45465601	ENSG00000232926.1	AC000078.5	4.83	2.01e-06	0.00122	0.33	0.25	Glaucoma (primary open-angle);	chr22:19881155	chr22:19887289~19887970:+
STAD	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-4.83	2.01e-06	0.00122	-0.33	-0.25	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
STAD	cis	rs35934224	0.783	rs7288061	ENSG00000232926.1	AC000078.5	4.83	2.01e-06	0.00122	0.38	0.25	Glaucoma (primary open-angle);	chr22:19876716	chr22:19887289~19887970:+
STAD	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-4.83	2.01e-06	0.00123	-0.32	-0.25	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
STAD	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-4.83	2.01e-06	0.00123	-0.32	-0.25	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
STAD	cis	rs875971	0.862	rs10256544	ENSG00000236529.1	RP13-254B10.1	4.83	2.01e-06	0.00123	0.26	0.25	Aortic root size;	chr7:66210141	chr7:65840212~65840596:+
STAD	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-4.83	2.02e-06	0.00123	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
STAD	cis	rs7829975	0.606	rs10112585	ENSG00000254340.1	RP11-10A14.3	-4.83	2.02e-06	0.00123	-0.31	-0.25	Mood instability;	chr8:8937520	chr8:9141424~9145435:+
STAD	cis	rs4950322	0.57	rs72692907	ENSG00000278811.3	LINC00624	4.83	2.02e-06	0.00123	0.27	0.25	Protein quantitative trait loci;	chr1:147301921	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72692914	ENSG00000278811.3	LINC00624	4.83	2.02e-06	0.00123	0.27	0.25	Protein quantitative trait loci;	chr1:147302946	chr1:147258885~147517875:-
STAD	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-4.83	2.02e-06	0.00123	-0.24	-0.25	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
STAD	cis	rs801193	0.613	rs2659900	ENSG00000236529.1	RP13-254B10.1	4.83	2.02e-06	0.00123	0.26	0.25	Aortic root size;	chr7:66719456	chr7:65840212~65840596:+
STAD	cis	rs9813712	0.597	rs11711883	ENSG00000253540.4	FAM86HP	-4.83	2.02e-06	0.00123	-0.27	-0.25	Response to amphetamines;	chr3:130241367	chr3:130099092~130111472:-
STAD	cis	rs9813712	0.574	rs62281647	ENSG00000253540.4	FAM86HP	-4.83	2.02e-06	0.00123	-0.27	-0.25	Response to amphetamines;	chr3:130242670	chr3:130099092~130111472:-
STAD	cis	rs2933343	0.679	rs789221	ENSG00000261159.1	RP11-723O4.9	4.83	2.02e-06	0.00123	0.31	0.25	IgG glycosylation;	chr3:128872782	chr3:128859716~128860526:-
STAD	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-4.83	2.02e-06	0.00123	-0.27	-0.25	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
STAD	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	4.83	2.02e-06	0.00123	0.36	0.25	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
STAD	cis	rs8097348	0.947	rs2111929	ENSG00000266602.1	RP11-476K15.1	-4.83	2.02e-06	0.00123	-0.32	-0.25	Exercise (leisure time);	chr18:1607582	chr18:1509183~1647097:+
STAD	cis	rs2933343	0.621	rs4927921	ENSG00000261159.1	RP11-723O4.9	-4.83	2.02e-06	0.00123	-0.31	-0.25	IgG glycosylation;	chr3:128850025	chr3:128859716~128860526:-
STAD	cis	rs227275	0.554	rs223467	ENSG00000248971.2	KRT8P46	-4.83	2.02e-06	0.00123	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102728746~102730171:-
STAD	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-4.83	2.02e-06	0.00123	-0.23	-0.25	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
STAD	cis	rs747650	0.504	rs7114683	ENSG00000271350.1	CTD-2384B9.1	-4.83	2.02e-06	0.00123	-0.33	-0.25	Acne (severe);	chr11:47055695	chr11:47041027~47041945:-
STAD	cis	rs747650	0.504	rs10838652	ENSG00000271350.1	CTD-2384B9.1	-4.83	2.02e-06	0.00123	-0.33	-0.25	Acne (severe);	chr11:47056286	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.738	rs72918577	ENSG00000260091.1	RP11-33B1.4	4.83	2.03e-06	0.00123	0.25	0.25	Corneal astigmatism;	chr4:119405546	chr4:119409333~119410233:+
STAD	cis	rs801193	0.66	rs2659914	ENSG00000236529.1	RP13-254B10.1	4.83	2.03e-06	0.00123	0.26	0.25	Aortic root size;	chr7:66691927	chr7:65840212~65840596:+
STAD	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	4.83	2.03e-06	0.00123	0.31	0.25	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
STAD	cis	rs10510102	0.935	rs11200203	ENSG00000226864.1	ATE1-AS1	4.83	2.03e-06	0.00123	0.4	0.25	Breast cancer;	chr10:121874014	chr10:121928312~121951965:+
STAD	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-4.83	2.03e-06	0.00123	-0.26	-0.25	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
STAD	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-4.83	2.03e-06	0.00123	-0.29	-0.25	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
STAD	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	4.83	2.03e-06	0.00123	0.33	0.25	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
STAD	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	4.83	2.03e-06	0.00123	0.33	0.25	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
STAD	cis	rs9463078	0.565	rs6922660	ENSG00000219384.1	RP11-491H9.3	-4.83	2.03e-06	0.00123	-0.24	-0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45091937	chr6:45158870~45159511:+
STAD	cis	rs875971	0.862	rs11773628	ENSG00000236529.1	RP13-254B10.1	-4.83	2.03e-06	0.00123	-0.25	-0.25	Aortic root size;	chr7:66517644	chr7:65840212~65840596:+
STAD	cis	rs11676348	0.751	rs6715591	ENSG00000237281.1	CATIP-AS2	4.83	2.03e-06	0.00123	0.26	0.25	Ulcerative colitis;	chr2:218155148	chr2:218326889~218357966:-
STAD	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-4.83	2.03e-06	0.00123	-0.3	-0.25	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
STAD	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-4.83	2.03e-06	0.00123	-0.3	-0.25	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
STAD	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	4.83	2.03e-06	0.00124	0.38	0.25	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	4.83	2.03e-06	0.00124	0.38	0.25	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
STAD	cis	rs891378	1	rs10864181	ENSG00000274245.1	RP11-357P18.2	-4.83	2.03e-06	0.00124	-0.32	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207274706	chr1:207372559~207373252:+
STAD	cis	rs1799949	1	rs8176273	ENSG00000279602.1	CTD-3014M21.1	4.83	2.03e-06	0.00124	0.32	0.25	Menopause (age at onset);	chr17:43059636	chr17:43360041~43361361:-
STAD	cis	rs11638352	1	rs2733221	ENSG00000205771.5	CATSPER2P1	4.83	2.03e-06	0.00124	0.5	0.25	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44097672	chr15:43726918~43747094:-
STAD	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-4.83	2.03e-06	0.00124	-0.3	-0.25	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
STAD	cis	rs4691139	0.557	rs4485779	ENSG00000248632.1	RP11-366M4.11	4.83	2.03e-06	0.00124	0.25	0.25	Ovarian cancer in BRCA1 mutation carriers;	chr4:165002877	chr4:164968587~164970002:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000224205.1	AP000351.4	4.83	2.03e-06	0.00124	0.28	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23987320~23991421:-
STAD	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-4.83	2.03e-06	0.00124	-0.28	-0.25	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
STAD	cis	rs227275	0.554	rs223457	ENSG00000248971.2	KRT8P46	-4.83	2.04e-06	0.00124	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102728746~102730171:-
STAD	cis	rs2384207	0.818	rs7299870	ENSG00000277566.1	RP11-545P7.9	-4.83	2.04e-06	0.00124	-0.34	-0.25	Response to fenofibrate (adiponectin levels);	chr12:113270785	chr12:113249466~113250042:+
STAD	cis	rs3758911	0.828	rs17106875	ENSG00000261098.1	RP11-819C21.1	-4.83	2.05e-06	0.00124	-0.23	-0.25	Coronary artery disease;	chr11:107407957	chr11:107312132~107316271:-
STAD	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-4.83	2.05e-06	0.00124	-0.26	-0.25	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-4.83	2.05e-06	0.00124	-0.26	-0.25	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-4.83	2.05e-06	0.00124	-0.26	-0.25	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
STAD	cis	rs227275	0.556	rs3886723	ENSG00000248971.2	KRT8P46	-4.83	2.05e-06	0.00124	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102728746~102730171:-
STAD	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	4.83	2.05e-06	0.00124	0.27	0.25	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
STAD	cis	rs1707322	0.752	rs7541962	ENSG00000225447.1	RPS15AP10	4.83	2.05e-06	0.00125	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45645816~45646197:-
STAD	cis	rs1799949	1	rs8176202	ENSG00000236383.6	LINC00854	-4.83	2.05e-06	0.00125	-0.21	-0.25	Menopause (age at onset);	chr17:43078211	chr17:43216941~43305976:-
STAD	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-4.83	2.05e-06	0.00125	-0.22	-0.25	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
STAD	cis	rs11169552	0.51	rs4238108	ENSG00000200183.1	RNU6-238P	-4.83	2.05e-06	0.00125	-0.24	-0.25	Colorectal cancer;	chr12:50665908	chr12:50656973~50657078:+
STAD	cis	rs17507216	0.628	rs17158396	ENSG00000259429.4	UBE2Q2P2	-4.83	2.05e-06	0.00125	-0.37	-0.25	Excessive daytime sleepiness;	chr15:82615688	chr15:82355142~82420075:+
STAD	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-4.83	2.05e-06	0.00125	-0.38	-0.25	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
STAD	cis	rs7932354	0.583	rs2306026	ENSG00000271350.1	CTD-2384B9.1	-4.83	2.05e-06	0.00125	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46868162	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.537	rs3816614	ENSG00000271350.1	CTD-2384B9.1	-4.83	2.05e-06	0.00125	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46868614	chr11:47041027~47041945:-
STAD	cis	rs12682352	0.652	rs1567398	ENSG00000173295.6	FAM86B3P	-4.83	2.05e-06	0.00125	-0.28	-0.25	Neuroticism;	chr8:8869294	chr8:8228595~8244865:+
STAD	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.83	2.05e-06	0.00125	0.24	0.25	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.83	2.05e-06	0.00125	0.24	0.25	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
STAD	cis	rs5769707	0.609	rs739247	ENSG00000280224.1	CTA-722E9.1	-4.83	2.05e-06	0.00125	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49500568~49501585:+
STAD	cis	rs13113518	0.812	rs6849474	ENSG00000223305.1	RN7SKP30	4.83	2.06e-06	0.00125	0.28	0.25	Height;	chr4:55452295	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs2412648	ENSG00000223305.1	RN7SKP30	4.83	2.06e-06	0.00125	0.28	0.25	Height;	chr4:55454900	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs12512737	ENSG00000223305.1	RN7SKP30	4.83	2.06e-06	0.00125	0.28	0.25	Height;	chr4:55454938	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs13125984	ENSG00000223305.1	RN7SKP30	4.83	2.06e-06	0.00125	0.28	0.25	Height;	chr4:55455102	chr4:55540502~55540835:-
STAD	cis	rs7665090	1	rs2272697	ENSG00000230069.3	LRRC37A15P	-4.83	2.06e-06	0.00125	-0.27	-0.25	Primary biliary cholangitis;	chr4:102634835	chr4:102727274~102730721:-
STAD	cis	rs9549367	0.713	rs3024743	ENSG00000269125.1	RP11-98F14.11	-4.83	2.06e-06	0.00125	-0.31	-0.25	Platelet distribution width;	chr13:113167116	chr13:113165002~113165183:-
STAD	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-4.83	2.06e-06	0.00125	-0.32	-0.25	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
STAD	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-4.83	2.06e-06	0.00125	-0.34	-0.25	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
STAD	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	4.83	2.06e-06	0.00125	0.34	0.25	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
STAD	cis	rs891378	1	rs971317	ENSG00000274245.1	RP11-357P18.2	-4.83	2.06e-06	0.00125	-0.32	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302695	chr1:207372559~207373252:+
STAD	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-4.83	2.06e-06	0.00125	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-4.83	2.06e-06	0.00125	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-4.83	2.06e-06	0.00125	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	4.83	2.06e-06	0.00125	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	4.83	2.06e-06	0.00125	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	4.83	2.06e-06	0.00125	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	4.83	2.06e-06	0.00125	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
STAD	cis	rs2404602	0.692	rs58973160	ENSG00000259422.1	RP11-593F23.1	4.83	2.06e-06	0.00125	0.27	0.25	Blood metabolite levels;	chr15:76708001	chr15:76174891~76181486:-
STAD	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	4.83	2.06e-06	0.00125	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
STAD	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-4.83	2.06e-06	0.00125	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
STAD	cis	rs7429990	0.965	rs319689	ENSG00000224895.1	VPS26BP1	-4.83	2.06e-06	0.00125	-0.24	-0.25	Educational attainment (years of education);	chr3:47886677	chr3:47960327~47961081:-
STAD	cis	rs35934224	0.783	rs7288170	ENSG00000232926.1	AC000078.5	4.83	2.06e-06	0.00125	0.33	0.25	Glaucoma (primary open-angle);	chr22:19876729	chr22:19887289~19887970:+
STAD	cis	rs1015362	0.869	rs6088411	ENSG00000275784.1	RP5-1125A11.6	4.83	2.06e-06	0.00125	0.26	0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33989480~33991818:-
STAD	cis	rs10510102	0.872	rs10887032	ENSG00000226864.1	ATE1-AS1	-4.83	2.06e-06	0.00125	-0.38	-0.25	Breast cancer;	chr10:121955887	chr10:121928312~121951965:+
STAD	cis	rs2439831	1	rs2601014	ENSG00000275601.1	AC011330.13	-4.83	2.06e-06	0.00125	-0.35	-0.25	Lung cancer in ever smokers;	chr15:43463815	chr15:43642389~43643023:-
STAD	cis	rs11976180	0.569	rs12703565	ENSG00000204959.4	ARHGEF34P	4.83	2.07e-06	0.00125	0.43	0.25	Obesity-related traits;	chr7:144057308	chr7:144272445~144286966:-
STAD	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-4.83	2.07e-06	0.00125	-0.26	-0.25	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
STAD	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	4.83	2.07e-06	0.00125	0.33	0.25	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
STAD	cis	rs13113518	0.513	rs13132085	ENSG00000223305.1	RN7SKP30	-4.83	2.07e-06	0.00125	-0.29	-0.25	Height;	chr4:55593918	chr4:55540502~55540835:-
STAD	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	4.83	2.07e-06	0.00125	0.38	0.25	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
STAD	cis	rs2384207	0.818	rs2288365	ENSG00000277566.1	RP11-545P7.9	-4.83	2.07e-06	0.00126	-0.36	-0.25	Response to fenofibrate (adiponectin levels);	chr12:113297937	chr12:113249466~113250042:+
STAD	cis	rs2384207	0.818	rs12405	ENSG00000277566.1	RP11-545P7.9	-4.83	2.07e-06	0.00126	-0.36	-0.25	Response to fenofibrate (adiponectin levels);	chr12:113298316	chr12:113249466~113250042:+
STAD	cis	rs13113518	1	rs13122619	ENSG00000223305.1	RN7SKP30	4.83	2.07e-06	0.00126	0.28	0.25	Height;	chr4:55479339	chr4:55540502~55540835:-
STAD	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-4.83	2.07e-06	0.00126	-0.27	-0.25	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
STAD	cis	rs7829975	0.782	rs6990746	ENSG00000253981.4	ALG1L13P	-4.83	2.08e-06	0.00126	-0.31	-0.25	Mood instability;	chr8:8690301	chr8:8236003~8244667:-
STAD	cis	rs7615952	0.932	rs9841157	ENSG00000272840.1	RP11-379B18.6	4.83	2.08e-06	0.00126	0.47	0.25	Blood pressure (smoking interaction);	chr3:125916812	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.551	rs12695470	ENSG00000272840.1	RP11-379B18.6	4.83	2.08e-06	0.00126	0.47	0.25	Blood pressure (smoking interaction);	chr3:125916875	chr3:125774714~125797953:+
STAD	cis	rs13113518	0.902	rs12642716	ENSG00000223305.1	RN7SKP30	4.83	2.08e-06	0.00126	0.28	0.25	Height;	chr4:55479996	chr4:55540502~55540835:-
STAD	cis	rs8040855	0.603	rs10520585	ENSG00000229212.6	RP11-561C5.4	-4.83	2.08e-06	0.00126	-0.37	-0.25	Bulimia nervosa;	chr15:85118275	chr15:85205440~85234795:-
STAD	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-4.83	2.08e-06	0.00126	-0.21	-0.25	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
STAD	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-4.83	2.08e-06	0.00126	-0.21	-0.25	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
STAD	cis	rs7487075	0.859	rs7968173	ENSG00000272369.1	RP11-446N19.1	-4.83	2.08e-06	0.00126	-0.32	-0.25	Itch intensity from mosquito bite;	chr12:46365234	chr12:46537502~46652550:+
STAD	cis	rs2273156	0.706	rs7153331	ENSG00000241052.1	RP11-173D9.1	-4.83	2.08e-06	0.00126	-0.29	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35032464	chr14:35144021~35144480:-
STAD	cis	rs7078219	0.743	rs17094148	ENSG00000228778.1	RP11-129J12.1	-4.83	2.08e-06	0.00126	-0.32	-0.25	Dental caries;	chr10:99520522	chr10:99527081~99528261:+
STAD	cis	rs2273156	0.706	rs7153550	ENSG00000241052.1	RP11-173D9.1	-4.83	2.08e-06	0.00126	-0.29	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35032594	chr14:35144021~35144480:-
STAD	cis	rs7429990	0.833	rs35582375	ENSG00000224895.1	VPS26BP1	4.83	2.09e-06	0.00126	0.24	0.25	Educational attainment (years of education);	chr3:47829639	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs13077230	ENSG00000224895.1	VPS26BP1	4.83	2.09e-06	0.00126	0.24	0.25	Educational attainment (years of education);	chr3:47832232	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs11710199	ENSG00000224895.1	VPS26BP1	4.83	2.09e-06	0.00126	0.24	0.25	Educational attainment (years of education);	chr3:47836588	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs17290490	ENSG00000224895.1	VPS26BP1	4.83	2.09e-06	0.00126	0.24	0.25	Educational attainment (years of education);	chr3:47841237	chr3:47960327~47961081:-
STAD	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-4.83	2.09e-06	0.00127	-0.29	-0.25	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-4.83	2.09e-06	0.00127	-0.29	-0.25	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
STAD	cis	rs3758911	0.894	rs11212154	ENSG00000261098.1	RP11-819C21.1	-4.83	2.09e-06	0.00127	-0.23	-0.25	Coronary artery disease;	chr11:107319238	chr11:107312132~107316271:-
STAD	cis	rs4970988	0.556	rs2280078	ENSG00000274963.1	Metazoa_SRP	-4.83	2.09e-06	0.00127	-0.21	-0.25	Urate levels;	chr1:150627705	chr1:150568971~150569269:-
STAD	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-4.83	2.09e-06	0.00127	-0.26	-0.25	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
STAD	cis	rs1707322	0.627	rs3014213	ENSG00000281133.1	AL355480.3	4.83	2.09e-06	0.00127	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.686	rs2152078	ENSG00000281133.1	AL355480.3	4.83	2.09e-06	0.00127	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.686	rs2991979	ENSG00000281133.1	AL355480.3	4.83	2.09e-06	0.00127	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45580892~45580996:-
STAD	cis	rs227275	0.554	rs223439	ENSG00000248971.2	KRT8P46	-4.83	2.09e-06	0.00127	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223436	ENSG00000248971.2	KRT8P46	-4.83	2.09e-06	0.00127	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102728746~102730171:-
STAD	cis	rs2006771	0.818	rs8142376	ENSG00000236132.1	CTA-440B3.1	4.83	2.09e-06	0.00127	0.26	0.25	Nonsyndromic cleft lip with cleft palate;	chr22:31605051	chr22:31816379~31817491:-
STAD	cis	rs1707322	0.686	rs3014236	ENSG00000281133.1	AL355480.3	4.83	2.09e-06	0.00127	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45580892~45580996:-
STAD	cis	rs7615952	0.611	rs35321002	ENSG00000239804.1	RP11-379B18.1	4.83	2.09e-06	0.00127	0.46	0.25	Blood pressure (smoking interaction);	chr3:125893222	chr3:125787888~125788146:-
STAD	cis	rs4950322	0.57	rs11800580	ENSG00000278811.3	LINC00624	-4.83	2.1e-06	0.00127	-0.28	-0.25	Protein quantitative trait loci;	chr1:147261053	chr1:147258885~147517875:-
STAD	cis	rs11846409	0.652	rs10143549	ENSG00000211972.2	IGHV3-66	4.83	2.1e-06	0.00127	0.26	0.25	Rheumatic heart disease;	chr14:106644643	chr14:106675017~106675544:-
STAD	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-4.83	2.1e-06	0.00127	-0.28	-0.25	QT interval;	chr12:29298788	chr12:29280418~29317848:-
STAD	cis	rs3758911	0.861	rs10789593	ENSG00000261098.1	RP11-819C21.1	-4.83	2.1e-06	0.00127	-0.23	-0.25	Coronary artery disease;	chr11:107286154	chr11:107312132~107316271:-
STAD	cis	rs875971	0.83	rs427973	ENSG00000236529.1	RP13-254B10.1	4.83	2.1e-06	0.00127	0.27	0.25	Aortic root size;	chr7:66061661	chr7:65840212~65840596:+
STAD	cis	rs2933343	0.7	rs1683779	ENSG00000261159.1	RP11-723O4.9	4.83	2.1e-06	0.00127	0.31	0.25	IgG glycosylation;	chr3:128923205	chr3:128859716~128860526:-
STAD	cis	rs875971	0.825	rs6951503	ENSG00000236529.1	RP13-254B10.1	-4.83	2.1e-06	0.00127	-0.26	-0.25	Aortic root size;	chr7:66253949	chr7:65840212~65840596:+
STAD	cis	rs7932354	0.583	rs11039014	ENSG00000271350.1	CTD-2384B9.1	-4.83	2.1e-06	0.00127	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46873827	chr11:47041027~47041945:-
STAD	cis	rs7487075	0.859	rs4768698	ENSG00000257261.4	RP11-96H19.1	-4.83	2.1e-06	0.00127	-0.3	-0.25	Itch intensity from mosquito bite;	chr12:46355305	chr12:46383679~46876159:+
STAD	cis	rs7015630	0.542	rs13280951	ENSG00000251136.7	RP11-37B2.1	-4.83	2.1e-06	0.00127	-0.35	-0.25	Inflammatory bowel disease;Crohn's disease;	chr8:89809746	chr8:89609409~89757727:-
STAD	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	4.82	2.1e-06	0.00127	0.31	0.25	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
STAD	cis	rs9910055	0.53	rs11652651	ENSG00000260793.2	RP5-882C2.2	4.82	2.1e-06	0.00127	0.27	0.25	Total body bone mineral density;	chr17:44225539	chr17:44221401~44223710:+
STAD	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-4.82	2.11e-06	0.00127	-0.4	-0.25	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-4.82	2.11e-06	0.00127	-0.4	-0.25	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
STAD	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-4.82	2.11e-06	0.00127	-0.38	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
STAD	cis	rs4950322	0.748	rs17356680	ENSG00000278811.3	LINC00624	4.82	2.11e-06	0.00128	0.27	0.25	Protein quantitative trait loci;	chr1:147354934	chr1:147258885~147517875:-
STAD	cis	rs1799949	1	rs8176220	ENSG00000236383.6	LINC00854	-4.82	2.11e-06	0.00128	-0.21	-0.25	Menopause (age at onset);	chr17:43070445	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs1799966	ENSG00000236383.6	LINC00854	-4.82	2.11e-06	0.00128	-0.21	-0.25	Menopause (age at onset);	chr17:43071077	chr17:43216941~43305976:-
STAD	cis	rs172166	0.56	rs203878	ENSG00000220721.1	OR1F12	4.82	2.11e-06	0.00128	0.24	0.25	Cardiac Troponin-T levels;	chr6:28081218	chr6:28073316~28074233:+
STAD	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-4.82	2.11e-06	0.00128	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
STAD	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-4.82	2.11e-06	0.00128	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
STAD	cis	rs5758659	1	rs5758677	ENSG00000182057.4	OGFRP1	4.82	2.11e-06	0.00128	0.26	0.25	Cognitive function;	chr22:42247033	chr22:42269753~42275196:+
STAD	cis	rs4273100	0.526	rs2074280	ENSG00000265185.4	SNORD3B-1	4.82	2.12e-06	0.00128	0.34	0.25	Schizophrenia;	chr17:19014602	chr17:19061912~19062669:+
STAD	cis	rs721917	0.506	rs2244451	ENSG00000244733.5	RP11-506M13.3	-4.82	2.12e-06	0.00128	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2265961	ENSG00000244733.5	RP11-506M13.3	-4.82	2.12e-06	0.00128	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs7088752	ENSG00000244733.5	RP11-506M13.3	-4.82	2.12e-06	0.00128	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs7078242	ENSG00000244733.5	RP11-506M13.3	-4.82	2.12e-06	0.00128	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79660891~79677996:+
STAD	cis	rs721917	0.525	rs2244001	ENSG00000244733.5	RP11-506M13.3	-4.82	2.12e-06	0.00128	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs1811886	ENSG00000244733.5	RP11-506M13.3	-4.82	2.12e-06	0.00128	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2819113	ENSG00000244733.5	RP11-506M13.3	-4.82	2.12e-06	0.00128	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79660891~79677996:+
STAD	cis	rs11676348	0.846	rs6723449	ENSG00000237281.1	CATIP-AS2	-4.82	2.12e-06	0.00128	-0.25	-0.25	Ulcerative colitis;	chr2:218132857	chr2:218326889~218357966:-
STAD	cis	rs728616	0.681	rs34816332	ENSG00000225484.5	NUTM2B-AS1	-4.82	2.12e-06	0.00128	-0.46	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148211	chr10:79663088~79826594:-
STAD	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	4.82	2.12e-06	0.00128	0.34	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
STAD	cis	rs4713118	0.739	rs2893931	ENSG00000280107.1	AL022393.9	-4.82	2.12e-06	0.00128	-0.34	-0.25	Parkinson's disease;	chr6:27780231	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.824	rs2092075	ENSG00000280107.1	AL022393.9	-4.82	2.12e-06	0.00128	-0.34	-0.25	Parkinson's disease;	chr6:27781551	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.824	rs13211701	ENSG00000280107.1	AL022393.9	-4.82	2.12e-06	0.00128	-0.34	-0.25	Parkinson's disease;	chr6:27782300	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.824	rs9468229	ENSG00000280107.1	AL022393.9	-4.82	2.12e-06	0.00128	-0.34	-0.25	Parkinson's disease;	chr6:27782307	chr6:28170845~28172521:+
STAD	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-4.82	2.12e-06	0.00128	-0.28	-0.25	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
STAD	cis	rs7989332	0.662	rs9285125	ENSG00000238286.1	SLC35E1P1	4.82	2.12e-06	0.00128	0.32	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20488501	chr13:20607268~20608131:+
STAD	cis	rs7989332	0.662	rs9315624	ENSG00000238286.1	SLC35E1P1	4.82	2.12e-06	0.00128	0.32	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20488538	chr13:20607268~20608131:+
STAD	cis	rs1345301	1	rs12470560	ENSG00000234389.1	AC007278.3	-4.82	2.12e-06	0.00128	-0.26	-0.25	Waist circumference;	chr2:102252380	chr2:102438713~102440475:+
STAD	cis	rs1345301	1	rs10200410	ENSG00000234389.1	AC007278.3	-4.82	2.12e-06	0.00128	-0.26	-0.25	Waist circumference;	chr2:102254411	chr2:102438713~102440475:+
STAD	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	4.82	2.12e-06	0.00128	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
STAD	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-4.82	2.12e-06	0.00128	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
STAD	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-4.82	2.12e-06	0.00128	-0.25	-0.25	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
STAD	cis	rs228614	0.51	rs223434	ENSG00000248971.2	KRT8P46	-4.82	2.12e-06	0.00128	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102728746~102730171:-
STAD	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-4.82	2.13e-06	0.00128	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-4.82	2.13e-06	0.00128	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-4.82	2.13e-06	0.00128	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-4.82	2.13e-06	0.00128	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
STAD	cis	rs9467773	0.511	rs17278688	ENSG00000241549.7	GUSBP2	4.82	2.13e-06	0.00129	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26871484~26956554:-
STAD	cis	rs748404	0.666	rs10518812	ENSG00000249839.1	AC011330.5	4.82	2.13e-06	0.00129	0.45	0.25	Lung cancer;	chr15:43360739	chr15:43663654~43684339:-
STAD	cis	rs7615952	0.604	rs9837847	ENSG00000272840.1	RP11-379B18.6	4.82	2.13e-06	0.00129	0.51	0.25	Blood pressure (smoking interaction);	chr3:125905076	chr3:125774714~125797953:+
STAD	cis	rs17507216	0.667	rs13379724	ENSG00000259429.4	UBE2Q2P2	-4.82	2.13e-06	0.00129	-0.38	-0.25	Excessive daytime sleepiness;	chr15:82619892	chr15:82355142~82420075:+
STAD	cis	rs1594829	0.535	rs11784209	ENSG00000228451.3	SDAD1P1	4.82	2.13e-06	0.00129	0.26	0.25	Height;	chr8:26312730	chr8:26379259~26382953:-
STAD	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-4.82	2.13e-06	0.00129	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
STAD	cis	rs875971	0.545	rs6460281	ENSG00000236529.1	RP13-254B10.1	4.82	2.13e-06	0.00129	0.29	0.25	Aortic root size;	chr7:66216128	chr7:65840212~65840596:+
STAD	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-4.82	2.13e-06	0.00129	-0.28	-0.25	QT interval;	chr12:29297620	chr12:29280418~29317848:-
STAD	cis	rs13113518	0.812	rs12500601	ENSG00000223305.1	RN7SKP30	4.82	2.14e-06	0.00129	0.28	0.25	Height;	chr4:55451489	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs12501636	ENSG00000223305.1	RN7SKP30	4.82	2.14e-06	0.00129	0.28	0.25	Height;	chr4:55482317	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs6858803	ENSG00000223305.1	RN7SKP30	4.82	2.14e-06	0.00129	0.28	0.25	Height;	chr4:55484534	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs13114841	ENSG00000223305.1	RN7SKP30	4.82	2.14e-06	0.00129	0.28	0.25	Height;	chr4:55485974	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs939823	ENSG00000223305.1	RN7SKP30	4.82	2.14e-06	0.00129	0.28	0.25	Height;	chr4:55487368	chr4:55540502~55540835:-
STAD	cis	rs7429990	0.932	rs936428	ENSG00000224895.1	VPS26BP1	4.82	2.14e-06	0.00129	0.25	0.25	Educational attainment (years of education);	chr3:48125791	chr3:47960327~47961081:-
STAD	cis	rs6714710	0.603	rs11123974	ENSG00000235833.1	AC159540.14	-4.82	2.14e-06	0.00129	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97989519	chr2:97523949~97524976:-
STAD	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	4.82	2.14e-06	0.00129	0.33	0.25	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
STAD	cis	rs1707322	0.686	rs2991987	ENSG00000281133.1	AL355480.3	4.82	2.14e-06	0.00129	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45580892~45580996:-
STAD	cis	rs1799949	1	rs34942571	ENSG00000236383.6	LINC00854	-4.82	2.14e-06	0.00129	-0.21	-0.25	Menopause (age at onset);	chr17:43121362	chr17:43216941~43305976:-
STAD	cis	rs5758659	1	rs5758660	ENSG00000182057.4	OGFRP1	4.82	2.14e-06	0.00129	0.26	0.25	Cognitive function;	chr22:42227712	chr22:42269753~42275196:+
STAD	cis	rs6714710	0.58	rs13032265	ENSG00000235833.1	AC159540.14	-4.82	2.14e-06	0.00129	-0.28	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97793102	chr2:97523949~97524976:-
STAD	cis	rs2833693	1	rs2833693	ENSG00000261610.1	AP000265.1	4.82	2.14e-06	0.00129	0.28	0.25	Temperament;	chr21:32180200	chr21:32259804~32261585:-
STAD	cis	rs1799949	0.965	rs9646418	ENSG00000279602.1	CTD-3014M21.1	4.82	2.14e-06	0.00129	0.31	0.25	Menopause (age at onset);	chr17:43348533	chr17:43360041~43361361:-
STAD	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	4.82	2.14e-06	0.00129	0.25	0.25	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
STAD	cis	rs858239	0.601	rs15775	ENSG00000226816.2	AC005082.12	4.82	2.14e-06	0.00129	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23206013~23208045:+
STAD	cis	rs728616	0.681	rs35420115	ENSG00000225484.5	NUTM2B-AS1	-4.82	2.14e-06	0.00129	-0.46	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148432	chr10:79663088~79826594:-
STAD	cis	rs7208859	0.573	rs8070182	ENSG00000263603.1	CTD-2349P21.5	-4.82	2.15e-06	0.00129	-0.31	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30729469~30731202:+
STAD	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-4.82	2.15e-06	0.0013	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
STAD	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	4.82	2.15e-06	0.0013	0.31	0.25	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
STAD	cis	rs747650	0.532	rs3922684	ENSG00000271350.1	CTD-2384B9.1	4.82	2.15e-06	0.0013	0.33	0.25	Acne (severe);	chr11:47099625	chr11:47041027~47041945:-
STAD	cis	rs9549367	0.713	rs3024746	ENSG00000269125.1	RP11-98F14.11	-4.82	2.15e-06	0.0013	-0.31	-0.25	Platelet distribution width;	chr13:113167463	chr13:113165002~113165183:-
STAD	cis	rs9549367	0.713	rs3024747	ENSG00000269125.1	RP11-98F14.11	-4.82	2.15e-06	0.0013	-0.31	-0.25	Platelet distribution width;	chr13:113167473	chr13:113165002~113165183:-
STAD	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-4.82	2.15e-06	0.0013	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-4.82	2.15e-06	0.0013	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-4.82	2.15e-06	0.0013	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
STAD	cis	rs916888	0.821	rs199504	ENSG00000232300.1	FAM215B	-4.82	2.15e-06	0.0013	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46558830~46562795:-
STAD	cis	rs1056107	0.872	rs10981315	ENSG00000225513.1	RP11-165N19.2	-4.82	2.15e-06	0.0013	-0.29	-0.25	Colorectal cancer;	chr9:112210139	chr9:112173522~112173971:-
STAD	cis	rs1426063	0.614	rs17266308	ENSG00000248165.1	RP11-44F21.2	-4.82	2.16e-06	0.0013	-0.49	-0.25	QT interval;	chr4:75137695	chr4:74993877~75034824:-
STAD	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	4.82	2.16e-06	0.0013	0.26	0.25	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
STAD	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-4.82	2.16e-06	0.0013	-0.28	-0.25	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
STAD	cis	rs11676348	0.846	rs7594532	ENSG00000237281.1	CATIP-AS2	4.82	2.16e-06	0.0013	0.25	0.25	Ulcerative colitis;	chr2:218143277	chr2:218326889~218357966:-
STAD	cis	rs7665090	0.875	rs6813322	ENSG00000248971.2	KRT8P46	-4.82	2.16e-06	0.0013	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634462	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs6839064	ENSG00000248971.2	KRT8P46	-4.82	2.16e-06	0.0013	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634519	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs2272695	ENSG00000248971.2	KRT8P46	-4.82	2.16e-06	0.0013	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634646	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs2272696	ENSG00000248971.2	KRT8P46	-4.82	2.16e-06	0.0013	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634664	chr4:102728746~102730171:-
STAD	cis	rs2337406	0.866	rs8003852	ENSG00000211972.2	IGHV3-66	4.82	2.16e-06	0.0013	0.25	0.25	Alzheimer's disease (late onset);	chr14:106776648	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs988131	ENSG00000211972.2	IGHV3-66	4.82	2.16e-06	0.0013	0.25	0.25	Alzheimer's disease (late onset);	chr14:106776833	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs8005518	ENSG00000211972.2	IGHV3-66	4.82	2.16e-06	0.0013	0.25	0.25	Alzheimer's disease (late onset);	chr14:106777009	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs988130	ENSG00000211972.2	IGHV3-66	4.82	2.16e-06	0.0013	0.25	0.25	Alzheimer's disease (late onset);	chr14:106777154	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs57684263	ENSG00000211972.2	IGHV3-66	4.82	2.16e-06	0.0013	0.25	0.25	Alzheimer's disease (late onset);	chr14:106777263	chr14:106675017~106675544:-
STAD	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	4.82	2.16e-06	0.0013	0.32	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
STAD	cis	rs7951870	0.617	rs7932354	ENSG00000271350.1	CTD-2384B9.1	-4.82	2.16e-06	0.0013	-0.31	-0.25	Schizophrenia;	chr11:46700671	chr11:47041027~47041945:-
STAD	cis	rs7951870	0.617	rs12361673	ENSG00000271350.1	CTD-2384B9.1	-4.82	2.16e-06	0.0013	-0.31	-0.25	Schizophrenia;	chr11:46702387	chr11:47041027~47041945:-
STAD	cis	rs2337406	0.866	rs2301535	ENSG00000211972.2	IGHV3-66	4.82	2.16e-06	0.0013	0.27	0.25	Alzheimer's disease (late onset);	chr14:106790663	chr14:106675017~106675544:-
STAD	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	4.82	2.16e-06	0.0013	0.25	0.25	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
STAD	cis	rs7826238	0.623	rs2976893	ENSG00000253981.4	ALG1L13P	-4.82	2.17e-06	0.00131	-0.29	-0.25	Systolic blood pressure;	chr8:8480709	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.627	rs2979172	ENSG00000253981.4	ALG1L13P	4.82	2.17e-06	0.00131	0.31	0.25	Mood instability;	chr8:8452998	chr8:8236003~8244667:-
STAD	cis	rs237743	1	rs8123912	ENSG00000222365.1	SNORD12B	-4.82	2.17e-06	0.00131	-0.34	-0.25	Height;	chr20:49246745	chr20:49280319~49280409:+
STAD	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-4.82	2.17e-06	0.00131	-0.3	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
STAD	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	4.82	2.17e-06	0.00131	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
STAD	cis	rs3733585	0.631	rs7699671	ENSG00000250613.1	RP11-136I13.1	4.82	2.17e-06	0.00131	0.25	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10124250	chr4:10410996~10411644:+
STAD	cis	rs1799949	0.965	rs7212284	ENSG00000236383.6	LINC00854	-4.82	2.17e-06	0.00131	-0.2	-0.25	Menopause (age at onset);	chr17:43053924	chr17:43216941~43305976:-
STAD	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-4.82	2.17e-06	0.00131	-0.31	-0.25	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
STAD	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-4.82	2.17e-06	0.00131	-0.31	-0.25	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
STAD	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	4.82	2.17e-06	0.00131	0.32	0.25	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
STAD	cis	rs2288493	0.53	rs2300541	ENSG00000258675.1	RP11-299L17.3	4.82	2.18e-06	0.00131	0.33	0.25	Obstetric antiphospholipid syndrome;	chr14:81141486	chr14:81441987~81450157:-
STAD	cis	rs1707322	0.752	rs6678444	ENSG00000225447.1	RPS15AP10	4.82	2.18e-06	0.00131	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45645816~45646197:-
STAD	cis	rs62560775	0.541	rs12352425	ENSG00000279670.1	RP11-70L8.5	4.82	2.18e-06	0.00131	0.38	0.25	Lung cancer;Lung adenocarcinoma;	chr9:22042087	chr9:21892188~21893857:+
STAD	cis	rs2075677	0.506	rs2273101	ENSG00000222365.1	SNORD12B	-4.82	2.18e-06	0.00131	-0.33	-0.25	Subjective well-being;	chr20:48921796	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.7	rs67777906	ENSG00000222365.1	SNORD12B	-4.82	2.18e-06	0.00131	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:48940592	chr20:49280319~49280409:+
STAD	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	4.82	2.18e-06	0.00131	0.32	0.25	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
STAD	cis	rs7078219	0.714	rs12413565	ENSG00000228778.1	RP11-129J12.1	-4.82	2.18e-06	0.00131	-0.32	-0.25	Dental caries;	chr10:99525359	chr10:99527081~99528261:+
STAD	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	4.82	2.18e-06	0.00131	0.3	0.25	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
STAD	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	4.82	2.18e-06	0.00131	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
STAD	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-4.82	2.18e-06	0.00131	-0.21	-0.25	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000224205.1	AP000351.4	4.82	2.18e-06	0.00131	0.28	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23987320~23991421:-
STAD	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	4.82	2.18e-06	0.00131	0.25	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
STAD	cis	rs7247513	0.964	rs4804202	ENSG00000230310.1	CTD-2192J16.11	-4.82	2.18e-06	0.00131	-0.32	-0.25	Bipolar disorder;	chr19:12607805	chr19:12552597~12553644:+
STAD	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-4.82	2.18e-06	0.00131	-0.32	-0.25	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
STAD	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-4.82	2.18e-06	0.00131	-0.27	-0.25	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
STAD	cis	rs9463078	0.526	rs1159131	ENSG00000219384.1	RP11-491H9.3	-4.82	2.18e-06	0.00131	-0.24	-0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45004472	chr6:45158870~45159511:+
STAD	cis	rs7829975	0.627	rs876954	ENSG00000253981.4	ALG1L13P	4.82	2.18e-06	0.00131	0.31	0.25	Mood instability;	chr8:8453413	chr8:8236003~8244667:-
STAD	cis	rs10510102	0.935	rs11200252	ENSG00000226864.1	ATE1-AS1	4.82	2.18e-06	0.00131	0.41	0.25	Breast cancer;	chr10:121914728	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12254184	ENSG00000226864.1	ATE1-AS1	4.82	2.18e-06	0.00131	0.41	0.25	Breast cancer;	chr10:121914971	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200253	ENSG00000226864.1	ATE1-AS1	4.82	2.18e-06	0.00131	0.41	0.25	Breast cancer;	chr10:121915114	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200254	ENSG00000226864.1	ATE1-AS1	4.82	2.18e-06	0.00131	0.41	0.25	Breast cancer;	chr10:121915241	chr10:121928312~121951965:+
STAD	cis	rs2948294	0.566	rs13274039	ENSG00000254340.1	RP11-10A14.3	4.82	2.19e-06	0.00132	0.3	0.25	Red cell distribution width;	chr8:8254137	chr8:9141424~9145435:+
STAD	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-4.82	2.19e-06	0.00132	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-4.82	2.19e-06	0.00132	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-4.82	2.19e-06	0.00132	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
STAD	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-4.82	2.19e-06	0.00132	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
STAD	cis	rs875971	0.964	rs160635	ENSG00000236529.1	RP13-254B10.1	4.82	2.19e-06	0.00132	0.26	0.25	Aortic root size;	chr7:66063931	chr7:65840212~65840596:+
STAD	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	4.82	2.19e-06	0.00132	0.33	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
STAD	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	4.82	2.19e-06	0.00132	0.35	0.25	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
STAD	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	4.82	2.19e-06	0.00132	0.35	0.25	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
STAD	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	4.82	2.19e-06	0.00132	0.35	0.25	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
STAD	cis	rs7665090	0.967	rs13106304	ENSG00000248971.2	KRT8P46	-4.82	2.19e-06	0.00132	-0.26	-0.25	Primary biliary cholangitis;	chr4:102633818	chr4:102728746~102730171:-
STAD	cis	rs2948294	0.566	rs13261997	ENSG00000254340.1	RP11-10A14.3	4.82	2.19e-06	0.00132	0.31	0.25	Red cell distribution width;	chr8:8254773	chr8:9141424~9145435:+
STAD	cis	rs747650	0.699	rs4237547	ENSG00000271350.1	CTD-2384B9.1	-4.82	2.19e-06	0.00132	-0.3	-0.25	Acne (severe);	chr11:47214854	chr11:47041027~47041945:-
STAD	cis	rs8067354	0.645	rs2132715	ENSG00000266701.1	AC005702.4	4.82	2.19e-06	0.00132	0.34	0.25	Hemoglobin concentration;	chr17:59781013	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs2173119	ENSG00000266701.1	AC005702.4	4.82	2.19e-06	0.00132	0.34	0.25	Hemoglobin concentration;	chr17:59782344	chr17:60042546~60042627:-
STAD	cis	rs4388249	0.578	rs427691	ENSG00000271849.1	CTC-332L22.1	-4.82	2.19e-06	0.00132	-0.38	-0.25	Schizophrenia;	chr5:109678809	chr5:109687802~109688329:-
STAD	cis	rs13113518	1	rs6838882	ENSG00000223305.1	RN7SKP30	4.82	2.19e-06	0.00132	0.28	0.25	Height;	chr4:55489310	chr4:55540502~55540835:-
STAD	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-4.82	2.2e-06	0.00132	-0.3	-0.25	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
STAD	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-4.82	2.2e-06	0.00132	-0.37	-0.25	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-4.82	2.2e-06	0.00132	-0.37	-0.25	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
STAD	cis	rs3733418	0.929	rs17623445	ENSG00000248632.1	RP11-366M4.11	4.82	2.2e-06	0.00132	0.3	0.25	Obesity-related traits;	chr4:164973506	chr4:164968587~164970002:-
STAD	cis	rs1799949	1	rs12944597	ENSG00000279602.1	CTD-3014M21.1	4.82	2.2e-06	0.00132	0.32	0.25	Menopause (age at onset);	chr17:43035667	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs12942277	ENSG00000279602.1	CTD-3014M21.1	4.82	2.2e-06	0.00132	0.32	0.25	Menopause (age at onset);	chr17:43035957	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs34616041	ENSG00000279602.1	CTD-3014M21.1	4.82	2.2e-06	0.00132	0.32	0.25	Menopause (age at onset);	chr17:43036769	chr17:43360041~43361361:-
STAD	cis	rs6095360	0.7	rs79941596	ENSG00000222365.1	SNORD12B	-4.82	2.2e-06	0.00132	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49177259	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.689	rs7274851	ENSG00000222365.1	SNORD12B	-4.82	2.2e-06	0.00132	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49177818	chr20:49280319~49280409:+
STAD	cis	rs1707322	0.752	rs4660313	ENSG00000225447.1	RPS15AP10	-4.82	2.2e-06	0.00132	-0.2	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45645816~45646197:-
STAD	cis	rs6430585	0.583	rs6728946	ENSG00000231890.6	DARS-AS1	-4.82	2.2e-06	0.00132	-0.28	-0.25	Corneal structure;	chr2:135877773	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs79176913	ENSG00000231890.6	DARS-AS1	-4.82	2.2e-06	0.00132	-0.28	-0.25	Corneal structure;	chr2:135880543	chr2:135985176~136022593:+
STAD	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-4.82	2.2e-06	0.00132	-0.26	-0.25	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
STAD	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	4.82	2.2e-06	0.00132	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
STAD	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-4.82	2.2e-06	0.00132	-0.37	-0.25	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
STAD	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	4.82	2.2e-06	0.00133	0.35	0.25	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
STAD	cis	rs227275	0.554	rs223399	ENSG00000248971.2	KRT8P46	-4.81	2.2e-06	0.00133	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102728746~102730171:-
STAD	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	4.81	2.21e-06	0.00133	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
STAD	cis	rs2836950	0.565	rs2150414	ENSG00000238141.2	BRWD1-AS1	-4.81	2.21e-06	0.00133	-0.26	-0.25	Menarche (age at onset);	chr21:39243062	chr21:39315707~39323218:+
STAD	cis	rs453301	0.598	rs1025395	ENSG00000233609.3	RP11-62H7.2	4.81	2.21e-06	0.00133	0.29	0.25	Joint mobility (Beighton score);	chr8:8979093	chr8:8961200~8979025:+
STAD	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.21e-06	0.00133	-0.26	-0.25	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
STAD	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-4.81	2.21e-06	0.00133	-0.38	-0.25	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-4.81	2.21e-06	0.00133	-0.38	-0.25	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-4.81	2.21e-06	0.00133	-0.38	-0.25	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
STAD	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	4.81	2.21e-06	0.00133	0.26	0.25	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
STAD	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	4.81	2.21e-06	0.00133	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
STAD	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	4.81	2.22e-06	0.00133	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
STAD	cis	rs7665090	1	rs2272697	ENSG00000248971.2	KRT8P46	-4.81	2.22e-06	0.00133	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634835	chr4:102728746~102730171:-
STAD	cis	rs13113518	0.966	rs13144598	ENSG00000223305.1	RN7SKP30	4.81	2.22e-06	0.00133	0.28	0.25	Height;	chr4:55570311	chr4:55540502~55540835:-
STAD	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	4.81	2.22e-06	0.00133	0.39	0.25	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
STAD	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	4.81	2.22e-06	0.00133	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
STAD	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	4.81	2.22e-06	0.00133	0.25	0.25	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
STAD	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	4.81	2.22e-06	0.00133	0.25	0.25	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
STAD	cis	rs17660992	0.603	rs8108345	ENSG00000273837.1	LLNLR-470E3.1	-4.81	2.22e-06	0.00133	-0.3	-0.25	Blood protein levels;	chr19:51661033	chr19:51639478~51639931:-
STAD	cis	rs17660992	0.603	rs2167422	ENSG00000273837.1	LLNLR-470E3.1	-4.81	2.22e-06	0.00133	-0.3	-0.25	Blood protein levels;	chr19:51661130	chr19:51639478~51639931:-
STAD	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	-4.81	2.22e-06	0.00133	-0.28	-0.25	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
STAD	cis	rs3736858	1	rs3736858	ENSG00000261105.4	LMO7-AS1	4.81	2.22e-06	0.00133	0.4	0.25	Interleukin-9 levels;	chr13:75841243	chr13:75604700~75635994:-
STAD	cis	rs7932354	0.583	rs10769212	ENSG00000271350.1	CTD-2384B9.1	-4.81	2.22e-06	0.00133	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46871947	chr11:47041027~47041945:-
STAD	cis	rs891378	0.675	rs7543002	ENSG00000274245.1	RP11-357P18.2	-4.81	2.22e-06	0.00133	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205496	chr1:207372559~207373252:+
STAD	cis	rs891378	0.785	rs7554219	ENSG00000274245.1	RP11-357P18.2	-4.81	2.22e-06	0.00133	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205712	chr1:207372559~207373252:+
STAD	cis	rs2115536	1	rs7163338	ENSG00000278600.1	RP11-81A1.6	-4.81	2.22e-06	0.00133	-0.21	-0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79906066	chr15:79920195~79922455:-
STAD	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-4.81	2.22e-06	0.00133	-0.31	-0.25	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
STAD	cis	rs4604732	0.603	rs4546958	ENSG00000227135.1	GCSAML-AS1	-4.81	2.22e-06	0.00133	-0.32	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476176	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.642	rs7515859	ENSG00000227135.1	GCSAML-AS1	-4.81	2.22e-06	0.00133	-0.32	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476755	chr1:247524679~247526752:-
STAD	cis	rs4604732	0.642	rs7549312	ENSG00000227135.1	GCSAML-AS1	-4.81	2.22e-06	0.00133	-0.32	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476776	chr1:247524679~247526752:-
STAD	cis	rs7429990	0.864	rs6785669	ENSG00000224895.1	VPS26BP1	4.81	2.22e-06	0.00134	0.24	0.25	Educational attainment (years of education);	chr3:47715771	chr3:47960327~47961081:-
STAD	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-4.81	2.22e-06	0.00134	-0.3	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
STAD	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-4.81	2.22e-06	0.00134	-0.3	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
STAD	cis	rs1150668	0.796	rs1052215	ENSG00000220721.1	OR1F12	-4.81	2.22e-06	0.00134	-0.24	-0.25	Pubertal anthropometrics;	chr6:28380381	chr6:28073316~28074233:+
STAD	cis	rs7615952	0.546	rs2922194	ENSG00000272840.1	RP11-379B18.6	4.81	2.23e-06	0.00134	0.44	0.25	Blood pressure (smoking interaction);	chr3:125613419	chr3:125774714~125797953:+
STAD	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	4.81	2.23e-06	0.00134	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
STAD	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	4.81	2.23e-06	0.00134	0.3	0.25	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
STAD	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	4.81	2.23e-06	0.00134	0.3	0.25	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
STAD	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	4.81	2.23e-06	0.00134	0.3	0.25	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
STAD	cis	rs4568518	0.535	rs7781290	ENSG00000279048.1	RP11-511H23.2	4.81	2.23e-06	0.00134	0.23	0.25	Measles;	chr7:18022987	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.535	rs4555994	ENSG00000279048.1	RP11-511H23.2	4.81	2.23e-06	0.00134	0.23	0.25	Measles;	chr7:18023034	chr7:17940503~17942922:+
STAD	cis	rs7487075	0.859	rs7974529	ENSG00000257261.4	RP11-96H19.1	4.81	2.23e-06	0.00134	0.3	0.25	Itch intensity from mosquito bite;	chr12:46357605	chr12:46383679~46876159:+
STAD	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-4.81	2.23e-06	0.00134	-0.3	-0.25	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
STAD	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-4.81	2.23e-06	0.00134	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-4.81	2.23e-06	0.00134	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
STAD	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	4.81	2.23e-06	0.00134	0.3	0.25	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
STAD	cis	rs1799949	0.93	rs3092987	ENSG00000236383.6	LINC00854	-4.81	2.23e-06	0.00134	-0.21	-0.25	Menopause (age at onset);	chr17:43070706	chr17:43216941~43305976:-
STAD	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	4.81	2.23e-06	0.00134	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
STAD	cis	rs7829975	0.626	rs332040	ENSG00000253981.4	ALG1L13P	4.81	2.23e-06	0.00134	0.3	0.25	Mood instability;	chr8:8872978	chr8:8236003~8244667:-
STAD	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-4.81	2.24e-06	0.00134	-0.39	-0.25	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
STAD	cis	rs7665090	1	rs735404	ENSG00000230069.3	LRRC37A15P	-4.81	2.24e-06	0.00134	-0.27	-0.25	Primary biliary cholangitis;	chr4:102632508	chr4:102727274~102730721:-
STAD	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.24e-06	0.00134	-0.26	-0.25	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
STAD	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-4.81	2.24e-06	0.00134	-0.37	-0.25	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
STAD	cis	rs4713118	0.869	rs7776351	ENSG00000280107.1	AL022393.9	4.81	2.24e-06	0.00134	0.33	0.25	Parkinson's disease;	chr6:27758952	chr6:28170845~28172521:+
STAD	cis	rs1707322	0.752	rs28890893	ENSG00000225447.1	RPS15AP10	4.81	2.24e-06	0.00134	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45645816~45646197:-
STAD	cis	rs6095360	0.727	rs71351953	ENSG00000222365.1	SNORD12B	-4.81	2.24e-06	0.00134	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:48958210	chr20:49280319~49280409:+
STAD	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	4.81	2.24e-06	0.00135	0.28	0.25	Height;	chr4:55532542	chr4:55540502~55540835:-
STAD	cis	rs3758911	0.894	rs10890718	ENSG00000261098.1	RP11-819C21.1	-4.81	2.24e-06	0.00135	-0.23	-0.25	Coronary artery disease;	chr11:107326257	chr11:107312132~107316271:-
STAD	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-4.81	2.24e-06	0.00135	-0.27	-0.25	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
STAD	cis	rs7924176	0.521	rs11001022	ENSG00000213731.2	RAB5CP1	-4.81	2.25e-06	0.00135	-0.26	-0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74423435~74424014:-
STAD	cis	rs4604732	0.642	rs4266925	ENSG00000227135.1	GCSAML-AS1	-4.81	2.25e-06	0.00135	-0.32	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247475863	chr1:247524679~247526752:-
STAD	cis	rs9463078	0.585	rs1285004	ENSG00000219384.1	RP11-491H9.3	-4.81	2.25e-06	0.00135	-0.24	-0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45130464	chr6:45158870~45159511:+
STAD	cis	rs4639966	0.836	rs4499035	ENSG00000255239.1	AP002954.6	-4.81	2.25e-06	0.00135	-0.32	-0.25	Systemic lupus erythematosus;	chr11:118739754	chr11:118688039~118690600:-
STAD	cis	rs11079159	0.585	rs8079998	ENSG00000263096.1	RP11-515O17.2	4.81	2.25e-06	0.00135	0.31	0.25	QRS duration;	chr17:55308138	chr17:55271504~55273653:-
STAD	cis	rs611744	0.503	rs13282220	ENSG00000253754.1	RP11-35G22.1	-4.81	2.25e-06	0.00135	-0.23	-0.25	Dupuytren's disease;	chr8:108250814	chr8:108226200~108227544:+
STAD	cis	rs11098499	0.738	rs28408407	ENSG00000260091.1	RP11-33B1.4	4.81	2.25e-06	0.00135	0.24	0.25	Corneal astigmatism;	chr4:119454875	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs1809406	ENSG00000260091.1	RP11-33B1.4	4.81	2.25e-06	0.00135	0.24	0.25	Corneal astigmatism;	chr4:119455967	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs2389809	ENSG00000260091.1	RP11-33B1.4	4.81	2.25e-06	0.00135	0.24	0.25	Corneal astigmatism;	chr4:119456244	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.697	rs10020027	ENSG00000260091.1	RP11-33B1.4	4.81	2.25e-06	0.00135	0.24	0.25	Corneal astigmatism;	chr4:119460724	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.779	rs7356491	ENSG00000260091.1	RP11-33B1.4	4.81	2.25e-06	0.00135	0.24	0.25	Corneal astigmatism;	chr4:119460819	chr4:119409333~119410233:+
STAD	cis	rs238295	0.766	rs6139759	ENSG00000230563.2	RP5-828H9.1	-4.81	2.25e-06	0.00135	-0.28	-0.25	Occipital cortical area (total cortical area interaction);	chr20:5531096	chr20:5471207~5475182:+
STAD	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-4.81	2.25e-06	0.00135	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
STAD	cis	rs7665090	0.87	rs228614	ENSG00000246560.2	RP11-10L12.4	-4.81	2.25e-06	0.00135	-0.3	-0.25	Primary biliary cholangitis;	chr4:102657480	chr4:102828055~102844075:+
STAD	cis	rs891378	0.959	rs6703860	ENSG00000274245.1	RP11-357P18.2	-4.81	2.25e-06	0.00135	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270226	chr1:207372559~207373252:+
STAD	cis	rs8099594	0.64	rs504246	ENSG00000266696.1	RP11-30L3.2	4.81	2.25e-06	0.00135	0.24	0.25	Height;	chr18:49332619	chr18:49205912~49208781:+
STAD	cis	rs2404602	0.692	rs34272342	ENSG00000259422.1	RP11-593F23.1	4.81	2.25e-06	0.00135	0.26	0.25	Blood metabolite levels;	chr15:76719935	chr15:76174891~76181486:-
STAD	cis	rs17630293	0.737	rs3769459	ENSG00000201649.1	RNY4P34	-4.81	2.26e-06	0.00135	-0.37	-0.25	Schizophrenia;	chr2:200369849	chr2:200373175~200373269:+
STAD	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-4.81	2.26e-06	0.00135	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
STAD	cis	rs228614	0.51	rs223412	ENSG00000248971.2	KRT8P46	-4.81	2.26e-06	0.00135	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102728746~102730171:-
STAD	cis	rs10510102	0.935	rs10510101	ENSG00000226864.1	ATE1-AS1	4.81	2.26e-06	0.00135	0.4	0.25	Breast cancer;	chr10:121898614	chr10:121928312~121951965:+
STAD	cis	rs858239	0.601	rs10224327	ENSG00000230042.1	AK3P3	-4.81	2.26e-06	0.00135	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23129178~23129841:+
STAD	cis	rs2404602	0.669	rs8036703	ENSG00000259422.1	RP11-593F23.1	4.81	2.26e-06	0.00135	0.26	0.25	Blood metabolite levels;	chr15:76658699	chr15:76174891~76181486:-
STAD	cis	rs7487075	0.82	rs4586238	ENSG00000272369.1	RP11-446N19.1	4.81	2.26e-06	0.00135	0.33	0.25	Itch intensity from mosquito bite;	chr12:46326044	chr12:46537502~46652550:+
STAD	cis	rs4691139	0.634	rs4583719	ENSG00000248632.1	RP11-366M4.11	4.81	2.26e-06	0.00135	0.24	0.25	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003505	chr4:164968587~164970002:-
STAD	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	4.81	2.26e-06	0.00135	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
STAD	cis	rs6951245	0.554	rs78999139	ENSG00000229043.2	AC091729.9	-4.81	2.26e-06	0.00135	-0.34	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1160374~1165267:+
STAD	cis	rs6951245	0.58	rs78894484	ENSG00000229043.2	AC091729.9	-4.81	2.26e-06	0.00135	-0.34	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1160374~1165267:+
STAD	cis	rs4243830	0.85	rs3986418	ENSG00000229519.2	RP11-58A11.2	4.81	2.26e-06	0.00136	0.29	0.25	Body mass index;	chr1:6561936	chr1:6547905~6548619:+
STAD	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-4.81	2.26e-06	0.00136	-0.21	-0.25	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-4.81	2.26e-06	0.00136	-0.19	-0.25	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
STAD	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-4.81	2.26e-06	0.00136	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
STAD	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	4.81	2.27e-06	0.00136	0.3	0.25	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
STAD	cis	rs1707322	0.682	rs3014241	ENSG00000281133.1	AL355480.3	4.81	2.27e-06	0.00136	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45580892~45580996:-
STAD	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-4.81	2.27e-06	0.00136	-0.34	-0.25	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
STAD	cis	rs7487075	0.578	rs11183486	ENSG00000257261.4	RP11-96H19.1	4.81	2.27e-06	0.00136	0.31	0.25	Itch intensity from mosquito bite;	chr12:46443921	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs4768724	ENSG00000257261.4	RP11-96H19.1	4.81	2.27e-06	0.00136	0.31	0.25	Itch intensity from mosquito bite;	chr12:46454633	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs4768725	ENSG00000257261.4	RP11-96H19.1	4.81	2.27e-06	0.00136	0.31	0.25	Itch intensity from mosquito bite;	chr12:46454695	chr12:46383679~46876159:+
STAD	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-4.81	2.27e-06	0.00136	-0.31	-0.25	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
STAD	cis	rs13392177	0.66	rs12988046	ENSG00000237281.1	CATIP-AS2	4.81	2.27e-06	0.00136	0.26	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218326889~218357966:-
STAD	cis	rs1707322	0.686	rs1084086	ENSG00000281133.1	AL355480.3	4.81	2.27e-06	0.00136	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45580892~45580996:-
STAD	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-4.81	2.27e-06	0.00136	-0.39	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
STAD	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-4.81	2.27e-06	0.00136	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
STAD	cis	rs2833693	1	rs2833695	ENSG00000261610.1	AP000265.1	4.81	2.27e-06	0.00136	0.28	0.25	Temperament;	chr21:32181819	chr21:32259804~32261585:-
STAD	cis	rs721917	0.506	rs2493722	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79660891~79677996:+
STAD	cis	rs721917	0.545	rs2758542	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs7914360	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2493725	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2254025	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79660891~79677996:+
STAD	cis	rs721917	0.525	rs2254017	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2254013	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2253875	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79660891~79677996:+
STAD	cis	rs721917	0.544	rs9325567	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79660891~79677996:+
STAD	cis	rs721917	0.506	rs2758543	ENSG00000244733.5	RP11-506M13.3	-4.81	2.27e-06	0.00136	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79660891~79677996:+
STAD	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	4.81	2.28e-06	0.00136	0.28	0.25	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
STAD	cis	rs7119038	0.818	rs73003215	ENSG00000255422.1	AP002954.4	4.81	2.28e-06	0.00136	0.32	0.25	Sjögren's syndrome;	chr11:118778803	chr11:118704607~118750263:+
STAD	cis	rs11169552	0.51	rs10783384	ENSG00000200183.1	RNU6-238P	-4.81	2.28e-06	0.00136	-0.24	-0.25	Colorectal cancer;	chr12:50724211	chr12:50656973~50657078:+
STAD	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-4.81	2.28e-06	0.00136	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
STAD	cis	rs1799949	0.894	rs36062488	ENSG00000279602.1	CTD-3014M21.1	-4.81	2.28e-06	0.00136	-0.3	-0.25	Menopause (age at onset);	chr17:43185455	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-4.81	2.28e-06	0.00137	-0.28	-0.25	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-4.81	2.28e-06	0.00137	-0.29	-0.25	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-4.81	2.28e-06	0.00137	-0.29	-0.25	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
STAD	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	4.81	2.28e-06	0.00137	0.47	0.25	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
STAD	cis	rs919433	0.963	rs2043016	ENSG00000231621.1	AC013264.2	4.81	2.28e-06	0.00137	0.21	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197281657	chr2:197197991~197199273:+
STAD	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	4.81	2.28e-06	0.00137	0.26	0.25	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
STAD	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-4.81	2.28e-06	0.00137	-0.28	-0.25	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
STAD	cis	rs12534093	0.562	rs66797912	ENSG00000234286.1	AC006026.13	-4.81	2.29e-06	0.00137	-0.33	-0.25	Infant length;Height;	chr7:23537569	chr7:23680195~23680786:-
STAD	cis	rs507080	0.922	rs478296	ENSG00000278376.1	RP11-158I9.8	-4.81	2.29e-06	0.00137	-0.26	-0.25	Serum metabolite levels;	chr11:118696666	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs493834	ENSG00000278376.1	RP11-158I9.8	-4.81	2.29e-06	0.00137	-0.26	-0.25	Serum metabolite levels;	chr11:118696735	chr11:118791254~118793137:+
STAD	cis	rs8097348	0.817	rs2100448	ENSG00000266602.1	RP11-476K15.1	-4.81	2.29e-06	0.00137	-0.28	-0.25	Exercise (leisure time);	chr18:1673537	chr18:1509183~1647097:+
STAD	cis	rs17401966	0.838	rs4846206	ENSG00000199562.1	RNU6-37P	4.81	2.29e-06	0.00137	0.19	0.25	Hepatocellular carcinoma;	chr1:10250200	chr1:10298966~10299072:+
STAD	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-4.81	2.29e-06	0.00137	-0.38	-0.25	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
STAD	cis	rs1150668	0.83	rs2859365	ENSG00000220721.1	OR1F12	-4.81	2.3e-06	0.00137	-0.25	-0.25	Pubertal anthropometrics;	chr6:28423688	chr6:28073316~28074233:+
STAD	cis	rs2337406	1	rs17113276	ENSG00000211972.2	IGHV3-66	-4.81	2.3e-06	0.00137	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106683485	chr14:106675017~106675544:-
STAD	cis	rs2408955	0.561	rs9971924	ENSG00000258273.1	RP11-370I10.4	4.81	2.3e-06	0.00137	0.3	0.25	Glycated hemoglobin levels;	chr12:48086049	chr12:48333755~48333901:-
STAD	cis	rs2408955	0.522	rs7139330	ENSG00000258273.1	RP11-370I10.4	4.81	2.3e-06	0.00137	0.3	0.25	Glycated hemoglobin levels;	chr12:48089701	chr12:48333755~48333901:-
STAD	cis	rs2408955	0.522	rs2051851	ENSG00000258273.1	RP11-370I10.4	4.81	2.3e-06	0.00137	0.3	0.25	Glycated hemoglobin levels;	chr12:48092157	chr12:48333755~48333901:-
STAD	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-4.81	2.3e-06	0.00137	-0.21	-0.25	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
STAD	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-4.81	2.3e-06	0.00137	-0.29	-0.25	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
STAD	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	4.81	2.3e-06	0.00137	0.36	0.25	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
STAD	cis	rs1345301	1	rs12474199	ENSG00000234389.1	AC007278.3	-4.81	2.3e-06	0.00137	-0.25	-0.25	Waist circumference;	chr2:102252520	chr2:102438713~102440475:+
STAD	cis	rs1345301	1	rs1420093	ENSG00000234389.1	AC007278.3	-4.81	2.3e-06	0.00137	-0.25	-0.25	Waist circumference;	chr2:102253998	chr2:102438713~102440475:+
STAD	cis	rs11038871	1	rs11038871	ENSG00000271350.1	CTD-2384B9.1	-4.81	2.3e-06	0.00137	-0.3	-0.25	Immunoglobulin A;	chr11:46357892	chr11:47041027~47041945:-
STAD	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	4.81	2.3e-06	0.00137	0.27	0.25	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
STAD	cis	rs36423	0.528	rs1205066	ENSG00000266869.1	RP6-114E22.1	4.81	2.3e-06	0.00137	0.39	0.25	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71880340	chr14:71848606~71908430:+
STAD	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-4.81	2.3e-06	0.00138	-0.32	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
STAD	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	4.81	2.3e-06	0.00138	0.3	0.25	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
STAD	cis	rs1007738	0.542	rs11603373	ENSG00000271350.1	CTD-2384B9.1	4.81	2.3e-06	0.00138	0.33	0.25	Bone mineral density (hip);	chr11:47181694	chr11:47041027~47041945:-
STAD	cis	rs2404602	0.692	rs72738889	ENSG00000259422.1	RP11-593F23.1	4.81	2.31e-06	0.00138	0.26	0.25	Blood metabolite levels;	chr15:76699722	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs3816266	ENSG00000259422.1	RP11-593F23.1	4.81	2.31e-06	0.00138	0.26	0.25	Blood metabolite levels;	chr15:76701494	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs2304920	ENSG00000259422.1	RP11-593F23.1	4.81	2.31e-06	0.00138	0.26	0.25	Blood metabolite levels;	chr15:76701526	chr15:76174891~76181486:-
STAD	cis	rs10266483	0.545	rs12540100	ENSG00000271550.1	BNIP3P11	4.8	2.31e-06	0.00138	0.35	0.25	Response to statin therapy;	chr7:64289924	chr7:64678954~64687393:-
STAD	cis	rs561341	1	rs506766	ENSG00000265798.5	RP11-271K11.5	4.8	2.31e-06	0.00138	0.39	0.25	Hip circumference adjusted for BMI;	chr17:31962640	chr17:31038575~31059121:-
STAD	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	4.8	2.31e-06	0.00138	0.29	0.25	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
STAD	cis	rs7932354	0.583	rs964551	ENSG00000271350.1	CTD-2384B9.1	-4.8	2.32e-06	0.00138	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46876444	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.583	rs10742784	ENSG00000271350.1	CTD-2384B9.1	-4.8	2.32e-06	0.00138	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46877731	chr11:47041027~47041945:-
STAD	cis	rs891378	1	rs971318	ENSG00000274245.1	RP11-357P18.2	4.8	2.32e-06	0.00138	0.31	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302251	chr1:207372559~207373252:+
STAD	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-4.8	2.32e-06	0.00138	-0.31	-0.25	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
STAD	cis	rs6832769	1	rs6851838	ENSG00000272969.1	RP11-528I4.2	-4.8	2.32e-06	0.00139	-0.32	-0.25	Personality dimensions;	chr4:55554580	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs10034433	ENSG00000272969.1	RP11-528I4.2	-4.8	2.32e-06	0.00139	-0.32	-0.25	Personality dimensions;	chr4:55555009	chr4:55547112~55547889:+
STAD	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-4.8	2.32e-06	0.00139	-0.3	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
STAD	cis	rs11098499	0.909	rs9994810	ENSG00000260091.1	RP11-33B1.4	4.8	2.32e-06	0.00139	0.24	0.25	Corneal astigmatism;	chr4:119460435	chr4:119409333~119410233:+
STAD	cis	rs9467773	0.596	rs2451751	ENSG00000243307.2	POM121L6P	4.8	2.32e-06	0.00139	0.25	0.25	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26896952~26898777:+
STAD	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-4.8	2.32e-06	0.00139	-0.29	-0.25	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
STAD	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	4.8	2.33e-06	0.00139	0.29	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	4.8	2.33e-06	0.00139	0.29	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	4.8	2.33e-06	0.00139	0.29	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
STAD	cis	rs6951245	0.744	rs10275401	ENSG00000229043.2	AC091729.9	-4.8	2.33e-06	0.00139	-0.39	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1160374~1165267:+
STAD	cis	rs1799949	0.965	rs8176087	ENSG00000279602.1	CTD-3014M21.1	4.8	2.33e-06	0.00139	0.32	0.25	Menopause (age at onset);	chr17:43118649	chr17:43360041~43361361:-
STAD	cis	rs9860428	0.526	rs9823363	ENSG00000240057.4	RP11-572M11.4	-4.8	2.33e-06	0.00139	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112940231	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs9834353	ENSG00000240057.4	RP11-572M11.4	-4.8	2.33e-06	0.00139	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942339	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs9871985	ENSG00000240057.4	RP11-572M11.4	-4.8	2.33e-06	0.00139	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942507	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs9854885	ENSG00000240057.4	RP11-572M11.4	-4.8	2.33e-06	0.00139	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942871	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs4682125	ENSG00000240057.4	RP11-572M11.4	-4.8	2.33e-06	0.00139	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112943772	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs6769091	ENSG00000240057.4	RP11-572M11.4	-4.8	2.33e-06	0.00139	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112943929	chr3:113019532~113183301:+
STAD	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-4.8	2.33e-06	0.00139	-0.31	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
STAD	cis	rs11846409	0.932	rs60917084	ENSG00000211972.2	IGHV3-66	4.8	2.34e-06	0.00139	0.26	0.25	Rheumatic heart disease;	chr14:106634621	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs28378201	ENSG00000211972.2	IGHV3-66	4.8	2.34e-06	0.00139	0.26	0.25	Rheumatic heart disease;	chr14:106637262	chr14:106675017~106675544:-
STAD	cis	rs801193	0.569	rs2659907	ENSG00000224316.1	RP11-479O9.2	4.8	2.34e-06	0.00139	0.25	0.25	Aortic root size;	chr7:66699045	chr7:65773620~65802067:+
STAD	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	4.8	2.34e-06	0.00139	0.25	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
STAD	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-4.8	2.34e-06	0.00139	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
STAD	cis	rs8097348	0.817	rs8098873	ENSG00000266602.1	RP11-476K15.1	4.8	2.34e-06	0.0014	0.29	0.25	Exercise (leisure time);	chr18:1623754	chr18:1509183~1647097:+
STAD	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.34e-06	0.0014	-0.29	-0.25	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	4.8	2.34e-06	0.0014	0.28	0.25	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
STAD	cis	rs7665090	0.934	rs35112949	ENSG00000248971.2	KRT8P46	-4.8	2.34e-06	0.0014	-0.27	-0.25	Primary biliary cholangitis;	chr4:102638473	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.87	rs34349956	ENSG00000248971.2	KRT8P46	-4.8	2.34e-06	0.0014	-0.27	-0.25	Primary biliary cholangitis;	chr4:102638476	chr4:102728746~102730171:-
STAD	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-4.8	2.34e-06	0.0014	-0.28	-0.25	QT interval;	chr12:29287150	chr12:29280418~29317848:-
STAD	cis	rs7818382	0.967	rs7812465	ENSG00000253528.2	RP11-347C18.4	-4.8	2.35e-06	0.0014	-0.22	-0.25	Alzheimer's disease (late onset);	chr8:95038329	chr8:94974573~94974853:-
STAD	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-4.8	2.35e-06	0.0014	-0.25	-0.25	Breast cancer;	chr11:743813	chr11:781645~782105:+
STAD	cis	rs2688608	0.592	rs7909544	ENSG00000271816.1	BMS1P4	4.8	2.35e-06	0.0014	0.27	0.25	Inflammatory bowel disease;	chr10:73724246	chr10:73699151~73730487:-
STAD	cis	rs2688608	0.592	rs10762559	ENSG00000271816.1	BMS1P4	4.8	2.35e-06	0.0014	0.27	0.25	Inflammatory bowel disease;	chr10:73726695	chr10:73699151~73730487:-
STAD	cis	rs4568518	0.535	rs4555993	ENSG00000279048.1	RP11-511H23.2	-4.8	2.35e-06	0.0014	-0.23	-0.25	Measles;	chr7:18022944	chr7:17940503~17942922:+
STAD	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	4.8	2.35e-06	0.0014	0.32	0.25	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
STAD	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	4.8	2.35e-06	0.0014	0.3	0.25	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	4.8	2.35e-06	0.0014	0.3	0.25	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
STAD	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	4.8	2.35e-06	0.0014	0.33	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
STAD	cis	rs3758911	1	rs6588965	ENSG00000261098.1	RP11-819C21.1	-4.8	2.36e-06	0.0014	-0.23	-0.25	Coronary artery disease;	chr11:107330963	chr11:107312132~107316271:-
STAD	cis	rs4589258	1	rs4423148	ENSG00000280367.1	RP11-121L10.2	4.8	2.36e-06	0.00141	0.26	0.25	Intelligence (multi-trait analysis);	chr11:90763285	chr11:90223153~90226538:+
STAD	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-4.8	2.36e-06	0.00141	-0.28	-0.25	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
STAD	cis	rs7665090	0.967	rs6533022	ENSG00000230069.3	LRRC37A15P	-4.8	2.36e-06	0.00141	-0.27	-0.25	Primary biliary cholangitis;	chr4:102637794	chr4:102727274~102730721:-
STAD	cis	rs7932354	0.528	rs11039112	ENSG00000271350.1	CTD-2384B9.1	4.8	2.36e-06	0.00141	0.29	0.25	Bone mineral density (hip);Bone mineral density;	chr11:47152745	chr11:47041027~47041945:-
STAD	cis	rs2404602	0.692	rs1838048	ENSG00000259422.1	RP11-593F23.1	4.8	2.37e-06	0.00141	0.26	0.25	Blood metabolite levels;	chr15:76639338	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs56193230	ENSG00000259422.1	RP11-593F23.1	4.8	2.37e-06	0.00141	0.26	0.25	Blood metabolite levels;	chr15:76642131	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs35077207	ENSG00000259422.1	RP11-593F23.1	4.8	2.37e-06	0.00141	0.26	0.25	Blood metabolite levels;	chr15:76642965	chr15:76174891~76181486:-
STAD	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	4.8	2.37e-06	0.00141	0.29	0.25	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
STAD	cis	rs9463078	0.691	rs1852986	ENSG00000219384.1	RP11-491H9.3	4.8	2.37e-06	0.00141	0.24	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45361752	chr6:45158870~45159511:+
STAD	cis	rs7829975	0.774	rs11249893	ENSG00000173295.6	FAM86B3P	4.8	2.37e-06	0.00141	0.28	0.25	Mood instability;	chr8:8843341	chr8:8228595~8244865:+
STAD	cis	rs891378	1	rs2782828	ENSG00000274245.1	RP11-357P18.2	-4.8	2.37e-06	0.00141	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207323654	chr1:207372559~207373252:+
STAD	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-4.8	2.37e-06	0.00141	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
STAD	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	4.8	2.37e-06	0.00141	0.3	0.25	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
STAD	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	4.8	2.38e-06	0.00141	0.3	0.25	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
STAD	cis	rs227275	0.554	rs223466	ENSG00000248971.2	KRT8P46	-4.8	2.38e-06	0.00142	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102728746~102730171:-
STAD	cis	rs916888	0.821	rs199512	ENSG00000232300.1	FAM215B	-4.8	2.38e-06	0.00142	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46558830~46562795:-
STAD	cis	rs916888	0.821	rs199509	ENSG00000232300.1	FAM215B	-4.8	2.38e-06	0.00142	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46558830~46562795:-
STAD	cis	rs916888	0.821	rs199507	ENSG00000232300.1	FAM215B	-4.8	2.38e-06	0.00142	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46558830~46562795:-
STAD	cis	rs916888	0.821	rs199505	ENSG00000232300.1	FAM215B	-4.8	2.38e-06	0.00142	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46558830~46562795:-
STAD	cis	rs916888	0.821	rs70602	ENSG00000232300.1	FAM215B	-4.8	2.38e-06	0.00142	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46558830~46562795:-
STAD	cis	rs8099594	0.601	rs7235696	ENSG00000266696.1	RP11-30L3.2	4.8	2.38e-06	0.00142	0.24	0.25	Height;	chr18:49388901	chr18:49205912~49208781:+
STAD	cis	rs10986311	0.609	rs944340	ENSG00000227200.1	RP11-121A14.3	-4.8	2.38e-06	0.00142	-0.27	-0.25	Vitiligo;	chr9:124298152	chr9:124262876~124265809:+
STAD	cis	rs13113518	1	rs13113518	ENSG00000223305.1	RN7SKP30	4.8	2.38e-06	0.00142	0.27	0.25	Height;	chr4:55533481	chr4:55540502~55540835:-
STAD	cis	rs7665090	1	rs735405	ENSG00000230069.3	LRRC37A15P	-4.8	2.38e-06	0.00142	-0.27	-0.25	Primary biliary cholangitis;	chr4:102632759	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs1077358	ENSG00000230069.3	LRRC37A15P	-4.8	2.38e-06	0.00142	-0.27	-0.25	Primary biliary cholangitis;	chr4:102632769	chr4:102727274~102730721:-
STAD	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-4.8	2.38e-06	0.00142	-0.25	-0.25	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
STAD	cis	rs10510102	0.872	rs12247367	ENSG00000226864.1	ATE1-AS1	4.8	2.38e-06	0.00142	0.39	0.25	Breast cancer;	chr10:121961556	chr10:121928312~121951965:+
STAD	cis	rs1799949	1	rs8176083	ENSG00000236383.6	LINC00854	-4.8	2.38e-06	0.00142	-0.2	-0.25	Menopause (age at onset);	chr17:43123134	chr17:43216941~43305976:-
STAD	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-4.8	2.38e-06	0.00142	-0.24	-0.25	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
STAD	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-4.8	2.39e-06	0.00142	-0.25	-0.25	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
STAD	cis	rs1056107	0.897	rs10817282	ENSG00000225513.1	RP11-165N19.2	-4.8	2.39e-06	0.00142	-0.29	-0.25	Colorectal cancer;	chr9:112194636	chr9:112173522~112173971:-
STAD	cis	rs9549367	0.789	rs35569628	ENSG00000269125.1	RP11-98F14.11	-4.8	2.39e-06	0.00142	-0.29	-0.25	Platelet distribution width;	chr13:113218398	chr13:113165002~113165183:-
STAD	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	4.8	2.39e-06	0.00142	0.3	0.25	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
STAD	cis	rs4927850	1	rs6799572	ENSG00000242086.7	LINC00969	4.8	2.39e-06	0.00142	0.23	0.25	Pancreatic cancer;	chr3:196013537	chr3:195658062~195739964:+
STAD	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	4.8	2.4e-06	0.00143	0.24	0.25	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
STAD	cis	rs2337406	0.925	rs76288499	ENSG00000280411.1	IGHV1-69-2	-4.8	2.4e-06	0.00143	-0.31	-0.25	Alzheimer's disease (late onset);	chr14:106686309	chr14:106762092~106762588:-
STAD	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	4.8	2.4e-06	0.00143	0.3	0.25	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	4.8	2.4e-06	0.00143	0.3	0.25	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	4.8	2.4e-06	0.00143	0.3	0.25	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	4.8	2.4e-06	0.00143	0.3	0.25	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
STAD	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-4.8	2.4e-06	0.00143	-0.22	-0.25	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
STAD	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	4.8	2.4e-06	0.00143	0.31	0.25	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
STAD	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-4.8	2.4e-06	0.00143	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
STAD	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	4.8	2.4e-06	0.00143	0.3	0.25	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
STAD	cis	rs10510102	0.935	rs78525391	ENSG00000226864.1	ATE1-AS1	4.8	2.4e-06	0.00143	0.41	0.25	Breast cancer;	chr10:121901102	chr10:121928312~121951965:+
STAD	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	4.8	2.4e-06	0.00143	0.27	0.25	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
STAD	cis	rs9463078	0.585	rs1285022	ENSG00000219384.1	RP11-491H9.3	4.8	2.4e-06	0.00143	0.24	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45143275	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs1285023	ENSG00000219384.1	RP11-491H9.3	4.8	2.4e-06	0.00143	0.24	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45144012	chr6:45158870~45159511:+
STAD	cis	rs13113518	1	rs4865013	ENSG00000223305.1	RN7SKP30	4.8	2.4e-06	0.00143	0.28	0.25	Height;	chr4:55559957	chr4:55540502~55540835:-
STAD	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-4.8	2.41e-06	0.00143	-0.32	-0.25	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
STAD	cis	rs7829975	0.871	rs7829826	ENSG00000173295.6	FAM86B3P	-4.8	2.41e-06	0.00143	-0.28	-0.25	Mood instability;	chr8:8720610	chr8:8228595~8244865:+
STAD	cis	rs9784649	0.76	rs17343923	ENSG00000245662.2	RP11-184E9.1	4.8	2.41e-06	0.00143	0.36	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25052305	chr5:25190682~25306172:+
STAD	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	4.8	2.41e-06	0.00143	0.27	0.25	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
STAD	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-4.8	2.41e-06	0.00143	-0.24	-0.25	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
STAD	cis	rs7665090	1	rs6821119	ENSG00000248971.2	KRT8P46	-4.8	2.41e-06	0.00143	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634076	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.934	rs6844332	ENSG00000248971.2	KRT8P46	-4.8	2.41e-06	0.00143	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634095	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.967	rs6821133	ENSG00000248971.2	KRT8P46	-4.8	2.41e-06	0.00143	-0.26	-0.25	Primary biliary cholangitis;	chr4:102634096	chr4:102728746~102730171:-
STAD	cis	rs4589258	0.933	rs4491180	ENSG00000280367.1	RP11-121L10.2	-4.8	2.41e-06	0.00143	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90672856	chr11:90223153~90226538:+
STAD	cis	rs853679	0.527	rs213228	ENSG00000220721.1	OR1F12	4.8	2.41e-06	0.00143	0.26	0.25	Depression;	chr6:28363475	chr6:28073316~28074233:+
STAD	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	4.8	2.41e-06	0.00143	0.43	0.25	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
STAD	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	4.8	2.41e-06	0.00143	0.28	0.25	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
STAD	cis	rs891378	1	rs2914937	ENSG00000274245.1	RP11-357P18.2	-4.8	2.41e-06	0.00143	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207315423	chr1:207372559~207373252:+
STAD	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	4.8	2.41e-06	0.00143	0.27	0.25	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
STAD	cis	rs7474896	0.583	rs11011346	ENSG00000120555.12	SEPT7P9	4.8	2.41e-06	0.00143	0.3	0.25	Obesity (extreme);	chr10:37720555	chr10:38383069~38402916:-
STAD	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.41e-06	0.00144	-0.29	-0.25	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.41e-06	0.00144	-0.29	-0.25	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.41e-06	0.00144	-0.29	-0.25	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.41e-06	0.00144	-0.29	-0.25	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.41e-06	0.00144	-0.29	-0.25	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.41e-06	0.00144	-0.29	-0.25	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.41e-06	0.00144	-0.29	-0.25	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
STAD	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	4.8	2.42e-06	0.00144	0.32	0.25	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
STAD	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	4.8	2.42e-06	0.00144	0.32	0.25	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
STAD	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	4.8	2.42e-06	0.00144	0.32	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
STAD	cis	rs3736858	1	rs61959583	ENSG00000261105.4	LMO7-AS1	-4.8	2.42e-06	0.00144	-0.42	-0.25	Interleukin-9 levels;	chr13:75854458	chr13:75604700~75635994:-
STAD	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	4.8	2.42e-06	0.00144	0.36	0.25	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
STAD	cis	rs2404602	0.692	rs7350777	ENSG00000259422.1	RP11-593F23.1	4.8	2.42e-06	0.00144	0.26	0.25	Blood metabolite levels;	chr15:76693100	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs35395069	ENSG00000259422.1	RP11-593F23.1	4.8	2.42e-06	0.00144	0.26	0.25	Blood metabolite levels;	chr15:76693993	chr15:76174891~76181486:-
STAD	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	4.8	2.42e-06	0.00144	0.28	0.25	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
STAD	cis	rs2404602	0.692	rs35195096	ENSG00000259422.1	RP11-593F23.1	4.79	2.42e-06	0.00144	0.26	0.25	Blood metabolite levels;	chr15:76646106	chr15:76174891~76181486:-
STAD	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-4.79	2.43e-06	0.00144	-0.41	-0.25	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
STAD	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-4.79	2.43e-06	0.00144	-0.41	-0.25	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
STAD	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-4.79	2.43e-06	0.00144	-0.41	-0.25	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
STAD	cis	rs9307551	0.584	rs12508756	ENSG00000250334.4	LINC00989	-4.79	2.43e-06	0.00144	-0.3	-0.25	Refractive error;	chr4:79486715	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.552	rs4975089	ENSG00000250334.4	LINC00989	-4.79	2.43e-06	0.00144	-0.3	-0.25	Refractive error;	chr4:79490790	chr4:79492416~79576460:+
STAD	cis	rs227275	0.554	rs223395	ENSG00000248971.2	KRT8P46	-4.79	2.43e-06	0.00144	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223388	ENSG00000248971.2	KRT8P46	-4.79	2.43e-06	0.00144	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223386	ENSG00000248971.2	KRT8P46	-4.79	2.43e-06	0.00144	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223385	ENSG00000248971.2	KRT8P46	-4.79	2.43e-06	0.00144	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102728746~102730171:-
STAD	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-4.79	2.43e-06	0.00145	-0.25	-0.25	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
STAD	cis	rs13113518	0.513	rs13147861	ENSG00000223305.1	RN7SKP30	4.79	2.43e-06	0.00145	0.29	0.25	Height;	chr4:55611014	chr4:55540502~55540835:-
STAD	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-4.79	2.43e-06	0.00145	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
STAD	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-4.79	2.44e-06	0.00145	-0.19	-0.25	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-4.79	2.44e-06	0.00145	-0.19	-0.25	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-4.79	2.44e-06	0.00145	-0.19	-0.25	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-4.79	2.44e-06	0.00145	-0.19	-0.25	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
STAD	cis	rs7665090	1	rs1054029	ENSG00000230069.3	LRRC37A15P	-4.79	2.44e-06	0.00145	-0.27	-0.25	Primary biliary cholangitis;	chr4:102631896	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs3194585	ENSG00000230069.3	LRRC37A15P	-4.79	2.44e-06	0.00145	-0.27	-0.25	Primary biliary cholangitis;	chr4:102631933	chr4:102727274~102730721:-
STAD	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	4.79	2.44e-06	0.00145	0.32	0.25	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
STAD	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-4.79	2.44e-06	0.00145	-0.21	-0.25	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
STAD	cis	rs9860428	0.844	rs9878913	ENSG00000240057.4	RP11-572M11.4	-4.79	2.44e-06	0.00145	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866272	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs2399442	ENSG00000240057.4	RP11-572M11.4	-4.79	2.44e-06	0.00145	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866426	chr3:113019532~113183301:+
STAD	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	4.79	2.44e-06	0.00145	0.4	0.25	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
STAD	cis	rs8099594	0.64	rs527265	ENSG00000266696.1	RP11-30L3.2	4.79	2.44e-06	0.00145	0.24	0.25	Height;	chr18:49332354	chr18:49205912~49208781:+
STAD	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	4.79	2.45e-06	0.00145	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
STAD	cis	rs7615952	0.673	rs34209763	ENSG00000239804.1	RP11-379B18.1	4.79	2.45e-06	0.00145	0.45	0.25	Blood pressure (smoking interaction);	chr3:125880752	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.8	rs35390120	ENSG00000239804.1	RP11-379B18.1	4.79	2.45e-06	0.00145	0.45	0.25	Blood pressure (smoking interaction);	chr3:125880966	chr3:125787888~125788146:-
STAD	cis	rs12922317	0.86	rs2541583	ENSG00000260224.1	UBL5P4	4.79	2.45e-06	0.00145	0.25	0.25	Schizophrenia;	chr16:12037264	chr16:11968508~11968743:-
STAD	cis	rs227275	0.586	rs223448	ENSG00000248971.2	KRT8P46	-4.79	2.45e-06	0.00145	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102728746~102730171:-
STAD	cis	rs875971	0.545	rs73146609	ENSG00000236529.1	RP13-254B10.1	4.79	2.45e-06	0.00145	0.3	0.25	Aortic root size;	chr7:66302477	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs2173571	ENSG00000236529.1	RP13-254B10.1	4.79	2.45e-06	0.00145	0.3	0.25	Aortic root size;	chr7:66305392	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs11770063	ENSG00000236529.1	RP13-254B10.1	4.79	2.45e-06	0.00145	0.3	0.25	Aortic root size;	chr7:66318029	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs3936065	ENSG00000236529.1	RP13-254B10.1	4.79	2.45e-06	0.00145	0.3	0.25	Aortic root size;	chr7:66325577	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs4718335	ENSG00000236529.1	RP13-254B10.1	4.79	2.45e-06	0.00145	0.3	0.25	Aortic root size;	chr7:66339619	chr7:65840212~65840596:+
STAD	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	4.79	2.45e-06	0.00146	0.33	0.25	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
STAD	cis	rs3770081	1	rs12617717	ENSG00000273080.1	RP11-301O19.1	-4.79	2.45e-06	0.00146	-0.6	-0.25	Facial emotion recognition (sad faces);	chr2:86115180	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs2303339	ENSG00000273080.1	RP11-301O19.1	4.79	2.45e-06	0.00146	0.6	0.25	Facial emotion recognition (sad faces);	chr2:86119057	chr2:86195590~86196049:+
STAD	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-4.79	2.45e-06	0.00146	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
STAD	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.45e-06	0.00146	-0.29	-0.25	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.45e-06	0.00146	-0.29	-0.25	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
STAD	cis	rs10466239	0.73	rs2946992	ENSG00000230555.2	RP11-517P14.2	-4.79	2.46e-06	0.00146	-0.34	-0.25	Telomere length;	chr10:43358831	chr10:43420738~43422100:+
STAD	cis	rs7665090	1	rs2866406	ENSG00000248971.2	KRT8P46	-4.79	2.46e-06	0.00146	-0.26	-0.25	Primary biliary cholangitis;	chr4:102632862	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs2866407	ENSG00000248971.2	KRT8P46	-4.79	2.46e-06	0.00146	-0.26	-0.25	Primary biliary cholangitis;	chr4:102632951	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs2866408	ENSG00000248971.2	KRT8P46	-4.79	2.46e-06	0.00146	-0.26	-0.25	Primary biliary cholangitis;	chr4:102632956	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs2866409	ENSG00000248971.2	KRT8P46	-4.79	2.46e-06	0.00146	-0.26	-0.25	Primary biliary cholangitis;	chr4:102633104	chr4:102728746~102730171:-
STAD	cis	rs728616	0.867	rs61858980	ENSG00000225484.5	NUTM2B-AS1	-4.79	2.46e-06	0.00146	-0.53	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:79663088~79826594:-
STAD	cis	rs7932354	0.536	rs7929294	ENSG00000271350.1	CTD-2384B9.1	-4.79	2.46e-06	0.00146	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46754626	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.583	rs10734548	ENSG00000271350.1	CTD-2384B9.1	-4.79	2.46e-06	0.00146	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46766023	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.583	rs6485692	ENSG00000271350.1	CTD-2384B9.1	-4.79	2.46e-06	0.00146	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46783033	chr11:47041027~47041945:-
STAD	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-4.79	2.46e-06	0.00146	-0.3	-0.25	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
STAD	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	4.79	2.46e-06	0.00146	0.39	0.25	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
STAD	cis	rs3758911	0.861	rs10890721	ENSG00000261098.1	RP11-819C21.1	-4.79	2.46e-06	0.00146	-0.23	-0.25	Coronary artery disease;	chr11:107336876	chr11:107312132~107316271:-
STAD	cis	rs875971	0.502	rs1796227	ENSG00000236529.1	RP13-254B10.1	-4.79	2.46e-06	0.00146	-0.29	-0.25	Aortic root size;	chr7:66622032	chr7:65840212~65840596:+
STAD	cis	rs9393777	0.546	rs9366673	ENSG00000241549.7	GUSBP2	4.79	2.47e-06	0.00146	0.34	0.25	Intelligence (multi-trait analysis);	chr6:26925550	chr6:26871484~26956554:-
STAD	cis	rs4061073	1	rs2297026	ENSG00000198711.5	SSBP3-AS1	-4.79	2.47e-06	0.00146	-0.2	-0.25	Body mass index;	chr1:54228541	chr1:54236440~54239063:+
STAD	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-4.79	2.47e-06	0.00146	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-4.79	2.47e-06	0.00146	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-4.79	2.47e-06	0.00146	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-4.79	2.47e-06	0.00146	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-4.79	2.47e-06	0.00146	-0.27	-0.25	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
STAD	cis	rs916888	0.773	rs199447	ENSG00000232300.1	FAM215B	4.79	2.47e-06	0.00146	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46558830~46562795:-
STAD	cis	rs13392177	0.684	rs6720449	ENSG00000237281.1	CATIP-AS2	4.79	2.47e-06	0.00146	0.26	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218326889~218357966:-
STAD	cis	rs7120173	0.693	rs12799198	ENSG00000254851.1	RP11-109L13.1	-4.79	2.47e-06	0.00146	-0.36	-0.25	Visceral adipose tissue adjusted for BMI;	chr11:116930706	chr11:117135528~117138582:+
STAD	cis	rs9549367	0.713	rs3024744	ENSG00000269125.1	RP11-98F14.11	-4.79	2.47e-06	0.00146	-0.31	-0.25	Platelet distribution width;	chr13:113167163	chr13:113165002~113165183:-
STAD	cis	rs6430585	0.528	rs12464050	ENSG00000231890.6	DARS-AS1	-4.79	2.47e-06	0.00146	-0.28	-0.25	Corneal structure;	chr2:135905540	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.591	rs77096272	ENSG00000231890.6	DARS-AS1	-4.79	2.47e-06	0.00146	-0.28	-0.25	Corneal structure;	chr2:135906035	chr2:135985176~136022593:+
STAD	cis	rs3736858	1	rs9318380	ENSG00000261105.4	LMO7-AS1	-4.79	2.47e-06	0.00146	-0.44	-0.25	Interleukin-9 levels;	chr13:75860990	chr13:75604700~75635994:-
STAD	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	4.79	2.47e-06	0.00147	0.29	0.25	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
STAD	cis	rs7429990	0.965	rs319685	ENSG00000224895.1	VPS26BP1	-4.79	2.47e-06	0.00147	-0.24	-0.25	Educational attainment (years of education);	chr3:47890494	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs319684	ENSG00000224895.1	VPS26BP1	-4.79	2.47e-06	0.00147	-0.24	-0.25	Educational attainment (years of education);	chr3:47890784	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs810334	ENSG00000224895.1	VPS26BP1	-4.79	2.47e-06	0.00147	-0.24	-0.25	Educational attainment (years of education);	chr3:47893813	chr3:47960327~47961081:-
STAD	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	4.79	2.47e-06	0.00147	0.23	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
STAD	cis	rs4970988	0.527	rs12067556	ENSG00000274963.1	Metazoa_SRP	4.79	2.48e-06	0.00147	0.22	0.25	Urate levels;	chr1:150642059	chr1:150568971~150569269:-
STAD	cis	rs7665090	1	rs12498722	ENSG00000248971.2	KRT8P46	-4.79	2.48e-06	0.00147	-0.26	-0.25	Primary biliary cholangitis;	chr4:102633365	chr4:102728746~102730171:-
STAD	cis	rs7845219	0.51	rs10113282	ENSG00000253528.2	RP11-347C18.4	4.79	2.48e-06	0.00147	0.23	0.25	Type 2 diabetes;	chr8:95026024	chr8:94974573~94974853:-
STAD	cis	rs1426063	0.748	rs7654088	ENSG00000260265.1	RP11-44F21.5	-4.79	2.48e-06	0.00147	-0.34	-0.25	QT interval;	chr4:75107103	chr4:75081702~75084717:-
STAD	cis	rs858239	0.6	rs2072369	ENSG00000226816.2	AC005082.12	4.79	2.48e-06	0.00147	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23206013~23208045:+
STAD	cis	rs7078219	0.505	rs1548964	ENSG00000257582.4	LINC01475	4.79	2.48e-06	0.00147	0.28	0.25	Dental caries;	chr10:99529896	chr10:99526350~99531177:-
STAD	cis	rs7487075	0.82	rs4238102	ENSG00000257261.4	RP11-96H19.1	4.79	2.48e-06	0.00147	0.3	0.25	Itch intensity from mosquito bite;	chr12:46332713	chr12:46383679~46876159:+
STAD	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	4.79	2.48e-06	0.00147	0.32	0.25	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
STAD	cis	rs4589258	1	rs2156830	ENSG00000280367.1	RP11-121L10.2	4.79	2.48e-06	0.00147	0.27	0.25	Intelligence (multi-trait analysis);	chr11:90729759	chr11:90223153~90226538:+
STAD	cis	rs1707322	0.752	rs6703748	ENSG00000281133.1	AL355480.3	-4.79	2.48e-06	0.00147	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45580892~45580996:-
STAD	cis	rs728616	0.558	rs35547640	ENSG00000225484.5	NUTM2B-AS1	-4.79	2.49e-06	0.00147	-0.48	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80379394	chr10:79663088~79826594:-
STAD	cis	rs2337406	0.789	rs9324095	ENSG00000211972.2	IGHV3-66	4.79	2.49e-06	0.00147	0.25	0.25	Alzheimer's disease (late onset);	chr14:106795885	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs58154560	ENSG00000211972.2	IGHV3-66	4.79	2.49e-06	0.00147	0.25	0.25	Alzheimer's disease (late onset);	chr14:106799601	chr14:106675017~106675544:-
STAD	cis	rs891378	1	rs1835307	ENSG00000274245.1	RP11-357P18.2	-4.79	2.49e-06	0.00147	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207253220	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs10864175	ENSG00000274245.1	RP11-357P18.2	-4.79	2.49e-06	0.00147	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207260004	chr1:207372559~207373252:+
STAD	cis	rs891378	0.848	rs1579484	ENSG00000274245.1	RP11-357P18.2	-4.79	2.49e-06	0.00147	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207262484	chr1:207372559~207373252:+
STAD	cis	rs891378	0.92	rs4611012	ENSG00000274245.1	RP11-357P18.2	-4.79	2.49e-06	0.00147	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207263470	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs6540896	ENSG00000274245.1	RP11-357P18.2	-4.79	2.49e-06	0.00147	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207267506	chr1:207372559~207373252:+
STAD	cis	rs4713118	0.824	rs7759217	ENSG00000280107.1	AL022393.9	-4.79	2.49e-06	0.00147	-0.33	-0.25	Parkinson's disease;	chr6:27762684	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.784	rs9468219	ENSG00000280107.1	AL022393.9	-4.79	2.49e-06	0.00147	-0.33	-0.25	Parkinson's disease;	chr6:27763976	chr6:28170845~28172521:+
STAD	cis	rs17401966	0.838	rs4846207	ENSG00000199562.1	RNU6-37P	4.79	2.49e-06	0.00147	0.19	0.25	Hepatocellular carcinoma;	chr1:10253753	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs1013952	ENSG00000199562.1	RNU6-37P	4.79	2.49e-06	0.00147	0.19	0.25	Hepatocellular carcinoma;	chr1:10259189	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs1013953	ENSG00000199562.1	RNU6-37P	4.79	2.49e-06	0.00147	0.19	0.25	Hepatocellular carcinoma;	chr1:10259401	chr1:10298966~10299072:+
STAD	cis	rs875971	0.545	rs2707851	ENSG00000236529.1	RP13-254B10.1	-4.79	2.49e-06	0.00147	-0.29	-0.25	Aortic root size;	chr7:66624178	chr7:65840212~65840596:+
STAD	cis	rs1056107	0.897	rs7851129	ENSG00000225513.1	RP11-165N19.2	-4.79	2.49e-06	0.00147	-0.29	-0.25	Colorectal cancer;	chr9:112193127	chr9:112173522~112173971:-
STAD	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-4.79	2.49e-06	0.00147	-0.27	-0.25	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
STAD	cis	rs11749727	0.787	rs13168609	ENSG00000242979.1	RPS15AP18	4.79	2.49e-06	0.00148	0.26	0.25	Initial pursuit acceleration;	chr5:180186262	chr5:179933805~179934196:-
STAD	cis	rs7829975	0.508	rs4841006	ENSG00000253981.4	ALG1L13P	-4.79	2.49e-06	0.00148	-0.29	-0.25	Mood instability;	chr8:8643964	chr8:8236003~8244667:-
STAD	cis	rs539514	0.516	rs9318377	ENSG00000261105.4	LMO7-AS1	-4.79	2.5e-06	0.00148	-0.31	-0.25	Type 1 diabetes;	chr13:75835882	chr13:75604700~75635994:-
STAD	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	4.79	2.5e-06	0.00148	0.29	0.25	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
STAD	cis	rs7567389	0.812	rs6710496	ENSG00000236682.1	AC068282.3	4.79	2.5e-06	0.00148	0.35	0.25	Self-rated health;	chr2:127218798	chr2:127389130~127400580:+
STAD	cis	rs7567389	0.889	rs1504136	ENSG00000236682.1	AC068282.3	4.79	2.5e-06	0.00148	0.35	0.25	Self-rated health;	chr2:127219542	chr2:127389130~127400580:+
STAD	cis	rs4713118	0.621	rs10484403	ENSG00000220721.1	OR1F12	4.79	2.5e-06	0.00148	0.31	0.25	Parkinson's disease;	chr6:28065745	chr6:28073316~28074233:+
STAD	cis	rs2404602	0.655	rs4886824	ENSG00000259422.1	RP11-593F23.1	4.79	2.5e-06	0.00148	0.26	0.25	Blood metabolite levels;	chr15:76676915	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs58361452	ENSG00000259422.1	RP11-593F23.1	4.79	2.5e-06	0.00148	0.26	0.25	Blood metabolite levels;	chr15:76681031	chr15:76174891~76181486:-
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000224205.1	AP000351.4	-4.79	2.5e-06	0.00148	-0.27	-0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23987320~23991421:-
STAD	cis	rs7829975	0.714	rs4840362	ENSG00000254340.1	RP11-10A14.3	-4.79	2.5e-06	0.00148	-0.29	-0.25	Mood instability;	chr8:8812572	chr8:9141424~9145435:+
STAD	cis	rs7665090	1	rs5026476	ENSG00000248971.2	KRT8P46	-4.79	2.5e-06	0.00148	-0.26	-0.25	Primary biliary cholangitis;	chr4:102633753	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.967	rs13106325	ENSG00000248971.2	KRT8P46	-4.79	2.5e-06	0.00148	-0.26	-0.25	Primary biliary cholangitis;	chr4:102633835	chr4:102728746~102730171:-
STAD	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	4.79	2.5e-06	0.00148	0.34	0.25	Depression;	chr6:28402301	chr6:28943877~28944537:+
STAD	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-4.79	2.5e-06	0.00148	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
STAD	cis	rs950881	0.601	rs3771164	ENSG00000234389.1	AC007278.3	4.79	2.5e-06	0.00148	0.33	0.25	Allergy;	chr2:102375326	chr2:102438713~102440475:+
STAD	cis	rs13113518	0.841	rs11133400	ENSG00000223305.1	RN7SKP30	4.79	2.5e-06	0.00148	0.28	0.25	Height;	chr4:55578787	chr4:55540502~55540835:-
STAD	cis	rs2404602	0.692	rs36070630	ENSG00000259422.1	RP11-593F23.1	4.79	2.5e-06	0.00148	0.26	0.25	Blood metabolite levels;	chr15:76656918	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs8037005	ENSG00000259422.1	RP11-593F23.1	4.79	2.5e-06	0.00148	0.26	0.25	Blood metabolite levels;	chr15:76658768	chr15:76174891~76181486:-
STAD	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-4.79	2.5e-06	0.00148	-0.19	-0.25	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
STAD	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-4.79	2.51e-06	0.00148	-0.25	-0.25	Height;	chr5:36963703	chr5:36666214~36725195:-
STAD	cis	rs2836950	0.52	rs8133927	ENSG00000238141.2	BRWD1-AS1	-4.79	2.51e-06	0.00148	-0.26	-0.25	Menarche (age at onset);	chr21:39318035	chr21:39315707~39323218:+
STAD	cis	rs2836950	0.52	rs8133928	ENSG00000238141.2	BRWD1-AS1	-4.79	2.51e-06	0.00148	-0.26	-0.25	Menarche (age at onset);	chr21:39318037	chr21:39315707~39323218:+
STAD	cis	rs2117029	0.898	rs10875914	ENSG00000258017.1	RP11-386G11.10	-4.79	2.51e-06	0.00148	-0.25	-0.25	Intelligence (multi-trait analysis);	chr12:49028311	chr12:49127782~49147869:+
STAD	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-4.79	2.51e-06	0.00148	-0.36	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
STAD	cis	rs11676348	0.818	rs7425447	ENSG00000237281.1	CATIP-AS2	4.79	2.51e-06	0.00148	0.25	0.25	Ulcerative colitis;	chr2:218115460	chr2:218326889~218357966:-
STAD	cis	rs7829975	0.627	rs876954	ENSG00000173295.6	FAM86B3P	4.79	2.51e-06	0.00148	0.29	0.25	Mood instability;	chr8:8453413	chr8:8228595~8244865:+
STAD	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	4.79	2.51e-06	0.00148	0.26	0.25	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
STAD	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-4.79	2.51e-06	0.00149	-0.19	-0.25	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
STAD	cis	rs3758911	0.861	rs11212175	ENSG00000261098.1	RP11-819C21.1	-4.79	2.51e-06	0.00149	-0.23	-0.25	Coronary artery disease;	chr11:107348581	chr11:107312132~107316271:-
STAD	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	4.79	2.52e-06	0.00149	0.27	0.25	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
STAD	cis	rs4713118	0.955	rs9380011	ENSG00000280107.1	AL022393.9	-4.79	2.52e-06	0.00149	-0.33	-0.25	Parkinson's disease;	chr6:27716145	chr6:28170845~28172521:+
STAD	cis	rs9813712	0.574	rs35856399	ENSG00000253540.4	FAM86HP	-4.79	2.52e-06	0.00149	-0.27	-0.25	Response to amphetamines;	chr3:130241961	chr3:130099092~130111472:-
STAD	cis	rs11169552	0.51	rs4768907	ENSG00000200183.1	RNU6-238P	-4.79	2.52e-06	0.00149	-0.24	-0.25	Colorectal cancer;	chr12:50725524	chr12:50656973~50657078:+
STAD	cis	rs9549367	0.756	rs9549702	ENSG00000269125.1	RP11-98F14.11	-4.79	2.52e-06	0.00149	-0.29	-0.25	Platelet distribution width;	chr13:113227630	chr13:113165002~113165183:-
STAD	cis	rs9733	0.65	rs1971378	ENSG00000274963.1	Metazoa_SRP	-4.79	2.52e-06	0.00149	-0.2	-0.25	Tonsillectomy;	chr1:150624785	chr1:150568971~150569269:-
STAD	cis	rs6432852	0.516	rs12477613	ENSG00000232411.1	AC009495.3	4.79	2.52e-06	0.00149	0.27	0.25	Diabetic kidney disease;	chr2:165860674	chr2:165833048~165839098:-
STAD	cis	rs507080	0.922	rs642662	ENSG00000278376.1	RP11-158I9.8	-4.79	2.52e-06	0.00149	-0.26	-0.25	Serum metabolite levels;	chr11:118696311	chr11:118791254~118793137:+
STAD	cis	rs747650	0.504	rs4752816	ENSG00000271350.1	CTD-2384B9.1	-4.79	2.52e-06	0.00149	-0.32	-0.25	Acne (severe);	chr11:46957472	chr11:47041027~47041945:-
STAD	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	4.79	2.52e-06	0.00149	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	4.79	2.52e-06	0.00149	0.3	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
STAD	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-4.79	2.52e-06	0.00149	-0.26	-0.25	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
STAD	cis	rs17660992	0.603	rs59485321	ENSG00000273837.1	LLNLR-470E3.1	-4.79	2.52e-06	0.00149	-0.3	-0.25	Blood protein levels;	chr19:51660710	chr19:51639478~51639931:-
STAD	cis	rs181553	0.664	rs7241593	ENSG00000266696.1	RP11-30L3.2	4.79	2.53e-06	0.00149	0.23	0.25	Hip circumference adjusted for BMI;	chr18:49173711	chr18:49205912~49208781:+
STAD	cis	rs7829975	0.684	rs474892	ENSG00000173295.6	FAM86B3P	-4.79	2.53e-06	0.00149	-0.28	-0.25	Mood instability;	chr8:8739221	chr8:8228595~8244865:+
STAD	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.53e-06	0.00149	-0.29	-0.25	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.53e-06	0.00149	-0.29	-0.25	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.53e-06	0.00149	-0.29	-0.25	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.53e-06	0.00149	-0.29	-0.25	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.53e-06	0.00149	-0.29	-0.25	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
STAD	cis	rs721917	0.506	rs2254016	ENSG00000244733.5	RP11-506M13.3	-4.79	2.53e-06	0.00149	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79660891~79677996:+
STAD	cis	rs858239	0.899	rs10262243	ENSG00000226816.2	AC005082.12	4.79	2.53e-06	0.00149	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23206013~23208045:+
STAD	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.53e-06	0.00149	-0.28	-0.25	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
STAD	cis	rs7674212	1	rs7691873	ENSG00000230069.3	LRRC37A15P	4.79	2.53e-06	0.00149	0.28	0.25	Type 2 diabetes;	chr4:103066742	chr4:102727274~102730721:-
STAD	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-4.79	2.53e-06	0.00149	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
STAD	cis	rs357618	1	rs165351	ENSG00000260581.1	CTB-113P19.4	4.79	2.53e-06	0.0015	0.28	0.25	Basophil percentage of white cells;	chr5:151475320	chr5:151652275~151655449:+
STAD	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-4.79	2.53e-06	0.0015	-0.25	-0.25	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
STAD	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-4.79	2.53e-06	0.0015	-0.19	-0.25	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
STAD	cis	rs9860428	0.526	rs7615462	ENSG00000240057.4	RP11-572M11.4	-4.78	2.54e-06	0.0015	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112934306	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs7615572	ENSG00000240057.4	RP11-572M11.4	-4.78	2.54e-06	0.0015	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112934486	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs9877631	ENSG00000240057.4	RP11-572M11.4	-4.78	2.54e-06	0.0015	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112936287	chr3:113019532~113183301:+
STAD	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	4.78	2.54e-06	0.0015	0.32	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
STAD	cis	rs3736858	0.932	rs17065145	ENSG00000261105.4	LMO7-AS1	-4.78	2.54e-06	0.0015	-0.41	-0.25	Interleukin-9 levels;	chr13:75854052	chr13:75604700~75635994:-
STAD	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-4.78	2.54e-06	0.0015	-0.29	-0.25	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
STAD	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-4.78	2.54e-06	0.0015	-0.25	-0.25	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
STAD	cis	rs1707322	0.752	rs11211168	ENSG00000225447.1	RPS15AP10	4.78	2.55e-06	0.0015	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs11211171	ENSG00000225447.1	RPS15AP10	4.78	2.55e-06	0.0015	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs28623463	ENSG00000225447.1	RPS15AP10	4.78	2.55e-06	0.0015	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.716	rs28370457	ENSG00000225447.1	RPS15AP10	4.78	2.55e-06	0.0015	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45645816~45646197:-
STAD	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-4.78	2.55e-06	0.0015	-0.25	-0.25	Height;	chr5:36982949	chr5:36666214~36725195:-
STAD	cis	rs7119038	0.818	rs11217042	ENSG00000255422.1	AP002954.4	4.78	2.55e-06	0.0015	0.32	0.25	Sjögren's syndrome;	chr11:118811819	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.818	rs17122453	ENSG00000255422.1	AP002954.4	4.78	2.55e-06	0.0015	0.32	0.25	Sjögren's syndrome;	chr11:118812855	chr11:118704607~118750263:+
STAD	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-4.78	2.55e-06	0.0015	-0.3	-0.25	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
STAD	cis	rs1707322	0.686	rs1084086	ENSG00000225447.1	RPS15AP10	-4.78	2.55e-06	0.00151	-0.2	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45645816~45646197:-
STAD	cis	rs875971	0.83	rs6976714	ENSG00000236529.1	RP13-254B10.1	4.78	2.55e-06	0.00151	0.26	0.25	Aortic root size;	chr7:66426474	chr7:65840212~65840596:+
STAD	cis	rs4589258	1	rs2187536	ENSG00000280367.1	RP11-121L10.2	-4.78	2.55e-06	0.00151	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90730107	chr11:90223153~90226538:+
STAD	cis	rs875971	0.545	rs13311962	ENSG00000236529.1	RP13-254B10.1	-4.78	2.55e-06	0.00151	-0.29	-0.25	Aortic root size;	chr7:66603142	chr7:65840212~65840596:+
STAD	cis	rs7078219	0.714	rs12414770	ENSG00000228778.1	RP11-129J12.1	-4.78	2.55e-06	0.00151	-0.32	-0.25	Dental caries;	chr10:99528481	chr10:99527081~99528261:+
STAD	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-4.78	2.55e-06	0.00151	-0.27	-0.25	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
STAD	cis	rs9910055	0.53	rs7222349	ENSG00000260793.2	RP5-882C2.2	-4.78	2.56e-06	0.00151	-0.28	-0.25	Total body bone mineral density;	chr17:44227276	chr17:44221401~44223710:+
STAD	cis	rs8028182	0.525	rs9920028	ENSG00000260269.4	CTD-2323K18.1	-4.78	2.56e-06	0.00151	-0.32	-0.25	Sudden cardiac arrest;	chr15:75635376	chr15:75527150~75601205:-
STAD	cis	rs227275	0.554	rs223363	ENSG00000248971.2	KRT8P46	-4.78	2.56e-06	0.00151	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102728746~102730171:-
STAD	cis	rs2638953	0.853	rs10843179	ENSG00000247934.4	RP11-967K21.1	4.78	2.56e-06	0.00151	0.28	0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28163298~28190738:-
STAD	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-4.78	2.56e-06	0.00151	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
STAD	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	4.78	2.56e-06	0.00151	0.35	0.25	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
STAD	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-4.78	2.56e-06	0.00151	-0.25	-0.25	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
STAD	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-4.78	2.56e-06	0.00151	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
STAD	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	4.78	2.56e-06	0.00151	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
STAD	cis	rs1757171	0.542	rs3818986	ENSG00000204110.6	RP1-153P14.8	-4.78	2.57e-06	0.00151	-0.27	-0.25	Cognitive performance;	chr6:37516573	chr6:37507348~37535616:+
STAD	cis	rs748404	0.518	rs2176870	ENSG00000249839.1	AC011330.5	4.78	2.57e-06	0.00151	0.34	0.25	Lung cancer;	chr15:43144212	chr15:43663654~43684339:-
STAD	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	4.78	2.57e-06	0.00151	0.25	0.25	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
STAD	cis	rs2337406	0.706	rs74090742	ENSG00000211972.2	IGHV3-66	4.78	2.57e-06	0.00152	0.29	0.25	Alzheimer's disease (late onset);	chr14:106696601	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.85	rs8014460	ENSG00000211972.2	IGHV3-66	4.78	2.57e-06	0.00152	0.29	0.25	Alzheimer's disease (late onset);	chr14:106697140	chr14:106675017~106675544:-
STAD	cis	rs2404602	0.692	rs7163397	ENSG00000259422.1	RP11-593F23.1	4.78	2.57e-06	0.00152	0.26	0.25	Blood metabolite levels;	chr15:76647974	chr15:76174891~76181486:-
STAD	cis	rs1799949	0.86	rs8176279	ENSG00000236383.6	LINC00854	-4.78	2.57e-06	0.00152	-0.2	-0.25	Menopause (age at onset);	chr17:43058379	chr17:43216941~43305976:-
STAD	cis	rs4243830	0.85	rs7552196	ENSG00000229519.2	RP11-58A11.2	4.78	2.57e-06	0.00152	0.27	0.25	Body mass index;	chr1:6530442	chr1:6547905~6548619:+
STAD	cis	rs11169552	0.51	rs4768858	ENSG00000200183.1	RNU6-238P	-4.78	2.58e-06	0.00152	-0.24	-0.25	Colorectal cancer;	chr12:50646035	chr12:50656973~50657078:+
STAD	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	4.78	2.58e-06	0.00152	0.39	0.25	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	4.78	2.58e-06	0.00152	0.39	0.25	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
STAD	cis	rs2404602	0.692	rs8024476	ENSG00000259422.1	RP11-593F23.1	4.78	2.58e-06	0.00152	0.26	0.25	Blood metabolite levels;	chr15:76691613	chr15:76174891~76181486:-
STAD	cis	rs7665090	1	rs2903283	ENSG00000230069.3	LRRC37A15P	-4.78	2.58e-06	0.00152	-0.27	-0.25	Primary biliary cholangitis;	chr4:102636596	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs4579121	ENSG00000230069.3	LRRC37A15P	-4.78	2.58e-06	0.00152	-0.27	-0.25	Primary biliary cholangitis;	chr4:102637012	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.934	rs6533020	ENSG00000230069.3	LRRC37A15P	-4.78	2.58e-06	0.00152	-0.27	-0.25	Primary biliary cholangitis;	chr4:102637648	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.934	rs6533021	ENSG00000230069.3	LRRC37A15P	-4.78	2.58e-06	0.00152	-0.27	-0.25	Primary biliary cholangitis;	chr4:102637696	chr4:102727274~102730721:-
STAD	cis	rs6430585	0.583	rs59213715	ENSG00000231890.6	DARS-AS1	-4.78	2.58e-06	0.00152	-0.28	-0.25	Corneal structure;	chr2:135889012	chr2:135985176~136022593:+
STAD	cis	rs2337406	0.866	rs4280141	ENSG00000211972.2	IGHV3-66	-4.78	2.58e-06	0.00152	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106780476	chr14:106675017~106675544:-
STAD	cis	rs7665090	1	rs7665090	ENSG00000230069.3	LRRC37A15P	4.78	2.58e-06	0.00152	0.27	0.25	Primary biliary cholangitis;	chr4:102630446	chr4:102727274~102730721:-
STAD	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	4.78	2.58e-06	0.00152	0.32	0.25	Myopia;	chr6:28302807	chr6:28943877~28944537:+
STAD	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	4.78	2.58e-06	0.00152	0.36	0.25	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
STAD	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-4.78	2.58e-06	0.00152	-0.26	-0.25	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-4.78	2.58e-06	0.00152	-0.26	-0.25	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
STAD	cis	rs6142102	0.812	rs6059574	ENSG00000275784.1	RP5-1125A11.6	4.78	2.59e-06	0.00152	0.25	0.25	Skin pigmentation;	chr20:33935366	chr20:33989480~33991818:-
STAD	cis	rs7487075	0.504	rs1000405	ENSG00000272369.1	RP11-446N19.1	4.78	2.59e-06	0.00152	0.31	0.25	Itch intensity from mosquito bite;	chr12:46262739	chr12:46537502~46652550:+
STAD	cis	rs172166	0.516	rs1225710	ENSG00000220721.1	OR1F12	-4.78	2.59e-06	0.00152	-0.25	-0.25	Cardiac Troponin-T levels;	chr6:28132862	chr6:28073316~28074233:+
STAD	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-4.78	2.59e-06	0.00153	-0.29	-0.25	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
STAD	cis	rs9733	0.818	rs7520022	ENSG00000274963.1	Metazoa_SRP	-4.78	2.59e-06	0.00153	-0.2	-0.25	Tonsillectomy;	chr1:150686697	chr1:150568971~150569269:-
STAD	cis	rs4713118	0.869	rs9461405	ENSG00000280107.1	AL022393.9	-4.78	2.59e-06	0.00153	-0.33	-0.25	Parkinson's disease;	chr6:27751596	chr6:28170845~28172521:+
STAD	cis	rs6095360	0.727	rs6095391	ENSG00000222365.1	SNORD12B	-4.78	2.59e-06	0.00153	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:49002298	chr20:49280319~49280409:+
STAD	cis	rs2404602	0.692	rs35498563	ENSG00000259422.1	RP11-593F23.1	4.78	2.59e-06	0.00153	0.26	0.25	Blood metabolite levels;	chr15:76666527	chr15:76174891~76181486:-
STAD	cis	rs7665090	1	rs1054029	ENSG00000248971.2	KRT8P46	-4.78	2.59e-06	0.00153	-0.26	-0.25	Primary biliary cholangitis;	chr4:102631896	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs3194585	ENSG00000248971.2	KRT8P46	-4.78	2.59e-06	0.00153	-0.26	-0.25	Primary biliary cholangitis;	chr4:102631933	chr4:102728746~102730171:-
STAD	cis	rs10483853	0.579	rs58546337	ENSG00000258695.2	RP3-414A15.2	-4.78	2.59e-06	0.00153	-0.33	-0.25	Coronary artery calcification;	chr14:73483753	chr14:73522878~73530610:+
STAD	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-4.78	2.59e-06	0.00153	-0.26	-0.25	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
STAD	cis	rs7826238	0.601	rs2979206	ENSG00000254340.1	RP11-10A14.3	4.78	2.59e-06	0.00153	0.29	0.25	Systolic blood pressure;	chr8:8488071	chr8:9141424~9145435:+
STAD	cis	rs2281636	0.691	rs11190218	ENSG00000233690.1	EBAG9P1	4.78	2.59e-06	0.00153	0.28	0.25	Obesity-related traits;	chr10:99650305	chr10:99697407~99697949:-
STAD	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-4.78	2.6e-06	0.00153	-0.3	-0.25	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
STAD	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	4.78	2.6e-06	0.00153	0.31	0.25	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.908	rs28499576	ENSG00000260091.1	RP11-33B1.4	4.78	2.6e-06	0.00153	0.24	0.25	Corneal astigmatism;	chr4:119465522	chr4:119409333~119410233:+
STAD	cis	rs172166	0.694	rs203876	ENSG00000220721.1	OR1F12	4.78	2.6e-06	0.00153	0.27	0.25	Cardiac Troponin-T levels;	chr6:28078895	chr6:28073316~28074233:+
STAD	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-4.78	2.6e-06	0.00153	-0.39	-0.25	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
STAD	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-4.78	2.6e-06	0.00153	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-4.78	2.6e-06	0.00153	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
STAD	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	4.78	2.6e-06	0.00153	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
STAD	cis	rs858239	0.6	rs28646184	ENSG00000226816.2	AC005082.12	4.78	2.6e-06	0.00153	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs7785842	ENSG00000226816.2	AC005082.12	4.78	2.6e-06	0.00153	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs7456915	ENSG00000226816.2	AC005082.12	4.78	2.6e-06	0.00153	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs13438179	ENSG00000226816.2	AC005082.12	4.78	2.6e-06	0.00153	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23206013~23208045:+
STAD	cis	rs7932354	0.536	rs10838620	ENSG00000271350.1	CTD-2384B9.1	-4.78	2.6e-06	0.00153	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46796548	chr11:47041027~47041945:-
STAD	cis	rs227275	0.554	rs223424	ENSG00000248971.2	KRT8P46	-4.78	2.6e-06	0.00153	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102728746~102730171:-
STAD	cis	rs875971	1	rs2087647	ENSG00000236529.1	RP13-254B10.1	-4.78	2.6e-06	0.00153	-0.26	-0.25	Aortic root size;	chr7:66128201	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6958484	ENSG00000236529.1	RP13-254B10.1	-4.78	2.6e-06	0.00153	-0.26	-0.25	Aortic root size;	chr7:66134459	chr7:65840212~65840596:+
STAD	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	4.78	2.6e-06	0.00153	0.29	0.25	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
STAD	cis	rs831571	0.668	rs34723451	ENSG00000280620.1	SCAANT1	4.78	2.61e-06	0.00153	0.36	0.25	Type 2 diabetes;	chr3:64096160	chr3:63911518~63911772:-
STAD	cis	rs2337406	0.789	rs112027230	ENSG00000211972.2	IGHV3-66	4.78	2.61e-06	0.00153	0.27	0.25	Alzheimer's disease (late onset);	chr14:106810329	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-4.78	2.61e-06	0.00153	-0.19	-0.25	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
STAD	cis	rs7665090	0.87	rs228614	ENSG00000248971.2	KRT8P46	4.78	2.61e-06	0.00154	0.26	0.25	Primary biliary cholangitis;	chr4:102657480	chr4:102728746~102730171:-
STAD	cis	rs6832769	1	rs28514423	ENSG00000272969.1	RP11-528I4.2	-4.78	2.61e-06	0.00154	-0.32	-0.25	Personality dimensions;	chr4:55563072	chr4:55547112~55547889:+
STAD	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	4.78	2.61e-06	0.00154	0.36	0.25	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
STAD	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	4.78	2.62e-06	0.00154	0.25	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
STAD	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-4.78	2.62e-06	0.00154	-0.39	-0.25	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
STAD	cis	rs2337406	0.866	rs112089985	ENSG00000280411.1	IGHV1-69-2	-4.78	2.62e-06	0.00154	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106780074	chr14:106762092~106762588:-
STAD	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-4.78	2.62e-06	0.00154	-0.37	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
STAD	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-4.78	2.62e-06	0.00154	-0.27	-0.25	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
STAD	cis	rs8097348	0.779	rs4141814	ENSG00000266602.1	RP11-476K15.1	-4.78	2.62e-06	0.00154	-0.28	-0.25	Exercise (leisure time);	chr18:1669426	chr18:1509183~1647097:+
STAD	cis	rs6095360	0.649	rs34832487	ENSG00000222365.1	SNORD12B	-4.78	2.62e-06	0.00154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:48930575	chr20:49280319~49280409:+
STAD	cis	rs13113518	0.678	rs7663650	ENSG00000223305.1	RN7SKP30	-4.78	2.62e-06	0.00154	-0.28	-0.25	Height;	chr4:55364952	chr4:55540502~55540835:-
STAD	cis	rs2404602	0.74	rs34924128	ENSG00000259422.1	RP11-593F23.1	4.78	2.62e-06	0.00154	0.26	0.25	Blood metabolite levels;	chr15:76672828	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.692	rs67010831	ENSG00000259422.1	RP11-593F23.1	4.78	2.62e-06	0.00154	0.26	0.25	Blood metabolite levels;	chr15:76672967	chr15:76174891~76181486:-
STAD	cis	rs12554020	0.579	rs59326991	ENSG00000227603.1	RP11-165J3.6	4.78	2.62e-06	0.00154	0.47	0.25	Schizophrenia;	chr9:93473603	chr9:93435332~93437121:-
STAD	cis	rs875971	0.862	rs880166	ENSG00000236529.1	RP13-254B10.1	-4.78	2.62e-06	0.00154	-0.26	-0.25	Aortic root size;	chr7:66205775	chr7:65840212~65840596:+
STAD	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	4.78	2.63e-06	0.00155	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
STAD	cis	rs12701220	0.503	rs12702047	ENSG00000229043.2	AC091729.9	-4.78	2.63e-06	0.00155	-0.4	-0.25	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1160374~1165267:+
STAD	cis	rs7665090	1	rs735405	ENSG00000248971.2	KRT8P46	-4.78	2.63e-06	0.00155	-0.26	-0.25	Primary biliary cholangitis;	chr4:102632759	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs1077358	ENSG00000248971.2	KRT8P46	-4.78	2.63e-06	0.00155	-0.26	-0.25	Primary biliary cholangitis;	chr4:102632769	chr4:102728746~102730171:-
STAD	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-4.78	2.63e-06	0.00155	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
STAD	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-4.78	2.63e-06	0.00155	-0.19	-0.25	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
STAD	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-4.78	2.63e-06	0.00155	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-4.78	2.63e-06	0.00155	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
STAD	cis	rs7932354	0.583	rs7107778	ENSG00000271350.1	CTD-2384B9.1	-4.78	2.64e-06	0.00155	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46839304	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.536	rs1551744	ENSG00000271350.1	CTD-2384B9.1	-4.78	2.64e-06	0.00155	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46843449	chr11:47041027~47041945:-
STAD	cis	rs10510102	0.935	rs11200257	ENSG00000226864.1	ATE1-AS1	4.78	2.64e-06	0.00155	0.4	0.25	Breast cancer;	chr10:121917232	chr10:121928312~121951965:+
STAD	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	4.78	2.64e-06	0.00155	0.35	0.25	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
STAD	cis	rs393951	1	rs1809055	ENSG00000260969.1	RP11-190D6.2	-4.78	2.64e-06	0.00155	-0.3	-0.25	Childhood ear infection;	chr16:77585946	chr16:78237362~78241218:-
STAD	cis	rs11038871	1	rs1317826	ENSG00000271350.1	CTD-2384B9.1	4.78	2.64e-06	0.00155	0.31	0.25	Immunoglobulin A;	chr11:46366318	chr11:47041027~47041945:-
STAD	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-4.78	2.64e-06	0.00155	-0.28	-0.25	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
STAD	cis	rs875971	0.651	rs2420596	ENSG00000236529.1	RP13-254B10.1	4.78	2.64e-06	0.00155	0.26	0.25	Aortic root size;	chr7:66450996	chr7:65840212~65840596:+
STAD	cis	rs875971	0.52	rs2420597	ENSG00000236529.1	RP13-254B10.1	4.78	2.64e-06	0.00155	0.26	0.25	Aortic root size;	chr7:66450999	chr7:65840212~65840596:+
STAD	cis	rs4950322	0.57	rs17356492	ENSG00000278811.3	LINC00624	4.78	2.64e-06	0.00155	0.27	0.25	Protein quantitative trait loci;	chr1:147296089	chr1:147258885~147517875:-
STAD	cis	rs5758659	1	rs5758659	ENSG00000182057.4	OGFRP1	4.78	2.64e-06	0.00155	0.26	0.25	Cognitive function;	chr22:42225997	chr22:42269753~42275196:+
STAD	cis	rs4713118	0.621	rs9295755	ENSG00000220721.1	OR1F12	-4.78	2.65e-06	0.00156	-0.29	-0.25	Parkinson's disease;	chr6:28065396	chr6:28073316~28074233:+
STAD	cis	rs916888	0.821	rs70600	ENSG00000232300.1	FAM215B	4.78	2.65e-06	0.00156	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46558830~46562795:-
STAD	cis	rs7580658	0.521	rs35577992	ENSG00000200250.1	RNU6-1147P	4.78	2.66e-06	0.00156	0.24	0.25	Protein C levels;	chr2:127183748	chr2:127316873~127316979:+
STAD	cis	rs891378	1	rs877049	ENSG00000274245.1	RP11-357P18.2	-4.78	2.66e-06	0.00156	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207249651	chr1:207372559~207373252:+
STAD	cis	rs7429990	0.965	rs1550914	ENSG00000224895.1	VPS26BP1	-4.78	2.66e-06	0.00156	-0.25	-0.25	Educational attainment (years of education);	chr3:47953678	chr3:47960327~47961081:-
STAD	cis	rs10510102	0.872	rs7916008	ENSG00000226864.1	ATE1-AS1	4.78	2.66e-06	0.00156	0.39	0.25	Breast cancer;	chr10:121943578	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs7916380	ENSG00000226864.1	ATE1-AS1	4.78	2.66e-06	0.00156	0.39	0.25	Breast cancer;	chr10:121943773	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.808	rs7920024	ENSG00000226864.1	ATE1-AS1	4.78	2.66e-06	0.00156	0.39	0.25	Breast cancer;	chr10:121944063	chr10:121928312~121951965:+
STAD	cis	rs8099594	0.64	rs528691	ENSG00000266696.1	RP11-30L3.2	4.78	2.66e-06	0.00156	0.25	0.25	Height;	chr18:49343863	chr18:49205912~49208781:+
STAD	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	4.77	2.66e-06	0.00156	0.31	0.25	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
STAD	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-4.77	2.66e-06	0.00156	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
STAD	cis	rs7487075	0.619	rs10785629	ENSG00000257261.4	RP11-96H19.1	4.77	2.66e-06	0.00156	0.3	0.25	Itch intensity from mosquito bite;	chr12:46460944	chr12:46383679~46876159:+
STAD	cis	rs12534093	0.562	rs6461715	ENSG00000234286.1	AC006026.13	-4.77	2.66e-06	0.00156	-0.33	-0.25	Infant length;Height;	chr7:23539496	chr7:23680195~23680786:-
STAD	cis	rs10971721	0.554	rs55917897	ENSG00000281128.1	PTENP1-AS	4.77	2.66e-06	0.00156	0.45	0.25	Body mass index;	chr9:33795952	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.643	rs12378415	ENSG00000281128.1	PTENP1-AS	4.77	2.66e-06	0.00156	0.45	0.25	Body mass index;	chr9:33797335	chr9:33677268~33688011:+
STAD	cis	rs2404602	0.679	rs12908421	ENSG00000259422.1	RP11-593F23.1	4.77	2.66e-06	0.00156	0.26	0.25	Blood metabolite levels;	chr15:76589453	chr15:76174891~76181486:-
STAD	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-4.77	2.66e-06	0.00156	-0.27	-0.25	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
STAD	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-4.77	2.66e-06	0.00156	-0.31	-0.25	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
STAD	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-4.77	2.67e-06	0.00156	-0.22	-0.25	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
STAD	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-4.77	2.67e-06	0.00157	-0.28	-0.25	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
STAD	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	4.77	2.67e-06	0.00157	0.27	0.25	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
STAD	cis	rs891378	1	rs1507758	ENSG00000274245.1	RP11-357P18.2	-4.77	2.67e-06	0.00157	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207334136	chr1:207372559~207373252:+
STAD	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	4.77	2.67e-06	0.00157	0.27	0.25	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
STAD	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-4.77	2.67e-06	0.00157	-0.28	-0.25	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
STAD	cis	rs1707322	0.752	rs11488313	ENSG00000225447.1	RPS15AP10	4.77	2.67e-06	0.00157	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45645816~45646197:-
STAD	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	4.77	2.67e-06	0.00157	0.31	0.25	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
STAD	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-4.77	2.67e-06	0.00157	-0.36	-0.25	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
STAD	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	4.77	2.67e-06	0.00157	0.33	0.25	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
STAD	cis	rs9307551	0.584	rs1115519	ENSG00000250334.4	LINC00989	-4.77	2.67e-06	0.00157	-0.3	-0.25	Refractive error;	chr4:79491857	chr4:79492416~79576460:+
STAD	cis	rs7916697	0.593	rs7912895	ENSG00000233590.1	RP11-153K11.3	-4.77	2.67e-06	0.00157	-0.29	-0.25	Optic disc area;	chr10:68261741	chr10:68233251~68242379:-
STAD	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	4.77	2.67e-06	0.00157	0.37	0.25	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
STAD	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-4.77	2.67e-06	0.00157	-0.32	-0.25	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
STAD	cis	rs7429990	0.864	rs13094264	ENSG00000224895.1	VPS26BP1	4.77	2.68e-06	0.00157	0.24	0.25	Educational attainment (years of education);	chr3:47722723	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs4858851	ENSG00000224895.1	VPS26BP1	4.77	2.68e-06	0.00157	0.24	0.25	Educational attainment (years of education);	chr3:47724165	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.833	rs34777284	ENSG00000224895.1	VPS26BP1	4.77	2.68e-06	0.00157	0.24	0.25	Educational attainment (years of education);	chr3:47726585	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.833	rs7649393	ENSG00000224895.1	VPS26BP1	4.77	2.68e-06	0.00157	0.24	0.25	Educational attainment (years of education);	chr3:47727501	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7638103	ENSG00000224895.1	VPS26BP1	4.77	2.68e-06	0.00157	0.24	0.25	Educational attainment (years of education);	chr3:47727585	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs11130148	ENSG00000224895.1	VPS26BP1	4.77	2.68e-06	0.00157	0.24	0.25	Educational attainment (years of education);	chr3:47729797	chr3:47960327~47961081:-
STAD	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	4.77	2.68e-06	0.00157	0.25	0.25	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
STAD	cis	rs7429990	0.932	rs60446735	ENSG00000224895.1	VPS26BP1	-4.77	2.68e-06	0.00157	-0.25	-0.25	Educational attainment (years of education);	chr3:47929958	chr3:47960327~47961081:-
STAD	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-4.77	2.68e-06	0.00157	-0.35	-0.25	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
STAD	cis	rs858239	0.669	rs1006709	ENSG00000230042.1	AK3P3	-4.77	2.68e-06	0.00157	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23129178~23129841:+
STAD	cis	rs1707322	0.752	rs28719889	ENSG00000225447.1	RPS15AP10	4.77	2.68e-06	0.00157	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs28812624	ENSG00000225447.1	RPS15AP10	4.77	2.68e-06	0.00157	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs28568986	ENSG00000225447.1	RPS15AP10	4.77	2.68e-06	0.00157	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.717	rs10890345	ENSG00000225447.1	RPS15AP10	4.77	2.68e-06	0.00157	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10789471	ENSG00000225447.1	RPS15AP10	4.77	2.68e-06	0.00157	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs11211173	ENSG00000225447.1	RPS15AP10	4.77	2.68e-06	0.00157	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45645816~45646197:-
STAD	cis	rs858239	1	rs858240	ENSG00000230042.1	AK3P3	-4.77	2.68e-06	0.00157	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23129178~23129841:+
STAD	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-4.77	2.68e-06	0.00157	-0.29	-0.25	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
STAD	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-4.77	2.68e-06	0.00157	-0.29	-0.25	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
STAD	cis	rs240993	0.812	rs7766610	ENSG00000230177.1	RP5-1112D6.4	-4.77	2.68e-06	0.00157	-0.25	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111277932~111278742:+
STAD	cis	rs858239	0.511	rs10256996	ENSG00000226816.2	AC005082.12	-4.77	2.68e-06	0.00157	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23206013~23208045:+
STAD	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	4.77	2.68e-06	0.00157	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
STAD	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-4.77	2.68e-06	0.00157	-0.29	-0.25	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
STAD	cis	rs2337406	0.866	rs7152809	ENSG00000280411.1	IGHV1-69-2	-4.77	2.68e-06	0.00157	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106778385	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs7152832	ENSG00000280411.1	IGHV1-69-2	-4.77	2.68e-06	0.00157	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106778427	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.5	rs7152934	ENSG00000280411.1	IGHV1-69-2	-4.77	2.68e-06	0.00157	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106778702	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.789	rs12050392	ENSG00000280411.1	IGHV1-69-2	-4.77	2.68e-06	0.00157	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106779073	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74092505	ENSG00000280411.1	IGHV1-69-2	-4.77	2.68e-06	0.00157	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106779163	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.789	rs74092507	ENSG00000280411.1	IGHV1-69-2	-4.77	2.68e-06	0.00157	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106779174	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74092511	ENSG00000280411.1	IGHV1-69-2	-4.77	2.68e-06	0.00157	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106779234	chr14:106762092~106762588:-
STAD	cis	rs6095360	0.727	rs17450430	ENSG00000222365.1	SNORD12B	-4.77	2.69e-06	0.00157	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49155727	chr20:49280319~49280409:+
STAD	cis	rs227275	0.554	rs150895	ENSG00000248971.2	KRT8P46	-4.77	2.69e-06	0.00157	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223442	ENSG00000248971.2	KRT8P46	-4.77	2.69e-06	0.00157	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223441	ENSG00000248971.2	KRT8P46	-4.77	2.69e-06	0.00157	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102728746~102730171:-
STAD	cis	rs8097348	0.948	rs9949884	ENSG00000266602.1	RP11-476K15.1	-4.77	2.69e-06	0.00158	-0.31	-0.25	Exercise (leisure time);	chr18:1605847	chr18:1509183~1647097:+
STAD	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-4.77	2.69e-06	0.00158	-0.38	-0.25	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
STAD	cis	rs7665090	0.967	rs6812747	ENSG00000230069.3	LRRC37A15P	-4.77	2.69e-06	0.00158	-0.27	-0.25	Primary biliary cholangitis;	chr4:102634260	chr4:102727274~102730721:-
STAD	cis	rs916888	0.773	rs199439	ENSG00000232300.1	FAM215B	4.77	2.69e-06	0.00158	0.32	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46558830~46562795:-
STAD	cis	rs1799949	1	rs4793194	ENSG00000236383.6	LINC00854	-4.77	2.69e-06	0.00158	-0.2	-0.25	Menopause (age at onset);	chr17:43066316	chr17:43216941~43305976:-
STAD	cis	rs875971	0.8	rs427557	ENSG00000236529.1	RP13-254B10.1	4.77	2.69e-06	0.00158	0.26	0.25	Aortic root size;	chr7:66054263	chr7:65840212~65840596:+
STAD	cis	rs875971	0.83	rs587360	ENSG00000236529.1	RP13-254B10.1	4.77	2.69e-06	0.00158	0.26	0.25	Aortic root size;	chr7:66057711	chr7:65840212~65840596:+
STAD	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	4.77	2.69e-06	0.00158	0.38	0.25	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
STAD	cis	rs7078219	0.505	rs7916751	ENSG00000257582.4	LINC01475	-4.77	2.69e-06	0.00158	-0.28	-0.25	Dental caries;	chr10:99525893	chr10:99526350~99531177:-
STAD	cis	rs7078219	0.505	rs6584281	ENSG00000257582.4	LINC01475	-4.77	2.69e-06	0.00158	-0.28	-0.25	Dental caries;	chr10:99526723	chr10:99526350~99531177:-
STAD	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-4.77	2.69e-06	0.00158	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
STAD	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	4.77	2.69e-06	0.00158	0.25	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
STAD	cis	rs13392177	0.66	rs62185964	ENSG00000237281.1	CATIP-AS2	4.77	2.69e-06	0.00158	0.26	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218326889~218357966:-
STAD	cis	rs13392177	0.684	rs62185965	ENSG00000237281.1	CATIP-AS2	4.77	2.69e-06	0.00158	0.26	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218326889~218357966:-
STAD	cis	rs13392177	0.66	rs10932762	ENSG00000237281.1	CATIP-AS2	4.77	2.69e-06	0.00158	0.26	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218326889~218357966:-
STAD	cis	rs7487075	0.578	rs12319162	ENSG00000257261.4	RP11-96H19.1	4.77	2.7e-06	0.00158	0.3	0.25	Itch intensity from mosquito bite;	chr12:46444131	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs7134289	ENSG00000257261.4	RP11-96H19.1	4.77	2.7e-06	0.00158	0.3	0.25	Itch intensity from mosquito bite;	chr12:46444553	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs10880973	ENSG00000257261.4	RP11-96H19.1	4.77	2.7e-06	0.00158	0.3	0.25	Itch intensity from mosquito bite;	chr12:46459426	chr12:46383679~46876159:+
STAD	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	4.77	2.7e-06	0.00158	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
STAD	cis	rs17630293	0.737	rs295130	ENSG00000201649.1	RNY4P34	4.77	2.7e-06	0.00158	0.36	0.25	Schizophrenia;	chr2:200365261	chr2:200373175~200373269:+
STAD	cis	rs17630293	0.737	rs295131	ENSG00000201649.1	RNY4P34	4.77	2.7e-06	0.00158	0.36	0.25	Schizophrenia;	chr2:200365551	chr2:200373175~200373269:+
STAD	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-4.77	2.7e-06	0.00158	-0.31	-0.25	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
STAD	cis	rs8097348	0.761	rs4797934	ENSG00000266602.1	RP11-476K15.1	-4.77	2.7e-06	0.00158	-0.28	-0.25	Exercise (leisure time);	chr18:1638529	chr18:1509183~1647097:+
STAD	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	4.77	2.7e-06	0.00158	0.26	0.25	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
STAD	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	4.77	2.7e-06	0.00158	0.43	0.25	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	4.77	2.7e-06	0.00158	0.43	0.25	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
STAD	cis	rs13113518	1	rs4864547	ENSG00000223305.1	RN7SKP30	4.77	2.7e-06	0.00158	0.27	0.25	Height;	chr4:55538228	chr4:55540502~55540835:-
STAD	cis	rs6754311	0.861	rs12475139	ENSG00000231890.6	DARS-AS1	-4.77	2.7e-06	0.00158	-0.24	-0.25	Mosquito bite size;	chr2:136029081	chr2:135985176~136022593:+
STAD	cis	rs6750795	0.87	rs6754952	ENSG00000223198.1	RNU2-22P	4.77	2.7e-06	0.00158	0.28	0.25	Height;	chr2:231516534	chr2:231501990~231502201:-
STAD	cis	rs11694172	0.826	rs56712316	ENSG00000273456.1	RP11-686O6.2	4.77	2.71e-06	0.00159	0.28	0.25	Cholesterol, total;	chr2:202766724	chr2:202374932~202375604:-
STAD	cis	rs11694172	0.826	rs16839311	ENSG00000273456.1	RP11-686O6.2	4.77	2.71e-06	0.00159	0.28	0.25	Cholesterol, total;	chr2:202766833	chr2:202374932~202375604:-
STAD	cis	rs3806843	0.52	rs265312	ENSG00000202111.1	VTRNA1-2	-4.77	2.71e-06	0.00159	-0.25	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140916687	chr5:140718925~140719013:+
STAD	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	4.77	2.71e-06	0.00159	0.3	0.25	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
STAD	cis	rs748404	0.666	rs12900259	ENSG00000249839.1	AC011330.5	-4.77	2.71e-06	0.00159	-0.42	-0.25	Lung cancer;	chr15:43427369	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs34921640	ENSG00000249839.1	AC011330.5	-4.77	2.71e-06	0.00159	-0.42	-0.25	Lung cancer;	chr15:43429187	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs62020574	ENSG00000249839.1	AC011330.5	-4.77	2.71e-06	0.00159	-0.42	-0.25	Lung cancer;	chr15:43429380	chr15:43663654~43684339:-
STAD	cis	rs875971	0.83	rs427575	ENSG00000236529.1	RP13-254B10.1	4.77	2.72e-06	0.00159	0.26	0.25	Aortic root size;	chr7:66054232	chr7:65840212~65840596:+
STAD	cis	rs1005277	0.579	rs1740735	ENSG00000276805.1	RP11-291L22.6	4.77	2.72e-06	0.00159	0.27	0.25	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38451030~38451785:+
STAD	cis	rs6430585	0.528	rs309154	ENSG00000231890.6	DARS-AS1	-4.77	2.72e-06	0.00159	-0.28	-0.25	Corneal structure;	chr2:135968997	chr2:135985176~136022593:+
STAD	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	4.77	2.72e-06	0.00159	0.24	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
STAD	cis	rs7487075	0.859	rs3782904	ENSG00000257261.4	RP11-96H19.1	4.77	2.72e-06	0.00159	0.3	0.25	Itch intensity from mosquito bite;	chr12:46364202	chr12:46383679~46876159:+
STAD	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	4.77	2.72e-06	0.00159	0.31	0.25	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
STAD	cis	rs9307551	0.584	rs13102787	ENSG00000250334.4	LINC00989	-4.77	2.72e-06	0.00159	-0.3	-0.25	Refractive error;	chr4:79477407	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.584	rs10025450	ENSG00000250334.4	LINC00989	-4.77	2.72e-06	0.00159	-0.3	-0.25	Refractive error;	chr4:79477687	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.619	rs10857096	ENSG00000250334.4	LINC00989	-4.77	2.72e-06	0.00159	-0.3	-0.25	Refractive error;	chr4:79478691	chr4:79492416~79576460:+
STAD	cis	rs858239	0.6	rs10256361	ENSG00000226816.2	AC005082.12	4.77	2.72e-06	0.00159	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23206013~23208045:+
STAD	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-4.77	2.72e-06	0.0016	-0.36	-0.25	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
STAD	cis	rs3806843	0.576	rs155361	ENSG00000202111.1	VTRNA1-2	-4.77	2.73e-06	0.0016	-0.24	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140927699	chr5:140718925~140719013:+
STAD	cis	rs2337406	0.538	rs10141701	ENSG00000211970.3	IGHV4-61	4.77	2.73e-06	0.0016	0.27	0.25	Alzheimer's disease (late onset);	chr14:106633467	chr14:106639119~106639657:-
STAD	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	4.77	2.73e-06	0.0016	0.43	0.25	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	4.77	2.73e-06	0.0016	0.43	0.25	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
STAD	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	4.77	2.73e-06	0.0016	0.43	0.25	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
STAD	cis	rs2348418	0.966	rs11049698	ENSG00000247934.4	RP11-967K21.1	4.77	2.73e-06	0.0016	0.23	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28535354	chr12:28163298~28190738:-
STAD	cis	rs9467773	0.838	rs3734540	ENSG00000243307.2	POM121L6P	4.77	2.73e-06	0.0016	0.24	0.25	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26896952~26898777:+
STAD	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-4.77	2.73e-06	0.0016	-0.28	-0.25	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
STAD	cis	rs13113518	1	rs55699500	ENSG00000223305.1	RN7SKP30	4.77	2.73e-06	0.0016	0.27	0.25	Height;	chr4:55540912	chr4:55540502~55540835:-
STAD	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	4.77	2.73e-06	0.0016	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.525	rs11760133	ENSG00000220721.1	OR1F12	4.77	2.73e-06	0.0016	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28073316~28074233:+
STAD	cis	rs11235843	0.714	rs7128512	ENSG00000255928.1	RP11-456I15.2	-4.77	2.73e-06	0.0016	-0.34	-0.25	Hand grip strength;	chr11:73661254	chr11:73722349~73722694:+
STAD	cis	rs9860428	1	rs9814893	ENSG00000240057.4	RP11-572M11.4	-4.77	2.74e-06	0.0016	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868645	chr3:113019532~113183301:+
STAD	cis	rs7924176	0.521	rs12359775	ENSG00000213731.2	RAB5CP1	-4.77	2.74e-06	0.0016	-0.26	-0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74423435~74424014:-
STAD	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-4.77	2.74e-06	0.0016	-0.32	-0.25	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
STAD	cis	rs1707322	0.721	rs11211149	ENSG00000225447.1	RPS15AP10	4.77	2.74e-06	0.0016	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs11211152	ENSG00000225447.1	RPS15AP10	4.77	2.74e-06	0.0016	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.681	rs12048866	ENSG00000225447.1	RPS15AP10	4.77	2.74e-06	0.0016	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs12024590	ENSG00000225447.1	RPS15AP10	4.77	2.74e-06	0.0016	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs12027622	ENSG00000225447.1	RPS15AP10	4.77	2.74e-06	0.0016	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.716	rs6699444	ENSG00000225447.1	RPS15AP10	4.77	2.74e-06	0.0016	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45645816~45646197:-
STAD	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	4.77	2.74e-06	0.0016	0.3	0.25	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
STAD	cis	rs7487075	0.619	rs10748450	ENSG00000257261.4	RP11-96H19.1	4.77	2.74e-06	0.0016	0.31	0.25	Itch intensity from mosquito bite;	chr12:46463319	chr12:46383679~46876159:+
STAD	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	4.77	2.74e-06	0.0016	0.28	0.25	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
STAD	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-4.77	2.74e-06	0.0016	-0.37	-0.25	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
STAD	cis	rs8097348	0.817	rs4141813	ENSG00000266602.1	RP11-476K15.1	-4.77	2.74e-06	0.0016	-0.28	-0.25	Exercise (leisure time);	chr18:1666391	chr18:1509183~1647097:+
STAD	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-4.77	2.74e-06	0.0016	-0.3	-0.25	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
STAD	cis	rs301901	0.686	rs158795	ENSG00000250155.1	CTD-2353F22.1	-4.77	2.74e-06	0.0016	-0.27	-0.25	Height;	chr5:36882886	chr5:36666214~36725195:-
STAD	cis	rs7924176	0.521	rs11000999	ENSG00000213731.2	RAB5CP1	-4.77	2.74e-06	0.0016	-0.26	-0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74423435~74424014:-
STAD	cis	rs891378	1	rs2564978	ENSG00000274245.1	RP11-357P18.2	-4.77	2.75e-06	0.00161	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207321071	chr1:207372559~207373252:+
STAD	cis	rs7119038	0.818	rs6589685	ENSG00000255422.1	AP002954.4	4.77	2.75e-06	0.00161	0.32	0.25	Sjögren's syndrome;	chr11:118741488	chr11:118704607~118750263:+
STAD	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-4.77	2.75e-06	0.00161	-0.37	-0.25	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-4.77	2.75e-06	0.00161	-0.37	-0.25	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-4.77	2.75e-06	0.00161	-0.37	-0.25	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
STAD	cis	rs6951245	0.554	rs35126802	ENSG00000229043.2	AC091729.9	-4.77	2.75e-06	0.00161	-0.34	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1160374~1165267:+
STAD	cis	rs6430585	0.528	rs115553816	ENSG00000231890.6	DARS-AS1	-4.77	2.75e-06	0.00161	-0.28	-0.25	Corneal structure;	chr2:135935323	chr2:135985176~136022593:+
STAD	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-4.77	2.75e-06	0.00161	-0.29	-0.25	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
STAD	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	4.77	2.75e-06	0.00161	0.36	0.25	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
STAD	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-4.77	2.75e-06	0.00161	-0.25	-0.25	Height;	chr5:36990381	chr5:36666214~36725195:-
STAD	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-4.77	2.75e-06	0.00161	-0.27	-0.25	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
STAD	cis	rs8099594	0.64	rs498929	ENSG00000266696.1	RP11-30L3.2	4.77	2.75e-06	0.00161	0.24	0.25	Height;	chr18:49333154	chr18:49205912~49208781:+
STAD	cis	rs227275	0.525	rs3974604	ENSG00000248971.2	KRT8P46	-4.77	2.75e-06	0.00161	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102728746~102730171:-
STAD	cis	rs875971	0.756	rs4718328	ENSG00000236529.1	RP13-254B10.1	-4.77	2.76e-06	0.00161	-0.26	-0.25	Aortic root size;	chr7:66228350	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs4718330	ENSG00000236529.1	RP13-254B10.1	-4.77	2.76e-06	0.00161	-0.26	-0.25	Aortic root size;	chr7:66250256	chr7:65840212~65840596:+
STAD	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-4.77	2.76e-06	0.00161	-0.38	-0.25	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
STAD	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-4.77	2.76e-06	0.00161	-0.46	-0.25	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
STAD	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	4.77	2.76e-06	0.00161	0.37	0.25	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
STAD	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-4.77	2.76e-06	0.00161	-0.28	-0.25	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
STAD	cis	rs11846409	0.789	rs34917868	ENSG00000211972.2	IGHV3-66	4.77	2.77e-06	0.00162	0.27	0.25	Rheumatic heart disease;	chr14:106618321	chr14:106675017~106675544:-
STAD	cis	rs9926296	0.715	rs2115401	ENSG00000260259.1	RP11-368I7.4	-4.77	2.77e-06	0.00162	-0.27	-0.25	Vitiligo;	chr16:89674201	chr16:89682620~89686569:-
STAD	cis	rs6585424	1	rs12268619	ENSG00000225484.5	NUTM2B-AS1	-4.77	2.77e-06	0.00162	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80160904	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs35497678	ENSG00000225484.5	NUTM2B-AS1	-4.77	2.77e-06	0.00162	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80161322	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs2304410	ENSG00000225484.5	NUTM2B-AS1	-4.77	2.77e-06	0.00162	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162054	chr10:79663088~79826594:-
STAD	cis	rs6585424	0.778	rs12257082	ENSG00000225484.5	NUTM2B-AS1	-4.77	2.77e-06	0.00162	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162365	chr10:79663088~79826594:-
STAD	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	4.77	2.77e-06	0.00162	0.27	0.25	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	4.77	2.77e-06	0.00162	0.27	0.25	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
STAD	cis	rs2273156	1	rs17102967	ENSG00000241052.1	RP11-173D9.1	-4.77	2.77e-06	0.00162	-0.27	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011182	chr14:35144021~35144480:-
STAD	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-4.77	2.77e-06	0.00162	-0.29	-0.25	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
STAD	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	4.77	2.77e-06	0.00162	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
STAD	cis	rs7829975	1	rs7829975	ENSG00000253981.4	ALG1L13P	-4.77	2.78e-06	0.00162	-0.3	-0.25	Mood instability;	chr8:8690607	chr8:8236003~8244667:-
STAD	cis	rs6832769	0.961	rs1873092	ENSG00000272969.1	RP11-528I4.2	-4.77	2.78e-06	0.00162	-0.32	-0.25	Personality dimensions;	chr4:55578133	chr4:55547112~55547889:+
STAD	cis	rs7487075	0.82	rs7304622	ENSG00000272369.1	RP11-446N19.1	4.77	2.78e-06	0.00162	0.33	0.25	Itch intensity from mosquito bite;	chr12:46305077	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.82	rs10785617	ENSG00000272369.1	RP11-446N19.1	4.77	2.78e-06	0.00162	0.33	0.25	Itch intensity from mosquito bite;	chr12:46305460	chr12:46537502~46652550:+
STAD	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-4.77	2.78e-06	0.00162	-0.39	-0.25	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
STAD	cis	rs3758911	0.929	rs10789600	ENSG00000261098.1	RP11-819C21.1	-4.77	2.78e-06	0.00162	-0.22	-0.25	Coronary artery disease;	chr11:107310335	chr11:107312132~107316271:-
STAD	cis	rs1799949	1	rs915945	ENSG00000279602.1	CTD-3014M21.1	4.77	2.78e-06	0.00162	0.32	0.25	Menopause (age at onset);	chr17:43027847	chr17:43360041~43361361:-
STAD	cis	rs3806843	0.576	rs155363	ENSG00000202111.1	VTRNA1-2	-4.77	2.78e-06	0.00162	-0.24	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140921958	chr5:140718925~140719013:+
STAD	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	4.77	2.78e-06	0.00162	0.33	0.25	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
STAD	cis	rs7665090	0.934	rs35112949	ENSG00000230069.3	LRRC37A15P	-4.76	2.79e-06	0.00163	-0.28	-0.25	Primary biliary cholangitis;	chr4:102638473	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.87	rs34349956	ENSG00000230069.3	LRRC37A15P	-4.76	2.79e-06	0.00163	-0.28	-0.25	Primary biliary cholangitis;	chr4:102638476	chr4:102727274~102730721:-
STAD	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	4.76	2.79e-06	0.00163	0.32	0.25	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
STAD	cis	rs6782228	0.606	rs4634140	ENSG00000277250.1	Metazoa_SRP	4.76	2.79e-06	0.00163	0.26	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128673681~128674021:-
STAD	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	4.76	2.79e-06	0.00163	0.39	0.25	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
STAD	cis	rs5758659	1	rs134902	ENSG00000182057.4	OGFRP1	4.76	2.79e-06	0.00163	0.25	0.25	Cognitive function;	chr22:42287991	chr22:42269753~42275196:+
STAD	cis	rs4243830	0.85	rs7536908	ENSG00000229519.2	RP11-58A11.2	4.76	2.79e-06	0.00163	0.27	0.25	Body mass index;	chr1:6547754	chr1:6547905~6548619:+
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000224373.3	IGHV4-59	4.76	2.79e-06	0.00163	0.18	0.25	Kawasaki disease;	chr14:106807157	chr14:106627249~106627825:-
STAD	cis	rs2836950	0.501	rs11702505	ENSG00000238141.2	BRWD1-AS1	-4.76	2.79e-06	0.00163	-0.26	-0.25	Menarche (age at onset);	chr21:39328688	chr21:39315707~39323218:+
STAD	cis	rs2836950	0.501	rs2836985	ENSG00000238141.2	BRWD1-AS1	-4.76	2.79e-06	0.00163	-0.26	-0.25	Menarche (age at onset);	chr21:39329243	chr21:39315707~39323218:+
STAD	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	4.76	2.8e-06	0.00163	0.45	0.25	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
STAD	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	4.76	2.8e-06	0.00163	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	4.76	2.8e-06	0.00163	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	4.76	2.8e-06	0.00163	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	4.76	2.8e-06	0.00163	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	4.76	2.8e-06	0.00163	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	4.76	2.8e-06	0.00163	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	4.76	2.8e-06	0.00163	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
STAD	cis	rs3758911	0.894	rs11212179	ENSG00000261098.1	RP11-819C21.1	-4.76	2.8e-06	0.00163	-0.23	-0.25	Coronary artery disease;	chr11:107357254	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.856	rs11212180	ENSG00000261098.1	RP11-819C21.1	-4.76	2.8e-06	0.00163	-0.23	-0.25	Coronary artery disease;	chr11:107358630	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.856	rs11212181	ENSG00000261098.1	RP11-819C21.1	-4.76	2.8e-06	0.00163	-0.23	-0.25	Coronary artery disease;	chr11:107360169	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.894	rs11212182	ENSG00000261098.1	RP11-819C21.1	-4.76	2.8e-06	0.00163	-0.23	-0.25	Coronary artery disease;	chr11:107360879	chr11:107312132~107316271:-
STAD	cis	rs3758911	0.894	rs11607304	ENSG00000261098.1	RP11-819C21.1	-4.76	2.8e-06	0.00163	-0.23	-0.25	Coronary artery disease;	chr11:107361870	chr11:107312132~107316271:-
STAD	cis	rs1799949	1	rs4793215	ENSG00000279602.1	CTD-3014M21.1	4.76	2.8e-06	0.00163	0.31	0.25	Menopause (age at onset);	chr17:43166915	chr17:43360041~43361361:-
STAD	cis	rs4589258	0.933	rs1792604	ENSG00000280367.1	RP11-121L10.2	4.76	2.8e-06	0.00163	0.27	0.25	Intelligence (multi-trait analysis);	chr11:90704161	chr11:90223153~90226538:+
STAD	cis	rs916888	0.821	rs199506	ENSG00000232300.1	FAM215B	-4.76	2.8e-06	0.00163	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46558830~46562795:-
STAD	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	4.76	2.8e-06	0.00163	0.33	0.25	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
STAD	cis	rs11098499	0.863	rs7699064	ENSG00000260091.1	RP11-33B1.4	-4.76	2.8e-06	0.00163	-0.25	-0.25	Corneal astigmatism;	chr4:119507154	chr4:119409333~119410233:+
STAD	cis	rs3758911	0.894	rs4343000	ENSG00000261098.1	RP11-819C21.1	-4.76	2.8e-06	0.00163	-0.23	-0.25	Coronary artery disease;	chr11:107353992	chr11:107312132~107316271:-
STAD	cis	rs4639966	0.836	rs1893029	ENSG00000255239.1	AP002954.6	-4.76	2.8e-06	0.00163	-0.32	-0.25	Systemic lupus erythematosus;	chr11:118740117	chr11:118688039~118690600:-
STAD	cis	rs9860428	0.844	rs7639603	ENSG00000240057.4	RP11-572M11.4	-4.76	2.81e-06	0.00164	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112887289	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs9853006	ENSG00000240057.4	RP11-572M11.4	-4.76	2.81e-06	0.00164	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112887488	chr3:113019532~113183301:+
STAD	cis	rs7615952	0.546	rs11717632	ENSG00000272840.1	RP11-379B18.6	4.76	2.81e-06	0.00164	0.44	0.25	Blood pressure (smoking interaction);	chr3:125602286	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.546	rs2922197	ENSG00000272840.1	RP11-379B18.6	4.76	2.81e-06	0.00164	0.44	0.25	Blood pressure (smoking interaction);	chr3:125603188	chr3:125774714~125797953:+
STAD	cis	rs12534093	0.522	rs11768826	ENSG00000234286.1	AC006026.13	-4.76	2.81e-06	0.00164	-0.33	-0.25	Infant length;Height;	chr7:23534595	chr7:23680195~23680786:-
STAD	cis	rs12534093	0.562	rs6461714	ENSG00000234286.1	AC006026.13	-4.76	2.81e-06	0.00164	-0.33	-0.25	Infant length;Height;	chr7:23536633	chr7:23680195~23680786:-
STAD	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-4.76	2.81e-06	0.00164	-0.28	-0.25	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-4.76	2.81e-06	0.00164	-0.28	-0.25	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
STAD	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	4.76	2.81e-06	0.00164	0.36	0.25	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	4.76	2.81e-06	0.00164	0.36	0.25	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	4.76	2.81e-06	0.00164	0.36	0.25	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	4.76	2.81e-06	0.00164	0.36	0.25	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	4.76	2.81e-06	0.00164	0.36	0.25	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	4.76	2.81e-06	0.00164	0.36	0.25	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
STAD	cis	rs3806843	0.612	rs246075	ENSG00000202111.1	VTRNA1-2	-4.76	2.81e-06	0.00164	-0.24	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140920972	chr5:140718925~140719013:+
STAD	cis	rs228614	0.51	rs150893	ENSG00000248971.2	KRT8P46	4.76	2.81e-06	0.00164	0.25	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102728746~102730171:-
STAD	cis	rs13113518	0.966	rs11942472	ENSG00000223305.1	RN7SKP30	4.76	2.82e-06	0.00164	0.28	0.25	Height;	chr4:55574959	chr4:55540502~55540835:-
STAD	cis	rs1799949	0.501	rs2343819	ENSG00000279602.1	CTD-3014M21.1	4.76	2.82e-06	0.00164	0.31	0.25	Menopause (age at onset);	chr17:43332285	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.501	rs35399157	ENSG00000279602.1	CTD-3014M21.1	4.76	2.82e-06	0.00164	0.31	0.25	Menopause (age at onset);	chr17:43334234	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.602	rs4600503	ENSG00000279602.1	CTD-3014M21.1	4.76	2.82e-06	0.00164	0.31	0.25	Menopause (age at onset);	chr17:43336956	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.501	rs9675035	ENSG00000279602.1	CTD-3014M21.1	4.76	2.82e-06	0.00164	0.31	0.25	Menopause (age at onset);	chr17:43337648	chr17:43360041~43361361:-
STAD	cis	rs7083	0.84	rs509565	ENSG00000254851.1	RP11-109L13.1	4.76	2.82e-06	0.00164	0.27	0.25	Blood protein levels;	chr11:117249757	chr11:117135528~117138582:+
STAD	cis	rs1799949	0.965	rs8176087	ENSG00000236383.6	LINC00854	-4.76	2.82e-06	0.00164	-0.2	-0.25	Menopause (age at onset);	chr17:43118649	chr17:43216941~43305976:-
STAD	cis	rs4243830	0.85	rs1114661	ENSG00000229519.2	RP11-58A11.2	4.76	2.82e-06	0.00164	0.26	0.25	Body mass index;	chr1:6536811	chr1:6547905~6548619:+
STAD	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	4.76	2.82e-06	0.00164	0.23	0.25	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
STAD	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-4.76	2.82e-06	0.00164	-0.31	-0.25	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
STAD	cis	rs35934224	0.783	rs5993849	ENSG00000232926.1	AC000078.5	4.76	2.82e-06	0.00164	0.33	0.25	Glaucoma (primary open-angle);	chr22:19878671	chr22:19887289~19887970:+
STAD	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	4.76	2.82e-06	0.00164	0.25	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
STAD	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-4.76	2.83e-06	0.00165	-0.27	-0.25	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
STAD	cis	rs7429990	0.965	rs7653368	ENSG00000224895.1	VPS26BP1	-4.76	2.83e-06	0.00165	-0.24	-0.25	Educational attainment (years of education);	chr3:47943871	chr3:47960327~47961081:-
STAD	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	4.76	2.83e-06	0.00165	0.25	0.25	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
STAD	cis	rs1707322	1	rs6677777	ENSG00000225447.1	RPS15AP10	4.76	2.83e-06	0.00165	0.19	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45645816~45646197:-
STAD	cis	rs4950322	0.57	rs17356219	ENSG00000278811.3	LINC00624	4.76	2.83e-06	0.00165	0.27	0.25	Protein quantitative trait loci;	chr1:147265684	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691041	ENSG00000278811.3	LINC00624	4.76	2.83e-06	0.00165	0.27	0.25	Protein quantitative trait loci;	chr1:147267084	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs17356233	ENSG00000278811.3	LINC00624	4.76	2.83e-06	0.00165	0.27	0.25	Protein quantitative trait loci;	chr1:147268843	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs17356240	ENSG00000278811.3	LINC00624	4.76	2.83e-06	0.00165	0.27	0.25	Protein quantitative trait loci;	chr1:147269877	chr1:147258885~147517875:-
STAD	cis	rs1707322	0.752	rs4586014	ENSG00000225447.1	RPS15AP10	4.76	2.83e-06	0.00165	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45645816~45646197:-
STAD	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-4.76	2.83e-06	0.00165	-0.36	-0.25	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-4.76	2.83e-06	0.00165	-0.36	-0.25	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
STAD	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-4.76	2.83e-06	0.00165	-0.36	-0.25	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-4.76	2.83e-06	0.00165	-0.36	-0.25	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
STAD	cis	rs10510102	0.935	rs7906667	ENSG00000226864.1	ATE1-AS1	4.76	2.83e-06	0.00165	0.41	0.25	Breast cancer;	chr10:121909142	chr10:121928312~121951965:+
STAD	cis	rs6095360	0.727	rs17448715	ENSG00000222365.1	SNORD12B	-4.76	2.83e-06	0.00165	-0.33	-0.25	Intelligence (multi-trait analysis);	chr20:49075206	chr20:49280319~49280409:+
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000224373.3	IGHV4-59	4.76	2.83e-06	0.00165	0.18	0.25	Kawasaki disease;	chr14:106792798	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000224373.3	IGHV4-59	4.76	2.83e-06	0.00165	0.18	0.25	Kawasaki disease;	chr14:106800208	chr14:106627249~106627825:-
STAD	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-4.76	2.83e-06	0.00165	-0.26	-0.25	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
STAD	cis	rs7487075	0.82	rs7314069	ENSG00000257261.4	RP11-96H19.1	4.76	2.84e-06	0.00165	0.3	0.25	Itch intensity from mosquito bite;	chr12:46314954	chr12:46383679~46876159:+
STAD	cis	rs2439831	0.867	rs496584	ENSG00000275601.1	AC011330.13	-4.76	2.84e-06	0.00165	-0.32	-0.25	Lung cancer in ever smokers;	chr15:43539725	chr15:43642389~43643023:-
STAD	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	4.76	2.84e-06	0.00165	0.38	0.25	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
STAD	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-4.76	2.84e-06	0.00165	-0.28	-0.25	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
STAD	cis	rs1707322	0.682	rs12041197	ENSG00000225447.1	RPS15AP10	4.76	2.84e-06	0.00165	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.717	rs12023439	ENSG00000225447.1	RPS15AP10	4.76	2.84e-06	0.00165	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs11211146	ENSG00000225447.1	RPS15AP10	4.76	2.84e-06	0.00165	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs11211147	ENSG00000225447.1	RPS15AP10	4.76	2.84e-06	0.00165	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45645816~45646197:-
STAD	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	4.76	2.84e-06	0.00165	0.31	0.25	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
STAD	cis	rs875971	0.502	rs11769702	ENSG00000236529.1	RP13-254B10.1	4.76	2.84e-06	0.00166	0.29	0.25	Aortic root size;	chr7:66255529	chr7:65840212~65840596:+
STAD	cis	rs891378	0.883	rs6540888	ENSG00000274245.1	RP11-357P18.2	-4.76	2.84e-06	0.00166	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207247514	chr1:207372559~207373252:+
STAD	cis	rs4713118	0.505	rs156740	ENSG00000220721.1	OR1F12	4.76	2.84e-06	0.00166	0.25	0.25	Parkinson's disease;	chr6:27992657	chr6:28073316~28074233:+
STAD	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	4.76	2.84e-06	0.00166	0.3	0.25	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	4.76	2.84e-06	0.00166	0.3	0.25	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
STAD	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-4.76	2.85e-06	0.00166	-0.4	-0.25	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
STAD	cis	rs3806843	0.576	rs246072	ENSG00000202111.1	VTRNA1-2	-4.76	2.85e-06	0.00166	-0.24	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140940841	chr5:140718925~140719013:+
STAD	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-4.76	2.85e-06	0.00166	-0.25	-0.25	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
STAD	cis	rs17301013	0.861	rs333418	ENSG00000227373.4	RP11-160H22.5	4.76	2.85e-06	0.00166	0.3	0.25	Systemic lupus erythematosus;	chr1:174707294	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.828	rs332783	ENSG00000227373.4	RP11-160H22.5	4.76	2.85e-06	0.00166	0.3	0.25	Systemic lupus erythematosus;	chr1:174719260	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.861	rs170768	ENSG00000227373.4	RP11-160H22.5	4.76	2.85e-06	0.00166	0.3	0.25	Systemic lupus erythematosus;	chr1:174720787	chr1:174115300~174160004:-
STAD	cis	rs1707322	0.717	rs1547925	ENSG00000281133.1	AL355480.3	4.76	2.85e-06	0.00166	0.31	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45580892~45580996:-
STAD	cis	rs357618	1	rs357629	ENSG00000260581.1	CTB-113P19.4	-4.76	2.85e-06	0.00166	-0.28	-0.25	Basophil percentage of white cells;	chr5:151471385	chr5:151652275~151655449:+
STAD	cis	rs3770081	1	rs3770066	ENSG00000273080.1	RP11-301O19.1	-4.76	2.85e-06	0.00166	-0.52	-0.25	Facial emotion recognition (sad faces);	chr2:86165227	chr2:86195590~86196049:+
STAD	cis	rs11169552	0.51	rs10459235	ENSG00000200183.1	RNU6-238P	-4.76	2.86e-06	0.00166	-0.24	-0.25	Colorectal cancer;	chr12:50702400	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.51	rs4768906	ENSG00000200183.1	RNU6-238P	-4.76	2.86e-06	0.00166	-0.24	-0.25	Colorectal cancer;	chr12:50713040	chr12:50656973~50657078:+
STAD	cis	rs1005277	1	rs1005277	ENSG00000099251.13	HSD17B7P2	-4.76	2.86e-06	0.00166	-0.29	-0.25	Extrinsic epigenetic age acceleration;	chr10:37929331	chr10:38356380~38378505:+
STAD	cis	rs507080	0.733	rs601318	ENSG00000278376.1	RP11-158I9.8	-4.76	2.86e-06	0.00166	-0.26	-0.25	Serum metabolite levels;	chr11:118648845	chr11:118791254~118793137:+
STAD	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	4.76	2.86e-06	0.00166	0.33	0.25	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
STAD	cis	rs1007738	0.58	rs11039028	ENSG00000271350.1	CTD-2384B9.1	4.76	2.86e-06	0.00166	0.32	0.25	Bone mineral density (hip);	chr11:46922645	chr11:47041027~47041945:-
STAD	cis	rs10978777	0.765	rs1805332	ENSG00000276883.1	AL137852.1	-4.76	2.86e-06	0.00167	-0.25	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107318686	chr9:107292369~107292456:-
STAD	cis	rs721917	0.525	rs2758545	ENSG00000244733.5	RP11-506M13.3	-4.76	2.86e-06	0.00167	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79660891~79677996:+
STAD	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-4.76	2.86e-06	0.00167	-0.25	-0.25	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
STAD	cis	rs13392177	0.684	rs11682371	ENSG00000237281.1	CATIP-AS2	4.76	2.87e-06	0.00167	0.26	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218326889~218357966:-
STAD	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-4.76	2.87e-06	0.00167	-0.24	-0.25	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
STAD	cis	rs393951	0.626	rs403285	ENSG00000260969.1	RP11-190D6.2	4.76	2.87e-06	0.00167	0.35	0.25	Childhood ear infection;	chr16:77550842	chr16:78237362~78241218:-
STAD	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-4.76	2.87e-06	0.00167	-0.3	-0.25	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
STAD	cis	rs916888	0.821	rs199513	ENSG00000232300.1	FAM215B	-4.76	2.87e-06	0.00167	-0.31	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46558830~46562795:-
STAD	cis	rs3758911	0.964	rs10890703	ENSG00000261098.1	RP11-819C21.1	-4.76	2.87e-06	0.00167	-0.23	-0.25	Coronary artery disease;	chr11:107310403	chr11:107312132~107316271:-
STAD	cis	rs1485395	0.732	rs57408986	ENSG00000257379.1	RP11-793H13.8	4.76	2.87e-06	0.00167	0.49	0.25	Migraine without aura;	chr12:53493005	chr12:53441741~53467528:+
STAD	cis	rs3733418	0.929	rs12507869	ENSG00000248632.1	RP11-366M4.11	4.76	2.87e-06	0.00167	0.31	0.25	Obesity-related traits;	chr4:164974522	chr4:164968587~164970002:-
STAD	cis	rs4589258	0.933	rs11019133	ENSG00000280367.1	RP11-121L10.2	-4.76	2.88e-06	0.00167	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90672272	chr11:90223153~90226538:+
STAD	cis	rs875971	0.545	rs10950036	ENSG00000236529.1	RP13-254B10.1	4.76	2.88e-06	0.00167	0.29	0.25	Aortic root size;	chr7:66353241	chr7:65840212~65840596:+
STAD	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	4.76	2.88e-06	0.00167	0.29	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
STAD	cis	rs4568518	0.535	rs12699955	ENSG00000279048.1	RP11-511H23.2	4.76	2.88e-06	0.00167	0.24	0.25	Measles;	chr7:18022111	chr7:17940503~17942922:+
STAD	cis	rs7119038	0.818	rs76704408	ENSG00000255422.1	AP002954.4	4.76	2.88e-06	0.00167	0.31	0.25	Sjögren's syndrome;	chr11:118812618	chr11:118704607~118750263:+
STAD	cis	rs8099594	0.51	rs7233575	ENSG00000266696.1	RP11-30L3.2	4.76	2.88e-06	0.00167	0.23	0.25	Height;	chr18:49168712	chr18:49205912~49208781:+
STAD	cis	rs3758911	0.861	rs10789621	ENSG00000261098.1	RP11-819C21.1	4.76	2.88e-06	0.00167	0.22	0.25	Coronary artery disease;	chr11:107388345	chr11:107312132~107316271:-
STAD	cis	rs375092	0.543	rs6461708	ENSG00000230658.1	KLHL7-AS1	-4.76	2.88e-06	0.00167	-0.38	-0.25	Personality dimensions;	chr7:23375698	chr7:23101228~23105703:-
STAD	cis	rs9860428	0.844	rs9846377	ENSG00000240057.4	RP11-572M11.4	-4.76	2.88e-06	0.00167	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112902091	chr3:113019532~113183301:+
STAD	cis	rs7078219	0.714	rs12360459	ENSG00000228778.1	RP11-129J12.1	-4.76	2.88e-06	0.00167	-0.31	-0.25	Dental caries;	chr10:99526397	chr10:99527081~99528261:+
STAD	cis	rs35934224	0.783	rs7290770	ENSG00000232926.1	AC000078.5	4.76	2.88e-06	0.00168	0.38	0.25	Glaucoma (primary open-angle);	chr22:19873638	chr22:19887289~19887970:+
STAD	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	4.76	2.88e-06	0.00168	0.31	0.25	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
STAD	cis	rs7487075	0.859	rs956910	ENSG00000257261.4	RP11-96H19.1	4.76	2.88e-06	0.00168	0.3	0.25	Itch intensity from mosquito bite;	chr12:46366005	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.786	rs7980775	ENSG00000257261.4	RP11-96H19.1	4.76	2.88e-06	0.00168	0.32	0.25	Itch intensity from mosquito bite;	chr12:46281090	chr12:46383679~46876159:+
STAD	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-4.76	2.88e-06	0.00168	-0.25	-0.25	Height;	chr5:36878678	chr5:36666214~36725195:-
STAD	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-4.76	2.88e-06	0.00168	-0.25	-0.25	Height;	chr5:36880769	chr5:36666214~36725195:-
STAD	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-4.76	2.88e-06	0.00168	-0.25	-0.25	Height;	chr5:36882917	chr5:36666214~36725195:-
STAD	cis	rs453301	0.686	rs2409120	ENSG00000254340.1	RP11-10A14.3	-4.76	2.88e-06	0.00168	-0.32	-0.25	Joint mobility (Beighton score);	chr8:9025061	chr8:9141424~9145435:+
STAD	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	4.76	2.88e-06	0.00168	0.38	0.25	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	4.76	2.88e-06	0.00168	0.38	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	4.76	2.88e-06	0.00168	0.38	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-4.76	2.89e-06	0.00168	-0.19	-0.25	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
STAD	cis	rs1007738	0.58	rs61897844	ENSG00000271350.1	CTD-2384B9.1	4.76	2.89e-06	0.00168	0.32	0.25	Bone mineral density (hip);	chr11:47169309	chr11:47041027~47041945:-
STAD	cis	rs6095360	0.727	rs17378391	ENSG00000222365.1	SNORD12B	-4.76	2.89e-06	0.00168	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49156064	chr20:49280319~49280409:+
STAD	cis	rs17401966	0.898	rs12117635	ENSG00000199562.1	RNU6-37P	4.76	2.89e-06	0.00168	0.19	0.25	Hepatocellular carcinoma;	chr1:10257387	chr1:10298966~10299072:+
STAD	cis	rs1799949	0.86	rs8176279	ENSG00000279602.1	CTD-3014M21.1	4.76	2.89e-06	0.00168	0.31	0.25	Menopause (age at onset);	chr17:43058379	chr17:43360041~43361361:-
STAD	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-4.76	2.89e-06	0.00168	-0.3	-0.25	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
STAD	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-4.76	2.89e-06	0.00168	-0.31	-0.25	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
STAD	cis	rs7615952	0.673	rs7632557	ENSG00000272840.1	RP11-379B18.6	4.76	2.89e-06	0.00168	0.46	0.25	Blood pressure (smoking interaction);	chr3:125916038	chr3:125774714~125797953:+
STAD	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-4.76	2.9e-06	0.00168	-0.29	-0.25	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
STAD	cis	rs1007738	0.542	rs10838664	ENSG00000271350.1	CTD-2384B9.1	4.76	2.9e-06	0.00168	0.32	0.25	Bone mineral density (hip);	chr11:47182353	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	4.76	2.9e-06	0.00168	0.26	0.25	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
STAD	cis	rs7429990	0.965	rs777015	ENSG00000224895.1	VPS26BP1	-4.76	2.9e-06	0.00168	-0.24	-0.25	Educational attainment (years of education);	chr3:47895582	chr3:47960327~47961081:-
STAD	cis	rs7487075	0.619	rs6582657	ENSG00000257261.4	RP11-96H19.1	4.76	2.9e-06	0.00169	0.3	0.25	Itch intensity from mosquito bite;	chr12:46462236	chr12:46383679~46876159:+
STAD	cis	rs6921919	0.583	rs7740351	ENSG00000220721.1	OR1F12	4.76	2.9e-06	0.00169	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28073316~28074233:+
STAD	cis	rs17592366	0.54	rs7145614	ENSG00000251726.1	RNU7-41P	4.76	2.9e-06	0.00169	0.22	0.25	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34821640	chr14:34845300~34845360:-
STAD	cis	rs227932	0.764	rs6461725	ENSG00000234286.1	AC006026.13	-4.76	2.9e-06	0.00169	-0.44	-0.25	Schizophrenia;	chr7:23690555	chr7:23680195~23680786:-
STAD	cis	rs875971	0.929	rs778712	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66384991	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs778710	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66389847	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs778708	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66391332	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs778696	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66405826	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs778694	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66406571	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs4718344	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66409394	chr7:65840212~65840596:+
STAD	cis	rs875971	0.737	rs7803424	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66415618	chr7:65840212~65840596:+
STAD	cis	rs875971	0.83	rs7799834	ENSG00000236529.1	RP13-254B10.1	4.76	2.91e-06	0.00169	0.26	0.25	Aortic root size;	chr7:66415707	chr7:65840212~65840596:+
STAD	cis	rs4713118	0.955	rs9468201	ENSG00000280107.1	AL022393.9	-4.76	2.91e-06	0.00169	-0.33	-0.25	Parkinson's disease;	chr6:27719256	chr6:28170845~28172521:+
STAD	cis	rs12534093	0.562	rs6461716	ENSG00000234286.1	AC006026.13	-4.76	2.91e-06	0.00169	-0.33	-0.25	Infant length;Height;	chr7:23540935	chr7:23680195~23680786:-
STAD	cis	rs13113518	0.738	rs6849883	ENSG00000223305.1	RN7SKP30	4.76	2.91e-06	0.00169	0.28	0.25	Height;	chr4:55387515	chr4:55540502~55540835:-
STAD	cis	rs9291683	0.527	rs73212848	ENSG00000250613.1	RP11-136I13.1	4.76	2.91e-06	0.00169	0.26	0.25	Bone mineral density;	chr4:10091675	chr4:10410996~10411644:+
STAD	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	4.76	2.91e-06	0.00169	0.25	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
STAD	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	4.76	2.91e-06	0.00169	0.22	0.25	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
STAD	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.76	2.91e-06	0.00169	-0.28	-0.25	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
STAD	cis	rs4950322	0.57	rs17356184	ENSG00000278811.3	LINC00624	4.76	2.91e-06	0.00169	0.27	0.25	Protein quantitative trait loci;	chr1:147262943	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs80270233	ENSG00000278811.3	LINC00624	4.76	2.91e-06	0.00169	0.27	0.25	Protein quantitative trait loci;	chr1:147263320	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs4950392	ENSG00000278811.3	LINC00624	4.76	2.91e-06	0.00169	0.27	0.25	Protein quantitative trait loci;	chr1:147264889	chr1:147258885~147517875:-
STAD	cis	rs4061073	0.924	rs67060003	ENSG00000198711.5	SSBP3-AS1	-4.76	2.91e-06	0.00169	-0.2	-0.25	Body mass index;	chr1:54232568	chr1:54236440~54239063:+
STAD	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-4.76	2.91e-06	0.00169	-0.4	-0.25	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
STAD	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-4.76	2.91e-06	0.00169	-0.24	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
STAD	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-4.76	2.92e-06	0.00169	-0.33	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
STAD	cis	rs3736858	0.866	rs41287008	ENSG00000261105.4	LMO7-AS1	-4.75	2.92e-06	0.00169	-0.42	-0.25	Interleukin-9 levels;	chr13:75821948	chr13:75604700~75635994:-
STAD	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	4.75	2.92e-06	0.00169	0.27	0.25	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
STAD	cis	rs1707322	0.686	rs1547924	ENSG00000281133.1	AL355480.3	-4.75	2.92e-06	0.00169	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45580892~45580996:-
STAD	cis	rs9549328	0.8	rs1317507	ENSG00000267868.1	RP11-120K24.3	4.75	2.92e-06	0.00169	0.34	0.25	Systolic blood pressure;	chr13:112977466	chr13:112964835~112966131:-
STAD	cis	rs7487075	0.82	rs7976362	ENSG00000257261.4	RP11-96H19.1	4.75	2.92e-06	0.0017	0.3	0.25	Itch intensity from mosquito bite;	chr12:46315779	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.786	rs59919892	ENSG00000257261.4	RP11-96H19.1	4.75	2.92e-06	0.0017	0.3	0.25	Itch intensity from mosquito bite;	chr12:46318447	chr12:46383679~46876159:+
STAD	cis	rs950169	0.84	rs62019457	ENSG00000259295.5	CSPG4P12	4.75	2.92e-06	0.0017	0.36	0.25	Schizophrenia;	chr15:84558911	chr15:85191438~85213905:+
STAD	cis	rs1056107	0.763	rs10115594	ENSG00000225513.1	RP11-165N19.2	-4.75	2.92e-06	0.0017	-0.29	-0.25	Colorectal cancer;	chr9:112174198	chr9:112173522~112173971:-
STAD	cis	rs7078219	0.505	rs10883365	ENSG00000228778.1	RP11-129J12.1	-4.75	2.92e-06	0.0017	-0.28	-0.25	Dental caries;	chr10:99528007	chr10:99527081~99528261:+
STAD	cis	rs6095360	0.7	rs7262349	ENSG00000222365.1	SNORD12B	-4.75	2.93e-06	0.0017	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49178768	chr20:49280319~49280409:+
STAD	cis	rs9860428	0.844	rs2220397	ENSG00000240057.4	RP11-572M11.4	-4.75	2.93e-06	0.0017	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112895600	chr3:113019532~113183301:+
STAD	cis	rs7951870	0.645	rs10769205	ENSG00000271350.1	CTD-2384B9.1	4.75	2.93e-06	0.0017	0.31	0.25	Schizophrenia;	chr11:46702053	chr11:47041027~47041945:-
STAD	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.93e-06	0.0017	-0.29	-0.25	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.93e-06	0.0017	-0.29	-0.25	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.93e-06	0.0017	-0.29	-0.25	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
STAD	cis	rs6142102	0.651	rs6119463	ENSG00000275784.1	RP5-1125A11.6	4.75	2.93e-06	0.0017	0.26	0.25	Skin pigmentation;	chr20:34149412	chr20:33989480~33991818:-
STAD	cis	rs10978777	0.802	rs4978849	ENSG00000276883.1	AL137852.1	-4.75	2.93e-06	0.0017	-0.25	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107319882	chr9:107292369~107292456:-
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	4.75	2.93e-06	0.0017	0.3	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
STAD	cis	rs1799949	0.628	rs4474733	ENSG00000279602.1	CTD-3014M21.1	4.75	2.93e-06	0.0017	0.33	0.25	Menopause (age at onset);	chr17:43356292	chr17:43360041~43361361:-
STAD	cis	rs728616	0.867	rs55835350	ENSG00000225484.5	NUTM2B-AS1	-4.75	2.93e-06	0.0017	-0.52	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs79904324	ENSG00000225484.5	NUTM2B-AS1	-4.75	2.93e-06	0.0017	-0.52	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs41297151	ENSG00000225484.5	NUTM2B-AS1	-4.75	2.93e-06	0.0017	-0.52	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs17096197	ENSG00000225484.5	NUTM2B-AS1	-4.75	2.93e-06	0.0017	-0.52	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:79663088~79826594:-
STAD	cis	rs1056107	0.897	rs7867278	ENSG00000225513.1	RP11-165N19.2	-4.75	2.93e-06	0.0017	-0.29	-0.25	Colorectal cancer;	chr9:112196676	chr9:112173522~112173971:-
STAD	cis	rs1056107	0.897	rs1972322	ENSG00000225513.1	RP11-165N19.2	-4.75	2.93e-06	0.0017	-0.29	-0.25	Colorectal cancer;	chr9:112197447	chr9:112173522~112173971:-
STAD	cis	rs4950322	0.57	rs2354428	ENSG00000278811.3	LINC00624	4.75	2.93e-06	0.0017	0.27	0.25	Protein quantitative trait loci;	chr1:147277512	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs72691054	ENSG00000278811.3	LINC00624	4.75	2.93e-06	0.0017	0.27	0.25	Protein quantitative trait loci;	chr1:147277942	chr1:147258885~147517875:-
STAD	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-4.75	2.93e-06	0.0017	-0.32	-0.25	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
STAD	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	4.75	2.93e-06	0.0017	0.37	0.25	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
STAD	cis	rs2337406	1	rs11850709	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.27	0.25	Alzheimer's disease (late onset);	chr14:106670844	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs7152809	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.25	0.25	Alzheimer's disease (late onset);	chr14:106778385	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs7152832	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.25	0.25	Alzheimer's disease (late onset);	chr14:106778427	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.5	rs7152934	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.25	0.25	Alzheimer's disease (late onset);	chr14:106778702	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.789	rs12050392	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.25	0.25	Alzheimer's disease (late onset);	chr14:106779073	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74092505	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.25	0.25	Alzheimer's disease (late onset);	chr14:106779163	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.789	rs74092507	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.25	0.25	Alzheimer's disease (late onset);	chr14:106779174	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74092511	ENSG00000211972.2	IGHV3-66	4.75	2.94e-06	0.0017	0.25	0.25	Alzheimer's disease (late onset);	chr14:106779234	chr14:106675017~106675544:-
STAD	cis	rs228614	0.517	rs3886722	ENSG00000248971.2	KRT8P46	-4.75	2.94e-06	0.0017	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102728746~102730171:-
STAD	cis	rs7078219	0.576	rs989979	ENSG00000228778.1	RP11-129J12.1	-4.75	2.94e-06	0.0017	-0.28	-0.25	Dental caries;	chr10:99562666	chr10:99527081~99528261:+
STAD	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.94e-06	0.0017	-0.29	-0.25	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.94e-06	0.0017	-0.29	-0.25	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.94e-06	0.0017	-0.29	-0.25	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.94e-06	0.0017	-0.29	-0.25	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
STAD	cis	rs2143950	0.564	rs17103246	ENSG00000241052.1	RP11-173D9.1	-4.75	2.94e-06	0.0017	-0.28	-0.25	Atopic dermatitis;	chr14:35365319	chr14:35144021~35144480:-
STAD	cis	rs2143950	0.564	rs17103255	ENSG00000241052.1	RP11-173D9.1	-4.75	2.94e-06	0.0017	-0.28	-0.25	Atopic dermatitis;	chr14:35366204	chr14:35144021~35144480:-
STAD	cis	rs9860428	0.844	rs6807722	ENSG00000240057.4	RP11-572M11.4	-4.75	2.94e-06	0.0017	-0.24	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896320	chr3:113019532~113183301:+
STAD	cis	rs13113518	1	rs7662966	ENSG00000223305.1	RN7SKP30	4.75	2.94e-06	0.00171	0.28	0.25	Height;	chr4:55548261	chr4:55540502~55540835:-
STAD	cis	rs17660992	0.525	rs10421946	ENSG00000273837.1	LLNLR-470E3.1	-4.75	2.95e-06	0.00171	-0.29	-0.25	Blood protein levels;	chr19:51661797	chr19:51639478~51639931:-
STAD	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	4.75	2.95e-06	0.00171	0.32	0.25	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
STAD	cis	rs6095360	0.727	rs10485609	ENSG00000222365.1	SNORD12B	-4.75	2.95e-06	0.00171	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49049075	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs35843274	ENSG00000222365.1	SNORD12B	-4.75	2.95e-06	0.00171	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49049366	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs2227946	ENSG00000222365.1	SNORD12B	-4.75	2.95e-06	0.00171	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49068783	chr20:49280319~49280409:+
STAD	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-4.75	2.95e-06	0.00171	-0.25	-0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
STAD	cis	rs6142102	1	rs6142102	ENSG00000275784.1	RP5-1125A11.6	-4.75	2.95e-06	0.00171	-0.25	-0.25	Skin pigmentation;	chr20:34116821	chr20:33989480~33991818:-
STAD	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-4.75	2.95e-06	0.00171	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
STAD	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	4.75	2.95e-06	0.00171	0.26	0.25	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000211973.2	IGHV1-69	4.75	2.95e-06	0.00171	0.21	0.25	Kawasaki disease;	chr14:106781985	chr14:106714684~106715181:-
STAD	cis	rs35934224	0.783	rs13056219	ENSG00000232926.1	AC000078.5	4.75	2.95e-06	0.00171	0.38	0.25	Glaucoma (primary open-angle);	chr22:19873323	chr22:19887289~19887970:+
STAD	cis	rs4950322	1	rs4950429	ENSG00000278811.3	LINC00624	4.75	2.95e-06	0.00171	0.27	0.25	Protein quantitative trait loci;	chr1:147400227	chr1:147258885~147517875:-
STAD	cis	rs4950322	1	rs59498179	ENSG00000278811.3	LINC00624	4.75	2.95e-06	0.00171	0.27	0.25	Protein quantitative trait loci;	chr1:147400417	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.947	rs58671552	ENSG00000278811.3	LINC00624	4.75	2.95e-06	0.00171	0.27	0.25	Protein quantitative trait loci;	chr1:147409534	chr1:147258885~147517875:-
STAD	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.96e-06	0.00171	-0.29	-0.25	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
STAD	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-4.75	2.96e-06	0.00171	-0.38	-0.25	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
STAD	cis	rs17401966	0.898	rs12757288	ENSG00000199562.1	RNU6-37P	4.75	2.96e-06	0.00171	0.19	0.25	Hepatocellular carcinoma;	chr1:10263863	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs12737239	ENSG00000199562.1	RNU6-37P	4.75	2.96e-06	0.00171	0.19	0.25	Hepatocellular carcinoma;	chr1:10263915	chr1:10298966~10299072:+
STAD	cis	rs1707322	0.721	rs10890346	ENSG00000225447.1	RPS15AP10	-4.75	2.96e-06	0.00171	-0.19	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45645816~45646197:-
STAD	cis	rs2408955	0.522	rs4760679	ENSG00000258273.1	RP11-370I10.4	4.75	2.96e-06	0.00172	0.3	0.25	Glycated hemoglobin levels;	chr12:48067852	chr12:48333755~48333901:-
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000211973.2	IGHV1-69	4.75	2.96e-06	0.00172	0.21	0.25	Kawasaki disease;	chr14:106782288	chr14:106714684~106715181:-
STAD	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-4.75	2.97e-06	0.00172	-0.31	-0.25	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
STAD	cis	rs13113518	0.902	rs12505266	ENSG00000223305.1	RN7SKP30	4.75	2.97e-06	0.00172	0.28	0.25	Height;	chr4:55546002	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs56154935	ENSG00000223305.1	RN7SKP30	4.75	2.97e-06	0.00172	0.28	0.25	Height;	chr4:55546378	chr4:55540502~55540835:-
STAD	cis	rs875971	1	rs2420168	ENSG00000236529.1	RP13-254B10.1	-4.75	2.97e-06	0.00172	-0.26	-0.25	Aortic root size;	chr7:66165644	chr7:65840212~65840596:+
STAD	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.97e-06	0.00172	-0.29	-0.25	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
STAD	cis	rs858239	0.6	rs10256524	ENSG00000226816.2	AC005082.12	4.75	2.97e-06	0.00172	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23206013~23208045:+
STAD	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-4.75	2.97e-06	0.00172	-0.29	-0.25	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
STAD	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	4.75	2.97e-06	0.00172	0.3	0.25	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
STAD	cis	rs7932354	0.583	rs7934421	ENSG00000271350.1	CTD-2384B9.1	-4.75	2.97e-06	0.00172	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46831202	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.583	rs7480140	ENSG00000271350.1	CTD-2384B9.1	-4.75	2.97e-06	0.00172	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46834784	chr11:47041027~47041945:-
STAD	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	4.75	2.97e-06	0.00172	0.31	0.25	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
STAD	cis	rs7924176	0.521	rs11000986	ENSG00000213731.2	RAB5CP1	-4.75	2.97e-06	0.00172	-0.26	-0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74423435~74424014:-
STAD	cis	rs7924176	0.521	rs10824147	ENSG00000213731.2	RAB5CP1	-4.75	2.97e-06	0.00172	-0.26	-0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74423435~74424014:-
STAD	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-4.75	2.97e-06	0.00172	-0.31	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
STAD	cis	rs6921919	0.583	rs16894108	ENSG00000220721.1	OR1F12	4.75	2.98e-06	0.00172	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28073316~28074233:+
STAD	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	4.75	2.98e-06	0.00172	0.27	0.25	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
STAD	cis	rs210138	0.591	rs1408711	ENSG00000197251.3	LINC00336	-4.75	2.98e-06	0.00172	-0.33	-0.25	Testicular germ cell tumor;	chr6:33652231	chr6:33586106~33593338:-
STAD	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	4.75	2.98e-06	0.00172	0.26	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
STAD	cis	rs8177876	0.749	rs2549891	ENSG00000261838.4	RP11-303E16.6	-4.75	2.98e-06	0.00172	-0.48	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81069854~81076598:+
STAD	cis	rs4950322	0.515	rs11239954	ENSG00000278811.3	LINC00624	4.75	2.98e-06	0.00172	0.26	0.25	Protein quantitative trait loci;	chr1:147246045	chr1:147258885~147517875:-
STAD	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-4.75	2.98e-06	0.00172	-0.29	-0.25	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
STAD	cis	rs13020137	1	rs13020137	ENSG00000231240.1	KLF2P1	-4.75	2.98e-06	0.00172	-0.26	-0.25	Schizophrenia;	chr2:129999731	chr2:130036958~130038422:+
STAD	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	4.75	2.98e-06	0.00173	0.37	0.25	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
STAD	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-4.75	2.98e-06	0.00173	-0.28	-0.25	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
STAD	cis	rs2177312	0.596	rs13108845	ENSG00000251129.1	RP11-734I18.1	-4.75	2.98e-06	0.00173	-0.31	-0.25	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31995660	chr4:31997397~32155406:+
STAD	cis	rs7829975	0.514	rs2920983	ENSG00000173295.6	FAM86B3P	4.75	2.98e-06	0.00173	0.27	0.25	Mood instability;	chr8:8410553	chr8:8228595~8244865:+
STAD	cis	rs875971	1	rs11971949	ENSG00000236529.1	RP13-254B10.1	-4.75	2.98e-06	0.00173	-0.26	-0.25	Aortic root size;	chr7:66161027	chr7:65840212~65840596:+
STAD	cis	rs6142102	0.923	rs4911379	ENSG00000275784.1	RP5-1125A11.6	-4.75	2.99e-06	0.00173	-0.25	-0.25	Skin pigmentation;	chr20:33947499	chr20:33989480~33991818:-
STAD	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	4.75	2.99e-06	0.00173	0.34	0.25	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
STAD	cis	rs13113518	0.934	rs10866425	ENSG00000223305.1	RN7SKP30	4.75	2.99e-06	0.00173	0.28	0.25	Height;	chr4:55582068	chr4:55540502~55540835:-
STAD	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	4.75	2.99e-06	0.00173	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
STAD	cis	rs4950322	0.57	rs79810882	ENSG00000278811.3	LINC00624	4.75	2.99e-06	0.00173	0.27	0.25	Protein quantitative trait loci;	chr1:147235575	chr1:147258885~147517875:-
STAD	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	4.75	2.99e-06	0.00173	0.32	0.25	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
STAD	cis	rs728616	0.867	rs56123058	ENSG00000225484.5	NUTM2B-AS1	-4.75	2.99e-06	0.00173	-0.52	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:79663088~79826594:-
STAD	cis	rs875971	0.862	rs2420174	ENSG00000236529.1	RP13-254B10.1	-4.75	2.99e-06	0.00173	-0.26	-0.25	Aortic root size;	chr7:66180374	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs2420173	ENSG00000236529.1	RP13-254B10.1	-4.75	2.99e-06	0.00173	-0.26	-0.25	Aortic root size;	chr7:66180412	chr7:65840212~65840596:+
STAD	cis	rs9987353	0.518	rs4841110	ENSG00000254340.1	RP11-10A14.3	4.75	3e-06	0.00173	0.34	0.25	Recombination measurement;	chr8:9228513	chr8:9141424~9145435:+
STAD	cis	rs13413635	0.66	rs744397	ENSG00000225808.1	DNAJC19P5	4.75	3e-06	0.00173	0.3	0.25	Heart rate;	chr2:177994391	chr2:177229191~177229506:-
STAD	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-4.75	3e-06	0.00173	-0.31	-0.25	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
STAD	cis	rs8097348	0.744	rs2123935	ENSG00000266602.1	RP11-476K15.1	-4.75	3e-06	0.00173	-0.28	-0.25	Exercise (leisure time);	chr18:1668839	chr18:1509183~1647097:+
STAD	cis	rs875971	0.862	rs4718319	ENSG00000236529.1	RP13-254B10.1	-4.75	3.01e-06	0.00174	-0.26	-0.25	Aortic root size;	chr7:66187797	chr7:65840212~65840596:+
STAD	cis	rs875971	0.723	rs28391294	ENSG00000236529.1	RP13-254B10.1	-4.75	3.01e-06	0.00174	-0.26	-0.25	Aortic root size;	chr7:66189328	chr7:65840212~65840596:+
STAD	cis	rs875971	0.83	rs6967708	ENSG00000236529.1	RP13-254B10.1	-4.75	3.01e-06	0.00174	-0.26	-0.25	Aortic root size;	chr7:66192326	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs7782806	ENSG00000236529.1	RP13-254B10.1	-4.75	3.01e-06	0.00174	-0.26	-0.25	Aortic root size;	chr7:66192910	chr7:65840212~65840596:+
STAD	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	4.75	3.01e-06	0.00174	0.31	0.25	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
STAD	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	4.75	3.01e-06	0.00174	0.32	0.25	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
STAD	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	4.75	3.01e-06	0.00174	0.3	0.25	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
STAD	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-4.75	3.01e-06	0.00174	-0.28	-0.25	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-4.75	3.01e-06	0.00174	-0.28	-0.25	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-4.75	3.01e-06	0.00174	-0.28	-0.25	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
STAD	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-4.75	3.01e-06	0.00174	-0.25	-0.25	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
STAD	cis	rs3758911	0.828	rs11212173	ENSG00000261098.1	RP11-819C21.1	-4.75	3.01e-06	0.00174	-0.23	-0.25	Coronary artery disease;	chr11:107343881	chr11:107312132~107316271:-
STAD	cis	rs801193	0.569	rs7800620	ENSG00000224316.1	RP11-479O9.2	4.75	3.01e-06	0.00174	0.24	0.25	Aortic root size;	chr7:66758701	chr7:65773620~65802067:+
STAD	cis	rs13113518	0.783	rs12504300	ENSG00000272969.1	RP11-528I4.2	4.75	3.01e-06	0.00174	0.32	0.25	Height;	chr4:55482360	chr4:55547112~55547889:+
STAD	cis	rs227275	0.525	rs6533050	ENSG00000248971.2	KRT8P46	-4.75	3.01e-06	0.00174	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs10032234	ENSG00000248971.2	KRT8P46	-4.75	3.01e-06	0.00174	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs28845922	ENSG00000248971.2	KRT8P46	-4.75	3.01e-06	0.00174	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102728746~102730171:-
STAD	cis	rs35934224	0.542	rs8139091	ENSG00000232926.1	AC000078.5	4.75	3.01e-06	0.00174	0.29	0.25	Glaucoma (primary open-angle);	chr22:19857760	chr22:19887289~19887970:+
STAD	cis	rs2337406	1	rs3858878	ENSG00000211972.2	IGHV3-66	4.75	3.02e-06	0.00174	0.26	0.25	Alzheimer's disease (late onset);	chr14:106688061	chr14:106675017~106675544:-
STAD	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-4.75	3.02e-06	0.00174	-0.36	-0.25	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
STAD	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-4.75	3.02e-06	0.00174	-0.36	-0.25	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
STAD	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-4.75	3.02e-06	0.00174	-0.24	-0.25	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-4.75	3.02e-06	0.00174	-0.24	-0.25	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
STAD	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-4.75	3.02e-06	0.00175	-0.29	-0.25	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-4.75	3.02e-06	0.00175	-0.29	-0.25	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
STAD	cis	rs4589258	0.966	rs7116531	ENSG00000280367.1	RP11-121L10.2	4.75	3.02e-06	0.00175	0.27	0.25	Intelligence (multi-trait analysis);	chr11:90741490	chr11:90223153~90226538:+
STAD	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-4.75	3.03e-06	0.00175	-0.38	-0.25	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
STAD	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	4.75	3.03e-06	0.00175	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	4.75	3.03e-06	0.00175	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
STAD	cis	rs227275	0.525	rs7685399	ENSG00000248971.2	KRT8P46	-4.75	3.03e-06	0.00175	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs2866417	ENSG00000248971.2	KRT8P46	-4.75	3.03e-06	0.00175	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs1383733	ENSG00000248971.2	KRT8P46	-4.75	3.03e-06	0.00175	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102728746~102730171:-
STAD	cis	rs7615952	0.932	rs11922218	ENSG00000272840.1	RP11-379B18.6	4.75	3.03e-06	0.00175	0.45	0.25	Blood pressure (smoking interaction);	chr3:125912446	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.866	rs11922276	ENSG00000272840.1	RP11-379B18.6	4.75	3.03e-06	0.00175	0.45	0.25	Blood pressure (smoking interaction);	chr3:125912483	chr3:125774714~125797953:+
STAD	cis	rs875971	0.545	rs2279757	ENSG00000236529.1	RP13-254B10.1	4.75	3.03e-06	0.00175	0.29	0.25	Aortic root size;	chr7:66363676	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs11766183	ENSG00000236529.1	RP13-254B10.1	4.75	3.03e-06	0.00175	0.29	0.25	Aortic root size;	chr7:66374173	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs1065265	ENSG00000236529.1	RP13-254B10.1	4.75	3.03e-06	0.00175	0.29	0.25	Aortic root size;	chr7:66376216	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs55962648	ENSG00000236529.1	RP13-254B10.1	-4.75	3.03e-06	0.00175	-0.26	-0.25	Aortic root size;	chr7:66160764	chr7:65840212~65840596:+
STAD	cis	rs227275	0.524	rs223423	ENSG00000248971.2	KRT8P46	-4.75	3.03e-06	0.00175	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102728746~102730171:-
STAD	cis	rs17507216	1	rs17158413	ENSG00000255769.6	GOLGA2P10	-4.75	3.03e-06	0.00175	-0.37	-0.25	Excessive daytime sleepiness;	chr15:82566658	chr15:82472993~82513950:-
STAD	cis	rs13113518	1	rs4865011	ENSG00000223305.1	RN7SKP30	4.75	3.03e-06	0.00175	0.28	0.25	Height;	chr4:55554456	chr4:55540502~55540835:-
STAD	cis	rs360071	0.528	rs360098	ENSG00000242861.1	RP11-285F7.2	-4.75	3.03e-06	0.00175	-0.23	-0.25	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225878990	chr1:225840883~225846522:-
STAD	cis	rs9463078	0.546	rs1324540	ENSG00000219384.1	RP11-491H9.3	4.75	3.03e-06	0.00175	0.24	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45235353	chr6:45158870~45159511:+
STAD	cis	rs748404	0.666	rs8027748	ENSG00000249839.1	AC011330.5	-4.75	3.03e-06	0.00175	-0.43	-0.25	Lung cancer;	chr15:43447622	chr15:43663654~43684339:-
STAD	cis	rs7924176	0.521	rs1904062	ENSG00000213731.2	RAB5CP1	-4.75	3.03e-06	0.00175	-0.26	-0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74423435~74424014:-
STAD	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	4.75	3.04e-06	0.00175	0.3	0.25	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
STAD	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	4.75	3.04e-06	0.00175	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
STAD	cis	rs228614	0.536	rs223420	ENSG00000248971.2	KRT8P46	-4.75	3.04e-06	0.00175	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102728746~102730171:-
STAD	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-4.75	3.04e-06	0.00175	-0.26	-0.25	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
STAD	cis	rs7665090	1	rs5026472	ENSG00000230069.3	LRRC37A15P	-4.75	3.04e-06	0.00175	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633616	chr4:102727274~102730721:-
STAD	cis	rs4950322	0.57	rs1999820	ENSG00000278811.3	LINC00624	4.75	3.04e-06	0.00175	0.27	0.25	Protein quantitative trait loci;	chr1:147270329	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs3737855	ENSG00000278811.3	LINC00624	4.75	3.04e-06	0.00175	0.27	0.25	Protein quantitative trait loci;	chr1:147271257	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.57	rs4950316	ENSG00000278811.3	LINC00624	4.75	3.04e-06	0.00175	0.27	0.25	Protein quantitative trait loci;	chr1:147273712	chr1:147258885~147517875:-
STAD	cis	rs17214007	0.877	rs10852376	ENSG00000263335.1	AF001548.5	4.75	3.04e-06	0.00175	0.28	0.25	Cognitive function;	chr16:15778216	chr16:15726674~15732993:+
STAD	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-4.75	3.04e-06	0.00175	-0.35	-0.25	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
STAD	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-4.75	3.04e-06	0.00175	-0.25	-0.25	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
STAD	cis	rs228614	0.536	rs223419	ENSG00000248971.2	KRT8P46	-4.75	3.05e-06	0.00176	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102728746~102730171:-
STAD	cis	rs228614	0.536	rs223418	ENSG00000248971.2	KRT8P46	-4.75	3.05e-06	0.00176	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102728746~102730171:-
STAD	cis	rs728616	0.681	rs55838345	ENSG00000225484.5	NUTM2B-AS1	-4.75	3.05e-06	0.00176	-0.49	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80325364	chr10:79663088~79826594:-
STAD	cis	rs728616	0.614	rs61859191	ENSG00000225484.5	NUTM2B-AS1	-4.75	3.05e-06	0.00176	-0.49	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80331271	chr10:79663088~79826594:-
STAD	cis	rs728616	0.614	rs17678338	ENSG00000225484.5	NUTM2B-AS1	-4.75	3.05e-06	0.00176	-0.49	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80338390	chr10:79663088~79826594:-
STAD	cis	rs17660992	0.716	rs8111426	ENSG00000273837.1	LLNLR-470E3.1	-4.75	3.05e-06	0.00176	-0.29	-0.25	Blood protein levels;	chr19:51662110	chr19:51639478~51639931:-
STAD	cis	rs7665090	0.967	rs5026469	ENSG00000230069.3	LRRC37A15P	-4.75	3.05e-06	0.00176	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633556	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.967	rs5026470	ENSG00000230069.3	LRRC37A15P	-4.75	3.05e-06	0.00176	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633565	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.967	rs5026471	ENSG00000230069.3	LRRC37A15P	-4.75	3.05e-06	0.00176	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633576	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.936	rs5026474	ENSG00000230069.3	LRRC37A15P	-4.75	3.05e-06	0.00176	-0.27	-0.25	Primary biliary cholangitis;	chr4:102633653	chr4:102727274~102730721:-
STAD	cis	rs10129255	0.5	rs10143242	ENSG00000211973.2	IGHV1-69	4.75	3.05e-06	0.00176	0.21	0.25	Kawasaki disease;	chr14:106681814	chr14:106714684~106715181:-
STAD	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-4.75	3.05e-06	0.00176	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
STAD	cis	rs7615952	0.673	rs16834637	ENSG00000239804.1	RP11-379B18.1	4.75	3.05e-06	0.00176	0.45	0.25	Blood pressure (smoking interaction);	chr3:125886628	chr3:125787888~125788146:-
STAD	cis	rs227275	0.555	rs223402	ENSG00000248971.2	KRT8P46	-4.75	3.05e-06	0.00176	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102728746~102730171:-
STAD	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	4.74	3.06e-06	0.00176	0.36	0.25	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
STAD	cis	rs228614	0.51	rs223415	ENSG00000248971.2	KRT8P46	-4.74	3.06e-06	0.00176	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102728746~102730171:-
STAD	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	4.74	3.06e-06	0.00176	0.3	0.25	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	4.74	3.06e-06	0.00176	0.3	0.25	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	4.74	3.06e-06	0.00176	0.3	0.25	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
STAD	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-4.74	3.06e-06	0.00176	-0.25	-0.25	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
STAD	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	4.74	3.06e-06	0.00176	0.33	0.25	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
STAD	cis	rs11098499	0.954	rs10017371	ENSG00000260091.1	RP11-33B1.4	4.74	3.06e-06	0.00177	0.24	0.25	Corneal astigmatism;	chr4:119372621	chr4:119409333~119410233:+
STAD	cis	rs516805	0.597	rs666046	ENSG00000279453.1	RP3-425C14.4	-4.74	3.06e-06	0.00177	-0.37	-0.25	Lymphocyte counts;	chr6:122290427	chr6:122436789~122439223:-
STAD	cis	rs716804	0.837	rs1372811	ENSG00000254554.1	RP11-351I24.1	-4.74	3.06e-06	0.00177	-0.37	-0.25	Neuroticism;	chr11:10220653	chr11:10302657~10303704:-
STAD	cis	rs716804	0.837	rs4910102	ENSG00000254554.1	RP11-351I24.1	-4.74	3.06e-06	0.00177	-0.37	-0.25	Neuroticism;	chr11:10221506	chr11:10302657~10303704:-
STAD	cis	rs228614	0.51	rs223410	ENSG00000248971.2	KRT8P46	-4.74	3.07e-06	0.00177	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102728746~102730171:-
STAD	cis	rs13113518	1	rs13115828	ENSG00000223305.1	RN7SKP30	4.74	3.07e-06	0.00177	0.28	0.25	Height;	chr4:55551447	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11934897	ENSG00000223305.1	RN7SKP30	4.74	3.07e-06	0.00177	0.28	0.25	Height;	chr4:55553396	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.934	rs11932293	ENSG00000223305.1	RN7SKP30	4.74	3.07e-06	0.00177	0.28	0.25	Height;	chr4:55554025	chr4:55540502~55540835:-
STAD	cis	rs875971	0.545	rs1796217	ENSG00000236529.1	RP13-254B10.1	-4.74	3.07e-06	0.00177	-0.28	-0.25	Aortic root size;	chr7:66620931	chr7:65840212~65840596:+
STAD	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.07e-06	0.00177	-0.28	-0.25	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
STAD	cis	rs8177876	0.915	rs8059692	ENSG00000261061.1	RP11-303E16.2	-4.74	3.07e-06	0.00177	-0.51	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81030770~81031485:+
STAD	cis	rs4950322	1	rs72694750	ENSG00000278811.3	LINC00624	4.74	3.07e-06	0.00177	0.27	0.25	Protein quantitative trait loci;	chr1:147396856	chr1:147258885~147517875:-
STAD	cis	rs4950322	1	rs1986987	ENSG00000278811.3	LINC00624	4.74	3.07e-06	0.00177	0.27	0.25	Protein quantitative trait loci;	chr1:147397553	chr1:147258885~147517875:-
STAD	cis	rs4950322	1	rs61230354	ENSG00000278811.3	LINC00624	4.74	3.07e-06	0.00177	0.27	0.25	Protein quantitative trait loci;	chr1:147398161	chr1:147258885~147517875:-
STAD	cis	rs9907295	0.748	rs4251719	ENSG00000270894.1	AC015849.13	-4.74	3.08e-06	0.00177	-0.25	-0.25	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35818399~35823713:+
STAD	cis	rs34929064	0.781	rs2905324	ENSG00000179428.2	AC073072.5	-4.74	3.08e-06	0.00177	-0.27	-0.25	Major depression and alcohol dependence;	chr7:22669384	chr7:22725395~22727620:-
STAD	cis	rs11676348	0.818	rs6436031	ENSG00000237281.1	CATIP-AS2	4.74	3.08e-06	0.00177	0.24	0.25	Ulcerative colitis;	chr2:218114536	chr2:218326889~218357966:-
STAD	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	4.74	3.08e-06	0.00177	0.27	0.25	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
STAD	cis	rs2337406	0.539	rs2583292	ENSG00000211972.2	IGHV3-66	4.74	3.08e-06	0.00177	0.26	0.25	Alzheimer's disease (late onset);	chr14:106649040	chr14:106675017~106675544:-
STAD	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-4.74	3.08e-06	0.00177	-0.37	-0.25	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
STAD	cis	rs11846409	0.872	rs2516914	ENSG00000211972.2	IGHV3-66	-4.74	3.08e-06	0.00177	-0.26	-0.25	Rheumatic heart disease;	chr14:106629835	chr14:106675017~106675544:-
STAD	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	4.74	3.08e-06	0.00177	0.3	0.25	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
STAD	cis	rs10510102	0.935	rs11200243	ENSG00000226864.1	ATE1-AS1	4.74	3.08e-06	0.00177	0.41	0.25	Breast cancer;	chr10:121906888	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200244	ENSG00000226864.1	ATE1-AS1	4.74	3.08e-06	0.00177	0.41	0.25	Breast cancer;	chr10:121906944	chr10:121928312~121951965:+
STAD	cis	rs13113518	1	rs4864549	ENSG00000223305.1	RN7SKP30	4.74	3.08e-06	0.00178	0.28	0.25	Height;	chr4:55554380	chr4:55540502~55540835:-
STAD	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-4.74	3.08e-06	0.00178	-0.25	-0.25	Height;	chr5:36997725	chr5:36666214~36725195:-
STAD	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	4.74	3.09e-06	0.00178	0.3	0.25	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
STAD	cis	rs3736858	1	rs9544049	ENSG00000261105.4	LMO7-AS1	-4.74	3.09e-06	0.00178	-0.42	-0.25	Interleukin-9 levels;	chr13:75826906	chr13:75604700~75635994:-
STAD	cis	rs7829975	0.846	rs1879957	ENSG00000253981.4	ALG1L13P	-4.74	3.09e-06	0.00178	-0.3	-0.25	Mood instability;	chr8:8687298	chr8:8236003~8244667:-
STAD	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	4.74	3.09e-06	0.00178	0.29	0.25	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
STAD	cis	rs1056107	0.763	rs60623018	ENSG00000225513.1	RP11-165N19.2	-4.74	3.09e-06	0.00178	-0.29	-0.25	Colorectal cancer;	chr9:112175922	chr9:112173522~112173971:-
STAD	cis	rs7615952	0.932	rs13321217	ENSG00000272840.1	RP11-379B18.6	4.74	3.09e-06	0.00178	0.44	0.25	Blood pressure (smoking interaction);	chr3:125912928	chr3:125774714~125797953:+
STAD	cis	rs13113518	0.934	rs11133397	ENSG00000223305.1	RN7SKP30	4.74	3.09e-06	0.00178	0.27	0.25	Height;	chr4:55534166	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.934	rs11133398	ENSG00000223305.1	RN7SKP30	4.74	3.09e-06	0.00178	0.27	0.25	Height;	chr4:55534180	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs13152173	ENSG00000223305.1	RN7SKP30	4.74	3.09e-06	0.00178	0.27	0.25	Height;	chr4:55534788	chr4:55540502~55540835:-
STAD	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	4.74	3.09e-06	0.00178	0.26	0.25	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
STAD	cis	rs2337406	0.866	rs8015361	ENSG00000280411.1	IGHV1-69-2	-4.74	3.1e-06	0.00178	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106783991	chr14:106762092~106762588:-
STAD	cis	rs916888	0.773	rs1378358	ENSG00000232300.1	FAM215B	4.74	3.1e-06	0.00178	0.33	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46558830~46562795:-
STAD	cis	rs4589258	1	rs4603267	ENSG00000280367.1	RP11-121L10.2	4.74	3.1e-06	0.00178	0.27	0.25	Intelligence (multi-trait analysis);	chr11:90772530	chr11:90223153~90226538:+
STAD	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	4.74	3.1e-06	0.00178	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	4.74	3.1e-06	0.00178	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
STAD	cis	rs2404602	0.692	rs34287706	ENSG00000259422.1	RP11-593F23.1	4.74	3.1e-06	0.00178	0.26	0.25	Blood metabolite levels;	chr15:76650061	chr15:76174891~76181486:-
STAD	cis	rs2404602	0.669	rs12438540	ENSG00000259422.1	RP11-593F23.1	4.74	3.1e-06	0.00178	0.26	0.25	Blood metabolite levels;	chr15:76650872	chr15:76174891~76181486:-
STAD	cis	rs73219805	0.838	rs7840859	ENSG00000228451.3	SDAD1P1	-4.74	3.1e-06	0.00178	-0.33	-0.25	Schizophrenia;	chr8:26377501	chr8:26379259~26382953:-
STAD	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	4.74	3.1e-06	0.00178	0.3	0.25	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	4.74	3.1e-06	0.00178	0.3	0.25	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	4.74	3.1e-06	0.00178	0.3	0.25	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
STAD	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	4.74	3.1e-06	0.00178	0.39	0.25	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
STAD	cis	rs17301013	0.861	rs332796	ENSG00000227373.4	RP11-160H22.5	4.74	3.1e-06	0.00178	0.3	0.25	Systemic lupus erythematosus;	chr1:174727142	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.861	rs332799	ENSG00000227373.4	RP11-160H22.5	4.74	3.1e-06	0.00178	0.3	0.25	Systemic lupus erythematosus;	chr1:174731110	chr1:174115300~174160004:-
STAD	cis	rs17401966	0.838	rs4846209	ENSG00000199562.1	RNU6-37P	4.74	3.1e-06	0.00178	0.19	0.25	Hepatocellular carcinoma;	chr1:10261996	chr1:10298966~10299072:+
STAD	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	4.74	3.1e-06	0.00178	0.34	0.25	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
STAD	cis	rs4589258	1	rs4615986	ENSG00000280367.1	RP11-121L10.2	4.74	3.1e-06	0.00178	0.26	0.25	Intelligence (multi-trait analysis);	chr11:90769288	chr11:90223153~90226538:+
STAD	cis	rs4970988	0.556	rs6681426	ENSG00000274963.1	Metazoa_SRP	-4.74	3.1e-06	0.00179	-0.21	-0.25	Urate levels;	chr1:150614495	chr1:150568971~150569269:-
STAD	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	4.74	3.11e-06	0.00179	0.3	0.25	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
STAD	cis	rs2281636	0.6	rs56901709	ENSG00000233690.1	EBAG9P1	4.74	3.11e-06	0.00179	0.27	0.25	Obesity-related traits;	chr10:99639205	chr10:99697407~99697949:-
STAD	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-4.74	3.11e-06	0.00179	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
STAD	cis	rs6921919	0.583	rs16894060	ENSG00000220721.1	OR1F12	4.74	3.11e-06	0.00179	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28073316~28074233:+
STAD	cis	rs1707322	0.717	rs1135812	ENSG00000281133.1	AL355480.3	-4.74	3.11e-06	0.00179	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45580892~45580996:-
STAD	cis	rs8099594	0.565	rs7238371	ENSG00000266696.1	RP11-30L3.2	4.74	3.12e-06	0.00179	0.23	0.25	Height;	chr18:49185269	chr18:49205912~49208781:+
STAD	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	4.74	3.12e-06	0.00179	0.25	0.25	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
STAD	cis	rs728616	0.867	rs2152550	ENSG00000225484.5	NUTM2B-AS1	-4.74	3.12e-06	0.00179	-0.52	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:79663088~79826594:-
STAD	cis	rs7078219	0.505	rs10883367	ENSG00000228778.1	RP11-129J12.1	-4.74	3.12e-06	0.00179	-0.28	-0.25	Dental caries;	chr10:99528233	chr10:99527081~99528261:+
STAD	cis	rs10776614	0.642	rs7894707	ENSG00000189014.7	FAM35DP	-4.74	3.12e-06	0.00179	-0.32	-0.25	Self-employment;	chr10:48559954	chr10:47689707~47730436:+
STAD	cis	rs4243830	0.85	rs12563717	ENSG00000229519.2	RP11-58A11.2	-4.74	3.13e-06	0.0018	-0.28	-0.25	Body mass index;	chr1:6539497	chr1:6547905~6548619:+
STAD	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-4.74	3.13e-06	0.0018	-0.27	-0.25	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
STAD	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.13e-06	0.0018	-0.28	-0.25	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
STAD	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-4.74	3.13e-06	0.0018	-0.36	-0.25	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-4.74	3.13e-06	0.0018	-0.36	-0.25	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-4.74	3.13e-06	0.0018	-0.36	-0.25	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
STAD	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-4.74	3.13e-06	0.0018	-0.36	-0.25	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-4.74	3.13e-06	0.0018	-0.36	-0.25	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
STAD	cis	rs716804	0.805	rs2403291	ENSG00000254554.1	RP11-351I24.1	-4.74	3.13e-06	0.0018	-0.36	-0.25	Neuroticism;	chr11:10217758	chr11:10302657~10303704:-
STAD	cis	rs716804	0.837	rs1988725	ENSG00000254554.1	RP11-351I24.1	-4.74	3.13e-06	0.0018	-0.36	-0.25	Neuroticism;	chr11:10217911	chr11:10302657~10303704:-
STAD	cis	rs716804	0.869	rs1837978	ENSG00000254554.1	RP11-351I24.1	-4.74	3.13e-06	0.0018	-0.36	-0.25	Neuroticism;	chr11:10218449	chr11:10302657~10303704:-
STAD	cis	rs716804	0.805	rs4910101	ENSG00000254554.1	RP11-351I24.1	-4.74	3.13e-06	0.0018	-0.36	-0.25	Neuroticism;	chr11:10221432	chr11:10302657~10303704:-
STAD	cis	rs716804	0.837	rs1114426	ENSG00000254554.1	RP11-351I24.1	-4.74	3.13e-06	0.0018	-0.36	-0.25	Neuroticism;	chr11:10221880	chr11:10302657~10303704:-
STAD	cis	rs7932354	0.528	rs747650	ENSG00000271350.1	CTD-2384B9.1	4.74	3.13e-06	0.0018	0.3	0.25	Bone mineral density (hip);Bone mineral density;	chr11:47154454	chr11:47041027~47041945:-
STAD	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.13e-06	0.0018	-0.28	-0.25	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
STAD	cis	rs1723838	0.826	rs2037709	ENSG00000255928.1	RP11-456I15.2	-4.74	3.14e-06	0.0018	-0.53	-0.25	Obesity-related traits;	chr11:73730727	chr11:73722349~73722694:+
STAD	cis	rs4243830	0.522	rs10864614	ENSG00000229519.2	RP11-58A11.2	4.74	3.14e-06	0.0018	0.26	0.25	Body mass index;	chr1:6535948	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.51	rs7518459	ENSG00000229519.2	RP11-58A11.2	4.74	3.14e-06	0.0018	0.26	0.25	Body mass index;	chr1:6536618	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.85	rs12744992	ENSG00000229519.2	RP11-58A11.2	4.74	3.14e-06	0.0018	0.26	0.25	Body mass index;	chr1:6541230	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.85	rs4434862	ENSG00000229519.2	RP11-58A11.2	4.74	3.14e-06	0.0018	0.26	0.25	Body mass index;	chr1:6542181	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.85	rs2412309	ENSG00000229519.2	RP11-58A11.2	4.74	3.14e-06	0.0018	0.26	0.25	Body mass index;	chr1:6543091	chr1:6547905~6548619:+
STAD	cis	rs4061073	0.961	rs9012	ENSG00000198711.5	SSBP3-AS1	-4.74	3.14e-06	0.0018	-0.2	-0.25	Body mass index;	chr1:54225792	chr1:54236440~54239063:+
STAD	cis	rs1056107	0.933	rs7037658	ENSG00000225513.1	RP11-165N19.2	-4.74	3.14e-06	0.0018	-0.28	-0.25	Colorectal cancer;	chr9:112309244	chr9:112173522~112173971:-
STAD	cis	rs1799949	0.93	rs4584865	ENSG00000279602.1	CTD-3014M21.1	4.74	3.14e-06	0.0018	0.31	0.25	Menopause (age at onset);	chr17:43347551	chr17:43360041~43361361:-
STAD	cis	rs11098499	0.863	rs10018280	ENSG00000260091.1	RP11-33B1.4	4.74	3.14e-06	0.0018	0.25	0.25	Corneal astigmatism;	chr4:119556984	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs6534141	ENSG00000260091.1	RP11-33B1.4	4.74	3.14e-06	0.0018	0.25	0.25	Corneal astigmatism;	chr4:119564068	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs2127823	ENSG00000260091.1	RP11-33B1.4	4.74	3.14e-06	0.0018	0.25	0.25	Corneal astigmatism;	chr4:119564515	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3775858	ENSG00000260091.1	RP11-33B1.4	4.74	3.14e-06	0.0018	0.25	0.25	Corneal astigmatism;	chr4:119564873	chr4:119409333~119410233:+
STAD	cis	rs10510102	0.935	rs79360006	ENSG00000226864.1	ATE1-AS1	4.74	3.14e-06	0.0018	0.41	0.25	Breast cancer;	chr10:121912856	chr10:121928312~121951965:+
STAD	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.14e-06	0.0018	-0.29	-0.25	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.14e-06	0.0018	-0.29	-0.25	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.14e-06	0.0018	-0.29	-0.25	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.14e-06	0.0018	-0.29	-0.25	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
STAD	cis	rs2337406	0.85	rs11161008	ENSG00000211972.2	IGHV3-66	4.74	3.14e-06	0.0018	0.27	0.25	Alzheimer's disease (late onset);	chr14:106705261	chr14:106675017~106675544:-
STAD	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-4.74	3.14e-06	0.0018	-0.32	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
STAD	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	4.74	3.14e-06	0.0018	0.43	0.25	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
STAD	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	4.74	3.15e-06	0.00181	0.26	0.25	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
STAD	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-4.74	3.15e-06	0.00181	-0.26	-0.25	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
STAD	cis	rs875971	0.964	rs60193905	ENSG00000236529.1	RP13-254B10.1	4.74	3.15e-06	0.00181	0.26	0.25	Aortic root size;	chr7:66506273	chr7:65840212~65840596:+
STAD	cis	rs11846409	0.932	rs2583329	ENSG00000211972.2	IGHV3-66	-4.74	3.15e-06	0.00181	-0.26	-0.25	Rheumatic heart disease;	chr14:106632971	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs2015469	ENSG00000211972.2	IGHV3-66	4.74	3.15e-06	0.00181	0.26	0.25	Rheumatic heart disease;	chr14:106631857	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs56167903	ENSG00000211972.2	IGHV3-66	4.74	3.15e-06	0.00181	0.26	0.25	Rheumatic heart disease;	chr14:106632070	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.86	rs10150951	ENSG00000211972.2	IGHV3-66	4.74	3.15e-06	0.00181	0.26	0.25	Rheumatic heart disease;	chr14:106632988	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.86	rs17112419	ENSG00000211972.2	IGHV3-66	4.74	3.15e-06	0.00181	0.26	0.25	Rheumatic heart disease;	chr14:106633260	chr14:106675017~106675544:-
STAD	cis	rs3770081	1	rs1036554	ENSG00000273080.1	RP11-301O19.1	-4.74	3.15e-06	0.00181	-0.56	-0.25	Facial emotion recognition (sad faces);	chr2:86008976	chr2:86195590~86196049:+
STAD	cis	rs1799949	0.965	rs8176323	ENSG00000236383.6	LINC00854	-4.74	3.15e-06	0.00181	-0.2	-0.25	Menopause (age at onset);	chr17:43043694	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs8176322	ENSG00000236383.6	LINC00854	-4.74	3.15e-06	0.00181	-0.2	-0.25	Menopause (age at onset);	chr17:43043756	chr17:43216941~43305976:-
STAD	cis	rs875971	0.545	rs6969224	ENSG00000236529.1	RP13-254B10.1	4.74	3.16e-06	0.00181	0.29	0.25	Aortic root size;	chr7:66370011	chr7:65840212~65840596:+
STAD	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-4.74	3.16e-06	0.00181	-0.25	-0.25	Height;	chr5:36904297	chr5:36666214~36725195:-
STAD	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-4.74	3.16e-06	0.00181	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
STAD	cis	rs10741780	0.697	rs4757821	ENSG00000254544.1	PCNAP4	4.74	3.16e-06	0.00181	0.32	0.25	HIV-1 susceptibility;	chr11:19591783	chr11:19274540~19275269:-
STAD	cis	rs7487075	0.558	rs7959095	ENSG00000272369.1	RP11-446N19.1	4.74	3.16e-06	0.00181	0.3	0.25	Itch intensity from mosquito bite;	chr12:46239545	chr12:46537502~46652550:+
STAD	cis	rs11098499	0.866	rs72676074	ENSG00000260091.1	RP11-33B1.4	4.74	3.16e-06	0.00181	0.24	0.25	Corneal astigmatism;	chr4:119438686	chr4:119409333~119410233:+
STAD	cis	rs7665090	1	rs7664828	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102630219	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.967	rs7690123	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102630602	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs7665659	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102630661	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs7665854	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102630752	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.846	rs7690700	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102630911	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs13112557	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102631096	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs12644381	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102631273	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs1054037	ENSG00000230069.3	LRRC37A15P	-4.74	3.16e-06	0.00181	-0.27	-0.25	Primary biliary cholangitis;	chr4:102631552	chr4:102727274~102730721:-
STAD	cis	rs13113518	1	rs4865007	ENSG00000223305.1	RN7SKP30	-4.74	3.16e-06	0.00181	-0.27	-0.25	Height;	chr4:55537550	chr4:55540502~55540835:-
STAD	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	4.74	3.16e-06	0.00181	0.4	0.25	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
STAD	cis	rs35955747	0.633	rs5998021	ENSG00000236132.1	CTA-440B3.1	4.74	3.16e-06	0.00181	0.26	0.25	Neutrophil count;Sum basophil neutrophil counts;	chr22:31511441	chr22:31816379~31817491:-
STAD	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	4.74	3.16e-06	0.00181	0.28	0.25	QT interval;	chr12:29292489	chr12:29280418~29317848:-
STAD	cis	rs6095360	0.689	rs35667796	ENSG00000222365.1	SNORD12B	-4.74	3.17e-06	0.00181	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:49186764	chr20:49280319~49280409:+
STAD	cis	rs2286503	1	rs2286503	ENSG00000221740.1	SNORD93	4.74	3.17e-06	0.00182	0.28	0.25	Fibrinogen;	chr7:22816987	chr7:22856613~22856686:+
STAD	cis	rs2286503	1	rs2286501	ENSG00000221740.1	SNORD93	4.74	3.17e-06	0.00182	0.28	0.25	Fibrinogen;	chr7:22817166	chr7:22856613~22856686:+
STAD	cis	rs875971	1	rs697970	ENSG00000236529.1	RP13-254B10.1	-4.74	3.17e-06	0.00182	-0.26	-0.25	Aortic root size;	chr7:66095065	chr7:65840212~65840596:+
STAD	cis	rs13113518	1	rs13136282	ENSG00000223305.1	RN7SKP30	4.74	3.17e-06	0.00182	0.28	0.25	Height;	chr4:55551845	chr4:55540502~55540835:-
STAD	cis	rs7662987	0.793	rs12697	ENSG00000272777.1	RP11-571L19.8	-4.74	3.17e-06	0.00182	-0.44	-0.25	Smoking initiation;	chr4:99072225	chr4:99067256~99068125:-
STAD	cis	rs4589258	0.788	rs4477404	ENSG00000280367.1	RP11-121L10.2	4.74	3.17e-06	0.00182	0.24	0.25	Intelligence (multi-trait analysis);	chr11:90732238	chr11:90223153~90226538:+
STAD	cis	rs1799949	1	rs12516	ENSG00000236383.6	LINC00854	-4.74	3.17e-06	0.00182	-0.2	-0.25	Menopause (age at onset);	chr17:43044391	chr17:43216941~43305976:-
STAD	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-4.74	3.17e-06	0.00182	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
STAD	cis	rs11676348	0.811	rs4674255	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.24	0.25	Ulcerative colitis;	chr2:218122602	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.818	rs1126579	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.25	0.25	Ulcerative colitis;	chr2:218136011	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.846	rs4674260	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.25	0.25	Ulcerative colitis;	chr2:218137653	chr2:218326889~218357966:-
STAD	cis	rs11722779	0.873	rs223384	ENSG00000248971.2	KRT8P46	-4.74	3.18e-06	0.00182	-0.25	-0.25	Schizophrenia;	chr4:102829976	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223383	ENSG00000248971.2	KRT8P46	-4.74	3.18e-06	0.00182	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102728746~102730171:-
STAD	cis	rs2921036	0.529	rs2979192	ENSG00000253981.4	ALG1L13P	4.74	3.18e-06	0.00182	0.3	0.25	Neuroticism;	chr8:8480637	chr8:8236003~8244667:-
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-4.74	3.18e-06	0.00182	-0.19	-0.25	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-4.74	3.18e-06	0.00182	-0.19	-0.25	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
STAD	cis	rs3758911	0.894	rs11212162	ENSG00000261098.1	RP11-819C21.1	-4.74	3.18e-06	0.00182	-0.22	-0.25	Coronary artery disease;	chr11:107327884	chr11:107312132~107316271:-
STAD	cis	rs507080	0.769	rs2077173	ENSG00000278376.1	RP11-158I9.8	-4.74	3.18e-06	0.00182	-0.26	-0.25	Serum metabolite levels;	chr11:118621876	chr11:118791254~118793137:+
STAD	cis	rs11676348	0.783	rs4674252	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.24	0.25	Ulcerative colitis;	chr2:218119755	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.818	rs7423433	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.24	0.25	Ulcerative colitis;	chr2:218120361	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.714	rs4674254	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.24	0.25	Ulcerative colitis;	chr2:218121354	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.818	rs4674256	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.24	0.25	Ulcerative colitis;	chr2:218123170	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.846	rs4674257	ENSG00000237281.1	CATIP-AS2	4.74	3.18e-06	0.00182	0.24	0.25	Ulcerative colitis;	chr2:218124051	chr2:218326889~218357966:-
STAD	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-4.74	3.18e-06	0.00182	-0.35	-0.25	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
STAD	cis	rs7119038	0.774	rs7945144	ENSG00000255422.1	AP002954.4	4.74	3.19e-06	0.00183	0.32	0.25	Sjögren's syndrome;	chr11:118738007	chr11:118704607~118750263:+
STAD	cis	rs2273156	1	rs2273158	ENSG00000241052.1	RP11-173D9.1	4.74	3.19e-06	0.00183	0.27	0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:34996578	chr14:35144021~35144480:-
STAD	cis	rs73219805	0.793	rs1564576	ENSG00000228451.3	SDAD1P1	-4.74	3.19e-06	0.00183	-0.33	-0.25	Schizophrenia;	chr8:26333320	chr8:26379259~26382953:-
STAD	cis	rs853679	0.55	rs1233704	ENSG00000220721.1	OR1F12	-4.74	3.19e-06	0.00183	-0.28	-0.25	Depression;	chr6:28199145	chr6:28073316~28074233:+
STAD	cis	rs6714710	0.603	rs11680321	ENSG00000235833.1	AC159540.14	-4.74	3.19e-06	0.00183	-0.27	-0.25	Posterior cortical atrophy and Alzheimer's disease;	chr2:97762804	chr2:97523949~97524976:-
STAD	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	4.74	3.2e-06	0.00183	0.37	0.25	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
STAD	cis	rs8028182	0.636	rs4886699	ENSG00000260269.4	CTD-2323K18.1	-4.74	3.2e-06	0.00183	-0.31	-0.25	Sudden cardiac arrest;	chr15:75399962	chr15:75527150~75601205:-
STAD	cis	rs1056107	0.863	rs1320460	ENSG00000225513.1	RP11-165N19.2	-4.74	3.2e-06	0.00183	-0.28	-0.25	Colorectal cancer;	chr9:112194345	chr9:112173522~112173971:-
STAD	cis	rs6832769	1	rs17085889	ENSG00000272969.1	RP11-528I4.2	-4.74	3.2e-06	0.00183	-0.32	-0.25	Personality dimensions;	chr4:55535948	chr4:55547112~55547889:+
STAD	cis	rs858239	0.636	rs28706766	ENSG00000230042.1	AK3P3	-4.74	3.2e-06	0.00183	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23129178~23129841:+
STAD	cis	rs13113518	0.934	rs11935823	ENSG00000223305.1	RN7SKP30	4.74	3.2e-06	0.00183	0.28	0.25	Height;	chr4:55589624	chr4:55540502~55540835:-
STAD	cis	rs8141529	0.778	rs763073	ENSG00000272858.1	CTA-292E10.8	-4.73	3.2e-06	0.00183	-0.27	-0.25	Lymphocyte counts;	chr22:28819554	chr22:28814914~28815662:+
STAD	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-4.73	3.2e-06	0.00183	-0.36	-0.25	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
STAD	cis	rs6430585	0.528	rs111682961	ENSG00000231890.6	DARS-AS1	-4.73	3.2e-06	0.00183	-0.28	-0.25	Corneal structure;	chr2:135896278	chr2:135985176~136022593:+
STAD	cis	rs858239	0.6	rs7787110	ENSG00000226816.2	AC005082.12	4.73	3.21e-06	0.00183	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23206013~23208045:+
STAD	cis	rs6832769	1	rs10005989	ENSG00000272969.1	RP11-528I4.2	-4.73	3.21e-06	0.00184	-0.32	-0.25	Personality dimensions;	chr4:55539039	chr4:55547112~55547889:+
STAD	cis	rs7665090	1	rs7665090	ENSG00000248971.2	KRT8P46	4.73	3.21e-06	0.00184	0.26	0.25	Primary biliary cholangitis;	chr4:102630446	chr4:102728746~102730171:-
STAD	cis	rs17301013	0.729	rs12094143	ENSG00000227373.4	RP11-160H22.5	4.73	3.21e-06	0.00184	0.29	0.25	Systemic lupus erythematosus;	chr1:174511986	chr1:174115300~174160004:-
STAD	cis	rs4713118	0.869	rs6922574	ENSG00000280107.1	AL022393.9	-4.73	3.21e-06	0.00184	-0.33	-0.25	Parkinson's disease;	chr6:27725224	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs6902689	ENSG00000280107.1	AL022393.9	-4.73	3.21e-06	0.00184	-0.33	-0.25	Parkinson's disease;	chr6:27741662	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.869	rs9468214	ENSG00000280107.1	AL022393.9	-4.73	3.21e-06	0.00184	-0.33	-0.25	Parkinson's disease;	chr6:27745520	chr6:28170845~28172521:+
STAD	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-4.73	3.21e-06	0.00184	-0.25	-0.25	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
STAD	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-4.73	3.21e-06	0.00184	-0.31	-0.25	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
STAD	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	4.73	3.22e-06	0.00184	0.25	0.25	Height;	chr5:36941665	chr5:36666214~36725195:-
STAD	cis	rs9733	0.791	rs11800059	ENSG00000274963.1	Metazoa_SRP	-4.73	3.22e-06	0.00184	-0.2	-0.25	Tonsillectomy;	chr1:150678699	chr1:150568971~150569269:-
STAD	cis	rs2337406	0.587	rs916547	ENSG00000211972.2	IGHV3-66	4.73	3.22e-06	0.00184	0.26	0.25	Alzheimer's disease (late onset);	chr14:106646735	chr14:106675017~106675544:-
STAD	cis	rs875971	1	rs9986696	ENSG00000236529.1	RP13-254B10.1	-4.73	3.22e-06	0.00184	-0.26	-0.25	Aortic root size;	chr7:66239589	chr7:65840212~65840596:+
STAD	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	4.73	3.22e-06	0.00184	0.32	0.25	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
STAD	cis	rs10978777	1	rs9969728	ENSG00000276883.1	AL137852.1	-4.73	3.22e-06	0.00184	-0.24	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107277353	chr9:107292369~107292456:-
STAD	cis	rs4713118	0.662	rs9393881	ENSG00000220721.1	OR1F12	4.73	3.22e-06	0.00184	0.29	0.25	Parkinson's disease;	chr6:28055973	chr6:28073316~28074233:+
STAD	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	4.73	3.22e-06	0.00184	0.37	0.25	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
STAD	cis	rs11676348	0.846	rs3890158	ENSG00000237281.1	CATIP-AS2	4.73	3.23e-06	0.00184	0.24	0.25	Ulcerative colitis;	chr2:218125569	chr2:218326889~218357966:-
STAD	cis	rs71327718	1	rs71327718	ENSG00000239804.1	RP11-379B18.1	4.73	3.23e-06	0.00184	0.45	0.25	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125787888~125788146:-
STAD	cis	rs891378	1	rs1507761	ENSG00000274245.1	RP11-357P18.2	4.73	3.23e-06	0.00184	0.31	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207336454	chr1:207372559~207373252:+
STAD	cis	rs13392177	0.684	rs6720105	ENSG00000237281.1	CATIP-AS2	4.73	3.23e-06	0.00185	0.25	0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218326889~218357966:-
STAD	cis	rs2273156	1	rs2273156	ENSG00000241052.1	RP11-173D9.1	-4.73	3.23e-06	0.00185	-0.28	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:34969593	chr14:35144021~35144480:-
STAD	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-4.73	3.23e-06	0.00185	-0.28	-0.25	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
STAD	cis	rs2273156	0.706	rs7144617	ENSG00000241052.1	RP11-173D9.1	-4.73	3.24e-06	0.00185	-0.29	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35028853	chr14:35144021~35144480:-
STAD	cis	rs9860428	0.844	rs2399441	ENSG00000240057.4	RP11-572M11.4	-4.73	3.24e-06	0.00185	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868165	chr3:113019532~113183301:+
STAD	cis	rs11992186	0.597	rs11781841	ENSG00000253893.2	FAM85B	4.73	3.24e-06	0.00185	0.33	0.25	Neuroticism;	chr8:8737753	chr8:8167819~8226614:-
STAD	cis	rs1594829	0.553	rs7003030	ENSG00000228451.3	SDAD1P1	4.73	3.24e-06	0.00185	0.26	0.25	Height;	chr8:26315183	chr8:26379259~26382953:-
STAD	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	4.73	3.24e-06	0.00185	0.34	0.25	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
STAD	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	4.73	3.24e-06	0.00185	0.34	0.25	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
STAD	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-4.73	3.24e-06	0.00185	-0.34	-0.25	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
STAD	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-4.73	3.24e-06	0.00185	-0.25	-0.25	Height;	chr5:36954710	chr5:36666214~36725195:-
STAD	cis	rs35934224	0.504	rs7288631	ENSG00000232926.1	AC000078.5	4.73	3.24e-06	0.00185	0.4	0.25	Glaucoma (primary open-angle);	chr22:19848625	chr22:19887289~19887970:+
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-4.73	3.24e-06	0.00185	-0.19	-0.25	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-4.73	3.24e-06	0.00185	-0.19	-0.25	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
STAD	cis	rs7665090	1	rs4013	ENSG00000230069.3	LRRC37A15P	-4.73	3.24e-06	0.00185	-0.27	-0.25	Primary biliary cholangitis;	chr4:102631656	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.967	rs4019	ENSG00000230069.3	LRRC37A15P	-4.73	3.24e-06	0.00185	-0.27	-0.25	Primary biliary cholangitis;	chr4:102631673	chr4:102727274~102730721:-
STAD	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	4.73	3.24e-06	0.00185	0.36	0.25	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	4.73	3.24e-06	0.00185	0.36	0.25	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
STAD	cis	rs227275	0.531	rs223460	ENSG00000248971.2	KRT8P46	-4.73	3.25e-06	0.00185	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.844	rs223345	ENSG00000248971.2	KRT8P46	-4.73	3.25e-06	0.00185	-0.25	-0.25	Schizophrenia;	chr4:102859366	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.873	rs223344	ENSG00000248971.2	KRT8P46	-4.73	3.25e-06	0.00185	-0.25	-0.25	Schizophrenia;	chr4:102859765	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.775	rs223341	ENSG00000248971.2	KRT8P46	-4.73	3.25e-06	0.00185	-0.25	-0.25	Schizophrenia;	chr4:102862343	chr4:102728746~102730171:-
STAD	cis	rs4589258	0.933	rs7947602	ENSG00000280367.1	RP11-121L10.2	-4.73	3.25e-06	0.00186	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90673426	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs56124711	ENSG00000280367.1	RP11-121L10.2	-4.73	3.25e-06	0.00186	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90674127	chr11:90223153~90226538:+
STAD	cis	rs13113518	1	rs13108499	ENSG00000223305.1	RN7SKP30	4.73	3.25e-06	0.00186	0.27	0.25	Height;	chr4:55526514	chr4:55540502~55540835:-
STAD	cis	rs2836950	0.501	rs11088470	ENSG00000238141.2	BRWD1-AS1	-4.73	3.25e-06	0.00186	-0.25	-0.25	Menarche (age at onset);	chr21:39317236	chr21:39315707~39323218:+
STAD	cis	rs2836950	0.501	rs2836983	ENSG00000238141.2	BRWD1-AS1	-4.73	3.25e-06	0.00186	-0.25	-0.25	Menarche (age at onset);	chr21:39317410	chr21:39315707~39323218:+
STAD	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	4.73	3.25e-06	0.00186	0.41	0.25	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
STAD	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-4.73	3.25e-06	0.00186	-0.37	-0.25	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
STAD	cis	rs858239	1	rs156421	ENSG00000230042.1	AK3P3	-4.73	3.25e-06	0.00186	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23129178~23129841:+
STAD	cis	rs11676348	0.846	rs7607437	ENSG00000237281.1	CATIP-AS2	4.73	3.25e-06	0.00186	0.24	0.25	Ulcerative colitis;	chr2:218143669	chr2:218326889~218357966:-
STAD	cis	rs2439831	1	rs2256764	ENSG00000249839.1	AC011330.5	-4.73	3.26e-06	0.00186	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43443565	chr15:43663654~43684339:-
STAD	cis	rs748404	0.723	rs565658	ENSG00000275601.1	AC011330.13	-4.73	3.26e-06	0.00186	-0.26	-0.25	Lung cancer;	chr15:43264109	chr15:43642389~43643023:-
STAD	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-4.73	3.26e-06	0.00186	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
STAD	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	4.73	3.26e-06	0.00186	0.27	0.25	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
STAD	cis	rs4950322	0.517	rs114823926	ENSG00000278811.3	LINC00624	4.73	3.26e-06	0.00186	0.27	0.25	Protein quantitative trait loci;	chr1:147281805	chr1:147258885~147517875:-
STAD	cis	rs7665090	1	rs4013	ENSG00000248971.2	KRT8P46	-4.73	3.26e-06	0.00186	-0.26	-0.25	Primary biliary cholangitis;	chr4:102631656	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.967	rs4019	ENSG00000248971.2	KRT8P46	-4.73	3.26e-06	0.00186	-0.26	-0.25	Primary biliary cholangitis;	chr4:102631673	chr4:102728746~102730171:-
STAD	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	4.73	3.26e-06	0.00186	0.31	0.25	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
STAD	cis	rs1799949	0.832	rs2070835	ENSG00000267681.1	CTD-3199J23.6	-4.73	3.27e-06	0.00186	-0.29	-0.25	Menopause (age at onset);	chr17:43022008	chr17:43144956~43145255:+
STAD	cis	rs237743	1	rs237711	ENSG00000222365.1	SNORD12B	-4.73	3.27e-06	0.00187	-0.33	-0.25	Height;	chr20:49310319	chr20:49280319~49280409:+
STAD	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-4.73	3.27e-06	0.00187	-0.33	-0.25	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
STAD	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-4.73	3.27e-06	0.00187	-0.33	-0.25	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
STAD	cis	rs7665090	1	rs7677509	ENSG00000230069.3	LRRC37A15P	-4.73	3.27e-06	0.00187	-0.27	-0.25	Primary biliary cholangitis;	chr4:102628849	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.967	rs7699231	ENSG00000230069.3	LRRC37A15P	-4.73	3.27e-06	0.00187	-0.27	-0.25	Primary biliary cholangitis;	chr4:102628918	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs7699678	ENSG00000230069.3	LRRC37A15P	-4.73	3.27e-06	0.00187	-0.27	-0.25	Primary biliary cholangitis;	chr4:102628939	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs11724614	ENSG00000230069.3	LRRC37A15P	-4.73	3.27e-06	0.00187	-0.27	-0.25	Primary biliary cholangitis;	chr4:102629091	chr4:102727274~102730721:-
STAD	cis	rs7115242	0.92	rs6589574	ENSG00000280143.1	AP000892.6	4.73	3.28e-06	0.00187	0.31	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117204967~117210292:+
STAD	cis	rs7487075	1	rs12832425	ENSG00000257261.4	RP11-96H19.1	4.73	3.28e-06	0.00187	0.3	0.25	Itch intensity from mosquito bite;	chr12:46429035	chr12:46383679~46876159:+
STAD	cis	rs7487075	1	rs12814341	ENSG00000257261.4	RP11-96H19.1	4.73	3.28e-06	0.00187	0.3	0.25	Itch intensity from mosquito bite;	chr12:46429489	chr12:46383679~46876159:+
STAD	cis	rs7487075	1	rs7301001	ENSG00000257261.4	RP11-96H19.1	4.73	3.28e-06	0.00187	0.3	0.25	Itch intensity from mosquito bite;	chr12:46437058	chr12:46383679~46876159:+
STAD	cis	rs10510102	0.81	rs11200240	ENSG00000226864.1	ATE1-AS1	4.73	3.28e-06	0.00187	0.41	0.25	Breast cancer;	chr10:121903265	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs74914751	ENSG00000226864.1	ATE1-AS1	4.73	3.28e-06	0.00187	0.41	0.25	Breast cancer;	chr10:121904496	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200242	ENSG00000226864.1	ATE1-AS1	4.73	3.28e-06	0.00187	0.41	0.25	Breast cancer;	chr10:121905378	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12246704	ENSG00000226864.1	ATE1-AS1	4.73	3.28e-06	0.00187	0.41	0.25	Breast cancer;	chr10:121906165	chr10:121928312~121951965:+
STAD	cis	rs7945705	0.791	rs7944560	ENSG00000254860.4	TMEM9B-AS1	-4.73	3.28e-06	0.00187	-0.26	-0.25	Hemoglobin concentration;	chr11:8795729	chr11:8964675~8977527:+
STAD	cis	rs1723838	0.826	rs1723839	ENSG00000255928.1	RP11-456I15.2	4.73	3.28e-06	0.00187	0.53	0.25	Obesity-related traits;	chr11:73765678	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs4944854	ENSG00000255928.1	RP11-456I15.2	-4.73	3.28e-06	0.00187	-0.53	-0.25	Obesity-related traits;	chr11:73667576	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.702	rs6592529	ENSG00000255928.1	RP11-456I15.2	-4.73	3.28e-06	0.00187	-0.53	-0.25	Obesity-related traits;	chr11:73687235	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.702	rs4944027	ENSG00000255928.1	RP11-456I15.2	-4.73	3.28e-06	0.00187	-0.53	-0.25	Obesity-related traits;	chr11:73696343	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.702	rs4944030	ENSG00000255928.1	RP11-456I15.2	-4.73	3.28e-06	0.00187	-0.53	-0.25	Obesity-related traits;	chr11:73697922	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs7108695	ENSG00000255928.1	RP11-456I15.2	-4.73	3.28e-06	0.00187	-0.53	-0.25	Obesity-related traits;	chr11:73703126	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.702	rs4944859	ENSG00000255928.1	RP11-456I15.2	-4.73	3.28e-06	0.00187	-0.53	-0.25	Obesity-related traits;	chr11:73713090	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.623	rs9634024	ENSG00000255928.1	RP11-456I15.2	-4.73	3.28e-06	0.00187	-0.53	-0.25	Obesity-related traits;	chr11:73728714	chr11:73722349~73722694:+
STAD	cis	rs11098499	0.908	rs1002152	ENSG00000260091.1	RP11-33B1.4	4.73	3.28e-06	0.00187	0.24	0.25	Corneal astigmatism;	chr4:119352232	chr4:119409333~119410233:+
STAD	cis	rs1150668	0.796	rs2531825	ENSG00000220721.1	OR1F12	4.73	3.28e-06	0.00187	0.24	0.25	Pubertal anthropometrics;	chr6:28381487	chr6:28073316~28074233:+
STAD	cis	rs181553	0.629	rs12232591	ENSG00000266696.1	RP11-30L3.2	4.73	3.28e-06	0.00187	0.23	0.25	Hip circumference adjusted for BMI;	chr18:49164091	chr18:49205912~49208781:+
STAD	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-4.73	3.28e-06	0.00187	-0.25	-0.25	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
STAD	cis	rs7119038	0.818	rs10892279	ENSG00000255422.1	AP002954.4	4.73	3.28e-06	0.00187	0.32	0.25	Sjögren's syndrome;	chr11:118741072	chr11:118704607~118750263:+
STAD	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-4.73	3.28e-06	0.00187	-0.34	-0.25	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
STAD	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-4.73	3.28e-06	0.00187	-0.34	-0.25	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
STAD	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-4.73	3.28e-06	0.00187	-0.26	-0.25	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
STAD	cis	rs9928842	0.54	rs8051363	ENSG00000280152.1	RP11-331F4.5	4.73	3.29e-06	0.00187	0.28	0.25	Alcoholic chronic pancreatitis;	chr16:75221319	chr16:75245994~75250077:-
STAD	cis	rs4950322	0.543	rs4950319	ENSG00000278811.3	LINC00624	4.73	3.29e-06	0.00187	0.26	0.25	Protein quantitative trait loci;	chr1:147316250	chr1:147258885~147517875:-
STAD	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	4.73	3.29e-06	0.00187	0.32	0.25	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
STAD	cis	rs17826219	0.706	rs2322197	ENSG00000263603.1	CTD-2349P21.5	-4.73	3.29e-06	0.00188	-0.31	-0.25	Body mass index;	chr17:30778787	chr17:30729469~30731202:+
STAD	cis	rs1723838	0.826	rs1723845	ENSG00000255928.1	RP11-456I15.2	4.73	3.29e-06	0.00188	0.53	0.25	Obesity-related traits;	chr11:73786879	chr11:73722349~73722694:+
STAD	cis	rs1799949	1	rs8176133	ENSG00000279602.1	CTD-3014M21.1	4.73	3.3e-06	0.00188	0.31	0.25	Menopause (age at onset);	chr17:43105441	chr17:43360041~43361361:-
STAD	cis	rs7429990	0.965	rs6791834	ENSG00000224895.1	VPS26BP1	4.73	3.3e-06	0.00188	0.24	0.25	Educational attainment (years of education);	chr3:48073598	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs35689209	ENSG00000224895.1	VPS26BP1	4.73	3.3e-06	0.00188	0.24	0.25	Educational attainment (years of education);	chr3:48078273	chr3:47960327~47961081:-
STAD	cis	rs7829975	0.871	rs7829826	ENSG00000254340.1	RP11-10A14.3	-4.73	3.3e-06	0.00188	-0.29	-0.25	Mood instability;	chr8:8720610	chr8:9141424~9145435:+
STAD	cis	rs3758911	0.894	rs72990443	ENSG00000261098.1	RP11-819C21.1	-4.73	3.3e-06	0.00188	-0.22	-0.25	Coronary artery disease;	chr11:107352050	chr11:107312132~107316271:-
STAD	cis	rs6584283	0.875	rs1548962	ENSG00000228778.1	RP11-129J12.1	4.73	3.3e-06	0.00188	0.28	0.25	Ulcerative colitis;	chr10:99529978	chr10:99527081~99528261:+
STAD	cis	rs8099594	0.601	rs7504446	ENSG00000266696.1	RP11-30L3.2	4.73	3.3e-06	0.00188	0.24	0.25	Height;	chr18:49390750	chr18:49205912~49208781:+
STAD	cis	rs875971	0.862	rs1860469	ENSG00000224316.1	RP11-479O9.2	-4.73	3.3e-06	0.00188	-0.24	-0.25	Aortic root size;	chr7:66641888	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs4718383	ENSG00000224316.1	RP11-479O9.2	-4.73	3.3e-06	0.00188	-0.24	-0.25	Aortic root size;	chr7:66643422	chr7:65773620~65802067:+
STAD	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-4.73	3.3e-06	0.00188	-0.26	-0.25	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-4.73	3.3e-06	0.00188	-0.26	-0.25	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-4.73	3.3e-06	0.00188	-0.26	-0.25	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
STAD	cis	rs2273156	1	rs35797365	ENSG00000241052.1	RP11-173D9.1	-4.73	3.3e-06	0.00188	-0.27	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:34983553	chr14:35144021~35144480:-
STAD	cis	rs1707322	0.752	rs12062535	ENSG00000225447.1	RPS15AP10	4.73	3.3e-06	0.00188	0.2	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45645816~45646197:-
STAD	cis	rs7924176	0.521	rs7899920	ENSG00000213731.2	RAB5CP1	4.73	3.31e-06	0.00188	0.26	0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74423435~74424014:-
STAD	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-4.73	3.31e-06	0.00188	-0.31	-0.25	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
STAD	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	4.73	3.31e-06	0.00188	0.27	0.25	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
STAD	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	4.73	3.31e-06	0.00189	0.28	0.25	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
STAD	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-4.73	3.31e-06	0.00189	-0.3	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
STAD	cis	rs916888	0.773	rs538628	ENSG00000232300.1	FAM215B	4.73	3.32e-06	0.00189	0.32	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46558830~46562795:-
STAD	cis	rs2933343	0.7	rs876754	ENSG00000261159.1	RP11-723O4.9	4.73	3.32e-06	0.00189	0.3	0.25	IgG glycosylation;	chr3:128908910	chr3:128859716~128860526:-
STAD	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-4.73	3.32e-06	0.00189	-0.27	-0.25	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
STAD	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	4.73	3.32e-06	0.00189	0.3	0.25	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
STAD	cis	rs10851478	0.54	rs16962440	ENSG00000259545.2	RP11-325E5.4	4.73	3.32e-06	0.00189	0.27	0.25	Oral cavity cancer;	chr15:49424648	chr15:49177610~49178741:-
STAD	cis	rs1707322	0.686	rs3014251	ENSG00000281133.1	AL355480.3	4.73	3.32e-06	0.00189	0.3	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.682	rs12037459	ENSG00000281133.1	AL355480.3	-4.73	3.32e-06	0.00189	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45580892~45580996:-
STAD	cis	rs7078219	0.743	rs11190128	ENSG00000228778.1	RP11-129J12.1	-4.73	3.33e-06	0.00189	-0.31	-0.25	Dental caries;	chr10:99515392	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.686	rs12412214	ENSG00000228778.1	RP11-129J12.1	-4.73	3.33e-06	0.00189	-0.31	-0.25	Dental caries;	chr10:99516499	chr10:99527081~99528261:+
STAD	cis	rs2337406	0.539	rs2583292	ENSG00000211970.3	IGHV4-61	4.73	3.33e-06	0.00189	0.27	0.25	Alzheimer's disease (late onset);	chr14:106649040	chr14:106639119~106639657:-
STAD	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	4.73	3.33e-06	0.00189	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
STAD	cis	rs539514	0.516	rs2273996	ENSG00000261105.4	LMO7-AS1	-4.73	3.33e-06	0.00189	-0.31	-0.25	Type 1 diabetes;	chr13:75836589	chr13:75604700~75635994:-
STAD	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-4.73	3.33e-06	0.00189	-0.27	-0.25	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	4.73	3.33e-06	0.0019	0.3	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
STAD	cis	rs2337406	0.778	rs58113768	ENSG00000274576.2	IGHV2-70	-4.73	3.33e-06	0.0019	-0.32	-0.25	Alzheimer's disease (late onset);	chr14:106700213	chr14:106770577~106771020:-
STAD	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-4.73	3.33e-06	0.0019	-0.32	-0.25	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
STAD	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-4.73	3.33e-06	0.0019	-0.36	-0.25	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
STAD	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-4.73	3.33e-06	0.0019	-0.3	-0.25	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
STAD	cis	rs12906542	0.516	rs4886992	ENSG00000259792.1	RP11-114H24.6	-4.73	3.34e-06	0.0019	-0.44	-0.25	Breast cancer;	chr15:78032887	chr15:77993405~77995289:+
STAD	cis	rs875971	0.928	rs2036263	ENSG00000236529.1	RP13-254B10.1	-4.73	3.34e-06	0.0019	-0.25	-0.25	Aortic root size;	chr7:66335210	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10240949	ENSG00000236529.1	RP13-254B10.1	-4.73	3.34e-06	0.0019	-0.25	-0.25	Aortic root size;	chr7:66339430	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs7782704	ENSG00000236529.1	RP13-254B10.1	-4.73	3.34e-06	0.0019	-0.25	-0.25	Aortic root size;	chr7:66340379	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs6460290	ENSG00000236529.1	RP13-254B10.1	-4.73	3.34e-06	0.0019	-0.25	-0.25	Aortic root size;	chr7:66344119	chr7:65840212~65840596:+
STAD	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-4.73	3.34e-06	0.0019	-0.3	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
STAD	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-4.73	3.34e-06	0.0019	-0.3	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
STAD	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	4.73	3.34e-06	0.0019	0.28	0.25	Height;	chr4:55542243	chr4:55540502~55540835:-
STAD	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	4.73	3.34e-06	0.0019	0.26	0.25	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
STAD	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	4.73	3.34e-06	0.0019	0.26	0.25	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
STAD	cis	rs4589258	0.933	rs1783790	ENSG00000280367.1	RP11-121L10.2	-4.73	3.34e-06	0.0019	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90705839	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1621068	ENSG00000280367.1	RP11-121L10.2	-4.73	3.34e-06	0.0019	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90707530	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1792600	ENSG00000280367.1	RP11-121L10.2	-4.73	3.34e-06	0.0019	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90707739	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs726125	ENSG00000280367.1	RP11-121L10.2	-4.73	3.34e-06	0.0019	-0.27	-0.25	Intelligence (multi-trait analysis);	chr11:90710131	chr11:90223153~90226538:+
STAD	cis	rs10510102	0.872	rs7906462	ENSG00000226864.1	ATE1-AS1	4.73	3.34e-06	0.0019	0.39	0.25	Breast cancer;	chr10:121948098	chr10:121928312~121951965:+
STAD	cis	rs4713118	0.629	rs203888	ENSG00000220721.1	OR1F12	4.73	3.34e-06	0.0019	0.28	0.25	Parkinson's disease;	chr6:28053811	chr6:28073316~28074233:+
STAD	cis	rs8028182	0.549	rs4886696	ENSG00000260269.4	CTD-2323K18.1	4.73	3.34e-06	0.0019	0.31	0.25	Sudden cardiac arrest;	chr15:75372229	chr15:75527150~75601205:-
STAD	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-4.73	3.34e-06	0.0019	-0.19	-0.25	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
STAD	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-4.73	3.34e-06	0.0019	-0.38	-0.25	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
STAD	cis	rs227275	0.555	rs223403	ENSG00000248971.2	KRT8P46	-4.73	3.35e-06	0.0019	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102728746~102730171:-
STAD	cis	rs56080343	0.748	rs56190986	ENSG00000275759.1	RP11-131L12.3	-4.73	3.35e-06	0.0019	-0.48	-0.25	Neuroticism;	chr12:118408458	chr12:118428281~118428870:+
STAD	cis	rs7665090	0.875	rs6813687	ENSG00000230069.3	LRRC37A15P	-4.73	3.35e-06	0.0019	-0.27	-0.25	Primary biliary cholangitis;	chr4:102634455	chr4:102727274~102730721:-
STAD	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-4.73	3.35e-06	0.0019	-0.32	-0.25	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
STAD	cis	rs7429990	0.932	rs7620736	ENSG00000224895.1	VPS26BP1	4.73	3.35e-06	0.0019	0.24	0.25	Educational attainment (years of education);	chr3:48068479	chr3:47960327~47961081:-
STAD	cis	rs1056107	0.902	rs10124118	ENSG00000225513.1	RP11-165N19.2	-4.73	3.35e-06	0.00191	-0.28	-0.25	Colorectal cancer;	chr9:112240354	chr9:112173522~112173971:-
STAD	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-4.73	3.35e-06	0.00191	-0.3	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
STAD	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-4.72	3.35e-06	0.00191	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
STAD	cis	rs11676348	0.818	rs6436033	ENSG00000237281.1	CATIP-AS2	4.72	3.35e-06	0.00191	0.24	0.25	Ulcerative colitis;	chr2:218119040	chr2:218326889~218357966:-
STAD	cis	rs6430585	0.528	rs12474975	ENSG00000231890.6	DARS-AS1	-4.72	3.35e-06	0.00191	-0.28	-0.25	Corneal structure;	chr2:135944548	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs895285	ENSG00000231890.6	DARS-AS1	-4.72	3.35e-06	0.00191	-0.28	-0.25	Corneal structure;	chr2:135952984	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs75524146	ENSG00000231890.6	DARS-AS1	-4.72	3.35e-06	0.00191	-0.28	-0.25	Corneal structure;	chr2:135967889	chr2:135985176~136022593:+
STAD	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-4.72	3.35e-06	0.00191	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-4.72	3.35e-06	0.00191	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-4.72	3.35e-06	0.00191	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-4.72	3.35e-06	0.00191	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-4.72	3.35e-06	0.00191	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
STAD	cis	rs6832769	0.885	rs6815516	ENSG00000272969.1	RP11-528I4.2	-4.72	3.35e-06	0.00191	-0.31	-0.25	Personality dimensions;	chr4:55533017	chr4:55547112~55547889:+
STAD	cis	rs2115630	0.936	rs8033459	ENSG00000225151.9	GOLGA2P7	4.72	3.36e-06	0.00191	0.27	0.25	P wave terminal force;	chr15:84710027	chr15:84199311~84230136:-
STAD	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-4.72	3.36e-06	0.00191	-0.27	-0.25	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
STAD	cis	rs9860428	0.679	rs1032726	ENSG00000240057.4	RP11-572M11.4	-4.72	3.36e-06	0.00191	-0.23	-0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112967228	chr3:113019532~113183301:+
STAD	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-4.72	3.36e-06	0.00191	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
STAD	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	4.72	3.36e-06	0.00191	0.35	0.25	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
STAD	cis	rs1799949	1	rs35330014	ENSG00000236383.6	LINC00854	-4.72	3.36e-06	0.00191	-0.2	-0.25	Menopause (age at onset);	chr17:43060530	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs3092994	ENSG00000236383.6	LINC00854	-4.72	3.36e-06	0.00191	-0.2	-0.25	Menopause (age at onset);	chr17:43063808	chr17:43216941~43305976:-
STAD	cis	rs5758659	0.904	rs134877	ENSG00000182057.4	OGFRP1	4.72	3.37e-06	0.00191	0.26	0.25	Cognitive function;	chr22:42266365	chr22:42269753~42275196:+
STAD	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	4.72	3.37e-06	0.00191	0.34	0.25	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
STAD	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-4.72	3.37e-06	0.00191	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
STAD	cis	rs875971	0.862	rs778734	ENSG00000236529.1	RP13-254B10.1	4.72	3.37e-06	0.00191	0.25	0.25	Aortic root size;	chr7:66349862	chr7:65840212~65840596:+
STAD	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-4.72	3.37e-06	0.00192	-0.25	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-4.72	3.37e-06	0.00192	-0.19	-0.25	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
STAD	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-4.72	3.38e-06	0.00192	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
STAD	cis	rs7680126	0.596	rs11731652	ENSG00000250613.1	RP11-136I13.1	4.72	3.38e-06	0.00192	0.26	0.25	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10291360	chr4:10410996~10411644:+
STAD	cis	rs2933343	0.649	rs1683786	ENSG00000261159.1	RP11-723O4.9	4.72	3.38e-06	0.00192	0.3	0.25	IgG glycosylation;	chr3:128908109	chr3:128859716~128860526:-
STAD	cis	rs721917	0.506	rs7073842	ENSG00000244733.5	RP11-506M13.3	-4.72	3.38e-06	0.00192	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79660891~79677996:+
STAD	cis	rs172166	0.585	rs149963	ENSG00000220721.1	OR1F12	4.72	3.38e-06	0.00192	0.24	0.25	Cardiac Troponin-T levels;	chr6:28049354	chr6:28073316~28074233:+
STAD	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-4.72	3.38e-06	0.00192	-0.27	-0.25	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
STAD	cis	rs3770081	1	rs11899576	ENSG00000273080.1	RP11-301O19.1	-4.72	3.38e-06	0.00192	-0.54	-0.25	Facial emotion recognition (sad faces);	chr2:86029070	chr2:86195590~86196049:+
STAD	cis	rs4237845	0.844	rs4630335	ENSG00000273805.1	RP11-620J15.4	-4.72	3.38e-06	0.00192	-0.27	-0.25	Intelligence (multi-trait analysis);	chr12:57908475	chr12:57894232~57896846:+
STAD	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-4.72	3.38e-06	0.00192	-0.26	-0.25	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-4.72	3.38e-06	0.00192	-0.26	-0.25	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-4.72	3.38e-06	0.00192	-0.26	-0.25	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-4.72	3.38e-06	0.00192	-0.26	-0.25	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
STAD	cis	rs8141529	0.719	rs5762825	ENSG00000272858.1	CTA-292E10.8	-4.72	3.38e-06	0.00192	-0.27	-0.25	Lymphocyte counts;	chr22:28827654	chr22:28814914~28815662:+
STAD	cis	rs8141529	0.764	rs5752809	ENSG00000272858.1	CTA-292E10.8	-4.72	3.38e-06	0.00192	-0.27	-0.25	Lymphocyte counts;	chr22:28829512	chr22:28814914~28815662:+
STAD	cis	rs8141529	0.764	rs5752812	ENSG00000272858.1	CTA-292E10.8	-4.72	3.38e-06	0.00192	-0.27	-0.25	Lymphocyte counts;	chr22:28829615	chr22:28814914~28815662:+
STAD	cis	rs3736858	0.932	rs3783025	ENSG00000261105.4	LMO7-AS1	-4.72	3.39e-06	0.00192	-0.42	-0.25	Interleukin-9 levels;	chr13:75830174	chr13:75604700~75635994:-
STAD	cis	rs3736858	1	rs9544050	ENSG00000261105.4	LMO7-AS1	-4.72	3.39e-06	0.00192	-0.42	-0.25	Interleukin-9 levels;	chr13:75831254	chr13:75604700~75635994:-
STAD	cis	rs3736858	1	rs3825439	ENSG00000261105.4	LMO7-AS1	-4.72	3.39e-06	0.00192	-0.42	-0.25	Interleukin-9 levels;	chr13:75832713	chr13:75604700~75635994:-
STAD	cis	rs3736858	0.866	rs9544051	ENSG00000261105.4	LMO7-AS1	-4.72	3.39e-06	0.00192	-0.42	-0.25	Interleukin-9 levels;	chr13:75832845	chr13:75604700~75635994:-
STAD	cis	rs4713118	0.696	rs2394002	ENSG00000280107.1	AL022393.9	-4.72	3.39e-06	0.00192	-0.33	-0.25	Parkinson's disease;	chr6:27780236	chr6:28170845~28172521:+
STAD	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.39e-06	0.00192	-0.28	-0.25	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.39e-06	0.00192	-0.28	-0.25	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
STAD	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	4.72	3.4e-06	0.00193	0.37	0.25	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
STAD	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	4.72	3.4e-06	0.00193	0.3	0.25	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
STAD	cis	rs10510102	0.688	rs76573813	ENSG00000226864.1	ATE1-AS1	4.72	3.4e-06	0.00193	0.39	0.25	Breast cancer;	chr10:121928955	chr10:121928312~121951965:+
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000224373.3	IGHV4-59	4.72	3.4e-06	0.00193	0.17	0.25	Kawasaki disease;	chr14:106786292	chr14:106627249~106627825:-
STAD	cis	rs7932354	0.502	rs10769233	ENSG00000271350.1	CTD-2384B9.1	-4.72	3.41e-06	0.00193	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47051104	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.528	rs7103581	ENSG00000271350.1	CTD-2384B9.1	-4.72	3.41e-06	0.00193	-0.3	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47051254	chr11:47041027~47041945:-
STAD	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-4.72	3.41e-06	0.00193	-0.3	-0.25	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
STAD	cis	rs2337406	0.636	rs74090069	ENSG00000211972.2	IGHV3-66	4.72	3.41e-06	0.00193	0.25	0.25	Alzheimer's disease (late onset);	chr14:106777532	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.866	rs74090071	ENSG00000211972.2	IGHV3-66	4.72	3.41e-06	0.00193	0.25	0.25	Alzheimer's disease (late onset);	chr14:106777533	chr14:106675017~106675544:-
STAD	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-4.72	3.41e-06	0.00193	-0.25	-0.25	Height;	chr5:36968438	chr5:36666214~36725195:-
STAD	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	4.72	3.41e-06	0.00193	0.27	0.25	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
STAD	cis	rs237743	1	rs13038202	ENSG00000222365.1	SNORD12B	-4.72	3.41e-06	0.00193	-0.33	-0.25	Height;	chr20:49219081	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-4.72	3.41e-06	0.00193	-0.33	-0.25	Height;	chr20:49220669	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs2273145	ENSG00000222365.1	SNORD12B	-4.72	3.41e-06	0.00193	-0.33	-0.25	Height;	chr20:49223054	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs11553387	ENSG00000222365.1	SNORD12B	-4.72	3.41e-06	0.00193	-0.33	-0.25	Height;	chr20:49225123	chr20:49280319~49280409:+
STAD	cis	rs10510102	0.935	rs4627017	ENSG00000226864.1	ATE1-AS1	4.72	3.41e-06	0.00193	0.4	0.25	Breast cancer;	chr10:121901878	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs7098562	ENSG00000226864.1	ATE1-AS1	4.72	3.41e-06	0.00193	0.4	0.25	Breast cancer;	chr10:121902148	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs7098822	ENSG00000226864.1	ATE1-AS1	4.72	3.41e-06	0.00193	0.4	0.25	Breast cancer;	chr10:121902157	chr10:121928312~121951965:+
STAD	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-4.72	3.42e-06	0.00194	-0.24	-0.25	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
STAD	cis	rs891378	0.958	rs1354942	ENSG00000274245.1	RP11-357P18.2	4.72	3.42e-06	0.00194	0.31	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335147	chr1:207372559~207373252:+
STAD	cis	rs7429990	0.965	rs2631721	ENSG00000224895.1	VPS26BP1	-4.72	3.42e-06	0.00194	-0.24	-0.25	Educational attainment (years of education);	chr3:47881807	chr3:47960327~47961081:-
STAD	cis	rs319690	1	rs319690	ENSG00000224895.1	VPS26BP1	-4.72	3.42e-06	0.00194	-0.24	-0.25	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:47960327~47961081:-
STAD	cis	rs2337406	1	rs1858677	ENSG00000211972.2	IGHV3-66	4.72	3.42e-06	0.00194	0.27	0.25	Alzheimer's disease (late onset);	chr14:106706828	chr14:106675017~106675544:-
STAD	cis	rs8141529	0.753	rs5752813	ENSG00000272858.1	CTA-292E10.8	-4.72	3.42e-06	0.00194	-0.27	-0.25	Lymphocyte counts;	chr22:28830582	chr22:28814914~28815662:+
STAD	cis	rs4589258	1	rs4753029	ENSG00000280367.1	RP11-121L10.2	4.72	3.42e-06	0.00194	0.26	0.25	Intelligence (multi-trait analysis);	chr11:90744560	chr11:90223153~90226538:+
STAD	cis	rs4589258	1	rs2213090	ENSG00000280367.1	RP11-121L10.2	4.72	3.42e-06	0.00194	0.26	0.25	Intelligence (multi-trait analysis);	chr11:90744981	chr11:90223153~90226538:+
STAD	cis	rs2337406	0.866	rs74092512	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106779306	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.789	rs74092514	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106779385	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74092520	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106779632	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs4583128	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106780669	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.929	rs59263250	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781183	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs58083017	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781256	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.789	rs60390024	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781327	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74092532	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781363	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74092534	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781364	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74092535	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781722	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74092537	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781883	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.81	rs74092538	ENSG00000280411.1	IGHV1-69-2	-4.72	3.42e-06	0.00194	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781942	chr14:106762092~106762588:-
STAD	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	4.72	3.43e-06	0.00194	0.3	0.25	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
STAD	cis	rs17401966	0.838	rs11580854	ENSG00000199562.1	RNU6-37P	4.72	3.43e-06	0.00194	0.19	0.25	Hepatocellular carcinoma;	chr1:10233507	chr1:10298966~10299072:+
STAD	cis	rs6430585	0.528	rs78274583	ENSG00000231890.6	DARS-AS1	-4.72	3.43e-06	0.00194	-0.28	-0.25	Corneal structure;	chr2:135976999	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs16832417	ENSG00000231890.6	DARS-AS1	-4.72	3.43e-06	0.00194	-0.28	-0.25	Corneal structure;	chr2:135987108	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs721765	ENSG00000231890.6	DARS-AS1	-4.72	3.43e-06	0.00194	-0.28	-0.25	Corneal structure;	chr2:135991209	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs10496738	ENSG00000231890.6	DARS-AS1	-4.72	3.43e-06	0.00194	-0.28	-0.25	Corneal structure;	chr2:135993918	chr2:135985176~136022593:+
STAD	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	4.72	3.43e-06	0.00194	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	4.72	3.43e-06	0.00194	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
STAD	cis	rs9828933	0.752	rs12633353	ENSG00000280620.1	SCAANT1	4.72	3.43e-06	0.00194	0.42	0.25	Type 2 diabetes;	chr3:63984604	chr3:63911518~63911772:-
STAD	cis	rs4237845	0.844	rs7306124	ENSG00000273805.1	RP11-620J15.4	-4.72	3.43e-06	0.00194	-0.28	-0.25	Intelligence (multi-trait analysis);	chr12:57909566	chr12:57894232~57896846:+
STAD	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	4.72	3.43e-06	0.00194	0.35	0.25	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
STAD	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	4.72	3.43e-06	0.00194	0.32	0.25	Height;	chr6:109478720	chr6:109382795~109383666:+
STAD	cis	rs2221894	0.616	rs10112345	ENSG00000273710.1	Metazoa_SRP	-4.72	3.43e-06	0.00194	-0.26	-0.25	Obesity-related traits;	chr8:29107153	chr8:28915579~28915864:-
STAD	cis	rs875971	0.545	rs1547529	ENSG00000236529.1	RP13-254B10.1	4.72	3.44e-06	0.00195	0.29	0.25	Aortic root size;	chr7:66258859	chr7:65840212~65840596:+
STAD	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	4.72	3.44e-06	0.00195	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
STAD	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-4.72	3.44e-06	0.00195	-0.19	-0.25	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
STAD	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-4.72	3.44e-06	0.00195	-0.25	-0.25	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
STAD	cis	rs73219805	0.838	rs17055172	ENSG00000228451.3	SDAD1P1	-4.72	3.44e-06	0.00195	-0.32	-0.25	Schizophrenia;	chr8:26368096	chr8:26379259~26382953:-
STAD	cis	rs858239	0.899	rs2268745	ENSG00000226816.2	AC005082.12	4.72	3.44e-06	0.00195	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23206013~23208045:+
STAD	cis	rs17401966	0.838	rs10864449	ENSG00000199562.1	RNU6-37P	4.72	3.45e-06	0.00195	0.19	0.25	Hepatocellular carcinoma;	chr1:10236864	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs1538557	ENSG00000199562.1	RNU6-37P	4.72	3.45e-06	0.00195	0.19	0.25	Hepatocellular carcinoma;	chr1:10237172	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs34565762	ENSG00000199562.1	RNU6-37P	4.72	3.45e-06	0.00195	0.19	0.25	Hepatocellular carcinoma;	chr1:10240061	chr1:10298966~10299072:+
STAD	cis	rs2273156	0.706	rs8015622	ENSG00000241052.1	RP11-173D9.1	-4.72	3.45e-06	0.00195	-0.29	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35017894	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.706	rs35030792	ENSG00000241052.1	RP11-173D9.1	-4.72	3.45e-06	0.00195	-0.29	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35019917	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.706	rs7155696	ENSG00000241052.1	RP11-173D9.1	-4.72	3.45e-06	0.00195	-0.29	-0.25	Immunoglobulin light chain (AL) amyloidosis;	chr14:35027548	chr14:35144021~35144480:-
STAD	cis	rs1723838	0.826	rs1525750	ENSG00000255928.1	RP11-456I15.2	4.72	3.45e-06	0.00195	0.52	0.25	Obesity-related traits;	chr11:73758831	chr11:73722349~73722694:+
STAD	cis	rs721917	0.525	rs2758541	ENSG00000244733.5	RP11-506M13.3	-4.72	3.45e-06	0.00195	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79660891~79677996:+
STAD	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	4.72	3.46e-06	0.00195	0.52	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
STAD	cis	rs1040	0.69	rs9393165	ENSG00000261039.2	RP11-417E7.2	-4.72	3.46e-06	0.00196	-0.29	-0.25	Joint mobility (Beighton score);	chr6:169220152	chr6:169175304~169182740:-
STAD	cis	rs1040	0.727	rs7382431	ENSG00000261039.2	RP11-417E7.2	-4.72	3.46e-06	0.00196	-0.29	-0.25	Joint mobility (Beighton score);	chr6:169221734	chr6:169175304~169182740:-
STAD	cis	rs7078219	0.686	rs12412391	ENSG00000228778.1	RP11-129J12.1	-4.72	3.46e-06	0.00196	-0.31	-0.25	Dental caries;	chr10:99529178	chr10:99527081~99528261:+
STAD	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	4.72	3.46e-06	0.00196	0.29	0.25	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
STAD	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-4.72	3.46e-06	0.00196	-0.26	-0.25	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-4.72	3.46e-06	0.00196	-0.26	-0.25	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-4.72	3.46e-06	0.00196	-0.26	-0.25	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-4.72	3.46e-06	0.00196	-0.26	-0.25	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
STAD	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.47e-06	0.00196	-0.28	-0.25	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.47e-06	0.00196	-0.28	-0.25	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
STAD	cis	rs13113518	1	rs4865004	ENSG00000223305.1	RN7SKP30	4.72	3.47e-06	0.00196	0.27	0.25	Height;	chr4:55515118	chr4:55540502~55540835:-
STAD	cis	rs891378	1	rs2017760	ENSG00000274245.1	RP11-357P18.2	-4.72	3.47e-06	0.00196	-0.31	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207282076	chr1:207372559~207373252:+
STAD	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-4.72	3.47e-06	0.00196	-0.26	-0.25	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-4.72	3.47e-06	0.00196	-0.26	-0.25	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-4.72	3.47e-06	0.00196	-0.26	-0.25	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-4.72	3.47e-06	0.00196	-0.26	-0.25	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-4.72	3.47e-06	0.00196	-0.26	-0.25	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-4.72	3.47e-06	0.00196	-0.26	-0.25	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
STAD	cis	rs2337406	0.714	rs117798641	ENSG00000211972.2	IGHV3-66	4.72	3.48e-06	0.00197	0.25	0.25	Alzheimer's disease (late onset);	chr14:106777984	chr14:106675017~106675544:-
STAD	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-4.72	3.48e-06	0.00197	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
STAD	cis	rs2286503	1	rs2286499	ENSG00000221740.1	SNORD93	4.72	3.48e-06	0.00197	0.28	0.25	Fibrinogen;	chr7:22817858	chr7:22856613~22856686:+
STAD	cis	rs2836950	0.501	rs4818018	ENSG00000238141.2	BRWD1-AS1	-4.72	3.48e-06	0.00197	-0.25	-0.25	Menarche (age at onset);	chr21:39322146	chr21:39315707~39323218:+
STAD	cis	rs2836950	0.501	rs4818019	ENSG00000238141.2	BRWD1-AS1	-4.72	3.48e-06	0.00197	-0.25	-0.25	Menarche (age at onset);	chr21:39322530	chr21:39315707~39323218:+
STAD	cis	rs8067354	0.645	rs72838857	ENSG00000266701.1	AC005702.4	4.72	3.48e-06	0.00197	0.33	0.25	Hemoglobin concentration;	chr17:59759406	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs16943838	ENSG00000266701.1	AC005702.4	4.72	3.48e-06	0.00197	0.33	0.25	Hemoglobin concentration;	chr17:59762243	chr17:60042546~60042627:-
STAD	cis	rs8067354	0.645	rs1874548	ENSG00000266701.1	AC005702.4	4.72	3.48e-06	0.00197	0.33	0.25	Hemoglobin concentration;	chr17:59763996	chr17:60042546~60042627:-
STAD	cis	rs606458	0.841	rs683841	ENSG00000269038.1	AP001462.6	-4.72	3.48e-06	0.00197	-0.34	-0.25	Urate levels;	chr11:64781109	chr11:64778954~64779405:+
STAD	cis	rs7474896	0.583	rs4934898	ENSG00000120555.12	SEPT7P9	4.72	3.48e-06	0.00197	0.29	0.25	Obesity (extreme);	chr10:37701467	chr10:38383069~38402916:-
STAD	cis	rs8098244	0.706	rs720064	ENSG00000267301.1	RPL23AP77	-4.72	3.49e-06	0.00197	-0.29	-0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23890360	chr18:23709825~23710287:-
STAD	cis	rs7078219	1	rs7081330	ENSG00000228778.1	RP11-129J12.1	-4.72	3.49e-06	0.00197	-0.29	-0.25	Dental caries;	chr10:99514708	chr10:99527081~99528261:+
STAD	cis	rs2337406	0.929	rs12050233	ENSG00000280411.1	IGHV1-69-2	-4.72	3.49e-06	0.00197	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781123	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.852	rs12050466	ENSG00000280411.1	IGHV1-69-2	-4.72	3.49e-06	0.00197	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106781131	chr14:106762092~106762588:-
STAD	cis	rs1150668	0.835	rs203869	ENSG00000220721.1	OR1F12	4.72	3.49e-06	0.00197	0.24	0.25	Pubertal anthropometrics;	chr6:28073041	chr6:28073316~28074233:+
STAD	cis	rs875971	1	rs4718307	ENSG00000236529.1	RP13-254B10.1	-4.72	3.49e-06	0.00197	-0.26	-0.25	Aortic root size;	chr7:66146001	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs7801282	ENSG00000236529.1	RP13-254B10.1	-4.72	3.49e-06	0.00197	-0.26	-0.25	Aortic root size;	chr7:66148700	chr7:65840212~65840596:+
STAD	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-4.72	3.49e-06	0.00197	-0.26	-0.25	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
STAD	cis	rs721917	0.506	rs927452	ENSG00000244733.5	RP11-506M13.3	-4.72	3.49e-06	0.00197	-0.3	-0.25	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79660891~79677996:+
STAD	cis	rs2337406	0.866	rs7152038	ENSG00000211972.2	IGHV3-66	4.72	3.49e-06	0.00197	0.25	0.25	Alzheimer's disease (late onset);	chr14:106778230	chr14:106675017~106675544:-
STAD	cis	rs4713118	0.621	rs9368548	ENSG00000220721.1	OR1F12	4.72	3.49e-06	0.00197	0.3	0.25	Parkinson's disease;	chr6:28066959	chr6:28073316~28074233:+
STAD	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-4.72	3.49e-06	0.00197	-0.37	-0.25	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
STAD	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-4.72	3.49e-06	0.00197	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-4.72	3.49e-06	0.00197	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-4.72	3.49e-06	0.00197	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-4.72	3.49e-06	0.00197	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
STAD	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.49e-06	0.00197	-0.29	-0.25	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
STAD	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	4.72	3.49e-06	0.00197	0.3	0.25	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	4.72	3.49e-06	0.00197	0.3	0.25	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
STAD	cis	rs10504130	0.696	rs11785805	ENSG00000272024.1	RP11-546K22.3	-4.72	3.5e-06	0.00197	-0.35	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51950284~51950690:+
STAD	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	4.72	3.5e-06	0.00197	0.37	0.25	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
STAD	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-4.72	3.5e-06	0.00197	-0.36	-0.25	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
STAD	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-4.72	3.5e-06	0.00197	-0.33	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
STAD	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.5e-06	0.00197	-0.28	-0.25	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.5e-06	0.00197	-0.28	-0.25	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.5e-06	0.00197	-0.28	-0.25	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.5e-06	0.00197	-0.28	-0.25	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-4.72	3.5e-06	0.00197	-0.28	-0.25	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
STAD	cis	rs7829975	0.54	rs2976909	ENSG00000254340.1	RP11-10A14.3	-4.72	3.5e-06	0.00198	-0.29	-0.25	Mood instability;	chr8:8489180	chr8:9141424~9145435:+
STAD	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-4.72	3.5e-06	0.00198	-0.37	-0.25	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
STAD	cis	rs227275	0.525	rs2086499	ENSG00000248971.2	KRT8P46	-4.72	3.5e-06	0.00198	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102728746~102730171:-
STAD	cis	rs7429990	1	rs1684942	ENSG00000224895.1	VPS26BP1	-4.72	3.51e-06	0.00198	-0.24	-0.25	Educational attainment (years of education);	chr3:47859213	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs800762	ENSG00000224895.1	VPS26BP1	-4.72	3.51e-06	0.00198	-0.24	-0.25	Educational attainment (years of education);	chr3:47864080	chr3:47960327~47961081:-
STAD	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-4.71	3.51e-06	0.00198	-0.28	-0.25	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
STAD	cis	rs6832769	0.961	rs10009593	ENSG00000272969.1	RP11-528I4.2	-4.71	3.51e-06	0.00198	-0.31	-0.25	Personality dimensions;	chr4:55570514	chr4:55547112~55547889:+
STAD	cis	rs13392177	0.672	rs1877715	ENSG00000237281.1	CATIP-AS2	-4.71	3.51e-06	0.00198	-0.25	-0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218326889~218357966:-
STAD	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	4.71	3.52e-06	0.00198	0.28	0.25	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
STAD	cis	rs17401966	0.838	rs12120042	ENSG00000199562.1	RNU6-37P	4.71	3.52e-06	0.00198	0.19	0.25	Hepatocellular carcinoma;	chr1:10285267	chr1:10298966~10299072:+
STAD	cis	rs6142102	0.651	rs6059692	ENSG00000275784.1	RP5-1125A11.6	4.71	3.52e-06	0.00198	0.26	0.25	Skin pigmentation;	chr20:34158397	chr20:33989480~33991818:-
STAD	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-4.71	3.52e-06	0.00198	-0.37	-0.25	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
STAD	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	4.71	3.52e-06	0.00198	0.34	0.25	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
STAD	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	4.71	3.52e-06	0.00198	0.34	0.25	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
STAD	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	4.71	3.52e-06	0.00198	0.34	0.25	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
STAD	cis	rs1150668	0.768	rs1150709	ENSG00000204709.4	LINC01556	-4.71	3.52e-06	0.00198	-0.3	-0.25	Pubertal anthropometrics;	chr6:28239585	chr6:28943877~28944537:+
STAD	cis	rs4970988	0.556	rs6695123	ENSG00000274963.1	Metazoa_SRP	-4.71	3.52e-06	0.00198	-0.22	-0.25	Urate levels;	chr1:150591007	chr1:150568971~150569269:-
STAD	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	4.71	3.52e-06	0.00199	0.28	0.25	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
STAD	cis	rs6095360	0.727	rs13040426	ENSG00000222365.1	SNORD12B	-4.71	3.52e-06	0.00199	-0.31	-0.25	Intelligence (multi-trait analysis);	chr20:49097916	chr20:49280319~49280409:+
STAD	cis	rs6832769	0.961	rs13152650	ENSG00000272969.1	RP11-528I4.2	4.71	3.52e-06	0.00199	0.31	0.25	Personality dimensions;	chr4:55491691	chr4:55547112~55547889:+
STAD	cis	rs76917914	0.954	rs7855432	ENSG00000236896.1	RP11-535C21.3	4.71	3.52e-06	0.00199	0.33	0.25	Immature fraction of reticulocytes;	chr9:97997831	chr9:97986551~97987656:-
STAD	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	4.71	3.52e-06	0.00199	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	4.71	3.52e-06	0.00199	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
STAD	cis	rs11846409	0.86	rs59055020	ENSG00000211972.2	IGHV3-66	4.71	3.52e-06	0.00199	0.25	0.25	Rheumatic heart disease;	chr14:106631573	chr14:106675017~106675544:-
STAD	cis	rs748404	0.666	rs66629206	ENSG00000249839.1	AC011330.5	-4.71	3.53e-06	0.00199	-0.42	-0.25	Lung cancer;	chr15:43458804	chr15:43663654~43684339:-
STAD	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-4.71	3.53e-06	0.00199	-0.34	-0.25	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
STAD	cis	rs6095360	0.727	rs34385643	ENSG00000222365.1	SNORD12B	-4.71	3.53e-06	0.00199	-0.32	-0.25	Intelligence (multi-trait analysis);	chr20:48956879	chr20:49280319~49280409:+
STAD	cis	rs7074356	0.831	rs12764048	ENSG00000225484.5	NUTM2B-AS1	-4.71	3.53e-06	0.00199	-0.47	-0.25	Borderline personality disorder;	chr10:80389207	chr10:79663088~79826594:-
STAD	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	4.71	3.53e-06	0.00199	0.35	0.25	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
STAD	cis	rs7429990	0.965	rs6772396	ENSG00000224895.1	VPS26BP1	-4.71	3.53e-06	0.00199	-0.24	-0.25	Educational attainment (years of education);	chr3:47918280	chr3:47960327~47961081:-
STAD	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-4.71	3.53e-06	0.00199	-0.36	-0.25	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
STAD	cis	rs858239	0.509	rs57611130	ENSG00000230042.1	AK3P3	-4.71	3.53e-06	0.00199	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23129178~23129841:+
STAD	cis	rs875971	0.825	rs4587224	ENSG00000236529.1	RP13-254B10.1	-4.71	3.53e-06	0.00199	-0.25	-0.25	Aortic root size;	chr7:66271195	chr7:65840212~65840596:+
STAD	cis	rs875971	0.792	rs6971752	ENSG00000236529.1	RP13-254B10.1	-4.71	3.53e-06	0.00199	-0.25	-0.25	Aortic root size;	chr7:66272999	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10950033	ENSG00000236529.1	RP13-254B10.1	-4.71	3.53e-06	0.00199	-0.25	-0.25	Aortic root size;	chr7:66274686	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs11760844	ENSG00000236529.1	RP13-254B10.1	-4.71	3.53e-06	0.00199	-0.25	-0.25	Aortic root size;	chr7:66274896	chr7:65840212~65840596:+
STAD	cis	rs801193	0.569	rs11772819	ENSG00000224316.1	RP11-479O9.2	4.71	3.53e-06	0.00199	0.24	0.25	Aortic root size;	chr7:66752983	chr7:65773620~65802067:+
STAD	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-4.71	3.53e-06	0.00199	-0.24	-0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
STAD	cis	rs5758659	0.967	rs5751250	ENSG00000182057.4	OGFRP1	4.71	3.53e-06	0.00199	0.26	0.25	Cognitive function;	chr22:42243639	chr22:42269753~42275196:+
STAD	cis	rs748404	0.697	rs531910	ENSG00000275601.1	AC011330.13	-4.71	3.54e-06	0.00199	-0.26	-0.25	Lung cancer;	chr15:43268409	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs492743	ENSG00000275601.1	AC011330.13	-4.71	3.54e-06	0.00199	-0.26	-0.25	Lung cancer;	chr15:43268747	chr15:43642389~43643023:-
STAD	cis	rs8099594	0.64	rs6507906	ENSG00000266696.1	RP11-30L3.2	4.71	3.54e-06	0.00199	0.24	0.25	Height;	chr18:49408635	chr18:49205912~49208781:+
STAD	cis	rs1799949	1	rs8176242	ENSG00000236383.6	LINC00854	-4.71	3.54e-06	0.00199	-0.2	-0.25	Menopause (age at onset);	chr17:43065857	chr17:43216941~43305976:-
STAD	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	4.71	3.54e-06	0.00199	0.29	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
STAD	cis	rs10129255	0.5	rs7161740	ENSG00000211973.2	IGHV1-69	4.71	3.54e-06	0.002	0.2	0.25	Kawasaki disease;	chr14:106776119	chr14:106714684~106715181:-
STAD	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	4.71	3.54e-06	0.002	0.27	0.25	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
STAD	cis	rs10129255	0.518	rs11847766	ENSG00000211973.2	IGHV1-69	4.71	3.55e-06	0.002	0.2	0.25	Kawasaki disease;	chr14:106779186	chr14:106714684~106715181:-
STAD	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-4.71	3.55e-06	0.002	-0.26	-0.25	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
STAD	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-4.71	3.55e-06	0.002	-0.19	-0.25	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-4.71	3.55e-06	0.002	-0.19	-0.25	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
STAD	cis	rs11098499	0.954	rs6820115	ENSG00000260091.1	RP11-33B1.4	4.71	3.55e-06	0.002	0.24	0.25	Corneal astigmatism;	chr4:119477027	chr4:119409333~119410233:+
STAD	cis	rs1799949	1	rs4793236	ENSG00000279602.1	CTD-3014M21.1	4.71	3.55e-06	0.002	0.31	0.25	Menopause (age at onset);	chr17:43359072	chr17:43360041~43361361:-
STAD	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-4.71	3.55e-06	0.002	-0.29	-0.25	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
STAD	cis	rs9307551	0.857	rs2218212	ENSG00000250334.4	LINC00989	-4.71	3.55e-06	0.002	-0.29	-0.25	Refractive error;	chr4:79614887	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.857	rs2218213	ENSG00000250334.4	LINC00989	-4.71	3.55e-06	0.002	-0.29	-0.25	Refractive error;	chr4:79614890	chr4:79492416~79576460:+
STAD	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	4.71	3.56e-06	0.002	0.3	0.25	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
STAD	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-4.71	3.56e-06	0.002	-0.3	-0.25	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
STAD	cis	rs10504130	0.569	rs4626585	ENSG00000272024.1	RP11-546K22.3	4.71	3.56e-06	0.002	0.34	0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51950284~51950690:+
STAD	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-4.71	3.56e-06	0.002	-0.3	-0.25	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
STAD	cis	rs8097348	0.817	rs2219125	ENSG00000266602.1	RP11-476K15.1	-4.71	3.56e-06	0.002	-0.28	-0.25	Exercise (leisure time);	chr18:1654052	chr18:1509183~1647097:+
STAD	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	4.71	3.56e-06	0.00201	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
STAD	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-4.71	3.56e-06	0.00201	-0.36	-0.25	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
STAD	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	4.71	3.56e-06	0.00201	0.26	0.25	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
STAD	cis	rs2337406	0.85	rs1858678	ENSG00000211972.2	IGHV3-66	4.71	3.56e-06	0.00201	0.27	0.25	Alzheimer's disease (late onset);	chr14:106706790	chr14:106675017~106675544:-
STAD	cis	rs6832769	1	rs1522110	ENSG00000272969.1	RP11-528I4.2	4.71	3.56e-06	0.00201	0.31	0.25	Personality dimensions;	chr4:55514116	chr4:55547112~55547889:+
STAD	cis	rs17401966	0.838	rs9332414	ENSG00000199562.1	RNU6-37P	4.71	3.57e-06	0.00201	0.19	0.25	Hepatocellular carcinoma;	chr1:10266905	chr1:10298966~10299072:+
STAD	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	4.71	3.57e-06	0.00201	0.3	0.25	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
STAD	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-4.71	3.57e-06	0.00201	-0.32	-0.25	Height;	chr20:49291523	chr20:49280319~49280409:+
STAD	cis	rs10510102	0.872	rs11200268	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121932661	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11200269	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121934021	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11498944	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121938748	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.81	rs12267347	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121939110	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.808	rs12253007	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121939360	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs79865971	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121941208	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs74318512	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121941465	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12257207	ENSG00000226864.1	ATE1-AS1	4.71	3.57e-06	0.00201	0.39	0.25	Breast cancer;	chr10:121941737	chr10:121928312~121951965:+
STAD	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	4.71	3.57e-06	0.00201	0.26	0.25	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
STAD	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	4.71	3.57e-06	0.00201	0.36	0.25	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
STAD	cis	rs10129255	0.5	rs9324092	ENSG00000211973.2	IGHV1-69	-4.71	3.57e-06	0.00201	-0.21	-0.25	Kawasaki disease;	chr14:106683806	chr14:106714684~106715181:-
STAD	cis	rs7615952	0.611	rs2971298	ENSG00000272840.1	RP11-379B18.6	4.71	3.57e-06	0.00201	0.49	0.25	Blood pressure (smoking interaction);	chr3:125883870	chr3:125774714~125797953:+
STAD	cis	rs3736858	1	rs9544053	ENSG00000261105.4	LMO7-AS1	-4.71	3.58e-06	0.00201	-0.41	-0.25	Interleukin-9 levels;	chr13:75853716	chr13:75604700~75635994:-
STAD	cis	rs11169552	0.51	rs17124930	ENSG00000200183.1	RNU6-238P	-4.71	3.58e-06	0.00201	-0.23	-0.25	Colorectal cancer;	chr12:50722152	chr12:50656973~50657078:+
STAD	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	4.71	3.58e-06	0.00201	0.35	0.25	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
STAD	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	4.71	3.58e-06	0.00201	0.35	0.25	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
STAD	cis	rs10129255	0.518	rs10136903	ENSG00000211973.2	IGHV1-69	4.71	3.58e-06	0.00202	0.2	0.25	Kawasaki disease;	chr14:106778866	chr14:106714684~106715181:-
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000224205.1	AP000351.4	4.71	3.58e-06	0.00202	0.27	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23987320~23991421:-
STAD	cis	rs4950322	0.543	rs4950318	ENSG00000278811.3	LINC00624	4.71	3.58e-06	0.00202	0.26	0.25	Protein quantitative trait loci;	chr1:147316240	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.543	rs4453096	ENSG00000278811.3	LINC00624	4.71	3.58e-06	0.00202	0.26	0.25	Protein quantitative trait loci;	chr1:147316574	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.571	rs4373796	ENSG00000278811.3	LINC00624	4.71	3.58e-06	0.00202	0.26	0.25	Protein quantitative trait loci;	chr1:147316747	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.543	rs4568882	ENSG00000278811.3	LINC00624	4.71	3.58e-06	0.00202	0.26	0.25	Protein quantitative trait loci;	chr1:147316885	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.543	rs2883323	ENSG00000278811.3	LINC00624	4.71	3.58e-06	0.00202	0.26	0.25	Protein quantitative trait loci;	chr1:147316995	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.543	rs2883324	ENSG00000278811.3	LINC00624	4.71	3.58e-06	0.00202	0.26	0.25	Protein quantitative trait loci;	chr1:147317157	chr1:147258885~147517875:-
STAD	cis	rs1723838	0.826	rs4548648	ENSG00000255928.1	RP11-456I15.2	4.71	3.59e-06	0.00202	0.52	0.25	Obesity-related traits;	chr11:73790730	chr11:73722349~73722694:+
STAD	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	4.71	3.59e-06	0.00202	0.3	0.25	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
STAD	cis	rs748404	0.66	rs690446	ENSG00000275601.1	AC011330.13	-4.71	3.59e-06	0.00202	-0.26	-0.25	Lung cancer;	chr15:43469066	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs518288	ENSG00000275601.1	AC011330.13	-4.71	3.59e-06	0.00202	-0.26	-0.25	Lung cancer;	chr15:43471801	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs560191	ENSG00000275601.1	AC011330.13	-4.71	3.59e-06	0.00202	-0.26	-0.25	Lung cancer;	chr15:43475576	chr15:43642389~43643023:-
STAD	cis	rs4950322	0.748	rs17360812	ENSG00000278811.3	LINC00624	-4.71	3.59e-06	0.00202	-0.27	-0.25	Protein quantitative trait loci;	chr1:147355010	chr1:147258885~147517875:-
STAD	cis	rs1707322	0.686	rs2230658	ENSG00000281133.1	AL355480.3	4.71	3.59e-06	0.00202	0.3	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.686	rs2230659	ENSG00000281133.1	AL355480.3	4.71	3.59e-06	0.00202	0.3	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45580892~45580996:-
STAD	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	4.71	3.59e-06	0.00202	0.25	0.25	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
STAD	cis	rs944722	0.935	rs2314809	ENSG00000266786.1	LGALS9DP	4.71	3.59e-06	0.00202	0.3	0.25	Fractional exhaled nitric oxide (childhood);	chr17:27768352	chr17:27746132~27754954:+
STAD	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-4.71	3.6e-06	0.00202	-0.36	-0.25	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-4.71	3.6e-06	0.00202	-0.36	-0.25	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
STAD	cis	rs7429990	0.93	rs7374516	ENSG00000224895.1	VPS26BP1	-4.71	3.6e-06	0.00202	-0.24	-0.25	Educational attainment (years of education);	chr3:47961150	chr3:47960327~47961081:-
STAD	cis	rs875971	0.545	rs2420456	ENSG00000236529.1	RP13-254B10.1	4.71	3.6e-06	0.00202	0.29	0.25	Aortic root size;	chr7:66280619	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs7783889	ENSG00000236529.1	RP13-254B10.1	4.71	3.6e-06	0.00202	0.29	0.25	Aortic root size;	chr7:66283366	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs11767262	ENSG00000236529.1	RP13-254B10.1	4.71	3.6e-06	0.00202	0.29	0.25	Aortic root size;	chr7:66302237	chr7:65840212~65840596:+
STAD	cis	rs875971	0.545	rs66594357	ENSG00000236529.1	RP13-254B10.1	4.71	3.6e-06	0.00202	0.29	0.25	Aortic root size;	chr7:66327797	chr7:65840212~65840596:+
STAD	cis	rs728616	0.558	rs34268041	ENSG00000225484.5	NUTM2B-AS1	-4.71	3.6e-06	0.00202	-0.47	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80388883	chr10:79663088~79826594:-
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000224373.3	IGHV4-59	4.71	3.6e-06	0.00202	0.17	0.25	Kawasaki disease;	chr14:106785926	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000224373.3	IGHV4-59	4.71	3.6e-06	0.00202	0.17	0.25	Kawasaki disease;	chr14:106787090	chr14:106627249~106627825:-
STAD	cis	rs12025262	0.546	rs10754539	ENSG00000215795.2	RP11-488L18.3	4.71	3.6e-06	0.00203	0.28	0.25	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247183813~247185482:-
STAD	cis	rs13113518	0.783	rs11943206	ENSG00000223305.1	RN7SKP30	4.71	3.6e-06	0.00203	0.28	0.25	Height;	chr4:55570843	chr4:55540502~55540835:-
STAD	cis	rs9926664	0.591	rs16882	ENSG00000274134.1	MIR6774	4.71	3.6e-06	0.00203	0.34	0.25	Neutrophil count;Sum basophil neutrophil counts;	chr16:85901967	chr16:85918347~85918416:+
STAD	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-4.71	3.61e-06	0.00203	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
STAD	cis	rs9368481	0.554	rs2754603	ENSG00000224843.5	LINC00240	4.71	3.61e-06	0.00203	0.28	0.25	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26956992~27023924:+
STAD	cis	rs9368481	0.761	rs9357028	ENSG00000224843.5	LINC00240	4.71	3.61e-06	0.00203	0.28	0.25	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26956992~27023924:+
STAD	cis	rs7429990	0.965	rs2053767	ENSG00000224895.1	VPS26BP1	-4.71	3.61e-06	0.00203	-0.24	-0.25	Educational attainment (years of education);	chr3:47958184	chr3:47960327~47961081:-
STAD	cis	rs1056107	0.731	rs10114892	ENSG00000225513.1	RP11-165N19.2	-4.71	3.61e-06	0.00203	-0.29	-0.25	Colorectal cancer;	chr9:112173696	chr9:112173522~112173971:-
STAD	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-4.71	3.61e-06	0.00203	-0.28	-0.25	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
STAD	cis	rs4713118	0.869	rs9283883	ENSG00000280107.1	AL022393.9	-4.71	3.61e-06	0.00203	-0.33	-0.25	Parkinson's disease;	chr6:27747691	chr6:28170845~28172521:+
STAD	cis	rs13113518	1	rs13141049	ENSG00000223305.1	RN7SKP30	4.71	3.62e-06	0.00203	0.27	0.25	Height;	chr4:55535489	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.967	rs12507722	ENSG00000223305.1	RN7SKP30	4.71	3.62e-06	0.00203	0.27	0.25	Height;	chr4:55536421	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.967	rs7696832	ENSG00000223305.1	RN7SKP30	4.71	3.62e-06	0.00203	0.27	0.25	Height;	chr4:55537080	chr4:55540502~55540835:-
STAD	cis	rs181553	0.699	rs12970381	ENSG00000266696.1	RP11-30L3.2	4.71	3.62e-06	0.00203	0.23	0.25	Hip circumference adjusted for BMI;	chr18:49167450	chr18:49205912~49208781:+
STAD	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-4.71	3.62e-06	0.00203	-0.32	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
STAD	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-4.71	3.62e-06	0.00203	-0.32	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
STAD	cis	rs10129255	0.5	rs6576230	ENSG00000211973.2	IGHV1-69	4.71	3.62e-06	0.00203	0.2	0.25	Kawasaki disease;	chr14:106778539	chr14:106714684~106715181:-
STAD	cis	rs7665090	0.517	rs1585214	ENSG00000246560.2	RP11-10L12.4	4.71	3.62e-06	0.00203	0.31	0.25	Primary biliary cholangitis;	chr4:102523376	chr4:102828055~102844075:+
STAD	cis	rs10851478	0.54	rs1904316	ENSG00000259545.2	RP11-325E5.4	4.71	3.62e-06	0.00203	0.26	0.25	Oral cavity cancer;	chr15:49416513	chr15:49177610~49178741:-
STAD	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	4.71	3.62e-06	0.00204	0.32	0.25	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
STAD	cis	rs7176527	0.519	rs12148368	ENSG00000229212.6	RP11-561C5.4	4.71	3.62e-06	0.00204	0.33	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85205440~85234795:-
STAD	cis	rs10129255	0.5	rs988132	ENSG00000211973.2	IGHV1-69	4.71	3.63e-06	0.00204	0.21	0.25	Kawasaki disease;	chr14:106776758	chr14:106714684~106715181:-
STAD	cis	rs858239	0.6	rs1468592	ENSG00000226816.2	AC005082.12	-4.71	3.63e-06	0.00204	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23206013~23208045:+
STAD	cis	rs763014	0.966	rs4984903	ENSG00000228201.1	AL022341.3	4.71	3.63e-06	0.00204	0.29	0.25	Height;	chr16:630695	chr16:648473~649200:-
STAD	cis	rs763014	0.966	rs4984904	ENSG00000228201.1	AL022341.3	4.71	3.63e-06	0.00204	0.29	0.25	Height;	chr16:630809	chr16:648473~649200:-
STAD	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	4.71	3.63e-06	0.00204	0.3	0.25	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
STAD	cis	rs9341808	0.59	rs4706841	ENSG00000272129.1	RP11-250B2.6	4.71	3.63e-06	0.00204	0.27	0.25	Sitting height ratio;	chr6:80348110	chr6:80355424~80356859:+
STAD	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-4.71	3.63e-06	0.00204	-0.19	-0.25	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-4.71	3.63e-06	0.00204	-0.19	-0.25	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-4.71	3.63e-06	0.00204	-0.19	-0.25	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
STAD	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	4.71	3.63e-06	0.00204	0.28	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
STAD	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-4.71	3.63e-06	0.00204	-0.28	-0.25	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
STAD	cis	rs858239	0.867	rs10250602	ENSG00000226816.2	AC005082.12	4.71	3.63e-06	0.00204	0.32	0.25	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23206013~23208045:+
STAD	cis	rs9902453	0.619	rs2244585	ENSG00000240074.1	RPL9P30	-4.71	3.63e-06	0.00204	-0.21	-0.25	Coffee consumption (cups per day);	chr17:29745158	chr17:29855759~29856332:+
STAD	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-4.71	3.63e-06	0.00204	-0.27	-0.25	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
STAD	cis	rs9307551	0.584	rs1115518	ENSG00000250334.4	LINC00989	-4.71	3.63e-06	0.00204	-0.3	-0.25	Refractive error;	chr4:79491423	chr4:79492416~79576460:+
STAD	cis	rs7829975	0.714	rs12544992	ENSG00000254340.1	RP11-10A14.3	4.71	3.63e-06	0.00204	0.29	0.25	Mood instability;	chr8:8804171	chr8:9141424~9145435:+
STAD	cis	rs858239	0.601	rs11984129	ENSG00000230042.1	AK3P3	-4.71	3.64e-06	0.00204	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23129178~23129841:+
STAD	cis	rs228614	0.51	rs170565	ENSG00000248971.2	KRT8P46	-4.71	3.64e-06	0.00204	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102728746~102730171:-
STAD	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-4.71	3.64e-06	0.00204	-0.25	-0.25	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
STAD	cis	rs6584283	0.846	rs7917446	ENSG00000257582.4	LINC01475	-4.71	3.64e-06	0.00204	-0.28	-0.25	Ulcerative colitis;	chr10:99526450	chr10:99526350~99531177:-
STAD	cis	rs6061231	0.74	rs11698650	ENSG00000275437.1	RP5-908M14.10	4.71	3.64e-06	0.00204	0.22	0.25	Colorectal cancer;	chr20:62383318	chr20:62402236~62405935:-
STAD	cis	rs17630293	0.649	rs296769	ENSG00000201649.1	RNY4P34	4.71	3.64e-06	0.00204	0.35	0.25	Schizophrenia;	chr2:200370159	chr2:200373175~200373269:+
STAD	cis	rs17630293	0.737	rs295111	ENSG00000201649.1	RNY4P34	4.71	3.64e-06	0.00204	0.35	0.25	Schizophrenia;	chr2:200371164	chr2:200373175~200373269:+
STAD	cis	rs17630293	0.737	rs295112	ENSG00000201649.1	RNY4P34	4.71	3.64e-06	0.00204	0.35	0.25	Schizophrenia;	chr2:200371294	chr2:200373175~200373269:+
STAD	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-4.71	3.64e-06	0.00204	-0.31	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
STAD	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-4.71	3.64e-06	0.00204	-0.31	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
STAD	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-4.71	3.64e-06	0.00204	-0.32	-0.25	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
STAD	cis	rs3806843	0.576	rs246074	ENSG00000202111.1	VTRNA1-2	-4.71	3.64e-06	0.00205	-0.24	-0.25	Depressive symptoms (multi-trait analysis);	chr5:140928384	chr5:140718925~140719013:+
STAD	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	4.71	3.64e-06	0.00205	0.43	0.25	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
STAD	cis	rs4691139	1	rs12498808	ENSG00000248632.1	RP11-366M4.11	4.71	3.65e-06	0.00205	0.24	0.25	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985753	chr4:164968587~164970002:-
STAD	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-4.71	3.65e-06	0.00205	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
STAD	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	4.71	3.65e-06	0.00205	0.27	0.25	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
STAD	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-4.71	3.65e-06	0.00205	-0.28	-0.25	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
STAD	cis	rs11676348	0.776	rs11690316	ENSG00000237281.1	CATIP-AS2	4.71	3.65e-06	0.00205	0.25	0.25	Ulcerative colitis;	chr2:218152739	chr2:218326889~218357966:-
STAD	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-4.71	3.66e-06	0.00205	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
STAD	cis	rs1723838	0.826	rs1880642	ENSG00000255928.1	RP11-456I15.2	-4.71	3.66e-06	0.00205	-0.52	-0.25	Obesity-related traits;	chr11:73701723	chr11:73722349~73722694:+
STAD	cis	rs237743	0.963	rs73611371	ENSG00000222365.1	SNORD12B	-4.71	3.66e-06	0.00205	-0.34	-0.25	Height;	chr20:49218618	chr20:49280319~49280409:+
STAD	cis	rs7487075	0.619	rs1472178	ENSG00000257261.4	RP11-96H19.1	4.71	3.66e-06	0.00205	0.33	0.25	Itch intensity from mosquito bite;	chr12:46410392	chr12:46383679~46876159:+
STAD	cis	rs1799949	1	rs11657835	ENSG00000279602.1	CTD-3014M21.1	4.71	3.66e-06	0.00205	0.31	0.25	Menopause (age at onset);	chr17:43139936	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs1135214	ENSG00000279602.1	CTD-3014M21.1	4.71	3.66e-06	0.00205	0.31	0.25	Menopause (age at onset);	chr17:43140306	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11652332	ENSG00000279602.1	CTD-3014M21.1	4.71	3.66e-06	0.00205	0.31	0.25	Menopause (age at onset);	chr17:43143472	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs4793212	ENSG00000279602.1	CTD-3014M21.1	4.71	3.66e-06	0.00205	0.31	0.25	Menopause (age at onset);	chr17:43150733	chr17:43360041~43361361:-
STAD	cis	rs17818399	0.962	rs7565274	ENSG00000279254.1	RP11-536C12.1	-4.71	3.66e-06	0.00206	-0.27	-0.25	Height;	chr2:46614722	chr2:46668870~46670778:+
STAD	cis	rs9926296	0.568	rs417323	ENSG00000260259.1	RP11-368I7.4	4.71	3.67e-06	0.00206	0.31	0.25	Vitiligo;	chr16:89679869	chr16:89682620~89686569:-
STAD	cis	rs748404	0.66	rs690472	ENSG00000275601.1	AC011330.13	-4.71	3.67e-06	0.00206	-0.26	-0.25	Lung cancer;	chr15:43472170	chr15:43642389~43643023:-
STAD	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	4.71	3.67e-06	0.00206	0.37	0.25	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	4.71	3.67e-06	0.00206	0.37	0.25	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
STAD	cis	rs4243830	0.85	rs12029123	ENSG00000229519.2	RP11-58A11.2	-4.71	3.67e-06	0.00206	-0.27	-0.25	Body mass index;	chr1:6547082	chr1:6547905~6548619:+
STAD	cis	rs9532580	0.614	rs17446614	ENSG00000229456.1	RLIMP1	-4.71	3.67e-06	0.00206	-0.29	-0.25	Mean corpuscular hemoglobin;	chr13:40565740	chr13:40618738~40621348:+
STAD	cis	rs5758659	0.845	rs5758645	ENSG00000182057.4	OGFRP1	4.71	3.67e-06	0.00206	0.26	0.25	Cognitive function;	chr22:42202945	chr22:42269753~42275196:+
STAD	cis	rs4691139	1	rs6855591	ENSG00000248632.1	RP11-366M4.11	4.7	3.68e-06	0.00206	0.24	0.25	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985571	chr4:164968587~164970002:-
STAD	cis	rs2115630	0.936	rs11073663	ENSG00000225151.9	GOLGA2P7	4.7	3.68e-06	0.00206	0.27	0.25	P wave terminal force;	chr15:84717037	chr15:84199311~84230136:-
STAD	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-4.7	3.68e-06	0.00206	-0.29	-0.25	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
STAD	cis	rs10510102	0.935	rs11200237	ENSG00000226864.1	ATE1-AS1	4.7	3.68e-06	0.00206	0.4	0.25	Breast cancer;	chr10:121900715	chr10:121928312~121951965:+
STAD	cis	rs2880765	0.506	rs719138	ENSG00000259295.5	CSPG4P12	4.7	3.68e-06	0.00206	0.34	0.25	Coronary artery disease;	chr15:85511831	chr15:85191438~85213905:+
STAD	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	4.7	3.68e-06	0.00206	0.42	0.25	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
STAD	cis	rs11846409	0.932	rs74091728	ENSG00000211972.2	IGHV3-66	4.7	3.68e-06	0.00206	0.25	0.25	Rheumatic heart disease;	chr14:106638762	chr14:106675017~106675544:-
STAD	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-4.7	3.69e-06	0.00207	-0.26	-0.25	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-4.7	3.69e-06	0.00207	-0.26	-0.25	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-4.7	3.69e-06	0.00207	-0.26	-0.25	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-4.7	3.69e-06	0.00207	-0.26	-0.25	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
STAD	cis	rs2337406	0.704	rs1858679	ENSG00000211972.2	IGHV3-66	4.7	3.69e-06	0.00207	0.27	0.25	Alzheimer's disease (late onset);	chr14:106706726	chr14:106675017~106675544:-
STAD	cis	rs1707322	0.717	rs2275086	ENSG00000281133.1	AL355480.3	4.7	3.69e-06	0.00207	0.3	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45580892~45580996:-
STAD	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	4.7	3.69e-06	0.00207	0.39	0.25	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
STAD	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-4.7	3.69e-06	0.00207	-0.25	-0.25	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
STAD	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	4.7	3.69e-06	0.00207	0.25	0.25	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
STAD	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-4.7	3.7e-06	0.00207	-0.26	-0.25	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-4.7	3.7e-06	0.00207	-0.26	-0.25	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
STAD	cis	rs5758659	1	rs134873	ENSG00000182057.4	OGFRP1	4.7	3.7e-06	0.00207	0.26	0.25	Cognitive function;	chr22:42261560	chr22:42269753~42275196:+
STAD	cis	rs76917914	1	rs7850685	ENSG00000236896.1	RP11-535C21.3	-4.7	3.7e-06	0.00207	-0.32	-0.25	Immature fraction of reticulocytes;	chr9:98001608	chr9:97986551~97987656:-
STAD	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-4.7	3.7e-06	0.00207	-0.26	-0.25	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
STAD	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-4.7	3.7e-06	0.00207	-0.26	-0.25	Height;	chr3:52819385	chr3:53064283~53065091:-
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000224205.1	AP000351.4	4.7	3.7e-06	0.00207	0.27	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23987320~23991421:-
STAD	cis	rs2337406	0.789	rs60000589	ENSG00000280411.1	IGHV1-69-2	-4.7	3.7e-06	0.00207	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106782459	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs111881598	ENSG00000280411.1	IGHV1-69-2	-4.7	3.7e-06	0.00207	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106783113	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs61164979	ENSG00000280411.1	IGHV1-69-2	-4.7	3.7e-06	0.00207	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106783133	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs61419485	ENSG00000280411.1	IGHV1-69-2	-4.7	3.7e-06	0.00207	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106783374	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs74090151	ENSG00000280411.1	IGHV1-69-2	-4.7	3.7e-06	0.00207	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106785377	chr14:106762092~106762588:-
STAD	cis	rs13113518	1	rs56362210	ENSG00000223305.1	RN7SKP30	4.7	3.7e-06	0.00207	0.27	0.25	Height;	chr4:55540972	chr4:55540502~55540835:-
STAD	cis	rs891378	0.959	rs7533825	ENSG00000274245.1	RP11-357P18.2	-4.7	3.7e-06	0.00207	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248817	chr1:207372559~207373252:+
STAD	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	4.7	3.7e-06	0.00207	0.4	0.25	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
STAD	cis	rs330048	0.561	rs330088	ENSG00000254340.1	RP11-10A14.3	4.7	3.71e-06	0.00208	0.3	0.25	Systemic lupus erythematosus;	chr8:9292236	chr8:9141424~9145435:+
STAD	cis	rs1075265	0.704	rs10181999	ENSG00000235937.1	AC008280.1	4.7	3.71e-06	0.00208	0.22	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54029552~54030682:-
STAD	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	4.7	3.72e-06	0.00208	0.31	0.25	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
STAD	cis	rs12682352	0.715	rs332039	ENSG00000173295.6	FAM86B3P	4.7	3.72e-06	0.00208	0.28	0.25	Neuroticism;	chr8:8866141	chr8:8228595~8244865:+
STAD	cis	rs891378	1	rs7543250	ENSG00000274245.1	RP11-357P18.2	4.7	3.72e-06	0.00208	0.3	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251698	chr1:207372559~207373252:+
STAD	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-4.7	3.72e-06	0.00208	-0.26	-0.25	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
STAD	cis	rs7615952	0.611	rs9681518	ENSG00000239804.1	RP11-379B18.1	4.7	3.72e-06	0.00208	0.45	0.25	Blood pressure (smoking interaction);	chr3:125896287	chr3:125787888~125788146:-
STAD	cis	rs9532580	0.614	rs61963261	ENSG00000229456.1	RLIMP1	4.7	3.72e-06	0.00208	0.3	0.25	Mean corpuscular hemoglobin;	chr13:40568158	chr13:40618738~40621348:+
STAD	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	4.7	3.72e-06	0.00208	0.3	0.25	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
STAD	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	4.7	3.73e-06	0.00209	0.31	0.25	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	4.7	3.73e-06	0.00209	0.31	0.25	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
STAD	cis	rs2404602	0.619	rs7342603	ENSG00000259422.1	RP11-593F23.1	4.7	3.73e-06	0.00209	0.26	0.25	Blood metabolite levels;	chr15:76690284	chr15:76174891~76181486:-
STAD	cis	rs7932354	0.55	rs10769208	ENSG00000271350.1	CTD-2384B9.1	-4.7	3.73e-06	0.00209	-0.29	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46800690	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.55	rs10734549	ENSG00000271350.1	CTD-2384B9.1	-4.7	3.73e-06	0.00209	-0.29	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46801136	chr11:47041027~47041945:-
STAD	cis	rs7932354	0.583	rs4294527	ENSG00000271350.1	CTD-2384B9.1	-4.7	3.73e-06	0.00209	-0.29	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46807249	chr11:47041027~47041945:-
STAD	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-4.7	3.73e-06	0.00209	-0.29	-0.25	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
STAD	cis	rs4474742	1	rs4474742	ENSG00000240074.1	RPL9P30	-4.7	3.73e-06	0.00209	-0.21	-0.25	Monocyte count;	chr17:29738560	chr17:29855759~29856332:+
STAD	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-4.7	3.73e-06	0.00209	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
STAD	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-4.7	3.73e-06	0.00209	-0.38	-0.25	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
STAD	cis	rs875971	1	rs778706	ENSG00000236529.1	RP13-254B10.1	4.7	3.73e-06	0.00209	0.26	0.25	Aortic root size;	chr7:66395437	chr7:65840212~65840596:+
STAD	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	4.7	3.74e-06	0.00209	0.35	0.25	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
STAD	cis	rs1707322	0.721	rs11211181	ENSG00000281133.1	AL355480.3	-4.7	3.74e-06	0.00209	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45580892~45580996:-
STAD	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	4.7	3.74e-06	0.00209	0.36	0.25	Height;	chr6:109741085	chr6:109382795~109383666:+
STAD	cis	rs1005277	0.579	rs1621040	ENSG00000276805.1	RP11-291L22.6	4.7	3.74e-06	0.00209	0.27	0.25	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38451030~38451785:+
STAD	cis	rs2933343	0.672	rs1872545	ENSG00000261159.1	RP11-723O4.9	4.7	3.75e-06	0.0021	0.3	0.25	IgG glycosylation;	chr3:128926196	chr3:128859716~128860526:-
STAD	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	4.7	3.75e-06	0.0021	0.26	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
STAD	cis	rs858239	0.601	rs6969733	ENSG00000230042.1	AK3P3	-4.7	3.75e-06	0.0021	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs4440529	ENSG00000230042.1	AK3P3	-4.7	3.75e-06	0.0021	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23129178~23129841:+
STAD	cis	rs7829975	0.514	rs2920991	ENSG00000253981.4	ALG1L13P	4.7	3.76e-06	0.0021	0.28	0.24	Mood instability;	chr8:8401607	chr8:8236003~8244667:-
STAD	cis	rs763014	1	rs763014	ENSG00000228201.1	AL022341.3	4.7	3.76e-06	0.0021	0.29	0.24	Height;	chr16:625680	chr16:648473~649200:-
STAD	cis	rs11098499	0.909	rs11723839	ENSG00000260091.1	RP11-33B1.4	4.7	3.76e-06	0.0021	0.24	0.24	Corneal astigmatism;	chr4:119378518	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs12506546	ENSG00000260091.1	RP11-33B1.4	4.7	3.76e-06	0.0021	0.24	0.24	Corneal astigmatism;	chr4:119380463	chr4:119409333~119410233:+
STAD	cis	rs7665090	0.967	rs6533022	ENSG00000248971.2	KRT8P46	-4.7	3.76e-06	0.0021	-0.26	-0.24	Primary biliary cholangitis;	chr4:102637794	chr4:102728746~102730171:-
STAD	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	4.7	3.77e-06	0.00211	0.3	0.24	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	4.7	3.77e-06	0.00211	0.3	0.24	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
STAD	cis	rs720064	0.586	rs9958904	ENSG00000267301.1	RPL23AP77	4.7	3.77e-06	0.00211	0.29	0.24	Strep throat;	chr18:23969940	chr18:23709825~23710287:-
STAD	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-4.7	3.77e-06	0.00211	-0.26	-0.24	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
STAD	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-4.7	3.77e-06	0.00211	-0.35	-0.24	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
STAD	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-4.7	3.77e-06	0.00211	-0.31	-0.24	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
STAD	cis	rs35934224	0.783	rs12106549	ENSG00000232926.1	AC000078.5	4.7	3.77e-06	0.00211	0.31	0.24	Glaucoma (primary open-angle);	chr22:19859464	chr22:19887289~19887970:+
STAD	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-4.7	3.78e-06	0.00211	-0.36	-0.24	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
STAD	cis	rs7429990	0.864	rs12495520	ENSG00000224895.1	VPS26BP1	4.7	3.78e-06	0.00211	0.24	0.24	Educational attainment (years of education);	chr3:47766269	chr3:47960327~47961081:-
STAD	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-4.7	3.78e-06	0.00211	-0.25	-0.24	Height;	chr5:36865567	chr5:36666214~36725195:-
STAD	cis	rs172166	0.538	rs149956	ENSG00000220721.1	OR1F12	4.7	3.78e-06	0.00211	0.24	0.24	Cardiac Troponin-T levels;	chr6:28068473	chr6:28073316~28074233:+
STAD	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-4.7	3.78e-06	0.00211	-0.26	-0.24	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
STAD	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	4.7	3.78e-06	0.00211	0.27	0.24	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
STAD	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-4.7	3.78e-06	0.00211	-0.37	-0.24	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
STAD	cis	rs17401966	0.867	rs6696056	ENSG00000199562.1	RNU6-37P	4.7	3.79e-06	0.00212	0.19	0.24	Hepatocellular carcinoma;	chr1:10245934	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs4529713	ENSG00000199562.1	RNU6-37P	4.7	3.79e-06	0.00212	0.19	0.24	Hepatocellular carcinoma;	chr1:10247237	chr1:10298966~10299072:+
STAD	cis	rs55823223	0.68	rs57287238	ENSG00000267801.1	RP11-552F3.9	4.7	3.79e-06	0.00212	0.35	0.24	Psoriasis;	chr17:75854859	chr17:75876372~75879546:+
STAD	cis	rs55823223	0.648	rs936394	ENSG00000267801.1	RP11-552F3.9	4.7	3.79e-06	0.00212	0.35	0.24	Psoriasis;	chr17:75855927	chr17:75876372~75879546:+
STAD	cis	rs7665090	1	rs7664828	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102630219	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.967	rs7690123	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102630602	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs7665659	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102630661	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs7665854	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102630752	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.846	rs7690700	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102630911	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs13112557	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102631096	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs12644381	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102631273	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs1054037	ENSG00000248971.2	KRT8P46	-4.7	3.8e-06	0.00212	-0.25	-0.24	Primary biliary cholangitis;	chr4:102631552	chr4:102728746~102730171:-
STAD	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-4.7	3.8e-06	0.00212	-0.39	-0.24	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
STAD	cis	rs4589258	0.966	rs2187535	ENSG00000280367.1	RP11-121L10.2	4.7	3.8e-06	0.00212	0.27	0.24	Intelligence (multi-trait analysis);	chr11:90773974	chr11:90223153~90226538:+
STAD	cis	rs7078219	0.714	rs60386053	ENSG00000228778.1	RP11-129J12.1	-4.7	3.8e-06	0.00212	-0.31	-0.24	Dental caries;	chr10:99529104	chr10:99527081~99528261:+
STAD	cis	rs13113518	1	rs4864993	ENSG00000223305.1	RN7SKP30	4.7	3.82e-06	0.00213	0.27	0.24	Height;	chr4:55450662	chr4:55540502~55540835:-
STAD	cis	rs853679	0.76	rs9393910	ENSG00000220721.1	OR1F12	4.7	3.82e-06	0.00213	0.29	0.24	Depression;	chr6:28240414	chr6:28073316~28074233:+
STAD	cis	rs853679	0.76	rs9368563	ENSG00000220721.1	OR1F12	4.7	3.82e-06	0.00213	0.29	0.24	Depression;	chr6:28240780	chr6:28073316~28074233:+
STAD	cis	rs853679	0.76	rs9295768	ENSG00000220721.1	OR1F12	4.7	3.82e-06	0.00213	0.29	0.24	Depression;	chr6:28241324	chr6:28073316~28074233:+
STAD	cis	rs1799949	1	rs35956818	ENSG00000279602.1	CTD-3014M21.1	4.7	3.82e-06	0.00213	0.31	0.24	Menopause (age at onset);	chr17:43345617	chr17:43360041~43361361:-
STAD	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	4.7	3.82e-06	0.00213	0.25	0.24	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	4.7	3.82e-06	0.00213	0.25	0.24	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
STAD	cis	rs7429990	0.965	rs7619882	ENSG00000224895.1	VPS26BP1	-4.7	3.82e-06	0.00213	-0.24	-0.24	Educational attainment (years of education);	chr3:47943334	chr3:47960327~47961081:-
STAD	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-4.7	3.82e-06	0.00213	-0.31	-0.24	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
STAD	cis	rs7829975	0.572	rs28730413	ENSG00000254340.1	RP11-10A14.3	-4.7	3.83e-06	0.00213	-0.3	-0.24	Mood instability;	chr8:8937937	chr8:9141424~9145435:+
STAD	cis	rs8028182	0.636	rs4564532	ENSG00000260269.4	CTD-2323K18.1	-4.7	3.83e-06	0.00213	-0.31	-0.24	Sudden cardiac arrest;	chr15:75413955	chr15:75527150~75601205:-
STAD	cis	rs2836950	0.501	rs62223052	ENSG00000238141.2	BRWD1-AS1	-4.7	3.83e-06	0.00213	-0.26	-0.24	Menarche (age at onset);	chr21:39336776	chr21:39315707~39323218:+
STAD	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-4.7	3.83e-06	0.00213	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
STAD	cis	rs393951	1	rs615153	ENSG00000260969.1	RP11-190D6.2	-4.7	3.83e-06	0.00214	-0.3	-0.24	Childhood ear infection;	chr16:77583149	chr16:78237362~78241218:-
STAD	cis	rs10129255	0.5	rs988134	ENSG00000211973.2	IGHV1-69	4.7	3.83e-06	0.00214	0.2	0.24	Kawasaki disease;	chr14:106776698	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000211973.2	IGHV1-69	4.7	3.83e-06	0.00214	0.2	0.24	Kawasaki disease;	chr14:106776724	chr14:106714684~106715181:-
STAD	cis	rs2273156	1	rs7141292	ENSG00000241052.1	RP11-173D9.1	-4.7	3.83e-06	0.00214	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34993700	chr14:35144021~35144480:-
STAD	cis	rs7665090	1	rs5026476	ENSG00000230069.3	LRRC37A15P	-4.7	3.83e-06	0.00214	-0.27	-0.24	Primary biliary cholangitis;	chr4:102633753	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.967	rs13106325	ENSG00000230069.3	LRRC37A15P	-4.7	3.83e-06	0.00214	-0.27	-0.24	Primary biliary cholangitis;	chr4:102633835	chr4:102727274~102730721:-
STAD	cis	rs4589258	1	rs7109167	ENSG00000280367.1	RP11-121L10.2	4.7	3.84e-06	0.00214	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90720049	chr11:90223153~90226538:+
STAD	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-4.7	3.84e-06	0.00214	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
STAD	cis	rs2115630	0.641	rs11073613	ENSG00000225151.9	GOLGA2P7	4.7	3.84e-06	0.00214	0.27	0.24	P wave terminal force;	chr15:84642662	chr15:84199311~84230136:-
STAD	cis	rs2839874	0.741	rs2761687	ENSG00000233817.1	RP11-168K11.3	4.7	3.84e-06	0.00214	0.33	0.24	Social communication problems;	chr9:114136978	chr9:113619228~113622634:+
STAD	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-4.7	3.84e-06	0.00214	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
STAD	cis	rs2695743	0.647	rs1344922	ENSG00000225808.1	DNAJC19P5	-4.7	3.84e-06	0.00214	-0.28	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177823807	chr2:177229191~177229506:-
STAD	cis	rs507080	0.961	rs642530	ENSG00000278376.1	RP11-158I9.8	-4.7	3.84e-06	0.00214	-0.24	-0.24	Serum metabolite levels;	chr11:118680047	chr11:118791254~118793137:+
STAD	cis	rs875971	0.964	rs1643388	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66379575	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs778722	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66379841	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs778721	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66380410	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs778700	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66401463	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs778699	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66403303	chr7:65840212~65840596:+
STAD	cis	rs875971	0.929	rs778692	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66407462	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs4718343	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66409301	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs1968225	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66409786	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6460295	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66417741	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs6978721	ENSG00000236529.1	RP13-254B10.1	4.7	3.84e-06	0.00214	0.26	0.24	Aortic root size;	chr7:66418217	chr7:65840212~65840596:+
STAD	cis	rs6430585	0.591	rs3098103	ENSG00000231890.6	DARS-AS1	-4.7	3.84e-06	0.00214	-0.27	-0.24	Corneal structure;	chr2:135898524	chr2:135985176~136022593:+
STAD	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-4.7	3.85e-06	0.00214	-0.26	-0.24	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
STAD	cis	rs2337406	0.866	rs11488879	ENSG00000280411.1	IGHV1-69-2	-4.69	3.85e-06	0.00214	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106786097	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs8012619	ENSG00000280411.1	IGHV1-69-2	-4.69	3.85e-06	0.00214	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106793907	chr14:106762092~106762588:-
STAD	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-4.69	3.85e-06	0.00215	-0.24	-0.24	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
STAD	cis	rs8067354	0.645	rs2645467	ENSG00000266701.1	AC005702.4	4.69	3.86e-06	0.00215	0.33	0.24	Hemoglobin concentration;	chr17:59777422	chr17:60042546~60042627:-
STAD	cis	rs858239	0.73	rs10255155	ENSG00000226816.2	AC005082.12	-4.69	3.86e-06	0.00215	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23206013~23208045:+
STAD	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-4.69	3.86e-06	0.00215	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
STAD	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-4.69	3.86e-06	0.00215	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
STAD	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-4.69	3.86e-06	0.00215	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
STAD	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-4.69	3.86e-06	0.00215	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
STAD	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-4.69	3.86e-06	0.00215	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
STAD	cis	rs12906542	0.516	rs894301	ENSG00000259792.1	RP11-114H24.6	-4.69	3.86e-06	0.00215	-0.44	-0.24	Breast cancer;	chr15:78005183	chr15:77993405~77995289:+
STAD	cis	rs8062405	1	rs8062405	ENSG00000278665.1	RP11-666O2.4	-4.69	3.86e-06	0.00215	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28599241~28601881:-
STAD	cis	rs728616	0.614	rs958865	ENSG00000225484.5	NUTM2B-AS1	-4.69	3.86e-06	0.00215	-0.38	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948273	chr10:79663088~79826594:-
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000211973.2	IGHV1-69	4.69	3.86e-06	0.00215	0.2	0.24	Kawasaki disease;	chr14:106777494	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000211973.2	IGHV1-69	4.69	3.86e-06	0.00215	0.2	0.24	Kawasaki disease;	chr14:106777510	chr14:106714684~106715181:-
STAD	cis	rs9368481	0.729	rs9379950	ENSG00000224843.5	LINC00240	4.69	3.86e-06	0.00215	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26956992~27023924:+
STAD	cis	rs9368481	1	rs9368481	ENSG00000224843.5	LINC00240	4.69	3.86e-06	0.00215	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26956992~27023924:+
STAD	cis	rs858239	0.6	rs61292332	ENSG00000230042.1	AK3P3	-4.69	3.86e-06	0.00215	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23129178~23129841:+
STAD	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	4.69	3.86e-06	0.00215	0.26	0.24	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
STAD	cis	rs11098499	0.954	rs1546505	ENSG00000260091.1	RP11-33B1.4	4.69	3.86e-06	0.00215	0.24	0.24	Corneal astigmatism;	chr4:119320069	chr4:119409333~119410233:+
STAD	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-4.69	3.86e-06	0.00215	-0.23	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
STAD	cis	rs13113518	0.557	rs13142096	ENSG00000272969.1	RP11-528I4.2	4.69	3.87e-06	0.00215	0.32	0.24	Height;	chr4:55566291	chr4:55547112~55547889:+
STAD	cis	rs2933343	0.7	rs2624910	ENSG00000261159.1	RP11-723O4.9	4.69	3.87e-06	0.00215	0.3	0.24	IgG glycosylation;	chr3:128931432	chr3:128859716~128860526:-
STAD	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	4.69	3.87e-06	0.00215	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
STAD	cis	rs875971	1	rs6979382	ENSG00000236529.1	RP13-254B10.1	4.69	3.87e-06	0.00215	0.25	0.24	Aortic root size;	chr7:66421388	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6961990	ENSG00000236529.1	RP13-254B10.1	4.69	3.87e-06	0.00215	0.25	0.24	Aortic root size;	chr7:66423583	chr7:65840212~65840596:+
STAD	cis	rs9307551	0.584	rs1922284	ENSG00000250334.4	LINC00989	-4.69	3.87e-06	0.00215	-0.3	-0.24	Refractive error;	chr4:79479200	chr4:79492416~79576460:+
STAD	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	4.69	3.87e-06	0.00216	0.26	0.24	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
STAD	cis	rs6832769	1	rs28572116	ENSG00000272969.1	RP11-528I4.2	-4.69	3.87e-06	0.00216	-0.31	-0.24	Personality dimensions;	chr4:55558177	chr4:55547112~55547889:+
STAD	cis	rs858239	0.899	rs28458177	ENSG00000226816.2	AC005082.12	4.69	3.88e-06	0.00216	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23206013~23208045:+
STAD	cis	rs6095360	0.727	rs11906450	ENSG00000222365.1	SNORD12B	-4.69	3.88e-06	0.00216	-0.33	-0.24	Intelligence (multi-trait analysis);	chr20:48938545	chr20:49280319~49280409:+
STAD	cis	rs11098499	0.865	rs4507344	ENSG00000260091.1	RP11-33B1.4	4.69	3.88e-06	0.00216	0.24	0.24	Corneal astigmatism;	chr4:119386330	chr4:119409333~119410233:+
STAD	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	4.69	3.88e-06	0.00216	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	4.69	3.88e-06	0.00216	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
STAD	cis	rs6585424	1	rs34100029	ENSG00000225484.5	NUTM2B-AS1	-4.69	3.88e-06	0.00216	-0.43	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163842	chr10:79663088~79826594:-
STAD	cis	rs801193	0.569	rs7782587	ENSG00000224316.1	RP11-479O9.2	4.69	3.88e-06	0.00216	0.24	0.24	Aortic root size;	chr7:66701485	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs4717315	ENSG00000224316.1	RP11-479O9.2	4.69	3.88e-06	0.00216	0.24	0.24	Aortic root size;	chr7:66713338	chr7:65773620~65802067:+
STAD	cis	rs801193	0.527	rs2707837	ENSG00000224316.1	RP11-479O9.2	4.69	3.88e-06	0.00216	0.24	0.24	Aortic root size;	chr7:66716086	chr7:65773620~65802067:+
STAD	cis	rs2933343	0.729	rs813732	ENSG00000231305.3	RP11-723O4.2	4.69	3.88e-06	0.00216	0.27	0.24	IgG glycosylation;	chr3:128900514	chr3:128861313~128871540:-
STAD	cis	rs7429990	0.965	rs7649981	ENSG00000224895.1	VPS26BP1	-4.69	3.88e-06	0.00216	-0.24	-0.24	Educational attainment (years of education);	chr3:47957847	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs9811277	ENSG00000224895.1	VPS26BP1	-4.69	3.88e-06	0.00216	-0.24	-0.24	Educational attainment (years of education);	chr3:47970148	chr3:47960327~47961081:-
STAD	cis	rs11169552	0.51	rs10506294	ENSG00000200183.1	RNU6-238P	4.69	3.89e-06	0.00216	0.23	0.24	Colorectal cancer;	chr12:50676771	chr12:50656973~50657078:+
STAD	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-4.69	3.89e-06	0.00216	-0.38	-0.24	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
STAD	cis	rs6430585	0.528	rs114760827	ENSG00000231890.6	DARS-AS1	-4.69	3.89e-06	0.00216	-0.27	-0.24	Corneal structure;	chr2:135903540	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs79826902	ENSG00000231890.6	DARS-AS1	-4.69	3.89e-06	0.00216	-0.27	-0.24	Corneal structure;	chr2:135912849	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs16832205	ENSG00000231890.6	DARS-AS1	-4.69	3.89e-06	0.00216	-0.27	-0.24	Corneal structure;	chr2:135927062	chr2:135985176~136022593:+
STAD	cis	rs7078219	0.714	rs10883363	ENSG00000228778.1	RP11-129J12.1	-4.69	3.89e-06	0.00216	-0.31	-0.24	Dental caries;	chr10:99527823	chr10:99527081~99528261:+
STAD	cis	rs989978	0.532	rs10883364	ENSG00000228778.1	RP11-129J12.1	-4.69	3.89e-06	0.00216	-0.31	-0.24	Red blood cell count;	chr10:99527829	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.714	rs11190136	ENSG00000228778.1	RP11-129J12.1	-4.69	3.89e-06	0.00216	-0.31	-0.24	Dental caries;	chr10:99527924	chr10:99527081~99528261:+
STAD	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-4.69	3.89e-06	0.00216	-0.38	-0.24	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
STAD	cis	rs10978777	0.921	rs817838	ENSG00000276883.1	AL137852.1	4.69	3.89e-06	0.00217	0.25	0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107336451	chr9:107292369~107292456:-
STAD	cis	rs228614	0.534	rs223387	ENSG00000248971.2	KRT8P46	-4.69	3.9e-06	0.00217	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102728746~102730171:-
STAD	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	4.69	3.9e-06	0.00217	0.35	0.24	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
STAD	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	4.69	3.9e-06	0.00217	0.35	0.24	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
STAD	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	4.69	3.9e-06	0.00217	0.35	0.24	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
STAD	cis	rs1015362	0.504	rs6059552	ENSG00000275784.1	RP5-1125A11.6	-4.69	3.9e-06	0.00217	-0.29	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33989480~33991818:-
STAD	cis	rs11098499	0.779	rs7699346	ENSG00000260091.1	RP11-33B1.4	4.69	3.9e-06	0.00217	0.24	0.24	Corneal astigmatism;	chr4:119389387	chr4:119409333~119410233:+
STAD	cis	rs801193	0.569	rs11761542	ENSG00000224316.1	RP11-479O9.2	4.69	3.9e-06	0.00217	0.24	0.24	Aortic root size;	chr7:66753209	chr7:65773620~65802067:+
STAD	cis	rs4927850	1	rs4927704	ENSG00000242086.7	LINC00969	4.69	3.9e-06	0.00217	0.23	0.24	Pancreatic cancer;	chr3:196011357	chr3:195658062~195739964:+
STAD	cis	rs4927850	1	rs4927848	ENSG00000242086.7	LINC00969	4.69	3.9e-06	0.00217	0.23	0.24	Pancreatic cancer;	chr3:196011535	chr3:195658062~195739964:+
STAD	cis	rs4589258	1	rs4400760	ENSG00000280367.1	RP11-121L10.2	4.69	3.9e-06	0.00217	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90761607	chr11:90223153~90226538:+
STAD	cis	rs1799949	1	rs3092988	ENSG00000279602.1	CTD-3014M21.1	4.69	3.9e-06	0.00217	0.31	0.24	Menopause (age at onset);	chr17:43049685	chr17:43360041~43361361:-
STAD	cis	rs7829975	0.514	rs2945873	ENSG00000173295.6	FAM86B3P	4.69	3.91e-06	0.00217	0.27	0.24	Mood instability;	chr8:8402935	chr8:8228595~8244865:+
STAD	cis	rs112158604	1	rs112158604	ENSG00000274963.1	Metazoa_SRP	-4.69	3.91e-06	0.00217	-0.2	-0.24	Lymphocyte counts;	chr1:150724325	chr1:150568971~150569269:-
STAD	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	4.69	3.92e-06	0.00218	0.24	0.24	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
STAD	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	4.69	3.92e-06	0.00218	0.24	0.24	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
STAD	cis	rs6095360	0.7	rs67623477	ENSG00000222365.1	SNORD12B	-4.69	3.92e-06	0.00218	-0.32	-0.24	Intelligence (multi-trait analysis);	chr20:49052640	chr20:49280319~49280409:+
STAD	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	4.69	3.92e-06	0.00218	0.22	0.24	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
STAD	cis	rs1707322	0.506	rs2991983	ENSG00000281133.1	AL355480.3	4.69	3.92e-06	0.00218	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45580892~45580996:-
STAD	cis	rs728616	0.558	rs7097080	ENSG00000225484.5	NUTM2B-AS1	-4.69	3.92e-06	0.00218	-0.38	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406944	chr10:79663088~79826594:-
STAD	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-4.69	3.92e-06	0.00218	-0.25	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
STAD	cis	rs13113518	1	rs4864546	ENSG00000223305.1	RN7SKP30	4.69	3.92e-06	0.00218	0.27	0.24	Height;	chr4:55537960	chr4:55540502~55540835:-
STAD	cis	rs1799949	1	rs12951869	ENSG00000236383.6	LINC00854	-4.69	3.93e-06	0.00218	-0.2	-0.24	Menopause (age at onset);	chr17:43035550	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11654452	ENSG00000236383.6	LINC00854	-4.69	3.93e-06	0.00218	-0.2	-0.24	Menopause (age at onset);	chr17:43037366	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs4793189	ENSG00000236383.6	LINC00854	-4.69	3.93e-06	0.00218	-0.2	-0.24	Menopause (age at onset);	chr17:43038698	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11657053	ENSG00000236383.6	LINC00854	-4.69	3.93e-06	0.00218	-0.2	-0.24	Menopause (age at onset);	chr17:43039112	chr17:43216941~43305976:-
STAD	cis	rs7824557	1	rs7824557	ENSG00000254866.2	DEFB109P3	4.69	3.93e-06	0.00218	0.31	0.24	Retinal vascular caliber;	chr8:11246602	chr8:12150895~12151134:-
STAD	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-4.69	3.93e-06	0.00218	-0.26	-0.24	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-4.69	3.93e-06	0.00218	-0.26	-0.24	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-4.69	3.93e-06	0.00218	-0.26	-0.24	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
STAD	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	4.69	3.93e-06	0.00218	0.24	0.24	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
STAD	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	4.69	3.93e-06	0.00218	0.26	0.24	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
STAD	cis	rs7665090	0.967	rs13106304	ENSG00000230069.3	LRRC37A15P	-4.69	3.94e-06	0.00219	-0.27	-0.24	Primary biliary cholangitis;	chr4:102633818	chr4:102727274~102730721:-
STAD	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	4.69	3.94e-06	0.00219	0.24	0.24	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
STAD	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-4.69	3.94e-06	0.00219	-0.26	-0.24	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
STAD	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-4.69	3.94e-06	0.00219	-0.37	-0.24	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
STAD	cis	rs8097348	0.779	rs2045113	ENSG00000266602.1	RP11-476K15.1	-4.69	3.94e-06	0.00219	-0.28	-0.24	Exercise (leisure time);	chr18:1652062	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.779	rs2045115	ENSG00000266602.1	RP11-476K15.1	-4.69	3.94e-06	0.00219	-0.28	-0.24	Exercise (leisure time);	chr18:1652067	chr18:1509183~1647097:+
STAD	cis	rs1799949	1	rs11659028	ENSG00000236383.6	LINC00854	-4.69	3.94e-06	0.00219	-0.2	-0.24	Menopause (age at onset);	chr17:43043008	chr17:43216941~43305976:-
STAD	cis	rs7924176	0.521	rs61863363	ENSG00000213731.2	RAB5CP1	-4.69	3.94e-06	0.00219	-0.25	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74423435~74424014:-
STAD	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	4.69	3.94e-06	0.00219	0.24	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
STAD	cis	rs13113518	1	rs11133381	ENSG00000223305.1	RN7SKP30	4.69	3.94e-06	0.00219	0.27	0.24	Height;	chr4:55450812	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs4864995	ENSG00000223305.1	RN7SKP30	4.69	3.94e-06	0.00219	0.27	0.24	Height;	chr4:55452853	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs12651640	ENSG00000223305.1	RN7SKP30	4.69	3.94e-06	0.00219	0.27	0.24	Height;	chr4:55454154	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs1554483	ENSG00000223305.1	RN7SKP30	4.69	3.94e-06	0.00219	0.27	0.24	Height;	chr4:55455650	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs1464490	ENSG00000223305.1	RN7SKP30	4.69	3.94e-06	0.00219	0.27	0.24	Height;	chr4:55456620	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs10517346	ENSG00000223305.1	RN7SKP30	4.69	3.94e-06	0.00219	0.27	0.24	Height;	chr4:55457027	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11133384	ENSG00000223305.1	RN7SKP30	4.69	3.94e-06	0.00219	0.27	0.24	Height;	chr4:55457086	chr4:55540502~55540835:-
STAD	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	4.69	3.94e-06	0.00219	0.29	0.24	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
STAD	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-4.69	3.94e-06	0.00219	-0.26	-0.24	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
STAD	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	4.69	3.94e-06	0.00219	0.29	0.24	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
STAD	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-4.69	3.95e-06	0.00219	-0.23	-0.24	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
STAD	cis	rs7429990	0.965	rs34380889	ENSG00000224895.1	VPS26BP1	-4.69	3.96e-06	0.0022	-0.24	-0.24	Educational attainment (years of education);	chr3:47905692	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs4858871	ENSG00000224895.1	VPS26BP1	-4.69	3.96e-06	0.0022	-0.24	-0.24	Educational attainment (years of education);	chr3:47911915	chr3:47960327~47961081:-
STAD	cis	rs13113518	0.812	rs12505880	ENSG00000223305.1	RN7SKP30	4.69	3.96e-06	0.0022	0.27	0.24	Height;	chr4:55440988	chr4:55540502~55540835:-
STAD	cis	rs2446066	0.872	rs2071558	ENSG00000257379.1	RP11-793H13.8	4.69	3.96e-06	0.0022	0.4	0.24	Red blood cell count;	chr12:53425683	chr12:53441741~53467528:+
STAD	cis	rs4604732	1	rs4604732	ENSG00000227135.1	GCSAML-AS1	4.69	3.96e-06	0.0022	0.31	0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460570	chr1:247524679~247526752:-
STAD	cis	rs11169552	0.51	rs10783383	ENSG00000200183.1	RNU6-238P	-4.69	3.97e-06	0.0022	-0.23	-0.24	Colorectal cancer;	chr12:50709086	chr12:50656973~50657078:+
STAD	cis	rs7786877	0.521	rs2293767	ENSG00000236305.1	RP11-126L15.4	-4.69	3.97e-06	0.0022	-0.26	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100764052	chr7:100837314~100852616:-
STAD	cis	rs875971	0.862	rs6460302	ENSG00000236529.1	RP13-254B10.1	4.69	3.97e-06	0.0022	0.25	0.24	Aortic root size;	chr7:66495270	chr7:65840212~65840596:+
STAD	cis	rs4691139	0.903	rs13127188	ENSG00000248632.1	RP11-366M4.11	4.69	3.97e-06	0.0022	0.24	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997524	chr4:164968587~164970002:-
STAD	cis	rs4691139	0.903	rs6835415	ENSG00000248632.1	RP11-366M4.11	4.69	3.97e-06	0.0022	0.24	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998932	chr4:164968587~164970002:-
STAD	cis	rs4691139	0.903	rs6812591	ENSG00000248632.1	RP11-366M4.11	4.69	3.97e-06	0.0022	0.24	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999023	chr4:164968587~164970002:-
STAD	cis	rs4691139	0.903	rs6812776	ENSG00000248632.1	RP11-366M4.11	4.69	3.97e-06	0.0022	0.24	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999097	chr4:164968587~164970002:-
STAD	cis	rs4589258	1	rs2213088	ENSG00000280367.1	RP11-121L10.2	4.69	3.97e-06	0.0022	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90747349	chr11:90223153~90226538:+
STAD	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-4.69	3.97e-06	0.0022	-0.26	-0.24	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
STAD	cis	rs1707322	0.721	rs6699418	ENSG00000281133.1	AL355480.3	-4.69	3.97e-06	0.0022	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs4431884	ENSG00000281133.1	AL355480.3	-4.69	3.97e-06	0.0022	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.65	rs4660879	ENSG00000281133.1	AL355480.3	-4.69	3.97e-06	0.0022	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45580892~45580996:-
STAD	cis	rs801193	0.569	rs2707824	ENSG00000224316.1	RP11-479O9.2	4.69	3.97e-06	0.0022	0.24	0.24	Aortic root size;	chr7:66724256	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs2659893	ENSG00000224316.1	RP11-479O9.2	4.69	3.97e-06	0.0022	0.24	0.24	Aortic root size;	chr7:66735006	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs2659892	ENSG00000224316.1	RP11-479O9.2	4.69	3.97e-06	0.0022	0.24	0.24	Aortic root size;	chr7:66735318	chr7:65773620~65802067:+
STAD	cis	rs801193	0.548	rs2659891	ENSG00000224316.1	RP11-479O9.2	4.69	3.97e-06	0.0022	0.24	0.24	Aortic root size;	chr7:66736127	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs2707847	ENSG00000224316.1	RP11-479O9.2	4.69	3.97e-06	0.0022	0.24	0.24	Aortic root size;	chr7:66737884	chr7:65773620~65802067:+
STAD	cis	rs801193	0.548	rs7805152	ENSG00000224316.1	RP11-479O9.2	4.69	3.97e-06	0.0022	0.24	0.24	Aortic root size;	chr7:66744266	chr7:65773620~65802067:+
STAD	cis	rs6539288	0.63	rs3759316	ENSG00000260329.1	RP11-412D9.4	-4.69	3.98e-06	0.00221	-0.25	-0.24	Total body bone mineral density;	chr12:106976432	chr12:106954029~106955497:-
STAD	cis	rs12906542	0.516	rs4886989	ENSG00000259792.1	RP11-114H24.6	-4.69	3.98e-06	0.00221	-0.44	-0.24	Breast cancer;	chr15:78011406	chr15:77993405~77995289:+
STAD	cis	rs227275	0.525	rs4699037	ENSG00000248971.2	KRT8P46	-4.69	3.99e-06	0.00221	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs3857198	ENSG00000248971.2	KRT8P46	-4.69	3.99e-06	0.00221	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102728746~102730171:-
STAD	cis	rs1723838	1	rs1723846	ENSG00000255928.1	RP11-456I15.2	4.69	3.99e-06	0.00221	0.53	0.24	Obesity-related traits;	chr11:73788869	chr11:73722349~73722694:+
STAD	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	4.69	3.99e-06	0.00221	0.26	0.24	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
STAD	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	4.69	3.99e-06	0.00221	0.26	0.24	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
STAD	cis	rs1150668	0.796	rs9468372	ENSG00000220721.1	OR1F12	4.69	3.99e-06	0.00221	0.24	0.24	Pubertal anthropometrics;	chr6:28411584	chr6:28073316~28074233:+
STAD	cis	rs875971	1	rs6961717	ENSG00000236529.1	RP13-254B10.1	-4.69	3.99e-06	0.00221	-0.26	-0.24	Aortic root size;	chr7:66122550	chr7:65840212~65840596:+
STAD	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-4.69	3.99e-06	0.00221	-0.37	-0.24	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
STAD	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-4.69	4e-06	0.00221	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
STAD	cis	rs17301013	0.861	rs2038025	ENSG00000227373.4	RP11-160H22.5	4.69	4e-06	0.00221	0.3	0.24	Systemic lupus erythematosus;	chr1:174574712	chr1:174115300~174160004:-
STAD	cis	rs748404	0.66	rs2602141	ENSG00000275601.1	AC011330.13	-4.69	4e-06	0.00222	-0.26	-0.24	Lung cancer;	chr15:43432448	chr15:43642389~43643023:-
STAD	cis	rs7829975	0.711	rs4841051	ENSG00000253981.4	ALG1L13P	-4.69	4e-06	0.00222	-0.29	-0.24	Mood instability;	chr8:8828136	chr8:8236003~8244667:-
STAD	cis	rs17630293	0.579	rs296789	ENSG00000201649.1	RNY4P34	4.69	4e-06	0.00222	0.35	0.24	Schizophrenia;	chr2:200367999	chr2:200373175~200373269:+
STAD	cis	rs2273156	1	rs7141293	ENSG00000241052.1	RP11-173D9.1	-4.69	4e-06	0.00222	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34993704	chr14:35144021~35144480:-
STAD	cis	rs1426063	0.614	rs17000264	ENSG00000249717.1	RP11-44F21.3	4.69	4e-06	0.00222	0.51	0.24	QT interval;	chr4:75108962	chr4:74955974~74970362:-
STAD	cis	rs8177876	0.822	rs12443549	ENSG00000261061.1	RP11-303E16.2	4.69	4e-06	0.00222	0.42	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81030770~81031485:+
STAD	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	4.69	4e-06	0.00222	0.19	0.24	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
STAD	cis	rs916888	0.773	rs169201	ENSG00000232300.1	FAM215B	4.69	4e-06	0.00222	0.32	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46558830~46562795:-
STAD	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	4.69	4e-06	0.00222	0.25	0.24	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
STAD	cis	rs8097348	0.817	rs9303881	ENSG00000266602.1	RP11-476K15.1	-4.69	4.01e-06	0.00222	-0.28	-0.24	Exercise (leisure time);	chr18:1660071	chr18:1509183~1647097:+
STAD	cis	rs858239	0.699	rs955187	ENSG00000230042.1	AK3P3	4.69	4.01e-06	0.00222	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23129178~23129841:+
STAD	cis	rs748404	0.69	rs2924369	ENSG00000275601.1	AC011330.13	4.69	4.01e-06	0.00222	0.26	0.24	Lung cancer;	chr15:43485787	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs2444251	ENSG00000275601.1	AC011330.13	-4.69	4.01e-06	0.00222	-0.26	-0.24	Lung cancer;	chr15:43496397	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs548704	ENSG00000275601.1	AC011330.13	-4.69	4.01e-06	0.00222	-0.26	-0.24	Lung cancer;	chr15:43499508	chr15:43642389~43643023:-
STAD	cis	rs891378	0.958	rs10746462	ENSG00000274245.1	RP11-357P18.2	-4.69	4.01e-06	0.00222	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207337203	chr1:207372559~207373252:+
STAD	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-4.69	4.01e-06	0.00222	-0.25	-0.24	Height;	chr5:36995103	chr5:36666214~36725195:-
STAD	cis	rs4691139	0.566	rs60664011	ENSG00000248632.1	RP11-366M4.11	4.69	4.01e-06	0.00222	0.24	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165000370	chr4:164968587~164970002:-
STAD	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.01e-06	0.00222	-0.28	-0.24	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
STAD	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-4.69	4.01e-06	0.00222	-0.3	-0.24	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
STAD	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-4.69	4.02e-06	0.00222	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-4.69	4.02e-06	0.00222	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-4.69	4.02e-06	0.00222	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-4.69	4.02e-06	0.00222	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-4.69	4.02e-06	0.00222	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
STAD	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	4.69	4.02e-06	0.00222	0.29	0.24	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
STAD	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-4.69	4.02e-06	0.00222	-0.26	-0.24	Height;	chr2:231490121	chr2:231508426~231514339:-
STAD	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-4.69	4.02e-06	0.00222	-0.26	-0.24	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
STAD	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	4.69	4.02e-06	0.00222	0.26	0.24	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	4.69	4.02e-06	0.00222	0.26	0.24	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	4.69	4.02e-06	0.00222	0.26	0.24	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	4.69	4.02e-06	0.00222	0.26	0.24	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
STAD	cis	rs748404	0.697	rs491804	ENSG00000275601.1	AC011330.13	-4.69	4.02e-06	0.00222	-0.26	-0.24	Lung cancer;	chr15:43268627	chr15:43642389~43643023:-
STAD	cis	rs227275	0.554	rs223382	ENSG00000248971.2	KRT8P46	-4.69	4.02e-06	0.00222	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102728746~102730171:-
STAD	cis	rs1488193	0.51	rs4682447	ENSG00000240057.4	RP11-572M11.4	-4.69	4.02e-06	0.00222	-0.36	-0.24	Economic and political preferences;	chr3:112944090	chr3:113019532~113183301:+
STAD	cis	rs9907295	0.901	rs9909416	ENSG00000270894.1	AC015849.13	-4.69	4.02e-06	0.00222	-0.24	-0.24	Fibroblast growth factor basic levels;	chr17:35870979	chr17:35818399~35823713:+
STAD	cis	rs7176527	0.848	rs3748374	ENSG00000188388.10	GOLGA6L3	4.69	4.02e-06	0.00222	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85240472~85247170:+
STAD	cis	rs2836950	0.501	rs2836980	ENSG00000238141.2	BRWD1-AS1	-4.69	4.02e-06	0.00223	-0.25	-0.24	Menarche (age at onset);	chr21:39315692	chr21:39315707~39323218:+
STAD	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	4.69	4.03e-06	0.00223	0.27	0.24	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
STAD	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-4.68	4.03e-06	0.00223	-0.42	-0.24	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
STAD	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-4.68	4.03e-06	0.00223	-0.29	-0.24	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
STAD	cis	rs7829975	0.626	rs332040	ENSG00000173295.6	FAM86B3P	4.68	4.03e-06	0.00223	0.28	0.24	Mood instability;	chr8:8872978	chr8:8228595~8244865:+
STAD	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-4.68	4.03e-06	0.00223	-0.37	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
STAD	cis	rs7487075	0.619	rs4427617	ENSG00000257261.4	RP11-96H19.1	4.68	4.03e-06	0.00223	0.33	0.24	Itch intensity from mosquito bite;	chr12:46400719	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs2131371	ENSG00000257261.4	RP11-96H19.1	4.68	4.03e-06	0.00223	0.33	0.24	Itch intensity from mosquito bite;	chr12:46402739	chr12:46383679~46876159:+
STAD	cis	rs9733	0.65	rs2048558	ENSG00000274963.1	Metazoa_SRP	-4.68	4.03e-06	0.00223	-0.2	-0.24	Tonsillectomy;	chr1:150599254	chr1:150568971~150569269:-
STAD	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	4.68	4.04e-06	0.00223	0.31	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
STAD	cis	rs853679	0.76	rs967005	ENSG00000220721.1	OR1F12	4.68	4.04e-06	0.00224	0.29	0.24	Depression;	chr6:28242910	chr6:28073316~28074233:+
STAD	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-4.68	4.04e-06	0.00224	-0.25	-0.24	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
STAD	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	4.68	4.04e-06	0.00224	0.3	0.24	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
STAD	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	4.68	4.04e-06	0.00224	0.37	0.24	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
STAD	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	4.68	4.04e-06	0.00224	0.31	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
STAD	cis	rs801193	0.569	rs2659908	ENSG00000224316.1	RP11-479O9.2	4.68	4.05e-06	0.00224	0.24	0.24	Aortic root size;	chr7:66695835	chr7:65773620~65802067:+
STAD	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-4.68	4.05e-06	0.00224	-0.38	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
STAD	cis	rs2337406	0.866	rs8015361	ENSG00000211972.2	IGHV3-66	4.68	4.05e-06	0.00224	0.25	0.24	Alzheimer's disease (late onset);	chr14:106783991	chr14:106675017~106675544:-
STAD	cis	rs7119038	0.686	rs55894437	ENSG00000255422.1	AP002954.4	4.68	4.05e-06	0.00224	0.32	0.24	Sjögren's syndrome;	chr11:118736708	chr11:118704607~118750263:+
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000224373.3	IGHV4-59	4.68	4.05e-06	0.00224	0.17	0.24	Kawasaki disease;	chr14:106804049	chr14:106627249~106627825:-
STAD	cis	rs7429990	0.965	rs9814961	ENSG00000224895.1	VPS26BP1	-4.68	4.05e-06	0.00224	-0.24	-0.24	Educational attainment (years of education);	chr3:47976127	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs6770467	ENSG00000224895.1	VPS26BP1	4.68	4.05e-06	0.00224	0.24	0.24	Educational attainment (years of education);	chr3:47977742	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs6770477	ENSG00000224895.1	VPS26BP1	4.68	4.05e-06	0.00224	0.24	0.24	Educational attainment (years of education);	chr3:47977768	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs28637561	ENSG00000224895.1	VPS26BP1	4.68	4.05e-06	0.00224	0.24	0.24	Educational attainment (years of education);	chr3:47979528	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs7427418	ENSG00000224895.1	VPS26BP1	4.68	4.05e-06	0.00224	0.24	0.24	Educational attainment (years of education);	chr3:47981217	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs13075795	ENSG00000224895.1	VPS26BP1	4.68	4.05e-06	0.00224	0.24	0.24	Educational attainment (years of education);	chr3:47983139	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs7431572	ENSG00000224895.1	VPS26BP1	4.68	4.05e-06	0.00224	0.24	0.24	Educational attainment (years of education);	chr3:47986361	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs13074973	ENSG00000224895.1	VPS26BP1	4.68	4.05e-06	0.00224	0.24	0.24	Educational attainment (years of education);	chr3:47986654	chr3:47960327~47961081:-
STAD	cis	rs875971	1	rs6460296	ENSG00000236529.1	RP13-254B10.1	4.68	4.06e-06	0.00224	0.26	0.24	Aortic root size;	chr7:66430152	chr7:65840212~65840596:+
STAD	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	4.68	4.06e-06	0.00224	0.27	0.24	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
STAD	cis	rs11204677	1	rs11204677	ENSG00000274963.1	Metazoa_SRP	-4.68	4.06e-06	0.00224	-0.2	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:150602219	chr1:150568971~150569269:-
STAD	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-4.68	4.06e-06	0.00225	-0.27	-0.24	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
STAD	cis	rs4912314	0.693	rs6688564	ENSG00000236776.1	RPL21P23	-4.68	4.06e-06	0.00225	-0.31	-0.24	Waist-to-hip ratio adjusted for body mass index;	chr1:56450416	chr1:56538452~56538911:+
STAD	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-4.68	4.06e-06	0.00225	-0.28	-0.24	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
STAD	cis	rs7924176	0.521	rs10762599	ENSG00000213731.2	RAB5CP1	-4.68	4.07e-06	0.00225	-0.25	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74423435~74424014:-
STAD	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-4.68	4.07e-06	0.00225	-0.28	-0.24	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
STAD	cis	rs11098499	0.863	rs9997631	ENSG00000260091.1	RP11-33B1.4	4.68	4.07e-06	0.00225	0.24	0.24	Corneal astigmatism;	chr4:119548840	chr4:119409333~119410233:+
STAD	cis	rs4243830	0.522	rs11122086	ENSG00000229519.2	RP11-58A11.2	4.68	4.07e-06	0.00225	0.26	0.24	Body mass index;	chr1:6541186	chr1:6547905~6548619:+
STAD	cis	rs228614	0.51	rs223470	ENSG00000248971.2	KRT8P46	-4.68	4.08e-06	0.00225	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223468	ENSG00000248971.2	KRT8P46	-4.68	4.08e-06	0.00225	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102728746~102730171:-
STAD	cis	rs11846409	0.932	rs28617526	ENSG00000211972.2	IGHV3-66	4.68	4.08e-06	0.00225	0.25	0.24	Rheumatic heart disease;	chr14:106637322	chr14:106675017~106675544:-
STAD	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	4.68	4.08e-06	0.00225	0.35	0.24	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
STAD	cis	rs228614	0.51	rs223465	ENSG00000248971.2	KRT8P46	-4.68	4.08e-06	0.00225	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223464	ENSG00000248971.2	KRT8P46	-4.68	4.08e-06	0.00225	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102728746~102730171:-
STAD	cis	rs7487075	0.786	rs12298619	ENSG00000257261.4	RP11-96H19.1	4.68	4.08e-06	0.00225	0.31	0.24	Itch intensity from mosquito bite;	chr12:46279718	chr12:46383679~46876159:+
STAD	cis	rs611744	0.647	rs2298603	ENSG00000253754.1	RP11-35G22.1	-4.68	4.08e-06	0.00225	-0.21	-0.24	Dupuytren's disease;	chr8:108259197	chr8:108226200~108227544:+
STAD	cis	rs7208859	0.524	rs73988172	ENSG00000263603.1	CTD-2349P21.5	-4.68	4.08e-06	0.00225	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30729469~30731202:+
STAD	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-4.68	4.08e-06	0.00226	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
STAD	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-4.68	4.08e-06	0.00226	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
STAD	cis	rs1150668	0.796	rs728122	ENSG00000220721.1	OR1F12	4.68	4.08e-06	0.00226	0.24	0.24	Pubertal anthropometrics;	chr6:28431347	chr6:28073316~28074233:+
STAD	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-4.68	4.08e-06	0.00226	-0.26	-0.24	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
STAD	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-4.68	4.08e-06	0.00226	-0.39	-0.24	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
STAD	cis	rs4691139	0.619	rs2139218	ENSG00000248632.1	RP11-366M4.11	4.68	4.09e-06	0.00226	0.24	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001275	chr4:164968587~164970002:-
STAD	cis	rs4691139	0.595	rs10000199	ENSG00000248632.1	RP11-366M4.11	4.68	4.09e-06	0.00226	0.24	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001813	chr4:164968587~164970002:-
STAD	cis	rs6832769	1	rs3805157	ENSG00000272969.1	RP11-528I4.2	4.68	4.09e-06	0.00226	0.31	0.24	Personality dimensions;	chr4:55497936	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs2177129	ENSG00000272969.1	RP11-528I4.2	4.68	4.09e-06	0.00226	0.31	0.24	Personality dimensions;	chr4:55499247	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.89	rs1980273	ENSG00000272969.1	RP11-528I4.2	4.68	4.09e-06	0.00226	0.31	0.24	Personality dimensions;	chr4:55501234	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs6819660	ENSG00000272969.1	RP11-528I4.2	4.68	4.09e-06	0.00226	0.31	0.24	Personality dimensions;	chr4:55508410	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs28582059	ENSG00000272969.1	RP11-528I4.2	-4.68	4.09e-06	0.00226	-0.31	-0.24	Personality dimensions;	chr4:55542237	chr4:55547112~55547889:+
STAD	cis	rs7119038	0.774	rs73005426	ENSG00000255422.1	AP002954.4	4.68	4.09e-06	0.00226	0.31	0.24	Sjögren's syndrome;	chr11:118810374	chr11:118704607~118750263:+
STAD	cis	rs748404	0.69	rs1079309	ENSG00000275601.1	AC011330.13	-4.68	4.09e-06	0.00226	-0.26	-0.24	Lung cancer;	chr15:43490966	chr15:43642389~43643023:-
STAD	cis	rs858239	0.899	rs1881203	ENSG00000226816.2	AC005082.12	4.68	4.09e-06	0.00226	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23206013~23208045:+
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000224373.3	IGHV4-59	4.68	4.09e-06	0.00226	0.17	0.24	Kawasaki disease;	chr14:106808609	chr14:106627249~106627825:-
STAD	cis	rs227275	0.525	rs4699039	ENSG00000248971.2	KRT8P46	-4.68	4.09e-06	0.00226	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102728746~102730171:-
STAD	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	4.68	4.1e-06	0.00226	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
STAD	cis	rs8067354	0.574	rs2526354	ENSG00000266701.1	AC005702.4	4.68	4.1e-06	0.00226	0.35	0.24	Hemoglobin concentration;	chr17:59899297	chr17:60042546~60042627:-
STAD	cis	rs721917	0.506	rs2758539	ENSG00000244733.5	RP11-506M13.3	-4.68	4.1e-06	0.00226	-0.3	-0.24	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79660891~79677996:+
STAD	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	4.68	4.1e-06	0.00226	0.33	0.24	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
STAD	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	4.68	4.1e-06	0.00226	0.38	0.24	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
STAD	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-4.68	4.1e-06	0.00226	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-4.68	4.1e-06	0.00226	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
STAD	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-4.68	4.1e-06	0.00226	-0.26	-0.24	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-4.68	4.1e-06	0.00226	-0.26	-0.24	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-4.68	4.1e-06	0.00226	-0.26	-0.24	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
STAD	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	4.68	4.1e-06	0.00226	0.3	0.24	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	4.68	4.1e-06	0.00226	0.3	0.24	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	4.68	4.1e-06	0.00226	0.3	0.24	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	4.68	4.1e-06	0.00226	0.3	0.24	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
STAD	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-4.68	4.1e-06	0.00226	-0.32	-0.24	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
STAD	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	4.68	4.1e-06	0.00226	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
STAD	cis	rs2933343	0.7	rs789233	ENSG00000261159.1	RP11-723O4.9	4.68	4.1e-06	0.00226	0.3	0.24	IgG glycosylation;	chr3:128884307	chr3:128859716~128860526:-
STAD	cis	rs227275	0.556	rs6821173	ENSG00000248971.2	KRT8P46	-4.68	4.11e-06	0.00227	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223334	ENSG00000248971.2	KRT8P46	4.68	4.11e-06	0.00227	0.25	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102728746~102730171:-
STAD	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-4.68	4.11e-06	0.00227	-0.3	-0.24	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
STAD	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-4.68	4.11e-06	0.00227	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
STAD	cis	rs9425766	0.566	rs4442420	ENSG00000227373.4	RP11-160H22.5	4.68	4.11e-06	0.00227	0.3	0.24	Life satisfaction;	chr1:174199667	chr1:174115300~174160004:-
STAD	cis	rs35934224	0.843	rs34175429	ENSG00000232926.1	AC000078.5	4.68	4.11e-06	0.00227	0.32	0.24	Glaucoma (primary open-angle);	chr22:19879753	chr22:19887289~19887970:+
STAD	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-4.68	4.11e-06	0.00227	-0.27	-0.24	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
STAD	cis	rs6095360	0.727	rs1983528	ENSG00000222365.1	SNORD12B	4.68	4.11e-06	0.00227	0.31	0.24	Intelligence (multi-trait analysis);	chr20:49069753	chr20:49280319~49280409:+
STAD	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
STAD	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	4.68	4.11e-06	0.00227	0.3	0.24	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
STAD	cis	rs1799949	1	rs8176289	ENSG00000236383.6	LINC00854	-4.68	4.11e-06	0.00227	-0.2	-0.24	Menopause (age at onset);	chr17:43054039	chr17:43216941~43305976:-
STAD	cis	rs7220401	0.789	rs3760456	ENSG00000240074.1	RPL9P30	-4.68	4.11e-06	0.00227	-0.21	-0.24	Coronary artery disease;	chr17:29621826	chr17:29855759~29856332:+
STAD	cis	rs8012947	0.527	rs1190981	ENSG00000279636.2	LINC00216	-4.68	4.11e-06	0.00227	-0.23	-0.24	Alcohol consumption in current drinkers;	chr14:58348357	chr14:58288033~58289158:+
STAD	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	4.68	4.12e-06	0.00227	0.35	0.24	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
STAD	cis	rs875971	0.862	rs778720	ENSG00000236529.1	RP13-254B10.1	-4.68	4.12e-06	0.00227	-0.25	-0.24	Aortic root size;	chr7:66381288	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10276077	ENSG00000236529.1	RP13-254B10.1	-4.68	4.12e-06	0.00227	-0.25	-0.24	Aortic root size;	chr7:66263424	chr7:65840212~65840596:+
STAD	cis	rs858239	0.669	rs10950940	ENSG00000230042.1	AK3P3	4.68	4.12e-06	0.00227	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23129178~23129841:+
STAD	cis	rs2688482	0.557	rs3103952	ENSG00000185485.13	SDHAP1	4.68	4.12e-06	0.00227	0.32	0.24	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195959748~195990318:-
STAD	cis	rs13113518	1	rs13116194	ENSG00000223305.1	RN7SKP30	4.68	4.12e-06	0.00227	0.27	0.24	Height;	chr4:55531150	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs13117836	ENSG00000223305.1	RN7SKP30	4.68	4.12e-06	0.00227	0.27	0.24	Height;	chr4:55531218	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs7668429	ENSG00000223305.1	RN7SKP30	4.68	4.12e-06	0.00227	0.27	0.24	Height;	chr4:55531811	chr4:55540502~55540835:-
STAD	cis	rs12468226	0.938	rs10931993	ENSG00000226261.1	AC064836.3	4.68	4.13e-06	0.00228	0.39	0.24	Urate levels;	chr2:202243017	chr2:202336024~202336727:-
STAD	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	4.68	4.13e-06	0.00228	0.27	0.24	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
STAD	cis	rs4243830	0.737	rs11122091	ENSG00000229519.2	RP11-58A11.2	4.68	4.13e-06	0.00228	0.26	0.24	Body mass index;	chr1:6549499	chr1:6547905~6548619:+
STAD	cis	rs748404	0.66	rs2467738	ENSG00000275601.1	AC011330.13	-4.68	4.13e-06	0.00228	-0.26	-0.24	Lung cancer;	chr15:43447738	chr15:43642389~43643023:-
STAD	cis	rs11121022	0.601	rs707455	ENSG00000269925.1	RP3-467L1.6	4.68	4.13e-06	0.00228	0.23	0.24	Morning vs. evening chronotype;	chr1:7765251	chr1:7776383~7776775:+
STAD	cis	rs8177876	0.686	rs804897	ENSG00000261838.4	RP11-303E16.6	-4.68	4.14e-06	0.00228	-0.53	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067590	chr16:81069854~81076598:+
STAD	cis	rs8028182	0.636	rs10152155	ENSG00000260269.4	CTD-2323K18.1	-4.68	4.14e-06	0.00228	-0.31	-0.24	Sudden cardiac arrest;	chr15:75409213	chr15:75527150~75601205:-
STAD	cis	rs763014	0.932	rs2384972	ENSG00000228201.1	AL022341.3	4.68	4.14e-06	0.00228	0.29	0.24	Height;	chr16:624424	chr16:648473~649200:-
STAD	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	4.68	4.14e-06	0.00228	0.3	0.24	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
STAD	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	4.68	4.15e-06	0.00228	0.27	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
STAD	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	4.68	4.15e-06	0.00228	0.28	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
STAD	cis	rs2836950	0.565	rs2150413	ENSG00000238141.2	BRWD1-AS1	-4.68	4.15e-06	0.00228	-0.25	-0.24	Menarche (age at onset);	chr21:39242952	chr21:39315707~39323218:+
STAD	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	4.68	4.15e-06	0.00229	0.26	0.24	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
STAD	cis	rs1426063	0.614	rs17000262	ENSG00000249717.1	RP11-44F21.3	4.68	4.15e-06	0.00229	0.47	0.24	QT interval;	chr4:75108836	chr4:74955974~74970362:-
STAD	cis	rs875971	1	rs3735148	ENSG00000236529.1	RP13-254B10.1	4.68	4.15e-06	0.00229	0.25	0.24	Aortic root size;	chr7:66506022	chr7:65840212~65840596:+
STAD	cis	rs4713118	0.869	rs9348775	ENSG00000280107.1	AL022393.9	-4.68	4.16e-06	0.00229	-0.33	-0.24	Parkinson's disease;	chr6:27727550	chr6:28170845~28172521:+
STAD	cis	rs3758911	0.861	rs2161965	ENSG00000261098.1	RP11-819C21.1	-4.68	4.16e-06	0.00229	-0.22	-0.24	Coronary artery disease;	chr11:107397123	chr11:107312132~107316271:-
STAD	cis	rs716804	0.837	rs1822293	ENSG00000254554.1	RP11-351I24.1	-4.68	4.16e-06	0.00229	-0.36	-0.24	Neuroticism;	chr11:10217427	chr11:10302657~10303704:-
STAD	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-4.68	4.16e-06	0.00229	-0.25	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
STAD	cis	rs4589258	1	rs4589258	ENSG00000280367.1	RP11-121L10.2	4.68	4.16e-06	0.00229	0.27	0.24	Intelligence (multi-trait analysis);	chr11:90738066	chr11:90223153~90226538:+
STAD	cis	rs2483058	0.739	rs3860302	ENSG00000261000.1	RP11-534L20.5	4.68	4.16e-06	0.00229	0.29	0.24	Cholesterol and Triglycerides;	chr1:206451299	chr1:206503948~206504456:+
STAD	cis	rs4713118	0.869	rs10214440	ENSG00000280107.1	AL022393.9	-4.68	4.16e-06	0.00229	-0.33	-0.24	Parkinson's disease;	chr6:27734661	chr6:28170845~28172521:+
STAD	cis	rs1426063	0.614	rs17000260	ENSG00000249717.1	RP11-44F21.3	4.68	4.17e-06	0.0023	0.51	0.24	QT interval;	chr4:75108576	chr4:74955974~74970362:-
STAD	cis	rs58873874	1	rs75720504	ENSG00000251405.2	CTB-109A12.1	4.68	4.17e-06	0.0023	0.42	0.24	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157362615~157460078:-
STAD	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-4.68	4.17e-06	0.0023	-0.34	-0.24	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
STAD	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	4.68	4.17e-06	0.0023	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	4.68	4.17e-06	0.0023	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
STAD	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	4.68	4.17e-06	0.0023	0.32	0.24	Depression;	chr6:28363475	chr6:28943877~28944537:+
STAD	cis	rs9733	0.65	rs11204680	ENSG00000274963.1	Metazoa_SRP	-4.68	4.17e-06	0.0023	-0.19	-0.24	Tonsillectomy;	chr1:150614664	chr1:150568971~150569269:-
STAD	cis	rs9307551	0.948	rs13109727	ENSG00000250334.4	LINC00989	-4.68	4.17e-06	0.0023	-0.31	-0.24	Refractive error;	chr4:79609563	chr4:79492416~79576460:+
STAD	cis	rs7474896	0.559	rs10740949	ENSG00000120555.12	SEPT7P9	4.68	4.17e-06	0.0023	0.28	0.24	Obesity (extreme);	chr10:37689507	chr10:38383069~38402916:-
STAD	cis	rs7429990	0.52	rs78838427	ENSG00000224895.1	VPS26BP1	4.68	4.17e-06	0.0023	0.23	0.24	Educational attainment (years of education);	chr3:47595561	chr3:47960327~47961081:-
STAD	cis	rs4589258	0.966	rs4631841	ENSG00000280367.1	RP11-121L10.2	4.68	4.17e-06	0.0023	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90723169	chr11:90223153~90226538:+
STAD	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-4.68	4.17e-06	0.0023	-0.37	-0.24	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
STAD	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-4.68	4.18e-06	0.0023	-0.3	-0.24	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
STAD	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	4.68	4.18e-06	0.0023	0.31	0.24	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	4.68	4.18e-06	0.0023	0.3	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
STAD	cis	rs11098499	0.78	rs7692994	ENSG00000260091.1	RP11-33B1.4	4.68	4.18e-06	0.0023	0.24	0.24	Corneal astigmatism;	chr4:119506334	chr4:119409333~119410233:+
STAD	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	4.68	4.18e-06	0.0023	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	4.68	4.18e-06	0.0023	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	4.68	4.18e-06	0.0023	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	4.68	4.18e-06	0.0023	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	4.68	4.18e-06	0.0023	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
STAD	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-4.68	4.18e-06	0.0023	-0.26	-0.24	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
STAD	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	4.68	4.18e-06	0.0023	0.23	0.24	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
STAD	cis	rs321358	0.731	rs516110	ENSG00000271584.1	RP11-89C3.4	4.68	4.18e-06	0.0023	0.31	0.24	Body mass index;	chr11:111166525	chr11:111091932~111097357:-
STAD	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-4.68	4.19e-06	0.0023	-0.32	-0.24	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
STAD	cis	rs9368481	0.546	rs12664610	ENSG00000241549.7	GUSBP2	4.68	4.19e-06	0.0023	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26871484~26956554:-
STAD	cis	rs4589258	0.788	rs4463819	ENSG00000280367.1	RP11-121L10.2	4.68	4.19e-06	0.00231	0.24	0.24	Intelligence (multi-trait analysis);	chr11:90729376	chr11:90223153~90226538:+
STAD	cis	rs2446066	0.52	rs34649330	ENSG00000257379.1	RP11-793H13.8	4.68	4.19e-06	0.00231	0.5	0.24	Red blood cell count;	chr12:53499247	chr12:53441741~53467528:+
STAD	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.2e-06	0.00231	-0.28	-0.24	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
STAD	cis	rs7680126	0.596	rs4698029	ENSG00000250613.1	RP11-136I13.1	-4.68	4.2e-06	0.00231	-0.26	-0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10311174	chr4:10410996~10411644:+
STAD	cis	rs9467773	0.804	rs2073526	ENSG00000243307.2	POM121L6P	-4.68	4.2e-06	0.00231	-0.23	-0.24	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26896952~26898777:+
STAD	cis	rs2503875	1	rs2460538	ENSG00000230555.2	RP11-517P14.2	4.68	4.2e-06	0.00231	0.25	0.24	Multiple sclerosis;	chr10:43317998	chr10:43420738~43422100:+
STAD	cis	rs944722	0.621	rs9904749	ENSG00000266786.1	LGALS9DP	4.68	4.2e-06	0.00231	0.3	0.24	Fractional exhaled nitric oxide (childhood);	chr17:27707236	chr17:27746132~27754954:+
STAD	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-4.68	4.2e-06	0.00231	-0.34	-0.24	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
STAD	cis	rs3733418	0.929	rs13134940	ENSG00000248632.1	RP11-366M4.11	4.68	4.2e-06	0.00231	0.3	0.24	Obesity-related traits;	chr4:164968460	chr4:164968587~164970002:-
STAD	cis	rs3733418	0.929	rs13110309	ENSG00000248632.1	RP11-366M4.11	4.68	4.2e-06	0.00231	0.3	0.24	Obesity-related traits;	chr4:164968520	chr4:164968587~164970002:-
STAD	cis	rs950881	0.799	rs72823669	ENSG00000234389.1	AC007278.3	4.68	4.2e-06	0.00231	0.33	0.24	Allergy;	chr2:102365573	chr2:102438713~102440475:+
STAD	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	4.68	4.21e-06	0.00231	0.38	0.24	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
STAD	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	4.68	4.21e-06	0.00231	0.27	0.24	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
STAD	cis	rs1799949	1	rs4793190	ENSG00000236383.6	LINC00854	-4.68	4.21e-06	0.00231	-0.2	-0.24	Menopause (age at onset);	chr17:43048092	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs8176297	ENSG00000236383.6	LINC00854	-4.68	4.21e-06	0.00231	-0.2	-0.24	Menopause (age at onset);	chr17:43051308	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs8176296	ENSG00000236383.6	LINC00854	-4.68	4.21e-06	0.00231	-0.2	-0.24	Menopause (age at onset);	chr17:43051574	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs4793191	ENSG00000236383.6	LINC00854	-4.68	4.21e-06	0.00231	-0.2	-0.24	Menopause (age at onset);	chr17:43052360	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs4793192	ENSG00000236383.6	LINC00854	-4.68	4.21e-06	0.00231	-0.2	-0.24	Menopause (age at onset);	chr17:43052373	chr17:43216941~43305976:-
STAD	cis	rs853679	0.699	rs9468318	ENSG00000220721.1	OR1F12	4.68	4.21e-06	0.00231	0.29	0.24	Depression;	chr6:28241753	chr6:28073316~28074233:+
STAD	cis	rs853679	0.76	rs9357067	ENSG00000220721.1	OR1F12	4.68	4.21e-06	0.00231	0.29	0.24	Depression;	chr6:28242515	chr6:28073316~28074233:+
STAD	cis	rs7487075	0.554	rs7960819	ENSG00000272369.1	RP11-446N19.1	4.68	4.21e-06	0.00231	0.29	0.24	Itch intensity from mosquito bite;	chr12:46234999	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.554	rs7957777	ENSG00000272369.1	RP11-446N19.1	4.68	4.21e-06	0.00231	0.29	0.24	Itch intensity from mosquito bite;	chr12:46235006	chr12:46537502~46652550:+
STAD	cis	rs7487075	0.719	rs2279560	ENSG00000257261.4	RP11-96H19.1	4.68	4.21e-06	0.00231	0.33	0.24	Itch intensity from mosquito bite;	chr12:46267496	chr12:46383679~46876159:+
STAD	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-4.68	4.21e-06	0.00231	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
STAD	cis	rs747650	0.892	rs1976143	ENSG00000271350.1	CTD-2384B9.1	-4.68	4.21e-06	0.00232	-0.29	-0.24	Acne (severe);	chr11:47203983	chr11:47041027~47041945:-
STAD	cis	rs747650	0.892	rs1976142	ENSG00000271350.1	CTD-2384B9.1	-4.68	4.21e-06	0.00232	-0.29	-0.24	Acne (severe);	chr11:47204143	chr11:47041027~47041945:-
STAD	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	4.68	4.22e-06	0.00232	0.34	0.24	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
STAD	cis	rs2933343	0.7	rs2249514	ENSG00000261159.1	RP11-723O4.9	4.68	4.22e-06	0.00232	0.3	0.24	IgG glycosylation;	chr3:128924969	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.7	rs2630257	ENSG00000261159.1	RP11-723O4.9	4.68	4.22e-06	0.00232	0.3	0.24	IgG glycosylation;	chr3:128925172	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.729	rs1680785	ENSG00000261159.1	RP11-723O4.9	4.68	4.22e-06	0.00232	0.3	0.24	IgG glycosylation;	chr3:128925973	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.729	rs1680786	ENSG00000261159.1	RP11-723O4.9	4.68	4.22e-06	0.00232	0.3	0.24	IgG glycosylation;	chr3:128925997	chr3:128859716~128860526:-
STAD	cis	rs875971	0.545	rs316328	ENSG00000236529.1	RP13-254B10.1	-4.67	4.22e-06	0.00232	-0.28	-0.24	Aortic root size;	chr7:66143851	chr7:65840212~65840596:+
STAD	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-4.67	4.22e-06	0.00232	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
STAD	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-4.67	4.22e-06	0.00232	-0.3	-0.24	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
STAD	cis	rs10971721	1	rs10971721	ENSG00000260947.1	RP11-384P7.7	4.67	4.23e-06	0.00232	0.37	0.24	Body mass index;	chr9:33827696	chr9:33697459~33700986:+
STAD	cis	rs2933343	0.818	rs6764681	ENSG00000231305.3	RP11-723O4.2	-4.67	4.23e-06	0.00232	-0.28	-0.24	IgG glycosylation;	chr3:128849537	chr3:128861313~128871540:-
STAD	cis	rs4691139	0.658	rs4690798	ENSG00000248632.1	RP11-366M4.11	4.67	4.23e-06	0.00232	0.23	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005434	chr4:164968587~164970002:-
STAD	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-4.67	4.23e-06	0.00232	-0.34	-0.24	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
STAD	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-4.67	4.23e-06	0.00233	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
STAD	cis	rs7250849	0.688	rs78019331	ENSG00000273837.1	LLNLR-470E3.1	-4.67	4.24e-06	0.00233	-0.36	-0.24	Blood protein levels;	chr19:51658484	chr19:51639478~51639931:-
STAD	cis	rs1799949	1	rs8176318	ENSG00000279602.1	CTD-3014M21.1	4.67	4.24e-06	0.00233	0.3	0.24	Menopause (age at onset);	chr17:43045257	chr17:43360041~43361361:-
STAD	cis	rs7119038	0.818	rs11217040	ENSG00000255422.1	AP002954.4	4.67	4.24e-06	0.00233	0.32	0.24	Sjögren's syndrome;	chr11:118809939	chr11:118704607~118750263:+
STAD	cis	rs3733585	0.605	rs4697708	ENSG00000250613.1	RP11-136I13.1	4.67	4.24e-06	0.00233	0.24	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10119565	chr4:10410996~10411644:+
STAD	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	4.67	4.25e-06	0.00233	0.27	0.24	QT interval;	chr12:29310426	chr12:29280418~29317848:-
STAD	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-4.67	4.25e-06	0.00233	-0.24	-0.24	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
STAD	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-4.67	4.25e-06	0.00233	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
STAD	cis	rs11098499	0.954	rs6848389	ENSG00000260091.1	RP11-33B1.4	4.67	4.25e-06	0.00233	0.24	0.24	Corneal astigmatism;	chr4:119481467	chr4:119409333~119410233:+
STAD	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	4.67	4.25e-06	0.00233	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	4.67	4.25e-06	0.00233	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	4.67	4.25e-06	0.00233	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs28483572	ENSG00000226816.2	AC005082.12	4.67	4.25e-06	0.00233	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs6961406	ENSG00000226816.2	AC005082.12	4.67	4.25e-06	0.00233	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs6461690	ENSG00000226816.2	AC005082.12	4.67	4.25e-06	0.00233	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23206013~23208045:+
STAD	cis	rs858239	0.6	rs6967419	ENSG00000226816.2	AC005082.12	4.67	4.25e-06	0.00233	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23206013~23208045:+
STAD	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-4.67	4.25e-06	0.00233	-0.27	-0.24	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
STAD	cis	rs891378	1	rs7555030	ENSG00000274245.1	RP11-357P18.2	-4.67	4.25e-06	0.00234	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335385	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs7512422	ENSG00000274245.1	RP11-357P18.2	-4.67	4.25e-06	0.00234	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335605	chr1:207372559~207373252:+
STAD	cis	rs12571093	0.504	rs4443961	ENSG00000233590.1	RP11-153K11.3	4.67	4.26e-06	0.00234	0.35	0.24	Optic nerve measurement (disc area);	chr10:68285725	chr10:68233251~68242379:-
STAD	cis	rs11098499	0.954	rs2389803	ENSG00000260091.1	RP11-33B1.4	-4.67	4.26e-06	0.00234	-0.24	-0.24	Corneal astigmatism;	chr4:119472356	chr4:119409333~119410233:+
STAD	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	4.67	4.26e-06	0.00234	0.29	0.24	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
STAD	cis	rs3002131	0.522	rs2378583	ENSG00000225265.1	TAF1A-AS1	-4.67	4.26e-06	0.00234	-0.37	-0.24	Interleukin-10 levels;	chr1:222565958	chr1:222589825~222593032:+
STAD	cis	rs237743	1	rs67375757	ENSG00000222365.1	SNORD12B	-4.67	4.26e-06	0.00234	-0.33	-0.24	Height;	chr20:49299758	chr20:49280319~49280409:+
STAD	cis	rs3758911	0.861	rs11212114	ENSG00000261098.1	RP11-819C21.1	4.67	4.27e-06	0.00234	0.22	0.24	Coronary artery disease;	chr11:107274940	chr11:107312132~107316271:-
STAD	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-4.67	4.27e-06	0.00234	-0.32	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-4.67	4.27e-06	0.00234	-0.32	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-4.67	4.27e-06	0.00234	-0.32	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
STAD	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-4.67	4.27e-06	0.00234	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
STAD	cis	rs7429990	0.965	rs7430913	ENSG00000224895.1	VPS26BP1	4.67	4.27e-06	0.00234	0.24	0.24	Educational attainment (years of education);	chr3:47990867	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs7430879	ENSG00000224895.1	VPS26BP1	4.67	4.27e-06	0.00234	0.24	0.24	Educational attainment (years of education);	chr3:47997224	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs4293721	ENSG00000224895.1	VPS26BP1	4.67	4.27e-06	0.00234	0.24	0.24	Educational attainment (years of education);	chr3:48003647	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs5012971	ENSG00000224895.1	VPS26BP1	4.67	4.27e-06	0.00234	0.24	0.24	Educational attainment (years of education);	chr3:48033057	chr3:47960327~47961081:-
STAD	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	4.67	4.28e-06	0.00235	0.25	0.24	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	4.67	4.28e-06	0.00235	0.25	0.24	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	4.67	4.28e-06	0.00235	0.25	0.24	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
STAD	cis	rs2688608	0.592	rs13013	ENSG00000271816.1	BMS1P4	4.67	4.28e-06	0.00235	0.26	0.24	Inflammatory bowel disease;	chr10:73802403	chr10:73699151~73730487:-
STAD	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-4.67	4.28e-06	0.00235	-0.33	-0.24	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
STAD	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	4.67	4.28e-06	0.00235	0.25	0.24	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
STAD	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	4.67	4.29e-06	0.00235	0.29	0.24	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
STAD	cis	rs7665090	0.875	rs6813687	ENSG00000248971.2	KRT8P46	-4.67	4.29e-06	0.00235	-0.25	-0.24	Primary biliary cholangitis;	chr4:102634455	chr4:102728746~102730171:-
STAD	cis	rs2337406	0.538	rs2015470	ENSG00000211972.2	IGHV3-66	4.67	4.29e-06	0.00235	0.26	0.24	Alzheimer's disease (late onset);	chr14:106631885	chr14:106675017~106675544:-
STAD	cis	rs7015630	0.657	rs2338882	ENSG00000251136.7	RP11-37B2.1	-4.67	4.29e-06	0.00235	-0.33	-0.24	Inflammatory bowel disease;Crohn's disease;	chr8:89809970	chr8:89609409~89757727:-
STAD	cis	rs6095360	0.727	rs1556876	ENSG00000222365.1	SNORD12B	-4.67	4.29e-06	0.00235	-0.31	-0.24	Intelligence (multi-trait analysis);	chr20:49099914	chr20:49280319~49280409:+
STAD	cis	rs3806843	1	rs2098058	ENSG00000202111.1	VTRNA1-2	4.67	4.29e-06	0.00235	0.24	0.24	Depressive symptoms (multi-trait analysis);	chr5:140777842	chr5:140718925~140719013:+
STAD	cis	rs2337406	0.714	rs117798641	ENSG00000280411.1	IGHV1-69-2	-4.67	4.29e-06	0.00235	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106777984	chr14:106762092~106762588:-
STAD	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-4.67	4.29e-06	0.00235	-0.33	-0.24	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
STAD	cis	rs9307551	1	rs9307551	ENSG00000250334.4	LINC00989	-4.67	4.3e-06	0.00235	-0.31	-0.24	Refractive error;	chr4:79609517	chr4:79492416~79576460:+
STAD	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-4.67	4.3e-06	0.00235	-0.25	-0.24	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
STAD	cis	rs11169552	0.51	rs10506295	ENSG00000200183.1	RNU6-238P	-4.67	4.3e-06	0.00235	-0.23	-0.24	Colorectal cancer;	chr12:50691688	chr12:50656973~50657078:+
STAD	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	4.67	4.3e-06	0.00236	0.26	0.24	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
STAD	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	4.67	4.3e-06	0.00236	0.27	0.24	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
STAD	cis	rs875971	0.597	rs11763224	ENSG00000236529.1	RP13-254B10.1	4.67	4.3e-06	0.00236	0.29	0.24	Aortic root size;	chr7:66518628	chr7:65840212~65840596:+
STAD	cis	rs8177876	0.658	rs75422577	ENSG00000261838.4	RP11-303E16.6	4.67	4.3e-06	0.00236	0.51	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81069854~81076598:+
STAD	cis	rs227275	0.525	rs4623004	ENSG00000248971.2	KRT8P46	-4.67	4.3e-06	0.00236	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102728746~102730171:-
STAD	cis	rs6430585	0.528	rs16832440	ENSG00000231890.6	DARS-AS1	-4.67	4.31e-06	0.00236	-0.27	-0.24	Corneal structure;	chr2:135996613	chr2:135985176~136022593:+
STAD	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	4.67	4.31e-06	0.00236	0.31	0.24	Height;	chr6:109350188	chr6:109382795~109383666:+
STAD	cis	rs4691139	0.658	rs6839773	ENSG00000248632.1	RP11-366M4.11	4.67	4.31e-06	0.00236	0.23	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165004694	chr4:164968587~164970002:-
STAD	cis	rs4691139	0.658	rs4691141	ENSG00000248632.1	RP11-366M4.11	4.67	4.31e-06	0.00236	0.23	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005070	chr4:164968587~164970002:-
STAD	cis	rs875971	1	rs12533997	ENSG00000236529.1	RP13-254B10.1	4.67	4.31e-06	0.00236	0.25	0.24	Aortic root size;	chr7:66500390	chr7:65840212~65840596:+
STAD	cis	rs875971	0.929	rs10950041	ENSG00000236529.1	RP13-254B10.1	4.67	4.31e-06	0.00236	0.25	0.24	Aortic root size;	chr7:66508888	chr7:65840212~65840596:+
STAD	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	4.67	4.31e-06	0.00236	0.5	0.24	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	4.67	4.31e-06	0.00236	0.5	0.24	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	4.67	4.31e-06	0.00236	0.5	0.24	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	4.67	4.31e-06	0.00236	0.5	0.24	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	4.67	4.31e-06	0.00236	0.5	0.24	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
STAD	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-4.67	4.31e-06	0.00236	-0.27	-0.24	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
STAD	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	4.67	4.32e-06	0.00237	0.3	0.24	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	4.67	4.32e-06	0.00237	0.3	0.24	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	4.67	4.32e-06	0.00237	0.3	0.24	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
STAD	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-4.67	4.32e-06	0.00237	-0.36	-0.24	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
STAD	cis	rs227275	0.525	rs11737544	ENSG00000248971.2	KRT8P46	-4.67	4.32e-06	0.00237	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs7672319	ENSG00000248971.2	KRT8P46	-4.67	4.32e-06	0.00237	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs6533051	ENSG00000248971.2	KRT8P46	-4.67	4.32e-06	0.00237	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs6533052	ENSG00000248971.2	KRT8P46	-4.67	4.32e-06	0.00237	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs3974485	ENSG00000248971.2	KRT8P46	-4.67	4.32e-06	0.00237	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs7688940	ENSG00000248971.2	KRT8P46	-4.67	4.32e-06	0.00237	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102728746~102730171:-
STAD	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	4.67	4.32e-06	0.00237	0.33	0.24	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
STAD	cis	rs240993	0.812	rs4945881	ENSG00000230177.1	RP5-1112D6.4	4.67	4.33e-06	0.00237	0.25	0.24	Inflammatory skin disease;Psoriasis;	chr6:111470260	chr6:111277932~111278742:+
STAD	cis	rs1318937	0.764	rs2129947	ENSG00000224660.1	SH3BP5-AS1	4.67	4.33e-06	0.00237	0.25	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15180755	chr3:15254184~15264493:+
STAD	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-4.67	4.33e-06	0.00237	-0.19	-0.24	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
STAD	cis	rs6832769	0.922	rs28665088	ENSG00000272969.1	RP11-528I4.2	4.67	4.33e-06	0.00237	0.31	0.24	Personality dimensions;	chr4:55384913	chr4:55547112~55547889:+
STAD	cis	rs1707322	0.721	rs10789468	ENSG00000281133.1	AL355480.3	-4.67	4.33e-06	0.00237	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs6429574	ENSG00000281133.1	AL355480.3	-4.67	4.33e-06	0.00237	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45580892~45580996:-
STAD	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-4.67	4.33e-06	0.00237	-0.37	-0.24	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
STAD	cis	rs7932354	0.583	rs6485695	ENSG00000271350.1	CTD-2384B9.1	-4.67	4.33e-06	0.00237	-0.29	-0.24	Bone mineral density (hip);Bone mineral density;	chr11:46814615	chr11:47041027~47041945:-
STAD	cis	rs13113518	1	rs4864994	ENSG00000223305.1	RN7SKP30	4.67	4.33e-06	0.00237	0.27	0.24	Height;	chr4:55451955	chr4:55540502~55540835:-
STAD	cis	rs3770081	1	rs58672934	ENSG00000273080.1	RP11-301O19.1	-4.67	4.33e-06	0.00237	-0.56	-0.24	Facial emotion recognition (sad faces);	chr2:85936113	chr2:86195590~86196049:+
STAD	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-4.67	4.34e-06	0.00237	-0.28	-0.24	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-4.67	4.34e-06	0.00237	-0.28	-0.24	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
STAD	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	4.67	4.34e-06	0.00237	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
STAD	cis	rs9733	0.621	rs12746899	ENSG00000274963.1	Metazoa_SRP	-4.67	4.34e-06	0.00238	-0.2	-0.24	Tonsillectomy;	chr1:150607202	chr1:150568971~150569269:-
STAD	cis	rs4713118	0.955	rs9468200	ENSG00000280107.1	AL022393.9	-4.67	4.34e-06	0.00238	-0.33	-0.24	Parkinson's disease;	chr6:27715284	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.955	rs34752872	ENSG00000280107.1	AL022393.9	-4.67	4.34e-06	0.00238	-0.33	-0.24	Parkinson's disease;	chr6:27715465	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.911	rs2394000	ENSG00000280107.1	AL022393.9	-4.67	4.34e-06	0.00238	-0.33	-0.24	Parkinson's disease;	chr6:27719212	chr6:28170845~28172521:+
STAD	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	4.67	4.34e-06	0.00238	0.46	0.24	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
STAD	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	4.67	4.34e-06	0.00238	0.46	0.24	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
STAD	cis	rs2337406	0.866	rs79901786	ENSG00000211972.2	IGHV3-66	4.67	4.35e-06	0.00238	0.25	0.24	Alzheimer's disease (late onset);	chr14:106777623	chr14:106675017~106675544:-
STAD	cis	rs1426063	1	rs28515115	ENSG00000248165.1	RP11-44F21.2	4.67	4.35e-06	0.00238	0.41	0.24	QT interval;	chr4:75101904	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs10026801	ENSG00000248165.1	RP11-44F21.2	4.67	4.35e-06	0.00238	0.41	0.24	QT interval;	chr4:75103167	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs17000242	ENSG00000248165.1	RP11-44F21.2	4.67	4.35e-06	0.00238	0.41	0.24	QT interval;	chr4:75103857	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs7666371	ENSG00000248165.1	RP11-44F21.2	4.67	4.35e-06	0.00238	0.41	0.24	QT interval;	chr4:75104325	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs6829858	ENSG00000248165.1	RP11-44F21.2	4.67	4.35e-06	0.00238	0.41	0.24	QT interval;	chr4:75105202	chr4:74993877~75034824:-
STAD	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	4.67	4.35e-06	0.00238	0.38	0.24	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
STAD	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-4.67	4.35e-06	0.00238	-0.32	-0.24	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
STAD	cis	rs10504130	0.66	rs6473666	ENSG00000272024.1	RP11-546K22.3	-4.67	4.35e-06	0.00238	-0.31	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51950284~51950690:+
STAD	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	4.67	4.35e-06	0.00238	0.3	0.24	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
STAD	cis	rs237743	0.928	rs237714	ENSG00000222365.1	SNORD12B	-4.67	4.35e-06	0.00238	-0.32	-0.24	Height;	chr20:49306363	chr20:49280319~49280409:+
STAD	cis	rs2273156	0.929	rs7144646	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34985495	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs56686328	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34988864	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs7153068	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34990275	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12050390	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34991873	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12050402	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992610	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12050404	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992664	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12050447	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992759	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs74046408	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34997929	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs8017191	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000785	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs8018114	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000813	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12880809	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006450	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12880928	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006472	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs36112862	ENSG00000241052.1	RP11-173D9.1	-4.67	4.36e-06	0.00238	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:35009227	chr14:35144021~35144480:-
STAD	cis	rs891378	1	rs7545125	ENSG00000274245.1	RP11-357P18.2	-4.67	4.36e-06	0.00238	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251382	chr1:207372559~207373252:+
STAD	cis	rs7120173	0.778	rs548638	ENSG00000254851.1	RP11-109L13.1	-4.67	4.36e-06	0.00238	-0.37	-0.24	Visceral adipose tissue adjusted for BMI;	chr11:116866377	chr11:117135528~117138582:+
STAD	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	4.67	4.36e-06	0.00238	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
STAD	cis	rs7665090	0.528	rs3774968	ENSG00000248971.2	KRT8P46	-4.67	4.36e-06	0.00239	-0.26	-0.24	Primary biliary cholangitis;	chr4:102609955	chr4:102728746~102730171:-
STAD	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-4.67	4.37e-06	0.00239	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
STAD	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-4.67	4.37e-06	0.00239	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
STAD	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-4.67	4.37e-06	0.00239	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
STAD	cis	rs4132699	0.511	rs1571534	ENSG00000225460.1	RP13-93L13.1	4.67	4.37e-06	0.00239	0.26	0.24	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89502837	chr9:89472237~89472692:+
STAD	cis	rs9368481	0.524	rs9393768	ENSG00000241549.7	GUSBP2	4.67	4.37e-06	0.00239	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26871484~26956554:-
STAD	cis	rs62245779	1	rs62245779	ENSG00000236062.1	GSTM5P1	4.67	4.37e-06	0.00239	0.4	0.24	Chronic sinus infection;	chr3:11624009	chr3:12257801~12258460:-
STAD	cis	rs3770081	1	rs61477982	ENSG00000273080.1	RP11-301O19.1	-4.67	4.38e-06	0.00239	-0.55	-0.24	Facial emotion recognition (sad faces);	chr2:85933409	chr2:86195590~86196049:+
STAD	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-4.67	4.38e-06	0.00239	-0.32	-0.24	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
STAD	cis	rs6095360	0.7	rs4599176	ENSG00000222365.1	SNORD12B	-4.67	4.38e-06	0.00239	-0.31	-0.24	Intelligence (multi-trait analysis);	chr20:48903557	chr20:49280319~49280409:+
STAD	cis	rs10129255	0.5	rs1974468	ENSG00000211973.2	IGHV1-69	4.67	4.39e-06	0.0024	0.2	0.24	Kawasaki disease;	chr14:106686149	chr14:106714684~106715181:-
STAD	cis	rs1799949	1	rs8176269	ENSG00000236383.6	LINC00854	-4.67	4.39e-06	0.0024	-0.2	-0.24	Menopause (age at onset);	chr17:43061609	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs8176265	ENSG00000236383.6	LINC00854	-4.67	4.39e-06	0.0024	-0.2	-0.24	Menopause (age at onset);	chr17:43061979	chr17:43216941~43305976:-
STAD	cis	rs748404	0.666	rs12908460	ENSG00000249839.1	AC011330.5	-4.67	4.39e-06	0.0024	-0.42	-0.24	Lung cancer;	chr15:43413472	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs2230451	ENSG00000249839.1	AC011330.5	-4.67	4.39e-06	0.0024	-0.42	-0.24	Lung cancer;	chr15:43415610	chr15:43663654~43684339:-
STAD	cis	rs748404	0.666	rs62021180	ENSG00000249839.1	AC011330.5	-4.67	4.39e-06	0.0024	-0.42	-0.24	Lung cancer;	chr15:43420139	chr15:43663654~43684339:-
STAD	cis	rs357618	1	rs441652	ENSG00000260581.1	CTB-113P19.4	4.67	4.39e-06	0.0024	0.28	0.24	Basophil percentage of white cells;	chr5:151467944	chr5:151652275~151655449:+
STAD	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	4.67	4.39e-06	0.0024	0.3	0.24	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
STAD	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	4.67	4.39e-06	0.0024	0.32	0.24	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	4.67	4.4e-06	0.0024	0.32	0.24	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
STAD	cis	rs67311347	0.521	rs2887963	ENSG00000223797.4	ENTPD3-AS1	-4.67	4.4e-06	0.0024	-0.27	-0.24	Renal cell carcinoma;	chr3:40201975	chr3:40313802~40453329:-
STAD	cis	rs916888	0.61	rs199530	ENSG00000260075.1	NSFP1	-4.67	4.4e-06	0.0024	-0.32	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46372855~46487141:+
STAD	cis	rs9860428	0.787	rs12489734	ENSG00000240057.4	RP11-572M11.4	-4.67	4.4e-06	0.00241	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112847644	chr3:113019532~113183301:+
STAD	cis	rs4604732	0.642	rs10925048	ENSG00000227135.1	GCSAML-AS1	-4.67	4.41e-06	0.00241	-0.3	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247477434	chr1:247524679~247526752:-
STAD	cis	rs507080	0.922	rs7114458	ENSG00000278376.1	RP11-158I9.8	-4.67	4.41e-06	0.00241	-0.25	-0.24	Serum metabolite levels;	chr11:118695466	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs7114216	ENSG00000278376.1	RP11-158I9.8	-4.67	4.41e-06	0.00241	-0.25	-0.24	Serum metabolite levels;	chr11:118695525	chr11:118791254~118793137:+
STAD	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-4.67	4.41e-06	0.00241	-0.26	-0.24	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
STAD	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	4.67	4.41e-06	0.00241	0.28	0.24	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
STAD	cis	rs13113518	1	rs4864548	ENSG00000223305.1	RN7SKP30	-4.67	4.41e-06	0.00241	-0.27	-0.24	Height;	chr4:55547636	chr4:55540502~55540835:-
STAD	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-4.67	4.41e-06	0.00241	-0.36	-0.24	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
STAD	cis	rs4589258	1	rs10830564	ENSG00000280367.1	RP11-121L10.2	4.67	4.41e-06	0.00241	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90727446	chr11:90223153~90226538:+
STAD	cis	rs875971	0.545	rs75840613	ENSG00000236529.1	RP13-254B10.1	4.67	4.42e-06	0.00241	0.28	0.24	Aortic root size;	chr7:66376399	chr7:65840212~65840596:+
STAD	cis	rs9890032	0.57	rs8068504	ENSG00000266490.1	CTD-2349P21.9	4.67	4.42e-06	0.00241	0.2	0.24	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30792372~30792833:+
STAD	cis	rs875971	1	rs1565531	ENSG00000236529.1	RP13-254B10.1	-4.67	4.42e-06	0.00241	-0.26	-0.24	Aortic root size;	chr7:66198126	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.686	rs1250	ENSG00000281133.1	AL355480.3	-4.67	4.42e-06	0.00241	-0.3	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45580892~45580996:-
STAD	cis	rs7680126	0.596	rs4698009	ENSG00000250613.1	RP11-136I13.1	4.66	4.42e-06	0.00241	0.26	0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10283369	chr4:10410996~10411644:+
STAD	cis	rs7487075	0.786	rs7966288	ENSG00000257261.4	RP11-96H19.1	4.66	4.42e-06	0.00241	0.31	0.24	Itch intensity from mosquito bite;	chr12:46281187	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.786	rs7965629	ENSG00000257261.4	RP11-96H19.1	4.66	4.42e-06	0.00241	0.31	0.24	Itch intensity from mosquito bite;	chr12:46281283	chr12:46383679~46876159:+
STAD	cis	rs2857078	0.654	rs4793083	ENSG00000260793.2	RP5-882C2.2	4.66	4.42e-06	0.00242	0.26	0.24	Red cell distribution width;Reticulocyte count;	chr17:44235605	chr17:44221401~44223710:+
STAD	cis	rs3733585	0.753	rs12500805	ENSG00000250613.1	RP11-136I13.1	-4.66	4.43e-06	0.00242	-0.25	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10016355	chr4:10410996~10411644:+
STAD	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-4.66	4.43e-06	0.00242	-0.25	-0.24	Height;	chr5:37022673	chr5:36666214~36725195:-
STAD	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	4.66	4.43e-06	0.00242	0.29	0.24	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
STAD	cis	rs891378	0.959	rs12133548	ENSG00000274245.1	RP11-357P18.2	-4.66	4.43e-06	0.00242	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207333261	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs11120733	ENSG00000274245.1	RP11-357P18.2	-4.66	4.43e-06	0.00242	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207333304	chr1:207372559~207373252:+
STAD	cis	rs891378	0.959	rs1507759	ENSG00000274245.1	RP11-357P18.2	-4.66	4.43e-06	0.00242	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207334283	chr1:207372559~207373252:+
STAD	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	4.66	4.43e-06	0.00242	0.25	0.24	Height;	chr5:36887793	chr5:36666214~36725195:-
STAD	cis	rs1707322	0.691	rs61784799	ENSG00000225447.1	RPS15AP10	-4.66	4.43e-06	0.00242	-0.2	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45645816~45646197:-
STAD	cis	rs7396835	0.551	rs10750098	ENSG00000280143.1	AP000892.6	4.66	4.43e-06	0.00242	0.26	0.24	Quantitative traits;	chr11:116834852	chr11:117204967~117210292:+
STAD	cis	rs1707322	0.686	rs2991986	ENSG00000281133.1	AL355480.3	4.66	4.43e-06	0.00242	0.3	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45580892~45580996:-
STAD	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	4.66	4.44e-06	0.00242	0.3	0.24	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
STAD	cis	rs1707322	0.717	rs3014245	ENSG00000225447.1	RPS15AP10	-4.66	4.44e-06	0.00242	-0.2	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45645816~45646197:-
STAD	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-4.66	4.44e-06	0.00242	-0.3	-0.24	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
STAD	cis	rs516805	0.667	rs9490411	ENSG00000279453.1	RP3-425C14.4	4.66	4.44e-06	0.00242	0.37	0.24	Lymphocyte counts;	chr6:122217270	chr6:122436789~122439223:-
STAD	cis	rs7924176	0.521	rs11516630	ENSG00000213731.2	RAB5CP1	-4.66	4.44e-06	0.00242	-0.25	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74423435~74424014:-
STAD	cis	rs507080	0.922	rs533646	ENSG00000278376.1	RP11-158I9.8	-4.66	4.44e-06	0.00242	-0.25	-0.24	Serum metabolite levels;	chr11:118696037	chr11:118791254~118793137:+
STAD	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-4.66	4.45e-06	0.00243	-0.32	-0.24	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
STAD	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-4.66	4.45e-06	0.00243	-0.32	-0.24	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
STAD	cis	rs9860428	0.844	rs28782232	ENSG00000240057.4	RP11-572M11.4	-4.66	4.45e-06	0.00243	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112849314	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs6806976	ENSG00000240057.4	RP11-572M11.4	-4.66	4.45e-06	0.00243	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112852143	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs6765575	ENSG00000240057.4	RP11-572M11.4	-4.66	4.45e-06	0.00243	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112854322	chr3:113019532~113183301:+
STAD	cis	rs9902453	0.619	rs1038088	ENSG00000240074.1	RPL9P30	-4.66	4.45e-06	0.00243	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29747545	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.619	rs2617866	ENSG00000240074.1	RPL9P30	-4.66	4.45e-06	0.00243	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29749199	chr17:29855759~29856332:+
STAD	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	4.66	4.45e-06	0.00243	0.36	0.24	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
STAD	cis	rs237743	1	rs36016605	ENSG00000222365.1	SNORD12B	-4.66	4.46e-06	0.00243	-0.33	-0.24	Height;	chr20:49279608	chr20:49280319~49280409:+
STAD	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-4.66	4.46e-06	0.00243	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-4.66	4.46e-06	0.00243	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-4.66	4.46e-06	0.00243	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-4.66	4.46e-06	0.00243	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-4.66	4.46e-06	0.00243	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-4.66	4.46e-06	0.00243	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-4.66	4.46e-06	0.00243	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
STAD	cis	rs875971	1	rs6963646	ENSG00000236529.1	RP13-254B10.1	-4.66	4.46e-06	0.00243	-0.26	-0.24	Aortic root size;	chr7:66220780	chr7:65840212~65840596:+
STAD	cis	rs2688608	0.592	rs7908825	ENSG00000271816.1	BMS1P4	-4.66	4.46e-06	0.00243	-0.26	-0.24	Inflammatory bowel disease;	chr10:73794783	chr10:73699151~73730487:-
STAD	cis	rs4950322	0.542	rs17159914	ENSG00000278811.3	LINC00624	-4.66	4.47e-06	0.00243	-0.24	-0.24	Protein quantitative trait loci;	chr1:147183226	chr1:147258885~147517875:-
STAD	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-4.66	4.47e-06	0.00244	-0.3	-0.24	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
STAD	cis	rs7429990	0.965	rs2882668	ENSG00000224895.1	VPS26BP1	-4.66	4.47e-06	0.00244	-0.23	-0.24	Educational attainment (years of education);	chr3:47938816	chr3:47960327~47961081:-
STAD	cis	rs13113518	1	rs2279458	ENSG00000223305.1	RN7SKP30	4.66	4.47e-06	0.00244	0.28	0.24	Height;	chr4:55562653	chr4:55540502~55540835:-
STAD	cis	rs875971	0.862	rs778724	ENSG00000236529.1	RP13-254B10.1	4.66	4.47e-06	0.00244	0.25	0.24	Aortic root size;	chr7:66364304	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs778686	ENSG00000236529.1	RP13-254B10.1	4.66	4.47e-06	0.00244	0.25	0.24	Aortic root size;	chr7:66370923	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs778684	ENSG00000236529.1	RP13-254B10.1	4.66	4.47e-06	0.00244	0.25	0.24	Aortic root size;	chr7:66371416	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs778680	ENSG00000236529.1	RP13-254B10.1	4.66	4.47e-06	0.00244	0.25	0.24	Aortic root size;	chr7:66375427	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs11769079	ENSG00000236529.1	RP13-254B10.1	4.66	4.47e-06	0.00244	0.25	0.24	Aortic root size;	chr7:66377141	chr7:65840212~65840596:+
STAD	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	4.66	4.48e-06	0.00244	0.3	0.24	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
STAD	cis	rs9910055	0.53	rs2269906	ENSG00000260793.2	RP5-882C2.2	4.66	4.48e-06	0.00244	0.26	0.24	Total body bone mineral density;	chr17:44216969	chr17:44221401~44223710:+
STAD	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	4.66	4.48e-06	0.00244	0.3	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
STAD	cis	rs7665090	1	rs5026473	ENSG00000230069.3	LRRC37A15P	-4.66	4.48e-06	0.00244	-0.27	-0.24	Primary biliary cholangitis;	chr4:102633636	chr4:102727274~102730721:-
STAD	cis	rs11722779	0.935	rs3974481	ENSG00000248971.2	KRT8P46	-4.66	4.48e-06	0.00244	-0.25	-0.24	Schizophrenia;	chr4:102956834	chr4:102728746~102730171:-
STAD	cis	rs853679	0.517	rs1340004	ENSG00000220721.1	OR1F12	4.66	4.48e-06	0.00244	0.29	0.24	Depression;	chr6:28135913	chr6:28073316~28074233:+
STAD	cis	rs13113518	0.702	rs78829811	ENSG00000223305.1	RN7SKP30	4.66	4.49e-06	0.00245	0.28	0.24	Height;	chr4:55558258	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.702	rs75801206	ENSG00000223305.1	RN7SKP30	4.66	4.49e-06	0.00245	0.28	0.24	Height;	chr4:55558259	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.702	rs34658078	ENSG00000223305.1	RN7SKP30	4.66	4.49e-06	0.00245	0.28	0.24	Height;	chr4:55558261	chr4:55540502~55540835:-
STAD	cis	rs11169552	0.51	rs10876076	ENSG00000200183.1	RNU6-238P	-4.66	4.49e-06	0.00245	-0.24	-0.24	Colorectal cancer;	chr12:50655300	chr12:50656973~50657078:+
STAD	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	4.66	4.49e-06	0.00245	0.34	0.24	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
STAD	cis	rs7680126	0.596	rs917826	ENSG00000250613.1	RP11-136I13.1	4.66	4.49e-06	0.00245	0.26	0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10293971	chr4:10410996~10411644:+
STAD	cis	rs7487075	0.619	rs6582658	ENSG00000257261.4	RP11-96H19.1	4.66	4.49e-06	0.00245	0.3	0.24	Itch intensity from mosquito bite;	chr12:46462312	chr12:46383679~46876159:+
STAD	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	4.66	4.49e-06	0.00245	0.24	0.24	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
STAD	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	4.66	4.49e-06	0.00245	0.27	0.24	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
STAD	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	4.66	4.49e-06	0.00245	0.38	0.24	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
STAD	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-4.66	4.5e-06	0.00245	-0.25	-0.24	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
STAD	cis	rs6782228	1	rs6801509	ENSG00000277250.1	Metazoa_SRP	4.66	4.5e-06	0.00245	0.31	0.24	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128673681~128674021:-
STAD	cis	rs1056107	0.731	rs7047547	ENSG00000225513.1	RP11-165N19.2	-4.66	4.5e-06	0.00245	-0.28	-0.24	Colorectal cancer;	chr9:112173568	chr9:112173522~112173971:-
STAD	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	4.66	4.51e-06	0.00245	0.3	0.24	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	4.66	4.51e-06	0.00245	0.3	0.24	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	4.66	4.51e-06	0.00245	0.3	0.24	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
STAD	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-4.66	4.51e-06	0.00245	-0.35	-0.24	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
STAD	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-4.66	4.51e-06	0.00245	-0.35	-0.24	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
STAD	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-4.66	4.51e-06	0.00245	-0.26	-0.24	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
STAD	cis	rs11098499	0.954	rs12505469	ENSG00000260091.1	RP11-33B1.4	4.66	4.51e-06	0.00245	0.24	0.24	Corneal astigmatism;	chr4:119328430	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.908	rs2017057	ENSG00000260091.1	RP11-33B1.4	4.66	4.51e-06	0.00245	0.24	0.24	Corneal astigmatism;	chr4:119336556	chr4:119409333~119410233:+
STAD	cis	rs1850744	0.826	rs10939504	ENSG00000250268.3	ALG1L14P	4.66	4.51e-06	0.00245	0.5	0.24	Economic and political preferences;	chr4:9765746	chr4:9166297~9170270:-
STAD	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-4.66	4.51e-06	0.00245	-0.31	-0.24	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
STAD	cis	rs1007190	0.57	rs12185253	ENSG00000267405.1	CTC-296K1.4	-4.66	4.51e-06	0.00246	-0.3	-0.24	DNA methylation (variation);	chr17:44790589	chr17:44794747~44797783:-
STAD	cis	rs1426063	1	rs1426063	ENSG00000248165.1	RP11-44F21.2	-4.66	4.51e-06	0.00246	-0.42	-0.24	QT interval;	chr4:75105711	chr4:74993877~75034824:-
STAD	cis	rs7924176	0.521	rs10509347	ENSG00000213731.2	RAB5CP1	-4.66	4.51e-06	0.00246	-0.25	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74423435~74424014:-
STAD	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-4.66	4.52e-06	0.00246	-0.31	-0.24	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
STAD	cis	rs875971	0.965	rs28682868	ENSG00000236529.1	RP13-254B10.1	-4.66	4.52e-06	0.00246	-0.26	-0.24	Aortic root size;	chr7:66224822	chr7:65840212~65840596:+
STAD	cis	rs2836950	0.501	rs35994303	ENSG00000238141.2	BRWD1-AS1	-4.66	4.52e-06	0.00246	-0.25	-0.24	Menarche (age at onset);	chr21:39314094	chr21:39315707~39323218:+
STAD	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	4.66	4.52e-06	0.00246	0.35	0.24	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000224373.3	IGHV4-59	4.66	4.52e-06	0.00246	0.17	0.24	Kawasaki disease;	chr14:106802182	chr14:106627249~106627825:-
STAD	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-4.66	4.52e-06	0.00246	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
STAD	cis	rs6714710	0.58	rs11690737	ENSG00000235833.1	AC159540.14	-4.66	4.53e-06	0.00246	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845490	chr2:97523949~97524976:-
STAD	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	4.66	4.53e-06	0.00246	0.4	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
STAD	cis	rs2483058	0.767	rs4127124	ENSG00000261000.1	RP11-534L20.5	4.66	4.53e-06	0.00246	0.29	0.24	Cholesterol and Triglycerides;	chr1:206451019	chr1:206503948~206504456:+
STAD	cis	rs8141529	0.509	rs5762863	ENSG00000226471.5	CTA-292E10.6	-4.66	4.53e-06	0.00246	-0.3	-0.24	Lymphocyte counts;	chr22:28857347	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.509	rs5762864	ENSG00000226471.5	CTA-292E10.6	-4.66	4.53e-06	0.00246	-0.3	-0.24	Lymphocyte counts;	chr22:28857376	chr22:28800683~28848559:+
STAD	cis	rs10510102	1	rs11200181	ENSG00000226864.1	ATE1-AS1	4.66	4.53e-06	0.00246	0.38	0.24	Breast cancer;	chr10:121828528	chr10:121928312~121951965:+
STAD	cis	rs6714710	0.663	rs71429376	ENSG00000235833.1	AC159540.14	-4.66	4.54e-06	0.00247	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97917949	chr2:97523949~97524976:-
STAD	cis	rs875971	0.898	rs6977501	ENSG00000236529.1	RP13-254B10.1	-4.66	4.54e-06	0.00247	-0.26	-0.24	Aortic root size;	chr7:66228355	chr7:65840212~65840596:+
STAD	cis	rs875971	0.965	rs6971509	ENSG00000236529.1	RP13-254B10.1	-4.66	4.54e-06	0.00247	-0.26	-0.24	Aortic root size;	chr7:66249983	chr7:65840212~65840596:+
STAD	cis	rs10510102	0.935	rs10887014	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121892322	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11818735	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121892472	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.81	rs12259902	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121893017	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200228	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121893358	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200229	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121893519	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs10887016	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121893830	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs10887018	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121894457	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200230	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121895117	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs11200234	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121895851	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs12244951	ENSG00000226864.1	ATE1-AS1	4.66	4.54e-06	0.00247	0.4	0.24	Breast cancer;	chr10:121896879	chr10:121928312~121951965:+
STAD	cis	rs228614	0.51	rs223377	ENSG00000248971.2	KRT8P46	-4.66	4.54e-06	0.00247	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102728746~102730171:-
STAD	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-4.66	4.54e-06	0.00247	-0.28	-0.24	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
STAD	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-4.66	4.54e-06	0.00247	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
STAD	cis	rs9902453	0.765	rs2874505	ENSG00000240074.1	RPL9P30	4.66	4.54e-06	0.00247	0.21	0.24	Coffee consumption (cups per day);	chr17:29710905	chr17:29855759~29856332:+
STAD	cis	rs7429990	0.932	rs6803741	ENSG00000224895.1	VPS26BP1	4.66	4.54e-06	0.00247	0.24	0.24	Educational attainment (years of education);	chr3:48082050	chr3:47960327~47961081:-
STAD	cis	rs4617927	0.79	rs1477141	ENSG00000263096.1	RP11-515O17.2	4.66	4.55e-06	0.00247	0.28	0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr17:55284477	chr17:55271504~55273653:-
STAD	cis	rs10978777	1	rs7036284	ENSG00000276883.1	AL137852.1	4.66	4.55e-06	0.00247	0.25	0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107278949	chr9:107292369~107292456:-
STAD	cis	rs4835473	0.9	rs10027246	ENSG00000249741.2	RP11-673E1.3	4.66	4.55e-06	0.00247	0.28	0.24	Immature fraction of reticulocytes;	chr4:143935069	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.808	rs11725413	ENSG00000249741.2	RP11-673E1.3	4.66	4.55e-06	0.00247	0.28	0.24	Immature fraction of reticulocytes;	chr4:143943366	chr4:143911514~143912053:-
STAD	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-4.66	4.55e-06	0.00247	-0.31	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
STAD	cis	rs9907295	0.818	rs4251737	ENSG00000270894.1	AC015849.13	-4.66	4.55e-06	0.00247	-0.24	-0.24	Fibroblast growth factor basic levels;	chr17:35819814	chr17:35818399~35823713:+
STAD	cis	rs9368481	0.569	rs6907403	ENSG00000241549.7	GUSBP2	4.66	4.55e-06	0.00247	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26871484~26956554:-
STAD	cis	rs9368481	0.502	rs3933232	ENSG00000241549.7	GUSBP2	4.66	4.55e-06	0.00247	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26871484~26956554:-
STAD	cis	rs9368481	0.524	rs12530345	ENSG00000241549.7	GUSBP2	4.66	4.55e-06	0.00247	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26871484~26956554:-
STAD	cis	rs2337406	0.866	rs8003852	ENSG00000280411.1	IGHV1-69-2	-4.66	4.56e-06	0.00247	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106776648	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs988131	ENSG00000280411.1	IGHV1-69-2	-4.66	4.56e-06	0.00247	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106776833	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs8005518	ENSG00000280411.1	IGHV1-69-2	-4.66	4.56e-06	0.00247	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106777009	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs988130	ENSG00000280411.1	IGHV1-69-2	-4.66	4.56e-06	0.00247	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106777154	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs57684263	ENSG00000280411.1	IGHV1-69-2	-4.66	4.56e-06	0.00247	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106777263	chr14:106762092~106762588:-
STAD	cis	rs8099594	0.64	rs7505791	ENSG00000266696.1	RP11-30L3.2	4.66	4.56e-06	0.00247	0.24	0.24	Height;	chr18:49348631	chr18:49205912~49208781:+
STAD	cis	rs4243830	0.826	rs12565181	ENSG00000229519.2	RP11-58A11.2	-4.66	4.56e-06	0.00247	-0.27	-0.24	Body mass index;	chr1:6560485	chr1:6547905~6548619:+
STAD	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	4.66	4.56e-06	0.00248	0.27	0.24	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
STAD	cis	rs3733585	0.631	rs4697925	ENSG00000250613.1	RP11-136I13.1	4.66	4.56e-06	0.00248	0.25	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10122706	chr4:10410996~10411644:+
STAD	cis	rs7429990	0.965	rs319682	ENSG00000224895.1	VPS26BP1	-4.66	4.56e-06	0.00248	-0.24	-0.24	Educational attainment (years of education);	chr3:47873628	chr3:47960327~47961081:-
STAD	cis	rs7487075	0.558	rs12303214	ENSG00000257261.4	RP11-96H19.1	4.66	4.56e-06	0.00248	0.29	0.24	Itch intensity from mosquito bite;	chr12:46255745	chr12:46383679~46876159:+
STAD	cis	rs875971	0.862	rs6959268	ENSG00000236529.1	RP13-254B10.1	-4.66	4.56e-06	0.00248	-0.25	-0.24	Aortic root size;	chr7:66347979	chr7:65840212~65840596:+
STAD	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	4.66	4.57e-06	0.00248	0.3	0.24	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	4.66	4.57e-06	0.00248	0.3	0.24	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	4.66	4.57e-06	0.00248	0.3	0.24	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
STAD	cis	rs9828933	0.577	rs832193	ENSG00000280620.1	SCAANT1	-4.66	4.57e-06	0.00248	-0.38	-0.24	Type 2 diabetes;	chr3:63868769	chr3:63911518~63911772:-
STAD	cis	rs6095360	0.727	rs7274612	ENSG00000222365.1	SNORD12B	4.66	4.57e-06	0.00248	0.29	0.24	Intelligence (multi-trait analysis);	chr20:49086284	chr20:49280319~49280409:+
STAD	cis	rs227275	0.556	rs4455413	ENSG00000248971.2	KRT8P46	-4.66	4.57e-06	0.00248	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102728746~102730171:-
STAD	cis	rs10978777	1	rs10119641	ENSG00000276883.1	AL137852.1	4.66	4.57e-06	0.00248	0.25	0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107279966	chr9:107292369~107292456:-
STAD	cis	rs9368481	0.594	rs7768643	ENSG00000241549.7	GUSBP2	4.66	4.57e-06	0.00248	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26871484~26956554:-
STAD	cis	rs9368481	0.594	rs7768814	ENSG00000241549.7	GUSBP2	4.66	4.57e-06	0.00248	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26871484~26956554:-
STAD	cis	rs17826219	0.706	rs28469200	ENSG00000263603.1	CTD-2349P21.5	-4.66	4.57e-06	0.00248	-0.31	-0.24	Body mass index;	chr17:30806554	chr17:30729469~30731202:+
STAD	cis	rs10129255	0.5	rs7159033	ENSG00000211970.3	IGHV4-61	-4.66	4.57e-06	0.00248	-0.19	-0.24	Kawasaki disease;	chr14:106701709	chr14:106639119~106639657:-
STAD	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	4.66	4.57e-06	0.00248	0.29	0.24	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
STAD	cis	rs7487075	0.786	rs2172398	ENSG00000257261.4	RP11-96H19.1	4.66	4.57e-06	0.00248	0.29	0.24	Itch intensity from mosquito bite;	chr12:46278788	chr12:46383679~46876159:+
STAD	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	4.66	4.57e-06	0.00248	0.32	0.24	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
STAD	cis	rs748404	0.697	rs493177	ENSG00000275601.1	AC011330.13	-4.66	4.57e-06	0.00248	-0.25	-0.24	Lung cancer;	chr15:43251060	chr15:43642389~43643023:-
STAD	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-4.66	4.58e-06	0.00248	-0.27	-0.24	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
STAD	cis	rs3770081	0.59	rs11891333	ENSG00000273080.1	RP11-301O19.1	-4.66	4.58e-06	0.00248	-0.49	-0.24	Facial emotion recognition (sad faces);	chr2:85951271	chr2:86195590~86196049:+
STAD	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	4.66	4.58e-06	0.00249	0.35	0.24	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
STAD	cis	rs728616	0.867	rs1054054	ENSG00000225484.5	NUTM2B-AS1	-4.66	4.58e-06	0.00249	-0.58	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61859766	ENSG00000225484.5	NUTM2B-AS1	-4.66	4.58e-06	0.00249	-0.58	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:79663088~79826594:-
STAD	cis	rs11722779	0.935	rs7681629	ENSG00000248971.2	KRT8P46	-4.66	4.58e-06	0.00249	-0.25	-0.24	Schizophrenia;	chr4:102974407	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.844	rs17033381	ENSG00000248971.2	KRT8P46	-4.66	4.58e-06	0.00249	-0.25	-0.24	Schizophrenia;	chr4:102974952	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs4699045	ENSG00000248971.2	KRT8P46	-4.66	4.58e-06	0.00249	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102728746~102730171:-
STAD	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	4.66	4.59e-06	0.00249	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
STAD	cis	rs4568518	0.535	rs7800421	ENSG00000279048.1	RP11-511H23.2	4.66	4.59e-06	0.00249	0.23	0.24	Measles;	chr7:18023132	chr7:17940503~17942922:+
STAD	cis	rs3733418	0.929	rs7657444	ENSG00000248632.1	RP11-366M4.11	4.66	4.59e-06	0.00249	0.3	0.24	Obesity-related traits;	chr4:164965407	chr4:164968587~164970002:-
STAD	cis	rs7184046	0.797	rs13737	ENSG00000260269.4	CTD-2323K18.1	-4.66	4.59e-06	0.00249	-0.32	-0.24	Height;	chr15:75639788	chr15:75527150~75601205:-
STAD	cis	rs6832769	1	rs13102385	ENSG00000272969.1	RP11-528I4.2	4.66	4.59e-06	0.00249	0.31	0.24	Personality dimensions;	chr4:55479088	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs11947623	ENSG00000272969.1	RP11-528I4.2	4.66	4.59e-06	0.00249	0.31	0.24	Personality dimensions;	chr4:55483023	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs11939815	ENSG00000272969.1	RP11-528I4.2	4.66	4.59e-06	0.00249	0.31	0.24	Personality dimensions;	chr4:55492116	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.826	rs58894703	ENSG00000272969.1	RP11-528I4.2	4.66	4.59e-06	0.00249	0.31	0.24	Personality dimensions;	chr4:55492371	chr4:55547112~55547889:+
STAD	cis	rs2337406	0.789	rs9324095	ENSG00000280411.1	IGHV1-69-2	-4.66	4.59e-06	0.00249	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106795885	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.866	rs58154560	ENSG00000280411.1	IGHV1-69-2	-4.66	4.59e-06	0.00249	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106799601	chr14:106762092~106762588:-
STAD	cis	rs1707322	0.717	rs3014249	ENSG00000281133.1	AL355480.3	4.66	4.59e-06	0.00249	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45580892~45580996:-
STAD	cis	rs9733	0.621	rs6669122	ENSG00000274963.1	Metazoa_SRP	-4.66	4.59e-06	0.00249	-0.19	-0.24	Tonsillectomy;	chr1:150619256	chr1:150568971~150569269:-
STAD	cis	rs13315649	0.724	rs28787069	ENSG00000242551.2	POU5F1P6	-4.66	4.6e-06	0.00249	-0.26	-0.24	Sum eosinophil basophil counts;	chr3:128695613	chr3:128674735~128677005:-
STAD	cis	rs7208859	0.573	rs7214313	ENSG00000263603.1	CTD-2349P21.5	-4.66	4.6e-06	0.00249	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30729469~30731202:+
STAD	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-4.66	4.6e-06	0.00249	-0.27	-0.24	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
STAD	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-4.66	4.6e-06	0.00249	-0.28	-0.24	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
STAD	cis	rs12908161	1	rs35808647	ENSG00000259295.5	CSPG4P12	4.66	4.6e-06	0.00249	0.35	0.24	Schizophrenia;	chr15:84834210	chr15:85191438~85213905:+
STAD	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	4.66	4.6e-06	0.00249	0.24	0.24	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
STAD	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	4.66	4.6e-06	0.00249	0.24	0.24	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
STAD	cis	rs9463078	0.587	rs1150806	ENSG00000219384.1	RP11-491H9.3	4.66	4.6e-06	0.0025	0.23	0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44930050	chr6:45158870~45159511:+
STAD	cis	rs10510102	0.688	rs74570569	ENSG00000226864.1	ATE1-AS1	4.66	4.6e-06	0.0025	0.38	0.24	Breast cancer;	chr10:121945347	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs7076727	ENSG00000226864.1	ATE1-AS1	4.66	4.6e-06	0.0025	0.38	0.24	Breast cancer;	chr10:121947000	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.745	rs7076882	ENSG00000226864.1	ATE1-AS1	4.66	4.6e-06	0.0025	0.38	0.24	Breast cancer;	chr10:121947039	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs7077035	ENSG00000226864.1	ATE1-AS1	4.66	4.6e-06	0.0025	0.38	0.24	Breast cancer;	chr10:121947130	chr10:121928312~121951965:+
STAD	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.37	-0.24	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
STAD	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	4.66	4.61e-06	0.0025	0.27	0.24	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
STAD	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-4.66	4.61e-06	0.0025	-0.36	-0.24	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
STAD	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	4.66	4.61e-06	0.0025	0.25	0.24	Height;	chr5:37041491	chr5:36666214~36725195:-
STAD	cis	rs853679	0.55	rs1237875	ENSG00000220721.1	OR1F12	-4.66	4.61e-06	0.0025	-0.28	-0.24	Depression;	chr6:28205232	chr6:28073316~28074233:+
STAD	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	4.66	4.62e-06	0.0025	0.28	0.24	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
STAD	cis	rs10483853	0.579	rs10134243	ENSG00000258695.2	RP3-414A15.2	-4.66	4.62e-06	0.0025	-0.32	-0.24	Coronary artery calcification;	chr14:73478444	chr14:73522878~73530610:+
STAD	cis	rs7665090	1	rs909349	ENSG00000248971.2	KRT8P46	4.66	4.62e-06	0.0025	0.25	0.24	Primary biliary cholangitis;	chr4:102635159	chr4:102728746~102730171:-
STAD	cis	rs2115536	0.73	rs4238512	ENSG00000278600.1	RP11-81A1.6	4.66	4.62e-06	0.0025	0.21	0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79891556	chr15:79920195~79922455:-
STAD	cis	rs10510102	0.872	rs12264046	ENSG00000226864.1	ATE1-AS1	4.65	4.62e-06	0.00251	0.4	0.24	Breast cancer;	chr10:121894996	chr10:121928312~121951965:+
STAD	cis	rs7829975	0.711	rs4481596	ENSG00000173295.6	FAM86B3P	4.65	4.63e-06	0.00251	0.28	0.24	Mood instability;	chr8:8846820	chr8:8228595~8244865:+
STAD	cis	rs11098499	0.863	rs13134665	ENSG00000260091.1	RP11-33B1.4	4.65	4.63e-06	0.00251	0.24	0.24	Corneal astigmatism;	chr4:119505275	chr4:119409333~119410233:+
STAD	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	4.65	4.63e-06	0.00251	0.25	0.24	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
STAD	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	4.65	4.63e-06	0.00251	0.25	0.24	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
STAD	cis	rs891378	1	rs2802234	ENSG00000274245.1	RP11-357P18.2	-4.65	4.64e-06	0.00251	-0.31	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207298244	chr1:207372559~207373252:+
STAD	cis	rs858239	0.899	rs858271	ENSG00000230042.1	AK3P3	-4.65	4.64e-06	0.00251	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23129178~23129841:+
STAD	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-4.65	4.64e-06	0.00251	-0.36	-0.24	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
STAD	cis	rs2273156	1	rs7145608	ENSG00000241052.1	RP11-173D9.1	-4.65	4.64e-06	0.00252	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34994291	chr14:35144021~35144480:-
STAD	cis	rs1040	0.674	rs9393166	ENSG00000261039.2	RP11-417E7.2	-4.65	4.65e-06	0.00252	-0.29	-0.24	Joint mobility (Beighton score);	chr6:169200760	chr6:169175304~169182740:-
STAD	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	4.65	4.65e-06	0.00252	0.46	0.24	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
STAD	cis	rs10978777	0.726	rs10816473	ENSG00000276883.1	AL137852.1	4.65	4.65e-06	0.00252	0.25	0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107242013	chr9:107292369~107292456:-
STAD	cis	rs7078219	0.505	rs10883362	ENSG00000257582.4	LINC01475	-4.65	4.65e-06	0.00252	-0.27	-0.24	Dental caries;	chr10:99527227	chr10:99526350~99531177:-
STAD	cis	rs7078219	0.523	rs10883366	ENSG00000257582.4	LINC01475	-4.65	4.65e-06	0.00252	-0.27	-0.24	Dental caries;	chr10:99528028	chr10:99526350~99531177:-
STAD	cis	rs9400467	0.528	rs17539197	ENSG00000230177.1	RP5-1112D6.4	-4.65	4.65e-06	0.00252	-0.22	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111277932~111278742:+
STAD	cis	rs10978777	0.921	rs817840	ENSG00000276883.1	AL137852.1	-4.65	4.66e-06	0.00252	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107336776	chr9:107292369~107292456:-
STAD	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	4.65	4.66e-06	0.00252	0.24	0.24	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
STAD	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	4.65	4.66e-06	0.00252	0.24	0.24	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
STAD	cis	rs227275	0.525	rs223462	ENSG00000248971.2	KRT8P46	-4.65	4.66e-06	0.00252	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223459	ENSG00000248971.2	KRT8P46	-4.65	4.66e-06	0.00252	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102728746~102730171:-
STAD	cis	rs227275	0.588	rs223458	ENSG00000248971.2	KRT8P46	-4.65	4.66e-06	0.00252	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102728746~102730171:-
STAD	cis	rs7615952	0.604	rs9837847	ENSG00000239804.1	RP11-379B18.1	4.65	4.66e-06	0.00252	0.45	0.24	Blood pressure (smoking interaction);	chr3:125905076	chr3:125787888~125788146:-
STAD	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	4.65	4.66e-06	0.00252	0.32	0.24	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
STAD	cis	rs13113518	0.812	rs11932712	ENSG00000223305.1	RN7SKP30	4.65	4.66e-06	0.00252	0.27	0.24	Height;	chr4:55436423	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.812	rs12501746	ENSG00000223305.1	RN7SKP30	4.65	4.66e-06	0.00252	0.27	0.24	Height;	chr4:55437438	chr4:55540502~55540835:-
STAD	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	4.65	4.66e-06	0.00252	0.3	0.24	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
STAD	cis	rs17401966	0.809	rs12406943	ENSG00000199562.1	RNU6-37P	4.65	4.66e-06	0.00252	0.19	0.24	Hepatocellular carcinoma;	chr1:10248487	chr1:10298966~10299072:+
STAD	cis	rs227275	0.556	rs4699044	ENSG00000248971.2	KRT8P46	-4.65	4.67e-06	0.00252	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102728746~102730171:-
STAD	cis	rs875971	0.867	rs1002053	ENSG00000236529.1	RP13-254B10.1	-4.65	4.67e-06	0.00253	-0.25	-0.24	Aortic root size;	chr7:66333558	chr7:65840212~65840596:+
STAD	cis	rs7617773	0.925	rs7374376	ENSG00000224895.1	VPS26BP1	4.65	4.67e-06	0.00253	0.25	0.24	Coronary artery disease;	chr3:48131197	chr3:47960327~47961081:-
STAD	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	4.65	4.67e-06	0.00253	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
STAD	cis	rs227275	0.554	rs223339	ENSG00000248971.2	KRT8P46	-4.65	4.67e-06	0.00253	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223333	ENSG00000248971.2	KRT8P46	-4.65	4.67e-06	0.00253	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223328	ENSG00000248971.2	KRT8P46	-4.65	4.67e-06	0.00253	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102728746~102730171:-
STAD	cis	rs228614	0.536	rs223325	ENSG00000248971.2	KRT8P46	-4.65	4.67e-06	0.00253	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102728746~102730171:-
STAD	cis	rs8141529	0.732	rs5762788	ENSG00000272858.1	CTA-292E10.8	-4.65	4.68e-06	0.00253	-0.27	-0.24	Lymphocyte counts;	chr22:28778782	chr22:28814914~28815662:+
STAD	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	4.65	4.68e-06	0.00253	0.28	0.24	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
STAD	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-4.65	4.68e-06	0.00253	-0.27	-0.24	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
STAD	cis	rs748404	0.66	rs2439846	ENSG00000275601.1	AC011330.13	-4.65	4.68e-06	0.00253	-0.25	-0.24	Lung cancer;	chr15:43448772	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs2467741	ENSG00000275601.1	AC011330.13	-4.65	4.68e-06	0.00253	-0.25	-0.24	Lung cancer;	chr15:43450428	chr15:43642389~43643023:-
STAD	cis	rs1348850	0.872	rs4893959	ENSG00000271825.1	RP11-337N6.2	4.65	4.68e-06	0.00253	0.21	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177535476	chr2:177300600~177302006:+
STAD	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-4.65	4.68e-06	0.00253	-0.24	-0.24	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
STAD	cis	rs7665090	1	rs10027437	ENSG00000248971.2	KRT8P46	-4.65	4.69e-06	0.00253	-0.25	-0.24	Primary biliary cholangitis;	chr4:102636094	chr4:102728746~102730171:-
STAD	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-4.65	4.69e-06	0.00253	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
STAD	cis	rs6584283	0.875	rs10748783	ENSG00000257582.4	LINC01475	-4.65	4.69e-06	0.00253	-0.27	-0.24	Ulcerative colitis;	chr10:99526115	chr10:99526350~99531177:-
STAD	cis	rs9646944	0.531	rs17027029	ENSG00000234389.1	AC007278.3	4.65	4.69e-06	0.00254	0.32	0.24	Blood protein levels;	chr2:102374188	chr2:102438713~102440475:+
STAD	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	4.65	4.69e-06	0.00254	0.28	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
STAD	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	4.65	4.7e-06	0.00254	0.3	0.24	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
STAD	cis	rs11098499	0.863	rs12508173	ENSG00000260091.1	RP11-33B1.4	4.65	4.7e-06	0.00254	0.24	0.24	Corneal astigmatism;	chr4:119397371	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.908	rs12504149	ENSG00000260091.1	RP11-33B1.4	4.65	4.7e-06	0.00254	0.24	0.24	Corneal astigmatism;	chr4:119397422	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs10008392	ENSG00000260091.1	RP11-33B1.4	4.65	4.7e-06	0.00254	0.24	0.24	Corneal astigmatism;	chr4:119397684	chr4:119409333~119410233:+
STAD	cis	rs938554	0.612	rs7669607	ENSG00000250613.1	RP11-136I13.1	4.65	4.7e-06	0.00254	0.26	0.24	Blood metabolite levels;	chr4:9996177	chr4:10410996~10411644:+
STAD	cis	rs6061231	0.755	rs11699160	ENSG00000275437.1	RP5-908M14.10	4.65	4.7e-06	0.00254	0.22	0.24	Colorectal cancer;	chr20:62383595	chr20:62402236~62405935:-
STAD	cis	rs858239	1	rs858239	ENSG00000230042.1	AK3P3	-4.65	4.71e-06	0.00254	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23129178~23129841:+
STAD	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-4.65	4.71e-06	0.00255	-0.35	-0.24	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
STAD	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	4.65	4.71e-06	0.00255	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	4.65	4.71e-06	0.00255	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	4.65	4.71e-06	0.00255	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	4.65	4.71e-06	0.00255	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	4.65	4.71e-06	0.00255	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
STAD	cis	rs8028182	0.636	rs28623700	ENSG00000260269.4	CTD-2323K18.1	-4.65	4.72e-06	0.00255	-0.31	-0.24	Sudden cardiac arrest;	chr15:75557373	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.577	rs28693593	ENSG00000260269.4	CTD-2323K18.1	-4.65	4.72e-06	0.00255	-0.31	-0.24	Sudden cardiac arrest;	chr15:75557435	chr15:75527150~75601205:-
STAD	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	4.65	4.72e-06	0.00255	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
STAD	cis	rs228614	0.536	rs223437	ENSG00000248971.2	KRT8P46	-4.65	4.72e-06	0.00255	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102728746~102730171:-
STAD	cis	rs7078219	0.505	rs10883367	ENSG00000257582.4	LINC01475	-4.65	4.72e-06	0.00255	-0.27	-0.24	Dental caries;	chr10:99528233	chr10:99526350~99531177:-
STAD	cis	rs9733	0.818	rs6694531	ENSG00000274963.1	Metazoa_SRP	-4.65	4.73e-06	0.00255	-0.2	-0.24	Tonsillectomy;	chr1:150711036	chr1:150568971~150569269:-
STAD	cis	rs9733	0.818	rs10888388	ENSG00000274963.1	Metazoa_SRP	-4.65	4.73e-06	0.00255	-0.2	-0.24	Tonsillectomy;	chr1:150714820	chr1:150568971~150569269:-
STAD	cis	rs9733	0.818	rs12130363	ENSG00000274963.1	Metazoa_SRP	-4.65	4.73e-06	0.00255	-0.2	-0.24	Tonsillectomy;	chr1:150716120	chr1:150568971~150569269:-
STAD	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-4.65	4.73e-06	0.00255	-0.25	-0.24	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
STAD	cis	rs2337406	0.85	rs11161008	ENSG00000274576.2	IGHV2-70	-4.65	4.73e-06	0.00255	-0.31	-0.24	Alzheimer's disease (late onset);	chr14:106705261	chr14:106770577~106771020:-
STAD	cis	rs2446066	0.872	rs2002555	ENSG00000257379.1	RP11-793H13.8	4.65	4.73e-06	0.00256	0.4	0.24	Red blood cell count;	chr12:53423453	chr12:53441741~53467528:+
STAD	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-4.65	4.74e-06	0.00256	-0.23	-0.24	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
STAD	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	4.65	4.74e-06	0.00256	0.35	0.24	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
STAD	cis	rs11976180	0.517	rs6949375	ENSG00000204959.4	ARHGEF34P	4.65	4.74e-06	0.00256	0.42	0.24	Obesity-related traits;	chr7:144076758	chr7:144272445~144286966:-
STAD	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-4.65	4.74e-06	0.00256	-0.26	-0.24	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-4.65	4.74e-06	0.00256	-0.26	-0.24	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
STAD	cis	rs2695743	0.592	rs59406093	ENSG00000225808.1	DNAJC19P5	-4.65	4.74e-06	0.00256	-0.28	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177819925	chr2:177229191~177229506:-
STAD	cis	rs721917	0.525	rs2819106	ENSG00000244733.5	RP11-506M13.3	-4.65	4.75e-06	0.00257	-0.3	-0.24	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79660891~79677996:+
STAD	cis	rs1799949	1	rs8176126	ENSG00000279602.1	CTD-3014M21.1	-4.65	4.75e-06	0.00257	-0.3	-0.24	Menopause (age at onset);	chr17:43107032	chr17:43360041~43361361:-
STAD	cis	rs9733	0.818	rs12403609	ENSG00000274963.1	Metazoa_SRP	-4.65	4.75e-06	0.00257	-0.2	-0.24	Tonsillectomy;	chr1:150704009	chr1:150568971~150569269:-
STAD	cis	rs1007738	0.507	rs7940240	ENSG00000271350.1	CTD-2384B9.1	-4.65	4.75e-06	0.00257	-0.31	-0.24	Bone mineral density (hip);	chr11:47181517	chr11:47041027~47041945:-
STAD	cis	rs41369048	0.669	rs11589654	ENSG00000257551.1	HLX-AS1	-4.65	4.75e-06	0.00257	-0.38	-0.24	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866646	chr1:220832763~220880140:-
STAD	cis	rs6430585	0.583	rs2839740	ENSG00000231890.6	DARS-AS1	-4.65	4.76e-06	0.00257	-0.28	-0.24	Corneal structure;	chr2:135891313	chr2:135985176~136022593:+
STAD	cis	rs1799949	1	rs34534709	ENSG00000279602.1	CTD-3014M21.1	4.65	4.76e-06	0.00257	0.31	0.24	Menopause (age at onset);	chr17:43150923	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs34059614	ENSG00000279602.1	CTD-3014M21.1	4.65	4.76e-06	0.00257	0.31	0.24	Menopause (age at onset);	chr17:43151054	chr17:43360041~43361361:-
STAD	cis	rs10849893	0.557	rs10849890	ENSG00000258435.1	RP11-711D18.2	-4.65	4.76e-06	0.00257	-0.26	-0.24	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121464922	chr12:121391962~121399859:+
STAD	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	4.65	4.76e-06	0.00257	0.3	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
STAD	cis	rs3806843	0.608	rs155364	ENSG00000202111.1	VTRNA1-2	-4.65	4.76e-06	0.00257	-0.24	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140966883	chr5:140718925~140719013:+
STAD	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-4.65	4.76e-06	0.00257	-0.27	-0.24	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
STAD	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-4.65	4.76e-06	0.00257	-0.39	-0.24	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
STAD	cis	rs1707322	0.721	rs12069121	ENSG00000225447.1	RPS15AP10	4.65	4.76e-06	0.00257	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45645816~45646197:-
STAD	cis	rs9860428	0.844	rs9826834	ENSG00000240057.4	RP11-572M11.4	-4.65	4.77e-06	0.00257	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112858340	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs6781547	ENSG00000240057.4	RP11-572M11.4	-4.65	4.77e-06	0.00257	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112864167	chr3:113019532~113183301:+
STAD	cis	rs13113518	1	rs34648901	ENSG00000223305.1	RN7SKP30	4.65	4.77e-06	0.00257	0.27	0.24	Height;	chr4:55541259	chr4:55540502~55540835:-
STAD	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	4.65	4.77e-06	0.00257	0.25	0.24	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
STAD	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-4.65	4.77e-06	0.00257	-0.22	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
STAD	cis	rs748404	0.69	rs2467737	ENSG00000275601.1	AC011330.13	-4.65	4.77e-06	0.00257	-0.25	-0.24	Lung cancer;	chr15:43444990	chr15:43642389~43643023:-
STAD	cis	rs10510102	0.688	rs56094144	ENSG00000226864.1	ATE1-AS1	4.65	4.77e-06	0.00257	0.4	0.24	Breast cancer;	chr10:121903941	chr10:121928312~121951965:+
STAD	cis	rs35934224	0.628	rs2073750	ENSG00000232926.1	AC000078.5	4.65	4.77e-06	0.00257	0.27	0.24	Glaucoma (primary open-angle);	chr22:19885834	chr22:19887289~19887970:+
STAD	cis	rs10851478	0.5	rs36023246	ENSG00000259545.2	RP11-325E5.4	-4.65	4.78e-06	0.00258	-0.28	-0.24	Oral cavity cancer;	chr15:49407114	chr15:49177610~49178741:-
STAD	cis	rs17630293	0.737	rs295127	ENSG00000201649.1	RNY4P34	4.65	4.78e-06	0.00258	0.33	0.24	Schizophrenia;	chr2:200362466	chr2:200373175~200373269:+
STAD	cis	rs4568518	0.53	rs6461368	ENSG00000279048.1	RP11-511H23.2	4.65	4.78e-06	0.00258	0.23	0.24	Measles;	chr7:18023449	chr7:17940503~17942922:+
STAD	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-4.65	4.78e-06	0.00258	-0.25	-0.24	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
STAD	cis	rs9733	0.818	rs4970924	ENSG00000274963.1	Metazoa_SRP	-4.65	4.78e-06	0.00258	-0.2	-0.24	Tonsillectomy;	chr1:150660603	chr1:150568971~150569269:-
STAD	cis	rs9733	0.818	rs11204695	ENSG00000274963.1	Metazoa_SRP	-4.65	4.78e-06	0.00258	-0.2	-0.24	Tonsillectomy;	chr1:150684535	chr1:150568971~150569269:-
STAD	cis	rs9733	0.818	rs4970926	ENSG00000274963.1	Metazoa_SRP	-4.65	4.78e-06	0.00258	-0.2	-0.24	Tonsillectomy;	chr1:150701208	chr1:150568971~150569269:-
STAD	cis	rs9860428	0.844	rs13063847	ENSG00000240057.4	RP11-572M11.4	-4.65	4.78e-06	0.00258	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112850701	chr3:113019532~113183301:+
STAD	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	4.65	4.79e-06	0.00258	0.3	0.24	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
STAD	cis	rs7487075	0.751	rs7310869	ENSG00000257261.4	RP11-96H19.1	4.65	4.8e-06	0.00259	0.29	0.24	Itch intensity from mosquito bite;	chr12:46271603	chr12:46383679~46876159:+
STAD	cis	rs228614	0.51	rs223435	ENSG00000248971.2	KRT8P46	-4.65	4.8e-06	0.00259	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102728746~102730171:-
STAD	cis	rs6832769	0.922	rs11133376	ENSG00000272969.1	RP11-528I4.2	4.65	4.8e-06	0.00259	0.31	0.24	Personality dimensions;	chr4:55386866	chr4:55547112~55547889:+
STAD	cis	rs2749592	0.531	rs1208559	ENSG00000099251.13	HSD17B7P2	-4.65	4.8e-06	0.00259	-0.27	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38356380~38378505:+
STAD	cis	rs595244	0.831	rs55694948	ENSG00000259705.1	RP11-227D13.1	4.65	4.81e-06	0.00259	0.33	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48465935	chr15:48645951~48652016:+
STAD	cis	rs1799949	0.93	rs4445938	ENSG00000279602.1	CTD-3014M21.1	4.65	4.81e-06	0.00259	0.3	0.24	Menopause (age at onset);	chr17:43185883	chr17:43360041~43361361:-
STAD	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-4.65	4.81e-06	0.00259	-0.31	-0.24	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
STAD	cis	rs7829975	0.714	rs6994038	ENSG00000253981.4	ALG1L13P	4.65	4.81e-06	0.00259	0.28	0.24	Mood instability;	chr8:8803028	chr8:8236003~8244667:-
STAD	cis	rs10510102	0.688	rs11812208	ENSG00000226864.1	ATE1-AS1	4.65	4.81e-06	0.00259	0.4	0.24	Breast cancer;	chr10:121924831	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs77447688	ENSG00000226864.1	ATE1-AS1	4.65	4.81e-06	0.00259	0.4	0.24	Breast cancer;	chr10:121925721	chr10:121928312~121951965:+
STAD	cis	rs10978777	0.883	rs817839	ENSG00000276883.1	AL137852.1	4.65	4.81e-06	0.00259	0.25	0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107336541	chr9:107292369~107292456:-
STAD	cis	rs357618	1	rs357627	ENSG00000260581.1	CTB-113P19.4	4.65	4.81e-06	0.00259	0.28	0.24	Basophil percentage of white cells;	chr5:151470699	chr5:151652275~151655449:+
STAD	cis	rs357618	1	rs357628	ENSG00000260581.1	CTB-113P19.4	4.65	4.81e-06	0.00259	0.28	0.24	Basophil percentage of white cells;	chr5:151470791	chr5:151652275~151655449:+
STAD	cis	rs357618	1	rs165352	ENSG00000260581.1	CTB-113P19.4	4.65	4.81e-06	0.00259	0.28	0.24	Basophil percentage of white cells;	chr5:151476546	chr5:151652275~151655449:+
STAD	cis	rs357618	1	rs165353	ENSG00000260581.1	CTB-113P19.4	4.65	4.81e-06	0.00259	0.28	0.24	Basophil percentage of white cells;	chr5:151477196	chr5:151652275~151655449:+
STAD	cis	rs748404	0.697	rs513970	ENSG00000275601.1	AC011330.13	-4.65	4.82e-06	0.0026	-0.26	-0.24	Lung cancer;	chr15:43287368	chr15:43642389~43643023:-
STAD	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	4.65	4.82e-06	0.0026	0.31	0.24	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
STAD	cis	rs3733418	0.929	rs72697952	ENSG00000248632.1	RP11-366M4.11	4.65	4.82e-06	0.0026	0.3	0.24	Obesity-related traits;	chr4:164979776	chr4:164968587~164970002:-
STAD	cis	rs2281636	0.63	rs12355655	ENSG00000233690.1	EBAG9P1	4.65	4.82e-06	0.0026	0.28	0.24	Obesity-related traits;	chr10:99616982	chr10:99697407~99697949:-
STAD	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-4.65	4.82e-06	0.0026	-0.32	-0.24	AIDS;	chr2:105313444	chr2:105324210~105330529:+
STAD	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-4.65	4.82e-06	0.0026	-0.32	-0.24	AIDS;	chr2:105319955	chr2:105324210~105330529:+
STAD	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	4.65	4.82e-06	0.0026	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	4.65	4.82e-06	0.0026	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
STAD	cis	rs8099594	0.565	rs1943001	ENSG00000266696.1	RP11-30L3.2	4.65	4.83e-06	0.0026	0.22	0.24	Height;	chr18:49193057	chr18:49205912~49208781:+
STAD	cis	rs11846409	0.86	rs1974470	ENSG00000211970.3	IGHV4-61	4.65	4.83e-06	0.0026	0.28	0.24	Rheumatic heart disease;	chr14:106621300	chr14:106639119~106639657:-
STAD	cis	rs8099594	0.565	rs1942999	ENSG00000266696.1	RP11-30L3.2	4.65	4.83e-06	0.0026	0.22	0.24	Height;	chr18:49186458	chr18:49205912~49208781:+
STAD	cis	rs228614	0.51	rs223400	ENSG00000248971.2	KRT8P46	-4.65	4.83e-06	0.0026	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102728746~102730171:-
STAD	cis	rs2273156	1	rs12897612	ENSG00000241052.1	RP11-173D9.1	-4.65	4.83e-06	0.0026	-0.27	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:35001941	chr14:35144021~35144480:-
STAD	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-4.65	4.83e-06	0.0026	-0.25	-0.24	Height;	chr5:37053874	chr5:36666214~36725195:-
STAD	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	4.65	4.83e-06	0.0026	0.44	0.24	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
STAD	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-4.65	4.84e-06	0.00261	-0.19	-0.24	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
STAD	cis	rs3806843	0.576	rs405192	ENSG00000202111.1	VTRNA1-2	-4.64	4.84e-06	0.00261	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140945125	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.548	rs246056	ENSG00000202111.1	VTRNA1-2	-4.64	4.84e-06	0.00261	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140946015	chr5:140718925~140719013:+
STAD	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-4.64	4.84e-06	0.00261	-0.19	-0.24	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
STAD	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	4.64	4.84e-06	0.00261	0.24	0.24	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
STAD	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	4.64	4.84e-06	0.00261	0.35	0.24	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
STAD	cis	rs17630293	0.85	rs66515236	ENSG00000201649.1	RNY4P34	-4.64	4.85e-06	0.00261	-0.34	-0.24	Schizophrenia;	chr2:200326799	chr2:200373175~200373269:+
STAD	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-4.64	4.85e-06	0.00261	-0.28	-0.24	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
STAD	cis	rs9733	0.818	rs11204702	ENSG00000274963.1	Metazoa_SRP	-4.64	4.85e-06	0.00261	-0.2	-0.24	Tonsillectomy;	chr1:150691031	chr1:150568971~150569269:-
STAD	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-4.64	4.85e-06	0.00261	-0.33	-0.24	Height;	chr20:49295502	chr20:49280319~49280409:+
STAD	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	4.64	4.85e-06	0.00261	0.27	0.24	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
STAD	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	4.64	4.85e-06	0.00261	0.27	0.24	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
STAD	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	4.64	4.85e-06	0.00261	0.27	0.24	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
STAD	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-4.64	4.86e-06	0.00261	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
STAD	cis	rs1799949	1	rs16940	ENSG00000279602.1	CTD-3014M21.1	4.64	4.86e-06	0.00262	0.31	0.24	Menopause (age at onset);	chr17:43093220	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.93	rs66499067	ENSG00000279602.1	CTD-3014M21.1	4.64	4.86e-06	0.00262	0.31	0.24	Menopause (age at onset);	chr17:43096467	chr17:43360041~43361361:-
STAD	cis	rs9532580	0.656	rs2721068	ENSG00000229456.1	RLIMP1	4.64	4.86e-06	0.00262	0.22	0.24	Mean corpuscular hemoglobin;	chr13:40565575	chr13:40618738~40621348:+
STAD	cis	rs2483058	0.767	rs10779631	ENSG00000261000.1	RP11-534L20.5	4.64	4.86e-06	0.00262	0.29	0.24	Cholesterol and Triglycerides;	chr1:206448943	chr1:206503948~206504456:+
STAD	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	4.64	4.86e-06	0.00262	0.25	0.24	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
STAD	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	4.64	4.86e-06	0.00262	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
STAD	cis	rs1723838	0.609	rs1723849	ENSG00000255928.1	RP11-456I15.2	-4.64	4.87e-06	0.00262	-0.52	-0.24	Obesity-related traits;	chr11:73747980	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs1792196	ENSG00000255928.1	RP11-456I15.2	-4.64	4.87e-06	0.00262	-0.52	-0.24	Obesity-related traits;	chr11:73749981	chr11:73722349~73722694:+
STAD	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-4.64	4.87e-06	0.00262	-0.29	-0.24	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
STAD	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-4.64	4.87e-06	0.00262	-0.38	-0.24	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
STAD	cis	rs10510102	0.872	rs116521083	ENSG00000226864.1	ATE1-AS1	4.64	4.88e-06	0.00262	0.38	0.24	Breast cancer;	chr10:121950611	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.748	rs4589226	ENSG00000226864.1	ATE1-AS1	4.64	4.88e-06	0.00262	0.38	0.24	Breast cancer;	chr10:121951073	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.81	rs34738294	ENSG00000226864.1	ATE1-AS1	4.64	4.88e-06	0.00262	0.38	0.24	Breast cancer;	chr10:121951357	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12258234	ENSG00000226864.1	ATE1-AS1	4.64	4.88e-06	0.00262	0.38	0.24	Breast cancer;	chr10:121952828	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.515	rs11200285	ENSG00000226864.1	ATE1-AS1	4.64	4.88e-06	0.00262	0.38	0.24	Breast cancer;	chr10:121953931	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs75831447	ENSG00000226864.1	ATE1-AS1	4.64	4.88e-06	0.00262	0.38	0.24	Breast cancer;	chr10:121953963	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.63	rs79960726	ENSG00000226864.1	ATE1-AS1	4.64	4.88e-06	0.00262	0.38	0.24	Breast cancer;	chr10:121954358	chr10:121928312~121951965:+
STAD	cis	rs748404	0.697	rs564946	ENSG00000275601.1	AC011330.13	-4.64	4.88e-06	0.00262	-0.25	-0.24	Lung cancer;	chr15:43264074	chr15:43642389~43643023:-
STAD	cis	rs1707322	0.717	rs1135812	ENSG00000225447.1	RPS15AP10	4.64	4.88e-06	0.00262	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45645816~45646197:-
STAD	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-4.64	4.88e-06	0.00263	-0.38	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
STAD	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-4.64	4.89e-06	0.00263	-0.28	-0.24	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
STAD	cis	rs6430585	0.528	rs309151	ENSG00000231890.6	DARS-AS1	-4.64	4.89e-06	0.00263	-0.27	-0.24	Corneal structure;	chr2:135903580	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs309167	ENSG00000231890.6	DARS-AS1	-4.64	4.89e-06	0.00263	-0.27	-0.24	Corneal structure;	chr2:135911694	chr2:135985176~136022593:+
STAD	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-4.64	4.89e-06	0.00263	-0.28	-0.24	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
STAD	cis	rs8028182	0.636	rs62027181	ENSG00000260269.4	CTD-2323K18.1	-4.64	4.89e-06	0.00263	-0.31	-0.24	Sudden cardiac arrest;	chr15:75547611	chr15:75527150~75601205:-
STAD	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	4.64	4.89e-06	0.00263	0.27	0.24	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
STAD	cis	rs4589258	0.933	rs61905335	ENSG00000280367.1	RP11-121L10.2	-4.64	4.9e-06	0.00263	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90676795	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs34264659	ENSG00000280367.1	RP11-121L10.2	-4.64	4.9e-06	0.00263	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90677251	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs7952184	ENSG00000280367.1	RP11-121L10.2	-4.64	4.9e-06	0.00263	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90677405	chr11:90223153~90226538:+
STAD	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	4.64	4.9e-06	0.00263	0.32	0.24	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
STAD	cis	rs7829975	0.51	rs2921073	ENSG00000253981.4	ALG1L13P	4.64	4.9e-06	0.00263	0.3	0.24	Mood instability;	chr8:8450133	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.51	rs2979160	ENSG00000253981.4	ALG1L13P	4.64	4.9e-06	0.00263	0.3	0.24	Mood instability;	chr8:8450156	chr8:8236003~8244667:-
STAD	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	4.64	4.91e-06	0.00264	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
STAD	cis	rs891378	1	rs1507760	ENSG00000274245.1	RP11-357P18.2	4.64	4.91e-06	0.00264	0.3	0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207336020	chr1:207372559~207373252:+
STAD	cis	rs67079557	1	rs67079557	ENSG00000260269.4	CTD-2323K18.1	-4.64	4.91e-06	0.00264	-0.32	-0.24	Breast cancer;	chr15:75637966	chr15:75527150~75601205:-
STAD	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	4.64	4.91e-06	0.00264	0.24	0.24	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
STAD	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-4.64	4.92e-06	0.00264	-0.32	-0.24	Height;	chr20:49278705	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-4.64	4.92e-06	0.00264	-0.32	-0.24	Height;	chr20:49287143	chr20:49280319~49280409:+
STAD	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-4.64	4.92e-06	0.00264	-0.23	-0.24	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
STAD	cis	rs4589258	0.933	rs4753294	ENSG00000280367.1	RP11-121L10.2	-4.64	4.92e-06	0.00264	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90675984	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs34226552	ENSG00000280367.1	RP11-121L10.2	-4.64	4.92e-06	0.00264	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90676187	chr11:90223153~90226538:+
STAD	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	4.64	4.92e-06	0.00265	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
STAD	cis	rs5769707	0.542	rs739242	ENSG00000280224.1	CTA-722E9.1	-4.64	4.93e-06	0.00265	-0.28	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49500568~49501585:+
STAD	cis	rs4713118	0.738	rs200465	ENSG00000280107.1	AL022393.9	-4.64	4.93e-06	0.00265	-0.33	-0.24	Parkinson's disease;	chr6:27789875	chr6:28170845~28172521:+
STAD	cis	rs10510102	0.935	rs11200260	ENSG00000226864.1	ATE1-AS1	4.64	4.93e-06	0.00265	0.38	0.24	Breast cancer;	chr10:121920169	chr10:121928312~121951965:+
STAD	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	4.64	4.93e-06	0.00265	0.25	0.24	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	4.64	4.93e-06	0.00265	0.25	0.24	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
STAD	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	4.64	4.93e-06	0.00265	0.25	0.24	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
STAD	cis	rs9463078	0.625	rs500773	ENSG00000219384.1	RP11-491H9.3	4.64	4.93e-06	0.00265	0.23	0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44920727	chr6:45158870~45159511:+
STAD	cis	rs1799949	0.965	rs8176193	ENSG00000279602.1	CTD-3014M21.1	4.64	4.93e-06	0.00265	0.3	0.24	Menopause (age at onset);	chr17:43079499	chr17:43360041~43361361:-
STAD	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	4.64	4.94e-06	0.00265	0.29	0.24	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
STAD	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	4.64	4.94e-06	0.00265	0.48	0.24	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
STAD	cis	rs228614	0.51	rs65671	ENSG00000248971.2	KRT8P46	-4.64	4.94e-06	0.00265	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102728746~102730171:-
STAD	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	4.64	4.94e-06	0.00265	0.28	0.24	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
STAD	cis	rs9813712	0.597	rs1453255	ENSG00000253540.4	FAM86HP	-4.64	4.95e-06	0.00266	-0.26	-0.24	Response to amphetamines;	chr3:130258815	chr3:130099092~130111472:-
STAD	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-4.64	4.95e-06	0.00266	-0.3	-0.24	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
STAD	cis	rs7665090	1	rs2866413	ENSG00000230069.3	LRRC37A15P	-4.64	4.95e-06	0.00266	-0.26	-0.24	Primary biliary cholangitis;	chr4:102635920	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs4547797	ENSG00000230069.3	LRRC37A15P	-4.64	4.95e-06	0.00266	-0.26	-0.24	Primary biliary cholangitis;	chr4:102636035	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs2866414	ENSG00000230069.3	LRRC37A15P	-4.64	4.95e-06	0.00266	-0.26	-0.24	Primary biliary cholangitis;	chr4:102636062	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs9996834	ENSG00000230069.3	LRRC37A15P	-4.64	4.95e-06	0.00266	-0.26	-0.24	Primary biliary cholangitis;	chr4:102636372	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs11727546	ENSG00000230069.3	LRRC37A15P	-4.64	4.95e-06	0.00266	-0.26	-0.24	Primary biliary cholangitis;	chr4:102636507	chr4:102727274~102730721:-
STAD	cis	rs7615952	0.546	rs11711150	ENSG00000272840.1	RP11-379B18.6	4.64	4.95e-06	0.00266	0.43	0.24	Blood pressure (smoking interaction);	chr3:125596819	chr3:125774714~125797953:+
STAD	cis	rs1005277	0.579	rs1780133	ENSG00000276805.1	RP11-291L22.6	4.64	4.96e-06	0.00266	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1780136	ENSG00000276805.1	RP11-291L22.6	4.64	4.96e-06	0.00266	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1780138	ENSG00000276805.1	RP11-291L22.6	4.64	4.96e-06	0.00266	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1780139	ENSG00000276805.1	RP11-291L22.6	4.64	4.96e-06	0.00266	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.602	rs1780141	ENSG00000276805.1	RP11-291L22.6	4.64	4.96e-06	0.00266	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38451030~38451785:+
STAD	cis	rs2117029	0.767	rs11168838	ENSG00000258017.1	RP11-386G11.10	-4.64	4.96e-06	0.00266	-0.25	-0.24	Intelligence (multi-trait analysis);	chr12:49061223	chr12:49127782~49147869:+
STAD	cis	rs7829975	0.711	rs1039916	ENSG00000253981.4	ALG1L13P	4.64	4.96e-06	0.00266	0.29	0.24	Mood instability;	chr8:8828344	chr8:8236003~8244667:-
STAD	cis	rs5769707	0.521	rs7285764	ENSG00000280224.1	CTA-722E9.1	-4.64	4.97e-06	0.00267	-0.28	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.521	rs9616715	ENSG00000280224.1	CTA-722E9.1	-4.64	4.97e-06	0.00267	-0.28	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.521	rs6009805	ENSG00000280224.1	CTA-722E9.1	-4.64	4.97e-06	0.00267	-0.28	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.521	rs6009807	ENSG00000280224.1	CTA-722E9.1	-4.64	4.97e-06	0.00267	-0.28	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49500568~49501585:+
STAD	cis	rs875971	1	rs11974219	ENSG00000236529.1	RP13-254B10.1	-4.64	4.98e-06	0.00267	-0.26	-0.24	Aortic root size;	chr7:66182423	chr7:65840212~65840596:+
STAD	cis	rs7429990	0.965	rs11130154	ENSG00000224895.1	VPS26BP1	4.64	4.98e-06	0.00267	0.24	0.24	Educational attainment (years of education);	chr3:48027752	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.813	rs7637622	ENSG00000224895.1	VPS26BP1	4.64	4.98e-06	0.00267	0.24	0.24	Educational attainment (years of education);	chr3:48051561	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs7627645	ENSG00000224895.1	VPS26BP1	4.64	4.98e-06	0.00267	0.24	0.24	Educational attainment (years of education);	chr3:48051643	chr3:47960327~47961081:-
STAD	cis	rs831571	0.653	rs73120967	ENSG00000280620.1	SCAANT1	4.64	4.98e-06	0.00267	0.36	0.24	Type 2 diabetes;	chr3:64084696	chr3:63911518~63911772:-
STAD	cis	rs9291683	0.679	rs2241483	ENSG00000250613.1	RP11-136I13.1	4.64	4.98e-06	0.00267	0.23	0.24	Bone mineral density;	chr4:10098207	chr4:10410996~10411644:+
STAD	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-4.64	4.98e-06	0.00267	-0.29	-0.24	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
STAD	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-4.64	4.98e-06	0.00267	-0.32	-0.24	Height;	chr20:49262572	chr20:49280319~49280409:+
STAD	cis	rs13113518	0.595	rs13120635	ENSG00000272969.1	RP11-528I4.2	4.64	4.98e-06	0.00267	0.32	0.24	Height;	chr4:55361200	chr4:55547112~55547889:+
STAD	cis	rs748404	0.66	rs509306	ENSG00000275601.1	AC011330.13	-4.64	4.99e-06	0.00267	-0.25	-0.24	Lung cancer;	chr15:43422973	chr15:43642389~43643023:-
STAD	cis	rs875971	1	rs11974264	ENSG00000236529.1	RP13-254B10.1	-4.64	4.99e-06	0.00268	-0.26	-0.24	Aortic root size;	chr7:66182595	chr7:65840212~65840596:+
STAD	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	4.64	4.99e-06	0.00268	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
STAD	cis	rs1707322	0.752	rs11211145	ENSG00000225447.1	RPS15AP10	4.64	5e-06	0.00268	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45645816~45646197:-
STAD	cis	rs1799949	0.832	rs2070835	ENSG00000236383.6	LINC00854	-4.64	5e-06	0.00268	-0.2	-0.24	Menopause (age at onset);	chr17:43022008	chr17:43216941~43305976:-
STAD	cis	rs875971	1	rs1540651	ENSG00000236529.1	RP13-254B10.1	-4.64	5e-06	0.00268	-0.26	-0.24	Aortic root size;	chr7:66185134	chr7:65840212~65840596:+
STAD	cis	rs6832769	0.925	rs1965467	ENSG00000272969.1	RP11-528I4.2	4.64	5e-06	0.00268	0.31	0.24	Personality dimensions;	chr4:55456573	chr4:55547112~55547889:+
STAD	cis	rs9902453	0.765	rs2628167	ENSG00000240074.1	RPL9P30	-4.64	5e-06	0.00268	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29737480	chr17:29855759~29856332:+
STAD	cis	rs9307551	1	rs13104009	ENSG00000250334.4	LINC00989	-4.64	5.01e-06	0.00269	-0.31	-0.24	Refractive error;	chr4:79609584	chr4:79492416~79576460:+
STAD	cis	rs516805	0.683	rs502071	ENSG00000279453.1	RP3-425C14.4	-4.64	5.01e-06	0.00269	-0.37	-0.24	Lymphocyte counts;	chr6:122417917	chr6:122436789~122439223:-
STAD	cis	rs453301	0.653	rs7016139	ENSG00000233609.3	RP11-62H7.2	-4.64	5.01e-06	0.00269	-0.28	-0.24	Joint mobility (Beighton score);	chr8:9037960	chr8:8961200~8979025:+
STAD	cis	rs4243830	0.85	rs3761927	ENSG00000229519.2	RP11-58A11.2	4.64	5.01e-06	0.00269	0.26	0.24	Body mass index;	chr1:6541713	chr1:6547905~6548619:+
STAD	cis	rs12468226	0.938	rs12463937	ENSG00000226261.1	AC064836.3	4.64	5.01e-06	0.00269	0.39	0.24	Urate levels;	chr2:202246543	chr2:202336024~202336727:-
STAD	cis	rs8141529	0.644	rs5752795	ENSG00000272858.1	CTA-292E10.8	-4.64	5.02e-06	0.00269	-0.26	-0.24	Lymphocyte counts;	chr22:28782832	chr22:28814914~28815662:+
STAD	cis	rs8141529	0.732	rs2347447	ENSG00000272858.1	CTA-292E10.8	-4.64	5.02e-06	0.00269	-0.26	-0.24	Lymphocyte counts;	chr22:28783751	chr22:28814914~28815662:+
STAD	cis	rs8141529	0.732	rs5752798	ENSG00000272858.1	CTA-292E10.8	-4.64	5.02e-06	0.00269	-0.26	-0.24	Lymphocyte counts;	chr22:28785880	chr22:28814914~28815662:+
STAD	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-4.64	5.02e-06	0.00269	-0.28	-0.24	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
STAD	cis	rs7665090	1	rs12498722	ENSG00000230069.3	LRRC37A15P	-4.64	5.02e-06	0.00269	-0.26	-0.24	Primary biliary cholangitis;	chr4:102633365	chr4:102727274~102730721:-
STAD	cis	rs1005277	0.541	rs1740741	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.528	rs2057228	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1740742	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.602	rs1740743	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1740745	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1740747	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1740749	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1780115	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.529	rs1780125	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2800485	ENSG00000276805.1	RP11-291L22.6	4.64	5.02e-06	0.00269	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38451030~38451785:+
STAD	cis	rs17818399	0.962	rs2122715	ENSG00000279254.1	RP11-536C12.1	-4.64	5.02e-06	0.00269	-0.26	-0.24	Height;	chr2:46618710	chr2:46668870~46670778:+
STAD	cis	rs11098499	0.954	rs1480931	ENSG00000260091.1	RP11-33B1.4	4.64	5.02e-06	0.00269	0.24	0.24	Corneal astigmatism;	chr4:119474654	chr4:119409333~119410233:+
STAD	cis	rs7615952	0.611	rs2971298	ENSG00000239804.1	RP11-379B18.1	4.64	5.02e-06	0.00269	0.44	0.24	Blood pressure (smoking interaction);	chr3:125883870	chr3:125787888~125788146:-
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000224373.3	IGHV4-59	4.64	5.02e-06	0.00269	0.17	0.24	Kawasaki disease;	chr14:106807047	chr14:106627249~106627825:-
STAD	cis	rs748404	0.666	rs34178146	ENSG00000249839.1	AC011330.5	-4.64	5.03e-06	0.00269	-0.43	-0.24	Lung cancer;	chr15:43384406	chr15:43663654~43684339:-
STAD	cis	rs9467773	0.62	rs2451741	ENSG00000243307.2	POM121L6P	4.64	5.03e-06	0.00269	0.24	0.24	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26896952~26898777:+
STAD	cis	rs1799949	1	rs11653231	ENSG00000279602.1	CTD-3014M21.1	4.64	5.03e-06	0.0027	0.3	0.24	Menopause (age at onset);	chr17:43179443	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs1399323	ENSG00000279602.1	CTD-3014M21.1	4.64	5.03e-06	0.0027	0.3	0.24	Menopause (age at onset);	chr17:43180313	chr17:43360041~43361361:-
STAD	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	4.64	5.04e-06	0.0027	0.28	0.24	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
STAD	cis	rs11168351	0.927	rs7971880	ENSG00000258273.1	RP11-370I10.4	-4.64	5.04e-06	0.0027	-0.3	-0.24	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48333755~48333901:-
STAD	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	4.64	5.05e-06	0.0027	0.34	0.24	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
STAD	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	4.64	5.05e-06	0.0027	0.34	0.24	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
STAD	cis	rs507080	0.807	rs7926944	ENSG00000278376.1	RP11-158I9.8	-4.64	5.05e-06	0.0027	-0.25	-0.24	Serum metabolite levels;	chr11:118689119	chr11:118791254~118793137:+
STAD	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	4.64	5.05e-06	0.0027	0.34	0.24	Depression;	chr6:28407125	chr6:28943877~28944537:+
STAD	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-4.64	5.06e-06	0.00271	-0.3	-0.24	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
STAD	cis	rs181553	0.664	rs4567802	ENSG00000266696.1	RP11-30L3.2	4.64	5.06e-06	0.00271	0.22	0.24	Hip circumference adjusted for BMI;	chr18:49170994	chr18:49205912~49208781:+
STAD	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-4.64	5.06e-06	0.00271	-0.28	-0.24	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
STAD	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-4.63	5.07e-06	0.00271	-0.3	-0.24	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
STAD	cis	rs891378	1	rs6662070	ENSG00000274245.1	RP11-357P18.2	-4.63	5.07e-06	0.00271	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207332364	chr1:207372559~207373252:+
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-4.63	5.07e-06	0.00272	-0.19	-0.24	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
STAD	cis	rs6832769	0.961	rs11133382	ENSG00000272969.1	RP11-528I4.2	4.63	5.07e-06	0.00272	0.31	0.24	Personality dimensions;	chr4:55450813	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs2412646	ENSG00000272969.1	RP11-528I4.2	4.63	5.07e-06	0.00272	0.31	0.24	Personality dimensions;	chr4:55452605	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs11733864	ENSG00000272969.1	RP11-528I4.2	4.63	5.07e-06	0.00272	0.31	0.24	Personality dimensions;	chr4:55455363	chr4:55547112~55547889:+
STAD	cis	rs9733	0.65	rs6698495	ENSG00000274963.1	Metazoa_SRP	-4.63	5.08e-06	0.00272	-0.2	-0.24	Tonsillectomy;	chr1:150592000	chr1:150568971~150569269:-
STAD	cis	rs875971	0.862	rs709596	ENSG00000236529.1	RP13-254B10.1	4.63	5.08e-06	0.00272	0.25	0.24	Aortic root size;	chr7:66360926	chr7:65840212~65840596:+
STAD	cis	rs8141529	0.509	rs6005927	ENSG00000226471.5	CTA-292E10.6	-4.63	5.08e-06	0.00272	-0.3	-0.24	Lymphocyte counts;	chr22:28859896	chr22:28800683~28848559:+
STAD	cis	rs1005277	0.502	rs2800484	ENSG00000276805.1	RP11-291L22.6	4.63	5.08e-06	0.00272	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38451030~38451785:+
STAD	cis	rs240993	0.812	rs6937734	ENSG00000230177.1	RP5-1112D6.4	4.63	5.08e-06	0.00272	0.25	0.24	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111277932~111278742:+
STAD	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-4.63	5.08e-06	0.00272	-0.27	-0.24	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
STAD	cis	rs7120173	0.735	rs518547	ENSG00000254851.1	RP11-109L13.1	-4.63	5.09e-06	0.00272	-0.37	-0.24	Visceral adipose tissue adjusted for BMI;	chr11:116867330	chr11:117135528~117138582:+
STAD	cis	rs2638953	0.672	rs10843203	ENSG00000247934.4	RP11-967K21.1	-4.63	5.09e-06	0.00272	-0.27	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28563555	chr12:28163298~28190738:-
STAD	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-4.63	5.09e-06	0.00272	-0.32	-0.24	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
STAD	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	4.63	5.09e-06	0.00272	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
STAD	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	4.63	5.09e-06	0.00272	0.25	0.24	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
STAD	cis	rs8099594	0.64	rs1701877	ENSG00000266696.1	RP11-30L3.2	4.63	5.09e-06	0.00273	0.23	0.24	Height;	chr18:49290207	chr18:49205912~49208781:+
STAD	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-4.63	5.1e-06	0.00273	-0.37	-0.24	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
STAD	cis	rs747650	0.892	rs7111764	ENSG00000271350.1	CTD-2384B9.1	-4.63	5.1e-06	0.00273	-0.29	-0.24	Acne (severe);	chr11:47211658	chr11:47041027~47041945:-
STAD	cis	rs747650	0.892	rs2029298	ENSG00000271350.1	CTD-2384B9.1	-4.63	5.1e-06	0.00273	-0.29	-0.24	Acne (severe);	chr11:47213167	chr11:47041027~47041945:-
STAD	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	4.63	5.1e-06	0.00273	0.29	0.24	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
STAD	cis	rs8141529	0.764	rs5752807	ENSG00000272858.1	CTA-292E10.8	-4.63	5.1e-06	0.00273	-0.26	-0.24	Lymphocyte counts;	chr22:28827181	chr22:28814914~28815662:+
STAD	cis	rs891378	1	rs2802217	ENSG00000274245.1	RP11-357P18.2	-4.63	5.1e-06	0.00273	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207309625	chr1:207372559~207373252:+
STAD	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-4.63	5.11e-06	0.00273	-0.25	-0.24	Height;	chr5:37053881	chr5:36666214~36725195:-
STAD	cis	rs9807989	0.839	rs1362348	ENSG00000234389.1	AC007278.3	4.63	5.11e-06	0.00273	0.25	0.24	Asthma;	chr2:102368164	chr2:102438713~102440475:+
STAD	cis	rs1707322	0.821	rs11211182	ENSG00000225447.1	RPS15AP10	4.63	5.11e-06	0.00273	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45645816~45646197:-
STAD	cis	rs9467773	0.62	rs2101581	ENSG00000243307.2	POM121L6P	4.63	5.11e-06	0.00273	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26896952~26898777:+
STAD	cis	rs2439831	0.85	rs12442297	ENSG00000275601.1	AC011330.13	-4.63	5.11e-06	0.00273	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43876272	chr15:43642389~43643023:-
STAD	cis	rs6832769	1	rs13121235	ENSG00000272969.1	RP11-528I4.2	4.63	5.12e-06	0.00273	0.31	0.24	Personality dimensions;	chr4:55445780	chr4:55547112~55547889:+
STAD	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	4.63	5.12e-06	0.00274	0.31	0.24	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
STAD	cis	rs2337406	0.587	rs11624678	ENSG00000211972.2	IGHV3-66	-4.63	5.12e-06	0.00274	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106650408	chr14:106675017~106675544:-
STAD	cis	rs7674212	0.865	rs1481279	ENSG00000230069.3	LRRC37A15P	4.63	5.12e-06	0.00274	0.28	0.24	Type 2 diabetes;	chr4:103056781	chr4:102727274~102730721:-
STAD	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-4.63	5.12e-06	0.00274	-0.23	-0.24	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
STAD	cis	rs2117029	0.782	rs11168850	ENSG00000258017.1	RP11-386G11.10	-4.63	5.12e-06	0.00274	-0.24	-0.24	Intelligence (multi-trait analysis);	chr12:49079182	chr12:49127782~49147869:+
STAD	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	4.63	5.13e-06	0.00274	0.27	0.24	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
STAD	cis	rs9860428	0.815	rs9865066	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112858647	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs10934196	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112861497	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs10154832	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112862041	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.76	rs9816107	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112863436	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.733	rs9816110	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112863437	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs6782188	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112864592	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs9878597	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866101	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs2895401	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112867783	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.844	rs57371910	ENSG00000240057.4	RP11-572M11.4	-4.63	5.13e-06	0.00274	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112869960	chr3:113019532~113183301:+
STAD	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	4.63	5.13e-06	0.00274	0.42	0.24	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	4.63	5.13e-06	0.00274	0.42	0.24	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	4.63	5.13e-06	0.00274	0.42	0.24	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	4.63	5.13e-06	0.00274	0.42	0.24	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	4.63	5.13e-06	0.00274	0.42	0.24	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	4.63	5.13e-06	0.00274	0.42	0.24	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	4.63	5.13e-06	0.00274	0.42	0.24	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
STAD	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-4.63	5.13e-06	0.00274	-0.32	-0.24	AIDS;	chr2:105333211	chr2:105324210~105330529:+
STAD	cis	rs2980439	0.607	rs2980419	ENSG00000254340.1	RP11-10A14.3	4.63	5.13e-06	0.00274	0.29	0.24	Neuroticism;	chr8:8256619	chr8:9141424~9145435:+
STAD	cis	rs9425766	0.566	rs4447042	ENSG00000227373.4	RP11-160H22.5	4.63	5.13e-06	0.00274	0.3	0.24	Life satisfaction;	chr1:174212747	chr1:174115300~174160004:-
STAD	cis	rs9467773	0.523	rs2498399	ENSG00000243307.2	POM121L6P	4.63	5.13e-06	0.00274	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26896952~26898777:+
STAD	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	4.63	5.14e-06	0.00275	0.27	0.24	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
STAD	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	4.63	5.14e-06	0.00275	0.34	0.24	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
STAD	cis	rs4589258	0.933	rs1783808	ENSG00000280367.1	RP11-121L10.2	-4.63	5.14e-06	0.00275	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90703637	chr11:90223153~90226538:+
STAD	cis	rs2933343	0.729	rs1683816	ENSG00000231305.3	RP11-723O4.2	-4.63	5.14e-06	0.00275	-0.26	-0.24	IgG glycosylation;	chr3:128932352	chr3:128861313~128871540:-
STAD	cis	rs8014252	0.803	rs7145530	ENSG00000259158.2	ADAM20P1	-4.63	5.15e-06	0.00275	-0.33	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70569793	chr14:70468881~70483756:-
STAD	cis	rs1167827	0.68	rs1167796	ENSG00000165178.9	NCF1C	-4.63	5.15e-06	0.00275	-0.18	-0.24	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75156639~75172044:-
STAD	cis	rs11098499	0.954	rs878373	ENSG00000260091.1	RP11-33B1.4	4.63	5.15e-06	0.00275	0.24	0.24	Corneal astigmatism;	chr4:119316329	chr4:119409333~119410233:+
STAD	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	4.63	5.15e-06	0.00275	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	4.63	5.15e-06	0.00275	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	4.63	5.15e-06	0.00275	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
STAD	cis	rs1007190	0.57	rs8064954	ENSG00000267405.1	CTC-296K1.4	-4.63	5.15e-06	0.00275	-0.3	-0.24	DNA methylation (variation);	chr17:44790075	chr17:44794747~44797783:-
STAD	cis	rs7191700	0.511	rs8058983	ENSG00000262703.1	RP11-485G7.6	-4.63	5.15e-06	0.00275	-0.23	-0.24	Multiple sclerosis;	chr16:11266992	chr16:11348143~11349321:-
STAD	cis	rs11846409	0.86	rs74091720	ENSG00000211972.2	IGHV3-66	4.63	5.15e-06	0.00275	0.25	0.24	Rheumatic heart disease;	chr14:106638192	chr14:106675017~106675544:-
STAD	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	4.63	5.16e-06	0.00275	0.26	0.24	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
STAD	cis	rs10129255	0.5	rs1024350	ENSG00000211973.2	IGHV1-69	4.63	5.16e-06	0.00275	0.2	0.24	Kawasaki disease;	chr14:106685105	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.518	rs7143784	ENSG00000211973.2	IGHV1-69	4.63	5.16e-06	0.00275	0.2	0.24	Kawasaki disease;	chr14:106687277	chr14:106714684~106715181:-
STAD	cis	rs11676348	0.967	rs4674258	ENSG00000237281.1	CATIP-AS2	4.63	5.16e-06	0.00275	0.24	0.24	Ulcerative colitis;	chr2:218125863	chr2:218326889~218357966:-
STAD	cis	rs6832769	0.961	rs3736545	ENSG00000272969.1	RP11-528I4.2	4.63	5.16e-06	0.00276	0.3	0.24	Personality dimensions;	chr4:55444176	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs12643926	ENSG00000272969.1	RP11-528I4.2	4.63	5.16e-06	0.00276	0.3	0.24	Personality dimensions;	chr4:55444454	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs12647034	ENSG00000272969.1	RP11-528I4.2	4.63	5.16e-06	0.00276	0.3	0.24	Personality dimensions;	chr4:55444455	chr4:55547112~55547889:+
STAD	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-4.63	5.16e-06	0.00276	-0.35	-0.24	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
STAD	cis	rs9733	0.65	rs11204668	ENSG00000274963.1	Metazoa_SRP	-4.63	5.17e-06	0.00276	-0.2	-0.24	Tonsillectomy;	chr1:150571210	chr1:150568971~150569269:-
STAD	cis	rs9733	0.65	rs12406712	ENSG00000274963.1	Metazoa_SRP	-4.63	5.17e-06	0.00276	-0.2	-0.24	Tonsillectomy;	chr1:150572608	chr1:150568971~150569269:-
STAD	cis	rs6714710	0.58	rs6711101	ENSG00000235833.1	AC159540.14	-4.63	5.17e-06	0.00276	-0.27	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97763350	chr2:97523949~97524976:-
STAD	cis	rs2380205	0.58	rs907687	ENSG00000232807.2	RP11-536K7.3	-4.63	5.17e-06	0.00276	-0.24	-0.24	Breast cancer;	chr10:5858799	chr10:5934270~5945900:-
STAD	cis	rs8028182	0.636	rs12708520	ENSG00000260269.4	CTD-2323K18.1	-4.63	5.17e-06	0.00276	-0.31	-0.24	Sudden cardiac arrest;	chr15:75538198	chr15:75527150~75601205:-
STAD	cis	rs3733585	0.631	rs4697924	ENSG00000250613.1	RP11-136I13.1	4.63	5.17e-06	0.00276	0.25	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10122615	chr4:10410996~10411644:+
STAD	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	4.63	5.18e-06	0.00277	0.37	0.24	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
STAD	cis	rs6714710	0.603	rs35255677	ENSG00000235833.1	AC159540.14	-4.63	5.18e-06	0.00277	-0.28	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97951357	chr2:97523949~97524976:-
STAD	cis	rs7924176	0.521	rs7098200	ENSG00000213731.2	RAB5CP1	4.63	5.19e-06	0.00277	0.25	0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74423435~74424014:-
STAD	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	4.63	5.19e-06	0.00277	0.3	0.24	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
STAD	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	4.63	5.19e-06	0.00277	0.3	0.24	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
STAD	cis	rs6921919	0.583	rs2071965	ENSG00000220721.1	OR1F12	4.63	5.19e-06	0.00277	0.25	0.24	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28073316~28074233:+
STAD	cis	rs6832769	0.961	rs6817663	ENSG00000272969.1	RP11-528I4.2	-4.63	5.19e-06	0.00277	-0.31	-0.24	Personality dimensions;	chr4:55581048	chr4:55547112~55547889:+
STAD	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	4.63	5.19e-06	0.00277	0.26	0.24	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
STAD	cis	rs9467773	0.62	rs2451731	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs9295701	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2494700	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.584	rs1021372	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.583	rs1021373	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2451744	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2494701	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs1027204	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2504592	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2504599	ENSG00000243307.2	POM121L6P	4.63	5.19e-06	0.00277	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26896952~26898777:+
STAD	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-4.63	5.2e-06	0.00277	-0.3	-0.24	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
STAD	cis	rs10510102	0.935	rs11200201	ENSG00000226864.1	ATE1-AS1	4.63	5.2e-06	0.00277	0.38	0.24	Breast cancer;	chr10:121864790	chr10:121928312~121951965:+
STAD	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-4.63	5.2e-06	0.00277	-0.21	-0.24	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-4.63	5.2e-06	0.00277	-0.19	-0.24	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
STAD	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-4.63	5.2e-06	0.00278	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
STAD	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	4.63	5.21e-06	0.00278	0.3	0.24	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
STAD	cis	rs801193	0.66	rs2659897	ENSG00000236529.1	RP13-254B10.1	-4.63	5.21e-06	0.00278	-0.25	-0.24	Aortic root size;	chr7:66722728	chr7:65840212~65840596:+
STAD	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	-4.63	5.21e-06	0.00278	-0.27	-0.24	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
STAD	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	4.63	5.22e-06	0.00278	0.24	0.24	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
STAD	cis	rs3736858	1	rs2296093	ENSG00000261105.4	LMO7-AS1	-4.63	5.22e-06	0.00278	-0.41	-0.24	Interleukin-9 levels;	chr13:75856325	chr13:75604700~75635994:-
STAD	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	4.63	5.22e-06	0.00278	0.41	0.24	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
STAD	cis	rs8097348	0.817	rs1159375	ENSG00000266602.1	RP11-476K15.1	-4.63	5.22e-06	0.00278	-0.28	-0.24	Exercise (leisure time);	chr18:1653197	chr18:1509183~1647097:+
STAD	cis	rs6142102	1	rs12480839	ENSG00000275784.1	RP5-1125A11.6	-4.63	5.22e-06	0.00278	-0.25	-0.24	Skin pigmentation;	chr20:34139624	chr20:33989480~33991818:-
STAD	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	4.63	5.22e-06	0.00278	0.25	0.24	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
STAD	cis	rs2836950	0.545	rs11701805	ENSG00000238141.2	BRWD1-AS1	-4.63	5.22e-06	0.00278	-0.25	-0.24	Menarche (age at onset);	chr21:39246757	chr21:39315707~39323218:+
STAD	cis	rs750460	0.816	rs4886778	ENSG00000261801.4	LOXL1-AS1	4.63	5.22e-06	0.00278	0.29	0.24	Height;	chr15:73933047	chr15:73908071~73928248:-
STAD	cis	rs750460	0.844	rs8027022	ENSG00000261801.4	LOXL1-AS1	4.63	5.22e-06	0.00278	0.29	0.24	Height;	chr15:73933797	chr15:73908071~73928248:-
STAD	cis	rs750460	0.844	rs2028386	ENSG00000261801.4	LOXL1-AS1	4.63	5.22e-06	0.00278	0.29	0.24	Height;	chr15:73934367	chr15:73908071~73928248:-
STAD	cis	rs750460	0.816	rs4337252	ENSG00000261801.4	LOXL1-AS1	4.63	5.22e-06	0.00278	0.29	0.24	Height;	chr15:73934424	chr15:73908071~73928248:-
STAD	cis	rs7191700	0.644	rs12149160	ENSG00000262703.1	RP11-485G7.6	-4.63	5.23e-06	0.00279	-0.23	-0.24	Multiple sclerosis;	chr16:11345446	chr16:11348143~11349321:-
STAD	cis	rs9902453	0.704	rs2628179	ENSG00000240074.1	RPL9P30	-4.63	5.23e-06	0.00279	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29744778	chr17:29855759~29856332:+
STAD	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-4.63	5.23e-06	0.00279	-0.36	-0.24	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
STAD	cis	rs228614	0.51	rs223392	ENSG00000248971.2	KRT8P46	-4.63	5.23e-06	0.00279	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223390	ENSG00000248971.2	KRT8P46	-4.63	5.23e-06	0.00279	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102728746~102730171:-
STAD	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	4.63	5.23e-06	0.00279	0.3	0.24	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
STAD	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-4.63	5.23e-06	0.00279	-0.33	-0.24	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
STAD	cis	rs2638953	0.924	rs11049416	ENSG00000247934.4	RP11-967K21.1	4.63	5.24e-06	0.00279	0.27	0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28163298~28190738:-
STAD	cis	rs9902453	0.619	rs2255489	ENSG00000240074.1	RPL9P30	-4.63	5.24e-06	0.00279	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29757956	chr17:29855759~29856332:+
STAD	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	4.63	5.24e-06	0.00279	0.49	0.24	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
STAD	cis	rs801193	0.569	rs13226966	ENSG00000224316.1	RP11-479O9.2	4.63	5.25e-06	0.00279	0.23	0.24	Aortic root size;	chr7:66768636	chr7:65773620~65802067:+
STAD	cis	rs721917	0.506	rs2758558	ENSG00000244733.5	RP11-506M13.3	-4.63	5.25e-06	0.0028	-0.3	-0.24	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79660891~79677996:+
STAD	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	4.63	5.25e-06	0.0028	0.3	0.24	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
STAD	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	4.63	5.25e-06	0.0028	0.27	0.24	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
STAD	cis	rs7429990	0.864	rs1464614	ENSG00000224895.1	VPS26BP1	-4.63	5.25e-06	0.0028	-0.22	-0.24	Educational attainment (years of education);	chr3:47612885	chr3:47960327~47961081:-
STAD	cis	rs6832769	0.89	rs1522107	ENSG00000272969.1	RP11-528I4.2	4.63	5.25e-06	0.0028	0.31	0.24	Personality dimensions;	chr4:55514606	chr4:55547112~55547889:+
STAD	cis	rs7615952	0.673	rs35955861	ENSG00000272840.1	RP11-379B18.6	4.63	5.25e-06	0.0028	0.49	0.24	Blood pressure (smoking interaction);	chr3:125907358	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.673	rs35001498	ENSG00000272840.1	RP11-379B18.6	4.63	5.25e-06	0.0028	0.49	0.24	Blood pressure (smoking interaction);	chr3:125909801	chr3:125774714~125797953:+
STAD	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-4.63	5.25e-06	0.0028	-0.29	-0.24	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
STAD	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-4.63	5.26e-06	0.0028	-0.31	-0.24	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
STAD	cis	rs4237845	0.611	rs7298370	ENSG00000273805.1	RP11-620J15.4	-4.63	5.26e-06	0.0028	-0.28	-0.24	Intelligence (multi-trait analysis);	chr12:57925114	chr12:57894232~57896846:+
STAD	cis	rs3858145	0.588	rs10998059	ENSG00000233590.1	RP11-153K11.3	4.63	5.26e-06	0.0028	0.29	0.24	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68302750	chr10:68233251~68242379:-
STAD	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	4.63	5.26e-06	0.0028	0.28	0.24	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
STAD	cis	rs9910055	1	rs2071167	ENSG00000260793.2	RP5-882C2.2	4.63	5.26e-06	0.0028	0.27	0.24	Total body bone mineral density;	chr17:44210151	chr17:44221401~44223710:+
STAD	cis	rs12906542	0.516	rs76398134	ENSG00000259792.1	RP11-114H24.6	-4.63	5.26e-06	0.0028	-0.43	-0.24	Breast cancer;	chr15:77996385	chr15:77993405~77995289:+
STAD	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	4.63	5.26e-06	0.0028	0.37	0.24	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
STAD	cis	rs17401966	0.838	rs946502	ENSG00000199562.1	RNU6-37P	4.63	5.26e-06	0.0028	0.19	0.24	Hepatocellular carcinoma;	chr1:10249221	chr1:10298966~10299072:+
STAD	cis	rs9368481	0.569	rs10946868	ENSG00000241549.7	GUSBP2	4.63	5.26e-06	0.0028	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26871484~26956554:-
STAD	cis	rs9902453	0.704	rs2617874	ENSG00000240074.1	RPL9P30	4.63	5.26e-06	0.0028	0.21	0.24	Coffee consumption (cups per day);	chr17:29758154	chr17:29855759~29856332:+
STAD	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	4.63	5.26e-06	0.0028	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
STAD	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	4.63	5.27e-06	0.0028	0.31	0.24	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	4.63	5.27e-06	0.0028	0.31	0.24	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
STAD	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-4.63	5.27e-06	0.0028	-0.26	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
STAD	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	4.63	5.27e-06	0.00281	0.35	0.24	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
STAD	cis	rs1799949	1	rs3092988	ENSG00000236383.6	LINC00854	-4.63	5.27e-06	0.00281	-0.2	-0.24	Menopause (age at onset);	chr17:43049685	chr17:43216941~43305976:-
STAD	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-4.63	5.28e-06	0.00281	-0.27	-0.24	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
STAD	cis	rs338389	0.543	rs449487	ENSG00000260657.2	RP11-315D16.4	-4.63	5.28e-06	0.00281	-0.28	-0.24	Survival in rectal cancer;	chr15:67948410	chr15:68267792~68277994:-
STAD	cis	rs11676348	0.935	rs4674250	ENSG00000237281.1	CATIP-AS2	4.63	5.28e-06	0.00281	0.24	0.24	Ulcerative colitis;	chr2:218112808	chr2:218326889~218357966:-
STAD	cis	rs8177876	0.749	rs2278024	ENSG00000261061.1	RP11-303E16.2	-4.63	5.28e-06	0.00281	-0.42	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81030770~81031485:+
STAD	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	4.63	5.28e-06	0.00281	0.32	0.24	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	4.63	5.28e-06	0.00281	0.32	0.24	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	4.63	5.28e-06	0.00281	0.32	0.24	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	4.63	5.28e-06	0.00281	0.32	0.24	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	4.63	5.28e-06	0.00281	0.32	0.24	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
STAD	cis	rs11098499	0.954	rs10006706	ENSG00000260091.1	RP11-33B1.4	4.63	5.28e-06	0.00281	0.23	0.24	Corneal astigmatism;	chr4:119487997	chr4:119409333~119410233:+
STAD	cis	rs4243830	0.85	rs4908912	ENSG00000229519.2	RP11-58A11.2	4.63	5.29e-06	0.00281	0.27	0.24	Body mass index;	chr1:6539498	chr1:6547905~6548619:+
STAD	cis	rs6584283	0.846	rs11190135	ENSG00000257582.4	LINC01475	-4.63	5.29e-06	0.00281	-0.27	-0.24	Ulcerative colitis;	chr10:99527091	chr10:99526350~99531177:-
STAD	cis	rs2836950	0.501	rs2836984	ENSG00000238141.2	BRWD1-AS1	-4.63	5.29e-06	0.00281	-0.25	-0.24	Menarche (age at onset);	chr21:39329023	chr21:39315707~39323218:+
STAD	cis	rs1799949	1	rs12944458	ENSG00000236383.6	LINC00854	-4.63	5.29e-06	0.00281	-0.2	-0.24	Menopause (age at onset);	chr17:43028755	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs72829113	ENSG00000236383.6	LINC00854	-4.63	5.29e-06	0.00281	-0.2	-0.24	Menopause (age at onset);	chr17:43029818	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs11653253	ENSG00000236383.6	LINC00854	-4.63	5.29e-06	0.00281	-0.2	-0.24	Menopause (age at onset);	chr17:43030645	chr17:43216941~43305976:-
STAD	cis	rs938554	0.577	rs4591605	ENSG00000250613.1	RP11-136I13.1	-4.63	5.29e-06	0.00281	-0.27	-0.24	Blood metabolite levels;	chr4:10001095	chr4:10410996~10411644:+
STAD	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	4.63	5.29e-06	0.00282	0.26	0.24	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
STAD	cis	rs7680126	0.596	rs12510549	ENSG00000250613.1	RP11-136I13.1	4.63	5.3e-06	0.00282	0.26	0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10274843	chr4:10410996~10411644:+
STAD	cis	rs7208859	0.623	rs8081299	ENSG00000263603.1	CTD-2349P21.5	-4.63	5.3e-06	0.00282	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs8068645	ENSG00000263603.1	CTD-2349P21.5	-4.63	5.3e-06	0.00282	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs55811708	ENSG00000263603.1	CTD-2349P21.5	-4.63	5.3e-06	0.00282	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30729469~30731202:+
STAD	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	4.62	5.3e-06	0.00282	0.38	0.24	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
STAD	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-4.62	5.3e-06	0.00282	-0.27	-0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
STAD	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-4.62	5.3e-06	0.00282	-0.27	-0.24	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
STAD	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	4.62	5.3e-06	0.00282	0.35	0.24	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
STAD	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	4.62	5.31e-06	0.00282	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
STAD	cis	rs2337406	0.866	rs7152038	ENSG00000280411.1	IGHV1-69-2	-4.62	5.31e-06	0.00282	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106778230	chr14:106762092~106762588:-
STAD	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-4.62	5.31e-06	0.00282	-0.27	-0.24	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-4.62	5.31e-06	0.00282	-0.27	-0.24	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
STAD	cis	rs7208859	0.524	rs11653605	ENSG00000263603.1	CTD-2349P21.5	-4.62	5.31e-06	0.00282	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30729469~30731202:+
STAD	cis	rs2337406	0.929	rs12050200	ENSG00000280411.1	IGHV1-69-2	-4.62	5.31e-06	0.00282	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106780983	chr14:106762092~106762588:-
STAD	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	4.62	5.31e-06	0.00282	0.3	0.24	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
STAD	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-4.62	5.31e-06	0.00282	-0.34	-0.24	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
STAD	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-4.62	5.31e-06	0.00282	-0.34	-0.24	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-4.62	5.31e-06	0.00282	-0.34	-0.24	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
STAD	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-4.62	5.31e-06	0.00282	-0.34	-0.24	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-4.62	5.31e-06	0.00282	-0.34	-0.24	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-4.62	5.31e-06	0.00282	-0.34	-0.24	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-4.62	5.31e-06	0.00282	-0.34	-0.24	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
STAD	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	4.62	5.31e-06	0.00282	0.27	0.24	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
STAD	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-4.62	5.31e-06	0.00282	-0.27	-0.24	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
STAD	cis	rs4604732	0.754	rs12080212	ENSG00000227135.1	GCSAML-AS1	-4.62	5.32e-06	0.00282	-0.31	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468304	chr1:247524679~247526752:-
STAD	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	4.62	5.32e-06	0.00282	0.42	0.24	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
STAD	cis	rs17630293	0.85	rs3820883	ENSG00000201649.1	RNY4P34	-4.62	5.32e-06	0.00283	-0.33	-0.24	Schizophrenia;	chr2:200356627	chr2:200373175~200373269:+
STAD	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	4.62	5.32e-06	0.00283	0.27	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
STAD	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-4.62	5.32e-06	0.00283	-0.32	-0.24	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
STAD	cis	rs875971	1	rs2077593	ENSG00000236529.1	RP13-254B10.1	4.62	5.32e-06	0.00283	0.25	0.24	Aortic root size;	chr7:66427543	chr7:65840212~65840596:+
STAD	cis	rs1850744	0.536	rs10014408	ENSG00000163612.10	FAM86KP	-4.62	5.33e-06	0.00283	-0.54	-0.24	Economic and political preferences;	chr4:9693521	chr4:9153296~9165451:+
STAD	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-4.62	5.33e-06	0.00283	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
STAD	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	4.62	5.33e-06	0.00283	0.36	0.24	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
STAD	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	4.62	5.33e-06	0.00283	0.36	0.24	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
STAD	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	4.62	5.33e-06	0.00283	0.36	0.24	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
STAD	cis	rs55823223	0.648	rs936393	ENSG00000267801.1	RP11-552F3.9	4.62	5.33e-06	0.00283	0.34	0.24	Psoriasis;	chr17:75851532	chr17:75876372~75879546:+
STAD	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-4.62	5.33e-06	0.00283	-0.28	-0.24	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
STAD	cis	rs9309473	0.66	rs56131703	ENSG00000163016.8	ALMS1P	4.62	5.34e-06	0.00284	0.37	0.24	Metabolite levels;	chr2:73620133	chr2:73644919~73685576:+
STAD	cis	rs1007738	0.542	rs2279438	ENSG00000271350.1	CTD-2384B9.1	-4.62	5.34e-06	0.00284	-0.31	-0.24	Bone mineral density (hip);	chr11:47182624	chr11:47041027~47041945:-
STAD	cis	rs2337406	1	rs7145100	ENSG00000211972.2	IGHV3-66	4.62	5.35e-06	0.00284	0.27	0.24	Alzheimer's disease (late onset);	chr14:106704673	chr14:106675017~106675544:-
STAD	cis	rs7429990	0.864	rs4274776	ENSG00000224895.1	VPS26BP1	-4.62	5.35e-06	0.00284	-0.23	-0.24	Educational attainment (years of education);	chr3:47605868	chr3:47960327~47961081:-
STAD	cis	rs9860428	0.844	rs6763318	ENSG00000240057.4	RP11-572M11.4	4.62	5.35e-06	0.00284	0.22	0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112848305	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.787	rs11713508	ENSG00000240057.4	RP11-572M11.4	-4.62	5.35e-06	0.00284	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112865339	chr3:113019532~113183301:+
STAD	cis	rs7665090	1	rs2866406	ENSG00000230069.3	LRRC37A15P	-4.62	5.35e-06	0.00284	-0.26	-0.24	Primary biliary cholangitis;	chr4:102632862	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs2866407	ENSG00000230069.3	LRRC37A15P	-4.62	5.35e-06	0.00284	-0.26	-0.24	Primary biliary cholangitis;	chr4:102632951	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs2866408	ENSG00000230069.3	LRRC37A15P	-4.62	5.35e-06	0.00284	-0.26	-0.24	Primary biliary cholangitis;	chr4:102632956	chr4:102727274~102730721:-
STAD	cis	rs7665090	1	rs2866409	ENSG00000230069.3	LRRC37A15P	-4.62	5.35e-06	0.00284	-0.26	-0.24	Primary biliary cholangitis;	chr4:102633104	chr4:102727274~102730721:-
STAD	cis	rs2692947	0.702	rs4907291	ENSG00000237510.6	AC008268.2	4.62	5.35e-06	0.00284	0.29	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95988857	chr2:95789654~95800166:+
STAD	cis	rs804280	0.509	rs13276433	ENSG00000254527.1	ENPP7P12	4.62	5.35e-06	0.00284	0.27	0.24	Myopia (pathological);	chr8:11925527	chr8:12205759~12206389:-
STAD	cis	rs9646944	0.501	rs13030642	ENSG00000234389.1	AC007278.3	4.62	5.35e-06	0.00284	0.32	0.24	Blood protein levels;	chr2:102475126	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs13030675	ENSG00000234389.1	AC007278.3	4.62	5.35e-06	0.00284	0.32	0.24	Blood protein levels;	chr2:102475159	chr2:102438713~102440475:+
STAD	cis	rs2579519	0.547	rs2463560	ENSG00000237510.6	AC008268.2	4.62	5.36e-06	0.00284	0.29	0.24	Diastolic blood pressure;	chr2:95929841	chr2:95789654~95800166:+
STAD	cis	rs2692947	0.695	rs12464148	ENSG00000237510.6	AC008268.2	4.62	5.36e-06	0.00284	0.29	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95930962	chr2:95789654~95800166:+
STAD	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-4.62	5.36e-06	0.00284	-0.37	-0.24	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
STAD	cis	rs228614	0.51	rs4699033	ENSG00000248971.2	KRT8P46	-4.62	5.36e-06	0.00284	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102728746~102730171:-
STAD	cis	rs3736858	0.932	rs12430940	ENSG00000261105.4	LMO7-AS1	-4.62	5.36e-06	0.00285	-0.41	-0.24	Interleukin-9 levels;	chr13:75827479	chr13:75604700~75635994:-
STAD	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	4.62	5.36e-06	0.00285	0.25	0.24	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
STAD	cis	rs7924176	0.502	rs1874151	ENSG00000213731.2	RAB5CP1	-4.62	5.37e-06	0.00285	-0.24	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74423435~74424014:-
STAD	cis	rs9463078	0.608	rs608941	ENSG00000219384.1	RP11-491H9.3	4.62	5.37e-06	0.00285	0.23	0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44921003	chr6:45158870~45159511:+
STAD	cis	rs35934224	0.891	rs73148965	ENSG00000232926.1	AC000078.5	4.62	5.37e-06	0.00285	0.39	0.24	Glaucoma (primary open-angle);	chr22:19885412	chr22:19887289~19887970:+
STAD	cis	rs507080	0.922	rs502601	ENSG00000278376.1	RP11-158I9.8	-4.62	5.38e-06	0.00285	-0.25	-0.24	Serum metabolite levels;	chr11:118694970	chr11:118791254~118793137:+
STAD	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-4.62	5.38e-06	0.00285	-0.25	-0.24	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
STAD	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-4.62	5.38e-06	0.00285	-0.25	-0.24	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
STAD	cis	rs10851478	0.529	rs12901929	ENSG00000259545.2	RP11-325E5.4	-4.62	5.38e-06	0.00286	-0.28	-0.24	Oral cavity cancer;	chr15:49383111	chr15:49177610~49178741:-
STAD	cis	rs606458	0.764	rs2073798	ENSG00000269038.1	AP001462.6	4.62	5.38e-06	0.00286	0.31	0.24	Urate levels;	chr11:64743850	chr11:64778954~64779405:+
STAD	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-4.62	5.4e-06	0.00286	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
STAD	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-4.62	5.4e-06	0.00286	-0.29	-0.24	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
STAD	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-4.62	5.4e-06	0.00286	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
STAD	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-4.62	5.41e-06	0.00287	-0.26	-0.24	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
STAD	cis	rs748404	0.66	rs690367	ENSG00000275601.1	AC011330.13	4.62	5.41e-06	0.00287	0.26	0.24	Lung cancer;	chr15:43456106	chr15:43642389~43643023:-
STAD	cis	rs7429990	0.965	rs1061003	ENSG00000224895.1	VPS26BP1	-4.62	5.41e-06	0.00287	-0.24	-0.24	Educational attainment (years of education);	chr3:47851089	chr3:47960327~47961081:-
STAD	cis	rs8141529	0.764	rs5762824	ENSG00000272858.1	CTA-292E10.8	-4.62	5.41e-06	0.00287	-0.26	-0.24	Lymphocyte counts;	chr22:28826942	chr22:28814914~28815662:+
STAD	cis	rs1150668	0.796	rs2531832	ENSG00000220721.1	OR1F12	4.62	5.41e-06	0.00287	0.24	0.24	Pubertal anthropometrics;	chr6:28421445	chr6:28073316~28074233:+
STAD	cis	rs10978777	0.921	rs817843	ENSG00000276883.1	AL137852.1	-4.62	5.42e-06	0.00288	-0.25	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107338582	chr9:107292369~107292456:-
STAD	cis	rs4713118	0.621	rs4713132	ENSG00000220721.1	OR1F12	4.62	5.43e-06	0.00288	0.29	0.24	Parkinson's disease;	chr6:28066257	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.621	rs4713133	ENSG00000220721.1	OR1F12	4.62	5.43e-06	0.00288	0.29	0.24	Parkinson's disease;	chr6:28066263	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.621	rs4713134	ENSG00000220721.1	OR1F12	4.62	5.43e-06	0.00288	0.29	0.24	Parkinson's disease;	chr6:28066343	chr6:28073316~28074233:+
STAD	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-4.62	5.43e-06	0.00288	-0.34	-0.24	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
STAD	cis	rs748404	0.697	rs471122	ENSG00000275601.1	AC011330.13	4.62	5.44e-06	0.00288	0.25	0.24	Lung cancer;	chr15:43266376	chr15:43642389~43643023:-
STAD	cis	rs11098499	0.908	rs7696649	ENSG00000260091.1	RP11-33B1.4	4.62	5.44e-06	0.00288	0.24	0.24	Corneal astigmatism;	chr4:119401022	chr4:119409333~119410233:+
STAD	cis	rs13113518	0.812	rs11945371	ENSG00000223305.1	RN7SKP30	4.62	5.44e-06	0.00288	0.27	0.24	Height;	chr4:55409063	chr4:55540502~55540835:-
STAD	cis	rs10510102	0.872	rs3750837	ENSG00000226864.1	ATE1-AS1	4.62	5.44e-06	0.00288	0.39	0.24	Breast cancer;	chr10:121899080	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs3750836	ENSG00000226864.1	ATE1-AS1	4.62	5.44e-06	0.00288	0.39	0.24	Breast cancer;	chr10:121899087	chr10:121928312~121951965:+
STAD	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	4.62	5.44e-06	0.00288	0.38	0.24	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	4.62	5.44e-06	0.00288	0.38	0.24	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
STAD	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-4.62	5.45e-06	0.00289	-0.26	-0.24	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
STAD	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	4.62	5.45e-06	0.00289	0.29	0.24	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
STAD	cis	rs10510102	0.935	rs12264495	ENSG00000226864.1	ATE1-AS1	4.62	5.45e-06	0.00289	0.39	0.24	Breast cancer;	chr10:121919967	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs11200261	ENSG00000226864.1	ATE1-AS1	4.62	5.45e-06	0.00289	0.39	0.24	Breast cancer;	chr10:121921133	chr10:121928312~121951965:+
STAD	cis	rs9646944	0.501	rs10174323	ENSG00000234389.1	AC007278.3	4.62	5.46e-06	0.00289	0.32	0.24	Blood protein levels;	chr2:102396321	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs3732127	ENSG00000234389.1	AC007278.3	4.62	5.46e-06	0.00289	0.32	0.24	Blood protein levels;	chr2:102397290	chr2:102438713~102440475:+
STAD	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	4.62	5.46e-06	0.00289	0.31	0.24	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
STAD	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	4.62	5.46e-06	0.00289	0.21	0.24	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
STAD	cis	rs4927850	0.958	rs2044599	ENSG00000242086.7	LINC00969	4.62	5.47e-06	0.0029	0.22	0.24	Pancreatic cancer;	chr3:196009869	chr3:195658062~195739964:+
STAD	cis	rs2692947	0.55	rs12623771	ENSG00000237510.6	AC008268.2	4.62	5.47e-06	0.0029	0.29	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95967756	chr2:95789654~95800166:+
STAD	cis	rs2692947	0.826	rs7423942	ENSG00000237510.6	AC008268.2	4.62	5.47e-06	0.0029	0.29	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979509	chr2:95789654~95800166:+
STAD	cis	rs2404602	0.598	rs11855999	ENSG00000196274.5	Metazoa_SRP	-4.62	5.47e-06	0.0029	-0.22	-0.24	Blood metabolite levels;	chr15:76334992	chr15:76230048~76230390:-
STAD	cis	rs1707322	0.717	rs3014246	ENSG00000225447.1	RPS15AP10	-4.62	5.47e-06	0.0029	-0.2	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45645816~45646197:-
STAD	cis	rs7487075	0.786	rs4768110	ENSG00000257261.4	RP11-96H19.1	4.62	5.47e-06	0.0029	0.29	0.24	Itch intensity from mosquito bite;	chr12:46283678	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.786	rs4768694	ENSG00000257261.4	RP11-96H19.1	4.62	5.47e-06	0.0029	0.29	0.24	Itch intensity from mosquito bite;	chr12:46283875	chr12:46383679~46876159:+
STAD	cis	rs7615952	0.932	rs13325495	ENSG00000272840.1	RP11-379B18.6	4.62	5.48e-06	0.0029	0.44	0.24	Blood pressure (smoking interaction);	chr3:125918573	chr3:125774714~125797953:+
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000211973.2	IGHV1-69	4.62	5.48e-06	0.0029	0.2	0.24	Kawasaki disease;	chr14:106776442	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000211973.2	IGHV1-69	4.62	5.48e-06	0.0029	0.2	0.24	Kawasaki disease;	chr14:106776448	chr14:106714684~106715181:-
STAD	cis	rs9368481	0.761	rs9348746	ENSG00000224843.5	LINC00240	4.62	5.48e-06	0.0029	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26956992~27023924:+
STAD	cis	rs9368481	0.761	rs9357030	ENSG00000224843.5	LINC00240	4.62	5.48e-06	0.0029	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26956992~27023924:+
STAD	cis	rs9368481	0.761	rs9379952	ENSG00000224843.5	LINC00240	4.62	5.48e-06	0.0029	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26956992~27023924:+
STAD	cis	rs8141529	0.778	rs7287806	ENSG00000272858.1	CTA-292E10.8	-4.62	5.48e-06	0.0029	-0.26	-0.24	Lymphocyte counts;	chr22:28817023	chr22:28814914~28815662:+
STAD	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-4.62	5.48e-06	0.0029	-0.25	-0.24	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
STAD	cis	rs9467773	0.62	rs2504540	ENSG00000243307.2	POM121L6P	4.62	5.48e-06	0.0029	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26896952~26898777:+
STAD	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	4.62	5.49e-06	0.0029	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
STAD	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-4.62	5.49e-06	0.0029	-0.38	-0.24	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
STAD	cis	rs3733418	0.929	rs13120990	ENSG00000248632.1	RP11-366M4.11	4.62	5.49e-06	0.0029	0.3	0.24	Obesity-related traits;	chr4:164983966	chr4:164968587~164970002:-
STAD	cis	rs3733418	0.929	rs13149062	ENSG00000248632.1	RP11-366M4.11	4.62	5.49e-06	0.0029	0.3	0.24	Obesity-related traits;	chr4:164984208	chr4:164968587~164970002:-
STAD	cis	rs7429990	0.833	rs4858801	ENSG00000224895.1	VPS26BP1	4.62	5.49e-06	0.00291	0.23	0.24	Educational attainment (years of education);	chr3:47599432	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs61620099	ENSG00000224895.1	VPS26BP1	4.62	5.49e-06	0.00291	0.23	0.24	Educational attainment (years of education);	chr3:47600755	chr3:47960327~47961081:-
STAD	cis	rs11676348	0.838	rs17844697	ENSG00000237281.1	CATIP-AS2	4.62	5.49e-06	0.00291	0.24	0.24	Ulcerative colitis;	chr2:218134532	chr2:218326889~218357966:-
STAD	cis	rs4713118	0.869	rs9461405	ENSG00000243307.2	POM121L6P	-4.62	5.49e-06	0.00291	-0.27	-0.24	Parkinson's disease;	chr6:27751596	chr6:26896952~26898777:+
STAD	cis	rs6430585	0.528	rs75667274	ENSG00000231890.6	DARS-AS1	-4.62	5.49e-06	0.00291	-0.27	-0.24	Corneal structure;	chr2:135924916	chr2:135985176~136022593:+
STAD	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	4.62	5.5e-06	0.00291	0.26	0.24	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
STAD	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-4.62	5.5e-06	0.00291	-0.26	-0.24	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
STAD	cis	rs2115536	0.73	rs4573897	ENSG00000278600.1	RP11-81A1.6	-4.62	5.5e-06	0.00291	-0.21	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79894883	chr15:79920195~79922455:-
STAD	cis	rs875971	0.545	rs2420612	ENSG00000236529.1	RP13-254B10.1	4.62	5.5e-06	0.00291	0.28	0.24	Aortic root size;	chr7:66536825	chr7:65840212~65840596:+
STAD	cis	rs1707322	1	rs6677777	ENSG00000281133.1	AL355480.3	-4.62	5.5e-06	0.00291	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45580892~45580996:-
STAD	cis	rs1426063	0.614	rs114761716	ENSG00000249717.1	RP11-44F21.3	4.62	5.5e-06	0.00291	0.5	0.24	QT interval;	chr4:75107209	chr4:74955974~74970362:-
STAD	cis	rs1598856	1	rs1598856	ENSG00000246560.2	RP11-10L12.4	4.62	5.51e-06	0.00292	0.3	0.24	Primary biliary cholangitis;	chr4:102524958	chr4:102828055~102844075:+
STAD	cis	rs7208859	0.623	rs7220289	ENSG00000263603.1	CTD-2349P21.5	-4.62	5.51e-06	0.00292	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30729469~30731202:+
STAD	cis	rs9532580	0.614	rs2180961	ENSG00000229456.1	RLIMP1	4.62	5.52e-06	0.00292	0.29	0.24	Mean corpuscular hemoglobin;	chr13:40565907	chr13:40618738~40621348:+
STAD	cis	rs7137301	0.927	rs11047940	ENSG00000274987.1	RP11-295I5.3	4.62	5.52e-06	0.00292	0.24	0.24	Dysmenorrheic pain;	chr12:25298643	chr12:25210652~25211233:+
STAD	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-4.62	5.52e-06	0.00292	-0.31	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
STAD	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	4.62	5.52e-06	0.00292	0.26	0.24	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
STAD	cis	rs2692947	0.86	rs2579520	ENSG00000237510.6	AC008268.2	-4.62	5.52e-06	0.00292	-0.29	-0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95994552	chr2:95789654~95800166:+
STAD	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-4.62	5.52e-06	0.00292	-0.28	-0.24	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-4.62	5.52e-06	0.00292	-0.28	-0.24	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-4.62	5.52e-06	0.00292	-0.28	-0.24	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
STAD	cis	rs1007738	0.542	rs4752970	ENSG00000271350.1	CTD-2384B9.1	-4.62	5.53e-06	0.00292	-0.31	-0.24	Bone mineral density (hip);	chr11:47187431	chr11:47041027~47041945:-
STAD	cis	rs1322639	0.614	rs9364356	ENSG00000261039.2	RP11-417E7.2	-4.62	5.55e-06	0.00293	-0.39	-0.24	Pulse pressure;	chr6:169167013	chr6:169175304~169182740:-
STAD	cis	rs748404	0.66	rs694725	ENSG00000275601.1	AC011330.13	-4.61	5.55e-06	0.00293	-0.25	-0.24	Lung cancer;	chr15:43464012	chr15:43642389~43643023:-
STAD	cis	rs2980439	0.557	rs2976876	ENSG00000253981.4	ALG1L13P	4.61	5.55e-06	0.00293	0.29	0.24	Neuroticism;	chr8:8461340	chr8:8236003~8244667:-
STAD	cis	rs2980439	0.557	rs2921056	ENSG00000253981.4	ALG1L13P	4.61	5.55e-06	0.00293	0.29	0.24	Neuroticism;	chr8:8461672	chr8:8236003~8244667:-
STAD	cis	rs7826238	0.524	rs2921055	ENSG00000253981.4	ALG1L13P	4.61	5.55e-06	0.00293	0.29	0.24	Systolic blood pressure;	chr8:8461832	chr8:8236003~8244667:-
STAD	cis	rs17826219	0.636	rs7221463	ENSG00000263603.1	CTD-2349P21.5	-4.61	5.55e-06	0.00293	-0.31	-0.24	Body mass index;	chr17:30753533	chr17:30729469~30731202:+
STAD	cis	rs4589258	1	rs10765384	ENSG00000280367.1	RP11-121L10.2	4.61	5.55e-06	0.00293	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90750859	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.966	rs2213093	ENSG00000280367.1	RP11-121L10.2	4.61	5.55e-06	0.00293	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90754408	chr11:90223153~90226538:+
STAD	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	4.61	5.55e-06	0.00294	0.54	0.24	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
STAD	cis	rs4308124	1	rs62160391	ENSG00000227992.1	AC108463.2	-4.61	5.55e-06	0.00294	-0.3	-0.24	Vitiligo;	chr2:111251258	chr2:111203964~111206215:-
STAD	cis	rs6832769	0.961	rs11133379	ENSG00000272969.1	RP11-528I4.2	4.61	5.56e-06	0.00294	0.3	0.24	Personality dimensions;	chr4:55439944	chr4:55547112~55547889:+
STAD	cis	rs172166	0.694	rs2791332	ENSG00000220721.1	OR1F12	4.61	5.56e-06	0.00294	0.26	0.24	Cardiac Troponin-T levels;	chr6:28141010	chr6:28073316~28074233:+
STAD	cis	rs228614	0.51	rs223447	ENSG00000248971.2	KRT8P46	-4.61	5.56e-06	0.00294	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102728746~102730171:-
STAD	cis	rs7208859	0.623	rs56812022	ENSG00000263603.1	CTD-2349P21.5	-4.61	5.56e-06	0.00294	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs1054397	ENSG00000263603.1	CTD-2349P21.5	-4.61	5.56e-06	0.00294	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30729469~30731202:+
STAD	cis	rs8028182	0.636	rs28783769	ENSG00000260269.4	CTD-2323K18.1	-4.61	5.56e-06	0.00294	-0.31	-0.24	Sudden cardiac arrest;	chr15:75556668	chr15:75527150~75601205:-
STAD	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-4.61	5.57e-06	0.00294	-0.3	-0.24	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
STAD	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-4.61	5.57e-06	0.00294	-0.35	-0.24	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
STAD	cis	rs3806843	0.576	rs155359	ENSG00000202111.1	VTRNA1-2	-4.61	5.57e-06	0.00295	-0.24	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140935840	chr5:140718925~140719013:+
STAD	cis	rs1005277	0.579	rs2103938	ENSG00000276805.1	RP11-291L22.6	4.61	5.57e-06	0.00295	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38451030~38451785:+
STAD	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-4.61	5.58e-06	0.00295	-0.39	-0.24	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
STAD	cis	rs10129255	0.5	rs7159033	ENSG00000211973.2	IGHV1-69	4.61	5.58e-06	0.00295	0.2	0.24	Kawasaki disease;	chr14:106701709	chr14:106714684~106715181:-
STAD	cis	rs891378	1	rs10864231	ENSG00000274245.1	RP11-357P18.2	-4.61	5.58e-06	0.00295	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207332984	chr1:207372559~207373252:+
STAD	cis	rs7078219	0.714	rs10883369	ENSG00000228778.1	RP11-129J12.1	-4.61	5.58e-06	0.00295	-0.3	-0.24	Dental caries;	chr10:99531610	chr10:99527081~99528261:+
STAD	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	4.61	5.58e-06	0.00295	0.28	0.24	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
STAD	cis	rs1426063	0.614	rs17199779	ENSG00000249717.1	RP11-44F21.3	-4.61	5.58e-06	0.00295	-0.46	-0.24	QT interval;	chr4:75105647	chr4:74955974~74970362:-
STAD	cis	rs7829975	0.742	rs882462	ENSG00000253981.4	ALG1L13P	4.61	5.58e-06	0.00295	0.28	0.24	Mood instability;	chr8:8821020	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.774	rs11775523	ENSG00000253981.4	ALG1L13P	4.61	5.58e-06	0.00295	0.28	0.24	Mood instability;	chr8:8821666	chr8:8236003~8244667:-
STAD	cis	rs919433	1	rs2889363	ENSG00000231621.1	AC013264.2	4.61	5.59e-06	0.00295	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298975	chr2:197197991~197199273:+
STAD	cis	rs6921919	0.609	rs67211468	ENSG00000220721.1	OR1F12	4.61	5.59e-06	0.00295	0.25	0.24	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28073316~28074233:+
STAD	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-4.61	5.59e-06	0.00295	-0.35	-0.24	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
STAD	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	4.61	5.59e-06	0.00296	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
STAD	cis	rs1598856	1	rs93059	ENSG00000248971.2	KRT8P46	-4.61	5.6e-06	0.00296	-0.26	-0.24	Primary biliary cholangitis;	chr4:102547361	chr4:102728746~102730171:-
STAD	cis	rs1056107	0.931	rs7027240	ENSG00000225513.1	RP11-165N19.2	-4.61	5.6e-06	0.00296	-0.27	-0.24	Colorectal cancer;	chr9:112258733	chr9:112173522~112173971:-
STAD	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-4.61	5.6e-06	0.00296	-0.24	-0.24	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
STAD	cis	rs2933343	0.7	rs883602	ENSG00000261159.1	RP11-723O4.9	4.61	5.6e-06	0.00296	0.29	0.24	IgG glycosylation;	chr3:128935109	chr3:128859716~128860526:-
STAD	cis	rs1007190	0.764	rs4793153	ENSG00000267405.1	CTC-296K1.4	-4.61	5.6e-06	0.00296	-0.28	-0.24	DNA methylation (variation);	chr17:44796424	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.57	rs7224712	ENSG00000267405.1	CTC-296K1.4	-4.61	5.6e-06	0.00296	-0.28	-0.24	DNA methylation (variation);	chr17:44796850	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.764	rs8082522	ENSG00000267405.1	CTC-296K1.4	-4.61	5.6e-06	0.00296	-0.28	-0.24	DNA methylation (variation);	chr17:44798972	chr17:44794747~44797783:-
STAD	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	4.61	5.61e-06	0.00296	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
STAD	cis	rs7474896	0.583	rs10764144	ENSG00000120555.12	SEPT7P9	4.61	5.61e-06	0.00296	0.28	0.24	Obesity (extreme);	chr10:37686804	chr10:38383069~38402916:-
STAD	cis	rs4589258	0.933	rs1783789	ENSG00000280367.1	RP11-121L10.2	-4.61	5.61e-06	0.00296	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90704825	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1792603	ENSG00000280367.1	RP11-121L10.2	-4.61	5.61e-06	0.00296	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90706242	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1616765	ENSG00000280367.1	RP11-121L10.2	-4.61	5.61e-06	0.00296	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90706986	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1792601	ENSG00000280367.1	RP11-121L10.2	-4.61	5.61e-06	0.00296	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90707363	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1783796	ENSG00000280367.1	RP11-121L10.2	-4.61	5.61e-06	0.00296	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90708502	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1792596	ENSG00000280367.1	RP11-121L10.2	-4.61	5.61e-06	0.00296	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90710577	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs2511313	ENSG00000280367.1	RP11-121L10.2	-4.61	5.61e-06	0.00296	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90711621	chr11:90223153~90226538:+
STAD	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	4.61	5.61e-06	0.00296	0.27	0.24	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
STAD	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-4.61	5.62e-06	0.00296	-0.25	-0.24	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
STAD	cis	rs2337406	0.587	rs2516889	ENSG00000211972.2	IGHV3-66	-4.61	5.62e-06	0.00296	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106648903	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.587	rs10129888	ENSG00000211972.2	IGHV3-66	4.61	5.62e-06	0.00296	0.25	0.24	Alzheimer's disease (late onset);	chr14:106647421	chr14:106675017~106675544:-
STAD	cis	rs6430585	0.646	rs1057031	ENSG00000231890.6	DARS-AS1	-4.61	5.62e-06	0.00297	-0.27	-0.24	Corneal structure;	chr2:135876392	chr2:135985176~136022593:+
STAD	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-4.61	5.62e-06	0.00297	-0.24	-0.24	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
STAD	cis	rs7924176	0.502	rs12784355	ENSG00000213731.2	RAB5CP1	-4.61	5.63e-06	0.00297	-0.24	-0.24	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74423435~74424014:-
STAD	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-4.61	5.63e-06	0.00297	-0.35	-0.24	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
STAD	cis	rs6676180	0.514	rs868675	ENSG00000231365.4	RP11-418J17.1	-4.61	5.63e-06	0.00297	-0.28	-0.24	Monobrow;	chr1:119230973	chr1:119140396~119275973:+
STAD	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-4.61	5.63e-06	0.00297	-0.29	-0.24	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
STAD	cis	rs9813712	0.597	rs10934931	ENSG00000253540.4	FAM86HP	-4.61	5.63e-06	0.00297	-0.26	-0.24	Response to amphetamines;	chr3:130261365	chr3:130099092~130111472:-
STAD	cis	rs17361889	0.502	rs10807780	ENSG00000224683.1	RPL36AP29	-4.61	5.63e-06	0.00297	-0.25	-0.24	Pediatric bone mineral content (hip);	chr7:16179743	chr7:16208945~16209265:+
STAD	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-4.61	5.64e-06	0.00298	-0.28	-0.24	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
STAD	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-4.61	5.64e-06	0.00298	-0.24	-0.24	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
STAD	cis	rs17507216	0.718	rs72751662	ENSG00000259429.4	UBE2Q2P2	-4.61	5.64e-06	0.00298	-0.38	-0.24	Excessive daytime sleepiness;	chr15:82594705	chr15:82355142~82420075:+
STAD	cis	rs1816752	0.679	rs8181826	ENSG00000273628.1	RP11-756A22.7	-4.61	5.64e-06	0.00298	-0.28	-0.24	Obesity-related traits;	chr13:24396570	chr13:24933006~24936796:+
STAD	cis	rs875971	0.895	rs3857684	ENSG00000236529.1	RP13-254B10.1	4.61	5.64e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66473171	chr7:65840212~65840596:+
STAD	cis	rs9646944	0.501	rs7586983	ENSG00000234389.1	AC007278.3	4.61	5.65e-06	0.00298	0.31	0.24	Blood protein levels;	chr2:102411606	chr2:102438713~102440475:+
STAD	cis	rs7429990	0.864	rs7631950	ENSG00000224895.1	VPS26BP1	4.61	5.65e-06	0.00298	0.23	0.24	Educational attainment (years of education);	chr3:47591865	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.833	rs11716582	ENSG00000224895.1	VPS26BP1	4.61	5.65e-06	0.00298	0.23	0.24	Educational attainment (years of education);	chr3:47592269	chr3:47960327~47961081:-
STAD	cis	rs875971	0.964	rs6978429	ENSG00000236529.1	RP13-254B10.1	4.61	5.65e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66494889	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs4718357	ENSG00000236529.1	RP13-254B10.1	4.61	5.65e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66495891	chr7:65840212~65840596:+
STAD	cis	rs875971	0.929	rs12535036	ENSG00000236529.1	RP13-254B10.1	4.61	5.65e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66499076	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs12532998	ENSG00000236529.1	RP13-254B10.1	4.61	5.65e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66502472	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs12698523	ENSG00000236529.1	RP13-254B10.1	4.61	5.65e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66503126	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6970030	ENSG00000236529.1	RP13-254B10.1	4.61	5.65e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66503692	chr7:65840212~65840596:+
STAD	cis	rs875971	0.928	rs6970357	ENSG00000236529.1	RP13-254B10.1	4.61	5.65e-06	0.00298	0.25	0.24	Aortic root size;	chr7:66503891	chr7:65840212~65840596:+
STAD	cis	rs7074356	0.915	rs17680103	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.65e-06	0.00298	-0.48	-0.24	Borderline personality disorder;	chr10:80447862	chr10:79663088~79826594:-
STAD	cis	rs2921036	0.503	rs7817832	ENSG00000254340.1	RP11-10A14.3	4.61	5.65e-06	0.00298	0.39	0.24	Neuroticism;	chr8:8523311	chr8:9141424~9145435:+
STAD	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-4.61	5.65e-06	0.00298	-0.39	-0.24	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
STAD	cis	rs7932354	0.583	rs1007738	ENSG00000271350.1	CTD-2384B9.1	4.61	5.65e-06	0.00298	0.29	0.24	Bone mineral density (hip);Bone mineral density;	chr11:46827809	chr11:47041027~47041945:-
STAD	cis	rs9788721	0.836	rs2009746	ENSG00000259419.2	HNRNPCP3	4.61	5.65e-06	0.00298	0.26	0.24	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78461760	chr15:79236332~79237206:+
STAD	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-4.61	5.66e-06	0.00298	-0.28	-0.24	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
STAD	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-4.61	5.66e-06	0.00298	-0.21	-0.24	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
STAD	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	4.61	5.66e-06	0.00298	0.26	0.24	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
STAD	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-4.61	5.66e-06	0.00299	-0.33	-0.24	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
STAD	cis	rs10744955	0.679	rs4775867	ENSG00000244879.4	GABPB1-AS1	-4.61	5.67e-06	0.00299	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr15:50165065	chr15:50354959~50372202:+
STAD	cis	rs10744955	0.727	rs6493413	ENSG00000244879.4	GABPB1-AS1	-4.61	5.67e-06	0.00299	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr15:50165538	chr15:50354959~50372202:+
STAD	cis	rs10744955	0.727	rs11070759	ENSG00000244879.4	GABPB1-AS1	4.61	5.67e-06	0.00299	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr15:50165661	chr15:50354959~50372202:+
STAD	cis	rs875971	0.929	rs6970860	ENSG00000236529.1	RP13-254B10.1	4.61	5.67e-06	0.00299	0.25	0.24	Aortic root size;	chr7:66511647	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6957199	ENSG00000236529.1	RP13-254B10.1	4.61	5.67e-06	0.00299	0.25	0.24	Aortic root size;	chr7:66513532	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6958271	ENSG00000236529.1	RP13-254B10.1	4.61	5.67e-06	0.00299	0.25	0.24	Aortic root size;	chr7:66514344	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6958277	ENSG00000236529.1	RP13-254B10.1	4.61	5.67e-06	0.00299	0.25	0.24	Aortic root size;	chr7:66514362	chr7:65840212~65840596:+
STAD	cis	rs17401966	0.838	rs1556917	ENSG00000199562.1	RNU6-37P	4.61	5.67e-06	0.00299	0.19	0.24	Hepatocellular carcinoma;	chr1:10340932	chr1:10298966~10299072:+
STAD	cis	rs801193	0.548	rs6975044	ENSG00000224316.1	RP11-479O9.2	4.61	5.67e-06	0.00299	0.24	0.24	Aortic root size;	chr7:66762495	chr7:65773620~65802067:+
STAD	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-4.61	5.67e-06	0.00299	-0.24	-0.24	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-4.61	5.67e-06	0.00299	-0.24	-0.24	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
STAD	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	4.61	5.67e-06	0.00299	0.3	0.24	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	4.61	5.67e-06	0.00299	0.3	0.24	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	4.61	5.67e-06	0.00299	0.3	0.24	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	4.61	5.67e-06	0.00299	0.3	0.24	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
STAD	cis	rs748404	0.66	rs693510	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00299	-0.25	-0.24	Lung cancer;	chr15:43422427	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs690512	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00299	-0.25	-0.24	Lung cancer;	chr15:43425480	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs542898	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00299	-0.25	-0.24	Lung cancer;	chr15:43427194	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs2249952	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00299	-0.25	-0.24	Lung cancer;	chr15:43428335	chr15:43642389~43643023:-
STAD	cis	rs748404	0.66	rs689767	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00299	-0.25	-0.24	Lung cancer;	chr15:43429879	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs2467745	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00299	-0.25	-0.24	Lung cancer;	chr15:43430544	chr15:43642389~43643023:-
STAD	cis	rs4568518	0.869	rs6969961	ENSG00000279048.1	RP11-511H23.2	4.61	5.68e-06	0.00299	0.22	0.24	Measles;	chr7:17990462	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.873	rs6952559	ENSG00000279048.1	RP11-511H23.2	4.61	5.68e-06	0.00299	0.22	0.24	Measles;	chr7:17990547	chr7:17940503~17942922:+
STAD	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-4.61	5.68e-06	0.00299	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
STAD	cis	rs11846409	0.86	rs1858692	ENSG00000211970.3	IGHV4-61	-4.61	5.68e-06	0.00299	-0.27	-0.24	Rheumatic heart disease;	chr14:106622776	chr14:106639119~106639657:-
STAD	cis	rs338389	0.521	rs338381	ENSG00000260657.2	RP11-315D16.4	-4.61	5.68e-06	0.00299	-0.27	-0.24	Survival in rectal cancer;	chr15:67951850	chr15:68267792~68277994:-
STAD	cis	rs11098499	0.909	rs71614422	ENSG00000260091.1	RP11-33B1.4	4.61	5.69e-06	0.003	0.24	0.24	Corneal astigmatism;	chr4:119438185	chr4:119409333~119410233:+
STAD	cis	rs8014252	0.803	rs73283917	ENSG00000259158.2	ADAM20P1	-4.61	5.69e-06	0.003	-0.33	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70566439	chr14:70468881~70483756:-
STAD	cis	rs11846409	0.86	rs1858692	ENSG00000211972.2	IGHV3-66	-4.61	5.69e-06	0.003	-0.26	-0.24	Rheumatic heart disease;	chr14:106622776	chr14:106675017~106675544:-
STAD	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-4.61	5.69e-06	0.003	-0.24	-0.24	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
STAD	cis	rs11722779	0.873	rs6533041	ENSG00000248971.2	KRT8P46	-4.61	5.69e-06	0.003	-0.25	-0.24	Schizophrenia;	chr4:102951615	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223463	ENSG00000248971.2	KRT8P46	-4.61	5.69e-06	0.003	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102728746~102730171:-
STAD	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	4.61	5.7e-06	0.003	0.3	0.24	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
STAD	cis	rs6921919	0.583	rs3734563	ENSG00000220721.1	OR1F12	4.61	5.7e-06	0.003	0.25	0.24	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs1591913	ENSG00000220721.1	OR1F12	4.61	5.7e-06	0.003	0.25	0.24	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28073316~28074233:+
STAD	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	4.61	5.7e-06	0.003	0.25	0.24	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
STAD	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	4.61	5.7e-06	0.003	0.25	0.24	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
STAD	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	4.61	5.7e-06	0.003	0.25	0.24	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
STAD	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-4.61	5.7e-06	0.003	-0.35	-0.24	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
STAD	cis	rs11098499	0.954	rs3890049	ENSG00000260091.1	RP11-33B1.4	4.61	5.7e-06	0.003	0.24	0.24	Corneal astigmatism;	chr4:119405128	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs71629403	ENSG00000260091.1	RP11-33B1.4	4.61	5.7e-06	0.003	0.24	0.24	Corneal astigmatism;	chr4:119451412	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs28571712	ENSG00000260091.1	RP11-33B1.4	4.61	5.7e-06	0.003	0.24	0.24	Corneal astigmatism;	chr4:119454825	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs9994730	ENSG00000260091.1	RP11-33B1.4	4.61	5.7e-06	0.003	0.24	0.24	Corneal astigmatism;	chr4:119460409	chr4:119409333~119410233:+
STAD	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	4.61	5.71e-06	0.003	0.28	0.24	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
STAD	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-4.61	5.71e-06	0.003	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
STAD	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-4.61	5.71e-06	0.003	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
STAD	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	4.61	5.71e-06	0.00301	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
STAD	cis	rs2919917	1	rs4739134	ENSG00000254352.1	RP11-578O24.2	4.61	5.71e-06	0.00301	0.36	0.24	Lymphocyte counts;	chr8:78643913	chr8:78723796~78724136:-
STAD	cis	rs875971	0.767	rs1643394	ENSG00000236529.1	RP13-254B10.1	4.61	5.72e-06	0.00301	0.25	0.24	Aortic root size;	chr7:66371107	chr7:65840212~65840596:+
STAD	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	4.61	5.72e-06	0.00301	0.49	0.24	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	4.61	5.72e-06	0.00301	0.49	0.24	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	4.61	5.72e-06	0.00301	0.49	0.24	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-4.61	5.72e-06	0.00301	-0.18	-0.24	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-4.61	5.72e-06	0.00301	-0.18	-0.24	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
STAD	cis	rs916888	0.687	rs199456	ENSG00000232300.1	FAM215B	4.61	5.72e-06	0.00301	0.32	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46558830~46562795:-
STAD	cis	rs916888	0.773	rs199451	ENSG00000232300.1	FAM215B	4.61	5.72e-06	0.00301	0.32	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46558830~46562795:-
STAD	cis	rs17401966	0.838	rs17034643	ENSG00000199562.1	RNU6-37P	-4.61	5.73e-06	0.00301	-0.19	-0.24	Hepatocellular carcinoma;	chr1:10272044	chr1:10298966~10299072:+
STAD	cis	rs4589258	0.788	rs7942155	ENSG00000280367.1	RP11-121L10.2	4.61	5.73e-06	0.00301	0.24	0.24	Intelligence (multi-trait analysis);	chr11:90734350	chr11:90223153~90226538:+
STAD	cis	rs875971	0.83	rs4718358	ENSG00000236529.1	RP13-254B10.1	4.61	5.73e-06	0.00301	0.25	0.24	Aortic root size;	chr7:66508681	chr7:65840212~65840596:+
STAD	cis	rs8097348	0.744	rs59597615	ENSG00000266602.1	RP11-476K15.1	-4.61	5.73e-06	0.00302	-0.29	-0.24	Exercise (leisure time);	chr18:1601198	chr18:1509183~1647097:+
STAD	cis	rs8099594	0.72	rs7506911	ENSG00000266696.1	RP11-30L3.2	4.61	5.73e-06	0.00302	0.24	0.24	Height;	chr18:49350091	chr18:49205912~49208781:+
STAD	cis	rs9990333	0.562	rs56224853	ENSG00000252174.1	RNU7-18P	-4.61	5.74e-06	0.00302	-0.27	-0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:196072819~196072880:+
STAD	cis	rs9990333	0.544	rs73210008	ENSG00000252174.1	RNU7-18P	-4.61	5.74e-06	0.00302	-0.27	-0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:196072819~196072880:+
STAD	cis	rs7702057	0.53	rs3087831	ENSG00000271918.1	CTD-2287O16.5	4.61	5.74e-06	0.00302	0.45	0.24	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs3087832	ENSG00000271918.1	CTD-2287O16.5	4.61	5.74e-06	0.00302	0.45	0.24	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs73780832	ENSG00000271918.1	CTD-2287O16.5	4.61	5.74e-06	0.00302	0.45	0.24	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs17138850	ENSG00000271918.1	CTD-2287O16.5	4.61	5.74e-06	0.00302	0.45	0.24	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116083807~116085416:-
STAD	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	4.61	5.74e-06	0.00302	0.26	0.24	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
STAD	cis	rs9467773	0.869	rs9295689	ENSG00000243307.2	POM121L6P	4.61	5.74e-06	0.00302	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26455583	chr6:26896952~26898777:+
STAD	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	4.61	5.74e-06	0.00302	0.26	0.24	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
STAD	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	4.61	5.74e-06	0.00302	0.26	0.24	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	4.61	5.74e-06	0.00302	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
STAD	cis	rs4950322	0.542	rs4950384	ENSG00000278811.3	LINC00624	4.61	5.75e-06	0.00302	0.27	0.24	Protein quantitative trait loci;	chr1:147177310	chr1:147258885~147517875:-
STAD	cis	rs763014	0.966	rs7185390	ENSG00000228201.1	AL022341.3	4.61	5.75e-06	0.00302	0.29	0.24	Height;	chr16:616382	chr16:648473~649200:-
STAD	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-4.61	5.75e-06	0.00303	-0.36	-0.24	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
STAD	cis	rs1005277	0.579	rs1740732	ENSG00000276805.1	RP11-291L22.6	4.61	5.75e-06	0.00303	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38451030~38451785:+
STAD	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-4.61	5.75e-06	0.00303	-0.26	-0.24	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
STAD	cis	rs9646944	0.501	rs3771161	ENSG00000234389.1	AC007278.3	4.61	5.75e-06	0.00303	0.32	0.24	Blood protein levels;	chr2:102387501	chr2:102438713~102440475:+
STAD	cis	rs357618	1	rs357625	ENSG00000260581.1	CTB-113P19.4	4.61	5.76e-06	0.00303	0.28	0.24	Basophil percentage of white cells;	chr5:151469313	chr5:151652275~151655449:+
STAD	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	4.61	5.76e-06	0.00303	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	4.61	5.76e-06	0.00303	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
STAD	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-4.61	5.76e-06	0.00303	-0.25	-0.24	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
STAD	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	4.61	5.76e-06	0.00303	0.35	0.24	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
STAD	cis	rs6832769	0.925	rs6817267	ENSG00000272969.1	RP11-528I4.2	4.61	5.76e-06	0.00303	0.31	0.24	Personality dimensions;	chr4:55472374	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs11931061	ENSG00000272969.1	RP11-528I4.2	4.61	5.76e-06	0.00303	0.31	0.24	Personality dimensions;	chr4:55472626	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs7668147	ENSG00000272969.1	RP11-528I4.2	4.61	5.76e-06	0.00303	0.31	0.24	Personality dimensions;	chr4:55473217	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs11947476	ENSG00000272969.1	RP11-528I4.2	4.61	5.76e-06	0.00303	0.31	0.24	Personality dimensions;	chr4:55473584	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.767	rs6850524	ENSG00000272969.1	RP11-528I4.2	4.61	5.77e-06	0.00303	0.31	0.24	Personality dimensions;	chr4:55515830	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.767	rs11133394	ENSG00000272969.1	RP11-528I4.2	4.61	5.77e-06	0.00303	0.31	0.24	Personality dimensions;	chr4:55517071	chr4:55547112~55547889:+
STAD	cis	rs1799949	1	rs8176234	ENSG00000236383.6	LINC00854	-4.61	5.77e-06	0.00303	-0.2	-0.24	Menopause (age at onset);	chr17:43067763	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs8176233	ENSG00000236383.6	LINC00854	-4.61	5.77e-06	0.00303	-0.2	-0.24	Menopause (age at onset);	chr17:43067787	chr17:43216941~43305976:-
STAD	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-4.61	5.77e-06	0.00303	-0.37	-0.24	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
STAD	cis	rs7680126	0.633	rs11727390	ENSG00000250613.1	RP11-136I13.1	4.61	5.77e-06	0.00303	0.26	0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10295136	chr4:10410996~10411644:+
STAD	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-4.61	5.77e-06	0.00303	-0.24	-0.24	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
STAD	cis	rs7074356	0.915	rs17617970	ENSG00000225484.5	NUTM2B-AS1	4.61	5.77e-06	0.00303	0.49	0.24	Borderline personality disorder;	chr10:80447136	chr10:79663088~79826594:-
STAD	cis	rs227932	0.764	rs4722246	ENSG00000234286.1	AC006026.13	4.61	5.77e-06	0.00303	0.43	0.24	Schizophrenia;	chr7:23682359	chr7:23680195~23680786:-
STAD	cis	rs227932	0.614	rs12700458	ENSG00000234286.1	AC006026.13	4.61	5.77e-06	0.00303	0.43	0.24	Schizophrenia;	chr7:23682525	chr7:23680195~23680786:-
STAD	cis	rs4589258	0.966	rs4451691	ENSG00000280367.1	RP11-121L10.2	4.61	5.77e-06	0.00304	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90740188	chr11:90223153~90226538:+
STAD	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	4.61	5.78e-06	0.00304	0.26	0.24	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
STAD	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	4.61	5.78e-06	0.00304	0.26	0.24	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
STAD	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	4.61	5.78e-06	0.00304	0.26	0.24	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000224205.1	AP000351.4	4.61	5.78e-06	0.00304	0.27	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23987320~23991421:-
STAD	cis	rs748404	0.697	rs579651	ENSG00000275601.1	AC011330.13	-4.61	5.78e-06	0.00304	-0.25	-0.24	Lung cancer;	chr15:43266178	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs473016	ENSG00000275601.1	AC011330.13	-4.61	5.78e-06	0.00304	-0.25	-0.24	Lung cancer;	chr15:43266625	chr15:43642389~43643023:-
STAD	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	4.61	5.79e-06	0.00304	0.41	0.24	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
STAD	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-4.61	5.79e-06	0.00304	-0.28	-0.24	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
STAD	cis	rs11722779	0.935	rs3857199	ENSG00000248971.2	KRT8P46	-4.61	5.8e-06	0.00305	-0.25	-0.24	Schizophrenia;	chr4:102957991	chr4:102728746~102730171:-
STAD	cis	rs763014	0.966	rs12935215	ENSG00000228201.1	AL022341.3	4.61	5.8e-06	0.00305	0.29	0.24	Height;	chr16:620605	chr16:648473~649200:-
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-4.61	5.8e-06	0.00305	-0.18	-0.24	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-4.61	5.8e-06	0.00305	-0.18	-0.24	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
STAD	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	4.6	5.8e-06	0.00305	0.31	0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
STAD	cis	rs8028182	0.636	rs12909863	ENSG00000260269.4	CTD-2323K18.1	-4.6	5.8e-06	0.00305	-0.3	-0.24	Sudden cardiac arrest;	chr15:75533481	chr15:75527150~75601205:-
STAD	cis	rs9921338	0.961	rs6498185	ENSG00000263080.1	RP11-485G7.5	4.6	5.81e-06	0.00305	0.37	0.24	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11341809~11345211:-
STAD	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-4.6	5.81e-06	0.00305	-0.26	-0.24	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-4.6	5.81e-06	0.00305	-0.26	-0.24	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
STAD	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	4.6	5.81e-06	0.00305	0.36	0.24	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
STAD	cis	rs748404	0.697	rs574065	ENSG00000275601.1	AC011330.13	4.6	5.82e-06	0.00305	0.25	0.24	Lung cancer;	chr15:43258457	chr15:43642389~43643023:-
STAD	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	4.6	5.82e-06	0.00305	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
STAD	cis	rs10510102	0.872	rs12246693	ENSG00000226864.1	ATE1-AS1	4.6	5.82e-06	0.00306	0.37	0.24	Breast cancer;	chr10:121957373	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12248806	ENSG00000226864.1	ATE1-AS1	4.6	5.82e-06	0.00306	0.37	0.24	Breast cancer;	chr10:121958638	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12255832	ENSG00000226864.1	ATE1-AS1	4.6	5.82e-06	0.00306	0.37	0.24	Breast cancer;	chr10:121958762	chr10:121928312~121951965:+
STAD	cis	rs227275	0.525	rs5028609	ENSG00000248971.2	KRT8P46	-4.6	5.83e-06	0.00306	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs6815540	ENSG00000248971.2	KRT8P46	-4.6	5.83e-06	0.00306	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs4698867	ENSG00000248971.2	KRT8P46	-4.6	5.83e-06	0.00306	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102728746~102730171:-
STAD	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-4.6	5.83e-06	0.00306	-0.26	-0.24	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
STAD	cis	rs8141529	0.732	rs5997408	ENSG00000272858.1	CTA-292E10.8	-4.6	5.83e-06	0.00306	-0.26	-0.24	Lymphocyte counts;	chr22:28811927	chr22:28814914~28815662:+
STAD	cis	rs6430585	0.583	rs4988145	ENSG00000231890.6	DARS-AS1	-4.6	5.83e-06	0.00306	-0.28	-0.24	Corneal structure;	chr2:135874730	chr2:135985176~136022593:+
STAD	cis	rs4237845	0.844	rs4628718	ENSG00000273805.1	RP11-620J15.4	-4.6	5.83e-06	0.00306	-0.27	-0.24	Intelligence (multi-trait analysis);	chr12:57907817	chr12:57894232~57896846:+
STAD	cis	rs2337406	1	rs10459466	ENSG00000280411.1	IGHV1-69-2	-4.6	5.83e-06	0.00306	-0.31	-0.24	Alzheimer's disease (late onset);	chr14:106689255	chr14:106762092~106762588:-
STAD	cis	rs357618	0.931	rs394736	ENSG00000260581.1	CTB-113P19.4	4.6	5.83e-06	0.00306	0.28	0.24	Basophil percentage of white cells;	chr5:151467948	chr5:151652275~151655449:+
STAD	cis	rs357618	0.965	rs357621	ENSG00000260581.1	CTB-113P19.4	4.6	5.83e-06	0.00306	0.28	0.24	Basophil percentage of white cells;	chr5:151467993	chr5:151652275~151655449:+
STAD	cis	rs357618	1	rs193299	ENSG00000260581.1	CTB-113P19.4	4.6	5.83e-06	0.00306	0.28	0.24	Basophil percentage of white cells;	chr5:151468094	chr5:151652275~151655449:+
STAD	cis	rs357618	0.965	rs187180	ENSG00000260581.1	CTB-113P19.4	4.6	5.83e-06	0.00306	0.28	0.24	Basophil percentage of white cells;	chr5:151468434	chr5:151652275~151655449:+
STAD	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	4.6	5.83e-06	0.00306	0.25	0.24	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
STAD	cis	rs6832769	0.961	rs13128582	ENSG00000272969.1	RP11-528I4.2	4.6	5.83e-06	0.00306	0.31	0.24	Personality dimensions;	chr4:55462777	chr4:55547112~55547889:+
STAD	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	4.6	5.83e-06	0.00306	0.32	0.24	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
STAD	cis	rs7829975	0.514	rs2979139	ENSG00000173295.6	FAM86B3P	4.6	5.84e-06	0.00306	0.26	0.24	Mood instability;	chr8:8410803	chr8:8228595~8244865:+
STAD	cis	rs4713118	0.955	rs9393848	ENSG00000220721.1	OR1F12	4.6	5.84e-06	0.00306	0.26	0.24	Parkinson's disease;	chr6:27720590	chr6:28073316~28074233:+
STAD	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	4.6	5.84e-06	0.00306	0.33	0.24	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
STAD	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-4.6	5.84e-06	0.00307	-0.24	-0.24	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
STAD	cis	rs2337406	1	rs11846866	ENSG00000211972.2	IGHV3-66	4.6	5.84e-06	0.00307	0.27	0.24	Alzheimer's disease (late onset);	chr14:106703003	chr14:106675017~106675544:-
STAD	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-4.6	5.84e-06	0.00307	-0.3	-0.24	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
STAD	cis	rs4589258	0.933	rs4564292	ENSG00000280367.1	RP11-121L10.2	4.6	5.84e-06	0.00307	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90773082	chr11:90223153~90226538:+
STAD	cis	rs1799949	1	rs8176273	ENSG00000236383.6	LINC00854	-4.6	5.84e-06	0.00307	-0.2	-0.24	Menopause (age at onset);	chr17:43059636	chr17:43216941~43305976:-
STAD	cis	rs8141529	0.778	rs5762795	ENSG00000272858.1	CTA-292E10.8	-4.6	5.85e-06	0.00307	-0.26	-0.24	Lymphocyte counts;	chr22:28786512	chr22:28814914~28815662:+
STAD	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	4.6	5.85e-06	0.00307	0.26	0.24	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
STAD	cis	rs9467773	0.596	rs3001369	ENSG00000243307.2	POM121L6P	4.6	5.85e-06	0.00307	0.24	0.24	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26896952~26898777:+
STAD	cis	rs801193	0.569	rs35070132	ENSG00000224316.1	RP11-479O9.2	4.6	5.85e-06	0.00307	0.24	0.24	Aortic root size;	chr7:66773096	chr7:65773620~65802067:+
STAD	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	4.6	5.85e-06	0.00307	0.25	0.24	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
STAD	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-4.6	5.85e-06	0.00307	-0.24	-0.24	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-4.6	5.85e-06	0.00307	-0.24	-0.24	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-4.6	5.85e-06	0.00307	-0.24	-0.24	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	4.6	5.85e-06	0.00307	0.24	0.24	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
STAD	cis	rs9307551	0.857	rs2196978	ENSG00000250334.4	LINC00989	4.6	5.86e-06	0.00307	0.29	0.24	Refractive error;	chr4:79614815	chr4:79492416~79576460:+
STAD	cis	rs357618	1	rs357622	ENSG00000260581.1	CTB-113P19.4	4.6	5.86e-06	0.00307	0.28	0.24	Basophil percentage of white cells;	chr5:151468844	chr5:151652275~151655449:+
STAD	cis	rs357618	1	rs357623	ENSG00000260581.1	CTB-113P19.4	4.6	5.86e-06	0.00307	0.28	0.24	Basophil percentage of white cells;	chr5:151468939	chr5:151652275~151655449:+
STAD	cis	rs357618	1	rs357624	ENSG00000260581.1	CTB-113P19.4	4.6	5.86e-06	0.00307	0.28	0.24	Basophil percentage of white cells;	chr5:151469140	chr5:151652275~151655449:+
STAD	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	4.6	5.86e-06	0.00307	0.36	0.24	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	4.6	5.86e-06	0.00307	0.36	0.24	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
STAD	cis	rs227275	0.525	rs7663876	ENSG00000248971.2	KRT8P46	-4.6	5.86e-06	0.00307	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102728746~102730171:-
STAD	cis	rs748404	0.65	rs518234	ENSG00000275601.1	AC011330.13	-4.6	5.86e-06	0.00308	-0.25	-0.24	Lung cancer;	chr15:43281223	chr15:43642389~43643023:-
STAD	cis	rs748404	0.65	rs518261	ENSG00000275601.1	AC011330.13	-4.6	5.86e-06	0.00308	-0.25	-0.24	Lung cancer;	chr15:43281231	chr15:43642389~43643023:-
STAD	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	4.6	5.87e-06	0.00308	0.35	0.24	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
STAD	cis	rs1426063	0.614	rs74949513	ENSG00000249717.1	RP11-44F21.3	4.6	5.87e-06	0.00308	0.51	0.24	QT interval;	chr4:75124631	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs77982391	ENSG00000249717.1	RP11-44F21.3	4.6	5.87e-06	0.00308	0.51	0.24	QT interval;	chr4:75125224	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.541	rs116664844	ENSG00000249717.1	RP11-44F21.3	4.6	5.87e-06	0.00308	0.51	0.24	QT interval;	chr4:75125677	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.541	rs114162294	ENSG00000249717.1	RP11-44F21.3	4.6	5.87e-06	0.00308	0.51	0.24	QT interval;	chr4:75125682	chr4:74955974~74970362:-
STAD	cis	rs7131987	0.65	rs16934135	ENSG00000275476.1	RP11-996F15.4	-4.6	5.87e-06	0.00308	-0.27	-0.24	QT interval;	chr12:29331030	chr12:29277397~29277882:-
STAD	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	4.6	5.87e-06	0.00308	0.27	0.24	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
STAD	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	4.6	5.87e-06	0.00308	0.27	0.24	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
STAD	cis	rs11722779	0.658	rs6533044	ENSG00000248971.2	KRT8P46	-4.6	5.87e-06	0.00308	-0.25	-0.24	Schizophrenia;	chr4:102965261	chr4:102728746~102730171:-
STAD	cis	rs62246343	0.605	rs17746498	ENSG00000214041.4	PGAM1P4	4.6	5.87e-06	0.00308	0.35	0.24	Fibrinogen levels;	chr3:9411976	chr3:9348443~9349192:+
STAD	cis	rs858239	0.6	rs4321896	ENSG00000230042.1	AK3P3	-4.6	5.87e-06	0.00308	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs59073109	ENSG00000230042.1	AK3P3	-4.6	5.87e-06	0.00308	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs7788821	ENSG00000230042.1	AK3P3	-4.6	5.87e-06	0.00308	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs6956595	ENSG00000230042.1	AK3P3	-4.6	5.87e-06	0.00308	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23129178~23129841:+
STAD	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-4.6	5.88e-06	0.00308	-0.25	-0.24	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
STAD	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-4.6	5.88e-06	0.00308	-0.25	-0.24	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
STAD	cis	rs7487075	0.786	rs11504511	ENSG00000257261.4	RP11-96H19.1	4.6	5.88e-06	0.00308	0.29	0.24	Itch intensity from mosquito bite;	chr12:46283261	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.786	rs7316773	ENSG00000257261.4	RP11-96H19.1	4.6	5.88e-06	0.00308	0.29	0.24	Itch intensity from mosquito bite;	chr12:46290664	chr12:46383679~46876159:+
STAD	cis	rs919433	0.89	rs979020	ENSG00000231621.1	AC013264.2	4.6	5.88e-06	0.00308	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305025	chr2:197197991~197199273:+
STAD	cis	rs1816752	0.669	rs7984513	ENSG00000273628.1	RP11-756A22.7	-4.6	5.88e-06	0.00308	-0.29	-0.24	Obesity-related traits;	chr13:24445117	chr13:24933006~24936796:+
STAD	cis	rs728616	0.867	rs56235549	ENSG00000225484.5	NUTM2B-AS1	-4.6	5.88e-06	0.00308	-0.52	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:79663088~79826594:-
STAD	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-4.6	5.88e-06	0.00308	-0.25	-0.24	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
STAD	cis	rs6951245	0.706	rs28685743	ENSG00000229043.2	AC091729.9	-4.6	5.88e-06	0.00308	-0.37	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1160374~1165267:+
STAD	cis	rs4568518	0.873	rs13309934	ENSG00000279048.1	RP11-511H23.2	-4.6	5.88e-06	0.00308	-0.22	-0.24	Measles;	chr7:17991173	chr7:17940503~17942922:+
STAD	cis	rs7176527	0.796	rs1057946	ENSG00000225151.9	GOLGA2P7	4.6	5.89e-06	0.00309	0.32	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:84199311~84230136:-
STAD	cis	rs6714710	0.603	rs2044458	ENSG00000235833.1	AC159540.14	-4.6	5.89e-06	0.00309	-0.27	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97761049	chr2:97523949~97524976:-
STAD	cis	rs2337406	1	rs17113331	ENSG00000211972.2	IGHV3-66	4.6	5.89e-06	0.00309	0.27	0.24	Alzheimer's disease (late onset);	chr14:106703843	chr14:106675017~106675544:-
STAD	cis	rs2337406	1	rs7145172	ENSG00000211972.2	IGHV3-66	4.6	5.89e-06	0.00309	0.27	0.24	Alzheimer's disease (late onset);	chr14:106704924	chr14:106675017~106675544:-
STAD	cis	rs4865169	0.871	rs9918067	ENSG00000269949.1	RP11-738E22.3	-4.6	5.89e-06	0.00309	-0.26	-0.24	Breast cancer;	chr4:57004378	chr4:56960927~56961373:-
STAD	cis	rs2348418	0.733	rs7294486	ENSG00000247934.4	RP11-967K21.1	-4.6	5.89e-06	0.00309	-0.23	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28163298~28190738:-
STAD	cis	rs5769707	0.521	rs739244	ENSG00000280224.1	CTA-722E9.1	-4.6	5.89e-06	0.00309	-0.26	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49500568~49501585:+
STAD	cis	rs7487075	0.82	rs12816413	ENSG00000257261.4	RP11-96H19.1	4.6	5.9e-06	0.00309	0.29	0.24	Itch intensity from mosquito bite;	chr12:46329506	chr12:46383679~46876159:+
STAD	cis	rs728616	0.614	rs61859196	ENSG00000225484.5	NUTM2B-AS1	-4.6	5.9e-06	0.00309	-0.47	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80349292	chr10:79663088~79826594:-
STAD	cis	rs1799949	1	rs16941	ENSG00000279602.1	CTD-3014M21.1	4.6	5.9e-06	0.00309	0.3	0.24	Menopause (age at onset);	chr17:43092418	chr17:43360041~43361361:-
STAD	cis	rs950881	0.808	rs72823677	ENSG00000234389.1	AC007278.3	4.6	5.9e-06	0.00309	0.38	0.24	Allergy;	chr2:102380591	chr2:102438713~102440475:+
STAD	cis	rs6832769	1	rs59804446	ENSG00000272969.1	RP11-528I4.2	-4.6	5.9e-06	0.00309	-0.31	-0.24	Personality dimensions;	chr4:55563374	chr4:55547112~55547889:+
STAD	cis	rs2337406	0.538	rs10141701	ENSG00000211972.2	IGHV3-66	4.6	5.91e-06	0.00309	0.24	0.24	Alzheimer's disease (late onset);	chr14:106633467	chr14:106675017~106675544:-
STAD	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	4.6	5.91e-06	0.0031	0.28	0.24	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
STAD	cis	rs10851478	0.591	rs11634786	ENSG00000259545.2	RP11-325E5.4	4.6	5.91e-06	0.0031	0.26	0.24	Oral cavity cancer;	chr15:49452370	chr15:49177610~49178741:-
STAD	cis	rs62432291	0.681	rs438853	ENSG00000235086.1	FNDC1-IT1	-4.6	5.91e-06	0.0031	-0.34	-0.24	Joint mobility (Beighton score);	chr6:159209320	chr6:159240786~159243329:+
STAD	cis	rs6832769	1	rs6554286	ENSG00000272969.1	RP11-528I4.2	-4.6	5.92e-06	0.0031	-0.3	-0.24	Personality dimensions;	chr4:55534137	chr4:55547112~55547889:+
STAD	cis	rs8177876	0.749	rs76892049	ENSG00000261838.4	RP11-303E16.6	4.6	5.92e-06	0.0031	0.5	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81069854~81076598:+
STAD	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	4.6	5.93e-06	0.0031	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
STAD	cis	rs7487075	0.82	rs1586905	ENSG00000257261.4	RP11-96H19.1	4.6	5.93e-06	0.00311	0.29	0.24	Itch intensity from mosquito bite;	chr12:46313835	chr12:46383679~46876159:+
STAD	cis	rs73186030	0.841	rs34173813	ENSG00000272758.4	RP11-299J3.8	4.6	5.93e-06	0.00311	0.41	0.24	Serum parathyroid hormone levels;	chr3:122341557	chr3:122416207~122443180:+
STAD	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-4.6	5.94e-06	0.00311	-0.28	-0.24	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
STAD	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-4.6	5.94e-06	0.00311	-0.25	-0.24	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
STAD	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	4.6	5.94e-06	0.00311	0.3	0.24	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
STAD	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	4.6	5.95e-06	0.00311	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	4.6	5.95e-06	0.00311	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
STAD	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	4.6	5.95e-06	0.00311	0.27	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
STAD	cis	rs9907295	0.748	rs4251769	ENSG00000270894.1	AC015849.13	-4.6	5.95e-06	0.00311	-0.24	-0.24	Fibroblast growth factor basic levels;	chr17:35837523	chr17:35818399~35823713:+
STAD	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	4.6	5.95e-06	0.00312	0.3	0.24	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
STAD	cis	rs10986311	0.609	rs10118498	ENSG00000227200.1	RP11-121A14.3	4.6	5.95e-06	0.00312	0.26	0.24	Vitiligo;	chr9:124297845	chr9:124262876~124265809:+
STAD	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-4.6	5.96e-06	0.00312	-0.28	-0.24	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-4.6	5.96e-06	0.00312	-0.28	-0.24	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
STAD	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	4.6	5.96e-06	0.00312	0.27	0.24	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
STAD	cis	rs1075265	0.73	rs7559380	ENSG00000235937.1	AC008280.1	4.6	5.96e-06	0.00312	0.21	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54029552~54030682:-
STAD	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-4.6	5.97e-06	0.00312	-0.27	-0.24	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
STAD	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	4.6	5.97e-06	0.00312	0.39	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
STAD	cis	rs2880765	0.566	rs55899824	ENSG00000229212.6	RP11-561C5.4	4.6	5.97e-06	0.00312	0.34	0.24	Coronary artery disease;	chr15:85460860	chr15:85205440~85234795:-
STAD	cis	rs2880765	0.631	rs55767890	ENSG00000229212.6	RP11-561C5.4	4.6	5.97e-06	0.00312	0.34	0.24	Coronary artery disease;	chr15:85460911	chr15:85205440~85234795:-
STAD	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	4.6	5.97e-06	0.00312	0.26	0.24	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
STAD	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-4.6	5.97e-06	0.00312	-0.3	-0.24	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-4.6	5.97e-06	0.00312	-0.3	-0.24	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
STAD	cis	rs4243830	0.85	rs10864612	ENSG00000229519.2	RP11-58A11.2	4.6	5.98e-06	0.00313	0.25	0.24	Body mass index;	chr1:6533770	chr1:6547905~6548619:+
STAD	cis	rs8062405	0.824	rs28698667	ENSG00000278665.1	RP11-666O2.4	4.6	5.98e-06	0.00313	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28599241~28601881:-
STAD	cis	rs2337406	1	rs3858878	ENSG00000280411.1	IGHV1-69-2	-4.6	5.98e-06	0.00313	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106688061	chr14:106762092~106762588:-
STAD	cis	rs9307551	0.948	rs10022663	ENSG00000250334.4	LINC00989	-4.6	5.99e-06	0.00313	-0.3	-0.24	Refractive error;	chr4:79568460	chr4:79492416~79576460:+
STAD	cis	rs7474896	0.609	rs11011336	ENSG00000120555.12	SEPT7P9	4.6	5.99e-06	0.00313	0.29	0.24	Obesity (extreme);	chr10:37696388	chr10:38383069~38402916:-
STAD	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-4.6	5.99e-06	0.00313	-0.35	-0.24	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
STAD	cis	rs1007738	0.542	rs7937410	ENSG00000271350.1	CTD-2384B9.1	4.6	5.99e-06	0.00313	0.31	0.24	Bone mineral density (hip);	chr11:47184531	chr11:47041027~47041945:-
STAD	cis	rs13113518	1	rs3805148	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55440643	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11133380	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55441110	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs12510110	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55441567	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs12510990	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55441907	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs3805149	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55442184	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11945370	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55442875	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs12647677	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55444253	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.902	rs3805150	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55446869	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs4864990	ENSG00000223305.1	RN7SKP30	4.6	5.99e-06	0.00313	0.27	0.24	Height;	chr4:55447523	chr4:55540502~55540835:-
STAD	cis	rs801193	0.66	rs1962050	ENSG00000236529.1	RP13-254B10.1	-4.6	5.99e-06	0.00314	-0.25	-0.24	Aortic root size;	chr7:66775021	chr7:65840212~65840596:+
STAD	cis	rs1707322	1	rs4074225	ENSG00000281133.1	AL355480.3	-4.6	6e-06	0.00314	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4134387	ENSG00000281133.1	AL355480.3	-4.6	6e-06	0.00314	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10789485	ENSG00000281133.1	AL355480.3	-4.6	6e-06	0.00314	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45580892~45580996:-
STAD	cis	rs858239	0.6	rs6461692	ENSG00000230042.1	AK3P3	-4.6	6e-06	0.00314	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23129178~23129841:+
STAD	cis	rs6832769	1	rs7677526	ENSG00000272969.1	RP11-528I4.2	4.6	6.01e-06	0.00314	0.31	0.24	Personality dimensions;	chr4:55483741	chr4:55547112~55547889:+
STAD	cis	rs11098499	0.909	rs1546502	ENSG00000260091.1	RP11-33B1.4	4.6	6.01e-06	0.00314	0.24	0.24	Corneal astigmatism;	chr4:119314743	chr4:119409333~119410233:+
STAD	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	4.6	6.02e-06	0.00314	0.3	0.24	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	4.6	6.02e-06	0.00314	0.3	0.24	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	4.6	6.02e-06	0.00314	0.3	0.24	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
STAD	cis	rs11098499	0.954	rs13107475	ENSG00000260091.1	RP11-33B1.4	4.6	6.03e-06	0.00315	0.23	0.24	Corneal astigmatism;	chr4:119471856	chr4:119409333~119410233:+
STAD	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-4.6	6.03e-06	0.00315	-0.36	-0.24	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
STAD	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-4.6	6.03e-06	0.00315	-0.2	-0.24	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
STAD	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-4.6	6.03e-06	0.00315	-0.32	-0.24	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
STAD	cis	rs227275	0.556	rs223449	ENSG00000248971.2	KRT8P46	-4.6	6.03e-06	0.00315	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223446	ENSG00000248971.2	KRT8P46	-4.6	6.03e-06	0.00315	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223445	ENSG00000248971.2	KRT8P46	-4.6	6.03e-06	0.00315	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223443	ENSG00000248971.2	KRT8P46	-4.6	6.03e-06	0.00315	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102728746~102730171:-
STAD	cis	rs11676348	0.901	rs7562334	ENSG00000237281.1	CATIP-AS2	4.6	6.04e-06	0.00315	0.24	0.24	Ulcerative colitis;	chr2:218138637	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.967	rs4672873	ENSG00000237281.1	CATIP-AS2	4.6	6.04e-06	0.00315	0.24	0.24	Ulcerative colitis;	chr2:218140487	chr2:218326889~218357966:-
STAD	cis	rs1015362	0.581	rs4911373	ENSG00000275784.1	RP5-1125A11.6	-4.6	6.04e-06	0.00316	-0.28	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33989480~33991818:-
STAD	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	4.6	6.04e-06	0.00316	0.26	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
STAD	cis	rs11098499	0.697	rs11941899	ENSG00000260091.1	RP11-33B1.4	4.6	6.04e-06	0.00316	0.24	0.24	Corneal astigmatism;	chr4:119461603	chr4:119409333~119410233:+
STAD	cis	rs2337406	0.852	rs12050239	ENSG00000280411.1	IGHV1-69-2	-4.6	6.04e-06	0.00316	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106781132	chr14:106762092~106762588:-
STAD	cis	rs4589258	0.762	rs1792595	ENSG00000280367.1	RP11-121L10.2	-4.6	6.05e-06	0.00316	-0.24	-0.24	Intelligence (multi-trait analysis);	chr11:90712980	chr11:90223153~90226538:+
STAD	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-4.6	6.05e-06	0.00316	-0.2	-0.24	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
STAD	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-4.6	6.05e-06	0.00316	-0.27	-0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
STAD	cis	rs1707322	1	rs10890370	ENSG00000225447.1	RPS15AP10	4.6	6.05e-06	0.00316	0.18	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45645816~45646197:-
STAD	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	4.6	6.05e-06	0.00316	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
STAD	cis	rs6585424	1	rs35180576	ENSG00000225484.5	NUTM2B-AS1	-4.6	6.05e-06	0.00316	-0.43	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163215	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs34148644	ENSG00000225484.5	NUTM2B-AS1	-4.6	6.05e-06	0.00316	-0.43	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163700	chr10:79663088~79826594:-
STAD	cis	rs7487075	0.786	rs898242	ENSG00000257261.4	RP11-96H19.1	4.6	6.05e-06	0.00316	0.29	0.24	Itch intensity from mosquito bite;	chr12:46327036	chr12:46383679~46876159:+
STAD	cis	rs1075265	0.901	rs7569743	ENSG00000233266.1	HMGB1P31	4.6	6.06e-06	0.00317	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54137806	chr2:54051334~54051760:+
STAD	cis	rs4589258	0.788	rs1573546	ENSG00000280367.1	RP11-121L10.2	4.6	6.06e-06	0.00317	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90731602	chr11:90223153~90226538:+
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-4.6	6.06e-06	0.00317	-0.18	-0.24	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
STAD	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	4.6	6.06e-06	0.00317	0.28	0.24	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
STAD	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	4.6	6.06e-06	0.00317	0.26	0.24	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
STAD	cis	rs516805	0.667	rs2816165	ENSG00000279453.1	RP3-425C14.4	-4.6	6.06e-06	0.00317	-0.34	-0.24	Lymphocyte counts;	chr6:122114717	chr6:122436789~122439223:-
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-4.6	6.07e-06	0.00317	-0.18	-0.24	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
STAD	cis	rs56080343	0.748	rs2893771	ENSG00000275759.1	RP11-131L12.3	-4.6	6.07e-06	0.00317	-0.47	-0.24	Neuroticism;	chr12:118440051	chr12:118428281~118428870:+
STAD	cis	rs7429990	0.833	rs2030596	ENSG00000224895.1	VPS26BP1	4.59	6.07e-06	0.00317	0.23	0.24	Educational attainment (years of education);	chr3:47701712	chr3:47960327~47961081:-
STAD	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-4.59	6.07e-06	0.00317	-0.22	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
STAD	cis	rs10129255	0.957	rs6576233	ENSG00000224373.3	IGHV4-59	4.59	6.08e-06	0.00317	0.19	0.24	Kawasaki disease;	chr14:106787239	chr14:106627249~106627825:-
STAD	cis	rs8141529	0.732	rs6005872	ENSG00000272858.1	CTA-292E10.8	-4.59	6.08e-06	0.00317	-0.26	-0.24	Lymphocyte counts;	chr22:28776910	chr22:28814914~28815662:+
STAD	cis	rs4713118	0.662	rs149946	ENSG00000220721.1	OR1F12	-4.59	6.08e-06	0.00318	-0.28	-0.24	Parkinson's disease;	chr6:28002253	chr6:28073316~28074233:+
STAD	cis	rs7487075	0.558	rs12303214	ENSG00000272369.1	RP11-446N19.1	4.59	6.08e-06	0.00318	0.29	0.24	Itch intensity from mosquito bite;	chr12:46255745	chr12:46537502~46652550:+
STAD	cis	rs2348418	0.966	rs11049695	ENSG00000247934.4	RP11-967K21.1	4.59	6.09e-06	0.00318	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28527934	chr12:28163298~28190738:-
STAD	cis	rs9860428	0.967	rs9842637	ENSG00000240057.4	RP11-572M11.4	-4.59	6.09e-06	0.00318	-0.22	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112861222	chr3:113019532~113183301:+
STAD	cis	rs9646944	0.501	rs12712144	ENSG00000234389.1	AC007278.3	4.59	6.09e-06	0.00318	0.32	0.24	Blood protein levels;	chr2:102379140	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs3213733	ENSG00000234389.1	AC007278.3	4.59	6.09e-06	0.00318	0.32	0.24	Blood protein levels;	chr2:102381424	chr2:102438713~102440475:+
STAD	cis	rs8141529	0.764	rs8137969	ENSG00000272858.1	CTA-292E10.8	-4.59	6.09e-06	0.00318	-0.26	-0.24	Lymphocyte counts;	chr22:28832496	chr22:28814914~28815662:+
STAD	cis	rs416603	0.967	rs11640138	ENSG00000262703.1	RP11-485G7.6	4.59	6.09e-06	0.00318	0.23	0.24	Type 1 diabetes;	chr16:11268872	chr16:11348143~11349321:-
STAD	cis	rs763014	1	rs7205409	ENSG00000228201.1	AL022341.3	4.59	6.09e-06	0.00318	0.29	0.24	Height;	chr16:592610	chr16:648473~649200:-
STAD	cis	rs12468226	1	rs7597156	ENSG00000226261.1	AC064836.3	4.59	6.1e-06	0.00318	0.37	0.24	Urate levels;	chr2:202329339	chr2:202336024~202336727:-
STAD	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-4.59	6.1e-06	0.00318	-0.22	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
STAD	cis	rs11098499	0.954	rs10518331	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119402440	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs13133522	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119403269	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs35091806	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119404374	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs35165976	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119404475	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs2389802	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119404577	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs6846442	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119405168	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.738	rs34566984	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119440115	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.738	rs34965784	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119440431	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs17009122	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119441248	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs9685777	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119444810	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs71614438	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119450097	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs66506550	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119450290	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs7659501	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119450397	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.697	rs28655325	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119451844	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.657	rs71614442	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119458191	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs2892848	ENSG00000260091.1	RP11-33B1.4	4.59	6.1e-06	0.00318	0.24	0.24	Corneal astigmatism;	chr4:119460186	chr4:119409333~119410233:+
STAD	cis	rs3806843	0.607	rs246044	ENSG00000202111.1	VTRNA1-2	-4.59	6.1e-06	0.00318	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140951071	chr5:140718925~140719013:+
STAD	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	4.59	6.1e-06	0.00318	0.27	0.24	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
STAD	cis	rs875971	0.862	rs4149461	ENSG00000236529.1	RP13-254B10.1	-4.59	6.11e-06	0.00318	-0.25	-0.24	Aortic root size;	chr7:66279745	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10261398	ENSG00000236529.1	RP13-254B10.1	-4.59	6.11e-06	0.00318	-0.25	-0.24	Aortic root size;	chr7:66285177	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs10224872	ENSG00000236529.1	RP13-254B10.1	-4.59	6.11e-06	0.00318	-0.25	-0.24	Aortic root size;	chr7:66294786	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs949930	ENSG00000236529.1	RP13-254B10.1	-4.59	6.11e-06	0.00318	-0.25	-0.24	Aortic root size;	chr7:66301835	chr7:65840212~65840596:+
STAD	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-4.59	6.11e-06	0.00318	-0.29	-0.24	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
STAD	cis	rs763014	0.593	rs28455838	ENSG00000228201.1	AL022341.3	4.59	6.12e-06	0.00319	0.28	0.24	Height;	chr16:631966	chr16:648473~649200:-
STAD	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	4.59	6.12e-06	0.00319	0.36	0.24	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	4.59	6.12e-06	0.00319	0.36	0.24	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	4.59	6.12e-06	0.00319	0.36	0.24	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
STAD	cis	rs9307551	0.741	rs1822106	ENSG00000250334.4	LINC00989	-4.59	6.12e-06	0.00319	-0.31	-0.24	Refractive error;	chr4:79487310	chr4:79492416~79576460:+
STAD	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	4.59	6.12e-06	0.00319	0.32	0.24	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
STAD	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	4.59	6.12e-06	0.00319	0.29	0.24	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
STAD	cis	rs891378	1	rs1572275	ENSG00000274245.1	RP11-357P18.2	4.59	6.12e-06	0.00319	0.3	0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207305635	chr1:207372559~207373252:+
STAD	cis	rs1707322	1	rs10890376	ENSG00000281133.1	AL355480.3	-4.59	6.12e-06	0.00319	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45580892~45580996:-
STAD	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	4.59	6.12e-06	0.00319	0.35	0.24	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
STAD	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	4.59	6.12e-06	0.00319	0.32	0.24	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
STAD	cis	rs172166	0.694	rs203877	ENSG00000220721.1	OR1F12	4.59	6.12e-06	0.00319	0.26	0.24	Cardiac Troponin-T levels;	chr6:28080846	chr6:28073316~28074233:+
STAD	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-4.59	6.12e-06	0.00319	-0.31	-0.24	Height;	chr20:49282523	chr20:49280319~49280409:+
STAD	cis	rs7191700	0.644	rs918738	ENSG00000262703.1	RP11-485G7.6	-4.59	6.13e-06	0.00319	-0.23	-0.24	Multiple sclerosis;	chr16:11345822	chr16:11348143~11349321:-
STAD	cis	rs4780355	0.843	rs243325	ENSG00000262703.1	RP11-485G7.6	4.59	6.13e-06	0.00319	0.23	0.24	Crohn's disease and psoriasis;	chr16:11260640	chr16:11348143~11349321:-
STAD	cis	rs11098499	0.908	rs7695996	ENSG00000260091.1	RP11-33B1.4	4.59	6.13e-06	0.00319	0.24	0.24	Corneal astigmatism;	chr4:119400878	chr4:119409333~119410233:+
STAD	cis	rs2337406	0.587	rs10139664	ENSG00000211972.2	IGHV3-66	4.59	6.13e-06	0.00319	0.25	0.24	Alzheimer's disease (late onset);	chr14:106647254	chr14:106675017~106675544:-
STAD	cis	rs875971	0.862	rs9791712	ENSG00000224316.1	RP11-479O9.2	-4.59	6.14e-06	0.0032	-0.23	-0.24	Aortic root size;	chr7:66640176	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs9791713	ENSG00000224316.1	RP11-479O9.2	-4.59	6.14e-06	0.0032	-0.23	-0.24	Aortic root size;	chr7:66640211	chr7:65773620~65802067:+
STAD	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-4.59	6.14e-06	0.0032	-0.31	-0.24	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-4.59	6.14e-06	0.0032	-0.31	-0.24	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
STAD	cis	rs2446066	0.872	rs11170549	ENSG00000257379.1	RP11-793H13.8	4.59	6.14e-06	0.0032	0.4	0.24	Red blood cell count;	chr12:53420596	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.872	rs11170550	ENSG00000257379.1	RP11-793H13.8	4.59	6.14e-06	0.0032	0.4	0.24	Red blood cell count;	chr12:53420930	chr12:53441741~53467528:+
STAD	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-4.59	6.14e-06	0.0032	-0.18	-0.24	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
STAD	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	4.59	6.14e-06	0.0032	0.26	0.24	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-4.59	6.14e-06	0.0032	-0.18	-0.24	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
STAD	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	4.59	6.14e-06	0.0032	0.27	0.24	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
STAD	cis	rs3808502	0.549	rs7831039	ENSG00000270154.1	RP11-419I17.1	-4.59	6.14e-06	0.0032	-0.26	-0.24	Neuroticism;	chr8:11570128	chr8:12476462~12477122:+
STAD	cis	rs2834288	0.613	rs2040113	ENSG00000237945.6	LINC00649	4.59	6.15e-06	0.0032	0.3	0.24	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33915534~33977691:+
STAD	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	4.59	6.15e-06	0.0032	0.34	0.24	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
STAD	cis	rs4691139	0.611	rs11100590	ENSG00000248632.1	RP11-366M4.11	4.59	6.16e-06	0.00321	0.23	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003635	chr4:164968587~164970002:-
STAD	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	4.59	6.17e-06	0.00321	0.47	0.24	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
STAD	cis	rs7176527	1	rs3762169	ENSG00000225151.9	GOLGA2P7	4.59	6.17e-06	0.00321	0.31	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84199311~84230136:-
STAD	cis	rs916888	0.773	rs199457	ENSG00000232300.1	FAM215B	4.59	6.18e-06	0.00322	0.32	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46558830~46562795:-
STAD	cis	rs875971	0.545	rs12671152	ENSG00000236529.1	RP13-254B10.1	4.59	6.18e-06	0.00322	0.29	0.24	Aortic root size;	chr7:66311140	chr7:65840212~65840596:+
STAD	cis	rs4865169	1	rs4865169	ENSG00000269949.1	RP11-738E22.3	-4.59	6.18e-06	0.00322	-0.26	-0.24	Breast cancer;	chr4:57013626	chr4:56960927~56961373:-
STAD	cis	rs4589258	1	rs7112243	ENSG00000280367.1	RP11-121L10.2	4.59	6.19e-06	0.00322	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90723835	chr11:90223153~90226538:+
STAD	cis	rs6788895	0.661	rs1533711	ENSG00000244265.1	SIAH2-AS1	-4.59	6.19e-06	0.00322	-0.41	-0.24	Breast cancer;	chr3:150752209	chr3:150761937~150762538:+
STAD	cis	rs801193	0.548	rs2659904	ENSG00000236529.1	RP13-254B10.1	4.59	6.19e-06	0.00322	0.25	0.24	Aortic root size;	chr7:66713615	chr7:65840212~65840596:+
STAD	cis	rs1707322	1	rs12077974	ENSG00000281133.1	AL355480.3	-4.59	6.19e-06	0.00322	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45580892~45580996:-
STAD	cis	rs11846409	0.932	rs61233250	ENSG00000211972.2	IGHV3-66	4.59	6.19e-06	0.00322	0.25	0.24	Rheumatic heart disease;	chr14:106634072	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs60659763	ENSG00000211972.2	IGHV3-66	4.59	6.19e-06	0.00322	0.25	0.24	Rheumatic heart disease;	chr14:106634172	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs57080270	ENSG00000211972.2	IGHV3-66	4.59	6.19e-06	0.00322	0.25	0.24	Rheumatic heart disease;	chr14:106634215	chr14:106675017~106675544:-
STAD	cis	rs17747401	0.778	rs1538311	ENSG00000236900.1	TIMM9P1	4.59	6.19e-06	0.00322	0.26	0.24	Hypospadias;	chr10:74655751	chr10:74344550~74344805:-
STAD	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	4.59	6.19e-06	0.00322	0.25	0.24	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
STAD	cis	rs2273156	0.929	rs34678475	ENSG00000241052.1	RP11-173D9.1	-4.59	6.2e-06	0.00322	-0.26	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34981897	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12890307	ENSG00000241052.1	RP11-173D9.1	-4.59	6.2e-06	0.00322	-0.26	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34982926	chr14:35144021~35144480:-
STAD	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	6.2e-06	0.00323	-0.21	-0.24	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
STAD	cis	rs228614	0.536	rs150898	ENSG00000248971.2	KRT8P46	-4.59	6.21e-06	0.00323	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102728746~102730171:-
STAD	cis	rs228614	0.509	rs223476	ENSG00000248971.2	KRT8P46	-4.59	6.21e-06	0.00323	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102728746~102730171:-
STAD	cis	rs228614	0.509	rs150896	ENSG00000248971.2	KRT8P46	-4.59	6.21e-06	0.00323	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102728746~102730171:-
STAD	cis	rs427691	0.545	rs25914	ENSG00000271849.1	CTC-332L22.1	-4.59	6.21e-06	0.00323	-0.41	-0.24	Autism spectrum disorder or schizophrenia;	chr5:109657320	chr5:109687802~109688329:-
STAD	cis	rs13113518	0.812	rs12500686	ENSG00000272969.1	RP11-528I4.2	4.59	6.21e-06	0.00323	0.31	0.24	Height;	chr4:55457922	chr4:55547112~55547889:+
STAD	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-4.59	6.22e-06	0.00323	-0.29	-0.24	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
STAD	cis	rs11694172	0.826	rs16839308	ENSG00000273456.1	RP11-686O6.2	-4.59	6.22e-06	0.00323	-0.27	-0.24	Cholesterol, total;	chr2:202757077	chr2:202374932~202375604:-
STAD	cis	rs4589258	1	rs10765387	ENSG00000280367.1	RP11-121L10.2	4.59	6.22e-06	0.00323	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90753683	chr11:90223153~90226538:+
STAD	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	4.59	6.22e-06	0.00323	0.32	0.24	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
STAD	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	4.59	6.22e-06	0.00323	0.25	0.24	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
STAD	cis	rs853679	0.55	rs1233699	ENSG00000220721.1	OR1F12	4.59	6.22e-06	0.00323	0.27	0.24	Depression;	chr6:28201380	chr6:28073316~28074233:+
STAD	cis	rs747650	0.859	rs4567413	ENSG00000271350.1	CTD-2384B9.1	-4.59	6.22e-06	0.00323	-0.28	-0.24	Acne (severe);	chr11:47210633	chr11:47041027~47041945:-
STAD	cis	rs9307551	0.584	rs9990911	ENSG00000250334.4	LINC00989	-4.59	6.22e-06	0.00323	-0.3	-0.24	Refractive error;	chr4:79477923	chr4:79492416~79576460:+
STAD	cis	rs7829975	0.811	rs7011229	ENSG00000173295.6	FAM86B3P	-4.59	6.23e-06	0.00324	-0.28	-0.24	Mood instability;	chr8:8685814	chr8:8228595~8244865:+
STAD	cis	rs748404	0.697	rs1814323	ENSG00000275601.1	AC011330.13	4.59	6.23e-06	0.00324	0.25	0.24	Lung cancer;	chr15:43271039	chr15:43642389~43643023:-
STAD	cis	rs7487075	0.786	rs1492892	ENSG00000257261.4	RP11-96H19.1	4.59	6.23e-06	0.00324	0.29	0.24	Itch intensity from mosquito bite;	chr12:46297704	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.82	rs35497251	ENSG00000257261.4	RP11-96H19.1	4.59	6.23e-06	0.00324	0.29	0.24	Itch intensity from mosquito bite;	chr12:46298698	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.82	rs7967669	ENSG00000257261.4	RP11-96H19.1	4.59	6.23e-06	0.00324	0.29	0.24	Itch intensity from mosquito bite;	chr12:46299208	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.82	rs2018424	ENSG00000257261.4	RP11-96H19.1	4.59	6.23e-06	0.00324	0.29	0.24	Itch intensity from mosquito bite;	chr12:46300874	chr12:46383679~46876159:+
STAD	cis	rs8028182	0.636	rs4075522	ENSG00000260269.4	CTD-2323K18.1	-4.59	6.24e-06	0.00324	-0.31	-0.24	Sudden cardiac arrest;	chr15:75571994	chr15:75527150~75601205:-
STAD	cis	rs4589258	0.788	rs1792616	ENSG00000280367.1	RP11-121L10.2	4.59	6.24e-06	0.00324	0.24	0.24	Intelligence (multi-trait analysis);	chr11:90719058	chr11:90223153~90226538:+
STAD	cis	rs6832769	1	rs9684708	ENSG00000272969.1	RP11-528I4.2	-4.59	6.24e-06	0.00324	-0.3	-0.24	Personality dimensions;	chr4:55564214	chr4:55547112~55547889:+
STAD	cis	rs228614	0.536	rs223478	ENSG00000248971.2	KRT8P46	-4.59	6.24e-06	0.00324	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102728746~102730171:-
STAD	cis	rs7176527	0.5	rs895571	ENSG00000229212.6	RP11-561C5.4	4.59	6.24e-06	0.00324	0.32	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:85205440~85234795:-
STAD	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	4.59	6.25e-06	0.00324	0.36	0.24	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	4.59	6.25e-06	0.00324	0.36	0.24	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	4.59	6.25e-06	0.00324	0.36	0.24	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
STAD	cis	rs3806843	0.547	rs246065	ENSG00000202111.1	VTRNA1-2	-4.59	6.25e-06	0.00325	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140944053	chr5:140718925~140719013:+
STAD	cis	rs1075232	1	rs1075232	ENSG00000270055.1	CTD-3092A11.2	-4.59	6.25e-06	0.00325	-0.42	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31449013	chr15:30487963~30490313:+
STAD	cis	rs11169552	0.51	rs4768903	ENSG00000200183.1	RNU6-238P	-4.59	6.26e-06	0.00325	-0.23	-0.24	Colorectal cancer;	chr12:50651666	chr12:50656973~50657078:+
STAD	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-4.59	6.26e-06	0.00325	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
STAD	cis	rs11098499	0.954	rs10006877	ENSG00000260091.1	RP11-33B1.4	4.59	6.26e-06	0.00325	0.23	0.24	Corneal astigmatism;	chr4:119321638	chr4:119409333~119410233:+
STAD	cis	rs6832769	1	rs726967	ENSG00000272969.1	RP11-528I4.2	-4.59	6.26e-06	0.00325	-0.31	-0.24	Personality dimensions;	chr4:55555546	chr4:55547112~55547889:+
STAD	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-4.59	6.27e-06	0.00325	-0.29	-0.24	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
STAD	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-4.59	6.27e-06	0.00326	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
STAD	cis	rs7487075	0.82	rs7953659	ENSG00000257261.4	RP11-96H19.1	4.59	6.27e-06	0.00326	0.29	0.24	Itch intensity from mosquito bite;	chr12:46304900	chr12:46383679~46876159:+
STAD	cis	rs7951870	0.673	rs13448	ENSG00000271350.1	CTD-2384B9.1	4.59	6.28e-06	0.00326	0.29	0.24	Schizophrenia;	chr11:46673864	chr11:47041027~47041945:-
STAD	cis	rs7119038	0.509	rs11216964	ENSG00000255422.1	AP002954.4	4.59	6.28e-06	0.00326	0.29	0.24	Sjögren's syndrome;	chr11:118711186	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.509	rs10892259	ENSG00000255422.1	AP002954.4	4.59	6.28e-06	0.00326	0.29	0.24	Sjögren's syndrome;	chr11:118712293	chr11:118704607~118750263:+
STAD	cis	rs3733585	0.579	rs4235356	ENSG00000250613.1	RP11-136I13.1	4.59	6.29e-06	0.00326	0.24	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10121482	chr4:10410996~10411644:+
STAD	cis	rs1707322	0.656	rs9429172	ENSG00000225447.1	RPS15AP10	-4.59	6.29e-06	0.00326	-0.19	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.717	rs1135850	ENSG00000225447.1	RPS15AP10	4.59	6.29e-06	0.00326	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45645816~45646197:-
STAD	cis	rs2115630	0.967	rs8027779	ENSG00000225151.9	GOLGA2P7	4.59	6.29e-06	0.00327	0.27	0.24	P wave terminal force;	chr15:84712154	chr15:84199311~84230136:-
STAD	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-4.59	6.3e-06	0.00327	-0.29	-0.24	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
STAD	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-4.59	6.3e-06	0.00327	-0.3	-0.24	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
STAD	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-4.59	6.3e-06	0.00327	-0.3	-0.24	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
STAD	cis	rs6921919	0.583	rs6928771	ENSG00000220721.1	OR1F12	4.59	6.3e-06	0.00327	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs6928773	ENSG00000220721.1	OR1F12	4.59	6.3e-06	0.00327	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28073316~28074233:+
STAD	cis	rs17401966	0.838	rs946501	ENSG00000199562.1	RNU6-37P	4.59	6.3e-06	0.00327	0.18	0.24	Hepatocellular carcinoma;	chr1:10249522	chr1:10298966~10299072:+
STAD	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
STAD	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
STAD	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	4.59	6.32e-06	0.00328	0.3	0.24	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
STAD	cis	rs3808502	0.516	rs6983727	ENSG00000270154.1	RP11-419I17.1	4.59	6.32e-06	0.00328	0.26	0.24	Neuroticism;	chr8:11558303	chr8:12476462~12477122:+
STAD	cis	rs7208859	0.573	rs7222803	ENSG00000263603.1	CTD-2349P21.5	-4.59	6.32e-06	0.00328	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30729469~30731202:+
STAD	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-4.59	6.32e-06	0.00328	-0.24	-0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
STAD	cis	rs228614	0.509	rs223482	ENSG00000248971.2	KRT8P46	-4.59	6.32e-06	0.00328	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102728746~102730171:-
STAD	cis	rs228614	0.509	rs223481	ENSG00000248971.2	KRT8P46	-4.59	6.32e-06	0.00328	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102728746~102730171:-
STAD	cis	rs62246343	0.719	rs1152314	ENSG00000214041.4	PGAM1P4	4.59	6.33e-06	0.00328	0.41	0.24	Fibrinogen levels;	chr3:9450656	chr3:9348443~9349192:+
STAD	cis	rs61270009	0.955	rs12657757	ENSG00000247828.6	TMEM161B-AS1	-4.59	6.33e-06	0.00328	-0.32	-0.24	Depressive symptoms;	chr5:88280952	chr5:88268895~88436685:+
STAD	cis	rs1799949	1	rs67060599	ENSG00000279602.1	CTD-3014M21.1	4.59	6.33e-06	0.00328	0.3	0.24	Menopause (age at onset);	chr17:43103085	chr17:43360041~43361361:-
STAD	cis	rs11098499	0.908	rs9995234	ENSG00000260091.1	RP11-33B1.4	4.59	6.33e-06	0.00328	0.24	0.24	Corneal astigmatism;	chr4:119400672	chr4:119409333~119410233:+
STAD	cis	rs891378	1	rs2184476	ENSG00000274245.1	RP11-357P18.2	-4.59	6.34e-06	0.00329	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207331324	chr1:207372559~207373252:+
STAD	cis	rs891378	0.959	rs1507757	ENSG00000274245.1	RP11-357P18.2	-4.59	6.34e-06	0.00329	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207331403	chr1:207372559~207373252:+
STAD	cis	rs9467773	0.595	rs13207371	ENSG00000243307.2	POM121L6P	4.59	6.34e-06	0.00329	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26896952~26898777:+
STAD	cis	rs1707322	0.963	rs10890373	ENSG00000281133.1	AL355480.3	-4.59	6.34e-06	0.00329	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45580892~45580996:-
STAD	cis	rs721917	0.565	rs7476563	ENSG00000244733.5	RP11-506M13.3	-4.59	6.34e-06	0.00329	-0.27	-0.24	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79660891~79677996:+
STAD	cis	rs507080	0.922	rs471227	ENSG00000278376.1	RP11-158I9.8	-4.59	6.34e-06	0.00329	-0.25	-0.24	Serum metabolite levels;	chr11:118693892	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs516153	ENSG00000278376.1	RP11-158I9.8	-4.59	6.34e-06	0.00329	-0.25	-0.24	Serum metabolite levels;	chr11:118694053	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs518028	ENSG00000278376.1	RP11-158I9.8	-4.59	6.34e-06	0.00329	-0.25	-0.24	Serum metabolite levels;	chr11:118694273	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs519982	ENSG00000278376.1	RP11-158I9.8	-4.59	6.34e-06	0.00329	-0.25	-0.24	Serum metabolite levels;	chr11:118694522	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs478371	ENSG00000278376.1	RP11-158I9.8	-4.59	6.34e-06	0.00329	-0.25	-0.24	Serum metabolite levels;	chr11:118694627	chr11:118791254~118793137:+
STAD	cis	rs7824557	0.564	rs13260727	ENSG00000205879.4	FAM90A2P	4.59	6.35e-06	0.00329	0.26	0.24	Retinal vascular caliber;	chr8:11375351	chr8:12172202~12178575:-
STAD	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	4.58	6.35e-06	0.00329	0.74	0.24	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
STAD	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	4.58	6.35e-06	0.00329	0.74	0.24	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
STAD	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	4.58	6.35e-06	0.00329	0.74	0.24	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
STAD	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	4.58	6.35e-06	0.00329	0.74	0.24	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
STAD	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-4.58	6.35e-06	0.00329	-0.23	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-4.58	6.36e-06	0.00329	-0.18	-0.24	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-4.58	6.36e-06	0.00329	-0.18	-0.24	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
STAD	cis	rs8141529	0.843	rs1065497	ENSG00000226471.5	CTA-292E10.6	-4.58	6.36e-06	0.00329	-0.29	-0.24	Lymphocyte counts;	chr22:28884003	chr22:28800683~28848559:+
STAD	cis	rs2348418	0.966	rs4144964	ENSG00000247934.4	RP11-967K21.1	4.58	6.36e-06	0.0033	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28531249	chr12:28163298~28190738:-
STAD	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-4.58	6.36e-06	0.0033	-0.3	-0.24	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
STAD	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-4.58	6.37e-06	0.0033	-0.23	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
STAD	cis	rs748404	0.66	rs2467742	ENSG00000275601.1	AC011330.13	-4.58	6.37e-06	0.0033	-0.25	-0.24	Lung cancer;	chr15:43458039	chr15:43642389~43643023:-
STAD	cis	rs748404	0.69	rs2244981	ENSG00000275601.1	AC011330.13	-4.58	6.37e-06	0.0033	-0.25	-0.24	Lung cancer;	chr15:43460553	chr15:43642389~43643023:-
STAD	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	4.58	6.37e-06	0.0033	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
STAD	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	4.58	6.37e-06	0.0033	0.27	0.24	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
STAD	cis	rs17401966	0.627	rs35859381	ENSG00000199562.1	RNU6-37P	4.58	6.38e-06	0.0033	0.19	0.24	Hepatocellular carcinoma;	chr1:10405983	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs11579365	ENSG00000199562.1	RNU6-37P	4.58	6.38e-06	0.0033	0.19	0.24	Hepatocellular carcinoma;	chr1:10410789	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs35759975	ENSG00000199562.1	RNU6-37P	4.58	6.38e-06	0.0033	0.19	0.24	Hepatocellular carcinoma;	chr1:10414373	chr1:10298966~10299072:+
STAD	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	4.58	6.38e-06	0.0033	0.33	0.24	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
STAD	cis	rs858239	1	rs166663	ENSG00000230042.1	AK3P3	-4.58	6.38e-06	0.00331	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23129178~23129841:+
STAD	cis	rs62432291	0.681	rs436277	ENSG00000235086.1	FNDC1-IT1	4.58	6.38e-06	0.00331	0.36	0.24	Joint mobility (Beighton score);	chr6:159213110	chr6:159240786~159243329:+
STAD	cis	rs3806843	0.576	rs246066	ENSG00000202111.1	VTRNA1-2	-4.58	6.38e-06	0.00331	-0.24	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140943562	chr5:140718925~140719013:+
STAD	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	4.58	6.39e-06	0.00331	0.29	0.24	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	4.58	6.39e-06	0.00331	0.29	0.24	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
STAD	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-4.58	6.39e-06	0.00331	-0.31	-0.24	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
STAD	cis	rs10504130	0.502	rs12674620	ENSG00000272024.1	RP11-546K22.3	4.58	6.4e-06	0.00331	0.36	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51755043	chr8:51950284~51950690:+
STAD	cis	rs7487075	0.93	rs4076248	ENSG00000272963.1	OR7A19P	4.58	6.4e-06	0.00332	0.22	0.24	Itch intensity from mosquito bite;	chr12:46439822	chr12:46592573~46593305:+
STAD	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	4.58	6.41e-06	0.00332	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
STAD	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	4.58	6.41e-06	0.00332	0.3	0.24	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	4.58	6.41e-06	0.00332	0.3	0.24	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
STAD	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	4.58	6.41e-06	0.00332	0.3	0.24	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
STAD	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-4.58	6.41e-06	0.00332	-0.31	-0.24	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
STAD	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	4.58	6.41e-06	0.00332	0.37	0.24	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
STAD	cis	rs9902453	0.765	rs2628185	ENSG00000240074.1	RPL9P30	-4.58	6.41e-06	0.00332	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29743089	chr17:29855759~29856332:+
STAD	cis	rs7078219	0.965	rs7081858	ENSG00000228778.1	RP11-129J12.1	-4.58	6.41e-06	0.00332	-0.28	-0.24	Dental caries;	chr10:99514808	chr10:99527081~99528261:+
STAD	cis	rs748404	0.723	rs573169	ENSG00000275601.1	AC011330.13	-4.58	6.41e-06	0.00332	-0.25	-0.24	Lung cancer;	chr15:43258383	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs524547	ENSG00000275601.1	AC011330.13	-4.58	6.41e-06	0.00332	-0.25	-0.24	Lung cancer;	chr15:43258825	chr15:43642389~43643023:-
STAD	cis	rs7617773	0.963	rs6800730	ENSG00000224895.1	VPS26BP1	-4.58	6.42e-06	0.00332	-0.25	-0.24	Coronary artery disease;	chr3:48132720	chr3:47960327~47961081:-
STAD	cis	rs6832769	0.922	rs9993675	ENSG00000272969.1	RP11-528I4.2	4.58	6.42e-06	0.00333	0.3	0.24	Personality dimensions;	chr4:55377355	chr4:55547112~55547889:+
STAD	cis	rs227275	0.554	rs223381	ENSG00000248971.2	KRT8P46	-4.58	6.43e-06	0.00333	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102728746~102730171:-
STAD	cis	rs7487075	0.752	rs1060735	ENSG00000257261.4	RP11-96H19.1	4.58	6.43e-06	0.00333	0.32	0.24	Itch intensity from mosquito bite;	chr12:46267604	chr12:46383679~46876159:+
STAD	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-4.58	6.44e-06	0.00333	-0.31	-0.24	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
STAD	cis	rs17660992	0.584	rs11672561	ENSG00000273837.1	LLNLR-470E3.1	-4.58	6.44e-06	0.00333	-0.27	-0.24	Blood protein levels;	chr19:51656353	chr19:51639478~51639931:-
STAD	cis	rs1015362	0.54	rs2378026	ENSG00000275784.1	RP5-1125A11.6	-4.58	6.44e-06	0.00333	-0.28	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33989480~33991818:-
STAD	cis	rs4589258	0.966	rs1783803	ENSG00000280367.1	RP11-121L10.2	4.58	6.44e-06	0.00333	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90719202	chr11:90223153~90226538:+
STAD	cis	rs17264034	0.861	rs414396	ENSG00000250786.1	SNHG18	4.58	6.45e-06	0.00333	0.39	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9550596	chr5:9546200~9550609:+
STAD	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-4.58	6.45e-06	0.00334	-0.23	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
STAD	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	4.58	6.45e-06	0.00334	0.52	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000224205.1	AP000351.4	4.58	6.45e-06	0.00334	0.27	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23987320~23991421:-
STAD	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	4.58	6.45e-06	0.00334	0.26	0.24	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
STAD	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-4.58	6.45e-06	0.00334	-0.31	-0.24	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
STAD	cis	rs2503875	1	rs2460540	ENSG00000230555.2	RP11-517P14.2	4.58	6.45e-06	0.00334	0.25	0.24	Multiple sclerosis;	chr10:43314122	chr10:43420738~43422100:+
STAD	cis	rs7665090	1	rs2903283	ENSG00000248971.2	KRT8P46	-4.58	6.45e-06	0.00334	-0.25	-0.24	Primary biliary cholangitis;	chr4:102636596	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs4579121	ENSG00000248971.2	KRT8P46	-4.58	6.45e-06	0.00334	-0.25	-0.24	Primary biliary cholangitis;	chr4:102637012	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.934	rs6533020	ENSG00000248971.2	KRT8P46	-4.58	6.45e-06	0.00334	-0.25	-0.24	Primary biliary cholangitis;	chr4:102637648	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.934	rs6533021	ENSG00000248971.2	KRT8P46	-4.58	6.45e-06	0.00334	-0.25	-0.24	Primary biliary cholangitis;	chr4:102637696	chr4:102728746~102730171:-
STAD	cis	rs11098499	0.863	rs3775854	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119550816	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs2306456	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119551267	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs2306457	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119551684	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs11947234	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119553704	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs6853998	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119554705	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs6858777	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119554811	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs11933966	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119555560	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs36040693	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119556461	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs11731756	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119557541	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs34308924	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119560276	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs2170276	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119564669	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs1552092	ENSG00000260091.1	RP11-33B1.4	4.58	6.46e-06	0.00334	0.24	0.24	Corneal astigmatism;	chr4:119567341	chr4:119409333~119410233:+
STAD	cis	rs748404	0.66	rs690012	ENSG00000275601.1	AC011330.13	-4.58	6.46e-06	0.00334	-0.25	-0.24	Lung cancer;	chr15:43427557	chr15:43642389~43643023:-
STAD	cis	rs737008	0.922	rs2550475	ENSG00000262703.1	RP11-485G7.6	4.58	6.47e-06	0.00334	0.23	0.24	Obesity-related traits;	chr16:11278129	chr16:11348143~11349321:-
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-4.58	6.47e-06	0.00335	-0.18	-0.24	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-4.58	6.47e-06	0.00335	-0.18	-0.24	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
STAD	cis	rs7474896	1	rs11011344	ENSG00000120555.12	SEPT7P9	4.58	6.47e-06	0.00335	0.33	0.24	Obesity (extreme);	chr10:37715918	chr10:38383069~38402916:-
STAD	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-4.58	6.47e-06	0.00335	-0.38	-0.24	Gout;	chr7:66679692	chr7:66654538~66669855:+
STAD	cis	rs721917	0.525	rs1054053	ENSG00000244733.5	RP11-506M13.3	-4.58	6.47e-06	0.00335	-0.29	-0.24	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79660891~79677996:+
STAD	cis	rs721917	0.525	rs2258874	ENSG00000244733.5	RP11-506M13.3	-4.58	6.47e-06	0.00335	-0.29	-0.24	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79660891~79677996:+
STAD	cis	rs227275	0.524	rs223337	ENSG00000248971.2	KRT8P46	-4.58	6.47e-06	0.00335	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102728746~102730171:-
STAD	cis	rs8141529	0.732	rs5762815	ENSG00000272858.1	CTA-292E10.8	-4.58	6.48e-06	0.00335	-0.26	-0.24	Lymphocyte counts;	chr22:28809088	chr22:28814914~28815662:+
STAD	cis	rs7487075	0.619	rs11183483	ENSG00000257261.4	RP11-96H19.1	4.58	6.48e-06	0.00335	0.32	0.24	Itch intensity from mosquito bite;	chr12:46432698	chr12:46383679~46876159:+
STAD	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-4.58	6.49e-06	0.00335	-0.35	-0.24	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
STAD	cis	rs721917	0.506	rs2819102	ENSG00000244733.5	RP11-506M13.3	-4.58	6.49e-06	0.00335	-0.29	-0.24	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79660891~79677996:+
STAD	cis	rs611744	0.507	rs1579924	ENSG00000253754.1	RP11-35G22.1	-4.58	6.5e-06	0.00336	-0.22	-0.24	Dupuytren's disease;	chr8:108312655	chr8:108226200~108227544:+
STAD	cis	rs2384207	0.818	rs34326408	ENSG00000277566.1	RP11-545P7.9	-4.58	6.5e-06	0.00336	-0.33	-0.24	Response to fenofibrate (adiponectin levels);	chr12:113209532	chr12:113249466~113250042:+
STAD	cis	rs7078219	0.965	rs11190134	ENSG00000228778.1	RP11-129J12.1	-4.58	6.5e-06	0.00336	-0.3	-0.24	Dental caries;	chr10:99522443	chr10:99527081~99528261:+
STAD	cis	rs1799949	1	rs8176234	ENSG00000279602.1	CTD-3014M21.1	4.58	6.5e-06	0.00336	0.3	0.24	Menopause (age at onset);	chr17:43067763	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs8176233	ENSG00000279602.1	CTD-3014M21.1	4.58	6.5e-06	0.00336	0.3	0.24	Menopause (age at onset);	chr17:43067787	chr17:43360041~43361361:-
STAD	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-4.58	6.51e-06	0.00336	-0.24	-0.24	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
STAD	cis	rs11233413	0.508	rs10792666	ENSG00000246067.6	RAB30-AS1	4.58	6.51e-06	0.00336	0.22	0.24	Economic and political preferences (feminism/equality);	chr11:82938958	chr11:83072066~83106719:+
STAD	cis	rs8028182	0.636	rs62027209	ENSG00000260269.4	CTD-2323K18.1	-4.58	6.51e-06	0.00336	-0.31	-0.24	Sudden cardiac arrest;	chr15:75579285	chr15:75527150~75601205:-
STAD	cis	rs1056107	0.831	rs10981305	ENSG00000225513.1	RP11-165N19.2	-4.58	6.52e-06	0.00336	-0.28	-0.24	Colorectal cancer;	chr9:112197858	chr9:112173522~112173971:-
STAD	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	4.58	6.52e-06	0.00336	0.3	0.24	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
STAD	cis	rs7208859	0.524	rs77498725	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs73267865	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.706	rs57698184	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30737900	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.524	rs59923796	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.5	rs57005940	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30739311	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs73267872	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.706	rs9893922	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30741407	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.524	rs57670615	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.5	rs2874724	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30745415	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.568	rs9898097	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30745654	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.5	rs9891256	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30745674	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9911490	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7503542	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7503335	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs11656278	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs6505207	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs7223803	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.568	rs2626985	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30750419	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs55814012	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.5	rs2449749	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30751280	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9894709	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9896603	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7219712	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs8078656	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs8080882	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs28556733	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.5	rs28452421	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30756962	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs28433704	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs28779471	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.5	rs61685770	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30758695	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs57486336	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.706	rs55764512	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30758740	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs12103440	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs12103508	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11657777	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7217984	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs73269916	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.524	rs60114476	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.562	rs8078897	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs8075163	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.706	rs8075107	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Body mass index;	chr17:30779631	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7223209	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7223404	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9916725	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9916727	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9914499	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs73269945	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9897728	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs1054400	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9890558	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9912283	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs12006	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs3752021	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs3752020	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9890855	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9891166	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs73269974	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.52e-06	0.00336	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30729469~30731202:+
STAD	cis	rs2483058	0.767	rs11809494	ENSG00000261000.1	RP11-534L20.5	4.58	6.52e-06	0.00336	0.28	0.24	Cholesterol and Triglycerides;	chr1:206450521	chr1:206503948~206504456:+
STAD	cis	rs1799949	1	rs35070007	ENSG00000279602.1	CTD-3014M21.1	-4.58	6.53e-06	0.00336	-0.29	-0.24	Menopause (age at onset);	chr17:43164730	chr17:43360041~43361361:-
STAD	cis	rs228614	0.51	rs223455	ENSG00000248971.2	KRT8P46	-4.58	6.53e-06	0.00336	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102728746~102730171:-
STAD	cis	rs2117029	0.782	rs10459232	ENSG00000258017.1	RP11-386G11.10	-4.58	6.53e-06	0.00337	-0.24	-0.24	Intelligence (multi-trait analysis);	chr12:49073293	chr12:49127782~49147869:+
STAD	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-4.58	6.53e-06	0.00337	-0.28	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
STAD	cis	rs7702057	0.53	rs7703978	ENSG00000271918.1	CTD-2287O16.5	4.58	6.54e-06	0.00337	0.45	0.24	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116083807~116085416:-
STAD	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-4.58	6.54e-06	0.00337	-0.25	-0.24	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
STAD	cis	rs7615952	0.688	rs17334074	ENSG00000242229.1	RPS3AP14	-4.58	6.54e-06	0.00337	-0.28	-0.24	Blood pressure (smoking interaction);	chr3:125821617	chr3:125795106~125795885:+
STAD	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	4.58	6.54e-06	0.00337	0.26	0.24	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
STAD	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	4.58	6.54e-06	0.00337	0.26	0.24	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	4.58	6.55e-06	0.00338	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
STAD	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	4.58	6.55e-06	0.00338	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	4.58	6.55e-06	0.00338	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
STAD	cis	rs1614887	1	rs1614887	ENSG00000243307.2	POM121L6P	4.58	6.55e-06	0.00338	0.23	0.24	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr6:26896952~26898777:+
STAD	cis	rs9902453	0.817	rs17226179	ENSG00000240074.1	RPL9P30	4.58	6.55e-06	0.00338	0.2	0.24	Coffee consumption (cups per day);	chr17:29841555	chr17:29855759~29856332:+
STAD	cis	rs17826219	0.636	rs4055314	ENSG00000263603.1	CTD-2349P21.5	-4.58	6.55e-06	0.00338	-0.31	-0.24	Body mass index;	chr17:30752751	chr17:30729469~30731202:+
STAD	cis	rs227275	0.556	rs12508069	ENSG00000248971.2	KRT8P46	-4.58	6.56e-06	0.00338	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102728746~102730171:-
STAD	cis	rs227275	0.527	rs12500379	ENSG00000248971.2	KRT8P46	-4.58	6.56e-06	0.00338	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102728746~102730171:-
STAD	cis	rs1799949	1	rs36036395	ENSG00000236383.6	LINC00854	-4.58	6.56e-06	0.00338	-0.2	-0.24	Menopause (age at onset);	chr17:43029280	chr17:43216941~43305976:-
STAD	cis	rs9902453	0.689	rs56788338	ENSG00000240074.1	RPL9P30	4.58	6.56e-06	0.00338	0.21	0.24	Coffee consumption (cups per day);	chr17:29859539	chr17:29855759~29856332:+
STAD	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	4.58	6.56e-06	0.00338	0.28	0.24	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
STAD	cis	rs875971	1	rs709595	ENSG00000236529.1	RP13-254B10.1	4.58	6.56e-06	0.00338	0.25	0.24	Aortic root size;	chr7:66352346	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs811880	ENSG00000236529.1	RP13-254B10.1	4.58	6.56e-06	0.00338	0.25	0.24	Aortic root size;	chr7:66353659	chr7:65840212~65840596:+
STAD	cis	rs8141529	0.732	rs2269577	ENSG00000272858.1	CTA-292E10.8	-4.58	6.57e-06	0.00338	-0.26	-0.24	Lymphocyte counts;	chr22:28800769	chr22:28814914~28815662:+
STAD	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	4.58	6.57e-06	0.00338	0.25	0.24	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
STAD	cis	rs860295	0.702	rs5005770	ENSG00000225855.5	RUSC1-AS1	-4.58	6.57e-06	0.00338	-0.2	-0.24	Body mass index;	chr1:155375252	chr1:155316863~155324176:-
STAD	cis	rs11098499	0.866	rs10518329	ENSG00000260091.1	RP11-33B1.4	4.58	6.57e-06	0.00338	0.23	0.24	Corneal astigmatism;	chr4:119480680	chr4:119409333~119410233:+
STAD	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	4.58	6.57e-06	0.00339	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
STAD	cis	rs9990333	0.562	rs12632706	ENSG00000252174.1	RNU7-18P	-4.58	6.57e-06	0.00339	-0.25	-0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:196072819~196072880:+
STAD	cis	rs227275	0.556	rs10015289	ENSG00000248971.2	KRT8P46	-4.58	6.58e-06	0.00339	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs6852141	ENSG00000248971.2	KRT8P46	-4.58	6.58e-06	0.00339	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs9999303	ENSG00000248971.2	KRT8P46	-4.58	6.58e-06	0.00339	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102728746~102730171:-
STAD	cis	rs228614	0.509	rs4455415	ENSG00000248971.2	KRT8P46	-4.58	6.58e-06	0.00339	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs6853193	ENSG00000248971.2	KRT8P46	-4.58	6.58e-06	0.00339	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102728746~102730171:-
STAD	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-4.58	6.58e-06	0.00339	-0.44	-0.24	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
STAD	cis	rs831571	0.774	rs254858	ENSG00000280620.1	SCAANT1	-4.58	6.58e-06	0.00339	-0.33	-0.24	Type 2 diabetes;	chr3:64070579	chr3:63911518~63911772:-
STAD	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	4.58	6.58e-06	0.00339	0.27	0.24	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
STAD	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-4.58	6.59e-06	0.00339	-0.3	-0.24	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
STAD	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	4.58	6.59e-06	0.00339	0.28	0.24	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
STAD	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	4.58	6.59e-06	0.00339	0.28	0.24	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
STAD	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	4.58	6.59e-06	0.00339	0.3	0.24	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
STAD	cis	rs2921036	0.545	rs4840975	ENSG00000254340.1	RP11-10A14.3	-4.58	6.6e-06	0.0034	-0.33	-0.24	Neuroticism;	chr8:8505748	chr8:9141424~9145435:+
STAD	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	4.58	6.6e-06	0.0034	0.29	0.24	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
STAD	cis	rs7487075	0.558	rs56988021	ENSG00000272369.1	RP11-446N19.1	4.58	6.6e-06	0.0034	0.29	0.24	Itch intensity from mosquito bite;	chr12:46243568	chr12:46537502~46652550:+
STAD	cis	rs10129255	0.5	rs8021941	ENSG00000211973.2	IGHV1-69	4.58	6.6e-06	0.0034	0.2	0.24	Kawasaki disease;	chr14:106781490	chr14:106714684~106715181:-
STAD	cis	rs227932	0.764	rs76349338	ENSG00000234286.1	AC006026.13	-4.58	6.61e-06	0.0034	-0.43	-0.24	Schizophrenia;	chr7:23709138	chr7:23680195~23680786:-
STAD	cis	rs11098499	0.505	rs75122014	ENSG00000260091.1	RP11-33B1.4	4.58	6.61e-06	0.0034	0.24	0.24	Corneal astigmatism;	chr4:119441271	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs10026736	ENSG00000260091.1	RP11-33B1.4	4.58	6.61e-06	0.0034	0.24	0.24	Corneal astigmatism;	chr4:119463167	chr4:119409333~119410233:+
STAD	cis	rs7078219	0.505	rs7085798	ENSG00000257582.4	LINC01475	-4.58	6.61e-06	0.0034	-0.27	-0.24	Dental caries;	chr10:99528590	chr10:99526350~99531177:-
STAD	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	4.58	6.61e-06	0.0034	0.24	0.24	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
STAD	cis	rs875971	0.964	rs778735	ENSG00000236529.1	RP13-254B10.1	4.58	6.61e-06	0.0034	0.25	0.24	Aortic root size;	chr7:66349822	chr7:65840212~65840596:+
STAD	cis	rs1799949	0.965	rs35954893	ENSG00000279602.1	CTD-3014M21.1	4.58	6.61e-06	0.0034	0.3	0.24	Menopause (age at onset);	chr17:43181769	chr17:43360041~43361361:-
STAD	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	4.58	6.62e-06	0.00341	0.29	0.24	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
STAD	cis	rs7119038	0.509	rs11216960	ENSG00000255422.1	AP002954.4	4.58	6.62e-06	0.00341	0.29	0.24	Sjögren's syndrome;	chr11:118707164	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.509	rs10892256	ENSG00000255422.1	AP002954.4	4.58	6.62e-06	0.00341	0.29	0.24	Sjögren's syndrome;	chr11:118707996	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.509	rs10892257	ENSG00000255422.1	AP002954.4	4.58	6.62e-06	0.00341	0.29	0.24	Sjögren's syndrome;	chr11:118708618	chr11:118704607~118750263:+
STAD	cis	rs1488193	1	rs1488193	ENSG00000240057.4	RP11-572M11.4	-4.58	6.63e-06	0.00341	-0.35	-0.24	Economic and political preferences;	chr3:112962738	chr3:113019532~113183301:+
STAD	cis	rs7487075	0.558	rs4768692	ENSG00000272369.1	RP11-446N19.1	4.58	6.63e-06	0.00341	0.29	0.24	Itch intensity from mosquito bite;	chr12:46245852	chr12:46537502~46652550:+
STAD	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	4.58	6.64e-06	0.00341	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
STAD	cis	rs9807989	0.839	rs7603730	ENSG00000234389.1	AC007278.3	4.57	6.65e-06	0.00342	0.25	0.24	Asthma;	chr2:102357911	chr2:102438713~102440475:+
STAD	cis	rs6095360	0.7	rs11908024	ENSG00000222365.1	SNORD12B	-4.57	6.65e-06	0.00342	-0.3	-0.24	Intelligence (multi-trait analysis);	chr20:49081649	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs2075677	ENSG00000222365.1	SNORD12B	-4.57	6.65e-06	0.00342	-0.3	-0.24	Intelligence (multi-trait analysis);	chr20:49084487	chr20:49280319~49280409:+
STAD	cis	rs6095360	0.727	rs7264419	ENSG00000222365.1	SNORD12B	-4.57	6.65e-06	0.00342	-0.3	-0.24	Intelligence (multi-trait analysis);	chr20:49084772	chr20:49280319~49280409:+
STAD	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-4.57	6.66e-06	0.00342	-0.27	-0.24	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
STAD	cis	rs3777722	1	rs3777722	ENSG00000265828.1	MIR3939	4.57	6.66e-06	0.00342	0.36	0.24	Spontaneous preterm birth (preterm birth);	chr6:166938616	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs2298862	ENSG00000236383.6	LINC00854	-4.57	6.66e-06	0.00343	-0.2	-0.24	Menopause (age at onset);	chr17:43024671	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.93	rs2298861	ENSG00000236383.6	LINC00854	-4.57	6.66e-06	0.00343	-0.2	-0.24	Menopause (age at onset);	chr17:43024814	chr17:43216941~43305976:-
STAD	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	4.57	6.66e-06	0.00343	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	4.57	6.66e-06	0.00343	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
STAD	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-4.57	6.66e-06	0.00343	-0.18	-0.24	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
STAD	cis	rs17214007	0.877	rs2075515	ENSG00000263335.1	AF001548.5	-4.57	6.67e-06	0.00343	-0.27	-0.24	Cognitive function;	chr16:15778462	chr16:15726674~15732993:+
STAD	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	4.57	6.67e-06	0.00343	0.29	0.24	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
STAD	cis	rs77956314	0.515	rs12299065	ENSG00000274554.1	RP11-240G22.5	-4.57	6.67e-06	0.00343	-0.3	-0.24	Hippocampal volume;Subcortical brain region volumes;	chr12:117004499	chr12:116948738~116951422:-
STAD	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	4.57	6.68e-06	0.00343	0.23	0.24	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
STAD	cis	rs875971	0.964	rs778723	ENSG00000236529.1	RP13-254B10.1	4.57	6.69e-06	0.00344	0.25	0.24	Aortic root size;	chr7:66364510	chr7:65840212~65840596:+
STAD	cis	rs5758659	0.935	rs134879	ENSG00000182057.4	OGFRP1	4.57	6.69e-06	0.00344	0.25	0.24	Cognitive function;	chr22:42268195	chr22:42269753~42275196:+
STAD	cis	rs6479901	0.512	rs4746244	ENSG00000232075.1	MRPL35P2	-4.57	6.69e-06	0.00344	-0.37	-0.24	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63634317~63634827:-
STAD	cis	rs7078219	0.505	rs6584282	ENSG00000257582.4	LINC01475	-4.57	6.69e-06	0.00344	-0.27	-0.24	Dental caries;	chr10:99526738	chr10:99526350~99531177:-
STAD	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-4.57	6.7e-06	0.00344	-0.35	-0.24	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
STAD	cis	rs6584283	0.875	rs1548962	ENSG00000257582.4	LINC01475	4.57	6.7e-06	0.00344	0.27	0.24	Ulcerative colitis;	chr10:99529978	chr10:99526350~99531177:-
STAD	cis	rs6095360	0.69	rs1115535	ENSG00000222365.1	SNORD12B	-4.57	6.71e-06	0.00344	-0.31	-0.24	Intelligence (multi-trait analysis);	chr20:48974027	chr20:49280319~49280409:+
STAD	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	4.57	6.71e-06	0.00345	0.29	0.24	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
STAD	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-4.57	6.71e-06	0.00345	-0.24	-0.24	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
STAD	cis	rs4691139	0.619	rs7441550	ENSG00000248632.1	RP11-366M4.11	4.57	6.71e-06	0.00345	0.23	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003160	chr4:164968587~164970002:-
STAD	cis	rs7829975	0.807	rs519019	ENSG00000173295.6	FAM86B3P	-4.57	6.71e-06	0.00345	-0.27	-0.24	Mood instability;	chr8:8737594	chr8:8228595~8244865:+
STAD	cis	rs1707322	0.682	rs3014241	ENSG00000225447.1	RPS15AP10	-4.57	6.72e-06	0.00345	-0.19	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45645816~45646197:-
STAD	cis	rs7429990	0.833	rs883661	ENSG00000224895.1	VPS26BP1	4.57	6.72e-06	0.00345	0.23	0.24	Educational attainment (years of education);	chr3:47618611	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs11130144	ENSG00000224895.1	VPS26BP1	4.57	6.72e-06	0.00345	0.23	0.24	Educational attainment (years of education);	chr3:47626444	chr3:47960327~47961081:-
STAD	cis	rs875971	1	rs7781698	ENSG00000236529.1	RP13-254B10.1	4.57	6.72e-06	0.00345	0.25	0.24	Aortic root size;	chr7:66431325	chr7:65840212~65840596:+
STAD	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-4.57	6.72e-06	0.00345	-0.28	-0.24	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
STAD	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-4.57	6.72e-06	0.00345	-0.4	-0.24	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
STAD	cis	rs1322639	0.657	rs9355135	ENSG00000261039.2	RP11-417E7.2	-4.57	6.73e-06	0.00345	-0.39	-0.24	Pulse pressure;	chr6:169172911	chr6:169175304~169182740:-
STAD	cis	rs8062405	0.789	rs240704	ENSG00000278665.1	RP11-666O2.4	4.57	6.73e-06	0.00346	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28599241~28601881:-
STAD	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	4.57	6.73e-06	0.00346	0.3	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
STAD	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	4.57	6.74e-06	0.00346	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
STAD	cis	rs8177876	0.749	rs78707250	ENSG00000261061.1	RP11-303E16.2	-4.57	6.74e-06	0.00346	-0.4	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81030770~81031485:+
STAD	cis	rs7487075	1	rs12813763	ENSG00000257261.4	RP11-96H19.1	-4.57	6.74e-06	0.00346	-0.29	-0.24	Itch intensity from mosquito bite;	chr12:46429121	chr12:46383679~46876159:+
STAD	cis	rs891378	0.92	rs10864156	ENSG00000274245.1	RP11-357P18.2	-4.57	6.74e-06	0.00346	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207240416	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs6664815	ENSG00000274245.1	RP11-357P18.2	-4.57	6.74e-06	0.00346	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207242218	chr1:207372559~207373252:+
STAD	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	4.57	6.74e-06	0.00346	0.29	0.24	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
STAD	cis	rs2921036	0.505	rs35190619	ENSG00000253981.4	ALG1L13P	-4.57	6.74e-06	0.00346	-0.35	-0.24	Neuroticism;	chr8:8504313	chr8:8236003~8244667:-
STAD	cis	rs227275	0.525	rs4699046	ENSG00000248971.2	KRT8P46	-4.57	6.75e-06	0.00346	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs4699047	ENSG00000248971.2	KRT8P46	-4.57	6.75e-06	0.00346	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102728746~102730171:-
STAD	cis	rs831571	0.695	rs73120926	ENSG00000280620.1	SCAANT1	4.57	6.75e-06	0.00346	0.35	0.24	Type 2 diabetes;	chr3:64051274	chr3:63911518~63911772:-
STAD	cis	rs58873874	0.522	rs111370613	ENSG00000251405.2	CTB-109A12.1	4.57	6.75e-06	0.00346	0.41	0.24	Bipolar disorder (body mass index interaction);	chr5:157271128	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.522	rs77458926	ENSG00000251405.2	CTB-109A12.1	4.57	6.75e-06	0.00346	0.41	0.24	Bipolar disorder (body mass index interaction);	chr5:157271198	chr5:157362615~157460078:-
STAD	cis	rs227275	0.556	rs223426	ENSG00000248971.2	KRT8P46	-4.57	6.75e-06	0.00346	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223425	ENSG00000248971.2	KRT8P46	-4.57	6.75e-06	0.00346	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102728746~102730171:-
STAD	cis	rs1150668	0.768	rs1150716	ENSG00000220721.1	OR1F12	4.57	6.75e-06	0.00347	0.23	0.24	Pubertal anthropometrics;	chr6:28294921	chr6:28073316~28074233:+
STAD	cis	rs7487075	0.619	rs4077707	ENSG00000257261.4	RP11-96H19.1	4.57	6.76e-06	0.00347	0.3	0.24	Itch intensity from mosquito bite;	chr12:46464715	chr12:46383679~46876159:+
STAD	cis	rs9788721	0.802	rs56219465	ENSG00000259419.2	HNRNPCP3	4.57	6.76e-06	0.00347	0.26	0.24	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78450237	chr15:79236332~79237206:+
STAD	cis	rs11846409	0.818	rs2516909	ENSG00000211970.3	IGHV4-61	-4.57	6.76e-06	0.00347	-0.27	-0.24	Rheumatic heart disease;	chr14:106630317	chr14:106639119~106639657:-
STAD	cis	rs2286503	0.78	rs929464	ENSG00000228649.7	AC005682.5	4.57	6.76e-06	0.00347	0.28	0.24	Fibrinogen;	chr7:22835151	chr7:22854178~22861579:+
STAD	cis	rs9646944	0.501	rs1403552	ENSG00000234389.1	AC007278.3	4.57	6.77e-06	0.00347	0.32	0.24	Blood protein levels;	chr2:102472317	chr2:102438713~102440475:+
STAD	cis	rs9902453	0.845	rs2628165	ENSG00000240074.1	RPL9P30	4.57	6.77e-06	0.00347	0.21	0.24	Coffee consumption (cups per day);	chr17:29794148	chr17:29855759~29856332:+
STAD	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	4.57	6.77e-06	0.00347	0.3	0.24	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	4.57	6.77e-06	0.00347	0.3	0.24	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
STAD	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	4.57	6.77e-06	0.00347	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
STAD	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	4.57	6.77e-06	0.00348	0.3	0.24	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	4.57	6.77e-06	0.00348	0.3	0.24	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
STAD	cis	rs72687362	0.834	rs72687350	ENSG00000261693.1	RP13-467H17.1	4.57	6.78e-06	0.00348	0.39	0.24	Autism spectrum disorder or schizophrenia;	chr8:142266125	chr8:142403652~142407028:+
STAD	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	4.57	6.78e-06	0.00348	0.48	0.24	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
STAD	cis	rs9902453	0.765	rs1531553	ENSG00000240074.1	RPL9P30	-4.57	6.78e-06	0.00348	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29739734	chr17:29855759~29856332:+
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-4.57	6.78e-06	0.00348	-0.18	-0.24	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
STAD	cis	rs7191700	0.511	rs12923756	ENSG00000262703.1	RP11-485G7.6	-4.57	6.78e-06	0.00348	-0.22	-0.24	Multiple sclerosis;	chr16:11265818	chr16:11348143~11349321:-
STAD	cis	rs7429990	0.833	rs3755638	ENSG00000224895.1	VPS26BP1	4.57	6.79e-06	0.00348	0.23	0.24	Educational attainment (years of education);	chr3:47580841	chr3:47960327~47961081:-
STAD	cis	rs9463078	0.625	rs538801	ENSG00000219384.1	RP11-491H9.3	-4.57	6.8e-06	0.00349	-0.23	-0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44908025	chr6:45158870~45159511:+
STAD	cis	rs1167827	0.71	rs1167836	ENSG00000165178.9	NCF1C	4.57	6.8e-06	0.00349	0.18	0.24	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75156639~75172044:-
STAD	cis	rs237743	1	rs34804433	ENSG00000222365.1	SNORD12B	-4.57	6.8e-06	0.00349	-0.32	-0.24	Height;	chr20:49279650	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs67214274	ENSG00000222365.1	SNORD12B	-4.57	6.8e-06	0.00349	-0.32	-0.24	Height;	chr20:49282024	chr20:49280319~49280409:+
STAD	cis	rs237743	0.963	rs35772539	ENSG00000222365.1	SNORD12B	-4.57	6.8e-06	0.00349	-0.32	-0.24	Height;	chr20:49282748	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs35387764	ENSG00000222365.1	SNORD12B	-4.57	6.8e-06	0.00349	-0.32	-0.24	Height;	chr20:49286304	chr20:49280319~49280409:+
STAD	cis	rs8141529	0.732	rs2239815	ENSG00000272858.1	CTA-292E10.8	4.57	6.81e-06	0.00349	0.26	0.24	Lymphocyte counts;	chr22:28796682	chr22:28814914~28815662:+
STAD	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-4.57	6.81e-06	0.00349	-0.3	-0.24	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
STAD	cis	rs2273156	1	rs17102970	ENSG00000241052.1	RP11-173D9.1	-4.57	6.81e-06	0.00349	-0.26	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011363	chr14:35144021~35144480:-
STAD	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	4.57	6.82e-06	0.00349	0.3	0.24	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
STAD	cis	rs8062405	0.824	rs240702	ENSG00000278665.1	RP11-666O2.4	4.57	6.82e-06	0.00349	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.824	rs62034319	ENSG00000278665.1	RP11-666O2.4	4.57	6.82e-06	0.00349	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28599241~28601881:-
STAD	cis	rs11676348	0.808	rs61700947	ENSG00000237281.1	CATIP-AS2	-4.57	6.82e-06	0.0035	-0.24	-0.24	Ulcerative colitis;	chr2:218181448	chr2:218326889~218357966:-
STAD	cis	rs4308124	1	rs4308124	ENSG00000227992.1	AC108463.2	-4.57	6.83e-06	0.0035	-0.3	-0.24	Vitiligo;	chr2:111252909	chr2:111203964~111206215:-
STAD	cis	rs7932354	0.583	rs2070851	ENSG00000271350.1	CTD-2384B9.1	4.57	6.83e-06	0.0035	0.31	0.24	Bone mineral density (hip);Bone mineral density;	chr11:46722978	chr11:47041027~47041945:-
STAD	cis	rs9910055	0.53	rs11656758	ENSG00000260793.2	RP5-882C2.2	-4.57	6.83e-06	0.0035	-0.26	-0.24	Total body bone mineral density;	chr17:44224173	chr17:44221401~44223710:+
STAD	cis	rs11022119	1	rs11022119	ENSG00000255067.1	RP11-47J17.1	4.57	6.83e-06	0.0035	0.24	0.24	Blood protein levels;	chr11:12029105	chr11:12848795~12849433:+
STAD	cis	rs8028182	0.636	rs4486847	ENSG00000260269.4	CTD-2323K18.1	-4.57	6.83e-06	0.0035	-0.3	-0.24	Sudden cardiac arrest;	chr15:75436190	chr15:75527150~75601205:-
STAD	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	4.57	6.83e-06	0.0035	0.35	0.24	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
STAD	cis	rs7474896	0.507	rs2474555	ENSG00000120555.12	SEPT7P9	4.57	6.84e-06	0.0035	0.3	0.24	Obesity (extreme);	chr10:38176292	chr10:38383069~38402916:-
STAD	cis	rs2483058	0.767	rs963894	ENSG00000261000.1	RP11-534L20.5	4.57	6.84e-06	0.0035	0.28	0.24	Cholesterol and Triglycerides;	chr1:206452085	chr1:206503948~206504456:+
STAD	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	4.57	6.84e-06	0.0035	0.31	0.24	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
STAD	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	4.57	6.84e-06	0.0035	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
STAD	cis	rs10504130	0.696	rs60796336	ENSG00000272024.1	RP11-546K22.3	-4.57	6.84e-06	0.00351	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51950284~51950690:+
STAD	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	4.57	6.84e-06	0.00351	0.3	0.24	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
STAD	cis	rs1707322	1	rs11211232	ENSG00000281133.1	AL355480.3	-4.57	6.84e-06	0.00351	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45580892~45580996:-
STAD	cis	rs7208859	0.573	rs79505916	ENSG00000263603.1	CTD-2349P21.5	-4.57	6.85e-06	0.00351	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30729469~30731202:+
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-4.57	6.85e-06	0.00351	-0.18	-0.24	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
STAD	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	4.57	6.85e-06	0.00351	0.25	0.24	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
STAD	cis	rs7615952	0.688	rs7624806	ENSG00000239804.1	RP11-379B18.1	4.57	6.85e-06	0.00351	0.39	0.24	Blood pressure (smoking interaction);	chr3:125880231	chr3:125787888~125788146:-
STAD	cis	rs875971	0.861	rs801215	ENSG00000224316.1	RP11-479O9.2	-4.57	6.85e-06	0.00351	-0.23	-0.24	Aortic root size;	chr7:66546951	chr7:65773620~65802067:+
STAD	cis	rs227275	0.525	rs28778380	ENSG00000248971.2	KRT8P46	-4.57	6.86e-06	0.00351	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102728746~102730171:-
STAD	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-4.57	6.86e-06	0.00351	-0.3	-0.24	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
STAD	cis	rs6921919	0.583	rs3800328	ENSG00000220721.1	OR1F12	4.57	6.87e-06	0.00352	0.25	0.24	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28073316~28074233:+
STAD	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	4.57	6.87e-06	0.00352	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	4.57	6.87e-06	0.00352	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
STAD	cis	rs9463078	0.625	rs679713	ENSG00000219384.1	RP11-491H9.3	4.57	6.87e-06	0.00352	0.23	0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44931895	chr6:45158870~45159511:+
STAD	cis	rs1007738	0.507	rs10742797	ENSG00000271350.1	CTD-2384B9.1	4.57	6.88e-06	0.00352	0.31	0.24	Bone mineral density (hip);	chr11:47218939	chr11:47041027~47041945:-
STAD	cis	rs7760535	0.764	rs2343614	ENSG00000230177.1	RP5-1112D6.4	-4.57	6.88e-06	0.00352	-0.21	-0.24	Metabolic traits;	chr6:111383955	chr6:111277932~111278742:+
STAD	cis	rs2695743	0.619	rs1438062	ENSG00000225808.1	DNAJC19P5	-4.57	6.88e-06	0.00352	-0.28	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177831003	chr2:177229191~177229506:-
STAD	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	4.57	6.89e-06	0.00353	0.27	0.24	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
STAD	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	4.57	6.89e-06	0.00353	0.28	0.24	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
STAD	cis	rs5753618	0.509	rs5997902	ENSG00000236132.1	CTA-440B3.1	4.57	6.89e-06	0.00353	0.28	0.24	Colorectal cancer;	chr22:31187021	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.509	rs4820951	ENSG00000236132.1	CTA-440B3.1	4.57	6.89e-06	0.00353	0.28	0.24	Colorectal cancer;	chr22:31190262	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.509	rs5749229	ENSG00000236132.1	CTA-440B3.1	4.57	6.89e-06	0.00353	0.28	0.24	Colorectal cancer;	chr22:31191232	chr22:31816379~31817491:-
STAD	cis	rs4141404	0.787	rs4820042	ENSG00000236132.1	CTA-440B3.1	4.57	6.89e-06	0.00353	0.28	0.24	Paclitaxel-induced neuropathy;	chr22:31193070	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.509	rs5997912	ENSG00000236132.1	CTA-440B3.1	4.57	6.89e-06	0.00353	0.28	0.24	Colorectal cancer;	chr22:31197875	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.509	rs5997913	ENSG00000236132.1	CTA-440B3.1	4.57	6.89e-06	0.00353	0.28	0.24	Colorectal cancer;	chr22:31197973	chr22:31816379~31817491:-
STAD	cis	rs6019512	0.647	rs4810888	ENSG00000227431.4	CSE1L-AS1	-4.57	6.89e-06	0.00353	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48906783	chr20:49040463~49046044:-
STAD	cis	rs6019512	0.625	rs4810890	ENSG00000227431.4	CSE1L-AS1	-4.57	6.89e-06	0.00353	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48908920	chr20:49040463~49046044:-
STAD	cis	rs6019512	0.625	rs4810891	ENSG00000227431.4	CSE1L-AS1	-4.57	6.89e-06	0.00353	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48908981	chr20:49040463~49046044:-
STAD	cis	rs721917	0.646	rs2819096	ENSG00000244733.5	RP11-506M13.3	-4.57	6.89e-06	0.00353	-0.26	-0.24	Chronic obstructive pulmonary disease;	chr10:79947857	chr10:79660891~79677996:+
STAD	cis	rs7208859	0.573	rs56031503	ENSG00000263603.1	CTD-2349P21.5	-4.57	6.9e-06	0.00353	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30729469~30731202:+
STAD	cis	rs8141529	0.509	rs12628211	ENSG00000226471.5	CTA-292E10.6	-4.57	6.9e-06	0.00353	-0.29	-0.24	Lymphocyte counts;	chr22:28843262	chr22:28800683~28848559:+
STAD	cis	rs1007738	0.507	rs4752969	ENSG00000271350.1	CTD-2384B9.1	4.57	6.9e-06	0.00353	0.31	0.24	Bone mineral density (hip);	chr11:47163959	chr11:47041027~47041945:-
STAD	cis	rs9646944	0.501	rs2075186	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Blood protein levels;	chr2:102440791	chr2:102438713~102440475:+
STAD	cis	rs950881	0.601	rs11465705	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Allergy;	chr2:102442350	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs11465736	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Blood protein levels;	chr2:102451470	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs10169676	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Blood protein levels;	chr2:102458459	chr2:102438713~102440475:+
STAD	cis	rs950881	0.562	rs11692335	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Allergy;	chr2:102461433	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs10186052	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Blood protein levels;	chr2:102463148	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs36049530	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Blood protein levels;	chr2:102463528	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs17027246	ENSG00000234389.1	AC007278.3	4.57	6.9e-06	0.00353	0.31	0.24	Blood protein levels;	chr2:102463595	chr2:102438713~102440475:+
STAD	cis	rs227275	0.556	rs223398	ENSG00000248971.2	KRT8P46	-4.57	6.9e-06	0.00353	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102728746~102730171:-
STAD	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	4.57	6.91e-06	0.00353	0.29	0.24	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	4.57	6.91e-06	0.00353	0.29	0.24	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
STAD	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-4.57	6.91e-06	0.00353	-0.24	-0.24	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
STAD	cis	rs9990333	0.562	rs58079878	ENSG00000252174.1	RNU7-18P	-4.57	6.91e-06	0.00353	-0.26	-0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:196072819~196072880:+
STAD	cis	rs3758911	0.894	rs6588964	ENSG00000261098.1	RP11-819C21.1	-4.57	6.91e-06	0.00354	-0.22	-0.24	Coronary artery disease;	chr11:107330725	chr11:107312132~107316271:-
STAD	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	4.57	6.92e-06	0.00354	0.17	0.24	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
STAD	cis	rs10978777	0.921	rs7040217	ENSG00000276883.1	AL137852.1	4.57	6.92e-06	0.00354	0.24	0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107281690	chr9:107292369~107292456:-
STAD	cis	rs891378	0.959	rs11120586	ENSG00000274245.1	RP11-357P18.2	-4.57	6.92e-06	0.00354	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207268152	chr1:207372559~207373252:+
STAD	cis	rs6019512	0.604	rs1997850	ENSG00000227431.4	CSE1L-AS1	-4.57	6.92e-06	0.00354	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48909823	chr20:49040463~49046044:-
STAD	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	4.57	6.92e-06	0.00354	0.24	0.24	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
STAD	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-4.57	6.92e-06	0.00354	-0.38	-0.24	Gout;	chr7:66654674	chr7:66654538~66669855:+
STAD	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-4.57	6.92e-06	0.00354	-0.38	-0.24	Gout;	chr7:66661502	chr7:66654538~66669855:+
STAD	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-4.57	6.93e-06	0.00354	-0.3	-0.24	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
STAD	cis	rs7487075	0.722	rs4768111	ENSG00000257261.4	RP11-96H19.1	4.57	6.93e-06	0.00355	0.29	0.24	Itch intensity from mosquito bite;	chr12:46311978	chr12:46383679~46876159:+
STAD	cis	rs3811273	0.614	rs7155927	ENSG00000211816.2	TRAV38-1	4.57	6.93e-06	0.00355	0.3	0.24	Periodontal disease-related phenotypes;	chr14:22263097	chr14:22271968~22272563:+
STAD	cis	rs7665090	1	rs735404	ENSG00000248971.2	KRT8P46	-4.57	6.93e-06	0.00355	-0.25	-0.24	Primary biliary cholangitis;	chr4:102632508	chr4:102728746~102730171:-
STAD	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-4.57	6.93e-06	0.00355	-0.32	-0.24	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs67265404	ENSG00000260091.1	RP11-33B1.4	4.57	6.94e-06	0.00355	0.24	0.24	Corneal astigmatism;	chr4:119438115	chr4:119409333~119410233:+
STAD	cis	rs7829975	0.66	rs10093926	ENSG00000253981.4	ALG1L13P	-4.57	6.94e-06	0.00355	-0.3	-0.24	Mood instability;	chr8:8691510	chr8:8236003~8244667:-
STAD	cis	rs6832769	1	rs28670674	ENSG00000272969.1	RP11-528I4.2	-4.57	6.94e-06	0.00355	-0.3	-0.24	Personality dimensions;	chr4:55540936	chr4:55547112~55547889:+
STAD	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	4.57	6.94e-06	0.00355	0.32	0.24	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
STAD	cis	rs6480314	0.522	rs10762212	ENSG00000233590.1	RP11-153K11.3	4.57	6.95e-06	0.00355	0.32	0.24	Optic nerve measurement (disc area);	chr10:68295190	chr10:68233251~68242379:-
STAD	cis	rs17826219	0.636	rs79565452	ENSG00000263603.1	CTD-2349P21.5	-4.57	6.95e-06	0.00355	-0.31	-0.24	Body mass index;	chr17:30815823	chr17:30729469~30731202:+
STAD	cis	rs6951245	0.58	rs10257426	ENSG00000229043.2	AC091729.9	-4.57	6.95e-06	0.00355	-0.32	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1160374~1165267:+
STAD	cis	rs875971	0.825	rs1129531	ENSG00000224316.1	RP11-479O9.2	-4.56	6.95e-06	0.00355	-0.23	-0.24	Aortic root size;	chr7:66154117	chr7:65773620~65802067:+
STAD	cis	rs1707322	1	rs1707303	ENSG00000225447.1	RPS15AP10	-4.56	6.95e-06	0.00355	-0.19	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45645816~45646197:-
STAD	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	4.56	6.95e-06	0.00356	0.25	0.24	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
STAD	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	4.56	6.96e-06	0.00356	0.25	0.24	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
STAD	cis	rs4713118	0.539	rs200988	ENSG00000280107.1	AL022393.9	-4.56	6.96e-06	0.00356	-0.31	-0.24	Parkinson's disease;	chr6:27851575	chr6:28170845~28172521:+
STAD	cis	rs55823223	0.648	rs11867582	ENSG00000267801.1	RP11-552F3.9	4.56	6.97e-06	0.00356	0.34	0.24	Psoriasis;	chr17:75861225	chr17:75876372~75879546:+
STAD	cis	rs2933343	0.601	rs1680759	ENSG00000261159.1	RP11-723O4.9	4.56	6.97e-06	0.00356	0.29	0.24	IgG glycosylation;	chr3:128876053	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.601	rs1680758	ENSG00000261159.1	RP11-723O4.9	4.56	6.97e-06	0.00356	0.29	0.24	IgG glycosylation;	chr3:128876054	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.649	rs789214	ENSG00000261159.1	RP11-723O4.9	4.56	6.97e-06	0.00356	0.29	0.24	IgG glycosylation;	chr3:128876152	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.729	rs789224	ENSG00000261159.1	RP11-723O4.9	4.56	6.97e-06	0.00356	0.29	0.24	IgG glycosylation;	chr3:128879388	chr3:128859716~128860526:-
STAD	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	4.56	6.98e-06	0.00357	0.33	0.24	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
STAD	cis	rs2286503	0.901	rs10950922	ENSG00000221740.1	SNORD93	4.56	6.98e-06	0.00357	0.27	0.24	Fibrinogen;	chr7:22814387	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.966	rs2286507	ENSG00000221740.1	SNORD93	4.56	6.98e-06	0.00357	0.27	0.24	Fibrinogen;	chr7:22815141	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.901	rs2286505	ENSG00000221740.1	SNORD93	4.56	6.98e-06	0.00357	0.27	0.24	Fibrinogen;	chr7:22815221	chr7:22856613~22856686:+
STAD	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	4.56	6.98e-06	0.00357	0.22	0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
STAD	cis	rs3733418	0.929	rs13149738	ENSG00000248632.1	RP11-366M4.11	4.56	6.98e-06	0.00357	0.3	0.24	Obesity-related traits;	chr4:164984545	chr4:164968587~164970002:-
STAD	cis	rs919433	1	rs1429414	ENSG00000231621.1	AC013264.2	4.56	6.98e-06	0.00357	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197297706	chr2:197197991~197199273:+
STAD	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-4.56	6.98e-06	0.00357	-0.36	-0.24	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-4.56	6.98e-06	0.00357	-0.36	-0.24	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-4.56	6.98e-06	0.00357	-0.36	-0.24	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-4.56	6.98e-06	0.00357	-0.36	-0.24	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-4.56	6.98e-06	0.00357	-0.36	-0.24	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
STAD	cis	rs7944584	0.545	rs7118178	ENSG00000280615.1	Y_RNA	4.56	6.99e-06	0.00357	0.26	0.24	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47637583	chr11:47614898~47614994:-
STAD	cis	rs7665090	1	rs2866413	ENSG00000248971.2	KRT8P46	-4.56	6.99e-06	0.00357	-0.25	-0.24	Primary biliary cholangitis;	chr4:102635920	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs4547797	ENSG00000248971.2	KRT8P46	-4.56	6.99e-06	0.00357	-0.25	-0.24	Primary biliary cholangitis;	chr4:102636035	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs2866414	ENSG00000248971.2	KRT8P46	-4.56	6.99e-06	0.00357	-0.25	-0.24	Primary biliary cholangitis;	chr4:102636062	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs9996834	ENSG00000248971.2	KRT8P46	-4.56	6.99e-06	0.00357	-0.25	-0.24	Primary biliary cholangitis;	chr4:102636372	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs11727546	ENSG00000248971.2	KRT8P46	-4.56	6.99e-06	0.00357	-0.25	-0.24	Primary biliary cholangitis;	chr4:102636507	chr4:102728746~102730171:-
STAD	cis	rs891378	1	rs7522701	ENSG00000274245.1	RP11-357P18.2	-4.56	6.99e-06	0.00357	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207237620	chr1:207372559~207373252:+
STAD	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	4.56	7e-06	0.00357	0.31	0.24	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
STAD	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-4.56	7e-06	0.00357	-0.35	-0.24	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
STAD	cis	rs867371	0.826	rs2047678	ENSG00000255769.6	GOLGA2P10	-4.56	7e-06	0.00358	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472993~82513950:-
STAD	cis	rs2933343	0.621	rs883843	ENSG00000261159.1	RP11-723O4.9	-4.56	7e-06	0.00358	-0.29	-0.24	IgG glycosylation;	chr3:128848540	chr3:128859716~128860526:-
STAD	cis	rs17401966	0.867	rs61775872	ENSG00000199562.1	RNU6-37P	4.56	7e-06	0.00358	0.18	0.24	Hepatocellular carcinoma;	chr1:10219250	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs61775885	ENSG00000199562.1	RNU6-37P	4.56	7e-06	0.00358	0.18	0.24	Hepatocellular carcinoma;	chr1:10221387	chr1:10298966~10299072:+
STAD	cis	rs7829975	0.623	rs10092965	ENSG00000254340.1	RP11-10A14.3	4.56	7e-06	0.00358	0.28	0.24	Mood instability;	chr8:8515975	chr8:9141424~9145435:+
STAD	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	4.56	7.01e-06	0.00358	0.26	0.24	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
STAD	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	4.56	7.01e-06	0.00358	0.26	0.24	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
STAD	cis	rs1723838	0.536	rs4944858	ENSG00000255928.1	RP11-456I15.2	-4.56	7.01e-06	0.00358	-0.5	-0.24	Obesity-related traits;	chr11:73708012	chr11:73722349~73722694:+
STAD	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-4.56	7.01e-06	0.00358	-0.28	-0.24	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
STAD	cis	rs4589258	0.933	rs11019128	ENSG00000280367.1	RP11-121L10.2	-4.56	7.01e-06	0.00358	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90660419	chr11:90223153~90226538:+
STAD	cis	rs875971	0.825	rs1000464	ENSG00000236529.1	RP13-254B10.1	-4.56	7.02e-06	0.00359	-0.25	-0.24	Aortic root size;	chr7:66312922	chr7:65840212~65840596:+
STAD	cis	rs10504130	0.542	rs1589079	ENSG00000272024.1	RP11-546K22.3	-4.56	7.02e-06	0.00359	-0.31	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51923739	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.569	rs7820177	ENSG00000272024.1	RP11-546K22.3	-4.56	7.02e-06	0.00359	-0.31	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51924373	chr8:51950284~51950690:+
STAD	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-4.56	7.02e-06	0.00359	-0.28	-0.24	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
STAD	cis	rs4713118	0.621	rs9295756	ENSG00000220721.1	OR1F12	4.56	7.02e-06	0.00359	0.28	0.24	Parkinson's disease;	chr6:28065618	chr6:28073316~28074233:+
STAD	cis	rs7665090	0.528	rs4235405	ENSG00000248971.2	KRT8P46	-4.56	7.03e-06	0.00359	-0.26	-0.24	Primary biliary cholangitis;	chr4:102595654	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs4698874	ENSG00000248971.2	KRT8P46	-4.56	7.03e-06	0.00359	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102728746~102730171:-
STAD	cis	rs1707322	0.627	rs3014213	ENSG00000225447.1	RPS15AP10	-4.56	7.03e-06	0.00359	-0.19	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.686	rs2152078	ENSG00000225447.1	RPS15AP10	-4.56	7.03e-06	0.00359	-0.19	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.686	rs2991979	ENSG00000225447.1	RPS15AP10	-4.56	7.03e-06	0.00359	-0.19	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45645816~45646197:-
STAD	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	4.56	7.03e-06	0.00359	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
STAD	cis	rs237743	1	rs8117111	ENSG00000222365.1	SNORD12B	-4.56	7.03e-06	0.00359	-0.33	-0.24	Height;	chr20:49267648	chr20:49280319~49280409:+
STAD	cis	rs237743	1	rs11905214	ENSG00000222365.1	SNORD12B	-4.56	7.03e-06	0.00359	-0.33	-0.24	Height;	chr20:49272073	chr20:49280319~49280409:+
STAD	cis	rs875971	1	rs10215948	ENSG00000236529.1	RP13-254B10.1	-4.56	7.03e-06	0.00359	-0.25	-0.24	Aortic root size;	chr7:66282799	chr7:65840212~65840596:+
STAD	cis	rs13113518	0.812	rs12648271	ENSG00000272969.1	RP11-528I4.2	4.56	7.04e-06	0.00359	0.31	0.24	Height;	chr4:55501955	chr4:55547112~55547889:+
STAD	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	4.56	7.04e-06	0.00359	0.3	0.24	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
STAD	cis	rs11098499	0.954	rs10034623	ENSG00000260091.1	RP11-33B1.4	4.56	7.04e-06	0.00359	0.23	0.24	Corneal astigmatism;	chr4:119476674	chr4:119409333~119410233:+
STAD	cis	rs4589258	0.788	rs10830562	ENSG00000280367.1	RP11-121L10.2	-4.56	7.04e-06	0.00359	-0.23	-0.24	Intelligence (multi-trait analysis);	chr11:90720450	chr11:90223153~90226538:+
STAD	cis	rs4713118	0.869	rs7776351	ENSG00000243307.2	POM121L6P	4.56	7.05e-06	0.0036	0.27	0.24	Parkinson's disease;	chr6:27758952	chr6:26896952~26898777:+
STAD	cis	rs891378	1	rs891378	ENSG00000274245.1	RP11-357P18.2	-4.56	7.05e-06	0.0036	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207316974	chr1:207372559~207373252:+
STAD	cis	rs11098499	0.821	rs28665282	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119463031	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.738	rs10026493	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119463039	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs7681214	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119464165	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.908	rs28559989	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119465472	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs28632018	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119465575	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.908	rs71614449	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119465900	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs35063680	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119465947	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs34858317	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119465955	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs17046116	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119466104	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs17046118	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119466341	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs7654587	ENSG00000260091.1	RP11-33B1.4	4.56	7.05e-06	0.0036	0.23	0.24	Corneal astigmatism;	chr4:119467251	chr4:119409333~119410233:+
STAD	cis	rs12571093	0.572	rs10762216	ENSG00000233590.1	RP11-153K11.3	4.56	7.05e-06	0.0036	0.32	0.24	Optic nerve measurement (disc area);	chr10:68308820	chr10:68233251~68242379:-
STAD	cis	rs1799949	1	rs1973646	ENSG00000279602.1	CTD-3014M21.1	4.56	7.06e-06	0.0036	0.3	0.24	Menopause (age at onset);	chr17:43158478	chr17:43360041~43361361:-
STAD	cis	rs3733585	0.605	rs4235355	ENSG00000250613.1	RP11-136I13.1	4.56	7.06e-06	0.0036	0.24	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10121454	chr4:10410996~10411644:+
STAD	cis	rs11846409	0.932	rs756588	ENSG00000211972.2	IGHV3-66	-4.56	7.07e-06	0.0036	-0.27	-0.24	Rheumatic heart disease;	chr14:106632316	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.86	rs55745256	ENSG00000211972.2	IGHV3-66	4.56	7.07e-06	0.0036	0.27	0.24	Rheumatic heart disease;	chr14:106632365	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs731013	ENSG00000211972.2	IGHV3-66	4.56	7.07e-06	0.0036	0.27	0.24	Rheumatic heart disease;	chr14:106632481	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs731012	ENSG00000211972.2	IGHV3-66	4.56	7.07e-06	0.0036	0.27	0.24	Rheumatic heart disease;	chr14:106632578	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs731011	ENSG00000211972.2	IGHV3-66	4.56	7.07e-06	0.0036	0.27	0.24	Rheumatic heart disease;	chr14:106632619	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.932	rs10138537	ENSG00000211972.2	IGHV3-66	4.56	7.07e-06	0.0036	0.27	0.24	Rheumatic heart disease;	chr14:106632778	chr14:106675017~106675544:-
STAD	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-4.56	7.07e-06	0.00361	-0.24	-0.24	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
STAD	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	4.56	7.08e-06	0.00361	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
STAD	cis	rs11121022	1	rs11121022	ENSG00000269925.1	RP3-467L1.6	-4.56	7.08e-06	0.00361	-0.24	-0.24	Morning vs. evening chronotype;	chr1:7776599	chr1:7776383~7776775:+
STAD	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	4.56	7.08e-06	0.00361	0.31	0.24	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
STAD	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	4.56	7.08e-06	0.00361	0.22	0.24	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
STAD	cis	rs11098499	0.818	rs55825515	ENSG00000260091.1	RP11-33B1.4	4.56	7.08e-06	0.00361	0.24	0.24	Corneal astigmatism;	chr4:119565247	chr4:119409333~119410233:+
STAD	cis	rs8097348	0.857	rs984426	ENSG00000266602.1	RP11-476K15.1	-4.56	7.09e-06	0.00361	-0.27	-0.24	Exercise (leisure time);	chr18:1635814	chr18:1509183~1647097:+
STAD	cis	rs55661361	0.532	rs3802902	ENSG00000254941.1	RP11-677M14.5	-4.56	7.09e-06	0.00361	-0.28	-0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124765139	chr11:124807822~124808269:-
STAD	cis	rs494453	0.883	rs474722	ENSG00000234020.1	CHIAP3	-4.56	7.09e-06	0.00361	-0.23	-0.24	Osteoporosis-related phenotypes;	chr1:111674356	chr1:111353275~111367409:-
STAD	cis	rs8099594	0.55	rs8088875	ENSG00000266696.1	RP11-30L3.2	4.56	7.1e-06	0.00362	0.23	0.24	Height;	chr18:49415109	chr18:49205912~49208781:+
STAD	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-4.56	7.1e-06	0.00362	-0.35	-0.24	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
STAD	cis	rs9907295	0.818	rs4795093	ENSG00000270894.1	AC015849.13	-4.56	7.1e-06	0.00362	-0.24	-0.24	Fibroblast growth factor basic levels;	chr17:35853137	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.818	rs2306630	ENSG00000270894.1	AC015849.13	-4.56	7.1e-06	0.00362	-0.24	-0.24	Fibroblast growth factor basic levels;	chr17:35855337	chr17:35818399~35823713:+
STAD	cis	rs853679	0.76	rs11967137	ENSG00000220721.1	OR1F12	4.56	7.1e-06	0.00362	0.28	0.24	Depression;	chr6:28231986	chr6:28073316~28074233:+
STAD	cis	rs853679	0.723	rs9366718	ENSG00000220721.1	OR1F12	4.56	7.1e-06	0.00362	0.28	0.24	Depression;	chr6:28237724	chr6:28073316~28074233:+
STAD	cis	rs11638352	1	rs2412854	ENSG00000249839.1	AC011330.5	4.56	7.1e-06	0.00362	0.51	0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44002274	chr15:43663654~43684339:-
STAD	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-4.56	7.1e-06	0.00362	-0.28	-0.24	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
STAD	cis	rs893363	0.621	rs14165	ENSG00000271916.1	RP11-884K10.6	-4.56	7.11e-06	0.00362	-0.31	-0.24	Axial length;	chr3:53813381	chr3:53797764~53798019:-
STAD	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	4.56	7.11e-06	0.00362	0.24	0.24	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
STAD	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-4.56	7.11e-06	0.00362	-0.24	-0.24	Height;	chr5:36999896	chr5:36666214~36725195:-
STAD	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-4.56	7.11e-06	0.00362	-0.24	-0.24	Height;	chr5:37005003	chr5:36666214~36725195:-
STAD	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-4.56	7.11e-06	0.00362	-0.24	-0.24	Height;	chr5:37007527	chr5:36666214~36725195:-
STAD	cis	rs6832769	1	rs576779	ENSG00000272969.1	RP11-528I4.2	4.56	7.11e-06	0.00362	0.3	0.24	Personality dimensions;	chr4:55408140	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs480479	ENSG00000272969.1	RP11-528I4.2	4.56	7.11e-06	0.00362	0.3	0.24	Personality dimensions;	chr4:55408163	chr4:55547112~55547889:+
STAD	cis	rs9907295	0.688	rs2735475	ENSG00000271013.1	AC015849.15	-4.56	7.11e-06	0.00362	-0.36	-0.24	Fibroblast growth factor basic levels;	chr17:35931003	chr17:35912635~35918010:-
STAD	cis	rs2933343	0.761	rs789225	ENSG00000261159.1	RP11-723O4.9	4.56	7.12e-06	0.00363	0.29	0.24	IgG glycosylation;	chr3:128881386	chr3:128859716~128860526:-
STAD	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-4.56	7.13e-06	0.00363	-0.24	-0.24	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
STAD	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	4.56	7.13e-06	0.00363	0.28	0.24	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
STAD	cis	rs858239	0.665	rs858305	ENSG00000230042.1	AK3P3	4.56	7.13e-06	0.00363	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23129178~23129841:+
STAD	cis	rs11651753	0.636	rs4793737	ENSG00000264920.1	RP11-6N17.4	-4.56	7.13e-06	0.00363	-0.31	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964891	chr17:47891255~47895812:-
STAD	cis	rs2483058	0.767	rs2336939	ENSG00000261000.1	RP11-534L20.5	4.56	7.13e-06	0.00363	0.28	0.24	Cholesterol and Triglycerides;	chr1:206446827	chr1:206503948~206504456:+
STAD	cis	rs9813712	0.526	rs62281641	ENSG00000253540.4	FAM86HP	-4.56	7.13e-06	0.00363	-0.26	-0.24	Response to amphetamines;	chr3:130235668	chr3:130099092~130111472:-
STAD	cis	rs8028182	0.636	rs7163451	ENSG00000260269.4	CTD-2323K18.1	-4.56	7.13e-06	0.00363	-0.3	-0.24	Sudden cardiac arrest;	chr15:75568735	chr15:75527150~75601205:-
STAD	cis	rs9860428	0.567	rs4103791	ENSG00000240057.4	RP11-572M11.4	-4.56	7.14e-06	0.00364	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112945351	chr3:113019532~113183301:+
STAD	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	4.56	7.14e-06	0.00364	0.26	0.24	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
STAD	cis	rs11039216	1	rs11039216	ENSG00000280615.1	Y_RNA	4.56	7.14e-06	0.00364	0.24	0.24	Neuroticism;	chr11:47385041	chr11:47614898~47614994:-
STAD	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	4.56	7.14e-06	0.00364	0.29	0.24	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	4.56	7.14e-06	0.00364	0.29	0.24	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
STAD	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	4.56	7.14e-06	0.00364	0.26	0.24	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	4.56	7.14e-06	0.00364	0.26	0.24	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	4.56	7.14e-06	0.00364	0.26	0.24	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
STAD	cis	rs1876905	0.539	rs241003	ENSG00000271789.1	RP5-1112D6.7	4.56	7.15e-06	0.00364	0.28	0.24	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111297126~111298510:+
STAD	cis	rs1876905	0.539	rs190246	ENSG00000271789.1	RP5-1112D6.7	4.56	7.15e-06	0.00364	0.28	0.24	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111297126~111298510:+
STAD	cis	rs7119038	0.58	rs7123726	ENSG00000255422.1	AP002954.4	4.56	7.15e-06	0.00364	0.31	0.24	Sjögren's syndrome;	chr11:118823838	chr11:118704607~118750263:+
STAD	cis	rs8028182	0.636	rs7163907	ENSG00000260269.4	CTD-2323K18.1	-4.56	7.16e-06	0.00364	-0.3	-0.24	Sudden cardiac arrest;	chr15:75552756	chr15:75527150~75601205:-
STAD	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	4.56	7.16e-06	0.00364	0.28	0.24	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
STAD	cis	rs3733585	0.631	rs3822236	ENSG00000250613.1	RP11-136I13.1	4.56	7.16e-06	0.00364	0.23	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10118337	chr4:10410996~10411644:+
STAD	cis	rs4243830	0.85	rs13513	ENSG00000229519.2	RP11-58A11.2	4.56	7.16e-06	0.00364	0.26	0.24	Body mass index;	chr1:6525744	chr1:6547905~6548619:+
STAD	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-4.56	7.16e-06	0.00364	-0.31	-0.24	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
STAD	cis	rs6832769	0.922	rs6825994	ENSG00000272969.1	RP11-528I4.2	-4.56	7.16e-06	0.00364	-0.31	-0.24	Personality dimensions;	chr4:55524244	chr4:55547112~55547889:+
STAD	cis	rs2337406	1	rs11845269	ENSG00000280411.1	IGHV1-69-2	-4.56	7.16e-06	0.00365	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106683851	chr14:106762092~106762588:-
STAD	cis	rs2337406	0.925	rs11851094	ENSG00000280411.1	IGHV1-69-2	-4.56	7.17e-06	0.00365	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106688967	chr14:106762092~106762588:-
STAD	cis	rs7078219	0.524	rs1548963	ENSG00000257582.4	LINC01475	-4.56	7.17e-06	0.00365	-0.26	-0.24	Dental caries;	chr10:99529946	chr10:99526350~99531177:-
STAD	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	4.56	7.17e-06	0.00365	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
STAD	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	4.56	7.17e-06	0.00365	0.35	0.24	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
STAD	cis	rs7208859	0.623	rs7208441	ENSG00000263603.1	CTD-2349P21.5	-4.56	7.17e-06	0.00365	-0.31	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30729469~30731202:+
STAD	cis	rs6095360	0.644	rs35269800	ENSG00000222365.1	SNORD12B	-4.56	7.18e-06	0.00365	-0.29	-0.24	Intelligence (multi-trait analysis);	chr20:48896484	chr20:49280319~49280409:+
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-4.56	7.18e-06	0.00365	-0.18	-0.24	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-4.56	7.18e-06	0.00365	-0.18	-0.24	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
STAD	cis	rs11676348	0.774	rs57545959	ENSG00000237281.1	CATIP-AS2	-4.56	7.19e-06	0.00365	-0.24	-0.24	Ulcerative colitis;	chr2:218182995	chr2:218326889~218357966:-
STAD	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-4.56	7.19e-06	0.00365	-0.24	-0.24	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-4.56	7.19e-06	0.00365	-0.24	-0.24	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
STAD	cis	rs9902453	0.817	rs880749	ENSG00000240074.1	RPL9P30	-4.56	7.19e-06	0.00366	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29732952	chr17:29855759~29856332:+
STAD	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	4.56	7.19e-06	0.00366	0.31	0.24	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
STAD	cis	rs1799949	0.683	rs55737636	ENSG00000279602.1	CTD-3014M21.1	4.56	7.19e-06	0.00366	0.3	0.24	Menopause (age at onset);	chr17:43112722	chr17:43360041~43361361:-
STAD	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	4.56	7.2e-06	0.00366	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	4.56	7.2e-06	0.00366	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
STAD	cis	rs3733585	0.631	rs4697707	ENSG00000250613.1	RP11-136I13.1	4.56	7.2e-06	0.00366	0.23	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:10118163	chr4:10410996~10411644:+
STAD	cis	rs7429990	0.864	rs12633604	ENSG00000224895.1	VPS26BP1	4.56	7.2e-06	0.00366	0.23	0.24	Educational attainment (years of education);	chr3:47673308	chr3:47960327~47961081:-
STAD	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	4.56	7.2e-06	0.00366	0.29	0.24	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
STAD	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	4.56	7.2e-06	0.00366	0.38	0.24	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
STAD	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	4.56	7.21e-06	0.00366	0.24	0.24	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
STAD	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	4.56	7.21e-06	0.00366	0.26	0.24	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
STAD	cis	rs227275	0.554	rs223371	ENSG00000248971.2	KRT8P46	-4.56	7.21e-06	0.00366	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102728746~102730171:-
STAD	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	4.56	7.21e-06	0.00367	0.26	0.24	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
STAD	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-4.56	7.21e-06	0.00367	-0.24	-0.24	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
STAD	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	4.56	7.21e-06	0.00367	0.26	0.24	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
STAD	cis	rs7688014	1	rs7688014	ENSG00000248971.2	KRT8P46	-4.56	7.22e-06	0.00367	-0.25	-0.24	Schizophrenia;	chr4:103053903	chr4:102728746~102730171:-
STAD	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-4.56	7.22e-06	0.00367	-0.33	-0.24	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
STAD	cis	rs9646944	0.501	rs10176820	ENSG00000234389.1	AC007278.3	4.56	7.22e-06	0.00367	0.31	0.24	Blood protein levels;	chr2:102437960	chr2:102438713~102440475:+
STAD	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-4.56	7.22e-06	0.00367	-0.27	-0.24	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
STAD	cis	rs6430585	0.528	rs56064699	ENSG00000231890.6	DARS-AS1	-4.56	7.22e-06	0.00367	-0.27	-0.24	Corneal structure;	chr2:135838136	chr2:135985176~136022593:+
STAD	cis	rs11676348	0.808	rs4674267	ENSG00000237281.1	CATIP-AS2	4.56	7.23e-06	0.00367	0.24	0.24	Ulcerative colitis;	chr2:218181714	chr2:218326889~218357966:-
STAD	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-4.56	7.23e-06	0.00367	-0.44	-0.24	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
STAD	cis	rs9860428	0.526	rs12497951	ENSG00000240057.4	RP11-572M11.4	-4.56	7.23e-06	0.00367	-0.23	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112937216	chr3:113019532~113183301:+
STAD	cis	rs56046484	0.75	rs7173332	ENSG00000259295.5	CSPG4P12	4.56	7.23e-06	0.00367	0.42	0.24	Testicular germ cell tumor;	chr15:84978503	chr15:85191438~85213905:+
STAD	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	4.56	7.23e-06	0.00367	0.26	0.24	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
STAD	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	4.56	7.23e-06	0.00367	0.26	0.24	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
STAD	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	4.56	7.23e-06	0.00367	0.26	0.24	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
STAD	cis	rs891378	1	rs2802233	ENSG00000274245.1	RP11-357P18.2	4.56	7.23e-06	0.00367	0.3	0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207297879	chr1:207372559~207373252:+
STAD	cis	rs11098499	0.954	rs11098525	ENSG00000260091.1	RP11-33B1.4	4.56	7.23e-06	0.00367	0.23	0.24	Corneal astigmatism;	chr4:119468997	chr4:119409333~119410233:+
STAD	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	4.56	7.24e-06	0.00368	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
STAD	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-4.56	7.24e-06	0.00368	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
STAD	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-4.56	7.25e-06	0.00368	-0.27	-0.24	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
STAD	cis	rs6142102	1	rs2143230	ENSG00000275784.1	RP5-1125A11.6	-4.56	7.25e-06	0.00368	-0.24	-0.24	Skin pigmentation;	chr20:34136539	chr20:33989480~33991818:-
STAD	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-4.56	7.25e-06	0.00368	-0.29	-0.24	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
STAD	cis	rs9860428	0.679	rs12494693	ENSG00000240057.4	RP11-572M11.4	-4.56	7.25e-06	0.00368	-0.22	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112958682	chr3:113019532~113183301:+
STAD	cis	rs11098499	0.954	rs9993199	ENSG00000260091.1	RP11-33B1.4	-4.56	7.25e-06	0.00368	-0.23	-0.24	Corneal astigmatism;	chr4:119471718	chr4:119409333~119410233:+
STAD	cis	rs7665090	1	rs735403	ENSG00000230069.3	LRRC37A15P	4.56	7.26e-06	0.00368	0.26	0.24	Primary biliary cholangitis;	chr4:102632386	chr4:102727274~102730721:-
STAD	cis	rs11098499	0.954	rs10017543	ENSG00000260091.1	RP11-33B1.4	4.56	7.26e-06	0.00369	0.23	0.24	Corneal astigmatism;	chr4:119400265	chr4:119409333~119410233:+
STAD	cis	rs12908161	1	rs36033486	ENSG00000259295.5	CSPG4P12	4.56	7.26e-06	0.00369	0.34	0.24	Schizophrenia;	chr15:84776461	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs62019469	ENSG00000259295.5	CSPG4P12	4.56	7.26e-06	0.00369	0.34	0.24	Schizophrenia;	chr15:84777989	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs12908549	ENSG00000259295.5	CSPG4P12	4.56	7.26e-06	0.00369	0.34	0.24	Schizophrenia;	chr15:84779120	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs12906348	ENSG00000259295.5	CSPG4P12	4.56	7.26e-06	0.00369	0.34	0.24	Schizophrenia;	chr15:84786190	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs34342559	ENSG00000259295.5	CSPG4P12	4.56	7.26e-06	0.00369	0.34	0.24	Schizophrenia;	chr15:84788040	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs62019472	ENSG00000259295.5	CSPG4P12	4.56	7.26e-06	0.00369	0.34	0.24	Schizophrenia;	chr15:84788262	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs35557864	ENSG00000259295.5	CSPG4P12	4.56	7.26e-06	0.00369	0.34	0.24	Schizophrenia;	chr15:84788398	chr15:85191438~85213905:+
STAD	cis	rs10510102	0.935	rs12255859	ENSG00000226864.1	ATE1-AS1	4.56	7.27e-06	0.00369	0.38	0.24	Breast cancer;	chr10:121831661	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.935	rs7923634	ENSG00000226864.1	ATE1-AS1	4.56	7.27e-06	0.00369	0.38	0.24	Breast cancer;	chr10:121832800	chr10:121928312~121951965:+
STAD	cis	rs2446066	0.872	rs10876451	ENSG00000257379.1	RP11-793H13.8	4.56	7.27e-06	0.00369	0.39	0.24	Red blood cell count;	chr12:53419640	chr12:53441741~53467528:+
STAD	cis	rs3806843	0.551	rs184996	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140944188	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246064	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140944724	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246063	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140944907	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246062	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140944995	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.521	rs246061	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140945071	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.607	rs246060	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140945164	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246059	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140945425	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.548	rs246058	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140945549	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.548	rs246057	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140945998	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.548	rs246055	ENSG00000202111.1	VTRNA1-2	-4.56	7.27e-06	0.00369	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140946077	chr5:140718925~140719013:+
STAD	cis	rs11157436	1	rs12587166	ENSG00000211813.2	TRAV34	4.55	7.27e-06	0.00369	0.29	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22207522~22208129:+
STAD	cis	rs5760092	0.755	rs915589	ENSG00000224205.1	AP000351.4	-4.55	7.27e-06	0.00369	-0.3	-0.24	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23987320~23991421:-
STAD	cis	rs12682352	0.602	rs13260419	ENSG00000254340.1	RP11-10A14.3	4.55	7.27e-06	0.00369	0.3	0.24	Neuroticism;	chr8:8817666	chr8:9141424~9145435:+
STAD	cis	rs6539288	0.677	rs10778515	ENSG00000260329.1	RP11-412D9.4	-4.55	7.28e-06	0.00369	-0.25	-0.24	Total body bone mineral density;	chr12:106938703	chr12:106954029~106955497:-
STAD	cis	rs8005677	0.828	rs2295680	ENSG00000257285.4	RP11-298I3.1	-4.55	7.28e-06	0.00369	-0.29	-0.24	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:22929609~22955562:+
STAD	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	4.55	7.28e-06	0.00369	0.33	0.24	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
STAD	cis	rs6430585	0.583	rs4988163	ENSG00000231890.6	DARS-AS1	-4.55	7.29e-06	0.0037	-0.27	-0.24	Corneal structure;	chr2:135870551	chr2:135985176~136022593:+
STAD	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	4.55	7.29e-06	0.0037	0.25	0.24	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
STAD	cis	rs2384207	0.789	rs7137793	ENSG00000277566.1	RP11-545P7.9	-4.55	7.29e-06	0.0037	-0.33	-0.24	Response to fenofibrate (adiponectin levels);	chr12:113220319	chr12:113249466~113250042:+
STAD	cis	rs1707322	0.682	rs12041197	ENSG00000281133.1	AL355480.3	-4.55	7.3e-06	0.0037	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.717	rs12023439	ENSG00000281133.1	AL355480.3	-4.55	7.3e-06	0.0037	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs11211146	ENSG00000281133.1	AL355480.3	-4.55	7.3e-06	0.0037	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs11211147	ENSG00000281133.1	AL355480.3	-4.55	7.3e-06	0.0037	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45580892~45580996:-
STAD	cis	rs7078219	0.505	rs7908704	ENSG00000257582.4	LINC01475	-4.55	7.3e-06	0.0037	-0.27	-0.24	Dental caries;	chr10:99533561	chr10:99526350~99531177:-
STAD	cis	rs7078219	0.505	rs7893840	ENSG00000257582.4	LINC01475	-4.55	7.3e-06	0.0037	-0.27	-0.24	Dental caries;	chr10:99533584	chr10:99526350~99531177:-
STAD	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	4.55	7.3e-06	0.0037	0.27	0.24	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
STAD	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-4.55	7.3e-06	0.0037	-0.28	-0.24	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
STAD	cis	rs4713118	0.628	rs9295740	ENSG00000280107.1	AL022393.9	-4.55	7.3e-06	0.0037	-0.34	-0.24	Parkinson's disease;	chr6:27721723	chr6:28170845~28172521:+
STAD	cis	rs1318937	1	rs8225	ENSG00000224660.1	SH3BP5-AS1	4.55	7.3e-06	0.0037	0.22	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264363	chr3:15254184~15264493:+
STAD	cis	rs6019512	0.549	rs6019515	ENSG00000227431.4	CSE1L-AS1	-4.55	7.31e-06	0.0037	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48911800	chr20:49040463~49046044:-
STAD	cis	rs919433	0.963	rs1366837	ENSG00000231621.1	AC013264.2	4.55	7.31e-06	0.00371	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197295777	chr2:197197991~197199273:+
STAD	cis	rs1707322	1	rs7532204	ENSG00000281133.1	AL355480.3	4.55	7.31e-06	0.00371	0.28	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.835	rs946525	ENSG00000281133.1	AL355480.3	4.55	7.31e-06	0.00371	0.28	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs946524	ENSG00000281133.1	AL355480.3	4.55	7.31e-06	0.00371	0.28	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4660336	ENSG00000281133.1	AL355480.3	4.55	7.31e-06	0.00371	0.28	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785478	ENSG00000281133.1	AL355480.3	4.55	7.31e-06	0.00371	0.28	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45580892~45580996:-
STAD	cis	rs7208859	0.623	rs34756112	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs60724269	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs76633166	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs1061346	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs1061343	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs1061342	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs55938328	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs73269988	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs55961983	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.673	rs9899525	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.568	rs7213925	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Body mass index;	chr17:30794616	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.524	rs11653098	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11658945	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11657990	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9911784	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9911997	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9890862	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs78071511	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11650982	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs2035494	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9915546	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs8064686	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11657369	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs8075341	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs73271842	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.673	rs9895815	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.673	rs8077116	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.524	rs28760584	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.706	rs73271850	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Body mass index;	chr17:30815122	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7208088	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs7212991	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs28627615	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.31e-06	0.00371	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30729469~30731202:+
STAD	cis	rs9907295	0.748	rs11868785	ENSG00000270894.1	AC015849.13	-4.55	7.32e-06	0.00371	-0.23	-0.24	Fibroblast growth factor basic levels;	chr17:35812214	chr17:35818399~35823713:+
STAD	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-4.55	7.32e-06	0.00371	-0.23	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
STAD	cis	rs1707322	0.721	rs10890341	ENSG00000225447.1	RPS15AP10	4.55	7.32e-06	0.00371	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45645816~45646197:-
STAD	cis	rs2739330	0.789	rs5760109	ENSG00000272787.1	KB-226F1.2	-4.55	7.32e-06	0.00371	-0.25	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23969211~23969873:+
STAD	cis	rs2348418	0.966	rs7136139	ENSG00000247934.4	RP11-967K21.1	4.55	7.32e-06	0.00371	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28531087	chr12:28163298~28190738:-
STAD	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	4.55	7.32e-06	0.00371	0.29	0.24	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
STAD	cis	rs8097348	0.544	rs9945073	ENSG00000266602.1	RP11-476K15.1	-4.55	7.33e-06	0.00371	-0.28	-0.24	Exercise (leisure time);	chr18:1683703	chr18:1509183~1647097:+
STAD	cis	rs1707322	1	rs7527079	ENSG00000281133.1	AL355480.3	-4.55	7.33e-06	0.00371	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs34446427	ENSG00000281133.1	AL355480.3	-4.55	7.33e-06	0.00371	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs4660900	ENSG00000281133.1	AL355480.3	-4.55	7.33e-06	0.00371	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4454479	ENSG00000281133.1	AL355480.3	-4.55	7.33e-06	0.00371	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs7517560	ENSG00000281133.1	AL355480.3	-4.55	7.33e-06	0.00371	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45580892~45580996:-
STAD	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	4.55	7.33e-06	0.00371	0.3	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	4.55	7.33e-06	0.00371	0.3	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
STAD	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	4.55	7.33e-06	0.00371	0.34	0.24	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
STAD	cis	rs9987353	0.544	rs2929470	ENSG00000254340.1	RP11-10A14.3	-4.55	7.34e-06	0.00372	-0.31	-0.24	Recombination measurement;	chr8:9204980	chr8:9141424~9145435:+
STAD	cis	rs6921919	0.583	rs6908137	ENSG00000220721.1	OR1F12	4.55	7.34e-06	0.00372	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28073316~28074233:+
STAD	cis	rs7615952	1	rs7615952	ENSG00000272840.1	RP11-379B18.6	-4.55	7.35e-06	0.00372	-0.39	-0.24	Blood pressure (smoking interaction);	chr3:125930560	chr3:125774714~125797953:+
STAD	cis	rs7078219	0.505	rs41290504	ENSG00000257582.4	LINC01475	-4.55	7.35e-06	0.00372	-0.27	-0.24	Dental caries;	chr10:99533278	chr10:99526350~99531177:-
STAD	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	4.55	7.35e-06	0.00372	0.23	0.24	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
STAD	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-4.55	7.35e-06	0.00372	-0.3	-0.24	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
STAD	cis	rs2337406	0.714	rs7145254	ENSG00000280411.1	IGHV1-69-2	-4.55	7.35e-06	0.00372	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106817783	chr14:106762092~106762588:-
STAD	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	4.55	7.35e-06	0.00372	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
STAD	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	4.55	7.35e-06	0.00372	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
STAD	cis	rs227275	0.554	rs223319	ENSG00000248971.2	KRT8P46	-4.55	7.36e-06	0.00372	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102728746~102730171:-
STAD	cis	rs228614	0.509	rs223318	ENSG00000248971.2	KRT8P46	-4.55	7.36e-06	0.00372	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102728746~102730171:-
STAD	cis	rs1005277	0.557	rs2983338	ENSG00000276805.1	RP11-291L22.6	4.55	7.36e-06	0.00373	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38451030~38451785:+
STAD	cis	rs2695743	0.592	rs6705118	ENSG00000225808.1	DNAJC19P5	-4.55	7.36e-06	0.00373	-0.27	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177824873	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs732363	ENSG00000225808.1	DNAJC19P5	-4.55	7.36e-06	0.00373	-0.27	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177826479	chr2:177229191~177229506:-
STAD	cis	rs9902453	0.817	rs2729449	ENSG00000240074.1	RPL9P30	-4.55	7.36e-06	0.00373	-0.21	-0.24	Coffee consumption (cups per day);	chr17:29762733	chr17:29855759~29856332:+
STAD	cis	rs916888	0.61	rs199454	ENSG00000260075.1	NSFP1	-4.55	7.36e-06	0.00373	-0.32	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46372855~46487141:+
STAD	cis	rs228614	0.51	rs223453	ENSG00000248971.2	KRT8P46	-4.55	7.37e-06	0.00373	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102728746~102730171:-
STAD	cis	rs2310173	0.575	rs11123902	ENSG00000281162.1	LINC01127	-4.55	7.37e-06	0.00373	-0.31	-0.24	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101994180	chr2:101962056~101987167:+
STAD	cis	rs11676348	0.774	rs11683524	ENSG00000237281.1	CATIP-AS2	4.55	7.37e-06	0.00373	0.24	0.24	Ulcerative colitis;	chr2:218119881	chr2:218326889~218357966:-
STAD	cis	rs2337406	1	rs17095456	ENSG00000280411.1	IGHV1-69-2	-4.55	7.38e-06	0.00373	-0.3	-0.24	Alzheimer's disease (late onset);	chr14:106676559	chr14:106762092~106762588:-
STAD	cis	rs2638953	0.888	rs10843189	ENSG00000247934.4	RP11-967K21.1	-4.55	7.38e-06	0.00373	-0.27	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28163298~28190738:-
STAD	cis	rs6430585	0.583	rs2304371	ENSG00000231890.6	DARS-AS1	-4.55	7.38e-06	0.00373	-0.26	-0.24	Corneal structure;	chr2:135803987	chr2:135985176~136022593:+
STAD	cis	rs2695743	0.647	rs6736927	ENSG00000225808.1	DNAJC19P5	-4.55	7.38e-06	0.00373	-0.27	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177824961	chr2:177229191~177229506:-
STAD	cis	rs4589258	1	rs10765380	ENSG00000280367.1	RP11-121L10.2	4.55	7.38e-06	0.00373	0.26	0.24	Intelligence (multi-trait analysis);	chr11:90727214	chr11:90223153~90226538:+
STAD	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	4.55	7.38e-06	0.00373	0.24	0.24	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
STAD	cis	rs6019512	0.647	rs6066906	ENSG00000227431.4	CSE1L-AS1	-4.55	7.38e-06	0.00373	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48911114	chr20:49040463~49046044:-
STAD	cis	rs6019512	0.625	rs6019514	ENSG00000227431.4	CSE1L-AS1	-4.55	7.38e-06	0.00373	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48911502	chr20:49040463~49046044:-
STAD	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-4.55	7.38e-06	0.00373	-0.36	-0.24	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-4.55	7.38e-06	0.00373	-0.36	-0.24	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-4.55	7.38e-06	0.00373	-0.36	-0.24	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-4.55	7.38e-06	0.00373	-0.36	-0.24	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-4.55	7.38e-06	0.00373	-0.36	-0.24	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-4.55	7.38e-06	0.00373	-0.36	-0.24	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-4.55	7.38e-06	0.00373	-0.36	-0.24	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
STAD	cis	rs6095360	0.727	rs13044144	ENSG00000222365.1	SNORD12B	-4.55	7.38e-06	0.00373	-0.29	-0.24	Intelligence (multi-trait analysis);	chr20:48912271	chr20:49280319~49280409:+
STAD	cis	rs7208859	0.623	rs9893422	ENSG00000263603.1	CTD-2349P21.5	-4.55	7.39e-06	0.00374	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30729469~30731202:+
STAD	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	4.55	7.39e-06	0.00374	0.29	0.24	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
STAD	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	4.55	7.39e-06	0.00374	0.27	0.24	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
STAD	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	4.55	7.39e-06	0.00374	0.27	0.24	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
STAD	cis	rs76210638	1	rs4943168	ENSG00000276672.1	RP11-142E9.1	4.55	7.39e-06	0.00374	0.31	0.24	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33927141	chr13:33846190~33850825:+
STAD	cis	rs6714710	0.603	rs34974566	ENSG00000235833.1	AC159540.14	-4.55	7.39e-06	0.00374	-0.27	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935836	chr2:97523949~97524976:-
STAD	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	4.55	7.39e-06	0.00374	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
STAD	cis	rs9400467	0.528	rs240954	ENSG00000230177.1	RP5-1112D6.4	-4.55	7.39e-06	0.00374	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111277932~111278742:+
STAD	cis	rs4713118	0.662	rs149901	ENSG00000220721.1	OR1F12	4.55	7.4e-06	0.00374	0.27	0.24	Parkinson's disease;	chr6:27997725	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs464312	ENSG00000220721.1	OR1F12	4.55	7.4e-06	0.00374	0.27	0.24	Parkinson's disease;	chr6:27999813	chr6:28073316~28074233:+
STAD	cis	rs950881	0.808	rs11679146	ENSG00000234389.1	AC007278.3	4.55	7.4e-06	0.00374	0.39	0.24	Allergy;	chr2:102392952	chr2:102438713~102440475:+
STAD	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	4.55	7.41e-06	0.00374	0.26	0.24	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
STAD	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	4.55	7.41e-06	0.00374	0.35	0.24	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
STAD	cis	rs938554	0.57	rs7696983	ENSG00000250613.1	RP11-136I13.1	-4.55	7.41e-06	0.00374	-0.27	-0.24	Blood metabolite levels;	chr4:9994205	chr4:10410996~10411644:+
STAD	cis	rs10851478	0.558	rs17478785	ENSG00000259545.2	RP11-325E5.4	-4.55	7.41e-06	0.00374	-0.27	-0.24	Oral cavity cancer;	chr15:49448107	chr15:49177610~49178741:-
STAD	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	4.55	7.42e-06	0.00375	0.31	0.24	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
STAD	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	4.55	7.42e-06	0.00375	0.31	0.24	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
STAD	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	4.55	7.42e-06	0.00375	0.31	0.24	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
STAD	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	4.55	7.42e-06	0.00375	0.31	0.24	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
STAD	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	4.55	7.42e-06	0.00375	0.31	0.24	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
STAD	cis	rs172166	0.61	rs156737	ENSG00000220721.1	OR1F12	4.55	7.42e-06	0.00375	0.24	0.24	Cardiac Troponin-T levels;	chr6:27927435	chr6:28073316~28074233:+
STAD	cis	rs8097348	0.947	rs8094734	ENSG00000266602.1	RP11-476K15.1	4.55	7.42e-06	0.00375	0.31	0.24	Exercise (leisure time);	chr18:1594835	chr18:1509183~1647097:+
STAD	cis	rs7131987	0.65	rs11050187	ENSG00000275476.1	RP11-996F15.4	-4.55	7.42e-06	0.00375	-0.26	-0.24	QT interval;	chr12:29319943	chr12:29277397~29277882:-
STAD	cis	rs858239	0.932	rs1728313	ENSG00000230042.1	AK3P3	-4.55	7.43e-06	0.00375	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23129178~23129841:+
STAD	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-4.55	7.43e-06	0.00375	-0.25	-0.24	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
STAD	cis	rs875971	0.895	rs4718349	ENSG00000236529.1	RP13-254B10.1	4.55	7.44e-06	0.00376	0.25	0.24	Aortic root size;	chr7:66444024	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs2042133	ENSG00000236529.1	RP13-254B10.1	4.55	7.44e-06	0.00376	0.25	0.24	Aortic root size;	chr7:66466935	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs2161065	ENSG00000236529.1	RP13-254B10.1	4.55	7.44e-06	0.00376	0.25	0.24	Aortic root size;	chr7:66467918	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs12698521	ENSG00000236529.1	RP13-254B10.1	4.55	7.44e-06	0.00376	0.25	0.24	Aortic root size;	chr7:66474502	chr7:65840212~65840596:+
STAD	cis	rs7932354	0.583	rs3136447	ENSG00000271350.1	CTD-2384B9.1	4.55	7.44e-06	0.00376	0.31	0.24	Bone mineral density (hip);Bone mineral density;	chr11:46722818	chr11:47041027~47041945:-
STAD	cis	rs11168351	0.926	rs10875719	ENSG00000258273.1	RP11-370I10.4	-4.55	7.44e-06	0.00376	-0.28	-0.24	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48333755~48333901:-
STAD	cis	rs10504130	0.696	rs75833886	ENSG00000272024.1	RP11-546K22.3	-4.55	7.44e-06	0.00376	-0.36	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51929844	chr8:51950284~51950690:+
STAD	cis	rs11098499	0.909	rs9759478	ENSG00000260091.1	RP11-33B1.4	4.55	7.45e-06	0.00376	0.24	0.24	Corneal astigmatism;	chr4:119446843	chr4:119409333~119410233:+
STAD	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	4.55	7.45e-06	0.00376	0.24	0.24	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
STAD	cis	rs228614	0.536	rs223477	ENSG00000248971.2	KRT8P46	-4.55	7.46e-06	0.00377	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102728746~102730171:-
STAD	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-4.55	7.46e-06	0.00377	-0.29	-0.24	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
STAD	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-4.55	7.46e-06	0.00377	-0.38	-0.24	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
STAD	cis	rs75920871	0.588	rs6589580	ENSG00000254851.1	RP11-109L13.1	4.55	7.46e-06	0.00377	0.26	0.24	Subjective well-being;	chr11:116949157	chr11:117135528~117138582:+
STAD	cis	rs1056107	0.831	rs11787835	ENSG00000225513.1	RP11-165N19.2	-4.55	7.46e-06	0.00377	-0.27	-0.24	Colorectal cancer;	chr9:112188318	chr9:112173522~112173971:-
STAD	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-4.55	7.46e-06	0.00377	-0.28	-0.24	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
STAD	cis	rs8097348	0.817	rs1020637	ENSG00000266602.1	RP11-476K15.1	4.55	7.47e-06	0.00377	0.26	0.24	Exercise (leisure time);	chr18:1668544	chr18:1509183~1647097:+
STAD	cis	rs7665090	1	rs6810869	ENSG00000248971.2	KRT8P46	-4.55	7.47e-06	0.00377	-0.25	-0.24	Primary biliary cholangitis;	chr4:102637357	chr4:102728746~102730171:-
STAD	cis	rs4604732	0.631	rs12031694	ENSG00000227135.1	GCSAML-AS1	-4.55	7.48e-06	0.00378	-0.32	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460351	chr1:247524679~247526752:-
STAD	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-4.55	7.48e-06	0.00378	-0.28	-0.24	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
STAD	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-4.55	7.48e-06	0.00378	-0.33	-0.24	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
STAD	cis	rs8099594	0.565	rs7235532	ENSG00000266696.1	RP11-30L3.2	-4.55	7.48e-06	0.00378	-0.22	-0.24	Height;	chr18:49188326	chr18:49205912~49208781:+
STAD	cis	rs875971	0.965	rs9969301	ENSG00000236529.1	RP13-254B10.1	-4.55	7.49e-06	0.00378	-0.25	-0.24	Aortic root size;	chr7:66316668	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6460292	ENSG00000236529.1	RP13-254B10.1	-4.55	7.49e-06	0.00378	-0.25	-0.24	Aortic root size;	chr7:66345088	chr7:65840212~65840596:+
STAD	cis	rs1075232	1	rs66581165	ENSG00000270055.1	CTD-3092A11.2	-4.55	7.49e-06	0.00378	-0.42	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30487963~30490313:+
STAD	cis	rs12922317	0.589	rs7192491	ENSG00000260224.1	UBL5P4	-4.55	7.49e-06	0.00378	-0.25	-0.24	Schizophrenia;	chr16:12050169	chr16:11968508~11968743:-
STAD	cis	rs867371	0.82	rs7164362	ENSG00000255769.6	GOLGA2P10	-4.55	7.49e-06	0.00378	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472993~82513950:-
STAD	cis	rs2638953	0.962	rs10771408	ENSG00000247934.4	RP11-967K21.1	-4.55	7.49e-06	0.00378	-0.27	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28147679	chr12:28163298~28190738:-
STAD	cis	rs2739330	0.828	rs5760107	ENSG00000272787.1	KB-226F1.2	-4.55	7.49e-06	0.00378	-0.25	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23969211~23969873:+
STAD	cis	rs708547	0.581	rs10020462	ENSG00000269949.1	RP11-738E22.3	-4.55	7.49e-06	0.00378	-0.27	-0.24	Response to bleomycin (chromatid breaks);	chr4:56959427	chr4:56960927~56961373:-
STAD	cis	rs7665090	1	rs7677509	ENSG00000248971.2	KRT8P46	-4.55	7.5e-06	0.00378	-0.25	-0.24	Primary biliary cholangitis;	chr4:102628849	chr4:102728746~102730171:-
STAD	cis	rs7665090	0.967	rs7699231	ENSG00000248971.2	KRT8P46	-4.55	7.5e-06	0.00378	-0.25	-0.24	Primary biliary cholangitis;	chr4:102628918	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs7699678	ENSG00000248971.2	KRT8P46	-4.55	7.5e-06	0.00378	-0.25	-0.24	Primary biliary cholangitis;	chr4:102628939	chr4:102728746~102730171:-
STAD	cis	rs7665090	1	rs11724614	ENSG00000248971.2	KRT8P46	-4.55	7.5e-06	0.00378	-0.25	-0.24	Primary biliary cholangitis;	chr4:102629091	chr4:102728746~102730171:-
STAD	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	4.55	7.5e-06	0.00378	0.29	0.24	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
STAD	cis	rs748404	0.697	rs1095389	ENSG00000275601.1	AC011330.13	-4.55	7.5e-06	0.00379	-0.25	-0.24	Lung cancer;	chr15:43274473	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs473554	ENSG00000275601.1	AC011330.13	-4.55	7.5e-06	0.00379	-0.25	-0.24	Lung cancer;	chr15:43276009	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs530683	ENSG00000275601.1	AC011330.13	4.55	7.5e-06	0.00379	0.25	0.24	Lung cancer;	chr15:43276801	chr15:43642389~43643023:-
STAD	cis	rs9860428	0.774	rs13094280	ENSG00000240057.4	RP11-572M11.4	-4.55	7.5e-06	0.00379	-0.22	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112825903	chr3:113019532~113183301:+
STAD	cis	rs7932354	0.502	rs7118546	ENSG00000271350.1	CTD-2384B9.1	-4.55	7.5e-06	0.00379	-0.29	-0.24	Bone mineral density (hip);Bone mineral density;	chr11:47065577	chr11:47041027~47041945:-
STAD	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
STAD	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Depression;	chr6:28399886	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	4.55	7.5e-06	0.00379	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
STAD	cis	rs2117029	1	rs10783299	ENSG00000258017.1	RP11-386G11.10	-4.55	7.5e-06	0.00379	-0.24	-0.24	Intelligence (multi-trait analysis);	chr12:48996894	chr12:49127782~49147869:+
STAD	cis	rs11098499	1	rs13435802	ENSG00000260091.1	RP11-33B1.4	-4.55	7.51e-06	0.00379	-0.23	-0.24	Corneal astigmatism;	chr4:119256805	chr4:119409333~119410233:+
STAD	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	4.55	7.52e-06	0.00379	0.33	0.24	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	4.55	7.52e-06	0.00379	0.33	0.24	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	4.55	7.52e-06	0.00379	0.33	0.24	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	4.55	7.52e-06	0.00379	0.33	0.24	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	4.55	7.52e-06	0.00379	0.33	0.24	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	4.55	7.52e-06	0.00379	0.33	0.24	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
STAD	cis	rs7119038	0.509	rs11216961	ENSG00000255422.1	AP002954.4	4.55	7.52e-06	0.00379	0.29	0.24	Sjögren's syndrome;	chr11:118709629	chr11:118704607~118750263:+
STAD	cis	rs496547	0.52	rs11216963	ENSG00000255422.1	AP002954.4	4.55	7.52e-06	0.00379	0.29	0.24	Hip minimal joint space width;	chr11:118710105	chr11:118704607~118750263:+
STAD	cis	rs7829975	0.744	rs2409092	ENSG00000253981.4	ALG1L13P	4.55	7.53e-06	0.0038	0.27	0.24	Mood instability;	chr8:8824682	chr8:8236003~8244667:-
STAD	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	4.55	7.53e-06	0.0038	0.29	0.24	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
STAD	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	4.55	7.53e-06	0.0038	0.35	0.24	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
STAD	cis	rs7131987	0.718	rs7976961	ENSG00000275476.1	RP11-996F15.4	-4.55	7.53e-06	0.0038	-0.26	-0.24	QT interval;	chr12:29310155	chr12:29277397~29277882:-
STAD	cis	rs9646944	0.501	rs2293223	ENSG00000234389.1	AC007278.3	4.55	7.53e-06	0.0038	0.31	0.24	Blood protein levels;	chr2:102419008	chr2:102438713~102440475:+
STAD	cis	rs11846409	0.86	rs61686131	ENSG00000211970.3	IGHV4-61	4.55	7.53e-06	0.0038	0.27	0.24	Rheumatic heart disease;	chr14:106631568	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs10151046	ENSG00000211970.3	IGHV4-61	4.55	7.53e-06	0.0038	0.27	0.24	Rheumatic heart disease;	chr14:106633095	chr14:106639119~106639657:-
STAD	cis	rs8141529	0.732	rs3788409	ENSG00000272858.1	CTA-292E10.8	-4.55	7.53e-06	0.0038	-0.26	-0.24	Lymphocyte counts;	chr22:28802163	chr22:28814914~28815662:+
STAD	cis	rs8028182	0.636	rs8036884	ENSG00000260269.4	CTD-2323K18.1	-4.55	7.54e-06	0.0038	-0.3	-0.24	Sudden cardiac arrest;	chr15:75570552	chr15:75527150~75601205:-
STAD	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-4.55	7.54e-06	0.0038	-0.27	-0.24	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
STAD	cis	rs7120173	0.571	rs634044	ENSG00000254851.1	RP11-109L13.1	-4.55	7.54e-06	0.0038	-0.35	-0.24	Visceral adipose tissue adjusted for BMI;	chr11:116881842	chr11:117135528~117138582:+
STAD	cis	rs875971	1	rs937495	ENSG00000236529.1	RP13-254B10.1	-4.55	7.54e-06	0.0038	-0.25	-0.24	Aortic root size;	chr7:66314811	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs2036264	ENSG00000236529.1	RP13-254B10.1	-4.55	7.54e-06	0.0038	-0.25	-0.24	Aortic root size;	chr7:66334917	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs7783613	ENSG00000236529.1	RP13-254B10.1	-4.55	7.54e-06	0.0038	-0.25	-0.24	Aortic root size;	chr7:66340274	chr7:65840212~65840596:+
STAD	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-4.55	7.55e-06	0.0038	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
STAD	cis	rs875971	0.964	rs6945019	ENSG00000236529.1	RP13-254B10.1	4.55	7.55e-06	0.00381	0.25	0.24	Aortic root size;	chr7:66457471	chr7:65840212~65840596:+
STAD	cis	rs7429990	0.833	rs2293226	ENSG00000224895.1	VPS26BP1	-4.55	7.56e-06	0.00381	-0.22	-0.24	Educational attainment (years of education);	chr3:47585292	chr3:47960327~47961081:-
STAD	cis	rs2337406	0.587	rs2516886	ENSG00000211972.2	IGHV3-66	-4.55	7.56e-06	0.00381	-0.24	-0.24	Alzheimer's disease (late onset);	chr14:106649674	chr14:106675017~106675544:-
STAD	cis	rs9990333	0.562	rs73210005	ENSG00000252174.1	RNU7-18P	-4.55	7.57e-06	0.00381	-0.26	-0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:196072819~196072880:+
STAD	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	4.55	7.57e-06	0.00382	0.26	0.24	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
STAD	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	4.55	7.57e-06	0.00382	0.21	0.24	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
STAD	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	4.55	7.57e-06	0.00382	0.21	0.24	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
STAD	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	4.55	7.57e-06	0.00382	0.21	0.24	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
STAD	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	4.55	7.59e-06	0.00382	0.39	0.24	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
STAD	cis	rs11098499	0.863	rs7678400	ENSG00000260091.1	RP11-33B1.4	4.55	7.59e-06	0.00382	0.23	0.24	Corneal astigmatism;	chr4:119540802	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs1480936	ENSG00000260091.1	RP11-33B1.4	4.55	7.59e-06	0.00382	0.23	0.24	Corneal astigmatism;	chr4:119541706	chr4:119409333~119410233:+
STAD	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-4.54	7.61e-06	0.00383	-0.36	-0.24	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
STAD	cis	rs9467773	0.967	rs6941022	ENSG00000243307.2	POM121L6P	4.54	7.61e-06	0.00383	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs2224380	ENSG00000243307.2	POM121L6P	4.54	7.61e-06	0.00383	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs9461271	ENSG00000243307.2	POM121L6P	4.54	7.61e-06	0.00383	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs9467787	ENSG00000243307.2	POM121L6P	4.54	7.61e-06	0.00383	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs767471	ENSG00000243307.2	POM121L6P	4.54	7.61e-06	0.00383	0.23	0.24	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26896952~26898777:+
STAD	cis	rs11098499	0.874	rs13139045	ENSG00000260091.1	RP11-33B1.4	4.54	7.61e-06	0.00383	0.23	0.24	Corneal astigmatism;	chr4:119247433	chr4:119409333~119410233:+
STAD	cis	rs2337406	0.925	rs34064152	ENSG00000280411.1	IGHV1-69-2	-4.54	7.62e-06	0.00384	-0.31	-0.24	Alzheimer's disease (late onset);	chr14:106700364	chr14:106762092~106762588:-
STAD	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	4.54	7.63e-06	0.00384	0.32	0.24	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
STAD	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-4.54	7.63e-06	0.00384	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
STAD	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	4.54	7.63e-06	0.00384	0.27	0.24	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
STAD	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	4.54	7.63e-06	0.00384	0.27	0.24	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
STAD	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	4.54	7.63e-06	0.00384	0.27	0.24	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
STAD	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	4.54	7.63e-06	0.00384	0.27	0.24	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
STAD	cis	rs507080	0.922	rs558781	ENSG00000278376.1	RP11-158I9.8	-4.54	7.63e-06	0.00384	-0.24	-0.24	Serum metabolite levels;	chr11:118693688	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs508640	ENSG00000278376.1	RP11-158I9.8	-4.54	7.63e-06	0.00384	-0.24	-0.24	Serum metabolite levels;	chr11:118693704	chr11:118791254~118793137:+
STAD	cis	rs227275	0.556	rs11731885	ENSG00000248971.2	KRT8P46	-4.54	7.64e-06	0.00384	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102728746~102730171:-
STAD	cis	rs73219805	0.818	rs117325001	ENSG00000228451.3	SDAD1P1	-4.54	7.64e-06	0.00384	-0.32	-0.24	Schizophrenia;	chr8:26384756	chr8:26379259~26382953:-
STAD	cis	rs6782228	0.606	rs2253144	ENSG00000277250.1	Metazoa_SRP	4.54	7.65e-06	0.00385	0.24	0.24	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128673681~128674021:-
STAD	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	4.54	7.65e-06	0.00385	0.25	0.24	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
STAD	cis	rs919433	0.963	rs1429417	ENSG00000231621.1	AC013264.2	4.54	7.65e-06	0.00385	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293447	chr2:197197991~197199273:+
STAD	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-4.54	7.65e-06	0.00385	-0.3	-0.24	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
STAD	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-4.54	7.65e-06	0.00385	-0.27	-0.24	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
STAD	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	4.54	7.65e-06	0.00385	0.3	0.24	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
STAD	cis	rs2286503	0.752	rs59538378	ENSG00000228649.7	AC005682.5	4.54	7.65e-06	0.00385	0.29	0.24	Fibrinogen;	chr7:22837478	chr7:22854178~22861579:+
STAD	cis	rs801193	0.591	rs4506088	ENSG00000224316.1	RP11-479O9.2	-4.54	7.66e-06	0.00385	-0.23	-0.24	Aortic root size;	chr7:66670470	chr7:65773620~65802067:+
STAD	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	4.54	7.66e-06	0.00385	0.22	0.24	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
STAD	cis	rs7119038	0.509	rs10892260	ENSG00000255422.1	AP002954.4	4.54	7.66e-06	0.00386	0.29	0.24	Sjögren's syndrome;	chr11:118712816	chr11:118704607~118750263:+
STAD	cis	rs4589258	0.737	rs2226919	ENSG00000280367.1	RP11-121L10.2	4.54	7.67e-06	0.00386	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90731273	chr11:90223153~90226538:+
STAD	cis	rs73219805	1	rs3808581	ENSG00000228451.3	SDAD1P1	-4.54	7.67e-06	0.00386	-0.32	-0.24	Schizophrenia;	chr8:26392531	chr8:26379259~26382953:-
STAD	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	4.54	7.68e-06	0.00386	0.35	0.24	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	4.54	7.68e-06	0.00386	0.35	0.24	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
STAD	cis	rs1322639	0.697	rs12661910	ENSG00000261039.2	RP11-417E7.2	-4.54	7.68e-06	0.00386	-0.37	-0.24	Pulse pressure;	chr6:169184293	chr6:169175304~169182740:-
STAD	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-4.54	7.68e-06	0.00386	-0.23	-0.24	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
STAD	cis	rs1799949	0.965	rs33961729	ENSG00000279602.1	CTD-3014M21.1	4.54	7.68e-06	0.00386	0.3	0.24	Menopause (age at onset);	chr17:43135907	chr17:43360041~43361361:-
STAD	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	4.54	7.68e-06	0.00386	0.29	0.24	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
STAD	cis	rs7829975	0.533	rs1039917	ENSG00000253981.4	ALG1L13P	4.54	7.69e-06	0.00386	0.27	0.24	Mood instability;	chr8:8861340	chr8:8236003~8244667:-
STAD	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-4.54	7.69e-06	0.00386	-0.31	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
STAD	cis	rs1348850	0.914	rs11893448	ENSG00000271825.1	RP11-337N6.2	4.54	7.69e-06	0.00386	0.2	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177415285	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.914	rs2060929	ENSG00000271825.1	RP11-337N6.2	4.54	7.69e-06	0.00386	0.2	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177415303	chr2:177300600~177302006:+
STAD	cis	rs17301013	0.861	rs12568655	ENSG00000227373.4	RP11-160H22.5	4.54	7.69e-06	0.00387	0.29	0.24	Systemic lupus erythematosus;	chr1:174465194	chr1:174115300~174160004:-
STAD	cis	rs7119038	0.629	rs11216994	ENSG00000255422.1	AP002954.4	4.54	7.69e-06	0.00387	0.31	0.24	Sjögren's syndrome;	chr11:118732811	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.629	rs11216995	ENSG00000255422.1	AP002954.4	4.54	7.69e-06	0.00387	0.31	0.24	Sjögren's syndrome;	chr11:118732817	chr11:118704607~118750263:+
STAD	cis	rs17401966	0.931	rs4846205	ENSG00000199562.1	RNU6-37P	4.54	7.7e-06	0.00387	0.19	0.24	Hepatocellular carcinoma;	chr1:10250156	chr1:10298966~10299072:+
STAD	cis	rs2919917	0.628	rs11776243	ENSG00000254352.1	RP11-578O24.2	4.54	7.7e-06	0.00387	0.39	0.24	Lymphocyte counts;	chr8:78648848	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs10110524	ENSG00000254352.1	RP11-578O24.2	4.54	7.7e-06	0.00387	0.39	0.24	Lymphocyte counts;	chr8:78648871	chr8:78723796~78724136:-
STAD	cis	rs7680126	0.644	rs4697703	ENSG00000250613.1	RP11-136I13.1	4.54	7.7e-06	0.00387	0.28	0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10105807	chr4:10410996~10411644:+
STAD	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	4.54	7.7e-06	0.00387	0.26	0.24	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	4.54	7.7e-06	0.00387	0.26	0.24	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
STAD	cis	rs7487075	0.619	rs4768709	ENSG00000257261.4	RP11-96H19.1	4.54	7.7e-06	0.00387	0.32	0.24	Itch intensity from mosquito bite;	chr12:46411982	chr12:46383679~46876159:+
STAD	cis	rs944722	0.526	rs2297516	ENSG00000266786.1	LGALS9DP	4.54	7.71e-06	0.00387	0.28	0.24	Fractional exhaled nitric oxide (childhood);	chr17:27768704	chr17:27746132~27754954:+
STAD	cis	rs17301013	0.861	rs7538650	ENSG00000227373.4	RP11-160H22.5	-4.54	7.71e-06	0.00387	-0.29	-0.24	Systemic lupus erythematosus;	chr1:174788821	chr1:174115300~174160004:-
STAD	cis	rs7760535	0.764	rs240994	ENSG00000230177.1	RP5-1112D6.4	-4.54	7.71e-06	0.00387	-0.21	-0.24	Metabolic traits;	chr6:111354554	chr6:111277932~111278742:+
STAD	cis	rs7760535	0.794	rs463860	ENSG00000230177.1	RP5-1112D6.4	-4.54	7.71e-06	0.00387	-0.21	-0.24	Metabolic traits;	chr6:111370518	chr6:111277932~111278742:+
STAD	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	4.54	7.71e-06	0.00387	0.37	0.24	Gout;	chr7:66682070	chr7:66654538~66669855:+
STAD	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	4.54	7.71e-06	0.00387	0.37	0.24	Gout;	chr7:66682162	chr7:66654538~66669855:+
STAD	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-4.54	7.71e-06	0.00387	-0.37	-0.24	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
STAD	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	4.54	7.71e-06	0.00387	0.26	0.24	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
STAD	cis	rs17401966	0.838	rs6541089	ENSG00000199562.1	RNU6-37P	4.54	7.71e-06	0.00388	0.18	0.24	Hepatocellular carcinoma;	chr1:10342727	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs1556916	ENSG00000199562.1	RNU6-37P	4.54	7.71e-06	0.00388	0.18	0.24	Hepatocellular carcinoma;	chr1:10343424	chr1:10298966~10299072:+
STAD	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-4.54	7.71e-06	0.00388	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
STAD	cis	rs8028182	0.636	rs11636199	ENSG00000260269.4	CTD-2323K18.1	-4.54	7.72e-06	0.00388	-0.3	-0.24	Sudden cardiac arrest;	chr15:75532996	chr15:75527150~75601205:-
STAD	cis	rs9860428	0.774	rs7651207	ENSG00000240057.4	RP11-572M11.4	-4.54	7.73e-06	0.00388	-0.22	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112822625	chr3:113019532~113183301:+
STAD	cis	rs883565	0.502	rs4496420	ENSG00000230683.1	DDTP1	4.54	7.73e-06	0.00388	0.25	0.24	Handedness;	chr3:38901225	chr3:38515448~38515830:-
STAD	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-4.54	7.74e-06	0.00389	-0.17	-0.24	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
STAD	cis	rs4243830	0.85	rs2274553	ENSG00000229519.2	RP11-58A11.2	4.54	7.74e-06	0.00389	0.26	0.24	Body mass index;	chr1:6526493	chr1:6547905~6548619:+
STAD	cis	rs7015630	0.563	rs28461337	ENSG00000251136.7	RP11-37B2.1	-4.54	7.74e-06	0.00389	-0.29	-0.24	Inflammatory bowel disease;Crohn's disease;	chr8:89812907	chr8:89609409~89757727:-
STAD	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	4.54	7.75e-06	0.00389	0.31	0.24	Height;	chr20:49286482	chr20:49280319~49280409:+
STAD	cis	rs10129255	0.5	rs2105991	ENSG00000211973.2	IGHV1-69	4.54	7.75e-06	0.00389	0.2	0.24	Kawasaki disease;	chr14:106682022	chr14:106714684~106715181:-
STAD	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	4.54	7.76e-06	0.00389	0.44	0.24	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
STAD	cis	rs2337406	0.925	rs2011167	ENSG00000280411.1	IGHV1-69-2	-4.54	7.76e-06	0.00389	-0.29	-0.24	Alzheimer's disease (late onset);	chr14:106680831	chr14:106762092~106762588:-
STAD	cis	rs7487075	0.859	rs7968283	ENSG00000257261.4	RP11-96H19.1	4.54	7.76e-06	0.0039	0.3	0.24	Itch intensity from mosquito bite;	chr12:46365353	chr12:46383679~46876159:+
STAD	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	4.54	7.76e-06	0.0039	0.29	0.24	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	4.54	7.76e-06	0.0039	0.29	0.24	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
STAD	cis	rs7826238	0.517	rs35144760	ENSG00000253981.4	ALG1L13P	-4.54	7.76e-06	0.0039	-0.35	-0.24	Systolic blood pressure;	chr8:8504213	chr8:8236003~8244667:-
STAD	cis	rs2337406	1	rs11845269	ENSG00000211972.2	IGHV3-66	4.54	7.77e-06	0.0039	0.25	0.24	Alzheimer's disease (late onset);	chr14:106683851	chr14:106675017~106675544:-
STAD	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-4.54	7.77e-06	0.0039	-0.38	-0.24	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
STAD	cis	rs13421350	0.579	rs74355465	ENSG00000232788.1	AC078883.3	4.54	7.77e-06	0.0039	0.43	0.24	Diabetic kidney disease;	chr2:172545440	chr2:172464262~172466022:-
STAD	cis	rs13421350	0.579	rs115160117	ENSG00000232788.1	AC078883.3	4.54	7.77e-06	0.0039	0.43	0.24	Diabetic kidney disease;	chr2:172546276	chr2:172464262~172466022:-
STAD	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-4.54	7.77e-06	0.0039	-0.35	-0.24	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
STAD	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-4.54	7.77e-06	0.0039	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
STAD	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	4.54	7.78e-06	0.0039	0.26	0.24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
STAD	cis	rs6921919	0.583	rs34513104	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs9461456	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.525	rs9468360	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs16894021	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs11751693	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs7749736	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.525	rs9468361	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs7775132	ENSG00000220721.1	OR1F12	4.54	7.78e-06	0.0039	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28073316~28074233:+
STAD	cis	rs6539288	0.677	rs1348566	ENSG00000260329.1	RP11-412D9.4	-4.54	7.79e-06	0.00391	-0.24	-0.24	Total body bone mineral density;	chr12:106931870	chr12:106954029~106955497:-
STAD	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	4.54	7.79e-06	0.00391	0.31	0.24	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
STAD	cis	rs10073892	0.62	rs7730106	ENSG00000250682.4	LINC00491	-4.54	7.79e-06	0.00391	-0.25	-0.24	Cognitive decline (age-related);	chr5:102629339	chr5:102609156~102671559:-
STAD	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-4.54	7.79e-06	0.00391	-0.28	-0.24	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
STAD	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	4.54	7.79e-06	0.00391	0.29	0.24	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
STAD	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	4.54	7.79e-06	0.00391	0.29	0.24	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
STAD	cis	rs4589258	0.933	rs10830575	ENSG00000280367.1	RP11-121L10.2	4.54	7.79e-06	0.00391	0.25	0.24	Intelligence (multi-trait analysis);	chr11:90775148	chr11:90223153~90226538:+
STAD	cis	rs6539288	0.63	rs1055332	ENSG00000260329.1	RP11-412D9.4	-4.54	7.8e-06	0.00391	-0.25	-0.24	Total body bone mineral density;	chr12:106954847	chr12:106954029~106955497:-
STAD	cis	rs6539288	0.677	rs2287163	ENSG00000260329.1	RP11-412D9.4	-4.54	7.8e-06	0.00391	-0.25	-0.24	Total body bone mineral density;	chr12:106955516	chr12:106954029~106955497:-
STAD	cis	rs831571	0.774	rs40610	ENSG00000280620.1	SCAANT1	4.54	7.8e-06	0.00391	0.32	0.24	Type 2 diabetes;	chr3:64023832	chr3:63911518~63911772:-
STAD	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-4.54	7.8e-06	0.00391	-0.24	-0.24	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
STAD	cis	rs919433	0.963	rs1896854	ENSG00000231621.1	AC013264.2	4.54	7.81e-06	0.00392	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283052	chr2:197197991~197199273:+
STAD	cis	rs11722779	0.815	rs223347	ENSG00000248971.2	KRT8P46	-4.54	7.81e-06	0.00392	-0.24	-0.24	Schizophrenia;	chr4:102858815	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.873	rs223346	ENSG00000248971.2	KRT8P46	-4.54	7.81e-06	0.00392	-0.24	-0.24	Schizophrenia;	chr4:102859339	chr4:102728746~102730171:-
STAD	cis	rs6714710	0.603	rs11679828	ENSG00000235833.1	AC159540.14	-4.54	7.81e-06	0.00392	-0.27	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97901163	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.58	rs11692470	ENSG00000235833.1	AC159540.14	-4.54	7.81e-06	0.00392	-0.27	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97904101	chr2:97523949~97524976:-
STAD	cis	rs11722779	0.838	rs6821247	ENSG00000248971.2	KRT8P46	-4.54	7.81e-06	0.00392	-0.24	-0.24	Schizophrenia;	chr4:102913483	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs9917919	ENSG00000248971.2	KRT8P46	-4.54	7.81e-06	0.00392	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102728746~102730171:-
STAD	cis	rs6584283	0.713	rs1332100	ENSG00000257582.4	LINC01475	4.54	7.82e-06	0.00392	0.27	0.24	Ulcerative colitis;	chr10:99541589	chr10:99526350~99531177:-
STAD	cis	rs2695743	0.675	rs1438063	ENSG00000225808.1	DNAJC19P5	-4.54	7.82e-06	0.00392	-0.27	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177831117	chr2:177229191~177229506:-
STAD	cis	rs2273156	1	rs17102904	ENSG00000241052.1	RP11-173D9.1	4.54	7.82e-06	0.00392	0.26	0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34971843	chr14:35144021~35144480:-
STAD	cis	rs10744955	0.727	rs8042657	ENSG00000244879.4	GABPB1-AS1	-4.54	7.82e-06	0.00392	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr15:50160504	chr15:50354959~50372202:+
STAD	cis	rs10744955	0.702	rs12591392	ENSG00000244879.4	GABPB1-AS1	-4.54	7.82e-06	0.00392	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr15:50161192	chr15:50354959~50372202:+
STAD	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	4.54	7.83e-06	0.00393	0.31	0.24	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
STAD	cis	rs2286503	0.65	rs1990279	ENSG00000221740.1	SNORD93	4.54	7.83e-06	0.00393	0.26	0.24	Fibrinogen;	chr7:22851123	chr7:22856613~22856686:+
STAD	cis	rs9902453	0.791	rs55655651	ENSG00000240074.1	RPL9P30	4.54	7.83e-06	0.00393	0.2	0.24	Coffee consumption (cups per day);	chr17:29917268	chr17:29855759~29856332:+
STAD	cis	rs6832769	1	rs9998146	ENSG00000272969.1	RP11-528I4.2	-4.54	7.84e-06	0.00393	-0.3	-0.24	Personality dimensions;	chr4:55531810	chr4:55547112~55547889:+
STAD	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	4.54	7.85e-06	0.00393	0.33	0.24	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
STAD	cis	rs6539288	0.677	rs1348565	ENSG00000260329.1	RP11-412D9.4	-4.54	7.85e-06	0.00393	-0.25	-0.24	Total body bone mineral density;	chr12:106935326	chr12:106954029~106955497:-
STAD	cis	rs17826219	0.706	rs8075357	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Body mass index;	chr17:30730179	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs59447372	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.706	rs61643715	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Body mass index;	chr17:30730744	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.636	rs8080829	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Body mass index;	chr17:30731712	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs8079891	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs73267858	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs56095789	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11656844	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11652533	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs11652631	ENSG00000263603.1	CTD-2349P21.5	-4.54	7.85e-06	0.00393	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30729469~30731202:+
STAD	cis	rs858239	0.699	rs858260	ENSG00000230042.1	AK3P3	-4.54	7.86e-06	0.00394	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23129178~23129841:+
STAD	cis	rs1598856	0.932	rs230530	ENSG00000246560.2	RP11-10L12.4	-4.54	7.86e-06	0.00394	-0.29	-0.24	Primary biliary cholangitis;	chr4:102532823	chr4:102828055~102844075:+
STAD	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	4.54	7.86e-06	0.00394	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
STAD	cis	rs893363	0.61	rs920252	ENSG00000271916.1	RP11-884K10.6	-4.54	7.87e-06	0.00394	-0.31	-0.24	Axial length;	chr3:53814645	chr3:53797764~53798019:-
STAD	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	4.54	7.87e-06	0.00394	0.28	0.24	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	4.54	7.87e-06	0.00394	0.28	0.24	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
STAD	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	4.54	7.88e-06	0.00395	0.26	0.24	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
STAD	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-4.54	7.89e-06	0.00395	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
STAD	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-4.54	7.89e-06	0.00395	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
STAD	cis	rs5753618	0.561	rs2073857	ENSG00000236132.1	CTA-440B3.1	4.54	7.89e-06	0.00395	0.28	0.24	Colorectal cancer;	chr22:31262295	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.561	rs737684	ENSG00000236132.1	CTA-440B3.1	4.54	7.89e-06	0.00395	0.28	0.24	Colorectal cancer;	chr22:31263841	chr22:31816379~31817491:-
STAD	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	4.54	7.89e-06	0.00395	0.23	0.24	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
STAD	cis	rs227275	0.556	rs4235407	ENSG00000248971.2	KRT8P46	-4.54	7.89e-06	0.00395	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102728746~102730171:-
STAD	cis	rs6832769	0.961	rs28713343	ENSG00000272969.1	RP11-528I4.2	-4.54	7.9e-06	0.00395	-0.3	-0.24	Personality dimensions;	chr4:55590924	chr4:55547112~55547889:+
STAD	cis	rs6951245	0.554	rs10246354	ENSG00000229043.2	AC091729.9	-4.54	7.9e-06	0.00395	-0.33	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1160374~1165267:+
STAD	cis	rs9463078	0.625	rs6926370	ENSG00000219384.1	RP11-491H9.3	4.54	7.9e-06	0.00396	0.23	0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44979543	chr6:45158870~45159511:+
STAD	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-4.54	7.9e-06	0.00396	-0.38	-0.24	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
STAD	cis	rs7131987	0.903	rs2194519	ENSG00000257176.2	RP11-996F15.2	4.54	7.91e-06	0.00396	0.26	0.24	QT interval;	chr12:29270650	chr12:29280418~29317848:-
STAD	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-4.54	7.91e-06	0.00396	-0.27	-0.24	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
STAD	cis	rs228614	0.51	rs223451	ENSG00000248971.2	KRT8P46	-4.54	7.91e-06	0.00396	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223450	ENSG00000248971.2	KRT8P46	-4.54	7.91e-06	0.00396	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102728746~102730171:-
STAD	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-4.54	7.91e-06	0.00396	-0.37	-0.24	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
STAD	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-4.54	7.92e-06	0.00396	-0.25	-0.24	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
STAD	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-4.54	7.92e-06	0.00396	-0.25	-0.24	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
STAD	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	4.54	7.92e-06	0.00396	0.31	0.24	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
STAD	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	4.54	7.92e-06	0.00396	0.28	0.24	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	4.54	7.92e-06	0.00396	0.28	0.24	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	4.54	7.92e-06	0.00396	0.28	0.24	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
STAD	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	4.54	7.92e-06	0.00396	0.36	0.24	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
STAD	cis	rs12468226	0.938	rs4675274	ENSG00000226261.1	AC064836.3	-4.54	7.93e-06	0.00397	-0.38	-0.24	Urate levels;	chr2:202243145	chr2:202336024~202336727:-
STAD	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-4.54	7.93e-06	0.00397	-0.27	-0.24	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
STAD	cis	rs2115630	0.653	rs61394864	ENSG00000275120.1	RP11-182J1.17	-4.54	7.93e-06	0.00397	-0.26	-0.24	P wave terminal force;	chr15:84626943	chr15:84599434~84606463:-
STAD	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	4.54	7.93e-06	0.00397	0.29	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
STAD	cis	rs1707322	0.721	rs11211149	ENSG00000281133.1	AL355480.3	-4.54	7.93e-06	0.00397	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs11211152	ENSG00000281133.1	AL355480.3	-4.54	7.93e-06	0.00397	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.681	rs12048866	ENSG00000281133.1	AL355480.3	-4.54	7.93e-06	0.00397	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs12024590	ENSG00000281133.1	AL355480.3	-4.54	7.93e-06	0.00397	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs12027622	ENSG00000281133.1	AL355480.3	-4.54	7.93e-06	0.00397	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.716	rs6699444	ENSG00000281133.1	AL355480.3	-4.54	7.93e-06	0.00397	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45580892~45580996:-
STAD	cis	rs1876905	0.539	rs240969	ENSG00000271789.1	RP5-1112D6.7	4.54	7.93e-06	0.00397	0.27	0.24	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111297126~111298510:+
STAD	cis	rs9467773	1	rs6922824	ENSG00000243307.2	POM121L6P	-4.54	7.94e-06	0.00397	-0.23	-0.24	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26896952~26898777:+
STAD	cis	rs12908161	1	rs17600551	ENSG00000259295.5	CSPG4P12	4.54	7.94e-06	0.00397	0.34	0.24	Schizophrenia;	chr15:84776027	chr15:85191438~85213905:+
STAD	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-4.54	7.94e-06	0.00397	-0.3	-0.24	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
STAD	cis	rs75583333	0.502	rs2032836	ENSG00000247699.2	CTB-127C13.1	4.54	7.94e-06	0.00397	0.27	0.24	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160204355	chr5:160195744~160204826:-
STAD	cis	rs2278796	0.693	rs2794859	ENSG00000231691.1	RP11-203F10.5	-4.54	7.94e-06	0.00397	-0.28	-0.24	Mean platelet volume;	chr1:204998128	chr1:204277005~204277948:+
STAD	cis	rs801193	0.66	rs4610622	ENSG00000224316.1	RP11-479O9.2	4.54	7.94e-06	0.00397	0.23	0.24	Aortic root size;	chr7:66759510	chr7:65773620~65802067:+
STAD	cis	rs4835473	0.897	rs2590034	ENSG00000249741.2	RP11-673E1.3	-4.54	7.94e-06	0.00397	-0.27	-0.24	Immature fraction of reticulocytes;	chr4:143926778	chr4:143911514~143912053:-
STAD	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	4.54	7.95e-06	0.00397	0.28	0.24	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
STAD	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	4.54	7.95e-06	0.00398	0.27	0.24	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
STAD	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	4.54	7.95e-06	0.00398	0.29	0.24	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
STAD	cis	rs8062405	0.54	rs480400	ENSG00000278665.1	RP11-666O2.4	4.53	7.95e-06	0.00398	0.27	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28599241~28601881:-
STAD	cis	rs721917	0.525	rs11201011	ENSG00000244733.5	RP11-506M13.3	-4.53	7.96e-06	0.00398	-0.26	-0.24	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79660891~79677996:+
STAD	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	4.53	7.96e-06	0.00398	0.28	0.24	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
STAD	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-4.53	7.96e-06	0.00398	-0.28	-0.24	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
STAD	cis	rs875971	0.862	rs4236208	ENSG00000236529.1	RP13-254B10.1	-4.53	7.97e-06	0.00398	-0.24	-0.24	Aortic root size;	chr7:66284091	chr7:65840212~65840596:+
STAD	cis	rs7078219	0.714	rs10883368	ENSG00000228778.1	RP11-129J12.1	-4.53	7.97e-06	0.00399	-0.29	-0.24	Dental caries;	chr10:99530241	chr10:99527081~99528261:+
STAD	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-4.53	7.98e-06	0.00399	-0.23	-0.24	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-4.53	7.98e-06	0.00399	-0.23	-0.24	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-4.53	7.98e-06	0.00399	-0.23	-0.24	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-4.53	7.98e-06	0.00399	-0.23	-0.24	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
STAD	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-4.53	7.98e-06	0.00399	-0.26	-0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
STAD	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-4.53	7.98e-06	0.00399	-0.24	-0.24	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
STAD	cis	rs1056107	0.933	rs10759546	ENSG00000225513.1	RP11-165N19.2	-4.53	7.99e-06	0.00399	-0.27	-0.24	Colorectal cancer;	chr9:112260664	chr9:112173522~112173971:-
STAD	cis	rs1850744	0.826	rs7659176	ENSG00000250268.3	ALG1L14P	-4.53	7.99e-06	0.00399	-0.56	-0.24	Economic and political preferences;	chr4:9719442	chr4:9166297~9170270:-
STAD	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-4.53	7.99e-06	0.004	-0.33	-0.24	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
STAD	cis	rs9733	0.65	rs4970923	ENSG00000274963.1	Metazoa_SRP	-4.53	8e-06	0.004	-0.19	-0.24	Tonsillectomy;	chr1:150635824	chr1:150568971~150569269:-
STAD	cis	rs9733	0.65	rs11204684	ENSG00000274963.1	Metazoa_SRP	-4.53	8e-06	0.004	-0.19	-0.24	Tonsillectomy;	chr1:150636418	chr1:150568971~150569269:-
STAD	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	4.53	8e-06	0.004	0.29	0.24	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
STAD	cis	rs7487075	0.502	rs12299843	ENSG00000272369.1	RP11-446N19.1	4.53	8e-06	0.004	0.29	0.24	Itch intensity from mosquito bite;	chr12:46242227	chr12:46537502~46652550:+
STAD	cis	rs11098499	0.58	rs12509234	ENSG00000260091.1	RP11-33B1.4	4.53	8e-06	0.004	0.23	0.24	Corneal astigmatism;	chr4:119398279	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs10014719	ENSG00000260091.1	RP11-33B1.4	4.53	8e-06	0.004	0.23	0.24	Corneal astigmatism;	chr4:119399560	chr4:119409333~119410233:+
STAD	cis	rs77956314	0.515	rs4767490	ENSG00000274554.1	RP11-240G22.5	-4.53	8e-06	0.004	-0.3	-0.24	Hippocampal volume;Subcortical brain region volumes;	chr12:116997211	chr12:116948738~116951422:-
STAD	cis	rs7429990	0.833	rs870622	ENSG00000224895.1	VPS26BP1	4.53	8.01e-06	0.004	0.23	0.24	Educational attainment (years of education);	chr3:47618683	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs868255	ENSG00000224895.1	VPS26BP1	4.53	8.01e-06	0.004	0.23	0.24	Educational attainment (years of education);	chr3:47619074	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs4858842	ENSG00000224895.1	VPS26BP1	4.53	8.01e-06	0.004	0.23	0.24	Educational attainment (years of education);	chr3:47619574	chr3:47960327~47961081:-
STAD	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-4.53	8.01e-06	0.004	-0.26	-0.24	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
STAD	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-4.53	8.01e-06	0.004	-0.33	-0.24	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
STAD	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-4.53	8.02e-06	0.00401	-0.37	-0.24	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
STAD	cis	rs11121022	0.965	rs11121021	ENSG00000269925.1	RP3-467L1.6	-4.53	8.02e-06	0.00401	-0.24	-0.24	Morning vs. evening chronotype;	chr1:7775639	chr1:7776383~7776775:+
STAD	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-4.53	8.02e-06	0.00401	-0.28	-0.24	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
STAD	cis	rs17401966	0.8	rs12725210	ENSG00000199562.1	RNU6-37P	4.53	8.03e-06	0.00401	0.18	0.24	Hepatocellular carcinoma;	chr1:10356935	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.867	rs7546364	ENSG00000199562.1	RNU6-37P	4.53	8.03e-06	0.00401	0.18	0.24	Hepatocellular carcinoma;	chr1:10358757	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs12738317	ENSG00000199562.1	RNU6-37P	4.53	8.03e-06	0.00401	0.18	0.24	Hepatocellular carcinoma;	chr1:10359605	chr1:10298966~10299072:+
STAD	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-4.53	8.03e-06	0.00401	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
STAD	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-4.53	8.03e-06	0.00401	-0.28	-0.24	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
STAD	cis	rs8097348	0.817	rs1159374	ENSG00000266602.1	RP11-476K15.1	4.53	8.03e-06	0.00401	0.27	0.24	Exercise (leisure time);	chr18:1652979	chr18:1509183~1647097:+
STAD	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-4.53	8.03e-06	0.00401	-0.35	-0.24	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
STAD	cis	rs1075265	0.901	rs2112124	ENSG00000233266.1	HMGB1P31	4.53	8.03e-06	0.00401	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54137385	chr2:54051334~54051760:+
STAD	cis	rs13315649	0.562	rs6797317	ENSG00000242551.2	POU5F1P6	-4.53	8.04e-06	0.00402	-0.25	-0.24	Sum eosinophil basophil counts;	chr3:128684381	chr3:128674735~128677005:-
STAD	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-4.53	8.04e-06	0.00402	-0.38	-0.24	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
STAD	cis	rs12682352	0.65	rs13265731	ENSG00000254340.1	RP11-10A14.3	4.53	8.05e-06	0.00402	0.3	0.24	Neuroticism;	chr8:8815810	chr8:9141424~9145435:+
STAD	cis	rs919433	0.963	rs10199410	ENSG00000231621.1	AC013264.2	4.53	8.05e-06	0.00402	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197291052	chr2:197197991~197199273:+
STAD	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-4.53	8.05e-06	0.00402	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-4.53	8.05e-06	0.00402	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-4.53	8.05e-06	0.00402	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
STAD	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-4.53	8.05e-06	0.00402	-0.25	-0.24	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-4.53	8.05e-06	0.00402	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-4.53	8.05e-06	0.00402	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
STAD	cis	rs2439831	0.681	rs478104	ENSG00000275601.1	AC011330.13	-4.53	8.05e-06	0.00402	-0.29	-0.24	Lung cancer in ever smokers;	chr15:43302702	chr15:43642389~43643023:-
STAD	cis	rs8059260	0.673	rs77240340	ENSG00000274038.1	RP11-66H6.4	-4.53	8.05e-06	0.00402	-0.4	-0.24	Alcohol consumption over the past year;	chr16:10945778	chr16:11056556~11057034:+
STAD	cis	rs4243830	0.85	rs908273	ENSG00000229519.2	RP11-58A11.2	4.53	8.05e-06	0.00402	0.26	0.24	Body mass index;	chr1:6528544	chr1:6547905~6548619:+
STAD	cis	rs7487075	0.82	rs12311507	ENSG00000257261.4	RP11-96H19.1	4.53	8.06e-06	0.00402	0.29	0.24	Itch intensity from mosquito bite;	chr12:46329407	chr12:46383679~46876159:+
STAD	cis	rs2337406	0.587	rs916547	ENSG00000211970.3	IGHV4-61	4.53	8.06e-06	0.00402	0.26	0.24	Alzheimer's disease (late onset);	chr14:106646735	chr14:106639119~106639657:-
STAD	cis	rs11169552	0.51	rs12580051	ENSG00000200183.1	RNU6-238P	-4.53	8.06e-06	0.00402	-0.23	-0.24	Colorectal cancer;	chr12:50651289	chr12:50656973~50657078:+
STAD	cis	rs9902453	0.612	rs2617868	ENSG00000240074.1	RPL9P30	-4.53	8.06e-06	0.00403	-0.2	-0.24	Coffee consumption (cups per day);	chr17:29746229	chr17:29855759~29856332:+
STAD	cis	rs3806843	0.576	rs155360	ENSG00000202111.1	VTRNA1-2	-4.53	8.07e-06	0.00403	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140929431	chr5:140718925~140719013:+
STAD	cis	rs11098499	0.863	rs10019674	ENSG00000260091.1	RP11-33B1.4	-4.53	8.08e-06	0.00403	-0.23	-0.24	Corneal astigmatism;	chr4:119522334	chr4:119409333~119410233:+
STAD	cis	rs7932354	0.617	rs2306035	ENSG00000271350.1	CTD-2384B9.1	-4.53	8.09e-06	0.00404	-0.29	-0.24	Bone mineral density (hip);Bone mineral density;	chr11:46889906	chr11:47041027~47041945:-
STAD	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	4.53	8.09e-06	0.00404	0.29	0.24	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
STAD	cis	rs9646944	0.501	rs10172116	ENSG00000234389.1	AC007278.3	4.53	8.09e-06	0.00404	0.31	0.24	Blood protein levels;	chr2:102471113	chr2:102438713~102440475:+
STAD	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-4.53	8.09e-06	0.00404	-0.27	-0.24	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
STAD	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-4.53	8.09e-06	0.00404	-0.27	-0.24	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
STAD	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-4.53	8.09e-06	0.00404	-0.38	-0.24	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
STAD	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-4.53	8.09e-06	0.00404	-0.24	-0.24	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
STAD	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-4.53	8.09e-06	0.00404	-0.24	-0.24	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
STAD	cis	rs11846409	0.932	rs73378158	ENSG00000211972.2	IGHV3-66	4.53	8.1e-06	0.00404	0.25	0.24	Rheumatic heart disease;	chr14:106638433	chr14:106675017~106675544:-
STAD	cis	rs8177876	0.749	rs79834398	ENSG00000261061.1	RP11-303E16.2	-4.53	8.11e-06	0.00404	-0.4	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81030770~81031485:+
STAD	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-4.53	8.11e-06	0.00404	-0.21	-0.24	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
STAD	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-4.53	8.11e-06	0.00404	-0.21	-0.24	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
STAD	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-4.53	8.11e-06	0.00404	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-4.53	8.11e-06	0.00404	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
STAD	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	4.53	8.11e-06	0.00404	0.29	0.24	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
STAD	cis	rs7429990	0.932	rs13085054	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.23	0.24	Educational attainment (years of education);	chr3:48092647	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.87	rs13089844	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.23	0.24	Educational attainment (years of education);	chr3:48098741	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs12493348	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.23	0.24	Educational attainment (years of education);	chr3:48102048	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs12486714	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.23	0.24	Educational attainment (years of education);	chr3:48107210	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs2361684	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.23	0.24	Educational attainment (years of education);	chr3:48111128	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.896	rs7427648	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.23	0.24	Educational attainment (years of education);	chr3:48116749	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs11130143	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.22	0.24	Educational attainment (years of education);	chr3:47614943	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs6774170	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.22	0.24	Educational attainment (years of education);	chr3:47615977	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs1403578	ENSG00000224895.1	VPS26BP1	4.53	8.11e-06	0.00404	0.22	0.24	Educational attainment (years of education);	chr3:47617997	chr3:47960327~47961081:-
STAD	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-4.53	8.12e-06	0.00405	-0.29	-0.24	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
STAD	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-4.53	8.12e-06	0.00405	-0.24	-0.24	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
STAD	cis	rs6019512	0.625	rs1997853	ENSG00000227431.4	CSE1L-AS1	-4.53	8.12e-06	0.00405	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48910083	chr20:49040463~49046044:-
STAD	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	4.53	8.12e-06	0.00405	0.35	0.24	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
STAD	cis	rs2695743	0.592	rs7581861	ENSG00000225808.1	DNAJC19P5	-4.53	8.12e-06	0.00405	-0.27	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177820072	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs13386870	ENSG00000225808.1	DNAJC19P5	-4.53	8.12e-06	0.00405	-0.27	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177820402	chr2:177229191~177229506:-
STAD	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	4.53	8.12e-06	0.00405	0.25	0.24	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
STAD	cis	rs8177876	0.749	rs2278024	ENSG00000261838.4	RP11-303E16.6	4.53	8.13e-06	0.00405	0.51	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81069854~81076598:+
STAD	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-4.53	8.13e-06	0.00405	-0.28	-0.24	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-4.53	8.13e-06	0.00405	-0.28	-0.24	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
STAD	cis	rs7208859	0.623	rs9898084	ENSG00000263603.1	CTD-2349P21.5	-4.53	8.13e-06	0.00405	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30729469~30731202:+
STAD	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-4.53	8.13e-06	0.00405	-0.3	-0.24	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
STAD	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-4.53	8.14e-06	0.00406	-0.26	-0.24	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
STAD	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	4.53	8.14e-06	0.00406	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
STAD	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	4.53	8.15e-06	0.00406	0.3	0.24	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	4.53	8.15e-06	0.00406	0.3	0.24	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	4.53	8.15e-06	0.00406	0.3	0.24	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	4.53	8.15e-06	0.00406	0.3	0.24	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
STAD	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-4.53	8.15e-06	0.00406	-0.26	-0.24	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
STAD	cis	rs10851478	0.558	rs17478694	ENSG00000259545.2	RP11-325E5.4	-4.53	8.16e-06	0.00406	-0.27	-0.24	Oral cavity cancer;	chr15:49446345	chr15:49177610~49178741:-
STAD	cis	rs2115536	0.967	rs934137	ENSG00000278600.1	RP11-81A1.6	-4.53	8.17e-06	0.00407	-0.2	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79919426	chr15:79920195~79922455:-
STAD	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	4.53	8.18e-06	0.00407	0.39	0.24	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
STAD	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	4.53	8.18e-06	0.00407	0.3	0.24	Height;	chr6:109332622	chr6:109382795~109383666:+
STAD	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-4.53	8.19e-06	0.00407	-0.3	-0.24	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
STAD	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	4.53	8.19e-06	0.00407	0.38	0.24	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
STAD	cis	rs8141529	0.778	rs9625566	ENSG00000272858.1	CTA-292E10.8	-4.53	8.19e-06	0.00408	-0.26	-0.24	Lymphocyte counts;	chr22:28766518	chr22:28814914~28815662:+
STAD	cis	rs1799949	1	rs2037075	ENSG00000279602.1	CTD-3014M21.1	4.53	8.2e-06	0.00408	0.3	0.24	Menopause (age at onset);	chr17:43153809	chr17:43360041~43361361:-
STAD	cis	rs6430585	0.528	rs586964	ENSG00000231890.6	DARS-AS1	-4.53	8.21e-06	0.00408	-0.27	-0.24	Corneal structure;	chr2:135894921	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs499483	ENSG00000231890.6	DARS-AS1	-4.53	8.21e-06	0.00408	-0.27	-0.24	Corneal structure;	chr2:135894954	chr2:135985176~136022593:+
STAD	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	4.53	8.21e-06	0.00408	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
STAD	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	4.53	8.21e-06	0.00408	0.26	0.24	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
STAD	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	4.53	8.22e-06	0.00409	0.29	0.24	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
STAD	cis	rs2836974	0.563	rs6517522	ENSG00000232608.1	TIMM9P2	-4.53	8.22e-06	0.00409	-0.24	-0.24	Cognitive function;	chr21:39181919	chr21:39216624~39217506:+
STAD	cis	rs6832769	0.961	rs1011095	ENSG00000272969.1	RP11-528I4.2	4.53	8.22e-06	0.00409	0.3	0.24	Personality dimensions;	chr4:55398774	chr4:55547112~55547889:+
STAD	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-4.53	8.22e-06	0.00409	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
STAD	cis	rs748404	0.587	rs690276	ENSG00000275601.1	AC011330.13	-4.53	8.22e-06	0.00409	-0.25	-0.24	Lung cancer;	chr15:43412360	chr15:43642389~43643023:-
STAD	cis	rs1723838	0.826	rs2515091	ENSG00000255928.1	RP11-456I15.2	4.53	8.22e-06	0.00409	0.5	0.24	Obesity-related traits;	chr11:73823409	chr11:73722349~73722694:+
STAD	cis	rs1707322	0.716	rs10890342	ENSG00000225447.1	RPS15AP10	4.53	8.23e-06	0.00409	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs6658700	ENSG00000225447.1	RPS15AP10	4.53	8.23e-06	0.00409	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs12047629	ENSG00000225447.1	RPS15AP10	4.53	8.23e-06	0.00409	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs11211169	ENSG00000225447.1	RPS15AP10	4.53	8.23e-06	0.00409	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45645816~45646197:-
STAD	cis	rs6921919	0.583	rs35560946	ENSG00000220721.1	OR1F12	4.53	8.23e-06	0.00409	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs740622	ENSG00000220721.1	OR1F12	4.53	8.23e-06	0.00409	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28073316~28074233:+
STAD	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	4.53	8.23e-06	0.00409	0.3	0.24	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
STAD	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	4.53	8.25e-06	0.0041	0.28	0.24	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
STAD	cis	rs4950322	0.542	rs3766520	ENSG00000278811.3	LINC00624	4.53	8.25e-06	0.0041	0.26	0.24	Protein quantitative trait loci;	chr1:147214658	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.542	rs3766519	ENSG00000278811.3	LINC00624	4.53	8.25e-06	0.0041	0.26	0.24	Protein quantitative trait loci;	chr1:147214802	chr1:147258885~147517875:-
STAD	cis	rs2880765	0.566	rs17553790	ENSG00000229212.6	RP11-561C5.4	-4.53	8.26e-06	0.0041	-0.33	-0.24	Coronary artery disease;	chr15:85470434	chr15:85205440~85234795:-
STAD	cis	rs1707322	0.721	rs61784800	ENSG00000281133.1	AL355480.3	4.53	8.26e-06	0.00411	0.28	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45580892~45580996:-
STAD	cis	rs7487075	0.786	rs12302984	ENSG00000257261.4	RP11-96H19.1	4.53	8.26e-06	0.00411	0.29	0.24	Itch intensity from mosquito bite;	chr12:46290287	chr12:46383679~46876159:+
STAD	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-4.53	8.26e-06	0.00411	-0.28	-0.24	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
STAD	cis	rs9860428	0.815	rs11717778	ENSG00000240057.4	RP11-572M11.4	-4.53	8.27e-06	0.00411	-0.22	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112853801	chr3:113019532~113183301:+
STAD	cis	rs748404	0.697	rs498227	ENSG00000275601.1	AC011330.13	-4.53	8.27e-06	0.00411	-0.25	-0.24	Lung cancer;	chr15:43280854	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-4.53	8.27e-06	0.00411	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
STAD	cis	rs9307551	0.619	rs1899232	ENSG00000250334.4	LINC00989	-4.53	8.28e-06	0.00411	-0.29	-0.24	Refractive error;	chr4:79501789	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.619	rs7684683	ENSG00000250334.4	LINC00989	-4.53	8.28e-06	0.00411	-0.29	-0.24	Refractive error;	chr4:79501867	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.584	rs7663844	ENSG00000250334.4	LINC00989	-4.53	8.28e-06	0.00411	-0.29	-0.24	Refractive error;	chr4:79502053	chr4:79492416~79576460:+
STAD	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-4.53	8.28e-06	0.00412	-0.29	-0.24	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
STAD	cis	rs8062405	0.824	rs7191618	ENSG00000278665.1	RP11-666O2.4	4.53	8.29e-06	0.00412	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.754	rs3859172	ENSG00000278665.1	RP11-666O2.4	4.53	8.29e-06	0.00412	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28599241~28601881:-
STAD	cis	rs2933343	0.7	rs6787833	ENSG00000261159.1	RP11-723O4.9	4.53	8.29e-06	0.00412	0.29	0.24	IgG glycosylation;	chr3:128937341	chr3:128859716~128860526:-
STAD	cis	rs7615952	0.673	rs9821905	ENSG00000272840.1	RP11-379B18.6	-4.53	8.29e-06	0.00412	-0.47	-0.24	Blood pressure (smoking interaction);	chr3:125902007	chr3:125774714~125797953:+
STAD	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	4.53	8.3e-06	0.00412	0.31	0.24	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
STAD	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	4.53	8.3e-06	0.00412	0.31	0.24	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
STAD	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	4.53	8.3e-06	0.00412	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
STAD	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	4.53	8.3e-06	0.00412	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
STAD	cis	rs3770081	1	rs2241437	ENSG00000273080.1	RP11-301O19.1	-4.53	8.3e-06	0.00412	-0.54	-0.24	Facial emotion recognition (sad faces);	chr2:86133450	chr2:86195590~86196049:+
STAD	cis	rs11676348	0.808	rs4674261	ENSG00000237281.1	CATIP-AS2	4.53	8.31e-06	0.00412	0.23	0.24	Ulcerative colitis;	chr2:218140286	chr2:218326889~218357966:-
STAD	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-4.53	8.31e-06	0.00413	-0.23	-0.24	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
STAD	cis	rs9646944	0.501	rs12991737	ENSG00000234389.1	AC007278.3	4.53	8.31e-06	0.00413	0.31	0.24	Blood protein levels;	chr2:102401668	chr2:102438713~102440475:+
STAD	cis	rs1075265	0.568	rs805416	ENSG00000235937.1	AC008280.1	-4.52	8.31e-06	0.00413	-0.21	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54029552~54030682:-
STAD	cis	rs11098499	0.863	rs11098531	ENSG00000260091.1	RP11-33B1.4	4.52	8.32e-06	0.00413	0.23	0.24	Corneal astigmatism;	chr4:119543846	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs28718422	ENSG00000260091.1	RP11-33B1.4	4.52	8.32e-06	0.00413	0.23	0.24	Corneal astigmatism;	chr4:119545149	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs12498539	ENSG00000260091.1	RP11-33B1.4	4.52	8.32e-06	0.00413	0.23	0.24	Corneal astigmatism;	chr4:119547215	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.818	rs12498599	ENSG00000260091.1	RP11-33B1.4	4.52	8.32e-06	0.00413	0.23	0.24	Corneal astigmatism;	chr4:119547348	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs10009626	ENSG00000260091.1	RP11-33B1.4	4.52	8.32e-06	0.00413	0.23	0.24	Corneal astigmatism;	chr4:119548850	chr4:119409333~119410233:+
STAD	cis	rs2380205	0.58	rs980230	ENSG00000232807.2	RP11-536K7.3	4.52	8.32e-06	0.00413	0.25	0.24	Breast cancer;	chr10:5863268	chr10:5934270~5945900:-
STAD	cis	rs1799949	1	rs12944597	ENSG00000236383.6	LINC00854	-4.52	8.32e-06	0.00413	-0.2	-0.24	Menopause (age at onset);	chr17:43035667	chr17:43216941~43305976:-
STAD	cis	rs1799949	1	rs12942277	ENSG00000236383.6	LINC00854	-4.52	8.32e-06	0.00413	-0.2	-0.24	Menopause (age at onset);	chr17:43035957	chr17:43216941~43305976:-
STAD	cis	rs1799949	0.965	rs34616041	ENSG00000236383.6	LINC00854	-4.52	8.32e-06	0.00413	-0.2	-0.24	Menopause (age at onset);	chr17:43036769	chr17:43216941~43305976:-
STAD	cis	rs8028182	0.636	rs4886715	ENSG00000260269.4	CTD-2323K18.1	-4.52	8.32e-06	0.00413	-0.3	-0.24	Sudden cardiac arrest;	chr15:75539108	chr15:75527150~75601205:-
STAD	cis	rs1707322	0.662	rs11211160	ENSG00000225447.1	RPS15AP10	4.52	8.32e-06	0.00413	0.18	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45645816~45646197:-
STAD	cis	rs539514	0.501	rs8000656	ENSG00000261105.4	LMO7-AS1	-4.52	8.32e-06	0.00413	-0.3	-0.24	Type 1 diabetes;	chr13:75826504	chr13:75604700~75635994:-
STAD	cis	rs11676348	0.774	rs13397673	ENSG00000237281.1	CATIP-AS2	4.52	8.32e-06	0.00413	0.24	0.24	Ulcerative colitis;	chr2:218183059	chr2:218326889~218357966:-
STAD	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-4.52	8.33e-06	0.00413	-0.24	-0.24	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
STAD	cis	rs1348850	0.872	rs4893825	ENSG00000271825.1	RP11-337N6.2	4.52	8.34e-06	0.00414	0.21	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177433959	chr2:177300600~177302006:+
STAD	cis	rs7078219	1	rs6584278	ENSG00000228778.1	RP11-129J12.1	-4.52	8.34e-06	0.00414	-0.29	-0.24	Dental caries;	chr10:99518342	chr10:99527081~99528261:+
STAD	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-4.52	8.34e-06	0.00414	-0.24	-0.24	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
STAD	cis	rs6921919	0.583	rs7759191	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs7764737	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs9461458	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.609	rs9468365	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs1361385	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs1416918	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs9468367	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs9461459	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs28360638	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs9468368	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.609	rs1005127	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28073316~28074233:+
STAD	cis	rs853679	0.515	rs4580862	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Depression;	chr6:28399886	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs4357130	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs11755942	ENSG00000220721.1	OR1F12	4.52	8.34e-06	0.00414	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28073316~28074233:+
STAD	cis	rs9807989	0.839	rs10192036	ENSG00000234389.1	AC007278.3	4.52	8.34e-06	0.00414	0.25	0.24	Asthma;	chr2:102351751	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs10204137	ENSG00000234389.1	AC007278.3	4.52	8.34e-06	0.00414	0.25	0.24	Asthma;	chr2:102351752	chr2:102438713~102440475:+
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000224373.3	IGHV4-59	4.52	8.34e-06	0.00414	0.17	0.24	Kawasaki disease;	chr14:106783414	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000224373.3	IGHV4-59	4.52	8.34e-06	0.00414	0.17	0.24	Kawasaki disease;	chr14:106783693	chr14:106627249~106627825:-
STAD	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-4.52	8.35e-06	0.00414	-0.29	-0.24	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
STAD	cis	rs7429990	0.864	rs2047559	ENSG00000224895.1	VPS26BP1	4.52	8.35e-06	0.00414	0.22	0.24	Educational attainment (years of education);	chr3:47704695	chr3:47960327~47961081:-
STAD	cis	rs2503875	1	rs2503875	ENSG00000230555.2	RP11-517P14.2	4.52	8.35e-06	0.00414	0.24	0.24	Multiple sclerosis;	chr10:43318601	chr10:43420738~43422100:+
STAD	cis	rs11098499	0.863	rs1010740	ENSG00000260091.1	RP11-33B1.4	-4.52	8.35e-06	0.00414	-0.24	-0.24	Corneal astigmatism;	chr4:119542254	chr4:119409333~119410233:+
STAD	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	4.52	8.35e-06	0.00414	0.29	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
STAD	cis	rs748404	0.66	rs2439845	ENSG00000275601.1	AC011330.13	-4.52	8.36e-06	0.00415	-0.25	-0.24	Lung cancer;	chr15:43430412	chr15:43642389~43643023:-
STAD	cis	rs6019512	0.625	rs6019513	ENSG00000227431.4	CSE1L-AS1	-4.52	8.36e-06	0.00415	-0.22	-0.24	Intelligence (multi-trait analysis);	chr20:48910269	chr20:49040463~49046044:-
STAD	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	4.52	8.37e-06	0.00415	0.26	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
STAD	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-4.52	8.37e-06	0.00415	-0.3	-0.24	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
STAD	cis	rs7176527	0.519	rs12148368	ENSG00000188388.10	GOLGA6L3	4.52	8.38e-06	0.00415	0.3	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85240472~85247170:+
STAD	cis	rs6832769	0.961	rs7660808	ENSG00000272969.1	RP11-528I4.2	-4.52	8.4e-06	0.00416	-0.3	-0.24	Personality dimensions;	chr4:55590505	chr4:55547112~55547889:+
STAD	cis	rs8177876	0.749	rs11537	ENSG00000261838.4	RP11-303E16.6	4.52	8.4e-06	0.00416	0.49	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81069854~81076598:+
STAD	cis	rs831571	0.668	rs17069879	ENSG00000280620.1	SCAANT1	-4.52	8.4e-06	0.00416	-0.35	-0.24	Type 2 diabetes;	chr3:64097741	chr3:63911518~63911772:-
STAD	cis	rs7131987	0.65	rs7973786	ENSG00000275476.1	RP11-996F15.4	-4.52	8.4e-06	0.00416	-0.26	-0.24	QT interval;	chr12:29309811	chr12:29277397~29277882:-
STAD	cis	rs1005277	0.579	rs1780137	ENSG00000276805.1	RP11-291L22.6	4.52	8.4e-06	0.00416	0.25	0.24	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38451030~38451785:+
STAD	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	4.52	8.4e-06	0.00416	0.24	0.24	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
STAD	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-4.52	8.4e-06	0.00417	-0.37	-0.24	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
STAD	cis	rs1150668	0.796	rs2247002	ENSG00000220721.1	OR1F12	4.52	8.4e-06	0.00417	0.23	0.24	Pubertal anthropometrics;	chr6:28430174	chr6:28073316~28074233:+
STAD	cis	rs7078219	0.543	rs10786557	ENSG00000257582.4	LINC01475	-4.52	8.41e-06	0.00417	-0.27	-0.24	Dental caries;	chr10:99523571	chr10:99526350~99531177:-
STAD	cis	rs7680126	0.633	rs11730631	ENSG00000250613.1	RP11-136I13.1	-4.52	8.42e-06	0.00417	-0.25	-0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10291344	chr4:10410996~10411644:+
STAD	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	4.52	8.42e-06	0.00417	0.27	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
STAD	cis	rs2933343	0.621	rs789249	ENSG00000261159.1	RP11-723O4.9	4.52	8.42e-06	0.00417	0.29	0.24	IgG glycosylation;	chr3:128859610	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.621	rs789241	ENSG00000261159.1	RP11-723O4.9	4.52	8.42e-06	0.00417	0.29	0.24	IgG glycosylation;	chr3:128866909	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.649	rs2638845	ENSG00000261159.1	RP11-723O4.9	4.52	8.42e-06	0.00417	0.29	0.24	IgG glycosylation;	chr3:128868526	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.649	rs728839	ENSG00000261159.1	RP11-723O4.9	4.52	8.42e-06	0.00417	0.29	0.24	IgG glycosylation;	chr3:128870516	chr3:128859716~128860526:-
STAD	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-4.52	8.42e-06	0.00417	-0.36	-0.24	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
STAD	cis	rs2739330	0.828	rs2330635	ENSG00000272787.1	KB-226F1.2	-4.52	8.42e-06	0.00417	-0.25	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23969211~23969873:+
STAD	cis	rs8141529	0.732	rs6005881	ENSG00000272858.1	CTA-292E10.8	-4.52	8.43e-06	0.00417	-0.25	-0.24	Lymphocyte counts;	chr22:28787145	chr22:28814914~28815662:+
STAD	cis	rs10504130	0.696	rs79740712	ENSG00000272024.1	RP11-546K22.3	-4.52	8.43e-06	0.00417	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51950284~51950690:+
STAD	cis	rs10504130	0.696	rs77958054	ENSG00000272024.1	RP11-546K22.3	-4.52	8.43e-06	0.00417	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51926157	chr8:51950284~51950690:+
STAD	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	4.52	8.43e-06	0.00417	0.35	0.24	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
STAD	cis	rs9902453	0.74	rs2254414	ENSG00000240074.1	RPL9P30	-4.52	8.44e-06	0.00418	-0.2	-0.24	Coffee consumption (cups per day);	chr17:29734112	chr17:29855759~29856332:+
STAD	cis	rs4691139	0.658	rs4691142	ENSG00000248632.1	RP11-366M4.11	4.52	8.44e-06	0.00418	0.23	0.24	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005634	chr4:164968587~164970002:-
STAD	cis	rs9879311	0.966	rs28113	ENSG00000240288.6	GHRLOS	4.52	8.44e-06	0.00418	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358959	chr3:10285754~10293449:+
STAD	cis	rs4713118	0.955	rs9468203	ENSG00000220721.1	OR1F12	4.52	8.44e-06	0.00418	0.25	0.24	Parkinson's disease;	chr6:27720888	chr6:28073316~28074233:+
STAD	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	4.52	8.44e-06	0.00418	0.3	0.24	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
STAD	cis	rs10073892	0.66	rs1113814	ENSG00000250682.4	LINC00491	-4.52	8.45e-06	0.00418	-0.26	-0.24	Cognitive decline (age-related);	chr5:102646335	chr5:102609156~102671559:-
STAD	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-4.52	8.45e-06	0.00418	-0.36	-0.24	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
STAD	cis	rs9902453	0.845	rs2617875	ENSG00000240074.1	RPL9P30	4.52	8.45e-06	0.00419	0.2	0.24	Coffee consumption (cups per day);	chr17:29763006	chr17:29855759~29856332:+
STAD	cis	rs1799949	0.965	rs4239149	ENSG00000279602.1	CTD-3014M21.1	-4.52	8.45e-06	0.00419	-0.29	-0.24	Menopause (age at onset);	chr17:43176078	chr17:43360041~43361361:-
STAD	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	4.52	8.45e-06	0.00419	0.26	0.24	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
STAD	cis	rs4243830	0.737	rs4908923	ENSG00000229519.2	RP11-58A11.2	4.52	8.46e-06	0.00419	0.26	0.24	Body mass index;	chr1:6554475	chr1:6547905~6548619:+
STAD	cis	rs2933343	0.649	rs789219	ENSG00000261159.1	RP11-723O4.9	4.52	8.46e-06	0.00419	0.29	0.24	IgG glycosylation;	chr3:128873677	chr3:128859716~128860526:-
STAD	cis	rs858239	0.867	rs10250602	ENSG00000230042.1	AK3P3	-4.52	8.46e-06	0.00419	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23129178~23129841:+
STAD	cis	rs227275	0.554	rs223485	ENSG00000248971.2	KRT8P46	-4.52	8.46e-06	0.00419	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102728746~102730171:-
STAD	cis	rs1707322	1	rs6657720	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs7519181	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs7526369	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs10890371	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10890372	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.928	rs6681068	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211228	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs11211229	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs9803784	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs12022335	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs10789484	ENSG00000281133.1	AL355480.3	-4.52	8.46e-06	0.00419	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45580892~45580996:-
STAD	cis	rs9879311	0.966	rs775018	ENSG00000240288.6	GHRLOS	4.52	8.46e-06	0.00419	0.24	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358461	chr3:10285754~10293449:+
STAD	cis	rs2739330	0.892	rs4822455	ENSG00000272787.1	KB-226F1.2	-4.52	8.46e-06	0.00419	-0.25	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23969211~23969873:+
STAD	cis	rs2006771	0.765	rs6518752	ENSG00000236132.1	CTA-440B3.1	-4.52	8.46e-06	0.00419	-0.24	-0.24	Nonsyndromic cleft lip with cleft palate;	chr22:31603141	chr22:31816379~31817491:-
STAD	cis	rs7617773	0.963	rs12493256	ENSG00000224895.1	VPS26BP1	4.52	8.46e-06	0.00419	0.24	0.24	Coronary artery disease;	chr3:48135257	chr3:47960327~47961081:-
STAD	cis	rs7617773	0.963	rs12494304	ENSG00000224895.1	VPS26BP1	4.52	8.46e-06	0.00419	0.24	0.24	Coronary artery disease;	chr3:48136539	chr3:47960327~47961081:-
STAD	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	4.52	8.46e-06	0.00419	0.25	0.24	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
STAD	cis	rs7131987	0.621	rs11050181	ENSG00000275476.1	RP11-996F15.4	-4.52	8.47e-06	0.00419	-0.26	-0.24	QT interval;	chr12:29314736	chr12:29277397~29277882:-
STAD	cis	rs17507216	0.718	rs7165690	ENSG00000259429.4	UBE2Q2P2	-4.52	8.47e-06	0.00419	-0.37	-0.24	Excessive daytime sleepiness;	chr15:82654804	chr15:82355142~82420075:+
STAD	cis	rs858239	1	rs199351	ENSG00000230042.1	AK3P3	-4.52	8.47e-06	0.00419	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23129178~23129841:+
STAD	cis	rs4589258	0.966	rs4463818	ENSG00000280367.1	RP11-121L10.2	4.52	8.48e-06	0.0042	0.25	0.24	Intelligence (multi-trait analysis);	chr11:90774204	chr11:90223153~90226538:+
STAD	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-4.52	8.48e-06	0.0042	-0.23	-0.24	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
STAD	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	4.52	8.48e-06	0.0042	0.34	0.24	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
STAD	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	4.52	8.48e-06	0.0042	0.35	0.24	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
STAD	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-4.52	8.48e-06	0.0042	-0.21	-0.24	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
STAD	cis	rs1426063	0.614	rs76087197	ENSG00000249717.1	RP11-44F21.3	4.52	8.48e-06	0.0042	0.5	0.24	QT interval;	chr4:75134108	chr4:74955974~74970362:-
STAD	cis	rs10978777	0.889	rs10978769	ENSG00000276883.1	AL137852.1	4.52	8.49e-06	0.0042	0.23	0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107245862	chr9:107292369~107292456:-
STAD	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	4.52	8.49e-06	0.0042	0.26	0.24	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	4.52	8.49e-06	0.0042	0.26	0.24	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
STAD	cis	rs227275	0.554	rs6810668	ENSG00000248971.2	KRT8P46	-4.52	8.49e-06	0.0042	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102728746~102730171:-
STAD	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	4.52	8.49e-06	0.0042	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	4.52	8.49e-06	0.0042	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	4.52	8.49e-06	0.0042	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	4.52	8.49e-06	0.0042	0.27	0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
STAD	cis	rs9291683	0.507	rs6849273	ENSG00000250613.1	RP11-136I13.1	-4.52	8.5e-06	0.0042	-0.24	-0.24	Bone mineral density;	chr4:10019971	chr4:10410996~10411644:+
STAD	cis	rs1426063	1	rs10022563	ENSG00000248165.1	RP11-44F21.2	4.52	8.5e-06	0.0042	0.4	0.24	QT interval;	chr4:75100989	chr4:74993877~75034824:-
STAD	cis	rs1426063	1	rs10033857	ENSG00000248165.1	RP11-44F21.2	4.52	8.5e-06	0.0042	0.4	0.24	QT interval;	chr4:75103208	chr4:74993877~75034824:-
STAD	cis	rs1876905	0.539	rs240980	ENSG00000271789.1	RP5-1112D6.7	4.52	8.51e-06	0.00421	0.28	0.24	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111297126~111298510:+
STAD	cis	rs7429990	0.864	rs12492915	ENSG00000224895.1	VPS26BP1	4.52	8.51e-06	0.00421	0.22	0.24	Educational attainment (years of education);	chr3:47636545	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs12636863	ENSG00000224895.1	VPS26BP1	4.52	8.51e-06	0.00421	0.22	0.24	Educational attainment (years of education);	chr3:47638629	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7613934	ENSG00000224895.1	VPS26BP1	4.52	8.51e-06	0.00421	0.22	0.24	Educational attainment (years of education);	chr3:47640681	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs6772301	ENSG00000224895.1	VPS26BP1	4.52	8.51e-06	0.00421	0.22	0.24	Educational attainment (years of education);	chr3:47682366	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs13063042	ENSG00000224895.1	VPS26BP1	4.52	8.51e-06	0.00421	0.22	0.24	Educational attainment (years of education);	chr3:47683825	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs2133601	ENSG00000224895.1	VPS26BP1	4.52	8.51e-06	0.00421	0.22	0.24	Educational attainment (years of education);	chr3:47692525	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs6792497	ENSG00000224895.1	VPS26BP1	4.52	8.51e-06	0.00421	0.22	0.24	Educational attainment (years of education);	chr3:47693684	chr3:47960327~47961081:-
STAD	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	4.52	8.51e-06	0.00421	0.3	0.24	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
STAD	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-4.52	8.51e-06	0.00421	-0.33	-0.24	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
STAD	cis	rs9646944	0.501	rs10181785	ENSG00000234389.1	AC007278.3	4.52	8.51e-06	0.00421	0.31	0.24	Blood protein levels;	chr2:102408814	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.54	rs12712148	ENSG00000234389.1	AC007278.3	4.52	8.51e-06	0.00421	0.31	0.24	Blood protein levels;	chr2:102409087	chr2:102438713~102440475:+
STAD	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	4.52	8.52e-06	0.00421	0.3	0.24	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
STAD	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	4.52	8.52e-06	0.00421	0.24	0.24	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
STAD	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	4.52	8.52e-06	0.00421	0.24	0.24	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
STAD	cis	rs172166	0.561	rs149973	ENSG00000220721.1	OR1F12	4.52	8.52e-06	0.00421	0.23	0.24	Cardiac Troponin-T levels;	chr6:28015835	chr6:28073316~28074233:+
STAD	cis	rs172166	0.561	rs149974	ENSG00000220721.1	OR1F12	4.52	8.52e-06	0.00421	0.23	0.24	Cardiac Troponin-T levels;	chr6:28017318	chr6:28073316~28074233:+
STAD	cis	rs11992186	0.597	rs77717027	ENSG00000253981.4	ALG1L13P	-4.52	8.52e-06	0.00421	-0.31	-0.24	Neuroticism;	chr8:8734122	chr8:8236003~8244667:-
STAD	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	4.52	8.52e-06	0.00421	0.32	0.24	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
STAD	cis	rs36423	0.702	rs17103830	ENSG00000266869.1	RP6-114E22.1	4.52	8.53e-06	0.00422	0.4	0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71868681	chr14:71848606~71908430:+
STAD	cis	rs6142102	1	rs4911410	ENSG00000275784.1	RP5-1125A11.6	-4.52	8.53e-06	0.00422	-0.24	-0.24	Skin pigmentation;	chr20:34123168	chr20:33989480~33991818:-
STAD	cis	rs2692947	0.76	rs2438924	ENSG00000237510.6	AC008268.2	4.52	8.54e-06	0.00422	0.28	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979321	chr2:95789654~95800166:+
STAD	cis	rs5769707	0.521	rs6009810	ENSG00000280224.1	CTA-722E9.1	-4.52	8.55e-06	0.00422	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49500568~49501585:+
STAD	cis	rs9860428	0.844	rs9829184	ENSG00000240057.4	RP11-572M11.4	-4.52	8.55e-06	0.00423	-0.22	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112853837	chr3:113019532~113183301:+
STAD	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-4.52	8.55e-06	0.00423	-0.29	-0.24	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
STAD	cis	rs7208859	0.623	rs56018041	ENSG00000263603.1	CTD-2349P21.5	-4.52	8.55e-06	0.00423	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30729469~30731202:+
STAD	cis	rs8028182	0.636	rs4886707	ENSG00000260269.4	CTD-2323K18.1	-4.52	8.55e-06	0.00423	-0.3	-0.24	Sudden cardiac arrest;	chr15:75463126	chr15:75527150~75601205:-
STAD	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-4.52	8.55e-06	0.00423	-0.37	-0.24	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
STAD	cis	rs2836950	0.545	rs1888489	ENSG00000238141.2	BRWD1-AS1	-4.52	8.56e-06	0.00423	-0.24	-0.24	Menarche (age at onset);	chr21:39161238	chr21:39315707~39323218:+
STAD	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-4.52	8.56e-06	0.00423	-0.28	-0.24	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
STAD	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
STAD	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	4.52	8.56e-06	0.00423	0.35	0.24	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
STAD	cis	rs10129255	0.536	rs6576201	ENSG00000211973.2	IGHV1-69	-4.52	8.56e-06	0.00423	-0.2	-0.24	Kawasaki disease;	chr14:106683696	chr14:106714684~106715181:-
STAD	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-4.52	8.57e-06	0.00423	-0.28	-0.24	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
STAD	cis	rs950169	0.512	rs4374136	ENSG00000259728.4	LINC00933	4.52	8.57e-06	0.00423	0.34	0.24	Schizophrenia;	chr15:83976255	chr15:84570649~84580175:+
STAD	cis	rs516805	0.596	rs1531186	ENSG00000279453.1	RP3-425C14.4	-4.52	8.58e-06	0.00424	-0.36	-0.24	Lymphocyte counts;	chr6:122208219	chr6:122436789~122439223:-
STAD	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	4.52	8.58e-06	0.00424	0.37	0.24	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
STAD	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	4.52	8.58e-06	0.00424	0.31	0.24	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
STAD	cis	rs4589258	0.933	rs1792610	ENSG00000280367.1	RP11-121L10.2	-4.52	8.59e-06	0.00424	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90699627	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs2511315	ENSG00000280367.1	RP11-121L10.2	-4.52	8.59e-06	0.00424	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90701593	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.898	rs2511314	ENSG00000280367.1	RP11-121L10.2	-4.52	8.59e-06	0.00424	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90701639	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs2508411	ENSG00000280367.1	RP11-121L10.2	-4.52	8.59e-06	0.00424	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90701722	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1783785	ENSG00000280367.1	RP11-121L10.2	-4.52	8.59e-06	0.00424	-0.26	-0.24	Intelligence (multi-trait analysis);	chr11:90702537	chr11:90223153~90226538:+
STAD	cis	rs2337406	0.641	rs10133227	ENSG00000280411.1	IGHV1-69-2	4.52	8.59e-06	0.00424	0.27	0.24	Alzheimer's disease (late onset);	chr14:106814260	chr14:106762092~106762588:-
STAD	cis	rs2404602	0.967	rs7167613	ENSG00000259422.1	RP11-593F23.1	4.52	8.59e-06	0.00424	0.25	0.24	Blood metabolite levels;	chr15:76748851	chr15:76174891~76181486:-
STAD	cis	rs17401966	0.838	rs34636442	ENSG00000199562.1	RNU6-37P	4.52	8.59e-06	0.00424	0.18	0.24	Hepatocellular carcinoma;	chr1:10367401	chr1:10298966~10299072:+
STAD	cis	rs8028182	0.666	rs4886708	ENSG00000260269.4	CTD-2323K18.1	-4.52	8.6e-06	0.00425	-0.3	-0.24	Sudden cardiac arrest;	chr15:75470267	chr15:75527150~75601205:-
STAD	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-4.52	8.6e-06	0.00425	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
STAD	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	4.52	8.6e-06	0.00425	0.43	0.24	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	4.52	8.6e-06	0.00425	0.43	0.24	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
STAD	cis	rs237743	1	rs67652499	ENSG00000222365.1	SNORD12B	-4.52	8.61e-06	0.00425	-0.32	-0.24	Height;	chr20:49310154	chr20:49280319~49280409:+
STAD	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-4.52	8.61e-06	0.00425	-0.3	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
STAD	cis	rs1707322	0.752	rs4607935	ENSG00000225447.1	RPS15AP10	4.52	8.61e-06	0.00425	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs3811436	ENSG00000225447.1	RPS15AP10	4.52	8.61e-06	0.00425	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs4415615	ENSG00000225447.1	RPS15AP10	4.52	8.61e-06	0.00425	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs7529699	ENSG00000225447.1	RPS15AP10	4.52	8.61e-06	0.00425	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs10430105	ENSG00000225447.1	RPS15AP10	4.52	8.61e-06	0.00425	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45645816~45646197:-
STAD	cis	rs6142102	0.924	rs6059662	ENSG00000275784.1	RP5-1125A11.6	4.52	8.61e-06	0.00425	0.24	0.24	Skin pigmentation;	chr20:34087921	chr20:33989480~33991818:-
STAD	cis	rs10851478	0.836	rs62021589	ENSG00000259545.2	RP11-325E5.4	-4.52	8.62e-06	0.00425	-0.28	-0.24	Oral cavity cancer;	chr15:49576621	chr15:49177610~49178741:-
STAD	cis	rs4237845	0.816	rs61935769	ENSG00000273805.1	RP11-620J15.4	-4.52	8.62e-06	0.00425	-0.27	-0.24	Intelligence (multi-trait analysis);	chr12:57900561	chr12:57894232~57896846:+
STAD	cis	rs7429990	0.864	rs7621236	ENSG00000224895.1	VPS26BP1	4.52	8.62e-06	0.00425	0.22	0.24	Educational attainment (years of education);	chr3:47646677	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7624474	ENSG00000224895.1	VPS26BP1	4.52	8.62e-06	0.00425	0.22	0.24	Educational attainment (years of education);	chr3:47647786	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs4858846	ENSG00000224895.1	VPS26BP1	4.52	8.62e-06	0.00425	0.22	0.24	Educational attainment (years of education);	chr3:47654591	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.803	rs13081356	ENSG00000224895.1	VPS26BP1	4.52	8.62e-06	0.00425	0.22	0.24	Educational attainment (years of education);	chr3:47660067	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.803	rs11130145	ENSG00000224895.1	VPS26BP1	4.52	8.62e-06	0.00425	0.22	0.24	Educational attainment (years of education);	chr3:47661780	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs2140335	ENSG00000224895.1	VPS26BP1	4.52	8.62e-06	0.00425	0.22	0.24	Educational attainment (years of education);	chr3:47663625	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs11130146	ENSG00000224895.1	VPS26BP1	4.52	8.62e-06	0.00425	0.22	0.24	Educational attainment (years of education);	chr3:47666322	chr3:47960327~47961081:-
STAD	cis	rs17401966	0.898	rs11587495	ENSG00000199562.1	RNU6-37P	4.52	8.62e-06	0.00426	0.19	0.24	Hepatocellular carcinoma;	chr1:10388942	chr1:10298966~10299072:+
STAD	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-4.52	8.62e-06	0.00426	-0.29	-0.24	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
STAD	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-4.52	8.63e-06	0.00426	-0.27	-0.24	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
STAD	cis	rs6921919	0.583	rs740621	ENSG00000220721.1	OR1F12	4.52	8.63e-06	0.00426	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28073316~28074233:+
STAD	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	4.52	8.63e-06	0.00426	0.39	0.24	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
STAD	cis	rs10971721	0.822	rs56370320	ENSG00000260947.1	RP11-384P7.7	4.52	8.64e-06	0.00427	0.35	0.24	Body mass index;	chr9:33865630	chr9:33697459~33700986:+
STAD	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	4.52	8.64e-06	0.00427	0.29	0.24	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
STAD	cis	rs9807989	0.839	rs3771166	ENSG00000234389.1	AC007278.3	4.52	8.64e-06	0.00427	0.25	0.24	Asthma;	chr2:102369762	chr2:102438713~102440475:+
STAD	cis	rs853679	0.55	rs1233707	ENSG00000220721.1	OR1F12	4.52	8.65e-06	0.00427	0.27	0.24	Depression;	chr6:28205175	chr6:28073316~28074233:+
STAD	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	4.52	8.66e-06	0.00427	0.36	0.24	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
STAD	cis	rs938554	0.612	rs4385059	ENSG00000250613.1	RP11-136I13.1	4.52	8.66e-06	0.00427	0.27	0.24	Blood metabolite levels;	chr4:9987609	chr4:10410996~10411644:+
STAD	cis	rs721917	0.565	rs2255601	ENSG00000244733.5	RP11-506M13.3	-4.52	8.66e-06	0.00427	-0.26	-0.24	Chronic obstructive pulmonary disease;	chr10:79944803	chr10:79660891~79677996:+
STAD	cis	rs721917	0.525	rs4281433	ENSG00000244733.5	RP11-506M13.3	-4.52	8.66e-06	0.00427	-0.26	-0.24	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79660891~79677996:+
STAD	cis	rs7829975	0.714	rs11777085	ENSG00000253981.4	ALG1L13P	4.52	8.66e-06	0.00427	0.27	0.24	Mood instability;	chr8:8814919	chr8:8236003~8244667:-
STAD	cis	rs9807989	0.811	rs11688568	ENSG00000234389.1	AC007278.3	4.52	8.67e-06	0.00428	0.25	0.24	Asthma;	chr2:102353489	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.811	rs11688573	ENSG00000234389.1	AC007278.3	4.52	8.67e-06	0.00428	0.25	0.24	Asthma;	chr2:102353511	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.811	rs11689730	ENSG00000234389.1	AC007278.3	4.52	8.67e-06	0.00428	0.25	0.24	Asthma;	chr2:102353524	chr2:102438713~102440475:+
STAD	cis	rs7429990	0.901	rs7374482	ENSG00000224895.1	VPS26BP1	4.52	8.67e-06	0.00428	0.23	0.24	Educational attainment (years of education);	chr3:48126900	chr3:47960327~47961081:-
STAD	cis	rs1707322	0.716	rs28375469	ENSG00000225447.1	RPS15AP10	4.52	8.67e-06	0.00428	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs28545085	ENSG00000225447.1	RPS15AP10	4.52	8.67e-06	0.00428	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs28507722	ENSG00000225447.1	RPS15AP10	4.52	8.67e-06	0.00428	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.717	rs28396194	ENSG00000225447.1	RPS15AP10	4.52	8.67e-06	0.00428	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.717	rs28752166	ENSG00000225447.1	RPS15AP10	4.52	8.67e-06	0.00428	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45645816~45646197:-
STAD	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	4.52	8.68e-06	0.00428	0.35	0.24	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
STAD	cis	rs4589258	0.788	rs4472902	ENSG00000280367.1	RP11-121L10.2	4.52	8.68e-06	0.00428	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90730937	chr11:90223153~90226538:+
STAD	cis	rs10744955	0.727	rs7179848	ENSG00000244879.4	GABPB1-AS1	-4.52	8.68e-06	0.00428	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr15:50154851	chr15:50354959~50372202:+
STAD	cis	rs10744955	0.727	rs59983467	ENSG00000244879.4	GABPB1-AS1	-4.52	8.68e-06	0.00428	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr15:50156817	chr15:50354959~50372202:+
STAD	cis	rs10744955	0.727	rs8035794	ENSG00000244879.4	GABPB1-AS1	-4.52	8.68e-06	0.00428	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr15:50157506	chr15:50354959~50372202:+
STAD	cis	rs228614	0.51	rs50034	ENSG00000248971.2	KRT8P46	-4.52	8.68e-06	0.00428	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102728746~102730171:-
STAD	cis	rs13113518	1	rs11133378	ENSG00000223305.1	RN7SKP30	4.52	8.69e-06	0.00428	0.26	0.24	Height;	chr4:55439472	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11942279	ENSG00000223305.1	RN7SKP30	4.52	8.69e-06	0.00428	0.26	0.24	Height;	chr4:55439652	chr4:55540502~55540835:-
STAD	cis	rs62432291	0.681	rs400477	ENSG00000235086.1	FNDC1-IT1	4.52	8.69e-06	0.00428	0.34	0.24	Joint mobility (Beighton score);	chr6:159214911	chr6:159240786~159243329:+
STAD	cis	rs919433	0.857	rs36071109	ENSG00000231621.1	AC013264.2	4.52	8.69e-06	0.00428	0.2	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318467	chr2:197197991~197199273:+
STAD	cis	rs7829975	0.684	rs488904	ENSG00000173295.6	FAM86B3P	-4.52	8.69e-06	0.00428	-0.26	-0.24	Mood instability;	chr8:8730061	chr8:8228595~8244865:+
STAD	cis	rs17660992	1	rs17660992	ENSG00000273837.1	LLNLR-470E3.1	-4.52	8.69e-06	0.00428	-0.26	-0.24	Blood protein levels;	chr19:51660695	chr19:51639478~51639931:-
STAD	cis	rs4604732	0.642	rs4489599	ENSG00000227135.1	GCSAML-AS1	4.52	8.69e-06	0.00428	0.29	0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247471911	chr1:247524679~247526752:-
STAD	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	4.51	8.7e-06	0.00429	0.29	0.24	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
STAD	cis	rs2503875	0.965	rs2503874	ENSG00000230555.2	RP11-517P14.2	4.51	8.7e-06	0.00429	0.24	0.24	Multiple sclerosis;	chr10:43315908	chr10:43420738~43422100:+
STAD	cis	rs11722779	0.903	rs6830193	ENSG00000248971.2	KRT8P46	-4.51	8.7e-06	0.00429	-0.24	-0.24	Schizophrenia;	chr4:102955457	chr4:102728746~102730171:-
STAD	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	4.51	8.7e-06	0.00429	0.49	0.24	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
STAD	cis	rs2833693	0.519	rs2833699	ENSG00000261610.1	AP000265.1	4.51	8.7e-06	0.00429	0.26	0.24	Temperament;	chr21:32184240	chr21:32259804~32261585:-
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000211973.2	IGHV1-69	4.51	8.7e-06	0.00429	0.2	0.24	Kawasaki disease;	chr14:106767802	chr14:106714684~106715181:-
STAD	cis	rs13113518	1	rs3749474	ENSG00000223305.1	RN7SKP30	4.51	8.7e-06	0.00429	0.26	0.24	Height;	chr4:55434518	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs1474271	ENSG00000223305.1	RN7SKP30	4.51	8.7e-06	0.00429	0.26	0.24	Height;	chr4:55435912	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs11937487	ENSG00000223305.1	RN7SKP30	4.51	8.7e-06	0.00429	0.26	0.24	Height;	chr4:55436576	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs3805146	ENSG00000223305.1	RN7SKP30	4.51	8.7e-06	0.00429	0.26	0.24	Height;	chr4:55436985	chr4:55540502~55540835:-
STAD	cis	rs11098499	0.909	rs7681978	ENSG00000260091.1	RP11-33B1.4	4.51	8.71e-06	0.00429	0.23	0.24	Corneal astigmatism;	chr4:119462620	chr4:119409333~119410233:+
STAD	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	4.51	8.71e-06	0.00429	0.35	0.24	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
STAD	cis	rs7004769	0.613	rs441177	ENSG00000233609.3	RP11-62H7.2	-4.51	8.71e-06	0.00429	-0.34	-0.24	Fibrinogen levels;	chr8:9313419	chr8:8961200~8979025:+
STAD	cis	rs8097348	0.817	rs8096095	ENSG00000266602.1	RP11-476K15.1	-4.51	8.71e-06	0.00429	-0.26	-0.24	Exercise (leisure time);	chr18:1670018	chr18:1509183~1647097:+
STAD	cis	rs875971	0.929	rs34406470	ENSG00000236529.1	RP13-254B10.1	4.51	8.72e-06	0.00429	0.25	0.24	Aortic root size;	chr7:66464969	chr7:65840212~65840596:+
STAD	cis	rs6565180	1	rs8049108	ENSG00000273724.1	RP11-347C12.12	-4.51	8.72e-06	0.00429	-0.25	-0.24	Tonsillectomy;	chr16:30365165	chr16:30336400~30343336:+
STAD	cis	rs1075265	0.868	rs4671872	ENSG00000233266.1	HMGB1P31	4.51	8.72e-06	0.0043	0.22	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54134035	chr2:54051334~54051760:+
STAD	cis	rs1707322	1	rs12077546	ENSG00000281133.1	AL355480.3	-4.51	8.72e-06	0.0043	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs12124291	ENSG00000281133.1	AL355480.3	-4.51	8.72e-06	0.0043	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45580892~45580996:-
STAD	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-4.51	8.73e-06	0.0043	-0.35	-0.24	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-4.51	8.73e-06	0.0043	-0.35	-0.24	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-4.51	8.73e-06	0.0043	-0.35	-0.24	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-4.51	8.73e-06	0.0043	-0.35	-0.24	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
STAD	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	4.51	8.73e-06	0.0043	0.46	0.24	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
STAD	cis	rs17301013	0.861	rs10912824	ENSG00000227373.4	RP11-160H22.5	4.51	8.73e-06	0.0043	0.29	0.24	Systemic lupus erythematosus;	chr1:174625846	chr1:174115300~174160004:-
STAD	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	4.51	8.73e-06	0.0043	0.29	0.24	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
STAD	cis	rs1707322	1	rs10890375	ENSG00000281133.1	AL355480.3	-4.51	8.73e-06	0.0043	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10890377	ENSG00000281133.1	AL355480.3	-4.51	8.73e-06	0.0043	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45580892~45580996:-
STAD	cis	rs7208859	0.623	rs9915566	ENSG00000263603.1	CTD-2349P21.5	-4.51	8.73e-06	0.0043	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30729469~30731202:+
STAD	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-4.51	8.73e-06	0.0043	-0.27	-0.24	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs8176109	ENSG00000279602.1	CTD-3014M21.1	4.51	8.73e-06	0.0043	0.29	0.24	Menopause (age at onset);	chr17:43113759	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.896	rs8176098	ENSG00000279602.1	CTD-3014M21.1	4.51	8.73e-06	0.0043	0.29	0.24	Menopause (age at onset);	chr17:43116189	chr17:43360041~43361361:-
STAD	cis	rs11722779	0.844	rs10003326	ENSG00000248971.2	KRT8P46	-4.51	8.74e-06	0.0043	-0.24	-0.24	Schizophrenia;	chr4:102948193	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.787	rs6533040	ENSG00000248971.2	KRT8P46	-4.51	8.74e-06	0.0043	-0.24	-0.24	Schizophrenia;	chr4:102951421	chr4:102728746~102730171:-
STAD	cis	rs227917	1	rs227917	ENSG00000234286.1	AC006026.13	4.51	8.74e-06	0.0043	0.33	0.24	Common carotid intima-media thickness in HIV negative individuals;	chr7:23606698	chr7:23680195~23680786:-
STAD	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	4.51	8.74e-06	0.0043	0.25	0.24	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
STAD	cis	rs539514	0.637	rs2025354	ENSG00000261105.4	LMO7-AS1	4.51	8.75e-06	0.00431	0.29	0.24	Type 1 diabetes;	chr13:75701441	chr13:75604700~75635994:-
STAD	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-4.51	8.75e-06	0.00431	-0.25	-0.24	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
STAD	cis	rs4237845	0.735	rs11172375	ENSG00000273805.1	RP11-620J15.4	-4.51	8.76e-06	0.00431	-0.27	-0.24	Intelligence (multi-trait analysis);	chr12:57897791	chr12:57894232~57896846:+
STAD	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	4.51	8.76e-06	0.00431	0.27	0.24	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
STAD	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	4.51	8.76e-06	0.00431	0.25	0.24	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
STAD	cis	rs875971	0.767	rs1695815	ENSG00000236529.1	RP13-254B10.1	4.51	8.77e-06	0.00432	0.25	0.24	Aortic root size;	chr7:66366357	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs778685	ENSG00000236529.1	RP13-254B10.1	4.51	8.77e-06	0.00432	0.25	0.24	Aortic root size;	chr7:66371189	chr7:65840212~65840596:+
STAD	cis	rs875971	0.929	rs778682	ENSG00000236529.1	RP13-254B10.1	4.51	8.77e-06	0.00432	0.25	0.24	Aortic root size;	chr7:66372947	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs11765965	ENSG00000236529.1	RP13-254B10.1	4.51	8.77e-06	0.00432	0.25	0.24	Aortic root size;	chr7:66377234	chr7:65840212~65840596:+
STAD	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	4.51	8.78e-06	0.00432	0.25	0.24	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
STAD	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	4.51	8.79e-06	0.00432	0.25	0.24	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
STAD	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	4.51	8.79e-06	0.00432	0.34	0.24	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
STAD	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	4.51	8.79e-06	0.00433	0.28	0.24	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
STAD	cis	rs3811273	0.614	rs7153774	ENSG00000211816.2	TRAV38-1	4.51	8.79e-06	0.00433	0.29	0.24	Periodontal disease-related phenotypes;	chr14:22263044	chr14:22271968~22272563:+
STAD	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-4.51	8.8e-06	0.00433	-0.27	-0.24	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
STAD	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-4.51	8.8e-06	0.00433	-0.27	-0.24	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
STAD	cis	rs891378	1	rs2564974	ENSG00000274245.1	RP11-357P18.2	4.51	8.8e-06	0.00433	0.29	0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207310100	chr1:207372559~207373252:+
STAD	cis	rs8014252	0.803	rs45523543	ENSG00000259158.2	ADAM20P1	-4.51	8.8e-06	0.00433	-0.33	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70584371	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs56922268	ENSG00000259158.2	ADAM20P1	-4.51	8.8e-06	0.00433	-0.33	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70585454	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs17108246	ENSG00000259158.2	ADAM20P1	-4.51	8.8e-06	0.00433	-0.33	-0.24	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70588275	chr14:70468881~70483756:-
STAD	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-4.51	8.81e-06	0.00433	-0.23	-0.24	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000224373.3	IGHV4-59	4.51	8.81e-06	0.00433	0.17	0.24	Kawasaki disease;	chr14:106784149	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000224373.3	IGHV4-59	4.51	8.81e-06	0.00433	0.17	0.24	Kawasaki disease;	chr14:106785139	chr14:106627249~106627825:-
STAD	cis	rs13392177	0.684	rs11695527	ENSG00000237281.1	CATIP-AS2	-4.51	8.82e-06	0.00434	-0.24	-0.24	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218326889~218357966:-
STAD	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	4.51	8.82e-06	0.00434	0.36	0.24	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
STAD	cis	rs7674212	0.507	rs223413	ENSG00000248971.2	KRT8P46	4.51	8.82e-06	0.00434	0.25	0.24	Type 2 diabetes;	chr4:102811709	chr4:102728746~102730171:-
STAD	cis	rs12908161	1	rs35726233	ENSG00000259295.5	CSPG4P12	4.51	8.83e-06	0.00434	0.33	0.24	Schizophrenia;	chr15:84794569	chr15:85191438~85213905:+
STAD	cis	rs2286503	0.966	rs6949233	ENSG00000221740.1	SNORD93	4.51	8.83e-06	0.00434	0.27	0.24	Fibrinogen;	chr7:22818572	chr7:22856613~22856686:+
STAD	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	4.51	8.84e-06	0.00434	0.29	0.24	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
STAD	cis	rs728616	1	rs56317427	ENSG00000225484.5	NUTM2B-AS1	-4.51	8.84e-06	0.00435	-0.5	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80102178	chr10:79663088~79826594:-
STAD	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-4.51	8.84e-06	0.00435	-0.37	-0.24	Gout;	chr7:66645053	chr7:66654538~66669855:+
STAD	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-4.51	8.84e-06	0.00435	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
STAD	cis	rs7078219	0.897	rs10883360	ENSG00000228778.1	RP11-129J12.1	-4.51	8.85e-06	0.00435	-0.29	-0.24	Dental caries;	chr10:99521401	chr10:99527081~99528261:+
STAD	cis	rs12468226	0.938	rs3731700	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202291213	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	4.51	8.85e-06	0.00435	0.39	0.24	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
STAD	cis	rs1862618	0.671	rs2591966	ENSG00000271828.1	CTD-2310F14.1	-4.51	8.85e-06	0.00435	-0.29	-0.24	Initial pursuit acceleration;	chr5:56937861	chr5:56927874~56929573:+
STAD	cis	rs4568518	0.503	rs12699956	ENSG00000279048.1	RP11-511H23.2	4.51	8.86e-06	0.00435	0.22	0.24	Measles;	chr7:18022143	chr7:17940503~17942922:+
STAD	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	4.51	8.86e-06	0.00435	0.3	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
STAD	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-4.51	8.86e-06	0.00435	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
STAD	cis	rs228614	0.51	rs223397	ENSG00000248971.2	KRT8P46	-4.51	8.86e-06	0.00435	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102728746~102730171:-
STAD	cis	rs1322639	0.614	rs9364361	ENSG00000261039.2	RP11-417E7.2	-4.51	8.87e-06	0.00436	-0.38	-0.24	Pulse pressure;	chr6:169180404	chr6:169175304~169182740:-
STAD	cis	rs7131987	0.65	rs10843384	ENSG00000275476.1	RP11-996F15.4	-4.51	8.87e-06	0.00436	-0.26	-0.24	QT interval;	chr12:29319476	chr12:29277397~29277882:-
STAD	cis	rs7131987	0.65	rs11050188	ENSG00000275476.1	RP11-996F15.4	-4.51	8.87e-06	0.00436	-0.26	-0.24	QT interval;	chr12:29320175	chr12:29277397~29277882:-
STAD	cis	rs7131987	0.683	rs12366505	ENSG00000275476.1	RP11-996F15.4	-4.51	8.87e-06	0.00436	-0.26	-0.24	QT interval;	chr12:29321177	chr12:29277397~29277882:-
STAD	cis	rs7131987	0.65	rs12366527	ENSG00000275476.1	RP11-996F15.4	-4.51	8.87e-06	0.00436	-0.26	-0.24	QT interval;	chr12:29321323	chr12:29277397~29277882:-
STAD	cis	rs7131987	0.65	rs7311912	ENSG00000275476.1	RP11-996F15.4	-4.51	8.87e-06	0.00436	-0.26	-0.24	QT interval;	chr12:29322770	chr12:29277397~29277882:-
STAD	cis	rs62246343	0.786	rs73126664	ENSG00000214041.4	PGAM1P4	4.51	8.87e-06	0.00436	0.38	0.24	Fibrinogen levels;	chr3:9362966	chr3:9348443~9349192:+
STAD	cis	rs11722779	0.935	rs6533046	ENSG00000248971.2	KRT8P46	-4.51	8.87e-06	0.00436	-0.24	-0.24	Schizophrenia;	chr4:102965917	chr4:102728746~102730171:-
STAD	cis	rs748404	0.66	rs493377	ENSG00000275601.1	AC011330.13	-4.51	8.87e-06	0.00436	-0.25	-0.24	Lung cancer;	chr15:43481269	chr15:43642389~43643023:-
STAD	cis	rs6676180	0.555	rs871665	ENSG00000231365.4	RP11-418J17.1	-4.51	8.87e-06	0.00436	-0.28	-0.24	Monobrow;	chr1:119230040	chr1:119140396~119275973:+
STAD	cis	rs1723838	0.826	rs2462617	ENSG00000255928.1	RP11-456I15.2	4.51	8.88e-06	0.00436	0.5	0.24	Obesity-related traits;	chr11:73800651	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs1792157	ENSG00000255928.1	RP11-456I15.2	4.51	8.88e-06	0.00436	0.5	0.24	Obesity-related traits;	chr11:73818909	chr11:73722349~73722694:+
STAD	cis	rs875971	1	rs778726	ENSG00000236529.1	RP13-254B10.1	4.51	8.88e-06	0.00436	0.25	0.24	Aortic root size;	chr7:66363744	chr7:65840212~65840596:+
STAD	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	4.51	8.88e-06	0.00436	0.34	0.24	Depression;	chr6:28428413	chr6:28943877~28944537:+
STAD	cis	rs891378	1	rs10864167	ENSG00000274245.1	RP11-357P18.2	-4.51	8.88e-06	0.00436	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248227	chr1:207372559~207373252:+
STAD	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	4.51	8.89e-06	0.00437	0.34	0.24	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	4.51	8.89e-06	0.00437	0.34	0.24	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	4.51	8.89e-06	0.00437	0.34	0.24	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	4.51	8.89e-06	0.00437	0.34	0.24	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
STAD	cis	rs56114371	0.53	rs9348774	ENSG00000220721.1	OR1F12	4.51	8.89e-06	0.00437	0.28	0.24	Breast cancer;	chr6:27721151	chr6:28073316~28074233:+
STAD	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-4.51	8.89e-06	0.00437	-0.33	-0.24	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-4.51	8.89e-06	0.00437	-0.33	-0.24	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-4.51	8.89e-06	0.00437	-0.33	-0.24	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
STAD	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-4.51	8.89e-06	0.00437	-0.27	-0.24	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-4.51	8.89e-06	0.00437	-0.27	-0.24	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-4.51	8.89e-06	0.00437	-0.27	-0.24	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
STAD	cis	rs559928	0.606	rs12419038	ENSG00000236935.1	AP003774.1	4.51	8.89e-06	0.00437	0.34	0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145264	chr11:64325050~64329504:-
STAD	cis	rs6832769	0.89	rs564762	ENSG00000272969.1	RP11-528I4.2	4.51	8.89e-06	0.00437	0.3	0.24	Personality dimensions;	chr4:55418464	chr4:55547112~55547889:+
STAD	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-4.51	8.9e-06	0.00437	-0.23	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
STAD	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	4.51	8.9e-06	0.00437	0.29	0.24	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
STAD	cis	rs11018874	0.597	rs4393275	ENSG00000280367.1	RP11-121L10.2	4.51	8.9e-06	0.00437	0.29	0.24	White blood cell types;	chr11:90153229	chr11:90223153~90226538:+
STAD	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	4.51	8.9e-06	0.00437	0.24	0.24	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
STAD	cis	rs763014	0.932	rs34498660	ENSG00000228201.1	AL022341.3	4.51	8.91e-06	0.00437	0.28	0.24	Height;	chr16:616149	chr16:648473~649200:-
STAD	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	-4.51	8.91e-06	0.00438	-0.25	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
STAD	cis	rs9646944	0.501	rs3771158	ENSG00000234389.1	AC007278.3	4.51	8.91e-06	0.00438	0.3	0.24	Blood protein levels;	chr2:102393434	chr2:102438713~102440475:+
STAD	cis	rs1707322	0.682	rs10890334	ENSG00000225447.1	RPS15AP10	4.51	8.91e-06	0.00438	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.682	rs10890335	ENSG00000225447.1	RPS15AP10	4.51	8.91e-06	0.00438	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.716	rs6694889	ENSG00000225447.1	RPS15AP10	4.51	8.91e-06	0.00438	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45645816~45646197:-
STAD	cis	rs10504130	0.696	rs17284746	ENSG00000272024.1	RP11-546K22.3	-4.51	8.92e-06	0.00438	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51930320	chr8:51950284~51950690:+
STAD	cis	rs9307551	0.741	rs4101007	ENSG00000250334.4	LINC00989	-4.51	8.93e-06	0.00438	-0.31	-0.24	Refractive error;	chr4:79490540	chr4:79492416~79576460:+
STAD	cis	rs227275	0.554	rs223454	ENSG00000248971.2	KRT8P46	-4.51	8.93e-06	0.00438	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102728746~102730171:-
STAD	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-4.51	8.93e-06	0.00438	-0.23	-0.24	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
STAD	cis	rs8012947	1	rs7153897	ENSG00000279636.2	LINC00216	-4.51	8.93e-06	0.00438	-0.23	-0.24	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58288033~58289158:+
STAD	cis	rs8099594	0.64	rs487767	ENSG00000266696.1	RP11-30L3.2	4.51	8.93e-06	0.00438	0.23	0.24	Height;	chr18:49291622	chr18:49205912~49208781:+
STAD	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-4.51	8.93e-06	0.00439	-0.29	-0.24	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
STAD	cis	rs62432291	0.681	rs397476	ENSG00000235086.1	FNDC1-IT1	-4.51	8.94e-06	0.00439	-0.35	-0.24	Joint mobility (Beighton score);	chr6:159218252	chr6:159240786~159243329:+
STAD	cis	rs875971	0.862	rs12537823	ENSG00000236529.1	RP13-254B10.1	4.51	8.94e-06	0.00439	0.24	0.24	Aortic root size;	chr7:66255897	chr7:65840212~65840596:+
STAD	cis	rs2483058	0.767	rs61817176	ENSG00000261000.1	RP11-534L20.5	4.51	8.94e-06	0.00439	0.28	0.24	Cholesterol and Triglycerides;	chr1:206447682	chr1:206503948~206504456:+
STAD	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	4.51	8.94e-06	0.00439	0.38	0.24	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
STAD	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-4.51	8.94e-06	0.00439	-0.31	-0.24	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
STAD	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-4.51	8.95e-06	0.00439	-0.36	-0.24	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
STAD	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-4.51	8.95e-06	0.00439	-0.23	-0.24	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
STAD	cis	rs6921919	0.609	rs9461455	ENSG00000220721.1	OR1F12	4.51	8.95e-06	0.00439	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28073316~28074233:+
STAD	cis	rs7474896	1	rs11011344	ENSG00000099251.13	HSD17B7P2	4.51	8.96e-06	0.0044	0.35	0.24	Obesity (extreme);	chr10:37715918	chr10:38356380~38378505:+
STAD	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-4.51	8.97e-06	0.0044	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-4.51	8.97e-06	0.0044	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-4.51	8.97e-06	0.0044	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-4.51	8.97e-06	0.0044	-0.25	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
STAD	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-4.51	8.97e-06	0.0044	-0.3	-0.24	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
STAD	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	4.51	8.97e-06	0.0044	0.29	0.24	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
STAD	cis	rs17507216	0.718	rs72751675	ENSG00000259429.4	UBE2Q2P2	-4.51	8.98e-06	0.0044	-0.38	-0.24	Excessive daytime sleepiness;	chr15:82630452	chr15:82355142~82420075:+
STAD	cis	rs7429990	0.864	rs6806860	ENSG00000224895.1	VPS26BP1	4.51	8.98e-06	0.0044	0.23	0.24	Educational attainment (years of education);	chr3:47708218	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs6768699	ENSG00000224895.1	VPS26BP1	4.51	8.98e-06	0.0044	0.23	0.24	Educational attainment (years of education);	chr3:47711258	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7618758	ENSG00000224895.1	VPS26BP1	4.51	8.98e-06	0.0044	0.23	0.24	Educational attainment (years of education);	chr3:47720993	chr3:47960327~47961081:-
STAD	cis	rs8062405	0.824	rs4788085	ENSG00000278665.1	RP11-666O2.4	4.51	8.99e-06	0.00441	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.824	rs28772958	ENSG00000278665.1	RP11-666O2.4	4.51	8.99e-06	0.00441	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.789	rs2106480	ENSG00000278665.1	RP11-666O2.4	4.51	8.99e-06	0.00441	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28599241~28601881:-
STAD	cis	rs4589258	0.788	rs4237552	ENSG00000280367.1	RP11-121L10.2	4.51	8.99e-06	0.00441	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90725371	chr11:90223153~90226538:+
STAD	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	4.51	8.99e-06	0.00441	0.25	0.24	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	4.51	8.99e-06	0.00441	0.25	0.24	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	4.51	8.99e-06	0.00441	0.25	0.24	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
STAD	cis	rs4950322	0.744	rs2353987	ENSG00000278811.3	LINC00624	4.51	9e-06	0.00441	0.25	0.24	Protein quantitative trait loci;	chr1:147355845	chr1:147258885~147517875:-
STAD	cis	rs6714710	0.603	rs55776387	ENSG00000235833.1	AC159540.14	-4.51	9.01e-06	0.00442	-0.27	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97788571	chr2:97523949~97524976:-
STAD	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-4.51	9.01e-06	0.00442	-0.29	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
STAD	cis	rs4407350	0.694	rs131163	ENSG00000279642.1	RP5-1033E15.3	-4.51	9.01e-06	0.00442	-0.23	-0.24	Intelligence (multi-trait analysis);	chr22:44496255	chr22:44486295~44486914:-
STAD	cis	rs4589258	0.788	rs2226920	ENSG00000280367.1	RP11-121L10.2	4.51	9.01e-06	0.00442	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90731220	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs1573549	ENSG00000280367.1	RP11-121L10.2	4.51	9.01e-06	0.00442	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90731347	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs7945337	ENSG00000280367.1	RP11-121L10.2	4.51	9.01e-06	0.00442	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90731845	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs4488164	ENSG00000280367.1	RP11-121L10.2	4.51	9.01e-06	0.00442	0.23	0.24	Intelligence (multi-trait analysis);	chr11:90732250	chr11:90223153~90226538:+
STAD	cis	rs2439831	0.85	rs28413881	ENSG00000275601.1	AC011330.13	-4.51	9.02e-06	0.00442	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43881901	chr15:43642389~43643023:-
STAD	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	4.51	9.02e-06	0.00442	0.25	0.24	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
STAD	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	4.51	9.02e-06	0.00442	0.25	0.24	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
STAD	cis	rs10504130	0.696	rs76522329	ENSG00000272024.1	RP11-546K22.3	-4.51	9.02e-06	0.00442	-0.34	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51950284~51950690:+
STAD	cis	rs6539288	0.677	rs2216221	ENSG00000260329.1	RP11-412D9.4	-4.51	9.02e-06	0.00442	-0.24	-0.24	Total body bone mineral density;	chr12:106933453	chr12:106954029~106955497:-
STAD	cis	rs55726902	0.553	rs2525053	ENSG00000276691.1	RP5-1057I20.5	4.51	9.02e-06	0.00442	0.28	0.24	Allergic disease (asthma, hay fever or eczema);	chr12:47801565	chr12:47788426~47788971:+
STAD	cis	rs2348418	0.966	rs11049699	ENSG00000247934.4	RP11-967K21.1	4.51	9.02e-06	0.00442	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28535487	chr12:28163298~28190738:-
STAD	cis	rs7015630	0.657	rs34525502	ENSG00000251136.7	RP11-37B2.1	-4.51	9.02e-06	0.00442	-0.32	-0.24	Inflammatory bowel disease;Crohn's disease;	chr8:89840352	chr8:89609409~89757727:-
STAD	cis	rs11722779	0.869	rs223323	ENSG00000248971.2	KRT8P46	-4.51	9.03e-06	0.00442	-0.24	-0.24	Schizophrenia;	chr4:102878412	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.901	rs28674656	ENSG00000248971.2	KRT8P46	-4.51	9.03e-06	0.00442	-0.24	-0.24	Schizophrenia;	chr4:102944396	chr4:102728746~102730171:-
STAD	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	4.51	9.03e-06	0.00443	0.25	0.24	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
STAD	cis	rs1707322	0.682	rs10890334	ENSG00000281133.1	AL355480.3	-4.51	9.03e-06	0.00443	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.682	rs10890335	ENSG00000281133.1	AL355480.3	-4.51	9.03e-06	0.00443	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.716	rs6694889	ENSG00000281133.1	AL355480.3	-4.51	9.03e-06	0.00443	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45580892~45580996:-
STAD	cis	rs17630293	0.85	rs3769481	ENSG00000201649.1	RNY4P34	-4.51	9.04e-06	0.00443	-0.33	-0.24	Schizophrenia;	chr2:200308897	chr2:200373175~200373269:+
STAD	cis	rs17630293	0.85	rs3769479	ENSG00000201649.1	RNY4P34	-4.51	9.04e-06	0.00443	-0.33	-0.24	Schizophrenia;	chr2:200311108	chr2:200373175~200373269:+
STAD	cis	rs17630293	0.85	rs17592552	ENSG00000201649.1	RNY4P34	-4.51	9.04e-06	0.00443	-0.33	-0.24	Schizophrenia;	chr2:200311348	chr2:200373175~200373269:+
STAD	cis	rs17630293	0.85	rs67067836	ENSG00000201649.1	RNY4P34	-4.51	9.04e-06	0.00443	-0.33	-0.24	Schizophrenia;	chr2:200317342	chr2:200373175~200373269:+
STAD	cis	rs4713118	0.869	rs4713121	ENSG00000243307.2	POM121L6P	-4.51	9.04e-06	0.00443	-0.28	-0.24	Parkinson's disease;	chr6:27754285	chr6:26896952~26898777:+
STAD	cis	rs11051970	0.559	rs11051944	ENSG00000274964.1	RP11-817I4.1	-4.51	9.04e-06	0.00443	-0.3	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32332984	chr12:32339368~32340724:+
STAD	cis	rs11098499	0.863	rs3822195	ENSG00000260091.1	RP11-33B1.4	4.51	9.04e-06	0.00443	0.23	0.24	Corneal astigmatism;	chr4:119550505	chr4:119409333~119410233:+
STAD	cis	rs27524	0.734	rs27037	ENSG00000248734.2	CTD-2260A17.1	4.51	9.04e-06	0.00443	0.25	0.24	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96784777~96785999:+
STAD	cis	rs2273156	1	rs35106382	ENSG00000241052.1	RP11-173D9.1	-4.51	9.04e-06	0.00443	-0.26	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34965085	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs8014327	ENSG00000241052.1	RP11-173D9.1	-4.51	9.04e-06	0.00443	-0.26	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34965530	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12894365	ENSG00000241052.1	RP11-173D9.1	-4.51	9.04e-06	0.00443	-0.26	-0.24	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966185	chr14:35144021~35144480:-
STAD	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	4.51	9.04e-06	0.00443	0.23	0.24	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
STAD	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	4.51	9.05e-06	0.00443	0.36	0.24	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000211973.2	IGHV1-69	4.51	9.05e-06	0.00443	0.2	0.24	Kawasaki disease;	chr14:106768275	chr14:106714684~106715181:-
STAD	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	4.51	9.05e-06	0.00443	0.33	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
STAD	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	4.51	9.05e-06	0.00443	0.33	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
STAD	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	4.51	9.05e-06	0.00443	0.33	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
STAD	cis	rs2836950	0.545	rs2836959	ENSG00000238141.2	BRWD1-AS1	-4.51	9.05e-06	0.00443	-0.24	-0.24	Menarche (age at onset);	chr21:39251742	chr21:39315707~39323218:+
STAD	cis	rs3825942	0.568	rs9944214	ENSG00000261801.4	LOXL1-AS1	4.51	9.05e-06	0.00444	0.32	0.24	Glaucoma (exfoliation);	chr15:73939516	chr15:73908071~73928248:-
STAD	cis	rs1876905	0.539	rs240956	ENSG00000271789.1	RP5-1112D6.7	4.51	9.06e-06	0.00444	0.26	0.24	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111297126~111298510:+
STAD	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	4.51	9.06e-06	0.00444	0.3	0.24	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	4.51	9.06e-06	0.00444	0.3	0.24	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
STAD	cis	rs1150668	0.796	rs213237	ENSG00000220721.1	OR1F12	4.51	9.06e-06	0.00444	0.23	0.24	Pubertal anthropometrics;	chr6:28356161	chr6:28073316~28074233:+
STAD	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-4.51	9.07e-06	0.00444	-0.24	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
STAD	cis	rs7429990	0.833	rs6777632	ENSG00000224895.1	VPS26BP1	4.51	9.07e-06	0.00444	0.23	0.24	Educational attainment (years of education);	chr3:47748775	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs13098128	ENSG00000224895.1	VPS26BP1	4.51	9.07e-06	0.00444	0.23	0.24	Educational attainment (years of education);	chr3:47756066	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7637950	ENSG00000224895.1	VPS26BP1	4.51	9.07e-06	0.00444	0.23	0.24	Educational attainment (years of education);	chr3:47758204	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs6442085	ENSG00000224895.1	VPS26BP1	4.51	9.07e-06	0.00444	0.23	0.24	Educational attainment (years of education);	chr3:47760080	chr3:47960327~47961081:-
STAD	cis	rs561341	0.941	rs2428336	ENSG00000265798.5	RP11-271K11.5	4.51	9.07e-06	0.00444	0.36	0.24	Hip circumference adjusted for BMI;	chr17:31963558	chr17:31038575~31059121:-
STAD	cis	rs6832769	1	rs6853192	ENSG00000272969.1	RP11-528I4.2	-4.51	9.07e-06	0.00444	-0.3	-0.24	Personality dimensions;	chr4:55543087	chr4:55547112~55547889:+
STAD	cis	rs17264034	0.861	rs431288	ENSG00000250786.1	SNHG18	4.51	9.07e-06	0.00444	0.38	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9549347	chr5:9546200~9550609:+
STAD	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	4.51	9.08e-06	0.00445	0.29	0.24	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
STAD	cis	rs1075265	0.868	rs1877906	ENSG00000233266.1	HMGB1P31	4.51	9.08e-06	0.00445	0.22	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54136700	chr2:54051334~54051760:+
STAD	cis	rs228614	0.51	rs3774987	ENSG00000248971.2	KRT8P46	-4.51	9.08e-06	0.00445	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102728746~102730171:-
STAD	cis	rs2143950	0.564	rs11621391	ENSG00000241052.1	RP11-173D9.1	-4.51	9.08e-06	0.00445	-0.27	-0.24	Atopic dermatitis;	chr14:35365352	chr14:35144021~35144480:-
STAD	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	4.51	9.08e-06	0.00445	0.32	0.24	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
STAD	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	4.51	9.08e-06	0.00445	0.44	0.24	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
STAD	cis	rs1075265	0.589	rs2253760	ENSG00000235937.1	AC008280.1	4.51	9.09e-06	0.00445	0.22	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54029552~54030682:-
STAD	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	4.51	9.09e-06	0.00445	0.29	0.24	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
STAD	cis	rs875971	0.545	rs12671152	ENSG00000224316.1	RP11-479O9.2	4.51	9.09e-06	0.00445	0.27	0.24	Aortic root size;	chr7:66311140	chr7:65773620~65802067:+
STAD	cis	rs4407350	0.729	rs9819	ENSG00000279642.1	RP5-1033E15.3	4.51	9.09e-06	0.00445	0.23	0.24	Intelligence (multi-trait analysis);	chr22:44493506	chr22:44486295~44486914:-
STAD	cis	rs10073892	0.789	rs7356787	ENSG00000250682.4	LINC00491	4.5	9.09e-06	0.00445	0.26	0.24	Cognitive decline (age-related);	chr5:102471182	chr5:102609156~102671559:-
STAD	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-4.5	9.09e-06	0.00445	-0.18	-0.24	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
STAD	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-4.5	9.1e-06	0.00445	-0.36	-0.24	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-4.5	9.1e-06	0.00445	-0.36	-0.24	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-4.5	9.1e-06	0.00445	-0.36	-0.24	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-4.5	9.1e-06	0.00445	-0.36	-0.24	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
STAD	cis	rs9291683	0.585	rs12648479	ENSG00000250613.1	RP11-136I13.1	4.5	9.1e-06	0.00445	0.22	0.24	Bone mineral density;	chr4:10102947	chr4:10410996~10411644:+
STAD	cis	rs507080	0.845	rs667982	ENSG00000278376.1	RP11-158I9.8	-4.5	9.1e-06	0.00445	-0.24	-0.24	Serum metabolite levels;	chr11:118692058	chr11:118791254~118793137:+
STAD	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	4.5	9.1e-06	0.00445	0.3	0.24	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
STAD	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	4.5	9.1e-06	0.00445	0.3	0.24	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
STAD	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	4.5	9.1e-06	0.00445	0.3	0.24	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
STAD	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-4.5	9.1e-06	0.00445	-0.28	-0.24	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000224205.1	AP000351.4	4.5	9.11e-06	0.00446	0.26	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23987320~23991421:-
STAD	cis	rs3764400	0.506	rs72827851	ENSG00000278765.1	RP5-890E16.5	4.5	9.11e-06	0.00446	0.32	0.24	Body mass index;	chr17:48375133	chr17:48066704~48067293:-
STAD	cis	rs10129255	0.518	rs12590732	ENSG00000211973.2	IGHV1-69	-4.5	9.11e-06	0.00446	-0.2	-0.24	Kawasaki disease;	chr14:106779612	chr14:106714684~106715181:-
STAD	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-4.5	9.11e-06	0.00446	-0.23	-0.24	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
STAD	cis	rs3806843	0.547	rs246054	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140946574	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.548	rs246052	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140946828	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.52	rs246051	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140946879	chr5:140718925~140719013:+
STAD	cis	rs31872	0.521	rs246050	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Visceral adipose tissue adjusted for BMI;	chr5:140947275	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246049	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140948005	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246047	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140948752	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246046	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140949679	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246045	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140950299	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246043	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140951339	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.608	rs246042	ENSG00000202111.1	VTRNA1-2	-4.5	9.12e-06	0.00446	-0.23	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140951382	chr5:140718925~140719013:+
STAD	cis	rs1150668	0.799	rs2142730	ENSG00000220721.1	OR1F12	4.5	9.12e-06	0.00446	0.23	0.24	Pubertal anthropometrics;	chr6:28298372	chr6:28073316~28074233:+
STAD	cis	rs67180937	0.583	rs2936054	ENSG00000272750.1	RP11-378J18.8	4.5	9.12e-06	0.00446	0.26	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222627290	chr1:222658867~222661512:-
STAD	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-4.5	9.12e-06	0.00446	-0.33	-0.24	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
STAD	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	4.5	9.12e-06	0.00446	0.25	0.24	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
STAD	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-4.5	9.13e-06	0.00446	-0.26	-0.24	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
STAD	cis	rs1707322	0.752	rs61784793	ENSG00000225447.1	RPS15AP10	4.5	9.13e-06	0.00447	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.648	rs4439382	ENSG00000225447.1	RPS15AP10	4.5	9.13e-06	0.00447	0.19	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45645816~45646197:-
STAD	cis	rs1005277	0.579	rs1614236	ENSG00000276805.1	RP11-291L22.6	4.5	9.13e-06	0.00447	0.25	0.24	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2749616	ENSG00000276805.1	RP11-291L22.6	4.5	9.13e-06	0.00447	0.25	0.24	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38451030~38451785:+
STAD	cis	rs9907295	0.688	rs2526327	ENSG00000271013.1	AC015849.15	4.5	9.14e-06	0.00447	0.34	0.24	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35912635~35918010:-
STAD	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	4.5	9.14e-06	0.00447	0.3	0.24	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	4.5	9.14e-06	0.00447	0.3	0.24	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
STAD	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.5	9.14e-06	0.00447	0.22	0.24	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
STAD	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-4.5	9.14e-06	0.00447	-0.23	-0.24	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
STAD	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	4.5	9.14e-06	0.00447	0.36	0.24	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
STAD	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-4.5	9.14e-06	0.00447	-0.25	-0.24	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
STAD	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	4.5	9.15e-06	0.00447	0.29	0.24	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	4.5	9.15e-06	0.00447	0.29	0.24	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
STAD	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-4.5	9.15e-06	0.00447	-0.28	-0.24	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
STAD	cis	rs9860428	0.844	rs11711087	ENSG00000240057.4	RP11-572M11.4	-4.5	9.15e-06	0.00448	-0.22	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868702	chr3:113019532~113183301:+
STAD	cis	rs9646944	0.501	rs741284	ENSG00000234389.1	AC007278.3	4.5	9.16e-06	0.00448	0.31	0.24	Blood protein levels;	chr2:102466864	chr2:102438713~102440475:+
STAD	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	4.5	9.17e-06	0.00448	0.46	0.24	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
STAD	cis	rs1005277	0.579	rs1740737	ENSG00000276805.1	RP11-291L22.6	4.5	9.18e-06	0.00448	0.25	0.24	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38451030~38451785:+
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000211970.3	IGHV4-61	-4.5	9.18e-06	0.00449	-0.18	-0.24	Kawasaki disease;	chr14:106767802	chr14:106639119~106639657:-
STAD	cis	rs10851478	0.5	rs10519225	ENSG00000259545.2	RP11-325E5.4	-4.5	9.18e-06	0.00449	-0.26	-0.24	Oral cavity cancer;	chr15:49428581	chr15:49177610~49178741:-
STAD	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-4.5	9.18e-06	0.00449	-0.23	-0.24	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
STAD	cis	rs3777722	0.584	rs3798303	ENSG00000265828.1	MIR3939	4.5	9.19e-06	0.00449	0.36	0.24	Spontaneous preterm birth (preterm birth);	chr6:166940880	chr6:166997807~166997912:-
STAD	cis	rs1799949	1	rs8176120	ENSG00000279602.1	CTD-3014M21.1	4.5	9.19e-06	0.00449	0.29	0.24	Menopause (age at onset);	chr17:43109216	chr17:43360041~43361361:-
STAD	cis	rs62246343	0.786	rs11547584	ENSG00000214041.4	PGAM1P4	4.5	9.2e-06	0.00449	0.37	0.24	Fibrinogen levels;	chr3:9365020	chr3:9348443~9349192:+
STAD	cis	rs4950322	0.542	rs17159924	ENSG00000278811.3	LINC00624	4.5	9.2e-06	0.00449	0.26	0.24	Protein quantitative trait loci;	chr1:147199463	chr1:147258885~147517875:-
STAD	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	4.5	9.2e-06	0.0045	0.26	0.24	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
STAD	cis	rs12908161	0.959	rs17598603	ENSG00000259295.5	CSPG4P12	-4.5	9.21e-06	0.0045	-0.34	-0.24	Schizophrenia;	chr15:84656980	chr15:85191438~85213905:+
STAD	cis	rs12744757	1	rs12744757	ENSG00000242349.4	NPPA-AS1	-4.5	9.21e-06	0.0045	-0.5	-0.24	Systolic blood pressure;	chr1:11846764	chr1:11841017~11848079:+
STAD	cis	rs9902453	0.808	rs12452288	ENSG00000240074.1	RPL9P30	4.5	9.21e-06	0.0045	0.2	0.24	Coffee consumption (cups per day);	chr17:29908202	chr17:29855759~29856332:+
STAD	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	4.5	9.22e-06	0.0045	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
STAD	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	4.5	9.22e-06	0.0045	0.26	0.24	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	4.5	9.22e-06	0.0045	0.26	0.24	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
STAD	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	4.5	9.22e-06	0.0045	0.3	0.24	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	4.5	9.22e-06	0.0045	0.3	0.24	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
STAD	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	4.5	9.22e-06	0.0045	0.28	0.24	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
STAD	cis	rs2281636	0.691	rs6584306	ENSG00000233690.1	EBAG9P1	4.5	9.23e-06	0.00451	0.26	0.24	Obesity-related traits;	chr10:99662739	chr10:99697407~99697949:-
STAD	cis	rs860295	0.58	rs6672284	ENSG00000225855.5	RUSC1-AS1	4.5	9.23e-06	0.00451	0.2	0.24	Body mass index;	chr1:155308172	chr1:155316863~155324176:-
STAD	cis	rs17507216	0.718	rs7161977	ENSG00000259429.4	UBE2Q2P2	-4.5	9.24e-06	0.00451	-0.37	-0.24	Excessive daytime sleepiness;	chr15:82646782	chr15:82355142~82420075:+
STAD	cis	rs9902453	0.78	rs3115093	ENSG00000240074.1	RPL9P30	4.5	9.24e-06	0.00451	0.2	0.24	Coffee consumption (cups per day);	chr17:29712737	chr17:29855759~29856332:+
STAD	cis	rs7671266	0.611	rs10939833	ENSG00000250613.1	RP11-136I13.1	4.5	9.24e-06	0.00451	0.25	0.24	Cardiovascular disease risk factors;	chr4:10307913	chr4:10410996~10411644:+
STAD	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-4.5	9.24e-06	0.00451	-0.25	-0.24	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
STAD	cis	rs7078219	0.523	rs4129134	ENSG00000257582.4	LINC01475	-4.5	9.25e-06	0.00451	-0.27	-0.24	Dental caries;	chr10:99524588	chr10:99526350~99531177:-
STAD	cis	rs6832769	0.925	rs6554292	ENSG00000272969.1	RP11-528I4.2	-4.5	9.25e-06	0.00451	-0.3	-0.24	Personality dimensions;	chr4:55584943	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs10026692	ENSG00000272969.1	RP11-528I4.2	-4.5	9.25e-06	0.00451	-0.3	-0.24	Personality dimensions;	chr4:55586539	chr4:55547112~55547889:+
STAD	cis	rs6430585	0.583	rs3769013	ENSG00000231890.6	DARS-AS1	-4.5	9.26e-06	0.00452	-0.27	-0.24	Corneal structure;	chr2:135798612	chr2:135985176~136022593:+
STAD	cis	rs9902453	0.845	rs7222842	ENSG00000240074.1	RPL9P30	4.5	9.26e-06	0.00452	0.2	0.24	Coffee consumption (cups per day);	chr17:29919925	chr17:29855759~29856332:+
STAD	cis	rs4141404	0.604	rs5753625	ENSG00000236132.1	CTA-440B3.1	4.5	9.26e-06	0.00452	0.25	0.24	Paclitaxel-induced neuropathy;	chr22:31458860	chr22:31816379~31817491:-
STAD	cis	rs17507216	0.718	rs72751657	ENSG00000259429.4	UBE2Q2P2	-4.5	9.27e-06	0.00452	-0.38	-0.24	Excessive daytime sleepiness;	chr15:82581259	chr15:82355142~82420075:+
STAD	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-4.5	9.27e-06	0.00453	-0.34	-0.24	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
STAD	cis	rs227275	0.525	rs223332	ENSG00000248971.2	KRT8P46	-4.5	9.29e-06	0.00453	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102728746~102730171:-
STAD	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-4.5	9.29e-06	0.00453	-0.24	-0.24	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
STAD	cis	rs9291683	0.507	rs3796837	ENSG00000250613.1	RP11-136I13.1	-4.5	9.29e-06	0.00453	-0.25	-0.24	Bone mineral density;	chr4:10009697	chr4:10410996~10411644:+
STAD	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-4.5	9.29e-06	0.00453	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
STAD	cis	rs1005277	0.579	rs1780146	ENSG00000276805.1	RP11-291L22.6	4.5	9.29e-06	0.00453	0.25	0.24	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38451030~38451785:+
STAD	cis	rs2638953	0.924	rs11049403	ENSG00000247934.4	RP11-967K21.1	-4.5	9.29e-06	0.00453	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28177105	chr12:28163298~28190738:-
STAD	cis	rs8098244	0.638	rs12955083	ENSG00000267301.1	RPL23AP77	4.5	9.3e-06	0.00454	0.27	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23853002	chr18:23709825~23710287:-
STAD	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-4.5	9.3e-06	0.00454	-0.25	-0.24	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
STAD	cis	rs181553	0.664	rs1838962	ENSG00000266696.1	RP11-30L3.2	4.5	9.3e-06	0.00454	0.22	0.24	Hip circumference adjusted for BMI;	chr18:49153529	chr18:49205912~49208781:+
STAD	cis	rs10510102	0.872	rs7906271	ENSG00000226864.1	ATE1-AS1	-4.5	9.3e-06	0.00454	-0.37	-0.24	Breast cancer;	chr10:121948207	chr10:121928312~121951965:+
STAD	cis	rs8062405	0.824	rs153106	ENSG00000278665.1	RP11-666O2.4	4.5	9.31e-06	0.00454	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.754	rs62034323	ENSG00000278665.1	RP11-666O2.4	4.5	9.31e-06	0.00454	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.824	rs62034324	ENSG00000278665.1	RP11-666O2.4	4.5	9.31e-06	0.00454	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.824	rs62034326	ENSG00000278665.1	RP11-666O2.4	4.5	9.31e-06	0.00454	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.824	rs4788084	ENSG00000278665.1	RP11-666O2.4	4.5	9.31e-06	0.00454	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.792	rs12446550	ENSG00000278665.1	RP11-666O2.4	4.5	9.31e-06	0.00454	0.26	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28599241~28601881:-
STAD	cis	rs7680126	0.633	rs4697743	ENSG00000250613.1	RP11-136I13.1	4.5	9.32e-06	0.00454	0.26	0.24	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10293209	chr4:10410996~10411644:+
STAD	cis	rs7829975	0.774	rs57312668	ENSG00000253981.4	ALG1L13P	4.5	9.32e-06	0.00455	0.27	0.24	Mood instability;	chr8:8822967	chr8:8236003~8244667:-
STAD	cis	rs13315649	0.642	rs9811914	ENSG00000242551.2	POU5F1P6	-4.5	9.33e-06	0.00455	-0.25	-0.24	Sum eosinophil basophil counts;	chr3:128676517	chr3:128674735~128677005:-
STAD	cis	rs8097348	0.711	rs2061011	ENSG00000266602.1	RP11-476K15.1	-4.5	9.33e-06	0.00455	-0.29	-0.24	Exercise (leisure time);	chr18:1596687	chr18:1509183~1647097:+
STAD	cis	rs7598759	0.548	rs1584462	ENSG00000223198.1	RNU2-22P	-4.5	9.33e-06	0.00455	-0.27	-0.24	Noise-induced hearing loss;	chr2:231505087	chr2:231501990~231502201:-
STAD	cis	rs449789	0.857	rs9355713	ENSG00000235086.1	FNDC1-IT1	-4.5	9.33e-06	0.00455	-0.31	-0.24	Pulse pressure;	chr6:159301516	chr6:159240786~159243329:+
STAD	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-4.5	9.34e-06	0.00455	-0.25	-0.24	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
STAD	cis	rs17630293	0.737	rs192680	ENSG00000201649.1	RNY4P34	4.5	9.34e-06	0.00455	0.32	0.24	Schizophrenia;	chr2:200364167	chr2:200373175~200373269:+
STAD	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	4.5	9.34e-06	0.00455	0.3	0.24	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	4.5	9.34e-06	0.00455	0.3	0.24	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
STAD	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-4.5	9.34e-06	0.00455	-0.36	-0.24	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
STAD	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-4.5	9.34e-06	0.00455	-0.24	-0.24	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
STAD	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-4.5	9.34e-06	0.00455	-0.23	-0.24	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
STAD	cis	rs61841072	0.714	rs2907192	ENSG00000214837.7	LINC01347	-4.5	9.34e-06	0.00456	-0.24	-0.24	Schizophrenia;	chr1:242974088	chr1:243056307~243101744:-
STAD	cis	rs606458	0.92	rs76355571	ENSG00000269038.1	AP001462.6	-4.5	9.35e-06	0.00456	-0.32	-0.24	Urate levels;	chr11:64683094	chr11:64778954~64779405:+
STAD	cis	rs7829975	0.806	rs2428	ENSG00000253981.4	ALG1L13P	4.5	9.36e-06	0.00456	0.28	0.24	Mood instability;	chr8:8783635	chr8:8236003~8244667:-
STAD	cis	rs6951245	0.678	rs28600085	ENSG00000229043.2	AC091729.9	-4.5	9.36e-06	0.00456	-0.36	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1160374~1165267:+
STAD	cis	rs6951245	0.706	rs28483034	ENSG00000229043.2	AC091729.9	-4.5	9.36e-06	0.00456	-0.36	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1160374~1165267:+
STAD	cis	rs17401966	0.838	rs11121551	ENSG00000199562.1	RNU6-37P	4.5	9.36e-06	0.00456	0.18	0.24	Hepatocellular carcinoma;	chr1:10375112	chr1:10298966~10299072:+
STAD	cis	rs1707322	0.721	rs12043945	ENSG00000281133.1	AL355480.3	-4.5	9.36e-06	0.00456	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs12091503	ENSG00000281133.1	AL355480.3	-4.5	9.36e-06	0.00456	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45580892~45580996:-
STAD	cis	rs2695743	0.592	rs11684953	ENSG00000225808.1	DNAJC19P5	-4.5	9.36e-06	0.00456	-0.27	-0.24	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177822846	chr2:177229191~177229506:-
STAD	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	4.5	9.37e-06	0.00456	0.23	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
STAD	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-4.5	9.37e-06	0.00456	-0.32	-0.24	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
STAD	cis	rs9463078	0.608	rs6925017	ENSG00000219384.1	RP11-491H9.3	4.5	9.37e-06	0.00456	0.23	0.24	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44983091	chr6:45158870~45159511:+
STAD	cis	rs375092	0.689	rs187985	ENSG00000230658.1	KLHL7-AS1	4.5	9.37e-06	0.00456	0.34	0.24	Personality dimensions;	chr7:23386613	chr7:23101228~23105703:-
STAD	cis	rs427691	0.625	rs370575	ENSG00000271849.1	CTC-332L22.1	-4.5	9.37e-06	0.00457	-0.39	-0.24	Autism spectrum disorder or schizophrenia;	chr5:109675587	chr5:109687802~109688329:-
STAD	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	4.5	9.37e-06	0.00457	0.29	0.24	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
STAD	cis	rs11676348	1	rs11676348	ENSG00000237281.1	CATIP-AS2	4.5	9.37e-06	0.00457	0.23	0.24	Ulcerative colitis;	chr2:218145423	chr2:218326889~218357966:-
STAD	cis	rs6832769	1	rs1522108	ENSG00000272969.1	RP11-528I4.2	4.5	9.38e-06	0.00457	0.3	0.24	Personality dimensions;	chr4:55514566	chr4:55547112~55547889:+
STAD	cis	rs950881	0.932	rs13408661	ENSG00000234389.1	AC007278.3	4.5	9.39e-06	0.00457	0.32	0.24	Allergy;	chr2:102338622	chr2:102438713~102440475:+
STAD	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	4.5	9.39e-06	0.00457	0.34	0.24	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
STAD	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	4.5	9.39e-06	0.00458	0.3	0.24	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
STAD	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	4.5	9.39e-06	0.00458	0.38	0.24	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
STAD	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-4.5	9.39e-06	0.00458	-0.24	-0.24	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
STAD	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	4.5	9.39e-06	0.00458	0.3	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
STAD	cis	rs7429990	0.864	rs12497826	ENSG00000224895.1	VPS26BP1	4.5	9.41e-06	0.00458	0.23	0.24	Educational attainment (years of education);	chr3:47628059	chr3:47960327~47961081:-
STAD	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	4.5	9.42e-06	0.00459	0.26	0.23	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
STAD	cis	rs2688608	0.588	rs10128205	ENSG00000272140.2	RP11-574K11.29	4.5	9.43e-06	0.00459	0.21	0.23	Inflammatory bowel disease;	chr10:73709890	chr10:73703735~73713581:-
STAD	cis	rs7826238	0.623	rs2976893	ENSG00000254340.1	RP11-10A14.3	-4.5	9.43e-06	0.00459	-0.27	-0.23	Systolic blood pressure;	chr8:8480709	chr8:9141424~9145435:+
STAD	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	4.5	9.43e-06	0.00459	0.37	0.23	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
STAD	cis	rs7615952	0.546	rs2979307	ENSG00000272840.1	RP11-379B18.6	-4.5	9.43e-06	0.00459	-0.38	-0.23	Blood pressure (smoking interaction);	chr3:125590730	chr3:125774714~125797953:+
STAD	cis	rs728616	1	rs728616	ENSG00000225484.5	NUTM2B-AS1	-4.5	9.44e-06	0.00459	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:79663088~79826594:-
STAD	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	4.5	9.44e-06	0.0046	0.31	0.23	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
STAD	cis	rs7103648	0.63	rs7120548	ENSG00000280615.1	Y_RNA	4.5	9.44e-06	0.0046	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47641380	chr11:47614898~47614994:-
STAD	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-4.5	9.45e-06	0.0046	-0.29	-0.23	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
STAD	cis	rs875971	0.767	rs61348003	ENSG00000224316.1	RP11-479O9.2	4.5	9.45e-06	0.0046	0.23	0.23	Aortic root size;	chr7:66540947	chr7:65773620~65802067:+
STAD	cis	rs875971	0.756	rs2901210	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66552518	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs13536	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66554203	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs801209	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66554403	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs801206	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66556979	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs801204	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66557934	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs801203	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66558025	chr7:65773620~65802067:+
STAD	cis	rs875971	0.825	rs801202	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66558942	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs801195	ENSG00000224316.1	RP11-479O9.2	-4.5	9.45e-06	0.0046	-0.23	-0.23	Aortic root size;	chr7:66561128	chr7:65773620~65802067:+
STAD	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	4.5	9.46e-06	0.0046	0.32	0.23	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
STAD	cis	rs9907295	0.748	rs2526328	ENSG00000271013.1	AC015849.15	-4.5	9.46e-06	0.0046	-0.35	-0.23	Fibroblast growth factor basic levels;	chr17:35932348	chr17:35912635~35918010:-
STAD	cis	rs4713118	0.568	rs9468213	ENSG00000280107.1	AL022393.9	-4.5	9.46e-06	0.00461	-0.29	-0.23	Parkinson's disease;	chr6:27738401	chr6:28170845~28172521:+
STAD	cis	rs17401966	0.838	rs61775887	ENSG00000199562.1	RNU6-37P	4.5	9.46e-06	0.00461	0.18	0.23	Hepatocellular carcinoma;	chr1:10224675	chr1:10298966~10299072:+
STAD	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-4.5	9.47e-06	0.00461	-0.27	-0.23	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-4.5	9.47e-06	0.00461	-0.27	-0.23	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-4.5	9.47e-06	0.00461	-0.27	-0.23	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-4.5	9.47e-06	0.00461	-0.27	-0.23	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
STAD	cis	rs4589258	0.966	rs4381333	ENSG00000280367.1	RP11-121L10.2	4.5	9.47e-06	0.00461	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90769311	chr11:90223153~90226538:+
STAD	cis	rs4589258	1	rs9651551	ENSG00000280367.1	RP11-121L10.2	4.5	9.47e-06	0.00461	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90769728	chr11:90223153~90226538:+
STAD	cis	rs227275	0.525	rs11097796	ENSG00000248971.2	KRT8P46	-4.5	9.48e-06	0.00461	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs11097797	ENSG00000248971.2	KRT8P46	-4.5	9.48e-06	0.00461	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs13117110	ENSG00000248971.2	KRT8P46	-4.5	9.48e-06	0.00461	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs13144033	ENSG00000248971.2	KRT8P46	-4.5	9.48e-06	0.00461	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223452	ENSG00000248971.2	KRT8P46	-4.5	9.48e-06	0.00461	-0.25	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102728746~102730171:-
STAD	cis	rs9307551	0.618	rs10021556	ENSG00000250334.4	LINC00989	-4.5	9.48e-06	0.00461	-0.31	-0.23	Refractive error;	chr4:79475741	chr4:79492416~79576460:+
STAD	cis	rs3806843	0.576	rs246009	ENSG00000202111.1	VTRNA1-2	4.5	9.48e-06	0.00461	0.23	0.23	Depressive symptoms (multi-trait analysis);	chr5:140958484	chr5:140718925~140719013:+
STAD	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	4.5	9.48e-06	0.00461	0.29	0.23	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
STAD	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-4.5	9.49e-06	0.00462	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
STAD	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	4.5	9.49e-06	0.00462	0.24	0.23	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
STAD	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-4.5	9.49e-06	0.00462	-0.24	-0.23	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
STAD	cis	rs6142102	0.961	rs4911411	ENSG00000275784.1	RP5-1125A11.6	-4.5	9.49e-06	0.00462	-0.24	-0.23	Skin pigmentation;	chr20:34128036	chr20:33989480~33991818:-
STAD	cis	rs4243830	0.649	rs11579888	ENSG00000229519.2	RP11-58A11.2	4.5	9.5e-06	0.00462	0.25	0.23	Body mass index;	chr1:6549836	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.737	rs11581831	ENSG00000229519.2	RP11-58A11.2	4.5	9.5e-06	0.00462	0.25	0.23	Body mass index;	chr1:6549898	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.85	rs2063806	ENSG00000229519.2	RP11-58A11.2	4.5	9.5e-06	0.00462	0.25	0.23	Body mass index;	chr1:6550322	chr1:6547905~6548619:+
STAD	cis	rs801193	0.66	rs1016265	ENSG00000224316.1	RP11-479O9.2	4.5	9.5e-06	0.00462	0.23	0.23	Aortic root size;	chr7:66749580	chr7:65773620~65802067:+
STAD	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-4.5	9.5e-06	0.00462	-0.26	-0.23	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
STAD	cis	rs11976180	1	rs2951371	ENSG00000170356.8	OR2A20P	-4.49	9.51e-06	0.00462	-0.36	-0.23	Obesity-related traits;	chr7:144053235	chr7:144250045~144252957:-
STAD	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	4.49	9.51e-06	0.00462	0.26	0.23	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
STAD	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	4.49	9.51e-06	0.00462	0.33	0.23	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
STAD	cis	rs4865169	0.691	rs1056364	ENSG00000269949.1	RP11-738E22.3	-4.49	9.51e-06	0.00462	-0.27	-0.23	Breast cancer;	chr4:57023511	chr4:56960927~56961373:-
STAD	cis	rs2442825	0.54	rs35728233	ENSG00000206573.7	THUMPD3-AS1	-4.49	9.52e-06	0.00463	-0.21	-0.23	Cerebrospinal fluid clusterin levels;	chr3:9387510	chr3:9349689~9398579:-
STAD	cis	rs4589258	0.933	rs6483068	ENSG00000280367.1	RP11-121L10.2	-4.49	9.52e-06	0.00463	-0.26	-0.23	Intelligence (multi-trait analysis);	chr11:90666590	chr11:90223153~90226538:+
STAD	cis	rs7487075	0.82	rs7134855	ENSG00000257261.4	RP11-96H19.1	4.49	9.52e-06	0.00463	0.29	0.23	Itch intensity from mosquito bite;	chr12:46317527	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.637	rs4438106	ENSG00000257261.4	RP11-96H19.1	4.49	9.52e-06	0.00463	0.29	0.23	Itch intensity from mosquito bite;	chr12:46321745	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.786	rs11183441	ENSG00000257261.4	RP11-96H19.1	4.49	9.52e-06	0.00463	0.29	0.23	Itch intensity from mosquito bite;	chr12:46322137	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.82	rs2408505	ENSG00000257261.4	RP11-96H19.1	4.49	9.52e-06	0.00463	0.29	0.23	Itch intensity from mosquito bite;	chr12:46324041	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.82	rs7967549	ENSG00000257261.4	RP11-96H19.1	4.49	9.52e-06	0.00463	0.29	0.23	Itch intensity from mosquito bite;	chr12:46329909	chr12:46383679~46876159:+
STAD	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	4.49	9.53e-06	0.00463	0.3	0.23	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
STAD	cis	rs9467773	1	rs10484442	ENSG00000243307.2	POM121L6P	4.49	9.53e-06	0.00463	0.23	0.23	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26896952~26898777:+
STAD	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-4.49	9.53e-06	0.00463	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-4.49	9.53e-06	0.00463	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
STAD	cis	rs393951	1	rs1809054	ENSG00000260969.1	RP11-190D6.2	-4.49	9.53e-06	0.00463	-0.29	-0.23	Childhood ear infection;	chr16:77585877	chr16:78237362~78241218:-
STAD	cis	rs875971	0.862	rs13232191	ENSG00000224316.1	RP11-479O9.2	4.49	9.53e-06	0.00463	0.23	0.23	Aortic root size;	chr7:66521661	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs35378740	ENSG00000224316.1	RP11-479O9.2	4.49	9.53e-06	0.00463	0.23	0.23	Aortic root size;	chr7:66522725	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs10950043	ENSG00000224316.1	RP11-479O9.2	4.49	9.53e-06	0.00463	0.23	0.23	Aortic root size;	chr7:66523623	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs17747530	ENSG00000224316.1	RP11-479O9.2	4.49	9.53e-06	0.00463	0.23	0.23	Aortic root size;	chr7:66529742	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs13226170	ENSG00000224316.1	RP11-479O9.2	4.49	9.53e-06	0.00463	0.23	0.23	Aortic root size;	chr7:66534311	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs2420611	ENSG00000224316.1	RP11-479O9.2	4.49	9.53e-06	0.00463	0.23	0.23	Aortic root size;	chr7:66534333	chr7:65773620~65802067:+
STAD	cis	rs8014252	0.803	rs8012025	ENSG00000259158.2	ADAM20P1	-4.49	9.53e-06	0.00463	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70545488	chr14:70468881~70483756:-
STAD	cis	rs11098499	0.779	rs28495013	ENSG00000260091.1	RP11-33B1.4	4.49	9.54e-06	0.00463	0.23	0.23	Corneal astigmatism;	chr4:119454676	chr4:119409333~119410233:+
STAD	cis	rs8099594	0.64	rs1539965	ENSG00000266696.1	RP11-30L3.2	4.49	9.54e-06	0.00464	0.23	0.23	Height;	chr18:49327971	chr18:49205912~49208781:+
STAD	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-4.49	9.54e-06	0.00464	-0.24	-0.23	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
STAD	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-4.49	9.55e-06	0.00464	-0.21	-0.23	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
STAD	cis	rs2695743	0.647	rs4413189	ENSG00000225808.1	DNAJC19P5	-4.49	9.56e-06	0.00464	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177827967	chr2:177229191~177229506:-
STAD	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-4.49	9.56e-06	0.00464	-0.23	-0.23	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
STAD	cis	rs2919917	0.578	rs922928	ENSG00000254352.1	RP11-578O24.2	4.49	9.57e-06	0.00465	0.38	0.23	Lymphocyte counts;	chr8:78645085	chr8:78723796~78724136:-
STAD	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	4.49	9.57e-06	0.00465	0.25	0.23	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
STAD	cis	rs10510102	0.872	rs28586586	ENSG00000226864.1	ATE1-AS1	4.49	9.58e-06	0.00465	0.36	0.23	Breast cancer;	chr10:121950228	chr10:121928312~121951965:+
STAD	cis	rs7487075	0.893	rs4768115	ENSG00000257261.4	RP11-96H19.1	4.49	9.59e-06	0.00466	0.28	0.23	Itch intensity from mosquito bite;	chr12:46338736	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.893	rs4547171	ENSG00000257261.4	RP11-96H19.1	4.49	9.59e-06	0.00466	0.28	0.23	Itch intensity from mosquito bite;	chr12:46339609	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.828	rs2169030	ENSG00000257261.4	RP11-96H19.1	4.49	9.59e-06	0.00466	0.28	0.23	Itch intensity from mosquito bite;	chr12:46341273	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.893	rs12317787	ENSG00000257261.4	RP11-96H19.1	4.49	9.59e-06	0.00466	0.28	0.23	Itch intensity from mosquito bite;	chr12:46342946	chr12:46383679~46876159:+
STAD	cis	rs13113518	0.966	rs7677952	ENSG00000223305.1	RN7SKP30	4.49	9.6e-06	0.00466	0.26	0.23	Height;	chr4:55425312	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs1047354	ENSG00000223305.1	RN7SKP30	4.49	9.6e-06	0.00466	0.26	0.23	Height;	chr4:55429416	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs1056547	ENSG00000223305.1	RN7SKP30	4.49	9.6e-06	0.00466	0.26	0.23	Height;	chr4:55430596	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs1056545	ENSG00000223305.1	RN7SKP30	4.49	9.6e-06	0.00466	0.26	0.23	Height;	chr4:55430730	chr4:55540502~55540835:-
STAD	cis	rs13113518	1	rs5863	ENSG00000223305.1	RN7SKP30	4.49	9.6e-06	0.00466	0.26	0.23	Height;	chr4:55430740	chr4:55540502~55540835:-
STAD	cis	rs13113518	0.966	rs6828570	ENSG00000223305.1	RN7SKP30	4.49	9.6e-06	0.00466	0.26	0.23	Height;	chr4:55431595	chr4:55540502~55540835:-
STAD	cis	rs7829975	0.777	rs6989926	ENSG00000253981.4	ALG1L13P	-4.49	9.61e-06	0.00466	-0.3	-0.23	Mood instability;	chr8:8689803	chr8:8236003~8244667:-
STAD	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	4.49	9.61e-06	0.00466	0.34	0.23	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
STAD	cis	rs4713118	0.955	rs9468206	ENSG00000220721.1	OR1F12	4.49	9.61e-06	0.00466	0.26	0.23	Parkinson's disease;	chr6:27722674	chr6:28073316~28074233:+
STAD	cis	rs227275	0.525	rs10029073	ENSG00000248971.2	KRT8P46	-4.49	9.61e-06	0.00466	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102728746~102730171:-
STAD	cis	rs13413635	0.571	rs6710818	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Heart rate;	chr2:177813832	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs6713981	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814043	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs6729216	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814056	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs13384016	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814132	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs13409414	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814146	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.539	rs11884289	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814210	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs6729482	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814324	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs6714519	ENSG00000225808.1	DNAJC19P5	-4.49	9.62e-06	0.00467	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814441	chr2:177229191~177229506:-
STAD	cis	rs4698412	0.874	rs3213710	ENSG00000214846.4	RP11-115L11.1	-4.49	9.62e-06	0.00467	-0.26	-0.23	Parkinson's disease;	chr4:15715698	chr4:15730962~15731627:-
STAD	cis	rs9307551	0.741	rs880988	ENSG00000250334.4	LINC00989	-4.49	9.62e-06	0.00467	-0.31	-0.23	Refractive error;	chr4:79494318	chr4:79492416~79576460:+
STAD	cis	rs11079159	0.565	rs4794563	ENSG00000263096.1	RP11-515O17.2	4.49	9.62e-06	0.00467	0.29	0.23	QRS duration;	chr17:55304524	chr17:55271504~55273653:-
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-4.49	9.62e-06	0.00467	-0.18	-0.23	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
STAD	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	4.49	9.63e-06	0.00467	0.25	0.23	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
STAD	cis	rs8177876	0.749	rs76892049	ENSG00000261061.1	RP11-303E16.2	-4.49	9.63e-06	0.00467	-0.4	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81030770~81031485:+
STAD	cis	rs9788721	0.836	rs7181486	ENSG00000259419.2	HNRNPCP3	-4.49	9.64e-06	0.00467	-0.25	-0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78449276	chr15:79236332~79237206:+
STAD	cis	rs7680126	0.633	rs4698023	ENSG00000250613.1	RP11-136I13.1	4.49	9.64e-06	0.00468	0.25	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10303102	chr4:10410996~10411644:+
STAD	cis	rs8028182	0.636	rs8034317	ENSG00000260269.4	CTD-2323K18.1	-4.49	9.64e-06	0.00468	-0.3	-0.23	Sudden cardiac arrest;	chr15:75472002	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs28737338	ENSG00000260269.4	CTD-2323K18.1	-4.49	9.64e-06	0.00468	-0.3	-0.23	Sudden cardiac arrest;	chr15:75476338	chr15:75527150~75601205:-
STAD	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-4.49	9.64e-06	0.00468	-0.21	-0.23	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
STAD	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-4.49	9.64e-06	0.00468	-0.21	-0.23	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
STAD	cis	rs6832769	0.925	rs3817444	ENSG00000272969.1	RP11-528I4.2	4.49	9.64e-06	0.00468	0.3	0.23	Personality dimensions;	chr4:55509814	chr4:55547112~55547889:+
STAD	cis	rs11846409	0.799	rs2583330	ENSG00000274576.2	IGHV2-70	4.49	9.65e-06	0.00468	0.3	0.23	Rheumatic heart disease;	chr14:106621051	chr14:106770577~106771020:-
STAD	cis	rs7131987	0.65	rs7954871	ENSG00000275476.1	RP11-996F15.4	-4.49	9.65e-06	0.00468	-0.26	-0.23	QT interval;	chr12:29306799	chr12:29277397~29277882:-
STAD	cis	rs875971	1	rs6946143	ENSG00000224316.1	RP11-479O9.2	4.49	9.65e-06	0.00468	0.23	0.23	Aortic root size;	chr7:66114735	chr7:65773620~65802067:+
STAD	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	4.49	9.66e-06	0.00468	0.22	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
STAD	cis	rs5753618	0.583	rs71324184	ENSG00000236132.1	CTA-440B3.1	-4.49	9.67e-06	0.00469	-0.25	-0.23	Colorectal cancer;	chr22:31356075	chr22:31816379~31817491:-
STAD	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	4.49	9.67e-06	0.00469	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	4.49	9.67e-06	0.00469	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
STAD	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	4.49	9.68e-06	0.00469	0.3	0.23	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
STAD	cis	rs8141529	0.719	rs2097461	ENSG00000272858.1	CTA-292E10.8	-4.49	9.68e-06	0.00469	-0.25	-0.23	Lymphocyte counts;	chr22:28795891	chr22:28814914~28815662:+
STAD	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	4.49	9.68e-06	0.00469	0.29	0.23	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
STAD	cis	rs7474896	1	rs11011339	ENSG00000120555.12	SEPT7P9	4.49	9.68e-06	0.0047	0.33	0.23	Obesity (extreme);	chr10:37707418	chr10:38383069~38402916:-
STAD	cis	rs2337406	1	rs79452530	ENSG00000274576.2	IGHV2-70	-4.49	9.69e-06	0.0047	-0.3	-0.23	Alzheimer's disease (late onset);	chr14:106699992	chr14:106770577~106771020:-
STAD	cis	rs4780355	1	rs1111186	ENSG00000262703.1	RP11-485G7.6	4.49	9.69e-06	0.0047	0.23	0.23	Crohn's disease and psoriasis;	chr16:11253191	chr16:11348143~11349321:-
STAD	cis	rs7674212	0.507	rs223471	ENSG00000248971.2	KRT8P46	-4.49	9.69e-06	0.0047	-0.25	-0.23	Type 2 diabetes;	chr4:102777629	chr4:102728746~102730171:-
STAD	cis	rs7119038	0.629	rs73001429	ENSG00000255422.1	AP002954.4	4.49	9.69e-06	0.0047	0.3	0.23	Sjögren's syndrome;	chr11:118732456	chr11:118704607~118750263:+
STAD	cis	rs2337406	0.925	rs873534	ENSG00000280411.1	IGHV1-69-2	-4.49	9.69e-06	0.0047	-0.29	-0.23	Alzheimer's disease (late onset);	chr14:106667423	chr14:106762092~106762588:-
STAD	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-4.49	9.69e-06	0.0047	-0.3	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
STAD	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	4.49	9.69e-06	0.0047	0.31	0.23	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
STAD	cis	rs721917	0.525	rs10788338	ENSG00000225484.5	NUTM2B-AS1	-4.49	9.69e-06	0.0047	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79663088~79826594:-
STAD	cis	rs9902453	0.845	rs3115101	ENSG00000240074.1	RPL9P30	4.49	9.7e-06	0.0047	0.2	0.23	Coffee consumption (cups per day);	chr17:29714609	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.845	rs3102556	ENSG00000240074.1	RPL9P30	4.49	9.7e-06	0.0047	0.2	0.23	Coffee consumption (cups per day);	chr17:29715524	chr17:29855759~29856332:+
STAD	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	4.49	9.7e-06	0.0047	0.3	0.23	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	4.49	9.7e-06	0.0047	0.3	0.23	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
STAD	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	4.49	9.7e-06	0.0047	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
STAD	cis	rs7824557	1	rs2736371	ENSG00000254866.2	DEFB109P3	4.49	9.7e-06	0.0047	0.3	0.23	Retinal vascular caliber;	chr8:11248020	chr8:12150895~12151134:-
STAD	cis	rs62246343	0.719	rs62246302	ENSG00000214041.4	PGAM1P4	4.49	9.72e-06	0.00471	0.39	0.23	Fibrinogen levels;	chr3:9411761	chr3:9348443~9349192:+
STAD	cis	rs3770081	1	rs2289237	ENSG00000273080.1	RP11-301O19.1	4.49	9.72e-06	0.00471	0.55	0.23	Facial emotion recognition (sad faces);	chr2:86039151	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs17026854	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86053373	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs3770082	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86053799	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs2278087	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86054823	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs60649958	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86055877	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs17618001	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86062180	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs75109362	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86062766	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs75713195	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86063536	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs79152960	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86063538	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs57398459	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86064203	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs77309268	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86066171	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs76052260	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86101604	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs77621359	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86103230	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs3810827	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86107263	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs3731819	ENSG00000273080.1	RP11-301O19.1	-4.49	9.72e-06	0.00471	-0.55	-0.23	Facial emotion recognition (sad faces);	chr2:86141518	chr2:86195590~86196049:+
STAD	cis	rs4407350	0.609	rs1962220	ENSG00000279642.1	RP5-1033E15.3	4.49	9.73e-06	0.00471	0.23	0.23	Intelligence (multi-trait analysis);	chr22:44492183	chr22:44486295~44486914:-
STAD	cis	rs9291683	0.62	rs717615	ENSG00000250613.1	RP11-136I13.1	-4.49	9.73e-06	0.00471	-0.22	-0.23	Bone mineral density;	chr4:10103046	chr4:10410996~10411644:+
STAD	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	4.49	9.73e-06	0.00471	0.24	0.23	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
STAD	cis	rs8028182	0.636	rs28432989	ENSG00000260269.4	CTD-2323K18.1	-4.49	9.74e-06	0.00472	-0.3	-0.23	Sudden cardiac arrest;	chr15:75475956	chr15:75527150~75601205:-
STAD	cis	rs6921919	0.515	rs1558205	ENSG00000220721.1	OR1F12	-4.49	9.75e-06	0.00472	-0.24	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28073316~28074233:+
STAD	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	4.49	9.75e-06	0.00472	0.29	0.23	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
STAD	cis	rs875971	1	rs4717292	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66430611	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs2420591	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66447394	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs10755833	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66448930	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs12668936	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66449417	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs12698520	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66453720	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs1833495	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66456608	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs6945032	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66457499	chr7:65840212~65840596:+
STAD	cis	rs875971	0.929	rs12673810	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66458866	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs35149210	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66464938	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs6961155	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66468308	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs7789768	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66473993	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs1363055	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66478288	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs9691480	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66479319	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs7789554	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66481051	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs1974769	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66485627	chr7:65840212~65840596:+
STAD	cis	rs875971	0.895	rs6460300	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66487937	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs7803416	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66489212	chr7:65840212~65840596:+
STAD	cis	rs875971	0.862	rs1981799	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66490572	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs2277911	ENSG00000236529.1	RP13-254B10.1	4.49	9.75e-06	0.00472	0.25	0.23	Aortic root size;	chr7:66493638	chr7:65840212~65840596:+
STAD	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-4.49	9.75e-06	0.00472	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
STAD	cis	rs875971	0.862	rs801194	ENSG00000224316.1	RP11-479O9.2	-4.49	9.75e-06	0.00472	-0.23	-0.23	Aortic root size;	chr7:66563508	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs2024192	ENSG00000224316.1	RP11-479O9.2	-4.49	9.75e-06	0.00472	-0.23	-0.23	Aortic root size;	chr7:66576460	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6955837	ENSG00000224316.1	RP11-479O9.2	-4.49	9.75e-06	0.00472	-0.23	-0.23	Aortic root size;	chr7:66578155	chr7:65773620~65802067:+
STAD	cis	rs875971	0.825	rs10281499	ENSG00000224316.1	RP11-479O9.2	-4.49	9.75e-06	0.00472	-0.23	-0.23	Aortic root size;	chr7:66583979	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs4718377	ENSG00000224316.1	RP11-479O9.2	-4.49	9.75e-06	0.00472	-0.23	-0.23	Aortic root size;	chr7:66584691	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs10278014	ENSG00000224316.1	RP11-479O9.2	-4.49	9.75e-06	0.00472	-0.23	-0.23	Aortic root size;	chr7:66586277	chr7:65773620~65802067:+
STAD	cis	rs11846409	0.86	rs4774167	ENSG00000211970.3	IGHV4-61	4.49	9.75e-06	0.00472	0.27	0.23	Rheumatic heart disease;	chr14:106619987	chr14:106639119~106639657:-
STAD	cis	rs4142995	0.586	rs2389858	ENSG00000279048.1	RP11-511H23.2	-4.49	9.76e-06	0.00472	-0.21	-0.23	HDL cholesterol;HDL cholesterol levels;	chr7:17868507	chr7:17940503~17942922:+
STAD	cis	rs6750795	0.746	rs1667301	ENSG00000223198.1	RNU2-22P	-4.49	9.77e-06	0.00473	-0.28	-0.23	Height;	chr2:231559006	chr2:231501990~231502201:-
STAD	cis	rs228614	0.536	rs223375	ENSG00000248971.2	KRT8P46	-4.49	9.77e-06	0.00473	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102728746~102730171:-
STAD	cis	rs10776614	0.642	rs10776616	ENSG00000189014.7	FAM35DP	-4.49	9.78e-06	0.00473	-0.32	-0.23	Self-employment;	chr10:48563019	chr10:47689707~47730436:+
STAD	cis	rs8099594	0.565	rs8090015	ENSG00000266696.1	RP11-30L3.2	4.49	9.78e-06	0.00473	0.22	0.23	Height;	chr18:49187716	chr18:49205912~49208781:+
STAD	cis	rs875971	1	rs4717300	ENSG00000236529.1	RP13-254B10.1	4.49	9.78e-06	0.00473	0.25	0.23	Aortic root size;	chr7:66482393	chr7:65840212~65840596:+
STAD	cis	rs9902453	0.765	rs2729448	ENSG00000240074.1	RPL9P30	-4.49	9.78e-06	0.00473	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29764935	chr17:29855759~29856332:+
STAD	cis	rs9807989	0.839	rs4988957	ENSG00000234389.1	AC007278.3	-4.49	9.78e-06	0.00473	-0.24	-0.23	Asthma;	chr2:102351615	chr2:102438713~102440475:+
STAD	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-4.49	9.78e-06	0.00473	-0.22	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
STAD	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	4.49	9.79e-06	0.00474	0.28	0.23	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	4.49	9.79e-06	0.00474	0.28	0.23	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
STAD	cis	rs7924176	0.601	rs2131957	ENSG00000213731.2	RAB5CP1	-4.49	9.79e-06	0.00474	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74423435~74424014:-
STAD	cis	rs4589258	0.737	rs1783798	ENSG00000280367.1	RP11-121L10.2	-4.49	9.79e-06	0.00474	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90710178	chr11:90223153~90226538:+
STAD	cis	rs7829975	0.684	rs546603	ENSG00000254340.1	RP11-10A14.3	-4.49	9.8e-06	0.00474	-0.28	-0.23	Mood instability;	chr8:8738328	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.846	rs7005216	ENSG00000253981.4	ALG1L13P	-4.49	9.8e-06	0.00474	-0.29	-0.23	Mood instability;	chr8:8689600	chr8:8236003~8244667:-
STAD	cis	rs7680126	0.596	rs17418533	ENSG00000250613.1	RP11-136I13.1	4.49	9.8e-06	0.00474	0.26	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10315317	chr4:10410996~10411644:+
STAD	cis	rs7924176	0.521	rs12357370	ENSG00000213731.2	RAB5CP1	-4.49	9.8e-06	0.00474	-0.24	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74423435~74424014:-
STAD	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-4.49	9.8e-06	0.00474	-0.27	-0.23	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
STAD	cis	rs17301013	0.861	rs10218528	ENSG00000227373.4	RP11-160H22.5	4.49	9.81e-06	0.00474	0.29	0.23	Systemic lupus erythematosus;	chr1:174478450	chr1:174115300~174160004:-
STAD	cis	rs748404	0.631	rs7163288	ENSG00000275601.1	AC011330.13	-4.49	9.81e-06	0.00475	-0.24	-0.23	Lung cancer;	chr15:43379157	chr15:43642389~43643023:-
STAD	cis	rs2695743	0.592	rs2365895	ENSG00000225808.1	DNAJC19P5	-4.49	9.81e-06	0.00475	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177818543	chr2:177229191~177229506:-
STAD	cis	rs17401966	0.867	rs10492973	ENSG00000199562.1	RNU6-37P	4.49	9.81e-06	0.00475	0.18	0.23	Hepatocellular carcinoma;	chr1:10338927	chr1:10298966~10299072:+
STAD	cis	rs228614	0.536	rs150897	ENSG00000248971.2	KRT8P46	-4.49	9.81e-06	0.00475	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs223380	ENSG00000248971.2	KRT8P46	-4.49	9.82e-06	0.00475	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs223379	ENSG00000248971.2	KRT8P46	-4.49	9.82e-06	0.00475	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102728746~102730171:-
STAD	cis	rs7474896	0.515	rs2505233	ENSG00000120555.12	SEPT7P9	4.49	9.82e-06	0.00475	0.29	0.23	Obesity (extreme);	chr10:38051337	chr10:38383069~38402916:-
STAD	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	4.49	9.82e-06	0.00475	0.29	0.23	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
STAD	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-4.49	9.82e-06	0.00475	-0.3	-0.23	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
STAD	cis	rs7829975	0.593	rs2921077	ENSG00000254340.1	RP11-10A14.3	4.49	9.83e-06	0.00475	0.27	0.23	Mood instability;	chr8:8446992	chr8:9141424~9145435:+
STAD	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-4.49	9.83e-06	0.00475	-0.24	-0.23	Height;	chr5:37023796	chr5:36666214~36725195:-
STAD	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	4.49	9.83e-06	0.00475	0.29	0.23	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	4.49	9.83e-06	0.00475	0.29	0.23	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
STAD	cis	rs7131987	0.65	rs7957339	ENSG00000275476.1	RP11-996F15.4	-4.49	9.83e-06	0.00475	-0.26	-0.23	QT interval;	chr12:29303562	chr12:29277397~29277882:-
STAD	cis	rs1707322	0.752	rs4607935	ENSG00000281133.1	AL355480.3	-4.49	9.83e-06	0.00475	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs3811436	ENSG00000281133.1	AL355480.3	-4.49	9.83e-06	0.00475	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs4415615	ENSG00000281133.1	AL355480.3	-4.49	9.83e-06	0.00475	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs7529699	ENSG00000281133.1	AL355480.3	-4.49	9.83e-06	0.00475	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs10430105	ENSG00000281133.1	AL355480.3	-4.49	9.83e-06	0.00475	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45580892~45580996:-
STAD	cis	rs9860428	0.526	rs9826308	ENSG00000240057.4	RP11-572M11.4	-4.49	9.84e-06	0.00476	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112928985	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.588	rs6438117	ENSG00000240057.4	RP11-572M11.4	-4.49	9.84e-06	0.00476	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112929278	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.632	rs4596117	ENSG00000240057.4	RP11-572M11.4	-4.49	9.84e-06	0.00476	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112929280	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs6808249	ENSG00000240057.4	RP11-572M11.4	-4.49	9.84e-06	0.00476	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112930138	chr3:113019532~113183301:+
STAD	cis	rs1032726	0.718	rs6772799	ENSG00000240057.4	RP11-572M11.4	-4.49	9.84e-06	0.00476	-0.23	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112930275	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs6438118	ENSG00000240057.4	RP11-572M11.4	-4.49	9.84e-06	0.00476	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112930539	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.546	rs6438119	ENSG00000240057.4	RP11-572M11.4	-4.49	9.84e-06	0.00476	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112930554	chr3:113019532~113183301:+
STAD	cis	rs11676348	0.772	rs11687200	ENSG00000237281.1	CATIP-AS2	4.49	9.84e-06	0.00476	0.23	0.23	Ulcerative colitis;	chr2:218079892	chr2:218326889~218357966:-
STAD	cis	rs9549328	0.8	rs9549326	ENSG00000267868.1	RP11-120K24.3	4.49	9.84e-06	0.00476	0.33	0.23	Systolic blood pressure;	chr13:112976139	chr13:112964835~112966131:-
STAD	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-4.49	9.84e-06	0.00476	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-4.49	9.84e-06	0.00476	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-4.49	9.84e-06	0.00476	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-4.49	9.84e-06	0.00476	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-4.49	9.84e-06	0.00476	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
STAD	cis	rs7760535	0.735	rs240974	ENSG00000230177.1	RP5-1112D6.4	-4.49	9.84e-06	0.00476	-0.21	-0.23	Metabolic traits;	chr6:111328113	chr6:111277932~111278742:+
STAD	cis	rs875971	0.895	rs7788984	ENSG00000236529.1	RP13-254B10.1	4.49	9.85e-06	0.00476	0.25	0.23	Aortic root size;	chr7:66450629	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs1981798	ENSG00000236529.1	RP13-254B10.1	4.49	9.85e-06	0.00476	0.25	0.23	Aortic root size;	chr7:66489916	chr7:65840212~65840596:+
STAD	cis	rs6840360	0.582	rs4696259	ENSG00000270265.1	RP11-731D1.4	-4.49	9.85e-06	0.00476	-0.28	-0.23	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151333775~151353224:-
STAD	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	4.49	9.85e-06	0.00476	0.26	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
STAD	cis	rs944722	0.749	rs8081248	ENSG00000266786.1	LGALS9DP	4.49	9.86e-06	0.00476	0.29	0.23	Fractional exhaled nitric oxide (childhood);	chr17:27754938	chr17:27746132~27754954:+
STAD	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-4.49	9.86e-06	0.00476	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
STAD	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	4.49	9.87e-06	0.00477	0.33	0.23	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
STAD	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-4.49	9.87e-06	0.00477	-0.26	-0.23	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
STAD	cis	rs9733	0.519	rs2184833	ENSG00000274963.1	Metazoa_SRP	4.49	9.88e-06	0.00477	0.21	0.23	Tonsillectomy;	chr1:150703007	chr1:150568971~150569269:-
STAD	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-4.49	9.89e-06	0.00478	-0.24	-0.23	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
STAD	cis	rs1707322	0.721	rs10890341	ENSG00000281133.1	AL355480.3	-4.49	9.9e-06	0.00478	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45580892~45580996:-
STAD	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	4.49	9.9e-06	0.00478	0.26	0.23	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
STAD	cis	rs7674212	0.772	rs13113099	ENSG00000246560.2	RP11-10L12.4	4.49	9.9e-06	0.00478	0.3	0.23	Type 2 diabetes;	chr4:103052965	chr4:102828055~102844075:+
STAD	cis	rs7829975	0.774	rs1039915	ENSG00000253981.4	ALG1L13P	4.49	9.9e-06	0.00478	0.27	0.23	Mood instability;	chr8:8822104	chr8:8236003~8244667:-
STAD	cis	rs9910055	0.53	rs8072954	ENSG00000260793.2	RP5-882C2.2	-4.49	9.91e-06	0.00479	-0.26	-0.23	Total body bone mineral density;	chr17:44217354	chr17:44221401~44223710:+
STAD	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-4.49	9.91e-06	0.00479	-0.29	-0.23	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
STAD	cis	rs1150668	0.83	rs2531831	ENSG00000220721.1	OR1F12	4.49	9.91e-06	0.00479	0.23	0.23	Pubertal anthropometrics;	chr6:28420988	chr6:28073316~28074233:+
STAD	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	4.49	9.92e-06	0.00479	0.34	0.23	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
STAD	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-4.49	9.92e-06	0.00479	-0.24	-0.23	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
STAD	cis	rs7078219	0.543	rs4919342	ENSG00000257582.4	LINC01475	-4.49	9.92e-06	0.00479	-0.27	-0.23	Dental caries;	chr10:99522796	chr10:99526350~99531177:-
STAD	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-4.48	9.93e-06	0.0048	-0.26	-0.23	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
STAD	cis	rs2695743	0.539	rs7570898	ENSG00000225808.1	DNAJC19P5	-4.48	9.94e-06	0.0048	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177817385	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.514	rs7557136	ENSG00000225808.1	DNAJC19P5	-4.48	9.94e-06	0.0048	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177817527	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.514	rs7557138	ENSG00000225808.1	DNAJC19P5	-4.48	9.94e-06	0.0048	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177817529	chr2:177229191~177229506:-
STAD	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	4.48	9.94e-06	0.0048	0.34	0.23	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
STAD	cis	rs9910055	0.53	rs2269905	ENSG00000260793.2	RP5-882C2.2	-4.48	9.94e-06	0.0048	-0.26	-0.23	Total body bone mineral density;	chr17:44217094	chr17:44221401~44223710:+
STAD	cis	rs6714710	0.58	rs11680018	ENSG00000235833.1	AC159540.14	-4.48	9.94e-06	0.0048	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97863118	chr2:97523949~97524976:-
STAD	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	4.48	9.94e-06	0.0048	0.34	0.23	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	4.48	9.94e-06	0.0048	0.34	0.23	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	4.48	9.94e-06	0.0048	0.34	0.23	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
STAD	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	4.48	9.95e-06	0.0048	0.31	0.23	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
STAD	cis	rs227275	0.527	rs223338	ENSG00000248971.2	KRT8P46	-4.48	9.95e-06	0.0048	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102728746~102730171:-
STAD	cis	rs944722	0.623	rs9913854	ENSG00000266786.1	LGALS9DP	4.48	9.96e-06	0.00481	0.29	0.23	Fractional exhaled nitric oxide (childhood);	chr17:27735336	chr17:27746132~27754954:+
STAD	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-4.48	9.96e-06	0.00481	-0.27	-0.23	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
STAD	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-4.48	9.96e-06	0.00481	-0.34	-0.23	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
STAD	cis	rs8177876	0.749	rs12444969	ENSG00000261061.1	RP11-303E16.2	-4.48	9.97e-06	0.00481	-0.4	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81030770~81031485:+
STAD	cis	rs1799949	1	rs8176103	ENSG00000279602.1	CTD-3014M21.1	4.48	9.97e-06	0.00481	0.29	0.23	Menopause (age at onset);	chr17:43115033	chr17:43360041~43361361:-
STAD	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	4.48	9.97e-06	0.00481	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
STAD	cis	rs7665090	1	rs735403	ENSG00000248971.2	KRT8P46	4.48	9.97e-06	0.00481	0.25	0.23	Primary biliary cholangitis;	chr4:102632386	chr4:102728746~102730171:-
STAD	cis	rs228614	0.543	rs223330	ENSG00000248971.2	KRT8P46	-4.48	9.98e-06	0.00482	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223329	ENSG00000248971.2	KRT8P46	-4.48	9.98e-06	0.00482	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102728746~102730171:-
STAD	cis	rs228614	0.536	rs223327	ENSG00000248971.2	KRT8P46	-4.48	9.98e-06	0.00482	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223326	ENSG00000248971.2	KRT8P46	-4.48	9.98e-06	0.00482	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223324	ENSG00000248971.2	KRT8P46	-4.48	9.98e-06	0.00482	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102728746~102730171:-
STAD	cis	rs891378	1	rs6700168	ENSG00000274245.1	RP11-357P18.2	4.48	9.98e-06	0.00482	0.29	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329189	chr1:207372559~207373252:+
STAD	cis	rs3770081	1	rs78297976	ENSG00000273080.1	RP11-301O19.1	-4.48	9.99e-06	0.00482	-0.53	-0.23	Facial emotion recognition (sad faces);	chr2:85917118	chr2:86195590~86196049:+
STAD	cis	rs2957692	0.548	rs11042623	ENSG00000254554.1	RP11-351I24.1	4.48	9.99e-06	0.00482	0.39	0.23	Circulating vasoactive peptide levels;	chr11:10095787	chr11:10302657~10303704:-
STAD	cis	rs3733418	0.929	rs4690797	ENSG00000248632.1	RP11-366M4.11	4.48	9.99e-06	0.00482	0.29	0.23	Obesity-related traits;	chr4:164987353	chr4:164968587~164970002:-
STAD	cis	rs3733418	0.929	rs4691138	ENSG00000248632.1	RP11-366M4.11	4.48	9.99e-06	0.00482	0.29	0.23	Obesity-related traits;	chr4:164987489	chr4:164968587~164970002:-
STAD	cis	rs3733418	0.929	rs12512234	ENSG00000248632.1	RP11-366M4.11	4.48	9.99e-06	0.00482	0.29	0.23	Obesity-related traits;	chr4:164987713	chr4:164968587~164970002:-
STAD	cis	rs3733418	0.929	rs12510464	ENSG00000248632.1	RP11-366M4.11	4.48	9.99e-06	0.00482	0.29	0.23	Obesity-related traits;	chr4:164997888	chr4:164968587~164970002:-
STAD	cis	rs8028182	0.636	rs4886703	ENSG00000260269.4	CTD-2323K18.1	-4.48	1e-05	0.00483	-0.29	-0.23	Sudden cardiac arrest;	chr15:75438025	chr15:75527150~75601205:-
STAD	cis	rs916888	0.61	rs199446	ENSG00000260075.1	NSFP1	-4.48	1e-05	0.00483	-0.31	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46372855~46487141:+
STAD	cis	rs916888	0.61	rs199536	ENSG00000260075.1	NSFP1	-4.48	1e-05	0.00483	-0.31	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46372855~46487141:+
STAD	cis	rs9733	0.519	rs11204717	ENSG00000274963.1	Metazoa_SRP	4.48	1e-05	0.00483	0.21	0.23	Tonsillectomy;	chr1:150736653	chr1:150568971~150569269:-
STAD	cis	rs35955747	0.601	rs7289941	ENSG00000236132.1	CTA-440B3.1	-4.48	1e-05	0.00483	-0.24	-0.23	Neutrophil count;Sum basophil neutrophil counts;	chr22:31488419	chr22:31816379~31817491:-
STAD	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-4.48	1e-05	0.00483	-0.3	-0.23	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
STAD	cis	rs7487075	0.856	rs1079780	ENSG00000257261.4	RP11-96H19.1	4.48	1e-05	0.00483	0.31	0.23	Itch intensity from mosquito bite;	chr12:46342240	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.797	rs12816358	ENSG00000257261.4	RP11-96H19.1	4.48	1e-05	0.00483	0.31	0.23	Itch intensity from mosquito bite;	chr12:46342863	chr12:46383679~46876159:+
STAD	cis	rs2836950	0.52	rs59916147	ENSG00000238141.2	BRWD1-AS1	-4.48	1e-05	0.00483	-0.24	-0.23	Menarche (age at onset);	chr21:39262776	chr21:39315707~39323218:+
STAD	cis	rs2273156	0.929	rs12894820	ENSG00000241052.1	RP11-173D9.1	4.48	1e-05	0.00483	0.26	0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966319	chr14:35144021~35144480:-
STAD	cis	rs1707322	1	rs10890370	ENSG00000281133.1	AL355480.3	-4.48	1e-05	0.00483	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45580892~45580996:-
STAD	cis	rs858239	0.509	rs6962213	ENSG00000230042.1	AK3P3	-4.48	1e-05	0.00483	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23129178~23129841:+
STAD	cis	rs1020064	0.583	rs2576775	ENSG00000235319.1	AC012360.4	-4.48	1e-05	0.00483	-0.31	-0.23	AIDS;	chr2:105356755	chr2:105324210~105330529:+
STAD	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	4.48	1e-05	0.00483	0.33	0.23	Depression;	chr6:28386473	chr6:28943877~28944537:+
STAD	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	4.48	1e-05	0.00483	0.33	0.23	Depression;	chr6:28391932	chr6:28943877~28944537:+
STAD	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	4.48	1e-05	0.00483	0.33	0.23	Depression;	chr6:28399846	chr6:28943877~28944537:+
STAD	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-4.48	1e-05	0.00484	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
STAD	cis	rs7617773	0.963	rs9822496	ENSG00000224895.1	VPS26BP1	-4.48	1e-05	0.00484	-0.23	-0.23	Coronary artery disease;	chr3:48139843	chr3:47960327~47961081:-
STAD	cis	rs8062405	0.824	rs4788083	ENSG00000278665.1	RP11-666O2.4	4.48	1e-05	0.00484	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28599241~28601881:-
STAD	cis	rs4237845	0.742	rs3751330	ENSG00000273805.1	RP11-620J15.4	-4.48	1e-05	0.00484	-0.26	-0.23	Intelligence (multi-trait analysis);	chr12:57896443	chr12:57894232~57896846:+
STAD	cis	rs1040	0.674	rs7381269	ENSG00000261039.2	RP11-417E7.2	-4.48	1e-05	0.00484	-0.28	-0.23	Joint mobility (Beighton score);	chr6:169200066	chr6:169175304~169182740:-
STAD	cis	rs9733	0.519	rs1336899	ENSG00000274963.1	Metazoa_SRP	4.48	1e-05	0.00484	0.21	0.23	Tonsillectomy;	chr1:150706434	chr1:150568971~150569269:-
STAD	cis	rs7412746	0.611	rs11803940	ENSG00000274963.1	Metazoa_SRP	4.48	1e-05	0.00484	0.21	0.23	Melanoma;	chr1:150713359	chr1:150568971~150569269:-
STAD	cis	rs9733	0.519	rs7521898	ENSG00000274963.1	Metazoa_SRP	4.48	1e-05	0.00484	0.21	0.23	Tonsillectomy;	chr1:150735120	chr1:150568971~150569269:-
STAD	cis	rs9733	0.519	rs7511673	ENSG00000274963.1	Metazoa_SRP	4.48	1e-05	0.00484	0.21	0.23	Tonsillectomy;	chr1:150735160	chr1:150568971~150569269:-
STAD	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	4.48	1e-05	0.00484	0.47	0.23	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
STAD	cis	rs516805	0.59	rs1430816	ENSG00000279453.1	RP3-425C14.4	-4.48	1.01e-05	0.00484	-0.38	-0.23	Lymphocyte counts;	chr6:122591978	chr6:122436789~122439223:-
STAD	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.48	1.01e-05	0.00484	0.21	0.23	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
STAD	cis	rs4568518	0.873	rs4602778	ENSG00000279048.1	RP11-511H23.2	4.48	1.01e-05	0.00485	0.21	0.23	Measles;	chr7:17989131	chr7:17940503~17942922:+
STAD	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-4.48	1.01e-05	0.00485	-0.24	-0.23	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
STAD	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-4.48	1.01e-05	0.00485	-0.24	-0.23	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
STAD	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	4.48	1.01e-05	0.00485	0.35	0.23	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
STAD	cis	rs11846409	0.629	rs76295389	ENSG00000211972.2	IGHV3-66	-4.48	1.01e-05	0.00485	-0.24	-0.23	Rheumatic heart disease;	chr14:106650437	chr14:106675017~106675544:-
STAD	cis	rs11846409	0.698	rs71419854	ENSG00000211972.2	IGHV3-66	-4.48	1.01e-05	0.00485	-0.24	-0.23	Rheumatic heart disease;	chr14:106650440	chr14:106675017~106675544:-
STAD	cis	rs2337406	0.5	rs71419855	ENSG00000211972.2	IGHV3-66	-4.48	1.01e-05	0.00485	-0.24	-0.23	Alzheimer's disease (late onset);	chr14:106650444	chr14:106675017~106675544:-
STAD	cis	rs4589258	0.788	rs10830565	ENSG00000280367.1	RP11-121L10.2	4.48	1.01e-05	0.00485	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90727649	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs11019164	ENSG00000280367.1	RP11-121L10.2	4.48	1.01e-05	0.00485	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90727687	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs7929571	ENSG00000280367.1	RP11-121L10.2	4.48	1.01e-05	0.00485	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90728052	chr11:90223153~90226538:+
STAD	cis	rs1707322	0.963	rs34907901	ENSG00000281133.1	AL355480.3	-4.48	1.01e-05	0.00485	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45580892~45580996:-
STAD	cis	rs11992186	0.57	rs17628941	ENSG00000253981.4	ALG1L13P	-4.48	1.01e-05	0.00486	-0.31	-0.23	Neuroticism;	chr8:8730024	chr8:8236003~8244667:-
STAD	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	4.48	1.01e-05	0.00486	0.33	0.23	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
STAD	cis	rs4713118	0.662	rs9380045	ENSG00000220721.1	OR1F12	4.48	1.01e-05	0.00486	0.28	0.23	Parkinson's disease;	chr6:28057501	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs9468274	ENSG00000220721.1	OR1F12	4.48	1.01e-05	0.00486	0.28	0.23	Parkinson's disease;	chr6:28058299	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs9468275	ENSG00000220721.1	OR1F12	4.48	1.01e-05	0.00486	0.28	0.23	Parkinson's disease;	chr6:28058358	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs9468276	ENSG00000220721.1	OR1F12	4.48	1.01e-05	0.00486	0.28	0.23	Parkinson's disease;	chr6:28059910	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs9468277	ENSG00000220721.1	OR1F12	4.48	1.01e-05	0.00486	0.28	0.23	Parkinson's disease;	chr6:28060612	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs9468278	ENSG00000220721.1	OR1F12	4.48	1.01e-05	0.00486	0.28	0.23	Parkinson's disease;	chr6:28060704	chr6:28073316~28074233:+
STAD	cis	rs870825	0.616	rs4616798	ENSG00000249173.4	LINC01093	4.48	1.01e-05	0.00486	0.38	0.23	Blood protein levels;	chr4:184712990	chr4:184893871~184899454:-
STAD	cis	rs9860428	0.526	rs7652504	ENSG00000240057.4	RP11-572M11.4	-4.48	1.01e-05	0.00486	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112930766	chr3:113019532~113183301:+
STAD	cis	rs227275	0.554	rs223315	ENSG00000248971.2	KRT8P46	-4.48	1.01e-05	0.00486	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102728746~102730171:-
STAD	cis	rs5758659	0.716	rs2143138	ENSG00000182057.4	OGFRP1	4.48	1.01e-05	0.00486	0.24	0.23	Cognitive function;	chr22:42222334	chr22:42269753~42275196:+
STAD	cis	rs919433	1	rs6761919	ENSG00000231621.1	AC013264.2	4.48	1.01e-05	0.00486	0.2	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298604	chr2:197197991~197199273:+
STAD	cis	rs4243830	0.522	rs10157142	ENSG00000229519.2	RP11-58A11.2	4.48	1.01e-05	0.00486	0.26	0.23	Body mass index;	chr1:6558725	chr1:6547905~6548619:+
STAD	cis	rs227275	0.554	rs223367	ENSG00000248971.2	KRT8P46	-4.48	1.01e-05	0.00486	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102728746~102730171:-
STAD	cis	rs62246343	0.719	rs62246301	ENSG00000214041.4	PGAM1P4	4.48	1.01e-05	0.00486	0.39	0.23	Fibrinogen levels;	chr3:9409599	chr3:9348443~9349192:+
STAD	cis	rs62246343	0.719	rs62246303	ENSG00000214041.4	PGAM1P4	4.48	1.01e-05	0.00486	0.39	0.23	Fibrinogen levels;	chr3:9413078	chr3:9348443~9349192:+
STAD	cis	rs62246343	0.719	rs6767213	ENSG00000214041.4	PGAM1P4	4.48	1.01e-05	0.00486	0.39	0.23	Fibrinogen levels;	chr3:9415588	chr3:9348443~9349192:+
STAD	cis	rs62246343	0.719	rs62246305	ENSG00000214041.4	PGAM1P4	4.48	1.01e-05	0.00486	0.39	0.23	Fibrinogen levels;	chr3:9416565	chr3:9348443~9349192:+
STAD	cis	rs62246343	0.719	rs56782786	ENSG00000214041.4	PGAM1P4	4.48	1.01e-05	0.00486	0.39	0.23	Fibrinogen levels;	chr3:9425388	chr3:9348443~9349192:+
STAD	cis	rs62246343	0.719	rs62246308	ENSG00000214041.4	PGAM1P4	4.48	1.01e-05	0.00486	0.39	0.23	Fibrinogen levels;	chr3:9427603	chr3:9348443~9349192:+
STAD	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	4.48	1.01e-05	0.00487	0.26	0.23	Depression;	chr6:28430971	chr6:28176188~28176674:+
STAD	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	4.48	1.01e-05	0.00487	0.26	0.23	Depression;	chr6:28431469	chr6:28176188~28176674:+
STAD	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	4.48	1.01e-05	0.00487	0.26	0.23	Depression;	chr6:28432562	chr6:28176188~28176674:+
STAD	cis	rs237743	1	rs1567865	ENSG00000222365.1	SNORD12B	-4.48	1.01e-05	0.00487	-0.33	-0.23	Height;	chr20:49265430	chr20:49280319~49280409:+
STAD	cis	rs17401966	0.931	rs4240911	ENSG00000199562.1	RNU6-37P	4.48	1.01e-05	0.00487	0.18	0.23	Hepatocellular carcinoma;	chr1:10247395	chr1:10298966~10299072:+
STAD	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-4.48	1.01e-05	0.00487	-0.28	-0.23	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
STAD	cis	rs227275	0.527	rs223308	ENSG00000248971.2	KRT8P46	-4.48	1.01e-05	0.00487	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102728746~102730171:-
STAD	cis	rs13113518	0.678	rs13149568	ENSG00000223305.1	RN7SKP30	4.48	1.01e-05	0.00488	0.26	0.23	Height;	chr4:55370412	chr4:55540502~55540835:-
STAD	cis	rs10851478	0.874	rs1507618	ENSG00000259545.2	RP11-325E5.4	-4.48	1.01e-05	0.00488	-0.26	-0.23	Oral cavity cancer;	chr15:49684891	chr15:49177610~49178741:-
STAD	cis	rs9807989	0.839	rs1974675	ENSG00000234389.1	AC007278.3	4.48	1.01e-05	0.00488	0.25	0.23	Asthma;	chr2:102369915	chr2:102438713~102440475:+
STAD	cis	rs4780355	0.918	rs1646019	ENSG00000262703.1	RP11-485G7.6	4.48	1.01e-05	0.00488	0.22	0.23	Crohn's disease and psoriasis;	chr16:11265823	chr16:11348143~11349321:-
STAD	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-4.48	1.01e-05	0.00488	-0.29	-0.23	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
STAD	cis	rs17401966	0.931	rs10492972	ENSG00000199562.1	RNU6-37P	4.48	1.01e-05	0.00489	0.18	0.23	Hepatocellular carcinoma;	chr1:10293054	chr1:10298966~10299072:+
STAD	cis	rs2739330	0.929	rs5751775	ENSG00000272787.1	KB-226F1.2	-4.48	1.02e-05	0.00489	-0.25	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23969211~23969873:+
STAD	cis	rs6714710	0.58	rs35564270	ENSG00000235833.1	AC159540.14	-4.48	1.02e-05	0.00489	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97985702	chr2:97523949~97524976:-
STAD	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	4.48	1.02e-05	0.00489	0.38	0.23	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
STAD	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	4.48	1.02e-05	0.00489	0.38	0.23	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	4.48	1.02e-05	0.00489	0.38	0.23	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
STAD	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	4.48	1.02e-05	0.00489	0.38	0.23	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
STAD	cis	rs4589258	0.762	rs4486591	ENSG00000280367.1	RP11-121L10.2	4.48	1.02e-05	0.00489	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90730911	chr11:90223153~90226538:+
STAD	cis	rs11673344	0.523	rs7260488	ENSG00000267672.1	CTD-2293H3.1	4.48	1.02e-05	0.00489	0.21	0.23	Obesity-related traits;	chr19:37058883	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs8110158	ENSG00000267672.1	CTD-2293H3.1	4.48	1.02e-05	0.00489	0.21	0.23	Obesity-related traits;	chr19:37063491	chr19:37091341~37092564:+
STAD	cis	rs8014252	0.803	rs74938470	ENSG00000259158.2	ADAM20P1	-4.48	1.02e-05	0.00489	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70573305	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs61388426	ENSG00000259158.2	ADAM20P1	-4.48	1.02e-05	0.00489	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70578285	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs56328037	ENSG00000259158.2	ADAM20P1	-4.48	1.02e-05	0.00489	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70578624	chr14:70468881~70483756:-
STAD	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-4.48	1.02e-05	0.0049	-0.28	-0.23	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
STAD	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	4.48	1.02e-05	0.0049	0.2	0.23	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
STAD	cis	rs7131987	0.683	rs7954278	ENSG00000275476.1	RP11-996F15.4	-4.48	1.02e-05	0.0049	-0.26	-0.23	QT interval;	chr12:29306357	chr12:29277397~29277882:-
STAD	cis	rs1707322	0.721	rs10890336	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs11211151	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs12045096	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs4609469	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs12049027	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs10789467	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs10890337	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs3811435	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs9793568	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs11211157	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs11211158	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs6429575	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.685	rs6690926	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs8179402	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs8179296	ENSG00000281133.1	AL355480.3	-4.48	1.02e-05	0.0049	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45580892~45580996:-
STAD	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	4.48	1.02e-05	0.0049	0.33	0.23	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
STAD	cis	rs301901	0.861	rs217797	ENSG00000250155.1	CTD-2353F22.1	-4.48	1.02e-05	0.0049	-0.23	-0.23	Height;	chr5:37318193	chr5:36666214~36725195:-
STAD	cis	rs6832769	1	rs6811520	ENSG00000272969.1	RP11-528I4.2	4.48	1.02e-05	0.0049	0.3	0.23	Personality dimensions;	chr4:55449011	chr4:55547112~55547889:+
STAD	cis	rs891378	1	rs1652333	ENSG00000274245.1	RP11-357P18.2	4.48	1.02e-05	0.0049	0.29	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207297115	chr1:207372559~207373252:+
STAD	cis	rs875971	0.895	rs6460278	ENSG00000224316.1	RP11-479O9.2	-4.48	1.02e-05	0.0049	-0.23	-0.23	Aortic root size;	chr7:66197749	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6460279	ENSG00000224316.1	RP11-479O9.2	-4.48	1.02e-05	0.0049	-0.23	-0.23	Aortic root size;	chr7:66197774	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs28491091	ENSG00000224316.1	RP11-479O9.2	-4.48	1.02e-05	0.0049	-0.23	-0.23	Aortic root size;	chr7:66204077	chr7:65773620~65802067:+
STAD	cis	rs7829975	0.591	rs12677543	ENSG00000173295.6	FAM86B3P	4.48	1.02e-05	0.0049	0.26	0.23	Mood instability;	chr8:8786764	chr8:8228595~8244865:+
STAD	cis	rs6471393	0.964	rs12056877	ENSG00000253848.1	RP11-10N23.5	-4.48	1.02e-05	0.00491	-0.27	-0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93710234	chr8:93741193~93744534:+
STAD	cis	rs9902453	0.845	rs2617865	ENSG00000240074.1	RPL9P30	-4.48	1.02e-05	0.00491	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29722786	chr17:29855759~29856332:+
STAD	cis	rs1876905	0.539	rs240962	ENSG00000271789.1	RP5-1112D6.7	4.48	1.02e-05	0.00491	0.27	0.23	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111297126~111298510:+
STAD	cis	rs1876905	0.539	rs457497	ENSG00000271789.1	RP5-1112D6.7	4.48	1.02e-05	0.00491	0.26	0.23	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111297126~111298510:+
STAD	cis	rs6019512	1	rs6019512	ENSG00000227431.4	CSE1L-AS1	-4.48	1.02e-05	0.00491	-0.23	-0.23	Intelligence (multi-trait analysis);	chr20:48909470	chr20:49040463~49046044:-
STAD	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-4.48	1.02e-05	0.00492	-0.24	-0.23	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
STAD	cis	rs4713118	0.662	rs469228	ENSG00000220721.1	OR1F12	4.48	1.02e-05	0.00492	0.27	0.23	Parkinson's disease;	chr6:28002926	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.54	rs469227	ENSG00000220721.1	OR1F12	4.48	1.02e-05	0.00492	0.27	0.23	Parkinson's disease;	chr6:28002927	chr6:28073316~28074233:+
STAD	cis	rs1799949	1	rs2271574	ENSG00000279602.1	CTD-3014M21.1	4.48	1.02e-05	0.00492	0.29	0.23	Menopause (age at onset);	chr17:43175631	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs33994002	ENSG00000279602.1	CTD-3014M21.1	4.48	1.02e-05	0.00492	0.29	0.23	Menopause (age at onset);	chr17:43176801	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs33920795	ENSG00000279602.1	CTD-3014M21.1	4.48	1.02e-05	0.00492	0.29	0.23	Menopause (age at onset);	chr17:43176993	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs33918839	ENSG00000279602.1	CTD-3014M21.1	4.48	1.02e-05	0.00492	0.29	0.23	Menopause (age at onset);	chr17:43177155	chr17:43360041~43361361:-
STAD	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	4.48	1.02e-05	0.00492	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
STAD	cis	rs9807989	0.839	rs4988958	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102351825	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs10192157	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102351896	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs10206753	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102351902	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.773	rs72823661	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102352256	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.801	rs72823663	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102352278	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.811	rs67088699	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102352291	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.773	rs5010059	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102352366	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.811	rs11688559	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102353453	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs11695627	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102353645	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.801	rs7558339	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102353783	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.811	rs7608638	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102353829	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.811	rs4485584	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102354290	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.811	rs4485585	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102354299	chr2:102438713~102440475:+
STAD	cis	rs9807989	1	rs9807989	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102354740	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs9808453	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102354846	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs4851565	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102355021	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.765	rs9807962	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102355204	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.801	rs4851566	ENSG00000234389.1	AC007278.3	4.48	1.02e-05	0.00492	0.24	0.23	Asthma;	chr2:102356339	chr2:102438713~102440475:+
STAD	cis	rs7829975	0.514	rs2920983	ENSG00000254340.1	RP11-10A14.3	4.48	1.02e-05	0.00492	0.27	0.23	Mood instability;	chr8:8410553	chr8:9141424~9145435:+
STAD	cis	rs7176527	0.796	rs1057946	ENSG00000229212.6	RP11-561C5.4	4.48	1.02e-05	0.00492	0.35	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85205440~85234795:-
STAD	cis	rs1015362	0.503	rs1883708	ENSG00000275784.1	RP5-1125A11.6	-4.48	1.02e-05	0.00492	-0.27	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33989480~33991818:-
STAD	cis	rs2933343	0.679	rs1091938	ENSG00000261159.1	RP11-723O4.9	4.48	1.02e-05	0.00492	0.29	0.23	IgG glycosylation;	chr3:128918182	chr3:128859716~128860526:-
STAD	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-4.48	1.02e-05	0.00492	-0.31	-0.23	Height;	chr20:49283115	chr20:49280319~49280409:+
STAD	cis	rs11846409	1	rs11846409	ENSG00000211972.2	IGHV3-66	4.48	1.03e-05	0.00493	0.24	0.23	Rheumatic heart disease;	chr14:106645692	chr14:106675017~106675544:-
STAD	cis	rs7680126	0.596	rs28441463	ENSG00000250613.1	RP11-136I13.1	4.48	1.03e-05	0.00493	0.25	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10287953	chr4:10410996~10411644:+
STAD	cis	rs919433	1	rs2195510	ENSG00000231621.1	AC013264.2	4.48	1.03e-05	0.00493	0.2	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197296471	chr2:197197991~197199273:+
STAD	cis	rs2921073	0.509	rs2976931	ENSG00000253981.4	ALG1L13P	4.48	1.03e-05	0.00493	0.27	0.23	Parkinson's disease;	chr8:8399807	chr8:8236003~8244667:-
STAD	cis	rs6832769	1	rs10016506	ENSG00000272969.1	RP11-528I4.2	-4.48	1.03e-05	0.00493	-0.29	-0.23	Personality dimensions;	chr4:55530507	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs28790098	ENSG00000272969.1	RP11-528I4.2	-4.48	1.03e-05	0.00493	-0.29	-0.23	Personality dimensions;	chr4:55531942	chr4:55547112~55547889:+
STAD	cis	rs1594829	0.553	rs2046224	ENSG00000228451.3	SDAD1P1	4.48	1.03e-05	0.00493	0.24	0.23	Height;	chr8:26294088	chr8:26379259~26382953:-
STAD	cis	rs1594829	0.553	rs2046226	ENSG00000228451.3	SDAD1P1	4.48	1.03e-05	0.00493	0.24	0.23	Height;	chr8:26294534	chr8:26379259~26382953:-
STAD	cis	rs1594829	0.535	rs1434022	ENSG00000228451.3	SDAD1P1	4.48	1.03e-05	0.00493	0.24	0.23	Height;	chr8:26295706	chr8:26379259~26382953:-
STAD	cis	rs1594829	0.553	rs6996531	ENSG00000228451.3	SDAD1P1	4.48	1.03e-05	0.00493	0.24	0.23	Height;	chr8:26295939	chr8:26379259~26382953:-
STAD	cis	rs1594829	0.553	rs17055108	ENSG00000228451.3	SDAD1P1	4.48	1.03e-05	0.00493	0.24	0.23	Height;	chr8:26303223	chr8:26379259~26382953:-
STAD	cis	rs1594829	0.553	rs11135933	ENSG00000228451.3	SDAD1P1	4.48	1.03e-05	0.00493	0.24	0.23	Height;	chr8:26304848	chr8:26379259~26382953:-
STAD	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-4.48	1.03e-05	0.00493	-0.27	-0.23	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
STAD	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	4.48	1.03e-05	0.00494	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	4.48	1.03e-05	0.00494	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	4.48	1.03e-05	0.00494	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
STAD	cis	rs2503875	0.965	rs2505517	ENSG00000230555.2	RP11-517P14.2	4.48	1.03e-05	0.00494	0.24	0.23	Multiple sclerosis;	chr10:43313076	chr10:43420738~43422100:+
STAD	cis	rs7487075	0.893	rs1471223	ENSG00000257261.4	RP11-96H19.1	-4.48	1.03e-05	0.00494	-0.28	-0.23	Itch intensity from mosquito bite;	chr12:46333987	chr12:46383679~46876159:+
STAD	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-4.48	1.03e-05	0.00494	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-4.48	1.03e-05	0.00494	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
STAD	cis	rs10129255	0.536	rs17113249	ENSG00000211973.2	IGHV1-69	4.48	1.03e-05	0.00494	0.2	0.23	Kawasaki disease;	chr14:106678273	chr14:106714684~106715181:-
STAD	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-4.48	1.03e-05	0.00494	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
STAD	cis	rs1850744	0.826	rs7685513	ENSG00000250268.3	ALG1L14P	4.48	1.03e-05	0.00494	0.51	0.23	Economic and political preferences;	chr4:9726975	chr4:9166297~9170270:-
STAD	cis	rs13413635	0.528	rs6711034	ENSG00000225808.1	DNAJC19P5	-4.48	1.03e-05	0.00494	-0.28	-0.23	Heart rate;	chr2:177813834	chr2:177229191~177229506:-
STAD	cis	rs720475	0.732	rs7784282	ENSG00000244198.4	RP4-545C24.1	-4.48	1.03e-05	0.00494	-0.3	-0.23	Breast cancer;	chr7:144431561	chr7:144194858~144280547:+
STAD	cis	rs62432291	0.681	rs365045	ENSG00000235086.1	FNDC1-IT1	4.48	1.03e-05	0.00494	0.35	0.23	Joint mobility (Beighton score);	chr6:159211218	chr6:159240786~159243329:+
STAD	cis	rs7924176	0.601	rs1874152	ENSG00000236900.1	TIMM9P1	-4.48	1.03e-05	0.00495	-0.25	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74076361	chr10:74344550~74344805:-
STAD	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-4.48	1.03e-05	0.00495	-0.27	-0.23	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
STAD	cis	rs4950322	0.515	rs76327075	ENSG00000278811.3	LINC00624	4.48	1.03e-05	0.00495	0.25	0.23	Protein quantitative trait loci;	chr1:147246319	chr1:147258885~147517875:-
STAD	cis	rs1707322	0.721	rs6665808	ENSG00000281133.1	AL355480.3	-4.48	1.03e-05	0.00495	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45580892~45580996:-
STAD	cis	rs7487075	0.82	rs10880953	ENSG00000257261.4	RP11-96H19.1	4.48	1.03e-05	0.00495	0.29	0.23	Itch intensity from mosquito bite;	chr12:46332086	chr12:46383679~46876159:+
STAD	cis	rs11673344	0.523	rs8108509	ENSG00000267672.1	CTD-2293H3.1	4.48	1.03e-05	0.00495	0.22	0.23	Obesity-related traits;	chr19:37060370	chr19:37091341~37092564:+
STAD	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	4.48	1.03e-05	0.00495	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
STAD	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-4.48	1.03e-05	0.00495	-0.3	-0.23	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
STAD	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-4.48	1.03e-05	0.00495	-0.3	-0.23	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
STAD	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	4.48	1.03e-05	0.00495	0.27	0.23	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
STAD	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	4.48	1.03e-05	0.00495	0.27	0.23	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
STAD	cis	rs6142102	0.923	rs6059586	ENSG00000264616.1	MIR4755	4.48	1.03e-05	0.00495	0.24	0.23	Skin pigmentation;	chr20:33952695	chr20:34049119~34049190:+
STAD	cis	rs13315649	0.525	rs62270822	ENSG00000242551.2	POU5F1P6	-4.48	1.03e-05	0.00496	-0.25	-0.23	Sum eosinophil basophil counts;	chr3:128683677	chr3:128674735~128677005:-
STAD	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	4.48	1.03e-05	0.00496	0.35	0.23	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	4.48	1.03e-05	0.00496	0.35	0.23	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
STAD	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-4.48	1.03e-05	0.00496	-0.38	-0.23	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
STAD	cis	rs2695743	0.592	rs10930809	ENSG00000225808.1	DNAJC19P5	-4.48	1.03e-05	0.00496	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177812559	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.565	rs2886500	ENSG00000225808.1	DNAJC19P5	-4.48	1.03e-05	0.00496	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177812585	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs2365897	ENSG00000225808.1	DNAJC19P5	-4.48	1.03e-05	0.00496	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177812826	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs2365896	ENSG00000225808.1	DNAJC19P5	-4.48	1.03e-05	0.00496	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177812965	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs6739044	ENSG00000225808.1	DNAJC19P5	-4.48	1.03e-05	0.00496	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177813560	chr2:177229191~177229506:-
STAD	cis	rs11169552	0.51	rs10783382	ENSG00000200183.1	RNU6-238P	-4.48	1.03e-05	0.00496	-0.23	-0.23	Colorectal cancer;	chr12:50661167	chr12:50656973~50657078:+
STAD	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-4.48	1.03e-05	0.00496	-0.23	-0.23	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
STAD	cis	rs8062405	1	rs2008514	ENSG00000278665.1	RP11-666O2.4	-4.48	1.03e-05	0.00496	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28599241~28601881:-
STAD	cis	rs6539288	0.677	rs10735418	ENSG00000260329.1	RP11-412D9.4	-4.48	1.04e-05	0.00497	-0.24	-0.23	Total body bone mineral density;	chr12:106949598	chr12:106954029~106955497:-
STAD	cis	rs227275	0.554	rs223359	ENSG00000248971.2	KRT8P46	-4.48	1.04e-05	0.00497	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102728746~102730171:-
STAD	cis	rs858239	0.537	rs2286272	ENSG00000230042.1	AK3P3	-4.48	1.04e-05	0.00497	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23129178~23129841:+
STAD	cis	rs858239	0.537	rs6955115	ENSG00000230042.1	AK3P3	-4.48	1.04e-05	0.00497	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23129178~23129841:+
STAD	cis	rs858239	0.537	rs10279691	ENSG00000230042.1	AK3P3	-4.48	1.04e-05	0.00497	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23129178~23129841:+
STAD	cis	rs1723838	0.826	rs1723844	ENSG00000255928.1	RP11-456I15.2	4.48	1.04e-05	0.00498	0.5	0.23	Obesity-related traits;	chr11:73758532	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs1525751	ENSG00000255928.1	RP11-456I15.2	4.48	1.04e-05	0.00498	0.5	0.23	Obesity-related traits;	chr11:73758816	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs1723842	ENSG00000255928.1	RP11-456I15.2	4.48	1.04e-05	0.00498	0.5	0.23	Obesity-related traits;	chr11:73760340	chr11:73722349~73722694:+
STAD	cis	rs7131987	0.65	rs3782509	ENSG00000275476.1	RP11-996F15.4	-4.48	1.04e-05	0.00498	-0.26	-0.23	QT interval;	chr12:29300845	chr12:29277397~29277882:-
STAD	cis	rs3777722	0.584	rs3777723	ENSG00000265828.1	MIR3939	4.48	1.04e-05	0.00498	0.35	0.23	Spontaneous preterm birth (preterm birth);	chr6:166940213	chr6:166997807~166997912:-
STAD	cis	rs2115630	0.875	rs8039472	ENSG00000275120.1	RP11-182J1.17	-4.47	1.04e-05	0.00498	-0.26	-0.23	P wave terminal force;	chr15:84818413	chr15:84599434~84606463:-
STAD	cis	rs1598856	0.873	rs230510	ENSG00000246560.2	RP11-10L12.4	-4.47	1.04e-05	0.00498	-0.29	-0.23	Primary biliary cholangitis;	chr4:102555009	chr4:102828055~102844075:+
STAD	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
STAD	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.00498	0.29	0.23	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
STAD	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	4.47	1.04e-05	0.00498	0.3	0.23	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
STAD	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	4.47	1.04e-05	0.00498	0.29	0.23	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
STAD	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-4.47	1.04e-05	0.00498	-0.23	-0.23	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
STAD	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	4.47	1.04e-05	0.00499	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	4.47	1.04e-05	0.00499	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
STAD	cis	rs748404	0.697	rs546170	ENSG00000275601.1	AC011330.13	-4.47	1.04e-05	0.00499	-0.24	-0.23	Lung cancer;	chr15:43272651	chr15:43642389~43643023:-
STAD	cis	rs9291683	0.527	rs11727087	ENSG00000250613.1	RP11-136I13.1	-4.47	1.04e-05	0.00499	-0.24	-0.23	Bone mineral density;	chr4:10094396	chr4:10410996~10411644:+
STAD	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	4.47	1.04e-05	0.00499	0.36	0.23	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
STAD	cis	rs7615952	0.611	rs9681518	ENSG00000241346.1	SNRPCP11	4.47	1.04e-05	0.00499	0.41	0.23	Blood pressure (smoking interaction);	chr3:125896287	chr3:125816082~125816286:-
STAD	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	4.47	1.04e-05	0.00499	0.26	0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	4.47	1.04e-05	0.00499	0.26	0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	4.47	1.04e-05	0.00499	0.26	0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
STAD	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-4.47	1.04e-05	0.00499	-0.27	-0.23	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
STAD	cis	rs4780355	0.918	rs243323	ENSG00000262703.1	RP11-485G7.6	4.47	1.04e-05	0.00499	0.22	0.23	Crohn's disease and psoriasis;	chr16:11267345	chr16:11348143~11349321:-
STAD	cis	rs227932	0.764	rs78660981	ENSG00000234286.1	AC006026.13	-4.47	1.04e-05	0.00499	-0.41	-0.23	Schizophrenia;	chr7:23719296	chr7:23680195~23680786:-
STAD	cis	rs919433	1	rs1346649	ENSG00000231621.1	AC013264.2	4.47	1.04e-05	0.00499	0.2	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301393	chr2:197197991~197199273:+
STAD	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-4.47	1.04e-05	0.005	-0.29	-0.23	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
STAD	cis	rs2834288	0.959	rs2834294	ENSG00000237945.6	LINC00649	-4.47	1.04e-05	0.005	-0.3	-0.23	Gut microbiota (bacterial taxa);	chr21:33908326	chr21:33915534~33977691:+
STAD	cis	rs1594829	0.553	rs1564577	ENSG00000228451.3	SDAD1P1	4.47	1.04e-05	0.005	0.24	0.23	Height;	chr8:26307207	chr8:26379259~26382953:-
STAD	cis	rs516805	0.63	rs2606638	ENSG00000279453.1	RP3-425C14.4	-4.47	1.04e-05	0.005	-0.33	-0.23	Lymphocyte counts;	chr6:122102107	chr6:122436789~122439223:-
STAD	cis	rs228614	0.51	rs223472	ENSG00000248971.2	KRT8P46	-4.47	1.04e-05	0.005	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102728746~102730171:-
STAD	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	4.47	1.04e-05	0.005	0.29	0.23	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
STAD	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-4.47	1.04e-05	0.005	-0.25	-0.23	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
STAD	cis	rs6964833	0.554	rs112506907	ENSG00000277072.3	STAG3L2	4.47	1.04e-05	0.005	0.26	0.23	Menarche (age at onset);	chr7:74654407	chr7:74882163~74890610:-
STAD	cis	rs9902453	0.967	rs4994355	ENSG00000240074.1	RPL9P30	-4.47	1.04e-05	0.00501	-0.2	-0.23	Coffee consumption (cups per day);	chr17:30059266	chr17:29855759~29856332:+
STAD	cis	rs1799949	1	rs8176318	ENSG00000236383.6	LINC00854	-4.47	1.05e-05	0.00501	-0.18	-0.23	Menopause (age at onset);	chr17:43045257	chr17:43216941~43305976:-
STAD	cis	rs6430585	0.583	rs3769008	ENSG00000231890.6	DARS-AS1	-4.47	1.05e-05	0.00502	-0.27	-0.23	Corneal structure;	chr2:135828613	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs12373779	ENSG00000231890.6	DARS-AS1	-4.47	1.05e-05	0.00502	-0.27	-0.23	Corneal structure;	chr2:135829270	chr2:135985176~136022593:+
STAD	cis	rs4243830	0.737	rs925745	ENSG00000229519.2	RP11-58A11.2	4.47	1.05e-05	0.00502	0.25	0.23	Body mass index;	chr1:6555630	chr1:6547905~6548619:+
STAD	cis	rs17711722	0.653	rs2460421	ENSG00000273024.4	INTS4P2	4.47	1.05e-05	0.00502	0.23	0.23	Calcium levels;	chr7:66026136	chr7:65647864~65715661:+
STAD	cis	rs7829975	0.681	rs2271342	ENSG00000173295.6	FAM86B3P	4.47	1.05e-05	0.00502	0.26	0.23	Mood instability;	chr8:8786428	chr8:8228595~8244865:+
STAD	cis	rs801193	0.66	rs974239	ENSG00000224316.1	RP11-479O9.2	4.47	1.05e-05	0.00502	0.23	0.23	Aortic root size;	chr7:66748504	chr7:65773620~65802067:+
STAD	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-4.47	1.05e-05	0.00502	-0.24	-0.23	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
STAD	cis	rs8062405	1	rs62037369	ENSG00000278665.1	RP11-666O2.4	4.47	1.05e-05	0.00502	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.965	rs7359397	ENSG00000278665.1	RP11-666O2.4	4.47	1.05e-05	0.00502	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28599241~28601881:-
STAD	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	4.47	1.05e-05	0.00502	0.38	0.23	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
STAD	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-4.47	1.05e-05	0.00503	-0.26	-0.23	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
STAD	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-4.47	1.05e-05	0.00503	-0.24	-0.23	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
STAD	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-4.47	1.05e-05	0.00503	-0.37	-0.23	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
STAD	cis	rs35955747	0.714	rs4820048	ENSG00000236132.1	CTA-440B3.1	4.47	1.05e-05	0.00503	0.25	0.23	Neutrophil count;Sum basophil neutrophil counts;	chr22:31458384	chr22:31816379~31817491:-
STAD	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	4.47	1.05e-05	0.00503	0.24	0.23	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
STAD	cis	rs875971	0.755	rs76288834	ENSG00000224316.1	RP11-479O9.2	-4.47	1.05e-05	0.00503	-0.23	-0.23	Aortic root size;	chr7:66604815	chr7:65773620~65802067:+
STAD	cis	rs4243830	0.579	rs10779794	ENSG00000229519.2	RP11-58A11.2	4.47	1.05e-05	0.00504	0.25	0.23	Body mass index;	chr1:6552591	chr1:6547905~6548619:+
STAD	cis	rs858239	0.669	rs56400441	ENSG00000230042.1	AK3P3	-4.47	1.05e-05	0.00504	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23129178~23129841:+
STAD	cis	rs17630293	0.737	rs295121	ENSG00000201649.1	RNY4P34	4.47	1.05e-05	0.00504	0.32	0.23	Schizophrenia;	chr2:200377212	chr2:200373175~200373269:+
STAD	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	4.47	1.05e-05	0.00505	0.29	0.23	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
STAD	cis	rs763014	0.932	rs2269559	ENSG00000228201.1	AL022341.3	4.47	1.05e-05	0.00505	0.28	0.23	Height;	chr16:632297	chr16:648473~649200:-
STAD	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	4.47	1.05e-05	0.00505	0.42	0.23	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
STAD	cis	rs12908161	1	rs17601029	ENSG00000259295.5	CSPG4P12	4.47	1.05e-05	0.00505	0.33	0.23	Schizophrenia;	chr15:84804478	chr15:85191438~85213905:+
STAD	cis	rs11673344	0.523	rs6510585	ENSG00000267672.1	CTD-2293H3.1	4.47	1.05e-05	0.00505	0.21	0.23	Obesity-related traits;	chr19:37063081	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs17206540	ENSG00000267672.1	CTD-2293H3.1	4.47	1.05e-05	0.00505	0.21	0.23	Obesity-related traits;	chr19:37069009	chr19:37091341~37092564:+
STAD	cis	rs1075265	0.589	rs2542571	ENSG00000235937.1	AC008280.1	4.47	1.05e-05	0.00505	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54029552~54030682:-
STAD	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	4.47	1.05e-05	0.00505	0.26	0.23	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
STAD	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	4.47	1.05e-05	0.00505	0.25	0.23	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
STAD	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-4.47	1.05e-05	0.00505	-0.33	-0.23	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
STAD	cis	rs7078219	0.743	rs7095953	ENSG00000228778.1	RP11-129J12.1	4.47	1.06e-05	0.00505	0.29	0.23	Dental caries;	chr10:99514668	chr10:99527081~99528261:+
STAD	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-4.47	1.06e-05	0.00505	-0.27	-0.23	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
STAD	cis	rs62246343	0.719	rs62246275	ENSG00000214041.4	PGAM1P4	4.47	1.06e-05	0.00505	0.39	0.23	Fibrinogen levels;	chr3:9399496	chr3:9348443~9349192:+
STAD	cis	rs62246343	0.719	rs73115804	ENSG00000214041.4	PGAM1P4	4.47	1.06e-05	0.00505	0.39	0.23	Fibrinogen levels;	chr3:9399858	chr3:9348443~9349192:+
STAD	cis	rs9902453	0.765	rs2259857	ENSG00000240074.1	RPL9P30	-4.47	1.06e-05	0.00505	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29770762	chr17:29855759~29856332:+
STAD	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-4.47	1.06e-05	0.00505	-0.37	-0.23	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
STAD	cis	rs11846409	0.655	rs79296226	ENSG00000211972.2	IGHV3-66	-4.47	1.06e-05	0.00506	-0.24	-0.23	Rheumatic heart disease;	chr14:106650436	chr14:106675017~106675544:-
STAD	cis	rs2337406	1	rs17112416	ENSG00000211972.2	IGHV3-66	-4.47	1.06e-05	0.00506	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106686773	chr14:106675017~106675544:-
STAD	cis	rs11098499	0.954	rs11098526	ENSG00000260091.1	RP11-33B1.4	4.47	1.06e-05	0.00506	0.23	0.23	Corneal astigmatism;	chr4:119469204	chr4:119409333~119410233:+
STAD	cis	rs7487075	0.93	rs12814298	ENSG00000257261.4	RP11-96H19.1	4.47	1.06e-05	0.00506	0.28	0.23	Itch intensity from mosquito bite;	chr12:46443841	chr12:46383679~46876159:+
STAD	cis	rs6471393	0.964	rs2914944	ENSG00000253848.1	RP11-10N23.5	-4.47	1.06e-05	0.00506	-0.27	-0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93711815	chr8:93741193~93744534:+
STAD	cis	rs6471393	0.964	rs2914942	ENSG00000253848.1	RP11-10N23.5	-4.47	1.06e-05	0.00506	-0.27	-0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93714189	chr8:93741193~93744534:+
STAD	cis	rs8062405	1	rs11861174	ENSG00000278665.1	RP11-666O2.4	4.47	1.06e-05	0.00506	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28599241~28601881:-
STAD	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	4.47	1.06e-05	0.00507	0.32	0.23	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
STAD	cis	rs938554	0.612	rs9991278	ENSG00000250613.1	RP11-136I13.1	-4.47	1.06e-05	0.00507	-0.26	-0.23	Blood metabolite levels;	chr4:10001041	chr4:10410996~10411644:+
STAD	cis	rs2692947	0.759	rs11687113	ENSG00000237510.6	AC008268.2	4.47	1.06e-05	0.00507	0.29	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95992840	chr2:95789654~95800166:+
STAD	cis	rs950881	0.867	rs72823641	ENSG00000234389.1	AC007278.3	4.47	1.06e-05	0.00507	0.36	0.23	Allergy;	chr2:102319699	chr2:102438713~102440475:+
STAD	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	4.47	1.06e-05	0.00507	0.29	0.23	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	4.47	1.06e-05	0.00507	0.29	0.23	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
STAD	cis	rs7829975	0.522	rs6601689	ENSG00000173295.6	FAM86B3P	4.47	1.06e-05	0.00507	0.27	0.23	Mood instability;	chr8:8314761	chr8:8228595~8244865:+
STAD	cis	rs801193	0.636	rs2659895	ENSG00000224316.1	RP11-479O9.2	4.47	1.06e-05	0.00507	0.23	0.23	Aortic root size;	chr7:66731484	chr7:65773620~65802067:+
STAD	cis	rs7680126	0.596	rs74778870	ENSG00000250613.1	RP11-136I13.1	4.47	1.06e-05	0.00508	0.25	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10296959	chr4:10410996~10411644:+
STAD	cis	rs11098499	0.863	rs3775843	ENSG00000260091.1	RP11-33B1.4	4.47	1.06e-05	0.00508	0.23	0.23	Corneal astigmatism;	chr4:119506689	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3775844	ENSG00000260091.1	RP11-33B1.4	4.47	1.06e-05	0.00508	0.23	0.23	Corneal astigmatism;	chr4:119506878	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3822190	ENSG00000260091.1	RP11-33B1.4	4.47	1.06e-05	0.00508	0.23	0.23	Corneal astigmatism;	chr4:119506943	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3822191	ENSG00000260091.1	RP11-33B1.4	4.47	1.06e-05	0.00508	0.23	0.23	Corneal astigmatism;	chr4:119506946	chr4:119409333~119410233:+
STAD	cis	rs4713118	0.824	rs9468225	ENSG00000280107.1	AL022393.9	-4.47	1.06e-05	0.00508	-0.32	-0.23	Parkinson's disease;	chr6:27777940	chr6:28170845~28172521:+
STAD	cis	rs1816752	0.875	rs59531061	ENSG00000273628.1	RP11-756A22.7	4.47	1.06e-05	0.00508	0.29	0.23	Obesity-related traits;	chr13:24507297	chr13:24933006~24936796:+
STAD	cis	rs721917	0.565	rs2255601	ENSG00000225484.5	NUTM2B-AS1	-4.47	1.06e-05	0.00508	-0.28	-0.23	Chronic obstructive pulmonary disease;	chr10:79944803	chr10:79663088~79826594:-
STAD	cis	rs3770081	1	rs6750765	ENSG00000273080.1	RP11-301O19.1	-4.47	1.06e-05	0.00508	-0.52	-0.23	Facial emotion recognition (sad faces);	chr2:86073185	chr2:86195590~86196049:+
STAD	cis	rs9733	0.519	rs11587444	ENSG00000274963.1	Metazoa_SRP	4.47	1.06e-05	0.00508	0.21	0.23	Tonsillectomy;	chr1:150750368	chr1:150568971~150569269:-
STAD	cis	rs1707322	0.682	rs28508523	ENSG00000281133.1	AL355480.3	-4.47	1.06e-05	0.00508	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.691	rs11211175	ENSG00000281133.1	AL355480.3	-4.47	1.06e-05	0.00508	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45580892~45580996:-
STAD	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	4.47	1.06e-05	0.00508	0.19	0.23	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
STAD	cis	rs357618	0.897	rs165362	ENSG00000260581.1	CTB-113P19.4	4.47	1.06e-05	0.00509	0.27	0.23	Basophil percentage of white cells;	chr5:151483526	chr5:151652275~151655449:+
STAD	cis	rs763014	0.966	rs15564	ENSG00000228201.1	AL022341.3	4.47	1.06e-05	0.00509	0.27	0.23	Height;	chr16:627854	chr16:648473~649200:-
STAD	cis	rs6547705	0.702	rs4832049	ENSG00000231259.4	AC125232.1	4.47	1.06e-05	0.00509	0.34	0.23	Progressive supranuclear palsy;	chr2:86826596	chr2:87031815~87053069:-
STAD	cis	rs55823223	0.648	rs11867560	ENSG00000267801.1	RP11-552F3.9	4.47	1.06e-05	0.00509	0.33	0.23	Psoriasis;	chr17:75861125	chr17:75876372~75879546:+
STAD	cis	rs1707322	1	rs1622208	ENSG00000281133.1	AL355480.3	4.47	1.07e-05	0.00509	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45580892~45580996:-
STAD	cis	rs5752326	0.717	rs5761545	ENSG00000261188.1	CTA-445C9.14	4.47	1.07e-05	0.00509	0.46	0.23	Ischemic stroke;	chr22:26466806	chr22:26512537~26514568:+
STAD	cis	rs1876905	0.539	rs240969	ENSG00000230177.1	RP5-1112D6.4	4.47	1.07e-05	0.00509	0.26	0.23	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111277932~111278742:+
STAD	cis	rs7429990	0.864	rs6786001	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47718500	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs12495204	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47720540	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7612219	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47739676	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs35148469	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47739873	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs17079785	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47743160	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs6442082	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47743991	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.747	rs6442083	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47744305	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.786	rs13064183	ENSG00000224895.1	VPS26BP1	4.47	1.07e-05	0.0051	0.22	0.23	Educational attainment (years of education);	chr3:47745405	chr3:47960327~47961081:-
STAD	cis	rs938554	0.577	rs7683856	ENSG00000250613.1	RP11-136I13.1	-4.47	1.07e-05	0.0051	-0.26	-0.23	Blood metabolite levels;	chr4:9999323	chr4:10410996~10411644:+
STAD	cis	rs7233060	1	rs7231598	ENSG00000274828.1	RP11-567M16.6	-4.47	1.07e-05	0.0051	-0.35	-0.23	Schizophrenia;	chr18:79630317	chr18:79677287~79679358:-
STAD	cis	rs17507216	0.609	rs1431716	ENSG00000259429.4	UBE2Q2P2	-4.47	1.07e-05	0.0051	-0.37	-0.23	Excessive daytime sleepiness;	chr15:82676180	chr15:82355142~82420075:+
STAD	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-4.47	1.07e-05	0.00511	-0.21	-0.23	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
STAD	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-4.47	1.07e-05	0.00511	-0.27	-0.23	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
STAD	cis	rs12908161	0.959	rs3748376	ENSG00000259295.5	CSPG4P12	4.47	1.07e-05	0.00511	0.33	0.23	Schizophrenia;	chr15:84785121	chr15:85191438~85213905:+
STAD	cis	rs8099594	0.64	rs9949963	ENSG00000266696.1	RP11-30L3.2	4.47	1.07e-05	0.00511	0.23	0.23	Height;	chr18:49410356	chr18:49205912~49208781:+
STAD	cis	rs7615952	0.546	rs2979306	ENSG00000272840.1	RP11-379B18.6	4.47	1.07e-05	0.00511	0.4	0.23	Blood pressure (smoking interaction);	chr3:125593286	chr3:125774714~125797953:+
STAD	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-4.47	1.07e-05	0.00511	-0.23	-0.23	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-4.47	1.07e-05	0.00511	-0.23	-0.23	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-4.47	1.07e-05	0.00511	-0.23	-0.23	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
STAD	cis	rs12908161	0.92	rs35758837	ENSG00000259295.5	CSPG4P12	4.47	1.07e-05	0.00512	0.33	0.23	Schizophrenia;	chr15:84768151	chr15:85191438~85213905:+
STAD	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	-4.47	1.07e-05	0.00512	-0.27	-0.23	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
STAD	cis	rs694739	0.861	rs479552	ENSG00000236935.1	AP003774.1	4.47	1.07e-05	0.00512	0.26	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343211	chr11:64325050~64329504:-
STAD	cis	rs3825942	0.587	rs2304720	ENSG00000261801.4	LOXL1-AS1	4.47	1.07e-05	0.00512	0.32	0.23	Glaucoma (exfoliation);	chr15:73946393	chr15:73908071~73928248:-
STAD	cis	rs6019512	0.625	rs1997852	ENSG00000227431.4	CSE1L-AS1	4.47	1.07e-05	0.00512	0.21	0.23	Intelligence (multi-trait analysis);	chr20:48910022	chr20:49040463~49046044:-
STAD	cis	rs10978777	1	rs12345455	ENSG00000276883.1	AL137852.1	4.47	1.07e-05	0.00512	0.24	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107270217	chr9:107292369~107292456:-
STAD	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-4.47	1.07e-05	0.00512	-0.35	-0.23	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
STAD	cis	rs8012947	0.848	rs1190982	ENSG00000279636.2	LINC00216	-4.47	1.07e-05	0.00513	-0.23	-0.23	Alcohol consumption in current drinkers;	chr14:58349121	chr14:58288033~58289158:+
STAD	cis	rs1005277	0.54	rs2474598	ENSG00000276805.1	RP11-291L22.6	-4.47	1.08e-05	0.00513	-0.25	-0.23	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38451030~38451785:+
STAD	cis	rs9902453	0.845	rs12452201	ENSG00000240074.1	RPL9P30	4.47	1.08e-05	0.00513	0.2	0.23	Coffee consumption (cups per day);	chr17:29887155	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.845	rs58575982	ENSG00000240074.1	RPL9P30	4.47	1.08e-05	0.00513	0.2	0.23	Coffee consumption (cups per day);	chr17:29894758	chr17:29855759~29856332:+
STAD	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-4.47	1.08e-05	0.00513	-0.27	-0.23	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
STAD	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	4.47	1.08e-05	0.00513	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
STAD	cis	rs11338569	1	rs11338569	ENSG00000236896.1	RP11-535C21.3	4.47	1.08e-05	0.00514	0.31	0.23	Mean corpuscular hemoglobin;Red blood cell count;	chr9:98001175	chr9:97986551~97987656:-
STAD	cis	rs11694172	0.826	rs11676950	ENSG00000273456.1	RP11-686O6.2	4.47	1.08e-05	0.00514	0.26	0.23	Cholesterol, total;	chr2:202746217	chr2:202374932~202375604:-
STAD	cis	rs507080	0.883	rs558593	ENSG00000278376.1	RP11-158I9.8	-4.47	1.08e-05	0.00514	-0.24	-0.23	Serum metabolite levels;	chr11:118691811	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs582630	ENSG00000278376.1	RP11-158I9.8	-4.47	1.08e-05	0.00514	-0.24	-0.23	Serum metabolite levels;	chr11:118692090	chr11:118791254~118793137:+
STAD	cis	rs507080	0.883	rs527475	ENSG00000278376.1	RP11-158I9.8	-4.47	1.08e-05	0.00514	-0.24	-0.23	Serum metabolite levels;	chr11:118692530	chr11:118791254~118793137:+
STAD	cis	rs6832769	1	rs3805152	ENSG00000272969.1	RP11-528I4.2	4.47	1.08e-05	0.00515	0.3	0.23	Personality dimensions;	chr4:55493491	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs6824057	ENSG00000272969.1	RP11-528I4.2	4.47	1.08e-05	0.00515	0.3	0.23	Personality dimensions;	chr4:55501111	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs12646078	ENSG00000272969.1	RP11-528I4.2	4.47	1.08e-05	0.00515	0.3	0.23	Personality dimensions;	chr4:55502037	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs6837710	ENSG00000272969.1	RP11-528I4.2	4.47	1.08e-05	0.00515	0.3	0.23	Personality dimensions;	chr4:55508288	chr4:55547112~55547889:+
STAD	cis	rs10129255	0.5	rs4774008	ENSG00000211973.2	IGHV1-69	4.47	1.08e-05	0.00515	0.19	0.23	Kawasaki disease;	chr14:106681273	chr14:106714684~106715181:-
STAD	cis	rs1707322	0.964	rs785516	ENSG00000281133.1	AL355480.3	4.47	1.08e-05	0.00515	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785517	ENSG00000281133.1	AL355480.3	4.47	1.08e-05	0.00515	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785490	ENSG00000281133.1	AL355480.3	4.47	1.08e-05	0.00515	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45580892~45580996:-
STAD	cis	rs237743	1	rs35506374	ENSG00000222365.1	SNORD12B	-4.47	1.08e-05	0.00515	-0.32	-0.23	Height;	chr20:49311346	chr20:49280319~49280409:+
STAD	cis	rs62246343	0.719	rs73130116	ENSG00000214041.4	PGAM1P4	4.47	1.08e-05	0.00515	0.39	0.23	Fibrinogen levels;	chr3:9452827	chr3:9348443~9349192:+
STAD	cis	rs7487075	0.82	rs7135897	ENSG00000257261.4	RP11-96H19.1	-4.47	1.08e-05	0.00515	-0.31	-0.23	Itch intensity from mosquito bite;	chr12:46305119	chr12:46383679~46876159:+
STAD	cis	rs10851478	0.558	rs4389093	ENSG00000259545.2	RP11-325E5.4	-4.47	1.08e-05	0.00516	-0.26	-0.23	Oral cavity cancer;	chr15:49450872	chr15:49177610~49178741:-
STAD	cis	rs507080	0.883	rs12798453	ENSG00000278376.1	RP11-158I9.8	-4.47	1.08e-05	0.00516	-0.24	-0.23	Serum metabolite levels;	chr11:118690701	chr11:118791254~118793137:+
STAD	cis	rs891378	1	rs4844591	ENSG00000274245.1	RP11-357P18.2	-4.47	1.08e-05	0.00516	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207326948	chr1:207372559~207373252:+
STAD	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-4.47	1.08e-05	0.00516	-0.18	-0.23	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
STAD	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-4.47	1.08e-05	0.00516	-0.3	-0.23	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
STAD	cis	rs56114371	0.53	rs9348774	ENSG00000280107.1	AL022393.9	-4.47	1.08e-05	0.00516	-0.33	-0.23	Breast cancer;	chr6:27721151	chr6:28170845~28172521:+
STAD	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	4.47	1.08e-05	0.00516	0.26	0.23	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
STAD	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-4.47	1.08e-05	0.00516	-0.29	-0.23	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
STAD	cis	rs9902453	0.845	rs12601963	ENSG00000240074.1	RPL9P30	4.47	1.08e-05	0.00516	0.2	0.23	Coffee consumption (cups per day);	chr17:29919340	chr17:29855759~29856332:+
STAD	cis	rs4691139	1	rs1914859	ENSG00000248632.1	RP11-366M4.11	4.47	1.08e-05	0.00516	0.22	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164984989	chr4:164968587~164970002:-
STAD	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-4.47	1.08e-05	0.00517	-0.29	-0.23	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
STAD	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	4.47	1.08e-05	0.00517	0.19	0.23	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
STAD	cis	rs11992162	0.56	rs13256329	ENSG00000255495.1	AC145124.2	-4.47	1.08e-05	0.00517	-0.27	-0.23	Monocyte count;	chr8:11924705	chr8:12194467~12196280:+
STAD	cis	rs10435719	0.638	rs67146188	ENSG00000255495.1	AC145124.2	-4.47	1.08e-05	0.00517	-0.27	-0.23	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:12194467~12196280:+
STAD	cis	rs11992162	0.551	rs13268217	ENSG00000255495.1	AC145124.2	-4.47	1.08e-05	0.00517	-0.27	-0.23	Monocyte count;	chr8:11925100	chr8:12194467~12196280:+
STAD	cis	rs11992162	0.573	rs13264994	ENSG00000255495.1	AC145124.2	-4.47	1.08e-05	0.00517	-0.27	-0.23	Monocyte count;	chr8:11925250	chr8:12194467~12196280:+
STAD	cis	rs11992162	0.573	rs13275808	ENSG00000255495.1	AC145124.2	-4.47	1.08e-05	0.00517	-0.27	-0.23	Monocyte count;	chr8:11925306	chr8:12194467~12196280:+
STAD	cis	rs8141529	0.687	rs6005867	ENSG00000272858.1	CTA-292E10.8	-4.47	1.08e-05	0.00517	-0.26	-0.23	Lymphocyte counts;	chr22:28769132	chr22:28814914~28815662:+
STAD	cis	rs9902453	0.74	rs2628189	ENSG00000240074.1	RPL9P30	-4.47	1.08e-05	0.00517	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29761795	chr17:29855759~29856332:+
STAD	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-4.47	1.08e-05	0.00517	-0.23	-0.23	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
STAD	cis	rs858239	0.665	rs6964665	ENSG00000230042.1	AK3P3	-4.46	1.09e-05	0.00517	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23129178~23129841:+
STAD	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	4.46	1.09e-05	0.00517	0.3	0.23	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	4.46	1.09e-05	0.00517	0.3	0.23	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
STAD	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	4.46	1.09e-05	0.00517	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	4.46	1.09e-05	0.00517	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	4.46	1.09e-05	0.00517	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	4.46	1.09e-05	0.00517	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	4.46	1.09e-05	0.00517	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
STAD	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-4.46	1.09e-05	0.00517	-0.24	-0.23	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
STAD	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	4.46	1.09e-05	0.00517	0.24	0.23	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
STAD	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	4.46	1.09e-05	0.00517	0.29	0.23	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	4.46	1.09e-05	0.00517	0.29	0.23	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
STAD	cis	rs4950322	0.57	rs17360443	ENSG00000278811.3	LINC00624	4.46	1.09e-05	0.00517	0.26	0.23	Protein quantitative trait loci;	chr1:147279737	chr1:147258885~147517875:-
STAD	cis	rs6019512	0.625	rs6066908	ENSG00000227431.4	CSE1L-AS1	-4.46	1.09e-05	0.00518	-0.21	-0.23	Intelligence (multi-trait analysis);	chr20:48912414	chr20:49040463~49046044:-
STAD	cis	rs6019512	0.625	rs4810893	ENSG00000227431.4	CSE1L-AS1	-4.46	1.09e-05	0.00518	-0.21	-0.23	Intelligence (multi-trait analysis);	chr20:48912974	chr20:49040463~49046044:-
STAD	cis	rs11098499	0.909	rs1546504	ENSG00000260091.1	RP11-33B1.4	4.46	1.09e-05	0.00518	0.23	0.23	Corneal astigmatism;	chr4:119320024	chr4:119409333~119410233:+
STAD	cis	rs7487075	0.82	rs7315493	ENSG00000257261.4	RP11-96H19.1	4.46	1.09e-05	0.00518	0.31	0.23	Itch intensity from mosquito bite;	chr12:46295644	chr12:46383679~46876159:+
STAD	cis	rs10986311	0.537	rs10818938	ENSG00000227200.1	RP11-121A14.3	-4.46	1.09e-05	0.00518	-0.25	-0.23	Vitiligo;	chr9:124286958	chr9:124262876~124265809:+
STAD	cis	rs6951245	0.882	rs10252404	ENSG00000229043.2	AC091729.9	-4.46	1.09e-05	0.00518	-0.37	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1160374~1165267:+
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000224373.3	IGHV4-59	4.46	1.09e-05	0.00518	0.17	0.23	Kawasaki disease;	chr14:106782288	chr14:106627249~106627825:-
STAD	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-4.46	1.09e-05	0.00518	-0.29	-0.23	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
STAD	cis	rs875971	0.825	rs28480509	ENSG00000224316.1	RP11-479O9.2	-4.46	1.09e-05	0.00518	-0.23	-0.23	Aortic root size;	chr7:66634237	chr7:65773620~65802067:+
STAD	cis	rs4691139	1	rs7692919	ENSG00000248632.1	RP11-366M4.11	4.46	1.09e-05	0.00519	0.22	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981629	chr4:164968587~164970002:-
STAD	cis	rs10744955	0.727	rs2414032	ENSG00000244879.4	GABPB1-AS1	-4.46	1.09e-05	0.00519	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr15:50166464	chr15:50354959~50372202:+
STAD	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-4.46	1.09e-05	0.00519	-0.35	-0.23	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-4.46	1.09e-05	0.00519	-0.35	-0.23	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-4.46	1.09e-05	0.00519	-0.35	-0.23	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
STAD	cis	rs6951245	0.678	rs4724725	ENSG00000229043.2	AC091729.9	-4.46	1.09e-05	0.00519	-0.37	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1175115	chr7:1160374~1165267:+
STAD	cis	rs867371	1	rs13380317	ENSG00000276710.3	CSPG4P8	4.46	1.09e-05	0.00519	0.27	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82459472~82477258:+
STAD	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	4.46	1.09e-05	0.00519	0.35	0.23	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
STAD	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-4.46	1.09e-05	0.00519	-0.31	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
STAD	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-4.46	1.09e-05	0.00519	-0.26	-0.23	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
STAD	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-4.46	1.09e-05	0.00519	-0.26	-0.23	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
STAD	cis	rs7078219	1	rs11190130	ENSG00000228778.1	RP11-129J12.1	-4.46	1.09e-05	0.00519	-0.28	-0.23	Dental caries;	chr10:99515449	chr10:99527081~99528261:+
STAD	cis	rs950881	0.932	rs3771180	ENSG00000234389.1	AC007278.3	4.46	1.09e-05	0.0052	0.32	0.23	Allergy;	chr2:102337157	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs72823646	ENSG00000234389.1	AC007278.3	4.46	1.09e-05	0.0052	0.32	0.23	Allergy;	chr2:102337753	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs13431828	ENSG00000234389.1	AC007278.3	4.46	1.09e-05	0.0052	0.32	0.23	Allergy;	chr2:102338193	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs13408569	ENSG00000234389.1	AC007278.3	4.46	1.09e-05	0.0052	0.32	0.23	Allergy;	chr2:102338596	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs10173081	ENSG00000234389.1	AC007278.3	4.46	1.09e-05	0.0052	0.32	0.23	Allergy;	chr2:102340888	chr2:102438713~102440475:+
STAD	cis	rs1850744	0.826	rs4554078	ENSG00000163612.10	FAM86KP	-4.46	1.09e-05	0.0052	-0.53	-0.23	Economic and political preferences;	chr4:9699920	chr4:9153296~9165451:+
STAD	cis	rs875971	0.929	rs4122249	ENSG00000236529.1	RP13-254B10.1	4.46	1.09e-05	0.0052	0.24	0.23	Aortic root size;	chr7:66455949	chr7:65840212~65840596:+
STAD	cis	rs228614	0.514	rs59550147	ENSG00000248971.2	KRT8P46	-4.46	1.09e-05	0.0052	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102728746~102730171:-
STAD	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	4.46	1.09e-05	0.0052	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
STAD	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	4.46	1.09e-05	0.0052	0.34	0.23	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
STAD	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-4.46	1.09e-05	0.00521	-0.27	-0.23	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
STAD	cis	rs4691139	0.967	rs4588418	ENSG00000248632.1	RP11-366M4.11	4.46	1.09e-05	0.00521	0.22	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981136	chr4:164968587~164970002:-
STAD	cis	rs11722779	0.838	rs4533776	ENSG00000248971.2	KRT8P46	-4.46	1.09e-05	0.00521	-0.24	-0.23	Schizophrenia;	chr4:102912732	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs10028116	ENSG00000248971.2	KRT8P46	-4.46	1.09e-05	0.00521	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102728746~102730171:-
STAD	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	4.46	1.09e-05	0.00521	0.33	0.23	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	4.46	1.09e-05	0.00521	0.33	0.23	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	4.46	1.09e-05	0.00521	0.33	0.23	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	4.46	1.09e-05	0.00521	0.33	0.23	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	4.46	1.09e-05	0.00521	0.33	0.23	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
STAD	cis	rs9438901	0.614	rs2375278	ENSG00000261349.1	RP3-465N24.5	4.46	1.09e-05	0.00521	0.33	0.23	Red cell distribution width;	chr1:25202547	chr1:25266102~25267136:-
STAD	cis	rs728616	0.867	rs17098720	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.09e-05	0.00521	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80080480	chr10:79663088~79826594:-
STAD	cis	rs728616	0.717	rs12414332	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.09e-05	0.00521	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80081199	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs57257258	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.09e-05	0.00521	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80084264	chr10:79663088~79826594:-
STAD	cis	rs728616	1	rs728615	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.09e-05	0.00521	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:79663088~79826594:-
STAD	cis	rs357618	0.897	rs357630	ENSG00000260581.1	CTB-113P19.4	4.46	1.09e-05	0.00521	0.27	0.23	Basophil percentage of white cells;	chr5:151471697	chr5:151652275~151655449:+
STAD	cis	rs1707322	0.717	rs11211161	ENSG00000225447.1	RPS15AP10	4.46	1.1e-05	0.00521	0.19	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45645816~45646197:-
STAD	cis	rs11098499	0.863	rs3822194	ENSG00000260091.1	RP11-33B1.4	4.46	1.1e-05	0.00521	0.23	0.23	Corneal astigmatism;	chr4:119550493	chr4:119409333~119410233:+
STAD	cis	rs227275	0.525	rs3974608	ENSG00000248971.2	KRT8P46	-4.46	1.1e-05	0.00522	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102728746~102730171:-
STAD	cis	rs7412746	0.611	rs111842513	ENSG00000274963.1	Metazoa_SRP	4.46	1.1e-05	0.00522	0.21	0.23	Melanoma;	chr1:150740450	chr1:150568971~150569269:-
STAD	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	4.46	1.1e-05	0.00522	0.34	0.23	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
STAD	cis	rs11098499	0.954	rs12508504	ENSG00000260091.1	RP11-33B1.4	4.46	1.1e-05	0.00522	0.23	0.23	Corneal astigmatism;	chr4:119489452	chr4:119409333~119410233:+
STAD	cis	rs7487075	0.82	rs6582625	ENSG00000272369.1	RP11-446N19.1	4.46	1.1e-05	0.00522	0.31	0.23	Itch intensity from mosquito bite;	chr12:46304534	chr12:46537502~46652550:+
STAD	cis	rs606458	0.92	rs17146121	ENSG00000269038.1	AP001462.6	-4.46	1.1e-05	0.00522	-0.32	-0.23	Urate levels;	chr11:64619054	chr11:64778954~64779405:+
STAD	cis	rs2688608	0.56	rs10128354	ENSG00000272140.2	RP11-574K11.29	4.46	1.1e-05	0.00522	0.21	0.23	Inflammatory bowel disease;	chr10:73710287	chr10:73703735~73713581:-
STAD	cis	rs9646944	0.501	rs11687768	ENSG00000234389.1	AC007278.3	4.46	1.1e-05	0.00523	0.3	0.23	Blood protein levels;	chr2:102409278	chr2:102438713~102440475:+
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000224373.3	IGHV4-59	4.46	1.1e-05	0.00523	0.17	0.23	Kawasaki disease;	chr14:106784065	chr14:106627249~106627825:-
STAD	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-4.46	1.1e-05	0.00523	-0.31	-0.23	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
STAD	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-4.46	1.1e-05	0.00523	-0.31	-0.23	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
STAD	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-4.46	1.1e-05	0.00523	-0.31	-0.23	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
STAD	cis	rs875971	0.862	rs6952182	ENSG00000224316.1	RP11-479O9.2	-4.46	1.1e-05	0.00523	-0.23	-0.23	Aortic root size;	chr7:66218330	chr7:65773620~65802067:+
STAD	cis	rs10792665	0.671	rs3862772	ENSG00000246067.6	RAB30-AS1	4.46	1.1e-05	0.00523	0.22	0.23	Obesity-related traits;	chr11:82960888	chr11:83072066~83106719:+
STAD	cis	rs181553	0.664	rs1965843	ENSG00000266696.1	RP11-30L3.2	4.46	1.1e-05	0.00523	0.22	0.23	Hip circumference adjusted for BMI;	chr18:49155947	chr18:49205912~49208781:+
STAD	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-4.46	1.1e-05	0.00523	-0.27	-0.23	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
STAD	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-4.46	1.1e-05	0.00523	-0.34	-0.23	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
STAD	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-4.46	1.1e-05	0.00524	-0.24	-0.23	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-4.46	1.1e-05	0.00524	-0.24	-0.23	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
STAD	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-4.46	1.1e-05	0.00524	-0.24	-0.23	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
STAD	cis	rs7924176	0.521	rs12415957	ENSG00000213731.2	RAB5CP1	4.46	1.1e-05	0.00524	0.24	0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74423435~74424014:-
STAD	cis	rs2836950	0.545	rs8132424	ENSG00000238141.2	BRWD1-AS1	4.46	1.1e-05	0.00524	0.24	0.23	Menarche (age at onset);	chr21:39212486	chr21:39315707~39323218:+
STAD	cis	rs17507216	0.681	rs28877110	ENSG00000259429.4	UBE2Q2P2	-4.46	1.1e-05	0.00524	-0.37	-0.23	Excessive daytime sleepiness;	chr15:82672111	chr15:82355142~82420075:+
STAD	cis	rs10744955	0.727	rs11637945	ENSG00000244879.4	GABPB1-AS1	-4.46	1.1e-05	0.00524	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr15:50162489	chr15:50354959~50372202:+
STAD	cis	rs10744955	0.727	rs2414030	ENSG00000244879.4	GABPB1-AS1	-4.46	1.1e-05	0.00524	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr15:50164293	chr15:50354959~50372202:+
STAD	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	4.46	1.1e-05	0.00524	0.34	0.23	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	4.46	1.1e-05	0.00524	0.34	0.23	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
STAD	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-4.46	1.1e-05	0.00524	-0.34	-0.23	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
STAD	cis	rs17301013	0.794	rs1793293	ENSG00000227373.4	RP11-160H22.5	-4.46	1.1e-05	0.00524	-0.28	-0.23	Systemic lupus erythematosus;	chr1:174774451	chr1:174115300~174160004:-
STAD	cis	rs9902453	0.808	rs8069669	ENSG00000240074.1	RPL9P30	4.46	1.1e-05	0.00524	0.2	0.23	Coffee consumption (cups per day);	chr17:29912484	chr17:29855759~29856332:+
STAD	cis	rs7665090	0.728	rs228617	ENSG00000230069.3	LRRC37A15P	4.46	1.1e-05	0.00525	0.26	0.23	Primary biliary cholangitis;	chr4:102659631	chr4:102727274~102730721:-
STAD	cis	rs801193	0.591	rs2707839	ENSG00000224316.1	RP11-479O9.2	4.46	1.1e-05	0.00525	0.23	0.23	Aortic root size;	chr7:66728097	chr7:65773620~65802067:+
STAD	cis	rs7078219	0.714	rs888208	ENSG00000228778.1	RP11-129J12.1	-4.46	1.1e-05	0.00525	-0.3	-0.23	Dental caries;	chr10:99536106	chr10:99527081~99528261:+
STAD	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	4.46	1.1e-05	0.00525	0.34	0.23	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	4.46	1.1e-05	0.00525	0.34	0.23	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	4.46	1.1e-05	0.00525	0.34	0.23	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	4.46	1.1e-05	0.00525	0.34	0.23	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
STAD	cis	rs17401966	0.894	rs12141201	ENSG00000199562.1	RNU6-37P	4.46	1.1e-05	0.00525	0.18	0.23	Hepatocellular carcinoma;	chr1:10394657	chr1:10298966~10299072:+
STAD	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-4.46	1.11e-05	0.00525	-0.28	-0.23	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
STAD	cis	rs801193	0.613	rs2659900	ENSG00000224316.1	RP11-479O9.2	4.46	1.11e-05	0.00525	0.23	0.23	Aortic root size;	chr7:66719456	chr7:65773620~65802067:+
STAD	cis	rs10851478	0.872	rs12912703	ENSG00000259545.2	RP11-325E5.4	-4.46	1.11e-05	0.00525	-0.28	-0.23	Oral cavity cancer;	chr15:49576944	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs4775816	ENSG00000259545.2	RP11-325E5.4	-4.46	1.11e-05	0.00525	-0.28	-0.23	Oral cavity cancer;	chr15:49579306	chr15:49177610~49178741:-
STAD	cis	rs7429990	0.694	rs7645846	ENSG00000224895.1	VPS26BP1	4.46	1.11e-05	0.00526	0.22	0.23	Educational attainment (years of education);	chr3:47740829	chr3:47960327~47961081:-
STAD	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	4.46	1.11e-05	0.00526	0.24	0.23	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
STAD	cis	rs4243830	0.737	rs11122085	ENSG00000229519.2	RP11-58A11.2	-4.46	1.11e-05	0.00526	-0.26	-0.23	Body mass index;	chr1:6537801	chr1:6547905~6548619:+
STAD	cis	rs6539288	0.677	rs7315989	ENSG00000260329.1	RP11-412D9.4	-4.46	1.11e-05	0.00526	-0.24	-0.23	Total body bone mineral density;	chr12:106946010	chr12:106954029~106955497:-
STAD	cis	rs6539288	0.641	rs12318060	ENSG00000260329.1	RP11-412D9.4	-4.46	1.11e-05	0.00526	-0.24	-0.23	Total body bone mineral density;	chr12:106946834	chr12:106954029~106955497:-
STAD	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	4.46	1.11e-05	0.00526	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
STAD	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-4.46	1.11e-05	0.00526	-0.36	-0.23	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
STAD	cis	rs9860428	0.526	rs9834840	ENSG00000240057.4	RP11-572M11.4	-4.46	1.11e-05	0.00526	-0.22	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942669	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs6784838	ENSG00000240057.4	RP11-572M11.4	-4.46	1.11e-05	0.00526	-0.22	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112944432	chr3:113019532~113183301:+
STAD	cis	rs1032726	0.753	rs9870335	ENSG00000240057.4	RP11-572M11.4	-4.46	1.11e-05	0.00526	-0.22	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112945570	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs7646849	ENSG00000240057.4	RP11-572M11.4	-4.46	1.11e-05	0.00526	-0.22	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112946451	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.526	rs6438120	ENSG00000240057.4	RP11-572M11.4	-4.46	1.11e-05	0.00526	-0.22	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112947121	chr3:113019532~113183301:+
STAD	cis	rs10510102	0.935	rs11200263	ENSG00000226864.1	ATE1-AS1	4.46	1.11e-05	0.00526	0.38	0.23	Breast cancer;	chr10:121922836	chr10:121928312~121951965:+
STAD	cis	rs7208859	0.673	rs2470251	ENSG00000263603.1	CTD-2349P21.5	-4.46	1.11e-05	0.00527	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.673	rs11652370	ENSG00000263603.1	CTD-2349P21.5	-4.46	1.11e-05	0.00527	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30729469~30731202:+
STAD	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	4.46	1.11e-05	0.00527	0.38	0.23	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs80282360	ENSG00000226261.1	AC064836.3	4.46	1.11e-05	0.00527	0.38	0.23	Urate levels;	chr2:202275121	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	4.46	1.11e-05	0.00527	0.38	0.23	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
STAD	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	4.46	1.11e-05	0.00527	0.33	0.23	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
STAD	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	4.46	1.11e-05	0.00527	0.4	0.23	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
STAD	cis	rs7487075	0.558	rs3847985	ENSG00000272369.1	RP11-446N19.1	4.46	1.11e-05	0.00527	0.28	0.23	Itch intensity from mosquito bite;	chr12:46261504	chr12:46537502~46652550:+
STAD	cis	rs4589258	0.762	rs4360665	ENSG00000280367.1	RP11-121L10.2	-4.46	1.11e-05	0.00528	-0.24	-0.23	Intelligence (multi-trait analysis);	chr11:90676782	chr11:90223153~90226538:+
STAD	cis	rs1598856	1	rs93059	ENSG00000246560.2	RP11-10L12.4	4.46	1.11e-05	0.00528	0.29	0.23	Primary biliary cholangitis;	chr4:102547361	chr4:102828055~102844075:+
STAD	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	4.46	1.11e-05	0.00528	0.28	0.23	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
STAD	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	4.46	1.11e-05	0.00528	0.31	0.23	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
STAD	cis	rs2836974	0.623	rs34240248	ENSG00000238141.2	BRWD1-AS1	-4.46	1.11e-05	0.00528	-0.24	-0.23	Cognitive function;	chr21:39313313	chr21:39315707~39323218:+
STAD	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-4.46	1.11e-05	0.00529	-0.29	-0.23	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
STAD	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-4.46	1.11e-05	0.00529	-0.29	-0.23	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
STAD	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-4.46	1.11e-05	0.00529	-0.35	-0.23	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
STAD	cis	rs7131987	0.621	rs6487805	ENSG00000275476.1	RP11-996F15.4	4.46	1.11e-05	0.00529	0.26	0.23	QT interval;	chr12:29304617	chr12:29277397~29277882:-
STAD	cis	rs7916697	0.626	rs3858146	ENSG00000233590.1	RP11-153K11.3	-4.46	1.11e-05	0.00529	-0.27	-0.23	Optic disc area;	chr10:68253493	chr10:68233251~68242379:-
STAD	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-4.46	1.11e-05	0.00529	-0.27	-0.23	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
STAD	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-4.46	1.12e-05	0.00529	-0.3	-0.23	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
STAD	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.12e-05	0.00529	-0.24	-0.23	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
STAD	cis	rs17401966	0.898	rs11582123	ENSG00000199562.1	RNU6-37P	4.46	1.12e-05	0.00529	0.18	0.23	Hepatocellular carcinoma;	chr1:10243884	chr1:10298966~10299072:+
STAD	cis	rs1528149	0.504	rs1527215	ENSG00000224683.1	RPL36AP29	-4.46	1.12e-05	0.0053	-0.25	-0.23	Sitting height ratio;	chr7:16127184	chr7:16208945~16209265:+
STAD	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-4.46	1.12e-05	0.0053	-0.27	-0.23	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
STAD	cis	rs4407350	0.756	rs6519877	ENSG00000279642.1	RP5-1033E15.3	-4.46	1.12e-05	0.0053	-0.23	-0.23	Intelligence (multi-trait analysis);	chr22:44494312	chr22:44486295~44486914:-
STAD	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	4.46	1.12e-05	0.0053	0.35	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
STAD	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-4.46	1.12e-05	0.0053	-0.27	-0.23	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-4.46	1.12e-05	0.0053	-0.27	-0.23	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-4.46	1.12e-05	0.0053	-0.27	-0.23	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
STAD	cis	rs7078219	0.505	rs4409764	ENSG00000257582.4	LINC01475	-4.46	1.12e-05	0.0053	-0.26	-0.23	Dental caries;	chr10:99524480	chr10:99526350~99531177:-
STAD	cis	rs7078219	0.505	rs4129133	ENSG00000257582.4	LINC01475	-4.46	1.12e-05	0.0053	-0.26	-0.23	Dental caries;	chr10:99524813	chr10:99526350~99531177:-
STAD	cis	rs7078219	0.505	rs4129132	ENSG00000257582.4	LINC01475	-4.46	1.12e-05	0.0053	-0.26	-0.23	Dental caries;	chr10:99524880	chr10:99526350~99531177:-
STAD	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	4.46	1.12e-05	0.00531	0.25	0.23	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
STAD	cis	rs1707322	0.721	rs10890333	ENSG00000281133.1	AL355480.3	-4.46	1.12e-05	0.00531	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45580892~45580996:-
STAD	cis	rs17401966	0.931	rs1555849	ENSG00000199562.1	RNU6-37P	-4.46	1.12e-05	0.00531	-0.18	-0.23	Hepatocellular carcinoma;	chr1:10340544	chr1:10298966~10299072:+
STAD	cis	rs1799949	1	rs11659028	ENSG00000279602.1	CTD-3014M21.1	4.46	1.12e-05	0.00531	0.3	0.23	Menopause (age at onset);	chr17:43043008	chr17:43360041~43361361:-
STAD	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	4.46	1.12e-05	0.00531	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
STAD	cis	rs7924176	0.54	rs61866073	ENSG00000213731.2	RAB5CP1	-4.46	1.12e-05	0.00531	-0.24	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74423435~74424014:-
STAD	cis	rs853679	0.55	rs1225598	ENSG00000220721.1	OR1F12	4.46	1.12e-05	0.00531	0.26	0.23	Depression;	chr6:28193021	chr6:28073316~28074233:+
STAD	cis	rs7671266	0.559	rs7681212	ENSG00000250613.1	RP11-136I13.1	-4.46	1.12e-05	0.00531	-0.26	-0.23	Cardiovascular disease risk factors;	chr4:10357340	chr4:10410996~10411644:+
STAD	cis	rs17826219	0.636	rs12946563	ENSG00000263603.1	CTD-2349P21.5	-4.46	1.12e-05	0.00531	-0.3	-0.23	Body mass index;	chr17:30776148	chr17:30729469~30731202:+
STAD	cis	rs611744	0.507	rs2121900	ENSG00000253754.1	RP11-35G22.1	-4.46	1.12e-05	0.00531	-0.21	-0.23	Dupuytren's disease;	chr8:108321313	chr8:108226200~108227544:+
STAD	cis	rs7680126	0.633	rs74469609	ENSG00000250613.1	RP11-136I13.1	4.46	1.12e-05	0.00532	0.26	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10292800	chr4:10410996~10411644:+
STAD	cis	rs2503875	1	rs2503867	ENSG00000230555.2	RP11-517P14.2	4.46	1.12e-05	0.00532	0.24	0.23	Multiple sclerosis;	chr10:43311090	chr10:43420738~43422100:+
STAD	cis	rs9733	0.65	rs61820165	ENSG00000274963.1	Metazoa_SRP	-4.46	1.12e-05	0.00532	-0.19	-0.23	Tonsillectomy;	chr1:150583511	chr1:150568971~150569269:-
STAD	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.12e-05	0.00532	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
STAD	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-4.46	1.12e-05	0.00533	-0.23	-0.23	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
STAD	cis	rs2980439	0.87	rs2945230	ENSG00000254340.1	RP11-10A14.3	4.46	1.12e-05	0.00533	0.28	0.23	Neuroticism;	chr8:8252414	chr8:9141424~9145435:+
STAD	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	4.46	1.12e-05	0.00533	0.26	0.23	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
STAD	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-4.46	1.12e-05	0.00533	-0.21	-0.23	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
STAD	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	4.46	1.13e-05	0.00534	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	4.46	1.13e-05	0.00534	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
STAD	cis	rs11098499	0.821	rs10032151	ENSG00000260091.1	RP11-33B1.4	4.46	1.13e-05	0.00534	0.23	0.23	Corneal astigmatism;	chr4:119470473	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs10032158	ENSG00000260091.1	RP11-33B1.4	4.46	1.13e-05	0.00534	0.23	0.23	Corneal astigmatism;	chr4:119470477	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs6838814	ENSG00000260091.1	RP11-33B1.4	4.46	1.13e-05	0.00534	0.23	0.23	Corneal astigmatism;	chr4:119471288	chr4:119409333~119410233:+
STAD	cis	rs3785309	0.519	rs7197253	ENSG00000268836.1	LA16c-OS12.2	-4.46	1.13e-05	0.00534	-0.41	-0.23	Immature fraction of reticulocytes;	chr16:226550	chr16:185748~186294:-
STAD	cis	rs9847710	0.967	rs2564934	ENSG00000242142.1	SERBP1P3	4.46	1.13e-05	0.00534	0.22	0.23	Ulcerative colitis;	chr3:52990564	chr3:53064283~53065091:-
STAD	cis	rs7487075	0.893	rs2408508	ENSG00000257261.4	RP11-96H19.1	4.46	1.13e-05	0.00535	0.28	0.23	Itch intensity from mosquito bite;	chr12:46336817	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.828	rs7132228	ENSG00000257261.4	RP11-96H19.1	4.46	1.13e-05	0.00535	0.28	0.23	Itch intensity from mosquito bite;	chr12:46338178	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.893	rs4768116	ENSG00000257261.4	RP11-96H19.1	4.46	1.13e-05	0.00535	0.28	0.23	Itch intensity from mosquito bite;	chr12:46339247	chr12:46383679~46876159:+
STAD	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-4.46	1.13e-05	0.00535	-0.25	-0.23	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
STAD	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-4.46	1.13e-05	0.00535	-0.29	-0.23	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
STAD	cis	rs853679	0.55	rs1233701	ENSG00000220721.1	OR1F12	-4.46	1.13e-05	0.00535	-0.26	-0.23	Depression;	chr6:28200948	chr6:28073316~28074233:+
STAD	cis	rs17301013	0.861	rs7521870	ENSG00000227373.4	RP11-160H22.5	-4.46	1.13e-05	0.00535	-0.28	-0.23	Systemic lupus erythematosus;	chr1:174497239	chr1:174115300~174160004:-
STAD	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-4.46	1.13e-05	0.00535	-0.24	-0.23	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
STAD	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	4.46	1.13e-05	0.00535	0.25	0.23	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
STAD	cis	rs2638953	0.64	rs11049729	ENSG00000247934.4	RP11-967K21.1	4.46	1.13e-05	0.00535	0.27	0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28586694	chr12:28163298~28190738:-
STAD	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-4.46	1.13e-05	0.00535	-0.3	-0.23	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
STAD	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-4.46	1.13e-05	0.00535	-0.23	-0.23	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-4.46	1.13e-05	0.00535	-0.23	-0.23	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
STAD	cis	rs9860428	0.526	rs9870568	ENSG00000240057.4	RP11-572M11.4	-4.46	1.13e-05	0.00535	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112924713	chr3:113019532~113183301:+
STAD	cis	rs516805	0.667	rs2606600	ENSG00000279453.1	RP3-425C14.4	4.46	1.13e-05	0.00535	0.32	0.23	Lymphocyte counts;	chr6:122204398	chr6:122436789~122439223:-
STAD	cis	rs891378	1	rs1429906	ENSG00000274245.1	RP11-357P18.2	-4.46	1.13e-05	0.00535	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207246982	chr1:207372559~207373252:+
STAD	cis	rs10978777	0.96	rs2417776	ENSG00000276883.1	AL137852.1	4.46	1.13e-05	0.00535	0.23	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107254886	chr9:107292369~107292456:-
STAD	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	4.46	1.13e-05	0.00535	0.25	0.23	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
STAD	cis	rs7924176	0.521	rs10824137	ENSG00000213731.2	RAB5CP1	4.46	1.13e-05	0.00536	0.24	0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74423435~74424014:-
STAD	cis	rs12918713	0.793	rs71381165	ENSG00000262636.1	CTD-3088G3.4	4.46	1.13e-05	0.00536	0.48	0.23	Breast cancer;	chr16:10640415	chr16:11380859~11381118:-
STAD	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	4.46	1.13e-05	0.00536	0.24	0.23	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
STAD	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-4.46	1.13e-05	0.00536	-0.29	-0.23	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
STAD	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	4.46	1.13e-05	0.00536	0.23	0.23	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
STAD	cis	rs1348850	0.837	rs4243388	ENSG00000271825.1	RP11-337N6.2	4.46	1.13e-05	0.00536	0.2	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177419876	chr2:177300600~177302006:+
STAD	cis	rs2695743	0.592	rs6720891	ENSG00000225808.1	DNAJC19P5	-4.46	1.13e-05	0.00536	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177817876	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs3821010	ENSG00000225808.1	DNAJC19P5	-4.46	1.13e-05	0.00536	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177817928	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.565	rs6737549	ENSG00000225808.1	DNAJC19P5	-4.46	1.13e-05	0.00536	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177818332	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs4522644	ENSG00000225808.1	DNAJC19P5	-4.46	1.13e-05	0.00536	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177818410	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs2886499	ENSG00000225808.1	DNAJC19P5	-4.46	1.13e-05	0.00536	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177818427	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs4446096	ENSG00000225808.1	DNAJC19P5	-4.46	1.13e-05	0.00536	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177818832	chr2:177229191~177229506:-
STAD	cis	rs1799949	0.773	rs2137990	ENSG00000279602.1	CTD-3014M21.1	-4.46	1.13e-05	0.00536	-0.28	-0.23	Menopause (age at onset);	chr17:43165879	chr17:43360041~43361361:-
STAD	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	4.46	1.13e-05	0.00537	0.24	0.23	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
STAD	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	4.46	1.13e-05	0.00537	0.34	0.23	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
STAD	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	4.46	1.13e-05	0.00537	0.34	0.23	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
STAD	cis	rs7829975	0.623	rs7010753	ENSG00000254340.1	RP11-10A14.3	4.46	1.13e-05	0.00537	0.28	0.23	Mood instability;	chr8:8516446	chr8:9141424~9145435:+
STAD	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-4.46	1.13e-05	0.00537	-0.27	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
STAD	cis	rs9467773	0.572	rs62394558	ENSG00000241549.7	GUSBP2	4.46	1.13e-05	0.00537	0.23	0.23	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26871484~26956554:-
STAD	cis	rs11679564	0.714	rs4389320	ENSG00000252756.1	RNU6-577P	-4.45	1.13e-05	0.00537	-0.26	-0.23	Immature fraction of reticulocytes;	chr2:36945388	chr2:36867398~36867495:-
STAD	cis	rs9291683	0.527	rs3822247	ENSG00000250613.1	RP11-136I13.1	4.45	1.14e-05	0.00537	0.23	0.23	Bone mineral density;	chr4:10093047	chr4:10410996~10411644:+
STAD	cis	rs2337406	1	rs17113257	ENSG00000280411.1	IGHV1-69-2	-4.45	1.14e-05	0.00537	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106679574	chr14:106762092~106762588:-
STAD	cis	rs6921919	0.583	rs4254981	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.525	rs6929825	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs35599905	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs1124131	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs6899389	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs6922374	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs6899603	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs6922429	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs6922169	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.559	rs13210866	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.609	rs36018474	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs13201726	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs2027361	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.00537	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28073316~28074233:+
STAD	cis	rs11676348	0.712	rs12694426	ENSG00000237281.1	CATIP-AS2	4.45	1.14e-05	0.00538	0.23	0.23	Ulcerative colitis;	chr2:218077628	chr2:218326889~218357966:-
STAD	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-4.45	1.14e-05	0.00538	-0.28	-0.23	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
STAD	cis	rs4589258	0.933	rs16923789	ENSG00000280367.1	RP11-121L10.2	-4.45	1.14e-05	0.00538	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90679709	chr11:90223153~90226538:+
STAD	cis	rs9860428	0.844	rs9852286	ENSG00000240057.4	RP11-572M11.4	-4.45	1.14e-05	0.00538	-0.23	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896161	chr3:113019532~113183301:+
STAD	cis	rs2688608	0.653	rs12775558	ENSG00000271816.1	BMS1P4	4.45	1.14e-05	0.00538	0.25	0.23	Inflammatory bowel disease;	chr10:73811110	chr10:73699151~73730487:-
STAD	cis	rs891378	1	rs7548463	ENSG00000274245.1	RP11-357P18.2	-4.45	1.14e-05	0.00539	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329546	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs925130	ENSG00000274245.1	RP11-357P18.2	-4.45	1.14e-05	0.00539	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207330087	chr1:207372559~207373252:+
STAD	cis	rs227275	0.554	rs223357	ENSG00000248971.2	KRT8P46	-4.45	1.14e-05	0.00539	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102728746~102730171:-
STAD	cis	rs7829975	0.514	rs2979139	ENSG00000254340.1	RP11-10A14.3	4.45	1.14e-05	0.00539	0.27	0.23	Mood instability;	chr8:8410803	chr8:9141424~9145435:+
STAD	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	4.45	1.14e-05	0.00539	0.27	0.23	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
STAD	cis	rs9902453	0.817	rs2617881	ENSG00000240074.1	RPL9P30	-4.45	1.14e-05	0.00539	-0.19	-0.23	Coffee consumption (cups per day);	chr17:29736257	chr17:29855759~29856332:+
STAD	cis	rs6832769	0.922	rs60797008	ENSG00000272969.1	RP11-528I4.2	-4.45	1.14e-05	0.00539	-0.3	-0.23	Personality dimensions;	chr4:55522505	chr4:55547112~55547889:+
STAD	cis	rs11846409	0.872	rs74091715	ENSG00000211970.3	IGHV4-61	4.45	1.14e-05	0.00539	0.26	0.23	Rheumatic heart disease;	chr14:106637731	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs74091721	ENSG00000211970.3	IGHV4-61	4.45	1.14e-05	0.00539	0.26	0.23	Rheumatic heart disease;	chr14:106638262	chr14:106639119~106639657:-
STAD	cis	rs2945232	1	rs2945232	ENSG00000253893.2	FAM85B	-4.45	1.14e-05	0.0054	-0.28	-0.23	Schizophrenia;	chr8:8240516	chr8:8167819~8226614:-
STAD	cis	rs11722779	0.935	rs3857200	ENSG00000248971.2	KRT8P46	-4.45	1.14e-05	0.0054	-0.24	-0.23	Schizophrenia;	chr4:103001864	chr4:102728746~102730171:-
STAD	cis	rs4713118	0.616	rs9348789	ENSG00000220721.1	OR1F12	4.45	1.14e-05	0.0054	0.28	0.23	Parkinson's disease;	chr6:28057708	chr6:28073316~28074233:+
STAD	cis	rs9907295	0.818	rs4251702	ENSG00000270894.1	AC015849.13	4.45	1.14e-05	0.0054	0.27	0.23	Fibroblast growth factor basic levels;	chr17:35807933	chr17:35818399~35823713:+
STAD	cis	rs9393777	1	rs9393777	ENSG00000224843.5	LINC00240	4.45	1.14e-05	0.0054	0.4	0.23	Intelligence (multi-trait analysis);	chr6:26974248	chr6:26956992~27023924:+
STAD	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	4.45	1.14e-05	0.00541	0.43	0.23	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
STAD	cis	rs1707322	0.964	rs12067716	ENSG00000281133.1	AL355480.3	-4.45	1.14e-05	0.00541	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45580892~45580996:-
STAD	cis	rs12819124	0.502	rs10875718	ENSG00000258273.1	RP11-370I10.4	-4.45	1.14e-05	0.00541	-0.28	-0.23	Glycated hemoglobin levels;	chr12:48017319	chr12:48333755~48333901:-
STAD	cis	rs2273156	1	rs761506	ENSG00000241052.1	RP11-173D9.1	4.45	1.14e-05	0.00541	0.26	0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34947974	chr14:35144021~35144480:-
STAD	cis	rs2695743	0.592	rs6433697	ENSG00000225808.1	DNAJC19P5	-4.45	1.14e-05	0.00541	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177816720	chr2:177229191~177229506:-
STAD	cis	rs4568518	0.873	rs4535616	ENSG00000279048.1	RP11-511H23.2	4.45	1.14e-05	0.00541	0.21	0.23	Measles;	chr7:17989040	chr7:17940503~17942922:+
STAD	cis	rs9467773	1	rs6930120	ENSG00000243307.2	POM121L6P	4.45	1.14e-05	0.00541	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26896952~26898777:+
STAD	cis	rs1318937	0.679	rs9310471	ENSG00000224660.1	SH3BP5-AS1	4.45	1.15e-05	0.00542	0.23	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15195342	chr3:15254184~15264493:+
STAD	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	4.45	1.15e-05	0.00542	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	4.45	1.15e-05	0.00542	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
STAD	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	4.45	1.15e-05	0.00542	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
STAD	cis	rs11098499	0.954	rs3733520	ENSG00000260091.1	RP11-33B1.4	4.45	1.15e-05	0.00542	0.23	0.23	Corneal astigmatism;	chr4:119502325	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs7664986	ENSG00000260091.1	RP11-33B1.4	4.45	1.15e-05	0.00542	0.23	0.23	Corneal astigmatism;	chr4:119508797	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.818	rs10008791	ENSG00000260091.1	RP11-33B1.4	4.45	1.15e-05	0.00542	0.23	0.23	Corneal astigmatism;	chr4:119510314	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs11736416	ENSG00000260091.1	RP11-33B1.4	4.45	1.15e-05	0.00542	0.23	0.23	Corneal astigmatism;	chr4:119510506	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3775845	ENSG00000260091.1	RP11-33B1.4	4.45	1.15e-05	0.00542	0.23	0.23	Corneal astigmatism;	chr4:119511292	chr4:119409333~119410233:+
STAD	cis	rs2348418	0.733	rs12229219	ENSG00000247934.4	RP11-967K21.1	-4.45	1.15e-05	0.00542	-0.22	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28158414	chr12:28163298~28190738:-
STAD	cis	rs35934224	0.783	rs35554477	ENSG00000232926.1	AC000078.5	4.45	1.15e-05	0.00542	0.31	0.23	Glaucoma (primary open-angle);	chr22:19869038	chr22:19887289~19887970:+
STAD	cis	rs181553	0.664	rs11874831	ENSG00000266696.1	RP11-30L3.2	4.45	1.15e-05	0.00542	0.21	0.23	Hip circumference adjusted for BMI;	chr18:49176221	chr18:49205912~49208781:+
STAD	cis	rs7429990	0.864	rs7637372	ENSG00000224895.1	VPS26BP1	4.45	1.15e-05	0.00542	0.22	0.23	Educational attainment (years of education);	chr3:47750385	chr3:47960327~47961081:-
STAD	cis	rs1707322	1	rs785493	ENSG00000281133.1	AL355480.3	4.45	1.15e-05	0.00542	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.964	rs785496	ENSG00000281133.1	AL355480.3	4.45	1.15e-05	0.00542	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785497	ENSG00000281133.1	AL355480.3	4.45	1.15e-05	0.00542	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45580892~45580996:-
STAD	cis	rs13315649	0.614	rs7609765	ENSG00000242551.2	POU5F1P6	-4.45	1.15e-05	0.00543	-0.25	-0.23	Sum eosinophil basophil counts;	chr3:128688295	chr3:128674735~128677005:-
STAD	cis	rs13315649	0.639	rs7612926	ENSG00000242551.2	POU5F1P6	-4.45	1.15e-05	0.00543	-0.25	-0.23	Sum eosinophil basophil counts;	chr3:128689221	chr3:128674735~128677005:-
STAD	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-4.45	1.15e-05	0.00543	-0.25	-0.23	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
STAD	cis	rs8177876	0.749	rs2549891	ENSG00000261061.1	RP11-303E16.2	4.45	1.15e-05	0.00543	0.37	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81030770~81031485:+
STAD	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.15e-05	0.00544	-0.29	-0.23	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
STAD	cis	rs8177876	0.658	rs75422577	ENSG00000261061.1	RP11-303E16.2	-4.45	1.15e-05	0.00544	-0.39	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81030770~81031485:+
STAD	cis	rs2695743	0.592	rs1946813	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814914	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs10182386	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177815491	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs10169917	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177815505	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs10930810	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177815534	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs10930811	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177815535	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs7595951	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177815727	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs6758543	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177816416	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs13423418	ENSG00000225808.1	DNAJC19P5	-4.45	1.15e-05	0.00544	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177816469	chr2:177229191~177229506:-
STAD	cis	rs801193	0.66	rs2659914	ENSG00000224316.1	RP11-479O9.2	4.45	1.15e-05	0.00544	0.23	0.23	Aortic root size;	chr7:66691927	chr7:65773620~65802067:+
STAD	cis	rs9307551	0.619	rs11736348	ENSG00000250334.4	LINC00989	-4.45	1.15e-05	0.00544	-0.29	-0.23	Refractive error;	chr4:79498711	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.619	rs1561639	ENSG00000250334.4	LINC00989	-4.45	1.15e-05	0.00544	-0.29	-0.23	Refractive error;	chr4:79498986	chr4:79492416~79576460:+
STAD	cis	rs11079159	0.651	rs2287223	ENSG00000263096.1	RP11-515O17.2	4.45	1.15e-05	0.00544	0.28	0.23	QRS duration;	chr17:55315491	chr17:55271504~55273653:-
STAD	cis	rs2337406	1	rs79452530	ENSG00000211972.2	IGHV3-66	4.45	1.15e-05	0.00544	0.26	0.23	Alzheimer's disease (late onset);	chr14:106699992	chr14:106675017~106675544:-
STAD	cis	rs4589258	0.737	rs4753026	ENSG00000280367.1	RP11-121L10.2	-4.45	1.15e-05	0.00544	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90676114	chr11:90223153~90226538:+
STAD	cis	rs4535700	0.501	rs28828764	ENSG00000226278.1	PSPHP1	4.45	1.15e-05	0.00545	0.3	0.23	Macular telangiectasia type 2;	chr7:55920986	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.501	rs2135116	ENSG00000226278.1	PSPHP1	4.45	1.15e-05	0.00545	0.3	0.23	Macular telangiectasia type 2;	chr7:55923451	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.543	rs2174459	ENSG00000226278.1	PSPHP1	4.45	1.15e-05	0.00545	0.3	0.23	Macular telangiectasia type 2;	chr7:55923600	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.504	rs66528253	ENSG00000226278.1	PSPHP1	4.45	1.15e-05	0.00545	0.3	0.23	Macular telangiectasia type 2;	chr7:55929070	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.501	rs11765577	ENSG00000226278.1	PSPHP1	4.45	1.15e-05	0.00545	0.3	0.23	Macular telangiectasia type 2;	chr7:55930245	chr7:55764797~55773288:+
STAD	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-4.45	1.15e-05	0.00545	-0.34	-0.23	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-4.45	1.15e-05	0.00545	-0.34	-0.23	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-4.45	1.15e-05	0.00545	-0.34	-0.23	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-4.45	1.15e-05	0.00545	-0.34	-0.23	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-4.45	1.15e-05	0.00545	-0.34	-0.23	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-4.45	1.15e-05	0.00545	-0.34	-0.23	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
STAD	cis	rs9646944	0.501	rs10210176	ENSG00000234389.1	AC007278.3	-4.45	1.15e-05	0.00545	-0.3	-0.23	Blood protein levels;	chr2:102463056	chr2:102438713~102440475:+
STAD	cis	rs2337406	1	rs11850600	ENSG00000280411.1	IGHV1-69-2	-4.45	1.15e-05	0.00545	-0.29	-0.23	Alzheimer's disease (late onset);	chr14:106670765	chr14:106762092~106762588:-
STAD	cis	rs950881	0.867	rs56179005	ENSG00000234389.1	AC007278.3	4.45	1.15e-05	0.00545	0.31	0.23	Allergy;	chr2:102357868	chr2:102438713~102440475:+
STAD	cis	rs6832769	0.925	rs2412663	ENSG00000272969.1	RP11-528I4.2	-4.45	1.15e-05	0.00545	-0.29	-0.23	Personality dimensions;	chr4:55589649	chr4:55547112~55547889:+
STAD	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-4.45	1.15e-05	0.00545	-0.27	-0.23	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
STAD	cis	rs516805	0.63	rs225087	ENSG00000279453.1	RP3-425C14.4	-4.45	1.15e-05	0.00545	-0.35	-0.23	Lymphocyte counts;	chr6:122277884	chr6:122436789~122439223:-
STAD	cis	rs1876905	0.539	rs240987	ENSG00000271789.1	RP5-1112D6.7	-4.45	1.16e-05	0.00546	-0.26	-0.23	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111297126~111298510:+
STAD	cis	rs11673344	0.523	rs2385415	ENSG00000267672.1	CTD-2293H3.1	4.45	1.16e-05	0.00546	0.21	0.23	Obesity-related traits;	chr19:37035291	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs7246739	ENSG00000267672.1	CTD-2293H3.1	4.45	1.16e-05	0.00546	0.21	0.23	Obesity-related traits;	chr19:37040829	chr19:37091341~37092564:+
STAD	cis	rs7647973	0.516	rs4308307	ENSG00000225399.4	RP11-3B7.1	4.45	1.16e-05	0.00546	0.25	0.23	Menarche (age at onset);	chr3:49155783	chr3:49260085~49261316:+
STAD	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	4.45	1.16e-05	0.00546	0.34	0.23	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
STAD	cis	rs1707322	1	rs785484	ENSG00000281133.1	AL355480.3	4.45	1.16e-05	0.00546	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45580892~45580996:-
STAD	cis	rs4308124	1	rs57874285	ENSG00000227992.1	AC108463.2	-4.45	1.16e-05	0.00547	-0.29	-0.23	Vitiligo;	chr2:111255095	chr2:111203964~111206215:-
STAD	cis	rs4308124	1	rs57707030	ENSG00000227992.1	AC108463.2	-4.45	1.16e-05	0.00547	-0.29	-0.23	Vitiligo;	chr2:111255105	chr2:111203964~111206215:-
STAD	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	4.45	1.16e-05	0.00547	0.35	0.23	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
STAD	cis	rs11098499	0.722	rs10025925	ENSG00000260091.1	RP11-33B1.4	4.45	1.16e-05	0.00547	0.22	0.23	Corneal astigmatism;	chr4:119350589	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.731	rs10015579	ENSG00000260091.1	RP11-33B1.4	4.45	1.16e-05	0.00547	0.22	0.23	Corneal astigmatism;	chr4:119350647	chr4:119409333~119410233:+
STAD	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.16e-05	0.00547	-0.27	-0.23	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
STAD	cis	rs9733	0.596	rs2867300	ENSG00000274963.1	Metazoa_SRP	4.45	1.16e-05	0.00547	0.2	0.23	Tonsillectomy;	chr1:150694514	chr1:150568971~150569269:-
STAD	cis	rs2446066	0.872	rs11170516	ENSG00000257379.1	RP11-793H13.8	4.45	1.16e-05	0.00547	0.39	0.23	Red blood cell count;	chr12:53358908	chr12:53441741~53467528:+
STAD	cis	rs606458	0.687	rs2073797	ENSG00000269038.1	AP001462.6	4.45	1.16e-05	0.00547	0.29	0.23	Urate levels;	chr11:64743578	chr11:64778954~64779405:+
STAD	cis	rs7208859	0.673	rs1347360	ENSG00000263603.1	CTD-2349P21.5	-4.45	1.16e-05	0.00548	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30729469~30731202:+
STAD	cis	rs7674212	0.556	rs223401	ENSG00000248971.2	KRT8P46	-4.45	1.16e-05	0.00548	-0.25	-0.23	Type 2 diabetes;	chr4:102817815	chr4:102728746~102730171:-
STAD	cis	rs853679	0.527	rs707907	ENSG00000220721.1	OR1F12	4.45	1.16e-05	0.00548	0.23	0.23	Depression;	chr6:28323463	chr6:28073316~28074233:+
STAD	cis	rs7615952	0.604	rs9837847	ENSG00000241346.1	SNRPCP11	4.45	1.16e-05	0.00548	0.41	0.23	Blood pressure (smoking interaction);	chr3:125905076	chr3:125816082~125816286:-
STAD	cis	rs11098499	0.863	rs6858592	ENSG00000260091.1	RP11-33B1.4	4.45	1.16e-05	0.00548	0.23	0.23	Corneal astigmatism;	chr4:119537537	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs6849171	ENSG00000260091.1	RP11-33B1.4	4.45	1.16e-05	0.00548	0.23	0.23	Corneal astigmatism;	chr4:119488394	chr4:119409333~119410233:+
STAD	cis	rs9807989	0.839	rs10182710	ENSG00000234389.1	AC007278.3	4.45	1.16e-05	0.00549	0.24	0.23	Asthma;	chr2:102364846	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs13392100	ENSG00000234389.1	AC007278.3	4.45	1.16e-05	0.00549	0.24	0.23	Asthma;	chr2:102365634	chr2:102438713~102440475:+
STAD	cis	rs9860428	0.583	rs1466872	ENSG00000240057.4	RP11-572M11.4	-4.45	1.16e-05	0.00549	-0.22	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112928766	chr3:113019532~113183301:+
STAD	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-4.45	1.16e-05	0.00549	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
STAD	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	4.45	1.17e-05	0.0055	0.33	0.23	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	4.45	1.17e-05	0.0055	0.33	0.23	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	4.45	1.17e-05	0.0055	0.33	0.23	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	4.45	1.17e-05	0.0055	0.33	0.23	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	4.45	1.17e-05	0.0055	0.33	0.23	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
STAD	cis	rs3806843	0.583	rs408652	ENSG00000202111.1	VTRNA1-2	-4.45	1.17e-05	0.0055	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140950428	chr5:140718925~140719013:+
STAD	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	4.45	1.17e-05	0.0055	0.31	0.23	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
STAD	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	4.45	1.17e-05	0.0055	0.31	0.23	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
STAD	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-4.45	1.17e-05	0.0055	-0.21	-0.23	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
STAD	cis	rs8141529	0.584	rs58004020	ENSG00000272858.1	CTA-292E10.8	-4.45	1.17e-05	0.0055	-0.25	-0.23	Lymphocyte counts;	chr22:28861062	chr22:28814914~28815662:+
STAD	cis	rs7074356	0.915	rs1870146	ENSG00000225484.5	NUTM2B-AS1	4.45	1.17e-05	0.0055	0.45	0.23	Borderline personality disorder;	chr10:80450623	chr10:79663088~79826594:-
STAD	cis	rs2933343	0.729	rs813732	ENSG00000261159.1	RP11-723O4.9	4.45	1.17e-05	0.00551	0.29	0.23	IgG glycosylation;	chr3:128900514	chr3:128859716~128860526:-
STAD	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-4.45	1.17e-05	0.00551	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-4.45	1.17e-05	0.00551	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
STAD	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	4.45	1.17e-05	0.00552	0.31	0.23	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
STAD	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-4.45	1.17e-05	0.00552	-0.23	-0.23	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
STAD	cis	rs11009175	0.725	rs4934646	ENSG00000273038.2	RP11-479G22.8	-4.45	1.17e-05	0.00552	-0.35	-0.23	Depression (quantitative trait);	chr10:33007681	chr10:32887255~32889311:-
STAD	cis	rs4589258	0.737	rs11019135	ENSG00000280367.1	RP11-121L10.2	-4.45	1.17e-05	0.00552	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90674132	chr11:90223153~90226538:+
STAD	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-4.45	1.17e-05	0.00552	-0.23	-0.23	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
STAD	cis	rs938554	0.501	rs7671266	ENSG00000250613.1	RP11-136I13.1	4.45	1.17e-05	0.00552	0.27	0.23	Blood metabolite levels;	chr4:10054752	chr4:10410996~10411644:+
STAD	cis	rs6832769	0.925	rs2899037	ENSG00000272969.1	RP11-528I4.2	-4.45	1.17e-05	0.00552	-0.3	-0.23	Personality dimensions;	chr4:55591180	chr4:55547112~55547889:+
STAD	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	4.45	1.17e-05	0.00553	0.31	0.23	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
STAD	cis	rs7487075	0.538	rs1125909	ENSG00000257261.4	RP11-96H19.1	4.45	1.17e-05	0.00553	0.32	0.23	Itch intensity from mosquito bite;	chr12:46392611	chr12:46383679~46876159:+
STAD	cis	rs7829975	0.871	rs777709	ENSG00000173295.6	FAM86B3P	-4.45	1.17e-05	0.00553	-0.26	-0.23	Mood instability;	chr8:8726362	chr8:8228595~8244865:+
STAD	cis	rs891378	0.785	rs1346720	ENSG00000274245.1	RP11-357P18.2	4.45	1.17e-05	0.00553	0.29	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207214421	chr1:207372559~207373252:+
STAD	cis	rs10776614	0.642	rs7896644	ENSG00000189014.7	FAM35DP	-4.45	1.17e-05	0.00553	-0.31	-0.23	Self-employment;	chr10:48556005	chr10:47689707~47730436:+
STAD	cis	rs10510102	0.935	rs11200183	ENSG00000226864.1	ATE1-AS1	4.45	1.17e-05	0.00553	0.38	0.23	Breast cancer;	chr10:121829908	chr10:121928312~121951965:+
STAD	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	4.45	1.17e-05	0.00553	0.28	0.23	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
STAD	cis	rs9463078	0.585	rs56138724	ENSG00000219384.1	RP11-491H9.3	-4.45	1.17e-05	0.00553	-0.22	-0.23	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45080313	chr6:45158870~45159511:+
STAD	cis	rs4589258	1	rs4601725	ENSG00000280367.1	RP11-121L10.2	4.45	1.18e-05	0.00553	0.25	0.23	Intelligence (multi-trait analysis);	chr11:90722898	chr11:90223153~90226538:+
STAD	cis	rs1850744	0.826	rs7659176	ENSG00000250942.1	ENPP7P11	4.45	1.18e-05	0.00553	0.46	0.23	Economic and political preferences;	chr4:9719442	chr4:9677308~9677934:+
STAD	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-4.45	1.18e-05	0.00554	-0.24	-0.23	Height;	chr5:37045739	chr5:36666214~36725195:-
STAD	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-4.45	1.18e-05	0.00554	-0.24	-0.23	Height;	chr5:37046524	chr5:36666214~36725195:-
STAD	cis	rs8062405	0.755	rs1074631	ENSG00000278665.1	RP11-666O2.4	-4.45	1.18e-05	0.00554	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28599241~28601881:-
STAD	cis	rs1850744	0.702	rs7668469	ENSG00000250268.3	ALG1L14P	-4.45	1.18e-05	0.00554	-0.53	-0.23	Economic and political preferences;	chr4:9742906	chr4:9166297~9170270:-
STAD	cis	rs11767557	1	rs11763230	ENSG00000229153.4	EPHA1-AS1	4.45	1.18e-05	0.00554	0.39	0.23	Alzheimer's disease (late onset);	chr7:143411748	chr7:143407813~143523449:+
STAD	cis	rs2446066	0.872	rs10876452	ENSG00000257379.1	RP11-793H13.8	4.45	1.18e-05	0.00554	0.38	0.23	Red blood cell count;	chr12:53420474	chr12:53441741~53467528:+
STAD	cis	rs4950322	0.515	rs12060046	ENSG00000278811.3	LINC00624	4.45	1.18e-05	0.00554	0.25	0.23	Protein quantitative trait loci;	chr1:147249278	chr1:147258885~147517875:-
STAD	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	4.45	1.18e-05	0.00554	0.28	0.23	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
STAD	cis	rs10129255	0.719	rs7156660	ENSG00000224373.3	IGHV4-59	4.45	1.18e-05	0.00555	0.18	0.23	Kawasaki disease;	chr14:106673171	chr14:106627249~106627825:-
STAD	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.18e-05	0.00555	-0.27	-0.23	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
STAD	cis	rs9902453	0.765	rs2127001	ENSG00000240074.1	RPL9P30	-4.45	1.18e-05	0.00555	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29771201	chr17:29855759~29856332:+
STAD	cis	rs3733585	0.605	rs56178126	ENSG00000250613.1	RP11-136I13.1	4.45	1.18e-05	0.00555	0.24	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:10121957	chr4:10410996~10411644:+
STAD	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	4.45	1.18e-05	0.00555	0.29	0.23	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
STAD	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	4.45	1.18e-05	0.00555	0.21	0.23	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
STAD	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-4.45	1.18e-05	0.00555	-0.23	-0.23	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-4.45	1.18e-05	0.00555	-0.23	-0.23	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-4.45	1.18e-05	0.00555	-0.23	-0.23	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
STAD	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	4.45	1.18e-05	0.00556	0.33	0.23	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
STAD	cis	rs8062405	1	rs62036616	ENSG00000278665.1	RP11-666O2.4	4.45	1.18e-05	0.00556	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28599241~28601881:-
STAD	cis	rs76917914	0.954	rs3739672	ENSG00000236896.1	RP11-535C21.3	4.45	1.18e-05	0.00556	0.31	0.23	Immature fraction of reticulocytes;	chr9:97983620	chr9:97986551~97987656:-
STAD	cis	rs2348418	0.702	rs10843116	ENSG00000247934.4	RP11-967K21.1	-4.45	1.18e-05	0.00556	-0.22	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28162248	chr12:28163298~28190738:-
STAD	cis	rs6471393	0.929	rs56108220	ENSG00000253848.1	RP11-10N23.5	4.45	1.18e-05	0.00556	0.27	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93736965	chr8:93741193~93744534:+
STAD	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	4.45	1.18e-05	0.00557	0.24	0.23	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
STAD	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-4.45	1.18e-05	0.00557	-0.25	-0.23	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
STAD	cis	rs1348850	0.831	rs7606235	ENSG00000271825.1	RP11-337N6.2	4.45	1.18e-05	0.00557	0.2	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177536560	chr2:177300600~177302006:+
STAD	cis	rs12935418	0.887	rs3743503	ENSG00000261061.1	RP11-303E16.2	-4.45	1.18e-05	0.00557	-0.34	-0.23	Mean corpuscular volume;	chr16:81022836	chr16:81030770~81031485:+
STAD	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-4.45	1.18e-05	0.00557	-0.25	-0.23	Height;	chr2:231539118	chr2:231508426~231514339:-
STAD	cis	rs6430585	0.591	rs309118	ENSG00000231890.6	DARS-AS1	-4.45	1.19e-05	0.00558	-0.25	-0.23	Corneal structure;	chr2:135988654	chr2:135985176~136022593:+
STAD	cis	rs4243830	0.85	rs932112	ENSG00000229519.2	RP11-58A11.2	4.44	1.19e-05	0.00558	0.25	0.23	Body mass index;	chr1:6531877	chr1:6547905~6548619:+
STAD	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-4.44	1.19e-05	0.00558	-0.26	-0.23	Migraine;	chr4:56880659	chr4:56960927~56961373:-
STAD	cis	rs17401966	0.931	rs11584023	ENSG00000199562.1	RNU6-37P	4.44	1.19e-05	0.00558	0.18	0.23	Hepatocellular carcinoma;	chr1:10242538	chr1:10298966~10299072:+
STAD	cis	rs7487075	0.554	rs12229299	ENSG00000272963.1	OR7A19P	4.44	1.19e-05	0.00558	0.22	0.23	Itch intensity from mosquito bite;	chr12:46691110	chr12:46592573~46593305:+
STAD	cis	rs7617773	1	rs12496784	ENSG00000224895.1	VPS26BP1	4.44	1.19e-05	0.00558	0.23	0.23	Coronary artery disease;	chr3:48144777	chr3:47960327~47961081:-
STAD	cis	rs7665090	1	rs10027437	ENSG00000246560.2	RP11-10L12.4	4.44	1.19e-05	0.00559	0.27	0.23	Primary biliary cholangitis;	chr4:102636094	chr4:102828055~102844075:+
STAD	cis	rs3770081	0.536	rs7562837	ENSG00000273080.1	RP11-301O19.1	-4.44	1.19e-05	0.00559	-0.41	-0.23	Facial emotion recognition (sad faces);	chr2:86079128	chr2:86195590~86196049:+
STAD	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	4.44	1.19e-05	0.00559	0.3	0.23	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
STAD	cis	rs12908161	1	rs11637142	ENSG00000259295.5	CSPG4P12	4.44	1.19e-05	0.00559	0.33	0.23	Schizophrenia;	chr15:84752696	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs12910012	ENSG00000259295.5	CSPG4P12	4.44	1.19e-05	0.00559	0.33	0.23	Schizophrenia;	chr15:84755431	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs12899981	ENSG00000259295.5	CSPG4P12	4.44	1.19e-05	0.00559	0.33	0.23	Schizophrenia;	chr15:84759142	chr15:85191438~85213905:+
STAD	cis	rs35828350	1	rs35828350	ENSG00000259295.5	CSPG4P12	4.44	1.19e-05	0.00559	0.33	0.23	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs56864281	ENSG00000259295.5	CSPG4P12	4.44	1.19e-05	0.00559	0.33	0.23	Schizophrenia;	chr15:84814418	chr15:85191438~85213905:+
STAD	cis	rs8097348	1	rs2160961	ENSG00000266602.1	RP11-476K15.1	-4.44	1.19e-05	0.00559	-0.28	-0.23	Exercise (leisure time);	chr18:1597435	chr18:1509183~1647097:+
STAD	cis	rs1005277	0.579	rs1780116	ENSG00000276805.1	RP11-291L22.6	4.44	1.19e-05	0.00559	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1780121	ENSG00000276805.1	RP11-291L22.6	4.44	1.19e-05	0.00559	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1780122	ENSG00000276805.1	RP11-291L22.6	4.44	1.19e-05	0.00559	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs1780145	ENSG00000276805.1	RP11-291L22.6	4.44	1.19e-05	0.00559	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38451030~38451785:+
STAD	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-4.44	1.19e-05	0.00559	-0.27	-0.23	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-4.44	1.19e-05	0.00559	-0.27	-0.23	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
STAD	cis	rs6921919	0.583	rs7773051	ENSG00000220721.1	OR1F12	4.44	1.19e-05	0.00559	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28073316~28074233:+
STAD	cis	rs34779708	0.868	rs2384352	ENSG00000271335.4	RP11-324I22.4	4.44	1.19e-05	0.00559	0.28	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35314552~35336401:-
STAD	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	4.44	1.19e-05	0.0056	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
STAD	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	4.44	1.19e-05	0.0056	0.33	0.23	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
STAD	cis	rs11673344	0.562	rs7257320	ENSG00000267672.1	CTD-2293H3.1	4.44	1.19e-05	0.0056	0.21	0.23	Obesity-related traits;	chr19:37080933	chr19:37091341~37092564:+
STAD	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	4.44	1.19e-05	0.0056	0.25	0.23	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
STAD	cis	rs10776614	0.642	rs7916108	ENSG00000189014.7	FAM35DP	4.44	1.19e-05	0.0056	0.31	0.23	Self-employment;	chr10:48560067	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.642	rs7894971	ENSG00000189014.7	FAM35DP	4.44	1.19e-05	0.0056	0.31	0.23	Self-employment;	chr10:48560113	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.642	rs4838623	ENSG00000189014.7	FAM35DP	4.44	1.19e-05	0.0056	0.31	0.23	Self-employment;	chr10:48560848	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.642	rs11101384	ENSG00000189014.7	FAM35DP	4.44	1.19e-05	0.0056	0.31	0.23	Self-employment;	chr10:48560968	chr10:47689707~47730436:+
STAD	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-4.44	1.19e-05	0.00561	-0.27	-0.23	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
STAD	cis	rs4604732	0.685	rs4925673	ENSG00000227135.1	GCSAML-AS1	-4.44	1.19e-05	0.00561	-0.29	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473498	chr1:247524679~247526752:-
STAD	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-4.44	1.2e-05	0.00562	-0.29	-0.23	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
STAD	cis	rs875971	0.862	rs6460282	ENSG00000224316.1	RP11-479O9.2	-4.44	1.2e-05	0.00562	-0.23	-0.23	Aortic root size;	chr7:66226259	chr7:65773620~65802067:+
STAD	cis	rs6832769	1	rs9997288	ENSG00000272969.1	RP11-528I4.2	4.44	1.2e-05	0.00562	0.3	0.23	Personality dimensions;	chr4:55481060	chr4:55547112~55547889:+
STAD	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-4.44	1.2e-05	0.00562	-0.27	-0.23	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-4.44	1.2e-05	0.00562	-0.27	-0.23	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
STAD	cis	rs11846409	0.587	rs1806881	ENSG00000211970.3	IGHV4-61	-4.44	1.2e-05	0.00562	-0.26	-0.23	Rheumatic heart disease;	chr14:106650770	chr14:106639119~106639657:-
STAD	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	4.44	1.2e-05	0.00562	0.36	0.23	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
STAD	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	4.44	1.2e-05	0.00562	0.36	0.23	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
STAD	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-4.44	1.2e-05	0.00563	-0.36	-0.23	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
STAD	cis	rs8062405	0.757	rs2411453	ENSG00000278665.1	RP11-666O2.4	-4.44	1.2e-05	0.00563	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28599241~28601881:-
STAD	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-4.44	1.2e-05	0.00563	-0.28	-0.23	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
STAD	cis	rs801193	0.569	rs13242290	ENSG00000224316.1	RP11-479O9.2	-4.44	1.2e-05	0.00563	-0.23	-0.23	Aortic root size;	chr7:66656898	chr7:65773620~65802067:+
STAD	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	4.44	1.2e-05	0.00563	0.26	0.23	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
STAD	cis	rs6095360	0.727	rs111235329	ENSG00000222365.1	SNORD12B	-4.44	1.2e-05	0.00563	-0.32	-0.23	Intelligence (multi-trait analysis);	chr20:48891540	chr20:49280319~49280409:+
STAD	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	4.44	1.2e-05	0.00563	0.27	0.23	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	4.44	1.2e-05	0.00563	0.27	0.23	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
STAD	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-4.44	1.2e-05	0.00563	-0.29	-0.23	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
STAD	cis	rs4869931	0.929	rs4869927	ENSG00000218358.2	RAET1K	4.44	1.2e-05	0.00564	0.37	0.23	Systolic blood pressure in sickle cell anemia;	chr6:150680102	chr6:149998019~150005157:-
STAD	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	4.44	1.2e-05	0.00564	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	4.44	1.2e-05	0.00564	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
STAD	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	4.44	1.2e-05	0.00564	0.34	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
STAD	cis	rs2277027	0.541	rs56168343	ENSG00000251405.2	CTB-109A12.1	4.44	1.2e-05	0.00564	0.32	0.23	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157501000	chr5:157362615~157460078:-
STAD	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-4.44	1.2e-05	0.00564	-0.23	-0.23	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
STAD	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	4.44	1.2e-05	0.00564	0.29	0.23	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
STAD	cis	rs10129255	0.5	rs10143242	ENSG00000224373.3	IGHV4-59	4.44	1.2e-05	0.00564	0.16	0.23	Kawasaki disease;	chr14:106681814	chr14:106627249~106627825:-
STAD	cis	rs11169552	0.51	rs12231317	ENSG00000200183.1	RNU6-238P	-4.44	1.2e-05	0.00564	-0.22	-0.23	Colorectal cancer;	chr12:50647222	chr12:50656973~50657078:+
STAD	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	4.44	1.2e-05	0.00564	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
STAD	cis	rs1528149	0.504	rs10227232	ENSG00000224683.1	RPL36AP29	-4.44	1.2e-05	0.00564	-0.24	-0.23	Sitting height ratio;	chr7:16138475	chr7:16208945~16209265:+
STAD	cis	rs7615952	0.673	rs34209763	ENSG00000241346.1	SNRPCP11	4.44	1.2e-05	0.00565	0.4	0.23	Blood pressure (smoking interaction);	chr3:125880752	chr3:125816082~125816286:-
STAD	cis	rs7615952	0.8	rs35390120	ENSG00000241346.1	SNRPCP11	4.44	1.2e-05	0.00565	0.4	0.23	Blood pressure (smoking interaction);	chr3:125880966	chr3:125816082~125816286:-
STAD	cis	rs12922317	0.589	rs350215	ENSG00000260224.1	UBL5P4	-4.44	1.2e-05	0.00565	-0.24	-0.23	Schizophrenia;	chr16:12057426	chr16:11968508~11968743:-
STAD	cis	rs10073892	0.62	rs36059004	ENSG00000250682.4	LINC00491	-4.44	1.2e-05	0.00565	-0.24	-0.23	Cognitive decline (age-related);	chr5:102608304	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.62	rs57189793	ENSG00000250682.4	LINC00491	-4.44	1.2e-05	0.00565	-0.24	-0.23	Cognitive decline (age-related);	chr5:102608474	chr5:102609156~102671559:-
STAD	cis	rs2836974	0.627	rs9981301	ENSG00000238141.2	BRWD1-AS1	-4.44	1.2e-05	0.00565	-0.24	-0.23	Cognitive function;	chr21:39314152	chr21:39315707~39323218:+
STAD	cis	rs2836974	0.666	rs4624474	ENSG00000238141.2	BRWD1-AS1	-4.44	1.2e-05	0.00565	-0.24	-0.23	Cognitive function;	chr21:39314401	chr21:39315707~39323218:+
STAD	cis	rs8014252	0.803	rs74062743	ENSG00000259158.2	ADAM20P1	-4.44	1.2e-05	0.00565	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70556694	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs74062746	ENSG00000259158.2	ADAM20P1	-4.44	1.2e-05	0.00565	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70558227	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.708	rs74062750	ENSG00000259158.2	ADAM20P1	-4.44	1.2e-05	0.00565	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70559335	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs58092588	ENSG00000259158.2	ADAM20P1	-4.44	1.2e-05	0.00565	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70561961	chr14:70468881~70483756:-
STAD	cis	rs2337406	0.714	rs8022729	ENSG00000280411.1	IGHV1-69-2	4.44	1.2e-05	0.00565	0.25	0.23	Alzheimer's disease (late onset);	chr14:106816928	chr14:106762092~106762588:-
STAD	cis	rs4835473	0.868	rs1822841	ENSG00000249741.2	RP11-673E1.3	-4.44	1.21e-05	0.00565	-0.27	-0.23	Immature fraction of reticulocytes;	chr4:143921485	chr4:143911514~143912053:-
STAD	cis	rs4604732	0.642	rs4472786	ENSG00000227135.1	GCSAML-AS1	-4.44	1.21e-05	0.00565	-0.29	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473216	chr1:247524679~247526752:-
STAD	cis	rs11673344	0.523	rs7245520	ENSG00000267672.1	CTD-2293H3.1	4.44	1.21e-05	0.00566	0.21	0.23	Obesity-related traits;	chr19:37036416	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs7256380	ENSG00000267672.1	CTD-2293H3.1	4.44	1.21e-05	0.00566	0.21	0.23	Obesity-related traits;	chr19:37041178	chr19:37091341~37092564:+
STAD	cis	rs7615952	0.673	rs35955861	ENSG00000239804.1	RP11-379B18.1	4.44	1.21e-05	0.00566	0.43	0.23	Blood pressure (smoking interaction);	chr3:125907358	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.673	rs35001498	ENSG00000239804.1	RP11-379B18.1	4.44	1.21e-05	0.00566	0.43	0.23	Blood pressure (smoking interaction);	chr3:125909801	chr3:125787888~125788146:-
STAD	cis	rs11846409	0.789	rs34917868	ENSG00000211970.3	IGHV4-61	4.44	1.21e-05	0.00566	0.27	0.23	Rheumatic heart disease;	chr14:106618321	chr14:106639119~106639657:-
STAD	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-4.44	1.21e-05	0.00567	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
STAD	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	4.44	1.21e-05	0.00567	0.25	0.23	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
STAD	cis	rs17507216	0.718	rs72751662	ENSG00000255769.6	GOLGA2P10	-4.44	1.21e-05	0.00567	-0.39	-0.23	Excessive daytime sleepiness;	chr15:82594705	chr15:82472993~82513950:-
STAD	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	4.44	1.21e-05	0.00567	0.31	0.23	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
STAD	cis	rs858239	0.614	rs2014816	ENSG00000230042.1	AK3P3	-4.44	1.21e-05	0.00567	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23129178~23129841:+
STAD	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-4.44	1.21e-05	0.00567	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
STAD	cis	rs7313075	0.81	rs71466207	ENSG00000258308.4	RP11-554E23.2	4.44	1.21e-05	0.00568	0.35	0.23	Height;	chr12:102284057	chr12:101954998~101962390:-
STAD	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-4.44	1.21e-05	0.00568	-0.29	-0.23	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
STAD	cis	rs6921919	0.583	rs1054372	ENSG00000220721.1	OR1F12	4.44	1.21e-05	0.00568	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs9468354	ENSG00000220721.1	OR1F12	4.44	1.21e-05	0.00568	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs12697938	ENSG00000220721.1	OR1F12	4.44	1.21e-05	0.00568	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.583	rs13437294	ENSG00000220721.1	OR1F12	4.44	1.21e-05	0.00568	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28073316~28074233:+
STAD	cis	rs6921919	0.609	rs9468357	ENSG00000220721.1	OR1F12	4.44	1.21e-05	0.00568	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28073316~28074233:+
STAD	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-4.44	1.21e-05	0.00568	-0.24	-0.23	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
STAD	cis	rs2980439	0.556	rs2921059	ENSG00000253981.4	ALG1L13P	4.44	1.21e-05	0.00568	0.28	0.23	Neuroticism;	chr8:8460377	chr8:8236003~8244667:-
STAD	cis	rs7131987	0.683	rs3782511	ENSG00000275476.1	RP11-996F15.4	-4.44	1.21e-05	0.00568	-0.26	-0.23	QT interval;	chr12:29343291	chr12:29277397~29277882:-
STAD	cis	rs7131987	0.621	rs57803026	ENSG00000275476.1	RP11-996F15.4	-4.44	1.21e-05	0.00568	-0.26	-0.23	QT interval;	chr12:29344573	chr12:29277397~29277882:-
STAD	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-4.44	1.21e-05	0.00569	-0.32	-0.23	Depression;	chr6:28422360	chr6:28943877~28944537:+
STAD	cis	rs721917	0.525	rs10788338	ENSG00000244733.5	RP11-506M13.3	-4.44	1.21e-05	0.00569	-0.25	-0.23	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79660891~79677996:+
STAD	cis	rs4713118	0.662	rs149961	ENSG00000220721.1	OR1F12	4.44	1.21e-05	0.00569	0.27	0.23	Parkinson's disease;	chr6:28047791	chr6:28073316~28074233:+
STAD	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-4.44	1.21e-05	0.00569	-0.36	-0.23	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-4.44	1.21e-05	0.00569	-0.36	-0.23	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
STAD	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-4.44	1.21e-05	0.00569	-0.36	-0.23	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-4.44	1.21e-05	0.00569	-0.36	-0.23	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-4.44	1.21e-05	0.00569	-0.36	-0.23	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-4.44	1.21e-05	0.00569	-0.36	-0.23	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
STAD	cis	rs2348418	0.966	rs11049694	ENSG00000247934.4	RP11-967K21.1	4.44	1.21e-05	0.00569	0.22	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28527925	chr12:28163298~28190738:-
STAD	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	4.44	1.21e-05	0.00569	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
STAD	cis	rs853679	0.527	rs853683	ENSG00000220721.1	OR1F12	4.44	1.21e-05	0.00569	0.23	0.23	Depression;	chr6:28327262	chr6:28073316~28074233:+
STAD	cis	rs1707322	0.964	rs785483	ENSG00000281133.1	AL355480.3	4.44	1.21e-05	0.00569	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.964	rs796773	ENSG00000281133.1	AL355480.3	4.44	1.21e-05	0.00569	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.896	rs785518	ENSG00000281133.1	AL355480.3	4.44	1.21e-05	0.00569	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785519	ENSG00000281133.1	AL355480.3	4.44	1.21e-05	0.00569	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785486	ENSG00000281133.1	AL355480.3	4.44	1.21e-05	0.00569	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45580892~45580996:-
STAD	cis	rs6714710	0.603	rs11690687	ENSG00000235833.1	AC159540.14	-4.44	1.22e-05	0.00569	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845358	chr2:97523949~97524976:-
STAD	cis	rs2281636	0.723	rs11190195	ENSG00000233690.1	EBAG9P1	-4.44	1.22e-05	0.0057	-0.25	-0.23	Obesity-related traits;	chr10:99626710	chr10:99697407~99697949:-
STAD	cis	rs4950322	0.542	rs56080828	ENSG00000278811.3	LINC00624	4.44	1.22e-05	0.0057	0.26	0.23	Protein quantitative trait loci;	chr1:147183447	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.542	rs28381210	ENSG00000278811.3	LINC00624	4.44	1.22e-05	0.0057	0.26	0.23	Protein quantitative trait loci;	chr1:147201925	chr1:147258885~147517875:-
STAD	cis	rs9902453	0.817	rs2729435	ENSG00000240074.1	RPL9P30	-4.44	1.22e-05	0.0057	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29794514	chr17:29855759~29856332:+
STAD	cis	rs1075265	0.564	rs2111851	ENSG00000233266.1	HMGB1P31	4.44	1.22e-05	0.0057	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53655030	chr2:54051334~54051760:+
STAD	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-4.44	1.22e-05	0.0057	-0.22	-0.23	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
STAD	cis	rs1961102	0.695	rs2570940	ENSG00000253385.1	KB-1254G8.1	4.44	1.22e-05	0.00571	0.25	0.23	QT interval;	chr8:102845088	chr8:102854455~102856075:+
STAD	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-4.44	1.22e-05	0.00571	-0.36	-0.23	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
STAD	cis	rs8014252	0.711	rs58069917	ENSG00000259158.2	ADAM20P1	-4.44	1.22e-05	0.00571	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70576840	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.711	rs59044667	ENSG00000259158.2	ADAM20P1	-4.44	1.22e-05	0.00571	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70576987	chr14:70468881~70483756:-
STAD	cis	rs10744955	0.727	rs57187078	ENSG00000244879.4	GABPB1-AS1	-4.44	1.22e-05	0.00571	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr15:50157016	chr15:50354959~50372202:+
STAD	cis	rs10744955	0.727	rs12913072	ENSG00000244879.4	GABPB1-AS1	-4.44	1.22e-05	0.00571	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr15:50159293	chr15:50354959~50372202:+
STAD	cis	rs11098499	0.863	rs6534139	ENSG00000260091.1	RP11-33B1.4	-4.44	1.22e-05	0.00572	-0.23	-0.23	Corneal astigmatism;	chr4:119528301	chr4:119409333~119410233:+
STAD	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-4.44	1.22e-05	0.00572	-0.24	-0.23	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
STAD	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-4.44	1.22e-05	0.00572	-0.24	-0.23	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
STAD	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	4.44	1.22e-05	0.00572	0.29	0.23	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
STAD	cis	rs9902453	0.791	rs2628166	ENSG00000240074.1	RPL9P30	-4.44	1.22e-05	0.00572	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29786105	chr17:29855759~29856332:+
STAD	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-4.44	1.22e-05	0.00572	-0.24	-0.23	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
STAD	cis	rs6832769	0.961	rs7684810	ENSG00000272969.1	RP11-528I4.2	4.44	1.22e-05	0.00572	0.29	0.23	Personality dimensions;	chr4:55486627	chr4:55547112~55547889:+
STAD	cis	rs17401966	0.931	rs1002076	ENSG00000199562.1	RNU6-37P	4.44	1.22e-05	0.00572	0.19	0.23	Hepatocellular carcinoma;	chr1:10378834	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.931	rs11585794	ENSG00000199562.1	RNU6-37P	4.44	1.22e-05	0.00572	0.19	0.23	Hepatocellular carcinoma;	chr1:10383809	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.931	rs11587854	ENSG00000199562.1	RNU6-37P	4.44	1.22e-05	0.00572	0.19	0.23	Hepatocellular carcinoma;	chr1:10387565	chr1:10298966~10299072:+
STAD	cis	rs12908161	1	rs11638290	ENSG00000259295.5	CSPG4P12	4.44	1.22e-05	0.00572	0.33	0.23	Schizophrenia;	chr15:84684405	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs34028043	ENSG00000259295.5	CSPG4P12	4.44	1.22e-05	0.00572	0.33	0.23	Schizophrenia;	chr15:84688354	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs34784022	ENSG00000259295.5	CSPG4P12	4.44	1.22e-05	0.00572	0.33	0.23	Schizophrenia;	chr15:84688675	chr15:85191438~85213905:+
STAD	cis	rs2439831	0.681	rs484846	ENSG00000275601.1	AC011330.13	-4.44	1.22e-05	0.00573	-0.29	-0.23	Lung cancer in ever smokers;	chr15:43308605	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.681	rs540388	ENSG00000275601.1	AC011330.13	-4.44	1.22e-05	0.00573	-0.29	-0.23	Lung cancer in ever smokers;	chr15:43314296	chr15:43642389~43643023:-
STAD	cis	rs875971	0.862	rs10274883	ENSG00000224316.1	RP11-479O9.2	-4.44	1.22e-05	0.00573	-0.23	-0.23	Aortic root size;	chr7:66651104	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs881285	ENSG00000224316.1	RP11-479O9.2	-4.44	1.22e-05	0.00573	-0.23	-0.23	Aortic root size;	chr7:66654433	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs3846973	ENSG00000224316.1	RP11-479O9.2	-4.44	1.22e-05	0.00573	-0.23	-0.23	Aortic root size;	chr7:66655048	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs2013908	ENSG00000224316.1	RP11-479O9.2	-4.44	1.22e-05	0.00573	-0.23	-0.23	Aortic root size;	chr7:66656082	chr7:65773620~65802067:+
STAD	cis	rs801193	0.548	rs2109297	ENSG00000224316.1	RP11-479O9.2	-4.44	1.22e-05	0.00573	-0.23	-0.23	Aortic root size;	chr7:66657397	chr7:65773620~65802067:+
STAD	cis	rs801193	0.591	rs721717	ENSG00000224316.1	RP11-479O9.2	-4.44	1.22e-05	0.00573	-0.23	-0.23	Aortic root size;	chr7:66665305	chr7:65773620~65802067:+
STAD	cis	rs801193	0.569	rs6951302	ENSG00000224316.1	RP11-479O9.2	-4.44	1.22e-05	0.00573	-0.23	-0.23	Aortic root size;	chr7:66667525	chr7:65773620~65802067:+
STAD	cis	rs7915414	0.531	rs2298037	ENSG00000230338.1	MTND4P19	4.44	1.22e-05	0.00573	0.29	0.23	Clopidogrel active metabolite levels;	chr10:94986321	chr10:94774156~94774633:-
STAD	cis	rs6832769	0.961	rs13138697	ENSG00000272969.1	RP11-528I4.2	4.44	1.23e-05	0.00573	0.3	0.23	Personality dimensions;	chr4:55497142	chr4:55547112~55547889:+
STAD	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-4.44	1.23e-05	0.00573	-0.27	-0.23	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
STAD	cis	rs2638953	0.815	rs11049709	ENSG00000247934.4	RP11-967K21.1	-4.44	1.23e-05	0.00574	-0.27	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28545099	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.782	rs11049710	ENSG00000247934.4	RP11-967K21.1	-4.44	1.23e-05	0.00574	-0.27	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28546231	chr12:28163298~28190738:-
STAD	cis	rs2790457	0.76	rs1265834	ENSG00000254635.4	WAC-AS1	4.44	1.23e-05	0.00574	0.28	0.23	Multiple myeloma;	chr10:28652932	chr10:28522652~28532743:-
STAD	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-4.44	1.23e-05	0.00574	-0.34	-0.23	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
STAD	cis	rs721917	0.565	rs7476563	ENSG00000225484.5	NUTM2B-AS1	-4.44	1.23e-05	0.00574	-0.28	-0.23	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79663088~79826594:-
STAD	cis	rs1723838	0.826	rs1880643	ENSG00000255928.1	RP11-456I15.2	4.44	1.23e-05	0.00574	0.51	0.23	Obesity-related traits;	chr11:73701969	chr11:73722349~73722694:+
STAD	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-4.44	1.23e-05	0.00574	-0.25	-0.23	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
STAD	cis	rs4589258	0.737	rs35972962	ENSG00000280367.1	RP11-121L10.2	4.44	1.23e-05	0.00574	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90723147	chr11:90223153~90226538:+
STAD	cis	rs2749592	0.513	rs1208708	ENSG00000099251.13	HSD17B7P2	4.44	1.23e-05	0.00574	0.26	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38356380~38378505:+
STAD	cis	rs1850744	0.702	rs10805314	ENSG00000163612.10	FAM86KP	-4.44	1.23e-05	0.00575	-0.53	-0.23	Economic and political preferences;	chr4:9701557	chr4:9153296~9165451:+
STAD	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	4.44	1.23e-05	0.00575	0.24	0.23	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
STAD	cis	rs9425766	0.591	rs2049991	ENSG00000227373.4	RP11-160H22.5	4.44	1.23e-05	0.00575	0.28	0.23	Life satisfaction;	chr1:174356428	chr1:174115300~174160004:-
STAD	cis	rs9425766	0.566	rs10912773	ENSG00000227373.4	RP11-160H22.5	4.44	1.23e-05	0.00575	0.28	0.23	Life satisfaction;	chr1:174374567	chr1:174115300~174160004:-
STAD	cis	rs427691	0.625	rs845738	ENSG00000271849.1	CTC-332L22.1	-4.44	1.23e-05	0.00575	-0.38	-0.23	Autism spectrum disorder or schizophrenia;	chr5:109682414	chr5:109687802~109688329:-
STAD	cis	rs4604732	0.642	rs10925047	ENSG00000227135.1	GCSAML-AS1	-4.44	1.23e-05	0.00576	-0.29	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476841	chr1:247524679~247526752:-
STAD	cis	rs748404	0.646	rs2253268	ENSG00000275601.1	AC011330.13	-4.44	1.23e-05	0.00576	-0.25	-0.23	Lung cancer;	chr15:43508770	chr15:43642389~43643023:-
STAD	cis	rs2273156	1	rs17102923	ENSG00000241052.1	RP11-173D9.1	-4.44	1.23e-05	0.00576	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34980633	chr14:35144021~35144480:-
STAD	cis	rs4589258	0.898	rs10501733	ENSG00000280367.1	RP11-121L10.2	-4.44	1.23e-05	0.00576	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90680054	chr11:90223153~90226538:+
STAD	cis	rs1707322	1	rs12403666	ENSG00000281133.1	AL355480.3	-4.44	1.23e-05	0.00576	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45580892~45580996:-
STAD	cis	rs6496667	0.565	rs7162107	ENSG00000259262.1	NDUFA3P4	4.44	1.23e-05	0.00576	0.29	0.23	Rheumatoid arthritis;	chr15:90345814	chr15:90385814~90386063:+
STAD	cis	rs12682352	0.652	rs3789843	ENSG00000173295.6	FAM86B3P	4.44	1.23e-05	0.00577	0.27	0.23	Neuroticism;	chr8:8866747	chr8:8228595~8244865:+
STAD	cis	rs12682352	0.652	rs3827806	ENSG00000173295.6	FAM86B3P	4.44	1.23e-05	0.00577	0.27	0.23	Neuroticism;	chr8:8866766	chr8:8228595~8244865:+
STAD	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-4.44	1.23e-05	0.00577	-0.3	-0.23	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
STAD	cis	rs1707322	1	rs11211200	ENSG00000225447.1	RPS15AP10	4.44	1.23e-05	0.00577	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45645816~45646197:-
STAD	cis	rs5753618	0.539	rs1034588	ENSG00000236132.1	CTA-440B3.1	4.44	1.23e-05	0.00577	0.27	0.23	Colorectal cancer;	chr22:31220315	chr22:31816379~31817491:-
STAD	cis	rs2034088	0.833	rs9748016	ENSG00000280279.1	RP11-1228E12.1	-4.44	1.23e-05	0.00577	-0.26	-0.23	Hip circumference adjusted for BMI;	chr17:507211	chr17:64099~76866:-
STAD	cis	rs5753618	0.509	rs5749224	ENSG00000236132.1	CTA-440B3.1	4.44	1.24e-05	0.00578	0.27	0.23	Colorectal cancer;	chr22:31162563	chr22:31816379~31817491:-
STAD	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	4.44	1.24e-05	0.00578	0.29	0.23	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
STAD	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	4.44	1.24e-05	0.00578	0.29	0.23	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
STAD	cis	rs7989332	0.662	rs9552202	ENSG00000238286.1	SLC35E1P1	4.44	1.24e-05	0.00578	0.28	0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20487830	chr13:20607268~20608131:+
STAD	cis	rs7989332	0.593	rs9315623	ENSG00000238286.1	SLC35E1P1	4.44	1.24e-05	0.00578	0.28	0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20488214	chr13:20607268~20608131:+
STAD	cis	rs8028182	0.636	rs7184046	ENSG00000260269.4	CTD-2323K18.1	-4.44	1.24e-05	0.00578	-0.3	-0.23	Sudden cardiac arrest;	chr15:75573809	chr15:75527150~75601205:-
STAD	cis	rs721917	0.525	rs7903576	ENSG00000244733.5	RP11-506M13.3	-4.44	1.24e-05	0.00578	-0.26	-0.23	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79660891~79677996:+
STAD	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	4.44	1.24e-05	0.00578	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
STAD	cis	rs950169	0.922	rs11633534	ENSG00000259295.5	CSPG4P12	4.44	1.24e-05	0.00578	0.34	0.23	Schizophrenia;	chr15:84581411	chr15:85191438~85213905:+
STAD	cis	rs950169	0.65	rs12902052	ENSG00000259295.5	CSPG4P12	4.44	1.24e-05	0.00578	0.34	0.23	Schizophrenia;	chr15:84582607	chr15:85191438~85213905:+
STAD	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	4.44	1.24e-05	0.00578	0.24	0.23	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
STAD	cis	rs10776614	0.642	rs2120910	ENSG00000189014.7	FAM35DP	-4.44	1.24e-05	0.00578	-0.3	-0.23	Self-employment;	chr10:48560387	chr10:47689707~47730436:+
STAD	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-4.43	1.24e-05	0.00579	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
STAD	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-4.43	1.24e-05	0.00579	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
STAD	cis	rs7487075	0.558	rs12580460	ENSG00000272369.1	RP11-446N19.1	4.43	1.24e-05	0.00579	0.28	0.23	Itch intensity from mosquito bite;	chr12:46255200	chr12:46537502~46652550:+
STAD	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-4.43	1.24e-05	0.00579	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
STAD	cis	rs7916697	0.52	rs4745957	ENSG00000233590.1	RP11-153K11.3	4.43	1.24e-05	0.00579	0.27	0.23	Optic disc area;	chr10:68284945	chr10:68233251~68242379:-
STAD	cis	rs11676348	0.71	rs11894169	ENSG00000237281.1	CATIP-AS2	-4.43	1.24e-05	0.00579	-0.24	-0.23	Ulcerative colitis;	chr2:218182123	chr2:218326889~218357966:-
STAD	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-4.43	1.24e-05	0.00579	-0.27	-0.23	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-4.43	1.24e-05	0.00579	-0.27	-0.23	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
STAD	cis	rs10073892	0.66	rs10515327	ENSG00000250682.4	LINC00491	-4.43	1.24e-05	0.00579	-0.25	-0.23	Cognitive decline (age-related);	chr5:102627812	chr5:102609156~102671559:-
STAD	cis	rs1816752	0.716	rs7995304	ENSG00000273628.1	RP11-756A22.7	-4.43	1.24e-05	0.00579	-0.28	-0.23	Obesity-related traits;	chr13:24514284	chr13:24933006~24936796:+
STAD	cis	rs2638953	0.853	rs10843178	ENSG00000247934.4	RP11-967K21.1	-4.43	1.24e-05	0.00579	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460501	chr12:28163298~28190738:-
STAD	cis	rs357618	1	rs357618	ENSG00000260581.1	CTB-113P19.4	4.43	1.24e-05	0.00579	0.27	0.23	Basophil percentage of white cells;	chr5:151467051	chr5:151652275~151655449:+
STAD	cis	rs11676348	0.783	rs13035513	ENSG00000237281.1	CATIP-AS2	4.43	1.24e-05	0.0058	0.23	0.23	Ulcerative colitis;	chr2:218095957	chr2:218326889~218357966:-
STAD	cis	rs11098499	0.863	rs1383532	ENSG00000260091.1	RP11-33B1.4	-4.43	1.25e-05	0.00581	-0.23	-0.23	Corneal astigmatism;	chr4:119513249	chr4:119409333~119410233:+
STAD	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-4.43	1.25e-05	0.00582	-0.23	-0.23	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
STAD	cis	rs9990333	0.544	rs112577972	ENSG00000252174.1	RNU7-18P	-4.43	1.25e-05	0.00582	-0.26	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:196072819~196072880:+
STAD	cis	rs4713118	0.662	rs149969	ENSG00000220721.1	OR1F12	4.43	1.25e-05	0.00582	0.26	0.23	Parkinson's disease;	chr6:28009959	chr6:28073316~28074233:+
STAD	cis	rs2337406	0.587	rs10150642	ENSG00000211972.2	IGHV3-66	-4.43	1.25e-05	0.00582	-0.23	-0.23	Alzheimer's disease (late onset);	chr14:106647269	chr14:106675017~106675544:-
STAD	cis	rs17401966	0.838	rs55676616	ENSG00000199562.1	RNU6-37P	4.43	1.25e-05	0.00582	0.18	0.23	Hepatocellular carcinoma;	chr1:10230068	chr1:10298966~10299072:+
STAD	cis	rs11846409	0.872	rs2956482	ENSG00000211972.2	IGHV3-66	-4.43	1.25e-05	0.00582	-0.24	-0.23	Rheumatic heart disease;	chr14:106630013	chr14:106675017~106675544:-
STAD	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-4.43	1.25e-05	0.00583	-0.25	-0.23	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
STAD	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-4.43	1.25e-05	0.00583	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
STAD	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	4.43	1.25e-05	0.00583	0.28	0.23	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
STAD	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	4.43	1.25e-05	0.00583	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
STAD	cis	rs1723838	1	rs1723838	ENSG00000255928.1	RP11-456I15.2	4.43	1.25e-05	0.00583	0.48	0.23	Obesity-related traits;	chr11:73766000	chr11:73722349~73722694:+
STAD	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	4.43	1.25e-05	0.00583	0.31	0.23	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
STAD	cis	rs7615952	0.611	rs35321002	ENSG00000241346.1	SNRPCP11	4.43	1.25e-05	0.00583	0.4	0.23	Blood pressure (smoking interaction);	chr3:125893222	chr3:125816082~125816286:-
STAD	cis	rs950169	0.881	rs72750843	ENSG00000259295.5	CSPG4P12	4.43	1.25e-05	0.00583	0.34	0.23	Schizophrenia;	chr15:84592552	chr15:85191438~85213905:+
STAD	cis	rs7829975	0.846	rs11779061	ENSG00000253981.4	ALG1L13P	-4.43	1.25e-05	0.00584	-0.29	-0.23	Mood instability;	chr8:8691922	chr8:8236003~8244667:-
STAD	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	4.43	1.25e-05	0.00584	0.25	0.23	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
STAD	cis	rs989978	1	rs7903634	ENSG00000228778.1	RP11-129J12.1	-4.43	1.25e-05	0.00584	-0.28	-0.23	Red blood cell count;	chr10:99562437	chr10:99527081~99528261:+
STAD	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	4.43	1.25e-05	0.00584	0.29	0.23	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
STAD	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-4.43	1.25e-05	0.00584	-0.26	-0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
STAD	cis	rs10073892	0.66	rs7723461	ENSG00000250682.4	LINC00491	-4.43	1.25e-05	0.00584	-0.24	-0.23	Cognitive decline (age-related);	chr5:102609089	chr5:102609156~102671559:-
STAD	cis	rs4243830	0.737	rs4908909	ENSG00000229519.2	RP11-58A11.2	4.43	1.25e-05	0.00584	0.25	0.23	Body mass index;	chr1:6538981	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.85	rs4908910	ENSG00000229519.2	RP11-58A11.2	4.43	1.25e-05	0.00584	0.25	0.23	Body mass index;	chr1:6539302	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.85	rs4908911	ENSG00000229519.2	RP11-58A11.2	4.43	1.25e-05	0.00584	0.25	0.23	Body mass index;	chr1:6539463	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.85	rs10779787	ENSG00000229519.2	RP11-58A11.2	4.43	1.25e-05	0.00584	0.25	0.23	Body mass index;	chr1:6539695	chr1:6547905~6548619:+
STAD	cis	rs4243830	0.737	rs11122088	ENSG00000229519.2	RP11-58A11.2	4.43	1.25e-05	0.00584	0.25	0.23	Body mass index;	chr1:6543617	chr1:6547905~6548619:+
STAD	cis	rs7924176	0.521	rs11000959	ENSG00000213731.2	RAB5CP1	-4.43	1.25e-05	0.00585	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74287053	chr10:74423435~74424014:-
STAD	cis	rs11676348	0.774	rs4672870	ENSG00000237281.1	CATIP-AS2	4.43	1.25e-05	0.00585	0.23	0.23	Ulcerative colitis;	chr2:218077193	chr2:218326889~218357966:-
STAD	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	4.43	1.25e-05	0.00585	0.28	0.23	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
STAD	cis	rs7826238	0.566	rs2945886	ENSG00000254340.1	RP11-10A14.3	4.43	1.26e-05	0.00585	0.27	0.23	Systolic blood pressure;	chr8:8290748	chr8:9141424~9145435:+
STAD	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	4.43	1.26e-05	0.00586	0.26	0.23	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
STAD	cis	rs9902453	0.845	rs2259855	ENSG00000240074.1	RPL9P30	-4.43	1.26e-05	0.00586	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29770842	chr17:29855759~29856332:+
STAD	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	4.43	1.26e-05	0.00586	0.21	0.23	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
STAD	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	4.43	1.26e-05	0.00586	0.26	0.23	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
STAD	cis	rs6019512	0.625	rs6012556	ENSG00000227431.4	CSE1L-AS1	-4.43	1.26e-05	0.00586	-0.21	-0.23	Intelligence (multi-trait analysis);	chr20:48911906	chr20:49040463~49046044:-
STAD	cis	rs2739330	0.828	rs4822454	ENSG00000272787.1	KB-226F1.2	-4.43	1.26e-05	0.00586	-0.24	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23969211~23969873:+
STAD	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	4.43	1.26e-05	0.00586	0.33	0.23	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
STAD	cis	rs9467773	0.967	rs7753565	ENSG00000243307.2	POM121L6P	4.43	1.26e-05	0.00586	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6940188	ENSG00000243307.2	POM121L6P	4.43	1.26e-05	0.00586	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6940053	ENSG00000243307.2	POM121L6P	4.43	1.26e-05	0.00586	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26896952~26898777:+
STAD	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	4.43	1.26e-05	0.00586	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
STAD	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-4.43	1.26e-05	0.00586	-0.23	-0.23	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
STAD	cis	rs4589258	0.933	rs1783791	ENSG00000280367.1	RP11-121L10.2	-4.43	1.26e-05	0.00586	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90706408	chr11:90223153~90226538:+
STAD	cis	rs9902453	0.817	rs55974138	ENSG00000240074.1	RPL9P30	4.43	1.26e-05	0.00587	0.2	0.23	Coffee consumption (cups per day);	chr17:29888528	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.845	rs2321493	ENSG00000240074.1	RPL9P30	4.43	1.26e-05	0.00587	0.2	0.23	Coffee consumption (cups per day);	chr17:29903341	chr17:29855759~29856332:+
STAD	cis	rs875971	0.965	rs10267430	ENSG00000236529.1	RP13-254B10.1	-4.43	1.26e-05	0.00587	-0.24	-0.23	Aortic root size;	chr7:66278036	chr7:65840212~65840596:+
STAD	cis	rs875971	1	rs10257427	ENSG00000236529.1	RP13-254B10.1	-4.43	1.26e-05	0.00587	-0.24	-0.23	Aortic root size;	chr7:66278221	chr7:65840212~65840596:+
STAD	cis	rs875971	0.964	rs55748098	ENSG00000236529.1	RP13-254B10.1	-4.43	1.26e-05	0.00587	-0.24	-0.23	Aortic root size;	chr7:66298631	chr7:65840212~65840596:+
STAD	cis	rs1707322	0.752	rs4660880	ENSG00000225447.1	RPS15AP10	4.43	1.26e-05	0.00587	0.19	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45645816~45646197:-
STAD	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	4.43	1.26e-05	0.00588	0.45	0.23	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
STAD	cis	rs7824557	0.564	rs2736295	ENSG00000205879.4	FAM90A2P	4.43	1.26e-05	0.00588	0.25	0.23	Retinal vascular caliber;	chr8:11377271	chr8:12172202~12178575:-
STAD	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	4.43	1.26e-05	0.00588	0.29	0.23	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	4.43	1.26e-05	0.00588	0.29	0.23	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
STAD	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	4.43	1.26e-05	0.00588	0.29	0.23	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	4.43	1.26e-05	0.00588	0.29	0.23	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
STAD	cis	rs9307551	0.779	rs12501981	ENSG00000250334.4	LINC00989	-4.43	1.26e-05	0.00588	-0.28	-0.23	Refractive error;	chr4:79591850	chr4:79492416~79576460:+
STAD	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	4.43	1.26e-05	0.00588	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
STAD	cis	rs227275	0.554	rs9307281	ENSG00000248971.2	KRT8P46	-4.43	1.26e-05	0.00588	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.903	rs6533037	ENSG00000248971.2	KRT8P46	-4.43	1.26e-05	0.00588	-0.24	-0.23	Schizophrenia;	chr4:102935865	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.903	rs4530634	ENSG00000248971.2	KRT8P46	-4.43	1.26e-05	0.00588	-0.24	-0.23	Schizophrenia;	chr4:102937924	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs7676943	ENSG00000248971.2	KRT8P46	-4.43	1.26e-05	0.00588	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs6419160	ENSG00000248971.2	KRT8P46	-4.43	1.26e-05	0.00588	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.838	rs3974494	ENSG00000248971.2	KRT8P46	-4.43	1.26e-05	0.00588	-0.24	-0.23	Schizophrenia;	chr4:102945323	chr4:102728746~102730171:-
STAD	cis	rs6832769	1	rs7670225	ENSG00000272969.1	RP11-528I4.2	4.43	1.26e-05	0.00588	0.29	0.23	Personality dimensions;	chr4:55501851	chr4:55547112~55547889:+
STAD	cis	rs4589258	0.933	rs7102324	ENSG00000280367.1	RP11-121L10.2	-4.43	1.26e-05	0.00588	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90662948	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs7129615	ENSG00000280367.1	RP11-121L10.2	-4.43	1.26e-05	0.00588	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90663057	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs7102581	ENSG00000280367.1	RP11-121L10.2	-4.43	1.26e-05	0.00588	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90663159	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs7102571	ENSG00000280367.1	RP11-121L10.2	-4.43	1.26e-05	0.00588	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90663345	chr11:90223153~90226538:+
STAD	cis	rs1707322	1	rs1612419	ENSG00000281133.1	AL355480.3	4.43	1.26e-05	0.00588	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45580892~45580996:-
STAD	cis	rs7487075	0.722	rs5016479	ENSG00000257261.4	RP11-96H19.1	4.43	1.26e-05	0.00588	0.31	0.23	Itch intensity from mosquito bite;	chr12:46319001	chr12:46383679~46876159:+
STAD	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-4.43	1.26e-05	0.00588	-0.35	-0.23	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
STAD	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-4.43	1.26e-05	0.00589	-0.29	-0.23	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
STAD	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	4.43	1.26e-05	0.00589	0.34	0.23	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
STAD	cis	rs1707322	0.721	rs10890333	ENSG00000225447.1	RPS15AP10	4.43	1.27e-05	0.00589	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45645816~45646197:-
STAD	cis	rs2439831	0.85	rs7181039	ENSG00000275601.1	AC011330.13	-4.43	1.27e-05	0.00589	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43886914	chr15:43642389~43643023:-
STAD	cis	rs2337406	0.866	rs4280141	ENSG00000280411.1	IGHV1-69-2	4.43	1.27e-05	0.0059	0.26	0.23	Alzheimer's disease (late onset);	chr14:106780476	chr14:106762092~106762588:-
STAD	cis	rs9902453	1	rs4328498	ENSG00000240074.1	RPL9P30	-4.43	1.27e-05	0.0059	-0.2	-0.23	Coffee consumption (cups per day);	chr17:30017258	chr17:29855759~29856332:+
STAD	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	4.43	1.27e-05	0.0059	0.29	0.23	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	4.43	1.27e-05	0.0059	0.29	0.23	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
STAD	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	4.43	1.27e-05	0.0059	0.27	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
STAD	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	4.43	1.27e-05	0.0059	0.27	0.23	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
STAD	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	4.43	1.27e-05	0.0059	0.27	0.23	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
STAD	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	4.43	1.27e-05	0.0059	0.27	0.23	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
STAD	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-4.43	1.27e-05	0.0059	-0.26	-0.23	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
STAD	cis	rs5753618	0.561	rs2040533	ENSG00000236132.1	CTA-440B3.1	4.43	1.27e-05	0.0059	0.27	0.23	Colorectal cancer;	chr22:31283124	chr22:31816379~31817491:-
STAD	cis	rs35851103	0.6	rs4841662	ENSG00000270154.1	RP11-419I17.1	-4.43	1.27e-05	0.0059	-0.24	-0.23	Neuroticism;	chr8:11986249	chr8:12476462~12477122:+
STAD	cis	rs1007738	0.542	rs901747	ENSG00000271350.1	CTD-2384B9.1	-4.43	1.27e-05	0.0059	-0.3	-0.23	Bone mineral density (hip);	chr11:47183430	chr11:47041027~47041945:-
STAD	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	4.43	1.27e-05	0.0059	0.24	0.23	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
STAD	cis	rs989978	1	rs989978	ENSG00000228778.1	RP11-129J12.1	4.43	1.27e-05	0.00591	0.28	0.23	Red blood cell count;	chr10:99562798	chr10:99527081~99528261:+
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000224205.1	AP000351.4	4.43	1.27e-05	0.00591	0.26	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23987320~23991421:-
STAD	cis	rs2483058	0.515	rs2987936	ENSG00000261000.1	RP11-534L20.5	-4.43	1.27e-05	0.00591	-0.28	-0.23	Cholesterol and Triglycerides;	chr1:206432728	chr1:206503948~206504456:+
STAD	cis	rs804280	0.509	rs13276433	ENSG00000270154.1	RP11-419I17.1	4.43	1.27e-05	0.00591	0.24	0.23	Myopia (pathological);	chr8:11925527	chr8:12476462~12477122:+
STAD	cis	rs4589258	0.931	rs4550185	ENSG00000280367.1	RP11-121L10.2	4.43	1.27e-05	0.00591	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90774882	chr11:90223153~90226538:+
STAD	cis	rs875971	0.838	rs2173570	ENSG00000236529.1	RP13-254B10.1	-4.43	1.27e-05	0.00591	-0.24	-0.23	Aortic root size;	chr7:66297976	chr7:65840212~65840596:+
STAD	cis	rs1707322	1	rs6671754	ENSG00000281133.1	AL355480.3	-4.43	1.27e-05	0.00591	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs6666763	ENSG00000281133.1	AL355480.3	-4.43	1.27e-05	0.00591	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4489497	ENSG00000281133.1	AL355480.3	-4.43	1.27e-05	0.00591	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45580892~45580996:-
STAD	cis	rs6832769	1	rs9312662	ENSG00000272969.1	RP11-528I4.2	-4.43	1.27e-05	0.00591	-0.29	-0.23	Personality dimensions;	chr4:55520204	chr4:55547112~55547889:+
STAD	cis	rs11846409	0.86	rs4774166	ENSG00000274576.2	IGHV2-70	-4.43	1.27e-05	0.00591	-0.29	-0.23	Rheumatic heart disease;	chr14:106619598	chr14:106770577~106771020:-
STAD	cis	rs1823874	0.677	rs4381582	ENSG00000182397.13	DNM1P46	-4.43	1.27e-05	0.00592	-0.25	-0.23	IgG glycosylation;	chr15:99820308	chr15:99790156~99806927:-
STAD	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	4.43	1.27e-05	0.00592	0.29	0.23	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
STAD	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-4.43	1.27e-05	0.00592	-0.37	-0.23	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
STAD	cis	rs938554	0.542	rs7678287	ENSG00000250613.1	RP11-136I13.1	-4.43	1.27e-05	0.00592	-0.26	-0.23	Blood metabolite levels;	chr4:9998877	chr4:10410996~10411644:+
STAD	cis	rs8098244	0.628	rs8083184	ENSG00000267301.1	RPL23AP77	-4.43	1.27e-05	0.00592	-0.27	-0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23683708	chr18:23709825~23710287:-
STAD	cis	rs35934224	0.783	rs58714937	ENSG00000232926.1	AC000078.5	4.43	1.27e-05	0.00592	0.31	0.23	Glaucoma (primary open-angle);	chr22:19869187	chr22:19887289~19887970:+
STAD	cis	rs35934224	0.783	rs34593728	ENSG00000232926.1	AC000078.5	4.43	1.27e-05	0.00592	0.31	0.23	Glaucoma (primary open-angle);	chr22:19869966	chr22:19887289~19887970:+
STAD	cis	rs1928295	0.786	rs10983712	ENSG00000233569.1	RP11-500B12.1	4.43	1.27e-05	0.00592	0.25	0.23	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117606458	chr9:117648606~117657027:+
STAD	cis	rs1928295	0.786	rs7038943	ENSG00000233569.1	RP11-500B12.1	4.43	1.27e-05	0.00592	0.25	0.23	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117614900	chr9:117648606~117657027:+
STAD	cis	rs4407350	0.837	rs5765710	ENSG00000279642.1	RP5-1033E15.3	4.43	1.27e-05	0.00592	0.22	0.23	Intelligence (multi-trait analysis);	chr22:44518474	chr22:44486295~44486914:-
STAD	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-4.43	1.27e-05	0.00593	-0.35	-0.23	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
STAD	cis	rs11169552	0.51	rs12231309	ENSG00000200183.1	RNU6-238P	-4.43	1.27e-05	0.00593	-0.22	-0.23	Colorectal cancer;	chr12:50647279	chr12:50656973~50657078:+
STAD	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-4.43	1.27e-05	0.00593	-0.24	-0.23	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
STAD	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	4.43	1.27e-05	0.00593	0.24	0.23	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
STAD	cis	rs1528149	0.504	rs6943936	ENSG00000224683.1	RPL36AP29	-4.43	1.27e-05	0.00593	-0.24	-0.23	Sitting height ratio;	chr7:16128648	chr7:16208945~16209265:+
STAD	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	4.43	1.28e-05	0.00593	0.34	0.23	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	4.43	1.28e-05	0.00593	0.34	0.23	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
STAD	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-4.43	1.28e-05	0.00593	-0.22	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
STAD	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-4.43	1.28e-05	0.00593	-0.27	-0.23	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
STAD	cis	rs10978777	0.515	rs12555417	ENSG00000276883.1	AL137852.1	4.43	1.28e-05	0.00594	0.25	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107278761	chr9:107292369~107292456:-
STAD	cis	rs10978777	0.515	rs10816480	ENSG00000276883.1	AL137852.1	4.43	1.28e-05	0.00594	0.25	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107279917	chr9:107292369~107292456:-
STAD	cis	rs1707322	0.717	rs11211161	ENSG00000281133.1	AL355480.3	-4.43	1.28e-05	0.00594	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45580892~45580996:-
STAD	cis	rs11638815	0.603	rs2678448	ENSG00000255769.6	GOLGA2P10	-4.43	1.28e-05	0.00594	-0.27	-0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:82472993~82513950:-
STAD	cis	rs2688608	0.592	rs10824031	ENSG00000271816.1	BMS1P4	4.43	1.28e-05	0.00594	0.25	0.23	Inflammatory bowel disease;	chr10:73749515	chr10:73699151~73730487:-
STAD	cis	rs2688608	0.62	rs7076525	ENSG00000271816.1	BMS1P4	4.43	1.28e-05	0.00594	0.25	0.23	Inflammatory bowel disease;	chr10:73753039	chr10:73699151~73730487:-
STAD	cis	rs7680126	0.596	rs4698030	ENSG00000250613.1	RP11-136I13.1	4.43	1.28e-05	0.00595	0.25	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10314226	chr4:10410996~10411644:+
STAD	cis	rs2115630	0.805	rs8042926	ENSG00000225151.9	GOLGA2P7	4.43	1.28e-05	0.00595	0.26	0.23	P wave terminal force;	chr15:84662223	chr15:84199311~84230136:-
STAD	cis	rs1528149	0.504	rs6968537	ENSG00000224683.1	RPL36AP29	-4.43	1.28e-05	0.00595	-0.24	-0.23	Sitting height ratio;	chr7:16129083	chr7:16208945~16209265:+
STAD	cis	rs9329221	0.617	rs483916	ENSG00000254340.1	RP11-10A14.3	-4.43	1.28e-05	0.00595	-0.28	-0.23	Neuroticism;	chr8:9936091	chr8:9141424~9145435:+
STAD	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	4.43	1.28e-05	0.00595	0.27	0.23	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
STAD	cis	rs7924176	0.521	rs10824142	ENSG00000213731.2	RAB5CP1	-4.43	1.28e-05	0.00595	-0.24	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74423435~74424014:-
STAD	cis	rs7924176	0.521	rs11000965	ENSG00000213731.2	RAB5CP1	-4.43	1.28e-05	0.00595	-0.24	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74423435~74424014:-
STAD	cis	rs9467773	1	rs10214634	ENSG00000243307.2	POM121L6P	4.43	1.28e-05	0.00595	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.873	rs9295698	ENSG00000243307.2	POM121L6P	4.43	1.28e-05	0.00595	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6456733	ENSG00000243307.2	POM121L6P	4.43	1.28e-05	0.00595	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6456734	ENSG00000243307.2	POM121L6P	4.43	1.28e-05	0.00595	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26896952~26898777:+
STAD	cis	rs2404602	0.598	rs71405204	ENSG00000196274.5	Metazoa_SRP	-4.43	1.28e-05	0.00595	-0.21	-0.23	Blood metabolite levels;	chr15:76342964	chr15:76230048~76230390:-
STAD	cis	rs4950322	0.515	rs11239958	ENSG00000278811.3	LINC00624	4.43	1.28e-05	0.00595	0.25	0.23	Protein quantitative trait loci;	chr1:147247454	chr1:147258885~147517875:-
STAD	cis	rs9902453	0.765	rs3115087	ENSG00000240074.1	RPL9P30	4.43	1.28e-05	0.00595	0.2	0.23	Coffee consumption (cups per day);	chr17:29703249	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.817	rs3115089	ENSG00000240074.1	RPL9P30	4.43	1.28e-05	0.00595	0.2	0.23	Coffee consumption (cups per day);	chr17:29704863	chr17:29855759~29856332:+
STAD	cis	rs1876905	0.539	rs240958	ENSG00000271789.1	RP5-1112D6.7	4.43	1.28e-05	0.00596	0.26	0.23	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111297126~111298510:+
STAD	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-4.43	1.28e-05	0.00596	-0.22	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
STAD	cis	rs11846409	0.799	rs2583330	ENSG00000211970.3	IGHV4-61	-4.43	1.28e-05	0.00596	-0.27	-0.23	Rheumatic heart disease;	chr14:106621051	chr14:106639119~106639657:-
STAD	cis	rs1707322	0.929	rs785500	ENSG00000281133.1	AL355480.3	4.43	1.28e-05	0.00596	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785504	ENSG00000281133.1	AL355480.3	4.43	1.28e-05	0.00596	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45580892~45580996:-
STAD	cis	rs2337406	1	rs1961901	ENSG00000280411.1	IGHV1-69-2	-4.43	1.28e-05	0.00596	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106680856	chr14:106762092~106762588:-
STAD	cis	rs2337406	1	rs4774172	ENSG00000280411.1	IGHV1-69-2	-4.43	1.28e-05	0.00596	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106681320	chr14:106762092~106762588:-
STAD	cis	rs1707322	1	rs10890378	ENSG00000281133.1	AL355480.3	4.43	1.28e-05	0.00596	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45580892~45580996:-
STAD	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	4.43	1.28e-05	0.00596	0.34	0.23	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	4.43	1.28e-05	0.00596	0.34	0.23	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
STAD	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	4.43	1.28e-05	0.00597	0.31	0.23	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
STAD	cis	rs17401966	1	rs12141416	ENSG00000199562.1	RNU6-37P	4.43	1.28e-05	0.00597	0.18	0.23	Hepatocellular carcinoma;	chr1:10267809	chr1:10298966~10299072:+
STAD	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	4.43	1.28e-05	0.00597	0.25	0.23	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
STAD	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-4.43	1.28e-05	0.00597	-0.27	-0.23	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
STAD	cis	rs9902453	0.817	rs1038089	ENSG00000240074.1	RPL9P30	4.43	1.28e-05	0.00597	0.2	0.23	Coffee consumption (cups per day);	chr17:29851706	chr17:29855759~29856332:+
STAD	cis	rs4845875	0.514	rs198393	ENSG00000242349.4	NPPA-AS1	-4.43	1.28e-05	0.00597	-0.23	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11819628	chr1:11841017~11848079:+
STAD	cis	rs9847710	0.967	rs2244552	ENSG00000242142.1	SERBP1P3	4.43	1.28e-05	0.00597	0.22	0.23	Ulcerative colitis;	chr3:53021506	chr3:53064283~53065091:-
STAD	cis	rs6430585	0.583	rs58509842	ENSG00000231890.6	DARS-AS1	-4.43	1.28e-05	0.00597	-0.27	-0.23	Corneal structure;	chr2:135828457	chr2:135985176~136022593:+
STAD	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-4.43	1.29e-05	0.00597	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
STAD	cis	rs6921919	0.583	rs4642462	ENSG00000220721.1	OR1F12	4.43	1.29e-05	0.00597	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28073316~28074233:+
STAD	cis	rs9467773	1	rs1535277	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs1884948	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs1884949	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs9467796	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs9467797	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs1078679	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6932156	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6924838	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6925895	ENSG00000243307.2	POM121L6P	4.43	1.29e-05	0.00597	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26896952~26898777:+
STAD	cis	rs4780355	0.918	rs243318	ENSG00000262703.1	RP11-485G7.6	4.43	1.29e-05	0.00597	0.22	0.23	Crohn's disease and psoriasis;	chr16:11264161	chr16:11348143~11349321:-
STAD	cis	rs9902453	0.845	rs3115099	ENSG00000240074.1	RPL9P30	4.43	1.29e-05	0.00597	0.2	0.23	Coffee consumption (cups per day);	chr17:29692275	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.845	rs58606097	ENSG00000240074.1	RPL9P30	4.43	1.29e-05	0.00597	0.2	0.23	Coffee consumption (cups per day);	chr17:29693361	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.845	rs3102558	ENSG00000240074.1	RPL9P30	4.43	1.29e-05	0.00597	0.2	0.23	Coffee consumption (cups per day);	chr17:29696124	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.845	rs2321331	ENSG00000240074.1	RPL9P30	4.43	1.29e-05	0.00597	0.2	0.23	Coffee consumption (cups per day);	chr17:29698510	chr17:29855759~29856332:+
STAD	cis	rs8028182	0.636	rs4451914	ENSG00000260269.4	CTD-2323K18.1	-4.43	1.29e-05	0.00597	-0.29	-0.23	Sudden cardiac arrest;	chr15:75447483	chr15:75527150~75601205:-
STAD	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-4.43	1.29e-05	0.00597	-0.27	-0.23	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
STAD	cis	rs7208859	0.673	rs56846352	ENSG00000263603.1	CTD-2349P21.5	-4.43	1.29e-05	0.00597	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.673	rs7211776	ENSG00000263603.1	CTD-2349P21.5	-4.43	1.29e-05	0.00597	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30729469~30731202:+
STAD	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	4.43	1.29e-05	0.00597	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	4.43	1.29e-05	0.00597	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
STAD	cis	rs4713118	0.506	rs9366697	ENSG00000280107.1	AL022393.9	-4.43	1.29e-05	0.00597	-0.28	-0.23	Parkinson's disease;	chr6:27665239	chr6:28170845~28172521:+
STAD	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	4.43	1.29e-05	0.00597	0.28	0.23	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
STAD	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-4.43	1.29e-05	0.00598	-0.27	-0.23	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
STAD	cis	rs4237845	1	rs4237845	ENSG00000273805.1	RP11-620J15.4	4.43	1.29e-05	0.00598	0.25	0.23	Intelligence (multi-trait analysis);	chr12:57908653	chr12:57894232~57896846:+
STAD	cis	rs453301	0.624	rs2979265	ENSG00000233609.3	RP11-62H7.2	4.43	1.29e-05	0.00598	0.26	0.23	Joint mobility (Beighton score);	chr8:9001207	chr8:8961200~8979025:+
STAD	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-4.43	1.29e-05	0.00598	-0.35	-0.23	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
STAD	cis	rs801193	0.569	rs6978178	ENSG00000224316.1	RP11-479O9.2	-4.43	1.29e-05	0.00598	-0.23	-0.23	Aortic root size;	chr7:66658097	chr7:65773620~65802067:+
STAD	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-4.43	1.29e-05	0.00598	-0.24	-0.23	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
STAD	cis	rs227275	0.53	rs3960788	ENSG00000230069.3	LRRC37A15P	-4.43	1.29e-05	0.00598	-0.25	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102727274~102730721:-
STAD	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	4.43	1.29e-05	0.00599	0.3	0.23	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
STAD	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-4.43	1.29e-05	0.00599	-0.29	-0.23	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
STAD	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-4.43	1.29e-05	0.00599	-0.28	-0.23	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
STAD	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-4.43	1.29e-05	0.00599	-0.24	-0.23	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
STAD	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	4.43	1.29e-05	0.00599	0.26	0.23	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
STAD	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	4.43	1.29e-05	0.00599	0.26	0.23	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
STAD	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	4.43	1.29e-05	0.00599	0.26	0.23	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
STAD	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	4.43	1.29e-05	0.00599	0.26	0.23	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
STAD	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	4.43	1.29e-05	0.00599	0.26	0.23	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
STAD	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-4.43	1.29e-05	0.00599	-0.25	-0.23	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
STAD	cis	rs12682352	0.535	rs12677550	ENSG00000253981.4	ALG1L13P	-4.43	1.29e-05	0.006	-0.28	-0.23	Neuroticism;	chr8:8786812	chr8:8236003~8244667:-
STAD	cis	rs12908161	0.92	rs35738019	ENSG00000259295.5	CSPG4P12	4.43	1.29e-05	0.006	0.33	0.23	Schizophrenia;	chr15:84736979	chr15:85191438~85213905:+
STAD	cis	rs1723838	0.702	rs4944865	ENSG00000255928.1	RP11-456I15.2	-4.43	1.29e-05	0.006	-0.47	-0.23	Obesity-related traits;	chr11:73745459	chr11:73722349~73722694:+
STAD	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	4.43	1.29e-05	0.006	0.21	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
STAD	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	4.43	1.29e-05	0.006	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
STAD	cis	rs6832769	1	rs28448438	ENSG00000272969.1	RP11-528I4.2	-4.43	1.29e-05	0.006	-0.29	-0.23	Personality dimensions;	chr4:55550498	chr4:55547112~55547889:+
STAD	cis	rs2283792	0.567	rs2027789	ENSG00000228050.1	TOP3BP1	4.43	1.29e-05	0.006	0.28	0.23	Multiple sclerosis;	chr22:21933490	chr22:22223187~22224566:-
STAD	cis	rs875971	0.83	rs778711	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66386670	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs1083554	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66387354	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs778707	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66392040	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs778705	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66396128	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs778697	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66405439	chr7:65773620~65802067:+
STAD	cis	rs875971	0.798	rs7789615	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66413674	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6978028	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66421313	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6947339	ENSG00000224316.1	RP11-479O9.2	4.43	1.29e-05	0.006	0.22	0.23	Aortic root size;	chr7:66423483	chr7:65773620~65802067:+
STAD	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	4.42	1.29e-05	0.00601	0.28	0.23	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
STAD	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-4.42	1.29e-05	0.00601	-0.27	-0.23	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
STAD	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	4.42	1.29e-05	0.00601	0.28	0.23	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
STAD	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	4.42	1.29e-05	0.00601	0.29	0.23	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
STAD	cis	rs5769707	0.521	rs5769719	ENSG00000280224.1	CTA-722E9.1	-4.42	1.3e-05	0.00601	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.521	rs5769720	ENSG00000280224.1	CTA-722E9.1	-4.42	1.3e-05	0.00601	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49500568~49501585:+
STAD	cis	rs5769707	0.521	rs5770633	ENSG00000280224.1	CTA-722E9.1	-4.42	1.3e-05	0.00601	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49500568~49501585:+
STAD	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	4.42	1.3e-05	0.00601	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
STAD	cis	rs7078219	0.576	rs989979	ENSG00000257582.4	LINC01475	-4.42	1.3e-05	0.00601	-0.26	-0.23	Dental caries;	chr10:99562666	chr10:99526350~99531177:-
STAD	cis	rs12908161	1	rs35960805	ENSG00000259295.5	CSPG4P12	4.42	1.3e-05	0.00601	0.33	0.23	Schizophrenia;	chr15:84800749	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs12912388	ENSG00000259295.5	CSPG4P12	4.42	1.3e-05	0.00601	0.33	0.23	Schizophrenia;	chr15:84801319	chr15:85191438~85213905:+
STAD	cis	rs1707322	0.717	rs3014249	ENSG00000225447.1	RPS15AP10	-4.42	1.3e-05	0.00602	-0.19	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45645816~45646197:-
STAD	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-4.42	1.3e-05	0.00603	-0.29	-0.23	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
STAD	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	4.42	1.3e-05	0.00603	0.24	0.23	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
STAD	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	4.42	1.3e-05	0.00603	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
STAD	cis	rs13315649	0.639	rs73196928	ENSG00000242551.2	POU5F1P6	-4.42	1.3e-05	0.00603	-0.24	-0.23	Sum eosinophil basophil counts;	chr3:128670583	chr3:128674735~128677005:-
STAD	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	4.42	1.3e-05	0.00603	0.28	0.23	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	4.42	1.3e-05	0.00603	0.28	0.23	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
STAD	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	4.42	1.3e-05	0.00603	0.26	0.23	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
STAD	cis	rs12908161	1	rs35316992	ENSG00000259295.5	CSPG4P12	4.42	1.3e-05	0.00604	0.33	0.23	Schizophrenia;	chr15:84704902	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs4643294	ENSG00000259295.5	CSPG4P12	4.42	1.3e-05	0.00604	0.33	0.23	Schizophrenia;	chr15:84707022	chr15:85191438~85213905:+
STAD	cis	rs11676348	0.818	rs7426289	ENSG00000237281.1	CATIP-AS2	4.42	1.3e-05	0.00604	0.23	0.23	Ulcerative colitis;	chr2:218101592	chr2:218326889~218357966:-
STAD	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	4.42	1.3e-05	0.00604	0.31	0.23	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
STAD	cis	rs721917	0.526	rs2256574	ENSG00000244733.5	RP11-506M13.3	-4.42	1.3e-05	0.00604	-0.28	-0.23	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79660891~79677996:+
STAD	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	4.42	1.31e-05	0.00605	0.34	0.23	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
STAD	cis	rs4713118	0.869	rs7773070	ENSG00000243307.2	POM121L6P	-4.42	1.31e-05	0.00605	-0.26	-0.23	Parkinson's disease;	chr6:27761048	chr6:26896952~26898777:+
STAD	cis	rs2790457	0.792	rs1265830	ENSG00000254635.4	WAC-AS1	4.42	1.31e-05	0.00605	0.28	0.23	Multiple myeloma;	chr10:28623294	chr10:28522652~28532743:-
STAD	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	4.42	1.31e-05	0.00605	0.34	0.23	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	4.42	1.31e-05	0.00605	0.34	0.23	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	4.42	1.31e-05	0.00605	0.34	0.23	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
STAD	cis	rs2834288	0.613	rs2834297	ENSG00000237945.6	LINC00649	-4.42	1.31e-05	0.00605	-0.29	-0.23	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33915534~33977691:+
STAD	cis	rs11638815	0.581	rs28808991	ENSG00000255769.6	GOLGA2P10	-4.42	1.31e-05	0.00605	-0.26	-0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82592229	chr15:82472993~82513950:-
STAD	cis	rs7680126	0.596	rs4698032	ENSG00000250613.1	RP11-136I13.1	4.42	1.31e-05	0.00606	0.25	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10314958	chr4:10410996~10411644:+
STAD	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-4.42	1.31e-05	0.00606	-0.25	-0.23	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
STAD	cis	rs9467773	1	rs9467791	ENSG00000243307.2	POM121L6P	-4.42	1.31e-05	0.00606	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26896952~26898777:+
STAD	cis	rs7487075	0.619	rs7312259	ENSG00000257261.4	RP11-96H19.1	4.42	1.31e-05	0.00606	0.32	0.23	Itch intensity from mosquito bite;	chr12:46397751	chr12:46383679~46876159:+
STAD	cis	rs4535700	0.501	rs9642405	ENSG00000226278.1	PSPHP1	4.42	1.31e-05	0.00606	0.3	0.23	Macular telangiectasia type 2;	chr7:55910473	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.501	rs57251705	ENSG00000226278.1	PSPHP1	4.42	1.31e-05	0.00606	0.3	0.23	Macular telangiectasia type 2;	chr7:55913390	chr7:55764797~55773288:+
STAD	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	4.42	1.31e-05	0.00606	0.35	0.23	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
STAD	cis	rs4589258	0.933	rs7102601	ENSG00000280367.1	RP11-121L10.2	-4.42	1.31e-05	0.00606	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90663210	chr11:90223153~90226538:+
STAD	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-4.42	1.31e-05	0.00606	-0.25	-0.23	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
STAD	cis	rs561341	0.629	rs7216107	ENSG00000265798.5	RP11-271K11.5	4.42	1.31e-05	0.00607	0.27	0.23	Hip circumference adjusted for BMI;	chr17:31897400	chr17:31038575~31059121:-
STAD	cis	rs9467773	1	rs9295695	ENSG00000243307.2	POM121L6P	-4.42	1.31e-05	0.00607	-0.23	-0.23	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26896952~26898777:+
STAD	cis	rs7671266	0.571	rs4643800	ENSG00000250613.1	RP11-136I13.1	4.42	1.31e-05	0.00607	0.27	0.23	Cardiovascular disease risk factors;	chr4:10405948	chr4:10410996~10411644:+
STAD	cis	rs9733	0.68	rs3738484	ENSG00000274963.1	Metazoa_SRP	-4.42	1.31e-05	0.00607	-0.19	-0.23	Tonsillectomy;	chr1:150579854	chr1:150568971~150569269:-
STAD	cis	rs9733	0.65	rs9803935	ENSG00000274963.1	Metazoa_SRP	-4.42	1.31e-05	0.00607	-0.19	-0.23	Tonsillectomy;	chr1:150580146	chr1:150568971~150569269:-
STAD	cis	rs879620	0.89	rs2601781	ENSG00000262185.1	RP11-462G12.1	-4.42	1.31e-05	0.00607	-0.22	-0.23	Hip circumference;Body mass index;	chr16:3967391	chr16:3947609~3950444:-
STAD	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-4.42	1.31e-05	0.00608	-0.21	-0.23	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
STAD	cis	rs9807989	0.729	rs10170583	ENSG00000234389.1	AC007278.3	4.42	1.31e-05	0.00608	0.24	0.23	Asthma;	chr2:102358304	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.801	rs10173193	ENSG00000234389.1	AC007278.3	4.42	1.31e-05	0.00608	0.24	0.23	Asthma;	chr2:102358590	chr2:102438713~102440475:+
STAD	cis	rs11169552	0.51	rs876079	ENSG00000200183.1	RNU6-238P	-4.42	1.31e-05	0.00608	-0.22	-0.23	Colorectal cancer;	chr12:50636926	chr12:50656973~50657078:+
STAD	cis	rs55823223	0.648	rs72860389	ENSG00000267801.1	RP11-552F3.9	4.42	1.31e-05	0.00608	0.35	0.23	Psoriasis;	chr17:75869990	chr17:75876372~75879546:+
STAD	cis	rs451417	1	rs236105	ENSG00000275632.1	RP5-967N21.11	-4.42	1.31e-05	0.00608	-0.29	-0.23	Menopause (age at onset);	chr20:5979186	chr20:6000418~6000941:+
STAD	cis	rs6921919	0.551	rs13201753	ENSG00000220721.1	OR1F12	4.42	1.31e-05	0.00608	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28073316~28074233:+
STAD	cis	rs62246343	0.654	rs7631372	ENSG00000214041.4	PGAM1P4	4.42	1.31e-05	0.00608	0.38	0.23	Fibrinogen levels;	chr3:9451631	chr3:9348443~9349192:+
STAD	cis	rs4237845	0.837	rs7954591	ENSG00000273805.1	RP11-620J15.4	-4.42	1.31e-05	0.00608	-0.25	-0.23	Intelligence (multi-trait analysis);	chr12:57905254	chr12:57894232~57896846:+
STAD	cis	rs4237845	0.837	rs7954957	ENSG00000273805.1	RP11-620J15.4	-4.42	1.31e-05	0.00608	-0.25	-0.23	Intelligence (multi-trait analysis);	chr12:57905467	chr12:57894232~57896846:+
STAD	cis	rs6479891	0.915	rs10761744	ENSG00000235816.3	PRELID1P3	-4.42	1.31e-05	0.00608	-0.28	-0.23	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63427297~63427939:+
STAD	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	4.42	1.31e-05	0.00608	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
STAD	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-4.42	1.31e-05	0.00609	-0.23	-0.23	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
STAD	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-4.42	1.32e-05	0.00609	-0.36	-0.23	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
STAD	cis	rs2992257	0.958	rs3006804	ENSG00000251839.1	RNU7-12P	4.42	1.32e-05	0.00609	0.23	0.23	Response to angiotensin II receptor blocker therapy;	chr10:26443919	chr10:27232255~27232316:-
STAD	cis	rs11157436	0.56	rs11623957	ENSG00000211812.1	TRAV26-2	-4.42	1.32e-05	0.0061	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22202583~22203368:+
STAD	cis	rs9902453	0.791	rs9904051	ENSG00000240074.1	RPL9P30	4.42	1.32e-05	0.0061	0.2	0.23	Coffee consumption (cups per day);	chr17:29917104	chr17:29855759~29856332:+
STAD	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	4.42	1.32e-05	0.0061	0.28	0.23	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
STAD	cis	rs7617773	0.963	rs12495221	ENSG00000224895.1	VPS26BP1	4.42	1.32e-05	0.0061	0.22	0.23	Coronary artery disease;	chr3:48137688	chr3:47960327~47961081:-
STAD	cis	rs1816752	0.669	rs2862906	ENSG00000273628.1	RP11-756A22.7	-4.42	1.32e-05	0.00611	-0.28	-0.23	Obesity-related traits;	chr13:24494482	chr13:24933006~24936796:+
STAD	cis	rs6921919	0.583	rs2041230	ENSG00000220721.1	OR1F12	4.42	1.32e-05	0.00611	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28073316~28074233:+
STAD	cis	rs8062405	1	rs12446589	ENSG00000278665.1	RP11-666O2.4	4.42	1.32e-05	0.00611	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28599241~28601881:-
STAD	cis	rs1816752	0.646	rs2902359	ENSG00000273628.1	RP11-756A22.7	-4.42	1.32e-05	0.00611	-0.28	-0.23	Obesity-related traits;	chr13:24461783	chr13:24933006~24936796:+
STAD	cis	rs561341	1	rs55962687	ENSG00000265798.5	RP11-271K11.5	4.42	1.32e-05	0.00611	0.35	0.23	Hip circumference adjusted for BMI;	chr17:31933350	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs55643307	ENSG00000265798.5	RP11-271K11.5	4.42	1.32e-05	0.00611	0.35	0.23	Hip circumference adjusted for BMI;	chr17:31936055	chr17:31038575~31059121:-
STAD	cis	rs9902453	0.845	rs3102559	ENSG00000240074.1	RPL9P30	4.42	1.32e-05	0.00611	0.2	0.23	Coffee consumption (cups per day);	chr17:29702705	chr17:29855759~29856332:+
STAD	cis	rs875971	0.862	rs6964437	ENSG00000224316.1	RP11-479O9.2	-4.42	1.32e-05	0.00611	-0.23	-0.23	Aortic root size;	chr7:66221457	chr7:65773620~65802067:+
STAD	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	4.42	1.32e-05	0.00611	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
STAD	cis	rs227275	0.556	rs6842179	ENSG00000248971.2	KRT8P46	-4.42	1.32e-05	0.00612	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102728746~102730171:-
STAD	cis	rs62246343	0.719	rs62246276	ENSG00000214041.4	PGAM1P4	4.42	1.32e-05	0.00612	0.38	0.23	Fibrinogen levels;	chr3:9403489	chr3:9348443~9349192:+
STAD	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	4.42	1.32e-05	0.00612	0.29	0.23	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	4.42	1.32e-05	0.00612	0.29	0.23	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	4.42	1.32e-05	0.00612	0.29	0.23	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
STAD	cis	rs7829975	0.514	rs2976926	ENSG00000254340.1	RP11-10A14.3	4.42	1.32e-05	0.00612	0.27	0.23	Mood instability;	chr8:8404114	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.913	rs67073020	ENSG00000260091.1	RP11-33B1.4	4.42	1.32e-05	0.00612	0.23	0.23	Corneal astigmatism;	chr4:119231402	chr4:119409333~119410233:+
STAD	cis	rs2692947	1	rs2692947	ENSG00000237510.6	AC008268.2	4.42	1.32e-05	0.00613	0.27	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96008368	chr2:95789654~95800166:+
STAD	cis	rs11098499	0.691	rs12510133	ENSG00000260091.1	RP11-33B1.4	4.42	1.32e-05	0.00613	0.22	0.23	Corneal astigmatism;	chr4:119350189	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs12506487	ENSG00000260091.1	RP11-33B1.4	4.42	1.32e-05	0.00613	0.22	0.23	Corneal astigmatism;	chr4:119350206	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.691	rs12502524	ENSG00000260091.1	RP11-33B1.4	4.42	1.32e-05	0.00613	0.22	0.23	Corneal astigmatism;	chr4:119350259	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.691	rs28396837	ENSG00000260091.1	RP11-33B1.4	4.42	1.32e-05	0.00613	0.22	0.23	Corneal astigmatism;	chr4:119350386	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.629	rs28369518	ENSG00000260091.1	RP11-33B1.4	4.42	1.32e-05	0.00613	0.22	0.23	Corneal astigmatism;	chr4:119350475	chr4:119409333~119410233:+
STAD	cis	rs8062405	0.823	rs7202948	ENSG00000278665.1	RP11-666O2.4	4.42	1.32e-05	0.00613	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.69	rs7187604	ENSG00000278665.1	RP11-666O2.4	4.42	1.33e-05	0.00613	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28599241~28601881:-
STAD	cis	rs7824557	0.564	rs7839307	ENSG00000205879.4	FAM90A2P	4.42	1.33e-05	0.00613	0.26	0.23	Retinal vascular caliber;	chr8:11341283	chr8:12172202~12178575:-
STAD	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-4.42	1.33e-05	0.00613	-0.29	-0.23	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
STAD	cis	rs9329221	0.683	rs4598253	ENSG00000254340.1	RP11-10A14.3	-4.42	1.33e-05	0.00613	-0.29	-0.23	Neuroticism;	chr8:10032794	chr8:9141424~9145435:+
STAD	cis	rs10073892	0.66	rs10043147	ENSG00000250682.4	LINC00491	-4.42	1.33e-05	0.00613	-0.25	-0.23	Cognitive decline (age-related);	chr5:102620521	chr5:102609156~102671559:-
STAD	cis	rs2439831	0.681	rs28578454	ENSG00000249839.1	AC011330.5	-4.42	1.33e-05	0.00613	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43310834	chr15:43663654~43684339:-
STAD	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	4.42	1.33e-05	0.00614	0.73	0.23	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
STAD	cis	rs10776614	0.642	rs4838421	ENSG00000189014.7	FAM35DP	4.42	1.33e-05	0.00615	0.31	0.23	Self-employment;	chr10:48561482	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.642	rs4838422	ENSG00000189014.7	FAM35DP	4.42	1.33e-05	0.00615	0.31	0.23	Self-employment;	chr10:48561687	chr10:47689707~47730436:+
STAD	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	4.42	1.33e-05	0.00615	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	4.42	1.33e-05	0.00615	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
STAD	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-4.42	1.33e-05	0.00615	-0.24	-0.23	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
STAD	cis	rs3811273	0.614	rs7154715	ENSG00000211816.2	TRAV38-1	-4.42	1.33e-05	0.00615	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22263528	chr14:22271968~22272563:+
STAD	cis	rs7487075	0.719	rs2408496	ENSG00000257261.4	RP11-96H19.1	4.42	1.33e-05	0.00615	0.31	0.23	Itch intensity from mosquito bite;	chr12:46256954	chr12:46383679~46876159:+
STAD	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-4.42	1.33e-05	0.00616	-0.27	-0.23	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
STAD	cis	rs2337406	0.587	rs11624678	ENSG00000274576.2	IGHV2-70	4.42	1.33e-05	0.00616	0.28	0.23	Alzheimer's disease (late onset);	chr14:106650408	chr14:106770577~106771020:-
STAD	cis	rs8062405	0.755	rs4787456	ENSG00000278665.1	RP11-666O2.4	4.42	1.33e-05	0.00616	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.755	rs4788078	ENSG00000278665.1	RP11-666O2.4	4.42	1.33e-05	0.00616	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.755	rs62034350	ENSG00000278665.1	RP11-666O2.4	4.42	1.33e-05	0.00616	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28599241~28601881:-
STAD	cis	rs1707322	1	rs12124847	ENSG00000281133.1	AL355480.3	-4.42	1.33e-05	0.00616	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45580892~45580996:-
STAD	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	4.42	1.33e-05	0.00616	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
STAD	cis	rs7078219	0.714	rs10883359	ENSG00000228778.1	RP11-129J12.1	4.42	1.33e-05	0.00616	0.3	0.23	Dental caries;	chr10:99514276	chr10:99527081~99528261:+
STAD	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-4.42	1.33e-05	0.00616	-0.25	-0.23	Depression;	chr6:28422360	chr6:28176188~28176674:+
STAD	cis	rs1816752	0.646	rs750390	ENSG00000273628.1	RP11-756A22.7	-4.42	1.33e-05	0.00617	-0.28	-0.23	Obesity-related traits;	chr13:24461603	chr13:24933006~24936796:+
STAD	cis	rs12922317	0.589	rs350216	ENSG00000260224.1	UBL5P4	4.42	1.33e-05	0.00617	0.24	0.23	Schizophrenia;	chr16:12057283	chr16:11968508~11968743:-
STAD	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-4.42	1.34e-05	0.00617	-0.27	-0.23	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
STAD	cis	rs7395581	0.959	rs326222	ENSG00000271350.1	CTD-2384B9.1	-4.42	1.34e-05	0.00617	-0.28	-0.23	HDL cholesterol;	chr11:47238117	chr11:47041027~47041945:-
STAD	cis	rs77956314	0.515	rs4238051	ENSG00000274554.1	RP11-240G22.5	-4.42	1.34e-05	0.00617	-0.29	-0.23	Hippocampal volume;Subcortical brain region volumes;	chr12:116928494	chr12:116948738~116951422:-
STAD	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-4.42	1.34e-05	0.00617	-0.27	-0.23	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
STAD	cis	rs12439619	0.508	rs17354842	ENSG00000255769.6	GOLGA2P10	4.42	1.34e-05	0.00617	0.28	0.23	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472993~82513950:-
STAD	cis	rs11907546	1	rs11907546	ENSG00000275784.1	RP5-1125A11.6	-4.42	1.34e-05	0.00618	-0.23	-0.23	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33989480~33991818:-
STAD	cis	rs10978777	0.666	rs1535767	ENSG00000276883.1	AL137852.1	4.42	1.34e-05	0.00618	0.23	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107250586	chr9:107292369~107292456:-
STAD	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-4.42	1.34e-05	0.00618	-0.28	-0.23	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
STAD	cis	rs6832769	1	rs473005	ENSG00000272969.1	RP11-528I4.2	4.42	1.34e-05	0.00618	0.3	0.23	Personality dimensions;	chr4:55421958	chr4:55547112~55547889:+
STAD	cis	rs1348850	0.872	rs13004955	ENSG00000271825.1	RP11-337N6.2	-4.42	1.34e-05	0.00619	-0.2	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177534195	chr2:177300600~177302006:+
STAD	cis	rs4713118	0.662	rs13218430	ENSG00000220721.1	OR1F12	4.42	1.34e-05	0.00619	0.27	0.23	Parkinson's disease;	chr6:28062059	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs9380046	ENSG00000220721.1	OR1F12	4.42	1.34e-05	0.00619	0.27	0.23	Parkinson's disease;	chr6:28062721	chr6:28073316~28074233:+
STAD	cis	rs561341	0.882	rs28649357	ENSG00000265798.5	RP11-271K11.5	4.42	1.34e-05	0.00619	0.3	0.23	Hip circumference adjusted for BMI;	chr17:32040171	chr17:31038575~31059121:-
STAD	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-4.42	1.34e-05	0.0062	-0.27	-0.23	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
STAD	cis	rs11673344	0.503	rs10414520	ENSG00000267672.1	CTD-2293H3.1	4.42	1.34e-05	0.0062	0.21	0.23	Obesity-related traits;	chr19:37057279	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.503	rs1829603	ENSG00000267672.1	CTD-2293H3.1	4.42	1.34e-05	0.0062	0.21	0.23	Obesity-related traits;	chr19:37065396	chr19:37091341~37092564:+
STAD	cis	rs4604732	0.642	rs4400652	ENSG00000227135.1	GCSAML-AS1	-4.42	1.34e-05	0.0062	-0.29	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473177	chr1:247524679~247526752:-
STAD	cis	rs9291683	0.679	rs3756225	ENSG00000250613.1	RP11-136I13.1	4.42	1.34e-05	0.0062	0.22	0.23	Bone mineral density;	chr4:10092509	chr4:10410996~10411644:+
STAD	cis	rs7191700	0.511	rs8043625	ENSG00000262703.1	RP11-485G7.6	-4.42	1.35e-05	0.00621	-0.22	-0.23	Multiple sclerosis;	chr16:11268038	chr16:11348143~11349321:-
STAD	cis	rs17767294	0.612	rs9461425	ENSG00000220721.1	OR1F12	4.42	1.35e-05	0.00621	0.36	0.23	Parkinson's disease;	chr6:27951910	chr6:28073316~28074233:+
STAD	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-4.42	1.35e-05	0.00621	-0.23	-0.23	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
STAD	cis	rs935334	1	rs12147952	ENSG00000258454.1	RP11-361H10.3	-4.42	1.35e-05	0.00621	-0.34	-0.23	Blood pressure;	chr14:76158541	chr14:76235817~76263474:+
STAD	cis	rs3770081	1	rs59968392	ENSG00000273080.1	RP11-301O19.1	-4.42	1.35e-05	0.00622	-0.52	-0.23	Facial emotion recognition (sad faces);	chr2:85907490	chr2:86195590~86196049:+
STAD	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	4.42	1.35e-05	0.00622	0.32	0.23	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
STAD	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-4.42	1.35e-05	0.00622	-0.36	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
STAD	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	4.42	1.35e-05	0.00622	0.35	0.23	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
STAD	cis	rs9902453	0.808	rs4595850	ENSG00000240074.1	RPL9P30	4.42	1.35e-05	0.00622	0.2	0.23	Coffee consumption (cups per day);	chr17:29879308	chr17:29855759~29856332:+
STAD	cis	rs6539288	0.677	rs11113144	ENSG00000260329.1	RP11-412D9.4	-4.42	1.35e-05	0.00622	-0.24	-0.23	Total body bone mineral density;	chr12:106929644	chr12:106954029~106955497:-
STAD	cis	rs708547	0.581	rs13121027	ENSG00000269949.1	RP11-738E22.3	-4.42	1.35e-05	0.00623	-0.27	-0.23	Response to bleomycin (chromatid breaks);	chr4:56947203	chr4:56960927~56961373:-
STAD	cis	rs77956314	0.515	rs9804817	ENSG00000274554.1	RP11-240G22.5	4.42	1.35e-05	0.00623	0.29	0.23	Hippocampal volume;Subcortical brain region volumes;	chr12:117002415	chr12:116948738~116951422:-
STAD	cis	rs77956314	0.515	rs10850741	ENSG00000274554.1	RP11-240G22.5	-4.42	1.35e-05	0.00623	-0.29	-0.23	Hippocampal volume;Subcortical brain region volumes;	chr12:116994199	chr12:116948738~116951422:-
STAD	cis	rs77956314	0.515	rs7302025	ENSG00000274554.1	RP11-240G22.5	-4.42	1.35e-05	0.00623	-0.29	-0.23	Hippocampal volume;Subcortical brain region volumes;	chr12:117005097	chr12:116948738~116951422:-
STAD	cis	rs17401966	0.931	rs12409754	ENSG00000199562.1	RNU6-37P	4.42	1.35e-05	0.00623	0.18	0.23	Hepatocellular carcinoma;	chr1:10397483	chr1:10298966~10299072:+
STAD	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-4.42	1.35e-05	0.00623	-0.37	-0.23	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
STAD	cis	rs2695743	0.619	rs11680652	ENSG00000225808.1	DNAJC19P5	-4.42	1.35e-05	0.00623	-0.27	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177823564	chr2:177229191~177229506:-
STAD	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-4.42	1.35e-05	0.00623	-0.4	-0.23	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
STAD	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	4.42	1.35e-05	0.00623	0.29	0.23	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
STAD	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	4.42	1.35e-05	0.00623	0.22	0.23	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
STAD	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-4.42	1.35e-05	0.00623	-0.34	-0.23	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-4.42	1.35e-05	0.00623	-0.34	-0.23	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	4.42	1.35e-05	0.00623	0.34	0.23	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	4.42	1.35e-05	0.00623	0.34	0.23	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
STAD	cis	rs875971	0.545	rs73378304	ENSG00000236529.1	RP13-254B10.1	4.42	1.35e-05	0.00623	0.26	0.23	Aortic root size;	chr7:66175760	chr7:65840212~65840596:+
STAD	cis	rs6832769	0.925	rs6829182	ENSG00000272969.1	RP11-528I4.2	4.41	1.35e-05	0.00624	0.29	0.23	Personality dimensions;	chr4:55587989	chr4:55547112~55547889:+
STAD	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	4.41	1.35e-05	0.00624	0.19	0.23	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
STAD	cis	rs748404	0.697	rs501884	ENSG00000275601.1	AC011330.13	-4.41	1.35e-05	0.00624	-0.24	-0.23	Lung cancer;	chr15:43261784	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs504417	ENSG00000275601.1	AC011330.13	-4.41	1.35e-05	0.00624	-0.24	-0.23	Lung cancer;	chr15:43262028	chr15:43642389~43643023:-
STAD	cis	rs748404	0.723	rs560134	ENSG00000275601.1	AC011330.13	-4.41	1.35e-05	0.00624	-0.24	-0.23	Lung cancer;	chr15:43263501	chr15:43642389~43643023:-
STAD	cis	rs875971	0.798	rs12698522	ENSG00000224316.1	RP11-479O9.2	4.41	1.35e-05	0.00624	0.22	0.23	Aortic root size;	chr7:66502354	chr7:65773620~65802067:+
STAD	cis	rs875971	0.83	rs28714531	ENSG00000224316.1	RP11-479O9.2	4.41	1.35e-05	0.00624	0.22	0.23	Aortic root size;	chr7:66503250	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs12698526	ENSG00000224316.1	RP11-479O9.2	4.41	1.35e-05	0.00624	0.22	0.23	Aortic root size;	chr7:66504118	chr7:65773620~65802067:+
STAD	cis	rs1322639	0.657	rs12203887	ENSG00000261039.2	RP11-417E7.2	-4.41	1.35e-05	0.00624	-0.38	-0.23	Pulse pressure;	chr6:169172157	chr6:169175304~169182740:-
STAD	cis	rs6584283	1	rs6584283	ENSG00000257582.4	LINC01475	-4.41	1.36e-05	0.00625	-0.26	-0.23	Ulcerative colitis;	chr10:99530544	chr10:99526350~99531177:-
STAD	cis	rs2688608	0.592	rs7923045	ENSG00000272140.2	RP11-574K11.29	4.41	1.36e-05	0.00625	0.2	0.23	Inflammatory bowel disease;	chr10:73727740	chr10:73703735~73713581:-
STAD	cis	rs7615952	0.512	rs2979336	ENSG00000171084.14	FAM86JP	4.41	1.36e-05	0.00626	0.34	0.23	Blood pressure (smoking interaction);	chr3:125638626	chr3:125916620~125930024:+
STAD	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	4.41	1.36e-05	0.00626	0.33	0.23	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
STAD	cis	rs8028182	0.501	rs11072553	ENSG00000260269.4	CTD-2323K18.1	-4.41	1.36e-05	0.00626	-0.31	-0.23	Sudden cardiac arrest;	chr15:75640436	chr15:75527150~75601205:-
STAD	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-4.41	1.36e-05	0.00626	-0.24	-0.23	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
STAD	cis	rs8012947	1	rs4595719	ENSG00000279636.2	LINC00216	-4.41	1.36e-05	0.00626	-0.23	-0.23	Alcohol consumption in current drinkers;	chr14:58302084	chr14:58288033~58289158:+
STAD	cis	rs12571093	0.571	rs4517412	ENSG00000233590.1	RP11-153K11.3	4.41	1.36e-05	0.00626	0.32	0.23	Optic nerve measurement (disc area);	chr10:68303779	chr10:68233251~68242379:-
STAD	cis	rs12571093	0.571	rs7097498	ENSG00000233590.1	RP11-153K11.3	4.41	1.36e-05	0.00626	0.32	0.23	Optic nerve measurement (disc area);	chr10:68303780	chr10:68233251~68242379:-
STAD	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-4.41	1.36e-05	0.00627	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
STAD	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	4.41	1.36e-05	0.00627	0.34	0.23	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
STAD	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	4.41	1.36e-05	0.00627	0.43	0.23	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
STAD	cis	rs2904967	0.598	rs2904978	ENSG00000254614.2	AP003068.23	4.41	1.36e-05	0.00628	0.34	0.23	Mean corpuscular volume;	chr11:65233007	chr11:65177606~65181834:-
STAD	cis	rs944990	0.538	rs10115234	ENSG00000227603.1	RP11-165J3.6	-4.41	1.36e-05	0.00628	-0.25	-0.23	Body mass index;	chr9:93538990	chr9:93435332~93437121:-
STAD	cis	rs2880765	0.545	rs11631739	ENSG00000229212.6	RP11-561C5.4	4.41	1.36e-05	0.00628	0.33	0.23	Coronary artery disease;	chr15:85469347	chr15:85205440~85234795:-
STAD	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-4.41	1.36e-05	0.00628	-0.35	-0.23	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
STAD	cis	rs4141404	0.604	rs2103853	ENSG00000236132.1	CTA-440B3.1	-4.41	1.37e-05	0.00629	-0.25	-0.23	Paclitaxel-induced neuropathy;	chr22:31459489	chr22:31816379~31817491:-
STAD	cis	rs73186030	0.591	rs56098325	ENSG00000272758.4	RP11-299J3.8	4.41	1.37e-05	0.00629	0.39	0.23	Serum parathyroid hormone levels;	chr3:122342362	chr3:122416207~122443180:+
STAD	cis	rs4142995	0.772	rs2691584	ENSG00000279048.1	RP11-511H23.2	-4.41	1.37e-05	0.00629	-0.22	-0.23	HDL cholesterol;HDL cholesterol levels;	chr7:17777193	chr7:17940503~17942922:+
STAD	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	4.41	1.37e-05	0.00629	0.24	0.23	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	4.41	1.37e-05	0.00629	0.24	0.23	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
STAD	cis	rs9329221	0.683	rs658385	ENSG00000254340.1	RP11-10A14.3	-4.41	1.37e-05	0.00629	-0.29	-0.23	Neuroticism;	chr8:10034667	chr8:9141424~9145435:+
STAD	cis	rs6813195	0.716	rs2054757	ENSG00000243417.1	RP11-555K12.1	-4.41	1.37e-05	0.0063	-0.23	-0.23	Type 2 diabetes;	chr4:152564767	chr4:152551277~152552364:-
STAD	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	4.41	1.37e-05	0.0063	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
STAD	cis	rs10129255	0.536	rs10139058	ENSG00000211973.2	IGHV1-69	4.41	1.37e-05	0.0063	0.19	0.23	Kawasaki disease;	chr14:106685899	chr14:106714684~106715181:-
STAD	cis	rs1594829	0.553	rs2046225	ENSG00000228451.3	SDAD1P1	-4.41	1.37e-05	0.0063	-0.24	-0.23	Height;	chr8:26294286	chr8:26379259~26382953:-
STAD	cis	rs7671266	0.622	rs11943276	ENSG00000250613.1	RP11-136I13.1	4.41	1.37e-05	0.00631	0.26	0.23	Cardiovascular disease risk factors;	chr4:10401921	chr4:10410996~10411644:+
STAD	cis	rs4589258	0.897	rs7112861	ENSG00000280367.1	RP11-121L10.2	-4.41	1.37e-05	0.00631	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90683511	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs12806535	ENSG00000280367.1	RP11-121L10.2	-4.41	1.37e-05	0.00631	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90692410	chr11:90223153~90226538:+
STAD	cis	rs9788721	0.836	rs72738736	ENSG00000259419.2	HNRNPCP3	4.41	1.37e-05	0.00631	0.25	0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78472780	chr15:79236332~79237206:+
STAD	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-4.41	1.37e-05	0.00631	-0.23	-0.23	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
STAD	cis	rs4589258	0.762	rs7925702	ENSG00000280367.1	RP11-121L10.2	-4.41	1.37e-05	0.00631	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90663435	chr11:90223153~90226538:+
STAD	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-4.41	1.37e-05	0.00631	-0.28	-0.23	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
STAD	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	4.41	1.37e-05	0.00631	0.2	0.23	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
STAD	cis	rs8012947	1	rs1957038	ENSG00000279636.2	LINC00216	-4.41	1.37e-05	0.00631	-0.23	-0.23	Alcohol consumption in current drinkers;	chr14:58299899	chr14:58288033~58289158:+
STAD	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	4.41	1.37e-05	0.00632	0.25	0.23	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
STAD	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	4.41	1.37e-05	0.00632	0.35	0.23	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
STAD	cis	rs2483058	0.796	rs11120291	ENSG00000261000.1	RP11-534L20.5	4.41	1.37e-05	0.00632	0.28	0.23	Cholesterol and Triglycerides;	chr1:206442751	chr1:206503948~206504456:+
STAD	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-4.41	1.37e-05	0.00632	-0.24	-0.23	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-4.41	1.37e-05	0.00632	-0.24	-0.23	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
STAD	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-4.41	1.37e-05	0.00632	-0.27	-0.23	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
STAD	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	4.41	1.38e-05	0.00633	0.28	0.23	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
STAD	cis	rs73198271	0.71	rs11779565	ENSG00000233609.3	RP11-62H7.2	-4.41	1.38e-05	0.00633	-0.29	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:8961200~8979025:+
STAD	cis	rs1707322	0.506	rs2991983	ENSG00000225447.1	RPS15AP10	-4.41	1.38e-05	0.00633	-0.19	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45645816~45646197:-
STAD	cis	rs8062405	0.723	rs4788079	ENSG00000278665.1	RP11-666O2.4	4.41	1.38e-05	0.00633	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28599241~28601881:-
STAD	cis	rs149313	0.577	rs26506	ENSG00000272109.1	CTD-2260A17.3	-4.41	1.38e-05	0.00633	-0.27	-0.23	Blood protein levels;	chr5:96743698	chr5:96804353~96806105:+
STAD	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00633	-0.34	-0.23	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00633	-0.34	-0.23	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00633	-0.34	-0.23	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00633	-0.34	-0.23	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00633	-0.34	-0.23	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
STAD	cis	rs7487075	0.504	rs7312682	ENSG00000272369.1	RP11-446N19.1	4.41	1.38e-05	0.00633	0.28	0.23	Itch intensity from mosquito bite;	chr12:46254215	chr12:46537502~46652550:+
STAD	cis	rs7487075	1	rs12827740	ENSG00000257261.4	RP11-96H19.1	4.41	1.38e-05	0.00633	0.28	0.23	Itch intensity from mosquito bite;	chr12:46454332	chr12:46383679~46876159:+
STAD	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	4.41	1.38e-05	0.00633	0.24	0.23	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	4.41	1.38e-05	0.00633	0.24	0.23	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
STAD	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	-4.41	1.38e-05	0.00634	-0.26	-0.23	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
STAD	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	4.41	1.38e-05	0.00634	0.3	0.23	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	4.41	1.38e-05	0.00634	0.3	0.23	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	4.41	1.38e-05	0.00634	0.3	0.23	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
STAD	cis	rs7015630	0.657	rs34126178	ENSG00000251136.7	RP11-37B2.1	-4.41	1.38e-05	0.00634	-0.34	-0.23	Inflammatory bowel disease;Crohn's disease;	chr8:89807953	chr8:89609409~89757727:-
STAD	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-4.41	1.38e-05	0.00634	-0.21	-0.23	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
STAD	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	4.41	1.38e-05	0.00634	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
STAD	cis	rs7176527	0.5	rs895571	ENSG00000188388.10	GOLGA6L3	4.41	1.38e-05	0.00634	0.29	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:85240472~85247170:+
STAD	cis	rs7937890	0.81	rs10734224	ENSG00000254418.1	RP11-21L19.1	4.41	1.38e-05	0.00634	0.25	0.23	Mitochondrial DNA levels;	chr11:14402578	chr11:14262846~14273691:-
STAD	cis	rs2273156	1	rs12893021	ENSG00000241052.1	RP11-173D9.1	-4.41	1.38e-05	0.00634	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34971474	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12895051	ENSG00000241052.1	RP11-173D9.1	-4.41	1.38e-05	0.00634	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34974864	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs35090385	ENSG00000241052.1	RP11-173D9.1	-4.41	1.38e-05	0.00634	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34975229	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs71421920	ENSG00000241052.1	RP11-173D9.1	-4.41	1.38e-05	0.00634	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34977539	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs8019179	ENSG00000241052.1	RP11-173D9.1	-4.41	1.38e-05	0.00634	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34978589	chr14:35144021~35144480:-
STAD	cis	rs4589258	0.737	rs10501731	ENSG00000280367.1	RP11-121L10.2	-4.41	1.38e-05	0.00634	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90672161	chr11:90223153~90226538:+
STAD	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	4.41	1.38e-05	0.00635	0.3	0.23	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
STAD	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-4.41	1.38e-05	0.00635	-0.37	-0.23	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-4.41	1.38e-05	0.00635	-0.37	-0.23	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-4.41	1.38e-05	0.00635	-0.37	-0.23	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-4.41	1.38e-05	0.00635	-0.37	-0.23	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
STAD	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66692349	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66693433	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66694214	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66701371	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66702658	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66706390	chr7:66654538~66669855:+
STAD	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66710076	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66715944	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66721259	chr7:66654538~66669855:+
STAD	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-4.41	1.38e-05	0.00635	-0.36	-0.23	Gout;	chr7:66732812	chr7:66654538~66669855:+
STAD	cis	rs9291683	0.655	rs3822242	ENSG00000250613.1	RP11-136I13.1	4.41	1.38e-05	0.00635	0.22	0.23	Bone mineral density;	chr4:10093280	chr4:10410996~10411644:+
STAD	cis	rs7690978	1	rs7690978	ENSG00000248165.1	RP11-44F21.2	4.41	1.38e-05	0.00635	0.28	0.23	Interferon gamma-induced protein 10 levels;	chr4:75066634	chr4:74993877~75034824:-
STAD	cis	rs8055167	1	rs8055167	ENSG00000280152.1	RP11-331F4.5	4.41	1.38e-05	0.00635	0.26	0.23	Alcoholic chronic pancreatitis;	chr16:75220991	chr16:75245994~75250077:-
STAD	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	4.41	1.38e-05	0.00635	0.24	0.23	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
STAD	cis	rs11846409	0.789	rs34917868	ENSG00000274576.2	IGHV2-70	-4.41	1.38e-05	0.00635	-0.29	-0.23	Rheumatic heart disease;	chr14:106618321	chr14:106770577~106771020:-
STAD	cis	rs7615952	0.558	rs17334039	ENSG00000242229.1	RPS3AP14	4.41	1.38e-05	0.00636	0.28	0.23	Blood pressure (smoking interaction);	chr3:125821465	chr3:125795106~125795885:+
STAD	cis	rs7615952	0.688	rs12638240	ENSG00000242229.1	RPS3AP14	4.41	1.38e-05	0.00636	0.28	0.23	Blood pressure (smoking interaction);	chr3:125822395	chr3:125795106~125795885:+
STAD	cis	rs7615952	0.688	rs12638224	ENSG00000242229.1	RPS3AP14	4.41	1.38e-05	0.00636	0.28	0.23	Blood pressure (smoking interaction);	chr3:125822477	chr3:125795106~125795885:+
STAD	cis	rs6951245	0.744	rs1133122	ENSG00000229043.2	AC091729.9	-4.41	1.38e-05	0.00636	-0.36	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1160374~1165267:+
STAD	cis	rs8014252	0.803	rs59233924	ENSG00000259158.2	ADAM20P1	-4.41	1.39e-05	0.00637	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70583943	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs10483830	ENSG00000259158.2	ADAM20P1	-4.41	1.39e-05	0.00637	-0.32	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70587761	chr14:70468881~70483756:-
STAD	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-4.41	1.39e-05	0.00637	-0.33	-0.23	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
STAD	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	4.41	1.39e-05	0.00637	0.23	0.23	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
STAD	cis	rs6430585	0.528	rs309123	ENSG00000231890.6	DARS-AS1	-4.41	1.39e-05	0.00637	-0.25	-0.23	Corneal structure;	chr2:136003605	chr2:135985176~136022593:+
STAD	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	4.41	1.39e-05	0.00637	0.35	0.23	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	4.41	1.39e-05	0.00637	0.35	0.23	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
STAD	cis	rs6921919	0.583	rs6907950	ENSG00000220721.1	OR1F12	4.41	1.39e-05	0.00637	0.24	0.23	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28073316~28074233:+
STAD	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	4.41	1.39e-05	0.00637	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
STAD	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	4.41	1.39e-05	0.00637	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
STAD	cis	rs228614	0.536	rs223475	ENSG00000248971.2	KRT8P46	-4.41	1.39e-05	0.00638	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102728746~102730171:-
STAD	cis	rs228614	0.536	rs223474	ENSG00000248971.2	KRT8P46	-4.41	1.39e-05	0.00638	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102728746~102730171:-
STAD	cis	rs10129255	0.917	rs7155356	ENSG00000232216.1	IGHV3-43	4.41	1.39e-05	0.00638	0.23	0.23	Kawasaki disease;	chr14:106697376	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.917	rs10137601	ENSG00000232216.1	IGHV3-43	4.41	1.39e-05	0.00638	0.23	0.23	Kawasaki disease;	chr14:106697476	chr14:106470264~106470800:-
STAD	cis	rs17301013	0.829	rs2006197	ENSG00000227373.4	RP11-160H22.5	4.41	1.39e-05	0.00638	0.28	0.23	Systemic lupus erythematosus;	chr1:174432825	chr1:174115300~174160004:-
STAD	cis	rs853679	0.506	rs1150711	ENSG00000220721.1	OR1F12	4.41	1.39e-05	0.00638	0.23	0.23	Depression;	chr6:28240757	chr6:28073316~28074233:+
STAD	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	4.41	1.39e-05	0.00638	0.28	0.23	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000211959.2	IGHV4-39	4.41	1.39e-05	0.00639	0.2	0.23	Kawasaki disease;	chr14:106807157	chr14:106421711~106422218:-
STAD	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	4.41	1.39e-05	0.00639	0.33	0.23	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	4.41	1.39e-05	0.00639	0.33	0.23	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
STAD	cis	rs6832769	1	rs1522106	ENSG00000272969.1	RP11-528I4.2	-4.41	1.39e-05	0.00639	-0.29	-0.23	Personality dimensions;	chr4:55441047	chr4:55547112~55547889:+
STAD	cis	rs9307551	0.894	rs6812760	ENSG00000250334.4	LINC00989	-4.41	1.39e-05	0.00639	-0.29	-0.23	Refractive error;	chr4:79560702	chr4:79492416~79576460:+
STAD	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-4.41	1.39e-05	0.00639	-0.3	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
STAD	cis	rs1799949	1	rs915945	ENSG00000236383.6	LINC00854	-4.41	1.39e-05	0.0064	-0.19	-0.23	Menopause (age at onset);	chr17:43027847	chr17:43216941~43305976:-
STAD	cis	rs11098499	0.908	rs11098527	ENSG00000260091.1	RP11-33B1.4	4.41	1.39e-05	0.0064	0.23	0.23	Corneal astigmatism;	chr4:119478751	chr4:119409333~119410233:+
STAD	cis	rs5758659	0.714	rs5751220	ENSG00000182057.4	OGFRP1	-4.41	1.39e-05	0.0064	-0.25	-0.23	Cognitive function;	chr22:42120201	chr22:42269753~42275196:+
STAD	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	4.41	1.39e-05	0.0064	0.28	0.23	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	4.41	1.39e-05	0.0064	0.28	0.23	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
STAD	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-4.41	1.39e-05	0.0064	-0.26	-0.23	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
STAD	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-4.41	1.4e-05	0.0064	-0.35	-0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
STAD	cis	rs8012947	0.877	rs10136481	ENSG00000279636.2	LINC00216	-4.41	1.4e-05	0.0064	-0.23	-0.23	Alcohol consumption in current drinkers;	chr14:58302690	chr14:58288033~58289158:+
STAD	cis	rs9486594	1	rs58558730	ENSG00000238490.1	Y_RNA	4.41	1.4e-05	0.00641	0.46	0.23	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:107450832	chr6:108060818~108060930:+
STAD	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
STAD	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
STAD	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
STAD	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
STAD	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
STAD	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
STAD	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-4.41	1.4e-05	0.00641	-0.24	-0.23	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
STAD	cis	rs6832769	0.961	rs11735267	ENSG00000272969.1	RP11-528I4.2	4.41	1.4e-05	0.00641	0.29	0.23	Personality dimensions;	chr4:55481120	chr4:55547112~55547889:+
STAD	cis	rs8141529	0.509	rs5762853	ENSG00000226471.5	CTA-292E10.6	-4.41	1.4e-05	0.00641	-0.28	-0.23	Lymphocyte counts;	chr22:28849243	chr22:28800683~28848559:+
STAD	cis	rs8177876	0.749	rs804895	ENSG00000261838.4	RP11-303E16.6	-4.41	1.4e-05	0.00641	-0.47	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81066108	chr16:81069854~81076598:+
STAD	cis	rs6714710	0.603	rs17489984	ENSG00000235833.1	AC159540.14	-4.41	1.4e-05	0.00641	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97804901	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.603	rs2044459	ENSG00000235833.1	AC159540.14	-4.41	1.4e-05	0.00641	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97830541	chr2:97523949~97524976:-
STAD	cis	rs6714710	0.557	rs17490429	ENSG00000235833.1	AC159540.14	-4.41	1.4e-05	0.00641	-0.27	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97832561	chr2:97523949~97524976:-
STAD	cis	rs4589258	0.933	rs1783788	ENSG00000280367.1	RP11-121L10.2	4.41	1.4e-05	0.00642	0.25	0.23	Intelligence (multi-trait analysis);	chr11:90701023	chr11:90223153~90226538:+
STAD	cis	rs227932	0.618	rs3807888	ENSG00000234286.1	AC006026.13	-4.41	1.4e-05	0.00642	-0.41	-0.23	Schizophrenia;	chr7:23710213	chr7:23680195~23680786:-
STAD	cis	rs559928	0.606	rs61083753	ENSG00000236935.1	AP003774.1	4.41	1.4e-05	0.00642	0.34	0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64125193	chr11:64325050~64329504:-
STAD	cis	rs4713118	0.869	rs9295743	ENSG00000243307.2	POM121L6P	-4.41	1.4e-05	0.00642	-0.27	-0.23	Parkinson's disease;	chr6:27747323	chr6:26896952~26898777:+
STAD	cis	rs1707322	0.717	rs1547925	ENSG00000225447.1	RPS15AP10	-4.41	1.4e-05	0.00642	-0.19	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45645816~45646197:-
STAD	cis	rs5753618	0.539	rs737888	ENSG00000236132.1	CTA-440B3.1	4.41	1.4e-05	0.00642	0.27	0.23	Colorectal cancer;	chr22:31215563	chr22:31816379~31817491:-
STAD	cis	rs9902453	0.817	rs67206808	ENSG00000240074.1	RPL9P30	4.41	1.4e-05	0.00642	0.2	0.23	Coffee consumption (cups per day);	chr17:29863078	chr17:29855759~29856332:+
STAD	cis	rs2337406	0.85	rs75196489	ENSG00000211972.2	IGHV3-66	4.41	1.4e-05	0.00642	0.26	0.23	Alzheimer's disease (late onset);	chr14:106699438	chr14:106675017~106675544:-
STAD	cis	rs6471393	0.964	rs7001808	ENSG00000253848.1	RP11-10N23.5	4.41	1.4e-05	0.00642	0.27	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93725043	chr8:93741193~93744534:+
STAD	cis	rs7103648	0.838	rs2293576	ENSG00000280615.1	Y_RNA	-4.41	1.4e-05	0.00643	-0.24	-0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47413435	chr11:47614898~47614994:-
STAD	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-4.41	1.4e-05	0.00643	-0.3	-0.23	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
STAD	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	4.41	1.4e-05	0.00643	0.33	0.23	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
STAD	cis	rs2408955	0.522	rs6580650	ENSG00000258273.1	RP11-370I10.4	4.41	1.4e-05	0.00643	0.28	0.23	Glycated hemoglobin levels;	chr12:48024773	chr12:48333755~48333901:-
STAD	cis	rs72687362	0.874	rs72687343	ENSG00000261693.1	RP13-467H17.1	4.41	1.4e-05	0.00644	0.37	0.23	Autism spectrum disorder or schizophrenia;	chr8:142264766	chr8:142403652~142407028:+
STAD	cis	rs9549328	0.67	rs2873372	ENSG00000267868.1	RP11-120K24.3	4.41	1.4e-05	0.00644	0.31	0.23	Systolic blood pressure;	chr13:112959069	chr13:112964835~112966131:-
STAD	cis	rs935334	1	rs2121077	ENSG00000258454.1	RP11-361H10.3	-4.41	1.4e-05	0.00644	-0.34	-0.23	Blood pressure;	chr14:76210012	chr14:76235817~76263474:+
STAD	cis	rs228614	0.509	rs223480	ENSG00000248971.2	KRT8P46	-4.41	1.4e-05	0.00644	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102728746~102730171:-
STAD	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-4.41	1.4e-05	0.00644	-0.23	-0.23	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
STAD	cis	rs11676348	0.808	rs12694430	ENSG00000237281.1	CATIP-AS2	4.41	1.41e-05	0.00644	0.23	0.23	Ulcerative colitis;	chr2:218151076	chr2:218326889~218357966:-
STAD	cis	rs1707322	0.721	rs11211165	ENSG00000281133.1	AL355480.3	-4.41	1.41e-05	0.00644	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs11211166	ENSG00000281133.1	AL355480.3	-4.41	1.41e-05	0.00644	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs12077974	ENSG00000225447.1	RPS15AP10	4.41	1.41e-05	0.00644	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45645816~45646197:-
STAD	cis	rs1032726	0.536	rs1488591	ENSG00000240057.4	RP11-572M11.4	-4.41	1.41e-05	0.00645	-0.21	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112802672	chr3:113019532~113183301:+
STAD	cis	rs1707322	1	rs11211248	ENSG00000281133.1	AL355480.3	-4.41	1.41e-05	0.00645	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45580892~45580996:-
STAD	cis	rs17401966	0.8	rs12122029	ENSG00000199562.1	RNU6-37P	4.41	1.41e-05	0.00645	0.18	0.23	Hepatocellular carcinoma;	chr1:10279764	chr1:10298966~10299072:+
STAD	cis	rs2695743	0.507	rs2695757	ENSG00000225808.1	DNAJC19P5	-4.41	1.41e-05	0.00645	-0.3	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177953302	chr2:177229191~177229506:-
STAD	cis	rs7680126	0.596	rs4698031	ENSG00000250613.1	RP11-136I13.1	4.41	1.41e-05	0.00646	0.25	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10314297	chr4:10410996~10411644:+
STAD	cis	rs9425766	0.566	rs12079820	ENSG00000227373.4	RP11-160H22.5	4.41	1.41e-05	0.00646	0.28	0.23	Life satisfaction;	chr1:174240771	chr1:174115300~174160004:-
STAD	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	4.41	1.41e-05	0.00646	0.39	0.23	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	4.41	1.41e-05	0.00646	0.39	0.23	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
STAD	cis	rs11673344	0.562	rs6510580	ENSG00000267672.1	CTD-2293H3.1	4.41	1.41e-05	0.00646	0.21	0.23	Obesity-related traits;	chr19:37038452	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs2082009	ENSG00000267672.1	CTD-2293H3.1	4.41	1.41e-05	0.00646	0.21	0.23	Obesity-related traits;	chr19:37039834	chr19:37091341~37092564:+
STAD	cis	rs748404	0.578	rs2584701	ENSG00000275601.1	AC011330.13	-4.41	1.41e-05	0.00647	-0.24	-0.23	Lung cancer;	chr15:43392741	chr15:43642389~43643023:-
STAD	cis	rs3811273	0.614	rs7146368	ENSG00000211816.2	TRAV38-1	-4.41	1.41e-05	0.00647	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22265436	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs7151848	ENSG00000211816.2	TRAV38-1	-4.41	1.41e-05	0.00647	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22265503	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.667	rs7147374	ENSG00000211816.2	TRAV38-1	-4.41	1.41e-05	0.00647	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22265607	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs7145658	ENSG00000211816.2	TRAV38-1	-4.41	1.41e-05	0.00647	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22265772	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs7152255	ENSG00000211816.2	TRAV38-1	-4.41	1.41e-05	0.00647	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22265774	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs7147116	ENSG00000211816.2	TRAV38-1	-4.41	1.41e-05	0.00647	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22265811	chr14:22271968~22272563:+
STAD	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	4.4	1.41e-05	0.00647	0.26	0.23	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
STAD	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	4.4	1.41e-05	0.00647	0.36	0.23	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
STAD	cis	rs1707322	1	rs7538978	ENSG00000225447.1	RPS15AP10	-4.4	1.41e-05	0.00647	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45645816~45646197:-
STAD	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	4.4	1.41e-05	0.00648	0.27	0.23	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
STAD	cis	rs2692947	0.759	rs2949885	ENSG00000237510.6	AC008268.2	4.4	1.41e-05	0.00648	0.29	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95996667	chr2:95789654~95800166:+
STAD	cis	rs1707322	0.964	rs1768802	ENSG00000281133.1	AL355480.3	4.4	1.42e-05	0.00648	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs1588663	ENSG00000281133.1	AL355480.3	4.4	1.42e-05	0.00648	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs1768801	ENSG00000281133.1	AL355480.3	4.4	1.42e-05	0.00648	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs1768800	ENSG00000281133.1	AL355480.3	4.4	1.42e-05	0.00648	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45580892~45580996:-
STAD	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	4.4	1.42e-05	0.00648	0.27	0.23	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
STAD	cis	rs932287	0.651	rs1111010	ENSG00000254860.4	TMEM9B-AS1	-4.4	1.42e-05	0.00648	-0.25	-0.23	Colonoscopy-negative controls vs population controls;	chr11:9028388	chr11:8964675~8977527:+
STAD	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	4.4	1.42e-05	0.00648	0.28	0.23	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	4.4	1.42e-05	0.00648	0.28	0.23	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
STAD	cis	rs4834770	1	rs878375	ENSG00000248280.1	RP11-33B1.2	4.4	1.42e-05	0.00649	0.27	0.23	Blood protein levels;	chr4:119316419	chr4:119440561~119450157:-
STAD	cis	rs2836974	0.644	rs2836986	ENSG00000238141.2	BRWD1-AS1	-4.4	1.42e-05	0.00649	-0.24	-0.23	Cognitive function;	chr21:39330210	chr21:39315707~39323218:+
STAD	cis	rs6832769	0.826	rs10462035	ENSG00000272969.1	RP11-528I4.2	4.4	1.42e-05	0.00649	0.29	0.23	Personality dimensions;	chr4:55513011	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs2177127	ENSG00000272969.1	RP11-528I4.2	4.4	1.42e-05	0.00649	0.29	0.23	Personality dimensions;	chr4:55513792	chr4:55547112~55547889:+
STAD	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	4.4	1.42e-05	0.00649	0.28	0.23	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
STAD	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	4.4	1.42e-05	0.0065	0.33	0.23	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
STAD	cis	rs561341	1	rs113115092	ENSG00000265798.5	RP11-271K11.5	4.4	1.42e-05	0.0065	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31957145	chr17:31038575~31059121:-
STAD	cis	rs1799949	0.93	rs34210004	ENSG00000279602.1	CTD-3014M21.1	4.4	1.42e-05	0.0065	0.29	0.23	Menopause (age at onset);	chr17:43218318	chr17:43360041~43361361:-
STAD	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	4.4	1.42e-05	0.0065	0.29	0.23	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
STAD	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	4.4	1.42e-05	0.0065	0.28	0.23	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
STAD	cis	rs2836950	0.501	rs13047518	ENSG00000238141.2	BRWD1-AS1	-4.4	1.42e-05	0.00651	-0.24	-0.23	Menarche (age at onset);	chr21:39335381	chr21:39315707~39323218:+
STAD	cis	rs721917	0.525	rs7903576	ENSG00000225484.5	NUTM2B-AS1	-4.4	1.42e-05	0.00651	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79663088~79826594:-
STAD	cis	rs721917	0.569	rs2247820	ENSG00000244733.5	RP11-506M13.3	-4.4	1.42e-05	0.00651	-0.26	-0.23	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79660891~79677996:+
STAD	cis	rs6832769	1	rs35767091	ENSG00000272969.1	RP11-528I4.2	4.4	1.42e-05	0.00651	0.29	0.23	Personality dimensions;	chr4:55480556	chr4:55547112~55547889:+
STAD	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	4.4	1.42e-05	0.00651	0.29	0.23	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
STAD	cis	rs6832769	0.925	rs4371676	ENSG00000272969.1	RP11-528I4.2	4.4	1.42e-05	0.00651	0.29	0.23	Personality dimensions;	chr4:55462841	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs4864998	ENSG00000272969.1	RP11-528I4.2	4.4	1.42e-05	0.00651	0.29	0.23	Personality dimensions;	chr4:55466439	chr4:55547112~55547889:+
STAD	cis	rs6832769	0.961	rs2140077	ENSG00000272969.1	RP11-528I4.2	4.4	1.42e-05	0.00651	0.29	0.23	Personality dimensions;	chr4:55472786	chr4:55547112~55547889:+
STAD	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-4.4	1.42e-05	0.00652	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-4.4	1.42e-05	0.00652	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-4.4	1.42e-05	0.00652	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-4.4	1.42e-05	0.00652	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
STAD	cis	rs801193	0.66	rs10950049	ENSG00000224316.1	RP11-479O9.2	4.4	1.43e-05	0.00652	0.23	0.23	Aortic root size;	chr7:66765873	chr7:65773620~65802067:+
STAD	cis	rs237743	1	rs34580798	ENSG00000222365.1	SNORD12B	-4.4	1.43e-05	0.00652	-0.31	-0.23	Height;	chr20:49283420	chr20:49280319~49280409:+
STAD	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	4.4	1.43e-05	0.00652	0.25	0.23	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
STAD	cis	rs17264034	0.821	rs374218	ENSG00000250786.1	SNHG18	4.4	1.43e-05	0.00653	0.37	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9548331	chr5:9546200~9550609:+
STAD	cis	rs9902453	0.765	rs2628180	ENSG00000240074.1	RPL9P30	-4.4	1.43e-05	0.00653	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29774705	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.765	rs2729440	ENSG00000240074.1	RPL9P30	-4.4	1.43e-05	0.00653	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29779856	chr17:29855759~29856332:+
STAD	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	4.4	1.43e-05	0.00653	0.33	0.23	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
STAD	cis	rs9467773	0.62	rs2451737	ENSG00000243307.2	POM121L6P	4.4	1.43e-05	0.00653	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.596	rs2494693	ENSG00000243307.2	POM121L6P	4.4	1.43e-05	0.00653	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2494694	ENSG00000243307.2	POM121L6P	4.4	1.43e-05	0.00653	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.595	rs2451736	ENSG00000243307.2	POM121L6P	4.4	1.43e-05	0.00653	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26896952~26898777:+
STAD	cis	rs393951	0.81	rs452742	ENSG00000260969.1	RP11-190D6.2	-4.4	1.43e-05	0.00653	-0.26	-0.23	Childhood ear infection;	chr16:77586790	chr16:78237362~78241218:-
STAD	cis	rs516805	0.596	rs2606625	ENSG00000279453.1	RP3-425C14.4	-4.4	1.43e-05	0.00653	-0.35	-0.23	Lymphocyte counts;	chr6:122165363	chr6:122436789~122439223:-
STAD	cis	rs822354	0.926	rs266740	ENSG00000230951.1	GPS2P2	-4.4	1.43e-05	0.00653	-0.29	-0.23	Adiponectin levels;	chr3:186759540	chr3:186772589~186773476:+
STAD	cis	rs12908161	1	rs12911736	ENSG00000259295.5	CSPG4P12	4.4	1.43e-05	0.00653	0.33	0.23	Schizophrenia;	chr15:84696777	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs12908699	ENSG00000259295.5	CSPG4P12	4.4	1.43e-05	0.00653	0.33	0.23	Schizophrenia;	chr15:84697172	chr15:85191438~85213905:+
STAD	cis	rs7120173	0.915	rs12786797	ENSG00000254851.1	RP11-109L13.1	-4.4	1.43e-05	0.00654	-0.34	-0.23	Visceral adipose tissue adjusted for BMI;	chr11:117017035	chr11:117135528~117138582:+
STAD	cis	rs8141529	0.719	rs6005916	ENSG00000272858.1	CTA-292E10.8	-4.4	1.43e-05	0.00654	-0.25	-0.23	Lymphocyte counts;	chr22:28837354	chr22:28814914~28815662:+
STAD	cis	rs9807989	0.801	rs6734742	ENSG00000234389.1	AC007278.3	4.4	1.43e-05	0.00654	0.24	0.23	Asthma;	chr2:102351397	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.801	rs6752482	ENSG00000234389.1	AC007278.3	4.4	1.43e-05	0.00654	0.24	0.23	Asthma;	chr2:102351398	chr2:102438713~102440475:+
STAD	cis	rs7818382	1	rs7818382	ENSG00000253528.2	RP11-347C18.4	4.4	1.43e-05	0.00654	0.21	0.23	Alzheimer's disease (late onset);	chr8:95041772	chr8:94974573~94974853:-
STAD	cis	rs7665090	0.87	rs227361	ENSG00000248971.2	KRT8P46	-4.4	1.43e-05	0.00654	-0.23	-0.23	Primary biliary cholangitis;	chr4:102665820	chr4:102728746~102730171:-
STAD	cis	rs507080	0.922	rs585039	ENSG00000278376.1	RP11-158I9.8	-4.4	1.43e-05	0.00655	-0.24	-0.23	Serum metabolite levels;	chr11:118692672	chr11:118791254~118793137:+
STAD	cis	rs9807989	0.801	rs10176664	ENSG00000234389.1	AC007278.3	4.4	1.43e-05	0.00655	0.24	0.23	Asthma;	chr2:102359712	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs6543123	ENSG00000234389.1	AC007278.3	4.4	1.43e-05	0.00655	0.24	0.23	Asthma;	chr2:102360736	chr2:102438713~102440475:+
STAD	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	4.4	1.43e-05	0.00655	0.34	0.23	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
STAD	cis	rs9847710	0.967	rs4687694	ENSG00000242142.1	SERBP1P3	4.4	1.43e-05	0.00655	0.22	0.23	Ulcerative colitis;	chr3:53015031	chr3:53064283~53065091:-
STAD	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-4.4	1.43e-05	0.00655	-0.33	-0.23	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000224373.3	IGHV4-59	4.4	1.43e-05	0.00656	0.16	0.23	Kawasaki disease;	chr14:106782219	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000224373.3	IGHV4-59	4.4	1.43e-05	0.00656	0.16	0.23	Kawasaki disease;	chr14:106782337	chr14:106627249~106627825:-
STAD	cis	rs2938670	1	rs2938670	ENSG00000259419.2	HNRNPCP3	4.4	1.44e-05	0.00656	0.25	0.23	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;	chr15:78448346	chr15:79236332~79237206:+
STAD	cis	rs9788721	0.836	rs2656052	ENSG00000259419.2	HNRNPCP3	4.4	1.44e-05	0.00656	0.25	0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78448590	chr15:79236332~79237206:+
STAD	cis	rs853679	0.55	rs1150689	ENSG00000220721.1	OR1F12	4.4	1.44e-05	0.00656	0.26	0.23	Depression;	chr6:28197321	chr6:28073316~28074233:+
STAD	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	4.4	1.44e-05	0.00656	0.23	0.23	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
STAD	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	4.4	1.44e-05	0.00656	0.36	0.23	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	4.4	1.44e-05	0.00656	0.36	0.23	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	4.4	1.44e-05	0.00656	0.36	0.23	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
STAD	cis	rs1707322	1	rs785480	ENSG00000281133.1	AL355480.3	-4.4	1.44e-05	0.00657	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45580892~45580996:-
STAD	cis	rs6714710	0.603	rs6738389	ENSG00000235833.1	AC159540.14	-4.4	1.44e-05	0.00657	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97770268	chr2:97523949~97524976:-
STAD	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	4.4	1.44e-05	0.00657	0.25	0.23	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
STAD	cis	rs9291683	0.51	rs4318649	ENSG00000250613.1	RP11-136I13.1	-4.4	1.44e-05	0.00658	-0.24	-0.23	Bone mineral density;	chr4:10015191	chr4:10410996~10411644:+
STAD	cis	rs3733585	0.746	rs4318650	ENSG00000250613.1	RP11-136I13.1	-4.4	1.44e-05	0.00658	-0.24	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:10015244	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.526	rs6827785	ENSG00000250613.1	RP11-136I13.1	-4.4	1.44e-05	0.00658	-0.24	-0.23	Bone mineral density;	chr4:10016581	chr4:10410996~10411644:+
STAD	cis	rs4604732	0.603	rs10802512	ENSG00000227135.1	GCSAML-AS1	-4.4	1.44e-05	0.00658	-0.29	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247470428	chr1:247524679~247526752:-
STAD	cis	rs858239	0.863	rs466225	ENSG00000230042.1	AK3P3	-4.4	1.44e-05	0.00658	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23129178~23129841:+
STAD	cis	rs9807989	0.839	rs4988956	ENSG00000234389.1	AC007278.3	4.4	1.44e-05	0.00658	0.24	0.23	Asthma;	chr2:102351547	chr2:102438713~102440475:+
STAD	cis	rs10129255	0.518	rs10150460	ENSG00000211973.2	IGHV1-69	-4.4	1.44e-05	0.00659	-0.19	-0.23	Kawasaki disease;	chr14:106677179	chr14:106714684~106715181:-
STAD	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-4.4	1.44e-05	0.00659	-0.24	-0.23	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
STAD	cis	rs12908161	1	rs62021219	ENSG00000259295.5	CSPG4P12	4.4	1.44e-05	0.00659	0.33	0.23	Schizophrenia;	chr15:84712928	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs34900908	ENSG00000259295.5	CSPG4P12	4.4	1.44e-05	0.00659	0.33	0.23	Schizophrenia;	chr15:84714368	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs35524990	ENSG00000259295.5	CSPG4P12	4.4	1.44e-05	0.00659	0.33	0.23	Schizophrenia;	chr15:84714972	chr15:85191438~85213905:+
STAD	cis	rs427691	0.625	rs372062	ENSG00000271849.1	CTC-332L22.1	-4.4	1.44e-05	0.00659	-0.39	-0.23	Autism spectrum disorder or schizophrenia;	chr5:109674826	chr5:109687802~109688329:-
STAD	cis	rs4388249	0.516	rs435494	ENSG00000271849.1	CTC-332L22.1	-4.4	1.44e-05	0.00659	-0.39	-0.23	Schizophrenia;	chr5:109674877	chr5:109687802~109688329:-
STAD	cis	rs1816752	0.774	rs2862895	ENSG00000232858.1	RPL34P27	4.4	1.44e-05	0.00659	0.14	0.23	Obesity-related traits;	chr13:24410328	chr13:24988577~24988925:-
STAD	cis	rs7598759	0.527	rs12987949	ENSG00000223198.1	RNU2-22P	-4.4	1.45e-05	0.0066	-0.27	-0.23	Noise-induced hearing loss;	chr2:231502800	chr2:231501990~231502201:-
STAD	cis	rs875971	1	rs6945843	ENSG00000236529.1	RP13-254B10.1	-4.4	1.45e-05	0.0066	-0.24	-0.23	Aortic root size;	chr7:66269796	chr7:65840212~65840596:+
STAD	cis	rs1799949	1	rs4793194	ENSG00000279602.1	CTD-3014M21.1	4.4	1.45e-05	0.0066	0.29	0.23	Menopause (age at onset);	chr17:43066316	chr17:43360041~43361361:-
STAD	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-4.4	1.45e-05	0.0066	-0.23	-0.23	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-4.4	1.45e-05	0.0066	-0.22	-0.23	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
STAD	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-4.4	1.45e-05	0.0066	-0.32	-0.23	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000211959.2	IGHV4-39	4.4	1.45e-05	0.0066	0.2	0.23	Kawasaki disease;	chr14:106802182	chr14:106421711~106422218:-
STAD	cis	rs911555	0.57	rs11625397	ENSG00000258851.1	RP11-894P9.2	4.4	1.45e-05	0.0066	0.28	0.23	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103553421~103561877:+
STAD	cis	rs3811273	0.614	rs7156203	ENSG00000211816.2	TRAV38-1	-4.4	1.45e-05	0.0066	-0.29	-0.23	Periodontal disease-related phenotypes;	chr14:22263640	chr14:22271968~22272563:+
STAD	cis	rs4950322	0.634	rs4950415	ENSG00000278811.3	LINC00624	4.4	1.45e-05	0.0066	0.25	0.23	Protein quantitative trait loci;	chr1:147350951	chr1:147258885~147517875:-
STAD	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-4.4	1.45e-05	0.00661	-0.3	-0.23	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
STAD	cis	rs7119038	0.509	rs11216956	ENSG00000255422.1	AP002954.4	4.4	1.45e-05	0.00661	0.29	0.23	Sjögren's syndrome;	chr11:118704617	chr11:118704607~118750263:+
STAD	cis	rs11018874	0.532	rs11018867	ENSG00000280367.1	RP11-121L10.2	4.4	1.45e-05	0.00661	0.29	0.23	White blood cell types;	chr11:90129177	chr11:90223153~90226538:+
STAD	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-4.4	1.45e-05	0.00662	-0.3	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
STAD	cis	rs2836974	0.644	rs11088471	ENSG00000238141.2	BRWD1-AS1	-4.4	1.45e-05	0.00662	-0.24	-0.23	Cognitive function;	chr21:39327387	chr21:39315707~39323218:+
STAD	cis	rs822354	0.963	rs266741	ENSG00000230951.1	GPS2P2	-4.4	1.45e-05	0.00662	-0.29	-0.23	Adiponectin levels;	chr3:186759497	chr3:186772589~186773476:+
STAD	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-4.4	1.45e-05	0.00662	-0.22	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
STAD	cis	rs6921919	0.583	rs9468370	ENSG00000220721.1	OR1F12	4.4	1.45e-05	0.00662	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28073316~28074233:+
STAD	cis	rs7849270	0.679	rs10988217	ENSG00000268707.1	RP11-247A12.7	-4.4	1.45e-05	0.00662	-0.26	-0.23	Blood metabolite ratios;	chr9:129125837	chr9:129170434~129170940:+
STAD	cis	rs4589258	0.788	rs10741362	ENSG00000280367.1	RP11-121L10.2	4.4	1.45e-05	0.00662	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90736650	chr11:90223153~90226538:+
STAD	cis	rs875971	0.862	rs11765791	ENSG00000224316.1	RP11-479O9.2	4.4	1.45e-05	0.00663	0.22	0.23	Aortic root size;	chr7:66471587	chr7:65773620~65802067:+
STAD	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	4.4	1.45e-05	0.00663	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
STAD	cis	rs9807989	0.765	rs13424006	ENSG00000234389.1	AC007278.3	4.4	1.45e-05	0.00663	0.24	0.23	Asthma;	chr2:102350776	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.765	rs6751967	ENSG00000234389.1	AC007278.3	4.4	1.45e-05	0.00663	0.24	0.23	Asthma;	chr2:102350953	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.765	rs6751977	ENSG00000234389.1	AC007278.3	4.4	1.45e-05	0.00663	0.24	0.23	Asthma;	chr2:102350970	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.765	rs6704565	ENSG00000234389.1	AC007278.3	4.4	1.45e-05	0.00663	0.24	0.23	Asthma;	chr2:102350971	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs6749114	ENSG00000234389.1	AC007278.3	4.4	1.45e-05	0.00663	0.24	0.23	Asthma;	chr2:102351127	chr2:102438713~102440475:+
STAD	cis	rs9788721	0.836	rs17483929	ENSG00000259419.2	HNRNPCP3	4.4	1.45e-05	0.00663	0.25	0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78450034	chr15:79236332~79237206:+
STAD	cis	rs2337406	0.587	rs10139664	ENSG00000211970.3	IGHV4-61	4.4	1.45e-05	0.00663	0.25	0.23	Alzheimer's disease (late onset);	chr14:106647254	chr14:106639119~106639657:-
STAD	cis	rs6471393	0.964	rs16916191	ENSG00000253848.1	RP11-10N23.5	4.4	1.46e-05	0.00664	0.26	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737337	chr8:93741193~93744534:+
STAD	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-4.4	1.46e-05	0.00664	-0.27	-0.23	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
STAD	cis	rs4589258	0.75	rs1547882	ENSG00000280367.1	RP11-121L10.2	4.4	1.46e-05	0.00664	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90738520	chr11:90223153~90226538:+
STAD	cis	rs858239	0.932	rs858272	ENSG00000230042.1	AK3P3	-4.4	1.46e-05	0.00664	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23129178~23129841:+
STAD	cis	rs11098499	0.866	rs7665125	ENSG00000260091.1	RP11-33B1.4	4.4	1.46e-05	0.00664	0.22	0.23	Corneal astigmatism;	chr4:119480924	chr4:119409333~119410233:+
STAD	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-4.4	1.46e-05	0.00665	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
STAD	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	4.4	1.46e-05	0.00665	0.34	0.23	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
STAD	cis	rs77956314	0.515	rs60940473	ENSG00000274554.1	RP11-240G22.5	4.4	1.46e-05	0.00665	0.29	0.23	Hippocampal volume;Subcortical brain region volumes;	chr12:117024777	chr12:116948738~116951422:-
STAD	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-4.4	1.46e-05	0.00665	-0.34	-0.23	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-4.4	1.46e-05	0.00665	-0.34	-0.23	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
STAD	cis	rs737008	1	rs737008	ENSG00000262703.1	RP11-485G7.6	-4.4	1.46e-05	0.00665	-0.23	-0.23	Obesity-related traits;	chr16:11281009	chr16:11348143~11349321:-
STAD	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	4.4	1.46e-05	0.00665	0.3	0.23	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
STAD	cis	rs1598856	0.873	rs230510	ENSG00000248971.2	KRT8P46	4.4	1.46e-05	0.00665	0.25	0.23	Primary biliary cholangitis;	chr4:102555009	chr4:102728746~102730171:-
STAD	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-4.4	1.46e-05	0.00665	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
STAD	cis	rs1928295	0.786	rs10983720	ENSG00000233569.1	RP11-500B12.1	4.4	1.46e-05	0.00665	0.25	0.23	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117625209	chr9:117648606~117657027:+
STAD	cis	rs1928295	0.75	rs10818054	ENSG00000233569.1	RP11-500B12.1	4.4	1.46e-05	0.00665	0.25	0.23	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117625739	chr9:117648606~117657027:+
STAD	cis	rs6603134	0.502	rs6603131	ENSG00000267939.1	CTD-2325M2.1	-4.4	1.46e-05	0.00665	-0.27	-0.23	Blood protein levels;	chr19:8037873	chr19:8008729~8016025:+
STAD	cis	rs4805566	0.685	rs11666325	ENSG00000267006.1	CTC-448F2.4	4.4	1.46e-05	0.00665	0.25	0.23	Body mass index;	chr19:30416882	chr19:30028741~30029916:-
STAD	cis	rs77956314	0.515	rs4767473	ENSG00000274554.1	RP11-240G22.5	-4.4	1.46e-05	0.00666	-0.29	-0.23	Hippocampal volume;Subcortical brain region volumes;	chr12:116927701	chr12:116948738~116951422:-
STAD	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	4.4	1.46e-05	0.00666	0.33	0.23	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
STAD	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-4.4	1.46e-05	0.00666	-0.23	-0.23	Height;	chr2:46615271	chr2:46668870~46670778:+
STAD	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-4.4	1.46e-05	0.00666	-0.23	-0.23	Height;	chr2:46616492	chr2:46668870~46670778:+
STAD	cis	rs732716	0.752	rs11085072	ENSG00000269318.1	AC007292.3	-4.4	1.46e-05	0.00666	-0.33	-0.23	Mean corpuscular volume;	chr19:4368145	chr19:4356637~4358448:-
STAD	cis	rs11673344	0.523	rs2082010	ENSG00000267672.1	CTD-2293H3.1	4.4	1.46e-05	0.00666	0.21	0.23	Obesity-related traits;	chr19:37039874	chr19:37091341~37092564:+
STAD	cis	rs2034650	0.544	rs600791	ENSG00000223313.1	RNU6-516P	4.4	1.46e-05	0.00667	0.26	0.23	Interstitial lung disease;	chr15:40428868	chr15:40529570~40529673:+
STAD	cis	rs6471393	0.964	rs3813853	ENSG00000253848.1	RP11-10N23.5	4.4	1.46e-05	0.00667	0.27	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93740526	chr8:93741193~93744534:+
STAD	cis	rs1799949	0.965	rs7223952	ENSG00000279602.1	CTD-3014M21.1	4.4	1.47e-05	0.00668	0.29	0.23	Menopause (age at onset);	chr17:43042868	chr17:43360041~43361361:-
STAD	cis	rs6951245	0.706	rs28522260	ENSG00000229043.2	AC091729.9	-4.4	1.47e-05	0.00668	-0.36	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:1160374~1165267:+
STAD	cis	rs1056107	0.831	rs10125827	ENSG00000225513.1	RP11-165N19.2	4.4	1.47e-05	0.00668	0.27	0.23	Colorectal cancer;	chr9:112182226	chr9:112173522~112173971:-
STAD	cis	rs708547	0.533	rs3806746	ENSG00000269949.1	RP11-738E22.3	-4.4	1.47e-05	0.00668	-0.27	-0.23	Response to bleomycin (chromatid breaks);	chr4:56907164	chr4:56960927~56961373:-
STAD	cis	rs708547	0.581	rs781661	ENSG00000269949.1	RP11-738E22.3	-4.4	1.47e-05	0.00668	-0.27	-0.23	Response to bleomycin (chromatid breaks);	chr4:56914141	chr4:56960927~56961373:-
STAD	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	4.4	1.47e-05	0.00669	0.32	0.23	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
STAD	cis	rs8097348	1	rs759740	ENSG00000266602.1	RP11-476K15.1	-4.4	1.47e-05	0.00669	-0.29	-0.23	Exercise (leisure time);	chr18:1604629	chr18:1509183~1647097:+
STAD	cis	rs1823874	0.71	rs2085086	ENSG00000182397.13	DNM1P46	-4.4	1.47e-05	0.00669	-0.24	-0.23	IgG glycosylation;	chr15:99819887	chr15:99790156~99806927:-
STAD	cis	rs4589258	0.762	rs1783792	ENSG00000280367.1	RP11-121L10.2	-4.4	1.47e-05	0.00669	-0.22	-0.23	Intelligence (multi-trait analysis);	chr11:90706502	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1792597	ENSG00000280367.1	RP11-121L10.2	-4.4	1.47e-05	0.00669	-0.22	-0.23	Intelligence (multi-trait analysis);	chr11:90710416	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.661	rs1783799	ENSG00000280367.1	RP11-121L10.2	-4.4	1.47e-05	0.00669	-0.22	-0.23	Intelligence (multi-trait analysis);	chr11:90711124	chr11:90223153~90226538:+
STAD	cis	rs2836950	0.502	rs12627205	ENSG00000238141.2	BRWD1-AS1	-4.4	1.47e-05	0.00669	-0.24	-0.23	Menarche (age at onset);	chr21:39258101	chr21:39315707~39323218:+
STAD	cis	rs6601327	1	rs6601327	ENSG00000254340.1	RP11-10A14.3	-4.4	1.47e-05	0.00669	-0.29	-0.23	Multiple myeloma (hyperdiploidy);	chr8:9538022	chr8:9141424~9145435:+
STAD	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-4.4	1.47e-05	0.00669	-0.34	-0.23	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
STAD	cis	rs1707322	0.964	rs785499	ENSG00000281133.1	AL355480.3	4.4	1.47e-05	0.0067	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45580892~45580996:-
STAD	cis	rs916888	0.779	rs199498	ENSG00000261575.2	RP11-259G18.1	4.4	1.47e-05	0.0067	0.31	0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46267037~46268694:+
STAD	cis	rs893363	1	rs893363	ENSG00000271916.1	RP11-884K10.6	-4.4	1.47e-05	0.0067	-0.26	-0.23	Axial length;	chr3:53813035	chr3:53797764~53798019:-
STAD	cis	rs1707322	0.865	rs785501	ENSG00000281133.1	AL355480.3	4.4	1.47e-05	0.00671	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45580892~45580996:-
STAD	cis	rs6714710	0.603	rs12988571	ENSG00000235833.1	AC159540.14	-4.4	1.47e-05	0.00671	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789232	chr2:97523949~97524976:-
STAD	cis	rs1707322	0.752	rs11211145	ENSG00000281133.1	AL355480.3	-4.4	1.47e-05	0.00671	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45580892~45580996:-
STAD	cis	rs13113518	0.683	rs9761521	ENSG00000223305.1	RN7SKP30	4.39	1.48e-05	0.00672	0.26	0.23	Height;	chr4:55363436	chr4:55540502~55540835:-
STAD	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	4.39	1.48e-05	0.00672	0.33	0.23	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	4.39	1.48e-05	0.00672	0.33	0.23	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
STAD	cis	rs7829975	0.511	rs2948286	ENSG00000254340.1	RP11-10A14.3	4.39	1.48e-05	0.00672	0.27	0.23	Mood instability;	chr8:8272638	chr8:9141424~9145435:+
STAD	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	4.39	1.48e-05	0.00672	0.34	0.23	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
STAD	cis	rs9307551	0.741	rs7691868	ENSG00000250334.4	LINC00989	-4.39	1.48e-05	0.00672	-0.3	-0.23	Refractive error;	chr4:79495250	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.697	rs7691918	ENSG00000250334.4	LINC00989	-4.39	1.48e-05	0.00672	-0.3	-0.23	Refractive error;	chr4:79495337	chr4:79492416~79576460:+
STAD	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	4.39	1.48e-05	0.00673	0.29	0.23	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
STAD	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-4.39	1.48e-05	0.00673	-0.27	-0.23	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
STAD	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-4.39	1.48e-05	0.00673	-0.24	-0.23	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
STAD	cis	rs916888	0.821	rs199514	ENSG00000232300.1	FAM215B	-4.39	1.48e-05	0.00673	-0.3	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46558830~46562795:-
STAD	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-4.39	1.48e-05	0.00674	-0.23	-0.23	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
STAD	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-4.39	1.48e-05	0.00674	-0.26	-0.23	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-4.39	1.48e-05	0.00674	-0.26	-0.23	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-4.39	1.48e-05	0.00674	-0.26	-0.23	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
STAD	cis	rs2348418	0.798	rs11049486	ENSG00000247934.4	RP11-967K21.1	-4.39	1.48e-05	0.00674	-0.22	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28253224	chr12:28163298~28190738:-
STAD	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	4.39	1.48e-05	0.00674	0.29	0.23	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
STAD	cis	rs7412746	0.597	rs868751	ENSG00000274963.1	Metazoa_SRP	4.39	1.48e-05	0.00674	0.2	0.23	Melanoma;	chr1:150696938	chr1:150568971~150569269:-
STAD	cis	rs4243830	0.85	rs10746502	ENSG00000229519.2	RP11-58A11.2	4.39	1.48e-05	0.00675	0.24	0.23	Body mass index;	chr1:6547139	chr1:6547905~6548619:+
STAD	cis	rs6921919	0.583	rs7764722	ENSG00000220721.1	OR1F12	4.39	1.48e-05	0.00675	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28073316~28074233:+
STAD	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-4.39	1.48e-05	0.00675	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
STAD	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-4.39	1.48e-05	0.00675	-0.26	-0.23	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
STAD	cis	rs935334	1	rs2289836	ENSG00000258454.1	RP11-361H10.3	-4.39	1.49e-05	0.00676	-0.34	-0.23	Blood pressure;	chr14:76173782	chr14:76235817~76263474:+
STAD	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-4.39	1.49e-05	0.00676	-0.34	-0.23	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
STAD	cis	rs1578862	0.55	rs57653401	ENSG00000215795.2	RP11-488L18.3	4.39	1.49e-05	0.00676	0.33	0.23	Monocyte percentage of white cells;	chr1:247294145	chr1:247183813~247185482:-
STAD	cis	rs12682352	0.602	rs28399241	ENSG00000253981.4	ALG1L13P	4.39	1.49e-05	0.00676	0.28	0.23	Neuroticism;	chr8:8805705	chr8:8236003~8244667:-
STAD	cis	rs422249	0.634	rs174609	ENSG00000279632.1	RP11-286N22.6	4.39	1.49e-05	0.00676	0.23	0.23	Trans fatty acid levels;	chr11:61860339	chr11:61426448~61427325:-
STAD	cis	rs422249	0.593	rs174613	ENSG00000279632.1	RP11-286N22.6	4.39	1.49e-05	0.00676	0.23	0.23	Trans fatty acid levels;	chr11:61861020	chr11:61426448~61427325:-
STAD	cis	rs7487075	0.786	rs2242355	ENSG00000257261.4	RP11-96H19.1	4.39	1.49e-05	0.00677	0.28	0.23	Itch intensity from mosquito bite;	chr12:46268702	chr12:46383679~46876159:+
STAD	cis	rs9784649	0.641	rs72755823	ENSG00000245662.2	RP11-184E9.1	4.39	1.49e-05	0.00677	0.35	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25075428	chr5:25190682~25306172:+
STAD	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	4.39	1.49e-05	0.00677	0.29	0.23	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
STAD	cis	rs11098499	0.954	rs12499324	ENSG00000260091.1	RP11-33B1.4	4.39	1.49e-05	0.00677	0.23	0.23	Corneal astigmatism;	chr4:119472631	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs9998585	ENSG00000260091.1	RP11-33B1.4	4.39	1.49e-05	0.00677	0.23	0.23	Corneal astigmatism;	chr4:119475647	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs6842762	ENSG00000260091.1	RP11-33B1.4	4.39	1.49e-05	0.00677	0.23	0.23	Corneal astigmatism;	chr4:119477081	chr4:119409333~119410233:+
STAD	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	4.39	1.49e-05	0.00677	0.31	0.23	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
STAD	cis	rs13413635	0.626	rs12473461	ENSG00000225808.1	DNAJC19P5	4.39	1.49e-05	0.00677	0.29	0.23	Heart rate;	chr2:178009587	chr2:177229191~177229506:-
STAD	cis	rs35934224	0.783	rs7284106	ENSG00000232926.1	AC000078.5	4.39	1.49e-05	0.00677	0.31	0.23	Glaucoma (primary open-angle);	chr22:19870026	chr22:19887289~19887970:+
STAD	cis	rs11098499	0.863	rs10004484	ENSG00000260091.1	RP11-33B1.4	4.39	1.49e-05	0.00678	0.23	0.23	Corneal astigmatism;	chr4:119521273	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs1155576	ENSG00000260091.1	RP11-33B1.4	4.39	1.49e-05	0.00678	0.23	0.23	Corneal astigmatism;	chr4:119529004	chr4:119409333~119410233:+
STAD	cis	rs2115536	0.967	rs3826008	ENSG00000278600.1	RP11-81A1.6	-4.39	1.49e-05	0.00678	-0.2	-0.23	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897463	chr15:79920195~79922455:-
STAD	cis	rs2115536	1	rs2115540	ENSG00000278600.1	RP11-81A1.6	-4.39	1.49e-05	0.00678	-0.2	-0.23	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897966	chr15:79920195~79922455:-
STAD	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	4.39	1.49e-05	0.00678	0.31	0.23	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
STAD	cis	rs7829975	0.714	rs60315134	ENSG00000253981.4	ALG1L13P	4.39	1.49e-05	0.00678	0.27	0.23	Mood instability;	chr8:8813089	chr8:8236003~8244667:-
STAD	cis	rs561341	1	rs117029332	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31939066	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs72821971	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31942324	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs117979353	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31945847	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs72823785	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31946765	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs55978022	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31948918	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs72823787	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31956790	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs72823789	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31957065	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs2470243	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31963936	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs483301	ENSG00000265798.5	RP11-271K11.5	4.39	1.49e-05	0.00679	0.34	0.23	Hip circumference adjusted for BMI;	chr17:31966379	chr17:31038575~31059121:-
STAD	cis	rs9467773	0.534	rs34453863	ENSG00000241549.7	GUSBP2	4.39	1.49e-05	0.00679	0.23	0.23	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26871484~26956554:-
STAD	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	4.39	1.49e-05	0.00679	0.31	0.23	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
STAD	cis	rs6585424	1	rs3851055	ENSG00000225484.5	NUTM2B-AS1	-4.39	1.49e-05	0.00679	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178340	chr10:79663088~79826594:-
STAD	cis	rs12682352	0.652	rs3789843	ENSG00000253981.4	ALG1L13P	4.39	1.5e-05	0.00679	0.28	0.23	Neuroticism;	chr8:8866747	chr8:8236003~8244667:-
STAD	cis	rs12682352	0.652	rs3827806	ENSG00000253981.4	ALG1L13P	4.39	1.5e-05	0.00679	0.28	0.23	Neuroticism;	chr8:8866766	chr8:8236003~8244667:-
STAD	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	4.39	1.5e-05	0.0068	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
STAD	cis	rs4589258	0.737	rs2212350	ENSG00000280367.1	RP11-121L10.2	-4.39	1.5e-05	0.00681	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90678124	chr11:90223153~90226538:+
STAD	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	4.39	1.5e-05	0.00681	0.22	0.23	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
STAD	cis	rs9733	0.65	rs12125672	ENSG00000274963.1	Metazoa_SRP	-4.39	1.5e-05	0.00681	-0.19	-0.23	Tonsillectomy;	chr1:150581994	chr1:150568971~150569269:-
STAD	cis	rs6585424	1	rs11202031	ENSG00000225484.5	NUTM2B-AS1	-4.39	1.5e-05	0.00682	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184287	chr10:79663088~79826594:-
STAD	cis	rs4780355	1	rs4780355	ENSG00000262703.1	RP11-485G7.6	4.39	1.5e-05	0.00682	0.22	0.23	Crohn's disease and psoriasis;	chr16:11254001	chr16:11348143~11349321:-
STAD	cis	rs11168351	0.517	rs10875754	ENSG00000226413.2	OR8T1P	4.39	1.5e-05	0.00682	0.26	0.23	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48442030~48442947:-
STAD	cis	rs7103648	0.695	rs11039290	ENSG00000280615.1	Y_RNA	4.39	1.5e-05	0.00682	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47550727	chr11:47614898~47614994:-
STAD	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	4.39	1.5e-05	0.00682	0.24	0.23	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
STAD	cis	rs593531	0.614	rs623065	ENSG00000280269.1	AP000577.2	-4.39	1.5e-05	0.00682	-0.24	-0.23	Neuroticism;	chr11:74360165	chr11:74204869~74205746:+
STAD	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-4.39	1.5e-05	0.00683	-0.22	-0.23	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
STAD	cis	rs891378	1	rs6700079	ENSG00000274245.1	RP11-357P18.2	-4.39	1.51e-05	0.00683	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207328527	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs6702997	ENSG00000274245.1	RP11-357P18.2	-4.39	1.51e-05	0.00683	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329002	chr1:207372559~207373252:+
STAD	cis	rs891378	1	rs6703002	ENSG00000274245.1	RP11-357P18.2	-4.39	1.51e-05	0.00683	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329027	chr1:207372559~207373252:+
STAD	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	4.39	1.51e-05	0.00684	0.24	0.23	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
STAD	cis	rs2273156	1	rs36008567	ENSG00000241052.1	RP11-173D9.1	-4.39	1.51e-05	0.00684	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34951870	chr14:35144021~35144480:-
STAD	cis	rs2273156	0.925	rs12890056	ENSG00000241052.1	RP11-173D9.1	-4.39	1.51e-05	0.00684	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34952928	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12161905	ENSG00000241052.1	RP11-173D9.1	-4.39	1.51e-05	0.00684	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34953087	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12897044	ENSG00000241052.1	RP11-173D9.1	-4.39	1.51e-05	0.00684	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34953938	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12888272	ENSG00000241052.1	RP11-173D9.1	-4.39	1.51e-05	0.00684	-0.26	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34956396	chr14:35144021~35144480:-
STAD	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-4.39	1.51e-05	0.00684	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
STAD	cis	rs2933343	0.621	rs728838	ENSG00000261159.1	RP11-723O4.9	4.39	1.51e-05	0.00684	0.27	0.23	IgG glycosylation;	chr3:128870170	chr3:128859716~128860526:-
STAD	cis	rs7829975	0.714	rs4841040	ENSG00000173295.6	FAM86B3P	4.39	1.51e-05	0.00684	0.25	0.23	Mood instability;	chr8:8797017	chr8:8228595~8244865:+
STAD	cis	rs2337406	1	rs4774173	ENSG00000280411.1	IGHV1-69-2	-4.39	1.51e-05	0.00684	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106682029	chr14:106762092~106762588:-
STAD	cis	rs8177876	0.822	rs56166222	ENSG00000261838.4	RP11-303E16.6	4.39	1.51e-05	0.00685	0.53	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81069854~81076598:+
STAD	cis	rs1707322	1	rs10789486	ENSG00000281133.1	AL355480.3	-4.39	1.51e-05	0.00685	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45580892~45580996:-
STAD	cis	rs875971	0.862	rs10256544	ENSG00000224316.1	RP11-479O9.2	4.39	1.51e-05	0.00685	0.23	0.23	Aortic root size;	chr7:66210141	chr7:65773620~65802067:+
STAD	cis	rs853679	0.55	rs9295762	ENSG00000220721.1	OR1F12	-4.39	1.51e-05	0.00685	-0.25	-0.23	Depression;	chr6:28187640	chr6:28073316~28074233:+
STAD	cis	rs7474896	1	rs61858629	ENSG00000099251.13	HSD17B7P2	4.39	1.51e-05	0.00685	0.35	0.23	Obesity (extreme);	chr10:37725842	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs35258216	ENSG00000099251.13	HSD17B7P2	4.39	1.51e-05	0.00685	0.35	0.23	Obesity (extreme);	chr10:37729292	chr10:38356380~38378505:+
STAD	cis	rs4589258	0.737	rs2155072	ENSG00000280367.1	RP11-121L10.2	-4.39	1.51e-05	0.00686	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90676956	chr11:90223153~90226538:+
STAD	cis	rs875971	0.767	rs12668005	ENSG00000224316.1	RP11-479O9.2	4.39	1.51e-05	0.00686	0.22	0.23	Aortic root size;	chr7:66444034	chr7:65773620~65802067:+
STAD	cis	rs7224610	1	rs7224610	ENSG00000263096.1	RP11-515O17.2	4.39	1.51e-05	0.00687	0.29	0.23	Urate levels;	chr17:55287427	chr17:55271504~55273653:-
STAD	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-4.39	1.51e-05	0.00687	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
STAD	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-4.39	1.51e-05	0.00687	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
STAD	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	4.39	1.51e-05	0.00687	0.38	0.23	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
STAD	cis	rs9847710	0.869	rs2564917	ENSG00000242142.1	SERBP1P3	4.39	1.51e-05	0.00687	0.22	0.23	Ulcerative colitis;	chr3:53003679	chr3:53064283~53065091:-
STAD	cis	rs4589258	0.737	rs1792608	ENSG00000280367.1	RP11-121L10.2	-4.39	1.51e-05	0.00687	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90699760	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.698	rs2508413	ENSG00000280367.1	RP11-121L10.2	-4.39	1.51e-05	0.00687	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90700672	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1783787	ENSG00000280367.1	RP11-121L10.2	-4.39	1.51e-05	0.00687	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90701226	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.601	rs1792606	ENSG00000280367.1	RP11-121L10.2	-4.39	1.51e-05	0.00687	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90702089	chr11:90223153~90226538:+
STAD	cis	rs1528149	0.576	rs1881242	ENSG00000224683.1	RPL36AP29	-4.39	1.52e-05	0.00688	-0.24	-0.23	Sitting height ratio;	chr7:16073822	chr7:16208945~16209265:+
STAD	cis	rs1707322	0.686	rs61784833	ENSG00000225447.1	RPS15AP10	4.39	1.52e-05	0.00688	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs7519900	ENSG00000225447.1	RPS15AP10	4.39	1.52e-05	0.00688	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45645816~45646197:-
STAD	cis	rs4589258	0.788	rs10765377	ENSG00000280367.1	RP11-121L10.2	4.39	1.52e-05	0.00688	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90721525	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs10830563	ENSG00000280367.1	RP11-121L10.2	4.39	1.52e-05	0.00688	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90721581	chr11:90223153~90226538:+
STAD	cis	rs4713118	0.869	rs9283880	ENSG00000243307.2	POM121L6P	-4.39	1.52e-05	0.00688	-0.27	-0.23	Parkinson's disease;	chr6:27747464	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9283881	ENSG00000243307.2	POM121L6P	-4.39	1.52e-05	0.00688	-0.27	-0.23	Parkinson's disease;	chr6:27747476	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9283882	ENSG00000243307.2	POM121L6P	-4.39	1.52e-05	0.00688	-0.27	-0.23	Parkinson's disease;	chr6:27747479	chr6:26896952~26898777:+
STAD	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-4.39	1.52e-05	0.00688	-0.23	-0.23	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
STAD	cis	rs2836950	0.501	rs2056844	ENSG00000238141.2	BRWD1-AS1	-4.39	1.52e-05	0.00688	-0.24	-0.23	Menarche (age at onset);	chr21:39298534	chr21:39315707~39323218:+
STAD	cis	rs2337406	0.929	rs11847182	ENSG00000211972.2	IGHV3-66	4.39	1.52e-05	0.00688	0.27	0.23	Alzheimer's disease (late onset);	chr14:106697724	chr14:106675017~106675544:-
STAD	cis	rs9532563	0.55	rs61963699	ENSG00000229456.1	RLIMP1	4.39	1.52e-05	0.00688	0.31	0.23	Mean corpuscular volume;	chr13:40566345	chr13:40618738~40621348:+
STAD	cis	rs1345301	0.587	rs12464251	ENSG00000234389.1	AC007278.3	-4.39	1.52e-05	0.00688	-0.23	-0.23	Waist circumference;	chr2:102250748	chr2:102438713~102440475:+
STAD	cis	rs1345301	0.609	rs56389410	ENSG00000234389.1	AC007278.3	-4.39	1.52e-05	0.00688	-0.23	-0.23	Waist circumference;	chr2:102251203	chr2:102438713~102440475:+
STAD	cis	rs1816752	0.646	rs750388	ENSG00000273628.1	RP11-756A22.7	-4.39	1.52e-05	0.00689	-0.28	-0.23	Obesity-related traits;	chr13:24461690	chr13:24933006~24936796:+
STAD	cis	rs5760092	0.572	rs738806	ENSG00000099984.9	GSTT2	-4.39	1.52e-05	0.00689	-0.31	-0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23980123~23983911:+
STAD	cis	rs11168351	0.927	rs10875716	ENSG00000258273.1	RP11-370I10.4	-4.39	1.52e-05	0.00689	-0.29	-0.23	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48333755~48333901:-
STAD	cis	rs498872	1	rs498872	ENSG00000255239.1	AP002954.6	4.39	1.52e-05	0.00689	0.26	0.23	Glioma;	chr11:118606652	chr11:118688039~118690600:-
STAD	cis	rs10028773	0.666	rs12498657	ENSG00000260091.1	RP11-33B1.4	4.39	1.52e-05	0.0069	0.22	0.23	Educational attainment;	chr4:119341711	chr4:119409333~119410233:+
STAD	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	4.39	1.52e-05	0.0069	0.37	0.23	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
STAD	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	4.39	1.52e-05	0.0069	0.37	0.23	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	4.39	1.52e-05	0.0069	0.37	0.23	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
STAD	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	4.39	1.52e-05	0.0069	0.37	0.23	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
STAD	cis	rs1799949	0.965	rs9646413	ENSG00000279602.1	CTD-3014M21.1	4.39	1.52e-05	0.0069	0.28	0.23	Menopause (age at onset);	chr17:43348789	chr17:43360041~43361361:-
STAD	cis	rs8012947	1	rs11158203	ENSG00000279636.2	LINC00216	-4.39	1.52e-05	0.0069	-0.23	-0.23	Alcohol consumption in current drinkers;	chr14:58303305	chr14:58288033~58289158:+
STAD	cis	rs8012947	1	rs10145280	ENSG00000279636.2	LINC00216	-4.39	1.52e-05	0.0069	-0.23	-0.23	Alcohol consumption in current drinkers;	chr14:58303337	chr14:58288033~58289158:+
STAD	cis	rs9847710	0.838	rs2581795	ENSG00000242142.1	SERBP1P3	-4.39	1.52e-05	0.0069	-0.22	-0.23	Ulcerative colitis;	chr3:53004770	chr3:53064283~53065091:-
STAD	cis	rs7829975	0.774	rs13259216	ENSG00000253981.4	ALG1L13P	4.39	1.52e-05	0.00691	0.27	0.23	Mood instability;	chr8:8816091	chr8:8236003~8244667:-
STAD	cis	rs11673344	0.523	rs7258438	ENSG00000267672.1	CTD-2293H3.1	4.39	1.53e-05	0.00691	0.21	0.23	Obesity-related traits;	chr19:37032534	chr19:37091341~37092564:+
STAD	cis	rs6832769	0.961	rs2412647	ENSG00000272969.1	RP11-528I4.2	4.39	1.53e-05	0.00691	0.29	0.23	Personality dimensions;	chr4:55452938	chr4:55547112~55547889:+
STAD	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-4.39	1.53e-05	0.00692	-0.27	-0.23	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
STAD	cis	rs9307551	0.948	rs13112067	ENSG00000250334.4	LINC00989	-4.39	1.53e-05	0.00692	-0.29	-0.23	Refractive error;	chr4:79561744	chr4:79492416~79576460:+
STAD	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-4.39	1.53e-05	0.00692	-0.3	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
STAD	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	4.39	1.53e-05	0.00693	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	4.39	1.53e-05	0.00693	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
STAD	cis	rs7829975	0.774	rs35431455	ENSG00000253981.4	ALG1L13P	4.39	1.53e-05	0.00693	0.27	0.23	Mood instability;	chr8:8816226	chr8:8236003~8244667:-
STAD	cis	rs9926664	0.591	rs11649549	ENSG00000274134.1	MIR6774	4.39	1.53e-05	0.00693	0.31	0.23	Neutrophil count;Sum basophil neutrophil counts;	chr16:85902191	chr16:85918347~85918416:+
STAD	cis	rs9921338	0.54	rs2868410	ENSG00000263080.1	RP11-485G7.5	4.39	1.53e-05	0.00694	0.29	0.23	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334244	chr16:11341809~11345211:-
STAD	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	4.39	1.53e-05	0.00694	0.3	0.23	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
STAD	cis	rs17401966	0.838	rs12127604	ENSG00000199562.1	RNU6-37P	4.39	1.53e-05	0.00694	0.18	0.23	Hepatocellular carcinoma;	chr1:10292742	chr1:10298966~10299072:+
STAD	cis	rs6832769	1	rs7667849	ENSG00000272969.1	RP11-528I4.2	-4.39	1.53e-05	0.00695	-0.29	-0.23	Personality dimensions;	chr4:55522032	chr4:55547112~55547889:+
STAD	cis	rs1707322	0.963	rs10789478	ENSG00000281133.1	AL355480.3	-4.39	1.53e-05	0.00695	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45580892~45580996:-
STAD	cis	rs11098499	0.954	rs12502423	ENSG00000260091.1	RP11-33B1.4	4.39	1.53e-05	0.00695	0.22	0.23	Corneal astigmatism;	chr4:119503017	chr4:119409333~119410233:+
STAD	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	4.39	1.54e-05	0.00696	0.3	0.23	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
STAD	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	4.39	1.54e-05	0.00696	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	4.39	1.54e-05	0.00696	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	4.39	1.54e-05	0.00696	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
STAD	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	4.39	1.54e-05	0.00696	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
STAD	cis	rs11098499	0.954	rs17006190	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119497683	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs28685688	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119499179	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs7687843	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119500056	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs2306455	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119500814	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs10031483	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119501481	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs10031665	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119501697	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs3733519	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119502293	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs3733523	ENSG00000260091.1	RP11-33B1.4	4.39	1.54e-05	0.00696	0.22	0.23	Corneal astigmatism;	chr4:119502564	chr4:119409333~119410233:+
STAD	cis	rs748404	0.697	rs493444	ENSG00000275601.1	AC011330.13	-4.39	1.54e-05	0.00696	-0.24	-0.23	Lung cancer;	chr15:43274272	chr15:43642389~43643023:-
STAD	cis	rs6479891	1	rs9415705	ENSG00000235816.3	PRELID1P3	4.39	1.54e-05	0.00697	0.29	0.23	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63427297~63427939:+
STAD	cis	rs9307551	0.619	rs13118924	ENSG00000250334.4	LINC00989	-4.39	1.54e-05	0.00697	-0.29	-0.23	Refractive error;	chr4:79502369	chr4:79492416~79576460:+
STAD	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-4.39	1.54e-05	0.00697	-0.29	-0.23	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
STAD	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	4.39	1.54e-05	0.00697	0.29	0.23	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
STAD	cis	rs6832769	1	rs6834676	ENSG00000272969.1	RP11-528I4.2	4.38	1.54e-05	0.00698	0.29	0.23	Personality dimensions;	chr4:55432247	chr4:55547112~55547889:+
STAD	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-4.38	1.54e-05	0.00698	-0.21	-0.23	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
STAD	cis	rs1799949	0.965	rs8071278	ENSG00000279602.1	CTD-3014M21.1	4.38	1.54e-05	0.00698	0.28	0.23	Menopause (age at onset);	chr17:43041893	chr17:43360041~43361361:-
STAD	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-4.38	1.54e-05	0.00698	-0.32	-0.23	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-4.38	1.54e-05	0.00698	-0.32	-0.23	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
STAD	cis	rs7487075	0.893	rs1492894	ENSG00000257261.4	RP11-96H19.1	4.38	1.54e-05	0.00698	0.27	0.23	Itch intensity from mosquito bite;	chr12:46334885	chr12:46383679~46876159:+
STAD	cis	rs8062405	1	rs3888190	ENSG00000278665.1	RP11-666O2.4	4.38	1.54e-05	0.00699	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28599241~28601881:-
STAD	cis	rs1900504	1	rs1900504	ENSG00000266200.5	PNLIPRP2	4.38	1.54e-05	0.00699	0.33	0.23	Tonsillectomy;	chr10:116625761	chr10:116620953~116645143:+
STAD	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-4.38	1.54e-05	0.00699	-0.27	-0.23	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
STAD	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	4.38	1.55e-05	0.00699	0.34	0.23	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
STAD	cis	rs4713118	0.523	rs2179096	ENSG00000280107.1	AL022393.9	-4.38	1.55e-05	0.00699	-0.28	-0.23	Parkinson's disease;	chr6:27698141	chr6:28170845~28172521:+
STAD	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-4.38	1.55e-05	0.00699	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
STAD	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-4.38	1.55e-05	0.00699	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
STAD	cis	rs2688608	0.617	rs6480709	ENSG00000271816.1	BMS1P4	4.38	1.55e-05	0.007	0.25	0.23	Inflammatory bowel disease;	chr10:73719367	chr10:73699151~73730487:-
STAD	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-4.38	1.55e-05	0.007	-0.23	-0.23	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
STAD	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	4.38	1.55e-05	0.007	0.28	0.23	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
STAD	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	4.38	1.55e-05	0.007	0.32	0.23	Depression;	chr6:28379133	chr6:28943877~28944537:+
STAD	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	4.38	1.55e-05	0.007	0.32	0.23	Depression;	chr6:28379168	chr6:28943877~28944537:+
STAD	cis	rs1707322	0.929	rs785500	ENSG00000225447.1	RPS15AP10	-4.38	1.55e-05	0.007	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785504	ENSG00000225447.1	RPS15AP10	-4.38	1.55e-05	0.007	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45645816~45646197:-
STAD	cis	rs2483058	0.767	rs2336938	ENSG00000261000.1	RP11-534L20.5	4.38	1.55e-05	0.007	0.27	0.23	Cholesterol and Triglycerides;	chr1:206445453	chr1:206503948~206504456:+
STAD	cis	rs338389	0.542	rs28694418	ENSG00000260657.2	RP11-315D16.4	-4.38	1.55e-05	0.00701	-0.26	-0.23	Survival in rectal cancer;	chr15:67949855	chr15:68267792~68277994:-
STAD	cis	rs338389	0.542	rs12914946	ENSG00000260657.2	RP11-315D16.4	-4.38	1.55e-05	0.00701	-0.26	-0.23	Survival in rectal cancer;	chr15:67949990	chr15:68267792~68277994:-
STAD	cis	rs12550612	1	rs12550612	ENSG00000253616.4	RP11-875O11.3	4.38	1.55e-05	0.00701	0.38	0.23	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109256	chr8:23071377~23074488:-
STAD	cis	rs3758911	0.724	rs2216998	ENSG00000261098.1	RP11-819C21.1	-4.38	1.55e-05	0.00701	-0.22	-0.23	Coronary artery disease;	chr11:107246965	chr11:107312132~107316271:-
STAD	cis	rs1799949	1	rs35668327	ENSG00000279602.1	CTD-3014M21.1	4.38	1.55e-05	0.00701	0.29	0.23	Menopause (age at onset);	chr17:43121078	chr17:43360041~43361361:-
STAD	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	4.38	1.55e-05	0.00701	0.37	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
STAD	cis	rs230529	0.51	rs1120986	ENSG00000246560.2	RP11-10L12.4	4.38	1.55e-05	0.00701	0.29	0.23	Schizophrenia (treatment resistant);	chr4:102515484	chr4:102828055~102844075:+
STAD	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-4.38	1.55e-05	0.00701	-0.26	-0.23	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-4.38	1.55e-05	0.00701	-0.26	-0.23	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-4.38	1.55e-05	0.00701	-0.26	-0.23	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-4.38	1.55e-05	0.00701	-0.26	-0.23	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-4.38	1.55e-05	0.00701	-0.26	-0.23	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-4.38	1.55e-05	0.00701	-0.26	-0.23	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-4.38	1.55e-05	0.00701	-0.26	-0.23	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
STAD	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	4.38	1.55e-05	0.00701	0.26	0.23	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
STAD	cis	rs2337406	0.714	rs115401799	ENSG00000211972.2	IGHV3-66	4.38	1.55e-05	0.00701	0.25	0.23	Alzheimer's disease (late onset);	chr14:106813739	chr14:106675017~106675544:-
STAD	cis	rs7665090	1	rs10027437	ENSG00000230069.3	LRRC37A15P	-4.38	1.55e-05	0.00701	-0.25	-0.23	Primary biliary cholangitis;	chr4:102636094	chr4:102727274~102730721:-
STAD	cis	rs2310173	0.575	rs13022757	ENSG00000281162.1	LINC01127	-4.38	1.55e-05	0.00702	-0.3	-0.23	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101997084	chr2:101962056~101987167:+
STAD	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-4.38	1.55e-05	0.00702	-0.27	-0.23	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
STAD	cis	rs1707322	1	rs34694458	ENSG00000225447.1	RPS15AP10	4.38	1.55e-05	0.00702	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45645816~45646197:-
STAD	cis	rs13315649	0.562	rs6439137	ENSG00000242551.2	POU5F1P6	-4.38	1.55e-05	0.00702	-0.24	-0.23	Sum eosinophil basophil counts;	chr3:128668107	chr3:128674735~128677005:-
STAD	cis	rs7208859	0.623	rs73269913	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.55e-05	0.00702	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30729469~30731202:+
STAD	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	4.38	1.55e-05	0.00702	0.28	0.23	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
STAD	cis	rs6832769	0.961	rs3805147	ENSG00000272969.1	RP11-528I4.2	4.38	1.55e-05	0.00702	0.29	0.23	Personality dimensions;	chr4:55440563	chr4:55547112~55547889:+
STAD	cis	rs6832769	1	rs3736544	ENSG00000272969.1	RP11-528I4.2	4.38	1.55e-05	0.00702	0.29	0.23	Personality dimensions;	chr4:55443825	chr4:55547112~55547889:+
STAD	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-4.38	1.55e-05	0.00703	-0.28	-0.23	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
STAD	cis	rs7131987	0.65	rs6487808	ENSG00000275476.1	RP11-996F15.4	4.38	1.55e-05	0.00703	0.25	0.23	QT interval;	chr12:29310426	chr12:29277397~29277882:-
STAD	cis	rs2446066	0.605	rs7298336	ENSG00000257379.1	RP11-793H13.8	4.38	1.56e-05	0.00703	0.49	0.23	Red blood cell count;	chr12:53563546	chr12:53441741~53467528:+
STAD	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-4.38	1.56e-05	0.00703	-0.27	-0.23	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000224205.1	AP000351.4	4.38	1.56e-05	0.00703	0.26	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23987320~23991421:-
STAD	cis	rs875971	0.862	rs1968126	ENSG00000224316.1	RP11-479O9.2	-4.38	1.56e-05	0.00704	-0.22	-0.23	Aortic root size;	chr7:66592017	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6460306	ENSG00000224316.1	RP11-479O9.2	-4.38	1.56e-05	0.00704	-0.22	-0.23	Aortic root size;	chr7:66595806	chr7:65773620~65802067:+
STAD	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-4.38	1.56e-05	0.00704	-0.28	-0.23	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
STAD	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	4.38	1.56e-05	0.00704	0.33	0.23	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
STAD	cis	rs11722779	0.844	rs3974602	ENSG00000248971.2	KRT8P46	-4.38	1.56e-05	0.00704	-0.24	-0.23	Schizophrenia;	chr4:102928840	chr4:102728746~102730171:-
STAD	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-4.38	1.56e-05	0.00704	-0.29	-0.23	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
STAD	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	4.38	1.56e-05	0.00704	0.33	0.23	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
STAD	cis	rs11018874	0.597	rs4268468	ENSG00000280367.1	RP11-121L10.2	4.38	1.56e-05	0.00705	0.28	0.23	White blood cell types;	chr11:90153116	chr11:90223153~90226538:+
STAD	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-4.38	1.56e-05	0.00705	-0.23	-0.23	Height;	chr5:37019252	chr5:36666214~36725195:-
STAD	cis	rs853679	0.55	rs6901017	ENSG00000220721.1	OR1F12	4.38	1.56e-05	0.00705	0.26	0.23	Depression;	chr6:28184805	chr6:28073316~28074233:+
STAD	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-4.38	1.56e-05	0.00705	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
STAD	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	4.38	1.56e-05	0.00706	0.34	0.23	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
STAD	cis	rs858239	0.899	rs2268745	ENSG00000230042.1	AK3P3	-4.38	1.56e-05	0.00706	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23129178~23129841:+
STAD	cis	rs4691139	1	rs6821283	ENSG00000248632.1	RP11-366M4.11	4.38	1.56e-05	0.00706	0.23	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164980493	chr4:164968587~164970002:-
STAD	cis	rs4243830	0.85	rs4908904	ENSG00000229519.2	RP11-58A11.2	-4.38	1.56e-05	0.00707	-0.23	-0.23	Body mass index;	chr1:6520190	chr1:6547905~6548619:+
STAD	cis	rs10073892	0.66	rs10040591	ENSG00000250682.4	LINC00491	-4.38	1.57e-05	0.00707	-0.25	-0.23	Cognitive decline (age-related);	chr5:102607341	chr5:102609156~102671559:-
STAD	cis	rs7078219	0.543	rs7096296	ENSG00000257582.4	LINC01475	4.38	1.57e-05	0.00707	0.27	0.23	Dental caries;	chr10:99518059	chr10:99526350~99531177:-
STAD	cis	rs9326248	0.574	rs1263173	ENSG00000280143.1	AP000892.6	4.38	1.57e-05	0.00707	0.18	0.23	Blood protein levels;	chr11:116810292	chr11:117204967~117210292:+
STAD	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	4.38	1.57e-05	0.00707	0.28	0.23	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
STAD	cis	rs9902453	0.791	rs28492945	ENSG00000240074.1	RPL9P30	4.38	1.57e-05	0.00707	0.2	0.23	Coffee consumption (cups per day);	chr17:29896964	chr17:29855759~29856332:+
STAD	cis	rs3806843	0.576	rs246008	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00707	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140958900	chr5:140718925~140719013:+
STAD	cis	rs8028182	0.636	rs8036758	ENSG00000260269.4	CTD-2323K18.1	-4.38	1.57e-05	0.00707	-0.29	-0.23	Sudden cardiac arrest;	chr15:75525221	chr15:75527150~75601205:-
STAD	cis	rs7671266	0.528	rs11728025	ENSG00000250613.1	RP11-136I13.1	4.38	1.57e-05	0.00707	0.27	0.23	Cardiovascular disease risk factors;	chr4:10406597	chr4:10410996~10411644:+
STAD	cis	rs1723838	0.826	rs74635683	ENSG00000255928.1	RP11-456I15.2	4.38	1.57e-05	0.00707	0.5	0.23	Obesity-related traits;	chr11:73666910	chr11:73722349~73722694:+
STAD	cis	rs1723838	0.826	rs118089862	ENSG00000255928.1	RP11-456I15.2	4.38	1.57e-05	0.00707	0.5	0.23	Obesity-related traits;	chr11:73717724	chr11:73722349~73722694:+
STAD	cis	rs7615952	0.673	rs16834637	ENSG00000241346.1	SNRPCP11	4.38	1.57e-05	0.00708	0.4	0.23	Blood pressure (smoking interaction);	chr3:125886628	chr3:125816082~125816286:-
STAD	cis	rs4589258	0.644	rs55838813	ENSG00000280367.1	RP11-121L10.2	-4.38	1.57e-05	0.00708	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90677029	chr11:90223153~90226538:+
STAD	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	4.38	1.57e-05	0.00708	0.26	0.23	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
STAD	cis	rs9733	0.526	rs11204696	ENSG00000274963.1	Metazoa_SRP	4.38	1.57e-05	0.00708	0.2	0.23	Tonsillectomy;	chr1:150686245	chr1:150568971~150569269:-
STAD	cis	rs9733	0.526	rs11204698	ENSG00000274963.1	Metazoa_SRP	4.38	1.57e-05	0.00708	0.2	0.23	Tonsillectomy;	chr1:150687069	chr1:150568971~150569269:-
STAD	cis	rs12908161	1	rs12903134	ENSG00000259295.5	CSPG4P12	4.38	1.57e-05	0.00708	0.33	0.23	Schizophrenia;	chr15:84794468	chr15:85191438~85213905:+
STAD	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	4.38	1.57e-05	0.00708	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
STAD	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	4.38	1.57e-05	0.00708	0.33	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
STAD	cis	rs3806843	0.576	rs246041	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140951543	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.548	rs246038	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952114	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246037	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952261	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246036	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952301	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246034	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952479	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.547	rs246033	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952530	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246032	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952962	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.517	rs246031	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953522	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246030	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953569	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246029	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953641	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246028	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953928	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246027	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140954016	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246021	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140954919	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246020	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140955186	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.551	rs246018	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140955458	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.518	rs173471	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140955641	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.549	rs246012	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140956692	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246011	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140956820	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.547	rs246010	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140957050	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246006	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140959643	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246005	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140960299	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.576	rs246003	ENSG00000202111.1	VTRNA1-2	-4.38	1.57e-05	0.00708	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140961280	chr5:140718925~140719013:+
STAD	cis	rs7829975	0.682	rs7013471	ENSG00000253981.4	ALG1L13P	-4.38	1.57e-05	0.00709	-0.27	-0.23	Mood instability;	chr8:8829815	chr8:8236003~8244667:-
STAD	cis	rs2992257	0.958	rs7901931	ENSG00000251839.1	RNU7-12P	-4.38	1.57e-05	0.00709	-0.23	-0.23	Response to angiotensin II receptor blocker therapy;	chr10:26425978	chr10:27232255~27232316:-
STAD	cis	rs2337406	0.866	rs4773949	ENSG00000211972.2	IGHV3-66	-4.38	1.57e-05	0.00709	-0.23	-0.23	Alzheimer's disease (late onset);	chr14:106808070	chr14:106675017~106675544:-
STAD	cis	rs7176527	0.784	rs62021162	ENSG00000225151.9	GOLGA2P7	4.38	1.57e-05	0.00709	0.3	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84199311~84230136:-
STAD	cis	rs2739330	0.652	rs2000469	ENSG00000224205.1	AP000351.4	4.38	1.57e-05	0.0071	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23987320~23991421:-
STAD	cis	rs4713118	0.955	rs9468204	ENSG00000220721.1	OR1F12	4.38	1.57e-05	0.0071	0.25	0.23	Parkinson's disease;	chr6:27721030	chr6:28073316~28074233:+
STAD	cis	rs10129255	0.701	rs2005643	ENSG00000224373.3	IGHV4-59	4.38	1.57e-05	0.0071	0.18	0.23	Kawasaki disease;	chr14:106676288	chr14:106627249~106627825:-
STAD	cis	rs1799949	1	rs33946455	ENSG00000279602.1	CTD-3014M21.1	4.38	1.57e-05	0.0071	0.29	0.23	Menopause (age at onset);	chr17:43169829	chr17:43360041~43361361:-
STAD	cis	rs1961102	0.723	rs2916558	ENSG00000253385.1	KB-1254G8.1	4.38	1.57e-05	0.0071	0.25	0.23	QT interval;	chr8:102835171	chr8:102854455~102856075:+
STAD	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	4.38	1.57e-05	0.0071	0.29	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
STAD	cis	rs2440129	0.632	rs2292353	ENSG00000262089.1	RP11-589P10.5	4.38	1.58e-05	0.0071	0.26	0.23	Tonsillectomy;	chr17:7000218	chr17:6994642~6995189:-
STAD	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	4.38	1.58e-05	0.00711	0.28	0.23	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	4.38	1.58e-05	0.00711	0.28	0.23	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	4.38	1.58e-05	0.00711	0.28	0.23	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
STAD	cis	rs4713118	0.615	rs57252182	ENSG00000280107.1	AL022393.9	-4.38	1.58e-05	0.00711	-0.28	-0.23	Parkinson's disease;	chr6:27752470	chr6:28170845~28172521:+
STAD	cis	rs34034915	1	rs34034915	ENSG00000280107.1	AL022393.9	-4.38	1.58e-05	0.00711	-0.28	-0.23	Hepatitis A;	chr6:27752924	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.527	rs36042294	ENSG00000280107.1	AL022393.9	-4.38	1.58e-05	0.00711	-0.28	-0.23	Parkinson's disease;	chr6:27752933	chr6:28170845~28172521:+
STAD	cis	rs11098499	0.954	rs7436506	ENSG00000260091.1	RP11-33B1.4	4.38	1.58e-05	0.00711	0.22	0.23	Corneal astigmatism;	chr4:119472614	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs10008459	ENSG00000260091.1	RP11-33B1.4	4.38	1.58e-05	0.00711	0.22	0.23	Corneal astigmatism;	chr4:119473076	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs2127821	ENSG00000260091.1	RP11-33B1.4	4.38	1.58e-05	0.00711	0.22	0.23	Corneal astigmatism;	chr4:119473380	chr4:119409333~119410233:+
STAD	cis	rs3770081	1	rs73947314	ENSG00000273080.1	RP11-301O19.1	-4.38	1.58e-05	0.00712	-0.53	-0.23	Facial emotion recognition (sad faces);	chr2:86045993	chr2:86195590~86196049:+
STAD	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-4.38	1.58e-05	0.00712	-0.27	-0.23	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
STAD	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	4.38	1.58e-05	0.00712	0.36	0.23	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	4.38	1.58e-05	0.00712	0.36	0.23	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	4.38	1.58e-05	0.00712	0.36	0.23	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
STAD	cis	rs6539288	0.63	rs10778520	ENSG00000260329.1	RP11-412D9.4	4.38	1.58e-05	0.00712	0.24	0.23	Total body bone mineral density;	chr12:106971095	chr12:106954029~106955497:-
STAD	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-4.38	1.58e-05	0.00712	-0.3	-0.23	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
STAD	cis	rs748404	0.65	rs556851	ENSG00000275601.1	AC011330.13	-4.38	1.58e-05	0.00713	-0.24	-0.23	Lung cancer;	chr15:43279021	chr15:43642389~43643023:-
STAD	cis	rs1485394	0.778	rs2280448	ENSG00000257379.1	RP11-793H13.8	4.38	1.58e-05	0.00713	0.47	0.23	Electroencephalogram traits;	chr12:53503200	chr12:53441741~53467528:+
STAD	cis	rs7487075	0.82	rs4586238	ENSG00000257261.4	RP11-96H19.1	4.38	1.58e-05	0.00713	0.3	0.23	Itch intensity from mosquito bite;	chr12:46326044	chr12:46383679~46876159:+
STAD	cis	rs3736858	1	rs60560195	ENSG00000261105.4	LMO7-AS1	-4.38	1.58e-05	0.00714	-0.37	-0.23	Interleukin-9 levels;	chr13:75853715	chr13:75604700~75635994:-
STAD	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	4.38	1.58e-05	0.00714	0.26	0.23	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
STAD	cis	rs12908161	1	rs60957376	ENSG00000259295.5	CSPG4P12	4.38	1.58e-05	0.00714	0.32	0.23	Schizophrenia;	chr15:84737561	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs11632465	ENSG00000259295.5	CSPG4P12	4.38	1.58e-05	0.00714	0.32	0.23	Schizophrenia;	chr15:84738814	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.96	rs62019463	ENSG00000259295.5	CSPG4P12	4.38	1.58e-05	0.00714	0.32	0.23	Schizophrenia;	chr15:84744856	chr15:85191438~85213905:+
STAD	cis	rs12908161	1	rs62019464	ENSG00000259295.5	CSPG4P12	4.38	1.58e-05	0.00714	0.32	0.23	Schizophrenia;	chr15:84751238	chr15:85191438~85213905:+
STAD	cis	rs8028182	0.636	rs4886716	ENSG00000260269.4	CTD-2323K18.1	-4.38	1.58e-05	0.00714	-0.29	-0.23	Sudden cardiac arrest;	chr15:75563681	chr15:75527150~75601205:-
STAD	cis	rs7176527	0.848	rs1374463	ENSG00000225151.9	GOLGA2P7	4.38	1.58e-05	0.00714	0.34	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:84199311~84230136:-
STAD	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	4.38	1.58e-05	0.00714	0.38	0.23	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	4.38	1.58e-05	0.00714	0.38	0.23	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
STAD	cis	rs5753618	0.561	rs2078803	ENSG00000236132.1	CTA-440B3.1	4.38	1.58e-05	0.00714	0.27	0.23	Colorectal cancer;	chr22:31256866	chr22:31816379~31817491:-
STAD	cis	rs2337406	0.85	rs4774179	ENSG00000211972.2	IGHV3-66	4.38	1.59e-05	0.00714	0.26	0.23	Alzheimer's disease (late onset);	chr14:106700837	chr14:106675017~106675544:-
STAD	cis	rs7208859	0.673	rs9912122	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.59e-05	0.00715	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30729469~30731202:+
STAD	cis	rs1075265	0.87	rs7569214	ENSG00000235937.1	AC008280.1	4.38	1.59e-05	0.00715	0.21	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.729	rs10201364	ENSG00000235937.1	AC008280.1	4.38	1.59e-05	0.00715	0.21	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54029552~54030682:-
STAD	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-4.38	1.59e-05	0.00715	-0.23	-0.23	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
STAD	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	4.38	1.59e-05	0.00715	0.34	0.23	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	4.38	1.59e-05	0.00715	0.34	0.23	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
STAD	cis	rs1913185	0.787	rs2864794	ENSG00000240032.1	RP11-274H2.3	-4.38	1.59e-05	0.00715	-0.33	-0.23	Obesity-related traits;	chr3:146148583	chr3:146066344~146069185:-
STAD	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	4.38	1.59e-05	0.00716	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	4.38	1.59e-05	0.00716	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
STAD	cis	rs2337406	1	rs78857163	ENSG00000211972.2	IGHV3-66	4.38	1.59e-05	0.00716	0.27	0.23	Alzheimer's disease (late onset);	chr14:106707435	chr14:106675017~106675544:-
STAD	cis	rs935334	1	rs2121075	ENSG00000258454.1	RP11-361H10.3	4.38	1.59e-05	0.00716	0.33	0.23	Blood pressure;	chr14:76209197	chr14:76235817~76263474:+
STAD	cis	rs2337406	0.538	rs2015470	ENSG00000211970.3	IGHV4-61	4.38	1.59e-05	0.00716	0.25	0.23	Alzheimer's disease (late onset);	chr14:106631885	chr14:106639119~106639657:-
STAD	cis	rs7119038	0.509	rs10790261	ENSG00000255422.1	AP002954.4	-4.38	1.59e-05	0.00717	-0.29	-0.23	Sjögren's syndrome;	chr11:118709038	chr11:118704607~118750263:+
STAD	cis	rs9646944	0.501	rs10166330	ENSG00000234389.1	AC007278.3	4.38	1.59e-05	0.00717	0.3	0.23	Blood protein levels;	chr2:102433930	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.501	rs2110736	ENSG00000234389.1	AC007278.3	4.38	1.59e-05	0.00717	0.3	0.23	Blood protein levels;	chr2:102434395	chr2:102438713~102440475:+
STAD	cis	rs1928295	0.786	rs10759926	ENSG00000233569.1	RP11-500B12.1	4.38	1.59e-05	0.00717	0.25	0.23	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117603947	chr9:117648606~117657027:+
STAD	cis	rs822354	1	rs266738	ENSG00000230951.1	GPS2P2	-4.38	1.59e-05	0.00717	-0.28	-0.23	Adiponectin levels;	chr3:186759698	chr3:186772589~186773476:+
STAD	cis	rs11638815	0.626	rs1313492	ENSG00000255769.6	GOLGA2P10	-4.38	1.59e-05	0.00717	-0.26	-0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:82472993~82513950:-
STAD	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-4.38	1.59e-05	0.00717	-0.23	-0.23	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
STAD	cis	rs4835473	0.932	rs13103072	ENSG00000249741.2	RP11-673E1.3	4.38	1.59e-05	0.00718	0.27	0.23	Immature fraction of reticulocytes;	chr4:143952116	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.864	rs28609839	ENSG00000249741.2	RP11-673E1.3	4.38	1.59e-05	0.00718	0.27	0.23	Immature fraction of reticulocytes;	chr4:143954160	chr4:143911514~143912053:-
STAD	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	4.38	1.59e-05	0.00718	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	4.38	1.59e-05	0.00718	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	4.38	1.59e-05	0.00718	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	4.38	1.59e-05	0.00718	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
STAD	cis	rs12821008	1	rs12821008	ENSG00000258017.1	RP11-386G11.10	-4.38	1.6e-05	0.00718	-0.24	-0.23	Bone mineral density;	chr12:49080822	chr12:49127782~49147869:+
STAD	cis	rs1707322	0.655	rs3014240	ENSG00000225447.1	RPS15AP10	-4.38	1.6e-05	0.00718	-0.19	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45645816~45646197:-
STAD	cis	rs7665090	1	rs6810869	ENSG00000246560.2	RP11-10L12.4	4.38	1.6e-05	0.00719	0.27	0.23	Primary biliary cholangitis;	chr4:102637357	chr4:102828055~102844075:+
STAD	cis	rs1707322	0.685	rs56177313	ENSG00000225447.1	RPS15AP10	4.38	1.6e-05	0.00719	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs11211178	ENSG00000225447.1	RPS15AP10	4.38	1.6e-05	0.00719	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs4660314	ENSG00000225447.1	RPS15AP10	4.38	1.6e-05	0.00719	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45645816~45646197:-
STAD	cis	rs8028182	0.636	rs4243034	ENSG00000260269.4	CTD-2323K18.1	-4.38	1.6e-05	0.00719	-0.29	-0.23	Sudden cardiac arrest;	chr15:75458628	chr15:75527150~75601205:-
STAD	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	4.38	1.6e-05	0.00719	0.22	0.23	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
STAD	cis	rs6832769	1	rs10002541	ENSG00000272969.1	RP11-528I4.2	-4.38	1.6e-05	0.00719	-0.29	-0.23	Personality dimensions;	chr4:55528844	chr4:55547112~55547889:+
STAD	cis	rs11098499	0.909	rs79026312	ENSG00000260091.1	RP11-33B1.4	4.38	1.6e-05	0.00719	0.23	0.23	Corneal astigmatism;	chr4:119519522	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs35111518	ENSG00000260091.1	RP11-33B1.4	4.38	1.6e-05	0.00719	0.23	0.23	Corneal astigmatism;	chr4:119519527	chr4:119409333~119410233:+
STAD	cis	rs1153858	0.945	rs16943246	ENSG00000259433.2	CTD-2651B20.4	-4.38	1.6e-05	0.00719	-0.25	-0.23	Homoarginine levels;	chr15:45428399	chr15:45330209~45332634:-
STAD	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-4.38	1.6e-05	0.00719	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-4.38	1.6e-05	0.00719	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
STAD	cis	rs1928295	0.786	rs28693508	ENSG00000233569.1	RP11-500B12.1	4.38	1.6e-05	0.0072	0.25	0.23	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117599140	chr9:117648606~117657027:+
STAD	cis	rs7224610	0.966	rs3794748	ENSG00000263096.1	RP11-515O17.2	4.38	1.6e-05	0.0072	0.29	0.23	Urate levels;	chr17:55287811	chr17:55271504~55273653:-
STAD	cis	rs11638815	0.603	rs7171180	ENSG00000255769.6	GOLGA2P10	4.38	1.6e-05	0.0072	0.26	0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:82472993~82513950:-
STAD	cis	rs2273156	0.929	rs12050171	ENSG00000241052.1	RP11-173D9.1	-4.38	1.6e-05	0.0072	-0.25	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34926245	chr14:35144021~35144480:-
STAD	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-4.38	1.6e-05	0.0072	-0.28	-0.23	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
STAD	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-4.38	1.6e-05	0.0072	-0.28	-0.23	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
STAD	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-4.38	1.6e-05	0.0072	-0.27	-0.23	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
STAD	cis	rs6142102	0.651	rs6088412	ENSG00000275784.1	RP5-1125A11.6	4.38	1.6e-05	0.0072	0.25	0.23	Skin pigmentation;	chr20:34154262	chr20:33989480~33991818:-
STAD	cis	rs7829975	0.742	rs7832968	ENSG00000173295.6	FAM86B3P	4.38	1.6e-05	0.00721	0.26	0.23	Mood instability;	chr8:8795379	chr8:8228595~8244865:+
STAD	cis	rs4691139	1	rs6536882	ENSG00000248632.1	RP11-366M4.11	4.38	1.6e-05	0.00721	0.23	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979528	chr4:164968587~164970002:-
STAD	cis	rs4691139	1	rs6536883	ENSG00000248632.1	RP11-366M4.11	4.38	1.6e-05	0.00721	0.23	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979552	chr4:164968587~164970002:-
STAD	cis	rs11012350	0.85	rs11012396	ENSG00000240291.1	RP11-499P20.2	-4.38	1.6e-05	0.00721	-0.44	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18054867	chr10:18513115~18545651:-
STAD	cis	rs12908161	0.959	rs2175567	ENSG00000259295.5	CSPG4P12	4.38	1.6e-05	0.00721	0.32	0.23	Schizophrenia;	chr15:84657715	chr15:85191438~85213905:+
STAD	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-4.38	1.6e-05	0.00722	-0.27	-0.23	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
STAD	cis	rs1707322	1	rs946527	ENSG00000281133.1	AL355480.3	-4.38	1.6e-05	0.00722	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45580892~45580996:-
STAD	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-4.38	1.6e-05	0.00722	-0.28	-0.23	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
STAD	cis	rs1005277	0.579	rs1780130	ENSG00000276805.1	RP11-291L22.6	4.38	1.6e-05	0.00722	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38451030~38451785:+
STAD	cis	rs6142102	0.847	rs4911413	ENSG00000275784.1	RP5-1125A11.6	-4.38	1.6e-05	0.00722	-0.23	-0.23	Skin pigmentation;	chr20:34133969	chr20:33989480~33991818:-
STAD	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-4.38	1.61e-05	0.00722	-0.27	-0.23	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-4.38	1.61e-05	0.00722	-0.27	-0.23	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-4.38	1.61e-05	0.00722	-0.27	-0.23	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
STAD	cis	rs561341	0.882	rs16967101	ENSG00000265798.5	RP11-271K11.5	4.38	1.61e-05	0.00722	0.3	0.23	Hip circumference adjusted for BMI;	chr17:32050143	chr17:31038575~31059121:-
STAD	cis	rs7829975	0.684	rs474892	ENSG00000254340.1	RP11-10A14.3	-4.38	1.61e-05	0.00722	-0.27	-0.23	Mood instability;	chr8:8739221	chr8:9141424~9145435:+
STAD	cis	rs7647973	0.516	rs4955419	ENSG00000225399.4	RP11-3B7.1	4.38	1.61e-05	0.00723	0.25	0.23	Menarche (age at onset);	chr3:49163259	chr3:49260085~49261316:+
STAD	cis	rs9733	0.544	rs72700902	ENSG00000274963.1	Metazoa_SRP	4.38	1.61e-05	0.00723	0.2	0.23	Tonsillectomy;	chr1:150660871	chr1:150568971~150569269:-
STAD	cis	rs9733	0.519	rs10788792	ENSG00000274963.1	Metazoa_SRP	4.38	1.61e-05	0.00723	0.2	0.23	Tonsillectomy;	chr1:150666096	chr1:150568971~150569269:-
STAD	cis	rs6142102	0.961	rs2284387	ENSG00000264616.1	MIR4755	4.38	1.61e-05	0.00723	0.24	0.23	Skin pigmentation;	chr20:34056782	chr20:34049119~34049190:+
STAD	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-4.38	1.61e-05	0.00723	-0.27	-0.23	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
STAD	cis	rs17301013	0.861	rs1894200	ENSG00000227373.4	RP11-160H22.5	-4.38	1.61e-05	0.00723	-0.28	-0.23	Systemic lupus erythematosus;	chr1:174842039	chr1:174115300~174160004:-
STAD	cis	rs7680126	0.633	rs11737564	ENSG00000250613.1	RP11-136I13.1	4.38	1.61e-05	0.00723	0.25	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10242846	chr4:10410996~10411644:+
STAD	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-4.37	1.61e-05	0.00724	-0.26	-0.23	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-4.37	1.61e-05	0.00724	-0.26	-0.23	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-4.37	1.61e-05	0.00724	-0.26	-0.23	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-4.37	1.61e-05	0.00724	-0.26	-0.23	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-4.37	1.61e-05	0.00724	-0.26	-0.23	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-4.37	1.61e-05	0.00724	-0.26	-0.23	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
STAD	cis	rs9860428	0.567	rs6438122	ENSG00000240057.4	RP11-572M11.4	-4.37	1.61e-05	0.00724	-0.22	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112969649	chr3:113019532~113183301:+
STAD	cis	rs2117029	1	rs11168839	ENSG00000258017.1	RP11-386G11.10	4.37	1.61e-05	0.00725	0.24	0.23	Intelligence (multi-trait analysis);	chr12:49063852	chr12:49127782~49147869:+
STAD	cis	rs11098499	0.954	rs11729521	ENSG00000260091.1	RP11-33B1.4	4.37	1.61e-05	0.00725	0.22	0.23	Corneal astigmatism;	chr4:119495633	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs11734241	ENSG00000260091.1	RP11-33B1.4	4.37	1.61e-05	0.00725	0.22	0.23	Corneal astigmatism;	chr4:119495717	chr4:119409333~119410233:+
STAD	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-4.37	1.61e-05	0.00725	-0.33	-0.23	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
STAD	cis	rs2337406	1	rs11850709	ENSG00000280411.1	IGHV1-69-2	-4.37	1.61e-05	0.00725	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106670844	chr14:106762092~106762588:-
STAD	cis	rs4589258	0.933	rs10830574	ENSG00000280367.1	RP11-121L10.2	-4.37	1.61e-05	0.00725	-0.24	-0.23	Intelligence (multi-trait analysis);	chr11:90774393	chr11:90223153~90226538:+
STAD	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	4.37	1.61e-05	0.00725	0.24	0.23	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
STAD	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.61e-05	0.00725	-0.26	-0.23	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.61e-05	0.00725	-0.26	-0.23	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
STAD	cis	rs4589258	0.689	rs1783802	ENSG00000280367.1	RP11-121L10.2	4.37	1.61e-05	0.00725	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90719169	chr11:90223153~90226538:+
STAD	cis	rs8062405	0.964	rs11860513	ENSG00000278665.1	RP11-666O2.4	4.37	1.61e-05	0.00725	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28599241~28601881:-
STAD	cis	rs449789	0.857	rs10806706	ENSG00000235086.1	FNDC1-IT1	4.37	1.62e-05	0.00726	0.3	0.23	Pulse pressure;	chr6:159300913	chr6:159240786~159243329:+
STAD	cis	rs8099594	0.565	rs1942998	ENSG00000266696.1	RP11-30L3.2	4.37	1.62e-05	0.00726	0.21	0.23	Height;	chr18:49186420	chr18:49205912~49208781:+
STAD	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-4.37	1.62e-05	0.00726	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
STAD	cis	rs9291683	0.597	rs11722989	ENSG00000250613.1	RP11-136I13.1	4.37	1.62e-05	0.00727	0.22	0.23	Bone mineral density;	chr4:10124515	chr4:10410996~10411644:+
STAD	cis	rs2692947	0.666	rs7566050	ENSG00000237510.6	AC008268.2	4.37	1.62e-05	0.00727	0.29	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95960282	chr2:95789654~95800166:+
STAD	cis	rs2692947	0.637	rs72492201	ENSG00000237510.6	AC008268.2	4.37	1.62e-05	0.00727	0.29	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95964453	chr2:95789654~95800166:+
STAD	cis	rs2692947	0.667	rs4144055	ENSG00000237510.6	AC008268.2	4.37	1.62e-05	0.00727	0.29	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95982108	chr2:95789654~95800166:+
STAD	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-4.37	1.62e-05	0.00727	-0.25	-0.23	Migraine;	chr4:56880007	chr4:56960927~56961373:-
STAD	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-4.37	1.62e-05	0.00727	-0.25	-0.23	Migraine;	chr4:56880190	chr4:56960927~56961373:-
STAD	cis	rs11169552	0.51	rs11169515	ENSG00000200183.1	RNU6-238P	-4.37	1.62e-05	0.00727	-0.22	-0.23	Colorectal cancer;	chr12:50659732	chr12:50656973~50657078:+
STAD	cis	rs2115536	1	rs2903105	ENSG00000278600.1	RP11-81A1.6	-4.37	1.62e-05	0.00728	-0.2	-0.23	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897181	chr15:79920195~79922455:-
STAD	cis	rs539514	0.69	rs34545980	ENSG00000261105.4	LMO7-AS1	4.37	1.62e-05	0.00728	0.27	0.23	Type 1 diabetes;	chr13:75735501	chr13:75604700~75635994:-
STAD	cis	rs227917	1	rs227924	ENSG00000234286.1	AC006026.13	4.37	1.62e-05	0.00728	0.33	0.23	Common carotid intima-media thickness in HIV negative individuals;	chr7:23619580	chr7:23680195~23680786:-
STAD	cis	rs1528149	0.504	rs1990364	ENSG00000224683.1	RPL36AP29	4.37	1.62e-05	0.00728	0.24	0.23	Sitting height ratio;	chr7:16129300	chr7:16208945~16209265:+
STAD	cis	rs11098499	1	rs58601355	ENSG00000260091.1	RP11-33B1.4	4.37	1.62e-05	0.00728	0.23	0.23	Corneal astigmatism;	chr4:119265212	chr4:119409333~119410233:+
STAD	cis	rs1707322	0.929	rs785513	ENSG00000281133.1	AL355480.3	4.37	1.62e-05	0.00728	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45580892~45580996:-
STAD	cis	rs7615952	0.673	rs9841194	ENSG00000272840.1	RP11-379B18.6	4.37	1.62e-05	0.00728	0.48	0.23	Blood pressure (smoking interaction);	chr3:125916896	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.673	rs9289270	ENSG00000272840.1	RP11-379B18.6	4.37	1.62e-05	0.00728	0.48	0.23	Blood pressure (smoking interaction);	chr3:125918136	chr3:125774714~125797953:+
STAD	cis	rs10971721	0.822	rs10971818	ENSG00000260947.1	RP11-384P7.7	-4.37	1.62e-05	0.00729	-0.31	-0.23	Body mass index;	chr9:33952155	chr9:33697459~33700986:+
STAD	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	4.37	1.62e-05	0.00729	0.24	0.23	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
STAD	cis	rs1007738	0.507	rs61897857	ENSG00000271350.1	CTD-2384B9.1	4.37	1.62e-05	0.00729	0.3	0.23	Bone mineral density (hip);	chr11:47211907	chr11:47041027~47041945:-
STAD	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.62e-05	0.00729	-0.26	-0.23	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
STAD	cis	rs10129255	0.536	rs8004835	ENSG00000211973.2	IGHV1-69	4.37	1.62e-05	0.00729	0.19	0.23	Kawasaki disease;	chr14:106686361	chr14:106714684~106715181:-
STAD	cis	rs539514	0.612	rs9573648	ENSG00000261105.4	LMO7-AS1	4.37	1.63e-05	0.0073	0.27	0.23	Type 1 diabetes;	chr13:75735143	chr13:75604700~75635994:-
STAD	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-4.37	1.63e-05	0.0073	-0.34	-0.23	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
STAD	cis	rs2720460	0.502	rs223374	ENSG00000248971.2	KRT8P46	-4.37	1.63e-05	0.0073	-0.25	-0.23	Testicular germ cell tumor;	chr4:102837144	chr4:102728746~102730171:-
STAD	cis	rs2992257	0.958	rs3006822	ENSG00000251839.1	RNU7-12P	-4.37	1.63e-05	0.0073	-0.23	-0.23	Response to angiotensin II receptor blocker therapy;	chr10:26427410	chr10:27232255~27232316:-
STAD	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	4.37	1.63e-05	0.00731	0.25	0.23	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	4.37	1.63e-05	0.00731	0.25	0.23	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	4.37	1.63e-05	0.00731	0.25	0.23	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	4.37	1.63e-05	0.00731	0.25	0.23	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
STAD	cis	rs6951245	0.882	rs10256720	ENSG00000229043.2	AC091729.9	-4.37	1.63e-05	0.00731	-0.37	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1171189	chr7:1160374~1165267:+
STAD	cis	rs9646944	0.578	rs13418548	ENSG00000234389.1	AC007278.3	4.37	1.63e-05	0.00731	0.31	0.23	Blood protein levels;	chr2:102300779	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs72823619	ENSG00000234389.1	AC007278.3	4.37	1.63e-05	0.00731	0.31	0.23	Allergy;	chr2:102308155	chr2:102438713~102440475:+
STAD	cis	rs9329221	0.683	rs3105738	ENSG00000254340.1	RP11-10A14.3	-4.37	1.63e-05	0.00731	-0.28	-0.23	Neuroticism;	chr8:10032404	chr8:9141424~9145435:+
STAD	cis	rs7176527	0.8	rs56747535	ENSG00000225151.9	GOLGA2P7	4.37	1.63e-05	0.00731	0.3	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:84199311~84230136:-
STAD	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	4.37	1.63e-05	0.00731	0.27	0.23	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
STAD	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-4.37	1.63e-05	0.00732	-0.35	-0.23	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
STAD	cis	rs9307551	0.948	rs4975056	ENSG00000250334.4	LINC00989	-4.37	1.63e-05	0.00732	-0.29	-0.23	Refractive error;	chr4:79563716	chr4:79492416~79576460:+
STAD	cis	rs4589258	0.933	rs1792602	ENSG00000280367.1	RP11-121L10.2	-4.37	1.63e-05	0.00732	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90706465	chr11:90223153~90226538:+
STAD	cis	rs748404	0.631	rs7167882	ENSG00000275601.1	AC011330.13	-4.37	1.63e-05	0.00733	-0.24	-0.23	Lung cancer;	chr15:43386465	chr15:43642389~43643023:-
STAD	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	4.37	1.63e-05	0.00733	0.28	0.23	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
STAD	cis	rs1799949	1	rs12951869	ENSG00000279602.1	CTD-3014M21.1	4.37	1.63e-05	0.00733	0.29	0.23	Menopause (age at onset);	chr17:43035550	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11654452	ENSG00000279602.1	CTD-3014M21.1	4.37	1.63e-05	0.00733	0.29	0.23	Menopause (age at onset);	chr17:43037366	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs4793189	ENSG00000279602.1	CTD-3014M21.1	4.37	1.63e-05	0.00733	0.29	0.23	Menopause (age at onset);	chr17:43038698	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11657053	ENSG00000279602.1	CTD-3014M21.1	4.37	1.63e-05	0.00733	0.29	0.23	Menopause (age at onset);	chr17:43039112	chr17:43360041~43361361:-
STAD	cis	rs2337406	0.587	rs10129888	ENSG00000211970.3	IGHV4-61	4.37	1.63e-05	0.00733	0.25	0.23	Alzheimer's disease (late onset);	chr14:106647421	chr14:106639119~106639657:-
STAD	cis	rs2337406	0.587	rs2516889	ENSG00000211970.3	IGHV4-61	-4.37	1.63e-05	0.00733	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106648903	chr14:106639119~106639657:-
STAD	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-4.37	1.63e-05	0.00733	-0.34	-0.23	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
STAD	cis	rs4142995	0.772	rs2723509	ENSG00000279048.1	RP11-511H23.2	-4.37	1.63e-05	0.00733	-0.21	-0.23	HDL cholesterol;HDL cholesterol levels;	chr7:17777413	chr7:17940503~17942922:+
STAD	cis	rs8062405	1	rs1987472	ENSG00000278665.1	RP11-666O2.4	4.37	1.64e-05	0.00733	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.895	rs56186137	ENSG00000278665.1	RP11-666O2.4	4.37	1.64e-05	0.00733	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28599241~28601881:-
STAD	cis	rs10129255	0.556	rs9324093	ENSG00000211973.2	IGHV1-69	4.37	1.64e-05	0.00733	0.19	0.23	Kawasaki disease;	chr14:106683893	chr14:106714684~106715181:-
STAD	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.64e-05	0.00733	-0.27	-0.23	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.64e-05	0.00733	-0.27	-0.23	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.64e-05	0.00733	-0.27	-0.23	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs12944458	ENSG00000279602.1	CTD-3014M21.1	4.37	1.64e-05	0.00734	0.29	0.23	Menopause (age at onset);	chr17:43028755	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs72829113	ENSG00000279602.1	CTD-3014M21.1	4.37	1.64e-05	0.00734	0.29	0.23	Menopause (age at onset);	chr17:43029818	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11653253	ENSG00000279602.1	CTD-3014M21.1	4.37	1.64e-05	0.00734	0.29	0.23	Menopause (age at onset);	chr17:43030645	chr17:43360041~43361361:-
STAD	cis	rs2638953	0.924	rs11049454	ENSG00000247934.4	RP11-967K21.1	-4.37	1.64e-05	0.00734	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204755	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs10843134	ENSG00000247934.4	RP11-967K21.1	-4.37	1.64e-05	0.00734	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205710	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs1824768	ENSG00000247934.4	RP11-967K21.1	-4.37	1.64e-05	0.00734	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206530	chr12:28163298~28190738:-
STAD	cis	rs11846409	0.86	rs4774167	ENSG00000274576.2	IGHV2-70	-4.37	1.64e-05	0.00734	-0.28	-0.23	Rheumatic heart disease;	chr14:106619987	chr14:106770577~106771020:-
STAD	cis	rs7103648	0.695	rs7933019	ENSG00000280615.1	Y_RNA	4.37	1.64e-05	0.00734	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47487585	chr11:47614898~47614994:-
STAD	cis	rs7944584	0.511	rs10838725	ENSG00000280615.1	Y_RNA	4.37	1.64e-05	0.00734	0.24	0.23	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47536319	chr11:47614898~47614994:-
STAD	cis	rs7103648	0.695	rs10838726	ENSG00000280615.1	Y_RNA	4.37	1.64e-05	0.00734	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47546792	chr11:47614898~47614994:-
STAD	cis	rs7944584	0.511	rs10838731	ENSG00000280615.1	Y_RNA	4.37	1.64e-05	0.00734	0.24	0.23	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47585583	chr11:47614898~47614994:-
STAD	cis	rs9860428	0.844	rs10804505	ENSG00000240057.4	RP11-572M11.4	4.37	1.64e-05	0.00734	0.21	0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112855409	chr3:113019532~113183301:+
STAD	cis	rs10129255	0.556	rs8010005	ENSG00000224373.3	IGHV4-59	4.37	1.64e-05	0.00735	0.16	0.23	Kawasaki disease;	chr14:106777987	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.556	rs6576224	ENSG00000224373.3	IGHV4-59	4.37	1.64e-05	0.00735	0.16	0.23	Kawasaki disease;	chr14:106777997	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.518	rs8010020	ENSG00000224373.3	IGHV4-59	4.37	1.64e-05	0.00735	0.16	0.23	Kawasaki disease;	chr14:106778016	chr14:106627249~106627825:-
STAD	cis	rs2337406	1	rs11849532	ENSG00000280411.1	IGHV1-69-2	-4.37	1.64e-05	0.00735	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106669877	chr14:106762092~106762588:-
STAD	cis	rs227275	0.525	rs13113923	ENSG00000248971.2	KRT8P46	-4.37	1.64e-05	0.00735	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102728746~102730171:-
STAD	cis	rs301901	1	rs300051	ENSG00000250155.1	CTD-2353F22.1	-4.37	1.64e-05	0.00735	-0.23	-0.23	Height;	chr5:37088525	chr5:36666214~36725195:-
STAD	cis	rs721917	0.646	rs2819096	ENSG00000225484.5	NUTM2B-AS1	-4.37	1.64e-05	0.00736	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79947857	chr10:79663088~79826594:-
STAD	cis	rs6471393	0.964	rs16916186	ENSG00000253848.1	RP11-10N23.5	4.37	1.64e-05	0.00736	0.27	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93733158	chr8:93741193~93744534:+
STAD	cis	rs11722779	0.935	rs6856176	ENSG00000248971.2	KRT8P46	-4.37	1.64e-05	0.00736	-0.24	-0.23	Schizophrenia;	chr4:102902574	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs11722779	ENSG00000248971.2	KRT8P46	-4.37	1.64e-05	0.00736	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102728746~102730171:-
STAD	cis	rs6142102	0.961	rs4911389	ENSG00000264616.1	MIR4755	4.37	1.64e-05	0.00736	0.24	0.23	Skin pigmentation;	chr20:33977235	chr20:34049119~34049190:+
STAD	cis	rs11846409	1	rs11846409	ENSG00000211970.3	IGHV4-61	4.37	1.64e-05	0.00736	0.25	0.23	Rheumatic heart disease;	chr14:106645692	chr14:106639119~106639657:-
STAD	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-4.37	1.64e-05	0.00736	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
STAD	cis	rs17401966	0.8	rs2039778	ENSG00000199562.1	RNU6-37P	4.37	1.65e-05	0.00737	0.18	0.23	Hepatocellular carcinoma;	chr1:10294543	chr1:10298966~10299072:+
STAD	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	4.37	1.65e-05	0.00737	0.31	0.23	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
STAD	cis	rs4589258	0.843	rs7128572	ENSG00000280367.1	RP11-121L10.2	4.37	1.65e-05	0.00737	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90749821	chr11:90223153~90226538:+
STAD	cis	rs4589258	1	rs4462299	ENSG00000280367.1	RP11-121L10.2	4.37	1.65e-05	0.00737	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90750106	chr11:90223153~90226538:+
STAD	cis	rs4589258	1	rs5009703	ENSG00000280367.1	RP11-121L10.2	4.37	1.65e-05	0.00737	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90754676	chr11:90223153~90226538:+
STAD	cis	rs7665090	1	rs3733202	ENSG00000248971.2	KRT8P46	-4.37	1.65e-05	0.00737	-0.24	-0.23	Primary biliary cholangitis;	chr4:102635704	chr4:102728746~102730171:-
STAD	cis	rs858239	0.539	rs10254544	ENSG00000230042.1	AK3P3	-4.37	1.65e-05	0.00738	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23129178~23129841:+
STAD	cis	rs7250849	0.565	rs73052857	ENSG00000273837.1	LLNLR-470E3.1	-4.37	1.65e-05	0.00738	-0.34	-0.23	Blood protein levels;	chr19:51661182	chr19:51639478~51639931:-
STAD	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	4.37	1.65e-05	0.00738	0.28	0.23	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
STAD	cis	rs858239	0.669	rs1990365	ENSG00000230042.1	AK3P3	-4.37	1.65e-05	0.00738	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23129178~23129841:+
STAD	cis	rs227275	0.556	rs28367331	ENSG00000248971.2	KRT8P46	-4.37	1.65e-05	0.00738	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102728746~102730171:-
STAD	cis	rs17401966	0.931	rs10864448	ENSG00000199562.1	RNU6-37P	4.37	1.65e-05	0.00739	0.18	0.23	Hepatocellular carcinoma;	chr1:10217439	chr1:10298966~10299072:+
STAD	cis	rs1020064	0.636	rs12476328	ENSG00000235319.1	AC012360.4	-4.37	1.65e-05	0.00739	-0.31	-0.23	AIDS;	chr2:105359887	chr2:105324210~105330529:+
STAD	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	4.37	1.65e-05	0.00739	0.21	0.23	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
STAD	cis	rs7760535	1	rs7760535	ENSG00000230177.1	RP5-1112D6.4	4.37	1.65e-05	0.00739	0.21	0.23	Metabolic traits;	chr6:111425880	chr6:111277932~111278742:+
STAD	cis	rs9307551	0.948	rs1371993	ENSG00000250334.4	LINC00989	-4.37	1.65e-05	0.00739	-0.29	-0.23	Refractive error;	chr4:79560662	chr4:79492416~79576460:+
STAD	cis	rs858239	0.899	rs28635122	ENSG00000230042.1	AK3P3	-4.37	1.65e-05	0.00739	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23129178~23129841:+
STAD	cis	rs1348850	0.914	rs4893950	ENSG00000271825.1	RP11-337N6.2	4.37	1.65e-05	0.0074	0.2	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177440157	chr2:177300600~177302006:+
STAD	cis	rs12906542	0.516	rs10444863	ENSG00000259792.1	RP11-114H24.6	-4.37	1.65e-05	0.0074	-0.41	-0.23	Breast cancer;	chr15:78066495	chr15:77993405~77995289:+
STAD	cis	rs2337406	0.587	rs11624678	ENSG00000211970.3	IGHV4-61	-4.37	1.65e-05	0.0074	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106650408	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.872	rs2956482	ENSG00000211970.3	IGHV4-61	-4.37	1.65e-05	0.0074	-0.25	-0.23	Rheumatic heart disease;	chr14:106630013	chr14:106639119~106639657:-
STAD	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	4.37	1.65e-05	0.0074	0.27	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
STAD	cis	rs10129255	0.913	rs28861466	ENSG00000232216.1	IGHV3-43	4.37	1.66e-05	0.00741	0.23	0.23	Kawasaki disease;	chr14:106718572	chr14:106470264~106470800:-
STAD	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-4.37	1.66e-05	0.00741	-0.37	-0.23	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
STAD	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-4.37	1.66e-05	0.00741	-0.24	-0.23	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
STAD	cis	rs9368481	0.743	rs9368480	ENSG00000224843.5	LINC00240	-4.37	1.66e-05	0.00741	-0.27	-0.23	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26956992~27023924:+
STAD	cis	rs422249	0.634	rs174610	ENSG00000279632.1	RP11-286N22.6	4.37	1.66e-05	0.00741	0.23	0.23	Trans fatty acid levels;	chr11:61860361	chr11:61426448~61427325:-
STAD	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	4.37	1.66e-05	0.00742	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
STAD	cis	rs10073892	0.62	rs10440758	ENSG00000250682.4	LINC00491	-4.37	1.66e-05	0.00742	-0.25	-0.23	Cognitive decline (age-related);	chr5:102593801	chr5:102609156~102671559:-
STAD	cis	rs4589258	0.737	rs2187537	ENSG00000280367.1	RP11-121L10.2	4.37	1.66e-05	0.00742	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90729683	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs2156829	ENSG00000280367.1	RP11-121L10.2	4.37	1.66e-05	0.00742	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90729793	chr11:90223153~90226538:+
STAD	cis	rs6142102	0.961	rs2284386	ENSG00000264616.1	MIR4755	4.37	1.66e-05	0.00742	0.24	0.23	Skin pigmentation;	chr20:34056590	chr20:34049119~34049190:+
STAD	cis	rs12908161	0.959	rs17534709	ENSG00000259295.5	CSPG4P12	4.37	1.66e-05	0.00743	0.33	0.23	Schizophrenia;	chr15:84771166	chr15:85191438~85213905:+
STAD	cis	rs8141529	0.764	rs5762854	ENSG00000272858.1	CTA-292E10.8	-4.37	1.66e-05	0.00743	-0.25	-0.23	Lymphocyte counts;	chr22:28850290	chr22:28814914~28815662:+
STAD	cis	rs1823874	0.71	rs2085087	ENSG00000182397.13	DNM1P46	-4.37	1.66e-05	0.00743	-0.24	-0.23	IgG glycosylation;	chr15:99819938	chr15:99790156~99806927:-
STAD	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	4.37	1.66e-05	0.00743	0.18	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
STAD	cis	rs710865	0.527	rs2275403	ENSG00000270728.1	RP4-657E11.10	4.37	1.66e-05	0.00743	0.26	0.23	Brain structure;	chr1:19231219	chr1:19297080~19297903:+
STAD	cis	rs2337406	1	rs17112416	ENSG00000280411.1	IGHV1-69-2	4.37	1.66e-05	0.00744	0.27	0.23	Alzheimer's disease (late onset);	chr14:106686773	chr14:106762092~106762588:-
STAD	cis	rs12745968	0.653	rs10874736	ENSG00000229052.2	RP11-386I23.1	-4.37	1.66e-05	0.00744	-0.22	-0.23	Bipolar disorder and schizophrenia;	chr1:92714639	chr1:92930696~92934098:+
STAD	cis	rs728616	0.558	rs2343302	ENSG00000225484.5	NUTM2B-AS1	-4.37	1.67e-05	0.00745	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79663088~79826594:-
STAD	cis	rs728616	0.558	rs2880599	ENSG00000225484.5	NUTM2B-AS1	-4.37	1.67e-05	0.00745	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79663088~79826594:-
STAD	cis	rs9987353	0.519	rs2929465	ENSG00000254340.1	RP11-10A14.3	-4.37	1.67e-05	0.00745	-0.31	-0.23	Recombination measurement;	chr8:9206492	chr8:9141424~9145435:+
STAD	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-4.37	1.67e-05	0.00745	-0.35	-0.23	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-4.37	1.67e-05	0.00745	-0.35	-0.23	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-4.37	1.67e-05	0.00745	-0.35	-0.23	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
STAD	cis	rs539514	0.513	rs7324353	ENSG00000261105.4	LMO7-AS1	4.37	1.67e-05	0.00745	0.29	0.23	Type 1 diabetes;	chr13:75698147	chr13:75604700~75635994:-
STAD	cis	rs9807989	0.801	rs11123925	ENSG00000234389.1	AC007278.3	4.37	1.67e-05	0.00745	0.24	0.23	Asthma;	chr2:102361051	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs10204837	ENSG00000234389.1	AC007278.3	4.37	1.67e-05	0.00745	0.24	0.23	Asthma;	chr2:102361270	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs3755276	ENSG00000234389.1	AC007278.3	4.37	1.67e-05	0.00745	0.24	0.23	Asthma;	chr2:102361999	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs9308857	ENSG00000234389.1	AC007278.3	4.37	1.67e-05	0.00745	0.24	0.23	Asthma;	chr2:102363164	chr2:102438713~102440475:+
STAD	cis	rs9807989	0.839	rs1420099	ENSG00000234389.1	AC007278.3	4.37	1.67e-05	0.00745	0.24	0.23	Asthma;	chr2:102364083	chr2:102438713~102440475:+
STAD	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	4.37	1.67e-05	0.00746	0.25	0.23	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
STAD	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-4.37	1.67e-05	0.00746	-0.26	-0.23	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
STAD	cis	rs11846409	0.86	rs4774167	ENSG00000211972.2	IGHV3-66	4.37	1.67e-05	0.00746	0.25	0.23	Rheumatic heart disease;	chr14:106619987	chr14:106675017~106675544:-
STAD	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	4.37	1.67e-05	0.00746	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	4.37	1.67e-05	0.00746	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
STAD	cis	rs9467773	0.572	rs13213953	ENSG00000241549.7	GUSBP2	4.37	1.67e-05	0.00747	0.23	0.23	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26871484~26956554:-
STAD	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	4.37	1.67e-05	0.00747	0.26	0.23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
STAD	cis	rs5850	0.602	rs1005786	ENSG00000230042.1	AK3P3	-4.37	1.67e-05	0.00747	-0.24	-0.23	Blood protein levels;	chr7:23106218	chr7:23129178~23129841:+
STAD	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-4.37	1.67e-05	0.00747	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
STAD	cis	rs2337406	0.587	rs2516886	ENSG00000211970.3	IGHV4-61	-4.37	1.67e-05	0.00747	-0.24	-0.23	Alzheimer's disease (late onset);	chr14:106649674	chr14:106639119~106639657:-
STAD	cis	rs9646944	0.501	rs9807934	ENSG00000234389.1	AC007278.3	4.37	1.67e-05	0.00747	0.3	0.23	Blood protein levels;	chr2:102423722	chr2:102438713~102440475:+
STAD	cis	rs17264034	0.861	rs1651285	ENSG00000250786.1	SNHG18	4.37	1.67e-05	0.00748	0.37	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547829	chr5:9546200~9550609:+
STAD	cis	rs17264034	0.861	rs1398337	ENSG00000250786.1	SNHG18	4.37	1.67e-05	0.00748	0.37	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547986	chr5:9546200~9550609:+
STAD	cis	rs9425766	0.541	rs4652274	ENSG00000227373.4	RP11-160H22.5	4.37	1.67e-05	0.00748	0.28	0.23	Life satisfaction;	chr1:174249434	chr1:174115300~174160004:-
STAD	cis	rs10129255	0.957	rs8009948	ENSG00000232216.1	IGHV3-43	4.37	1.68e-05	0.00748	0.24	0.23	Kawasaki disease;	chr14:106805607	chr14:106470264~106470800:-
STAD	cis	rs422249	0.615	rs174612	ENSG00000279632.1	RP11-286N22.6	4.37	1.68e-05	0.00749	0.23	0.23	Trans fatty acid levels;	chr11:61860794	chr11:61426448~61427325:-
STAD	cis	rs4834770	1	rs4834770	ENSG00000248280.1	RP11-33B1.2	4.37	1.68e-05	0.00749	0.27	0.23	Blood protein levels;	chr4:119320694	chr4:119440561~119450157:-
STAD	cis	rs4834770	1	rs6823963	ENSG00000248280.1	RP11-33B1.2	4.37	1.68e-05	0.00749	0.27	0.23	Blood protein levels;	chr4:119321009	chr4:119440561~119450157:-
STAD	cis	rs4834770	1	rs4834771	ENSG00000248280.1	RP11-33B1.2	4.37	1.68e-05	0.00749	0.27	0.23	Blood protein levels;	chr4:119321617	chr4:119440561~119450157:-
STAD	cis	rs4834770	1	rs1397613	ENSG00000248280.1	RP11-33B1.2	4.37	1.68e-05	0.00749	0.27	0.23	Blood protein levels;	chr4:119321774	chr4:119440561~119450157:-
STAD	cis	rs4834770	1	rs6857641	ENSG00000248280.1	RP11-33B1.2	4.37	1.68e-05	0.00749	0.27	0.23	Blood protein levels;	chr4:119322356	chr4:119440561~119450157:-
STAD	cis	rs4834770	1	rs2282688	ENSG00000248280.1	RP11-33B1.2	4.37	1.68e-05	0.00749	0.27	0.23	Blood protein levels;	chr4:119322567	chr4:119440561~119450157:-
STAD	cis	rs181553	0.664	rs8094480	ENSG00000266696.1	RP11-30L3.2	4.37	1.68e-05	0.00749	0.21	0.23	Hip circumference adjusted for BMI;	chr18:49161306	chr18:49205912~49208781:+
STAD	cis	rs4243830	0.85	rs10779790	ENSG00000229519.2	RP11-58A11.2	4.37	1.68e-05	0.00749	0.24	0.23	Body mass index;	chr1:6548375	chr1:6547905~6548619:+
STAD	cis	rs2408955	0.561	rs11168365	ENSG00000258273.1	RP11-370I10.4	4.37	1.68e-05	0.00749	0.27	0.23	Glycated hemoglobin levels;	chr12:48027989	chr12:48333755~48333901:-
STAD	cis	rs763014	0.966	rs4247097	ENSG00000228201.1	AL022341.3	4.37	1.68e-05	0.00749	0.27	0.23	Height;	chr16:604224	chr16:648473~649200:-
STAD	cis	rs1075265	0.564	rs2160930	ENSG00000233266.1	HMGB1P31	4.37	1.68e-05	0.00749	0.23	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53655390	chr2:54051334~54051760:+
STAD	cis	rs6832769	0.696	rs7660054	ENSG00000272969.1	RP11-528I4.2	4.37	1.68e-05	0.0075	0.29	0.23	Personality dimensions;	chr4:55402340	chr4:55547112~55547889:+
STAD	cis	rs1707322	0.717	rs2253862	ENSG00000225447.1	RPS15AP10	-4.37	1.68e-05	0.0075	-0.19	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.717	rs2991988	ENSG00000225447.1	RPS15AP10	-4.37	1.68e-05	0.0075	-0.19	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.717	rs2991989	ENSG00000225447.1	RPS15AP10	-4.37	1.68e-05	0.0075	-0.19	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45645816~45646197:-
STAD	cis	rs7829975	0.774	rs1039915	ENSG00000233609.3	RP11-62H7.2	4.37	1.68e-05	0.0075	0.25	0.23	Mood instability;	chr8:8822104	chr8:8961200~8979025:+
STAD	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	4.37	1.68e-05	0.0075	0.24	0.23	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
STAD	cis	rs13413635	0.66	rs1546813	ENSG00000225808.1	DNAJC19P5	4.36	1.68e-05	0.0075	0.28	0.23	Heart rate;	chr2:178009055	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.66	rs7570423	ENSG00000225808.1	DNAJC19P5	4.36	1.68e-05	0.0075	0.28	0.23	Heart rate;	chr2:178009704	chr2:177229191~177229506:-
STAD	cis	rs6832769	1	rs4865008	ENSG00000272969.1	RP11-528I4.2	-4.36	1.68e-05	0.00751	-0.29	-0.23	Personality dimensions;	chr4:55544688	chr4:55547112~55547889:+
STAD	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-4.36	1.68e-05	0.00751	-0.25	-0.23	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
STAD	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	4.36	1.68e-05	0.00751	0.31	0.23	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
STAD	cis	rs6832769	0.961	rs6824955	ENSG00000272969.1	RP11-528I4.2	4.36	1.68e-05	0.00751	0.29	0.23	Personality dimensions;	chr4:55450969	chr4:55547112~55547889:+
STAD	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	4.36	1.68e-05	0.00751	0.33	0.23	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
STAD	cis	rs6430585	0.583	rs111837148	ENSG00000231890.6	DARS-AS1	-4.36	1.68e-05	0.00751	-0.26	-0.23	Corneal structure;	chr2:135854466	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs61253125	ENSG00000231890.6	DARS-AS1	-4.36	1.68e-05	0.00751	-0.26	-0.23	Corneal structure;	chr2:135860608	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs4988201	ENSG00000231890.6	DARS-AS1	-4.36	1.68e-05	0.00751	-0.26	-0.23	Corneal structure;	chr2:135860937	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs3087343	ENSG00000231890.6	DARS-AS1	-4.36	1.68e-05	0.00751	-0.26	-0.23	Corneal structure;	chr2:135864973	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs4594504	ENSG00000231890.6	DARS-AS1	-4.36	1.68e-05	0.00751	-0.26	-0.23	Corneal structure;	chr2:135867543	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs3769001	ENSG00000231890.6	DARS-AS1	-4.36	1.68e-05	0.00751	-0.26	-0.23	Corneal structure;	chr2:135868508	chr2:135985176~136022593:+
STAD	cis	rs6142102	1	rs4911414	ENSG00000264616.1	MIR4755	4.36	1.68e-05	0.00751	0.24	0.23	Skin pigmentation;	chr20:34141638	chr20:34049119~34049190:+
STAD	cis	rs58873874	0.737	rs9313608	ENSG00000251405.2	CTB-109A12.1	-4.36	1.69e-05	0.00752	-0.41	-0.23	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157362615~157460078:-
STAD	cis	rs6471393	0.964	rs2914940	ENSG00000253848.1	RP11-10N23.5	4.36	1.69e-05	0.00752	0.27	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93719598	chr8:93741193~93744534:+
STAD	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	4.36	1.69e-05	0.00752	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
STAD	cis	rs1322639	0.574	rs9689193	ENSG00000261039.2	RP11-417E7.2	-4.36	1.69e-05	0.00752	-0.38	-0.23	Pulse pressure;	chr6:169187979	chr6:169175304~169182740:-
STAD	cis	rs7615952	0.609	rs13088451	ENSG00000239804.1	RP11-379B18.1	4.36	1.69e-05	0.00753	0.31	0.23	Blood pressure (smoking interaction);	chr3:125834656	chr3:125787888~125788146:-
STAD	cis	rs9902453	0.791	rs62068629	ENSG00000240074.1	RPL9P30	4.36	1.69e-05	0.00753	0.2	0.23	Coffee consumption (cups per day);	chr17:29860578	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.817	rs1842026	ENSG00000240074.1	RPL9P30	4.36	1.69e-05	0.00753	0.2	0.23	Coffee consumption (cups per day);	chr17:29861093	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.78	rs7210991	ENSG00000240074.1	RPL9P30	4.36	1.69e-05	0.00753	0.2	0.23	Coffee consumption (cups per day);	chr17:29863943	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.817	rs12051834	ENSG00000240074.1	RPL9P30	4.36	1.69e-05	0.00753	0.2	0.23	Coffee consumption (cups per day);	chr17:29865767	chr17:29855759~29856332:+
STAD	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	4.36	1.69e-05	0.00753	0.24	0.23	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
STAD	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	4.36	1.69e-05	0.00753	0.35	0.23	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	4.36	1.69e-05	0.00753	0.35	0.23	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	4.36	1.69e-05	0.00753	0.35	0.23	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
STAD	cis	rs858239	0.6	rs6967475	ENSG00000226816.2	AC005082.12	4.36	1.69e-05	0.00753	0.27	0.23	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23206013~23208045:+
STAD	cis	rs76917914	0.954	rs111292969	ENSG00000236896.1	RP11-535C21.3	4.36	1.69e-05	0.00753	0.3	0.23	Immature fraction of reticulocytes;	chr9:98025909	chr9:97986551~97987656:-
STAD	cis	rs11676348	0.772	rs11676275	ENSG00000237281.1	CATIP-AS2	4.36	1.69e-05	0.00754	0.23	0.23	Ulcerative colitis;	chr2:218080085	chr2:218326889~218357966:-
STAD	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-4.36	1.69e-05	0.00755	-0.26	-0.23	Migraine;	chr4:56881195	chr4:56960927~56961373:-
STAD	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-4.36	1.69e-05	0.00755	-0.26	-0.23	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
STAD	cis	rs17401966	0.838	rs10492971	ENSG00000199562.1	RNU6-37P	4.36	1.69e-05	0.00755	0.18	0.23	Hepatocellular carcinoma;	chr1:10282917	chr1:10298966~10299072:+
STAD	cis	rs8062405	1	rs12443881	ENSG00000278665.1	RP11-666O2.4	4.36	1.7e-05	0.00756	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28599241~28601881:-
STAD	cis	rs728616	0.51	rs17679603	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.7e-05	0.00756	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80421678	chr10:79663088~79826594:-
STAD	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	4.36	1.7e-05	0.00756	0.34	0.23	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
STAD	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-4.36	1.7e-05	0.00756	-0.36	-0.23	Gout;	chr7:66693028	chr7:66654538~66669855:+
STAD	cis	rs4713118	0.824	rs2179095	ENSG00000243307.2	POM121L6P	4.36	1.7e-05	0.00757	0.26	0.23	Parkinson's disease;	chr6:27783079	chr6:26896952~26898777:+
STAD	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	4.36	1.7e-05	0.00757	0.25	0.23	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
STAD	cis	rs17660992	0.928	rs12460840	ENSG00000273837.1	LLNLR-470E3.1	-4.36	1.7e-05	0.00757	-0.25	-0.23	Blood protein levels;	chr19:51662141	chr19:51639478~51639931:-
STAD	cis	rs7829975	0.535	rs4841005	ENSG00000173295.6	FAM86B3P	-4.36	1.7e-05	0.00757	-0.26	-0.23	Mood instability;	chr8:8643720	chr8:8228595~8244865:+
STAD	cis	rs17818399	0.541	rs12712976	ENSG00000279254.1	RP11-536C12.1	-4.36	1.7e-05	0.00758	-0.24	-0.23	Height;	chr2:46559352	chr2:46668870~46670778:+
STAD	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-4.36	1.7e-05	0.00758	-0.31	-0.23	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
STAD	cis	rs181553	0.699	rs8092003	ENSG00000266696.1	RP11-30L3.2	4.36	1.7e-05	0.00758	0.21	0.23	Hip circumference adjusted for BMI;	chr18:49165560	chr18:49205912~49208781:+
STAD	cis	rs10978777	0.515	rs28848858	ENSG00000276883.1	AL137852.1	4.36	1.7e-05	0.00758	0.25	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107278492	chr9:107292369~107292456:-
STAD	cis	rs1707322	1	rs2458400	ENSG00000225447.1	RPS15AP10	-4.36	1.7e-05	0.00759	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs9429186	ENSG00000225447.1	RPS15AP10	-4.36	1.7e-05	0.00759	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785506	ENSG00000225447.1	RPS15AP10	-4.36	1.7e-05	0.00759	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45645816~45646197:-
STAD	cis	rs17401966	0.931	rs3748577	ENSG00000199562.1	RNU6-37P	-4.36	1.7e-05	0.00759	-0.18	-0.23	Hepatocellular carcinoma;	chr1:10297348	chr1:10298966~10299072:+
STAD	cis	rs76917914	1	rs874610	ENSG00000236896.1	RP11-535C21.3	4.36	1.7e-05	0.00759	0.3	0.23	Immature fraction of reticulocytes;	chr9:98020413	chr9:97986551~97987656:-
STAD	cis	rs2192161	0.667	rs2822560	ENSG00000201812.1	RNA5SP488	-4.36	1.71e-05	0.0076	-0.38	-0.23	Non-word repetition;	chr21:14302311	chr21:14070871~14070986:+
STAD	cis	rs1707322	1	rs785467	ENSG00000281133.1	AL355480.3	4.36	1.71e-05	0.0076	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45580892~45580996:-
STAD	cis	rs17214007	0.877	rs7201553	ENSG00000263335.1	AF001548.5	-4.36	1.71e-05	0.00761	-0.27	-0.23	Cognitive function;	chr16:15781186	chr16:15726674~15732993:+
STAD	cis	rs7474896	0.616	rs2505239	ENSG00000120555.12	SEPT7P9	4.36	1.71e-05	0.00761	0.29	0.23	Obesity (extreme);	chr10:38151837	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.561	rs2474603	ENSG00000120555.12	SEPT7P9	4.36	1.71e-05	0.00761	0.29	0.23	Obesity (extreme);	chr10:38156754	chr10:38383069~38402916:-
STAD	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	4.36	1.71e-05	0.00761	0.23	0.23	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
STAD	cis	rs6813195	0.554	rs10021011	ENSG00000243417.1	RP11-555K12.1	-4.36	1.71e-05	0.00761	-0.23	-0.23	Type 2 diabetes;	chr4:152489238	chr4:152551277~152552364:-
STAD	cis	rs9543976	0.623	rs6562914	ENSG00000261553.4	RP11-29G8.3	4.36	1.71e-05	0.00762	0.34	0.23	Diabetic retinopathy;	chr13:75593401	chr13:75549773~75807120:+
STAD	cis	rs2803122	0.502	rs1329731	ENSG00000273226.1	RP11-513M16.8	-4.36	1.71e-05	0.00762	-0.25	-0.23	Pulse pressure;	chr9:19234910	chr9:19375451~19375996:+
STAD	cis	rs17264034	0.861	rs55713652	ENSG00000250786.1	SNHG18	4.36	1.71e-05	0.00762	0.39	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557010	chr5:9546200~9550609:+
STAD	cis	rs748404	0.697	rs554001	ENSG00000275601.1	AC011330.13	-4.36	1.71e-05	0.00762	-0.24	-0.23	Lung cancer;	chr15:43259721	chr15:43642389~43643023:-
STAD	cis	rs1365505	0.537	rs2052759	ENSG00000244879.4	GABPB1-AS1	-4.36	1.71e-05	0.00762	-0.26	-0.23	Blood metabolite ratios;	chr15:50183225	chr15:50354959~50372202:+
STAD	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	4.36	1.71e-05	0.00762	0.25	0.23	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	4.36	1.71e-05	0.00762	0.25	0.23	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	4.36	1.71e-05	0.00762	0.25	0.23	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
STAD	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-4.36	1.71e-05	0.00762	-0.26	-0.23	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-4.36	1.71e-05	0.00762	-0.26	-0.23	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
STAD	cis	rs858239	0.636	rs7808488	ENSG00000230042.1	AK3P3	-4.36	1.71e-05	0.00762	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23129178~23129841:+
STAD	cis	rs4589258	0.788	rs7126992	ENSG00000280367.1	RP11-121L10.2	4.36	1.71e-05	0.00762	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90745215	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs2105797	ENSG00000280367.1	RP11-121L10.2	4.36	1.71e-05	0.00762	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90745413	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs2097169	ENSG00000280367.1	RP11-121L10.2	4.36	1.71e-05	0.00762	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90746256	chr11:90223153~90226538:+
STAD	cis	rs2638953	0.886	rs11049393	ENSG00000247934.4	RP11-967K21.1	-4.36	1.71e-05	0.00763	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170273	chr12:28163298~28190738:-
STAD	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-4.36	1.71e-05	0.00763	-0.36	-0.23	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
STAD	cis	rs10857712	0.521	rs10857714	ENSG00000273327.1	OR6L2P	-4.36	1.72e-05	0.00764	-0.23	-0.23	Systemic lupus erythematosus;	chr10:133421866	chr10:133430394~133431318:-
STAD	cis	rs10040610	1	rs10040003	ENSG00000250490.1	FLJ33360	4.36	1.72e-05	0.00764	0.33	0.23	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6353618	chr5:6310441~6339884:-
STAD	cis	rs9902453	0.74	rs2617884	ENSG00000240074.1	RPL9P30	-4.36	1.72e-05	0.00764	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29793412	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.765	rs2617883	ENSG00000240074.1	RPL9P30	-4.36	1.72e-05	0.00764	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29793470	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.765	rs2729436	ENSG00000240074.1	RPL9P30	-4.36	1.72e-05	0.00764	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29793652	chr17:29855759~29856332:+
STAD	cis	rs2901460	0.628	rs12713454	ENSG00000229503.1	AC092155.1	-4.36	1.72e-05	0.00764	-0.19	-0.23	Mean corpuscular volume;	chr2:62133877	chr2:62532583~62533059:-
STAD	cis	rs1707322	0.752	rs28550303	ENSG00000225447.1	RPS15AP10	4.36	1.72e-05	0.00764	0.19	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45645816~45646197:-
STAD	cis	rs4589258	0.737	rs10741359	ENSG00000280367.1	RP11-121L10.2	4.36	1.72e-05	0.00764	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90721101	chr11:90223153~90226538:+
STAD	cis	rs55823223	0.648	rs56901103	ENSG00000267801.1	RP11-552F3.9	4.36	1.72e-05	0.00764	0.33	0.23	Psoriasis;	chr17:75869586	chr17:75876372~75879546:+
STAD	cis	rs1707322	0.896	rs809774	ENSG00000281133.1	AL355480.3	4.36	1.72e-05	0.00765	0.26	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45580892~45580996:-
STAD	cis	rs1816752	0.875	rs17384871	ENSG00000273628.1	RP11-756A22.7	4.36	1.72e-05	0.00765	0.29	0.23	Obesity-related traits;	chr13:24484959	chr13:24933006~24936796:+
STAD	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	4.36	1.72e-05	0.00765	0.28	0.23	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	4.36	1.72e-05	0.00766	0.27	0.23	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
STAD	cis	rs5753618	0.509	rs5753500	ENSG00000236132.1	CTA-440B3.1	4.36	1.72e-05	0.00766	0.27	0.23	Colorectal cancer;	chr22:31182893	chr22:31816379~31817491:-
STAD	cis	rs227275	0.554	rs223316	ENSG00000248971.2	KRT8P46	-4.36	1.72e-05	0.00766	-0.23	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102728746~102730171:-
STAD	cis	rs721917	0.569	rs2247820	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.72e-05	0.00766	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79663088~79826594:-
STAD	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	4.36	1.72e-05	0.00766	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
STAD	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	4.36	1.72e-05	0.00766	0.38	0.23	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
STAD	cis	rs449789	0.857	rs4708817	ENSG00000235086.1	FNDC1-IT1	-4.36	1.72e-05	0.00767	-0.3	-0.23	Pulse pressure;	chr6:159299608	chr6:159240786~159243329:+
STAD	cis	rs1799949	1	rs35330014	ENSG00000279602.1	CTD-3014M21.1	4.36	1.72e-05	0.00767	0.29	0.23	Menopause (age at onset);	chr17:43060530	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs3092994	ENSG00000279602.1	CTD-3014M21.1	4.36	1.72e-05	0.00767	0.29	0.23	Menopause (age at onset);	chr17:43063808	chr17:43360041~43361361:-
STAD	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-4.36	1.73e-05	0.00768	-0.38	-0.23	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
STAD	cis	rs12908161	1	rs12908161	ENSG00000259295.5	CSPG4P12	4.36	1.73e-05	0.00768	0.33	0.23	Schizophrenia;	chr15:84664594	chr15:85191438~85213905:+
STAD	cis	rs7829975	0.846	rs11779061	ENSG00000254340.1	RP11-10A14.3	-4.36	1.73e-05	0.00769	-0.29	-0.23	Mood instability;	chr8:8691922	chr8:9141424~9145435:+
STAD	cis	rs1707322	1	rs1707317	ENSG00000281133.1	AL355480.3	4.36	1.73e-05	0.00769	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45580892~45580996:-
STAD	cis	rs9467773	1	rs9986382	ENSG00000243307.2	POM121L6P	4.36	1.73e-05	0.00769	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26896952~26898777:+
STAD	cis	rs2337406	1	rs17113276	ENSG00000280411.1	IGHV1-69-2	4.36	1.73e-05	0.00769	0.27	0.23	Alzheimer's disease (late onset);	chr14:106683485	chr14:106762092~106762588:-
STAD	cis	rs9902453	0.765	rs2729447	ENSG00000240074.1	RPL9P30	-4.36	1.73e-05	0.0077	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29771984	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.74	rs2729446	ENSG00000240074.1	RPL9P30	-4.36	1.73e-05	0.0077	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29775481	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.74	rs2244247	ENSG00000240074.1	RPL9P30	-4.36	1.73e-05	0.0077	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29783156	chr17:29855759~29856332:+
STAD	cis	rs1707322	1	rs10789479	ENSG00000281133.1	AL355480.3	-4.36	1.73e-05	0.0077	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.964	rs7512395	ENSG00000281133.1	AL355480.3	-4.36	1.73e-05	0.0077	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45580892~45580996:-
STAD	cis	rs9788721	0.836	rs2568494	ENSG00000259419.2	HNRNPCP3	4.36	1.73e-05	0.0077	0.24	0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78448622	chr15:79236332~79237206:+
STAD	cis	rs10129255	0.5	rs8021941	ENSG00000224373.3	IGHV4-59	4.36	1.73e-05	0.0077	0.16	0.23	Kawasaki disease;	chr14:106781490	chr14:106627249~106627825:-
STAD	cis	rs1707322	0.691	rs61784799	ENSG00000281133.1	AL355480.3	4.36	1.73e-05	0.0077	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45580892~45580996:-
STAD	cis	rs4982731	0.965	rs10143875	ENSG00000279656.1	RP11-298I3.6	4.36	1.73e-05	0.00771	0.24	0.23	Basophil percentage of granulocytes;Acute lymphoblastic leukemia (childhood);Basophil percentage of white cells;	chr14:23115056	chr14:23023083~23024217:-
STAD	cis	rs4604732	0.812	rs6663238	ENSG00000227135.1	GCSAML-AS1	4.36	1.73e-05	0.00771	0.29	0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461669	chr1:247524679~247526752:-
STAD	cis	rs875971	0.862	rs10282433	ENSG00000236529.1	RP13-254B10.1	-4.36	1.74e-05	0.00771	-0.23	-0.23	Aortic root size;	chr7:66256452	chr7:65840212~65840596:+
STAD	cis	rs41369048	0.669	rs6660867	ENSG00000257551.1	HLX-AS1	-4.36	1.74e-05	0.00772	-0.36	-0.23	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220832763~220880140:-
STAD	cis	rs11169552	0.51	rs10783381	ENSG00000200183.1	RNU6-238P	-4.36	1.74e-05	0.00773	-0.22	-0.23	Colorectal cancer;	chr12:50622667	chr12:50656973~50657078:+
STAD	cis	rs728616	0.558	rs61859215	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.74e-05	0.00773	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391392	chr10:79663088~79826594:-
STAD	cis	rs728616	0.558	rs72817596	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.74e-05	0.00773	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391838	chr10:79663088~79826594:-
STAD	cis	rs728616	0.558	rs12772945	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.74e-05	0.00773	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80394740	chr10:79663088~79826594:-
STAD	cis	rs728616	0.558	rs12414691	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.74e-05	0.00773	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79663088~79826594:-
STAD	cis	rs728616	0.558	rs12767261	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.74e-05	0.00773	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79663088~79826594:-
STAD	cis	rs7208859	0.623	rs8067035	ENSG00000263603.1	CTD-2349P21.5	-4.36	1.74e-05	0.00773	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30729469~30731202:+
STAD	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	4.36	1.74e-05	0.00773	0.47	0.23	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
STAD	cis	rs9860428	0.682	rs9809444	ENSG00000240057.4	RP11-572M11.4	-4.36	1.74e-05	0.00773	-0.21	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112807206	chr3:113019532~113183301:+
STAD	cis	rs9860428	0.711	rs9810246	ENSG00000240057.4	RP11-572M11.4	-4.36	1.74e-05	0.00773	-0.21	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112807706	chr3:113019532~113183301:+
STAD	cis	rs7487075	0.656	rs3936214	ENSG00000257261.4	RP11-96H19.1	4.36	1.74e-05	0.00774	0.31	0.23	Itch intensity from mosquito bite;	chr12:46432029	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs10880969	ENSG00000257261.4	RP11-96H19.1	4.36	1.74e-05	0.00774	0.31	0.23	Itch intensity from mosquito bite;	chr12:46433240	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs7489242	ENSG00000257261.4	RP11-96H19.1	4.36	1.74e-05	0.00774	0.31	0.23	Itch intensity from mosquito bite;	chr12:46434848	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs7485599	ENSG00000257261.4	RP11-96H19.1	4.36	1.74e-05	0.00774	0.31	0.23	Itch intensity from mosquito bite;	chr12:46436696	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs12832777	ENSG00000257261.4	RP11-96H19.1	4.36	1.74e-05	0.00774	0.31	0.23	Itch intensity from mosquito bite;	chr12:46437346	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.578	rs4768716	ENSG00000257261.4	RP11-96H19.1	4.36	1.74e-05	0.00774	0.31	0.23	Itch intensity from mosquito bite;	chr12:46437375	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.578	rs4768122	ENSG00000257261.4	RP11-96H19.1	4.36	1.74e-05	0.00774	0.31	0.23	Itch intensity from mosquito bite;	chr12:46438551	chr12:46383679~46876159:+
STAD	cis	rs1707322	0.785	rs10890348	ENSG00000281133.1	AL355480.3	-4.36	1.74e-05	0.00774	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45580892~45580996:-
STAD	cis	rs11169552	0.51	rs11169507	ENSG00000200183.1	RNU6-238P	4.36	1.74e-05	0.00774	0.22	0.23	Colorectal cancer;	chr12:50621726	chr12:50656973~50657078:+
STAD	cis	rs1005277	0.579	rs2749612	ENSG00000276805.1	RP11-291L22.6	4.36	1.74e-05	0.00774	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38451030~38451785:+
STAD	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-4.36	1.74e-05	0.00774	-0.29	-0.23	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
STAD	cis	rs748404	0.697	rs572959	ENSG00000275601.1	AC011330.13	-4.36	1.74e-05	0.00774	-0.24	-0.23	Lung cancer;	chr15:43258304	chr15:43642389~43643023:-
STAD	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	4.36	1.74e-05	0.00774	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
STAD	cis	rs4589258	0.815	rs1792615	ENSG00000280367.1	RP11-121L10.2	4.36	1.74e-05	0.00774	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90719293	chr11:90223153~90226538:+
STAD	cis	rs2262909	0.925	rs73019838	ENSG00000213976.4	CTD-2561J22.2	4.36	1.74e-05	0.00774	0.29	0.23	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22064930	chr19:21382865~21387177:+
STAD	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-4.36	1.74e-05	0.00774	-0.28	-0.23	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
STAD	cis	rs593531	0.513	rs479968	ENSG00000280269.1	AP000577.2	4.36	1.74e-05	0.00774	0.23	0.23	Neuroticism;	chr11:74327229	chr11:74204869~74205746:+
STAD	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	4.36	1.74e-05	0.00775	0.28	0.23	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
STAD	cis	rs9733	0.65	rs3738485	ENSG00000274963.1	Metazoa_SRP	-4.36	1.74e-05	0.00775	-0.19	-0.23	Tonsillectomy;	chr1:150579916	chr1:150568971~150569269:-
STAD	cis	rs7647973	0.516	rs12490393	ENSG00000225399.4	RP11-3B7.1	4.36	1.75e-05	0.00776	0.25	0.23	Menarche (age at onset);	chr3:49158699	chr3:49260085~49261316:+
STAD	cis	rs228614	0.51	rs223349	ENSG00000248971.2	KRT8P46	-4.36	1.75e-05	0.00776	-0.23	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102728746~102730171:-
STAD	cis	rs4589258	0.788	rs4303201	ENSG00000280367.1	RP11-121L10.2	4.36	1.75e-05	0.00776	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90729396	chr11:90223153~90226538:+
STAD	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	4.36	1.75e-05	0.00776	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
STAD	cis	rs4713118	0.662	rs149948	ENSG00000220721.1	OR1F12	4.36	1.75e-05	0.00776	0.27	0.23	Parkinson's disease;	chr6:28007039	chr6:28073316~28074233:+
STAD	cis	rs11098499	0.863	rs58452170	ENSG00000260091.1	RP11-33B1.4	4.36	1.75e-05	0.00776	0.23	0.23	Corneal astigmatism;	chr4:119538519	chr4:119409333~119410233:+
STAD	cis	rs10073892	0.66	rs10067699	ENSG00000250682.4	LINC00491	-4.36	1.75e-05	0.00777	-0.25	-0.23	Cognitive decline (age-related);	chr5:102617412	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.66	rs11746498	ENSG00000250682.4	LINC00491	-4.36	1.75e-05	0.00777	-0.25	-0.23	Cognitive decline (age-related);	chr5:102619394	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.66	rs9327868	ENSG00000250682.4	LINC00491	-4.36	1.75e-05	0.00777	-0.25	-0.23	Cognitive decline (age-related);	chr5:102620022	chr5:102609156~102671559:-
STAD	cis	rs2638953	0.815	rs11049696	ENSG00000247934.4	RP11-967K21.1	-4.36	1.75e-05	0.00777	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28528922	chr12:28163298~28190738:-
STAD	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-4.36	1.75e-05	0.00777	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
STAD	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	4.36	1.75e-05	0.00777	0.3	0.23	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
STAD	cis	rs4950322	0.515	rs17160050	ENSG00000278811.3	LINC00624	4.36	1.75e-05	0.00778	0.25	0.23	Protein quantitative trait loci;	chr1:147255558	chr1:147258885~147517875:-
STAD	cis	rs858239	0.665	rs858306	ENSG00000230042.1	AK3P3	-4.36	1.75e-05	0.00778	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23129178~23129841:+
STAD	cis	rs858239	0.698	rs858295	ENSG00000230042.1	AK3P3	-4.36	1.75e-05	0.00778	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23129178~23129841:+
STAD	cis	rs9987353	0.566	rs34491841	ENSG00000254340.1	RP11-10A14.3	-4.36	1.75e-05	0.00778	-0.32	-0.23	Recombination measurement;	chr8:9208000	chr8:9141424~9145435:+
STAD	cis	rs4237845	0.773	rs6650217	ENSG00000273805.1	RP11-620J15.4	-4.36	1.75e-05	0.00778	-0.25	-0.23	Intelligence (multi-trait analysis);	chr12:57895289	chr12:57894232~57896846:+
STAD	cis	rs4237845	0.773	rs6650218	ENSG00000273805.1	RP11-620J15.4	-4.36	1.75e-05	0.00778	-0.25	-0.23	Intelligence (multi-trait analysis);	chr12:57895295	chr12:57894232~57896846:+
STAD	cis	rs4141404	0.757	rs5749272	ENSG00000236132.1	CTA-440B3.1	4.36	1.75e-05	0.00779	0.24	0.23	Paclitaxel-induced neuropathy;	chr22:31434365	chr22:31816379~31817491:-
STAD	cis	rs2439831	0.681	rs524527	ENSG00000275601.1	AC011330.13	4.36	1.75e-05	0.00779	0.28	0.23	Lung cancer in ever smokers;	chr15:43306918	chr15:43642389~43643023:-
STAD	cis	rs11169552	0.51	rs10783373	ENSG00000200183.1	RNU6-238P	-4.36	1.75e-05	0.00779	-0.22	-0.23	Colorectal cancer;	chr12:50573197	chr12:50656973~50657078:+
STAD	cis	rs6430585	0.583	rs79633114	ENSG00000231890.6	DARS-AS1	-4.35	1.76e-05	0.00779	-0.27	-0.23	Corneal structure;	chr2:135829255	chr2:135985176~136022593:+
STAD	cis	rs11172055	0.902	rs10783807	ENSG00000269903.1	RP11-571M6.18	4.35	1.76e-05	0.00779	0.27	0.23	Migraine;	chr12:56872529	chr12:57814494~57814926:+
STAD	cis	rs7176527	0.8	rs56747535	ENSG00000229212.6	RP11-561C5.4	4.35	1.76e-05	0.0078	0.34	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85205440~85234795:-
STAD	cis	rs11098499	0.954	rs12510138	ENSG00000260091.1	RP11-33B1.4	4.35	1.76e-05	0.0078	0.22	0.23	Corneal astigmatism;	chr4:119502780	chr4:119409333~119410233:+
STAD	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	4.35	1.76e-05	0.0078	0.72	0.23	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
STAD	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	4.35	1.76e-05	0.0078	0.72	0.23	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
STAD	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	4.35	1.76e-05	0.0078	0.72	0.23	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
STAD	cis	rs7474896	0.832	rs12570943	ENSG00000120555.12	SEPT7P9	4.35	1.76e-05	0.0078	0.33	0.23	Obesity (extreme);	chr10:37733541	chr10:38383069~38402916:-
STAD	cis	rs832540	0.669	rs832539	ENSG00000271828.1	CTD-2310F14.1	4.35	1.76e-05	0.0078	0.27	0.23	Coronary artery disease;	chr5:56903559	chr5:56927874~56929573:+
STAD	cis	rs8062405	0.69	rs62034351	ENSG00000278665.1	RP11-666O2.4	4.35	1.76e-05	0.0078	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28599241~28601881:-
STAD	cis	rs7119038	0.509	rs10892258	ENSG00000255422.1	AP002954.4	-4.35	1.76e-05	0.0078	-0.27	-0.23	Sjögren's syndrome;	chr11:118709156	chr11:118704607~118750263:+
STAD	cis	rs3770081	1	rs3770089	ENSG00000273080.1	RP11-301O19.1	-4.35	1.76e-05	0.0078	-0.53	-0.23	Facial emotion recognition (sad faces);	chr2:86036692	chr2:86195590~86196049:+
STAD	cis	rs1707322	0.964	rs785483	ENSG00000225447.1	RPS15AP10	-4.35	1.76e-05	0.0078	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.964	rs796773	ENSG00000225447.1	RPS15AP10	-4.35	1.76e-05	0.0078	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.896	rs785518	ENSG00000225447.1	RPS15AP10	-4.35	1.76e-05	0.0078	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785519	ENSG00000225447.1	RPS15AP10	-4.35	1.76e-05	0.0078	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785486	ENSG00000225447.1	RPS15AP10	-4.35	1.76e-05	0.0078	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45645816~45646197:-
STAD	cis	rs9902453	0.874	rs4474741	ENSG00000240074.1	RPL9P30	-4.35	1.76e-05	0.0078	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29821099	chr17:29855759~29856332:+
STAD	cis	rs12908161	1	rs12905057	ENSG00000259295.5	CSPG4P12	4.35	1.76e-05	0.0078	0.33	0.23	Schizophrenia;	chr15:84667534	chr15:85191438~85213905:+
STAD	cis	rs8098244	0.737	rs1154232	ENSG00000267301.1	RPL23AP77	4.35	1.76e-05	0.00781	0.31	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23931070	chr18:23709825~23710287:-
STAD	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	4.35	1.76e-05	0.00781	0.32	0.23	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
STAD	cis	rs12722605	0.503	rs12722606	ENSG00000215267.7	AKR1C7P	4.35	1.76e-05	0.00781	0.41	0.23	Inflammatory biomarkers;	chr10:6011170	chr10:5275173~5288470:-
STAD	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	4.35	1.76e-05	0.00781	0.26	0.23	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
STAD	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	4.35	1.76e-05	0.00782	0.24	0.23	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
STAD	cis	rs422249	0.727	rs174606	ENSG00000279632.1	RP11-286N22.6	4.35	1.76e-05	0.00782	0.23	0.23	Trans fatty acid levels;	chr11:61859501	chr11:61426448~61427325:-
STAD	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	4.35	1.76e-05	0.00782	0.34	0.23	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
STAD	cis	rs10073892	0.66	rs28490970	ENSG00000250682.4	LINC00491	-4.35	1.76e-05	0.00782	-0.25	-0.23	Cognitive decline (age-related);	chr5:102607513	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.66	rs56170429	ENSG00000250682.4	LINC00491	-4.35	1.76e-05	0.00782	-0.25	-0.23	Cognitive decline (age-related);	chr5:102608710	chr5:102609156~102671559:-
STAD	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-4.35	1.76e-05	0.00782	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
STAD	cis	rs792448	0.743	rs351393	ENSG00000212044.2	AL360091.1	-4.35	1.76e-05	0.00782	-0.24	-0.23	White blood cell count (basophil);	chr1:212303177	chr1:212349978~212350069:+
STAD	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-4.35	1.76e-05	0.00783	-0.3	-0.23	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
STAD	cis	rs1816752	0.716	rs1539096	ENSG00000273628.1	RP11-756A22.7	-4.35	1.77e-05	0.00783	-0.28	-0.23	Obesity-related traits;	chr13:24501721	chr13:24933006~24936796:+
STAD	cis	rs4141404	0.828	rs2413043	ENSG00000236132.1	CTA-440B3.1	4.35	1.77e-05	0.00783	0.27	0.23	Paclitaxel-induced neuropathy;	chr22:31252590	chr22:31816379~31817491:-
STAD	cis	rs9902453	0.769	rs7210288	ENSG00000240074.1	RPL9P30	4.35	1.77e-05	0.00784	0.19	0.23	Coffee consumption (cups per day);	chr17:29916455	chr17:29855759~29856332:+
STAD	cis	rs7665090	1	rs3733202	ENSG00000230069.3	LRRC37A15P	-4.35	1.77e-05	0.00784	-0.25	-0.23	Primary biliary cholangitis;	chr4:102635704	chr4:102727274~102730721:-
STAD	cis	rs5753618	0.561	rs1858821	ENSG00000236132.1	CTA-440B3.1	4.35	1.77e-05	0.00784	0.27	0.23	Colorectal cancer;	chr22:31280468	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.519	rs5997939	ENSG00000236132.1	CTA-440B3.1	4.35	1.77e-05	0.00784	0.27	0.23	Colorectal cancer;	chr22:31281144	chr22:31816379~31817491:-
STAD	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	4.35	1.77e-05	0.00784	0.34	0.23	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	4.35	1.77e-05	0.00784	0.34	0.23	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
STAD	cis	rs11638815	0.581	rs783535	ENSG00000255769.6	GOLGA2P10	-4.35	1.77e-05	0.00784	-0.26	-0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82581676	chr15:82472993~82513950:-
STAD	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	4.35	1.77e-05	0.00784	0.29	0.23	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	4.35	1.77e-05	0.00784	0.29	0.23	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
STAD	cis	rs1707322	0.752	rs12062535	ENSG00000281133.1	AL355480.3	-4.35	1.77e-05	0.00785	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45580892~45580996:-
STAD	cis	rs4792901	0.765	rs28874115	ENSG00000279602.1	CTD-3014M21.1	-4.35	1.77e-05	0.00785	-0.31	-0.23	Dupuytren's disease;	chr17:43460886	chr17:43360041~43361361:-
STAD	cis	rs763014	0.932	rs2269560	ENSG00000228201.1	AL022341.3	4.35	1.77e-05	0.00785	0.27	0.23	Height;	chr16:632442	chr16:648473~649200:-
STAD	cis	rs11722779	0.935	rs7676736	ENSG00000248971.2	KRT8P46	-4.35	1.77e-05	0.00785	-0.23	-0.23	Schizophrenia;	chr4:103016729	chr4:102728746~102730171:-
STAD	cis	rs8028182	0.636	rs12708519	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75510859	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs8029112	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75516631	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs4322627	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75518318	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs28610581	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75520133	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs4886712	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75520547	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs8030802	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75520812	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.577	rs8023268	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75522331	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs8023815	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75522363	chr15:75527150~75601205:-
STAD	cis	rs8028182	0.636	rs11636031	ENSG00000260269.4	CTD-2323K18.1	-4.35	1.77e-05	0.00785	-0.29	-0.23	Sudden cardiac arrest;	chr15:75523417	chr15:75527150~75601205:-
STAD	cis	rs8062405	0.755	rs62034358	ENSG00000278665.1	RP11-666O2.4	4.35	1.77e-05	0.00786	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.755	rs12445823	ENSG00000278665.1	RP11-666O2.4	4.35	1.77e-05	0.00786	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.723	rs12445744	ENSG00000278665.1	RP11-666O2.4	4.35	1.77e-05	0.00786	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.755	rs4787455	ENSG00000278665.1	RP11-666O2.4	4.35	1.77e-05	0.00786	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28599241~28601881:-
STAD	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-4.35	1.78e-05	0.00787	-0.27	-0.23	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
STAD	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	4.35	1.78e-05	0.00787	0.25	0.23	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
STAD	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	4.35	1.78e-05	0.00787	0.26	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
STAD	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-4.35	1.78e-05	0.00788	-0.3	-0.23	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
STAD	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-4.35	1.78e-05	0.00788	-0.24	-0.23	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
STAD	cis	rs801193	0.66	rs2659897	ENSG00000224316.1	RP11-479O9.2	-4.35	1.78e-05	0.00788	-0.22	-0.23	Aortic root size;	chr7:66722728	chr7:65773620~65802067:+
STAD	cis	rs853679	0.55	rs1225599	ENSG00000220721.1	OR1F12	4.35	1.78e-05	0.00788	0.26	0.23	Depression;	chr6:28197412	chr6:28073316~28074233:+
STAD	cis	rs853679	0.574	rs1233705	ENSG00000220721.1	OR1F12	4.35	1.78e-05	0.00788	0.26	0.23	Depression;	chr6:28198669	chr6:28073316~28074233:+
STAD	cis	rs1816752	0.755	rs1981277	ENSG00000232858.1	RPL34P27	4.35	1.78e-05	0.00788	0.14	0.23	Obesity-related traits;	chr13:24409375	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.712	rs9507335	ENSG00000232858.1	RPL34P27	4.35	1.78e-05	0.00788	0.14	0.23	Obesity-related traits;	chr13:24409766	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.811	rs9507337	ENSG00000232858.1	RPL34P27	4.35	1.78e-05	0.00788	0.14	0.23	Obesity-related traits;	chr13:24410807	chr13:24988577~24988925:-
STAD	cis	rs5753618	0.539	rs8135344	ENSG00000236132.1	CTA-440B3.1	4.35	1.78e-05	0.00788	0.27	0.23	Colorectal cancer;	chr22:31275946	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.539	rs5997933	ENSG00000236132.1	CTA-440B3.1	4.35	1.78e-05	0.00788	0.27	0.23	Colorectal cancer;	chr22:31276766	chr22:31816379~31817491:-
STAD	cis	rs2836950	0.52	rs2836966	ENSG00000238141.2	BRWD1-AS1	-4.35	1.78e-05	0.00788	-0.23	-0.23	Menarche (age at onset);	chr21:39265595	chr21:39315707~39323218:+
STAD	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-4.35	1.78e-05	0.00788	-0.23	-0.23	Height;	chr5:37061159	chr5:36666214~36725195:-
STAD	cis	rs2638953	0.64	rs11049726	ENSG00000247934.4	RP11-967K21.1	-4.35	1.78e-05	0.00788	-0.27	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582703	chr12:28163298~28190738:-
STAD	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-4.35	1.78e-05	0.00788	-0.35	-0.23	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
STAD	cis	rs1707322	1	rs10890382	ENSG00000281133.1	AL355480.3	-4.35	1.78e-05	0.00788	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.663	rs3935296	ENSG00000225447.1	RPS15AP10	-4.35	1.78e-05	0.00789	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs28817701	ENSG00000225447.1	RPS15AP10	4.35	1.78e-05	0.00789	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.691	rs28495425	ENSG00000225447.1	RPS15AP10	4.35	1.78e-05	0.00789	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45645816~45646197:-
STAD	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	4.35	1.78e-05	0.00789	0.31	0.23	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
STAD	cis	rs7924176	0.564	rs4564273	ENSG00000213731.2	RAB5CP1	-4.35	1.78e-05	0.00789	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74423435~74424014:-
STAD	cis	rs2688608	0.592	rs10762563	ENSG00000272140.2	RP11-574K11.29	4.35	1.78e-05	0.00789	0.21	0.23	Inflammatory bowel disease;	chr10:73765044	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.592	rs10824032	ENSG00000272140.2	RP11-574K11.29	4.35	1.78e-05	0.00789	0.21	0.23	Inflammatory bowel disease;	chr10:73768372	chr10:73703735~73713581:-
STAD	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-4.35	1.78e-05	0.00789	-0.26	-0.23	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
STAD	cis	rs7924176	0.601	rs10824072	ENSG00000213731.2	RAB5CP1	-4.35	1.78e-05	0.00789	-0.22	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74423435~74424014:-
STAD	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-4.35	1.78e-05	0.00789	-0.26	-0.23	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
STAD	cis	rs9902453	0.791	rs7219163	ENSG00000240074.1	RPL9P30	4.35	1.78e-05	0.0079	0.2	0.23	Coffee consumption (cups per day);	chr17:29883685	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.765	rs62068653	ENSG00000240074.1	RPL9P30	4.35	1.78e-05	0.0079	0.2	0.23	Coffee consumption (cups per day);	chr17:29885645	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.845	rs7221516	ENSG00000240074.1	RPL9P30	4.35	1.78e-05	0.0079	0.2	0.23	Coffee consumption (cups per day);	chr17:29905488	chr17:29855759~29856332:+
STAD	cis	rs7487075	0.82	rs4768113	ENSG00000257261.4	RP11-96H19.1	4.35	1.78e-05	0.0079	0.28	0.23	Itch intensity from mosquito bite;	chr12:46314253	chr12:46383679~46876159:+
STAD	cis	rs7429990	0.93	rs13075457	ENSG00000224895.1	VPS26BP1	4.35	1.78e-05	0.0079	0.23	0.23	Educational attainment (years of education);	chr3:48013063	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.93	rs11130152	ENSG00000224895.1	VPS26BP1	4.35	1.78e-05	0.0079	0.23	0.23	Educational attainment (years of education);	chr3:48014919	chr3:47960327~47961081:-
STAD	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	4.35	1.79e-05	0.0079	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
STAD	cis	rs1707322	0.691	rs11211174	ENSG00000225447.1	RPS15AP10	4.35	1.79e-05	0.0079	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45645816~45646197:-
STAD	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-4.35	1.79e-05	0.0079	-0.26	-0.23	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
STAD	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	4.35	1.79e-05	0.0079	0.3	0.23	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	4.35	1.79e-05	0.0079	0.3	0.23	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	4.35	1.79e-05	0.0079	0.3	0.23	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	4.35	1.79e-05	0.0079	0.3	0.23	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	4.35	1.79e-05	0.0079	0.3	0.23	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
STAD	cis	rs763014	1	rs2269558	ENSG00000228201.1	AL022341.3	4.35	1.79e-05	0.0079	0.27	0.23	Height;	chr16:632250	chr16:648473~649200:-
STAD	cis	rs228614	0.51	rs223362	ENSG00000248971.2	KRT8P46	-4.35	1.79e-05	0.0079	-0.23	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102728746~102730171:-
STAD	cis	rs7487075	0.82	rs7488482	ENSG00000257261.4	RP11-96H19.1	4.35	1.79e-05	0.0079	0.3	0.23	Itch intensity from mosquito bite;	chr12:46331704	chr12:46383679~46876159:+
STAD	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	4.35	1.79e-05	0.0079	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
STAD	cis	rs3106598	0.564	rs9570447	ENSG00000223815.1	DIAPH3-AS2	4.35	1.79e-05	0.00791	0.22	0.23	Longevity;	chr13:61077561	chr13:60144698~60153505:+
STAD	cis	rs4792901	0.543	rs9894814	ENSG00000279602.1	CTD-3014M21.1	-4.35	1.79e-05	0.00791	-0.32	-0.23	Dupuytren's disease;	chr17:43453618	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.507	rs9910371	ENSG00000279602.1	CTD-3014M21.1	-4.35	1.79e-05	0.00791	-0.32	-0.23	Dupuytren's disease;	chr17:43453619	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.543	rs56124217	ENSG00000279602.1	CTD-3014M21.1	-4.35	1.79e-05	0.00791	-0.32	-0.23	Dupuytren's disease;	chr17:43453630	chr17:43360041~43361361:-
STAD	cis	rs737008	0.922	rs2070923	ENSG00000262703.1	RP11-485G7.6	4.35	1.79e-05	0.00791	0.22	0.23	Obesity-related traits;	chr16:11275998	chr16:11348143~11349321:-
STAD	cis	rs2278796	0.724	rs2794860	ENSG00000231691.1	RP11-203F10.5	-4.35	1.79e-05	0.00791	-0.28	-0.23	Mean platelet volume;	chr1:204999264	chr1:204277005~204277948:+
STAD	cis	rs950881	0.667	rs72825916	ENSG00000234389.1	AC007278.3	4.35	1.79e-05	0.00792	0.36	0.23	Allergy;	chr2:102454522	chr2:102438713~102440475:+
STAD	cis	rs9467773	0.549	rs9467805	ENSG00000243307.2	POM121L6P	4.35	1.79e-05	0.00792	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26896952~26898777:+
STAD	cis	rs3806843	0.576	rs246007	ENSG00000202111.1	VTRNA1-2	-4.35	1.79e-05	0.00792	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140959163	chr5:140718925~140719013:+
STAD	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	4.35	1.79e-05	0.00792	0.25	0.23	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
STAD	cis	rs11676348	0.873	rs10210012	ENSG00000237281.1	CATIP-AS2	4.35	1.79e-05	0.00792	0.23	0.23	Ulcerative colitis;	chr2:218148611	chr2:218326889~218357966:-
STAD	cis	rs891378	0.959	rs1864370	ENSG00000274245.1	RP11-357P18.2	-4.35	1.79e-05	0.00792	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207245687	chr1:207372559~207373252:+
STAD	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	4.35	1.79e-05	0.00793	0.23	0.23	Height;	chr5:37468413	chr5:36666214~36725195:-
STAD	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	4.35	1.79e-05	0.00793	0.23	0.23	Height;	chr5:37454360	chr5:36666214~36725195:-
STAD	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-4.35	1.79e-05	0.00793	-0.27	-0.23	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
STAD	cis	rs12682352	0.652	rs1567398	ENSG00000233609.3	RP11-62H7.2	-4.35	1.79e-05	0.00793	-0.25	-0.23	Neuroticism;	chr8:8869294	chr8:8961200~8979025:+
STAD	cis	rs3811273	0.568	rs4981417	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22261486	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs12589726	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22262396	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs12587104	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22262556	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs7150591	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22262926	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs10149605	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22263646	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.667	rs10152083	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22263764	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.73	rs10152089	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22263774	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs9944149	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22263875	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs9944066	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264001	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs9943971	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264098	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs9943999	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264135	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs9944001	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264193	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.504	rs9943972	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264267	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.554	rs12586764	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264564	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs12588618	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264645	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs4982592	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22264791	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs4981418	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22265131	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs4982593	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22265205	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs6572344	ENSG00000211816.2	TRAV38-1	-4.35	1.79e-05	0.00794	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22265267	chr14:22271968~22272563:+
STAD	cis	rs227917	1	rs227923	ENSG00000234286.1	AC006026.13	4.35	1.8e-05	0.00794	0.32	0.23	Common carotid intima-media thickness in HIV negative individuals;	chr7:23615929	chr7:23680195~23680786:-
STAD	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	4.35	1.8e-05	0.00795	0.22	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
STAD	cis	rs9902453	0.834	rs9901694	ENSG00000240074.1	RPL9P30	4.35	1.8e-05	0.00795	0.2	0.23	Coffee consumption (cups per day);	chr17:29944627	chr17:29855759~29856332:+
STAD	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	4.35	1.8e-05	0.00795	0.23	0.23	Height;	chr5:37454091	chr5:36666214~36725195:-
STAD	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-4.35	1.8e-05	0.00795	-0.27	-0.23	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
STAD	cis	rs2638953	0.924	rs12372372	ENSG00000247934.4	RP11-967K21.1	-4.35	1.8e-05	0.00795	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28147877	chr12:28163298~28190738:-
STAD	cis	rs13401620	0.555	rs1437421	ENSG00000224789.1	AC012363.4	-4.35	1.8e-05	0.00795	-0.27	-0.23	Breast size;	chr2:120218255	chr2:120174885~120216544:-
STAD	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-4.35	1.8e-05	0.00795	-0.2	-0.23	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
STAD	cis	rs6832769	1	rs1522111	ENSG00000272969.1	RP11-528I4.2	4.35	1.8e-05	0.00795	0.29	0.23	Personality dimensions;	chr4:55463396	chr4:55547112~55547889:+
STAD	cis	rs748404	0.697	rs567357	ENSG00000275601.1	AC011330.13	-4.35	1.8e-05	0.00795	-0.24	-0.23	Lung cancer;	chr15:43279192	chr15:43642389~43643023:-
STAD	cis	rs6832769	1	rs28463765	ENSG00000272969.1	RP11-528I4.2	-4.35	1.8e-05	0.00795	-0.29	-0.23	Personality dimensions;	chr4:55546267	chr4:55547112~55547889:+
STAD	cis	rs12745968	0.653	rs6604013	ENSG00000229052.2	RP11-386I23.1	-4.35	1.8e-05	0.00796	-0.22	-0.23	Bipolar disorder and schizophrenia;	chr1:92726577	chr1:92930696~92934098:+
STAD	cis	rs11051970	0.559	rs7956708	ENSG00000274964.1	RP11-817I4.1	-4.35	1.8e-05	0.00796	-0.31	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32315908	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs11536026	ENSG00000274964.1	RP11-817I4.1	-4.35	1.8e-05	0.00796	-0.31	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32316593	chr12:32339368~32340724:+
STAD	cis	rs240993	0.516	rs241004	ENSG00000230177.1	RP5-1112D6.4	-4.35	1.8e-05	0.00796	-0.25	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111275341	chr6:111277932~111278742:+
STAD	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	4.35	1.8e-05	0.00796	0.3	0.23	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
STAD	cis	rs7119038	0.865	rs11217044	ENSG00000255422.1	AP002954.4	4.35	1.8e-05	0.00796	0.29	0.23	Sjögren's syndrome;	chr11:118825313	chr11:118704607~118750263:+
STAD	cis	rs8062405	0.737	rs11861132	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs4788102	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62037367	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs7198606	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.929	rs11864750	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.964	rs7193733	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs8055982	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs7498665	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.964	rs11864107	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62037371	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs8055138	ENSG00000278665.1	RP11-666O2.4	4.35	1.8e-05	0.00796	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28599241~28601881:-
STAD	cis	rs7208859	0.623	rs7219361	ENSG00000263603.1	CTD-2349P21.5	-4.35	1.8e-05	0.00797	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	4.35	1.8e-05	0.00797	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
STAD	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	4.35	1.8e-05	0.00797	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
STAD	cis	rs4834770	1	rs878374	ENSG00000248280.1	RP11-33B1.2	4.35	1.8e-05	0.00797	0.27	0.23	Blood protein levels;	chr4:119316409	chr4:119440561~119450157:-
STAD	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	4.35	1.8e-05	0.00797	0.29	0.23	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
STAD	cis	rs1950326	0.515	rs12884221	ENSG00000258526.4	RP11-111A21.1	-4.35	1.8e-05	0.00797	-0.27	-0.23	Verbal memory performance (residualized delayed recall level);	chr14:39571372	chr14:39474840~39513780:+
STAD	cis	rs2390582	0.656	rs4658159	ENSG00000228175.3	GEMIN8P4	4.35	1.8e-05	0.00797	0.34	0.23	Coronary artery calcification;	chr1:90385104	chr1:89993593~89994321:-
STAD	cis	rs7156960	1	rs7152893	ENSG00000258454.1	RP11-361H10.3	4.35	1.8e-05	0.00797	0.24	0.23	Acute lymphoblastic leukemia (childhood);	chr14:76244842	chr14:76235817~76263474:+
STAD	cis	rs9646944	1	rs6719123	ENSG00000234389.1	AC007278.3	4.35	1.81e-05	0.00798	0.27	0.23	Blood protein levels;	chr2:102259080	chr2:102438713~102440475:+
STAD	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	4.35	1.81e-05	0.00798	0.24	0.23	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
STAD	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-4.35	1.81e-05	0.00798	-0.24	-0.23	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
STAD	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-4.35	1.81e-05	0.00798	-0.27	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
STAD	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	4.35	1.81e-05	0.00798	0.36	0.23	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
STAD	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-4.35	1.81e-05	0.00798	-0.23	-0.23	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
STAD	cis	rs9659323	0.804	rs10923722	ENSG00000231365.4	RP11-418J17.1	-4.35	1.81e-05	0.00799	-0.29	-0.23	Body mass index;	chr1:119000863	chr1:119140396~119275973:+
STAD	cis	rs9659323	0.745	rs10923723	ENSG00000231365.4	RP11-418J17.1	-4.35	1.81e-05	0.00799	-0.29	-0.23	Body mass index;	chr1:119001379	chr1:119140396~119275973:+
STAD	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-4.35	1.81e-05	0.00799	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
STAD	cis	rs4691139	0.658	rs11100589	ENSG00000248632.1	RP11-366M4.11	4.35	1.81e-05	0.00799	0.22	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003568	chr4:164968587~164970002:-
STAD	cis	rs11169552	0.51	rs10876073	ENSG00000200183.1	RNU6-238P	-4.35	1.81e-05	0.00799	-0.22	-0.23	Colorectal cancer;	chr12:50632127	chr12:50656973~50657078:+
STAD	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	4.35	1.81e-05	0.00799	0.37	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
STAD	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	4.35	1.81e-05	0.00799	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	4.35	1.81e-05	0.00799	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	4.35	1.81e-05	0.00799	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	4.35	1.81e-05	0.00799	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
STAD	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	4.35	1.81e-05	0.00799	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
STAD	cis	rs11012350	0.85	rs11012386	ENSG00000240291.1	RP11-499P20.2	-4.35	1.81e-05	0.00799	-0.44	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18053406	chr10:18513115~18545651:-
STAD	cis	rs11012350	0.85	rs11012397	ENSG00000240291.1	RP11-499P20.2	-4.35	1.81e-05	0.00799	-0.44	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18055083	chr10:18513115~18545651:-
STAD	cis	rs11012350	0.85	rs11012398	ENSG00000240291.1	RP11-499P20.2	-4.35	1.81e-05	0.00799	-0.44	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18055118	chr10:18513115~18545651:-
STAD	cis	rs449789	0.857	rs1553482	ENSG00000235086.1	FNDC1-IT1	-4.35	1.81e-05	0.00799	-0.3	-0.23	Pulse pressure;	chr6:159301115	chr6:159240786~159243329:+
STAD	cis	rs737008	0.96	rs949429	ENSG00000262703.1	RP11-485G7.6	-4.35	1.81e-05	0.00799	-0.22	-0.23	Obesity-related traits;	chr16:11282172	chr16:11348143~11349321:-
STAD	cis	rs453301	0.624	rs6987558	ENSG00000233609.3	RP11-62H7.2	4.35	1.81e-05	0.008	0.25	0.23	Joint mobility (Beighton score);	chr8:9005011	chr8:8961200~8979025:+
STAD	cis	rs7131987	0.622	rs7294598	ENSG00000275476.1	RP11-996F15.4	4.35	1.81e-05	0.008	0.25	0.23	QT interval;	chr12:29379056	chr12:29277397~29277882:-
STAD	cis	rs4589258	0.788	rs4448655	ENSG00000280367.1	RP11-121L10.2	4.35	1.81e-05	0.008	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90726448	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs4434965	ENSG00000280367.1	RP11-121L10.2	4.35	1.81e-05	0.008	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90725015	chr11:90223153~90226538:+
STAD	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	4.35	1.81e-05	0.00801	0.26	0.23	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
STAD	cis	rs9291683	0.546	rs13146686	ENSG00000250613.1	RP11-136I13.1	-4.35	1.81e-05	0.00801	-0.24	-0.23	Bone mineral density;	chr4:10033309	chr4:10410996~10411644:+
STAD	cis	rs9463078	0.625	rs1329710	ENSG00000219384.1	RP11-491H9.3	4.35	1.81e-05	0.00801	0.22	0.23	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45001388	chr6:45158870~45159511:+
STAD	cis	rs11098499	0.779	rs80242894	ENSG00000260091.1	RP11-33B1.4	4.35	1.81e-05	0.00801	0.23	0.23	Corneal astigmatism;	chr4:119454597	chr4:119409333~119410233:+
STAD	cis	rs5753618	0.509	rs2079431	ENSG00000236132.1	CTA-440B3.1	4.35	1.81e-05	0.00801	0.27	0.23	Colorectal cancer;	chr22:31168348	chr22:31816379~31817491:-
STAD	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	4.35	1.81e-05	0.00801	0.19	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
STAD	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-4.35	1.81e-05	0.00801	-0.28	-0.23	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
STAD	cis	rs891378	0.959	rs6681853	ENSG00000274245.1	RP11-357P18.2	-4.35	1.82e-05	0.00802	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207325299	chr1:207372559~207373252:+
STAD	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	4.35	1.82e-05	0.00802	0.22	0.23	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
STAD	cis	rs853679	0.527	rs853690	ENSG00000220721.1	OR1F12	4.35	1.82e-05	0.00802	0.23	0.23	Depression;	chr6:28317705	chr6:28073316~28074233:+
STAD	cis	rs9902453	0.765	rs2467334	ENSG00000240074.1	RPL9P30	-4.35	1.82e-05	0.00802	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29808490	chr17:29855759~29856332:+
STAD	cis	rs10978777	0.921	rs10978776	ENSG00000276883.1	AL137852.1	4.35	1.82e-05	0.00803	0.23	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107265871	chr9:107292369~107292456:-
STAD	cis	rs10978777	1	rs942291	ENSG00000276883.1	AL137852.1	4.35	1.82e-05	0.00803	0.23	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107269464	chr9:107292369~107292456:-
STAD	cis	rs1707322	0.896	rs946528	ENSG00000281133.1	AL355480.3	4.35	1.82e-05	0.00803	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45580892~45580996:-
STAD	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	4.35	1.82e-05	0.00804	0.33	0.23	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
STAD	cis	rs938554	0.692	rs4428284	ENSG00000250613.1	RP11-136I13.1	-4.35	1.82e-05	0.00804	-0.27	-0.23	Blood metabolite levels;	chr4:9994768	chr4:10410996~10411644:+
STAD	cis	rs17401966	0.838	rs7553228	ENSG00000199562.1	RNU6-37P	4.35	1.82e-05	0.00804	0.18	0.23	Hepatocellular carcinoma;	chr1:10290380	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs12125535	ENSG00000199562.1	RNU6-37P	4.35	1.82e-05	0.00804	0.18	0.23	Hepatocellular carcinoma;	chr1:10290791	chr1:10298966~10299072:+
STAD	cis	rs2337406	0.866	rs4773949	ENSG00000280411.1	IGHV1-69-2	4.35	1.82e-05	0.00804	0.25	0.23	Alzheimer's disease (late onset);	chr14:106808070	chr14:106762092~106762588:-
STAD	cis	rs728616	0.867	rs12411407	ENSG00000225484.5	NUTM2B-AS1	-4.35	1.82e-05	0.00805	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:79663088~79826594:-
STAD	cis	rs728616	0.867	rs61859008	ENSG00000225484.5	NUTM2B-AS1	-4.35	1.82e-05	0.00805	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:79663088~79826594:-
STAD	cis	rs55823223	0.648	rs9894383	ENSG00000267801.1	RP11-552F3.9	4.35	1.82e-05	0.00805	0.32	0.23	Psoriasis;	chr17:75869576	chr17:75876372~75879546:+
STAD	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-4.35	1.83e-05	0.00805	-0.34	-0.23	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
STAD	cis	rs3770081	1	rs12612513	ENSG00000273080.1	RP11-301O19.1	-4.35	1.83e-05	0.00805	-0.54	-0.23	Facial emotion recognition (sad faces);	chr2:86074102	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs12614260	ENSG00000273080.1	RP11-301O19.1	-4.35	1.83e-05	0.00805	-0.54	-0.23	Facial emotion recognition (sad faces);	chr2:86075956	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs74733602	ENSG00000273080.1	RP11-301O19.1	-4.35	1.83e-05	0.00805	-0.54	-0.23	Facial emotion recognition (sad faces);	chr2:86076319	chr2:86195590~86196049:+
STAD	cis	rs2933343	0.729	rs1680780	ENSG00000261159.1	RP11-723O4.9	4.35	1.83e-05	0.00805	0.28	0.23	IgG glycosylation;	chr3:128893816	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.729	rs1680781	ENSG00000261159.1	RP11-723O4.9	4.35	1.83e-05	0.00805	0.28	0.23	IgG glycosylation;	chr3:128893987	chr3:128859716~128860526:-
STAD	cis	rs9902453	0.765	rs2250320	ENSG00000240074.1	RPL9P30	-4.35	1.83e-05	0.00806	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29801639	chr17:29855759~29856332:+
STAD	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-4.35	1.83e-05	0.00806	-0.27	-0.23	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
STAD	cis	rs7103648	1	rs10838709	ENSG00000280615.1	Y_RNA	4.35	1.83e-05	0.00806	0.23	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47425795	chr11:47614898~47614994:-
STAD	cis	rs875971	0.862	rs1612452	ENSG00000224316.1	RP11-479O9.2	-4.35	1.83e-05	0.00806	-0.23	-0.23	Aortic root size;	chr7:66108909	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs1167390	ENSG00000224316.1	RP11-479O9.2	-4.35	1.83e-05	0.00806	-0.23	-0.23	Aortic root size;	chr7:66110906	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs35034167	ENSG00000224316.1	RP11-479O9.2	-4.35	1.83e-05	0.00806	-0.23	-0.23	Aortic root size;	chr7:66115179	chr7:65773620~65802067:+
STAD	cis	rs1598856	0.932	rs230530	ENSG00000248971.2	KRT8P46	4.35	1.83e-05	0.00806	0.25	0.23	Primary biliary cholangitis;	chr4:102532823	chr4:102728746~102730171:-
STAD	cis	rs728616	0.681	rs12412762	ENSG00000225484.5	NUTM2B-AS1	4.35	1.83e-05	0.00807	0.42	0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147714	chr10:79663088~79826594:-
STAD	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-4.35	1.83e-05	0.00807	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-4.35	1.83e-05	0.00807	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-4.35	1.83e-05	0.00807	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-4.35	1.83e-05	0.00807	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
STAD	cis	rs1707322	1	rs7538978	ENSG00000281133.1	AL355480.3	4.35	1.83e-05	0.00807	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45580892~45580996:-
STAD	cis	rs11846409	0.655	rs79296226	ENSG00000211970.3	IGHV4-61	-4.35	1.83e-05	0.00807	-0.24	-0.23	Rheumatic heart disease;	chr14:106650436	chr14:106639119~106639657:-
STAD	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	4.35	1.83e-05	0.00808	0.26	0.23	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
STAD	cis	rs7224610	0.898	rs4299205	ENSG00000263096.1	RP11-515O17.2	4.34	1.83e-05	0.00808	0.29	0.23	Urate levels;	chr17:55288785	chr17:55271504~55273653:-
STAD	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-4.34	1.83e-05	0.00809	-0.3	-0.23	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
STAD	cis	rs9425766	0.541	rs12691474	ENSG00000227373.4	RP11-160H22.5	4.34	1.83e-05	0.00809	0.28	0.23	Life satisfaction;	chr1:174200867	chr1:174115300~174160004:-
STAD	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	4.34	1.83e-05	0.00809	0.29	0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
STAD	cis	rs1075265	0.756	rs6751105	ENSG00000235937.1	AC008280.1	4.34	1.84e-05	0.0081	0.2	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54029552~54030682:-
STAD	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-4.34	1.84e-05	0.0081	-0.26	-0.23	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
STAD	cis	rs6479891	1	rs6479899	ENSG00000235816.3	PRELID1P3	-4.34	1.84e-05	0.0081	-0.28	-0.23	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs9415696	ENSG00000235816.3	PRELID1P3	4.34	1.84e-05	0.0081	0.28	0.23	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs9415697	ENSG00000235816.3	PRELID1P3	4.34	1.84e-05	0.0081	0.28	0.23	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs724553	ENSG00000235816.3	PRELID1P3	4.34	1.84e-05	0.0081	0.28	0.23	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63427297~63427939:+
STAD	cis	rs2880765	0.835	rs6497202	ENSG00000259295.5	CSPG4P12	4.34	1.84e-05	0.0081	0.28	0.23	Coronary artery disease;	chr15:85478144	chr15:85191438~85213905:+
STAD	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-4.34	1.84e-05	0.0081	-0.2	-0.23	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
STAD	cis	rs4713118	1	rs4713118	ENSG00000280107.1	AL022393.9	-4.34	1.84e-05	0.0081	-0.31	-0.23	Parkinson's disease;	chr6:27709015	chr6:28170845~28172521:+
STAD	cis	rs4713118	1	rs13215072	ENSG00000280107.1	AL022393.9	-4.34	1.84e-05	0.0081	-0.31	-0.23	Parkinson's disease;	chr6:27709949	chr6:28170845~28172521:+
STAD	cis	rs11846409	0.86	rs1974470	ENSG00000274576.2	IGHV2-70	-4.34	1.84e-05	0.0081	-0.29	-0.23	Rheumatic heart disease;	chr14:106621300	chr14:106770577~106771020:-
STAD	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-4.34	1.84e-05	0.00811	-0.28	-0.23	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
STAD	cis	rs4713118	0.629	rs149899	ENSG00000220721.1	OR1F12	4.34	1.84e-05	0.00811	0.27	0.23	Parkinson's disease;	chr6:28052201	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.629	rs172165	ENSG00000220721.1	OR1F12	4.34	1.84e-05	0.00811	0.27	0.23	Parkinson's disease;	chr6:28053036	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.597	rs172166	ENSG00000220721.1	OR1F12	4.34	1.84e-05	0.00811	0.27	0.23	Parkinson's disease;	chr6:28053042	chr6:28073316~28074233:+
STAD	cis	rs8062405	0.72	rs9926245	ENSG00000278665.1	RP11-666O2.4	4.34	1.84e-05	0.00811	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28599241~28601881:-
STAD	cis	rs1707322	0.721	rs11211165	ENSG00000225447.1	RPS15AP10	4.34	1.84e-05	0.00811	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs11211166	ENSG00000225447.1	RPS15AP10	4.34	1.84e-05	0.00811	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45645816~45646197:-
STAD	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	4.34	1.84e-05	0.00811	0.22	0.23	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
STAD	cis	rs9788721	0.836	rs2656065	ENSG00000259419.2	HNRNPCP3	4.34	1.84e-05	0.00812	0.23	0.23	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78458207	chr15:79236332~79237206:+
STAD	cis	rs1707322	1	rs6687301	ENSG00000281133.1	AL355480.3	-4.34	1.84e-05	0.00812	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45580892~45580996:-
STAD	cis	rs9902453	0.817	rs2321333	ENSG00000240074.1	RPL9P30	4.34	1.84e-05	0.00812	0.2	0.23	Coffee consumption (cups per day);	chr17:29813839	chr17:29855759~29856332:+
STAD	cis	rs4589258	0.762	rs7939546	ENSG00000280367.1	RP11-121L10.2	-4.34	1.84e-05	0.00812	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90677646	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs11019138	ENSG00000280367.1	RP11-121L10.2	-4.34	1.84e-05	0.00812	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90678738	chr11:90223153~90226538:+
STAD	cis	rs9902453	0.726	rs3115092	ENSG00000240074.1	RPL9P30	4.34	1.84e-05	0.00812	0.2	0.23	Coffee consumption (cups per day);	chr17:29709332	chr17:29855759~29856332:+
STAD	cis	rs7474896	1	rs61858629	ENSG00000120555.12	SEPT7P9	4.34	1.84e-05	0.00812	0.33	0.23	Obesity (extreme);	chr10:37725842	chr10:38383069~38402916:-
STAD	cis	rs7474896	1	rs35258216	ENSG00000120555.12	SEPT7P9	4.34	1.84e-05	0.00812	0.33	0.23	Obesity (extreme);	chr10:37729292	chr10:38383069~38402916:-
STAD	cis	rs4604732	0.603	rs10925051	ENSG00000227135.1	GCSAML-AS1	-4.34	1.84e-05	0.00812	-0.29	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247478532	chr1:247524679~247526752:-
STAD	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-4.34	1.84e-05	0.00812	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
STAD	cis	rs7809950	0.817	rs2222845	ENSG00000238832.1	snoU109	4.34	1.84e-05	0.00812	0.31	0.23	Coronary artery disease;	chr7:107641384	chr7:107603363~107603507:+
STAD	cis	rs9543976	0.588	rs7324195	ENSG00000261553.4	RP11-29G8.3	4.34	1.84e-05	0.00812	0.33	0.23	Diabetic retinopathy;	chr13:75618386	chr13:75549773~75807120:+
STAD	cis	rs11157436	0.602	rs2075493	ENSG00000211813.2	TRAV34	4.34	1.84e-05	0.00812	0.26	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163782	chr14:22207522~22208129:+
STAD	cis	rs853679	0.76	rs11962305	ENSG00000220721.1	OR1F12	4.34	1.84e-05	0.00812	0.27	0.23	Depression;	chr6:28232159	chr6:28073316~28074233:+
STAD	cis	rs728616	0.51	rs61860860	ENSG00000225484.5	NUTM2B-AS1	-4.34	1.84e-05	0.00813	-0.42	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79998816	chr10:79663088~79826594:-
STAD	cis	rs227275	0.556	rs6815526	ENSG00000248971.2	KRT8P46	-4.34	1.85e-05	0.00813	-0.23	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102728746~102730171:-
STAD	cis	rs227275	0.556	rs6824070	ENSG00000248971.2	KRT8P46	-4.34	1.85e-05	0.00813	-0.23	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102728746~102730171:-
STAD	cis	rs822354	1	rs266737	ENSG00000230951.1	GPS2P2	-4.34	1.85e-05	0.00813	-0.28	-0.23	Adiponectin levels;	chr3:186759720	chr3:186772589~186773476:+
STAD	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	4.34	1.85e-05	0.00813	0.25	0.23	Depression;	chr6:28428413	chr6:28176188~28176674:+
STAD	cis	rs7924176	0.521	rs11000960	ENSG00000213731.2	RAB5CP1	-4.34	1.85e-05	0.00813	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74423435~74424014:-
STAD	cis	rs7829975	0.51	rs2921073	ENSG00000173295.6	FAM86B3P	4.34	1.85e-05	0.00813	0.27	0.23	Mood instability;	chr8:8450133	chr8:8228595~8244865:+
STAD	cis	rs7829975	0.51	rs2979160	ENSG00000173295.6	FAM86B3P	4.34	1.85e-05	0.00813	0.27	0.23	Mood instability;	chr8:8450156	chr8:8228595~8244865:+
STAD	cis	rs1823913	0.927	rs1454761	ENSG00000280083.1	RP11-317J9.1	-4.34	1.85e-05	0.00813	-0.28	-0.23	Obesity-related traits;	chr2:191237092	chr2:191154118~191156070:-
STAD	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	4.34	1.85e-05	0.00814	0.33	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
STAD	cis	rs7924176	0.521	rs7477710	ENSG00000213731.2	RAB5CP1	-4.34	1.85e-05	0.00814	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74423435~74424014:-
STAD	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-4.34	1.85e-05	0.00814	-0.27	-0.23	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
STAD	cis	rs3764021	0.933	rs2268146	ENSG00000256673.1	RP11-599J14.2	-4.34	1.85e-05	0.00814	-0.25	-0.23	Type 1 diabetes;	chr12:9716675	chr12:9398355~9414851:-
STAD	cis	rs11098499	0.954	rs7681544	ENSG00000260091.1	RP11-33B1.4	4.34	1.85e-05	0.00814	0.22	0.23	Corneal astigmatism;	chr4:119490100	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs11940028	ENSG00000260091.1	RP11-33B1.4	4.34	1.85e-05	0.00814	0.22	0.23	Corneal astigmatism;	chr4:119490752	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs11935596	ENSG00000260091.1	RP11-33B1.4	4.34	1.85e-05	0.00814	0.22	0.23	Corneal astigmatism;	chr4:119491302	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs12507964	ENSG00000260091.1	RP11-33B1.4	4.34	1.85e-05	0.00814	0.22	0.23	Corneal astigmatism;	chr4:119491906	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs11098530	ENSG00000260091.1	RP11-33B1.4	4.34	1.85e-05	0.00814	0.22	0.23	Corneal astigmatism;	chr4:119491999	chr4:119409333~119410233:+
STAD	cis	rs5753618	0.561	rs4141404	ENSG00000236132.1	CTA-440B3.1	4.34	1.85e-05	0.00815	0.27	0.23	Colorectal cancer;	chr22:31279199	chr22:31816379~31817491:-
STAD	cis	rs2638953	0.741	rs12184491	ENSG00000247934.4	RP11-967K21.1	-4.34	1.85e-05	0.00815	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535619	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs58416107	ENSG00000247934.4	RP11-967K21.1	-4.34	1.85e-05	0.00815	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28543645	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs11049708	ENSG00000247934.4	RP11-967K21.1	-4.34	1.85e-05	0.00815	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28544881	chr12:28163298~28190738:-
STAD	cis	rs5752326	1	rs5761529	ENSG00000261188.1	CTA-445C9.14	4.34	1.85e-05	0.00815	0.42	0.23	Ischemic stroke;	chr22:26447742	chr22:26512537~26514568:+
STAD	cis	rs5752326	1	rs5752326	ENSG00000261188.1	CTA-445C9.14	4.34	1.85e-05	0.00815	0.42	0.23	Ischemic stroke;	chr22:26448024	chr22:26512537~26514568:+
STAD	cis	rs5752326	1	rs5752327	ENSG00000261188.1	CTA-445C9.14	4.34	1.85e-05	0.00815	0.42	0.23	Ischemic stroke;	chr22:26448104	chr22:26512537~26514568:+
STAD	cis	rs9902453	0.817	rs2617880	ENSG00000240074.1	RPL9P30	-4.34	1.85e-05	0.00815	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29779100	chr17:29855759~29856332:+
STAD	cis	rs935334	0.932	rs8008819	ENSG00000258454.1	RP11-361H10.3	-4.34	1.85e-05	0.00815	-0.33	-0.23	Blood pressure;	chr14:76155693	chr14:76235817~76263474:+
STAD	cis	rs10851478	0.529	rs9920722	ENSG00000259545.2	RP11-325E5.4	4.34	1.86e-05	0.00817	0.24	0.23	Oral cavity cancer;	chr15:49442915	chr15:49177610~49178741:-
STAD	cis	rs858239	0.899	rs5850	ENSG00000230042.1	AK3P3	-4.34	1.86e-05	0.00817	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23129178~23129841:+
STAD	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-4.34	1.86e-05	0.00817	-0.32	-0.23	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
STAD	cis	rs9902453	0.74	rs1382391	ENSG00000240074.1	RPL9P30	-4.34	1.86e-05	0.00817	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29784968	chr17:29855759~29856332:+
STAD	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-4.34	1.86e-05	0.00817	-0.34	-0.23	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
STAD	cis	rs7474896	0.515	rs675628	ENSG00000120555.12	SEPT7P9	-4.34	1.86e-05	0.00818	-0.28	-0.23	Obesity (extreme);	chr10:38016403	chr10:38383069~38402916:-
STAD	cis	rs5753618	0.561	rs5753521	ENSG00000236132.1	CTA-440B3.1	4.34	1.86e-05	0.00819	0.27	0.23	Colorectal cancer;	chr22:31242041	chr22:31816379~31817491:-
STAD	cis	rs11168351	0.75	rs11168366	ENSG00000258273.1	RP11-370I10.4	4.34	1.86e-05	0.00819	0.28	0.23	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48333755~48333901:-
STAD	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	4.34	1.86e-05	0.00819	0.3	0.23	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
STAD	cis	rs2880765	0.566	rs12911430	ENSG00000229212.6	RP11-561C5.4	4.34	1.86e-05	0.00819	0.32	0.23	Coronary artery disease;	chr15:85468033	chr15:85205440~85234795:-
STAD	cis	rs875971	0.862	rs6971059	ENSG00000224316.1	RP11-479O9.2	-4.34	1.86e-05	0.00819	-0.22	-0.23	Aortic root size;	chr7:66602045	chr7:65773620~65802067:+
STAD	cis	rs875971	0.789	rs7808013	ENSG00000224316.1	RP11-479O9.2	-4.34	1.86e-05	0.00819	-0.22	-0.23	Aortic root size;	chr7:66606209	chr7:65773620~65802067:+
STAD	cis	rs875971	0.825	rs7384021	ENSG00000224316.1	RP11-479O9.2	-4.34	1.86e-05	0.00819	-0.22	-0.23	Aortic root size;	chr7:66612917	chr7:65773620~65802067:+
STAD	cis	rs875971	0.825	rs66981195	ENSG00000224316.1	RP11-479O9.2	-4.34	1.86e-05	0.00819	-0.22	-0.23	Aortic root size;	chr7:66614048	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs3926380	ENSG00000224316.1	RP11-479O9.2	-4.34	1.86e-05	0.00819	-0.22	-0.23	Aortic root size;	chr7:66615658	chr7:65773620~65802067:+
STAD	cis	rs875971	0.825	rs1860472	ENSG00000224316.1	RP11-479O9.2	-4.34	1.86e-05	0.00819	-0.22	-0.23	Aortic root size;	chr7:66617736	chr7:65773620~65802067:+
STAD	cis	rs853679	0.55	rs1150692	ENSG00000220721.1	OR1F12	4.34	1.86e-05	0.00819	0.26	0.23	Depression;	chr6:28206179	chr6:28073316~28074233:+
STAD	cis	rs9659323	0.612	rs10923721	ENSG00000231365.4	RP11-418J17.1	-4.34	1.86e-05	0.0082	-0.29	-0.23	Body mass index;	chr1:118999564	chr1:119140396~119275973:+
STAD	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-4.34	1.86e-05	0.0082	-0.34	-0.23	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.954	rs6857105	ENSG00000260091.1	RP11-33B1.4	4.34	1.87e-05	0.00821	0.22	0.23	Corneal astigmatism;	chr4:119301143	chr4:119409333~119410233:+
STAD	cis	rs1707322	0.963	rs12145287	ENSG00000281133.1	AL355480.3	-4.34	1.87e-05	0.00821	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45580892~45580996:-
STAD	cis	rs2688608	0.592	rs7909544	ENSG00000272140.2	RP11-574K11.29	4.34	1.87e-05	0.00821	0.2	0.23	Inflammatory bowel disease;	chr10:73724246	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.592	rs10762559	ENSG00000272140.2	RP11-574K11.29	4.34	1.87e-05	0.00821	0.2	0.23	Inflammatory bowel disease;	chr10:73726695	chr10:73703735~73713581:-
STAD	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	4.34	1.87e-05	0.00821	0.28	0.23	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	4.34	1.87e-05	0.00821	0.28	0.23	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
STAD	cis	rs6012953	0.874	rs6063534	ENSG00000208018.1	MIR645	4.34	1.87e-05	0.00821	0.23	0.23	Vitiligo;	chr20:50572631	chr20:50585786~50585879:+
STAD	cis	rs7924176	0.564	rs10762588	ENSG00000213731.2	RAB5CP1	-4.34	1.87e-05	0.00822	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74423435~74424014:-
STAD	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-4.34	1.87e-05	0.00822	-0.26	-0.23	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
STAD	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-4.34	1.87e-05	0.00823	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
STAD	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-4.34	1.87e-05	0.00823	-0.24	-0.23	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
STAD	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-4.34	1.87e-05	0.00823	-0.24	-0.23	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
STAD	cis	rs831571	1	rs17069791	ENSG00000280620.1	SCAANT1	4.34	1.87e-05	0.00824	0.34	0.23	Type 2 diabetes;	chr3:64066603	chr3:63911518~63911772:-
STAD	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	4.34	1.88e-05	0.00824	0.49	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
STAD	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-4.34	1.88e-05	0.00825	-0.36	-0.23	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-4.34	1.88e-05	0.00825	-0.36	-0.23	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
STAD	cis	rs7924176	0.58	rs12360119	ENSG00000213731.2	RAB5CP1	-4.34	1.88e-05	0.00825	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74423435~74424014:-
STAD	cis	rs9907295	0.688	rs2251660	ENSG00000271013.1	AC015849.15	-4.34	1.88e-05	0.00825	-0.32	-0.23	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35912635~35918010:-
STAD	cis	rs755249	0.883	rs12035330	ENSG00000182109.6	RP11-69E11.4	4.34	1.88e-05	0.00825	0.28	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39522280~39546187:-
STAD	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-4.34	1.88e-05	0.00825	-0.26	-0.23	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-4.34	1.88e-05	0.00825	-0.26	-0.23	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-4.34	1.88e-05	0.00825	-0.26	-0.23	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
STAD	cis	rs8097348	0.948	rs10513937	ENSG00000266602.1	RP11-476K15.1	-4.34	1.88e-05	0.00825	-0.27	-0.23	Exercise (leisure time);	chr18:1600711	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs9953158	ENSG00000266602.1	RP11-476K15.1	-4.34	1.88e-05	0.00825	-0.27	-0.23	Exercise (leisure time);	chr18:1603118	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs9945721	ENSG00000266602.1	RP11-476K15.1	-4.34	1.88e-05	0.00825	-0.27	-0.23	Exercise (leisure time);	chr18:1603779	chr18:1509183~1647097:+
STAD	cis	rs35934224	0.783	rs13053818	ENSG00000232926.1	AC000078.5	4.34	1.88e-05	0.00826	0.37	0.23	Glaucoma (primary open-angle);	chr22:19872129	chr22:19887289~19887970:+
STAD	cis	rs2933343	0.621	rs6764682	ENSG00000261159.1	RP11-723O4.9	-4.34	1.88e-05	0.00826	-0.28	-0.23	IgG glycosylation;	chr3:128849540	chr3:128859716~128860526:-
STAD	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-4.34	1.88e-05	0.00826	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
STAD	cis	rs8062405	0.723	rs4788077	ENSG00000278665.1	RP11-666O2.4	4.34	1.88e-05	0.00826	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28599241~28601881:-
STAD	cis	rs2688608	0.592	rs3933085	ENSG00000272140.2	RP11-574K11.29	4.34	1.88e-05	0.00826	0.2	0.23	Inflammatory bowel disease;	chr10:73723573	chr10:73703735~73713581:-
STAD	cis	rs7429990	0.864	rs34616865	ENSG00000224895.1	VPS26BP1	4.34	1.88e-05	0.00826	0.21	0.23	Educational attainment (years of education);	chr3:47608508	chr3:47960327~47961081:-
STAD	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	4.34	1.88e-05	0.00826	0.27	0.23	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
STAD	cis	rs935334	1	rs2360977	ENSG00000258454.1	RP11-361H10.3	4.34	1.88e-05	0.00826	0.33	0.23	Blood pressure;	chr14:76188138	chr14:76235817~76263474:+
STAD	cis	rs935334	0.935	rs1900124	ENSG00000258454.1	RP11-361H10.3	4.34	1.88e-05	0.00826	0.33	0.23	Blood pressure;	chr14:76190323	chr14:76235817~76263474:+
STAD	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	4.34	1.88e-05	0.00826	0.34	0.23	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
STAD	cis	rs12699921	0.526	rs12699916	ENSG00000279048.1	RP11-511H23.2	-4.34	1.88e-05	0.00827	-0.22	-0.23	Fibrinogen levels;	chr7:17868923	chr7:17940503~17942922:+
STAD	cis	rs950881	0.741	rs11465702	ENSG00000234389.1	AC007278.3	4.34	1.88e-05	0.00827	0.36	0.23	Allergy;	chr2:102441432	chr2:102438713~102440475:+
STAD	cis	rs950881	0.709	rs11465723	ENSG00000234389.1	AC007278.3	4.34	1.88e-05	0.00827	0.36	0.23	Allergy;	chr2:102447060	chr2:102438713~102440475:+
STAD	cis	rs227275	0.525	rs28445579	ENSG00000248971.2	KRT8P46	-4.34	1.88e-05	0.00827	-0.23	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102728746~102730171:-
STAD	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-4.34	1.88e-05	0.00827	-0.28	-0.23	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
STAD	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-4.34	1.88e-05	0.00827	-0.36	-0.23	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
STAD	cis	rs7004769	0.613	rs330092	ENSG00000233609.3	RP11-62H7.2	-4.34	1.88e-05	0.00827	-0.34	-0.23	Fibrinogen levels;	chr8:9318534	chr8:8961200~8979025:+
STAD	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	4.34	1.88e-05	0.00828	0.3	0.23	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
STAD	cis	rs7487075	0.82	rs12310125	ENSG00000257261.4	RP11-96H19.1	4.34	1.88e-05	0.00828	0.27	0.23	Itch intensity from mosquito bite;	chr12:46299371	chr12:46383679~46876159:+
STAD	cis	rs1707322	0.752	rs28719889	ENSG00000281133.1	AL355480.3	-4.34	1.88e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs28812624	ENSG00000281133.1	AL355480.3	-4.34	1.88e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs28568986	ENSG00000281133.1	AL355480.3	-4.34	1.88e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.717	rs10890345	ENSG00000281133.1	AL355480.3	-4.34	1.88e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs10789471	ENSG00000281133.1	AL355480.3	-4.34	1.88e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs11211173	ENSG00000281133.1	AL355480.3	-4.34	1.88e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs11211168	ENSG00000281133.1	AL355480.3	-4.34	1.89e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs11211171	ENSG00000281133.1	AL355480.3	-4.34	1.89e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs28623463	ENSG00000281133.1	AL355480.3	-4.34	1.89e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.716	rs28370457	ENSG00000281133.1	AL355480.3	-4.34	1.89e-05	0.00828	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45580892~45580996:-
STAD	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-4.34	1.89e-05	0.00828	-0.27	-0.23	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
STAD	cis	rs7208859	0.623	rs426434	ENSG00000263603.1	CTD-2349P21.5	-4.34	1.89e-05	0.00828	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30729469~30731202:+
STAD	cis	rs8028182	0.636	rs7171507	ENSG00000260269.4	CTD-2323K18.1	-4.34	1.89e-05	0.00828	-0.29	-0.23	Sudden cardiac arrest;	chr15:75444946	chr15:75527150~75601205:-
STAD	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	4.34	1.89e-05	0.00828	0.24	0.23	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
STAD	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	4.34	1.89e-05	0.00829	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
STAD	cis	rs950169	0.922	rs4842939	ENSG00000235370.6	DNM1P51	-4.34	1.89e-05	0.00829	-0.26	-0.23	Schizophrenia;	chr15:84159214	chr15:84398316~84411701:-
STAD	cis	rs4691139	1	rs10007789	ENSG00000248632.1	RP11-366M4.11	4.34	1.89e-05	0.00829	0.22	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164969225	chr4:164968587~164970002:-
STAD	cis	rs4589258	1	rs4437994	ENSG00000280367.1	RP11-121L10.2	4.34	1.89e-05	0.00829	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90724347	chr11:90223153~90226538:+
STAD	cis	rs1816752	0.624	rs2862901	ENSG00000273628.1	RP11-756A22.7	-4.34	1.89e-05	0.0083	-0.28	-0.23	Obesity-related traits;	chr13:24461101	chr13:24933006~24936796:+
STAD	cis	rs7131987	0.903	rs6487796	ENSG00000257176.2	RP11-996F15.2	-4.34	1.89e-05	0.0083	-0.25	-0.23	QT interval;	chr12:29269831	chr12:29280418~29317848:-
STAD	cis	rs944722	0.628	rs4795051	ENSG00000266786.1	LGALS9DP	4.34	1.89e-05	0.00831	0.29	0.23	Fractional exhaled nitric oxide (childhood);	chr17:27752471	chr17:27746132~27754954:+
STAD	cis	rs10508774	0.925	rs77694327	ENSG00000273038.2	RP11-479G22.8	4.34	1.89e-05	0.00831	0.48	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32885923	chr10:32887255~32889311:-
STAD	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-4.34	1.89e-05	0.00831	-0.23	-0.23	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
STAD	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-4.34	1.89e-05	0.00831	-0.24	-0.23	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
STAD	cis	rs228614	0.536	rs223484	ENSG00000248971.2	KRT8P46	-4.34	1.89e-05	0.00831	-0.23	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102728746~102730171:-
STAD	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	4.34	1.89e-05	0.00831	0.22	0.23	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
STAD	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	4.34	1.89e-05	0.00831	0.22	0.23	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
STAD	cis	rs1707322	0.691	rs61784803	ENSG00000281133.1	AL355480.3	4.34	1.9e-05	0.00832	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45580892~45580996:-
STAD	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	4.34	1.9e-05	0.00832	0.2	0.23	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
STAD	cis	rs2836974	0.644	rs2410123	ENSG00000238141.2	BRWD1-AS1	-4.34	1.9e-05	0.00833	-0.24	-0.23	Cognitive function;	chr21:39328167	chr21:39315707~39323218:+
STAD	cis	rs9902453	0.808	rs62068617	ENSG00000240074.1	RPL9P30	4.34	1.9e-05	0.00833	0.2	0.23	Coffee consumption (cups per day);	chr17:29817710	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.791	rs2729451	ENSG00000240074.1	RPL9P30	-4.34	1.9e-05	0.00833	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29804316	chr17:29855759~29856332:+
STAD	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	4.34	1.9e-05	0.00833	0.32	0.23	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
STAD	cis	rs2836974	0.584	rs34436313	ENSG00000238141.2	BRWD1-AS1	-4.34	1.9e-05	0.00833	-0.24	-0.23	Cognitive function;	chr21:39313320	chr21:39315707~39323218:+
STAD	cis	rs11098499	0.954	rs10518328	ENSG00000260091.1	RP11-33B1.4	4.34	1.9e-05	0.00834	0.22	0.23	Corneal astigmatism;	chr4:119480624	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs6822679	ENSG00000260091.1	RP11-33B1.4	4.34	1.9e-05	0.00834	0.22	0.23	Corneal astigmatism;	chr4:119481547	chr4:119409333~119410233:+
STAD	cis	rs1799949	0.965	rs6503727	ENSG00000279602.1	CTD-3014M21.1	4.34	1.9e-05	0.00834	0.28	0.23	Menopause (age at onset);	chr17:43160842	chr17:43360041~43361361:-
STAD	cis	rs2836974	0.666	rs35182074	ENSG00000238141.2	BRWD1-AS1	-4.34	1.9e-05	0.00834	-0.24	-0.23	Cognitive function;	chr21:39313358	chr21:39315707~39323218:+
STAD	cis	rs172166	0.561	rs149971	ENSG00000220721.1	OR1F12	4.34	1.9e-05	0.00835	0.23	0.23	Cardiac Troponin-T levels;	chr6:28014374	chr6:28073316~28074233:+
STAD	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	4.34	1.9e-05	0.00835	0.25	0.23	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
STAD	cis	rs66887589	0.87	rs10518336	ENSG00000249244.1	RP11-548H18.2	4.34	1.9e-05	0.00835	0.28	0.23	Diastolic blood pressure;	chr4:119601779	chr4:119391831~119395335:-
STAD	cis	rs1707322	0.752	rs28890893	ENSG00000281133.1	AL355480.3	-4.34	1.9e-05	0.00835	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.928	rs7527244	ENSG00000225447.1	RPS15AP10	4.34	1.91e-05	0.00835	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45645816~45646197:-
STAD	cis	rs1005277	0.683	rs7923868	ENSG00000099251.13	HSD17B7P2	4.34	1.91e-05	0.00836	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38356380~38378505:+
STAD	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-4.34	1.91e-05	0.00837	-0.24	-0.23	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
STAD	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	4.34	1.91e-05	0.00837	0.31	0.23	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
STAD	cis	rs8014252	0.803	rs1959477	ENSG00000259158.2	ADAM20P1	-4.34	1.91e-05	0.00838	-0.31	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70567499	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs2877672	ENSG00000259158.2	ADAM20P1	-4.34	1.91e-05	0.00838	-0.31	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70569542	chr14:70468881~70483756:-
STAD	cis	rs17507216	0.628	rs28737193	ENSG00000259429.4	UBE2Q2P2	-4.34	1.91e-05	0.00838	-0.33	-0.23	Excessive daytime sleepiness;	chr15:82701318	chr15:82355142~82420075:+
STAD	cis	rs1395	0.744	rs62130714	ENSG00000234072.1	AC074117.10	-4.33	1.91e-05	0.00839	-0.22	-0.23	Blood metabolite levels;	chr2:27310002	chr2:27356246~27367622:+
STAD	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	4.33	1.91e-05	0.00839	0.33	0.23	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	4.33	1.91e-05	0.00839	0.33	0.23	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
STAD	cis	rs950169	0.58	rs11633762	ENSG00000259295.5	CSPG4P12	4.33	1.92e-05	0.00839	0.32	0.23	Schizophrenia;	chr15:84643921	chr15:85191438~85213905:+
STAD	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	-4.33	1.92e-05	0.00839	-0.22	-0.23	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
STAD	cis	rs858239	1	rs199347	ENSG00000230042.1	AK3P3	-4.33	1.92e-05	0.0084	-0.23	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23129178~23129841:+
STAD	cis	rs12908161	0.96	rs34452033	ENSG00000259295.5	CSPG4P12	4.33	1.92e-05	0.0084	0.32	0.23	Schizophrenia;	chr15:84678762	chr15:85191438~85213905:+
STAD	cis	rs7487075	0.647	rs12580583	ENSG00000257261.4	RP11-96H19.1	4.33	1.92e-05	0.0084	0.28	0.23	Itch intensity from mosquito bite;	chr12:46313218	chr12:46383679~46876159:+
STAD	cis	rs6471393	0.929	rs7017036	ENSG00000253848.1	RP11-10N23.5	4.33	1.92e-05	0.00841	0.27	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743216	chr8:93741193~93744534:+
STAD	cis	rs5753618	0.539	rs2106294	ENSG00000236132.1	CTA-440B3.1	4.33	1.92e-05	0.00841	0.26	0.23	Colorectal cancer;	chr22:31249773	chr22:31816379~31817491:-
STAD	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-4.33	1.92e-05	0.00841	-0.26	-0.23	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
STAD	cis	rs4589258	0.737	rs1792609	ENSG00000280367.1	RP11-121L10.2	-4.33	1.92e-05	0.00841	-0.23	-0.23	Intelligence (multi-trait analysis);	chr11:90699669	chr11:90223153~90226538:+
STAD	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	4.33	1.92e-05	0.00841	0.39	0.23	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
STAD	cis	rs11098499	0.954	rs6834796	ENSG00000260091.1	RP11-33B1.4	4.33	1.92e-05	0.00841	0.22	0.23	Corneal astigmatism;	chr4:119493538	chr4:119409333~119410233:+
STAD	cis	rs7474896	1	rs12571820	ENSG00000099251.13	HSD17B7P2	4.33	1.92e-05	0.00842	0.38	0.23	Obesity (extreme);	chr10:37720426	chr10:38356380~38378505:+
STAD	cis	rs4243830	0.85	rs4908915	ENSG00000229519.2	RP11-58A11.2	4.33	1.92e-05	0.00842	0.24	0.23	Body mass index;	chr1:6541547	chr1:6547905~6548619:+
STAD	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-4.33	1.92e-05	0.00842	-0.24	-0.23	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
STAD	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-4.33	1.92e-05	0.00842	-0.24	-0.23	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
STAD	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-4.33	1.92e-05	0.00842	-0.3	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
STAD	cis	rs2115536	0.967	rs4778734	ENSG00000278600.1	RP11-81A1.6	-4.33	1.92e-05	0.00842	-0.19	-0.23	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79918509	chr15:79920195~79922455:-
STAD	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.33	1.92e-05	0.00843	-0.28	-0.23	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
STAD	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-4.33	1.92e-05	0.00843	-0.28	-0.23	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
STAD	cis	rs7809950	1	rs10258385	ENSG00000238832.1	snoU109	4.33	1.92e-05	0.00843	0.3	0.23	Coronary artery disease;	chr7:107602905	chr7:107603363~107603507:+
STAD	cis	rs2115630	1	rs4633690	ENSG00000275120.1	RP11-182J1.17	-4.33	1.93e-05	0.00843	-0.25	-0.23	P wave terminal force;	chr15:84818729	chr15:84599434~84606463:-
STAD	cis	rs5770917	1	rs2269382	ENSG00000273272.1	CTA-384D8.34	4.33	1.93e-05	0.00843	0.42	0.23	Narcolepsy;	chr22:50580482	chr22:50542650~50543011:+
STAD	cis	rs1823874	0.71	rs56186545	ENSG00000182397.13	DNM1P46	-4.33	1.93e-05	0.00843	-0.25	-0.23	IgG glycosylation;	chr15:99820554	chr15:99790156~99806927:-
STAD	cis	rs3811273	0.505	rs7145836	ENSG00000211816.2	TRAV38-1	-4.33	1.93e-05	0.00843	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22265875	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs7157477	ENSG00000211816.2	TRAV38-1	-4.33	1.93e-05	0.00843	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22266229	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs4982594	ENSG00000211816.2	TRAV38-1	-4.33	1.93e-05	0.00843	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22266671	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs4982595	ENSG00000211816.2	TRAV38-1	-4.33	1.93e-05	0.00843	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22266915	chr14:22271968~22272563:+
STAD	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-4.33	1.93e-05	0.00844	-0.26	-0.23	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
STAD	cis	rs1707322	1	rs7531911	ENSG00000225447.1	RPS15AP10	4.33	1.93e-05	0.00844	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs10890359	ENSG00000225447.1	RPS15AP10	4.33	1.93e-05	0.00844	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45645816~45646197:-
STAD	cis	rs7926906	1	rs12291122	ENSG00000280367.1	RP11-121L10.2	4.33	1.93e-05	0.00845	0.23	0.23	Intelligence (multi-trait analysis);	chr11:90798410	chr11:90223153~90226538:+
STAD	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	4.33	1.93e-05	0.00845	0.29	0.23	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
STAD	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-4.33	1.93e-05	0.00845	-0.27	-0.23	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
STAD	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	4.33	1.93e-05	0.00845	0.27	0.23	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
STAD	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	4.33	1.93e-05	0.00846	0.34	0.23	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	4.33	1.93e-05	0.00846	0.34	0.23	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
STAD	cis	rs935334	0.877	rs7158766	ENSG00000258454.1	RP11-361H10.3	4.33	1.93e-05	0.00846	0.33	0.23	Blood pressure;	chr14:76197208	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs6574278	ENSG00000258454.1	RP11-361H10.3	4.33	1.93e-05	0.00846	0.33	0.23	Blood pressure;	chr14:76197495	chr14:76235817~76263474:+
STAD	cis	rs935334	0.935	rs6574279	ENSG00000258454.1	RP11-361H10.3	4.33	1.93e-05	0.00846	0.33	0.23	Blood pressure;	chr14:76197595	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs2121071	ENSG00000258454.1	RP11-361H10.3	4.33	1.93e-05	0.00846	0.33	0.23	Blood pressure;	chr14:76199134	chr14:76235817~76263474:+
STAD	cis	rs1075265	0.568	rs3095756	ENSG00000235937.1	AC008280.1	4.33	1.93e-05	0.00846	0.21	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54029552~54030682:-
STAD	cis	rs11098499	0.954	rs10006525	ENSG00000260091.1	RP11-33B1.4	4.33	1.93e-05	0.00846	0.22	0.23	Corneal astigmatism;	chr4:119487776	chr4:119409333~119410233:+
STAD	cis	rs4388249	1	rs4388249	ENSG00000271849.1	CTC-332L22.1	4.33	1.93e-05	0.00846	0.33	0.23	Schizophrenia;	chr5:109700365	chr5:109687802~109688329:-
STAD	cis	rs10851478	0.59	rs12591300	ENSG00000259545.2	RP11-325E5.4	4.33	1.93e-05	0.00846	0.27	0.23	Oral cavity cancer;	chr15:49412544	chr15:49177610~49178741:-
STAD	cis	rs9463078	0.63	rs7775717	ENSG00000219384.1	RP11-491H9.3	4.33	1.93e-05	0.00846	0.22	0.23	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45000024	chr6:45158870~45159511:+
STAD	cis	rs9784649	0.76	rs17403440	ENSG00000245662.2	RP11-184E9.1	4.33	1.93e-05	0.00846	0.32	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25053895	chr5:25190682~25306172:+
STAD	cis	rs17214007	0.735	rs8045778	ENSG00000263335.1	AF001548.5	4.33	1.94e-05	0.00846	0.25	0.23	Cognitive function;	chr16:15784395	chr16:15726674~15732993:+
STAD	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-4.33	1.94e-05	0.00846	-0.26	-0.23	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
STAD	cis	rs1707322	1	rs4660906	ENSG00000281133.1	AL355480.3	-4.33	1.94e-05	0.00847	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45580892~45580996:-
STAD	cis	rs9659323	0.73	rs10923720	ENSG00000231365.4	RP11-418J17.1	-4.33	1.94e-05	0.00847	-0.29	-0.23	Body mass index;	chr1:118999256	chr1:119140396~119275973:+
STAD	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	4.33	1.94e-05	0.00847	0.24	0.23	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
STAD	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	4.33	1.94e-05	0.00848	0.39	0.23	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	4.33	1.94e-05	0.00848	0.39	0.23	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	4.33	1.94e-05	0.00848	0.39	0.23	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
STAD	cis	rs8097348	0.593	rs9957292	ENSG00000266602.1	RP11-476K15.1	-4.33	1.94e-05	0.00849	-0.26	-0.23	Exercise (leisure time);	chr18:1700149	chr18:1509183~1647097:+
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000224373.3	IGHV4-59	4.33	1.94e-05	0.00849	0.16	0.23	Kawasaki disease;	chr14:106781985	chr14:106627249~106627825:-
STAD	cis	rs11098499	0.863	rs13140391	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119582282	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs13140409	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119582305	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs6833334	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119583072	chr4:119409333~119410233:+
STAD	cis	rs1707322	1	rs6695421	ENSG00000281133.1	AL355480.3	-4.33	1.94e-05	0.00849	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45580892~45580996:-
STAD	cis	rs11098499	0.863	rs59732491	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119568433	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs9884402	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119568827	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.731	rs9995026	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119569344	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs11723090	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119569437	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs11098532	ENSG00000260091.1	RP11-33B1.4	4.33	1.94e-05	0.00849	0.23	0.23	Corneal astigmatism;	chr4:119569571	chr4:119409333~119410233:+
STAD	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-4.33	1.94e-05	0.00849	-0.23	-0.23	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
STAD	cis	rs1707322	0.964	rs1768802	ENSG00000225447.1	RPS15AP10	-4.33	1.94e-05	0.00849	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs1588663	ENSG00000225447.1	RPS15AP10	-4.33	1.94e-05	0.00849	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs1768801	ENSG00000225447.1	RPS15AP10	-4.33	1.94e-05	0.00849	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs1768800	ENSG00000225447.1	RPS15AP10	-4.33	1.94e-05	0.00849	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45645816~45646197:-
STAD	cis	rs9890032	0.618	rs1979507	ENSG00000266490.1	CTD-2349P21.9	4.33	1.94e-05	0.00849	0.19	0.23	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30792372~30792833:+
STAD	cis	rs1707322	0.752	rs4660313	ENSG00000281133.1	AL355480.3	4.33	1.94e-05	0.00849	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45580892~45580996:-
STAD	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	4.33	1.94e-05	0.00849	0.24	0.23	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
STAD	cis	rs7924176	0.502	rs10824134	ENSG00000213731.2	RAB5CP1	-4.33	1.94e-05	0.0085	-0.23	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74261866	chr10:74423435~74424014:-
STAD	cis	rs9890032	0.618	rs55872374	ENSG00000266490.1	CTD-2349P21.9	4.33	1.94e-05	0.0085	0.19	0.23	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30792372~30792833:+
STAD	cis	rs1707322	0.686	rs3014235	ENSG00000225447.1	RPS15AP10	-4.33	1.94e-05	0.0085	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45645816~45646197:-
STAD	cis	rs35955747	0.714	rs5997989	ENSG00000236132.1	CTA-440B3.1	4.33	1.95e-05	0.0085	0.24	0.23	Neutrophil count;Sum basophil neutrophil counts;	chr22:31443964	chr22:31816379~31817491:-
STAD	cis	rs2739330	0.796	rs1006771	ENSG00000272787.1	KB-226F1.2	-4.33	1.95e-05	0.00851	-0.23	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23969211~23969873:+
STAD	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-4.33	1.95e-05	0.00851	-0.33	-0.23	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
STAD	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-4.33	1.95e-05	0.00851	-0.33	-0.23	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
STAD	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-4.33	1.95e-05	0.00851	-0.33	-0.23	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
STAD	cis	rs935334	1	rs2543383	ENSG00000258454.1	RP11-361H10.3	4.33	1.95e-05	0.00851	0.33	0.23	Blood pressure;	chr14:76160360	chr14:76235817~76263474:+
STAD	cis	rs7429990	0.76	rs319694	ENSG00000224895.1	VPS26BP1	-4.33	1.95e-05	0.00851	-0.22	-0.23	Educational attainment (years of education);	chr3:47843463	chr3:47960327~47961081:-
STAD	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	4.33	1.95e-05	0.00851	0.31	0.23	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
STAD	cis	rs2230624	1	rs76823085	ENSG00000242349.4	NPPA-AS1	-4.33	1.95e-05	0.00852	-0.5	-0.23	Mosquito bite size;	chr1:11823491	chr1:11841017~11848079:+
STAD	cis	rs11098499	0.954	rs17005535	ENSG00000260091.1	RP11-33B1.4	4.33	1.95e-05	0.00852	0.22	0.23	Corneal astigmatism;	chr4:119490407	chr4:119409333~119410233:+
STAD	cis	rs76917914	1	rs4742711	ENSG00000236896.1	RP11-535C21.3	4.33	1.95e-05	0.00852	0.3	0.23	Immature fraction of reticulocytes;	chr9:98018508	chr9:97986551~97987656:-
STAD	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	4.33	1.95e-05	0.00852	0.23	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
STAD	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	4.33	1.95e-05	0.00852	0.24	0.23	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
STAD	cis	rs1950326	0.515	rs8010499	ENSG00000258526.4	RP11-111A21.1	-4.33	1.95e-05	0.00853	-0.26	-0.23	Verbal memory performance (residualized delayed recall level);	chr14:39565767	chr14:39474840~39513780:+
STAD	cis	rs66887589	0.66	rs4833613	ENSG00000248280.1	RP11-33B1.2	-4.33	1.95e-05	0.00853	-0.27	-0.23	Diastolic blood pressure;	chr4:119229001	chr4:119440561~119450157:-
STAD	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-4.33	1.95e-05	0.00854	-0.28	-0.23	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
STAD	cis	rs6142102	1	rs6059681	ENSG00000264616.1	MIR4755	4.33	1.96e-05	0.00854	0.24	0.23	Skin pigmentation;	chr20:34135535	chr20:34049119~34049190:+
STAD	cis	rs7487075	0.578	rs4072304	ENSG00000257261.4	RP11-96H19.1	4.33	1.96e-05	0.00854	0.3	0.23	Itch intensity from mosquito bite;	chr12:46432404	chr12:46383679~46876159:+
STAD	cis	rs1707322	1	rs785465	ENSG00000281133.1	AL355480.3	-4.33	1.96e-05	0.00854	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785469	ENSG00000281133.1	AL355480.3	4.33	1.96e-05	0.00854	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785468	ENSG00000281133.1	AL355480.3	4.33	1.96e-05	0.00854	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785493	ENSG00000225447.1	RPS15AP10	-4.33	1.96e-05	0.00855	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.964	rs785496	ENSG00000225447.1	RPS15AP10	-4.33	1.96e-05	0.00855	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785497	ENSG00000225447.1	RPS15AP10	-4.33	1.96e-05	0.00855	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45645816~45646197:-
STAD	cis	rs2638953	0.924	rs11049467	ENSG00000247934.4	RP11-967K21.1	-4.33	1.96e-05	0.00855	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215602	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049468	ENSG00000247934.4	RP11-967K21.1	-4.33	1.96e-05	0.00855	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215684	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049469	ENSG00000247934.4	RP11-967K21.1	-4.33	1.96e-05	0.00855	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28216729	chr12:28163298~28190738:-
STAD	cis	rs6479891	1	rs16918575	ENSG00000235816.3	PRELID1P3	-4.33	1.96e-05	0.00855	-0.3	-0.23	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63427297~63427939:+
STAD	cis	rs1707322	0.865	rs785501	ENSG00000225447.1	RPS15AP10	-4.33	1.96e-05	0.00855	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45645816~45646197:-
STAD	cis	rs7829975	0.501	rs4840353	ENSG00000253893.2	FAM85B	4.33	1.96e-05	0.00855	0.3	0.23	Mood instability;	chr8:8723060	chr8:8167819~8226614:-
STAD	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	4.33	1.96e-05	0.00855	0.27	0.23	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
STAD	cis	rs35955747	0.738	rs2012451	ENSG00000236132.1	CTA-440B3.1	4.33	1.96e-05	0.00855	0.24	0.23	Neutrophil count;Sum basophil neutrophil counts;	chr22:31448387	chr22:31816379~31817491:-
STAD	cis	rs1707322	0.721	rs11211163	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs12037803	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10789470	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs61784796	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10749856	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10890344	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs4564187	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs28438704	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs28442079	ENSG00000225447.1	RPS15AP10	4.33	1.96e-05	0.00855	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45645816~45646197:-
STAD	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-4.33	1.96e-05	0.00855	-0.24	-0.23	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-4.33	1.96e-05	0.00855	-0.24	-0.23	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
STAD	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-4.33	1.96e-05	0.00856	-0.35	-0.23	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-4.33	1.96e-05	0.00856	-0.35	-0.23	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-4.33	1.96e-05	0.00856	-0.35	-0.23	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
STAD	cis	rs6584283	1	rs6584283	ENSG00000228778.1	RP11-129J12.1	-4.33	1.96e-05	0.00856	-0.26	-0.23	Ulcerative colitis;	chr10:99530544	chr10:99527081~99528261:+
STAD	cis	rs8099594	0.64	rs2957171	ENSG00000266696.1	RP11-30L3.2	4.33	1.96e-05	0.00856	0.22	0.23	Height;	chr18:49323901	chr18:49205912~49208781:+
STAD	cis	rs7487075	0.786	rs7316127	ENSG00000257261.4	RP11-96H19.1	4.33	1.96e-05	0.00856	0.29	0.23	Itch intensity from mosquito bite;	chr12:46280466	chr12:46383679~46876159:+
STAD	cis	rs4589258	0.737	rs1792607	ENSG00000280367.1	RP11-121L10.2	-4.33	1.96e-05	0.00856	-0.22	-0.23	Intelligence (multi-trait analysis);	chr11:90701999	chr11:90223153~90226538:+
STAD	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-4.33	1.96e-05	0.00856	-0.2	-0.23	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
STAD	cis	rs1005277	0.638	rs1005278	ENSG00000099251.13	HSD17B7P2	-4.33	1.96e-05	0.00856	-0.26	-0.23	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38356380~38378505:+
STAD	cis	rs17401966	0.838	rs946503	ENSG00000199562.1	RNU6-37P	-4.33	1.96e-05	0.00856	-0.17	-0.23	Hepatocellular carcinoma;	chr1:10248573	chr1:10298966~10299072:+
STAD	cis	rs2337406	0.587	rs2583291	ENSG00000211970.3	IGHV4-61	-4.33	1.96e-05	0.00856	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106649293	chr14:106639119~106639657:-
STAD	cis	rs6504622	0.643	rs3851804	ENSG00000262879.4	RP11-156P1.3	4.33	1.96e-05	0.00856	0.19	0.23	Orofacial clefts;	chr17:47003235	chr17:46984045~47100323:-
STAD	cis	rs7487075	0.82	rs10467213	ENSG00000257261.4	RP11-96H19.1	4.33	1.96e-05	0.00857	0.3	0.23	Itch intensity from mosquito bite;	chr12:46326480	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.82	rs7958774	ENSG00000257261.4	RP11-96H19.1	4.33	1.96e-05	0.00857	0.3	0.23	Itch intensity from mosquito bite;	chr12:46330885	chr12:46383679~46876159:+
STAD	cis	rs253959	0.545	rs6896147	ENSG00000271918.1	CTD-2287O16.5	-4.33	1.96e-05	0.00857	-0.25	-0.23	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116083807~116085416:-
STAD	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-4.33	1.96e-05	0.00857	-0.28	-0.23	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
STAD	cis	rs2337406	0.85	rs11849578	ENSG00000280411.1	IGHV1-69-2	-4.33	1.96e-05	0.00857	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106670302	chr14:106762092~106762588:-
STAD	cis	rs72807246	1	rs72807246	ENSG00000228701.1	TNKS2-AS1	4.33	1.96e-05	0.00857	0.47	0.23	Breast cancer;	chr10:92172529	chr10:91782839~91798291:-
STAD	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	4.33	1.97e-05	0.00857	0.32	0.23	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
STAD	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-4.33	1.97e-05	0.00858	-0.25	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
STAD	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-4.33	1.97e-05	0.00858	-0.33	-0.23	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
STAD	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-4.33	1.97e-05	0.00858	-0.26	-0.23	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
STAD	cis	rs10073892	0.66	rs9327869	ENSG00000250682.4	LINC00491	-4.33	1.97e-05	0.00858	-0.25	-0.23	Cognitive decline (age-related);	chr5:102638877	chr5:102609156~102671559:-
STAD	cis	rs2836950	0.565	rs7276046	ENSG00000238141.2	BRWD1-AS1	-4.33	1.97e-05	0.00859	-0.23	-0.23	Menarche (age at onset);	chr21:39209367	chr21:39315707~39323218:+
STAD	cis	rs2836950	0.545	rs8132143	ENSG00000238141.2	BRWD1-AS1	-4.33	1.97e-05	0.00859	-0.23	-0.23	Menarche (age at onset);	chr21:39212332	chr21:39315707~39323218:+
STAD	cis	rs4713118	0.662	rs175954	ENSG00000220721.1	OR1F12	4.33	1.97e-05	0.00859	0.26	0.23	Parkinson's disease;	chr6:28043807	chr6:28073316~28074233:+
STAD	cis	rs7429990	0.965	rs7651237	ENSG00000228638.1	FCF1P2	4.33	1.97e-05	0.00859	0.34	0.23	Educational attainment (years of education);	chr3:48064038	chr3:48290793~48291375:-
STAD	cis	rs6430585	0.528	rs309172	ENSG00000231890.6	DARS-AS1	-4.33	1.97e-05	0.0086	-0.25	-0.23	Corneal structure;	chr2:135916458	chr2:135985176~136022593:+
STAD	cis	rs8177876	0.749	rs10459871	ENSG00000261061.1	RP11-303E16.2	-4.33	1.97e-05	0.0086	-0.37	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81030770~81031485:+
STAD	cis	rs1707322	1	rs1707337	ENSG00000281133.1	AL355480.3	4.33	1.97e-05	0.00861	0.26	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs1768807	ENSG00000281133.1	AL355480.3	4.33	1.97e-05	0.00861	0.26	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45580892~45580996:-
STAD	cis	rs748404	0.697	rs505249	ENSG00000275601.1	AC011330.13	-4.33	1.98e-05	0.00861	-0.23	-0.23	Lung cancer;	chr15:43267762	chr15:43642389~43643023:-
STAD	cis	rs11239930	0.538	rs4950362	ENSG00000278811.3	LINC00624	4.33	1.98e-05	0.00861	0.23	0.23	AIDS progression;	chr1:147088336	chr1:147258885~147517875:-
STAD	cis	rs7487075	0.93	rs11183468	ENSG00000272963.1	OR7A19P	4.33	1.98e-05	0.00861	0.21	0.23	Itch intensity from mosquito bite;	chr12:46412478	chr12:46592573~46593305:+
STAD	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	4.33	1.98e-05	0.00862	0.28	0.23	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
STAD	cis	rs7615952	0.512	rs2979351	ENSG00000171084.14	FAM86JP	4.33	1.98e-05	0.00862	0.33	0.23	Blood pressure (smoking interaction);	chr3:125644755	chr3:125916620~125930024:+
STAD	cis	rs7680126	0.672	rs10939819	ENSG00000250613.1	RP11-136I13.1	4.33	1.98e-05	0.00862	0.24	0.23	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10289037	chr4:10410996~10411644:+
STAD	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	4.33	1.98e-05	0.00862	0.3	0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
STAD	cis	rs4535700	0.501	rs6943341	ENSG00000226278.1	PSPHP1	4.33	1.98e-05	0.00863	0.29	0.23	Macular telangiectasia type 2;	chr7:55907489	chr7:55764797~55773288:+
STAD	cis	rs7617773	0.963	rs6766754	ENSG00000224895.1	VPS26BP1	4.33	1.98e-05	0.00863	0.22	0.23	Coronary artery disease;	chr3:48141099	chr3:47960327~47961081:-
STAD	cis	rs7617773	0.832	rs6775114	ENSG00000224895.1	VPS26BP1	4.33	1.98e-05	0.00863	0.22	0.23	Coronary artery disease;	chr3:48141130	chr3:47960327~47961081:-
STAD	cis	rs4604732	0.603	rs10802513	ENSG00000227135.1	GCSAML-AS1	-4.33	1.98e-05	0.00863	-0.28	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247470617	chr1:247524679~247526752:-
STAD	cis	rs4631830	0.54	rs2926493	ENSG00000264204.2	AGAP7P	4.33	1.98e-05	0.00863	0.29	0.23	Prostate-specific antigen levels;	chr10:46103691	chr10:46109621~46131358:+
STAD	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-4.33	1.98e-05	0.00864	-0.33	-0.23	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
STAD	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-4.33	1.98e-05	0.00864	-0.33	-0.23	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
STAD	cis	rs2836974	0.568	rs11910906	ENSG00000238141.2	BRWD1-AS1	-4.33	1.98e-05	0.00864	-0.24	-0.23	Cognitive function;	chr21:39313736	chr21:39315707~39323218:+
STAD	cis	rs1707322	0.963	rs4508055	ENSG00000281133.1	AL355480.3	-4.33	1.98e-05	0.00864	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs12076580	ENSG00000281133.1	AL355480.3	-4.33	1.98e-05	0.00864	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45580892~45580996:-
STAD	cis	rs858239	0.539	rs10270695	ENSG00000226816.2	AC005082.12	-4.33	1.98e-05	0.00864	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23206013~23208045:+
STAD	cis	rs2439831	1	rs9920763	ENSG00000249839.1	AC011330.5	-4.33	1.99e-05	0.00865	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43468310	chr15:43663654~43684339:-
STAD	cis	rs4950322	0.542	rs2883434	ENSG00000278811.3	LINC00624	4.33	1.99e-05	0.00866	0.23	0.23	Protein quantitative trait loci;	chr1:147177505	chr1:147258885~147517875:-
STAD	cis	rs393951	0.621	rs415868	ENSG00000260969.1	RP11-190D6.2	-4.33	1.99e-05	0.00866	-0.31	-0.23	Childhood ear infection;	chr16:77570211	chr16:78237362~78241218:-
STAD	cis	rs1816752	0.608	rs4770690	ENSG00000273628.1	RP11-756A22.7	-4.33	1.99e-05	0.00866	-0.27	-0.23	Obesity-related traits;	chr13:24467049	chr13:24933006~24936796:+
STAD	cis	rs11098499	0.863	rs3775841	ENSG00000260091.1	RP11-33B1.4	4.33	1.99e-05	0.00866	0.22	0.23	Corneal astigmatism;	chr4:119504622	chr4:119409333~119410233:+
STAD	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	4.33	1.99e-05	0.00866	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
STAD	cis	rs4792901	0.802	rs72833123	ENSG00000279602.1	CTD-3014M21.1	-4.33	1.99e-05	0.00866	-0.31	-0.23	Dupuytren's disease;	chr17:43475035	chr17:43360041~43361361:-
STAD	cis	rs1707322	0.721	rs10890336	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs11211151	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs12045096	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs4609469	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs12049027	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs10789467	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10890337	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs3811435	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs9793568	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs11211157	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs11211158	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs6429575	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.685	rs6690926	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs8179402	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs8179296	ENSG00000225447.1	RPS15AP10	4.33	1.99e-05	0.00866	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45645816~45646197:-
STAD	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	4.33	1.99e-05	0.00866	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
STAD	cis	rs1707322	1	rs4660335	ENSG00000281133.1	AL355480.3	-4.33	1.99e-05	0.00866	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45580892~45580996:-
STAD	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	4.33	1.99e-05	0.00867	0.27	0.23	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	4.33	1.99e-05	0.00867	0.27	0.23	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	4.33	1.99e-05	0.00867	0.27	0.23	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	4.33	1.99e-05	0.00867	0.27	0.23	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs11727546	ENSG00000246560.2	RP11-10L12.4	4.33	1.99e-05	0.00867	0.27	0.23	Primary biliary cholangitis;	chr4:102636507	chr4:102828055~102844075:+
STAD	cis	rs7474896	0.515	rs688608	ENSG00000120555.12	SEPT7P9	-4.33	1.99e-05	0.00867	-0.29	-0.23	Obesity (extreme);	chr10:38042696	chr10:38383069~38402916:-
STAD	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-4.33	1.99e-05	0.00867	-0.24	-0.23	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
STAD	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	4.33	1.99e-05	0.00867	0.27	0.23	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
STAD	cis	rs10229583	0.527	rs6979634	ENSG00000279078.1	SND1-IT1	-4.33	1.99e-05	0.00867	-0.22	-0.23	Type 2 diabetes;	chr7:127683911	chr7:127997597~128000077:+
STAD	cis	rs5753618	0.509	rs2413033	ENSG00000236132.1	CTA-440B3.1	4.33	1.99e-05	0.00867	0.26	0.23	Colorectal cancer;	chr22:31178227	chr22:31816379~31817491:-
STAD	cis	rs55675132	0.515	rs7555948	ENSG00000236480.1	PKMP1	4.33	1.99e-05	0.00867	0.21	0.23	Schizophrenia;	chr1:114745080	chr1:114535995~114537840:+
STAD	cis	rs393951	0.711	rs280854	ENSG00000260969.1	RP11-190D6.2	-4.33	1.99e-05	0.00868	-0.32	-0.23	Childhood ear infection;	chr16:77575259	chr16:78237362~78241218:-
STAD	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-4.33	1.99e-05	0.00868	-0.28	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
STAD	cis	rs6095360	0.615	rs17445665	ENSG00000222365.1	SNORD12B	4.33	1.99e-05	0.00868	0.28	0.23	Intelligence (multi-trait analysis);	chr20:48893954	chr20:49280319~49280409:+
STAD	cis	rs1015362	0.54	rs2050209	ENSG00000275784.1	RP5-1125A11.6	4.33	1.99e-05	0.00868	0.26	0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33989480~33991818:-
STAD	cis	rs6714710	0.603	rs34373359	ENSG00000235833.1	AC159540.14	-4.33	2e-05	0.00869	-0.26	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97825739	chr2:97523949~97524976:-
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000211959.2	IGHV4-39	4.33	2e-05	0.00869	0.2	0.23	Kawasaki disease;	chr14:106792798	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000211959.2	IGHV4-39	4.33	2e-05	0.00869	0.2	0.23	Kawasaki disease;	chr14:106800208	chr14:106421711~106422218:-
STAD	cis	rs7824557	0.815	rs958648	ENSG00000254866.2	DEFB109P3	4.33	2e-05	0.00869	0.27	0.23	Retinal vascular caliber;	chr8:11246386	chr8:12150895~12151134:-
STAD	cis	rs1816752	0.875	rs59686377	ENSG00000273628.1	RP11-756A22.7	4.33	2e-05	0.00869	0.28	0.23	Obesity-related traits;	chr13:24475869	chr13:24933006~24936796:+
STAD	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-4.33	2e-05	0.00869	-0.35	-0.23	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
STAD	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-4.32	2e-05	0.0087	-0.23	-0.23	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
STAD	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	4.32	2e-05	0.0087	0.33	0.23	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
STAD	cis	rs17507216	0.718	rs72751657	ENSG00000255769.6	GOLGA2P10	-4.32	2e-05	0.0087	-0.38	-0.23	Excessive daytime sleepiness;	chr15:82581259	chr15:82472993~82513950:-
STAD	cis	rs9733	0.519	rs6700022	ENSG00000274963.1	Metazoa_SRP	-4.32	2e-05	0.0087	-0.2	-0.23	Tonsillectomy;	chr1:150698008	chr1:150568971~150569269:-
STAD	cis	rs7139978	0.539	rs9547910	ENSG00000230390.1	LINC01048	-4.32	2e-05	0.00871	-0.25	-0.23	Life satisfaction;	chr13:37495862	chr13:37481467~37484769:-
STAD	cis	rs7139978	0.539	rs4941870	ENSG00000230390.1	LINC01048	-4.32	2e-05	0.00871	-0.25	-0.23	Life satisfaction;	chr13:37496412	chr13:37481467~37484769:-
STAD	cis	rs7829975	0.777	rs486781	ENSG00000253981.4	ALG1L13P	-4.32	2e-05	0.00871	-0.27	-0.23	Mood instability;	chr8:8782230	chr8:8236003~8244667:-
STAD	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	4.32	2e-05	0.00872	0.3	0.23	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	4.32	2e-05	0.00872	0.3	0.23	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	4.32	2e-05	0.00872	0.3	0.23	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	4.32	2e-05	0.00872	0.3	0.23	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	4.32	2e-05	0.00872	0.3	0.23	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	4.32	2e-05	0.00872	0.3	0.23	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
STAD	cis	rs11235843	0.853	rs11235922	ENSG00000255928.1	RP11-456I15.2	4.32	2e-05	0.00872	0.4	0.23	Hand grip strength;	chr11:73825653	chr11:73722349~73722694:+
STAD	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-4.32	2e-05	0.00872	-0.26	-0.23	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
STAD	cis	rs189798	0.592	rs10111263	ENSG00000233609.3	RP11-62H7.2	-4.32	2e-05	0.00872	-0.26	-0.23	Myopia (pathological);	chr8:9111923	chr8:8961200~8979025:+
STAD	cis	rs17826219	0.568	rs59858012	ENSG00000263603.1	CTD-2349P21.5	-4.32	2.01e-05	0.00872	-0.33	-0.23	Body mass index;	chr17:30751564	chr17:30729469~30731202:+
STAD	cis	rs11098499	0.955	rs1397608	ENSG00000260091.1	RP11-33B1.4	4.32	2.01e-05	0.00872	0.22	0.23	Corneal astigmatism;	chr4:119240589	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs7685268	ENSG00000260091.1	RP11-33B1.4	4.32	2.01e-05	0.00872	0.22	0.23	Corneal astigmatism;	chr4:119241033	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs7684942	ENSG00000260091.1	RP11-33B1.4	4.32	2.01e-05	0.00872	0.22	0.23	Corneal astigmatism;	chr4:119241046	chr4:119409333~119410233:+
STAD	cis	rs7103648	0.669	rs12577383	ENSG00000280615.1	Y_RNA	4.32	2.01e-05	0.00873	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47752686	chr11:47614898~47614994:-
STAD	cis	rs7103648	0.669	rs7927445	ENSG00000280615.1	Y_RNA	4.32	2.01e-05	0.00873	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47759202	chr11:47614898~47614994:-
STAD	cis	rs7103648	0.695	rs12223593	ENSG00000280615.1	Y_RNA	4.32	2.01e-05	0.00873	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47767530	chr11:47614898~47614994:-
STAD	cis	rs1799949	1	rs36036395	ENSG00000279602.1	CTD-3014M21.1	4.32	2.01e-05	0.00873	0.29	0.23	Menopause (age at onset);	chr17:43029280	chr17:43360041~43361361:-
STAD	cis	rs4589258	0.713	rs1792614	ENSG00000280367.1	RP11-121L10.2	4.32	2.01e-05	0.00873	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90719344	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.698	rs1792617	ENSG00000280367.1	RP11-121L10.2	-4.32	2.01e-05	0.00873	-0.22	-0.23	Intelligence (multi-trait analysis);	chr11:90715996	chr11:90223153~90226538:+
STAD	cis	rs55702914	0.839	rs2059922	ENSG00000231621.1	AC013264.2	4.32	2.01e-05	0.00873	0.2	0.23	Major depression and alcohol dependence;	chr2:197324179	chr2:197197991~197199273:+
STAD	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-4.32	2.01e-05	0.00874	-0.26	-0.23	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
STAD	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	4.32	2.01e-05	0.00874	0.34	0.23	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
STAD	cis	rs1075265	0.548	rs2542575	ENSG00000235937.1	AC008280.1	4.32	2.01e-05	0.00874	0.21	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54029552~54030682:-
STAD	cis	rs8099594	0.666	rs573978	ENSG00000266696.1	RP11-30L3.2	4.32	2.01e-05	0.00874	0.22	0.23	Height;	chr18:49300942	chr18:49205912~49208781:+
STAD	cis	rs11694172	0.69	rs11691958	ENSG00000273456.1	RP11-686O6.2	4.32	2.01e-05	0.00874	0.26	0.23	Cholesterol, total;	chr2:202743630	chr2:202374932~202375604:-
STAD	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	4.32	2.01e-05	0.00874	0.27	0.23	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	4.32	2.01e-05	0.00874	0.27	0.23	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
STAD	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	4.32	2.01e-05	0.00874	0.24	0.23	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
STAD	cis	rs4691139	1	rs12512283	ENSG00000248632.1	RP11-366M4.11	4.32	2.01e-05	0.00874	0.22	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987775	chr4:164968587~164970002:-
STAD	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-4.32	2.01e-05	0.00874	-0.26	-0.23	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
STAD	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	4.32	2.01e-05	0.00874	0.27	0.23	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
STAD	cis	rs4295623	0.559	rs4841600	ENSG00000270154.1	RP11-419I17.1	4.32	2.01e-05	0.00874	0.25	0.23	Morning vs. evening chronotype;	chr8:11830639	chr8:12476462~12477122:+
STAD	cis	rs1707322	0.691	rs61784803	ENSG00000225447.1	RPS15AP10	-4.32	2.01e-05	0.00875	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.752	rs4586014	ENSG00000281133.1	AL355480.3	-4.32	2.01e-05	0.00875	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45580892~45580996:-
STAD	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-4.32	2.01e-05	0.00875	-0.26	-0.23	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
STAD	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	4.32	2.01e-05	0.00875	0.24	0.23	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
STAD	cis	rs2695743	0.592	rs6433698	ENSG00000225808.1	DNAJC19P5	4.32	2.01e-05	0.00875	0.26	0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177816807	chr2:177229191~177229506:-
STAD	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-4.32	2.01e-05	0.00875	-0.34	-0.23	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-4.32	2.01e-05	0.00875	-0.34	-0.23	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-4.32	2.01e-05	0.00875	-0.34	-0.23	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-4.32	2.01e-05	0.00875	-0.34	-0.23	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-4.32	2.01e-05	0.00875	-0.34	-0.23	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-4.32	2.01e-05	0.00875	-0.34	-0.23	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-4.32	2.01e-05	0.00875	-0.34	-0.23	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
STAD	cis	rs2695743	0.592	rs3770048	ENSG00000225808.1	DNAJC19P5	-4.32	2.01e-05	0.00875	-0.26	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177824211	chr2:177229191~177229506:-
STAD	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	4.32	2.01e-05	0.00876	0.33	0.23	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
STAD	cis	rs4589258	0.788	rs7935026	ENSG00000280367.1	RP11-121L10.2	4.32	2.01e-05	0.00876	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90733132	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.689	rs9645609	ENSG00000280367.1	RP11-121L10.2	4.32	2.01e-05	0.00876	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90733690	chr11:90223153~90226538:+
STAD	cis	rs720475	0.732	rs73159066	ENSG00000244198.4	RP4-545C24.1	-4.32	2.02e-05	0.00876	-0.29	-0.23	Breast cancer;	chr7:144426495	chr7:144194858~144280547:+
STAD	cis	rs720475	0.732	rs17172978	ENSG00000244198.4	RP4-545C24.1	-4.32	2.02e-05	0.00876	-0.29	-0.23	Breast cancer;	chr7:144429551	chr7:144194858~144280547:+
STAD	cis	rs8062405	0.964	rs62036614	ENSG00000278665.1	RP11-666O2.4	4.32	2.02e-05	0.00876	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28599241~28601881:-
STAD	cis	rs721917	0.629	rs1304463	ENSG00000244733.5	RP11-506M13.3	-4.32	2.02e-05	0.00877	-0.25	-0.23	Chronic obstructive pulmonary disease;	chr10:79969516	chr10:79660891~79677996:+
STAD	cis	rs2688608	0.592	rs11000759	ENSG00000272140.2	RP11-574K11.29	4.32	2.02e-05	0.00877	0.2	0.23	Inflammatory bowel disease;	chr10:73733968	chr10:73703735~73713581:-
STAD	cis	rs9987353	0.566	rs34389718	ENSG00000254340.1	RP11-10A14.3	-4.32	2.02e-05	0.00878	-0.32	-0.23	Recombination measurement;	chr8:9208015	chr8:9141424~9145435:+
STAD	cis	rs875971	1	rs7792762	ENSG00000224316.1	RP11-479O9.2	4.32	2.02e-05	0.00878	0.22	0.23	Aortic root size;	chr7:66539151	chr7:65773620~65802067:+
STAD	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-4.32	2.02e-05	0.00878	-0.31	-0.23	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
STAD	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-4.32	2.02e-05	0.00878	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
STAD	cis	rs453301	0.653	rs11784393	ENSG00000233609.3	RP11-62H7.2	4.32	2.02e-05	0.00878	0.25	0.23	Joint mobility (Beighton score);	chr8:9045624	chr8:8961200~8979025:+
STAD	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	4.32	2.02e-05	0.00878	0.22	0.23	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
STAD	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	4.32	2.02e-05	0.00879	0.71	0.23	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
STAD	cis	rs7220401	0.789	rs4794859	ENSG00000240074.1	RPL9P30	-4.32	2.02e-05	0.00879	-0.19	-0.23	Coronary artery disease;	chr17:29635375	chr17:29855759~29856332:+
STAD	cis	rs1075265	0.568	rs2542577	ENSG00000235937.1	AC008280.1	4.32	2.02e-05	0.00879	0.21	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54029552~54030682:-
STAD	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	4.32	2.02e-05	0.00879	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
STAD	cis	rs2337406	1	rs61268362	ENSG00000211972.2	IGHV3-66	4.32	2.02e-05	0.00879	0.27	0.23	Alzheimer's disease (late onset);	chr14:106697010	chr14:106675017~106675544:-
STAD	cis	rs9467773	0.62	rs2494696	ENSG00000243307.2	POM121L6P	4.32	2.02e-05	0.00879	0.22	0.23	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26896952~26898777:+
STAD	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	4.32	2.02e-05	0.00879	0.24	0.23	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
STAD	cis	rs7202877	0.656	rs6564245	ENSG00000261783.1	RP11-252K23.2	4.32	2.03e-05	0.0088	0.37	0.23	Type 1 diabetes;Type 2 diabetes;	chr16:75275001	chr16:75379818~75381260:-
STAD	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-4.32	2.03e-05	0.0088	-0.26	-0.23	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
STAD	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	4.32	2.03e-05	0.0088	0.22	0.23	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
STAD	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-4.32	2.03e-05	0.0088	-0.26	-0.23	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
STAD	cis	rs9307551	0.619	rs7670107	ENSG00000250334.4	LINC00989	-4.32	2.03e-05	0.0088	-0.28	-0.23	Refractive error;	chr4:79502861	chr4:79492416~79576460:+
STAD	cis	rs1707322	0.89	rs2297883	ENSG00000281133.1	AL355480.3	4.32	2.03e-05	0.00881	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs1707338	ENSG00000281133.1	AL355480.3	4.32	2.03e-05	0.00881	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.964	rs1707339	ENSG00000281133.1	AL355480.3	4.32	2.03e-05	0.00881	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs1768818	ENSG00000281133.1	AL355480.3	4.32	2.03e-05	0.00881	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs1768817	ENSG00000281133.1	AL355480.3	4.32	2.03e-05	0.00881	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785470	ENSG00000281133.1	AL355480.3	4.32	2.03e-05	0.00881	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45580892~45580996:-
STAD	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	4.32	2.03e-05	0.00881	0.25	0.23	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
STAD	cis	rs11098499	0.909	rs73842633	ENSG00000260091.1	RP11-33B1.4	4.32	2.03e-05	0.00881	0.23	0.23	Corneal astigmatism;	chr4:119454309	chr4:119409333~119410233:+
STAD	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-4.32	2.03e-05	0.00882	-0.28	-0.23	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
STAD	cis	rs2739330	0.828	rs2877178	ENSG00000272787.1	KB-226F1.2	-4.32	2.03e-05	0.00882	-0.24	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23969211~23969873:+
STAD	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-4.32	2.03e-05	0.00882	-0.21	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
STAD	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.03e-05	0.00882	-0.27	-0.23	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.03e-05	0.00882	-0.27	-0.23	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
STAD	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.03e-05	0.00882	-0.27	-0.23	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
STAD	cis	rs9860428	0.774	rs9814008	ENSG00000240057.4	RP11-572M11.4	-4.32	2.03e-05	0.00882	-0.21	-0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112845336	chr3:113019532~113183301:+
STAD	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	-4.32	2.03e-05	0.00882	-0.22	-0.23	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
STAD	cis	rs17401966	0.838	rs12141246	ENSG00000199562.1	RNU6-37P	4.32	2.03e-05	0.00882	0.18	0.23	Hepatocellular carcinoma;	chr1:10267349	chr1:10298966~10299072:+
STAD	cis	rs1823913	1	rs68014803	ENSG00000280083.1	RP11-317J9.1	-4.32	2.03e-05	0.00882	-0.28	-0.23	Obesity-related traits;	chr2:191241877	chr2:191154118~191156070:-
STAD	cis	rs1823913	0.963	rs4146105	ENSG00000280083.1	RP11-317J9.1	-4.32	2.03e-05	0.00882	-0.28	-0.23	Obesity-related traits;	chr2:191245240	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs13019004	ENSG00000280083.1	RP11-317J9.1	-4.32	2.03e-05	0.00882	-0.28	-0.23	Obesity-related traits;	chr2:191245493	chr2:191154118~191156070:-
STAD	cis	rs1056107	0.763	rs10759529	ENSG00000225513.1	RP11-165N19.2	-4.32	2.03e-05	0.00882	-0.26	-0.23	Colorectal cancer;	chr9:112176651	chr9:112173522~112173971:-
STAD	cis	rs17401966	0.838	rs912963	ENSG00000199562.1	RNU6-37P	4.32	2.03e-05	0.00883	0.17	0.23	Hepatocellular carcinoma;	chr1:10287984	chr1:10298966~10299072:+
STAD	cis	rs10129255	0.5	rs6576226	ENSG00000224373.3	IGHV4-59	4.32	2.03e-05	0.00883	0.16	0.23	Kawasaki disease;	chr14:106778135	chr14:106627249~106627825:-
STAD	cis	rs2739330	0.796	rs2154594	ENSG00000272787.1	KB-226F1.2	4.32	2.03e-05	0.00883	0.24	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23969211~23969873:+
STAD	cis	rs11239930	0.538	rs59064267	ENSG00000278811.3	LINC00624	4.32	2.03e-05	0.00883	0.23	0.23	AIDS progression;	chr1:147089146	chr1:147258885~147517875:-
STAD	cis	rs1823874	0.677	rs2100446	ENSG00000182397.13	DNM1P46	-4.32	2.03e-05	0.00883	-0.24	-0.23	IgG glycosylation;	chr15:99820169	chr15:99790156~99806927:-
STAD	cis	rs1823874	0.677	rs2100447	ENSG00000182397.13	DNM1P46	-4.32	2.03e-05	0.00883	-0.24	-0.23	IgG glycosylation;	chr15:99820188	chr15:99790156~99806927:-
STAD	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-4.32	2.04e-05	0.00884	-0.34	-0.23	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
STAD	cis	rs6432852	1	rs7609164	ENSG00000229195.1	AC009495.4	4.32	2.04e-05	0.00884	0.26	0.23	Diabetic kidney disease;	chr2:165925886	chr2:165794857~165846091:-
STAD	cis	rs6432852	1	rs12476570	ENSG00000229195.1	AC009495.4	4.32	2.04e-05	0.00884	0.26	0.23	Diabetic kidney disease;	chr2:165935489	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.902	rs13018773	ENSG00000229195.1	AC009495.4	4.32	2.04e-05	0.00884	0.26	0.23	Diabetic kidney disease;	chr2:165935793	chr2:165794857~165846091:-
STAD	cis	rs3806843	0.576	rs246002	ENSG00000202111.1	VTRNA1-2	-4.32	2.04e-05	0.00884	-0.22	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140961519	chr5:140718925~140719013:+
STAD	cis	rs7826238	0.535	rs2979179	ENSG00000254340.1	RP11-10A14.3	4.32	2.04e-05	0.00884	0.27	0.23	Systolic blood pressure;	chr8:8462519	chr8:9141424~9145435:+
STAD	cis	rs2537594	0.56	rs2723521	ENSG00000279048.1	RP11-511H23.2	-4.32	2.04e-05	0.00884	-0.22	-0.23	Mean corpuscular hemoglobin;	chr7:17774027	chr7:17940503~17942922:+
STAD	cis	rs763014	0.966	rs35642938	ENSG00000228201.1	AL022341.3	4.32	2.04e-05	0.00884	0.27	0.23	Height;	chr16:592249	chr16:648473~649200:-
STAD	cis	rs11722779	0.869	rs223350	ENSG00000248971.2	KRT8P46	-4.32	2.04e-05	0.00885	-0.23	-0.23	Schizophrenia;	chr4:102856899	chr4:102728746~102730171:-
STAD	cis	rs11098499	1	rs6849889	ENSG00000260091.1	RP11-33B1.4	4.32	2.04e-05	0.00885	0.22	0.23	Corneal astigmatism;	chr4:119265193	chr4:119409333~119410233:+
STAD	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	4.32	2.04e-05	0.00885	0.25	0.23	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
STAD	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-4.32	2.04e-05	0.00885	-0.28	-0.23	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
STAD	cis	rs7429990	0.965	rs184388	ENSG00000224895.1	VPS26BP1	-4.32	2.04e-05	0.00885	-0.23	-0.23	Educational attainment (years of education);	chr3:47898136	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs319696	ENSG00000224895.1	VPS26BP1	-4.32	2.04e-05	0.00885	-0.23	-0.23	Educational attainment (years of education);	chr3:47902371	chr3:47960327~47961081:-
STAD	cis	rs10073892	0.581	rs1027660	ENSG00000250682.4	LINC00491	-4.32	2.04e-05	0.00885	-0.24	-0.23	Cognitive decline (age-related);	chr5:102598127	chr5:102609156~102671559:-
STAD	cis	rs2337406	0.925	rs873533	ENSG00000280411.1	IGHV1-69-2	-4.32	2.04e-05	0.00886	-0.28	-0.23	Alzheimer's disease (late onset);	chr14:106667442	chr14:106762092~106762588:-
STAD	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	4.32	2.04e-05	0.00886	0.34	0.23	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
STAD	cis	rs853679	0.506	rs1150693	ENSG00000220721.1	OR1F12	4.32	2.04e-05	0.00886	0.26	0.23	Depression;	chr6:28206812	chr6:28073316~28074233:+
STAD	cis	rs10129255	0.5	rs6576225	ENSG00000224373.3	IGHV4-59	4.32	2.04e-05	0.00886	0.16	0.23	Kawasaki disease;	chr14:106778120	chr14:106627249~106627825:-
STAD	cis	rs7474896	1	rs11011339	ENSG00000099251.13	HSD17B7P2	4.32	2.04e-05	0.00886	0.34	0.23	Obesity (extreme);	chr10:37707418	chr10:38356380~38378505:+
STAD	cis	rs5753618	0.561	rs2283881	ENSG00000236132.1	CTA-440B3.1	4.32	2.04e-05	0.00886	0.26	0.23	Colorectal cancer;	chr22:31242946	chr22:31816379~31817491:-
STAD	cis	rs801193	0.636	rs10233806	ENSG00000224316.1	RP11-479O9.2	-4.32	2.04e-05	0.00887	-0.22	-0.23	Aortic root size;	chr7:66653261	chr7:65773620~65802067:+
STAD	cis	rs10129255	0.53	rs11624912	ENSG00000211973.2	IGHV1-69	4.32	2.05e-05	0.00887	0.19	0.23	Kawasaki disease;	chr14:106673891	chr14:106714684~106715181:-
STAD	cis	rs1799949	0.965	rs8176130	ENSG00000279602.1	CTD-3014M21.1	4.32	2.05e-05	0.00887	0.28	0.23	Menopause (age at onset);	chr17:43106026	chr17:43360041~43361361:-
STAD	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-4.32	2.05e-05	0.00887	-0.28	-0.23	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
STAD	cis	rs8099594	0.565	rs4939846	ENSG00000266696.1	RP11-30L3.2	-4.32	2.05e-05	0.00887	-0.2	-0.23	Height;	chr18:49189715	chr18:49205912~49208781:+
STAD	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-4.32	2.05e-05	0.00887	-0.37	-0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
STAD	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-4.32	2.05e-05	0.00887	-0.35	-0.23	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-4.32	2.05e-05	0.00887	-0.35	-0.23	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-4.32	2.05e-05	0.00887	-0.35	-0.23	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-4.32	2.05e-05	0.00887	-0.35	-0.23	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-4.32	2.05e-05	0.00887	-0.35	-0.23	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-4.32	2.05e-05	0.00887	-0.35	-0.23	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
STAD	cis	rs7829975	0.6	rs1719381	ENSG00000254340.1	RP11-10A14.3	-4.32	2.05e-05	0.00887	-0.27	-0.23	Mood instability;	chr8:8744834	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.954	rs4577559	ENSG00000260091.1	RP11-33B1.4	4.32	2.05e-05	0.00888	0.22	0.23	Corneal astigmatism;	chr4:119482888	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs7656252	ENSG00000260091.1	RP11-33B1.4	4.32	2.05e-05	0.00888	0.22	0.23	Corneal astigmatism;	chr4:119483113	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs28845498	ENSG00000260091.1	RP11-33B1.4	4.32	2.05e-05	0.00888	0.22	0.23	Corneal astigmatism;	chr4:119484031	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs28753180	ENSG00000260091.1	RP11-33B1.4	4.32	2.05e-05	0.00888	0.22	0.23	Corneal astigmatism;	chr4:119484212	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.954	rs56270433	ENSG00000260091.1	RP11-33B1.4	4.32	2.05e-05	0.00888	0.22	0.23	Corneal astigmatism;	chr4:119484875	chr4:119409333~119410233:+
STAD	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-4.32	2.05e-05	0.00888	-0.21	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
STAD	cis	rs9890032	0.509	rs11656986	ENSG00000266490.1	CTD-2349P21.9	4.32	2.05e-05	0.00888	0.19	0.23	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30792372~30792833:+
STAD	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-4.32	2.05e-05	0.00888	-0.26	-0.23	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-4.32	2.05e-05	0.00888	-0.26	-0.23	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
STAD	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	4.32	2.05e-05	0.00889	0.28	0.23	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
STAD	cis	rs11846409	0.932	rs28617526	ENSG00000211970.3	IGHV4-61	4.32	2.05e-05	0.00889	0.25	0.23	Rheumatic heart disease;	chr14:106637322	chr14:106639119~106639657:-
STAD	cis	rs1799949	1	rs8077486	ENSG00000279602.1	CTD-3014M21.1	4.32	2.05e-05	0.00889	0.28	0.23	Menopause (age at onset);	chr17:43060788	chr17:43360041~43361361:-
STAD	cis	rs2408955	0.522	rs10875721	ENSG00000258273.1	RP11-370I10.4	4.32	2.05e-05	0.00889	0.27	0.23	Glycated hemoglobin levels;	chr12:48019810	chr12:48333755~48333901:-
STAD	cis	rs138491296	1	rs138491296	ENSG00000240074.1	RPL9P30	-4.32	2.05e-05	0.00889	-0.2	-0.23	White blood cell count;	chr17:29634549	chr17:29855759~29856332:+
STAD	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	4.32	2.05e-05	0.0089	0.33	0.23	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
STAD	cis	rs9847710	0.967	rs2581778	ENSG00000242142.1	SERBP1P3	4.32	2.05e-05	0.0089	0.22	0.23	Ulcerative colitis;	chr3:53021295	chr3:53064283~53065091:-
STAD	cis	rs1876905	0.539	rs240985	ENSG00000230177.1	RP5-1112D6.4	4.32	2.05e-05	0.0089	0.26	0.23	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111277932~111278742:+
STAD	cis	rs765787	0.53	rs13329228	ENSG00000259539.1	CTD-2651B20.1	4.32	2.05e-05	0.0089	0.26	0.23	Uric acid levels;	chr15:45240819	chr15:45152664~45167526:-
STAD	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	4.32	2.05e-05	0.00891	0.32	0.23	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
STAD	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-4.32	2.05e-05	0.00891	-0.26	-0.23	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-4.32	2.05e-05	0.00891	-0.26	-0.23	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
STAD	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	4.32	2.05e-05	0.00891	0.25	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
STAD	cis	rs9902453	0.817	rs59420007	ENSG00000263477.1	RP11-338L22.2	4.32	2.06e-05	0.00891	0.19	0.23	Coffee consumption (cups per day);	chr17:29869096	chr17:29863402~29866092:+
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000211959.2	IGHV4-39	4.32	2.06e-05	0.00892	0.2	0.23	Kawasaki disease;	chr14:106786292	chr14:106421711~106422218:-
STAD	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	4.32	2.06e-05	0.00892	0.24	0.23	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
STAD	cis	rs1009077	0.514	rs71614451	ENSG00000260091.1	RP11-33B1.4	-4.32	2.06e-05	0.00892	-0.29	-0.23	Endometriosis;	chr4:119483305	chr4:119409333~119410233:+
STAD	cis	rs227275	0.525	rs13150426	ENSG00000248971.2	KRT8P46	-4.32	2.06e-05	0.00892	-0.23	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102728746~102730171:-
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000224373.3	IGHV4-59	4.32	2.06e-05	0.00892	0.16	0.23	Kawasaki disease;	chr14:106782523	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000224373.3	IGHV4-59	4.32	2.06e-05	0.00892	0.16	0.23	Kawasaki disease;	chr14:106782559	chr14:106627249~106627825:-
STAD	cis	rs9902453	0.845	rs72823935	ENSG00000240074.1	RPL9P30	4.32	2.06e-05	0.00892	0.2	0.23	Coffee consumption (cups per day);	chr17:29681577	chr17:29855759~29856332:+
STAD	cis	rs12468226	0.873	rs60722019	ENSG00000226261.1	AC064836.3	4.32	2.06e-05	0.00893	0.37	0.23	Urate levels;	chr2:202282060	chr2:202336024~202336727:-
STAD	cis	rs11846409	0.932	rs60917084	ENSG00000211970.3	IGHV4-61	4.32	2.06e-05	0.00893	0.24	0.23	Rheumatic heart disease;	chr14:106634621	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs28378201	ENSG00000211970.3	IGHV4-61	4.32	2.06e-05	0.00893	0.24	0.23	Rheumatic heart disease;	chr14:106637262	chr14:106639119~106639657:-
STAD	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	4.32	2.06e-05	0.00893	0.27	0.23	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
STAD	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	4.32	2.06e-05	0.00893	0.27	0.23	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
STAD	cis	rs11098499	0.954	rs1022145	ENSG00000260091.1	RP11-33B1.4	4.32	2.06e-05	0.00893	0.22	0.23	Corneal astigmatism;	chr4:119309824	chr4:119409333~119410233:+
STAD	cis	rs7142881	0.844	rs10144137	ENSG00000258648.1	UBE2CP1	4.32	2.06e-05	0.00893	0.25	0.23	Response to iloperidone treatment (QT prolongation);	chr14:31563008	chr14:30683045~30683598:-
STAD	cis	rs6430585	0.528	rs6711493	ENSG00000231890.6	DARS-AS1	-4.32	2.06e-05	0.00893	-0.24	-0.23	Corneal structure;	chr2:135934983	chr2:135985176~136022593:+
STAD	cis	rs8177876	0.822	rs4324141	ENSG00000261061.1	RP11-303E16.2	4.32	2.06e-05	0.00893	0.38	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81030770~81031485:+
STAD	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	4.32	2.06e-05	0.00894	0.4	0.23	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
STAD	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	4.32	2.06e-05	0.00894	0.27	0.23	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	4.32	2.06e-05	0.00894	0.27	0.23	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	4.32	2.06e-05	0.00894	0.27	0.23	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	4.32	2.06e-05	0.00894	0.27	0.23	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	4.32	2.06e-05	0.00894	0.27	0.23	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
STAD	cis	rs875971	0.862	rs28470208	ENSG00000224316.1	RP11-479O9.2	-4.32	2.06e-05	0.00894	-0.23	-0.23	Aortic root size;	chr7:66119713	chr7:65773620~65802067:+
STAD	cis	rs2921036	0.545	rs4840975	ENSG00000173295.6	FAM86B3P	-4.32	2.06e-05	0.00894	-0.3	-0.23	Neuroticism;	chr8:8505748	chr8:8228595~8244865:+
STAD	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-4.32	2.06e-05	0.00894	-0.29	-0.23	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
STAD	cis	rs1707322	0.685	rs28617418	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.682	rs28490344	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs28501477	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs28641748	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs6697821	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs4330955	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.691	rs12031182	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10430123	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs12043945	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs12091503	ENSG00000225447.1	RPS15AP10	4.32	2.06e-05	0.00894	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45645816~45646197:-
STAD	cis	rs2836950	0.545	rs4818001	ENSG00000238141.2	BRWD1-AS1	-4.32	2.07e-05	0.00894	-0.23	-0.23	Menarche (age at onset);	chr21:39203162	chr21:39315707~39323218:+
STAD	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	4.32	2.07e-05	0.00894	0.29	0.23	Axial length;	chr3:53815483	chr3:53797764~53798019:-
STAD	cis	rs4589258	0.933	rs7117293	ENSG00000280367.1	RP11-121L10.2	-4.32	2.07e-05	0.00895	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90663219	chr11:90223153~90226538:+
STAD	cis	rs2337406	0.587	rs10150642	ENSG00000211970.3	IGHV4-61	-4.32	2.07e-05	0.00895	-0.24	-0.23	Alzheimer's disease (late onset);	chr14:106647269	chr14:106639119~106639657:-
STAD	cis	rs748404	0.631	rs8042688	ENSG00000275601.1	AC011330.13	-4.32	2.07e-05	0.00895	-0.23	-0.23	Lung cancer;	chr15:43346327	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs4296223	ENSG00000275601.1	AC011330.13	-4.32	2.07e-05	0.00896	-0.23	-0.23	Lung cancer;	chr15:43353048	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs6493084	ENSG00000275601.1	AC011330.13	-4.32	2.07e-05	0.00896	-0.23	-0.23	Lung cancer;	chr15:43355429	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs12905772	ENSG00000275601.1	AC011330.13	-4.32	2.07e-05	0.00896	-0.23	-0.23	Lung cancer;	chr15:43356246	chr15:43642389~43643023:-
STAD	cis	rs748404	0.676	rs4401024	ENSG00000275601.1	AC011330.13	-4.32	2.07e-05	0.00896	-0.23	-0.23	Lung cancer;	chr15:43358137	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs6493086	ENSG00000275601.1	AC011330.13	-4.32	2.07e-05	0.00896	-0.23	-0.23	Lung cancer;	chr15:43363196	chr15:43642389~43643023:-
STAD	cis	rs891378	1	rs1858001	ENSG00000274245.1	RP11-357P18.2	4.32	2.07e-05	0.00896	0.28	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207314659	chr1:207372559~207373252:+
STAD	cis	rs7131987	0.903	rs67517901	ENSG00000257176.2	RP11-996F15.2	-4.32	2.07e-05	0.00896	-0.25	-0.23	QT interval;	chr12:29268413	chr12:29280418~29317848:-
STAD	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	4.32	2.07e-05	0.00896	0.27	0.23	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
STAD	cis	rs12264252	0.767	rs7902355	ENSG00000225484.5	NUTM2B-AS1	-4.32	2.07e-05	0.00896	-0.36	-0.23	Coronary artery disease;	chr10:80489352	chr10:79663088~79826594:-
STAD	cis	rs6921919	0.525	rs16894095	ENSG00000220721.1	OR1F12	4.32	2.07e-05	0.00897	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28073316~28074233:+
STAD	cis	rs2442825	0.526	rs6443237	ENSG00000206573.7	THUMPD3-AS1	-4.32	2.07e-05	0.00897	-0.19	-0.23	Cerebrospinal fluid clusterin levels;	chr3:9395777	chr3:9349689~9398579:-
STAD	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-4.32	2.07e-05	0.00897	-0.26	-0.23	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
STAD	cis	rs7487075	0.751	rs10880947	ENSG00000257261.4	RP11-96H19.1	-4.32	2.07e-05	0.00897	-0.29	-0.23	Itch intensity from mosquito bite;	chr12:46283501	chr12:46383679~46876159:+
STAD	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	4.32	2.07e-05	0.00897	0.25	0.23	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
STAD	cis	rs1348850	0.874	rs1348848	ENSG00000271825.1	RP11-337N6.2	-4.32	2.07e-05	0.00897	-0.19	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177493505	chr2:177300600~177302006:+
STAD	cis	rs4927850	1	rs4927850	ENSG00000278820.1	AC024937.1	-4.32	2.07e-05	0.00897	-0.25	-0.23	Pancreatic cancer;	chr3:196024759	chr3:195960500~195960612:-
STAD	cis	rs10073892	0.66	rs35369487	ENSG00000250682.4	LINC00491	-4.32	2.07e-05	0.00897	-0.25	-0.23	Cognitive decline (age-related);	chr5:102623465	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.66	rs35664711	ENSG00000250682.4	LINC00491	-4.32	2.07e-05	0.00897	-0.25	-0.23	Cognitive decline (age-related);	chr5:102623490	chr5:102609156~102671559:-
STAD	cis	rs4792901	0.729	rs12603059	ENSG00000279602.1	CTD-3014M21.1	-4.32	2.07e-05	0.00898	-0.3	-0.23	Dupuytren's disease;	chr17:43461078	chr17:43360041~43361361:-
STAD	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	4.32	2.07e-05	0.00898	0.24	0.23	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
STAD	cis	rs516805	0.683	rs115988443	ENSG00000279453.1	RP3-425C14.4	4.32	2.07e-05	0.00898	0.34	0.23	Lymphocyte counts;	chr6:122383201	chr6:122436789~122439223:-
STAD	cis	rs6142102	0.923	rs6059635	ENSG00000264616.1	MIR4755	4.32	2.07e-05	0.00898	0.24	0.23	Skin pigmentation;	chr20:34025687	chr20:34049119~34049190:+
STAD	cis	rs4792901	0.523	rs28597956	ENSG00000279602.1	CTD-3014M21.1	-4.32	2.08e-05	0.00898	-0.31	-0.23	Dupuytren's disease;	chr17:43449844	chr17:43360041~43361361:-
STAD	cis	rs822354	0.963	rs266739	ENSG00000230951.1	GPS2P2	-4.32	2.08e-05	0.00898	-0.28	-0.23	Adiponectin levels;	chr3:186759629	chr3:186772589~186773476:+
STAD	cis	rs9902453	0.838	rs3110495	ENSG00000240074.1	RPL9P30	-4.32	2.08e-05	0.00899	-0.2	-0.23	Coffee consumption (cups per day);	chr17:29651437	chr17:29855759~29856332:+
STAD	cis	rs1707322	0.964	rs6697830	ENSG00000225447.1	RPS15AP10	4.32	2.08e-05	0.00899	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs12060274	ENSG00000225447.1	RPS15AP10	4.32	2.08e-05	0.00899	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs10890353	ENSG00000225447.1	RPS15AP10	4.32	2.08e-05	0.00899	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45645816~45646197:-
STAD	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-4.32	2.08e-05	0.00899	-0.26	-0.23	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-4.32	2.08e-05	0.00899	-0.26	-0.23	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
STAD	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	4.32	2.08e-05	0.009	0.36	0.23	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	4.32	2.08e-05	0.009	0.36	0.23	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
STAD	cis	rs7131987	0.65	rs67146951	ENSG00000275476.1	RP11-996F15.4	-4.32	2.08e-05	0.009	-0.25	-0.23	QT interval;	chr12:29297620	chr12:29277397~29277882:-
STAD	cis	rs17401966	0.931	rs12408430	ENSG00000199562.1	RNU6-37P	4.32	2.08e-05	0.009	0.18	0.23	Hepatocellular carcinoma;	chr1:10263281	chr1:10298966~10299072:+
STAD	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	4.32	2.08e-05	0.00901	0.48	0.23	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
STAD	cis	rs6832769	1	rs4865010	ENSG00000272969.1	RP11-528I4.2	-4.32	2.08e-05	0.00901	-0.28	-0.23	Personality dimensions;	chr4:55548795	chr4:55547112~55547889:+
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000224373.3	IGHV4-59	4.32	2.08e-05	0.00901	0.16	0.23	Kawasaki disease;	chr14:106767802	chr14:106627249~106627825:-
STAD	cis	rs9860428	0.679	rs1392785	ENSG00000240057.4	RP11-572M11.4	4.31	2.09e-05	0.00902	0.21	0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112970690	chr3:113019532~113183301:+
STAD	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-4.31	2.09e-05	0.00902	-0.35	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
STAD	cis	rs6750795	0.765	rs6742387	ENSG00000223198.1	RNU2-22P	-4.31	2.09e-05	0.00903	-0.26	-0.23	Height;	chr2:231490121	chr2:231501990~231502201:-
STAD	cis	rs7598759	0.548	rs1823328	ENSG00000223198.1	RNU2-22P	-4.31	2.09e-05	0.00903	-0.26	-0.23	Noise-induced hearing loss;	chr2:231490473	chr2:231501990~231502201:-
STAD	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	4.31	2.09e-05	0.00903	0.22	0.23	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
STAD	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-4.31	2.09e-05	0.00903	-0.22	-0.23	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
STAD	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-4.31	2.09e-05	0.00903	-0.22	-0.23	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
STAD	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	4.31	2.09e-05	0.00903	0.29	0.23	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
STAD	cis	rs7474896	0.832	rs12570943	ENSG00000099251.13	HSD17B7P2	4.31	2.09e-05	0.00903	0.35	0.23	Obesity (extreme);	chr10:37733541	chr10:38356380~38378505:+
STAD	cis	rs4237845	0.788	rs1962047	ENSG00000273805.1	RP11-620J15.4	-4.31	2.09e-05	0.00903	-0.25	-0.23	Intelligence (multi-trait analysis);	chr12:57898924	chr12:57894232~57896846:+
STAD	cis	rs4713118	0.669	rs200997	ENSG00000280107.1	AL022393.9	-4.31	2.09e-05	0.00903	-0.28	-0.23	Parkinson's disease;	chr6:27844037	chr6:28170845~28172521:+
STAD	cis	rs10129255	0.536	rs3944157	ENSG00000211973.2	IGHV1-69	4.31	2.09e-05	0.00904	0.19	0.23	Kawasaki disease;	chr14:106682286	chr14:106714684~106715181:-
STAD	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	4.31	2.09e-05	0.00904	0.34	0.23	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
STAD	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-4.31	2.09e-05	0.00904	-0.22	-0.23	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
STAD	cis	rs721917	0.607	rs4319455	ENSG00000244733.5	RP11-506M13.3	-4.31	2.09e-05	0.00904	-0.25	-0.23	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79660891~79677996:+
STAD	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-4.31	2.09e-05	0.00904	-0.28	-0.23	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
STAD	cis	rs1167827	1	rs1167827	ENSG00000165178.9	NCF1C	4.31	2.09e-05	0.00905	0.17	0.23	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75156639~75172044:-
STAD	cis	rs12554020	0.786	rs75395683	ENSG00000227603.1	RP11-165J3.6	4.31	2.09e-05	0.00905	0.43	0.23	Schizophrenia;	chr9:93415128	chr9:93435332~93437121:-
STAD	cis	rs12554020	1	rs55846141	ENSG00000227603.1	RP11-165J3.6	4.31	2.09e-05	0.00905	0.43	0.23	Schizophrenia;	chr9:93427679	chr9:93435332~93437121:-
STAD	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	4.31	2.09e-05	0.00905	0.35	0.23	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
STAD	cis	rs8014252	0.803	rs60860517	ENSG00000259158.2	ADAM20P1	-4.31	2.09e-05	0.00905	-0.3	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70563202	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs10135356	ENSG00000259158.2	ADAM20P1	-4.31	2.09e-05	0.00905	-0.3	-0.23	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70563638	chr14:70468881~70483756:-
STAD	cis	rs1707322	0.682	rs12037459	ENSG00000225447.1	RPS15AP10	4.31	2.09e-05	0.00905	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45645816~45646197:-
STAD	cis	rs11089937	0.597	rs9619793	ENSG00000211640.3	IGLV6-57	4.31	2.09e-05	0.00905	0.17	0.23	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22195713~22196460:+
STAD	cis	rs7665090	0.87	rs228613	ENSG00000230069.3	LRRC37A15P	4.31	2.1e-05	0.00906	0.25	0.23	Primary biliary cholangitis;	chr4:102656308	chr4:102727274~102730721:-
STAD	cis	rs6840360	0.582	rs6535796	ENSG00000270265.1	RP11-731D1.4	-4.31	2.1e-05	0.00906	-0.27	-0.23	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151333775~151353224:-
STAD	cis	rs3764021	1	rs3764021	ENSG00000256673.1	RP11-599J14.2	-4.31	2.1e-05	0.00906	-0.24	-0.23	Type 1 diabetes;	chr12:9681032	chr12:9398355~9414851:-
STAD	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	4.31	2.1e-05	0.00906	0.48	0.23	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
STAD	cis	rs3770081	1	rs3770081	ENSG00000273080.1	RP11-301O19.1	-4.31	2.1e-05	0.00906	-0.54	-0.23	Facial emotion recognition (sad faces);	chr2:86053802	chr2:86195590~86196049:+
STAD	cis	rs10129255	0.5	rs7161740	ENSG00000224373.3	IGHV4-59	4.31	2.1e-05	0.00907	0.16	0.23	Kawasaki disease;	chr14:106776119	chr14:106627249~106627825:-
STAD	cis	rs4927850	0.723	rs7630825	ENSG00000185485.13	SDHAP1	4.31	2.1e-05	0.00907	0.22	0.23	Pancreatic cancer;	chr3:196026869	chr3:195959748~195990318:-
STAD	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	4.31	2.1e-05	0.00907	0.24	0.23	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
STAD	cis	rs10971721	0.822	rs10971739	ENSG00000260947.1	RP11-384P7.7	4.31	2.1e-05	0.00907	0.32	0.23	Body mass index;	chr9:33855467	chr9:33697459~33700986:+
STAD	cis	rs13177755	1	rs13177755	ENSG00000247828.6	TMEM161B-AS1	4.31	2.1e-05	0.00908	0.31	0.23	Depressive symptoms (multi-trait analysis);	chr5:88296420	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs13159835	ENSG00000247828.6	TMEM161B-AS1	4.31	2.1e-05	0.00908	0.31	0.23	Depressive symptoms;	chr5:88305576	chr5:88268895~88436685:+
STAD	cis	rs7647973	0.58	rs7652746	ENSG00000225399.4	RP11-3B7.1	-4.31	2.1e-05	0.00908	-0.24	-0.23	Menarche (age at onset);	chr3:49224874	chr3:49260085~49261316:+
STAD	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-4.31	2.1e-05	0.00908	-0.22	-0.23	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-4.31	2.1e-05	0.00908	-0.22	-0.23	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
STAD	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-4.31	2.1e-05	0.00908	-0.22	-0.23	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
STAD	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	4.31	2.1e-05	0.00908	0.47	0.23	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
STAD	cis	rs67180937	0.583	rs3008616	ENSG00000272750.1	RP11-378J18.8	4.31	2.1e-05	0.00909	0.25	0.23	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623831	chr1:222658867~222661512:-
STAD	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	4.31	2.1e-05	0.00909	0.44	0.23	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
STAD	cis	rs422249	0.634	rs174614	ENSG00000279632.1	RP11-286N22.6	4.31	2.11e-05	0.00909	0.23	0.23	Trans fatty acid levels;	chr11:61861443	chr11:61426448~61427325:-
STAD	cis	rs422249	0.634	rs174615	ENSG00000279632.1	RP11-286N22.6	4.31	2.11e-05	0.00909	0.23	0.23	Trans fatty acid levels;	chr11:61861492	chr11:61426448~61427325:-
STAD	cis	rs11673344	0.504	rs10403975	ENSG00000267672.1	CTD-2293H3.1	4.31	2.11e-05	0.00909	0.21	0.23	Obesity-related traits;	chr19:37082172	chr19:37091341~37092564:+
STAD	cis	rs7208859	0.623	rs7214570	ENSG00000263603.1	CTD-2349P21.5	-4.31	2.11e-05	0.00909	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30729469~30731202:+
STAD	cis	rs11846409	0.932	rs73378155	ENSG00000211970.3	IGHV4-61	4.31	2.11e-05	0.00909	0.24	0.23	Rheumatic heart disease;	chr14:106637840	chr14:106639119~106639657:-
STAD	cis	rs3770081	0.826	rs1019591	ENSG00000273080.1	RP11-301O19.1	-4.31	2.11e-05	0.00909	-0.5	-0.23	Facial emotion recognition (sad faces);	chr2:86071476	chr2:86195590~86196049:+
STAD	cis	rs2390582	0.771	rs17131045	ENSG00000228175.3	GEMIN8P4	4.31	2.11e-05	0.00909	0.35	0.23	Coronary artery calcification;	chr1:90436726	chr1:89993593~89994321:-
STAD	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-4.31	2.11e-05	0.00909	-0.28	-0.23	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
STAD	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-4.31	2.11e-05	0.00909	-0.26	-0.23	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
STAD	cis	rs2880765	0.566	rs11630381	ENSG00000229212.6	RP11-561C5.4	4.31	2.11e-05	0.0091	0.32	0.23	Coronary artery disease;	chr15:85469272	chr15:85205440~85234795:-
STAD	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	4.31	2.11e-05	0.0091	0.23	0.23	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
STAD	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	4.31	2.11e-05	0.0091	0.23	0.23	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
STAD	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	4.31	2.11e-05	0.0091	0.23	0.23	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
STAD	cis	rs893363	0.583	rs4687586	ENSG00000271916.1	RP11-884K10.6	-4.31	2.11e-05	0.0091	-0.3	-0.23	Axial length;	chr3:53803944	chr3:53797764~53798019:-
STAD	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-4.31	2.11e-05	0.0091	-0.34	-0.23	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
STAD	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	4.31	2.11e-05	0.0091	0.42	0.23	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
STAD	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	4.31	2.11e-05	0.0091	0.33	0.23	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
STAD	cis	rs1707322	0.647	rs6686944	ENSG00000225447.1	RPS15AP10	4.31	2.11e-05	0.0091	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45645816~45646197:-
STAD	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	4.31	2.11e-05	0.00911	0.32	0.23	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
STAD	cis	rs12682352	0.602	rs28399241	ENSG00000254340.1	RP11-10A14.3	4.31	2.11e-05	0.00912	0.27	0.23	Neuroticism;	chr8:8805705	chr8:9141424~9145435:+
STAD	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-4.31	2.11e-05	0.00912	-0.22	-0.23	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
STAD	cis	rs1707322	1	rs785469	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00912	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785468	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00912	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785465	ENSG00000225447.1	RPS15AP10	4.31	2.11e-05	0.00912	0.17	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45645816~45646197:-
STAD	cis	rs4713118	0.588	rs200994	ENSG00000280107.1	AL022393.9	4.31	2.11e-05	0.00913	0.31	0.23	Parkinson's disease;	chr6:27846035	chr6:28170845~28172521:+
STAD	cis	rs1707322	0.89	rs2297883	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00913	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs1707338	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00913	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.964	rs1707339	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00913	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs1768818	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00913	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs1768817	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00913	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785470	ENSG00000225447.1	RPS15AP10	-4.31	2.11e-05	0.00913	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45645816~45646197:-
STAD	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	4.31	2.12e-05	0.00913	0.24	0.23	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
STAD	cis	rs1950326	0.515	rs12881979	ENSG00000258526.4	RP11-111A21.1	4.31	2.12e-05	0.00913	0.26	0.23	Verbal memory performance (residualized delayed recall level);	chr14:39568834	chr14:39474840~39513780:+
STAD	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	4.31	2.12e-05	0.00913	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
STAD	cis	rs10129255	0.5	rs2105991	ENSG00000224373.3	IGHV4-59	4.31	2.12e-05	0.00913	0.16	0.23	Kawasaki disease;	chr14:106682022	chr14:106627249~106627825:-
STAD	cis	rs7829975	0.501	rs2980769	ENSG00000254340.1	RP11-10A14.3	4.31	2.12e-05	0.00913	0.27	0.23	Mood instability;	chr8:8462781	chr8:9141424~9145435:+
STAD	cis	rs1707322	1	rs10890381	ENSG00000281133.1	AL355480.3	-4.31	2.12e-05	0.00913	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45580892~45580996:-
STAD	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	4.31	2.12e-05	0.00913	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
STAD	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	4.31	2.12e-05	0.00914	0.34	0.23	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
STAD	cis	rs7824557	0.51	rs1435274	ENSG00000205879.4	FAM90A2P	-4.31	2.12e-05	0.00914	-0.25	-0.23	Retinal vascular caliber;	chr8:11378401	chr8:12172202~12178575:-
STAD	cis	rs950169	0.84	rs12905223	ENSG00000259295.5	CSPG4P12	4.31	2.12e-05	0.00914	0.32	0.23	Schizophrenia;	chr15:84571037	chr15:85191438~85213905:+
STAD	cis	rs8141529	0.732	rs11556025	ENSG00000272858.1	CTA-292E10.8	-4.31	2.12e-05	0.00914	-0.25	-0.23	Lymphocyte counts;	chr22:28772767	chr22:28814914~28815662:+
STAD	cis	rs7078219	0.965	rs11190126	ENSG00000228778.1	RP11-129J12.1	-4.31	2.12e-05	0.00914	-0.28	-0.23	Dental caries;	chr10:99512032	chr10:99527081~99528261:+
STAD	cis	rs561341	0.882	rs2428337	ENSG00000265798.5	RP11-271K11.5	4.31	2.12e-05	0.00915	0.33	0.23	Hip circumference adjusted for BMI;	chr17:31972448	chr17:31038575~31059121:-
STAD	cis	rs17264034	0.808	rs1706987	ENSG00000250786.1	SNHG18	4.31	2.12e-05	0.00915	0.37	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547853	chr5:9546200~9550609:+
STAD	cis	rs210138	0.706	rs3916279	ENSG00000197251.3	LINC00336	4.31	2.12e-05	0.00915	0.29	0.23	Testicular germ cell tumor;	chr6:33607173	chr6:33586106~33593338:-
STAD	cis	rs2638953	0.924	rs11049478	ENSG00000247934.4	RP11-967K21.1	-4.31	2.12e-05	0.00915	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244827	chr12:28163298~28190738:-
STAD	cis	rs10851478	0.657	rs12916839	ENSG00000259545.2	RP11-325E5.4	-4.31	2.12e-05	0.00915	-0.26	-0.23	Oral cavity cancer;	chr15:49443468	chr15:49177610~49178741:-
STAD	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-4.31	2.12e-05	0.00916	-0.34	-0.23	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
STAD	cis	rs7829975	0.559	rs4841025	ENSG00000254340.1	RP11-10A14.3	-4.31	2.12e-05	0.00916	-0.27	-0.23	Mood instability;	chr8:8745650	chr8:9141424~9145435:+
STAD	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-4.31	2.12e-05	0.00916	-0.26	-0.23	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-4.31	2.12e-05	0.00916	-0.26	-0.23	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
STAD	cis	rs11673344	0.523	rs2562594	ENSG00000267672.1	CTD-2293H3.1	4.31	2.12e-05	0.00916	0.21	0.23	Obesity-related traits;	chr19:37023783	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs8101392	ENSG00000267672.1	CTD-2293H3.1	4.31	2.12e-05	0.00916	0.21	0.23	Obesity-related traits;	chr19:37024416	chr19:37091341~37092564:+
STAD	cis	rs9307551	1	rs1371989	ENSG00000250334.4	LINC00989	4.31	2.12e-05	0.00916	0.28	0.23	Refractive error;	chr4:79600692	chr4:79492416~79576460:+
STAD	cis	rs2836974	0.644	rs1882779	ENSG00000238141.2	BRWD1-AS1	-4.31	2.12e-05	0.00916	-0.24	-0.23	Cognitive function;	chr21:39319012	chr21:39315707~39323218:+
STAD	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	4.31	2.12e-05	0.00916	0.3	0.23	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
STAD	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	4.31	2.13e-05	0.00917	0.46	0.23	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
STAD	cis	rs5758659	0.714	rs133376	ENSG00000182057.4	OGFRP1	4.31	2.13e-05	0.00917	0.24	0.23	Cognitive function;	chr22:42070901	chr22:42269753~42275196:+
STAD	cis	rs5758659	0.653	rs133383	ENSG00000182057.4	OGFRP1	4.31	2.13e-05	0.00917	0.24	0.23	Cognitive function;	chr22:42077599	chr22:42269753~42275196:+
STAD	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-4.31	2.13e-05	0.00917	-0.26	-0.23	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-4.31	2.13e-05	0.00917	-0.26	-0.23	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
STAD	cis	rs4713118	0.824	rs7759217	ENSG00000243307.2	POM121L6P	-4.31	2.13e-05	0.00917	-0.26	-0.23	Parkinson's disease;	chr6:27762684	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.784	rs9468219	ENSG00000243307.2	POM121L6P	-4.31	2.13e-05	0.00917	-0.26	-0.23	Parkinson's disease;	chr6:27763976	chr6:26896952~26898777:+
STAD	cis	rs4834770	0.765	rs1511016	ENSG00000248280.1	RP11-33B1.2	4.31	2.13e-05	0.00917	0.27	0.23	Blood protein levels;	chr4:119249200	chr4:119440561~119450157:-
STAD	cis	rs2695743	0.592	rs7557283	ENSG00000225808.1	DNAJC19P5	4.31	2.13e-05	0.00917	0.26	0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177817445	chr2:177229191~177229506:-
STAD	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-4.31	2.13e-05	0.00918	-0.28	-0.23	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
STAD	cis	rs748404	0.697	rs555001	ENSG00000275601.1	AC011330.13	-4.31	2.13e-05	0.00918	-0.24	-0.23	Lung cancer;	chr15:43253530	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs475261	ENSG00000275601.1	AC011330.13	-4.31	2.13e-05	0.00918	-0.24	-0.23	Lung cancer;	chr15:43254258	chr15:43642389~43643023:-
STAD	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	4.31	2.13e-05	0.00918	0.25	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
STAD	cis	rs513349	0.964	rs210141	ENSG00000197251.3	LINC00336	4.31	2.13e-05	0.00918	0.25	0.23	Platelet count;	chr6:33579048	chr6:33586106~33593338:-
STAD	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-4.31	2.13e-05	0.00919	-0.26	-0.23	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
STAD	cis	rs2739330	0.828	rs4820572	ENSG00000272787.1	KB-226F1.2	-4.31	2.13e-05	0.00919	-0.24	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23969211~23969873:+
STAD	cis	rs516805	0.748	rs155461	ENSG00000279453.1	RP3-425C14.4	-4.31	2.13e-05	0.00919	-0.35	-0.23	Lymphocyte counts;	chr6:122499547	chr6:122436789~122439223:-
STAD	cis	rs7103648	0.695	rs6485758	ENSG00000280615.1	Y_RNA	4.31	2.13e-05	0.00919	0.23	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47508472	chr11:47614898~47614994:-
STAD	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-4.31	2.13e-05	0.00919	-0.33	-0.23	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
STAD	cis	rs2836950	0.52	rs11911087	ENSG00000238141.2	BRWD1-AS1	-4.31	2.13e-05	0.00919	-0.23	-0.23	Menarche (age at onset);	chr21:39293266	chr21:39315707~39323218:+
STAD	cis	rs7829975	0.626	rs907183	ENSG00000233609.3	RP11-62H7.2	-4.31	2.13e-05	0.00919	-0.25	-0.23	Mood instability;	chr8:8872251	chr8:8961200~8979025:+
STAD	cis	rs11676348	0.755	rs6436026	ENSG00000237281.1	CATIP-AS2	4.31	2.13e-05	0.0092	0.22	0.23	Ulcerative colitis;	chr2:218087015	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.791	rs6726126	ENSG00000237281.1	CATIP-AS2	4.31	2.13e-05	0.0092	0.22	0.23	Ulcerative colitis;	chr2:218087510	chr2:218326889~218357966:-
STAD	cis	rs10776614	0.642	rs1345104	ENSG00000189014.7	FAM35DP	-4.31	2.13e-05	0.0092	-0.29	-0.23	Self-employment;	chr10:48557192	chr10:47689707~47730436:+
STAD	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	4.31	2.13e-05	0.0092	0.31	0.23	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
STAD	cis	rs227932	0.618	rs2109348	ENSG00000234286.1	AC006026.13	4.31	2.14e-05	0.0092	0.42	0.23	Schizophrenia;	chr7:23644160	chr7:23680195~23680786:-
STAD	cis	rs227932	0.558	rs55941756	ENSG00000234286.1	AC006026.13	4.31	2.14e-05	0.0092	0.42	0.23	Schizophrenia;	chr7:23654887	chr7:23680195~23680786:-
STAD	cis	rs9807989	0.708	rs6543124	ENSG00000234389.1	AC007278.3	4.31	2.14e-05	0.00921	0.24	0.23	Asthma;	chr2:102370999	chr2:102438713~102440475:+
STAD	cis	rs8097348	1	rs9944863	ENSG00000266602.1	RP11-476K15.1	4.31	2.14e-05	0.00921	0.27	0.23	Exercise (leisure time);	chr18:1600971	chr18:1509183~1647097:+
STAD	cis	rs7131987	0.65	rs7301398	ENSG00000275476.1	RP11-996F15.4	-4.31	2.14e-05	0.00921	-0.25	-0.23	QT interval;	chr12:29302457	chr12:29277397~29277882:-
STAD	cis	rs7131987	0.65	rs7301188	ENSG00000275476.1	RP11-996F15.4	-4.31	2.14e-05	0.00921	-0.25	-0.23	QT interval;	chr12:29302458	chr12:29277397~29277882:-
STAD	cis	rs1707322	1	rs785507	ENSG00000225447.1	RPS15AP10	-4.31	2.14e-05	0.00921	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45645816~45646197:-
STAD	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	4.31	2.14e-05	0.00921	0.33	0.23	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
STAD	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	4.31	2.14e-05	0.00922	0.26	0.23	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
STAD	cis	rs1707322	0.964	rs10890358	ENSG00000225447.1	RPS15AP10	4.31	2.14e-05	0.00922	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45645816~45646197:-
STAD	cis	rs12908161	1	rs34570071	ENSG00000259295.5	CSPG4P12	4.31	2.14e-05	0.00922	0.32	0.23	Schizophrenia;	chr15:84736981	chr15:85191438~85213905:+
STAD	cis	rs1707322	0.662	rs11211160	ENSG00000281133.1	AL355480.3	-4.31	2.14e-05	0.00922	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45580892~45580996:-
STAD	cis	rs7598759	0.548	rs11693738	ENSG00000223198.1	RNU2-22P	-4.31	2.14e-05	0.00922	-0.26	-0.23	Noise-induced hearing loss;	chr2:231495773	chr2:231501990~231502201:-
STAD	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-4.31	2.14e-05	0.00923	-0.26	-0.23	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-4.31	2.14e-05	0.00923	-0.26	-0.23	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-4.31	2.14e-05	0.00923	-0.26	-0.23	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
STAD	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-4.31	2.14e-05	0.00923	-0.23	-0.23	Height;	chr2:46640019	chr2:46668870~46670778:+
STAD	cis	rs7474896	0.515	rs594594	ENSG00000120555.12	SEPT7P9	-4.31	2.14e-05	0.00923	-0.28	-0.23	Obesity (extreme);	chr10:38018795	chr10:38383069~38402916:-
STAD	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-4.31	2.14e-05	0.00923	-0.26	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
STAD	cis	rs561341	1	rs555629	ENSG00000265798.5	RP11-271K11.5	4.31	2.14e-05	0.00924	0.33	0.23	Hip circumference adjusted for BMI;	chr17:31967117	chr17:31038575~31059121:-
STAD	cis	rs561341	0.769	rs559228	ENSG00000265798.5	RP11-271K11.5	4.31	2.14e-05	0.00924	0.33	0.23	Hip circumference adjusted for BMI;	chr17:31967508	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs1681718	ENSG00000265798.5	RP11-271K11.5	4.31	2.14e-05	0.00924	0.33	0.23	Hip circumference adjusted for BMI;	chr17:31969426	chr17:31038575~31059121:-
STAD	cis	rs721917	0.525	rs4281433	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.15e-05	0.00924	-0.27	-0.23	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79663088~79826594:-
STAD	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	4.31	2.15e-05	0.00924	0.3	0.23	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
STAD	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-4.31	2.15e-05	0.00924	-0.3	-0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
STAD	cis	rs6061231	0.624	rs8668	ENSG00000275437.1	RP5-908M14.10	-4.31	2.15e-05	0.00924	-0.21	-0.23	Colorectal cancer;	chr20:62389008	chr20:62402236~62405935:-
STAD	cis	rs708547	0.581	rs6554400	ENSG00000269949.1	RP11-738E22.3	-4.31	2.15e-05	0.00924	-0.26	-0.23	Response to bleomycin (chromatid breaks);	chr4:56939140	chr4:56960927~56961373:-
STAD	cis	rs6142102	0.962	rs2206448	ENSG00000264616.1	MIR4755	4.31	2.15e-05	0.00924	0.23	0.23	Skin pigmentation;	chr20:34121719	chr20:34049119~34049190:+
STAD	cis	rs9348729	1	rs9348729	ENSG00000224843.5	LINC00240	4.31	2.15e-05	0.00925	0.32	0.23	Intelligence (multi-trait analysis);	chr6:26664040	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs1104871	ENSG00000224843.5	LINC00240	4.31	2.15e-05	0.00925	0.32	0.23	Intelligence (multi-trait analysis);	chr6:26665007	chr6:26956992~27023924:+
STAD	cis	rs2034650	0.563	rs12914710	ENSG00000223313.1	RNU6-516P	4.31	2.15e-05	0.00925	0.25	0.23	Interstitial lung disease;	chr15:40421650	chr15:40529570~40529673:+
STAD	cis	rs2695743	0.647	rs1946814	ENSG00000225808.1	DNAJC19P5	-4.31	2.15e-05	0.00926	-0.26	-0.23	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177814949	chr2:177229191~177229506:-
STAD	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-4.31	2.15e-05	0.00926	-0.25	-0.23	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
STAD	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	4.31	2.15e-05	0.00926	0.27	0.23	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
STAD	cis	rs935334	1	rs4899586	ENSG00000258454.1	RP11-361H10.3	4.31	2.15e-05	0.00926	0.32	0.23	Blood pressure;	chr14:76194513	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs11159183	ENSG00000258454.1	RP11-361H10.3	4.31	2.15e-05	0.00926	0.32	0.23	Blood pressure;	chr14:76196559	chr14:76235817~76263474:+
STAD	cis	rs11098499	0.954	rs11722872	ENSG00000260091.1	RP11-33B1.4	4.31	2.15e-05	0.00926	0.22	0.23	Corneal astigmatism;	chr4:119311875	chr4:119409333~119410233:+
STAD	cis	rs4604732	0.642	rs6426252	ENSG00000227135.1	GCSAML-AS1	-4.31	2.15e-05	0.00927	-0.28	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476585	chr1:247524679~247526752:-
STAD	cis	rs9733	0.596	rs12077833	ENSG00000274963.1	Metazoa_SRP	4.31	2.15e-05	0.00927	0.2	0.23	Tonsillectomy;	chr1:150701857	chr1:150568971~150569269:-
STAD	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	4.31	2.15e-05	0.00927	0.27	0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
STAD	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	4.31	2.16e-05	0.00928	0.29	0.23	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
STAD	cis	rs10851478	0.872	rs12908635	ENSG00000259545.2	RP11-325E5.4	-4.31	2.16e-05	0.00928	-0.26	-0.23	Oral cavity cancer;	chr15:49563723	chr15:49177610~49178741:-
STAD	cis	rs1799949	0.827	rs74252763	ENSG00000279602.1	CTD-3014M21.1	4.31	2.16e-05	0.00928	0.3	0.23	Menopause (age at onset);	chr17:43324652	chr17:43360041~43361361:-
STAD	cis	rs9926664	0.591	rs305083	ENSG00000274134.1	MIR6774	4.31	2.16e-05	0.00928	0.3	0.23	Neutrophil count;Sum basophil neutrophil counts;	chr16:85902272	chr16:85918347~85918416:+
STAD	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-4.31	2.16e-05	0.00929	-0.4	-0.23	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
STAD	cis	rs1850744	0.536	rs10014408	ENSG00000250268.3	ALG1L14P	-4.31	2.16e-05	0.00929	-0.5	-0.23	Economic and political preferences;	chr4:9693521	chr4:9166297~9170270:-
STAD	cis	rs858239	0.699	rs1881201	ENSG00000230042.1	AK3P3	4.31	2.16e-05	0.00929	0.25	0.23	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23129178~23129841:+
STAD	cis	rs539514	0.664	rs1323712	ENSG00000261105.4	LMO7-AS1	4.31	2.16e-05	0.00929	0.28	0.23	Type 1 diabetes;	chr13:75725949	chr13:75604700~75635994:-
STAD	cis	rs4589258	0.689	rs7113980	ENSG00000280367.1	RP11-121L10.2	4.31	2.16e-05	0.00929	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90728625	chr11:90223153~90226538:+
STAD	cis	rs1707322	0.65	rs4553239	ENSG00000225447.1	RPS15AP10	4.31	2.16e-05	0.0093	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45645816~45646197:-
STAD	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-4.31	2.16e-05	0.0093	-0.26	-0.23	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
STAD	cis	rs950881	0.932	rs72823621	ENSG00000234389.1	AC007278.3	4.31	2.16e-05	0.0093	0.31	0.23	Allergy;	chr2:102308975	chr2:102438713~102440475:+
STAD	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	4.31	2.16e-05	0.0093	0.27	0.23	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
STAD	cis	rs875971	0.862	rs7798630	ENSG00000224316.1	RP11-479O9.2	-4.31	2.16e-05	0.0093	-0.22	-0.23	Aortic root size;	chr7:66306492	chr7:65773620~65802067:+
STAD	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-4.31	2.16e-05	0.0093	-0.22	-0.23	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
STAD	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-4.31	2.16e-05	0.0093	-0.22	-0.23	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
STAD	cis	rs9733	0.596	rs12063547	ENSG00000274963.1	Metazoa_SRP	-4.31	2.16e-05	0.0093	-0.2	-0.23	Tonsillectomy;	chr1:150701577	chr1:150568971~150569269:-
STAD	cis	rs2957692	0.548	rs61878587	ENSG00000254554.1	RP11-351I24.1	4.31	2.16e-05	0.00931	0.38	0.23	Circulating vasoactive peptide levels;	chr11:10092733	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs12421931	ENSG00000254554.1	RP11-351I24.1	4.31	2.16e-05	0.00931	0.38	0.23	Circulating vasoactive peptide levels;	chr11:10093178	chr11:10302657~10303704:-
STAD	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-4.31	2.16e-05	0.00931	-0.22	-0.23	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
STAD	cis	rs4713118	0.614	rs9380007	ENSG00000280107.1	AL022393.9	-4.31	2.17e-05	0.00931	-0.27	-0.23	Parkinson's disease;	chr6:27692729	chr6:28170845~28172521:+
STAD	cis	rs1707322	0.789	rs7540578	ENSG00000281133.1	AL355480.3	-4.31	2.17e-05	0.00932	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45580892~45580996:-
STAD	cis	rs6669008	1	rs6669008	ENSG00000232450.1	RP4-730K3.3	-4.31	2.17e-05	0.00932	-0.24	-0.23	Bacteremia;	chr1:113623939	chr1:113698884~113699631:-
STAD	cis	rs7829975	0.742	rs1533058	ENSG00000233609.3	RP11-62H7.2	4.31	2.17e-05	0.00932	0.24	0.23	Mood instability;	chr8:8827680	chr8:8961200~8979025:+
STAD	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	4.31	2.17e-05	0.00932	0.3	0.23	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
STAD	cis	rs4388249	0.861	rs34387996	ENSG00000271849.1	CTC-332L22.1	-4.31	2.17e-05	0.00932	-0.33	-0.23	Schizophrenia;	chr5:109730763	chr5:109687802~109688329:-
STAD	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	4.31	2.17e-05	0.00932	0.25	0.23	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	4.31	2.17e-05	0.00932	0.25	0.23	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
STAD	cis	rs9733	0.566	rs112967224	ENSG00000274963.1	Metazoa_SRP	4.31	2.17e-05	0.00932	0.2	0.23	Tonsillectomy;	chr1:150704787	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72702552	ENSG00000274963.1	Metazoa_SRP	4.31	2.17e-05	0.00932	0.2	0.23	Tonsillectomy;	chr1:150704986	chr1:150568971~150569269:-
STAD	cis	rs5753618	0.555	rs5749286	ENSG00000236132.1	CTA-440B3.1	-4.31	2.17e-05	0.00933	-0.25	-0.23	Colorectal cancer;	chr22:31504373	chr22:31816379~31817491:-
STAD	cis	rs7202877	0.706	rs4993971	ENSG00000261783.1	RP11-252K23.2	4.31	2.17e-05	0.00933	0.37	0.23	Type 1 diabetes;Type 2 diabetes;	chr16:75377736	chr16:75379818~75381260:-
STAD	cis	rs11098499	0.863	rs10030660	ENSG00000260091.1	RP11-33B1.4	4.31	2.17e-05	0.00933	0.22	0.23	Corneal astigmatism;	chr4:119515549	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs13149407	ENSG00000260091.1	RP11-33B1.4	4.31	2.17e-05	0.00933	0.22	0.23	Corneal astigmatism;	chr4:119516670	chr4:119409333~119410233:+
STAD	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	4.31	2.17e-05	0.00933	0.27	0.23	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	4.31	2.17e-05	0.00933	0.27	0.23	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	4.31	2.17e-05	0.00933	0.27	0.23	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
STAD	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	4.31	2.17e-05	0.00933	0.31	0.23	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
STAD	cis	rs11846409	0.86	rs1858692	ENSG00000274576.2	IGHV2-70	4.31	2.17e-05	0.00934	0.28	0.23	Rheumatic heart disease;	chr14:106622776	chr14:106770577~106771020:-
STAD	cis	rs2836974	0.602	rs2836987	ENSG00000238141.2	BRWD1-AS1	-4.31	2.17e-05	0.00934	-0.24	-0.23	Cognitive function;	chr21:39334668	chr21:39315707~39323218:+
STAD	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-4.31	2.17e-05	0.00934	-0.34	-0.23	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
STAD	cis	rs11235843	0.853	rs1869433	ENSG00000255928.1	RP11-456I15.2	4.31	2.18e-05	0.00935	0.39	0.23	Hand grip strength;	chr11:73828498	chr11:73722349~73722694:+
STAD	cis	rs9393777	0.623	rs34313099	ENSG00000241549.7	GUSBP2	4.31	2.18e-05	0.00935	0.31	0.23	Intelligence (multi-trait analysis);	chr6:26489379	chr6:26871484~26956554:-
STAD	cis	rs7131987	0.65	rs10843382	ENSG00000275476.1	RP11-996F15.4	-4.31	2.18e-05	0.00935	-0.25	-0.23	QT interval;	chr12:29298788	chr12:29277397~29277882:-
STAD	cis	rs7829975	0.56	rs56094035	ENSG00000254340.1	RP11-10A14.3	-4.31	2.18e-05	0.00935	-0.31	-0.23	Mood instability;	chr8:8694112	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.539	rs4841012	ENSG00000254340.1	RP11-10A14.3	-4.31	2.18e-05	0.00935	-0.31	-0.23	Mood instability;	chr8:8694200	chr8:9141424~9145435:+
STAD	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-4.31	2.18e-05	0.00936	-0.26	-0.23	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
STAD	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-4.3	2.18e-05	0.00936	-0.35	-0.23	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
STAD	cis	rs4713118	0.591	rs2056924	ENSG00000280107.1	AL022393.9	-4.3	2.18e-05	0.00936	-0.28	-0.23	Parkinson's disease;	chr6:27722395	chr6:28170845~28172521:+
STAD	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	4.3	2.18e-05	0.00936	0.29	0.23	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
STAD	cis	rs4691139	1	rs10517825	ENSG00000248632.1	RP11-366M4.11	-4.3	2.18e-05	0.00936	-0.22	-0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:164972334	chr4:164968587~164970002:-
STAD	cis	rs11169552	0.51	rs4768893	ENSG00000200183.1	RNU6-238P	-4.3	2.18e-05	0.00937	-0.22	-0.23	Colorectal cancer;	chr12:50566697	chr12:50656973~50657078:+
STAD	cis	rs7103648	0.712	rs10838703	ENSG00000280615.1	Y_RNA	4.3	2.18e-05	0.00937	0.24	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47401310	chr11:47614898~47614994:-
STAD	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	4.3	2.18e-05	0.00937	0.27	0.23	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	4.3	2.18e-05	0.00937	0.27	0.23	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
STAD	cis	rs2337406	0.539	rs2583290	ENSG00000211970.3	IGHV4-61	-4.3	2.18e-05	0.00937	-0.24	-0.23	Alzheimer's disease (late onset);	chr14:106650277	chr14:106639119~106639657:-
STAD	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-4.3	2.18e-05	0.00937	-0.4	-0.23	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
STAD	cis	rs1707322	0.752	rs6662164	ENSG00000281133.1	AL355480.3	-4.3	2.18e-05	0.00937	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45580892~45580996:-
STAD	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	4.3	2.18e-05	0.00938	0.29	0.23	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	4.3	2.18e-05	0.00938	0.29	0.23	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	4.3	2.18e-05	0.00938	0.29	0.23	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
STAD	cis	rs5769707	0.632	rs1476037	ENSG00000280224.1	CTA-722E9.1	-4.3	2.18e-05	0.00938	-0.26	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49500568~49501585:+
STAD	cis	rs9859260	0.614	rs493661	ENSG00000185485.13	SDHAP1	-4.3	2.18e-05	0.00938	-0.23	-0.23	Mean corpuscular volume;	chr3:196059618	chr3:195959748~195990318:-
STAD	cis	rs1707322	0.721	rs4559551	ENSG00000225447.1	RPS15AP10	4.3	2.18e-05	0.00938	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45645816~45646197:-
STAD	cis	rs12908161	0.959	rs11637728	ENSG00000259295.5	CSPG4P12	4.3	2.18e-05	0.00938	0.33	0.23	Schizophrenia;	chr15:84660161	chr15:85191438~85213905:+
STAD	cis	rs2115536	1	rs11637477	ENSG00000278600.1	RP11-81A1.6	-4.3	2.18e-05	0.00938	-0.19	-0.23	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79900953	chr15:79920195~79922455:-
STAD	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-4.3	2.18e-05	0.00938	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
STAD	cis	rs3733418	1	rs3733419	ENSG00000248632.1	RP11-366M4.11	4.3	2.18e-05	0.00938	0.26	0.23	Obesity-related traits;	chr4:164957018	chr4:164968587~164970002:-
STAD	cis	rs72791417	0.826	rs1941988	ENSG00000228065.9	LINC01515	-4.3	2.19e-05	0.00939	-0.4	-0.23	Bronchopulmonary dysplasia;	chr10:65961263	chr10:65570338~65768835:+
STAD	cis	rs11638815	0.581	rs2870965	ENSG00000255769.6	GOLGA2P10	-4.3	2.19e-05	0.00939	-0.26	-0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:82472993~82513950:-
STAD	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-4.3	2.19e-05	0.00939	-0.25	-0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
STAD	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	4.3	2.19e-05	0.00939	0.34	0.23	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
STAD	cis	rs11673344	0.523	rs2562605	ENSG00000267672.1	CTD-2293H3.1	4.3	2.19e-05	0.00939	0.21	0.23	Obesity-related traits;	chr19:37029302	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs2562607	ENSG00000267672.1	CTD-2293H3.1	4.3	2.19e-05	0.00939	0.21	0.23	Obesity-related traits;	chr19:37031358	chr19:37091341~37092564:+
STAD	cis	rs1850744	0.826	rs4554078	ENSG00000250268.3	ALG1L14P	-4.3	2.19e-05	0.00939	-0.51	-0.23	Economic and political preferences;	chr4:9699920	chr4:9166297~9170270:-
STAD	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	4.3	2.19e-05	0.00939	0.24	0.23	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
STAD	cis	rs11098499	0.954	rs6849561	ENSG00000260091.1	RP11-33B1.4	-4.3	2.19e-05	0.00939	-0.22	-0.23	Corneal astigmatism;	chr4:119488539	chr4:119409333~119410233:+
STAD	cis	rs2836974	0.644	rs2836982	ENSG00000238141.2	BRWD1-AS1	-4.3	2.19e-05	0.0094	-0.24	-0.23	Cognitive function;	chr21:39317245	chr21:39315707~39323218:+
STAD	cis	rs2404602	0.692	rs1867197	ENSG00000259422.1	RP11-593F23.1	-4.3	2.19e-05	0.00941	-0.23	-0.23	Blood metabolite levels;	chr15:76617690	chr15:76174891~76181486:-
STAD	cis	rs4589258	0.788	rs6483070	ENSG00000280367.1	RP11-121L10.2	4.3	2.19e-05	0.00941	0.22	0.23	Intelligence (multi-trait analysis);	chr11:90736024	chr11:90223153~90226538:+
STAD	cis	rs1707322	1	rs10890350	ENSG00000281133.1	AL355480.3	-4.3	2.19e-05	0.00941	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45580892~45580996:-
STAD	cis	rs4780355	0.776	rs9936459	ENSG00000262703.1	RP11-485G7.6	-4.3	2.19e-05	0.00941	-0.21	-0.23	Crohn's disease and psoriasis;	chr16:11343922	chr16:11348143~11349321:-
STAD	cis	rs1707322	1	rs34444543	ENSG00000225447.1	RPS15AP10	4.3	2.19e-05	0.00941	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45645816~45646197:-
STAD	cis	rs8012947	1	rs6573199	ENSG00000279636.2	LINC00216	-4.3	2.19e-05	0.00942	-0.22	-0.23	Alcohol consumption in current drinkers;	chr14:58318063	chr14:58288033~58289158:+
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000211959.2	IGHV4-39	4.3	2.19e-05	0.00942	0.2	0.23	Kawasaki disease;	chr14:106808609	chr14:106421711~106422218:-
STAD	cis	rs6585424	0.925	rs11201964	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.19e-05	0.00942	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80171611	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs11201966	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.19e-05	0.00942	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172024	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs11201972	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.19e-05	0.00942	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172924	chr10:79663088~79826594:-
STAD	cis	rs12468226	1	rs13389798	ENSG00000226261.1	AC064836.3	4.3	2.2e-05	0.00942	0.36	0.23	Urate levels;	chr2:202348370	chr2:202336024~202336727:-
STAD	cis	rs561341	0.941	rs8066156	ENSG00000265798.5	RP11-271K11.5	4.3	2.2e-05	0.00942	0.29	0.23	Hip circumference adjusted for BMI;	chr17:32034610	chr17:31038575~31059121:-
STAD	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-4.3	2.2e-05	0.00942	-0.26	-0.23	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
STAD	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-4.3	2.2e-05	0.00942	-0.27	-0.23	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
STAD	cis	rs6019512	0.625	rs4810885	ENSG00000227431.4	CSE1L-AS1	-4.3	2.2e-05	0.00943	-0.21	-0.23	Intelligence (multi-trait analysis);	chr20:48906417	chr20:49040463~49046044:-
STAD	cis	rs34779708	0.966	rs4934735	ENSG00000271335.4	RP11-324I22.4	-4.3	2.2e-05	0.00943	-0.26	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35314552~35336401:-
STAD	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	4.3	2.2e-05	0.00943	0.34	0.23	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
STAD	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-4.3	2.2e-05	0.00943	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
STAD	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-4.3	2.2e-05	0.00943	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
STAD	cis	rs6496667	0.632	rs6496658	ENSG00000259262.1	NDUFA3P4	4.3	2.2e-05	0.00943	0.28	0.23	Rheumatoid arthritis;	chr15:90340873	chr15:90385814~90386063:+
STAD	cis	rs4648045	0.565	rs11733749	ENSG00000230069.3	LRRC37A15P	-4.3	2.2e-05	0.00944	-0.26	-0.23	Lymphocyte percentage of white cells;	chr4:102625985	chr4:102727274~102730721:-
STAD	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-4.3	2.2e-05	0.00944	-0.26	-0.23	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
STAD	cis	rs2688608	0.592	rs12253482	ENSG00000272140.2	RP11-574K11.29	4.3	2.2e-05	0.00944	0.2	0.23	Inflammatory bowel disease;	chr10:73736372	chr10:73703735~73713581:-
STAD	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-4.3	2.2e-05	0.00945	-0.26	-0.23	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
STAD	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	4.3	2.2e-05	0.00945	0.29	0.23	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.913	rs10010696	ENSG00000260091.1	RP11-33B1.4	4.3	2.2e-05	0.00945	0.22	0.23	Corneal astigmatism;	chr4:119243148	chr4:119409333~119410233:+
STAD	cis	rs9733	0.596	rs17658705	ENSG00000274963.1	Metazoa_SRP	-4.3	2.2e-05	0.00945	-0.2	-0.23	Tonsillectomy;	chr1:150705595	chr1:150568971~150569269:-
STAD	cis	rs9733	0.566	rs72702554	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150705758	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs11586422	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150706882	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72702557	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150707654	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs17606613	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150710539	chr1:150568971~150569269:-
STAD	cis	rs9733	0.543	rs72702558	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150710775	chr1:150568971~150569269:-
STAD	cis	rs9733	0.628	rs11807409	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150710947	chr1:150568971~150569269:-
STAD	cis	rs9733	0.565	rs11804276	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150713285	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs12072339	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150713623	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs34600506	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150715332	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72702570	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150715720	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs11582840	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150716011	chr1:150568971~150569269:-
STAD	cis	rs9733	0.569	rs11588404	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150716053	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72702573	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150716574	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72702580	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150718809	chr1:150568971~150569269:-
STAD	cis	rs9733	0.525	rs11584184	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150723213	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs6669369	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150723416	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs6681990	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150723453	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs6692960	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150723489	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72702585	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150723951	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs12086472	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150725234	chr1:150568971~150569269:-
STAD	cis	rs9733	0.628	rs7540874	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150730187	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs1136808	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150730241	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs1415148	ENSG00000274963.1	Metazoa_SRP	4.3	2.2e-05	0.00945	0.2	0.23	Tonsillectomy;	chr1:150733279	chr1:150568971~150569269:-
STAD	cis	rs8099594	0.64	rs9789092	ENSG00000266696.1	RP11-30L3.2	-4.3	2.2e-05	0.00945	-0.22	-0.23	Height;	chr18:49303096	chr18:49205912~49208781:+
STAD	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-4.3	2.2e-05	0.00945	-0.26	-0.23	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-4.3	2.2e-05	0.00945	-0.26	-0.23	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-4.3	2.2e-05	0.00945	-0.26	-0.23	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
STAD	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	4.3	2.2e-05	0.00945	0.33	0.23	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
STAD	cis	rs2638953	0.924	rs11524516	ENSG00000247934.4	RP11-967K21.1	-4.3	2.2e-05	0.00945	-0.26	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209517	chr12:28163298~28190738:-
STAD	cis	rs301901	1	rs300049	ENSG00000250155.1	CTD-2353F22.1	-4.3	2.2e-05	0.00945	-0.23	-0.23	Height;	chr5:37083971	chr5:36666214~36725195:-
STAD	cis	rs606458	0.764	rs7938455	ENSG00000269038.1	AP001462.6	-4.3	2.2e-05	0.00945	-0.31	-0.23	Urate levels;	chr11:64757309	chr11:64778954~64779405:+
STAD	cis	rs9463078	0.625	rs7742360	ENSG00000219384.1	RP11-491H9.3	4.3	2.2e-05	0.00945	0.22	0.23	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45030955	chr6:45158870~45159511:+
STAD	cis	rs9847710	0.967	rs2564931	ENSG00000242142.1	SERBP1P3	4.3	2.2e-05	0.00945	0.22	0.23	Ulcerative colitis;	chr3:52986543	chr3:53064283~53065091:-
STAD	cis	rs6832769	1	rs4580704	ENSG00000272969.1	RP11-528I4.2	-4.3	2.2e-05	0.00945	-0.28	-0.23	Personality dimensions;	chr4:55460540	chr4:55547112~55547889:+
STAD	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-4.3	2.21e-05	0.00946	-0.26	-0.23	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
STAD	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	4.3	2.21e-05	0.00946	0.29	0.23	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
STAD	cis	rs858239	0.899	rs2268747	ENSG00000230042.1	AK3P3	-4.3	2.21e-05	0.00946	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23129178~23129841:+
STAD	cis	rs8028182	0.636	rs11634863	ENSG00000260269.4	CTD-2323K18.1	-4.3	2.21e-05	0.00946	-0.29	-0.23	Sudden cardiac arrest;	chr15:75474331	chr15:75527150~75601205:-
STAD	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-4.3	2.21e-05	0.00946	-0.24	-0.23	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
STAD	cis	rs8062405	1	rs72793811	ENSG00000278665.1	RP11-666O2.4	4.3	2.21e-05	0.00947	0.26	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28599241~28601881:-
STAD	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	4.3	2.21e-05	0.00947	0.42	0.23	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
STAD	cis	rs2337406	0.778	rs58113768	ENSG00000280411.1	IGHV1-69-2	-4.3	2.21e-05	0.00947	-0.29	-0.23	Alzheimer's disease (late onset);	chr14:106700213	chr14:106762092~106762588:-
STAD	cis	rs2337406	1	rs75651733	ENSG00000280411.1	IGHV1-69-2	-4.3	2.21e-05	0.00947	-0.29	-0.23	Alzheimer's disease (late onset);	chr14:106701309	chr14:106762092~106762588:-
STAD	cis	rs1823874	0.71	rs56160817	ENSG00000182397.13	DNM1P46	-4.3	2.21e-05	0.00948	-0.24	-0.23	IgG glycosylation;	chr15:99820472	chr15:99790156~99806927:-
STAD	cis	rs1823874	0.677	rs56096943	ENSG00000182397.13	DNM1P46	-4.3	2.21e-05	0.00948	-0.24	-0.23	IgG glycosylation;	chr15:99820513	chr15:99790156~99806927:-
STAD	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	4.3	2.21e-05	0.00948	0.25	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
STAD	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	4.3	2.21e-05	0.00948	0.3	0.23	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
STAD	cis	rs1707322	1	rs11211235	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.893	rs9919275	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211236	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4660328	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.928	rs61785614	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs9793167	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211237	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs11211238	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4460583	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs4459051	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211239	ENSG00000281133.1	AL355480.3	-4.3	2.21e-05	0.00948	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45580892~45580996:-
STAD	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-4.3	2.21e-05	0.00949	-0.35	-0.23	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
STAD	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-4.3	2.21e-05	0.00949	-0.35	-0.23	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
STAD	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	4.3	2.21e-05	0.00949	0.34	0.23	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
STAD	cis	rs10853057	0.717	rs4791242	ENSG00000214174.7	AMZ2P1	-4.3	2.21e-05	0.00949	-0.41	-0.23	White matter microstructure (global fractional anisotropy);	chr17:65061533	chr17:64966550~64975576:-
STAD	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-4.3	2.21e-05	0.00949	-0.3	-0.23	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
STAD	cis	rs3947	0.906	rs709822	ENSG00000270154.1	RP11-419I17.1	-4.3	2.21e-05	0.00949	-0.28	-0.23	Blood protein levels;	chr8:11844804	chr8:12476462~12477122:+
STAD	cis	rs4713118	0.662	rs9357060	ENSG00000220721.1	OR1F12	4.3	2.22e-05	0.00949	0.26	0.23	Parkinson's disease;	chr6:28056708	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.662	rs9468271	ENSG00000220721.1	OR1F12	4.3	2.22e-05	0.00949	0.26	0.23	Parkinson's disease;	chr6:28056792	chr6:28073316~28074233:+
STAD	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	4.3	2.22e-05	0.0095	0.35	0.23	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
STAD	cis	rs5760092	0.755	rs4585126	ENSG00000228039.3	KB-1125A3.10	-4.3	2.22e-05	0.0095	-0.3	-0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23963780~23964374:+
STAD	cis	rs2273156	0.673	rs12887885	ENSG00000258738.1	RP11-73E17.2	-4.3	2.22e-05	0.0095	-0.31	-0.23	Immunoglobulin light chain (AL) amyloidosis;	chr14:34906876	chr14:34874343~34876459:+
STAD	cis	rs12745968	0.653	rs6660136	ENSG00000229052.2	RP11-386I23.1	-4.3	2.22e-05	0.0095	-0.21	-0.23	Bipolar disorder and schizophrenia;	chr1:92699650	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.623	rs6604007	ENSG00000229052.2	RP11-386I23.1	-4.3	2.22e-05	0.0095	-0.21	-0.23	Bipolar disorder and schizophrenia;	chr1:92705007	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.653	rs12123935	ENSG00000229052.2	RP11-386I23.1	-4.3	2.22e-05	0.0095	-0.21	-0.23	Bipolar disorder and schizophrenia;	chr1:92710257	chr1:92930696~92934098:+
STAD	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	4.3	2.22e-05	0.0095	0.29	0.23	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	4.3	2.22e-05	0.0095	0.29	0.23	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
STAD	cis	rs338389	0.609	rs338382	ENSG00000260657.2	RP11-315D16.4	-4.3	2.22e-05	0.00951	-0.27	-0.23	Survival in rectal cancer;	chr15:67952045	chr15:68267792~68277994:-
STAD	cis	rs4691139	0.582	rs4133108	ENSG00000248632.1	RP11-366M4.11	4.3	2.22e-05	0.00951	0.22	0.23	Ovarian cancer in BRCA1 mutation carriers;	chr4:165031283	chr4:164968587~164970002:-
STAD	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	4.3	2.22e-05	0.00951	0.32	0.23	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
STAD	cis	rs1348850	0.872	rs10165785	ENSG00000271825.1	RP11-337N6.2	4.3	2.22e-05	0.00951	0.19	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177428567	chr2:177300600~177302006:+
STAD	cis	rs8062405	0.929	rs11150609	ENSG00000278665.1	RP11-666O2.4	4.3	2.22e-05	0.00951	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28599241~28601881:-
STAD	cis	rs5770917	1	rs2269381	ENSG00000273272.1	CTA-384D8.34	4.3	2.22e-05	0.00952	0.43	0.23	Narcolepsy;	chr22:50581640	chr22:50542650~50543011:+
STAD	cis	rs10073892	0.62	rs10068654	ENSG00000250682.4	LINC00491	-4.3	2.22e-05	0.00952	-0.25	-0.23	Cognitive decline (age-related);	chr5:102643593	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.66	rs1961737	ENSG00000250682.4	LINC00491	-4.3	2.22e-05	0.00952	-0.25	-0.23	Cognitive decline (age-related);	chr5:102646075	chr5:102609156~102671559:-
STAD	cis	rs1707322	0.896	rs785512	ENSG00000225447.1	RPS15AP10	-4.3	2.22e-05	0.00952	-0.17	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45645816~45646197:-
STAD	cis	rs7208859	0.623	rs7220999	ENSG00000263603.1	CTD-2349P21.5	-4.3	2.22e-05	0.00952	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs55638872	ENSG00000263603.1	CTD-2349P21.5	-4.3	2.22e-05	0.00952	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs9899268	ENSG00000263603.1	CTD-2349P21.5	-4.3	2.22e-05	0.00952	-0.28	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30729469~30731202:+
STAD	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	4.3	2.22e-05	0.00952	0.24	0.23	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
STAD	cis	rs12745968	0.623	rs6680578	ENSG00000229052.2	RP11-386I23.1	-4.3	2.22e-05	0.00952	-0.21	-0.23	Bipolar disorder and schizophrenia;	chr1:92711321	chr1:92930696~92934098:+
STAD	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-4.3	2.22e-05	0.00953	-0.26	-0.23	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
STAD	cis	rs1816752	0.646	rs750389	ENSG00000273628.1	RP11-756A22.7	-4.3	2.23e-05	0.00953	-0.27	-0.23	Obesity-related traits;	chr13:24461677	chr13:24933006~24936796:+
STAD	cis	rs12500234	0.934	rs12644913	ENSG00000249207.1	RP11-360F5.1	-4.3	2.23e-05	0.00954	-0.23	-0.23	Colorectal cancer;	chr4:39615158	chr4:39112677~39126818:-
STAD	cis	rs34779708	0.931	rs11592404	ENSG00000271335.4	RP11-324I22.4	4.3	2.23e-05	0.00954	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35314552~35336401:-
STAD	cis	rs1707322	0.964	rs785516	ENSG00000225447.1	RPS15AP10	-4.3	2.23e-05	0.00954	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785517	ENSG00000225447.1	RPS15AP10	-4.3	2.23e-05	0.00954	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785490	ENSG00000225447.1	RPS15AP10	-4.3	2.23e-05	0.00954	-0.18	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45645816~45646197:-
STAD	cis	rs11098499	0.865	rs28634456	ENSG00000260091.1	RP11-33B1.4	4.3	2.23e-05	0.00955	0.23	0.23	Corneal astigmatism;	chr4:119454623	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs78332141	ENSG00000260091.1	RP11-33B1.4	4.3	2.23e-05	0.00955	0.23	0.23	Corneal astigmatism;	chr4:119454627	chr4:119409333~119410233:+
STAD	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	4.3	2.23e-05	0.00955	0.27	0.23	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
STAD	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	4.3	2.23e-05	0.00955	0.24	0.23	Depression;	chr6:28386473	chr6:28176188~28176674:+
STAD	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	4.3	2.23e-05	0.00955	0.24	0.23	Depression;	chr6:28391932	chr6:28176188~28176674:+
STAD	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	4.3	2.23e-05	0.00955	0.24	0.23	Depression;	chr6:28399846	chr6:28176188~28176674:+
STAD	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	4.3	2.23e-05	0.00955	0.27	0.23	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	4.3	2.23e-05	0.00955	0.27	0.23	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	4.3	2.23e-05	0.00955	0.27	0.23	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	4.3	2.23e-05	0.00955	0.27	0.23	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
STAD	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	4.3	2.23e-05	0.00956	0.35	0.23	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
STAD	cis	rs4589258	0.737	rs4633421	ENSG00000280367.1	RP11-121L10.2	-4.3	2.23e-05	0.00956	-0.22	-0.23	Intelligence (multi-trait analysis);	chr11:90666189	chr11:90223153~90226538:+
STAD	cis	rs2657294	0.62	rs7475340	ENSG00000233313.2	HMGA1P5	-4.3	2.23e-05	0.00956	-0.29	-0.23	Pneumonia;	chr10:75079597	chr10:75276376~75276646:-
STAD	cis	rs6142102	1	rs12480839	ENSG00000264616.1	MIR4755	4.3	2.24e-05	0.00957	0.23	0.23	Skin pigmentation;	chr20:34139624	chr20:34049119~34049190:+
STAD	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	4.3	2.24e-05	0.00957	0.32	0.23	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
STAD	cis	rs6430585	0.583	rs1435577	ENSG00000231890.6	DARS-AS1	-4.3	2.24e-05	0.00957	-0.26	-0.23	Corneal structure;	chr2:135867377	chr2:135985176~136022593:+
STAD	cis	rs13392177	0.637	rs61041183	ENSG00000237281.1	CATIP-AS2	-4.3	2.24e-05	0.00957	-0.23	-0.23	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218326889~218357966:-
STAD	cis	rs4589258	1	rs10741371	ENSG00000280367.1	RP11-121L10.2	4.3	2.24e-05	0.00958	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90766985	chr11:90223153~90226538:+
STAD	cis	rs6432852	1	rs12692787	ENSG00000229195.1	AC009495.4	4.3	2.24e-05	0.00958	0.26	0.23	Diabetic kidney disease;	chr2:165897642	chr2:165794857~165846091:-
STAD	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	4.3	2.24e-05	0.00958	0.33	0.23	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
STAD	cis	rs2564921	0.57	rs3821831	ENSG00000280417.1	RP11-5O17.1	4.3	2.24e-05	0.00958	0.25	0.23	Height;	chr3:52819385	chr3:53046166~53048122:+
STAD	cis	rs4780355	0.877	rs243317	ENSG00000262703.1	RP11-485G7.6	-4.3	2.24e-05	0.00958	-0.21	-0.23	Crohn's disease and psoriasis;	chr16:11263474	chr16:11348143~11349321:-
STAD	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-4.3	2.24e-05	0.00959	-0.19	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
STAD	cis	rs1850744	0.702	rs10805314	ENSG00000250268.3	ALG1L14P	-4.3	2.24e-05	0.00959	-0.5	-0.23	Economic and political preferences;	chr4:9701557	chr4:9166297~9170270:-
STAD	cis	rs11673344	0.523	rs2562609	ENSG00000267672.1	CTD-2293H3.1	4.3	2.24e-05	0.00959	0.21	0.23	Obesity-related traits;	chr19:37036255	chr19:37091341~37092564:+
STAD	cis	rs3811273	0.614	rs10150341	ENSG00000211816.2	TRAV38-1	-4.3	2.24e-05	0.00959	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22267213	chr14:22271968~22272563:+
STAD	cis	rs3811273	0.614	rs10150343	ENSG00000211816.2	TRAV38-1	-4.3	2.24e-05	0.00959	-0.28	-0.23	Periodontal disease-related phenotypes;	chr14:22267219	chr14:22271968~22272563:+
STAD	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	4.3	2.24e-05	0.00959	0.24	0.23	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
STAD	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-4.3	2.24e-05	0.00959	-0.26	-0.23	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-4.3	2.24e-05	0.00959	-0.26	-0.23	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-4.3	2.24e-05	0.00959	-0.26	-0.23	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
STAD	cis	rs4589258	0.872	rs34255967	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90680820	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs55643244	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90681713	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs7113248	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90683781	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs2155068	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90684654	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs11824840	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90684770	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.898	rs11019143	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90685464	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.864	rs12575846	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90685654	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.864	rs7119442	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90689706	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.83	rs7942616	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90691083	chr11:90223153~90226538:+
STAD	cis	rs7948975	1	rs7948975	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Educational attainment (years of education);	chr11:90691470	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.898	rs35469130	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90692792	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs7118269	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90694072	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.898	rs1792593	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90694461	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs2508414	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90695404	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1783809	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90696083	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1792613	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90696421	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1783806	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90696964	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.933	rs1632631	ENSG00000280367.1	RP11-121L10.2	-4.3	2.24e-05	0.00959	-0.25	-0.23	Intelligence (multi-trait analysis);	chr11:90697654	chr11:90223153~90226538:+
STAD	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-4.3	2.24e-05	0.0096	-0.31	-0.23	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
STAD	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	4.3	2.25e-05	0.0096	0.29	0.23	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
STAD	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	4.3	2.25e-05	0.0096	0.22	0.23	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
STAD	cis	rs7829975	0.774	rs57312668	ENSG00000233609.3	RP11-62H7.2	4.3	2.25e-05	0.0096	0.24	0.23	Mood instability;	chr8:8822967	chr8:8961200~8979025:+
STAD	cis	rs1075265	0.84	rs805309	ENSG00000235937.1	AC008280.1	4.3	2.25e-05	0.00961	0.2	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54029552~54030682:-
STAD	cis	rs1707322	1	rs785498	ENSG00000281133.1	AL355480.3	4.3	2.25e-05	0.00961	0.26	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45580892~45580996:-
STAD	cis	rs2034650	0.563	rs11070270	ENSG00000223313.1	RNU6-516P	-4.3	2.25e-05	0.00961	-0.24	-0.23	Interstitial lung disease;	chr15:40416223	chr15:40529570~40529673:+
STAD	cis	rs7429990	0.864	rs1014228	ENSG00000224895.1	VPS26BP1	4.3	2.25e-05	0.00961	0.21	0.23	Educational attainment (years of education);	chr3:47611149	chr3:47960327~47961081:-
STAD	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	4.3	2.25e-05	0.00961	0.27	0.23	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
STAD	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	4.3	2.25e-05	0.00961	0.23	0.23	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
STAD	cis	rs1707322	0.927	rs6690386	ENSG00000281133.1	AL355480.3	-4.3	2.25e-05	0.00962	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs4630155	ENSG00000281133.1	AL355480.3	-4.3	2.25e-05	0.00962	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45580892~45580996:-
STAD	cis	rs6471393	0.964	rs2914953	ENSG00000253848.1	RP11-10N23.5	4.3	2.25e-05	0.00962	0.26	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93730122	chr8:93741193~93744534:+
STAD	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-4.3	2.25e-05	0.00962	-0.29	-0.23	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
STAD	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-4.3	2.25e-05	0.00962	-0.29	-0.23	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
STAD	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	4.3	2.25e-05	0.00963	0.21	0.23	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
STAD	cis	rs6430585	0.583	rs2322813	ENSG00000231890.6	DARS-AS1	-4.3	2.25e-05	0.00963	-0.26	-0.23	Corneal structure;	chr2:135825239	chr2:135985176~136022593:+
STAD	cis	rs1150668	0.796	rs213236	ENSG00000220721.1	OR1F12	4.3	2.25e-05	0.00963	0.22	0.23	Pubertal anthropometrics;	chr6:28356620	chr6:28073316~28074233:+
STAD	cis	rs919433	1	rs6741380	ENSG00000231621.1	AC013264.2	-4.3	2.25e-05	0.00964	-0.19	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197300397	chr2:197197991~197199273:+
STAD	cis	rs9902453	0.935	rs7220151	ENSG00000240074.1	RPL9P30	-4.3	2.26e-05	0.00964	-0.19	-0.23	Coffee consumption (cups per day);	chr17:30007692	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.838	rs7217638	ENSG00000240074.1	RPL9P30	-4.3	2.26e-05	0.00964	-0.19	-0.23	Coffee consumption (cups per day);	chr17:30009754	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs9912741	ENSG00000240074.1	RPL9P30	-4.3	2.26e-05	0.00964	-0.19	-0.23	Coffee consumption (cups per day);	chr17:30032493	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs9891871	ENSG00000240074.1	RPL9P30	-4.3	2.26e-05	0.00964	-0.19	-0.23	Coffee consumption (cups per day);	chr17:30043173	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.967	rs6505155	ENSG00000240074.1	RPL9P30	-4.3	2.26e-05	0.00964	-0.19	-0.23	Coffee consumption (cups per day);	chr17:30045765	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs9890205	ENSG00000240074.1	RPL9P30	-4.3	2.26e-05	0.00964	-0.19	-0.23	Coffee consumption (cups per day);	chr17:30055686	chr17:29855759~29856332:+
STAD	cis	rs449789	0.857	rs10455775	ENSG00000235086.1	FNDC1-IT1	-4.3	2.26e-05	0.00964	-0.3	-0.23	Pulse pressure;	chr6:159302689	chr6:159240786~159243329:+
STAD	cis	rs9902453	0.935	rs9898424	ENSG00000240074.1	RPL9P30	-4.3	2.26e-05	0.00964	-0.19	-0.23	Coffee consumption (cups per day);	chr17:30065928	chr17:29855759~29856332:+
STAD	cis	rs2836950	0.565	rs2836945	ENSG00000238141.2	BRWD1-AS1	-4.3	2.26e-05	0.00964	-0.23	-0.23	Menarche (age at onset);	chr21:39224831	chr21:39315707~39323218:+
STAD	cis	rs1707322	1	rs11211223	ENSG00000225447.1	RPS15AP10	4.3	2.26e-05	0.00964	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4298677	ENSG00000225447.1	RPS15AP10	4.3	2.26e-05	0.00965	0.18	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45645816~45646197:-
STAD	cis	rs4589258	1	rs10741363	ENSG00000280367.1	RP11-121L10.2	4.3	2.26e-05	0.00966	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90751632	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.966	rs10765386	ENSG00000280367.1	RP11-121L10.2	4.3	2.26e-05	0.00966	0.24	0.23	Intelligence (multi-trait analysis);	chr11:90752813	chr11:90223153~90226538:+
STAD	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	4.3	2.26e-05	0.00966	0.35	0.23	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
STAD	cis	rs1816752	0.692	rs6490944	ENSG00000273628.1	RP11-756A22.7	-4.3	2.26e-05	0.00966	-0.27	-0.23	Obesity-related traits;	chr13:24513866	chr13:24933006~24936796:+
STAD	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-4.3	2.26e-05	0.00966	-0.32	-0.23	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
STAD	cis	rs9902453	0.845	rs7501472	ENSG00000240074.1	RPL9P30	4.3	2.26e-05	0.00967	0.19	0.23	Coffee consumption (cups per day);	chr17:29683610	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.808	rs1986555	ENSG00000240074.1	RPL9P30	4.3	2.26e-05	0.00967	0.19	0.23	Coffee consumption (cups per day);	chr17:29687430	chr17:29855759~29856332:+
STAD	cis	rs748404	0.631	rs28702649	ENSG00000275601.1	AC011330.13	-4.3	2.26e-05	0.00967	-0.23	-0.23	Lung cancer;	chr15:43356431	chr15:43642389~43643023:-
STAD	cis	rs6951245	0.706	rs1133116	ENSG00000229043.2	AC091729.9	-4.3	2.26e-05	0.00967	-0.35	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1160374~1165267:+
STAD	cis	rs3770081	1	rs58365138	ENSG00000273080.1	RP11-301O19.1	-4.3	2.26e-05	0.00967	-0.53	-0.23	Facial emotion recognition (sad faces);	chr2:85985982	chr2:86195590~86196049:+
STAD	cis	rs11098499	0.863	rs34868248	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119521275	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3733525	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119525893	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3775847	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119526487	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3775848	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119526569	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs10013305	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119529269	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs3775849	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119529753	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.818	rs7688802	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119530513	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs7695620	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119531621	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs12502389	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119533036	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.821	rs3775852	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119533401	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.82	rs6534140	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119534156	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs7657849	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119534339	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs10034450	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119534494	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs1480939	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119535772	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs1480940	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119536527	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs6835635	ENSG00000260091.1	RP11-33B1.4	4.3	2.26e-05	0.00967	0.22	0.23	Corneal astigmatism;	chr4:119537712	chr4:119409333~119410233:+
STAD	cis	rs494453	0.922	rs2477428	ENSG00000234020.1	CHIAP3	-4.3	2.27e-05	0.00967	-0.22	-0.23	Osteoporosis-related phenotypes;	chr1:111671634	chr1:111353275~111367409:-
STAD	cis	rs6571943	0.517	rs10134241	ENSG00000258526.4	RP11-111A21.1	-4.3	2.27e-05	0.00967	-0.26	-0.23	Verbal memory performance (residualized delayed recall level);	chr14:39553759	chr14:39474840~39513780:+
STAD	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-4.3	2.27e-05	0.00967	-0.26	-0.23	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-4.3	2.27e-05	0.00967	-0.26	-0.23	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
STAD	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-4.3	2.27e-05	0.00968	-0.26	-0.23	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
STAD	cis	rs7647973	0.516	rs4536858	ENSG00000225399.4	RP11-3B7.1	4.3	2.27e-05	0.00968	0.25	0.23	Menarche (age at onset);	chr3:49155648	chr3:49260085~49261316:+
STAD	cis	rs4713118	0.869	rs9283883	ENSG00000243307.2	POM121L6P	-4.3	2.27e-05	0.00969	-0.26	-0.22	Parkinson's disease;	chr6:27747691	chr6:26896952~26898777:+
STAD	cis	rs944722	0.651	rs4293436	ENSG00000266786.1	LGALS9DP	4.3	2.27e-05	0.00969	0.28	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27737916	chr17:27746132~27754954:+
STAD	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	4.3	2.27e-05	0.0097	0.29	0.22	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
STAD	cis	rs938554	0.692	rs6449213	ENSG00000250613.1	RP11-136I13.1	4.3	2.27e-05	0.0097	0.26	0.22	Blood metabolite levels;	chr4:9992591	chr4:10410996~10411644:+
STAD	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	4.29	2.27e-05	0.0097	0.33	0.22	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
STAD	cis	rs950881	0.932	rs72823635	ENSG00000234389.1	AC007278.3	4.29	2.27e-05	0.0097	0.31	0.22	Allergy;	chr2:102315152	chr2:102438713~102440475:+
STAD	cis	rs950881	1	rs950881	ENSG00000234389.1	AC007278.3	4.29	2.27e-05	0.0097	0.31	0.22	Allergy;	chr2:102316052	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs10179458	ENSG00000234389.1	AC007278.3	4.29	2.27e-05	0.0097	0.31	0.22	Allergy;	chr2:102318514	chr2:102438713~102440475:+
STAD	cis	rs422249	0.634	rs174617	ENSG00000279632.1	RP11-286N22.6	4.29	2.27e-05	0.0097	0.23	0.22	Trans fatty acid levels;	chr11:61861694	chr11:61426448~61427325:-
STAD	cis	rs1707322	1	rs12097761	ENSG00000281133.1	AL355480.3	-4.29	2.28e-05	0.00971	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs6429581	ENSG00000281133.1	AL355480.3	-4.29	2.28e-05	0.00971	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45580892~45580996:-
STAD	cis	rs6571943	0.517	rs10483536	ENSG00000258526.4	RP11-111A21.1	-4.29	2.28e-05	0.00972	-0.26	-0.22	Verbal memory performance (residualized delayed recall level);	chr14:39557694	chr14:39474840~39513780:+
STAD	cis	rs720475	0.732	rs62483106	ENSG00000244198.4	RP4-545C24.1	-4.29	2.28e-05	0.00972	-0.29	-0.22	Breast cancer;	chr7:144439533	chr7:144194858~144280547:+
STAD	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-4.29	2.28e-05	0.00973	-0.26	-0.22	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-4.29	2.28e-05	0.00973	-0.26	-0.22	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-4.29	2.28e-05	0.00973	-0.26	-0.22	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-4.29	2.28e-05	0.00973	-0.26	-0.22	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-4.29	2.28e-05	0.00973	-0.26	-0.22	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
STAD	cis	rs11098499	0.691	rs10028773	ENSG00000260091.1	RP11-33B1.4	-4.29	2.28e-05	0.00973	-0.21	-0.22	Corneal astigmatism;	chr4:119344104	chr4:119409333~119410233:+
STAD	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-4.29	2.28e-05	0.00974	-0.47	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
STAD	cis	rs10129255	0.5	rs988134	ENSG00000224373.3	IGHV4-59	4.29	2.28e-05	0.00974	0.16	0.22	Kawasaki disease;	chr14:106776698	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000224373.3	IGHV4-59	4.29	2.28e-05	0.00974	0.16	0.22	Kawasaki disease;	chr14:106776724	chr14:106627249~106627825:-
STAD	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	4.29	2.28e-05	0.00974	0.24	0.22	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	4.29	2.28e-05	0.00974	0.24	0.22	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	4.29	2.28e-05	0.00974	0.24	0.22	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
STAD	cis	rs7208859	0.524	rs8065744	ENSG00000263603.1	CTD-2349P21.5	-4.29	2.29e-05	0.00974	-0.29	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.706	rs8071236	ENSG00000263603.1	CTD-2349P21.5	-4.29	2.29e-05	0.00974	-0.29	-0.22	Body mass index;	chr17:30772984	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.636	rs2449770	ENSG00000263603.1	CTD-2349P21.5	-4.29	2.29e-05	0.00974	-0.29	-0.22	Body mass index;	chr17:30774046	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.524	rs59913838	ENSG00000263603.1	CTD-2349P21.5	-4.29	2.29e-05	0.00974	-0.29	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs56163556	ENSG00000263603.1	CTD-2349P21.5	-4.29	2.29e-05	0.00974	-0.29	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.623	rs8067338	ENSG00000263603.1	CTD-2349P21.5	-4.29	2.29e-05	0.00974	-0.29	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.573	rs4055105	ENSG00000263603.1	CTD-2349P21.5	-4.29	2.29e-05	0.00974	-0.29	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30729469~30731202:+
STAD	cis	rs1075265	0.783	rs6545376	ENSG00000235937.1	AC008280.1	4.29	2.29e-05	0.00975	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54029552~54030682:-
STAD	cis	rs11239930	0.538	rs17160592	ENSG00000278811.3	LINC00624	4.29	2.29e-05	0.00975	0.23	0.22	AIDS progression;	chr1:147083644	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.538	rs56060937	ENSG00000278811.3	LINC00624	4.29	2.29e-05	0.00975	0.23	0.22	AIDS progression;	chr1:147083854	chr1:147258885~147517875:-
STAD	cis	rs4568518	0.803	rs13232648	ENSG00000279048.1	RP11-511H23.2	4.29	2.29e-05	0.00975	0.2	0.22	Measles;	chr7:17992618	chr7:17940503~17942922:+
STAD	cis	rs11700536	1	rs2839636	ENSG00000236663.1	AP001631.9	4.29	2.29e-05	0.00975	0.28	0.22	Interleukin-18 levels;	chr21:43139085	chr21:43140523~43141092:-
STAD	cis	rs1707322	1	rs11211217	ENSG00000281133.1	AL355480.3	-4.29	2.29e-05	0.00976	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45580892~45580996:-
STAD	cis	rs11846409	0.932	rs2015469	ENSG00000211970.3	IGHV4-61	4.29	2.29e-05	0.00976	0.24	0.22	Rheumatic heart disease;	chr14:106631857	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs56167903	ENSG00000211970.3	IGHV4-61	4.29	2.29e-05	0.00976	0.24	0.22	Rheumatic heart disease;	chr14:106632070	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.86	rs10150951	ENSG00000211970.3	IGHV4-61	4.29	2.29e-05	0.00976	0.24	0.22	Rheumatic heart disease;	chr14:106632988	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.86	rs17112419	ENSG00000211970.3	IGHV4-61	4.29	2.29e-05	0.00976	0.24	0.22	Rheumatic heart disease;	chr14:106633260	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs2583329	ENSG00000211970.3	IGHV4-61	-4.29	2.29e-05	0.00976	-0.24	-0.22	Rheumatic heart disease;	chr14:106632971	chr14:106639119~106639657:-
STAD	cis	rs10129255	0.518	rs11847766	ENSG00000224373.3	IGHV4-59	4.29	2.29e-05	0.00976	0.16	0.22	Kawasaki disease;	chr14:106779186	chr14:106627249~106627825:-
STAD	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	4.29	2.29e-05	0.00976	0.36	0.22	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
STAD	cis	rs6585424	0.929	rs12256429	ENSG00000225484.5	NUTM2B-AS1	-4.29	2.29e-05	0.00976	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178876	chr10:79663088~79826594:-
STAD	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	4.29	2.29e-05	0.00976	0.46	0.22	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
STAD	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	4.29	2.29e-05	0.00977	0.3	0.22	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
STAD	cis	rs7671266	0.589	rs10938772	ENSG00000250613.1	RP11-136I13.1	4.29	2.29e-05	0.00977	0.25	0.22	Cardiovascular disease risk factors;	chr4:10373704	chr4:10410996~10411644:+
STAD	cis	rs7615952	0.673	rs9821905	ENSG00000241346.1	SNRPCP11	-4.29	2.29e-05	0.00978	-0.38	-0.22	Blood pressure (smoking interaction);	chr3:125902007	chr3:125816082~125816286:-
STAD	cis	rs748404	0.631	rs11070399	ENSG00000275601.1	AC011330.13	-4.29	2.3e-05	0.00978	-0.23	-0.22	Lung cancer;	chr15:43354149	chr15:43642389~43643023:-
STAD	cis	rs7487075	0.79	rs4074773	ENSG00000272963.1	OR7A19P	-4.29	2.3e-05	0.00978	-0.21	-0.22	Itch intensity from mosquito bite;	chr12:46525398	chr12:46592573~46593305:+
STAD	cis	rs9902453	1	rs57411618	ENSG00000240074.1	RPL9P30	4.29	2.3e-05	0.00979	0.19	0.22	Coffee consumption (cups per day);	chr17:29946034	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs7222308	ENSG00000240074.1	RPL9P30	4.29	2.3e-05	0.00979	0.19	0.22	Coffee consumption (cups per day);	chr17:29950023	chr17:29855759~29856332:+
STAD	cis	rs2921073	0.509	rs2976931	ENSG00000254340.1	RP11-10A14.3	4.29	2.3e-05	0.00979	0.26	0.22	Parkinson's disease;	chr8:8399807	chr8:9141424~9145435:+
STAD	cis	rs1823874	0.71	rs55947799	ENSG00000182397.13	DNM1P46	-4.29	2.3e-05	0.00979	-0.24	-0.22	IgG glycosylation;	chr15:99820700	chr15:99790156~99806927:-
STAD	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	4.29	2.3e-05	0.00979	0.27	0.22	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
STAD	cis	rs228614	0.51	rs223311	ENSG00000248971.2	KRT8P46	-4.29	2.3e-05	0.0098	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102728746~102730171:-
STAD	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	4.29	2.3e-05	0.0098	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
STAD	cis	rs7824557	0.564	rs35009431	ENSG00000205879.4	FAM90A2P	-4.29	2.3e-05	0.0098	-0.25	-0.22	Retinal vascular caliber;	chr8:11375279	chr8:12172202~12178575:-
STAD	cis	rs2446066	0.659	rs11170566	ENSG00000257379.1	RP11-793H13.8	4.29	2.3e-05	0.0098	0.45	0.22	Red blood cell count;	chr12:53513283	chr12:53441741~53467528:+
STAD	cis	rs1348850	0.914	rs12693120	ENSG00000271825.1	RP11-337N6.2	4.29	2.3e-05	0.00981	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177418560	chr2:177300600~177302006:+
STAD	cis	rs494453	0.922	rs476515	ENSG00000234020.1	CHIAP3	-4.29	2.3e-05	0.00981	-0.22	-0.22	Osteoporosis-related phenotypes;	chr1:111672454	chr1:111353275~111367409:-
STAD	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	4.29	2.3e-05	0.00981	0.29	0.22	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
STAD	cis	rs875971	1	rs3981131	ENSG00000236529.1	RP13-254B10.1	4.29	2.31e-05	0.00982	0.24	0.22	Aortic root size;	chr7:66486690	chr7:65840212~65840596:+
STAD	cis	rs12571093	0.571	rs10762205	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68290145	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs10740294	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68301595	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs4363487	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68301809	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs10762214	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68302555	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs12769008	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68302836	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs61857263	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68303370	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.614	rs7067601	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68304213	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs10733843	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68304752	chr10:68233251~68242379:-
STAD	cis	rs12571093	0.571	rs10823175	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68306024	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs4746759	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68306040	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs4746760	ENSG00000233590.1	RP11-153K11.3	4.29	2.31e-05	0.00982	0.31	0.22	Optic nerve measurement (disc area);	chr10:68306122	chr10:68233251~68242379:-
STAD	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	4.29	2.31e-05	0.00982	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
STAD	cis	rs227275	0.525	rs724446	ENSG00000248971.2	KRT8P46	-4.29	2.31e-05	0.00982	-0.23	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102728746~102730171:-
STAD	cis	rs227275	0.554	rs223314	ENSG00000248971.2	KRT8P46	-4.29	2.31e-05	0.00982	-0.23	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs7254	ENSG00000248971.2	KRT8P46	-4.29	2.31e-05	0.00982	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102728746~102730171:-
STAD	cis	rs11722779	0.566	rs6822658	ENSG00000248971.2	KRT8P46	-4.29	2.31e-05	0.00982	-0.23	-0.22	Schizophrenia;	chr4:102891964	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs6823625	ENSG00000248971.2	KRT8P46	-4.29	2.31e-05	0.00982	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs6846762	ENSG00000248971.2	KRT8P46	-4.29	2.31e-05	0.00982	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs4699032	ENSG00000248971.2	KRT8P46	-4.29	2.31e-05	0.00982	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102728746~102730171:-
STAD	cis	rs7078219	0.505	rs10883365	ENSG00000257582.4	LINC01475	-4.29	2.31e-05	0.00982	-0.25	-0.22	Dental caries;	chr10:99528007	chr10:99526350~99531177:-
STAD	cis	rs2688608	0.618	rs28553894	ENSG00000272140.2	RP11-574K11.29	4.29	2.31e-05	0.00982	0.2	0.22	Inflammatory bowel disease;	chr10:73730085	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.618	rs28718766	ENSG00000272140.2	RP11-574K11.29	4.29	2.31e-05	0.00982	0.2	0.22	Inflammatory bowel disease;	chr10:73730086	chr10:73703735~73713581:-
STAD	cis	rs950881	0.932	rs10189154	ENSG00000234389.1	AC007278.3	4.29	2.31e-05	0.00982	0.31	0.22	Allergy;	chr2:102321084	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs10189526	ENSG00000234389.1	AC007278.3	4.29	2.31e-05	0.00982	0.31	0.22	Allergy;	chr2:102321423	chr2:102438713~102440475:+
STAD	cis	rs10865050	1	rs10865050	ENSG00000234389.1	AC007278.3	4.29	2.31e-05	0.00982	0.31	0.22	Allergic disease (asthma, hay fever or eczema);	chr2:102324851	chr2:102438713~102440475:+
STAD	cis	rs1799949	0.929	rs799906	ENSG00000279602.1	CTD-3014M21.1	4.29	2.31e-05	0.00982	0.27	0.22	Menopause (age at onset);	chr17:43126099	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs799908	ENSG00000279602.1	CTD-3014M21.1	4.29	2.31e-05	0.00982	0.27	0.22	Menopause (age at onset);	chr17:43126899	chr17:43360041~43361361:-
STAD	cis	rs2739330	0.796	rs5760106	ENSG00000272787.1	KB-226F1.2	4.29	2.31e-05	0.00982	0.23	0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23969211~23969873:+
STAD	cis	rs10129255	0.957	rs6576233	ENSG00000211973.2	IGHV1-69	4.29	2.31e-05	0.00983	0.21	0.22	Kawasaki disease;	chr14:106787239	chr14:106714684~106715181:-
STAD	cis	rs5753618	0.555	rs5749286	ENSG00000202019.1	Y_RNA	-4.29	2.31e-05	0.00983	-0.3	-0.22	Colorectal cancer;	chr22:31504373	chr22:31230071~31230172:-
STAD	cis	rs4589258	0.762	rs4497368	ENSG00000280367.1	RP11-121L10.2	-4.29	2.31e-05	0.00983	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90672802	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs7947495	ENSG00000280367.1	RP11-121L10.2	-4.29	2.31e-05	0.00983	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90673352	chr11:90223153~90226538:+
STAD	cis	rs1707322	1	rs1707337	ENSG00000225447.1	RPS15AP10	-4.29	2.31e-05	0.00983	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs1768807	ENSG00000225447.1	RPS15AP10	-4.29	2.31e-05	0.00983	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45645816~45646197:-
STAD	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-4.29	2.31e-05	0.00983	-0.48	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
STAD	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	4.29	2.31e-05	0.00983	0.27	0.22	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
STAD	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-4.29	2.31e-05	0.00983	-0.33	-0.22	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
STAD	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-4.29	2.31e-05	0.00983	-0.33	-0.22	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
STAD	cis	rs2638953	0.886	rs11049465	ENSG00000247934.4	RP11-967K21.1	-4.29	2.31e-05	0.00984	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28212086	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7980441	ENSG00000247934.4	RP11-967K21.1	-4.29	2.31e-05	0.00984	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28214748	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs11049470	ENSG00000247934.4	RP11-967K21.1	-4.29	2.31e-05	0.00984	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28221449	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs10843140	ENSG00000247934.4	RP11-967K21.1	-4.29	2.31e-05	0.00984	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227273	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049472	ENSG00000247934.4	RP11-967K21.1	-4.29	2.31e-05	0.00984	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28229772	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.888	rs2061760	ENSG00000247934.4	RP11-967K21.1	-4.29	2.31e-05	0.00984	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28234492	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs11049474	ENSG00000247934.4	RP11-967K21.1	-4.29	2.31e-05	0.00984	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28235512	chr12:28163298~28190738:-
STAD	cis	rs1075265	0.729	rs7571086	ENSG00000235937.1	AC008280.1	4.29	2.31e-05	0.00984	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54029552~54030682:-
STAD	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	4.29	2.31e-05	0.00984	0.27	0.22	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
STAD	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	4.29	2.32e-05	0.00985	0.3	0.22	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
STAD	cis	rs8028182	0.636	rs7495610	ENSG00000260269.4	CTD-2323K18.1	-4.29	2.32e-05	0.00985	-0.28	-0.22	Sudden cardiac arrest;	chr15:75492100	chr15:75527150~75601205:-
STAD	cis	rs6585424	1	rs6585424	ENSG00000225484.5	NUTM2B-AS1	-4.29	2.32e-05	0.00985	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173992	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs56190825	ENSG00000225484.5	NUTM2B-AS1	-4.29	2.32e-05	0.00985	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80174980	chr10:79663088~79826594:-
STAD	cis	rs2695743	0.592	rs7568068	ENSG00000225808.1	DNAJC19P5	-4.29	2.32e-05	0.00985	-0.26	-0.22	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177811194	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs934800	ENSG00000225808.1	DNAJC19P5	-4.29	2.32e-05	0.00985	-0.26	-0.22	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177811874	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.592	rs934801	ENSG00000225808.1	DNAJC19P5	-4.29	2.32e-05	0.00985	-0.26	-0.22	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177812177	chr2:177229191~177229506:-
STAD	cis	rs1850744	0.609	rs2037315	ENSG00000250942.1	ENPP7P11	4.29	2.32e-05	0.00986	0.44	0.22	Economic and political preferences;	chr4:9720784	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.536	rs2037313	ENSG00000250942.1	ENPP7P11	4.29	2.32e-05	0.00986	0.44	0.22	Economic and political preferences;	chr4:9723087	chr4:9677308~9677934:+
STAD	cis	rs8177876	0.642	rs56032321	ENSG00000261838.4	RP11-303E16.6	4.29	2.32e-05	0.00986	0.49	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81069854~81076598:+
STAD	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	4.29	2.32e-05	0.00986	0.3	0.22	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	4.29	2.32e-05	0.00986	0.3	0.22	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
STAD	cis	rs72615157	0.628	rs7801070	ENSG00000242294.5	STAG3L5P	4.29	2.32e-05	0.00986	0.22	0.22	Lung function (FEV1/FVC);	chr7:100249524	chr7:100336079~100351900:+
STAD	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	4.29	2.32e-05	0.00986	0.29	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
STAD	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	4.29	2.32e-05	0.00986	0.29	0.22	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
STAD	cis	rs4234798	0.5	rs7661077	ENSG00000202392.1	RN7SKP292	-4.29	2.32e-05	0.00986	-0.27	-0.22	Insulin-like growth factors;	chr4:7218162	chr4:6997012~6997328:+
STAD	cis	rs1707322	0.716	rs10890342	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00986	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs6658700	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00986	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs12047629	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00986	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs11211169	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00986	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45580892~45580996:-
STAD	cis	rs6565180	0.888	rs12447833	ENSG00000273724.1	RP11-347C12.12	4.29	2.32e-05	0.00986	0.24	0.22	Tonsillectomy;	chr16:30378993	chr16:30336400~30343336:+
STAD	cis	rs1823913	1	rs10445782	ENSG00000280083.1	RP11-317J9.1	4.29	2.32e-05	0.00986	0.28	0.22	Obesity-related traits;	chr2:191236639	chr2:191154118~191156070:-
STAD	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	4.29	2.32e-05	0.00987	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
STAD	cis	rs9902453	0.578	rs8073217	ENSG00000240074.1	RPL9P30	4.29	2.32e-05	0.00987	0.19	0.22	Coffee consumption (cups per day);	chr17:29837245	chr17:29855759~29856332:+
STAD	cis	rs1707322	1	rs1707303	ENSG00000281133.1	AL355480.3	4.29	2.32e-05	0.00987	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45580892~45580996:-
STAD	cis	rs9368481	0.761	rs12661756	ENSG00000224843.5	LINC00240	-4.29	2.32e-05	0.00987	-0.26	-0.22	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26956992~27023924:+
STAD	cis	rs8062405	1	rs72793812	ENSG00000278665.1	RP11-666O2.4	4.29	2.32e-05	0.00987	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28599241~28601881:-
STAD	cis	rs1075265	0.901	rs7591194	ENSG00000235937.1	AC008280.1	-4.29	2.32e-05	0.00987	-0.2	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54029552~54030682:-
STAD	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-4.29	2.32e-05	0.00988	-0.33	-0.22	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
STAD	cis	rs11098499	1	rs28374891	ENSG00000260091.1	RP11-33B1.4	4.29	2.32e-05	0.00988	0.22	0.22	Corneal astigmatism;	chr4:119262395	chr4:119409333~119410233:+
STAD	cis	rs1707322	0.716	rs28375469	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00988	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs28545085	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00988	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs28507722	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00988	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.717	rs28396194	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00988	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.717	rs28752166	ENSG00000281133.1	AL355480.3	-4.29	2.32e-05	0.00988	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45580892~45580996:-
STAD	cis	rs9532679	0.515	rs9315801	ENSG00000229456.1	RLIMP1	4.29	2.33e-05	0.00988	0.23	0.22	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr13:41011918	chr13:40618738~40621348:+
STAD	cis	rs8141529	0.509	rs7287124	ENSG00000226471.5	CTA-292E10.6	-4.29	2.33e-05	0.00988	-0.28	-0.22	Lymphocyte counts;	chr22:28843169	chr22:28800683~28848559:+
STAD	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-4.29	2.33e-05	0.00988	-0.27	-0.22	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
STAD	cis	rs4132699	0.566	rs6559350	ENSG00000225460.1	RP13-93L13.1	-4.29	2.33e-05	0.00989	-0.26	-0.22	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89395881	chr9:89472237~89472692:+
STAD	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-4.29	2.33e-05	0.00989	-0.36	-0.22	Gout;	chr7:66642037	chr7:66654538~66669855:+
STAD	cis	rs1707322	0.964	rs785499	ENSG00000225447.1	RPS15AP10	-4.29	2.33e-05	0.00989	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45645816~45646197:-
STAD	cis	rs875971	0.895	rs12531677	ENSG00000224316.1	RP11-479O9.2	-4.29	2.33e-05	0.00989	-0.22	-0.22	Aortic root size;	chr7:66304099	chr7:65773620~65802067:+
STAD	cis	rs7131987	0.617	rs3764953	ENSG00000275476.1	RP11-996F15.4	-4.29	2.33e-05	0.0099	-0.25	-0.22	QT interval;	chr12:29349303	chr12:29277397~29277882:-
STAD	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-4.29	2.33e-05	0.0099	-0.29	-0.22	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
STAD	cis	rs8012947	1	rs8012947	ENSG00000279636.2	LINC00216	-4.29	2.33e-05	0.0099	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58317737	chr14:58288033~58289158:+
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000224373.3	IGHV4-59	4.29	2.33e-05	0.0099	0.16	0.22	Kawasaki disease;	chr14:106777494	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000224373.3	IGHV4-59	4.29	2.33e-05	0.0099	0.16	0.22	Kawasaki disease;	chr14:106777510	chr14:106627249~106627825:-
STAD	cis	rs9329221	0.683	rs525726	ENSG00000254340.1	RP11-10A14.3	-4.29	2.33e-05	0.0099	-0.28	-0.22	Neuroticism;	chr8:10030287	chr8:9141424~9145435:+
STAD	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-4.29	2.33e-05	0.0099	-0.34	-0.22	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
STAD	cis	rs6432852	1	rs7581810	ENSG00000229195.1	AC009495.4	4.29	2.33e-05	0.00991	0.26	0.22	Diabetic kidney disease;	chr2:165932455	chr2:165794857~165846091:-
STAD	cis	rs7690978	1	rs7690978	ENSG00000249717.1	RP11-44F21.3	4.29	2.33e-05	0.00991	0.27	0.22	Interferon gamma-induced protein 10 levels;	chr4:75066634	chr4:74955974~74970362:-
STAD	cis	rs11239930	0.538	rs719969	ENSG00000278811.3	LINC00624	4.29	2.33e-05	0.00991	0.23	0.22	AIDS progression;	chr1:147084111	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.538	rs4950359	ENSG00000278811.3	LINC00624	4.29	2.33e-05	0.00991	0.23	0.22	AIDS progression;	chr1:147087196	chr1:147258885~147517875:-
STAD	cis	rs7487075	0.578	rs4768119	ENSG00000257261.4	RP11-96H19.1	4.29	2.33e-05	0.00991	0.3	0.22	Itch intensity from mosquito bite;	chr12:46414119	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.578	rs4258438	ENSG00000257261.4	RP11-96H19.1	4.29	2.33e-05	0.00991	0.3	0.22	Itch intensity from mosquito bite;	chr12:46415343	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.55	rs1472179	ENSG00000257261.4	RP11-96H19.1	4.29	2.33e-05	0.00991	0.3	0.22	Itch intensity from mosquito bite;	chr12:46416731	chr12:46383679~46876159:+
STAD	cis	rs9393777	0.623	rs9358946	ENSG00000241549.7	GUSBP2	4.29	2.34e-05	0.00991	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26478699	chr6:26871484~26956554:-
STAD	cis	rs9393777	0.623	rs9358947	ENSG00000241549.7	GUSBP2	4.29	2.34e-05	0.00991	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26478772	chr6:26871484~26956554:-
STAD	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-4.29	2.34e-05	0.00992	-0.22	-0.22	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
STAD	cis	rs1950326	0.515	rs4902773	ENSG00000258526.4	RP11-111A21.1	-4.29	2.34e-05	0.00992	-0.26	-0.22	Verbal memory performance (residualized delayed recall level);	chr14:39562784	chr14:39474840~39513780:+
STAD	cis	rs4950322	0.542	rs4950382	ENSG00000278811.3	LINC00624	4.29	2.34e-05	0.00992	0.23	0.22	Protein quantitative trait loci;	chr1:147176645	chr1:147258885~147517875:-
STAD	cis	rs2688608	0.617	rs6480709	ENSG00000272140.2	RP11-574K11.29	4.29	2.34e-05	0.00993	0.2	0.22	Inflammatory bowel disease;	chr10:73719367	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.592	rs7076585	ENSG00000272140.2	RP11-574K11.29	4.29	2.34e-05	0.00993	0.2	0.22	Inflammatory bowel disease;	chr10:73743934	chr10:73703735~73713581:-
STAD	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-4.29	2.34e-05	0.00994	-0.26	-0.22	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
STAD	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-4.29	2.34e-05	0.00994	-0.32	-0.22	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
STAD	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	4.29	2.34e-05	0.00994	0.26	0.22	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
STAD	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-4.29	2.34e-05	0.00994	-0.26	-0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
STAD	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	4.29	2.34e-05	0.00994	0.29	0.22	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
STAD	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	4.29	2.34e-05	0.00994	0.31	0.22	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
STAD	cis	rs1707322	0.963	rs10890373	ENSG00000225447.1	RPS15AP10	4.29	2.35e-05	0.00995	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45645816~45646197:-
STAD	cis	rs7487075	0.897	rs7979418	ENSG00000257261.4	RP11-96H19.1	4.29	2.35e-05	0.00995	0.29	0.22	Itch intensity from mosquito bite;	chr12:46380988	chr12:46383679~46876159:+
STAD	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	4.29	2.35e-05	0.00995	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
STAD	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	4.29	2.35e-05	0.00996	0.31	0.22	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
STAD	cis	rs8099594	0.565	rs7240563	ENSG00000266696.1	RP11-30L3.2	4.29	2.35e-05	0.00996	0.21	0.22	Height;	chr18:49236812	chr18:49205912~49208781:+
STAD	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	4.29	2.35e-05	0.00996	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000211959.2	IGHV4-39	4.29	2.35e-05	0.00996	0.2	0.22	Kawasaki disease;	chr14:106807047	chr14:106421711~106422218:-
STAD	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-4.29	2.35e-05	0.00996	-0.34	-0.22	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
STAD	cis	rs1707322	1	rs10158032	ENSG00000225447.1	RPS15AP10	4.29	2.35e-05	0.00997	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45645816~45646197:-
STAD	cis	rs5753618	0.539	rs2228619	ENSG00000236132.1	CTA-440B3.1	4.29	2.35e-05	0.00997	0.26	0.22	Colorectal cancer;	chr22:31267856	chr22:31816379~31817491:-
STAD	cis	rs172166	0.61	rs276369	ENSG00000220721.1	OR1F12	4.29	2.35e-05	0.00997	0.22	0.22	Cardiac Troponin-T levels;	chr6:27951465	chr6:28073316~28074233:+
STAD	cis	rs7137301	0.963	rs10842527	ENSG00000274987.1	RP11-295I5.3	-4.29	2.35e-05	0.00998	-0.23	-0.22	Dysmenorrheic pain;	chr12:25298661	chr12:25210652~25211233:+
STAD	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	4.29	2.35e-05	0.00998	0.35	0.22	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
STAD	cis	rs11098499	1	rs35643470	ENSG00000260091.1	RP11-33B1.4	4.29	2.35e-05	0.00998	0.22	0.22	Corneal astigmatism;	chr4:119263793	chr4:119409333~119410233:+
STAD	cis	rs8062405	1	rs62036622	ENSG00000278665.1	RP11-666O2.4	4.29	2.35e-05	0.00998	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28599241~28601881:-
STAD	cis	rs1015362	0.503	rs4911371	ENSG00000275784.1	RP5-1125A11.6	-4.29	2.35e-05	0.00998	-0.27	-0.22	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33989480~33991818:-
STAD	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-4.29	2.36e-05	0.00999	-0.33	-0.22	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
STAD	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	4.29	2.36e-05	0.01	0.34	0.22	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
STAD	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	-4.29	2.36e-05	0.01	-0.25	-0.22	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
STAD	cis	rs6142102	1	rs4911409	ENSG00000264616.1	MIR4755	4.29	2.36e-05	0.01	0.23	0.22	Skin pigmentation;	chr20:34122904	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.961	rs4911411	ENSG00000264616.1	MIR4755	4.29	2.36e-05	0.01	0.23	0.22	Skin pigmentation;	chr20:34128036	chr20:34049119~34049190:+
STAD	cis	rs17507216	0.718	rs4779033	ENSG00000259429.4	UBE2Q2P2	4.29	2.36e-05	0.01	0.36	0.22	Excessive daytime sleepiness;	chr15:82576634	chr15:82355142~82420075:+
STAD	cis	rs7615952	0.611	rs7632305	ENSG00000272840.1	RP11-379B18.6	4.29	2.36e-05	0.01	0.47	0.22	Blood pressure (smoking interaction);	chr3:125915924	chr3:125774714~125797953:+
STAD	cis	rs11098499	0.955	rs4145951	ENSG00000260091.1	RP11-33B1.4	4.29	2.36e-05	0.01	0.22	0.22	Corneal astigmatism;	chr4:119234662	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs35916640	ENSG00000260091.1	RP11-33B1.4	4.29	2.36e-05	0.01	0.22	0.22	Corneal astigmatism;	chr4:119234697	chr4:119409333~119410233:+
STAD	cis	rs1850744	0.609	rs2037315	ENSG00000250268.3	ALG1L14P	-4.29	2.36e-05	0.01	-0.52	-0.22	Economic and political preferences;	chr4:9720784	chr4:9166297~9170270:-
STAD	cis	rs1850744	0.536	rs2037313	ENSG00000250268.3	ALG1L14P	-4.29	2.36e-05	0.01	-0.52	-0.22	Economic and political preferences;	chr4:9723087	chr4:9166297~9170270:-
STAD	cis	rs6142102	0.961	rs8119937	ENSG00000264616.1	MIR4755	4.29	2.36e-05	0.01	0.23	0.22	Skin pigmentation;	chr20:34057745	chr20:34049119~34049190:+
STAD	cis	rs1799949	0.896	rs33933393	ENSG00000279602.1	CTD-3014M21.1	4.29	2.36e-05	0.01	0.28	0.22	Menopause (age at onset);	chr17:43165415	chr17:43360041~43361361:-
STAD	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	4.29	2.36e-05	0.01	0.36	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
STAD	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	4.29	2.36e-05	0.01	0.36	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
STAD	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	4.29	2.36e-05	0.01	0.36	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
STAD	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	4.29	2.36e-05	0.01	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
STAD	cis	rs6686842	0.536	rs12123384	ENSG00000235358.1	RP11-399E6.1	-4.29	2.36e-05	0.01	-0.24	-0.22	Height;	chr1:41239346	chr1:41242373~41284861:+
STAD	cis	rs13401620	0.555	rs3820768	ENSG00000224789.1	AC012363.4	4.29	2.36e-05	0.01	0.27	0.22	Breast size;	chr2:120220792	chr2:120174885~120216544:-
STAD	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-4.29	2.36e-05	0.01	-0.26	-0.22	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
STAD	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-4.29	2.37e-05	0.01	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
STAD	cis	rs9747201	0.962	rs11656153	ENSG00000281517.1	Metazoa_SRP	4.29	2.37e-05	0.01	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82115074	chr17:81718849~81719095:-
STAD	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	4.29	2.37e-05	0.01	0.34	0.22	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-4.29	2.37e-05	0.01	-0.34	-0.22	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
STAD	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	4.29	2.37e-05	0.01	0.29	0.22	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
STAD	cis	rs3733585	0.605	rs4697926	ENSG00000250613.1	RP11-136I13.1	-4.29	2.37e-05	0.01	-0.22	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10122943	chr4:10410996~10411644:+
STAD	cis	rs10073892	0.66	rs2400833	ENSG00000250682.4	LINC00491	-4.29	2.37e-05	0.01	-0.25	-0.22	Cognitive decline (age-related);	chr5:102647838	chr5:102609156~102671559:-
STAD	cis	rs11098499	1	rs12506395	ENSG00000260091.1	RP11-33B1.4	4.29	2.37e-05	0.01	0.22	0.22	Corneal astigmatism;	chr4:119263939	chr4:119409333~119410233:+
STAD	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	4.29	2.37e-05	0.01	0.25	0.22	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
STAD	cis	rs7989332	0.698	rs9315620	ENSG00000238286.1	SLC35E1P1	4.29	2.37e-05	0.01	0.27	0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486906	chr13:20607268~20608131:+
STAD	cis	rs7989332	0.698	rs9315621	ENSG00000238286.1	SLC35E1P1	4.29	2.37e-05	0.01	0.27	0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486914	chr13:20607268~20608131:+
STAD	cis	rs7176527	0.579	rs366717	ENSG00000225151.9	GOLGA2P7	4.29	2.37e-05	0.01	0.29	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84199311~84230136:-
STAD	cis	rs9902453	0.845	rs62068583	ENSG00000240074.1	RPL9P30	4.29	2.37e-05	0.01	0.19	0.22	Coffee consumption (cups per day);	chr17:29674464	chr17:29855759~29856332:+
STAD	cis	rs9291683	0.668	rs2241474	ENSG00000250613.1	RP11-136I13.1	-4.29	2.37e-05	0.01	-0.21	-0.22	Bone mineral density;	chr4:10084391	chr4:10410996~10411644:+
STAD	cis	rs875971	0.862	rs10250544	ENSG00000224316.1	RP11-479O9.2	-4.29	2.37e-05	0.01	-0.22	-0.22	Aortic root size;	chr7:66301574	chr7:65773620~65802067:+
STAD	cis	rs9879311	0.866	rs775017	ENSG00000240288.6	GHRLOS	4.28	2.37e-05	0.01	0.23	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10357280	chr3:10285754~10293449:+
STAD	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-4.28	2.37e-05	0.01	-0.22	-0.22	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
STAD	cis	rs8062405	0.755	rs4787457	ENSG00000278665.1	RP11-666O2.4	4.28	2.38e-05	0.0101	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.755	rs4788080	ENSG00000278665.1	RP11-666O2.4	4.28	2.38e-05	0.0101	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28599241~28601881:-
STAD	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	4.28	2.38e-05	0.0101	0.22	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
STAD	cis	rs8028182	0.636	rs6495182	ENSG00000260269.4	CTD-2323K18.1	-4.28	2.38e-05	0.0101	-0.29	-0.22	Sudden cardiac arrest;	chr15:75522047	chr15:75527150~75601205:-
STAD	cis	rs12745968	0.653	rs2107519	ENSG00000229052.2	RP11-386I23.1	-4.28	2.38e-05	0.0101	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92727313	chr1:92930696~92934098:+
STAD	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-4.28	2.38e-05	0.0101	-0.25	-0.22	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
STAD	cis	rs2638953	0.853	rs10506037	ENSG00000247934.4	RP11-967K21.1	-4.28	2.38e-05	0.0101	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28163298~28190738:-
STAD	cis	rs7702057	0.53	rs17138834	ENSG00000271918.1	CTD-2287O16.5	-4.28	2.38e-05	0.0101	-0.4	-0.22	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116083807~116085416:-
STAD	cis	rs1707322	0.721	rs11211163	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs12037803	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs10789470	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs61784796	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs10749856	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs10890344	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs4564187	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.752	rs28438704	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs28442079	ENSG00000281133.1	AL355480.3	-4.28	2.38e-05	0.0101	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45580892~45580996:-
STAD	cis	rs8177876	0.731	rs4889227	ENSG00000261838.4	RP11-303E16.6	-4.28	2.38e-05	0.0101	-0.48	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81069854~81076598:+
STAD	cis	rs10129255	0.957	rs10136817	ENSG00000232216.1	IGHV3-43	4.28	2.39e-05	0.0101	0.23	0.22	Kawasaki disease;	chr14:106787730	chr14:106470264~106470800:-
STAD	cis	rs1799949	1	rs8070085	ENSG00000279602.1	CTD-3014M21.1	-4.28	2.39e-05	0.0101	-0.28	-0.22	Menopause (age at onset);	chr17:43189967	chr17:43360041~43361361:-
STAD	cis	rs12468226	1	rs58288071	ENSG00000226261.1	AC064836.3	4.28	2.39e-05	0.0101	0.36	0.22	Urate levels;	chr2:202350016	chr2:202336024~202336727:-
STAD	cis	rs1799949	0.965	rs7212284	ENSG00000279602.1	CTD-3014M21.1	4.28	2.39e-05	0.0101	0.27	0.22	Menopause (age at onset);	chr17:43053924	chr17:43360041~43361361:-
STAD	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-4.28	2.39e-05	0.0101	-0.35	-0.22	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
STAD	cis	rs4713118	0.869	rs6901520	ENSG00000243307.2	POM121L6P	-4.28	2.39e-05	0.0101	-0.26	-0.22	Parkinson's disease;	chr6:27746796	chr6:26896952~26898777:+
STAD	cis	rs12468226	1	rs7587234	ENSG00000226261.1	AC064836.3	4.28	2.39e-05	0.0101	0.36	0.22	Urate levels;	chr2:202351699	chr2:202336024~202336727:-
STAD	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	4.28	2.39e-05	0.0101	0.26	0.22	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
STAD	cis	rs6750795	0.569	rs1667305	ENSG00000223198.1	RNU2-22P	-4.28	2.39e-05	0.0101	-0.26	-0.22	Height;	chr2:231539118	chr2:231501990~231502201:-
STAD	cis	rs1707322	0.752	rs6662164	ENSG00000225447.1	RPS15AP10	4.28	2.39e-05	0.0101	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45645816~45646197:-
STAD	cis	rs3733418	1	rs3733418	ENSG00000248632.1	RP11-366M4.11	4.28	2.39e-05	0.0101	0.26	0.22	Obesity-related traits;	chr4:164957183	chr4:164968587~164970002:-
STAD	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	4.28	2.39e-05	0.0101	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
STAD	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	4.28	2.39e-05	0.0101	0.29	0.22	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
STAD	cis	rs7665090	0.87	rs228627	ENSG00000230069.3	LRRC37A15P	4.28	2.39e-05	0.0101	0.24	0.22	Primary biliary cholangitis;	chr4:102651925	chr4:102727274~102730721:-
STAD	cis	rs2253762	0.507	rs10159582	ENSG00000226864.1	ATE1-AS1	4.28	2.39e-05	0.0101	0.36	0.22	Breast cancer;	chr10:121993110	chr10:121928312~121951965:+
STAD	cis	rs2253762	0.507	rs10159583	ENSG00000226864.1	ATE1-AS1	4.28	2.39e-05	0.0101	0.36	0.22	Breast cancer;	chr10:121993154	chr10:121928312~121951965:+
STAD	cis	rs2253762	0.507	rs75383663	ENSG00000226864.1	ATE1-AS1	4.28	2.39e-05	0.0101	0.36	0.22	Breast cancer;	chr10:121993340	chr10:121928312~121951965:+
STAD	cis	rs4237845	0.78	rs3751331	ENSG00000273805.1	RP11-620J15.4	-4.28	2.39e-05	0.0101	-0.25	-0.22	Intelligence (multi-trait analysis);	chr12:57896495	chr12:57894232~57896846:+
STAD	cis	rs12468226	0.873	rs1474267	ENSG00000226261.1	AC064836.3	-4.28	2.39e-05	0.0101	-0.38	-0.22	Urate levels;	chr2:202178596	chr2:202336024~202336727:-
STAD	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	4.28	2.39e-05	0.0101	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
STAD	cis	rs11157436	0.56	rs2242543	ENSG00000211812.1	TRAV26-2	-4.28	2.39e-05	0.0101	-0.22	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22226436	chr14:22202583~22203368:+
STAD	cis	rs4589258	0.713	rs12795930	ENSG00000280367.1	RP11-121L10.2	-4.28	2.39e-05	0.0101	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90669864	chr11:90223153~90226538:+
STAD	cis	rs944722	1	rs4796034	ENSG00000266786.1	LGALS9DP	4.28	2.39e-05	0.0101	0.28	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27766766	chr17:27746132~27754954:+
STAD	cis	rs944722	1	rs28662210	ENSG00000266786.1	LGALS9DP	4.28	2.39e-05	0.0101	0.28	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27766838	chr17:27746132~27754954:+
STAD	cis	rs12908161	0.959	rs1051168	ENSG00000259295.5	CSPG4P12	4.28	2.4e-05	0.0101	0.32	0.22	Schizophrenia;	chr15:84657289	chr15:85191438~85213905:+
STAD	cis	rs13401620	0.555	rs2018962	ENSG00000224789.1	AC012363.4	4.28	2.4e-05	0.0101	0.27	0.22	Breast size;	chr2:120217026	chr2:120174885~120216544:-
STAD	cis	rs9902453	0.817	rs59420007	ENSG00000240074.1	RPL9P30	4.28	2.4e-05	0.0101	0.19	0.22	Coffee consumption (cups per day);	chr17:29869096	chr17:29855759~29856332:+
STAD	cis	rs2384207	0.818	rs7962969	ENSG00000277566.1	RP11-545P7.9	-4.28	2.4e-05	0.0101	-0.31	-0.22	Response to fenofibrate (adiponectin levels);	chr12:113236656	chr12:113249466~113250042:+
STAD	cis	rs228614	0.51	rs223358	ENSG00000248971.2	KRT8P46	-4.28	2.4e-05	0.0101	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102728746~102730171:-
STAD	cis	rs2733201	1	rs1426658	ENSG00000205771.5	CATSPER2P1	4.28	2.4e-05	0.0101	0.39	0.22	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44046721	chr15:43726918~43747094:-
STAD	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-4.28	2.4e-05	0.0101	-0.33	-0.22	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
STAD	cis	rs2836950	0.585	rs1029004	ENSG00000238141.2	BRWD1-AS1	-4.28	2.4e-05	0.0101	-0.23	-0.22	Menarche (age at onset);	chr21:39243417	chr21:39315707~39323218:+
STAD	cis	rs2562456	0.833	rs516519	ENSG00000268119.4	CTD-2561J22.5	-4.28	2.4e-05	0.0101	-0.28	-0.22	Pain;	chr19:21298730	chr19:21444241~21463908:-
STAD	cis	rs7631605	0.576	rs6806158	ENSG00000236411.1	NDUFAF4P3	-4.28	2.4e-05	0.0101	-0.23	-0.22	Cerebrospinal P-tau181p levels;	chr3:36924576	chr3:37789921~37790445:-
STAD	cis	rs1799949	1	rs2298862	ENSG00000279602.1	CTD-3014M21.1	4.28	2.4e-05	0.0101	0.29	0.22	Menopause (age at onset);	chr17:43024671	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.93	rs2298861	ENSG00000279602.1	CTD-3014M21.1	4.28	2.4e-05	0.0101	0.29	0.22	Menopause (age at onset);	chr17:43024814	chr17:43360041~43361361:-
STAD	cis	rs6471393	0.964	rs2976366	ENSG00000253848.1	RP11-10N23.5	-4.28	2.4e-05	0.0101	-0.26	-0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93708829	chr8:93741193~93744534:+
STAD	cis	rs422249	0.634	rs174616	ENSG00000279632.1	RP11-286N22.6	4.28	2.4e-05	0.0101	0.22	0.22	Trans fatty acid levels;	chr11:61861650	chr11:61426448~61427325:-
STAD	cis	rs9902453	0.838	rs8064689	ENSG00000240074.1	RPL9P30	4.28	2.4e-05	0.0102	0.19	0.22	Coffee consumption (cups per day);	chr17:29890035	chr17:29855759~29856332:+
STAD	cis	rs228614	0.51	rs223356	ENSG00000248971.2	KRT8P46	-4.28	2.4e-05	0.0102	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223353	ENSG00000248971.2	KRT8P46	-4.28	2.4e-05	0.0102	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102728746~102730171:-
STAD	cis	rs228614	0.51	rs223352	ENSG00000248971.2	KRT8P46	-4.28	2.4e-05	0.0102	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102728746~102730171:-
STAD	cis	rs7120173	0.779	rs7103842	ENSG00000254851.1	RP11-109L13.1	-4.28	2.41e-05	0.0102	-0.34	-0.22	Visceral adipose tissue adjusted for BMI;	chr11:117087312	chr11:117135528~117138582:+
STAD	cis	rs17401966	0.838	rs8019	ENSG00000199562.1	RNU6-37P	4.28	2.41e-05	0.0102	0.17	0.22	Hepatocellular carcinoma;	chr1:10306429	chr1:10298966~10299072:+
STAD	cis	rs7615952	0.611	rs2971298	ENSG00000241346.1	SNRPCP11	4.28	2.41e-05	0.0102	0.39	0.22	Blood pressure (smoking interaction);	chr3:125883870	chr3:125816082~125816286:-
STAD	cis	rs2992257	0.958	rs2281	ENSG00000251839.1	RNU7-12P	-4.28	2.41e-05	0.0102	-0.23	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26442372	chr10:27232255~27232316:-
STAD	cis	rs2992257	0.871	rs3006805	ENSG00000251839.1	RNU7-12P	-4.28	2.41e-05	0.0102	-0.23	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26443902	chr10:27232255~27232316:-
STAD	cis	rs2992257	1	rs2992257	ENSG00000251839.1	RNU7-12P	-4.28	2.41e-05	0.0102	-0.23	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26445658	chr10:27232255~27232316:-
STAD	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	4.28	2.41e-05	0.0102	0.28	0.22	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	4.28	2.41e-05	0.0102	0.28	0.22	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	4.28	2.41e-05	0.0102	0.28	0.22	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
STAD	cis	rs1075265	0.756	rs1075264	ENSG00000235937.1	AC008280.1	4.28	2.41e-05	0.0102	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54029552~54030682:-
STAD	cis	rs6142102	1	rs6059681	ENSG00000275784.1	RP5-1125A11.6	-4.28	2.41e-05	0.0102	-0.23	-0.22	Skin pigmentation;	chr20:34135535	chr20:33989480~33991818:-
STAD	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	4.28	2.41e-05	0.0102	0.24	0.22	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
STAD	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
STAD	cis	rs935334	1	rs4903386	ENSG00000258454.1	RP11-361H10.3	4.28	2.42e-05	0.0102	0.32	0.22	Blood pressure;	chr14:76203315	chr14:76235817~76263474:+
STAD	cis	rs1426063	0.614	rs75345649	ENSG00000249717.1	RP11-44F21.3	4.28	2.42e-05	0.0102	0.47	0.22	QT interval;	chr4:75100963	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs77333523	ENSG00000249717.1	RP11-44F21.3	4.28	2.42e-05	0.0102	0.47	0.22	QT interval;	chr4:75101024	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs17199632	ENSG00000249717.1	RP11-44F21.3	4.28	2.42e-05	0.0102	0.47	0.22	QT interval;	chr4:75103663	chr4:74955974~74970362:-
STAD	cis	rs1426063	0.614	rs76931926	ENSG00000249717.1	RP11-44F21.3	4.28	2.42e-05	0.0102	0.47	0.22	QT interval;	chr4:75106902	chr4:74955974~74970362:-
STAD	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	4.28	2.42e-05	0.0102	0.32	0.22	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
STAD	cis	rs10129255	0.518	rs10136903	ENSG00000224373.3	IGHV4-59	4.28	2.42e-05	0.0102	0.16	0.22	Kawasaki disease;	chr14:106778866	chr14:106627249~106627825:-
STAD	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-4.28	2.42e-05	0.0102	-0.32	-0.22	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
STAD	cis	rs1075265	0.87	rs6724389	ENSG00000235937.1	AC008280.1	4.28	2.42e-05	0.0102	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54029552~54030682:-
STAD	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-4.28	2.42e-05	0.0102	-0.23	-0.22	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
STAD	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-4.28	2.42e-05	0.0102	-0.23	-0.22	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
STAD	cis	rs4713118	0.539	rs200951	ENSG00000280107.1	AL022393.9	-4.28	2.42e-05	0.0102	-0.29	-0.22	Parkinson's disease;	chr6:27868152	chr6:28170845~28172521:+
STAD	cis	rs12908161	1	rs58416181	ENSG00000259295.5	CSPG4P12	4.28	2.42e-05	0.0102	0.32	0.22	Schizophrenia;	chr15:84721230	chr15:85191438~85213905:+
STAD	cis	rs1707322	0.685	rs28617418	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.682	rs28490344	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs28501477	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs28641748	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs6697821	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs4330955	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.691	rs12031182	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs10430123	ENSG00000281133.1	AL355480.3	-4.28	2.42e-05	0.0102	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45580892~45580996:-
STAD	cis	rs1799949	0.965	rs9911630	ENSG00000279602.1	CTD-3014M21.1	4.28	2.42e-05	0.0102	0.28	0.22	Menopause (age at onset);	chr17:43036325	chr17:43360041~43361361:-
STAD	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	4.28	2.42e-05	0.0102	0.36	0.22	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
STAD	cis	rs17301013	0.897	rs1793291	ENSG00000227373.4	RP11-160H22.5	-4.28	2.42e-05	0.0102	-0.28	-0.22	Systemic lupus erythematosus;	chr1:174822675	chr1:174115300~174160004:-
STAD	cis	rs41411047	0.702	rs57740238	ENSG00000224831.3	RP11-651P23.4	-4.28	2.42e-05	0.0102	-0.33	-0.22	Myocardial infarction;	chr3:149959117	chr3:149982181~149983308:-
STAD	cis	rs5758659	0.716	rs5758661	ENSG00000182057.4	OGFRP1	4.28	2.42e-05	0.0102	0.23	0.22	Cognitive function;	chr22:42228439	chr22:42269753~42275196:+
STAD	cis	rs17401966	0.931	rs3737155	ENSG00000199562.1	RNU6-37P	4.28	2.42e-05	0.0102	0.18	0.22	Hepatocellular carcinoma;	chr1:10399722	chr1:10298966~10299072:+
STAD	cis	rs17401966	1	rs12118323	ENSG00000199562.1	RNU6-37P	4.28	2.42e-05	0.0102	0.18	0.22	Hepatocellular carcinoma;	chr1:10409584	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.931	rs2236678	ENSG00000199562.1	RNU6-37P	4.28	2.42e-05	0.0102	0.18	0.22	Hepatocellular carcinoma;	chr1:10411732	chr1:10298966~10299072:+
STAD	cis	rs17401966	1	rs2229687	ENSG00000199562.1	RNU6-37P	4.28	2.42e-05	0.0102	0.18	0.22	Hepatocellular carcinoma;	chr1:10413139	chr1:10298966~10299072:+
STAD	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	4.28	2.42e-05	0.0102	0.29	0.22	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
STAD	cis	rs8005677	0.649	rs11629120	ENSG00000279656.1	RP11-298I3.6	-4.28	2.43e-05	0.0102	-0.22	-0.22	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:23023083~23024217:-
STAD	cis	rs4589258	0.788	rs10734133	ENSG00000280367.1	RP11-121L10.2	4.28	2.43e-05	0.0102	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90724022	chr11:90223153~90226538:+
STAD	cis	rs6061231	0.544	rs2427314	ENSG00000275437.1	RP5-908M14.10	4.28	2.43e-05	0.0102	0.21	0.22	Colorectal cancer;	chr20:62398610	chr20:62402236~62405935:-
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000211959.2	IGHV4-39	4.28	2.43e-05	0.0102	0.2	0.22	Kawasaki disease;	chr14:106768275	chr14:106421711~106422218:-
STAD	cis	rs453301	0.653	rs1562211	ENSG00000233609.3	RP11-62H7.2	-4.28	2.43e-05	0.0102	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9044914	chr8:8961200~8979025:+
STAD	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
STAD	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	4.28	2.43e-05	0.0102	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
STAD	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	4.28	2.43e-05	0.0102	0.33	0.22	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
STAD	cis	rs10129255	0.828	rs10140989	ENSG00000232216.1	IGHV3-43	4.28	2.43e-05	0.0102	0.23	0.22	Kawasaki disease;	chr14:106668657	chr14:106470264~106470800:-
STAD	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-4.28	2.43e-05	0.0102	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
STAD	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-4.28	2.43e-05	0.0102	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
STAD	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-4.28	2.43e-05	0.0103	-0.35	-0.22	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
STAD	cis	rs5769707	0.609	rs2007024	ENSG00000280224.1	CTA-722E9.1	-4.28	2.43e-05	0.0103	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49500568~49501585:+
STAD	cis	rs875971	1	rs10244498	ENSG00000224316.1	RP11-479O9.2	4.28	2.43e-05	0.0103	0.22	0.22	Aortic root size;	chr7:66651069	chr7:65773620~65802067:+
STAD	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-4.28	2.43e-05	0.0103	-0.22	-0.22	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
STAD	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	4.28	2.43e-05	0.0103	0.22	0.22	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
STAD	cis	rs6432852	0.527	rs10206075	ENSG00000229195.1	AC009495.4	-4.28	2.44e-05	0.0103	-0.25	-0.22	Diabetic kidney disease;	chr2:165920609	chr2:165794857~165846091:-
STAD	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-4.28	2.44e-05	0.0103	-0.22	-0.22	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-4.28	2.44e-05	0.0103	-0.22	-0.22	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-4.28	2.44e-05	0.0103	-0.22	-0.22	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
STAD	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-4.28	2.44e-05	0.0103	-0.22	-0.22	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
STAD	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-4.28	2.44e-05	0.0103	-0.22	-0.22	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
STAD	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-4.28	2.44e-05	0.0103	-0.22	-0.22	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
STAD	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	4.28	2.44e-05	0.0103	0.22	0.22	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
STAD	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	4.28	2.44e-05	0.0103	0.22	0.22	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
STAD	cis	rs7924176	0.564	rs6480727	ENSG00000213731.2	RAB5CP1	-4.28	2.44e-05	0.0103	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74423435~74424014:-
STAD	cis	rs7680126	0.596	rs17198547	ENSG00000250613.1	RP11-136I13.1	-4.28	2.44e-05	0.0103	-0.26	-0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10139795	chr4:10410996~10411644:+
STAD	cis	rs561341	0.783	rs512698	ENSG00000265798.5	RP11-271K11.5	4.28	2.44e-05	0.0103	0.33	0.22	Hip circumference adjusted for BMI;	chr17:31965488	chr17:31038575~31059121:-
STAD	cis	rs8062405	0.722	rs3785354	ENSG00000278665.1	RP11-666O2.4	4.28	2.44e-05	0.0103	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28599241~28601881:-
STAD	cis	rs5758659	0.714	rs6002607	ENSG00000182057.4	OGFRP1	-4.28	2.44e-05	0.0103	-0.24	-0.22	Cognitive function;	chr22:42100502	chr22:42269753~42275196:+
STAD	cis	rs2695743	0.647	rs13424417	ENSG00000225808.1	DNAJC19P5	-4.28	2.44e-05	0.0103	-0.26	-0.22	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177802270	chr2:177229191~177229506:-
STAD	cis	rs9733	0.596	rs6686525	ENSG00000274963.1	Metazoa_SRP	4.28	2.44e-05	0.0103	0.2	0.22	Tonsillectomy;	chr1:150663335	chr1:150568971~150569269:-
STAD	cis	rs4927850	0.752	rs7624460	ENSG00000185485.13	SDHAP1	4.28	2.44e-05	0.0103	0.22	0.22	Pancreatic cancer;	chr3:196021659	chr3:195959748~195990318:-
STAD	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-4.28	2.44e-05	0.0103	-0.32	-0.22	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
STAD	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-4.28	2.44e-05	0.0103	-0.35	-0.22	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
STAD	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-4.28	2.44e-05	0.0103	-0.35	-0.22	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
STAD	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-4.28	2.44e-05	0.0103	-0.35	-0.22	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
STAD	cis	rs12468226	0.873	rs59293950	ENSG00000226261.1	AC064836.3	4.28	2.45e-05	0.0103	0.37	0.22	Urate levels;	chr2:202214069	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.873	rs12472035	ENSG00000226261.1	AC064836.3	4.28	2.45e-05	0.0103	0.37	0.22	Urate levels;	chr2:202221970	chr2:202336024~202336727:-
STAD	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	4.28	2.45e-05	0.0103	0.24	0.22	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
STAD	cis	rs11098499	0.955	rs35197422	ENSG00000260091.1	RP11-33B1.4	4.28	2.45e-05	0.0103	0.22	0.22	Corneal astigmatism;	chr4:119248159	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs1511015	ENSG00000260091.1	RP11-33B1.4	4.28	2.45e-05	0.0103	0.22	0.22	Corneal astigmatism;	chr4:119249318	chr4:119409333~119410233:+
STAD	cis	rs11098499	1	rs10029750	ENSG00000260091.1	RP11-33B1.4	4.28	2.45e-05	0.0103	0.22	0.22	Corneal astigmatism;	chr4:119251388	chr4:119409333~119410233:+
STAD	cis	rs34779708	0.931	rs4934700	ENSG00000271335.4	RP11-324I22.4	4.28	2.45e-05	0.0103	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs2384283	ENSG00000271335.4	RP11-324I22.4	4.28	2.45e-05	0.0103	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs66887762	ENSG00000271335.4	RP11-324I22.4	4.28	2.45e-05	0.0103	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35314552~35336401:-
STAD	cis	rs1336900	0.641	rs6587756	ENSG00000274963.1	Metazoa_SRP	-4.28	2.45e-05	0.0103	-0.2	-0.22	Blood protein levels;	chr1:150574389	chr1:150568971~150569269:-
STAD	cis	rs9847710	0.901	rs2564937	ENSG00000242142.1	SERBP1P3	4.28	2.45e-05	0.0103	0.22	0.22	Ulcerative colitis;	chr3:52991843	chr3:53064283~53065091:-
STAD	cis	rs9926664	0.591	rs1519978	ENSG00000274134.1	MIR6774	4.28	2.45e-05	0.0103	0.31	0.22	Neutrophil count;Sum basophil neutrophil counts;	chr16:85901605	chr16:85918347~85918416:+
STAD	cis	rs8014252	0.614	rs28612538	ENSG00000259158.2	ADAM20P1	-4.28	2.45e-05	0.0103	-0.3	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70558489	chr14:70468881~70483756:-
STAD	cis	rs6832769	1	rs6832769	ENSG00000272969.1	RP11-528I4.2	4.28	2.45e-05	0.0103	0.29	0.22	Personality dimensions;	chr4:55432027	chr4:55547112~55547889:+
STAD	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	4.28	2.45e-05	0.0103	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
STAD	cis	rs1056107	0.831	rs7856196	ENSG00000225513.1	RP11-165N19.2	-4.28	2.45e-05	0.0103	-0.26	-0.22	Colorectal cancer;	chr9:112181635	chr9:112173522~112173971:-
STAD	cis	rs34779708	0.931	rs4934524	ENSG00000271335.4	RP11-324I22.4	4.28	2.45e-05	0.0103	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934693	ENSG00000271335.4	RP11-324I22.4	4.28	2.45e-05	0.0103	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35314552~35336401:-
STAD	cis	rs4237845	0.742	rs6650219	ENSG00000273805.1	RP11-620J15.4	-4.28	2.45e-05	0.0103	-0.25	-0.22	Intelligence (multi-trait analysis);	chr12:57895317	chr12:57894232~57896846:+
STAD	cis	rs1707322	0.721	rs28817701	ENSG00000281133.1	AL355480.3	-4.28	2.45e-05	0.0103	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.691	rs28495425	ENSG00000281133.1	AL355480.3	-4.28	2.45e-05	0.0103	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.663	rs3935296	ENSG00000281133.1	AL355480.3	4.28	2.45e-05	0.0103	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45580892~45580996:-
STAD	cis	rs2836974	0.644	rs4818017	ENSG00000238141.2	BRWD1-AS1	-4.28	2.45e-05	0.0103	-0.23	-0.22	Cognitive function;	chr21:39318635	chr21:39315707~39323218:+
STAD	cis	rs11168351	0.889	rs12817104	ENSG00000258273.1	RP11-370I10.4	-4.28	2.45e-05	0.0103	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48333755~48333901:-
STAD	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-4.28	2.46e-05	0.0103	-0.3	-0.22	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
STAD	cis	rs304029	0.553	rs2633848	ENSG00000229241.1	PNPT1P1	-4.28	2.46e-05	0.0103	-0.27	-0.22	Diabetic kidney disease;	chr3:4473535	chr3:3981981~3984295:-
STAD	cis	rs9307551	0.948	rs13112577	ENSG00000250334.4	LINC00989	-4.28	2.46e-05	0.0103	-0.28	-0.22	Refractive error;	chr4:79561246	chr4:79492416~79576460:+
STAD	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	4.28	2.46e-05	0.0103	0.36	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
STAD	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	4.28	2.46e-05	0.0103	0.36	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
STAD	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	4.28	2.46e-05	0.0103	0.36	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
STAD	cis	rs2638953	0.853	rs11049635	ENSG00000247934.4	RP11-967K21.1	-4.28	2.46e-05	0.0103	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28163298~28190738:-
STAD	cis	rs4589258	0.762	rs10437566	ENSG00000280367.1	RP11-121L10.2	4.28	2.46e-05	0.0103	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90730718	chr11:90223153~90226538:+
STAD	cis	rs11157436	0.56	rs988997	ENSG00000211812.1	TRAV26-2	-4.28	2.46e-05	0.0103	-0.22	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22225937	chr14:22202583~22203368:+
STAD	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	4.28	2.46e-05	0.0103	0.33	0.22	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
STAD	cis	rs1799949	1	rs8176289	ENSG00000279602.1	CTD-3014M21.1	4.28	2.46e-05	0.0103	0.28	0.22	Menopause (age at onset);	chr17:43054039	chr17:43360041~43361361:-
STAD	cis	rs17214007	0.778	rs17213271	ENSG00000263335.1	AF001548.5	-4.28	2.46e-05	0.0104	-0.27	-0.22	Cognitive function;	chr16:15770487	chr16:15726674~15732993:+
STAD	cis	rs9788721	0.836	rs72738732	ENSG00000259419.2	HNRNPCP3	4.28	2.46e-05	0.0104	0.25	0.22	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78459846	chr15:79236332~79237206:+
STAD	cis	rs9788721	0.836	rs17484235	ENSG00000259419.2	HNRNPCP3	4.28	2.46e-05	0.0104	0.25	0.22	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78469072	chr15:79236332~79237206:+
STAD	cis	rs7829975	0.56	rs4841013	ENSG00000254340.1	RP11-10A14.3	-4.28	2.46e-05	0.0104	-0.3	-0.22	Mood instability;	chr8:8694503	chr8:9141424~9145435:+
STAD	cis	rs1823913	0.963	rs12614848	ENSG00000280083.1	RP11-317J9.1	4.28	2.46e-05	0.0104	0.28	0.22	Obesity-related traits;	chr2:191231993	chr2:191154118~191156070:-
STAD	cis	rs1823913	0.926	rs12615901	ENSG00000280083.1	RP11-317J9.1	4.28	2.46e-05	0.0104	0.28	0.22	Obesity-related traits;	chr2:191233381	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs7574570	ENSG00000280083.1	RP11-317J9.1	4.28	2.46e-05	0.0104	0.28	0.22	Obesity-related traits;	chr2:191233790	chr2:191154118~191156070:-
STAD	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	4.28	2.46e-05	0.0104	0.25	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
STAD	cis	rs11846409	0.872	rs2516914	ENSG00000211970.3	IGHV4-61	-4.28	2.46e-05	0.0104	-0.24	-0.22	Rheumatic heart disease;	chr14:106629835	chr14:106639119~106639657:-
STAD	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-4.28	2.46e-05	0.0104	-0.27	-0.22	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
STAD	cis	rs8028182	0.609	rs10220738	ENSG00000260269.4	CTD-2323K18.1	4.28	2.46e-05	0.0104	0.29	0.22	Sudden cardiac arrest;	chr15:75374205	chr15:75527150~75601205:-
STAD	cis	rs1707322	1	rs1612419	ENSG00000225447.1	RPS15AP10	-4.28	2.46e-05	0.0104	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45645816~45646197:-
STAD	cis	rs28512361	0.557	rs80521	ENSG00000279954.1	WI2-85898F10.2	-4.28	2.47e-05	0.0104	-0.27	-0.22	Breast cancer;	chr22:45845780	chr22:45875932~45879247:+
STAD	cis	rs7078219	1	rs61872688	ENSG00000228778.1	RP11-129J12.1	-4.28	2.47e-05	0.0104	-0.27	-0.22	Dental caries;	chr10:99513789	chr10:99527081~99528261:+
STAD	cis	rs7078219	0.965	rs10883358	ENSG00000228778.1	RP11-129J12.1	-4.28	2.47e-05	0.0104	-0.27	-0.22	Dental caries;	chr10:99514100	chr10:99527081~99528261:+
STAD	cis	rs1850744	0.826	rs9291607	ENSG00000163612.10	FAM86KP	4.28	2.47e-05	0.0104	0.47	0.22	Economic and political preferences;	chr4:9707174	chr4:9153296~9165451:+
STAD	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	4.28	2.47e-05	0.0104	0.24	0.22	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
STAD	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	4.28	2.47e-05	0.0104	0.23	0.22	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
STAD	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-4.28	2.47e-05	0.0104	-0.26	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
STAD	cis	rs7615952	0.546	rs2976733	ENSG00000171084.14	FAM86JP	4.28	2.47e-05	0.0104	0.32	0.22	Blood pressure (smoking interaction);	chr3:125695294	chr3:125916620~125930024:+
STAD	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	4.28	2.47e-05	0.0104	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
STAD	cis	rs1005277	0.505	rs7099777	ENSG00000099251.13	HSD17B7P2	-4.28	2.47e-05	0.0104	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.505	rs7917943	ENSG00000099251.13	HSD17B7P2	-4.28	2.47e-05	0.0104	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38356380~38378505:+
STAD	cis	rs9860428	0.774	rs10934188	ENSG00000240057.4	RP11-572M11.4	-4.27	2.48e-05	0.0104	-0.21	-0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112821421	chr3:113019532~113183301:+
STAD	cis	rs7487075	0.619	rs7488450	ENSG00000257261.4	RP11-96H19.1	4.27	2.48e-05	0.0104	0.3	0.22	Itch intensity from mosquito bite;	chr12:46427255	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs11183479	ENSG00000257261.4	RP11-96H19.1	4.27	2.48e-05	0.0104	0.3	0.22	Itch intensity from mosquito bite;	chr12:46430381	chr12:46383679~46876159:+
STAD	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-4.27	2.48e-05	0.0104	-0.34	-0.22	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
STAD	cis	rs9859260	0.744	rs539816	ENSG00000185485.13	SDHAP1	-4.27	2.48e-05	0.0104	-0.22	-0.22	Mean corpuscular volume;	chr3:196057205	chr3:195959748~195990318:-
STAD	cis	rs9859260	0.744	rs492349	ENSG00000185485.13	SDHAP1	-4.27	2.48e-05	0.0104	-0.22	-0.22	Mean corpuscular volume;	chr3:196057321	chr3:195959748~195990318:-
STAD	cis	rs9859260	0.744	rs492288	ENSG00000185485.13	SDHAP1	-4.27	2.48e-05	0.0104	-0.22	-0.22	Mean corpuscular volume;	chr3:196057339	chr3:195959748~195990318:-
STAD	cis	rs9902453	0.765	rs8071576	ENSG00000240074.1	RPL9P30	4.27	2.48e-05	0.0104	0.19	0.22	Coffee consumption (cups per day);	chr17:29861536	chr17:29855759~29856332:+
STAD	cis	rs6772849	0.931	rs60825080	ENSG00000242551.2	POU5F1P6	-4.27	2.48e-05	0.0104	-0.23	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128674735~128677005:-
STAD	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	4.27	2.48e-05	0.0104	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
STAD	cis	rs10129255	0.5	rs6576230	ENSG00000224373.3	IGHV4-59	4.27	2.48e-05	0.0104	0.16	0.22	Kawasaki disease;	chr14:106778539	chr14:106627249~106627825:-
STAD	cis	rs1707322	0.821	rs10749857	ENSG00000281133.1	AL355480.3	-4.27	2.48e-05	0.0104	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10789486	ENSG00000225447.1	RPS15AP10	4.27	2.48e-05	0.0104	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45645816~45646197:-
STAD	cis	rs831571	0.703	rs55714137	ENSG00000280620.1	SCAANT1	4.27	2.48e-05	0.0104	0.34	0.22	Type 2 diabetes;	chr3:64091103	chr3:63911518~63911772:-
STAD	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-4.27	2.48e-05	0.0104	-0.26	-0.22	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-4.27	2.48e-05	0.0104	-0.26	-0.22	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-4.27	2.48e-05	0.0104	-0.26	-0.22	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-4.27	2.48e-05	0.0104	-0.26	-0.22	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-4.27	2.48e-05	0.0104	-0.26	-0.22	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-4.27	2.48e-05	0.0104	-0.26	-0.22	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
STAD	cis	rs721917	0.525	rs11201011	ENSG00000225484.5	NUTM2B-AS1	-4.27	2.48e-05	0.0104	-0.27	-0.22	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79663088~79826594:-
STAD	cis	rs1707322	0.752	rs61784793	ENSG00000281133.1	AL355480.3	-4.27	2.48e-05	0.0104	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.648	rs4439382	ENSG00000281133.1	AL355480.3	-4.27	2.48e-05	0.0104	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45580892~45580996:-
STAD	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-4.27	2.49e-05	0.0104	-0.26	-0.22	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
STAD	cis	rs1075265	0.791	rs1833498	ENSG00000235937.1	AC008280.1	4.27	2.49e-05	0.0104	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54029552~54030682:-
STAD	cis	rs9595908	0.965	rs9595877	ENSG00000281026.1	N4BP2L2-IT2	-4.27	2.49e-05	0.0105	-0.18	-0.22	Body mass index;	chr13:32589512	chr13:32504506~32509395:-
STAD	cis	rs1336900	0.637	rs35967040	ENSG00000274963.1	Metazoa_SRP	-4.27	2.49e-05	0.0105	-0.2	-0.22	Blood protein levels;	chr1:150583112	chr1:150568971~150569269:-
STAD	cis	rs4713118	0.662	rs149947	ENSG00000220721.1	OR1F12	4.27	2.49e-05	0.0105	0.26	0.22	Parkinson's disease;	chr6:28004655	chr6:28073316~28074233:+
STAD	cis	rs1799949	1	rs12516	ENSG00000279602.1	CTD-3014M21.1	4.27	2.49e-05	0.0105	0.28	0.22	Menopause (age at onset);	chr17:43044391	chr17:43360041~43361361:-
STAD	cis	rs7916697	0.593	rs10762198	ENSG00000234102.1	KRT19P4	4.27	2.49e-05	0.0105	0.24	0.22	Optic disc area;	chr10:68263296	chr10:68260557~68261499:+
STAD	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	4.27	2.49e-05	0.0105	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
STAD	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-4.27	2.49e-05	0.0105	-0.45	-0.22	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
STAD	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	4.27	2.5e-05	0.0105	0.3	0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
STAD	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	4.27	2.5e-05	0.0105	0.21	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
STAD	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	4.27	2.5e-05	0.0105	0.21	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
STAD	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	4.27	2.5e-05	0.0105	0.26	0.22	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
STAD	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	4.27	2.5e-05	0.0105	0.26	0.22	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
STAD	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	4.27	2.5e-05	0.0105	0.26	0.22	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
STAD	cis	rs2638953	0.962	rs10771409	ENSG00000247934.4	RP11-967K21.1	-4.27	2.5e-05	0.0105	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28154129	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs10771410	ENSG00000247934.4	RP11-967K21.1	-4.27	2.5e-05	0.0105	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28154271	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs1479492	ENSG00000247934.4	RP11-967K21.1	-4.27	2.5e-05	0.0105	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28155491	chr12:28163298~28190738:-
STAD	cis	rs9646944	0.53	rs11690644	ENSG00000234389.1	AC007278.3	4.27	2.5e-05	0.0105	0.37	0.22	Blood protein levels;	chr2:102297754	chr2:102438713~102440475:+
STAD	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-4.27	2.5e-05	0.0105	-0.34	-0.22	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
STAD	cis	rs1816752	0.748	rs6490912	ENSG00000232858.1	RPL34P27	4.27	2.5e-05	0.0105	0.14	0.22	Obesity-related traits;	chr13:24408941	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.819	rs1981276	ENSG00000232858.1	RPL34P27	4.27	2.5e-05	0.0105	0.14	0.22	Obesity-related traits;	chr13:24409361	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.837	rs57052031	ENSG00000232858.1	RPL34P27	4.27	2.5e-05	0.0105	0.14	0.22	Obesity-related traits;	chr13:24409730	chr13:24988577~24988925:-
STAD	cis	rs6565180	1	rs11646130	ENSG00000273724.1	RP11-347C12.12	-4.27	2.5e-05	0.0105	-0.24	-0.22	Tonsillectomy;	chr16:30365638	chr16:30336400~30343336:+
STAD	cis	rs593531	0.614	rs10736795	ENSG00000280269.1	AP000577.2	-4.27	2.5e-05	0.0105	-0.23	-0.22	Neuroticism;	chr11:74328501	chr11:74204869~74205746:+
STAD	cis	rs11846409	0.86	rs4774166	ENSG00000211970.3	IGHV4-61	4.27	2.5e-05	0.0105	0.25	0.22	Rheumatic heart disease;	chr14:106619598	chr14:106639119~106639657:-
STAD	cis	rs11673344	0.523	rs6510584	ENSG00000267672.1	CTD-2293H3.1	4.27	2.5e-05	0.0105	0.2	0.22	Obesity-related traits;	chr19:37058699	chr19:37091341~37092564:+
STAD	cis	rs4691139	0.658	rs1401398	ENSG00000248632.1	RP11-366M4.11	4.27	2.5e-05	0.0105	0.22	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:165006580	chr4:164968587~164970002:-
STAD	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	4.27	2.5e-05	0.0105	0.29	0.22	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
STAD	cis	rs9733	0.519	rs1134067	ENSG00000274963.1	Metazoa_SRP	4.27	2.5e-05	0.0105	0.2	0.22	Tonsillectomy;	chr1:150748699	chr1:150568971~150569269:-
STAD	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	4.27	2.5e-05	0.0105	0.25	0.22	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
STAD	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-4.27	2.5e-05	0.0105	-0.3	-0.22	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
STAD	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-4.27	2.5e-05	0.0105	-0.21	-0.22	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
STAD	cis	rs858239	0.899	rs7794684	ENSG00000230042.1	AK3P3	-4.27	2.5e-05	0.0105	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23129178~23129841:+
STAD	cis	rs4589258	0.933	rs35622960	ENSG00000280367.1	RP11-121L10.2	-4.27	2.5e-05	0.0105	-0.24	-0.22	Intelligence (multi-trait analysis);	chr11:90680485	chr11:90223153~90226538:+
STAD	cis	rs9393777	0.623	rs7756567	ENSG00000241549.7	GUSBP2	4.27	2.51e-05	0.0105	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26481414	chr6:26871484~26956554:-
STAD	cis	rs9393777	0.623	rs9358948	ENSG00000241549.7	GUSBP2	4.27	2.51e-05	0.0105	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26483578	chr6:26871484~26956554:-
STAD	cis	rs6432852	0.966	rs13405162	ENSG00000229195.1	AC009495.4	4.27	2.51e-05	0.0105	0.26	0.22	Diabetic kidney disease;	chr2:165905383	chr2:165794857~165846091:-
STAD	cis	rs6432852	1	rs11897687	ENSG00000229195.1	AC009495.4	4.27	2.51e-05	0.0105	0.26	0.22	Diabetic kidney disease;	chr2:165908088	chr2:165794857~165846091:-
STAD	cis	rs935334	1	rs2543382	ENSG00000258454.1	RP11-361H10.3	4.27	2.51e-05	0.0105	0.33	0.22	Blood pressure;	chr14:76158544	chr14:76235817~76263474:+
STAD	cis	rs12468226	0.938	rs10166594	ENSG00000226261.1	AC064836.3	4.27	2.51e-05	0.0105	0.35	0.22	Urate levels;	chr2:202250262	chr2:202336024~202336727:-
STAD	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	4.27	2.51e-05	0.0105	0.32	0.22	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
STAD	cis	rs950169	0.58	rs4603535	ENSG00000259295.5	CSPG4P12	4.27	2.51e-05	0.0105	0.32	0.22	Schizophrenia;	chr15:84630641	chr15:85191438~85213905:+
STAD	cis	rs8012947	1	rs56208804	ENSG00000279636.2	LINC00216	-4.27	2.51e-05	0.0105	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58313408	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.959	rs3945957	ENSG00000279636.2	LINC00216	-4.27	2.51e-05	0.0105	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58316335	chr14:58288033~58289158:+
STAD	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	4.27	2.51e-05	0.0105	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
STAD	cis	rs9926664	0.908	rs8064111	ENSG00000274134.1	MIR6774	4.27	2.51e-05	0.0105	0.38	0.22	Neutrophil count;Sum basophil neutrophil counts;	chr16:85913869	chr16:85918347~85918416:+
STAD	cis	rs454422	0.556	rs6053817	ENSG00000275632.1	RP5-967N21.11	4.27	2.51e-05	0.0105	0.3	0.22	HIV-1 viral setpoint;	chr20:6000052	chr20:6000418~6000941:+
STAD	cis	rs6961102	0.548	rs2402968	ENSG00000244218.3	RN7SL81P	4.27	2.51e-05	0.0105	0.46	0.22	Platelet distribution width;	chr7:129681807	chr7:128761338~128761598:+
STAD	cis	rs561341	0.7	rs6505266	ENSG00000265798.5	RP11-271K11.5	4.27	2.51e-05	0.0105	0.27	0.22	Hip circumference adjusted for BMI;	chr17:31898794	chr17:31038575~31059121:-
STAD	cis	rs561341	0.7	rs79272796	ENSG00000265798.5	RP11-271K11.5	4.27	2.51e-05	0.0105	0.27	0.22	Hip circumference adjusted for BMI;	chr17:31899955	chr17:31038575~31059121:-
STAD	cis	rs7395581	0.959	rs2013867	ENSG00000271350.1	CTD-2384B9.1	4.27	2.51e-05	0.0105	0.28	0.22	HDL cholesterol;	chr11:47238721	chr11:47041027~47041945:-
STAD	cis	rs72615157	0.645	rs11771660	ENSG00000242294.5	STAG3L5P	4.27	2.51e-05	0.0105	0.22	0.22	Lung function (FEV1/FVC);	chr7:100253646	chr7:100336079~100351900:+
STAD	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	4.27	2.51e-05	0.0105	0.26	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	4.27	2.51e-05	0.0105	0.26	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
STAD	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	4.27	2.51e-05	0.0105	0.28	0.22	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
STAD	cis	rs7702057	0.53	rs74583480	ENSG00000271918.1	CTD-2287O16.5	4.27	2.51e-05	0.0105	0.43	0.22	Amyotrophic lateral sclerosis;	chr5:116085200	chr5:116083807~116085416:-
STAD	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-4.27	2.52e-05	0.0105	-0.26	-0.22	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
STAD	cis	rs6539288	0.803	rs10778517	ENSG00000260329.1	RP11-412D9.4	4.27	2.52e-05	0.0105	0.23	0.22	Total body bone mineral density;	chr12:106947886	chr12:106954029~106955497:-
STAD	cis	rs935334	1	rs2543376	ENSG00000258454.1	RP11-361H10.3	4.27	2.52e-05	0.0105	0.32	0.22	Blood pressure;	chr14:76143580	chr14:76235817~76263474:+
STAD	cis	rs11679564	0.714	rs10490657	ENSG00000252756.1	RNU6-577P	-4.27	2.52e-05	0.0105	-0.25	-0.22	Immature fraction of reticulocytes;	chr2:36951112	chr2:36867398~36867495:-
STAD	cis	rs10129255	0.912	rs61997792	ENSG00000232216.1	IGHV3-43	4.27	2.52e-05	0.0106	0.23	0.22	Kawasaki disease;	chr14:106799304	chr14:106470264~106470800:-
STAD	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	4.27	2.52e-05	0.0106	0.27	0.22	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
STAD	cis	rs6142102	0.961	rs6088361	ENSG00000264616.1	MIR4755	4.27	2.52e-05	0.0106	0.23	0.22	Skin pigmentation;	chr20:33969520	chr20:34049119~34049190:+
STAD	cis	rs7680126	0.5	rs4697933	ENSG00000250613.1	RP11-136I13.1	4.27	2.52e-05	0.0106	0.26	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10144869	chr4:10410996~10411644:+
STAD	cis	rs17685	0.753	rs6976532	ENSG00000280388.1	RP11-229D13.3	-4.27	2.53e-05	0.0106	-0.19	-0.22	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76043977~76045963:-
STAD	cis	rs858239	0.896	rs1637193	ENSG00000230042.1	AK3P3	-4.27	2.53e-05	0.0106	-0.23	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23129178~23129841:+
STAD	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	4.27	2.53e-05	0.0106	0.33	0.22	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs9318361	ENSG00000261553.4	RP11-29G8.3	4.27	2.53e-05	0.0106	0.33	0.22	Diabetic retinopathy;	chr13:75602944	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs8192764	ENSG00000261553.4	RP11-29G8.3	4.27	2.53e-05	0.0106	0.33	0.22	Diabetic retinopathy;	chr13:75605079	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs9544004	ENSG00000261553.4	RP11-29G8.3	4.27	2.53e-05	0.0106	0.33	0.22	Diabetic retinopathy;	chr13:75617748	chr13:75549773~75807120:+
STAD	cis	rs748404	0.723	rs512431	ENSG00000275601.1	AC011330.13	4.27	2.53e-05	0.0106	0.23	0.22	Lung cancer;	chr15:43249741	chr15:43642389~43643023:-
STAD	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-4.27	2.53e-05	0.0106	-0.31	-0.22	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
STAD	cis	rs1005277	0.505	rs13503	ENSG00000099251.13	HSD17B7P2	-4.27	2.53e-05	0.0106	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.505	rs7069702	ENSG00000099251.13	HSD17B7P2	-4.27	2.53e-05	0.0106	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38356380~38378505:+
STAD	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-4.27	2.53e-05	0.0106	-0.26	-0.22	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
STAD	cis	rs2836950	0.501	rs2070865	ENSG00000238141.2	BRWD1-AS1	-4.27	2.53e-05	0.0106	-0.23	-0.22	Menarche (age at onset);	chr21:39343593	chr21:39315707~39323218:+
STAD	cis	rs7647973	0.621	rs3774800	ENSG00000225399.4	RP11-3B7.1	-4.27	2.53e-05	0.0106	-0.25	-0.22	Menarche (age at onset);	chr3:49297335	chr3:49260085~49261316:+
STAD	cis	rs4713118	0.662	rs4713120	ENSG00000280107.1	AL022393.9	-4.27	2.53e-05	0.0106	-0.26	-0.22	Parkinson's disease;	chr6:27754056	chr6:28170845~28172521:+
STAD	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	4.27	2.53e-05	0.0106	0.23	0.22	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
STAD	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	4.27	2.53e-05	0.0106	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
STAD	cis	rs494453	0.922	rs484495	ENSG00000234020.1	CHIAP3	-4.27	2.53e-05	0.0106	-0.22	-0.22	Osteoporosis-related phenotypes;	chr1:111693680	chr1:111353275~111367409:-
STAD	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	4.27	2.53e-05	0.0106	0.27	0.22	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
STAD	cis	rs1707322	0.826	rs10890349	ENSG00000281133.1	AL355480.3	-4.27	2.53e-05	0.0106	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.758	rs10789474	ENSG00000281133.1	AL355480.3	-4.27	2.53e-05	0.0106	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45580892~45580996:-
STAD	cis	rs2739330	0.828	rs5760108	ENSG00000272787.1	KB-226F1.2	-4.27	2.54e-05	0.0106	-0.23	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23969211~23969873:+
STAD	cis	rs7680126	0.633	rs4697975	ENSG00000250613.1	RP11-136I13.1	4.27	2.54e-05	0.0106	0.25	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10208342	chr4:10410996~10411644:+
STAD	cis	rs9902453	0.904	rs8078638	ENSG00000240074.1	RPL9P30	4.27	2.54e-05	0.0106	0.19	0.22	Coffee consumption (cups per day);	chr17:29963340	chr17:29855759~29856332:+
STAD	cis	rs4589258	0.788	rs10765381	ENSG00000280367.1	RP11-121L10.2	4.27	2.54e-05	0.0106	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90736763	chr11:90223153~90226538:+
STAD	cis	rs6750795	0.746	rs2916579	ENSG00000223198.1	RNU2-22P	-4.27	2.54e-05	0.0106	-0.27	-0.22	Height;	chr2:231556448	chr2:231501990~231502201:-
STAD	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	4.27	2.54e-05	0.0106	0.27	0.22	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
STAD	cis	rs4927850	1	rs6799572	ENSG00000278820.1	AC024937.1	4.27	2.54e-05	0.0106	0.25	0.22	Pancreatic cancer;	chr3:196013537	chr3:195960500~195960612:-
STAD	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-4.27	2.54e-05	0.0106	-0.34	-0.22	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
STAD	cis	rs56046484	0.871	rs7177110	ENSG00000229212.6	RP11-561C5.4	4.27	2.54e-05	0.0106	0.36	0.22	Testicular germ cell tumor;	chr15:85128524	chr15:85205440~85234795:-
STAD	cis	rs2957692	0.548	rs7928959	ENSG00000254554.1	RP11-351I24.1	4.27	2.54e-05	0.0106	0.37	0.22	Circulating vasoactive peptide levels;	chr11:10036466	chr11:10302657~10303704:-
STAD	cis	rs10040610	0.524	rs271422	ENSG00000250490.1	FLJ33360	4.27	2.54e-05	0.0106	0.26	0.22	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6355594	chr5:6310441~6339884:-
STAD	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	4.27	2.54e-05	0.0106	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	4.27	2.54e-05	0.0106	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
STAD	cis	rs9733	0.519	rs11807450	ENSG00000274963.1	Metazoa_SRP	4.27	2.54e-05	0.0106	0.2	0.22	Tonsillectomy;	chr1:150705243	chr1:150568971~150569269:-
STAD	cis	rs9733	0.519	rs3768005	ENSG00000274963.1	Metazoa_SRP	4.27	2.54e-05	0.0106	0.2	0.22	Tonsillectomy;	chr1:150708512	chr1:150568971~150569269:-
STAD	cis	rs9733	0.519	rs72704603	ENSG00000274963.1	Metazoa_SRP	4.27	2.54e-05	0.0106	0.2	0.22	Tonsillectomy;	chr1:150735516	chr1:150568971~150569269:-
STAD	cis	rs1707322	0.65	rs4553239	ENSG00000281133.1	AL355480.3	-4.27	2.54e-05	0.0106	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45580892~45580996:-
STAD	cis	rs9326248	0.515	rs2727793	ENSG00000280143.1	AP000892.6	4.27	2.54e-05	0.0106	0.18	0.22	Blood protein levels;	chr11:116812658	chr11:117204967~117210292:+
STAD	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	4.27	2.54e-05	0.0106	0.22	0.22	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
STAD	cis	rs7487075	0.82	rs7304622	ENSG00000257261.4	RP11-96H19.1	4.27	2.54e-05	0.0106	0.29	0.22	Itch intensity from mosquito bite;	chr12:46305077	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.82	rs10785617	ENSG00000257261.4	RP11-96H19.1	4.27	2.54e-05	0.0106	0.29	0.22	Itch intensity from mosquito bite;	chr12:46305460	chr12:46383679~46876159:+
STAD	cis	rs17507216	0.671	rs4779035	ENSG00000259429.4	UBE2Q2P2	-4.27	2.54e-05	0.0106	-0.35	-0.22	Excessive daytime sleepiness;	chr15:82591686	chr15:82355142~82420075:+
STAD	cis	rs10129255	0.518	rs2006284	ENSG00000211973.2	IGHV1-69	4.27	2.54e-05	0.0106	0.19	0.22	Kawasaki disease;	chr14:106676185	chr14:106714684~106715181:-
STAD	cis	rs9788721	0.836	rs1504550	ENSG00000259419.2	HNRNPCP3	4.27	2.54e-05	0.0106	0.25	0.22	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78473908	chr15:79236332~79237206:+
STAD	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	4.27	2.54e-05	0.0106	0.35	0.22	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
STAD	cis	rs1816752	0.692	rs2282409	ENSG00000273628.1	RP11-756A22.7	-4.27	2.54e-05	0.0106	-0.27	-0.22	Obesity-related traits;	chr13:24512388	chr13:24933006~24936796:+
STAD	cis	rs2638953	0.924	rs10843139	ENSG00000247934.4	RP11-967K21.1	-4.27	2.54e-05	0.0106	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227160	chr12:28163298~28190738:-
STAD	cis	rs1707322	0.691	rs11211174	ENSG00000281133.1	AL355480.3	-4.27	2.54e-05	0.0106	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45580892~45580996:-
STAD	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	4.27	2.54e-05	0.0106	0.23	0.22	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
STAD	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-4.27	2.54e-05	0.0106	-0.33	-0.22	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
STAD	cis	rs4388249	0.904	rs2284991	ENSG00000271849.1	CTC-332L22.1	-4.27	2.55e-05	0.0106	-0.32	-0.22	Schizophrenia;	chr5:109857500	chr5:109687802~109688329:-
STAD	cis	rs7615952	0.512	rs34085484	ENSG00000242229.1	RPS3AP14	4.27	2.55e-05	0.0106	0.28	0.22	Blood pressure (smoking interaction);	chr3:125825343	chr3:125795106~125795885:+
STAD	cis	rs7615952	0.608	rs35668111	ENSG00000242229.1	RPS3AP14	4.27	2.55e-05	0.0106	0.28	0.22	Blood pressure (smoking interaction);	chr3:125825792	chr3:125795106~125795885:+
STAD	cis	rs9291683	0.546	rs6820188	ENSG00000250613.1	RP11-136I13.1	-4.27	2.55e-05	0.0107	-0.23	-0.22	Bone mineral density;	chr4:10050031	chr4:10410996~10411644:+
STAD	cis	rs9902453	0.689	rs56788338	ENSG00000263477.1	RP11-338L22.2	4.27	2.55e-05	0.0107	0.19	0.22	Coffee consumption (cups per day);	chr17:29859539	chr17:29863402~29866092:+
STAD	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	4.27	2.55e-05	0.0107	0.27	0.22	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	4.27	2.55e-05	0.0107	0.27	0.22	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	4.27	2.55e-05	0.0107	0.27	0.22	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	4.27	2.55e-05	0.0107	0.27	0.22	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
STAD	cis	rs1850744	0.826	rs6858644	ENSG00000250268.3	ALG1L14P	-4.27	2.55e-05	0.0107	-0.5	-0.22	Economic and political preferences;	chr4:9740057	chr4:9166297~9170270:-
STAD	cis	rs539514	0.69	rs1924214	ENSG00000261105.4	LMO7-AS1	4.27	2.55e-05	0.0107	0.27	0.22	Type 1 diabetes;	chr13:75743496	chr13:75604700~75635994:-
STAD	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	4.27	2.55e-05	0.0107	0.29	0.22	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
STAD	cis	rs7395581	0.959	rs901746	ENSG00000271350.1	CTD-2384B9.1	4.27	2.55e-05	0.0107	0.27	0.22	HDL cholesterol;	chr11:47238768	chr11:47041027~47041945:-
STAD	cis	rs593531	0.614	rs655719	ENSG00000280269.1	AP000577.2	-4.27	2.55e-05	0.0107	-0.24	-0.22	Neuroticism;	chr11:74331196	chr11:74204869~74205746:+
STAD	cis	rs7131987	0.801	rs6487804	ENSG00000257176.2	RP11-996F15.2	-4.27	2.55e-05	0.0107	-0.25	-0.22	QT interval;	chr12:29302001	chr12:29280418~29317848:-
STAD	cis	rs55823223	0.564	rs9894009	ENSG00000267801.1	RP11-552F3.9	4.27	2.55e-05	0.0107	0.29	0.22	Psoriasis;	chr17:75854333	chr17:75876372~75879546:+
STAD	cis	rs55823223	0.564	rs1463485	ENSG00000267801.1	RP11-552F3.9	4.27	2.55e-05	0.0107	0.29	0.22	Psoriasis;	chr17:75855710	chr17:75876372~75879546:+
STAD	cis	rs1707322	0.686	rs2050376	ENSG00000225447.1	RPS15AP10	4.27	2.55e-05	0.0107	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45645816~45646197:-
STAD	cis	rs17401966	0.894	rs61778406	ENSG00000199562.1	RNU6-37P	4.27	2.55e-05	0.0107	0.18	0.22	Hepatocellular carcinoma;	chr1:10375758	chr1:10298966~10299072:+
STAD	cis	rs7142881	0.844	rs7152067	ENSG00000258648.1	UBE2CP1	4.27	2.55e-05	0.0107	0.25	0.22	Response to iloperidone treatment (QT prolongation);	chr14:31563847	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.844	rs7152506	ENSG00000258648.1	UBE2CP1	4.27	2.55e-05	0.0107	0.25	0.22	Response to iloperidone treatment (QT prolongation);	chr14:31563887	chr14:30683045~30683598:-
STAD	cis	rs1707322	1	rs7553924	ENSG00000281133.1	AL355480.3	-4.27	2.55e-05	0.0107	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4641257	ENSG00000281133.1	AL355480.3	-4.27	2.55e-05	0.0107	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs6693336	ENSG00000281133.1	AL355480.3	-4.27	2.55e-05	0.0107	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4539075	ENSG00000281133.1	AL355480.3	-4.27	2.55e-05	0.0107	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211219	ENSG00000281133.1	AL355480.3	-4.27	2.55e-05	0.0107	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211222	ENSG00000281133.1	AL355480.3	-4.27	2.55e-05	0.0107	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45580892~45580996:-
STAD	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	4.27	2.56e-05	0.0107	0.25	0.22	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
STAD	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-4.27	2.56e-05	0.0107	-0.23	-0.22	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
STAD	cis	rs2836950	0.545	rs2836952	ENSG00000238141.2	BRWD1-AS1	-4.27	2.56e-05	0.0107	-0.23	-0.22	Menarche (age at onset);	chr21:39244725	chr21:39315707~39323218:+
STAD	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	4.27	2.56e-05	0.0107	0.24	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
STAD	cis	rs228614	0.509	rs223486	ENSG00000248971.2	KRT8P46	-4.27	2.56e-05	0.0107	-0.22	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102728746~102730171:-
STAD	cis	rs10129255	0.913	rs10140943	ENSG00000232216.1	IGHV3-43	4.27	2.56e-05	0.0107	0.23	0.22	Kawasaki disease;	chr14:106767441	chr14:106470264~106470800:-
STAD	cis	rs4589258	0.713	rs11019139	ENSG00000280367.1	RP11-121L10.2	-4.27	2.56e-05	0.0107	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90679019	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs7480338	ENSG00000280367.1	RP11-121L10.2	-4.27	2.56e-05	0.0107	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90679634	chr11:90223153~90226538:+
STAD	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	4.27	2.56e-05	0.0107	0.24	0.22	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
STAD	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	4.27	2.56e-05	0.0107	0.32	0.22	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
STAD	cis	rs3770081	1	rs2241435	ENSG00000273080.1	RP11-301O19.1	-4.27	2.56e-05	0.0107	-0.51	-0.22	Facial emotion recognition (sad faces);	chr2:86133793	chr2:86195590~86196049:+
STAD	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	4.27	2.57e-05	0.0107	0.29	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
STAD	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	4.27	2.57e-05	0.0107	0.29	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
STAD	cis	rs34779708	0.931	rs4934697	ENSG00000271335.4	RP11-324I22.4	4.27	2.57e-05	0.0107	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35314552~35336401:-
STAD	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	4.27	2.57e-05	0.0107	0.24	0.22	Depression;	chr6:28379133	chr6:28176188~28176674:+
STAD	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	4.27	2.57e-05	0.0107	0.24	0.22	Depression;	chr6:28379168	chr6:28176188~28176674:+
STAD	cis	rs17401966	0.931	rs12130563	ENSG00000199562.1	RNU6-37P	4.27	2.57e-05	0.0107	0.18	0.22	Hepatocellular carcinoma;	chr1:10368394	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.931	rs12131441	ENSG00000199562.1	RNU6-37P	4.27	2.57e-05	0.0107	0.18	0.22	Hepatocellular carcinoma;	chr1:10368894	chr1:10298966~10299072:+
STAD	cis	rs8177876	0.749	rs78707250	ENSG00000261838.4	RP11-303E16.6	4.27	2.57e-05	0.0107	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81069854~81076598:+
STAD	cis	rs9902453	0.845	rs12452201	ENSG00000263477.1	RP11-338L22.2	4.27	2.57e-05	0.0107	0.19	0.22	Coffee consumption (cups per day);	chr17:29887155	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.845	rs58575982	ENSG00000263477.1	RP11-338L22.2	4.27	2.57e-05	0.0107	0.19	0.22	Coffee consumption (cups per day);	chr17:29894758	chr17:29863402~29866092:+
STAD	cis	rs539514	0.69	rs528783	ENSG00000261105.4	LMO7-AS1	4.27	2.57e-05	0.0107	0.27	0.22	Type 1 diabetes;	chr13:75745324	chr13:75604700~75635994:-
STAD	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-4.27	2.57e-05	0.0107	-0.22	-0.22	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
STAD	cis	rs9902453	0.765	rs2628191	ENSG00000240074.1	RPL9P30	-4.27	2.57e-05	0.0107	-0.19	-0.22	Coffee consumption (cups per day);	chr17:29724122	chr17:29855759~29856332:+
STAD	cis	rs9467773	0.595	rs7767847	ENSG00000243307.2	POM121L6P	4.27	2.57e-05	0.0107	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs3800303	ENSG00000243307.2	POM121L6P	4.27	2.57e-05	0.0107	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs9467810	ENSG00000243307.2	POM121L6P	4.27	2.57e-05	0.0107	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26896952~26898777:+
STAD	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	4.27	2.57e-05	0.0107	0.33	0.22	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
STAD	cis	rs7665090	0.743	rs228626	ENSG00000230069.3	LRRC37A15P	4.27	2.57e-05	0.0107	0.24	0.22	Primary biliary cholangitis;	chr4:102651789	chr4:102727274~102730721:-
STAD	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	4.27	2.57e-05	0.0107	0.33	0.22	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
STAD	cis	rs4691139	0.903	rs6812176	ENSG00000248632.1	RP11-366M4.11	4.27	2.57e-05	0.0107	0.22	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998820	chr4:164968587~164970002:-
STAD	cis	rs7829975	0.711	rs1039916	ENSG00000173295.6	FAM86B3P	4.27	2.57e-05	0.0107	0.25	0.22	Mood instability;	chr8:8828344	chr8:8228595~8244865:+
STAD	cis	rs9813712	0.585	rs9855392	ENSG00000249846.5	RP11-77P16.4	-4.27	2.57e-05	0.0107	-0.32	-0.22	Response to amphetamines;	chr3:130214403	chr3:130112550~130120579:+
STAD	cis	rs9902453	0.689	rs7216948	ENSG00000263477.1	RP11-338L22.2	4.27	2.57e-05	0.0107	0.19	0.22	Coffee consumption (cups per day);	chr17:29876155	chr17:29863402~29866092:+
STAD	cis	rs794185	0.625	rs2259801	ENSG00000231249.1	ITPR1-AS1	-4.27	2.57e-05	0.0107	-0.25	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471859	chr3:4490891~4493163:-
STAD	cis	rs12468226	0.938	rs10931993	ENSG00000272966.1	RP11-686O6.1	4.27	2.57e-05	0.0108	0.33	0.22	Urate levels;	chr2:202243017	chr2:202336739~202337200:+
STAD	cis	rs1816752	0.716	rs1441058	ENSG00000273628.1	RP11-756A22.7	-4.27	2.57e-05	0.0108	-0.27	-0.22	Obesity-related traits;	chr13:24516275	chr13:24933006~24936796:+
STAD	cis	rs2790457	0.833	rs1265843	ENSG00000254635.4	WAC-AS1	-4.27	2.57e-05	0.0108	-0.28	-0.22	Multiple myeloma;	chr10:28636088	chr10:28522652~28532743:-
STAD	cis	rs1707322	1	rs785507	ENSG00000281133.1	AL355480.3	4.27	2.58e-05	0.0108	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45580892~45580996:-
STAD	cis	rs1823874	0.71	rs4965543	ENSG00000182397.13	DNM1P46	-4.27	2.58e-05	0.0108	-0.24	-0.22	IgG glycosylation;	chr15:99821050	chr15:99790156~99806927:-
STAD	cis	rs10851478	0.872	rs12907944	ENSG00000259545.2	RP11-325E5.4	-4.27	2.58e-05	0.0108	-0.27	-0.22	Oral cavity cancer;	chr15:49614774	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs10851479	ENSG00000259545.2	RP11-325E5.4	-4.27	2.58e-05	0.0108	-0.27	-0.22	Oral cavity cancer;	chr15:49617544	chr15:49177610~49178741:-
STAD	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	4.27	2.58e-05	0.0108	0.27	0.22	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
STAD	cis	rs9902453	0.791	rs55655651	ENSG00000263477.1	RP11-338L22.2	4.27	2.58e-05	0.0108	0.19	0.22	Coffee consumption (cups per day);	chr17:29917268	chr17:29863402~29866092:+
STAD	cis	rs2688608	0.618	rs28553894	ENSG00000271816.1	BMS1P4	4.27	2.58e-05	0.0108	0.24	0.22	Inflammatory bowel disease;	chr10:73730085	chr10:73699151~73730487:-
STAD	cis	rs2688608	0.618	rs28718766	ENSG00000271816.1	BMS1P4	4.27	2.58e-05	0.0108	0.24	0.22	Inflammatory bowel disease;	chr10:73730086	chr10:73699151~73730487:-
STAD	cis	rs7615952	0.736	rs13063122	ENSG00000272840.1	RP11-379B18.6	4.27	2.58e-05	0.0108	0.41	0.22	Blood pressure (smoking interaction);	chr3:125925017	chr3:125774714~125797953:+
STAD	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	4.27	2.58e-05	0.0108	0.27	0.22	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
STAD	cis	rs10851478	0.802	rs12593917	ENSG00000259545.2	RP11-325E5.4	-4.27	2.58e-05	0.0108	-0.26	-0.22	Oral cavity cancer;	chr15:49544670	chr15:49177610~49178741:-
STAD	cis	rs2933343	0.729	rs813945	ENSG00000261159.1	RP11-723O4.9	4.27	2.58e-05	0.0108	0.28	0.22	IgG glycosylation;	chr3:128942094	chr3:128859716~128860526:-
STAD	cis	rs13413635	0.955	rs3910519	ENSG00000225808.1	DNAJC19P5	-4.27	2.58e-05	0.0108	-0.31	-0.22	Heart rate;	chr2:177828321	chr2:177229191~177229506:-
STAD	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-4.27	2.58e-05	0.0108	-0.3	-0.22	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
STAD	cis	rs494453	0.883	rs1099800	ENSG00000234020.1	CHIAP3	-4.26	2.58e-05	0.0108	-0.22	-0.22	Osteoporosis-related phenotypes;	chr1:111682961	chr1:111353275~111367409:-
STAD	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	4.26	2.58e-05	0.0108	0.22	0.22	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
STAD	cis	rs9902453	1	rs12600855	ENSG00000240074.1	RPL9P30	4.26	2.59e-05	0.0108	0.19	0.22	Coffee consumption (cups per day);	chr17:29952573	chr17:29855759~29856332:+
STAD	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	4.26	2.59e-05	0.0108	0.49	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	4.26	2.59e-05	0.0108	0.49	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	4.26	2.59e-05	0.0108	0.49	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
STAD	cis	rs4589258	0.762	rs12294086	ENSG00000280367.1	RP11-121L10.2	-4.26	2.59e-05	0.0108	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90664393	chr11:90223153~90226538:+
STAD	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	4.26	2.59e-05	0.0108	0.17	0.22	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
STAD	cis	rs7829975	0.511	rs1401390	ENSG00000254340.1	RP11-10A14.3	4.26	2.59e-05	0.0108	0.27	0.22	Mood instability;	chr8:8278888	chr8:9141424~9145435:+
STAD	cis	rs7944584	0.563	rs61895112	ENSG00000280615.1	Y_RNA	4.26	2.59e-05	0.0108	0.24	0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47538881	chr11:47614898~47614994:-
STAD	cis	rs7103648	0.618	rs11039284	ENSG00000280615.1	Y_RNA	4.26	2.59e-05	0.0108	0.24	0.22	Systolic blood pressure;Diastolic blood pressure;	chr11:47543233	chr11:47614898~47614994:-
STAD	cis	rs7944584	0.563	rs2280231	ENSG00000280615.1	Y_RNA	4.26	2.59e-05	0.0108	0.24	0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47578886	chr11:47614898~47614994:-
STAD	cis	rs1707322	1	rs11211223	ENSG00000281133.1	AL355480.3	-4.26	2.59e-05	0.0108	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45580892~45580996:-
STAD	cis	rs9291683	0.507	rs6845554	ENSG00000250613.1	RP11-136I13.1	-4.26	2.59e-05	0.0108	-0.23	-0.22	Bone mineral density;	chr4:10011549	chr4:10410996~10411644:+
STAD	cis	rs7647973	0.58	rs2334958	ENSG00000225399.4	RP11-3B7.1	4.26	2.59e-05	0.0108	0.24	0.22	Menarche (age at onset);	chr3:49214931	chr3:49260085~49261316:+
STAD	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	4.26	2.59e-05	0.0108	0.27	0.22	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
STAD	cis	rs11098499	0.863	rs1383533	ENSG00000260091.1	RP11-33B1.4	4.26	2.59e-05	0.0108	0.22	0.22	Corneal astigmatism;	chr4:119513421	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.863	rs2291185	ENSG00000260091.1	RP11-33B1.4	4.26	2.59e-05	0.0108	0.22	0.22	Corneal astigmatism;	chr4:119513678	chr4:119409333~119410233:+
STAD	cis	rs8141529	0.748	rs132529	ENSG00000226471.5	CTA-292E10.6	4.26	2.59e-05	0.0108	0.26	0.22	Lymphocyte counts;	chr22:28900664	chr22:28800683~28848559:+
STAD	cis	rs9902453	0.967	rs9900911	ENSG00000240074.1	RPL9P30	-4.26	2.59e-05	0.0108	-0.19	-0.22	Coffee consumption (cups per day);	chr17:30003262	chr17:29855759~29856332:+
STAD	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-4.26	2.6e-05	0.0108	-0.33	-0.22	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
STAD	cis	rs6471393	0.964	rs11549490	ENSG00000253848.1	RP11-10N23.5	-4.26	2.6e-05	0.0108	-0.26	-0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732822	chr8:93741193~93744534:+
STAD	cis	rs7826238	0.517	rs35144760	ENSG00000173295.6	FAM86B3P	-4.26	2.6e-05	0.0108	-0.31	-0.22	Systolic blood pressure;	chr8:8504213	chr8:8228595~8244865:+
STAD	cis	rs6940116	1	rs6940116	ENSG00000280107.1	AL022393.9	-4.26	2.6e-05	0.0108	-0.37	-0.22	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28170845~28172521:+
STAD	cis	rs1707322	1	rs1707322	ENSG00000225447.1	RPS15AP10	4.26	2.6e-05	0.0108	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45645816~45646197:-
STAD	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-4.26	2.6e-05	0.0108	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
STAD	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-4.26	2.6e-05	0.0108	-0.25	-0.22	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
STAD	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	4.26	2.6e-05	0.0108	0.29	0.22	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
STAD	cis	rs1707322	1	rs10890365	ENSG00000225447.1	RPS15AP10	4.26	2.6e-05	0.0108	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45645816~45646197:-
STAD	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	4.26	2.6e-05	0.0108	0.31	0.22	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
STAD	cis	rs9902453	1	rs9890886	ENSG00000240074.1	RPL9P30	-4.26	2.6e-05	0.0108	-0.19	-0.22	Coffee consumption (cups per day);	chr17:30064058	chr17:29855759~29856332:+
STAD	cis	rs17401966	0.931	rs3748579	ENSG00000199562.1	RNU6-37P	4.26	2.6e-05	0.0108	0.18	0.22	Hepatocellular carcinoma;	chr1:10360879	chr1:10298966~10299072:+
STAD	cis	rs11157436	0.958	rs3811277	ENSG00000211813.2	TRAV34	4.26	2.6e-05	0.0108	0.27	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22207522~22208129:+
STAD	cis	rs6142102	0.961	rs6088360	ENSG00000264616.1	MIR4755	4.26	2.6e-05	0.0108	0.23	0.22	Skin pigmentation;	chr20:33969383	chr20:34049119~34049190:+
STAD	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	4.26	2.6e-05	0.0108	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
STAD	cis	rs7665090	0.87	rs228616	ENSG00000230069.3	LRRC37A15P	4.26	2.6e-05	0.0109	0.24	0.22	Primary biliary cholangitis;	chr4:102658534	chr4:102727274~102730721:-
STAD	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-4.26	2.6e-05	0.0109	-0.29	-0.22	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
STAD	cis	rs4845875	0.6	rs6699881	ENSG00000242349.4	NPPA-AS1	4.26	2.6e-05	0.0109	0.25	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776571	chr1:11841017~11848079:+
STAD	cis	rs4589258	0.713	rs2508409	ENSG00000280367.1	RP11-121L10.2	-4.26	2.61e-05	0.0109	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90704300	chr11:90223153~90226538:+
STAD	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-4.26	2.61e-05	0.0109	-0.23	-0.22	Height;	chr5:37068442	chr5:36666214~36725195:-
STAD	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-4.26	2.61e-05	0.0109	-0.23	-0.22	Height;	chr5:37072722	chr5:36666214~36725195:-
STAD	cis	rs6840360	0.582	rs11733820	ENSG00000270265.1	RP11-731D1.4	-4.26	2.61e-05	0.0109	-0.27	-0.22	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151333775~151353224:-
STAD	cis	rs13413635	0.66	rs13030747	ENSG00000225808.1	DNAJC19P5	4.26	2.61e-05	0.0109	0.27	0.22	Heart rate;	chr2:178001767	chr2:177229191~177229506:-
STAD	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	4.26	2.61e-05	0.0109	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
STAD	cis	rs449789	0.857	rs1875816	ENSG00000235086.1	FNDC1-IT1	-4.26	2.61e-05	0.0109	-0.29	-0.22	Pulse pressure;	chr6:159299282	chr6:159240786~159243329:+
STAD	cis	rs10508774	0.925	rs12268767	ENSG00000273038.2	RP11-479G22.8	4.26	2.61e-05	0.0109	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32863779	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12269463	ENSG00000273038.2	RP11-479G22.8	4.26	2.61e-05	0.0109	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32864727	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs56185149	ENSG00000273038.2	RP11-479G22.8	4.26	2.61e-05	0.0109	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32866782	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12264294	ENSG00000273038.2	RP11-479G22.8	4.26	2.61e-05	0.0109	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32867299	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs11009121	ENSG00000273038.2	RP11-479G22.8	4.26	2.61e-05	0.0109	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32877178	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs10827150	ENSG00000273038.2	RP11-479G22.8	4.26	2.61e-05	0.0109	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32877888	chr10:32887255~32889311:-
STAD	cis	rs9659323	0.65	rs10802064	ENSG00000231365.4	RP11-418J17.1	-4.26	2.61e-05	0.0109	-0.3	-0.22	Body mass index;	chr1:118915514	chr1:119140396~119275973:+
STAD	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	4.26	2.61e-05	0.0109	0.33	0.22	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	4.26	2.61e-05	0.0109	0.33	0.22	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	4.26	2.61e-05	0.0109	0.33	0.22	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
STAD	cis	rs9902453	1	rs9902453	ENSG00000240074.1	RPL9P30	-4.26	2.61e-05	0.0109	-0.19	-0.22	Coffee consumption (cups per day);	chr17:30022077	chr17:29855759~29856332:+
STAD	cis	rs58873874	0.579	rs77042939	ENSG00000251405.2	CTB-109A12.1	4.26	2.61e-05	0.0109	0.39	0.22	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157362615~157460078:-
STAD	cis	rs7680126	0.632	rs78030862	ENSG00000250613.1	RP11-136I13.1	4.26	2.61e-05	0.0109	0.27	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10148788	chr4:10410996~10411644:+
STAD	cis	rs656319	0.625	rs4526366	ENSG00000254340.1	RP11-10A14.3	-4.26	2.61e-05	0.0109	-0.3	-0.22	Myopia (pathological);	chr8:10032669	chr8:9141424~9145435:+
STAD	cis	rs737008	0.922	rs28567501	ENSG00000262703.1	RP11-485G7.6	-4.26	2.61e-05	0.0109	-0.22	-0.22	Obesity-related traits;	chr16:11285071	chr16:11348143~11349321:-
STAD	cis	rs1348850	0.914	rs1348849	ENSG00000271825.1	RP11-337N6.2	4.26	2.62e-05	0.0109	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177493344	chr2:177300600~177302006:+
STAD	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	4.26	2.62e-05	0.0109	0.3	0.22	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
STAD	cis	rs944722	0.967	rs2297512	ENSG00000266786.1	LGALS9DP	4.26	2.62e-05	0.0109	0.28	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27765529	chr17:27746132~27754954:+
STAD	cis	rs944722	1	rs1060822	ENSG00000266786.1	LGALS9DP	4.26	2.62e-05	0.0109	0.28	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27765605	chr17:27746132~27754954:+
STAD	cis	rs7646881	0.812	rs75107964	ENSG00000240207.5	RP11-379F4.4	-4.26	2.62e-05	0.0109	-0.4	-0.22	Tetralogy of Fallot;	chr3:158740962	chr3:158732263~158784070:+
STAD	cis	rs11098499	0.954	rs3733524	ENSG00000260091.1	RP11-33B1.4	4.26	2.62e-05	0.0109	0.22	0.22	Corneal astigmatism;	chr4:119502574	chr4:119409333~119410233:+
STAD	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	4.26	2.62e-05	0.0109	0.28	0.22	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
STAD	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	4.26	2.62e-05	0.0109	0.24	0.22	Depression;	chr6:28402301	chr6:28176188~28176674:+
STAD	cis	rs2638953	0.924	rs11049418	ENSG00000247934.4	RP11-967K21.1	-4.26	2.62e-05	0.0109	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192154	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs12367188	ENSG00000247934.4	RP11-967K21.1	-4.26	2.62e-05	0.0109	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192511	chr12:28163298~28190738:-
STAD	cis	rs7200543	0.848	rs62039480	ENSG00000207425.1	Y_RNA	-4.26	2.62e-05	0.0109	-0.23	-0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:14915457~14915556:-
STAD	cis	rs6430585	0.528	rs309122	ENSG00000231890.6	DARS-AS1	-4.26	2.62e-05	0.0109	-0.24	-0.22	Corneal structure;	chr2:136004283	chr2:135985176~136022593:+
STAD	cis	rs9902453	0.817	rs17226179	ENSG00000263477.1	RP11-338L22.2	4.26	2.62e-05	0.0109	0.19	0.22	Coffee consumption (cups per day);	chr17:29841555	chr17:29863402~29866092:+
STAD	cis	rs1322639	0.618	rs9505942	ENSG00000261039.2	RP11-417E7.2	-4.26	2.62e-05	0.0109	-0.37	-0.22	Pulse pressure;	chr6:169191698	chr6:169175304~169182740:-
STAD	cis	rs1348850	0.872	rs2084233	ENSG00000271825.1	RP11-337N6.2	4.26	2.62e-05	0.0109	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177466478	chr2:177300600~177302006:+
STAD	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-4.26	2.62e-05	0.0109	-0.27	-0.22	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
STAD	cis	rs8099594	0.524	rs12961466	ENSG00000266696.1	RP11-30L3.2	4.26	2.63e-05	0.0109	0.21	0.22	Height;	chr18:49212792	chr18:49205912~49208781:+
STAD	cis	rs2638953	0.962	rs11049370	ENSG00000247934.4	RP11-967K21.1	-4.26	2.63e-05	0.0109	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28146904	chr12:28163298~28190738:-
STAD	cis	rs227932	0.51	rs10950957	ENSG00000234286.1	AC006026.13	4.26	2.63e-05	0.0109	0.38	0.22	Schizophrenia;	chr7:23723661	chr7:23680195~23680786:-
STAD	cis	rs7395581	0.959	rs2167079	ENSG00000271350.1	CTD-2384B9.1	4.26	2.63e-05	0.0109	0.27	0.22	HDL cholesterol;	chr11:47248704	chr11:47041027~47041945:-
STAD	cis	rs11676348	0.772	rs10932745	ENSG00000237281.1	CATIP-AS2	4.26	2.63e-05	0.0109	0.22	0.22	Ulcerative colitis;	chr2:218078253	chr2:218326889~218357966:-
STAD	cis	rs7278690	0.777	rs6517070	ENSG00000235609.7	AF127936.9	4.26	2.63e-05	0.0109	0.5	0.22	Breast cancer;	chr21:14866227	chr21:14818843~15014430:-
STAD	cis	rs2836974	0.666	rs11910705	ENSG00000238141.2	BRWD1-AS1	-4.26	2.63e-05	0.0109	-0.23	-0.22	Cognitive function;	chr21:39313678	chr21:39315707~39323218:+
STAD	cis	rs7937890	0.587	rs11023204	ENSG00000254418.1	RP11-21L19.1	4.26	2.63e-05	0.0109	0.24	0.22	Mitochondrial DNA levels;	chr11:14389677	chr11:14262846~14273691:-
STAD	cis	rs12745968	0.653	rs11164810	ENSG00000229052.2	RP11-386I23.1	-4.26	2.63e-05	0.0109	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92779423	chr1:92930696~92934098:+
STAD	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	4.26	2.63e-05	0.0109	0.26	0.22	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
STAD	cis	rs7829975	0.56	rs17154599	ENSG00000254340.1	RP11-10A14.3	-4.26	2.63e-05	0.011	-0.3	-0.22	Mood instability;	chr8:8693908	chr8:9141424~9145435:+
STAD	cis	rs1707322	0.964	rs6675259	ENSG00000281133.1	AL355480.3	4.26	2.64e-05	0.011	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45580892~45580996:-
STAD	cis	rs9425766	0.626	rs6691053	ENSG00000227373.4	RP11-160H22.5	4.26	2.64e-05	0.011	0.31	0.22	Life satisfaction;	chr1:173899817	chr1:174115300~174160004:-
STAD	cis	rs12908161	1	rs35630683	ENSG00000259295.5	CSPG4P12	4.26	2.64e-05	0.011	0.32	0.22	Schizophrenia;	chr15:84806000	chr15:85191438~85213905:+
STAD	cis	rs9291683	0.552	rs11736410	ENSG00000250613.1	RP11-136I13.1	-4.26	2.64e-05	0.011	-0.21	-0.22	Bone mineral density;	chr4:10015617	chr4:10410996~10411644:+
STAD	cis	rs13413635	0.66	rs764780	ENSG00000225808.1	DNAJC19P5	4.26	2.64e-05	0.011	0.27	0.22	Heart rate;	chr2:178006475	chr2:177229191~177229506:-
STAD	cis	rs4925166	1	rs4925166	ENSG00000233327.9	USP32P2	-4.26	2.64e-05	0.011	-0.27	-0.22	Multiple sclerosis;	chr17:18307496	chr17:18511262~18525930:-
STAD	cis	rs1823874	0.71	rs3919790	ENSG00000182397.13	DNM1P46	-4.26	2.64e-05	0.011	-0.24	-0.22	IgG glycosylation;	chr15:99821130	chr15:99790156~99806927:-
STAD	cis	rs1823874	0.71	rs1840298	ENSG00000182397.13	DNM1P46	-4.26	2.64e-05	0.011	-0.24	-0.22	IgG glycosylation;	chr15:99821889	chr15:99790156~99806927:-
STAD	cis	rs1707322	1	rs785467	ENSG00000225447.1	RPS15AP10	-4.26	2.64e-05	0.011	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45645816~45646197:-
STAD	cis	rs2439831	0.85	rs67541383	ENSG00000275601.1	AC011330.13	-4.26	2.65e-05	0.011	-0.36	-0.22	Lung cancer in ever smokers;	chr15:43880350	chr15:43642389~43643023:-
STAD	cis	rs4589258	0.788	rs2226918	ENSG00000280367.1	RP11-121L10.2	4.26	2.65e-05	0.011	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90734523	chr11:90223153~90226538:+
STAD	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-4.26	2.65e-05	0.011	-0.26	-0.22	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
STAD	cis	rs9467773	0.62	rs1490488	ENSG00000243307.2	POM121L6P	4.26	2.65e-05	0.011	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs2494692	ENSG00000243307.2	POM121L6P	4.26	2.65e-05	0.011	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26896952~26898777:+
STAD	cis	rs7474896	0.515	rs2738203	ENSG00000120555.12	SEPT7P9	-4.26	2.65e-05	0.011	-0.29	-0.22	Obesity (extreme);	chr10:37988668	chr10:38383069~38402916:-
STAD	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
STAD	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
STAD	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
STAD	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
STAD	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
STAD	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
STAD	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
STAD	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
STAD	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	4.26	2.65e-05	0.011	0.31	0.22	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
STAD	cis	rs12554020	0.685	rs55893789	ENSG00000227603.1	RP11-165J3.6	4.26	2.65e-05	0.011	0.42	0.22	Schizophrenia;	chr9:93408608	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.681	rs78759589	ENSG00000227603.1	RP11-165J3.6	4.26	2.65e-05	0.011	0.42	0.22	Schizophrenia;	chr9:93409518	chr9:93435332~93437121:-
STAD	cis	rs8062405	0.755	rs7193402	ENSG00000278665.1	RP11-666O2.4	4.26	2.65e-05	0.011	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28599241~28601881:-
STAD	cis	rs935334	1	rs2121070	ENSG00000258454.1	RP11-361H10.3	4.26	2.65e-05	0.011	0.32	0.22	Blood pressure;	chr14:76184421	chr14:76235817~76263474:+
STAD	cis	rs8177876	0.822	rs8177950	ENSG00000261838.4	RP11-303E16.6	4.26	2.65e-05	0.011	0.49	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.731	rs8177948	ENSG00000261838.4	RP11-303E16.6	4.26	2.65e-05	0.011	0.49	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81069854~81076598:+
STAD	cis	rs9902453	0.904	rs4077465	ENSG00000240074.1	RPL9P30	4.26	2.65e-05	0.011	0.19	0.22	Coffee consumption (cups per day);	chr17:29973126	chr17:29855759~29856332:+
STAD	cis	rs11098499	0.661	rs10015965	ENSG00000260091.1	RP11-33B1.4	4.26	2.65e-05	0.011	0.21	0.22	Corneal astigmatism;	chr4:119347082	chr4:119409333~119410233:+
STAD	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-4.26	2.65e-05	0.011	-0.32	-0.22	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
STAD	cis	rs62400317	0.762	rs62436376	ENSG00000219384.1	RP11-491H9.3	-4.26	2.65e-05	0.011	-0.26	-0.22	Total body bone mineral density;	chr6:44918080	chr6:45158870~45159511:+
STAD	cis	rs11098499	0.955	rs1511018	ENSG00000260091.1	RP11-33B1.4	4.26	2.65e-05	0.011	0.22	0.22	Corneal astigmatism;	chr4:119240425	chr4:119409333~119410233:+
STAD	cis	rs9859260	0.744	rs406271	ENSG00000185485.13	SDHAP1	-4.26	2.66e-05	0.011	-0.22	-0.22	Mean corpuscular volume;	chr3:196050105	chr3:195959748~195990318:-
STAD	cis	rs9859260	0.71	rs419068	ENSG00000185485.13	SDHAP1	-4.26	2.66e-05	0.011	-0.22	-0.22	Mean corpuscular volume;	chr3:196055305	chr3:195959748~195990318:-
STAD	cis	rs9859260	0.71	rs366268	ENSG00000185485.13	SDHAP1	-4.26	2.66e-05	0.011	-0.22	-0.22	Mean corpuscular volume;	chr3:196055306	chr3:195959748~195990318:-
STAD	cis	rs9859260	0.744	rs419059	ENSG00000185485.13	SDHAP1	-4.26	2.66e-05	0.011	-0.22	-0.22	Mean corpuscular volume;	chr3:196055313	chr3:195959748~195990318:-
STAD	cis	rs1816752	1	rs1816752	ENSG00000232858.1	RPL34P27	4.26	2.66e-05	0.011	0.14	0.22	Obesity-related traits;	chr13:24406811	chr13:24988577~24988925:-
STAD	cis	rs6142102	0.961	rs6120519	ENSG00000264616.1	MIR4755	4.26	2.66e-05	0.011	0.23	0.22	Skin pigmentation;	chr20:34100307	chr20:34049119~34049190:+
STAD	cis	rs794185	0.806	rs711637	ENSG00000231249.1	ITPR1-AS1	-4.26	2.66e-05	0.011	-0.25	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4445582	chr3:4490891~4493163:-
STAD	cis	rs7474896	0.515	rs624359	ENSG00000120555.12	SEPT7P9	-4.26	2.66e-05	0.0111	-0.28	-0.22	Obesity (extreme);	chr10:38010204	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.537	rs598857	ENSG00000120555.12	SEPT7P9	-4.26	2.66e-05	0.0111	-0.28	-0.22	Obesity (extreme);	chr10:38013998	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.515	rs2738208	ENSG00000120555.12	SEPT7P9	-4.26	2.66e-05	0.0111	-0.28	-0.22	Obesity (extreme);	chr10:38017200	chr10:38383069~38402916:-
STAD	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-4.26	2.66e-05	0.0111	-0.32	-0.22	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
STAD	cis	rs6565180	0.926	rs4787643	ENSG00000273724.1	RP11-347C12.12	4.26	2.66e-05	0.0111	0.25	0.22	Tonsillectomy;	chr16:30382339	chr16:30336400~30343336:+
STAD	cis	rs6565180	0.926	rs4788409	ENSG00000273724.1	RP11-347C12.12	4.26	2.66e-05	0.0111	0.25	0.22	Tonsillectomy;	chr16:30382450	chr16:30336400~30343336:+
STAD	cis	rs9393777	0.623	rs2093169	ENSG00000241549.7	GUSBP2	4.26	2.66e-05	0.0111	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26494871	chr6:26871484~26956554:-
STAD	cis	rs4589258	0.687	rs1783793	ENSG00000280367.1	RP11-121L10.2	-4.26	2.66e-05	0.0111	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90706777	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1792599	ENSG00000280367.1	RP11-121L10.2	-4.26	2.66e-05	0.0111	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90709072	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1783797	ENSG00000280367.1	RP11-121L10.2	-4.26	2.66e-05	0.0111	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90709083	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1783800	ENSG00000280367.1	RP11-121L10.2	-4.26	2.66e-05	0.0111	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90712303	chr11:90223153~90226538:+
STAD	cis	rs539514	0.612	rs1830760	ENSG00000261105.4	LMO7-AS1	4.26	2.66e-05	0.0111	0.28	0.22	Type 1 diabetes;	chr13:75722489	chr13:75604700~75635994:-
STAD	cis	rs7829975	0.755	rs3789849	ENSG00000253981.4	ALG1L13P	4.26	2.66e-05	0.0111	0.25	0.22	Mood instability;	chr8:8829544	chr8:8236003~8244667:-
STAD	cis	rs2638953	0.853	rs10506038	ENSG00000247934.4	RP11-967K21.1	4.26	2.66e-05	0.0111	0.25	0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506239	chr12:28163298~28190738:-
STAD	cis	rs55823223	0.564	rs936396	ENSG00000267801.1	RP11-552F3.9	4.26	2.67e-05	0.0111	0.29	0.22	Psoriasis;	chr17:75850748	chr17:75876372~75879546:+
STAD	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	4.26	2.67e-05	0.0111	0.19	0.22	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
STAD	cis	rs10851478	0.872	rs12232355	ENSG00000259545.2	RP11-325E5.4	-4.26	2.67e-05	0.0111	-0.26	-0.22	Oral cavity cancer;	chr15:49540181	chr15:49177610~49178741:-
STAD	cis	rs1707322	1	rs10890365	ENSG00000281133.1	AL355480.3	-4.26	2.67e-05	0.0111	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45580892~45580996:-
STAD	cis	rs13413635	0.913	rs62184549	ENSG00000225808.1	DNAJC19P5	-4.26	2.67e-05	0.0111	-0.31	-0.22	Heart rate;	chr2:177830263	chr2:177229191~177229506:-
STAD	cis	rs1348850	0.914	rs3902850	ENSG00000271825.1	RP11-337N6.2	4.26	2.67e-05	0.0111	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177451171	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.914	rs1453370	ENSG00000271825.1	RP11-337N6.2	4.26	2.67e-05	0.0111	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177462999	chr2:177300600~177302006:+
STAD	cis	rs9902453	0.904	rs6505148	ENSG00000240074.1	RPL9P30	4.26	2.67e-05	0.0111	0.19	0.22	Coffee consumption (cups per day);	chr17:29962800	chr17:29855759~29856332:+
STAD	cis	rs875971	1	rs709597	ENSG00000236529.1	RP13-254B10.1	-4.26	2.67e-05	0.0111	-0.23	-0.22	Aortic root size;	chr7:66360996	chr7:65840212~65840596:+
STAD	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	4.26	2.67e-05	0.0111	0.31	0.22	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
STAD	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-4.26	2.67e-05	0.0111	-0.34	-0.22	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
STAD	cis	rs593531	0.614	rs486758	ENSG00000280269.1	AP000577.2	-4.26	2.67e-05	0.0111	-0.23	-0.22	Neuroticism;	chr11:74347887	chr11:74204869~74205746:+
STAD	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	4.26	2.67e-05	0.0111	0.35	0.22	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
STAD	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	4.26	2.67e-05	0.0111	0.38	0.22	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
STAD	cis	rs240993	0.516	rs240981	ENSG00000230177.1	RP5-1112D6.4	-4.26	2.67e-05	0.0111	-0.24	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111289990	chr6:111277932~111278742:+
STAD	cis	rs5758659	0.714	rs5758589	ENSG00000182057.4	OGFRP1	-4.26	2.67e-05	0.0111	-0.24	-0.22	Cognitive function;	chr22:42122378	chr22:42269753~42275196:+
STAD	cis	rs858239	0.539	rs6975852	ENSG00000230042.1	AK3P3	-4.26	2.67e-05	0.0111	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23129178~23129841:+
STAD	cis	rs11098499	0.691	rs17009144	ENSG00000260091.1	RP11-33B1.4	-4.26	2.67e-05	0.0111	-0.21	-0.22	Corneal astigmatism;	chr4:119349640	chr4:119409333~119410233:+
STAD	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-4.26	2.68e-05	0.0111	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
STAD	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-4.26	2.68e-05	0.0111	-0.27	-0.22	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
STAD	cis	rs765787	0.53	rs11634794	ENSG00000259539.1	CTD-2651B20.1	4.26	2.68e-05	0.0111	0.26	0.22	Uric acid levels;	chr15:45242294	chr15:45152664~45167526:-
STAD	cis	rs8028182	0.636	rs11637586	ENSG00000260269.4	CTD-2323K18.1	-4.26	2.68e-05	0.0111	-0.29	-0.22	Sudden cardiac arrest;	chr15:75498771	chr15:75527150~75601205:-
STAD	cis	rs6432852	0.527	rs7590559	ENSG00000229195.1	AC009495.4	-4.26	2.68e-05	0.0111	-0.25	-0.22	Diabetic kidney disease;	chr2:165915153	chr2:165794857~165846091:-
STAD	cis	rs7615952	0.609	rs13088451	ENSG00000242229.1	RPS3AP14	4.26	2.68e-05	0.0111	0.29	0.22	Blood pressure (smoking interaction);	chr3:125834656	chr3:125795106~125795885:+
STAD	cis	rs6432852	0.966	rs2288701	ENSG00000229195.1	AC009495.4	4.26	2.68e-05	0.0111	0.26	0.22	Diabetic kidney disease;	chr2:165948117	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.966	rs35049552	ENSG00000229195.1	AC009495.4	4.26	2.68e-05	0.0111	0.26	0.22	Diabetic kidney disease;	chr2:165948757	chr2:165794857~165846091:-
STAD	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-4.26	2.68e-05	0.0111	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
STAD	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-4.26	2.68e-05	0.0111	-0.26	-0.22	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
STAD	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	4.26	2.68e-05	0.0111	0.33	0.22	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
STAD	cis	rs9788721	0.836	rs17484524	ENSG00000259419.2	HNRNPCP3	4.26	2.68e-05	0.0111	0.25	0.22	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78480334	chr15:79236332~79237206:+
STAD	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	4.26	2.68e-05	0.0111	0.29	0.22	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
STAD	cis	rs935334	1	rs2543387	ENSG00000258454.1	RP11-361H10.3	4.26	2.68e-05	0.0111	0.32	0.22	Blood pressure;	chr14:76162703	chr14:76235817~76263474:+
STAD	cis	rs2992257	0.958	rs2050447	ENSG00000251839.1	RNU7-12P	-4.26	2.69e-05	0.0111	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26441387	chr10:27232255~27232316:-
STAD	cis	rs2992257	0.958	rs3006803	ENSG00000251839.1	RNU7-12P	-4.26	2.69e-05	0.0111	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26444352	chr10:27232255~27232316:-
STAD	cis	rs4237845	0.591	rs10431506	ENSG00000273805.1	RP11-620J15.4	-4.26	2.69e-05	0.0111	-0.26	-0.22	Intelligence (multi-trait analysis);	chr12:57917741	chr12:57894232~57896846:+
STAD	cis	rs9902453	0.791	rs28492945	ENSG00000263477.1	RP11-338L22.2	4.26	2.69e-05	0.0111	0.19	0.22	Coffee consumption (cups per day);	chr17:29896964	chr17:29863402~29866092:+
STAD	cis	rs2980439	0.557	rs2976876	ENSG00000254340.1	RP11-10A14.3	4.26	2.69e-05	0.0111	0.27	0.22	Neuroticism;	chr8:8461340	chr8:9141424~9145435:+
STAD	cis	rs2980439	0.557	rs2921056	ENSG00000254340.1	RP11-10A14.3	4.26	2.69e-05	0.0111	0.27	0.22	Neuroticism;	chr8:8461672	chr8:9141424~9145435:+
STAD	cis	rs7826238	0.524	rs2921055	ENSG00000254340.1	RP11-10A14.3	4.26	2.69e-05	0.0111	0.27	0.22	Systolic blood pressure;	chr8:8461832	chr8:9141424~9145435:+
STAD	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	4.26	2.69e-05	0.0111	0.43	0.22	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
STAD	cis	rs1707322	0.963	rs10789478	ENSG00000225447.1	RPS15AP10	4.26	2.69e-05	0.0111	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45645816~45646197:-
STAD	cis	rs11846409	0.521	rs10143547	ENSG00000211970.3	IGHV4-61	4.26	2.69e-05	0.0111	0.24	0.22	Rheumatic heart disease;	chr14:106644638	chr14:106639119~106639657:-
STAD	cis	rs875971	0.862	rs3893216	ENSG00000224316.1	RP11-479O9.2	-4.26	2.69e-05	0.0111	-0.22	-0.22	Aortic root size;	chr7:66325720	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6958294	ENSG00000224316.1	RP11-479O9.2	-4.26	2.69e-05	0.0111	-0.22	-0.22	Aortic root size;	chr7:66329809	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs2088655	ENSG00000224316.1	RP11-479O9.2	-4.26	2.69e-05	0.0111	-0.22	-0.22	Aortic root size;	chr7:66330724	chr7:65773620~65802067:+
STAD	cis	rs875971	0.895	rs10447522	ENSG00000224316.1	RP11-479O9.2	-4.26	2.69e-05	0.0111	-0.22	-0.22	Aortic root size;	chr7:66331087	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs2088653	ENSG00000224316.1	RP11-479O9.2	-4.26	2.69e-05	0.0111	-0.22	-0.22	Aortic root size;	chr7:66343621	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6460293	ENSG00000224316.1	RP11-479O9.2	-4.26	2.69e-05	0.0111	-0.22	-0.22	Aortic root size;	chr7:66345205	chr7:65773620~65802067:+
STAD	cis	rs5769765	0.671	rs138832	ENSG00000279494.1	RP11-494O16.4	4.26	2.69e-05	0.0112	0.3	0.22	Schizophrenia;	chr22:49784434	chr22:49851425~49853364:+
STAD	cis	rs1348850	0.914	rs10170667	ENSG00000271825.1	RP11-337N6.2	4.26	2.69e-05	0.0112	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177472150	chr2:177300600~177302006:+
STAD	cis	rs2221894	0.511	rs13250513	ENSG00000273710.1	Metazoa_SRP	-4.26	2.69e-05	0.0112	-0.23	-0.22	Obesity-related traits;	chr8:29077208	chr8:28915579~28915864:-
STAD	cis	rs4061073	0.509	rs3088379	ENSG00000198711.5	SSBP3-AS1	-4.26	2.69e-05	0.0112	-0.16	-0.22	Body mass index;	chr1:54225281	chr1:54236440~54239063:+
STAD	cis	rs228614	0.51	rs223313	ENSG00000248971.2	KRT8P46	-4.26	2.69e-05	0.0112	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102728746~102730171:-
STAD	cis	rs375092	0.543	rs7808331	ENSG00000230658.1	KLHL7-AS1	4.26	2.69e-05	0.0112	0.36	0.22	Personality dimensions;	chr7:23374070	chr7:23101228~23105703:-
STAD	cis	rs765787	0.505	rs11630884	ENSG00000259539.1	CTD-2651B20.1	4.26	2.69e-05	0.0112	0.26	0.22	Uric acid levels;	chr15:45240048	chr15:45152664~45167526:-
STAD	cis	rs34779708	0.897	rs4934529	ENSG00000271335.4	RP11-324I22.4	4.25	2.7e-05	0.0112	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs7920095	ENSG00000271335.4	RP11-324I22.4	4.25	2.7e-05	0.0112	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35314552~35336401:-
STAD	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	4.25	2.7e-05	0.0112	0.27	0.22	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	4.25	2.7e-05	0.0112	0.27	0.22	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
STAD	cis	rs6693567	0.545	rs7411534	ENSG00000203819.6	HIST2H2BC	4.25	2.7e-05	0.0112	0.25	0.22	Migraine;	chr1:150474793	chr1:149850193~149850772:-
STAD	cis	rs6430585	0.583	rs59243420	ENSG00000231890.6	DARS-AS1	-4.25	2.7e-05	0.0112	-0.26	-0.22	Corneal structure;	chr2:135826968	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs58116536	ENSG00000231890.6	DARS-AS1	-4.25	2.7e-05	0.0112	-0.26	-0.22	Corneal structure;	chr2:135827753	chr2:135985176~136022593:+
STAD	cis	rs2579500	0.807	rs10177168	ENSG00000230606.9	AC159540.1	4.25	2.7e-05	0.0112	0.27	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96614503	chr2:97416165~97433527:-
STAD	cis	rs2579500	0.807	rs6576978	ENSG00000230606.9	AC159540.1	4.25	2.7e-05	0.0112	0.27	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96620115	chr2:97416165~97433527:-
STAD	cis	rs2579500	0.807	rs6741277	ENSG00000230606.9	AC159540.1	4.25	2.7e-05	0.0112	0.27	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96629166	chr2:97416165~97433527:-
STAD	cis	rs2579500	0.807	rs7584930	ENSG00000230606.9	AC159540.1	4.25	2.7e-05	0.0112	0.27	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96632553	chr2:97416165~97433527:-
STAD	cis	rs9393777	0.513	rs7759969	ENSG00000224843.5	LINC00240	4.25	2.7e-05	0.0112	0.32	0.22	Intelligence (multi-trait analysis);	chr6:26662868	chr6:26956992~27023924:+
STAD	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	4.25	2.7e-05	0.0112	0.42	0.22	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
STAD	cis	rs2638953	0.924	rs17801436	ENSG00000247934.4	RP11-967K21.1	-4.25	2.7e-05	0.0112	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165421	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049385	ENSG00000247934.4	RP11-967K21.1	-4.25	2.7e-05	0.0112	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167559	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049387	ENSG00000247934.4	RP11-967K21.1	-4.25	2.7e-05	0.0112	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167609	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs12371462	ENSG00000247934.4	RP11-967K21.1	-4.25	2.7e-05	0.0112	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28168770	chr12:28163298~28190738:-
STAD	cis	rs301901	0.766	rs12521993	ENSG00000250155.1	CTD-2353F22.1	4.25	2.7e-05	0.0112	0.23	0.22	Height;	chr5:37488095	chr5:36666214~36725195:-
STAD	cis	rs4713118	0.869	rs2056925	ENSG00000243307.2	POM121L6P	-4.25	2.7e-05	0.0112	-0.26	-0.22	Parkinson's disease;	chr6:27723126	chr6:26896952~26898777:+
STAD	cis	rs8141529	0.664	rs5762862	ENSG00000226471.5	CTA-292E10.6	-4.25	2.7e-05	0.0112	-0.28	-0.22	Lymphocyte counts;	chr22:28856744	chr22:28800683~28848559:+
STAD	cis	rs1900504	0.584	rs2915754	ENSG00000266200.5	PNLIPRP2	-4.25	2.7e-05	0.0112	-0.31	-0.22	Tonsillectomy;	chr10:116605306	chr10:116620953~116645143:+
STAD	cis	rs9291683	0.526	rs12506122	ENSG00000250613.1	RP11-136I13.1	-4.25	2.7e-05	0.0112	-0.23	-0.22	Bone mineral density;	chr4:10031914	chr4:10410996~10411644:+
STAD	cis	rs227275	0.556	rs7676765	ENSG00000248971.2	KRT8P46	4.25	2.7e-05	0.0112	0.23	0.22	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102728746~102730171:-
STAD	cis	rs8099594	0.565	rs1893526	ENSG00000266696.1	RP11-30L3.2	4.25	2.7e-05	0.0112	0.2	0.22	Height;	chr18:49185406	chr18:49205912~49208781:+
STAD	cis	rs9548119	0.941	rs9576404	ENSG00000223685.4	LINC00571	-4.25	2.7e-05	0.0112	-0.34	-0.22	Self-rated health;	chr13:37953276	chr13:38050817~38143232:-
STAD	cis	rs2579500	0.807	rs4907200	ENSG00000230606.9	AC159540.1	4.25	2.71e-05	0.0112	0.27	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96655000	chr2:97416165~97433527:-
STAD	cis	rs6142102	1	rs4911414	ENSG00000275784.1	RP5-1125A11.6	-4.25	2.71e-05	0.0112	-0.23	-0.22	Skin pigmentation;	chr20:34141638	chr20:33989480~33991818:-
STAD	cis	rs2688608	0.592	rs2306328	ENSG00000271816.1	BMS1P4	4.25	2.71e-05	0.0112	0.24	0.22	Inflammatory bowel disease;	chr10:73819752	chr10:73699151~73730487:-
STAD	cis	rs6832769	1	rs6812042	ENSG00000272969.1	RP11-528I4.2	4.25	2.71e-05	0.0112	0.28	0.22	Personality dimensions;	chr4:55529912	chr4:55547112~55547889:+
STAD	cis	rs6480314	0.522	rs10762210	ENSG00000233590.1	RP11-153K11.3	4.25	2.71e-05	0.0112	0.31	0.22	Optic nerve measurement (disc area);	chr10:68290860	chr10:68233251~68242379:-
STAD	cis	rs2933343	0.951	rs9871612	ENSG00000261159.1	RP11-723O4.9	4.25	2.71e-05	0.0112	0.29	0.22	IgG glycosylation;	chr3:128851559	chr3:128859716~128860526:-
STAD	cis	rs11673344	0.504	rs35162188	ENSG00000267672.1	CTD-2293H3.1	4.25	2.71e-05	0.0112	0.2	0.22	Obesity-related traits;	chr19:37088908	chr19:37091341~37092564:+
STAD	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-4.25	2.71e-05	0.0112	-0.25	-0.22	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
STAD	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-4.25	2.71e-05	0.0112	-0.23	-0.22	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
STAD	cis	rs935334	1	rs12437310	ENSG00000258454.1	RP11-361H10.3	4.25	2.71e-05	0.0112	0.32	0.22	Blood pressure;	chr14:76176414	chr14:76235817~76263474:+
STAD	cis	rs1707322	1	rs2458400	ENSG00000281133.1	AL355480.3	4.25	2.71e-05	0.0112	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs9429186	ENSG00000281133.1	AL355480.3	4.25	2.71e-05	0.0112	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs785506	ENSG00000281133.1	AL355480.3	4.25	2.71e-05	0.0112	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45580892~45580996:-
STAD	cis	rs8012947	0.959	rs4520767	ENSG00000279636.2	LINC00216	-4.25	2.71e-05	0.0112	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58302220	chr14:58288033~58289158:+
STAD	cis	rs4691139	0.873	rs12509081	ENSG00000248632.1	RP11-366M4.11	4.25	2.71e-05	0.0112	0.22	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971812	chr4:164968587~164970002:-
STAD	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	4.25	2.71e-05	0.0112	0.29	0.22	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
STAD	cis	rs11846409	0.932	rs73378158	ENSG00000211970.3	IGHV4-61	4.25	2.71e-05	0.0112	0.24	0.22	Rheumatic heart disease;	chr14:106638433	chr14:106639119~106639657:-
STAD	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-4.25	2.72e-05	0.0112	-0.35	-0.22	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
STAD	cis	rs76917914	1	rs76917914	ENSG00000236896.1	RP11-535C21.3	4.25	2.72e-05	0.0112	0.3	0.22	Immature fraction of reticulocytes;	chr9:98009158	chr9:97986551~97987656:-
STAD	cis	rs11071200	0.637	rs8025445	ENSG00000276533.1	RP11-139H15.5	4.25	2.72e-05	0.0112	0.25	0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr15:55674444	chr15:55288849~55289346:-
STAD	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	4.25	2.72e-05	0.0112	0.31	0.22	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
STAD	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	4.25	2.72e-05	0.0112	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
STAD	cis	rs4713118	0.911	rs9295746	ENSG00000243307.2	POM121L6P	-4.25	2.72e-05	0.0112	-0.27	-0.22	Parkinson's disease;	chr6:27762285	chr6:26896952~26898777:+
STAD	cis	rs34779708	0.931	rs59418206	ENSG00000271335.4	RP11-324I22.4	4.25	2.72e-05	0.0112	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35314552~35336401:-
STAD	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	4.25	2.72e-05	0.0112	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
STAD	cis	rs749052	0.706	rs2085024	ENSG00000251485.1	AC068134.10	-4.25	2.72e-05	0.0113	-0.43	-0.22	Height;	chr2:232091640	chr2:232343116~232343903:+
STAD	cis	rs1950326	0.515	rs175677	ENSG00000258526.4	RP11-111A21.1	-4.25	2.72e-05	0.0113	-0.26	-0.22	Verbal memory performance (residualized delayed recall level);	chr14:39580491	chr14:39474840~39513780:+
STAD	cis	rs4691139	1	rs13134489	ENSG00000248632.1	RP11-366M4.11	4.25	2.72e-05	0.0113	0.22	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968285	chr4:164968587~164970002:-
STAD	cis	rs7202877	0.561	rs4888369	ENSG00000261783.1	RP11-252K23.2	-4.25	2.72e-05	0.0113	-0.37	-0.22	Type 1 diabetes;Type 2 diabetes;	chr16:75273379	chr16:75379818~75381260:-
STAD	cis	rs1707322	1	rs6687301	ENSG00000225447.1	RPS15AP10	4.25	2.72e-05	0.0113	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45645816~45646197:-
STAD	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-4.25	2.72e-05	0.0113	-0.26	-0.22	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
STAD	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-4.25	2.72e-05	0.0113	-0.26	-0.22	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
STAD	cis	rs1707322	0.721	rs10890346	ENSG00000281133.1	AL355480.3	4.25	2.72e-05	0.0113	0.27	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45580892~45580996:-
STAD	cis	rs2739330	0.892	rs5751776	ENSG00000272787.1	KB-226F1.2	-4.25	2.72e-05	0.0113	-0.23	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23969211~23969873:+
STAD	cis	rs11098499	0.82	rs6829903	ENSG00000260091.1	RP11-33B1.4	4.25	2.72e-05	0.0113	0.22	0.22	Corneal astigmatism;	chr4:119585729	chr4:119409333~119410233:+
STAD	cis	rs453301	0.506	rs686189	ENSG00000253981.4	ALG1L13P	-4.25	2.72e-05	0.0113	-0.26	-0.22	Joint mobility (Beighton score);	chr8:8766127	chr8:8236003~8244667:-
STAD	cis	rs7615952	0.8	rs11915699	ENSG00000239804.1	RP11-379B18.1	4.25	2.72e-05	0.0113	0.37	0.22	Blood pressure (smoking interaction);	chr3:125913841	chr3:125787888~125788146:-
STAD	cis	rs1005277	0.505	rs10827836	ENSG00000099251.13	HSD17B7P2	-4.25	2.72e-05	0.0113	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38356380~38378505:+
STAD	cis	rs2901460	0.628	rs12713455	ENSG00000229503.1	AC092155.1	-4.25	2.73e-05	0.0113	-0.18	-0.22	Mean corpuscular volume;	chr2:62134913	chr2:62532583~62533059:-
STAD	cis	rs7191700	0.583	rs243314	ENSG00000262703.1	RP11-485G7.6	4.25	2.73e-05	0.0113	0.21	0.22	Multiple sclerosis;	chr16:11291247	chr16:11348143~11349321:-
STAD	cis	rs9307551	0.857	rs7662551	ENSG00000250334.4	LINC00989	-4.25	2.73e-05	0.0113	-0.26	-0.22	Refractive error;	chr4:79616484	chr4:79492416~79576460:+
STAD	cis	rs935334	0.866	rs11850433	ENSG00000258454.1	RP11-361H10.3	-4.25	2.73e-05	0.0113	-0.33	-0.22	Blood pressure;	chr14:76215140	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs57844481	ENSG00000258454.1	RP11-361H10.3	-4.25	2.73e-05	0.0113	-0.33	-0.22	Blood pressure;	chr14:76218150	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs10137323	ENSG00000258454.1	RP11-361H10.3	-4.25	2.73e-05	0.0113	-0.33	-0.22	Blood pressure;	chr14:76219390	chr14:76235817~76263474:+
STAD	cis	rs1707322	1	rs11211200	ENSG00000281133.1	AL355480.3	-4.25	2.73e-05	0.0113	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45580892~45580996:-
STAD	cis	rs875971	0.862	rs2909688	ENSG00000224316.1	RP11-479O9.2	4.25	2.73e-05	0.0113	0.22	0.22	Aortic root size;	chr7:66376625	chr7:65773620~65802067:+
STAD	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-4.25	2.73e-05	0.0113	-0.33	-0.22	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
STAD	cis	rs8062405	1	rs12325113	ENSG00000278665.1	RP11-666O2.4	4.25	2.73e-05	0.0113	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28599241~28601881:-
STAD	cis	rs6432852	0.966	rs6432851	ENSG00000229195.1	AC009495.4	-4.25	2.73e-05	0.0113	-0.25	-0.22	Diabetic kidney disease;	chr2:165892403	chr2:165794857~165846091:-
STAD	cis	rs935334	1	rs4442739	ENSG00000258454.1	RP11-361H10.3	4.25	2.73e-05	0.0113	0.31	0.22	Blood pressure;	chr14:76181302	chr14:76235817~76263474:+
STAD	cis	rs12444156	1	rs12444156	ENSG00000260886.1	TAT-AS1	4.25	2.73e-05	0.0113	0.42	0.22	Post bronchodilator FEV1;	chr16:71807354	chr16:71565789~71578187:+
STAD	cis	rs1809889	0.719	rs904647	ENSG00000269997.1	RP11-214K3.21	4.25	2.73e-05	0.0113	0.19	0.22	Hip circumference adjusted for BMI;Height;	chr12:124314841	chr12:123966077~123966629:-
STAD	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	4.25	2.73e-05	0.0113	0.42	0.22	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
STAD	cis	rs11169552	0.51	rs4768892	ENSG00000200183.1	RNU6-238P	-4.25	2.74e-05	0.0113	-0.21	-0.22	Colorectal cancer;	chr12:50566525	chr12:50656973~50657078:+
STAD	cis	rs7680126	0.596	rs12511337	ENSG00000250613.1	RP11-136I13.1	-4.25	2.74e-05	0.0113	-0.24	-0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10310348	chr4:10410996~10411644:+
STAD	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-4.25	2.74e-05	0.0113	-0.33	-0.22	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
STAD	cis	rs935334	1	rs935334	ENSG00000258454.1	RP11-361H10.3	4.25	2.74e-05	0.0113	0.32	0.22	Blood pressure;	chr14:76147335	chr14:76235817~76263474:+
STAD	cis	rs4589258	0.737	rs2155071	ENSG00000280367.1	RP11-121L10.2	-4.25	2.74e-05	0.0113	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90676991	chr11:90223153~90226538:+
STAD	cis	rs10978777	0.515	rs12342066	ENSG00000276883.1	AL137852.1	4.25	2.74e-05	0.0113	0.24	0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107262772	chr9:107292369~107292456:-
STAD	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	4.25	2.74e-05	0.0113	0.32	0.22	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
STAD	cis	rs1348850	0.914	rs9789582	ENSG00000271825.1	RP11-337N6.2	4.25	2.74e-05	0.0113	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177465445	chr2:177300600~177302006:+
STAD	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-4.25	2.74e-05	0.0113	-0.22	-0.22	Height;	chr2:46636733	chr2:46668870~46670778:+
STAD	cis	rs6903823	0.508	rs1778484	ENSG00000220721.1	OR1F12	4.25	2.74e-05	0.0113	0.21	0.22	Pulmonary function;	chr6:28273021	chr6:28073316~28074233:+
STAD	cis	rs17711722	0.653	rs2460421	ENSG00000222364.1	RNU6-96P	4.25	2.74e-05	0.0113	0.24	0.22	Calcium levels;	chr7:66026136	chr7:66395191~66395286:+
STAD	cis	rs4970988	0.501	rs11204713	ENSG00000274963.1	Metazoa_SRP	4.25	2.74e-05	0.0113	0.2	0.22	Urate levels;	chr1:150722147	chr1:150568971~150569269:-
STAD	cis	rs2348418	0.832	rs1032391	ENSG00000247934.4	RP11-967K21.1	4.25	2.74e-05	0.0113	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28383775	chr12:28163298~28190738:-
STAD	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	4.25	2.74e-05	0.0113	0.26	0.22	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
STAD	cis	rs4835473	0.9	rs10003922	ENSG00000249741.2	RP11-673E1.3	4.25	2.74e-05	0.0113	0.26	0.22	Immature fraction of reticulocytes;	chr4:143921235	chr4:143911514~143912053:-
STAD	cis	rs1823874	0.613	rs4608318	ENSG00000182397.13	DNM1P46	-4.25	2.75e-05	0.0113	-0.24	-0.22	IgG glycosylation;	chr15:99823621	chr15:99790156~99806927:-
STAD	cis	rs2262909	0.962	rs11667209	ENSG00000213976.4	CTD-2561J22.2	4.25	2.75e-05	0.0113	0.28	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22076665	chr19:21382865~21387177:+
STAD	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	4.25	2.75e-05	0.0113	0.24	0.22	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
STAD	cis	rs11009175	0.725	rs10827170	ENSG00000273038.2	RP11-479G22.8	4.25	2.75e-05	0.0114	0.32	0.22	Depression (quantitative trait);	chr10:33001415	chr10:32887255~32889311:-
STAD	cis	rs1823913	1	rs4853561	ENSG00000280083.1	RP11-317J9.1	4.25	2.75e-05	0.0114	0.27	0.22	Obesity-related traits;	chr2:191242980	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs6704784	ENSG00000280083.1	RP11-317J9.1	4.25	2.75e-05	0.0114	0.27	0.22	Obesity-related traits;	chr2:191244832	chr2:191154118~191156070:-
STAD	cis	rs935334	1	rs4304957	ENSG00000258454.1	RP11-361H10.3	4.25	2.75e-05	0.0114	0.32	0.22	Blood pressure;	chr14:76181229	chr14:76235817~76263474:+
STAD	cis	rs935334	0.825	rs4389088	ENSG00000258454.1	RP11-361H10.3	4.25	2.75e-05	0.0114	0.32	0.22	Blood pressure;	chr14:76181254	chr14:76235817~76263474:+
STAD	cis	rs7131987	0.903	rs11050152	ENSG00000257176.2	RP11-996F15.2	-4.25	2.75e-05	0.0114	-0.25	-0.22	QT interval;	chr12:29251491	chr12:29280418~29317848:-
STAD	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	4.25	2.75e-05	0.0114	0.29	0.22	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	4.25	2.75e-05	0.0114	0.29	0.22	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
STAD	cis	rs62560775	0.541	rs12352425	ENSG00000265194.1	RP11-70L8.4	4.25	2.75e-05	0.0114	0.36	0.22	Lung cancer;Lung adenocarcinoma;	chr9:22042087	chr9:21858910~21861926:-
STAD	cis	rs7131987	0.65	rs11050208	ENSG00000275476.1	RP11-996F15.4	-4.25	2.75e-05	0.0114	-0.25	-0.22	QT interval;	chr12:29357436	chr12:29277397~29277882:-
STAD	cis	rs1707322	1	rs11211217	ENSG00000225447.1	RPS15AP10	4.25	2.75e-05	0.0114	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45645816~45646197:-
STAD	cis	rs10508774	1	rs72784043	ENSG00000273038.2	RP11-479G22.8	4.25	2.75e-05	0.0114	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32886644	chr10:32887255~32889311:-
STAD	cis	rs875971	0.862	rs7783779	ENSG00000224316.1	RP11-479O9.2	-4.25	2.76e-05	0.0114	-0.22	-0.22	Aortic root size;	chr7:66331639	chr7:65773620~65802067:+
STAD	cis	rs7487075	0.619	rs11183478	ENSG00000257261.4	RP11-96H19.1	4.25	2.76e-05	0.0114	0.3	0.22	Itch intensity from mosquito bite;	chr12:46430283	chr12:46383679~46876159:+
STAD	cis	rs6840360	0.582	rs4473638	ENSG00000270265.1	RP11-731D1.4	-4.25	2.76e-05	0.0114	-0.27	-0.22	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151333775~151353224:-
STAD	cis	rs1816752	0.608	rs9511290	ENSG00000273628.1	RP11-756A22.7	-4.25	2.76e-05	0.0114	-0.27	-0.22	Obesity-related traits;	chr13:24467189	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511291	ENSG00000273628.1	RP11-756A22.7	-4.25	2.76e-05	0.0114	-0.27	-0.22	Obesity-related traits;	chr13:24467609	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511292	ENSG00000273628.1	RP11-756A22.7	-4.25	2.76e-05	0.0114	-0.27	-0.22	Obesity-related traits;	chr13:24467623	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511293	ENSG00000273628.1	RP11-756A22.7	-4.25	2.76e-05	0.0114	-0.27	-0.22	Obesity-related traits;	chr13:24467747	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511294	ENSG00000273628.1	RP11-756A22.7	-4.25	2.76e-05	0.0114	-0.27	-0.22	Obesity-related traits;	chr13:24467773	chr13:24933006~24936796:+
STAD	cis	rs9733	0.596	rs11204704	ENSG00000274963.1	Metazoa_SRP	4.25	2.76e-05	0.0114	0.19	0.22	Tonsillectomy;	chr1:150699154	chr1:150568971~150569269:-
STAD	cis	rs17767294	0.612	rs9461424	ENSG00000220721.1	OR1F12	4.25	2.76e-05	0.0114	0.35	0.22	Parkinson's disease;	chr6:27951623	chr6:28073316~28074233:+
STAD	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	4.25	2.76e-05	0.0114	0.26	0.22	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
STAD	cis	rs4589258	0.788	rs1547883	ENSG00000280367.1	RP11-121L10.2	4.25	2.76e-05	0.0114	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90738218	chr11:90223153~90226538:+
STAD	cis	rs76917914	1	rs4743150	ENSG00000236896.1	RP11-535C21.3	4.25	2.76e-05	0.0114	0.3	0.22	Immature fraction of reticulocytes;	chr9:97977842	chr9:97986551~97987656:-
STAD	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	4.25	2.76e-05	0.0114	0.25	0.22	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
STAD	cis	rs8012947	1	rs7155580	ENSG00000279636.2	LINC00216	-4.25	2.76e-05	0.0114	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58304914	chr14:58288033~58289158:+
STAD	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-4.25	2.76e-05	0.0114	-0.29	-0.22	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
STAD	cis	rs9902453	0.765	rs2169810	ENSG00000240074.1	RPL9P30	4.25	2.76e-05	0.0114	0.19	0.22	Coffee consumption (cups per day);	chr17:29840923	chr17:29855759~29856332:+
STAD	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-4.25	2.76e-05	0.0114	-0.28	-0.22	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
STAD	cis	rs1799949	0.965	rs12950779	ENSG00000279602.1	CTD-3014M21.1	4.25	2.76e-05	0.0114	0.28	0.22	Menopause (age at onset);	chr17:43154506	chr17:43360041~43361361:-
STAD	cis	rs9902453	0.904	rs4598962	ENSG00000240074.1	RPL9P30	4.25	2.77e-05	0.0114	0.19	0.22	Coffee consumption (cups per day);	chr17:29966930	chr17:29855759~29856332:+
STAD	cis	rs11098499	0.955	rs56386062	ENSG00000260091.1	RP11-33B1.4	4.25	2.77e-05	0.0114	0.22	0.22	Corneal astigmatism;	chr4:119233980	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs13114751	ENSG00000260091.1	RP11-33B1.4	4.25	2.77e-05	0.0114	0.22	0.22	Corneal astigmatism;	chr4:119235462	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.913	rs35271032	ENSG00000260091.1	RP11-33B1.4	4.25	2.77e-05	0.0114	0.22	0.22	Corneal astigmatism;	chr4:119235504	chr4:119409333~119410233:+
STAD	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-4.25	2.77e-05	0.0114	-0.26	-0.22	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
STAD	cis	rs10129255	0.912	rs61996059	ENSG00000232216.1	IGHV3-43	4.25	2.77e-05	0.0114	0.23	0.22	Kawasaki disease;	chr14:106716897	chr14:106470264~106470800:-
STAD	cis	rs9902453	0.73	rs2020939	ENSG00000240074.1	RPL9P30	-4.25	2.77e-05	0.0114	-0.2	-0.22	Coffee consumption (cups per day);	chr17:30223714	chr17:29855759~29856332:+
STAD	cis	rs1395	0.571	rs114507490	ENSG00000234072.1	AC074117.10	-4.25	2.77e-05	0.0114	-0.21	-0.22	Blood metabolite levels;	chr2:27304378	chr2:27356246~27367622:+
STAD	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-4.25	2.77e-05	0.0114	-0.27	-0.22	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-4.25	2.77e-05	0.0114	-0.27	-0.22	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
STAD	cis	rs9549260	0.561	rs61963209	ENSG00000229456.1	RLIMP1	4.25	2.77e-05	0.0114	0.26	0.22	Red blood cell count;	chr13:40928452	chr13:40618738~40621348:+
STAD	cis	rs763014	0.966	rs4144003	ENSG00000228201.1	AL022341.3	4.25	2.77e-05	0.0114	0.27	0.22	Height;	chr16:595968	chr16:648473~649200:-
STAD	cis	rs17401966	0.838	rs12139981	ENSG00000199562.1	RNU6-37P	4.25	2.77e-05	0.0114	0.17	0.22	Hepatocellular carcinoma;	chr1:10330638	chr1:10298966~10299072:+
STAD	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	4.25	2.77e-05	0.0114	0.34	0.22	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
STAD	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-4.25	2.78e-05	0.0115	-0.26	-0.22	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
STAD	cis	rs2921036	0.529	rs2979192	ENSG00000254340.1	RP11-10A14.3	4.25	2.78e-05	0.0115	0.27	0.22	Neuroticism;	chr8:8480637	chr8:9141424~9145435:+
STAD	cis	rs3806843	0.576	rs246024	ENSG00000202111.1	VTRNA1-2	-4.25	2.78e-05	0.0115	-0.21	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140954367	chr5:140718925~140719013:+
STAD	cis	rs3806843	0.546	rs246023	ENSG00000202111.1	VTRNA1-2	-4.25	2.78e-05	0.0115	-0.21	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140954405	chr5:140718925~140719013:+
STAD	cis	rs2262909	0.962	rs55735642	ENSG00000213976.4	CTD-2561J22.2	4.25	2.78e-05	0.0115	0.28	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22058374	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs4932952	ENSG00000213976.4	CTD-2561J22.2	4.25	2.78e-05	0.0115	0.28	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22063986	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs73019842	ENSG00000213976.4	CTD-2561J22.2	4.25	2.78e-05	0.0115	0.28	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22067107	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs73019844	ENSG00000213976.4	CTD-2561J22.2	4.25	2.78e-05	0.0115	0.28	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22067123	chr19:21382865~21387177:+
STAD	cis	rs10073892	0.789	rs72779917	ENSG00000250682.4	LINC00491	-4.25	2.78e-05	0.0115	-0.25	-0.22	Cognitive decline (age-related);	chr5:102356897	chr5:102609156~102671559:-
STAD	cis	rs1707322	1	rs4606257	ENSG00000225447.1	RPS15AP10	4.25	2.78e-05	0.0115	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45645816~45646197:-
STAD	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	4.25	2.78e-05	0.0115	0.29	0.22	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	4.25	2.78e-05	0.0115	0.29	0.22	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
STAD	cis	rs11239930	0.538	rs9663073	ENSG00000278811.3	LINC00624	4.25	2.78e-05	0.0115	0.23	0.22	AIDS progression;	chr1:147083022	chr1:147258885~147517875:-
STAD	cis	rs935334	0.877	rs2197480	ENSG00000258454.1	RP11-361H10.3	4.25	2.78e-05	0.0115	0.32	0.22	Blood pressure;	chr14:76159099	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs1900120	ENSG00000258454.1	RP11-361H10.3	4.25	2.78e-05	0.0115	0.32	0.22	Blood pressure;	chr14:76160173	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs2543384	ENSG00000258454.1	RP11-361H10.3	4.25	2.78e-05	0.0115	0.32	0.22	Blood pressure;	chr14:76160958	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs1900122	ENSG00000258454.1	RP11-361H10.3	4.25	2.78e-05	0.0115	0.32	0.22	Blood pressure;	chr14:76163174	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs2591092	ENSG00000258454.1	RP11-361H10.3	4.25	2.78e-05	0.0115	0.32	0.22	Blood pressure;	chr14:76163790	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs2591094	ENSG00000258454.1	RP11-361H10.3	4.25	2.78e-05	0.0115	0.32	0.22	Blood pressure;	chr14:76165992	chr14:76235817~76263474:+
STAD	cis	rs935334	1	rs8005686	ENSG00000258454.1	RP11-361H10.3	4.25	2.78e-05	0.0115	0.32	0.22	Blood pressure;	chr14:76167624	chr14:76235817~76263474:+
STAD	cis	rs3808502	0.516	rs6983727	ENSG00000205879.4	FAM90A2P	4.25	2.78e-05	0.0115	0.25	0.22	Neuroticism;	chr8:11558303	chr8:12172202~12178575:-
STAD	cis	rs1707322	0.821	rs10749857	ENSG00000225447.1	RPS15AP10	4.25	2.78e-05	0.0115	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45645816~45646197:-
STAD	cis	rs1876905	0.539	rs240980	ENSG00000230177.1	RP5-1112D6.4	4.25	2.78e-05	0.0115	0.26	0.22	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111277932~111278742:+
STAD	cis	rs10851478	0.872	rs12906972	ENSG00000259545.2	RP11-325E5.4	-4.25	2.78e-05	0.0115	-0.26	-0.22	Oral cavity cancer;	chr15:49566704	chr15:49177610~49178741:-
STAD	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-4.25	2.78e-05	0.0115	-0.23	-0.22	Height;	chr5:37081780	chr5:36666214~36725195:-
STAD	cis	rs9733	0.596	rs12089989	ENSG00000274963.1	Metazoa_SRP	4.25	2.78e-05	0.0115	0.19	0.22	Tonsillectomy;	chr1:150743306	chr1:150568971~150569269:-
STAD	cis	rs9902453	0.791	rs9904051	ENSG00000263477.1	RP11-338L22.2	4.25	2.78e-05	0.0115	0.19	0.22	Coffee consumption (cups per day);	chr17:29917104	chr17:29863402~29866092:+
STAD	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	4.25	2.78e-05	0.0115	0.24	0.22	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
STAD	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	4.25	2.78e-05	0.0115	0.28	0.22	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
STAD	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-4.25	2.78e-05	0.0115	-0.29	-0.22	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
STAD	cis	rs1707322	0.686	rs11211179	ENSG00000281133.1	AL355480.3	-4.25	2.79e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs10157795	ENSG00000281133.1	AL355480.3	-4.25	2.79e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45580892~45580996:-
STAD	cis	rs34929064	0.846	rs2905342	ENSG00000179428.2	AC073072.5	4.25	2.79e-05	0.0115	0.24	0.22	Major depression and alcohol dependence;	chr7:22691425	chr7:22725395~22727620:-
STAD	cis	rs11846409	0.652	rs10143549	ENSG00000211970.3	IGHV4-61	4.25	2.79e-05	0.0115	0.25	0.22	Rheumatic heart disease;	chr14:106644643	chr14:106639119~106639657:-
STAD	cis	rs1816752	0.646	rs2862902	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24461965	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs734715	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24462041	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs730030	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24462509	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs7992667	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24462821	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs7995958	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24462895	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs8002741	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24462918	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs7998198	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24462979	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs7998203	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24462989	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs7998600	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24463222	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511279	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24463348	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511280	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24463364	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511281	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24463441	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.624	rs9511282	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24463597	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.583	rs9511283	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24463656	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9507351	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24465118	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs12431171	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24466380	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs12854523	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24466460	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9578740	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24466692	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.631	rs4769358	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24466940	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.608	rs4769359	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24466966	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.608	rs4769360	ENSG00000273628.1	RP11-756A22.7	-4.25	2.79e-05	0.0115	-0.27	-0.22	Obesity-related traits;	chr13:24467016	chr13:24933006~24936796:+
STAD	cis	rs4141404	0.923	rs2413046	ENSG00000236132.1	CTA-440B3.1	4.25	2.79e-05	0.0115	0.26	0.22	Paclitaxel-induced neuropathy;	chr22:31269923	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.561	rs2413047	ENSG00000236132.1	CTA-440B3.1	4.25	2.79e-05	0.0115	0.26	0.22	Colorectal cancer;	chr22:31270040	chr22:31816379~31817491:-
STAD	cis	rs1707322	1	rs6675222	ENSG00000281133.1	AL355480.3	-4.25	2.79e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4660895	ENSG00000281133.1	AL355480.3	-4.25	2.79e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs4660318	ENSG00000281133.1	AL355480.3	-4.25	2.79e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10890360	ENSG00000281133.1	AL355480.3	-4.25	2.79e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs6682683	ENSG00000281133.1	AL355480.3	-4.25	2.79e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45580892~45580996:-
STAD	cis	rs11089937	0.524	rs2877021	ENSG00000211640.3	IGLV6-57	4.25	2.79e-05	0.0115	0.16	0.22	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22195713~22196460:+
STAD	cis	rs853679	0.527	rs9468333	ENSG00000220721.1	OR1F12	4.25	2.79e-05	0.0115	0.22	0.22	Depression;	chr6:28303421	chr6:28073316~28074233:+
STAD	cis	rs1707322	1	rs4524994	ENSG00000225447.1	RPS15AP10	4.25	2.79e-05	0.0115	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs9787412	ENSG00000225447.1	RPS15AP10	4.25	2.79e-05	0.0115	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10430124	ENSG00000225447.1	RPS15AP10	4.25	2.79e-05	0.0115	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45645816~45646197:-
STAD	cis	rs10129255	0.917	rs7142373	ENSG00000232216.1	IGHV3-43	4.25	2.79e-05	0.0115	0.23	0.22	Kawasaki disease;	chr14:106708947	chr14:106470264~106470800:-
STAD	cis	rs6142102	0.961	rs6059596	ENSG00000264616.1	MIR4755	4.25	2.79e-05	0.0115	0.23	0.22	Skin pigmentation;	chr20:33969313	chr20:34049119~34049190:+
STAD	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	4.25	2.79e-05	0.0115	0.22	0.22	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
STAD	cis	rs1799949	0.965	rs8176323	ENSG00000279602.1	CTD-3014M21.1	4.25	2.79e-05	0.0115	0.28	0.22	Menopause (age at onset);	chr17:43043694	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs8176322	ENSG00000279602.1	CTD-3014M21.1	4.25	2.79e-05	0.0115	0.28	0.22	Menopause (age at onset);	chr17:43043756	chr17:43360041~43361361:-
STAD	cis	rs2390582	0.771	rs17131048	ENSG00000228175.3	GEMIN8P4	4.25	2.79e-05	0.0115	0.34	0.22	Coronary artery calcification;	chr1:90449351	chr1:89993593~89994321:-
STAD	cis	rs11846409	0.629	rs76295389	ENSG00000274576.2	IGHV2-70	4.25	2.8e-05	0.0115	0.26	0.22	Rheumatic heart disease;	chr14:106650437	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.698	rs71419854	ENSG00000274576.2	IGHV2-70	4.25	2.8e-05	0.0115	0.26	0.22	Rheumatic heart disease;	chr14:106650440	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.5	rs71419855	ENSG00000274576.2	IGHV2-70	4.25	2.8e-05	0.0115	0.26	0.22	Alzheimer's disease (late onset);	chr14:106650444	chr14:106770577~106771020:-
STAD	cis	rs10073892	0.66	rs60284576	ENSG00000250682.4	LINC00491	-4.25	2.8e-05	0.0115	-0.24	-0.22	Cognitive decline (age-related);	chr5:102608628	chr5:102609156~102671559:-
STAD	cis	rs8012947	1	rs12323535	ENSG00000279636.2	LINC00216	-4.25	2.8e-05	0.0115	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58303137	chr14:58288033~58289158:+
STAD	cis	rs8012947	1	rs10145481	ENSG00000279636.2	LINC00216	-4.25	2.8e-05	0.0115	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58303671	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.959	rs1951204	ENSG00000279636.2	LINC00216	-4.25	2.8e-05	0.0115	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58303983	chr14:58288033~58289158:+
STAD	cis	rs7829975	0.508	rs4841006	ENSG00000173295.6	FAM86B3P	-4.25	2.8e-05	0.0115	-0.25	-0.22	Mood instability;	chr8:8643964	chr8:8228595~8244865:+
STAD	cis	rs2253762	0.507	rs12264894	ENSG00000226864.1	ATE1-AS1	4.25	2.8e-05	0.0115	0.36	0.22	Breast cancer;	chr10:121992087	chr10:121928312~121951965:+
STAD	cis	rs2836950	0.545	rs2836940	ENSG00000238141.2	BRWD1-AS1	-4.25	2.8e-05	0.0115	-0.23	-0.22	Menarche (age at onset);	chr21:39216770	chr21:39315707~39323218:+
STAD	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-4.25	2.8e-05	0.0115	-0.38	-0.22	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
STAD	cis	rs17301013	0.861	rs1793319	ENSG00000227373.4	RP11-160H22.5	4.25	2.8e-05	0.0115	0.27	0.22	Systemic lupus erythematosus;	chr1:174795470	chr1:174115300~174160004:-
STAD	cis	rs453301	0.506	rs476845	ENSG00000253981.4	ALG1L13P	-4.25	2.8e-05	0.0115	-0.26	-0.22	Joint mobility (Beighton score);	chr8:8765367	chr8:8236003~8244667:-
STAD	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	4.25	2.8e-05	0.0115	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
STAD	cis	rs5758659	0.714	rs5758574	ENSG00000182057.4	OGFRP1	-4.25	2.8e-05	0.0115	-0.24	-0.22	Cognitive function;	chr22:42085396	chr22:42269753~42275196:+
STAD	cis	rs1707322	1	rs4606257	ENSG00000281133.1	AL355480.3	-4.25	2.8e-05	0.0115	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45580892~45580996:-
STAD	cis	rs494453	0.922	rs498787	ENSG00000234020.1	CHIAP3	-4.25	2.8e-05	0.0115	-0.22	-0.22	Osteoporosis-related phenotypes;	chr1:111690722	chr1:111353275~111367409:-
STAD	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-4.25	2.8e-05	0.0115	-0.22	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
STAD	cis	rs1707322	1	rs4660896	ENSG00000281133.1	AL355480.3	-4.25	2.8e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.928	rs10732844	ENSG00000281133.1	AL355480.3	-4.25	2.8e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs12133129	ENSG00000281133.1	AL355480.3	-4.25	2.8e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs4553121	ENSG00000281133.1	AL355480.3	-4.25	2.8e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs6690652	ENSG00000281133.1	AL355480.3	-4.25	2.8e-05	0.0115	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45580892~45580996:-
STAD	cis	rs7829975	0.744	rs2409092	ENSG00000233609.3	RP11-62H7.2	4.25	2.8e-05	0.0115	0.24	0.22	Mood instability;	chr8:8824682	chr8:8961200~8979025:+
STAD	cis	rs6142102	0.961	rs2377957	ENSG00000264616.1	MIR4755	4.25	2.8e-05	0.0115	0.23	0.22	Skin pigmentation;	chr20:33966667	chr20:34049119~34049190:+
STAD	cis	rs1707322	1	rs10789479	ENSG00000225447.1	RPS15AP10	4.25	2.8e-05	0.0115	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.964	rs7512395	ENSG00000225447.1	RPS15AP10	4.25	2.8e-05	0.0115	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45645816~45646197:-
STAD	cis	rs6676180	0.555	rs12060730	ENSG00000231365.4	RP11-418J17.1	-4.25	2.81e-05	0.0115	-0.26	-0.22	Monobrow;	chr1:119228079	chr1:119140396~119275973:+
STAD	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	4.25	2.81e-05	0.0115	0.25	0.22	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
STAD	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	4.25	2.81e-05	0.0115	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	4.25	2.81e-05	0.0115	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	4.25	2.81e-05	0.0115	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs8177940	ENSG00000261838.4	RP11-303E16.6	4.25	2.81e-05	0.0115	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.73	rs76656387	ENSG00000261838.4	RP11-303E16.6	4.25	2.81e-05	0.0115	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81069854~81076598:+
STAD	cis	rs11098499	0.779	rs6815934	ENSG00000260091.1	RP11-33B1.4	4.25	2.81e-05	0.0116	0.21	0.22	Corneal astigmatism;	chr4:119346155	chr4:119409333~119410233:+
STAD	cis	rs17401966	0.931	rs61778401	ENSG00000199562.1	RNU6-37P	4.25	2.81e-05	0.0116	0.18	0.22	Hepatocellular carcinoma;	chr1:10366416	chr1:10298966~10299072:+
STAD	cis	rs2273156	0.929	rs4573843	ENSG00000241052.1	RP11-173D9.1	-4.25	2.81e-05	0.0116	-0.25	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:34922563	chr14:35144021~35144480:-
STAD	cis	rs4927850	0.752	rs7618864	ENSG00000185485.13	SDHAP1	4.25	2.81e-05	0.0116	0.22	0.22	Pancreatic cancer;	chr3:196022690	chr3:195959748~195990318:-
STAD	cis	rs1075265	0.84	rs2884254	ENSG00000235937.1	AC008280.1	4.25	2.81e-05	0.0116	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54029552~54030682:-
STAD	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-4.25	2.81e-05	0.0116	-0.25	-0.22	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
STAD	cis	rs4713118	0.866	rs9468217	ENSG00000243307.2	POM121L6P	-4.24	2.81e-05	0.0116	-0.27	-0.22	Parkinson's disease;	chr6:27758688	chr6:26896952~26898777:+
STAD	cis	rs11098499	0.913	rs56122576	ENSG00000260091.1	RP11-33B1.4	4.24	2.81e-05	0.0116	0.22	0.22	Corneal astigmatism;	chr4:119208181	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.913	rs68128210	ENSG00000260091.1	RP11-33B1.4	4.24	2.81e-05	0.0116	0.22	0.22	Corneal astigmatism;	chr4:119216664	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.913	rs13126596	ENSG00000260091.1	RP11-33B1.4	4.24	2.81e-05	0.0116	0.22	0.22	Corneal astigmatism;	chr4:119219574	chr4:119409333~119410233:+
STAD	cis	rs935334	1	rs2121067	ENSG00000258454.1	RP11-361H10.3	4.24	2.81e-05	0.0116	0.32	0.22	Blood pressure;	chr14:76151308	chr14:76235817~76263474:+
STAD	cis	rs11976180	1	rs2961117	ENSG00000204959.4	ARHGEF34P	4.24	2.81e-05	0.0116	0.31	0.22	Obesity-related traits;	chr7:144058160	chr7:144272445~144286966:-
STAD	cis	rs950881	0.866	rs72823628	ENSG00000234389.1	AC007278.3	4.24	2.81e-05	0.0116	0.3	0.22	Allergy;	chr2:102312157	chr2:102438713~102440475:+
STAD	cis	rs950881	0.932	rs72823632	ENSG00000234389.1	AC007278.3	4.24	2.81e-05	0.0116	0.3	0.22	Allergy;	chr2:102315074	chr2:102438713~102440475:+
STAD	cis	rs875971	0.755	rs10228885	ENSG00000224316.1	RP11-479O9.2	-4.24	2.81e-05	0.0116	-0.22	-0.22	Aortic root size;	chr7:66315542	chr7:65773620~65802067:+
STAD	cis	rs10028773	0.6	rs4001390	ENSG00000260091.1	RP11-33B1.4	4.24	2.82e-05	0.0116	0.21	0.22	Educational attainment;	chr4:119344628	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.691	rs2136911	ENSG00000260091.1	RP11-33B1.4	4.24	2.82e-05	0.0116	0.21	0.22	Corneal astigmatism;	chr4:119344704	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.554	rs2175381	ENSG00000260091.1	RP11-33B1.4	4.24	2.82e-05	0.0116	0.21	0.22	Corneal astigmatism;	chr4:119344812	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.599	rs3864142	ENSG00000260091.1	RP11-33B1.4	4.24	2.82e-05	0.0116	0.21	0.22	Corneal astigmatism;	chr4:119345036	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.605	rs6833140	ENSG00000260091.1	RP11-33B1.4	4.24	2.82e-05	0.0116	0.21	0.22	Corneal astigmatism;	chr4:119345667	chr4:119409333~119410233:+
STAD	cis	rs10028773	0.568	rs6838457	ENSG00000260091.1	RP11-33B1.4	4.24	2.82e-05	0.0116	0.21	0.22	Educational attainment;	chr4:119346212	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.535	rs10005542	ENSG00000260091.1	RP11-33B1.4	4.24	2.82e-05	0.0116	0.21	0.22	Corneal astigmatism;	chr4:119347147	chr4:119409333~119410233:+
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000211959.2	IGHV4-39	4.24	2.82e-05	0.0116	0.2	0.22	Kawasaki disease;	chr14:106783414	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000211959.2	IGHV4-39	4.24	2.82e-05	0.0116	0.2	0.22	Kawasaki disease;	chr14:106783693	chr14:106421711~106422218:-
STAD	cis	rs210138	0.706	rs444697	ENSG00000197251.3	LINC00336	4.24	2.82e-05	0.0116	0.29	0.22	Testicular germ cell tumor;	chr6:33607232	chr6:33586106~33593338:-
STAD	cis	rs7429990	0.965	rs4599334	ENSG00000224895.1	VPS26BP1	4.24	2.82e-05	0.0116	0.22	0.22	Educational attainment (years of education);	chr3:48024910	chr3:47960327~47961081:-
STAD	cis	rs9379945	1	rs9379945	ENSG00000224843.5	LINC00240	4.24	2.82e-05	0.0116	0.4	0.22	Intelligence (multi-trait analysis);	chr6:26940052	chr6:26956992~27023924:+
STAD	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-4.24	2.82e-05	0.0116	-0.25	-0.22	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
STAD	cis	rs7429990	0.932	rs34025851	ENSG00000224895.1	VPS26BP1	-4.24	2.82e-05	0.0116	-0.22	-0.22	Educational attainment (years of education);	chr3:47912243	chr3:47960327~47961081:-
STAD	cis	rs6903823	0.527	rs4713158	ENSG00000220721.1	OR1F12	4.24	2.82e-05	0.0116	0.22	0.22	Pulmonary function;	chr6:28309994	chr6:28073316~28074233:+
STAD	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	4.24	2.83e-05	0.0116	0.41	0.22	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
STAD	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-4.24	2.83e-05	0.0116	-0.25	-0.22	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
STAD	cis	rs7829975	0.774	rs35039922	ENSG00000253981.4	ALG1L13P	4.24	2.83e-05	0.0116	0.26	0.22	Mood instability;	chr8:8817815	chr8:8236003~8244667:-
STAD	cis	rs9348739	1	rs9348739	ENSG00000224843.5	LINC00240	4.24	2.83e-05	0.0116	0.4	0.22	Autism spectrum disorder or schizophrenia;	chr6:26955320	chr6:26956992~27023924:+
STAD	cis	rs2034650	0.544	rs8034416	ENSG00000223313.1	RNU6-516P	4.24	2.83e-05	0.0116	0.24	0.22	Interstitial lung disease;	chr15:40411140	chr15:40529570~40529673:+
STAD	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	4.24	2.83e-05	0.0116	0.23	0.22	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
STAD	cis	rs6496667	0.609	rs7183707	ENSG00000259262.1	NDUFA3P4	4.24	2.83e-05	0.0116	0.28	0.22	Rheumatoid arthritis;	chr15:90340501	chr15:90385814~90386063:+
STAD	cis	rs10229583	0.527	rs10249616	ENSG00000279078.1	SND1-IT1	4.24	2.83e-05	0.0116	0.21	0.22	Type 2 diabetes;	chr7:127759446	chr7:127997597~128000077:+
STAD	cis	rs10229583	0.527	rs10239440	ENSG00000279078.1	SND1-IT1	4.24	2.83e-05	0.0116	0.21	0.22	Type 2 diabetes;	chr7:127765995	chr7:127997597~128000077:+
STAD	cis	rs7829975	0.714	rs7823757	ENSG00000253981.4	ALG1L13P	4.24	2.83e-05	0.0116	0.26	0.22	Mood instability;	chr8:8812667	chr8:8236003~8244667:-
STAD	cis	rs9902453	0.765	rs8079209	ENSG00000240074.1	RPL9P30	4.24	2.83e-05	0.0116	0.19	0.22	Coffee consumption (cups per day);	chr17:29859755	chr17:29855759~29856332:+
STAD	cis	rs12550612	0.83	rs9918919	ENSG00000253616.4	RP11-875O11.3	4.24	2.83e-05	0.0116	0.37	0.22	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109777	chr8:23071377~23074488:-
STAD	cis	rs1707322	0.963	rs12145287	ENSG00000225447.1	RPS15AP10	4.24	2.83e-05	0.0116	0.18	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45645816~45646197:-
STAD	cis	rs2803122	0.745	rs10123714	ENSG00000273226.1	RP11-513M16.8	-4.24	2.83e-05	0.0116	-0.22	-0.22	Pulse pressure;	chr9:19231645	chr9:19375451~19375996:+
STAD	cis	rs9926296	0.744	rs164749	ENSG00000261373.1	VPS9D1-AS1	4.24	2.83e-05	0.0116	0.23	0.22	Vitiligo;	chr16:89641816	chr16:89711856~89718165:+
STAD	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	4.24	2.83e-05	0.0116	0.29	0.22	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
STAD	cis	rs950881	0.867	rs10197862	ENSG00000234389.1	AC007278.3	4.24	2.83e-05	0.0116	0.3	0.22	Allergy;	chr2:102350089	chr2:102438713~102440475:+
STAD	cis	rs12682352	0.602	rs4841044	ENSG00000254340.1	RP11-10A14.3	-4.24	2.83e-05	0.0116	-0.27	-0.22	Neuroticism;	chr8:8807430	chr8:9141424~9145435:+
STAD	cis	rs9467773	0.62	rs2101582	ENSG00000243307.2	POM121L6P	4.24	2.83e-05	0.0116	0.21	0.22	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26896952~26898777:+
STAD	cis	rs9902453	0.791	rs7219163	ENSG00000263477.1	RP11-338L22.2	4.24	2.83e-05	0.0116	0.19	0.22	Coffee consumption (cups per day);	chr17:29883685	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.765	rs62068653	ENSG00000263477.1	RP11-338L22.2	4.24	2.83e-05	0.0116	0.19	0.22	Coffee consumption (cups per day);	chr17:29885645	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.845	rs7221516	ENSG00000263477.1	RP11-338L22.2	4.24	2.83e-05	0.0116	0.19	0.22	Coffee consumption (cups per day);	chr17:29905488	chr17:29863402~29866092:+
STAD	cis	rs10073892	0.66	rs10477821	ENSG00000250682.4	LINC00491	-4.24	2.84e-05	0.0116	-0.24	-0.22	Cognitive decline (age-related);	chr5:102610906	chr5:102609156~102671559:-
STAD	cis	rs2836950	0.805	rs2836961	ENSG00000238141.2	BRWD1-AS1	-4.24	2.84e-05	0.0116	-0.24	-0.22	Menarche (age at onset);	chr21:39255094	chr21:39315707~39323218:+
STAD	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	4.24	2.84e-05	0.0116	0.28	0.22	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
STAD	cis	rs1707322	0.721	rs10430124	ENSG00000281133.1	AL355480.3	-4.24	2.84e-05	0.0116	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45580892~45580996:-
STAD	cis	rs893363	0.61	rs893362	ENSG00000271916.1	RP11-884K10.6	-4.24	2.84e-05	0.0116	-0.28	-0.22	Axial length;	chr3:53813767	chr3:53797764~53798019:-
STAD	cis	rs7429990	0.864	rs6442081	ENSG00000224895.1	VPS26BP1	4.24	2.84e-05	0.0117	0.22	0.22	Educational attainment (years of education);	chr3:47728890	chr3:47960327~47961081:-
STAD	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	4.24	2.84e-05	0.0117	0.34	0.22	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
STAD	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	4.24	2.84e-05	0.0117	0.24	0.22	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
STAD	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-4.24	2.84e-05	0.0117	-0.29	-0.22	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
STAD	cis	rs1707322	1	rs4524994	ENSG00000281133.1	AL355480.3	-4.24	2.84e-05	0.0117	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.963	rs9787412	ENSG00000281133.1	AL355480.3	-4.24	2.84e-05	0.0117	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45580892~45580996:-
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000211959.2	IGHV4-39	4.24	2.84e-05	0.0117	0.2	0.22	Kawasaki disease;	chr14:106784149	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000211959.2	IGHV4-39	4.24	2.84e-05	0.0117	0.2	0.22	Kawasaki disease;	chr14:106785139	chr14:106421711~106422218:-
STAD	cis	rs9307551	0.645	rs7655446	ENSG00000250334.4	LINC00989	-4.24	2.84e-05	0.0117	-0.29	-0.22	Refractive error;	chr4:79499947	chr4:79492416~79576460:+
STAD	cis	rs728616	0.867	rs56271768	ENSG00000225484.5	NUTM2B-AS1	-4.24	2.84e-05	0.0117	-0.46	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:79663088~79826594:-
STAD	cis	rs3002131	0.604	rs17163214	ENSG00000225265.1	TAF1A-AS1	-4.24	2.85e-05	0.0117	-0.34	-0.22	Interleukin-10 levels;	chr1:222559675	chr1:222589825~222593032:+
STAD	cis	rs11098499	0.863	rs7669520	ENSG00000260091.1	RP11-33B1.4	4.24	2.85e-05	0.0117	0.22	0.22	Corneal astigmatism;	chr4:119594123	chr4:119409333~119410233:+
STAD	cis	rs55702914	0.809	rs3097385	ENSG00000231621.1	AC013264.2	4.24	2.85e-05	0.0117	0.2	0.22	Major depression and alcohol dependence;	chr2:197334573	chr2:197197991~197199273:+
STAD	cis	rs7208859	0.573	rs73267873	ENSG00000263603.1	CTD-2349P21.5	-4.24	2.85e-05	0.0117	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30729469~30731202:+
STAD	cis	rs17826219	0.561	rs4085382	ENSG00000263603.1	CTD-2349P21.5	-4.24	2.85e-05	0.0117	-0.27	-0.22	Body mass index;	chr17:30744184	chr17:30729469~30731202:+
STAD	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	4.24	2.85e-05	0.0117	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
STAD	cis	rs6471393	0.929	rs7016930	ENSG00000253848.1	RP11-10N23.5	4.24	2.85e-05	0.0117	0.26	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743185	chr8:93741193~93744534:+
STAD	cis	rs6471393	0.929	rs4734251	ENSG00000253848.1	RP11-10N23.5	4.24	2.85e-05	0.0117	0.26	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744195	chr8:93741193~93744534:+
STAD	cis	rs6471393	0.929	rs4734252	ENSG00000253848.1	RP11-10N23.5	4.24	2.85e-05	0.0117	0.26	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744286	chr8:93741193~93744534:+
STAD	cis	rs6471393	0.929	rs4464937	ENSG00000253848.1	RP11-10N23.5	4.24	2.85e-05	0.0117	0.26	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744689	chr8:93741193~93744534:+
STAD	cis	rs7474896	1	rs12781703	ENSG00000099251.13	HSD17B7P2	4.24	2.85e-05	0.0117	0.37	0.22	Obesity (extreme);	chr10:37755699	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs12360411	ENSG00000099251.13	HSD17B7P2	4.24	2.85e-05	0.0117	0.37	0.22	Obesity (extreme);	chr10:37757706	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs10827824	ENSG00000099251.13	HSD17B7P2	4.24	2.85e-05	0.0117	0.37	0.22	Obesity (extreme);	chr10:37758111	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.943	rs11011355	ENSG00000099251.13	HSD17B7P2	4.24	2.85e-05	0.0117	0.37	0.22	Obesity (extreme);	chr10:37759257	chr10:38356380~38378505:+
STAD	cis	rs4713118	0.911	rs9461406	ENSG00000220721.1	OR1F12	-4.24	2.85e-05	0.0117	-0.26	-0.22	Parkinson's disease;	chr6:27751985	chr6:28073316~28074233:+
STAD	cis	rs3858145	0.546	rs7912806	ENSG00000233590.1	RP11-153K11.3	4.24	2.85e-05	0.0117	0.27	0.22	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68296578	chr10:68233251~68242379:-
STAD	cis	rs7680126	0.633	rs4698014	ENSG00000250613.1	RP11-136I13.1	4.24	2.85e-05	0.0117	0.24	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10284677	chr4:10410996~10411644:+
STAD	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	4.24	2.85e-05	0.0117	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
STAD	cis	rs4879656	0.741	rs10813942	ENSG00000225693.1	LAGE3P1	-4.24	2.85e-05	0.0117	-0.31	-0.22	Menopause (age at onset);	chr9:33092837	chr9:33019682~33020165:-
STAD	cis	rs716804	0.592	rs10770106	ENSG00000254554.1	RP11-351I24.1	4.24	2.85e-05	0.0117	0.33	0.22	Neuroticism;	chr11:10290530	chr11:10302657~10303704:-
STAD	cis	rs2273156	0.929	rs8017225	ENSG00000241052.1	RP11-173D9.1	-4.24	2.85e-05	0.0117	-0.24	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000843	chr14:35144021~35144480:-
STAD	cis	rs56114371	0.53	rs2056923	ENSG00000243307.2	POM121L6P	-4.24	2.85e-05	0.0117	-0.32	-0.22	Breast cancer;	chr6:27722160	chr6:26896952~26898777:+
STAD	cis	rs12682352	0.602	rs4841044	ENSG00000253981.4	ALG1L13P	-4.24	2.85e-05	0.0117	-0.27	-0.22	Neuroticism;	chr8:8807430	chr8:8236003~8244667:-
STAD	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	4.24	2.85e-05	0.0117	0.3	0.22	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	4.24	2.85e-05	0.0117	0.3	0.22	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	4.24	2.85e-05	0.0117	0.3	0.22	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
STAD	cis	rs7829975	0.56	rs6994131	ENSG00000254340.1	RP11-10A14.3	-4.24	2.86e-05	0.0117	-0.3	-0.22	Mood instability;	chr8:8693448	chr8:9141424~9145435:+
STAD	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-4.24	2.86e-05	0.0117	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
STAD	cis	rs4243830	0.737	rs4908926	ENSG00000229519.2	RP11-58A11.2	4.24	2.86e-05	0.0117	0.24	0.22	Body mass index;	chr1:6556981	chr1:6547905~6548619:+
STAD	cis	rs2836974	0.526	rs1888488	ENSG00000238141.2	BRWD1-AS1	-4.24	2.86e-05	0.0117	-0.23	-0.22	Cognitive function;	chr21:39314595	chr21:39315707~39323218:+
STAD	cis	rs2273156	1	rs2383688	ENSG00000241052.1	RP11-173D9.1	-4.24	2.86e-05	0.0117	-0.25	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:34934245	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs2383689	ENSG00000241052.1	RP11-173D9.1	-4.24	2.86e-05	0.0117	-0.25	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:34934814	chr14:35144021~35144480:-
STAD	cis	rs2273156	1	rs12050267	ENSG00000241052.1	RP11-173D9.1	-4.24	2.86e-05	0.0117	-0.25	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:34942222	chr14:35144021~35144480:-
STAD	cis	rs10043228	0.609	rs12518933	ENSG00000248445.4	SEMA6A-AS1	-4.24	2.86e-05	0.0117	-0.31	-0.22	Asthma or chronic obstructive pulmonary disease;	chr5:116374908	chr5:116447547~116508276:+
STAD	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	4.24	2.86e-05	0.0117	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
STAD	cis	rs8028182	0.636	rs4299117	ENSG00000260269.4	CTD-2323K18.1	-4.24	2.86e-05	0.0117	-0.29	-0.22	Sudden cardiac arrest;	chr15:75497103	chr15:75527150~75601205:-
STAD	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-4.24	2.86e-05	0.0117	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
STAD	cis	rs6584485	0.589	rs7083450	ENSG00000272933.1	RP11-47A8.5	-4.24	2.86e-05	0.0117	-0.29	-0.22	Mean corpuscular volume;	chr10:102224303	chr10:102642792~102644140:-
STAD	cis	rs1799949	0.896	rs8176086	ENSG00000279602.1	CTD-3014M21.1	4.24	2.86e-05	0.0117	0.28	0.22	Menopause (age at onset);	chr17:43122761	chr17:43360041~43361361:-
STAD	cis	rs9307551	0.744	rs4975095	ENSG00000250334.4	LINC00989	-4.24	2.86e-05	0.0117	-0.28	-0.22	Refractive error;	chr4:79563197	chr4:79492416~79576460:+
STAD	cis	rs7395581	1	rs7395581	ENSG00000271350.1	CTD-2384B9.1	-4.24	2.86e-05	0.0117	-0.28	-0.22	HDL cholesterol;	chr11:47224846	chr11:47041027~47041945:-
STAD	cis	rs1707322	1	rs7553924	ENSG00000225447.1	RPS15AP10	4.24	2.86e-05	0.0117	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4641257	ENSG00000225447.1	RPS15AP10	4.24	2.86e-05	0.0117	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs6693336	ENSG00000225447.1	RPS15AP10	4.24	2.86e-05	0.0117	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4539075	ENSG00000225447.1	RPS15AP10	4.24	2.86e-05	0.0117	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211219	ENSG00000225447.1	RPS15AP10	4.24	2.86e-05	0.0117	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211222	ENSG00000225447.1	RPS15AP10	4.24	2.86e-05	0.0117	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45645816~45646197:-
STAD	cis	rs2115536	1	rs2115536	ENSG00000278600.1	RP11-81A1.6	-4.24	2.86e-05	0.0117	-0.19	-0.22	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79901905	chr15:79920195~79922455:-
STAD	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-4.24	2.87e-05	0.0117	-0.29	-0.22	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
STAD	cis	rs58873874	1	rs58873874	ENSG00000251405.2	CTB-109A12.1	4.24	2.87e-05	0.0117	0.38	0.22	Bipolar disorder (body mass index interaction);	chr5:157518140	chr5:157362615~157460078:-
STAD	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-4.24	2.87e-05	0.0118	-0.24	-0.22	Height;	chr2:46609767	chr2:46668870~46670778:+
STAD	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	4.24	2.87e-05	0.0118	0.28	0.22	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
STAD	cis	rs449789	0.817	rs1875814	ENSG00000235086.1	FNDC1-IT1	-4.24	2.87e-05	0.0118	-0.29	-0.22	Pulse pressure;	chr6:159299234	chr6:159240786~159243329:+
STAD	cis	rs6496667	0.821	rs4412956	ENSG00000259262.1	NDUFA3P4	-4.24	2.87e-05	0.0118	-0.31	-0.22	Rheumatoid arthritis;	chr15:90342485	chr15:90385814~90386063:+
STAD	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	4.24	2.87e-05	0.0118	0.27	0.22	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	4.24	2.87e-05	0.0118	0.27	0.22	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
STAD	cis	rs10073892	0.62	rs10440756	ENSG00000250682.4	LINC00491	-4.24	2.87e-05	0.0118	-0.24	-0.22	Cognitive decline (age-related);	chr5:102593725	chr5:102609156~102671559:-
STAD	cis	rs4293777	0.904	rs11929839	ENSG00000250896.1	RNPS1P1	4.24	2.87e-05	0.0118	0.17	0.22	Primary sclerosing cholangitis;	chr4:10724985	chr4:11371975~11372892:+
STAD	cis	rs5758659	0.714	rs2284087	ENSG00000182057.4	OGFRP1	-4.24	2.87e-05	0.0118	-0.24	-0.22	Cognitive function;	chr22:42089667	chr22:42269753~42275196:+
STAD	cis	rs6539288	0.691	rs10746071	ENSG00000260329.1	RP11-412D9.4	4.24	2.87e-05	0.0118	0.23	0.22	Total body bone mineral density;	chr12:106959817	chr12:106954029~106955497:-
STAD	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	4.24	2.87e-05	0.0118	0.24	0.22	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
STAD	cis	rs9902453	0.704	rs2628179	ENSG00000263477.1	RP11-338L22.2	-4.24	2.88e-05	0.0118	-0.19	-0.22	Coffee consumption (cups per day);	chr17:29744778	chr17:29863402~29866092:+
STAD	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-4.24	2.88e-05	0.0118	-0.22	-0.22	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
STAD	cis	rs7598759	0.548	rs11686485	ENSG00000223198.1	RNU2-22P	-4.24	2.88e-05	0.0118	-0.25	-0.22	Noise-induced hearing loss;	chr2:231495986	chr2:231501990~231502201:-
STAD	cis	rs2380205	0.601	rs4293039	ENSG00000232807.2	RP11-536K7.3	4.24	2.88e-05	0.0118	0.23	0.22	Breast cancer;	chr10:5856261	chr10:5934270~5945900:-
STAD	cis	rs2695743	0.592	rs41440047	ENSG00000225808.1	DNAJC19P5	-4.24	2.88e-05	0.0118	-0.25	-0.22	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177820093	chr2:177229191~177229506:-
STAD	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	4.24	2.88e-05	0.0118	0.23	0.22	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
STAD	cis	rs10508774	1	rs1999534	ENSG00000273038.2	RP11-479G22.8	4.24	2.88e-05	0.0118	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32556941	chr10:32887255~32889311:-
STAD	cis	rs765787	0.53	rs1706834	ENSG00000259539.1	CTD-2651B20.1	4.24	2.88e-05	0.0118	0.26	0.22	Uric acid levels;	chr15:45225656	chr15:45152664~45167526:-
STAD	cis	rs1900504	0.584	rs2915756	ENSG00000266200.5	PNLIPRP2	-4.24	2.88e-05	0.0118	-0.31	-0.22	Tonsillectomy;	chr10:116603428	chr10:116620953~116645143:+
STAD	cis	rs7615952	0.688	rs9754526	ENSG00000242229.1	RPS3AP14	4.24	2.88e-05	0.0118	0.28	0.22	Blood pressure (smoking interaction);	chr3:125824023	chr3:125795106~125795885:+
STAD	cis	rs1426063	0.614	rs79750906	ENSG00000249717.1	RP11-44F21.3	4.24	2.88e-05	0.0118	0.47	0.22	QT interval;	chr4:75139193	chr4:74955974~74970362:-
STAD	cis	rs9902453	0.845	rs10853135	ENSG00000240074.1	RPL9P30	4.24	2.88e-05	0.0118	0.19	0.22	Coffee consumption (cups per day);	chr17:29861657	chr17:29855759~29856332:+
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000272787.1	KB-226F1.2	-4.24	2.88e-05	0.0118	-0.24	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23969211~23969873:+
STAD	cis	rs13392177	0.543	rs12623716	ENSG00000237281.1	CATIP-AS2	4.24	2.88e-05	0.0118	0.23	0.22	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218326889~218357966:-
STAD	cis	rs4535700	0.501	rs57153841	ENSG00000226278.1	PSPHP1	4.24	2.88e-05	0.0118	0.29	0.22	Macular telangiectasia type 2;	chr7:55927400	chr7:55764797~55773288:+
STAD	cis	rs17780086	0.529	rs7406406	ENSG00000265798.5	RP11-271K11.5	4.24	2.88e-05	0.0118	0.26	0.22	Height;	chr17:31893134	chr17:31038575~31059121:-
STAD	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	4.24	2.88e-05	0.0118	0.31	0.22	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
STAD	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-4.24	2.89e-05	0.0118	-0.23	-0.22	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
STAD	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-4.24	2.89e-05	0.0118	-0.23	-0.22	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
STAD	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-4.24	2.89e-05	0.0118	-0.23	-0.22	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
STAD	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-4.24	2.89e-05	0.0118	-0.23	-0.22	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
STAD	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-4.24	2.89e-05	0.0118	-0.26	-0.22	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
STAD	cis	rs2836950	0.509	rs11088466	ENSG00000238141.2	BRWD1-AS1	-4.24	2.89e-05	0.0118	-0.23	-0.22	Menarche (age at onset);	chr21:39208091	chr21:39315707~39323218:+
STAD	cis	rs117785887	0.536	rs12205195	ENSG00000270638.1	RP3-466P17.1	4.24	2.89e-05	0.0118	0.39	0.22	Interleukin-17 levels;	chr6:146043164	chr6:145735570~145737218:+
STAD	cis	rs1707322	1	rs1707317	ENSG00000225447.1	RPS15AP10	-4.24	2.89e-05	0.0118	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45645816~45646197:-
STAD	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	4.24	2.89e-05	0.0118	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
STAD	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	4.24	2.89e-05	0.0118	0.23	0.22	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
STAD	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	4.24	2.89e-05	0.0118	0.27	0.22	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
STAD	cis	rs9902453	0.791	rs62068629	ENSG00000263477.1	RP11-338L22.2	4.24	2.89e-05	0.0118	0.19	0.22	Coffee consumption (cups per day);	chr17:29860578	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.817	rs1842026	ENSG00000263477.1	RP11-338L22.2	4.24	2.89e-05	0.0118	0.19	0.22	Coffee consumption (cups per day);	chr17:29861093	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.78	rs7210991	ENSG00000263477.1	RP11-338L22.2	4.24	2.89e-05	0.0118	0.19	0.22	Coffee consumption (cups per day);	chr17:29863943	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.817	rs12051834	ENSG00000263477.1	RP11-338L22.2	4.24	2.89e-05	0.0118	0.19	0.22	Coffee consumption (cups per day);	chr17:29865767	chr17:29863402~29866092:+
STAD	cis	rs13413635	0.908	rs6724505	ENSG00000225808.1	DNAJC19P5	-4.24	2.89e-05	0.0118	-0.3	-0.22	Heart rate;	chr2:177818558	chr2:177229191~177229506:-
STAD	cis	rs6480314	0.522	rs10047355	ENSG00000233590.1	RP11-153K11.3	-4.24	2.89e-05	0.0118	-0.33	-0.22	Optic nerve measurement (disc area);	chr10:68300321	chr10:68233251~68242379:-
STAD	cis	rs4237845	0.591	rs4760344	ENSG00000273805.1	RP11-620J15.4	-4.24	2.89e-05	0.0118	-0.25	-0.22	Intelligence (multi-trait analysis);	chr12:57927000	chr12:57894232~57896846:+
STAD	cis	rs7156960	1	rs10143886	ENSG00000258454.1	RP11-361H10.3	4.24	2.89e-05	0.0118	0.24	0.22	Acute lymphoblastic leukemia (childhood);	chr14:76244208	chr14:76235817~76263474:+
STAD	cis	rs9902453	0.619	rs2255489	ENSG00000263477.1	RP11-338L22.2	-4.24	2.89e-05	0.0118	-0.19	-0.22	Coffee consumption (cups per day);	chr17:29757956	chr17:29863402~29866092:+
STAD	cis	rs2992257	0.914	rs871367	ENSG00000251839.1	RNU7-12P	-4.24	2.89e-05	0.0118	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26415687	chr10:27232255~27232316:-
STAD	cis	rs4713118	0.662	rs149900	ENSG00000220721.1	OR1F12	4.24	2.89e-05	0.0118	0.26	0.22	Parkinson's disease;	chr6:28046819	chr6:28073316~28074233:+
STAD	cis	rs2573652	0.722	rs12914180	ENSG00000270127.2	RP11-526I2.5	-4.24	2.9e-05	0.0118	-0.24	-0.22	Height;	chr15:100004211	chr15:100547765~100550153:-
STAD	cis	rs12439619	1	rs12439619	ENSG00000259429.4	UBE2Q2P2	-4.24	2.9e-05	0.0118	-0.28	-0.22	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82355142~82420075:+
STAD	cis	rs1876905	0.539	rs240962	ENSG00000230177.1	RP5-1112D6.4	4.24	2.9e-05	0.0118	0.25	0.22	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111277932~111278742:+
STAD	cis	rs1538970	0.504	rs3790585	ENSG00000280836.1	AL355480.1	-4.24	2.9e-05	0.0118	-0.37	-0.22	Platelet count;	chr1:45557684	chr1:45581219~45581321:-
STAD	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-4.24	2.9e-05	0.0118	-0.26	-0.22	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-4.24	2.9e-05	0.0118	-0.26	-0.22	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
STAD	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-4.24	2.9e-05	0.0118	-0.28	-0.22	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
STAD	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	4.24	2.9e-05	0.0119	0.25	0.22	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
STAD	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	4.24	2.9e-05	0.0119	0.38	0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
STAD	cis	rs989978	0.958	rs7901824	ENSG00000228778.1	RP11-129J12.1	-4.24	2.9e-05	0.0119	-0.26	-0.22	Red blood cell count;	chr10:99565066	chr10:99527081~99528261:+
STAD	cis	rs9291683	0.507	rs3775940	ENSG00000250613.1	RP11-136I13.1	-4.24	2.9e-05	0.0119	-0.23	-0.22	Bone mineral density;	chr4:10023539	chr4:10410996~10411644:+
STAD	cis	rs870825	0.616	rs7678900	ENSG00000249173.4	LINC01093	-4.24	2.9e-05	0.0119	-0.35	-0.22	Blood protein levels;	chr4:184714095	chr4:184893871~184899454:-
STAD	cis	rs1816752	0.646	rs4770688	ENSG00000273628.1	RP11-756A22.7	-4.24	2.9e-05	0.0119	-0.27	-0.22	Obesity-related traits;	chr13:24466007	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs4770689	ENSG00000273628.1	RP11-756A22.7	-4.24	2.9e-05	0.0119	-0.27	-0.22	Obesity-related traits;	chr13:24466008	chr13:24933006~24936796:+
STAD	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	4.24	2.9e-05	0.0119	0.31	0.22	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
STAD	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-4.24	2.9e-05	0.0119	-0.36	-0.22	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
STAD	cis	rs451417	1	rs236115	ENSG00000275632.1	RP5-967N21.11	4.24	2.9e-05	0.0119	0.3	0.22	Menopause (age at onset);	chr20:5954803	chr20:6000418~6000941:+
STAD	cis	rs5753618	0.561	rs714909	ENSG00000236132.1	CTA-440B3.1	-4.24	2.9e-05	0.0119	-0.26	-0.22	Colorectal cancer;	chr22:31345081	chr22:31816379~31817491:-
STAD	cis	rs950169	0.519	rs7237	ENSG00000275120.1	RP11-182J1.17	4.24	2.91e-05	0.0119	0.29	0.22	Schizophrenia;	chr15:84643346	chr15:84599434~84606463:-
STAD	cis	rs1707322	1	rs6675222	ENSG00000225447.1	RPS15AP10	4.24	2.91e-05	0.0119	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4660895	ENSG00000225447.1	RPS15AP10	4.24	2.91e-05	0.0119	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4660318	ENSG00000225447.1	RPS15AP10	4.24	2.91e-05	0.0119	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs10890360	ENSG00000225447.1	RPS15AP10	4.24	2.91e-05	0.0119	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs6682683	ENSG00000225447.1	RPS15AP10	4.24	2.91e-05	0.0119	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45645816~45646197:-
STAD	cis	rs1913185	0.787	rs59384952	ENSG00000240032.1	RP11-274H2.3	-4.24	2.91e-05	0.0119	-0.34	-0.22	Obesity-related traits;	chr3:146060012	chr3:146066344~146069185:-
STAD	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
STAD	cis	rs4589258	0.762	rs10741360	ENSG00000280367.1	RP11-121L10.2	4.24	2.91e-05	0.0119	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90723837	chr11:90223153~90226538:+
STAD	cis	rs11673344	0.503	rs7246720	ENSG00000267672.1	CTD-2293H3.1	4.24	2.91e-05	0.0119	0.2	0.22	Obesity-related traits;	chr19:37073726	chr19:37091341~37092564:+
STAD	cis	rs449789	0.857	rs591953	ENSG00000235086.1	FNDC1-IT1	-4.24	2.91e-05	0.0119	-0.29	-0.22	Pulse pressure;	chr6:159295714	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs606833	ENSG00000235086.1	FNDC1-IT1	-4.24	2.91e-05	0.0119	-0.29	-0.22	Pulse pressure;	chr6:159296744	chr6:159240786~159243329:+
STAD	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	4.24	2.91e-05	0.0119	0.29	0.22	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
STAD	cis	rs17818399	0.51	rs12105801	ENSG00000279254.1	RP11-536C12.1	-4.24	2.91e-05	0.0119	-0.23	-0.22	Height;	chr2:46572204	chr2:46668870~46670778:+
STAD	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-4.24	2.91e-05	0.0119	-0.27	-0.22	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
STAD	cis	rs3198697	1	rs3198697	ENSG00000207425.1	Y_RNA	4.24	2.91e-05	0.0119	0.26	0.22	Triglycerides;	chr16:15036083	chr16:14915457~14915556:-
STAD	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	4.24	2.91e-05	0.0119	0.29	0.22	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
STAD	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-4.24	2.91e-05	0.0119	-0.28	-0.22	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
STAD	cis	rs2836974	0.644	rs2836981	ENSG00000238141.2	BRWD1-AS1	-4.24	2.91e-05	0.0119	-0.23	-0.22	Cognitive function;	chr21:39316439	chr21:39315707~39323218:+
STAD	cis	rs4691139	1	rs4691139	ENSG00000248632.1	RP11-366M4.11	4.24	2.91e-05	0.0119	0.22	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987569	chr4:164968587~164970002:-
STAD	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-4.24	2.91e-05	0.0119	-0.35	-0.22	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
STAD	cis	rs4761702	0.857	rs1135400	ENSG00000257252.4	RP11-486A14.2	4.24	2.92e-05	0.0119	0.25	0.22	Immature fraction of reticulocytes;	chr12:93315763	chr12:93317135~93377736:-
STAD	cis	rs6693567	0.545	rs4446975	ENSG00000203819.6	HIST2H2BC	4.24	2.92e-05	0.0119	0.25	0.22	Migraine;	chr1:150483693	chr1:149850193~149850772:-
STAD	cis	rs1707322	1	rs785484	ENSG00000225447.1	RPS15AP10	-4.24	2.92e-05	0.0119	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45645816~45646197:-
STAD	cis	rs447735	0.587	rs7188458	ENSG00000260259.1	RP11-368I7.4	4.24	2.92e-05	0.0119	0.26	0.22	Hemoglobin concentration;	chr16:89660076	chr16:89682620~89686569:-
STAD	cis	rs2836950	0.565	rs2836943	ENSG00000238141.2	BRWD1-AS1	-4.24	2.92e-05	0.0119	-0.23	-0.22	Menarche (age at onset);	chr21:39220685	chr21:39315707~39323218:+
STAD	cis	rs7786877	0.521	rs4729606	ENSG00000236305.1	RP11-126L15.4	4.24	2.92e-05	0.0119	0.29	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100724167	chr7:100837314~100852616:-
STAD	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-4.24	2.92e-05	0.0119	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-4.24	2.92e-05	0.0119	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
STAD	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-4.24	2.92e-05	0.0119	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-4.24	2.92e-05	0.0119	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
STAD	cis	rs6095360	0.727	rs8119476	ENSG00000222365.1	SNORD12B	-4.24	2.92e-05	0.0119	-0.3	-0.22	Intelligence (multi-trait analysis);	chr20:49073599	chr20:49280319~49280409:+
STAD	cis	rs721917	1	rs721917	ENSG00000225484.5	NUTM2B-AS1	4.24	2.92e-05	0.0119	0.27	0.22	Chronic obstructive pulmonary disease;	chr10:79946568	chr10:79663088~79826594:-
STAD	cis	rs4237845	0.804	rs11172372	ENSG00000273805.1	RP11-620J15.4	-4.24	2.93e-05	0.0119	-0.24	-0.22	Intelligence (multi-trait analysis);	chr12:57892490	chr12:57894232~57896846:+
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000211959.2	IGHV4-39	4.24	2.93e-05	0.0119	0.2	0.22	Kawasaki disease;	chr14:106785926	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000211959.2	IGHV4-39	4.24	2.93e-05	0.0119	0.2	0.22	Kawasaki disease;	chr14:106787090	chr14:106421711~106422218:-
STAD	cis	rs2286503	0.65	rs1990279	ENSG00000226329.2	AC005682.6	4.24	2.93e-05	0.0119	0.22	0.22	Fibrinogen;	chr7:22851123	chr7:22863874~22881350:-
STAD	cis	rs2957692	0.548	rs11042618	ENSG00000254554.1	RP11-351I24.1	4.24	2.93e-05	0.0119	0.38	0.22	Circulating vasoactive peptide levels;	chr11:10087237	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs12421096	ENSG00000254554.1	RP11-351I24.1	4.24	2.93e-05	0.0119	0.38	0.22	Circulating vasoactive peptide levels;	chr11:10090444	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs12421179	ENSG00000254554.1	RP11-351I24.1	4.24	2.93e-05	0.0119	0.38	0.22	Circulating vasoactive peptide levels;	chr11:10091489	chr11:10302657~10303704:-
STAD	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	4.24	2.93e-05	0.0119	0.24	0.22	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
STAD	cis	rs2836950	0.565	rs8130320	ENSG00000238141.2	BRWD1-AS1	-4.24	2.93e-05	0.0119	-0.23	-0.22	Menarche (age at onset);	chr21:39208332	chr21:39315707~39323218:+
STAD	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-4.24	2.93e-05	0.0119	-0.32	-0.22	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-4.24	2.93e-05	0.0119	-0.32	-0.22	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-4.24	2.93e-05	0.0119	-0.32	-0.22	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
STAD	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	4.24	2.93e-05	0.0119	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	4.24	2.93e-05	0.0119	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	4.24	2.93e-05	0.0119	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	4.24	2.93e-05	0.0119	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	4.24	2.93e-05	0.0119	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
STAD	cis	rs10129255	0.5	rs2105989	ENSG00000224373.3	IGHV4-59	4.24	2.93e-05	0.0119	0.16	0.22	Kawasaki disease;	chr14:106682199	chr14:106627249~106627825:-
STAD	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-4.24	2.93e-05	0.0119	-0.26	-0.22	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
STAD	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-4.24	2.93e-05	0.012	-0.26	-0.22	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
STAD	cis	rs10851478	0.872	rs12591317	ENSG00000259545.2	RP11-325E5.4	-4.24	2.93e-05	0.012	-0.27	-0.22	Oral cavity cancer;	chr15:49653478	chr15:49177610~49178741:-
STAD	cis	rs2638953	0.924	rs11049386	ENSG00000247934.4	RP11-967K21.1	-4.24	2.93e-05	0.012	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167603	chr12:28163298~28190738:-
STAD	cis	rs12745968	0.653	rs1003116	ENSG00000229052.2	RP11-386I23.1	-4.23	2.93e-05	0.012	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92700844	chr1:92930696~92934098:+
STAD	cis	rs1799949	0.93	rs33968979	ENSG00000279602.1	CTD-3014M21.1	4.23	2.93e-05	0.012	0.28	0.22	Menopause (age at onset);	chr17:43145975	chr17:43360041~43361361:-
STAD	cis	rs7924176	0.564	rs2270551	ENSG00000213731.2	RAB5CP1	-4.23	2.93e-05	0.012	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74109307	chr10:74423435~74424014:-
STAD	cis	rs17507216	0.628	rs17158396	ENSG00000255769.6	GOLGA2P10	-4.23	2.94e-05	0.012	-0.35	-0.22	Excessive daytime sleepiness;	chr15:82615688	chr15:82472993~82513950:-
STAD	cis	rs17401966	0.931	rs17034821	ENSG00000199562.1	RNU6-37P	4.23	2.94e-05	0.012	0.18	0.22	Hepatocellular carcinoma;	chr1:10354587	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.931	rs2185252	ENSG00000199562.1	RNU6-37P	4.23	2.94e-05	0.012	0.18	0.22	Hepatocellular carcinoma;	chr1:10355854	chr1:10298966~10299072:+
STAD	cis	rs9902453	1	rs4465649	ENSG00000240074.1	RPL9P30	-4.23	2.94e-05	0.012	-0.19	-0.22	Coffee consumption (cups per day);	chr17:30067729	chr17:29855759~29856332:+
STAD	cis	rs1707322	0.721	rs4559551	ENSG00000281133.1	AL355480.3	-4.23	2.94e-05	0.012	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45580892~45580996:-
STAD	cis	rs7615952	0.512	rs4234285	ENSG00000171084.14	FAM86JP	4.23	2.94e-05	0.012	0.32	0.22	Blood pressure (smoking interaction);	chr3:125685633	chr3:125916620~125930024:+
STAD	cis	rs55823223	0.646	rs55868394	ENSG00000267801.1	RP11-552F3.9	4.23	2.94e-05	0.012	0.38	0.22	Psoriasis;	chr17:75855032	chr17:75876372~75879546:+
STAD	cis	rs7829975	0.66	rs10093926	ENSG00000254340.1	RP11-10A14.3	-4.23	2.94e-05	0.012	-0.28	-0.22	Mood instability;	chr8:8691510	chr8:9141424~9145435:+
STAD	cis	rs4639966	0.836	rs7110526	ENSG00000255239.1	AP002954.6	-4.23	2.94e-05	0.012	-0.28	-0.22	Systemic lupus erythematosus;	chr11:118762824	chr11:118688039~118690600:-
STAD	cis	rs4639966	0.797	rs11217021	ENSG00000255239.1	AP002954.6	-4.23	2.94e-05	0.012	-0.28	-0.22	Systemic lupus erythematosus;	chr11:118770119	chr11:118688039~118690600:-
STAD	cis	rs1850744	0.826	rs6858644	ENSG00000250942.1	ENPP7P11	4.23	2.94e-05	0.012	0.42	0.22	Economic and political preferences;	chr4:9740057	chr4:9677308~9677934:+
STAD	cis	rs2929282	1	rs2929282	ENSG00000205771.5	CATSPER2P1	-4.23	2.95e-05	0.012	-0.4	-0.22	Triglycerides;Triglyceride levels;	chr15:43953733	chr15:43726918~43747094:-
STAD	cis	rs875971	0.789	rs10260426	ENSG00000224316.1	RP11-479O9.2	-4.23	2.95e-05	0.012	-0.22	-0.22	Aortic root size;	chr7:66271055	chr7:65773620~65802067:+
STAD	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-4.23	2.95e-05	0.012	-0.28	-0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
STAD	cis	rs10129255	0.872	rs10133674	ENSG00000232216.1	IGHV3-43	4.23	2.95e-05	0.012	0.22	0.22	Kawasaki disease;	chr14:106692788	chr14:106470264~106470800:-
STAD	cis	rs2880765	0.835	rs7180213	ENSG00000259295.5	CSPG4P12	4.23	2.95e-05	0.012	0.27	0.22	Coronary artery disease;	chr15:85477956	chr15:85191438~85213905:+
STAD	cis	rs8141529	0.673	rs132548	ENSG00000226471.5	CTA-292E10.6	4.23	2.95e-05	0.012	0.25	0.22	Lymphocyte counts;	chr22:28921571	chr22:28800683~28848559:+
STAD	cis	rs9646944	0.891	rs13027294	ENSG00000234389.1	AC007278.3	4.23	2.95e-05	0.012	0.27	0.22	Blood protein levels;	chr2:102243614	chr2:102438713~102440475:+
STAD	cis	rs11846409	0.86	rs4774166	ENSG00000211972.2	IGHV3-66	4.23	2.95e-05	0.012	0.24	0.22	Rheumatic heart disease;	chr14:106619598	chr14:106675017~106675544:-
STAD	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-4.23	2.95e-05	0.012	-0.27	-0.22	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
STAD	cis	rs1005277	0.563	rs2505215	ENSG00000276805.1	RP11-291L22.6	4.23	2.96e-05	0.012	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.563	rs2505216	ENSG00000276805.1	RP11-291L22.6	4.23	2.96e-05	0.012	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.563	rs2800550	ENSG00000276805.1	RP11-291L22.6	4.23	2.96e-05	0.012	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38451030~38451785:+
STAD	cis	rs875971	0.862	rs4368860	ENSG00000224316.1	RP11-479O9.2	-4.23	2.96e-05	0.012	-0.22	-0.22	Aortic root size;	chr7:66143495	chr7:65773620~65802067:+
STAD	cis	rs4589258	0.788	rs2511320	ENSG00000280367.1	RP11-121L10.2	4.23	2.96e-05	0.012	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90719569	chr11:90223153~90226538:+
STAD	cis	rs12908161	0.92	rs12904605	ENSG00000259295.5	CSPG4P12	4.23	2.96e-05	0.012	0.32	0.22	Schizophrenia;	chr15:84658188	chr15:85191438~85213905:+
STAD	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-4.23	2.96e-05	0.012	-0.24	-0.22	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
STAD	cis	rs7702057	0.53	rs17138866	ENSG00000271918.1	CTD-2287O16.5	4.23	2.96e-05	0.0121	0.41	0.22	Amyotrophic lateral sclerosis;	chr5:116088914	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs59429923	ENSG00000271918.1	CTD-2287O16.5	4.23	2.96e-05	0.0121	0.41	0.22	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116083807~116085416:-
STAD	cis	rs1816752	0.646	rs2862905	ENSG00000273628.1	RP11-756A22.7	-4.23	2.96e-05	0.0121	-0.27	-0.22	Obesity-related traits;	chr13:24485142	chr13:24933006~24936796:+
STAD	cis	rs2921036	0.545	rs4840975	ENSG00000253981.4	ALG1L13P	-4.23	2.96e-05	0.0121	-0.31	-0.22	Neuroticism;	chr8:8505748	chr8:8236003~8244667:-
STAD	cis	rs481331	0.799	rs7076849	ENSG00000230555.2	RP11-517P14.2	4.23	2.96e-05	0.0121	0.35	0.22	Systemic juvenile idiopathic arthritis;	chr10:42480411	chr10:43420738~43422100:+
STAD	cis	rs1348850	0.567	rs3770005	ENSG00000271825.1	RP11-337N6.2	4.23	2.96e-05	0.0121	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177664146	chr2:177300600~177302006:+
STAD	cis	rs9902453	0.765	rs3102562	ENSG00000240074.1	RPL9P30	4.23	2.96e-05	0.0121	0.19	0.22	Coffee consumption (cups per day);	chr17:29713385	chr17:29855759~29856332:+
STAD	cis	rs2880765	0.545	rs17553734	ENSG00000229212.6	RP11-561C5.4	-4.23	2.96e-05	0.0121	-0.31	-0.22	Coronary artery disease;	chr15:85469828	chr15:85205440~85234795:-
STAD	cis	rs9910055	0.53	rs2269908	ENSG00000260793.2	RP5-882C2.2	-4.23	2.96e-05	0.0121	-0.24	-0.22	Total body bone mineral density;	chr17:44216830	chr17:44221401~44223710:+
STAD	cis	rs9910055	0.53	rs2269907	ENSG00000260793.2	RP5-882C2.2	-4.23	2.96e-05	0.0121	-0.24	-0.22	Total body bone mineral density;	chr17:44216847	chr17:44221401~44223710:+
STAD	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	4.23	2.96e-05	0.0121	0.25	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
STAD	cis	rs10851478	0.872	rs11854568	ENSG00000259545.2	RP11-325E5.4	-4.23	2.97e-05	0.0121	-0.26	-0.22	Oral cavity cancer;	chr15:49551550	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.836	rs11070706	ENSG00000259545.2	RP11-325E5.4	-4.23	2.97e-05	0.0121	-0.26	-0.22	Oral cavity cancer;	chr15:49553099	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs1395901	ENSG00000259545.2	RP11-325E5.4	-4.23	2.97e-05	0.0121	-0.26	-0.22	Oral cavity cancer;	chr15:49557477	chr15:49177610~49178741:-
STAD	cis	rs1707322	0.964	rs6675259	ENSG00000225447.1	RPS15AP10	-4.23	2.97e-05	0.0121	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45645816~45646197:-
STAD	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	4.23	2.97e-05	0.0121	0.25	0.22	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
STAD	cis	rs6813195	0.881	rs7659677	ENSG00000243417.1	RP11-555K12.1	-4.23	2.97e-05	0.0121	-0.22	-0.22	Type 2 diabetes;	chr4:152595014	chr4:152551277~152552364:-
STAD	cis	rs9902453	0.765	rs6505143	ENSG00000240074.1	RPL9P30	4.23	2.97e-05	0.0121	0.19	0.22	Coffee consumption (cups per day);	chr17:29823567	chr17:29855759~29856332:+
STAD	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	4.23	2.97e-05	0.0121	0.29	0.22	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
STAD	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	4.23	2.97e-05	0.0121	0.29	0.22	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
STAD	cis	rs9902453	0.904	rs4567782	ENSG00000240074.1	RPL9P30	4.23	2.97e-05	0.0121	0.19	0.22	Coffee consumption (cups per day);	chr17:29941782	chr17:29855759~29856332:+
STAD	cis	rs5753618	0.561	rs2283879	ENSG00000236132.1	CTA-440B3.1	4.23	2.97e-05	0.0121	0.26	0.22	Colorectal cancer;	chr22:31242462	chr22:31816379~31817491:-
STAD	cis	rs9987353	0.566	rs13260067	ENSG00000254340.1	RP11-10A14.3	-4.23	2.98e-05	0.0121	-0.3	-0.22	Recombination measurement;	chr8:9213523	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.863	rs3822192	ENSG00000260091.1	RP11-33B1.4	4.23	2.98e-05	0.0121	0.22	0.22	Corneal astigmatism;	chr4:119524565	chr4:119409333~119410233:+
STAD	cis	rs3811273	0.614	rs7152167	ENSG00000211816.2	TRAV38-1	-4.23	2.98e-05	0.0121	-0.28	-0.22	Periodontal disease-related phenotypes;	chr14:22266254	chr14:22271968~22272563:+
STAD	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	4.23	2.98e-05	0.0121	0.26	0.22	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
STAD	cis	rs6479891	0.915	rs9415699	ENSG00000235816.3	PRELID1P3	-4.23	2.98e-05	0.0121	-0.27	-0.22	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63427297~63427939:+
STAD	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	4.23	2.98e-05	0.0121	0.32	0.22	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
STAD	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-4.23	2.98e-05	0.0121	-0.25	-0.22	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
STAD	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-4.23	2.98e-05	0.0121	-0.2	-0.22	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
STAD	cis	rs17401966	0.858	rs61778404	ENSG00000199562.1	RNU6-37P	4.23	2.98e-05	0.0121	0.18	0.22	Hepatocellular carcinoma;	chr1:10372821	chr1:10298966~10299072:+
STAD	cis	rs11169552	0.51	rs4131769	ENSG00000200183.1	RNU6-238P	-4.23	2.98e-05	0.0121	-0.21	-0.22	Colorectal cancer;	chr12:50558239	chr12:50656973~50657078:+
STAD	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	4.23	2.98e-05	0.0121	0.29	0.22	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
STAD	cis	rs1075265	0.935	rs6545384	ENSG00000235937.1	AC008280.1	4.23	2.98e-05	0.0121	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54029552~54030682:-
STAD	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	4.23	2.98e-05	0.0121	0.28	0.22	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
STAD	cis	rs1707322	0.685	rs11211177	ENSG00000281133.1	AL355480.3	-4.23	2.98e-05	0.0121	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45580892~45580996:-
STAD	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	4.23	2.98e-05	0.0121	0.31	0.22	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
STAD	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	4.23	2.99e-05	0.0121	0.29	0.22	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
STAD	cis	rs11846409	0.799	rs10467899	ENSG00000211970.3	IGHV4-61	4.23	2.99e-05	0.0121	0.24	0.22	Rheumatic heart disease;	chr14:106644012	chr14:106639119~106639657:-
STAD	cis	rs10851478	0.872	rs1948975	ENSG00000259545.2	RP11-325E5.4	-4.23	2.99e-05	0.0121	-0.27	-0.22	Oral cavity cancer;	chr15:49692608	chr15:49177610~49178741:-
STAD	cis	rs2688608	0.592	rs10824031	ENSG00000272140.2	RP11-574K11.29	4.23	2.99e-05	0.0121	0.2	0.22	Inflammatory bowel disease;	chr10:73749515	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.62	rs7076525	ENSG00000272140.2	RP11-574K11.29	4.23	2.99e-05	0.0121	0.2	0.22	Inflammatory bowel disease;	chr10:73753039	chr10:73703735~73713581:-
STAD	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	4.23	2.99e-05	0.0122	0.23	0.22	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
STAD	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	4.23	2.99e-05	0.0122	0.27	0.22	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	4.23	2.99e-05	0.0122	0.27	0.22	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
STAD	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	4.23	2.99e-05	0.0122	0.29	0.22	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
STAD	cis	rs1850744	0.702	rs7668469	ENSG00000250942.1	ENPP7P11	4.23	2.99e-05	0.0122	0.43	0.22	Economic and political preferences;	chr4:9742906	chr4:9677308~9677934:+
STAD	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-4.23	2.99e-05	0.0122	-0.27	-0.22	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
STAD	cis	rs950169	0.519	rs7237	ENSG00000259295.5	CSPG4P12	4.23	2.99e-05	0.0122	0.32	0.22	Schizophrenia;	chr15:84643346	chr15:85191438~85213905:+
STAD	cis	rs875971	0.862	rs7786892	ENSG00000224316.1	RP11-479O9.2	-4.23	3e-05	0.0122	-0.22	-0.22	Aortic root size;	chr7:66163889	chr7:65773620~65802067:+
STAD	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	4.23	3e-05	0.0122	0.31	0.22	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
STAD	cis	rs12682352	0.602	rs6988939	ENSG00000253981.4	ALG1L13P	4.23	3e-05	0.0122	0.27	0.22	Neuroticism;	chr8:8809406	chr8:8236003~8244667:-
STAD	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	4.23	3e-05	0.0122	0.22	0.22	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
STAD	cis	rs1707322	1	rs3922887	ENSG00000225447.1	RPS15AP10	4.23	3e-05	0.0122	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs3922886	ENSG00000225447.1	RPS15AP10	4.23	3e-05	0.0122	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45645816~45646197:-
STAD	cis	rs8062405	1	rs4788095	ENSG00000278665.1	RP11-666O2.4	4.23	3e-05	0.0122	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.964	rs72793809	ENSG00000278665.1	RP11-666O2.4	4.23	3e-05	0.0122	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62036620	ENSG00000278665.1	RP11-666O2.4	4.23	3e-05	0.0122	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62036621	ENSG00000278665.1	RP11-666O2.4	4.23	3e-05	0.0122	0.26	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28599241~28601881:-
STAD	cis	rs10129255	0.833	rs61997797	ENSG00000232216.1	IGHV3-43	4.23	3e-05	0.0122	0.22	0.22	Kawasaki disease;	chr14:106815190	chr14:106470264~106470800:-
STAD	cis	rs9420	0.884	rs644883	ENSG00000265566.2	RN7SL605P	4.23	3e-05	0.0122	0.32	0.22	Schizophrenia;	chr11:57896050	chr11:57528085~57528365:-
STAD	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	4.23	3e-05	0.0122	0.29	0.22	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
STAD	cis	rs4745216	0.643	rs2795119	ENSG00000225434.2	LINC01504	4.23	3e-05	0.0122	0.39	0.22	Blood protein levels;	chr9:73165798	chr9:72305430~72343210:+
STAD	cis	rs8141529	1	rs8141529	ENSG00000226471.5	CTA-292E10.6	-4.23	3e-05	0.0122	-0.28	-0.22	Lymphocyte counts;	chr22:28873704	chr22:28800683~28848559:+
STAD	cis	rs10073892	0.62	rs1354618	ENSG00000250682.4	LINC00491	-4.23	3e-05	0.0122	-0.24	-0.22	Cognitive decline (age-related);	chr5:102649416	chr5:102609156~102671559:-
STAD	cis	rs7829975	0.682	rs7013471	ENSG00000233609.3	RP11-62H7.2	-4.23	3.01e-05	0.0122	-0.25	-0.22	Mood instability;	chr8:8829815	chr8:8961200~8979025:+
STAD	cis	rs4589258	0.933	rs1783805	ENSG00000280367.1	RP11-121L10.2	-4.23	3.01e-05	0.0122	-0.24	-0.22	Intelligence (multi-trait analysis);	chr11:90697207	chr11:90223153~90226538:+
STAD	cis	rs412050	1	rs412050	ENSG00000228050.1	TOP3BP1	-4.23	3.01e-05	0.0122	-0.35	-0.22	Attention deficit hyperactivity disorder;	chr22:21953147	chr22:22223187~22224566:-
STAD	cis	rs12530	0.715	rs5749416	ENSG00000230736.2	RP1-149A16.3	4.23	3.01e-05	0.0122	0.28	0.22	IgG glycosylation;	chr22:32381136	chr22:32376664~32384343:+
STAD	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	4.23	3.01e-05	0.0122	0.27	0.22	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	4.23	3.01e-05	0.0122	0.27	0.22	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	4.23	3.01e-05	0.0122	0.27	0.22	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	4.23	3.01e-05	0.0122	0.27	0.22	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	4.23	3.01e-05	0.0122	0.27	0.22	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
STAD	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-4.23	3.01e-05	0.0122	-0.26	-0.22	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
STAD	cis	rs11676348	0.712	rs11687434	ENSG00000237281.1	CATIP-AS2	4.23	3.01e-05	0.0122	0.22	0.22	Ulcerative colitis;	chr2:218080420	chr2:218326889~218357966:-
STAD	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-4.23	3.01e-05	0.0122	-0.24	-0.22	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
STAD	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-4.23	3.01e-05	0.0122	-0.24	-0.22	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
STAD	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-4.23	3.01e-05	0.0122	-0.24	-0.22	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
STAD	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-4.23	3.01e-05	0.0122	-0.24	-0.22	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
STAD	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-4.23	3.01e-05	0.0122	-0.24	-0.22	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
STAD	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-4.23	3.01e-05	0.0122	-0.33	-0.22	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
STAD	cis	rs9902453	0.765	rs8071576	ENSG00000263477.1	RP11-338L22.2	4.23	3.02e-05	0.0122	0.19	0.22	Coffee consumption (cups per day);	chr17:29861536	chr17:29863402~29866092:+
STAD	cis	rs1707322	1	rs3922887	ENSG00000281133.1	AL355480.3	-4.23	3.02e-05	0.0122	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs3922886	ENSG00000281133.1	AL355480.3	-4.23	3.02e-05	0.0122	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45580892~45580996:-
STAD	cis	rs9910055	1	rs9895423	ENSG00000260793.2	RP5-882C2.2	-4.23	3.02e-05	0.0123	-0.26	-0.22	Total body bone mineral density;	chr17:44208372	chr17:44221401~44223710:+
STAD	cis	rs11098499	0.698	rs4422403	ENSG00000260091.1	RP11-33B1.4	4.23	3.02e-05	0.0123	0.21	0.22	Corneal astigmatism;	chr4:119337039	chr4:119409333~119410233:+
STAD	cis	rs4589258	0.788	rs1783801	ENSG00000280367.1	RP11-121L10.2	-4.23	3.02e-05	0.0123	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90699332	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs2508412	ENSG00000280367.1	RP11-121L10.2	-4.23	3.02e-05	0.0123	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90701705	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.601	rs1792605	ENSG00000280367.1	RP11-121L10.2	-4.23	3.02e-05	0.0123	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90702090	chr11:90223153~90226538:+
STAD	cis	rs9902453	0.904	rs7208579	ENSG00000240074.1	RPL9P30	4.23	3.02e-05	0.0123	0.19	0.22	Coffee consumption (cups per day);	chr17:29936049	chr17:29855759~29856332:+
STAD	cis	rs34779708	0.931	rs7923217	ENSG00000271335.4	RP11-324I22.4	4.23	3.02e-05	0.0123	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35314552~35336401:-
STAD	cis	rs1799949	1	rs4793190	ENSG00000279602.1	CTD-3014M21.1	4.23	3.02e-05	0.0123	0.28	0.22	Menopause (age at onset);	chr17:43048092	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs8176297	ENSG00000279602.1	CTD-3014M21.1	4.23	3.02e-05	0.0123	0.28	0.22	Menopause (age at onset);	chr17:43051308	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs8176296	ENSG00000279602.1	CTD-3014M21.1	4.23	3.02e-05	0.0123	0.28	0.22	Menopause (age at onset);	chr17:43051574	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs4793191	ENSG00000279602.1	CTD-3014M21.1	4.23	3.02e-05	0.0123	0.28	0.22	Menopause (age at onset);	chr17:43052360	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs4793192	ENSG00000279602.1	CTD-3014M21.1	4.23	3.02e-05	0.0123	0.28	0.22	Menopause (age at onset);	chr17:43052373	chr17:43360041~43361361:-
STAD	cis	rs1322639	0.614	rs9455889	ENSG00000261039.2	RP11-417E7.2	-4.23	3.02e-05	0.0123	-0.34	-0.22	Pulse pressure;	chr6:169165992	chr6:169175304~169182740:-
STAD	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-4.23	3.02e-05	0.0123	-0.24	-0.22	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
STAD	cis	rs7615952	0.575	rs35949599	ENSG00000242229.1	RPS3AP14	4.23	3.02e-05	0.0123	0.28	0.22	Blood pressure (smoking interaction);	chr3:125825359	chr3:125795106~125795885:+
STAD	cis	rs11676348	0.772	rs7422358	ENSG00000237281.1	CATIP-AS2	4.23	3.03e-05	0.0123	0.22	0.22	Ulcerative colitis;	chr2:218088055	chr2:218326889~218357966:-
STAD	cis	rs4845875	0.563	rs11121829	ENSG00000242349.4	NPPA-AS1	4.23	3.03e-05	0.0123	0.25	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11774708	chr1:11841017~11848079:+
STAD	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-4.23	3.03e-05	0.0123	-0.35	-0.22	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
STAD	cis	rs858239	0.899	rs10085838	ENSG00000230042.1	AK3P3	-4.23	3.03e-05	0.0123	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23129178~23129841:+
STAD	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-4.23	3.03e-05	0.0123	-0.25	-0.22	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
STAD	cis	rs763014	0.932	rs35067229	ENSG00000228201.1	AL022341.3	4.23	3.03e-05	0.0123	0.26	0.22	Height;	chr16:599638	chr16:648473~649200:-
STAD	cis	rs853679	0.723	rs1736904	ENSG00000220721.1	OR1F12	4.23	3.03e-05	0.0123	0.24	0.22	Depression;	chr6:28251492	chr6:28073316~28074233:+
STAD	cis	rs9646944	0.501	rs34946515	ENSG00000234389.1	AC007278.3	4.23	3.03e-05	0.0123	0.29	0.22	Blood protein levels;	chr2:102426860	chr2:102438713~102440475:+
STAD	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-4.23	3.03e-05	0.0123	-0.27	-0.22	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
STAD	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	4.23	3.03e-05	0.0123	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
STAD	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	4.23	3.03e-05	0.0123	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
STAD	cis	rs7474896	1	rs734512	ENSG00000120555.12	SEPT7P9	-4.23	3.03e-05	0.0123	-0.3	-0.22	Obesity (extreme);	chr10:37684144	chr10:38383069~38402916:-
STAD	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	4.23	3.03e-05	0.0123	0.29	0.22	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
STAD	cis	rs9859260	0.71	rs41298097	ENSG00000185485.13	SDHAP1	-4.23	3.03e-05	0.0123	-0.22	-0.22	Mean corpuscular volume;	chr3:196052284	chr3:195959748~195990318:-
STAD	cis	rs9859260	0.71	rs34906439	ENSG00000185485.13	SDHAP1	-4.23	3.03e-05	0.0123	-0.22	-0.22	Mean corpuscular volume;	chr3:196052835	chr3:195959748~195990318:-
STAD	cis	rs9859260	0.744	rs557527	ENSG00000185485.13	SDHAP1	-4.23	3.03e-05	0.0123	-0.22	-0.22	Mean corpuscular volume;	chr3:196053838	chr3:195959748~195990318:-
STAD	cis	rs7176527	0.848	rs1374463	ENSG00000229212.6	RP11-561C5.4	4.23	3.03e-05	0.0123	0.36	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:85205440~85234795:-
STAD	cis	rs539514	0.69	rs2328953	ENSG00000261105.4	LMO7-AS1	4.23	3.03e-05	0.0123	0.27	0.22	Type 1 diabetes;	chr13:75743323	chr13:75604700~75635994:-
STAD	cis	rs181553	0.664	rs948789	ENSG00000266696.1	RP11-30L3.2	-4.23	3.03e-05	0.0123	-0.2	-0.22	Hip circumference adjusted for BMI;	chr18:49174326	chr18:49205912~49208781:+
STAD	cis	rs1056107	0.763	rs7024998	ENSG00000225513.1	RP11-165N19.2	-4.23	3.03e-05	0.0123	-0.26	-0.22	Colorectal cancer;	chr9:112175379	chr9:112173522~112173971:-
STAD	cis	rs17507216	0.718	rs4779034	ENSG00000255769.6	GOLGA2P10	-4.23	3.04e-05	0.0123	-0.35	-0.22	Excessive daytime sleepiness;	chr15:82576799	chr15:82472993~82513950:-
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000211959.2	IGHV4-39	4.23	3.04e-05	0.0123	0.19	0.22	Kawasaki disease;	chr14:106804049	chr14:106421711~106422218:-
STAD	cis	rs2739330	0.731	rs2000468	ENSG00000272787.1	KB-226F1.2	-4.23	3.04e-05	0.0123	-0.23	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23969211~23969873:+
STAD	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-4.23	3.04e-05	0.0123	-0.24	-0.22	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
STAD	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	4.23	3.04e-05	0.0123	0.3	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
STAD	cis	rs875971	0.862	rs1983372	ENSG00000224316.1	RP11-479O9.2	-4.23	3.04e-05	0.0123	-0.22	-0.22	Aortic root size;	chr7:66146364	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs7809814	ENSG00000224316.1	RP11-479O9.2	-4.23	3.04e-05	0.0123	-0.22	-0.22	Aortic root size;	chr7:66150410	chr7:65773620~65802067:+
STAD	cis	rs11673344	0.523	rs1402468	ENSG00000267672.1	CTD-2293H3.1	4.23	3.04e-05	0.0123	0.21	0.22	Obesity-related traits;	chr19:37129346	chr19:37091341~37092564:+
STAD	cis	rs7474896	0.515	rs662928	ENSG00000120555.12	SEPT7P9	-4.23	3.04e-05	0.0123	-0.27	-0.22	Obesity (extreme);	chr10:38027288	chr10:38383069~38402916:-
STAD	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	4.23	3.04e-05	0.0123	0.24	0.22	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
STAD	cis	rs8072100	0.967	rs8072644	ENSG00000264243.1	RP11-6N17.1	-4.23	3.04e-05	0.0123	-0.2	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47863342~47865190:+
STAD	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	4.23	3.04e-05	0.0123	0.23	0.22	Height;	chr5:37499677	chr5:36666214~36725195:-
STAD	cis	rs11767557	1	rs11767557	ENSG00000229153.4	EPHA1-AS1	4.23	3.05e-05	0.0123	0.37	0.22	Alzheimer's disease (late onset);	chr7:143412046	chr7:143407813~143523449:+
STAD	cis	rs1790761	0.554	rs12787511	ENSG00000231793.4	DOC2GP	-4.23	3.05e-05	0.0123	-0.29	-0.22	Mean corpuscular volume;	chr11:67634164	chr11:67612653~67616257:-
STAD	cis	rs5758659	0.714	rs133373	ENSG00000182057.4	OGFRP1	4.23	3.05e-05	0.0124	0.23	0.22	Cognitive function;	chr22:42069784	chr22:42269753~42275196:+
STAD	cis	rs5758659	0.714	rs5758578	ENSG00000182057.4	OGFRP1	-4.23	3.05e-05	0.0124	-0.23	-0.22	Cognitive function;	chr22:42094288	chr22:42269753~42275196:+
STAD	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-4.23	3.05e-05	0.0124	-0.27	-0.22	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-4.23	3.05e-05	0.0124	-0.27	-0.22	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
STAD	cis	rs7812879	0.571	rs4841540	ENSG00000255556.2	RP11-351I21.6	-4.23	3.05e-05	0.0124	-0.27	-0.22	Systemic lupus erythematosus;	chr8:11451998	chr8:12378679~12380265:-
STAD	cis	rs11098499	0.644	rs17517414	ENSG00000260091.1	RP11-33B1.4	4.23	3.05e-05	0.0124	0.21	0.22	Corneal astigmatism;	chr4:119340946	chr4:119409333~119410233:+
STAD	cis	rs4713118	0.715	rs200480	ENSG00000280107.1	AL022393.9	-4.23	3.05e-05	0.0124	-0.26	-0.22	Parkinson's disease;	chr6:27805886	chr6:28170845~28172521:+
STAD	cis	rs1707322	1	rs12097761	ENSG00000225447.1	RPS15AP10	4.23	3.05e-05	0.0124	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs6429581	ENSG00000225447.1	RPS15AP10	4.23	3.05e-05	0.0124	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45645816~45646197:-
STAD	cis	rs786425	0.899	rs908373	ENSG00000247373.3	RP11-486O12.2	-4.23	3.05e-05	0.0124	-0.17	-0.22	Pubertal anthropometrics;	chr12:123628772	chr12:123575891~123585115:-
STAD	cis	rs10129255	0.957	rs10136560	ENSG00000224373.3	IGHV4-59	4.23	3.05e-05	0.0124	0.18	0.22	Kawasaki disease;	chr14:106787630	chr14:106627249~106627825:-
STAD	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	4.23	3.05e-05	0.0124	0.37	0.22	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
STAD	cis	rs10782582	0.593	rs6675212	ENSG00000181227.3	RP4-682C21.2	4.23	3.06e-05	0.0124	0.23	0.22	Daytime sleep phenotypes;	chr1:75765144	chr1:75743423~75744776:-
STAD	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	4.23	3.06e-05	0.0124	0.22	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
STAD	cis	rs12500234	1	rs7693722	ENSG00000249207.1	RP11-360F5.1	-4.23	3.06e-05	0.0124	-0.23	-0.22	Colorectal cancer;	chr4:39624469	chr4:39112677~39126818:-
STAD	cis	rs7665090	0.51	rs223498	ENSG00000248971.2	KRT8P46	4.23	3.06e-05	0.0124	0.23	0.22	Primary biliary cholangitis;	chr4:102730805	chr4:102728746~102730171:-
STAD	cis	rs1075265	0.84	rs10084355	ENSG00000235937.1	AC008280.1	4.23	3.06e-05	0.0124	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54029552~54030682:-
STAD	cis	rs4589258	0.83	rs7930635	ENSG00000280367.1	RP11-121L10.2	-4.23	3.06e-05	0.0124	-0.23	-0.22	Intelligence (multi-trait analysis);	chr11:90691539	chr11:90223153~90226538:+
STAD	cis	rs3770081	0.59	rs34522092	ENSG00000273080.1	RP11-301O19.1	-4.23	3.06e-05	0.0124	-0.52	-0.22	Facial emotion recognition (sad faces);	chr2:85981182	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs56326127	ENSG00000273080.1	RP11-301O19.1	-4.23	3.06e-05	0.0124	-0.52	-0.22	Facial emotion recognition (sad faces);	chr2:85985078	chr2:86195590~86196049:+
STAD	cis	rs4589258	0.737	rs10501732	ENSG00000280367.1	RP11-121L10.2	4.22	3.06e-05	0.0124	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90672180	chr11:90223153~90226538:+
STAD	cis	rs3770081	1	rs73945535	ENSG00000273080.1	RP11-301O19.1	-4.22	3.06e-05	0.0124	-0.51	-0.22	Facial emotion recognition (sad faces);	chr2:85897750	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs73943909	ENSG00000273080.1	RP11-301O19.1	-4.22	3.06e-05	0.0124	-0.51	-0.22	Facial emotion recognition (sad faces);	chr2:85916255	chr2:86195590~86196049:+
STAD	cis	rs1707322	0.789	rs10789473	ENSG00000281133.1	AL355480.3	-4.22	3.06e-05	0.0124	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45580892~45580996:-
STAD	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	4.22	3.06e-05	0.0124	0.26	0.22	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
STAD	cis	rs13392177	0.672	rs4674270	ENSG00000237281.1	CATIP-AS2	4.22	3.06e-05	0.0124	0.22	0.22	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218326889~218357966:-
STAD	cis	rs3733585	0.605	rs4697710	ENSG00000250613.1	RP11-136I13.1	4.22	3.06e-05	0.0124	0.23	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10121025	chr4:10410996~10411644:+
STAD	cis	rs3733585	0.579	rs4235353	ENSG00000250613.1	RP11-136I13.1	4.22	3.06e-05	0.0124	0.23	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10121310	chr4:10410996~10411644:+
STAD	cis	rs3733585	0.605	rs4235354	ENSG00000250613.1	RP11-136I13.1	4.22	3.06e-05	0.0124	0.23	0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10121318	chr4:10410996~10411644:+
STAD	cis	rs6142102	0.847	rs4911413	ENSG00000264616.1	MIR4755	4.22	3.07e-05	0.0124	0.23	0.22	Skin pigmentation;	chr20:34133969	chr20:34049119~34049190:+
STAD	cis	rs1598856	1	rs11934404	ENSG00000246560.2	RP11-10L12.4	4.22	3.07e-05	0.0124	0.28	0.22	Primary biliary cholangitis;	chr4:102516444	chr4:102828055~102844075:+
STAD	cis	rs4845875	0.53	rs6667720	ENSG00000242349.4	NPPA-AS1	-4.22	3.07e-05	0.0124	-0.24	-0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11771558	chr1:11841017~11848079:+
STAD	cis	rs7829975	0.511	rs1543238	ENSG00000254340.1	RP11-10A14.3	4.22	3.07e-05	0.0124	0.27	0.22	Mood instability;	chr8:8277287	chr8:9141424~9145435:+
STAD	cis	rs561341	1	rs72825712	ENSG00000265798.5	RP11-271K11.5	4.22	3.07e-05	0.0124	0.32	0.22	Hip circumference adjusted for BMI;	chr17:31989100	chr17:31038575~31059121:-
STAD	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	4.22	3.07e-05	0.0124	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
STAD	cis	rs1816752	0.716	rs9553330	ENSG00000273628.1	RP11-756A22.7	-4.22	3.07e-05	0.0124	-0.27	-0.22	Obesity-related traits;	chr13:24516018	chr13:24933006~24936796:+
STAD	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-4.22	3.07e-05	0.0124	-0.23	-0.22	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
STAD	cis	rs1485395	0.945	rs11611695	ENSG00000257379.1	RP11-793H13.8	-4.22	3.07e-05	0.0124	-0.37	-0.22	Migraine without aura;	chr12:53659977	chr12:53441741~53467528:+
STAD	cis	rs891378	1	rs4844592	ENSG00000274245.1	RP11-357P18.2	-4.22	3.08e-05	0.0125	-0.27	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207327866	chr1:207372559~207373252:+
STAD	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-4.22	3.08e-05	0.0125	-0.29	-0.22	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
STAD	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	4.22	3.08e-05	0.0125	0.26	0.22	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	4.22	3.08e-05	0.0125	0.26	0.22	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
STAD	cis	rs911555	0.511	rs2296483	ENSG00000258851.1	RP11-894P9.2	-4.22	3.08e-05	0.0125	-0.26	-0.22	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103553421~103561877:+
STAD	cis	rs7951911	0.915	rs56113106	ENSG00000254427.1	RP11-430H10.1	4.22	3.08e-05	0.0125	0.46	0.22	IgG glycosylation;	chr11:45065600	chr11:45355371~45366121:+
STAD	cis	rs8141529	0.748	rs132528	ENSG00000226471.5	CTA-292E10.6	4.22	3.08e-05	0.0125	0.26	0.22	Lymphocyte counts;	chr22:28899910	chr22:28800683~28848559:+
STAD	cis	rs9902453	0.765	rs3102555	ENSG00000240074.1	RPL9P30	4.22	3.08e-05	0.0125	0.19	0.22	Coffee consumption (cups per day);	chr17:29717083	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.791	rs3115100	ENSG00000240074.1	RPL9P30	4.22	3.08e-05	0.0125	0.19	0.22	Coffee consumption (cups per day);	chr17:29718726	chr17:29855759~29856332:+
STAD	cis	rs5753618	0.561	rs4820043	ENSG00000236132.1	CTA-440B3.1	4.22	3.08e-05	0.0125	0.26	0.22	Colorectal cancer;	chr22:31251108	chr22:31816379~31817491:-
STAD	cis	rs11098499	0.604	rs2389887	ENSG00000260091.1	RP11-33B1.4	4.22	3.08e-05	0.0125	0.22	0.22	Corneal astigmatism;	chr4:119649489	chr4:119409333~119410233:+
STAD	cis	rs301901	0.793	rs11750212	ENSG00000250155.1	CTD-2353F22.1	4.22	3.08e-05	0.0125	0.22	0.22	Height;	chr5:37463644	chr5:36666214~36725195:-
STAD	cis	rs2836974	0.644	rs9978775	ENSG00000238141.2	BRWD1-AS1	-4.22	3.08e-05	0.0125	-0.23	-0.22	Cognitive function;	chr21:39322600	chr21:39315707~39323218:+
STAD	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-4.22	3.08e-05	0.0125	-0.33	-0.22	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
STAD	cis	rs10129255	0.53	rs11624912	ENSG00000224373.3	IGHV4-59	4.22	3.08e-05	0.0125	0.16	0.22	Kawasaki disease;	chr14:106673891	chr14:106627249~106627825:-
STAD	cis	rs765787	0.53	rs11636395	ENSG00000259539.1	CTD-2651B20.1	4.22	3.09e-05	0.0125	0.26	0.22	Uric acid levels;	chr15:45243486	chr15:45152664~45167526:-
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000224373.3	IGHV4-59	4.22	3.09e-05	0.0125	0.16	0.22	Kawasaki disease;	chr14:106768275	chr14:106627249~106627825:-
STAD	cis	rs11089937	0.589	rs4239891	ENSG00000211640.3	IGLV6-57	4.22	3.09e-05	0.0125	0.16	0.22	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22195713~22196460:+
STAD	cis	rs7916697	0.626	rs3858144	ENSG00000233590.1	RP11-153K11.3	-4.22	3.09e-05	0.0125	-0.25	-0.22	Optic disc area;	chr10:68251597	chr10:68233251~68242379:-
STAD	cis	rs9902453	0.904	rs9905638	ENSG00000240074.1	RPL9P30	4.22	3.09e-05	0.0125	0.19	0.22	Coffee consumption (cups per day);	chr17:29934004	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.874	rs62070271	ENSG00000240074.1	RPL9P30	4.22	3.09e-05	0.0125	0.19	0.22	Coffee consumption (cups per day);	chr17:29941340	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs9894893	ENSG00000240074.1	RPL9P30	4.22	3.09e-05	0.0125	0.19	0.22	Coffee consumption (cups per day);	chr17:29943332	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.935	rs9909093	ENSG00000240074.1	RPL9P30	4.22	3.09e-05	0.0125	0.19	0.22	Coffee consumption (cups per day);	chr17:29944189	chr17:29855759~29856332:+
STAD	cis	rs11098499	1	rs6837898	ENSG00000260091.1	RP11-33B1.4	4.22	3.09e-05	0.0125	0.22	0.22	Corneal astigmatism;	chr4:119257999	chr4:119409333~119410233:+
STAD	cis	rs1799949	1	rs11656097	ENSG00000279602.1	CTD-3014M21.1	4.22	3.09e-05	0.0125	0.28	0.22	Menopause (age at onset);	chr17:43138596	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11658754	ENSG00000279602.1	CTD-3014M21.1	4.22	3.09e-05	0.0125	0.28	0.22	Menopause (age at onset);	chr17:43140722	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs12952790	ENSG00000279602.1	CTD-3014M21.1	4.22	3.09e-05	0.0125	0.28	0.22	Menopause (age at onset);	chr17:43147590	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs12950607	ENSG00000279602.1	CTD-3014M21.1	4.22	3.09e-05	0.0125	0.28	0.22	Menopause (age at onset);	chr17:43147911	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11079056	ENSG00000279602.1	CTD-3014M21.1	4.22	3.09e-05	0.0125	0.28	0.22	Menopause (age at onset);	chr17:43148782	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs12936816	ENSG00000279602.1	CTD-3014M21.1	4.22	3.09e-05	0.0125	0.28	0.22	Menopause (age at onset);	chr17:43149692	chr17:43360041~43361361:-
STAD	cis	rs4589258	0.762	rs4448654	ENSG00000280367.1	RP11-121L10.2	4.22	3.09e-05	0.0125	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90726113	chr11:90223153~90226538:+
STAD	cis	rs5760092	0.618	rs4461358	ENSG00000224205.1	AP000351.4	-4.22	3.09e-05	0.0125	-0.26	-0.22	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23987320~23991421:-
STAD	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	4.22	3.09e-05	0.0125	0.29	0.22	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
STAD	cis	rs860295	0.702	rs11264387	ENSG00000225855.5	RUSC1-AS1	4.22	3.09e-05	0.0125	0.18	0.22	Body mass index;	chr1:155593361	chr1:155316863~155324176:-
STAD	cis	rs4589258	0.737	rs12806862	ENSG00000280367.1	RP11-121L10.2	-4.22	3.09e-05	0.0125	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90692262	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.698	rs7102040	ENSG00000280367.1	RP11-121L10.2	-4.22	3.09e-05	0.0125	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90692783	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1792594	ENSG00000280367.1	RP11-121L10.2	-4.22	3.09e-05	0.0125	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90694699	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs55716654	ENSG00000280367.1	RP11-121L10.2	-4.22	3.09e-05	0.0125	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90697037	chr11:90223153~90226538:+
STAD	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	4.22	3.09e-05	0.0125	0.27	0.22	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
STAD	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	4.22	3.09e-05	0.0125	0.32	0.22	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
STAD	cis	rs875971	1	rs875971	ENSG00000224316.1	RP11-479O9.2	-4.22	3.09e-05	0.0125	-0.22	-0.22	Aortic root size;	chr7:66152608	chr7:65773620~65802067:+
STAD	cis	rs2880765	0.566	rs17553249	ENSG00000229212.6	RP11-561C5.4	4.22	3.09e-05	0.0125	0.32	0.22	Coronary artery disease;	chr15:85463463	chr15:85205440~85234795:-
STAD	cis	rs73193808	1	rs2832227	ENSG00000273017.1	AP000240.9	4.22	3.09e-05	0.0125	0.24	0.22	Coronary artery disease;	chr21:29160755	chr21:29359002~29359453:+
STAD	cis	rs7647973	0.6	rs35174559	ENSG00000225399.4	RP11-3B7.1	4.22	3.1e-05	0.0125	0.24	0.22	Menarche (age at onset);	chr3:49250326	chr3:49260085~49261316:+
STAD	cis	rs6480314	0.522	rs4746754	ENSG00000233590.1	RP11-153K11.3	4.22	3.1e-05	0.0125	0.3	0.22	Optic nerve measurement (disc area);	chr10:68289862	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs10762204	ENSG00000233590.1	RP11-153K11.3	4.22	3.1e-05	0.0125	0.3	0.22	Optic nerve measurement (disc area);	chr10:68290006	chr10:68233251~68242379:-
STAD	cis	rs7487075	0.718	rs4768735	ENSG00000272963.1	OR7A19P	-4.22	3.1e-05	0.0125	-0.21	-0.22	Itch intensity from mosquito bite;	chr12:46550351	chr12:46592573~46593305:+
STAD	cis	rs2337406	0.85	rs75196489	ENSG00000280411.1	IGHV1-69-2	-4.22	3.1e-05	0.0125	-0.28	-0.22	Alzheimer's disease (late onset);	chr14:106699438	chr14:106762092~106762588:-
STAD	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	4.22	3.1e-05	0.0125	0.27	0.22	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
STAD	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	4.22	3.1e-05	0.0125	0.27	0.22	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
STAD	cis	rs11676348	0.741	rs12694425	ENSG00000237281.1	CATIP-AS2	-4.22	3.1e-05	0.0125	-0.22	-0.22	Ulcerative colitis;	chr2:218077590	chr2:218326889~218357966:-
STAD	cis	rs916888	0.647	rs199524	ENSG00000260075.1	NSFP1	-4.22	3.1e-05	0.0125	-0.3	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46372855~46487141:+
STAD	cis	rs916888	0.647	rs199523	ENSG00000260075.1	NSFP1	-4.22	3.1e-05	0.0125	-0.3	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46372855~46487141:+
STAD	cis	rs2836974	0.623	rs7280326	ENSG00000238141.2	BRWD1-AS1	-4.22	3.1e-05	0.0125	-0.23	-0.22	Cognitive function;	chr21:39328482	chr21:39315707~39323218:+
STAD	cis	rs11846409	0.932	rs73378155	ENSG00000211972.2	IGHV3-66	4.22	3.1e-05	0.0125	0.23	0.22	Rheumatic heart disease;	chr14:106637840	chr14:106675017~106675544:-
STAD	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-4.22	3.1e-05	0.0125	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-4.22	3.1e-05	0.0125	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
STAD	cis	rs792448	0.798	rs612414	ENSG00000212044.2	AL360091.1	4.22	3.1e-05	0.0125	0.25	0.22	White blood cell count (basophil);	chr1:212428834	chr1:212349978~212350069:+
STAD	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	4.22	3.11e-05	0.0126	0.24	0.22	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
STAD	cis	rs16982689	1	rs16982689	ENSG00000253239.1	IGLVI-70	-4.22	3.11e-05	0.0126	-0.41	-0.22	Attention function in attention deficit hyperactive disorder;	chr22:22081907	chr22:22026076~22026593:+
STAD	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-4.22	3.11e-05	0.0126	-0.23	-0.22	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
STAD	cis	rs5758659	0.714	rs6002626	ENSG00000182057.4	OGFRP1	-4.22	3.11e-05	0.0126	-0.24	-0.22	Cognitive function;	chr22:42121985	chr22:42269753~42275196:+
STAD	cis	rs9733	0.596	rs12403255	ENSG00000274963.1	Metazoa_SRP	4.22	3.11e-05	0.0126	0.19	0.22	Tonsillectomy;	chr1:150687936	chr1:150568971~150569269:-
STAD	cis	rs10129255	0.5	rs9324092	ENSG00000224373.3	IGHV4-59	-4.22	3.11e-05	0.0126	-0.16	-0.22	Kawasaki disease;	chr14:106683806	chr14:106627249~106627825:-
STAD	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	4.22	3.11e-05	0.0126	0.39	0.22	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
STAD	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-4.22	3.11e-05	0.0126	-0.26	-0.22	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
STAD	cis	rs3811273	0.614	rs6572348	ENSG00000211816.2	TRAV38-1	-4.22	3.11e-05	0.0126	-0.28	-0.22	Periodontal disease-related phenotypes;	chr14:22268353	chr14:22271968~22272563:+
STAD	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	4.22	3.11e-05	0.0126	0.31	0.22	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
STAD	cis	rs950169	0.649	rs12901010	ENSG00000225151.9	GOLGA2P7	-4.22	3.11e-05	0.0126	-0.34	-0.22	Schizophrenia;	chr15:84030282	chr15:84199311~84230136:-
STAD	cis	rs950169	0.69	rs12901166	ENSG00000225151.9	GOLGA2P7	-4.22	3.11e-05	0.0126	-0.34	-0.22	Schizophrenia;	chr15:84030361	chr15:84199311~84230136:-
STAD	cis	rs7924176	0.564	rs12572820	ENSG00000213731.2	RAB5CP1	-4.22	3.11e-05	0.0126	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74423435~74424014:-
STAD	cis	rs7924176	0.601	rs7099026	ENSG00000213731.2	RAB5CP1	-4.22	3.11e-05	0.0126	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74423435~74424014:-
STAD	cis	rs9287719	0.649	rs12476554	ENSG00000243819.4	RN7SL832P	4.22	3.11e-05	0.0126	0.22	0.22	Prostate cancer;	chr2:10587621	chr2:10690344~10692099:+
STAD	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-4.22	3.11e-05	0.0126	-0.23	-0.22	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
STAD	cis	rs7829975	0.777	rs560544	ENSG00000253981.4	ALG1L13P	-4.22	3.11e-05	0.0126	-0.27	-0.22	Mood instability;	chr8:8779919	chr8:8236003~8244667:-
STAD	cis	rs2901460	0.587	rs13015217	ENSG00000229503.1	AC092155.1	-4.22	3.12e-05	0.0126	-0.18	-0.22	Mean corpuscular volume;	chr2:62142813	chr2:62532583~62533059:-
STAD	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	4.22	3.12e-05	0.0126	0.29	0.22	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
STAD	cis	rs2638953	0.606	rs10843213	ENSG00000247934.4	RP11-967K21.1	-4.22	3.12e-05	0.0126	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582853	chr12:28163298~28190738:-
STAD	cis	rs6142102	0.961	rs6119447	ENSG00000264616.1	MIR4755	4.22	3.12e-05	0.0126	0.23	0.22	Skin pigmentation;	chr20:34080770	chr20:34049119~34049190:+
STAD	cis	rs1707322	1	rs4660889	ENSG00000225447.1	RPS15AP10	4.22	3.12e-05	0.0126	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs10890355	ENSG00000225447.1	RPS15AP10	4.22	3.12e-05	0.0126	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211204	ENSG00000225447.1	RPS15AP10	4.22	3.12e-05	0.0126	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs7547189	ENSG00000225447.1	RPS15AP10	4.22	3.12e-05	0.0126	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs7547284	ENSG00000225447.1	RPS15AP10	4.22	3.12e-05	0.0126	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211205	ENSG00000225447.1	RPS15AP10	4.22	3.12e-05	0.0126	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45645816~45646197:-
STAD	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-4.22	3.12e-05	0.0126	-0.33	-0.22	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
STAD	cis	rs9393777	0.623	rs56296968	ENSG00000241549.7	GUSBP2	4.22	3.12e-05	0.0126	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26474343	chr6:26871484~26956554:-
STAD	cis	rs2786865	0.881	rs1543338	ENSG00000270733.1	RP11-231P20.5	4.22	3.12e-05	0.0126	0.34	0.22	Facial morphology (factor 11, projection of the nose);	chr1:25704702	chr1:26263041~26263398:-
STAD	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	4.22	3.12e-05	0.0126	0.27	0.22	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
STAD	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	4.22	3.12e-05	0.0126	0.21	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
STAD	cis	rs7078219	0.965	rs11190141	ENSG00000257582.4	LINC01475	-4.22	3.12e-05	0.0126	-0.26	-0.22	Dental caries;	chr10:99532633	chr10:99526350~99531177:-
STAD	cis	rs117785887	0.536	rs3811105	ENSG00000270638.1	RP3-466P17.1	4.22	3.12e-05	0.0126	0.4	0.22	Interleukin-17 levels;	chr6:146028615	chr6:145735570~145737218:+
STAD	cis	rs870825	0.929	rs1405939	ENSG00000249173.4	LINC01093	-4.22	3.12e-05	0.0126	-0.39	-0.22	Blood protein levels;	chr4:184670290	chr4:184893871~184899454:-
STAD	cis	rs9463078	0.547	rs9472362	ENSG00000219384.1	RP11-491H9.3	-4.22	3.12e-05	0.0126	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44783548	chr6:45158870~45159511:+
STAD	cis	rs2836974	0.644	rs7281853	ENSG00000238141.2	BRWD1-AS1	-4.22	3.13e-05	0.0126	-0.24	-0.22	Cognitive function;	chr21:39321564	chr21:39315707~39323218:+
STAD	cis	rs7702057	0.53	rs17138879	ENSG00000271918.1	CTD-2287O16.5	-4.22	3.13e-05	0.0126	-0.4	-0.22	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116083807~116085416:-
STAD	cis	rs765787	0.53	rs28524974	ENSG00000259539.1	CTD-2651B20.1	4.22	3.13e-05	0.0126	0.26	0.22	Uric acid levels;	chr15:45251330	chr15:45152664~45167526:-
STAD	cis	rs10851478	0.872	rs925104	ENSG00000259545.2	RP11-325E5.4	-4.22	3.13e-05	0.0126	-0.26	-0.22	Oral cavity cancer;	chr15:49624458	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs12902960	ENSG00000259545.2	RP11-325E5.4	-4.22	3.13e-05	0.0126	-0.26	-0.22	Oral cavity cancer;	chr15:49632844	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs12591659	ENSG00000259545.2	RP11-325E5.4	-4.22	3.13e-05	0.0126	-0.26	-0.22	Oral cavity cancer;	chr15:49641626	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs11852336	ENSG00000259545.2	RP11-325E5.4	-4.22	3.13e-05	0.0126	-0.26	-0.22	Oral cavity cancer;	chr15:49656627	chr15:49177610~49178741:-
STAD	cis	rs9307551	0.741	rs1971838	ENSG00000250334.4	LINC00989	-4.22	3.13e-05	0.0126	-0.28	-0.22	Refractive error;	chr4:79497477	chr4:79492416~79576460:+
STAD	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-4.22	3.13e-05	0.0126	-0.24	-0.22	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
STAD	cis	rs7474896	0.559	rs1208560	ENSG00000120555.12	SEPT7P9	-4.22	3.13e-05	0.0126	-0.27	-0.22	Obesity (extreme);	chr10:37932690	chr10:38383069~38402916:-
STAD	cis	rs1707322	1	rs10890380	ENSG00000281133.1	AL355480.3	-4.22	3.13e-05	0.0126	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45580892~45580996:-
STAD	cis	rs919433	0.963	rs4850787	ENSG00000231621.1	AC013264.2	4.22	3.13e-05	0.0126	0.19	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317026	chr2:197197991~197199273:+
STAD	cis	rs9420	0.528	rs7117896	ENSG00000265566.2	RN7SL605P	-4.22	3.13e-05	0.0127	-0.32	-0.22	Schizophrenia;	chr11:57621078	chr11:57528085~57528365:-
STAD	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	4.22	3.13e-05	0.0127	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	4.22	3.13e-05	0.0127	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
STAD	cis	rs7615952	0.932	rs13065725	ENSG00000239804.1	RP11-379B18.1	4.22	3.14e-05	0.0127	0.37	0.22	Blood pressure (smoking interaction);	chr3:125913446	chr3:125787888~125788146:-
STAD	cis	rs34779708	0.931	rs11597392	ENSG00000271335.4	RP11-324I22.4	4.22	3.14e-05	0.0127	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35314552~35336401:-
STAD	cis	rs8012947	0.916	rs28411823	ENSG00000180189.10	HMGB1P14	-4.22	3.14e-05	0.0127	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58239891	chr14:58284773~58285363:+
STAD	cis	rs875971	0.862	rs778736	ENSG00000224316.1	RP11-479O9.2	4.22	3.14e-05	0.0127	0.21	0.22	Aortic root size;	chr7:66348861	chr7:65773620~65802067:+
STAD	cis	rs832540	0.669	rs832538	ENSG00000271828.1	CTD-2310F14.1	4.22	3.14e-05	0.0127	0.27	0.22	Coronary artery disease;	chr5:56904189	chr5:56927874~56929573:+
STAD	cis	rs301901	0.828	rs10941337	ENSG00000250155.1	CTD-2353F22.1	4.22	3.14e-05	0.0127	0.23	0.22	Height;	chr5:37474023	chr5:36666214~36725195:-
STAD	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	4.22	3.14e-05	0.0127	0.23	0.22	Height;	chr5:37474739	chr5:36666214~36725195:-
STAD	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	4.22	3.14e-05	0.0127	0.23	0.22	Height;	chr5:37475788	chr5:36666214~36725195:-
STAD	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	4.22	3.14e-05	0.0127	0.23	0.22	Height;	chr5:37475789	chr5:36666214~36725195:-
STAD	cis	rs1707322	1	rs10158032	ENSG00000281133.1	AL355480.3	-4.22	3.14e-05	0.0127	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45580892~45580996:-
STAD	cis	rs831571	0.636	rs831565	ENSG00000280620.1	SCAANT1	-4.22	3.14e-05	0.0127	-0.32	-0.22	Type 2 diabetes;	chr3:64090682	chr3:63911518~63911772:-
STAD	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	4.22	3.14e-05	0.0127	0.3	0.22	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
STAD	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	4.22	3.14e-05	0.0127	0.35	0.22	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
STAD	cis	rs10851478	0.872	rs7172906	ENSG00000259545.2	RP11-325E5.4	-4.22	3.15e-05	0.0127	-0.26	-0.22	Oral cavity cancer;	chr15:49630578	chr15:49177610~49178741:-
STAD	cis	rs11638815	0.626	rs11633829	ENSG00000255769.6	GOLGA2P10	4.22	3.15e-05	0.0127	0.26	0.22	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:82472993~82513950:-
STAD	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-4.22	3.15e-05	0.0127	-0.32	-0.22	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
STAD	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	4.22	3.15e-05	0.0127	0.27	0.22	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
STAD	cis	rs7647973	0.516	rs4955418	ENSG00000225399.4	RP11-3B7.1	4.22	3.15e-05	0.0127	0.24	0.22	Menarche (age at onset);	chr3:49163194	chr3:49260085~49261316:+
STAD	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	4.22	3.15e-05	0.0127	0.37	0.22	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	4.22	3.15e-05	0.0127	0.37	0.22	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	4.22	3.15e-05	0.0127	0.37	0.22	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
STAD	cis	rs6430585	0.528	rs660002	ENSG00000231890.6	DARS-AS1	-4.22	3.15e-05	0.0127	-0.24	-0.22	Corneal structure;	chr2:135965934	chr2:135985176~136022593:+
STAD	cis	rs9907295	0.818	rs9303692	ENSG00000270977.1	AC015849.16	4.22	3.15e-05	0.0127	0.32	0.22	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35893707~35911023:-
STAD	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-4.22	3.15e-05	0.0127	-0.35	-0.22	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
STAD	cis	rs9307551	0.948	rs11941782	ENSG00000250334.4	LINC00989	-4.22	3.15e-05	0.0127	-0.28	-0.22	Refractive error;	chr4:79562385	chr4:79492416~79576460:+
STAD	cis	rs3764400	0.508	rs72823519	ENSG00000278765.1	RP5-890E16.5	4.22	3.16e-05	0.0127	0.3	0.22	Body mass index;	chr17:47984519	chr17:48066704~48067293:-
STAD	cis	rs10129255	0.5	rs988132	ENSG00000224373.3	IGHV4-59	4.22	3.16e-05	0.0127	0.16	0.22	Kawasaki disease;	chr14:106776758	chr14:106627249~106627825:-
STAD	cis	rs9549328	0.8	rs9549621	ENSG00000267868.1	RP11-120K24.3	4.22	3.16e-05	0.0127	0.31	0.22	Systolic blood pressure;	chr13:112979265	chr13:112964835~112966131:-
STAD	cis	rs2880765	0.706	rs7172006	ENSG00000259295.5	CSPG4P12	4.22	3.16e-05	0.0127	0.28	0.22	Coronary artery disease;	chr15:85510128	chr15:85191438~85213905:+
STAD	cis	rs11157436	0.602	rs12587826	ENSG00000211812.1	TRAV26-2	-4.22	3.16e-05	0.0127	-0.22	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22202583~22203368:+
STAD	cis	rs7951870	0.673	rs4606447	ENSG00000271350.1	CTD-2384B9.1	-4.22	3.16e-05	0.0127	-0.27	-0.22	Schizophrenia;	chr11:46670187	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	4.22	3.16e-05	0.0127	0.29	0.22	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
STAD	cis	rs2408955	0.522	rs4760612	ENSG00000258273.1	RP11-370I10.4	4.22	3.16e-05	0.0127	0.26	0.22	Glycated hemoglobin levels;	chr12:48028073	chr12:48333755~48333901:-
STAD	cis	rs11098499	0.955	rs6815725	ENSG00000260091.1	RP11-33B1.4	4.22	3.16e-05	0.0127	0.21	0.22	Corneal astigmatism;	chr4:119237255	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs1551	ENSG00000260091.1	RP11-33B1.4	4.22	3.16e-05	0.0127	0.21	0.22	Corneal astigmatism;	chr4:119237345	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs11931312	ENSG00000260091.1	RP11-33B1.4	4.22	3.16e-05	0.0127	0.21	0.22	Corneal astigmatism;	chr4:119237868	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.955	rs11944880	ENSG00000260091.1	RP11-33B1.4	-4.22	3.16e-05	0.0127	-0.21	-0.22	Corneal astigmatism;	chr4:119238179	chr4:119409333~119410233:+
STAD	cis	rs4713118	1	rs1139226	ENSG00000280107.1	AL022393.9	-4.22	3.16e-05	0.0127	-0.3	-0.22	Parkinson's disease;	chr6:27707511	chr6:28170845~28172521:+
STAD	cis	rs4713118	1	rs9468195	ENSG00000280107.1	AL022393.9	-4.22	3.16e-05	0.0127	-0.3	-0.22	Parkinson's disease;	chr6:27708530	chr6:28170845~28172521:+
STAD	cis	rs9902453	0.765	rs2264303	ENSG00000240074.1	RPL9P30	-4.22	3.16e-05	0.0128	-0.19	-0.22	Coffee consumption (cups per day);	chr17:29728330	chr17:29855759~29856332:+
STAD	cis	rs539514	0.69	rs776527	ENSG00000261105.4	LMO7-AS1	4.22	3.16e-05	0.0128	0.27	0.22	Type 1 diabetes;	chr13:75743658	chr13:75604700~75635994:-
STAD	cis	rs6142102	0.961	rs2235596	ENSG00000264616.1	MIR4755	-4.22	3.16e-05	0.0128	-0.22	-0.22	Skin pigmentation;	chr20:34096503	chr20:34049119~34049190:+
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000211959.2	IGHV4-39	4.22	3.17e-05	0.0128	0.19	0.22	Kawasaki disease;	chr14:106782219	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000211959.2	IGHV4-39	4.22	3.17e-05	0.0128	0.19	0.22	Kawasaki disease;	chr14:106782337	chr14:106421711~106422218:-
STAD	cis	rs1198872	0.516	rs1387572	ENSG00000272275.1	RP11-791G15.2	4.22	3.17e-05	0.0128	0.28	0.22	Cardiac Troponin-T levels;	chr2:10773111	chr2:10767875~10770058:-
STAD	cis	rs10073892	0.62	rs10440757	ENSG00000250682.4	LINC00491	-4.22	3.17e-05	0.0128	-0.24	-0.22	Cognitive decline (age-related);	chr5:102593773	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.62	rs62369729	ENSG00000250682.4	LINC00491	-4.22	3.17e-05	0.0128	-0.24	-0.22	Cognitive decline (age-related);	chr5:102595627	chr5:102609156~102671559:-
STAD	cis	rs875971	0.862	rs880166	ENSG00000224316.1	RP11-479O9.2	-4.22	3.17e-05	0.0128	-0.22	-0.22	Aortic root size;	chr7:66205775	chr7:65773620~65802067:+
STAD	cis	rs7647973	0.516	rs4499638	ENSG00000225399.4	RP11-3B7.1	4.22	3.17e-05	0.0128	0.24	0.22	Menarche (age at onset);	chr3:49165349	chr3:49260085~49261316:+
STAD	cis	rs4792901	0.765	rs2127224	ENSG00000279602.1	CTD-3014M21.1	-4.22	3.17e-05	0.0128	-0.29	-0.22	Dupuytren's disease;	chr17:43491657	chr17:43360041~43361361:-
STAD	cis	rs12682352	0.579	rs7006589	ENSG00000253981.4	ALG1L13P	4.22	3.17e-05	0.0128	0.26	0.22	Neuroticism;	chr8:8810976	chr8:8236003~8244667:-
STAD	cis	rs7665090	0.87	rs228615	ENSG00000230069.3	LRRC37A15P	4.22	3.17e-05	0.0128	0.24	0.22	Primary biliary cholangitis;	chr4:102658303	chr4:102727274~102730721:-
STAD	cis	rs8062405	0.721	rs151181	ENSG00000278665.1	RP11-666O2.4	4.22	3.17e-05	0.0128	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28599241~28601881:-
STAD	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-4.22	3.17e-05	0.0128	-0.29	-0.22	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
STAD	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-4.22	3.17e-05	0.0128	-0.29	-0.22	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
STAD	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-4.22	3.17e-05	0.0128	-0.29	-0.22	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
STAD	cis	rs875971	0.862	rs4718319	ENSG00000224316.1	RP11-479O9.2	-4.22	3.17e-05	0.0128	-0.22	-0.22	Aortic root size;	chr7:66187797	chr7:65773620~65802067:+
STAD	cis	rs875971	0.723	rs28391294	ENSG00000224316.1	RP11-479O9.2	-4.22	3.17e-05	0.0128	-0.22	-0.22	Aortic root size;	chr7:66189328	chr7:65773620~65802067:+
STAD	cis	rs875971	0.83	rs6967708	ENSG00000224316.1	RP11-479O9.2	-4.22	3.17e-05	0.0128	-0.22	-0.22	Aortic root size;	chr7:66192326	chr7:65773620~65802067:+
STAD	cis	rs875971	0.895	rs7782806	ENSG00000224316.1	RP11-479O9.2	-4.22	3.17e-05	0.0128	-0.22	-0.22	Aortic root size;	chr7:66192910	chr7:65773620~65802067:+
STAD	cis	rs7156960	1	rs7156960	ENSG00000258454.1	RP11-361H10.3	-4.22	3.18e-05	0.0128	-0.23	-0.22	Acute lymphoblastic leukemia (childhood);	chr14:76237008	chr14:76235817~76263474:+
STAD	cis	rs7598759	0.527	rs4973417	ENSG00000223198.1	RNU2-22P	-4.22	3.18e-05	0.0128	-0.26	-0.22	Noise-induced hearing loss;	chr2:231484925	chr2:231501990~231502201:-
STAD	cis	rs9902453	0.74	rs2617867	ENSG00000240074.1	RPL9P30	-4.22	3.18e-05	0.0128	-0.19	-0.22	Coffee consumption (cups per day);	chr17:29722381	chr17:29855759~29856332:+
STAD	cis	rs3825942	0.612	rs72745367	ENSG00000261801.4	LOXL1-AS1	4.22	3.18e-05	0.0128	0.3	0.22	Glaucoma (exfoliation);	chr15:73939725	chr15:73908071~73928248:-
STAD	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-4.22	3.18e-05	0.0128	-0.35	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
STAD	cis	rs749052	0.831	rs3100584	ENSG00000251485.1	AC068134.10	4.22	3.18e-05	0.0128	0.53	0.22	Height;	chr2:232081580	chr2:232343116~232343903:+
STAD	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	4.22	3.18e-05	0.0128	0.27	0.22	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
STAD	cis	rs7103648	0.966	rs11500477	ENSG00000280615.1	Y_RNA	4.22	3.18e-05	0.0128	0.23	0.22	Systolic blood pressure;Diastolic blood pressure;	chr11:47387500	chr11:47614898~47614994:-
STAD	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	4.22	3.18e-05	0.0128	0.33	0.22	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
STAD	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	4.22	3.18e-05	0.0128	0.27	0.22	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
STAD	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	4.22	3.18e-05	0.0128	0.22	0.22	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
STAD	cis	rs2992257	0.874	rs2992302	ENSG00000251839.1	RNU7-12P	-4.22	3.18e-05	0.0128	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26415135	chr10:27232255~27232316:-
STAD	cis	rs9902453	0.765	rs8079209	ENSG00000263477.1	RP11-338L22.2	4.22	3.19e-05	0.0128	0.19	0.22	Coffee consumption (cups per day);	chr17:29859755	chr17:29863402~29866092:+
STAD	cis	rs4589258	0.788	rs2213091	ENSG00000280367.1	RP11-121L10.2	4.22	3.19e-05	0.0128	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90742858	chr11:90223153~90226538:+
STAD	cis	rs4243830	1	rs12401795	ENSG00000229519.2	RP11-58A11.2	-4.22	3.19e-05	0.0128	-0.25	-0.22	Body mass index;	chr1:6534713	chr1:6547905~6548619:+
STAD	cis	rs2221894	0.511	rs13256557	ENSG00000273710.1	Metazoa_SRP	-4.21	3.19e-05	0.0129	-0.22	-0.22	Obesity-related traits;	chr8:29038997	chr8:28915579~28915864:-
STAD	cis	rs4722166	0.704	rs4321884	ENSG00000179428.2	AC073072.5	-4.21	3.19e-05	0.0129	-0.25	-0.22	Lung cancer;	chr7:22701840	chr7:22725395~22727620:-
STAD	cis	rs6813195	0.642	rs17028954	ENSG00000243417.1	RP11-555K12.1	4.21	3.19e-05	0.0129	0.22	0.22	Type 2 diabetes;	chr4:152517181	chr4:152551277~152552364:-
STAD	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	4.21	3.2e-05	0.0129	0.24	0.22	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
STAD	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	4.21	3.2e-05	0.0129	0.24	0.22	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
STAD	cis	rs1030877	0.515	rs17030766	ENSG00000235319.1	AC012360.4	4.21	3.2e-05	0.0129	0.3	0.22	Obesity-related traits;	chr2:105295448	chr2:105324210~105330529:+
STAD	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	4.21	3.2e-05	0.0129	0.3	0.22	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	4.21	3.2e-05	0.0129	0.3	0.22	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	4.21	3.2e-05	0.0129	0.3	0.22	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	4.21	3.2e-05	0.0129	0.3	0.22	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
STAD	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	4.21	3.2e-05	0.0129	0.31	0.22	Depression;	chr6:28364057	chr6:28943877~28944537:+
STAD	cis	rs12682352	0.602	rs1473029	ENSG00000254340.1	RP11-10A14.3	4.21	3.2e-05	0.0129	0.27	0.22	Neuroticism;	chr8:8811407	chr8:9141424~9145435:+
STAD	cis	rs2310173	0.575	rs4851527	ENSG00000281162.1	LINC01127	4.21	3.21e-05	0.0129	0.28	0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102005914	chr2:101962056~101987167:+
STAD	cis	rs2638953	0.64	rs10843211	ENSG00000247934.4	RP11-967K21.1	-4.21	3.21e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28577717	chr12:28163298~28190738:-
STAD	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	4.21	3.21e-05	0.0129	0.27	0.22	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
STAD	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	4.21	3.21e-05	0.0129	0.2	0.22	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
STAD	cis	rs6142102	1	rs2143230	ENSG00000264616.1	MIR4755	4.21	3.21e-05	0.0129	0.23	0.22	Skin pigmentation;	chr20:34136539	chr20:34049119~34049190:+
STAD	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-4.21	3.21e-05	0.0129	-0.29	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
STAD	cis	rs2638953	0.924	rs17801442	ENSG00000247934.4	RP11-967K21.1	-4.21	3.21e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165627	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049384	ENSG00000247934.4	RP11-967K21.1	-4.21	3.21e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28166089	chr12:28163298~28190738:-
STAD	cis	rs11676348	0.772	rs12694427	ENSG00000237281.1	CATIP-AS2	4.21	3.21e-05	0.0129	0.22	0.22	Ulcerative colitis;	chr2:218080322	chr2:218326889~218357966:-
STAD	cis	rs2638953	0.67	rs11049701	ENSG00000247934.4	RP11-967K21.1	-4.21	3.21e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28536042	chr12:28163298~28190738:-
STAD	cis	rs875971	0.862	rs2420174	ENSG00000224316.1	RP11-479O9.2	-4.21	3.22e-05	0.0129	-0.22	-0.22	Aortic root size;	chr7:66180374	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs2420173	ENSG00000224316.1	RP11-479O9.2	-4.21	3.22e-05	0.0129	-0.22	-0.22	Aortic root size;	chr7:66180412	chr7:65773620~65802067:+
STAD	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	4.21	3.22e-05	0.0129	0.24	0.22	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
STAD	cis	rs794185	0.714	rs711633	ENSG00000231249.1	ITPR1-AS1	4.21	3.22e-05	0.0129	0.25	0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4449577	chr3:4490891~4493163:-
STAD	cis	rs1823913	1	rs4853559	ENSG00000280083.1	RP11-317J9.1	4.21	3.22e-05	0.0129	0.27	0.22	Obesity-related traits;	chr2:191235965	chr2:191154118~191156070:-
STAD	cis	rs6142102	0.812	rs725478	ENSG00000264616.1	MIR4755	-4.21	3.22e-05	0.0129	-0.24	-0.22	Skin pigmentation;	chr20:33930548	chr20:34049119~34049190:+
STAD	cis	rs2638953	0.924	rs12368652	ENSG00000247934.4	RP11-967K21.1	-4.21	3.22e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049392	ENSG00000247934.4	RP11-967K21.1	-4.21	3.22e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049394	ENSG00000247934.4	RP11-967K21.1	-4.21	3.22e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs11049395	ENSG00000247934.4	RP11-967K21.1	-4.21	3.22e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs11049397	ENSG00000247934.4	RP11-967K21.1	-4.21	3.22e-05	0.0129	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28163298~28190738:-
STAD	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-4.21	3.22e-05	0.013	-0.34	-0.22	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
STAD	cis	rs2089162	1	rs2089162	ENSG00000259419.2	HNRNPCP3	4.21	3.22e-05	0.013	0.25	0.22	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78447421	chr15:79236332~79237206:+
STAD	cis	rs1723838	0.51	rs1723841	ENSG00000255928.1	RP11-456I15.2	4.21	3.22e-05	0.013	0.5	0.22	Obesity-related traits;	chr11:73762728	chr11:73722349~73722694:+
STAD	cis	rs875971	0.893	rs62465470	ENSG00000224316.1	RP11-479O9.2	-4.21	3.23e-05	0.013	-0.22	-0.22	Aortic root size;	chr7:66136231	chr7:65773620~65802067:+
STAD	cis	rs2337406	1	rs7145100	ENSG00000280411.1	IGHV1-69-2	-4.21	3.23e-05	0.013	-0.28	-0.22	Alzheimer's disease (late onset);	chr14:106704673	chr14:106762092~106762588:-
STAD	cis	rs4407350	0.756	rs131155	ENSG00000279642.1	RP5-1033E15.3	-4.21	3.23e-05	0.013	-0.22	-0.22	Intelligence (multi-trait analysis);	chr22:44495367	chr22:44486295~44486914:-
STAD	cis	rs10129255	0.957	rs28887506	ENSG00000232216.1	IGHV3-43	4.21	3.23e-05	0.013	0.23	0.22	Kawasaki disease;	chr14:106785589	chr14:106470264~106470800:-
STAD	cis	rs7951911	0.915	rs12791538	ENSG00000254427.1	RP11-430H10.1	4.21	3.23e-05	0.013	0.44	0.22	IgG glycosylation;	chr11:45083915	chr11:45355371~45366121:+
STAD	cis	rs3002142	0.57	rs3008633	ENSG00000272750.1	RP11-378J18.8	-4.21	3.23e-05	0.013	-0.33	-0.22	LDL peak particle diameter (total fat intake interaction);	chr1:222671498	chr1:222658867~222661512:-
STAD	cis	rs12682352	0.602	rs6988939	ENSG00000254340.1	RP11-10A14.3	4.21	3.23e-05	0.013	0.27	0.22	Neuroticism;	chr8:8809406	chr8:9141424~9145435:+
STAD	cis	rs34779708	0.931	rs9663401	ENSG00000271335.4	RP11-324I22.4	4.21	3.23e-05	0.013	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.897	rs9787566	ENSG00000271335.4	RP11-324I22.4	4.21	3.23e-05	0.013	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4351760	ENSG00000271335.4	RP11-324I22.4	4.21	3.23e-05	0.013	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.898	rs4934695	ENSG00000271335.4	RP11-324I22.4	4.21	3.23e-05	0.013	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs11597483	ENSG00000271335.4	RP11-324I22.4	4.21	3.23e-05	0.013	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs35317849	ENSG00000271335.4	RP11-324I22.4	4.21	3.23e-05	0.013	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35314552~35336401:-
STAD	cis	rs10851478	0.872	rs12901680	ENSG00000259545.2	RP11-325E5.4	-4.21	3.23e-05	0.013	-0.26	-0.22	Oral cavity cancer;	chr15:49588708	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.802	rs7162741	ENSG00000259545.2	RP11-325E5.4	-4.21	3.23e-05	0.013	-0.26	-0.22	Oral cavity cancer;	chr15:49613213	chr15:49177610~49178741:-
STAD	cis	rs375092	0.543	rs449271	ENSG00000230658.1	KLHL7-AS1	4.21	3.23e-05	0.013	0.36	0.22	Personality dimensions;	chr7:23376798	chr7:23101228~23105703:-
STAD	cis	rs7646881	0.812	rs73015644	ENSG00000240207.5	RP11-379F4.4	-4.21	3.23e-05	0.013	-0.37	-0.22	Tetralogy of Fallot;	chr3:158729955	chr3:158732263~158784070:+
STAD	cis	rs1876905	0.597	rs354538	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.23e-05	0.013	-0.26	-0.22	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111277932~111278742:+
STAD	cis	rs7809950	1	rs2293658	ENSG00000238832.1	snoU109	-4.21	3.23e-05	0.013	-0.3	-0.22	Coronary artery disease;	chr7:107630122	chr7:107603363~107603507:+
STAD	cis	rs4845875	0.534	rs6541003	ENSG00000242349.4	NPPA-AS1	4.21	3.23e-05	0.013	0.23	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11795810	chr1:11841017~11848079:+
STAD	cis	rs875971	0.862	rs908915	ENSG00000224316.1	RP11-479O9.2	-4.21	3.23e-05	0.013	-0.22	-0.22	Aortic root size;	chr7:66149664	chr7:65773620~65802067:+
STAD	cis	rs8141529	0.702	rs469991	ENSG00000226471.5	CTA-292E10.6	4.21	3.23e-05	0.013	0.25	0.22	Lymphocyte counts;	chr22:28911871	chr22:28800683~28848559:+
STAD	cis	rs561341	1	rs564714	ENSG00000265798.5	RP11-271K11.5	4.21	3.24e-05	0.013	0.32	0.22	Hip circumference adjusted for BMI;	chr17:31991385	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs510264	ENSG00000265798.5	RP11-271K11.5	4.21	3.24e-05	0.013	0.32	0.22	Hip circumference adjusted for BMI;	chr17:31996395	chr17:31038575~31059121:-
STAD	cis	rs7567389	0.568	rs7568070	ENSG00000236682.1	AC068282.3	-4.21	3.24e-05	0.013	-0.31	-0.22	Self-rated health;	chr2:127195478	chr2:127389130~127400580:+
STAD	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	4.21	3.24e-05	0.013	0.29	0.22	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
STAD	cis	rs9329221	0.683	rs688491	ENSG00000254340.1	RP11-10A14.3	-4.21	3.24e-05	0.013	-0.27	-0.22	Neuroticism;	chr8:10027313	chr8:9141424~9145435:+
STAD	cis	rs17401966	0.931	rs11121545	ENSG00000199562.1	RNU6-37P	4.21	3.24e-05	0.013	0.18	0.22	Hepatocellular carcinoma;	chr1:10351153	chr1:10298966~10299072:+
STAD	cis	rs1707322	0.964	rs7546237	ENSG00000225447.1	RPS15AP10	4.21	3.24e-05	0.013	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45645816~45646197:-
STAD	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-4.21	3.24e-05	0.013	-0.22	-0.22	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
STAD	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-4.21	3.24e-05	0.013	-0.22	-0.22	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
STAD	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	4.21	3.24e-05	0.013	0.29	0.22	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
STAD	cis	rs7824557	0.872	rs2572431	ENSG00000254866.2	DEFB109P3	4.21	3.24e-05	0.013	0.27	0.22	Retinal vascular caliber;	chr8:11247568	chr8:12150895~12151134:-
STAD	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-4.21	3.24e-05	0.013	-0.32	-0.22	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
STAD	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-4.21	3.24e-05	0.013	-0.33	-0.22	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-4.21	3.24e-05	0.013	-0.33	-0.22	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
STAD	cis	rs3764021	0.87	rs7956831	ENSG00000256673.1	RP11-599J14.2	4.21	3.24e-05	0.013	0.23	0.22	Type 1 diabetes;	chr12:9736561	chr12:9398355~9414851:-
STAD	cis	rs1040	1	rs1040	ENSG00000261039.2	RP11-417E7.2	-4.21	3.24e-05	0.013	-0.25	-0.22	Joint mobility (Beighton score);	chr6:169216252	chr6:169175304~169182740:-
STAD	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-4.21	3.25e-05	0.013	-0.33	-0.22	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
STAD	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-4.21	3.25e-05	0.013	-0.33	-0.22	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
STAD	cis	rs4589258	0.788	rs10734136	ENSG00000280367.1	RP11-121L10.2	4.21	3.25e-05	0.013	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90749399	chr11:90223153~90226538:+
STAD	cis	rs7665090	0.806	rs434644	ENSG00000230069.3	LRRC37A15P	4.21	3.25e-05	0.013	0.24	0.22	Primary biliary cholangitis;	chr4:102662032	chr4:102727274~102730721:-
STAD	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	4.21	3.25e-05	0.013	0.28	0.22	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
STAD	cis	rs2739330	0.828	rs5751770	ENSG00000272787.1	KB-226F1.2	-4.21	3.25e-05	0.013	-0.23	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23969211~23969873:+
STAD	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	4.21	3.25e-05	0.013	0.25	0.22	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
STAD	cis	rs7424096	0.515	rs17497343	ENSG00000252756.1	RNU6-577P	-4.21	3.25e-05	0.013	-0.25	-0.22	High light scatter reticulocyte percentage of red cells;	chr2:36945889	chr2:36867398~36867495:-
STAD	cis	rs4713118	0.955	rs9468201	ENSG00000220721.1	OR1F12	4.21	3.25e-05	0.013	0.24	0.22	Parkinson's disease;	chr6:27719256	chr6:28073316~28074233:+
STAD	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	4.21	3.25e-05	0.0131	0.33	0.22	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
STAD	cis	rs7916697	0.628	rs10998036	ENSG00000233590.1	RP11-153K11.3	4.21	3.25e-05	0.0131	0.28	0.22	Optic disc area;	chr10:68256921	chr10:68233251~68242379:-
STAD	cis	rs7176527	1	rs7176527	ENSG00000225151.9	GOLGA2P7	4.21	3.25e-05	0.0131	0.29	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84199311~84230136:-
STAD	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-4.21	3.26e-05	0.0131	-0.26	-0.22	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
STAD	cis	rs34779708	0.931	rs2244100	ENSG00000271335.4	RP11-324I22.4	-4.21	3.26e-05	0.0131	-0.27	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35314552~35336401:-
STAD	cis	rs2348418	0.765	rs11049381	ENSG00000247934.4	RP11-967K21.1	-4.21	3.26e-05	0.0131	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162107	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.765	rs7954851	ENSG00000247934.4	RP11-967K21.1	-4.21	3.26e-05	0.0131	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162909	chr12:28163298~28190738:-
STAD	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	4.21	3.26e-05	0.0131	0.31	0.22	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	4.21	3.26e-05	0.0131	0.31	0.22	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	4.21	3.26e-05	0.0131	0.31	0.22	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	4.21	3.26e-05	0.0131	0.31	0.22	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	4.21	3.26e-05	0.0131	0.31	0.22	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
STAD	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	-4.21	3.26e-05	0.0131	-0.26	-0.22	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
STAD	cis	rs116095464	0.558	rs12173015	ENSG00000250848.1	CTD-2083E4.5	4.21	3.26e-05	0.0131	0.32	0.22	Breast cancer;	chr5:269852	chr5:288833~290321:-
STAD	cis	rs9902453	0.845	rs12602426	ENSG00000240074.1	RPL9P30	4.21	3.26e-05	0.0131	0.19	0.22	Coffee consumption (cups per day);	chr17:29831797	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.817	rs62068620	ENSG00000240074.1	RPL9P30	4.21	3.26e-05	0.0131	0.19	0.22	Coffee consumption (cups per day);	chr17:29840656	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.808	rs76515799	ENSG00000240074.1	RPL9P30	4.21	3.26e-05	0.0131	0.19	0.22	Coffee consumption (cups per day);	chr17:29842473	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.808	rs78154346	ENSG00000240074.1	RPL9P30	4.21	3.26e-05	0.0131	0.19	0.22	Coffee consumption (cups per day);	chr17:29842475	chr17:29855759~29856332:+
STAD	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	4.21	3.26e-05	0.0131	0.29	0.22	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
STAD	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-4.21	3.26e-05	0.0131	-0.21	-0.22	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
STAD	cis	rs9467773	0.62	rs9461275	ENSG00000243307.2	POM121L6P	4.21	3.26e-05	0.0131	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs6925087	ENSG00000243307.2	POM121L6P	4.21	3.26e-05	0.0131	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs4368798	ENSG00000243307.2	POM121L6P	4.21	3.26e-05	0.0131	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.62	rs9461276	ENSG00000243307.2	POM121L6P	4.21	3.26e-05	0.0131	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26896952~26898777:+
STAD	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	4.21	3.26e-05	0.0131	0.24	0.22	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
STAD	cis	rs4321325	1	rs4321325	ENSG00000236682.1	AC068282.3	-4.21	3.26e-05	0.0131	-0.36	-0.22	Protein C levels;	chr2:127193421	chr2:127389130~127400580:+
STAD	cis	rs875971	0.862	rs11984115	ENSG00000224316.1	RP11-479O9.2	-4.21	3.26e-05	0.0131	-0.22	-0.22	Aortic root size;	chr7:66308872	chr7:65773620~65802067:+
STAD	cis	rs1707322	1	rs4298677	ENSG00000281133.1	AL355480.3	-4.21	3.26e-05	0.0131	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45580892~45580996:-
STAD	cis	rs12468226	0.873	rs12470401	ENSG00000226261.1	AC064836.3	4.21	3.26e-05	0.0131	0.37	0.22	Urate levels;	chr2:202236436	chr2:202336024~202336727:-
STAD	cis	rs8014252	0.803	rs7157618	ENSG00000259158.2	ADAM20P1	-4.21	3.27e-05	0.0131	-0.29	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543449	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs8006487	ENSG00000259158.2	ADAM20P1	-4.21	3.27e-05	0.0131	-0.29	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70545217	chr14:70468881~70483756:-
STAD	cis	rs9291683	0.551	rs2240720	ENSG00000250613.1	RP11-136I13.1	-4.21	3.27e-05	0.0131	-0.21	-0.22	Bone mineral density;	chr4:10018856	chr4:10410996~10411644:+
STAD	cis	rs2348418	0.765	rs7954877	ENSG00000247934.4	RP11-967K21.1	-4.21	3.27e-05	0.0131	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28163008	chr12:28163298~28190738:-
STAD	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	4.21	3.27e-05	0.0131	0.21	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
STAD	cis	rs7647973	0.6	rs12631989	ENSG00000225399.4	RP11-3B7.1	4.21	3.27e-05	0.0131	0.24	0.22	Menarche (age at onset);	chr3:49236563	chr3:49260085~49261316:+
STAD	cis	rs7647973	0.6	rs13064780	ENSG00000225399.4	RP11-3B7.1	4.21	3.27e-05	0.0131	0.24	0.22	Menarche (age at onset);	chr3:49237393	chr3:49260085~49261316:+
STAD	cis	rs7647973	0.58	rs35218722	ENSG00000225399.4	RP11-3B7.1	4.21	3.27e-05	0.0131	0.24	0.22	Menarche (age at onset);	chr3:49238372	chr3:49260085~49261316:+
STAD	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	4.21	3.27e-05	0.0131	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
STAD	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	4.21	3.27e-05	0.0131	0.22	0.22	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
STAD	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	4.21	3.27e-05	0.0131	0.22	0.22	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
STAD	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	4.21	3.27e-05	0.0131	0.28	0.22	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
STAD	cis	rs8098244	0.708	rs1154244	ENSG00000267301.1	RPL23AP77	-4.21	3.27e-05	0.0131	-0.3	-0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964052	chr18:23709825~23710287:-
STAD	cis	rs2348418	1	rs2348418	ENSG00000247934.4	RP11-967K21.1	4.21	3.27e-05	0.0131	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28536581	chr12:28163298~28190738:-
STAD	cis	rs4845875	0.564	rs2151655	ENSG00000242349.4	NPPA-AS1	4.21	3.27e-05	0.0131	0.25	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11785461	chr1:11841017~11848079:+
STAD	cis	rs301901	0.796	rs3941788	ENSG00000250155.1	CTD-2353F22.1	4.21	3.27e-05	0.0131	0.23	0.22	Height;	chr5:37498809	chr5:36666214~36725195:-
STAD	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	4.21	3.27e-05	0.0131	0.23	0.22	Height;	chr5:37533964	chr5:36666214~36725195:-
STAD	cis	rs7665090	0.806	rs413967	ENSG00000230069.3	LRRC37A15P	4.21	3.27e-05	0.0131	0.24	0.22	Primary biliary cholangitis;	chr4:102662039	chr4:102727274~102730721:-
STAD	cis	rs7665090	0.806	rs404574	ENSG00000230069.3	LRRC37A15P	4.21	3.27e-05	0.0131	0.24	0.22	Primary biliary cholangitis;	chr4:102662051	chr4:102727274~102730721:-
STAD	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	4.21	3.27e-05	0.0131	0.26	0.22	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
STAD	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-4.21	3.27e-05	0.0131	-0.26	-0.22	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
STAD	cis	rs42490	0.664	rs421411	ENSG00000251136.7	RP11-37B2.1	-4.21	3.27e-05	0.0131	-0.22	-0.22	Leprosy;	chr8:89808665	chr8:89609409~89757727:-
STAD	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	4.21	3.27e-05	0.0131	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
STAD	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-4.21	3.28e-05	0.0131	-0.26	-0.22	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
STAD	cis	rs516805	0.748	rs197680	ENSG00000279453.1	RP3-425C14.4	-4.21	3.28e-05	0.0131	-0.36	-0.22	Lymphocyte counts;	chr6:122548987	chr6:122436789~122439223:-
STAD	cis	rs10129255	0.957	rs10138532	ENSG00000232216.1	IGHV3-43	4.21	3.28e-05	0.0131	0.23	0.22	Kawasaki disease;	chr14:106803901	chr14:106470264~106470800:-
STAD	cis	rs2221894	0.511	rs17453617	ENSG00000273710.1	Metazoa_SRP	-4.21	3.28e-05	0.0131	-0.23	-0.22	Obesity-related traits;	chr8:29024393	chr8:28915579~28915864:-
STAD	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	4.21	3.28e-05	0.0131	0.23	0.22	Height;	chr5:37490184	chr5:36666214~36725195:-
STAD	cis	rs4713118	0.955	rs9380010	ENSG00000220721.1	OR1F12	4.21	3.28e-05	0.0131	0.24	0.22	Parkinson's disease;	chr6:27715793	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.955	rs9368528	ENSG00000220721.1	OR1F12	4.21	3.28e-05	0.0131	0.24	0.22	Parkinson's disease;	chr6:27716019	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.955	rs9368529	ENSG00000220721.1	OR1F12	4.21	3.28e-05	0.0131	0.24	0.22	Parkinson's disease;	chr6:27716852	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.955	rs9380012	ENSG00000220721.1	OR1F12	4.21	3.28e-05	0.0131	0.24	0.22	Parkinson's disease;	chr6:27716875	chr6:28073316~28074233:+
STAD	cis	rs561341	1	rs508192	ENSG00000265798.5	RP11-271K11.5	-4.21	3.28e-05	0.0132	-0.32	-0.22	Hip circumference adjusted for BMI;	chr17:31988128	chr17:31038575~31059121:-
STAD	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	4.21	3.28e-05	0.0132	0.23	0.22	Height;	chr5:37504063	chr5:36666214~36725195:-
STAD	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	4.21	3.28e-05	0.0132	0.23	0.22	Height;	chr5:37505544	chr5:36666214~36725195:-
STAD	cis	rs10129255	0.833	rs61997797	ENSG00000224373.3	IGHV4-59	4.21	3.29e-05	0.0132	0.18	0.22	Kawasaki disease;	chr14:106815190	chr14:106627249~106627825:-
STAD	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-4.21	3.29e-05	0.0132	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
STAD	cis	rs728616	0.51	rs34782759	ENSG00000225484.5	NUTM2B-AS1	-4.21	3.29e-05	0.0132	-0.42	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80435463	chr10:79663088~79826594:-
STAD	cis	rs34779708	0.931	rs11596502	ENSG00000271335.4	RP11-324I22.4	4.21	3.29e-05	0.0132	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35314552~35336401:-
STAD	cis	rs10129255	0.5	rs7159033	ENSG00000224373.3	IGHV4-59	4.21	3.29e-05	0.0132	0.16	0.22	Kawasaki disease;	chr14:106701709	chr14:106627249~106627825:-
STAD	cis	rs449789	0.502	rs529281	ENSG00000235086.1	FNDC1-IT1	-4.21	3.29e-05	0.0132	-0.29	-0.22	Pulse pressure;	chr6:159287473	chr6:159240786~159243329:+
STAD	cis	rs449789	0.817	rs534519	ENSG00000235086.1	FNDC1-IT1	-4.21	3.29e-05	0.0132	-0.29	-0.22	Pulse pressure;	chr6:159290897	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs2501175	ENSG00000235086.1	FNDC1-IT1	-4.21	3.29e-05	0.0132	-0.29	-0.22	Pulse pressure;	chr6:159293380	chr6:159240786~159243329:+
STAD	cis	rs449789	0.779	rs553197	ENSG00000235086.1	FNDC1-IT1	-4.21	3.29e-05	0.0132	-0.29	-0.22	Pulse pressure;	chr6:159293593	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs578714	ENSG00000235086.1	FNDC1-IT1	-4.21	3.29e-05	0.0132	-0.29	-0.22	Pulse pressure;	chr6:159294086	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs579533	ENSG00000235086.1	FNDC1-IT1	-4.21	3.29e-05	0.0132	-0.29	-0.22	Pulse pressure;	chr6:159294171	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs687314	ENSG00000235086.1	FNDC1-IT1	-4.21	3.29e-05	0.0132	-0.29	-0.22	Pulse pressure;	chr6:159295230	chr6:159240786~159243329:+
STAD	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	4.21	3.29e-05	0.0132	0.29	0.22	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	4.21	3.29e-05	0.0132	0.29	0.22	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	4.21	3.29e-05	0.0132	0.29	0.22	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
STAD	cis	rs7078219	0.505	rs7077040	ENSG00000257582.4	LINC01475	-4.21	3.29e-05	0.0132	-0.26	-0.22	Dental caries;	chr10:99521257	chr10:99526350~99531177:-
STAD	cis	rs181553	0.664	rs2166670	ENSG00000266696.1	RP11-30L3.2	4.21	3.29e-05	0.0132	0.2	0.22	Hip circumference adjusted for BMI;	chr18:49158540	chr18:49205912~49208781:+
STAD	cis	rs9307551	0.741	rs1561640	ENSG00000250334.4	LINC00989	-4.21	3.29e-05	0.0132	-0.28	-0.22	Refractive error;	chr4:79498874	chr4:79492416~79576460:+
STAD	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	4.21	3.29e-05	0.0132	0.27	0.22	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
STAD	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-4.21	3.29e-05	0.0132	-0.22	-0.22	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
STAD	cis	rs11169552	0.51	rs3935869	ENSG00000200183.1	RNU6-238P	-4.21	3.29e-05	0.0132	-0.21	-0.22	Colorectal cancer;	chr12:50570293	chr12:50656973~50657078:+
STAD	cis	rs2573652	0.674	rs11630583	ENSG00000270127.2	RP11-526I2.5	-4.21	3.29e-05	0.0132	-0.24	-0.22	Height;	chr15:100003150	chr15:100547765~100550153:-
STAD	cis	rs2573652	0.674	rs11630619	ENSG00000270127.2	RP11-526I2.5	-4.21	3.29e-05	0.0132	-0.24	-0.22	Height;	chr15:100003162	chr15:100547765~100550153:-
STAD	cis	rs9393777	0.623	rs3757150	ENSG00000241549.7	GUSBP2	4.21	3.3e-05	0.0132	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26476554	chr6:26871484~26956554:-
STAD	cis	rs9393777	0.623	rs16891717	ENSG00000241549.7	GUSBP2	4.21	3.3e-05	0.0132	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26476915	chr6:26871484~26956554:-
STAD	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	4.21	3.3e-05	0.0132	0.21	0.22	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
STAD	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	4.21	3.3e-05	0.0132	0.21	0.22	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
STAD	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	4.21	3.3e-05	0.0132	0.21	0.22	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
STAD	cis	rs9859260	0.744	rs3933	ENSG00000185485.13	SDHAP1	-4.21	3.3e-05	0.0132	-0.22	-0.22	Mean corpuscular volume;	chr3:196058126	chr3:195959748~195990318:-
STAD	cis	rs2638953	0.853	rs11049656	ENSG00000247934.4	RP11-967K21.1	-4.21	3.3e-05	0.0132	-0.22	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481705	chr12:28163298~28190738:-
STAD	cis	rs2992257	0.914	rs2992307	ENSG00000251839.1	RNU7-12P	-4.21	3.3e-05	0.0132	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26418239	chr10:27232255~27232316:-
STAD	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	4.21	3.3e-05	0.0132	0.37	0.22	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
STAD	cis	rs9847710	0.967	rs2581824	ENSG00000242142.1	SERBP1P3	-4.21	3.3e-05	0.0132	-0.21	-0.22	Ulcerative colitis;	chr3:52988392	chr3:53064283~53065091:-
STAD	cis	rs27434	0.605	rs12659825	ENSG00000248734.2	CTD-2260A17.1	-4.21	3.3e-05	0.0132	-0.28	-0.22	Ankylosing spondylitis;	chr5:96852380	chr5:96784777~96785999:+
STAD	cis	rs1850744	0.826	rs4554078	ENSG00000250942.1	ENPP7P11	4.21	3.3e-05	0.0132	0.42	0.22	Economic and political preferences;	chr4:9699920	chr4:9677308~9677934:+
STAD	cis	rs12468226	0.817	rs2350360	ENSG00000226261.1	AC064836.3	-4.21	3.3e-05	0.0132	-0.37	-0.22	Urate levels;	chr2:202222980	chr2:202336024~202336727:-
STAD	cis	rs2933343	0.729	rs1683780	ENSG00000261159.1	RP11-723O4.9	4.21	3.3e-05	0.0132	0.28	0.22	IgG glycosylation;	chr3:128921396	chr3:128859716~128860526:-
STAD	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-4.21	3.3e-05	0.0132	-0.24	-0.22	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
STAD	cis	rs1348850	0.914	rs8941	ENSG00000271825.1	RP11-337N6.2	4.21	3.3e-05	0.0132	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177541753	chr2:177300600~177302006:+
STAD	cis	rs1707322	1	rs785510	ENSG00000281133.1	AL355480.3	4.21	3.3e-05	0.0132	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45580892~45580996:-
STAD	cis	rs1823913	1	rs10445783	ENSG00000280083.1	RP11-317J9.1	4.21	3.31e-05	0.0132	0.27	0.22	Obesity-related traits;	chr2:191236772	chr2:191154118~191156070:-
STAD	cis	rs3764021	0.87	rs10492166	ENSG00000256673.1	RP11-599J14.2	-4.21	3.31e-05	0.0132	-0.24	-0.22	Type 1 diabetes;	chr12:9733403	chr12:9398355~9414851:-
STAD	cis	rs4835473	0.9	rs3856989	ENSG00000249741.2	RP11-673E1.3	-4.21	3.31e-05	0.0132	-0.25	-0.22	Immature fraction of reticulocytes;	chr4:143921752	chr4:143911514~143912053:-
STAD	cis	rs9733	0.596	rs72702523	ENSG00000274963.1	Metazoa_SRP	4.21	3.31e-05	0.0132	0.19	0.22	Tonsillectomy;	chr1:150677949	chr1:150568971~150569269:-
STAD	cis	rs8100891	0.614	rs6510243	ENSG00000267213.4	AC007773.2	-4.21	3.31e-05	0.0132	-0.26	-0.22	Neuroticism;	chr19:32342765	chr19:32390050~32405560:-
STAD	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-4.21	3.31e-05	0.0133	-0.23	-0.22	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
STAD	cis	rs950173	1	rs6716901	ENSG00000228389.1	AC068039.4	4.21	3.31e-05	0.0133	0.32	0.22	Hippocampal volume;	chr2:171816943	chr2:171773482~171775844:+
STAD	cis	rs6565180	1	rs11863150	ENSG00000273724.1	RP11-347C12.12	4.21	3.31e-05	0.0133	0.23	0.22	Tonsillectomy;	chr16:30374182	chr16:30336400~30343336:+
STAD	cis	rs8141529	0.748	rs132531	ENSG00000226471.5	CTA-292E10.6	4.21	3.31e-05	0.0133	0.26	0.22	Lymphocyte counts;	chr22:28901377	chr22:28800683~28848559:+
STAD	cis	rs4589258	0.788	rs10741366	ENSG00000280367.1	RP11-121L10.2	4.21	3.31e-05	0.0133	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90758002	chr11:90223153~90226538:+
STAD	cis	rs6840360	0.582	rs11732918	ENSG00000270265.1	RP11-731D1.4	-4.21	3.31e-05	0.0133	-0.26	-0.22	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151333775~151353224:-
STAD	cis	rs2803122	0.745	rs10811143	ENSG00000272842.1	RP11-513M16.7	-4.21	3.31e-05	0.0133	-0.2	-0.22	Pulse pressure;	chr9:19240221	chr9:19371386~19371945:-
STAD	cis	rs10129255	0.833	rs7156689	ENSG00000232216.1	IGHV3-43	4.21	3.32e-05	0.0133	0.22	0.22	Kawasaki disease;	chr14:106816039	chr14:106470264~106470800:-
STAD	cis	rs716804	0.905	rs2083714	ENSG00000254554.1	RP11-351I24.1	4.21	3.32e-05	0.0133	0.32	0.22	Neuroticism;	chr11:10232457	chr11:10302657~10303704:-
STAD	cis	rs716804	0.905	rs4612801	ENSG00000254554.1	RP11-351I24.1	4.21	3.32e-05	0.0133	0.32	0.22	Neuroticism;	chr11:10233010	chr11:10302657~10303704:-
STAD	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	4.21	3.32e-05	0.0133	0.21	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
STAD	cis	rs1395	0.626	rs72817537	ENSG00000234072.1	AC074117.10	-4.21	3.32e-05	0.0133	-0.21	-0.22	Blood metabolite levels;	chr2:27274681	chr2:27356246~27367622:+
STAD	cis	rs1395	0.778	rs60631624	ENSG00000234072.1	AC074117.10	-4.21	3.32e-05	0.0133	-0.21	-0.22	Blood metabolite levels;	chr2:27274947	chr2:27356246~27367622:+
STAD	cis	rs9902453	0.817	rs9909128	ENSG00000240074.1	RPL9P30	4.21	3.32e-05	0.0133	0.19	0.22	Coffee consumption (cups per day);	chr17:29834464	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.765	rs12601647	ENSG00000240074.1	RPL9P30	4.21	3.32e-05	0.0133	0.19	0.22	Coffee consumption (cups per day);	chr17:29837935	chr17:29855759~29856332:+
STAD	cis	rs494453	0.885	rs496296	ENSG00000234020.1	CHIAP3	-4.21	3.32e-05	0.0133	-0.22	-0.22	Osteoporosis-related phenotypes;	chr1:111682034	chr1:111353275~111367409:-
STAD	cis	rs10073892	0.62	rs13163706	ENSG00000250682.4	LINC00491	-4.21	3.32e-05	0.0133	-0.24	-0.22	Cognitive decline (age-related);	chr5:102667073	chr5:102609156~102671559:-
STAD	cis	rs8141529	0.748	rs6005936	ENSG00000226471.5	CTA-292E10.6	-4.21	3.32e-05	0.0133	-0.26	-0.22	Lymphocyte counts;	chr22:28893262	chr22:28800683~28848559:+
STAD	cis	rs12682352	0.602	rs1473029	ENSG00000253981.4	ALG1L13P	4.21	3.32e-05	0.0133	0.27	0.22	Neuroticism;	chr8:8811407	chr8:8236003~8244667:-
STAD	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-4.21	3.32e-05	0.0133	-0.28	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
STAD	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	4.21	3.32e-05	0.0133	0.27	0.22	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
STAD	cis	rs950169	0.541	rs10795	ENSG00000259295.5	CSPG4P12	4.21	3.32e-05	0.0133	0.32	0.22	Schizophrenia;	chr15:84634066	chr15:85191438~85213905:+
STAD	cis	rs950169	0.58	rs36126054	ENSG00000259295.5	CSPG4P12	4.21	3.32e-05	0.0133	0.32	0.22	Schizophrenia;	chr15:84634492	chr15:85191438~85213905:+
STAD	cis	rs9467773	0.583	rs2498380	ENSG00000243307.2	POM121L6P	-4.21	3.32e-05	0.0133	-0.21	-0.22	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26896952~26898777:+
STAD	cis	rs10129255	0.5	rs4774008	ENSG00000224373.3	IGHV4-59	4.21	3.32e-05	0.0133	0.15	0.22	Kawasaki disease;	chr14:106681273	chr14:106627249~106627825:-
STAD	cis	rs7078219	1	rs7078219	ENSG00000228778.1	RP11-129J12.1	4.21	3.33e-05	0.0133	0.26	0.22	Dental caries;	chr10:99514608	chr10:99527081~99528261:+
STAD	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	4.21	3.33e-05	0.0133	0.33	0.22	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
STAD	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-4.2	3.33e-05	0.0133	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
STAD	cis	rs716804	0.905	rs7937758	ENSG00000254554.1	RP11-351I24.1	-4.2	3.33e-05	0.0133	-0.32	-0.22	Neuroticism;	chr11:10214931	chr11:10302657~10303704:-
STAD	cis	rs716804	0.875	rs10770100	ENSG00000254554.1	RP11-351I24.1	-4.2	3.33e-05	0.0133	-0.32	-0.22	Neuroticism;	chr11:10216876	chr11:10302657~10303704:-
STAD	cis	rs716804	0.743	rs4258371	ENSG00000254554.1	RP11-351I24.1	4.2	3.33e-05	0.0133	0.32	0.22	Neuroticism;	chr11:10224144	chr11:10302657~10303704:-
STAD	cis	rs716804	0.935	rs4910104	ENSG00000254554.1	RP11-351I24.1	4.2	3.33e-05	0.0133	0.32	0.22	Neuroticism;	chr11:10224696	chr11:10302657~10303704:-
STAD	cis	rs716804	0.935	rs2197170	ENSG00000254554.1	RP11-351I24.1	4.2	3.33e-05	0.0133	0.32	0.22	Neuroticism;	chr11:10226252	chr11:10302657~10303704:-
STAD	cis	rs2573652	0.722	rs12914189	ENSG00000270127.2	RP11-526I2.5	4.2	3.33e-05	0.0133	0.23	0.22	Height;	chr15:100004224	chr15:100547765~100550153:-
STAD	cis	rs1949733	0.585	rs2631768	ENSG00000205959.3	RP11-689P11.2	4.2	3.33e-05	0.0133	0.24	0.22	Response to antineoplastic agents;	chr4:8471323	chr4:8482270~8512610:+
STAD	cis	rs6142102	0.607	rs6088408	ENSG00000275784.1	RP5-1125A11.6	4.2	3.33e-05	0.0133	0.24	0.22	Skin pigmentation;	chr20:34146800	chr20:33989480~33991818:-
STAD	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	4.2	3.33e-05	0.0133	0.3	0.22	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
STAD	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-4.2	3.33e-05	0.0133	-0.27	-0.22	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
STAD	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	4.2	3.33e-05	0.0133	0.26	0.22	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
STAD	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	4.2	3.33e-05	0.0133	0.29	0.22	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
STAD	cis	rs7131987	0.903	rs11050161	ENSG00000257176.2	RP11-996F15.2	-4.2	3.33e-05	0.0133	-0.25	-0.22	QT interval;	chr12:29267116	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.903	rs11050162	ENSG00000257176.2	RP11-996F15.2	-4.2	3.33e-05	0.0133	-0.25	-0.22	QT interval;	chr12:29267121	chr12:29280418~29317848:-
STAD	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-4.2	3.34e-05	0.0133	-0.27	-0.22	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
STAD	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-4.2	3.34e-05	0.0133	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
STAD	cis	rs4243830	0.737	rs925744	ENSG00000229519.2	RP11-58A11.2	4.2	3.34e-05	0.0133	0.24	0.22	Body mass index;	chr1:6555635	chr1:6547905~6548619:+
STAD	cis	rs8062405	0.679	rs72793818	ENSG00000278665.1	RP11-666O2.4	4.2	3.34e-05	0.0133	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28599241~28601881:-
STAD	cis	rs4691139	1	rs9917978	ENSG00000248632.1	RP11-366M4.11	4.2	3.34e-05	0.0133	0.22	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963991	chr4:164968587~164970002:-
STAD	cis	rs17818399	0.712	rs13008088	ENSG00000279254.1	RP11-536C12.1	-4.2	3.34e-05	0.0133	-0.24	-0.22	Height;	chr2:46554441	chr2:46668870~46670778:+
STAD	cis	rs4691139	0.903	rs13127378	ENSG00000248632.1	RP11-366M4.11	4.2	3.34e-05	0.0133	0.22	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997485	chr4:164968587~164970002:-
STAD	cis	rs9646944	0.501	rs10197310	ENSG00000234389.1	AC007278.3	-4.2	3.34e-05	0.0133	-0.3	-0.22	Blood protein levels;	chr2:102403570	chr2:102438713~102440475:+
STAD	cis	rs11051970	0.559	rs2291420	ENSG00000274964.1	RP11-817I4.1	-4.2	3.34e-05	0.0133	-0.29	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32334816	chr12:32339368~32340724:+
STAD	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	4.2	3.34e-05	0.0133	0.22	0.22	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
STAD	cis	rs2439831	0.681	rs956391	ENSG00000275601.1	AC011330.13	4.2	3.34e-05	0.0133	0.27	0.22	Lung cancer in ever smokers;	chr15:43325295	chr15:43642389~43643023:-
STAD	cis	rs2836974	0.583	rs9636957	ENSG00000238141.2	BRWD1-AS1	-4.2	3.34e-05	0.0133	-0.23	-0.22	Cognitive function;	chr21:39333921	chr21:39315707~39323218:+
STAD	cis	rs1707322	1	rs4660896	ENSG00000225447.1	RPS15AP10	4.2	3.34e-05	0.0133	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.928	rs10732844	ENSG00000225447.1	RPS15AP10	4.2	3.34e-05	0.0133	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs12133129	ENSG00000225447.1	RPS15AP10	4.2	3.34e-05	0.0133	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs4553121	ENSG00000225447.1	RPS15AP10	4.2	3.34e-05	0.0133	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs6690652	ENSG00000225447.1	RPS15AP10	4.2	3.34e-05	0.0133	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45645816~45646197:-
STAD	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-4.2	3.34e-05	0.0133	-0.25	-0.22	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-4.2	3.34e-05	0.0133	-0.25	-0.22	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-4.2	3.34e-05	0.0133	-0.25	-0.22	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-4.2	3.34e-05	0.0133	-0.25	-0.22	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
STAD	cis	rs748404	0.587	rs9920879	ENSG00000275601.1	AC011330.13	-4.2	3.34e-05	0.0133	-0.23	-0.22	Lung cancer;	chr15:43347572	chr15:43642389~43643023:-
STAD	cis	rs1707322	1	rs12124847	ENSG00000225447.1	RPS15AP10	4.2	3.35e-05	0.0134	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45645816~45646197:-
STAD	cis	rs117785887	0.536	rs12216492	ENSG00000270638.1	RP3-466P17.1	4.2	3.35e-05	0.0134	0.4	0.22	Interleukin-17 levels;	chr6:146055482	chr6:145735570~145737218:+
STAD	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-4.2	3.35e-05	0.0134	-0.34	-0.22	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
STAD	cis	rs1707322	1	rs4660889	ENSG00000281133.1	AL355480.3	-4.2	3.35e-05	0.0134	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10890355	ENSG00000281133.1	AL355480.3	-4.2	3.35e-05	0.0134	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211204	ENSG00000281133.1	AL355480.3	-4.2	3.35e-05	0.0134	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs7547189	ENSG00000281133.1	AL355480.3	-4.2	3.35e-05	0.0134	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs7547284	ENSG00000281133.1	AL355480.3	-4.2	3.35e-05	0.0134	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211205	ENSG00000281133.1	AL355480.3	-4.2	3.35e-05	0.0134	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45580892~45580996:-
STAD	cis	rs2041840	0.824	rs7593932	ENSG00000232973.10	CYP1B1-AS1	-4.2	3.35e-05	0.0134	-0.18	-0.22	Chronic lymphocytic leukemia;	chr2:37340083	chr2:38073447~38231651:+
STAD	cis	rs227275	0.525	rs7698608	ENSG00000248971.2	KRT8P46	-4.2	3.35e-05	0.0134	-0.23	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102728746~102730171:-
STAD	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-4.2	3.35e-05	0.0134	-0.22	-0.22	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
STAD	cis	rs748404	0.631	rs7166812	ENSG00000275601.1	AC011330.13	-4.2	3.35e-05	0.0134	-0.23	-0.22	Lung cancer;	chr15:43352562	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs1133395	ENSG00000275601.1	AC011330.13	-4.2	3.35e-05	0.0134	-0.23	-0.22	Lung cancer;	chr15:43358186	chr15:43642389~43643023:-
STAD	cis	rs748404	0.631	rs3809482	ENSG00000275601.1	AC011330.13	-4.2	3.35e-05	0.0134	-0.23	-0.22	Lung cancer;	chr15:43369604	chr15:43642389~43643023:-
STAD	cis	rs1075265	0.744	rs2909460	ENSG00000235937.1	AC008280.1	4.2	3.35e-05	0.0134	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.811	rs805308	ENSG00000235937.1	AC008280.1	4.2	3.35e-05	0.0134	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54029552~54030682:-
STAD	cis	rs7208859	0.623	rs9912440	ENSG00000263603.1	CTD-2349P21.5	-4.2	3.35e-05	0.0134	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30729469~30731202:+
STAD	cis	rs4237845	0.761	rs11172378	ENSG00000273805.1	RP11-620J15.4	-4.2	3.35e-05	0.0134	-0.25	-0.22	Intelligence (multi-trait analysis);	chr12:57904378	chr12:57894232~57896846:+
STAD	cis	rs7395581	0.959	rs7129661	ENSG00000271350.1	CTD-2384B9.1	4.2	3.35e-05	0.0134	0.27	0.22	HDL cholesterol;	chr11:47246999	chr11:47041027~47041945:-
STAD	cis	rs1707322	1	rs6695421	ENSG00000225447.1	RPS15AP10	4.2	3.35e-05	0.0134	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45645816~45646197:-
STAD	cis	rs4141404	0.923	rs2413035	ENSG00000236132.1	CTA-440B3.1	4.2	3.35e-05	0.0134	0.25	0.22	Paclitaxel-induced neuropathy;	chr22:31204474	chr22:31816379~31817491:-
STAD	cis	rs1850744	0.702	rs10805314	ENSG00000250942.1	ENPP7P11	4.2	3.35e-05	0.0134	0.42	0.22	Economic and political preferences;	chr4:9701557	chr4:9677308~9677934:+
STAD	cis	rs7812879	0.602	rs4840561	ENSG00000255556.2	RP11-351I21.6	-4.2	3.35e-05	0.0134	-0.26	-0.22	Systemic lupus erythematosus;	chr8:11448951	chr8:12378679~12380265:-
STAD	cis	rs7474896	0.537	rs1208683	ENSG00000120555.12	SEPT7P9	-4.2	3.35e-05	0.0134	-0.27	-0.22	Obesity (extreme);	chr10:37804795	chr10:38383069~38402916:-
STAD	cis	rs1823874	0.71	rs67068917	ENSG00000182397.13	DNM1P46	-4.2	3.35e-05	0.0134	-0.24	-0.22	IgG glycosylation;	chr15:99822310	chr15:99790156~99806927:-
STAD	cis	rs1823874	0.71	rs58572174	ENSG00000182397.13	DNM1P46	-4.2	3.35e-05	0.0134	-0.24	-0.22	IgG glycosylation;	chr15:99822635	chr15:99790156~99806927:-
STAD	cis	rs1823874	0.677	rs1993295	ENSG00000182397.13	DNM1P46	-4.2	3.35e-05	0.0134	-0.24	-0.22	IgG glycosylation;	chr15:99823332	chr15:99790156~99806927:-
STAD	cis	rs1823874	0.71	rs1993297	ENSG00000182397.13	DNM1P46	-4.2	3.35e-05	0.0134	-0.24	-0.22	IgG glycosylation;	chr15:99823423	chr15:99790156~99806927:-
STAD	cis	rs7131987	0.621	rs3782506	ENSG00000275476.1	RP11-996F15.4	4.2	3.35e-05	0.0134	0.24	0.22	QT interval;	chr12:29292489	chr12:29277397~29277882:-
STAD	cis	rs2836950	0.502	rs2150411	ENSG00000238141.2	BRWD1-AS1	-4.2	3.35e-05	0.0134	-0.23	-0.22	Menarche (age at onset);	chr21:39202626	chr21:39315707~39323218:+
STAD	cis	rs34929064	0.881	rs7802442	ENSG00000179428.2	AC073072.5	-4.2	3.35e-05	0.0134	-0.24	-0.22	Major depression and alcohol dependence;	chr7:22696827	chr7:22725395~22727620:-
STAD	cis	rs6840258	0.891	rs17012512	ENSG00000248180.1	GAPDHP60	4.2	3.35e-05	0.0134	0.17	0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87146352	chr4:87207092~87208086:+
STAD	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	4.2	3.36e-05	0.0134	0.23	0.22	Height;	chr5:37535278	chr5:36666214~36725195:-
STAD	cis	rs4589258	0.788	rs10734134	ENSG00000280367.1	RP11-121L10.2	-4.2	3.36e-05	0.0134	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90739668	chr11:90223153~90226538:+
STAD	cis	rs9907295	0.591	rs3817655	ENSG00000270894.1	AC015849.13	4.2	3.36e-05	0.0134	0.21	0.22	Fibroblast growth factor basic levels;	chr17:35872637	chr17:35818399~35823713:+
STAD	cis	rs5753618	0.509	rs1034589	ENSG00000236132.1	CTA-440B3.1	4.2	3.36e-05	0.0134	0.26	0.22	Colorectal cancer;	chr22:31183247	chr22:31816379~31817491:-
STAD	cis	rs11089937	0.616	rs5757244	ENSG00000211639.2	IGLV4-60	4.2	3.36e-05	0.0134	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22176637	chr22:22162199~22162681:+
STAD	cis	rs6585424	1	rs35025775	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164529	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs34749786	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164634	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs61860024	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165607	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs61860025	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165798	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs12411386	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166475	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs2228427	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166962	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs34332933	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166994	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs61860035	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172697	chr10:79663088~79826594:-
STAD	cis	rs6585424	0.85	rs75804987	ENSG00000225484.5	NUTM2B-AS1	-4.2	3.36e-05	0.0134	-0.4	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172753	chr10:79663088~79826594:-
STAD	cis	rs416603	0.967	rs7191538	ENSG00000262703.1	RP11-485G7.6	-4.2	3.36e-05	0.0134	-0.21	-0.22	Type 1 diabetes;	chr16:11269532	chr16:11348143~11349321:-
STAD	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	4.2	3.36e-05	0.0134	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	4.2	3.36e-05	0.0134	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	4.2	3.36e-05	0.0134	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
STAD	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-4.2	3.36e-05	0.0134	-0.23	-0.22	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
STAD	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-4.2	3.36e-05	0.0134	-0.27	-0.22	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-4.2	3.36e-05	0.0134	-0.27	-0.22	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-4.2	3.36e-05	0.0134	-0.27	-0.22	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
STAD	cis	rs2657294	0.73	rs1259505	ENSG00000226051.5	ZNF503-AS1	-4.2	3.36e-05	0.0134	-0.29	-0.22	Pneumonia;	chr10:75237183	chr10:75269819~75373500:+
STAD	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	4.2	3.36e-05	0.0134	0.26	0.22	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
STAD	cis	rs11846409	0.86	rs74091720	ENSG00000211970.3	IGHV4-61	4.2	3.36e-05	0.0134	0.24	0.22	Rheumatic heart disease;	chr14:106638192	chr14:106639119~106639657:-
STAD	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	4.2	3.36e-05	0.0134	0.29	0.22	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	4.2	3.36e-05	0.0134	0.29	0.22	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	4.2	3.36e-05	0.0134	0.29	0.22	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
STAD	cis	rs11673344	0.548	rs2058852	ENSG00000226686.6	LINC01535	4.2	3.36e-05	0.0134	0.27	0.22	Obesity-related traits;	chr19:37673701	chr19:37251912~37265535:+
STAD	cis	rs12682352	0.602	rs11783966	ENSG00000254340.1	RP11-10A14.3	-4.2	3.37e-05	0.0134	-0.26	-0.22	Neuroticism;	chr8:8807637	chr8:9141424~9145435:+
STAD	cis	rs9733	0.596	rs12089731	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150675322	chr1:150568971~150569269:-
STAD	cis	rs9733	0.519	rs12095002	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150676773	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs12085275	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150677789	chr1:150568971~150569269:-
STAD	cis	rs9733	0.544	rs2867302	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150681174	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs2867301	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150681319	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs7538493	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150682945	chr1:150568971~150569269:-
STAD	cis	rs4970988	0.64	rs7524734	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Urate levels;	chr1:150683210	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs6685702	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150683831	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs7549795	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150684397	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs11204697	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150686495	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs7529998	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150690055	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs11803569	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150691601	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs1336898	ENSG00000274963.1	Metazoa_SRP	4.2	3.37e-05	0.0134	0.19	0.22	Tonsillectomy;	chr1:150692574	chr1:150568971~150569269:-
STAD	cis	rs55823223	0.503	rs9906971	ENSG00000267801.1	RP11-552F3.9	4.2	3.37e-05	0.0134	0.29	0.22	Psoriasis;	chr17:75852396	chr17:75876372~75879546:+
STAD	cis	rs2348418	0.765	rs10843117	ENSG00000247934.4	RP11-967K21.1	-4.2	3.37e-05	0.0134	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162457	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.765	rs10843118	ENSG00000247934.4	RP11-967K21.1	-4.2	3.37e-05	0.0134	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28164396	chr12:28163298~28190738:-
STAD	cis	rs4965006	0.915	rs7969545	ENSG00000226356.2	RPS6P20	-4.2	3.37e-05	0.0134	-0.27	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934612	chr12:131292068~131293176:-
STAD	cis	rs12571093	0.571	rs7899387	ENSG00000233590.1	RP11-153K11.3	4.2	3.37e-05	0.0134	0.3	0.22	Optic nerve measurement (disc area);	chr10:68293278	chr10:68233251~68242379:-
STAD	cis	rs6480314	0.522	rs10733841	ENSG00000233590.1	RP11-153K11.3	4.2	3.37e-05	0.0134	0.3	0.22	Optic nerve measurement (disc area);	chr10:68293520	chr10:68233251~68242379:-
STAD	cis	rs4237845	0.591	rs10747788	ENSG00000273805.1	RP11-620J15.4	-4.2	3.37e-05	0.0134	-0.26	-0.22	Intelligence (multi-trait analysis);	chr12:57921555	chr12:57894232~57896846:+
STAD	cis	rs1876905	0.68	rs434034	ENSG00000230177.1	RP5-1112D6.4	-4.2	3.37e-05	0.0134	-0.26	-0.22	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111277932~111278742:+
STAD	cis	rs1707322	0.928	rs7527244	ENSG00000281133.1	AL355480.3	-4.2	3.37e-05	0.0134	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45580892~45580996:-
STAD	cis	rs12682352	0.602	rs6993494	ENSG00000254340.1	RP11-10A14.3	4.2	3.38e-05	0.0135	0.27	0.22	Neuroticism;	chr8:8809934	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-4.2	3.38e-05	0.0135	-0.29	-0.22	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
STAD	cis	rs2836974	0.568	rs428602	ENSG00000238141.2	BRWD1-AS1	4.2	3.38e-05	0.0135	0.22	0.22	Cognitive function;	chr21:39175078	chr21:39315707~39323218:+
STAD	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	4.2	3.38e-05	0.0135	0.26	0.22	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
STAD	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-4.2	3.38e-05	0.0135	-0.29	-0.22	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
STAD	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	4.2	3.38e-05	0.0135	0.27	0.22	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
STAD	cis	rs9902453	0.817	rs55974138	ENSG00000263477.1	RP11-338L22.2	4.2	3.38e-05	0.0135	0.18	0.22	Coffee consumption (cups per day);	chr17:29888528	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.845	rs2321493	ENSG00000263477.1	RP11-338L22.2	4.2	3.38e-05	0.0135	0.18	0.22	Coffee consumption (cups per day);	chr17:29903341	chr17:29863402~29866092:+
STAD	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-4.2	3.38e-05	0.0135	-0.25	-0.22	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
STAD	cis	rs7103648	0.669	rs7114011	ENSG00000280615.1	Y_RNA	4.2	3.38e-05	0.0135	0.23	0.22	Systolic blood pressure;Diastolic blood pressure;	chr11:47789757	chr11:47614898~47614994:-
STAD	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	4.2	3.38e-05	0.0135	0.31	0.22	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
STAD	cis	rs4950322	0.58	rs1813002	ENSG00000278811.3	LINC00624	4.2	3.38e-05	0.0135	0.23	0.22	Protein quantitative trait loci;	chr1:147112579	chr1:147258885~147517875:-
STAD	cis	rs10129255	0.957	rs8009073	ENSG00000232216.1	IGHV3-43	4.2	3.38e-05	0.0135	0.23	0.22	Kawasaki disease;	chr14:106777278	chr14:106470264~106470800:-
STAD	cis	rs7474896	1	rs11011366	ENSG00000099251.13	HSD17B7P2	4.2	3.38e-05	0.0135	0.36	0.22	Obesity (extreme);	chr10:37785230	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs11011370	ENSG00000099251.13	HSD17B7P2	4.2	3.38e-05	0.0135	0.36	0.22	Obesity (extreme);	chr10:37794090	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs11595684	ENSG00000099251.13	HSD17B7P2	4.2	3.38e-05	0.0135	0.36	0.22	Obesity (extreme);	chr10:37794876	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs12763390	ENSG00000099251.13	HSD17B7P2	4.2	3.38e-05	0.0135	0.36	0.22	Obesity (extreme);	chr10:37795504	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs11011372	ENSG00000099251.13	HSD17B7P2	4.2	3.38e-05	0.0135	0.36	0.22	Obesity (extreme);	chr10:37798355	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs35951606	ENSG00000099251.13	HSD17B7P2	4.2	3.38e-05	0.0135	0.36	0.22	Obesity (extreme);	chr10:37799419	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs3824584	ENSG00000099251.13	HSD17B7P2	4.2	3.38e-05	0.0135	0.36	0.22	Obesity (extreme);	chr10:37802381	chr10:38356380~38378505:+
STAD	cis	rs11673344	0.583	rs7254411	ENSG00000267672.1	CTD-2293H3.1	4.2	3.39e-05	0.0135	0.21	0.22	Obesity-related traits;	chr19:37034969	chr19:37091341~37092564:+
STAD	cis	rs7474896	0.559	rs1208645	ENSG00000120555.12	SEPT7P9	-4.2	3.39e-05	0.0135	-0.27	-0.22	Obesity (extreme);	chr10:37843159	chr10:38383069~38402916:-
STAD	cis	rs3811273	0.614	rs8003694	ENSG00000211816.2	TRAV38-1	-4.2	3.39e-05	0.0135	-0.27	-0.22	Periodontal disease-related phenotypes;	chr14:22264736	chr14:22271968~22272563:+
STAD	cis	rs6903823	0.508	rs1150726	ENSG00000220721.1	OR1F12	4.2	3.39e-05	0.0135	0.21	0.22	Pulmonary function;	chr6:28275265	chr6:28073316~28074233:+
STAD	cis	rs227275	0.556	rs724447	ENSG00000248971.2	KRT8P46	4.2	3.39e-05	0.0135	0.22	0.22	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102728746~102730171:-
STAD	cis	rs806321	0.556	rs2066634	ENSG00000237152.3	DLEU7-AS1	-4.2	3.39e-05	0.0135	-0.25	-0.22	Multiple sclerosis;	chr13:50190346	chr13:50807856~50849905:+
STAD	cis	rs3811273	0.614	rs4982598	ENSG00000211816.2	TRAV38-1	-4.2	3.39e-05	0.0135	-0.27	-0.22	Periodontal disease-related phenotypes;	chr14:22267740	chr14:22271968~22272563:+
STAD	cis	rs8062405	1	rs80275162	ENSG00000278665.1	RP11-666O2.4	4.2	3.39e-05	0.0135	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28599241~28601881:-
STAD	cis	rs749052	0.831	rs115560780	ENSG00000251485.1	AC068134.10	4.2	3.4e-05	0.0135	0.53	0.22	Height;	chr2:231934967	chr2:232343116~232343903:+
STAD	cis	rs749052	0.634	rs73995024	ENSG00000251485.1	AC068134.10	4.2	3.4e-05	0.0135	0.53	0.22	Height;	chr2:231935135	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs2580818	ENSG00000251485.1	AC068134.10	4.2	3.4e-05	0.0135	0.53	0.22	Height;	chr2:231937593	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs2580819	ENSG00000251485.1	AC068134.10	4.2	3.4e-05	0.0135	0.53	0.22	Height;	chr2:231937668	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs2580820	ENSG00000251485.1	AC068134.10	4.2	3.4e-05	0.0135	0.53	0.22	Height;	chr2:231938154	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs2580821	ENSG00000251485.1	AC068134.10	4.2	3.4e-05	0.0135	0.53	0.22	Height;	chr2:231939445	chr2:232343116~232343903:+
STAD	cis	rs11098499	0.955	rs35434465	ENSG00000260091.1	RP11-33B1.4	4.2	3.4e-05	0.0135	0.21	0.22	Corneal astigmatism;	chr4:119248223	chr4:119409333~119410233:+
STAD	cis	rs2562456	0.833	rs552800	ENSG00000268119.4	CTD-2561J22.5	-4.2	3.4e-05	0.0135	-0.28	-0.22	Pain;	chr19:21301840	chr19:21444241~21463908:-
STAD	cis	rs3829655	0.504	rs7251234	ENSG00000273837.1	LLNLR-470E3.1	4.2	3.4e-05	0.0135	0.23	0.22	Cerebrospinal fluid biomarker levels;	chr19:51614767	chr19:51639478~51639931:-
STAD	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	4.2	3.4e-05	0.0135	0.37	0.22	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
STAD	cis	rs12745968	0.566	rs2107518	ENSG00000229052.2	RP11-386I23.1	-4.2	3.4e-05	0.0135	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92782278	chr1:92930696~92934098:+
STAD	cis	rs17507216	0.718	rs28587782	ENSG00000255769.6	GOLGA2P10	-4.2	3.4e-05	0.0135	-0.36	-0.22	Excessive daytime sleepiness;	chr15:82576881	chr15:82472993~82513950:-
STAD	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	4.2	3.4e-05	0.0135	0.21	0.22	Breast size;	chr12:9228263	chr12:9277235~9313241:+
STAD	cis	rs55702914	0.809	rs2914982	ENSG00000231621.1	AC013264.2	4.2	3.4e-05	0.0135	0.19	0.22	Major depression and alcohol dependence;	chr2:197338069	chr2:197197991~197199273:+
STAD	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-4.2	3.4e-05	0.0135	-0.27	-0.22	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
STAD	cis	rs10129255	0.509	rs756583	ENSG00000211973.2	IGHV1-69	4.2	3.41e-05	0.0135	0.19	0.22	Kawasaki disease;	chr14:106680002	chr14:106714684~106715181:-
STAD	cis	rs2638953	0.853	rs10506036	ENSG00000247934.4	RP11-967K21.1	4.2	3.41e-05	0.0135	0.25	0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497632	chr12:28163298~28190738:-
STAD	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	4.2	3.41e-05	0.0135	0.29	0.22	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
STAD	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	4.2	3.41e-05	0.0136	0.31	0.22	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
STAD	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-4.2	3.41e-05	0.0136	-0.29	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
STAD	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	4.2	3.41e-05	0.0136	0.24	0.22	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
STAD	cis	rs7769051	1	rs10484629	ENSG00000179073.6	TAAR3	-4.2	3.41e-05	0.0136	-0.37	-0.22	Type 2 diabetes nephropathy;	chr6:132796731	chr6:132608225~132609302:-
STAD	cis	rs7769051	1	rs3813347	ENSG00000179073.6	TAAR3	-4.2	3.41e-05	0.0136	-0.37	-0.22	Type 2 diabetes nephropathy;	chr6:132798639	chr6:132608225~132609302:-
STAD	cis	rs6430585	0.583	rs12475516	ENSG00000231890.6	DARS-AS1	-4.2	3.41e-05	0.0136	-0.23	-0.22	Corneal structure;	chr2:135803191	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.583	rs2304370	ENSG00000231890.6	DARS-AS1	-4.2	3.41e-05	0.0136	-0.23	-0.22	Corneal structure;	chr2:135804165	chr2:135985176~136022593:+
STAD	cis	rs11846409	0.86	rs59055020	ENSG00000211970.3	IGHV4-61	4.2	3.41e-05	0.0136	0.24	0.22	Rheumatic heart disease;	chr14:106631573	chr14:106639119~106639657:-
STAD	cis	rs8014252	0.803	rs17108264	ENSG00000259158.2	ADAM20P1	-4.2	3.41e-05	0.0136	-0.3	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70599767	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs57598551	ENSG00000259158.2	ADAM20P1	-4.2	3.41e-05	0.0136	-0.3	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70601684	chr14:70468881~70483756:-
STAD	cis	rs4237845	0.967	rs4553410	ENSG00000273805.1	RP11-620J15.4	-4.2	3.41e-05	0.0136	-0.24	-0.22	Intelligence (multi-trait analysis);	chr12:57907428	chr12:57894232~57896846:+
STAD	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-4.2	3.42e-05	0.0136	-0.34	-0.22	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-4.2	3.42e-05	0.0136	-0.34	-0.22	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
STAD	cis	rs919433	0.929	rs10931779	ENSG00000231621.1	AC013264.2	4.2	3.42e-05	0.0136	0.18	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197302101	chr2:197197991~197199273:+
STAD	cis	rs1799949	1	rs3950989	ENSG00000279602.1	CTD-3014M21.1	4.2	3.42e-05	0.0136	0.28	0.22	Menopause (age at onset);	chr17:43085936	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs8176161	ENSG00000279602.1	CTD-3014M21.1	4.2	3.42e-05	0.0136	0.28	0.22	Menopause (age at onset);	chr17:43089373	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.894	rs8176160	ENSG00000279602.1	CTD-3014M21.1	4.2	3.42e-05	0.0136	0.28	0.22	Menopause (age at onset);	chr17:43089486	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs2070834	ENSG00000279602.1	CTD-3014M21.1	4.2	3.42e-05	0.0136	0.28	0.22	Menopause (age at onset);	chr17:43090268	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs16942	ENSG00000279602.1	CTD-3014M21.1	4.2	3.42e-05	0.0136	0.28	0.22	Menopause (age at onset);	chr17:43091983	chr17:43360041~43361361:-
STAD	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-4.2	3.42e-05	0.0136	-0.26	-0.22	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
STAD	cis	rs2836950	0.772	rs62222988	ENSG00000238141.2	BRWD1-AS1	-4.2	3.42e-05	0.0136	-0.25	-0.22	Menarche (age at onset);	chr21:39197582	chr21:39315707~39323218:+
STAD	cis	rs1009077	0.514	rs62319578	ENSG00000260091.1	RP11-33B1.4	-4.2	3.42e-05	0.0136	-0.28	-0.22	Endometriosis;	chr4:119487266	chr4:119409333~119410233:+
STAD	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-4.2	3.42e-05	0.0136	-0.27	-0.22	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-4.2	3.42e-05	0.0136	-0.27	-0.22	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-4.2	3.42e-05	0.0136	-0.27	-0.22	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-4.2	3.42e-05	0.0136	-0.27	-0.22	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-4.2	3.42e-05	0.0136	-0.27	-0.22	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-4.2	3.42e-05	0.0136	-0.27	-0.22	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-4.2	3.42e-05	0.0136	-0.27	-0.22	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
STAD	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	4.2	3.42e-05	0.0136	0.3	0.22	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
STAD	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	4.2	3.42e-05	0.0136	0.23	0.22	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
STAD	cis	rs1528149	0.504	rs12537888	ENSG00000224683.1	RPL36AP29	-4.2	3.42e-05	0.0136	-0.23	-0.22	Sitting height ratio;	chr7:16127873	chr7:16208945~16209265:+
STAD	cis	rs9467773	1	rs12526680	ENSG00000241549.7	GUSBP2	4.2	3.42e-05	0.0136	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26871484~26956554:-
STAD	cis	rs9291683	0.588	rs2240721	ENSG00000250613.1	RP11-136I13.1	-4.2	3.42e-05	0.0136	-0.2	-0.22	Bone mineral density;	chr4:10018940	chr4:10410996~10411644:+
STAD	cis	rs4792901	0.765	rs35557239	ENSG00000279602.1	CTD-3014M21.1	-4.2	3.42e-05	0.0136	-0.3	-0.22	Dupuytren's disease;	chr17:43470907	chr17:43360041~43361361:-
STAD	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-4.2	3.43e-05	0.0136	-0.22	-0.22	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
STAD	cis	rs593531	0.571	rs3862799	ENSG00000280269.1	AP000577.2	-4.2	3.43e-05	0.0136	-0.23	-0.22	Neuroticism;	chr11:74339217	chr11:74204869~74205746:+
STAD	cis	rs593531	0.55	rs592644	ENSG00000280269.1	AP000577.2	-4.2	3.43e-05	0.0136	-0.23	-0.22	Neuroticism;	chr11:74342502	chr11:74204869~74205746:+
STAD	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	4.2	3.43e-05	0.0136	0.27	0.22	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
STAD	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	4.2	3.43e-05	0.0136	0.37	0.22	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
STAD	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	4.2	3.43e-05	0.0136	0.37	0.22	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
STAD	cis	rs55823223	0.564	rs58363746	ENSG00000267801.1	RP11-552F3.9	4.2	3.43e-05	0.0136	0.29	0.22	Psoriasis;	chr17:75854738	chr17:75876372~75879546:+
STAD	cis	rs1707322	1	rs4073847	ENSG00000225447.1	RPS15AP10	-4.2	3.43e-05	0.0136	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45645816~45646197:-
STAD	cis	rs10073892	0.789	rs56268211	ENSG00000250682.4	LINC00491	-4.2	3.43e-05	0.0136	-0.25	-0.22	Cognitive decline (age-related);	chr5:102420540	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.789	rs111400704	ENSG00000250682.4	LINC00491	-4.2	3.43e-05	0.0136	-0.25	-0.22	Cognitive decline (age-related);	chr5:102420896	chr5:102609156~102671559:-
STAD	cis	rs4713118	0.615	rs9295747	ENSG00000280107.1	AL022393.9	4.2	3.43e-05	0.0136	0.27	0.22	Parkinson's disease;	chr6:27769214	chr6:28170845~28172521:+
STAD	cis	rs2638953	0.962	rs61922969	ENSG00000247934.4	RP11-967K21.1	-4.2	3.43e-05	0.0136	-0.26	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261721	chr12:28163298~28190738:-
STAD	cis	rs2933343	0.818	rs6764681	ENSG00000261159.1	RP11-723O4.9	-4.2	3.43e-05	0.0136	-0.29	-0.22	IgG glycosylation;	chr3:128849537	chr3:128859716~128860526:-
STAD	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	4.2	3.43e-05	0.0136	0.43	0.22	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	4.2	3.43e-05	0.0136	0.43	0.22	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	4.2	3.43e-05	0.0136	0.43	0.22	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	4.2	3.43e-05	0.0136	0.43	0.22	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	4.2	3.43e-05	0.0136	0.43	0.22	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
STAD	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	4.2	3.43e-05	0.0136	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
STAD	cis	rs2348418	0.966	rs7315631	ENSG00000247934.4	RP11-967K21.1	4.2	3.44e-05	0.0136	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28545311	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.966	rs7316351	ENSG00000247934.4	RP11-967K21.1	4.2	3.44e-05	0.0136	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28545595	chr12:28163298~28190738:-
STAD	cis	rs72079386	1	rs72079386	ENSG00000230606.9	AC159540.1	-4.2	3.44e-05	0.0137	-0.25	-0.22	Sum eosinophil basophil counts;	chr2:96565885	chr2:97416165~97433527:-
STAD	cis	rs34779708	0.931	rs72789609	ENSG00000271335.4	RP11-324I22.4	4.2	3.44e-05	0.0137	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs7908573	ENSG00000271335.4	RP11-324I22.4	4.2	3.44e-05	0.0137	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs17583009	ENSG00000271335.4	RP11-324I22.4	4.2	3.44e-05	0.0137	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.898	rs11595898	ENSG00000271335.4	RP11-324I22.4	4.2	3.44e-05	0.0137	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs35886556	ENSG00000271335.4	RP11-324I22.4	4.2	3.44e-05	0.0137	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35314552~35336401:-
STAD	cis	rs1799949	0.93	rs3765640	ENSG00000279602.1	CTD-3014M21.1	4.2	3.44e-05	0.0137	0.28	0.22	Menopause (age at onset);	chr17:43124230	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs8176077	ENSG00000279602.1	CTD-3014M21.1	4.2	3.44e-05	0.0137	0.28	0.22	Menopause (age at onset);	chr17:43124331	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11655505	ENSG00000279602.1	CTD-3014M21.1	4.2	3.44e-05	0.0137	0.28	0.22	Menopause (age at onset);	chr17:43126360	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs4793204	ENSG00000279602.1	CTD-3014M21.1	4.2	3.44e-05	0.0137	0.28	0.22	Menopause (age at onset);	chr17:43127281	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs12947782	ENSG00000279602.1	CTD-3014M21.1	4.2	3.44e-05	0.0137	0.28	0.22	Menopause (age at onset);	chr17:43127865	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs33945274	ENSG00000279602.1	CTD-3014M21.1	4.2	3.44e-05	0.0137	0.28	0.22	Menopause (age at onset);	chr17:43128056	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs11653069	ENSG00000279602.1	CTD-3014M21.1	4.2	3.44e-05	0.0137	0.28	0.22	Menopause (age at onset);	chr17:43131360	chr17:43360041~43361361:-
STAD	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-4.2	3.44e-05	0.0137	-0.24	-0.22	Height;	chr2:231559006	chr2:231508426~231514339:-
STAD	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	4.2	3.44e-05	0.0137	0.32	0.22	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
STAD	cis	rs10851478	1	rs10851478	ENSG00000259545.2	RP11-325E5.4	-4.2	3.44e-05	0.0137	-0.25	-0.22	Oral cavity cancer;	chr15:49536822	chr15:49177610~49178741:-
STAD	cis	rs11098499	0.754	rs10518300	ENSG00000260091.1	RP11-33B1.4	-4.2	3.44e-05	0.0137	-0.22	-0.22	Corneal astigmatism;	chr4:119328344	chr4:119409333~119410233:+
STAD	cis	rs9733	0.596	rs6587516	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150650745	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs6678013	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150650809	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs2175615	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150651625	chr1:150568971~150569269:-
STAD	cis	rs9733	0.628	rs72700895	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150653553	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72700897	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150653562	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs6661872	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150655881	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs11204687	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150657404	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs2867304	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150658519	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs6690725	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150659846	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs72702504	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150662898	chr1:150568971~150569269:-
STAD	cis	rs9733	0.536	rs6661415	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150663393	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs11807058	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150667999	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs34140753	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150670107	chr1:150568971~150569269:-
STAD	cis	rs9733	0.569	rs11204691	ENSG00000274963.1	Metazoa_SRP	4.2	3.44e-05	0.0137	0.19	0.22	Tonsillectomy;	chr1:150671863	chr1:150568971~150569269:-
STAD	cis	rs4237845	0.788	rs6581157	ENSG00000273805.1	RP11-620J15.4	-4.2	3.45e-05	0.0137	-0.25	-0.22	Intelligence (multi-trait analysis);	chr12:57895010	chr12:57894232~57896846:+
STAD	cis	rs11098499	0.955	rs1511019	ENSG00000260091.1	RP11-33B1.4	4.2	3.45e-05	0.0137	0.22	0.22	Corneal astigmatism;	chr4:119244852	chr4:119409333~119410233:+
STAD	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	4.2	3.45e-05	0.0137	0.24	0.22	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
STAD	cis	rs7429990	0.93	rs71323371	ENSG00000224895.1	VPS26BP1	-4.2	3.45e-05	0.0137	-0.22	-0.22	Educational attainment (years of education);	chr3:47904327	chr3:47960327~47961081:-
STAD	cis	rs3858145	0.588	rs731063	ENSG00000234102.1	KRT19P4	4.2	3.45e-05	0.0137	0.25	0.22	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68260557~68261499:+
STAD	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	4.2	3.45e-05	0.0137	0.3	0.22	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
STAD	cis	rs9549328	0.842	rs6577024	ENSG00000267868.1	RP11-120K24.3	4.2	3.46e-05	0.0137	0.31	0.22	Systolic blood pressure;	chr13:112979777	chr13:112964835~112966131:-
STAD	cis	rs9549328	0.718	rs7139939	ENSG00000267868.1	RP11-120K24.3	4.2	3.46e-05	0.0137	0.31	0.22	Systolic blood pressure;	chr13:112980095	chr13:112964835~112966131:-
STAD	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	4.2	3.46e-05	0.0137	0.27	0.22	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.932	rs73378155	ENSG00000274576.2	IGHV2-70	-4.2	3.46e-05	0.0137	-0.26	-0.22	Rheumatic heart disease;	chr14:106637840	chr14:106770577~106771020:-
STAD	cis	rs7829975	0.514	rs2945873	ENSG00000254340.1	RP11-10A14.3	4.2	3.46e-05	0.0137	0.25	0.22	Mood instability;	chr8:8402935	chr8:9141424~9145435:+
STAD	cis	rs2562456	0.833	rs2928211	ENSG00000268119.4	CTD-2561J22.5	-4.2	3.46e-05	0.0137	-0.28	-0.22	Pain;	chr19:21358495	chr19:21444241~21463908:-
STAD	cis	rs4561483	0.815	rs7198817	ENSG00000260224.1	UBL5P4	-4.2	3.46e-05	0.0137	-0.22	-0.22	Testicular germ cell tumor;	chr16:11851921	chr16:11968508~11968743:-
STAD	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	4.2	3.46e-05	0.0137	0.3	0.22	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
STAD	cis	rs11846409	0.629	rs76295389	ENSG00000211970.3	IGHV4-61	-4.2	3.47e-05	0.0137	-0.24	-0.22	Rheumatic heart disease;	chr14:106650437	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.698	rs71419854	ENSG00000211970.3	IGHV4-61	-4.2	3.47e-05	0.0137	-0.24	-0.22	Rheumatic heart disease;	chr14:106650440	chr14:106639119~106639657:-
STAD	cis	rs2337406	0.5	rs71419855	ENSG00000211970.3	IGHV4-61	-4.2	3.47e-05	0.0137	-0.24	-0.22	Alzheimer's disease (late onset);	chr14:106650444	chr14:106639119~106639657:-
STAD	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-4.2	3.47e-05	0.0137	-0.26	-0.22	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
STAD	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-4.2	3.47e-05	0.0137	-0.26	-0.22	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
STAD	cis	rs7139978	0.516	rs9547912	ENSG00000230390.1	LINC01048	-4.2	3.47e-05	0.0138	-0.24	-0.22	Life satisfaction;	chr13:37496998	chr13:37481467~37484769:-
STAD	cis	rs870825	0.616	rs6843185	ENSG00000249173.4	LINC01093	-4.2	3.47e-05	0.0138	-0.36	-0.22	Blood protein levels;	chr4:184728724	chr4:184893871~184899454:-
STAD	cis	rs801193	0.548	rs2659904	ENSG00000224316.1	RP11-479O9.2	4.2	3.47e-05	0.0138	0.22	0.22	Aortic root size;	chr7:66713615	chr7:65773620~65802067:+
STAD	cis	rs1707322	1	rs6661500	ENSG00000225447.1	RPS15AP10	4.2	3.47e-05	0.0138	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45645816~45646197:-
STAD	cis	rs2734839	0.964	rs7131440	ENSG00000270179.1	RP11-159N11.4	4.19	3.48e-05	0.0138	0.25	0.22	Information processing speed;	chr11:113429188	chr11:113368478~113369117:+
STAD	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-4.19	3.48e-05	0.0138	-0.38	-0.22	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
STAD	cis	rs748404	0.586	rs2584700	ENSG00000275601.1	AC011330.13	-4.19	3.48e-05	0.0138	-0.23	-0.22	Lung cancer;	chr15:43393134	chr15:43642389~43643023:-
STAD	cis	rs9463078	0.547	rs2038557	ENSG00000219384.1	RP11-491H9.3	-4.19	3.48e-05	0.0138	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44772734	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.505	rs2038556	ENSG00000219384.1	RP11-491H9.3	-4.19	3.48e-05	0.0138	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44772831	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs4714822	ENSG00000219384.1	RP11-491H9.3	-4.19	3.48e-05	0.0138	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44774553	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.527	rs2040032	ENSG00000219384.1	RP11-491H9.3	-4.19	3.48e-05	0.0138	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44775272	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs2038555	ENSG00000219384.1	RP11-491H9.3	-4.19	3.48e-05	0.0138	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44776296	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs9472360	ENSG00000219384.1	RP11-491H9.3	-4.19	3.48e-05	0.0138	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44779673	chr6:45158870~45159511:+
STAD	cis	rs6142102	1	rs4911412	ENSG00000275784.1	RP5-1125A11.6	-4.19	3.48e-05	0.0138	-0.23	-0.22	Skin pigmentation;	chr20:34128629	chr20:33989480~33991818:-
STAD	cis	rs9902453	0.808	rs12452288	ENSG00000263477.1	RP11-338L22.2	4.19	3.48e-05	0.0138	0.18	0.22	Coffee consumption (cups per day);	chr17:29908202	chr17:29863402~29866092:+
STAD	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	4.19	3.48e-05	0.0138	0.29	0.22	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
STAD	cis	rs6686842	0.513	rs11579483	ENSG00000235358.1	RP11-399E6.1	-4.19	3.48e-05	0.0138	-0.24	-0.22	Height;	chr1:41014192	chr1:41242373~41284861:+
STAD	cis	rs832540	0.669	rs173764	ENSG00000271828.1	CTD-2310F14.1	4.19	3.48e-05	0.0138	0.27	0.22	Coronary artery disease;	chr5:56903093	chr5:56927874~56929573:+
STAD	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-4.19	3.48e-05	0.0138	-0.25	-0.22	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
STAD	cis	rs2901460	0.587	rs12990282	ENSG00000229503.1	AC092155.1	-4.19	3.48e-05	0.0138	-0.19	-0.22	Mean corpuscular volume;	chr2:62186219	chr2:62532583~62533059:-
STAD	cis	rs7829975	0.742	rs1533059	ENSG00000233609.3	RP11-62H7.2	-4.19	3.48e-05	0.0138	-0.23	-0.22	Mood instability;	chr8:8827443	chr8:8961200~8979025:+
STAD	cis	rs8012947	0.92	rs7154498	ENSG00000279636.2	LINC00216	-4.19	3.48e-05	0.0138	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58295814	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.92	rs7155825	ENSG00000279636.2	LINC00216	-4.19	3.48e-05	0.0138	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58295819	chr14:58288033~58289158:+
STAD	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	4.19	3.48e-05	0.0138	0.3	0.22	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
STAD	cis	rs858239	0.932	rs858275	ENSG00000230042.1	AK3P3	-4.19	3.48e-05	0.0138	-0.23	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23129178~23129841:+
STAD	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	4.19	3.48e-05	0.0138	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
STAD	cis	rs1799949	0.931	rs34410138	ENSG00000279602.1	CTD-3014M21.1	4.19	3.49e-05	0.0138	0.28	0.22	Menopause (age at onset);	chr17:43127753	chr17:43360041~43361361:-
STAD	cis	rs12908161	0.96	rs11633450	ENSG00000259295.5	CSPG4P12	4.19	3.49e-05	0.0138	0.32	0.22	Schizophrenia;	chr15:84764056	chr15:85191438~85213905:+
STAD	cis	rs539514	0.69	rs585233	ENSG00000261105.4	LMO7-AS1	-4.19	3.49e-05	0.0138	-0.27	-0.22	Type 1 diabetes;	chr13:75743837	chr13:75604700~75635994:-
STAD	cis	rs34929064	0.846	rs2905340	ENSG00000179428.2	AC073072.5	4.19	3.49e-05	0.0138	0.24	0.22	Major depression and alcohol dependence;	chr7:22687579	chr7:22725395~22727620:-
STAD	cis	rs34929064	0.881	rs2961311	ENSG00000179428.2	AC073072.5	4.19	3.49e-05	0.0138	0.24	0.22	Major depression and alcohol dependence;	chr7:22687919	chr7:22725395~22727620:-
STAD	cis	rs9463078	0.625	rs1891412	ENSG00000219384.1	RP11-491H9.3	-4.19	3.49e-05	0.0138	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44792905	chr6:45158870~45159511:+
STAD	cis	rs7209700	0.788	rs12949936	ENSG00000228782.6	CTD-2026D20.3	-4.19	3.49e-05	0.0138	-0.22	-0.22	IgG glycosylation;	chr17:47295056	chr17:47450568~47492492:-
STAD	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	4.19	3.49e-05	0.0138	0.23	0.22	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
STAD	cis	rs6430585	0.583	rs730005	ENSG00000231890.6	DARS-AS1	-4.19	3.49e-05	0.0138	-0.26	-0.22	Corneal structure;	chr2:135825124	chr2:135985176~136022593:+
STAD	cis	rs17401966	0.931	rs4846213	ENSG00000199562.1	RNU6-37P	4.19	3.49e-05	0.0138	0.17	0.22	Hepatocellular carcinoma;	chr1:10339120	chr1:10298966~10299072:+
STAD	cis	rs561341	1	rs55959993	ENSG00000265798.5	RP11-271K11.5	4.19	3.49e-05	0.0138	0.34	0.22	Hip circumference adjusted for BMI;	chr17:31927752	chr17:31038575~31059121:-
STAD	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	4.19	3.49e-05	0.0138	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	4.19	3.49e-05	0.0138	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
STAD	cis	rs1707322	1	rs11211190	ENSG00000225447.1	RPS15AP10	4.19	3.49e-05	0.0138	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs6429580	ENSG00000225447.1	RPS15AP10	4.19	3.49e-05	0.0138	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45645816~45646197:-
STAD	cis	rs2980439	0.556	rs2921059	ENSG00000254340.1	RP11-10A14.3	4.19	3.5e-05	0.0138	0.26	0.22	Neuroticism;	chr8:8460377	chr8:9141424~9145435:+
STAD	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-4.19	3.5e-05	0.0138	-0.29	-0.22	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
STAD	cis	rs7474896	0.887	rs10827844	ENSG00000099251.13	HSD17B7P2	4.19	3.5e-05	0.0138	0.36	0.22	Obesity (extreme);	chr10:38065366	chr10:38356380~38378505:+
STAD	cis	rs11846409	0.86	rs73378154	ENSG00000211970.3	IGHV4-61	4.19	3.5e-05	0.0139	0.24	0.22	Rheumatic heart disease;	chr14:106637687	chr14:106639119~106639657:-
STAD	cis	rs6901004	0.605	rs2297939	ENSG00000230177.1	RP5-1112D6.4	-4.19	3.5e-05	0.0139	-0.21	-0.22	Blood metabolite levels;	chr6:111227959	chr6:111277932~111278742:+
STAD	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	4.19	3.5e-05	0.0139	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	4.19	3.5e-05	0.0139	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
STAD	cis	rs9393777	0.545	rs56303243	ENSG00000241549.7	GUSBP2	4.19	3.5e-05	0.0139	0.31	0.22	Intelligence (multi-trait analysis);	chr6:26485499	chr6:26871484~26956554:-
STAD	cis	rs9307551	0.584	rs1371996	ENSG00000250334.4	LINC00989	-4.19	3.5e-05	0.0139	-0.26	-0.22	Refractive error;	chr4:79532718	chr4:79492416~79576460:+
STAD	cis	rs1707322	0.827	rs12125508	ENSG00000281133.1	AL355480.3	-4.19	3.5e-05	0.0139	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45580892~45580996:-
STAD	cis	rs393951	0.957	rs280867	ENSG00000260969.1	RP11-190D6.2	-4.19	3.5e-05	0.0139	-0.27	-0.22	Childhood ear infection;	chr16:77619337	chr16:78237362~78241218:-
STAD	cis	rs393951	0.957	rs280865	ENSG00000260969.1	RP11-190D6.2	-4.19	3.5e-05	0.0139	-0.27	-0.22	Childhood ear infection;	chr16:77620099	chr16:78237362~78241218:-
STAD	cis	rs2348418	0.765	rs10843120	ENSG00000247934.4	RP11-967K21.1	-4.19	3.51e-05	0.0139	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28165881	chr12:28163298~28190738:-
STAD	cis	rs875971	0.545	rs7811204	ENSG00000273142.1	RP11-458F8.4	4.19	3.51e-05	0.0139	0.2	0.22	Aortic root size;	chr7:66387213	chr7:66902857~66906297:+
STAD	cis	rs10073892	0.62	rs12655805	ENSG00000250682.4	LINC00491	-4.19	3.51e-05	0.0139	-0.24	-0.22	Cognitive decline (age-related);	chr5:102591662	chr5:102609156~102671559:-
STAD	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	4.19	3.51e-05	0.0139	0.42	0.22	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
STAD	cis	rs1707322	1	rs34444543	ENSG00000281133.1	AL355480.3	-4.19	3.51e-05	0.0139	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45580892~45580996:-
STAD	cis	rs9329221	0.683	rs555200	ENSG00000254340.1	RP11-10A14.3	-4.19	3.51e-05	0.0139	-0.28	-0.22	Neuroticism;	chr8:10031219	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	4.19	3.51e-05	0.0139	0.29	0.22	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
STAD	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-4.19	3.51e-05	0.0139	-0.32	-0.22	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
STAD	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-4.19	3.51e-05	0.0139	-0.32	-0.22	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
STAD	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-4.19	3.51e-05	0.0139	-0.32	-0.22	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
STAD	cis	rs4589258	0.788	rs4296006	ENSG00000280367.1	RP11-121L10.2	4.19	3.52e-05	0.0139	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90773221	chr11:90223153~90226538:+
STAD	cis	rs2579500	0.807	rs6576976	ENSG00000230606.9	AC159540.1	4.19	3.52e-05	0.0139	0.26	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96580930	chr2:97416165~97433527:-
STAD	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	4.19	3.52e-05	0.0139	0.26	0.22	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
STAD	cis	rs9291683	0.588	rs3756238	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10011578	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.588	rs3756237	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10011754	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.588	rs3756236	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10011839	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.552	rs10939655	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10013018	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.517	rs11736479	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10015763	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.588	rs13113730	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10016004	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.588	rs6857693	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10016811	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.588	rs6844329	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10016920	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.588	rs3796829	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10017514	chr4:10410996~10411644:+
STAD	cis	rs3733585	0.773	rs13107466	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.588	rs13133766	ENSG00000250613.1	RP11-136I13.1	-4.19	3.52e-05	0.0139	-0.2	-0.22	Bone mineral density;	chr4:10018108	chr4:10410996~10411644:+
STAD	cis	rs4835473	0.932	rs1849136	ENSG00000249741.2	RP11-673E1.3	4.19	3.52e-05	0.0139	0.26	0.22	Immature fraction of reticulocytes;	chr4:143912380	chr4:143911514~143912053:-
STAD	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-4.19	3.52e-05	0.0139	-0.27	-0.22	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
STAD	cis	rs34779708	0.931	rs35848945	ENSG00000271335.4	RP11-324I22.4	4.19	3.52e-05	0.0139	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35314552~35336401:-
STAD	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-4.19	3.52e-05	0.0139	-0.26	-0.22	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
STAD	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	4.19	3.52e-05	0.0139	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
STAD	cis	rs749052	0.764	rs76842672	ENSG00000251485.1	AC068134.10	4.19	3.52e-05	0.0139	0.53	0.22	Height;	chr2:231943574	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs2679171	ENSG00000251485.1	AC068134.10	4.19	3.52e-05	0.0139	0.53	0.22	Height;	chr2:231945562	chr2:232343116~232343903:+
STAD	cis	rs4077341	0.966	rs12549481	ENSG00000253616.4	RP11-875O11.3	-4.19	3.53e-05	0.0139	-0.29	-0.22	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr8:23102545	chr8:23071377~23074488:-
STAD	cis	rs7429990	0.803	rs6776963	ENSG00000224895.1	VPS26BP1	4.19	3.53e-05	0.0139	0.22	0.22	Educational attainment (years of education);	chr3:47789251	chr3:47960327~47961081:-
STAD	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	4.19	3.53e-05	0.0139	0.28	0.22	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
STAD	cis	rs9902453	0.845	rs7222842	ENSG00000263477.1	RP11-338L22.2	4.19	3.53e-05	0.0139	0.18	0.22	Coffee consumption (cups per day);	chr17:29919925	chr17:29863402~29866092:+
STAD	cis	rs1009077	0.561	rs13107334	ENSG00000260091.1	RP11-33B1.4	-4.19	3.53e-05	0.0139	-0.26	-0.22	Endometriosis;	chr4:119503425	chr4:119409333~119410233:+
STAD	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-4.19	3.53e-05	0.014	-0.39	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-4.19	3.53e-05	0.014	-0.39	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-4.19	3.53e-05	0.014	-0.39	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-4.19	3.53e-05	0.014	-0.39	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
STAD	cis	rs4927850	1	rs7625570	ENSG00000278820.1	AC024937.1	4.19	3.53e-05	0.014	0.25	0.22	Pancreatic cancer;	chr3:196020527	chr3:195960500~195960612:-
STAD	cis	rs4927850	0.881	rs7624638	ENSG00000278820.1	AC024937.1	4.19	3.53e-05	0.014	0.25	0.22	Pancreatic cancer;	chr3:196021858	chr3:195960500~195960612:-
STAD	cis	rs4927850	1	rs10881564	ENSG00000278820.1	AC024937.1	4.19	3.53e-05	0.014	0.25	0.22	Pancreatic cancer;	chr3:196023455	chr3:195960500~195960612:-
STAD	cis	rs870825	0.616	rs7667409	ENSG00000249173.4	LINC01093	4.19	3.53e-05	0.014	0.36	0.22	Blood protein levels;	chr4:184729787	chr4:184893871~184899454:-
STAD	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-4.19	3.53e-05	0.014	-0.26	-0.22	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
STAD	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	4.19	3.53e-05	0.014	0.37	0.22	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
STAD	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	4.19	3.54e-05	0.014	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
STAD	cis	rs11157436	0.602	rs2075493	ENSG00000211812.1	TRAV26-2	-4.19	3.54e-05	0.014	-0.22	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163782	chr14:22202583~22203368:+
STAD	cis	rs2227564	0.533	rs3870402	ENSG00000271816.1	BMS1P4	4.19	3.54e-05	0.014	0.25	0.22	Crohn's disease;Inflammatory bowel disease;	chr10:73714029	chr10:73699151~73730487:-
STAD	cis	rs2227564	0.62	rs4746143	ENSG00000271816.1	BMS1P4	4.19	3.54e-05	0.014	0.25	0.22	Crohn's disease;Inflammatory bowel disease;	chr10:73717540	chr10:73699151~73730487:-
STAD	cis	rs5752326	0.702	rs3752589	ENSG00000261188.1	CTA-445C9.14	4.19	3.54e-05	0.014	0.41	0.22	Ischemic stroke;	chr22:26451620	chr22:26512537~26514568:+
STAD	cis	rs200986	1	rs200986	ENSG00000280107.1	AL022393.9	-4.19	3.54e-05	0.014	-0.28	-0.22	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28170845~28172521:+
STAD	cis	rs5758659	0.714	rs7245	ENSG00000182057.4	OGFRP1	-4.19	3.54e-05	0.014	-0.23	-0.22	Cognitive function;	chr22:42085845	chr22:42269753~42275196:+
STAD	cis	rs73198271	0.71	rs11779561	ENSG00000233609.3	RP11-62H7.2	-4.19	3.54e-05	0.014	-0.28	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8961200~8979025:+
STAD	cis	rs7487075	0.897	rs10880960	ENSG00000257261.4	RP11-96H19.1	4.19	3.54e-05	0.014	0.29	0.22	Itch intensity from mosquito bite;	chr12:46368046	chr12:46383679~46876159:+
STAD	cis	rs6585424	1	rs12769115	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.54e-05	0.014	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173745	chr10:79663088~79826594:-
STAD	cis	rs6585424	0.85	rs61860036	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.54e-05	0.014	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175103	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs12777867	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.54e-05	0.014	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175774	chr10:79663088~79826594:-
STAD	cis	rs451417	1	rs379418	ENSG00000275632.1	RP5-967N21.11	4.19	3.54e-05	0.014	0.29	0.22	Menopause (age at onset);	chr20:5961561	chr20:6000418~6000941:+
STAD	cis	rs11098499	0.604	rs2389886	ENSG00000260091.1	RP11-33B1.4	4.19	3.55e-05	0.014	0.22	0.22	Corneal astigmatism;	chr4:119649267	chr4:119409333~119410233:+
STAD	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	4.19	3.55e-05	0.014	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	4.19	3.55e-05	0.014	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	4.19	3.55e-05	0.014	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
STAD	cis	rs7615952	0.546	rs16836896	ENSG00000272840.1	RP11-379B18.6	4.19	3.55e-05	0.014	0.37	0.22	Blood pressure (smoking interaction);	chr3:125592418	chr3:125774714~125797953:+
STAD	cis	rs4132699	0.733	rs9410322	ENSG00000225460.1	RP13-93L13.1	-4.19	3.55e-05	0.014	-0.24	-0.22	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89456103	chr9:89472237~89472692:+
STAD	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	4.19	3.55e-05	0.014	0.44	0.22	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	4.19	3.55e-05	0.014	0.44	0.22	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
STAD	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	4.19	3.55e-05	0.014	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	4.19	3.55e-05	0.014	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
STAD	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-4.19	3.55e-05	0.014	-0.26	-0.22	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
STAD	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-4.19	3.55e-05	0.014	-0.26	-0.22	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
STAD	cis	rs9467773	0.596	rs62396201	ENSG00000243307.2	POM121L6P	4.19	3.55e-05	0.014	0.22	0.22	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26896952~26898777:+
STAD	cis	rs7665090	0.528	rs3774968	ENSG00000230069.3	LRRC37A15P	-4.19	3.55e-05	0.014	-0.25	-0.22	Primary biliary cholangitis;	chr4:102609955	chr4:102727274~102730721:-
STAD	cis	rs559928	0.597	rs947939	ENSG00000236935.1	AP003774.1	4.19	3.55e-05	0.014	0.36	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64117815	chr11:64325050~64329504:-
STAD	cis	rs9463078	0.605	rs4711799	ENSG00000219384.1	RP11-491H9.3	-4.19	3.56e-05	0.014	-0.2	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44798043	chr6:45158870~45159511:+
STAD	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	4.19	3.56e-05	0.014	0.35	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
STAD	cis	rs4589258	0.788	rs7126514	ENSG00000280367.1	RP11-121L10.2	4.19	3.56e-05	0.014	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90747080	chr11:90223153~90226538:+
STAD	cis	rs12682352	0.602	rs11783966	ENSG00000253981.4	ALG1L13P	-4.19	3.56e-05	0.014	-0.26	-0.22	Neuroticism;	chr8:8807637	chr8:8236003~8244667:-
STAD	cis	rs2638953	0.815	rs11049684	ENSG00000247934.4	RP11-967K21.1	-4.19	3.56e-05	0.014	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512426	chr12:28163298~28190738:-
STAD	cis	rs6479891	0.818	rs2393976	ENSG00000235816.3	PRELID1P3	4.19	3.56e-05	0.0141	0.28	0.22	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs72837056	ENSG00000235816.3	PRELID1P3	4.19	3.56e-05	0.0141	0.28	0.22	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63427297~63427939:+
STAD	cis	rs6479891	0.818	rs11815969	ENSG00000235816.3	PRELID1P3	4.19	3.56e-05	0.0141	0.28	0.22	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs72837070	ENSG00000235816.3	PRELID1P3	4.19	3.56e-05	0.0141	0.28	0.22	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs61853635	ENSG00000235816.3	PRELID1P3	4.19	3.56e-05	0.0141	0.28	0.22	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs4745729	ENSG00000235816.3	PRELID1P3	4.19	3.56e-05	0.0141	0.28	0.22	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs12416349	ENSG00000235816.3	PRELID1P3	4.19	3.56e-05	0.0141	0.28	0.22	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63427297~63427939:+
STAD	cis	rs6479891	0.908	rs7078456	ENSG00000235816.3	PRELID1P3	-4.19	3.56e-05	0.0141	-0.28	-0.22	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63427297~63427939:+
STAD	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-4.19	3.56e-05	0.0141	-0.27	-0.22	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
STAD	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	4.19	3.56e-05	0.0141	0.26	0.22	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
STAD	cis	rs1707322	0.686	rs3014251	ENSG00000225447.1	RPS15AP10	-4.19	3.56e-05	0.0141	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45645816~45646197:-
STAD	cis	rs4589258	0.737	rs34249130	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90681259	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs2155070	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90684264	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs2186613	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90684840	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs7129072	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90685440	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1792612	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90697254	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1792611	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90697330	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1632663	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90697640	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs1783804	ENSG00000280367.1	RP11-121L10.2	-4.19	3.56e-05	0.0141	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90698590	chr11:90223153~90226538:+
STAD	cis	rs12468226	1	rs16824599	ENSG00000226261.1	AC064836.3	4.19	3.57e-05	0.0141	0.35	0.22	Urate levels;	chr2:202358243	chr2:202336024~202336727:-
STAD	cis	rs11233413	0.532	rs2374349	ENSG00000246067.6	RAB30-AS1	4.19	3.57e-05	0.0141	0.21	0.22	Economic and political preferences (feminism/equality);	chr11:82959031	chr11:83072066~83106719:+
STAD	cis	rs5753618	0.561	rs13054220	ENSG00000236132.1	CTA-440B3.1	-4.19	3.57e-05	0.0141	-0.26	-0.22	Colorectal cancer;	chr22:31308506	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.561	rs9609254	ENSG00000236132.1	CTA-440B3.1	-4.19	3.57e-05	0.0141	-0.26	-0.22	Colorectal cancer;	chr22:31309956	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.561	rs9606830	ENSG00000236132.1	CTA-440B3.1	-4.19	3.57e-05	0.0141	-0.26	-0.22	Colorectal cancer;	chr22:31321813	chr22:31816379~31817491:-
STAD	cis	rs4243830	0.737	rs6692747	ENSG00000229519.2	RP11-58A11.2	-4.19	3.57e-05	0.0141	-0.25	-0.22	Body mass index;	chr1:6549989	chr1:6547905~6548619:+
STAD	cis	rs3864261	0.515	rs12186995	ENSG00000251467.1	CTC-250P20.2	4.19	3.57e-05	0.0141	0.23	0.22	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72996920~72997642:+
STAD	cis	rs4948102	0.642	rs6593297	ENSG00000226278.1	PSPHP1	4.19	3.57e-05	0.0141	0.25	0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55764797~55773288:+
STAD	cis	rs6832769	1	rs3805154	ENSG00000272969.1	RP11-528I4.2	4.19	3.57e-05	0.0141	0.28	0.22	Personality dimensions;	chr4:55497760	chr4:55547112~55547889:+
STAD	cis	rs7829975	1	rs7829975	ENSG00000173295.6	FAM86B3P	-4.19	3.57e-05	0.0141	-0.25	-0.22	Mood instability;	chr8:8690607	chr8:8228595~8244865:+
STAD	cis	rs1799949	0.965	rs799917	ENSG00000279602.1	CTD-3014M21.1	4.19	3.57e-05	0.0141	0.27	0.22	Menopause (age at onset);	chr17:43092919	chr17:43360041~43361361:-
STAD	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	4.19	3.57e-05	0.0141	0.23	0.22	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
STAD	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	4.19	3.57e-05	0.0141	0.23	0.22	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
STAD	cis	rs6142102	0.961	rs1055857	ENSG00000264616.1	MIR4755	4.19	3.57e-05	0.0141	0.23	0.22	Skin pigmentation;	chr20:34026067	chr20:34049119~34049190:+
STAD	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	4.19	3.58e-05	0.0141	0.31	0.22	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
STAD	cis	rs7429990	0.895	rs35790549	ENSG00000228638.1	FCF1P2	-4.19	3.58e-05	0.0141	-0.35	-0.22	Educational attainment (years of education);	chr3:48029998	chr3:48290793~48291375:-
STAD	cis	rs728616	0.51	rs12411989	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.58e-05	0.0141	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178094	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs35483545	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.58e-05	0.0141	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179417	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs34386571	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.58e-05	0.0141	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179676	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs34162901	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.58e-05	0.0141	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187100	chr10:79663088~79826594:-
STAD	cis	rs6585424	1	rs61860045	ENSG00000225484.5	NUTM2B-AS1	-4.19	3.58e-05	0.0141	-0.39	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187641	chr10:79663088~79826594:-
STAD	cis	rs7829975	0.714	rs12544992	ENSG00000253981.4	ALG1L13P	4.19	3.58e-05	0.0141	0.26	0.22	Mood instability;	chr8:8804171	chr8:8236003~8244667:-
STAD	cis	rs9549328	0.8	rs9549619	ENSG00000267868.1	RP11-120K24.3	4.19	3.58e-05	0.0141	0.31	0.22	Systolic blood pressure;	chr13:112978306	chr13:112964835~112966131:-
STAD	cis	rs2273156	0.57	rs11156875	ENSG00000258704.4	SRP54-AS1	-4.19	3.58e-05	0.0141	-0.27	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:35150610	chr14:34920858~34982532:-
STAD	cis	rs1707322	0.647	rs6686944	ENSG00000281133.1	AL355480.3	-4.19	3.59e-05	0.0141	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45580892~45580996:-
STAD	cis	rs11846409	0.932	rs61233250	ENSG00000211970.3	IGHV4-61	4.19	3.59e-05	0.0141	0.24	0.22	Rheumatic heart disease;	chr14:106634072	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs60659763	ENSG00000211970.3	IGHV4-61	4.19	3.59e-05	0.0141	0.24	0.22	Rheumatic heart disease;	chr14:106634172	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs57080270	ENSG00000211970.3	IGHV4-61	4.19	3.59e-05	0.0141	0.24	0.22	Rheumatic heart disease;	chr14:106634215	chr14:106639119~106639657:-
STAD	cis	rs8012947	1	rs7154212	ENSG00000279636.2	LINC00216	-4.19	3.59e-05	0.0141	-0.21	-0.22	Alcohol consumption in current drinkers;	chr14:58295491	chr14:58288033~58289158:+
STAD	cis	rs930421	0.689	rs13418278	ENSG00000226491.1	FTOP1	-4.19	3.59e-05	0.0141	-0.23	-0.22	Attention deficit hyperactivity disorder;	chr2:42755035	chr2:42797225~42798712:-
STAD	cis	rs2278796	0.639	rs4950976	ENSG00000231691.1	RP11-203F10.5	4.19	3.59e-05	0.0141	0.28	0.22	Mean platelet volume;	chr1:205001115	chr1:204277005~204277948:+
STAD	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	4.19	3.59e-05	0.0141	0.23	0.22	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
STAD	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-4.19	3.59e-05	0.0142	-0.27	-0.22	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
STAD	cis	rs2579500	0.768	rs11676886	ENSG00000230606.9	AC159540.1	4.19	3.59e-05	0.0142	0.26	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96583274	chr2:97416165~97433527:-
STAD	cis	rs559928	0.606	rs56207008	ENSG00000236935.1	AP003774.1	4.19	3.59e-05	0.0142	0.34	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64115743	chr11:64325050~64329504:-
STAD	cis	rs9902453	0.967	rs7212741	ENSG00000240074.1	RPL9P30	4.19	3.59e-05	0.0142	0.19	0.22	Coffee consumption (cups per day);	chr17:29995923	chr17:29855759~29856332:+
STAD	cis	rs2348418	0.932	rs12305750	ENSG00000247934.4	RP11-967K21.1	-4.19	3.59e-05	0.0142	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28535758	chr12:28163298~28190738:-
STAD	cis	rs7487075	0.859	rs2307061	ENSG00000257261.4	RP11-96H19.1	4.19	3.59e-05	0.0142	0.28	0.22	Itch intensity from mosquito bite;	chr12:46364711	chr12:46383679~46876159:+
STAD	cis	rs1348850	0.874	rs6742951	ENSG00000271825.1	RP11-337N6.2	4.19	3.59e-05	0.0142	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177476038	chr2:177300600~177302006:+
STAD	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-4.19	3.59e-05	0.0142	-0.27	-0.22	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
STAD	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-4.19	3.59e-05	0.0142	-0.27	-0.22	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
STAD	cis	rs6813195	0.554	rs17028932	ENSG00000243417.1	RP11-555K12.1	-4.19	3.59e-05	0.0142	-0.22	-0.22	Type 2 diabetes;	chr4:152494502	chr4:152551277~152552364:-
STAD	cis	rs7191700	0.712	rs7187741	ENSG00000262703.1	RP11-485G7.6	-4.19	3.6e-05	0.0142	-0.2	-0.22	Multiple sclerosis;	chr16:11339246	chr16:11348143~11349321:-
STAD	cis	rs870825	0.655	rs28661636	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184713064	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7678949	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184713864	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7678864	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184714004	chr4:184893871~184899454:-
STAD	cis	rs870825	0.549	rs7656993	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184714005	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs12502771	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184714680	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs12502860	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184714951	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28459754	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184715126	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6844146	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184715242	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs2003994	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184715414	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs2017101	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184716227	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs745656	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184716369	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6552804	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184716545	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6552805	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184716740	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6552806	ENSG00000249173.4	LINC01093	-4.19	3.6e-05	0.0142	-0.36	-0.22	Blood protein levels;	chr4:184717077	chr4:184893871~184899454:-
STAD	cis	rs867371	0.896	rs8033831	ENSG00000278603.1	RP13-608F4.5	4.19	3.6e-05	0.0142	0.25	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472203~82472426:+
STAD	cis	rs7103648	0.669	rs11039332	ENSG00000280615.1	Y_RNA	4.19	3.61e-05	0.0142	0.23	0.22	Systolic blood pressure;Diastolic blood pressure;	chr11:47674288	chr11:47614898~47614994:-
STAD	cis	rs7103648	0.643	rs12365079	ENSG00000280615.1	Y_RNA	4.19	3.61e-05	0.0142	0.23	0.22	Systolic blood pressure;Diastolic blood pressure;	chr11:47675044	chr11:47614898~47614994:-
STAD	cis	rs9847710	0.967	rs2564938	ENSG00000242142.1	SERBP1P3	4.19	3.61e-05	0.0142	0.21	0.22	Ulcerative colitis;	chr3:52992368	chr3:53064283~53065091:-
STAD	cis	rs9733	0.519	rs1336900	ENSG00000276103.1	U4	4.19	3.61e-05	0.0142	0.2	0.22	Tonsillectomy;	chr1:150706557	chr1:150608507~150608623:-
STAD	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	4.19	3.61e-05	0.0142	0.29	0.22	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
STAD	cis	rs875971	1	rs6956179	ENSG00000236529.1	RP13-254B10.1	-4.19	3.61e-05	0.0142	-0.23	-0.22	Aortic root size;	chr7:66341672	chr7:65840212~65840596:+
STAD	cis	rs7567389	0.568	rs7568070	ENSG00000200250.1	RNU6-1147P	-4.19	3.61e-05	0.0142	-0.24	-0.22	Self-rated health;	chr2:127195478	chr2:127316873~127316979:+
STAD	cis	rs7615952	0.611	rs7632305	ENSG00000239804.1	RP11-379B18.1	4.19	3.61e-05	0.0142	0.42	0.22	Blood pressure (smoking interaction);	chr3:125915924	chr3:125787888~125788146:-
STAD	cis	rs2901460	0.7	rs13033531	ENSG00000229503.1	AC092155.1	-4.19	3.61e-05	0.0142	-0.18	-0.22	Mean corpuscular volume;	chr2:62120707	chr2:62532583~62533059:-
STAD	cis	rs2439831	0.85	rs68079546	ENSG00000275601.1	AC011330.13	-4.19	3.61e-05	0.0142	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43844759	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs56909447	ENSG00000275601.1	AC011330.13	-4.19	3.61e-05	0.0142	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43845420	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28476182	ENSG00000275601.1	AC011330.13	-4.19	3.61e-05	0.0142	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43847445	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs28696802	ENSG00000275601.1	AC011330.13	-4.19	3.61e-05	0.0142	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43848197	chr15:43642389~43643023:-
STAD	cis	rs3947	1	rs1736084	ENSG00000227888.4	FAM66A	-4.19	3.61e-05	0.0142	-0.3	-0.22	Blood protein levels;	chr8:11846148	chr8:12362019~12388296:+
STAD	cis	rs3947	1	rs1736085	ENSG00000227888.4	FAM66A	-4.19	3.61e-05	0.0142	-0.3	-0.22	Blood protein levels;	chr8:11846150	chr8:12362019~12388296:+
STAD	cis	rs870825	0.616	rs4519834	ENSG00000249173.4	LINC01093	4.19	3.61e-05	0.0142	0.36	0.22	Blood protein levels;	chr4:184712711	chr4:184893871~184899454:-
STAD	cis	rs1007190	0.881	rs75199539	ENSG00000267405.1	CTC-296K1.4	4.19	3.62e-05	0.0142	0.27	0.22	DNA methylation (variation);	chr17:44852878	chr17:44794747~44797783:-
STAD	cis	rs9980	0.657	rs62052820	ENSG00000226232.7	RP11-419C5.2	-4.19	3.62e-05	0.0142	-0.26	-0.22	Blood osmolality (transformed sodium);	chr16:69541335	chr16:69976388~69996188:-
STAD	cis	rs56114371	0.568	rs200468	ENSG00000243307.2	POM121L6P	-4.19	3.62e-05	0.0142	-0.28	-0.22	Breast cancer;	chr6:27790076	chr6:26896952~26898777:+
STAD	cis	rs77861329	1	rs876782	ENSG00000280003.1	RP11-330H6.6	4.18	3.62e-05	0.0143	0.41	0.22	Macrophage inflammatory protein 1b levels;	chr3:52073893	chr3:52217016~52219012:-
STAD	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	4.18	3.62e-05	0.0143	0.29	0.22	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	4.18	3.62e-05	0.0143	0.29	0.22	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	4.18	3.62e-05	0.0143	0.29	0.22	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
STAD	cis	rs9902453	0.868	rs7212162	ENSG00000240074.1	RPL9P30	4.18	3.62e-05	0.0143	0.19	0.22	Coffee consumption (cups per day);	chr17:29994310	chr17:29855759~29856332:+
STAD	cis	rs8062405	0.558	rs151228	ENSG00000278665.1	RP11-666O2.4	4.18	3.62e-05	0.0143	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28599241~28601881:-
STAD	cis	rs7916697	0.593	rs3740587	ENSG00000234102.1	KRT19P4	4.18	3.62e-05	0.0143	0.23	0.22	Optic disc area;	chr10:68261045	chr10:68260557~68261499:+
STAD	cis	rs9393777	0.623	rs3734544	ENSG00000241549.7	GUSBP2	4.18	3.62e-05	0.0143	0.3	0.22	Intelligence (multi-trait analysis);	chr6:26468432	chr6:26871484~26956554:-
STAD	cis	rs10073892	0.62	rs13168111	ENSG00000250682.4	LINC00491	-4.18	3.62e-05	0.0143	-0.24	-0.22	Cognitive decline (age-related);	chr5:102615864	chr5:102609156~102671559:-
STAD	cis	rs4284742	1	rs4284742	ENSG00000273837.1	LLNLR-470E3.1	4.18	3.63e-05	0.0143	0.26	0.22	Aggressive periodontitis;	chr19:51628480	chr19:51639478~51639931:-
STAD	cis	rs6142102	0.961	rs4911392	ENSG00000264616.1	MIR4755	4.18	3.63e-05	0.0143	0.23	0.22	Skin pigmentation;	chr20:33982712	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.961	rs4911393	ENSG00000264616.1	MIR4755	4.18	3.63e-05	0.0143	0.23	0.22	Skin pigmentation;	chr20:33983120	chr20:34049119~34049190:+
STAD	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-4.18	3.63e-05	0.0143	-0.34	-0.22	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
STAD	cis	rs10508774	0.929	rs1581326	ENSG00000273038.2	RP11-479G22.8	-4.18	3.63e-05	0.0143	-0.41	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32651426	chr10:32887255~32889311:-
STAD	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	4.18	3.63e-05	0.0143	0.32	0.22	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
STAD	cis	rs2562456	0.833	rs2968076	ENSG00000268119.4	CTD-2561J22.5	-4.18	3.63e-05	0.0143	-0.28	-0.22	Pain;	chr19:21454299	chr19:21444241~21463908:-
STAD	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-4.18	3.63e-05	0.0143	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
STAD	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-4.18	3.63e-05	0.0143	-0.21	-0.22	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
STAD	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-4.18	3.63e-05	0.0143	-0.25	-0.22	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-4.18	3.63e-05	0.0143	-0.25	-0.22	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
STAD	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	4.18	3.63e-05	0.0143	0.31	0.22	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
STAD	cis	rs7429990	0.932	rs7630685	ENSG00000224895.1	VPS26BP1	4.18	3.63e-05	0.0143	0.23	0.22	Educational attainment (years of education);	chr3:48089680	chr3:47960327~47961081:-
STAD	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-4.18	3.63e-05	0.0143	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
STAD	cis	rs17401966	0.838	rs12120191	ENSG00000199562.1	RNU6-37P	4.18	3.63e-05	0.0143	0.17	0.22	Hepatocellular carcinoma;	chr1:10285714	chr1:10298966~10299072:+
STAD	cis	rs6565180	0.962	rs6565183	ENSG00000273724.1	RP11-347C12.12	-4.18	3.63e-05	0.0143	-0.23	-0.22	Tonsillectomy;	chr16:30371434	chr16:30336400~30343336:+
STAD	cis	rs2348418	0.765	rs10843119	ENSG00000247934.4	RP11-967K21.1	-4.18	3.63e-05	0.0143	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28164675	chr12:28163298~28190738:-
STAD	cis	rs1823913	0.927	rs35092718	ENSG00000280083.1	RP11-317J9.1	-4.18	3.63e-05	0.0143	-0.27	-0.22	Obesity-related traits;	chr2:191243882	chr2:191154118~191156070:-
STAD	cis	rs61270009	0.955	rs10942528	ENSG00000247828.6	TMEM161B-AS1	4.18	3.64e-05	0.0143	0.3	0.22	Depressive symptoms;	chr5:88314098	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.913	rs13190179	ENSG00000247828.6	TMEM161B-AS1	4.18	3.64e-05	0.0143	0.3	0.22	Depressive symptoms;	chr5:88314755	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs11738675	ENSG00000247828.6	TMEM161B-AS1	4.18	3.64e-05	0.0143	0.3	0.22	Depressive symptoms;	chr5:88315360	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs60331678	ENSG00000247828.6	TMEM161B-AS1	4.18	3.64e-05	0.0143	0.3	0.22	Depressive symptoms;	chr5:88315547	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs10462333	ENSG00000247828.6	TMEM161B-AS1	4.18	3.64e-05	0.0143	0.3	0.22	Depressive symptoms;	chr5:88315871	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs6872897	ENSG00000247828.6	TMEM161B-AS1	4.18	3.64e-05	0.0143	0.3	0.22	Depressive symptoms;	chr5:88322248	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.908	rs16903077	ENSG00000247828.6	TMEM161B-AS1	4.18	3.64e-05	0.0143	0.3	0.22	Depressive symptoms;	chr5:88323008	chr5:88268895~88436685:+
STAD	cis	rs4763879	0.502	rs11052552	ENSG00000256673.1	RP11-599J14.2	-4.18	3.64e-05	0.0143	-0.24	-0.22	Type 1 diabetes;	chr12:9703362	chr12:9398355~9414851:-
STAD	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	4.18	3.64e-05	0.0143	0.22	0.22	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
STAD	cis	rs7655841	0.704	rs7671508	ENSG00000248187.1	RP11-184M15.1	-4.18	3.64e-05	0.0143	-0.33	-0.22	Chronic obstructive pulmonary disease (moderate to severe);	chr4:129056512	chr4:128567972~128570531:-
STAD	cis	rs7655841	0.704	rs789982	ENSG00000248187.1	RP11-184M15.1	-4.18	3.64e-05	0.0143	-0.33	-0.22	Chronic obstructive pulmonary disease (moderate to severe);	chr4:129077916	chr4:128567972~128570531:-
STAD	cis	rs11239930	0.56	rs632334	ENSG00000278811.3	LINC00624	4.18	3.64e-05	0.0143	0.23	0.22	AIDS progression;	chr1:147079972	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.538	rs630630	ENSG00000278811.3	LINC00624	4.18	3.64e-05	0.0143	0.23	0.22	AIDS progression;	chr1:147080377	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.538	rs618575	ENSG00000278811.3	LINC00624	4.18	3.64e-05	0.0143	0.23	0.22	AIDS progression;	chr1:147080759	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.538	rs3011810	ENSG00000278811.3	LINC00624	4.18	3.64e-05	0.0143	0.23	0.22	AIDS progression;	chr1:147082079	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.517	rs4950354	ENSG00000278811.3	LINC00624	4.18	3.64e-05	0.0143	0.23	0.22	AIDS progression;	chr1:147082674	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.538	rs4950355	ENSG00000278811.3	LINC00624	4.18	3.64e-05	0.0143	0.23	0.22	AIDS progression;	chr1:147082700	chr1:147258885~147517875:-
STAD	cis	rs1345301	0.587	rs10186746	ENSG00000234389.1	AC007278.3	-4.18	3.64e-05	0.0143	-0.22	-0.22	Waist circumference;	chr2:102249917	chr2:102438713~102440475:+
STAD	cis	rs944722	0.875	rs4796041	ENSG00000266786.1	LGALS9DP	4.18	3.64e-05	0.0143	0.28	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27770515	chr17:27746132~27754954:+
STAD	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-4.18	3.64e-05	0.0143	-0.22	-0.22	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
STAD	cis	rs1707322	1	rs11211248	ENSG00000225447.1	RPS15AP10	4.18	3.64e-05	0.0143	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45645816~45646197:-
STAD	cis	rs2442825	0.691	rs2600182	ENSG00000206573.7	THUMPD3-AS1	4.18	3.65e-05	0.0143	0.16	0.22	Cerebrospinal fluid clusterin levels;	chr3:9396376	chr3:9349689~9398579:-
STAD	cis	rs4639966	0.836	rs11217018	ENSG00000255239.1	AP002954.6	-4.18	3.65e-05	0.0143	-0.28	-0.22	Systemic lupus erythematosus;	chr11:118764656	chr11:118688039~118690600:-
STAD	cis	rs919433	0.889	rs788001	ENSG00000231621.1	AC013264.2	-4.18	3.65e-05	0.0143	-0.19	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197348996	chr2:197197991~197199273:+
STAD	cis	rs2688608	0.62	rs7098444	ENSG00000271816.1	BMS1P4	4.18	3.65e-05	0.0143	0.24	0.22	Inflammatory bowel disease;	chr10:73820284	chr10:73699151~73730487:-
STAD	cis	rs10129255	0.5	rs1024350	ENSG00000224373.3	IGHV4-59	4.18	3.65e-05	0.0143	0.15	0.22	Kawasaki disease;	chr14:106685105	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.518	rs7143784	ENSG00000224373.3	IGHV4-59	4.18	3.65e-05	0.0143	0.15	0.22	Kawasaki disease;	chr14:106687277	chr14:106627249~106627825:-
STAD	cis	rs7680126	0.596	rs4697714	ENSG00000250613.1	RP11-136I13.1	4.18	3.65e-05	0.0143	0.26	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10142162	chr4:10410996~10411644:+
STAD	cis	rs9747201	0.926	rs8065606	ENSG00000281517.1	Metazoa_SRP	4.18	3.65e-05	0.0143	0.26	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82105650	chr17:81718849~81719095:-
STAD	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-4.18	3.65e-05	0.0143	-0.35	-0.22	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
STAD	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-4.18	3.65e-05	0.0143	-0.26	-0.22	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
STAD	cis	rs11846409	0.872	rs74091715	ENSG00000274576.2	IGHV2-70	-4.18	3.65e-05	0.0143	-0.27	-0.22	Rheumatic heart disease;	chr14:106637731	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.932	rs74091721	ENSG00000274576.2	IGHV2-70	-4.18	3.65e-05	0.0143	-0.27	-0.22	Rheumatic heart disease;	chr14:106638262	chr14:106770577~106771020:-
STAD	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-4.18	3.65e-05	0.0143	-0.28	-0.22	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
STAD	cis	rs10129255	0.869	rs7150549	ENSG00000232216.1	IGHV3-43	4.18	3.65e-05	0.0144	0.22	0.22	Kawasaki disease;	chr14:106705441	chr14:106470264~106470800:-
STAD	cis	rs561341	0.663	rs72821936	ENSG00000265798.5	RP11-271K11.5	4.18	3.65e-05	0.0144	0.26	0.22	Hip circumference adjusted for BMI;	chr17:31897049	chr17:31038575~31059121:-
STAD	cis	rs1816752	0.819	rs6490917	ENSG00000232858.1	RPL34P27	4.18	3.65e-05	0.0144	0.14	0.22	Obesity-related traits;	chr13:24423119	chr13:24988577~24988925:-
STAD	cis	rs7829975	0.811	rs7011229	ENSG00000254340.1	RP11-10A14.3	-4.18	3.66e-05	0.0144	-0.27	-0.22	Mood instability;	chr8:8685814	chr8:9141424~9145435:+
STAD	cis	rs853679	0.527	rs853693	ENSG00000220721.1	OR1F12	4.18	3.66e-05	0.0144	0.22	0.22	Depression;	chr6:28314871	chr6:28073316~28074233:+
STAD	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	4.18	3.66e-05	0.0144	0.29	0.22	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	4.18	3.66e-05	0.0144	0.29	0.22	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
STAD	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	4.18	3.66e-05	0.0144	0.22	0.22	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
STAD	cis	rs7131987	0.65	rs4331146	ENSG00000275476.1	RP11-996F15.4	-4.18	3.66e-05	0.0144	-0.24	-0.22	QT interval;	chr12:29287150	chr12:29277397~29277882:-
STAD	cis	rs4950322	0.518	rs61838936	ENSG00000278811.3	LINC00624	4.18	3.66e-05	0.0144	0.23	0.22	Protein quantitative trait loci;	chr1:147098422	chr1:147258885~147517875:-
STAD	cis	rs7680126	0.5	rs4697935	ENSG00000250613.1	RP11-136I13.1	4.18	3.66e-05	0.0144	0.26	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10147969	chr4:10410996~10411644:+
STAD	cis	rs7680126	0.5	rs4697717	ENSG00000250613.1	RP11-136I13.1	4.18	3.66e-05	0.0144	0.26	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10148160	chr4:10410996~10411644:+
STAD	cis	rs539514	0.69	rs2761398	ENSG00000261105.4	LMO7-AS1	4.18	3.66e-05	0.0144	0.26	0.22	Type 1 diabetes;	chr13:75742797	chr13:75604700~75635994:-
STAD	cis	rs1707322	0.686	rs2230658	ENSG00000225447.1	RPS15AP10	-4.18	3.66e-05	0.0144	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.686	rs2230659	ENSG00000225447.1	RPS15AP10	-4.18	3.66e-05	0.0144	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45645816~45646197:-
STAD	cis	rs539514	0.69	rs1092601	ENSG00000261105.4	LMO7-AS1	4.18	3.66e-05	0.0144	0.26	0.22	Type 1 diabetes;	chr13:75735610	chr13:75604700~75635994:-
STAD	cis	rs11098499	0.82	rs13128602	ENSG00000260091.1	RP11-33B1.4	-4.18	3.67e-05	0.0144	-0.22	-0.22	Corneal astigmatism;	chr4:119538211	chr4:119409333~119410233:+
STAD	cis	rs1707322	1	rs7531911	ENSG00000281133.1	AL355480.3	-4.18	3.67e-05	0.0144	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10890359	ENSG00000281133.1	AL355480.3	-4.18	3.67e-05	0.0144	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45580892~45580996:-
STAD	cis	rs11098499	0.955	rs13113112	ENSG00000260091.1	RP11-33B1.4	4.18	3.67e-05	0.0144	0.21	0.22	Corneal astigmatism;	chr4:119234885	chr4:119409333~119410233:+
STAD	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	4.18	3.67e-05	0.0144	0.33	0.22	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	4.18	3.67e-05	0.0144	0.33	0.22	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
STAD	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	4.18	3.67e-05	0.0144	0.33	0.22	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	4.18	3.67e-05	0.0144	0.33	0.22	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
STAD	cis	rs593531	0.531	rs662393	ENSG00000280269.1	AP000577.2	-4.18	3.67e-05	0.0144	-0.23	-0.22	Neuroticism;	chr11:74375263	chr11:74204869~74205746:+
STAD	cis	rs7829975	0.582	rs11783950	ENSG00000253981.4	ALG1L13P	-4.18	3.67e-05	0.0144	-0.28	-0.22	Mood instability;	chr8:8740321	chr8:8236003~8244667:-
STAD	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-4.18	3.67e-05	0.0144	-0.26	-0.22	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
STAD	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	4.18	3.67e-05	0.0144	0.22	0.22	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	4.18	3.67e-05	0.0144	0.22	0.22	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
STAD	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	4.18	3.68e-05	0.0144	0.27	0.22	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
STAD	cis	rs56163509	1	rs56163509	ENSG00000278665.1	RP11-666O2.4	4.18	3.68e-05	0.0144	0.25	0.22	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28599241~28601881:-
STAD	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-4.18	3.68e-05	0.0144	-0.27	-0.22	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
STAD	cis	rs4589258	0.788	rs11019176	ENSG00000280367.1	RP11-121L10.2	4.18	3.68e-05	0.0144	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90769749	chr11:90223153~90226538:+
STAD	cis	rs7520050	0.931	rs11211189	ENSG00000280836.1	AL355480.1	4.18	3.68e-05	0.0144	0.27	0.22	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45581219~45581321:-
STAD	cis	rs748404	0.604	rs2278857	ENSG00000275601.1	AC011330.13	-4.18	3.68e-05	0.0144	-0.23	-0.22	Lung cancer;	chr15:43340351	chr15:43642389~43643023:-
STAD	cis	rs2579500	0.807	rs6753926	ENSG00000230606.9	AC159540.1	4.18	3.68e-05	0.0144	0.26	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96633212	chr2:97416165~97433527:-
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000224373.3	IGHV4-59	4.18	3.68e-05	0.0144	0.15	0.22	Kawasaki disease;	chr14:106776442	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000224373.3	IGHV4-59	4.18	3.68e-05	0.0144	0.15	0.22	Kawasaki disease;	chr14:106776448	chr14:106627249~106627825:-
STAD	cis	rs451417	1	rs236102	ENSG00000275632.1	RP5-967N21.11	4.18	3.68e-05	0.0144	0.29	0.22	Menopause (age at onset);	chr20:5971320	chr20:6000418~6000941:+
STAD	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-4.18	3.68e-05	0.0144	-0.27	-0.22	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
STAD	cis	rs4835473	0.932	rs1877235	ENSG00000249741.2	RP11-673E1.3	4.18	3.68e-05	0.0144	0.24	0.22	Immature fraction of reticulocytes;	chr4:143986961	chr4:143911514~143912053:-
STAD	cis	rs2880765	0.835	rs900573	ENSG00000259295.5	CSPG4P12	-4.18	3.68e-05	0.0144	-0.27	-0.22	Coronary artery disease;	chr15:85494762	chr15:85191438~85213905:+
STAD	cis	rs4713118	0.869	rs6914924	ENSG00000243307.2	POM121L6P	-4.18	3.68e-05	0.0144	-0.25	-0.22	Parkinson's disease;	chr6:27743751	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs6930992	ENSG00000243307.2	POM121L6P	-4.18	3.68e-05	0.0144	-0.25	-0.22	Parkinson's disease;	chr6:27744341	chr6:26896952~26898777:+
STAD	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	4.18	3.68e-05	0.0145	0.33	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000224373.3	IGHV4-59	4.18	3.68e-05	0.0145	0.17	0.22	Kawasaki disease;	chr14:106799309	chr14:106627249~106627825:-
STAD	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	4.18	3.68e-05	0.0145	0.23	0.22	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	4.18	3.68e-05	0.0145	0.23	0.22	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
STAD	cis	rs8062405	0.558	rs231976	ENSG00000278665.1	RP11-666O2.4	4.18	3.68e-05	0.0145	0.24	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28599241~28601881:-
STAD	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	4.18	3.69e-05	0.0145	0.32	0.22	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
STAD	cis	rs7224610	0.932	rs10852974	ENSG00000263096.1	RP11-515O17.2	4.18	3.69e-05	0.0145	0.28	0.22	Urate levels;	chr17:55295205	chr17:55271504~55273653:-
STAD	cis	rs561341	0.714	rs473535	ENSG00000265798.5	RP11-271K11.5	4.18	3.69e-05	0.0145	0.32	0.22	Hip circumference adjusted for BMI;	chr17:31985346	chr17:31038575~31059121:-
STAD	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	4.18	3.69e-05	0.0145	0.21	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
STAD	cis	rs9307551	0.697	rs7356151	ENSG00000250334.4	LINC00989	-4.18	3.69e-05	0.0145	-0.28	-0.22	Refractive error;	chr4:79539532	chr4:79492416~79576460:+
STAD	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-4.18	3.69e-05	0.0145	-0.23	-0.22	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
STAD	cis	rs1876905	0.597	rs354551	ENSG00000230177.1	RP5-1112D6.4	-4.18	3.69e-05	0.0145	-0.26	-0.22	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111277932~111278742:+
STAD	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	4.18	3.69e-05	0.0145	0.3	0.22	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
STAD	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	4.18	3.69e-05	0.0145	0.27	0.22	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	4.18	3.69e-05	0.0145	0.27	0.22	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	4.18	3.69e-05	0.0145	0.27	0.22	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
STAD	cis	rs2273156	0.706	rs12881698	ENSG00000258704.4	SRP54-AS1	-4.18	3.69e-05	0.0145	-0.26	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:35034299	chr14:34920858~34982532:-
STAD	cis	rs1707322	0.827	rs6683274	ENSG00000281133.1	AL355480.3	-4.18	3.69e-05	0.0145	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45580892~45580996:-
STAD	cis	rs875971	0.862	rs6960446	ENSG00000224316.1	RP11-479O9.2	-4.18	3.69e-05	0.0145	-0.21	-0.22	Aortic root size;	chr7:66268272	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs7796162	ENSG00000224316.1	RP11-479O9.2	-4.18	3.69e-05	0.0145	-0.21	-0.22	Aortic root size;	chr7:66280771	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs2901152	ENSG00000224316.1	RP11-479O9.2	-4.18	3.69e-05	0.0145	-0.21	-0.22	Aortic root size;	chr7:66300017	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs10263690	ENSG00000224316.1	RP11-479O9.2	-4.18	3.69e-05	0.0145	-0.21	-0.22	Aortic root size;	chr7:66301466	chr7:65773620~65802067:+
STAD	cis	rs2446066	0.872	rs10876450	ENSG00000257379.1	RP11-793H13.8	-4.18	3.7e-05	0.0145	-0.35	-0.22	Red blood cell count;	chr12:53417250	chr12:53441741~53467528:+
STAD	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-4.18	3.7e-05	0.0145	-0.26	-0.22	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
STAD	cis	rs2739330	0.828	rs2154593	ENSG00000272787.1	KB-226F1.2	-4.18	3.7e-05	0.0145	-0.23	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23969211~23969873:+
STAD	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-4.18	3.7e-05	0.0145	-0.36	-0.22	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
STAD	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	4.18	3.7e-05	0.0145	0.23	0.22	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	4.18	3.7e-05	0.0145	0.23	0.22	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
STAD	cis	rs5753618	0.561	rs4603880	ENSG00000236132.1	CTA-440B3.1	-4.18	3.7e-05	0.0145	-0.26	-0.22	Colorectal cancer;	chr22:31348735	chr22:31816379~31817491:-
STAD	cis	rs1005277	0.602	rs1831315	ENSG00000276805.1	RP11-291L22.6	4.18	3.71e-05	0.0145	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38451030~38451785:+
STAD	cis	rs301901	0.796	rs4869520	ENSG00000250155.1	CTD-2353F22.1	4.18	3.71e-05	0.0145	0.22	0.22	Height;	chr5:37508981	chr5:36666214~36725195:-
STAD	cis	rs301901	0.796	rs1517789	ENSG00000250155.1	CTD-2353F22.1	4.18	3.71e-05	0.0145	0.22	0.22	Height;	chr5:37510578	chr5:36666214~36725195:-
STAD	cis	rs12220777	0.818	rs7918223	ENSG00000230091.5	TMEM254-AS1	4.18	3.71e-05	0.0145	0.29	0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090023	chr10:80046860~80078912:-
STAD	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-4.18	3.71e-05	0.0145	-0.33	-0.22	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
STAD	cis	rs10792665	0.671	rs4076574	ENSG00000246067.6	RAB30-AS1	4.18	3.71e-05	0.0145	0.2	0.22	Obesity-related traits;	chr11:82956684	chr11:83072066~83106719:+
STAD	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	4.18	3.71e-05	0.0145	0.31	0.22	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
STAD	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-4.18	3.71e-05	0.0145	-0.26	-0.22	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
STAD	cis	rs1707322	0.964	rs785508	ENSG00000281133.1	AL355480.3	4.18	3.71e-05	0.0145	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.964	rs785509	ENSG00000281133.1	AL355480.3	4.18	3.71e-05	0.0145	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45580892~45580996:-
STAD	cis	rs8014252	0.803	rs73282153	ENSG00000259158.2	ADAM20P1	-4.18	3.71e-05	0.0145	-0.3	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70535593	chr14:70468881~70483756:-
STAD	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-4.18	3.71e-05	0.0145	-0.28	-0.22	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
STAD	cis	rs9902453	0.689	rs7216948	ENSG00000240074.1	RPL9P30	4.18	3.71e-05	0.0145	0.19	0.22	Coffee consumption (cups per day);	chr17:29876155	chr17:29855759~29856332:+
STAD	cis	rs891378	0.92	rs2564975	ENSG00000274245.1	RP11-357P18.2	-4.18	3.72e-05	0.0146	-0.27	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207310612	chr1:207372559~207373252:+
STAD	cis	rs7487075	0.797	rs10880959	ENSG00000257261.4	RP11-96H19.1	4.18	3.72e-05	0.0146	0.28	0.22	Itch intensity from mosquito bite;	chr12:46367344	chr12:46383679~46876159:+
STAD	cis	rs7474896	0.559	rs2738185	ENSG00000120555.12	SEPT7P9	-4.18	3.72e-05	0.0146	-0.27	-0.22	Obesity (extreme);	chr10:37958808	chr10:38383069~38402916:-
STAD	cis	rs4293777	0.935	rs13103285	ENSG00000250896.1	RNPS1P1	4.18	3.72e-05	0.0146	0.17	0.22	Primary sclerosing cholangitis;	chr4:10724896	chr4:11371975~11372892:+
STAD	cis	rs9463078	0.715	rs9395049	ENSG00000219384.1	RP11-491H9.3	-4.18	3.72e-05	0.0146	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44824981	chr6:45158870~45159511:+
STAD	cis	rs1707322	0.964	rs7546237	ENSG00000281133.1	AL355480.3	-4.18	3.72e-05	0.0146	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45580892~45580996:-
STAD	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-4.18	3.72e-05	0.0146	-0.22	-0.22	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
STAD	cis	rs2836950	0.84	rs12482317	ENSG00000238141.2	BRWD1-AS1	-4.18	3.72e-05	0.0146	-0.24	-0.22	Menarche (age at onset);	chr21:39216315	chr21:39315707~39323218:+
STAD	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	4.18	3.72e-05	0.0146	0.33	0.22	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
STAD	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-4.18	3.72e-05	0.0146	-0.22	-0.22	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
STAD	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	4.18	3.72e-05	0.0146	0.29	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
STAD	cis	rs9467773	0.523	rs2498399	ENSG00000241549.7	GUSBP2	4.18	3.72e-05	0.0146	0.21	0.22	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26871484~26956554:-
STAD	cis	rs76917914	0.821	rs112500293	ENSG00000236896.1	RP11-535C21.3	4.18	3.73e-05	0.0146	0.29	0.22	Immature fraction of reticulocytes;	chr9:98001173	chr9:97986551~97987656:-
STAD	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	4.18	3.73e-05	0.0146	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
STAD	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	4.18	3.73e-05	0.0146	0.22	0.22	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
STAD	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	4.18	3.73e-05	0.0146	0.28	0.22	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
STAD	cis	rs720475	0.732	rs17195725	ENSG00000244198.4	RP4-545C24.1	4.18	3.73e-05	0.0146	0.28	0.22	Breast cancer;	chr7:144440044	chr7:144194858~144280547:+
STAD	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	4.18	3.73e-05	0.0146	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
STAD	cis	rs4589258	0.737	rs7127743	ENSG00000280367.1	RP11-121L10.2	-4.18	3.73e-05	0.0146	-0.22	-0.22	Intelligence (multi-trait analysis);	chr11:90661372	chr11:90223153~90226538:+
STAD	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	4.18	3.73e-05	0.0146	0.29	0.22	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
STAD	cis	rs56114371	0.53	rs2056923	ENSG00000280107.1	AL022393.9	-4.18	3.73e-05	0.0146	-0.37	-0.22	Breast cancer;	chr6:27722160	chr6:28170845~28172521:+
STAD	cis	rs8062405	0.964	rs7187333	ENSG00000278665.1	RP11-666O2.4	4.18	3.73e-05	0.0146	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28599241~28601881:-
STAD	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	4.18	3.73e-05	0.0146	0.44	0.22	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
STAD	cis	rs870825	0.616	rs28563856	ENSG00000249173.4	LINC01093	-4.18	3.73e-05	0.0146	-0.35	-0.22	Blood protein levels;	chr4:184714427	chr4:184893871~184899454:-
STAD	cis	rs7829975	0.533	rs13274028	ENSG00000254340.1	RP11-10A14.3	4.18	3.73e-05	0.0146	0.26	0.22	Mood instability;	chr8:8871683	chr8:9141424~9145435:+
STAD	cis	rs3764021	0.87	rs2401395	ENSG00000256673.1	RP11-599J14.2	-4.18	3.73e-05	0.0146	-0.24	-0.22	Type 1 diabetes;	chr12:9726944	chr12:9398355~9414851:-
STAD	cis	rs1950326	0.515	rs1955711	ENSG00000258526.4	RP11-111A21.1	-4.18	3.73e-05	0.0146	-0.25	-0.22	Verbal memory performance (residualized delayed recall level);	chr14:39563985	chr14:39474840~39513780:+
STAD	cis	rs4845875	0.6	rs6696752	ENSG00000242349.4	NPPA-AS1	4.18	3.73e-05	0.0146	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11775878	chr1:11841017~11848079:+
STAD	cis	rs4845875	0.6	rs4846039	ENSG00000242349.4	NPPA-AS1	4.18	3.73e-05	0.0146	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776811	chr1:11841017~11848079:+
STAD	cis	rs4845875	0.6	rs4846040	ENSG00000242349.4	NPPA-AS1	4.18	3.73e-05	0.0146	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776991	chr1:11841017~11848079:+
STAD	cis	rs4845875	0.6	rs4846041	ENSG00000242349.4	NPPA-AS1	4.18	3.73e-05	0.0146	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776994	chr1:11841017~11848079:+
STAD	cis	rs4845875	0.6	rs10779765	ENSG00000242349.4	NPPA-AS1	4.18	3.73e-05	0.0146	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11777954	chr1:11841017~11848079:+
STAD	cis	rs4845875	0.563	rs10864540	ENSG00000242349.4	NPPA-AS1	4.18	3.73e-05	0.0146	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11778042	chr1:11841017~11848079:+
STAD	cis	rs4845875	0.6	rs1889293	ENSG00000242349.4	NPPA-AS1	4.18	3.73e-05	0.0146	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11780805	chr1:11841017~11848079:+
STAD	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-4.18	3.74e-05	0.0146	-0.27	-0.22	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
STAD	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-4.18	3.74e-05	0.0146	-0.25	-0.22	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
STAD	cis	rs2143950	0.512	rs62625038	ENSG00000241052.1	RP11-173D9.1	-4.18	3.74e-05	0.0146	-0.24	-0.22	Atopic dermatitis;	chr14:35047811	chr14:35144021~35144480:-
STAD	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	4.18	3.74e-05	0.0146	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
STAD	cis	rs7951911	0.915	rs11038291	ENSG00000254427.1	RP11-430H10.1	4.18	3.74e-05	0.0146	0.45	0.22	IgG glycosylation;	chr11:45079747	chr11:45355371~45366121:+
STAD	cis	rs561341	1	rs561341	ENSG00000265798.5	RP11-271K11.5	4.18	3.74e-05	0.0146	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31989366	chr17:31038575~31059121:-
STAD	cis	rs7824557	0.564	rs6601584	ENSG00000205879.4	FAM90A2P	-4.18	3.74e-05	0.0146	-0.24	-0.22	Retinal vascular caliber;	chr8:11374834	chr8:12172202~12178575:-
STAD	cis	rs513349	1	rs210145	ENSG00000197251.3	LINC00336	4.18	3.74e-05	0.0146	0.24	0.22	Platelet count;	chr6:33579663	chr6:33586106~33593338:-
STAD	cis	rs2901460	0.759	rs11678889	ENSG00000229503.1	AC092155.1	-4.18	3.74e-05	0.0146	-0.18	-0.22	Mean corpuscular volume;	chr2:62129543	chr2:62532583~62533059:-
STAD	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-4.18	3.74e-05	0.0146	-0.26	-0.22	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
STAD	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-4.18	3.74e-05	0.0146	-0.26	-0.22	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
STAD	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-4.18	3.74e-05	0.0146	-0.26	-0.22	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
STAD	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-4.18	3.75e-05	0.0147	-0.36	-0.22	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-4.18	3.75e-05	0.0147	-0.36	-0.22	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-4.18	3.75e-05	0.0147	-0.36	-0.22	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-4.18	3.75e-05	0.0147	-0.36	-0.22	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-4.18	3.75e-05	0.0147	-0.36	-0.22	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-4.18	3.75e-05	0.0147	-0.36	-0.22	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
STAD	cis	rs11846409	0.818	rs2516909	ENSG00000274576.2	IGHV2-70	4.18	3.75e-05	0.0147	0.27	0.22	Rheumatic heart disease;	chr14:106630317	chr14:106770577~106771020:-
STAD	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	4.18	3.75e-05	0.0147	0.22	0.22	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
STAD	cis	rs858239	0.539	rs4559148	ENSG00000230042.1	AK3P3	-4.18	3.75e-05	0.0147	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23129178~23129841:+
STAD	cis	rs1707322	0.686	rs1541131	ENSG00000225447.1	RPS15AP10	-4.18	3.75e-05	0.0147	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.686	rs3014242	ENSG00000225447.1	RPS15AP10	-4.18	3.75e-05	0.0147	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.686	rs3014239	ENSG00000225447.1	RPS15AP10	-4.18	3.75e-05	0.0147	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45645816~45646197:-
STAD	cis	rs2562456	0.793	rs2562474	ENSG00000268119.4	CTD-2561J22.5	-4.18	3.75e-05	0.0147	-0.28	-0.22	Pain;	chr19:21463480	chr19:21444241~21463908:-
STAD	cis	rs4589258	0.788	rs10830572	ENSG00000280367.1	RP11-121L10.2	4.18	3.75e-05	0.0147	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90772547	chr11:90223153~90226538:+
STAD	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-4.18	3.75e-05	0.0147	-0.25	-0.22	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
STAD	cis	rs2221894	0.511	rs4732899	ENSG00000273710.1	Metazoa_SRP	-4.18	3.76e-05	0.0147	-0.22	-0.22	Obesity-related traits;	chr8:29036878	chr8:28915579~28915864:-
STAD	cis	rs8141529	0.664	rs5762861	ENSG00000226471.5	CTA-292E10.6	-4.18	3.76e-05	0.0147	-0.28	-0.22	Lymphocyte counts;	chr22:28854517	chr22:28800683~28848559:+
STAD	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	4.18	3.76e-05	0.0147	0.21	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
STAD	cis	rs1707322	0.717	rs2275086	ENSG00000225447.1	RPS15AP10	-4.18	3.76e-05	0.0147	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45645816~45646197:-
STAD	cis	rs2483058	0.531	rs3849277	ENSG00000261000.1	RP11-534L20.5	4.18	3.76e-05	0.0147	0.26	0.22	Cholesterol and Triglycerides;	chr1:206460421	chr1:206503948~206504456:+
STAD	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-4.18	3.76e-05	0.0147	-0.24	-0.22	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
STAD	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-4.18	3.76e-05	0.0147	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
STAD	cis	rs9987353	0.566	rs6998368	ENSG00000254340.1	RP11-10A14.3	-4.18	3.76e-05	0.0147	-0.31	-0.22	Recombination measurement;	chr8:9212778	chr8:9141424~9145435:+
STAD	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-4.18	3.77e-05	0.0147	-0.33	-0.22	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-4.18	3.77e-05	0.0147	-0.33	-0.22	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-4.18	3.77e-05	0.0147	-0.33	-0.22	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-4.18	3.77e-05	0.0147	-0.33	-0.22	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
STAD	cis	rs2859998	0.892	rs1057067	ENSG00000250031.1	RP11-114M5.1	-4.18	3.77e-05	0.0147	-0.19	-0.22	Narcolepsy with cataplexy;	chr8:58450065	chr8:58424588~58426685:-
STAD	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	4.18	3.77e-05	0.0147	0.23	0.22	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
STAD	cis	rs11098499	0.569	rs10023641	ENSG00000260091.1	RP11-33B1.4	4.18	3.77e-05	0.0147	0.2	0.22	Corneal astigmatism;	chr4:119337255	chr4:119409333~119410233:+
STAD	cis	rs7849270	0.921	rs7868476	ENSG00000234055.1	RP11-247A12.1	4.18	3.77e-05	0.0147	0.25	0.22	Blood metabolite ratios;	chr9:129155854	chr9:129097854~129100266:+
STAD	cis	rs7849270	0.959	rs2094704	ENSG00000234055.1	RP11-247A12.1	4.18	3.77e-05	0.0147	0.25	0.22	Blood metabolite ratios;	chr9:129156015	chr9:129097854~129100266:+
STAD	cis	rs7849270	1	rs9697030	ENSG00000234055.1	RP11-247A12.1	4.18	3.77e-05	0.0147	0.25	0.22	Blood metabolite ratios;	chr9:129157902	chr9:129097854~129100266:+
STAD	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-4.18	3.77e-05	0.0147	-0.27	-0.22	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
STAD	cis	rs6951245	0.542	rs28460147	ENSG00000229043.2	AC091729.9	-4.18	3.77e-05	0.0147	-0.35	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1177556	chr7:1160374~1165267:+
STAD	cis	rs2115630	0.967	rs11073731	ENSG00000225151.9	GOLGA2P7	4.18	3.77e-05	0.0147	0.24	0.22	P wave terminal force;	chr15:84811882	chr15:84199311~84230136:-
STAD	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	4.18	3.77e-05	0.0147	0.24	0.22	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
STAD	cis	rs1816752	0.716	rs9553331	ENSG00000273628.1	RP11-756A22.7	-4.18	3.77e-05	0.0147	-0.26	-0.22	Obesity-related traits;	chr13:24516030	chr13:24933006~24936796:+
STAD	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-4.18	3.77e-05	0.0147	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
STAD	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-4.17	3.78e-05	0.0148	-0.25	-0.22	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
STAD	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-4.17	3.78e-05	0.0148	-0.23	-0.22	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
STAD	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-4.17	3.78e-05	0.0148	-0.25	-0.22	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
STAD	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-4.17	3.78e-05	0.0148	-0.25	-0.22	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
STAD	cis	rs1426063	0.614	rs76512224	ENSG00000249717.1	RP11-44F21.3	4.17	3.78e-05	0.0148	0.46	0.22	QT interval;	chr4:75144808	chr4:74955974~74970362:-
STAD	cis	rs7615952	0.8	rs2062773	ENSG00000272840.1	RP11-379B18.6	4.17	3.78e-05	0.0148	0.39	0.22	Blood pressure (smoking interaction);	chr3:125920805	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.799	rs13315434	ENSG00000272840.1	RP11-379B18.6	4.17	3.78e-05	0.0148	0.39	0.22	Blood pressure (smoking interaction);	chr3:125922551	chr3:125774714~125797953:+
STAD	cis	rs6832769	1	rs7673908	ENSG00000272969.1	RP11-528I4.2	-4.17	3.78e-05	0.0148	-0.27	-0.22	Personality dimensions;	chr4:55528652	chr4:55547112~55547889:+
STAD	cis	rs9902453	0.845	rs62068583	ENSG00000263477.1	RP11-338L22.2	4.17	3.78e-05	0.0148	0.19	0.22	Coffee consumption (cups per day);	chr17:29674464	chr17:29863402~29866092:+
STAD	cis	rs7474896	1	rs2738191	ENSG00000099251.13	HSD17B7P2	4.17	3.78e-05	0.0148	0.35	0.22	Obesity (extreme);	chr10:37976858	chr10:38356380~38378505:+
STAD	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	4.17	3.79e-05	0.0148	0.26	0.22	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000211959.2	IGHV4-39	4.17	3.79e-05	0.0148	0.19	0.22	Kawasaki disease;	chr14:106782288	chr14:106421711~106422218:-
STAD	cis	rs794185	0.592	rs2633847	ENSG00000231249.1	ITPR1-AS1	-4.17	3.79e-05	0.0148	-0.25	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4472589	chr3:4490891~4493163:-
STAD	cis	rs2933343	0.729	rs1683816	ENSG00000261159.1	RP11-723O4.9	-4.17	3.79e-05	0.0148	-0.27	-0.22	IgG glycosylation;	chr3:128932352	chr3:128859716~128860526:-
STAD	cis	rs1707322	0.721	rs56255771	ENSG00000281133.1	AL355480.3	-4.17	3.79e-05	0.0148	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45580892~45580996:-
STAD	cis	rs1816752	0.583	rs9553311	ENSG00000273628.1	RP11-756A22.7	-4.17	3.79e-05	0.0148	-0.26	-0.22	Obesity-related traits;	chr13:24474016	chr13:24933006~24936796:+
STAD	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	4.17	3.79e-05	0.0148	0.26	0.22	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
STAD	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	4.17	3.79e-05	0.0148	0.27	0.22	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
STAD	cis	rs10129255	0.536	rs17113249	ENSG00000224373.3	IGHV4-59	4.17	3.79e-05	0.0148	0.15	0.22	Kawasaki disease;	chr14:106678273	chr14:106627249~106627825:-
STAD	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-4.17	3.79e-05	0.0148	-0.23	-0.22	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
STAD	cis	rs2638953	0.886	rs7973241	ENSG00000247934.4	RP11-967K21.1	-4.17	3.79e-05	0.0148	-0.24	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207583	chr12:28163298~28190738:-
STAD	cis	rs240993	0.516	rs241006	ENSG00000230177.1	RP5-1112D6.4	-4.17	3.79e-05	0.0148	-0.24	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111279910	chr6:111277932~111278742:+
STAD	cis	rs858239	0.539	rs4377861	ENSG00000230042.1	AK3P3	-4.17	3.79e-05	0.0148	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23129178~23129841:+
STAD	cis	rs11587682	0.705	rs74589051	ENSG00000274963.1	Metazoa_SRP	-4.17	3.79e-05	0.0148	-0.23	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150403665	chr1:150568971~150569269:-
STAD	cis	rs10073892	0.66	rs10479239	ENSG00000250682.4	LINC00491	4.17	3.79e-05	0.0148	0.24	0.22	Cognitive decline (age-related);	chr5:102611451	chr5:102609156~102671559:-
STAD	cis	rs5760092	0.618	rs5996631	ENSG00000224205.1	AP000351.4	-4.17	3.79e-05	0.0148	-0.26	-0.22	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23987320~23991421:-
STAD	cis	rs1707322	1	rs4660334	ENSG00000281133.1	AL355480.3	-4.17	3.79e-05	0.0148	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45580892~45580996:-
STAD	cis	rs10741780	0.697	rs11025186	ENSG00000254544.1	PCNAP4	4.17	3.79e-05	0.0148	0.31	0.22	HIV-1 susceptibility;	chr11:19581208	chr11:19274540~19275269:-
STAD	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	4.17	3.79e-05	0.0148	0.24	0.22	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
STAD	cis	rs1707322	1	rs6661500	ENSG00000281133.1	AL355480.3	-4.17	3.8e-05	0.0148	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45580892~45580996:-
STAD	cis	rs9549328	0.8	rs9549616	ENSG00000267868.1	RP11-120K24.3	4.17	3.8e-05	0.0148	0.31	0.22	Systolic blood pressure;	chr13:112973448	chr13:112964835~112966131:-
STAD	cis	rs721917	0.629	rs1304463	ENSG00000225484.5	NUTM2B-AS1	-4.17	3.8e-05	0.0148	-0.26	-0.22	Chronic obstructive pulmonary disease;	chr10:79969516	chr10:79663088~79826594:-
STAD	cis	rs11846409	0.86	rs61686131	ENSG00000274576.2	IGHV2-70	-4.17	3.8e-05	0.0148	-0.27	-0.22	Rheumatic heart disease;	chr14:106631568	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.932	rs10151046	ENSG00000274576.2	IGHV2-70	-4.17	3.8e-05	0.0148	-0.27	-0.22	Rheumatic heart disease;	chr14:106633095	chr14:106770577~106771020:-
STAD	cis	rs875971	0.862	rs1875057	ENSG00000224316.1	RP11-479O9.2	-4.17	3.8e-05	0.0148	-0.21	-0.22	Aortic root size;	chr7:66266868	chr7:65773620~65802067:+
STAD	cis	rs17401966	0.838	rs4623	ENSG00000199562.1	RNU6-37P	4.17	3.8e-05	0.0148	0.17	0.22	Hepatocellular carcinoma;	chr1:10306634	chr1:10298966~10299072:+
STAD	cis	rs11018874	0.597	rs10765243	ENSG00000280367.1	RP11-121L10.2	4.17	3.81e-05	0.0148	0.28	0.22	White blood cell types;	chr11:90121950	chr11:90223153~90226538:+
STAD	cis	rs5753618	0.539	rs4820962	ENSG00000236132.1	CTA-440B3.1	4.17	3.81e-05	0.0148	0.26	0.22	Colorectal cancer;	chr22:31293965	chr22:31816379~31817491:-
STAD	cis	rs9902453	1	rs4465650	ENSG00000263477.1	RP11-338L22.2	4.17	3.81e-05	0.0148	0.18	0.22	Coffee consumption (cups per day);	chr17:30069703	chr17:29863402~29866092:+
STAD	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-4.17	3.81e-05	0.0149	-0.29	-0.22	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
STAD	cis	rs539514	0.69	rs607095	ENSG00000261105.4	LMO7-AS1	4.17	3.81e-05	0.0149	0.26	0.22	Type 1 diabetes;	chr13:75742029	chr13:75604700~75635994:-
STAD	cis	rs7474896	1	rs61858625	ENSG00000099251.13	HSD17B7P2	4.17	3.81e-05	0.0149	0.36	0.22	Obesity (extreme);	chr10:37713114	chr10:38356380~38378505:+
STAD	cis	rs451417	1	rs236122	ENSG00000275632.1	RP5-967N21.11	4.17	3.81e-05	0.0149	0.29	0.22	Menopause (age at onset);	chr20:5992882	chr20:6000418~6000941:+
STAD	cis	rs7812879	0.564	rs12114115	ENSG00000255556.2	RP11-351I21.6	4.17	3.81e-05	0.0149	0.27	0.22	Systemic lupus erythematosus;	chr8:11441097	chr8:12378679~12380265:-
STAD	cis	rs7015630	0.657	rs62530908	ENSG00000251136.7	RP11-37B2.1	-4.17	3.81e-05	0.0149	-0.31	-0.22	Inflammatory bowel disease;Crohn's disease;	chr8:89835235	chr8:89609409~89757727:-
STAD	cis	rs1707322	0.752	rs4660880	ENSG00000281133.1	AL355480.3	-4.17	3.82e-05	0.0149	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45580892~45580996:-
STAD	cis	rs7074356	0.604	rs9665678	ENSG00000225484.5	NUTM2B-AS1	-4.17	3.82e-05	0.0149	-0.38	-0.22	Borderline personality disorder;	chr10:80473786	chr10:79663088~79826594:-
STAD	cis	rs7429990	0.864	rs4858863	ENSG00000224895.1	VPS26BP1	4.17	3.82e-05	0.0149	0.22	0.22	Educational attainment (years of education);	chr3:47814143	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs7629850	ENSG00000224895.1	VPS26BP1	4.17	3.82e-05	0.0149	0.22	0.22	Educational attainment (years of education);	chr3:47815592	chr3:47960327~47961081:-
STAD	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	4.17	3.82e-05	0.0149	0.37	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
STAD	cis	rs7208859	0.524	rs8069400	ENSG00000263603.1	CTD-2349P21.5	-4.17	3.82e-05	0.0149	-0.29	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30729469~30731202:+
STAD	cis	rs10073892	0.789	rs62372234	ENSG00000250682.4	LINC00491	-4.17	3.82e-05	0.0149	-0.25	-0.22	Cognitive decline (age-related);	chr5:102329256	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.711	rs62372236	ENSG00000250682.4	LINC00491	-4.17	3.82e-05	0.0149	-0.25	-0.22	Cognitive decline (age-related);	chr5:102331049	chr5:102609156~102671559:-
STAD	cis	rs7829975	0.626	rs332040	ENSG00000233609.3	RP11-62H7.2	4.17	3.82e-05	0.0149	0.25	0.22	Mood instability;	chr8:8872978	chr8:8961200~8979025:+
STAD	cis	rs11157436	0.602	rs928954	ENSG00000211812.1	TRAV26-2	-4.17	3.82e-05	0.0149	-0.22	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22202583~22203368:+
STAD	cis	rs1900504	0.584	rs3010501	ENSG00000266200.5	PNLIPRP2	-4.17	3.82e-05	0.0149	-0.31	-0.22	Tonsillectomy;	chr10:116604130	chr10:116620953~116645143:+
STAD	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	4.17	3.83e-05	0.0149	0.23	0.22	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
STAD	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	4.17	3.83e-05	0.0149	0.23	0.22	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
STAD	cis	rs9517906	0.581	rs8002438	ENSG00000218502.3	H2AFZP3	-4.17	3.83e-05	0.0149	-0.2	-0.22	Survival in pancreatic cancer;	chr13:99901006	chr13:99215372~99215758:-
STAD	cis	rs5758659	0.692	rs5751251	ENSG00000182057.4	OGFRP1	4.17	3.83e-05	0.0149	0.23	0.22	Cognitive function;	chr22:42244600	chr22:42269753~42275196:+
STAD	cis	rs6908034	0.654	rs6456272	ENSG00000228412.5	RP4-625H18.2	-4.17	3.83e-05	0.0149	-0.36	-0.22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804805	chr6:19802164~19804752:-
STAD	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	4.17	3.83e-05	0.0149	0.22	0.22	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
STAD	cis	rs117785887	0.536	rs12203355	ENSG00000270638.1	RP3-466P17.1	4.17	3.83e-05	0.0149	0.39	0.22	Interleukin-17 levels;	chr6:146063339	chr6:145735570~145737218:+
STAD	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-4.17	3.84e-05	0.0149	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-4.17	3.84e-05	0.0149	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
STAD	cis	rs10741780	0.697	rs7931514	ENSG00000254544.1	PCNAP4	4.17	3.84e-05	0.0149	0.3	0.22	HIV-1 susceptibility;	chr11:19593132	chr11:19274540~19275269:-
STAD	cis	rs10741780	0.697	rs7931824	ENSG00000254544.1	PCNAP4	4.17	3.84e-05	0.0149	0.3	0.22	HIV-1 susceptibility;	chr11:19593200	chr11:19274540~19275269:-
STAD	cis	rs9902453	0.845	rs10853135	ENSG00000263477.1	RP11-338L22.2	4.17	3.84e-05	0.015	0.18	0.22	Coffee consumption (cups per day);	chr17:29861657	chr17:29863402~29866092:+
STAD	cis	rs11098499	0.913	rs11098496	ENSG00000260091.1	RP11-33B1.4	4.17	3.84e-05	0.015	0.21	0.22	Corneal astigmatism;	chr4:119246311	chr4:119409333~119410233:+
STAD	cis	rs858239	0.6	rs6967475	ENSG00000230042.1	AK3P3	-4.17	3.84e-05	0.015	-0.23	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23129178~23129841:+
STAD	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	4.17	3.84e-05	0.015	0.27	0.22	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
STAD	cis	rs9307551	0.697	rs1561638	ENSG00000250334.4	LINC00989	-4.17	3.84e-05	0.015	-0.28	-0.22	Refractive error;	chr4:79499154	chr4:79492416~79576460:+
STAD	cis	rs7208859	0.623	rs56325146	ENSG00000263603.1	CTD-2349P21.5	-4.17	3.84e-05	0.015	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30729469~30731202:+
STAD	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-4.17	3.84e-05	0.015	-0.34	-0.22	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
STAD	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-4.17	3.84e-05	0.015	-0.34	-0.22	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
STAD	cis	rs17507216	0.667	rs72753916	ENSG00000255769.6	GOLGA2P10	-4.17	3.84e-05	0.015	-0.35	-0.22	Excessive daytime sleepiness;	chr15:82684001	chr15:82472993~82513950:-
STAD	cis	rs9329221	0.741	rs534523	ENSG00000254340.1	RP11-10A14.3	-4.17	3.84e-05	0.015	-0.27	-0.22	Neuroticism;	chr8:10027489	chr8:9141424~9145435:+
STAD	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	4.17	3.85e-05	0.015	0.32	0.22	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
STAD	cis	rs7829975	0.501	rs74345345	ENSG00000253893.2	FAM85B	4.17	3.85e-05	0.015	0.3	0.22	Mood instability;	chr8:8720925	chr8:8167819~8226614:-
STAD	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-4.17	3.85e-05	0.015	-0.23	-0.22	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
STAD	cis	rs1075265	0.783	rs805453	ENSG00000235937.1	AC008280.1	4.17	3.85e-05	0.015	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54029552~54030682:-
STAD	cis	rs1900504	0.509	rs11197765	ENSG00000266200.5	PNLIPRP2	4.17	3.85e-05	0.015	0.33	0.22	Tonsillectomy;	chr10:116624768	chr10:116620953~116645143:+
STAD	cis	rs8014252	0.803	rs58777530	ENSG00000259158.2	ADAM20P1	-4.17	3.85e-05	0.015	-0.29	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70534505	chr14:70468881~70483756:-
STAD	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-4.17	3.85e-05	0.015	-0.35	-0.22	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-4.17	3.85e-05	0.015	-0.35	-0.22	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
STAD	cis	rs4713118	0.824	rs9366702	ENSG00000243307.2	POM121L6P	-4.17	3.85e-05	0.015	-0.25	-0.22	Parkinson's disease;	chr6:27766691	chr6:26896952~26898777:+
STAD	cis	rs765787	0.53	rs28526629	ENSG00000259539.1	CTD-2651B20.1	4.17	3.85e-05	0.015	0.25	0.22	Uric acid levels;	chr15:45248264	chr15:45152664~45167526:-
STAD	cis	rs5753618	0.561	rs9606831	ENSG00000236132.1	CTA-440B3.1	-4.17	3.85e-05	0.015	-0.26	-0.22	Colorectal cancer;	chr22:31336526	chr22:31816379~31817491:-
STAD	cis	rs228614	0.51	rs6830407	ENSG00000248971.2	KRT8P46	-4.17	3.85e-05	0.015	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102728746~102730171:-
STAD	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-4.17	3.85e-05	0.015	-0.34	-0.22	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-4.17	3.85e-05	0.015	-0.34	-0.22	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-4.17	3.85e-05	0.015	-0.34	-0.22	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
STAD	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-4.17	3.85e-05	0.015	-0.33	-0.22	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
STAD	cis	rs11098499	0.863	rs17050695	ENSG00000260091.1	RP11-33B1.4	4.17	3.85e-05	0.015	0.21	0.22	Corneal astigmatism;	chr4:119568372	chr4:119409333~119410233:+
STAD	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	4.17	3.86e-05	0.015	0.27	0.22	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
STAD	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-4.17	3.86e-05	0.015	-0.26	-0.22	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
STAD	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-4.17	3.86e-05	0.015	-0.24	-0.22	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
STAD	cis	rs9463078	0.525	rs9395058	ENSG00000219384.1	RP11-491H9.3	4.17	3.86e-05	0.015	0.21	0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45016332	chr6:45158870~45159511:+
STAD	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-4.17	3.86e-05	0.015	-0.25	-0.22	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
STAD	cis	rs950169	0.58	rs1061737	ENSG00000259295.5	CSPG4P12	4.17	3.86e-05	0.015	0.31	0.22	Schizophrenia;	chr15:84640559	chr15:85191438~85213905:+
STAD	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	4.17	3.86e-05	0.015	0.23	0.22	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
STAD	cis	rs34779708	0.966	rs57081218	ENSG00000271335.4	RP11-324I22.4	4.17	3.86e-05	0.015	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35314552~35336401:-
STAD	cis	rs7131987	0.903	rs7302129	ENSG00000257176.2	RP11-996F15.2	-4.17	3.86e-05	0.015	-0.25	-0.22	QT interval;	chr12:29262347	chr12:29280418~29317848:-
STAD	cis	rs7665090	0.714	rs5026475	ENSG00000246560.2	RP11-10L12.4	4.17	3.86e-05	0.015	0.27	0.22	Primary biliary cholangitis;	chr4:102633664	chr4:102828055~102844075:+
STAD	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	4.17	3.86e-05	0.015	0.32	0.22	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
STAD	cis	rs9902453	0.845	rs72823935	ENSG00000263477.1	RP11-338L22.2	4.17	3.86e-05	0.015	0.19	0.22	Coffee consumption (cups per day);	chr17:29681577	chr17:29863402~29866092:+
STAD	cis	rs11157436	0.602	rs11157437	ENSG00000211813.2	TRAV34	4.17	3.87e-05	0.015	0.25	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22207522~22208129:+
STAD	cis	rs11157436	0.602	rs11157439	ENSG00000211813.2	TRAV34	4.17	3.87e-05	0.015	0.25	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22207522~22208129:+
STAD	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	4.17	3.87e-05	0.015	0.24	0.22	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
STAD	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	4.17	3.87e-05	0.015	0.27	0.22	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
STAD	cis	rs4293777	0.935	rs7678867	ENSG00000250896.1	RNPS1P1	4.17	3.87e-05	0.015	0.17	0.22	Primary sclerosing cholangitis;	chr4:10724435	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.935	rs7678879	ENSG00000250896.1	RNPS1P1	4.17	3.87e-05	0.015	0.17	0.22	Primary sclerosing cholangitis;	chr4:10724450	chr4:11371975~11372892:+
STAD	cis	rs7824557	0.564	rs11782430	ENSG00000205879.4	FAM90A2P	-4.17	3.87e-05	0.015	-0.25	-0.22	Retinal vascular caliber;	chr8:11368562	chr8:12172202~12178575:-
STAD	cis	rs728616	0.614	rs61859189	ENSG00000225484.5	NUTM2B-AS1	-4.17	3.87e-05	0.015	-0.36	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80329494	chr10:79663088~79826594:-
STAD	cis	rs8028182	0.609	rs8038760	ENSG00000260269.4	CTD-2323K18.1	-4.17	3.87e-05	0.015	-0.28	-0.22	Sudden cardiac arrest;	chr15:75449754	chr15:75527150~75601205:-
STAD	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	4.17	3.87e-05	0.015	0.24	0.22	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
STAD	cis	rs453301	0.598	rs10104303	ENSG00000233609.3	RP11-62H7.2	4.17	3.87e-05	0.0151	0.24	0.22	Joint mobility (Beighton score);	chr8:8977018	chr8:8961200~8979025:+
STAD	cis	rs7680126	0.632	rs6834645	ENSG00000250613.1	RP11-136I13.1	4.17	3.87e-05	0.0151	0.26	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10148550	chr4:10410996~10411644:+
STAD	cis	rs34779708	0.931	rs4934731	ENSG00000271335.4	RP11-324I22.4	4.17	3.87e-05	0.0151	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35314552~35336401:-
STAD	cis	rs4589258	0.788	rs4400761	ENSG00000280367.1	RP11-121L10.2	4.17	3.87e-05	0.0151	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90774729	chr11:90223153~90226538:+
STAD	cis	rs7809950	1	rs2178497	ENSG00000238832.1	snoU109	4.17	3.88e-05	0.0151	0.3	0.22	Coronary artery disease;	chr7:107638456	chr7:107603363~107603507:+
STAD	cis	rs11992162	0.56	rs13256329	ENSG00000254527.1	ENPP7P12	-4.17	3.88e-05	0.0151	-0.25	-0.22	Monocyte count;	chr8:11924705	chr8:12205759~12206389:-
STAD	cis	rs10435719	0.638	rs67146188	ENSG00000254527.1	ENPP7P12	-4.17	3.88e-05	0.0151	-0.25	-0.22	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:12205759~12206389:-
STAD	cis	rs11992162	0.551	rs13268217	ENSG00000254527.1	ENPP7P12	-4.17	3.88e-05	0.0151	-0.25	-0.22	Monocyte count;	chr8:11925100	chr8:12205759~12206389:-
STAD	cis	rs11992162	0.573	rs13264994	ENSG00000254527.1	ENPP7P12	-4.17	3.88e-05	0.0151	-0.25	-0.22	Monocyte count;	chr8:11925250	chr8:12205759~12206389:-
STAD	cis	rs11992162	0.573	rs13275808	ENSG00000254527.1	ENPP7P12	-4.17	3.88e-05	0.0151	-0.25	-0.22	Monocyte count;	chr8:11925306	chr8:12205759~12206389:-
STAD	cis	rs1707322	1	rs7539800	ENSG00000225447.1	RPS15AP10	-4.17	3.88e-05	0.0151	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45645816~45646197:-
STAD	cis	rs10508774	1	rs10827143	ENSG00000273038.2	RP11-479G22.8	4.17	3.88e-05	0.0151	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32850870	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.85	rs11009115	ENSG00000273038.2	RP11-479G22.8	4.17	3.88e-05	0.0151	0.46	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32851465	chr10:32887255~32889311:-
STAD	cis	rs1816752	0.646	rs7322329	ENSG00000273628.1	RP11-756A22.7	-4.17	3.88e-05	0.0151	-0.26	-0.22	Obesity-related traits;	chr13:24479193	chr13:24933006~24936796:+
STAD	cis	rs9291683	0.595	rs35501905	ENSG00000250613.1	RP11-136I13.1	-4.17	3.88e-05	0.0151	-0.21	-0.22	Bone mineral density;	chr4:10051807	chr4:10410996~10411644:+
STAD	cis	rs8062405	0.964	rs78613234	ENSG00000278665.1	RP11-666O2.4	4.17	3.88e-05	0.0151	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62036624	ENSG00000278665.1	RP11-666O2.4	4.17	3.88e-05	0.0151	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28599241~28601881:-
STAD	cis	rs1823913	1	rs1454749	ENSG00000280083.1	RP11-317J9.1	-4.17	3.88e-05	0.0151	-0.27	-0.22	Obesity-related traits;	chr2:191240909	chr2:191154118~191156070:-
STAD	cis	rs11638815	0.626	rs1367841	ENSG00000255769.6	GOLGA2P10	4.17	3.89e-05	0.0151	0.25	0.22	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:82472993~82513950:-
STAD	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	4.17	3.89e-05	0.0151	0.3	0.22	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
STAD	cis	rs7208859	0.573	rs8078182	ENSG00000263603.1	CTD-2349P21.5	-4.17	3.89e-05	0.0151	-0.26	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30729469~30731202:+
STAD	cis	rs2404602	0.583	rs2456076	ENSG00000196274.5	Metazoa_SRP	-4.17	3.89e-05	0.0151	-0.19	-0.22	Blood metabolite levels;	chr15:76265212	chr15:76230048~76230390:-
STAD	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	4.17	3.89e-05	0.0151	0.26	0.22	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
STAD	cis	rs9329221	0.65	rs657913	ENSG00000254340.1	RP11-10A14.3	-4.17	3.89e-05	0.0151	-0.28	-0.22	Neuroticism;	chr8:10025065	chr8:9141424~9145435:+
STAD	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-4.17	3.89e-05	0.0151	-0.21	-0.22	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
STAD	cis	rs2992257	0.958	rs3006824	ENSG00000251839.1	RNU7-12P	-4.17	3.89e-05	0.0151	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26424738	chr10:27232255~27232316:-
STAD	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	4.17	3.89e-05	0.0151	0.21	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
STAD	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	4.17	3.9e-05	0.0151	0.29	0.22	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
STAD	cis	rs6142102	0.961	rs2300204	ENSG00000264616.1	MIR4755	4.17	3.9e-05	0.0151	0.23	0.22	Skin pigmentation;	chr20:34000967	chr20:34049119~34049190:+
STAD	cis	rs9860428	0.935	rs6787688	ENSG00000240057.4	RP11-572M11.4	4.17	3.9e-05	0.0151	0.19	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112832131	chr3:113019532~113183301:+
STAD	cis	rs516805	0.528	rs2606628	ENSG00000279453.1	RP3-425C14.4	-4.17	3.9e-05	0.0151	-0.31	-0.22	Lymphocyte counts;	chr6:122097460	chr6:122436789~122439223:-
STAD	cis	rs181553	0.664	rs1838963	ENSG00000266696.1	RP11-30L3.2	4.17	3.9e-05	0.0151	0.2	0.22	Hip circumference adjusted for BMI;	chr18:49153498	chr18:49205912~49208781:+
STAD	cis	rs2638953	0.64	rs11049718	ENSG00000247934.4	RP11-967K21.1	-4.17	3.9e-05	0.0151	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28565739	chr12:28163298~28190738:-
STAD	cis	rs561341	0.556	rs542244	ENSG00000265798.5	RP11-271K11.5	4.17	3.9e-05	0.0151	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31980223	chr17:31038575~31059121:-
STAD	cis	rs3733418	0.86	rs2056252	ENSG00000248632.1	RP11-366M4.11	-4.17	3.9e-05	0.0151	-0.25	-0.22	Obesity-related traits;	chr4:165026338	chr4:164968587~164970002:-
STAD	cis	rs1790761	0.554	rs3758938	ENSG00000231793.4	DOC2GP	-4.17	3.9e-05	0.0151	-0.29	-0.22	Mean corpuscular volume;	chr11:67634891	chr11:67612653~67616257:-
STAD	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-4.17	3.9e-05	0.0151	-0.34	-0.22	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
STAD	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	4.17	3.9e-05	0.0151	0.33	0.22	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
STAD	cis	rs2310173	0.575	rs2071008	ENSG00000281162.1	LINC01127	-4.17	3.9e-05	0.0152	-0.29	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101998817	chr2:101962056~101987167:+
STAD	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	4.17	3.9e-05	0.0152	0.27	0.22	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
STAD	cis	rs5770917	1	rs5770917	ENSG00000273272.1	CTA-384D8.34	4.17	3.9e-05	0.0152	0.37	0.22	Narcolepsy;	chr22:50578924	chr22:50542650~50543011:+
STAD	cis	rs4763879	0.634	rs2098298	ENSG00000256673.1	RP11-599J14.2	4.17	3.9e-05	0.0152	0.23	0.22	Type 1 diabetes;	chr12:9707473	chr12:9398355~9414851:-
STAD	cis	rs9902453	0.765	rs2264302	ENSG00000240074.1	RPL9P30	-4.17	3.91e-05	0.0152	-0.19	-0.22	Coffee consumption (cups per day);	chr17:29730077	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.765	rs2447935	ENSG00000240074.1	RPL9P30	-4.17	3.91e-05	0.0152	-0.19	-0.22	Coffee consumption (cups per day);	chr17:29730506	chr17:29855759~29856332:+
STAD	cis	rs2573652	0.722	rs11636084	ENSG00000270127.2	RP11-526I2.5	-4.17	3.91e-05	0.0152	-0.24	-0.22	Height;	chr15:100003189	chr15:100547765~100550153:-
STAD	cis	rs9393777	0.623	rs9358945	ENSG00000241549.7	GUSBP2	-4.17	3.91e-05	0.0152	-0.3	-0.22	Intelligence (multi-trait analysis);	chr6:26471886	chr6:26871484~26956554:-
STAD	cis	rs4626924	0.843	rs12028581	ENSG00000236863.2	RPL23AP23	4.17	3.91e-05	0.0152	0.19	0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:234772423	chr1:235295865~235296335:+
STAD	cis	rs5758659	0.714	rs2413668	ENSG00000182057.4	OGFRP1	-4.17	3.91e-05	0.0152	-0.23	-0.22	Cognitive function;	chr22:42109837	chr22:42269753~42275196:+
STAD	cis	rs9902453	0.933	rs7225462	ENSG00000240074.1	RPL9P30	4.17	3.91e-05	0.0152	0.19	0.22	Coffee consumption (cups per day);	chr17:29994208	chr17:29855759~29856332:+
STAD	cis	rs1816752	0.646	rs8002599	ENSG00000273628.1	RP11-756A22.7	-4.17	3.91e-05	0.0152	-0.26	-0.22	Obesity-related traits;	chr13:24478486	chr13:24933006~24936796:+
STAD	cis	rs950169	0.58	rs11634320	ENSG00000259295.5	CSPG4P12	-4.17	3.91e-05	0.0152	-0.31	-0.22	Schizophrenia;	chr15:84628952	chr15:85191438~85213905:+
STAD	cis	rs806321	0.619	rs1359613	ENSG00000237152.3	DLEU7-AS1	-4.17	3.91e-05	0.0152	-0.25	-0.22	Multiple sclerosis;	chr13:50192104	chr13:50807856~50849905:+
STAD	cis	rs7615952	0.673	rs9821905	ENSG00000239804.1	RP11-379B18.1	-4.17	3.92e-05	0.0152	-0.39	-0.22	Blood pressure (smoking interaction);	chr3:125902007	chr3:125787888~125788146:-
STAD	cis	rs17401966	0.838	rs4333852	ENSG00000199562.1	RNU6-37P	-4.17	3.92e-05	0.0152	-0.17	-0.22	Hepatocellular carcinoma;	chr1:10327646	chr1:10298966~10299072:+
STAD	cis	rs11673344	0.542	rs826327	ENSG00000267672.1	CTD-2293H3.1	4.17	3.92e-05	0.0152	0.2	0.22	Obesity-related traits;	chr19:37004397	chr19:37091341~37092564:+
STAD	cis	rs9902453	0.791	rs6505141	ENSG00000263477.1	RP11-338L22.2	4.17	3.92e-05	0.0152	0.19	0.22	Coffee consumption (cups per day);	chr17:29671169	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.791	rs3098950	ENSG00000263477.1	RP11-338L22.2	4.17	3.92e-05	0.0152	0.19	0.22	Coffee consumption (cups per day);	chr17:29671367	chr17:29863402~29866092:+
STAD	cis	rs11846409	0.932	rs74091728	ENSG00000211970.3	IGHV4-61	4.17	3.92e-05	0.0152	0.24	0.22	Rheumatic heart disease;	chr14:106638762	chr14:106639119~106639657:-
STAD	cis	rs4639966	0.836	rs3825057	ENSG00000255239.1	AP002954.6	-4.17	3.92e-05	0.0152	-0.27	-0.22	Systemic lupus erythematosus;	chr11:118752276	chr11:118688039~118690600:-
STAD	cis	rs4639966	0.836	rs11217014	ENSG00000255239.1	AP002954.6	-4.17	3.92e-05	0.0152	-0.27	-0.22	Systemic lupus erythematosus;	chr11:118755577	chr11:118688039~118690600:-
STAD	cis	rs4639966	0.836	rs11217016	ENSG00000255239.1	AP002954.6	-4.17	3.92e-05	0.0152	-0.27	-0.22	Systemic lupus erythematosus;	chr11:118756440	chr11:118688039~118690600:-
STAD	cis	rs4639966	0.836	rs7130875	ENSG00000255239.1	AP002954.6	-4.17	3.92e-05	0.0152	-0.28	-0.22	Systemic lupus erythematosus;	chr11:118742965	chr11:118688039~118690600:-
STAD	cis	rs61270009	0.955	rs10462472	ENSG00000247828.6	TMEM161B-AS1	4.17	3.92e-05	0.0152	0.3	0.22	Depressive symptoms;	chr5:88346652	chr5:88268895~88436685:+
STAD	cis	rs2221894	0.511	rs13262991	ENSG00000273710.1	Metazoa_SRP	-4.17	3.92e-05	0.0152	-0.22	-0.22	Obesity-related traits;	chr8:29043826	chr8:28915579~28915864:-
STAD	cis	rs2944755	0.919	rs6578115	ENSG00000279766.1	RP11-642A1.2	-4.17	3.92e-05	0.0152	-0.3	-0.22	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140565760	chr8:140572142~140572812:-
STAD	cis	rs9879311	0.966	rs4684685	ENSG00000240288.6	GHRLOS	4.17	3.92e-05	0.0152	0.21	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369869	chr3:10285754~10293449:+
STAD	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	4.17	3.92e-05	0.0152	0.24	0.22	Migraine;	chr4:56881468	chr4:56960927~56961373:-
STAD	cis	rs1075265	0.73	rs2111868	ENSG00000235937.1	AC008280.1	4.17	3.92e-05	0.0152	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54029552~54030682:-
STAD	cis	rs4835473	0.618	rs12499429	ENSG00000249741.2	RP11-673E1.3	4.17	3.92e-05	0.0152	0.26	0.22	Immature fraction of reticulocytes;	chr4:143889914	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.801	rs28715976	ENSG00000249741.2	RP11-673E1.3	4.17	3.92e-05	0.0152	0.26	0.22	Immature fraction of reticulocytes;	chr4:143891603	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.838	rs12507468	ENSG00000249741.2	RP11-673E1.3	4.17	3.92e-05	0.0152	0.26	0.22	Immature fraction of reticulocytes;	chr4:143908061	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1849135	ENSG00000249741.2	RP11-673E1.3	4.17	3.92e-05	0.0152	0.26	0.22	Immature fraction of reticulocytes;	chr4:143912279	chr4:143911514~143912053:-
STAD	cis	rs9733	0.527	rs11204694	ENSG00000274963.1	Metazoa_SRP	4.17	3.92e-05	0.0152	0.19	0.22	Tonsillectomy;	chr1:150680915	chr1:150568971~150569269:-
STAD	cis	rs11098499	0.82	rs11737395	ENSG00000260091.1	RP11-33B1.4	4.17	3.92e-05	0.0152	0.22	0.22	Corneal astigmatism;	chr4:119599549	chr4:119409333~119410233:+
STAD	cis	rs763014	0.932	rs2384974	ENSG00000228201.1	AL022341.3	4.17	3.92e-05	0.0152	0.25	0.22	Height;	chr16:601279	chr16:648473~649200:-
STAD	cis	rs9517906	0.581	rs9513680	ENSG00000218502.3	H2AFZP3	-4.17	3.92e-05	0.0152	-0.2	-0.22	Survival in pancreatic cancer;	chr13:99900801	chr13:99215372~99215758:-
STAD	cis	rs9517906	0.581	rs11617041	ENSG00000218502.3	H2AFZP3	-4.17	3.92e-05	0.0152	-0.2	-0.22	Survival in pancreatic cancer;	chr13:99900906	chr13:99215372~99215758:-
STAD	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	4.17	3.92e-05	0.0152	0.2	0.22	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
STAD	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	4.17	3.93e-05	0.0152	0.34	0.22	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
STAD	cis	rs4835473	0.932	rs11724752	ENSG00000249741.2	RP11-673E1.3	4.17	3.93e-05	0.0152	0.26	0.22	Immature fraction of reticulocytes;	chr4:143769473	chr4:143911514~143912053:-
STAD	cis	rs7829975	0.714	rs4840362	ENSG00000253981.4	ALG1L13P	-4.17	3.93e-05	0.0152	-0.26	-0.22	Mood instability;	chr8:8812572	chr8:8236003~8244667:-
STAD	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-4.17	3.93e-05	0.0152	-0.25	-0.22	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
STAD	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	4.17	3.93e-05	0.0152	0.27	0.22	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	4.17	3.93e-05	0.0152	0.27	0.22	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	4.17	3.93e-05	0.0152	0.27	0.22	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	4.17	3.93e-05	0.0152	0.27	0.22	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	4.17	3.93e-05	0.0152	0.27	0.22	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	4.17	3.93e-05	0.0152	0.27	0.22	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
STAD	cis	rs1707322	0.963	rs11211202	ENSG00000281133.1	AL355480.3	-4.17	3.93e-05	0.0153	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45580892~45580996:-
STAD	cis	rs77988765	0.908	rs17333013	ENSG00000248844.5	RP11-626H12.3	-4.17	3.93e-05	0.0153	-0.41	-0.22	Post bronchodilator FEV1/FVC ratio;	chr11:70169952	chr11:70056230~70065371:-
STAD	cis	rs8062405	0.965	rs8049439	ENSG00000278665.1	RP11-666O2.4	4.17	3.93e-05	0.0153	0.24	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28599241~28601881:-
STAD	cis	rs9902453	0.845	rs7209622	ENSG00000240074.1	RPL9P30	4.17	3.93e-05	0.0153	0.19	0.22	Coffee consumption (cups per day);	chr17:29929789	chr17:29855759~29856332:+
STAD	cis	rs9549328	0.8	rs9549620	ENSG00000267868.1	RP11-120K24.3	4.17	3.94e-05	0.0153	0.31	0.22	Systolic blood pressure;	chr13:112979107	chr13:112964835~112966131:-
STAD	cis	rs263063	0.92	rs2240678	ENSG00000280239.1	CTB-50L17.8	4.17	3.94e-05	0.0153	0.32	0.22	Periodontitis (CDC/AAP);	chr19:5041167	chr19:4448810~4450836:+
STAD	cis	rs4763879	0.594	rs12427310	ENSG00000256673.1	RP11-599J14.2	4.17	3.94e-05	0.0153	0.23	0.22	Type 1 diabetes;	chr12:9707539	chr12:9398355~9414851:-
STAD	cis	rs8062405	1	rs7187776	ENSG00000278665.1	RP11-666O2.4	4.16	3.94e-05	0.0153	0.24	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28599241~28601881:-
STAD	cis	rs4792901	0.722	rs12603085	ENSG00000279602.1	CTD-3014M21.1	-4.16	3.94e-05	0.0153	-0.29	-0.22	Dupuytren's disease;	chr17:43468479	chr17:43360041~43361361:-
STAD	cis	rs1707322	1	rs785510	ENSG00000225447.1	RPS15AP10	-4.16	3.94e-05	0.0153	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45645816~45646197:-
STAD	cis	rs6940116	1	rs6940116	ENSG00000243307.2	POM121L6P	-4.16	3.94e-05	0.0153	-0.32	-0.22	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:26896952~26898777:+
STAD	cis	rs1707322	0.686	rs2991987	ENSG00000225447.1	RPS15AP10	-4.16	3.94e-05	0.0153	-0.18	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45645816~45646197:-
STAD	cis	rs2483058	0.739	rs963893	ENSG00000261000.1	RP11-534L20.5	4.16	3.94e-05	0.0153	0.25	0.22	Cholesterol and Triglycerides;	chr1:206452351	chr1:206503948~206504456:+
STAD	cis	rs1799949	0.965	rs33925201	ENSG00000279602.1	CTD-3014M21.1	4.16	3.94e-05	0.0153	0.27	0.22	Menopause (age at onset);	chr17:43128665	chr17:43360041~43361361:-
STAD	cis	rs950169	0.58	rs11635597	ENSG00000259295.5	CSPG4P12	4.16	3.94e-05	0.0153	0.31	0.22	Schizophrenia;	chr15:84622468	chr15:85191438~85213905:+
STAD	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	4.16	3.94e-05	0.0153	0.29	0.22	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
STAD	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-4.16	3.94e-05	0.0153	-0.22	-0.22	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
STAD	cis	rs1799949	1	rs8176145	ENSG00000279602.1	CTD-3014M21.1	4.16	3.94e-05	0.0153	0.28	0.22	Menopause (age at onset);	chr17:43097077	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs8176140	ENSG00000279602.1	CTD-3014M21.1	4.16	3.94e-05	0.0153	0.28	0.22	Menopause (age at onset);	chr17:43099629	chr17:43360041~43361361:-
STAD	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-4.16	3.95e-05	0.0153	-0.27	-0.22	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
STAD	cis	rs8141529	1	rs132534	ENSG00000226471.5	CTA-292E10.6	4.16	3.95e-05	0.0153	0.26	0.22	Lymphocyte counts;	chr22:28903818	chr22:28800683~28848559:+
STAD	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	4.16	3.95e-05	0.0153	0.33	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
STAD	cis	rs3947	0.906	rs709822	ENSG00000227888.4	FAM66A	-4.16	3.95e-05	0.0153	-0.28	-0.22	Blood protein levels;	chr8:11844804	chr8:12362019~12388296:+
STAD	cis	rs58873874	0.579	rs79615135	ENSG00000251405.2	CTB-109A12.1	4.16	3.95e-05	0.0153	0.38	0.22	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157362615~157460078:-
STAD	cis	rs2221894	0.553	rs7842930	ENSG00000273710.1	Metazoa_SRP	-4.16	3.96e-05	0.0153	-0.23	-0.22	Obesity-related traits;	chr8:28976393	chr8:28915579~28915864:-
STAD	cis	rs3002131	0.604	rs4400619	ENSG00000225265.1	TAF1A-AS1	-4.16	3.96e-05	0.0153	-0.38	-0.22	Interleukin-10 levels;	chr1:222556644	chr1:222589825~222593032:+
STAD	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	4.16	3.96e-05	0.0153	0.32	0.22	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
STAD	cis	rs1075265	0.73	rs4413193	ENSG00000235937.1	AC008280.1	4.16	3.96e-05	0.0154	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54029552~54030682:-
STAD	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-4.16	3.96e-05	0.0154	-0.27	-0.22	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
STAD	cis	rs875971	0.79	rs10257911	ENSG00000224316.1	RP11-479O9.2	-4.16	3.96e-05	0.0154	-0.21	-0.22	Aortic root size;	chr7:66278783	chr7:65773620~65802067:+
STAD	cis	rs8012947	0.565	rs12891852	ENSG00000279636.2	LINC00216	-4.16	3.97e-05	0.0154	-0.21	-0.22	Alcohol consumption in current drinkers;	chr14:58330922	chr14:58288033~58289158:+
STAD	cis	rs1707322	0.963	rs4508055	ENSG00000225447.1	RPS15AP10	4.16	3.97e-05	0.0154	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs12076580	ENSG00000225447.1	RPS15AP10	4.16	3.97e-05	0.0154	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45645816~45646197:-
STAD	cis	rs559928	0.606	rs56311067	ENSG00000236935.1	AP003774.1	4.16	3.97e-05	0.0154	0.35	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164135	chr11:64325050~64329504:-
STAD	cis	rs559928	0.556	rs11607903	ENSG00000236935.1	AP003774.1	4.16	3.97e-05	0.0154	0.35	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164668	chr11:64325050~64329504:-
STAD	cis	rs559928	0.606	rs55942618	ENSG00000236935.1	AP003774.1	4.16	3.97e-05	0.0154	0.35	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168533	chr11:64325050~64329504:-
STAD	cis	rs559928	0.606	rs76653616	ENSG00000236935.1	AP003774.1	4.16	3.97e-05	0.0154	0.35	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168667	chr11:64325050~64329504:-
STAD	cis	rs6142102	0.961	rs6120487	ENSG00000264616.1	MIR4755	4.16	3.97e-05	0.0154	0.22	0.22	Skin pigmentation;	chr20:34034802	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.961	rs1883524	ENSG00000264616.1	MIR4755	4.16	3.97e-05	0.0154	0.22	0.22	Skin pigmentation;	chr20:34038301	chr20:34049119~34049190:+
STAD	cis	rs1153858	0.887	rs28569043	ENSG00000259433.2	CTD-2651B20.4	-4.16	3.97e-05	0.0154	-0.24	-0.22	Homoarginine levels;	chr15:45438728	chr15:45330209~45332634:-
STAD	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	4.16	3.97e-05	0.0154	0.32	0.22	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
STAD	cis	rs9420	0.528	rs11607122	ENSG00000265566.2	RN7SL605P	-4.16	3.97e-05	0.0154	-0.31	-0.22	Schizophrenia;	chr11:57622264	chr11:57528085~57528365:-
STAD	cis	rs6772849	0.796	rs9841521	ENSG00000242551.2	POU5F1P6	-4.16	3.97e-05	0.0154	-0.22	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128674735~128677005:-
STAD	cis	rs2034650	0.544	rs8034217	ENSG00000223313.1	RNU6-516P	-4.16	3.97e-05	0.0154	-0.24	-0.22	Interstitial lung disease;	chr15:40429501	chr15:40529570~40529673:+
STAD	cis	rs62388641	1	rs62388641	ENSG00000281809.1	LINC01394	4.16	3.97e-05	0.0154	0.37	0.22	Daytime sleep phenotypes;	chr6:1539849	chr6:1321698~1324022:-
STAD	cis	rs11098499	1	rs7659194	ENSG00000260091.1	RP11-33B1.4	4.16	3.97e-05	0.0154	0.21	0.22	Corneal astigmatism;	chr4:119285992	chr4:119409333~119410233:+
STAD	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	4.16	3.98e-05	0.0154	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	4.16	3.98e-05	0.0154	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	4.16	3.98e-05	0.0154	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	4.16	3.98e-05	0.0154	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
STAD	cis	rs1395	0.744	rs62130709	ENSG00000234072.1	AC074117.10	-4.16	3.98e-05	0.0154	-0.21	-0.22	Blood metabolite levels;	chr2:27282914	chr2:27356246~27367622:+
STAD	cis	rs1395	0.744	rs11686131	ENSG00000234072.1	AC074117.10	-4.16	3.98e-05	0.0154	-0.21	-0.22	Blood metabolite levels;	chr2:27285842	chr2:27356246~27367622:+
STAD	cis	rs1395	0.744	rs4665962	ENSG00000234072.1	AC074117.10	-4.16	3.98e-05	0.0154	-0.21	-0.22	Blood metabolite levels;	chr2:27292237	chr2:27356246~27367622:+
STAD	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-4.16	3.98e-05	0.0154	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
STAD	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	4.16	3.98e-05	0.0154	0.3	0.22	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
STAD	cis	rs9907295	0.786	rs9901418	ENSG00000270894.1	AC015849.13	-4.16	3.98e-05	0.0154	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35915699	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs11080361	ENSG00000270894.1	AC015849.13	-4.16	3.98e-05	0.0154	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35916184	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs11080362	ENSG00000270894.1	AC015849.13	-4.16	3.98e-05	0.0154	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35916224	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs16971670	ENSG00000270894.1	AC015849.13	-4.16	3.98e-05	0.0154	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35916548	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9896658	ENSG00000270894.1	AC015849.13	-4.16	3.98e-05	0.0154	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35916758	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9894314	ENSG00000270894.1	AC015849.13	-4.16	3.98e-05	0.0154	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35916822	chr17:35818399~35823713:+
STAD	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	4.16	3.98e-05	0.0154	0.29	0.22	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
STAD	cis	rs2337406	1	rs79452530	ENSG00000280411.1	IGHV1-69-2	-4.16	3.98e-05	0.0154	-0.27	-0.22	Alzheimer's disease (late onset);	chr14:106699992	chr14:106762092~106762588:-
STAD	cis	rs7474896	0.616	rs1985260	ENSG00000120555.12	SEPT7P9	4.16	3.98e-05	0.0154	0.28	0.22	Obesity (extreme);	chr10:38145162	chr10:38383069~38402916:-
STAD	cis	rs832540	0.695	rs702686	ENSG00000271828.1	CTD-2310F14.1	4.16	3.98e-05	0.0154	0.27	0.22	Coronary artery disease;	chr5:56905523	chr5:56927874~56929573:+
STAD	cis	rs2562456	0.755	rs2650773	ENSG00000268119.4	CTD-2561J22.5	-4.16	3.98e-05	0.0154	-0.28	-0.22	Pain;	chr19:21461286	chr19:21444241~21463908:-
STAD	cis	rs56114371	0.53	rs9357045	ENSG00000280107.1	AL022393.9	-4.16	3.98e-05	0.0154	-0.31	-0.22	Breast cancer;	chr6:27721148	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.699	rs573179	ENSG00000280107.1	AL022393.9	-4.16	3.99e-05	0.0154	-0.31	-0.22	Parkinson's disease;	chr6:27881898	chr6:28170845~28172521:+
STAD	cis	rs4388249	0.651	rs31599	ENSG00000271849.1	CTC-332L22.1	-4.16	3.99e-05	0.0154	-0.39	-0.22	Schizophrenia;	chr5:109671554	chr5:109687802~109688329:-
STAD	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-4.16	3.99e-05	0.0154	-0.22	-0.22	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
STAD	cis	rs4835473	0.897	rs28701142	ENSG00000249741.2	RP11-673E1.3	-4.16	3.99e-05	0.0154	-0.25	-0.22	Immature fraction of reticulocytes;	chr4:143945730	chr4:143911514~143912053:-
STAD	cis	rs9847710	1	rs2564956	ENSG00000242142.1	SERBP1P3	4.16	3.99e-05	0.0154	0.21	0.22	Ulcerative colitis;	chr3:53036446	chr3:53064283~53065091:-
STAD	cis	rs8141529	0.748	rs5997412	ENSG00000226471.5	CTA-292E10.6	-4.16	3.99e-05	0.0154	-0.25	-0.22	Lymphocyte counts;	chr22:28880759	chr22:28800683~28848559:+
STAD	cis	rs858239	0.699	rs1881200	ENSG00000230042.1	AK3P3	4.16	3.99e-05	0.0154	0.24	0.22	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23129178~23129841:+
STAD	cis	rs1707322	1	rs6672115	ENSG00000281133.1	AL355480.3	-4.16	3.99e-05	0.0154	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45580892~45580996:-
STAD	cis	rs13413635	0.908	rs7558301	ENSG00000225808.1	DNAJC19P5	-4.16	3.99e-05	0.0154	-0.29	-0.22	Heart rate;	chr2:177812682	chr2:177229191~177229506:-
STAD	cis	rs6180	0.704	rs230819	ENSG00000250860.1	CTD-2265D6.2	-4.16	4e-05	0.0155	-0.18	-0.22	Height;	chr5:42805863	chr5:42466893~42468300:-
STAD	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	4.16	4e-05	0.0155	0.29	0.22	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
STAD	cis	rs8099594	0.666	rs9961129	ENSG00000266696.1	RP11-30L3.2	-4.16	4e-05	0.0155	-0.22	-0.22	Height;	chr18:49445362	chr18:49205912~49208781:+
STAD	cis	rs8141529	0.748	rs5762874	ENSG00000226471.5	CTA-292E10.6	-4.16	4e-05	0.0155	-0.25	-0.22	Lymphocyte counts;	chr22:28873670	chr22:28800683~28848559:+
STAD	cis	rs4388249	0.904	rs3797670	ENSG00000271849.1	CTC-332L22.1	-4.16	4e-05	0.0155	-0.32	-0.22	Schizophrenia;	chr5:109866331	chr5:109687802~109688329:-
STAD	cis	rs4388249	0.861	rs55968726	ENSG00000271849.1	CTC-332L22.1	-4.16	4e-05	0.0155	-0.32	-0.22	Schizophrenia;	chr5:109867595	chr5:109687802~109688329:-
STAD	cis	rs4388249	0.904	rs2241693	ENSG00000271849.1	CTC-332L22.1	-4.16	4e-05	0.0155	-0.32	-0.22	Schizophrenia;	chr5:109868220	chr5:109687802~109688329:-
STAD	cis	rs7937127	0.744	rs72902715	ENSG00000254907.1	RP11-484D2.2	4.16	4e-05	0.0155	0.38	0.22	Fibrinogen levels;	chr11:43491230	chr11:43328748~43359296:-
STAD	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	4.16	4e-05	0.0155	0.2	0.22	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
STAD	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	4.16	4e-05	0.0155	0.2	0.22	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
STAD	cis	rs4631830	0.54	rs10825187	ENSG00000264204.2	AGAP7P	-4.16	4e-05	0.0155	-0.28	-0.22	Prostate-specific antigen levels;	chr10:46103895	chr10:46109621~46131358:+
STAD	cis	rs4631830	0.54	rs4935090	ENSG00000264204.2	AGAP7P	-4.16	4e-05	0.0155	-0.28	-0.22	Prostate-specific antigen levels;	chr10:46104697	chr10:46109621~46131358:+
STAD	cis	rs58123204	1	rs58123204	ENSG00000257379.1	RP11-793H13.8	4.16	4e-05	0.0155	0.37	0.22	Mean corpuscular hemoglobin;	chr12:53366378	chr12:53441741~53467528:+
STAD	cis	rs8012947	1	rs1984549	ENSG00000279636.2	LINC00216	-4.16	4e-05	0.0155	-0.21	-0.22	Alcohol consumption in current drinkers;	chr14:58322121	chr14:58288033~58289158:+
STAD	cis	rs875971	0.756	rs4718328	ENSG00000224316.1	RP11-479O9.2	-4.16	4.01e-05	0.0155	-0.22	-0.22	Aortic root size;	chr7:66228350	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs4718330	ENSG00000224316.1	RP11-479O9.2	-4.16	4.01e-05	0.0155	-0.22	-0.22	Aortic root size;	chr7:66250256	chr7:65773620~65802067:+
STAD	cis	rs7142881	0.815	rs2165814	ENSG00000258648.1	UBE2CP1	-4.16	4.01e-05	0.0155	-0.23	-0.22	Response to iloperidone treatment (QT prolongation);	chr14:31624038	chr14:30683045~30683598:-
STAD	cis	rs11098499	0.604	rs34278750	ENSG00000260091.1	RP11-33B1.4	4.16	4.01e-05	0.0155	0.21	0.22	Corneal astigmatism;	chr4:119649981	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.604	rs10022185	ENSG00000260091.1	RP11-33B1.4	4.16	4.01e-05	0.0155	0.21	0.22	Corneal astigmatism;	chr4:119650610	chr4:119409333~119410233:+
STAD	cis	rs6012564	0.614	rs6019508	ENSG00000227431.4	CSE1L-AS1	-4.16	4.01e-05	0.0155	-0.2	-0.22	Anger;	chr20:48905546	chr20:49040463~49046044:-
STAD	cis	rs6142102	0.961	rs973409	ENSG00000264616.1	MIR4755	4.16	4.01e-05	0.0155	0.23	0.22	Skin pigmentation;	chr20:33948558	chr20:34049119~34049190:+
STAD	cis	rs1799949	0.965	rs799910	ENSG00000279602.1	CTD-3014M21.1	4.16	4.02e-05	0.0155	0.27	0.22	Menopause (age at onset);	chr17:43127544	chr17:43360041~43361361:-
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000232216.1	IGHV3-43	4.16	4.02e-05	0.0155	0.2	0.22	Kawasaki disease;	chr14:106767802	chr14:106470264~106470800:-
STAD	cis	rs72807246	0.54	rs72807258	ENSG00000228701.1	TNKS2-AS1	4.16	4.02e-05	0.0155	0.45	0.22	Breast cancer;	chr10:92209153	chr10:91782839~91798291:-
STAD	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	4.16	4.03e-05	0.0156	0.27	0.22	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
STAD	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	4.16	4.03e-05	0.0156	0.42	0.22	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
STAD	cis	rs9902453	0.817	rs67206808	ENSG00000263477.1	RP11-338L22.2	4.16	4.03e-05	0.0156	0.18	0.22	Coffee consumption (cups per day);	chr17:29863078	chr17:29863402~29866092:+
STAD	cis	rs593531	0.614	rs10793080	ENSG00000280269.1	AP000577.2	-4.16	4.03e-05	0.0156	-0.23	-0.22	Neuroticism;	chr11:74377698	chr11:74204869~74205746:+
STAD	cis	rs593531	0.571	rs7934621	ENSG00000280269.1	AP000577.2	-4.16	4.03e-05	0.0156	-0.23	-0.22	Neuroticism;	chr11:74379883	chr11:74204869~74205746:+
STAD	cis	rs10073892	0.66	rs13172780	ENSG00000250682.4	LINC00491	-4.16	4.03e-05	0.0156	-0.24	-0.22	Cognitive decline (age-related);	chr5:102650088	chr5:102609156~102671559:-
STAD	cis	rs9902453	0.904	rs55866125	ENSG00000240074.1	RPL9P30	4.16	4.03e-05	0.0156	0.19	0.22	Coffee consumption (cups per day);	chr17:29985975	chr17:29855759~29856332:+
STAD	cis	rs867371	0.929	rs1501371	ENSG00000278603.1	RP13-608F4.5	4.16	4.03e-05	0.0156	0.25	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472203~82472426:+
STAD	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	4.16	4.03e-05	0.0156	0.22	0.22	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
STAD	cis	rs11168351	1	rs11168351	ENSG00000258273.1	RP11-370I10.4	-4.16	4.04e-05	0.0156	-0.24	-0.22	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48333755~48333901:-
STAD	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	4.16	4.04e-05	0.0156	0.33	0.22	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
STAD	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	4.16	4.04e-05	0.0156	0.2	0.22	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
STAD	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	4.16	4.04e-05	0.0156	0.2	0.22	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
STAD	cis	rs6142102	0.961	rs4911144	ENSG00000264616.1	MIR4755	4.16	4.04e-05	0.0156	0.23	0.22	Skin pigmentation;	chr20:34026565	chr20:34049119~34049190:+
STAD	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-4.16	4.04e-05	0.0156	-0.34	-0.22	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-4.16	4.04e-05	0.0156	-0.34	-0.22	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
STAD	cis	rs1799949	0.832	rs2070835	ENSG00000279602.1	CTD-3014M21.1	4.16	4.04e-05	0.0156	0.28	0.22	Menopause (age at onset);	chr17:43022008	chr17:43360041~43361361:-
STAD	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	4.16	4.04e-05	0.0156	0.31	0.22	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
STAD	cis	rs9291683	0.62	rs11722946	ENSG00000250613.1	RP11-136I13.1	4.16	4.04e-05	0.0156	0.21	0.22	Bone mineral density;	chr4:10124366	chr4:10410996~10411644:+
STAD	cis	rs7412746	0.571	rs12402939	ENSG00000274963.1	Metazoa_SRP	4.16	4.04e-05	0.0156	0.19	0.22	Melanoma;	chr1:150642618	chr1:150568971~150569269:-
STAD	cis	rs9879311	0.966	rs4684684	ENSG00000240288.6	GHRLOS	4.16	4.04e-05	0.0156	0.22	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369660	chr3:10285754~10293449:+
STAD	cis	rs7924176	0.601	rs4638254	ENSG00000213731.2	RAB5CP1	-4.16	4.04e-05	0.0156	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74423435~74424014:-
STAD	cis	rs2638953	0.853	rs11049641	ENSG00000247934.4	RP11-967K21.1	-4.16	4.04e-05	0.0156	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471160	chr12:28163298~28190738:-
STAD	cis	rs2957692	0.548	rs61878622	ENSG00000254554.1	RP11-351I24.1	4.16	4.04e-05	0.0156	0.37	0.22	Circulating vasoactive peptide levels;	chr11:10095128	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs12418212	ENSG00000254554.1	RP11-351I24.1	4.16	4.04e-05	0.0156	0.37	0.22	Circulating vasoactive peptide levels;	chr11:10099610	chr11:10302657~10303704:-
STAD	cis	rs6813195	0.918	rs10011838	ENSG00000243417.1	RP11-555K12.1	4.16	4.05e-05	0.0156	0.22	0.22	Type 2 diabetes;	chr4:152599127	chr4:152551277~152552364:-
STAD	cis	rs9291683	0.597	rs11723016	ENSG00000250613.1	RP11-136I13.1	4.16	4.05e-05	0.0156	0.21	0.22	Bone mineral density;	chr4:10124565	chr4:10410996~10411644:+
STAD	cis	rs7131987	0.903	rs10843367	ENSG00000257176.2	RP11-996F15.2	-4.16	4.05e-05	0.0156	-0.25	-0.22	QT interval;	chr12:29255447	chr12:29280418~29317848:-
STAD	cis	rs4604732	0.642	rs10802514	ENSG00000227135.1	GCSAML-AS1	-4.16	4.05e-05	0.0156	-0.27	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247474447	chr1:247524679~247526752:-
STAD	cis	rs11169552	0.51	rs11613488	ENSG00000200183.1	RNU6-238P	-4.16	4.05e-05	0.0156	-0.21	-0.22	Colorectal cancer;	chr12:50584472	chr12:50656973~50657078:+
STAD	cis	rs10073892	0.789	rs72778000	ENSG00000250682.4	LINC00491	-4.16	4.05e-05	0.0156	-0.25	-0.22	Cognitive decline (age-related);	chr5:102329025	chr5:102609156~102671559:-
STAD	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-4.16	4.05e-05	0.0156	-0.35	-0.22	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-4.16	4.05e-05	0.0156	-0.35	-0.22	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-4.16	4.05e-05	0.0156	-0.35	-0.22	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
STAD	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-4.16	4.05e-05	0.0156	-0.35	-0.22	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
STAD	cis	rs8012947	1	rs7154076	ENSG00000279636.2	LINC00216	-4.16	4.05e-05	0.0156	-0.22	-0.22	Alcohol consumption in current drinkers;	chr14:58295564	chr14:58288033~58289158:+
STAD	cis	rs2390582	0.771	rs71666254	ENSG00000228175.3	GEMIN8P4	4.16	4.05e-05	0.0156	0.33	0.22	Coronary artery calcification;	chr1:90438181	chr1:89993593~89994321:-
STAD	cis	rs7829975	0.539	rs940031	ENSG00000254340.1	RP11-10A14.3	-4.16	4.06e-05	0.0156	-0.29	-0.22	Mood instability;	chr8:8689338	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	4.16	4.06e-05	0.0156	0.29	0.22	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
STAD	cis	rs989978	0.958	rs10458728	ENSG00000228778.1	RP11-129J12.1	-4.16	4.06e-05	0.0157	-0.27	-0.22	Red blood cell count;	chr10:99564219	chr10:99527081~99528261:+
STAD	cis	rs2957692	0.527	rs11042579	ENSG00000254554.1	RP11-351I24.1	4.16	4.06e-05	0.0157	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9978570	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.527	rs11042580	ENSG00000254554.1	RP11-351I24.1	4.16	4.06e-05	0.0157	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9978663	chr11:10302657~10303704:-
STAD	cis	rs1799949	1	rs2292595	ENSG00000279602.1	CTD-3014M21.1	4.16	4.06e-05	0.0157	0.27	0.22	Menopause (age at onset);	chr17:43138657	chr17:43360041~43361361:-
STAD	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	4.16	4.06e-05	0.0157	0.39	0.22	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
STAD	cis	rs7680126	0.633	rs887732	ENSG00000250613.1	RP11-136I13.1	4.16	4.07e-05	0.0157	0.26	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10181493	chr4:10410996~10411644:+
STAD	cis	rs3808502	0.516	rs6983727	ENSG00000254527.1	ENPP7P12	4.16	4.07e-05	0.0157	0.25	0.22	Neuroticism;	chr8:11558303	chr8:12205759~12206389:-
STAD	cis	rs4834770	1	rs4336213	ENSG00000248280.1	RP11-33B1.2	4.16	4.07e-05	0.0157	0.26	0.22	Blood protein levels;	chr4:119315314	chr4:119440561~119450157:-
STAD	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	4.16	4.07e-05	0.0157	0.3	0.22	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
STAD	cis	rs7924176	0.601	rs12414280	ENSG00000213731.2	RAB5CP1	-4.16	4.07e-05	0.0157	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74423435~74424014:-
STAD	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	4.16	4.07e-05	0.0157	0.29	0.22	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
STAD	cis	rs1707322	0.963	rs1768815	ENSG00000225447.1	RPS15AP10	-4.16	4.07e-05	0.0157	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45645816~45646197:-
STAD	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	4.16	4.07e-05	0.0157	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
STAD	cis	rs11098499	0.722	rs10006192	ENSG00000260091.1	RP11-33B1.4	4.16	4.07e-05	0.0157	0.2	0.22	Corneal astigmatism;	chr4:119341867	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.615	rs28551750	ENSG00000260091.1	RP11-33B1.4	4.16	4.07e-05	0.0157	0.2	0.22	Corneal astigmatism;	chr4:119343746	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.691	rs9995716	ENSG00000260091.1	RP11-33B1.4	4.16	4.07e-05	0.0157	0.2	0.22	Corneal astigmatism;	chr4:119343841	chr4:119409333~119410233:+
STAD	cis	rs1823874	0.677	rs8042705	ENSG00000182397.13	DNM1P46	-4.16	4.07e-05	0.0157	-0.23	-0.22	IgG glycosylation;	chr15:99824501	chr15:99790156~99806927:-
STAD	cis	rs6471393	0.929	rs62525163	ENSG00000253848.1	RP11-10N23.5	4.16	4.07e-05	0.0157	0.25	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749824	chr8:93741193~93744534:+
STAD	cis	rs6471393	0.929	rs62525164	ENSG00000253848.1	RP11-10N23.5	4.16	4.07e-05	0.0157	0.25	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93750084	chr8:93741193~93744534:+
STAD	cis	rs2253762	0.507	rs11200310	ENSG00000226864.1	ATE1-AS1	4.16	4.08e-05	0.0157	0.36	0.22	Breast cancer;	chr10:121989944	chr10:121928312~121951965:+
STAD	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	4.16	4.08e-05	0.0157	0.3	0.22	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
STAD	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	4.16	4.08e-05	0.0157	0.45	0.22	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
STAD	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-4.16	4.08e-05	0.0157	-0.24	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
STAD	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	4.16	4.08e-05	0.0157	0.31	0.22	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
STAD	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-4.16	4.08e-05	0.0157	-0.18	-0.22	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
STAD	cis	rs1707322	0.752	rs28550303	ENSG00000281133.1	AL355480.3	-4.16	4.08e-05	0.0157	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45580892~45580996:-
STAD	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	4.16	4.08e-05	0.0157	0.28	0.22	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
STAD	cis	rs2573652	0.722	rs11636047	ENSG00000270127.2	RP11-526I2.5	-4.16	4.08e-05	0.0157	-0.24	-0.22	Height;	chr15:100003136	chr15:100547765~100550153:-
STAD	cis	rs9902453	0.765	rs3102560	ENSG00000240074.1	RPL9P30	4.16	4.08e-05	0.0157	0.19	0.22	Coffee consumption (cups per day);	chr17:29702920	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.726	rs3115088	ENSG00000240074.1	RPL9P30	4.16	4.08e-05	0.0157	0.19	0.22	Coffee consumption (cups per day);	chr17:29704257	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.791	rs3115090	ENSG00000240074.1	RPL9P30	4.16	4.08e-05	0.0157	0.19	0.22	Coffee consumption (cups per day);	chr17:29707996	chr17:29855759~29856332:+
STAD	cis	rs11783469	0.524	rs2235116	ENSG00000253390.1	CTC-756D1.2	4.16	4.08e-05	0.0157	0.3	0.22	Reticulocyte count;	chr8:23479897	chr8:23458601~23484971:+
STAD	cis	rs9747201	0.962	rs62079995	ENSG00000281517.1	Metazoa_SRP	4.16	4.09e-05	0.0157	0.26	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82118748	chr17:81718849~81719095:-
STAD	cis	rs12745968	0.653	rs11164796	ENSG00000229052.2	RP11-386I23.1	-4.16	4.09e-05	0.0157	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92678523	chr1:92930696~92934098:+
STAD	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-4.16	4.09e-05	0.0157	-0.26	-0.22	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
STAD	cis	rs7226229	0.95	rs2291037	ENSG00000187870.7	RNFT1P3	4.16	4.09e-05	0.0157	0.26	0.22	Blood trace element (Se levels);	chr17:21021210	chr17:20743333~20754501:-
STAD	cis	rs6142102	1	rs4911412	ENSG00000264616.1	MIR4755	4.16	4.09e-05	0.0158	0.23	0.22	Skin pigmentation;	chr20:34128629	chr20:34049119~34049190:+
STAD	cis	rs1816752	0.646	rs6490937	ENSG00000273628.1	RP11-756A22.7	-4.16	4.09e-05	0.0158	-0.26	-0.22	Obesity-related traits;	chr13:24475834	chr13:24933006~24936796:+
STAD	cis	rs10508774	1	rs79749041	ENSG00000273038.2	RP11-479G22.8	4.16	4.09e-05	0.0158	0.45	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32864499	chr10:32887255~32889311:-
STAD	cis	rs1799949	0.929	rs799905	ENSG00000279602.1	CTD-3014M21.1	4.16	4.09e-05	0.0158	0.27	0.22	Menopause (age at onset);	chr17:43125170	chr17:43360041~43361361:-
STAD	cis	rs7474896	1	rs12358094	ENSG00000099251.13	HSD17B7P2	4.16	4.09e-05	0.0158	0.36	0.22	Obesity (extreme);	chr10:37726578	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs12358108	ENSG00000099251.13	HSD17B7P2	4.16	4.09e-05	0.0158	0.36	0.22	Obesity (extreme);	chr10:37726679	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.832	rs12783666	ENSG00000099251.13	HSD17B7P2	4.16	4.09e-05	0.0158	0.36	0.22	Obesity (extreme);	chr10:37728160	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs12766567	ENSG00000099251.13	HSD17B7P2	4.16	4.09e-05	0.0158	0.36	0.22	Obesity (extreme);	chr10:37746294	chr10:38356380~38378505:+
STAD	cis	rs1816752	0.646	rs9511301	ENSG00000273628.1	RP11-756A22.7	-4.16	4.09e-05	0.0158	-0.26	-0.22	Obesity-related traits;	chr13:24477034	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs7332220	ENSG00000273628.1	RP11-756A22.7	-4.16	4.09e-05	0.0158	-0.26	-0.22	Obesity-related traits;	chr13:24477081	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.624	rs11149109	ENSG00000273628.1	RP11-756A22.7	-4.16	4.09e-05	0.0158	-0.26	-0.22	Obesity-related traits;	chr13:24477290	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9511302	ENSG00000273628.1	RP11-756A22.7	-4.16	4.09e-05	0.0158	-0.26	-0.22	Obesity-related traits;	chr13:24477580	chr13:24933006~24936796:+
STAD	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-4.16	4.09e-05	0.0158	-0.28	-0.22	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
STAD	cis	rs1336900	0.513	rs56253522	ENSG00000274963.1	Metazoa_SRP	4.16	4.09e-05	0.0158	0.19	0.22	Blood protein levels;	chr1:150642393	chr1:150568971~150569269:-
STAD	cis	rs7829975	0.514	rs2976929	ENSG00000254340.1	RP11-10A14.3	4.16	4.09e-05	0.0158	0.25	0.22	Mood instability;	chr8:8401202	chr8:9141424~9145435:+
STAD	cis	rs10073892	0.62	rs55897698	ENSG00000250682.4	LINC00491	-4.16	4.09e-05	0.0158	-0.24	-0.22	Cognitive decline (age-related);	chr5:102599899	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.62	rs56076606	ENSG00000250682.4	LINC00491	-4.16	4.09e-05	0.0158	-0.24	-0.22	Cognitive decline (age-related);	chr5:102600161	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.62	rs13355922	ENSG00000250682.4	LINC00491	-4.16	4.09e-05	0.0158	-0.24	-0.22	Cognitive decline (age-related);	chr5:102600400	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.62	rs10035511	ENSG00000250682.4	LINC00491	-4.16	4.09e-05	0.0158	-0.24	-0.22	Cognitive decline (age-related);	chr5:102604705	chr5:102609156~102671559:-
STAD	cis	rs42490	0.59	rs441547	ENSG00000251136.7	RP11-37B2.1	-4.16	4.1e-05	0.0158	-0.22	-0.22	Leprosy;	chr8:89807954	chr8:89609409~89757727:-
STAD	cis	rs42490	0.614	rs441548	ENSG00000251136.7	RP11-37B2.1	-4.16	4.1e-05	0.0158	-0.22	-0.22	Leprosy;	chr8:89807955	chr8:89609409~89757727:-
STAD	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-4.16	4.1e-05	0.0158	-0.35	-0.22	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
STAD	cis	rs8099594	0.538	rs577081	ENSG00000266696.1	RP11-30L3.2	4.16	4.1e-05	0.0158	0.22	0.22	Height;	chr18:49314192	chr18:49205912~49208781:+
STAD	cis	rs6142102	1	rs2378078	ENSG00000275784.1	RP5-1125A11.6	-4.16	4.1e-05	0.0158	-0.22	-0.22	Skin pigmentation;	chr20:34126922	chr20:33989480~33991818:-
STAD	cis	rs2859998	0.892	rs2081688	ENSG00000250031.1	RP11-114M5.1	-4.16	4.1e-05	0.0158	-0.19	-0.22	Narcolepsy with cataplexy;	chr8:58438595	chr8:58424588~58426685:-
STAD	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-4.16	4.1e-05	0.0158	-0.26	-0.22	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
STAD	cis	rs2337406	0.714	rs2337463	ENSG00000280411.1	IGHV1-69-2	-4.15	4.11e-05	0.0158	-0.24	-0.22	Alzheimer's disease (late onset);	chr14:106816066	chr14:106762092~106762588:-
STAD	cis	rs1964356	0.967	rs2953802	ENSG00000233609.3	RP11-62H7.2	4.15	4.11e-05	0.0158	0.24	0.22	Mean corpuscular volume;	chr8:8994371	chr8:8961200~8979025:+
STAD	cis	rs10129255	0.5	rs2105989	ENSG00000211959.2	IGHV4-39	4.15	4.11e-05	0.0158	0.19	0.22	Kawasaki disease;	chr14:106682199	chr14:106421711~106422218:-
STAD	cis	rs1816752	0.583	rs9511284	ENSG00000273628.1	RP11-756A22.7	-4.15	4.11e-05	0.0158	-0.26	-0.22	Obesity-related traits;	chr13:24463660	chr13:24933006~24936796:+
STAD	cis	rs17301013	0.507	rs7515116	ENSG00000227373.4	RP11-160H22.5	-4.15	4.11e-05	0.0158	-0.33	-0.22	Systemic lupus erythematosus;	chr1:174474516	chr1:174115300~174160004:-
STAD	cis	rs7429990	0.965	rs1060407	ENSG00000224895.1	VPS26BP1	-4.15	4.11e-05	0.0158	-0.22	-0.22	Educational attainment (years of education);	chr3:47916547	chr3:47960327~47961081:-
STAD	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-4.15	4.11e-05	0.0158	-0.25	-0.22	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-4.15	4.11e-05	0.0158	-0.25	-0.22	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
STAD	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	4.15	4.11e-05	0.0158	0.36	0.22	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	4.15	4.11e-05	0.0158	0.36	0.22	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	4.15	4.11e-05	0.0158	0.36	0.22	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
STAD	cis	rs7829975	0.682	rs7013471	ENSG00000173295.6	FAM86B3P	-4.15	4.11e-05	0.0158	-0.25	-0.22	Mood instability;	chr8:8829815	chr8:8228595~8244865:+
STAD	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	4.15	4.11e-05	0.0158	0.3	0.22	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
STAD	cis	rs2351088	0.764	rs112928386	ENSG00000230634.1	RP5-996D20.3	-4.15	4.11e-05	0.0158	-0.34	-0.22	Tonsillectomy;	chr22:45821292	chr22:46481329~46481760:-
STAD	cis	rs1395	0.634	rs72817542	ENSG00000234072.1	AC074117.10	-4.15	4.11e-05	0.0158	-0.21	-0.22	Blood metabolite levels;	chr2:27303813	chr2:27356246~27367622:+
STAD	cis	rs6142102	0.923	rs3787230	ENSG00000264616.1	MIR4755	4.15	4.12e-05	0.0158	0.23	0.22	Skin pigmentation;	chr20:34052466	chr20:34049119~34049190:+
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000211959.2	IGHV4-39	4.15	4.12e-05	0.0158	0.19	0.22	Kawasaki disease;	chr14:106784065	chr14:106421711~106422218:-
STAD	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-4.15	4.12e-05	0.0158	-0.3	-0.22	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
STAD	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-4.15	4.12e-05	0.0158	-0.3	-0.22	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
STAD	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-4.15	4.12e-05	0.0158	-0.33	-0.22	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
STAD	cis	rs2992257	1	rs3006833	ENSG00000251839.1	RNU7-12P	-4.15	4.12e-05	0.0158	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26464429	chr10:27232255~27232316:-
STAD	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	4.15	4.12e-05	0.0158	0.29	0.22	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
STAD	cis	rs9291683	0.546	rs4575994	ENSG00000250613.1	RP11-136I13.1	-4.15	4.12e-05	0.0158	-0.22	-0.22	Bone mineral density;	chr4:9996355	chr4:10410996~10411644:+
STAD	cis	rs1426063	0.614	rs17000261	ENSG00000249717.1	RP11-44F21.3	4.15	4.12e-05	0.0159	0.43	0.22	QT interval;	chr4:75108766	chr4:74955974~74970362:-
STAD	cis	rs12530	0.54	rs5998471	ENSG00000230736.2	RP1-149A16.3	-4.15	4.12e-05	0.0159	-0.26	-0.22	IgG glycosylation;	chr22:32390230	chr22:32376664~32384343:+
STAD	cis	rs748404	0.631	rs2412781	ENSG00000275601.1	AC011330.13	4.15	4.12e-05	0.0159	0.23	0.22	Lung cancer;	chr15:43375702	chr15:43642389~43643023:-
STAD	cis	rs2115630	1	rs7183401	ENSG00000275120.1	RP11-182J1.17	-4.15	4.12e-05	0.0159	-0.24	-0.22	P wave terminal force;	chr15:84828713	chr15:84599434~84606463:-
STAD	cis	rs12468226	0.873	rs3181153	ENSG00000226261.1	AC064836.3	-4.15	4.13e-05	0.0159	-0.36	-0.22	Urate levels;	chr2:202205155	chr2:202336024~202336727:-
STAD	cis	rs1707322	1	rs34694458	ENSG00000281133.1	AL355480.3	-4.15	4.13e-05	0.0159	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45580892~45580996:-
STAD	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	4.15	4.13e-05	0.0159	0.27	0.22	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
STAD	cis	rs12824058	0.844	rs7956408	ENSG00000279343.1	RP11-200K12.3	4.15	4.13e-05	0.0159	0.24	0.22	Menopause (age at onset);	chr12:130323002	chr12:130350996~130351707:-
STAD	cis	rs4141404	0.582	rs5753630	ENSG00000236132.1	CTA-440B3.1	-4.15	4.13e-05	0.0159	-0.24	-0.22	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:31816379~31817491:-
STAD	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-4.15	4.13e-05	0.0159	-0.21	-0.22	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
STAD	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-4.15	4.13e-05	0.0159	-0.27	-0.22	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
STAD	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	4.15	4.13e-05	0.0159	0.27	0.22	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
STAD	cis	rs62400317	0.762	rs17423748	ENSG00000219384.1	RP11-491H9.3	-4.15	4.13e-05	0.0159	-0.25	-0.22	Total body bone mineral density;	chr6:44976245	chr6:45158870~45159511:+
STAD	cis	rs7119038	0.774	rs11217020	ENSG00000255422.1	AP002954.4	4.15	4.13e-05	0.0159	0.3	0.22	Sjögren's syndrome;	chr11:118768644	chr11:118704607~118750263:+
STAD	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	4.15	4.14e-05	0.0159	0.28	0.22	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
STAD	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	4.15	4.14e-05	0.0159	0.35	0.22	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	4.15	4.14e-05	0.0159	0.35	0.22	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
STAD	cis	rs561341	1	rs554078	ENSG00000265798.5	RP11-271K11.5	4.15	4.14e-05	0.0159	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32003090	chr17:31038575~31059121:-
STAD	cis	rs8062405	1	rs4451951	ENSG00000278665.1	RP11-666O2.4	4.15	4.14e-05	0.0159	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28599241~28601881:-
STAD	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	4.15	4.14e-05	0.0159	0.25	0.22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
STAD	cis	rs7824557	0.527	rs11785394	ENSG00000205879.4	FAM90A2P	-4.15	4.14e-05	0.0159	-0.25	-0.22	Retinal vascular caliber;	chr8:11380520	chr8:12172202~12178575:-
STAD	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	4.15	4.14e-05	0.0159	0.32	0.22	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
STAD	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-4.15	4.14e-05	0.0159	-0.31	-0.22	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
STAD	cis	rs3733585	0.736	rs4543113	ENSG00000250613.1	RP11-136I13.1	-4.15	4.14e-05	0.0159	-0.22	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10006681	chr4:10410996~10411644:+
STAD	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-4.15	4.14e-05	0.0159	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
STAD	cis	rs28472312	0.832	rs28433345	ENSG00000278665.1	RP11-666O2.4	4.15	4.14e-05	0.0159	0.25	0.22	Intelligence (multi-trait analysis);	chr16:28872006	chr16:28599241~28601881:-
STAD	cis	rs7924176	0.601	rs767809	ENSG00000213731.2	RAB5CP1	-4.15	4.15e-05	0.0159	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74105307	chr10:74423435~74424014:-
STAD	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-4.15	4.15e-05	0.0159	-0.27	-0.22	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
STAD	cis	rs875971	0.965	rs7794930	ENSG00000236529.1	RP13-254B10.1	-4.15	4.15e-05	0.0159	-0.23	-0.22	Aortic root size;	chr7:66313559	chr7:65840212~65840596:+
STAD	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-4.15	4.15e-05	0.0159	-0.25	-0.22	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
STAD	cis	rs11169552	0.51	rs876078	ENSG00000200183.1	RNU6-238P	-4.15	4.15e-05	0.0159	-0.21	-0.22	Colorectal cancer;	chr12:50636052	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.51	rs10876063	ENSG00000200183.1	RNU6-238P	-4.15	4.15e-05	0.0159	-0.21	-0.22	Colorectal cancer;	chr12:50578302	chr12:50656973~50657078:+
STAD	cis	rs858239	0.669	rs6461687	ENSG00000230042.1	AK3P3	-4.15	4.15e-05	0.0159	-0.23	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23129178~23129841:+
STAD	cis	rs9902453	1	rs9896062	ENSG00000240074.1	RPL9P30	-4.15	4.15e-05	0.0159	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30030029	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.967	rs9904336	ENSG00000240074.1	RPL9P30	-4.15	4.15e-05	0.0159	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30030062	chr17:29855759~29856332:+
STAD	cis	rs867371	0.892	rs4344697	ENSG00000276710.3	CSPG4P8	-4.15	4.15e-05	0.0159	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82459472~82477258:+
STAD	cis	rs2273156	1	rs60803103	ENSG00000241052.1	RP11-173D9.1	-4.15	4.15e-05	0.0159	-0.24	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:34944847	chr14:35144021~35144480:-
STAD	cis	rs8062405	1	rs55991577	ENSG00000278665.1	RP11-666O2.4	4.15	4.15e-05	0.0159	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs56358680	ENSG00000278665.1	RP11-666O2.4	4.15	4.15e-05	0.0159	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28599241~28601881:-
STAD	cis	rs10129255	0.5	rs1974468	ENSG00000224373.3	IGHV4-59	4.15	4.15e-05	0.0159	0.15	0.22	Kawasaki disease;	chr14:106686149	chr14:106627249~106627825:-
STAD	cis	rs1707322	0.927	rs6690386	ENSG00000225447.1	RPS15AP10	4.15	4.15e-05	0.0159	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs4630155	ENSG00000225447.1	RPS15AP10	4.15	4.15e-05	0.0159	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45645816~45646197:-
STAD	cis	rs7647973	0.56	rs7638154	ENSG00000225399.4	RP11-3B7.1	4.15	4.15e-05	0.0159	0.24	0.22	Menarche (age at onset);	chr3:49261942	chr3:49260085~49261316:+
STAD	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-4.15	4.15e-05	0.0159	-0.27	-0.22	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
STAD	cis	rs6061231	0.583	rs2427313	ENSG00000275437.1	RP5-908M14.10	4.15	4.15e-05	0.0159	0.21	0.22	Colorectal cancer;	chr20:62395619	chr20:62402236~62405935:-
STAD	cis	rs2337406	0.85	rs4774179	ENSG00000280411.1	IGHV1-69-2	-4.15	4.15e-05	0.0159	-0.27	-0.22	Alzheimer's disease (late onset);	chr14:106700837	chr14:106762092~106762588:-
STAD	cis	rs5758659	0.714	rs5751216	ENSG00000182057.4	OGFRP1	-4.15	4.15e-05	0.0159	-0.23	-0.22	Cognitive function;	chr22:42112933	chr22:42269753~42275196:+
STAD	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-4.15	4.15e-05	0.0159	-0.31	-0.22	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
STAD	cis	rs2143950	0.749	rs57275892	ENSG00000258704.4	SRP54-AS1	-4.15	4.16e-05	0.0159	-0.29	-0.22	Atopic dermatitis;	chr14:35278065	chr14:34920858~34982532:-
STAD	cis	rs2348418	0.83	rs4930821	ENSG00000247934.4	RP11-967K21.1	4.15	4.16e-05	0.016	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28410948	chr12:28163298~28190738:-
STAD	cis	rs4763879	0.634	rs11052582	ENSG00000256673.1	RP11-599J14.2	4.15	4.16e-05	0.016	0.24	0.22	Type 1 diabetes;	chr12:9706714	chr12:9398355~9414851:-
STAD	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	4.15	4.16e-05	0.016	0.27	0.22	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
STAD	cis	rs10129255	0.917	rs11625208	ENSG00000232216.1	IGHV3-43	4.15	4.16e-05	0.016	0.22	0.22	Kawasaki disease;	chr14:106698757	chr14:106470264~106470800:-
STAD	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	4.15	4.16e-05	0.016	0.24	0.22	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	4.15	4.16e-05	0.016	0.24	0.22	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	4.15	4.16e-05	0.016	0.24	0.22	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	4.15	4.16e-05	0.016	0.24	0.22	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	4.15	4.16e-05	0.016	0.24	0.22	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
STAD	cis	rs938554	0.612	rs13113918	ENSG00000250613.1	RP11-136I13.1	-4.15	4.16e-05	0.016	-0.25	-0.22	Blood metabolite levels;	chr4:9996869	chr4:10410996~10411644:+
STAD	cis	rs2262909	0.962	rs12609368	ENSG00000213976.4	CTD-2561J22.2	4.15	4.16e-05	0.016	0.27	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22081194	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs56369285	ENSG00000213976.4	CTD-2561J22.2	4.15	4.16e-05	0.016	0.27	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22084383	chr19:21382865~21387177:+
STAD	cis	rs950169	0.881	rs150965	ENSG00000259683.1	RP11-182J1.14	4.15	4.16e-05	0.016	0.23	0.22	Schizophrenia;	chr15:84537296	chr15:84389729~84395903:+
STAD	cis	rs238295	0.602	rs6053458	ENSG00000230563.2	RP5-828H9.1	-4.15	4.16e-05	0.016	-0.25	-0.22	Occipital cortical area (total cortical area interaction);	chr20:5529539	chr20:5471207~5475182:+
STAD	cis	rs4970966	0.951	rs11204682	ENSG00000276103.1	U4	-4.15	4.16e-05	0.016	-0.24	-0.22	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:150623061	chr1:150608507~150608623:-
STAD	cis	rs240993	0.516	rs414763	ENSG00000230177.1	RP5-1112D6.4	-4.15	4.16e-05	0.016	-0.26	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111324561	chr6:111277932~111278742:+
STAD	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-4.15	4.16e-05	0.016	-0.36	-0.22	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
STAD	cis	rs7119038	0.818	rs56758835	ENSG00000255422.1	AP002954.4	4.15	4.16e-05	0.016	0.3	0.22	Sjögren's syndrome;	chr11:118744631	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.818	rs1048024	ENSG00000255422.1	AP002954.4	4.15	4.16e-05	0.016	0.3	0.22	Sjögren's syndrome;	chr11:118748067	chr11:118704607~118750263:+
STAD	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	4.15	4.16e-05	0.016	0.26	0.22	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	4.15	4.16e-05	0.016	0.26	0.22	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
STAD	cis	rs449789	0.711	rs7765794	ENSG00000235086.1	FNDC1-IT1	-4.15	4.17e-05	0.016	-0.28	-0.22	Pulse pressure;	chr6:159283893	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs592212	ENSG00000235086.1	FNDC1-IT1	-4.15	4.17e-05	0.016	-0.28	-0.22	Pulse pressure;	chr6:159290051	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs2451988	ENSG00000235086.1	FNDC1-IT1	-4.15	4.17e-05	0.016	-0.28	-0.22	Pulse pressure;	chr6:159293358	chr6:159240786~159243329:+
STAD	cis	rs1799949	0.965	rs35521261	ENSG00000279602.1	CTD-3014M21.1	4.15	4.17e-05	0.016	0.27	0.22	Menopause (age at onset);	chr17:43161595	chr17:43360041~43361361:-
STAD	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-4.15	4.17e-05	0.016	-0.31	-0.22	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
STAD	cis	rs9813712	0.596	rs2587988	ENSG00000249846.5	RP11-77P16.4	-4.15	4.17e-05	0.016	-0.24	-0.22	Response to amphetamines;	chr3:130201415	chr3:130112550~130120579:+
STAD	cis	rs858239	1	rs199348	ENSG00000230042.1	AK3P3	-4.15	4.17e-05	0.016	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23129178~23129841:+
STAD	cis	rs6471393	0.929	rs58575315	ENSG00000253848.1	RP11-10N23.5	4.15	4.17e-05	0.016	0.25	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749495	chr8:93741193~93744534:+
STAD	cis	rs6471393	0.929	rs62525162	ENSG00000253848.1	RP11-10N23.5	4.15	4.17e-05	0.016	0.25	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749654	chr8:93741193~93744534:+
STAD	cis	rs7655841	0.704	rs28711799	ENSG00000248187.1	RP11-184M15.1	4.15	4.17e-05	0.016	0.34	0.22	Chronic obstructive pulmonary disease (moderate to severe);	chr4:128953341	chr4:128567972~128570531:-
STAD	cis	rs12500234	1	rs11097000	ENSG00000249207.1	RP11-360F5.1	-4.15	4.17e-05	0.016	-0.22	-0.22	Colorectal cancer;	chr4:39617132	chr4:39112677~39126818:-
STAD	cis	rs12500234	1	rs2381394	ENSG00000249207.1	RP11-360F5.1	-4.15	4.17e-05	0.016	-0.22	-0.22	Colorectal cancer;	chr4:39619924	chr4:39112677~39126818:-
STAD	cis	rs806321	0.587	rs2703088	ENSG00000237152.3	DLEU7-AS1	-4.15	4.17e-05	0.016	-0.25	-0.22	Multiple sclerosis;	chr13:50188808	chr13:50807856~50849905:+
STAD	cis	rs6430585	0.583	rs60253740	ENSG00000231890.6	DARS-AS1	-4.15	4.17e-05	0.016	-0.25	-0.22	Corneal structure;	chr2:135814282	chr2:135985176~136022593:+
STAD	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-4.15	4.18e-05	0.016	-0.22	-0.22	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
STAD	cis	rs7937890	1	rs6486190	ENSG00000254418.1	RP11-21L19.1	4.15	4.18e-05	0.016	0.23	0.22	Mitochondrial DNA levels;	chr11:14379670	chr11:14262846~14273691:-
STAD	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	4.15	4.18e-05	0.016	0.28	0.22	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
STAD	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	4.15	4.18e-05	0.016	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
STAD	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	4.15	4.18e-05	0.016	0.33	0.22	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
STAD	cis	rs7202877	0.706	rs247434	ENSG00000261783.1	RP11-252K23.2	4.15	4.18e-05	0.016	0.36	0.22	Type 1 diabetes;Type 2 diabetes;	chr16:75411406	chr16:75379818~75381260:-
STAD	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	4.15	4.18e-05	0.016	0.24	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-4.15	4.18e-05	0.016	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
STAD	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	4.15	4.18e-05	0.016	0.28	0.22	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
STAD	cis	rs7829975	0.714	rs59046059	ENSG00000253981.4	ALG1L13P	4.15	4.18e-05	0.016	0.26	0.22	Mood instability;	chr8:8813226	chr8:8236003~8244667:-
STAD	cis	rs7615952	0.551	rs6438945	ENSG00000239804.1	RP11-379B18.1	4.15	4.18e-05	0.016	0.36	0.22	Blood pressure (smoking interaction);	chr3:125915630	chr3:125787888~125788146:-
STAD	cis	rs2253762	0.54	rs4752631	ENSG00000226864.1	ATE1-AS1	4.15	4.19e-05	0.016	0.35	0.22	Breast cancer;	chr10:121996442	chr10:121928312~121951965:+
STAD	cis	rs2439831	0.85	rs7183809	ENSG00000275601.1	AC011330.13	-4.15	4.19e-05	0.0161	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43828670	chr15:43642389~43643023:-
STAD	cis	rs2439831	0.85	rs3759790	ENSG00000275601.1	AC011330.13	-4.15	4.19e-05	0.0161	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43828832	chr15:43642389~43643023:-
STAD	cis	rs1799949	0.93	rs1554063	ENSG00000279602.1	CTD-3014M21.1	4.15	4.19e-05	0.0161	0.27	0.22	Menopause (age at onset);	chr17:43135128	chr17:43360041~43361361:-
STAD	cis	rs875971	1	rs11971949	ENSG00000224316.1	RP11-479O9.2	-4.15	4.19e-05	0.0161	-0.22	-0.22	Aortic root size;	chr7:66161027	chr7:65773620~65802067:+
STAD	cis	rs4950322	0.58	rs2083720	ENSG00000278811.3	LINC00624	4.15	4.19e-05	0.0161	0.24	0.22	Protein quantitative trait loci;	chr1:147122296	chr1:147258885~147517875:-
STAD	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	4.15	4.19e-05	0.0161	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
STAD	cis	rs8141529	0.588	rs10222249	ENSG00000226471.5	CTA-292E10.6	-4.15	4.2e-05	0.0161	-0.28	-0.22	Lymphocyte counts;	chr22:28861159	chr22:28800683~28848559:+
STAD	cis	rs950027	0.787	rs1153845	ENSG00000275672.1	GATM-AS1	4.15	4.2e-05	0.0161	0.23	0.22	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45378700~45380123:+
STAD	cis	rs561341	0.7	rs2074101	ENSG00000265798.5	RP11-271K11.5	4.15	4.2e-05	0.0161	0.26	0.22	Hip circumference adjusted for BMI;	chr17:31901637	chr17:31038575~31059121:-
STAD	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	4.15	4.2e-05	0.0161	0.34	0.22	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
STAD	cis	rs34779708	0.966	rs6481941	ENSG00000271335.4	RP11-324I22.4	4.15	4.2e-05	0.0161	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35314552~35336401:-
STAD	cis	rs12745968	0.685	rs2180976	ENSG00000229052.2	RP11-386I23.1	-4.15	4.2e-05	0.0161	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92805775	chr1:92930696~92934098:+
STAD	cis	rs1707322	1	rs6657720	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs7519181	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs7526369	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs10890371	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs10890372	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.928	rs6681068	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211228	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs11211229	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs9803784	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs12022335	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs10789484	ENSG00000225447.1	RPS15AP10	4.15	4.2e-05	0.0161	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45645816~45646197:-
STAD	cis	rs1499614	1	rs2707832	ENSG00000273448.1	RP11-166O4.6	4.15	4.2e-05	0.0161	0.27	0.22	Gout;	chr7:66671562	chr7:67333047~67334383:+
STAD	cis	rs4561483	0.843	rs35153773	ENSG00000260224.1	UBL5P4	-4.15	4.2e-05	0.0161	-0.22	-0.22	Testicular germ cell tumor;	chr16:11842460	chr16:11968508~11968743:-
STAD	cis	rs451417	0.841	rs12106220	ENSG00000275632.1	RP5-967N21.11	4.15	4.2e-05	0.0161	0.29	0.22	Menopause (age at onset);	chr20:5963609	chr20:6000418~6000941:+
STAD	cis	rs6142102	0.659	rs6057945	ENSG00000264616.1	MIR4755	4.15	4.21e-05	0.0161	0.23	0.22	Skin pigmentation;	chr20:33929374	chr20:34049119~34049190:+
STAD	cis	rs1707322	0.827	rs6694302	ENSG00000281133.1	AL355480.3	-4.15	4.21e-05	0.0161	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45580892~45580996:-
STAD	cis	rs227275	0.525	rs17215211	ENSG00000248971.2	KRT8P46	-4.15	4.21e-05	0.0161	-0.23	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102728746~102730171:-
STAD	cis	rs561341	1	rs693116	ENSG00000265798.5	RP11-271K11.5	4.15	4.21e-05	0.0161	0.34	0.22	Hip circumference adjusted for BMI;	chr17:31919105	chr17:31038575~31059121:-
STAD	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-4.15	4.21e-05	0.0161	-0.25	-0.22	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
STAD	cis	rs4142995	0.703	rs2723511	ENSG00000279048.1	RP11-511H23.2	-4.15	4.21e-05	0.0161	-0.21	-0.22	HDL cholesterol;HDL cholesterol levels;	chr7:17776855	chr7:17940503~17942922:+
STAD	cis	rs4142995	0.695	rs2723510	ENSG00000279048.1	RP11-511H23.2	-4.15	4.21e-05	0.0161	-0.21	-0.22	HDL cholesterol;HDL cholesterol levels;	chr7:17777015	chr7:17940503~17942922:+
STAD	cis	rs11169552	0.51	rs10876061	ENSG00000200183.1	RNU6-238P	-4.15	4.21e-05	0.0161	-0.21	-0.22	Colorectal cancer;	chr12:50574902	chr12:50656973~50657078:+
STAD	cis	rs10129255	0.957	rs10136817	ENSG00000224373.3	IGHV4-59	4.15	4.21e-05	0.0161	0.18	0.22	Kawasaki disease;	chr14:106787730	chr14:106627249~106627825:-
STAD	cis	rs2921036	0.505	rs35190619	ENSG00000173295.6	FAM86B3P	-4.15	4.21e-05	0.0161	-0.31	-0.22	Neuroticism;	chr8:8504313	chr8:8228595~8244865:+
STAD	cis	rs11662586	0.517	rs11663082	ENSG00000261126.6	RP11-795F19.1	4.15	4.21e-05	0.0161	0.25	0.22	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953494	chr18:80046900~80095482:+
STAD	cis	rs11662586	0.517	rs11662894	ENSG00000261126.6	RP11-795F19.1	4.15	4.21e-05	0.0161	0.25	0.22	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953591	chr18:80046900~80095482:+
STAD	cis	rs7927771	0.832	rs10838697	ENSG00000271350.1	CTD-2384B9.1	-4.15	4.21e-05	0.0161	-0.24	-0.22	Subjective well-being;	chr11:47362933	chr11:47041027~47041945:-
STAD	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	4.15	4.21e-05	0.0161	0.23	0.22	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
STAD	cis	rs10829156	0.732	rs4747348	ENSG00000240291.1	RP11-499P20.2	4.15	4.21e-05	0.0161	0.25	0.22	Sudden cardiac arrest;	chr10:18506126	chr10:18513115~18545651:-
STAD	cis	rs2921073	0.605	rs2976933	ENSG00000253981.4	ALG1L13P	4.15	4.21e-05	0.0161	0.26	0.22	Parkinson's disease;	chr8:8397365	chr8:8236003~8244667:-
STAD	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	4.15	4.22e-05	0.0161	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
STAD	cis	rs1816752	0.646	rs1361578	ENSG00000273628.1	RP11-756A22.7	-4.15	4.22e-05	0.0161	-0.26	-0.22	Obesity-related traits;	chr13:24491117	chr13:24933006~24936796:+
STAD	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	4.15	4.22e-05	0.0161	0.42	0.22	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
STAD	cis	rs875971	1	rs2420168	ENSG00000224316.1	RP11-479O9.2	-4.15	4.22e-05	0.0161	-0.22	-0.22	Aortic root size;	chr7:66165644	chr7:65773620~65802067:+
STAD	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	4.15	4.22e-05	0.0161	0.3	0.22	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
STAD	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	4.15	4.22e-05	0.0161	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	4.15	4.22e-05	0.0161	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
STAD	cis	rs2579500	0.702	rs6576974	ENSG00000230606.9	AC159540.1	4.15	4.22e-05	0.0162	0.26	0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96578648	chr2:97416165~97433527:-
STAD	cis	rs9847710	1	rs9847710	ENSG00000242142.1	SERBP1P3	4.15	4.22e-05	0.0162	0.21	0.22	Ulcerative colitis;	chr3:53028645	chr3:53064283~53065091:-
STAD	cis	rs451417	1	rs236120	ENSG00000275632.1	RP5-967N21.11	4.15	4.22e-05	0.0162	0.29	0.22	Menopause (age at onset);	chr20:5959003	chr20:6000418~6000941:+
STAD	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	4.15	4.23e-05	0.0162	0.29	0.22	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	4.15	4.23e-05	0.0162	0.29	0.22	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	4.15	4.23e-05	0.0162	0.29	0.22	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	4.15	4.23e-05	0.0162	0.29	0.22	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	4.15	4.23e-05	0.0162	0.29	0.22	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
STAD	cis	rs9747201	0.925	rs11867806	ENSG00000281517.1	Metazoa_SRP	4.15	4.23e-05	0.0162	0.26	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82114173	chr17:81718849~81719095:-
STAD	cis	rs1707322	1	rs10890378	ENSG00000225447.1	RPS15AP10	-4.15	4.23e-05	0.0162	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45645816~45646197:-
STAD	cis	rs4589258	0.762	rs4306265	ENSG00000280367.1	RP11-121L10.2	4.15	4.23e-05	0.0162	0.22	0.22	Intelligence (multi-trait analysis);	chr11:90739564	chr11:90223153~90226538:+
STAD	cis	rs34779708	0.897	rs12830	ENSG00000271335.4	RP11-324I22.4	4.15	4.23e-05	0.0162	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35314552~35336401:-
STAD	cis	rs13401620	0.555	rs11550347	ENSG00000224789.1	AC012363.4	4.15	4.23e-05	0.0162	0.27	0.22	Breast size;	chr2:120222852	chr2:120174885~120216544:-
STAD	cis	rs2115630	1	rs55646601	ENSG00000275120.1	RP11-182J1.17	-4.15	4.23e-05	0.0162	-0.24	-0.22	P wave terminal force;	chr15:84780337	chr15:84599434~84606463:-
STAD	cis	rs11235843	0.715	rs12421900	ENSG00000255928.1	RP11-456I15.2	4.15	4.23e-05	0.0162	0.39	0.22	Hand grip strength;	chr11:73840111	chr11:73722349~73722694:+
STAD	cis	rs9784649	0.771	rs72755810	ENSG00000245662.2	RP11-184E9.1	4.15	4.23e-05	0.0162	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25039030	chr5:25190682~25306172:+
STAD	cis	rs7829975	0.782	rs6990746	ENSG00000254340.1	RP11-10A14.3	-4.15	4.23e-05	0.0162	-0.27	-0.22	Mood instability;	chr8:8690301	chr8:9141424~9145435:+
STAD	cis	rs8012947	1	rs12878264	ENSG00000279636.2	LINC00216	-4.15	4.23e-05	0.0162	-0.21	-0.22	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58288033~58289158:+
STAD	cis	rs2836950	0.509	rs4816618	ENSG00000238141.2	BRWD1-AS1	-4.15	4.23e-05	0.0162	-0.23	-0.22	Menarche (age at onset);	chr21:39227603	chr21:39315707~39323218:+
STAD	cis	rs2836950	0.527	rs2836948	ENSG00000238141.2	BRWD1-AS1	-4.15	4.23e-05	0.0162	-0.23	-0.22	Menarche (age at onset);	chr21:39227751	chr21:39315707~39323218:+
STAD	cis	rs34779708	0.966	rs12782948	ENSG00000271335.4	RP11-324I22.4	4.15	4.23e-05	0.0162	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35314552~35336401:-
STAD	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	4.15	4.24e-05	0.0162	0.25	0.22	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
STAD	cis	rs8081395	0.651	rs1292067	ENSG00000266701.1	AC005702.4	-4.15	4.24e-05	0.0162	-0.28	-0.22	White blood cell count;	chr17:59853285	chr17:60042546~60042627:-
STAD	cis	rs2348418	0.733	rs4931078	ENSG00000247934.4	RP11-967K21.1	-4.15	4.24e-05	0.0162	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28163298~28190738:-
STAD	cis	rs11587682	0.76	rs12116970	ENSG00000274963.1	Metazoa_SRP	-4.15	4.24e-05	0.0162	-0.22	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150494449	chr1:150568971~150569269:-
STAD	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	4.15	4.24e-05	0.0162	0.23	0.22	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
STAD	cis	rs2992257	0.915	rs2992319	ENSG00000251839.1	RNU7-12P	-4.15	4.24e-05	0.0162	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26420608	chr10:27232255~27232316:-
STAD	cis	rs2992257	0.871	rs2992320	ENSG00000251839.1	RNU7-12P	-4.15	4.24e-05	0.0162	-0.22	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26420705	chr10:27232255~27232316:-
STAD	cis	rs5753618	0.561	rs715510	ENSG00000236132.1	CTA-440B3.1	4.15	4.24e-05	0.0162	0.26	0.22	Colorectal cancer;	chr22:31294542	chr22:31816379~31817491:-
STAD	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	4.15	4.25e-05	0.0162	0.5	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
STAD	cis	rs12468226	0.938	rs56684065	ENSG00000272966.1	RP11-686O6.1	4.15	4.25e-05	0.0162	0.33	0.22	Urate levels;	chr2:202289528	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs1474001	ENSG00000272966.1	RP11-686O6.1	4.15	4.25e-05	0.0162	0.33	0.22	Urate levels;	chr2:202290230	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs76664732	ENSG00000272966.1	RP11-686O6.1	4.15	4.25e-05	0.0162	0.33	0.22	Urate levels;	chr2:202296298	chr2:202336739~202337200:+
STAD	cis	rs8014252	0.614	rs60251828	ENSG00000259158.2	ADAM20P1	-4.15	4.25e-05	0.0162	-0.3	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70594734	chr14:70468881~70483756:-
STAD	cis	rs2034650	0.544	rs661488	ENSG00000223313.1	RNU6-516P	4.15	4.25e-05	0.0162	0.25	0.22	Interstitial lung disease;	chr15:40429221	chr15:40529570~40529673:+
STAD	cis	rs6430585	0.528	rs309142	ENSG00000231890.6	DARS-AS1	-4.15	4.25e-05	0.0162	-0.24	-0.22	Corneal structure;	chr2:135957754	chr2:135985176~136022593:+
STAD	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-4.15	4.25e-05	0.0162	-0.25	-0.22	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
STAD	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-4.15	4.25e-05	0.0162	-0.25	-0.22	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
STAD	cis	rs4950322	0.518	rs56151278	ENSG00000278811.3	LINC00624	4.15	4.25e-05	0.0162	0.23	0.22	Protein quantitative trait loci;	chr1:147117421	chr1:147258885~147517875:-
STAD	cis	rs7615952	0.673	rs9841194	ENSG00000239804.1	RP11-379B18.1	4.15	4.25e-05	0.0162	0.41	0.22	Blood pressure (smoking interaction);	chr3:125916896	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.673	rs9289270	ENSG00000239804.1	RP11-379B18.1	4.15	4.25e-05	0.0162	0.41	0.22	Blood pressure (smoking interaction);	chr3:125918136	chr3:125787888~125788146:-
STAD	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-4.15	4.25e-05	0.0163	-0.32	-0.22	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
STAD	cis	rs1059312	0.545	rs7312683	ENSG00000279500.1	RP11-21K12.2	-4.15	4.26e-05	0.0163	-0.21	-0.22	Systemic lupus erythematosus;	chr12:128795560	chr12:128813186~128814750:-
STAD	cis	rs870825	0.616	rs6833858	ENSG00000249173.4	LINC01093	-4.15	4.26e-05	0.0163	-0.35	-0.22	Blood protein levels;	chr4:184718807	chr4:184893871~184899454:-
STAD	cis	rs73198271	0.722	rs488566	ENSG00000254340.1	RP11-10A14.3	-4.15	4.26e-05	0.0163	-0.29	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8782065	chr8:9141424~9145435:+
STAD	cis	rs2638953	0.64	rs11049723	ENSG00000247934.4	RP11-967K21.1	4.15	4.26e-05	0.0163	0.26	0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28575903	chr12:28163298~28190738:-
STAD	cis	rs11089937	0.929	rs2236727	ENSG00000211638.2	IGLV8-61	-4.15	4.26e-05	0.0163	-0.22	-0.22	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22098700~22099212:+
STAD	cis	rs561341	1	rs530209	ENSG00000265798.5	RP11-271K11.5	4.15	4.26e-05	0.0163	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31988268	chr17:31038575~31059121:-
STAD	cis	rs11907546	1	rs11907546	ENSG00000264616.1	MIR4755	4.15	4.26e-05	0.0163	0.22	0.22	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:34049119~34049190:+
STAD	cis	rs2273156	0.673	rs12887885	ENSG00000241052.1	RP11-173D9.1	-4.15	4.27e-05	0.0163	-0.24	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:34906876	chr14:35144021~35144480:-
STAD	cis	rs516805	0.528	rs1379094	ENSG00000279453.1	RP3-425C14.4	4.15	4.27e-05	0.0163	0.31	0.22	Lymphocyte counts;	chr6:122098054	chr6:122436789~122439223:-
STAD	cis	rs867371	0.964	rs7169961	ENSG00000276710.3	CSPG4P8	-4.15	4.27e-05	0.0163	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82459472~82477258:+
STAD	cis	rs867371	1	rs6495643	ENSG00000276710.3	CSPG4P8	-4.15	4.27e-05	0.0163	-0.25	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82459472~82477258:+
STAD	cis	rs938554	0.612	rs28592748	ENSG00000250613.1	RP11-136I13.1	-4.15	4.27e-05	0.0163	-0.25	-0.22	Blood metabolite levels;	chr4:9996981	chr4:10410996~10411644:+
STAD	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-4.15	4.27e-05	0.0163	-0.23	-0.22	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
STAD	cis	rs806321	0.587	rs2740518	ENSG00000237152.3	DLEU7-AS1	-4.15	4.27e-05	0.0163	-0.25	-0.22	Multiple sclerosis;	chr13:50188809	chr13:50807856~50849905:+
STAD	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	4.15	4.27e-05	0.0163	0.31	0.22	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
STAD	cis	rs62400317	0.762	rs62436411	ENSG00000219384.1	RP11-491H9.3	-4.15	4.27e-05	0.0163	-0.25	-0.22	Total body bone mineral density;	chr6:44972969	chr6:45158870~45159511:+
STAD	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	4.15	4.27e-05	0.0163	0.31	0.22	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
STAD	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	4.15	4.27e-05	0.0163	0.31	0.22	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
STAD	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	4.15	4.27e-05	0.0163	0.23	0.22	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
STAD	cis	rs944722	0.901	rs1060826	ENSG00000266786.1	LGALS9DP	4.15	4.28e-05	0.0163	0.27	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27762841	chr17:27746132~27754954:+
STAD	cis	rs944722	0.967	rs2297511	ENSG00000266786.1	LGALS9DP	4.15	4.28e-05	0.0163	0.27	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27764201	chr17:27746132~27754954:+
STAD	cis	rs71327718	1	rs71327718	ENSG00000241346.1	SNRPCP11	4.15	4.28e-05	0.0163	0.38	0.22	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125816082~125816286:-
STAD	cis	rs7655841	0.773	rs6812361	ENSG00000248187.1	RP11-184M15.1	4.14	4.28e-05	0.0163	0.33	0.22	Chronic obstructive pulmonary disease (moderate to severe);	chr4:128978603	chr4:128567972~128570531:-
STAD	cis	rs7139978	0.516	rs7991096	ENSG00000230390.1	LINC01048	-4.14	4.28e-05	0.0163	-0.24	-0.22	Life satisfaction;	chr13:37497719	chr13:37481467~37484769:-
STAD	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	4.14	4.28e-05	0.0163	0.25	0.22	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
STAD	cis	rs9595908	0.965	rs9595903	ENSG00000281026.1	N4BP2L2-IT2	-4.14	4.28e-05	0.0163	-0.17	-0.22	Body mass index;	chr13:32608003	chr13:32504506~32509395:-
STAD	cis	rs875971	1	rs55962648	ENSG00000224316.1	RP11-479O9.2	-4.14	4.28e-05	0.0163	-0.22	-0.22	Aortic root size;	chr7:66160764	chr7:65773620~65802067:+
STAD	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	4.14	4.28e-05	0.0163	0.29	0.22	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
STAD	cis	rs4845875	0.529	rs6680385	ENSG00000242349.4	NPPA-AS1	4.14	4.28e-05	0.0163	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11771699	chr1:11841017~11848079:+
STAD	cis	rs11098499	0.532	rs4504231	ENSG00000260091.1	RP11-33B1.4	4.14	4.28e-05	0.0163	0.21	0.22	Corneal astigmatism;	chr4:119665736	chr4:119409333~119410233:+
STAD	cis	rs2980439	0.557	rs2976876	ENSG00000173295.6	FAM86B3P	4.14	4.29e-05	0.0164	0.25	0.22	Neuroticism;	chr8:8461340	chr8:8228595~8244865:+
STAD	cis	rs2980439	0.557	rs2921056	ENSG00000173295.6	FAM86B3P	4.14	4.29e-05	0.0164	0.25	0.22	Neuroticism;	chr8:8461672	chr8:8228595~8244865:+
STAD	cis	rs7826238	0.524	rs2921055	ENSG00000173295.6	FAM86B3P	4.14	4.29e-05	0.0164	0.25	0.22	Systolic blood pressure;	chr8:8461832	chr8:8228595~8244865:+
STAD	cis	rs17401966	0.931	rs2276100	ENSG00000199562.1	RNU6-37P	4.14	4.29e-05	0.0164	0.17	0.22	Hepatocellular carcinoma;	chr1:10334478	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.894	rs12722830	ENSG00000199562.1	RNU6-37P	4.14	4.29e-05	0.0164	0.17	0.22	Hepatocellular carcinoma;	chr1:10335076	chr1:10298966~10299072:+
STAD	cis	rs1707322	0.686	rs11211179	ENSG00000225447.1	RPS15AP10	4.14	4.29e-05	0.0164	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs10157795	ENSG00000225447.1	RPS15AP10	4.14	4.29e-05	0.0164	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45645816~45646197:-
STAD	cis	rs10946940	0.897	rs6456801	ENSG00000280107.1	AL022393.9	-4.14	4.29e-05	0.0164	-0.25	-0.22	Systemic lupus erythematosus;	chr6:27657753	chr6:28170845~28172521:+
STAD	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-4.14	4.29e-05	0.0164	-0.26	-0.22	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
STAD	cis	rs10129255	0.869	rs72690553	ENSG00000232216.1	IGHV3-43	4.14	4.29e-05	0.0164	0.22	0.22	Kawasaki disease;	chr14:106715491	chr14:106470264~106470800:-
STAD	cis	rs2638953	0.924	rs7955118	ENSG00000247934.4	RP11-967K21.1	-4.14	4.29e-05	0.0164	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157159	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7955237	ENSG00000247934.4	RP11-967K21.1	-4.14	4.29e-05	0.0164	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157272	chr12:28163298~28190738:-
STAD	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-4.14	4.29e-05	0.0164	-0.28	-0.22	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
STAD	cis	rs561341	0.714	rs55925849	ENSG00000265798.5	RP11-271K11.5	4.14	4.29e-05	0.0164	0.34	0.22	Hip circumference adjusted for BMI;	chr17:31926066	chr17:31038575~31059121:-
STAD	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	4.14	4.3e-05	0.0164	0.23	0.22	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
STAD	cis	rs4763879	0.634	rs7974396	ENSG00000256673.1	RP11-599J14.2	4.14	4.3e-05	0.0164	0.24	0.22	Type 1 diabetes;	chr12:9708101	chr12:9398355~9414851:-
STAD	cis	rs2253762	0.507	rs10159998	ENSG00000226864.1	ATE1-AS1	4.14	4.3e-05	0.0164	0.35	0.22	Breast cancer;	chr10:121994550	chr10:121928312~121951965:+
STAD	cis	rs2253762	0.54	rs11200311	ENSG00000226864.1	ATE1-AS1	4.14	4.3e-05	0.0164	0.35	0.22	Breast cancer;	chr10:121995094	chr10:121928312~121951965:+
STAD	cis	rs2253762	0.54	rs79069897	ENSG00000226864.1	ATE1-AS1	4.14	4.3e-05	0.0164	0.35	0.22	Breast cancer;	chr10:121995680	chr10:121928312~121951965:+
STAD	cis	rs2253762	0.54	rs77032313	ENSG00000226864.1	ATE1-AS1	4.14	4.3e-05	0.0164	0.35	0.22	Breast cancer;	chr10:121995687	chr10:121928312~121951965:+
STAD	cis	rs2253762	0.54	rs11200313	ENSG00000226864.1	ATE1-AS1	4.14	4.3e-05	0.0164	0.35	0.22	Breast cancer;	chr10:121996523	chr10:121928312~121951965:+
STAD	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	4.14	4.3e-05	0.0164	0.24	0.22	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
STAD	cis	rs765787	0.53	rs1648289	ENSG00000259539.1	CTD-2651B20.1	4.14	4.3e-05	0.0164	0.25	0.22	Uric acid levels;	chr15:45224296	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs1648287	ENSG00000259539.1	CTD-2651B20.1	4.14	4.3e-05	0.0164	0.25	0.22	Uric acid levels;	chr15:45224758	chr15:45152664~45167526:-
STAD	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-4.14	4.3e-05	0.0164	-0.25	-0.22	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
STAD	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-4.14	4.3e-05	0.0164	-0.25	-0.22	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
STAD	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	4.14	4.3e-05	0.0164	0.29	0.22	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
STAD	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	4.14	4.3e-05	0.0164	0.29	0.22	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
STAD	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-4.14	4.3e-05	0.0164	-0.36	-0.22	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
STAD	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-4.14	4.3e-05	0.0164	-0.3	-0.22	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
STAD	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	4.14	4.3e-05	0.0164	0.35	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
STAD	cis	rs1799949	1	rs33926631	ENSG00000279602.1	CTD-3014M21.1	4.14	4.3e-05	0.0164	0.27	0.22	Menopause (age at onset);	chr17:43152446	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs1960605	ENSG00000279602.1	CTD-3014M21.1	4.14	4.3e-05	0.0164	0.27	0.22	Menopause (age at onset);	chr17:43153380	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs2037076	ENSG00000279602.1	CTD-3014M21.1	4.14	4.3e-05	0.0164	0.27	0.22	Menopause (age at onset);	chr17:43153866	chr17:43360041~43361361:-
STAD	cis	rs12586317	1	rs12586317	ENSG00000206588.1	RNU1-28P	4.14	4.3e-05	0.0164	0.24	0.22	Psoriasis;	chr14:35212966	chr14:34556226~34556389:-
STAD	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-4.14	4.3e-05	0.0164	-0.33	-0.22	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
STAD	cis	rs453301	0.624	rs2288671	ENSG00000233609.3	RP11-62H7.2	4.14	4.31e-05	0.0164	0.25	0.22	Joint mobility (Beighton score);	chr8:9003384	chr8:8961200~8979025:+
STAD	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-4.14	4.31e-05	0.0164	-0.21	-0.22	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
STAD	cis	rs42490	0.614	rs402434	ENSG00000251136.7	RP11-37B2.1	-4.14	4.31e-05	0.0164	-0.22	-0.22	Leprosy;	chr8:89808088	chr8:89609409~89757727:-
STAD	cis	rs42490	0.614	rs452694	ENSG00000251136.7	RP11-37B2.1	-4.14	4.31e-05	0.0164	-0.22	-0.22	Leprosy;	chr8:89808293	chr8:89609409~89757727:-
STAD	cis	rs42490	0.59	rs447611	ENSG00000251136.7	RP11-37B2.1	-4.14	4.31e-05	0.0164	-0.22	-0.22	Leprosy;	chr8:89808359	chr8:89609409~89757727:-
STAD	cis	rs10851478	0.872	rs34941109	ENSG00000259545.2	RP11-325E5.4	-4.14	4.31e-05	0.0164	-0.26	-0.22	Oral cavity cancer;	chr15:49699515	chr15:49177610~49178741:-
STAD	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	4.14	4.31e-05	0.0164	0.21	0.22	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
STAD	cis	rs11157436	0.602	rs12587826	ENSG00000211813.2	TRAV34	4.14	4.31e-05	0.0164	0.25	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22207522~22208129:+
STAD	cis	rs5752326	1	rs722997	ENSG00000261188.1	CTA-445C9.14	4.14	4.32e-05	0.0164	0.41	0.22	Ischemic stroke;	chr22:26453700	chr22:26512537~26514568:+
STAD	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	4.14	4.32e-05	0.0164	0.31	0.22	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	4.14	4.32e-05	0.0164	0.31	0.22	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	4.14	4.32e-05	0.0164	0.31	0.22	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	4.14	4.32e-05	0.0164	0.31	0.22	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
STAD	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-4.14	4.32e-05	0.0164	-0.21	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
STAD	cis	rs2638953	0.777	rs11049689	ENSG00000247934.4	RP11-967K21.1	-4.14	4.32e-05	0.0164	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28519177	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs61922546	ENSG00000247934.4	RP11-967K21.1	-4.14	4.32e-05	0.0164	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28524632	chr12:28163298~28190738:-
STAD	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	4.14	4.32e-05	0.0164	0.29	0.22	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
STAD	cis	rs6479891	1	rs11818194	ENSG00000235816.3	PRELID1P3	4.14	4.32e-05	0.0164	0.27	0.22	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63427297~63427939:+
STAD	cis	rs56283067	0.577	rs114009236	ENSG00000219384.1	RP11-491H9.3	-4.14	4.32e-05	0.0165	-0.25	-0.22	Total body bone mineral density;	chr6:44929780	chr6:45158870~45159511:+
STAD	cis	rs1075265	0.87	rs17268179	ENSG00000235937.1	AC008280.1	4.14	4.32e-05	0.0165	0.19	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.818	rs12713253	ENSG00000235937.1	AC008280.1	4.14	4.32e-05	0.0165	0.19	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54029552~54030682:-
STAD	cis	rs7924176	0.601	rs10824107	ENSG00000213731.2	RAB5CP1	-4.14	4.32e-05	0.0165	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74423435~74424014:-
STAD	cis	rs7924176	0.564	rs11000920	ENSG00000213731.2	RAB5CP1	-4.14	4.32e-05	0.0165	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74423435~74424014:-
STAD	cis	rs8062405	0.54	rs151226	ENSG00000278665.1	RP11-666O2.4	4.14	4.32e-05	0.0165	0.24	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28599241~28601881:-
STAD	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	4.14	4.32e-05	0.0165	0.32	0.22	Depression;	chr6:28430971	chr6:28943877~28944537:+
STAD	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	4.14	4.32e-05	0.0165	0.32	0.22	Depression;	chr6:28431469	chr6:28943877~28944537:+
STAD	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	4.14	4.32e-05	0.0165	0.32	0.22	Depression;	chr6:28432562	chr6:28943877~28944537:+
STAD	cis	rs3947	0.906	rs1692821	ENSG00000227888.4	FAM66A	-4.14	4.32e-05	0.0165	-0.28	-0.22	Blood protein levels;	chr8:11842479	chr8:12362019~12388296:+
STAD	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	4.14	4.33e-05	0.0165	0.25	0.22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
STAD	cis	rs10129255	0.518	rs10150460	ENSG00000224373.3	IGHV4-59	-4.14	4.33e-05	0.0165	-0.15	-0.22	Kawasaki disease;	chr14:106677179	chr14:106627249~106627825:-
STAD	cis	rs11157436	0.509	rs12589104	ENSG00000211813.2	TRAV34	4.14	4.33e-05	0.0165	0.25	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22207522~22208129:+
STAD	cis	rs10073892	0.549	rs13179639	ENSG00000250682.4	LINC00491	-4.14	4.33e-05	0.0165	-0.24	-0.22	Cognitive decline (age-related);	chr5:102641254	chr5:102609156~102671559:-
STAD	cis	rs944722	1	rs944722	ENSG00000266786.1	LGALS9DP	4.14	4.33e-05	0.0165	0.27	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27765011	chr17:27746132~27754954:+
STAD	cis	rs1816752	0.524	rs7996445	ENSG00000273628.1	RP11-756A22.7	-4.14	4.33e-05	0.0165	-0.26	-0.22	Obesity-related traits;	chr13:24475329	chr13:24933006~24936796:+
STAD	cis	rs4691139	1	rs7693977	ENSG00000248632.1	RP11-366M4.11	4.14	4.33e-05	0.0165	0.2	0.22	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981898	chr4:164968587~164970002:-
STAD	cis	rs7487075	0.93	rs4076484	ENSG00000272963.1	OR7A19P	4.14	4.33e-05	0.0165	0.2	0.22	Itch intensity from mosquito bite;	chr12:46440129	chr12:46592573~46593305:+
STAD	cis	rs11673344	0.523	rs36096221	ENSG00000267672.1	CTD-2293H3.1	4.14	4.33e-05	0.0165	0.2	0.22	Obesity-related traits;	chr19:37060838	chr19:37091341~37092564:+
STAD	cis	rs559928	0.606	rs11605856	ENSG00000236935.1	AP003774.1	4.14	4.33e-05	0.0165	0.34	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158056	chr11:64325050~64329504:-
STAD	cis	rs559928	0.606	rs11231710	ENSG00000236935.1	AP003774.1	4.14	4.33e-05	0.0165	0.34	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158271	chr11:64325050~64329504:-
STAD	cis	rs1707322	1	rs4660906	ENSG00000225447.1	RPS15AP10	4.14	4.33e-05	0.0165	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45645816~45646197:-
STAD	cis	rs4218	0.607	rs2414619	ENSG00000259732.1	RP11-59H7.3	-4.14	4.33e-05	0.0165	-0.24	-0.22	Social communication problems;	chr15:59113060	chr15:59121034~59133250:+
STAD	cis	rs10971721	0.822	rs12377078	ENSG00000260947.1	RP11-384P7.7	-4.14	4.34e-05	0.0165	-0.33	-0.22	Body mass index;	chr9:33934823	chr9:33697459~33700986:+
STAD	cis	rs10073892	0.66	rs10035133	ENSG00000250682.4	LINC00491	4.14	4.34e-05	0.0165	0.24	0.22	Cognitive decline (age-related);	chr5:102649969	chr5:102609156~102671559:-
STAD	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	4.14	4.34e-05	0.0165	0.2	0.22	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
STAD	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	4.14	4.34e-05	0.0165	0.28	0.22	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
STAD	cis	rs2579500	0.848	rs2438712	ENSG00000230606.9	AC159540.1	-4.14	4.34e-05	0.0165	-0.25	-0.22	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96553973	chr2:97416165~97433527:-
STAD	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-4.14	4.34e-05	0.0165	-0.34	-0.22	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
STAD	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-4.14	4.34e-05	0.0165	-0.22	-0.22	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
STAD	cis	rs867371	0.929	rs7173852	ENSG00000278603.1	RP13-608F4.5	4.14	4.34e-05	0.0165	0.25	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472203~82472426:+
STAD	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	4.14	4.34e-05	0.0165	0.28	0.22	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
STAD	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	4.14	4.34e-05	0.0165	0.28	0.22	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
STAD	cis	rs9907295	1	rs9896265	ENSG00000270894.1	AC015849.13	-4.14	4.34e-05	0.0165	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35916930	chr17:35818399~35823713:+
STAD	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	4.14	4.34e-05	0.0165	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
STAD	cis	rs2992257	0.958	rs3006820	ENSG00000251839.1	RNU7-12P	-4.14	4.35e-05	0.0165	-0.21	-0.22	Response to angiotensin II receptor blocker therapy;	chr10:26428930	chr10:27232255~27232316:-
STAD	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	4.14	4.35e-05	0.0165	0.32	0.22	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
STAD	cis	rs9987353	0.84	rs329994	ENSG00000254340.1	RP11-10A14.3	-4.14	4.35e-05	0.0165	-0.28	-0.22	Recombination measurement;	chr8:9265723	chr8:9141424~9145435:+
STAD	cis	rs561341	0.882	rs2521594	ENSG00000265798.5	RP11-271K11.5	4.14	4.35e-05	0.0165	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31975068	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs548957	ENSG00000265798.5	RP11-271K11.5	4.14	4.35e-05	0.0165	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31975392	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs542132	ENSG00000265798.5	RP11-271K11.5	4.14	4.35e-05	0.0165	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31980174	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs484175	ENSG00000265798.5	RP11-271K11.5	4.14	4.35e-05	0.0165	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31982022	chr17:31038575~31059121:-
STAD	cis	rs561341	0.941	rs4525554	ENSG00000265798.5	RP11-271K11.5	4.14	4.35e-05	0.0165	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31985800	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs501957	ENSG00000265798.5	RP11-271K11.5	4.14	4.35e-05	0.0165	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31987485	chr17:31038575~31059121:-
STAD	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	4.14	4.35e-05	0.0165	0.32	0.22	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
STAD	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-4.14	4.35e-05	0.0165	-0.19	-0.22	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
STAD	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-4.14	4.35e-05	0.0165	-0.19	-0.22	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
STAD	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-4.14	4.35e-05	0.0165	-0.23	-0.22	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
STAD	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-4.14	4.35e-05	0.0165	-0.23	-0.22	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
STAD	cis	rs763014	0.932	rs2384975	ENSG00000228201.1	AL022341.3	4.14	4.35e-05	0.0166	0.26	0.22	Height;	chr16:601115	chr16:648473~649200:-
STAD	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	4.14	4.35e-05	0.0166	0.22	0.22	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
STAD	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-4.14	4.36e-05	0.0166	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-4.14	4.36e-05	0.0166	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
STAD	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	4.14	4.36e-05	0.0166	0.27	0.22	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	4.14	4.36e-05	0.0166	0.27	0.22	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
STAD	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	4.14	4.36e-05	0.0166	0.31	0.22	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	4.14	4.36e-05	0.0166	0.31	0.22	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
STAD	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	4.14	4.36e-05	0.0166	0.42	0.22	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
STAD	cis	rs9902453	0.967	rs7212741	ENSG00000263477.1	RP11-338L22.2	4.14	4.37e-05	0.0166	0.18	0.22	Coffee consumption (cups per day);	chr17:29995923	chr17:29863402~29866092:+
STAD	cis	rs2562456	0.793	rs2650819	ENSG00000268119.4	CTD-2561J22.5	-4.14	4.37e-05	0.0166	-0.28	-0.22	Pain;	chr19:21456071	chr19:21444241~21463908:-
STAD	cis	rs11169552	0.58	rs7134976	ENSG00000200183.1	RNU6-238P	-4.14	4.37e-05	0.0166	-0.21	-0.22	Colorectal cancer;	chr12:50616309	chr12:50656973~50657078:+
STAD	cis	rs950169	0.58	rs11636189	ENSG00000259295.5	CSPG4P12	4.14	4.37e-05	0.0166	0.31	0.22	Schizophrenia;	chr15:84650323	chr15:85191438~85213905:+
STAD	cis	rs950169	0.58	rs35516100	ENSG00000259295.5	CSPG4P12	4.14	4.37e-05	0.0166	0.31	0.22	Schizophrenia;	chr15:84652199	chr15:85191438~85213905:+
STAD	cis	rs950169	0.58	rs62021208	ENSG00000259295.5	CSPG4P12	4.14	4.37e-05	0.0166	0.31	0.22	Schizophrenia;	chr15:84653013	chr15:85191438~85213905:+
STAD	cis	rs6142102	0.923	rs2268078	ENSG00000264616.1	MIR4755	4.14	4.37e-05	0.0166	0.23	0.22	Skin pigmentation;	chr20:34008898	chr20:34049119~34049190:+
STAD	cis	rs8177876	0.822	rs1563077	ENSG00000261838.4	RP11-303E16.6	4.14	4.37e-05	0.0166	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	4.14	4.37e-05	0.0166	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
STAD	cis	rs1707322	0.963	rs1768815	ENSG00000281133.1	AL355480.3	4.14	4.37e-05	0.0166	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45580892~45580996:-
STAD	cis	rs1816752	0.783	rs9507333	ENSG00000232858.1	RPL34P27	4.14	4.37e-05	0.0166	0.13	0.22	Obesity-related traits;	chr13:24404172	chr13:24988577~24988925:-
STAD	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	4.14	4.38e-05	0.0166	0.27	0.22	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
STAD	cis	rs1075265	0.87	rs1421617	ENSG00000235937.1	AC008280.1	4.14	4.38e-05	0.0166	0.19	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54029552~54030682:-
STAD	cis	rs10508774	1	rs72793602	ENSG00000273038.2	RP11-479G22.8	4.14	4.38e-05	0.0166	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32459444	chr10:32887255~32889311:-
STAD	cis	rs870825	0.616	rs56232457	ENSG00000249173.4	LINC01093	-4.14	4.38e-05	0.0166	-0.35	-0.22	Blood protein levels;	chr4:184706999	chr4:184893871~184899454:-
STAD	cis	rs5753618	0.561	rs9609264	ENSG00000236132.1	CTA-440B3.1	-4.14	4.38e-05	0.0166	-0.26	-0.22	Colorectal cancer;	chr22:31350733	chr22:31816379~31817491:-
STAD	cis	rs860295	0.702	rs12043132	ENSG00000225855.5	RUSC1-AS1	4.14	4.38e-05	0.0166	0.18	0.22	Body mass index;	chr1:155592576	chr1:155316863~155324176:-
STAD	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	4.14	4.38e-05	0.0166	0.26	0.22	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
STAD	cis	rs7119038	0.629	rs10892272	ENSG00000255422.1	AP002954.4	4.14	4.38e-05	0.0166	0.28	0.22	Sjögren's syndrome;	chr11:118731998	chr11:118704607~118750263:+
STAD	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	4.14	4.38e-05	0.0166	0.22	0.22	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
STAD	cis	rs9646944	1	rs9646944	ENSG00000234389.1	AC007278.3	4.14	4.38e-05	0.0166	0.26	0.22	Blood protein levels;	chr2:102249415	chr2:102438713~102440475:+
STAD	cis	rs10073892	0.62	rs10035158	ENSG00000250682.4	LINC00491	-4.14	4.38e-05	0.0166	-0.24	-0.22	Cognitive decline (age-related);	chr5:102587071	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.62	rs62369727	ENSG00000250682.4	LINC00491	-4.14	4.38e-05	0.0166	-0.24	-0.22	Cognitive decline (age-related);	chr5:102588531	chr5:102609156~102671559:-
STAD	cis	rs7829975	0.514	rs2920991	ENSG00000254340.1	RP11-10A14.3	4.14	4.39e-05	0.0167	0.25	0.22	Mood instability;	chr8:8401607	chr8:9141424~9145435:+
STAD	cis	rs253959	0.633	rs10477554	ENSG00000249026.2	CTNNAP1	-4.14	4.39e-05	0.0167	-0.25	-0.22	Bipolar disorder and schizophrenia;	chr5:116390094	chr5:115389643~115392370:-
STAD	cis	rs34779708	0.931	rs4007289	ENSG00000271335.4	RP11-324I22.4	4.14	4.39e-05	0.0167	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35314552~35336401:-
STAD	cis	rs1816752	0.646	rs2862903	ENSG00000273628.1	RP11-756A22.7	-4.14	4.39e-05	0.0167	-0.26	-0.22	Obesity-related traits;	chr13:24473169	chr13:24933006~24936796:+
STAD	cis	rs9517906	0.553	rs61972386	ENSG00000218502.3	H2AFZP3	-4.14	4.39e-05	0.0167	-0.2	-0.22	Survival in pancreatic cancer;	chr13:99900714	chr13:99215372~99215758:-
STAD	cis	rs4713118	0.629	rs203889	ENSG00000220721.1	OR1F12	4.14	4.39e-05	0.0167	0.26	0.22	Parkinson's disease;	chr6:28053997	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.629	rs203890	ENSG00000220721.1	OR1F12	4.14	4.39e-05	0.0167	0.26	0.22	Parkinson's disease;	chr6:28054470	chr6:28073316~28074233:+
STAD	cis	rs853679	0.527	rs1997660	ENSG00000220721.1	OR1F12	4.14	4.39e-05	0.0167	0.22	0.22	Depression;	chr6:28301886	chr6:28073316~28074233:+
STAD	cis	rs11931598	0.511	rs35772786	ENSG00000170846.14	AC093323.3	4.14	4.39e-05	0.0167	0.26	0.22	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7019484	chr4:6673451~6676047:+
STAD	cis	rs2348418	0.832	rs7294553	ENSG00000247934.4	RP11-967K21.1	4.14	4.39e-05	0.0167	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28334832	chr12:28163298~28190738:-
STAD	cis	rs10510102	0.516	rs12244921	ENSG00000226864.1	ATE1-AS1	4.14	4.39e-05	0.0167	0.35	0.22	Breast cancer;	chr10:121990342	chr10:121928312~121951965:+
STAD	cis	rs8177876	0.822	rs56119129	ENSG00000261838.4	RP11-303E16.6	4.14	4.39e-05	0.0167	0.48	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81069854~81076598:+
STAD	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	4.14	4.39e-05	0.0167	0.21	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
STAD	cis	rs7429990	0.932	rs11720151	ENSG00000224895.1	VPS26BP1	4.14	4.4e-05	0.0167	0.22	0.22	Educational attainment (years of education);	chr3:48099144	chr3:47960327~47961081:-
STAD	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-4.14	4.4e-05	0.0167	-0.33	-0.22	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
STAD	cis	rs6142102	0.961	rs6088355	ENSG00000264616.1	MIR4755	4.14	4.4e-05	0.0167	0.23	0.22	Skin pigmentation;	chr20:33958081	chr20:34049119~34049190:+
STAD	cis	rs4568518	0.804	rs12699934	ENSG00000279048.1	RP11-511H23.2	4.14	4.4e-05	0.0167	0.2	0.22	Measles;	chr7:17986396	chr7:17940503~17942922:+
STAD	cis	rs5758659	0.657	rs5758587	ENSG00000182057.4	OGFRP1	-4.14	4.4e-05	0.0167	-0.23	-0.22	Cognitive function;	chr22:42121632	chr22:42269753~42275196:+
STAD	cis	rs41369048	0.669	rs111238725	ENSG00000257551.1	HLX-AS1	-4.14	4.4e-05	0.0167	-0.36	-0.22	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220860320	chr1:220832763~220880140:-
STAD	cis	rs11089937	0.626	rs4820337	ENSG00000211640.3	IGLV6-57	-4.14	4.4e-05	0.0167	-0.17	-0.22	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22195713~22196460:+
STAD	cis	rs8141529	0.748	rs5752826	ENSG00000226471.5	CTA-292E10.6	-4.14	4.41e-05	0.0167	-0.25	-0.22	Lymphocyte counts;	chr22:28873820	chr22:28800683~28848559:+
STAD	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-4.14	4.41e-05	0.0167	-0.34	-0.22	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-4.14	4.41e-05	0.0167	-0.34	-0.22	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
STAD	cis	rs1005277	0.522	rs9417256	ENSG00000099251.13	HSD17B7P2	4.14	4.41e-05	0.0167	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38356380~38378505:+
STAD	cis	rs1707322	0.964	rs6697830	ENSG00000281133.1	AL355480.3	-4.14	4.41e-05	0.0167	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs12060274	ENSG00000281133.1	AL355480.3	-4.14	4.41e-05	0.0167	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs10890353	ENSG00000281133.1	AL355480.3	-4.14	4.41e-05	0.0167	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45580892~45580996:-
STAD	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	4.14	4.41e-05	0.0167	0.28	0.22	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	4.14	4.41e-05	0.0167	0.28	0.22	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	4.14	4.41e-05	0.0167	0.28	0.22	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	4.14	4.41e-05	0.0167	0.28	0.22	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
STAD	cis	rs6539288	0.63	rs10778519	ENSG00000260329.1	RP11-412D9.4	-4.14	4.41e-05	0.0167	-0.23	-0.22	Total body bone mineral density;	chr12:106963551	chr12:106954029~106955497:-
STAD	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	4.14	4.41e-05	0.0167	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
STAD	cis	rs6565180	0.962	rs6565182	ENSG00000273724.1	RP11-347C12.12	-4.14	4.41e-05	0.0167	-0.24	-0.22	Tonsillectomy;	chr16:30363060	chr16:30336400~30343336:+
STAD	cis	rs4713118	0.696	rs2394002	ENSG00000243307.2	POM121L6P	-4.14	4.41e-05	0.0167	-0.26	-0.22	Parkinson's disease;	chr6:27780236	chr6:26896952~26898777:+
STAD	cis	rs728616	0.867	rs41302709	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.41e-05	0.0167	-0.45	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047522	chr10:79663088~79826594:-
STAD	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	4.14	4.41e-05	0.0167	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	4.14	4.41e-05	0.0167	0.29	0.22	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
STAD	cis	rs1075265	0.901	rs1058320	ENSG00000235937.1	AC008280.1	4.14	4.42e-05	0.0168	0.19	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54029552~54030682:-
STAD	cis	rs7220401	0.542	rs55644350	ENSG00000240074.1	RPL9P30	4.14	4.42e-05	0.0168	0.19	0.22	Coronary artery disease;	chr17:29586350	chr17:29855759~29856332:+
STAD	cis	rs11673344	0.504	rs6510588	ENSG00000267672.1	CTD-2293H3.1	-4.14	4.42e-05	0.0168	-0.19	-0.22	Obesity-related traits;	chr19:37106493	chr19:37091341~37092564:+
STAD	cis	rs10129255	0.917	rs7155356	ENSG00000224373.3	IGHV4-59	4.14	4.42e-05	0.0168	0.17	0.22	Kawasaki disease;	chr14:106697376	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.917	rs10137601	ENSG00000224373.3	IGHV4-59	4.14	4.42e-05	0.0168	0.17	0.22	Kawasaki disease;	chr14:106697476	chr14:106627249~106627825:-
STAD	cis	rs5753618	0.561	rs737887	ENSG00000236132.1	CTA-440B3.1	4.14	4.42e-05	0.0168	0.26	0.22	Colorectal cancer;	chr22:31300629	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.561	rs4820963	ENSG00000236132.1	CTA-440B3.1	4.14	4.42e-05	0.0168	0.26	0.22	Colorectal cancer;	chr22:31302180	chr22:31816379~31817491:-
STAD	cis	rs2901460	0.759	rs1966820	ENSG00000229503.1	AC092155.1	-4.14	4.42e-05	0.0168	-0.18	-0.22	Mean corpuscular volume;	chr2:62130409	chr2:62532583~62533059:-
STAD	cis	rs3733585	0.762	rs6449217	ENSG00000250613.1	RP11-136I13.1	-4.14	4.42e-05	0.0168	-0.22	-0.22	Cleft plate (environmental tobacco smoke interaction);	chr4:10007527	chr4:10410996~10411644:+
STAD	cis	rs3811273	1	rs10139994	ENSG00000211816.2	TRAV38-1	-4.14	4.42e-05	0.0168	-0.31	-0.22	Periodontal disease-related phenotypes;	chr14:22254607	chr14:22271968~22272563:+
STAD	cis	rs9860428	0.526	rs9865242	ENSG00000240057.4	RP11-572M11.4	-4.14	4.43e-05	0.0168	-0.21	-0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112923721	chr3:113019532~113183301:+
STAD	cis	rs765787	0.53	rs11636404	ENSG00000259539.1	CTD-2651B20.1	4.14	4.43e-05	0.0168	0.25	0.22	Uric acid levels;	chr15:45243663	chr15:45152664~45167526:-
STAD	cis	rs935334	1	rs12879642	ENSG00000258454.1	RP11-361H10.3	4.14	4.43e-05	0.0168	0.32	0.22	Blood pressure;	chr14:76216624	chr14:76235817~76263474:+
STAD	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	4.14	4.43e-05	0.0168	0.31	0.22	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
STAD	cis	rs9902453	0.808	rs4595850	ENSG00000263477.1	RP11-338L22.2	4.14	4.43e-05	0.0168	0.18	0.22	Coffee consumption (cups per day);	chr17:29879308	chr17:29863402~29866092:+
STAD	cis	rs875971	1	rs9986696	ENSG00000224316.1	RP11-479O9.2	-4.14	4.44e-05	0.0168	-0.22	-0.22	Aortic root size;	chr7:66239589	chr7:65773620~65802067:+
STAD	cis	rs792448	1	rs792448	ENSG00000212044.2	AL360091.1	-4.14	4.44e-05	0.0168	-0.25	-0.22	White blood cell count (basophil);	chr1:212385055	chr1:212349978~212350069:+
STAD	cis	rs2638953	0.962	rs7303747	ENSG00000247934.4	RP11-967K21.1	-4.14	4.44e-05	0.0168	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28241969	chr12:28163298~28190738:-
STAD	cis	rs870825	0.616	rs7660064	ENSG00000249173.4	LINC01093	-4.14	4.44e-05	0.0168	-0.35	-0.22	Blood protein levels;	chr4:184696375	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7674952	ENSG00000249173.4	LINC01093	-4.14	4.44e-05	0.0168	-0.35	-0.22	Blood protein levels;	chr4:184701173	chr4:184893871~184899454:-
STAD	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	4.14	4.44e-05	0.0168	0.22	0.22	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
STAD	cis	rs7937127	1	rs7937127	ENSG00000254907.1	RP11-484D2.2	4.14	4.44e-05	0.0168	0.32	0.22	Fibrinogen levels;	chr11:43493381	chr11:43328748~43359296:-
STAD	cis	rs2562456	0.755	rs2914646	ENSG00000268119.4	CTD-2561J22.5	-4.14	4.44e-05	0.0168	-0.28	-0.22	Pain;	chr19:21454359	chr19:21444241~21463908:-
STAD	cis	rs7769051	1	rs58832890	ENSG00000179073.6	TAAR3	-4.14	4.44e-05	0.0168	-0.37	-0.22	Type 2 diabetes nephropathy;	chr6:132806000	chr6:132608225~132609302:-
STAD	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-4.14	4.44e-05	0.0168	-0.36	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
STAD	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	4.14	4.44e-05	0.0168	0.29	0.22	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
STAD	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-4.14	4.44e-05	0.0168	-0.22	-0.22	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
STAD	cis	rs6471393	0.895	rs4255106	ENSG00000253848.1	RP11-10N23.5	4.14	4.44e-05	0.0168	0.25	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93766367	chr8:93741193~93744534:+
STAD	cis	rs7487075	0.797	rs10785630	ENSG00000272963.1	OR7A19P	4.14	4.44e-05	0.0168	0.2	0.22	Itch intensity from mosquito bite;	chr12:46486597	chr12:46592573~46593305:+
STAD	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-4.14	4.44e-05	0.0168	-0.22	-0.22	Height;	chr2:46627225	chr2:46668870~46670778:+
STAD	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-4.14	4.44e-05	0.0168	-0.22	-0.22	Height;	chr2:46630262	chr2:46668870~46670778:+
STAD	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-4.14	4.44e-05	0.0168	-0.22	-0.22	Height;	chr2:46631182	chr2:46668870~46670778:+
STAD	cis	rs1707322	0.721	rs7520123	ENSG00000281133.1	AL355480.3	-4.14	4.45e-05	0.0168	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45580892~45580996:-
STAD	cis	rs5753618	0.561	rs5753543	ENSG00000236132.1	CTA-440B3.1	4.14	4.45e-05	0.0168	0.26	0.22	Colorectal cancer;	chr22:31289472	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.561	rs2413049	ENSG00000236132.1	CTA-440B3.1	4.14	4.45e-05	0.0168	0.26	0.22	Colorectal cancer;	chr22:31290158	chr22:31816379~31817491:-
STAD	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	4.14	4.45e-05	0.0168	0.24	0.22	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
STAD	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	4.14	4.45e-05	0.0168	0.24	0.22	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
STAD	cis	rs6479891	1	rs4746149	ENSG00000235816.3	PRELID1P3	-4.14	4.45e-05	0.0168	-0.28	-0.22	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63427297~63427939:+
STAD	cis	rs561341	0.941	rs736678	ENSG00000265798.5	RP11-271K11.5	4.14	4.45e-05	0.0169	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32020404	chr17:31038575~31059121:-
STAD	cis	rs3811273	0.614	rs8020929	ENSG00000211816.2	TRAV38-1	-4.14	4.45e-05	0.0169	-0.27	-0.22	Periodontal disease-related phenotypes;	chr14:22267444	chr14:22271968~22272563:+
STAD	cis	rs860295	0.702	rs56675301	ENSG00000225855.5	RUSC1-AS1	4.14	4.45e-05	0.0169	0.18	0.22	Body mass index;	chr1:155394536	chr1:155316863~155324176:-
STAD	cis	rs748404	0.56	rs572837	ENSG00000275601.1	AC011330.13	-4.14	4.45e-05	0.0169	-0.23	-0.22	Lung cancer;	chr15:43531615	chr15:43642389~43643023:-
STAD	cis	rs6142102	0.812	rs6059558	ENSG00000264616.1	MIR4755	4.14	4.45e-05	0.0169	0.23	0.22	Skin pigmentation;	chr20:33929024	chr20:34049119~34049190:+
STAD	cis	rs6496044	0.963	rs11853972	ENSG00000259407.1	RP11-158M2.3	-4.14	4.45e-05	0.0169	-0.23	-0.22	Interstitial lung disease;	chr15:85519209	chr15:85744109~85750281:-
STAD	cis	rs9733	0.519	rs1336900	ENSG00000274963.1	Metazoa_SRP	4.14	4.46e-05	0.0169	0.18	0.22	Tonsillectomy;	chr1:150706557	chr1:150568971~150569269:-
STAD	cis	rs1348850	0.768	rs57681892	ENSG00000271825.1	RP11-337N6.2	4.14	4.46e-05	0.0169	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177492917	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.914	rs1374437	ENSG00000271825.1	RP11-337N6.2	4.14	4.46e-05	0.0169	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177498695	chr2:177300600~177302006:+
STAD	cis	rs8068318	0.687	rs887258	ENSG00000267280.4	TBX2-AS1	-4.14	4.46e-05	0.0169	-0.26	-0.22	Creatinine levels;	chr17:61402219	chr17:61393456~61411555:-
STAD	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-4.14	4.46e-05	0.0169	-0.22	-0.22	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
STAD	cis	rs2638953	0.924	rs79712894	ENSG00000247934.4	RP11-967K21.1	-4.13	4.46e-05	0.0169	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239400	chr12:28163298~28190738:-
STAD	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	4.13	4.46e-05	0.0169	0.27	0.22	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
STAD	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-4.13	4.46e-05	0.0169	-0.25	-0.22	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
STAD	cis	rs9902453	0.838	rs8064689	ENSG00000263477.1	RP11-338L22.2	4.13	4.46e-05	0.0169	0.18	0.22	Coffee consumption (cups per day);	chr17:29890035	chr17:29863402~29866092:+
STAD	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	4.13	4.47e-05	0.0169	0.26	0.22	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
STAD	cis	rs4927850	0.958	rs1975582	ENSG00000278820.1	AC024937.1	4.13	4.47e-05	0.0169	0.24	0.22	Pancreatic cancer;	chr3:196024568	chr3:195960500~195960612:-
STAD	cis	rs1345301	0.518	rs2110661	ENSG00000234389.1	AC007278.3	-4.13	4.47e-05	0.0169	-0.22	-0.22	Waist circumference;	chr2:102246761	chr2:102438713~102440475:+
STAD	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	4.13	4.47e-05	0.0169	0.32	0.22	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	4.13	4.47e-05	0.0169	0.32	0.22	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
STAD	cis	rs11235843	0.853	rs1043234	ENSG00000255928.1	RP11-456I15.2	4.13	4.47e-05	0.0169	0.38	0.22	Hand grip strength;	chr11:73760716	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs3211165	ENSG00000255928.1	RP11-456I15.2	4.13	4.47e-05	0.0169	0.38	0.22	Hand grip strength;	chr11:73760733	chr11:73722349~73722694:+
STAD	cis	rs875971	0.571	rs78668714	ENSG00000273142.1	RP11-458F8.4	4.13	4.47e-05	0.0169	0.2	0.22	Aortic root size;	chr7:66474464	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs73150604	ENSG00000273142.1	RP11-458F8.4	4.13	4.47e-05	0.0169	0.2	0.22	Aortic root size;	chr7:66480545	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs7810213	ENSG00000273142.1	RP11-458F8.4	4.13	4.47e-05	0.0169	0.2	0.22	Aortic root size;	chr7:66481592	chr7:66902857~66906297:+
STAD	cis	rs11638815	0.603	rs783520	ENSG00000255769.6	GOLGA2P10	-4.13	4.47e-05	0.0169	-0.25	-0.22	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:82472993~82513950:-
STAD	cis	rs7615952	0.8	rs12489350	ENSG00000272840.1	RP11-379B18.6	4.13	4.47e-05	0.0169	0.39	0.22	Blood pressure (smoking interaction);	chr3:125925273	chr3:125774714~125797953:+
STAD	cis	rs4243830	0.85	rs12760251	ENSG00000229519.2	RP11-58A11.2	4.13	4.47e-05	0.0169	0.23	0.22	Body mass index;	chr1:6541276	chr1:6547905~6548619:+
STAD	cis	rs875971	0.964	rs697969	ENSG00000224316.1	RP11-479O9.2	-4.13	4.47e-05	0.0169	-0.22	-0.22	Aortic root size;	chr7:66093491	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs1182882	ENSG00000224316.1	RP11-479O9.2	-4.13	4.47e-05	0.0169	-0.22	-0.22	Aortic root size;	chr7:66097076	chr7:65773620~65802067:+
STAD	cis	rs2348418	0.798	rs10771423	ENSG00000247934.4	RP11-967K21.1	4.13	4.47e-05	0.0169	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28396205	chr12:28163298~28190738:-
STAD	cis	rs7702057	0.53	rs3946989	ENSG00000271918.1	CTD-2287O16.5	4.13	4.47e-05	0.0169	0.39	0.22	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs1567331	ENSG00000271918.1	CTD-2287O16.5	4.13	4.47e-05	0.0169	0.39	0.22	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs1567332	ENSG00000271918.1	CTD-2287O16.5	4.13	4.47e-05	0.0169	0.39	0.22	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116083807~116085416:-
STAD	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	4.13	4.47e-05	0.0169	0.26	0.22	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
STAD	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	4.13	4.47e-05	0.0169	0.22	0.22	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
STAD	cis	rs2638953	0.924	rs11049398	ENSG00000247934.4	RP11-967K21.1	-4.13	4.47e-05	0.0169	-0.24	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28163298~28190738:-
STAD	cis	rs2859998	0.857	rs7844502	ENSG00000250031.1	RP11-114M5.1	-4.13	4.48e-05	0.0169	-0.19	-0.22	Narcolepsy with cataplexy;	chr8:58454771	chr8:58424588~58426685:-
STAD	cis	rs728616	0.681	rs117420340	ENSG00000225484.5	NUTM2B-AS1	-4.13	4.48e-05	0.0169	-0.44	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406739	chr10:79663088~79826594:-
STAD	cis	rs7615952	0.609	rs13088451	ENSG00000241346.1	SNRPCP11	4.13	4.48e-05	0.0169	0.28	0.22	Blood pressure (smoking interaction);	chr3:125834656	chr3:125816082~125816286:-
STAD	cis	rs4835473	0.897	rs4054616	ENSG00000249741.2	RP11-673E1.3	-4.13	4.48e-05	0.0169	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143837472	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.897	rs2323325	ENSG00000249741.2	RP11-673E1.3	-4.13	4.48e-05	0.0169	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143837561	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.8	rs4835330	ENSG00000249741.2	RP11-673E1.3	-4.13	4.48e-05	0.0169	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143846303	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.736	rs6851661	ENSG00000249741.2	RP11-673E1.3	-4.13	4.48e-05	0.0169	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143850587	chr4:143911514~143912053:-
STAD	cis	rs198389	0.568	rs12406667	ENSG00000242349.4	NPPA-AS1	4.13	4.48e-05	0.0169	0.22	0.22	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813794	chr1:11841017~11848079:+
STAD	cis	rs9907295	1	rs9897095	ENSG00000270894.1	AC015849.13	-4.13	4.48e-05	0.0169	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35916928	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9900236	ENSG00000270894.1	AC015849.13	-4.13	4.48e-05	0.0169	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35917049	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.892	rs4795100	ENSG00000270894.1	AC015849.13	-4.13	4.48e-05	0.0169	-0.27	-0.22	Fibroblast growth factor basic levels;	chr17:35917470	chr17:35818399~35823713:+
STAD	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	4.13	4.48e-05	0.0169	0.32	0.22	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
STAD	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-4.13	4.48e-05	0.0169	-0.33	-0.22	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-4.13	4.48e-05	0.0169	-0.33	-0.22	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
STAD	cis	rs76917914	1	rs7019033	ENSG00000236896.1	RP11-535C21.3	4.13	4.48e-05	0.0169	0.3	0.22	Immature fraction of reticulocytes;	chr9:98030894	chr9:97986551~97987656:-
STAD	cis	rs76917914	0.954	rs12001675	ENSG00000236896.1	RP11-535C21.3	4.13	4.48e-05	0.0169	0.3	0.22	Immature fraction of reticulocytes;	chr9:98031425	chr9:97986551~97987656:-
STAD	cis	rs1816752	0.719	rs11843470	ENSG00000232858.1	RPL34P27	4.13	4.48e-05	0.017	0.14	0.22	Obesity-related traits;	chr13:24423561	chr13:24988577~24988925:-
STAD	cis	rs9747201	0.926	rs7222764	ENSG00000281517.1	Metazoa_SRP	4.13	4.48e-05	0.017	0.26	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82104822	chr17:81718849~81719095:-
STAD	cis	rs10129255	0.957	rs1024349	ENSG00000232216.1	IGHV3-43	4.13	4.48e-05	0.017	0.22	0.22	Kawasaki disease;	chr14:106689997	chr14:106470264~106470800:-
STAD	cis	rs6693567	0.565	rs834234	ENSG00000203819.6	HIST2H2BC	-4.13	4.49e-05	0.017	-0.25	-0.22	Migraine;	chr1:150380018	chr1:149850193~149850772:-
STAD	cis	rs858239	0.539	rs10247268	ENSG00000230042.1	AK3P3	-4.13	4.49e-05	0.017	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23129178~23129841:+
STAD	cis	rs858239	0.539	rs6461694	ENSG00000230042.1	AK3P3	-4.13	4.49e-05	0.017	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23129178~23129841:+
STAD	cis	rs858239	0.508	rs7805071	ENSG00000230042.1	AK3P3	-4.13	4.49e-05	0.017	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23129178~23129841:+
STAD	cis	rs858239	0.508	rs7805085	ENSG00000230042.1	AK3P3	-4.13	4.49e-05	0.017	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23129178~23129841:+
STAD	cis	rs6068583	0.86	rs6063965	ENSG00000197670.6	RP4-724E16.2	-4.13	4.49e-05	0.017	-0.33	-0.22	Colorectal adenoma (advanced);	chr20:53574661	chr20:53552770~53575863:+
STAD	cis	rs9902453	0.769	rs7210288	ENSG00000263477.1	RP11-338L22.2	4.13	4.49e-05	0.017	0.18	0.22	Coffee consumption (cups per day);	chr17:29916455	chr17:29863402~29866092:+
STAD	cis	rs1816752	0.646	rs4480642	ENSG00000273628.1	RP11-756A22.7	-4.13	4.49e-05	0.017	-0.26	-0.22	Obesity-related traits;	chr13:24471358	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9551108	ENSG00000273628.1	RP11-756A22.7	-4.13	4.49e-05	0.017	-0.26	-0.22	Obesity-related traits;	chr13:24471434	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.603	rs4238178	ENSG00000273628.1	RP11-756A22.7	-4.13	4.49e-05	0.017	-0.26	-0.22	Obesity-related traits;	chr13:24472344	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs7319207	ENSG00000273628.1	RP11-756A22.7	-4.13	4.49e-05	0.017	-0.26	-0.22	Obesity-related traits;	chr13:24473220	chr13:24933006~24936796:+
STAD	cis	rs8054556	0.74	rs11649612	ENSG00000261588.1	AC002310.17	4.13	4.49e-05	0.017	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30587662~30587920:-
STAD	cis	rs8054556	0.716	rs11642933	ENSG00000261588.1	AC002310.17	4.13	4.49e-05	0.017	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30587662~30587920:-
STAD	cis	rs4589258	0.788	rs10741369	ENSG00000280367.1	RP11-121L10.2	4.13	4.49e-05	0.017	0.21	0.22	Intelligence (multi-trait analysis);	chr11:90765643	chr11:90223153~90226538:+
STAD	cis	rs8396	1	rs4690909	ENSG00000271817.2	U3	-4.13	4.49e-05	0.017	-0.25	-0.22	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158707999	chr4:158700691~158700909:+
STAD	cis	rs875971	1	rs1540651	ENSG00000224316.1	RP11-479O9.2	-4.13	4.49e-05	0.017	-0.22	-0.22	Aortic root size;	chr7:66185134	chr7:65773620~65802067:+
STAD	cis	rs7078219	0.543	rs7095491	ENSG00000257582.4	LINC01475	-4.13	4.49e-05	0.017	-0.25	-0.22	Dental caries;	chr10:99514301	chr10:99526350~99531177:-
STAD	cis	rs561341	1	rs550264	ENSG00000265798.5	RP11-271K11.5	4.13	4.49e-05	0.017	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31990521	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs111454793	ENSG00000265798.5	RP11-271K11.5	4.13	4.49e-05	0.017	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31992248	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs527256	ENSG00000265798.5	RP11-271K11.5	4.13	4.49e-05	0.017	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31994274	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs473356	ENSG00000265798.5	RP11-271K11.5	4.13	4.49e-05	0.017	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31994743	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs576985	ENSG00000265798.5	RP11-271K11.5	4.13	4.49e-05	0.017	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31996304	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs15654	ENSG00000265798.5	RP11-271K11.5	4.13	4.49e-05	0.017	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31999341	chr17:31038575~31059121:-
STAD	cis	rs561341	1	rs550923	ENSG00000265798.5	RP11-271K11.5	4.13	4.49e-05	0.017	0.31	0.22	Hip circumference adjusted for BMI;	chr17:31999994	chr17:31038575~31059121:-
STAD	cis	rs950169	0.544	rs2036949	ENSG00000259295.5	CSPG4P12	4.13	4.49e-05	0.017	0.31	0.22	Schizophrenia;	chr15:84620374	chr15:85191438~85213905:+
STAD	cis	rs1707322	0.686	rs3014236	ENSG00000225447.1	RPS15AP10	-4.13	4.5e-05	0.017	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45645816~45646197:-
STAD	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-4.13	4.5e-05	0.017	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
STAD	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	4.13	4.5e-05	0.017	0.29	0.22	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
STAD	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	4.13	4.5e-05	0.017	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
STAD	cis	rs9425766	0.566	rs56188862	ENSG00000227373.4	RP11-160H22.5	4.13	4.5e-05	0.017	0.27	0.22	Life satisfaction;	chr1:174220131	chr1:174115300~174160004:-
STAD	cis	rs42490	0.664	rs40457	ENSG00000251136.7	RP11-37B2.1	-4.13	4.5e-05	0.017	-0.21	-0.22	Leprosy;	chr8:89811459	chr8:89609409~89757727:-
STAD	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-4.13	4.5e-05	0.017	-0.35	-0.22	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
STAD	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-4.13	4.5e-05	0.017	-0.35	-0.22	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
STAD	cis	rs34779708	0.931	rs12268745	ENSG00000271335.4	RP11-324I22.4	4.13	4.5e-05	0.017	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs7923172	ENSG00000271335.4	RP11-324I22.4	4.13	4.5e-05	0.017	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs3740083	ENSG00000271335.4	RP11-324I22.4	4.13	4.5e-05	0.017	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs12261654	ENSG00000271335.4	RP11-324I22.4	4.13	4.5e-05	0.017	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934704	ENSG00000271335.4	RP11-324I22.4	4.13	4.5e-05	0.017	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35314552~35336401:-
STAD	cis	rs4234798	0.5	rs7661066	ENSG00000202392.1	RN7SKP292	-4.13	4.5e-05	0.017	-0.26	-0.22	Insulin-like growth factors;	chr4:7218151	chr4:6997012~6997328:+
STAD	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	4.13	4.5e-05	0.017	0.24	0.22	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
STAD	cis	rs875971	1	rs11974264	ENSG00000224316.1	RP11-479O9.2	-4.13	4.5e-05	0.017	-0.22	-0.22	Aortic root size;	chr7:66182595	chr7:65773620~65802067:+
STAD	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	4.13	4.51e-05	0.017	0.16	0.22	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
STAD	cis	rs1348850	0.914	rs10194648	ENSG00000271825.1	RP11-337N6.2	4.13	4.51e-05	0.017	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177472303	chr2:177300600~177302006:+
STAD	cis	rs1322639	0.614	rs6900964	ENSG00000261039.2	RP11-417E7.2	-4.13	4.51e-05	0.017	-0.34	-0.22	Pulse pressure;	chr6:169166668	chr6:169175304~169182740:-
STAD	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	4.13	4.51e-05	0.017	0.2	0.22	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
STAD	cis	rs1850744	1	rs1533615	ENSG00000250268.3	ALG1L14P	4.13	4.51e-05	0.017	0.44	0.22	Economic and political preferences;	chr4:9802900	chr4:9166297~9170270:-
STAD	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	4.13	4.51e-05	0.017	0.28	0.22	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
STAD	cis	rs944722	0.934	rs4796040	ENSG00000266786.1	LGALS9DP	4.13	4.51e-05	0.0171	0.27	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27770454	chr17:27746132~27754954:+
STAD	cis	rs7924176	0.601	rs10824073	ENSG00000213731.2	RAB5CP1	-4.13	4.52e-05	0.0171	-0.21	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74423435~74424014:-
STAD	cis	rs6772849	0.775	rs9828414	ENSG00000242551.2	POU5F1P6	-4.13	4.52e-05	0.0171	-0.22	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128674735~128677005:-
STAD	cis	rs6772849	0.804	rs9832430	ENSG00000242551.2	POU5F1P6	-4.13	4.52e-05	0.0171	-0.22	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128674735~128677005:-
STAD	cis	rs9907295	0.584	rs2280787	ENSG00000271013.1	AC015849.15	-4.13	4.52e-05	0.0171	-0.33	-0.22	Fibroblast growth factor basic levels;	chr17:35930046	chr17:35912635~35918010:-
STAD	cis	rs860295	0.702	rs12239100	ENSG00000225855.5	RUSC1-AS1	4.13	4.52e-05	0.0171	0.18	0.22	Body mass index;	chr1:155458685	chr1:155316863~155324176:-
STAD	cis	rs1972460	0.506	rs62012050	ENSG00000259429.4	UBE2Q2P2	-4.13	4.52e-05	0.0171	-0.29	-0.22	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82355142~82420075:+
STAD	cis	rs2262909	0.962	rs422344	ENSG00000213976.4	CTD-2561J22.2	4.13	4.52e-05	0.0171	0.28	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22048154	chr19:21382865~21387177:+
STAD	cis	rs6951245	0.638	rs74976697	ENSG00000229043.2	AC091729.9	-4.13	4.52e-05	0.0171	-0.33	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1160374~1165267:+
STAD	cis	rs8177876	0.749	rs11537	ENSG00000261061.1	RP11-303E16.2	-4.13	4.52e-05	0.0171	-0.36	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81030770~81031485:+
STAD	cis	rs2253762	0.54	rs10887037	ENSG00000226864.1	ATE1-AS1	4.13	4.52e-05	0.0171	0.35	0.22	Breast cancer;	chr10:121997572	chr10:121928312~121951965:+
STAD	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	4.13	4.52e-05	0.0171	0.33	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
STAD	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	4.13	4.53e-05	0.0171	0.23	0.22	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
STAD	cis	rs56114371	0.53	rs9357045	ENSG00000220721.1	OR1F12	4.13	4.53e-05	0.0171	0.26	0.22	Breast cancer;	chr6:27721148	chr6:28073316~28074233:+
STAD	cis	rs10129255	0.912	rs61997792	ENSG00000224373.3	IGHV4-59	4.13	4.53e-05	0.0171	0.18	0.22	Kawasaki disease;	chr14:106799304	chr14:106627249~106627825:-
STAD	cis	rs875971	1	rs11974219	ENSG00000224316.1	RP11-479O9.2	-4.13	4.53e-05	0.0171	-0.22	-0.22	Aortic root size;	chr7:66182423	chr7:65773620~65802067:+
STAD	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	4.13	4.53e-05	0.0171	0.28	0.22	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
STAD	cis	rs7769051	1	rs6910639	ENSG00000179073.6	TAAR3	-4.13	4.53e-05	0.0171	-0.37	-0.22	Type 2 diabetes nephropathy;	chr6:132799414	chr6:132608225~132609302:-
STAD	cis	rs7769051	1	rs12204027	ENSG00000179073.6	TAAR3	-4.13	4.53e-05	0.0171	-0.37	-0.22	Type 2 diabetes nephropathy;	chr6:132801692	chr6:132608225~132609302:-
STAD	cis	rs7769051	1	rs9493444	ENSG00000179073.6	TAAR3	-4.13	4.53e-05	0.0171	-0.37	-0.22	Type 2 diabetes nephropathy;	chr6:132804181	chr6:132608225~132609302:-
STAD	cis	rs9733	0.596	rs6587518	ENSG00000274963.1	Metazoa_SRP	4.13	4.53e-05	0.0171	0.19	0.22	Tonsillectomy;	chr1:150689311	chr1:150568971~150569269:-
STAD	cis	rs539514	0.69	rs504273	ENSG00000261105.4	LMO7-AS1	4.13	4.53e-05	0.0171	0.26	0.22	Type 1 diabetes;	chr13:75736714	chr13:75604700~75635994:-
STAD	cis	rs539514	0.69	rs480929	ENSG00000261105.4	LMO7-AS1	4.13	4.53e-05	0.0171	0.26	0.22	Type 1 diabetes;	chr13:75738637	chr13:75604700~75635994:-
STAD	cis	rs10129255	0.843	rs7142649	ENSG00000232216.1	IGHV3-43	4.13	4.53e-05	0.0171	0.22	0.22	Kawasaki disease;	chr14:106708870	chr14:106470264~106470800:-
STAD	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	4.13	4.53e-05	0.0171	0.24	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
STAD	cis	rs1005277	0.54	rs2145487	ENSG00000099251.13	HSD17B7P2	4.13	4.53e-05	0.0171	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38356380~38378505:+
STAD	cis	rs1816752	0.875	rs3783076	ENSG00000273628.1	RP11-756A22.7	4.13	4.53e-05	0.0171	0.27	0.22	Obesity-related traits;	chr13:24490319	chr13:24933006~24936796:+
STAD	cis	rs2348418	0.832	rs7136426	ENSG00000247934.4	RP11-967K21.1	4.13	4.53e-05	0.0171	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28400129	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.864	rs11049578	ENSG00000247934.4	RP11-967K21.1	4.13	4.53e-05	0.0171	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28414520	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.864	rs11049580	ENSG00000247934.4	RP11-967K21.1	4.13	4.53e-05	0.0171	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28414696	chr12:28163298~28190738:-
STAD	cis	rs6496044	1	rs6496044	ENSG00000259407.1	RP11-158M2.3	-4.13	4.53e-05	0.0171	-0.23	-0.22	Interstitial lung disease;	chr15:85524075	chr15:85744109~85750281:-
STAD	cis	rs1913185	0.787	rs58874363	ENSG00000240032.1	RP11-274H2.3	-4.13	4.54e-05	0.0171	-0.32	-0.22	Obesity-related traits;	chr3:146126725	chr3:146066344~146069185:-
STAD	cis	rs1075265	0.933	rs7560947	ENSG00000235937.1	AC008280.1	4.13	4.54e-05	0.0171	0.19	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54029552~54030682:-
STAD	cis	rs2273156	0.706	rs7153550	ENSG00000258704.4	SRP54-AS1	-4.13	4.54e-05	0.0171	-0.26	-0.22	Immunoglobulin light chain (AL) amyloidosis;	chr14:35032594	chr14:34920858~34982532:-
STAD	cis	rs4713118	0.539	rs200967	ENSG00000280107.1	AL022393.9	-4.13	4.54e-05	0.0171	-0.28	-0.22	Parkinson's disease;	chr6:27894349	chr6:28170845~28172521:+
STAD	cis	rs831571	0.55	rs153734	ENSG00000280620.1	SCAANT1	4.13	4.54e-05	0.0171	0.3	0.22	Type 2 diabetes;	chr3:64092333	chr3:63911518~63911772:-
STAD	cis	rs263063	0.506	rs12611002	ENSG00000280239.1	CTB-50L17.8	4.13	4.54e-05	0.0171	0.33	0.22	Periodontitis (CDC/AAP);	chr19:5051644	chr19:4448810~4450836:+
STAD	cis	rs7615952	0.673	rs115942855	ENSG00000239804.1	RP11-379B18.1	4.13	4.54e-05	0.0171	0.42	0.22	Blood pressure (smoking interaction);	chr3:125883117	chr3:125787888~125788146:-
STAD	cis	rs3770081	1	rs58898686	ENSG00000273080.1	RP11-301O19.1	-4.13	4.55e-05	0.0171	-0.5	-0.22	Facial emotion recognition (sad faces);	chr2:85989786	chr2:86195590~86196049:+
STAD	cis	rs11783469	0.524	rs17089283	ENSG00000253390.1	CTC-756D1.2	-4.13	4.55e-05	0.0171	-0.31	-0.22	Reticulocyte count;	chr8:23478249	chr8:23458601~23484971:+
STAD	cis	rs7487075	1	rs7487075	ENSG00000272963.1	OR7A19P	4.13	4.55e-05	0.0171	0.2	0.22	Itch intensity from mosquito bite;	chr12:46435135	chr12:46592573~46593305:+
STAD	cis	rs9987353	0.83	rs4841114	ENSG00000254340.1	RP11-10A14.3	-4.13	4.55e-05	0.0171	-0.32	-0.22	Recombination measurement;	chr8:9272188	chr8:9141424~9145435:+
STAD	cis	rs950169	0.881	rs150965	ENSG00000235370.6	DNM1P51	4.13	4.55e-05	0.0171	0.28	0.22	Schizophrenia;	chr15:84537296	chr15:84398316~84411701:-
STAD	cis	rs7474896	1	rs2753878	ENSG00000099251.13	HSD17B7P2	-4.13	4.55e-05	0.0171	-0.35	-0.22	Obesity (extreme);	chr10:37882576	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2738223	ENSG00000099251.13	HSD17B7P2	-4.13	4.55e-05	0.0171	-0.35	-0.22	Obesity (extreme);	chr10:37896970	chr10:38356380~38378505:+
STAD	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-4.13	4.55e-05	0.0171	-0.27	-0.22	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
STAD	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-4.13	4.55e-05	0.0171	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
STAD	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	4.13	4.55e-05	0.0171	0.32	0.22	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
STAD	cis	rs7176527	0.848	rs3748374	ENSG00000225151.9	GOLGA2P7	4.13	4.55e-05	0.0172	0.29	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:84199311~84230136:-
STAD	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	4.13	4.55e-05	0.0172	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
STAD	cis	rs10073892	0.75	rs13355600	ENSG00000250682.4	LINC00491	-4.13	4.55e-05	0.0172	-0.25	-0.22	Cognitive decline (age-related);	chr5:102366496	chr5:102609156~102671559:-
STAD	cis	rs9549328	0.8	rs9549617	ENSG00000267868.1	RP11-120K24.3	4.13	4.55e-05	0.0172	0.31	0.22	Systolic blood pressure;	chr13:112973756	chr13:112964835~112966131:-
STAD	cis	rs7829975	0.742	rs882462	ENSG00000233609.3	RP11-62H7.2	4.13	4.55e-05	0.0172	0.23	0.22	Mood instability;	chr8:8821020	chr8:8961200~8979025:+
STAD	cis	rs7829975	0.774	rs11775523	ENSG00000233609.3	RP11-62H7.2	4.13	4.55e-05	0.0172	0.23	0.22	Mood instability;	chr8:8821666	chr8:8961200~8979025:+
STAD	cis	rs6142102	0.923	rs6057961	ENSG00000264616.1	MIR4755	4.13	4.55e-05	0.0172	0.23	0.22	Skin pigmentation;	chr20:33986005	chr20:34049119~34049190:+
STAD	cis	rs9902453	0.765	rs2874505	ENSG00000263477.1	RP11-338L22.2	4.13	4.55e-05	0.0172	0.18	0.22	Coffee consumption (cups per day);	chr17:29710905	chr17:29863402~29866092:+
STAD	cis	rs7647973	0.58	rs11130184	ENSG00000225399.4	RP11-3B7.1	4.13	4.55e-05	0.0172	0.24	0.22	Menarche (age at onset);	chr3:49192497	chr3:49260085~49261316:+
STAD	cis	rs7647973	0.58	rs11716334	ENSG00000225399.4	RP11-3B7.1	4.13	4.55e-05	0.0172	0.24	0.22	Menarche (age at onset);	chr3:49192663	chr3:49260085~49261316:+
STAD	cis	rs4713118	0.911	rs9461406	ENSG00000243307.2	POM121L6P	4.13	4.55e-05	0.0172	0.26	0.22	Parkinson's disease;	chr6:27751985	chr6:26896952~26898777:+
STAD	cis	rs2944755	0.919	rs2944753	ENSG00000279766.1	RP11-642A1.2	4.13	4.56e-05	0.0172	0.31	0.22	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140566264	chr8:140572142~140572812:-
STAD	cis	rs3947	1	rs4839	ENSG00000270154.1	RP11-419I17.1	-4.13	4.56e-05	0.0172	-0.28	-0.22	Blood protein levels;	chr8:11844424	chr8:12476462~12477122:+
STAD	cis	rs2836950	0.501	rs1474490	ENSG00000238141.2	BRWD1-AS1	-4.13	4.56e-05	0.0172	-0.22	-0.22	Menarche (age at onset);	chr21:39344210	chr21:39315707~39323218:+
STAD	cis	rs875971	1	rs1565531	ENSG00000224316.1	RP11-479O9.2	-4.13	4.56e-05	0.0172	-0.22	-0.22	Aortic root size;	chr7:66198126	chr7:65773620~65802067:+
STAD	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	4.13	4.56e-05	0.0172	0.35	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
STAD	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	4.13	4.56e-05	0.0172	0.35	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
STAD	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	4.13	4.56e-05	0.0172	0.35	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
STAD	cis	rs8068318	0.652	rs9907379	ENSG00000267280.4	TBX2-AS1	-4.13	4.56e-05	0.0172	-0.25	-0.22	Creatinine levels;	chr17:61412532	chr17:61393456~61411555:-
STAD	cis	rs12285276	0.576	rs2593756	ENSG00000205106.4	DKFZp779M0652	4.13	4.57e-05	0.0172	0.22	0.22	Visceral fat;	chr11:45746850	chr11:45771432~45772358:+
STAD	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	4.13	4.57e-05	0.0172	0.26	0.22	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
STAD	cis	rs7208859	0.573	rs8070182	ENSG00000280069.1	CTD-2349P21.3	-4.13	4.57e-05	0.0172	-0.22	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30738182~30740275:+
STAD	cis	rs1816752	0.638	rs9578730	ENSG00000232858.1	RPL34P27	4.13	4.57e-05	0.0172	0.13	0.22	Obesity-related traits;	chr13:24425545	chr13:24988577~24988925:-
STAD	cis	rs9902453	0.715	rs2628176	ENSG00000240074.1	RPL9P30	-4.13	4.57e-05	0.0172	-0.18	-0.22	Coffee consumption (cups per day);	chr17:29812274	chr17:29855759~29856332:+
STAD	cis	rs10129255	0.917	rs7142373	ENSG00000224373.3	IGHV4-59	4.13	4.57e-05	0.0172	0.18	0.22	Kawasaki disease;	chr14:106708947	chr14:106627249~106627825:-
STAD	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	4.13	4.57e-05	0.0172	0.25	0.22	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
STAD	cis	rs8062405	1	rs3088215	ENSG00000278665.1	RP11-666O2.4	4.13	4.57e-05	0.0172	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs28403629	ENSG00000278665.1	RP11-666O2.4	4.13	4.57e-05	0.0172	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs61737565	ENSG00000278665.1	RP11-666O2.4	4.13	4.57e-05	0.0172	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs4788099	ENSG00000278665.1	RP11-666O2.4	4.13	4.57e-05	0.0172	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28599241~28601881:-
STAD	cis	rs6142102	0.961	rs2056990	ENSG00000264616.1	MIR4755	4.13	4.57e-05	0.0172	0.23	0.22	Skin pigmentation;	chr20:34035658	chr20:34049119~34049190:+
STAD	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-4.13	4.57e-05	0.0172	-0.35	-0.22	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-4.13	4.57e-05	0.0172	-0.35	-0.22	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
STAD	cis	rs219780	1	rs219780	ENSG00000233818.1	AP000695.4	4.13	4.57e-05	0.0172	0.31	0.22	Kidney stones;	chr21:36461009	chr21:36445731~36532408:+
STAD	cis	rs2944755	0.845	rs2977459	ENSG00000279766.1	RP11-642A1.2	4.13	4.57e-05	0.0172	0.31	0.22	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140565770	chr8:140572142~140572812:-
STAD	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-4.13	4.57e-05	0.0172	-0.22	-0.22	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
STAD	cis	rs860295	0.702	rs12025532	ENSG00000225855.5	RUSC1-AS1	4.13	4.57e-05	0.0172	0.18	0.22	Body mass index;	chr1:155399511	chr1:155316863~155324176:-
STAD	cis	rs7615952	0.673	rs35955861	ENSG00000241346.1	SNRPCP11	4.13	4.57e-05	0.0172	0.38	0.22	Blood pressure (smoking interaction);	chr3:125907358	chr3:125816082~125816286:-
STAD	cis	rs7615952	0.673	rs35001498	ENSG00000241346.1	SNRPCP11	4.13	4.57e-05	0.0172	0.38	0.22	Blood pressure (smoking interaction);	chr3:125909801	chr3:125816082~125816286:-
STAD	cis	rs34779708	0.966	rs17591163	ENSG00000271335.4	RP11-324I22.4	4.13	4.57e-05	0.0172	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35314552~35336401:-
STAD	cis	rs12745968	0.653	rs4847301	ENSG00000229052.2	RP11-386I23.1	-4.13	4.58e-05	0.0172	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92735367	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.595	rs6604014	ENSG00000229052.2	RP11-386I23.1	-4.13	4.58e-05	0.0172	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92750161	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.561	rs4847306	ENSG00000229052.2	RP11-386I23.1	-4.13	4.58e-05	0.0172	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92751415	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.59	rs2391195	ENSG00000229052.2	RP11-386I23.1	-4.13	4.58e-05	0.0172	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92753126	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.59	rs1337107	ENSG00000229052.2	RP11-386I23.1	-4.13	4.58e-05	0.0172	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92753219	chr1:92930696~92934098:+
STAD	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	4.13	4.58e-05	0.0172	0.46	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
STAD	cis	rs870825	0.616	rs57316663	ENSG00000249173.4	LINC01093	-4.13	4.58e-05	0.0173	-0.35	-0.22	Blood protein levels;	chr4:184708857	chr4:184893871~184899454:-
STAD	cis	rs6430585	0.528	rs309161	ENSG00000231890.6	DARS-AS1	4.13	4.58e-05	0.0173	0.23	0.22	Corneal structure;	chr2:135931179	chr2:135985176~136022593:+
STAD	cis	rs8062405	1	rs62036626	ENSG00000278665.1	RP11-666O2.4	4.13	4.59e-05	0.0173	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62036657	ENSG00000278665.1	RP11-666O2.4	4.13	4.59e-05	0.0173	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs12444171	ENSG00000278665.1	RP11-666O2.4	4.13	4.59e-05	0.0173	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28599241~28601881:-
STAD	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-4.13	4.59e-05	0.0173	-0.3	-0.22	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
STAD	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-4.13	4.59e-05	0.0173	-0.3	-0.22	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
STAD	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	4.13	4.59e-05	0.0173	0.28	0.22	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	4.13	4.59e-05	0.0173	0.28	0.22	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
STAD	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-4.13	4.59e-05	0.0173	-0.23	-0.22	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
STAD	cis	rs34779708	0.931	rs79749947	ENSG00000271335.4	RP11-324I22.4	4.13	4.59e-05	0.0173	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35314552~35336401:-
STAD	cis	rs1007190	0.57	rs2906781	ENSG00000224505.2	AC002117.1	-4.13	4.59e-05	0.0173	-0.3	-0.22	DNA methylation (variation);	chr17:44716599	chr17:45150400~45161510:-
STAD	cis	rs9907295	0.688	rs4796138	ENSG00000271013.1	AC015849.15	-4.13	4.59e-05	0.0173	-0.33	-0.22	Fibroblast growth factor basic levels;	chr17:35932791	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.688	rs4795101	ENSG00000271013.1	AC015849.15	-4.13	4.59e-05	0.0173	-0.33	-0.22	Fibroblast growth factor basic levels;	chr17:35932989	chr17:35912635~35918010:-
STAD	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-4.13	4.59e-05	0.0173	-0.25	-0.22	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-4.13	4.59e-05	0.0173	-0.25	-0.22	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
STAD	cis	rs7829975	0.502	rs11785183	ENSG00000254340.1	RP11-10A14.3	-4.13	4.59e-05	0.0173	-0.3	-0.22	Mood instability;	chr8:8708447	chr8:9141424~9145435:+
STAD	cis	rs7474896	1	rs2738225	ENSG00000120555.12	SEPT7P9	-4.13	4.6e-05	0.0173	-0.35	-0.22	Obesity (extreme);	chr10:37904201	chr10:38383069~38402916:-
STAD	cis	rs17685	0.697	rs28689051	ENSG00000280388.1	RP11-229D13.3	-4.13	4.6e-05	0.0173	-0.18	-0.22	Coffee consumption (cups per day);Coffee consumption;	chr7:76134306	chr7:76043977~76045963:-
STAD	cis	rs3825942	0.666	rs2304719	ENSG00000261801.4	LOXL1-AS1	4.13	4.6e-05	0.0173	0.29	0.22	Glaucoma (exfoliation);	chr15:73943159	chr15:73908071~73928248:-
STAD	cis	rs2243480	0.706	rs34466769	ENSG00000222364.1	RNU6-96P	-4.13	4.6e-05	0.0173	-0.32	-0.22	Diabetic kidney disease;	chr7:65988305	chr7:66395191~66395286:+
STAD	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-4.13	4.6e-05	0.0173	-0.27	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
STAD	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-4.13	4.6e-05	0.0173	-0.22	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
STAD	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	4.13	4.6e-05	0.0173	0.24	0.22	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
STAD	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	4.13	4.6e-05	0.0173	0.26	0.22	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
STAD	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	4.13	4.6e-05	0.0173	0.26	0.22	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
STAD	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-4.13	4.6e-05	0.0173	-0.26	-0.22	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
STAD	cis	rs7824557	0.564	rs2572400	ENSG00000205879.4	FAM90A2P	-4.13	4.6e-05	0.0173	-0.24	-0.22	Retinal vascular caliber;	chr8:11376858	chr8:12172202~12178575:-
STAD	cis	rs875971	1	rs6963646	ENSG00000224316.1	RP11-479O9.2	-4.13	4.61e-05	0.0173	-0.22	-0.22	Aortic root size;	chr7:66220780	chr7:65773620~65802067:+
STAD	cis	rs2957692	0.548	rs11042571	ENSG00000254554.1	RP11-351I24.1	4.13	4.61e-05	0.0173	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9969447	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs17271847	ENSG00000254554.1	RP11-351I24.1	4.13	4.61e-05	0.0173	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9971373	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs17356792	ENSG00000254554.1	RP11-351I24.1	4.13	4.61e-05	0.0173	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9972974	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs7131445	ENSG00000254554.1	RP11-351I24.1	4.13	4.61e-05	0.0173	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9973558	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs12419923	ENSG00000254554.1	RP11-351I24.1	4.13	4.61e-05	0.0173	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9973708	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs10840338	ENSG00000254554.1	RP11-351I24.1	4.13	4.61e-05	0.0173	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9974378	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.569	rs11042578	ENSG00000254554.1	RP11-351I24.1	4.13	4.61e-05	0.0173	0.36	0.22	Circulating vasoactive peptide levels;	chr11:9977275	chr11:10302657~10303704:-
STAD	cis	rs8068318	0.652	rs2109019	ENSG00000267280.4	TBX2-AS1	-4.13	4.61e-05	0.0173	-0.25	-0.22	Creatinine levels;	chr17:61398527	chr17:61393456~61411555:-
STAD	cis	rs8068318	0.56	rs1476781	ENSG00000267280.4	TBX2-AS1	-4.13	4.61e-05	0.0173	-0.25	-0.22	Creatinine levels;	chr17:61399054	chr17:61393456~61411555:-
STAD	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	4.13	4.61e-05	0.0173	0.28	0.22	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	4.13	4.61e-05	0.0173	0.28	0.22	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	4.13	4.61e-05	0.0173	0.28	0.22	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
STAD	cis	rs6772849	0.93	rs7639400	ENSG00000242551.2	POU5F1P6	-4.13	4.61e-05	0.0173	-0.22	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:128674735~128677005:-
STAD	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-4.13	4.61e-05	0.0173	-0.27	-0.22	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
STAD	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-4.13	4.61e-05	0.0173	-0.3	-0.22	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
STAD	cis	rs1153858	0.945	rs1974981	ENSG00000259433.2	CTD-2651B20.4	4.13	4.61e-05	0.0173	0.23	0.22	Homoarginine levels;	chr15:45436925	chr15:45330209~45332634:-
STAD	cis	rs9902453	0.845	rs12601963	ENSG00000263477.1	RP11-338L22.2	4.13	4.62e-05	0.0174	0.18	0.22	Coffee consumption (cups per day);	chr17:29919340	chr17:29863402~29866092:+
STAD	cis	rs6142102	0.923	rs4911383	ENSG00000264616.1	MIR4755	4.13	4.62e-05	0.0174	0.23	0.22	Skin pigmentation;	chr20:33967973	chr20:34049119~34049190:+
STAD	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-4.13	4.62e-05	0.0174	-0.25	-0.22	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
STAD	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-4.13	4.62e-05	0.0174	-0.25	-0.22	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
STAD	cis	rs9291683	1	rs9291683	ENSG00000250613.1	RP11-136I13.1	-4.13	4.62e-05	0.0174	-0.2	-0.22	Bone mineral density;	chr4:10322536	chr4:10410996~10411644:+
STAD	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-4.13	4.62e-05	0.0174	-0.33	-0.22	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
STAD	cis	rs1707322	1	rs7532204	ENSG00000225447.1	RPS15AP10	-4.13	4.62e-05	0.0174	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.835	rs946525	ENSG00000225447.1	RPS15AP10	-4.13	4.62e-05	0.0174	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs946524	ENSG00000225447.1	RPS15AP10	-4.13	4.62e-05	0.0174	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4660336	ENSG00000225447.1	RPS15AP10	-4.13	4.62e-05	0.0174	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs785478	ENSG00000225447.1	RPS15AP10	-4.13	4.62e-05	0.0174	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45645816~45646197:-
STAD	cis	rs6142102	0.961	rs1007090	ENSG00000264616.1	MIR4755	4.13	4.62e-05	0.0174	0.23	0.22	Skin pigmentation;	chr20:33995065	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.923	rs2284377	ENSG00000264616.1	MIR4755	4.13	4.62e-05	0.0174	0.23	0.22	Skin pigmentation;	chr20:33998876	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.961	rs2284378	ENSG00000264616.1	MIR4755	4.13	4.62e-05	0.0174	0.23	0.22	Skin pigmentation;	chr20:34000289	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.961	rs2268080	ENSG00000264616.1	MIR4755	4.13	4.62e-05	0.0174	0.23	0.22	Skin pigmentation;	chr20:34009910	chr20:34049119~34049190:+
STAD	cis	rs11157436	0.602	rs928954	ENSG00000211813.2	TRAV34	4.13	4.62e-05	0.0174	0.25	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22207522~22208129:+
STAD	cis	rs516805	0.528	rs2679703	ENSG00000279453.1	RP3-425C14.4	-4.13	4.63e-05	0.0174	-0.31	-0.22	Lymphocyte counts;	chr6:122099490	chr6:122436789~122439223:-
STAD	cis	rs516805	0.528	rs2606632	ENSG00000279453.1	RP3-425C14.4	-4.13	4.63e-05	0.0174	-0.31	-0.22	Lymphocyte counts;	chr6:122099728	chr6:122436789~122439223:-
STAD	cis	rs516805	0.528	rs2606634	ENSG00000279453.1	RP3-425C14.4	-4.13	4.63e-05	0.0174	-0.31	-0.22	Lymphocyte counts;	chr6:122100337	chr6:122436789~122439223:-
STAD	cis	rs516805	0.563	rs2606635	ENSG00000279453.1	RP3-425C14.4	-4.13	4.63e-05	0.0174	-0.31	-0.22	Lymphocyte counts;	chr6:122101222	chr6:122436789~122439223:-
STAD	cis	rs516805	0.563	rs2816083	ENSG00000279453.1	RP3-425C14.4	-4.13	4.63e-05	0.0174	-0.31	-0.22	Lymphocyte counts;	chr6:122101611	chr6:122436789~122439223:-
STAD	cis	rs516805	0.528	rs2606637	ENSG00000279453.1	RP3-425C14.4	-4.13	4.63e-05	0.0174	-0.31	-0.22	Lymphocyte counts;	chr6:122101832	chr6:122436789~122439223:-
STAD	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	4.13	4.63e-05	0.0174	0.24	0.22	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
STAD	cis	rs10129255	0.833	rs7156689	ENSG00000224373.3	IGHV4-59	4.13	4.63e-05	0.0174	0.17	0.22	Kawasaki disease;	chr14:106816039	chr14:106627249~106627825:-
STAD	cis	rs1799949	0.965	rs8176310	ENSG00000279602.1	CTD-3014M21.1	4.13	4.63e-05	0.0174	0.26	0.22	Menopause (age at onset);	chr17:43047896	chr17:43360041~43361361:-
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000211959.2	IGHV4-39	4.13	4.63e-05	0.0174	0.19	0.22	Kawasaki disease;	chr14:106781985	chr14:106421711~106422218:-
STAD	cis	rs12468226	1	rs116635509	ENSG00000272966.1	RP11-686O6.1	4.13	4.63e-05	0.0174	0.31	0.22	Urate levels;	chr2:202460027	chr2:202336739~202337200:+
STAD	cis	rs9326248	0.581	rs7120963	ENSG00000280143.1	AP000892.6	-4.13	4.63e-05	0.0174	-0.17	-0.22	Blood protein levels;	chr11:116959545	chr11:117204967~117210292:+
STAD	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-4.13	4.63e-05	0.0174	-0.27	-0.22	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
STAD	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	4.13	4.63e-05	0.0174	0.26	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
STAD	cis	rs2638953	0.707	rs11049711	ENSG00000247934.4	RP11-967K21.1	-4.13	4.63e-05	0.0174	-0.24	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28553171	chr12:28163298~28190738:-
STAD	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-4.13	4.63e-05	0.0174	-0.25	-0.22	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
STAD	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	4.13	4.63e-05	0.0174	0.26	0.22	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
STAD	cis	rs28512361	0.557	rs136030	ENSG00000279954.1	WI2-85898F10.2	-4.13	4.63e-05	0.0174	-0.26	-0.22	Breast cancer;	chr22:45846268	chr22:45875932~45879247:+
STAD	cis	rs3864261	0.515	rs57149385	ENSG00000251467.1	CTC-250P20.2	4.13	4.63e-05	0.0174	0.22	0.22	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72996920~72997642:+
STAD	cis	rs3864261	0.515	rs10942539	ENSG00000251467.1	CTC-250P20.2	4.13	4.63e-05	0.0174	0.22	0.22	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72996920~72997642:+
STAD	cis	rs9847710	0.838	rs2564962	ENSG00000242142.1	SERBP1P3	4.13	4.63e-05	0.0174	0.22	0.22	Ulcerative colitis;	chr3:52997622	chr3:53064283~53065091:-
STAD	cis	rs12745968	0.589	rs10874727	ENSG00000229052.2	RP11-386I23.1	-4.13	4.63e-05	0.0174	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92637595	chr1:92930696~92934098:+
STAD	cis	rs6686842	0.56	rs6672508	ENSG00000235358.1	RP11-399E6.1	4.13	4.64e-05	0.0174	0.24	0.22	Height;	chr1:41200899	chr1:41242373~41284861:+
STAD	cis	rs1707322	0.963	rs11211202	ENSG00000225447.1	RPS15AP10	4.13	4.64e-05	0.0174	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45645816~45646197:-
STAD	cis	rs12682352	0.602	rs28399241	ENSG00000173295.6	FAM86B3P	4.13	4.64e-05	0.0174	0.25	0.22	Neuroticism;	chr8:8805705	chr8:8228595~8244865:+
STAD	cis	rs1816752	0.646	rs9511296	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24467962	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9634401	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24468072	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.624	rs9634402	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24468119	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9634403	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24468211	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs9581064	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24468251	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs4769361	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24468834	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs4770693	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24468835	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs4770695	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24468895	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs7337981	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24469245	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.646	rs7328391	ENSG00000273628.1	RP11-756A22.7	-4.13	4.64e-05	0.0174	-0.26	-0.22	Obesity-related traits;	chr13:24470325	chr13:24933006~24936796:+
STAD	cis	rs7615952	0.546	rs4428131	ENSG00000171084.14	FAM86JP	4.13	4.64e-05	0.0174	0.35	0.22	Blood pressure (smoking interaction);	chr3:125627635	chr3:125916620~125930024:+
STAD	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-4.13	4.64e-05	0.0174	-0.32	-0.22	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
STAD	cis	rs1707322	1	rs4660335	ENSG00000225447.1	RPS15AP10	4.13	4.64e-05	0.0174	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45645816~45646197:-
STAD	cis	rs10986311	0.722	rs871998	ENSG00000227200.1	RP11-121A14.3	-4.13	4.64e-05	0.0174	-0.23	-0.22	Vitiligo;	chr9:124295141	chr9:124262876~124265809:+
STAD	cis	rs9847710	0.869	rs2581793	ENSG00000242142.1	SERBP1P3	4.13	4.64e-05	0.0174	0.21	0.22	Ulcerative colitis;	chr3:53001639	chr3:53064283~53065091:-
STAD	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	4.13	4.64e-05	0.0174	0.23	0.22	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
STAD	cis	rs34779708	0.733	rs3936503	ENSG00000271335.4	RP11-324I22.4	-4.13	4.64e-05	0.0174	-0.27	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35314552~35336401:-
STAD	cis	rs9902453	0.904	rs9900112	ENSG00000240074.1	RPL9P30	4.13	4.64e-05	0.0174	0.19	0.22	Coffee consumption (cups per day);	chr17:29955892	chr17:29855759~29856332:+
STAD	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	4.13	4.64e-05	0.0174	0.26	0.22	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
STAD	cis	rs17818399	0.612	rs4952834	ENSG00000279254.1	RP11-536C12.1	-4.13	4.65e-05	0.0174	-0.23	-0.22	Height;	chr2:46550323	chr2:46668870~46670778:+
STAD	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	4.13	4.65e-05	0.0174	0.26	0.22	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
STAD	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	4.12	4.65e-05	0.0175	0.28	0.22	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
STAD	cis	rs9309473	0.607	rs1522927	ENSG00000163016.8	ALMS1P	4.12	4.65e-05	0.0175	0.23	0.22	Metabolite levels;	chr2:73329027	chr2:73644919~73685576:+
STAD	cis	rs17818399	0.716	rs62134741	ENSG00000279254.1	RP11-536C12.1	-4.12	4.65e-05	0.0175	-0.24	-0.22	Height;	chr2:46555050	chr2:46668870~46670778:+
STAD	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-4.12	4.65e-05	0.0175	-0.26	-0.22	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
STAD	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-4.12	4.65e-05	0.0175	-0.24	-0.22	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
STAD	cis	rs4713118	0.824	rs742046	ENSG00000243307.2	POM121L6P	-4.12	4.66e-05	0.0175	-0.25	-0.22	Parkinson's disease;	chr6:27771475	chr6:26896952~26898777:+
STAD	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	4.12	4.66e-05	0.0175	0.27	0.22	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
STAD	cis	rs7615952	0.546	rs2979333	ENSG00000171084.14	FAM86JP	4.12	4.66e-05	0.0175	0.34	0.22	Blood pressure (smoking interaction);	chr3:125641499	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.546	rs111812401	ENSG00000171084.14	FAM86JP	4.12	4.66e-05	0.0175	0.34	0.22	Blood pressure (smoking interaction);	chr3:125642651	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.546	rs2979350	ENSG00000171084.14	FAM86JP	4.12	4.66e-05	0.0175	0.34	0.22	Blood pressure (smoking interaction);	chr3:125643371	chr3:125916620~125930024:+
STAD	cis	rs4713118	0.869	rs9283880	ENSG00000220721.1	OR1F12	4.12	4.66e-05	0.0175	0.24	0.22	Parkinson's disease;	chr6:27747464	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs9283881	ENSG00000220721.1	OR1F12	4.12	4.66e-05	0.0175	0.24	0.22	Parkinson's disease;	chr6:27747476	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs9283882	ENSG00000220721.1	OR1F12	4.12	4.66e-05	0.0175	0.24	0.22	Parkinson's disease;	chr6:27747479	chr6:28073316~28074233:+
STAD	cis	rs7944584	0.551	rs12224672	ENSG00000280615.1	Y_RNA	4.12	4.67e-05	0.0175	0.23	0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47478848	chr11:47614898~47614994:-
STAD	cis	rs930421	0.689	rs13418277	ENSG00000226491.1	FTOP1	-4.12	4.67e-05	0.0175	-0.23	-0.22	Attention deficit hyperactivity disorder;	chr2:42755029	chr2:42797225~42798712:-
STAD	cis	rs9788721	1	rs9788721	ENSG00000259419.2	HNRNPCP3	-4.12	4.67e-05	0.0175	-0.23	-0.22	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78510527	chr15:79236332~79237206:+
STAD	cis	rs4234798	0.5	rs10937793	ENSG00000202392.1	RN7SKP292	-4.12	4.67e-05	0.0175	-0.26	-0.22	Insulin-like growth factors;	chr4:7217887	chr4:6997012~6997328:+
STAD	cis	rs2404602	0.716	rs67418609	ENSG00000196274.5	Metazoa_SRP	4.12	4.67e-05	0.0175	0.19	0.22	Blood metabolite levels;	chr15:76334748	chr15:76230048~76230390:-
STAD	cis	rs2404602	0.716	rs12440815	ENSG00000196274.5	Metazoa_SRP	4.12	4.67e-05	0.0175	0.19	0.22	Blood metabolite levels;	chr15:76334987	chr15:76230048~76230390:-
STAD	cis	rs2404602	0.716	rs3866543	ENSG00000196274.5	Metazoa_SRP	4.12	4.67e-05	0.0175	0.19	0.22	Blood metabolite levels;	chr15:76337268	chr15:76230048~76230390:-
STAD	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	4.12	4.67e-05	0.0175	0.31	0.22	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	4.12	4.67e-05	0.0175	0.31	0.22	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
STAD	cis	rs4713118	0.738	rs200465	ENSG00000243307.2	POM121L6P	-4.12	4.67e-05	0.0175	-0.26	-0.22	Parkinson's disease;	chr6:27789875	chr6:26896952~26898777:+
STAD	cis	rs6479891	1	rs7070052	ENSG00000235816.3	PRELID1P3	-4.12	4.67e-05	0.0175	-0.27	-0.22	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs61853336	ENSG00000235816.3	PRELID1P3	4.12	4.67e-05	0.0175	0.27	0.22	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs4746994	ENSG00000235816.3	PRELID1P3	4.12	4.67e-05	0.0175	0.27	0.22	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs12415984	ENSG00000235816.3	PRELID1P3	4.12	4.67e-05	0.0175	0.27	0.22	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63427297~63427939:+
STAD	cis	rs34779708	0.75	rs35032841	ENSG00000271335.4	RP11-324I22.4	4.12	4.68e-05	0.0175	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.742	rs35912711	ENSG00000271335.4	RP11-324I22.4	4.12	4.68e-05	0.0175	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934702	ENSG00000271335.4	RP11-324I22.4	4.12	4.68e-05	0.0175	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35314552~35336401:-
STAD	cis	rs7119038	0.818	rs2077579	ENSG00000255422.1	AP002954.4	4.12	4.68e-05	0.0176	0.3	0.22	Sjögren's syndrome;	chr11:118748338	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.774	rs2004781	ENSG00000255422.1	AP002954.4	4.12	4.68e-05	0.0176	0.3	0.22	Sjögren's syndrome;	chr11:118748544	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.818	rs3889239	ENSG00000255422.1	AP002954.4	4.12	4.68e-05	0.0176	0.3	0.22	Sjögren's syndrome;	chr11:118749251	chr11:118704607~118750263:+
STAD	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	4.12	4.68e-05	0.0176	0.3	0.22	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
STAD	cis	rs1816752	0.905	rs1348110	ENSG00000232858.1	RPL34P27	4.12	4.68e-05	0.0176	0.13	0.22	Obesity-related traits;	chr13:24406537	chr13:24988577~24988925:-
STAD	cis	rs10073892	0.789	rs10063981	ENSG00000250682.4	LINC00491	-4.12	4.68e-05	0.0176	-0.25	-0.22	Cognitive decline (age-related);	chr5:102428166	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.789	rs56028821	ENSG00000250682.4	LINC00491	-4.12	4.68e-05	0.0176	-0.25	-0.22	Cognitive decline (age-related);	chr5:102440696	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.744	rs10053827	ENSG00000250682.4	LINC00491	-4.12	4.68e-05	0.0176	-0.25	-0.22	Cognitive decline (age-related);	chr5:102450821	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.789	rs10044561	ENSG00000250682.4	LINC00491	-4.12	4.68e-05	0.0176	-0.25	-0.22	Cognitive decline (age-related);	chr5:102472009	chr5:102609156~102671559:-
STAD	cis	rs7989332	0.698	rs9552199	ENSG00000238286.1	SLC35E1P1	-4.12	4.68e-05	0.0176	-0.28	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486403	chr13:20607268~20608131:+
STAD	cis	rs1707322	1	rs4660905	ENSG00000225447.1	RPS15AP10	-4.12	4.68e-05	0.0176	-0.17	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45645816~45646197:-
STAD	cis	rs9291683	0.595	rs13150928	ENSG00000250613.1	RP11-136I13.1	-4.12	4.68e-05	0.0176	-0.21	-0.22	Bone mineral density;	chr4:10051337	chr4:10410996~10411644:+
STAD	cis	rs34779708	0.733	rs12240638	ENSG00000271335.4	RP11-324I22.4	4.12	4.69e-05	0.0176	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35314552~35336401:-
STAD	cis	rs720475	0.695	rs62483108	ENSG00000244198.4	RP4-545C24.1	-4.12	4.69e-05	0.0176	-0.28	-0.22	Breast cancer;	chr7:144442326	chr7:144194858~144280547:+
STAD	cis	rs1823874	0.677	rs2168069	ENSG00000182397.13	DNM1P46	-4.12	4.69e-05	0.0176	-0.23	-0.22	IgG glycosylation;	chr15:99823798	chr15:99790156~99806927:-
STAD	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	4.12	4.69e-05	0.0176	0.26	0.22	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
STAD	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	4.12	4.7e-05	0.0176	0.28	0.22	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
STAD	cis	rs11157436	0.602	rs12588757	ENSG00000211813.2	TRAV34	4.12	4.7e-05	0.0176	0.25	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22207522~22208129:+
STAD	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	4.12	4.7e-05	0.0176	0.29	0.22	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
STAD	cis	rs2836950	0.805	rs62223042	ENSG00000238141.2	BRWD1-AS1	-4.12	4.7e-05	0.0176	-0.24	-0.22	Menarche (age at onset);	chr21:39311814	chr21:39315707~39323218:+
STAD	cis	rs561341	1	rs55736640	ENSG00000265798.5	RP11-271K11.5	4.12	4.7e-05	0.0176	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32006829	chr17:31038575~31059121:-
STAD	cis	rs755249	0.756	rs72637908	ENSG00000182109.6	RP11-69E11.4	4.12	4.7e-05	0.0176	0.26	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39522280~39546187:-
STAD	cis	rs6933660	0.666	rs9371516	ENSG00000221469.1	AL133260.1	4.12	4.7e-05	0.0176	0.23	0.22	Menarche (age at onset);	chr6:151418507	chr6:151039916~151039971:-
STAD	cis	rs7520050	0.808	rs11211195	ENSG00000280836.1	AL355480.1	4.12	4.7e-05	0.0176	0.27	0.22	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.808	rs11211196	ENSG00000280836.1	AL355480.1	4.12	4.7e-05	0.0176	0.27	0.22	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45581219~45581321:-
STAD	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	4.12	4.7e-05	0.0176	0.3	0.22	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
STAD	cis	rs17301013	0.507	rs11799704	ENSG00000227373.4	RP11-160H22.5	4.12	4.7e-05	0.0176	0.31	0.22	Systemic lupus erythematosus;	chr1:174413640	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	4.12	4.7e-05	0.0176	0.31	0.22	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	4.12	4.7e-05	0.0176	0.31	0.22	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	4.12	4.7e-05	0.0176	0.31	0.22	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	4.12	4.7e-05	0.0176	0.31	0.22	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	4.12	4.7e-05	0.0176	0.31	0.22	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	4.12	4.7e-05	0.0176	0.31	0.22	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
STAD	cis	rs34779708	0.766	rs16935949	ENSG00000230534.5	RP11-297A16.2	4.12	4.71e-05	0.0176	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35262887	chr10:35098006~35127020:-
STAD	cis	rs301901	0.761	rs1533521	ENSG00000250155.1	CTD-2353F22.1	4.12	4.71e-05	0.0176	0.22	0.22	Height;	chr5:37540355	chr5:36666214~36725195:-
STAD	cis	rs7487075	0.823	rs34472481	ENSG00000272963.1	OR7A19P	4.12	4.71e-05	0.0177	0.2	0.22	Itch intensity from mosquito bite;	chr12:46442565	chr12:46592573~46593305:+
STAD	cis	rs9291683	0.609	rs3796836	ENSG00000250613.1	RP11-136I13.1	-4.12	4.71e-05	0.0177	-0.2	-0.22	Bone mineral density;	chr4:10009721	chr4:10410996~10411644:+
STAD	cis	rs8097348	1	rs2345037	ENSG00000266602.1	RP11-476K15.1	-4.12	4.71e-05	0.0177	-0.25	-0.22	Exercise (leisure time);	chr18:1598540	chr18:1509183~1647097:+
STAD	cis	rs8141529	0.748	rs715531	ENSG00000226471.5	CTA-292E10.6	-4.12	4.71e-05	0.0177	-0.25	-0.22	Lymphocyte counts;	chr22:28886691	chr22:28800683~28848559:+
STAD	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	4.12	4.72e-05	0.0177	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
STAD	cis	rs11169552	0.543	rs11169481	ENSG00000200183.1	RNU6-238P	-4.12	4.72e-05	0.0177	-0.21	-0.22	Colorectal cancer;	chr12:50532702	chr12:50656973~50657078:+
STAD	cis	rs28588043	0.594	rs9426914	ENSG00000201126.1	RNU6-773P	-4.12	4.72e-05	0.0177	-0.4	-0.22	Number of children (6+ vs. 0 or 1);	chr1:170953774	chr1:171519816~171519913:-
STAD	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-4.12	4.72e-05	0.0177	-0.28	-0.22	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
STAD	cis	rs9463078	0.625	rs1360197	ENSG00000219384.1	RP11-491H9.3	4.12	4.72e-05	0.0177	0.21	0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44981893	chr6:45158870~45159511:+
STAD	cis	rs12893668	0.608	rs12889721	ENSG00000258851.1	RP11-894P9.2	-4.12	4.73e-05	0.0177	-0.26	-0.22	Reticulocyte count;	chr14:103568526	chr14:103553421~103561877:+
STAD	cis	rs4763879	0.593	rs2080206	ENSG00000256673.1	RP11-599J14.2	4.12	4.73e-05	0.0177	0.23	0.22	Type 1 diabetes;	chr12:9715370	chr12:9398355~9414851:-
STAD	cis	rs6142102	0.961	rs4911385	ENSG00000264616.1	MIR4755	4.12	4.73e-05	0.0177	0.23	0.22	Skin pigmentation;	chr20:33970787	chr20:34049119~34049190:+
STAD	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	4.12	4.73e-05	0.0177	0.35	0.22	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	4.12	4.73e-05	0.0177	0.35	0.22	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	4.12	4.73e-05	0.0177	0.35	0.22	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
STAD	cis	rs7474896	0.806	rs1779150	ENSG00000099251.13	HSD17B7P2	4.12	4.73e-05	0.0177	0.36	0.22	Obesity (extreme);	chr10:37749759	chr10:38356380~38378505:+
STAD	cis	rs9549328	0.577	rs4907477	ENSG00000267868.1	RP11-120K24.3	4.12	4.73e-05	0.0177	0.31	0.22	Systolic blood pressure;	chr13:112964170	chr13:112964835~112966131:-
STAD	cis	rs9549328	0.577	rs4907478	ENSG00000267868.1	RP11-120K24.3	4.12	4.73e-05	0.0177	0.31	0.22	Systolic blood pressure;	chr13:112964173	chr13:112964835~112966131:-
STAD	cis	rs9549328	0.577	rs4907571	ENSG00000267868.1	RP11-120K24.3	4.12	4.73e-05	0.0177	0.31	0.22	Systolic blood pressure;	chr13:112964182	chr13:112964835~112966131:-
STAD	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	4.12	4.73e-05	0.0177	0.2	0.22	Shingles;	chr7:38346957	chr7:38358512~38359162:-
STAD	cis	rs561341	0.739	rs1978116	ENSG00000265798.5	RP11-271K11.5	4.12	4.74e-05	0.0177	0.26	0.22	Hip circumference adjusted for BMI;	chr17:31893959	chr17:31038575~31059121:-
STAD	cis	rs2262909	0.566	rs10419058	ENSG00000213976.4	CTD-2561J22.2	4.12	4.74e-05	0.0177	0.25	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22127170	chr19:21382865~21387177:+
STAD	cis	rs3764021	0.933	rs10492165	ENSG00000256673.1	RP11-599J14.2	-4.12	4.74e-05	0.0177	-0.23	-0.22	Type 1 diabetes;	chr12:9733365	chr12:9398355~9414851:-
STAD	cis	rs1799949	0.965	rs799912	ENSG00000279602.1	CTD-3014M21.1	4.12	4.74e-05	0.0177	0.27	0.22	Menopause (age at onset);	chr17:43105117	chr17:43360041~43361361:-
STAD	cis	rs2901460	0.759	rs733517	ENSG00000229503.1	AC092155.1	-4.12	4.74e-05	0.0177	-0.17	-0.22	Mean corpuscular volume;	chr2:62139553	chr2:62532583~62533059:-
STAD	cis	rs12745968	0.589	rs6695638	ENSG00000229052.2	RP11-386I23.1	-4.12	4.74e-05	0.0178	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92557929	chr1:92930696~92934098:+
STAD	cis	rs1007190	0.881	rs12941832	ENSG00000267405.1	CTC-296K1.4	4.12	4.74e-05	0.0178	0.25	0.22	DNA methylation (variation);	chr17:44910114	chr17:44794747~44797783:-
STAD	cis	rs9393777	0.623	rs9348719	ENSG00000241549.7	GUSBP2	4.12	4.75e-05	0.0178	0.3	0.22	Intelligence (multi-trait analysis);	chr6:26469804	chr6:26871484~26956554:-
STAD	cis	rs7671266	0.747	rs6827946	ENSG00000250613.1	RP11-136I13.1	4.12	4.75e-05	0.0178	0.26	0.22	Cardiovascular disease risk factors;	chr4:10149711	chr4:10410996~10411644:+
STAD	cis	rs6693567	0.516	rs519126	ENSG00000203819.6	HIST2H2BC	-4.12	4.75e-05	0.0178	-0.25	-0.22	Migraine;	chr1:150316418	chr1:149850193~149850772:-
STAD	cis	rs3123078	0.517	rs12783102	ENSG00000264204.2	AGAP7P	-4.12	4.75e-05	0.0178	-0.28	-0.22	Prostate cancer;	chr10:46106155	chr10:46109621~46131358:+
STAD	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	4.12	4.75e-05	0.0178	0.23	0.22	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
STAD	cis	rs4982731	1	rs8015478	ENSG00000279656.1	RP11-298I3.6	4.12	4.75e-05	0.0178	0.22	0.22	Basophil percentage of granulocytes;Acute lymphoblastic leukemia (childhood);Basophil percentage of white cells;	chr14:23116809	chr14:23023083~23024217:-
STAD	cis	rs4237845	0.68	rs10877033	ENSG00000273805.1	RP11-620J15.4	-4.12	4.75e-05	0.0178	-0.24	-0.22	Intelligence (multi-trait analysis);	chr12:57889948	chr12:57894232~57896846:+
STAD	cis	rs2115630	1	rs1030863	ENSG00000275120.1	RP11-182J1.17	-4.12	4.75e-05	0.0178	-0.24	-0.22	P wave terminal force;	chr15:84739404	chr15:84599434~84606463:-
STAD	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	4.12	4.75e-05	0.0178	0.28	0.22	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	4.12	4.75e-05	0.0178	0.28	0.22	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
STAD	cis	rs6142102	0.961	rs4911401	ENSG00000264616.1	MIR4755	4.12	4.75e-05	0.0178	0.23	0.22	Skin pigmentation;	chr20:34066756	chr20:34049119~34049190:+
STAD	cis	rs8062405	0.755	rs4788076	ENSG00000278665.1	RP11-666O2.4	4.12	4.75e-05	0.0178	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28599241~28601881:-
STAD	cis	rs61270009	0.955	rs11748798	ENSG00000247828.6	TMEM161B-AS1	4.12	4.75e-05	0.0178	0.29	0.22	Depressive symptoms;	chr5:88354925	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs11740836	ENSG00000247828.6	TMEM161B-AS1	4.12	4.75e-05	0.0178	0.29	0.22	Depressive symptoms;	chr5:88356311	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.913	rs13154590	ENSG00000247828.6	TMEM161B-AS1	4.12	4.75e-05	0.0178	0.29	0.22	Depressive symptoms;	chr5:88357208	chr5:88268895~88436685:+
STAD	cis	rs4243830	0.85	rs7540913	ENSG00000229519.2	RP11-58A11.2	4.12	4.75e-05	0.0178	0.23	0.22	Body mass index;	chr1:6521817	chr1:6547905~6548619:+
STAD	cis	rs4713118	0.786	rs200503	ENSG00000280107.1	AL022393.9	-4.12	4.76e-05	0.0178	-0.29	-0.22	Parkinson's disease;	chr6:27818104	chr6:28170845~28172521:+
STAD	cis	rs4713118	0.786	rs200502	ENSG00000280107.1	AL022393.9	-4.12	4.76e-05	0.0178	-0.29	-0.22	Parkinson's disease;	chr6:27820284	chr6:28170845~28172521:+
STAD	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-4.12	4.76e-05	0.0178	-0.22	-0.22	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
STAD	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-4.12	4.76e-05	0.0178	-0.22	-0.22	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
STAD	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	4.12	4.76e-05	0.0178	0.27	0.22	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	4.12	4.76e-05	0.0178	0.27	0.22	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	4.12	4.76e-05	0.0178	0.27	0.22	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	4.12	4.76e-05	0.0178	0.27	0.22	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	4.12	4.76e-05	0.0178	0.27	0.22	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
STAD	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	4.12	4.76e-05	0.0178	0.27	0.22	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
STAD	cis	rs4950322	0.518	rs61838951	ENSG00000278811.3	LINC00624	4.12	4.76e-05	0.0178	0.23	0.22	Protein quantitative trait loci;	chr1:147116081	chr1:147258885~147517875:-
STAD	cis	rs427691	0.625	rs845735	ENSG00000271849.1	CTC-332L22.1	4.12	4.76e-05	0.0178	0.36	0.22	Autism spectrum disorder or schizophrenia;	chr5:109688170	chr5:109687802~109688329:-
STAD	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-4.12	4.76e-05	0.0178	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
STAD	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-4.12	4.76e-05	0.0178	-0.25	-0.22	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-4.12	4.76e-05	0.0178	-0.25	-0.22	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-4.12	4.76e-05	0.0178	-0.25	-0.22	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
STAD	cis	rs4713118	0.513	rs200971	ENSG00000280107.1	AL022393.9	-4.12	4.76e-05	0.0178	-0.28	-0.22	Parkinson's disease;	chr6:27891126	chr6:28170845~28172521:+
STAD	cis	rs2933343	0.729	rs813945	ENSG00000231305.3	RP11-723O4.2	4.12	4.76e-05	0.0178	0.23	0.22	IgG glycosylation;	chr3:128942094	chr3:128861313~128871540:-
STAD	cis	rs9733	0.596	rs12086630	ENSG00000274963.1	Metazoa_SRP	4.12	4.76e-05	0.0178	0.19	0.22	Tonsillectomy;	chr1:150678479	chr1:150568971~150569269:-
STAD	cis	rs9733	0.596	rs2065900	ENSG00000274963.1	Metazoa_SRP	4.12	4.76e-05	0.0178	0.19	0.22	Tonsillectomy;	chr1:150679726	chr1:150568971~150569269:-
STAD	cis	rs7647973	0.58	rs4955432	ENSG00000225399.4	RP11-3B7.1	4.12	4.76e-05	0.0178	0.24	0.22	Menarche (age at onset);	chr3:49229339	chr3:49260085~49261316:+
STAD	cis	rs7647973	0.6	rs11920267	ENSG00000225399.4	RP11-3B7.1	4.12	4.76e-05	0.0178	0.24	0.22	Menarche (age at onset);	chr3:49238531	chr3:49260085~49261316:+
STAD	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	4.12	4.76e-05	0.0178	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
STAD	cis	rs9902453	1	rs12600993	ENSG00000240074.1	RPL9P30	4.12	4.76e-05	0.0178	0.18	0.22	Coffee consumption (cups per day);	chr17:29964204	chr17:29855759~29856332:+
STAD	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-4.12	4.76e-05	0.0178	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
STAD	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-4.12	4.77e-05	0.0178	-0.24	-0.22	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
STAD	cis	rs12550612	0.83	rs10111172	ENSG00000253616.4	RP11-875O11.3	-4.12	4.77e-05	0.0178	-0.35	-0.22	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23111578	chr8:23071377~23074488:-
STAD	cis	rs1816752	0.646	rs9511309	ENSG00000273628.1	RP11-756A22.7	-4.12	4.77e-05	0.0178	-0.26	-0.22	Obesity-related traits;	chr13:24515435	chr13:24933006~24936796:+
STAD	cis	rs10978777	0.515	rs10113916	ENSG00000276883.1	AL137852.1	4.12	4.77e-05	0.0178	0.24	0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107319050	chr9:107292369~107292456:-
STAD	cis	rs34929064	0.881	rs2961313	ENSG00000179428.2	AC073072.5	-4.12	4.77e-05	0.0178	-0.24	-0.22	Major depression and alcohol dependence;	chr7:22695601	chr7:22725395~22727620:-
STAD	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	4.12	4.77e-05	0.0178	0.32	0.22	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
STAD	cis	rs2115630	1	rs10220733	ENSG00000275120.1	RP11-182J1.17	-4.12	4.77e-05	0.0178	-0.24	-0.22	P wave terminal force;	chr15:84737633	chr15:84599434~84606463:-
STAD	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-4.12	4.77e-05	0.0178	-0.25	-0.22	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
STAD	cis	rs2859998	0.892	rs12547722	ENSG00000250031.1	RP11-114M5.1	-4.12	4.77e-05	0.0178	-0.19	-0.22	Narcolepsy with cataplexy;	chr8:58437201	chr8:58424588~58426685:-
STAD	cis	rs950169	0.922	rs62028133	ENSG00000235370.6	DNM1P51	4.12	4.77e-05	0.0178	0.27	0.22	Schizophrenia;	chr15:84250623	chr15:84398316~84411701:-
STAD	cis	rs4639966	0.723	rs11217022	ENSG00000255239.1	AP002954.6	-4.12	4.77e-05	0.0178	-0.27	-0.22	Systemic lupus erythematosus;	chr11:118770897	chr11:118688039~118690600:-
STAD	cis	rs7924176	0.668	rs7895133	ENSG00000213731.2	RAB5CP1	-4.12	4.78e-05	0.0179	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74423435~74424014:-
STAD	cis	rs13413635	0.913	rs13409408	ENSG00000225808.1	DNAJC19P5	-4.12	4.78e-05	0.0179	-0.29	-0.22	Heart rate;	chr2:177814126	chr2:177229191~177229506:-
STAD	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-4.12	4.78e-05	0.0179	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
STAD	cis	rs34779708	0.966	rs10827493	ENSG00000271335.4	RP11-324I22.4	4.12	4.78e-05	0.0179	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35314552~35336401:-
STAD	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-4.12	4.78e-05	0.0179	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-4.12	4.78e-05	0.0179	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
STAD	cis	rs1816752	0.646	rs4770700	ENSG00000273628.1	RP11-756A22.7	-4.12	4.78e-05	0.0179	-0.27	-0.22	Obesity-related traits;	chr13:24494796	chr13:24933006~24936796:+
STAD	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	4.12	4.78e-05	0.0179	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
STAD	cis	rs2638953	0.924	rs11049410	ENSG00000247934.4	RP11-967K21.1	-4.12	4.78e-05	0.0179	-0.25	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183438	chr12:28163298~28190738:-
STAD	cis	rs9902453	0.845	rs7501472	ENSG00000263477.1	RP11-338L22.2	4.12	4.78e-05	0.0179	0.18	0.22	Coffee consumption (cups per day);	chr17:29683610	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.808	rs1986555	ENSG00000263477.1	RP11-338L22.2	4.12	4.78e-05	0.0179	0.18	0.22	Coffee consumption (cups per day);	chr17:29687430	chr17:29863402~29866092:+
STAD	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	4.12	4.78e-05	0.0179	0.25	0.22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
STAD	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-4.12	4.79e-05	0.0179	-0.25	-0.22	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-4.12	4.79e-05	0.0179	-0.25	-0.22	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-4.12	4.79e-05	0.0179	-0.25	-0.22	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
STAD	cis	rs7131987	0.903	rs10843371	ENSG00000257176.2	RP11-996F15.2	-4.12	4.79e-05	0.0179	-0.25	-0.22	QT interval;	chr12:29261299	chr12:29280418~29317848:-
STAD	cis	rs2638953	0.886	rs10492369	ENSG00000247934.4	RP11-967K21.1	4.12	4.8e-05	0.0179	0.24	0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172185	chr12:28163298~28190738:-
STAD	cis	rs1005277	0.522	rs7090858	ENSG00000099251.13	HSD17B7P2	-4.12	4.8e-05	0.0179	-0.23	-0.22	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.522	rs11011343	ENSG00000099251.13	HSD17B7P2	4.12	4.8e-05	0.0179	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38356380~38378505:+
STAD	cis	rs2957692	0.548	rs7938647	ENSG00000254554.1	RP11-351I24.1	4.12	4.8e-05	0.0179	0.36	0.22	Circulating vasoactive peptide levels;	chr11:10039876	chr11:10302657~10303704:-
STAD	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-4.12	4.8e-05	0.0179	-0.25	-0.22	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
STAD	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	4.12	4.8e-05	0.0179	0.24	0.22	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
STAD	cis	rs6095298	0.574	rs67763459	ENSG00000227431.4	CSE1L-AS1	-4.12	4.8e-05	0.0179	-0.24	-0.22	Intelligence (multi-trait analysis);	chr20:48847927	chr20:49040463~49046044:-
STAD	cis	rs7915414	0.802	rs34195517	ENSG00000230338.1	MTND4P19	4.12	4.8e-05	0.0179	0.25	0.22	Clopidogrel active metabolite levels;	chr10:94627421	chr10:94774156~94774633:-
STAD	cis	rs6832769	1	rs3805154	ENSG00000223305.1	RN7SKP30	4.12	4.8e-05	0.0179	0.24	0.22	Personality dimensions;	chr4:55497760	chr4:55540502~55540835:-
STAD	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-4.12	4.81e-05	0.0179	-0.21	-0.22	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
STAD	cis	rs7829975	0.502	rs7820738	ENSG00000253981.4	ALG1L13P	-4.12	4.81e-05	0.0179	-0.25	-0.22	Mood instability;	chr8:8845097	chr8:8236003~8244667:-
STAD	cis	rs10851478	0.872	rs8032688	ENSG00000259545.2	RP11-325E5.4	-4.12	4.81e-05	0.018	-0.26	-0.22	Oral cavity cancer;	chr15:49637467	chr15:49177610~49178741:-
STAD	cis	rs11051970	0.559	rs4931621	ENSG00000274964.1	RP11-817I4.1	-4.12	4.81e-05	0.018	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32333569	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs3816819	ENSG00000274964.1	RP11-817I4.1	-4.12	4.81e-05	0.018	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32334123	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs2291421	ENSG00000274964.1	RP11-817I4.1	-4.12	4.81e-05	0.018	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32334173	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs10844188	ENSG00000274964.1	RP11-817I4.1	-4.12	4.81e-05	0.018	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32334710	chr12:32339368~32340724:+
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000211959.2	IGHV4-39	4.12	4.81e-05	0.018	0.19	0.22	Kawasaki disease;	chr14:106782523	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000211959.2	IGHV4-39	4.12	4.81e-05	0.018	0.19	0.22	Kawasaki disease;	chr14:106782559	chr14:106421711~106422218:-
STAD	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-4.12	4.81e-05	0.018	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
STAD	cis	rs11051970	0.513	rs7972023	ENSG00000274964.1	RP11-817I4.1	-4.12	4.81e-05	0.018	-0.29	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32312174	chr12:32339368~32340724:+
STAD	cis	rs7924176	0.564	rs34868542	ENSG00000213731.2	RAB5CP1	-4.12	4.82e-05	0.018	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226399	chr10:74423435~74424014:-
STAD	cis	rs801193	0.613	rs2016325	ENSG00000222364.1	RNU6-96P	4.12	4.82e-05	0.018	0.25	0.22	Aortic root size;	chr7:66858513	chr7:66395191~66395286:+
STAD	cis	rs2286503	1	rs2286498	ENSG00000221740.1	SNORD93	-4.12	4.83e-05	0.018	-0.25	-0.22	Fibrinogen;	chr7:22817885	chr7:22856613~22856686:+
STAD	cis	rs7131987	0.903	rs7308125	ENSG00000257176.2	RP11-996F15.2	-4.12	4.83e-05	0.018	-0.24	-0.22	QT interval;	chr12:29272278	chr12:29280418~29317848:-
STAD	cis	rs34864796	0.547	rs200476	ENSG00000243307.2	POM121L6P	-4.12	4.83e-05	0.018	-0.27	-0.22	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:26896952~26898777:+
STAD	cis	rs3794924	1	rs8091481	ENSG00000266521.1	RP11-650P15.1	4.12	4.83e-05	0.018	0.39	0.22	Survival in colon cancer;	chr18:31471714	chr18:31496645~31497195:-
STAD	cis	rs4950322	0.58	rs72706441	ENSG00000278811.3	LINC00624	4.12	4.83e-05	0.018	0.24	0.22	Protein quantitative trait loci;	chr1:147122601	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.547	rs17355509	ENSG00000278811.3	LINC00624	4.12	4.83e-05	0.018	0.24	0.22	Protein quantitative trait loci;	chr1:147123139	chr1:147258885~147517875:-
STAD	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-4.12	4.83e-05	0.018	-0.25	-0.22	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
STAD	cis	rs34779708	0.966	rs4934536	ENSG00000271335.4	RP11-324I22.4	4.12	4.83e-05	0.018	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs4934537	ENSG00000271335.4	RP11-324I22.4	4.12	4.83e-05	0.018	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35314552~35336401:-
STAD	cis	rs9902453	0.765	rs9890747	ENSG00000263477.1	RP11-338L22.2	4.12	4.83e-05	0.018	0.18	0.22	Coffee consumption (cups per day);	chr17:29680424	chr17:29863402~29866092:+
STAD	cis	rs1876905	0.539	rs457497	ENSG00000230177.1	RP5-1112D6.4	4.12	4.83e-05	0.018	0.24	0.22	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111277932~111278742:+
STAD	cis	rs10129255	0.518	rs12590732	ENSG00000224373.3	IGHV4-59	-4.12	4.83e-05	0.018	-0.15	-0.22	Kawasaki disease;	chr14:106779612	chr14:106627249~106627825:-
STAD	cis	rs7119038	0.818	rs10892280	ENSG00000255422.1	AP002954.4	4.12	4.83e-05	0.018	0.3	0.22	Sjögren's syndrome;	chr11:118741108	chr11:118704607~118750263:+
STAD	cis	rs12188164	0.9	rs72717425	ENSG00000221990.4	EXOC3-AS1	4.12	4.84e-05	0.018	0.24	0.22	Cystic fibrosis severity;	chr5:438694	chr5:441498~443160:-
STAD	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	4.12	4.84e-05	0.0181	0.35	0.22	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
STAD	cis	rs1348850	0.914	rs6710575	ENSG00000271825.1	RP11-337N6.2	4.12	4.84e-05	0.0181	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177512583	chr2:177300600~177302006:+
STAD	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-4.12	4.84e-05	0.0181	-0.18	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
STAD	cis	rs359980	0.908	rs392683	ENSG00000224159.1	HMGB1P9	-4.12	4.84e-05	0.0181	-0.51	-0.22	Obesity-related traits;	chr2:218970290	chr2:218200434~218201388:+
STAD	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-4.12	4.84e-05	0.0181	-0.28	-0.22	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
STAD	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	4.12	4.84e-05	0.0181	0.21	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
STAD	cis	rs2834188	1	rs9982088	ENSG00000272659.1	AP000295.10	-4.12	4.84e-05	0.0181	-0.3	-0.22	Narcolepsy;	chr21:33314536	chr21:33309491~33310181:+
STAD	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	4.12	4.84e-05	0.0181	0.24	0.22	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
STAD	cis	rs1075265	0.87	rs7569370	ENSG00000235937.1	AC008280.1	4.12	4.84e-05	0.0181	0.19	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54029552~54030682:-
STAD	cis	rs9902453	1	rs6505152	ENSG00000240074.1	RPL9P30	-4.12	4.84e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30004448	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs7223786	ENSG00000240074.1	RPL9P30	-4.12	4.84e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30005089	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.967	rs8072664	ENSG00000240074.1	RPL9P30	-4.12	4.84e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30006367	chr17:29855759~29856332:+
STAD	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-4.11	4.84e-05	0.0181	-0.32	-0.22	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
STAD	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	4.11	4.85e-05	0.0181	0.18	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
STAD	cis	rs9902453	0.817	rs880749	ENSG00000263477.1	RP11-338L22.2	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:29732952	chr17:29863402~29866092:+
STAD	cis	rs7924176	0.549	rs2395076	ENSG00000213731.2	RAB5CP1	-4.11	4.85e-05	0.0181	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74423435~74424014:-
STAD	cis	rs7924176	0.601	rs7089391	ENSG00000213731.2	RAB5CP1	-4.11	4.85e-05	0.0181	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74423435~74424014:-
STAD	cis	rs7924176	0.601	rs7093532	ENSG00000213731.2	RAB5CP1	-4.11	4.85e-05	0.0181	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74423435~74424014:-
STAD	cis	rs2115630	0.967	rs8028490	ENSG00000275120.1	RP11-182J1.17	-4.11	4.85e-05	0.0181	-0.24	-0.22	P wave terminal force;	chr15:84734657	chr15:84599434~84606463:-
STAD	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-4.11	4.85e-05	0.0181	-0.25	-0.22	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
STAD	cis	rs7665090	0.528	rs3774968	ENSG00000246560.2	RP11-10L12.4	4.11	4.85e-05	0.0181	0.27	0.22	Primary biliary cholangitis;	chr4:102609955	chr4:102828055~102844075:+
STAD	cis	rs9902453	0.817	rs1038089	ENSG00000263477.1	RP11-338L22.2	4.11	4.85e-05	0.0181	0.18	0.22	Coffee consumption (cups per day);	chr17:29851706	chr17:29863402~29866092:+
STAD	cis	rs6142102	0.961	rs4911390	ENSG00000264616.1	MIR4755	4.11	4.85e-05	0.0181	0.23	0.22	Skin pigmentation;	chr20:33977401	chr20:34049119~34049190:+
STAD	cis	rs4639966	0.758	rs11217013	ENSG00000255239.1	AP002954.6	-4.11	4.85e-05	0.0181	-0.27	-0.22	Systemic lupus erythematosus;	chr11:118754210	chr11:118688039~118690600:-
STAD	cis	rs4639966	0.836	rs73001486	ENSG00000255239.1	AP002954.6	-4.11	4.85e-05	0.0181	-0.27	-0.22	Systemic lupus erythematosus;	chr11:118758655	chr11:118688039~118690600:-
STAD	cis	rs9902453	0.791	rs57719820	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30008070	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs7212497	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30008931	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.935	rs9911794	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30022448	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs8071742	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30034651	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs4575590	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30034951	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs4074170	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30054123	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs4075623	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30059508	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs4795525	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30061469	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs4239227	ENSG00000240074.1	RPL9P30	-4.11	4.85e-05	0.0181	-0.18	-0.22	Coffee consumption (cups per day);	chr17:30062085	chr17:29855759~29856332:+
STAD	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	4.11	4.85e-05	0.0181	0.29	0.22	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	4.11	4.85e-05	0.0181	0.29	0.22	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
STAD	cis	rs9902453	0.791	rs3115086	ENSG00000240074.1	RPL9P30	4.11	4.85e-05	0.0181	0.19	0.22	Coffee consumption (cups per day);	chr17:29698931	chr17:29855759~29856332:+
STAD	cis	rs2733201	1	rs1426658	ENSG00000249839.1	AC011330.5	4.11	4.85e-05	0.0181	0.4	0.22	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44046721	chr15:43663654~43684339:-
STAD	cis	rs10782582	0.593	rs6673786	ENSG00000181227.3	RP4-682C21.2	4.11	4.85e-05	0.0181	0.23	0.22	Daytime sleep phenotypes;	chr1:75683952	chr1:75743423~75744776:-
STAD	cis	rs9291683	0.554	rs7668175	ENSG00000250613.1	RP11-136I13.1	4.11	4.85e-05	0.0181	0.2	0.22	Bone mineral density;	chr4:10124158	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.62	rs7699512	ENSG00000250613.1	RP11-136I13.1	4.11	4.85e-05	0.0181	0.2	0.22	Bone mineral density;	chr4:10124184	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.62	rs4383618	ENSG00000250613.1	RP11-136I13.1	4.11	4.86e-05	0.0181	0.2	0.22	Bone mineral density;	chr4:10123527	chr4:10410996~10411644:+
STAD	cis	rs7702057	0.53	rs6890263	ENSG00000271918.1	CTD-2287O16.5	4.11	4.86e-05	0.0181	0.39	0.22	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116083807~116085416:-
STAD	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	4.11	4.86e-05	0.0181	0.3	0.22	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
STAD	cis	rs1075265	0.655	rs13432632	ENSG00000235937.1	AC008280.1	4.11	4.86e-05	0.0181	0.2	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54029552~54030682:-
STAD	cis	rs2688608	0.592	rs10762560	ENSG00000272140.2	RP11-574K11.29	4.11	4.86e-05	0.0181	0.19	0.22	Inflammatory bowel disease;	chr10:73735647	chr10:73703735~73713581:-
STAD	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	4.11	4.86e-05	0.0181	0.22	0.22	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
STAD	cis	rs7176527	0.848	rs3748374	ENSG00000229212.6	RP11-561C5.4	4.11	4.86e-05	0.0181	0.32	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85205440~85234795:-
STAD	cis	rs2790457	0.792	rs1265845	ENSG00000254635.4	WAC-AS1	-4.11	4.87e-05	0.0181	-0.27	-0.22	Multiple myeloma;	chr10:28638294	chr10:28522652~28532743:-
STAD	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	4.11	4.87e-05	0.0181	0.34	0.22	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
STAD	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	4.11	4.87e-05	0.0181	0.28	0.22	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
STAD	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	4.11	4.87e-05	0.0181	0.28	0.22	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
STAD	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	4.11	4.87e-05	0.0181	0.28	0.22	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
STAD	cis	rs9322193	0.962	rs9505974	ENSG00000233330.1	RP1-12G14.7	4.11	4.87e-05	0.0181	0.24	0.22	Lung cancer;	chr6:149779294	chr6:149591755~149592663:-
STAD	cis	rs9322193	0.926	rs9689036	ENSG00000233330.1	RP1-12G14.7	4.11	4.87e-05	0.0181	0.24	0.22	Lung cancer;	chr6:149780563	chr6:149591755~149592663:-
STAD	cis	rs9322193	0.962	rs9322218	ENSG00000233330.1	RP1-12G14.7	4.11	4.87e-05	0.0181	0.24	0.22	Lung cancer;	chr6:149782183	chr6:149591755~149592663:-
STAD	cis	rs9322193	0.962	rs9322219	ENSG00000233330.1	RP1-12G14.7	4.11	4.87e-05	0.0181	0.24	0.22	Lung cancer;	chr6:149782263	chr6:149591755~149592663:-
STAD	cis	rs9322193	0.962	rs9322223	ENSG00000233330.1	RP1-12G14.7	4.11	4.87e-05	0.0181	0.24	0.22	Lung cancer;	chr6:149801509	chr6:149591755~149592663:-
STAD	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-4.11	4.87e-05	0.0181	-0.23	-0.22	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
STAD	cis	rs2442825	0.691	rs2596912	ENSG00000206573.7	THUMPD3-AS1	4.11	4.87e-05	0.0181	0.16	0.22	Cerebrospinal fluid clusterin levels;	chr3:9397062	chr3:9349689~9398579:-
STAD	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	4.11	4.87e-05	0.0181	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	4.11	4.87e-05	0.0181	0.47	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
STAD	cis	rs10508774	1	rs72782234	ENSG00000273038.2	RP11-479G22.8	4.11	4.87e-05	0.0181	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32646505	chr10:32887255~32889311:-
STAD	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	4.11	4.87e-05	0.0181	0.49	0.22	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
STAD	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	4.11	4.87e-05	0.0181	0.25	0.22	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
STAD	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-4.11	4.87e-05	0.0181	-0.22	-0.22	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
STAD	cis	rs449789	0.524	rs4345420	ENSG00000235086.1	FNDC1-IT1	-4.11	4.87e-05	0.0182	-0.28	-0.22	Pulse pressure;	chr6:159324005	chr6:159240786~159243329:+
STAD	cis	rs7103648	1	rs12292911	ENSG00000280615.1	Y_RNA	4.11	4.87e-05	0.0182	0.22	0.22	Systolic blood pressure;Diastolic blood pressure;	chr11:47427521	chr11:47614898~47614994:-
STAD	cis	rs2348418	0.966	rs1527578	ENSG00000247934.4	RP11-967K21.1	4.11	4.87e-05	0.0182	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.966	rs16932891	ENSG00000247934.4	RP11-967K21.1	4.11	4.87e-05	0.0182	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.966	rs2881910	ENSG00000247934.4	RP11-967K21.1	4.11	4.87e-05	0.0182	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28163298~28190738:-
STAD	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	4.11	4.87e-05	0.0182	0.28	0.22	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
STAD	cis	rs2638953	0.815	rs7139060	ENSG00000247934.4	RP11-967K21.1	-4.11	4.87e-05	0.0182	-0.24	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28540211	chr12:28163298~28190738:-
STAD	cis	rs11992186	0.597	rs11781841	ENSG00000253981.4	ALG1L13P	-4.11	4.88e-05	0.0182	-0.28	-0.22	Neuroticism;	chr8:8737753	chr8:8236003~8244667:-
STAD	cis	rs11089937	0.616	rs4991802	ENSG00000211639.2	IGLV4-60	4.11	4.88e-05	0.0182	0.22	0.22	Periodontitis (PAL4Q3);	chr22:22179031	chr22:22162199~22162681:+
STAD	cis	rs559928	0.606	rs1011219	ENSG00000236935.1	AP003774.1	-4.11	4.88e-05	0.0182	-0.34	-0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64205924	chr11:64325050~64329504:-
STAD	cis	rs2812197	0.55	rs2580188	ENSG00000237152.3	DLEU7-AS1	4.11	4.88e-05	0.0182	0.28	0.22	Multiple sclerosis;	chr13:50224594	chr13:50807856~50849905:+
STAD	cis	rs1345301	0.552	rs67880537	ENSG00000234389.1	AC007278.3	-4.11	4.88e-05	0.0182	-0.22	-0.22	Waist circumference;	chr2:102247646	chr2:102438713~102440475:+
STAD	cis	rs749052	0.831	rs2679178	ENSG00000251485.1	AC068134.10	-4.11	4.88e-05	0.0182	-0.51	-0.22	Height;	chr2:231933151	chr2:232343116~232343903:+
STAD	cis	rs7615952	0.736	rs11921945	ENSG00000272840.1	RP11-379B18.6	4.11	4.88e-05	0.0182	0.39	0.22	Blood pressure (smoking interaction);	chr3:125924876	chr3:125774714~125797953:+
STAD	cis	rs12530	0.54	rs737779	ENSG00000230736.2	RP1-149A16.3	-4.11	4.88e-05	0.0182	-0.26	-0.22	IgG glycosylation;	chr22:32400260	chr22:32376664~32384343:+
STAD	cis	rs10851478	0.872	rs12906134	ENSG00000259545.2	RP11-325E5.4	-4.11	4.88e-05	0.0182	-0.26	-0.22	Oral cavity cancer;	chr15:49677423	chr15:49177610~49178741:-
STAD	cis	rs4763879	0.634	rs12424826	ENSG00000256673.1	RP11-599J14.2	4.11	4.88e-05	0.0182	0.23	0.22	Type 1 diabetes;	chr12:9701981	chr12:9398355~9414851:-
STAD	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	4.11	4.88e-05	0.0182	0.28	0.22	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
STAD	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	4.11	4.88e-05	0.0182	0.29	0.22	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
STAD	cis	rs2657294	0.761	rs1259498	ENSG00000226051.5	ZNF503-AS1	-4.11	4.88e-05	0.0182	-0.29	-0.22	Pneumonia;	chr10:75226983	chr10:75269819~75373500:+
STAD	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-4.11	4.89e-05	0.0182	-0.22	-0.22	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
STAD	cis	rs860295	0.702	rs11264366	ENSG00000225855.5	RUSC1-AS1	4.11	4.89e-05	0.0182	0.18	0.22	Body mass index;	chr1:155365620	chr1:155316863~155324176:-
STAD	cis	rs7474896	1	rs2799495	ENSG00000099251.13	HSD17B7P2	-4.11	4.89e-05	0.0182	-0.35	-0.22	Obesity (extreme);	chr10:37949056	chr10:38356380~38378505:+
STAD	cis	rs2957692	0.548	rs7935934	ENSG00000254554.1	RP11-351I24.1	4.11	4.89e-05	0.0182	0.36	0.22	Circulating vasoactive peptide levels;	chr11:10179638	chr11:10302657~10303704:-
STAD	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-4.11	4.89e-05	0.0182	-0.24	-0.22	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
STAD	cis	rs9463078	0.631	rs6458427	ENSG00000219384.1	RP11-491H9.3	4.11	4.89e-05	0.0182	0.21	0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45212067	chr6:45158870~45159511:+
STAD	cis	rs1154275	0.537	rs9875150	ENSG00000240057.4	RP11-572M11.4	-4.11	4.89e-05	0.0182	-0.2	-0.22	Takotsubo syndrome;	chr3:112796937	chr3:113019532~113183301:+
STAD	cis	rs765787	0.53	rs1706837	ENSG00000259539.1	CTD-2651B20.1	4.11	4.89e-05	0.0182	0.25	0.22	Uric acid levels;	chr15:45226838	chr15:45152664~45167526:-
STAD	cis	rs9902453	0.933	rs7225462	ENSG00000263477.1	RP11-338L22.2	4.11	4.89e-05	0.0182	0.18	0.22	Coffee consumption (cups per day);	chr17:29994208	chr17:29863402~29866092:+
STAD	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	4.11	4.89e-05	0.0182	0.36	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
STAD	cis	rs654950	0.934	rs653369	ENSG00000229901.1	RP11-399E6.4	-4.11	4.89e-05	0.0182	-0.24	-0.22	Airway imaging phenotypes;	chr1:41536705	chr1:41375004~41375669:-
STAD	cis	rs7615952	0.932	rs13321217	ENSG00000239804.1	RP11-379B18.1	4.11	4.9e-05	0.0182	0.35	0.22	Blood pressure (smoking interaction);	chr3:125912928	chr3:125787888~125788146:-
STAD	cis	rs7647973	0.58	rs12629759	ENSG00000225399.4	RP11-3B7.1	4.11	4.9e-05	0.0182	0.24	0.22	Menarche (age at onset);	chr3:49199961	chr3:49260085~49261316:+
STAD	cis	rs1144713	0.531	rs1716941	ENSG00000223722.3	RP11-467L13.5	-4.11	4.9e-05	0.0182	-0.25	-0.22	Obesity-related traits;	chr12:32102160	chr12:31754720~31755121:+
STAD	cis	rs6142102	0.924	rs6059662	ENSG00000264616.1	MIR4755	-4.11	4.9e-05	0.0182	-0.22	-0.22	Skin pigmentation;	chr20:34087921	chr20:34049119~34049190:+
STAD	cis	rs9987353	0.876	rs73199666	ENSG00000254340.1	RP11-10A14.3	-4.11	4.9e-05	0.0182	-0.32	-0.22	Recombination measurement;	chr8:9268220	chr8:9141424~9145435:+
STAD	cis	rs9307551	0.584	rs2119421	ENSG00000250334.4	LINC00989	-4.11	4.9e-05	0.0182	-0.26	-0.22	Refractive error;	chr4:79529168	chr4:79492416~79576460:+
STAD	cis	rs1816752	0.633	rs8002387	ENSG00000232858.1	RPL34P27	4.11	4.9e-05	0.0182	0.13	0.22	Obesity-related traits;	chr13:24416306	chr13:24988577~24988925:-
STAD	cis	rs4835473	0.864	rs4835343	ENSG00000249741.2	RP11-673E1.3	-4.11	4.9e-05	0.0182	-0.25	-0.22	Immature fraction of reticulocytes;	chr4:143866038	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.831	rs1579816	ENSG00000249741.2	RP11-673E1.3	-4.11	4.9e-05	0.0182	-0.25	-0.22	Immature fraction of reticulocytes;	chr4:143866772	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs4240334	ENSG00000249741.2	RP11-673E1.3	-4.11	4.9e-05	0.0182	-0.25	-0.22	Immature fraction of reticulocytes;	chr4:143871352	chr4:143911514~143912053:-
STAD	cis	rs73001065	0.901	rs73002956	ENSG00000269191.1	AC005387.2	-4.11	4.9e-05	0.0182	-0.43	-0.22	LDL cholesterol;	chr19:19467934	chr19:18532908~18536188:+
STAD	cis	rs9467773	0.935	rs11752946	ENSG00000241549.7	GUSBP2	4.11	4.9e-05	0.0182	0.21	0.22	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26871484~26956554:-
STAD	cis	rs8028182	0.636	rs4545784	ENSG00000260269.4	CTD-2323K18.1	-4.11	4.91e-05	0.0183	-0.27	-0.22	Sudden cardiac arrest;	chr15:75463310	chr15:75527150~75601205:-
STAD	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	4.11	4.91e-05	0.0183	0.22	0.22	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
STAD	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	4.11	4.91e-05	0.0183	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
STAD	cis	rs1707322	0.821	rs11211182	ENSG00000281133.1	AL355480.3	-4.11	4.91e-05	0.0183	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45580892~45580996:-
STAD	cis	rs9646944	0.836	rs10178214	ENSG00000234389.1	AC007278.3	4.11	4.91e-05	0.0183	0.26	0.22	Blood protein levels;	chr2:102242461	chr2:102438713~102440475:+
STAD	cis	rs4293777	0.874	rs11930839	ENSG00000250896.1	RNPS1P1	4.11	4.91e-05	0.0183	0.17	0.22	Primary sclerosing cholangitis;	chr4:10725258	chr4:11371975~11372892:+
STAD	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	4.11	4.91e-05	0.0183	0.32	0.22	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
STAD	cis	rs6142102	0.961	rs2284379	ENSG00000264616.1	MIR4755	4.11	4.91e-05	0.0183	0.23	0.22	Skin pigmentation;	chr20:34006836	chr20:34049119~34049190:+
STAD	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	4.11	4.91e-05	0.0183	0.32	0.22	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
STAD	cis	rs1015362	0.503	rs1883708	ENSG00000276073.1	RP5-1125A11.7	-4.11	4.91e-05	0.0183	-0.25	-0.22	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33985617~33988989:-
STAD	cis	rs611744	0.563	rs7815105	ENSG00000253754.1	RP11-35G22.1	-4.11	4.91e-05	0.0183	-0.2	-0.22	Dupuytren's disease;	chr8:108286565	chr8:108226200~108227544:+
STAD	cis	rs3770081	1	rs80304739	ENSG00000273080.1	RP11-301O19.1	-4.11	4.91e-05	0.0183	-0.52	-0.22	Facial emotion recognition (sad faces);	chr2:85915416	chr2:86195590~86196049:+
STAD	cis	rs10129255	0.957	rs1056705	ENSG00000224373.3	IGHV4-59	4.11	4.92e-05	0.0183	0.18	0.22	Kawasaki disease;	chr14:106714323	chr14:106627249~106627825:-
STAD	cis	rs41411047	0.702	rs4373022	ENSG00000224831.3	RP11-651P23.4	-4.11	4.92e-05	0.0183	-0.31	-0.22	Myocardial infarction;	chr3:149959639	chr3:149982181~149983308:-
STAD	cis	rs7176527	0.848	rs72630462	ENSG00000229212.6	RP11-561C5.4	4.11	4.92e-05	0.0183	0.36	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:85205440~85234795:-
STAD	cis	rs11673344	0.523	rs2891766	ENSG00000267672.1	CTD-2293H3.1	4.11	4.92e-05	0.0183	0.2	0.22	Obesity-related traits;	chr19:37037057	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs7245453	ENSG00000267672.1	CTD-2293H3.1	4.11	4.92e-05	0.0183	0.2	0.22	Obesity-related traits;	chr19:37043447	chr19:37091341~37092564:+
STAD	cis	rs6142102	0.961	rs1555075	ENSG00000264616.1	MIR4755	4.11	4.92e-05	0.0183	0.23	0.22	Skin pigmentation;	chr20:34022595	chr20:34049119~34049190:+
STAD	cis	rs10510102	0.516	rs78586895	ENSG00000226864.1	ATE1-AS1	4.11	4.92e-05	0.0183	0.37	0.22	Breast cancer;	chr10:121977081	chr10:121928312~121951965:+
STAD	cis	rs2562456	0.917	rs11085463	ENSG00000268081.1	RP11-678G14.2	4.11	4.92e-05	0.0183	0.28	0.22	Pain;	chr19:21568500	chr19:21554640~21569237:-
STAD	cis	rs34779708	0.931	rs2148482	ENSG00000271335.4	RP11-324I22.4	4.11	4.92e-05	0.0183	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35314552~35336401:-
STAD	cis	rs9902453	1	rs4533340	ENSG00000240074.1	RPL9P30	4.11	4.92e-05	0.0183	0.19	0.22	Coffee consumption (cups per day);	chr17:29950933	chr17:29855759~29856332:+
STAD	cis	rs2348418	0.767	rs1478332	ENSG00000247934.4	RP11-967K21.1	-4.11	4.92e-05	0.0183	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28163298~28190738:-
STAD	cis	rs1059312	0.5	rs12303338	ENSG00000279500.1	RP11-21K12.2	4.11	4.93e-05	0.0183	0.2	0.22	Systemic lupus erythematosus;	chr12:128792096	chr12:128813186~128814750:-
STAD	cis	rs1056107	0.831	rs7856158	ENSG00000225513.1	RP11-165N19.2	4.11	4.93e-05	0.0183	0.25	0.22	Colorectal cancer;	chr9:112188892	chr9:112173522~112173971:-
STAD	cis	rs516805	0.528	rs2606611	ENSG00000279453.1	RP3-425C14.4	-4.11	4.93e-05	0.0183	-0.31	-0.22	Lymphocyte counts;	chr6:122094502	chr6:122436789~122439223:-
STAD	cis	rs516805	0.528	rs1402537	ENSG00000279453.1	RP3-425C14.4	-4.11	4.93e-05	0.0183	-0.31	-0.22	Lymphocyte counts;	chr6:122094962	chr6:122436789~122439223:-
STAD	cis	rs62400317	0.762	rs10456120	ENSG00000219384.1	RP11-491H9.3	-4.11	4.93e-05	0.0183	-0.25	-0.22	Total body bone mineral density;	chr6:44932370	chr6:45158870~45159511:+
STAD	cis	rs62400317	0.762	rs12208332	ENSG00000219384.1	RP11-491H9.3	-4.11	4.93e-05	0.0183	-0.25	-0.22	Total body bone mineral density;	chr6:44935484	chr6:45158870~45159511:+
STAD	cis	rs62400317	0.762	rs12190313	ENSG00000219384.1	RP11-491H9.3	-4.11	4.93e-05	0.0183	-0.25	-0.22	Total body bone mineral density;	chr6:44936165	chr6:45158870~45159511:+
STAD	cis	rs2390582	0.713	rs12741330	ENSG00000228175.3	GEMIN8P4	4.11	4.93e-05	0.0183	0.35	0.22	Coronary artery calcification;	chr1:90357801	chr1:89993593~89994321:-
STAD	cis	rs9291683	0.692	rs1558489	ENSG00000250613.1	RP11-136I13.1	4.11	4.93e-05	0.0183	0.21	0.22	Bone mineral density;	chr4:10323865	chr4:10410996~10411644:+
STAD	cis	rs11638815	0.581	rs783537	ENSG00000255769.6	GOLGA2P10	-4.11	4.93e-05	0.0183	-0.25	-0.22	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:82472993~82513950:-
STAD	cis	rs6421571	0.564	rs11216972	ENSG00000255422.1	AP002954.4	4.11	4.93e-05	0.0183	0.27	0.22	Primary biliary cholangitis;	chr11:118715117	chr11:118704607~118750263:+
STAD	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	4.11	4.93e-05	0.0183	0.3	0.22	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
STAD	cis	rs4835473	0.863	rs11735239	ENSG00000249741.2	RP11-673E1.3	4.11	4.93e-05	0.0183	0.25	0.22	Immature fraction of reticulocytes;	chr4:143689372	chr4:143911514~143912053:-
STAD	cis	rs2834188	0.924	rs6517160	ENSG00000272659.1	AP000295.10	-4.11	4.94e-05	0.0183	-0.3	-0.22	Narcolepsy;	chr21:33311207	chr21:33309491~33310181:+
STAD	cis	rs2834188	0.924	rs2409487	ENSG00000272659.1	AP000295.10	-4.11	4.94e-05	0.0183	-0.3	-0.22	Narcolepsy;	chr21:33312653	chr21:33309491~33310181:+
STAD	cis	rs9393777	0.623	rs7773938	ENSG00000241549.7	GUSBP2	4.11	4.94e-05	0.0183	0.3	0.22	Intelligence (multi-trait analysis);	chr6:26473816	chr6:26871484~26956554:-
STAD	cis	rs4293777	0.904	rs7683890	ENSG00000250896.1	RNPS1P1	4.11	4.94e-05	0.0184	0.17	0.22	Primary sclerosing cholangitis;	chr4:10724501	chr4:11371975~11372892:+
STAD	cis	rs7615952	0.932	rs13314869	ENSG00000272840.1	RP11-379B18.6	4.11	4.94e-05	0.0184	0.39	0.22	Blood pressure (smoking interaction);	chr3:125925826	chr3:125774714~125797953:+
STAD	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	4.11	4.94e-05	0.0184	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
STAD	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	4.11	4.94e-05	0.0184	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
STAD	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	4.11	4.94e-05	0.0184	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
STAD	cis	rs9907295	1	rs11653051	ENSG00000270894.1	AC015849.13	-4.11	4.94e-05	0.0184	-0.26	-0.22	Fibroblast growth factor basic levels;	chr17:35909166	chr17:35818399~35823713:+
STAD	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	4.11	4.94e-05	0.0184	0.29	0.22	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
STAD	cis	rs11157436	0.602	rs2075492	ENSG00000211813.2	TRAV34	4.11	4.94e-05	0.0184	0.24	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163321	chr14:22207522~22208129:+
STAD	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-4.11	4.94e-05	0.0184	-0.36	-0.22	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
STAD	cis	rs76210638	0.892	rs7989420	ENSG00000276672.1	RP11-142E9.1	-4.11	4.94e-05	0.0184	-0.26	-0.22	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33934664	chr13:33846190~33850825:+
STAD	cis	rs1799949	0.896	rs35908185	ENSG00000279602.1	CTD-3014M21.1	4.11	4.95e-05	0.0184	0.27	0.22	Menopause (age at onset);	chr17:43103094	chr17:43360041~43361361:-
STAD	cis	rs2836974	0.568	rs8130795	ENSG00000238141.2	BRWD1-AS1	4.11	4.95e-05	0.0184	0.22	0.22	Cognitive function;	chr21:39178057	chr21:39315707~39323218:+
STAD	cis	rs1816752	0.875	rs8001187	ENSG00000232858.1	RPL34P27	4.11	4.95e-05	0.0184	0.13	0.22	Obesity-related traits;	chr13:24402276	chr13:24988577~24988925:-
STAD	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	4.11	4.95e-05	0.0184	0.26	0.22	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	4.11	4.95e-05	0.0184	0.26	0.22	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	4.11	4.95e-05	0.0184	0.26	0.22	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
STAD	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	4.11	4.95e-05	0.0184	0.26	0.22	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
STAD	cis	rs11673344	0.504	rs2385375	ENSG00000267672.1	CTD-2293H3.1	4.11	4.95e-05	0.0184	0.2	0.22	Obesity-related traits;	chr19:37087620	chr19:37091341~37092564:+
STAD	cis	rs10986311	0.722	rs10760347	ENSG00000227200.1	RP11-121A14.3	-4.11	4.95e-05	0.0184	-0.23	-0.22	Vitiligo;	chr9:124290307	chr9:124262876~124265809:+
STAD	cis	rs453301	0.506	rs476845	ENSG00000254340.1	RP11-10A14.3	-4.11	4.95e-05	0.0184	-0.26	-0.22	Joint mobility (Beighton score);	chr8:8765367	chr8:9141424~9145435:+
STAD	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	4.11	4.95e-05	0.0184	0.22	0.22	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
STAD	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-4.11	4.95e-05	0.0184	-0.36	-0.22	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
STAD	cis	rs12745968	0.589	rs7513775	ENSG00000229052.2	RP11-386I23.1	-4.11	4.95e-05	0.0184	-0.21	-0.22	Bipolar disorder and schizophrenia;	chr1:92538940	chr1:92930696~92934098:+
STAD	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	4.11	4.95e-05	0.0184	0.24	0.22	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
STAD	cis	rs9733	0.596	rs72702556	ENSG00000274963.1	Metazoa_SRP	4.11	4.95e-05	0.0184	0.19	0.22	Tonsillectomy;	chr1:150707639	chr1:150568971~150569269:-
STAD	cis	rs6933660	0.72	rs6936936	ENSG00000221469.1	AL133260.1	4.11	4.95e-05	0.0184	0.23	0.22	Menarche (age at onset);	chr6:151432260	chr6:151039916~151039971:-
STAD	cis	rs6933660	0.72	rs6914656	ENSG00000221469.1	AL133260.1	4.11	4.95e-05	0.0184	0.23	0.22	Menarche (age at onset);	chr6:151432286	chr6:151039916~151039971:-
STAD	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	4.11	4.95e-05	0.0184	0.26	0.22	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
STAD	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-4.11	4.95e-05	0.0184	-0.31	-0.22	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
STAD	cis	rs7429990	0.932	rs6442101	ENSG00000224895.1	VPS26BP1	4.11	4.95e-05	0.0184	0.22	0.22	Educational attainment (years of education);	chr3:48089403	chr3:47960327~47961081:-
STAD	cis	rs5769707	0.609	rs2071890	ENSG00000213279.2	RP1-29C18.9	-4.11	4.96e-05	0.0184	-0.28	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49572264~49575426:-
STAD	cis	rs516805	0.528	rs2606622	ENSG00000279453.1	RP3-425C14.4	-4.11	4.96e-05	0.0184	-0.31	-0.22	Lymphocyte counts;	chr6:122096367	chr6:122436789~122439223:-
STAD	cis	rs516805	0.528	rs2606627	ENSG00000279453.1	RP3-425C14.4	-4.11	4.96e-05	0.0184	-0.31	-0.22	Lymphocyte counts;	chr6:122097129	chr6:122436789~122439223:-
STAD	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-4.11	4.96e-05	0.0184	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
STAD	cis	rs8177876	0.658	rs889516	ENSG00000261838.4	RP11-303E16.6	-4.11	4.96e-05	0.0184	-0.42	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034943	chr16:81069854~81076598:+
STAD	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-4.11	4.97e-05	0.0184	-0.25	-0.22	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-4.11	4.97e-05	0.0184	-0.25	-0.22	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-4.11	4.97e-05	0.0184	-0.25	-0.22	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-4.11	4.97e-05	0.0184	-0.25	-0.22	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-4.11	4.97e-05	0.0184	-0.25	-0.22	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
STAD	cis	rs6933660	0.745	rs9322320	ENSG00000221469.1	AL133260.1	4.11	4.97e-05	0.0185	0.23	0.22	Menarche (age at onset);	chr6:151430773	chr6:151039916~151039971:-
STAD	cis	rs7615952	0.512	rs2979334	ENSG00000239804.1	RP11-379B18.1	4.11	4.97e-05	0.0185	0.3	0.22	Blood pressure (smoking interaction);	chr3:125639980	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.512	rs11921452	ENSG00000239804.1	RP11-379B18.1	4.11	4.97e-05	0.0185	0.3	0.22	Blood pressure (smoking interaction);	chr3:125640906	chr3:125787888~125788146:-
STAD	cis	rs2638953	0.962	rs7980151	ENSG00000247934.4	RP11-967K21.1	-4.11	4.97e-05	0.0185	-0.24	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28149345	chr12:28163298~28190738:-
STAD	cis	rs1348850	0.519	rs4144275	ENSG00000271825.1	RP11-337N6.2	4.11	4.97e-05	0.0185	0.19	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658640	chr2:177300600~177302006:+
STAD	cis	rs1707322	0.964	rs10890358	ENSG00000281133.1	AL355480.3	-4.11	4.98e-05	0.0185	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45580892~45580996:-
STAD	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	4.11	4.98e-05	0.0185	0.26	0.22	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
STAD	cis	rs9902453	0.753	rs7226121	ENSG00000240074.1	RPL9P30	4.11	4.98e-05	0.0185	0.19	0.22	Coffee consumption (cups per day);	chr17:29881107	chr17:29855759~29856332:+
STAD	cis	rs8012947	0.727	rs10135729	ENSG00000279636.2	LINC00216	-4.11	4.98e-05	0.0185	-0.21	-0.22	Alcohol consumption in current drinkers;	chr14:58277859	chr14:58288033~58289158:+
STAD	cis	rs393951	0.711	rs428800	ENSG00000260969.1	RP11-190D6.2	4.11	4.98e-05	0.0185	0.31	0.22	Childhood ear infection;	chr16:77580824	chr16:78237362~78241218:-
STAD	cis	rs1707322	1	rs7539800	ENSG00000281133.1	AL355480.3	4.11	4.98e-05	0.0185	0.26	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45580892~45580996:-
STAD	cis	rs2483058	0.531	rs12565311	ENSG00000261000.1	RP11-534L20.5	4.11	4.98e-05	0.0185	0.26	0.22	Cholesterol and Triglycerides;	chr1:206458186	chr1:206503948~206504456:+
STAD	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	4.11	4.98e-05	0.0185	0.28	0.22	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
STAD	cis	rs11657217	0.638	rs4313839	ENSG00000267719.1	HP09025	4.11	4.98e-05	0.0185	0.22	0.22	Diastolic blood pressure response to hydrochlorothiazide in hypertension;	chr17:79724849	chr17:79707266~79712317:+
STAD	cis	rs720475	0.732	rs62483107	ENSG00000244198.4	RP4-545C24.1	-4.11	4.99e-05	0.0185	-0.28	-0.22	Breast cancer;	chr7:144442144	chr7:144194858~144280547:+
STAD	cis	rs12530	0.54	rs2294312	ENSG00000230736.2	RP1-149A16.3	-4.11	4.99e-05	0.0185	-0.26	-0.22	IgG glycosylation;	chr22:32397397	chr22:32376664~32384343:+
STAD	cis	rs17401966	0.931	rs12753426	ENSG00000199562.1	RNU6-37P	4.11	4.99e-05	0.0185	0.17	0.22	Hepatocellular carcinoma;	chr1:10312052	chr1:10298966~10299072:+
STAD	cis	rs28588043	0.609	rs28887824	ENSG00000201126.1	RNU6-773P	-4.11	4.99e-05	0.0185	-0.36	-0.22	Number of children (6+ vs. 0 or 1);	chr1:170979761	chr1:171519816~171519913:-
STAD	cis	rs17401966	0.838	rs2182326	ENSG00000199562.1	RNU6-37P	4.11	4.99e-05	0.0185	0.17	0.22	Hepatocellular carcinoma;	chr1:10325606	chr1:10298966~10299072:+
STAD	cis	rs12745968	0.685	rs11164807	ENSG00000229052.2	RP11-386I23.1	-4.11	4.99e-05	0.0185	-0.2	-0.22	Bipolar disorder and schizophrenia;	chr1:92768538	chr1:92930696~92934098:+
STAD	cis	rs2300206	1	rs2300206	ENSG00000264616.1	MIR4755	4.11	4.99e-05	0.0185	0.23	0.22	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:34049119~34049190:+
STAD	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-4.11	4.99e-05	0.0185	-0.21	-0.22	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
STAD	cis	rs2446066	0.872	rs11170532	ENSG00000257379.1	RP11-793H13.8	4.11	5e-05	0.0185	0.36	0.22	Red blood cell count;	chr12:53394551	chr12:53441741~53467528:+
STAD	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	4.11	5e-05	0.0185	0.47	0.22	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
STAD	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-4.11	5e-05	0.0185	-0.23	-0.22	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
STAD	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	4.11	5e-05	0.0186	0.25	0.22	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
STAD	cis	rs3770081	1	rs2012798	ENSG00000273080.1	RP11-301O19.1	-4.11	5.01e-05	0.0186	-0.5	-0.22	Facial emotion recognition (sad faces);	chr2:85955633	chr2:86195590~86196049:+
STAD	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-4.11	5.01e-05	0.0186	-0.29	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
STAD	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-4.11	5.01e-05	0.0186	-0.29	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
STAD	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-4.11	5.01e-05	0.0186	-0.29	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
STAD	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-4.11	5.01e-05	0.0186	-0.29	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
STAD	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-4.11	5.01e-05	0.0186	-0.29	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
STAD	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-4.11	5.01e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
STAD	cis	rs11098499	0.913	rs10006304	ENSG00000260091.1	RP11-33B1.4	4.11	5.01e-05	0.0186	0.21	0.22	Corneal astigmatism;	chr4:119203150	chr4:119409333~119410233:+
STAD	cis	rs8141529	0.719	rs9625619	ENSG00000226471.5	CTA-292E10.6	-4.11	5.01e-05	0.0186	-0.25	-0.22	Lymphocyte counts;	chr22:28876340	chr22:28800683~28848559:+
STAD	cis	rs516805	0.528	rs2606631	ENSG00000279453.1	RP3-425C14.4	-4.11	5.01e-05	0.0186	-0.32	-0.22	Lymphocyte counts;	chr6:122099510	chr6:122436789~122439223:-
STAD	cis	rs12468226	0.873	rs2350358	ENSG00000226261.1	AC064836.3	-4.11	5.01e-05	0.0186	-0.33	-0.22	Urate levels;	chr2:202199771	chr2:202336024~202336727:-
STAD	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	4.11	5.01e-05	0.0186	0.28	0.22	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
STAD	cis	rs11722779	0.903	rs13130741	ENSG00000248971.2	KRT8P46	-4.11	5.01e-05	0.0186	-0.22	-0.22	Schizophrenia;	chr4:103035799	chr4:102728746~102730171:-
STAD	cis	rs11235843	0.853	rs11235925	ENSG00000255928.1	RP11-456I15.2	4.11	5.01e-05	0.0186	0.38	0.22	Hand grip strength;	chr11:73841598	chr11:73722349~73722694:+
STAD	cis	rs6940638	0.688	rs2022272	ENSG00000243307.2	POM121L6P	-4.11	5.01e-05	0.0186	-0.21	-0.22	Intelligence (multi-trait analysis);	chr6:27135801	chr6:26896952~26898777:+
STAD	cis	rs9463078	0.547	rs4714819	ENSG00000219384.1	RP11-491H9.3	-4.11	5.02e-05	0.0186	-0.21	-0.22	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44767548	chr6:45158870~45159511:+
STAD	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-4.11	5.02e-05	0.0186	-0.34	-0.22	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
STAD	cis	rs6142102	0.961	rs4911407	ENSG00000264616.1	MIR4755	4.11	5.02e-05	0.0186	0.23	0.22	Skin pigmentation;	chr20:34095759	chr20:34049119~34049190:+
STAD	cis	rs9307551	0.619	rs1440862	ENSG00000250334.4	LINC00989	-4.11	5.02e-05	0.0186	-0.26	-0.22	Refractive error;	chr4:79503116	chr4:79492416~79576460:+
STAD	cis	rs8141529	0.956	rs469989	ENSG00000226471.5	CTA-292E10.6	4.11	5.02e-05	0.0186	0.26	0.22	Lymphocyte counts;	chr22:28907607	chr22:28800683~28848559:+
STAD	cis	rs7131987	0.845	rs2042511	ENSG00000257176.2	RP11-996F15.2	-4.11	5.02e-05	0.0186	-0.25	-0.22	QT interval;	chr12:29255847	chr12:29280418~29317848:-
STAD	cis	rs3858145	0.546	rs7912806	ENSG00000234102.1	KRT19P4	4.11	5.02e-05	0.0186	0.24	0.22	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68296578	chr10:68260557~68261499:+
STAD	cis	rs10129255	0.826	rs7150693	ENSG00000232216.1	IGHV3-43	4.11	5.02e-05	0.0186	0.22	0.22	Kawasaki disease;	chr14:106705382	chr14:106470264~106470800:-
STAD	cis	rs8062405	1	rs62036617	ENSG00000278665.1	RP11-666O2.4	4.11	5.02e-05	0.0186	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28599241~28601881:-
STAD	cis	rs12477438	0.501	rs1133977	ENSG00000231822.1	AC019097.7	-4.11	5.02e-05	0.0186	-0.22	-0.22	Chronic sinus infection;	chr2:99125521	chr2:99102018~99102752:+
STAD	cis	rs2384207	0.818	rs1458366	ENSG00000277566.1	RP11-545P7.9	-4.11	5.03e-05	0.0186	-0.3	-0.22	Response to fenofibrate (adiponectin levels);	chr12:113234772	chr12:113249466~113250042:+
STAD	cis	rs875971	1	rs1167612	ENSG00000224316.1	RP11-479O9.2	-4.11	5.03e-05	0.0186	-0.22	-0.22	Aortic root size;	chr7:66102989	chr7:65773620~65802067:+
STAD	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-4.11	5.03e-05	0.0186	-0.24	-0.22	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
STAD	cis	rs6693567	0.565	rs1260398	ENSG00000203819.6	HIST2H2BC	-4.11	5.03e-05	0.0186	-0.25	-0.22	Migraine;	chr1:150307442	chr1:149850193~149850772:-
STAD	cis	rs9733	0.596	rs72702536	ENSG00000274963.1	Metazoa_SRP	4.11	5.03e-05	0.0186	0.19	0.22	Tonsillectomy;	chr1:150690098	chr1:150568971~150569269:-
STAD	cis	rs330071	0.622	rs898797	ENSG00000233609.3	RP11-62H7.2	4.11	5.03e-05	0.0186	0.25	0.22	Acne (severe);	chr8:9372179	chr8:8961200~8979025:+
STAD	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	4.11	5.03e-05	0.0187	0.31	0.22	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	4.11	5.03e-05	0.0187	0.31	0.22	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	4.11	5.03e-05	0.0187	0.31	0.22	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	4.11	5.03e-05	0.0187	0.31	0.22	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-4.11	5.03e-05	0.0187	-0.31	-0.22	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	4.11	5.03e-05	0.0187	0.31	0.22	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
STAD	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	4.11	5.04e-05	0.0187	0.33	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
STAD	cis	rs7702057	0.53	rs61105089	ENSG00000271918.1	CTD-2287O16.5	4.11	5.04e-05	0.0187	0.4	0.22	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs2136213	ENSG00000271918.1	CTD-2287O16.5	4.11	5.04e-05	0.0187	0.4	0.22	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs61672521	ENSG00000271918.1	CTD-2287O16.5	4.11	5.04e-05	0.0187	0.4	0.22	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116083807~116085416:-
STAD	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-4.11	5.04e-05	0.0187	-0.26	-0.22	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
STAD	cis	rs6834538	0.597	rs9991830	ENSG00000234841.4	RP11-119H12.4	-4.11	5.04e-05	0.0187	-0.23	-0.22	Free thyroxine concentration;	chr4:112564216	chr4:112826307~112827607:+
STAD	cis	rs11169552	0.51	rs10876060	ENSG00000200183.1	RNU6-238P	-4.11	5.04e-05	0.0187	-0.2	-0.22	Colorectal cancer;	chr12:50571847	chr12:50656973~50657078:+
STAD	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	4.11	5.05e-05	0.0187	0.21	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
STAD	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	4.11	5.05e-05	0.0187	0.3	0.22	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
STAD	cis	rs13413635	0.908	rs58796031	ENSG00000225808.1	DNAJC19P5	-4.1	5.05e-05	0.0187	-0.28	-0.22	Heart rate;	chr2:177820152	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.955	rs13386827	ENSG00000225808.1	DNAJC19P5	-4.1	5.05e-05	0.0187	-0.28	-0.22	Heart rate;	chr2:177820194	chr2:177229191~177229506:-
STAD	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-4.1	5.05e-05	0.0187	-0.24	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
STAD	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-4.1	5.05e-05	0.0187	-0.28	-0.22	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
STAD	cis	rs806321	0.685	rs2812228	ENSG00000237152.3	DLEU7-AS1	-4.1	5.05e-05	0.0187	-0.25	-0.22	Multiple sclerosis;	chr13:50199654	chr13:50807856~50849905:+
STAD	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-4.1	5.06e-05	0.0187	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
STAD	cis	rs919433	0.963	rs6738836	ENSG00000231621.1	AC013264.2	4.1	5.06e-05	0.0187	0.19	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317708	chr2:197197991~197199273:+
STAD	cis	rs4407350	0.729	rs6007167	ENSG00000279642.1	RP5-1033E15.3	-4.1	5.06e-05	0.0187	-0.21	-0.22	Intelligence (multi-trait analysis);	chr22:44492244	chr22:44486295~44486914:-
STAD	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-4.1	5.06e-05	0.0187	-0.31	-0.22	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
STAD	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-4.1	5.06e-05	0.0187	-0.31	-0.22	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
STAD	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-4.1	5.06e-05	0.0187	-0.32	-0.22	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
STAD	cis	rs6142102	0.961	rs6057957	ENSG00000264616.1	MIR4755	4.1	5.06e-05	0.0187	0.23	0.22	Skin pigmentation;	chr20:33962052	chr20:34049119~34049190:+
STAD	cis	rs11846409	1	rs11846409	ENSG00000274576.2	IGHV2-70	-4.1	5.06e-05	0.0187	-0.26	-0.22	Rheumatic heart disease;	chr14:106645692	chr14:106770577~106771020:-
STAD	cis	rs528301	0.584	rs7604640	ENSG00000259439.2	RP11-89K21.1	4.1	5.06e-05	0.0187	0.3	0.22	Alcohol and nicotine co-dependence;	chr2:44894327	chr2:44921077~44939199:-
STAD	cis	rs11089937	0.651	rs2877023	ENSG00000211639.2	IGLV4-60	4.1	5.06e-05	0.0187	0.24	0.22	Periodontitis (PAL4Q3);	chr22:22182414	chr22:22162199~22162681:+
STAD	cis	rs6430585	0.528	rs309159	ENSG00000231890.6	DARS-AS1	-4.1	5.06e-05	0.0187	-0.23	-0.22	Corneal structure;	chr2:135927370	chr2:135985176~136022593:+
STAD	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-4.1	5.06e-05	0.0187	-0.25	-0.22	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
STAD	cis	rs262150	0.574	rs2730272	ENSG00000231419.5	LINC00689	4.1	5.07e-05	0.0187	0.24	0.22	Facial morphology (factor 20);	chr7:159005931	chr7:159006522~159030195:+
STAD	cis	rs7937127	0.744	rs72900934	ENSG00000254907.1	RP11-484D2.2	4.1	5.07e-05	0.0187	0.37	0.22	Fibrinogen levels;	chr11:43410740	chr11:43328748~43359296:-
STAD	cis	rs7937127	0.744	rs11602575	ENSG00000254907.1	RP11-484D2.2	4.1	5.07e-05	0.0187	0.37	0.22	Fibrinogen levels;	chr11:43411957	chr11:43328748~43359296:-
STAD	cis	rs13242809	1	rs13242809	ENSG00000179428.2	AC073072.5	-4.1	5.07e-05	0.0187	-0.24	-0.22	Lymphocyte counts;	chr7:22706945	chr7:22725395~22727620:-
STAD	cis	rs6832769	1	rs4865010	ENSG00000223305.1	RN7SKP30	-4.1	5.07e-05	0.0188	-0.24	-0.22	Personality dimensions;	chr4:55548795	chr4:55540502~55540835:-
STAD	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-4.1	5.07e-05	0.0188	-0.29	-0.22	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
STAD	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-4.1	5.07e-05	0.0188	-0.23	-0.22	Height;	chr2:46617930	chr2:46668870~46670778:+
STAD	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
STAD	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-4.1	5.08e-05	0.0188	-0.32	-0.22	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
STAD	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	4.1	5.08e-05	0.0188	0.17	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
STAD	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	4.1	5.08e-05	0.0188	0.22	0.22	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
STAD	cis	rs7924176	0.58	rs7912162	ENSG00000213731.2	RAB5CP1	-4.1	5.08e-05	0.0188	-0.22	-0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74423435~74424014:-
STAD	cis	rs2834188	1	rs2834187	ENSG00000272659.1	AP000295.10	-4.1	5.08e-05	0.0188	-0.3	-0.22	Narcolepsy;	chr21:33315105	chr21:33309491~33310181:+
STAD	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-4.1	5.08e-05	0.0188	-0.32	-0.22	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
STAD	cis	rs561341	1	rs72825740	ENSG00000265798.5	RP11-271K11.5	4.1	5.09e-05	0.0188	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32011337	chr17:31038575~31059121:-
STAD	cis	rs561341	0.941	rs17780080	ENSG00000265798.5	RP11-271K11.5	4.1	5.09e-05	0.0188	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32016127	chr17:31038575~31059121:-
STAD	cis	rs561341	0.941	rs17780086	ENSG00000265798.5	RP11-271K11.5	4.1	5.09e-05	0.0188	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32016263	chr17:31038575~31059121:-
STAD	cis	rs561341	0.941	rs72825746	ENSG00000265798.5	RP11-271K11.5	4.1	5.09e-05	0.0188	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32037591	chr17:31038575~31059121:-
STAD	cis	rs561341	0.882	rs72825748	ENSG00000265798.5	RP11-271K11.5	4.1	5.09e-05	0.0188	0.31	0.22	Hip circumference adjusted for BMI;	chr17:32040377	chr17:31038575~31059121:-
STAD	cis	rs794185	0.714	rs711636	ENSG00000231249.1	ITPR1-AS1	-4.1	5.09e-05	0.0188	-0.24	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4448093	chr3:4490891~4493163:-
STAD	cis	rs6142102	0.923	rs4911394	ENSG00000264616.1	MIR4755	4.1	5.09e-05	0.0188	0.23	0.22	Skin pigmentation;	chr20:33989521	chr20:34049119~34049190:+
STAD	cis	rs858239	0.899	rs28458177	ENSG00000230042.1	AK3P3	-4.1	5.09e-05	0.0188	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23129178~23129841:+
STAD	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-4.1	5.09e-05	0.0188	-0.28	-0.22	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
STAD	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-4.1	5.09e-05	0.0188	-0.25	-0.22	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-4.1	5.09e-05	0.0188	-0.25	-0.22	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-4.1	5.09e-05	0.0188	-0.25	-0.22	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
STAD	cis	rs12477438	0.501	rs12613624	ENSG00000231822.1	AC019097.7	-4.1	5.09e-05	0.0188	-0.22	-0.22	Chronic sinus infection;	chr2:99116278	chr2:99102018~99102752:+
STAD	cis	rs11051970	0.559	rs11051945	ENSG00000274964.1	RP11-817I4.1	-4.1	5.09e-05	0.0188	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32336191	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs11051946	ENSG00000274964.1	RP11-817I4.1	-4.1	5.09e-05	0.0188	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32336335	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.527	rs2388989	ENSG00000274964.1	RP11-817I4.1	-4.1	5.09e-05	0.0188	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32337341	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs2388988	ENSG00000274964.1	RP11-817I4.1	-4.1	5.09e-05	0.0188	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32337414	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs4604975	ENSG00000274964.1	RP11-817I4.1	-4.1	5.09e-05	0.0188	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32337441	chr12:32339368~32340724:+
STAD	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	4.1	5.09e-05	0.0188	0.31	0.22	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	4.1	5.09e-05	0.0188	0.31	0.22	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	4.1	5.09e-05	0.0188	0.31	0.22	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
STAD	cis	rs4834770	1	rs4834770	ENSG00000250412.1	KLHL2P1	4.1	5.09e-05	0.0188	0.28	0.22	Blood protein levels;	chr4:119320694	chr4:119334329~119378233:+
STAD	cis	rs4834770	1	rs6823963	ENSG00000250412.1	KLHL2P1	4.1	5.09e-05	0.0188	0.28	0.22	Blood protein levels;	chr4:119321009	chr4:119334329~119378233:+
STAD	cis	rs4834770	1	rs4834771	ENSG00000250412.1	KLHL2P1	4.1	5.09e-05	0.0188	0.28	0.22	Blood protein levels;	chr4:119321617	chr4:119334329~119378233:+
STAD	cis	rs4834770	1	rs1397613	ENSG00000250412.1	KLHL2P1	4.1	5.09e-05	0.0188	0.28	0.22	Blood protein levels;	chr4:119321774	chr4:119334329~119378233:+
STAD	cis	rs4834770	1	rs6857641	ENSG00000250412.1	KLHL2P1	4.1	5.09e-05	0.0188	0.28	0.22	Blood protein levels;	chr4:119322356	chr4:119334329~119378233:+
STAD	cis	rs4834770	1	rs2282688	ENSG00000250412.1	KLHL2P1	4.1	5.09e-05	0.0188	0.28	0.22	Blood protein levels;	chr4:119322567	chr4:119334329~119378233:+
STAD	cis	rs870825	0.549	rs28542773	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184696781	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28416641	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184696845	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7683615	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184697219	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs67798981	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184698413	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs2310104	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184698813	chr4:184893871~184899454:-
STAD	cis	rs870825	0.746	rs1107908	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184698959	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6552801	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184699469	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6552802	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184699597	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs877276	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184700095	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs79884757	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184700300	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28444118	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184700538	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4256263	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184701805	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28660669	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184702158	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs67641203	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184702691	chr4:184893871~184899454:-
STAD	cis	rs870825	0.698	rs66462315	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184702763	chr4:184893871~184899454:-
STAD	cis	rs870825	0.698	rs72703549	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184702809	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs67409049	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184702835	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4615214	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184702975	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4263438	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184703084	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4386643	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184703127	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4264873	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184703182	chr4:184893871~184899454:-
STAD	cis	rs870825	0.698	rs7673203	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184704243	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs9631782	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184705225	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs9631783	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184705357	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs55674580	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184705451	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28620459	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184705978	chr4:184893871~184899454:-
STAD	cis	rs870825	0.549	rs28579266	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184706108	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28673855	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184706262	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28500698	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184706592	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28558715	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184706607	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28497285	ENSG00000249173.4	LINC01093	-4.1	5.09e-05	0.0188	-0.34	-0.22	Blood protein levels;	chr4:184708015	chr4:184893871~184899454:-
STAD	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	4.1	5.09e-05	0.0188	0.24	0.22	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
STAD	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-4.1	5.09e-05	0.0188	-0.31	-0.22	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
STAD	cis	rs1816752	0.624	rs7330766	ENSG00000273628.1	RP11-756A22.7	-4.1	5.1e-05	0.0188	-0.26	-0.22	Obesity-related traits;	chr13:24495579	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.603	rs7984094	ENSG00000273628.1	RP11-756A22.7	-4.1	5.1e-05	0.0188	-0.26	-0.22	Obesity-related traits;	chr13:24496212	chr13:24933006~24936796:+
STAD	cis	rs9307551	0.948	rs11098779	ENSG00000250334.4	LINC00989	-4.1	5.1e-05	0.0188	-0.27	-0.22	Refractive error;	chr4:79619060	chr4:79492416~79576460:+
STAD	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-4.1	5.1e-05	0.0188	-0.36	-0.22	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
STAD	cis	rs9902453	0.817	rs2617881	ENSG00000263477.1	RP11-338L22.2	-4.1	5.1e-05	0.0188	-0.18	-0.22	Coffee consumption (cups per day);	chr17:29736257	chr17:29863402~29866092:+
STAD	cis	rs11157436	0.602	rs1894369	ENSG00000211812.1	TRAV26-2	4.1	5.1e-05	0.0188	0.21	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166597	chr14:22202583~22203368:+
STAD	cis	rs11235843	0.778	rs72976852	ENSG00000255928.1	RP11-456I15.2	4.1	5.1e-05	0.0188	0.36	0.22	Hand grip strength;	chr11:73731605	chr11:73722349~73722694:+
STAD	cis	rs12906542	0.544	rs35472584	ENSG00000269951.1	RP11-797A18.6	-4.1	5.1e-05	0.0188	-0.26	-0.22	Breast cancer;	chr15:77974385	chr15:77067654~77068325:-
STAD	cis	rs794185	0.564	rs1825915	ENSG00000231249.1	ITPR1-AS1	-4.1	5.1e-05	0.0188	-0.24	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4472186	chr3:4490891~4493163:-
STAD	cis	rs794185	0.565	rs1825916	ENSG00000231249.1	ITPR1-AS1	-4.1	5.1e-05	0.0188	-0.24	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4472228	chr3:4490891~4493163:-
STAD	cis	rs1345301	0.518	rs17689452	ENSG00000234389.1	AC007278.3	-4.1	5.1e-05	0.0189	-0.22	-0.22	Waist circumference;	chr2:102248221	chr2:102438713~102440475:+
STAD	cis	rs11089937	0.597	rs5757007	ENSG00000211640.3	IGLV6-57	4.1	5.1e-05	0.0189	0.16	0.22	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22195713~22196460:+
STAD	cis	rs17507216	0.681	rs28877110	ENSG00000255769.6	GOLGA2P10	-4.1	5.11e-05	0.0189	-0.36	-0.22	Excessive daytime sleepiness;	chr15:82672111	chr15:82472993~82513950:-
STAD	cis	rs6693567	0.565	rs1260407	ENSG00000203819.6	HIST2H2BC	4.1	5.11e-05	0.0189	0.25	0.22	Migraine;	chr1:150333654	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.565	rs3125808	ENSG00000203819.6	HIST2H2BC	4.1	5.11e-05	0.0189	0.25	0.22	Migraine;	chr1:150341796	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.526	rs698918	ENSG00000203819.6	HIST2H2BC	4.1	5.11e-05	0.0189	0.25	0.22	Migraine;	chr1:150347286	chr1:149850193~149850772:-
STAD	cis	rs2562456	0.833	rs2562507	ENSG00000268119.4	CTD-2561J22.5	-4.1	5.11e-05	0.0189	-0.27	-0.22	Pain;	chr19:21543535	chr19:21444241~21463908:-
STAD	cis	rs17401966	0.894	rs11587309	ENSG00000199562.1	RNU6-37P	4.1	5.11e-05	0.0189	0.17	0.22	Hepatocellular carcinoma;	chr1:10386538	chr1:10298966~10299072:+
STAD	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-4.1	5.12e-05	0.0189	-0.28	-0.22	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
STAD	cis	rs9907295	0.818	rs9303692	ENSG00000271013.1	AC015849.15	4.1	5.12e-05	0.0189	0.3	0.22	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35912635~35918010:-
STAD	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	4.1	5.12e-05	0.0189	0.28	0.22	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
STAD	cis	rs72627123	1	rs17093474	ENSG00000259065.1	RP5-1021I20.1	-4.1	5.12e-05	0.0189	-0.32	-0.22	Morning vs. evening chronotype;	chr14:73875710	chr14:73787360~73803270:+
STAD	cis	rs6940638	0.688	rs9379960	ENSG00000216915.2	RP1-97D16.1	-4.1	5.12e-05	0.0189	-0.24	-0.22	Intelligence (multi-trait analysis);	chr6:27153546	chr6:27737000~27738494:-
STAD	cis	rs10508774	1	rs12413262	ENSG00000273038.2	RP11-479G22.8	4.1	5.12e-05	0.0189	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32621576	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs1984071	ENSG00000273038.2	RP11-479G22.8	4.1	5.12e-05	0.0189	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32621878	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs1984072	ENSG00000273038.2	RP11-479G22.8	4.1	5.12e-05	0.0189	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32622085	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs957219	ENSG00000273038.2	RP11-479G22.8	4.1	5.12e-05	0.0189	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32642982	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72782237	ENSG00000273038.2	RP11-479G22.8	4.1	5.12e-05	0.0189	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32647743	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs11009018	ENSG00000273038.2	RP11-479G22.8	4.1	5.12e-05	0.0189	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32650793	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.85	rs11009020	ENSG00000273038.2	RP11-479G22.8	4.1	5.12e-05	0.0189	0.42	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32660069	chr10:32887255~32889311:-
STAD	cis	rs7474896	0.537	rs1779068	ENSG00000120555.12	SEPT7P9	-4.1	5.12e-05	0.0189	-0.27	-0.22	Obesity (extreme);	chr10:37961857	chr10:38383069~38402916:-
STAD	cis	rs2262909	0.962	rs55728714	ENSG00000213976.4	CTD-2561J22.2	4.1	5.12e-05	0.0189	0.27	0.22	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22080097	chr19:21382865~21387177:+
STAD	cis	rs1790761	0.803	rs2302264	ENSG00000231793.4	DOC2GP	-4.1	5.12e-05	0.0189	-0.26	-0.22	Mean corpuscular volume;	chr11:67439955	chr11:67612653~67616257:-
STAD	cis	rs10776614	0.799	rs4084916	ENSG00000189014.7	FAM35DP	4.1	5.12e-05	0.0189	0.34	0.22	Self-employment;	chr10:48568295	chr10:47689707~47730436:+
STAD	cis	rs1707322	1	rs6672115	ENSG00000225447.1	RPS15AP10	4.1	5.13e-05	0.0189	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45645816~45646197:-
STAD	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-4.1	5.13e-05	0.0189	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
STAD	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	4.1	5.13e-05	0.0189	0.26	0.22	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
STAD	cis	rs11846409	0.932	rs756588	ENSG00000211970.3	IGHV4-61	-4.1	5.13e-05	0.0189	-0.25	-0.22	Rheumatic heart disease;	chr14:106632316	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.86	rs55745256	ENSG00000211970.3	IGHV4-61	4.1	5.13e-05	0.0189	0.25	0.22	Rheumatic heart disease;	chr14:106632365	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs731013	ENSG00000211970.3	IGHV4-61	4.1	5.13e-05	0.0189	0.25	0.22	Rheumatic heart disease;	chr14:106632481	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs731012	ENSG00000211970.3	IGHV4-61	4.1	5.13e-05	0.0189	0.25	0.22	Rheumatic heart disease;	chr14:106632578	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs731011	ENSG00000211970.3	IGHV4-61	4.1	5.13e-05	0.0189	0.25	0.22	Rheumatic heart disease;	chr14:106632619	chr14:106639119~106639657:-
STAD	cis	rs11846409	0.932	rs10138537	ENSG00000211970.3	IGHV4-61	4.1	5.13e-05	0.0189	0.25	0.22	Rheumatic heart disease;	chr14:106632778	chr14:106639119~106639657:-
STAD	cis	rs2573652	0.722	rs12898366	ENSG00000270127.2	RP11-526I2.5	-4.1	5.13e-05	0.0189	-0.23	-0.22	Height;	chr15:100002862	chr15:100547765~100550153:-
STAD	cis	rs561341	0.739	rs6505267	ENSG00000265798.5	RP11-271K11.5	4.1	5.13e-05	0.0189	0.26	0.22	Hip circumference adjusted for BMI;	chr17:31898931	chr17:31038575~31059121:-
STAD	cis	rs10815468	0.542	rs10975834	ENSG00000223621.1	AK4P4	4.1	5.13e-05	0.0189	0.23	0.22	Bipolar disorder and schizophrenia;	chr9:6795668	chr9:5855781~5856426:-
STAD	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	4.1	5.13e-05	0.0189	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.733	rs2019011	ENSG00000247934.4	RP11-967K21.1	4.1	5.13e-05	0.0189	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	4.1	5.13e-05	0.0189	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
STAD	cis	rs10508774	1	rs11008970	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32546707	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs11008971	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32546863	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs11008974	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32555086	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs3824591	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32565472	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12266925	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32567517	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12268559	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32567818	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs116546771	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32595672	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12250212	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32661709	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs10160127	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32664791	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs11009023	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32665824	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs10159899	ENSG00000273038.2	RP11-479G22.8	4.1	5.13e-05	0.0189	0.41	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32666387	chr10:32887255~32889311:-
STAD	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-4.1	5.13e-05	0.0189	-0.28	-0.22	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
STAD	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-4.1	5.13e-05	0.0189	-0.37	-0.22	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
STAD	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	4.1	5.13e-05	0.0189	0.21	0.22	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
STAD	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	4.1	5.14e-05	0.0189	0.24	0.22	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
STAD	cis	rs2836950	0.565	rs8134214	ENSG00000238141.2	BRWD1-AS1	-4.1	5.14e-05	0.0189	-0.22	-0.22	Menarche (age at onset);	chr21:39170441	chr21:39315707~39323218:+
STAD	cis	rs2836950	0.565	rs2836931	ENSG00000238141.2	BRWD1-AS1	-4.1	5.14e-05	0.0189	-0.22	-0.22	Menarche (age at onset);	chr21:39174643	chr21:39315707~39323218:+
STAD	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	4.1	5.14e-05	0.019	0.31	0.22	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
STAD	cis	rs2901460	0.714	rs10184724	ENSG00000229503.1	AC092155.1	-4.1	5.14e-05	0.019	-0.17	-0.22	Mean corpuscular volume;	chr2:62137799	chr2:62532583~62533059:-
STAD	cis	rs9584850	0.834	rs7334078	ENSG00000231194.1	FARP1-AS1	-4.1	5.14e-05	0.019	-0.26	-0.22	Neuroticism;	chr13:98468230	chr13:98435405~98435840:-
STAD	cis	rs34779708	0.733	rs7070778	ENSG00000271335.4	RP11-324I22.4	4.1	5.14e-05	0.019	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35314552~35336401:-
STAD	cis	rs11157436	0.602	rs928955	ENSG00000211812.1	TRAV26-2	-4.1	5.15e-05	0.019	-0.21	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166273	chr14:22202583~22203368:+
STAD	cis	rs11157436	0.602	rs1894370	ENSG00000211812.1	TRAV26-2	-4.1	5.15e-05	0.019	-0.21	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166764	chr14:22202583~22203368:+
STAD	cis	rs4639966	0.836	rs7124498	ENSG00000255239.1	AP002954.6	-4.1	5.15e-05	0.019	-0.27	-0.22	Systemic lupus erythematosus;	chr11:118745544	chr11:118688039~118690600:-
STAD	cis	rs11992162	0.56	rs13256329	ENSG00000270154.1	RP11-419I17.1	-4.1	5.15e-05	0.019	-0.23	-0.22	Monocyte count;	chr8:11924705	chr8:12476462~12477122:+
STAD	cis	rs10435719	0.638	rs67146188	ENSG00000270154.1	RP11-419I17.1	-4.1	5.15e-05	0.019	-0.23	-0.22	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:12476462~12477122:+
STAD	cis	rs11992162	0.551	rs13268217	ENSG00000270154.1	RP11-419I17.1	-4.1	5.15e-05	0.019	-0.23	-0.22	Monocyte count;	chr8:11925100	chr8:12476462~12477122:+
STAD	cis	rs11992162	0.573	rs13264994	ENSG00000270154.1	RP11-419I17.1	-4.1	5.15e-05	0.019	-0.23	-0.22	Monocyte count;	chr8:11925250	chr8:12476462~12477122:+
STAD	cis	rs11992162	0.573	rs13275808	ENSG00000270154.1	RP11-419I17.1	-4.1	5.15e-05	0.019	-0.23	-0.22	Monocyte count;	chr8:11925306	chr8:12476462~12477122:+
STAD	cis	rs10129255	0.5	rs2027902	ENSG00000232216.1	IGHV3-43	4.1	5.16e-05	0.019	0.19	0.22	Kawasaki disease;	chr14:106807157	chr14:106470264~106470800:-
STAD	cis	rs494453	1	rs494453	ENSG00000234020.1	CHIAP3	-4.1	5.16e-05	0.019	-0.21	-0.22	Osteoporosis-related phenotypes;	chr1:111649500	chr1:111353275~111367409:-
STAD	cis	rs11098499	0.691	rs10010355	ENSG00000260091.1	RP11-33B1.4	4.1	5.16e-05	0.019	0.2	0.22	Corneal astigmatism;	chr4:119339888	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.691	rs9307471	ENSG00000260091.1	RP11-33B1.4	4.1	5.16e-05	0.019	0.2	0.22	Corneal astigmatism;	chr4:119340107	chr4:119409333~119410233:+
STAD	cis	rs1707322	0.752	rs6678444	ENSG00000281133.1	AL355480.3	-4.1	5.16e-05	0.019	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45580892~45580996:-
STAD	cis	rs806321	0.531	rs2066625	ENSG00000237152.3	DLEU7-AS1	-4.1	5.16e-05	0.019	-0.25	-0.22	Multiple sclerosis;	chr13:50180064	chr13:50807856~50849905:+
STAD	cis	rs3947	0.951	rs1692817	ENSG00000227888.4	FAM66A	-4.1	5.16e-05	0.019	-0.29	-0.22	Blood protein levels;	chr8:11847210	chr8:12362019~12388296:+
STAD	cis	rs4243830	1	rs12046884	ENSG00000229519.2	RP11-58A11.2	-4.1	5.16e-05	0.019	-0.24	-0.22	Body mass index;	chr1:6534501	chr1:6547905~6548619:+
STAD	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	4.1	5.16e-05	0.019	0.27	0.22	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
STAD	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	4.1	5.16e-05	0.019	0.36	0.22	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
STAD	cis	rs7202877	0.706	rs8046184	ENSG00000261783.1	RP11-252K23.2	-4.1	5.17e-05	0.019	-0.36	-0.22	Type 1 diabetes;Type 2 diabetes;	chr16:75377827	chr16:75379818~75381260:-
STAD	cis	rs919433	0.926	rs12618567	ENSG00000231621.1	AC013264.2	4.1	5.17e-05	0.019	0.18	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283467	chr2:197197991~197199273:+
STAD	cis	rs4927850	1	rs10881563	ENSG00000278820.1	AC024937.1	4.1	5.17e-05	0.019	0.24	0.22	Pancreatic cancer;	chr3:196023354	chr3:195960500~195960612:-
STAD	cis	rs1348850	0.874	rs952746	ENSG00000271825.1	RP11-337N6.2	4.1	5.17e-05	0.019	0.18	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177441856	chr2:177300600~177302006:+
STAD	cis	rs10229583	0.527	rs6943219	ENSG00000279078.1	SND1-IT1	4.1	5.17e-05	0.019	0.21	0.22	Type 2 diabetes;	chr7:127668332	chr7:127997597~128000077:+
STAD	cis	rs4538475	1	rs4273468	ENSG00000214846.4	RP11-115L11.1	-4.1	5.17e-05	0.019	-0.3	-0.22	Parkinson's disease;	chr4:15736240	chr4:15730962~15731627:-
STAD	cis	rs9467773	0.933	rs35355150	ENSG00000243307.2	POM121L6P	4.1	5.17e-05	0.019	0.21	0.22	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26896952~26898777:+
STAD	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	4.1	5.17e-05	0.0191	0.25	0.22	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
STAD	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	4.1	5.17e-05	0.0191	0.25	0.22	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
STAD	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	4.1	5.17e-05	0.0191	0.25	0.22	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
STAD	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	4.1	5.17e-05	0.0191	0.31	0.22	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
STAD	cis	rs4834770	0.718	rs4833618	ENSG00000248280.1	RP11-33B1.2	-4.1	5.17e-05	0.0191	-0.26	-0.22	Blood protein levels;	chr4:119388345	chr4:119440561~119450157:-
STAD	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	4.1	5.17e-05	0.0191	0.37	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
STAD	cis	rs794185	0.592	rs304085	ENSG00000231249.1	ITPR1-AS1	-4.1	5.17e-05	0.0191	-0.24	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4480447	chr3:4490891~4493163:-
STAD	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	4.1	5.17e-05	0.0191	0.29	0.22	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
STAD	cis	rs1707322	1	rs4390216	ENSG00000225447.1	RPS15AP10	4.1	5.17e-05	0.0191	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.964	rs10437063	ENSG00000225447.1	RPS15AP10	4.1	5.17e-05	0.0191	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs6676982	ENSG00000225447.1	RPS15AP10	4.1	5.17e-05	0.0191	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.927	rs11211194	ENSG00000225447.1	RPS15AP10	4.1	5.17e-05	0.0191	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45645816~45646197:-
STAD	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	4.1	5.18e-05	0.0191	0.34	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
STAD	cis	rs7487075	0.619	rs7968897	ENSG00000257261.4	RP11-96H19.1	4.1	5.18e-05	0.0191	0.29	0.22	Itch intensity from mosquito bite;	chr12:46420041	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs6582646	ENSG00000257261.4	RP11-96H19.1	4.1	5.18e-05	0.0191	0.29	0.22	Itch intensity from mosquito bite;	chr12:46420074	chr12:46383679~46876159:+
STAD	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	4.1	5.18e-05	0.0191	0.31	0.22	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	4.1	5.18e-05	0.0191	0.31	0.22	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
STAD	cis	rs6565180	0.962	rs11642676	ENSG00000273724.1	RP11-347C12.12	-4.1	5.18e-05	0.0191	-0.23	-0.22	Tonsillectomy;	chr16:30360334	chr16:30336400~30343336:+
STAD	cis	rs2836974	0.644	rs11088472	ENSG00000238141.2	BRWD1-AS1	-4.1	5.18e-05	0.0191	-0.23	-0.22	Cognitive function;	chr21:39327450	chr21:39315707~39323218:+
STAD	cis	rs34779708	0.931	rs10437420	ENSG00000271335.4	RP11-324I22.4	-4.1	5.19e-05	0.0191	-0.26	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35314552~35336401:-
STAD	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-4.1	5.19e-05	0.0191	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
STAD	cis	rs11250098	0.547	rs2409764	ENSG00000227888.4	FAM66A	4.1	5.19e-05	0.0191	0.23	0.22	Morning vs. evening chronotype;	chr8:11423764	chr8:12362019~12388296:+
STAD	cis	rs4589258	0.762	rs4420224	ENSG00000280367.1	RP11-121L10.2	4.1	5.19e-05	0.0191	0.21	0.22	Intelligence (multi-trait analysis);	chr11:90768664	chr11:90223153~90226538:+
STAD	cis	rs34779708	0.966	rs10508816	ENSG00000271335.4	RP11-324I22.4	4.1	5.19e-05	0.0191	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35314552~35336401:-
STAD	cis	rs6686842	0.56	rs3738368	ENSG00000235358.1	RP11-399E6.1	-4.1	5.19e-05	0.0191	-0.24	-0.22	Height;	chr1:41020230	chr1:41242373~41284861:+
STAD	cis	rs12701220	0.522	rs12334290	ENSG00000229043.2	AC091729.9	-4.1	5.19e-05	0.0191	-0.26	-0.22	Bronchopulmonary dysplasia;	chr7:1014881	chr7:1160374~1165267:+
STAD	cis	rs6840360	0.582	rs4696260	ENSG00000270265.1	RP11-731D1.4	-4.1	5.2e-05	0.0191	-0.26	-0.22	Intelligence (multi-trait analysis);	chr4:151397772	chr4:151333775~151353224:-
STAD	cis	rs6840360	0.515	rs11099811	ENSG00000270265.1	RP11-731D1.4	-4.1	5.2e-05	0.0191	-0.26	-0.22	Intelligence (multi-trait analysis);	chr4:151399380	chr4:151333775~151353224:-
STAD	cis	rs6840360	0.582	rs7691601	ENSG00000270265.1	RP11-731D1.4	-4.1	5.2e-05	0.0191	-0.26	-0.22	Intelligence (multi-trait analysis);	chr4:151400479	chr4:151333775~151353224:-
STAD	cis	rs12744310	0.836	rs12048808	ENSG00000235358.1	RP11-399E6.1	4.1	5.2e-05	0.0191	0.28	0.22	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348636	chr1:41242373~41284861:+
STAD	cis	rs1707322	1	rs4074225	ENSG00000225447.1	RPS15AP10	4.1	5.2e-05	0.0191	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4134387	ENSG00000225447.1	RPS15AP10	4.1	5.2e-05	0.0191	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs10789485	ENSG00000225447.1	RPS15AP10	4.1	5.2e-05	0.0191	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45645816~45646197:-
STAD	cis	rs10129255	0.784	rs7147210	ENSG00000232216.1	IGHV3-43	4.1	5.2e-05	0.0191	0.22	0.22	Kawasaki disease;	chr14:106705271	chr14:106470264~106470800:-
STAD	cis	rs792448	1	rs1086893	ENSG00000212044.2	AL360091.1	4.1	5.2e-05	0.0191	0.25	0.22	White blood cell count (basophil);	chr1:212389772	chr1:212349978~212350069:+
STAD	cis	rs8014252	0.803	rs17108274	ENSG00000259158.2	ADAM20P1	-4.1	5.2e-05	0.0191	-0.3	-0.22	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70603684	chr14:70468881~70483756:-
STAD	cis	rs9902453	0.845	rs2628165	ENSG00000263477.1	RP11-338L22.2	4.1	5.2e-05	0.0191	0.18	0.22	Coffee consumption (cups per day);	chr17:29794148	chr17:29863402~29866092:+
STAD	cis	rs7520050	0.743	rs61789988	ENSG00000280836.1	AL355480.1	4.1	5.2e-05	0.0192	0.27	0.22	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45581219~45581321:-
STAD	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-4.1	5.2e-05	0.0192	-0.21	-0.22	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
STAD	cis	rs17801127	0.818	rs35536703	ENSG00000231969.1	AC144449.1	4.1	5.2e-05	0.0192	0.46	0.22	Liver enzyme levels (alanine transaminase);	chr2:149840947	chr2:149587196~149848233:+
STAD	cis	rs7247513	0.701	rs8107642	ENSG00000230310.1	CTD-2192J16.11	-4.1	5.21e-05	0.0192	-0.27	-0.22	Bipolar disorder;	chr19:12655556	chr19:12552597~12553644:+
STAD	cis	rs6480314	0.522	rs10047388	ENSG00000233590.1	RP11-153K11.3	4.1	5.21e-05	0.0192	0.3	0.22	Optic nerve measurement (disc area);	chr10:68300456	chr10:68233251~68242379:-
STAD	cis	rs7078219	0.543	rs7092009	ENSG00000257582.4	LINC01475	-4.1	5.21e-05	0.0192	-0.25	-0.22	Dental caries;	chr10:99517482	chr10:99526350~99531177:-
STAD	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-4.1	5.21e-05	0.0192	-0.22	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
STAD	cis	rs6772849	0.775	rs67105978	ENSG00000242551.2	POU5F1P6	-4.1	5.21e-05	0.0192	-0.22	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128674735~128677005:-
STAD	cis	rs2573652	0.722	rs968412	ENSG00000270127.2	RP11-526I2.5	-4.1	5.21e-05	0.0192	-0.23	-0.22	Height;	chr15:100004307	chr15:100547765~100550153:-
STAD	cis	rs8097348	1	rs2345036	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1596535	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs11080871	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1596888	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs2111926	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1597148	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs2111925	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1597408	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs2052419	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1597981	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.841	rs12605872	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1598076	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.948	rs9646479	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1598182	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs9646456	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1598246	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.857	rs8095975	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1598886	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs8083526	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1599088	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs4389203	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1599123	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs8099756	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1599149	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs4797926	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1599211	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.948	rs4797928	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1599262	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.948	rs4797929	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1599380	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs4797930	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1599497	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.948	rs1869533	ENSG00000266602.1	RP11-476K15.1	-4.1	5.21e-05	0.0192	-0.25	-0.22	Exercise (leisure time);	chr18:1600215	chr18:1509183~1647097:+
STAD	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	4.1	5.22e-05	0.0192	0.31	0.22	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	4.1	5.22e-05	0.0192	0.31	0.22	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	4.1	5.22e-05	0.0192	0.31	0.22	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	4.1	5.22e-05	0.0192	0.31	0.22	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	4.1	5.22e-05	0.0192	0.31	0.22	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
STAD	cis	rs3770081	1	rs4292089	ENSG00000273080.1	RP11-301O19.1	-4.1	5.22e-05	0.0192	-0.49	-0.22	Facial emotion recognition (sad faces);	chr2:85912057	chr2:86195590~86196049:+
STAD	cis	rs451417	1	rs384578	ENSG00000275632.1	RP5-967N21.11	-4.1	5.22e-05	0.0192	-0.29	-0.22	Menopause (age at onset);	chr20:6000830	chr20:6000418~6000941:+
STAD	cis	rs2253762	0.54	rs10159634	ENSG00000226864.1	ATE1-AS1	-4.1	5.22e-05	0.0192	-0.34	-0.22	Breast cancer;	chr10:121994520	chr10:121928312~121951965:+
STAD	cis	rs9307551	0.948	rs894055	ENSG00000250334.4	LINC00989	-4.1	5.22e-05	0.0192	-0.27	-0.22	Refractive error;	chr4:79621498	chr4:79492416~79576460:+
STAD	cis	rs9307551	1	rs2709847	ENSG00000250334.4	LINC00989	-4.1	5.22e-05	0.0192	-0.27	-0.22	Refractive error;	chr4:79621672	chr4:79492416~79576460:+
STAD	cis	rs9307551	1	rs2582681	ENSG00000250334.4	LINC00989	-4.1	5.22e-05	0.0192	-0.27	-0.22	Refractive error;	chr4:79623064	chr4:79492416~79576460:+
STAD	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	4.1	5.22e-05	0.0192	0.32	0.22	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
STAD	cis	rs7474896	0.537	rs1208591	ENSG00000120555.12	SEPT7P9	4.1	5.22e-05	0.0192	0.26	0.22	Obesity (extreme);	chr10:37923574	chr10:38383069~38402916:-
STAD	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	4.1	5.22e-05	0.0192	0.3	0.22	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
STAD	cis	rs2050392	1	rs2265186	ENSG00000224473.1	CCND3P1	-4.1	5.22e-05	0.0192	-0.26	-0.22	Inflammatory bowel disease;	chr10:30402814	chr10:30403197~30403776:-
STAD	cis	rs1707322	1	rs4660331	ENSG00000225447.1	RPS15AP10	4.1	5.22e-05	0.0192	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs12097799	ENSG00000225447.1	RPS15AP10	4.1	5.22e-05	0.0192	0.17	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45645816~45646197:-
STAD	cis	rs7680126	0.596	rs10020887	ENSG00000250613.1	RP11-136I13.1	4.1	5.22e-05	0.0192	0.26	0.22	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10139127	chr4:10410996~10411644:+
STAD	cis	rs9393777	0.513	rs7740197	ENSG00000224843.5	LINC00240	-4.1	5.23e-05	0.0192	-0.31	-0.22	Intelligence (multi-trait analysis);	chr6:26663250	chr6:26956992~27023924:+
STAD	cis	rs34929064	0.846	rs59084784	ENSG00000179428.2	AC073072.5	-4.1	5.23e-05	0.0192	-0.24	-0.22	Major depression and alcohol dependence;	chr7:22699943	chr7:22725395~22727620:-
STAD	cis	rs10129255	0.5	rs7161740	ENSG00000211959.2	IGHV4-39	4.1	5.23e-05	0.0192	0.19	0.22	Kawasaki disease;	chr14:106776119	chr14:106421711~106422218:-
STAD	cis	rs2834188	0.889	rs8134026	ENSG00000272659.1	AP000295.10	-4.1	5.23e-05	0.0192	-0.3	-0.22	Narcolepsy;	chr21:33298793	chr21:33309491~33310181:+
STAD	cis	rs2098713	0.586	rs61435914	ENSG00000250155.1	CTD-2353F22.1	4.1	5.23e-05	0.0192	0.22	0.22	Telomere length;	chr5:37607239	chr5:36666214~36725195:-
STAD	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	4.1	5.23e-05	0.0192	0.33	0.22	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
STAD	cis	rs7202877	0.656	rs247427	ENSG00000261783.1	RP11-252K23.2	4.1	5.24e-05	0.0192	0.36	0.22	Type 1 diabetes;Type 2 diabetes;	chr16:75405234	chr16:75379818~75381260:-
STAD	cis	rs9914988	0.565	rs66811679	ENSG00000264647.1	RP11-68I3.7	4.1	5.24e-05	0.0192	0.33	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28969403	chr17:29591703~29592241:-
STAD	cis	rs9914988	0.613	rs67436963	ENSG00000264647.1	RP11-68I3.7	4.1	5.24e-05	0.0192	0.33	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28969490	chr17:29591703~29592241:-
STAD	cis	rs9914988	0.509	rs12453166	ENSG00000264647.1	RP11-68I3.7	4.1	5.24e-05	0.0192	0.33	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28971691	chr17:29591703~29592241:-
STAD	cis	rs330048	0.525	rs10112237	ENSG00000254340.1	RP11-10A14.3	-4.1	5.24e-05	0.0193	-0.25	-0.22	Systemic lupus erythematosus;	chr8:9215219	chr8:9141424~9145435:+
STAD	cis	rs9898641	1	rs9898641	ENSG00000267302.4	RP11-178C3.2	4.1	5.24e-05	0.0193	0.27	0.22	Interleukin-1-beta levels;	chr17:59493672	chr17:59964832~59996972:+
STAD	cis	rs3764400	0.567	rs2325784	ENSG00000278765.1	RP5-890E16.5	-4.1	5.24e-05	0.0193	-0.29	-0.22	Body mass index;	chr17:48134947	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs8079616	ENSG00000278765.1	RP5-890E16.5	-4.1	5.24e-05	0.0193	-0.29	-0.22	Body mass index;	chr17:48136126	chr17:48066704~48067293:-
STAD	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-4.1	5.24e-05	0.0193	-0.21	-0.22	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
STAD	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-4.1	5.24e-05	0.0193	-0.21	-0.22	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
STAD	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-4.1	5.24e-05	0.0193	-0.21	-0.22	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
STAD	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-4.1	5.24e-05	0.0193	-0.21	-0.22	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
STAD	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-4.1	5.24e-05	0.0193	-0.21	-0.22	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
STAD	cis	rs10776614	0.642	rs7905247	ENSG00000189014.7	FAM35DP	-4.1	5.24e-05	0.0193	-0.28	-0.22	Self-employment;	chr10:48557256	chr10:47689707~47730436:+
STAD	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	4.1	5.24e-05	0.0193	0.26	0.22	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
STAD	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-4.1	5.25e-05	0.0193	-0.28	-0.22	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
STAD	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-4.1	5.25e-05	0.0193	-0.17	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
STAD	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-4.1	5.25e-05	0.0193	-0.28	-0.22	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
STAD	cis	rs4589258	0.898	rs12575063	ENSG00000280367.1	RP11-121L10.2	-4.1	5.25e-05	0.0193	-0.24	-0.22	Intelligence (multi-trait analysis);	chr11:90685598	chr11:90223153~90226538:+
STAD	cis	rs6142102	0.886	rs4911147	ENSG00000264616.1	MIR4755	4.1	5.25e-05	0.0193	0.23	0.22	Skin pigmentation;	chr20:34079801	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.961	rs8123521	ENSG00000264616.1	MIR4755	4.1	5.25e-05	0.0193	0.23	0.22	Skin pigmentation;	chr20:34081079	chr20:34049119~34049190:+
STAD	cis	rs4589258	0.788	rs10741367	ENSG00000280367.1	RP11-121L10.2	4.1	5.25e-05	0.0193	0.21	0.22	Intelligence (multi-trait analysis);	chr11:90758232	chr11:90223153~90226538:+
STAD	cis	rs11089937	0.559	rs2330014	ENSG00000211640.3	IGLV6-57	4.1	5.25e-05	0.0193	0.16	0.22	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22195713~22196460:+
STAD	cis	rs4308124	1	rs57874285	ENSG00000230499.1	AC108463.1	-4.1	5.25e-05	0.0193	-0.27	-0.22	Vitiligo;	chr2:111255095	chr2:111195963~111206494:+
STAD	cis	rs4308124	1	rs57707030	ENSG00000230499.1	AC108463.1	-4.1	5.25e-05	0.0193	-0.27	-0.22	Vitiligo;	chr2:111255105	chr2:111195963~111206494:+
STAD	cis	rs10971721	0.822	rs72727351	ENSG00000281128.1	PTENP1-AS	4.1	5.25e-05	0.0193	0.32	0.22	Body mass index;	chr9:33950434	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971817	ENSG00000281128.1	PTENP1-AS	4.1	5.25e-05	0.0193	0.32	0.22	Body mass index;	chr9:33951886	chr9:33677268~33688011:+
STAD	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	4.1	5.25e-05	0.0193	0.24	0.22	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
STAD	cis	rs9902453	0.726	rs4795523	ENSG00000240074.1	RPL9P30	4.1	5.26e-05	0.0193	0.19	0.22	Coffee consumption (cups per day);	chr17:29849296	chr17:29855759~29856332:+
STAD	cis	rs11157436	0.602	rs10872984	ENSG00000211812.1	TRAV26-2	-4.1	5.26e-05	0.0193	-0.21	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171245	chr14:22202583~22203368:+
STAD	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-4.1	5.26e-05	0.0193	-0.25	-0.22	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-4.1	5.26e-05	0.0193	-0.25	-0.22	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
STAD	cis	rs7829975	0.535	rs4841005	ENSG00000254340.1	RP11-10A14.3	-4.09	5.26e-05	0.0193	-0.25	-0.21	Mood instability;	chr8:8643720	chr8:9141424~9145435:+
STAD	cis	rs712022	0.872	rs12419860	ENSG00000246225.5	RP11-17A1.3	4.09	5.26e-05	0.0193	0.28	0.21	Dialysis-related mortality;	chr11:22824515	chr11:22829380~22945393:+
STAD	cis	rs867371	1	rs8041924	ENSG00000276710.3	CSPG4P8	-4.09	5.26e-05	0.0193	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82459472~82477258:+
STAD	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-4.09	5.26e-05	0.0193	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
STAD	cis	rs2273156	0.673	rs12878219	ENSG00000258738.1	RP11-73E17.2	-4.09	5.27e-05	0.0193	-0.3	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34911931	chr14:34874343~34876459:+
STAD	cis	rs1707322	1	rs10890375	ENSG00000225447.1	RPS15AP10	4.09	5.27e-05	0.0193	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs10890377	ENSG00000225447.1	RPS15AP10	4.09	5.27e-05	0.0193	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45645816~45646197:-
STAD	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-4.09	5.27e-05	0.0193	-0.25	-0.21	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
STAD	cis	rs2390582	0.713	rs17131031	ENSG00000228175.3	GEMIN8P4	4.09	5.27e-05	0.0193	0.33	0.21	Coronary artery calcification;	chr1:90388701	chr1:89993593~89994321:-
STAD	cis	rs6686842	0.56	rs12408576	ENSG00000235358.1	RP11-399E6.1	-4.09	5.27e-05	0.0193	-0.24	-0.21	Height;	chr1:40998765	chr1:41242373~41284861:+
STAD	cis	rs330048	0.545	rs11249913	ENSG00000254340.1	RP11-10A14.3	-4.09	5.27e-05	0.0193	-0.25	-0.21	Systemic lupus erythematosus;	chr8:9286011	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.744	rs28517388	ENSG00000224373.3	IGHV4-59	4.09	5.27e-05	0.0193	0.18	0.21	Kawasaki disease;	chr14:106704323	chr14:106627249~106627825:-
STAD	cis	rs73198271	0.813	rs17697237	ENSG00000254340.1	RP11-10A14.3	4.09	5.27e-05	0.0193	0.3	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:9141424~9145435:+
STAD	cis	rs2880765	0.835	rs6496027	ENSG00000259295.5	CSPG4P12	4.09	5.27e-05	0.0193	0.26	0.21	Coronary artery disease;	chr15:85506757	chr15:85191438~85213905:+
STAD	cis	rs9291683	0.609	rs12500810	ENSG00000250613.1	RP11-136I13.1	-4.09	5.27e-05	0.0193	-0.2	-0.21	Bone mineral density;	chr4:10029444	chr4:10410996~10411644:+
STAD	cis	rs7829975	0.84	rs572366	ENSG00000233609.3	RP11-62H7.2	4.09	5.27e-05	0.0193	0.24	0.21	Mood instability;	chr8:8721284	chr8:8961200~8979025:+
STAD	cis	rs6142102	0.961	rs6059649	ENSG00000264616.1	MIR4755	4.09	5.27e-05	0.0194	0.22	0.21	Skin pigmentation;	chr20:34056071	chr20:34049119~34049190:+
STAD	cis	rs6142102	0.961	rs6059651	ENSG00000264616.1	MIR4755	4.09	5.27e-05	0.0194	0.22	0.21	Skin pigmentation;	chr20:34057246	chr20:34049119~34049190:+
STAD	cis	rs858239	0.508	rs2390754	ENSG00000230042.1	AK3P3	-4.09	5.27e-05	0.0194	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23129178~23129841:+
STAD	cis	rs9532679	0.515	rs61962744	ENSG00000229456.1	RLIMP1	4.09	5.27e-05	0.0194	0.22	0.21	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr13:41008002	chr13:40618738~40621348:+
STAD	cis	rs606458	0.92	rs11231853	ENSG00000269038.1	AP001462.6	-4.09	5.27e-05	0.0194	-0.29	-0.21	Urate levels;	chr11:64683007	chr11:64778954~64779405:+
STAD	cis	rs10129255	0.912	rs67410411	ENSG00000232216.1	IGHV3-43	4.09	5.27e-05	0.0194	0.22	0.21	Kawasaki disease;	chr14:106680324	chr14:106470264~106470800:-
STAD	cis	rs9307551	0.553	rs7673033	ENSG00000250334.4	LINC00989	-4.09	5.27e-05	0.0194	-0.26	-0.21	Refractive error;	chr4:79537914	chr4:79492416~79576460:+
STAD	cis	rs6430585	0.702	rs2015532	ENSG00000231890.6	DARS-AS1	4.09	5.28e-05	0.0194	0.25	0.21	Corneal structure;	chr2:135797955	chr2:135985176~136022593:+
STAD	cis	rs7829975	0.533	rs1039917	ENSG00000254340.1	RP11-10A14.3	4.09	5.28e-05	0.0194	0.24	0.21	Mood instability;	chr8:8861340	chr8:9141424~9145435:+
STAD	cis	rs891378	0.959	rs77542432	ENSG00000274245.1	RP11-357P18.2	-4.09	5.28e-05	0.0194	-0.27	-0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207301020	chr1:207372559~207373252:+
STAD	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-4.09	5.28e-05	0.0194	-0.25	-0.21	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-4.09	5.28e-05	0.0194	-0.25	-0.21	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-4.09	5.28e-05	0.0194	-0.25	-0.21	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-4.09	5.28e-05	0.0194	-0.25	-0.21	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
STAD	cis	rs2957692	0.548	rs11607703	ENSG00000254554.1	RP11-351I24.1	4.09	5.28e-05	0.0194	0.37	0.21	Circulating vasoactive peptide levels;	chr11:10094789	chr11:10302657~10303704:-
STAD	cis	rs1124609	1	rs1365506	ENSG00000244879.4	GABPB1-AS1	4.09	5.28e-05	0.0194	0.3	0.21	Subjective well-being;	chr15:50184942	chr15:50354959~50372202:+
STAD	cis	rs9307551	0.552	rs12506212	ENSG00000250334.4	LINC00989	-4.09	5.28e-05	0.0194	-0.26	-0.21	Refractive error;	chr4:79512944	chr4:79492416~79576460:+
STAD	cis	rs7829975	0.514	rs2979151	ENSG00000254340.1	RP11-10A14.3	-4.09	5.28e-05	0.0194	-0.24	-0.21	Mood instability;	chr8:8400509	chr8:9141424~9145435:+
STAD	cis	rs422249	0.896	rs174449	ENSG00000279632.1	RP11-286N22.6	4.09	5.28e-05	0.0194	0.21	0.21	Trans fatty acid levels;	chr11:61872907	chr11:61426448~61427325:-
STAD	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	4.09	5.29e-05	0.0194	0.32	0.21	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	4.09	5.29e-05	0.0194	0.32	0.21	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	4.09	5.29e-05	0.0194	0.32	0.21	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	4.09	5.29e-05	0.0194	0.32	0.21	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	4.09	5.29e-05	0.0194	0.32	0.21	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	4.09	5.29e-05	0.0194	0.32	0.21	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	4.09	5.29e-05	0.0194	0.32	0.21	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
STAD	cis	rs9368481	0.672	rs3931463	ENSG00000224843.5	LINC00240	-4.09	5.29e-05	0.0194	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26956992~27023924:+
STAD	cis	rs9368481	0.761	rs3931464	ENSG00000224843.5	LINC00240	-4.09	5.29e-05	0.0194	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26956992~27023924:+
STAD	cis	rs227275	0.525	rs1080081	ENSG00000248971.2	KRT8P46	-4.09	5.29e-05	0.0194	-0.22	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102728746~102730171:-
STAD	cis	rs227275	0.525	rs4699049	ENSG00000248971.2	KRT8P46	-4.09	5.29e-05	0.0194	-0.22	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102728746~102730171:-
STAD	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
STAD	cis	rs1005277	0.54	rs4934907	ENSG00000099251.13	HSD17B7P2	4.09	5.29e-05	0.0194	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.54	rs11011351	ENSG00000099251.13	HSD17B7P2	4.09	5.29e-05	0.0194	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38356380~38378505:+
STAD	cis	rs55823223	0.59	rs11870142	ENSG00000267801.1	RP11-552F3.9	4.09	5.29e-05	0.0194	0.29	0.21	Psoriasis;	chr17:75862921	chr17:75876372~75879546:+
STAD	cis	rs55823223	0.503	rs55699990	ENSG00000267801.1	RP11-552F3.9	4.09	5.29e-05	0.0194	0.29	0.21	Psoriasis;	chr17:75863105	chr17:75876372~75879546:+
STAD	cis	rs55823223	0.564	rs2034947	ENSG00000267801.1	RP11-552F3.9	4.09	5.29e-05	0.0194	0.29	0.21	Psoriasis;	chr17:75867848	chr17:75876372~75879546:+
STAD	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	4.09	5.29e-05	0.0194	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
STAD	cis	rs1876905	0.68	rs354527	ENSG00000271789.1	RP5-1112D6.7	-4.09	5.29e-05	0.0194	-0.26	-0.21	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111297126~111298510:+
STAD	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	4.09	5.29e-05	0.0194	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	4.09	5.29e-05	0.0194	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	4.09	5.29e-05	0.0194	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
STAD	cis	rs2836950	0.565	rs2836942	ENSG00000238141.2	BRWD1-AS1	-4.09	5.29e-05	0.0194	-0.22	-0.21	Menarche (age at onset);	chr21:39219455	chr21:39315707~39323218:+
STAD	cis	rs2638953	0.889	rs11049481	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252087	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049482	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252088	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049484	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252254	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049485	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs10843143	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28253484	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049488	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259439	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs57618147	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259902	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs716687	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.925	rs11049491	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049493	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049495	ENSG00000247934.4	RP11-967K21.1	-4.09	5.29e-05	0.0194	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28163298~28190738:-
STAD	cis	rs9307551	0.741	rs9307532	ENSG00000250334.4	LINC00989	-4.09	5.29e-05	0.0194	-0.28	-0.21	Refractive error;	chr4:79510067	chr4:79492416~79576460:+
STAD	cis	rs11696739	0.536	rs3761268	ENSG00000242324.1	RP4-576H24.2	4.09	5.3e-05	0.0194	0.29	0.21	Mean platelet volume;	chr20:1620521	chr20:1516759~1557653:-
STAD	cis	rs11673344	0.504	rs11084874	ENSG00000267672.1	CTD-2293H3.1	4.09	5.3e-05	0.0194	0.19	0.21	Obesity-related traits;	chr19:37096667	chr19:37091341~37092564:+
STAD	cis	rs9402743	0.926	rs7762826	ENSG00000236703.1	MYB-AS1	4.09	5.3e-05	0.0194	0.22	0.21	Systemic lupus erythematosus;	chr6:135654485	chr6:135195083~135195995:-
STAD	cis	rs4950322	0.58	rs7541393	ENSG00000278811.3	LINC00624	4.09	5.3e-05	0.0194	0.23	0.21	Protein quantitative trait loci;	chr1:147117186	chr1:147258885~147517875:-
STAD	cis	rs8098244	0.737	rs1258147	ENSG00000267301.1	RPL23AP77	4.09	5.3e-05	0.0194	0.28	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23939672	chr18:23709825~23710287:-
STAD	cis	rs8177876	0.642	rs4454990	ENSG00000261838.4	RP11-303E16.6	-4.09	5.3e-05	0.0194	-0.41	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81069854~81076598:+
STAD	cis	rs9307551	0.619	rs1074134	ENSG00000250334.4	LINC00989	-4.09	5.3e-05	0.0194	-0.26	-0.21	Refractive error;	chr4:79503752	chr4:79492416~79576460:+
STAD	cis	rs34779708	0.931	rs34087268	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs58159560	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs67976880	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs72789687	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs35997236	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934719	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934720	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.897	rs34481177	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs11593858	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934723	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs72789690	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs68039650	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs35136660	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.897	rs12764820	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs67261877	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs12768019	ENSG00000271335.4	RP11-324I22.4	4.09	5.3e-05	0.0194	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35314552~35336401:-
STAD	cis	rs870825	0.55	rs10000507	ENSG00000249173.4	LINC01093	-4.09	5.31e-05	0.0195	-0.34	-0.21	Blood protein levels;	chr4:184698127	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs10022818	ENSG00000249173.4	LINC01093	-4.09	5.31e-05	0.0195	-0.34	-0.21	Blood protein levels;	chr4:184698128	chr4:184893871~184899454:-
STAD	cis	rs6832769	0.961	rs6817663	ENSG00000223305.1	RN7SKP30	-4.09	5.31e-05	0.0195	-0.24	-0.21	Personality dimensions;	chr4:55581048	chr4:55540502~55540835:-
STAD	cis	rs4293777	0.935	rs7679089	ENSG00000250896.1	RNPS1P1	4.09	5.31e-05	0.0195	0.17	0.21	Primary sclerosing cholangitis;	chr4:10724594	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.935	rs7655068	ENSG00000250896.1	RNPS1P1	4.09	5.31e-05	0.0195	0.17	0.21	Primary sclerosing cholangitis;	chr4:10724607	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.935	rs7679275	ENSG00000250896.1	RNPS1P1	4.09	5.31e-05	0.0195	0.17	0.21	Primary sclerosing cholangitis;	chr4:10724662	chr4:11371975~11372892:+
STAD	cis	rs6432852	0.966	rs13404648	ENSG00000229195.1	AC009495.4	-4.09	5.31e-05	0.0195	-0.25	-0.21	Diabetic kidney disease;	chr2:165891275	chr2:165794857~165846091:-
STAD	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-4.09	5.31e-05	0.0195	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-4.09	5.31e-05	0.0195	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	4.09	5.31e-05	0.0195	0.31	0.21	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	4.09	5.31e-05	0.0195	0.31	0.21	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	4.09	5.31e-05	0.0195	0.31	0.21	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	4.09	5.31e-05	0.0195	0.31	0.21	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
STAD	cis	rs11671664	0.732	rs67775326	ENSG00000279095.1	AC092066.1	-4.09	5.31e-05	0.0195	-0.34	-0.21	Body mass index (SNP x SNP interaction);Body mass index;Type 2 diabetes;	chr19:45657711	chr19:44664131~44666158:+
STAD	cis	rs1426063	1	rs10022563	ENSG00000249717.1	RP11-44F21.3	4.09	5.31e-05	0.0195	0.36	0.21	QT interval;	chr4:75100989	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs10033857	ENSG00000249717.1	RP11-44F21.3	4.09	5.31e-05	0.0195	0.36	0.21	QT interval;	chr4:75103208	chr4:74955974~74970362:-
STAD	cis	rs2665103	0.589	rs2134046	ENSG00000259429.4	UBE2Q2P2	-4.09	5.31e-05	0.0195	-0.24	-0.21	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82355142~82420075:+
STAD	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	4.09	5.31e-05	0.0195	0.22	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
STAD	cis	rs9543976	0.623	rs7986566	ENSG00000261553.4	RP11-29G8.3	4.09	5.31e-05	0.0195	0.32	0.21	Diabetic retinopathy;	chr13:75623795	chr13:75549773~75807120:+
STAD	cis	rs11235843	0.929	rs11235844	ENSG00000255928.1	RP11-456I15.2	4.09	5.32e-05	0.0195	0.36	0.21	Hand grip strength;	chr11:73668030	chr11:73722349~73722694:+
STAD	cis	rs7829975	0.711	rs12682352	ENSG00000233609.3	RP11-62H7.2	4.09	5.32e-05	0.0195	0.24	0.21	Mood instability;	chr8:8788736	chr8:8961200~8979025:+
STAD	cis	rs8062405	1	rs56404918	ENSG00000278665.1	RP11-666O2.4	4.09	5.32e-05	0.0195	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs55719896	ENSG00000278665.1	RP11-666O2.4	4.09	5.32e-05	0.0195	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs55830740	ENSG00000278665.1	RP11-666O2.4	4.09	5.32e-05	0.0195	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28599241~28601881:-
STAD	cis	rs6933660	0.665	rs6921042	ENSG00000221469.1	AL133260.1	4.09	5.32e-05	0.0195	0.23	0.21	Menarche (age at onset);	chr6:151411250	chr6:151039916~151039971:-
STAD	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	4.09	5.32e-05	0.0195	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
STAD	cis	rs7992643	0.965	rs7992743	ENSG00000218502.3	H2AFZP3	4.09	5.33e-05	0.0195	0.19	0.21	Attention deficit hyperactivity disorder;	chr13:99903037	chr13:99215372~99215758:-
STAD	cis	rs6180	1	rs2973029	ENSG00000250860.1	CTD-2265D6.2	4.09	5.33e-05	0.0195	0.18	0.21	Height;	chr5:42746464	chr5:42466893~42468300:-
STAD	cis	rs4561483	0.815	rs11646545	ENSG00000260224.1	UBL5P4	-4.09	5.33e-05	0.0195	-0.21	-0.21	Testicular germ cell tumor;	chr16:11840737	chr16:11968508~11968743:-
STAD	cis	rs12264252	0.767	rs35998463	ENSG00000225484.5	NUTM2B-AS1	-4.09	5.33e-05	0.0195	-0.31	-0.21	Coronary artery disease;	chr10:80485754	chr10:79663088~79826594:-
STAD	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-4.09	5.33e-05	0.0195	-0.23	-0.21	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
STAD	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	4.09	5.33e-05	0.0195	0.26	0.21	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
STAD	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-4.09	5.34e-05	0.0195	-0.34	-0.21	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
STAD	cis	rs13413635	0.774	rs6738831	ENSG00000225808.1	DNAJC19P5	-4.09	5.34e-05	0.0195	-0.28	-0.21	Heart rate;	chr2:178019906	chr2:177229191~177229506:-
STAD	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	4.09	5.34e-05	0.0195	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
STAD	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	4.09	5.34e-05	0.0195	0.28	0.21	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
STAD	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	4.09	5.34e-05	0.0195	0.36	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
STAD	cis	rs42490	0.638	rs28144	ENSG00000251136.7	RP11-37B2.1	-4.09	5.34e-05	0.0195	-0.21	-0.21	Leprosy;	chr8:89810531	chr8:89609409~89757727:-
STAD	cis	rs7246657	0.525	rs10410594	ENSG00000267672.1	CTD-2293H3.1	4.09	5.34e-05	0.0195	0.28	0.21	Coronary artery calcification;	chr19:36986856	chr19:37091341~37092564:+
STAD	cis	rs2273156	1	rs2273158	ENSG00000258704.4	SRP54-AS1	4.09	5.34e-05	0.0195	0.24	0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34996578	chr14:34920858~34982532:-
STAD	cis	rs8042849	1	rs8042849	ENSG00000259419.2	HNRNPCP3	-4.09	5.34e-05	0.0196	-0.23	-0.21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;Parental lifespan;	chr15:78525587	chr15:79236332~79237206:+
STAD	cis	rs7924176	0.544	rs10824218	ENSG00000236900.1	TIMM9P1	4.09	5.34e-05	0.0196	0.24	0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74661458	chr10:74344550~74344805:-
STAD	cis	rs10129255	0.5	rs6576226	ENSG00000211959.2	IGHV4-39	4.09	5.34e-05	0.0196	0.19	0.21	Kawasaki disease;	chr14:106778135	chr14:106421711~106422218:-
STAD	cis	rs3764021	0.84	rs10743823	ENSG00000256673.1	RP11-599J14.2	-4.09	5.34e-05	0.0196	-0.23	-0.21	Type 1 diabetes;	chr12:9728529	chr12:9398355~9414851:-
STAD	cis	rs304029	0.716	rs2307068	ENSG00000229241.1	PNPT1P1	4.09	5.34e-05	0.0196	0.21	0.21	Diabetic kidney disease;	chr3:4491276	chr3:3981981~3984295:-
STAD	cis	rs2992257	0.958	rs17529213	ENSG00000251839.1	RNU7-12P	-4.09	5.34e-05	0.0196	-0.22	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26455539	chr10:27232255~27232316:-
STAD	cis	rs1426063	1	rs28515115	ENSG00000249717.1	RP11-44F21.3	4.09	5.34e-05	0.0196	0.37	0.21	QT interval;	chr4:75101904	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs10026801	ENSG00000249717.1	RP11-44F21.3	4.09	5.34e-05	0.0196	0.37	0.21	QT interval;	chr4:75103167	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs17000242	ENSG00000249717.1	RP11-44F21.3	4.09	5.34e-05	0.0196	0.37	0.21	QT interval;	chr4:75103857	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs7666371	ENSG00000249717.1	RP11-44F21.3	4.09	5.34e-05	0.0196	0.37	0.21	QT interval;	chr4:75104325	chr4:74955974~74970362:-
STAD	cis	rs1426063	1	rs6829858	ENSG00000249717.1	RP11-44F21.3	4.09	5.34e-05	0.0196	0.37	0.21	QT interval;	chr4:75105202	chr4:74955974~74970362:-
STAD	cis	rs7809950	0.906	rs2395907	ENSG00000238832.1	snoU109	4.09	5.35e-05	0.0196	0.29	0.21	Coronary artery disease;	chr7:107612859	chr7:107603363~107603507:+
STAD	cis	rs26868	0.766	rs30995	ENSG00000278987.1	LA16c-431H6.7	4.09	5.35e-05	0.0196	0.18	0.21	Height;	chr16:2198016	chr16:1688355~1690536:+
STAD	cis	rs950169	0.723	rs17589320	ENSG00000235370.6	DNM1P51	4.09	5.35e-05	0.0196	0.27	0.21	Schizophrenia;	chr15:84251244	chr15:84398316~84411701:-
STAD	cis	rs950169	0.845	rs4502182	ENSG00000235370.6	DNM1P51	4.09	5.35e-05	0.0196	0.27	0.21	Schizophrenia;	chr15:84254768	chr15:84398316~84411701:-
STAD	cis	rs12468226	0.873	rs78798541	ENSG00000226261.1	AC064836.3	4.09	5.35e-05	0.0196	0.36	0.21	Urate levels;	chr2:202194708	chr2:202336024~202336727:-
STAD	cis	rs8141529	0.702	rs8137262	ENSG00000272858.1	CTA-292E10.8	-4.09	5.35e-05	0.0196	-0.23	-0.21	Lymphocyte counts;	chr22:28896147	chr22:28814914~28815662:+
STAD	cis	rs77956314	0.818	rs12296869	ENSG00000274554.1	RP11-240G22.5	4.09	5.35e-05	0.0196	0.3	0.21	Hippocampal volume;Subcortical brain region volumes;	chr12:116993398	chr12:116948738~116951422:-
STAD	cis	rs7119038	0.629	rs10892273	ENSG00000255422.1	AP002954.4	4.09	5.35e-05	0.0196	0.28	0.21	Sjögren's syndrome;	chr11:118732100	chr11:118704607~118750263:+
STAD	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	4.09	5.35e-05	0.0196	0.26	0.21	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
STAD	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	4.09	5.35e-05	0.0196	0.26	0.21	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	4.09	5.35e-05	0.0196	0.26	0.21	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	4.09	5.35e-05	0.0196	0.26	0.21	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	4.09	5.35e-05	0.0196	0.26	0.21	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
STAD	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	4.09	5.35e-05	0.0196	0.23	0.21	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
STAD	cis	rs2486288	0.656	rs7167146	ENSG00000275672.1	GATM-AS1	-4.09	5.35e-05	0.0196	-0.23	-0.21	Glomerular filtration rate;	chr15:45279188	chr15:45378700~45380123:+
STAD	cis	rs3764021	0.87	rs10844622	ENSG00000256673.1	RP11-599J14.2	-4.09	5.35e-05	0.0196	-0.23	-0.21	Type 1 diabetes;	chr12:9732486	chr12:9398355~9414851:-
STAD	cis	rs3764021	0.84	rs12304510	ENSG00000256673.1	RP11-599J14.2	-4.09	5.35e-05	0.0196	-0.23	-0.21	Type 1 diabetes;	chr12:9732930	chr12:9398355~9414851:-
STAD	cis	rs4243830	0.677	rs6693922	ENSG00000229519.2	RP11-58A11.2	-4.09	5.35e-05	0.0196	-0.24	-0.21	Body mass index;	chr1:6524744	chr1:6547905~6548619:+
STAD	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	4.09	5.35e-05	0.0196	0.29	0.21	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	4.09	5.35e-05	0.0196	0.29	0.21	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
STAD	cis	rs451417	1	rs236108	ENSG00000275632.1	RP5-967N21.11	4.09	5.36e-05	0.0196	0.28	0.21	Menopause (age at onset);	chr20:5987913	chr20:6000418~6000941:+
STAD	cis	rs831571	0.703	rs831566	ENSG00000280620.1	SCAANT1	-4.09	5.36e-05	0.0196	-0.31	-0.21	Type 2 diabetes;	chr3:64090262	chr3:63911518~63911772:-
STAD	cis	rs2695743	0.592	rs934802	ENSG00000225808.1	DNAJC19P5	-4.09	5.37e-05	0.0196	-0.24	-0.21	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177812229	chr2:177229191~177229506:-
STAD	cis	rs6430585	0.528	rs2278682	ENSG00000231890.6	DARS-AS1	-4.09	5.37e-05	0.0196	-0.23	-0.21	Corneal structure;	chr2:135985573	chr2:135985176~136022593:+
STAD	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	4.09	5.37e-05	0.0196	0.21	0.21	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
STAD	cis	rs9329221	0.678	rs560638	ENSG00000254340.1	RP11-10A14.3	-4.09	5.37e-05	0.0196	-0.27	-0.21	Neuroticism;	chr8:10025257	chr8:9141424~9145435:+
STAD	cis	rs7826238	0.594	rs2948285	ENSG00000254340.1	RP11-10A14.3	4.09	5.37e-05	0.0196	0.26	0.21	Systolic blood pressure;	chr8:8273016	chr8:9141424~9145435:+
STAD	cis	rs1799949	1	rs4340367	ENSG00000279602.1	CTD-3014M21.1	4.09	5.37e-05	0.0196	0.27	0.21	Menopause (age at onset);	chr17:43155755	chr17:43360041~43361361:-
STAD	cis	rs1799949	1	rs4792981	ENSG00000279602.1	CTD-3014M21.1	4.09	5.37e-05	0.0196	0.27	0.21	Menopause (age at onset);	chr17:43156257	chr17:43360041~43361361:-
STAD	cis	rs9549328	0.837	rs9549618	ENSG00000267868.1	RP11-120K24.3	4.09	5.37e-05	0.0196	0.31	0.21	Systolic blood pressure;	chr13:112974334	chr13:112964835~112966131:-
STAD	cis	rs2665103	0.61	rs56398167	ENSG00000259429.4	UBE2Q2P2	-4.09	5.37e-05	0.0196	-0.24	-0.21	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82355142~82420075:+
STAD	cis	rs2665103	0.589	rs3858953	ENSG00000259429.4	UBE2Q2P2	-4.09	5.37e-05	0.0196	-0.24	-0.21	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82355142~82420075:+
STAD	cis	rs867371	0.929	rs7176075	ENSG00000276710.3	CSPG4P8	-4.09	5.37e-05	0.0196	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82459472~82477258:+
STAD	cis	rs867371	1	rs8041868	ENSG00000276710.3	CSPG4P8	-4.09	5.37e-05	0.0196	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82459472~82477258:+
STAD	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-4.09	5.38e-05	0.0197	-0.18	-0.21	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
STAD	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-4.09	5.38e-05	0.0197	-0.26	-0.21	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
STAD	cis	rs8141529	0.702	rs469991	ENSG00000272858.1	CTA-292E10.8	4.09	5.38e-05	0.0197	0.23	0.21	Lymphocyte counts;	chr22:28911871	chr22:28814914~28815662:+
STAD	cis	rs3764021	0.87	rs10743819	ENSG00000256673.1	RP11-599J14.2	-4.09	5.38e-05	0.0197	-0.23	-0.21	Type 1 diabetes;	chr12:9724172	chr12:9398355~9414851:-
STAD	cis	rs3764021	0.87	rs2401391	ENSG00000256673.1	RP11-599J14.2	-4.09	5.38e-05	0.0197	-0.23	-0.21	Type 1 diabetes;	chr12:9725987	chr12:9398355~9414851:-
STAD	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	4.09	5.38e-05	0.0197	0.22	0.21	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
STAD	cis	rs7989332	0.698	rs9509242	ENSG00000238286.1	SLC35E1P1	4.09	5.38e-05	0.0197	0.26	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486803	chr13:20607268~20608131:+
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000211959.2	IGHV4-39	4.09	5.38e-05	0.0197	0.19	0.21	Kawasaki disease;	chr14:106777494	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000211959.2	IGHV4-39	4.09	5.38e-05	0.0197	0.19	0.21	Kawasaki disease;	chr14:106777510	chr14:106421711~106422218:-
STAD	cis	rs7615952	0.673	rs115942855	ENSG00000241346.1	SNRPCP11	4.09	5.38e-05	0.0197	0.4	0.21	Blood pressure (smoking interaction);	chr3:125883117	chr3:125816082~125816286:-
STAD	cis	rs2115630	0.905	rs6496401	ENSG00000275120.1	RP11-182J1.17	-4.09	5.38e-05	0.0197	-0.23	-0.21	P wave terminal force;	chr15:84754562	chr15:84599434~84606463:-
STAD	cis	rs2115630	1	rs11854313	ENSG00000275120.1	RP11-182J1.17	-4.09	5.38e-05	0.0197	-0.23	-0.21	P wave terminal force;	chr15:84760817	chr15:84599434~84606463:-
STAD	cis	rs10946940	0.965	rs9393830	ENSG00000280107.1	AL022393.9	-4.09	5.38e-05	0.0197	-0.26	-0.21	Systemic lupus erythematosus;	chr6:27619248	chr6:28170845~28172521:+
STAD	cis	rs9813712	0.585	rs16824839	ENSG00000249846.5	RP11-77P16.4	-4.09	5.38e-05	0.0197	-0.32	-0.21	Response to amphetamines;	chr3:130220886	chr3:130112550~130120579:+
STAD	cis	rs1707322	0.721	rs6665808	ENSG00000225447.1	RPS15AP10	4.09	5.39e-05	0.0197	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45645816~45646197:-
STAD	cis	rs10132760	0.774	rs58030148	ENSG00000211778.2	TRAV4	-4.09	5.39e-05	0.0197	-0.22	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21718449	chr14:21736152~21736982:+
STAD	cis	rs10129255	1	rs10137758	ENSG00000232216.1	IGHV3-43	4.09	5.39e-05	0.0197	0.22	0.21	Kawasaki disease;	chr14:106697673	chr14:106470264~106470800:-
STAD	cis	rs7103648	0.63	rs7934481	ENSG00000280615.1	Y_RNA	4.09	5.39e-05	0.0197	0.22	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47861785	chr11:47614898~47614994:-
STAD	cis	rs1707322	0.721	rs56255771	ENSG00000225447.1	RPS15AP10	4.09	5.39e-05	0.0197	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45645816~45646197:-
STAD	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	4.09	5.39e-05	0.0197	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
STAD	cis	rs7176527	0.848	rs17600128	ENSG00000225151.9	GOLGA2P7	4.09	5.39e-05	0.0197	0.32	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:84199311~84230136:-
STAD	cis	rs4713118	0.869	rs6922574	ENSG00000243307.2	POM121L6P	-4.09	5.39e-05	0.0197	-0.25	-0.21	Parkinson's disease;	chr6:27725224	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs6902689	ENSG00000243307.2	POM121L6P	-4.09	5.39e-05	0.0197	-0.25	-0.21	Parkinson's disease;	chr6:27741662	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9468214	ENSG00000243307.2	POM121L6P	-4.09	5.39e-05	0.0197	-0.25	-0.21	Parkinson's disease;	chr6:27745520	chr6:26896952~26898777:+
STAD	cis	rs748404	0.697	rs530188	ENSG00000275601.1	AC011330.13	-4.09	5.39e-05	0.0197	-0.23	-0.21	Lung cancer;	chr15:43253116	chr15:43642389~43643023:-
STAD	cis	rs748404	0.697	rs475227	ENSG00000275601.1	AC011330.13	-4.09	5.39e-05	0.0197	-0.23	-0.21	Lung cancer;	chr15:43254248	chr15:43642389~43643023:-
STAD	cis	rs11673344	0.542	rs826324	ENSG00000267672.1	CTD-2293H3.1	4.09	5.39e-05	0.0197	0.2	0.21	Obesity-related traits;	chr19:37014343	chr19:37091341~37092564:+
STAD	cis	rs7937890	1	rs7937890	ENSG00000254418.1	RP11-21L19.1	4.09	5.39e-05	0.0197	0.23	0.21	Mitochondrial DNA levels;	chr11:14374939	chr11:14262846~14273691:-
STAD	cis	rs2638953	0.676	rs11049727	ENSG00000247934.4	RP11-967K21.1	-4.09	5.4e-05	0.0197	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28584864	chr12:28163298~28190738:-
STAD	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	4.09	5.4e-05	0.0197	0.2	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
STAD	cis	rs9914988	0.613	rs1873477	ENSG00000264647.1	RP11-68I3.7	4.09	5.4e-05	0.0197	0.33	0.21	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28984514	chr17:29591703~29592241:-
STAD	cis	rs4879656	0.741	rs10758183	ENSG00000225693.1	LAGE3P1	4.09	5.4e-05	0.0197	0.28	0.21	Menopause (age at onset);	chr9:33055473	chr9:33019682~33020165:-
STAD	cis	rs17630293	1	rs4673871	ENSG00000201649.1	RNY4P34	-4.09	5.4e-05	0.0197	-0.32	-0.21	Schizophrenia;	chr2:200278601	chr2:200373175~200373269:+
STAD	cis	rs17630293	1	rs55826210	ENSG00000201649.1	RNY4P34	-4.09	5.4e-05	0.0197	-0.32	-0.21	Schizophrenia;	chr2:200279387	chr2:200373175~200373269:+
STAD	cis	rs17630293	1	rs17630277	ENSG00000201649.1	RNY4P34	-4.09	5.4e-05	0.0197	-0.32	-0.21	Schizophrenia;	chr2:200280124	chr2:200373175~200373269:+
STAD	cis	rs17630293	1	rs67484322	ENSG00000201649.1	RNY4P34	-4.09	5.4e-05	0.0197	-0.32	-0.21	Schizophrenia;	chr2:200280300	chr2:200373175~200373269:+
STAD	cis	rs17630293	1	rs1835721	ENSG00000201649.1	RNY4P34	-4.09	5.4e-05	0.0197	-0.32	-0.21	Schizophrenia;	chr2:200281220	chr2:200373175~200373269:+
STAD	cis	rs17630293	1	rs1835720	ENSG00000201649.1	RNY4P34	-4.09	5.4e-05	0.0197	-0.32	-0.21	Schizophrenia;	chr2:200281251	chr2:200373175~200373269:+
STAD	cis	rs17630293	1	rs1835719	ENSG00000201649.1	RNY4P34	-4.09	5.4e-05	0.0197	-0.32	-0.21	Schizophrenia;	chr2:200281277	chr2:200373175~200373269:+
STAD	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-4.09	5.4e-05	0.0197	-0.25	-0.21	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
STAD	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-4.09	5.4e-05	0.0197	-0.25	-0.21	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
STAD	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-4.09	5.4e-05	0.0197	-0.25	-0.21	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
STAD	cis	rs5753618	0.554	rs5753648	ENSG00000236132.1	CTA-440B3.1	-4.09	5.4e-05	0.0197	-0.24	-0.21	Colorectal cancer;	chr22:31483479	chr22:31816379~31817491:-
STAD	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	4.09	5.4e-05	0.0197	0.36	0.21	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	4.09	5.4e-05	0.0197	0.36	0.21	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	4.09	5.4e-05	0.0197	0.36	0.21	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
STAD	cis	rs2273156	1	rs761506	ENSG00000258704.4	SRP54-AS1	4.09	5.41e-05	0.0197	0.24	0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34947974	chr14:34920858~34982532:-
STAD	cis	rs10129255	0.957	rs11847726	ENSG00000232216.1	IGHV3-43	4.09	5.41e-05	0.0198	0.22	0.21	Kawasaki disease;	chr14:106779116	chr14:106470264~106470800:-
STAD	cis	rs2227564	0.62	rs11000765	ENSG00000271816.1	BMS1P4	4.09	5.41e-05	0.0198	0.25	0.21	Crohn's disease;Inflammatory bowel disease;	chr10:73752694	chr10:73699151~73730487:-
STAD	cis	rs11673344	0.562	rs7250507	ENSG00000267672.1	CTD-2293H3.1	4.09	5.41e-05	0.0198	0.19	0.21	Obesity-related traits;	chr19:37095772	chr19:37091341~37092564:+
STAD	cis	rs561341	1	rs497479	ENSG00000265798.5	RP11-271K11.5	4.09	5.41e-05	0.0198	0.31	0.21	Hip circumference adjusted for BMI;	chr17:32001586	chr17:31038575~31059121:-
STAD	cis	rs17361889	0.514	rs10251171	ENSG00000224683.1	RPL36AP29	4.09	5.42e-05	0.0198	0.27	0.21	Pediatric bone mineral content (hip);	chr7:16353495	chr7:16208945~16209265:+
STAD	cis	rs7647973	0.506	rs11920251	ENSG00000225399.4	RP11-3B7.1	4.09	5.42e-05	0.0198	0.23	0.21	Menarche (age at onset);	chr3:49319238	chr3:49260085~49261316:+
STAD	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	4.09	5.42e-05	0.0198	0.23	0.21	Depression;	chr6:28407125	chr6:28176188~28176674:+
STAD	cis	rs7119038	0.818	rs6589686	ENSG00000255422.1	AP002954.4	4.09	5.42e-05	0.0198	0.29	0.21	Sjögren's syndrome;	chr11:118741856	chr11:118704607~118750263:+
STAD	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	4.09	5.43e-05	0.0198	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
STAD	cis	rs3799977	0.531	rs62436031	ENSG00000219384.1	RP11-491H9.3	-4.09	5.43e-05	0.0198	-0.21	-0.21	Attention deficit hyperactivity disorder;	chr6:44754466	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs1338908	ENSG00000219384.1	RP11-491H9.3	-4.09	5.43e-05	0.0198	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44761075	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs720576	ENSG00000219384.1	RP11-491H9.3	-4.09	5.43e-05	0.0198	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44762237	chr6:45158870~45159511:+
STAD	cis	rs112721625	1	rs112721625	ENSG00000266701.1	AC005702.4	4.09	5.43e-05	0.0198	0.27	0.21	Monocyte count;	chr17:59850066	chr17:60042546~60042627:-
STAD	cis	rs10129255	0.5	rs6576225	ENSG00000211959.2	IGHV4-39	4.09	5.43e-05	0.0198	0.19	0.21	Kawasaki disease;	chr14:106778120	chr14:106421711~106422218:-
STAD	cis	rs513349	1	rs513349	ENSG00000197251.3	LINC00336	4.09	5.43e-05	0.0198	0.23	0.21	Platelet count;	chr6:33573942	chr6:33586106~33593338:-
STAD	cis	rs112521149	1	rs112521149	ENSG00000242349.4	NPPA-AS1	-4.09	5.43e-05	0.0198	-0.35	-0.21	Mean corpuscular volume;	chr1:11829758	chr1:11841017~11848079:+
STAD	cis	rs7119038	0.629	rs10892271	ENSG00000255422.1	AP002954.4	4.09	5.43e-05	0.0198	0.28	0.21	Sjögren's syndrome;	chr11:118727835	chr11:118704607~118750263:+
STAD	cis	rs6840360	0.557	rs4696261	ENSG00000270265.1	RP11-731D1.4	-4.09	5.43e-05	0.0198	-0.26	-0.21	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151333775~151353224:-
STAD	cis	rs9902453	0.838	rs9646436	ENSG00000240074.1	RPL9P30	4.09	5.43e-05	0.0198	0.18	0.21	Coffee consumption (cups per day);	chr17:29882041	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.838	rs9646437	ENSG00000240074.1	RPL9P30	4.09	5.43e-05	0.0198	0.18	0.21	Coffee consumption (cups per day);	chr17:29882047	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.838	rs9646438	ENSG00000240074.1	RPL9P30	4.09	5.43e-05	0.0198	0.18	0.21	Coffee consumption (cups per day);	chr17:29882073	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.808	rs56216220	ENSG00000240074.1	RPL9P30	4.09	5.43e-05	0.0198	0.18	0.21	Coffee consumption (cups per day);	chr17:29882164	chr17:29855759~29856332:+
STAD	cis	rs6832769	0.922	rs501679	ENSG00000272969.1	RP11-528I4.2	4.09	5.43e-05	0.0198	0.27	0.21	Personality dimensions;	chr4:55371160	chr4:55547112~55547889:+
STAD	cis	rs62246343	0.605	rs9842540	ENSG00000214041.4	PGAM1P4	4.09	5.43e-05	0.0198	0.3	0.21	Fibrinogen levels;	chr3:9399389	chr3:9348443~9349192:+
STAD	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-4.09	5.43e-05	0.0198	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-4.09	5.43e-05	0.0198	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
STAD	cis	rs12935418	0.832	rs79957369	ENSG00000261061.1	RP11-303E16.2	-4.09	5.43e-05	0.0198	-0.33	-0.21	Mean corpuscular volume;	chr16:81025654	chr16:81030770~81031485:+
STAD	cis	rs7204230	1	rs12596829	ENSG00000261291.1	RP11-295M3.2	4.09	5.43e-05	0.0198	0.25	0.21	Fibrinogen;	chr16:53315088	chr16:53168522~53169450:+
STAD	cis	rs6832769	0.961	rs10009593	ENSG00000223305.1	RN7SKP30	-4.09	5.44e-05	0.0198	-0.24	-0.21	Personality dimensions;	chr4:55570514	chr4:55540502~55540835:-
STAD	cis	rs5753618	0.561	rs5753609	ENSG00000236132.1	CTA-440B3.1	-4.09	5.44e-05	0.0198	-0.23	-0.21	Colorectal cancer;	chr22:31423226	chr22:31816379~31817491:-
STAD	cis	rs7224610	0.931	rs7223342	ENSG00000263096.1	RP11-515O17.2	4.09	5.44e-05	0.0198	0.28	0.21	Urate levels;	chr17:55292233	chr17:55271504~55273653:-
STAD	cis	rs2573652	0.722	rs12908133	ENSG00000270127.2	RP11-526I2.5	-4.09	5.44e-05	0.0198	-0.23	-0.21	Height;	chr15:100004200	chr15:100547765~100550153:-
STAD	cis	rs7078219	0.524	rs6584277	ENSG00000257582.4	LINC01475	-4.09	5.44e-05	0.0198	-0.25	-0.21	Dental caries;	chr10:99518298	chr10:99526350~99531177:-
STAD	cis	rs9463078	0.547	rs9472336	ENSG00000219384.1	RP11-491H9.3	-4.09	5.44e-05	0.0198	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44742655	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs764396	ENSG00000219384.1	RP11-491H9.3	-4.09	5.44e-05	0.0198	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44742954	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs764397	ENSG00000219384.1	RP11-491H9.3	-4.09	5.44e-05	0.0198	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44743034	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.526	rs9472337	ENSG00000219384.1	RP11-491H9.3	-4.09	5.44e-05	0.0198	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44743839	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.547	rs34907292	ENSG00000219384.1	RP11-491H9.3	-4.09	5.44e-05	0.0199	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44761971	chr6:45158870~45159511:+
STAD	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	4.09	5.44e-05	0.0199	0.33	0.21	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
STAD	cis	rs8097348	0.948	rs34912303	ENSG00000266602.1	RP11-476K15.1	-4.09	5.44e-05	0.0199	-0.25	-0.21	Exercise (leisure time);	chr18:1605159	chr18:1509183~1647097:+
STAD	cis	rs9902453	0.584	rs3809790	ENSG00000263477.1	RP11-338L22.2	-4.09	5.45e-05	0.0199	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29628522	chr17:29863402~29866092:+
STAD	cis	rs12745968	0.623	rs4847432	ENSG00000229052.2	RP11-386I23.1	-4.09	5.45e-05	0.0199	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92653327	chr1:92930696~92934098:+
STAD	cis	rs9291683	0.546	rs10939672	ENSG00000250613.1	RP11-136I13.1	-4.09	5.45e-05	0.0199	-0.22	-0.21	Bone mineral density;	chr4:10050512	chr4:10410996~10411644:+
STAD	cis	rs3808502	0.549	rs7831039	ENSG00000254527.1	ENPP7P12	-4.09	5.45e-05	0.0199	-0.24	-0.21	Neuroticism;	chr8:11570128	chr8:12205759~12206389:-
STAD	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	4.09	5.45e-05	0.0199	0.23	0.21	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
STAD	cis	rs792448	0.743	rs12033246	ENSG00000212044.2	AL360091.1	4.09	5.45e-05	0.0199	0.23	0.21	White blood cell count (basophil);	chr1:212339906	chr1:212349978~212350069:+
STAD	cis	rs9463078	0.506	rs4714820	ENSG00000219384.1	RP11-491H9.3	-4.09	5.45e-05	0.0199	-0.21	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44769000	chr6:45158870~45159511:+
STAD	cis	rs2446066	0.605	rs7314664	ENSG00000257379.1	RP11-793H13.8	4.09	5.45e-05	0.0199	0.48	0.21	Red blood cell count;	chr12:53563802	chr12:53441741~53467528:+
STAD	cis	rs7487075	0.79	rs11183527	ENSG00000272963.1	OR7A19P	4.09	5.45e-05	0.0199	0.2	0.21	Itch intensity from mosquito bite;	chr12:46552580	chr12:46592573~46593305:+
STAD	cis	rs1348850	0.958	rs4893941	ENSG00000271825.1	RP11-337N6.2	4.09	5.46e-05	0.0199	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177404803	chr2:177300600~177302006:+
STAD	cis	rs453301	0.522	rs1964356	ENSG00000233609.3	RP11-62H7.2	4.09	5.46e-05	0.0199	0.24	0.21	Joint mobility (Beighton score);	chr8:8995760	chr8:8961200~8979025:+
STAD	cis	rs1707322	0.686	rs1547924	ENSG00000225447.1	RPS15AP10	4.09	5.46e-05	0.0199	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45645816~45646197:-
STAD	cis	rs10129255	0.5	rs6576230	ENSG00000211959.2	IGHV4-39	4.09	5.46e-05	0.0199	0.19	0.21	Kawasaki disease;	chr14:106778539	chr14:106421711~106422218:-
STAD	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-4.09	5.46e-05	0.0199	-0.29	-0.21	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
STAD	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	4.09	5.46e-05	0.0199	0.28	0.21	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
STAD	cis	rs11089937	0.626	rs5757011	ENSG00000211640.3	IGLV6-57	4.09	5.46e-05	0.0199	0.16	0.21	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22195713~22196460:+
STAD	cis	rs6142102	0.961	rs2268088	ENSG00000264616.1	MIR4755	4.09	5.46e-05	0.0199	0.23	0.21	Skin pigmentation;	chr20:34061258	chr20:34049119~34049190:+
STAD	cis	rs10857712	0.687	rs11101742	ENSG00000214279.11	SCART1	-4.09	5.46e-05	0.0199	-0.22	-0.21	Systemic lupus erythematosus;	chr10:133410868	chr10:133453928~133523558:+
STAD	cis	rs10129255	0.956	rs10137268	ENSG00000232216.1	IGHV3-43	4.09	5.46e-05	0.0199	0.22	0.21	Kawasaki disease;	chr14:106697402	chr14:106470264~106470800:-
STAD	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-4.09	5.46e-05	0.0199	-0.34	-0.21	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
STAD	cis	rs919433	0.926	rs787997	ENSG00000231621.1	AC013264.2	-4.09	5.46e-05	0.0199	-0.18	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351547	chr2:197197991~197199273:+
STAD	cis	rs7646881	0.812	rs73017541	ENSG00000240207.5	RP11-379F4.4	-4.09	5.47e-05	0.0199	-0.38	-0.21	Tetralogy of Fallot;	chr3:158743007	chr3:158732263~158784070:+
STAD	cis	rs4589258	0.737	rs7110548	ENSG00000280367.1	RP11-121L10.2	-4.09	5.47e-05	0.0199	-0.21	-0.21	Intelligence (multi-trait analysis);	chr11:90664593	chr11:90223153~90226538:+
STAD	cis	rs17401966	0.838	rs4846212	ENSG00000199562.1	RNU6-37P	4.09	5.47e-05	0.0199	0.17	0.21	Hepatocellular carcinoma;	chr1:10310254	chr1:10298966~10299072:+
STAD	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-4.09	5.47e-05	0.0199	-0.22	-0.21	Height;	chr2:46635327	chr2:46668870~46670778:+
STAD	cis	rs10129255	0.5	rs988134	ENSG00000211959.2	IGHV4-39	4.09	5.47e-05	0.0199	0.19	0.21	Kawasaki disease;	chr14:106776698	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000211959.2	IGHV4-39	4.09	5.47e-05	0.0199	0.19	0.21	Kawasaki disease;	chr14:106776724	chr14:106421711~106422218:-
STAD	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-4.09	5.47e-05	0.0199	-0.25	-0.21	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
STAD	cis	rs9902453	0.726	rs3115092	ENSG00000263477.1	RP11-338L22.2	4.09	5.47e-05	0.0199	0.18	0.21	Coffee consumption (cups per day);	chr17:29709332	chr17:29863402~29866092:+
STAD	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-4.09	5.47e-05	0.0199	-0.23	-0.21	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
STAD	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-4.09	5.47e-05	0.0199	-0.23	-0.21	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
STAD	cis	rs1005277	0.522	rs1208684	ENSG00000099251.13	HSD17B7P2	4.09	5.47e-05	0.0199	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38356380~38378505:+
STAD	cis	rs1572299	1	rs10984109	ENSG00000234782.3	TPT1P9	4.09	5.47e-05	0.0199	0.15	0.21	Schizophrenia;	chr9:118595304	chr9:118082869~118083382:-
STAD	cis	rs1572299	1	rs11788420	ENSG00000234782.3	TPT1P9	4.09	5.47e-05	0.0199	0.15	0.21	Schizophrenia;	chr9:118595959	chr9:118082869~118083382:-
STAD	cis	rs4407350	0.721	rs131156	ENSG00000279642.1	RP5-1033E15.3	-4.09	5.47e-05	0.0199	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44495490	chr22:44486295~44486914:-
STAD	cis	rs4407350	0.721	rs131157	ENSG00000279642.1	RP5-1033E15.3	-4.09	5.47e-05	0.0199	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44495842	chr22:44486295~44486914:-
STAD	cis	rs4407350	0.756	rs131158	ENSG00000279642.1	RP5-1033E15.3	-4.09	5.47e-05	0.0199	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44495993	chr22:44486295~44486914:-
STAD	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	4.09	5.48e-05	0.0199	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
STAD	cis	rs2638953	0.962	rs10843150	ENSG00000247934.4	RP11-967K21.1	4.09	5.48e-05	0.02	0.25	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28304869	chr12:28163298~28190738:-
STAD	cis	rs2692947	0.727	rs2692950	ENSG00000237510.6	AC008268.2	4.09	5.48e-05	0.02	0.27	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95789654~95800166:+
STAD	cis	rs2692947	0.794	rs2692949	ENSG00000237510.6	AC008268.2	4.09	5.48e-05	0.02	0.27	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007777	chr2:95789654~95800166:+
STAD	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-4.09	5.48e-05	0.02	-0.25	-0.21	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-4.09	5.48e-05	0.02	-0.25	-0.21	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
STAD	cis	rs10129255	0.518	rs10136903	ENSG00000211959.2	IGHV4-39	4.09	5.48e-05	0.02	0.19	0.21	Kawasaki disease;	chr14:106778866	chr14:106421711~106422218:-
STAD	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	4.09	5.48e-05	0.02	0.2	0.21	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
STAD	cis	rs4845875	0.6	rs11805138	ENSG00000242349.4	NPPA-AS1	4.08	5.48e-05	0.02	0.24	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11773102	chr1:11841017~11848079:+
STAD	cis	rs1799949	0.929	rs12937015	ENSG00000279602.1	CTD-3014M21.1	4.08	5.48e-05	0.02	0.27	0.21	Menopause (age at onset);	chr17:43155456	chr17:43360041~43361361:-
STAD	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	4.08	5.48e-05	0.02	0.2	0.21	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
STAD	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-4.08	5.48e-05	0.02	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
STAD	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	4.08	5.48e-05	0.02	0.28	0.21	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	4.08	5.48e-05	0.02	0.28	0.21	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	4.08	5.48e-05	0.02	0.28	0.21	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	4.08	5.48e-05	0.02	0.28	0.21	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	4.08	5.48e-05	0.02	0.28	0.21	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
STAD	cis	rs8014252	0.803	rs2018131	ENSG00000259158.2	ADAM20P1	-4.08	5.49e-05	0.02	-0.28	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595715	chr14:70468881~70483756:-
STAD	cis	rs393951	0.957	rs399389	ENSG00000260969.1	RP11-190D6.2	4.08	5.49e-05	0.02	0.26	0.21	Childhood ear infection;	chr16:77614703	chr16:78237362~78241218:-
STAD	cis	rs7116495	0.609	rs567851	ENSG00000254593.1	OR7E126P	4.08	5.49e-05	0.02	0.39	0.21	Severe influenza A (H1N1) infection;	chr11:71881373	chr11:71903194~71904081:+
STAD	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	4.08	5.49e-05	0.02	0.29	0.21	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
STAD	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	4.08	5.49e-05	0.02	0.24	0.21	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
STAD	cis	rs4589258	0.713	rs7949629	ENSG00000280367.1	RP11-121L10.2	4.08	5.49e-05	0.02	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90759458	chr11:90223153~90226538:+
STAD	cis	rs1707322	0.721	rs61784800	ENSG00000225447.1	RPS15AP10	-4.08	5.5e-05	0.02	-0.17	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45645816~45646197:-
STAD	cis	rs606458	0.764	rs532747	ENSG00000269038.1	AP001462.6	-4.08	5.5e-05	0.02	-0.29	-0.21	Urate levels;	chr11:64751590	chr11:64778954~64779405:+
STAD	cis	rs34779708	0.931	rs2384275	ENSG00000271335.4	RP11-324I22.4	4.08	5.5e-05	0.02	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs2001893	ENSG00000271335.4	RP11-324I22.4	4.08	5.5e-05	0.02	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35314552~35336401:-
STAD	cis	rs716804	0.935	rs4553358	ENSG00000254554.1	RP11-351I24.1	4.08	5.5e-05	0.02	0.31	0.21	Neuroticism;	chr11:10231277	chr11:10302657~10303704:-
STAD	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	4.08	5.5e-05	0.02	0.26	0.21	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
STAD	cis	rs765787	0.53	rs3759895	ENSG00000259539.1	CTD-2651B20.1	4.08	5.5e-05	0.02	0.24	0.21	Uric acid levels;	chr15:45251672	chr15:45152664~45167526:-
STAD	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-4.08	5.5e-05	0.02	-0.3	-0.21	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
STAD	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-4.08	5.5e-05	0.02	-0.3	-0.21	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
STAD	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	4.08	5.5e-05	0.02	0.29	0.21	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
STAD	cis	rs8054556	0.74	rs12716974	ENSG00000273724.1	RP11-347C12.12	-4.08	5.5e-05	0.02	-0.22	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30336400~30343336:+
STAD	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-4.08	5.5e-05	0.02	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-4.08	5.5e-05	0.02	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
STAD	cis	rs2446066	0.728	rs10876444	ENSG00000257379.1	RP11-793H13.8	4.08	5.5e-05	0.02	0.36	0.21	Red blood cell count;	chr12:53358697	chr12:53441741~53467528:+
STAD	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	4.08	5.5e-05	0.02	0.31	0.21	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	4.08	5.5e-05	0.02	0.31	0.21	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	4.08	5.5e-05	0.02	0.31	0.21	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	4.08	5.5e-05	0.02	0.31	0.21	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
STAD	cis	rs9907295	0.688	rs2735475	ENSG00000270977.1	AC015849.16	-4.08	5.5e-05	0.02	-0.34	-0.21	Fibroblast growth factor basic levels;	chr17:35931003	chr17:35893707~35911023:-
STAD	cis	rs748404	0.56	rs570933	ENSG00000275601.1	AC011330.13	-4.08	5.51e-05	0.02	-0.23	-0.21	Lung cancer;	chr15:43531832	chr15:43642389~43643023:-
STAD	cis	rs10508774	1	rs12416352	ENSG00000273038.2	RP11-479G22.8	4.08	5.51e-05	0.02	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32630821	chr10:32887255~32889311:-
STAD	cis	rs8012947	1	rs1885134	ENSG00000279636.2	LINC00216	-4.08	5.51e-05	0.02	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58270812	chr14:58288033~58289158:+
STAD	cis	rs8012947	1	rs2180871	ENSG00000279636.2	LINC00216	-4.08	5.51e-05	0.02	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58272819	chr14:58288033~58289158:+
STAD	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	4.08	5.51e-05	0.02	0.22	0.21	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
STAD	cis	rs2803122	0.745	rs10811143	ENSG00000273226.1	RP11-513M16.8	-4.08	5.51e-05	0.02	-0.22	-0.21	Pulse pressure;	chr9:19240221	chr9:19375451~19375996:+
STAD	cis	rs11157436	0.581	rs17255433	ENSG00000211812.1	TRAV26-2	-4.08	5.51e-05	0.0201	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22202583~22203368:+
STAD	cis	rs11157436	0.602	rs17255440	ENSG00000211812.1	TRAV26-2	-4.08	5.51e-05	0.0201	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22202583~22203368:+
STAD	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	4.08	5.51e-05	0.0201	0.3	0.21	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	4.08	5.51e-05	0.0201	0.3	0.21	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	4.08	5.51e-05	0.0201	0.3	0.21	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	4.08	5.51e-05	0.0201	0.3	0.21	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	4.08	5.51e-05	0.0201	0.3	0.21	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	4.08	5.51e-05	0.0201	0.3	0.21	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
STAD	cis	rs7474896	0.559	rs1208779	ENSG00000120555.12	SEPT7P9	4.08	5.51e-05	0.0201	0.27	0.21	Obesity (extreme);	chr10:37788801	chr10:38383069~38402916:-
STAD	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-4.08	5.51e-05	0.0201	-0.38	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
STAD	cis	rs4589258	0.788	rs4753027	ENSG00000280367.1	RP11-121L10.2	4.08	5.51e-05	0.0201	0.22	0.21	Intelligence (multi-trait analysis);	chr11:90742613	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs4753028	ENSG00000280367.1	RP11-121L10.2	4.08	5.51e-05	0.0201	0.22	0.21	Intelligence (multi-trait analysis);	chr11:90744471	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs4753030	ENSG00000280367.1	RP11-121L10.2	4.08	5.51e-05	0.0201	0.22	0.21	Intelligence (multi-trait analysis);	chr11:90744702	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs4298860	ENSG00000280367.1	RP11-121L10.2	4.08	5.51e-05	0.0201	0.22	0.21	Intelligence (multi-trait analysis);	chr11:90745367	chr11:90223153~90226538:+
STAD	cis	rs11846409	0.655	rs79296226	ENSG00000274576.2	IGHV2-70	4.08	5.51e-05	0.0201	0.25	0.21	Rheumatic heart disease;	chr14:106650436	chr14:106770577~106771020:-
STAD	cis	rs2992257	1	rs3006809	ENSG00000251839.1	RNU7-12P	-4.08	5.51e-05	0.0201	-0.22	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26462074	chr10:27232255~27232316:-
STAD	cis	rs2992257	1	rs2992267	ENSG00000251839.1	RNU7-12P	-4.08	5.51e-05	0.0201	-0.22	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26462222	chr10:27232255~27232316:-
STAD	cis	rs2992257	1	rs703007	ENSG00000251839.1	RNU7-12P	-4.08	5.51e-05	0.0201	-0.22	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26468849	chr10:27232255~27232316:-
STAD	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	4.08	5.52e-05	0.0201	0.36	0.21	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.873	rs78175596	ENSG00000226261.1	AC064836.3	4.08	5.52e-05	0.0201	0.36	0.21	Urate levels;	chr2:202287993	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.938	rs74454549	ENSG00000226261.1	AC064836.3	4.08	5.52e-05	0.0201	0.36	0.21	Urate levels;	chr2:202288044	chr2:202336024~202336727:-
STAD	cis	rs6565180	1	rs68051857	ENSG00000273724.1	RP11-347C12.12	-4.08	5.52e-05	0.0201	-0.23	-0.21	Tonsillectomy;	chr16:30348690	chr16:30336400~30343336:+
STAD	cis	rs6565180	1	rs6565180	ENSG00000273724.1	RP11-347C12.12	-4.08	5.52e-05	0.0201	-0.23	-0.21	Tonsillectomy;	chr16:30350020	chr16:30336400~30343336:+
STAD	cis	rs10129255	0.957	rs1056705	ENSG00000232216.1	IGHV3-43	4.08	5.52e-05	0.0201	0.22	0.21	Kawasaki disease;	chr14:106714323	chr14:106470264~106470800:-
STAD	cis	rs4747241	0.662	rs9415068	ENSG00000226163.1	RP11-167P22.3	-4.08	5.52e-05	0.0201	-0.23	-0.21	Heschl's gyrus morphology;	chr10:72353575	chr10:72501746~72502956:+
STAD	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	4.08	5.52e-05	0.0201	0.23	0.21	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
STAD	cis	rs529866	0.5	rs918739	ENSG00000262703.1	RP11-485G7.6	-4.08	5.52e-05	0.0201	-0.2	-0.21	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11348143~11349321:-
STAD	cis	rs7665090	0.528	rs4235405	ENSG00000246560.2	RP11-10L12.4	4.08	5.52e-05	0.0201	0.26	0.21	Primary biliary cholangitis;	chr4:102595654	chr4:102828055~102844075:+
STAD	cis	rs10851478	0.872	rs1911612	ENSG00000259545.2	RP11-325E5.4	-4.08	5.53e-05	0.0201	-0.25	-0.21	Oral cavity cancer;	chr15:49538511	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs34694913	ENSG00000259545.2	RP11-325E5.4	-4.08	5.53e-05	0.0201	-0.25	-0.21	Oral cavity cancer;	chr15:49539697	chr15:49177610~49178741:-
STAD	cis	rs606458	0.764	rs686171	ENSG00000269038.1	AP001462.6	-4.08	5.53e-05	0.0201	-0.29	-0.21	Urate levels;	chr11:64751873	chr11:64778954~64779405:+
STAD	cis	rs10129255	0.518	rs11847766	ENSG00000211959.2	IGHV4-39	4.08	5.53e-05	0.0201	0.19	0.21	Kawasaki disease;	chr14:106779186	chr14:106421711~106422218:-
STAD	cis	rs11098499	0.954	rs6847248	ENSG00000260091.1	RP11-33B1.4	4.08	5.53e-05	0.0201	0.21	0.21	Corneal astigmatism;	chr4:119304800	chr4:119409333~119410233:+
STAD	cis	rs12745968	0.62	rs4847267	ENSG00000229052.2	RP11-386I23.1	4.08	5.53e-05	0.0201	0.2	0.21	Bipolar disorder and schizophrenia;	chr1:92689790	chr1:92930696~92934098:+
STAD	cis	rs9847710	1	rs2581817	ENSG00000242142.1	SERBP1P3	4.08	5.54e-05	0.0201	0.21	0.21	Ulcerative colitis;	chr3:53037781	chr3:53064283~53065091:-
STAD	cis	rs5752326	0.867	rs1894705	ENSG00000261188.1	CTA-445C9.14	4.08	5.54e-05	0.0201	0.4	0.21	Ischemic stroke;	chr22:26458014	chr22:26512537~26514568:+
STAD	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-4.08	5.54e-05	0.0201	-0.3	-0.21	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
STAD	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-4.08	5.54e-05	0.0201	-0.3	-0.21	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
STAD	cis	rs4589258	0.737	rs7121155	ENSG00000280367.1	RP11-121L10.2	-4.08	5.54e-05	0.0201	-0.21	-0.21	Intelligence (multi-trait analysis);	chr11:90685035	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs7116727	ENSG00000280367.1	RP11-121L10.2	-4.08	5.54e-05	0.0201	-0.21	-0.21	Intelligence (multi-trait analysis);	chr11:90693609	chr11:90223153~90226538:+
STAD	cis	rs860295	0.702	rs11264381	ENSG00000225855.5	RUSC1-AS1	-4.08	5.54e-05	0.0201	-0.18	-0.21	Body mass index;	chr1:155552781	chr1:155316863~155324176:-
STAD	cis	rs7937127	0.696	rs11601684	ENSG00000254907.1	RP11-484D2.2	4.08	5.54e-05	0.0201	0.37	0.21	Fibrinogen levels;	chr11:43389017	chr11:43328748~43359296:-
STAD	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	4.08	5.54e-05	0.0201	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
STAD	cis	rs9304742	0.962	rs12459008	ENSG00000242779.5	ZNF702P	-4.08	5.54e-05	0.0201	-0.27	-0.21	Psoriasis;	chr19:52951536	chr19:52968251~53037898:-
STAD	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-4.08	5.54e-05	0.0202	-0.25	-0.21	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
STAD	cis	rs749052	0.831	rs2679172	ENSG00000251485.1	AC068134.10	4.08	5.55e-05	0.0202	0.51	0.21	Height;	chr2:231947081	chr2:232343116~232343903:+
STAD	cis	rs1005277	0.54	rs1987431	ENSG00000099251.13	HSD17B7P2	4.08	5.55e-05	0.0202	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38356380~38378505:+
STAD	cis	rs6565180	0.791	rs4247355	ENSG00000273724.1	RP11-347C12.12	4.08	5.55e-05	0.0202	0.23	0.21	Tonsillectomy;	chr16:30380778	chr16:30336400~30343336:+
STAD	cis	rs9307551	0.584	rs2903636	ENSG00000250334.4	LINC00989	-4.08	5.55e-05	0.0202	-0.26	-0.21	Refractive error;	chr4:79542125	chr4:79492416~79576460:+
STAD	cis	rs34779708	0.966	rs10827487	ENSG00000271335.4	RP11-324I22.4	4.08	5.55e-05	0.0202	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35314552~35336401:-
STAD	cis	rs1816752	0.819	rs7400583	ENSG00000232858.1	RPL34P27	4.08	5.55e-05	0.0202	0.13	0.21	Obesity-related traits;	chr13:24415916	chr13:24988577~24988925:-
STAD	cis	rs4554975	0.869	rs10881002	ENSG00000272369.1	RP11-446N19.1	-4.08	5.55e-05	0.0202	-0.26	-0.21	Metabolite levels (small molecules and protein measures);	chr12:46813270	chr12:46537502~46652550:+
STAD	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	4.08	5.55e-05	0.0202	0.26	0.21	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	4.08	5.55e-05	0.0202	0.26	0.21	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	4.08	5.55e-05	0.0202	0.26	0.21	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
STAD	cis	rs13412757	0.84	rs1000309	ENSG00000236790.4	LINC00299	-4.08	5.55e-05	0.0202	-0.24	-0.21	Asthma;Itch intensity from mosquito bite adjusted by bite size;	chr2:8346500	chr2:8007771~8383621:-
STAD	cis	rs1005277	0.579	rs932538	ENSG00000276805.1	RP11-291L22.6	4.08	5.55e-05	0.0202	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.541	rs2472177	ENSG00000276805.1	RP11-291L22.6	4.08	5.55e-05	0.0202	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2472178	ENSG00000276805.1	RP11-291L22.6	4.08	5.55e-05	0.0202	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2474572	ENSG00000276805.1	RP11-291L22.6	4.08	5.55e-05	0.0202	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2505198	ENSG00000276805.1	RP11-291L22.6	4.08	5.55e-05	0.0202	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38451030~38451785:+
STAD	cis	rs172166	0.769	rs149965	ENSG00000220721.1	OR1F12	4.08	5.56e-05	0.0202	0.23	0.21	Cardiac Troponin-T levels;	chr6:28050911	chr6:28073316~28074233:+
STAD	cis	rs11157436	0.509	rs12589104	ENSG00000211812.1	TRAV26-2	-4.08	5.56e-05	0.0202	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22202583~22203368:+
STAD	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	4.08	5.56e-05	0.0202	0.21	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
STAD	cis	rs755249	0.501	rs2455648	ENSG00000182109.6	RP11-69E11.4	4.08	5.56e-05	0.0202	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39522280~39546187:-
STAD	cis	rs1322639	0.614	rs7751131	ENSG00000261039.2	RP11-417E7.2	-4.08	5.56e-05	0.0202	-0.35	-0.21	Pulse pressure;	chr6:169178615	chr6:169175304~169182740:-
STAD	cis	rs1322639	0.574	rs9364360	ENSG00000261039.2	RP11-417E7.2	-4.08	5.56e-05	0.0202	-0.35	-0.21	Pulse pressure;	chr6:169180079	chr6:169175304~169182740:-
STAD	cis	rs9307551	0.584	rs2119420	ENSG00000250334.4	LINC00989	-4.08	5.56e-05	0.0202	-0.25	-0.21	Refractive error;	chr4:79515963	chr4:79492416~79576460:+
STAD	cis	rs8177876	0.658	rs77874075	ENSG00000261838.4	RP11-303E16.6	4.08	5.56e-05	0.0202	0.46	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81069854~81076598:+
STAD	cis	rs6693567	0.565	rs834243	ENSG00000203819.6	HIST2H2BC	4.08	5.56e-05	0.0202	0.25	0.21	Migraine;	chr1:150366814	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.565	rs1313570	ENSG00000203819.6	HIST2H2BC	4.08	5.56e-05	0.0202	0.25	0.21	Migraine;	chr1:150370166	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.565	rs1260458	ENSG00000203819.6	HIST2H2BC	4.08	5.56e-05	0.0202	0.25	0.21	Migraine;	chr1:150374978	chr1:149850193~149850772:-
STAD	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	4.08	5.56e-05	0.0202	0.24	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
STAD	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-4.08	5.57e-05	0.0202	-0.2	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-4.08	5.57e-05	0.0202	-0.2	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
STAD	cis	rs921665	0.831	rs7578217	ENSG00000236760.1	AC019118.3	4.08	5.57e-05	0.0202	0.32	0.21	World class endurance athleticism;	chr2:3171605	chr2:3131581~3145780:-
STAD	cis	rs10986311	0.747	rs2282084	ENSG00000227200.1	RP11-121A14.3	-4.08	5.57e-05	0.0202	-0.24	-0.21	Vitiligo;	chr9:124259253	chr9:124262876~124265809:+
STAD	cis	rs2404602	0.598	rs11634019	ENSG00000196274.5	Metazoa_SRP	-4.08	5.57e-05	0.0202	-0.19	-0.21	Blood metabolite levels;	chr15:76342339	chr15:76230048~76230390:-
STAD	cis	rs11051970	0.513	rs2892655	ENSG00000274964.1	RP11-817I4.1	-4.08	5.57e-05	0.0202	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32337295	chr12:32339368~32340724:+
STAD	cis	rs741668	0.795	rs17600555	ENSG00000235903.6	CPB2-AS1	4.08	5.57e-05	0.0202	0.26	0.21	Cerebrospinal fluid clusterin levels;	chr13:46049527	chr13:46052806~46113332:+
STAD	cis	rs741668	0.795	rs7324938	ENSG00000235903.6	CPB2-AS1	4.08	5.57e-05	0.0202	0.26	0.21	Cerebrospinal fluid clusterin levels;	chr13:46049937	chr13:46052806~46113332:+
STAD	cis	rs7829975	0.577	rs17684466	ENSG00000254340.1	RP11-10A14.3	-4.08	5.57e-05	0.0202	-0.29	-0.21	Mood instability;	chr8:8687723	chr8:9141424~9145435:+
STAD	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-4.08	5.57e-05	0.0202	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
STAD	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-4.08	5.57e-05	0.0202	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
STAD	cis	rs6432852	0.527	rs6761195	ENSG00000229195.1	AC009495.4	-4.08	5.57e-05	0.0202	-0.24	-0.21	Diabetic kidney disease;	chr2:165916622	chr2:165794857~165846091:-
STAD	cis	rs9463078	0.547	rs1418434	ENSG00000219384.1	RP11-491H9.3	4.08	5.58e-05	0.0202	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44780628	chr6:45158870~45159511:+
STAD	cis	rs10028773	0.632	rs34481394	ENSG00000249244.1	RP11-548H18.2	4.08	5.58e-05	0.0202	0.28	0.21	Educational attainment;	chr4:119327219	chr4:119391831~119395335:-
STAD	cis	rs10028773	0.666	rs35231872	ENSG00000249244.1	RP11-548H18.2	4.08	5.58e-05	0.0202	0.28	0.21	Educational attainment;	chr4:119327221	chr4:119391831~119395335:-
STAD	cis	rs10028773	0.7	rs35653026	ENSG00000249244.1	RP11-548H18.2	4.08	5.58e-05	0.0202	0.28	0.21	Educational attainment;	chr4:119327223	chr4:119391831~119395335:-
STAD	cis	rs911186	0.947	rs9379962	ENSG00000224843.5	LINC00240	4.08	5.58e-05	0.0203	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:27177532	chr6:26956992~27023924:+
STAD	cis	rs12188164	0.932	rs2230437	ENSG00000221990.4	EXOC3-AS1	4.08	5.58e-05	0.0203	0.24	0.21	Cystic fibrosis severity;	chr5:476238	chr5:441498~443160:-
STAD	cis	rs4713118	0.824	rs9468223	ENSG00000243307.2	POM121L6P	-4.08	5.58e-05	0.0203	-0.25	-0.21	Parkinson's disease;	chr6:27772887	chr6:26896952~26898777:+
STAD	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	4.08	5.58e-05	0.0203	0.28	0.21	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
STAD	cis	rs875971	0.898	rs6977501	ENSG00000224316.1	RP11-479O9.2	-4.08	5.59e-05	0.0203	-0.21	-0.21	Aortic root size;	chr7:66228355	chr7:65773620~65802067:+
STAD	cis	rs875971	0.965	rs6971509	ENSG00000224316.1	RP11-479O9.2	-4.08	5.59e-05	0.0203	-0.21	-0.21	Aortic root size;	chr7:66249983	chr7:65773620~65802067:+
STAD	cis	rs75920871	0.528	rs7950093	ENSG00000254851.1	RP11-109L13.1	4.08	5.59e-05	0.0203	0.23	0.21	Subjective well-being;	chr11:117092803	chr11:117135528~117138582:+
STAD	cis	rs9650657	0.572	rs11250098	ENSG00000249848.1	RP11-212F11.1	-4.08	5.59e-05	0.0203	-0.23	-0.21	Neuroticism;	chr8:10961097	chr8:10336782~10337677:-
STAD	cis	rs2221894	0.511	rs10503836	ENSG00000273710.1	Metazoa_SRP	4.08	5.59e-05	0.0203	0.22	0.21	Obesity-related traits;	chr8:29027953	chr8:28915579~28915864:-
STAD	cis	rs870825	0.616	rs4610378	ENSG00000249173.4	LINC01093	4.08	5.59e-05	0.0203	0.34	0.21	Blood protein levels;	chr4:184703066	chr4:184893871~184899454:-
STAD	cis	rs13413635	0.955	rs6715232	ENSG00000225808.1	DNAJC19P5	-4.08	5.59e-05	0.0203	-0.29	-0.21	Heart rate;	chr2:177814920	chr2:177229191~177229506:-
STAD	cis	rs13413635	1	rs13413635	ENSG00000225808.1	DNAJC19P5	-4.08	5.59e-05	0.0203	-0.29	-0.21	Heart rate;	chr2:177815704	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.955	rs6716496	ENSG00000225808.1	DNAJC19P5	-4.08	5.59e-05	0.0203	-0.29	-0.21	Heart rate;	chr2:177816567	chr2:177229191~177229506:-
STAD	cis	rs7829975	0.577	rs7816329	ENSG00000253981.4	ALG1L13P	-4.08	5.6e-05	0.0203	-0.29	-0.21	Mood instability;	chr8:8686333	chr8:8236003~8244667:-
STAD	cis	rs4834770	1	rs878375	ENSG00000249244.1	RP11-548H18.2	4.08	5.6e-05	0.0203	0.27	0.21	Blood protein levels;	chr4:119316419	chr4:119391831~119395335:-
STAD	cis	rs9291683	0.588	rs35099040	ENSG00000250613.1	RP11-136I13.1	-4.08	5.6e-05	0.0203	-0.2	-0.21	Bone mineral density;	chr4:10017215	chr4:10410996~10411644:+
STAD	cis	rs2337406	1	rs17113331	ENSG00000280411.1	IGHV1-69-2	-4.08	5.6e-05	0.0203	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106703843	chr14:106762092~106762588:-
STAD	cis	rs2337406	1	rs7145172	ENSG00000280411.1	IGHV1-69-2	-4.08	5.6e-05	0.0203	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106704924	chr14:106762092~106762588:-
STAD	cis	rs447735	0.507	rs11645271	ENSG00000274627.1	RP11-104N10.2	-4.08	5.6e-05	0.0203	-0.2	-0.21	Hemoglobin concentration;	chr16:89662717	chr16:89516797~89522217:+
STAD	cis	rs1426063	1	rs1426063	ENSG00000249717.1	RP11-44F21.3	-4.08	5.6e-05	0.0203	-0.37	-0.21	QT interval;	chr4:75105711	chr4:74955974~74970362:-
STAD	cis	rs9733	0.596	rs56058687	ENSG00000274963.1	Metazoa_SRP	4.08	5.61e-05	0.0203	0.19	0.21	Tonsillectomy;	chr1:150662590	chr1:150568971~150569269:-
STAD	cis	rs9902453	0.765	rs9890747	ENSG00000240074.1	RPL9P30	4.08	5.61e-05	0.0203	0.19	0.21	Coffee consumption (cups per day);	chr17:29680424	chr17:29855759~29856332:+
STAD	cis	rs7474896	0.559	rs1212108	ENSG00000120555.12	SEPT7P9	4.08	5.61e-05	0.0203	0.27	0.21	Obesity (extreme);	chr10:37805394	chr10:38383069~38402916:-
STAD	cis	rs561341	1	rs560132	ENSG00000265798.5	RP11-271K11.5	4.08	5.61e-05	0.0204	0.31	0.21	Hip circumference adjusted for BMI;	chr17:31993000	chr17:31038575~31059121:-
STAD	cis	rs6479891	1	rs4745706	ENSG00000235816.3	PRELID1P3	4.08	5.62e-05	0.0204	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs12415038	ENSG00000235816.3	PRELID1P3	4.08	5.62e-05	0.0204	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63427297~63427939:+
STAD	cis	rs7915414	0.531	rs9332184	ENSG00000230338.1	MTND4P19	4.08	5.62e-05	0.0204	0.26	0.21	Clopidogrel active metabolite levels;	chr10:94976757	chr10:94774156~94774633:-
STAD	cis	rs870825	0.655	rs28604350	ENSG00000249173.4	LINC01093	-4.08	5.62e-05	0.0204	-0.35	-0.21	Blood protein levels;	chr4:184717569	chr4:184893871~184899454:-
STAD	cis	rs10971721	0.822	rs72727336	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33931795	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971803	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33933289	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs41314578	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33933943	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs56274755	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33934273	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72727341	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33936878	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72727345	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33940200	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72727346	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33940420	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72727350	ENSG00000281128.1	PTENP1-AS	4.08	5.62e-05	0.0204	0.32	0.21	Body mass index;	chr9:33944732	chr9:33677268~33688011:+
STAD	cis	rs9307551	0.697	rs7691021	ENSG00000250334.4	LINC00989	-4.08	5.62e-05	0.0204	-0.28	-0.21	Refractive error;	chr4:79502775	chr4:79492416~79576460:+
STAD	cis	rs1707322	0.827	rs10890347	ENSG00000281133.1	AL355480.3	4.08	5.62e-05	0.0204	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45580892~45580996:-
STAD	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	4.08	5.62e-05	0.0204	0.23	0.21	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
STAD	cis	rs34779708	0.897	rs4934527	ENSG00000271335.4	RP11-324I22.4	4.08	5.62e-05	0.0204	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35314552~35336401:-
STAD	cis	rs2384207	1	rs2384207	ENSG00000277566.1	RP11-545P7.9	-4.08	5.62e-05	0.0204	-0.3	-0.21	Response to fenofibrate (adiponectin levels);	chr12:113169697	chr12:113249466~113250042:+
STAD	cis	rs7078219	0.543	rs10786556	ENSG00000257582.4	LINC01475	-4.08	5.62e-05	0.0204	-0.25	-0.21	Dental caries;	chr10:99518567	chr10:99526350~99531177:-
STAD	cis	rs875971	0.965	rs28682868	ENSG00000224316.1	RP11-479O9.2	-4.08	5.63e-05	0.0204	-0.21	-0.21	Aortic root size;	chr7:66224822	chr7:65773620~65802067:+
STAD	cis	rs253959	0.774	rs254151	ENSG00000248445.4	SEMA6A-AS1	-4.08	5.63e-05	0.0204	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr5:116306400	chr5:116447547~116508276:+
STAD	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-4.08	5.63e-05	0.0204	-0.36	-0.21	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
STAD	cis	rs7119038	0.731	rs10892283	ENSG00000255422.1	AP002954.4	4.08	5.63e-05	0.0204	0.29	0.21	Sjögren's syndrome;	chr11:118766272	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.818	rs10892286	ENSG00000255422.1	AP002954.4	4.08	5.63e-05	0.0204	0.29	0.21	Sjögren's syndrome;	chr11:118771376	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.818	rs10892288	ENSG00000255422.1	AP002954.4	4.08	5.63e-05	0.0204	0.29	0.21	Sjögren's syndrome;	chr11:118773985	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.818	rs10892289	ENSG00000255422.1	AP002954.4	4.08	5.63e-05	0.0204	0.29	0.21	Sjögren's syndrome;	chr11:118775294	chr11:118704607~118750263:+
STAD	cis	rs7474896	1	rs61859667	ENSG00000099251.13	HSD17B7P2	4.08	5.63e-05	0.0204	0.36	0.21	Obesity (extreme);	chr10:37727451	chr10:38356380~38378505:+
STAD	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	4.08	5.63e-05	0.0204	0.28	0.21	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	4.08	5.63e-05	0.0204	0.28	0.21	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	4.08	5.63e-05	0.0204	0.28	0.21	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
STAD	cis	rs9307551	1	rs894054	ENSG00000250334.4	LINC00989	-4.08	5.63e-05	0.0204	-0.27	-0.21	Refractive error;	chr4:79621254	chr4:79492416~79576460:+
STAD	cis	rs1005277	0.522	rs1208767	ENSG00000099251.13	HSD17B7P2	4.08	5.63e-05	0.0204	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38356380~38378505:+
STAD	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	4.08	5.63e-05	0.0204	0.3	0.21	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
STAD	cis	rs219780	0.898	rs219786	ENSG00000233818.1	AP000695.4	4.08	5.63e-05	0.0204	0.3	0.21	Kidney stones;	chr21:36459453	chr21:36445731~36532408:+
STAD	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-4.08	5.64e-05	0.0204	-0.23	-0.21	Height;	chr2:231541633	chr2:231508426~231514339:-
STAD	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-4.08	5.64e-05	0.0204	-0.21	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
STAD	cis	rs786425	0.804	rs10846535	ENSG00000247373.3	RP11-486O12.2	-4.08	5.64e-05	0.0204	-0.16	-0.21	Pubertal anthropometrics;	chr12:123645841	chr12:123575891~123585115:-
STAD	cis	rs6142102	0.961	rs2284388	ENSG00000264616.1	MIR4755	4.08	5.64e-05	0.0204	0.22	0.21	Skin pigmentation;	chr20:34067935	chr20:34049119~34049190:+
STAD	cis	rs7395581	0.797	rs10838681	ENSG00000271543.1	RP11-692M12.5	-4.08	5.64e-05	0.0204	-0.21	-0.21	HDL cholesterol;	chr11:47253513	chr11:47796169~47796379:+
STAD	cis	rs6479891	1	rs12416113	ENSG00000235816.3	PRELID1P3	4.08	5.64e-05	0.0204	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63427297~63427939:+
STAD	cis	rs17801127	0.818	rs73003921	ENSG00000231969.1	AC144449.1	4.08	5.64e-05	0.0205	0.46	0.21	Liver enzyme levels (alanine transaminase);	chr2:149844297	chr2:149587196~149848233:+
STAD	cis	rs12682352	0.602	rs4841044	ENSG00000173295.6	FAM86B3P	-4.08	5.64e-05	0.0205	-0.25	-0.21	Neuroticism;	chr8:8807430	chr8:8228595~8244865:+
STAD	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	4.08	5.65e-05	0.0205	0.28	0.21	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
STAD	cis	rs7615952	0.866	rs13063119	ENSG00000272840.1	RP11-379B18.6	4.08	5.65e-05	0.0205	0.38	0.21	Blood pressure (smoking interaction);	chr3:125925004	chr3:125774714~125797953:+
STAD	cis	rs2880765	0.835	rs4360875	ENSG00000259295.5	CSPG4P12	4.08	5.65e-05	0.0205	0.27	0.21	Coronary artery disease;	chr15:85497163	chr15:85191438~85213905:+
STAD	cis	rs4925386	0.765	rs6142737	ENSG00000273619.1	RP5-908M14.9	-4.08	5.65e-05	0.0205	-0.21	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62386303~62386970:-
STAD	cis	rs7487075	0.859	rs7960147	ENSG00000257261.4	RP11-96H19.1	4.08	5.65e-05	0.0205	0.27	0.21	Itch intensity from mosquito bite;	chr12:46357671	chr12:46383679~46876159:+
STAD	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	4.08	5.65e-05	0.0205	0.28	0.21	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
STAD	cis	rs10149470	0.549	rs9652403	ENSG00000258851.1	RP11-894P9.2	-4.08	5.65e-05	0.0205	-0.25	-0.21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103553421~103561877:+
STAD	cis	rs11673344	0.504	rs4254428	ENSG00000267672.1	CTD-2293H3.1	4.08	5.65e-05	0.0205	0.19	0.21	Obesity-related traits;	chr19:37093748	chr19:37091341~37092564:+
STAD	cis	rs2790457	0.833	rs1265847	ENSG00000254635.4	WAC-AS1	-4.08	5.65e-05	0.0205	-0.27	-0.21	Multiple myeloma;	chr10:28640757	chr10:28522652~28532743:-
STAD	cis	rs12576775	1	rs17138171	ENSG00000251323.2	RP11-452H21.4	-4.08	5.65e-05	0.0205	-0.31	-0.21	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:79351885	chr11:78423982~78429836:-
STAD	cis	rs1707322	1	rs10890382	ENSG00000225447.1	RPS15AP10	4.08	5.65e-05	0.0205	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45645816~45646197:-
STAD	cis	rs806321	0.587	rs2740516	ENSG00000237152.3	DLEU7-AS1	-4.08	5.65e-05	0.0205	-0.24	-0.21	Multiple sclerosis;	chr13:50187483	chr13:50807856~50849905:+
STAD	cis	rs7646881	0.812	rs73015665	ENSG00000240207.5	RP11-379F4.4	-4.08	5.65e-05	0.0205	-0.35	-0.21	Tetralogy of Fallot;	chr3:158736145	chr3:158732263~158784070:+
STAD	cis	rs12682352	0.602	rs11783966	ENSG00000173295.6	FAM86B3P	-4.08	5.65e-05	0.0205	-0.24	-0.21	Neuroticism;	chr8:8807637	chr8:8228595~8244865:+
STAD	cis	rs10971721	0.822	rs12376145	ENSG00000281128.1	PTENP1-AS	4.08	5.65e-05	0.0205	0.32	0.21	Body mass index;	chr9:34050408	chr9:33677268~33688011:+
STAD	cis	rs3002131	0.604	rs11487813	ENSG00000225265.1	TAF1A-AS1	-4.08	5.65e-05	0.0205	-0.32	-0.21	Interleukin-10 levels;	chr1:222563436	chr1:222589825~222593032:+
STAD	cis	rs10782582	0.532	rs78106188	ENSG00000181227.3	RP4-682C21.2	4.08	5.65e-05	0.0205	0.23	0.21	Daytime sleep phenotypes;	chr1:75672151	chr1:75743423~75744776:-
STAD	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-4.08	5.66e-05	0.0205	-0.25	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
STAD	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-4.08	5.66e-05	0.0205	-0.25	-0.21	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
STAD	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	4.08	5.66e-05	0.0205	0.2	0.21	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
STAD	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	4.08	5.66e-05	0.0205	0.2	0.21	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
STAD	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	4.08	5.66e-05	0.0205	0.2	0.21	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
STAD	cis	rs539514	0.563	rs7991448	ENSG00000261105.4	LMO7-AS1	4.08	5.66e-05	0.0205	0.26	0.21	Type 1 diabetes;	chr13:75759925	chr13:75604700~75635994:-
STAD	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	4.08	5.66e-05	0.0205	0.23	0.21	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
STAD	cis	rs728616	0.51	rs35671072	ENSG00000225484.5	NUTM2B-AS1	-4.08	5.66e-05	0.0205	-0.41	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80412499	chr10:79663088~79826594:-
STAD	cis	rs7849270	1	rs6478867	ENSG00000234055.1	RP11-247A12.1	-4.08	5.66e-05	0.0205	-0.24	-0.21	Blood metabolite ratios;	chr9:129141644	chr9:129097854~129100266:+
STAD	cis	rs733592	0.56	rs2158515	ENSG00000226413.2	OR8T1P	-4.08	5.66e-05	0.0205	-0.24	-0.21	Plateletcrit;	chr12:48113885	chr12:48442030~48442947:-
STAD	cis	rs1823913	0.927	rs34765012	ENSG00000280083.1	RP11-317J9.1	-4.08	5.67e-05	0.0205	-0.26	-0.21	Obesity-related traits;	chr2:191247926	chr2:191154118~191156070:-
STAD	cis	rs1322639	0.614	rs6937001	ENSG00000261039.2	RP11-417E7.2	4.08	5.67e-05	0.0205	0.33	0.21	Pulse pressure;	chr6:169164991	chr6:169175304~169182740:-
STAD	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-4.08	5.67e-05	0.0205	-0.32	-0.21	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
STAD	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-4.08	5.67e-05	0.0205	-0.32	-0.21	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
STAD	cis	rs6430585	0.528	rs309165	ENSG00000231890.6	DARS-AS1	-4.08	5.67e-05	0.0205	-0.23	-0.21	Corneal structure;	chr2:135909731	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs309158	ENSG00000231890.6	DARS-AS1	-4.08	5.67e-05	0.0205	-0.23	-0.21	Corneal structure;	chr2:135922964	chr2:135985176~136022593:+
STAD	cis	rs9291683	0.669	rs887733	ENSG00000250613.1	RP11-136I13.1	4.08	5.67e-05	0.0205	0.22	0.21	Bone mineral density;	chr4:10181484	chr4:10410996~10411644:+
STAD	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-4.08	5.67e-05	0.0205	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
STAD	cis	rs12500234	1	rs12500234	ENSG00000249207.1	RP11-360F5.1	-4.08	5.67e-05	0.0205	-0.22	-0.21	Colorectal cancer;	chr4:39618250	chr4:39112677~39126818:-
STAD	cis	rs2638953	0.672	rs11609619	ENSG00000247934.4	RP11-967K21.1	-4.08	5.67e-05	0.0205	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28557876	chr12:28163298~28190738:-
STAD	cis	rs9549328	0.731	rs55804996	ENSG00000267868.1	RP11-120K24.3	4.08	5.67e-05	0.0205	0.3	0.21	Systolic blood pressure;	chr13:112971053	chr13:112964835~112966131:-
STAD	cis	rs2836950	0.565	rs7279497	ENSG00000238141.2	BRWD1-AS1	4.08	5.68e-05	0.0206	0.22	0.21	Menarche (age at onset);	chr21:39159380	chr21:39315707~39323218:+
STAD	cis	rs72627123	0.582	rs62005101	ENSG00000259065.1	RP5-1021I20.1	-4.08	5.68e-05	0.0206	-0.3	-0.21	Morning vs. evening chronotype;	chr14:74033882	chr14:73787360~73803270:+
STAD	cis	rs72627123	0.582	rs62005102	ENSG00000259065.1	RP5-1021I20.1	-4.08	5.68e-05	0.0206	-0.3	-0.21	Morning vs. evening chronotype;	chr14:74033883	chr14:73787360~73803270:+
STAD	cis	rs7829975	0.846	rs1879957	ENSG00000254340.1	RP11-10A14.3	-4.08	5.68e-05	0.0206	-0.26	-0.21	Mood instability;	chr8:8687298	chr8:9141424~9145435:+
STAD	cis	rs559928	0.606	rs17773078	ENSG00000236935.1	AP003774.1	4.08	5.68e-05	0.0206	0.34	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64138752	chr11:64325050~64329504:-
STAD	cis	rs559928	0.606	rs60394481	ENSG00000236935.1	AP003774.1	4.08	5.68e-05	0.0206	0.34	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64141563	chr11:64325050~64329504:-
STAD	cis	rs559928	0.556	rs734762	ENSG00000236935.1	AP003774.1	4.08	5.68e-05	0.0206	0.34	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64144717	chr11:64325050~64329504:-
STAD	cis	rs559928	0.606	rs12417635	ENSG00000236935.1	AP003774.1	4.08	5.68e-05	0.0206	0.34	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145256	chr11:64325050~64329504:-
STAD	cis	rs1707322	0.682	rs28508523	ENSG00000225447.1	RPS15AP10	4.08	5.68e-05	0.0206	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.691	rs11211175	ENSG00000225447.1	RPS15AP10	4.08	5.68e-05	0.0206	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45645816~45646197:-
STAD	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	4.08	5.68e-05	0.0206	0.26	0.21	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
STAD	cis	rs860295	0.702	rs2025669	ENSG00000225855.5	RUSC1-AS1	4.08	5.68e-05	0.0206	0.18	0.21	Body mass index;	chr1:155387818	chr1:155316863~155324176:-
STAD	cis	rs860295	0.702	rs12081067	ENSG00000225855.5	RUSC1-AS1	4.08	5.68e-05	0.0206	0.18	0.21	Body mass index;	chr1:155389191	chr1:155316863~155324176:-
STAD	cis	rs860295	0.702	rs10908465	ENSG00000225855.5	RUSC1-AS1	4.08	5.68e-05	0.0206	0.18	0.21	Body mass index;	chr1:155419897	chr1:155316863~155324176:-
STAD	cis	rs6693567	0.545	rs1932934	ENSG00000203819.6	HIST2H2BC	4.08	5.68e-05	0.0206	0.25	0.21	Migraine;	chr1:150476719	chr1:149850193~149850772:-
STAD	cis	rs301901	0.9	rs300046	ENSG00000250155.1	CTD-2353F22.1	-4.08	5.68e-05	0.0206	-0.22	-0.21	Height;	chr5:37081603	chr5:36666214~36725195:-
STAD	cis	rs117785887	0.536	rs10457790	ENSG00000270638.1	RP3-466P17.1	4.08	5.68e-05	0.0206	0.38	0.21	Interleukin-17 levels;	chr6:146038729	chr6:145735570~145737218:+
STAD	cis	rs7702057	0.53	rs1567330	ENSG00000271918.1	CTD-2287O16.5	4.08	5.68e-05	0.0206	0.38	0.21	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116083807~116085416:-
STAD	cis	rs1816752	0.646	rs9511295	ENSG00000273628.1	RP11-756A22.7	-4.08	5.69e-05	0.0206	-0.26	-0.21	Obesity-related traits;	chr13:24467794	chr13:24933006~24936796:+
STAD	cis	rs7309687	0.527	rs6582412	ENSG00000199886.1	RNU6-249P	4.08	5.69e-05	0.0206	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr12:42668884	chr12:42398550~42398651:+
STAD	cis	rs7139978	0.516	rs9547908	ENSG00000230390.1	LINC01048	-4.08	5.69e-05	0.0206	-0.24	-0.21	Life satisfaction;	chr13:37495672	chr13:37481467~37484769:-
STAD	cis	rs6142102	0.961	rs909884	ENSG00000264616.1	MIR4755	4.08	5.69e-05	0.0206	0.22	0.21	Skin pigmentation;	chr20:34058257	chr20:34049119~34049190:+
STAD	cis	rs7246657	0.525	rs997516	ENSG00000267672.1	CTD-2293H3.1	4.08	5.69e-05	0.0206	0.28	0.21	Coronary artery calcification;	chr19:36983362	chr19:37091341~37092564:+
STAD	cis	rs11676348	0.729	rs13013361	ENSG00000237281.1	CATIP-AS2	4.08	5.69e-05	0.0206	0.21	0.21	Ulcerative colitis;	chr2:218082792	chr2:218326889~218357966:-
STAD	cis	rs561341	1	rs501312	ENSG00000265798.5	RP11-271K11.5	4.08	5.69e-05	0.0206	0.3	0.21	Hip circumference adjusted for BMI;	chr17:32002047	chr17:31038575~31059121:-
STAD	cis	rs561341	0.941	rs72825736	ENSG00000265798.5	RP11-271K11.5	4.08	5.69e-05	0.0206	0.3	0.21	Hip circumference adjusted for BMI;	chr17:32003267	chr17:31038575~31059121:-
STAD	cis	rs561341	0.941	rs8081016	ENSG00000265798.5	RP11-271K11.5	4.08	5.69e-05	0.0206	0.3	0.21	Hip circumference adjusted for BMI;	chr17:32004732	chr17:31038575~31059121:-
STAD	cis	rs603446	0.583	rs180377	ENSG00000280143.1	AP000892.6	4.08	5.69e-05	0.0206	0.16	0.21	Triglycerides;	chr11:116718411	chr11:117204967~117210292:+
STAD	cis	rs4792901	0.722	rs34558675	ENSG00000279602.1	CTD-3014M21.1	-4.08	5.69e-05	0.0206	-0.28	-0.21	Dupuytren's disease;	chr17:43473223	chr17:43360041~43361361:-
STAD	cis	rs7202877	0.706	rs247438	ENSG00000261783.1	RP11-252K23.2	4.08	5.69e-05	0.0206	0.35	0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75398751	chr16:75379818~75381260:-
STAD	cis	rs1816752	0.646	rs7322323	ENSG00000273628.1	RP11-756A22.7	-4.08	5.7e-05	0.0206	-0.26	-0.21	Obesity-related traits;	chr13:24479189	chr13:24933006~24936796:+
STAD	cis	rs2992257	0.958	rs2992258	ENSG00000251839.1	RNU7-12P	-4.08	5.7e-05	0.0206	-0.22	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26448954	chr10:27232255~27232316:-
STAD	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-4.08	5.7e-05	0.0206	-0.37	-0.21	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
STAD	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-4.08	5.7e-05	0.0206	-0.37	-0.21	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
STAD	cis	rs13413635	0.774	rs62183445	ENSG00000225808.1	DNAJC19P5	-4.08	5.7e-05	0.0206	-0.28	-0.21	Heart rate;	chr2:178023389	chr2:177229191~177229506:-
STAD	cis	rs1075265	0.87	rs6749817	ENSG00000235937.1	AC008280.1	4.08	5.7e-05	0.0206	0.19	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54029552~54030682:-
STAD	cis	rs10129255	0.784	rs7147210	ENSG00000224373.3	IGHV4-59	4.08	5.71e-05	0.0206	0.17	0.21	Kawasaki disease;	chr14:106705271	chr14:106627249~106627825:-
STAD	cis	rs9902453	0.834	rs9901694	ENSG00000263477.1	RP11-338L22.2	4.08	5.71e-05	0.0206	0.19	0.21	Coffee consumption (cups per day);	chr17:29944627	chr17:29863402~29866092:+
STAD	cis	rs9847710	0.933	rs1529544	ENSG00000242142.1	SERBP1P3	-4.08	5.71e-05	0.0207	-0.2	-0.21	Ulcerative colitis;	chr3:53005439	chr3:53064283~53065091:-
STAD	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	4.08	5.71e-05	0.0207	0.24	0.21	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
STAD	cis	rs448720	0.508	rs396174	ENSG00000260657.2	RP11-315D16.4	-4.08	5.71e-05	0.0207	-0.23	-0.21	Cognitive performance;	chr15:67928740	chr15:68267792~68277994:-
STAD	cis	rs2348418	0.765	rs12368743	ENSG00000247934.4	RP11-967K21.1	-4.07	5.71e-05	0.0207	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28163298~28190738:-
STAD	cis	rs17801127	0.818	rs35875583	ENSG00000231969.1	AC144449.1	4.07	5.71e-05	0.0207	0.46	0.21	Liver enzyme levels (alanine transaminase);	chr2:149845854	chr2:149587196~149848233:+
STAD	cis	rs7204230	1	rs2287078	ENSG00000261291.1	RP11-295M3.2	-4.07	5.71e-05	0.0207	-0.25	-0.21	Fibrinogen;	chr16:53292948	chr16:53168522~53169450:+
STAD	cis	rs9291683	0.588	rs12647117	ENSG00000250613.1	RP11-136I13.1	-4.07	5.71e-05	0.0207	-0.2	-0.21	Bone mineral density;	chr4:10020435	chr4:10410996~10411644:+
STAD	cis	rs2836950	0.52	rs1980407	ENSG00000238141.2	BRWD1-AS1	-4.07	5.72e-05	0.0207	-0.22	-0.21	Menarche (age at onset);	chr21:39172035	chr21:39315707~39323218:+
STAD	cis	rs451417	1	rs236107	ENSG00000275632.1	RP5-967N21.11	4.07	5.72e-05	0.0207	0.29	0.21	Menopause (age at onset);	chr20:5985085	chr20:6000418~6000941:+
STAD	cis	rs451417	1	rs236125	ENSG00000275632.1	RP5-967N21.11	4.07	5.72e-05	0.0207	0.29	0.21	Menopause (age at onset);	chr20:5996328	chr20:6000418~6000941:+
STAD	cis	rs11169552	0.51	rs10783372	ENSG00000200183.1	RNU6-238P	-4.07	5.72e-05	0.0207	-0.2	-0.21	Colorectal cancer;	chr12:50558741	chr12:50656973~50657078:+
STAD	cis	rs9921338	0.961	rs4781055	ENSG00000263080.1	RP11-485G7.5	4.07	5.72e-05	0.0207	0.33	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11275571	chr16:11341809~11345211:-
STAD	cis	rs9402743	1	rs6926161	ENSG00000236703.1	MYB-AS1	4.07	5.72e-05	0.0207	0.22	0.21	Systemic lupus erythematosus;	chr6:135653341	chr6:135195083~135195995:-
STAD	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	4.07	5.72e-05	0.0207	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	4.07	5.72e-05	0.0207	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
STAD	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-4.07	5.72e-05	0.0207	-0.22	-0.21	Height;	chr2:46611108	chr2:46668870~46670778:+
STAD	cis	rs219780	0.898	rs219785	ENSG00000233818.1	AP000695.4	4.07	5.72e-05	0.0207	0.3	0.21	Kidney stones;	chr21:36459562	chr21:36445731~36532408:+
STAD	cis	rs447735	0.587	rs11640702	ENSG00000274627.1	RP11-104N10.2	-4.07	5.73e-05	0.0207	-0.2	-0.21	Hemoglobin concentration;	chr16:89662761	chr16:89516797~89522217:+
STAD	cis	rs1707322	1	rs4390216	ENSG00000281133.1	AL355480.3	-4.07	5.73e-05	0.0207	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.964	rs10437063	ENSG00000281133.1	AL355480.3	-4.07	5.73e-05	0.0207	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs6676982	ENSG00000281133.1	AL355480.3	-4.07	5.73e-05	0.0207	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.927	rs11211194	ENSG00000281133.1	AL355480.3	-4.07	5.73e-05	0.0207	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45580892~45580996:-
STAD	cis	rs11089937	0.553	rs35336247	ENSG00000211638.2	IGLV8-61	-4.07	5.73e-05	0.0207	-0.23	-0.21	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22098700~22099212:+
STAD	cis	rs11089937	0.553	rs34088081	ENSG00000211638.2	IGLV8-61	-4.07	5.73e-05	0.0207	-0.23	-0.21	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22098700~22099212:+
STAD	cis	rs11089937	0.568	rs12160317	ENSG00000211638.2	IGLV8-61	-4.07	5.73e-05	0.0207	-0.23	-0.21	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22098700~22099212:+
STAD	cis	rs11089937	0.568	rs12160318	ENSG00000211638.2	IGLV8-61	-4.07	5.73e-05	0.0207	-0.23	-0.21	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22098700~22099212:+
STAD	cis	rs2262909	0.548	rs7249672	ENSG00000213976.4	CTD-2561J22.2	4.07	5.74e-05	0.0207	0.25	0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22118721	chr19:21382865~21387177:+
STAD	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	4.07	5.74e-05	0.0207	0.21	0.21	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
STAD	cis	rs7926906	1	rs4304731	ENSG00000280367.1	RP11-121L10.2	4.07	5.74e-05	0.0207	0.22	0.21	Intelligence (multi-trait analysis);	chr11:90790617	chr11:90223153~90226538:+
STAD	cis	rs9463078	0.677	rs6458423	ENSG00000219384.1	RP11-491H9.3	4.07	5.74e-05	0.0207	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45172908	chr6:45158870~45159511:+
STAD	cis	rs617219	0.755	rs9293768	ENSG00000206592.1	SNORA18	-4.07	5.74e-05	0.0207	-0.21	-0.21	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79277331	chr5:79220942~79221073:+
STAD	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-4.07	5.74e-05	0.0207	-0.29	-0.21	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
STAD	cis	rs62388641	0.802	rs13202504	ENSG00000281809.1	LINC01394	4.07	5.74e-05	0.0207	0.36	0.21	Daytime sleep phenotypes;	chr6:1537640	chr6:1321698~1324022:-
STAD	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	4.07	5.74e-05	0.0207	0.23	0.21	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	4.07	5.74e-05	0.0207	0.23	0.21	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
STAD	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	4.07	5.74e-05	0.0207	0.29	0.21	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
STAD	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	4.07	5.74e-05	0.0207	0.3	0.21	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
STAD	cis	rs12745968	0.623	rs4294424	ENSG00000229052.2	RP11-386I23.1	-4.07	5.74e-05	0.0208	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92673817	chr1:92930696~92934098:+
STAD	cis	rs4950322	0.518	rs4950304	ENSG00000278811.3	LINC00624	4.07	5.74e-05	0.0208	0.22	0.21	Protein quantitative trait loci;	chr1:147116685	chr1:147258885~147517875:-
STAD	cis	rs10458771	0.527	rs4638218	ENSG00000212332.1	RNU6-780P	-4.07	5.74e-05	0.0208	-0.24	-0.21	Amyotrophic lateral sclerosis (sporadic);	chr10:86422841	chr10:86488446~86488549:+
STAD	cis	rs10458771	0.527	rs7922840	ENSG00000212332.1	RNU6-780P	-4.07	5.74e-05	0.0208	-0.24	-0.21	Amyotrophic lateral sclerosis (sporadic);	chr10:86423921	chr10:86488446~86488549:+
STAD	cis	rs6565180	1	rs12930787	ENSG00000273724.1	RP11-347C12.12	-4.07	5.74e-05	0.0208	-0.23	-0.21	Tonsillectomy;	chr16:30369982	chr16:30336400~30343336:+
STAD	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	4.07	5.74e-05	0.0208	0.21	0.21	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
STAD	cis	rs11012350	0.85	rs7893893	ENSG00000240291.1	RP11-499P20.2	4.07	5.75e-05	0.0208	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18016768	chr10:18513115~18545651:-
STAD	cis	rs9368481	0.729	rs9379948	ENSG00000224843.5	LINC00240	-4.07	5.75e-05	0.0208	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26956992~27023924:+
STAD	cis	rs4218	0.573	rs16940998	ENSG00000259732.1	RP11-59H7.3	4.07	5.75e-05	0.0208	0.24	0.21	Social communication problems;	chr15:59086095	chr15:59121034~59133250:+
STAD	cis	rs7474896	0.583	rs1208770	ENSG00000120555.12	SEPT7P9	4.07	5.75e-05	0.0208	0.27	0.21	Obesity (extreme);	chr10:37755755	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.526	rs1742235	ENSG00000120555.12	SEPT7P9	4.07	5.75e-05	0.0208	0.27	0.21	Obesity (extreme);	chr10:37763328	chr10:38383069~38402916:-
STAD	cis	rs2221894	0.535	rs12550344	ENSG00000273710.1	Metazoa_SRP	-4.07	5.75e-05	0.0208	-0.22	-0.21	Obesity-related traits;	chr8:28922943	chr8:28915579~28915864:-
STAD	cis	rs806321	0.587	rs2066632	ENSG00000237152.3	DLEU7-AS1	4.07	5.75e-05	0.0208	0.24	0.21	Multiple sclerosis;	chr13:50187807	chr13:50807856~50849905:+
STAD	cis	rs9733	0.596	rs2275236	ENSG00000274963.1	Metazoa_SRP	-4.07	5.75e-05	0.0208	-0.19	-0.21	Tonsillectomy;	chr1:150697476	chr1:150568971~150569269:-
STAD	cis	rs950881	0.932	rs3771175	ENSG00000234389.1	AC007278.3	-4.07	5.75e-05	0.0208	-0.29	-0.21	Allergy;	chr2:102343750	chr2:102438713~102440475:+
STAD	cis	rs11846409	0.652	rs10143549	ENSG00000274576.2	IGHV2-70	-4.07	5.76e-05	0.0208	-0.26	-0.21	Rheumatic heart disease;	chr14:106644643	chr14:106770577~106771020:-
STAD	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.28	0.21	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.28	0.21	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.28	0.21	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.28	0.21	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.28	0.21	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.28	0.21	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.28	0.21	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
STAD	cis	rs8054556	0.74	rs12716975	ENSG00000261588.1	AC002310.17	4.07	5.76e-05	0.0208	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30587662~30587920:-
STAD	cis	rs10129255	0.833	rs61997797	ENSG00000211973.2	IGHV1-69	4.07	5.76e-05	0.0208	0.2	0.21	Kawasaki disease;	chr14:106815190	chr14:106714684~106715181:-
STAD	cis	rs3770081	1	rs2118521	ENSG00000273080.1	RP11-301O19.1	-4.07	5.76e-05	0.0208	-0.47	-0.21	Facial emotion recognition (sad faces);	chr2:85977256	chr2:86195590~86196049:+
STAD	cis	rs4141404	0.737	rs5998067	ENSG00000236132.1	CTA-440B3.1	4.07	5.76e-05	0.0208	0.23	0.21	Paclitaxel-induced neuropathy;	chr22:31647644	chr22:31816379~31817491:-
STAD	cis	rs4713118	0.868	rs9468220	ENSG00000243307.2	POM121L6P	4.07	5.76e-05	0.0208	0.26	0.21	Parkinson's disease;	chr6:27765197	chr6:26896952~26898777:+
STAD	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-4.07	5.76e-05	0.0208	-0.22	-0.21	Height;	chr2:46609300	chr2:46668870~46670778:+
STAD	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	4.07	5.76e-05	0.0208	0.29	0.21	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
STAD	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-4.07	5.76e-05	0.0208	-0.24	-0.21	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
STAD	cis	rs9393777	0.513	rs13195210	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26646293	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9368447	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26646446	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9393739	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26646738	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9368448	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26649127	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs3999471	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26650078	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9368450	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26652261	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9393741	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26653961	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9379907	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26654090	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9368451	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26654105	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs13210025	ENSG00000224843.5	LINC00240	4.07	5.76e-05	0.0208	0.31	0.21	Intelligence (multi-trait analysis);	chr6:26654589	chr6:26956992~27023924:+
STAD	cis	rs9463078	0.715	rs9463076	ENSG00000219384.1	RP11-491H9.3	-4.07	5.76e-05	0.0208	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45203625	chr6:45158870~45159511:+
STAD	cis	rs9291683	0.609	rs36084205	ENSG00000250613.1	RP11-136I13.1	-4.07	5.77e-05	0.0208	-0.2	-0.21	Bone mineral density;	chr4:10027054	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.609	rs13141233	ENSG00000250613.1	RP11-136I13.1	-4.07	5.77e-05	0.0208	-0.2	-0.21	Bone mineral density;	chr4:10027105	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.609	rs34709913	ENSG00000250613.1	RP11-136I13.1	-4.07	5.77e-05	0.0208	-0.2	-0.21	Bone mineral density;	chr4:10027331	chr4:10410996~10411644:+
STAD	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-4.07	5.77e-05	0.0208	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
STAD	cis	rs11098499	0.874	rs6851169	ENSG00000260091.1	RP11-33B1.4	4.07	5.77e-05	0.0208	0.21	0.21	Corneal astigmatism;	chr4:119196355	chr4:119409333~119410233:+
STAD	cis	rs528301	0.613	rs4953143	ENSG00000259439.2	RP11-89K21.1	-4.07	5.77e-05	0.0208	-0.29	-0.21	Alcohol and nicotine co-dependence;	chr2:44897152	chr2:44921077~44939199:-
STAD	cis	rs9733	0.596	rs7418501	ENSG00000274963.1	Metazoa_SRP	4.07	5.77e-05	0.0208	0.19	0.21	Tonsillectomy;	chr1:150739420	chr1:150568971~150569269:-
STAD	cis	rs11098499	0.644	rs3986377	ENSG00000260091.1	RP11-33B1.4	4.07	5.77e-05	0.0208	0.2	0.21	Corneal astigmatism;	chr4:119339115	chr4:119409333~119410233:+
STAD	cis	rs10028773	0.556	rs4473640	ENSG00000260091.1	RP11-33B1.4	4.07	5.77e-05	0.0208	0.2	0.21	Educational attainment;	chr4:119339282	chr4:119409333~119410233:+
STAD	cis	rs2739330	0.828	rs2186366	ENSG00000272787.1	KB-226F1.2	4.07	5.77e-05	0.0208	0.22	0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23969211~23969873:+
STAD	cis	rs1876905	0.68	rs373526	ENSG00000271789.1	RP5-1112D6.7	4.07	5.77e-05	0.0208	0.25	0.21	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111297126~111298510:+
STAD	cis	rs4699052	0.537	rs1580278	ENSG00000246560.2	RP11-10L12.4	-4.07	5.77e-05	0.0208	-0.25	-0.21	Testicular germ cell tumor;	chr4:103219691	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	4.07	5.78e-05	0.0208	0.25	0.21	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
STAD	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	4.07	5.78e-05	0.0208	0.22	0.21	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
STAD	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	4.07	5.78e-05	0.0209	0.34	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
STAD	cis	rs9788721	0.9	rs4243084	ENSG00000259419.2	HNRNPCP3	4.07	5.78e-05	0.0209	0.22	0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78619330	chr15:79236332~79237206:+
STAD	cis	rs6693567	0.565	rs834238	ENSG00000203819.6	HIST2H2BC	4.07	5.78e-05	0.0209	0.25	0.21	Migraine;	chr1:150393993	chr1:149850193~149850772:-
STAD	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-4.07	5.78e-05	0.0209	-0.24	-0.21	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
STAD	cis	rs11169552	0.51	rs10876058	ENSG00000200183.1	RNU6-238P	-4.07	5.79e-05	0.0209	-0.2	-0.21	Colorectal cancer;	chr12:50562483	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.51	rs4768852	ENSG00000200183.1	RNU6-238P	-4.07	5.79e-05	0.0209	-0.2	-0.21	Colorectal cancer;	chr12:50566506	chr12:50656973~50657078:+
STAD	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-4.07	5.79e-05	0.0209	-0.26	-0.21	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
STAD	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-4.07	5.79e-05	0.0209	-0.28	-0.21	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
STAD	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-4.07	5.79e-05	0.0209	-0.25	-0.21	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-4.07	5.79e-05	0.0209	-0.25	-0.21	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
STAD	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	4.07	5.79e-05	0.0209	0.21	0.21	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
STAD	cis	rs7655841	0.704	rs3113490	ENSG00000248187.1	RP11-184M15.1	-4.07	5.79e-05	0.0209	-0.32	-0.21	Chronic obstructive pulmonary disease (moderate to severe);	chr4:129044516	chr4:128567972~128570531:-
STAD	cis	rs9463078	0.647	rs6933449	ENSG00000219384.1	RP11-491H9.3	-4.07	5.79e-05	0.0209	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45357414	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.691	rs12194311	ENSG00000219384.1	RP11-491H9.3	-4.07	5.79e-05	0.0209	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45361311	chr6:45158870~45159511:+
STAD	cis	rs34779708	0.931	rs35126129	ENSG00000271335.4	RP11-324I22.4	4.07	5.8e-05	0.0209	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35314552~35336401:-
STAD	cis	rs7567389	0.583	rs11683427	ENSG00000200250.1	RNU6-1147P	-4.07	5.8e-05	0.0209	-0.23	-0.21	Self-rated health;	chr2:127198967	chr2:127316873~127316979:+
STAD	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	4.07	5.8e-05	0.0209	0.3	0.21	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
STAD	cis	rs7924176	0.601	rs10824071	ENSG00000213731.2	RAB5CP1	-4.07	5.8e-05	0.0209	-0.21	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74423435~74424014:-
STAD	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	4.07	5.8e-05	0.0209	0.48	0.21	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
STAD	cis	rs73193808	1	rs2832228	ENSG00000273017.1	AP000240.9	4.07	5.8e-05	0.0209	0.24	0.21	Coronary artery disease;	chr21:29162364	chr21:29359002~29359453:+
STAD	cis	rs73193808	1	rs73193808	ENSG00000273017.1	AP000240.9	4.07	5.8e-05	0.0209	0.24	0.21	Coronary artery disease;	chr21:29162981	chr21:29359002~29359453:+
STAD	cis	rs875971	0.545	rs6979636	ENSG00000273142.1	RP11-458F8.4	4.07	5.8e-05	0.0209	0.2	0.21	Aortic root size;	chr7:66276638	chr7:66902857~66906297:+
STAD	cis	rs9291683	0.551	rs2276961	ENSG00000250613.1	RP11-136I13.1	-4.07	5.8e-05	0.0209	-0.2	-0.21	Bone mineral density;	chr4:10021357	chr4:10410996~10411644:+
STAD	cis	rs73186030	0.764	rs17251221	ENSG00000272758.4	RP11-299J3.8	4.07	5.8e-05	0.0209	0.33	0.21	Serum parathyroid hormone levels;	chr3:122274400	chr3:122416207~122443180:+
STAD	cis	rs4713118	0.869	rs9366700	ENSG00000243307.2	POM121L6P	-4.07	5.81e-05	0.0209	-0.25	-0.21	Parkinson's disease;	chr6:27729172	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs6456802	ENSG00000243307.2	POM121L6P	-4.07	5.81e-05	0.0209	-0.25	-0.21	Parkinson's disease;	chr6:27730576	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9393851	ENSG00000243307.2	POM121L6P	-4.07	5.81e-05	0.0209	-0.25	-0.21	Parkinson's disease;	chr6:27731802	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9461400	ENSG00000243307.2	POM121L6P	-4.07	5.81e-05	0.0209	-0.25	-0.21	Parkinson's disease;	chr6:27732780	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9295742	ENSG00000243307.2	POM121L6P	-4.07	5.81e-05	0.0209	-0.25	-0.21	Parkinson's disease;	chr6:27735053	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.869	rs9461401	ENSG00000243307.2	POM121L6P	-4.07	5.81e-05	0.0209	-0.25	-0.21	Parkinson's disease;	chr6:27735512	chr6:26896952~26898777:+
STAD	cis	rs34779708	0.931	rs2490663	ENSG00000271335.4	RP11-324I22.4	-4.07	5.81e-05	0.0209	-0.26	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35314552~35336401:-
STAD	cis	rs7131987	0.834	rs1989478	ENSG00000257176.2	RP11-996F15.2	-4.07	5.81e-05	0.0209	-0.24	-0.21	QT interval;	chr12:29289296	chr12:29280418~29317848:-
STAD	cis	rs1823874	0.71	rs2902472	ENSG00000182397.13	DNM1P46	-4.07	5.81e-05	0.0209	-0.23	-0.21	IgG glycosylation;	chr15:99824257	chr15:99790156~99806927:-
STAD	cis	rs7829975	0.501	rs4840353	ENSG00000253981.4	ALG1L13P	-4.07	5.81e-05	0.0209	-0.28	-0.21	Mood instability;	chr8:8723060	chr8:8236003~8244667:-
STAD	cis	rs7901056	0.811	rs3006772	ENSG00000251839.1	RNU7-12P	-4.07	5.81e-05	0.0209	-0.2	-0.21	Lymphocyte counts;	chr10:26409728	chr10:27232255~27232316:-
STAD	cis	rs2115630	1	rs7183401	ENSG00000256278.1	RP11-182J1.5	-4.07	5.81e-05	0.0209	-0.2	-0.21	P wave terminal force;	chr15:84828713	chr15:84611689~84614969:-
STAD	cis	rs2221894	0.553	rs7002739	ENSG00000273710.1	Metazoa_SRP	-4.07	5.81e-05	0.0209	-0.22	-0.21	Obesity-related traits;	chr8:29009929	chr8:28915579~28915864:-
STAD	cis	rs7202877	0.519	rs3743606	ENSG00000261783.1	RP11-252K23.2	-4.07	5.81e-05	0.0209	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75301576	chr16:75379818~75381260:-
STAD	cis	rs34779708	0.931	rs10508815	ENSG00000271335.4	RP11-324I22.4	4.07	5.81e-05	0.0209	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35314552~35336401:-
STAD	cis	rs3770081	1	rs7570836	ENSG00000273080.1	RP11-301O19.1	-4.07	5.81e-05	0.0209	-0.49	-0.21	Facial emotion recognition (sad faces);	chr2:85914310	chr2:86195590~86196049:+
STAD	cis	rs8062405	0.755	rs56272201	ENSG00000278665.1	RP11-666O2.4	4.07	5.81e-05	0.021	0.25	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.755	rs62034355	ENSG00000278665.1	RP11-666O2.4	4.07	5.81e-05	0.021	0.25	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28599241~28601881:-
STAD	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-4.07	5.82e-05	0.021	-0.34	-0.21	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
STAD	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	4.07	5.82e-05	0.021	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
STAD	cis	rs6585424	1	rs10466228	ENSG00000225484.5	NUTM2B-AS1	-4.07	5.82e-05	0.021	-0.37	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164617	chr10:79663088~79826594:-
STAD	cis	rs2957692	0.548	rs28731164	ENSG00000254554.1	RP11-351I24.1	4.07	5.82e-05	0.021	0.36	0.21	Circulating vasoactive peptide levels;	chr11:10095632	chr11:10302657~10303704:-
STAD	cis	rs73186030	0.844	rs73186015	ENSG00000272758.4	RP11-299J3.8	4.07	5.82e-05	0.021	0.33	0.21	Serum parathyroid hormone levels;	chr3:122272236	chr3:122416207~122443180:+
STAD	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-4.07	5.82e-05	0.021	-0.22	-0.21	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
STAD	cis	rs10851478	0.874	rs12910284	ENSG00000259545.2	RP11-325E5.4	-4.07	5.82e-05	0.021	-0.24	-0.21	Oral cavity cancer;	chr15:49493719	chr15:49177610~49178741:-
STAD	cis	rs198389	0.589	rs198401	ENSG00000242349.4	NPPA-AS1	-4.07	5.83e-05	0.021	-0.22	-0.21	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11828327	chr1:11841017~11848079:+
STAD	cis	rs4982731	1	rs4982731	ENSG00000279656.1	RP11-298I3.6	4.07	5.83e-05	0.021	0.22	0.21	Basophil percentage of granulocytes;Acute lymphoblastic leukemia (childhood);Basophil percentage of white cells;	chr14:23116124	chr14:23023083~23024217:-
STAD	cis	rs4834770	1	rs10034579	ENSG00000248280.1	RP11-33B1.2	4.07	5.83e-05	0.021	0.25	0.21	Blood protein levels;	chr4:119322874	chr4:119440561~119450157:-
STAD	cis	rs1816752	0.646	rs9507355	ENSG00000273628.1	RP11-756A22.7	4.07	5.83e-05	0.021	0.26	0.21	Obesity-related traits;	chr13:24476819	chr13:24933006~24936796:+
STAD	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	4.07	5.83e-05	0.021	0.37	0.21	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
STAD	cis	rs7680126	0.596	rs10022911	ENSG00000250613.1	RP11-136I13.1	4.07	5.84e-05	0.021	0.26	0.21	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10138927	chr4:10410996~10411644:+
STAD	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	4.07	5.84e-05	0.021	0.26	0.21	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	4.07	5.84e-05	0.021	0.26	0.21	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
STAD	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	4.07	5.84e-05	0.021	0.34	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
STAD	cis	rs7202877	0.61	rs10871307	ENSG00000261783.1	RP11-252K23.2	-4.07	5.84e-05	0.021	-0.34	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75301216	chr16:75379818~75381260:-
STAD	cis	rs7829975	0.686	rs907180	ENSG00000253981.4	ALG1L13P	4.07	5.84e-05	0.021	0.24	0.21	Mood instability;	chr8:8845317	chr8:8236003~8244667:-
STAD	cis	rs13421350	0.579	rs6741759	ENSG00000232788.1	AC078883.3	4.07	5.84e-05	0.021	0.38	0.21	Diabetic kidney disease;	chr2:172536395	chr2:172464262~172466022:-
STAD	cis	rs13421350	0.579	rs6730284	ENSG00000232788.1	AC078883.3	4.07	5.84e-05	0.021	0.38	0.21	Diabetic kidney disease;	chr2:172536938	chr2:172464262~172466022:-
STAD	cis	rs2562456	0.833	rs2968078	ENSG00000268119.4	CTD-2561J22.5	-4.07	5.84e-05	0.021	-0.27	-0.21	Pain;	chr19:21458942	chr19:21444241~21463908:-
STAD	cis	rs2115630	1	rs2879828	ENSG00000275120.1	RP11-182J1.17	-4.07	5.84e-05	0.021	-0.23	-0.21	P wave terminal force;	chr15:84818746	chr15:84599434~84606463:-
STAD	cis	rs11931598	0.511	rs4689576	ENSG00000170846.14	AC093323.3	4.07	5.84e-05	0.021	0.25	0.21	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7023796	chr4:6673451~6676047:+
STAD	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	4.07	5.84e-05	0.021	0.44	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
STAD	cis	rs8098244	0.737	rs1786297	ENSG00000267301.1	RPL23AP77	4.07	5.84e-05	0.021	0.3	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23958122	chr18:23709825~23710287:-
STAD	cis	rs7119038	0.818	rs77209083	ENSG00000255422.1	AP002954.4	4.07	5.84e-05	0.021	0.29	0.21	Sjögren's syndrome;	chr11:118736860	chr11:118704607~118750263:+
STAD	cis	rs4243830	0.737	rs11122083	ENSG00000229519.2	RP11-58A11.2	4.07	5.85e-05	0.021	0.24	0.21	Body mass index;	chr1:6533472	chr1:6547905~6548619:+
STAD	cis	rs1816752	0.837	rs9318530	ENSG00000232858.1	RPL34P27	-4.07	5.85e-05	0.021	-0.13	-0.21	Obesity-related traits;	chr13:24424419	chr13:24988577~24988925:-
STAD	cis	rs11603023	1	rs11603023	ENSG00000278376.1	RP11-158I9.8	-4.07	5.85e-05	0.021	-0.23	-0.21	Cholesterol, total;	chr11:118615352	chr11:118791254~118793137:+
STAD	cis	rs2143950	0.512	rs77772792	ENSG00000241052.1	RP11-173D9.1	-4.07	5.85e-05	0.021	-0.24	-0.21	Atopic dermatitis;	chr14:35050921	chr14:35144021~35144480:-
STAD	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	4.07	5.85e-05	0.021	0.27	0.21	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
STAD	cis	rs17772222	0.606	rs449338	ENSG00000258789.1	RP11-507K2.3	4.07	5.85e-05	0.0211	0.26	0.21	Coronary artery calcification;	chr14:88411690	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.675	rs845758	ENSG00000258789.1	RP11-507K2.3	4.07	5.85e-05	0.0211	0.26	0.21	Coronary artery calcification;	chr14:88433746	chr14:88551597~88552493:+
STAD	cis	rs7809950	0.817	rs2807	ENSG00000238832.1	snoU109	4.07	5.85e-05	0.0211	0.3	0.21	Coronary artery disease;	chr7:107620333	chr7:107603363~107603507:+
STAD	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-4.07	5.85e-05	0.0211	-0.25	-0.21	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
STAD	cis	rs17401966	0.931	rs912961	ENSG00000199562.1	RNU6-37P	4.07	5.85e-05	0.0211	0.17	0.21	Hepatocellular carcinoma;	chr1:10296790	chr1:10298966~10299072:+
STAD	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-4.07	5.85e-05	0.0211	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
STAD	cis	rs1816752	0.624	rs9553312	ENSG00000273628.1	RP11-756A22.7	-4.07	5.85e-05	0.0211	-0.26	-0.21	Obesity-related traits;	chr13:24474055	chr13:24933006~24936796:+
STAD	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	4.07	5.85e-05	0.0211	0.27	0.21	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
STAD	cis	rs6432860	0.868	rs568141	ENSG00000229195.1	AC009495.4	4.07	5.85e-05	0.0211	0.27	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166069511	chr2:165794857~165846091:-
STAD	cis	rs6432860	0.868	rs570504	ENSG00000229195.1	AC009495.4	4.07	5.85e-05	0.0211	0.27	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166074062	chr2:165794857~165846091:-
STAD	cis	rs7142881	0.76	rs34822969	ENSG00000258648.1	UBE2CP1	-4.07	5.86e-05	0.0211	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31646848	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.76	rs12184972	ENSG00000258648.1	UBE2CP1	-4.07	5.86e-05	0.0211	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31650153	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs3861472	ENSG00000258648.1	UBE2CP1	-4.07	5.86e-05	0.0211	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31650604	chr14:30683045~30683598:-
STAD	cis	rs61160187	0.582	rs3797559	ENSG00000215032.2	GNL3LP1	4.07	5.86e-05	0.0211	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60891935~60893577:-
STAD	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-4.07	5.86e-05	0.0211	-0.29	-0.21	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
STAD	cis	rs7680126	0.644	rs62288518	ENSG00000250613.1	RP11-136I13.1	4.07	5.86e-05	0.0211	0.26	0.21	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10085840	chr4:10410996~10411644:+
STAD	cis	rs870825	0.616	rs12498890	ENSG00000249173.4	LINC01093	4.07	5.86e-05	0.0211	0.35	0.21	Blood protein levels;	chr4:184714942	chr4:184893871~184899454:-
STAD	cis	rs4753788	0.534	rs7931436	ENSG00000261098.1	RP11-819C21.1	-4.07	5.86e-05	0.0211	-0.18	-0.21	Coronary artery disease;	chr11:107266386	chr11:107312132~107316271:-
STAD	cis	rs4753788	0.511	rs1388168	ENSG00000261098.1	RP11-819C21.1	-4.07	5.86e-05	0.0211	-0.18	-0.21	Coronary artery disease;	chr11:107267191	chr11:107312132~107316271:-
STAD	cis	rs359980	0.908	rs410778	ENSG00000224159.1	HMGB1P9	-4.07	5.86e-05	0.0211	-0.46	-0.21	Obesity-related traits;	chr2:218970211	chr2:218200434~218201388:+
STAD	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-4.07	5.86e-05	0.0211	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
STAD	cis	rs9902453	0.791	rs6505141	ENSG00000240074.1	RPL9P30	4.07	5.86e-05	0.0211	0.19	0.21	Coffee consumption (cups per day);	chr17:29671169	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.791	rs3098950	ENSG00000240074.1	RPL9P30	4.07	5.86e-05	0.0211	0.19	0.21	Coffee consumption (cups per day);	chr17:29671367	chr17:29855759~29856332:+
STAD	cis	rs10508774	0.925	rs12268816	ENSG00000273038.2	RP11-479G22.8	4.07	5.86e-05	0.0211	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32635614	chr10:32887255~32889311:-
STAD	cis	rs10129255	0.5	rs988132	ENSG00000232216.1	IGHV3-43	4.07	5.86e-05	0.0211	0.19	0.21	Kawasaki disease;	chr14:106776758	chr14:106470264~106470800:-
STAD	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-4.07	5.86e-05	0.0211	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-4.07	5.86e-05	0.0211	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-4.07	5.86e-05	0.0211	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-4.07	5.86e-05	0.0211	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
STAD	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-4.07	5.86e-05	0.0211	-0.33	-0.21	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
STAD	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	4.07	5.86e-05	0.0211	0.25	0.21	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
STAD	cis	rs875971	1	rs4718307	ENSG00000224316.1	RP11-479O9.2	-4.07	5.86e-05	0.0211	-0.21	-0.21	Aortic root size;	chr7:66146001	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs7801282	ENSG00000224316.1	RP11-479O9.2	-4.07	5.86e-05	0.0211	-0.21	-0.21	Aortic root size;	chr7:66148700	chr7:65773620~65802067:+
STAD	cis	rs2348418	0.832	rs1552760	ENSG00000247934.4	RP11-967K21.1	4.07	5.86e-05	0.0211	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28383884	chr12:28163298~28190738:-
STAD	cis	rs1799949	0.965	rs8070179	ENSG00000279602.1	CTD-3014M21.1	4.07	5.86e-05	0.0211	0.26	0.21	Menopause (age at onset);	chr17:43050671	chr17:43360041~43361361:-
STAD	cis	rs7119038	0.818	rs4936444	ENSG00000255422.1	AP002954.4	-4.07	5.87e-05	0.0211	-0.29	-0.21	Sjögren's syndrome;	chr11:118872629	chr11:118704607~118750263:+
STAD	cis	rs4835473	0.863	rs13146607	ENSG00000249741.2	RP11-673E1.3	4.07	5.87e-05	0.0211	0.25	0.21	Immature fraction of reticulocytes;	chr4:143687283	chr4:143911514~143912053:-
STAD	cis	rs1005277	0.577	rs4934906	ENSG00000099251.13	HSD17B7P2	4.07	5.87e-05	0.0211	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38356380~38378505:+
STAD	cis	rs12745968	0.624	rs6675753	ENSG00000229052.2	RP11-386I23.1	-4.07	5.87e-05	0.0211	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92750039	chr1:92930696~92934098:+
STAD	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	4.07	5.88e-05	0.0211	0.28	0.21	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
STAD	cis	rs3858145	0.588	rs10998059	ENSG00000234102.1	KRT19P4	4.07	5.88e-05	0.0211	0.24	0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68302750	chr10:68260557~68261499:+
STAD	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	4.07	5.88e-05	0.0211	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	4.07	5.88e-05	0.0211	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	4.07	5.88e-05	0.0211	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	4.07	5.88e-05	0.0211	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	4.07	5.88e-05	0.0211	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
STAD	cis	rs7074356	0.688	rs7898558	ENSG00000225484.5	NUTM2B-AS1	-4.07	5.88e-05	0.0211	-0.29	-0.21	Borderline personality disorder;	chr10:80423749	chr10:79663088~79826594:-
STAD	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	4.07	5.88e-05	0.0211	0.23	0.21	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	4.07	5.88e-05	0.0211	0.23	0.21	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
STAD	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	4.07	5.88e-05	0.0211	0.28	0.21	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
STAD	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	4.07	5.88e-05	0.0211	0.28	0.21	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
STAD	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	4.07	5.88e-05	0.0211	0.28	0.21	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
STAD	cis	rs7915414	0.531	rs12572373	ENSG00000230338.1	MTND4P19	4.07	5.88e-05	0.0211	0.26	0.21	Clopidogrel active metabolite levels;	chr10:94967795	chr10:94774156~94774633:-
STAD	cis	rs2303282	0.506	rs600390	ENSG00000274031.1	RP11-413H22.3	4.07	5.88e-05	0.0211	0.24	0.21	Breast cancer;	chr16:56535016	chr16:56465642~56466162:-
STAD	cis	rs8177876	0.749	rs58144189	ENSG00000261838.4	RP11-303E16.6	4.07	5.88e-05	0.0211	0.47	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81069854~81076598:+
STAD	cis	rs728616	0.51	rs7074356	ENSG00000225484.5	NUTM2B-AS1	-4.07	5.88e-05	0.0211	-0.34	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80431578	chr10:79663088~79826594:-
STAD	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	4.07	5.88e-05	0.0212	0.24	0.21	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
STAD	cis	rs11157436	0.602	rs4982569	ENSG00000211813.2	TRAV34	4.07	5.88e-05	0.0212	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22207522~22208129:+
STAD	cis	rs11673344	0.543	rs1818748	ENSG00000267672.1	CTD-2293H3.1	4.07	5.88e-05	0.0212	0.2	0.21	Obesity-related traits;	chr19:37065416	chr19:37091341~37092564:+
STAD	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	4.07	5.88e-05	0.0212	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
STAD	cis	rs12745968	0.619	rs10874738	ENSG00000229052.2	RP11-386I23.1	-4.07	5.89e-05	0.0212	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92758662	chr1:92930696~92934098:+
STAD	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	4.07	5.89e-05	0.0212	0.24	0.21	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
STAD	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	4.07	5.89e-05	0.0212	0.24	0.21	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
STAD	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	4.07	5.89e-05	0.0212	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
STAD	cis	rs919433	0.889	rs788004	ENSG00000231621.1	AC013264.2	-4.07	5.89e-05	0.0212	-0.18	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197354308	chr2:197197991~197199273:+
STAD	cis	rs6180	1	rs2910869	ENSG00000250860.1	CTD-2265D6.2	4.07	5.89e-05	0.0212	0.18	0.21	Height;	chr5:42741744	chr5:42466893~42468300:-
STAD	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	-4.07	5.89e-05	0.0212	-0.24	-0.21	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
STAD	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	4.07	5.9e-05	0.0212	0.21	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
STAD	cis	rs516805	0.528	rs2816085	ENSG00000279453.1	RP3-425C14.4	-4.07	5.9e-05	0.0212	-0.31	-0.21	Lymphocyte counts;	chr6:122097324	chr6:122436789~122439223:-
STAD	cis	rs9902453	0.874	rs3936006	ENSG00000240074.1	RPL9P30	4.07	5.9e-05	0.0212	0.19	0.21	Coffee consumption (cups per day);	chr17:29930642	chr17:29855759~29856332:+
STAD	cis	rs10971721	0.822	rs72727362	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:33957324	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72727367	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:33965180	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971826	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:33972035	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971827	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:33972469	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971838	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:33997948	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72729316	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:34008175	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971850	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:34013910	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.731	rs10814061	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:34014032	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs12380173	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:34018500	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs12377970	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:34021269	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.731	rs10971857	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:34021621	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.908	rs10971858	ENSG00000281128.1	PTENP1-AS	4.07	5.9e-05	0.0212	0.32	0.21	Body mass index;	chr9:34023693	chr9:33677268~33688011:+
STAD	cis	rs4834770	1	rs4834770	ENSG00000249244.1	RP11-548H18.2	4.07	5.9e-05	0.0212	0.27	0.21	Blood protein levels;	chr4:119320694	chr4:119391831~119395335:-
STAD	cis	rs4834770	1	rs6823963	ENSG00000249244.1	RP11-548H18.2	4.07	5.9e-05	0.0212	0.27	0.21	Blood protein levels;	chr4:119321009	chr4:119391831~119395335:-
STAD	cis	rs4834770	1	rs4834771	ENSG00000249244.1	RP11-548H18.2	4.07	5.9e-05	0.0212	0.27	0.21	Blood protein levels;	chr4:119321617	chr4:119391831~119395335:-
STAD	cis	rs4834770	1	rs1397613	ENSG00000249244.1	RP11-548H18.2	4.07	5.9e-05	0.0212	0.27	0.21	Blood protein levels;	chr4:119321774	chr4:119391831~119395335:-
STAD	cis	rs4834770	1	rs6857641	ENSG00000249244.1	RP11-548H18.2	4.07	5.9e-05	0.0212	0.27	0.21	Blood protein levels;	chr4:119322356	chr4:119391831~119395335:-
STAD	cis	rs4834770	1	rs2282688	ENSG00000249244.1	RP11-548H18.2	4.07	5.9e-05	0.0212	0.27	0.21	Blood protein levels;	chr4:119322567	chr4:119391831~119395335:-
STAD	cis	rs7202877	0.656	rs9923834	ENSG00000261783.1	RP11-252K23.2	-4.07	5.9e-05	0.0212	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75473355	chr16:75379818~75381260:-
STAD	cis	rs7202877	0.706	rs37605	ENSG00000261783.1	RP11-252K23.2	4.07	5.9e-05	0.0212	0.35	0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75472674	chr16:75379818~75381260:-
STAD	cis	rs7487075	0.808	rs10880961	ENSG00000257261.4	RP11-96H19.1	4.07	5.9e-05	0.0212	0.28	0.21	Itch intensity from mosquito bite;	chr12:46371445	chr12:46383679~46876159:+
STAD	cis	rs7474896	1	rs11492508	ENSG00000099251.13	HSD17B7P2	4.07	5.9e-05	0.0212	0.35	0.21	Obesity (extreme);	chr10:37809208	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2891586	ENSG00000099251.13	HSD17B7P2	4.07	5.9e-05	0.0212	0.35	0.21	Obesity (extreme);	chr10:37812715	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs10827829	ENSG00000099251.13	HSD17B7P2	4.07	5.9e-05	0.0212	0.35	0.21	Obesity (extreme);	chr10:37815354	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs11597286	ENSG00000099251.13	HSD17B7P2	4.07	5.9e-05	0.0212	0.35	0.21	Obesity (extreme);	chr10:37817527	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9418288	ENSG00000099251.13	HSD17B7P2	4.07	5.9e-05	0.0212	0.35	0.21	Obesity (extreme);	chr10:37818208	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9418289	ENSG00000099251.13	HSD17B7P2	4.07	5.9e-05	0.0212	0.35	0.21	Obesity (extreme);	chr10:37820877	chr10:38356380~38378505:+
STAD	cis	rs17801127	0.818	rs9679510	ENSG00000231969.1	AC144449.1	4.07	5.9e-05	0.0212	0.46	0.21	Liver enzyme levels (alanine transaminase);	chr2:149844964	chr2:149587196~149848233:+
STAD	cis	rs11638815	0.626	rs4779041	ENSG00000255769.6	GOLGA2P10	4.07	5.9e-05	0.0212	0.25	0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82668307	chr15:82472993~82513950:-
STAD	cis	rs728616	0.614	rs59806247	ENSG00000225484.5	NUTM2B-AS1	-4.07	5.9e-05	0.0212	-0.35	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80338218	chr10:79663088~79826594:-
STAD	cis	rs7139978	0.539	rs9547906	ENSG00000230390.1	LINC01048	-4.07	5.9e-05	0.0212	-0.24	-0.21	Life satisfaction;	chr13:37495405	chr13:37481467~37484769:-
STAD	cis	rs7139978	0.539	rs9547907	ENSG00000230390.1	LINC01048	-4.07	5.9e-05	0.0212	-0.24	-0.21	Life satisfaction;	chr13:37495413	chr13:37481467~37484769:-
STAD	cis	rs41264869	0.891	rs2305278	ENSG00000280924.1	LINC00628	4.07	5.91e-05	0.0212	0.31	0.21	Blood protein levels;	chr1:205059453	chr1:204368431~204369719:-
STAD	cis	rs2115630	1	rs58581703	ENSG00000275120.1	RP11-182J1.17	-4.07	5.91e-05	0.0212	-0.23	-0.21	P wave terminal force;	chr15:84733704	chr15:84599434~84606463:-
STAD	cis	rs2638953	0.853	rs10843195	ENSG00000247934.4	RP11-967K21.1	-4.07	5.91e-05	0.0212	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513633	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs10843196	ENSG00000247934.4	RP11-967K21.1	-4.07	5.91e-05	0.0212	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513660	chr12:28163298~28190738:-
STAD	cis	rs6813195	0.881	rs7669833	ENSG00000243417.1	RP11-555K12.1	-4.07	5.91e-05	0.0212	-0.21	-0.21	Type 2 diabetes;	chr4:152592217	chr4:152551277~152552364:-
STAD	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	4.07	5.91e-05	0.0212	0.21	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
STAD	cis	rs9860428	0.565	rs9875551	ENSG00000240057.4	RP11-572M11.4	4.07	5.91e-05	0.0212	0.2	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112860542	chr3:113019532~113183301:+
STAD	cis	rs6772849	0.775	rs12486377	ENSG00000242551.2	POU5F1P6	-4.07	5.91e-05	0.0212	-0.22	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128674735~128677005:-
STAD	cis	rs328506	1	rs328506	ENSG00000231005.1	RP3-481F12.1	4.07	5.91e-05	0.0212	0.22	0.21	Type 2 diabetes;	chr20:57454548	chr20:57328546~57328696:+
STAD	cis	rs2245368	0.523	rs67814714	ENSG00000205482.8	AC007000.12	-4.07	5.91e-05	0.0212	-0.23	-0.21	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;	chr7:76888105	chr7:77052785~77059440:-
STAD	cis	rs7829975	0.511	rs2980426	ENSG00000254340.1	RP11-10A14.3	4.07	5.92e-05	0.0212	0.25	0.21	Mood instability;	chr8:8288087	chr8:9141424~9145435:+
STAD	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	4.07	5.92e-05	0.0212	0.28	0.21	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
STAD	cis	rs7829975	0.501	rs74345345	ENSG00000253981.4	ALG1L13P	-4.07	5.92e-05	0.0212	-0.29	-0.21	Mood instability;	chr8:8720925	chr8:8236003~8244667:-
STAD	cis	rs7829975	0.777	rs6989926	ENSG00000173295.6	FAM86B3P	-4.07	5.92e-05	0.0212	-0.26	-0.21	Mood instability;	chr8:8689803	chr8:8228595~8244865:+
STAD	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	4.07	5.92e-05	0.0213	0.42	0.21	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
STAD	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-4.07	5.92e-05	0.0213	-0.21	-0.21	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
STAD	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-4.07	5.92e-05	0.0213	-0.23	-0.21	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
STAD	cis	rs4407350	0.756	rs131154	ENSG00000279642.1	RP5-1033E15.3	-4.07	5.92e-05	0.0213	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44494965	chr22:44486295~44486914:-
STAD	cis	rs9368481	0.761	rs4713062	ENSG00000224843.5	LINC00240	4.07	5.92e-05	0.0213	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26956992~27023924:+
STAD	cis	rs8028182	0.636	rs11637068	ENSG00000260269.4	CTD-2323K18.1	-4.07	5.93e-05	0.0213	-0.27	-0.21	Sudden cardiac arrest;	chr15:75450661	chr15:75527150~75601205:-
STAD	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-4.07	5.93e-05	0.0213	-0.26	-0.21	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
STAD	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	4.07	5.93e-05	0.0213	0.26	0.21	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
STAD	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	4.07	5.93e-05	0.0213	0.26	0.21	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
STAD	cis	rs2921073	0.51	rs2976945	ENSG00000254340.1	RP11-10A14.3	4.07	5.93e-05	0.0213	0.25	0.21	Parkinson's disease;	chr8:8413361	chr8:9141424~9145435:+
STAD	cis	rs9902453	0.904	rs12939344	ENSG00000240074.1	RPL9P30	-4.07	5.93e-05	0.0213	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30001801	chr17:29855759~29856332:+
STAD	cis	rs10129255	0.957	rs67625077	ENSG00000232216.1	IGHV3-43	4.07	5.93e-05	0.0213	0.22	0.21	Kawasaki disease;	chr14:106715436	chr14:106470264~106470800:-
STAD	cis	rs9463078	0.691	rs17288278	ENSG00000219384.1	RP11-491H9.3	-4.07	5.93e-05	0.0213	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45330745	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.691	rs10948229	ENSG00000219384.1	RP11-491H9.3	-4.07	5.93e-05	0.0213	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45338634	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.585	rs10456552	ENSG00000219384.1	RP11-491H9.3	-4.07	5.93e-05	0.0213	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45346215	chr6:45158870~45159511:+
STAD	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	4.07	5.93e-05	0.0213	0.26	0.21	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
STAD	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	4.07	5.93e-05	0.0213	0.21	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
STAD	cis	rs10129255	1	rs10141557	ENSG00000232216.1	IGHV3-43	4.07	5.93e-05	0.0213	0.22	0.21	Kawasaki disease;	chr14:106767990	chr14:106470264~106470800:-
STAD	cis	rs6840360	0.642	rs2709842	ENSG00000270265.1	RP11-731D1.4	4.07	5.93e-05	0.0213	0.25	0.21	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151333775~151353224:-
STAD	cis	rs6142102	0.961	rs4911146	ENSG00000264616.1	MIR4755	4.07	5.94e-05	0.0213	0.22	0.21	Skin pigmentation;	chr20:34052241	chr20:34049119~34049190:+
STAD	cis	rs2836974	0.568	rs2142111	ENSG00000238141.2	BRWD1-AS1	4.07	5.94e-05	0.0213	0.22	0.21	Cognitive function;	chr21:39177363	chr21:39315707~39323218:+
STAD	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	4.07	5.94e-05	0.0213	0.21	0.21	Height;	chr2:46624894	chr2:46668870~46670778:+
STAD	cis	rs748404	0.578	rs2278856	ENSG00000275601.1	AC011330.13	-4.07	5.94e-05	0.0213	-0.22	-0.21	Lung cancer;	chr15:43339158	chr15:43642389~43643023:-
STAD	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-4.07	5.94e-05	0.0213	-0.25	-0.21	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-4.07	5.94e-05	0.0213	-0.25	-0.21	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-4.07	5.94e-05	0.0213	-0.25	-0.21	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
STAD	cis	rs8140097	0.566	rs5992428	ENSG00000237347.2	AC004461.4	-4.07	5.94e-05	0.0213	-0.35	-0.21	Recurrent major depressive disorder;	chr22:19575824	chr22:19055801~19056512:+
STAD	cis	rs7474896	0.515	rs2749582	ENSG00000120555.12	SEPT7P9	-4.07	5.95e-05	0.0213	-0.26	-0.21	Obesity (extreme);	chr10:37986356	chr10:38383069~38402916:-
STAD	cis	rs77956314	0.901	rs117425351	ENSG00000274554.1	RP11-240G22.5	4.07	5.95e-05	0.0213	0.37	0.21	Hippocampal volume;Subcortical brain region volumes;	chr12:116971947	chr12:116948738~116951422:-
STAD	cis	rs12682352	0.715	rs332039	ENSG00000233609.3	RP11-62H7.2	4.07	5.95e-05	0.0213	0.24	0.21	Neuroticism;	chr8:8866141	chr8:8961200~8979025:+
STAD	cis	rs2638953	0.962	rs12370271	ENSG00000247934.4	RP11-967K21.1	-4.07	5.95e-05	0.0213	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313840	chr12:28163298~28190738:-
STAD	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-4.07	5.95e-05	0.0213	-0.26	-0.21	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
STAD	cis	rs13412757	0.739	rs28376924	ENSG00000236790.4	LINC00299	-4.07	5.95e-05	0.0213	-0.24	-0.21	Asthma;Itch intensity from mosquito bite adjusted by bite size;	chr2:8332634	chr2:8007771~8383621:-
STAD	cis	rs2446066	0.524	rs7315185	ENSG00000257379.1	RP11-793H13.8	4.07	5.95e-05	0.0213	0.43	0.21	Red blood cell count;	chr12:53530575	chr12:53441741~53467528:+
STAD	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	4.06	5.95e-05	0.0213	0.26	0.21	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
STAD	cis	rs806321	0.755	rs1965800	ENSG00000237152.3	DLEU7-AS1	-4.06	5.95e-05	0.0213	-0.24	-0.21	Multiple sclerosis;	chr13:50210599	chr13:50807856~50849905:+
STAD	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	4.06	5.95e-05	0.0214	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	4.06	5.95e-05	0.0214	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
STAD	cis	rs7916697	0.52	rs12246624	ENSG00000234102.1	KRT19P4	-4.06	5.95e-05	0.0214	-0.23	-0.21	Optic disc area;	chr10:68276805	chr10:68260557~68261499:+
STAD	cis	rs7916697	0.52	rs12265247	ENSG00000234102.1	KRT19P4	-4.06	5.95e-05	0.0214	-0.23	-0.21	Optic disc area;	chr10:68278641	chr10:68260557~68261499:+
STAD	cis	rs950169	0.922	rs4338765	ENSG00000235370.6	DNM1P51	4.06	5.95e-05	0.0214	0.27	0.21	Schizophrenia;	chr15:84248084	chr15:84398316~84411701:-
STAD	cis	rs10500715	0.517	rs12421200	ENSG00000254554.1	RP11-351I24.1	4.06	5.95e-05	0.0214	0.35	0.21	Pancreatic cancer;	chr11:9966459	chr11:10302657~10303704:-
STAD	cis	rs2310173	0.575	rs719248	ENSG00000281162.1	LINC01127	-4.06	5.95e-05	0.0214	-0.27	-0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102007413	chr2:101962056~101987167:+
STAD	cis	rs1005277	0.579	rs2474568	ENSG00000276805.1	RP11-291L22.6	4.06	5.96e-05	0.0214	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38451030~38451785:+
STAD	cis	rs1348850	0.567	rs4144276	ENSG00000271825.1	RP11-337N6.2	4.06	5.96e-05	0.0214	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658692	chr2:177300600~177302006:+
STAD	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-4.06	5.96e-05	0.0214	-0.25	-0.21	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
STAD	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	4.06	5.96e-05	0.0214	0.22	0.21	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
STAD	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	4.06	5.96e-05	0.0214	0.22	0.21	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
STAD	cis	rs10986311	0.681	rs10986291	ENSG00000227200.1	RP11-121A14.3	-4.06	5.96e-05	0.0214	-0.24	-0.21	Vitiligo;	chr9:124253992	chr9:124262876~124265809:+
STAD	cis	rs2262909	1	rs765527	ENSG00000279377.1	AC003973.3	-4.06	5.96e-05	0.0214	-0.21	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21946753	chr19:21965708~21968529:-
STAD	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	4.06	5.97e-05	0.0214	0.44	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
STAD	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-4.06	5.97e-05	0.0214	-0.39	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-4.06	5.97e-05	0.0214	-0.39	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-4.06	5.97e-05	0.0214	-0.39	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
STAD	cis	rs6421571	0.565	rs10892263	ENSG00000255422.1	AP002954.4	4.06	5.98e-05	0.0214	0.28	0.21	Primary biliary cholangitis;	chr11:118716610	chr11:118704607~118750263:+
STAD	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-4.06	5.98e-05	0.0214	-0.26	-0.21	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
STAD	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	4.06	5.98e-05	0.0214	0.36	0.21	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
STAD	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	4.06	5.98e-05	0.0214	0.36	0.21	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
STAD	cis	rs57024841	0.562	rs7862602	ENSG00000270259.2	RP13-122B23.9	4.06	5.98e-05	0.0214	0.23	0.21	Beta-trace protein levels;	chr9:136946019	chr9:137286112~137287236:+
STAD	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	4.06	5.98e-05	0.0214	0.27	0.21	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
STAD	cis	rs2657294	0.62	rs4746261	ENSG00000233313.2	HMGA1P5	4.06	5.98e-05	0.0214	0.26	0.21	Pneumonia;	chr10:75085874	chr10:75276376~75276646:-
STAD	cis	rs4407350	0.87	rs131172	ENSG00000279642.1	RP5-1033E15.3	-4.06	5.98e-05	0.0214	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44506879	chr22:44486295~44486914:-
STAD	cis	rs7829975	0.56	rs17154599	ENSG00000253981.4	ALG1L13P	-4.06	5.98e-05	0.0214	-0.28	-0.21	Mood instability;	chr8:8693908	chr8:8236003~8244667:-
STAD	cis	rs7474896	0.537	rs2749586	ENSG00000120555.12	SEPT7P9	-4.06	5.98e-05	0.0214	-0.26	-0.21	Obesity (extreme);	chr10:37981286	chr10:38383069~38402916:-
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000211959.2	IGHV4-39	4.06	5.98e-05	0.0214	0.19	0.21	Kawasaki disease;	chr14:106776442	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000211959.2	IGHV4-39	4.06	5.98e-05	0.0214	0.19	0.21	Kawasaki disease;	chr14:106776448	chr14:106421711~106422218:-
STAD	cis	rs6539288	0.745	rs2041895	ENSG00000260329.1	RP11-412D9.4	-4.06	5.99e-05	0.0214	-0.23	-0.21	Total body bone mineral density;	chr12:106956310	chr12:106954029~106955497:-
STAD	cis	rs1816752	0.608	rs7326664	ENSG00000273628.1	RP11-756A22.7	-4.06	5.99e-05	0.0215	-0.26	-0.21	Obesity-related traits;	chr13:24475868	chr13:24933006~24936796:+
STAD	cis	rs34779708	0.966	rs113170867	ENSG00000271335.4	RP11-324I22.4	4.06	5.99e-05	0.0215	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35314552~35336401:-
STAD	cis	rs10129255	0.917	rs11625208	ENSG00000224373.3	IGHV4-59	4.06	5.99e-05	0.0215	0.17	0.21	Kawasaki disease;	chr14:106698757	chr14:106627249~106627825:-
STAD	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-4.06	5.99e-05	0.0215	-0.24	-0.21	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
STAD	cis	rs4835473	0.932	rs7697916	ENSG00000249741.2	RP11-673E1.3	4.06	5.99e-05	0.0215	0.25	0.21	Immature fraction of reticulocytes;	chr4:143765628	chr4:143911514~143912053:-
STAD	cis	rs875971	0.825	rs6951503	ENSG00000224316.1	RP11-479O9.2	-4.06	5.99e-05	0.0215	-0.21	-0.21	Aortic root size;	chr7:66253949	chr7:65773620~65802067:+
STAD	cis	rs11673344	0.542	rs2562585	ENSG00000267672.1	CTD-2293H3.1	4.06	5.99e-05	0.0215	0.2	0.21	Obesity-related traits;	chr19:37018321	chr19:37091341~37092564:+
STAD	cis	rs34779708	0.931	rs35388511	ENSG00000271335.4	RP11-324I22.4	4.06	5.99e-05	0.0215	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs34815241	ENSG00000271335.4	RP11-324I22.4	4.06	5.99e-05	0.0215	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35314552~35336401:-
STAD	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-4.06	5.99e-05	0.0215	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
STAD	cis	rs870825	0.616	rs4444872	ENSG00000249173.4	LINC01093	-4.06	6e-05	0.0215	-0.35	-0.21	Blood protein levels;	chr4:184707251	chr4:184893871~184899454:-
STAD	cis	rs494453	0.922	rs552802	ENSG00000234020.1	CHIAP3	-4.06	6e-05	0.0215	-0.22	-0.21	Osteoporosis-related phenotypes;	chr1:111715923	chr1:111353275~111367409:-
STAD	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-4.06	6e-05	0.0215	-0.28	-0.21	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
STAD	cis	rs1799949	1	rs2175957	ENSG00000279602.1	CTD-3014M21.1	4.06	6e-05	0.0215	0.27	0.21	Menopause (age at onset);	chr17:43134805	chr17:43360041~43361361:-
STAD	cis	rs1799949	0.965	rs33988650	ENSG00000279602.1	CTD-3014M21.1	4.06	6e-05	0.0215	0.27	0.21	Menopause (age at onset);	chr17:43135863	chr17:43360041~43361361:-
STAD	cis	rs4950322	0.58	rs4950371	ENSG00000278811.3	LINC00624	4.06	6.01e-05	0.0215	0.23	0.21	Protein quantitative trait loci;	chr1:147114243	chr1:147258885~147517875:-
STAD	cis	rs240993	0.516	rs465646	ENSG00000230177.1	RP5-1112D6.4	-4.06	6.01e-05	0.0215	-0.24	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:111277932~111278742:+
STAD	cis	rs1707322	1	rs4660332	ENSG00000281133.1	AL355480.3	-4.06	6.01e-05	0.0215	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45580892~45580996:-
STAD	cis	rs11971779	0.68	rs11768023	ENSG00000214815.2	AC008265.2	4.06	6.01e-05	0.0215	0.24	0.21	Diisocyanate-induced asthma;	chr7:139369649	chr7:138440690~138442238:+
STAD	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-4.06	6.01e-05	0.0215	-0.23	-0.21	Height;	chr2:231543307	chr2:231508426~231514339:-
STAD	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-4.06	6.01e-05	0.0215	-0.25	-0.21	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
STAD	cis	rs7202877	0.656	rs4887812	ENSG00000261783.1	RP11-252K23.2	-4.06	6.01e-05	0.0215	-0.36	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75276154	chr16:75379818~75381260:-
STAD	cis	rs2803122	0.967	rs10757040	ENSG00000272842.1	RP11-513M16.7	-4.06	6.01e-05	0.0215	-0.19	-0.21	Pulse pressure;	chr9:19241849	chr9:19371386~19371945:-
STAD	cis	rs2803122	0.934	rs2175378	ENSG00000272842.1	RP11-513M16.7	-4.06	6.01e-05	0.0215	-0.19	-0.21	Pulse pressure;	chr9:19241965	chr9:19371386~19371945:-
STAD	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	4.06	6.02e-05	0.0215	0.26	0.21	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
STAD	cis	rs792448	0.798	rs7521853	ENSG00000212044.2	AL360091.1	4.06	6.02e-05	0.0215	0.22	0.21	White blood cell count (basophil);	chr1:212330862	chr1:212349978~212350069:+
STAD	cis	rs17630293	1	rs68089021	ENSG00000201649.1	RNY4P34	-4.06	6.02e-05	0.0215	-0.32	-0.21	Schizophrenia;	chr2:200278066	chr2:200373175~200373269:+
STAD	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-4.06	6.02e-05	0.0215	-0.27	-0.21	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
STAD	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-4.06	6.02e-05	0.0215	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
STAD	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-4.06	6.02e-05	0.0215	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
STAD	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-4.06	6.02e-05	0.0215	-0.28	-0.21	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
STAD	cis	rs561341	1	rs56362439	ENSG00000265798.5	RP11-271K11.5	4.06	6.02e-05	0.0215	0.28	0.21	Hip circumference adjusted for BMI;	chr17:31926121	chr17:31038575~31059121:-
STAD	cis	rs6693567	0.565	rs8006	ENSG00000203819.6	HIST2H2BC	-4.06	6.02e-05	0.0215	-0.25	-0.21	Migraine;	chr1:150308367	chr1:149850193~149850772:-
STAD	cis	rs3754214	0.857	rs488271	ENSG00000203819.6	HIST2H2BC	-4.06	6.02e-05	0.0215	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr1:150312090	chr1:149850193~149850772:-
STAD	cis	rs867371	1	rs2088858	ENSG00000276710.3	CSPG4P8	-4.06	6.02e-05	0.0215	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82459472~82477258:+
STAD	cis	rs867371	1	rs4778982	ENSG00000276710.3	CSPG4P8	-4.06	6.02e-05	0.0215	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82459472~82477258:+
STAD	cis	rs867371	1	rs2867579	ENSG00000276710.3	CSPG4P8	-4.06	6.02e-05	0.0215	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82459472~82477258:+
STAD	cis	rs867371	1	rs881308	ENSG00000276710.3	CSPG4P8	-4.06	6.02e-05	0.0215	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82459472~82477258:+
STAD	cis	rs1707322	0.896	rs785512	ENSG00000281133.1	AL355480.3	4.06	6.02e-05	0.0216	0.25	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45580892~45580996:-
STAD	cis	rs67311347	0.544	rs2123998	ENSG00000280739.1	EIF1B-AS1	-4.06	6.02e-05	0.0216	-0.22	-0.21	Renal cell carcinoma;	chr3:40317514	chr3:40173145~40309698:-
STAD	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	4.06	6.02e-05	0.0216	0.26	0.21	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
STAD	cis	rs9561428	1	rs12585404	ENSG00000235784.2	HNRNPA1P29	4.06	6.02e-05	0.0216	0.45	0.21	Bipolar disorder and schizophrenia;	chr13:93660142	chr13:93394977~93395855:-
STAD	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	4.06	6.02e-05	0.0216	0.22	0.21	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
STAD	cis	rs1876905	0.539	rs240956	ENSG00000230177.1	RP5-1112D6.4	4.06	6.03e-05	0.0216	0.23	0.21	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111277932~111278742:+
STAD	cis	rs1707322	1	rs1707322	ENSG00000281133.1	AL355480.3	-4.06	6.03e-05	0.0216	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45580892~45580996:-
STAD	cis	rs4835473	0.669	rs56112476	ENSG00000249741.2	RP11-673E1.3	4.06	6.03e-05	0.0216	0.25	0.21	Immature fraction of reticulocytes;	chr4:143948716	chr4:143911514~143912053:-
STAD	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-4.06	6.03e-05	0.0216	-0.24	-0.21	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
STAD	cis	rs6693567	0.545	rs2275246	ENSG00000203819.6	HIST2H2BC	4.06	6.03e-05	0.0216	0.24	0.21	Migraine;	chr1:150487692	chr1:149850193~149850772:-
STAD	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	4.06	6.03e-05	0.0216	0.25	0.21	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
STAD	cis	rs12745968	0.62	rs6666831	ENSG00000229052.2	RP11-386I23.1	-4.06	6.03e-05	0.0216	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92757240	chr1:92930696~92934098:+
STAD	cis	rs10129255	0.556	rs8010005	ENSG00000211959.2	IGHV4-39	4.06	6.03e-05	0.0216	0.19	0.21	Kawasaki disease;	chr14:106777987	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.556	rs6576224	ENSG00000211959.2	IGHV4-39	4.06	6.03e-05	0.0216	0.19	0.21	Kawasaki disease;	chr14:106777997	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.518	rs8010020	ENSG00000211959.2	IGHV4-39	4.06	6.03e-05	0.0216	0.19	0.21	Kawasaki disease;	chr14:106778016	chr14:106421711~106422218:-
STAD	cis	rs8062405	1	rs9972693	ENSG00000278665.1	RP11-666O2.4	4.06	6.03e-05	0.0216	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.964	rs9972768	ENSG00000278665.1	RP11-666O2.4	4.06	6.03e-05	0.0216	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28599241~28601881:-
STAD	cis	rs8062405	0.965	rs62037363	ENSG00000278665.1	RP11-666O2.4	4.06	6.03e-05	0.0216	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs7205323	ENSG00000278665.1	RP11-666O2.4	4.06	6.03e-05	0.0216	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs4788101	ENSG00000278665.1	RP11-666O2.4	4.06	6.03e-05	0.0216	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62037364	ENSG00000278665.1	RP11-666O2.4	4.06	6.03e-05	0.0216	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28599241~28601881:-
STAD	cis	rs8062405	1	rs62037365	ENSG00000278665.1	RP11-666O2.4	4.06	6.03e-05	0.0216	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28599241~28601881:-
STAD	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-4.06	6.03e-05	0.0216	-0.36	-0.21	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
STAD	cis	rs716804	1	rs716804	ENSG00000254554.1	RP11-351I24.1	4.06	6.03e-05	0.0216	0.31	0.21	Neuroticism;	chr11:10225748	chr11:10302657~10303704:-
STAD	cis	rs6180	1	rs2910855	ENSG00000250860.1	CTD-2265D6.2	4.06	6.04e-05	0.0216	0.18	0.21	Height;	chr5:42782233	chr5:42466893~42468300:-
STAD	cis	rs7655841	0.732	rs3113407	ENSG00000248187.1	RP11-184M15.1	4.06	6.04e-05	0.0216	0.37	0.21	Chronic obstructive pulmonary disease (moderate to severe);	chr4:128905990	chr4:128567972~128570531:-
STAD	cis	rs13413635	0.955	rs72951087	ENSG00000225808.1	DNAJC19P5	-4.06	6.04e-05	0.0216	-0.28	-0.21	Heart rate;	chr2:177822727	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.955	rs72951090	ENSG00000225808.1	DNAJC19P5	-4.06	6.04e-05	0.0216	-0.28	-0.21	Heart rate;	chr2:177822728	chr2:177229191~177229506:-
STAD	cis	rs9634489	0.567	rs9516682	ENSG00000226977.1	HMGN1P24	4.06	6.04e-05	0.0216	0.22	0.21	Body mass index;	chr13:96399768	chr13:95809310~95809607:-
STAD	cis	rs749052	0.831	rs3100624	ENSG00000251485.1	AC068134.10	-4.06	6.04e-05	0.0216	-0.51	-0.21	Height;	chr2:232073873	chr2:232343116~232343903:+
STAD	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-4.06	6.04e-05	0.0216	-0.25	-0.21	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-4.06	6.04e-05	0.0216	-0.25	-0.21	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-4.06	6.04e-05	0.0216	-0.25	-0.21	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-4.06	6.04e-05	0.0216	-0.25	-0.21	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
STAD	cis	rs10938353	0.638	rs11732880	ENSG00000273369.1	RP11-700J17.1	-4.06	6.04e-05	0.0216	-0.25	-0.21	Body mass index;	chr4:44673497	chr4:44693946~44694386:-
STAD	cis	rs2348418	0.832	rs1907692	ENSG00000247934.4	RP11-967K21.1	4.06	6.04e-05	0.0216	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28385178	chr12:28163298~28190738:-
STAD	cis	rs2466029	0.732	rs1473581	ENSG00000254166.1	CASC19	-4.06	6.04e-05	0.0216	-0.3	-0.21	Chronic lymphocytic leukemia;	chr8:127191971	chr8:127185635~127203222:-
STAD	cis	rs12745968	0.569	rs7521752	ENSG00000229052.2	RP11-386I23.1	-4.06	6.04e-05	0.0216	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92551584	chr1:92930696~92934098:+
STAD	cis	rs451417	1	rs236110	ENSG00000275632.1	RP5-967N21.11	4.06	6.05e-05	0.0216	0.29	0.21	Menopause (age at onset);	chr20:5952462	chr20:6000418~6000941:+
STAD	cis	rs3811273	0.614	rs12589879	ENSG00000211816.2	TRAV38-1	-4.06	6.05e-05	0.0216	-0.27	-0.21	Periodontal disease-related phenotypes;	chr14:22266010	chr14:22271968~22272563:+
STAD	cis	rs8177876	0.749	rs58144189	ENSG00000261061.1	RP11-303E16.2	-4.06	6.05e-05	0.0216	-0.38	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81030770~81031485:+
STAD	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	4.06	6.05e-05	0.0216	0.4	0.21	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
STAD	cis	rs7665090	1	rs4586937	ENSG00000230069.3	LRRC37A15P	4.06	6.05e-05	0.0216	0.24	0.21	Primary biliary cholangitis;	chr4:102635305	chr4:102727274~102730721:-
STAD	cis	rs539514	0.69	rs4885345	ENSG00000261105.4	LMO7-AS1	-4.06	6.05e-05	0.0217	-0.25	-0.21	Type 1 diabetes;	chr13:75744317	chr13:75604700~75635994:-
STAD	cis	rs1395	0.744	rs1975384	ENSG00000234072.1	AC074117.10	-4.06	6.05e-05	0.0217	-0.2	-0.21	Blood metabolite levels;	chr2:27319174	chr2:27356246~27367622:+
STAD	cis	rs6693567	0.565	rs12093148	ENSG00000203819.6	HIST2H2BC	-4.06	6.06e-05	0.0217	-0.25	-0.21	Migraine;	chr1:150292753	chr1:149850193~149850772:-
STAD	cis	rs62025270	0.632	rs3169119	ENSG00000259295.5	CSPG4P12	-4.06	6.06e-05	0.0217	-0.37	-0.21	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85191438~85213905:+
STAD	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	4.06	6.06e-05	0.0217	0.25	0.21	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
STAD	cis	rs4535700	0.501	rs28678267	ENSG00000226278.1	PSPHP1	4.06	6.06e-05	0.0217	0.28	0.21	Macular telangiectasia type 2;	chr7:55941797	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.501	rs11765531	ENSG00000226278.1	PSPHP1	4.06	6.06e-05	0.0217	0.28	0.21	Macular telangiectasia type 2;	chr7:55942594	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.501	rs10227764	ENSG00000226278.1	PSPHP1	4.06	6.06e-05	0.0217	0.28	0.21	Macular telangiectasia type 2;	chr7:55944729	chr7:55764797~55773288:+
STAD	cis	rs4535700	0.501	rs60517461	ENSG00000226278.1	PSPHP1	4.06	6.06e-05	0.0217	0.28	0.21	Macular telangiectasia type 2;	chr7:55949952	chr7:55764797~55773288:+
STAD	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	4.06	6.06e-05	0.0217	0.29	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
STAD	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	4.06	6.06e-05	0.0217	0.29	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
STAD	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	4.06	6.06e-05	0.0217	0.29	0.21	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
STAD	cis	rs4698036	0.601	rs4698050	ENSG00000250613.1	RP11-136I13.1	4.06	6.06e-05	0.0217	0.24	0.21	Cardiovascular disease risk factors;	chr4:10409124	chr4:10410996~10411644:+
STAD	cis	rs9368481	0.7	rs6911401	ENSG00000224843.5	LINC00240	-4.06	6.06e-05	0.0217	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26956992~27023924:+
STAD	cis	rs6142102	0.812	rs6059578	ENSG00000264616.1	MIR4755	4.06	6.06e-05	0.0217	0.23	0.21	Skin pigmentation;	chr20:33939900	chr20:34049119~34049190:+
STAD	cis	rs11235843	0.706	rs12420099	ENSG00000255928.1	RP11-456I15.2	4.06	6.06e-05	0.0217	0.38	0.21	Hand grip strength;	chr11:73860796	chr11:73722349~73722694:+
STAD	cis	rs6142102	0.961	rs2235597	ENSG00000264616.1	MIR4755	4.06	6.06e-05	0.0217	0.22	0.21	Skin pigmentation;	chr20:34077808	chr20:34049119~34049190:+
STAD	cis	rs2638953	0.962	rs10843114	ENSG00000247934.4	RP11-967K21.1	-4.06	6.07e-05	0.0217	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28150363	chr12:28163298~28190738:-
STAD	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	4.06	6.07e-05	0.0217	0.29	0.21	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
STAD	cis	rs9902453	0.845	rs3115099	ENSG00000263477.1	RP11-338L22.2	4.06	6.07e-05	0.0217	0.18	0.21	Coffee consumption (cups per day);	chr17:29692275	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.845	rs58606097	ENSG00000263477.1	RP11-338L22.2	4.06	6.07e-05	0.0217	0.18	0.21	Coffee consumption (cups per day);	chr17:29693361	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.845	rs3102558	ENSG00000263477.1	RP11-338L22.2	4.06	6.07e-05	0.0217	0.18	0.21	Coffee consumption (cups per day);	chr17:29696124	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.845	rs2321331	ENSG00000263477.1	RP11-338L22.2	4.06	6.07e-05	0.0217	0.18	0.21	Coffee consumption (cups per day);	chr17:29698510	chr17:29863402~29866092:+
STAD	cis	rs8098244	0.708	rs1131521	ENSG00000267301.1	RPL23AP77	4.06	6.07e-05	0.0217	0.29	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23933804	chr18:23709825~23710287:-
STAD	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.06	6.08e-05	0.0217	0.22	0.21	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
STAD	cis	rs3002131	0.604	rs11485180	ENSG00000225265.1	TAF1A-AS1	-4.06	6.08e-05	0.0217	-0.32	-0.21	Interleukin-10 levels;	chr1:222563156	chr1:222589825~222593032:+
STAD	cis	rs8141529	0.702	rs469990	ENSG00000272858.1	CTA-292E10.8	-4.06	6.08e-05	0.0217	-0.23	-0.21	Lymphocyte counts;	chr22:28908212	chr22:28814914~28815662:+
STAD	cis	rs11169552	0.51	rs7956591	ENSG00000200183.1	RNU6-238P	-4.06	6.08e-05	0.0217	-0.2	-0.21	Colorectal cancer;	chr12:50555103	chr12:50656973~50657078:+
STAD	cis	rs9420	0.528	rs10896632	ENSG00000265566.2	RN7SL605P	-4.06	6.08e-05	0.0217	-0.31	-0.21	Schizophrenia;	chr11:57622829	chr11:57528085~57528365:-
STAD	cis	rs17685	0.753	rs8200	ENSG00000280388.1	RP11-229D13.3	4.06	6.08e-05	0.0217	0.18	0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76067288	chr7:76043977~76045963:-
STAD	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	4.06	6.09e-05	0.0217	0.21	0.21	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
STAD	cis	rs449789	0.857	rs543547	ENSG00000235086.1	FNDC1-IT1	-4.06	6.09e-05	0.0218	-0.28	-0.21	Pulse pressure;	chr6:159281319	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs625687	ENSG00000235086.1	FNDC1-IT1	-4.06	6.09e-05	0.0218	-0.28	-0.21	Pulse pressure;	chr6:159282262	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs625284	ENSG00000235086.1	FNDC1-IT1	-4.06	6.09e-05	0.0218	-0.28	-0.21	Pulse pressure;	chr6:159282341	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs575681	ENSG00000235086.1	FNDC1-IT1	-4.06	6.09e-05	0.0218	-0.28	-0.21	Pulse pressure;	chr6:159282502	chr6:159240786~159243329:+
STAD	cis	rs449789	0.857	rs9346784	ENSG00000235086.1	FNDC1-IT1	-4.06	6.09e-05	0.0218	-0.28	-0.21	Pulse pressure;	chr6:159282725	chr6:159240786~159243329:+
STAD	cis	rs449789	0.681	rs12529478	ENSG00000235086.1	FNDC1-IT1	-4.06	6.09e-05	0.0218	-0.28	-0.21	Pulse pressure;	chr6:159283690	chr6:159240786~159243329:+
STAD	cis	rs1707322	0.752	rs11488313	ENSG00000281133.1	AL355480.3	-4.06	6.09e-05	0.0218	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45580892~45580996:-
STAD	cis	rs478304	0.934	rs610037	ENSG00000213409.4	RP11-658F2.3	-4.06	6.09e-05	0.0218	-0.17	-0.21	Acne (severe);	chr11:65779386	chr11:66761575~66762399:-
STAD	cis	rs4462272	0.628	rs6584351	ENSG00000230224.1	PHBP9	4.06	6.09e-05	0.0218	0.15	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr10:100211240	chr10:100248271~100249095:+
STAD	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	4.06	6.09e-05	0.0218	0.24	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
STAD	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	4.06	6.09e-05	0.0218	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	4.06	6.09e-05	0.0218	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
STAD	cis	rs950169	0.922	rs4586394	ENSG00000235370.6	DNM1P51	-4.06	6.09e-05	0.0218	-0.27	-0.21	Schizophrenia;	chr15:84153633	chr15:84398316~84411701:-
STAD	cis	rs28588043	0.609	rs61815985	ENSG00000201126.1	RNU6-773P	-4.06	6.1e-05	0.0218	-0.36	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170977647	chr1:171519816~171519913:-
STAD	cis	rs6584485	0.589	rs10736156	ENSG00000272933.1	RP11-47A8.5	-4.06	6.1e-05	0.0218	-0.28	-0.21	Mean corpuscular volume;	chr10:102259690	chr10:102642792~102644140:-
STAD	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-4.06	6.1e-05	0.0218	-0.25	-0.21	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
STAD	cis	rs1707322	0.721	rs7520123	ENSG00000225447.1	RPS15AP10	4.06	6.1e-05	0.0218	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45645816~45646197:-
STAD	cis	rs10483554	0.671	rs34228032	ENSG00000258401.1	RP11-326E7.1	4.06	6.1e-05	0.0218	0.35	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49369115	chr14:49373966~49374383:+
STAD	cis	rs10483554	0.579	rs2354307	ENSG00000258401.1	RP11-326E7.1	4.06	6.1e-05	0.0218	0.35	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49371188	chr14:49373966~49374383:+
STAD	cis	rs7615952	0.673	rs7632557	ENSG00000239804.1	RP11-379B18.1	4.06	6.11e-05	0.0218	0.36	0.21	Blood pressure (smoking interaction);	chr3:125916038	chr3:125787888~125788146:-
STAD	cis	rs4835473	0.9	rs13101531	ENSG00000249741.2	RP11-673E1.3	4.06	6.11e-05	0.0218	0.25	0.21	Immature fraction of reticulocytes;	chr4:143982197	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs28668841	ENSG00000249741.2	RP11-673E1.3	4.06	6.11e-05	0.0218	0.25	0.21	Immature fraction of reticulocytes;	chr4:143982530	chr4:143911514~143912053:-
STAD	cis	rs9601248	0.756	rs928640	ENSG00000227676.3	LINC01068	-4.06	6.11e-05	0.0218	-0.26	-0.21	Major depressive disorder;	chr13:79603348	chr13:79566727~79571436:+
STAD	cis	rs2253762	0.54	rs10887036	ENSG00000226864.1	ATE1-AS1	4.06	6.11e-05	0.0218	0.34	0.21	Breast cancer;	chr10:121997570	chr10:121928312~121951965:+
STAD	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	4.06	6.11e-05	0.0218	0.25	0.21	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
STAD	cis	rs6832769	1	rs7667849	ENSG00000223305.1	RN7SKP30	-4.06	6.11e-05	0.0218	-0.24	-0.21	Personality dimensions;	chr4:55522032	chr4:55540502~55540835:-
STAD	cis	rs7397814	0.558	rs4764447	ENSG00000260423.1	RP13-735L24.1	4.06	6.11e-05	0.0218	0.2	0.21	IgG glycosylation;	chr12:9426513	chr12:9367464~9397617:+
STAD	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	-4.06	6.11e-05	0.0218	-0.21	-0.21	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
STAD	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	4.06	6.11e-05	0.0218	0.28	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
STAD	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	4.06	6.11e-05	0.0218	0.23	0.21	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
STAD	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-4.06	6.12e-05	0.0218	-0.29	-0.21	Pain;	chr19:21495996	chr19:21554640~21569237:-
STAD	cis	rs1135642	0.57	rs11728033	ENSG00000270244.1	RP11-123J14.4	4.06	6.12e-05	0.0218	0.45	0.21	Food addiction;	chr4:76942974	chr4:76886029~76886370:-
STAD	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-4.06	6.12e-05	0.0218	-0.21	-0.21	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
STAD	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-4.06	6.12e-05	0.0218	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-4.06	6.12e-05	0.0218	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-4.06	6.12e-05	0.0218	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
STAD	cis	rs6832769	0.925	rs11133383	ENSG00000272969.1	RP11-528I4.2	-4.06	6.12e-05	0.0218	-0.27	-0.21	Personality dimensions;	chr4:55450878	chr4:55547112~55547889:+
STAD	cis	rs9463078	0.691	rs9296458	ENSG00000219384.1	RP11-491H9.3	4.06	6.12e-05	0.0218	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45299446	chr6:45158870~45159511:+
STAD	cis	rs6964587	1	rs12540055	ENSG00000243107.1	AC000120.7	4.06	6.12e-05	0.0219	0.2	0.21	Breast cancer;	chr7:92078607	chr7:92200014~92206857:-
STAD	cis	rs198389	0.589	rs198399	ENSG00000242349.4	NPPA-AS1	-4.06	6.13e-05	0.0219	-0.22	-0.21	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11823572	chr1:11841017~11848079:+
STAD	cis	rs2562456	0.917	rs11085463	ENSG00000268119.4	CTD-2561J22.5	4.06	6.13e-05	0.0219	0.27	0.21	Pain;	chr19:21568500	chr19:21444241~21463908:-
STAD	cis	rs6933660	0.745	rs9397405	ENSG00000221469.1	AL133260.1	4.06	6.13e-05	0.0219	0.23	0.21	Menarche (age at onset);	chr6:151414949	chr6:151039916~151039971:-
STAD	cis	rs6933660	0.745	rs3778608	ENSG00000221469.1	AL133260.1	4.06	6.13e-05	0.0219	0.23	0.21	Menarche (age at onset);	chr6:151416996	chr6:151039916~151039971:-
STAD	cis	rs792448	0.66	rs12035647	ENSG00000212044.2	AL360091.1	4.06	6.13e-05	0.0219	0.22	0.21	White blood cell count (basophil);	chr1:212313969	chr1:212349978~212350069:+
STAD	cis	rs792448	0.743	rs7519959	ENSG00000212044.2	AL360091.1	4.06	6.13e-05	0.0219	0.22	0.21	White blood cell count (basophil);	chr1:212325310	chr1:212349978~212350069:+
STAD	cis	rs792448	0.743	rs4951589	ENSG00000212044.2	AL360091.1	4.06	6.13e-05	0.0219	0.22	0.21	White blood cell count (basophil);	chr1:212327351	chr1:212349978~212350069:+
STAD	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	4.06	6.13e-05	0.0219	0.3	0.21	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
STAD	cis	rs227275	0.53	rs3960788	ENSG00000248971.2	KRT8P46	-4.06	6.13e-05	0.0219	-0.22	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102728746~102730171:-
STAD	cis	rs34779708	0.966	rs4934732	ENSG00000271335.4	RP11-324I22.4	4.06	6.14e-05	0.0219	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35314552~35336401:-
STAD	cis	rs6834538	0.597	rs2029211	ENSG00000234841.4	RP11-119H12.4	-4.06	6.14e-05	0.0219	-0.23	-0.21	Free thyroxine concentration;	chr4:112566978	chr4:112826307~112827607:+
STAD	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	4.06	6.14e-05	0.0219	0.27	0.21	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs13129661	ENSG00000260091.1	RP11-33B1.4	4.06	6.14e-05	0.0219	0.21	0.21	Corneal astigmatism;	chr4:119231754	chr4:119409333~119410233:+
STAD	cis	rs2221894	0.511	rs2279442	ENSG00000273710.1	Metazoa_SRP	-4.06	6.14e-05	0.0219	-0.21	-0.21	Obesity-related traits;	chr8:29056371	chr8:28915579~28915864:-
STAD	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-4.06	6.14e-05	0.0219	-0.24	-0.21	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
STAD	cis	rs2957692	0.548	rs7947306	ENSG00000254554.1	RP11-351I24.1	4.06	6.14e-05	0.0219	0.35	0.21	Circulating vasoactive peptide levels;	chr11:10130375	chr11:10302657~10303704:-
STAD	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-4.06	6.14e-05	0.0219	-0.34	-0.21	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-4.06	6.14e-05	0.0219	-0.34	-0.21	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-4.06	6.14e-05	0.0219	-0.34	-0.21	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
STAD	cis	rs77988765	0.908	rs77436492	ENSG00000248844.5	RP11-626H12.3	-4.06	6.14e-05	0.0219	-0.42	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70173096	chr11:70056230~70065371:-
STAD	cis	rs1707322	1	rs4660903	ENSG00000225447.1	RPS15AP10	4.06	6.15e-05	0.0219	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45645816~45646197:-
STAD	cis	rs10845170	1	rs10845170	ENSG00000256667.5	KLRAP1	-4.06	6.15e-05	0.0219	-0.17	-0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:10571818	chr12:10588063~10599669:-
STAD	cis	rs2933343	0.729	rs789231	ENSG00000261159.1	RP11-723O4.9	4.06	6.15e-05	0.0219	0.26	0.21	IgG glycosylation;	chr3:128884004	chr3:128859716~128860526:-
STAD	cis	rs8012947	1	rs7153897	ENSG00000180189.10	HMGB1P14	-4.06	6.15e-05	0.0219	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58284773~58285363:+
STAD	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-4.06	6.15e-05	0.0219	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
STAD	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-4.06	6.16e-05	0.022	-0.22	-0.21	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
STAD	cis	rs117785887	0.536	rs12200649	ENSG00000270638.1	RP3-466P17.1	4.06	6.16e-05	0.022	0.38	0.21	Interleukin-17 levels;	chr6:146110918	chr6:145735570~145737218:+
STAD	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-4.06	6.16e-05	0.022	-0.36	-0.21	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
STAD	cis	rs950169	0.922	rs6603022	ENSG00000235370.6	DNM1P51	-4.06	6.16e-05	0.022	-0.27	-0.21	Schizophrenia;	chr15:84161418	chr15:84398316~84411701:-
STAD	cis	rs950169	0.922	rs11639244	ENSG00000235370.6	DNM1P51	4.06	6.16e-05	0.022	0.27	0.21	Schizophrenia;	chr15:84163898	chr15:84398316~84411701:-
STAD	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	4.06	6.16e-05	0.022	0.26	0.21	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
STAD	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-4.06	6.16e-05	0.022	-0.28	-0.21	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
STAD	cis	rs6992820	0.967	rs13265995	ENSG00000253541.1	SEPT10P1	4.06	6.16e-05	0.022	0.21	0.21	Mean platelet volume;	chr8:55772237	chr8:56476826~56477987:-
STAD	cis	rs6180	1	rs722677	ENSG00000250860.1	CTD-2265D6.2	4.06	6.16e-05	0.022	0.18	0.21	Height;	chr5:42748187	chr5:42466893~42468300:-
STAD	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	4.06	6.17e-05	0.022	0.29	0.21	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
STAD	cis	rs9393813	0.529	rs12526864	ENSG00000280107.1	AL022393.9	-4.06	6.17e-05	0.022	-0.23	-0.21	Bipolar disorder;	chr6:27488463	chr6:28170845~28172521:+
STAD	cis	rs6479891	1	rs7895348	ENSG00000235816.3	PRELID1P3	-4.06	6.17e-05	0.022	-0.27	-0.21	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63427297~63427939:+
STAD	cis	rs7849270	1	rs10988223	ENSG00000234055.1	RP11-247A12.1	4.06	6.17e-05	0.022	0.24	0.21	Blood metabolite ratios;	chr9:129140742	chr9:129097854~129100266:+
STAD	cis	rs2834188	0.889	rs1467849	ENSG00000272659.1	AP000295.10	-4.06	6.18e-05	0.022	-0.3	-0.21	Narcolepsy;	chr21:33309764	chr21:33309491~33310181:+
STAD	cis	rs4835473	0.808	rs6836630	ENSG00000249741.2	RP11-673E1.3	4.06	6.18e-05	0.022	0.25	0.21	Immature fraction of reticulocytes;	chr4:143801068	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs13101541	ENSG00000249741.2	RP11-673E1.3	4.06	6.18e-05	0.022	0.25	0.21	Immature fraction of reticulocytes;	chr4:143806590	chr4:143911514~143912053:-
STAD	cis	rs6142102	0.961	rs4911405	ENSG00000264616.1	MIR4755	4.06	6.18e-05	0.022	0.22	0.21	Skin pigmentation;	chr20:34087161	chr20:34049119~34049190:+
STAD	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	4.06	6.18e-05	0.022	0.25	0.21	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
STAD	cis	rs9291683	0.679	rs13137795	ENSG00000250613.1	RP11-136I13.1	-4.06	6.18e-05	0.022	-0.2	-0.21	Bone mineral density;	chr4:10049882	chr4:10410996~10411644:+
STAD	cis	rs2115630	0.967	rs12595786	ENSG00000275120.1	RP11-182J1.17	-4.06	6.18e-05	0.022	-0.23	-0.21	P wave terminal force;	chr15:84793439	chr15:84599434~84606463:-
STAD	cis	rs11169552	0.543	rs10876051	ENSG00000200183.1	RNU6-238P	-4.06	6.18e-05	0.022	-0.2	-0.21	Colorectal cancer;	chr12:50538553	chr12:50656973~50657078:+
STAD	cis	rs6496044	0.568	rs3743321	ENSG00000259295.5	CSPG4P12	4.06	6.18e-05	0.022	0.26	0.21	Interstitial lung disease;	chr15:85521737	chr15:85191438~85213905:+
STAD	cis	rs2243480	1	rs778729	ENSG00000273448.1	RP11-166O4.6	4.06	6.18e-05	0.022	0.25	0.21	Diabetic kidney disease;	chr7:66359432	chr7:67333047~67334383:+
STAD	cis	rs3126085	0.515	rs7515448	ENSG00000237975.5	FLG-AS1	4.06	6.18e-05	0.022	0.3	0.21	Atopic dermatitis;	chr1:152399559	chr1:152168125~152445456:+
STAD	cis	rs6940638	0.513	rs4424065	ENSG00000272312.1	RP11-239L20.6	4.06	6.19e-05	0.022	0.21	0.21	Intelligence (multi-trait analysis);	chr6:27068677	chr6:27001208~27001648:-
STAD	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	4.06	6.19e-05	0.022	0.28	0.21	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
STAD	cis	rs9987353	0.62	rs34455383	ENSG00000254340.1	RP11-10A14.3	-4.06	6.19e-05	0.022	-0.31	-0.21	Recombination measurement;	chr8:9208948	chr8:9141424~9145435:+
STAD	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-4.06	6.19e-05	0.0221	-0.34	-0.21	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-4.06	6.19e-05	0.0221	-0.34	-0.21	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-4.06	6.19e-05	0.0221	-0.34	-0.21	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-4.06	6.19e-05	0.0221	-0.34	-0.21	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
STAD	cis	rs1005277	0.522	rs200943	ENSG00000099251.13	HSD17B7P2	4.06	6.19e-05	0.0221	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.505	rs719569	ENSG00000099251.13	HSD17B7P2	-4.06	6.19e-05	0.0221	-0.23	-0.21	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38356380~38378505:+
STAD	cis	rs8062405	0.965	rs56040780	ENSG00000278665.1	RP11-666O2.4	4.06	6.19e-05	0.0221	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28599241~28601881:-
STAD	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	4.06	6.19e-05	0.0221	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
STAD	cis	rs7493	0.901	rs11764079	ENSG00000233942.1	AC004012.1	-4.06	6.19e-05	0.0221	-0.25	-0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396917	chr7:95471835~95473998:+
STAD	cis	rs2446066	0.872	rs2683524	ENSG00000257379.1	RP11-793H13.8	4.06	6.19e-05	0.0221	0.33	0.21	Red blood cell count;	chr12:53421069	chr12:53441741~53467528:+
STAD	cis	rs9307551	0.584	rs1978916	ENSG00000250334.4	LINC00989	-4.06	6.2e-05	0.0221	-0.26	-0.21	Refractive error;	chr4:79526106	chr4:79492416~79576460:+
STAD	cis	rs10129255	0.518	rs12590732	ENSG00000211959.2	IGHV4-39	-4.06	6.2e-05	0.0221	-0.19	-0.21	Kawasaki disease;	chr14:106779612	chr14:106421711~106422218:-
STAD	cis	rs17507216	0.718	rs28587782	ENSG00000259429.4	UBE2Q2P2	-4.05	6.2e-05	0.0221	-0.33	-0.21	Excessive daytime sleepiness;	chr15:82576881	chr15:82355142~82420075:+
STAD	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	4.05	6.21e-05	0.0221	0.23	0.21	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
STAD	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	4.05	6.21e-05	0.0221	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
STAD	cis	rs749052	0.656	rs3100613	ENSG00000251485.1	AC068134.10	-4.05	6.21e-05	0.0221	-0.52	-0.21	Height;	chr2:232044311	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs3100615	ENSG00000251485.1	AC068134.10	-4.05	6.21e-05	0.0221	-0.52	-0.21	Height;	chr2:232046858	chr2:232343116~232343903:+
STAD	cis	rs749052	0.764	rs3116236	ENSG00000251485.1	AC068134.10	-4.05	6.21e-05	0.0221	-0.52	-0.21	Height;	chr2:232047615	chr2:232343116~232343903:+
STAD	cis	rs749052	0.764	rs3100616	ENSG00000251485.1	AC068134.10	-4.05	6.21e-05	0.0221	-0.52	-0.21	Height;	chr2:232048972	chr2:232343116~232343903:+
STAD	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-4.05	6.21e-05	0.0221	-0.22	-0.21	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
STAD	cis	rs4713118	0.955	rs9380011	ENSG00000220721.1	OR1F12	4.05	6.21e-05	0.0221	0.24	0.21	Parkinson's disease;	chr6:27716145	chr6:28073316~28074233:+
STAD	cis	rs61270009	0.955	rs2115884	ENSG00000247828.6	TMEM161B-AS1	4.05	6.21e-05	0.0221	0.29	0.21	Depressive symptoms;	chr5:88358839	chr5:88268895~88436685:+
STAD	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	4.05	6.21e-05	0.0221	0.26	0.21	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
STAD	cis	rs478304	0.903	rs61895677	ENSG00000213409.4	RP11-658F2.3	-4.05	6.22e-05	0.0221	-0.17	-0.21	Acne (severe);	chr11:65781944	chr11:66761575~66762399:-
STAD	cis	rs478304	0.934	rs12801731	ENSG00000213409.4	RP11-658F2.3	-4.05	6.22e-05	0.0221	-0.17	-0.21	Acne (severe);	chr11:65782135	chr11:66761575~66762399:-
STAD	cis	rs749052	0.831	rs2679165	ENSG00000251485.1	AC068134.10	4.05	6.22e-05	0.0221	0.51	0.21	Height;	chr2:231956269	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs2679166	ENSG00000251485.1	AC068134.10	4.05	6.22e-05	0.0221	0.51	0.21	Height;	chr2:231957019	chr2:232343116~232343903:+
STAD	cis	rs749052	0.831	rs2679167	ENSG00000251485.1	AC068134.10	4.05	6.22e-05	0.0221	0.51	0.21	Height;	chr2:231957202	chr2:232343116~232343903:+
STAD	cis	rs5769707	0.732	rs135865	ENSG00000213279.2	RP1-29C18.9	-4.05	6.22e-05	0.0221	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49572264~49575426:-
STAD	cis	rs13413635	0.729	rs11695452	ENSG00000225808.1	DNAJC19P5	-4.05	6.22e-05	0.0221	-0.28	-0.21	Heart rate;	chr2:178014118	chr2:177229191~177229506:-
STAD	cis	rs792448	0.926	rs701905	ENSG00000212044.2	AL360091.1	4.05	6.22e-05	0.0221	0.25	0.21	White blood cell count (basophil);	chr1:212379769	chr1:212349978~212350069:+
STAD	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	4.05	6.22e-05	0.0221	0.42	0.21	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	4.05	6.22e-05	0.0221	0.42	0.21	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	4.05	6.22e-05	0.0221	0.42	0.21	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	4.05	6.22e-05	0.0221	0.42	0.21	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	4.05	6.22e-05	0.0221	0.42	0.21	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
STAD	cis	rs56114371	0.53	rs169262	ENSG00000243307.2	POM121L6P	-4.05	6.22e-05	0.0221	-0.27	-0.21	Breast cancer;	chr6:27803112	chr6:26896952~26898777:+
STAD	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-4.05	6.22e-05	0.0221	-0.32	-0.21	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
STAD	cis	rs2957692	0.527	rs7123820	ENSG00000254554.1	RP11-351I24.1	4.05	6.23e-05	0.0222	0.35	0.21	Circulating vasoactive peptide levels;	chr11:10038810	chr11:10302657~10303704:-
STAD	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-4.05	6.23e-05	0.0222	-0.25	-0.21	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-4.05	6.23e-05	0.0222	-0.25	-0.21	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
STAD	cis	rs2901460	0.628	rs13013036	ENSG00000229503.1	AC092155.1	-4.05	6.23e-05	0.0222	-0.17	-0.21	Mean corpuscular volume;	chr2:62147878	chr2:62532583~62533059:-
STAD	cis	rs9291683	0.609	rs55959894	ENSG00000250613.1	RP11-136I13.1	-4.05	6.23e-05	0.0222	-0.2	-0.21	Bone mineral density;	chr4:10024956	chr4:10410996~10411644:+
STAD	cis	rs6832769	1	rs11133399	ENSG00000272969.1	RP11-528I4.2	-4.05	6.23e-05	0.0222	-0.27	-0.21	Personality dimensions;	chr4:55547664	chr4:55547112~55547889:+
STAD	cis	rs2739330	0.828	rs5760102	ENSG00000272787.1	KB-226F1.2	-4.05	6.23e-05	0.0222	-0.23	-0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23969211~23969873:+
STAD	cis	rs77988765	0.908	rs77708297	ENSG00000248844.5	RP11-626H12.3	-4.05	6.23e-05	0.0222	-0.42	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70168494	chr11:70056230~70065371:-
STAD	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	4.05	6.23e-05	0.0222	0.22	0.21	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
STAD	cis	rs1707322	0.827	rs6683274	ENSG00000225447.1	RPS15AP10	4.05	6.23e-05	0.0222	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45645816~45646197:-
STAD	cis	rs7937890	0.869	rs2915404	ENSG00000254418.1	RP11-21L19.1	4.05	6.23e-05	0.0222	0.23	0.21	Mitochondrial DNA levels;	chr11:14383279	chr11:14262846~14273691:-
STAD	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	4.05	6.24e-05	0.0222	0.26	0.21	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
STAD	cis	rs11098499	0.909	rs10017335	ENSG00000260091.1	RP11-33B1.4	-4.05	6.24e-05	0.0222	-0.21	-0.21	Corneal astigmatism;	chr4:119460368	chr4:119409333~119410233:+
STAD	cis	rs238295	0.696	rs6053451	ENSG00000230563.2	RP5-828H9.1	4.05	6.24e-05	0.0222	0.24	0.21	Occipital cortical area (total cortical area interaction);	chr20:5513258	chr20:5471207~5475182:+
STAD	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-4.05	6.24e-05	0.0222	-0.27	-0.21	Height;	chr20:49316942	chr20:49280319~49280409:+
STAD	cis	rs34779708	0.931	rs4934535	ENSG00000271335.4	RP11-324I22.4	4.05	6.24e-05	0.0222	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs4934734	ENSG00000271335.4	RP11-324I22.4	4.05	6.24e-05	0.0222	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs12769575	ENSG00000271335.4	RP11-324I22.4	4.05	6.24e-05	0.0222	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35314552~35336401:-
STAD	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	4.05	6.24e-05	0.0222	0.26	0.21	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
STAD	cis	rs6095298	0.574	rs6095327	ENSG00000227431.4	CSE1L-AS1	-4.05	6.25e-05	0.0222	-0.24	-0.21	Intelligence (multi-trait analysis);	chr20:48850970	chr20:49040463~49046044:-
STAD	cis	rs1816752	0.669	rs4770699	ENSG00000273628.1	RP11-756A22.7	-4.05	6.25e-05	0.0222	-0.26	-0.21	Obesity-related traits;	chr13:24488234	chr13:24933006~24936796:+
STAD	cis	rs6903823	0.508	rs1150724	ENSG00000220721.1	OR1F12	4.05	6.25e-05	0.0222	0.21	0.21	Pulmonary function;	chr6:28282459	chr6:28073316~28074233:+
STAD	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	4.05	6.25e-05	0.0222	0.28	0.21	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
STAD	cis	rs7283707	0.681	rs79484267	ENSG00000228798.1	AP000473.5	-4.05	6.25e-05	0.0222	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15764715	chr21:16630827~16640683:+
STAD	cis	rs2836974	0.583	rs9981884	ENSG00000232608.1	TIMM9P2	-4.05	6.25e-05	0.0222	-0.21	-0.21	Cognitive function;	chr21:39213707	chr21:39216624~39217506:+
STAD	cis	rs1707322	1	rs4660903	ENSG00000281133.1	AL355480.3	-4.05	6.26e-05	0.0222	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45580892~45580996:-
STAD	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	4.05	6.26e-05	0.0223	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
STAD	cis	rs10129255	1	rs9324091	ENSG00000232216.1	IGHV3-43	4.05	6.26e-05	0.0223	0.22	0.21	Kawasaki disease;	chr14:106676625	chr14:106470264~106470800:-
STAD	cis	rs10129255	1	rs61997605	ENSG00000232216.1	IGHV3-43	4.05	6.26e-05	0.0223	0.22	0.21	Kawasaki disease;	chr14:106678368	chr14:106470264~106470800:-
STAD	cis	rs10129255	1	rs8012033	ENSG00000232216.1	IGHV3-43	4.05	6.26e-05	0.0223	0.22	0.21	Kawasaki disease;	chr14:106678854	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.912	rs8011090	ENSG00000232216.1	IGHV3-43	4.05	6.26e-05	0.0223	0.22	0.21	Kawasaki disease;	chr14:106678896	chr14:106470264~106470800:-
STAD	cis	rs3770081	0.59	rs57367442	ENSG00000273080.1	RP11-301O19.1	-4.05	6.26e-05	0.0223	-0.53	-0.21	Facial emotion recognition (sad faces);	chr2:86226275	chr2:86195590~86196049:+
STAD	cis	rs10500715	0.517	rs2403227	ENSG00000254554.1	RP11-351I24.1	-4.05	6.26e-05	0.0223	-0.32	-0.21	Pancreatic cancer;	chr11:9962591	chr11:10302657~10303704:-
STAD	cis	rs6142102	1	rs4911410	ENSG00000264616.1	MIR4755	4.05	6.26e-05	0.0223	0.22	0.21	Skin pigmentation;	chr20:34123168	chr20:34049119~34049190:+
STAD	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-4.05	6.26e-05	0.0223	-0.25	-0.21	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
STAD	cis	rs2688608	0.592	rs7909802	ENSG00000272140.2	RP11-574K11.29	4.05	6.26e-05	0.0223	0.19	0.21	Inflammatory bowel disease;	chr10:73724428	chr10:73703735~73713581:-
STAD	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	4.05	6.26e-05	0.0223	0.26	0.21	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
STAD	cis	rs13413635	0.913	rs17329062	ENSG00000225808.1	DNAJC19P5	-4.05	6.27e-05	0.0223	-0.29	-0.21	Heart rate;	chr2:177805826	chr2:177229191~177229506:-
STAD	cis	rs792448	0.743	rs11119904	ENSG00000212044.2	AL360091.1	4.05	6.27e-05	0.0223	0.23	0.21	White blood cell count (basophil);	chr1:212293262	chr1:212349978~212350069:+
STAD	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	4.05	6.27e-05	0.0223	0.27	0.21	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
STAD	cis	rs2243480	0.908	rs1532573	ENSG00000273448.1	RP11-166O4.6	-4.05	6.27e-05	0.0223	-0.25	-0.21	Diabetic kidney disease;	chr7:66333815	chr7:67333047~67334383:+
STAD	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	4.05	6.27e-05	0.0223	0.26	0.21	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
STAD	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	4.05	6.27e-05	0.0223	0.29	0.21	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
STAD	cis	rs4295623	0.556	rs10903343	ENSG00000270154.1	RP11-419I17.1	4.05	6.27e-05	0.0223	0.22	0.21	Morning vs. evening chronotype;	chr8:11838363	chr8:12476462~12477122:+
STAD	cis	rs1707322	1	rs7527079	ENSG00000225447.1	RPS15AP10	4.05	6.27e-05	0.0223	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs34446427	ENSG00000225447.1	RPS15AP10	4.05	6.27e-05	0.0223	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs4660900	ENSG00000225447.1	RPS15AP10	4.05	6.27e-05	0.0223	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4454479	ENSG00000225447.1	RPS15AP10	4.05	6.27e-05	0.0223	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs7517560	ENSG00000225447.1	RPS15AP10	4.05	6.27e-05	0.0223	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45645816~45646197:-
STAD	cis	rs7429990	0.864	rs319693	ENSG00000224895.1	VPS26BP1	-4.05	6.28e-05	0.0223	-0.22	-0.21	Educational attainment (years of education);	chr3:47845090	chr3:47960327~47961081:-
STAD	cis	rs10508774	0.733	rs12254344	ENSG00000273038.2	RP11-479G22.8	4.05	6.28e-05	0.0223	0.38	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32568301	chr10:32887255~32889311:-
STAD	cis	rs2273156	0.706	rs7153331	ENSG00000258704.4	SRP54-AS1	-4.05	6.28e-05	0.0223	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35032464	chr14:34920858~34982532:-
STAD	cis	rs13412757	0.84	rs28646278	ENSG00000236790.4	LINC00299	-4.05	6.28e-05	0.0223	-0.24	-0.21	Asthma;Itch intensity from mosquito bite adjusted by bite size;	chr2:8332712	chr2:8007771~8383621:-
STAD	cis	rs2348418	0.8	rs6487667	ENSG00000247934.4	RP11-967K21.1	-4.05	6.28e-05	0.0223	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-4.05	6.28e-05	0.0223	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-4.05	6.28e-05	0.0223	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-4.05	6.28e-05	0.0223	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-4.05	6.28e-05	0.0223	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.701	rs6487670	ENSG00000247934.4	RP11-967K21.1	-4.05	6.28e-05	0.0223	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.849	rs11049388	ENSG00000247934.4	RP11-967K21.1	-4.05	6.29e-05	0.0223	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28169054	chr12:28163298~28190738:-
STAD	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-4.05	6.29e-05	0.0223	-0.25	-0.21	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-4.05	6.29e-05	0.0223	-0.25	-0.21	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
STAD	cis	rs891058	0.558	rs13412022	ENSG00000236790.4	LINC00299	-4.05	6.3e-05	0.0224	-0.23	-0.21	Neutrophil percentage of granulocytes;	chr2:8328080	chr2:8007771~8383621:-
STAD	cis	rs9902453	0.845	rs3102559	ENSG00000263477.1	RP11-338L22.2	4.05	6.3e-05	0.0224	0.18	0.21	Coffee consumption (cups per day);	chr17:29702705	chr17:29863402~29866092:+
STAD	cis	rs7202877	0.61	rs3784936	ENSG00000261783.1	RP11-252K23.2	-4.05	6.3e-05	0.0224	-0.34	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75303685	chr16:75379818~75381260:-
STAD	cis	rs867371	1	rs1846911	ENSG00000276710.3	CSPG4P8	-4.05	6.3e-05	0.0224	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82459472~82477258:+
STAD	cis	rs4763879	0.634	rs61915473	ENSG00000256673.1	RP11-599J14.2	4.05	6.3e-05	0.0224	0.23	0.21	Type 1 diabetes;	chr12:9705282	chr12:9398355~9414851:-
STAD	cis	rs6471393	0.964	rs56282609	ENSG00000253848.1	RP11-10N23.5	4.05	6.3e-05	0.0224	0.25	0.21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737852	chr8:93741193~93744534:+
STAD	cis	rs2638953	0.924	rs12320545	ENSG00000247934.4	RP11-967K21.1	4.05	6.31e-05	0.0224	0.24	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28248047	chr12:28163298~28190738:-
STAD	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-4.05	6.31e-05	0.0224	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
STAD	cis	rs4568518	0.903	rs12699941	ENSG00000279048.1	RP11-511H23.2	4.05	6.31e-05	0.0224	0.19	0.21	Measles;	chr7:17997837	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.869	rs12699942	ENSG00000279048.1	RP11-511H23.2	4.05	6.31e-05	0.0224	0.19	0.21	Measles;	chr7:17998062	chr7:17940503~17942922:+
STAD	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-4.05	6.31e-05	0.0224	-0.24	-0.21	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
STAD	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	4.05	6.31e-05	0.0224	0.26	0.21	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
STAD	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-4.05	6.32e-05	0.0224	-0.24	-0.21	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
STAD	cis	rs875971	1	rs2087647	ENSG00000224316.1	RP11-479O9.2	-4.05	6.32e-05	0.0224	-0.21	-0.21	Aortic root size;	chr7:66128201	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs6958484	ENSG00000224316.1	RP11-479O9.2	-4.05	6.32e-05	0.0224	-0.21	-0.21	Aortic root size;	chr7:66134459	chr7:65773620~65802067:+
STAD	cis	rs1707322	0.685	rs56177313	ENSG00000281133.1	AL355480.3	-4.05	6.32e-05	0.0224	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs11211178	ENSG00000281133.1	AL355480.3	-4.05	6.32e-05	0.0224	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs4660314	ENSG00000281133.1	AL355480.3	-4.05	6.32e-05	0.0224	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45580892~45580996:-
STAD	cis	rs9902453	0.845	rs2617865	ENSG00000263477.1	RP11-338L22.2	-4.05	6.32e-05	0.0224	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29722786	chr17:29863402~29866092:+
STAD	cis	rs11676348	0.772	rs12471105	ENSG00000237281.1	CATIP-AS2	4.05	6.32e-05	0.0224	0.21	0.21	Ulcerative colitis;	chr2:218085486	chr2:218326889~218357966:-
STAD	cis	rs1707322	0.826	rs10890349	ENSG00000225447.1	RPS15AP10	4.05	6.32e-05	0.0224	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.758	rs10789474	ENSG00000225447.1	RPS15AP10	4.05	6.32e-05	0.0224	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45645816~45646197:-
STAD	cis	rs763121	0.925	rs5757165	ENSG00000280859.1	AL022326.1	-4.05	6.32e-05	0.0224	-0.24	-0.21	Menopause (age at onset);	chr22:38598572	chr22:39319019~39319147:-
STAD	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	4.05	6.32e-05	0.0224	0.31	0.21	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
STAD	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-4.05	6.32e-05	0.0224	-0.28	-0.21	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
STAD	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-4.05	6.32e-05	0.0224	-0.28	-0.21	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
STAD	cis	rs6452524	0.508	rs256795	ENSG00000243385.2	CTD-2110K23.1	-4.05	6.33e-05	0.0225	-0.25	-0.21	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83201229~83202141:+
STAD	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	4.05	6.33e-05	0.0225	0.24	0.21	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
STAD	cis	rs7615952	0.741	rs13314845	ENSG00000272840.1	RP11-379B18.6	4.05	6.33e-05	0.0225	0.38	0.21	Blood pressure (smoking interaction);	chr3:125925939	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.733	rs13314847	ENSG00000272840.1	RP11-379B18.6	4.05	6.33e-05	0.0225	0.38	0.21	Blood pressure (smoking interaction);	chr3:125925945	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.8	rs13086460	ENSG00000272840.1	RP11-379B18.6	4.05	6.33e-05	0.0225	0.38	0.21	Blood pressure (smoking interaction);	chr3:125927574	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.866	rs1976459	ENSG00000272840.1	RP11-379B18.6	4.05	6.33e-05	0.0225	0.38	0.21	Blood pressure (smoking interaction);	chr3:125928643	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.932	rs1976458	ENSG00000272840.1	RP11-379B18.6	4.05	6.33e-05	0.0225	0.38	0.21	Blood pressure (smoking interaction);	chr3:125928669	chr3:125774714~125797953:+
STAD	cis	rs1816752	0.646	rs7995190	ENSG00000273628.1	RP11-756A22.7	-4.05	6.33e-05	0.0225	-0.26	-0.21	Obesity-related traits;	chr13:24475709	chr13:24933006~24936796:+
STAD	cis	rs1485395	0.541	rs11170614	ENSG00000257379.1	RP11-793H13.8	4.05	6.33e-05	0.0225	0.44	0.21	Migraine without aura;	chr12:53623863	chr12:53441741~53467528:+
STAD	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	4.05	6.33e-05	0.0225	0.24	0.21	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
STAD	cis	rs6430585	0.528	rs3099429	ENSG00000231890.6	DARS-AS1	-4.05	6.33e-05	0.0225	-0.23	-0.21	Corneal structure;	chr2:135898012	chr2:135985176~136022593:+
STAD	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-4.05	6.33e-05	0.0225	-0.29	-0.21	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
STAD	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-4.05	6.34e-05	0.0225	-0.28	-0.21	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
STAD	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	4.05	6.34e-05	0.0225	0.34	0.21	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	4.05	6.34e-05	0.0225	0.34	0.21	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	4.05	6.34e-05	0.0225	0.34	0.21	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	4.05	6.34e-05	0.0225	0.34	0.21	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	4.05	6.34e-05	0.0225	0.34	0.21	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
STAD	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	4.05	6.34e-05	0.0225	0.34	0.21	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
STAD	cis	rs10040610	0.524	rs271414	ENSG00000250490.1	FLJ33360	4.05	6.34e-05	0.0225	0.25	0.21	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6349022	chr5:6310441~6339884:-
STAD	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	4.05	6.34e-05	0.0225	0.27	0.21	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
STAD	cis	rs6479891	1	rs10761745	ENSG00000235816.3	PRELID1P3	-4.05	6.34e-05	0.0225	-0.27	-0.21	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63427297~63427939:+
STAD	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	4.05	6.34e-05	0.0225	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
STAD	cis	rs4243830	0.85	rs1064835	ENSG00000229519.2	RP11-58A11.2	-4.05	6.34e-05	0.0225	-0.23	-0.21	Body mass index;	chr1:6525479	chr1:6547905~6548619:+
STAD	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	4.05	6.35e-05	0.0225	0.26	0.21	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
STAD	cis	rs6845263	1	rs6845263	ENSG00000254531.1	FLJ20021	4.05	6.35e-05	0.0225	0.25	0.21	Superior crus of antihelix expression;	chr4:101355525	chr4:101347780~101348883:+
STAD	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	4.05	6.35e-05	0.0225	0.33	0.21	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
STAD	cis	rs9926664	0.908	rs8054513	ENSG00000274134.1	MIR6774	4.05	6.35e-05	0.0225	0.36	0.21	Neutrophil count;Sum basophil neutrophil counts;	chr16:85915501	chr16:85918347~85918416:+
STAD	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-4.05	6.35e-05	0.0225	-0.38	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-4.05	6.35e-05	0.0225	-0.38	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-4.05	6.35e-05	0.0225	-0.38	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
STAD	cis	rs6479891	1	rs9414780	ENSG00000235816.3	PRELID1P3	4.05	6.35e-05	0.0225	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63427297~63427939:+
STAD	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-4.05	6.35e-05	0.0225	-0.3	-0.21	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
STAD	cis	rs2562456	0.917	rs2650825	ENSG00000268117.1	VN1R84P	4.05	6.36e-05	0.0225	0.3	0.21	Pain;	chr19:21516423	chr19:21719801~21720035:-
STAD	cis	rs7824557	0.606	rs2736273	ENSG00000205879.4	FAM90A2P	4.05	6.36e-05	0.0225	0.24	0.21	Retinal vascular caliber;	chr8:11342429	chr8:12172202~12178575:-
STAD	cis	rs6772849	0.93	rs13434160	ENSG00000242551.2	POU5F1P6	-4.05	6.36e-05	0.0226	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128674735~128677005:-
STAD	cis	rs6772849	0.93	rs4857916	ENSG00000242551.2	POU5F1P6	-4.05	6.36e-05	0.0226	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128674735~128677005:-
STAD	cis	rs1799949	0.965	rs799916	ENSG00000279602.1	CTD-3014M21.1	-4.05	6.36e-05	0.0226	-0.26	-0.21	Menopause (age at onset);	chr17:43091173	chr17:43360041~43361361:-
STAD	cis	rs4865169	0.623	rs6838975	ENSG00000269949.1	RP11-738E22.3	-4.05	6.36e-05	0.0226	-0.27	-0.21	Breast cancer;	chr4:56873650	chr4:56960927~56961373:-
STAD	cis	rs708547	0.541	rs6554392	ENSG00000269949.1	RP11-738E22.3	-4.05	6.36e-05	0.0226	-0.27	-0.21	Response to bleomycin (chromatid breaks);	chr4:56873782	chr4:56960927~56961373:-
STAD	cis	rs7142881	0.742	rs10143899	ENSG00000258648.1	UBE2CP1	-4.05	6.36e-05	0.0226	-0.25	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31562923	chr14:30683045~30683598:-
STAD	cis	rs6762	0.692	rs5030778	ENSG00000279672.1	CMB9-55F22.1	4.05	6.36e-05	0.0226	0.26	0.21	Mean platelet volume;	chr11:836008	chr11:779617~780755:+
STAD	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-4.05	6.36e-05	0.0226	-0.2	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-4.05	6.36e-05	0.0226	-0.2	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-4.05	6.36e-05	0.0226	-0.2	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
STAD	cis	rs453301	0.506	rs686189	ENSG00000254340.1	RP11-10A14.3	-4.05	6.37e-05	0.0226	-0.25	-0.21	Joint mobility (Beighton score);	chr8:8766127	chr8:9141424~9145435:+
STAD	cis	rs7927771	0.832	rs7105851	ENSG00000271350.1	CTD-2384B9.1	4.05	6.37e-05	0.0226	0.23	0.21	Subjective well-being;	chr11:47361724	chr11:47041027~47041945:-
STAD	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	4.05	6.37e-05	0.0226	0.28	0.21	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
STAD	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	4.05	6.37e-05	0.0226	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
STAD	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-4.05	6.38e-05	0.0226	-0.25	-0.21	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
STAD	cis	rs9463078	0.817	rs3799978	ENSG00000219384.1	RP11-491H9.3	4.05	6.38e-05	0.0226	0.21	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44869795	chr6:45158870~45159511:+
STAD	cis	rs11098499	1	rs11098499	ENSG00000260091.1	RP11-33B1.4	4.05	6.38e-05	0.0226	0.21	0.21	Corneal astigmatism;	chr4:119266456	chr4:119409333~119410233:+
STAD	cis	rs8012947	1	rs1885133	ENSG00000279636.2	LINC00216	-4.05	6.38e-05	0.0226	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58270684	chr14:58288033~58289158:+
STAD	cis	rs8012947	1	rs2348072	ENSG00000279636.2	LINC00216	-4.05	6.38e-05	0.0226	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58277034	chr14:58288033~58289158:+
STAD	cis	rs7927771	0.832	rs7924485	ENSG00000271350.1	CTD-2384B9.1	4.05	6.38e-05	0.0226	0.23	0.21	Subjective well-being;	chr11:47397578	chr11:47041027~47041945:-
STAD	cis	rs2688608	0.587	rs2894040	ENSG00000272140.2	RP11-574K11.29	4.05	6.38e-05	0.0226	0.19	0.21	Inflammatory bowel disease;	chr10:73718401	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.592	rs3849967	ENSG00000272140.2	RP11-574K11.29	4.05	6.38e-05	0.0226	0.19	0.21	Inflammatory bowel disease;	chr10:73723608	chr10:73703735~73713581:-
STAD	cis	rs10851478	0.872	rs7174135	ENSG00000259545.2	RP11-325E5.4	-4.05	6.38e-05	0.0226	-0.26	-0.21	Oral cavity cancer;	chr15:49463245	chr15:49177610~49178741:-
STAD	cis	rs9309473	0.583	rs6718864	ENSG00000163016.8	ALMS1P	4.05	6.38e-05	0.0226	0.22	0.21	Metabolite levels;	chr2:73347463	chr2:73644919~73685576:+
STAD	cis	rs561341	0.714	rs111760509	ENSG00000265798.5	RP11-271K11.5	4.05	6.39e-05	0.0226	0.31	0.21	Hip circumference adjusted for BMI;	chr17:31977301	chr17:31038575~31059121:-
STAD	cis	rs11638815	0.626	rs11635624	ENSG00000255769.6	GOLGA2P10	-4.05	6.39e-05	0.0226	-0.24	-0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:82472993~82513950:-
STAD	cis	rs9307551	0.948	rs1866835	ENSG00000250334.4	LINC00989	-4.05	6.39e-05	0.0226	-0.27	-0.21	Refractive error;	chr4:79626099	chr4:79492416~79576460:+
STAD	cis	rs34779708	0.966	rs4934539	ENSG00000271335.4	RP11-324I22.4	4.05	6.39e-05	0.0226	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35314552~35336401:-
STAD	cis	rs11098499	1	rs13116504	ENSG00000260091.1	RP11-33B1.4	4.05	6.39e-05	0.0226	0.21	0.21	Corneal astigmatism;	chr4:119288257	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.909	rs28555550	ENSG00000260091.1	RP11-33B1.4	4.05	6.39e-05	0.0226	0.21	0.21	Corneal astigmatism;	chr4:119289885	chr4:119409333~119410233:+
STAD	cis	rs11098499	1	rs28419773	ENSG00000260091.1	RP11-33B1.4	4.05	6.39e-05	0.0226	0.21	0.21	Corneal astigmatism;	chr4:119289906	chr4:119409333~119410233:+
STAD	cis	rs11098499	1	rs11726229	ENSG00000260091.1	RP11-33B1.4	4.05	6.39e-05	0.0226	0.21	0.21	Corneal astigmatism;	chr4:119290425	chr4:119409333~119410233:+
STAD	cis	rs2834188	1	rs1018741	ENSG00000272659.1	AP000295.10	-4.05	6.39e-05	0.0227	-0.3	-0.21	Narcolepsy;	chr21:33314040	chr21:33309491~33310181:+
STAD	cis	rs2834188	1	rs1018742	ENSG00000272659.1	AP000295.10	-4.05	6.39e-05	0.0227	-0.3	-0.21	Narcolepsy;	chr21:33314076	chr21:33309491~33310181:+
STAD	cis	rs6832769	0.925	rs2412663	ENSG00000223305.1	RN7SKP30	-4.05	6.4e-05	0.0227	-0.24	-0.21	Personality dimensions;	chr4:55589649	chr4:55540502~55540835:-
STAD	cis	rs11157436	0.602	rs2331594	ENSG00000211813.2	TRAV34	4.05	6.4e-05	0.0227	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22207522~22208129:+
STAD	cis	rs6142102	0.778	rs4911374	ENSG00000264616.1	MIR4755	4.05	6.4e-05	0.0227	0.23	0.21	Skin pigmentation;	chr20:33928195	chr20:34049119~34049190:+
STAD	cis	rs1030877	0.515	rs2679893	ENSG00000235319.1	AC012360.4	-4.05	6.4e-05	0.0227	-0.3	-0.21	Obesity-related traits;	chr2:105293097	chr2:105324210~105330529:+
STAD	cis	rs12468226	0.873	rs79071680	ENSG00000226261.1	AC064836.3	4.05	6.4e-05	0.0227	0.36	0.21	Urate levels;	chr2:202191520	chr2:202336024~202336727:-
STAD	cis	rs12468226	0.873	rs79860867	ENSG00000226261.1	AC064836.3	4.05	6.4e-05	0.0227	0.36	0.21	Urate levels;	chr2:202192397	chr2:202336024~202336727:-
STAD	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-4.05	6.41e-05	0.0227	-0.27	-0.21	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
STAD	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-4.05	6.41e-05	0.0227	-0.23	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
STAD	cis	rs17630293	0.826	rs1436162	ENSG00000201649.1	RNY4P34	-4.05	6.41e-05	0.0227	-0.31	-0.21	Schizophrenia;	chr2:200285346	chr2:200373175~200373269:+
STAD	cis	rs7937890	0.874	rs6486191	ENSG00000254418.1	RP11-21L19.1	4.05	6.41e-05	0.0227	0.22	0.21	Mitochondrial DNA levels;	chr11:14382193	chr11:14262846~14273691:-
STAD	cis	rs34779708	0.931	rs13376871	ENSG00000271335.4	RP11-324I22.4	4.05	6.41e-05	0.0227	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35314552~35336401:-
STAD	cis	rs1850744	0.702	rs10939427	ENSG00000163612.10	FAM86KP	-4.05	6.42e-05	0.0227	-0.46	-0.21	Economic and political preferences;	chr4:9626914	chr4:9153296~9165451:+
STAD	cis	rs4589258	0.788	rs2213089	ENSG00000280367.1	RP11-121L10.2	4.05	6.42e-05	0.0227	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90747258	chr11:90223153~90226538:+
STAD	cis	rs7487075	0.619	rs11183488	ENSG00000257261.4	RP11-96H19.1	4.05	6.42e-05	0.0227	0.29	0.21	Itch intensity from mosquito bite;	chr12:46448053	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs7486532	ENSG00000257261.4	RP11-96H19.1	4.05	6.42e-05	0.0227	0.29	0.21	Itch intensity from mosquito bite;	chr12:46449472	chr12:46383679~46876159:+
STAD	cis	rs7674212	0.865	rs1481279	ENSG00000246560.2	RP11-10L12.4	-4.05	6.42e-05	0.0227	-0.27	-0.21	Type 2 diabetes;	chr4:103056781	chr4:102828055~102844075:+
STAD	cis	rs12744310	0.887	rs17362424	ENSG00000235358.1	RP11-399E6.1	-4.05	6.42e-05	0.0227	-0.28	-0.21	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328731	chr1:41242373~41284861:+
STAD	cis	rs559928	0.597	rs2096706	ENSG00000236935.1	AP003774.1	4.05	6.42e-05	0.0227	0.35	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64156974	chr11:64325050~64329504:-
STAD	cis	rs748404	0.578	rs4547312	ENSG00000275601.1	AC011330.13	-4.05	6.42e-05	0.0227	-0.23	-0.21	Lung cancer;	chr15:43339940	chr15:43642389~43643023:-
STAD	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-4.05	6.42e-05	0.0227	-0.21	-0.21	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
STAD	cis	rs11638815	0.581	rs2870965	ENSG00000259429.4	UBE2Q2P2	-4.05	6.42e-05	0.0227	-0.23	-0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:82355142~82420075:+
STAD	cis	rs561341	0.825	rs2008368	ENSG00000265798.5	RP11-271K11.5	4.05	6.42e-05	0.0227	0.3	0.21	Hip circumference adjusted for BMI;	chr17:32020378	chr17:31038575~31059121:-
STAD	cis	rs6832769	1	rs9684708	ENSG00000223305.1	RN7SKP30	-4.05	6.42e-05	0.0227	-0.24	-0.21	Personality dimensions;	chr4:55564214	chr4:55540502~55540835:-
STAD	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	4.05	6.43e-05	0.0227	0.28	0.21	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
STAD	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	4.05	6.43e-05	0.0228	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
STAD	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-4.05	6.44e-05	0.0228	-0.25	-0.21	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
STAD	cis	rs11098499	0.874	rs6832670	ENSG00000260091.1	RP11-33B1.4	4.05	6.44e-05	0.0228	0.21	0.21	Corneal astigmatism;	chr4:119197637	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.874	rs6822498	ENSG00000260091.1	RP11-33B1.4	4.05	6.44e-05	0.0228	0.21	0.21	Corneal astigmatism;	chr4:119199028	chr4:119409333~119410233:+
STAD	cis	rs7615952	0.932	rs13086087	ENSG00000272840.1	RP11-379B18.6	4.05	6.44e-05	0.0228	0.38	0.21	Blood pressure (smoking interaction);	chr3:125927438	chr3:125774714~125797953:+
STAD	cis	rs1707322	1	rs6429588	ENSG00000225447.1	RPS15AP10	4.05	6.44e-05	0.0228	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45645816~45646197:-
STAD	cis	rs9463078	0.739	rs6458425	ENSG00000219384.1	RP11-491H9.3	4.05	6.44e-05	0.0228	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45206120	chr6:45158870~45159511:+
STAD	cis	rs10851478	0.872	rs62022665	ENSG00000259545.2	RP11-325E5.4	-4.05	6.44e-05	0.0228	-0.26	-0.21	Oral cavity cancer;	chr15:49581614	chr15:49177610~49178741:-
STAD	cis	rs9291683	0.546	rs13120348	ENSG00000250613.1	RP11-136I13.1	4.05	6.44e-05	0.0228	0.22	0.21	Bone mineral density;	chr4:10051531	chr4:10410996~10411644:+
STAD	cis	rs7973719	0.531	rs10743271	ENSG00000239002.3	SCARNA10	4.05	6.44e-05	0.0228	0.21	0.21	IgG glycosylation;	chr12:7201194	chr12:6510222~6510551:+
STAD	cis	rs9747201	1	rs58472289	ENSG00000281517.1	Metazoa_SRP	4.05	6.44e-05	0.0228	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82154019	chr17:81718849~81719095:-
STAD	cis	rs41369048	0.669	rs11589654	ENSG00000238078.1	LINC01352	-4.05	6.44e-05	0.0228	-0.33	-0.21	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866646	chr1:220829255~220832429:+
STAD	cis	rs6479891	1	rs868798	ENSG00000235816.3	PRELID1P3	4.05	6.45e-05	0.0228	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63427297~63427939:+
STAD	cis	rs8059260	0.541	rs12927046	ENSG00000274038.1	RP11-66H6.4	-4.05	6.45e-05	0.0228	-0.38	-0.21	Alcohol consumption over the past year;	chr16:11148334	chr16:11056556~11057034:+
STAD	cis	rs7015630	0.779	rs13260987	ENSG00000251136.7	RP11-37B2.1	-4.05	6.45e-05	0.0228	-0.27	-0.21	Inflammatory bowel disease;Crohn's disease;	chr8:89854126	chr8:89609409~89757727:-
STAD	cis	rs2351088	0.764	rs11702966	ENSG00000230634.1	RP5-996D20.3	-4.05	6.45e-05	0.0228	-0.35	-0.21	Tonsillectomy;	chr22:45780795	chr22:46481329~46481760:-
STAD	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-4.05	6.45e-05	0.0228	-0.21	-0.21	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
STAD	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-4.05	6.45e-05	0.0228	-0.26	-0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
STAD	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	4.05	6.45e-05	0.0228	0.23	0.21	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
STAD	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	4.05	6.45e-05	0.0228	0.23	0.21	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
STAD	cis	rs3794924	1	rs7236328	ENSG00000266521.1	RP11-650P15.1	-4.04	6.46e-05	0.0228	-0.36	-0.21	Survival in colon cancer;	chr18:31475130	chr18:31496645~31497195:-
STAD	cis	rs6479891	1	rs2893922	ENSG00000235816.3	PRELID1P3	-4.04	6.46e-05	0.0228	-0.28	-0.21	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63427297~63427939:+
STAD	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	4.04	6.46e-05	0.0229	0.22	0.21	Height;	chr5:37481330	chr5:36666214~36725195:-
STAD	cis	rs13256369	0.826	rs12678414	ENSG00000253981.4	ALG1L13P	4.04	6.46e-05	0.0229	0.27	0.21	Obesity-related traits;	chr8:8728506	chr8:8236003~8244667:-
STAD	cis	rs4554975	0.838	rs11183620	ENSG00000272369.1	RP11-446N19.1	-4.04	6.46e-05	0.0229	-0.26	-0.21	Metabolite levels (small molecules and protein measures);	chr12:46818587	chr12:46537502~46652550:+
STAD	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-4.04	6.46e-05	0.0229	-0.33	-0.21	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
STAD	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	4.04	6.46e-05	0.0229	0.28	0.21	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
STAD	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	4.04	6.46e-05	0.0229	0.28	0.21	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
STAD	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	4.04	6.47e-05	0.0229	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
STAD	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	4.04	6.47e-05	0.0229	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
STAD	cis	rs7103648	1	rs11039225	ENSG00000280615.1	Y_RNA	4.04	6.47e-05	0.0229	0.21	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47409048	chr11:47614898~47614994:-
STAD	cis	rs253959	0.696	rs1421846	ENSG00000248445.4	SEMA6A-AS1	4.04	6.47e-05	0.0229	0.19	0.21	Bipolar disorder and schizophrenia;	chr5:116365440	chr5:116447547~116508276:+
STAD	cis	rs2446066	0.605	rs7302835	ENSG00000257379.1	RP11-793H13.8	4.04	6.47e-05	0.0229	0.42	0.21	Red blood cell count;	chr12:53561282	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.538	rs1485394	ENSG00000257379.1	RP11-793H13.8	4.04	6.47e-05	0.0229	0.42	0.21	Red blood cell count;	chr12:53561701	chr12:53441741~53467528:+
STAD	cis	rs9463078	0.691	rs9349313	ENSG00000219384.1	RP11-491H9.3	4.04	6.47e-05	0.0229	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45152045	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.691	rs6938177	ENSG00000219384.1	RP11-491H9.3	4.04	6.47e-05	0.0229	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45304097	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.55	rs7769231	ENSG00000219384.1	RP11-491H9.3	4.04	6.47e-05	0.0229	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45317184	chr6:45158870~45159511:+
STAD	cis	rs2638953	0.64	rs11049721	ENSG00000247934.4	RP11-967K21.1	-4.04	6.47e-05	0.0229	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573743	chr12:28163298~28190738:-
STAD	cis	rs34779708	0.733	rs16935945	ENSG00000271335.4	RP11-324I22.4	4.04	6.47e-05	0.0229	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.733	rs12777960	ENSG00000271335.4	RP11-324I22.4	4.04	6.47e-05	0.0229	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.733	rs11010146	ENSG00000271335.4	RP11-324I22.4	4.04	6.47e-05	0.0229	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.733	rs7086715	ENSG00000271335.4	RP11-324I22.4	4.04	6.47e-05	0.0229	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.702	rs7087150	ENSG00000271335.4	RP11-324I22.4	4.04	6.47e-05	0.0229	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.733	rs60553075	ENSG00000271335.4	RP11-324I22.4	4.04	6.47e-05	0.0229	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.733	rs12249814	ENSG00000271335.4	RP11-324I22.4	4.04	6.47e-05	0.0229	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35314552~35336401:-
STAD	cis	rs7474896	0.832	rs11596492	ENSG00000099251.13	HSD17B7P2	4.04	6.47e-05	0.0229	0.34	0.21	Obesity (extreme);	chr10:37691541	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs7474896	ENSG00000099251.13	HSD17B7P2	4.04	6.47e-05	0.0229	0.34	0.21	Obesity (extreme);	chr10:37693169	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs12772239	ENSG00000099251.13	HSD17B7P2	4.04	6.47e-05	0.0229	0.34	0.21	Obesity (extreme);	chr10:37700016	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs34496143	ENSG00000099251.13	HSD17B7P2	4.04	6.47e-05	0.0229	0.34	0.21	Obesity (extreme);	chr10:37703730	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs12357418	ENSG00000099251.13	HSD17B7P2	4.04	6.47e-05	0.0229	0.34	0.21	Obesity (extreme);	chr10:37704932	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs72639533	ENSG00000099251.13	HSD17B7P2	4.04	6.47e-05	0.0229	0.34	0.21	Obesity (extreme);	chr10:37708882	chr10:38356380~38378505:+
STAD	cis	rs2692947	0.759	rs1917890	ENSG00000237510.6	AC008268.2	4.04	6.47e-05	0.0229	0.26	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96006253	chr2:95789654~95800166:+
STAD	cis	rs9368481	0.761	rs4358615	ENSG00000224843.5	LINC00240	-4.04	6.47e-05	0.0229	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26956992~27023924:+
STAD	cis	rs11235843	0.706	rs10898949	ENSG00000255928.1	RP11-456I15.2	-4.04	6.47e-05	0.0229	-0.37	-0.21	Hand grip strength;	chr11:73870627	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.706	rs17132397	ENSG00000255928.1	RP11-456I15.2	4.04	6.47e-05	0.0229	0.37	0.21	Hand grip strength;	chr11:73854872	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.706	rs11235931	ENSG00000255928.1	RP11-456I15.2	4.04	6.47e-05	0.0229	0.37	0.21	Hand grip strength;	chr11:73856475	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.706	rs12420751	ENSG00000255928.1	RP11-456I15.2	4.04	6.47e-05	0.0229	0.37	0.21	Hand grip strength;	chr11:73861364	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.706	rs17132411	ENSG00000255928.1	RP11-456I15.2	4.04	6.47e-05	0.0229	0.37	0.21	Hand grip strength;	chr11:73864275	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.706	rs72982926	ENSG00000255928.1	RP11-456I15.2	4.04	6.47e-05	0.0229	0.37	0.21	Hand grip strength;	chr11:73869383	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.706	rs72982937	ENSG00000255928.1	RP11-456I15.2	4.04	6.47e-05	0.0229	0.37	0.21	Hand grip strength;	chr11:73885464	chr11:73722349~73722694:+
STAD	cis	rs1850744	1	rs6833148	ENSG00000250268.3	ALG1L14P	-4.04	6.47e-05	0.0229	-0.47	-0.21	Economic and political preferences;	chr4:9759129	chr4:9166297~9170270:-
STAD	cis	rs6772849	0.93	rs9873888	ENSG00000242551.2	POU5F1P6	-4.04	6.48e-05	0.0229	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128674735~128677005:-
STAD	cis	rs11235843	0.866	rs11235888	ENSG00000255928.1	RP11-456I15.2	4.04	6.48e-05	0.0229	0.37	0.21	Hand grip strength;	chr11:73759512	chr11:73722349~73722694:+
STAD	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	4.04	6.48e-05	0.0229	0.21	0.21	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
STAD	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	4.04	6.48e-05	0.0229	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
STAD	cis	rs4589258	0.762	rs10830567	ENSG00000280367.1	RP11-121L10.2	4.04	6.48e-05	0.0229	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90743677	chr11:90223153~90226538:+
STAD	cis	rs3858145	0.588	rs61854831	ENSG00000234102.1	KRT19P4	-4.04	6.48e-05	0.0229	-0.24	-0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68260557~68261499:+
STAD	cis	rs3858145	0.588	rs55888445	ENSG00000234102.1	KRT19P4	-4.04	6.48e-05	0.0229	-0.24	-0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68260557~68261499:+
STAD	cis	rs1876905	0.539	rs240987	ENSG00000230177.1	RP5-1112D6.4	-4.04	6.48e-05	0.0229	-0.24	-0.21	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111277932~111278742:+
STAD	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	4.04	6.48e-05	0.0229	0.31	0.21	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
STAD	cis	rs34779708	0.966	rs12773647	ENSG00000271335.4	RP11-324I22.4	4.04	6.48e-05	0.0229	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35314552~35336401:-
STAD	cis	rs1350171	0.764	rs4631906	ENSG00000255471.1	RP11-736K20.5	-4.04	6.48e-05	0.0229	-0.23	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr11:86939240	chr11:86892214~86925037:-
STAD	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-4.04	6.48e-05	0.0229	-0.25	-0.21	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
STAD	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-4.04	6.48e-05	0.0229	-0.35	-0.21	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
STAD	cis	rs498872	0.507	rs10892247	ENSG00000255239.1	AP002954.6	-4.04	6.48e-05	0.0229	-0.26	-0.21	Glioma;	chr11:118619361	chr11:118688039~118690600:-
STAD	cis	rs992157	0.798	rs12053514	ENSG00000224928.2	KRT8P30	4.04	6.48e-05	0.0229	0.23	0.21	Colorectal cancer;	chr2:218303242	chr2:218953401~218954050:-
STAD	cis	rs7204230	1	rs7190909	ENSG00000261291.1	RP11-295M3.2	4.04	6.48e-05	0.0229	0.25	0.21	Fibrinogen;	chr16:53335375	chr16:53168522~53169450:+
STAD	cis	rs919433	0.963	rs1896857	ENSG00000231621.1	AC013264.2	4.04	6.48e-05	0.0229	0.18	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197299806	chr2:197197991~197199273:+
STAD	cis	rs1707322	1	rs10890376	ENSG00000225447.1	RPS15AP10	4.04	6.48e-05	0.0229	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45645816~45646197:-
STAD	cis	rs238295	0.805	rs1053399	ENSG00000230563.2	RP5-828H9.1	4.04	6.49e-05	0.0229	0.24	0.21	Occipital cortical area (total cortical area interaction);	chr20:5545340	chr20:5471207~5475182:+
STAD	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	4.04	6.49e-05	0.0229	0.28	0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
STAD	cis	rs72791417	1	rs72791417	ENSG00000228065.9	LINC01515	-4.04	6.49e-05	0.0229	-0.38	-0.21	Bronchopulmonary dysplasia;	chr10:65983896	chr10:65570338~65768835:+
STAD	cis	rs1858037	0.765	rs67404371	ENSG00000223739.1	AC007389.2	-4.04	6.49e-05	0.0229	-0.2	-0.21	Rheumatoid arthritis;	chr2:65370137	chr2:65511771~65512076:-
STAD	cis	rs9291683	0.588	rs35866697	ENSG00000250613.1	RP11-136I13.1	-4.04	6.49e-05	0.0229	-0.2	-0.21	Bone mineral density;	chr4:10016980	chr4:10410996~10411644:+
STAD	cis	rs17630293	1	rs76448786	ENSG00000201649.1	RNY4P34	-4.04	6.49e-05	0.0229	-0.32	-0.21	Schizophrenia;	chr2:200282681	chr2:200373175~200373269:+
STAD	cis	rs7655841	0.632	rs4975274	ENSG00000248187.1	RP11-184M15.1	-4.04	6.49e-05	0.0229	-0.35	-0.21	Chronic obstructive pulmonary disease (moderate to severe);	chr4:128856921	chr4:128567972~128570531:-
STAD	cis	rs1707322	0.928	rs925524	ENSG00000225447.1	RPS15AP10	-4.04	6.49e-05	0.0229	-0.17	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46031037	chr1:45645816~45646197:-
STAD	cis	rs2836950	0.52	rs8130240	ENSG00000238141.2	BRWD1-AS1	-4.04	6.49e-05	0.0229	-0.22	-0.21	Menarche (age at onset);	chr21:39166182	chr21:39315707~39323218:+
STAD	cis	rs875971	1	rs6961717	ENSG00000224316.1	RP11-479O9.2	-4.04	6.49e-05	0.0229	-0.21	-0.21	Aortic root size;	chr7:66122550	chr7:65773620~65802067:+
STAD	cis	rs891378	0.785	rs7516468	ENSG00000274245.1	RP11-357P18.2	-4.04	6.5e-05	0.023	-0.27	-0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207235943	chr1:207372559~207373252:+
STAD	cis	rs6565180	0.962	rs35480350	ENSG00000273724.1	RP11-347C12.12	-4.04	6.5e-05	0.023	-0.23	-0.21	Tonsillectomy;	chr16:30354718	chr16:30336400~30343336:+
STAD	cis	rs451417	1	rs236124	ENSG00000275632.1	RP5-967N21.11	4.04	6.5e-05	0.023	0.28	0.21	Menopause (age at onset);	chr20:5995333	chr20:6000418~6000941:+
STAD	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-4.04	6.5e-05	0.023	-0.29	-0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
STAD	cis	rs2803122	0.807	rs10757035	ENSG00000272842.1	RP11-513M16.7	-4.04	6.5e-05	0.023	-0.19	-0.21	Pulse pressure;	chr9:19230274	chr9:19371386~19371945:-
STAD	cis	rs10129255	0.5	rs8021941	ENSG00000211959.2	IGHV4-39	4.04	6.5e-05	0.023	0.19	0.21	Kawasaki disease;	chr14:106781490	chr14:106421711~106422218:-
STAD	cis	rs453301	0.506	rs686189	ENSG00000173295.6	FAM86B3P	-4.04	6.5e-05	0.023	-0.24	-0.21	Joint mobility (Beighton score);	chr8:8766127	chr8:8228595~8244865:+
STAD	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-4.04	6.51e-05	0.023	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-4.04	6.51e-05	0.023	-0.31	-0.21	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
STAD	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	4.04	6.51e-05	0.023	0.3	0.21	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
STAD	cis	rs9847710	1	rs12488768	ENSG00000242142.1	SERBP1P3	-4.04	6.51e-05	0.023	-0.21	-0.21	Ulcerative colitis;	chr3:53052218	chr3:53064283~53065091:-
STAD	cis	rs11673344	0.542	rs2562598	ENSG00000267672.1	CTD-2293H3.1	4.04	6.51e-05	0.023	0.19	0.21	Obesity-related traits;	chr19:37025318	chr19:37091341~37092564:+
STAD	cis	rs7927771	0.8	rs35996350	ENSG00000271350.1	CTD-2384B9.1	-4.04	6.51e-05	0.023	-0.23	-0.21	Subjective well-being;	chr11:47367672	chr11:47041027~47041945:-
STAD	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-4.04	6.51e-05	0.023	-0.3	-0.21	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
STAD	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-4.04	6.52e-05	0.023	-0.26	-0.21	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
STAD	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-4.04	6.52e-05	0.023	-0.17	-0.21	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
STAD	cis	rs7142881	0.76	rs11628819	ENSG00000258648.1	UBE2CP1	-4.04	6.52e-05	0.023	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31623574	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs11621036	ENSG00000258648.1	UBE2CP1	-4.04	6.52e-05	0.023	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31623939	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs11620949	ENSG00000258648.1	UBE2CP1	-4.04	6.52e-05	0.023	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31623946	chr14:30683045~30683598:-
STAD	cis	rs11169552	0.51	rs10876056	ENSG00000200183.1	RNU6-238P	-4.04	6.53e-05	0.023	-0.2	-0.21	Colorectal cancer;	chr12:50554734	chr12:50656973~50657078:+
STAD	cis	rs34779708	0.966	rs34630580	ENSG00000271335.4	RP11-324I22.4	4.04	6.53e-05	0.023	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs12769484	ENSG00000271335.4	RP11-324I22.4	4.04	6.53e-05	0.023	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35314552~35336401:-
STAD	cis	rs2098713	0.599	rs62359042	ENSG00000250155.1	CTD-2353F22.1	4.04	6.53e-05	0.023	0.22	0.21	Telomere length;	chr5:37577604	chr5:36666214~36725195:-
STAD	cis	rs3764400	0.567	rs8071879	ENSG00000278765.1	RP5-890E16.5	-4.04	6.53e-05	0.023	-0.28	-0.21	Body mass index;	chr17:48140095	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs2325804	ENSG00000278765.1	RP5-890E16.5	-4.04	6.53e-05	0.023	-0.28	-0.21	Body mass index;	chr17:48141183	chr17:48066704~48067293:-
STAD	cis	rs9903692	0.505	rs208009	ENSG00000278765.1	RP5-890E16.5	-4.04	6.53e-05	0.023	-0.28	-0.21	Pulse pressure;	chr17:48152329	chr17:48066704~48067293:-
STAD	cis	rs6479891	0.908	rs2616631	ENSG00000235816.3	PRELID1P3	4.04	6.53e-05	0.023	0.28	0.21	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63427297~63427939:+
STAD	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-4.04	6.53e-05	0.023	-0.36	-0.21	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
STAD	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-4.04	6.53e-05	0.023	-0.36	-0.21	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
STAD	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-4.04	6.53e-05	0.023	-0.25	-0.21	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
STAD	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	4.04	6.53e-05	0.023	0.29	0.21	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
STAD	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	4.04	6.53e-05	0.023	0.29	0.21	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
STAD	cis	rs4218	0.56	rs8039514	ENSG00000259732.1	RP11-59H7.3	-4.04	6.53e-05	0.0231	-0.24	-0.21	Social communication problems;	chr15:59114382	chr15:59121034~59133250:+
STAD	cis	rs11098499	0.954	rs11098524	ENSG00000249244.1	RP11-548H18.2	4.04	6.53e-05	0.0231	0.27	0.21	Corneal astigmatism;	chr4:119468877	chr4:119391831~119395335:-
STAD	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	4.04	6.54e-05	0.0231	0.34	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
STAD	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-4.04	6.54e-05	0.0231	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-4.04	6.54e-05	0.0231	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-4.04	6.54e-05	0.0231	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-4.04	6.54e-05	0.0231	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-4.04	6.54e-05	0.0231	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
STAD	cis	rs1707322	1	rs12403666	ENSG00000225447.1	RPS15AP10	4.04	6.54e-05	0.0231	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45645816~45646197:-
STAD	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	4.04	6.54e-05	0.0231	0.29	0.21	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
STAD	cis	rs4589258	0.788	rs10501737	ENSG00000280367.1	RP11-121L10.2	4.04	6.54e-05	0.0231	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90758072	chr11:90223153~90226538:+
STAD	cis	rs17401966	0.838	rs7553935	ENSG00000199562.1	RNU6-37P	4.04	6.55e-05	0.0231	0.16	0.21	Hepatocellular carcinoma;	chr1:10315121	chr1:10298966~10299072:+
STAD	cis	rs17401966	0.838	rs12132134	ENSG00000199562.1	RNU6-37P	4.04	6.55e-05	0.0231	0.16	0.21	Hepatocellular carcinoma;	chr1:10318370	chr1:10298966~10299072:+
STAD	cis	rs11051970	0.559	rs3789975	ENSG00000274964.1	RP11-817I4.1	-4.04	6.55e-05	0.0231	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32331469	chr12:32339368~32340724:+
STAD	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	4.04	6.55e-05	0.0231	0.3	0.21	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
STAD	cis	rs891378	0.883	rs6671700	ENSG00000274245.1	RP11-357P18.2	-4.04	6.55e-05	0.0231	-0.26	-0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207316614	chr1:207372559~207373252:+
STAD	cis	rs7829975	0.744	rs2409092	ENSG00000173295.6	FAM86B3P	4.04	6.55e-05	0.0231	0.23	0.21	Mood instability;	chr8:8824682	chr8:8228595~8244865:+
STAD	cis	rs7520050	0.966	rs7524495	ENSG00000280836.1	AL355480.1	4.04	6.55e-05	0.0231	0.27	0.21	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs12411269	ENSG00000280836.1	AL355480.1	4.04	6.55e-05	0.0231	0.27	0.21	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.931	rs11211198	ENSG00000280836.1	AL355480.1	4.04	6.55e-05	0.0231	0.27	0.21	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs10890352	ENSG00000280836.1	AL355480.1	4.04	6.55e-05	0.0231	0.27	0.21	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs6700597	ENSG00000280836.1	AL355480.1	4.04	6.55e-05	0.0231	0.27	0.21	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45581219~45581321:-
STAD	cis	rs10129255	0.518	rs2006284	ENSG00000224373.3	IGHV4-59	4.04	6.55e-05	0.0231	0.15	0.21	Kawasaki disease;	chr14:106676185	chr14:106627249~106627825:-
STAD	cis	rs741668	0.795	rs1041167	ENSG00000235903.6	CPB2-AS1	4.04	6.55e-05	0.0231	0.26	0.21	Cerebrospinal fluid clusterin levels;	chr13:46046000	chr13:46052806~46113332:+
STAD	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	4.04	6.55e-05	0.0231	0.37	0.21	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
STAD	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	4.04	6.55e-05	0.0231	0.29	0.21	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	4.04	6.55e-05	0.0231	0.29	0.21	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	4.04	6.55e-05	0.0231	0.29	0.21	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
STAD	cis	rs9322193	0.962	rs1889473	ENSG00000233330.1	RP1-12G14.7	4.04	6.56e-05	0.0231	0.23	0.21	Lung cancer;	chr6:149825485	chr6:149591755~149592663:-
STAD	cis	rs9322193	0.962	rs6903998	ENSG00000233330.1	RP1-12G14.7	4.04	6.56e-05	0.0231	0.23	0.21	Lung cancer;	chr6:149831357	chr6:149591755~149592663:-
STAD	cis	rs9322193	0.923	rs1984111	ENSG00000233330.1	RP1-12G14.7	4.04	6.56e-05	0.0231	0.23	0.21	Lung cancer;	chr6:149831720	chr6:149591755~149592663:-
STAD	cis	rs1318937	0.764	rs60896928	ENSG00000224660.1	SH3BP5-AS1	4.04	6.56e-05	0.0231	0.21	0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15201343	chr3:15254184~15264493:+
STAD	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	4.04	6.56e-05	0.0231	0.28	0.21	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	4.04	6.56e-05	0.0231	0.28	0.21	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
STAD	cis	rs7615952	0.512	rs2979336	ENSG00000239804.1	RP11-379B18.1	4.04	6.56e-05	0.0231	0.3	0.21	Blood pressure (smoking interaction);	chr3:125638626	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.673	rs3811677	ENSG00000272840.1	RP11-379B18.6	4.04	6.56e-05	0.0231	0.38	0.21	Blood pressure (smoking interaction);	chr3:125929237	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.932	rs3811679	ENSG00000272840.1	RP11-379B18.6	4.04	6.56e-05	0.0231	0.38	0.21	Blood pressure (smoking interaction);	chr3:125929440	chr3:125774714~125797953:+
STAD	cis	rs9291683	0.588	rs2240722	ENSG00000250613.1	RP11-136I13.1	-4.04	6.56e-05	0.0231	-0.2	-0.21	Bone mineral density;	chr4:10019133	chr4:10410996~10411644:+
STAD	cis	rs11051970	0.559	rs3748275	ENSG00000274964.1	RP11-817I4.1	-4.04	6.56e-05	0.0231	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32328159	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs11051938	ENSG00000274964.1	RP11-817I4.1	-4.04	6.56e-05	0.0231	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32329882	chr12:32339368~32340724:+
STAD	cis	rs17630293	1	rs68130469	ENSG00000201649.1	RNY4P34	-4.04	6.56e-05	0.0231	-0.32	-0.21	Schizophrenia;	chr2:200282885	chr2:200373175~200373269:+
STAD	cis	rs17507216	0.628	rs8032321	ENSG00000259429.4	UBE2Q2P2	-4.04	6.57e-05	0.0231	-0.32	-0.21	Excessive daytime sleepiness;	chr15:82698956	chr15:82355142~82420075:+
STAD	cis	rs17507216	0.628	rs8040488	ENSG00000259429.4	UBE2Q2P2	-4.04	6.57e-05	0.0231	-0.32	-0.21	Excessive daytime sleepiness;	chr15:82699081	chr15:82355142~82420075:+
STAD	cis	rs9322193	0.962	rs13215691	ENSG00000233330.1	RP1-12G14.7	4.04	6.57e-05	0.0232	0.23	0.21	Lung cancer;	chr6:149792666	chr6:149591755~149592663:-
STAD	cis	rs2688608	0.592	rs11000757	ENSG00000272140.2	RP11-574K11.29	4.04	6.57e-05	0.0232	0.19	0.21	Inflammatory bowel disease;	chr10:73727057	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.592	rs11814282	ENSG00000272140.2	RP11-574K11.29	4.04	6.57e-05	0.0232	0.19	0.21	Inflammatory bowel disease;	chr10:73730459	chr10:73703735~73713581:-
STAD	cis	rs2638953	0.672	rs11049715	ENSG00000247934.4	RP11-967K21.1	-4.04	6.57e-05	0.0232	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28561520	chr12:28163298~28190738:-
STAD	cis	rs34779708	0.931	rs11010101	ENSG00000271335.4	RP11-324I22.4	4.04	6.57e-05	0.0232	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs11010102	ENSG00000271335.4	RP11-324I22.4	4.04	6.57e-05	0.0232	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35314552~35336401:-
STAD	cis	rs1707322	1	rs4660905	ENSG00000281133.1	AL355480.3	4.04	6.57e-05	0.0232	0.25	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45580892~45580996:-
STAD	cis	rs7119038	0.818	rs11826521	ENSG00000255422.1	AP002954.4	4.04	6.57e-05	0.0232	0.29	0.21	Sjögren's syndrome;	chr11:118739840	chr11:118704607~118750263:+
STAD	cis	rs7074356	0.688	rs7898568	ENSG00000225484.5	NUTM2B-AS1	-4.04	6.58e-05	0.0232	-0.3	-0.21	Borderline personality disorder;	chr10:80423775	chr10:79663088~79826594:-
STAD	cis	rs875971	0.862	rs11773628	ENSG00000224316.1	RP11-479O9.2	-4.04	6.58e-05	0.0232	-0.21	-0.21	Aortic root size;	chr7:66517644	chr7:65773620~65802067:+
STAD	cis	rs7474896	1	rs3824585	ENSG00000099251.13	HSD17B7P2	4.04	6.58e-05	0.0232	0.35	0.21	Obesity (extreme);	chr10:37820493	chr10:38356380~38378505:+
STAD	cis	rs2348418	0.703	rs12368149	ENSG00000247934.4	RP11-967K21.1	-4.04	6.58e-05	0.0232	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28168625	chr12:28163298~28190738:-
STAD	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	4.04	6.58e-05	0.0232	0.29	0.21	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
STAD	cis	rs7142881	0.815	rs17098029	ENSG00000258648.1	UBE2CP1	-4.04	6.58e-05	0.0232	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31632769	chr14:30683045~30683598:-
STAD	cis	rs34779708	1	rs12769189	ENSG00000271335.4	RP11-324I22.4	4.04	6.58e-05	0.0232	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs11599606	ENSG00000271335.4	RP11-324I22.4	4.04	6.58e-05	0.0232	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35314552~35336401:-
STAD	cis	rs4293777	0.935	rs7678509	ENSG00000250896.1	RNPS1P1	4.04	6.58e-05	0.0232	0.16	0.21	Primary sclerosing cholangitis;	chr4:10724311	chr4:11371975~11372892:+
STAD	cis	rs7474896	0.537	rs2505255	ENSG00000120555.12	SEPT7P9	4.04	6.58e-05	0.0232	0.27	0.21	Obesity (extreme);	chr10:38070714	chr10:38383069~38402916:-
STAD	cis	rs7824557	0.564	rs13260727	ENSG00000255495.1	AC145124.2	4.04	6.58e-05	0.0232	0.24	0.21	Retinal vascular caliber;	chr8:11375351	chr8:12194467~12196280:+
STAD	cis	rs9921338	0.961	rs7626	ENSG00000263080.1	RP11-485G7.5	4.04	6.58e-05	0.0232	0.33	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11341809~11345211:-
STAD	cis	rs8098244	0.737	rs1154241	ENSG00000267301.1	RPL23AP77	4.04	6.59e-05	0.0232	0.29	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23944675	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.737	rs1258152	ENSG00000267301.1	RPL23AP77	4.04	6.59e-05	0.0232	0.29	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23948377	chr18:23709825~23710287:-
STAD	cis	rs34779708	0.897	rs9665538	ENSG00000271335.4	RP11-324I22.4	4.04	6.59e-05	0.0232	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35314552~35336401:-
STAD	cis	rs9463078	0.625	rs3799986	ENSG00000219384.1	RP11-491H9.3	-4.04	6.59e-05	0.0232	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44932516	chr6:45158870~45159511:+
STAD	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-4.04	6.59e-05	0.0232	-0.32	-0.21	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
STAD	cis	rs1816752	0.721	rs7399656	ENSG00000232858.1	RPL34P27	4.04	6.59e-05	0.0232	0.13	0.21	Obesity-related traits;	chr13:24415708	chr13:24988577~24988925:-
STAD	cis	rs6142102	0.812	rs761236	ENSG00000264616.1	MIR4755	4.04	6.59e-05	0.0232	0.22	0.21	Skin pigmentation;	chr20:33932245	chr20:34049119~34049190:+
STAD	cis	rs7809950	1	rs3801944	ENSG00000238832.1	snoU109	4.04	6.59e-05	0.0232	0.29	0.21	Coronary artery disease;	chr7:107615103	chr7:107603363~107603507:+
STAD	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-4.04	6.59e-05	0.0232	-0.26	-0.21	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
STAD	cis	rs2657294	0.796	rs1259501	ENSG00000226051.5	ZNF503-AS1	-4.04	6.59e-05	0.0232	-0.28	-0.21	Pneumonia;	chr10:75230427	chr10:75269819~75373500:+
STAD	cis	rs2310173	0.575	rs4850993	ENSG00000281162.1	LINC01127	-4.04	6.59e-05	0.0232	-0.27	-0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102006004	chr2:101962056~101987167:+
STAD	cis	rs10129255	0.744	rs28517388	ENSG00000232216.1	IGHV3-43	4.04	6.6e-05	0.0232	0.22	0.21	Kawasaki disease;	chr14:106704323	chr14:106470264~106470800:-
STAD	cis	rs9322193	0.962	rs9478848	ENSG00000233330.1	RP1-12G14.7	4.04	6.6e-05	0.0232	0.23	0.21	Lung cancer;	chr6:149825080	chr6:149591755~149592663:-
STAD	cis	rs7103648	1	rs7947450	ENSG00000280615.1	Y_RNA	4.04	6.6e-05	0.0233	0.21	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47408353	chr11:47614898~47614994:-
STAD	cis	rs1020064	0.945	rs1030878	ENSG00000235319.1	AC012360.4	-4.04	6.6e-05	0.0233	-0.3	-0.21	AIDS;	chr2:105294141	chr2:105324210~105330529:+
STAD	cis	rs6693567	0.565	rs3754217	ENSG00000203819.6	HIST2H2BC	4.04	6.61e-05	0.0233	0.24	0.21	Migraine;	chr1:150507897	chr1:149850193~149850772:-
STAD	cis	rs10510181	0.599	rs73013034	ENSG00000224318.4	CHL1-AS2	4.04	6.61e-05	0.0233	0.23	0.21	Adolescent idiopathic scoliosis;	chr3:79652	chr3:195758~197341:-
STAD	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-4.04	6.61e-05	0.0233	-0.26	-0.21	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
STAD	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-4.04	6.61e-05	0.0233	-0.26	-0.21	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
STAD	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-4.04	6.61e-05	0.0233	-0.26	-0.21	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
STAD	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-4.04	6.61e-05	0.0233	-0.26	-0.21	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
STAD	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-4.04	6.61e-05	0.0233	-0.26	-0.21	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
STAD	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	4.04	6.61e-05	0.0233	0.25	0.21	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	4.04	6.61e-05	0.0233	0.25	0.21	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	4.04	6.61e-05	0.0233	0.25	0.21	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
STAD	cis	rs4665630	0.614	rs12623694	ENSG00000223754.1	AC008073.9	-4.04	6.61e-05	0.0233	-0.37	-0.21	Hypertension;	chr2:23664283	chr2:24199839~24201698:-
STAD	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	4.04	6.62e-05	0.0233	0.26	0.21	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
STAD	cis	rs6964833	1	rs36044436	ENSG00000277072.3	STAG3L2	4.04	6.62e-05	0.0233	0.26	0.21	Menarche (age at onset);	chr7:74675495	chr7:74882163~74890610:-
STAD	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	4.04	6.62e-05	0.0233	0.31	0.21	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
STAD	cis	rs7819412	0.668	rs920047	ENSG00000254527.1	ENPP7P12	-4.04	6.62e-05	0.0233	-0.23	-0.21	Triglycerides;	chr8:11229966	chr8:12205759~12206389:-
STAD	cis	rs8062405	0.755	rs4788074	ENSG00000278665.1	RP11-666O2.4	-4.04	6.62e-05	0.0233	-0.25	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28599241~28601881:-
STAD	cis	rs8054556	0.73	rs4788190	ENSG00000261588.1	AC002310.17	4.04	6.62e-05	0.0233	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30587662~30587920:-
STAD	cis	rs7927771	0.77	rs11039203	ENSG00000271350.1	CTD-2384B9.1	-4.04	6.62e-05	0.0233	-0.23	-0.21	Subjective well-being;	chr11:47363046	chr11:47041027~47041945:-
STAD	cis	rs7927771	0.832	rs67116452	ENSG00000271350.1	CTD-2384B9.1	-4.04	6.62e-05	0.0233	-0.23	-0.21	Subjective well-being;	chr11:47363643	chr11:47041027~47041945:-
STAD	cis	rs5753618	0.583	rs8138596	ENSG00000236132.1	CTA-440B3.1	-4.04	6.62e-05	0.0233	-0.24	-0.21	Colorectal cancer;	chr22:31390975	chr22:31816379~31817491:-
STAD	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	4.04	6.63e-05	0.0233	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
STAD	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-4.04	6.63e-05	0.0233	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
STAD	cis	rs2834188	1	rs2096464	ENSG00000272659.1	AP000295.10	4.04	6.63e-05	0.0233	0.3	0.21	Narcolepsy;	chr21:33313744	chr21:33309491~33310181:+
STAD	cis	rs2836950	0.565	rs2836930	ENSG00000238141.2	BRWD1-AS1	-4.04	6.63e-05	0.0233	-0.22	-0.21	Menarche (age at onset);	chr21:39173730	chr21:39315707~39323218:+
STAD	cis	rs10040610	0.524	rs56085350	ENSG00000250490.1	FLJ33360	4.04	6.63e-05	0.0233	0.25	0.21	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6349890	chr5:6310441~6339884:-
STAD	cis	rs7615952	0.546	rs2979340	ENSG00000171084.14	FAM86JP	4.04	6.63e-05	0.0233	0.34	0.21	Blood pressure (smoking interaction);	chr3:125622540	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.546	rs2979338	ENSG00000171084.14	FAM86JP	4.04	6.63e-05	0.0233	0.34	0.21	Blood pressure (smoking interaction);	chr3:125624282	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.546	rs2922171	ENSG00000171084.14	FAM86JP	4.04	6.63e-05	0.0233	0.34	0.21	Blood pressure (smoking interaction);	chr3:125624349	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.546	rs112919177	ENSG00000171084.14	FAM86JP	4.04	6.63e-05	0.0233	0.34	0.21	Blood pressure (smoking interaction);	chr3:125627226	chr3:125916620~125930024:+
STAD	cis	rs9291683	0.609	rs13149985	ENSG00000250613.1	RP11-136I13.1	-4.04	6.63e-05	0.0233	-0.19	-0.21	Bone mineral density;	chr4:10026766	chr4:10410996~10411644:+
STAD	cis	rs9747201	0.962	rs62078313	ENSG00000281517.1	Metazoa_SRP	4.04	6.63e-05	0.0233	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82158832	chr17:81718849~81719095:-
STAD	cis	rs1892700	1	rs17646111	ENSG00000225555.1	AP000320.6	-4.04	6.63e-05	0.0233	-0.28	-0.21	Educational attainment;	chr21:33582476	chr21:34370802~34375348:-
STAD	cis	rs2638953	0.886	rs11049615	ENSG00000247934.4	RP11-967K21.1	-4.04	6.64e-05	0.0233	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452152	chr12:28163298~28190738:-
STAD	cis	rs4805566	0.78	rs2195948	ENSG00000267006.1	CTC-448F2.4	-4.04	6.64e-05	0.0234	-0.24	-0.21	Body mass index;	chr19:30417679	chr19:30028741~30029916:-
STAD	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	4.04	6.64e-05	0.0234	0.29	0.21	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
STAD	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	4.04	6.64e-05	0.0234	0.29	0.21	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
STAD	cis	rs6832769	0.961	rs28445925	ENSG00000223305.1	RN7SKP30	-4.04	6.64e-05	0.0234	-0.24	-0.21	Personality dimensions;	chr4:55569682	chr4:55540502~55540835:-
STAD	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	4.04	6.64e-05	0.0234	0.26	0.21	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
STAD	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-4.04	6.64e-05	0.0234	-0.33	-0.21	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-4.04	6.64e-05	0.0234	-0.33	-0.21	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
STAD	cis	rs8012947	0.877	rs12879675	ENSG00000180189.10	HMGB1P14	-4.04	6.64e-05	0.0234	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58240535	chr14:58284773~58285363:+
STAD	cis	rs4927850	1	rs7630875	ENSG00000278820.1	AC024937.1	4.04	6.64e-05	0.0234	0.24	0.21	Pancreatic cancer;	chr3:196026895	chr3:195960500~195960612:-
STAD	cis	rs786425	0.866	rs7139193	ENSG00000247373.3	RP11-486O12.2	-4.04	6.65e-05	0.0234	-0.16	-0.21	Pubertal anthropometrics;	chr12:123686629	chr12:123575891~123585115:-
STAD	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	4.04	6.65e-05	0.0234	0.25	0.21	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
STAD	cis	rs6452524	0.508	rs40214	ENSG00000243385.2	CTD-2110K23.1	-4.04	6.65e-05	0.0234	-0.24	-0.21	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83201229~83202141:+
STAD	cis	rs1707322	1	rs1622208	ENSG00000225447.1	RPS15AP10	-4.04	6.65e-05	0.0234	-0.17	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45645816~45646197:-
STAD	cis	rs4713118	0.513	rs149941	ENSG00000220721.1	OR1F12	4.04	6.65e-05	0.0234	0.22	0.21	Parkinson's disease;	chr6:28033255	chr6:28073316~28074233:+
STAD	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-4.04	6.65e-05	0.0234	-0.33	-0.21	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-4.04	6.65e-05	0.0234	-0.33	-0.21	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
STAD	cis	rs10129255	0.957	rs61997760	ENSG00000232216.1	IGHV3-43	4.04	6.65e-05	0.0234	0.21	0.21	Kawasaki disease;	chr14:106716993	chr14:106470264~106470800:-
STAD	cis	rs3770081	1	rs57083584	ENSG00000273080.1	RP11-301O19.1	-4.04	6.65e-05	0.0234	-0.51	-0.21	Facial emotion recognition (sad faces);	chr2:86056525	chr2:86195590~86196049:+
STAD	cis	rs1707322	0.721	rs10789468	ENSG00000225447.1	RPS15AP10	4.04	6.65e-05	0.0234	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs6429574	ENSG00000225447.1	RPS15AP10	4.04	6.65e-05	0.0234	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45645816~45646197:-
STAD	cis	rs34375054	0.525	rs7398636	ENSG00000279233.1	RP11-158L12.4	4.04	6.65e-05	0.0234	0.21	0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125114058	chr12:125138245~125141711:+
STAD	cis	rs60180747	1	rs77515996	ENSG00000252712.1	SCARNA14	4.04	6.66e-05	0.0234	0.25	0.21	Testicular germ cell tumor;	chr15:66416601	chr15:66347207~66347342:-
STAD	cis	rs7487075	0.859	rs7961994	ENSG00000257261.4	RP11-96H19.1	4.04	6.66e-05	0.0234	0.27	0.21	Itch intensity from mosquito bite;	chr12:46361329	chr12:46383679~46876159:+
STAD	cis	rs10129255	0.5	rs34326748	ENSG00000232216.1	IGHV3-43	4.04	6.66e-05	0.0234	0.19	0.21	Kawasaki disease;	chr14:106782523	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.5	rs10143385	ENSG00000232216.1	IGHV3-43	4.04	6.66e-05	0.0234	0.19	0.21	Kawasaki disease;	chr14:106782559	chr14:106470264~106470800:-
STAD	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	4.04	6.66e-05	0.0234	0.26	0.21	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
STAD	cis	rs34779708	0.966	rs878264	ENSG00000271335.4	RP11-324I22.4	4.04	6.67e-05	0.0234	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35314552~35336401:-
STAD	cis	rs8012947	0.651	rs8008129	ENSG00000279636.2	LINC00216	4.04	6.67e-05	0.0234	0.2	0.21	Alcohol consumption in current drinkers;	chr14:58362314	chr14:58288033~58289158:+
STAD	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	4.04	6.67e-05	0.0235	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
STAD	cis	rs935334	0.866	rs12587652	ENSG00000258454.1	RP11-361H10.3	-4.04	6.67e-05	0.0235	-0.31	-0.21	Blood pressure;	chr14:76222270	chr14:76235817~76263474:+
STAD	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	4.04	6.67e-05	0.0235	0.26	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
STAD	cis	rs4237845	0.537	rs11172367	ENSG00000273805.1	RP11-620J15.4	-4.04	6.67e-05	0.0235	-0.24	-0.21	Intelligence (multi-trait analysis);	chr12:57878703	chr12:57894232~57896846:+
STAD	cis	rs7771547	0.642	rs9470309	ENSG00000240733.3	RN7SL502P	4.04	6.68e-05	0.0235	0.19	0.21	Platelet distribution width;	chr6:36541974	chr6:36450912~36451201:-
STAD	cis	rs1348850	0.567	rs2222711	ENSG00000271825.1	RP11-337N6.2	4.04	6.68e-05	0.0235	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177669382	chr2:177300600~177302006:+
STAD	cis	rs4835473	0.932	rs9685306	ENSG00000249741.2	RP11-673E1.3	4.04	6.68e-05	0.0235	0.25	0.21	Immature fraction of reticulocytes;	chr4:143748843	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs13107719	ENSG00000249741.2	RP11-673E1.3	4.04	6.68e-05	0.0235	0.25	0.21	Immature fraction of reticulocytes;	chr4:143752034	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.897	rs2323194	ENSG00000249741.2	RP11-673E1.3	4.04	6.68e-05	0.0235	0.25	0.21	Immature fraction of reticulocytes;	chr4:143752879	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs35055653	ENSG00000249741.2	RP11-673E1.3	4.04	6.68e-05	0.0235	0.25	0.21	Immature fraction of reticulocytes;	chr4:143754836	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs35017645	ENSG00000249741.2	RP11-673E1.3	4.04	6.68e-05	0.0235	0.25	0.21	Immature fraction of reticulocytes;	chr4:143760196	chr4:143911514~143912053:-
STAD	cis	rs2115630	1	rs6496441	ENSG00000275120.1	RP11-182J1.17	-4.04	6.68e-05	0.0235	-0.23	-0.21	P wave terminal force;	chr15:84820117	chr15:84599434~84606463:-
STAD	cis	rs10129255	0.957	rs10142918	ENSG00000224373.3	IGHV4-59	4.04	6.68e-05	0.0235	0.17	0.21	Kawasaki disease;	chr14:106782206	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.957	rs10142859	ENSG00000224373.3	IGHV4-59	4.04	6.68e-05	0.0235	0.17	0.21	Kawasaki disease;	chr14:106782238	chr14:106627249~106627825:-
STAD	cis	rs7615952	0.688	rs17334074	ENSG00000239804.1	RP11-379B18.1	-4.04	6.68e-05	0.0235	-0.26	-0.21	Blood pressure (smoking interaction);	chr3:125821617	chr3:125787888~125788146:-
STAD	cis	rs9463078	0.691	rs10807318	ENSG00000219384.1	RP11-491H9.3	4.04	6.68e-05	0.0235	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45216716	chr6:45158870~45159511:+
STAD	cis	rs1858037	0.867	rs67453645	ENSG00000223739.1	AC007389.2	-4.04	6.68e-05	0.0235	-0.2	-0.21	Rheumatoid arthritis;	chr2:65358908	chr2:65511771~65512076:-
STAD	cis	rs1858037	0.867	rs57913336	ENSG00000223739.1	AC007389.2	-4.04	6.68e-05	0.0235	-0.2	-0.21	Rheumatoid arthritis;	chr2:65360485	chr2:65511771~65512076:-
STAD	cis	rs7829975	0.577	rs940030	ENSG00000254340.1	RP11-10A14.3	-4.04	6.68e-05	0.0235	-0.29	-0.21	Mood instability;	chr8:8689418	chr8:9141424~9145435:+
STAD	cis	rs870825	0.616	rs61653735	ENSG00000249173.4	LINC01093	-4.04	6.69e-05	0.0235	-0.35	-0.21	Blood protein levels;	chr4:184708871	chr4:184893871~184899454:-
STAD	cis	rs870825	0.581	rs28602720	ENSG00000249173.4	LINC01093	-4.04	6.69e-05	0.0235	-0.35	-0.21	Blood protein levels;	chr4:184709444	chr4:184893871~184899454:-
STAD	cis	rs4407350	0.756	rs3827401	ENSG00000279642.1	RP5-1033E15.3	-4.04	6.69e-05	0.0235	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44494738	chr22:44486295~44486914:-
STAD	cis	rs4407350	0.721	rs3827402	ENSG00000279642.1	RP5-1033E15.3	-4.04	6.69e-05	0.0235	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44494771	chr22:44486295~44486914:-
STAD	cis	rs4407350	0.756	rs135622	ENSG00000279642.1	RP5-1033E15.3	-4.04	6.69e-05	0.0235	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44494778	chr22:44486295~44486914:-
STAD	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	4.04	6.69e-05	0.0235	0.25	0.21	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
STAD	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	4.04	6.69e-05	0.0235	0.22	0.21	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
STAD	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-4.04	6.69e-05	0.0235	-0.23	-0.21	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
STAD	cis	rs7474896	1	rs72639538	ENSG00000099251.13	HSD17B7P2	4.04	6.69e-05	0.0235	0.35	0.21	Obesity (extreme);	chr10:38071588	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs61858886	ENSG00000099251.13	HSD17B7P2	4.04	6.69e-05	0.0235	0.35	0.21	Obesity (extreme);	chr10:38071773	chr10:38356380~38378505:+
STAD	cis	rs7924176	0.601	rs17676126	ENSG00000213731.2	RAB5CP1	-4.04	6.69e-05	0.0235	-0.22	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74145440	chr10:74423435~74424014:-
STAD	cis	rs2638953	0.962	rs73261702	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204118	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049455	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204758	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049457	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205050	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs10843131	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205259	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs10843132	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205348	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs10843133	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205571	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs10843135	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205809	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs11049458	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205834	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049459	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206011	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049460	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206021	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs1824767	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206653	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs1824766	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206655	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs1585682	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206841	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.888	rs9645745	ENSG00000247934.4	RP11-967K21.1	-4.04	6.69e-05	0.0235	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207082	chr12:28163298~28190738:-
STAD	cis	rs2688608	0.592	rs11000758	ENSG00000272140.2	RP11-574K11.29	4.04	6.7e-05	0.0235	0.19	0.21	Inflammatory bowel disease;	chr10:73733852	chr10:73703735~73713581:-
STAD	cis	rs2115630	0.967	rs8027779	ENSG00000275120.1	RP11-182J1.17	-4.04	6.7e-05	0.0235	-0.23	-0.21	P wave terminal force;	chr15:84712154	chr15:84599434~84606463:-
STAD	cis	rs453301	0.538	rs7830804	ENSG00000233609.3	RP11-62H7.2	-4.04	6.7e-05	0.0235	-0.25	-0.21	Joint mobility (Beighton score);	chr8:9113252	chr8:8961200~8979025:+
STAD	cis	rs393951	0.673	rs280857	ENSG00000260969.1	RP11-190D6.2	4.04	6.7e-05	0.0235	0.27	0.21	Childhood ear infection;	chr16:77562422	chr16:78237362~78241218:-
STAD	cis	rs7131987	0.903	rs1991114	ENSG00000257176.2	RP11-996F15.2	-4.04	6.7e-05	0.0235	-0.24	-0.21	QT interval;	chr12:29239149	chr12:29280418~29317848:-
STAD	cis	rs7131987	0.903	rs1035604	ENSG00000257176.2	RP11-996F15.2	-4.04	6.7e-05	0.0235	-0.24	-0.21	QT interval;	chr12:29240169	chr12:29280418~29317848:-
STAD	cis	rs2957692	0.528	rs12418514	ENSG00000254554.1	RP11-351I24.1	4.04	6.7e-05	0.0235	0.37	0.21	Circulating vasoactive peptide levels;	chr11:10296740	chr11:10302657~10303704:-
STAD	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	4.04	6.7e-05	0.0235	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
STAD	cis	rs7474896	1	rs2738191	ENSG00000120555.12	SEPT7P9	4.04	6.7e-05	0.0235	0.31	0.21	Obesity (extreme);	chr10:37976858	chr10:38383069~38402916:-
STAD	cis	rs11051970	0.559	rs4931012	ENSG00000274964.1	RP11-817I4.1	-4.04	6.71e-05	0.0235	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32328970	chr12:32339368~32340724:+
STAD	cis	rs4834770	0.792	rs7676969	ENSG00000248280.1	RP11-33B1.2	4.04	6.71e-05	0.0235	0.25	0.21	Blood protein levels;	chr4:119252569	chr4:119440561~119450157:-
STAD	cis	rs4834770	0.685	rs4496567	ENSG00000248280.1	RP11-33B1.2	4.04	6.71e-05	0.0235	0.25	0.21	Blood protein levels;	chr4:119254470	chr4:119440561~119450157:-
STAD	cis	rs4834770	0.792	rs6823331	ENSG00000248280.1	RP11-33B1.2	4.04	6.71e-05	0.0235	0.25	0.21	Blood protein levels;	chr4:119259635	chr4:119440561~119450157:-
STAD	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	4.04	6.71e-05	0.0235	0.23	0.21	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
STAD	cis	rs4713118	0.505	rs276371	ENSG00000220721.1	OR1F12	4.04	6.71e-05	0.0235	0.21	0.21	Parkinson's disease;	chr6:27942930	chr6:28073316~28074233:+
STAD	cis	rs9928842	0.941	rs1808427	ENSG00000280152.1	RP11-331F4.5	4.04	6.71e-05	0.0236	0.32	0.21	Alcoholic chronic pancreatitis;	chr16:75207496	chr16:75245994~75250077:-
STAD	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-4.04	6.71e-05	0.0236	-0.32	-0.21	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
STAD	cis	rs9287719	0.578	rs62127189	ENSG00000243819.4	RN7SL832P	4.04	6.71e-05	0.0236	0.21	0.21	Prostate cancer;	chr2:10621200	chr2:10690344~10692099:+
STAD	cis	rs858239	0.932	rs1637190	ENSG00000230042.1	AK3P3	-4.04	6.71e-05	0.0236	-0.23	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23129178~23129841:+
STAD	cis	rs6686842	0.56	rs213751	ENSG00000235358.1	RP11-399E6.1	-4.04	6.71e-05	0.0236	-0.23	-0.21	Height;	chr1:41144214	chr1:41242373~41284861:+
STAD	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	4.04	6.71e-05	0.0236	0.46	0.21	QT interval;	chr4:75108738	chr4:75081702~75084717:-
STAD	cis	rs34779708	0.966	rs12784482	ENSG00000271335.4	RP11-324I22.4	4.04	6.71e-05	0.0236	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs17499811	ENSG00000271335.4	RP11-324I22.4	4.04	6.71e-05	0.0236	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs35146199	ENSG00000271335.4	RP11-324I22.4	4.04	6.71e-05	0.0236	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35314552~35336401:-
STAD	cis	rs794185	0.714	rs793398	ENSG00000231249.1	ITPR1-AS1	-4.04	6.71e-05	0.0236	-0.24	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4454241	chr3:4490891~4493163:-
STAD	cis	rs2688608	0.592	rs11000760	ENSG00000272140.2	RP11-574K11.29	4.04	6.72e-05	0.0236	0.19	0.21	Inflammatory bowel disease;	chr10:73733976	chr10:73703735~73713581:-
STAD	cis	rs2688608	0.592	rs12253429	ENSG00000272140.2	RP11-574K11.29	4.04	6.72e-05	0.0236	0.19	0.21	Inflammatory bowel disease;	chr10:73736403	chr10:73703735~73713581:-
STAD	cis	rs28472312	0.667	rs3922668	ENSG00000278665.1	RP11-666O2.4	-4.04	6.72e-05	0.0236	-0.23	-0.21	Intelligence (multi-trait analysis);	chr16:28981325	chr16:28599241~28601881:-
STAD	cis	rs2992257	0.958	rs2992264	ENSG00000251839.1	RNU7-12P	-4.04	6.72e-05	0.0236	-0.21	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26454762	chr10:27232255~27232316:-
STAD	cis	rs2992257	1	rs2992265	ENSG00000251839.1	RNU7-12P	-4.04	6.72e-05	0.0236	-0.21	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26454826	chr10:27232255~27232316:-
STAD	cis	rs2638953	0.815	rs11049677	ENSG00000247934.4	RP11-967K21.1	4.04	6.72e-05	0.0236	0.24	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505106	chr12:28163298~28190738:-
STAD	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	4.04	6.72e-05	0.0236	0.25	0.21	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
STAD	cis	rs11235843	0.706	rs17132403	ENSG00000255928.1	RP11-456I15.2	4.03	6.73e-05	0.0236	0.37	0.21	Hand grip strength;	chr11:73858131	chr11:73722349~73722694:+
STAD	cis	rs7680126	0.597	rs78917351	ENSG00000250613.1	RP11-136I13.1	4.03	6.73e-05	0.0236	0.24	0.21	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10206439	chr4:10410996~10411644:+
STAD	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-4.03	6.73e-05	0.0236	-0.26	-0.21	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
STAD	cis	rs2901460	0.67	rs13020078	ENSG00000229503.1	AC092155.1	-4.03	6.73e-05	0.0236	-0.17	-0.21	Mean corpuscular volume;	chr2:62174748	chr2:62532583~62533059:-
STAD	cis	rs2901460	0.67	rs11687618	ENSG00000229503.1	AC092155.1	-4.03	6.73e-05	0.0236	-0.17	-0.21	Mean corpuscular volume;	chr2:62175101	chr2:62532583~62533059:-
STAD	cis	rs4589258	0.788	rs10741370	ENSG00000280367.1	RP11-121L10.2	4.03	6.73e-05	0.0236	0.22	0.21	Intelligence (multi-trait analysis);	chr11:90766942	chr11:90223153~90226538:+
STAD	cis	rs6061231	1	rs11696991	ENSG00000275437.1	RP5-908M14.10	4.03	6.73e-05	0.0236	0.21	0.21	Colorectal cancer;	chr20:62384638	chr20:62402236~62405935:-
STAD	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-4.03	6.73e-05	0.0236	-0.24	-0.21	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
STAD	cis	rs2562456	0.833	rs8106025	ENSG00000268119.4	CTD-2561J22.5	-4.03	6.74e-05	0.0236	-0.27	-0.21	Pain;	chr19:21451922	chr19:21444241~21463908:-
STAD	cis	rs34779708	0.931	rs12773169	ENSG00000271335.4	RP11-324I22.4	4.03	6.74e-05	0.0236	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35314552~35336401:-
STAD	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-4.03	6.74e-05	0.0236	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
STAD	cis	rs11673344	0.523	rs7248948	ENSG00000267672.1	CTD-2293H3.1	4.03	6.74e-05	0.0236	0.2	0.21	Obesity-related traits;	chr19:37056317	chr19:37091341~37092564:+
STAD	cis	rs1858037	0.867	rs61226353	ENSG00000223739.1	AC007389.2	-4.03	6.74e-05	0.0236	-0.2	-0.21	Rheumatoid arthritis;	chr2:65363637	chr2:65511771~65512076:-
STAD	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-4.03	6.74e-05	0.0236	-0.24	-0.21	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
STAD	cis	rs4879656	0.835	rs10813927	ENSG00000225693.1	LAGE3P1	-4.03	6.74e-05	0.0236	-0.27	-0.21	Menopause (age at onset);	chr9:33047912	chr9:33019682~33020165:-
STAD	cis	rs7142881	0.815	rs12437209	ENSG00000258648.1	UBE2CP1	-4.03	6.74e-05	0.0237	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31641313	chr14:30683045~30683598:-
STAD	cis	rs7615952	0.611	rs7632305	ENSG00000241346.1	SNRPCP11	4.03	6.75e-05	0.0237	0.38	0.21	Blood pressure (smoking interaction);	chr3:125915924	chr3:125816082~125816286:-
STAD	cis	rs8081395	0.58	rs180515	ENSG00000266701.1	AC005702.4	4.03	6.75e-05	0.0237	0.27	0.21	White blood cell count;	chr17:59946914	chr17:60042546~60042627:-
STAD	cis	rs6585424	1	rs10466226	ENSG00000225484.5	NUTM2B-AS1	4.03	6.75e-05	0.0237	0.37	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164299	chr10:79663088~79826594:-
STAD	cis	rs10851478	0.872	rs17479589	ENSG00000259545.2	RP11-325E5.4	-4.03	6.75e-05	0.0237	-0.26	-0.21	Oral cavity cancer;	chr15:49461335	chr15:49177610~49178741:-
STAD	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	4.03	6.76e-05	0.0237	0.25	0.21	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
STAD	cis	rs7915414	0.531	rs28371675	ENSG00000230338.1	MTND4P19	4.03	6.76e-05	0.0237	0.26	0.21	Clopidogrel active metabolite levels;	chr10:94942580	chr10:94774156~94774633:-
STAD	cis	rs728616	0.51	rs17617406	ENSG00000225484.5	NUTM2B-AS1	4.03	6.76e-05	0.0237	0.39	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80414800	chr10:79663088~79826594:-
STAD	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-4.03	6.76e-05	0.0237	-0.23	-0.21	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
STAD	cis	rs9463078	0.547	rs4711798	ENSG00000219384.1	RP11-491H9.3	4.03	6.76e-05	0.0237	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44783040	chr6:45158870~45159511:+
STAD	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	4.03	6.76e-05	0.0237	0.21	0.21	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
STAD	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	4.03	6.76e-05	0.0237	0.26	0.21	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
STAD	cis	rs12052479	0.619	rs2701268	ENSG00000232788.1	AC078883.3	4.03	6.77e-05	0.0237	0.26	0.21	Blood protein levels;	chr2:172486471	chr2:172464262~172466022:-
STAD	cis	rs10129255	0.957	rs8009464	ENSG00000224373.3	IGHV4-59	4.03	6.77e-05	0.0237	0.17	0.21	Kawasaki disease;	chr14:106777611	chr14:106627249~106627825:-
STAD	cis	rs55823223	0.564	rs4572466	ENSG00000267801.1	RP11-552F3.9	4.03	6.77e-05	0.0237	0.28	0.21	Psoriasis;	chr17:75850233	chr17:75876372~75879546:+
STAD	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-4.03	6.77e-05	0.0237	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
STAD	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	4.03	6.77e-05	0.0237	0.23	0.21	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
STAD	cis	rs4713118	0.513	rs149989	ENSG00000220721.1	OR1F12	4.03	6.78e-05	0.0237	0.22	0.21	Parkinson's disease;	chr6:28030406	chr6:28073316~28074233:+
STAD	cis	rs238295	0.805	rs6053500	ENSG00000230563.2	RP5-828H9.1	4.03	6.78e-05	0.0237	0.24	0.21	Occipital cortical area (total cortical area interaction);	chr20:5562037	chr20:5471207~5475182:+
STAD	cis	rs28472312	0.823	rs62037373	ENSG00000278665.1	RP11-666O2.4	4.03	6.78e-05	0.0238	0.24	0.21	Intelligence (multi-trait analysis);	chr16:28881974	chr16:28599241~28601881:-
STAD	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	4.03	6.78e-05	0.0238	0.28	0.21	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
STAD	cis	rs11098499	0.604	rs12642411	ENSG00000260091.1	RP11-33B1.4	4.03	6.78e-05	0.0238	0.21	0.21	Corneal astigmatism;	chr4:119659370	chr4:119409333~119410233:+
STAD	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	4.03	6.78e-05	0.0238	0.29	0.21	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
STAD	cis	rs9902453	0.726	rs3110494	ENSG00000240074.1	RPL9P30	4.03	6.78e-05	0.0238	0.18	0.21	Coffee consumption (cups per day);	chr17:29649579	chr17:29855759~29856332:+
STAD	cis	rs12682352	0.65	rs13265731	ENSG00000253981.4	ALG1L13P	4.03	6.78e-05	0.0238	0.26	0.21	Neuroticism;	chr8:8815810	chr8:8236003~8244667:-
STAD	cis	rs1816752	0.609	rs4770692	ENSG00000273628.1	RP11-756A22.7	-4.03	6.79e-05	0.0238	-0.25	-0.21	Obesity-related traits;	chr13:24468689	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.609	rs4770694	ENSG00000273628.1	RP11-756A22.7	-4.03	6.79e-05	0.0238	-0.25	-0.21	Obesity-related traits;	chr13:24468891	chr13:24933006~24936796:+
STAD	cis	rs1816752	0.624	rs9507354	ENSG00000273628.1	RP11-756A22.7	-4.03	6.79e-05	0.0238	-0.25	-0.21	Obesity-related traits;	chr13:24469227	chr13:24933006~24936796:+
STAD	cis	rs4834770	1	rs878374	ENSG00000249244.1	RP11-548H18.2	4.03	6.79e-05	0.0238	0.27	0.21	Blood protein levels;	chr4:119316409	chr4:119391831~119395335:-
STAD	cis	rs10510102	0.872	rs56108883	ENSG00000226864.1	ATE1-AS1	4.03	6.79e-05	0.0238	0.35	0.21	Breast cancer;	chr10:121825567	chr10:121928312~121951965:+
STAD	cis	rs4925386	0.802	rs6142735	ENSG00000273619.1	RP5-908M14.9	-4.03	6.79e-05	0.0238	-0.21	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62386303~62386970:-
STAD	cis	rs227932	0.614	rs4722260	ENSG00000234286.1	AC006026.13	4.03	6.79e-05	0.0238	0.36	0.21	Schizophrenia;	chr7:23719851	chr7:23680195~23680786:-
STAD	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	4.03	6.79e-05	0.0238	0.25	0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
STAD	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-4.03	6.79e-05	0.0238	-0.23	-0.21	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
STAD	cis	rs11722779	0.935	rs11938650	ENSG00000248971.2	KRT8P46	-4.03	6.79e-05	0.0238	-0.22	-0.21	Schizophrenia;	chr4:103021639	chr4:102728746~102730171:-
STAD	cis	rs447735	0.587	rs7188458	ENSG00000274627.1	RP11-104N10.2	4.03	6.79e-05	0.0238	0.2	0.21	Hemoglobin concentration;	chr16:89660076	chr16:89516797~89522217:+
STAD	cis	rs6832769	0.922	rs819271	ENSG00000223305.1	RN7SKP30	4.03	6.8e-05	0.0238	0.24	0.21	Personality dimensions;	chr4:55372680	chr4:55540502~55540835:-
STAD	cis	rs6693567	0.565	rs1694379	ENSG00000203819.6	HIST2H2BC	4.03	6.8e-05	0.0238	0.25	0.21	Migraine;	chr1:150319969	chr1:149850193~149850772:-
STAD	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	4.03	6.8e-05	0.0238	0.33	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
STAD	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	4.03	6.8e-05	0.0238	0.33	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
STAD	cis	rs7615952	0.512	rs4679430	ENSG00000239804.1	RP11-379B18.1	4.03	6.8e-05	0.0238	0.3	0.21	Blood pressure (smoking interaction);	chr3:125639049	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.512	rs34651730	ENSG00000239804.1	RP11-379B18.1	4.03	6.8e-05	0.0238	0.3	0.21	Blood pressure (smoking interaction);	chr3:125639796	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.512	rs11929125	ENSG00000239804.1	RP11-379B18.1	4.03	6.8e-05	0.0238	0.3	0.21	Blood pressure (smoking interaction);	chr3:125640599	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.512	rs2922175	ENSG00000239804.1	RP11-379B18.1	4.03	6.8e-05	0.0238	0.3	0.21	Blood pressure (smoking interaction);	chr3:125642516	chr3:125787888~125788146:-
STAD	cis	rs1790761	0.52	rs7124513	ENSG00000231793.4	DOC2GP	-4.03	6.8e-05	0.0238	-0.26	-0.21	Mean corpuscular volume;	chr11:67628243	chr11:67612653~67616257:-
STAD	cis	rs11157436	0.602	rs12588757	ENSG00000211812.1	TRAV26-2	-4.03	6.8e-05	0.0238	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22202583~22203368:+
STAD	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-4.03	6.8e-05	0.0238	-0.22	-0.21	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
STAD	cis	rs875971	0.862	rs778720	ENSG00000224316.1	RP11-479O9.2	-4.03	6.81e-05	0.0238	-0.2	-0.21	Aortic root size;	chr7:66381288	chr7:65773620~65802067:+
STAD	cis	rs34779708	0.966	rs1545757	ENSG00000271335.4	RP11-324I22.4	4.03	6.81e-05	0.0238	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35314552~35336401:-
STAD	cis	rs7142881	0.844	rs34872357	ENSG00000258648.1	UBE2CP1	4.03	6.81e-05	0.0238	0.24	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31564607	chr14:30683045~30683598:-
STAD	cis	rs6686842	0.56	rs6672914	ENSG00000235358.1	RP11-399E6.1	-4.03	6.81e-05	0.0238	-0.24	-0.21	Height;	chr1:41201257	chr1:41242373~41284861:+
STAD	cis	rs3764400	0.567	rs741058	ENSG00000278765.1	RP5-890E16.5	-4.03	6.81e-05	0.0238	-0.28	-0.21	Body mass index;	chr17:48127991	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs2109983	ENSG00000278765.1	RP5-890E16.5	-4.03	6.81e-05	0.0238	-0.28	-0.21	Body mass index;	chr17:48129786	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.517	rs7209042	ENSG00000278765.1	RP5-890E16.5	-4.03	6.81e-05	0.0238	-0.28	-0.21	Body mass index;	chr17:48130430	chr17:48066704~48067293:-
STAD	cis	rs10508774	1	rs117289882	ENSG00000273038.2	RP11-479G22.8	4.03	6.81e-05	0.0239	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32548999	chr10:32887255~32889311:-
STAD	cis	rs1850744	0.826	rs7659176	ENSG00000163612.10	FAM86KP	-4.03	6.81e-05	0.0239	-0.5	-0.21	Economic and political preferences;	chr4:9719442	chr4:9153296~9165451:+
STAD	cis	rs3213758	0.541	rs7187504	ENSG00000275191.1	RP11-36I17.2	-4.03	6.82e-05	0.0239	-0.34	-0.21	Vitiligo (non-segmental);	chr16:53696788	chr16:53628256~53628816:-
STAD	cis	rs3213758	0.541	rs7204936	ENSG00000275191.1	RP11-36I17.2	-4.03	6.82e-05	0.0239	-0.34	-0.21	Vitiligo (non-segmental);	chr16:53696879	chr16:53628256~53628816:-
STAD	cis	rs561341	0.7	rs8079471	ENSG00000265798.5	RP11-271K11.5	4.03	6.82e-05	0.0239	0.26	0.21	Hip circumference adjusted for BMI;	chr17:31891298	chr17:31038575~31059121:-
STAD	cis	rs12571093	0.572	rs10762216	ENSG00000234102.1	KRT19P4	4.03	6.82e-05	0.0239	0.26	0.21	Optic nerve measurement (disc area);	chr10:68308820	chr10:68260557~68261499:+
STAD	cis	rs1040	0.873	rs10280	ENSG00000261039.2	RP11-417E7.2	-4.03	6.82e-05	0.0239	-0.24	-0.21	Joint mobility (Beighton score);	chr6:169217335	chr6:169175304~169182740:-
STAD	cis	rs2273156	1	rs7141293	ENSG00000258704.4	SRP54-AS1	-4.03	6.82e-05	0.0239	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34993704	chr14:34920858~34982532:-
STAD	cis	rs9921338	0.961	rs8060767	ENSG00000263080.1	RP11-485G7.5	4.03	6.82e-05	0.0239	0.32	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11276741	chr16:11341809~11345211:-
STAD	cis	rs7915414	0.531	rs12572351	ENSG00000230338.1	MTND4P19	4.03	6.82e-05	0.0239	0.26	0.21	Clopidogrel active metabolite levels;	chr10:94943463	chr10:94774156~94774633:-
STAD	cis	rs10129255	0.833	rs7156689	ENSG00000211973.2	IGHV1-69	4.03	6.82e-05	0.0239	0.2	0.21	Kawasaki disease;	chr14:106816039	chr14:106714684~106715181:-
STAD	cis	rs11089937	0.929	rs5757155	ENSG00000211638.2	IGLV8-61	-4.03	6.82e-05	0.0239	-0.21	-0.21	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22098700~22099212:+
STAD	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	4.03	6.82e-05	0.0239	0.23	0.21	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
STAD	cis	rs8062405	1	rs8061590	ENSG00000278665.1	RP11-666O2.4	4.03	6.83e-05	0.0239	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28599241~28601881:-
STAD	cis	rs7521837	0.564	rs11808153	ENSG00000272030.1	RP1-178F15.4	4.03	6.83e-05	0.0239	0.46	0.21	Schizophrenia;	chr1:154265587	chr1:153631438~153634397:-
STAD	cis	rs9902453	0.904	rs4375718	ENSG00000240074.1	RPL9P30	-4.03	6.83e-05	0.0239	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30036624	chr17:29855759~29856332:+
STAD	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	4.03	6.83e-05	0.0239	0.31	0.21	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
STAD	cis	rs12682352	0.602	rs6993494	ENSG00000253981.4	ALG1L13P	4.03	6.83e-05	0.0239	0.26	0.21	Neuroticism;	chr8:8809934	chr8:8236003~8244667:-
STAD	cis	rs34779708	0.966	rs12260130	ENSG00000271335.4	RP11-324I22.4	4.03	6.83e-05	0.0239	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35314552~35336401:-
STAD	cis	rs7707921	0.757	rs226198	ENSG00000251374.1	RPS23P5	-4.03	6.84e-05	0.0239	-0.32	-0.21	Breast cancer;	chr5:82278173	chr5:82265157~82265259:-
STAD	cis	rs1551277	0.538	rs55652830	ENSG00000146666.5	LINC00525	4.03	6.84e-05	0.0239	0.31	0.21	Anxiety disorder;	chr7:47805887	chr7:47761476~47766772:+
STAD	cis	rs2292303	1	rs2292303	ENSG00000258308.4	RP11-554E23.2	-4.03	6.84e-05	0.0239	-0.43	-0.21	Height;	chr12:102119753	chr12:101954998~101962390:-
STAD	cis	rs2980439	0.556	rs2921059	ENSG00000173295.6	FAM86B3P	4.03	6.84e-05	0.0239	0.24	0.21	Neuroticism;	chr8:8460377	chr8:8228595~8244865:+
STAD	cis	rs2337406	0.925	rs10131226	ENSG00000211970.3	IGHV4-61	4.03	6.84e-05	0.0239	0.24	0.21	Alzheimer's disease (late onset);	chr14:106665764	chr14:106639119~106639657:-
STAD	cis	rs2337406	1	rs74090714	ENSG00000280411.1	IGHV1-69-2	-4.03	6.85e-05	0.0239	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106691225	chr14:106762092~106762588:-
STAD	cis	rs1348850	0.519	rs1544002	ENSG00000271825.1	RP11-337N6.2	4.03	6.85e-05	0.024	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177664806	chr2:177300600~177302006:+
STAD	cis	rs9287719	0.601	rs1861299	ENSG00000243819.4	RN7SL832P	4.03	6.85e-05	0.024	0.21	0.21	Prostate cancer;	chr2:10623631	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.601	rs1861300	ENSG00000243819.4	RN7SL832P	4.03	6.85e-05	0.024	0.21	0.21	Prostate cancer;	chr2:10623835	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.601	rs6755281	ENSG00000243819.4	RN7SL832P	4.03	6.85e-05	0.024	0.21	0.21	Prostate cancer;	chr2:10629729	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.601	rs10084172	ENSG00000243819.4	RN7SL832P	4.03	6.85e-05	0.024	0.21	0.21	Prostate cancer;	chr2:10631102	chr2:10690344~10692099:+
STAD	cis	rs9928842	0.771	rs4888363	ENSG00000280152.1	RP11-331F4.5	4.03	6.85e-05	0.024	0.3	0.21	Alcoholic chronic pancreatitis;	chr16:75243446	chr16:75245994~75250077:-
STAD	cis	rs9549367	0.588	rs9549360	ENSG00000269125.1	RP11-98F14.11	-4.03	6.85e-05	0.024	-0.29	-0.21	Platelet distribution width;	chr13:113238718	chr13:113165002~113165183:-
STAD	cis	rs1850744	0.536	rs10014408	ENSG00000250942.1	ENPP7P11	4.03	6.85e-05	0.024	0.4	0.21	Economic and political preferences;	chr4:9693521	chr4:9677308~9677934:+
STAD	cis	rs12468226	1	rs74766638	ENSG00000272966.1	RP11-686O6.1	4.03	6.86e-05	0.024	0.31	0.21	Urate levels;	chr2:202445168	chr2:202336739~202337200:+
STAD	cis	rs9903692	0.505	rs208008	ENSG00000278765.1	RP5-890E16.5	-4.03	6.86e-05	0.024	-0.28	-0.21	Pulse pressure;	chr17:48153476	chr17:48066704~48067293:-
STAD	cis	rs395157	0.591	rs357286	ENSG00000249911.1	LINC01265	4.03	6.86e-05	0.024	0.21	0.21	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:38837759	chr5:38710367~38720273:-
STAD	cis	rs494453	0.922	rs531692	ENSG00000234020.1	CHIAP3	-4.03	6.86e-05	0.024	-0.21	-0.21	Osteoporosis-related phenotypes;	chr1:111691954	chr1:111353275~111367409:-
STAD	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	4.03	6.87e-05	0.024	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
STAD	cis	rs7586085	0.903	rs13431319	ENSG00000229195.1	AC009495.4	4.03	6.87e-05	0.024	0.24	0.21	Total body bone mineral density;	chr2:165758067	chr2:165794857~165846091:-
STAD	cis	rs595244	1	rs685091	ENSG00000259705.1	RP11-227D13.1	4.03	6.87e-05	0.024	0.36	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48555933	chr15:48645951~48652016:+
STAD	cis	rs595244	1	rs10744953	ENSG00000259705.1	RP11-227D13.1	-4.03	6.87e-05	0.024	-0.36	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48567769	chr15:48645951~48652016:+
STAD	cis	rs1005277	0.505	rs200935	ENSG00000099251.13	HSD17B7P2	4.03	6.87e-05	0.024	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38356380~38378505:+
STAD	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	4.03	6.88e-05	0.024	0.3	0.21	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
STAD	cis	rs2688608	0.62	rs12253408	ENSG00000272140.2	RP11-574K11.29	4.03	6.88e-05	0.024	0.19	0.21	Inflammatory bowel disease;	chr10:73736198	chr10:73703735~73713581:-
STAD	cis	rs9307551	0.584	rs2119419	ENSG00000250334.4	LINC00989	-4.03	6.88e-05	0.024	-0.26	-0.21	Refractive error;	chr4:79515828	chr4:79492416~79576460:+
STAD	cis	rs2834188	0.924	rs2007849	ENSG00000272659.1	AP000295.10	-4.03	6.88e-05	0.024	-0.29	-0.21	Narcolepsy;	chr21:33308811	chr21:33309491~33310181:+
STAD	cis	rs559928	0.606	rs7941773	ENSG00000236935.1	AP003774.1	4.03	6.88e-05	0.0241	0.34	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64185287	chr11:64325050~64329504:-
STAD	cis	rs559928	0.606	rs57021319	ENSG00000236935.1	AP003774.1	4.03	6.88e-05	0.0241	0.34	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64188630	chr11:64325050~64329504:-
STAD	cis	rs559928	0.606	rs55970968	ENSG00000236935.1	AP003774.1	4.03	6.88e-05	0.0241	0.34	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64193961	chr11:64325050~64329504:-
STAD	cis	rs9902453	0.619	rs1038088	ENSG00000263477.1	RP11-338L22.2	-4.03	6.89e-05	0.0241	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29747545	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.619	rs2617866	ENSG00000263477.1	RP11-338L22.2	-4.03	6.89e-05	0.0241	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29749199	chr17:29863402~29866092:+
STAD	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	4.03	6.89e-05	0.0241	0.23	0.21	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
STAD	cis	rs2836974	0.584	rs7276774	ENSG00000238141.2	BRWD1-AS1	-4.03	6.89e-05	0.0241	-0.22	-0.21	Cognitive function;	chr21:39256799	chr21:39315707~39323218:+
STAD	cis	rs3002131	0.604	rs3008641	ENSG00000225265.1	TAF1A-AS1	-4.03	6.89e-05	0.0241	-0.31	-0.21	Interleukin-10 levels;	chr1:222566947	chr1:222589825~222593032:+
STAD	cis	rs3002131	0.604	rs1319392	ENSG00000225265.1	TAF1A-AS1	-4.03	6.89e-05	0.0241	-0.31	-0.21	Interleukin-10 levels;	chr1:222567271	chr1:222589825~222593032:+
STAD	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	4.03	6.89e-05	0.0241	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	4.03	6.89e-05	0.0241	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
STAD	cis	rs1707322	0.721	rs6699418	ENSG00000225447.1	RPS15AP10	4.03	6.9e-05	0.0241	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.721	rs4431884	ENSG00000225447.1	RPS15AP10	4.03	6.9e-05	0.0241	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.65	rs4660879	ENSG00000225447.1	RPS15AP10	4.03	6.9e-05	0.0241	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45645816~45646197:-
STAD	cis	rs11603023	0.967	rs7936556	ENSG00000278376.1	RP11-158I9.8	4.03	6.9e-05	0.0241	0.22	0.21	Cholesterol, total;	chr11:118630582	chr11:118791254~118793137:+
STAD	cis	rs448720	0.508	rs2414978	ENSG00000260657.2	RP11-315D16.4	4.03	6.9e-05	0.0241	0.24	0.21	Cognitive performance;	chr15:67928227	chr15:68267792~68277994:-
STAD	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	4.03	6.9e-05	0.0241	0.35	0.21	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
STAD	cis	rs8054556	0.74	rs12716974	ENSG00000261588.1	AC002310.17	4.03	6.91e-05	0.0241	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30587662~30587920:-
STAD	cis	rs2262909	0.925	rs56073035	ENSG00000213976.4	CTD-2561J22.2	4.03	6.91e-05	0.0241	0.27	0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22093496	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs73019889	ENSG00000213976.4	CTD-2561J22.2	4.03	6.91e-05	0.0241	0.27	0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22095024	chr19:21382865~21387177:+
STAD	cis	rs6832769	0.89	rs1522107	ENSG00000223305.1	RN7SKP30	4.03	6.91e-05	0.0241	0.24	0.21	Personality dimensions;	chr4:55514606	chr4:55540502~55540835:-
STAD	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-4.03	6.91e-05	0.0241	-0.27	-0.21	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
STAD	cis	rs950169	0.922	rs62029585	ENSG00000235370.6	DNM1P51	4.03	6.92e-05	0.0242	0.27	0.21	Schizophrenia;	chr15:84397176	chr15:84398316~84411701:-
STAD	cis	rs1850744	1	rs10939507	ENSG00000250268.3	ALG1L14P	-4.03	6.92e-05	0.0242	-0.49	-0.21	Economic and political preferences;	chr4:9767199	chr4:9166297~9170270:-
STAD	cis	rs7809950	0.817	rs3779495	ENSG00000238832.1	snoU109	4.03	6.92e-05	0.0242	0.29	0.21	Coronary artery disease;	chr7:107609815	chr7:107603363~107603507:+
STAD	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	4.03	6.93e-05	0.0242	0.47	0.21	QT interval;	chr4:75134108	chr4:75081702~75084717:-
STAD	cis	rs539514	0.563	rs7983875	ENSG00000261105.4	LMO7-AS1	4.03	6.93e-05	0.0242	0.25	0.21	Type 1 diabetes;	chr13:75755109	chr13:75604700~75635994:-
STAD	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	4.03	6.93e-05	0.0242	0.26	0.21	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
STAD	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-4.03	6.93e-05	0.0242	-0.38	-0.21	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
STAD	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-4.03	6.93e-05	0.0242	-0.38	-0.21	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
STAD	cis	rs7142881	0.53	rs2120141	ENSG00000258648.1	UBE2CP1	-4.03	6.93e-05	0.0242	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31641971	chr14:30683045~30683598:-
STAD	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	4.03	6.94e-05	0.0242	0.25	0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
STAD	cis	rs7615952	0.512	rs2979351	ENSG00000239804.1	RP11-379B18.1	4.03	6.94e-05	0.0242	0.3	0.21	Blood pressure (smoking interaction);	chr3:125644755	chr3:125787888~125788146:-
STAD	cis	rs8141529	0.702	rs132536	ENSG00000272858.1	CTA-292E10.8	4.03	6.94e-05	0.0242	0.22	0.21	Lymphocyte counts;	chr22:28906918	chr22:28814914~28815662:+
STAD	cis	rs2957692	0.548	rs11602465	ENSG00000254554.1	RP11-351I24.1	4.03	6.94e-05	0.0242	0.35	0.21	Circulating vasoactive peptide levels;	chr11:9943274	chr11:10302657~10303704:-
STAD	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-4.03	6.94e-05	0.0242	-0.25	-0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
STAD	cis	rs1005277	0.505	rs200910	ENSG00000099251.13	HSD17B7P2	4.03	6.94e-05	0.0242	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38356380~38378505:+
STAD	cis	rs1707322	1	rs10890380	ENSG00000225447.1	RPS15AP10	4.03	6.94e-05	0.0242	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45645816~45646197:-
STAD	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-4.03	6.94e-05	0.0242	-0.28	-0.21	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
STAD	cis	rs6961102	0.567	rs10255077	ENSG00000244218.3	RN7SL81P	4.03	6.95e-05	0.0242	0.39	0.21	Platelet distribution width;	chr7:129732245	chr7:128761338~128761598:+
STAD	cis	rs7615952	0.543	rs4645102	ENSG00000239804.1	RP11-379B18.1	4.03	6.95e-05	0.0242	0.3	0.21	Blood pressure (smoking interaction);	chr3:125705597	chr3:125787888~125788146:-
STAD	cis	rs2901460	0.67	rs13015611	ENSG00000229503.1	AC092155.1	-4.03	6.95e-05	0.0242	-0.17	-0.21	Mean corpuscular volume;	chr2:62170794	chr2:62532583~62533059:-
STAD	cis	rs2351088	0.611	rs60514881	ENSG00000230634.1	RP5-996D20.3	-4.03	6.95e-05	0.0242	-0.36	-0.21	Tonsillectomy;	chr22:45760701	chr22:46481329~46481760:-
STAD	cis	rs2351088	0.611	rs58099513	ENSG00000230634.1	RP5-996D20.3	-4.03	6.95e-05	0.0242	-0.36	-0.21	Tonsillectomy;	chr22:45760742	chr22:46481329~46481760:-
STAD	cis	rs2351088	0.611	rs56898998	ENSG00000230634.1	RP5-996D20.3	-4.03	6.95e-05	0.0242	-0.36	-0.21	Tonsillectomy;	chr22:45760810	chr22:46481329~46481760:-
STAD	cis	rs2276314	0.512	rs1789515	ENSG00000278986.1	RP11-723J4.3	4.03	6.95e-05	0.0242	0.25	0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:36055930	chr18:35972151~35973916:+
STAD	cis	rs1005277	0.522	rs289650	ENSG00000099251.13	HSD17B7P2	4.03	6.95e-05	0.0242	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38356380~38378505:+
STAD	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-4.03	6.95e-05	0.0242	-0.23	-0.21	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
STAD	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-4.03	6.95e-05	0.0242	-0.23	-0.21	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
STAD	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-4.03	6.95e-05	0.0242	-0.23	-0.21	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
STAD	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-4.03	6.95e-05	0.0242	-0.23	-0.21	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
STAD	cis	rs7655841	0.704	rs6824219	ENSG00000248187.1	RP11-184M15.1	4.03	6.95e-05	0.0242	0.33	0.21	Chronic obstructive pulmonary disease (moderate to severe);	chr4:128955681	chr4:128567972~128570531:-
STAD	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	4.03	6.96e-05	0.0243	0.25	0.21	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
STAD	cis	rs9859260	0.744	rs539816	ENSG00000242086.7	LINC00969	-4.03	6.96e-05	0.0243	-0.2	-0.21	Mean corpuscular volume;	chr3:196057205	chr3:195658062~195739964:+
STAD	cis	rs9859260	0.744	rs492349	ENSG00000242086.7	LINC00969	-4.03	6.96e-05	0.0243	-0.2	-0.21	Mean corpuscular volume;	chr3:196057321	chr3:195658062~195739964:+
STAD	cis	rs9859260	0.744	rs492288	ENSG00000242086.7	LINC00969	-4.03	6.96e-05	0.0243	-0.2	-0.21	Mean corpuscular volume;	chr3:196057339	chr3:195658062~195739964:+
STAD	cis	rs11673344	0.503	rs703531	ENSG00000267672.1	CTD-2293H3.1	4.03	6.96e-05	0.0243	0.2	0.21	Obesity-related traits;	chr19:37010050	chr19:37091341~37092564:+
STAD	cis	rs56046484	0.797	rs907260	ENSG00000229212.6	RP11-561C5.4	-4.03	6.96e-05	0.0243	-0.37	-0.21	Testicular germ cell tumor;	chr15:85133526	chr15:85205440~85234795:-
STAD	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	4.03	6.96e-05	0.0243	0.21	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
STAD	cis	rs393951	0.957	rs371896	ENSG00000260969.1	RP11-190D6.2	-4.03	6.96e-05	0.0243	-0.25	-0.21	Childhood ear infection;	chr16:77613594	chr16:78237362~78241218:-
STAD	cis	rs9535307	1	rs2897770	ENSG00000223676.1	RPL34P26	4.03	6.96e-05	0.0243	0.26	0.21	Obesity-related traits;	chr13:49750934	chr13:50361410~50361763:-
STAD	cis	rs1707322	1	rs785480	ENSG00000225447.1	RPS15AP10	4.03	6.97e-05	0.0243	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45645816~45646197:-
STAD	cis	rs2901460	0.731	rs13012093	ENSG00000229503.1	AC092155.1	-4.03	6.97e-05	0.0243	-0.17	-0.21	Mean corpuscular volume;	chr2:62124450	chr2:62532583~62533059:-
STAD	cis	rs867371	1	rs13380319	ENSG00000276710.3	CSPG4P8	-4.03	6.97e-05	0.0243	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82459472~82477258:+
STAD	cis	rs5758511	0.689	rs56906457	ENSG00000234735.1	AL022237.3	-4.03	6.97e-05	0.0243	-0.27	-0.21	Birth weight;	chr22:42232329	chr22:43092167~43092524:+
STAD	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-4.03	6.97e-05	0.0243	-0.23	-0.21	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
STAD	cis	rs7829975	0.742	rs882462	ENSG00000173295.6	FAM86B3P	4.03	6.97e-05	0.0243	0.23	0.21	Mood instability;	chr8:8821020	chr8:8228595~8244865:+
STAD	cis	rs7829975	0.774	rs11775523	ENSG00000173295.6	FAM86B3P	4.03	6.97e-05	0.0243	0.23	0.21	Mood instability;	chr8:8821666	chr8:8228595~8244865:+
STAD	cis	rs14403	0.874	rs3006923	ENSG00000240963.1	RP11-518L10.5	-4.03	6.98e-05	0.0243	-0.21	-0.21	Schizophrenia;	chr1:243485455	chr1:244375100~244409592:-
STAD	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	4.03	6.98e-05	0.0243	0.43	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
STAD	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	4.03	6.98e-05	0.0243	0.3	0.21	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
STAD	cis	rs6750795	0.569	rs1667308	ENSG00000223198.1	RNU2-22P	-4.03	6.98e-05	0.0243	-0.25	-0.21	Height;	chr2:231541633	chr2:231501990~231502201:-
STAD	cis	rs11676348	0.772	rs6738953	ENSG00000237281.1	CATIP-AS2	4.03	6.98e-05	0.0243	0.21	0.21	Ulcerative colitis;	chr2:218085313	chr2:218326889~218357966:-
STAD	cis	rs950169	0.922	rs11630507	ENSG00000259683.1	RP11-182J1.14	4.03	6.99e-05	0.0243	0.22	0.21	Schizophrenia;	chr15:84552494	chr15:84389729~84395903:+
STAD	cis	rs17818399	0.547	rs62134736	ENSG00000279254.1	RP11-536C12.1	-4.03	6.99e-05	0.0244	-0.24	-0.21	Height;	chr2:46539307	chr2:46668870~46670778:+
STAD	cis	rs3764021	0.743	rs7973535	ENSG00000256673.1	RP11-599J14.2	-4.03	6.99e-05	0.0244	-0.22	-0.21	Type 1 diabetes;	chr12:9727801	chr12:9398355~9414851:-
STAD	cis	rs3764021	0.87	rs7973638	ENSG00000256673.1	RP11-599J14.2	-4.03	6.99e-05	0.0244	-0.22	-0.21	Type 1 diabetes;	chr12:9727845	chr12:9398355~9414851:-
STAD	cis	rs10508774	1	rs12247495	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32513901	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.925	rs11008955	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32516274	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs10508774	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32518933	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs55773420	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32535982	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.925	rs12242792	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32542977	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs11815157	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32544670	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12241523	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32687170	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72782256	ENSG00000273038.2	RP11-479G22.8	4.03	6.99e-05	0.0244	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32689623	chr10:32887255~32889311:-
STAD	cis	rs72843166	0.545	rs1588368	ENSG00000272164.1	RP11-180P8.5	4.03	6.99e-05	0.0244	0.23	0.21	Intelligence (multi-trait analysis);	chr17:62938848	chr17:63004672~63005152:-
STAD	cis	rs8141529	0.748	rs1318026	ENSG00000226471.5	CTA-292E10.6	-4.03	6.99e-05	0.0244	-0.24	-0.21	Lymphocyte counts;	chr22:28887530	chr22:28800683~28848559:+
STAD	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	4.03	6.99e-05	0.0244	0.5	0.21	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
STAD	cis	rs4713118	0.869	rs9295743	ENSG00000220721.1	OR1F12	4.03	6.99e-05	0.0244	0.23	0.21	Parkinson's disease;	chr6:27747323	chr6:28073316~28074233:+
STAD	cis	rs5742933	0.857	rs13021611	ENSG00000253559.1	OSGEPL1-AS1	4.02	7e-05	0.0244	0.26	0.21	Ferritin levels;	chr2:189700038	chr2:189762704~189765556:+
STAD	cis	rs9902453	0.817	rs2628170	ENSG00000240074.1	RPL9P30	-4.02	7e-05	0.0244	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29729594	chr17:29855759~29856332:+
STAD	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	4.02	7e-05	0.0244	0.32	0.21	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
STAD	cis	rs9902453	0.904	rs9897794	ENSG00000240074.1	RPL9P30	4.02	7.01e-05	0.0244	0.18	0.21	Coffee consumption (cups per day);	chr17:29969309	chr17:29855759~29856332:+
STAD	cis	rs9362426	0.503	rs6454609	ENSG00000217776.1	RP11-156F23.2	-4.02	7.01e-05	0.0244	-0.22	-0.21	Depressive episodes in bipolar disorder;	chr6:87396310	chr6:87070156~87070461:-
STAD	cis	rs9859260	0.71	rs41298097	ENSG00000242086.7	LINC00969	-4.02	7.01e-05	0.0244	-0.2	-0.21	Mean corpuscular volume;	chr3:196052284	chr3:195658062~195739964:+
STAD	cis	rs9859260	0.71	rs34906439	ENSG00000242086.7	LINC00969	-4.02	7.01e-05	0.0244	-0.2	-0.21	Mean corpuscular volume;	chr3:196052835	chr3:195658062~195739964:+
STAD	cis	rs9859260	0.744	rs557527	ENSG00000242086.7	LINC00969	-4.02	7.01e-05	0.0244	-0.2	-0.21	Mean corpuscular volume;	chr3:196053838	chr3:195658062~195739964:+
STAD	cis	rs2483058	0.767	rs11579993	ENSG00000261000.1	RP11-534L20.5	4.02	7.01e-05	0.0244	0.25	0.21	Cholesterol and Triglycerides;	chr1:206445529	chr1:206503948~206504456:+
STAD	cis	rs34779708	0.801	rs12246600	ENSG00000271335.4	RP11-324I22.4	4.02	7.01e-05	0.0244	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.801	rs12098720	ENSG00000271335.4	RP11-324I22.4	4.02	7.01e-05	0.0244	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.801	rs34592588	ENSG00000271335.4	RP11-324I22.4	4.02	7.01e-05	0.0244	0.27	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35314552~35336401:-
STAD	cis	rs2348418	0.798	rs7309905	ENSG00000247934.4	RP11-967K21.1	4.02	7.02e-05	0.0244	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28373473	chr12:28163298~28190738:-
STAD	cis	rs11157436	0.602	rs11157437	ENSG00000211812.1	TRAV26-2	-4.02	7.02e-05	0.0244	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22202583~22203368:+
STAD	cis	rs11157436	0.602	rs11157439	ENSG00000211812.1	TRAV26-2	-4.02	7.02e-05	0.0244	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22202583~22203368:+
STAD	cis	rs7429990	0.965	rs35199727	ENSG00000224895.1	VPS26BP1	-4.02	7.02e-05	0.0244	-0.22	-0.21	Educational attainment (years of education);	chr3:47905218	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs11707679	ENSG00000224895.1	VPS26BP1	-4.02	7.02e-05	0.0244	-0.22	-0.21	Educational attainment (years of education);	chr3:47915016	chr3:47960327~47961081:-
STAD	cis	rs9902453	0.902	rs4075014	ENSG00000240074.1	RPL9P30	4.02	7.02e-05	0.0244	0.18	0.21	Coffee consumption (cups per day);	chr17:29978656	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.967	rs12602258	ENSG00000240074.1	RPL9P30	4.02	7.02e-05	0.0244	0.18	0.21	Coffee consumption (cups per day);	chr17:29990639	chr17:29855759~29856332:+
STAD	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	-4.02	7.02e-05	0.0244	-0.23	-0.21	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
STAD	cis	rs34779708	0.966	rs12762493	ENSG00000271335.4	RP11-324I22.4	4.02	7.02e-05	0.0244	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35314552~35336401:-
STAD	cis	rs10073892	0.664	rs12653423	ENSG00000250682.4	LINC00491	-4.02	7.02e-05	0.0244	-0.23	-0.21	Cognitive decline (age-related);	chr5:102572417	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs12659295	ENSG00000250682.4	LINC00491	-4.02	7.02e-05	0.0244	-0.23	-0.21	Cognitive decline (age-related);	chr5:102573272	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.626	rs72781838	ENSG00000250682.4	LINC00491	-4.02	7.02e-05	0.0244	-0.23	-0.21	Cognitive decline (age-related);	chr5:102573886	chr5:102609156~102671559:-
STAD	cis	rs950169	0.922	rs11638445	ENSG00000259295.5	CSPG4P12	4.02	7.02e-05	0.0244	0.31	0.21	Schizophrenia;	chr15:84594463	chr15:85191438~85213905:+
STAD	cis	rs4927850	1	rs7627706	ENSG00000278820.1	AC024937.1	4.02	7.02e-05	0.0244	0.24	0.21	Pancreatic cancer;	chr3:196026482	chr3:195960500~195960612:-
STAD	cis	rs4927850	0.881	rs7630489	ENSG00000278820.1	AC024937.1	4.02	7.02e-05	0.0244	0.24	0.21	Pancreatic cancer;	chr3:196026530	chr3:195960500~195960612:-
STAD	cis	rs4927850	1	rs7627868	ENSG00000278820.1	AC024937.1	4.02	7.02e-05	0.0244	0.24	0.21	Pancreatic cancer;	chr3:196026602	chr3:195960500~195960612:-
STAD	cis	rs9907295	1	rs9908525	ENSG00000270894.1	AC015849.13	-4.02	7.02e-05	0.0244	-0.26	-0.21	Fibroblast growth factor basic levels;	chr17:35908605	chr17:35818399~35823713:+
STAD	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-4.02	7.02e-05	0.0245	-0.28	-0.21	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
STAD	cis	rs867371	1	rs6495642	ENSG00000278603.1	RP13-608F4.5	4.02	7.03e-05	0.0245	0.25	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472203~82472426:+
STAD	cis	rs1707322	0.752	rs7541962	ENSG00000281133.1	AL355480.3	-4.02	7.03e-05	0.0245	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45580892~45580996:-
STAD	cis	rs34779708	0.658	rs4934715	ENSG00000271335.4	RP11-324I22.4	4.02	7.03e-05	0.0245	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs7079498	ENSG00000271335.4	RP11-324I22.4	4.02	7.03e-05	0.0245	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.897	rs7897827	ENSG00000271335.4	RP11-324I22.4	4.02	7.03e-05	0.0245	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35314552~35336401:-
STAD	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-4.02	7.03e-05	0.0245	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
STAD	cis	rs3858145	0.588	rs76854765	ENSG00000234102.1	KRT19P4	-4.02	7.03e-05	0.0245	-0.24	-0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68260557~68261499:+
STAD	cis	rs2933343	0.729	rs789228	ENSG00000261159.1	RP11-723O4.9	4.02	7.03e-05	0.0245	0.26	0.21	IgG glycosylation;	chr3:128882207	chr3:128859716~128860526:-
STAD	cis	rs748404	0.56	rs1060939	ENSG00000275601.1	AC011330.13	-4.02	7.03e-05	0.0245	-0.22	-0.21	Lung cancer;	chr15:43524719	chr15:43642389~43643023:-
STAD	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-4.02	7.03e-05	0.0245	-0.21	-0.21	Height;	chr2:46629946	chr2:46668870~46670778:+
STAD	cis	rs792448	0.743	rs7415843	ENSG00000212044.2	AL360091.1	4.02	7.04e-05	0.0245	0.22	0.21	White blood cell count (basophil);	chr1:212336420	chr1:212349978~212350069:+
STAD	cis	rs6832769	0.922	rs60797008	ENSG00000223305.1	RN7SKP30	-4.02	7.04e-05	0.0245	-0.24	-0.21	Personality dimensions;	chr4:55522505	chr4:55540502~55540835:-
STAD	cis	rs6142102	0.886	rs6142098	ENSG00000264616.1	MIR4755	4.02	7.04e-05	0.0245	0.22	0.21	Skin pigmentation;	chr20:34100488	chr20:34049119~34049190:+
STAD	cis	rs10741780	1	rs10741780	ENSG00000254544.1	PCNAP4	-4.02	7.04e-05	0.0245	-0.28	-0.21	HIV-1 susceptibility;	chr11:19578424	chr11:19274540~19275269:-
STAD	cis	rs2688608	0.53	rs71507081	ENSG00000272140.2	RP11-574K11.29	4.02	7.04e-05	0.0245	0.19	0.21	Inflammatory bowel disease;	chr10:73733378	chr10:73703735~73713581:-
STAD	cis	rs2675662	0.525	rs12264025	ENSG00000272140.2	RP11-574K11.29	4.02	7.04e-05	0.0245	0.19	0.21	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73703735~73713581:-
STAD	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	4.02	7.04e-05	0.0245	0.32	0.21	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
STAD	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	4.02	7.05e-05	0.0245	0.27	0.21	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
STAD	cis	rs4698036	0.586	rs7672759	ENSG00000250613.1	RP11-136I13.1	-4.02	7.05e-05	0.0245	-0.2	-0.21	Cardiovascular disease risk factors;	chr4:10283391	chr4:10410996~10411644:+
STAD	cis	rs62025270	0.747	rs17639314	ENSG00000259295.5	CSPG4P12	-4.02	7.05e-05	0.0245	-0.37	-0.21	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85191438~85213905:+
STAD	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	4.02	7.05e-05	0.0245	0.3	0.21	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
STAD	cis	rs4713118	0.513	rs149942	ENSG00000220721.1	OR1F12	4.02	7.05e-05	0.0245	0.22	0.21	Parkinson's disease;	chr6:28033832	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.513	rs149944	ENSG00000220721.1	OR1F12	4.02	7.05e-05	0.0245	0.22	0.21	Parkinson's disease;	chr6:28035040	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.513	rs149945	ENSG00000220721.1	OR1F12	4.02	7.05e-05	0.0245	0.22	0.21	Parkinson's disease;	chr6:28035075	chr6:28073316~28074233:+
STAD	cis	rs658191	0.661	rs12038951	ENSG00000237624.1	OXCT2P1	-4.02	7.05e-05	0.0245	-0.43	-0.21	Colorectal cancer;	chr1:39528849	chr1:39514956~39516490:+
STAD	cis	rs875971	0.545	rs6969224	ENSG00000273142.1	RP11-458F8.4	4.02	7.05e-05	0.0245	0.2	0.21	Aortic root size;	chr7:66370011	chr7:66902857~66906297:+
STAD	cis	rs7615952	0.932	rs6438948	ENSG00000272840.1	RP11-379B18.6	-4.02	7.06e-05	0.0245	-0.34	-0.21	Blood pressure (smoking interaction);	chr3:125931202	chr3:125774714~125797953:+
STAD	cis	rs28588043	0.55	rs9426921	ENSG00000201126.1	RNU6-773P	-4.02	7.06e-05	0.0245	-0.4	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170982723	chr1:171519816~171519913:-
STAD	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	4.02	7.06e-05	0.0245	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	4.02	7.06e-05	0.0245	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
STAD	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	4.02	7.06e-05	0.0245	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	4.02	7.06e-05	0.0245	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
STAD	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	4.02	7.06e-05	0.0245	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
STAD	cis	rs3733585	0.783	rs13148371	ENSG00000250613.1	RP11-136I13.1	-4.02	7.06e-05	0.0246	-0.19	-0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10410996~10411644:+
STAD	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-4.02	7.06e-05	0.0246	-0.22	-0.21	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
STAD	cis	rs11089937	0.584	rs6001213	ENSG00000211639.2	IGLV4-60	4.02	7.06e-05	0.0246	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22182108	chr22:22162199~22162681:+
STAD	cis	rs6480314	0.522	rs4746756	ENSG00000233590.1	RP11-153K11.3	4.02	7.06e-05	0.0246	0.29	0.21	Optic nerve measurement (disc area);	chr10:68301188	chr10:68233251~68242379:-
STAD	cis	rs860295	0.702	rs10796943	ENSG00000225855.5	RUSC1-AS1	4.02	7.06e-05	0.0246	0.18	0.21	Body mass index;	chr1:155444938	chr1:155316863~155324176:-
STAD	cis	rs2430307	0.556	rs3930019	ENSG00000205482.8	AC007000.12	-4.02	7.06e-05	0.0246	-0.22	-0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76912293	chr7:77052785~77059440:-
STAD	cis	rs13413635	0.729	rs62183443	ENSG00000225808.1	DNAJC19P5	-4.02	7.06e-05	0.0246	-0.28	-0.21	Heart rate;	chr2:178022775	chr2:177229191~177229506:-
STAD	cis	rs12554020	0.786	rs78547192	ENSG00000227603.1	RP11-165J3.6	4.02	7.06e-05	0.0246	0.45	0.21	Schizophrenia;	chr9:93597221	chr9:93435332~93437121:-
STAD	cis	rs4835473	0.932	rs34324222	ENSG00000249741.2	RP11-673E1.3	4.02	7.07e-05	0.0246	0.25	0.21	Immature fraction of reticulocytes;	chr4:143784572	chr4:143911514~143912053:-
STAD	cis	rs1850744	0.826	rs13101880	ENSG00000250268.3	ALG1L14P	-4.02	7.07e-05	0.0246	-0.48	-0.21	Economic and political preferences;	chr4:9706203	chr4:9166297~9170270:-
STAD	cis	rs1816752	0.669	rs9553309	ENSG00000273628.1	RP11-756A22.7	-4.02	7.07e-05	0.0246	-0.25	-0.21	Obesity-related traits;	chr13:24471476	chr13:24933006~24936796:+
STAD	cis	rs449789	0.524	rs875276	ENSG00000235086.1	FNDC1-IT1	-4.02	7.07e-05	0.0246	-0.27	-0.21	Pulse pressure;	chr6:159314170	chr6:159240786~159243329:+
STAD	cis	rs1113500	0.748	rs1781048	ENSG00000226822.1	RP11-356N1.2	4.02	7.07e-05	0.0246	0.26	0.21	Growth-regulated protein alpha levels;	chr1:108012428	chr1:108071482~108074519:+
STAD	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-4.02	7.07e-05	0.0246	-0.28	-0.21	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
STAD	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-4.02	7.07e-05	0.0246	-0.28	-0.21	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
STAD	cis	rs11169552	0.51	rs10876053	ENSG00000200183.1	RNU6-238P	-4.02	7.08e-05	0.0246	-0.2	-0.21	Colorectal cancer;	chr12:50541002	chr12:50656973~50657078:+
STAD	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-4.02	7.08e-05	0.0246	-0.23	-0.21	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
STAD	cis	rs12500234	0.966	rs73240622	ENSG00000249207.1	RP11-360F5.1	4.02	7.08e-05	0.0246	0.22	0.21	Colorectal cancer;	chr4:39604913	chr4:39112677~39126818:-
STAD	cis	rs12500234	0.933	rs7691939	ENSG00000249207.1	RP11-360F5.1	4.02	7.08e-05	0.0246	0.22	0.21	Colorectal cancer;	chr4:39606736	chr4:39112677~39126818:-
STAD	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	4.02	7.08e-05	0.0246	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
STAD	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-4.02	7.08e-05	0.0246	-0.23	-0.21	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
STAD	cis	rs10829156	0.679	rs4748476	ENSG00000240291.1	RP11-499P20.2	4.02	7.09e-05	0.0246	0.24	0.21	Sudden cardiac arrest;	chr10:18503946	chr10:18513115~18545651:-
STAD	cis	rs10829156	0.732	rs10741086	ENSG00000240291.1	RP11-499P20.2	4.02	7.09e-05	0.0246	0.24	0.21	Sudden cardiac arrest;	chr10:18505027	chr10:18513115~18545651:-
STAD	cis	rs7204230	1	rs62049814	ENSG00000261291.1	RP11-295M3.2	4.02	7.09e-05	0.0246	0.26	0.21	Fibrinogen;	chr16:53333541	chr16:53168522~53169450:+
STAD	cis	rs7204230	0.774	rs12596226	ENSG00000261291.1	RP11-295M3.2	4.02	7.09e-05	0.0246	0.26	0.21	Fibrinogen;	chr16:53334867	chr16:53168522~53169450:+
STAD	cis	rs10426930	1	rs10426930	ENSG00000267938.1	EIF1P6	-4.02	7.09e-05	0.0246	-0.24	-0.21	Monocyte percentage of white cells;	chr19:5038906	chr19:4347780~4349061:-
STAD	cis	rs3770081	0.59	rs12622715	ENSG00000273080.1	RP11-301O19.1	-4.02	7.09e-05	0.0246	-0.53	-0.21	Facial emotion recognition (sad faces);	chr2:86226440	chr2:86195590~86196049:+
STAD	cis	rs875971	0.545	rs2279757	ENSG00000273142.1	RP11-458F8.4	4.02	7.09e-05	0.0246	0.2	0.21	Aortic root size;	chr7:66363676	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs11766183	ENSG00000273142.1	RP11-458F8.4	4.02	7.09e-05	0.0246	0.2	0.21	Aortic root size;	chr7:66374173	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs1065265	ENSG00000273142.1	RP11-458F8.4	4.02	7.09e-05	0.0246	0.2	0.21	Aortic root size;	chr7:66376216	chr7:66902857~66906297:+
STAD	cis	rs3794924	1	rs7233484	ENSG00000266521.1	RP11-650P15.1	4.02	7.09e-05	0.0246	0.38	0.21	Survival in colon cancer;	chr18:31474869	chr18:31496645~31497195:-
STAD	cis	rs3794924	1	rs7236589	ENSG00000266521.1	RP11-650P15.1	4.02	7.09e-05	0.0246	0.38	0.21	Survival in colon cancer;	chr18:31475207	chr18:31496645~31497195:-
STAD	cis	rs748404	0.666	rs514438	ENSG00000205771.5	CATSPER2P1	-4.02	7.09e-05	0.0246	-0.32	-0.21	Lung cancer;	chr15:43328245	chr15:43726918~43747094:-
STAD	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	4.02	7.1e-05	0.0247	0.25	0.21	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
STAD	cis	rs2638953	0.962	rs11049527	ENSG00000247934.4	RP11-967K21.1	-4.02	7.1e-05	0.0247	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317667	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.925	rs11049528	ENSG00000247934.4	RP11-967K21.1	-4.02	7.1e-05	0.0247	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317914	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs10843151	ENSG00000247934.4	RP11-967K21.1	-4.02	7.1e-05	0.0247	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28318386	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs10843152	ENSG00000247934.4	RP11-967K21.1	-4.02	7.1e-05	0.0247	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319090	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs10843153	ENSG00000247934.4	RP11-967K21.1	-4.02	7.1e-05	0.0247	-0.25	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319168	chr12:28163298~28190738:-
STAD	cis	rs539514	0.587	rs7320602	ENSG00000261105.4	LMO7-AS1	4.02	7.1e-05	0.0247	0.25	0.21	Type 1 diabetes;	chr13:75758732	chr13:75604700~75635994:-
STAD	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-4.02	7.1e-05	0.0247	-0.25	-0.21	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
STAD	cis	rs867371	0.717	rs3858954	ENSG00000276710.3	CSPG4P8	-4.02	7.1e-05	0.0247	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82459472~82477258:+
STAD	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	4.02	7.11e-05	0.0247	0.16	0.21	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
STAD	cis	rs763121	0.925	rs4821797	ENSG00000280859.1	AL022326.1	-4.02	7.11e-05	0.0247	-0.24	-0.21	Menopause (age at onset);	chr22:38620177	chr22:39319019~39319147:-
STAD	cis	rs2337406	0.85	rs1858678	ENSG00000280411.1	IGHV1-69-2	-4.02	7.11e-05	0.0247	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106706790	chr14:106762092~106762588:-
STAD	cis	rs9733	0.596	rs12063547	ENSG00000276103.1	U4	-4.02	7.11e-05	0.0247	-0.2	-0.21	Tonsillectomy;	chr1:150701577	chr1:150608507~150608623:-
STAD	cis	rs9307551	0.584	rs9994403	ENSG00000250334.4	LINC00989	-4.02	7.11e-05	0.0247	-0.25	-0.21	Refractive error;	chr4:79521324	chr4:79492416~79576460:+
STAD	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-4.02	7.12e-05	0.0247	-0.25	-0.21	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
STAD	cis	rs9362426	0.526	rs7773804	ENSG00000217776.1	RP11-156F23.2	4.02	7.12e-05	0.0247	0.22	0.21	Depressive episodes in bipolar disorder;	chr6:87406432	chr6:87070156~87070461:-
STAD	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-4.02	7.12e-05	0.0247	-0.25	-0.21	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
STAD	cis	rs2284378	0.506	rs6142059	ENSG00000275784.1	RP5-1125A11.6	-4.02	7.12e-05	0.0247	-0.2	-0.21	Breast cancer;	chr20:33956521	chr20:33989480~33991818:-
STAD	cis	rs7586085	0.868	rs4667835	ENSG00000229195.1	AC009495.4	4.02	7.12e-05	0.0247	0.24	0.21	Total body bone mineral density;	chr2:165759045	chr2:165794857~165846091:-
STAD	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	4.02	7.12e-05	0.0247	0.28	0.21	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	4.02	7.12e-05	0.0247	0.28	0.21	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
STAD	cis	rs11051970	0.559	rs11051939	ENSG00000274964.1	RP11-817I4.1	4.02	7.12e-05	0.0247	0.28	0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32330107	chr12:32339368~32340724:+
STAD	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-4.02	7.13e-05	0.0247	-0.25	-0.21	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
STAD	cis	rs7074356	0.525	rs12246441	ENSG00000225484.5	NUTM2B-AS1	4.02	7.13e-05	0.0247	0.35	0.21	Borderline personality disorder;	chr10:80497980	chr10:79663088~79826594:-
STAD	cis	rs2338	0.769	rs9328061	ENSG00000272279.1	RP11-157J24.2	-4.02	7.13e-05	0.0247	-0.27	-0.21	Response to platinum-based agents;	chr6:1579978	chr6:1528364~1528911:-
STAD	cis	rs4308124	1	rs62160391	ENSG00000230499.1	AC108463.1	-4.02	7.13e-05	0.0247	-0.27	-0.21	Vitiligo;	chr2:111251258	chr2:111195963~111206494:+
STAD	cis	rs7487075	0.619	rs4768719	ENSG00000257261.4	RP11-96H19.1	4.02	7.13e-05	0.0247	0.29	0.21	Itch intensity from mosquito bite;	chr12:46447055	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs4768123	ENSG00000257261.4	RP11-96H19.1	4.02	7.13e-05	0.0247	0.29	0.21	Itch intensity from mosquito bite;	chr12:46458310	chr12:46383679~46876159:+
STAD	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	4.02	7.13e-05	0.0247	0.29	0.21	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
STAD	cis	rs10508774	0.733	rs3758380	ENSG00000273038.2	RP11-479G22.8	4.02	7.13e-05	0.0248	0.42	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32899525	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs10508776	ENSG00000273038.2	RP11-479G22.8	4.02	7.13e-05	0.0248	0.42	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32900099	chr10:32887255~32889311:-
STAD	cis	rs9902453	0.904	rs12936302	ENSG00000240074.1	RPL9P30	-4.02	7.13e-05	0.0248	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30022458	chr17:29855759~29856332:+
STAD	cis	rs763121	0.819	rs5757161	ENSG00000280859.1	AL022326.1	-4.02	7.13e-05	0.0248	-0.24	-0.21	Menopause (age at onset);	chr22:38594657	chr22:39319019~39319147:-
STAD	cis	rs7220401	0.542	rs55644350	ENSG00000263477.1	RP11-338L22.2	4.02	7.14e-05	0.0248	0.18	0.21	Coronary artery disease;	chr17:29586350	chr17:29863402~29866092:+
STAD	cis	rs11157436	0.581	rs17255433	ENSG00000211813.2	TRAV34	4.02	7.14e-05	0.0248	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22207522~22208129:+
STAD	cis	rs11157436	0.602	rs17255440	ENSG00000211813.2	TRAV34	4.02	7.14e-05	0.0248	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22207522~22208129:+
STAD	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	4.02	7.14e-05	0.0248	0.26	0.21	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
STAD	cis	rs494453	0.922	rs569504	ENSG00000234020.1	CHIAP3	-4.02	7.14e-05	0.0248	-0.21	-0.21	Osteoporosis-related phenotypes;	chr1:111669155	chr1:111353275~111367409:-
STAD	cis	rs1005277	0.505	rs1208689	ENSG00000099251.13	HSD17B7P2	4.02	7.14e-05	0.0248	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38356380~38378505:+
STAD	cis	rs11098499	0.78	rs12504773	ENSG00000260091.1	RP11-33B1.4	4.02	7.14e-05	0.0248	0.21	0.21	Corneal astigmatism;	chr4:119640994	chr4:119409333~119410233:+
STAD	cis	rs2834188	0.924	rs6517159	ENSG00000272659.1	AP000295.10	-4.02	7.15e-05	0.0248	-0.29	-0.21	Narcolepsy;	chr21:33301095	chr21:33309491~33310181:+
STAD	cis	rs4568518	0.869	rs12155371	ENSG00000279048.1	RP11-511H23.2	4.02	7.15e-05	0.0248	0.19	0.21	Measles;	chr7:17996541	chr7:17940503~17942922:+
STAD	cis	rs4568518	0.835	rs12155045	ENSG00000279048.1	RP11-511H23.2	4.02	7.15e-05	0.0248	0.19	0.21	Measles;	chr7:17996686	chr7:17940503~17942922:+
STAD	cis	rs10504130	0.569	rs16916966	ENSG00000272024.1	RP11-546K22.3	-4.02	7.15e-05	0.0248	-0.29	-0.21	Venous thromboembolism (SNP x SNP interaction);	chr8:51930769	chr8:51950284~51950690:+
STAD	cis	rs34779708	0.931	rs10466072	ENSG00000271335.4	RP11-324I22.4	4.02	7.15e-05	0.0248	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs998658	ENSG00000271335.4	RP11-324I22.4	4.02	7.15e-05	0.0248	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35314552~35336401:-
STAD	cis	rs9733	0.596	rs3087960	ENSG00000274963.1	Metazoa_SRP	4.02	7.15e-05	0.0248	0.19	0.21	Tonsillectomy;	chr1:150648093	chr1:150568971~150569269:-
STAD	cis	rs3811273	1	rs10148895	ENSG00000211816.2	TRAV38-1	4.02	7.15e-05	0.0248	0.3	0.21	Periodontal disease-related phenotypes;	chr14:22254840	chr14:22271968~22272563:+
STAD	cis	rs794185	0.605	rs2322683	ENSG00000229241.1	PNPT1P1	4.02	7.15e-05	0.0248	0.25	0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4426914	chr3:3981981~3984295:-
STAD	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-4.02	7.16e-05	0.0248	-0.25	-0.21	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
STAD	cis	rs867371	0.722	rs8033050	ENSG00000276710.3	CSPG4P8	-4.02	7.16e-05	0.0248	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82459472~82477258:+
STAD	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	4.02	7.16e-05	0.0248	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
STAD	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	4.02	7.16e-05	0.0248	0.28	0.21	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
STAD	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	4.02	7.16e-05	0.0248	0.28	0.21	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
STAD	cis	rs9926664	0.591	rs305082	ENSG00000274134.1	MIR6774	4.02	7.17e-05	0.0249	0.28	0.21	Neutrophil count;Sum basophil neutrophil counts;	chr16:85903372	chr16:85918347~85918416:+
STAD	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	4.02	7.17e-05	0.0249	0.3	0.21	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
STAD	cis	rs2286503	0.839	rs2240728	ENSG00000221740.1	SNORD93	4.02	7.18e-05	0.0249	0.24	0.21	Fibrinogen;	chr7:22812880	chr7:22856613~22856686:+
STAD	cis	rs7951911	0.915	rs12285394	ENSG00000254427.1	RP11-430H10.1	-4.02	7.18e-05	0.0249	-0.41	-0.21	IgG glycosylation;	chr11:45071817	chr11:45355371~45366121:+
STAD	cis	rs494453	0.807	rs2786966	ENSG00000234020.1	CHIAP3	4.02	7.18e-05	0.0249	0.21	0.21	Osteoporosis-related phenotypes;	chr1:111638035	chr1:111353275~111367409:-
STAD	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-4.02	7.18e-05	0.0249	-0.26	-0.21	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
STAD	cis	rs8012947	0.92	rs2348071	ENSG00000279636.2	LINC00216	-4.02	7.18e-05	0.0249	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58263908	chr14:58288033~58289158:+
STAD	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-4.02	7.18e-05	0.0249	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
STAD	cis	rs27434	0.602	rs2927620	ENSG00000248734.2	CTD-2260A17.1	4.02	7.18e-05	0.0249	0.27	0.21	Ankylosing spondylitis;	chr5:96845594	chr5:96784777~96785999:+
STAD	cis	rs2734839	0.507	rs2245805	ENSG00000270179.1	RP11-159N11.4	-4.02	7.18e-05	0.0249	-0.24	-0.21	Information processing speed;	chr11:113419977	chr11:113368478~113369117:+
STAD	cis	rs875971	1	rs2420820	ENSG00000224316.1	RP11-479O9.2	-4.02	7.18e-05	0.0249	-0.21	-0.21	Aortic root size;	chr7:66626920	chr7:65773620~65802067:+
STAD	cis	rs34779708	0.931	rs1926556	ENSG00000271335.4	RP11-324I22.4	4.02	7.18e-05	0.0249	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs1926554	ENSG00000271335.4	RP11-324I22.4	4.02	7.18e-05	0.0249	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934710	ENSG00000271335.4	RP11-324I22.4	4.02	7.18e-05	0.0249	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.897	rs35784065	ENSG00000271335.4	RP11-324I22.4	4.02	7.18e-05	0.0249	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs34304999	ENSG00000271335.4	RP11-324I22.4	4.02	7.18e-05	0.0249	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35314552~35336401:-
STAD	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-4.02	7.19e-05	0.0249	-0.33	-0.21	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
STAD	cis	rs68170813	0.523	rs11762152	ENSG00000273320.1	RP11-22N19.2	-4.02	7.19e-05	0.0249	-0.32	-0.21	Coronary artery disease;	chr7:107170929	chr7:106285480~106286326:+
STAD	cis	rs9902453	0.78	rs3115093	ENSG00000263477.1	RP11-338L22.2	4.02	7.19e-05	0.0249	0.18	0.21	Coffee consumption (cups per day);	chr17:29712737	chr17:29863402~29866092:+
STAD	cis	rs792448	0.743	rs351380	ENSG00000212044.2	AL360091.1	4.02	7.19e-05	0.0249	0.22	0.21	White blood cell count (basophil);	chr1:212309510	chr1:212349978~212350069:+
STAD	cis	rs1876905	0.597	rs1215964	ENSG00000271789.1	RP5-1112D6.7	-4.02	7.19e-05	0.0249	-0.26	-0.21	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111297126~111298510:+
STAD	cis	rs61270009	0.955	rs16903057	ENSG00000247828.6	TMEM161B-AS1	4.02	7.19e-05	0.0249	0.3	0.21	Depressive symptoms;	chr5:88292603	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs34241164	ENSG00000247828.6	TMEM161B-AS1	4.02	7.19e-05	0.0249	0.3	0.21	Depressive symptoms;	chr5:88293189	chr5:88268895~88436685:+
STAD	cis	rs8141529	0.748	rs7287918	ENSG00000226471.5	CTA-292E10.6	-4.02	7.19e-05	0.0249	-0.24	-0.21	Lymphocyte counts;	chr22:28885722	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.748	rs1318025	ENSG00000226471.5	CTA-292E10.6	-4.02	7.19e-05	0.0249	-0.24	-0.21	Lymphocyte counts;	chr22:28887769	chr22:28800683~28848559:+
STAD	cis	rs8098244	0.737	rs1258148	ENSG00000267301.1	RPL23AP77	4.02	7.2e-05	0.0249	0.29	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23940216	chr18:23709825~23710287:-
STAD	cis	rs6585424	1	rs6585454	ENSG00000225484.5	NUTM2B-AS1	4.02	7.2e-05	0.0249	0.38	0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180945	chr10:79663088~79826594:-
STAD	cis	rs3213758	0.541	rs5005161	ENSG00000275191.1	RP11-36I17.2	-4.02	7.2e-05	0.0249	-0.33	-0.21	Vitiligo (non-segmental);	chr16:53664764	chr16:53628256~53628816:-
STAD	cis	rs4927850	0.957	rs4927851	ENSG00000278820.1	AC024937.1	4.02	7.2e-05	0.0249	0.24	0.21	Pancreatic cancer;	chr3:196024982	chr3:195960500~195960612:-
STAD	cis	rs4927850	0.918	rs4361313	ENSG00000278820.1	AC024937.1	4.02	7.2e-05	0.0249	0.24	0.21	Pancreatic cancer;	chr3:196025389	chr3:195960500~195960612:-
STAD	cis	rs2933343	0.63	rs75824035	ENSG00000261159.1	RP11-723O4.9	4.02	7.2e-05	0.025	0.26	0.21	IgG glycosylation;	chr3:128934142	chr3:128859716~128860526:-
STAD	cis	rs4218	0.619	rs10851643	ENSG00000259732.1	RP11-59H7.3	-4.02	7.21e-05	0.025	-0.23	-0.21	Social communication problems;	chr15:59102985	chr15:59121034~59133250:+
STAD	cis	rs7487075	1	rs12813763	ENSG00000272963.1	OR7A19P	-4.02	7.21e-05	0.025	-0.21	-0.21	Itch intensity from mosquito bite;	chr12:46429121	chr12:46592573~46593305:+
STAD	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-4.02	7.21e-05	0.025	-0.39	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
STAD	cis	rs7829975	0.658	rs907181	ENSG00000253981.4	ALG1L13P	4.02	7.21e-05	0.025	0.24	0.21	Mood instability;	chr8:8845365	chr8:8236003~8244667:-
STAD	cis	rs6432860	0.932	rs13006006	ENSG00000229195.1	AC009495.4	4.02	7.21e-05	0.025	0.27	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:165988609	chr2:165794857~165846091:-
STAD	cis	rs9733	0.519	rs7529194	ENSG00000274963.1	Metazoa_SRP	4.02	7.21e-05	0.025	0.18	0.21	Tonsillectomy;	chr1:150650144	chr1:150568971~150569269:-
STAD	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	4.02	7.22e-05	0.025	0.28	0.21	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	4.02	7.22e-05	0.025	0.28	0.21	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	4.02	7.22e-05	0.025	0.28	0.21	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
STAD	cis	rs4784934	0.531	rs2042402	ENSG00000260186.4	RP11-481J2.2	4.02	7.22e-05	0.025	0.23	0.21	QT interval;	chr16:58430011	chr16:58421326~58462470:+
STAD	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	4.02	7.22e-05	0.025	0.25	0.21	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
STAD	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	4.02	7.22e-05	0.025	0.27	0.21	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
STAD	cis	rs2638953	0.924	rs11049399	ENSG00000247934.4	RP11-967K21.1	-4.02	7.22e-05	0.025	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs61920227	ENSG00000247934.4	RP11-967K21.1	-4.02	7.22e-05	0.025	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28163298~28190738:-
STAD	cis	rs2901460	0.714	rs13029356	ENSG00000229503.1	AC092155.1	-4.02	7.23e-05	0.025	-0.17	-0.21	Mean corpuscular volume;	chr2:62172849	chr2:62532583~62533059:-
STAD	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	4.02	7.23e-05	0.025	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
STAD	cis	rs7142881	0.815	rs34319089	ENSG00000258648.1	UBE2CP1	-4.02	7.23e-05	0.025	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31668895	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs2378936	ENSG00000258648.1	UBE2CP1	-4.02	7.23e-05	0.025	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31669196	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.746	rs55814060	ENSG00000258648.1	UBE2CP1	-4.02	7.23e-05	0.025	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31669590	chr14:30683045~30683598:-
STAD	cis	rs2638953	0.962	rs11049514	ENSG00000247934.4	RP11-967K21.1	-4.02	7.23e-05	0.025	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299461	chr12:28163298~28190738:-
STAD	cis	rs2834188	0.924	rs2834177	ENSG00000272659.1	AP000295.10	-4.02	7.23e-05	0.025	-0.29	-0.21	Narcolepsy;	chr21:33304501	chr21:33309491~33310181:+
STAD	cis	rs2803122	0.967	rs4977519	ENSG00000272842.1	RP11-513M16.7	-4.02	7.23e-05	0.025	-0.19	-0.21	Pulse pressure;	chr9:19241204	chr9:19371386~19371945:-
STAD	cis	rs944990	0.557	rs10821155	ENSG00000227603.1	RP11-165J3.6	4.02	7.23e-05	0.025	0.23	0.21	Body mass index;	chr9:93541996	chr9:93435332~93437121:-
STAD	cis	rs9907295	1	rs11653016	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35909756	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9889977	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35910691	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9894799	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35911085	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9903590	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35911286	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9897665	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35911595	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9912049	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35912530	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9911016	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35913349	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9912894	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35913452	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9303693	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35913595	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9914468	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35913727	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9893004	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35913855	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9899215	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35914215	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9907145	ENSG00000270894.1	AC015849.13	-4.02	7.23e-05	0.025	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35915237	chr17:35818399~35823713:+
STAD	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-4.02	7.23e-05	0.025	-0.33	-0.21	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
STAD	cis	rs4950322	0.547	rs61838945	ENSG00000278811.3	LINC00624	4.02	7.23e-05	0.025	0.22	0.21	Protein quantitative trait loci;	chr1:147111477	chr1:147258885~147517875:-
STAD	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-4.02	7.23e-05	0.025	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
STAD	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	4.02	7.24e-05	0.025	0.29	0.21	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	4.02	7.24e-05	0.025	0.29	0.21	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
STAD	cis	rs4713118	0.869	rs6901520	ENSG00000220721.1	OR1F12	4.02	7.24e-05	0.0251	0.23	0.21	Parkinson's disease;	chr6:27746796	chr6:28073316~28074233:+
STAD	cis	rs62064224	0.56	rs12162135	ENSG00000265139.1	RP11-227G15.2	-4.02	7.24e-05	0.0251	-0.23	-0.21	Schizophrenia;	chr17:32478777	chr17:32328441~32329395:+
STAD	cis	rs7142881	0.815	rs34782106	ENSG00000258648.1	UBE2CP1	-4.02	7.24e-05	0.0251	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31631701	chr14:30683045~30683598:-
STAD	cis	rs1005277	0.54	rs1814077	ENSG00000099251.13	HSD17B7P2	4.02	7.24e-05	0.0251	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38356380~38378505:+
STAD	cis	rs10741780	0.719	rs10766573	ENSG00000254544.1	PCNAP4	-4.02	7.24e-05	0.0251	-0.25	-0.21	HIV-1 susceptibility;	chr11:19588397	chr11:19274540~19275269:-
STAD	cis	rs9902453	0.808	rs8069669	ENSG00000263477.1	RP11-338L22.2	4.02	7.24e-05	0.0251	0.18	0.21	Coffee consumption (cups per day);	chr17:29912484	chr17:29863402~29866092:+
STAD	cis	rs867371	1	rs8041924	ENSG00000278603.1	RP13-608F4.5	4.02	7.24e-05	0.0251	0.25	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472203~82472426:+
STAD	cis	rs6180	0.869	rs2113088	ENSG00000250860.1	CTD-2265D6.2	4.02	7.24e-05	0.0251	0.18	0.21	Height;	chr5:42774275	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2910856	ENSG00000250860.1	CTD-2265D6.2	4.02	7.24e-05	0.0251	0.18	0.21	Height;	chr5:42781274	chr5:42466893~42468300:-
STAD	cis	rs17401966	1	rs7530167	ENSG00000199562.1	RNU6-37P	4.02	7.24e-05	0.0251	0.17	0.21	Hepatocellular carcinoma;	chr1:10393317	chr1:10298966~10299072:+
STAD	cis	rs6479891	0.818	rs9415700	ENSG00000235816.3	PRELID1P3	4.02	7.24e-05	0.0251	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs9415701	ENSG00000235816.3	PRELID1P3	4.02	7.24e-05	0.0251	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63427297~63427939:+
STAD	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-4.02	7.25e-05	0.0251	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-4.02	7.25e-05	0.0251	-0.4	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
STAD	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-4.02	7.25e-05	0.0251	-0.28	-0.21	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
STAD	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-4.02	7.25e-05	0.0251	-0.26	-0.21	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-4.02	7.25e-05	0.0251	-0.26	-0.21	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
STAD	cis	rs10129255	0.5	rs988132	ENSG00000211959.2	IGHV4-39	4.02	7.25e-05	0.0251	0.19	0.21	Kawasaki disease;	chr14:106776758	chr14:106421711~106422218:-
STAD	cis	rs7142881	0.815	rs8003788	ENSG00000258648.1	UBE2CP1	-4.02	7.25e-05	0.0251	-0.24	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31569474	chr14:30683045~30683598:-
STAD	cis	rs1348850	0.914	rs7604673	ENSG00000271825.1	RP11-337N6.2	4.02	7.25e-05	0.0251	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177527618	chr2:177300600~177302006:+
STAD	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-4.02	7.25e-05	0.0251	-0.24	-0.21	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
STAD	cis	rs4792901	0.765	rs12601607	ENSG00000279602.1	CTD-3014M21.1	-4.02	7.25e-05	0.0251	-0.29	-0.21	Dupuytren's disease;	chr17:43461415	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.729	rs12603131	ENSG00000279602.1	CTD-3014M21.1	-4.02	7.25e-05	0.0251	-0.29	-0.21	Dupuytren's disease;	chr17:43461471	chr17:43360041~43361361:-
STAD	cis	rs1816752	0.935	rs4770676	ENSG00000232858.1	RPL34P27	4.02	7.25e-05	0.0251	0.13	0.21	Obesity-related traits;	chr13:24429745	chr13:24988577~24988925:-
STAD	cis	rs1816752	1	rs7326932	ENSG00000232858.1	RPL34P27	4.02	7.25e-05	0.0251	0.13	0.21	Obesity-related traits;	chr13:24430355	chr13:24988577~24988925:-
STAD	cis	rs27434	0.615	rs61112531	ENSG00000248734.2	CTD-2260A17.1	-4.02	7.25e-05	0.0251	-0.27	-0.21	Ankylosing spondylitis;	chr5:96856117	chr5:96784777~96785999:+
STAD	cis	rs2243480	0.901	rs778687	ENSG00000273448.1	RP11-166O4.6	4.02	7.25e-05	0.0251	0.25	0.21	Diabetic kidney disease;	chr7:66370832	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs778679	ENSG00000273448.1	RP11-166O4.6	4.02	7.25e-05	0.0251	0.25	0.21	Diabetic kidney disease;	chr7:66375924	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs778704	ENSG00000273448.1	RP11-166O4.6	4.02	7.25e-05	0.0251	0.25	0.21	Diabetic kidney disease;	chr7:66398480	chr7:67333047~67334383:+
STAD	cis	rs2243480	0.901	rs778693	ENSG00000273448.1	RP11-166O4.6	4.02	7.25e-05	0.0251	0.25	0.21	Diabetic kidney disease;	chr7:66407358	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs778691	ENSG00000273448.1	RP11-166O4.6	4.02	7.25e-05	0.0251	0.25	0.21	Diabetic kidney disease;	chr7:66408105	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs13235972	ENSG00000273448.1	RP11-166O4.6	4.02	7.25e-05	0.0251	0.25	0.21	Diabetic kidney disease;	chr7:66418618	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs34192067	ENSG00000273448.1	RP11-166O4.6	4.02	7.25e-05	0.0251	0.25	0.21	Diabetic kidney disease;	chr7:66422670	chr7:67333047~67334383:+
STAD	cis	rs9902453	0.765	rs3115087	ENSG00000263477.1	RP11-338L22.2	4.02	7.25e-05	0.0251	0.18	0.21	Coffee consumption (cups per day);	chr17:29703249	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.817	rs3115089	ENSG00000263477.1	RP11-338L22.2	4.02	7.25e-05	0.0251	0.18	0.21	Coffee consumption (cups per day);	chr17:29704863	chr17:29863402~29866092:+
STAD	cis	rs2337406	1	rs1858677	ENSG00000280411.1	IGHV1-69-2	-4.02	7.26e-05	0.0251	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106706828	chr14:106762092~106762588:-
STAD	cis	rs73198271	0.74	rs10109886	ENSG00000254340.1	RP11-10A14.3	-4.02	7.26e-05	0.0251	-0.31	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:9141424~9145435:+
STAD	cis	rs9368481	0.645	rs10456350	ENSG00000224843.5	LINC00240	-4.02	7.26e-05	0.0251	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26956992~27023924:+
STAD	cis	rs9788721	0.806	rs4887056	ENSG00000259419.2	HNRNPCP3	4.02	7.26e-05	0.0251	0.23	0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78442243	chr15:79236332~79237206:+
STAD	cis	rs7829975	0.686	rs907180	ENSG00000233609.3	RP11-62H7.2	4.02	7.26e-05	0.0251	0.22	0.21	Mood instability;	chr8:8845317	chr8:8961200~8979025:+
STAD	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	4.02	7.26e-05	0.0251	0.25	0.21	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
STAD	cis	rs11673344	0.598	rs826326	ENSG00000267672.1	CTD-2293H3.1	4.02	7.27e-05	0.0251	0.2	0.21	Obesity-related traits;	chr19:37003863	chr19:37091341~37092564:+
STAD	cis	rs1876905	0.539	rs62420362	ENSG00000271789.1	RP5-1112D6.7	-4.02	7.27e-05	0.0251	-0.26	-0.21	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111297126~111298510:+
STAD	cis	rs9987353	0.824	rs55688575	ENSG00000254340.1	RP11-10A14.3	-4.02	7.27e-05	0.0251	-0.32	-0.21	Recombination measurement;	chr8:9275641	chr8:9141424~9145435:+
STAD	cis	rs732716	0.785	rs11085073	ENSG00000269318.1	AC007292.3	4.02	7.28e-05	0.0252	0.29	0.21	Mean corpuscular volume;	chr19:4375165	chr19:4356637~4358448:-
STAD	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	4.02	7.28e-05	0.0252	0.3	0.21	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
STAD	cis	rs9747201	1	rs36048409	ENSG00000281517.1	Metazoa_SRP	4.02	7.28e-05	0.0252	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82139085	chr17:81718849~81719095:-
STAD	cis	rs4407350	0.715	rs3827400	ENSG00000279642.1	RP5-1033E15.3	-4.02	7.28e-05	0.0252	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44494724	chr22:44486295~44486914:-
STAD	cis	rs6142102	0.812	rs761238	ENSG00000264616.1	MIR4755	-4.02	7.28e-05	0.0252	-0.22	-0.21	Skin pigmentation;	chr20:33932182	chr20:34049119~34049190:+
STAD	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-4.02	7.28e-05	0.0252	-0.33	-0.21	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-4.02	7.28e-05	0.0252	-0.33	-0.21	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-4.02	7.28e-05	0.0252	-0.33	-0.21	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
STAD	cis	rs4589258	0.788	rs4500454	ENSG00000280367.1	RP11-121L10.2	4.02	7.28e-05	0.0252	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90741369	chr11:90223153~90226538:+
STAD	cis	rs1167827	0.68	rs1167796	ENSG00000232729.6	AC083884.8	4.02	7.29e-05	0.0252	0.15	0.21	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:74688939~74729001:-
STAD	cis	rs8059260	0.541	rs12917947	ENSG00000274038.1	RP11-66H6.4	-4.02	7.29e-05	0.0252	-0.36	-0.21	Alcohol consumption over the past year;	chr16:11116386	chr16:11056556~11057034:+
STAD	cis	rs792448	0.728	rs2252044	ENSG00000212044.2	AL360091.1	4.02	7.29e-05	0.0252	0.22	0.21	White blood cell count (basophil);	chr1:212342903	chr1:212349978~212350069:+
STAD	cis	rs34779708	0.931	rs55724039	ENSG00000271335.4	RP11-324I22.4	4.02	7.29e-05	0.0252	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35314552~35336401:-
STAD	cis	rs6772849	0.93	rs12630379	ENSG00000242551.2	POU5F1P6	-4.02	7.29e-05	0.0252	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128674735~128677005:-
STAD	cis	rs9291683	0.588	rs4280729	ENSG00000250613.1	RP11-136I13.1	-4.01	7.3e-05	0.0252	-0.2	-0.21	Bone mineral density;	chr4:10012237	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.552	rs10939656	ENSG00000250613.1	RP11-136I13.1	-4.01	7.3e-05	0.0252	-0.2	-0.21	Bone mineral density;	chr4:10013022	chr4:10410996~10411644:+
STAD	cis	rs10043228	0.609	rs78035495	ENSG00000248445.4	SEMA6A-AS1	-4.01	7.3e-05	0.0252	-0.29	-0.21	Asthma or chronic obstructive pulmonary disease;	chr5:116361169	chr5:116447547~116508276:+
STAD	cis	rs10043228	0.609	rs1529443	ENSG00000248445.4	SEMA6A-AS1	-4.01	7.3e-05	0.0252	-0.29	-0.21	Asthma or chronic obstructive pulmonary disease;	chr5:116361339	chr5:116447547~116508276:+
STAD	cis	rs6479891	1	rs7081275	ENSG00000235816.3	PRELID1P3	-4.01	7.3e-05	0.0252	-0.27	-0.21	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63427297~63427939:+
STAD	cis	rs11098499	0.604	rs2389882	ENSG00000260091.1	RP11-33B1.4	4.01	7.3e-05	0.0252	0.2	0.21	Corneal astigmatism;	chr4:119645578	chr4:119409333~119410233:+
STAD	cis	rs806321	0.72	rs2580184	ENSG00000237152.3	DLEU7-AS1	-4.01	7.31e-05	0.0252	-0.24	-0.21	Multiple sclerosis;	chr13:50218455	chr13:50807856~50849905:+
STAD	cis	rs875971	1	rs1544549	ENSG00000224316.1	RP11-479O9.2	-4.01	7.31e-05	0.0252	-0.21	-0.21	Aortic root size;	chr7:66625676	chr7:65773620~65802067:+
STAD	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	4.01	7.31e-05	0.0252	0.23	0.21	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
STAD	cis	rs10851478	0.872	rs12595692	ENSG00000259545.2	RP11-325E5.4	-4.01	7.31e-05	0.0252	-0.25	-0.21	Oral cavity cancer;	chr15:49464911	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs11854671	ENSG00000259545.2	RP11-325E5.4	-4.01	7.31e-05	0.0252	-0.25	-0.21	Oral cavity cancer;	chr15:49473229	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs2899434	ENSG00000259545.2	RP11-325E5.4	-4.01	7.31e-05	0.0252	-0.25	-0.21	Oral cavity cancer;	chr15:49474771	chr15:49177610~49178741:-
STAD	cis	rs6496044	0.963	rs6496050	ENSG00000259407.1	RP11-158M2.3	-4.01	7.31e-05	0.0253	-0.22	-0.21	Interstitial lung disease;	chr15:85526019	chr15:85744109~85750281:-
STAD	cis	rs9902453	0.934	rs7213902	ENSG00000263477.1	RP11-338L22.2	4.01	7.31e-05	0.0253	0.18	0.21	Coffee consumption (cups per day);	chr17:29995917	chr17:29863402~29866092:+
STAD	cis	rs12745968	0.62	rs7551324	ENSG00000229052.2	RP11-386I23.1	-4.01	7.31e-05	0.0253	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92794676	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.625	rs7549341	ENSG00000229052.2	RP11-386I23.1	-4.01	7.31e-05	0.0253	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92801391	chr1:92930696~92934098:+
STAD	cis	rs16958440	0.867	rs80106524	ENSG00000267724.1	RP11-49K24.8	4.01	7.32e-05	0.0253	0.42	0.21	Sitting height ratio;	chr18:47150268	chr18:47105946~47108062:+
STAD	cis	rs16958440	0.867	rs79712753	ENSG00000267724.1	RP11-49K24.8	4.01	7.32e-05	0.0253	0.42	0.21	Sitting height ratio;	chr18:47150356	chr18:47105946~47108062:+
STAD	cis	rs16958440	0.867	rs3809966	ENSG00000267724.1	RP11-49K24.8	4.01	7.32e-05	0.0253	0.42	0.21	Sitting height ratio;	chr18:47151256	chr18:47105946~47108062:+
STAD	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	4.01	7.32e-05	0.0253	0.37	0.21	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
STAD	cis	rs9747201	0.962	rs34016823	ENSG00000281517.1	Metazoa_SRP	4.01	7.32e-05	0.0253	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82137552	chr17:81718849~81719095:-
STAD	cis	rs9747201	0.926	rs35131420	ENSG00000281517.1	Metazoa_SRP	4.01	7.32e-05	0.0253	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82145755	chr17:81718849~81719095:-
STAD	cis	rs9747201	1	rs55638685	ENSG00000281517.1	Metazoa_SRP	4.01	7.32e-05	0.0253	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82149690	chr17:81718849~81719095:-
STAD	cis	rs9747201	1	rs12943668	ENSG00000281517.1	Metazoa_SRP	4.01	7.32e-05	0.0253	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82152054	chr17:81718849~81719095:-
STAD	cis	rs9747201	1	rs3922470	ENSG00000281517.1	Metazoa_SRP	4.01	7.32e-05	0.0253	0.25	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82152283	chr17:81718849~81719095:-
STAD	cis	rs7587026	0.583	rs478389	ENSG00000229195.1	AC009495.4	4.01	7.32e-05	0.0253	0.24	0.21	Mesial temporal lobe epilepsy with hippocampal sclerosis;	chr2:166026318	chr2:165794857~165846091:-
STAD	cis	rs7587026	0.559	rs6730344	ENSG00000229195.1	AC009495.4	-4.01	7.32e-05	0.0253	-0.24	-0.21	Mesial temporal lobe epilepsy with hippocampal sclerosis;	chr2:166025712	chr2:165794857~165846091:-
STAD	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-4.01	7.32e-05	0.0253	-0.22	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
STAD	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-4.01	7.32e-05	0.0253	-0.33	-0.21	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
STAD	cis	rs2638953	0.924	rs11049400	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049401	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28163298~28190738:-
STAD	cis	rs8014252	0.803	rs11158863	ENSG00000259158.2	ADAM20P1	4.01	7.33e-05	0.0253	0.28	0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70514449	chr14:70468881~70483756:-
STAD	cis	rs8097348	1	rs16941818	ENSG00000266602.1	RP11-476K15.1	4.01	7.33e-05	0.0253	0.25	0.21	Exercise (leisure time);	chr18:1600944	chr18:1509183~1647097:+
STAD	cis	rs2638953	0.962	rs11049496	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.819	rs10843146	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28268352	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs2172299	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049503	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs61922974	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs61922975	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283705	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs61922976	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283837	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs61922977	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049505	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049507	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28289554	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049509	ENSG00000247934.4	RP11-967K21.1	-4.01	7.33e-05	0.0253	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28163298~28190738:-
STAD	cis	rs17818399	0.817	rs17767994	ENSG00000279254.1	RP11-536C12.1	4.01	7.33e-05	0.0253	0.22	0.21	Height;	chr2:46632940	chr2:46668870~46670778:+
STAD	cis	rs4237845	0.837	rs7971877	ENSG00000273805.1	RP11-620J15.4	-4.01	7.33e-05	0.0253	-0.23	-0.21	Intelligence (multi-trait analysis);	chr12:57893847	chr12:57894232~57896846:+
STAD	cis	rs7680126	0.626	rs929575	ENSG00000250613.1	RP11-136I13.1	4.01	7.33e-05	0.0253	0.25	0.21	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10195262	chr4:10410996~10411644:+
STAD	cis	rs7474896	1	rs12763409	ENSG00000099251.13	HSD17B7P2	4.01	7.33e-05	0.0253	0.35	0.21	Obesity (extreme);	chr10:37803762	chr10:38356380~38378505:+
STAD	cis	rs1707322	1	rs11211243	ENSG00000281133.1	AL355480.3	-4.01	7.34e-05	0.0253	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs11211244	ENSG00000281133.1	AL355480.3	-4.01	7.34e-05	0.0253	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45580892~45580996:-
STAD	cis	rs1318937	0.764	rs735659	ENSG00000224660.1	SH3BP5-AS1	4.01	7.34e-05	0.0253	0.21	0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15182487	chr3:15254184~15264493:+
STAD	cis	rs1318937	0.764	rs2077619	ENSG00000224660.1	SH3BP5-AS1	4.01	7.34e-05	0.0253	0.21	0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15182835	chr3:15254184~15264493:+
STAD	cis	rs1318937	0.679	rs9849394	ENSG00000224660.1	SH3BP5-AS1	4.01	7.34e-05	0.0253	0.21	0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15183135	chr3:15254184~15264493:+
STAD	cis	rs34779708	0.966	rs12765038	ENSG00000271335.4	RP11-324I22.4	4.01	7.34e-05	0.0253	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs2045917	ENSG00000271335.4	RP11-324I22.4	4.01	7.34e-05	0.0253	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35314552~35336401:-
STAD	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	4.01	7.34e-05	0.0253	0.23	0.21	QT interval;	chr12:29284120	chr12:29277397~29277882:-
STAD	cis	rs9291683	0.509	rs10939671	ENSG00000250613.1	RP11-136I13.1	-4.01	7.34e-05	0.0253	-0.22	-0.21	Bone mineral density;	chr4:10049191	chr4:10410996~10411644:+
STAD	cis	rs7924176	0.601	rs3180427	ENSG00000213731.2	RAB5CP1	-4.01	7.34e-05	0.0253	-0.21	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74423435~74424014:-
STAD	cis	rs10508774	1	rs72795556	ENSG00000273038.2	RP11-479G22.8	4.01	7.34e-05	0.0253	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32579912	chr10:32887255~32889311:-
STAD	cis	rs7829975	0.539	rs883647	ENSG00000253893.2	FAM85B	4.01	7.34e-05	0.0253	0.29	0.21	Mood instability;	chr8:8712214	chr8:8167819~8226614:-
STAD	cis	rs7119038	0.818	rs56043232	ENSG00000255422.1	AP002954.4	4.01	7.35e-05	0.0253	0.29	0.21	Sjögren's syndrome;	chr11:118777664	chr11:118704607~118750263:+
STAD	cis	rs6180	1	rs2910872	ENSG00000250860.1	CTD-2265D6.2	4.01	7.35e-05	0.0253	0.18	0.21	Height;	chr5:42730190	chr5:42466893~42468300:-
STAD	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-4.01	7.35e-05	0.0254	-0.24	-0.21	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
STAD	cis	rs2430307	0.518	rs67763033	ENSG00000205482.8	AC007000.12	-4.01	7.35e-05	0.0254	-0.22	-0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76888360	chr7:77052785~77059440:-
STAD	cis	rs11089937	0.597	rs9619794	ENSG00000211640.3	IGLV6-57	4.01	7.35e-05	0.0254	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22195713~22196460:+
STAD	cis	rs1790761	0.52	rs1551884	ENSG00000231793.4	DOC2GP	-4.01	7.35e-05	0.0254	-0.26	-0.21	Mean corpuscular volume;	chr11:67632130	chr11:67612653~67616257:-
STAD	cis	rs11051970	0.559	rs16919727	ENSG00000274964.1	RP11-817I4.1	-4.01	7.35e-05	0.0254	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32329976	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs11051940	ENSG00000274964.1	RP11-817I4.1	-4.01	7.35e-05	0.0254	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32330187	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs4316592	ENSG00000274964.1	RP11-817I4.1	-4.01	7.35e-05	0.0254	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32331076	chr12:32339368~32340724:+
STAD	cis	rs9902453	0.868	rs12944395	ENSG00000263477.1	RP11-338L22.2	-4.01	7.35e-05	0.0254	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29996481	chr17:29863402~29866092:+
STAD	cis	rs1348850	0.567	rs3770012	ENSG00000271825.1	RP11-337N6.2	-4.01	7.35e-05	0.0254	-0.19	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177673295	chr2:177300600~177302006:+
STAD	cis	rs9304742	0.683	rs10402714	ENSG00000242779.5	ZNF702P	4.01	7.36e-05	0.0254	0.27	0.21	Psoriasis;	chr19:52960427	chr19:52968251~53037898:-
STAD	cis	rs9921338	0.923	rs72771877	ENSG00000263080.1	RP11-485G7.5	4.01	7.36e-05	0.0254	0.32	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11274759	chr16:11341809~11345211:-
STAD	cis	rs2933343	0.679	rs789229	ENSG00000261159.1	RP11-723O4.9	4.01	7.36e-05	0.0254	0.26	0.21	IgG glycosylation;	chr3:128883683	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.729	rs789230	ENSG00000261159.1	RP11-723O4.9	4.01	7.36e-05	0.0254	0.26	0.21	IgG glycosylation;	chr3:128883715	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.661	rs2630259	ENSG00000261159.1	RP11-723O4.9	4.01	7.36e-05	0.0254	0.26	0.21	IgG glycosylation;	chr3:128887479	chr3:128859716~128860526:-
STAD	cis	rs2933343	0.729	rs6790091	ENSG00000261159.1	RP11-723O4.9	4.01	7.36e-05	0.0254	0.26	0.21	IgG glycosylation;	chr3:128889908	chr3:128859716~128860526:-
STAD	cis	rs6432852	0.527	rs1864812	ENSG00000229195.1	AC009495.4	4.01	7.36e-05	0.0254	0.24	0.21	Diabetic kidney disease;	chr2:165942486	chr2:165794857~165846091:-
STAD	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-4.01	7.36e-05	0.0254	-0.31	-0.21	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
STAD	cis	rs4713118	0.868	rs2893928	ENSG00000220721.1	OR1F12	4.01	7.36e-05	0.0254	0.25	0.21	Parkinson's disease;	chr6:27770651	chr6:28073316~28074233:+
STAD	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	4.01	7.36e-05	0.0254	0.21	0.21	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
STAD	cis	rs5769707	0.681	rs9616329	ENSG00000213279.2	RP1-29C18.9	-4.01	7.36e-05	0.0254	-0.27	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49572264~49575426:-
STAD	cis	rs6095298	0.595	rs6095323	ENSG00000227431.4	CSE1L-AS1	4.01	7.36e-05	0.0254	0.24	0.21	Intelligence (multi-trait analysis);	chr20:48832634	chr20:49040463~49046044:-
STAD	cis	rs792448	0.743	rs351398	ENSG00000212044.2	AL360091.1	4.01	7.36e-05	0.0254	0.22	0.21	White blood cell count (basophil);	chr1:212292897	chr1:212349978~212350069:+
STAD	cis	rs4835473	0.932	rs13152443	ENSG00000249741.2	RP11-673E1.3	4.01	7.37e-05	0.0254	0.25	0.21	Immature fraction of reticulocytes;	chr4:143742492	chr4:143911514~143912053:-
STAD	cis	rs11098499	0.866	rs3756156	ENSG00000260091.1	RP11-33B1.4	4.01	7.37e-05	0.0254	0.21	0.21	Corneal astigmatism;	chr4:119603686	chr4:119409333~119410233:+
STAD	cis	rs7474896	1	rs10827831	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37821885	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9417261	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37822841	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9417263	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37825762	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9418294	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37826658	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9417264	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37828642	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.945	rs9417265	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37829973	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9417268	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37844266	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs9418298	ENSG00000099251.13	HSD17B7P2	4.01	7.37e-05	0.0254	0.35	0.21	Obesity (extreme);	chr10:37848308	chr10:38356380~38378505:+
STAD	cis	rs2310173	0.612	rs3819369	ENSG00000281162.1	LINC01127	-4.01	7.37e-05	0.0254	-0.27	-0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102016120	chr2:101962056~101987167:+
STAD	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	4.01	7.37e-05	0.0254	0.23	0.21	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
STAD	cis	rs3794924	1	rs35242229	ENSG00000266521.1	RP11-650P15.1	4.01	7.37e-05	0.0254	0.39	0.21	Survival in colon cancer;	chr18:31472920	chr18:31496645~31497195:-
STAD	cis	rs3794924	1	rs71372018	ENSG00000266521.1	RP11-650P15.1	4.01	7.37e-05	0.0254	0.39	0.21	Survival in colon cancer;	chr18:31473571	chr18:31496645~31497195:-
STAD	cis	rs3794924	1	rs3810005	ENSG00000266521.1	RP11-650P15.1	4.01	7.37e-05	0.0254	0.39	0.21	Survival in colon cancer;	chr18:31473913	chr18:31496645~31497195:-
STAD	cis	rs7915414	0.531	rs34532201	ENSG00000230338.1	MTND4P19	4.01	7.37e-05	0.0254	0.25	0.21	Clopidogrel active metabolite levels;	chr10:94950407	chr10:94774156~94774633:-
STAD	cis	rs7915414	0.531	rs1578438	ENSG00000230338.1	MTND4P19	4.01	7.37e-05	0.0254	0.25	0.21	Clopidogrel active metabolite levels;	chr10:94954003	chr10:94774156~94774633:-
STAD	cis	rs6583954	0.789	rs9332167	ENSG00000230338.1	MTND4P19	4.01	7.37e-05	0.0254	0.25	0.21	Migraine;	chr10:94971457	chr10:94774156~94774633:-
STAD	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	4.01	7.37e-05	0.0254	0.24	0.21	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
STAD	cis	rs11673344	0.543	rs8108429	ENSG00000267672.1	CTD-2293H3.1	4.01	7.38e-05	0.0254	0.2	0.21	Obesity-related traits;	chr19:37145874	chr19:37091341~37092564:+
STAD	cis	rs11157436	0.602	rs2331594	ENSG00000211812.1	TRAV26-2	-4.01	7.38e-05	0.0254	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22202583~22203368:+
STAD	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	4.01	7.38e-05	0.0254	0.23	0.21	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
STAD	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	4.01	7.38e-05	0.0254	0.23	0.21	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
STAD	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	4.01	7.38e-05	0.0254	0.28	0.21	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	4.01	7.38e-05	0.0254	0.28	0.21	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
STAD	cis	rs1790761	0.967	rs12573992	ENSG00000231793.4	DOC2GP	-4.01	7.38e-05	0.0254	-0.25	-0.21	Mean corpuscular volume;	chr11:67430286	chr11:67612653~67616257:-
STAD	cis	rs1790761	0.967	rs4930427	ENSG00000231793.4	DOC2GP	-4.01	7.38e-05	0.0254	-0.25	-0.21	Mean corpuscular volume;	chr11:67433348	chr11:67612653~67616257:-
STAD	cis	rs737008	0.96	rs34764020	ENSG00000262703.1	RP11-485G7.6	-4.01	7.38e-05	0.0254	-0.2	-0.21	Obesity-related traits;	chr16:11284502	chr16:11348143~11349321:-
STAD	cis	rs7824557	0.606	rs1435277	ENSG00000205879.4	FAM90A2P	4.01	7.38e-05	0.0254	0.24	0.21	Retinal vascular caliber;	chr8:11339461	chr8:12172202~12178575:-
STAD	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	4.01	7.38e-05	0.0254	0.29	0.21	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
STAD	cis	rs3794924	1	rs35777565	ENSG00000266521.1	RP11-650P15.1	4.01	7.38e-05	0.0254	0.39	0.21	Survival in colon cancer;	chr18:31469409	chr18:31496645~31497195:-
STAD	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-4.01	7.38e-05	0.0254	-0.26	-0.21	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
STAD	cis	rs17772222	0.701	rs453112	ENSG00000258789.1	RP11-507K2.3	4.01	7.38e-05	0.0254	0.25	0.21	Coronary artery calcification;	chr14:88392657	chr14:88551597~88552493:+
STAD	cis	rs238295	0.805	rs6053499	ENSG00000230563.2	RP5-828H9.1	4.01	7.38e-05	0.0254	0.24	0.21	Occipital cortical area (total cortical area interaction);	chr20:5561900	chr20:5471207~5475182:+
STAD	cis	rs10129255	1	rs10137758	ENSG00000224373.3	IGHV4-59	4.01	7.39e-05	0.0255	0.17	0.21	Kawasaki disease;	chr14:106697673	chr14:106627249~106627825:-
STAD	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	4.01	7.39e-05	0.0255	0.23	0.21	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
STAD	cis	rs10129255	0.957	rs4387509	ENSG00000224373.3	IGHV4-59	4.01	7.39e-05	0.0255	0.17	0.21	Kawasaki disease;	chr14:106704386	chr14:106627249~106627825:-
STAD	cis	rs7512552	0.839	rs1498308	ENSG00000261716.1	RP11-196G18.22	4.01	7.39e-05	0.0255	0.22	0.21	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150322682	chr1:149844498~149849024:-
STAD	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	4.01	7.39e-05	0.0255	0.23	0.21	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
STAD	cis	rs6840258	0.831	rs3775211	ENSG00000248180.1	GAPDHP60	4.01	7.39e-05	0.0255	0.16	0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87117939	chr4:87207092~87208086:+
STAD	cis	rs858239	0.568	rs6970694	ENSG00000230042.1	AK3P3	-4.01	7.39e-05	0.0255	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23129178~23129841:+
STAD	cis	rs17361889	0.517	rs62441879	ENSG00000224683.1	RPL36AP29	4.01	7.39e-05	0.0255	0.28	0.21	Pediatric bone mineral content (hip);	chr7:16290195	chr7:16208945~16209265:+
STAD	cis	rs6693567	0.586	rs9661040	ENSG00000203819.6	HIST2H2BC	4.01	7.39e-05	0.0255	0.24	0.21	Migraine;	chr1:150510760	chr1:149850193~149850772:-
STAD	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	4.01	7.39e-05	0.0255	0.23	0.21	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
STAD	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	4.01	7.39e-05	0.0255	0.29	0.21	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
STAD	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-4.01	7.39e-05	0.0255	-0.27	-0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
STAD	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	4.01	7.4e-05	0.0255	0.25	0.21	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
STAD	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	4.01	7.4e-05	0.0255	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	4.01	7.4e-05	0.0255	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	4.01	7.4e-05	0.0255	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
STAD	cis	rs10129255	0.957	rs10136560	ENSG00000211973.2	IGHV1-69	4.01	7.4e-05	0.0255	0.2	0.21	Kawasaki disease;	chr14:106787630	chr14:106714684~106715181:-
STAD	cis	rs9733	0.596	rs72702536	ENSG00000276103.1	U4	4.01	7.41e-05	0.0255	0.2	0.21	Tonsillectomy;	chr1:150690098	chr1:150608507~150608623:-
STAD	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	4.01	7.41e-05	0.0255	0.28	0.21	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
STAD	cis	rs10851478	0.872	rs12148764	ENSG00000259545.2	RP11-325E5.4	4.01	7.41e-05	0.0255	0.25	0.21	Oral cavity cancer;	chr15:49463884	chr15:49177610~49178741:-
STAD	cis	rs7487075	0.647	rs4077708	ENSG00000257261.4	RP11-96H19.1	4.01	7.41e-05	0.0255	0.29	0.21	Itch intensity from mosquito bite;	chr12:46463590	chr12:46383679~46876159:+
STAD	cis	rs9847710	1	rs13088455	ENSG00000242142.1	SERBP1P3	-4.01	7.41e-05	0.0255	-0.2	-0.21	Ulcerative colitis;	chr3:53053466	chr3:53064283~53065091:-
STAD	cis	rs1707322	0.827	rs10890347	ENSG00000225447.1	RPS15AP10	-4.01	7.41e-05	0.0255	-0.17	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45645816~45646197:-
STAD	cis	rs2115630	0.967	rs11073702	ENSG00000275120.1	RP11-182J1.17	-4.01	7.41e-05	0.0255	-0.23	-0.21	P wave terminal force;	chr15:84766840	chr15:84599434~84606463:-
STAD	cis	rs34779708	0.931	rs4934724	ENSG00000271335.4	RP11-324I22.4	4.01	7.41e-05	0.0255	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs4934725	ENSG00000271335.4	RP11-324I22.4	4.01	7.41e-05	0.0255	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs12774834	ENSG00000271335.4	RP11-324I22.4	4.01	7.41e-05	0.0255	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs12775759	ENSG00000271335.4	RP11-324I22.4	4.01	7.41e-05	0.0255	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs34296409	ENSG00000271335.4	RP11-324I22.4	4.01	7.41e-05	0.0255	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs35777088	ENSG00000271335.4	RP11-324I22.4	4.01	7.41e-05	0.0255	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs11592567	ENSG00000271335.4	RP11-324I22.4	4.01	7.41e-05	0.0255	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35314552~35336401:-
STAD	cis	rs10129255	0.869	rs72690553	ENSG00000224373.3	IGHV4-59	4.01	7.41e-05	0.0255	0.17	0.21	Kawasaki disease;	chr14:106715491	chr14:106627249~106627825:-
STAD	cis	rs12908161	0.515	rs12907646	ENSG00000259728.4	LINC00933	4.01	7.42e-05	0.0255	0.29	0.21	Schizophrenia;	chr15:84860265	chr15:84570649~84580175:+
STAD	cis	rs2337406	0.929	rs11847182	ENSG00000254174.1	IGHV1-12	4.01	7.42e-05	0.0255	0.25	0.21	Alzheimer's disease (late onset);	chr14:106697724	chr14:106122420~106122709:-
STAD	cis	rs12439619	1	rs35152457	ENSG00000276710.3	CSPG4P8	-4.01	7.42e-05	0.0255	-0.29	-0.21	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82459472~82477258:+
STAD	cis	rs749052	0.706	rs2580817	ENSG00000251485.1	AC068134.10	4.01	7.42e-05	0.0256	0.44	0.21	Height;	chr2:231934013	chr2:232343116~232343903:+
STAD	cis	rs330048	0.509	rs36111783	ENSG00000254340.1	RP11-10A14.3	4.01	7.42e-05	0.0256	0.25	0.21	Systemic lupus erythematosus;	chr8:9288078	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.576	rs2157616	ENSG00000211959.2	IGHV4-39	4.01	7.42e-05	0.0256	0.19	0.21	Kawasaki disease;	chr14:106767802	chr14:106421711~106422218:-
STAD	cis	rs6180	1	rs2972767	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42748955	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs1074263	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42750649	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs1423653	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42751346	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs1862630	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42754141	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2972994	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42756398	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2972998	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42763410	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2910864	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42763605	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2972999	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42763695	chr5:42466893~42468300:-
STAD	cis	rs6180	0.967	rs2973001	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42764472	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs1895457	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42765230	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2910862	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42766302	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2973006	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42772052	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2910851	ENSG00000250860.1	CTD-2265D6.2	4.01	7.42e-05	0.0256	0.18	0.21	Height;	chr5:42787130	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2459629	ENSG00000250860.1	CTD-2265D6.2	-4.01	7.42e-05	0.0256	-0.18	-0.21	Height;	chr5:42790772	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs230812	ENSG00000250860.1	CTD-2265D6.2	-4.01	7.42e-05	0.0256	-0.18	-0.21	Height;	chr5:42797659	chr5:42466893~42468300:-
STAD	cis	rs7927771	0.832	rs4752994	ENSG00000271350.1	CTD-2384B9.1	4.01	7.42e-05	0.0256	0.23	0.21	Subjective well-being;	chr11:47389514	chr11:47041027~47041945:-
STAD	cis	rs7927771	0.832	rs10769262	ENSG00000271350.1	CTD-2384B9.1	4.01	7.42e-05	0.0256	0.23	0.21	Subjective well-being;	chr11:47390030	chr11:47041027~47041945:-
STAD	cis	rs3002131	0.604	rs2133185	ENSG00000225265.1	TAF1A-AS1	-4.01	7.42e-05	0.0256	-0.31	-0.21	Interleukin-10 levels;	chr1:222565628	chr1:222589825~222593032:+
STAD	cis	rs4869931	0.929	rs4869926	ENSG00000218358.2	RAET1K	4.01	7.42e-05	0.0256	0.33	0.21	Systolic blood pressure in sickle cell anemia;	chr6:150679737	chr6:149998019~150005157:-
STAD	cis	rs7103648	0.864	rs10742802	ENSG00000280615.1	Y_RNA	4.01	7.42e-05	0.0256	0.21	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47411174	chr11:47614898~47614994:-
STAD	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	4.01	7.43e-05	0.0256	0.23	0.21	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
STAD	cis	rs4388249	1	rs13172735	ENSG00000271849.1	CTC-332L22.1	4.01	7.43e-05	0.0256	0.31	0.21	Schizophrenia;	chr5:109724132	chr5:109687802~109688329:-
STAD	cis	rs9907295	0.681	rs9912284	ENSG00000270894.1	AC015849.13	-4.01	7.43e-05	0.0256	-0.24	-0.21	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35818399~35823713:+
STAD	cis	rs2351088	0.764	rs11703016	ENSG00000230634.1	RP5-996D20.3	-4.01	7.43e-05	0.0256	-0.35	-0.21	Tonsillectomy;	chr22:45789058	chr22:46481329~46481760:-
STAD	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-4.01	7.43e-05	0.0256	-0.26	-0.21	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
STAD	cis	rs606458	0.614	rs547066	ENSG00000269038.1	AP001462.6	4.01	7.43e-05	0.0256	0.29	0.21	Urate levels;	chr11:64756022	chr11:64778954~64779405:+
STAD	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	4.01	7.43e-05	0.0256	0.31	0.21	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
STAD	cis	rs34421088	0.624	rs13278982	ENSG00000227888.4	FAM66A	4.01	7.43e-05	0.0256	0.23	0.21	Neuroticism;	chr8:11731524	chr8:12362019~12388296:+
STAD	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	4.01	7.44e-05	0.0256	0.31	0.21	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	4.01	7.44e-05	0.0256	0.31	0.21	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
STAD	cis	rs34779708	0.931	rs4934721	ENSG00000271335.4	RP11-324I22.4	4.01	7.44e-05	0.0256	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35314552~35336401:-
STAD	cis	rs7646881	0.812	rs59192661	ENSG00000240207.5	RP11-379F4.4	-4.01	7.45e-05	0.0256	-0.35	-0.21	Tetralogy of Fallot;	chr3:158741238	chr3:158732263~158784070:+
STAD	cis	rs9463078	0.715	rs7738526	ENSG00000219384.1	RP11-491H9.3	4.01	7.45e-05	0.0256	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45200680	chr6:45158870~45159511:+
STAD	cis	rs6471393	0.964	rs2914959	ENSG00000253848.1	RP11-10N23.5	4.01	7.45e-05	0.0256	0.26	0.21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93727117	chr8:93741193~93744534:+
STAD	cis	rs9902453	0.765	rs2628191	ENSG00000263477.1	RP11-338L22.2	-4.01	7.45e-05	0.0256	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29724122	chr17:29863402~29866092:+
STAD	cis	rs12745968	0.589	rs7541942	ENSG00000229052.2	RP11-386I23.1	-4.01	7.45e-05	0.0256	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92555807	chr1:92930696~92934098:+
STAD	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	4.01	7.45e-05	0.0256	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
STAD	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	4.01	7.45e-05	0.0256	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
STAD	cis	rs2638953	0.924	rs10492368	ENSG00000247934.4	RP11-967K21.1	-4.01	7.45e-05	0.0256	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28163298~28190738:-
STAD	cis	rs992157	0.798	rs7587220	ENSG00000224928.2	KRT8P30	4.01	7.46e-05	0.0256	0.23	0.21	Colorectal cancer;	chr2:218296141	chr2:218953401~218954050:-
STAD	cis	rs992157	0.798	rs4674284	ENSG00000224928.2	KRT8P30	4.01	7.46e-05	0.0256	0.23	0.21	Colorectal cancer;	chr2:218296518	chr2:218953401~218954050:-
STAD	cis	rs10129255	0.957	rs12590735	ENSG00000232216.1	IGHV3-43	4.01	7.46e-05	0.0256	0.21	0.21	Kawasaki disease;	chr14:106779660	chr14:106470264~106470800:-
STAD	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-4.01	7.46e-05	0.0256	-0.29	-0.21	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
STAD	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-4.01	7.46e-05	0.0256	-0.29	-0.21	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
STAD	cis	rs77988765	0.908	rs59332014	ENSG00000248844.5	RP11-626H12.3	-4.01	7.46e-05	0.0256	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70171655	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs7944085	ENSG00000248844.5	RP11-626H12.3	-4.01	7.46e-05	0.0256	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70171992	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs79664737	ENSG00000248844.5	RP11-626H12.3	-4.01	7.46e-05	0.0256	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70174535	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs78243950	ENSG00000248844.5	RP11-626H12.3	-4.01	7.46e-05	0.0256	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70175038	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs75725796	ENSG00000248844.5	RP11-626H12.3	-4.01	7.46e-05	0.0256	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70175163	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs7926071	ENSG00000248844.5	RP11-626H12.3	-4.01	7.46e-05	0.0256	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70177251	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs74934548	ENSG00000248844.5	RP11-626H12.3	-4.01	7.46e-05	0.0256	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70179194	chr11:70056230~70065371:-
STAD	cis	rs4835473	0.932	rs17763107	ENSG00000249741.2	RP11-673E1.3	4.01	7.46e-05	0.0256	0.25	0.21	Immature fraction of reticulocytes;	chr4:143828512	chr4:143911514~143912053:-
STAD	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-4.01	7.46e-05	0.0257	-0.28	-0.21	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
STAD	cis	rs10986311	0.713	rs10986292	ENSG00000227200.1	RP11-121A14.3	-4.01	7.46e-05	0.0257	-0.24	-0.21	Vitiligo;	chr9:124254597	chr9:124262876~124265809:+
STAD	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	4.01	7.46e-05	0.0257	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
STAD	cis	rs10971721	0.731	rs10971819	ENSG00000281128.1	PTENP1-AS	4.01	7.47e-05	0.0257	0.31	0.21	Body mass index;	chr9:33954149	chr9:33677268~33688011:+
STAD	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	4.01	7.47e-05	0.0257	0.15	0.21	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
STAD	cis	rs1075265	0.836	rs10208233	ENSG00000235937.1	AC008280.1	4.01	7.47e-05	0.0257	0.21	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54029552~54030682:-
STAD	cis	rs2348418	0.832	rs11049587	ENSG00000247934.4	RP11-967K21.1	4.01	7.47e-05	0.0257	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28418090	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.832	rs4930822	ENSG00000247934.4	RP11-967K21.1	4.01	7.47e-05	0.0257	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28421789	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.832	rs4930823	ENSG00000247934.4	RP11-967K21.1	4.01	7.47e-05	0.0257	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28421892	chr12:28163298~28190738:-
STAD	cis	rs73193808	0.951	rs1999323	ENSG00000273017.1	AP000240.9	4.01	7.47e-05	0.0257	0.23	0.21	Coronary artery disease;	chr21:29161807	chr21:29359002~29359453:+
STAD	cis	rs4407350	0.756	rs131168	ENSG00000279642.1	RP5-1033E15.3	-4.01	7.47e-05	0.0257	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44500345	chr22:44486295~44486914:-
STAD	cis	rs393951	0.664	rs183997	ENSG00000260969.1	RP11-190D6.2	-4.01	7.47e-05	0.0257	-0.28	-0.21	Childhood ear infection;	chr16:77597623	chr16:78237362~78241218:-
STAD	cis	rs950169	0.922	rs4842939	ENSG00000259683.1	RP11-182J1.14	-4.01	7.47e-05	0.0257	-0.2	-0.21	Schizophrenia;	chr15:84159214	chr15:84389729~84395903:+
STAD	cis	rs2836974	0.602	rs8130854	ENSG00000238141.2	BRWD1-AS1	-4.01	7.48e-05	0.0257	-0.22	-0.21	Cognitive function;	chr21:39335115	chr21:39315707~39323218:+
STAD	cis	rs2836974	0.605	rs2836988	ENSG00000238141.2	BRWD1-AS1	-4.01	7.48e-05	0.0257	-0.22	-0.21	Cognitive function;	chr21:39336049	chr21:39315707~39323218:+
STAD	cis	rs728616	0.614	rs61859198	ENSG00000272447.1	RP11-182L21.6	-4.01	7.48e-05	0.0257	-0.33	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79825902~79827602:+
STAD	cis	rs2638953	0.924	rs7955094	ENSG00000247934.4	RP11-967K21.1	-4.01	7.48e-05	0.0257	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157097	chr12:28163298~28190738:-
STAD	cis	rs7204230	1	rs11075923	ENSG00000261291.1	RP11-295M3.2	4.01	7.48e-05	0.0257	0.25	0.21	Fibrinogen;	chr16:53334264	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs12596717	ENSG00000261291.1	RP11-295M3.2	4.01	7.48e-05	0.0257	0.25	0.21	Fibrinogen;	chr16:53334892	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62049819	ENSG00000261291.1	RP11-295M3.2	4.01	7.48e-05	0.0257	0.25	0.21	Fibrinogen;	chr16:53337551	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs7187151	ENSG00000261291.1	RP11-295M3.2	4.01	7.48e-05	0.0257	0.25	0.21	Fibrinogen;	chr16:53338049	chr16:53168522~53169450:+
STAD	cis	rs832540	0.564	rs33329	ENSG00000271828.1	CTD-2310F14.1	4.01	7.48e-05	0.0257	0.48	0.21	Coronary artery disease;	chr5:56849241	chr5:56927874~56929573:+
STAD	cis	rs7926906	1	rs7952309	ENSG00000280367.1	RP11-121L10.2	4.01	7.49e-05	0.0257	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90792946	chr11:90223153~90226538:+
STAD	cis	rs77956314	0.515	rs10850733	ENSG00000274554.1	RP11-240G22.5	-4.01	7.49e-05	0.0258	-0.27	-0.21	Hippocampal volume;Subcortical brain region volumes;	chr12:116943156	chr12:116948738~116951422:-
STAD	cis	rs794185	0.657	rs2633846	ENSG00000231249.1	ITPR1-AS1	-4.01	7.5e-05	0.0258	-0.24	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471781	chr3:4490891~4493163:-
STAD	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	4.01	7.5e-05	0.0258	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
STAD	cis	rs6832769	1	rs10002541	ENSG00000223305.1	RN7SKP30	-4.01	7.5e-05	0.0258	-0.23	-0.21	Personality dimensions;	chr4:55528844	chr4:55540502~55540835:-
STAD	cis	rs6180	1	rs230813	ENSG00000250860.1	CTD-2265D6.2	-4.01	7.5e-05	0.0258	-0.18	-0.21	Height;	chr5:42798931	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs230814	ENSG00000250860.1	CTD-2265D6.2	-4.01	7.5e-05	0.0258	-0.18	-0.21	Height;	chr5:42799169	chr5:42466893~42468300:-
STAD	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-4.01	7.51e-05	0.0258	-0.27	-0.21	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
STAD	cis	rs4713118	0.955	rs9393848	ENSG00000243307.2	POM121L6P	-4.01	7.51e-05	0.0258	-0.24	-0.21	Parkinson's disease;	chr6:27720590	chr6:26896952~26898777:+
STAD	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	4.01	7.51e-05	0.0258	0.23	0.21	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
STAD	cis	rs11098499	0.82	rs13122709	ENSG00000260091.1	RP11-33B1.4	4.01	7.51e-05	0.0258	0.21	0.21	Corneal astigmatism;	chr4:119634201	chr4:119409333~119410233:+
STAD	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	4.01	7.51e-05	0.0258	0.23	0.21	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
STAD	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	4.01	7.51e-05	0.0258	0.23	0.21	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
STAD	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	4.01	7.51e-05	0.0258	0.23	0.21	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
STAD	cis	rs11673344	0.504	rs4239587	ENSG00000267672.1	CTD-2293H3.1	4.01	7.51e-05	0.0258	0.19	0.21	Obesity-related traits;	chr19:37136211	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.504	rs4805202	ENSG00000267672.1	CTD-2293H3.1	4.01	7.51e-05	0.0258	0.19	0.21	Obesity-related traits;	chr19:37136499	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.504	rs4805203	ENSG00000267672.1	CTD-2293H3.1	4.01	7.51e-05	0.0258	0.19	0.21	Obesity-related traits;	chr19:37136586	chr19:37091341~37092564:+
STAD	cis	rs867371	1	rs8042464	ENSG00000278603.1	RP13-608F4.5	4.01	7.51e-05	0.0258	0.25	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472203~82472426:+
STAD	cis	rs34779708	0.966	rs11010135	ENSG00000271335.4	RP11-324I22.4	4.01	7.51e-05	0.0258	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35314552~35336401:-
STAD	cis	rs679711	0.601	rs1164205	ENSG00000214380.4	RP11-457K10.2	4.01	7.52e-05	0.0258	0.24	0.21	Sleep depth;	chr3:109905678	chr3:109915976~109916940:-
STAD	cis	rs679711	0.634	rs593695	ENSG00000214380.4	RP11-457K10.2	4.01	7.52e-05	0.0258	0.24	0.21	Sleep depth;	chr3:109906899	chr3:109915976~109916940:-
STAD	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-4.01	7.52e-05	0.0258	-0.25	-0.21	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
STAD	cis	rs2446066	0.872	rs36065378	ENSG00000257379.1	RP11-793H13.8	4.01	7.52e-05	0.0258	0.36	0.21	Red blood cell count;	chr12:53380995	chr12:53441741~53467528:+
STAD	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	4.01	7.52e-05	0.0258	0.27	0.21	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
STAD	cis	rs2638953	0.79	rs11049653	ENSG00000247934.4	RP11-967K21.1	-4.01	7.52e-05	0.0258	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28479882	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs11049654	ENSG00000247934.4	RP11-967K21.1	-4.01	7.52e-05	0.0258	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28480502	chr12:28163298~28190738:-
STAD	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	4.01	7.53e-05	0.0258	0.21	0.21	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
STAD	cis	rs11051970	0.559	rs11051941	ENSG00000274964.1	RP11-817I4.1	-4.01	7.53e-05	0.0258	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32330338	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs11051942	ENSG00000274964.1	RP11-817I4.1	-4.01	7.53e-05	0.0258	-0.28	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32330344	chr12:32339368~32340724:+
STAD	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-4.01	7.53e-05	0.0258	-0.24	-0.21	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
STAD	cis	rs12468226	0.938	rs116109808	ENSG00000272966.1	RP11-686O6.1	4.01	7.53e-05	0.0258	0.32	0.21	Urate levels;	chr2:202287356	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.873	rs78175596	ENSG00000272966.1	RP11-686O6.1	4.01	7.53e-05	0.0258	0.32	0.21	Urate levels;	chr2:202287993	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs74454549	ENSG00000272966.1	RP11-686O6.1	4.01	7.53e-05	0.0258	0.32	0.21	Urate levels;	chr2:202288044	chr2:202336739~202337200:+
STAD	cis	rs870825	0.655	rs10033035	ENSG00000249173.4	LINC01093	-4.01	7.53e-05	0.0258	-0.34	-0.21	Blood protein levels;	chr4:184709726	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs72703561	ENSG00000249173.4	LINC01093	-4.01	7.53e-05	0.0258	-0.34	-0.21	Blood protein levels;	chr4:184709736	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28666955	ENSG00000249173.4	LINC01093	-4.01	7.53e-05	0.0258	-0.34	-0.21	Blood protein levels;	chr4:184710184	chr4:184893871~184899454:-
STAD	cis	rs870825	0.55	rs28525282	ENSG00000249173.4	LINC01093	-4.01	7.53e-05	0.0258	-0.34	-0.21	Blood protein levels;	chr4:184710314	chr4:184893871~184899454:-
STAD	cis	rs6604026	0.666	rs11164830	ENSG00000229052.2	RP11-386I23.1	-4.01	7.53e-05	0.0258	-0.2	-0.21	Multiple sclerosis;	chr1:92891266	chr1:92930696~92934098:+
STAD	cis	rs6565180	1	rs11862806	ENSG00000273724.1	RP11-347C12.12	-4.01	7.53e-05	0.0258	-0.23	-0.21	Tonsillectomy;	chr16:30352750	chr16:30336400~30343336:+
STAD	cis	rs1707322	1	rs11211243	ENSG00000225447.1	RPS15AP10	4.01	7.53e-05	0.0259	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211244	ENSG00000225447.1	RPS15AP10	4.01	7.53e-05	0.0259	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45645816~45646197:-
STAD	cis	rs8012947	1	rs10151828	ENSG00000279636.2	LINC00216	-4.01	7.53e-05	0.0259	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58282711	chr14:58288033~58289158:+
STAD	cis	rs7927771	0.832	rs10769258	ENSG00000271350.1	CTD-2384B9.1	4.01	7.53e-05	0.0259	0.23	0.21	Subjective well-being;	chr11:47369488	chr11:47041027~47041945:-
STAD	cis	rs10073892	0.581	rs12653584	ENSG00000250682.4	LINC00491	-4.01	7.53e-05	0.0259	-0.23	-0.21	Cognitive decline (age-related);	chr5:102573564	chr5:102609156~102671559:-
STAD	cis	rs2638953	0.85	rs11049402	ENSG00000247934.4	RP11-967K21.1	-4.01	7.53e-05	0.0259	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs1551987	ENSG00000247934.4	RP11-967K21.1	-4.01	7.53e-05	0.0259	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs1551986	ENSG00000247934.4	RP11-967K21.1	-4.01	7.53e-05	0.0259	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs2078017	ENSG00000247934.4	RP11-967K21.1	-4.01	7.53e-05	0.0259	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28163298~28190738:-
STAD	cis	rs860295	0.676	rs2666826	ENSG00000203761.5	MSTO2P	-4.01	7.54e-05	0.0259	-0.19	-0.21	Body mass index;	chr1:155688294	chr1:155745829~155750137:+
STAD	cis	rs6832769	0.961	rs3805147	ENSG00000223305.1	RN7SKP30	4.01	7.54e-05	0.0259	0.23	0.21	Personality dimensions;	chr4:55440563	chr4:55540502~55540835:-
STAD	cis	rs6832769	1	rs3736544	ENSG00000223305.1	RN7SKP30	4.01	7.54e-05	0.0259	0.23	0.21	Personality dimensions;	chr4:55443825	chr4:55540502~55540835:-
STAD	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	4.01	7.54e-05	0.0259	0.24	0.21	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
STAD	cis	rs34779708	0.733	rs11597184	ENSG00000271335.4	RP11-324I22.4	4.01	7.54e-05	0.0259	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35314552~35336401:-
STAD	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-4.01	7.54e-05	0.0259	-0.24	-0.21	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-4.01	7.54e-05	0.0259	-0.24	-0.21	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-4.01	7.54e-05	0.0259	-0.24	-0.21	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
STAD	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-4.01	7.54e-05	0.0259	-0.22	-0.21	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
STAD	cis	rs516805	0.561	rs2684239	ENSG00000279453.1	RP3-425C14.4	-4.01	7.54e-05	0.0259	-0.3	-0.21	Lymphocyte counts;	chr6:122086976	chr6:122436789~122439223:-
STAD	cis	rs516805	0.561	rs2679640	ENSG00000279453.1	RP3-425C14.4	-4.01	7.54e-05	0.0259	-0.3	-0.21	Lymphocyte counts;	chr6:122087013	chr6:122436789~122439223:-
STAD	cis	rs3213758	0.541	rs10852520	ENSG00000275191.1	RP11-36I17.2	-4.01	7.55e-05	0.0259	-0.33	-0.21	Vitiligo (non-segmental);	chr16:53676961	chr16:53628256~53628816:-
STAD	cis	rs2839186	0.632	rs17176110	ENSG00000223768.1	LINC00205	-4.01	7.55e-05	0.0259	-0.25	-0.21	Testicular germ cell tumor;	chr21:46286621	chr21:45293285~45297354:+
STAD	cis	rs870825	0.616	rs7683537	ENSG00000249173.4	LINC01093	-4.01	7.55e-05	0.0259	-0.34	-0.21	Blood protein levels;	chr4:184710844	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs56844261	ENSG00000249173.4	LINC01093	-4.01	7.55e-05	0.0259	-0.34	-0.21	Blood protein levels;	chr4:184711324	chr4:184893871~184899454:-
STAD	cis	rs870825	0.587	rs28454955	ENSG00000249173.4	LINC01093	-4.01	7.55e-05	0.0259	-0.34	-0.21	Blood protein levels;	chr4:184711547	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs9715644	ENSG00000249173.4	LINC01093	-4.01	7.55e-05	0.0259	-0.34	-0.21	Blood protein levels;	chr4:184711811	chr4:184893871~184899454:-
STAD	cis	rs7683537	0.887	rs4540092	ENSG00000249173.4	LINC01093	-4.01	7.55e-05	0.0259	-0.34	-0.21	Systemic lupus erythematosus;	chr4:184712392	chr4:184893871~184899454:-
STAD	cis	rs1816752	0.87	rs9581025	ENSG00000232858.1	RPL34P27	4.01	7.55e-05	0.0259	0.13	0.21	Obesity-related traits;	chr13:24423687	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.87	rs9581027	ENSG00000232858.1	RPL34P27	4.01	7.55e-05	0.0259	0.13	0.21	Obesity-related traits;	chr13:24423790	chr13:24988577~24988925:-
STAD	cis	rs10129255	0.5	rs59939897	ENSG00000232216.1	IGHV3-43	4.01	7.55e-05	0.0259	0.19	0.21	Kawasaki disease;	chr14:106783414	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.5	rs6576231	ENSG00000232216.1	IGHV3-43	4.01	7.55e-05	0.0259	0.19	0.21	Kawasaki disease;	chr14:106783693	chr14:106470264~106470800:-
STAD	cis	rs6813195	0.622	rs4696324	ENSG00000243417.1	RP11-555K12.1	-4.01	7.55e-05	0.0259	-0.21	-0.21	Type 2 diabetes;	chr4:152564280	chr4:152551277~152552364:-
STAD	cis	rs77988765	0.908	rs114847464	ENSG00000248844.5	RP11-626H12.3	-4.01	7.55e-05	0.0259	-0.4	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70169448	chr11:70056230~70065371:-
STAD	cis	rs7647973	0.58	rs12637576	ENSG00000225399.4	RP11-3B7.1	4.01	7.56e-05	0.0259	0.23	0.21	Menarche (age at onset);	chr3:49199901	chr3:49260085~49261316:+
STAD	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	4.01	7.56e-05	0.0259	0.38	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
STAD	cis	rs1707322	1	rs11211190	ENSG00000281133.1	AL355480.3	-4.01	7.56e-05	0.0259	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs6429580	ENSG00000281133.1	AL355480.3	-4.01	7.56e-05	0.0259	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45580892~45580996:-
STAD	cis	rs1876905	0.539	rs241003	ENSG00000230177.1	RP5-1112D6.4	4.01	7.56e-05	0.0259	0.24	0.21	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111277932~111278742:+
STAD	cis	rs1876905	0.539	rs190246	ENSG00000230177.1	RP5-1112D6.4	4.01	7.56e-05	0.0259	0.24	0.21	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111277932~111278742:+
STAD	cis	rs11673344	0.504	rs35579954	ENSG00000267672.1	CTD-2293H3.1	4.01	7.56e-05	0.0259	0.19	0.21	Obesity-related traits;	chr19:37139308	chr19:37091341~37092564:+
STAD	cis	rs9902453	0.765	rs2628167	ENSG00000263477.1	RP11-338L22.2	-4.01	7.56e-05	0.0259	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29737480	chr17:29863402~29866092:+
STAD	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	4.01	7.56e-05	0.0259	0.29	0.21	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
STAD	cis	rs9467773	0.935	rs1884947	ENSG00000241549.7	GUSBP2	4.01	7.57e-05	0.0259	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26871484~26956554:-
STAD	cis	rs7131987	0.874	rs10843366	ENSG00000257176.2	RP11-996F15.2	-4.01	7.57e-05	0.0259	-0.24	-0.21	QT interval;	chr12:29254970	chr12:29280418~29317848:-
STAD	cis	rs4713118	0.615	rs9348772	ENSG00000280107.1	AL022393.9	-4.01	7.57e-05	0.0259	-0.25	-0.21	Parkinson's disease;	chr6:27688311	chr6:28170845~28172521:+
STAD	cis	rs2836950	0.545	rs2297256	ENSG00000238141.2	BRWD1-AS1	-4.01	7.57e-05	0.0259	-0.21	-0.21	Menarche (age at onset);	chr21:39186495	chr21:39315707~39323218:+
STAD	cis	rs34779708	0.966	rs10827492	ENSG00000271335.4	RP11-324I22.4	-4.01	7.57e-05	0.0259	-0.25	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35314552~35336401:-
STAD	cis	rs7204230	0.96	rs12596238	ENSG00000261291.1	RP11-295M3.2	4.01	7.57e-05	0.026	0.25	0.21	Fibrinogen;	chr16:53320819	chr16:53168522~53169450:+
STAD	cis	rs12745968	0.629	rs2145824	ENSG00000229052.2	RP11-386I23.1	-4.01	7.57e-05	0.026	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92734844	chr1:92930696~92934098:+
STAD	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	4.01	7.58e-05	0.026	0.22	0.21	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
STAD	cis	rs4713118	0.868	rs7756968	ENSG00000243307.2	POM121L6P	-4.01	7.58e-05	0.026	-0.26	-0.21	Parkinson's disease;	chr6:27767175	chr6:26896952~26898777:+
STAD	cis	rs34779708	0.733	rs7083266	ENSG00000271335.4	RP11-324I22.4	4.01	7.58e-05	0.026	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35314552~35336401:-
STAD	cis	rs2992257	0.914	rs3006812	ENSG00000251839.1	RNU7-12P	-4.01	7.59e-05	0.026	-0.21	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26435153	chr10:27232255~27232316:-
STAD	cis	rs2243480	0.901	rs778730	ENSG00000273448.1	RP11-166O4.6	4.01	7.59e-05	0.026	0.25	0.21	Diabetic kidney disease;	chr7:66358338	chr7:67333047~67334383:+
STAD	cis	rs7812879	0.602	rs4840561	ENSG00000227888.4	FAM66A	-4.01	7.59e-05	0.026	-0.25	-0.21	Systemic lupus erythematosus;	chr8:11448951	chr8:12362019~12388296:+
STAD	cis	rs7487075	0.619	rs10880971	ENSG00000257261.4	RP11-96H19.1	4.01	7.59e-05	0.026	0.28	0.21	Itch intensity from mosquito bite;	chr12:46445715	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs10467214	ENSG00000257261.4	RP11-96H19.1	4.01	7.59e-05	0.026	0.28	0.21	Itch intensity from mosquito bite;	chr12:46447427	chr12:46383679~46876159:+
STAD	cis	rs7487075	0.619	rs12298616	ENSG00000257261.4	RP11-96H19.1	4.01	7.59e-05	0.026	0.28	0.21	Itch intensity from mosquito bite;	chr12:46448389	chr12:46383679~46876159:+
STAD	cis	rs7709377	0.951	rs1478426	ENSG00000248445.4	SEMA6A-AS1	-4.01	7.59e-05	0.026	-0.22	-0.21	Metabolite levels  (X-11787);	chr5:116240329	chr5:116447547~116508276:+
STAD	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	4.01	7.59e-05	0.026	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
STAD	cis	rs10815468	0.542	rs6477109	ENSG00000223621.1	AK4P4	4	7.6e-05	0.026	0.23	0.21	Bipolar disorder and schizophrenia;	chr9:6794938	chr9:5855781~5856426:-
STAD	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	4	7.6e-05	0.026	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
STAD	cis	rs2786865	0.881	rs2092320	ENSG00000270733.1	RP11-231P20.5	4	7.6e-05	0.026	0.33	0.21	Facial morphology (factor 11, projection of the nose);	chr1:25693492	chr1:26263041~26263398:-
STAD	cis	rs9402743	0.811	rs6570024	ENSG00000236703.1	MYB-AS1	4	7.6e-05	0.026	0.21	0.21	Systemic lupus erythematosus;	chr6:135649186	chr6:135195083~135195995:-
STAD	cis	rs9402743	0.923	rs4896159	ENSG00000236703.1	MYB-AS1	4	7.6e-05	0.026	0.21	0.21	Systemic lupus erythematosus;	chr6:135650304	chr6:135195083~135195995:-
STAD	cis	rs1707322	0.721	rs10890343	ENSG00000225447.1	RPS15AP10	4	7.6e-05	0.026	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45645816~45646197:-
STAD	cis	rs9902453	0.904	rs9905638	ENSG00000263477.1	RP11-338L22.2	4	7.6e-05	0.026	0.18	0.21	Coffee consumption (cups per day);	chr17:29934004	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.874	rs62070271	ENSG00000263477.1	RP11-338L22.2	4	7.6e-05	0.026	0.18	0.21	Coffee consumption (cups per day);	chr17:29941340	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.904	rs9894893	ENSG00000263477.1	RP11-338L22.2	4	7.6e-05	0.026	0.18	0.21	Coffee consumption (cups per day);	chr17:29943332	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.935	rs9909093	ENSG00000263477.1	RP11-338L22.2	4	7.6e-05	0.026	0.18	0.21	Coffee consumption (cups per day);	chr17:29944189	chr17:29863402~29866092:+
STAD	cis	rs8012947	1	rs9743908	ENSG00000279636.2	LINC00216	-4	7.6e-05	0.026	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58256828	chr14:58288033~58289158:+
STAD	cis	rs8012947	1	rs6573197	ENSG00000279636.2	LINC00216	-4	7.6e-05	0.026	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58257490	chr14:58288033~58289158:+
STAD	cis	rs1348850	0.558	rs4337505	ENSG00000271825.1	RP11-337N6.2	4	7.6e-05	0.026	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177664986	chr2:177300600~177302006:+
STAD	cis	rs10782582	0.545	rs111927462	ENSG00000181227.3	RP4-682C21.2	4	7.61e-05	0.026	0.22	0.21	Daytime sleep phenotypes;	chr1:75729737	chr1:75743423~75744776:-
STAD	cis	rs4835473	0.932	rs17695238	ENSG00000249741.2	RP11-673E1.3	4	7.61e-05	0.0261	0.24	0.21	Immature fraction of reticulocytes;	chr4:143820720	chr4:143911514~143912053:-
STAD	cis	rs7119038	0.58	rs7123726	ENSG00000255163.1	HSPE1P18	-4	7.61e-05	0.0261	-0.21	-0.21	Sjögren's syndrome;	chr11:118823838	chr11:118208932~118209211:-
STAD	cis	rs1799949	0.628	rs4474733	ENSG00000236383.6	LINC00854	-4	7.62e-05	0.0261	-0.18	-0.21	Menopause (age at onset);	chr17:43356292	chr17:43216941~43305976:-
STAD	cis	rs3764021	0.87	rs2401394	ENSG00000256673.1	RP11-599J14.2	-4	7.62e-05	0.0261	-0.23	-0.21	Type 1 diabetes;	chr12:9726830	chr12:9398355~9414851:-
STAD	cis	rs950169	0.922	rs8037078	ENSG00000235370.6	DNM1P51	-4	7.62e-05	0.0261	-0.26	-0.21	Schizophrenia;	chr15:84150119	chr15:84398316~84411701:-
STAD	cis	rs8097348	0.948	rs7229607	ENSG00000266602.1	RP11-476K15.1	-4	7.62e-05	0.0261	-0.25	-0.21	Exercise (leisure time);	chr18:1601666	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs2193726	ENSG00000266602.1	RP11-476K15.1	-4	7.62e-05	0.0261	-0.25	-0.21	Exercise (leisure time);	chr18:1602748	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs11080872	ENSG00000266602.1	RP11-476K15.1	-4	7.62e-05	0.0261	-0.25	-0.21	Exercise (leisure time);	chr18:1603405	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs12604282	ENSG00000266602.1	RP11-476K15.1	-4	7.62e-05	0.0261	-0.25	-0.21	Exercise (leisure time);	chr18:1603622	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs12604794	ENSG00000266602.1	RP11-476K15.1	-4	7.62e-05	0.0261	-0.25	-0.21	Exercise (leisure time);	chr18:1604012	chr18:1509183~1647097:+
STAD	cis	rs8097348	0.948	rs12606415	ENSG00000266602.1	RP11-476K15.1	-4	7.62e-05	0.0261	-0.25	-0.21	Exercise (leisure time);	chr18:1604097	chr18:1509183~1647097:+
STAD	cis	rs8097348	1	rs8098457	ENSG00000266602.1	RP11-476K15.1	-4	7.62e-05	0.0261	-0.25	-0.21	Exercise (leisure time);	chr18:1604257	chr18:1509183~1647097:+
STAD	cis	rs7567389	0.535	rs4150416	ENSG00000200250.1	RNU6-1147P	4	7.62e-05	0.0261	0.24	0.21	Self-rated health;	chr2:127288972	chr2:127316873~127316979:+
STAD	cis	rs6142102	0.961	rs2284389	ENSG00000264616.1	MIR4755	4	7.62e-05	0.0261	0.22	0.21	Skin pigmentation;	chr20:34069035	chr20:34049119~34049190:+
STAD	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-4	7.62e-05	0.0261	-0.29	-0.21	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
STAD	cis	rs3947	0.851	rs1736089	ENSG00000227888.4	FAM66A	-4	7.63e-05	0.0261	-0.3	-0.21	Blood protein levels;	chr8:11848361	chr8:12362019~12388296:+
STAD	cis	rs7671266	0.628	rs11734783	ENSG00000250613.1	RP11-136I13.1	-4	7.63e-05	0.0261	-0.24	-0.21	Cardiovascular disease risk factors;	chr4:10239039	chr4:10410996~10411644:+
STAD	cis	rs9322193	0.962	rs3763163	ENSG00000233330.1	RP1-12G14.7	4	7.63e-05	0.0261	0.23	0.21	Lung cancer;	chr6:149819770	chr6:149591755~149592663:-
STAD	cis	rs259282	0.628	rs2287669	ENSG00000201388.1	SNORA68	4	7.63e-05	0.0261	0.21	0.21	Schizophrenia;	chr19:32619298	chr19:32608337~32608469:-
STAD	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	4	7.63e-05	0.0261	0.25	0.21	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	4	7.63e-05	0.0261	0.25	0.21	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
STAD	cis	rs6693567	0.565	rs578353	ENSG00000203819.6	HIST2H2BC	4	7.63e-05	0.0261	0.25	0.21	Migraine;	chr1:150315443	chr1:149850193~149850772:-
STAD	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-4	7.63e-05	0.0261	-0.22	-0.21	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
STAD	cis	rs2273156	0.57	rs78207779	ENSG00000258704.4	SRP54-AS1	-4	7.63e-05	0.0261	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35037181	chr14:34920858~34982532:-
STAD	cis	rs4561483	0.801	rs33640	ENSG00000260224.1	UBL5P4	4	7.64e-05	0.0261	0.21	0.21	Testicular germ cell tumor;	chr16:11893017	chr16:11968508~11968743:-
STAD	cis	rs227932	0.764	rs6945626	ENSG00000234286.1	AC006026.13	4	7.64e-05	0.0261	0.39	0.21	Schizophrenia;	chr7:23629233	chr7:23680195~23680786:-
STAD	cis	rs12439619	0.739	rs4778988	ENSG00000259429.4	UBE2Q2P2	-4	7.64e-05	0.0261	-0.28	-0.21	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82355142~82420075:+
STAD	cis	rs9326248	0.581	rs10892076	ENSG00000280143.1	AP000892.6	4	7.64e-05	0.0261	0.16	0.21	Blood protein levels;	chr11:117118220	chr11:117204967~117210292:+
STAD	cis	rs9467773	1	rs9467779	ENSG00000243307.2	POM121L6P	-4	7.64e-05	0.0262	-0.2	-0.21	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26896952~26898777:+
STAD	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	4	7.64e-05	0.0262	0.31	0.21	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
STAD	cis	rs12477438	0.501	rs6708878	ENSG00000231822.1	AC019097.7	4	7.64e-05	0.0262	0.22	0.21	Chronic sinus infection;	chr2:99185101	chr2:99102018~99102752:+
STAD	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	4	7.65e-05	0.0262	0.28	0.21	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
STAD	cis	rs10129255	0.509	rs756583	ENSG00000211959.2	IGHV4-39	4	7.65e-05	0.0262	0.19	0.21	Kawasaki disease;	chr14:106680002	chr14:106421711~106422218:-
STAD	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-4	7.65e-05	0.0262	-0.21	-0.21	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
STAD	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	4	7.65e-05	0.0262	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
STAD	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	4	7.65e-05	0.0262	0.29	0.21	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
STAD	cis	rs6940638	0.688	rs7744759	ENSG00000216915.2	RP1-97D16.1	-4	7.65e-05	0.0262	-0.24	-0.21	Intelligence (multi-trait analysis);	chr6:27152047	chr6:27737000~27738494:-
STAD	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	4	7.65e-05	0.0262	0.28	0.21	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
STAD	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-4	7.65e-05	0.0262	-0.28	-0.21	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-4	7.65e-05	0.0262	-0.28	-0.21	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
STAD	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	4	7.65e-05	0.0262	0.23	0.21	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
STAD	cis	rs9733	0.744	rs12568757	ENSG00000274963.1	Metazoa_SRP	-4	7.66e-05	0.0262	-0.18	-0.21	Tonsillectomy;	chr1:150757317	chr1:150568971~150569269:-
STAD	cis	rs3758911	0.788	rs10890680	ENSG00000261098.1	RP11-819C21.1	-4	7.66e-05	0.0262	-0.2	-0.21	Coronary artery disease;	chr11:107255139	chr11:107312132~107316271:-
STAD	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-4	7.66e-05	0.0262	-0.25	-0.21	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
STAD	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	4	7.66e-05	0.0262	0.27	0.21	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
STAD	cis	rs539514	0.587	rs9530466	ENSG00000261105.4	LMO7-AS1	4	7.66e-05	0.0262	0.25	0.21	Type 1 diabetes;	chr13:75749638	chr13:75604700~75635994:-
STAD	cis	rs238295	0.805	rs6053486	ENSG00000230563.2	RP5-828H9.1	4	7.66e-05	0.0262	0.24	0.21	Occipital cortical area (total cortical area interaction);	chr20:5550121	chr20:5471207~5475182:+
STAD	cis	rs10971721	0.822	rs72727332	ENSG00000281128.1	PTENP1-AS	4	7.66e-05	0.0262	0.32	0.21	Body mass index;	chr9:33929479	chr9:33677268~33688011:+
STAD	cis	rs72480748	0.509	rs3865457	ENSG00000237118.2	CYP2F2P	4	7.67e-05	0.0262	0.23	0.21	Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Post bronchodilator FEV1;	chr19:40893064	chr19:40818721~40826772:-
STAD	cis	rs3811273	0.764	rs60839960	ENSG00000211816.2	TRAV38-1	-4	7.67e-05	0.0262	-0.29	-0.21	Periodontal disease-related phenotypes;	chr14:22256540	chr14:22271968~22272563:+
STAD	cis	rs9402743	0.962	rs11967412	ENSG00000236703.1	MYB-AS1	4	7.67e-05	0.0262	0.21	0.21	Systemic lupus erythematosus;	chr6:135648288	chr6:135195083~135195995:-
STAD	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-4	7.67e-05	0.0262	-0.33	-0.21	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
STAD	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	4	7.67e-05	0.0262	0.21	0.21	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	4	7.67e-05	0.0262	0.21	0.21	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
STAD	cis	rs1707322	1	rs12077546	ENSG00000225447.1	RPS15AP10	4	7.67e-05	0.0262	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs12124291	ENSG00000225447.1	RPS15AP10	4	7.67e-05	0.0262	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45645816~45646197:-
STAD	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	4	7.68e-05	0.0263	0.3	0.21	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	4	7.68e-05	0.0263	0.3	0.21	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	4	7.68e-05	0.0263	0.3	0.21	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	4	7.68e-05	0.0263	0.3	0.21	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	4	7.68e-05	0.0263	0.3	0.21	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
STAD	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-4	7.68e-05	0.0263	-0.23	-0.21	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
STAD	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	4	7.68e-05	0.0263	0.21	0.21	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
STAD	cis	rs9902453	0.934	rs7213902	ENSG00000240074.1	RPL9P30	4	7.68e-05	0.0263	0.18	0.21	Coffee consumption (cups per day);	chr17:29995917	chr17:29855759~29856332:+
STAD	cis	rs4869931	0.929	rs9480526	ENSG00000218358.2	RAET1K	4	7.68e-05	0.0263	0.33	0.21	Systolic blood pressure in sickle cell anemia;	chr6:150679396	chr6:149998019~150005157:-
STAD	cis	rs17826219	0.706	rs609472	ENSG00000263603.1	CTD-2349P21.5	-4	7.68e-05	0.0263	-0.26	-0.21	Body mass index;	chr17:30624409	chr17:30729469~30731202:+
STAD	cis	rs2446066	0.872	rs10876449	ENSG00000257379.1	RP11-793H13.8	4	7.68e-05	0.0263	0.35	0.21	Red blood cell count;	chr12:53385991	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.872	rs11170525	ENSG00000257379.1	RP11-793H13.8	4	7.68e-05	0.0263	0.35	0.21	Red blood cell count;	chr12:53388844	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.818	rs7315782	ENSG00000257379.1	RP11-793H13.8	4	7.68e-05	0.0263	0.35	0.21	Red blood cell count;	chr12:53391129	chr12:53441741~53467528:+
STAD	cis	rs6693567	0.545	rs11205382	ENSG00000203819.6	HIST2H2BC	-4	7.68e-05	0.0263	-0.24	-0.21	Migraine;	chr1:150469990	chr1:149850193~149850772:-
STAD	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-4	7.68e-05	0.0263	-0.21	-0.21	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
STAD	cis	rs7702057	0.53	rs17138848	ENSG00000271918.1	CTD-2287O16.5	4	7.69e-05	0.0263	0.38	0.21	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116083807~116085416:-
STAD	cis	rs2574985	0.739	rs3011790	ENSG00000231345.3	BEND3P1	4	7.69e-05	0.0263	0.34	0.21	Subjective well-being;	chr10:50549943	chr10:50655967~50660472:+
STAD	cis	rs9368481	0.678	rs62402024	ENSG00000224843.5	LINC00240	-4	7.69e-05	0.0263	-0.24	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26956992~27023924:+
STAD	cis	rs2657294	0.62	rs7475340	ENSG00000226051.5	ZNF503-AS1	-4	7.69e-05	0.0263	-0.28	-0.21	Pneumonia;	chr10:75079597	chr10:75269819~75373500:+
STAD	cis	rs62432346	1	rs62432346	ENSG00000228506.1	RP11-98I9.4	-4	7.69e-05	0.0263	-0.48	-0.21	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr6:99541358	chr6:99424922~99431373:+
STAD	cis	rs6993244	1	rs6993244	ENSG00000233609.3	RP11-62H7.2	4	7.69e-05	0.0263	0.24	0.21	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8961200~8979025:+
STAD	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-4	7.69e-05	0.0263	-0.21	-0.21	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
STAD	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-4	7.69e-05	0.0263	-0.21	-0.21	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
STAD	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-4	7.69e-05	0.0263	-0.21	-0.21	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
STAD	cis	rs9902453	0.765	rs34585141	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30009414	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs4528633	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30029118	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs7225686	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30029726	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs4547389	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30037750	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs55633288	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30041178	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.874	rs7220004	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30042530	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs11654983	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30043024	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs7219456	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30047094	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.874	rs11653805	ENSG00000240074.1	RPL9P30	-4	7.69e-05	0.0263	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30051258	chr17:29855759~29856332:+
STAD	cis	rs3126085	0.935	rs4845431	ENSG00000237975.5	FLG-AS1	-4	7.7e-05	0.0263	-0.28	-0.21	Atopic dermatitis;	chr1:152255501	chr1:152168125~152445456:+
STAD	cis	rs9463078	0.677	rs1324537	ENSG00000219384.1	RP11-491H9.3	4	7.7e-05	0.0263	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45147054	chr6:45158870~45159511:+
STAD	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	4	7.7e-05	0.0263	0.48	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
STAD	cis	rs6480314	0.522	rs7902936	ENSG00000233590.1	RP11-153K11.3	4	7.7e-05	0.0263	0.29	0.21	Optic nerve measurement (disc area);	chr10:68299584	chr10:68233251~68242379:-
STAD	cis	rs12571093	0.571	rs7903251	ENSG00000233590.1	RP11-153K11.3	4	7.7e-05	0.0263	0.29	0.21	Optic nerve measurement (disc area);	chr10:68299969	chr10:68233251~68242379:-
STAD	cis	rs7829975	0.56	rs17154599	ENSG00000233609.3	RP11-62H7.2	-4	7.71e-05	0.0263	-0.26	-0.21	Mood instability;	chr8:8693908	chr8:8961200~8979025:+
STAD	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	4	7.72e-05	0.0264	0.29	0.21	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
STAD	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-4	7.72e-05	0.0264	-0.29	-0.21	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
STAD	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-4	7.72e-05	0.0264	-0.29	-0.21	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
STAD	cis	rs17507216	0.628	rs8032321	ENSG00000255769.6	GOLGA2P10	-4	7.72e-05	0.0264	-0.34	-0.21	Excessive daytime sleepiness;	chr15:82698956	chr15:82472993~82513950:-
STAD	cis	rs17507216	0.628	rs8040488	ENSG00000255769.6	GOLGA2P10	-4	7.72e-05	0.0264	-0.34	-0.21	Excessive daytime sleepiness;	chr15:82699081	chr15:82472993~82513950:-
STAD	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	4	7.72e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	4	7.72e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	4	7.72e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	4	7.72e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	4	7.72e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	4	7.72e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	4	7.72e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
STAD	cis	rs11089937	0.616	rs11705598	ENSG00000211639.2	IGLV4-60	4	7.72e-05	0.0264	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22178837	chr22:22162199~22162681:+
STAD	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-4	7.72e-05	0.0264	-0.23	-0.21	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
STAD	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	4	7.72e-05	0.0264	0.28	0.21	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	4	7.72e-05	0.0264	0.28	0.21	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
STAD	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	4	7.72e-05	0.0264	0.28	0.21	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
STAD	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	4	7.72e-05	0.0264	0.28	0.21	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
STAD	cis	rs61542988	0.57	rs10950919	ENSG00000228649.7	AC005682.5	4	7.72e-05	0.0264	0.27	0.21	Fibrinogen levels;	chr7:22794202	chr7:22854178~22861579:+
STAD	cis	rs10073892	0.703	rs12332575	ENSG00000250682.4	LINC00491	-4	7.73e-05	0.0264	-0.23	-0.21	Cognitive decline (age-related);	chr5:102530085	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.703	rs9885011	ENSG00000250682.4	LINC00491	-4	7.73e-05	0.0264	-0.23	-0.21	Cognitive decline (age-related);	chr5:102531158	chr5:102609156~102671559:-
STAD	cis	rs3947	0.906	rs709822	ENSG00000255556.2	RP11-351I21.6	-4	7.73e-05	0.0264	-0.26	-0.21	Blood protein levels;	chr8:11844804	chr8:12378679~12380265:-
STAD	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	4	7.73e-05	0.0264	0.29	0.21	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
STAD	cis	rs6539288	0.677	rs10778518	ENSG00000260329.1	RP11-412D9.4	4	7.73e-05	0.0264	0.22	0.21	Total body bone mineral density;	chr12:106950172	chr12:106954029~106955497:-
STAD	cis	rs2688608	0.62	rs11000767	ENSG00000271816.1	BMS1P4	4	7.73e-05	0.0264	0.23	0.21	Inflammatory bowel disease;	chr10:73756868	chr10:73699151~73730487:-
STAD	cis	rs11089937	0.626	rs5757013	ENSG00000211640.3	IGLV6-57	4	7.73e-05	0.0264	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs5757014	ENSG00000211640.3	IGLV6-57	4	7.73e-05	0.0264	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22195713~22196460:+
STAD	cis	rs1790761	0.967	rs10274	ENSG00000231793.4	DOC2GP	-4	7.74e-05	0.0264	-0.25	-0.21	Mean corpuscular volume;	chr11:67435355	chr11:67612653~67616257:-
STAD	cis	rs944722	0.839	rs8073631	ENSG00000266786.1	LGALS9DP	4	7.74e-05	0.0264	0.27	0.21	Fractional exhaled nitric oxide (childhood);	chr17:27777521	chr17:27746132~27754954:+
STAD	cis	rs8012947	0.959	rs2233752	ENSG00000279636.2	LINC00216	-4	7.74e-05	0.0264	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58288762	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.959	rs10132929	ENSG00000279636.2	LINC00216	-4	7.74e-05	0.0264	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58292289	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.959	rs7146801	ENSG00000279636.2	LINC00216	-4	7.74e-05	0.0264	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58292769	chr14:58288033~58289158:+
STAD	cis	rs17507216	0.588	rs28864981	ENSG00000259429.4	UBE2Q2P2	-4	7.74e-05	0.0264	-0.32	-0.21	Excessive daytime sleepiness;	chr15:82695420	chr15:82355142~82420075:+
STAD	cis	rs6432852	0.527	rs7592392	ENSG00000229195.1	AC009495.4	4	7.74e-05	0.0264	0.24	0.21	Diabetic kidney disease;	chr2:165940940	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.527	rs1432273	ENSG00000229195.1	AC009495.4	4	7.74e-05	0.0264	0.24	0.21	Diabetic kidney disease;	chr2:165941136	chr2:165794857~165846091:-
STAD	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-4	7.74e-05	0.0264	-0.24	-0.21	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
STAD	cis	rs4713118	0.868	rs35069907	ENSG00000220721.1	OR1F12	4	7.74e-05	0.0264	0.25	0.21	Parkinson's disease;	chr6:27778913	chr6:28073316~28074233:+
STAD	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-4	7.74e-05	0.0264	-0.21	-0.21	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
STAD	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	4	7.75e-05	0.0264	0.33	0.21	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
STAD	cis	rs61160187	0.582	rs976630	ENSG00000215032.2	GNL3LP1	4	7.75e-05	0.0264	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60891935~60893577:-
STAD	cis	rs7772486	0.712	rs1292335	ENSG00000235652.6	RP11-545I5.3	4	7.75e-05	0.0264	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145799409~145886585:+
STAD	cis	rs77861329	1	rs9809254	ENSG00000280003.1	RP11-330H6.6	-4	7.75e-05	0.0265	-0.4	-0.21	Macrophage inflammatory protein 1b levels;	chr3:52077458	chr3:52217016~52219012:-
STAD	cis	rs792448	0.603	rs12024665	ENSG00000212044.2	AL360091.1	4	7.75e-05	0.0265	0.22	0.21	White blood cell count (basophil);	chr1:212326553	chr1:212349978~212350069:+
STAD	cis	rs2573652	0.722	rs11630930	ENSG00000270127.2	RP11-526I2.5	-4	7.75e-05	0.0265	-0.23	-0.21	Height;	chr15:100003940	chr15:100547765~100550153:-
STAD	cis	rs3126085	0.935	rs3126091	ENSG00000237975.5	FLG-AS1	4	7.75e-05	0.0265	0.3	0.21	Atopic dermatitis;	chr1:152334862	chr1:152168125~152445456:+
STAD	cis	rs1707322	1	rs11211232	ENSG00000225447.1	RPS15AP10	4	7.75e-05	0.0265	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45645816~45646197:-
STAD	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	4	7.76e-05	0.0265	0.23	0.21	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
STAD	cis	rs870825	0.616	rs6817521	ENSG00000249173.4	LINC01093	4	7.76e-05	0.0265	0.33	0.21	Blood protein levels;	chr4:184728673	chr4:184893871~184899454:-
STAD	cis	rs9987353	0.83	rs4841117	ENSG00000254340.1	RP11-10A14.3	-4	7.76e-05	0.0265	-0.32	-0.21	Recombination measurement;	chr8:9272622	chr8:9141424~9145435:+
STAD	cis	rs2638953	0.64	rs10843204	ENSG00000247934.4	RP11-967K21.1	-4	7.76e-05	0.0265	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568028	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.64	rs10843205	ENSG00000247934.4	RP11-967K21.1	-4	7.76e-05	0.0265	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568220	chr12:28163298~28190738:-
STAD	cis	rs4388249	0.659	rs10078710	ENSG00000271849.1	CTC-332L22.1	4	7.76e-05	0.0265	0.28	0.21	Schizophrenia;	chr5:109748057	chr5:109687802~109688329:-
STAD	cis	rs73198271	0.96	rs73198286	ENSG00000233609.3	RP11-62H7.2	-4	7.76e-05	0.0265	-0.32	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8754512	chr8:8961200~8979025:+
STAD	cis	rs73198271	0.96	rs73198287	ENSG00000233609.3	RP11-62H7.2	-4	7.76e-05	0.0265	-0.32	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8755276	chr8:8961200~8979025:+
STAD	cis	rs12682352	0.535	rs12677550	ENSG00000254340.1	RP11-10A14.3	-4	7.76e-05	0.0265	-0.26	-0.21	Neuroticism;	chr8:8786812	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.667	rs1877119	ENSG00000233609.3	RP11-62H7.2	4	7.76e-05	0.0265	0.22	0.21	Mood instability;	chr8:8849687	chr8:8961200~8979025:+
STAD	cis	rs2638953	0.962	rs11049524	ENSG00000247934.4	RP11-967K21.1	-4	7.76e-05	0.0265	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28311956	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049525	ENSG00000247934.4	RP11-967K21.1	-4	7.76e-05	0.0265	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313227	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs12371974	ENSG00000247934.4	RP11-967K21.1	-4	7.76e-05	0.0265	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313969	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049526	ENSG00000247934.4	RP11-967K21.1	-4	7.76e-05	0.0265	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28314751	chr12:28163298~28190738:-
STAD	cis	rs9420	0.528	rs7102271	ENSG00000265566.2	RN7SL605P	-4	7.76e-05	0.0265	-0.3	-0.21	Schizophrenia;	chr11:57629352	chr11:57528085~57528365:-
STAD	cis	rs9420	0.528	rs73480556	ENSG00000265566.2	RN7SL605P	-4	7.76e-05	0.0265	-0.3	-0.21	Schizophrenia;	chr11:57632989	chr11:57528085~57528365:-
STAD	cis	rs34779708	0.966	rs1478463	ENSG00000271335.4	RP11-324I22.4	4	7.77e-05	0.0265	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35314552~35336401:-
STAD	cis	rs1122401	0.515	rs2564981	ENSG00000241230.3	RN7SL801P	-4	7.77e-05	0.0265	-0.24	-0.21	Smoking initiation;	chr5:54575075	chr5:54048007~54048308:-
STAD	cis	rs4948102	0.551	rs4275190	ENSG00000226278.1	PSPHP1	-4	7.77e-05	0.0265	-0.25	-0.21	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55764797~55773288:+
STAD	cis	rs6772849	0.896	rs9816260	ENSG00000242551.2	POU5F1P6	-4	7.77e-05	0.0265	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128674735~128677005:-
STAD	cis	rs6772849	0.83	rs7633674	ENSG00000242551.2	POU5F1P6	-4	7.77e-05	0.0265	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128674735~128677005:-
STAD	cis	rs4938573	0.526	rs11216973	ENSG00000255422.1	AP002954.4	4	7.78e-05	0.0265	0.27	0.21	Follicular lymphoma;	chr11:118716292	chr11:118704607~118750263:+
STAD	cis	rs9902453	0.904	rs4567782	ENSG00000263477.1	RP11-338L22.2	4	7.78e-05	0.0265	0.18	0.21	Coffee consumption (cups per day);	chr17:29941782	chr17:29863402~29866092:+
STAD	cis	rs6951245	0.507	rs11976805	ENSG00000229043.2	AC091729.9	-4	7.78e-05	0.0265	-0.25	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1160374~1165267:+
STAD	cis	rs4589258	0.762	rs10765378	ENSG00000280367.1	RP11-121L10.2	4	7.78e-05	0.0265	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90722070	chr11:90223153~90226538:+
STAD	cis	rs6964833	0.935	rs13238996	ENSG00000277072.3	STAG3L2	4	7.78e-05	0.0265	0.25	0.21	Menarche (age at onset);	chr7:74655318	chr7:74882163~74890610:-
STAD	cis	rs7395581	1	rs830085	ENSG00000271350.1	CTD-2384B9.1	-4	7.78e-05	0.0265	-0.26	-0.21	HDL cholesterol;	chr11:47229648	chr11:47041027~47041945:-
STAD	cis	rs10938353	0.68	rs66691259	ENSG00000273369.1	RP11-700J17.1	4	7.78e-05	0.0266	0.25	0.21	Body mass index;	chr4:44705036	chr4:44693946~44694386:-
STAD	cis	rs603446	0.678	rs664059	ENSG00000280143.1	AP000892.6	4	7.79e-05	0.0266	0.16	0.21	Triglycerides;	chr11:116771421	chr11:117204967~117210292:+
STAD	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	4	7.79e-05	0.0266	0.27	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
STAD	cis	rs3811273	0.614	rs6572346	ENSG00000211816.2	TRAV38-1	-4	7.79e-05	0.0266	-0.26	-0.21	Periodontal disease-related phenotypes;	chr14:22266389	chr14:22271968~22272563:+
STAD	cis	rs11051970	0.559	rs12578899	ENSG00000274964.1	RP11-817I4.1	-4	7.79e-05	0.0266	-0.27	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32332017	chr12:32339368~32340724:+
STAD	cis	rs7074356	0.569	rs1832683	ENSG00000225484.5	NUTM2B-AS1	-4	7.79e-05	0.0266	-0.34	-0.21	Borderline personality disorder;	chr10:80272575	chr10:79663088~79826594:-
STAD	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	4	7.79e-05	0.0266	0.15	0.21	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
STAD	cis	rs9595908	0.827	rs9595885	ENSG00000281026.1	N4BP2L2-IT2	-4	7.79e-05	0.0266	-0.17	-0.21	Body mass index;	chr13:32593913	chr13:32504506~32509395:-
STAD	cis	rs7474896	1	rs2749564	ENSG00000099251.13	HSD17B7P2	-4	7.79e-05	0.0266	-0.34	-0.21	Obesity (extreme);	chr10:37889887	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2738222	ENSG00000099251.13	HSD17B7P2	-4	7.79e-05	0.0266	-0.34	-0.21	Obesity (extreme);	chr10:37894746	chr10:38356380~38378505:+
STAD	cis	rs2562456	0.833	rs2562487	ENSG00000268119.4	CTD-2561J22.5	4	7.79e-05	0.0266	0.27	0.21	Pain;	chr19:21468580	chr19:21444241~21463908:-
STAD	cis	rs28588043	0.594	rs61815211	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170954675	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs61815212	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170954811	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs61815216	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170957266	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs61815217	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170957479	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs9427200	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170957630	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs61815218	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170957678	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.537	rs9427204	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170958108	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs17621142	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170958209	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs61815972	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170958231	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs10489245	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170958261	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs17563089	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170958474	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs17563130	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170958662	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs6682758	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170959941	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs6682775	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170959989	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs6683055	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170960073	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs6658534	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170960271	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs6674503	ENSG00000201126.1	RNU6-773P	-4	7.8e-05	0.0266	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170960393	chr1:171519816~171519913:-
STAD	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-4	7.8e-05	0.0266	-0.29	-0.21	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
STAD	cis	rs172166	0.637	rs1233708	ENSG00000280107.1	AL022393.9	-4	7.8e-05	0.0266	-0.26	-0.21	Cardiac Troponin-T levels;	chr6:28205441	chr6:28170845~28172521:+
STAD	cis	rs10776614	0.799	rs7098068	ENSG00000226964.1	RHEBP2	4	7.8e-05	0.0266	0.29	0.21	Self-employment;	chr10:48555672	chr10:47706203~47706802:+
STAD	cis	rs2351088	0.706	rs3747241	ENSG00000230634.1	RP5-996D20.3	-4	7.8e-05	0.0266	-0.34	-0.21	Tonsillectomy;	chr22:45819833	chr22:46481329~46481760:-
STAD	cis	rs17507216	0.588	rs28864981	ENSG00000255769.6	GOLGA2P10	-4	7.8e-05	0.0266	-0.34	-0.21	Excessive daytime sleepiness;	chr15:82695420	chr15:82472993~82513950:-
STAD	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-4	7.8e-05	0.0266	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-4	7.8e-05	0.0266	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-4	7.8e-05	0.0266	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
STAD	cis	rs2688608	0.592	rs7080579	ENSG00000272140.2	RP11-574K11.29	4	7.81e-05	0.0266	0.19	0.21	Inflammatory bowel disease;	chr10:73744271	chr10:73703735~73713581:-
STAD	cis	rs748404	0.56	rs689797	ENSG00000275601.1	AC011330.13	-4	7.81e-05	0.0266	-0.22	-0.21	Lung cancer;	chr15:43534359	chr15:43642389~43643023:-
STAD	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-4	7.81e-05	0.0266	-0.26	-0.21	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
STAD	cis	rs644799	0.622	rs1255167	ENSG00000213368.3	ST13P11	-4	7.81e-05	0.0266	-0.23	-0.21	Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);	chr11:95767049	chr11:94913047~94913766:+
STAD	cis	rs7937890	0.904	rs7484197	ENSG00000254418.1	RP11-21L19.1	4	7.81e-05	0.0266	0.22	0.21	Mitochondrial DNA levels;	chr11:14262108	chr11:14262846~14273691:-
STAD	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-4	7.81e-05	0.0266	-0.28	-0.21	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-4	7.81e-05	0.0266	-0.28	-0.21	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
STAD	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-4	7.81e-05	0.0266	-0.35	-0.21	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
STAD	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-4	7.82e-05	0.0266	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
STAD	cis	rs7829975	0.777	rs486781	ENSG00000173295.6	FAM86B3P	-4	7.82e-05	0.0266	-0.24	-0.21	Mood instability;	chr8:8782230	chr8:8228595~8244865:+
STAD	cis	rs7429990	0.901	rs7431567	ENSG00000224895.1	VPS26BP1	4	7.82e-05	0.0266	0.22	0.21	Educational attainment (years of education);	chr3:47986342	chr3:47960327~47961081:-
STAD	cis	rs12745968	0.589	rs10874710	ENSG00000229052.2	RP11-386I23.1	-4	7.82e-05	0.0266	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92552206	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.589	rs10874711	ENSG00000229052.2	RP11-386I23.1	-4	7.82e-05	0.0266	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92552431	chr1:92930696~92934098:+
STAD	cis	rs4713118	0.614	rs9468209	ENSG00000280107.1	AL022393.9	-4	7.82e-05	0.0266	-0.24	-0.21	Parkinson's disease;	chr6:27726642	chr6:28170845~28172521:+
STAD	cis	rs7520050	0.966	rs7550746	ENSG00000280836.1	AL355480.1	4	7.83e-05	0.0267	0.26	0.21	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45581219~45581321:-
STAD	cis	rs4835473	0.932	rs17695782	ENSG00000249741.2	RP11-673E1.3	4	7.83e-05	0.0267	0.24	0.21	Immature fraction of reticulocytes;	chr4:143830311	chr4:143911514~143912053:-
STAD	cis	rs792448	0.743	rs3767861	ENSG00000212044.2	AL360091.1	4	7.83e-05	0.0267	0.22	0.21	White blood cell count (basophil);	chr1:212364211	chr1:212349978~212350069:+
STAD	cis	rs792448	0.743	rs3767862	ENSG00000212044.2	AL360091.1	4	7.83e-05	0.0267	0.22	0.21	White blood cell count (basophil);	chr1:212364360	chr1:212349978~212350069:+
STAD	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-4	7.83e-05	0.0267	-0.29	-0.21	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
STAD	cis	rs950169	0.58	rs11630887	ENSG00000259295.5	CSPG4P12	4	7.83e-05	0.0267	0.3	0.21	Schizophrenia;	chr15:84649784	chr15:85191438~85213905:+
STAD	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	4	7.83e-05	0.0267	0.28	0.21	Depression;	chr6:28200948	chr6:28170845~28172521:+
STAD	cis	rs34779708	0.897	rs16935880	ENSG00000271335.4	RP11-324I22.4	4	7.83e-05	0.0267	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs4934730	ENSG00000271335.4	RP11-324I22.4	4	7.83e-05	0.0267	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs2045918	ENSG00000271335.4	RP11-324I22.4	4	7.83e-05	0.0267	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs4294520	ENSG00000271335.4	RP11-324I22.4	4	7.83e-05	0.0267	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35314552~35336401:-
STAD	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-4	7.84e-05	0.0267	-0.25	-0.21	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
STAD	cis	rs593531	0.614	rs596976	ENSG00000280269.1	AP000577.2	4	7.84e-05	0.0267	0.22	0.21	Neuroticism;	chr11:74332663	chr11:74204869~74205746:+
STAD	cis	rs728616	0.614	rs61859199	ENSG00000272447.1	RP11-182L21.6	-4	7.84e-05	0.0267	-0.33	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79825902~79827602:+
STAD	cis	rs728616	0.614	rs1538818	ENSG00000272447.1	RP11-182L21.6	-4	7.84e-05	0.0267	-0.33	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79825902~79827602:+
STAD	cis	rs728616	0.614	rs61859209	ENSG00000272447.1	RP11-182L21.6	-4	7.84e-05	0.0267	-0.33	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79825902~79827602:+
STAD	cis	rs728616	0.614	rs61859210	ENSG00000272447.1	RP11-182L21.6	-4	7.84e-05	0.0267	-0.33	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79825902~79827602:+
STAD	cis	rs7824557	0.527	rs2736298	ENSG00000205879.4	FAM90A2P	-4	7.84e-05	0.0267	-0.23	-0.21	Retinal vascular caliber;	chr8:11377627	chr8:12172202~12178575:-
STAD	cis	rs2446066	0.605	rs8938	ENSG00000257379.1	RP11-793H13.8	4	7.84e-05	0.0267	0.43	0.21	Red blood cell count;	chr12:53543094	chr12:53441741~53467528:+
STAD	cis	rs1485395	0.588	rs7969195	ENSG00000257379.1	RP11-793H13.8	4	7.84e-05	0.0267	0.43	0.21	Migraine without aura;	chr12:53549005	chr12:53441741~53467528:+
STAD	cis	rs17507216	0.609	rs1431716	ENSG00000255769.6	GOLGA2P10	-4	7.85e-05	0.0267	-0.35	-0.21	Excessive daytime sleepiness;	chr15:82676180	chr15:82472993~82513950:-
STAD	cis	rs6471393	0.893	rs2976350	ENSG00000253848.1	RP11-10N23.5	-4	7.85e-05	0.0267	-0.25	-0.21	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716818	chr8:93741193~93744534:+
STAD	cis	rs10073892	0.664	rs10072508	ENSG00000250682.4	LINC00491	-4	7.85e-05	0.0267	-0.23	-0.21	Cognitive decline (age-related);	chr5:102542917	chr5:102609156~102671559:-
STAD	cis	rs6772849	0.662	rs12494372	ENSG00000242551.2	POU5F1P6	-4	7.85e-05	0.0267	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128674735~128677005:-
STAD	cis	rs6772849	0.804	rs4857920	ENSG00000242551.2	POU5F1P6	-4	7.85e-05	0.0267	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128688780	chr3:128674735~128677005:-
STAD	cis	rs9907295	1	rs9901195	ENSG00000270894.1	AC015849.13	-4	7.85e-05	0.0267	-0.25	-0.21	Fibroblast growth factor basic levels;	chr17:35915576	chr17:35818399~35823713:+
STAD	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-4	7.86e-05	0.0267	-0.22	-0.21	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
STAD	cis	rs62400317	0.762	rs756	ENSG00000219384.1	RP11-491H9.3	-4	7.86e-05	0.0267	-0.24	-0.21	Total body bone mineral density;	chr6:44828035	chr6:45158870~45159511:+
STAD	cis	rs2239557	0.508	rs56120998	ENSG00000259065.1	RP5-1021I20.1	-4	7.86e-05	0.0268	-0.31	-0.21	Common traits (Other);	chr14:73844011	chr14:73787360~73803270:+
STAD	cis	rs10857712	0.551	rs12252576	ENSG00000214279.11	SCART1	-4	7.86e-05	0.0268	-0.22	-0.21	Systemic lupus erythematosus;	chr10:133413740	chr10:133453928~133523558:+
STAD	cis	rs8012947	0.959	rs7147470	ENSG00000279636.2	LINC00216	-4	7.86e-05	0.0268	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58292948	chr14:58288033~58289158:+
STAD	cis	rs2638953	0.924	rs11049369	ENSG00000247934.4	RP11-967K21.1	-4	7.86e-05	0.0268	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28146543	chr12:28163298~28190738:-
STAD	cis	rs6479891	0.524	rs10740107	ENSG00000235816.3	PRELID1P3	-4	7.86e-05	0.0268	-0.26	-0.21	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63427297~63427939:+
STAD	cis	rs6432852	0.527	rs6432853	ENSG00000229195.1	AC009495.4	4	7.87e-05	0.0268	0.24	0.21	Diabetic kidney disease;	chr2:165945414	chr2:165794857~165846091:-
STAD	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
STAD	cis	rs34779708	0.966	rs34605125	ENSG00000271335.4	RP11-324I22.4	4	7.87e-05	0.0268	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35314552~35336401:-
STAD	cis	rs8062405	0.755	rs17707300	ENSG00000278665.1	RP11-666O2.4	4	7.87e-05	0.0268	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28599241~28601881:-
STAD	cis	rs11157436	0.602	rs928955	ENSG00000211813.2	TRAV34	4	7.87e-05	0.0268	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166273	chr14:22207522~22208129:+
STAD	cis	rs11157436	0.602	rs1894370	ENSG00000211813.2	TRAV34	4	7.87e-05	0.0268	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166764	chr14:22207522~22208129:+
STAD	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	4	7.87e-05	0.0268	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
STAD	cis	rs6479891	1	rs9415692	ENSG00000235816.3	PRELID1P3	4	7.88e-05	0.0268	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63427297~63427939:+
STAD	cis	rs860295	0.676	rs11264374	ENSG00000225855.5	RUSC1-AS1	4	7.88e-05	0.0268	0.18	0.21	Body mass index;	chr1:155451721	chr1:155316863~155324176:-
STAD	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-4	7.88e-05	0.0268	-0.22	-0.21	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
STAD	cis	rs1020064	0.609	rs2576748	ENSG00000235319.1	AC012360.4	4	7.88e-05	0.0268	0.27	0.21	AIDS;	chr2:105294801	chr2:105324210~105330529:+
STAD	cis	rs7927771	0.832	rs4752990	ENSG00000271350.1	CTD-2384B9.1	-4	7.88e-05	0.0268	-0.23	-0.21	Subjective well-being;	chr11:47388842	chr11:47041027~47041945:-
STAD	cis	rs870825	0.549	rs7699919	ENSG00000249173.4	LINC01093	-4	7.88e-05	0.0268	-0.34	-0.21	Blood protein levels;	chr4:184727456	chr4:184893871~184899454:-
STAD	cis	rs7683537	0.887	rs7678412	ENSG00000249173.4	LINC01093	-4	7.88e-05	0.0268	-0.34	-0.21	Systemic lupus erythematosus;	chr4:184727457	chr4:184893871~184899454:-
STAD	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-4	7.88e-05	0.0268	-0.21	-0.21	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
STAD	cis	rs2337406	0.778	rs58113768	ENSG00000211972.2	IGHV3-66	4	7.89e-05	0.0268	0.24	0.21	Alzheimer's disease (late onset);	chr14:106700213	chr14:106675017~106675544:-
STAD	cis	rs2337406	1	rs75651733	ENSG00000211972.2	IGHV3-66	4	7.89e-05	0.0268	0.24	0.21	Alzheimer's disease (late onset);	chr14:106701309	chr14:106675017~106675544:-
STAD	cis	rs494453	0.922	rs531083	ENSG00000234020.1	CHIAP3	-4	7.89e-05	0.0268	-0.21	-0.21	Osteoporosis-related phenotypes;	chr1:111680532	chr1:111353275~111367409:-
STAD	cis	rs4141404	0.818	rs6518737	ENSG00000236132.1	CTA-440B3.1	4	7.89e-05	0.0268	0.23	0.21	Paclitaxel-induced neuropathy;	chr22:31186676	chr22:31816379~31817491:-
STAD	cis	rs4141404	0.787	rs11913992	ENSG00000236132.1	CTA-440B3.1	4	7.89e-05	0.0268	0.23	0.21	Paclitaxel-induced neuropathy;	chr22:31189234	chr22:31816379~31817491:-
STAD	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	4	7.9e-05	0.0269	0.26	0.21	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
STAD	cis	rs7204230	0.921	rs62049817	ENSG00000261291.1	RP11-295M3.2	4	7.9e-05	0.0269	0.25	0.21	Fibrinogen;	chr16:53336109	chr16:53168522~53169450:+
STAD	cis	rs870825	0.616	rs7694899	ENSG00000249173.4	LINC01093	-4	7.9e-05	0.0269	-0.33	-0.21	Blood protein levels;	chr4:184704236	chr4:184893871~184899454:-
STAD	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-4	7.9e-05	0.0269	-0.28	-0.21	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
STAD	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	4	7.9e-05	0.0269	0.33	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
STAD	cis	rs4763879	0.634	rs61915472	ENSG00000256673.1	RP11-599J14.2	4	7.9e-05	0.0269	0.23	0.21	Type 1 diabetes;	chr12:9700995	chr12:9398355~9414851:-
STAD	cis	rs739496	0.542	rs10219736	ENSG00000257595.2	RP3-473L9.4	4	7.9e-05	0.0269	0.3	0.21	Platelet count;	chr12:111350598	chr12:111369282~111403310:+
STAD	cis	rs12744310	0.887	rs12037129	ENSG00000235358.1	RP11-399E6.1	4	7.9e-05	0.0269	0.27	0.21	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328629	chr1:41242373~41284861:+
STAD	cis	rs11157436	0.602	rs10872984	ENSG00000211813.2	TRAV34	4	7.9e-05	0.0269	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171245	chr14:22207522~22208129:+
STAD	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	4	7.9e-05	0.0269	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
STAD	cis	rs2288327	0.818	rs3731751	ENSG00000279598.1	RP11-65L3.3	-4	7.9e-05	0.0269	-0.34	-0.21	Atrial fibrillation;	chr2:178541158	chr2:178554561~178558966:+
STAD	cis	rs2288327	0.818	rs3731749	ENSG00000279598.1	RP11-65L3.3	-4	7.9e-05	0.0269	-0.34	-0.21	Atrial fibrillation;	chr2:178541464	chr2:178554561~178558966:+
STAD	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-4	7.9e-05	0.0269	-0.2	-0.21	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
STAD	cis	rs6012564	1	rs3092039	ENSG00000227431.4	CSE1L-AS1	-4	7.91e-05	0.0269	-0.2	-0.21	Anger;	chr20:49062233	chr20:49040463~49046044:-
STAD	cis	rs11673344	0.542	rs826328	ENSG00000267672.1	CTD-2293H3.1	4	7.91e-05	0.0269	0.2	0.21	Obesity-related traits;	chr19:37004479	chr19:37091341~37092564:+
STAD	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-4	7.91e-05	0.0269	-0.18	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
STAD	cis	rs1371614	0.685	rs61007968	ENSG00000214465.3	SMARCE1P6	3.99	7.91e-05	0.0269	0.26	0.21	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26954560	chr2:26149204~26150731:+
STAD	cis	rs2638953	0.853	rs3926041	ENSG00000247934.4	RP11-967K21.1	-3.99	7.91e-05	0.0269	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461776	chr12:28163298~28190738:-
STAD	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	3.99	7.91e-05	0.0269	0.24	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
STAD	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	3.99	7.91e-05	0.0269	0.28	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
STAD	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	3.99	7.91e-05	0.0269	0.35	0.21	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
STAD	cis	rs34779708	0.649	rs34421369	ENSG00000271335.4	RP11-324I22.4	3.99	7.91e-05	0.0269	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.677	rs112355105	ENSG00000271335.4	RP11-324I22.4	3.99	7.91e-05	0.0269	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35314552~35336401:-
STAD	cis	rs1876905	0.68	rs354527	ENSG00000230177.1	RP5-1112D6.4	-3.99	7.91e-05	0.0269	-0.25	-0.21	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111277932~111278742:+
STAD	cis	rs2404602	0.583	rs11072580	ENSG00000196274.5	Metazoa_SRP	3.99	7.92e-05	0.0269	0.18	0.21	Blood metabolite levels;	chr15:76247890	chr15:76230048~76230390:-
STAD	cis	rs7937890	1	rs2970335	ENSG00000254418.1	RP11-21L19.1	3.99	7.92e-05	0.0269	0.22	0.21	Mitochondrial DNA levels;	chr11:14303855	chr11:14262846~14273691:-
STAD	cis	rs1876905	0.539	rs240985	ENSG00000272356.1	RP5-1112D6.8	3.99	7.92e-05	0.0269	0.21	0.21	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111309203~111313517:+
STAD	cis	rs11723530	0.546	rs10013860	ENSG00000201818.1	RNY4P17	3.99	7.92e-05	0.0269	0.22	0.21	Myopia (pathological);	chr4:169883200	chr4:169005249~169005344:+
STAD	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	3.99	7.92e-05	0.0269	0.21	0.21	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	3.99	7.92e-05	0.0269	0.21	0.21	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
STAD	cis	rs2638953	0.886	rs11049572	ENSG00000247934.4	RP11-967K21.1	-3.99	7.92e-05	0.0269	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:28163298~28190738:-
STAD	cis	rs7202877	0.706	rs4888393	ENSG00000261783.1	RP11-252K23.2	-3.99	7.92e-05	0.0269	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75379775	chr16:75379818~75381260:-
STAD	cis	rs7202877	0.656	rs4888394	ENSG00000261783.1	RP11-252K23.2	-3.99	7.92e-05	0.0269	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75379811	chr16:75379818~75381260:-
STAD	cis	rs7202877	0.611	rs4888395	ENSG00000261783.1	RP11-252K23.2	-3.99	7.92e-05	0.0269	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75379817	chr16:75379818~75381260:-
STAD	cis	rs17592366	1	rs17592366	ENSG00000251726.1	RNU7-41P	-3.99	7.93e-05	0.0269	-0.29	-0.21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34816956	chr14:34845300~34845360:-
STAD	cis	rs10911902	0.643	rs6667940	ENSG00000229739.2	RP11-295K2.3	-3.99	7.93e-05	0.0269	-0.3	-0.21	Schizophrenia;	chr1:186350448	chr1:186435161~186470291:+
STAD	cis	rs749052	0.831	rs3116158	ENSG00000251485.1	AC068134.10	-3.99	7.93e-05	0.0269	-0.52	-0.21	Height;	chr2:232090653	chr2:232343116~232343903:+
STAD	cis	rs9905704	0.647	rs2286299	ENSG00000224738.1	AC099850.1	3.99	7.93e-05	0.0269	0.24	0.21	Testicular germ cell tumor;	chr17:58966006	chr17:59106598~59118267:+
STAD	cis	rs4835473	0.932	rs62337619	ENSG00000249741.2	RP11-673E1.3	3.99	7.93e-05	0.0269	0.25	0.21	Immature fraction of reticulocytes;	chr4:143742083	chr4:143911514~143912053:-
STAD	cis	rs34779708	0.931	rs4934711	ENSG00000271335.4	RP11-324I22.4	3.99	7.93e-05	0.0269	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35314552~35336401:-
STAD	cis	rs2933343	0.729	rs6767104	ENSG00000261159.1	RP11-723O4.9	-3.99	7.93e-05	0.0269	-0.26	-0.21	IgG glycosylation;	chr3:128929274	chr3:128859716~128860526:-
STAD	cis	rs9902453	0.904	rs9900974	ENSG00000240074.1	RPL9P30	-3.99	7.93e-05	0.027	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30037438	chr17:29855759~29856332:+
STAD	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	3.99	7.93e-05	0.027	0.35	0.21	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
STAD	cis	rs3858145	0.588	rs78041174	ENSG00000234102.1	KRT19P4	-3.99	7.94e-05	0.027	-0.24	-0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68260557~68261499:+
STAD	cis	rs950169	0.881	rs4842852	ENSG00000235370.6	DNM1P51	3.99	7.94e-05	0.027	0.27	0.21	Schizophrenia;	chr15:84387263	chr15:84398316~84411701:-
STAD	cis	rs950169	0.84	rs4842853	ENSG00000235370.6	DNM1P51	3.99	7.94e-05	0.027	0.27	0.21	Schizophrenia;	chr15:84387606	chr15:84398316~84411701:-
STAD	cis	rs950169	0.922	rs4842946	ENSG00000235370.6	DNM1P51	3.99	7.94e-05	0.027	0.27	0.21	Schizophrenia;	chr15:84387633	chr15:84398316~84411701:-
STAD	cis	rs950169	0.84	rs4842854	ENSG00000235370.6	DNM1P51	3.99	7.94e-05	0.027	0.27	0.21	Schizophrenia;	chr15:84387641	chr15:84398316~84411701:-
STAD	cis	rs950169	0.84	rs2896002	ENSG00000235370.6	DNM1P51	3.99	7.94e-05	0.027	0.27	0.21	Schizophrenia;	chr15:84390423	chr15:84398316~84411701:-
STAD	cis	rs950169	0.887	rs3860265	ENSG00000235370.6	DNM1P51	3.99	7.94e-05	0.027	0.27	0.21	Schizophrenia;	chr15:84390487	chr15:84398316~84411701:-
STAD	cis	rs9902453	0.904	rs7208579	ENSG00000263477.1	RP11-338L22.2	3.99	7.94e-05	0.027	0.18	0.21	Coffee consumption (cups per day);	chr17:29936049	chr17:29863402~29866092:+
STAD	cis	rs4745216	1	rs4745215	ENSG00000225434.2	LINC01504	3.99	7.95e-05	0.027	0.59	0.21	Blood protein levels;	chr9:73129076	chr9:72305430~72343210:+
STAD	cis	rs4745216	1	rs4745216	ENSG00000225434.2	LINC01504	3.99	7.95e-05	0.027	0.59	0.21	Blood protein levels;	chr9:73129241	chr9:72305430~72343210:+
STAD	cis	rs4745216	1	rs4745217	ENSG00000225434.2	LINC01504	3.99	7.95e-05	0.027	0.59	0.21	Blood protein levels;	chr9:73129360	chr9:72305430~72343210:+
STAD	cis	rs4745216	1	rs4495498	ENSG00000225434.2	LINC01504	3.99	7.95e-05	0.027	0.59	0.21	Blood protein levels;	chr9:73131974	chr9:72305430~72343210:+
STAD	cis	rs4745216	1	rs17058508	ENSG00000225434.2	LINC01504	3.99	7.95e-05	0.027	0.59	0.21	Blood protein levels;	chr9:73134729	chr9:72305430~72343210:+
STAD	cis	rs4745216	1	rs17058511	ENSG00000225434.2	LINC01504	3.99	7.95e-05	0.027	0.59	0.21	Blood protein levels;	chr9:73137729	chr9:72305430~72343210:+
STAD	cis	rs4835473	0.771	rs4835097	ENSG00000249741.2	RP11-673E1.3	-3.99	7.95e-05	0.027	-0.24	-0.21	Immature fraction of reticulocytes;	chr4:143960687	chr4:143911514~143912053:-
STAD	cis	rs7951911	0.915	rs7943822	ENSG00000254427.1	RP11-430H10.1	3.99	7.95e-05	0.027	0.41	0.21	IgG glycosylation;	chr11:45066834	chr11:45355371~45366121:+
STAD	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-3.99	7.95e-05	0.027	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-3.99	7.95e-05	0.027	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
STAD	cis	rs5752326	1	rs5761530	ENSG00000261188.1	CTA-445C9.14	3.99	7.95e-05	0.027	0.36	0.21	Ischemic stroke;	chr22:26447950	chr22:26512537~26514568:+
STAD	cis	rs5752326	0.867	rs5761531	ENSG00000261188.1	CTA-445C9.14	3.99	7.95e-05	0.027	0.36	0.21	Ischemic stroke;	chr22:26448180	chr22:26512537~26514568:+
STAD	cis	rs11157436	0.602	rs1894371	ENSG00000211812.1	TRAV26-2	3.99	7.95e-05	0.027	0.2	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166799	chr14:22202583~22203368:+
STAD	cis	rs1707322	1	rs6671754	ENSG00000225447.1	RPS15AP10	3.99	7.95e-05	0.027	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs6666763	ENSG00000225447.1	RPS15AP10	3.99	7.95e-05	0.027	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4489497	ENSG00000225447.1	RPS15AP10	3.99	7.95e-05	0.027	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45645816~45646197:-
STAD	cis	rs2836974	0.59	rs9974757	ENSG00000238141.2	BRWD1-AS1	-3.99	7.95e-05	0.027	-0.22	-0.21	Cognitive function;	chr21:39245318	chr21:39315707~39323218:+
STAD	cis	rs393951	0.711	rs407490	ENSG00000260969.1	RP11-190D6.2	-3.99	7.96e-05	0.027	-0.29	-0.21	Childhood ear infection;	chr16:77579594	chr16:78237362~78241218:-
STAD	cis	rs10129255	0.872	rs1858683	ENSG00000232216.1	IGHV3-43	3.99	7.96e-05	0.027	0.22	0.21	Kawasaki disease;	chr14:106670217	chr14:106470264~106470800:-
STAD	cis	rs2836974	0.555	rs35909862	ENSG00000238141.2	BRWD1-AS1	-3.99	7.96e-05	0.027	-0.22	-0.21	Cognitive function;	chr21:39249232	chr21:39315707~39323218:+
STAD	cis	rs7131987	0.903	rs2194519	ENSG00000275476.1	RP11-996F15.4	3.99	7.96e-05	0.027	0.23	0.21	QT interval;	chr12:29270650	chr12:29277397~29277882:-
STAD	cis	rs2348418	0.932	rs61922464	ENSG00000247934.4	RP11-967K21.1	3.99	7.96e-05	0.027	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28485665	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.932	rs11049661	ENSG00000247934.4	RP11-967K21.1	3.99	7.96e-05	0.027	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28486215	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.932	rs11049662	ENSG00000247934.4	RP11-967K21.1	3.99	7.96e-05	0.027	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28487344	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.932	rs7306581	ENSG00000247934.4	RP11-967K21.1	3.99	7.96e-05	0.027	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28488641	chr12:28163298~28190738:-
STAD	cis	rs938554	0.779	rs9998811	ENSG00000250613.1	RP11-136I13.1	3.99	7.96e-05	0.027	0.24	0.21	Blood metabolite levels;	chr4:9964853	chr4:10410996~10411644:+
STAD	cis	rs3758141	0.79	rs13263453	ENSG00000278886.1	RP11-108A14.1	-3.99	7.96e-05	0.027	-0.27	-0.21	Body mass index (change over time) in gastrointestinal cancer;	chr8:18871986	chr8:18864681~18865247:-
STAD	cis	rs7926906	0.817	rs7941948	ENSG00000280367.1	RP11-121L10.2	3.99	7.97e-05	0.027	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90794381	chr11:90223153~90226538:+
STAD	cis	rs10129255	0.518	rs28378320	ENSG00000232216.1	IGHV3-43	3.99	7.97e-05	0.027	0.19	0.21	Kawasaki disease;	chr14:106808609	chr14:106470264~106470800:-
STAD	cis	rs2273156	0.636	rs12892552	ENSG00000258704.4	SRP54-AS1	-3.99	7.97e-05	0.027	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35036208	chr14:34920858~34982532:-
STAD	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	3.99	7.97e-05	0.027	0.25	0.21	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
STAD	cis	rs62025270	1	rs62025270	ENSG00000259295.5	CSPG4P12	-3.99	7.97e-05	0.0271	-0.38	-0.21	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85191438~85213905:+
STAD	cis	rs10129255	0.957	rs10138532	ENSG00000224373.3	IGHV4-59	3.99	7.97e-05	0.0271	0.17	0.21	Kawasaki disease;	chr14:106803901	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.5	rs8011115	ENSG00000232216.1	IGHV3-43	3.99	7.97e-05	0.0271	0.19	0.21	Kawasaki disease;	chr14:106786292	chr14:106470264~106470800:-
STAD	cis	rs4763879	0.739	rs2895988	ENSG00000256673.1	RP11-599J14.2	3.99	7.97e-05	0.0271	0.23	0.21	Type 1 diabetes;	chr12:9675831	chr12:9398355~9414851:-
STAD	cis	rs4763879	0.739	rs2114871	ENSG00000256673.1	RP11-599J14.2	3.99	7.97e-05	0.0271	0.23	0.21	Type 1 diabetes;	chr12:9676842	chr12:9398355~9414851:-
STAD	cis	rs6762	0.55	rs8672	ENSG00000279672.1	CMB9-55F22.1	3.99	7.98e-05	0.0271	0.26	0.21	Mean platelet volume;	chr11:838634	chr11:779617~780755:+
STAD	cis	rs930421	0.965	rs11681208	ENSG00000226491.1	FTOP1	-3.99	7.98e-05	0.0271	-0.22	-0.21	Attention deficit hyperactivity disorder;	chr2:42760128	chr2:42797225~42798712:-
STAD	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	3.99	7.98e-05	0.0271	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
STAD	cis	rs2957692	0.548	rs78169797	ENSG00000254554.1	RP11-351I24.1	3.99	7.98e-05	0.0271	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10024052	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs11042593	ENSG00000254554.1	RP11-351I24.1	3.99	7.98e-05	0.0271	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10025398	chr11:10302657~10303704:-
STAD	cis	rs10500715	0.517	rs79371669	ENSG00000254554.1	RP11-351I24.1	3.99	7.98e-05	0.0271	0.34	0.21	Pancreatic cancer;	chr11:10027790	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.506	rs10840344	ENSG00000254554.1	RP11-351I24.1	3.99	7.98e-05	0.0271	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10028610	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.527	rs7938502	ENSG00000254554.1	RP11-351I24.1	3.99	7.98e-05	0.0271	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10031865	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.527	rs61877048	ENSG00000254554.1	RP11-351I24.1	3.99	7.98e-05	0.0271	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10032057	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs61877049	ENSG00000254554.1	RP11-351I24.1	3.99	7.98e-05	0.0271	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10032313	chr11:10302657~10303704:-
STAD	cis	rs58873874	0.579	rs56666304	ENSG00000251405.2	CTB-109A12.1	3.99	7.98e-05	0.0271	0.36	0.21	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157362615~157460078:-
STAD	cis	rs62400317	0.762	rs6908606	ENSG00000219384.1	RP11-491H9.3	-3.99	7.98e-05	0.0271	-0.24	-0.21	Total body bone mineral density;	chr6:45031151	chr6:45158870~45159511:+
STAD	cis	rs60180747	0.863	rs11635184	ENSG00000252712.1	SCARNA14	3.99	7.98e-05	0.0271	0.25	0.21	Testicular germ cell tumor;	chr15:66422405	chr15:66347207~66347342:-
STAD	cis	rs4218	0.543	rs2414618	ENSG00000259732.1	RP11-59H7.3	-3.99	7.99e-05	0.0271	-0.23	-0.21	Social communication problems;	chr15:59019684	chr15:59121034~59133250:+
STAD	cis	rs10129255	0.957	rs8009638	ENSG00000224373.3	IGHV4-59	3.99	7.99e-05	0.0271	0.17	0.21	Kawasaki disease;	chr14:106777570	chr14:106627249~106627825:-
STAD	cis	rs2404602	0.583	rs2469542	ENSG00000196274.5	Metazoa_SRP	-3.99	8e-05	0.0271	-0.18	-0.21	Blood metabolite levels;	chr15:76265135	chr15:76230048~76230390:-
STAD	cis	rs360071	0.528	rs360094	ENSG00000242861.1	RP11-285F7.2	3.99	8e-05	0.0271	0.2	0.21	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225877146	chr1:225840883~225846522:-
STAD	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	3.99	8e-05	0.0271	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	3.99	8e-05	0.0271	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	3.99	8e-05	0.0271	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	3.99	8e-05	0.0271	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
STAD	cis	rs765787	0.53	rs2668737	ENSG00000259539.1	CTD-2651B20.1	3.99	8e-05	0.0271	0.24	0.21	Uric acid levels;	chr15:45230601	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs1706764	ENSG00000259539.1	CTD-2651B20.1	3.99	8e-05	0.0271	0.24	0.21	Uric acid levels;	chr15:45232058	chr15:45152664~45167526:-
STAD	cis	rs11098499	0.913	rs12186259	ENSG00000249244.1	RP11-548H18.2	3.99	8e-05	0.0272	0.28	0.21	Corneal astigmatism;	chr4:119230884	chr4:119391831~119395335:-
STAD	cis	rs9987353	0.784	rs4841116	ENSG00000254340.1	RP11-10A14.3	-3.99	8.01e-05	0.0272	-0.32	-0.21	Recombination measurement;	chr8:9272606	chr8:9141424~9145435:+
STAD	cis	rs7829975	0.774	rs57312668	ENSG00000173295.6	FAM86B3P	3.99	8.01e-05	0.0272	0.23	0.21	Mood instability;	chr8:8822967	chr8:8228595~8244865:+
STAD	cis	rs12906542	0.516	rs12593545	ENSG00000259792.1	RP11-114H24.6	-3.99	8.01e-05	0.0272	-0.37	-0.21	Breast cancer;	chr15:78045597	chr15:77993405~77995289:+
STAD	cis	rs4792901	0.765	rs9905358	ENSG00000279602.1	CTD-3014M21.1	-3.99	8.01e-05	0.0272	-0.28	-0.21	Dupuytren's disease;	chr17:43478106	chr17:43360041~43361361:-
STAD	cis	rs11976180	1	rs2961134	ENSG00000204959.4	ARHGEF34P	3.99	8.02e-05	0.0272	0.29	0.21	Obesity-related traits;	chr7:144073969	chr7:144272445~144286966:-
STAD	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	3.99	8.02e-05	0.0272	0.21	0.21	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
STAD	cis	rs2803122	0.502	rs1854552	ENSG00000272842.1	RP11-513M16.7	3.99	8.02e-05	0.0272	0.21	0.21	Pulse pressure;	chr9:19235049	chr9:19371386~19371945:-
STAD	cis	rs7702057	0.53	rs7728055	ENSG00000271918.1	CTD-2287O16.5	3.99	8.02e-05	0.0272	0.39	0.21	Amyotrophic lateral sclerosis;	chr5:116078170	chr5:116083807~116085416:-
STAD	cis	rs9928842	0.824	rs889515	ENSG00000280152.1	RP11-331F4.5	3.99	8.02e-05	0.0272	0.31	0.21	Alcoholic chronic pancreatitis;	chr16:75217401	chr16:75245994~75250077:-
STAD	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	3.99	8.02e-05	0.0272	0.28	0.21	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
STAD	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	3.99	8.02e-05	0.0272	0.28	0.21	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
STAD	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	3.99	8.02e-05	0.0272	0.28	0.21	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
STAD	cis	rs1345301	0.518	rs1558623	ENSG00000234389.1	AC007278.3	-3.99	8.02e-05	0.0272	-0.21	-0.21	Waist circumference;	chr2:102245942	chr2:102438713~102440475:+
STAD	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-3.99	8.02e-05	0.0272	-0.22	-0.21	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
STAD	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	3.99	8.02e-05	0.0272	0.24	0.21	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
STAD	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	3.99	8.02e-05	0.0272	0.33	0.21	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
STAD	cis	rs73198271	0.737	rs565203	ENSG00000254340.1	RP11-10A14.3	-3.99	8.02e-05	0.0272	-0.28	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:9141424~9145435:+
STAD	cis	rs9659323	0.7	rs2885226	ENSG00000231365.4	RP11-418J17.1	-3.99	8.03e-05	0.0272	-0.26	-0.21	Body mass index;	chr1:119081540	chr1:119140396~119275973:+
STAD	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-3.99	8.03e-05	0.0272	-0.22	-0.21	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
STAD	cis	rs2277027	0.552	rs5023028	ENSG00000251405.2	CTB-109A12.1	3.99	8.03e-05	0.0272	0.22	0.21	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157530428	chr5:157362615~157460078:-
STAD	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-3.99	8.03e-05	0.0272	-0.35	-0.21	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
STAD	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	3.99	8.03e-05	0.0272	0.46	0.21	QT interval;	chr4:75108962	chr4:75081702~75084717:-
STAD	cis	rs7487075	0.619	rs4768723	ENSG00000257261.4	RP11-96H19.1	3.99	8.03e-05	0.0272	0.28	0.21	Itch intensity from mosquito bite;	chr12:46451941	chr12:46383679~46876159:+
STAD	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	3.99	8.03e-05	0.0272	0.48	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	3.99	8.03e-05	0.0272	0.48	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
STAD	cis	rs765787	0.53	rs4514617	ENSG00000259539.1	CTD-2651B20.1	3.99	8.04e-05	0.0272	0.24	0.21	Uric acid levels;	chr15:45243241	chr15:45152664~45167526:-
STAD	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	3.99	8.04e-05	0.0272	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	3.99	8.04e-05	0.0272	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
STAD	cis	rs2834288	1	rs2834288	ENSG00000237945.6	LINC00649	3.99	8.04e-05	0.0272	0.27	0.21	Gut microbiota (bacterial taxa);	chr21:33892093	chr21:33915534~33977691:+
STAD	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-3.99	8.04e-05	0.0272	-0.28	-0.21	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
STAD	cis	rs1322639	0.614	rs6940913	ENSG00000261039.2	RP11-417E7.2	-3.99	8.04e-05	0.0273	-0.33	-0.21	Pulse pressure;	chr6:169163571	chr6:169175304~169182740:-
STAD	cis	rs10508774	1	rs72795539	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32553398	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs61299190	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32570591	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72795557	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32581579	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs117817425	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32590266	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72795564	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32599372	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72795567	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32607581	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs1333221	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32614495	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs1829545	ENSG00000273038.2	RP11-479G22.8	3.99	8.04e-05	0.0273	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32617449	chr10:32887255~32889311:-
STAD	cis	rs12586317	0.883	rs4982254	ENSG00000206588.1	RNU1-28P	3.99	8.05e-05	0.0273	0.23	0.21	Psoriasis;	chr14:35286531	chr14:34556226~34556389:-
STAD	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	3.99	8.05e-05	0.0273	0.2	0.21	Breast size;	chr12:9232939	chr12:9277235~9313241:+
STAD	cis	rs10508774	1	rs58783140	ENSG00000273038.2	RP11-479G22.8	3.99	8.05e-05	0.0273	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32620675	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs58339739	ENSG00000273038.2	RP11-479G22.8	3.99	8.05e-05	0.0273	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32620706	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72795571	ENSG00000273038.2	RP11-479G22.8	3.99	8.05e-05	0.0273	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32621005	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72795572	ENSG00000273038.2	RP11-479G22.8	3.99	8.05e-05	0.0273	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32621058	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs117557786	ENSG00000273038.2	RP11-479G22.8	3.99	8.05e-05	0.0273	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32641148	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.85	rs2152161	ENSG00000273038.2	RP11-479G22.8	3.99	8.05e-05	0.0273	0.41	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32643857	chr10:32887255~32889311:-
STAD	cis	rs867371	0.502	rs3759800	ENSG00000259429.4	UBE2Q2P2	3.99	8.05e-05	0.0273	0.22	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82355142~82420075:+
STAD	cis	rs7615952	0.546	rs11718647	ENSG00000171084.14	FAM86JP	3.99	8.05e-05	0.0273	0.33	0.21	Blood pressure (smoking interaction);	chr3:125633178	chr3:125916620~125930024:+
STAD	cis	rs7015630	0.657	rs10094579	ENSG00000251136.7	RP11-37B2.1	-3.99	8.05e-05	0.0273	-0.28	-0.21	Inflammatory bowel disease;Crohn's disease;	chr8:89837077	chr8:89609409~89757727:-
STAD	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	3.99	8.06e-05	0.0273	0.29	0.21	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
STAD	cis	rs2273156	0.706	rs8015622	ENSG00000258704.4	SRP54-AS1	-3.99	8.06e-05	0.0273	-0.25	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35017894	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.706	rs35030792	ENSG00000258704.4	SRP54-AS1	-3.99	8.06e-05	0.0273	-0.25	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35019917	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.706	rs7155696	ENSG00000258704.4	SRP54-AS1	-3.99	8.06e-05	0.0273	-0.25	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35027548	chr14:34920858~34982532:-
STAD	cis	rs9291683	0.525	rs12506455	ENSG00000250613.1	RP11-136I13.1	-3.99	8.06e-05	0.0273	-0.19	-0.21	Bone mineral density;	chr4:10029945	chr4:10410996~10411644:+
STAD	cis	rs831571	0.636	rs56228642	ENSG00000280620.1	SCAANT1	3.99	8.06e-05	0.0273	0.31	0.21	Type 2 diabetes;	chr3:64090083	chr3:63911518~63911772:-
STAD	cis	rs10129255	0.5	rs2027903	ENSG00000232216.1	IGHV3-43	3.99	8.07e-05	0.0273	0.19	0.21	Kawasaki disease;	chr14:106807047	chr14:106470264~106470800:-
STAD	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-3.99	8.07e-05	0.0273	-0.24	-0.21	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
STAD	cis	rs7119038	0.774	rs11217001	ENSG00000255422.1	AP002954.4	3.99	8.07e-05	0.0273	0.29	0.21	Sjögren's syndrome;	chr11:118736337	chr11:118704607~118750263:+
STAD	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-3.99	8.07e-05	0.0273	-0.28	-0.21	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
STAD	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	3.99	8.07e-05	0.0273	0.26	0.21	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	3.99	8.07e-05	0.0273	0.26	0.21	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
STAD	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	3.99	8.07e-05	0.0273	0.26	0.21	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	3.99	8.07e-05	0.0273	0.26	0.21	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	3.99	8.07e-05	0.0273	0.26	0.21	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
STAD	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	3.99	8.07e-05	0.0273	0.26	0.21	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
STAD	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	3.99	8.07e-05	0.0273	0.26	0.21	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
STAD	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	3.99	8.07e-05	0.0273	0.29	0.21	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	3.99	8.07e-05	0.0273	0.29	0.21	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	3.99	8.07e-05	0.0273	0.29	0.21	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	3.99	8.07e-05	0.0273	0.29	0.21	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	3.99	8.07e-05	0.0273	0.29	0.21	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
STAD	cis	rs2262909	0.962	rs409439	ENSG00000213976.4	CTD-2561J22.2	-3.99	8.07e-05	0.0273	-0.26	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22044630	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs425781	ENSG00000213976.4	CTD-2561J22.2	-3.99	8.07e-05	0.0273	-0.26	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22046504	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs409835	ENSG00000213976.4	CTD-2561J22.2	-3.99	8.07e-05	0.0273	-0.26	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22047869	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs411020	ENSG00000213976.4	CTD-2561J22.2	-3.99	8.07e-05	0.0273	-0.26	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22048300	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs408687	ENSG00000213976.4	CTD-2561J22.2	-3.99	8.07e-05	0.0273	-0.26	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22048321	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs436662	ENSG00000213976.4	CTD-2561J22.2	-3.99	8.07e-05	0.0273	-0.26	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22049305	chr19:21382865~21387177:+
STAD	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-3.99	8.07e-05	0.0273	-0.28	-0.21	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-3.99	8.07e-05	0.0273	-0.28	-0.21	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-3.99	8.07e-05	0.0273	-0.28	-0.21	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
STAD	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	3.99	8.07e-05	0.0273	0.25	0.21	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
STAD	cis	rs2493298	1	rs2493296	ENSG00000272088.1	RP11-168F9.2	3.99	8.07e-05	0.0273	0.32	0.21	Coronary artery disease;	chr1:3410468	chr1:3487246~3487627:+
STAD	cis	rs10129255	0.872	rs8015406	ENSG00000232216.1	IGHV3-43	3.99	8.08e-05	0.0273	0.22	0.21	Kawasaki disease;	chr14:106670611	chr14:106470264~106470800:-
STAD	cis	rs7119038	0.629	rs11217000	ENSG00000255422.1	AP002954.4	3.99	8.08e-05	0.0273	0.28	0.21	Sjögren's syndrome;	chr11:118734275	chr11:118704607~118750263:+
STAD	cis	rs7520050	0.831	rs61783170	ENSG00000280836.1	AL355480.1	3.99	8.08e-05	0.0274	0.26	0.21	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45581219~45581321:-
STAD	cis	rs5753618	0.504	rs8138525	ENSG00000236132.1	CTA-440B3.1	3.99	8.08e-05	0.0274	0.24	0.21	Colorectal cancer;	chr22:31615943	chr22:31816379~31817491:-
STAD	cis	rs12477438	0.834	rs1563107	ENSG00000231822.1	AC019097.7	3.99	8.08e-05	0.0274	0.24	0.21	Chronic sinus infection;	chr2:99084813	chr2:99102018~99102752:+
STAD	cis	rs12807809	0.945	rs1939214	ENSG00000245498.5	RP11-677M14.7	3.99	8.09e-05	0.0274	0.3	0.21	Schizophrenia;	chr11:124735394	chr11:124800450~124834487:+
STAD	cis	rs1707322	1	rs11211235	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.893	rs9919275	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211236	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4660328	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.928	rs61785614	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs9793167	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211237	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs11211238	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs4460583	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.963	rs4459051	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45645816~45646197:-
STAD	cis	rs1707322	1	rs11211239	ENSG00000225447.1	RPS15AP10	3.99	8.09e-05	0.0274	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45645816~45646197:-
STAD	cis	rs7395581	0.959	rs7120118	ENSG00000271350.1	CTD-2384B9.1	3.99	8.09e-05	0.0274	0.26	0.21	HDL cholesterol;	chr11:47264739	chr11:47041027~47041945:-
STAD	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	3.99	8.09e-05	0.0274	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	3.99	8.09e-05	0.0274	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	3.99	8.09e-05	0.0274	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	3.99	8.09e-05	0.0274	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	3.99	8.09e-05	0.0274	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
STAD	cis	rs2286503	0.839	rs1054471	ENSG00000221740.1	SNORD93	3.99	8.09e-05	0.0274	0.24	0.21	Fibrinogen;	chr7:22813024	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.839	rs2240726	ENSG00000221740.1	SNORD93	3.99	8.09e-05	0.0274	0.24	0.21	Fibrinogen;	chr7:22813516	chr7:22856613~22856686:+
STAD	cis	rs875971	0.862	rs1695820	ENSG00000224316.1	RP11-479O9.2	3.99	8.09e-05	0.0274	0.2	0.21	Aortic root size;	chr7:66379576	chr7:65773620~65802067:+
STAD	cis	rs875971	0.83	rs778715	ENSG00000224316.1	RP11-479O9.2	3.99	8.09e-05	0.0274	0.2	0.21	Aortic root size;	chr7:66384222	chr7:65773620~65802067:+
STAD	cis	rs875971	0.83	rs809025	ENSG00000224316.1	RP11-479O9.2	3.99	8.09e-05	0.0274	0.2	0.21	Aortic root size;	chr7:66384832	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs778702	ENSG00000224316.1	RP11-479O9.2	3.99	8.09e-05	0.0274	0.2	0.21	Aortic root size;	chr7:66399848	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs1643375	ENSG00000224316.1	RP11-479O9.2	3.99	8.09e-05	0.0274	0.2	0.21	Aortic root size;	chr7:66407690	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6962717	ENSG00000224316.1	RP11-479O9.2	3.99	8.09e-05	0.0274	0.2	0.21	Aortic root size;	chr7:66418748	chr7:65773620~65802067:+
STAD	cis	rs606458	0.92	rs10400348	ENSG00000269038.1	AP001462.6	-3.99	8.09e-05	0.0274	-0.29	-0.21	Urate levels;	chr11:64639913	chr11:64778954~64779405:+
STAD	cis	rs7142881	0.844	rs9972191	ENSG00000258648.1	UBE2CP1	3.99	8.1e-05	0.0274	0.24	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31560274	chr14:30683045~30683598:-
STAD	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	3.99	8.1e-05	0.0274	0.28	0.21	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	3.99	8.1e-05	0.0274	0.28	0.21	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	3.99	8.1e-05	0.0274	0.28	0.21	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	3.99	8.1e-05	0.0274	0.28	0.21	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
STAD	cis	rs7103648	0.569	rs11039266	ENSG00000280615.1	Y_RNA	3.99	8.1e-05	0.0274	0.23	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47510843	chr11:47614898~47614994:-
STAD	cis	rs4834770	1	rs10034579	ENSG00000250412.1	KLHL2P1	3.99	8.1e-05	0.0274	0.27	0.21	Blood protein levels;	chr4:119322874	chr4:119334329~119378233:+
STAD	cis	rs765787	0.53	rs11070451	ENSG00000259539.1	CTD-2651B20.1	3.99	8.1e-05	0.0274	0.24	0.21	Uric acid levels;	chr15:45241343	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs28897155	ENSG00000259539.1	CTD-2651B20.1	3.99	8.1e-05	0.0274	0.24	0.21	Uric acid levels;	chr15:45241776	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775831	ENSG00000259539.1	CTD-2651B20.1	3.99	8.1e-05	0.0274	0.24	0.21	Uric acid levels;	chr15:45242524	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775832	ENSG00000259539.1	CTD-2651B20.1	3.99	8.1e-05	0.0274	0.24	0.21	Uric acid levels;	chr15:45242630	chr15:45152664~45167526:-
STAD	cis	rs7665090	0.528	rs4235405	ENSG00000230069.3	LRRC37A15P	-3.99	8.1e-05	0.0274	-0.24	-0.21	Primary biliary cholangitis;	chr4:102595654	chr4:102727274~102730721:-
STAD	cis	rs11089937	0.597	rs9619812	ENSG00000211640.3	IGLV6-57	3.99	8.1e-05	0.0274	0.16	0.21	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22195713~22196460:+
STAD	cis	rs4308124	1	rs4308124	ENSG00000230499.1	AC108463.1	-3.99	8.11e-05	0.0274	-0.26	-0.21	Vitiligo;	chr2:111252909	chr2:111195963~111206494:+
STAD	cis	rs6832769	0.961	rs2412647	ENSG00000223305.1	RN7SKP30	3.99	8.11e-05	0.0274	0.23	0.21	Personality dimensions;	chr4:55452938	chr4:55540502~55540835:-
STAD	cis	rs7829975	0.774	rs1039915	ENSG00000173295.6	FAM86B3P	3.99	8.11e-05	0.0274	0.23	0.21	Mood instability;	chr8:8822104	chr8:8228595~8244865:+
STAD	cis	rs1005277	0.505	rs10827835	ENSG00000099251.13	HSD17B7P2	-3.99	8.11e-05	0.0274	-0.23	-0.21	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38356380~38378505:+
STAD	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	3.99	8.11e-05	0.0274	0.31	0.21	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
STAD	cis	rs9902453	0.904	rs12951836	ENSG00000263477.1	RP11-338L22.2	-3.99	8.11e-05	0.0274	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30083259	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.904	rs12948898	ENSG00000263477.1	RP11-338L22.2	-3.99	8.11e-05	0.0274	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30083306	chr17:29863402~29866092:+
STAD	cis	rs9813712	0.672	rs73210789	ENSG00000249846.5	RP11-77P16.4	3.99	8.11e-05	0.0274	0.3	0.21	Response to amphetamines;	chr3:130243418	chr3:130112550~130120579:+
STAD	cis	rs9813712	1	rs57804141	ENSG00000249846.5	RP11-77P16.4	3.99	8.11e-05	0.0274	0.3	0.21	Response to amphetamines;	chr3:130243669	chr3:130112550~130120579:+
STAD	cis	rs11089937	0.54	rs5756992	ENSG00000211640.3	IGLV6-57	3.99	8.11e-05	0.0274	0.16	0.21	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.597	rs9622919	ENSG00000211640.3	IGLV6-57	3.99	8.11e-05	0.0274	0.16	0.21	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22195713~22196460:+
STAD	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	3.99	8.11e-05	0.0274	0.63	0.21	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
STAD	cis	rs9788721	0.836	rs55983731	ENSG00000259419.2	HNRNPCP3	3.99	8.11e-05	0.0274	0.23	0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78442927	chr15:79236332~79237206:+
STAD	cis	rs9788721	0.836	rs72738718	ENSG00000259419.2	HNRNPCP3	3.99	8.11e-05	0.0274	0.23	0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78443096	chr15:79236332~79237206:+
STAD	cis	rs6479891	0.915	rs7091664	ENSG00000235816.3	PRELID1P3	-3.99	8.11e-05	0.0274	-0.27	-0.21	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63427297~63427939:+
STAD	cis	rs11098499	0.82	rs28394116	ENSG00000260091.1	RP11-33B1.4	3.99	8.12e-05	0.0275	0.21	0.21	Corneal astigmatism;	chr4:119603128	chr4:119409333~119410233:+
STAD	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	3.99	8.12e-05	0.0275	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
STAD	cis	rs997154	0.655	rs7147394	ENSG00000257285.4	RP11-298I3.1	3.99	8.12e-05	0.0275	0.32	0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:22929609~22955562:+
STAD	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-3.99	8.12e-05	0.0275	-0.23	-0.21	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
STAD	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	3.99	8.12e-05	0.0275	0.27	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
STAD	cis	rs9987353	0.544	rs2929470	ENSG00000253893.2	FAM85B	3.99	8.12e-05	0.0275	0.28	0.21	Recombination measurement;	chr8:9204980	chr8:8167819~8226614:-
STAD	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	3.99	8.12e-05	0.0275	0.28	0.21	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
STAD	cis	rs9807989	0.839	rs4988955	ENSG00000234389.1	AC007278.3	3.99	8.12e-05	0.0275	0.22	0.21	Asthma;	chr2:102351468	chr2:102438713~102440475:+
STAD	cis	rs1790761	0.52	rs12805884	ENSG00000231793.4	DOC2GP	-3.99	8.13e-05	0.0275	-0.26	-0.21	Mean corpuscular volume;	chr11:67620506	chr11:67612653~67616257:-
STAD	cis	rs9463078	0.691	rs7760342	ENSG00000219384.1	RP11-491H9.3	3.99	8.13e-05	0.0275	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45227687	chr6:45158870~45159511:+
STAD	cis	rs2348418	0.832	rs1552761	ENSG00000247934.4	RP11-967K21.1	3.99	8.13e-05	0.0275	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28383406	chr12:28163298~28190738:-
STAD	cis	rs2380205	0.504	rs591878	ENSG00000232807.2	RP11-536K7.3	3.99	8.13e-05	0.0275	0.21	0.21	Breast cancer;	chr10:5893474	chr10:5934270~5945900:-
STAD	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-3.99	8.13e-05	0.0275	-0.45	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
STAD	cis	rs4835473	0.932	rs13129993	ENSG00000249741.2	RP11-673E1.3	3.99	8.13e-05	0.0275	0.25	0.21	Immature fraction of reticulocytes;	chr4:143763076	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1580002	ENSG00000249741.2	RP11-673E1.3	3.99	8.13e-05	0.0275	0.25	0.21	Immature fraction of reticulocytes;	chr4:143766507	chr4:143911514~143912053:-
STAD	cis	rs7142881	0.844	rs1972925	ENSG00000258648.1	UBE2CP1	-3.99	8.14e-05	0.0275	-0.24	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31566913	chr14:30683045~30683598:-
STAD	cis	rs4938330	0.739	rs11216266	ENSG00000254851.1	RP11-109L13.1	3.99	8.14e-05	0.0275	0.23	0.21	Blood protein levels;	chr11:117079434	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.748	rs7106662	ENSG00000254851.1	RP11-109L13.1	3.99	8.14e-05	0.0275	0.23	0.21	Subjective well-being;	chr11:117080669	chr11:117135528~117138582:+
STAD	cis	rs13108904	0.65	rs3796618	ENSG00000254094.1	AC078852.1	-3.99	8.14e-05	0.0275	-0.23	-0.21	Obesity-related traits;	chr4:1355814	chr4:1356581~1358075:+
STAD	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	3.99	8.14e-05	0.0275	0.28	0.21	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
STAD	cis	rs7119038	0.774	rs10892290	ENSG00000255422.1	AP002954.4	3.99	8.15e-05	0.0275	0.29	0.21	Sjögren's syndrome;	chr11:118782794	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.774	rs874621	ENSG00000255422.1	AP002954.4	3.99	8.15e-05	0.0275	0.29	0.21	Sjögren's syndrome;	chr11:118784936	chr11:118704607~118750263:+
STAD	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-3.99	8.15e-05	0.0275	-0.25	-0.21	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
STAD	cis	rs9307551	0.619	rs998437	ENSG00000250334.4	LINC00989	-3.99	8.15e-05	0.0275	-0.25	-0.21	Refractive error;	chr4:79508616	chr4:79492416~79576460:+
STAD	cis	rs9910055	0.762	rs7213436	ENSG00000260793.2	RP5-882C2.2	3.99	8.15e-05	0.0275	0.24	0.21	Total body bone mineral density;	chr17:44174795	chr17:44221401~44223710:+
STAD	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	3.99	8.15e-05	0.0275	0.21	0.21	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
STAD	cis	rs6813195	0.554	rs1516819	ENSG00000243417.1	RP11-555K12.1	-3.99	8.15e-05	0.0275	-0.21	-0.21	Type 2 diabetes;	chr4:152512299	chr4:152551277~152552364:-
STAD	cis	rs7487075	0.619	rs10785628	ENSG00000257261.4	RP11-96H19.1	3.99	8.15e-05	0.0275	0.28	0.21	Itch intensity from mosquito bite;	chr12:46460893	chr12:46383679~46876159:+
STAD	cis	rs9902453	0.78	rs62068621	ENSG00000240074.1	RPL9P30	3.99	8.15e-05	0.0276	0.18	0.21	Coffee consumption (cups per day);	chr17:29843364	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.78	rs57037139	ENSG00000240074.1	RPL9P30	3.99	8.15e-05	0.0276	0.18	0.21	Coffee consumption (cups per day);	chr17:29846265	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.817	rs55758314	ENSG00000240074.1	RPL9P30	3.99	8.15e-05	0.0276	0.18	0.21	Coffee consumption (cups per day);	chr17:29846960	chr17:29855759~29856332:+
STAD	cis	rs4713118	0.955	rs9468206	ENSG00000243307.2	POM121L6P	-3.99	8.15e-05	0.0276	-0.24	-0.21	Parkinson's disease;	chr6:27722674	chr6:26896952~26898777:+
STAD	cis	rs860295	0.651	rs12239114	ENSG00000225855.5	RUSC1-AS1	3.99	8.16e-05	0.0276	0.18	0.21	Body mass index;	chr1:155352351	chr1:155316863~155324176:-
STAD	cis	rs11089937	0.616	rs928896	ENSG00000211639.2	IGLV4-60	3.99	8.16e-05	0.0276	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22162199~22162681:+
STAD	cis	rs143626010	1	rs143626010	ENSG00000278665.1	RP11-666O2.4	3.99	8.16e-05	0.0276	0.24	0.21	Mosquito bite size;	chr16:28528081	chr16:28599241~28601881:-
STAD	cis	rs72791417	0.826	rs1670139	ENSG00000228065.9	LINC01515	-3.99	8.16e-05	0.0276	-0.37	-0.21	Bronchopulmonary dysplasia;	chr10:65948676	chr10:65570338~65768835:+
STAD	cis	rs10043228	0.702	rs12521345	ENSG00000248445.4	SEMA6A-AS1	-3.99	8.16e-05	0.0276	-0.3	-0.21	Asthma or chronic obstructive pulmonary disease;	chr5:116317162	chr5:116447547~116508276:+
STAD	cis	rs34779708	0.931	rs17591135	ENSG00000271335.4	RP11-324I22.4	3.99	8.16e-05	0.0276	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35314552~35336401:-
STAD	cis	rs46522	0.585	rs79049364	ENSG00000248278.1	SUMO2P17	3.99	8.16e-05	0.0276	0.23	0.21	Coronary heart disease;	chr17:48937629	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.811	rs80032154	ENSG00000248278.1	SUMO2P17	3.99	8.16e-05	0.0276	0.23	0.21	Type 2 diabetes;	chr17:48937630	chr17:48874860~48908983:-
STAD	cis	rs12745968	0.589	rs10747446	ENSG00000229052.2	RP11-386I23.1	-3.99	8.17e-05	0.0276	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92642845	chr1:92930696~92934098:+
STAD	cis	rs11992186	0.57	rs17628941	ENSG00000253893.2	FAM85B	3.99	8.17e-05	0.0276	0.28	0.21	Neuroticism;	chr8:8730024	chr8:8167819~8226614:-
STAD	cis	rs9902453	0.838	rs3110495	ENSG00000263477.1	RP11-338L22.2	-3.99	8.17e-05	0.0276	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29651437	chr17:29863402~29866092:+
STAD	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-3.99	8.17e-05	0.0276	-0.27	-0.21	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-3.99	8.17e-05	0.0276	-0.27	-0.21	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-3.99	8.17e-05	0.0276	-0.27	-0.21	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-3.99	8.17e-05	0.0276	-0.27	-0.21	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-3.99	8.17e-05	0.0276	-0.27	-0.21	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-3.99	8.17e-05	0.0276	-0.27	-0.21	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-3.99	8.17e-05	0.0276	-0.27	-0.21	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
STAD	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	3.99	8.17e-05	0.0276	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
STAD	cis	rs7692387	0.666	rs2306557	ENSG00000260244.1	RP11-588K22.2	3.99	8.17e-05	0.0276	0.18	0.21	Coronary artery disease;	chr4:155696842	chr4:155734448~155737062:+
STAD	cis	rs6840360	0.548	rs4254751	ENSG00000270265.1	RP11-731D1.4	-3.99	8.18e-05	0.0276	-0.25	-0.21	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151333775~151353224:-
STAD	cis	rs11157436	0.602	rs4982569	ENSG00000211812.1	TRAV26-2	-3.99	8.19e-05	0.0276	-0.21	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22202583~22203368:+
STAD	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	3.99	8.19e-05	0.0276	0.26	0.21	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.805	rs11858817	ENSG00000259295.5	CSPG4P12	3.99	8.19e-05	0.0276	0.26	0.21	Coronary artery disease;	chr15:85488029	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs28874135	ENSG00000259295.5	CSPG4P12	3.99	8.19e-05	0.0276	0.26	0.21	Coronary artery disease;	chr15:85488272	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs11633604	ENSG00000259295.5	CSPG4P12	3.99	8.19e-05	0.0276	0.26	0.21	Coronary artery disease;	chr15:85488348	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	3.99	8.19e-05	0.0276	0.26	0.21	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	3.99	8.19e-05	0.0276	0.26	0.21	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	3.99	8.19e-05	0.0276	0.26	0.21	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
STAD	cis	rs6693567	0.545	rs35705743	ENSG00000203819.6	HIST2H2BC	3.99	8.19e-05	0.0276	0.24	0.21	Migraine;	chr1:150479356	chr1:149850193~149850772:-
STAD	cis	rs1707322	1	rs4660332	ENSG00000225447.1	RPS15AP10	3.99	8.19e-05	0.0277	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45645816~45646197:-
STAD	cis	rs7160336	0.604	rs4903150	ENSG00000259065.1	RP5-1021I20.1	3.99	8.2e-05	0.0277	0.26	0.21	Blood protein levels;	chr14:73844725	chr14:73787360~73803270:+
STAD	cis	rs860295	0.665	rs11264367	ENSG00000225855.5	RUSC1-AS1	3.99	8.2e-05	0.0277	0.18	0.21	Body mass index;	chr1:155367547	chr1:155316863~155324176:-
STAD	cis	rs9297145	0.509	rs13222381	ENSG00000272950.1	RP11-307C18.1	-3.99	8.2e-05	0.0277	-0.24	-0.21	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99187401	chr7:98322853~98323430:+
STAD	cis	rs2880765	0.835	rs4842886	ENSG00000259295.5	CSPG4P12	3.99	8.2e-05	0.0277	0.26	0.21	Coronary artery disease;	chr15:85492542	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	3.99	8.2e-05	0.0277	0.26	0.21	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
STAD	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-3.99	8.2e-05	0.0277	-0.32	-0.21	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
STAD	cis	rs494453	0.6	rs474860	ENSG00000234020.1	CHIAP3	-3.99	8.21e-05	0.0277	-0.2	-0.21	Osteoporosis-related phenotypes;	chr1:111672590	chr1:111353275~111367409:-
STAD	cis	rs494453	0.6	rs565612	ENSG00000234020.1	CHIAP3	-3.99	8.21e-05	0.0277	-0.2	-0.21	Osteoporosis-related phenotypes;	chr1:111677357	chr1:111353275~111367409:-
STAD	cis	rs4835473	0.868	rs35809032	ENSG00000249741.2	RP11-673E1.3	3.99	8.21e-05	0.0277	0.24	0.21	Immature fraction of reticulocytes;	chr4:143824797	chr4:143911514~143912053:-
STAD	cis	rs7474896	0.537	rs2749588	ENSG00000120555.12	SEPT7P9	3.99	8.21e-05	0.0277	0.26	0.21	Obesity (extreme);	chr10:37980529	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.559	rs1024202	ENSG00000120555.12	SEPT7P9	-3.99	8.21e-05	0.0277	-0.26	-0.21	Obesity (extreme);	chr10:37990049	chr10:38383069~38402916:-
STAD	cis	rs7474896	0.537	rs1022449	ENSG00000120555.12	SEPT7P9	-3.99	8.21e-05	0.0277	-0.26	-0.21	Obesity (extreme);	chr10:37990539	chr10:38383069~38402916:-
STAD	cis	rs6964833	0.872	rs4717903	ENSG00000277072.3	STAG3L2	3.99	8.21e-05	0.0277	0.25	0.21	Menarche (age at onset);	chr7:74653827	chr7:74882163~74890610:-
STAD	cis	rs2262909	0.962	rs17459246	ENSG00000213976.4	CTD-2561J22.2	3.99	8.21e-05	0.0277	0.26	0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22095319	chr19:21382865~21387177:+
STAD	cis	rs6430585	0.528	rs309119	ENSG00000231890.6	DARS-AS1	-3.99	8.21e-05	0.0277	-0.23	-0.21	Corneal structure;	chr2:135952802	chr2:135985176~136022593:+
STAD	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	3.99	8.22e-05	0.0277	0.28	0.21	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
STAD	cis	rs1790761	0.692	rs1148883	ENSG00000231793.4	DOC2GP	3.99	8.22e-05	0.0277	0.25	0.21	Mean corpuscular volume;	chr11:67537215	chr11:67612653~67616257:-
STAD	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	3.99	8.22e-05	0.0277	0.27	0.21	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
STAD	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	3.99	8.22e-05	0.0277	0.24	0.21	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
STAD	cis	rs1056107	0.7	rs10981293	ENSG00000225513.1	RP11-165N19.2	-3.99	8.22e-05	0.0277	-0.25	-0.21	Colorectal cancer;	chr9:112169467	chr9:112173522~112173971:-
STAD	cis	rs4589258	0.788	rs1894136	ENSG00000280367.1	RP11-121L10.2	-3.99	8.22e-05	0.0277	-0.21	-0.21	Intelligence (multi-trait analysis);	chr11:90764851	chr11:90223153~90226538:+
STAD	cis	rs10946940	0.965	rs6456799	ENSG00000280107.1	AL022393.9	3.99	8.22e-05	0.0277	0.25	0.21	Systemic lupus erythematosus;	chr6:27605757	chr6:28170845~28172521:+
STAD	cis	rs10857712	0.521	rs10857714	ENSG00000214279.11	SCART1	-3.99	8.23e-05	0.0278	-0.22	-0.21	Systemic lupus erythematosus;	chr10:133421866	chr10:133453928~133523558:+
STAD	cis	rs8098244	0.737	rs1786046	ENSG00000267301.1	RPL23AP77	3.99	8.23e-05	0.0278	0.29	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23955801	chr18:23709825~23710287:-
STAD	cis	rs5753618	0.583	rs5749268	ENSG00000236132.1	CTA-440B3.1	-3.99	8.23e-05	0.0278	-0.24	-0.21	Colorectal cancer;	chr22:31413166	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.583	rs34545960	ENSG00000236132.1	CTA-440B3.1	-3.99	8.23e-05	0.0278	-0.24	-0.21	Colorectal cancer;	chr22:31416476	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.583	rs5749270	ENSG00000236132.1	CTA-440B3.1	-3.99	8.23e-05	0.0278	-0.24	-0.21	Colorectal cancer;	chr22:31416867	chr22:31816379~31817491:-
STAD	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-3.98	8.24e-05	0.0278	-0.25	-0.21	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
STAD	cis	rs712022	0.534	rs4550218	ENSG00000246225.5	RP11-17A1.3	-3.98	8.24e-05	0.0278	-0.27	-0.21	Dialysis-related mortality;	chr11:22842112	chr11:22829380~22945393:+
STAD	cis	rs2018683	0.933	rs12536127	ENSG00000228421.2	AC005013.5	3.98	8.24e-05	0.0278	0.25	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28957667~28959345:+
STAD	cis	rs10782582	0.593	rs2147039	ENSG00000181227.3	RP4-682C21.2	3.98	8.25e-05	0.0278	0.22	0.21	Daytime sleep phenotypes;	chr1:75677481	chr1:75743423~75744776:-
STAD	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	3.98	8.25e-05	0.0278	0.26	0.21	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
STAD	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-3.98	8.25e-05	0.0278	-0.25	-0.21	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
STAD	cis	rs1348850	0.567	rs7605609	ENSG00000271825.1	RP11-337N6.2	3.98	8.26e-05	0.0278	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177670214	chr2:177300600~177302006:+
STAD	cis	rs2075671	0.903	rs11979818	ENSG00000236305.1	RP11-126L15.4	-3.98	8.26e-05	0.0278	-0.26	-0.21	Other erythrocyte phenotypes;	chr7:100696016	chr7:100837314~100852616:-
STAD	cis	rs1876905	0.539	rs240958	ENSG00000230177.1	RP5-1112D6.4	3.98	8.26e-05	0.0278	0.23	0.21	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111277932~111278742:+
STAD	cis	rs10508774	0.852	rs28364830	ENSG00000273038.2	RP11-479G22.8	3.98	8.26e-05	0.0278	0.43	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32902342	chr10:32887255~32889311:-
STAD	cis	rs7937127	0.64	rs12792780	ENSG00000254907.1	RP11-484D2.2	3.98	8.26e-05	0.0278	0.36	0.21	Fibrinogen levels;	chr11:43505357	chr11:43328748~43359296:-
STAD	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-3.98	8.26e-05	0.0279	-0.27	-0.21	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
STAD	cis	rs7560272	0.669	rs13008860	ENSG00000163016.8	ALMS1P	3.98	8.26e-05	0.0279	0.23	0.21	Schizophrenia;	chr2:73546892	chr2:73644919~73685576:+
STAD	cis	rs7937127	0.744	rs72902723	ENSG00000254907.1	RP11-484D2.2	3.98	8.26e-05	0.0279	0.36	0.21	Fibrinogen levels;	chr11:43497105	chr11:43328748~43359296:-
STAD	cis	rs2286503	1	rs1029740	ENSG00000226329.2	AC005682.6	3.98	8.27e-05	0.0279	0.21	0.21	Fibrinogen;	chr7:22833967	chr7:22863874~22881350:-
STAD	cis	rs2836974	0.666	rs12626405	ENSG00000238141.2	BRWD1-AS1	-3.98	8.27e-05	0.0279	-0.22	-0.21	Cognitive function;	chr21:39291195	chr21:39315707~39323218:+
STAD	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	3.98	8.27e-05	0.0279	0.25	0.21	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
STAD	cis	rs2430307	0.556	rs3905501	ENSG00000205482.8	AC007000.12	3.98	8.27e-05	0.0279	0.22	0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76912763	chr7:77052785~77059440:-
STAD	cis	rs10073892	1	rs10074257	ENSG00000250682.4	LINC00491	-3.98	8.27e-05	0.0279	-0.23	-0.21	Cognitive decline (age-related);	chr5:102361759	chr5:102609156~102671559:-
STAD	cis	rs13077017	0.736	rs2177153	ENSG00000272182.1	RP11-802O23.3	3.98	8.27e-05	0.0279	0.22	0.21	Eating disorders (purging via substances);	chr3:58106619	chr3:58428255~58428815:+
STAD	cis	rs679711	0.634	rs1164206	ENSG00000214380.4	RP11-457K10.2	3.98	8.27e-05	0.0279	0.24	0.21	Sleep depth;	chr3:109905580	chr3:109915976~109916940:-
STAD	cis	rs2337406	0.778	rs56965016	ENSG00000211970.3	IGHV4-61	3.98	8.28e-05	0.0279	0.24	0.21	Alzheimer's disease (late onset);	chr14:106656649	chr14:106639119~106639657:-
STAD	cis	rs2337406	0.778	rs56658355	ENSG00000211970.3	IGHV4-61	3.98	8.28e-05	0.0279	0.24	0.21	Alzheimer's disease (late onset);	chr14:106662151	chr14:106639119~106639657:-
STAD	cis	rs6772849	0.93	rs9813197	ENSG00000242551.2	POU5F1P6	-3.98	8.28e-05	0.0279	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128674735~128677005:-
STAD	cis	rs34779708	0.931	rs34375045	ENSG00000271335.4	RP11-324I22.4	3.98	8.28e-05	0.0279	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35314552~35336401:-
STAD	cis	rs11180559	0.534	rs11180591	ENSG00000257497.2	RP11-585P4.5	3.98	8.28e-05	0.0279	0.38	0.21	Daytime sleep phenotypes;	chr12:75601959	chr12:75483454~75489820:-
STAD	cis	rs13043901	0.539	rs6097480	ENSG00000197670.6	RP4-724E16.2	-3.98	8.28e-05	0.0279	-0.23	-0.21	Type 2 diabetes (age of onset);	chr20:53560021	chr20:53552770~53575863:+
STAD	cis	rs4388249	0.904	rs12656073	ENSG00000271849.1	CTC-332L22.1	-3.98	8.28e-05	0.0279	-0.3	-0.21	Schizophrenia;	chr5:109864852	chr5:109687802~109688329:-
STAD	cis	rs7202877	0.706	rs37602	ENSG00000261783.1	RP11-252K23.2	3.98	8.29e-05	0.0279	0.33	0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75471148	chr16:75379818~75381260:-
STAD	cis	rs14027	0.883	rs16893025	ENSG00000279347.1	RP11-85I17.2	-3.98	8.29e-05	0.0279	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119838736~119840385:-
STAD	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	3.98	8.29e-05	0.0279	0.31	0.21	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
STAD	cis	rs62400317	0.762	rs10948176	ENSG00000219384.1	RP11-491H9.3	-3.98	8.29e-05	0.0279	-0.24	-0.21	Total body bone mineral density;	chr6:44866176	chr6:45158870~45159511:+
STAD	cis	rs867371	1	rs7173339	ENSG00000276710.3	CSPG4P8	-3.98	8.29e-05	0.0279	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82459472~82477258:+
STAD	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-3.98	8.29e-05	0.0279	-0.25	-0.21	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
STAD	cis	rs7487075	0.897	rs2897968	ENSG00000257261.4	RP11-96H19.1	3.98	8.29e-05	0.0279	0.27	0.21	Itch intensity from mosquito bite;	chr12:46369903	chr12:46383679~46876159:+
STAD	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	3.98	8.29e-05	0.0279	0.25	0.21	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	3.98	8.29e-05	0.0279	0.25	0.21	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	3.98	8.29e-05	0.0279	0.25	0.21	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
STAD	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	3.98	8.29e-05	0.0279	0.25	0.21	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
STAD	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	3.98	8.29e-05	0.0279	0.21	0.21	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	3.98	8.29e-05	0.0279	0.21	0.21	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
STAD	cis	rs34779708	0.966	rs4934540	ENSG00000271335.4	RP11-324I22.4	3.98	8.3e-05	0.0279	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35314552~35336401:-
STAD	cis	rs6072091	0.855	rs6029252	ENSG00000273951.1	RP4-620E11.8	3.98	8.3e-05	0.0279	0.25	0.21	Nose morphology;	chr20:40649618	chr20:41485571~41486225:-
STAD	cis	rs9902453	0.845	rs12602426	ENSG00000263477.1	RP11-338L22.2	3.98	8.3e-05	0.0279	0.18	0.21	Coffee consumption (cups per day);	chr17:29831797	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.817	rs62068620	ENSG00000263477.1	RP11-338L22.2	3.98	8.3e-05	0.0279	0.18	0.21	Coffee consumption (cups per day);	chr17:29840656	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.808	rs76515799	ENSG00000263477.1	RP11-338L22.2	3.98	8.3e-05	0.0279	0.18	0.21	Coffee consumption (cups per day);	chr17:29842473	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.808	rs78154346	ENSG00000263477.1	RP11-338L22.2	3.98	8.3e-05	0.0279	0.18	0.21	Coffee consumption (cups per day);	chr17:29842475	chr17:29863402~29866092:+
STAD	cis	rs3743162	1	rs12917429	ENSG00000259728.4	LINC00933	-3.98	8.3e-05	0.028	-0.29	-0.21	Alzheimer's disease (age of onset);	chr15:84881866	chr15:84570649~84580175:+
STAD	cis	rs12745968	0.589	rs6697491	ENSG00000229052.2	RP11-386I23.1	-3.98	8.3e-05	0.028	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92567157	chr1:92930696~92934098:+
STAD	cis	rs4648045	0.796	rs3817685	ENSG00000230069.3	LRRC37A15P	-3.98	8.3e-05	0.028	-0.24	-0.21	Lymphocyte percentage of white cells;	chr4:102613403	chr4:102727274~102730721:-
STAD	cis	rs832187	0.704	rs3774720	ENSG00000280620.1	SCAANT1	3.98	8.3e-05	0.028	0.28	0.21	Schizophrenia;	chr3:63966089	chr3:63911518~63911772:-
STAD	cis	rs12682352	0.535	rs12677550	ENSG00000173295.6	FAM86B3P	-3.98	8.3e-05	0.028	-0.24	-0.21	Neuroticism;	chr8:8786812	chr8:8228595~8244865:+
STAD	cis	rs6686842	0.56	rs213758	ENSG00000235358.1	RP11-399E6.1	3.98	8.3e-05	0.028	0.23	0.21	Height;	chr1:41128452	chr1:41242373~41284861:+
STAD	cis	rs10129255	0.719	rs7156660	ENSG00000232216.1	IGHV3-43	3.98	8.3e-05	0.028	0.21	0.21	Kawasaki disease;	chr14:106673171	chr14:106470264~106470800:-
STAD	cis	rs2286503	0.78	rs2286506	ENSG00000221740.1	SNORD93	3.98	8.31e-05	0.028	0.24	0.21	Fibrinogen;	chr7:22815196	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.752	rs2286504	ENSG00000221740.1	SNORD93	3.98	8.31e-05	0.028	0.24	0.21	Fibrinogen;	chr7:22815228	chr7:22856613~22856686:+
STAD	cis	rs17818399	0.51	rs1451153	ENSG00000279254.1	RP11-536C12.1	-3.98	8.31e-05	0.028	-0.22	-0.21	Height;	chr2:46572713	chr2:46668870~46670778:+
STAD	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-3.98	8.31e-05	0.028	-0.24	-0.21	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
STAD	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	3.98	8.31e-05	0.028	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
STAD	cis	rs935334	1	rs1900125	ENSG00000258454.1	RP11-361H10.3	-3.98	8.31e-05	0.028	-0.3	-0.21	Blood pressure;	chr14:76191127	chr14:76235817~76263474:+
STAD	cis	rs2638953	0.925	rs11049520	ENSG00000247934.4	RP11-967K21.1	-3.98	8.31e-05	0.028	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310656	chr12:28163298~28190738:-
STAD	cis	rs6479891	1	rs9414793	ENSG00000235816.3	PRELID1P3	-3.98	8.32e-05	0.028	-0.27	-0.21	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63427297~63427939:+
STAD	cis	rs3858145	0.505	rs12765827	ENSG00000234102.1	KRT19P4	3.98	8.32e-05	0.028	0.25	0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68286821	chr10:68260557~68261499:+
STAD	cis	rs1850744	0.826	rs114657516	ENSG00000250942.1	ENPP7P11	-3.98	8.32e-05	0.028	-0.36	-0.21	Economic and political preferences;	chr4:9592233	chr4:9677308~9677934:+
STAD	cis	rs935334	1	rs8006048	ENSG00000258454.1	RP11-361H10.3	3.98	8.32e-05	0.028	0.31	0.21	Blood pressure;	chr14:76217165	chr14:76235817~76263474:+
STAD	cis	rs2278796	0.639	rs6661192	ENSG00000231691.1	RP11-203F10.5	-3.98	8.32e-05	0.028	-0.26	-0.21	Mean platelet volume;	chr1:205002285	chr1:204277005~204277948:+
STAD	cis	rs77988765	0.908	rs57900749	ENSG00000248844.5	RP11-626H12.3	-3.98	8.32e-05	0.028	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70170239	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.615	rs58254931	ENSG00000248844.5	RP11-626H12.3	-3.98	8.32e-05	0.028	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70171576	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.808	rs60365608	ENSG00000248844.5	RP11-626H12.3	-3.98	8.32e-05	0.028	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70172834	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs59821151	ENSG00000248844.5	RP11-626H12.3	-3.98	8.32e-05	0.028	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70173926	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs60705208	ENSG00000248844.5	RP11-626H12.3	-3.98	8.32e-05	0.028	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70173933	chr11:70056230~70065371:-
STAD	cis	rs4293777	0.904	rs6852722	ENSG00000250896.1	RNPS1P1	3.98	8.32e-05	0.028	0.16	0.21	Primary sclerosing cholangitis;	chr4:10723269	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.935	rs6829409	ENSG00000250896.1	RNPS1P1	3.98	8.32e-05	0.028	0.16	0.21	Primary sclerosing cholangitis;	chr4:10723429	chr4:11371975~11372892:+
STAD	cis	rs2786865	0.708	rs2786872	ENSG00000270733.1	RP11-231P20.5	3.98	8.32e-05	0.028	0.32	0.21	Facial morphology (factor 11, projection of the nose);	chr1:25712718	chr1:26263041~26263398:-
STAD	cis	rs1707322	0.721	rs12069121	ENSG00000281133.1	AL355480.3	-3.98	8.32e-05	0.028	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45580892~45580996:-
STAD	cis	rs6693567	0.545	rs7553647	ENSG00000203819.6	HIST2H2BC	3.98	8.32e-05	0.028	0.24	0.21	Migraine;	chr1:150500190	chr1:149850193~149850772:-
STAD	cis	rs3947	0.951	rs1692813	ENSG00000227888.4	FAM66A	-3.98	8.32e-05	0.028	-0.28	-0.21	Blood protein levels;	chr8:11846787	chr8:12362019~12388296:+
STAD	cis	rs3947	0.951	rs1692814	ENSG00000227888.4	FAM66A	-3.98	8.32e-05	0.028	-0.28	-0.21	Blood protein levels;	chr8:11846789	chr8:12362019~12388296:+
STAD	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	3.98	8.32e-05	0.028	0.48	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
STAD	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-3.98	8.32e-05	0.028	-0.23	-0.21	Height;	chr2:231551270	chr2:231508426~231514339:-
STAD	cis	rs9813712	0.595	rs1453240	ENSG00000253540.4	FAM86HP	-3.98	8.32e-05	0.028	-0.24	-0.21	Response to amphetamines;	chr3:130282849	chr3:130099092~130111472:-
STAD	cis	rs6072091	0.855	rs735031	ENSG00000273951.1	RP4-620E11.8	3.98	8.32e-05	0.028	0.25	0.21	Nose morphology;	chr20:40649002	chr20:41485571~41486225:-
STAD	cis	rs7204230	0.921	rs1080313	ENSG00000261291.1	RP11-295M3.2	3.98	8.32e-05	0.028	0.24	0.21	Fibrinogen;	chr16:53140954	chr16:53168522~53169450:+
STAD	cis	rs875971	0.83	rs6950137	ENSG00000224316.1	RP11-479O9.2	3.98	8.33e-05	0.028	0.2	0.21	Aortic root size;	chr7:66511623	chr7:65773620~65802067:+
STAD	cis	rs6940638	0.615	rs9393801	ENSG00000216901.1	AL022393.7	3.98	8.33e-05	0.028	0.2	0.21	Intelligence (multi-trait analysis);	chr6:27274902	chr6:28176188~28176674:+
STAD	cis	rs7156960	1	rs12590520	ENSG00000258454.1	RP11-361H10.3	-3.98	8.33e-05	0.028	-0.22	-0.21	Acute lymphoblastic leukemia (childhood);	chr14:76249591	chr14:76235817~76263474:+
STAD	cis	rs1348850	0.519	rs13034781	ENSG00000271825.1	RP11-337N6.2	3.98	8.33e-05	0.028	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658822	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.519	rs1527407	ENSG00000271825.1	RP11-337N6.2	3.98	8.33e-05	0.028	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660902	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.519	rs1527406	ENSG00000271825.1	RP11-337N6.2	3.98	8.33e-05	0.028	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660927	chr2:177300600~177302006:+
STAD	cis	rs9326248	0.52	rs7127881	ENSG00000280143.1	AP000892.6	3.98	8.33e-05	0.028	0.17	0.21	Blood protein levels;	chr11:117010082	chr11:117204967~117210292:+
STAD	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-3.98	8.33e-05	0.028	-0.26	-0.21	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
STAD	cis	rs1336472	0.509	rs4916031	ENSG00000234496.2	MRPS21P1	3.98	8.34e-05	0.0281	0.24	0.21	Venous thromboembolism (SNP x SNP interaction);	chr1:65215860	chr1:65092392~65092614:-
STAD	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	3.98	8.34e-05	0.0281	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
STAD	cis	rs2748331	0.645	rs62404005	ENSG00000218350.1	LYPLA1P3	-3.98	8.34e-05	0.0281	-0.23	-0.21	Venous thromboembolism;	chr6:70997672	chr6:71165076~71165770:+
STAD	cis	rs11089937	0.597	rs4821772	ENSG00000211638.2	IGLV8-61	3.98	8.34e-05	0.0281	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22098700~22099212:+
STAD	cis	rs4713118	0.628	rs9295740	ENSG00000243307.2	POM121L6P	-3.98	8.34e-05	0.0281	-0.26	-0.21	Parkinson's disease;	chr6:27721723	chr6:26896952~26898777:+
STAD	cis	rs9926296	0.744	rs460879	ENSG00000261373.1	VPS9D1-AS1	3.98	8.34e-05	0.0281	0.22	0.21	Vitiligo;	chr16:89646481	chr16:89711856~89718165:+
STAD	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	3.98	8.34e-05	0.0281	0.24	0.21	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
STAD	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-3.98	8.35e-05	0.0281	-0.27	-0.21	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
STAD	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-3.98	8.35e-05	0.0281	-0.27	-0.21	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
STAD	cis	rs9902453	0.726	rs4795523	ENSG00000263477.1	RP11-338L22.2	3.98	8.35e-05	0.0281	0.18	0.21	Coffee consumption (cups per day);	chr17:29849296	chr17:29863402~29866092:+
STAD	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	3.98	8.35e-05	0.0281	0.24	0.21	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
STAD	cis	rs12554020	0.579	rs76025942	ENSG00000227603.1	RP11-165J3.6	3.98	8.35e-05	0.0281	0.46	0.21	Schizophrenia;	chr9:93605618	chr9:93435332~93437121:-
STAD	cis	rs10429558	0.609	rs76290025	ENSG00000227603.1	RP11-165J3.6	3.98	8.35e-05	0.0281	0.46	0.21	Neuroticism;	chr9:93608100	chr9:93435332~93437121:-
STAD	cis	rs950169	0.922	rs4842941	ENSG00000235370.6	DNM1P51	-3.98	8.35e-05	0.0281	-0.26	-0.21	Schizophrenia;	chr15:84162560	chr15:84398316~84411701:-
STAD	cis	rs950169	0.922	rs12911223	ENSG00000235370.6	DNM1P51	-3.98	8.35e-05	0.0281	-0.26	-0.21	Schizophrenia;	chr15:84162919	chr15:84398316~84411701:-
STAD	cis	rs950169	0.845	rs4106951	ENSG00000235370.6	DNM1P51	3.98	8.35e-05	0.0281	0.26	0.21	Schizophrenia;	chr15:84164642	chr15:84398316~84411701:-
STAD	cis	rs875971	0.798	rs6460304	ENSG00000224316.1	RP11-479O9.2	3.98	8.35e-05	0.0281	0.2	0.21	Aortic root size;	chr7:66499741	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6945775	ENSG00000224316.1	RP11-479O9.2	3.98	8.35e-05	0.0281	0.2	0.21	Aortic root size;	chr7:66503987	chr7:65773620~65802067:+
STAD	cis	rs875971	0.798	rs57739047	ENSG00000224316.1	RP11-479O9.2	3.98	8.35e-05	0.0281	0.2	0.21	Aortic root size;	chr7:66507579	chr7:65773620~65802067:+
STAD	cis	rs2348418	0.868	rs12302861	ENSG00000247934.4	RP11-967K21.1	3.98	8.35e-05	0.0281	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28516269	chr12:28163298~28190738:-
STAD	cis	rs34779708	0.966	rs2045915	ENSG00000271335.4	RP11-324I22.4	3.98	8.35e-05	0.0281	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35314552~35336401:-
STAD	cis	rs35955747	0.722	rs5997898	ENSG00000236132.1	CTA-440B3.1	3.98	8.36e-05	0.0281	0.2	0.21	Neutrophil count;Sum basophil neutrophil counts;	chr22:31176977	chr22:31816379~31817491:-
STAD	cis	rs9307551	0.584	rs13118848	ENSG00000250334.4	LINC00989	-3.98	8.36e-05	0.0281	-0.25	-0.21	Refractive error;	chr4:79525215	chr4:79492416~79576460:+
STAD	cis	rs1075265	0.722	rs7596349	ENSG00000235937.1	AC008280.1	3.98	8.36e-05	0.0281	0.19	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54029552~54030682:-
STAD	cis	rs7142881	0.815	rs6571435	ENSG00000258648.1	UBE2CP1	3.98	8.37e-05	0.0281	0.23	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31567212	chr14:30683045~30683598:-
STAD	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	3.98	8.37e-05	0.0281	0.23	0.21	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
STAD	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	3.98	8.37e-05	0.0281	0.3	0.21	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
STAD	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-3.98	8.37e-05	0.0281	-0.28	-0.21	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
STAD	cis	rs9902453	1	rs4465650	ENSG00000240074.1	RPL9P30	3.98	8.37e-05	0.0281	0.18	0.21	Coffee consumption (cups per day);	chr17:30069703	chr17:29855759~29856332:+
STAD	cis	rs10851478	0.872	rs28819483	ENSG00000259545.2	RP11-325E5.4	-3.98	8.37e-05	0.0281	-0.26	-0.21	Oral cavity cancer;	chr15:49700665	chr15:49177610~49178741:-
STAD	cis	rs2018683	0.899	rs10269454	ENSG00000228421.2	AC005013.5	3.98	8.37e-05	0.0281	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28957667~28959345:+
STAD	cis	rs9987353	0.83	rs7010108	ENSG00000254340.1	RP11-10A14.3	-3.98	8.37e-05	0.0282	-0.31	-0.21	Recombination measurement;	chr8:9273164	chr8:9141424~9145435:+
STAD	cis	rs10851478	0.872	rs55904469	ENSG00000259545.2	RP11-325E5.4	-3.98	8.37e-05	0.0282	-0.25	-0.21	Oral cavity cancer;	chr15:49497774	chr15:49177610~49178741:-
STAD	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-3.98	8.38e-05	0.0282	-0.22	-0.21	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
STAD	cis	rs6840258	0.891	rs3755983	ENSG00000248180.1	GAPDHP60	3.98	8.38e-05	0.0282	0.16	0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87116640	chr4:87207092~87208086:+
STAD	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	3.98	8.38e-05	0.0282	0.21	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
STAD	cis	rs11673344	0.504	rs10403728	ENSG00000267672.1	CTD-2293H3.1	3.98	8.38e-05	0.0282	0.19	0.21	Obesity-related traits;	chr19:37091569	chr19:37091341~37092564:+
STAD	cis	rs1704198	0.789	rs2664683	ENSG00000274895.1	RP11-478J18.2	-3.98	8.38e-05	0.0282	-0.27	-0.21	Obesity;	chr1:213747016	chr1:213983793~213986419:-
STAD	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	3.98	8.39e-05	0.0282	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
STAD	cis	rs10782582	0.593	rs12132750	ENSG00000181227.3	RP4-682C21.2	3.98	8.39e-05	0.0282	0.22	0.21	Daytime sleep phenotypes;	chr1:75670537	chr1:75743423~75744776:-
STAD	cis	rs10782582	0.532	rs12132503	ENSG00000181227.3	RP4-682C21.2	3.98	8.39e-05	0.0282	0.22	0.21	Daytime sleep phenotypes;	chr1:75672077	chr1:75743423~75744776:-
STAD	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	3.98	8.39e-05	0.0282	0.21	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
STAD	cis	rs7202877	0.656	rs3851736	ENSG00000261783.1	RP11-252K23.2	-3.98	8.39e-05	0.0282	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75353434	chr16:75379818~75381260:-
STAD	cis	rs7202877	0.572	rs8051611	ENSG00000261783.1	RP11-252K23.2	-3.98	8.39e-05	0.0282	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75355035	chr16:75379818~75381260:-
STAD	cis	rs749052	0.731	rs2342292	ENSG00000251485.1	AC068134.10	-3.98	8.4e-05	0.0282	-0.51	-0.21	Height;	chr2:232055855	chr2:232343116~232343903:+
STAD	cis	rs9902453	0.817	rs62068625	ENSG00000240074.1	RPL9P30	3.98	8.4e-05	0.0282	0.18	0.21	Coffee consumption (cups per day);	chr17:29849563	chr17:29855759~29856332:+
STAD	cis	rs17708984	0.606	rs3826722	ENSG00000264250.2	RN7SL835P	3.98	8.4e-05	0.0282	0.18	0.21	Platelet distribution width;Platelet count;	chr19:16082088	chr19:16907462~16907723:+
STAD	cis	rs1707322	0.686	rs2991986	ENSG00000225447.1	RPS15AP10	-3.98	8.4e-05	0.0282	-0.17	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45645816~45646197:-
STAD	cis	rs11089937	0.616	rs5757258	ENSG00000211639.2	IGLV4-60	3.98	8.4e-05	0.0282	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22179648	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.522	rs5757259	ENSG00000211639.2	IGLV4-60	3.98	8.4e-05	0.0282	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22179649	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.616	rs12484472	ENSG00000211639.2	IGLV4-60	3.98	8.4e-05	0.0282	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22180136	chr22:22162199~22162681:+
STAD	cis	rs9902453	0.845	rs3115101	ENSG00000263477.1	RP11-338L22.2	3.98	8.4e-05	0.0282	0.18	0.21	Coffee consumption (cups per day);	chr17:29714609	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.845	rs3102556	ENSG00000263477.1	RP11-338L22.2	3.98	8.4e-05	0.0282	0.18	0.21	Coffee consumption (cups per day);	chr17:29715524	chr17:29863402~29866092:+
STAD	cis	rs875971	0.862	rs11763189	ENSG00000224316.1	RP11-479O9.2	3.98	8.4e-05	0.0282	0.2	0.21	Aortic root size;	chr7:66518542	chr7:65773620~65802067:+
STAD	cis	rs2834188	0.889	rs2040108	ENSG00000272659.1	AP000295.10	-3.98	8.4e-05	0.0282	-0.29	-0.21	Narcolepsy;	chr21:33303853	chr21:33309491~33310181:+
STAD	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-3.98	8.4e-05	0.0282	-0.28	-0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
STAD	cis	rs1075265	0.783	rs805450	ENSG00000235937.1	AC008280.1	3.98	8.41e-05	0.0282	0.19	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54029552~54030682:-
STAD	cis	rs875971	0.793	rs460678	ENSG00000224316.1	RP11-479O9.2	3.98	8.41e-05	0.0282	0.21	0.21	Aortic root size;	chr7:66062213	chr7:65773620~65802067:+
STAD	cis	rs10129255	0.5	rs12101190	ENSG00000232216.1	IGHV3-43	3.98	8.41e-05	0.0282	0.19	0.21	Kawasaki disease;	chr14:106784149	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.518	rs8004895	ENSG00000232216.1	IGHV3-43	3.98	8.41e-05	0.0282	0.19	0.21	Kawasaki disease;	chr14:106785139	chr14:106470264~106470800:-
STAD	cis	rs1348850	0.914	rs10170546	ENSG00000271825.1	RP11-337N6.2	3.98	8.41e-05	0.0282	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177384062	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.914	rs7591807	ENSG00000271825.1	RP11-337N6.2	3.98	8.41e-05	0.0282	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177388258	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.914	rs12104588	ENSG00000271825.1	RP11-337N6.2	3.98	8.41e-05	0.0282	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177388947	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.914	rs3813259	ENSG00000271825.1	RP11-337N6.2	3.98	8.41e-05	0.0282	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177392486	chr2:177300600~177302006:+
STAD	cis	rs6142102	0.886	rs6059583	ENSG00000264616.1	MIR4755	3.98	8.41e-05	0.0283	0.22	0.21	Skin pigmentation;	chr20:33944308	chr20:34049119~34049190:+
STAD	cis	rs1707322	0.686	rs61784833	ENSG00000281133.1	AL355480.3	-3.98	8.41e-05	0.0283	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45580892~45580996:-
STAD	cis	rs1707322	0.721	rs7519900	ENSG00000281133.1	AL355480.3	-3.98	8.41e-05	0.0283	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45580892~45580996:-
STAD	cis	rs2487032	0.573	rs2164560	ENSG00000226334.1	RP11-217B7.2	-3.98	8.41e-05	0.0283	-0.24	-0.21	Glaucoma (high intraocular pressure);	chr9:104945072	chr9:104927553~104928892:+
STAD	cis	rs765787	0.53	rs2668751	ENSG00000259539.1	CTD-2651B20.1	3.98	8.41e-05	0.0283	0.24	0.21	Uric acid levels;	chr15:45225095	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs1648286	ENSG00000259539.1	CTD-2651B20.1	3.98	8.41e-05	0.0283	0.24	0.21	Uric acid levels;	chr15:45225188	chr15:45152664~45167526:-
STAD	cis	rs3770081	1	rs12624126	ENSG00000273080.1	RP11-301O19.1	-3.98	8.41e-05	0.0283	-0.54	-0.21	Facial emotion recognition (sad faces);	chr2:86115243	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs12621992	ENSG00000273080.1	RP11-301O19.1	-3.98	8.41e-05	0.0283	-0.54	-0.21	Facial emotion recognition (sad faces);	chr2:86118226	chr2:86195590~86196049:+
STAD	cis	rs3770081	1	rs75038217	ENSG00000273080.1	RP11-301O19.1	-3.98	8.41e-05	0.0283	-0.54	-0.21	Facial emotion recognition (sad faces);	chr2:86120902	chr2:86195590~86196049:+
STAD	cis	rs10986311	0.851	rs7853472	ENSG00000227200.1	RP11-121A14.3	-3.98	8.42e-05	0.0283	-0.22	-0.21	Vitiligo;	chr9:124274388	chr9:124262876~124265809:+
STAD	cis	rs6772849	0.768	rs9820741	ENSG00000242551.2	POU5F1P6	-3.98	8.42e-05	0.0283	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128674735~128677005:-
STAD	cis	rs792448	0.743	rs10019	ENSG00000212044.2	AL360091.1	3.98	8.42e-05	0.0283	0.22	0.21	White blood cell count (basophil);	chr1:212361035	chr1:212349978~212350069:+
STAD	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	3.98	8.42e-05	0.0283	0.37	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
STAD	cis	rs2283792	0.765	rs5999749	ENSG00000211660.3	IGLV2-23	3.98	8.42e-05	0.0283	0.16	0.21	Multiple sclerosis;	chr22:21833371	chr22:22697789~22698407:+
STAD	cis	rs2836974	0.666	rs1888487	ENSG00000238141.2	BRWD1-AS1	-3.98	8.42e-05	0.0283	-0.22	-0.21	Cognitive function;	chr21:39311333	chr21:39315707~39323218:+
STAD	cis	rs7702057	0.53	rs56953556	ENSG00000271918.1	CTD-2287O16.5	3.98	8.42e-05	0.0283	0.37	0.21	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116083807~116085416:-
STAD	cis	rs2098713	0.599	rs12652658	ENSG00000250155.1	CTD-2353F22.1	3.98	8.42e-05	0.0283	0.21	0.21	Telomere length;	chr5:37555461	chr5:36666214~36725195:-
STAD	cis	rs8098244	0.737	rs1258131	ENSG00000267301.1	RPL23AP77	3.98	8.42e-05	0.0283	0.28	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959755	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.737	rs948432	ENSG00000267301.1	RPL23AP77	3.98	8.42e-05	0.0283	0.28	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959998	chr18:23709825~23710287:-
STAD	cis	rs860295	0.665	rs12028416	ENSG00000225855.5	RUSC1-AS1	3.98	8.42e-05	0.0283	0.18	0.21	Body mass index;	chr1:155431370	chr1:155316863~155324176:-
STAD	cis	rs860295	0.629	rs12026638	ENSG00000225855.5	RUSC1-AS1	3.98	8.42e-05	0.0283	0.18	0.21	Body mass index;	chr1:155431469	chr1:155316863~155324176:-
STAD	cis	rs9910055	0.664	rs433610	ENSG00000260793.2	RP5-882C2.2	3.98	8.42e-05	0.0283	0.24	0.21	Total body bone mineral density;	chr17:44119913	chr17:44221401~44223710:+
STAD	cis	rs867371	1	rs1174543	ENSG00000276710.3	CSPG4P8	3.98	8.42e-05	0.0283	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82459472~82477258:+
STAD	cis	rs867371	1	rs9944197	ENSG00000276710.3	CSPG4P8	-3.98	8.42e-05	0.0283	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82459472~82477258:+
STAD	cis	rs867371	1	rs7181655	ENSG00000278603.1	RP13-608F4.5	3.98	8.42e-05	0.0283	0.25	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs7180584	ENSG00000278603.1	RP13-608F4.5	3.98	8.42e-05	0.0283	0.25	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472203~82472426:+
STAD	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-3.98	8.42e-05	0.0283	-0.22	-0.21	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
STAD	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-3.98	8.43e-05	0.0283	-0.28	-0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
STAD	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	3.98	8.43e-05	0.0283	0.28	0.21	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
STAD	cis	rs2018683	0.803	rs12700920	ENSG00000228421.2	AC005013.5	3.98	8.43e-05	0.0283	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28957667~28959345:+
STAD	cis	rs4538475	1	rs4538475	ENSG00000214846.4	RP11-115L11.1	3.98	8.43e-05	0.0283	0.3	0.21	Parkinson's disease;	chr4:15736314	chr4:15730962~15731627:-
STAD	cis	rs6840360	0.582	rs59714108	ENSG00000270265.1	RP11-731D1.4	-3.98	8.43e-05	0.0283	-0.25	-0.21	Intelligence (multi-trait analysis);	chr4:151404787	chr4:151333775~151353224:-
STAD	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	3.98	8.43e-05	0.0283	0.24	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
STAD	cis	rs4407350	0.655	rs135623	ENSG00000279642.1	RP5-1033E15.3	-3.98	8.43e-05	0.0283	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44494792	chr22:44486295~44486914:-
STAD	cis	rs733592	0.524	rs10875741	ENSG00000226413.2	OR8T1P	-3.98	8.44e-05	0.0283	-0.23	-0.21	Plateletcrit;	chr12:48099139	chr12:48442030~48442947:-
STAD	cis	rs733592	0.507	rs7304428	ENSG00000226413.2	OR8T1P	-3.98	8.44e-05	0.0283	-0.23	-0.21	Plateletcrit;	chr12:48100492	chr12:48442030~48442947:-
STAD	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	3.98	8.44e-05	0.0283	0.44	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
STAD	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	3.98	8.44e-05	0.0283	0.29	0.21	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	3.98	8.44e-05	0.0283	0.29	0.21	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	3.98	8.44e-05	0.0283	0.29	0.21	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
STAD	cis	rs539514	0.664	rs560069	ENSG00000261105.4	LMO7-AS1	-3.98	8.44e-05	0.0283	-0.25	-0.21	Type 1 diabetes;	chr13:75735208	chr13:75604700~75635994:-
STAD	cis	rs77988765	0.908	rs112130213	ENSG00000248844.5	RP11-626H12.3	-3.98	8.44e-05	0.0283	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70168426	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs59331567	ENSG00000248844.5	RP11-626H12.3	-3.98	8.44e-05	0.0283	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70169382	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs59976074	ENSG00000248844.5	RP11-626H12.3	-3.98	8.44e-05	0.0283	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70169418	chr11:70056230~70065371:-
STAD	cis	rs77988765	0.908	rs56751551	ENSG00000248844.5	RP11-626H12.3	-3.98	8.44e-05	0.0283	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70169845	chr11:70056230~70065371:-
STAD	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	3.98	8.44e-05	0.0283	0.29	0.21	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
STAD	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	3.98	8.45e-05	0.0283	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
STAD	cis	rs2446066	0.659	rs2272002	ENSG00000257379.1	RP11-793H13.8	3.98	8.45e-05	0.0283	0.42	0.21	Red blood cell count;	chr12:53424132	chr12:53441741~53467528:+
STAD	cis	rs2337406	0.85	rs10131280	ENSG00000211970.3	IGHV4-61	3.98	8.45e-05	0.0283	0.24	0.21	Alzheimer's disease (late onset);	chr14:106665591	chr14:106639119~106639657:-
STAD	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	3.98	8.45e-05	0.0284	0.22	0.21	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
STAD	cis	rs6693567	0.545	rs1694380	ENSG00000203819.6	HIST2H2BC	3.98	8.45e-05	0.0284	0.25	0.21	Migraine;	chr1:150319893	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.565	rs1776276	ENSG00000203819.6	HIST2H2BC	3.98	8.45e-05	0.0284	0.25	0.21	Migraine;	chr1:150320630	chr1:149850193~149850772:-
STAD	cis	rs11667325	0.656	rs10423494	ENSG00000268316.1	AC006272.2	-3.98	8.45e-05	0.0284	-0.29	-0.21	Neutrophil percentage of granulocytes;	chr19:51796100	chr19:51839771~51840945:-
STAD	cis	rs7142881	0.815	rs34747628	ENSG00000258648.1	UBE2CP1	-3.98	8.45e-05	0.0284	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31668502	chr14:30683045~30683598:-
STAD	cis	rs34779708	0.733	rs7087099	ENSG00000271335.4	RP11-324I22.4	3.98	8.45e-05	0.0284	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35314552~35336401:-
STAD	cis	rs7474896	1	rs2799505	ENSG00000099251.13	HSD17B7P2	-3.98	8.45e-05	0.0284	-0.35	-0.21	Obesity (extreme);	chr10:37934086	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs1007133	ENSG00000099251.13	HSD17B7P2	-3.98	8.45e-05	0.0284	-0.35	-0.21	Obesity (extreme);	chr10:37936365	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.945	rs2799506	ENSG00000099251.13	HSD17B7P2	-3.98	8.45e-05	0.0284	-0.35	-0.21	Obesity (extreme);	chr10:37936431	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2799507	ENSG00000099251.13	HSD17B7P2	-3.98	8.45e-05	0.0284	-0.35	-0.21	Obesity (extreme);	chr10:37938136	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.945	rs2092993	ENSG00000099251.13	HSD17B7P2	-3.98	8.45e-05	0.0284	-0.35	-0.21	Obesity (extreme);	chr10:37939207	chr10:38356380~38378505:+
STAD	cis	rs6142102	0.961	rs6087557	ENSG00000264616.1	MIR4755	3.98	8.45e-05	0.0284	0.22	0.21	Skin pigmentation;	chr20:34110469	chr20:34049119~34049190:+
STAD	cis	rs2836950	0.565	rs2836934	ENSG00000238141.2	BRWD1-AS1	-3.98	8.46e-05	0.0284	-0.22	-0.21	Menarche (age at onset);	chr21:39192959	chr21:39315707~39323218:+
STAD	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-3.98	8.46e-05	0.0284	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
STAD	cis	rs4713118	0.869	rs10214440	ENSG00000243307.2	POM121L6P	-3.98	8.47e-05	0.0284	-0.24	-0.21	Parkinson's disease;	chr6:27734661	chr6:26896952~26898777:+
STAD	cis	rs304029	0.687	rs304091	ENSG00000231249.1	ITPR1-AS1	-3.98	8.47e-05	0.0284	-0.24	-0.21	Diabetic kidney disease;	chr3:4477611	chr3:4490891~4493163:-
STAD	cis	rs2638953	0.85	rs10843167	ENSG00000247934.4	RP11-967K21.1	-3.98	8.47e-05	0.0284	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28429860	chr12:28163298~28190738:-
STAD	cis	rs765787	0.53	rs4238377	ENSG00000259539.1	CTD-2651B20.1	3.98	8.47e-05	0.0284	0.24	0.21	Uric acid levels;	chr15:45249783	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775844	ENSG00000259539.1	CTD-2651B20.1	3.98	8.47e-05	0.0284	0.24	0.21	Uric acid levels;	chr15:45249850	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs3759893	ENSG00000259539.1	CTD-2651B20.1	3.98	8.47e-05	0.0284	0.24	0.21	Uric acid levels;	chr15:45250752	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs16941017	ENSG00000259539.1	CTD-2651B20.1	3.98	8.47e-05	0.0284	0.24	0.21	Uric acid levels;	chr15:45251083	chr15:45152664~45167526:-
STAD	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-3.98	8.47e-05	0.0284	-0.25	-0.21	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
STAD	cis	rs7204230	1	rs8057569	ENSG00000261291.1	RP11-295M3.2	3.98	8.48e-05	0.0284	0.25	0.21	Fibrinogen;	chr16:53139321	chr16:53168522~53169450:+
STAD	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-3.98	8.48e-05	0.0284	-0.26	-0.21	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-3.98	8.48e-05	0.0284	-0.26	-0.21	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
STAD	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-3.98	8.48e-05	0.0284	-0.26	-0.21	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
STAD	cis	rs11169552	0.51	rs4768853	ENSG00000200183.1	RNU6-238P	-3.98	8.48e-05	0.0284	-0.2	-0.21	Colorectal cancer;	chr12:50588002	chr12:50656973~50657078:+
STAD	cis	rs9733	0.519	rs11807450	ENSG00000276103.1	U4	3.98	8.48e-05	0.0284	0.2	0.21	Tonsillectomy;	chr1:150705243	chr1:150608507~150608623:-
STAD	cis	rs9733	0.519	rs3768005	ENSG00000276103.1	U4	3.98	8.48e-05	0.0284	0.2	0.21	Tonsillectomy;	chr1:150708512	chr1:150608507~150608623:-
STAD	cis	rs9733	0.519	rs72704603	ENSG00000276103.1	U4	3.98	8.48e-05	0.0284	0.2	0.21	Tonsillectomy;	chr1:150735516	chr1:150608507~150608623:-
STAD	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	3.98	8.49e-05	0.0285	0.21	0.21	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
STAD	cis	rs1348850	0.914	rs4893944	ENSG00000271825.1	RP11-337N6.2	3.98	8.49e-05	0.0285	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177424629	chr2:177300600~177302006:+
STAD	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-3.98	8.49e-05	0.0285	-0.35	-0.21	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
STAD	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-3.98	8.49e-05	0.0285	-0.35	-0.21	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
STAD	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-3.98	8.49e-05	0.0285	-0.35	-0.21	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
STAD	cis	rs870825	0.616	rs4519838	ENSG00000249173.4	LINC01093	-3.98	8.5e-05	0.0285	-0.33	-0.21	Blood protein levels;	chr4:184707303	chr4:184893871~184899454:-
STAD	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-3.98	8.5e-05	0.0285	-0.27	-0.21	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
STAD	cis	rs111342015	0.615	rs16896344	ENSG00000181524.6	RPL24P4	-3.98	8.5e-05	0.0285	-0.22	-0.21	Breast cancer;	chr6:43204692	chr6:42956345~42956765:-
STAD	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	3.98	8.5e-05	0.0285	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	3.98	8.5e-05	0.0285	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
STAD	cis	rs7702057	0.53	rs1129495	ENSG00000271918.1	CTD-2287O16.5	3.98	8.5e-05	0.0285	0.39	0.21	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116083807~116085416:-
STAD	cis	rs7702057	0.53	rs4921060	ENSG00000271918.1	CTD-2287O16.5	3.98	8.5e-05	0.0285	0.39	0.21	Amyotrophic lateral sclerosis;	chr5:116109004	chr5:116083807~116085416:-
STAD	cis	rs7849270	1	rs3739847	ENSG00000234055.1	RP11-247A12.1	-3.98	8.5e-05	0.0285	-0.24	-0.21	Blood metabolite ratios;	chr9:129149295	chr9:129097854~129100266:+
STAD	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	3.98	8.5e-05	0.0285	0.3	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
STAD	cis	rs765787	0.53	rs1706835	ENSG00000259539.1	CTD-2651B20.1	3.98	8.5e-05	0.0285	0.24	0.21	Uric acid levels;	chr15:45225686	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs1631533	ENSG00000259539.1	CTD-2651B20.1	3.98	8.5e-05	0.0285	0.24	0.21	Uric acid levels;	chr15:45226430	chr15:45152664~45167526:-
STAD	cis	rs4293777	0.967	rs11734769	ENSG00000250896.1	RNPS1P1	3.98	8.5e-05	0.0285	0.16	0.21	Primary sclerosing cholangitis;	chr4:10724104	chr4:11371975~11372892:+
STAD	cis	rs6832769	1	rs6834676	ENSG00000223305.1	RN7SKP30	3.98	8.5e-05	0.0285	0.23	0.21	Personality dimensions;	chr4:55432247	chr4:55540502~55540835:-
STAD	cis	rs9902453	0.765	rs3102560	ENSG00000263477.1	RP11-338L22.2	3.98	8.51e-05	0.0285	0.18	0.21	Coffee consumption (cups per day);	chr17:29702920	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.726	rs3115088	ENSG00000263477.1	RP11-338L22.2	3.98	8.51e-05	0.0285	0.18	0.21	Coffee consumption (cups per day);	chr17:29704257	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.791	rs3115090	ENSG00000263477.1	RP11-338L22.2	3.98	8.51e-05	0.0285	0.18	0.21	Coffee consumption (cups per day);	chr17:29707996	chr17:29863402~29866092:+
STAD	cis	rs10851411	0.697	rs17766258	ENSG00000174171.5	RP11-23P13.6	3.98	8.51e-05	0.0285	0.36	0.21	Glucose homeostasis traits;	chr15:42492939	chr15:41892793~41898575:+
STAD	cis	rs11084877	0.943	rs8109388	ENSG00000261770.1	CTC-459F4.1	3.98	8.51e-05	0.0285	0.24	0.21	Multiple system atrophy;	chr19:28220274	chr19:27757184~27760849:-
STAD	cis	rs76210638	1	rs12430947	ENSG00000276672.1	RP11-142E9.1	-3.98	8.51e-05	0.0285	-0.29	-0.21	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33933950	chr13:33846190~33850825:+
STAD	cis	rs10971721	0.822	rs12376279	ENSG00000281128.1	PTENP1-AS	3.98	8.51e-05	0.0285	0.32	0.21	Body mass index;	chr9:33804256	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.731	rs12377117	ENSG00000281128.1	PTENP1-AS	3.98	8.51e-05	0.0285	0.32	0.21	Body mass index;	chr9:33806586	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.73	rs72725361	ENSG00000281128.1	PTENP1-AS	3.98	8.51e-05	0.0285	0.32	0.21	Body mass index;	chr9:33806615	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs12376664	ENSG00000281128.1	PTENP1-AS	3.98	8.51e-05	0.0285	0.32	0.21	Body mass index;	chr9:33808705	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72725368	ENSG00000281128.1	PTENP1-AS	3.98	8.51e-05	0.0285	0.32	0.21	Body mass index;	chr9:33815457	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72725370	ENSG00000281128.1	PTENP1-AS	3.98	8.51e-05	0.0285	0.32	0.21	Body mass index;	chr9:33818459	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.554	rs10971712	ENSG00000281128.1	PTENP1-AS	3.98	8.51e-05	0.0285	0.32	0.21	Body mass index;	chr9:33820940	chr9:33677268~33688011:+
STAD	cis	rs7824557	0.564	rs2736293	ENSG00000205879.4	FAM90A2P	-3.98	8.51e-05	0.0285	-0.23	-0.21	Retinal vascular caliber;	chr8:11377104	chr8:12172202~12178575:-
STAD	cis	rs7824557	0.564	rs2736294	ENSG00000205879.4	FAM90A2P	-3.98	8.51e-05	0.0285	-0.23	-0.21	Retinal vascular caliber;	chr8:11377117	chr8:12172202~12178575:-
STAD	cis	rs7824557	0.527	rs2736296	ENSG00000205879.4	FAM90A2P	-3.98	8.51e-05	0.0285	-0.23	-0.21	Retinal vascular caliber;	chr8:11377335	chr8:12172202~12178575:-
STAD	cis	rs7824557	0.51	rs2736297	ENSG00000205879.4	FAM90A2P	-3.98	8.51e-05	0.0285	-0.23	-0.21	Retinal vascular caliber;	chr8:11377376	chr8:12172202~12178575:-
STAD	cis	rs7824557	0.527	rs57629785	ENSG00000205879.4	FAM90A2P	-3.98	8.51e-05	0.0285	-0.23	-0.21	Retinal vascular caliber;	chr8:11377641	chr8:12172202~12178575:-
STAD	cis	rs733592	0.524	rs10875744	ENSG00000226413.2	OR8T1P	3.98	8.52e-05	0.0285	0.23	0.21	Plateletcrit;	chr12:48104657	chr12:48442030~48442947:-
STAD	cis	rs8012947	1	rs10145437	ENSG00000279636.2	LINC00216	-3.98	8.52e-05	0.0285	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58294485	chr14:58288033~58289158:+
STAD	cis	rs2638953	0.962	rs10843158	ENSG00000247934.4	RP11-967K21.1	3.98	8.52e-05	0.0285	0.24	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354259	chr12:28163298~28190738:-
STAD	cis	rs10129255	0.5	rs10131875	ENSG00000232216.1	IGHV3-43	3.98	8.52e-05	0.0285	0.19	0.21	Kawasaki disease;	chr14:106792798	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.5	rs11628999	ENSG00000232216.1	IGHV3-43	3.98	8.52e-05	0.0285	0.19	0.21	Kawasaki disease;	chr14:106800208	chr14:106470264~106470800:-
STAD	cis	rs716804	0.653	rs1562782	ENSG00000254554.1	RP11-351I24.1	3.98	8.53e-05	0.0286	0.31	0.21	Neuroticism;	chr11:10321164	chr11:10302657~10303704:-
STAD	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	3.98	8.53e-05	0.0286	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
STAD	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-3.98	8.53e-05	0.0286	-0.26	-0.21	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
STAD	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-3.98	8.53e-05	0.0286	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-3.98	8.53e-05	0.0286	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-3.98	8.53e-05	0.0286	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
STAD	cis	rs9291683	0.546	rs6829727	ENSG00000250613.1	RP11-136I13.1	-3.98	8.53e-05	0.0286	-0.22	-0.21	Bone mineral density;	chr4:10050048	chr4:10410996~10411644:+
STAD	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	3.98	8.53e-05	0.0286	0.22	0.21	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
STAD	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	3.98	8.53e-05	0.0286	0.32	0.21	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
STAD	cis	rs6180	0.935	rs230820	ENSG00000250860.1	CTD-2265D6.2	-3.98	8.53e-05	0.0286	-0.18	-0.21	Height;	chr5:42807322	chr5:42466893~42468300:-
STAD	cis	rs748404	0.626	rs17780920	ENSG00000205771.5	CATSPER2P1	-3.98	8.53e-05	0.0286	-0.33	-0.21	Lung cancer;	chr15:43370164	chr15:43726918~43747094:-
STAD	cis	rs17630293	1	rs17630293	ENSG00000201649.1	RNY4P34	3.98	8.54e-05	0.0286	0.3	0.21	Schizophrenia;	chr2:200282053	chr2:200373175~200373269:+
STAD	cis	rs12745968	0.623	rs10874733	ENSG00000229052.2	RP11-386I23.1	-3.98	8.54e-05	0.0286	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92658176	chr1:92930696~92934098:+
STAD	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	3.98	8.54e-05	0.0286	0.28	0.21	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	3.98	8.54e-05	0.0286	0.28	0.21	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	3.98	8.54e-05	0.0286	0.28	0.21	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	3.98	8.54e-05	0.0286	0.28	0.21	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
STAD	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	3.98	8.54e-05	0.0286	0.28	0.21	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
STAD	cis	rs8099594	0.565	rs1893527	ENSG00000266696.1	RP11-30L3.2	-3.98	8.55e-05	0.0286	-0.19	-0.21	Height;	chr18:49185738	chr18:49205912~49208781:+
STAD	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	3.98	8.55e-05	0.0286	0.18	0.21	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
STAD	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-3.98	8.55e-05	0.0286	-0.24	-0.21	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-3.98	8.55e-05	0.0286	-0.24	-0.21	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-3.98	8.55e-05	0.0286	-0.24	-0.21	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-3.98	8.55e-05	0.0286	-0.24	-0.21	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-3.98	8.55e-05	0.0286	-0.24	-0.21	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-3.98	8.55e-05	0.0286	-0.24	-0.21	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-3.98	8.55e-05	0.0286	-0.24	-0.21	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
STAD	cis	rs6095298	0.574	rs6012541	ENSG00000227431.4	CSE1L-AS1	-3.98	8.55e-05	0.0286	-0.23	-0.21	Intelligence (multi-trait analysis);	chr20:48855039	chr20:49040463~49046044:-
STAD	cis	rs4792901	0.722	rs7220615	ENSG00000279602.1	CTD-3014M21.1	-3.98	8.55e-05	0.0286	-0.28	-0.21	Dupuytren's disease;	chr17:43463276	chr17:43360041~43361361:-
STAD	cis	rs7103648	0.553	rs12803857	ENSG00000280615.1	Y_RNA	3.98	8.55e-05	0.0286	0.23	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47868620	chr11:47614898~47614994:-
STAD	cis	rs6479891	1	rs61855465	ENSG00000235816.3	PRELID1P3	3.98	8.55e-05	0.0286	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs12413730	ENSG00000235816.3	PRELID1P3	3.98	8.55e-05	0.0286	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63427297~63427939:+
STAD	cis	rs6479891	0.908	rs11819167	ENSG00000235816.3	PRELID1P3	3.98	8.55e-05	0.0286	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs7099425	ENSG00000235816.3	PRELID1P3	-3.98	8.55e-05	0.0286	-0.26	-0.21	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs1904295	ENSG00000235816.3	PRELID1P3	-3.98	8.55e-05	0.0286	-0.26	-0.21	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63427297~63427939:+
STAD	cis	rs6479901	0.512	rs6415875	ENSG00000235816.3	PRELID1P3	-3.98	8.55e-05	0.0286	-0.26	-0.21	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63427297~63427939:+
STAD	cis	rs6479901	0.512	rs4439410	ENSG00000235816.3	PRELID1P3	-3.98	8.55e-05	0.0286	-0.26	-0.21	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63427297~63427939:+
STAD	cis	rs875971	0.83	rs6976714	ENSG00000224316.1	RP11-479O9.2	3.98	8.55e-05	0.0286	0.2	0.21	Aortic root size;	chr7:66426474	chr7:65773620~65802067:+
STAD	cis	rs7824557	0.778	rs6601572	ENSG00000254866.2	DEFB109P3	3.98	8.56e-05	0.0286	0.26	0.21	Retinal vascular caliber;	chr8:11235828	chr8:12150895~12151134:-
STAD	cis	rs11157436	0.602	rs11157435	ENSG00000211812.1	TRAV26-2	-3.98	8.56e-05	0.0286	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22202583~22203368:+
STAD	cis	rs6832769	0.961	rs13152650	ENSG00000223305.1	RN7SKP30	3.98	8.56e-05	0.0286	0.24	0.21	Personality dimensions;	chr4:55491691	chr4:55540502~55540835:-
STAD	cis	rs7204230	1	rs62049816	ENSG00000261291.1	RP11-295M3.2	3.98	8.56e-05	0.0286	0.25	0.21	Fibrinogen;	chr16:53336072	chr16:53168522~53169450:+
STAD	cis	rs17818399	0.749	rs13000560	ENSG00000279254.1	RP11-536C12.1	-3.98	8.56e-05	0.0287	-0.23	-0.21	Height;	chr2:46563858	chr2:46668870~46670778:+
STAD	cis	rs2836950	0.561	rs34705151	ENSG00000238141.2	BRWD1-AS1	-3.98	8.57e-05	0.0287	-0.21	-0.21	Menarche (age at onset);	chr21:39181418	chr21:39315707~39323218:+
STAD	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-3.98	8.57e-05	0.0287	-0.24	-0.21	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
STAD	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-3.98	8.57e-05	0.0287	-0.24	-0.21	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
STAD	cis	rs7520050	0.966	rs11211208	ENSG00000280836.1	AL355480.1	3.97	8.57e-05	0.0287	0.26	0.21	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45581219~45581321:-
STAD	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	3.97	8.57e-05	0.0287	0.27	0.21	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
STAD	cis	rs6772849	0.93	rs1962040	ENSG00000242551.2	POU5F1P6	-3.97	8.57e-05	0.0287	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:128674735~128677005:-
STAD	cis	rs6772849	0.93	rs6768344	ENSG00000242551.2	POU5F1P6	-3.97	8.57e-05	0.0287	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128674735~128677005:-
STAD	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-3.97	8.58e-05	0.0287	-0.27	-0.21	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
STAD	cis	rs875971	1	rs697970	ENSG00000224316.1	RP11-479O9.2	-3.97	8.58e-05	0.0287	-0.21	-0.21	Aortic root size;	chr7:66095065	chr7:65773620~65802067:+
STAD	cis	rs11673344	0.504	rs4806407	ENSG00000267672.1	CTD-2293H3.1	-3.97	8.58e-05	0.0287	-0.2	-0.21	Obesity-related traits;	chr19:37097849	chr19:37091341~37092564:+
STAD	cis	rs2404602	0.647	rs7181506	ENSG00000196274.5	Metazoa_SRP	3.97	8.58e-05	0.0287	0.18	0.21	Blood metabolite levels;	chr15:76643336	chr15:76230048~76230390:-
STAD	cis	rs11264799	0.639	rs6677622	ENSG00000231666.4	RP11-404O13.1	-3.97	8.59e-05	0.0287	-0.3	-0.21	IgA nephropathy;	chr1:157781566	chr1:158132044~158140639:-
STAD	cis	rs4237845	0.636	rs11172371	ENSG00000273805.1	RP11-620J15.4	-3.97	8.59e-05	0.0287	-0.24	-0.21	Intelligence (multi-trait analysis);	chr12:57892405	chr12:57894232~57896846:+
STAD	cis	rs7951911	0.915	rs10466475	ENSG00000254427.1	RP11-430H10.1	3.97	8.59e-05	0.0287	0.43	0.21	IgG glycosylation;	chr11:45076549	chr11:45355371~45366121:+
STAD	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	3.97	8.59e-05	0.0287	0.24	0.21	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
STAD	cis	rs6693567	0.545	rs4970922	ENSG00000203819.6	HIST2H2BC	3.97	8.59e-05	0.0287	0.24	0.21	Migraine;	chr1:150485618	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.545	rs9436009	ENSG00000203819.6	HIST2H2BC	3.97	8.59e-05	0.0287	0.24	0.21	Migraine;	chr1:150486950	chr1:149850193~149850772:-
STAD	cis	rs2337406	1	rs78631692	ENSG00000280411.1	IGHV1-69-2	-3.97	8.59e-05	0.0287	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106709371	chr14:106762092~106762588:-
STAD	cis	rs7103648	0.864	rs10769264	ENSG00000280615.1	Y_RNA	3.97	8.59e-05	0.0287	0.21	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47401789	chr11:47614898~47614994:-
STAD	cis	rs7103648	1	rs10838705	ENSG00000280615.1	Y_RNA	3.97	8.59e-05	0.0287	0.21	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47403380	chr11:47614898~47614994:-
STAD	cis	rs858239	0.601	rs7805206	ENSG00000230042.1	AK3P3	-3.97	8.59e-05	0.0287	-0.22	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23129178~23129841:+
STAD	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	3.97	8.6e-05	0.0287	0.15	0.21	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
STAD	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	3.97	8.6e-05	0.0287	0.15	0.21	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
STAD	cis	rs2562456	0.755	rs2562421	ENSG00000268119.4	CTD-2561J22.5	-3.97	8.6e-05	0.0287	-0.27	-0.21	Pain;	chr19:21448502	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.793	rs2562420	ENSG00000268119.4	CTD-2561J22.5	-3.97	8.6e-05	0.0287	-0.27	-0.21	Pain;	chr19:21448503	chr19:21444241~21463908:-
STAD	cis	rs2957692	0.548	rs12418619	ENSG00000254554.1	RP11-351I24.1	3.97	8.6e-05	0.0288	0.35	0.21	Circulating vasoactive peptide levels;	chr11:10083046	chr11:10302657~10303704:-
STAD	cis	rs1816752	0.603	rs9551099	ENSG00000273628.1	RP11-756A22.7	-3.97	8.6e-05	0.0288	-0.26	-0.21	Obesity-related traits;	chr13:24410978	chr13:24933006~24936796:+
STAD	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	3.97	8.6e-05	0.0288	0.24	0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
STAD	cis	rs1858037	0.867	rs1553675	ENSG00000223739.1	AC007389.2	3.97	8.61e-05	0.0288	0.19	0.21	Rheumatoid arthritis;	chr2:65343173	chr2:65511771~65512076:-
STAD	cis	rs12935418	0.733	rs12448615	ENSG00000261061.1	RP11-303E16.2	-3.97	8.61e-05	0.0288	-0.33	-0.21	Mean corpuscular volume;	chr16:80947132	chr16:81030770~81031485:+
STAD	cis	rs34779708	0.702	rs35969476	ENSG00000271335.4	RP11-324I22.4	3.97	8.61e-05	0.0288	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35314552~35336401:-
STAD	cis	rs6479891	1	rs4746974	ENSG00000235816.3	PRELID1P3	3.97	8.61e-05	0.0288	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63427297~63427939:+
STAD	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	3.97	8.61e-05	0.0288	0.3	0.21	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
STAD	cis	rs1348850	0.567	rs4893838	ENSG00000271825.1	RP11-337N6.2	3.97	8.62e-05	0.0288	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177666708	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.567	rs880897	ENSG00000271825.1	RP11-337N6.2	3.97	8.62e-05	0.0288	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177667775	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.567	rs7605493	ENSG00000271825.1	RP11-337N6.2	3.97	8.62e-05	0.0288	0.19	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177670255	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.651	rs1901826	ENSG00000271825.1	RP11-337N6.2	3.97	8.62e-05	0.0288	0.17	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177360538	chr2:177300600~177302006:+
STAD	cis	rs7474896	0.731	rs2749577	ENSG00000099251.13	HSD17B7P2	-3.97	8.62e-05	0.0288	-0.35	-0.21	Obesity (extreme);	chr10:37991957	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.945	rs2749575	ENSG00000099251.13	HSD17B7P2	-3.97	8.62e-05	0.0288	-0.35	-0.21	Obesity (extreme);	chr10:37993647	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2474550	ENSG00000099251.13	HSD17B7P2	-3.97	8.62e-05	0.0288	-0.35	-0.21	Obesity (extreme);	chr10:38001842	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2474549	ENSG00000099251.13	HSD17B7P2	-3.97	8.62e-05	0.0288	-0.35	-0.21	Obesity (extreme);	chr10:38001844	chr10:38356380~38378505:+
STAD	cis	rs2280018	0.609	rs2941253	ENSG00000260735.1	RP11-72I8.1	-3.97	8.62e-05	0.0288	-0.21	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15094411~15109197:+
STAD	cis	rs11673344	0.504	rs8109501	ENSG00000267672.1	CTD-2293H3.1	3.97	8.62e-05	0.0288	0.19	0.21	Obesity-related traits;	chr19:37102194	chr19:37091341~37092564:+
STAD	cis	rs1707322	1	rs4660334	ENSG00000225447.1	RPS15AP10	3.97	8.63e-05	0.0288	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45645816~45646197:-
STAD	cis	rs17507216	0.718	rs7161977	ENSG00000255769.6	GOLGA2P10	-3.97	8.63e-05	0.0289	-0.35	-0.21	Excessive daytime sleepiness;	chr15:82646782	chr15:82472993~82513950:-
STAD	cis	rs11239930	0.517	rs632861	ENSG00000278811.3	LINC00624	3.97	8.63e-05	0.0289	0.22	0.21	AIDS progression;	chr1:147079826	chr1:147258885~147517875:-
STAD	cis	rs449789	0.524	rs1553480	ENSG00000235086.1	FNDC1-IT1	-3.97	8.64e-05	0.0289	-0.27	-0.21	Pulse pressure;	chr6:159321564	chr6:159240786~159243329:+
STAD	cis	rs10458771	0.527	rs4934207	ENSG00000212332.1	RNU6-780P	-3.97	8.64e-05	0.0289	-0.22	-0.21	Amyotrophic lateral sclerosis (sporadic);	chr10:86434772	chr10:86488446~86488549:+
STAD	cis	rs9902453	0.817	rs2729449	ENSG00000263477.1	RP11-338L22.2	-3.97	8.64e-05	0.0289	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29762733	chr17:29863402~29866092:+
STAD	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	3.97	8.64e-05	0.0289	0.23	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
STAD	cis	rs7901056	0.811	rs867354	ENSG00000251839.1	RNU7-12P	-3.97	8.64e-05	0.0289	-0.2	-0.21	Lymphocyte counts;	chr10:26406821	chr10:27232255~27232316:-
STAD	cis	rs9304742	0.611	rs10415443	ENSG00000242779.5	ZNF702P	3.97	8.65e-05	0.0289	0.26	0.21	Psoriasis;	chr19:52961611	chr19:52968251~53037898:-
STAD	cis	rs259282	0.605	rs8101920	ENSG00000201388.1	SNORA68	3.97	8.65e-05	0.0289	0.21	0.21	Schizophrenia;	chr19:32618364	chr19:32608337~32608469:-
STAD	cis	rs1005277	0.505	rs200936	ENSG00000099251.13	HSD17B7P2	3.97	8.65e-05	0.0289	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38356380~38378505:+
STAD	cis	rs1005277	0.505	rs200937	ENSG00000099251.13	HSD17B7P2	3.97	8.65e-05	0.0289	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38356380~38378505:+
STAD	cis	rs7829975	0.658	rs907181	ENSG00000233609.3	RP11-62H7.2	3.97	8.65e-05	0.0289	0.22	0.21	Mood instability;	chr8:8845365	chr8:8961200~8979025:+
STAD	cis	rs2337406	1	rs61268362	ENSG00000254174.1	IGHV1-12	3.97	8.65e-05	0.0289	0.25	0.21	Alzheimer's disease (late onset);	chr14:106697010	chr14:106122420~106122709:-
STAD	cis	rs7487075	0.78	rs1873793	ENSG00000272963.1	OR7A19P	-3.97	8.65e-05	0.0289	-0.19	-0.21	Itch intensity from mosquito bite;	chr12:46367541	chr12:46592573~46593305:+
STAD	cis	rs7924176	0.601	rs11000882	ENSG00000213731.2	RAB5CP1	-3.97	8.65e-05	0.0289	-0.21	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74130145	chr10:74423435~74424014:-
STAD	cis	rs1345301	0.518	rs56238602	ENSG00000234389.1	AC007278.3	-3.97	8.65e-05	0.0289	-0.21	-0.21	Waist circumference;	chr2:102246635	chr2:102438713~102440475:+
STAD	cis	rs5758659	0.652	rs133340	ENSG00000182057.4	OGFRP1	-3.97	8.65e-05	0.0289	-0.22	-0.21	Cognitive function;	chr22:42021683	chr22:42269753~42275196:+
STAD	cis	rs9859260	0.744	rs406271	ENSG00000242086.7	LINC00969	-3.97	8.65e-05	0.0289	-0.19	-0.21	Mean corpuscular volume;	chr3:196050105	chr3:195658062~195739964:+
STAD	cis	rs9859260	0.71	rs419068	ENSG00000242086.7	LINC00969	-3.97	8.65e-05	0.0289	-0.19	-0.21	Mean corpuscular volume;	chr3:196055305	chr3:195658062~195739964:+
STAD	cis	rs9859260	0.71	rs366268	ENSG00000242086.7	LINC00969	-3.97	8.65e-05	0.0289	-0.19	-0.21	Mean corpuscular volume;	chr3:196055306	chr3:195658062~195739964:+
STAD	cis	rs9859260	0.744	rs419059	ENSG00000242086.7	LINC00969	-3.97	8.65e-05	0.0289	-0.19	-0.21	Mean corpuscular volume;	chr3:196055313	chr3:195658062~195739964:+
STAD	cis	rs2348418	0.832	rs10506031	ENSG00000247934.4	RP11-967K21.1	-3.97	8.65e-05	0.0289	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28379061	chr12:28163298~28190738:-
STAD	cis	rs8012947	1	rs10133305	ENSG00000279636.2	LINC00216	-3.97	8.66e-05	0.0289	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58294411	chr14:58288033~58289158:+
STAD	cis	rs2243480	1	rs4149468	ENSG00000273448.1	RP11-166O4.6	3.97	8.66e-05	0.0289	0.25	0.21	Diabetic kidney disease;	chr7:66360703	chr7:67333047~67334383:+
STAD	cis	rs9860428	0.564	rs10804503	ENSG00000240057.4	RP11-572M11.4	-3.97	8.66e-05	0.0289	-0.19	-0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112794511	chr3:113019532~113183301:+
STAD	cis	rs10776614	0.799	rs1838569	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48555632	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs1838568	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48555645	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs1445148	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48555664	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs7071095	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48555773	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs7085183	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48555984	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs7071480	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48556016	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs7085335	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48556086	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs1965170	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48556372	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs10857596	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48556629	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs1473323	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48556775	chr10:47706203~47706802:+
STAD	cis	rs10776614	0.799	rs1345110	ENSG00000226964.1	RHEBP2	3.97	8.66e-05	0.0289	0.3	0.21	Self-employment;	chr10:48557123	chr10:47706203~47706802:+
STAD	cis	rs867371	1	rs11855089	ENSG00000276710.3	CSPG4P8	-3.97	8.66e-05	0.0289	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82459472~82477258:+
STAD	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	3.97	8.66e-05	0.0289	0.21	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
STAD	cis	rs7631605	0.905	rs9823428	ENSG00000236411.1	NDUFAF4P3	-3.97	8.67e-05	0.0289	-0.23	-0.21	Cerebrospinal P-tau181p levels;	chr3:37069639	chr3:37789921~37790445:-
STAD	cis	rs7631605	0.905	rs17810211	ENSG00000236411.1	NDUFAF4P3	-3.97	8.67e-05	0.0289	-0.23	-0.21	Cerebrospinal P-tau181p levels;	chr3:37071914	chr3:37789921~37790445:-
STAD	cis	rs6686842	0.56	rs61781833	ENSG00000235358.1	RP11-399E6.1	-3.97	8.67e-05	0.0289	-0.23	-0.21	Height;	chr1:41175418	chr1:41242373~41284861:+
STAD	cis	rs6686842	0.56	rs74069080	ENSG00000235358.1	RP11-399E6.1	-3.97	8.67e-05	0.0289	-0.23	-0.21	Height;	chr1:41185358	chr1:41242373~41284861:+
STAD	cis	rs6686842	0.56	rs11209659	ENSG00000235358.1	RP11-399E6.1	-3.97	8.67e-05	0.0289	-0.23	-0.21	Height;	chr1:41194607	chr1:41242373~41284861:+
STAD	cis	rs6686842	0.56	rs60351276	ENSG00000235358.1	RP11-399E6.1	-3.97	8.67e-05	0.0289	-0.23	-0.21	Height;	chr1:41202879	chr1:41242373~41284861:+
STAD	cis	rs2278796	0.639	rs4950977	ENSG00000231691.1	RP11-203F10.5	-3.97	8.67e-05	0.0289	-0.26	-0.21	Mean platelet volume;	chr1:205001649	chr1:204277005~204277948:+
STAD	cis	rs10776614	0.642	rs1838579	ENSG00000189014.7	FAM35DP	3.97	8.67e-05	0.029	0.27	0.21	Self-employment;	chr10:48559501	chr10:47689707~47730436:+
STAD	cis	rs807029	0.758	rs807025	ENSG00000272572.1	RP11-179B2.2	-3.97	8.67e-05	0.029	-0.25	-0.21	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101005064	chr10:100911103~100912739:-
STAD	cis	rs1056107	0.7	rs10817274	ENSG00000225513.1	RP11-165N19.2	-3.97	8.68e-05	0.029	-0.24	-0.21	Colorectal cancer;	chr9:112167691	chr9:112173522~112173971:-
STAD	cis	rs4589258	0.788	rs2032380	ENSG00000280367.1	RP11-121L10.2	3.97	8.68e-05	0.029	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90756178	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs10741364	ENSG00000280367.1	RP11-121L10.2	3.97	8.68e-05	0.029	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90756923	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.737	rs10830569	ENSG00000280367.1	RP11-121L10.2	3.97	8.68e-05	0.029	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90756966	chr11:90223153~90226538:+
STAD	cis	rs17680741	0.542	rs35521186	ENSG00000225484.5	NUTM2B-AS1	-3.97	8.68e-05	0.029	-0.35	-0.21	Coronary artery disease;	chr10:80484325	chr10:79663088~79826594:-
STAD	cis	rs7915414	0.531	rs12782374	ENSG00000230338.1	MTND4P19	3.97	8.68e-05	0.029	0.26	0.21	Clopidogrel active metabolite levels;	chr10:94935594	chr10:94774156~94774633:-
STAD	cis	rs6142102	0.961	rs1319363	ENSG00000264616.1	MIR4755	3.97	8.68e-05	0.029	0.22	0.21	Skin pigmentation;	chr20:33954070	chr20:34049119~34049190:+
STAD	cis	rs7916697	0.54	rs4551651	ENSG00000234102.1	KRT19P4	-3.97	8.68e-05	0.029	-0.23	-0.21	Optic disc area;	chr10:68264772	chr10:68260557~68261499:+
STAD	cis	rs6693567	0.565	rs698917	ENSG00000203819.6	HIST2H2BC	3.97	8.68e-05	0.029	0.24	0.21	Migraine;	chr1:150347408	chr1:149850193~149850772:-
STAD	cis	rs6432860	0.868	rs490317	ENSG00000229195.1	AC009495.4	3.97	8.68e-05	0.029	0.27	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166039668	chr2:165794857~165846091:-
STAD	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	3.97	8.69e-05	0.029	0.25	0.21	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
STAD	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-3.97	8.69e-05	0.029	-0.3	-0.21	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
STAD	cis	rs7523273	0.565	rs34355011	ENSG00000227887.1	RPS26P13	3.97	8.69e-05	0.029	0.21	0.21	Schizophrenia;	chr1:207713977	chr1:208697369~208697698:-
STAD	cis	rs10851478	0.872	rs11858411	ENSG00000259545.2	RP11-325E5.4	-3.97	8.69e-05	0.029	-0.25	-0.21	Oral cavity cancer;	chr15:49499754	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs34246470	ENSG00000259545.2	RP11-325E5.4	-3.97	8.69e-05	0.029	-0.25	-0.21	Oral cavity cancer;	chr15:49504500	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs35698479	ENSG00000259545.2	RP11-325E5.4	-3.97	8.69e-05	0.029	-0.25	-0.21	Oral cavity cancer;	chr15:49504922	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs12908624	ENSG00000259545.2	RP11-325E5.4	-3.97	8.69e-05	0.029	-0.25	-0.21	Oral cavity cancer;	chr15:49505736	chr15:49177610~49178741:-
STAD	cis	rs4243830	0.85	rs1010584	ENSG00000229519.2	RP11-58A11.2	3.97	8.69e-05	0.029	0.22	0.21	Body mass index;	chr1:6519783	chr1:6547905~6548619:+
STAD	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	3.97	8.69e-05	0.029	0.29	0.21	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
STAD	cis	rs10129255	0.5	rs2105991	ENSG00000211959.2	IGHV4-39	3.97	8.69e-05	0.029	0.18	0.21	Kawasaki disease;	chr14:106682022	chr14:106421711~106422218:-
STAD	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-3.97	8.69e-05	0.029	-0.26	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
STAD	cis	rs60180747	1	rs74581464	ENSG00000252712.1	SCARNA14	3.97	8.7e-05	0.029	0.25	0.21	Testicular germ cell tumor;	chr15:66468642	chr15:66347207~66347342:-
STAD	cis	rs1874124	0.577	rs2807853	ENSG00000238078.1	LINC01352	3.97	8.7e-05	0.029	0.28	0.21	Cholesterol, total;	chr1:220851011	chr1:220829255~220832429:+
STAD	cis	rs1874124	0.504	rs2491257	ENSG00000238078.1	LINC01352	3.97	8.7e-05	0.029	0.28	0.21	Cholesterol, total;	chr1:220855900	chr1:220829255~220832429:+
STAD	cis	rs1707322	0.721	rs11211181	ENSG00000225447.1	RPS15AP10	3.97	8.7e-05	0.029	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45645816~45646197:-
STAD	cis	rs2638953	0.64	rs10843208	ENSG00000247934.4	RP11-967K21.1	-3.97	8.7e-05	0.029	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28572171	chr12:28163298~28190738:-
STAD	cis	rs870825	0.616	rs6814278	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184723263	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6844588	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184723363	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs28451943	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184724418	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6852082	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184724629	chr4:184893871~184899454:-
STAD	cis	rs870825	0.55	rs59051283	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184725322	chr4:184893871~184899454:-
STAD	cis	rs870825	0.55	rs57301026	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184725351	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28442259	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184725808	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs28555435	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184726146	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28672716	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184726191	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28375770	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184726241	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28524599	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184726260	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs2090589	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184726577	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs2090590	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184726696	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs2310110	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184726748	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7700216	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184727356	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7678616	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184727560	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7678849	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184727714	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7654208	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184727723	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28445002	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184727823	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28649620	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184727843	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28618216	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184727844	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs10022834	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184728277	chr4:184893871~184899454:-
STAD	cis	rs870825	0.52	rs10022842	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184728305	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs10025167	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184728397	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6818447	ENSG00000249173.4	LINC01093	-3.97	8.7e-05	0.029	-0.34	-0.21	Blood protein levels;	chr4:184729000	chr4:184893871~184899454:-
STAD	cis	rs1005277	0.505	rs200939	ENSG00000099251.13	HSD17B7P2	3.97	8.7e-05	0.029	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38356380~38378505:+
STAD	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	3.97	8.71e-05	0.029	0.29	0.21	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
STAD	cis	rs7680126	0.672	rs4697957	ENSG00000250613.1	RP11-136I13.1	3.97	8.71e-05	0.029	0.25	0.21	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10180630	chr4:10410996~10411644:+
STAD	cis	rs950169	0.763	rs35372971	ENSG00000235370.6	DNM1P51	3.97	8.71e-05	0.029	0.27	0.21	Schizophrenia;	chr15:84387097	chr15:84398316~84411701:-
STAD	cis	rs9921338	0.961	rs7193278	ENSG00000263080.1	RP11-485G7.5	3.97	8.72e-05	0.0291	0.32	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11341809~11345211:-
STAD	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	3.97	8.72e-05	0.0291	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
STAD	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-3.97	8.72e-05	0.0291	-0.25	-0.21	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
STAD	cis	rs765787	0.53	rs7167389	ENSG00000259539.1	CTD-2651B20.1	3.97	8.72e-05	0.0291	0.24	0.21	Uric acid levels;	chr15:45243485	chr15:45152664~45167526:-
STAD	cis	rs6430585	0.528	rs6743537	ENSG00000231890.6	DARS-AS1	-3.97	8.72e-05	0.0291	-0.24	-0.21	Corneal structure;	chr2:135945031	chr2:135985176~136022593:+
STAD	cis	rs6772849	0.93	rs4467479	ENSG00000242551.2	POU5F1P6	-3.97	8.73e-05	0.0291	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128674735~128677005:-
STAD	cis	rs1030877	0.515	rs2679895	ENSG00000235319.1	AC012360.4	-3.97	8.73e-05	0.0291	-0.28	-0.21	Obesity-related traits;	chr2:105290023	chr2:105324210~105330529:+
STAD	cis	rs7264396	0.635	rs3827030	ENSG00000199676.1	Y_RNA	-3.97	8.73e-05	0.0291	-0.25	-0.21	Total cholesterol levels;	chr20:35887025	chr20:35853252~35853364:-
STAD	cis	rs7142881	0.844	rs66665255	ENSG00000258648.1	UBE2CP1	-3.97	8.73e-05	0.0291	-0.23	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31576563	chr14:30683045~30683598:-
STAD	cis	rs8014252	0.803	rs74062733	ENSG00000259158.2	ADAM20P1	-3.97	8.73e-05	0.0291	-0.29	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70528677	chr14:70468881~70483756:-
STAD	cis	rs9291683	0.588	rs12506364	ENSG00000250613.1	RP11-136I13.1	-3.97	8.73e-05	0.0291	-0.19	-0.21	Bone mineral density;	chr4:10021824	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.61	rs993173	ENSG00000250613.1	RP11-136I13.1	3.97	8.74e-05	0.0291	0.2	0.21	Bone mineral density;	chr4:10322311	chr4:10410996~10411644:+
STAD	cis	rs2638953	0.962	rs3782517	ENSG00000247934.4	RP11-967K21.1	-3.97	8.74e-05	0.0291	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310254	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs3782515	ENSG00000247934.4	RP11-967K21.1	-3.97	8.74e-05	0.0291	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310511	chr12:28163298~28190738:-
STAD	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-3.97	8.74e-05	0.0291	-0.33	-0.21	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
STAD	cis	rs1928295	0.786	rs7032255	ENSG00000233569.1	RP11-500B12.1	3.97	8.74e-05	0.0291	0.23	0.21	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117637809	chr9:117648606~117657027:+
STAD	cis	rs2278796	0.639	rs11240330	ENSG00000231691.1	RP11-203F10.5	-3.97	8.74e-05	0.0291	-0.27	-0.21	Mean platelet volume;	chr1:204999130	chr1:204277005~204277948:+
STAD	cis	rs1790761	0.52	rs4930461	ENSG00000231793.4	DOC2GP	3.97	8.74e-05	0.0291	0.26	0.21	Mean corpuscular volume;	chr11:67627424	chr11:67612653~67616257:-
STAD	cis	rs9426935	0.966	rs9427232	ENSG00000272030.1	RP1-178F15.4	3.97	8.74e-05	0.0291	0.28	0.21	Lentiform nucleus volume;	chr1:153820482	chr1:153631438~153634397:-
STAD	cis	rs77956314	0.792	rs117924143	ENSG00000274554.1	RP11-240G22.5	3.97	8.74e-05	0.0291	0.36	0.21	Hippocampal volume;Subcortical brain region volumes;	chr12:117003153	chr12:116948738~116951422:-
STAD	cis	rs2390582	0.713	rs10922863	ENSG00000228175.3	GEMIN8P4	3.97	8.75e-05	0.0292	0.32	0.21	Coronary artery calcification;	chr1:90459612	chr1:89993593~89994321:-
STAD	cis	rs7131987	0.834	rs12228468	ENSG00000257176.2	RP11-996F15.2	3.97	8.75e-05	0.0292	0.23	0.21	QT interval;	chr12:29300677	chr12:29280418~29317848:-
STAD	cis	rs7829975	0.684	rs488904	ENSG00000254340.1	RP11-10A14.3	-3.97	8.75e-05	0.0292	-0.25	-0.21	Mood instability;	chr8:8730061	chr8:9141424~9145435:+
STAD	cis	rs17115310	1	rs17513907	ENSG00000255129.4	RP11-839D17.3	3.97	8.75e-05	0.0292	0.39	0.21	Gut microbiota (bacterial taxa);	chr11:113285258	chr11:113278437~113314437:-
STAD	cis	rs741668	0.759	rs3736943	ENSG00000235903.6	CPB2-AS1	3.97	8.75e-05	0.0292	0.25	0.21	Cerebrospinal fluid clusterin levels;	chr13:46044936	chr13:46052806~46113332:+
STAD	cis	rs3126085	0.935	rs2184953	ENSG00000237975.5	FLG-AS1	3.97	8.76e-05	0.0292	0.29	0.21	Atopic dermatitis;	chr1:152308306	chr1:152168125~152445456:+
STAD	cis	rs3126085	0.935	rs3120661	ENSG00000237975.5	FLG-AS1	3.97	8.76e-05	0.0292	0.29	0.21	Atopic dermatitis;	chr1:152321926	chr1:152168125~152445456:+
STAD	cis	rs4834770	1	rs878375	ENSG00000250412.1	KLHL2P1	3.97	8.76e-05	0.0292	0.27	0.21	Blood protein levels;	chr4:119316419	chr4:119334329~119378233:+
STAD	cis	rs4849845	0.664	rs12053228	ENSG00000224789.1	AC012363.4	3.97	8.76e-05	0.0292	0.25	0.21	Mean platelet volume;	chr2:120236843	chr2:120174885~120216544:-
STAD	cis	rs679711	0.634	rs2315	ENSG00000214380.4	RP11-457K10.2	3.97	8.76e-05	0.0292	0.24	0.21	Sleep depth;	chr3:109903989	chr3:109915976~109916940:-
STAD	cis	rs4835473	0.932	rs17750042	ENSG00000249741.2	RP11-673E1.3	3.97	8.76e-05	0.0292	0.25	0.21	Immature fraction of reticulocytes;	chr4:143726691	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1375989	ENSG00000249741.2	RP11-673E1.3	3.97	8.76e-05	0.0292	0.25	0.21	Immature fraction of reticulocytes;	chr4:143726893	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs35598827	ENSG00000249741.2	RP11-673E1.3	3.97	8.76e-05	0.0292	0.25	0.21	Immature fraction of reticulocytes;	chr4:143729605	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs34570929	ENSG00000249741.2	RP11-673E1.3	3.97	8.76e-05	0.0292	0.25	0.21	Immature fraction of reticulocytes;	chr4:143730766	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.9	rs17750172	ENSG00000249741.2	RP11-673E1.3	3.97	8.76e-05	0.0292	0.25	0.21	Immature fraction of reticulocytes;	chr4:143731094	chr4:143911514~143912053:-
STAD	cis	rs1005277	0.579	rs2008449	ENSG00000276805.1	RP11-291L22.6	-3.97	8.76e-05	0.0292	-0.23	-0.21	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38451030~38451785:+
STAD	cis	rs9307551	0.584	rs1371995	ENSG00000250334.4	LINC00989	-3.97	8.77e-05	0.0292	-0.25	-0.21	Refractive error;	chr4:79523353	chr4:79492416~79576460:+
STAD	cis	rs919433	0.926	rs787996	ENSG00000231621.1	AC013264.2	-3.97	8.77e-05	0.0292	-0.18	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352081	chr2:197197991~197199273:+
STAD	cis	rs7395581	0.959	rs35879051	ENSG00000271350.1	CTD-2384B9.1	3.97	8.77e-05	0.0292	0.25	0.21	HDL cholesterol;	chr11:47254331	chr11:47041027~47041945:-
STAD	cis	rs7395581	0.959	rs59663860	ENSG00000271350.1	CTD-2384B9.1	3.97	8.77e-05	0.0292	0.25	0.21	HDL cholesterol;	chr11:47254799	chr11:47041027~47041945:-
STAD	cis	rs7395581	0.879	rs3758673	ENSG00000271350.1	CTD-2384B9.1	3.97	8.77e-05	0.0292	0.25	0.21	HDL cholesterol;	chr11:47257366	chr11:47041027~47041945:-
STAD	cis	rs7395581	0.959	rs2279239	ENSG00000271350.1	CTD-2384B9.1	3.97	8.77e-05	0.0292	0.25	0.21	HDL cholesterol;	chr11:47260229	chr11:47041027~47041945:-
STAD	cis	rs412050	0.947	rs239914	ENSG00000228050.1	TOP3BP1	-3.97	8.77e-05	0.0292	-0.33	-0.21	Attention deficit hyperactivity disorder;	chr22:21962965	chr22:22223187~22224566:-
STAD	cis	rs6669008	1	rs55912359	ENSG00000232450.1	RP4-730K3.3	-3.97	8.77e-05	0.0292	-0.22	-0.21	Bacteremia;	chr1:113624477	chr1:113698884~113699631:-
STAD	cis	rs1707322	1	rs4660331	ENSG00000281133.1	AL355480.3	-3.97	8.77e-05	0.0292	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45580892~45580996:-
STAD	cis	rs1707322	1	rs12097799	ENSG00000281133.1	AL355480.3	-3.97	8.77e-05	0.0292	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45580892~45580996:-
STAD	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	3.97	8.77e-05	0.0292	0.23	0.21	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	3.97	8.77e-05	0.0292	0.23	0.21	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
STAD	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-3.97	8.78e-05	0.0292	-0.25	-0.21	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
STAD	cis	rs10129255	1	rs10134517	ENSG00000232216.1	IGHV3-43	3.97	8.78e-05	0.0292	0.21	0.21	Kawasaki disease;	chr14:106718498	chr14:106470264~106470800:-
STAD	cis	rs2286503	0.78	rs12113458	ENSG00000221740.1	SNORD93	3.97	8.78e-05	0.0292	0.24	0.21	Fibrinogen;	chr7:22816009	chr7:22856613~22856686:+
STAD	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	3.97	8.78e-05	0.0292	0.25	0.21	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
STAD	cis	rs2273156	0.517	rs8007274	ENSG00000258704.4	SRP54-AS1	-3.97	8.78e-05	0.0292	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043012	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.706	rs8009093	ENSG00000258704.4	SRP54-AS1	-3.97	8.78e-05	0.0292	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043497	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.57	rs1028449	ENSG00000258704.4	SRP54-AS1	-3.97	8.78e-05	0.0292	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043789	chr14:34920858~34982532:-
STAD	cis	rs6496044	0.568	rs11632326	ENSG00000259295.5	CSPG4P12	3.97	8.78e-05	0.0292	0.26	0.21	Interstitial lung disease;	chr15:85536603	chr15:85191438~85213905:+
STAD	cis	rs11098499	0.78	rs7680914	ENSG00000260091.1	RP11-33B1.4	3.97	8.79e-05	0.0293	0.21	0.21	Corneal astigmatism;	chr4:119641898	chr4:119409333~119410233:+
STAD	cis	rs1874124	0.836	rs7549963	ENSG00000238078.1	LINC01352	-3.97	8.79e-05	0.0293	-0.28	-0.21	Cholesterol, total;	chr1:220814918	chr1:220829255~220832429:+
STAD	cis	rs7487075	0.78	rs12307969	ENSG00000272963.1	OR7A19P	3.97	8.79e-05	0.0293	0.19	0.21	Itch intensity from mosquito bite;	chr12:46365274	chr12:46592573~46593305:+
STAD	cis	rs4835473	0.868	rs5025156	ENSG00000249741.2	RP11-673E1.3	3.97	8.79e-05	0.0293	0.24	0.21	Immature fraction of reticulocytes;	chr4:143738025	chr4:143911514~143912053:-
STAD	cis	rs12682352	0.579	rs7006589	ENSG00000254340.1	RP11-10A14.3	3.97	8.79e-05	0.0293	0.25	0.21	Neuroticism;	chr8:8810976	chr8:9141424~9145435:+
STAD	cis	rs34779708	0.931	rs34876468	ENSG00000271335.4	RP11-324I22.4	3.97	8.79e-05	0.0293	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs35814343	ENSG00000271335.4	RP11-324I22.4	3.97	8.79e-05	0.0293	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35314552~35336401:-
STAD	cis	rs2901460	0.67	rs2901457	ENSG00000229503.1	AC092155.1	-3.97	8.8e-05	0.0293	-0.17	-0.21	Mean corpuscular volume;	chr2:62159489	chr2:62532583~62533059:-
STAD	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	3.97	8.8e-05	0.0293	0.39	0.21	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
STAD	cis	rs11673344	0.523	rs2562599	ENSG00000267672.1	CTD-2293H3.1	-3.97	8.8e-05	0.0293	-0.19	-0.21	Obesity-related traits;	chr19:37025472	chr19:37091341~37092564:+
STAD	cis	rs5743030	1	rs4531962	ENSG00000223249.1	Y_RNA	-3.97	8.8e-05	0.0293	-0.38	-0.21	Subcutaneous adipose tissue;	chr2:189661957	chr2:189753464~189753559:+
STAD	cis	rs5743030	1	rs4643578	ENSG00000223249.1	Y_RNA	-3.97	8.8e-05	0.0293	-0.38	-0.21	Subcutaneous adipose tissue;	chr2:189661958	chr2:189753464~189753559:+
STAD	cis	rs2638953	0.815	rs11049682	ENSG00000247934.4	RP11-967K21.1	-3.97	8.8e-05	0.0293	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509062	chr12:28163298~28190738:-
STAD	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	3.97	8.8e-05	0.0293	0.35	0.21	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
STAD	cis	rs12745968	0.561	rs10874726	ENSG00000229052.2	RP11-386I23.1	-3.97	8.81e-05	0.0293	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92637542	chr1:92930696~92934098:+
STAD	cis	rs12745968	0.589	rs10782937	ENSG00000229052.2	RP11-386I23.1	-3.97	8.81e-05	0.0293	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92637644	chr1:92930696~92934098:+
STAD	cis	rs11169552	0.51	rs4238106	ENSG00000200183.1	RNU6-238P	-3.97	8.81e-05	0.0293	-0.2	-0.21	Colorectal cancer;	chr12:50603808	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.51	rs10876070	ENSG00000200183.1	RNU6-238P	-3.97	8.81e-05	0.0293	-0.2	-0.21	Colorectal cancer;	chr12:50608305	chr12:50656973~50657078:+
STAD	cis	rs7647973	0.58	rs2117938	ENSG00000225399.4	RP11-3B7.1	-3.97	8.81e-05	0.0293	-0.23	-0.21	Menarche (age at onset);	chr3:49226417	chr3:49260085~49261316:+
STAD	cis	rs6964833	0.935	rs34762099	ENSG00000277072.3	STAG3L2	3.97	8.81e-05	0.0293	0.24	0.21	Menarche (age at onset);	chr7:74636378	chr7:74882163~74890610:-
STAD	cis	rs453301	0.574	rs10081437	ENSG00000254340.1	RP11-10A14.3	-3.97	8.81e-05	0.0293	-0.27	-0.21	Joint mobility (Beighton score);	chr8:9091469	chr8:9141424~9145435:+
STAD	cis	rs7142881	0.508	rs2120142	ENSG00000258648.1	UBE2CP1	-3.97	8.81e-05	0.0293	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31641889	chr14:30683045~30683598:-
STAD	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	3.97	8.81e-05	0.0293	0.28	0.21	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
STAD	cis	rs7512552	0.839	rs834231	ENSG00000203819.6	HIST2H2BC	-3.97	8.81e-05	0.0293	-0.24	-0.21	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150416916	chr1:149850193~149850772:-
STAD	cis	rs72843166	0.545	rs72839491	ENSG00000272164.1	RP11-180P8.5	-3.97	8.81e-05	0.0293	-0.24	-0.21	Intelligence (multi-trait analysis);	chr17:62952547	chr17:63004672~63005152:-
STAD	cis	rs7829975	0.577	rs79495969	ENSG00000254340.1	RP11-10A14.3	-3.97	8.81e-05	0.0293	-0.28	-0.21	Mood instability;	chr8:8687740	chr8:9141424~9145435:+
STAD	cis	rs6686842	0.536	rs12128359	ENSG00000235358.1	RP11-399E6.1	-3.97	8.82e-05	0.0293	-0.23	-0.21	Height;	chr1:41243240	chr1:41242373~41284861:+
STAD	cis	rs6686842	0.536	rs59911668	ENSG00000235358.1	RP11-399E6.1	-3.97	8.82e-05	0.0293	-0.23	-0.21	Height;	chr1:41243803	chr1:41242373~41284861:+
STAD	cis	rs6686842	0.536	rs61774707	ENSG00000235358.1	RP11-399E6.1	-3.97	8.82e-05	0.0293	-0.23	-0.21	Height;	chr1:41247552	chr1:41242373~41284861:+
STAD	cis	rs4218	0.543	rs12050865	ENSG00000259732.1	RP11-59H7.3	-3.97	8.82e-05	0.0293	-0.23	-0.21	Social communication problems;	chr15:59020689	chr15:59121034~59133250:+
STAD	cis	rs4713118	0.739	rs2893931	ENSG00000243307.2	POM121L6P	-3.97	8.82e-05	0.0293	-0.25	-0.21	Parkinson's disease;	chr6:27780231	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.824	rs2092075	ENSG00000243307.2	POM121L6P	-3.97	8.82e-05	0.0293	-0.25	-0.21	Parkinson's disease;	chr6:27781551	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.824	rs13211701	ENSG00000243307.2	POM121L6P	-3.97	8.82e-05	0.0293	-0.25	-0.21	Parkinson's disease;	chr6:27782300	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.824	rs9468229	ENSG00000243307.2	POM121L6P	-3.97	8.82e-05	0.0293	-0.25	-0.21	Parkinson's disease;	chr6:27782307	chr6:26896952~26898777:+
STAD	cis	rs34779708	0.931	rs2384289	ENSG00000271335.4	RP11-324I22.4	3.97	8.82e-05	0.0293	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs11010082	ENSG00000271335.4	RP11-324I22.4	3.97	8.82e-05	0.0293	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs12767414	ENSG00000271335.4	RP11-324I22.4	3.97	8.82e-05	0.0293	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35314552~35336401:-
STAD	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	3.97	8.82e-05	0.0294	0.18	0.21	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
STAD	cis	rs4407350	1	rs12169248	ENSG00000279642.1	RP5-1033E15.3	-3.97	8.83e-05	0.0294	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44525119	chr22:44486295~44486914:-
STAD	cis	rs4407350	0.967	rs5765722	ENSG00000279642.1	RP5-1033E15.3	-3.97	8.83e-05	0.0294	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44525183	chr22:44486295~44486914:-
STAD	cis	rs4407350	1	rs5765724	ENSG00000279642.1	RP5-1033E15.3	-3.97	8.83e-05	0.0294	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44525695	chr22:44486295~44486914:-
STAD	cis	rs12439619	1	rs35152457	ENSG00000259429.4	UBE2Q2P2	-3.97	8.83e-05	0.0294	-0.28	-0.21	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82355142~82420075:+
STAD	cis	rs917195	0.855	rs2267716	ENSG00000264520.1	RP4-777O23.2	3.97	8.83e-05	0.0294	0.2	0.21	Type 2 diabetes;	chr7:30677027	chr7:30525731~30533613:+
STAD	cis	rs9902453	0.791	rs3115086	ENSG00000263477.1	RP11-338L22.2	3.97	8.83e-05	0.0294	0.18	0.21	Coffee consumption (cups per day);	chr17:29698931	chr17:29863402~29866092:+
STAD	cis	rs6686842	0.56	rs7534059	ENSG00000235358.1	RP11-399E6.1	-3.97	8.83e-05	0.0294	-0.23	-0.21	Height;	chr1:41015223	chr1:41242373~41284861:+
STAD	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-3.97	8.83e-05	0.0294	-0.25	-0.21	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
STAD	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	3.97	8.83e-05	0.0294	0.23	0.21	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
STAD	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	3.97	8.84e-05	0.0294	0.16	0.21	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
STAD	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-3.97	8.84e-05	0.0294	-0.21	-0.21	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
STAD	cis	rs870825	0.616	rs28582728	ENSG00000249173.4	LINC01093	-3.97	8.84e-05	0.0294	-0.34	-0.21	Blood protein levels;	chr4:184725766	chr4:184893871~184899454:-
STAD	cis	rs867371	1	rs1392976	ENSG00000276710.3	CSPG4P8	3.97	8.84e-05	0.0294	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82459472~82477258:+
STAD	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	3.97	8.84e-05	0.0294	0.25	0.21	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
STAD	cis	rs17507216	0.718	rs72751675	ENSG00000255769.6	GOLGA2P10	-3.97	8.84e-05	0.0294	-0.35	-0.21	Excessive daytime sleepiness;	chr15:82630452	chr15:82472993~82513950:-
STAD	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	3.97	8.84e-05	0.0294	0.3	0.21	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
STAD	cis	rs9733	0.519	rs11204717	ENSG00000276103.1	U4	3.97	8.84e-05	0.0294	0.2	0.21	Tonsillectomy;	chr1:150736653	chr1:150608507~150608623:-
STAD	cis	rs9326248	0.52	rs10892060	ENSG00000280143.1	AP000892.6	3.97	8.84e-05	0.0294	0.17	0.21	Blood protein levels;	chr11:117010946	chr11:117204967~117210292:+
STAD	cis	rs2098713	0.549	rs62359033	ENSG00000250155.1	CTD-2353F22.1	3.97	8.85e-05	0.0294	0.21	0.21	Telomere length;	chr5:37549741	chr5:36666214~36725195:-
STAD	cis	rs7192392	0.635	rs16948711	ENSG00000279991.1	RP11-190D6.1	3.97	8.85e-05	0.0294	0.19	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr16:78879218	chr16:78166717~78168514:-
STAD	cis	rs6479891	1	rs2616630	ENSG00000235816.3	PRELID1P3	3.97	8.85e-05	0.0294	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs2616629	ENSG00000235816.3	PRELID1P3	3.97	8.85e-05	0.0294	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63427297~63427939:+
STAD	cis	rs6432860	0.868	rs492299	ENSG00000229195.1	AC009495.4	3.97	8.85e-05	0.0294	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166065188	chr2:165794857~165846091:-
STAD	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	3.97	8.85e-05	0.0294	0.28	0.21	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
STAD	cis	rs606458	0.92	rs476037	ENSG00000269038.1	AP001462.6	-3.97	8.85e-05	0.0294	-0.31	-0.21	Urate levels;	chr11:64602068	chr11:64778954~64779405:+
STAD	cis	rs7655841	0.704	rs11934740	ENSG00000248187.1	RP11-184M15.1	3.97	8.85e-05	0.0294	0.31	0.21	Chronic obstructive pulmonary disease (moderate to severe);	chr4:128961593	chr4:128567972~128570531:-
STAD	cis	rs9463078	0.669	rs17288334	ENSG00000219384.1	RP11-491H9.3	-3.97	8.86e-05	0.0294	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45383654	chr6:45158870~45159511:+
STAD	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-3.97	8.86e-05	0.0295	-0.22	-0.21	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
STAD	cis	rs10508774	1	rs72780316	ENSG00000273038.2	RP11-479G22.8	3.97	8.86e-05	0.0295	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32635920	chr10:32887255~32889311:-
STAD	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-3.97	8.86e-05	0.0295	-0.18	-0.21	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
STAD	cis	rs17818399	0.533	rs4384837	ENSG00000279254.1	RP11-536C12.1	-3.97	8.86e-05	0.0295	-0.22	-0.21	Height;	chr2:46562375	chr2:46668870~46670778:+
STAD	cis	rs9907295	0.748	rs2526328	ENSG00000270977.1	AC015849.16	-3.97	8.86e-05	0.0295	-0.33	-0.21	Fibroblast growth factor basic levels;	chr17:35932348	chr17:35893707~35911023:-
STAD	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	3.97	8.86e-05	0.0295	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
STAD	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	3.97	8.86e-05	0.0295	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
STAD	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	3.97	8.86e-05	0.0295	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
STAD	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-3.97	8.86e-05	0.0295	-0.25	-0.21	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
STAD	cis	rs3794924	1	rs35585743	ENSG00000266521.1	RP11-650P15.1	3.97	8.87e-05	0.0295	0.38	0.21	Survival in colon cancer;	chr18:31470398	chr18:31496645~31497195:-
STAD	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-3.97	8.87e-05	0.0295	-0.25	-0.21	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
STAD	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	3.97	8.87e-05	0.0295	0.48	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
STAD	cis	rs2273156	1	rs35797365	ENSG00000258704.4	SRP54-AS1	-3.97	8.87e-05	0.0295	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34983553	chr14:34920858~34982532:-
STAD	cis	rs11157436	0.602	rs17255447	ENSG00000211812.1	TRAV26-2	3.97	8.87e-05	0.0295	0.2	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22202583~22203368:+
STAD	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	3.97	8.88e-05	0.0295	0.3	0.21	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
STAD	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	3.97	8.88e-05	0.0295	0.3	0.21	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
STAD	cis	rs4218	0.543	rs35658945	ENSG00000259732.1	RP11-59H7.3	-3.97	8.88e-05	0.0295	-0.23	-0.21	Social communication problems;	chr15:59018053	chr15:59121034~59133250:+
STAD	cis	rs1858037	0.867	rs67817304	ENSG00000223739.1	AC007389.2	-3.97	8.88e-05	0.0295	-0.2	-0.21	Rheumatoid arthritis;	chr2:65346982	chr2:65511771~65512076:-
STAD	cis	rs10129255	0.536	rs3944157	ENSG00000211959.2	IGHV4-39	3.97	8.88e-05	0.0295	0.19	0.21	Kawasaki disease;	chr14:106682286	chr14:106421711~106422218:-
STAD	cis	rs8012947	1	rs10147580	ENSG00000279636.2	LINC00216	-3.97	8.89e-05	0.0295	-0.2	-0.21	Alcohol consumption in current drinkers;	chr14:58247422	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.958	rs7158746	ENSG00000279636.2	LINC00216	-3.97	8.89e-05	0.0295	-0.2	-0.21	Alcohol consumption in current drinkers;	chr14:58254081	chr14:58288033~58289158:+
STAD	cis	rs17401966	0.931	rs12137880	ENSG00000199562.1	RNU6-37P	3.97	8.89e-05	0.0295	0.16	0.21	Hepatocellular carcinoma;	chr1:10328562	chr1:10298966~10299072:+
STAD	cis	rs870825	0.616	rs14969	ENSG00000249173.4	LINC01093	-3.97	8.89e-05	0.0295	-0.35	-0.21	Blood protein levels;	chr4:184694610	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs3184982	ENSG00000249173.4	LINC01093	-3.97	8.89e-05	0.0295	-0.35	-0.21	Blood protein levels;	chr4:184694614	chr4:184893871~184899454:-
STAD	cis	rs870825	0.587	rs6826883	ENSG00000249173.4	LINC01093	-3.97	8.89e-05	0.0295	-0.35	-0.21	Blood protein levels;	chr4:184695013	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs1527870	ENSG00000249173.4	LINC01093	-3.97	8.89e-05	0.0295	-0.35	-0.21	Blood protein levels;	chr4:184695477	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6810600	ENSG00000249173.4	LINC01093	-3.97	8.89e-05	0.0295	-0.35	-0.21	Blood protein levels;	chr4:184695660	chr4:184893871~184899454:-
STAD	cis	rs4407350	0.788	rs5764879	ENSG00000279642.1	RP5-1033E15.3	-3.97	8.89e-05	0.0295	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44524891	chr22:44486295~44486914:-
STAD	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	3.97	8.9e-05	0.0296	0.22	0.21	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
STAD	cis	rs10946940	0.93	rs10807029	ENSG00000280107.1	AL022393.9	3.97	8.9e-05	0.0296	0.25	0.21	Systemic lupus erythematosus;	chr6:27605684	chr6:28170845~28172521:+
STAD	cis	rs2351088	0.536	rs10483230	ENSG00000230634.1	RP5-996D20.3	3.97	8.9e-05	0.0296	0.31	0.21	Tonsillectomy;	chr22:45769221	chr22:46481329~46481760:-
STAD	cis	rs9907295	0.818	rs4796112	ENSG00000270894.1	AC015849.13	3.97	8.9e-05	0.0296	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35818399~35823713:+
STAD	cis	rs3770081	1	rs58686314	ENSG00000273080.1	RP11-301O19.1	-3.97	8.9e-05	0.0296	-0.47	-0.21	Facial emotion recognition (sad faces);	chr2:85896844	chr2:86195590~86196049:+
STAD	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	3.97	8.91e-05	0.0296	0.22	0.21	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
STAD	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	3.97	8.91e-05	0.0296	0.28	0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
STAD	cis	rs2115630	0.846	rs8024538	ENSG00000275120.1	RP11-182J1.17	-3.97	8.91e-05	0.0296	-0.24	-0.21	P wave terminal force;	chr15:84825188	chr15:84599434~84606463:-
STAD	cis	rs875971	0.651	rs2420596	ENSG00000224316.1	RP11-479O9.2	3.97	8.91e-05	0.0296	0.2	0.21	Aortic root size;	chr7:66450996	chr7:65773620~65802067:+
STAD	cis	rs875971	0.52	rs2420597	ENSG00000224316.1	RP11-479O9.2	3.97	8.91e-05	0.0296	0.2	0.21	Aortic root size;	chr7:66450999	chr7:65773620~65802067:+
STAD	cis	rs34779708	0.733	rs61449529	ENSG00000271335.4	RP11-324I22.4	3.97	8.91e-05	0.0296	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.733	rs59287215	ENSG00000271335.4	RP11-324I22.4	3.97	8.91e-05	0.0296	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35314552~35336401:-
STAD	cis	rs9291683	0.588	rs2240724	ENSG00000250613.1	RP11-136I13.1	-3.97	8.91e-05	0.0296	-0.19	-0.21	Bone mineral density;	chr4:10019666	chr4:10410996~10411644:+
STAD	cis	rs12931792	0.712	rs4787495	ENSG00000273724.1	RP11-347C12.12	-3.97	8.92e-05	0.0296	-0.2	-0.21	Tonsillectomy;	chr16:30154404	chr16:30336400~30343336:+
STAD	cis	rs10129255	0.536	rs6576201	ENSG00000211959.2	IGHV4-39	-3.97	8.92e-05	0.0296	-0.18	-0.21	Kawasaki disease;	chr14:106683696	chr14:106421711~106422218:-
STAD	cis	rs7208859	0.673	rs73263981	ENSG00000263603.1	CTD-2349P21.5	-3.97	8.92e-05	0.0296	-0.25	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30729469~30731202:+
STAD	cis	rs6432852	0.527	rs13409535	ENSG00000229195.1	AC009495.4	-3.96	8.92e-05	0.0296	-0.24	-0.21	Diabetic kidney disease;	chr2:165938560	chr2:165794857~165846091:-
STAD	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	3.96	8.92e-05	0.0296	0.36	0.21	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
STAD	cis	rs2638953	0.85	rs11049428	ENSG00000247934.4	RP11-967K21.1	-3.96	8.93e-05	0.0296	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194267	chr12:28163298~28190738:-
STAD	cis	rs9291683	0.595	rs11722930	ENSG00000250613.1	RP11-136I13.1	-3.96	8.93e-05	0.0296	-0.19	-0.21	Bone mineral density;	chr4:10033830	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.595	rs3733585	ENSG00000250613.1	RP11-136I13.1	-3.96	8.93e-05	0.0296	-0.19	-0.21	Bone mineral density;	chr4:10034715	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.561	rs3733584	ENSG00000250613.1	RP11-136I13.1	-3.96	8.93e-05	0.0296	-0.19	-0.21	Bone mineral density;	chr4:10034882	chr4:10410996~10411644:+
STAD	cis	rs10857712	0.551	rs12252576	ENSG00000273327.1	OR6L2P	-3.96	8.93e-05	0.0296	-0.21	-0.21	Systemic lupus erythematosus;	chr10:133413740	chr10:133430394~133431318:-
STAD	cis	rs4792901	0.802	rs79934399	ENSG00000279602.1	CTD-3014M21.1	-3.96	8.93e-05	0.0296	-0.28	-0.21	Dupuytren's disease;	chr17:43494593	chr17:43360041~43361361:-
STAD	cis	rs55661361	0.965	rs12293670	ENSG00000245498.5	RP11-677M14.7	3.96	8.94e-05	0.0297	0.25	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124743036	chr11:124800450~124834487:+
STAD	cis	rs8018967	0.622	rs2041073	ENSG00000258695.2	RP3-414A15.2	3.96	8.94e-05	0.0297	0.24	0.21	Blood metabolite ratios;	chr14:73505831	chr14:73522878~73530610:+
STAD	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-3.96	8.94e-05	0.0297	-0.23	-0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
STAD	cis	rs1075265	0.756	rs809280	ENSG00000235937.1	AC008280.1	3.96	8.94e-05	0.0297	0.19	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54029552~54030682:-
STAD	cis	rs78773383	0.505	rs13123782	ENSG00000249207.1	RP11-360F5.1	3.96	8.94e-05	0.0297	0.2	0.21	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39112677~39126818:-
STAD	cis	rs6693567	0.507	rs4970964	ENSG00000203819.6	HIST2H2BC	3.96	8.95e-05	0.0297	0.24	0.21	Migraine;	chr1:150485553	chr1:149850193~149850772:-
STAD	cis	rs938554	0.692	rs13111638	ENSG00000250613.1	RP11-136I13.1	-3.96	8.95e-05	0.0297	-0.25	-0.21	Blood metabolite levels;	chr4:9995266	chr4:10410996~10411644:+
STAD	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	3.96	8.95e-05	0.0297	0.31	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
STAD	cis	rs8012947	1	rs8009527	ENSG00000279636.2	LINC00216	-3.96	8.95e-05	0.0297	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58285394	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.959	rs10137327	ENSG00000279636.2	LINC00216	-3.96	8.95e-05	0.0297	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58287183	chr14:58288033~58289158:+
STAD	cis	rs8012947	1	rs7149735	ENSG00000279636.2	LINC00216	-3.96	8.95e-05	0.0297	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58289703	chr14:58288033~58289158:+
STAD	cis	rs8012947	0.959	rs6573198	ENSG00000279636.2	LINC00216	-3.96	8.95e-05	0.0297	-0.21	-0.21	Alcohol consumption in current drinkers;	chr14:58293044	chr14:58288033~58289158:+
STAD	cis	rs2638953	0.924	rs7973516	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207523	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7973656	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207679	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7971033	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208420	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7956418	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208566	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11519094	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209430	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11513465	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209483	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11513250	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209500	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11519330	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209720	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.85	rs11519331	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209995	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.888	rs11513466	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210111	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7298652	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210620	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs6487669	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210827	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs6487671	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210902	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs11049464	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28211637	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs10843137	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28218788	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs10843138	ENSG00000247934.4	RP11-967K21.1	-3.96	8.96e-05	0.0297	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28219210	chr12:28163298~28190738:-
STAD	cis	rs7474896	1	rs10827823	ENSG00000099251.13	HSD17B7P2	3.96	8.96e-05	0.0297	0.34	0.21	Obesity (extreme);	chr10:37750453	chr10:38356380~38378505:+
STAD	cis	rs1874124	0.836	rs17596947	ENSG00000238078.1	LINC01352	3.96	8.96e-05	0.0297	0.28	0.21	Cholesterol, total;	chr1:220820122	chr1:220829255~220832429:+
STAD	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	3.96	8.96e-05	0.0297	0.24	0.21	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
STAD	cis	rs2957692	0.548	rs55796222	ENSG00000254554.1	RP11-351I24.1	3.96	8.96e-05	0.0297	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10239771	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs12420122	ENSG00000254554.1	RP11-351I24.1	3.96	8.96e-05	0.0297	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10240755	chr11:10302657~10303704:-
STAD	cis	rs9907295	1	rs9908011	ENSG00000270894.1	AC015849.13	-3.96	8.96e-05	0.0297	-0.24	-0.21	Fibroblast growth factor basic levels;	chr17:35908371	chr17:35818399~35823713:+
STAD	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-3.96	8.96e-05	0.0297	-0.26	-0.21	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
STAD	cis	rs11169552	0.51	rs55877451	ENSG00000200183.1	RNU6-238P	-3.96	8.97e-05	0.0297	-0.2	-0.21	Colorectal cancer;	chr12:50593595	chr12:50656973~50657078:+
STAD	cis	rs11169552	0.51	rs4768899	ENSG00000200183.1	RNU6-238P	-3.96	8.97e-05	0.0297	-0.2	-0.21	Colorectal cancer;	chr12:50606883	chr12:50656973~50657078:+
STAD	cis	rs860295	0.702	rs2048431	ENSG00000225855.5	RUSC1-AS1	3.96	8.97e-05	0.0297	0.17	0.21	Body mass index;	chr1:155648839	chr1:155316863~155324176:-
STAD	cis	rs4792901	0.729	rs72833142	ENSG00000279602.1	CTD-3014M21.1	-3.96	8.97e-05	0.0297	-0.29	-0.21	Dupuytren's disease;	chr17:43538188	chr17:43360041~43361361:-
STAD	cis	rs2351088	0.764	rs10483231	ENSG00000230634.1	RP5-996D20.3	-3.96	8.97e-05	0.0298	-0.35	-0.21	Tonsillectomy;	chr22:45782129	chr22:46481329~46481760:-
STAD	cis	rs7474896	0.848	rs2738193	ENSG00000099251.13	HSD17B7P2	-3.96	8.97e-05	0.0298	-0.35	-0.21	Obesity (extreme);	chr10:37978834	chr10:38356380~38378505:+
STAD	cis	rs11603023	0.804	rs527619	ENSG00000278376.1	RP11-158I9.8	3.96	8.97e-05	0.0298	0.22	0.21	Cholesterol, total;	chr11:118692577	chr11:118791254~118793137:+
STAD	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	3.96	8.98e-05	0.0298	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
STAD	cis	rs1322639	0.575	rs9294966	ENSG00000261039.2	RP11-417E7.2	-3.96	8.98e-05	0.0298	-0.33	-0.21	Pulse pressure;	chr6:169165223	chr6:169175304~169182740:-
STAD	cis	rs1322639	0.614	rs7768154	ENSG00000261039.2	RP11-417E7.2	-3.96	8.98e-05	0.0298	-0.33	-0.21	Pulse pressure;	chr6:169165375	chr6:169175304~169182740:-
STAD	cis	rs1322639	0.614	rs6900200	ENSG00000261039.2	RP11-417E7.2	-3.96	8.98e-05	0.0298	-0.33	-0.21	Pulse pressure;	chr6:169166078	chr6:169175304~169182740:-
STAD	cis	rs259282	0.605	rs8101007	ENSG00000201388.1	SNORA68	3.96	8.98e-05	0.0298	0.21	0.21	Schizophrenia;	chr19:32618651	chr19:32608337~32608469:-
STAD	cis	rs6686842	0.536	rs12121121	ENSG00000235358.1	RP11-399E6.1	-3.96	8.98e-05	0.0298	-0.23	-0.21	Height;	chr1:41218784	chr1:41242373~41284861:+
STAD	cis	rs11976180	1	rs1919951	ENSG00000204959.4	ARHGEF34P	3.96	8.98e-05	0.0298	0.29	0.21	Obesity-related traits;	chr7:144071798	chr7:144272445~144286966:-
STAD	cis	rs2115630	1	rs11854291	ENSG00000275120.1	RP11-182J1.17	-3.96	8.98e-05	0.0298	-0.23	-0.21	P wave terminal force;	chr15:84820477	chr15:84599434~84606463:-
STAD	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	3.96	8.99e-05	0.0298	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	3.96	8.99e-05	0.0298	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	3.96	8.99e-05	0.0298	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
STAD	cis	rs10911902	0.688	rs113019508	ENSG00000229739.2	RP11-295K2.3	-3.96	8.99e-05	0.0298	-0.3	-0.21	Schizophrenia;	chr1:186349685	chr1:186435161~186470291:+
STAD	cis	rs919433	0.889	rs787995	ENSG00000231621.1	AC013264.2	-3.96	8.99e-05	0.0298	-0.18	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352129	chr2:197197991~197199273:+
STAD	cis	rs1858037	0.867	rs6727013	ENSG00000223739.1	AC007389.2	-3.96	8.99e-05	0.0298	-0.2	-0.21	Rheumatoid arthritis;	chr2:65331241	chr2:65511771~65512076:-
STAD	cis	rs5763662	1	rs1476514	ENSG00000233010.1	RPEP4	-3.96	8.99e-05	0.0298	-0.44	-0.21	LDL cholesterol levels;LDL cholesterol;	chr22:30037833	chr22:29608900~29609501:+
STAD	cis	rs5753618	0.561	rs5749265	ENSG00000236132.1	CTA-440B3.1	-3.96	9e-05	0.0298	-0.23	-0.21	Colorectal cancer;	chr22:31400911	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.583	rs5753601	ENSG00000236132.1	CTA-440B3.1	-3.96	9e-05	0.0298	-0.23	-0.21	Colorectal cancer;	chr22:31402273	chr22:31816379~31817491:-
STAD	cis	rs9425766	0.962	rs941989	ENSG00000227373.4	RP11-160H22.5	-3.96	9e-05	0.0298	-0.25	-0.21	Life satisfaction;	chr1:173912733	chr1:174115300~174160004:-
STAD	cis	rs9859260	0.614	rs493661	ENSG00000242086.7	LINC00969	-3.96	9e-05	0.0298	-0.19	-0.21	Mean corpuscular volume;	chr3:196059618	chr3:195658062~195739964:+
STAD	cis	rs4763879	0.729	rs10844472	ENSG00000256673.1	RP11-599J14.2	3.96	9e-05	0.0298	0.22	0.21	Type 1 diabetes;	chr12:9691137	chr12:9398355~9414851:-
STAD	cis	rs4589258	0.788	rs10765383	ENSG00000280367.1	RP11-121L10.2	3.96	9e-05	0.0298	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90748868	chr11:90223153~90226538:+
STAD	cis	rs304029	0.553	rs2633845	ENSG00000229241.1	PNPT1P1	-3.96	9e-05	0.0298	-0.26	-0.21	Diabetic kidney disease;	chr3:4471761	chr3:3981981~3984295:-
STAD	cis	rs304029	0.553	rs2819578	ENSG00000229241.1	PNPT1P1	-3.96	9e-05	0.0298	-0.26	-0.21	Diabetic kidney disease;	chr3:4471874	chr3:3981981~3984295:-
STAD	cis	rs304029	0.553	rs2819577	ENSG00000229241.1	PNPT1P1	-3.96	9e-05	0.0298	-0.26	-0.21	Diabetic kidney disease;	chr3:4472124	chr3:3981981~3984295:-
STAD	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	3.96	9.01e-05	0.0298	0.24	0.21	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
STAD	cis	rs7176527	0.848	rs72630462	ENSG00000225151.9	GOLGA2P7	3.96	9.01e-05	0.0298	0.31	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:84199311~84230136:-
STAD	cis	rs9517906	0.522	rs8002475	ENSG00000218502.3	H2AFZP3	3.96	9.01e-05	0.0298	0.19	0.21	Survival in pancreatic cancer;	chr13:99879202	chr13:99215372~99215758:-
STAD	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	3.96	9.01e-05	0.0298	0.3	0.21	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	3.96	9.01e-05	0.0298	0.3	0.21	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	3.96	9.01e-05	0.0298	0.3	0.21	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	3.96	9.01e-05	0.0298	0.3	0.21	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	3.96	9.01e-05	0.0298	0.3	0.21	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
STAD	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	3.96	9.01e-05	0.0298	0.3	0.21	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
STAD	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-3.96	9.01e-05	0.0298	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
STAD	cis	rs1816752	0.87	rs9318529	ENSG00000232858.1	RPL34P27	3.96	9.01e-05	0.0299	0.13	0.21	Obesity-related traits;	chr13:24424190	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.905	rs9511249	ENSG00000232858.1	RPL34P27	3.96	9.01e-05	0.0299	0.13	0.21	Obesity-related traits;	chr13:24425457	chr13:24988577~24988925:-
STAD	cis	rs6479891	0.915	rs4281380	ENSG00000235816.3	PRELID1P3	-3.96	9.02e-05	0.0299	-0.26	-0.21	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63427297~63427939:+
STAD	cis	rs896854	0.684	rs10098778	ENSG00000253528.2	RP11-347C18.4	3.96	9.02e-05	0.0299	0.19	0.21	Type 2 diabetes;	chr8:94979792	chr8:94974573~94974853:-
STAD	cis	rs3764021	0.87	rs2192437	ENSG00000256673.1	RP11-599J14.2	-3.96	9.02e-05	0.0299	-0.22	-0.21	Type 1 diabetes;	chr12:9726639	chr12:9398355~9414851:-
STAD	cis	rs3764021	0.87	rs10844617	ENSG00000256673.1	RP11-599J14.2	-3.96	9.02e-05	0.0299	-0.22	-0.21	Type 1 diabetes;	chr12:9726772	chr12:9398355~9414851:-
STAD	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	3.96	9.02e-05	0.0299	0.21	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
STAD	cis	rs11089937	0.539	rs6001075	ENSG00000211640.3	IGLV6-57	3.96	9.03e-05	0.0299	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22195713~22196460:+
STAD	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	3.96	9.03e-05	0.0299	0.31	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
STAD	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	3.96	9.03e-05	0.0299	0.31	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
STAD	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	3.96	9.03e-05	0.0299	0.31	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
STAD	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-3.96	9.03e-05	0.0299	-0.28	-0.21	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
STAD	cis	rs11169552	0.51	rs7307419	ENSG00000200183.1	RNU6-238P	-3.96	9.03e-05	0.0299	-0.2	-0.21	Colorectal cancer;	chr12:50613230	chr12:50656973~50657078:+
STAD	cis	rs2273156	0.929	rs7144646	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34985495	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs56686328	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34988864	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs7153068	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34990275	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs12050390	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34991873	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs12050402	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992610	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs12050404	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992664	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs12050447	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992759	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs74046408	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34997929	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs8017191	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000785	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs8018114	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000813	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs12880809	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006450	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs12880928	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006472	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs36112862	ENSG00000258704.4	SRP54-AS1	-3.96	9.03e-05	0.0299	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35009227	chr14:34920858~34982532:-
STAD	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	3.96	9.03e-05	0.0299	0.24	0.21	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
STAD	cis	rs6933660	0.721	rs2128945	ENSG00000221469.1	AL133260.1	3.96	9.03e-05	0.0299	0.22	0.21	Menarche (age at onset);	chr6:151446772	chr6:151039916~151039971:-
STAD	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	3.96	9.03e-05	0.0299	0.24	0.21	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
STAD	cis	rs2348418	0.932	rs7968515	ENSG00000247934.4	RP11-967K21.1	3.96	9.04e-05	0.0299	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28163298~28190738:-
STAD	cis	rs41411047	1	rs41411047	ENSG00000224831.3	RP11-651P23.4	3.96	9.04e-05	0.0299	0.38	0.21	Myocardial infarction;	chr3:149875124	chr3:149982181~149983308:-
STAD	cis	rs34779708	0.9	rs73262807	ENSG00000271335.4	RP11-324I22.4	3.96	9.04e-05	0.0299	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs4934736	ENSG00000271335.4	RP11-324I22.4	3.96	9.04e-05	0.0299	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs17591781	ENSG00000271335.4	RP11-324I22.4	3.96	9.04e-05	0.0299	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs17500582	ENSG00000271335.4	RP11-324I22.4	3.96	9.04e-05	0.0299	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs11010125	ENSG00000271335.4	RP11-324I22.4	3.96	9.04e-05	0.0299	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs17591857	ENSG00000271335.4	RP11-324I22.4	-3.96	9.04e-05	0.0299	-0.25	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35314552~35336401:-
STAD	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-3.96	9.04e-05	0.0299	-0.23	-0.21	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
STAD	cis	rs7429990	0.965	rs34750113	ENSG00000224895.1	VPS26BP1	-3.96	9.04e-05	0.0299	-0.21	-0.21	Educational attainment (years of education);	chr3:47944902	chr3:47960327~47961081:-
STAD	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	3.96	9.04e-05	0.0299	0.21	0.21	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
STAD	cis	rs11644601	1	rs11644601	ENSG00000263335.1	AF001548.5	-3.96	9.04e-05	0.0299	-0.27	-0.21	Metabolite levels (lipid measures);	chr16:15078261	chr16:15726674~15732993:+
STAD	cis	rs1790761	0.667	rs4147581	ENSG00000231793.4	DOC2GP	3.96	9.04e-05	0.0299	0.24	0.21	Mean corpuscular volume;	chr11:67584114	chr11:67612653~67616257:-
STAD	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	3.96	9.05e-05	0.0299	0.31	0.21	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
STAD	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-3.96	9.05e-05	0.0299	-0.22	-0.21	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
STAD	cis	rs2638953	0.741	rs10843199	ENSG00000247934.4	RP11-967K21.1	3.96	9.05e-05	0.0299	0.24	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535711	chr12:28163298~28190738:-
STAD	cis	rs9905704	0.647	rs6503888	ENSG00000224738.1	AC099850.1	3.96	9.05e-05	0.0299	0.24	0.21	Testicular germ cell tumor;	chr17:58950765	chr17:59106598~59118267:+
STAD	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-3.96	9.05e-05	0.0299	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
STAD	cis	rs6430585	0.697	rs6724569	ENSG00000231890.6	DARS-AS1	-3.96	9.05e-05	0.03	-0.25	-0.21	Corneal structure;	chr2:135759400	chr2:135985176~136022593:+
STAD	cis	rs3864261	0.515	rs55769858	ENSG00000251467.1	CTC-250P20.2	3.96	9.05e-05	0.03	0.22	0.21	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:72996920~72997642:+
STAD	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-3.96	9.05e-05	0.03	-0.28	-0.21	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
STAD	cis	rs2803122	0.871	rs10481512	ENSG00000272842.1	RP11-513M16.7	-3.96	9.06e-05	0.03	-0.19	-0.21	Pulse pressure;	chr9:19230741	chr9:19371386~19371945:-
STAD	cis	rs10782582	0.593	rs17585530	ENSG00000181227.3	RP4-682C21.2	3.96	9.06e-05	0.03	0.22	0.21	Daytime sleep phenotypes;	chr1:75669305	chr1:75743423~75744776:-
STAD	cis	rs10782582	0.593	rs114421765	ENSG00000181227.3	RP4-682C21.2	3.96	9.06e-05	0.03	0.22	0.21	Daytime sleep phenotypes;	chr1:75676117	chr1:75743423~75744776:-
STAD	cis	rs10776614	0.642	rs7896644	ENSG00000226964.1	RHEBP2	-3.96	9.06e-05	0.03	-0.26	-0.21	Self-employment;	chr10:48556005	chr10:47706203~47706802:+
STAD	cis	rs615632	0.53	rs10092464	ENSG00000254340.1	RP11-10A14.3	-3.96	9.07e-05	0.03	-0.25	-0.21	Neuroticism;	chr8:9946675	chr8:9141424~9145435:+
STAD	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	3.96	9.07e-05	0.03	0.3	0.21	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
STAD	cis	rs42490	0.664	rs422559	ENSG00000251136.7	RP11-37B2.1	-3.96	9.07e-05	0.03	-0.21	-0.21	Leprosy;	chr8:89809121	chr8:89609409~89757727:-
STAD	cis	rs11089937	0.626	rs5757017	ENSG00000211640.3	IGLV6-57	3.96	9.07e-05	0.03	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.568	rs59356111	ENSG00000211640.3	IGLV6-57	3.96	9.07e-05	0.03	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs5757019	ENSG00000211640.3	IGLV6-57	3.96	9.07e-05	0.03	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22195713~22196460:+
STAD	cis	rs10510102	0.516	rs11200300	ENSG00000226864.1	ATE1-AS1	3.96	9.07e-05	0.03	0.36	0.21	Breast cancer;	chr10:121977489	chr10:121928312~121951965:+
STAD	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-3.96	9.08e-05	0.03	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
STAD	cis	rs6693567	0.516	rs7554686	ENSG00000203819.6	HIST2H2BC	-3.96	9.08e-05	0.03	-0.25	-0.21	Migraine;	chr1:150293199	chr1:149850193~149850772:-
STAD	cis	rs10073892	0.789	rs62369688	ENSG00000250682.4	LINC00491	-3.96	9.08e-05	0.03	-0.24	-0.21	Cognitive decline (age-related);	chr5:102528135	chr5:102609156~102671559:-
STAD	cis	rs75583333	0.502	rs2032836	ENSG00000247699.2	CTB-127C13.1	-3.96	9.08e-05	0.03	-0.26	-0.21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160204355	chr5:160195744~160204826:-
STAD	cis	rs10129255	0.957	rs8009948	ENSG00000224373.3	IGHV4-59	3.96	9.09e-05	0.03	0.17	0.21	Kawasaki disease;	chr14:106805607	chr14:106627249~106627825:-
STAD	cis	rs867371	0.762	rs12905578	ENSG00000276710.3	CSPG4P8	3.96	9.09e-05	0.0301	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82459472~82477258:+
STAD	cis	rs4589258	0.788	rs7931598	ENSG00000280367.1	RP11-121L10.2	3.96	9.09e-05	0.0301	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90764616	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs1894137	ENSG00000280367.1	RP11-121L10.2	3.96	9.09e-05	0.0301	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90764815	chr11:90223153~90226538:+
STAD	cis	rs7849270	1	rs3124513	ENSG00000234055.1	RP11-247A12.1	-3.96	9.09e-05	0.0301	-0.24	-0.21	Blood metabolite ratios;	chr9:129142314	chr9:129097854~129100266:+
STAD	cis	rs7849270	1	rs3124514	ENSG00000234055.1	RP11-247A12.1	-3.96	9.09e-05	0.0301	-0.24	-0.21	Blood metabolite ratios;	chr9:129142329	chr9:129097854~129100266:+
STAD	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	3.96	9.09e-05	0.0301	0.23	0.21	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
STAD	cis	rs8097348	0.857	rs759741	ENSG00000266602.1	RP11-476K15.1	-3.96	9.1e-05	0.0301	-0.24	-0.21	Exercise (leisure time);	chr18:1604592	chr18:1509183~1647097:+
STAD	cis	rs12468226	0.938	rs76501067	ENSG00000272966.1	RP11-686O6.1	3.96	9.1e-05	0.0301	0.31	0.21	Urate levels;	chr2:202318042	chr2:202336739~202337200:+
STAD	cis	rs950169	0.579	rs881983	ENSG00000259728.4	LINC00933	3.96	9.1e-05	0.0301	0.31	0.21	Schizophrenia;	chr15:83978556	chr15:84570649~84580175:+
STAD	cis	rs7916697	0.593	rs7912895	ENSG00000234102.1	KRT19P4	-3.96	9.1e-05	0.0301	-0.23	-0.21	Optic disc area;	chr10:68261741	chr10:68260557~68261499:+
STAD	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-3.96	9.1e-05	0.0301	-0.27	-0.21	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
STAD	cis	rs7937127	0.744	rs72898994	ENSG00000254907.1	RP11-484D2.2	3.96	9.11e-05	0.0301	0.36	0.21	Fibrinogen levels;	chr11:43357020	chr11:43328748~43359296:-
STAD	cis	rs7937127	0.696	rs72898996	ENSG00000254907.1	RP11-484D2.2	3.96	9.11e-05	0.0301	0.36	0.21	Fibrinogen levels;	chr11:43359775	chr11:43328748~43359296:-
STAD	cis	rs2836950	0.565	rs3171465	ENSG00000238141.2	BRWD1-AS1	-3.96	9.11e-05	0.0301	-0.21	-0.21	Menarche (age at onset);	chr21:39180381	chr21:39315707~39323218:+
STAD	cis	rs853679	0.657	rs1778483	ENSG00000220721.1	OR1F12	3.96	9.11e-05	0.0301	0.2	0.21	Depression;	chr6:28273214	chr6:28073316~28074233:+
STAD	cis	rs13113518	0.729	rs11133377	ENSG00000223305.1	RN7SKP30	3.96	9.11e-05	0.0301	0.24	0.21	Height;	chr4:55413708	chr4:55540502~55540835:-
STAD	cis	rs9287719	0.615	rs12613769	ENSG00000243819.4	RN7SL832P	3.96	9.11e-05	0.0301	0.21	0.21	Prostate cancer;	chr2:10602164	chr2:10690344~10692099:+
STAD	cis	rs4713118	0.513	rs149972	ENSG00000220721.1	OR1F12	3.96	9.11e-05	0.0301	0.22	0.21	Parkinson's disease;	chr6:28015449	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.513	rs149975	ENSG00000220721.1	OR1F12	3.96	9.11e-05	0.0301	0.22	0.21	Parkinson's disease;	chr6:28018562	chr6:28073316~28074233:+
STAD	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	3.96	9.11e-05	0.0301	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
STAD	cis	rs7487075	0.576	rs10785635	ENSG00000257261.4	RP11-96H19.1	3.96	9.12e-05	0.0301	0.26	0.21	Itch intensity from mosquito bite;	chr12:46715034	chr12:46383679~46876159:+
STAD	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	3.96	9.12e-05	0.0301	0.26	0.21	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
STAD	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-3.96	9.12e-05	0.0301	-0.26	-0.21	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
STAD	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	3.96	9.12e-05	0.0301	0.28	0.21	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
STAD	cis	rs62223500	0.756	rs62223497	ENSG00000232079.5	AL035610.1	-3.96	9.12e-05	0.0301	-0.26	-0.21	Total body bone mineral density;	chr21:27402758	chr21:28048404~28137611:+
STAD	cis	rs904251	0.507	rs11756941	ENSG00000204110.6	RP1-153P14.8	-3.96	9.12e-05	0.0301	-0.25	-0.21	Cognitive performance;	chr6:37448443	chr6:37507348~37535616:+
STAD	cis	rs10998036	0.591	rs10823171	ENSG00000233590.1	RP11-153K11.3	3.96	9.12e-05	0.0301	0.27	0.21	Optic cup area;	chr10:68292171	chr10:68233251~68242379:-
STAD	cis	rs4535700	0.501	rs10245725	ENSG00000226278.1	PSPHP1	-3.96	9.12e-05	0.0301	-0.25	-0.21	Macular telangiectasia type 2;	chr7:55908855	chr7:55764797~55773288:+
STAD	cis	rs6686842	0.56	rs2802549	ENSG00000235358.1	RP11-399E6.1	3.96	9.13e-05	0.0302	0.23	0.21	Height;	chr1:41034874	chr1:41242373~41284861:+
STAD	cis	rs10129255	0.83	rs61997609	ENSG00000232216.1	IGHV3-43	3.96	9.13e-05	0.0302	0.21	0.21	Kawasaki disease;	chr14:106692376	chr14:106470264~106470800:-
STAD	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-3.96	9.13e-05	0.0302	-0.31	-0.21	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
STAD	cis	rs9326248	0.539	rs10892058	ENSG00000280143.1	AP000892.6	3.96	9.13e-05	0.0302	0.16	0.21	Blood protein levels;	chr11:117005905	chr11:117204967~117210292:+
STAD	cis	rs5769765	0.542	rs5770725	ENSG00000188511.11	C22orf34	-3.96	9.13e-05	0.0302	-0.29	-0.21	Schizophrenia;	chr22:49862661	chr22:49414524~49657542:-
STAD	cis	rs5770917	1	rs1056964	ENSG00000273272.1	CTA-384D8.34	3.96	9.13e-05	0.0302	0.33	0.21	Narcolepsy;	chr22:50579047	chr22:50542650~50543011:+
STAD	cis	rs2836974	0.674	rs1011413	ENSG00000238141.2	BRWD1-AS1	-3.96	9.14e-05	0.0302	-0.22	-0.21	Cognitive function;	chr21:39266315	chr21:39315707~39323218:+
STAD	cis	rs2836974	0.568	rs2836969	ENSG00000238141.2	BRWD1-AS1	-3.96	9.14e-05	0.0302	-0.22	-0.21	Cognitive function;	chr21:39276339	chr21:39315707~39323218:+
STAD	cis	rs2836974	0.605	rs2836971	ENSG00000238141.2	BRWD1-AS1	-3.96	9.14e-05	0.0302	-0.22	-0.21	Cognitive function;	chr21:39280114	chr21:39315707~39323218:+
STAD	cis	rs2836974	0.584	rs6517535	ENSG00000238141.2	BRWD1-AS1	-3.96	9.14e-05	0.0302	-0.22	-0.21	Cognitive function;	chr21:39281426	chr21:39315707~39323218:+
STAD	cis	rs2836974	0.627	rs7278985	ENSG00000238141.2	BRWD1-AS1	-3.96	9.14e-05	0.0302	-0.22	-0.21	Cognitive function;	chr21:39281841	chr21:39315707~39323218:+
STAD	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	3.96	9.14e-05	0.0302	0.29	0.21	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
STAD	cis	rs60180747	1	rs11636809	ENSG00000252712.1	SCARNA14	3.96	9.14e-05	0.0302	0.24	0.21	Testicular germ cell tumor;	chr15:66437589	chr15:66347207~66347342:-
STAD	cis	rs60180747	1	rs11630608	ENSG00000252712.1	SCARNA14	3.96	9.14e-05	0.0302	0.24	0.21	Testicular germ cell tumor;	chr15:66452799	chr15:66347207~66347342:-
STAD	cis	rs4950322	0.563	rs6686480	ENSG00000278811.3	LINC00624	3.96	9.14e-05	0.0302	0.22	0.21	Protein quantitative trait loci;	chr1:147111986	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.563	rs6700783	ENSG00000278811.3	LINC00624	3.96	9.14e-05	0.0302	0.22	0.21	Protein quantitative trait loci;	chr1:147111987	chr1:147258885~147517875:-
STAD	cis	rs3858145	0.5	rs4633337	ENSG00000234102.1	KRT19P4	3.96	9.14e-05	0.0302	0.24	0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68260557~68261499:+
STAD	cis	rs14027	0.883	rs10102038	ENSG00000279347.1	RP11-85I17.2	-3.96	9.14e-05	0.0302	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119838736~119840385:-
STAD	cis	rs14027	0.883	rs35660840	ENSG00000279347.1	RP11-85I17.2	-3.96	9.14e-05	0.0302	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119838736~119840385:-
STAD	cis	rs14027	0.883	rs1433953	ENSG00000279347.1	RP11-85I17.2	-3.96	9.14e-05	0.0302	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119838736~119840385:-
STAD	cis	rs14027	0.883	rs13272852	ENSG00000279347.1	RP11-85I17.2	-3.96	9.14e-05	0.0302	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119838736~119840385:-
STAD	cis	rs12362063	0.9	rs7949185	ENSG00000255450.1	CTD-2063L20.1	-3.96	9.14e-05	0.0302	-0.19	-0.21	Hepatitis B;	chr11:29243432	chr11:29275655~29276565:+
STAD	cis	rs10129255	0.869	rs7150549	ENSG00000224373.3	IGHV4-59	3.96	9.14e-05	0.0302	0.17	0.21	Kawasaki disease;	chr14:106705441	chr14:106627249~106627825:-
STAD	cis	rs4792901	0.802	rs2242598	ENSG00000279602.1	CTD-3014M21.1	-3.96	9.15e-05	0.0302	-0.28	-0.21	Dupuytren's disease;	chr17:43533030	chr17:43360041~43361361:-
STAD	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	3.96	9.15e-05	0.0302	0.27	0.21	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
STAD	cis	rs1876905	0.569	rs354523	ENSG00000271789.1	RP5-1112D6.7	-3.96	9.15e-05	0.0302	-0.24	-0.21	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111297126~111298510:+
STAD	cis	rs1876905	0.68	rs187130	ENSG00000271789.1	RP5-1112D6.7	-3.96	9.15e-05	0.0302	-0.24	-0.21	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111297126~111298510:+
STAD	cis	rs559928	0.606	rs11600628	ENSG00000236935.1	AP003774.1	3.96	9.15e-05	0.0302	0.33	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208555	chr11:64325050~64329504:-
STAD	cis	rs4568518	0.869	rs11531484	ENSG00000279048.1	RP11-511H23.2	3.96	9.15e-05	0.0302	0.19	0.21	Measles;	chr7:17996075	chr7:17940503~17942922:+
STAD	cis	rs11603023	0.967	rs4245184	ENSG00000278376.1	RP11-158I9.8	3.96	9.15e-05	0.0302	0.22	0.21	Cholesterol, total;	chr11:118639844	chr11:118791254~118793137:+
STAD	cis	rs11603023	0.967	rs644273	ENSG00000278376.1	RP11-158I9.8	3.96	9.15e-05	0.0302	0.22	0.21	Cholesterol, total;	chr11:118640634	chr11:118791254~118793137:+
STAD	cis	rs11603023	0.967	rs654423	ENSG00000278376.1	RP11-158I9.8	3.96	9.15e-05	0.0302	0.22	0.21	Cholesterol, total;	chr11:118641039	chr11:118791254~118793137:+
STAD	cis	rs9902453	1	rs4465649	ENSG00000263477.1	RP11-338L22.2	-3.96	9.15e-05	0.0302	-0.17	-0.21	Coffee consumption (cups per day);	chr17:30067729	chr17:29863402~29866092:+
STAD	cis	rs9420	0.816	rs674094	ENSG00000265566.2	RN7SL605P	3.96	9.15e-05	0.0302	0.3	0.21	Schizophrenia;	chr11:57897864	chr11:57528085~57528365:-
STAD	cis	rs860295	0.702	rs475550	ENSG00000225855.5	RUSC1-AS1	3.96	9.15e-05	0.0302	0.17	0.21	Body mass index;	chr1:155682290	chr1:155316863~155324176:-
STAD	cis	rs853679	0.585	rs201004	ENSG00000220721.1	OR1F12	3.96	9.16e-05	0.0302	0.24	0.21	Depression;	chr6:27837156	chr6:28073316~28074233:+
STAD	cis	rs6180	1	rs2973011	ENSG00000250860.1	CTD-2265D6.2	-3.96	9.16e-05	0.0302	-0.17	-0.21	Height;	chr5:42782390	chr5:42466893~42468300:-
STAD	cis	rs1790761	0.967	rs13859	ENSG00000231793.4	DOC2GP	-3.96	9.16e-05	0.0302	-0.25	-0.21	Mean corpuscular volume;	chr11:67434685	chr11:67612653~67616257:-
STAD	cis	rs2980439	0.525	rs2945238	ENSG00000254340.1	RP11-10A14.3	3.96	9.16e-05	0.0302	0.24	0.21	Neuroticism;	chr8:8312614	chr8:9141424~9145435:+
STAD	cis	rs3777722	0.688	rs2757045	ENSG00000265828.1	MIR3939	-3.96	9.16e-05	0.0302	-0.3	-0.21	Spontaneous preterm birth (preterm birth);	chr6:166937475	chr6:166997807~166997912:-
STAD	cis	rs9902453	0.78	rs62068621	ENSG00000263477.1	RP11-338L22.2	3.96	9.16e-05	0.0302	0.18	0.21	Coffee consumption (cups per day);	chr17:29843364	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.78	rs57037139	ENSG00000263477.1	RP11-338L22.2	3.96	9.16e-05	0.0302	0.18	0.21	Coffee consumption (cups per day);	chr17:29846265	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.817	rs55758314	ENSG00000263477.1	RP11-338L22.2	3.96	9.16e-05	0.0302	0.18	0.21	Coffee consumption (cups per day);	chr17:29846960	chr17:29863402~29866092:+
STAD	cis	rs5760842	0.967	rs5752054	ENSG00000203280.4	CTA-221G9.12	-3.96	9.17e-05	0.0303	-0.26	-0.21	Recurrent major depressive disorder;	chr22:25084905	chr22:25102433~25112692:-
STAD	cis	rs9902453	0.904	rs7212292	ENSG00000263477.1	RP11-338L22.2	-3.96	9.17e-05	0.0303	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30082246	chr17:29863402~29866092:+
STAD	cis	rs11089937	0.597	rs5756991	ENSG00000211640.3	IGLV6-57	3.96	9.17e-05	0.0303	0.16	0.21	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22195713~22196460:+
STAD	cis	rs721917	0.607	rs4319455	ENSG00000225484.5	NUTM2B-AS1	-3.96	9.17e-05	0.0303	-0.24	-0.21	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79663088~79826594:-
STAD	cis	rs7926906	0.967	rs7112148	ENSG00000280367.1	RP11-121L10.2	3.96	9.17e-05	0.0303	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90792757	chr11:90223153~90226538:+
STAD	cis	rs1154275	0.537	rs6772960	ENSG00000240057.4	RP11-572M11.4	-3.96	9.17e-05	0.0303	-0.19	-0.21	Takotsubo syndrome;	chr3:112796693	chr3:113019532~113183301:+
STAD	cis	rs5760842	0.933	rs5760837	ENSG00000203280.4	CTA-221G9.12	-3.96	9.17e-05	0.0303	-0.26	-0.21	Recurrent major depressive disorder;	chr22:25085119	chr22:25102433~25112692:-
STAD	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-3.96	9.17e-05	0.0303	-0.22	-0.21	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
STAD	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-3.96	9.17e-05	0.0303	-0.32	-0.21	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
STAD	cis	rs17592366	0.646	rs8015303	ENSG00000251726.1	RNU7-41P	-3.96	9.17e-05	0.0303	-0.34	-0.21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34777266	chr14:34845300~34845360:-
STAD	cis	rs17592366	0.646	rs76124700	ENSG00000251726.1	RNU7-41P	-3.96	9.17e-05	0.0303	-0.34	-0.21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34781943	chr14:34845300~34845360:-
STAD	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	3.96	9.17e-05	0.0303	0.36	0.21	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
STAD	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-3.96	9.17e-05	0.0303	-0.27	-0.21	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
STAD	cis	rs9362426	0.503	rs6454622	ENSG00000217776.1	RP11-156F23.2	3.96	9.17e-05	0.0303	0.21	0.21	Depressive episodes in bipolar disorder;	chr6:87424793	chr6:87070156~87070461:-
STAD	cis	rs6813195	0.554	rs10031972	ENSG00000243417.1	RP11-555K12.1	-3.96	9.17e-05	0.0303	-0.21	-0.21	Type 2 diabetes;	chr4:152450612	chr4:152551277~152552364:-
STAD	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-3.96	9.18e-05	0.0303	-0.25	-0.21	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
STAD	cis	rs7204230	1	rs8055218	ENSG00000261291.1	RP11-295M3.2	3.96	9.18e-05	0.0303	0.24	0.21	Fibrinogen;	chr16:53314295	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs8048169	ENSG00000261291.1	RP11-295M3.2	3.96	9.18e-05	0.0303	0.24	0.21	Fibrinogen;	chr16:53317871	chr16:53168522~53169450:+
STAD	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	3.96	9.18e-05	0.0303	0.24	0.21	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
STAD	cis	rs2115630	0.967	rs28595395	ENSG00000275120.1	RP11-182J1.17	-3.96	9.18e-05	0.0303	-0.23	-0.21	P wave terminal force;	chr15:84791721	chr15:84599434~84606463:-
STAD	cis	rs11673344	0.504	rs4806408	ENSG00000267672.1	CTD-2293H3.1	3.96	9.18e-05	0.0303	0.19	0.21	Obesity-related traits;	chr19:37097875	chr19:37091341~37092564:+
STAD	cis	rs6693567	0.586	rs4970979	ENSG00000203819.6	HIST2H2BC	3.96	9.18e-05	0.0303	0.24	0.21	Migraine;	chr1:150511364	chr1:149850193~149850772:-
STAD	cis	rs2638953	0.962	rs11049521	ENSG00000247934.4	RP11-967K21.1	-3.96	9.19e-05	0.0303	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310976	chr12:28163298~28190738:-
STAD	cis	rs9902453	0.817	rs62068625	ENSG00000263477.1	RP11-338L22.2	3.96	9.19e-05	0.0303	0.18	0.21	Coffee consumption (cups per day);	chr17:29849563	chr17:29863402~29866092:+
STAD	cis	rs3947	0.687	rs1736065	ENSG00000227888.4	FAM66A	-3.96	9.2e-05	0.0303	-0.29	-0.21	Blood protein levels;	chr8:11827944	chr8:12362019~12388296:+
STAD	cis	rs921665	1	rs921665	ENSG00000236760.1	AC019118.3	-3.96	9.2e-05	0.0303	-0.29	-0.21	World class endurance athleticism;	chr2:3170550	chr2:3131581~3145780:-
STAD	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-3.96	9.2e-05	0.0303	-0.26	-0.21	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
STAD	cis	rs1563304	1	rs1563304	ENSG00000261575.2	RP11-259G18.1	3.96	9.2e-05	0.0304	0.4	0.21	Neuroticism;	chr17:46797087	chr17:46267037~46268694:+
STAD	cis	rs7824557	0.564	rs2736295	ENSG00000255495.1	AC145124.2	3.96	9.2e-05	0.0304	0.24	0.21	Retinal vascular caliber;	chr8:11377271	chr8:12194467~12196280:+
STAD	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	3.96	9.21e-05	0.0304	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
STAD	cis	rs7204230	0.921	rs12597502	ENSG00000261291.1	RP11-295M3.2	3.96	9.21e-05	0.0304	0.25	0.21	Fibrinogen;	chr16:53136157	chr16:53168522~53169450:+
STAD	cis	rs7204230	0.846	rs62047991	ENSG00000261291.1	RP11-295M3.2	3.96	9.21e-05	0.0304	0.25	0.21	Fibrinogen;	chr16:53140359	chr16:53168522~53169450:+
STAD	cis	rs13413635	0.774	rs1852501	ENSG00000225808.1	DNAJC19P5	-3.96	9.21e-05	0.0304	-0.27	-0.21	Heart rate;	chr2:177996887	chr2:177229191~177229506:-
STAD	cis	rs34779708	0.931	rs7099036	ENSG00000271335.4	RP11-324I22.4	3.96	9.22e-05	0.0304	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs11010083	ENSG00000271335.4	RP11-324I22.4	3.96	9.22e-05	0.0304	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs7099593	ENSG00000271335.4	RP11-324I22.4	3.96	9.22e-05	0.0304	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs7084196	ENSG00000271335.4	RP11-324I22.4	3.96	9.22e-05	0.0304	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.897	rs4934716	ENSG00000271335.4	RP11-324I22.4	3.96	9.22e-05	0.0304	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs13376801	ENSG00000271335.4	RP11-324I22.4	3.96	9.22e-05	0.0304	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs7897457	ENSG00000271335.4	RP11-324I22.4	3.96	9.22e-05	0.0304	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35314552~35336401:-
STAD	cis	rs867371	1	rs1501372	ENSG00000276710.3	CSPG4P8	-3.96	9.22e-05	0.0304	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82459472~82477258:+
STAD	cis	rs73193808	1	rs2832232	ENSG00000273017.1	AP000240.9	3.96	9.22e-05	0.0304	0.23	0.21	Coronary artery disease;	chr21:29168238	chr21:29359002~29359453:+
STAD	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	3.96	9.22e-05	0.0304	0.41	0.21	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
STAD	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	3.96	9.22e-05	0.0304	0.41	0.21	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
STAD	cis	rs7809950	1	rs7793613	ENSG00000238832.1	snoU109	-3.96	9.23e-05	0.0304	-0.27	-0.21	Coronary artery disease;	chr7:107610039	chr7:107603363~107603507:+
STAD	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-3.96	9.23e-05	0.0304	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
STAD	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-3.96	9.23e-05	0.0304	-0.31	-0.21	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-3.96	9.23e-05	0.0304	-0.31	-0.21	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-3.96	9.23e-05	0.0304	-0.31	-0.21	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-3.96	9.23e-05	0.0304	-0.31	-0.21	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-3.96	9.23e-05	0.0304	-0.31	-0.21	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
STAD	cis	rs2262909	0.962	rs390730	ENSG00000213976.4	CTD-2561J22.2	-3.96	9.23e-05	0.0304	-0.26	-0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22050707	chr19:21382865~21387177:+
STAD	cis	rs4237845	0.804	rs10877034	ENSG00000273805.1	RP11-620J15.4	-3.96	9.23e-05	0.0304	-0.23	-0.21	Intelligence (multi-trait analysis);	chr12:57892661	chr12:57894232~57896846:+
STAD	cis	rs4589258	0.788	rs7936902	ENSG00000280367.1	RP11-121L10.2	3.96	9.24e-05	0.0304	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90759662	chr11:90223153~90226538:+
STAD	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-3.96	9.24e-05	0.0304	-0.24	-0.21	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
STAD	cis	rs9307551	0.619	rs7690520	ENSG00000250334.4	LINC00989	-3.96	9.24e-05	0.0304	-0.25	-0.21	Refractive error;	chr4:79507806	chr4:79492416~79576460:+
STAD	cis	rs7937127	0.744	rs55637777	ENSG00000254907.1	RP11-484D2.2	3.96	9.24e-05	0.0305	0.36	0.21	Fibrinogen levels;	chr11:43405323	chr11:43328748~43359296:-
STAD	cis	rs17592366	0.938	rs61580639	ENSG00000251726.1	RNU7-41P	-3.96	9.24e-05	0.0305	-0.28	-0.21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34748750	chr14:34845300~34845360:-
STAD	cis	rs1930961	1	rs6004675	ENSG00000272942.1	CTA-246H3.12	-3.96	9.24e-05	0.0305	-0.37	-0.21	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25434324~25435070:-
STAD	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-3.96	9.24e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
STAD	cis	rs34779708	0.931	rs11010077	ENSG00000271335.4	RP11-324I22.4	-3.96	9.25e-05	0.0305	-0.24	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35314552~35336401:-
STAD	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-3.96	9.25e-05	0.0305	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
STAD	cis	rs1850744	0.702	rs73802906	ENSG00000163612.10	FAM86KP	3.96	9.25e-05	0.0305	0.43	0.21	Economic and political preferences;	chr4:9596824	chr4:9153296~9165451:+
STAD	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	3.96	9.25e-05	0.0305	0.32	0.21	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
STAD	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	3.96	9.25e-05	0.0305	0.22	0.21	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
STAD	cis	rs10129255	0.556	rs9324093	ENSG00000211959.2	IGHV4-39	3.96	9.25e-05	0.0305	0.18	0.21	Kawasaki disease;	chr14:106683893	chr14:106421711~106422218:-
STAD	cis	rs1816752	1	rs9511272	ENSG00000232858.1	RPL34P27	3.96	9.26e-05	0.0305	0.13	0.21	Obesity-related traits;	chr13:24446495	chr13:24988577~24988925:-
STAD	cis	rs10851478	0.872	rs34414487	ENSG00000259545.2	RP11-325E5.4	-3.96	9.26e-05	0.0305	-0.24	-0.21	Oral cavity cancer;	chr15:49491578	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.842	rs34146550	ENSG00000259545.2	RP11-325E5.4	-3.96	9.26e-05	0.0305	-0.24	-0.21	Oral cavity cancer;	chr15:49498680	chr15:49177610~49178741:-
STAD	cis	rs2657294	0.73	rs1259505	ENSG00000233313.2	HMGA1P5	-3.96	9.26e-05	0.0305	-0.26	-0.21	Pneumonia;	chr10:75237183	chr10:75276376~75276646:-
STAD	cis	rs8141529	0.748	rs132533	ENSG00000272858.1	CTA-292E10.8	3.96	9.26e-05	0.0305	0.22	0.21	Lymphocyte counts;	chr22:28903583	chr22:28814914~28815662:+
STAD	cis	rs2638953	0.853	rs11049670	ENSG00000247934.4	RP11-967K21.1	3.96	9.26e-05	0.0305	0.24	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28499342	chr12:28163298~28190738:-
STAD	cis	rs10043228	1	rs57434520	ENSG00000248445.4	SEMA6A-AS1	-3.96	9.27e-05	0.0305	-0.3	-0.21	Asthma or chronic obstructive pulmonary disease;	chr5:116313068	chr5:116447547~116508276:+
STAD	cis	rs9905704	0.647	rs2036730	ENSG00000224738.1	AC099850.1	3.96	9.27e-05	0.0305	0.24	0.21	Testicular germ cell tumor;	chr17:58960921	chr17:59106598~59118267:+
STAD	cis	rs13178541	0.81	rs11959707	ENSG00000248211.1	TRPC7-AS1	-3.96	9.27e-05	0.0305	-0.27	-0.21	IgG glycosylation;	chr5:135775123	chr5:136214048~136222159:+
STAD	cis	rs13178541	0.745	rs11950987	ENSG00000248211.1	TRPC7-AS1	-3.96	9.27e-05	0.0305	-0.27	-0.21	IgG glycosylation;	chr5:135776266	chr5:136214048~136222159:+
STAD	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	3.96	9.27e-05	0.0305	0.32	0.21	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
STAD	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	3.96	9.27e-05	0.0305	0.32	0.21	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
STAD	cis	rs77580281	0.526	rs4594540	ENSG00000185065.6	AC000068.5	-3.96	9.27e-05	0.0305	-0.22	-0.21	Pediatric bone mineral density (hip);	chr22:19551674	chr22:19447893~19450105:+
STAD	cis	rs9608946	1	rs7289828	ENSG00000279159.1	RP3-394A18.1	-3.96	9.27e-05	0.0305	-0.18	-0.21	Red cell distribution width;	chr22:30525262	chr22:29978950~30028236:-
STAD	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-3.96	9.28e-05	0.0305	-0.34	-0.21	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
STAD	cis	rs1816752	0.819	rs4770665	ENSG00000232858.1	RPL34P27	3.96	9.28e-05	0.0305	0.13	0.21	Obesity-related traits;	chr13:24414810	chr13:24988577~24988925:-
STAD	cis	rs9733	0.519	rs1336899	ENSG00000276103.1	U4	3.96	9.28e-05	0.0306	0.2	0.21	Tonsillectomy;	chr1:150706434	chr1:150608507~150608623:-
STAD	cis	rs7412746	0.611	rs11803940	ENSG00000276103.1	U4	3.96	9.28e-05	0.0306	0.2	0.21	Melanoma;	chr1:150713359	chr1:150608507~150608623:-
STAD	cis	rs9733	0.519	rs7521898	ENSG00000276103.1	U4	3.96	9.28e-05	0.0306	0.2	0.21	Tonsillectomy;	chr1:150735120	chr1:150608507~150608623:-
STAD	cis	rs9733	0.519	rs7511673	ENSG00000276103.1	U4	3.96	9.28e-05	0.0306	0.2	0.21	Tonsillectomy;	chr1:150735160	chr1:150608507~150608623:-
STAD	cis	rs9307551	0.741	rs1440863	ENSG00000250334.4	LINC00989	-3.96	9.28e-05	0.0306	-0.27	-0.21	Refractive error;	chr4:79503061	chr4:79492416~79576460:+
STAD	cis	rs728616	0.614	rs12411833	ENSG00000225484.5	NUTM2B-AS1	-3.96	9.28e-05	0.0306	-0.34	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80343474	chr10:79663088~79826594:-
STAD	cis	rs728616	0.614	rs56080607	ENSG00000225484.5	NUTM2B-AS1	-3.96	9.28e-05	0.0306	-0.34	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80346208	chr10:79663088~79826594:-
STAD	cis	rs1876905	0.597	rs354526	ENSG00000271789.1	RP5-1112D6.7	-3.96	9.28e-05	0.0306	-0.25	-0.21	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111297126~111298510:+
STAD	cis	rs1336900	0.513	rs56253522	ENSG00000276103.1	U4	3.95	9.29e-05	0.0306	0.2	0.21	Blood protein levels;	chr1:150642393	chr1:150608507~150608623:-
STAD	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-3.95	9.29e-05	0.0306	-0.21	-0.21	Height;	chr2:46641180	chr2:46668870~46670778:+
STAD	cis	rs7829975	0.577	rs7816329	ENSG00000233609.3	RP11-62H7.2	-3.95	9.29e-05	0.0306	-0.26	-0.21	Mood instability;	chr8:8686333	chr8:8961200~8979025:+
STAD	cis	rs2310173	0.575	rs2110563	ENSG00000281162.1	LINC01127	-3.95	9.29e-05	0.0306	-0.26	-0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102011971	chr2:101962056~101987167:+
STAD	cis	rs2273156	0.517	rs77803033	ENSG00000258704.4	SRP54-AS1	-3.95	9.3e-05	0.0306	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35042646	chr14:34920858~34982532:-
STAD	cis	rs11638815	0.603	rs10162807	ENSG00000255769.6	GOLGA2P10	-3.95	9.31e-05	0.0306	-0.24	-0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:82472993~82513950:-
STAD	cis	rs6966038	1	rs6947726	ENSG00000236018.2	RP4-814D15.1	3.95	9.31e-05	0.0306	0.25	0.21	Response to citalopram treatment;	chr7:157083162	chr7:157197600~157198511:-
STAD	cis	rs17818399	0.89	rs34752561	ENSG00000279254.1	RP11-536C12.1	-3.95	9.31e-05	0.0306	-0.23	-0.21	Height;	chr2:46623011	chr2:46668870~46670778:+
STAD	cis	rs7204230	1	rs6499550	ENSG00000261291.1	RP11-295M3.2	3.95	9.31e-05	0.0306	0.24	0.21	Fibrinogen;	chr16:53308542	chr16:53168522~53169450:+
STAD	cis	rs7646881	0.812	rs7624408	ENSG00000240207.5	RP11-379F4.4	-3.95	9.31e-05	0.0306	-0.35	-0.21	Tetralogy of Fallot;	chr3:158742269	chr3:158732263~158784070:+
STAD	cis	rs7646881	0.812	rs7636023	ENSG00000240207.5	RP11-379F4.4	-3.95	9.31e-05	0.0306	-0.35	-0.21	Tetralogy of Fallot;	chr3:158742270	chr3:158732263~158784070:+
STAD	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	3.95	9.31e-05	0.0306	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	3.95	9.31e-05	0.0306	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	3.95	9.31e-05	0.0306	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	3.95	9.31e-05	0.0306	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	3.95	9.31e-05	0.0306	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
STAD	cis	rs3808502	0.516	rs6983727	ENSG00000255556.2	RP11-351I21.6	3.95	9.31e-05	0.0306	0.22	0.21	Neuroticism;	chr8:11558303	chr8:12378679~12380265:-
STAD	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	3.95	9.31e-05	0.0306	0.25	0.21	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
STAD	cis	rs259282	0.562	rs28505804	ENSG00000201388.1	SNORA68	3.95	9.31e-05	0.0306	0.21	0.21	Schizophrenia;	chr19:32619141	chr19:32608337~32608469:-
STAD	cis	rs755249	0.501	rs661316	ENSG00000182109.6	RP11-69E11.4	3.95	9.31e-05	0.0306	0.26	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39522280~39546187:-
STAD	cis	rs9902453	0.904	rs12951836	ENSG00000240074.1	RPL9P30	-3.95	9.32e-05	0.0306	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30083259	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.904	rs12948898	ENSG00000240074.1	RPL9P30	-3.95	9.32e-05	0.0306	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30083306	chr17:29855759~29856332:+
STAD	cis	rs4407350	1	rs5765745	ENSG00000279642.1	RP5-1033E15.3	-3.95	9.32e-05	0.0306	-0.21	-0.21	Intelligence (multi-trait analysis);	chr22:44529014	chr22:44486295~44486914:-
STAD	cis	rs3764021	0.87	rs10772085	ENSG00000256673.1	RP11-599J14.2	-3.95	9.32e-05	0.0307	-0.22	-0.21	Type 1 diabetes;	chr12:9724281	chr12:9398355~9414851:-
STAD	cis	rs3764021	0.87	rs7976584	ENSG00000256673.1	RP11-599J14.2	-3.95	9.32e-05	0.0307	-0.22	-0.21	Type 1 diabetes;	chr12:9726059	chr12:9398355~9414851:-
STAD	cis	rs749052	0.831	rs78894376	ENSG00000251485.1	AC068134.10	3.95	9.32e-05	0.0307	0.49	0.21	Height;	chr2:231948021	chr2:232343116~232343903:+
STAD	cis	rs749052	0.731	rs2580825	ENSG00000251485.1	AC068134.10	3.95	9.32e-05	0.0307	0.49	0.21	Height;	chr2:231950931	chr2:232343116~232343903:+
STAD	cis	rs749052	0.731	rs2580826	ENSG00000251485.1	AC068134.10	3.95	9.32e-05	0.0307	0.49	0.21	Height;	chr2:231951031	chr2:232343116~232343903:+
STAD	cis	rs749052	0.731	rs2679164	ENSG00000251485.1	AC068134.10	3.95	9.32e-05	0.0307	0.49	0.21	Height;	chr2:231952666	chr2:232343116~232343903:+
STAD	cis	rs1348850	0.914	rs4893961	ENSG00000271825.1	RP11-337N6.2	3.95	9.32e-05	0.0307	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177546347	chr2:177300600~177302006:+
STAD	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	3.95	9.32e-05	0.0307	0.26	0.21	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
STAD	cis	rs7937127	0.696	rs72902770	ENSG00000254907.1	RP11-484D2.2	3.95	9.32e-05	0.0307	0.36	0.21	Fibrinogen levels;	chr11:43513632	chr11:43328748~43359296:-
STAD	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-3.95	9.32e-05	0.0307	-0.2	-0.21	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
STAD	cis	rs7937127	0.744	rs72901001	ENSG00000254907.1	RP11-484D2.2	3.95	9.32e-05	0.0307	0.36	0.21	Fibrinogen levels;	chr11:43481151	chr11:43328748~43359296:-
STAD	cis	rs7937127	0.696	rs11606175	ENSG00000254907.1	RP11-484D2.2	3.95	9.32e-05	0.0307	0.36	0.21	Fibrinogen levels;	chr11:43481445	chr11:43328748~43359296:-
STAD	cis	rs7937127	0.696	rs72902705	ENSG00000254907.1	RP11-484D2.2	3.95	9.32e-05	0.0307	0.36	0.21	Fibrinogen levels;	chr11:43483152	chr11:43328748~43359296:-
STAD	cis	rs7937127	0.744	rs72902709	ENSG00000254907.1	RP11-484D2.2	3.95	9.32e-05	0.0307	0.36	0.21	Fibrinogen levels;	chr11:43483383	chr11:43328748~43359296:-
STAD	cis	rs12682352	0.602	rs6988939	ENSG00000173295.6	FAM86B3P	3.95	9.32e-05	0.0307	0.24	0.21	Neuroticism;	chr8:8809406	chr8:8228595~8244865:+
STAD	cis	rs7176527	0.848	rs17600128	ENSG00000229212.6	RP11-561C5.4	3.95	9.32e-05	0.0307	0.34	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:85205440~85234795:-
STAD	cis	rs7208859	0.623	rs8082537	ENSG00000263603.1	CTD-2349P21.5	-3.95	9.32e-05	0.0307	-0.26	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30729469~30731202:+
STAD	cis	rs10782582	0.593	rs12131493	ENSG00000181227.3	RP4-682C21.2	3.95	9.33e-05	0.0307	0.22	0.21	Daytime sleep phenotypes;	chr1:75673487	chr1:75743423~75744776:-
STAD	cis	rs12477438	0.52	rs4347885	ENSG00000231822.1	AC019097.7	3.95	9.33e-05	0.0307	0.21	0.21	Chronic sinus infection;	chr2:99187544	chr2:99102018~99102752:+
STAD	cis	rs7587026	0.559	rs498631	ENSG00000229195.1	AC009495.4	3.95	9.33e-05	0.0307	0.24	0.21	Mesial temporal lobe epilepsy with hippocampal sclerosis;	chr2:166020667	chr2:165794857~165846091:-
STAD	cis	rs4713118	0.955	rs9468204	ENSG00000243307.2	POM121L6P	-3.95	9.33e-05	0.0307	-0.24	-0.21	Parkinson's disease;	chr6:27721030	chr6:26896952~26898777:+
STAD	cis	rs11169552	0.51	rs10876072	ENSG00000200183.1	RNU6-238P	-3.95	9.33e-05	0.0307	-0.2	-0.21	Colorectal cancer;	chr12:50619776	chr12:50656973~50657078:+
STAD	cis	rs34779708	0.966	rs11010129	ENSG00000271335.4	RP11-324I22.4	3.95	9.33e-05	0.0307	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs4934737	ENSG00000271335.4	RP11-324I22.4	3.95	9.33e-05	0.0307	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35314552~35336401:-
STAD	cis	rs6479891	1	rs77494594	ENSG00000235816.3	PRELID1P3	3.95	9.33e-05	0.0307	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs2466128	ENSG00000235816.3	PRELID1P3	3.95	9.33e-05	0.0307	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs2719815	ENSG00000235816.3	PRELID1P3	3.95	9.33e-05	0.0307	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs10437345	ENSG00000235816.3	PRELID1P3	-3.95	9.33e-05	0.0307	-0.27	-0.21	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63427297~63427939:+
STAD	cis	rs12571093	0.571	rs10740295	ENSG00000233590.1	RP11-153K11.3	3.95	9.33e-05	0.0307	0.29	0.21	Optic nerve measurement (disc area);	chr10:68304313	chr10:68233251~68242379:-
STAD	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-3.95	9.33e-05	0.0307	-0.22	-0.21	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
STAD	cis	rs304029	0.553	rs304094	ENSG00000229241.1	PNPT1P1	-3.95	9.34e-05	0.0307	-0.25	-0.21	Diabetic kidney disease;	chr3:4475760	chr3:3981981~3984295:-
STAD	cis	rs73198271	0.74	rs10105920	ENSG00000254340.1	RP11-10A14.3	3.95	9.34e-05	0.0307	0.29	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.5	rs1974468	ENSG00000211959.2	IGHV4-39	3.95	9.34e-05	0.0307	0.18	0.21	Kawasaki disease;	chr14:106686149	chr14:106421711~106422218:-
STAD	cis	rs6813195	0.642	rs66479472	ENSG00000243417.1	RP11-555K12.1	-3.95	9.34e-05	0.0307	-0.21	-0.21	Type 2 diabetes;	chr4:152496452	chr4:152551277~152552364:-
STAD	cis	rs16944613	0.51	rs11636695	ENSG00000259314.1	CTD-3065B20.3	3.95	9.35e-05	0.0307	0.21	0.21	Colorectal cancer;	chr15:90609679	chr15:90604225~90614558:-
STAD	cis	rs1318937	0.764	rs11128738	ENSG00000224660.1	SH3BP5-AS1	3.95	9.35e-05	0.0307	0.2	0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15200989	chr3:15254184~15264493:+
STAD	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-3.95	9.35e-05	0.0307	-0.25	-0.21	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
STAD	cis	rs2980439	0.525	rs1850511	ENSG00000254340.1	RP11-10A14.3	3.95	9.35e-05	0.0307	0.24	0.21	Neuroticism;	chr8:8312807	chr8:9141424~9145435:+
STAD	cis	rs494453	0.557	rs2473842	ENSG00000234020.1	CHIAP3	-3.95	9.35e-05	0.0307	-0.2	-0.21	Osteoporosis-related phenotypes;	chr1:111684778	chr1:111353275~111367409:-
STAD	cis	rs11089937	0.616	rs7286793	ENSG00000211639.2	IGLV4-60	3.95	9.35e-05	0.0307	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.616	rs7291684	ENSG00000211639.2	IGLV4-60	3.95	9.35e-05	0.0307	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.616	rs6001219	ENSG00000211639.2	IGLV4-60	3.95	9.35e-05	0.0307	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.616	rs5995615	ENSG00000211639.2	IGLV4-60	3.95	9.35e-05	0.0307	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.616	rs6001223	ENSG00000211639.2	IGLV4-60	3.95	9.35e-05	0.0307	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.616	rs928895	ENSG00000211639.2	IGLV4-60	3.95	9.35e-05	0.0307	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22162199~22162681:+
STAD	cis	rs11089937	0.616	rs6001224	ENSG00000211639.2	IGLV4-60	3.95	9.35e-05	0.0307	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22162199~22162681:+
STAD	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	3.95	9.35e-05	0.0307	0.28	0.21	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
STAD	cis	rs10129255	0.642	rs11624918	ENSG00000232216.1	IGHV3-43	3.95	9.35e-05	0.0307	0.22	0.21	Kawasaki disease;	chr14:106664672	chr14:106470264~106470800:-
STAD	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-3.95	9.36e-05	0.0307	-0.24	-0.21	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
STAD	cis	rs765787	0.53	rs2554453	ENSG00000259539.1	CTD-2651B20.1	3.95	9.36e-05	0.0307	0.24	0.21	Uric acid levels;	chr15:45229909	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs11858988	ENSG00000259539.1	CTD-2651B20.1	3.95	9.36e-05	0.0307	0.24	0.21	Uric acid levels;	chr15:45229916	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs11855435	ENSG00000259539.1	CTD-2651B20.1	3.95	9.36e-05	0.0307	0.24	0.21	Uric acid levels;	chr15:45229919	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs2458224	ENSG00000259539.1	CTD-2651B20.1	3.95	9.36e-05	0.0307	0.24	0.21	Uric acid levels;	chr15:45229932	chr15:45152664~45167526:-
STAD	cis	rs806321	0.755	rs1985704	ENSG00000237152.3	DLEU7-AS1	-3.95	9.36e-05	0.0308	-0.24	-0.21	Multiple sclerosis;	chr13:50210716	chr13:50807856~50849905:+
STAD	cis	rs806321	0.755	rs1007852	ENSG00000237152.3	DLEU7-AS1	-3.95	9.36e-05	0.0308	-0.24	-0.21	Multiple sclerosis;	chr13:50210756	chr13:50807856~50849905:+
STAD	cis	rs55675132	0.515	rs12136312	ENSG00000236480.1	PKMP1	3.95	9.36e-05	0.0308	0.19	0.21	Schizophrenia;	chr1:114755844	chr1:114535995~114537840:+
STAD	cis	rs34779708	0.931	rs12776390	ENSG00000271335.4	RP11-324I22.4	3.95	9.36e-05	0.0308	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35314552~35336401:-
STAD	cis	rs765787	0.505	rs1648302	ENSG00000259539.1	CTD-2651B20.1	3.95	9.36e-05	0.0308	0.24	0.21	Uric acid levels;	chr15:45202040	chr15:45152664~45167526:-
STAD	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	3.95	9.36e-05	0.0308	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
STAD	cis	rs4589258	0.788	rs10734137	ENSG00000280367.1	RP11-121L10.2	3.95	9.36e-05	0.0308	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90764206	chr11:90223153~90226538:+
STAD	cis	rs13413635	0.862	rs55889420	ENSG00000225808.1	DNAJC19P5	-3.95	9.37e-05	0.0308	-0.28	-0.21	Heart rate;	chr2:177837312	chr2:177229191~177229506:-
STAD	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-3.95	9.37e-05	0.0308	-0.2	-0.21	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
STAD	cis	rs2638953	0.962	rs9645730	ENSG00000247934.4	RP11-967K21.1	-3.95	9.37e-05	0.0308	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317151	chr12:28163298~28190738:-
STAD	cis	rs9646944	0.636	rs72820194	ENSG00000234389.1	AC007278.3	3.95	9.37e-05	0.0308	0.32	0.21	Blood protein levels;	chr2:102261648	chr2:102438713~102440475:+
STAD	cis	rs9646944	0.636	rs60227565	ENSG00000234389.1	AC007278.3	3.95	9.37e-05	0.0308	0.32	0.21	Blood protein levels;	chr2:102275879	chr2:102438713~102440475:+
STAD	cis	rs7849270	1	rs1107328	ENSG00000234055.1	RP11-247A12.1	-3.95	9.37e-05	0.0308	-0.25	-0.21	Blood metabolite ratios;	chr9:129155255	chr9:129097854~129100266:+
STAD	cis	rs9535307	0.929	rs9535316	ENSG00000223676.1	RPL34P26	3.95	9.38e-05	0.0308	0.25	0.21	Obesity-related traits;	chr13:49738261	chr13:50361410~50361763:-
STAD	cis	rs6782228	1	rs34890930	ENSG00000277250.1	Metazoa_SRP	3.95	9.38e-05	0.0308	0.23	0.21	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128673681~128674021:-
STAD	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	3.95	9.38e-05	0.0308	0.22	0.21	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
STAD	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	3.95	9.38e-05	0.0308	0.22	0.21	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
STAD	cis	rs4950322	0.518	rs11811023	ENSG00000278811.3	LINC00624	-3.95	9.38e-05	0.0308	-0.21	-0.21	Protein quantitative trait loci;	chr1:147109536	chr1:147258885~147517875:-
STAD	cis	rs11098499	0.722	rs17595727	ENSG00000260091.1	RP11-33B1.4	-3.95	9.38e-05	0.0308	-0.19	-0.21	Corneal astigmatism;	chr4:119340919	chr4:119409333~119410233:+
STAD	cis	rs7615952	0.932	rs7630077	ENSG00000272840.1	RP11-379B18.6	3.95	9.38e-05	0.0308	0.35	0.21	Blood pressure (smoking interaction);	chr3:125930833	chr3:125774714~125797953:+
STAD	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-3.95	9.39e-05	0.0308	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-3.95	9.39e-05	0.0308	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
STAD	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-3.95	9.39e-05	0.0308	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-3.95	9.39e-05	0.0308	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-3.95	9.39e-05	0.0308	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
STAD	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-3.95	9.39e-05	0.0308	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
STAD	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-3.95	9.39e-05	0.0308	-0.24	-0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
STAD	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	3.95	9.39e-05	0.0308	0.23	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
STAD	cis	rs7769051	0.522	rs7738256	ENSG00000179073.6	TAAR3	-3.95	9.39e-05	0.0308	-0.48	-0.21	Type 2 diabetes nephropathy;	chr6:132791927	chr6:132608225~132609302:-
STAD	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-3.95	9.39e-05	0.0308	-0.25	-0.21	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
STAD	cis	rs3799379	0.55	rs9467736	ENSG00000243307.2	POM121L6P	-3.95	9.4e-05	0.0309	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26379804	chr6:26896952~26898777:+
STAD	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-3.95	9.4e-05	0.0309	-0.25	-0.21	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
STAD	cis	rs4845875	0.534	rs4846052	ENSG00000242349.4	NPPA-AS1	3.95	9.4e-05	0.0309	0.22	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11797894	chr1:11841017~11848079:+
STAD	cis	rs6813195	0.642	rs1961679	ENSG00000243417.1	RP11-555K12.1	-3.95	9.41e-05	0.0309	-0.21	-0.21	Type 2 diabetes;	chr4:152500182	chr4:152551277~152552364:-
STAD	cis	rs1816752	0.905	rs8002309	ENSG00000232858.1	RPL34P27	3.95	9.41e-05	0.0309	0.13	0.21	Obesity-related traits;	chr13:24402217	chr13:24988577~24988925:-
STAD	cis	rs728616	0.558	rs17616958	ENSG00000272447.1	RP11-182L21.6	-3.95	9.41e-05	0.0309	-0.33	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr10:79825902~79827602:+
STAD	cis	rs728616	0.558	rs17616964	ENSG00000272447.1	RP11-182L21.6	-3.95	9.41e-05	0.0309	-0.33	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr10:79825902~79827602:+
STAD	cis	rs794185	0.686	rs2633843	ENSG00000231249.1	ITPR1-AS1	-3.95	9.42e-05	0.0309	-0.24	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470109	chr3:4490891~4493163:-
STAD	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	3.95	9.42e-05	0.0309	0.24	0.21	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
STAD	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	3.95	9.42e-05	0.0309	0.24	0.21	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
STAD	cis	rs2901460	0.714	rs11125908	ENSG00000229503.1	AC092155.1	-3.95	9.42e-05	0.0309	-0.17	-0.21	Mean corpuscular volume;	chr2:62122368	chr2:62532583~62533059:-
STAD	cis	rs6142102	0.961	rs2268089	ENSG00000264616.1	MIR4755	3.95	9.42e-05	0.0309	0.21	0.21	Skin pigmentation;	chr20:34079492	chr20:34049119~34049190:+
STAD	cis	rs263063	0.834	rs710957	ENSG00000280239.1	CTB-50L17.8	3.95	9.43e-05	0.0309	0.28	0.21	Periodontitis (CDC/AAP);	chr19:5054334	chr19:4448810~4450836:+
STAD	cis	rs1075265	0.783	rs805359	ENSG00000235937.1	AC008280.1	3.95	9.43e-05	0.0309	0.19	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54029552~54030682:-
STAD	cis	rs6180	0.967	rs230816	ENSG00000250860.1	CTD-2265D6.2	-3.95	9.43e-05	0.0309	-0.17	-0.21	Height;	chr5:42801847	chr5:42466893~42468300:-
STAD	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	3.95	9.43e-05	0.0309	0.29	0.21	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
STAD	cis	rs875971	0.825	rs4587224	ENSG00000224316.1	RP11-479O9.2	-3.95	9.43e-05	0.0309	-0.2	-0.21	Aortic root size;	chr7:66271195	chr7:65773620~65802067:+
STAD	cis	rs875971	0.792	rs6971752	ENSG00000224316.1	RP11-479O9.2	-3.95	9.43e-05	0.0309	-0.2	-0.21	Aortic root size;	chr7:66272999	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs10950033	ENSG00000224316.1	RP11-479O9.2	-3.95	9.43e-05	0.0309	-0.2	-0.21	Aortic root size;	chr7:66274686	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs11760844	ENSG00000224316.1	RP11-479O9.2	-3.95	9.43e-05	0.0309	-0.2	-0.21	Aortic root size;	chr7:66274896	chr7:65773620~65802067:+
STAD	cis	rs561341	1	rs498391	ENSG00000265798.5	RP11-271K11.5	3.95	9.43e-05	0.031	0.29	0.21	Hip circumference adjusted for BMI;	chr17:32001685	chr17:31038575~31059121:-
STAD	cis	rs9847710	1	rs4687697	ENSG00000242142.1	SERBP1P3	-3.95	9.44e-05	0.031	-0.2	-0.21	Ulcerative colitis;	chr3:53056474	chr3:53064283~53065091:-
STAD	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-3.95	9.44e-05	0.031	-0.27	-0.21	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	3.95	9.44e-05	0.031	0.27	0.21	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	3.95	9.44e-05	0.031	0.27	0.21	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	3.95	9.44e-05	0.031	0.27	0.21	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
STAD	cis	rs9291683	0.655	rs55941493	ENSG00000250613.1	RP11-136I13.1	3.95	9.44e-05	0.031	0.2	0.21	Bone mineral density;	chr4:10098717	chr4:10410996~10411644:+
STAD	cis	rs7474896	1	rs9418299	ENSG00000099251.13	HSD17B7P2	3.95	9.44e-05	0.031	0.35	0.21	Obesity (extreme);	chr10:37851299	chr10:38356380~38378505:+
STAD	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-3.95	9.44e-05	0.031	-0.24	-0.21	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
STAD	cis	rs950169	0.922	rs4586394	ENSG00000259683.1	RP11-182J1.14	-3.95	9.44e-05	0.031	-0.22	-0.21	Schizophrenia;	chr15:84153633	chr15:84389729~84395903:+
STAD	cis	rs7615952	1	rs7616044	ENSG00000272840.1	RP11-379B18.6	3.95	9.44e-05	0.031	0.35	0.21	Blood pressure (smoking interaction);	chr3:125930511	chr3:125774714~125797953:+
STAD	cis	rs7615952	0.932	rs7629977	ENSG00000272840.1	RP11-379B18.6	3.95	9.44e-05	0.031	0.35	0.21	Blood pressure (smoking interaction);	chr3:125930730	chr3:125774714~125797953:+
STAD	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-3.95	9.44e-05	0.031	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-3.95	9.44e-05	0.031	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
STAD	cis	rs11673344	0.504	rs4806409	ENSG00000267672.1	CTD-2293H3.1	3.95	9.44e-05	0.031	0.19	0.21	Obesity-related traits;	chr19:37097923	chr19:37091341~37092564:+
STAD	cis	rs7665090	0.87	rs228614	ENSG00000230069.3	LRRC37A15P	3.95	9.44e-05	0.031	0.22	0.21	Primary biliary cholangitis;	chr4:102657480	chr4:102727274~102730721:-
STAD	cis	rs4589258	0.788	rs4558131	ENSG00000280367.1	RP11-121L10.2	3.95	9.45e-05	0.031	0.2	0.21	Intelligence (multi-trait analysis);	chr11:90771348	chr11:90223153~90226538:+
STAD	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-3.95	9.45e-05	0.031	-0.21	-0.21	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
STAD	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-3.95	9.45e-05	0.031	-0.21	-0.21	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
STAD	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	3.95	9.45e-05	0.031	0.26	0.21	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
STAD	cis	rs10040610	0.524	rs60844356	ENSG00000250490.1	FLJ33360	3.95	9.45e-05	0.031	0.24	0.21	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6354481	chr5:6310441~6339884:-
STAD	cis	rs7474896	0.537	rs2472149	ENSG00000120555.12	SEPT7P9	-3.95	9.45e-05	0.031	-0.25	-0.21	Obesity (extreme);	chr10:37973268	chr10:38383069~38402916:-
STAD	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	3.95	9.45e-05	0.031	0.26	0.21	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	3.95	9.45e-05	0.031	0.26	0.21	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
STAD	cis	rs1816752	0.905	rs2000153	ENSG00000232858.1	RPL34P27	3.95	9.46e-05	0.031	0.13	0.21	Obesity-related traits;	chr13:24405752	chr13:24988577~24988925:-
STAD	cis	rs6951245	0.507	rs11763865	ENSG00000229043.2	AC091729.9	-3.95	9.46e-05	0.031	-0.28	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1154638	chr7:1160374~1165267:+
STAD	cis	rs262150	0.544	rs2428780	ENSG00000231419.5	LINC00689	3.95	9.46e-05	0.031	0.23	0.21	Facial morphology (factor 20);	chr7:159019780	chr7:159006522~159030195:+
STAD	cis	rs4589258	0.788	rs10741368	ENSG00000280367.1	RP11-121L10.2	3.95	9.46e-05	0.031	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90758308	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs10830570	ENSG00000280367.1	RP11-121L10.2	3.95	9.46e-05	0.031	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90758746	chr11:90223153~90226538:+
STAD	cis	rs875971	0.545	rs6970498	ENSG00000273142.1	RP11-458F8.4	3.95	9.46e-05	0.031	0.19	0.21	Aortic root size;	chr7:66275908	chr7:66902857~66906297:+
STAD	cis	rs9393777	0.623	rs9358944	ENSG00000241549.7	GUSBP2	3.95	9.46e-05	0.031	0.29	0.21	Intelligence (multi-trait analysis);	chr6:26469647	chr6:26871484~26956554:-
STAD	cis	rs6095298	0.574	rs6019463	ENSG00000227431.4	CSE1L-AS1	-3.95	9.46e-05	0.031	-0.23	-0.21	Intelligence (multi-trait analysis);	chr20:48861330	chr20:49040463~49046044:-
STAD	cis	rs12682352	0.652	rs3789843	ENSG00000233609.3	RP11-62H7.2	3.95	9.47e-05	0.031	0.24	0.21	Neuroticism;	chr8:8866747	chr8:8961200~8979025:+
STAD	cis	rs12682352	0.652	rs3827806	ENSG00000233609.3	RP11-62H7.2	3.95	9.47e-05	0.031	0.24	0.21	Neuroticism;	chr8:8866766	chr8:8961200~8979025:+
STAD	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-3.95	9.47e-05	0.031	-0.21	-0.21	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
STAD	cis	rs7283707	0.681	rs17241430	ENSG00000228798.1	AP000473.5	-3.95	9.47e-05	0.031	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15767505	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs77644136	ENSG00000228798.1	AP000473.5	-3.95	9.47e-05	0.031	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15769933	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.579	rs78443437	ENSG00000228798.1	AP000473.5	-3.95	9.47e-05	0.031	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15771705	chr21:16630827~16640683:+
STAD	cis	rs1816752	0.749	rs77832754	ENSG00000232858.1	RPL34P27	3.95	9.47e-05	0.031	0.13	0.21	Obesity-related traits;	chr13:24416016	chr13:24988577~24988925:-
STAD	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	3.95	9.47e-05	0.0311	0.23	0.21	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
STAD	cis	rs950169	0.545	rs4842841	ENSG00000259728.4	LINC00933	3.95	9.47e-05	0.0311	0.3	0.21	Schizophrenia;	chr15:83972373	chr15:84570649~84580175:+
STAD	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-3.95	9.48e-05	0.0311	-0.22	-0.21	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
STAD	cis	rs62400317	0.762	rs10484625	ENSG00000219384.1	RP11-491H9.3	-3.95	9.48e-05	0.0311	-0.24	-0.21	Total body bone mineral density;	chr6:44855712	chr6:45158870~45159511:+
STAD	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-3.95	9.48e-05	0.0311	-0.28	-0.21	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
STAD	cis	rs6832769	1	rs35767091	ENSG00000223305.1	RN7SKP30	3.95	9.48e-05	0.0311	0.23	0.21	Personality dimensions;	chr4:55480556	chr4:55540502~55540835:-
STAD	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-3.95	9.48e-05	0.0311	-0.3	-0.21	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
STAD	cis	rs2273156	1	rs7141292	ENSG00000258704.4	SRP54-AS1	-3.95	9.49e-05	0.0311	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34993700	chr14:34920858~34982532:-
STAD	cis	rs2070488	0.804	rs1870914	ENSG00000229589.1	ACVR2B-AS1	3.95	9.49e-05	0.0311	0.25	0.21	Electrocardiographic conduction measures;	chr3:38452729	chr3:38451027~38454820:-
STAD	cis	rs7103648	0.838	rs11039244	ENSG00000280615.1	Y_RNA	3.95	9.49e-05	0.0311	0.22	0.21	Systolic blood pressure;Diastolic blood pressure;	chr11:47444890	chr11:47614898~47614994:-
STAD	cis	rs2337406	0.714	rs2337463	ENSG00000211972.2	IGHV3-66	3.95	9.49e-05	0.0311	0.21	0.21	Alzheimer's disease (late onset);	chr14:106816066	chr14:106675017~106675544:-
STAD	cis	rs34779708	0.966	rs11010122	ENSG00000271335.4	RP11-324I22.4	3.95	9.49e-05	0.0311	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35314552~35336401:-
STAD	cis	rs2957692	0.548	rs10770103	ENSG00000254554.1	RP11-351I24.1	3.95	9.49e-05	0.0311	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10245279	chr11:10302657~10303704:-
STAD	cis	rs10851478	0.872	rs6493372	ENSG00000259545.2	RP11-325E5.4	-3.95	9.49e-05	0.0311	-0.25	-0.21	Oral cavity cancer;	chr15:49466532	chr15:49177610~49178741:-
STAD	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-3.95	9.5e-05	0.0311	-0.27	-0.21	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs61074241	ENSG00000225151.9	GOLGA2P7	-3.95	9.5e-05	0.0311	-0.29	-0.21	Schizophrenia;	chr15:84790165	chr15:84199311~84230136:-
STAD	cis	rs6142102	0.778	rs6059555	ENSG00000264616.1	MIR4755	3.95	9.5e-05	0.0311	0.22	0.21	Skin pigmentation;	chr20:33926518	chr20:34049119~34049190:+
STAD	cis	rs9307551	1	rs3109166	ENSG00000250334.4	LINC00989	3.95	9.5e-05	0.0311	0.26	0.21	Refractive error;	chr4:79631045	chr4:79492416~79576460:+
STAD	cis	rs9902453	0.78	rs10445384	ENSG00000240074.1	RPL9P30	3.95	9.5e-05	0.0311	0.18	0.21	Coffee consumption (cups per day);	chr17:29855667	chr17:29855759~29856332:+
STAD	cis	rs7202877	0.61	rs3851735	ENSG00000261783.1	RP11-252K23.2	-3.95	9.5e-05	0.0311	-0.34	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75338194	chr16:75379818~75381260:-
STAD	cis	rs11157436	0.602	rs11157438	ENSG00000211813.2	TRAV34	3.95	9.5e-05	0.0311	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22207522~22208129:+
STAD	cis	rs10782582	0.593	rs17647178	ENSG00000181227.3	RP4-682C21.2	3.95	9.51e-05	0.0311	0.22	0.21	Daytime sleep phenotypes;	chr1:75744839	chr1:75743423~75744776:-
STAD	cis	rs9907295	0.688	rs2376287	ENSG00000271013.1	AC015849.15	-3.95	9.51e-05	0.0311	-0.3	-0.21	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.688	rs4796133	ENSG00000271013.1	AC015849.15	-3.95	9.51e-05	0.0311	-0.3	-0.21	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.688	rs7213636	ENSG00000271013.1	AC015849.15	-3.95	9.51e-05	0.0311	-0.3	-0.21	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.688	rs28722787	ENSG00000271013.1	AC015849.15	-3.95	9.51e-05	0.0311	-0.3	-0.21	Fibroblast growth factor basic levels;	chr17:35922795	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.688	rs4796135	ENSG00000271013.1	AC015849.15	-3.95	9.51e-05	0.0311	-0.3	-0.21	Fibroblast growth factor basic levels;	chr17:35924236	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.688	rs4796136	ENSG00000271013.1	AC015849.15	-3.95	9.51e-05	0.0311	-0.3	-0.21	Fibroblast growth factor basic levels;	chr17:35924397	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.688	rs4796137	ENSG00000271013.1	AC015849.15	-3.95	9.51e-05	0.0311	-0.3	-0.21	Fibroblast growth factor basic levels;	chr17:35924448	chr17:35912635~35918010:-
STAD	cis	rs10911902	0.643	rs78088787	ENSG00000229739.2	RP11-295K2.3	-3.95	9.51e-05	0.0311	-0.3	-0.21	Schizophrenia;	chr1:186364550	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs75490185	ENSG00000229739.2	RP11-295K2.3	-3.95	9.51e-05	0.0311	-0.3	-0.21	Schizophrenia;	chr1:186366319	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs112738913	ENSG00000229739.2	RP11-295K2.3	-3.95	9.51e-05	0.0311	-0.3	-0.21	Schizophrenia;	chr1:186367231	chr1:186435161~186470291:+
STAD	cis	rs806321	0.501	rs2066626	ENSG00000237152.3	DLEU7-AS1	-3.95	9.51e-05	0.0312	-0.24	-0.21	Multiple sclerosis;	chr13:50180079	chr13:50807856~50849905:+
STAD	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	3.95	9.51e-05	0.0312	0.29	0.21	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
STAD	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	3.95	9.51e-05	0.0312	0.29	0.21	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
STAD	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	3.95	9.51e-05	0.0312	0.29	0.21	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
STAD	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	3.95	9.51e-05	0.0312	0.29	0.21	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
STAD	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	3.95	9.51e-05	0.0312	0.29	0.21	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
STAD	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	3.95	9.51e-05	0.0312	0.29	0.21	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
STAD	cis	rs8141529	0.702	rs469990	ENSG00000226471.5	CTA-292E10.6	-3.95	9.51e-05	0.0312	-0.24	-0.21	Lymphocyte counts;	chr22:28908212	chr22:28800683~28848559:+
STAD	cis	rs60180747	1	rs11637556	ENSG00000252712.1	SCARNA14	3.95	9.51e-05	0.0312	0.24	0.21	Testicular germ cell tumor;	chr15:66436613	chr15:66347207~66347342:-
STAD	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	3.95	9.51e-05	0.0312	0.22	0.21	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
STAD	cis	rs2957692	0.548	rs10840337	ENSG00000254554.1	RP11-351I24.1	3.95	9.52e-05	0.0312	0.34	0.21	Circulating vasoactive peptide levels;	chr11:9969223	chr11:10302657~10303704:-
STAD	cis	rs8014252	0.803	rs74062769	ENSG00000259158.2	ADAM20P1	-3.95	9.52e-05	0.0312	-0.28	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70603859	chr14:70468881~70483756:-
STAD	cis	rs17772222	0.651	rs865285	ENSG00000258789.1	RP11-507K2.3	3.95	9.52e-05	0.0312	0.25	0.21	Coronary artery calcification;	chr14:88391138	chr14:88551597~88552493:+
STAD	cis	rs6940638	0.688	rs1028308	ENSG00000216915.2	RP1-97D16.1	-3.95	9.52e-05	0.0312	-0.23	-0.21	Intelligence (multi-trait analysis);	chr6:27161978	chr6:27737000~27738494:-
STAD	cis	rs453301	0.653	rs7005133	ENSG00000233609.3	RP11-62H7.2	3.95	9.53e-05	0.0312	0.23	0.21	Joint mobility (Beighton score);	chr8:9043712	chr8:8961200~8979025:+
STAD	cis	rs7512552	0.809	rs1694363	ENSG00000203819.6	HIST2H2BC	3.95	9.53e-05	0.0312	0.25	0.21	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150396201	chr1:149850193~149850772:-
STAD	cis	rs1007190	0.881	rs12937256	ENSG00000267405.1	CTC-296K1.4	3.95	9.53e-05	0.0312	0.24	0.21	DNA methylation (variation);	chr17:44904131	chr17:44794747~44797783:-
STAD	cis	rs12468226	0.938	rs3731700	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202291213	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs12464254	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202301641	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs16841867	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202303512	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs79117531	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202307690	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs16839065	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202308774	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs12471060	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202309597	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs115418918	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202315145	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs114922024	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202315958	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs77261109	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202316233	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs12466003	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202317317	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs80315897	ENSG00000272966.1	RP11-686O6.1	3.95	9.54e-05	0.0312	0.31	0.21	Urate levels;	chr2:202318044	chr2:202336739~202337200:+
STAD	cis	rs7512552	0.839	rs1260405	ENSG00000203819.6	HIST2H2BC	3.95	9.54e-05	0.0312	0.24	0.21	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150332310	chr1:149850193~149850772:-
STAD	cis	rs9435732	0.778	rs2076604	ENSG00000224621.1	RP11-276H7.3	3.95	9.54e-05	0.0312	0.23	0.21	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16991570	chr1:16159266~16161883:+
STAD	cis	rs1850744	0.702	rs55916508	ENSG00000163612.10	FAM86KP	3.95	9.55e-05	0.0312	0.43	0.21	Economic and political preferences;	chr4:9587710	chr4:9153296~9165451:+
STAD	cis	rs4713118	0.955	rs9393847	ENSG00000220721.1	OR1F12	3.95	9.55e-05	0.0313	0.23	0.21	Parkinson's disease;	chr6:27720194	chr6:28073316~28074233:+
STAD	cis	rs6772849	0.896	rs4557179	ENSG00000242551.2	POU5F1P6	-3.95	9.55e-05	0.0313	-0.21	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128674735~128677005:-
STAD	cis	rs1850744	0.702	rs7668469	ENSG00000163612.10	FAM86KP	-3.95	9.55e-05	0.0313	-0.48	-0.21	Economic and political preferences;	chr4:9742906	chr4:9153296~9165451:+
STAD	cis	rs1707322	0.928	rs925524	ENSG00000281133.1	AL355480.3	3.95	9.55e-05	0.0313	0.25	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46031037	chr1:45580892~45580996:-
STAD	cis	rs5753618	0.504	rs9609296	ENSG00000236132.1	CTA-440B3.1	-3.95	9.55e-05	0.0313	-0.23	-0.21	Colorectal cancer;	chr22:31495798	chr22:31816379~31817491:-
STAD	cis	rs1075265	0.783	rs6708095	ENSG00000235937.1	AC008280.1	3.95	9.56e-05	0.0313	0.19	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54029552~54030682:-
STAD	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	3.95	9.56e-05	0.0313	0.26	0.21	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
STAD	cis	rs73198271	1	rs11774744	ENSG00000233609.3	RP11-62H7.2	-3.95	9.56e-05	0.0313	-0.3	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:8961200~8979025:+
STAD	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	3.95	9.56e-05	0.0313	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
STAD	cis	rs180358	0.945	rs601634	ENSG00000280143.1	AP000892.6	3.95	9.56e-05	0.0313	0.2	0.21	Multiple sclerosis (severity);	chr11:116797795	chr11:117204967~117210292:+
STAD	cis	rs7927771	0.793	rs12803525	ENSG00000271350.1	CTD-2384B9.1	-3.95	9.57e-05	0.0313	-0.22	-0.21	Subjective well-being;	chr11:47391924	chr11:47041027~47041945:-
STAD	cis	rs2957692	0.548	rs12417184	ENSG00000254554.1	RP11-351I24.1	3.95	9.57e-05	0.0313	0.34	0.21	Circulating vasoactive peptide levels;	chr11:10115313	chr11:10302657~10303704:-
STAD	cis	rs14027	0.883	rs13255850	ENSG00000279347.1	RP11-85I17.2	-3.95	9.57e-05	0.0313	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119838736~119840385:-
STAD	cis	rs12621278	0.655	rs16860643	ENSG00000232788.1	AC078883.3	3.95	9.57e-05	0.0313	0.36	0.21	Prostate cancer (SNP x SNP interaction);Prostate cancer;	chr2:172506550	chr2:172464262~172466022:-
STAD	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	3.95	9.58e-05	0.0313	0.3	0.21	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	3.95	9.58e-05	0.0313	0.3	0.21	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	3.95	9.58e-05	0.0313	0.3	0.21	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	3.95	9.58e-05	0.0313	0.3	0.21	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
STAD	cis	rs1009077	0.68	rs13121569	ENSG00000260091.1	RP11-33B1.4	3.95	9.58e-05	0.0313	0.24	0.21	Endometriosis;	chr4:119507249	chr4:119409333~119410233:+
STAD	cis	rs9291683	0.507	rs6827754	ENSG00000250613.1	RP11-136I13.1	3.95	9.58e-05	0.0313	0.22	0.21	Bone mineral density;	chr4:10016529	chr4:10410996~10411644:+
STAD	cis	rs10510181	0.548	rs115377075	ENSG00000224318.4	CHL1-AS2	3.95	9.58e-05	0.0313	0.22	0.21	Adolescent idiopathic scoliosis;	chr3:69037	chr3:195758~197341:-
STAD	cis	rs17592366	0.591	rs76204064	ENSG00000251726.1	RNU7-41P	-3.95	9.58e-05	0.0313	-0.34	-0.21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34758173	chr14:34845300~34845360:-
STAD	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	3.95	9.58e-05	0.0313	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
STAD	cis	rs870825	0.616	rs7659201	ENSG00000249173.4	LINC01093	-3.95	9.58e-05	0.0313	-0.34	-0.21	Blood protein levels;	chr4:184710859	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs7683556	ENSG00000249173.4	LINC01093	-3.95	9.58e-05	0.0313	-0.34	-0.21	Blood protein levels;	chr4:184710865	chr4:184893871~184899454:-
STAD	cis	rs7283707	0.681	rs112722151	ENSG00000228798.1	AP000473.5	-3.95	9.58e-05	0.0313	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15767781	chr21:16630827~16640683:+
STAD	cis	rs11169552	0.51	rs10431486	ENSG00000200183.1	RNU6-238P	-3.95	9.58e-05	0.0313	-0.2	-0.21	Colorectal cancer;	chr12:50547242	chr12:50656973~50657078:+
STAD	cis	rs2657294	0.726	rs4746275	ENSG00000226051.5	ZNF503-AS1	-3.95	9.58e-05	0.0313	-0.27	-0.21	Pneumonia;	chr10:75214940	chr10:75269819~75373500:+
STAD	cis	rs7474896	0.895	rs2749587	ENSG00000099251.13	HSD17B7P2	-3.95	9.58e-05	0.0313	-0.34	-0.21	Obesity (extreme);	chr10:37980609	chr10:38356380~38378505:+
STAD	cis	rs7512552	0.803	rs9435997	ENSG00000203819.6	HIST2H2BC	-3.95	9.59e-05	0.0314	-0.24	-0.21	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150317053	chr1:149850193~149850772:-
STAD	cis	rs55675132	0.515	rs72687886	ENSG00000236480.1	PKMP1	3.95	9.59e-05	0.0314	0.19	0.21	Schizophrenia;	chr1:114743450	chr1:114535995~114537840:+
STAD	cis	rs17708984	0.606	rs3786573	ENSG00000267275.1	CTD-2562J15.6	3.95	9.59e-05	0.0314	0.22	0.21	Platelet distribution width;Platelet count;	chr19:16082975	chr19:16283359~16324514:-
STAD	cis	rs8012947	1	rs8011191	ENSG00000279636.2	LINC00216	-3.95	9.59e-05	0.0314	-0.2	-0.21	Alcohol consumption in current drinkers;	chr14:58250295	chr14:58288033~58289158:+
STAD	cis	rs11098499	0.754	rs17595608	ENSG00000260091.1	RP11-33B1.4	3.95	9.59e-05	0.0314	0.2	0.21	Corneal astigmatism;	chr4:119329351	chr4:119409333~119410233:+
STAD	cis	rs12468226	0.606	rs79092351	ENSG00000226261.1	AC064836.3	3.95	9.59e-05	0.0314	0.3	0.21	Urate levels;	chr2:202204388	chr2:202336024~202336727:-
STAD	cis	rs4589258	0.788	rs7943744	ENSG00000280367.1	RP11-121L10.2	3.95	9.59e-05	0.0314	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90760476	chr11:90223153~90226538:+
STAD	cis	rs7512552	0.582	rs834233	ENSG00000203819.6	HIST2H2BC	3.95	9.59e-05	0.0314	0.24	0.21	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150381800	chr1:149850193~149850772:-
STAD	cis	rs2404602	0.622	rs11637296	ENSG00000196274.5	Metazoa_SRP	-3.95	9.6e-05	0.0314	-0.18	-0.21	Blood metabolite levels;	chr15:76915544	chr15:76230048~76230390:-
STAD	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	3.95	9.6e-05	0.0314	0.21	0.21	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
STAD	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	3.95	9.6e-05	0.0314	0.21	0.21	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
STAD	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	3.95	9.6e-05	0.0314	0.26	0.21	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
STAD	cis	rs55823223	0.564	rs12103594	ENSG00000267801.1	RP11-552F3.9	3.95	9.6e-05	0.0314	0.28	0.21	Psoriasis;	chr17:75859198	chr17:75876372~75879546:+
STAD	cis	rs77861329	1	rs9857878	ENSG00000270941.1	RP5-966M1.5	-3.95	9.61e-05	0.0314	-0.4	-0.21	Macrophage inflammatory protein 1b levels;	chr3:52075652	chr3:52734735~52735013:+
STAD	cis	rs919433	0.854	rs787994	ENSG00000231621.1	AC013264.2	-3.95	9.61e-05	0.0314	-0.18	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197358397	chr2:197197991~197199273:+
STAD	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	3.95	9.61e-05	0.0314	0.26	0.21	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
STAD	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	3.95	9.61e-05	0.0314	0.25	0.21	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
STAD	cis	rs7474896	0.945	rs2749561	ENSG00000099251.13	HSD17B7P2	-3.95	9.61e-05	0.0314	-0.35	-0.21	Obesity (extreme);	chr10:37909119	chr10:38356380~38378505:+
STAD	cis	rs10129255	0.701	rs2005643	ENSG00000232216.1	IGHV3-43	3.95	9.61e-05	0.0314	0.2	0.21	Kawasaki disease;	chr14:106676288	chr14:106470264~106470800:-
STAD	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	3.95	9.61e-05	0.0314	0.24	0.21	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	3.95	9.61e-05	0.0314	0.24	0.21	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
STAD	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-3.95	9.62e-05	0.0314	-0.26	-0.21	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
STAD	cis	rs7202877	0.656	rs977986	ENSG00000261783.1	RP11-252K23.2	-3.95	9.62e-05	0.0314	-0.34	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75472798	chr16:75379818~75381260:-
STAD	cis	rs4713118	0.955	rs9468200	ENSG00000220721.1	OR1F12	3.95	9.62e-05	0.0314	0.23	0.21	Parkinson's disease;	chr6:27715284	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.955	rs34752872	ENSG00000220721.1	OR1F12	3.95	9.62e-05	0.0314	0.23	0.21	Parkinson's disease;	chr6:27715465	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.911	rs2394000	ENSG00000220721.1	OR1F12	3.95	9.62e-05	0.0314	0.23	0.21	Parkinson's disease;	chr6:27719212	chr6:28073316~28074233:+
STAD	cis	rs1876905	0.68	rs373526	ENSG00000230177.1	RP5-1112D6.4	3.95	9.62e-05	0.0314	0.24	0.21	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111277932~111278742:+
STAD	cis	rs3858145	0.588	rs61854833	ENSG00000234102.1	KRT19P4	-3.95	9.62e-05	0.0314	-0.24	-0.21	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68260557~68261499:+
STAD	cis	rs2098713	0.562	rs55794983	ENSG00000250155.1	CTD-2353F22.1	3.95	9.62e-05	0.0314	0.21	0.21	Telomere length;	chr5:37549046	chr5:36666214~36725195:-
STAD	cis	rs10129255	0.5	rs11627315	ENSG00000232216.1	IGHV3-43	3.95	9.62e-05	0.0314	0.18	0.21	Kawasaki disease;	chr14:106802182	chr14:106470264~106470800:-
STAD	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	3.95	9.62e-05	0.0314	0.26	0.21	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
STAD	cis	rs13413635	0.695	rs7598623	ENSG00000225808.1	DNAJC19P5	-3.95	9.63e-05	0.0314	-0.27	-0.21	Heart rate;	chr2:178043233	chr2:177229191~177229506:-
STAD	cis	rs870825	0.616	rs2130394	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184721423	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6552808	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184721711	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6419939	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184721715	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4594761	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184721848	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4623061	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184722007	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4437299	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184722069	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4437295	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184722182	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs1401360	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184722417	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs1401361	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184722588	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs1401362	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184722621	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6552810	ENSG00000249173.4	LINC01093	-3.95	9.63e-05	0.0315	-0.33	-0.21	Blood protein levels;	chr4:184722989	chr4:184893871~184899454:-
STAD	cis	rs6832769	1	rs9312662	ENSG00000223305.1	RN7SKP30	-3.95	9.63e-05	0.0315	-0.23	-0.21	Personality dimensions;	chr4:55520204	chr4:55540502~55540835:-
STAD	cis	rs7208859	0.673	rs75142521	ENSG00000263603.1	CTD-2349P21.5	-3.95	9.63e-05	0.0315	-0.26	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30729469~30731202:+
STAD	cis	rs9905704	0.647	rs10221208	ENSG00000224738.1	AC099850.1	3.95	9.63e-05	0.0315	0.24	0.21	Testicular germ cell tumor;	chr17:58970524	chr17:59106598~59118267:+
STAD	cis	rs7829975	0.66	rs10093926	ENSG00000173295.6	FAM86B3P	-3.95	9.63e-05	0.0315	-0.25	-0.21	Mood instability;	chr8:8691510	chr8:8228595~8244865:+
STAD	cis	rs9902453	0.578	rs8073217	ENSG00000263477.1	RP11-338L22.2	3.95	9.63e-05	0.0315	0.18	0.21	Coffee consumption (cups per day);	chr17:29837245	chr17:29863402~29866092:+
STAD	cis	rs858239	0.537	rs6942981	ENSG00000230042.1	AK3P3	-3.95	9.64e-05	0.0315	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23129178~23129841:+
STAD	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-3.95	9.64e-05	0.0315	-0.23	-0.21	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
STAD	cis	rs62400317	0.762	rs12215263	ENSG00000219384.1	RP11-491H9.3	-3.95	9.64e-05	0.0315	-0.24	-0.21	Total body bone mineral density;	chr6:44863627	chr6:45158870~45159511:+
STAD	cis	rs61542988	0.57	rs62448268	ENSG00000228649.7	AC005682.5	3.95	9.64e-05	0.0315	0.27	0.21	Fibrinogen levels;	chr7:22789845	chr7:22854178~22861579:+
STAD	cis	rs4805566	0.743	rs9676557	ENSG00000267006.1	CTC-448F2.4	-3.95	9.64e-05	0.0315	-0.23	-0.21	Body mass index;	chr19:30415114	chr19:30028741~30029916:-
STAD	cis	rs2115630	1	rs55646601	ENSG00000256278.1	RP11-182J1.5	-3.95	9.64e-05	0.0315	-0.2	-0.21	P wave terminal force;	chr15:84780337	chr15:84611689~84614969:-
STAD	cis	rs3808502	0.503	rs2061830	ENSG00000270154.1	RP11-419I17.1	3.95	9.64e-05	0.0315	0.23	0.21	Neuroticism;	chr8:11539948	chr8:12476462~12477122:+
STAD	cis	rs638893	1	rs636736	ENSG00000255422.1	AP002954.4	-3.95	9.64e-05	0.0315	-0.34	-0.21	Vitiligo;	chr11:118834436	chr11:118704607~118750263:+
STAD	cis	rs4730250	0.707	rs61014091	ENSG00000273320.1	RP11-22N19.2	-3.95	9.65e-05	0.0315	-0.32	-0.21	Osteoarthritis;	chr7:107169662	chr7:106285480~106286326:+
STAD	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	3.95	9.65e-05	0.0315	0.25	0.21	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	3.95	9.65e-05	0.0315	0.25	0.21	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
STAD	cis	rs950169	0.922	rs12906983	ENSG00000235370.6	DNM1P51	3.95	9.65e-05	0.0315	0.27	0.21	Schizophrenia;	chr15:84262270	chr15:84398316~84411701:-
STAD	cis	rs10129255	0.843	rs7142649	ENSG00000224373.3	IGHV4-59	3.95	9.65e-05	0.0315	0.16	0.21	Kawasaki disease;	chr14:106708870	chr14:106627249~106627825:-
STAD	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	3.95	9.65e-05	0.0315	0.27	0.21	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
STAD	cis	rs7829975	0.582	rs11783950	ENSG00000254340.1	RP11-10A14.3	-3.95	9.66e-05	0.0315	-0.27	-0.21	Mood instability;	chr8:8740321	chr8:9141424~9145435:+
STAD	cis	rs853679	0.657	rs1778482	ENSG00000220721.1	OR1F12	3.95	9.66e-05	0.0315	0.2	0.21	Depression;	chr6:28273215	chr6:28073316~28074233:+
STAD	cis	rs6964833	0.935	rs34630792	ENSG00000277072.3	STAG3L2	3.95	9.66e-05	0.0315	0.24	0.21	Menarche (age at onset);	chr7:74646869	chr7:74882163~74890610:-
STAD	cis	rs919433	1	rs919433	ENSG00000231621.1	AC013264.2	3.95	9.66e-05	0.0315	0.18	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301841	chr2:197197991~197199273:+
STAD	cis	rs6832769	1	rs1522110	ENSG00000223305.1	RN7SKP30	3.95	9.66e-05	0.0315	0.23	0.21	Personality dimensions;	chr4:55514116	chr4:55540502~55540835:-
STAD	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	3.95	9.66e-05	0.0315	0.25	0.21	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	3.95	9.66e-05	0.0315	0.25	0.21	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	3.95	9.66e-05	0.0315	0.25	0.21	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
STAD	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	3.94	9.67e-05	0.0316	0.2	0.21	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
STAD	cis	rs7204230	1	rs3743771	ENSG00000261291.1	RP11-295M3.2	3.94	9.67e-05	0.0316	0.25	0.21	Fibrinogen;	chr16:53324527	chr16:53168522~53169450:+
STAD	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-3.94	9.67e-05	0.0316	-0.3	-0.21	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
STAD	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	3.94	9.67e-05	0.0316	0.16	0.21	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
STAD	cis	rs4792901	0.802	rs58141510	ENSG00000279602.1	CTD-3014M21.1	-3.94	9.68e-05	0.0316	-0.28	-0.21	Dupuytren's disease;	chr17:43509107	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs28532791	ENSG00000279602.1	CTD-3014M21.1	-3.94	9.68e-05	0.0316	-0.28	-0.21	Dupuytren's disease;	chr17:43512111	chr17:43360041~43361361:-
STAD	cis	rs9733	0.596	rs12089989	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150743306	chr1:150608507~150608623:-
STAD	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	3.94	9.68e-05	0.0316	0.24	0.21	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
STAD	cis	rs925550	0.526	rs62322204	ENSG00000224786.1	CETN4P	-3.94	9.68e-05	0.0316	-0.28	-0.21	Primary biliary cholangitis;	chr4:122707934	chr4:122730548~122732193:-
STAD	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-3.94	9.68e-05	0.0316	-0.21	-0.21	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
STAD	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-3.94	9.68e-05	0.0316	-0.21	-0.21	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
STAD	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-3.94	9.68e-05	0.0316	-0.21	-0.21	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
STAD	cis	rs202072	0.725	rs445590	ENSG00000272379.1	RP1-257A7.5	3.94	9.68e-05	0.0316	0.26	0.21	HIV-1 viral setpoint;	chr6:13280632	chr6:13290018~13290490:-
STAD	cis	rs9733	0.596	rs17658705	ENSG00000276103.1	U4	-3.94	9.68e-05	0.0316	-0.19	-0.21	Tonsillectomy;	chr1:150705595	chr1:150608507~150608623:-
STAD	cis	rs9733	0.566	rs72702554	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150705758	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs11586422	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150706882	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72702557	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150707654	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs17606613	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150710539	chr1:150608507~150608623:-
STAD	cis	rs9733	0.543	rs72702558	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150710775	chr1:150608507~150608623:-
STAD	cis	rs9733	0.628	rs11807409	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150710947	chr1:150608507~150608623:-
STAD	cis	rs9733	0.565	rs11804276	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150713285	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs12072339	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150713623	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs34600506	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150715332	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72702570	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150715720	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs11582840	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150716011	chr1:150608507~150608623:-
STAD	cis	rs9733	0.569	rs11588404	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150716053	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72702573	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150716574	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72702580	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150718809	chr1:150608507~150608623:-
STAD	cis	rs9733	0.525	rs11584184	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150723213	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs6669369	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150723416	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs6681990	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150723453	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs6692960	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150723489	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72702585	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150723951	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs12086472	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150725234	chr1:150608507~150608623:-
STAD	cis	rs9733	0.628	rs7540874	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150730187	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs1136808	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150730241	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs1415148	ENSG00000276103.1	U4	3.94	9.68e-05	0.0316	0.19	0.21	Tonsillectomy;	chr1:150733279	chr1:150608507~150608623:-
STAD	cis	rs6430585	0.697	rs7607174	ENSG00000231890.6	DARS-AS1	-3.94	9.68e-05	0.0316	-0.25	-0.21	Corneal structure;	chr2:135756100	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.697	rs115944351	ENSG00000231890.6	DARS-AS1	-3.94	9.68e-05	0.0316	-0.25	-0.21	Corneal structure;	chr2:135757888	chr2:135985176~136022593:+
STAD	cis	rs111342015	0.615	rs6914964	ENSG00000181524.6	RPL24P4	-3.94	9.69e-05	0.0316	-0.23	-0.21	Breast cancer;	chr6:43178649	chr6:42956345~42956765:-
STAD	cis	rs11169552	0.51	rs10783370	ENSG00000200183.1	RNU6-238P	-3.94	9.69e-05	0.0316	-0.2	-0.21	Colorectal cancer;	chr12:50543366	chr12:50656973~50657078:+
STAD	cis	rs1799949	0.965	rs8176198	ENSG00000279602.1	CTD-3014M21.1	3.94	9.69e-05	0.0316	0.25	0.21	Menopause (age at onset);	chr17:43078520	chr17:43360041~43361361:-
STAD	cis	rs62400317	0.762	rs6909047	ENSG00000219384.1	RP11-491H9.3	-3.94	9.7e-05	0.0316	-0.24	-0.21	Total body bone mineral density;	chr6:45031178	chr6:45158870~45159511:+
STAD	cis	rs11169552	0.51	rs7138604	ENSG00000200183.1	RNU6-238P	-3.94	9.7e-05	0.0316	-0.19	-0.21	Colorectal cancer;	chr12:50559014	chr12:50656973~50657078:+
STAD	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	3.94	9.71e-05	0.0317	0.26	0.21	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
STAD	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	3.94	9.71e-05	0.0317	0.36	0.21	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
STAD	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	3.94	9.71e-05	0.0317	0.36	0.21	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
STAD	cis	rs6019512	0.846	rs2024596	ENSG00000227431.4	CSE1L-AS1	3.94	9.72e-05	0.0317	0.2	0.21	Intelligence (multi-trait analysis);	chr20:48901515	chr20:49040463~49046044:-
STAD	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	3.94	9.72e-05	0.0317	0.26	0.21	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
STAD	cis	rs478304	0.903	rs12293022	ENSG00000213409.4	RP11-658F2.3	-3.94	9.72e-05	0.0317	-0.16	-0.21	Acne (severe);	chr11:65764227	chr11:66761575~66762399:-
STAD	cis	rs478304	0.934	rs603645	ENSG00000213409.4	RP11-658F2.3	-3.94	9.72e-05	0.0317	-0.16	-0.21	Acne (severe);	chr11:65765529	chr11:66761575~66762399:-
STAD	cis	rs7520050	0.966	rs785491	ENSG00000280836.1	AL355480.1	3.94	9.72e-05	0.0317	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs785492	ENSG00000280836.1	AL355480.1	3.94	9.72e-05	0.0317	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs785503	ENSG00000280836.1	AL355480.1	3.94	9.72e-05	0.0317	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45581219~45581321:-
STAD	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	3.94	9.73e-05	0.0317	0.33	0.21	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
STAD	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	3.94	9.73e-05	0.0317	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
STAD	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-3.94	9.73e-05	0.0317	-0.22	-0.21	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
STAD	cis	rs6479891	1	rs9414788	ENSG00000235816.3	PRELID1P3	-3.94	9.73e-05	0.0317	-0.26	-0.21	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63427297~63427939:+
STAD	cis	rs2836950	0.762	rs8134638	ENSG00000238141.2	BRWD1-AS1	-3.94	9.73e-05	0.0317	-0.23	-0.21	Menarche (age at onset);	chr21:39272244	chr21:39315707~39323218:+
STAD	cis	rs2803122	0.967	rs10811148	ENSG00000272842.1	RP11-513M16.7	-3.94	9.74e-05	0.0317	-0.19	-0.21	Pulse pressure;	chr9:19246469	chr9:19371386~19371945:-
STAD	cis	rs6813195	0.554	rs2676343	ENSG00000243417.1	RP11-555K12.1	3.94	9.74e-05	0.0318	0.21	0.21	Type 2 diabetes;	chr4:152389475	chr4:152551277~152552364:-
STAD	cis	rs755249	0.501	rs2484133	ENSG00000182109.6	RP11-69E11.4	3.94	9.75e-05	0.0318	0.26	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39522280~39546187:-
STAD	cis	rs75920871	0.748	rs61905689	ENSG00000254851.1	RP11-109L13.1	3.94	9.75e-05	0.0318	0.26	0.21	Subjective well-being;	chr11:116998501	chr11:117135528~117138582:+
STAD	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-3.94	9.75e-05	0.0318	-0.27	-0.21	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-3.94	9.75e-05	0.0318	-0.27	-0.21	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-3.94	9.75e-05	0.0318	-0.27	-0.21	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-3.94	9.75e-05	0.0318	-0.27	-0.21	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
STAD	cis	rs5753618	0.583	rs8141150	ENSG00000236132.1	CTA-440B3.1	-3.94	9.75e-05	0.0318	-0.23	-0.21	Colorectal cancer;	chr22:31404350	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.583	rs9606839	ENSG00000236132.1	CTA-440B3.1	-3.94	9.75e-05	0.0318	-0.23	-0.21	Colorectal cancer;	chr22:31406724	chr22:31816379~31817491:-
STAD	cis	rs6832769	0.89	rs564762	ENSG00000223305.1	RN7SKP30	3.94	9.75e-05	0.0318	0.23	0.21	Personality dimensions;	chr4:55418464	chr4:55540502~55540835:-
STAD	cis	rs10508774	0.925	rs72795540	ENSG00000273038.2	RP11-479G22.8	3.94	9.76e-05	0.0318	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32554254	chr10:32887255~32889311:-
STAD	cis	rs925550	0.56	rs17006053	ENSG00000224786.1	CETN4P	-3.94	9.76e-05	0.0318	-0.28	-0.21	Primary biliary cholangitis;	chr4:122708506	chr4:122730548~122732193:-
STAD	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-3.94	9.76e-05	0.0318	-0.25	-0.21	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
STAD	cis	rs2337406	0.704	rs1858679	ENSG00000280411.1	IGHV1-69-2	-3.94	9.76e-05	0.0318	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106706726	chr14:106762092~106762588:-
STAD	cis	rs6604026	0.74	rs10874747	ENSG00000229052.2	RP11-386I23.1	-3.94	9.76e-05	0.0318	-0.2	-0.21	Multiple sclerosis;	chr1:92886934	chr1:92930696~92934098:+
STAD	cis	rs6604026	0.74	rs10782946	ENSG00000229052.2	RP11-386I23.1	-3.94	9.76e-05	0.0318	-0.2	-0.21	Multiple sclerosis;	chr1:92887112	chr1:92930696~92934098:+
STAD	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-3.94	9.76e-05	0.0318	-0.22	-0.21	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
STAD	cis	rs35955747	0.778	rs9609263	ENSG00000236132.1	CTA-440B3.1	3.94	9.77e-05	0.0318	0.2	0.21	Neutrophil count;Sum basophil neutrophil counts;	chr22:31349288	chr22:31816379~31817491:-
STAD	cis	rs875971	0.545	rs73146609	ENSG00000273142.1	RP11-458F8.4	3.94	9.77e-05	0.0318	0.19	0.21	Aortic root size;	chr7:66302477	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs2173571	ENSG00000273142.1	RP11-458F8.4	3.94	9.77e-05	0.0318	0.19	0.21	Aortic root size;	chr7:66305392	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs11770063	ENSG00000273142.1	RP11-458F8.4	3.94	9.77e-05	0.0318	0.19	0.21	Aortic root size;	chr7:66318029	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs3936065	ENSG00000273142.1	RP11-458F8.4	3.94	9.77e-05	0.0318	0.19	0.21	Aortic root size;	chr7:66325577	chr7:66902857~66906297:+
STAD	cis	rs875971	0.545	rs4718335	ENSG00000273142.1	RP11-458F8.4	3.94	9.77e-05	0.0318	0.19	0.21	Aortic root size;	chr7:66339619	chr7:66902857~66906297:+
STAD	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-3.94	9.77e-05	0.0318	-0.28	-0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
STAD	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	3.94	9.77e-05	0.0318	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
STAD	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	3.94	9.77e-05	0.0318	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
STAD	cis	rs2803122	0.871	rs3802333	ENSG00000272842.1	RP11-513M16.7	-3.94	9.77e-05	0.0318	-0.19	-0.21	Pulse pressure;	chr9:19232137	chr9:19371386~19371945:-
STAD	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-3.94	9.78e-05	0.0318	-0.22	-0.21	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
STAD	cis	rs7204230	0.961	rs7203402	ENSG00000261291.1	RP11-295M3.2	3.94	9.78e-05	0.0318	0.25	0.21	Fibrinogen;	chr16:53307406	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs12596466	ENSG00000261291.1	RP11-295M3.2	3.94	9.78e-05	0.0318	0.25	0.21	Fibrinogen;	chr16:53308948	chr16:53168522~53169450:+
STAD	cis	rs1707322	0.686	rs2275085	ENSG00000225447.1	RPS15AP10	-3.94	9.78e-05	0.0318	-0.17	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45645816~45646197:-
STAD	cis	rs12745968	0.589	rs7417452	ENSG00000229052.2	RP11-386I23.1	-3.94	9.78e-05	0.0318	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92566496	chr1:92930696~92934098:+
STAD	cis	rs17292804	0.506	rs71417868	ENSG00000258851.1	RP11-894P9.2	-3.94	9.79e-05	0.0319	-0.25	-0.21	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103553421~103561877:+
STAD	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	3.94	9.79e-05	0.0319	0.22	0.21	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
STAD	cis	rs7915414	0.951	rs2104543	ENSG00000230338.1	MTND4P19	3.94	9.8e-05	0.0319	0.24	0.21	Clopidogrel active metabolite levels;	chr10:94670214	chr10:94774156~94774633:-
STAD	cis	rs11071200	0.571	rs16976436	ENSG00000276533.1	RP11-139H15.5	3.94	9.8e-05	0.0319	0.28	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr15:55631757	chr15:55288849~55289346:-
STAD	cis	rs870825	0.655	rs10013685	ENSG00000249173.4	LINC01093	-3.94	9.8e-05	0.0319	-0.33	-0.21	Blood protein levels;	chr4:184696631	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7658186	ENSG00000249173.4	LINC01093	-3.94	9.8e-05	0.0319	-0.33	-0.21	Blood protein levels;	chr4:184701355	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs67380800	ENSG00000249173.4	LINC01093	-3.94	9.8e-05	0.0319	-0.33	-0.21	Blood protein levels;	chr4:184702634	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28636679	ENSG00000249173.4	LINC01093	-3.94	9.8e-05	0.0319	-0.33	-0.21	Blood protein levels;	chr4:184706327	chr4:184893871~184899454:-
STAD	cis	rs6480314	0.522	rs10047355	ENSG00000234102.1	KRT19P4	-3.94	9.8e-05	0.0319	-0.28	-0.21	Optic nerve measurement (disc area);	chr10:68300321	chr10:68260557~68261499:+
STAD	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	3.94	9.8e-05	0.0319	0.26	0.21	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
STAD	cis	rs748404	0.578	rs507178	ENSG00000275601.1	AC011330.13	-3.94	9.8e-05	0.0319	-0.22	-0.21	Lung cancer;	chr15:43317937	chr15:43642389~43643023:-
STAD	cis	rs748404	0.578	rs478028	ENSG00000275601.1	AC011330.13	-3.94	9.8e-05	0.0319	-0.22	-0.21	Lung cancer;	chr15:43318574	chr15:43642389~43643023:-
STAD	cis	rs748404	0.578	rs552701	ENSG00000275601.1	AC011330.13	-3.94	9.8e-05	0.0319	-0.22	-0.21	Lung cancer;	chr15:43321612	chr15:43642389~43643023:-
STAD	cis	rs748404	0.578	rs573615	ENSG00000275601.1	AC011330.13	-3.94	9.8e-05	0.0319	-0.22	-0.21	Lung cancer;	chr15:43322083	chr15:43642389~43643023:-
STAD	cis	rs1007190	0.881	rs6503406	ENSG00000267405.1	CTC-296K1.4	3.94	9.8e-05	0.0319	0.25	0.21	DNA methylation (variation);	chr17:44859737	chr17:44794747~44797783:-
STAD	cis	rs992157	0.767	rs2382822	ENSG00000224928.2	KRT8P30	3.94	9.81e-05	0.0319	0.22	0.21	Colorectal cancer;	chr2:218308604	chr2:218953401~218954050:-
STAD	cis	rs11846409	0.872	rs2956482	ENSG00000274576.2	IGHV2-70	3.94	9.81e-05	0.0319	0.25	0.21	Rheumatic heart disease;	chr14:106630013	chr14:106770577~106771020:-
STAD	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	3.94	9.81e-05	0.0319	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
STAD	cis	rs4835473	0.742	rs7654409	ENSG00000249741.2	RP11-673E1.3	-3.94	9.81e-05	0.0319	-0.24	-0.21	Immature fraction of reticulocytes;	chr4:143956842	chr4:143911514~143912053:-
STAD	cis	rs5743030	1	rs5743030	ENSG00000223249.1	Y_RNA	-3.94	9.81e-05	0.0319	-0.37	-0.21	Subcutaneous adipose tissue;	chr2:189813819	chr2:189753464~189753559:+
STAD	cis	rs6432860	0.932	rs1821181	ENSG00000229195.1	AC009495.4	3.94	9.82e-05	0.0319	0.27	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:165970089	chr2:165794857~165846091:-
STAD	cis	rs6142102	0.812	rs6059554	ENSG00000264616.1	MIR4755	3.94	9.82e-05	0.0319	0.22	0.21	Skin pigmentation;	chr20:33926286	chr20:34049119~34049190:+
STAD	cis	rs4713118	0.525	rs9357042	ENSG00000280107.1	AL022393.9	-3.94	9.82e-05	0.0319	-0.25	-0.21	Parkinson's disease;	chr6:27615016	chr6:28170845~28172521:+
STAD	cis	rs17680741	0.697	rs12269629	ENSG00000225484.5	NUTM2B-AS1	-3.94	9.82e-05	0.032	-0.35	-0.21	Coronary artery disease;	chr10:80477592	chr10:79663088~79826594:-
STAD	cis	rs1858037	0.806	rs12612780	ENSG00000223739.1	AC007389.2	-3.94	9.82e-05	0.032	-0.19	-0.21	Rheumatoid arthritis;	chr2:65355967	chr2:65511771~65512076:-
STAD	cis	rs870825	0.698	rs28412823	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184717675	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28450662	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184717746	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs28726376	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184717800	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs10428373	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184717848	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs35764203	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184717924	chr4:184893871~184899454:-
STAD	cis	rs870825	0.655	rs35397385	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184717941	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs36022027	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718038	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs2310108	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718321	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4416519	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718348	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs57086463	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718371	chr4:184893871~184899454:-
STAD	cis	rs870825	0.55	rs35981185	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718566	chr4:184893871~184899454:-
STAD	cis	rs870825	0.587	rs35377170	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718574	chr4:184893871~184899454:-
STAD	cis	rs870825	0.587	rs58332461	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718588	chr4:184893871~184899454:-
STAD	cis	rs870825	0.587	rs35845099	ENSG00000249173.4	LINC01093	-3.94	9.82e-05	0.032	-0.34	-0.21	Blood protein levels;	chr4:184718608	chr4:184893871~184899454:-
STAD	cis	rs11673344	0.542	rs826331	ENSG00000267672.1	CTD-2293H3.1	3.94	9.82e-05	0.032	0.19	0.21	Obesity-related traits;	chr19:37007360	chr19:37091341~37092564:+
STAD	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	3.94	9.82e-05	0.032	0.25	0.21	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
STAD	cis	rs7829975	0.714	rs11777085	ENSG00000173295.6	FAM86B3P	3.94	9.83e-05	0.032	0.23	0.21	Mood instability;	chr8:8814919	chr8:8228595~8244865:+
STAD	cis	rs794185	0.605	rs9872911	ENSG00000229241.1	PNPT1P1	3.94	9.83e-05	0.032	0.25	0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4425268	chr3:3981981~3984295:-
STAD	cis	rs10129255	0.957	rs12589190	ENSG00000224373.3	IGHV4-59	3.94	9.83e-05	0.032	0.17	0.21	Kawasaki disease;	chr14:106783079	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.957	rs7493713	ENSG00000224373.3	IGHV4-59	3.94	9.83e-05	0.032	0.17	0.21	Kawasaki disease;	chr14:106783685	chr14:106627249~106627825:-
STAD	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	3.94	9.83e-05	0.032	0.26	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
STAD	cis	rs9368481	0.729	rs10946881	ENSG00000272312.1	RP11-239L20.6	-3.94	9.84e-05	0.032	-0.22	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:27001208~27001648:-
STAD	cis	rs62402013	1	rs62402013	ENSG00000272312.1	RP11-239L20.6	-3.94	9.84e-05	0.032	-0.22	-0.21	Schizophrenia;	chr6:26947221	chr6:27001208~27001648:-
STAD	cis	rs2348418	0.831	rs10843173	ENSG00000247934.4	RP11-967K21.1	3.94	9.84e-05	0.032	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28453092	chr12:28163298~28190738:-
STAD	cis	rs2348418	0.864	rs10843174	ENSG00000247934.4	RP11-967K21.1	3.94	9.84e-05	0.032	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28453135	chr12:28163298~28190738:-
STAD	cis	rs17767294	1	rs17767294	ENSG00000220721.1	OR1F12	3.94	9.84e-05	0.032	0.37	0.21	Parkinson's disease;	chr6:28086420	chr6:28073316~28074233:+
STAD	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-3.94	9.84e-05	0.032	-0.24	-0.21	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
STAD	cis	rs997295	0.57	rs737226	ENSG00000270964.1	RP11-502I4.3	-3.94	9.84e-05	0.032	-0.25	-0.21	Motion sickness;	chr15:67548435	chr15:67541072~67542604:-
STAD	cis	rs997295	0.57	rs11632574	ENSG00000270964.1	RP11-502I4.3	-3.94	9.84e-05	0.032	-0.25	-0.21	Motion sickness;	chr15:67560067	chr15:67541072~67542604:-
STAD	cis	rs6142102	0.961	rs4911408	ENSG00000264616.1	MIR4755	3.94	9.84e-05	0.032	0.22	0.21	Skin pigmentation;	chr20:34112760	chr20:34049119~34049190:+
STAD	cis	rs10789491	1	rs1545206	ENSG00000225506.2	CYP4A22-AS1	3.94	9.84e-05	0.032	0.31	0.21	Response to hepatitis C treatment;	chr1:46719410	chr1:47096653~47179271:-
STAD	cis	rs28588043	0.609	rs17621839	ENSG00000201126.1	RNU6-773P	-3.94	9.85e-05	0.032	-0.33	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170984363	chr1:171519816~171519913:-
STAD	cis	rs17507216	0.671	rs4779035	ENSG00000255769.6	GOLGA2P10	-3.94	9.85e-05	0.032	-0.34	-0.21	Excessive daytime sleepiness;	chr15:82591686	chr15:82472993~82513950:-
STAD	cis	rs13413635	0.647	rs7588973	ENSG00000225808.1	DNAJC19P5	-3.94	9.85e-05	0.032	-0.27	-0.21	Heart rate;	chr2:178007501	chr2:177229191~177229506:-
STAD	cis	rs7924176	0.564	rs12359146	ENSG00000213731.2	RAB5CP1	-3.94	9.85e-05	0.032	-0.21	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74205914	chr10:74423435~74424014:-
STAD	cis	rs3764400	0.508	rs978263	ENSG00000278765.1	RP5-890E16.5	-3.94	9.85e-05	0.032	-0.27	-0.21	Body mass index;	chr17:48103302	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs12600980	ENSG00000278765.1	RP5-890E16.5	-3.94	9.85e-05	0.032	-0.27	-0.21	Body mass index;	chr17:48109779	chr17:48066704~48067293:-
STAD	cis	rs9307551	0.741	rs6824396	ENSG00000250334.4	LINC00989	-3.94	9.86e-05	0.0321	-0.26	-0.21	Refractive error;	chr4:79541178	chr4:79492416~79576460:+
STAD	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-3.94	9.86e-05	0.0321	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
STAD	cis	rs6964833	0.786	rs35633336	ENSG00000277072.3	STAG3L2	3.94	9.86e-05	0.0321	0.24	0.21	Menarche (age at onset);	chr7:74643961	chr7:74882163~74890610:-
STAD	cis	rs6964833	0.935	rs35735900	ENSG00000277072.3	STAG3L2	3.94	9.86e-05	0.0321	0.24	0.21	Menarche (age at onset);	chr7:74651887	chr7:74882163~74890610:-
STAD	cis	rs11696739	0.536	rs11696842	ENSG00000242324.1	RP4-576H24.2	3.94	9.86e-05	0.0321	0.27	0.21	Mean platelet volume;	chr20:1620148	chr20:1516759~1557653:-
STAD	cis	rs7671266	0.518	rs16895984	ENSG00000250613.1	RP11-136I13.1	-3.94	9.86e-05	0.0321	-0.2	-0.21	Cardiovascular disease risk factors;	chr4:10283103	chr4:10410996~10411644:+
STAD	cis	rs12439619	1	rs12439619	ENSG00000276710.3	CSPG4P8	-3.94	9.87e-05	0.0321	-0.27	-0.21	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82459472~82477258:+
STAD	cis	rs2348418	0.932	rs6487685	ENSG00000247934.4	RP11-967K21.1	3.94	9.87e-05	0.0321	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28505417	chr12:28163298~28190738:-
STAD	cis	rs7927771	0.832	rs935914	ENSG00000271350.1	CTD-2384B9.1	3.94	9.87e-05	0.0321	0.23	0.21	Subjective well-being;	chr11:47366048	chr11:47041027~47041945:-
STAD	cis	rs7283707	0.681	rs75316565	ENSG00000228798.1	AP000473.5	-3.94	9.87e-05	0.0321	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15764157	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs79116136	ENSG00000228798.1	AP000473.5	-3.94	9.87e-05	0.0321	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15765020	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs76815432	ENSG00000228798.1	AP000473.5	-3.94	9.87e-05	0.0321	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15765116	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs17307170	ENSG00000228798.1	AP000473.5	-3.94	9.87e-05	0.0321	-0.34	-0.21	QRS complex (12-leadsum);	chr21:15765253	chr21:16630827~16640683:+
STAD	cis	rs2688608	0.62	rs11000767	ENSG00000272140.2	RP11-574K11.29	3.94	9.87e-05	0.0321	0.19	0.21	Inflammatory bowel disease;	chr10:73756868	chr10:73703735~73713581:-
STAD	cis	rs1816752	0.646	rs7997248	ENSG00000273628.1	RP11-756A22.7	-3.94	9.87e-05	0.0321	-0.25	-0.21	Obesity-related traits;	chr13:24507050	chr13:24933006~24936796:+
STAD	cis	rs12500234	1	rs12512211	ENSG00000249207.1	RP11-360F5.1	-3.94	9.88e-05	0.0321	-0.21	-0.21	Colorectal cancer;	chr4:39614928	chr4:39112677~39126818:-
STAD	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-3.94	9.88e-05	0.0321	-0.27	-0.21	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
STAD	cis	rs516805	0.528	rs2606633	ENSG00000279453.1	RP3-425C14.4	-3.94	9.88e-05	0.0321	-0.31	-0.21	Lymphocyte counts;	chr6:122100131	chr6:122436789~122439223:-
STAD	cis	rs11098499	0.754	rs9991959	ENSG00000260091.1	RP11-33B1.4	-3.94	9.88e-05	0.0321	-0.19	-0.21	Corneal astigmatism;	chr4:119332618	chr4:119409333~119410233:+
STAD	cis	rs4713118	0.868	rs742047	ENSG00000220721.1	OR1F12	3.94	9.88e-05	0.0321	0.24	0.21	Parkinson's disease;	chr6:27771601	chr6:28073316~28074233:+
STAD	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	3.94	9.89e-05	0.0321	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	3.94	9.89e-05	0.0321	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
STAD	cis	rs7512552	0.839	rs1260405	ENSG00000261716.1	RP11-196G18.22	3.94	9.89e-05	0.0321	0.22	0.21	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150332310	chr1:149844498~149849024:-
STAD	cis	rs8141529	0.702	rs8137262	ENSG00000226471.5	CTA-292E10.6	-3.94	9.89e-05	0.0321	-0.24	-0.21	Lymphocyte counts;	chr22:28896147	chr22:28800683~28848559:+
STAD	cis	rs1858037	0.867	rs953312	ENSG00000223739.1	AC007389.2	-3.94	9.89e-05	0.0321	-0.19	-0.21	Rheumatoid arthritis;	chr2:65340556	chr2:65511771~65512076:-
STAD	cis	rs2348418	0.832	rs11049560	ENSG00000247934.4	RP11-967K21.1	3.94	9.89e-05	0.0321	0.19	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28372504	chr12:28163298~28190738:-
STAD	cis	rs11089937	0.616	rs12484496	ENSG00000211639.2	IGLV4-60	-3.94	9.9e-05	0.0322	-0.21	-0.21	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22162199~22162681:+
STAD	cis	rs7208859	0.673	rs999796	ENSG00000263603.1	CTD-2349P21.5	-3.94	9.9e-05	0.0322	-0.25	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30729469~30731202:+
STAD	cis	rs10129255	0.957	rs10142918	ENSG00000232216.1	IGHV3-43	3.94	9.9e-05	0.0322	0.21	0.21	Kawasaki disease;	chr14:106782206	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.957	rs10142859	ENSG00000232216.1	IGHV3-43	3.94	9.9e-05	0.0322	0.21	0.21	Kawasaki disease;	chr14:106782238	chr14:106470264~106470800:-
STAD	cis	rs17592366	1	rs2010608	ENSG00000251726.1	RNU7-41P	-3.94	9.9e-05	0.0322	-0.27	-0.21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34750139	chr14:34845300~34845360:-
STAD	cis	rs61270009	1	rs61270009	ENSG00000247828.6	TMEM161B-AS1	3.94	9.9e-05	0.0322	0.29	0.21	Depressive symptoms;	chr5:88280322	chr5:88268895~88436685:+
STAD	cis	rs9747201	1	rs56051385	ENSG00000281517.1	Metazoa_SRP	3.94	9.9e-05	0.0322	0.24	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82168836	chr17:81718849~81719095:-
STAD	cis	rs4835473	0.932	rs36018946	ENSG00000249741.2	RP11-673E1.3	3.94	9.9e-05	0.0322	0.24	0.21	Immature fraction of reticulocytes;	chr4:143980942	chr4:143911514~143912053:-
STAD	cis	rs12590640	0.933	rs8008376	ENSG00000258827.2	RP11-537P22.2	-3.94	9.91e-05	0.0322	-0.19	-0.21	Malaria;	chr14:36404535	chr14:37097062~37098563:-
STAD	cis	rs2278796	0.639	rs6697344	ENSG00000231691.1	RP11-203F10.5	-3.94	9.91e-05	0.0322	-0.26	-0.21	Mean platelet volume;	chr1:205002357	chr1:204277005~204277948:+
STAD	cis	rs6693567	0.586	rs12031973	ENSG00000203819.6	HIST2H2BC	3.94	9.91e-05	0.0322	0.24	0.21	Migraine;	chr1:150513090	chr1:149850193~149850772:-
STAD	cis	rs860295	0.702	rs4971095	ENSG00000225855.5	RUSC1-AS1	-3.94	9.91e-05	0.0322	-0.17	-0.21	Body mass index;	chr1:155636433	chr1:155316863~155324176:-
STAD	cis	rs4792901	0.802	rs9894910	ENSG00000279602.1	CTD-3014M21.1	-3.94	9.91e-05	0.0322	-0.28	-0.21	Dupuytren's disease;	chr17:43496938	chr17:43360041~43361361:-
STAD	cis	rs10971721	0.631	rs10971945	ENSG00000281128.1	PTENP1-AS	3.94	9.91e-05	0.0322	0.31	0.21	Body mass index;	chr9:34129397	chr9:33677268~33688011:+
STAD	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-3.94	9.91e-05	0.0322	-0.26	-0.21	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
STAD	cis	rs57024841	0.5	rs10116414	ENSG00000270259.2	RP13-122B23.9	3.94	9.92e-05	0.0322	0.23	0.21	Beta-trace protein levels;	chr9:136937244	chr9:137286112~137287236:+
STAD	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	3.94	9.92e-05	0.0322	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
STAD	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-3.94	9.92e-05	0.0322	-0.26	-0.21	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
STAD	cis	rs2880765	0.835	rs7169429	ENSG00000259295.5	CSPG4P12	3.94	9.92e-05	0.0322	0.26	0.21	Coronary artery disease;	chr15:85493417	chr15:85191438~85213905:+
STAD	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	3.94	9.92e-05	0.0322	0.31	0.21	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
STAD	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	3.94	9.92e-05	0.0322	0.31	0.21	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
STAD	cis	rs2351088	0.572	rs11703006	ENSG00000230634.1	RP5-996D20.3	-3.94	9.93e-05	0.0322	-0.32	-0.21	Tonsillectomy;	chr22:45775625	chr22:46481329~46481760:-
STAD	cis	rs7937127	0.744	rs2862958	ENSG00000254907.1	RP11-484D2.2	3.94	9.93e-05	0.0322	0.36	0.21	Fibrinogen levels;	chr11:43497572	chr11:43328748~43359296:-
STAD	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	3.94	9.93e-05	0.0322	0.26	0.21	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
STAD	cis	rs4835473	0.838	rs34521499	ENSG00000249741.2	RP11-673E1.3	3.94	9.93e-05	0.0322	0.24	0.21	Immature fraction of reticulocytes;	chr4:143777628	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.9	rs34264936	ENSG00000249741.2	RP11-673E1.3	3.94	9.93e-05	0.0322	0.24	0.21	Immature fraction of reticulocytes;	chr4:143780294	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.9	rs13140028	ENSG00000249741.2	RP11-673E1.3	3.94	9.93e-05	0.0322	0.24	0.21	Immature fraction of reticulocytes;	chr4:143782195	chr4:143911514~143912053:-
STAD	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-3.94	9.93e-05	0.0323	-0.32	-0.21	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
STAD	cis	rs7429990	0.965	rs4858810	ENSG00000224895.1	VPS26BP1	3.94	9.93e-05	0.0323	0.21	0.21	Educational attainment (years of education);	chr3:48002247	chr3:47960327~47961081:-
STAD	cis	rs6686842	0.56	rs213765	ENSG00000235358.1	RP11-399E6.1	3.94	9.93e-05	0.0323	0.23	0.21	Height;	chr1:41116334	chr1:41242373~41284861:+
STAD	cis	rs6832769	1	rs59804446	ENSG00000223305.1	RN7SKP30	-3.94	9.94e-05	0.0323	-0.24	-0.21	Personality dimensions;	chr4:55563374	chr4:55540502~55540835:-
STAD	cis	rs4589258	0.788	rs2051462	ENSG00000280367.1	RP11-121L10.2	3.94	9.94e-05	0.0323	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90767965	chr11:90223153~90226538:+
STAD	cis	rs10946940	0.965	rs6921256	ENSG00000280107.1	AL022393.9	-3.94	9.94e-05	0.0323	-0.24	-0.21	Systemic lupus erythematosus;	chr6:27619739	chr6:28170845~28172521:+
STAD	cis	rs7474896	1	rs12782327	ENSG00000099251.13	HSD17B7P2	3.94	9.94e-05	0.0323	0.34	0.21	Obesity (extreme);	chr10:37803515	chr10:38356380~38378505:+
STAD	cis	rs11587682	0.76	rs10788874	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150456449	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.714	rs12739019	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150458485	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs6686809	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150459240	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs12131083	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150461347	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs66513313	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150464739	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs12130082	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150465580	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.714	rs115578438	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150465876	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs74335909	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150465886	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs12129491	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150467298	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs55816515	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150467803	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.714	rs72698829	ENSG00000274963.1	Metazoa_SRP	-3.94	9.94e-05	0.0323	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150467965	chr1:150568971~150569269:-
STAD	cis	rs950169	0.84	rs62029595	ENSG00000235370.6	DNM1P51	3.94	9.94e-05	0.0323	0.26	0.21	Schizophrenia;	chr15:84400603	chr15:84398316~84411701:-
STAD	cis	rs42490	0.664	rs43226	ENSG00000251136.7	RP11-37B2.1	-3.94	9.94e-05	0.0323	-0.2	-0.21	Leprosy;	chr8:89809048	chr8:89609409~89757727:-
STAD	cis	rs1858037	0.867	rs4671660	ENSG00000223739.1	AC007389.2	-3.94	9.94e-05	0.0323	-0.19	-0.21	Rheumatoid arthritis;	chr2:65349302	chr2:65511771~65512076:-
STAD	cis	rs9463078	0.585	rs1521355	ENSG00000219384.1	RP11-491H9.3	3.94	9.95e-05	0.0323	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44965018	chr6:45158870~45159511:+
STAD	cis	rs7429990	0.901	rs9825114	ENSG00000224895.1	VPS26BP1	3.94	9.95e-05	0.0323	0.21	0.21	Educational attainment (years of education);	chr3:48096592	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.932	rs6766641	ENSG00000224895.1	VPS26BP1	3.94	9.95e-05	0.0323	0.21	0.21	Educational attainment (years of education);	chr3:48103734	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs6777081	ENSG00000224895.1	VPS26BP1	3.94	9.95e-05	0.0323	0.21	0.21	Educational attainment (years of education);	chr3:48114079	chr3:47960327~47961081:-
STAD	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-3.94	9.95e-05	0.0323	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-3.94	9.95e-05	0.0323	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
STAD	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-3.94	9.95e-05	0.0323	-0.24	-0.21	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
STAD	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	3.94	9.95e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
STAD	cis	rs10851478	0.802	rs12050614	ENSG00000259545.2	RP11-325E5.4	-3.94	9.95e-05	0.0323	-0.24	-0.21	Oral cavity cancer;	chr15:49497216	chr15:49177610~49178741:-
STAD	cis	rs2638953	0.924	rs11049417	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192152	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs12372059	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192370	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs12372073	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192462	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs56318627	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192719	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.814	rs11049419	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192951	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.85	rs11049420	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193179	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.744	rs11049421	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193324	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.744	rs11049426	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193573	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.886	rs11049429	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194332	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.779	rs11049432	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194454	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.85	rs4284426	ENSG00000247934.4	RP11-967K21.1	-3.94	9.96e-05	0.0323	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194543	chr12:28163298~28190738:-
STAD	cis	rs1707322	0.686	rs1250	ENSG00000225447.1	RPS15AP10	3.94	9.96e-05	0.0323	0.17	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45645816~45646197:-
STAD	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	3.94	9.96e-05	0.0323	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
STAD	cis	rs116095464	0.558	rs6555058	ENSG00000250848.1	CTD-2083E4.5	3.94	9.96e-05	0.0323	0.31	0.21	Breast cancer;	chr5:226261	chr5:288833~290321:-
STAD	cis	rs9420	0.961	rs7938083	ENSG00000265566.2	RN7SL605P	-3.94	9.96e-05	0.0323	-0.3	-0.21	Schizophrenia;	chr11:57726150	chr11:57528085~57528365:-
STAD	cis	rs7474896	0.943	rs2799496	ENSG00000099251.13	HSD17B7P2	-3.94	9.96e-05	0.0323	-0.34	-0.21	Obesity (extreme);	chr10:37954871	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2103936	ENSG00000099251.13	HSD17B7P2	-3.94	9.96e-05	0.0323	-0.34	-0.21	Obesity (extreme);	chr10:37964405	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.945	rs2092995	ENSG00000099251.13	HSD17B7P2	-3.94	9.96e-05	0.0323	-0.34	-0.21	Obesity (extreme);	chr10:37964646	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.945	rs2749593	ENSG00000099251.13	HSD17B7P2	-3.94	9.96e-05	0.0323	-0.34	-0.21	Obesity (extreme);	chr10:37965179	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2738186	ENSG00000099251.13	HSD17B7P2	-3.94	9.96e-05	0.0323	-0.34	-0.21	Obesity (extreme);	chr10:37967061	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2738187	ENSG00000099251.13	HSD17B7P2	-3.94	9.96e-05	0.0323	-0.34	-0.21	Obesity (extreme);	chr10:37971377	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.895	rs2245081	ENSG00000099251.13	HSD17B7P2	-3.94	9.96e-05	0.0323	-0.34	-0.21	Obesity (extreme);	chr10:37971479	chr10:38356380~38378505:+
STAD	cis	rs7204230	1	rs12598505	ENSG00000261291.1	RP11-295M3.2	3.94	9.97e-05	0.0323	0.25	0.21	Fibrinogen;	chr16:53312907	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62049810	ENSG00000261291.1	RP11-295M3.2	3.94	9.97e-05	0.0323	0.25	0.21	Fibrinogen;	chr16:53314245	chr16:53168522~53169450:+
STAD	cis	rs1858037	0.867	rs4671658	ENSG00000223739.1	AC007389.2	3.94	9.97e-05	0.0323	0.19	0.21	Rheumatoid arthritis;	chr2:65334258	chr2:65511771~65512076:-
STAD	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	3.94	9.98e-05	0.0323	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
STAD	cis	rs8073060	0.518	rs225285	ENSG00000267369.1	RP11-1094M14.8	-3.94	9.98e-05	0.0323	-0.19	-0.21	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35604065	chr17:35498218~35499175:+
STAD	cis	rs9368481	0.761	rs6918835	ENSG00000224843.5	LINC00240	3.94	9.98e-05	0.0323	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26956992~27023924:+
STAD	cis	rs1499614	1	rs2707840	ENSG00000273448.1	RP11-166O4.6	3.94	9.98e-05	0.0324	0.25	0.21	Gout;	chr7:66693028	chr7:67333047~67334383:+
STAD	cis	rs8177876	0.822	rs77475047	ENSG00000261061.1	RP11-303E16.2	-3.94	9.98e-05	0.0324	-0.39	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81030770~81031485:+
STAD	cis	rs8177876	0.822	rs55939311	ENSG00000261061.1	RP11-303E16.2	-3.94	9.98e-05	0.0324	-0.39	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81030770~81031485:+
STAD	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	3.94	9.98e-05	0.0324	0.3	0.21	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
STAD	cis	rs7615952	0.546	rs16836896	ENSG00000171084.14	FAM86JP	3.94	9.98e-05	0.0324	0.33	0.21	Blood pressure (smoking interaction);	chr3:125592418	chr3:125916620~125930024:+
STAD	cis	rs2273156	1	rs12897612	ENSG00000258704.4	SRP54-AS1	-3.94	9.99e-05	0.0324	-0.23	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35001941	chr14:34920858~34982532:-
STAD	cis	rs1528149	0.576	rs10277151	ENSG00000224683.1	RPL36AP29	3.94	9.99e-05	0.0324	0.21	0.21	Sitting height ratio;	chr7:16075788	chr7:16208945~16209265:+
STAD	cis	rs938554	0.578	rs7663032	ENSG00000250613.1	RP11-136I13.1	-3.94	9.99e-05	0.0324	-0.2	-0.21	Blood metabolite levels;	chr4:9992214	chr4:10410996~10411644:+
STAD	cis	rs2638953	0.924	rs4573721	ENSG00000247934.4	RP11-967K21.1	-3.94	1e-04	0.0324	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs4554927	ENSG00000247934.4	RP11-967K21.1	-3.94	1e-04	0.0324	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28163298~28190738:-
STAD	cis	rs1707322	0.721	rs4660883	ENSG00000281133.1	AL355480.3	-3.94	1e-04	0.0324	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45580892~45580996:-
STAD	cis	rs2262909	0.925	rs73019900	ENSG00000213976.4	CTD-2561J22.2	3.94	1e-04	0.0324	0.26	0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22103878	chr19:21382865~21387177:+
STAD	cis	rs10129255	0.53	rs11624912	ENSG00000211959.2	IGHV4-39	3.94	1e-04	0.0324	0.18	0.21	Kawasaki disease;	chr14:106673891	chr14:106421711~106422218:-
STAD	cis	rs5753618	0.539	rs5753596	ENSG00000236132.1	CTA-440B3.1	3.94	1e-04	0.0324	0.22	0.21	Colorectal cancer;	chr22:31391486	chr22:31816379~31817491:-
STAD	cis	rs2273156	1	rs17102970	ENSG00000258704.4	SRP54-AS1	-3.94	1e-04	0.0324	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011363	chr14:34920858~34982532:-
STAD	cis	rs5769765	0.505	rs4561759	ENSG00000188511.11	C22orf34	-3.94	1e-04	0.0324	-0.29	-0.21	Schizophrenia;	chr22:49863038	chr22:49414524~49657542:-
STAD	cis	rs5769765	0.565	rs8137232	ENSG00000188511.11	C22orf34	-3.94	1e-04	0.0324	-0.29	-0.21	Schizophrenia;	chr22:49863237	chr22:49414524~49657542:-
STAD	cis	rs5769765	0.657	rs8136116	ENSG00000188511.11	C22orf34	-3.94	1e-04	0.0324	-0.29	-0.21	Schizophrenia;	chr22:49863238	chr22:49414524~49657542:-
STAD	cis	rs6964833	1	rs4717907	ENSG00000277072.3	STAG3L2	3.94	1e-04	0.0324	0.24	0.21	Menarche (age at onset);	chr7:74672169	chr7:74882163~74890610:-
STAD	cis	rs7829975	0.539	rs883647	ENSG00000254340.1	RP11-10A14.3	-3.94	1e-04	0.0324	-0.28	-0.21	Mood instability;	chr8:8712214	chr8:9141424~9145435:+
STAD	cis	rs2351088	0.505	rs78476361	ENSG00000230634.1	RP5-996D20.3	-3.94	1e-04	0.0324	-0.32	-0.21	Tonsillectomy;	chr22:45772764	chr22:46481329~46481760:-
STAD	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-3.94	1e-04	0.0324	-0.26	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
STAD	cis	rs11638815	0.626	rs4779039	ENSG00000255769.6	GOLGA2P10	3.94	1e-04	0.0324	0.24	0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:82472993~82513950:-
STAD	cis	rs4835473	0.797	rs34585546	ENSG00000249741.2	RP11-673E1.3	3.94	1e-04	0.0324	0.25	0.21	Immature fraction of reticulocytes;	chr4:143680693	chr4:143911514~143912053:-
STAD	cis	rs2404602	0.583	rs4381566	ENSG00000196274.5	Metazoa_SRP	3.94	1e-04	0.0325	0.18	0.21	Blood metabolite levels;	chr15:76296921	chr15:76230048~76230390:-
STAD	cis	rs2834188	1	rs2834190	ENSG00000272659.1	AP000295.10	3.94	1e-04	0.0325	0.29	0.21	Narcolepsy;	chr21:33320706	chr21:33309491~33310181:+
STAD	cis	rs11673344	0.504	rs7245882	ENSG00000267672.1	CTD-2293H3.1	-3.94	1e-04	0.0325	-0.19	-0.21	Obesity-related traits;	chr19:37089513	chr19:37091341~37092564:+
STAD	cis	rs870825	0.616	rs6810635	ENSG00000249173.4	LINC01093	-3.94	1e-04	0.0325	-0.35	-0.21	Blood protein levels;	chr4:184695705	chr4:184893871~184899454:-
STAD	cis	rs77861329	1	rs72964044	ENSG00000270941.1	RP5-966M1.5	3.94	1e-04	0.0325	0.41	0.21	Macrophage inflammatory protein 1b levels;	chr3:52058654	chr3:52734735~52735013:+
STAD	cis	rs593531	0.513	rs7120394	ENSG00000280269.1	AP000577.2	3.94	1e-04	0.0325	0.21	0.21	Neuroticism;	chr11:74323428	chr11:74204869~74205746:+
STAD	cis	rs911186	0.73	rs2393911	ENSG00000224843.5	LINC00240	3.94	1e-04	0.0325	0.26	0.21	Autism spectrum disorder or schizophrenia;	chr6:27089300	chr6:26956992~27023924:+
STAD	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	3.94	1e-04	0.0325	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
STAD	cis	rs1850744	0.702	rs116079424	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9591580	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs115282360	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9591752	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.826	rs115893429	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9592194	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs73805540	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9592340	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.826	rs116509172	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9592499	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.59	rs35509001	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9593247	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.793	rs34495260	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9593700	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs55813730	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9593994	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs9799502	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9594318	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs57171822	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9594831	chr4:9153296~9165451:+
STAD	cis	rs1850744	1	rs76469957	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9595993	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.793	rs75043790	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9596032	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.826	rs76738832	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9596185	chr4:9153296~9165451:+
STAD	cis	rs1850744	1	rs114290083	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9596370	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs114945335	ENSG00000163612.10	FAM86KP	3.94	1e-04	0.0325	0.43	0.21	Economic and political preferences;	chr4:9596567	chr4:9153296~9165451:+
STAD	cis	rs748404	0.518	rs480108	ENSG00000275601.1	AC011330.13	-3.94	1e-04	0.0325	-0.22	-0.21	Lung cancer;	chr15:43525208	chr15:43642389~43643023:-
STAD	cis	rs7631605	0.905	rs6808735	ENSG00000236411.1	NDUFAF4P3	-3.94	1e-04	0.0325	-0.23	-0.21	Cerebrospinal P-tau181p levels;	chr3:37062755	chr3:37789921~37790445:-
STAD	cis	rs7615952	0.932	rs9841157	ENSG00000239804.1	RP11-379B18.1	3.94	1e-04	0.0325	0.35	0.21	Blood pressure (smoking interaction);	chr3:125916812	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.551	rs12695470	ENSG00000239804.1	RP11-379B18.1	3.94	1e-04	0.0325	0.35	0.21	Blood pressure (smoking interaction);	chr3:125916875	chr3:125787888~125788146:-
STAD	cis	rs10073892	1	rs62369275	ENSG00000250682.4	LINC00491	-3.94	1e-04	0.0325	-0.23	-0.21	Cognitive decline (age-related);	chr5:102363400	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.913	rs10078757	ENSG00000250682.4	LINC00491	-3.94	1e-04	0.0325	-0.23	-0.21	Cognitive decline (age-related);	chr5:102364203	chr5:102609156~102671559:-
STAD	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	3.94	1e-04	0.0325	0.23	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
STAD	cis	rs1348850	0.626	rs1901825	ENSG00000271825.1	RP11-337N6.2	3.94	1e-04	0.0325	0.17	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177360603	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.608	rs2364845	ENSG00000271825.1	RP11-337N6.2	3.94	1e-04	0.0325	0.17	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177361512	chr2:177300600~177302006:+
STAD	cis	rs12030196	0.788	rs11207352	ENSG00000230812.4	LINC01358	3.94	1e-04	0.0325	0.26	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58957939	chr1:59020387~59044614:+
STAD	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	3.94	1e-04	0.0325	0.23	0.21	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
STAD	cis	rs6832769	0.826	rs10462035	ENSG00000223305.1	RN7SKP30	3.94	1e-04	0.0325	0.23	0.21	Personality dimensions;	chr4:55513011	chr4:55540502~55540835:-
STAD	cis	rs6832769	0.961	rs2177127	ENSG00000223305.1	RN7SKP30	3.94	1e-04	0.0325	0.23	0.21	Personality dimensions;	chr4:55513792	chr4:55540502~55540835:-
STAD	cis	rs4834770	1	rs10034579	ENSG00000249244.1	RP11-548H18.2	3.94	1e-04	0.0325	0.26	0.21	Blood protein levels;	chr4:119322874	chr4:119391831~119395335:-
STAD	cis	rs4293777	1	rs4293777	ENSG00000250896.1	RNPS1P1	3.94	0.000101	0.0325	0.15	0.21	Primary sclerosing cholangitis;	chr4:10715315	chr4:11371975~11372892:+
STAD	cis	rs6432860	0.545	rs1461201	ENSG00000229195.1	AC009495.4	-3.94	0.000101	0.0325	-0.24	-0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166061184	chr2:165794857~165846091:-
STAD	cis	rs2278796	0.528	rs4951151	ENSG00000231691.1	RP11-203F10.5	-3.94	0.000101	0.0325	-0.26	-0.21	Mean platelet volume;	chr1:205001174	chr1:204277005~204277948:+
STAD	cis	rs4727443	0.899	rs6954978	ENSG00000214142.2	RPL7P60	3.93	0.000101	0.0325	0.22	0.21	Interstitial lung disease;	chr7:99984589	chr7:100139629~100140682:-
STAD	cis	rs4835473	0.699	rs4835127	ENSG00000249741.2	RP11-673E1.3	-3.93	0.000101	0.0325	-0.24	-0.21	Immature fraction of reticulocytes;	chr4:143997972	chr4:143911514~143912053:-
STAD	cis	rs9463078	0.691	rs6928753	ENSG00000219384.1	RP11-491H9.3	-3.93	0.000101	0.0325	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45372333	chr6:45158870~45159511:+
STAD	cis	rs9733	0.565	rs7524620	ENSG00000274963.1	Metazoa_SRP	-3.93	0.000101	0.0325	-0.18	-0.21	Tonsillectomy;	chr1:150644223	chr1:150568971~150569269:-
STAD	cis	rs11157436	0.602	rs1894369	ENSG00000211813.2	TRAV34	-3.93	0.000101	0.0325	-0.23	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166597	chr14:22207522~22208129:+
STAD	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-3.93	0.000101	0.0325	-0.25	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
STAD	cis	rs9399186	1	rs9373167	ENSG00000272189.1	RP3-325F22.5	3.93	0.000101	0.0326	0.4	0.21	Pursuit maintenance gain;	chr6:136512202	chr6:136550661~136552554:+
STAD	cis	rs6832769	0.961	rs11735267	ENSG00000223305.1	RN7SKP30	3.93	0.000101	0.0326	0.23	0.21	Personality dimensions;	chr4:55481120	chr4:55540502~55540835:-
STAD	cis	rs2404602	0.583	rs3759853	ENSG00000196274.5	Metazoa_SRP	3.93	0.000101	0.0326	0.18	0.21	Blood metabolite levels;	chr15:76295436	chr15:76230048~76230390:-
STAD	cis	rs7937127	0.744	rs72900981	ENSG00000254907.1	RP11-484D2.2	3.93	0.000101	0.0326	0.35	0.21	Fibrinogen levels;	chr11:43469757	chr11:43328748~43359296:-
STAD	cis	rs7937127	0.696	rs7114180	ENSG00000254907.1	RP11-484D2.2	3.93	0.000101	0.0326	0.35	0.21	Fibrinogen levels;	chr11:43471236	chr11:43328748~43359296:-
STAD	cis	rs2957692	0.528	rs11042731	ENSG00000254554.1	RP11-351I24.1	3.93	0.000101	0.0326	0.35	0.21	Circulating vasoactive peptide levels;	chr11:10318876	chr11:10302657~10303704:-
STAD	cis	rs4293777	1	rs9685212	ENSG00000250896.1	RNPS1P1	3.93	0.000101	0.0326	0.15	0.21	Primary sclerosing cholangitis;	chr4:10716645	chr4:11371975~11372892:+
STAD	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	3.93	0.000101	0.0326	0.18	0.21	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
STAD	cis	rs4713118	0.868	rs7756968	ENSG00000220721.1	OR1F12	3.93	0.000101	0.0326	0.24	0.21	Parkinson's disease;	chr6:27767175	chr6:28073316~28074233:+
STAD	cis	rs151997	0.925	rs27270	ENSG00000250360.1	CTD-2089N3.1	3.93	0.000101	0.0326	0.19	0.21	Callous-unemotional behaviour;	chr5:50887878	chr5:50965687~50967008:-
STAD	cis	rs4293777	0.967	rs7437047	ENSG00000250896.1	RNPS1P1	3.93	0.000101	0.0326	0.15	0.21	Primary sclerosing cholangitis;	chr4:10716965	chr4:11371975~11372892:+
STAD	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	3.93	0.000101	0.0326	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
STAD	cis	rs870825	0.872	rs12507711	ENSG00000249173.4	LINC01093	-3.93	0.000101	0.0326	-0.36	-0.21	Blood protein levels;	chr4:184650622	chr4:184893871~184899454:-
STAD	cis	rs259282	0.605	rs34727912	ENSG00000201388.1	SNORA68	3.93	0.000101	0.0326	0.21	0.21	Schizophrenia;	chr19:32619152	chr19:32608337~32608469:-
STAD	cis	rs1198872	0.516	rs1734413	ENSG00000272275.1	RP11-791G15.2	-3.93	0.000101	0.0326	-0.26	-0.21	Cardiac Troponin-T levels;	chr2:10772910	chr2:10767875~10770058:-
STAD	cis	rs4293777	0.967	rs56817615	ENSG00000250896.1	RNPS1P1	3.93	0.000101	0.0326	0.15	0.21	Primary sclerosing cholangitis;	chr4:10717222	chr4:11371975~11372892:+
STAD	cis	rs4293777	1	rs6817932	ENSG00000250896.1	RNPS1P1	3.93	0.000101	0.0326	0.15	0.21	Primary sclerosing cholangitis;	chr4:10718925	chr4:11371975~11372892:+
STAD	cis	rs11235843	0.853	rs10501412	ENSG00000255928.1	RP11-456I15.2	-3.93	0.000101	0.0326	-0.35	-0.21	Hand grip strength;	chr11:73830380	chr11:73722349~73722694:+
STAD	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	3.93	0.000101	0.0326	0.27	0.21	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
STAD	cis	rs4293777	0.935	rs4276275	ENSG00000250896.1	RNPS1P1	3.93	0.000101	0.0326	0.15	0.21	Primary sclerosing cholangitis;	chr4:10722061	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.967	rs4295251	ENSG00000250896.1	RNPS1P1	3.93	0.000101	0.0326	0.15	0.21	Primary sclerosing cholangitis;	chr4:10722596	chr4:11371975~11372892:+
STAD	cis	rs10129255	1	rs11627342	ENSG00000232216.1	IGHV3-43	3.93	0.000101	0.0326	0.21	0.21	Kawasaki disease;	chr14:106675823	chr14:106470264~106470800:-
STAD	cis	rs11673344	0.504	rs2595555	ENSG00000267672.1	CTD-2293H3.1	3.93	0.000101	0.0326	0.19	0.21	Obesity-related traits;	chr19:37000219	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.504	rs1667377	ENSG00000267672.1	CTD-2293H3.1	3.93	0.000101	0.0326	0.19	0.21	Obesity-related traits;	chr19:37000966	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.523	rs1667379	ENSG00000267672.1	CTD-2293H3.1	3.93	0.000101	0.0326	0.19	0.21	Obesity-related traits;	chr19:37001192	chr19:37091341~37092564:+
STAD	cis	rs7487075	0.688	rs12227156	ENSG00000272369.1	RP11-446N19.1	3.93	0.000101	0.0326	0.24	0.21	Itch intensity from mosquito bite;	chr12:46615645	chr12:46537502~46652550:+
STAD	cis	rs2286503	1	rs1029740	ENSG00000221740.1	SNORD93	3.93	0.000101	0.0326	0.24	0.21	Fibrinogen;	chr7:22833967	chr7:22856613~22856686:+
STAD	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	3.93	0.000101	0.0327	0.31	0.21	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
STAD	cis	rs9948	1	rs11897786	ENSG00000235833.1	AC159540.14	3.93	0.000101	0.0327	0.28	0.21	Erectile dysfunction and prostate cancer treatment;	chr2:96841135	chr2:97523949~97524976:-
STAD	cis	rs7078219	0.714	rs11190137	ENSG00000228778.1	RP11-129J12.1	3.93	0.000101	0.0327	0.26	0.21	Dental caries;	chr10:99528187	chr10:99527081~99528261:+
STAD	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-3.93	0.000101	0.0327	-0.25	-0.21	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-3.93	0.000101	0.0327	-0.25	-0.21	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
STAD	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-3.93	0.000101	0.0327	-0.26	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
STAD	cis	rs1538970	0.504	rs3790585	ENSG00000225447.1	RPS15AP10	3.93	0.000101	0.0327	0.2	0.21	Platelet count;	chr1:45557684	chr1:45645816~45646197:-
STAD	cis	rs4141404	0.74	rs9609301	ENSG00000236132.1	CTA-440B3.1	-3.93	0.000101	0.0327	-0.23	-0.21	Paclitaxel-induced neuropathy;	chr22:31499954	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.555	rs9609302	ENSG00000236132.1	CTA-440B3.1	-3.93	0.000101	0.0327	-0.23	-0.21	Colorectal cancer;	chr22:31500001	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.504	rs9609303	ENSG00000236132.1	CTA-440B3.1	-3.93	0.000101	0.0327	-0.23	-0.21	Colorectal cancer;	chr22:31500323	chr22:31816379~31817491:-
STAD	cis	rs10938353	0.68	rs12645110	ENSG00000273369.1	RP11-700J17.1	3.93	0.000101	0.0327	0.25	0.21	Body mass index;	chr4:44667706	chr4:44693946~44694386:-
STAD	cis	rs7589728	1	rs7425670	ENSG00000240671.2	IGKV1-8	3.93	0.000101	0.0327	0.26	0.21	Plasma clusterin levels;	chr2:88222509	chr2:88857361~88992931:-
STAD	cis	rs2018683	0.899	rs10479816	ENSG00000228421.2	AC005013.5	3.93	0.000101	0.0327	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28957667~28959345:+
STAD	cis	rs2018683	0.899	rs10479817	ENSG00000228421.2	AC005013.5	3.93	0.000101	0.0327	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938531	chr7:28957667~28959345:+
STAD	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-3.93	0.000101	0.0327	-0.23	-0.21	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
STAD	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-3.93	0.000101	0.0327	-0.24	-0.21	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
STAD	cis	rs2957692	0.528	rs7104093	ENSG00000254554.1	RP11-351I24.1	3.93	0.000101	0.0327	0.35	0.21	Circulating vasoactive peptide levels;	chr11:10317587	chr11:10302657~10303704:-
STAD	cis	rs75920871	0.528	rs7109649	ENSG00000254851.1	RP11-109L13.1	3.93	0.000101	0.0327	0.22	0.21	Subjective well-being;	chr11:117072828	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.528	rs1531706	ENSG00000254851.1	RP11-109L13.1	3.93	0.000101	0.0327	0.22	0.21	Subjective well-being;	chr11:117073236	chr11:117135528~117138582:+
STAD	cis	rs7204230	1	rs11859353	ENSG00000261291.1	RP11-295M3.2	3.93	0.000101	0.0327	0.25	0.21	Fibrinogen;	chr16:53333699	chr16:53168522~53169450:+
STAD	cis	rs7204230	0.96	rs12596696	ENSG00000261291.1	RP11-295M3.2	3.93	0.000101	0.0327	0.25	0.21	Fibrinogen;	chr16:53334858	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs8051675	ENSG00000261291.1	RP11-295M3.2	3.93	0.000101	0.0327	0.25	0.21	Fibrinogen;	chr16:53338677	chr16:53168522~53169450:+
STAD	cis	rs7915414	0.502	rs12765793	ENSG00000230338.1	MTND4P19	3.93	0.000101	0.0327	0.25	0.21	Clopidogrel active metabolite levels;	chr10:94653315	chr10:94774156~94774633:-
STAD	cis	rs4753788	0.534	rs10789590	ENSG00000261098.1	RP11-819C21.1	-3.93	0.000101	0.0327	-0.17	-0.21	Coronary artery disease;	chr11:107266877	chr11:107312132~107316271:-
STAD	cis	rs733592	0.507	rs7299704	ENSG00000226413.2	OR8T1P	3.93	0.000101	0.0327	0.23	0.21	Plateletcrit;	chr12:48050705	chr12:48442030~48442947:-
STAD	cis	rs7924176	0.564	rs12569971	ENSG00000213731.2	RAB5CP1	-3.93	0.000101	0.0327	-0.21	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74194617	chr10:74423435~74424014:-
STAD	cis	rs9426935	0.966	rs6668066	ENSG00000272030.1	RP1-178F15.4	3.93	0.000101	0.0327	0.27	0.21	Lentiform nucleus volume;	chr1:153813706	chr1:153631438~153634397:-
STAD	cis	rs9859260	0.744	rs3933	ENSG00000242086.7	LINC00969	-3.93	0.000101	0.0327	-0.19	-0.21	Mean corpuscular volume;	chr3:196058126	chr3:195658062~195739964:+
STAD	cis	rs2299433	0.573	rs1476454	ENSG00000227199.1	ST7-AS1	-3.93	0.000101	0.0327	-0.32	-0.21	Hematocrit;	chr7:116717314	chr7:116952446~116954334:-
STAD	cis	rs7429990	0.833	rs869508	ENSG00000224895.1	VPS26BP1	-3.93	0.000101	0.0327	-0.21	-0.21	Educational attainment (years of education);	chr3:47571812	chr3:47960327~47961081:-
STAD	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	3.93	0.000101	0.0327	0.24	0.21	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
STAD	cis	rs10129255	0.5	rs8004923	ENSG00000232216.1	IGHV3-43	3.93	0.000101	0.0327	0.18	0.21	Kawasaki disease;	chr14:106785926	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.5	rs6576232	ENSG00000232216.1	IGHV3-43	3.93	0.000101	0.0327	0.18	0.21	Kawasaki disease;	chr14:106787090	chr14:106470264~106470800:-
STAD	cis	rs2115630	0.818	rs7176522	ENSG00000225151.9	GOLGA2P7	3.93	0.000101	0.0327	0.23	0.21	P wave terminal force;	chr15:84672152	chr15:84199311~84230136:-
STAD	cis	rs9646944	0.501	rs10202813	ENSG00000234389.1	AC007278.3	-3.93	0.000101	0.0328	-0.25	-0.21	Blood protein levels;	chr2:102403280	chr2:102438713~102440475:+
STAD	cis	rs2574985	0.739	rs3011794	ENSG00000231345.3	BEND3P1	-3.93	0.000101	0.0328	-0.33	-0.21	Subjective well-being;	chr10:50556830	chr10:50655967~50660472:+
STAD	cis	rs875971	0.8	rs427557	ENSG00000224316.1	RP11-479O9.2	3.93	0.000101	0.0328	0.21	0.21	Aortic root size;	chr7:66054263	chr7:65773620~65802067:+
STAD	cis	rs875971	0.83	rs587360	ENSG00000224316.1	RP11-479O9.2	3.93	0.000101	0.0328	0.21	0.21	Aortic root size;	chr7:66057711	chr7:65773620~65802067:+
STAD	cis	rs2262909	0.849	rs2666447	ENSG00000279377.1	AC003973.3	3.93	0.000101	0.0328	0.21	0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21950066	chr19:21965708~21968529:-
STAD	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-3.93	0.000102	0.0328	-0.23	-0.21	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
STAD	cis	rs7927771	0.832	rs55677087	ENSG00000271350.1	CTD-2384B9.1	-3.93	0.000102	0.0328	-0.22	-0.21	Subjective well-being;	chr11:47376163	chr11:47041027~47041945:-
STAD	cis	rs6903823	0.508	rs1150721	ENSG00000220721.1	OR1F12	3.93	0.000102	0.0328	0.2	0.21	Pulmonary function;	chr6:28287263	chr6:28073316~28074233:+
STAD	cis	rs2657294	0.796	rs2804535	ENSG00000226051.5	ZNF503-AS1	3.93	0.000102	0.0328	0.28	0.21	Pneumonia;	chr10:75212086	chr10:75269819~75373500:+
STAD	cis	rs2638953	0.853	rs10843180	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000102	0.0328	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462221	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.925	rs11049510	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000102	0.0328	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290839	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs61922978	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000102	0.0328	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292075	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.925	rs17432330	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000102	0.0328	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292336	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs12372448	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000102	0.0328	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28293956	chr12:28163298~28190738:-
STAD	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000102	0.0328	-0.32	-0.21	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
STAD	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000102	0.0328	-0.32	-0.21	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
STAD	cis	rs748404	0.631	rs6493083	ENSG00000275601.1	AC011330.13	-3.93	0.000102	0.0328	-0.22	-0.21	Lung cancer;	chr15:43345787	chr15:43642389~43643023:-
STAD	cis	rs1348850	0.914	rs4893938	ENSG00000271825.1	RP11-337N6.2	3.93	0.000102	0.0328	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177385367	chr2:177300600~177302006:+
STAD	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-3.93	0.000102	0.0328	-0.22	-0.21	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
STAD	cis	rs3733418	0.929	rs7656863	ENSG00000248632.1	RP11-366M4.11	3.93	0.000102	0.0328	0.25	0.21	Obesity-related traits;	chr4:164962092	chr4:164968587~164970002:-
STAD	cis	rs5769707	0.681	rs135879	ENSG00000213279.2	RP1-29C18.9	-3.93	0.000102	0.0328	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49572264~49575426:-
STAD	cis	rs5769707	0.642	rs135880	ENSG00000213279.2	RP1-29C18.9	-3.93	0.000102	0.0328	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49572264~49575426:-
STAD	cis	rs73198271	0.751	rs617813	ENSG00000254340.1	RP11-10A14.3	-3.93	0.000102	0.0328	-0.27	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:9141424~9145435:+
STAD	cis	rs34779708	0.931	rs34954932	ENSG00000271335.4	RP11-324I22.4	3.93	0.000102	0.0328	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35314552~35336401:-
STAD	cis	rs7202877	0.706	rs4888375	ENSG00000261783.1	RP11-252K23.2	-3.93	0.000102	0.0329	-0.34	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75288458	chr16:75379818~75381260:-
STAD	cis	rs7202877	0.706	rs11149812	ENSG00000261783.1	RP11-252K23.2	-3.93	0.000102	0.0329	-0.34	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75289747	chr16:75379818~75381260:-
STAD	cis	rs8177876	0.584	rs2602404	ENSG00000261838.4	RP11-303E16.6	-3.93	0.000102	0.0329	-0.36	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056042	chr16:81069854~81076598:+
STAD	cis	rs9902453	0.967	rs12150261	ENSG00000263477.1	RP11-338L22.2	-3.93	0.000102	0.0329	-0.17	-0.21	Coffee consumption (cups per day);	chr17:29993455	chr17:29863402~29866092:+
STAD	cis	rs867371	1	rs2088858	ENSG00000278603.1	RP13-608F4.5	3.93	0.000102	0.0329	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs4778982	ENSG00000278603.1	RP13-608F4.5	3.93	0.000102	0.0329	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs2867579	ENSG00000278603.1	RP13-608F4.5	3.93	0.000102	0.0329	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs881308	ENSG00000278603.1	RP13-608F4.5	3.93	0.000102	0.0329	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472203~82472426:+
STAD	cis	rs12918713	1	rs12924231	ENSG00000260756.1	RP11-609N14.1	-3.93	0.000102	0.0329	-0.25	-0.21	Breast cancer;	chr16:10597659	chr16:10351440~10352752:-
STAD	cis	rs12468226	1	rs11899836	ENSG00000272966.1	RP11-686O6.1	3.93	0.000102	0.0329	0.31	0.21	Urate levels;	chr2:202371316	chr2:202336739~202337200:+
STAD	cis	rs202072	0.769	rs445591	ENSG00000272379.1	RP1-257A7.5	3.93	0.000102	0.0329	0.26	0.21	HIV-1 viral setpoint;	chr6:13280634	chr6:13290018~13290490:-
STAD	cis	rs875971	0.83	rs427575	ENSG00000224316.1	RP11-479O9.2	3.93	0.000102	0.0329	0.21	0.21	Aortic root size;	chr7:66054232	chr7:65773620~65802067:+
STAD	cis	rs72627123	1	rs45559033	ENSG00000259065.1	RP5-1021I20.1	-3.93	0.000102	0.0329	-0.31	-0.21	Morning vs. evening chronotype;	chr14:73874421	chr14:73787360~73803270:+
STAD	cis	rs2348418	0.798	rs10843161	ENSG00000247934.4	RP11-967K21.1	3.93	0.000102	0.0329	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28367688	chr12:28163298~28190738:-
STAD	cis	rs2243480	1	rs1796220	ENSG00000273448.1	RP11-166O4.6	3.93	0.000102	0.0329	0.26	0.21	Diabetic kidney disease;	chr7:66597113	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs2707831	ENSG00000273448.1	RP11-166O4.6	3.93	0.000102	0.0329	0.26	0.21	Diabetic kidney disease;	chr7:66597524	chr7:67333047~67334383:+
STAD	cis	rs34779708	1	rs34779708	ENSG00000271335.4	RP11-324I22.4	3.93	0.000102	0.0329	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35314552~35336401:-
STAD	cis	rs259282	0.605	rs28615461	ENSG00000201388.1	SNORA68	3.93	0.000102	0.0329	0.21	0.21	Schizophrenia;	chr19:32619243	chr19:32608337~32608469:-
STAD	cis	rs2638953	0.924	rs7957382	ENSG00000247934.4	RP11-967K21.1	3.93	0.000102	0.0329	0.22	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28163298~28190738:-
STAD	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-3.93	0.000102	0.0329	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
STAD	cis	rs10129255	0.536	rs10139058	ENSG00000211959.2	IGHV4-39	3.93	0.000102	0.0329	0.18	0.21	Kawasaki disease;	chr14:106685899	chr14:106421711~106422218:-
STAD	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-3.93	0.000102	0.0329	-0.22	-0.21	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
STAD	cis	rs4713118	0.826	rs2893929	ENSG00000243307.2	POM121L6P	-3.93	0.000102	0.0329	-0.26	-0.21	Parkinson's disease;	chr6:27770953	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.666	rs4140646	ENSG00000243307.2	POM121L6P	-3.93	0.000102	0.0329	-0.26	-0.21	Parkinson's disease;	chr6:27771022	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.666	rs2893930	ENSG00000243307.2	POM121L6P	-3.93	0.000102	0.0329	-0.26	-0.21	Parkinson's disease;	chr6:27771027	chr6:26896952~26898777:+
STAD	cis	rs10515750	0.643	rs10063539	ENSG00000248544.2	CTB-47B11.3	3.93	0.000102	0.0329	0.25	0.21	Lung function (FEV1/FVC);	chr5:157384666	chr5:157375741~157384950:-
STAD	cis	rs1075232	1	rs67634762	ENSG00000270055.1	CTD-3092A11.2	-3.93	0.000102	0.0329	-0.37	-0.21	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30487963~30490313:+
STAD	cis	rs7142881	0.787	rs4981858	ENSG00000258648.1	UBE2CP1	3.93	0.000102	0.0329	0.22	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31585360	chr14:30683045~30683598:-
STAD	cis	rs10129255	0.5	rs4774189	ENSG00000232216.1	IGHV3-43	3.93	0.000102	0.0329	0.18	0.21	Kawasaki disease;	chr14:106768275	chr14:106470264~106470800:-
STAD	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-3.93	0.000102	0.0329	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
STAD	cis	rs11157436	0.602	rs11157438	ENSG00000211812.1	TRAV26-2	-3.93	0.000102	0.0329	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22202583~22203368:+
STAD	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	3.93	0.000102	0.0329	0.33	0.21	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
STAD	cis	rs6496044	0.568	rs4842888	ENSG00000259295.5	CSPG4P12	-3.93	0.000102	0.0329	-0.25	-0.21	Interstitial lung disease;	chr15:85519902	chr15:85191438~85213905:+
STAD	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	3.93	0.000102	0.0329	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
STAD	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	3.93	0.000102	0.0329	0.27	0.21	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
STAD	cis	rs860295	0.702	rs11264397	ENSG00000225855.5	RUSC1-AS1	3.93	0.000102	0.033	0.17	0.21	Body mass index;	chr1:155641694	chr1:155316863~155324176:-
STAD	cis	rs860295	0.702	rs12040100	ENSG00000225855.5	RUSC1-AS1	3.93	0.000102	0.033	0.17	0.21	Body mass index;	chr1:155642056	chr1:155316863~155324176:-
STAD	cis	rs10986311	0.681	rs35068124	ENSG00000227200.1	RP11-121A14.3	-3.93	0.000102	0.033	-0.23	-0.21	Vitiligo;	chr9:124265531	chr9:124262876~124265809:+
STAD	cis	rs11089937	0.597	rs6001072	ENSG00000211640.3	IGLV6-57	3.93	0.000102	0.033	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.512	rs6001073	ENSG00000211640.3	IGLV6-57	3.93	0.000102	0.033	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.616	rs4145537	ENSG00000211639.2	IGLV4-60	-3.93	0.000102	0.033	-0.22	-0.21	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22162199~22162681:+
STAD	cis	rs7474896	0.526	rs1208716	ENSG00000120555.12	SEPT7P9	3.93	0.000102	0.033	0.26	0.21	Obesity (extreme);	chr10:37800345	chr10:38383069~38402916:-
STAD	cis	rs7474896	1	rs2144845	ENSG00000099251.13	HSD17B7P2	-3.93	0.000102	0.033	-0.35	-0.21	Obesity (extreme);	chr10:37932591	chr10:38356380~38378505:+
STAD	cis	rs1838105	0.51	rs3851795	ENSG00000263142.4	LRRC37A17P	-3.93	0.000102	0.033	-0.18	-0.21	Nonsyndromic cleft lip with cleft palate;	chr17:46983711	chr17:46978481~47054569:+
STAD	cis	rs1485395	0.836	rs10444558	ENSG00000257379.1	RP11-793H13.8	3.93	0.000102	0.033	0.35	0.21	Migraine without aura;	chr12:53661701	chr12:53441741~53467528:+
STAD	cis	rs716804	0.774	rs2957689	ENSG00000254554.1	RP11-351I24.1	3.93	0.000102	0.033	0.3	0.21	Neuroticism;	chr11:10346207	chr11:10302657~10303704:-
STAD	cis	rs716804	0.715	rs2957691	ENSG00000254554.1	RP11-351I24.1	3.93	0.000102	0.033	0.3	0.21	Neuroticism;	chr11:10346311	chr11:10302657~10303704:-
STAD	cis	rs1816752	0.819	rs7316961	ENSG00000232858.1	RPL34P27	3.93	0.000102	0.033	0.13	0.21	Obesity-related traits;	chr13:24411039	chr13:24988577~24988925:-
STAD	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	3.93	0.000102	0.033	0.28	0.21	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
STAD	cis	rs6933660	0.745	rs6557138	ENSG00000221469.1	AL133260.1	3.93	0.000102	0.033	0.22	0.21	Menarche (age at onset);	chr6:151410882	chr6:151039916~151039971:-
STAD	cis	rs712022	1	rs10766969	ENSG00000246225.5	RP11-17A1.3	-3.93	0.000102	0.033	-0.26	-0.21	Dialysis-related mortality;	chr11:22828406	chr11:22829380~22945393:+
STAD	cis	rs1876905	0.597	rs354551	ENSG00000272356.1	RP5-1112D6.8	-3.93	0.000102	0.033	-0.22	-0.21	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111309203~111313517:+
STAD	cis	rs2638953	0.925	rs11049511	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.033	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28294393	chr12:28163298~28190738:-
STAD	cis	rs7937127	0.744	rs10501297	ENSG00000254907.1	RP11-484D2.2	3.93	0.000103	0.033	0.36	0.21	Fibrinogen levels;	chr11:43400172	chr11:43328748~43359296:-
STAD	cis	rs262150	0.574	rs2730273	ENSG00000231419.5	LINC00689	3.93	0.000103	0.033	0.22	0.21	Facial morphology (factor 20);	chr7:159005063	chr7:159006522~159030195:+
STAD	cis	rs4950322	0.58	rs972368	ENSG00000278811.3	LINC00624	3.93	0.000103	0.033	0.22	0.21	Protein quantitative trait loci;	chr1:147111142	chr1:147258885~147517875:-
STAD	cis	rs6813195	0.881	rs4696135	ENSG00000243417.1	RP11-555K12.1	-3.93	0.000103	0.033	-0.21	-0.21	Type 2 diabetes;	chr4:152589436	chr4:152551277~152552364:-
STAD	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-3.93	0.000103	0.033	-0.25	-0.21	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
STAD	cis	rs6813195	0.554	rs1351903	ENSG00000243417.1	RP11-555K12.1	-3.93	0.000103	0.0331	-0.21	-0.21	Type 2 diabetes;	chr4:152534950	chr4:152551277~152552364:-
STAD	cis	rs2895526	0.521	rs6602606	ENSG00000252118.1	RNU6ATAC39P	-3.93	0.000103	0.0331	-0.21	-0.21	Headache;	chr10:12671902	chr10:12456483~12456631:+
STAD	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-3.93	0.000103	0.0331	-0.16	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
STAD	cis	rs807029	0.758	rs807027	ENSG00000272572.1	RP11-179B2.2	-3.93	0.000103	0.0331	-0.25	-0.21	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101004850	chr10:100911103~100912739:-
STAD	cis	rs1816752	0.624	rs4770701	ENSG00000273628.1	RP11-756A22.7	-3.93	0.000103	0.0331	-0.25	-0.21	Obesity-related traits;	chr13:24508806	chr13:24933006~24936796:+
STAD	cis	rs2957692	0.506	rs11042559	ENSG00000254554.1	RP11-351I24.1	3.93	0.000103	0.0331	0.34	0.21	Circulating vasoactive peptide levels;	chr11:9939784	chr11:10302657~10303704:-
STAD	cis	rs4648045	0.565	rs62327181	ENSG00000230069.3	LRRC37A15P	-3.93	0.000103	0.0331	-0.24	-0.21	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102727274~102730721:-
STAD	cis	rs8012947	1	rs8009579	ENSG00000279636.2	LINC00216	-3.93	0.000103	0.0331	-0.2	-0.21	Alcohol consumption in current drinkers;	chr14:58246841	chr14:58288033~58289158:+
STAD	cis	rs13413635	0.862	rs6759109	ENSG00000225808.1	DNAJC19P5	-3.93	0.000103	0.0331	-0.27	-0.21	Heart rate;	chr2:177985692	chr2:177229191~177229506:-
STAD	cis	rs11098499	1	rs11098500	ENSG00000260091.1	RP11-33B1.4	3.93	0.000103	0.0331	0.2	0.21	Corneal astigmatism;	chr4:119298084	chr4:119409333~119410233:+
STAD	cis	rs10782582	0.569	rs2131557	ENSG00000181227.3	RP4-682C21.2	-3.93	0.000103	0.0331	-0.22	-0.21	Daytime sleep phenotypes;	chr1:75922904	chr1:75743423~75744776:-
STAD	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-3.93	0.000103	0.0331	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
STAD	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	3.93	0.000103	0.0331	0.21	0.21	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
STAD	cis	rs7824557	0.564	rs2572399	ENSG00000205879.4	FAM90A2P	-3.93	0.000103	0.0331	-0.23	-0.21	Retinal vascular caliber;	chr8:11377011	chr8:12172202~12178575:-
STAD	cis	rs9608946	1	rs17670707	ENSG00000279159.1	RP3-394A18.1	-3.93	0.000103	0.0331	-0.18	-0.21	Red cell distribution width;	chr22:30481949	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs2189835	ENSG00000279159.1	RP3-394A18.1	-3.93	0.000103	0.0331	-0.18	-0.21	Red cell distribution width;	chr22:30482230	chr22:29978950~30028236:-
STAD	cis	rs9608946	0.956	rs7289820	ENSG00000279159.1	RP3-394A18.1	-3.93	0.000103	0.0331	-0.18	-0.21	Red cell distribution width;	chr22:30482677	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs9608936	ENSG00000279159.1	RP3-394A18.1	-3.93	0.000103	0.0331	-0.18	-0.21	Red cell distribution width;	chr22:30485258	chr22:29978950~30028236:-
STAD	cis	rs2739330	0.731	rs5751792	ENSG00000272787.1	KB-226F1.2	-3.93	0.000103	0.0331	-0.22	-0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23969211~23969873:+
STAD	cis	rs4869313	0.655	rs2617438	ENSG00000248734.2	CTD-2260A17.1	-3.93	0.000103	0.0331	-0.22	-0.21	Pediatric autoimmune diseases;	chr5:96870670	chr5:96784777~96785999:+
STAD	cis	rs5753618	0.583	rs5753632	ENSG00000236132.1	CTA-440B3.1	-3.93	0.000103	0.0331	-0.22	-0.21	Colorectal cancer;	chr22:31467111	chr22:31816379~31817491:-
STAD	cis	rs12468226	0.606	rs10445793	ENSG00000226261.1	AC064836.3	3.93	0.000103	0.0331	0.3	0.21	Urate levels;	chr2:202190799	chr2:202336024~202336727:-
STAD	cis	rs1707322	1	rs6429588	ENSG00000281133.1	AL355480.3	-3.93	0.000103	0.0331	-0.25	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45580892~45580996:-
STAD	cis	rs9463078	0.625	rs12190136	ENSG00000219384.1	RP11-491H9.3	3.93	0.000103	0.0332	0.19	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44799335	chr6:45158870~45159511:+
STAD	cis	rs7589728	0.688	rs76734941	ENSG00000240671.2	IGKV1-8	3.93	0.000103	0.0332	0.27	0.21	Plasma clusterin levels;	chr2:88230935	chr2:88857361~88992931:-
STAD	cis	rs9907295	1	rs11080360	ENSG00000270894.1	AC015849.13	-3.93	0.000103	0.0332	-0.27	-0.21	Fibroblast growth factor basic levels;	chr17:35916086	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs11869976	ENSG00000270894.1	AC015849.13	-3.93	0.000103	0.0332	-0.27	-0.21	Fibroblast growth factor basic levels;	chr17:35916492	chr17:35818399~35823713:+
STAD	cis	rs8081395	0.627	rs180536	ENSG00000266701.1	AC005702.4	3.93	0.000103	0.0332	0.26	0.21	White blood cell count;	chr17:59919445	chr17:60042546~60042627:-
STAD	cis	rs13413635	0.913	rs11674299	ENSG00000225808.1	DNAJC19P5	-3.93	0.000103	0.0332	-0.28	-0.21	Heart rate;	chr2:177810456	chr2:177229191~177229506:-
STAD	cis	rs2638953	0.853	rs11614463	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467278	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs10843183	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467775	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs11494781	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469166	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs11049638	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469687	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs11049639	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469868	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs11049642	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471325	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs11049643	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471581	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.777	rs11049644	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471724	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs11049645	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28472615	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs10843184	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473339	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs61920658	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475519	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs12367657	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000103	0.0332	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475816	chr12:28163298~28190738:-
STAD	cis	rs1348850	0.651	rs1901824	ENSG00000271825.1	RP11-337N6.2	3.93	0.000103	0.0332	0.17	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177360738	chr2:177300600~177302006:+
STAD	cis	rs72791417	0.826	rs716905	ENSG00000228065.9	LINC01515	-3.93	0.000103	0.0332	-0.36	-0.21	Bronchopulmonary dysplasia;	chr10:65968342	chr10:65570338~65768835:+
STAD	cis	rs10911902	0.643	rs7556543	ENSG00000229739.2	RP11-295K2.3	-3.93	0.000103	0.0332	-0.3	-0.21	Schizophrenia;	chr1:186301287	chr1:186435161~186470291:+
STAD	cis	rs11239930	0.517	rs685741	ENSG00000278811.3	LINC00624	3.93	0.000103	0.0332	0.22	0.21	AIDS progression;	chr1:147074503	chr1:147258885~147517875:-
STAD	cis	rs2657294	0.796	rs1259499	ENSG00000226051.5	ZNF503-AS1	-3.93	0.000103	0.0332	-0.27	-0.21	Pneumonia;	chr10:75228308	chr10:75269819~75373500:+
STAD	cis	rs4589258	0.788	rs10741372	ENSG00000280367.1	RP11-121L10.2	3.93	0.000103	0.0332	0.21	0.21	Intelligence (multi-trait analysis);	chr11:90767159	chr11:90223153~90226538:+
STAD	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-3.93	0.000103	0.0332	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
STAD	cis	rs7119038	0.818	rs715412	ENSG00000255422.1	AP002954.4	3.93	0.000103	0.0332	0.28	0.21	Sjögren's syndrome;	chr11:118813901	chr11:118704607~118750263:+
STAD	cis	rs792448	0.701	rs3099112	ENSG00000212044.2	AL360091.1	3.93	0.000103	0.0332	0.22	0.21	White blood cell count (basophil);	chr1:212369068	chr1:212349978~212350069:+
STAD	cis	rs593531	0.524	rs634608	ENSG00000280269.1	AP000577.2	-3.93	0.000103	0.0332	-0.21	-0.21	Neuroticism;	chr11:74373684	chr11:74204869~74205746:+
STAD	cis	rs263063	0.764	rs2291148	ENSG00000280239.1	CTB-50L17.8	-3.93	0.000103	0.0332	-0.32	-0.21	Periodontitis (CDC/AAP);	chr19:5077572	chr19:4448810~4450836:+
STAD	cis	rs5753618	0.583	rs2899164	ENSG00000236132.1	CTA-440B3.1	-3.93	0.000103	0.0332	-0.23	-0.21	Colorectal cancer;	chr22:31394303	chr22:31816379~31817491:-
STAD	cis	rs76210638	1	rs7331341	ENSG00000276672.1	RP11-142E9.1	-3.93	0.000103	0.0332	-0.28	-0.21	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33932338	chr13:33846190~33850825:+
STAD	cis	rs76210638	1	rs17080236	ENSG00000276672.1	RP11-142E9.1	-3.93	0.000103	0.0332	-0.28	-0.21	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33933656	chr13:33846190~33850825:+
STAD	cis	rs1005277	0.579	rs2472183	ENSG00000276805.1	RP11-291L22.6	3.93	0.000103	0.0332	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38451030~38451785:+
STAD	cis	rs765787	0.53	rs2413786	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000103	0.0332	0.24	0.21	Uric acid levels;	chr15:45233196	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775822	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000103	0.0332	0.24	0.21	Uric acid levels;	chr15:45234929	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs11854294	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000103	0.0332	0.24	0.21	Uric acid levels;	chr15:45235798	chr15:45152664~45167526:-
STAD	cis	rs870825	0.616	rs7678900	ENSG00000251230.4	RP11-701P16.5	-3.93	0.000103	0.0333	-0.38	-0.21	Blood protein levels;	chr4:184714095	chr4:184844585~184855751:-
STAD	cis	rs1555322	0.556	rs7272884	ENSG00000126005.14	MMP24-AS1	-3.93	0.000103	0.0333	-0.27	-0.21	Attention deficit hyperactivity disorder;	chr20:35295212	chr20:35216462~35278131:-
STAD	cis	rs2348418	0.832	rs1405811	ENSG00000247934.4	RP11-967K21.1	3.93	0.000103	0.0333	0.19	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28428169	chr12:28163298~28190738:-
STAD	cis	rs2154319	0.559	rs183334	ENSG00000235358.1	RP11-399E6.1	3.93	0.000103	0.0333	0.23	0.21	Height;	chr1:41146431	chr1:41242373~41284861:+
STAD	cis	rs2836974	0.602	rs2037925	ENSG00000238141.2	BRWD1-AS1	-3.93	0.000103	0.0333	-0.22	-0.21	Cognitive function;	chr21:39328005	chr21:39315707~39323218:+
STAD	cis	rs915364	1	rs915364	ENSG00000259023.2	LINC00524	3.93	0.000103	0.0333	0.24	0.21	Magnesium levels;	chr14:101132605	chr14:101405987~101407922:-
STAD	cis	rs10508774	0.81	rs13377150	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32566929	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs11008979	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32571339	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs72795559	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32584043	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs72795563	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32591476	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs11008987	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32592723	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs77579695	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32597789	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs12251853	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32661922	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs10218979	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32663101	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs10159499	ENSG00000273038.2	RP11-479G22.8	3.93	0.000104	0.0333	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32664630	chr10:32887255~32889311:-
STAD	cis	rs765787	0.53	rs28815867	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000104	0.0333	0.24	0.21	Uric acid levels;	chr15:45234607	chr15:45152664~45167526:-
STAD	cis	rs6832769	1	rs28572116	ENSG00000223305.1	RN7SKP30	-3.93	0.000104	0.0333	-0.23	-0.21	Personality dimensions;	chr4:55558177	chr4:55540502~55540835:-
STAD	cis	rs14403	0.913	rs12042298	ENSG00000240963.1	RP11-518L10.5	3.93	0.000104	0.0333	0.21	0.21	Schizophrenia;	chr1:243488504	chr1:244375100~244409592:-
STAD	cis	rs73108077	1	rs73108027	ENSG00000277692.1	RP11-358N2.2	-3.93	0.000104	0.0333	-0.33	-0.21	Red blood cell density in sickle cell anemia;	chr20:31398778	chr20:32355053~32355734:+
STAD	cis	rs6832769	1	rs7670225	ENSG00000223305.1	RN7SKP30	3.93	0.000104	0.0333	0.23	0.21	Personality dimensions;	chr4:55501851	chr4:55540502~55540835:-
STAD	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-3.93	0.000104	0.0333	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-3.93	0.000104	0.0333	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
STAD	cis	rs4763879	0.778	rs2895989	ENSG00000256673.1	RP11-599J14.2	3.93	0.000104	0.0333	0.22	0.21	Type 1 diabetes;	chr12:9688735	chr12:9398355~9414851:-
STAD	cis	rs117785887	0.536	rs12192366	ENSG00000270638.1	RP3-466P17.1	3.93	0.000104	0.0333	0.37	0.21	Interleukin-17 levels;	chr6:146088854	chr6:145735570~145737218:+
STAD	cis	rs4835473	0.722	rs7666296	ENSG00000249741.2	RP11-673E1.3	3.93	0.000104	0.0333	0.24	0.21	Immature fraction of reticulocytes;	chr4:143999004	chr4:143911514~143912053:-
STAD	cis	rs2278796	0.639	rs6661381	ENSG00000231691.1	RP11-203F10.5	-3.93	0.000104	0.0333	-0.26	-0.21	Mean platelet volume;	chr1:205002425	chr1:204277005~204277948:+
STAD	cis	rs6432860	0.932	rs7571778	ENSG00000229195.1	AC009495.4	3.93	0.000104	0.0333	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:165977728	chr2:165794857~165846091:-
STAD	cis	rs7615952	0.673	rs9841194	ENSG00000241346.1	SNRPCP11	3.93	0.000104	0.0333	0.37	0.21	Blood pressure (smoking interaction);	chr3:125916896	chr3:125816082~125816286:-
STAD	cis	rs7615952	0.673	rs9289270	ENSG00000241346.1	SNRPCP11	3.93	0.000104	0.0333	0.37	0.21	Blood pressure (smoking interaction);	chr3:125918136	chr3:125816082~125816286:-
STAD	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-3.93	0.000104	0.0333	-0.26	-0.21	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
STAD	cis	rs2098713	0.535	rs56044522	ENSG00000250155.1	CTD-2353F22.1	3.93	0.000104	0.0333	0.21	0.21	Telomere length;	chr5:37582698	chr5:36666214~36725195:-
STAD	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	3.93	0.000104	0.0334	0.24	0.21	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
STAD	cis	rs6933660	0.745	rs6912830	ENSG00000221469.1	AL133260.1	3.93	0.000104	0.0334	0.22	0.21	Menarche (age at onset);	chr6:151422494	chr6:151039916~151039971:-
STAD	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	3.93	0.000104	0.0334	0.21	0.21	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
STAD	cis	rs1707322	0.964	rs12067716	ENSG00000225447.1	RPS15AP10	3.93	0.000104	0.0334	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45645816~45646197:-
STAD	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	3.93	0.000104	0.0334	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
STAD	cis	rs55661361	1	rs55661361	ENSG00000245498.5	RP11-677M14.7	3.93	0.000104	0.0334	0.25	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124744061	chr11:124800450~124834487:+
STAD	cis	rs2446066	1	rs2446066	ENSG00000257379.1	RP11-793H13.8	3.93	0.000104	0.0334	0.32	0.21	Red blood cell count;	chr12:53384866	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.872	rs2683522	ENSG00000257379.1	RP11-793H13.8	3.93	0.000104	0.0334	0.32	0.21	Red blood cell count;	chr12:53389612	chr12:53441741~53467528:+
STAD	cis	rs2446066	0.872	rs2694847	ENSG00000257379.1	RP11-793H13.8	3.93	0.000104	0.0334	0.32	0.21	Red blood cell count;	chr12:53391244	chr12:53441741~53467528:+
STAD	cis	rs2460882	1	rs2460882	ENSG00000257379.1	RP11-793H13.8	3.93	0.000104	0.0334	0.32	0.21	Percentage gas trapping;	chr12:53394169	chr12:53441741~53467528:+
STAD	cis	rs2154319	0.666	rs3856251	ENSG00000235358.1	RP11-399E6.1	-3.93	0.000104	0.0334	-0.23	-0.21	Height;	chr1:41250375	chr1:41242373~41284861:+
STAD	cis	rs2154319	0.609	rs3899207	ENSG00000235358.1	RP11-399E6.1	-3.93	0.000104	0.0334	-0.23	-0.21	Height;	chr1:41256005	chr1:41242373~41284861:+
STAD	cis	rs7074356	0.522	rs878651	ENSG00000225484.5	NUTM2B-AS1	-3.93	0.000104	0.0334	-0.39	-0.21	Borderline personality disorder;	chr10:80474861	chr10:79663088~79826594:-
STAD	cis	rs2404602	0.583	rs12908334	ENSG00000196274.5	Metazoa_SRP	3.93	0.000104	0.0334	0.18	0.21	Blood metabolite levels;	chr15:76289251	chr15:76230048~76230390:-
STAD	cis	rs765787	0.53	rs2413785	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000104	0.0334	0.24	0.21	Uric acid levels;	chr15:45238183	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs2413784	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000104	0.0334	0.24	0.21	Uric acid levels;	chr15:45238318	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs7165889	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000104	0.0334	0.24	0.21	Uric acid levels;	chr15:45239442	chr15:45152664~45167526:-
STAD	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-3.93	0.000104	0.0334	-0.3	-0.21	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
STAD	cis	rs6432860	1	rs536744	ENSG00000229195.1	AC009495.4	3.93	0.000104	0.0334	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166025380	chr2:165794857~165846091:-
STAD	cis	rs1499614	1	rs2659913	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66692349	chr7:67333047~67334383:+
STAD	cis	rs1499614	1	rs2659911	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66693433	chr7:67333047~67334383:+
STAD	cis	rs1499614	1	rs2707838	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66694214	chr7:67333047~67334383:+
STAD	cis	rs1499614	1	rs60326618	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66701371	chr7:67333047~67334383:+
STAD	cis	rs1499614	1	rs2707830	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66702658	chr7:67333047~67334383:+
STAD	cis	rs1499614	1	rs2707828	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66706390	chr7:67333047~67334383:+
STAD	cis	rs1499614	0.803	rs1922723	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66710076	chr7:67333047~67334383:+
STAD	cis	rs1499614	1	rs2659903	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66715944	chr7:67333047~67334383:+
STAD	cis	rs1499614	1	rs2141924	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66721259	chr7:67333047~67334383:+
STAD	cis	rs1499614	0.901	rs2178742	ENSG00000273448.1	RP11-166O4.6	3.93	0.000104	0.0334	0.25	0.21	Gout;	chr7:66732812	chr7:67333047~67334383:+
STAD	cis	rs1348850	0.632	rs11678875	ENSG00000271825.1	RP11-337N6.2	3.93	0.000104	0.0334	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177644340	chr2:177300600~177302006:+
STAD	cis	rs748404	0.601	rs489964	ENSG00000275601.1	AC011330.13	3.93	0.000104	0.0334	0.21	0.21	Lung cancer;	chr15:43225356	chr15:43642389~43643023:-
STAD	cis	rs11761441	0.669	rs13241486	ENSG00000242611.1	AC093627.8	-3.93	0.000104	0.0334	-0.23	-0.21	Alzheimer's disease in APOE e4- carriers;	chr7:79536	chr7:77038~80418:+
STAD	cis	rs858239	0.539	rs10270695	ENSG00000230042.1	AK3P3	3.93	0.000104	0.0334	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23129178~23129841:+
STAD	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-3.93	0.000104	0.0334	-0.23	-0.21	Height;	chr2:231556448	chr2:231508426~231514339:-
STAD	cis	rs1144713	0.802	rs2652008	ENSG00000223722.3	RP11-467L13.5	-3.93	0.000104	0.0334	-0.2	-0.21	Obesity-related traits;	chr12:32093609	chr12:31754720~31755121:+
STAD	cis	rs1639906	0.893	rs13233298	ENSG00000201794.1	RN7SKP130	3.93	0.000104	0.0334	0.2	0.21	Colonoscopy-negative controls vs population controls;	chr7:2188072	chr7:2999094~2999394:+
STAD	cis	rs11089937	0.584	rs5757245	ENSG00000211639.2	IGLV4-60	3.93	0.000104	0.0335	0.21	0.21	Periodontitis (PAL4Q3);	chr22:22176674	chr22:22162199~22162681:+
STAD	cis	rs6940638	0.688	rs9461335	ENSG00000216915.2	RP1-97D16.1	-3.93	0.000104	0.0335	-0.23	-0.21	Intelligence (multi-trait analysis);	chr6:27170750	chr6:27737000~27738494:-
STAD	cis	rs4835473	0.864	rs13101482	ENSG00000249741.2	RP11-673E1.3	-3.93	0.000104	0.0335	-0.23	-0.21	Immature fraction of reticulocytes;	chr4:143989463	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.864	rs13135472	ENSG00000249741.2	RP11-673E1.3	-3.93	0.000104	0.0335	-0.23	-0.21	Immature fraction of reticulocytes;	chr4:143989465	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1849118	ENSG00000249741.2	RP11-673E1.3	-3.93	0.000104	0.0335	-0.23	-0.21	Immature fraction of reticulocytes;	chr4:143989822	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.663	rs1511423	ENSG00000249741.2	RP11-673E1.3	-3.93	0.000104	0.0335	-0.23	-0.21	Immature fraction of reticulocytes;	chr4:143990136	chr4:143911514~143912053:-
STAD	cis	rs4388249	1	rs2284990	ENSG00000271849.1	CTC-332L22.1	-3.93	0.000104	0.0335	-0.31	-0.21	Schizophrenia;	chr5:109743666	chr5:109687802~109688329:-
STAD	cis	rs2836974	0.644	rs719230	ENSG00000238141.2	BRWD1-AS1	-3.93	0.000104	0.0335	-0.21	-0.21	Cognitive function;	chr21:39304381	chr21:39315707~39323218:+
STAD	cis	rs9426935	0.902	rs4596938	ENSG00000272030.1	RP1-178F15.4	3.93	0.000104	0.0335	0.27	0.21	Lentiform nucleus volume;	chr1:153822221	chr1:153631438~153634397:-
STAD	cis	rs5753618	0.504	rs9609297	ENSG00000236132.1	CTA-440B3.1	-3.93	0.000104	0.0335	-0.23	-0.21	Colorectal cancer;	chr22:31497745	chr22:31816379~31817491:-
STAD	cis	rs6813195	0.881	rs13103278	ENSG00000243417.1	RP11-555K12.1	-3.93	0.000104	0.0335	-0.21	-0.21	Type 2 diabetes;	chr4:152575076	chr4:152551277~152552364:-
STAD	cis	rs6822892	0.711	rs342314	ENSG00000248629.1	RP11-154F14.2	3.93	0.000104	0.0335	0.21	0.21	HDL cholesterol levels;	chr4:156885606	chr4:156841359~156842236:+
STAD	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	3.93	0.000104	0.0335	0.21	0.21	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
STAD	cis	rs9948	1	rs1320149	ENSG00000235833.1	AC159540.14	3.93	0.000104	0.0335	0.28	0.21	Erectile dysfunction and prostate cancer treatment;	chr2:96828140	chr2:97523949~97524976:-
STAD	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-3.93	0.000104	0.0335	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
STAD	cis	rs6432860	1	rs508585	ENSG00000229195.1	AC009495.4	3.93	0.000104	0.0335	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166027122	chr2:165794857~165846091:-
STAD	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	3.93	0.000105	0.0335	0.25	0.21	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
STAD	cis	rs10986311	0.654	rs4838161	ENSG00000227200.1	RP11-121A14.3	-3.93	0.000105	0.0335	-0.22	-0.21	Vitiligo;	chr9:124316974	chr9:124262876~124265809:+
STAD	cis	rs2199351	0.959	rs72991342	ENSG00000242899.1	RPL7P16	-3.93	0.000105	0.0335	-0.24	-0.21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr3:131893700	chr3:132243528~132244265:-
STAD	cis	rs10129255	0.5	rs8006888	ENSG00000232216.1	IGHV3-43	3.93	0.000105	0.0335	0.18	0.21	Kawasaki disease;	chr14:106782219	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.536	rs10142951	ENSG00000232216.1	IGHV3-43	3.93	0.000105	0.0335	0.18	0.21	Kawasaki disease;	chr14:106782337	chr14:106470264~106470800:-
STAD	cis	rs4950322	0.58	rs7515160	ENSG00000278811.3	LINC00624	3.93	0.000105	0.0335	0.22	0.21	Protein quantitative trait loci;	chr1:147120714	chr1:147258885~147517875:-
STAD	cis	rs4792901	0.765	rs3809751	ENSG00000279602.1	CTD-3014M21.1	-3.93	0.000105	0.0335	-0.28	-0.21	Dupuytren's disease;	chr17:43482417	chr17:43360041~43361361:-
STAD	cis	rs10829156	0.629	rs7069955	ENSG00000240291.1	RP11-499P20.2	3.93	0.000105	0.0336	0.24	0.21	Sudden cardiac arrest;	chr10:18688210	chr10:18513115~18545651:-
STAD	cis	rs765787	0.53	rs2899381	ENSG00000259539.1	CTD-2651B20.1	3.93	0.000105	0.0336	0.24	0.21	Uric acid levels;	chr15:45237432	chr15:45152664~45167526:-
STAD	cis	rs10508774	0.81	rs12269551	ENSG00000273038.2	RP11-479G22.8	3.93	0.000105	0.0336	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32623623	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs955971	ENSG00000273038.2	RP11-479G22.8	3.93	0.000105	0.0336	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32633071	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs74437766	ENSG00000273038.2	RP11-479G22.8	3.93	0.000105	0.0336	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32636374	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.659	rs72782235	ENSG00000273038.2	RP11-479G22.8	3.93	0.000105	0.0336	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32647591	chr10:32887255~32889311:-
STAD	cis	rs3764021	0.87	rs10844597	ENSG00000256673.1	RP11-599J14.2	-3.92	0.000105	0.0336	-0.22	-0.21	Type 1 diabetes;	chr12:9722303	chr12:9398355~9414851:-
STAD	cis	rs2638953	0.853	rs11049679	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000105	0.0336	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28163298~28190738:-
STAD	cis	rs9902453	0.74	rs2617867	ENSG00000263477.1	RP11-338L22.2	-3.92	0.000105	0.0336	-0.17	-0.21	Coffee consumption (cups per day);	chr17:29722381	chr17:29863402~29866092:+
STAD	cis	rs2273156	0.57	rs8013540	ENSG00000258704.4	SRP54-AS1	-3.92	0.000105	0.0336	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35044554	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.57	rs60693825	ENSG00000258704.4	SRP54-AS1	-3.92	0.000105	0.0336	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045250	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.587	rs3809449	ENSG00000258704.4	SRP54-AS1	-3.92	0.000105	0.0336	-0.26	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045751	chr14:34920858~34982532:-
STAD	cis	rs7915414	0.531	rs12783288	ENSG00000230338.1	MTND4P19	3.92	0.000105	0.0336	0.25	0.21	Clopidogrel active metabolite levels;	chr10:94960414	chr10:94774156~94774633:-
STAD	cis	rs7915414	0.531	rs9332140	ENSG00000230338.1	MTND4P19	3.92	0.000105	0.0336	0.25	0.21	Clopidogrel active metabolite levels;	chr10:94961850	chr10:94774156~94774633:-
STAD	cis	rs7915414	0.531	rs12569850	ENSG00000230338.1	MTND4P19	3.92	0.000105	0.0336	0.25	0.21	Clopidogrel active metabolite levels;	chr10:94967403	chr10:94774156~94774633:-
STAD	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	3.92	0.000105	0.0336	0.25	0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
STAD	cis	rs11157436	0.602	rs2075492	ENSG00000211812.1	TRAV26-2	-3.92	0.000105	0.0336	-0.2	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163321	chr14:22202583~22203368:+
STAD	cis	rs240993	0.516	rs240968	ENSG00000230177.1	RP5-1112D6.4	-3.92	0.000105	0.0336	-0.22	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111277932~111278742:+
STAD	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-3.92	0.000105	0.0336	-0.23	-0.21	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
STAD	cis	rs1850744	0.702	rs116079424	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9591580	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs115282360	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9591752	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.826	rs115893429	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9592194	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs73805540	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9592340	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.826	rs116509172	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9592499	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.59	rs35509001	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9593247	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.793	rs34495260	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9593700	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs55813730	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9593994	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs9799502	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9594318	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs57171822	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9594831	chr4:9677308~9677934:+
STAD	cis	rs1850744	1	rs76469957	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9595993	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.793	rs75043790	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9596032	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.826	rs76738832	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9596185	chr4:9677308~9677934:+
STAD	cis	rs1850744	1	rs114290083	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9596370	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs114945335	ENSG00000250942.1	ENPP7P11	-3.92	0.000105	0.0336	-0.36	-0.21	Economic and political preferences;	chr4:9596567	chr4:9677308~9677934:+
STAD	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-3.92	0.000105	0.0336	-0.26	-0.21	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
STAD	cis	rs1005277	0.579	rs2505248	ENSG00000276805.1	RP11-291L22.6	3.92	0.000105	0.0336	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38451030~38451785:+
STAD	cis	rs56318008	0.773	rs2268177	ENSG00000218510.5	LINC00339	3.92	0.000105	0.0336	0.29	0.21	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22088917	chr1:22025188~22031223:+
STAD	cis	rs10857712	0.687	rs11101742	ENSG00000273327.1	OR6L2P	-3.92	0.000105	0.0336	-0.2	-0.21	Systemic lupus erythematosus;	chr10:133410868	chr10:133430394~133431318:-
STAD	cis	rs10129255	0.5	rs1024350	ENSG00000211959.2	IGHV4-39	3.92	0.000105	0.0336	0.18	0.21	Kawasaki disease;	chr14:106685105	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.518	rs7143784	ENSG00000211959.2	IGHV4-39	3.92	0.000105	0.0336	0.18	0.21	Kawasaki disease;	chr14:106687277	chr14:106421711~106422218:-
STAD	cis	rs2739330	0.761	rs5760176	ENSG00000272787.1	KB-226F1.2	3.92	0.000105	0.0336	0.22	0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23969211~23969873:+
STAD	cis	rs7631605	0.905	rs7651033	ENSG00000236411.1	NDUFAF4P3	3.92	0.000105	0.0337	0.23	0.21	Cerebrospinal P-tau181p levels;	chr3:37074551	chr3:37789921~37790445:-
STAD	cis	rs1876905	0.68	rs1150082	ENSG00000230177.1	RP5-1112D6.4	-3.92	0.000105	0.0337	-0.23	-0.21	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111277932~111278742:+
STAD	cis	rs2901460	0.628	rs12993527	ENSG00000229503.1	AC092155.1	-3.92	0.000105	0.0337	-0.17	-0.21	Mean corpuscular volume;	chr2:62174690	chr2:62532583~62533059:-
STAD	cis	rs11118620	0.81	rs4587570	ENSG00000257551.1	HLX-AS1	3.92	0.000105	0.0337	0.24	0.21	Heart failure;	chr1:220860693	chr1:220832763~220880140:-
STAD	cis	rs4561483	0.801	rs33649	ENSG00000260224.1	UBL5P4	3.92	0.000105	0.0337	0.2	0.21	Testicular germ cell tumor;	chr16:11885751	chr16:11968508~11968743:-
STAD	cis	rs34779708	0.833	rs12777517	ENSG00000271335.4	RP11-324I22.4	3.92	0.000105	0.0337	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35314552~35336401:-
STAD	cis	rs12745968	0.623	rs10874732	ENSG00000229052.2	RP11-386I23.1	-3.92	0.000105	0.0337	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92658002	chr1:92930696~92934098:+
STAD	cis	rs2657294	0.761	rs1259498	ENSG00000233313.2	HMGA1P5	-3.92	0.000105	0.0337	-0.26	-0.21	Pneumonia;	chr10:75226983	chr10:75276376~75276646:-
STAD	cis	rs7474896	0.895	rs650873	ENSG00000099251.13	HSD17B7P2	-3.92	0.000105	0.0337	-0.35	-0.21	Obesity (extreme);	chr10:38035537	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.779	rs647617	ENSG00000099251.13	HSD17B7P2	-3.92	0.000105	0.0337	-0.35	-0.21	Obesity (extreme);	chr10:38041377	chr10:38356380~38378505:+
STAD	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	3.92	0.000105	0.0337	0.25	0.21	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
STAD	cis	rs10938353	0.638	rs61549581	ENSG00000273369.1	RP11-700J17.1	3.92	0.000105	0.0337	0.24	0.21	Body mass index;	chr4:44692702	chr4:44693946~44694386:-
STAD	cis	rs151997	0.925	rs27624	ENSG00000250360.1	CTD-2089N3.1	-3.92	0.000105	0.0337	-0.19	-0.21	Callous-unemotional behaviour;	chr5:50871828	chr5:50965687~50967008:-
STAD	cis	rs2278796	0.639	rs6702469	ENSG00000231691.1	RP11-203F10.5	-3.92	0.000105	0.0337	-0.27	-0.21	Mean platelet volume;	chr1:204999659	chr1:204277005~204277948:+
STAD	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-3.92	0.000105	0.0337	-0.24	-0.21	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
STAD	cis	rs7655841	0.579	rs2162126	ENSG00000248187.1	RP11-184M15.1	3.92	0.000105	0.0337	0.33	0.21	Chronic obstructive pulmonary disease (moderate to severe);	chr4:128857921	chr4:128567972~128570531:-
STAD	cis	rs2859998	0.892	rs7001028	ENSG00000250031.1	RP11-114M5.1	-3.92	0.000105	0.0337	-0.19	-0.21	Narcolepsy with cataplexy;	chr8:58460092	chr8:58424588~58426685:-
STAD	cis	rs1797885	0.524	rs2255648	ENSG00000231362.1	RP11-715I4.1	3.92	0.000105	0.0337	0.18	0.21	Immature fraction of reticulocytes;	chr3:12557464	chr3:13052967~13053122:-
STAD	cis	rs10129255	1	rs8010605	ENSG00000232216.1	IGHV3-43	3.92	0.000105	0.0337	0.21	0.21	Kawasaki disease;	chr14:106678742	chr14:106470264~106470800:-
STAD	cis	rs2446066	0.872	rs34148420	ENSG00000257379.1	RP11-793H13.8	3.92	0.000105	0.0337	0.34	0.21	Red blood cell count;	chr12:53405024	chr12:53441741~53467528:+
STAD	cis	rs6479891	1	rs16918567	ENSG00000235816.3	PRELID1P3	3.92	0.000105	0.0337	0.28	0.21	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs16918573	ENSG00000235816.3	PRELID1P3	3.92	0.000105	0.0337	0.28	0.21	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs12414796	ENSG00000235816.3	PRELID1P3	3.92	0.000105	0.0337	0.28	0.21	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63427297~63427939:+
STAD	cis	rs7520050	0.966	rs785494	ENSG00000280836.1	AL355480.1	3.92	0.000105	0.0337	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45581219~45581321:-
STAD	cis	rs875971	0.545	rs1796219	ENSG00000273142.1	RP11-458F8.4	-3.92	0.000105	0.0338	-0.19	-0.21	Aortic root size;	chr7:66645977	chr7:66902857~66906297:+
STAD	cis	rs7617773	0.925	rs35942721	ENSG00000224895.1	VPS26BP1	-3.92	0.000105	0.0338	-0.25	-0.21	Coronary artery disease;	chr3:48131579	chr3:47960327~47961081:-
STAD	cis	rs10510102	0.516	rs12256693	ENSG00000226864.1	ATE1-AS1	3.92	0.000105	0.0338	0.36	0.21	Breast cancer;	chr10:121976839	chr10:121928312~121951965:+
STAD	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-3.92	0.000106	0.0338	-0.23	-0.21	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
STAD	cis	rs4589258	0.788	rs1894135	ENSG00000280367.1	RP11-121L10.2	3.92	0.000106	0.0338	0.2	0.21	Intelligence (multi-trait analysis);	chr11:90765059	chr11:90223153~90226538:+
STAD	cis	rs6693567	0.565	rs471738	ENSG00000203819.6	HIST2H2BC	-3.92	0.000106	0.0338	-0.24	-0.21	Migraine;	chr1:150304001	chr1:149850193~149850772:-
STAD	cis	rs6813195	1	rs6813195	ENSG00000243417.1	RP11-555K12.1	3.92	0.000106	0.0338	0.21	0.21	Type 2 diabetes;	chr4:152599323	chr4:152551277~152552364:-
STAD	cis	rs10508774	0.81	rs12244832	ENSG00000273038.2	RP11-479G22.8	3.92	0.000106	0.0338	0.37	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32583192	chr10:32887255~32889311:-
STAD	cis	rs11089937	0.555	rs6001226	ENSG00000211639.2	IGLV4-60	3.92	0.000106	0.0338	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22162199~22162681:+
STAD	cis	rs6012564	0.788	rs6095404	ENSG00000227431.4	CSE1L-AS1	3.92	0.000106	0.0338	0.19	0.21	Anger;	chr20:49040144	chr20:49040463~49046044:-
STAD	cis	rs7142881	0.76	rs34042472	ENSG00000258648.1	UBE2CP1	-3.92	0.000106	0.0338	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31590135	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.787	rs11625161	ENSG00000258648.1	UBE2CP1	-3.92	0.000106	0.0338	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31592177	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.844	rs4981860	ENSG00000258648.1	UBE2CP1	-3.92	0.000106	0.0338	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31594574	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.76	rs8016832	ENSG00000258648.1	UBE2CP1	-3.92	0.000106	0.0338	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31597912	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs4981105	ENSG00000258648.1	UBE2CP1	-3.92	0.000106	0.0338	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31599036	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs35117360	ENSG00000258648.1	UBE2CP1	-3.92	0.000106	0.0338	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31600473	chr14:30683045~30683598:-
STAD	cis	rs8177876	0.731	rs76093926	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000106	0.0338	-0.38	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81030770~81031485:+
STAD	cis	rs765787	0.53	rs4238376	ENSG00000259539.1	CTD-2651B20.1	3.92	0.000106	0.0338	0.24	0.21	Uric acid levels;	chr15:45249689	chr15:45152664~45167526:-
STAD	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-3.92	0.000106	0.0338	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-3.92	0.000106	0.0338	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
STAD	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	3.92	0.000106	0.0338	0.27	0.21	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	3.92	0.000106	0.0338	0.27	0.21	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
STAD	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	3.92	0.000106	0.0338	0.27	0.21	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
STAD	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	3.92	0.000106	0.0338	0.27	0.21	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
STAD	cis	rs765787	0.53	rs2554455	ENSG00000259539.1	CTD-2651B20.1	3.92	0.000106	0.0338	0.24	0.21	Uric acid levels;	chr15:45229106	chr15:45152664~45167526:-
STAD	cis	rs11239930	0.517	rs942689	ENSG00000278811.3	LINC00624	3.92	0.000106	0.0338	0.22	0.21	AIDS progression;	chr1:147079231	chr1:147258885~147517875:-
STAD	cis	rs7771547	0.607	rs584196	ENSG00000240733.3	RN7SL502P	3.92	0.000106	0.0338	0.18	0.21	Platelet distribution width;	chr6:36488466	chr6:36450912~36451201:-
STAD	cis	rs7771547	0.607	rs632943	ENSG00000240733.3	RN7SL502P	3.92	0.000106	0.0338	0.18	0.21	Platelet distribution width;	chr6:36501344	chr6:36450912~36451201:-
STAD	cis	rs7771547	0.573	rs621796	ENSG00000240733.3	RN7SL502P	3.92	0.000106	0.0338	0.18	0.21	Platelet distribution width;	chr6:36504482	chr6:36450912~36451201:-
STAD	cis	rs7771547	0.607	rs614028	ENSG00000240733.3	RN7SL502P	3.92	0.000106	0.0338	0.18	0.21	Platelet distribution width;	chr6:36516475	chr6:36450912~36451201:-
STAD	cis	rs34779708	0.966	rs7913615	ENSG00000271335.4	RP11-324I22.4	3.92	0.000106	0.0338	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35314552~35336401:-
STAD	cis	rs919433	0.783	rs805497	ENSG00000231621.1	AC013264.2	-3.92	0.000106	0.0338	-0.18	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197357824	chr2:197197991~197199273:+
STAD	cis	rs1154275	0.537	rs6797028	ENSG00000240057.4	RP11-572M11.4	-3.92	0.000106	0.0338	-0.19	-0.21	Takotsubo syndrome;	chr3:112796340	chr3:113019532~113183301:+
STAD	cis	rs9907295	1	rs9913488	ENSG00000270894.1	AC015849.13	-3.92	0.000106	0.0338	-0.24	-0.21	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9912571	ENSG00000270894.1	AC015849.13	-3.92	0.000106	0.0338	-0.24	-0.21	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs9912793	ENSG00000270894.1	AC015849.13	-3.92	0.000106	0.0338	-0.24	-0.21	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35818399~35823713:+
STAD	cis	rs9907295	1	rs11655533	ENSG00000270894.1	AC015849.13	-3.92	0.000106	0.0338	-0.24	-0.21	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35818399~35823713:+
STAD	cis	rs748404	0.56	rs529611	ENSG00000275601.1	AC011330.13	-3.92	0.000106	0.0338	-0.22	-0.21	Lung cancer;	chr15:43513790	chr15:43642389~43643023:-
STAD	cis	rs7580658	0.545	rs13006847	ENSG00000236682.1	AC068282.3	3.92	0.000106	0.0339	0.25	0.21	Protein C levels;	chr2:127194687	chr2:127389130~127400580:+
STAD	cis	rs2098713	0.599	rs1812818	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000106	0.0339	0.21	0.21	Telomere length;	chr5:37546652	chr5:36666214~36725195:-
STAD	cis	rs9902453	1	rs57411618	ENSG00000263477.1	RP11-338L22.2	3.92	0.000106	0.0339	0.17	0.21	Coffee consumption (cups per day);	chr17:29946034	chr17:29863402~29866092:+
STAD	cis	rs9902453	1	rs7222308	ENSG00000263477.1	RP11-338L22.2	3.92	0.000106	0.0339	0.17	0.21	Coffee consumption (cups per day);	chr17:29950023	chr17:29863402~29866092:+
STAD	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	3.92	0.000106	0.0339	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
STAD	cis	rs4763879	0.593	rs7960328	ENSG00000256673.1	RP11-599J14.2	3.92	0.000106	0.0339	0.22	0.21	Type 1 diabetes;	chr12:9699584	chr12:9398355~9414851:-
STAD	cis	rs17507216	0.667	rs13379724	ENSG00000255769.6	GOLGA2P10	-3.92	0.000106	0.0339	-0.33	-0.21	Excessive daytime sleepiness;	chr15:82619892	chr15:82472993~82513950:-
STAD	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	3.92	0.000106	0.0339	0.31	0.21	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
STAD	cis	rs6832769	1	rs6811520	ENSG00000223305.1	RN7SKP30	3.92	0.000106	0.0339	0.23	0.21	Personality dimensions;	chr4:55449011	chr4:55540502~55540835:-
STAD	cis	rs17818399	0.547	rs35178974	ENSG00000279254.1	RP11-536C12.1	-3.92	0.000106	0.0339	-0.23	-0.21	Height;	chr2:46536759	chr2:46668870~46670778:+
STAD	cis	rs2278796	0.918	rs2290138	ENSG00000231691.1	RP11-203F10.5	3.92	0.000106	0.0339	0.25	0.21	Mean platelet volume;	chr1:204987197	chr1:204277005~204277948:+
STAD	cis	rs11945798	1	rs7692152	ENSG00000249780.1	RP11-352E6.2	3.92	0.000106	0.0339	0.38	0.21	Word reading;	chr4:12747914	chr4:12640298~12640637:-
STAD	cis	rs5758659	0.737	rs10854749	ENSG00000182057.4	OGFRP1	3.92	0.000106	0.0339	0.21	0.21	Cognitive function;	chr22:42051337	chr22:42269753~42275196:+
STAD	cis	rs9902453	0.74	rs2254414	ENSG00000263477.1	RP11-338L22.2	-3.92	0.000106	0.0339	-0.17	-0.21	Coffee consumption (cups per day);	chr17:29734112	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.765	rs2264303	ENSG00000263477.1	RP11-338L22.2	-3.92	0.000106	0.0339	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29728330	chr17:29863402~29866092:+
STAD	cis	rs6693567	0.565	rs3754214	ENSG00000203819.6	HIST2H2BC	3.92	0.000106	0.0339	0.24	0.21	Migraine;	chr1:150506147	chr1:149850193~149850772:-
STAD	cis	rs950169	0.96	rs35159785	ENSG00000235370.6	DNM1P51	3.92	0.000106	0.0339	0.27	0.21	Schizophrenia;	chr15:84135262	chr15:84398316~84411701:-
STAD	cis	rs66486766	1	rs66486766	ENSG00000235370.6	DNM1P51	3.92	0.000106	0.0339	0.27	0.21	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84398316~84411701:-
STAD	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-3.92	0.000106	0.0339	-0.26	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
STAD	cis	rs2273156	0.57	rs28399702	ENSG00000258704.4	SRP54-AS1	-3.92	0.000106	0.0339	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35156011	chr14:34920858~34982532:-
STAD	cis	rs867371	1	rs13380319	ENSG00000278603.1	RP13-608F4.5	3.92	0.000106	0.0339	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472203~82472426:+
STAD	cis	rs6964833	1	rs34324835	ENSG00000277072.3	STAG3L2	3.92	0.000106	0.0339	0.25	0.21	Menarche (age at onset);	chr7:74717986	chr7:74882163~74890610:-
STAD	cis	rs728616	0.614	rs17678737	ENSG00000272447.1	RP11-182L21.6	-3.92	0.000106	0.0339	-0.32	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79825902~79827602:+
STAD	cis	rs6180	0.904	rs2972783	ENSG00000250860.1	CTD-2265D6.2	3.92	0.000106	0.0339	0.17	0.21	Height;	chr5:42762318	chr5:42466893~42468300:-
STAD	cis	rs2638953	0.853	rs11049659	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000106	0.0339	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482147	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs1918418	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000106	0.0339	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483789	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs1511550	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000106	0.0339	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28484182	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs12370338	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000106	0.0339	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28486787	chr12:28163298~28190738:-
STAD	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	3.92	0.000106	0.0339	0.31	0.21	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	3.92	0.000106	0.0339	0.31	0.21	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
STAD	cis	rs10510102	0.516	rs11200301	ENSG00000226864.1	ATE1-AS1	3.92	0.000106	0.0339	0.35	0.21	Breast cancer;	chr10:121977976	chr10:121928312~121951965:+
STAD	cis	rs1876905	0.569	rs354523	ENSG00000230177.1	RP5-1112D6.4	-3.92	0.000106	0.0339	-0.23	-0.21	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111277932~111278742:+
STAD	cis	rs1876905	0.68	rs187130	ENSG00000230177.1	RP5-1112D6.4	-3.92	0.000106	0.0339	-0.23	-0.21	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111277932~111278742:+
STAD	cis	rs769267	0.74	rs2965185	ENSG00000268199.2	CTD-3137H5.1	-3.92	0.000106	0.0339	-0.26	-0.21	Tonsillectomy;	chr19:19414983	chr19:18441419~18443597:+
STAD	cis	rs8177876	0.749	rs75923695	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000106	0.0339	-0.34	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81030770~81031485:+
STAD	cis	rs12468226	0.938	rs6435139	ENSG00000272966.1	RP11-686O6.1	-3.92	0.000106	0.0339	-0.31	-0.21	Urate levels;	chr2:202255145	chr2:202336739~202337200:+
STAD	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	3.92	0.000106	0.0339	0.22	0.21	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
STAD	cis	rs1858037	0.867	rs72621551	ENSG00000223739.1	AC007389.2	-3.92	0.000106	0.0339	-0.19	-0.21	Rheumatoid arthritis;	chr2:65388087	chr2:65511771~65512076:-
STAD	cis	rs1858037	0.867	rs55945621	ENSG00000223739.1	AC007389.2	-3.92	0.000106	0.0339	-0.19	-0.21	Rheumatoid arthritis;	chr2:65388220	chr2:65511771~65512076:-
STAD	cis	rs1858037	0.836	rs2576923	ENSG00000223739.1	AC007389.2	3.92	0.000106	0.0339	0.19	0.21	Rheumatoid arthritis;	chr2:65406750	chr2:65511771~65512076:-
STAD	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-3.92	0.000106	0.0339	-0.25	-0.21	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
STAD	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-3.92	0.000106	0.0339	-0.25	-0.21	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
STAD	cis	rs4927850	0.752	rs7618864	ENSG00000278820.1	AC024937.1	3.92	0.000106	0.034	0.23	0.21	Pancreatic cancer;	chr3:196022690	chr3:195960500~195960612:-
STAD	cis	rs9733	0.519	rs2184833	ENSG00000276103.1	U4	3.92	0.000106	0.034	0.19	0.21	Tonsillectomy;	chr1:150703007	chr1:150608507~150608623:-
STAD	cis	rs6480314	0.522	rs10733842	ENSG00000233590.1	RP11-153K11.3	3.92	0.000106	0.034	0.27	0.21	Optic nerve measurement (disc area);	chr10:68299286	chr10:68233251~68242379:-
STAD	cis	rs3947	0.951	rs1736086	ENSG00000227888.4	FAM66A	-3.92	0.000106	0.034	-0.28	-0.21	Blood protein levels;	chr8:11847388	chr8:12362019~12388296:+
STAD	cis	rs2446066	0.872	rs114075368	ENSG00000257379.1	RP11-793H13.8	3.92	0.000106	0.034	0.33	0.21	Red blood cell count;	chr12:53407960	chr12:53441741~53467528:+
STAD	cis	rs11673344	0.523	rs10420330	ENSG00000267672.1	CTD-2293H3.1	3.92	0.000106	0.034	0.19	0.21	Obesity-related traits;	chr19:37111269	chr19:37091341~37092564:+
STAD	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-3.92	0.000106	0.034	-0.25	-0.21	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
STAD	cis	rs7474896	1	rs2738209	ENSG00000099251.13	HSD17B7P2	-3.92	0.000106	0.034	-0.34	-0.21	Obesity (extreme);	chr10:38018286	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.945	rs615718	ENSG00000099251.13	HSD17B7P2	-3.92	0.000106	0.034	-0.34	-0.21	Obesity (extreme);	chr10:38022937	chr10:38356380~38378505:+
STAD	cis	rs7474896	0.836	rs633029	ENSG00000099251.13	HSD17B7P2	-3.92	0.000106	0.034	-0.34	-0.21	Obesity (extreme);	chr10:38029325	chr10:38356380~38378505:+
STAD	cis	rs8012947	0.959	rs6573196	ENSG00000279636.2	LINC00216	-3.92	0.000106	0.034	-0.2	-0.21	Alcohol consumption in current drinkers;	chr14:58255821	chr14:58288033~58289158:+
STAD	cis	rs10129255	0.5	rs8014529	ENSG00000232216.1	IGHV3-43	3.92	0.000106	0.034	0.18	0.21	Kawasaki disease;	chr14:106784065	chr14:106470264~106470800:-
STAD	cis	rs3947	0.951	rs1692819	ENSG00000227888.4	FAM66A	-3.92	0.000106	0.034	-0.29	-0.21	Blood protein levels;	chr8:11847939	chr8:12362019~12388296:+
STAD	cis	rs7429990	0.901	rs6442091	ENSG00000224895.1	VPS26BP1	3.92	0.000106	0.034	0.21	0.21	Educational attainment (years of education);	chr3:48001568	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.965	rs4296617	ENSG00000224895.1	VPS26BP1	3.92	0.000106	0.034	0.21	0.21	Educational attainment (years of education);	chr3:48026818	chr3:47960327~47961081:-
STAD	cis	rs2834188	0.924	rs2040107	ENSG00000272659.1	AP000295.10	3.92	0.000106	0.034	0.28	0.21	Narcolepsy;	chr21:33303657	chr21:33309491~33310181:+
STAD	cis	rs8141529	0.719	rs5762880	ENSG00000272858.1	CTA-292E10.8	-3.92	0.000106	0.034	-0.22	-0.21	Lymphocyte counts;	chr22:28891828	chr22:28814914~28815662:+
STAD	cis	rs8141529	0.748	rs5762882	ENSG00000272858.1	CTA-292E10.8	-3.92	0.000106	0.034	-0.22	-0.21	Lymphocyte counts;	chr22:28894692	chr22:28814914~28815662:+
STAD	cis	rs34779708	0.931	rs2384287	ENSG00000271335.4	RP11-324I22.4	3.92	0.000107	0.034	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35314552~35336401:-
STAD	cis	rs987724	0.519	rs9818684	ENSG00000240875.4	LINC00886	3.92	0.000107	0.034	0.24	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156806431	chr3:156747346~156817062:-
STAD	cis	rs7829975	0.502	rs11785183	ENSG00000253893.2	FAM85B	3.92	0.000107	0.034	0.28	0.21	Mood instability;	chr8:8708447	chr8:8167819~8226614:-
STAD	cis	rs447735	0.587	rs11647958	ENSG00000274627.1	RP11-104N10.2	3.92	0.000107	0.034	0.19	0.21	Hemoglobin concentration;	chr16:89654501	chr16:89516797~89522217:+
STAD	cis	rs7523273	0.565	rs12733108	ENSG00000227887.1	RPS26P13	3.92	0.000107	0.034	0.21	0.21	Schizophrenia;	chr1:207713865	chr1:208697369~208697698:-
STAD	cis	rs7615952	0.546	rs11717632	ENSG00000171084.14	FAM86JP	3.92	0.000107	0.034	0.34	0.21	Blood pressure (smoking interaction);	chr3:125602286	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.546	rs2922197	ENSG00000171084.14	FAM86JP	3.92	0.000107	0.034	0.34	0.21	Blood pressure (smoking interaction);	chr3:125603188	chr3:125916620~125930024:+
STAD	cis	rs7165170	0.554	rs4244882	ENSG00000259314.1	CTD-3065B20.3	3.92	0.000107	0.034	0.24	0.21	Crohn's disease;Inflammatory bowel disease;	chr15:90605945	chr15:90604225~90614558:-
STAD	cis	rs7165170	0.554	rs4932175	ENSG00000259314.1	CTD-3065B20.3	3.92	0.000107	0.034	0.24	0.21	Crohn's disease;Inflammatory bowel disease;	chr15:90605958	chr15:90604225~90614558:-
STAD	cis	rs622217	0.806	rs376563	ENSG00000213071.9	LPAL2	3.92	0.000107	0.034	0.23	0.21	Type 2 diabetes;	chr6:160430734	chr6:160453428~160511124:-
STAD	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-3.92	0.000107	0.034	-0.25	-0.21	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
STAD	cis	rs76210638	1	rs76210638	ENSG00000276672.1	RP11-142E9.1	-3.92	0.000107	0.034	-0.28	-0.21	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33928046	chr13:33846190~33850825:+
STAD	cis	rs76210638	1	rs17080209	ENSG00000276672.1	RP11-142E9.1	-3.92	0.000107	0.034	-0.28	-0.21	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33928762	chr13:33846190~33850825:+
STAD	cis	rs765787	0.53	rs2554457	ENSG00000259539.1	CTD-2651B20.1	3.92	0.000107	0.034	0.24	0.21	Uric acid levels;	chr15:45228728	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs10467979	ENSG00000259539.1	CTD-2651B20.1	3.92	0.000107	0.034	0.24	0.21	Uric acid levels;	chr15:45229072	chr15:45152664~45167526:-
STAD	cis	rs875971	0.571	rs160641	ENSG00000273142.1	RP11-458F8.4	-3.92	0.000107	0.0341	-0.19	-0.21	Aortic root size;	chr7:66112359	chr7:66902857~66906297:+
STAD	cis	rs4713118	0.539	rs510987	ENSG00000280107.1	AL022393.9	-3.92	0.000107	0.0341	-0.27	-0.21	Parkinson's disease;	chr6:27879739	chr6:28170845~28172521:+
STAD	cis	rs7989332	0.627	rs9552201	ENSG00000238286.1	SLC35E1P1	-3.92	0.000107	0.0341	-0.25	-0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20487813	chr13:20607268~20608131:+
STAD	cis	rs6813195	0.642	rs9991574	ENSG00000243417.1	RP11-555K12.1	3.92	0.000107	0.0341	0.21	0.21	Type 2 diabetes;	chr4:152490691	chr4:152551277~152552364:-
STAD	cis	rs6496044	0.611	rs6496055	ENSG00000259295.5	CSPG4P12	3.92	0.000107	0.0341	0.25	0.21	Interstitial lung disease;	chr15:85527457	chr15:85191438~85213905:+
STAD	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-3.92	0.000107	0.0341	-0.27	-0.21	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
STAD	cis	rs11098499	0.874	rs9995277	ENSG00000260091.1	RP11-33B1.4	3.92	0.000107	0.0341	0.2	0.21	Corneal astigmatism;	chr4:119187448	chr4:119409333~119410233:+
STAD	cis	rs9307551	0.584	rs13113835	ENSG00000250334.4	LINC00989	-3.92	0.000107	0.0341	-0.25	-0.21	Refractive error;	chr4:79522945	chr4:79492416~79576460:+
STAD	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	3.92	0.000107	0.0341	0.29	0.21	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
STAD	cis	rs867371	1	rs1501372	ENSG00000278603.1	RP13-608F4.5	3.92	0.000107	0.0341	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472203~82472426:+
STAD	cis	rs6674176	0.551	rs2486003	ENSG00000271329.1	RP5-891H21.5	3.92	0.000107	0.0341	0.3	0.21	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43984098	chr1:44187943~44189049:-
STAD	cis	rs6432860	1	rs495681	ENSG00000229195.1	AC009495.4	3.92	0.000107	0.0341	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166020319	chr2:165794857~165846091:-
STAD	cis	rs2348418	0.864	rs7299039	ENSG00000247934.4	RP11-967K21.1	3.92	0.000107	0.0341	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28454083	chr12:28163298~28190738:-
STAD	cis	rs10129255	0.957	rs8009464	ENSG00000232216.1	IGHV3-43	3.92	0.000107	0.0341	0.21	0.21	Kawasaki disease;	chr14:106777611	chr14:106470264~106470800:-
STAD	cis	rs6903823	0.508	rs1233660	ENSG00000220721.1	OR1F12	3.92	0.000107	0.0341	0.2	0.21	Pulmonary function;	chr6:28292472	chr6:28073316~28074233:+
STAD	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-3.92	0.000107	0.0341	-0.2	-0.21	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
STAD	cis	rs860295	0.812	rs3820594	ENSG00000225855.5	RUSC1-AS1	3.92	0.000107	0.0341	0.17	0.21	Body mass index;	chr1:155859720	chr1:155316863~155324176:-
STAD	cis	rs792448	1	rs518793	ENSG00000212044.2	AL360091.1	3.92	0.000107	0.0341	0.24	0.21	White blood cell count (basophil);	chr1:212414864	chr1:212349978~212350069:+
STAD	cis	rs4218	0.543	rs8027536	ENSG00000259732.1	RP11-59H7.3	-3.92	0.000107	0.0341	-0.23	-0.21	Social communication problems;	chr15:59022364	chr15:59121034~59133250:+
STAD	cis	rs453301	0.624	rs330049	ENSG00000233609.3	RP11-62H7.2	3.92	0.000107	0.0341	0.23	0.21	Joint mobility (Beighton score);	chr8:9229789	chr8:8961200~8979025:+
STAD	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-3.92	0.000107	0.0341	-0.24	-0.21	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
STAD	cis	rs9291683	0.595	rs13145442	ENSG00000250613.1	RP11-136I13.1	-3.92	0.000107	0.0342	-0.19	-0.21	Bone mineral density;	chr4:10035637	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.595	rs11731110	ENSG00000250613.1	RP11-136I13.1	-3.92	0.000107	0.0342	-0.19	-0.21	Bone mineral density;	chr4:10035722	chr4:10410996~10411644:+
STAD	cis	rs17772222	0.701	rs376698	ENSG00000258789.1	RP11-507K2.3	3.92	0.000107	0.0342	0.24	0.21	Coronary artery calcification;	chr14:88391886	chr14:88551597~88552493:+
STAD	cis	rs17592366	0.838	rs74461006	ENSG00000251726.1	RNU7-41P	-3.92	0.000107	0.0342	-0.23	-0.21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34878842	chr14:34845300~34845360:-
STAD	cis	rs4792901	0.802	rs28581728	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000107	0.0342	-0.28	-0.21	Dupuytren's disease;	chr17:43531968	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs28608935	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000107	0.0342	-0.28	-0.21	Dupuytren's disease;	chr17:43532102	chr17:43360041~43361361:-
STAD	cis	rs34779708	0.966	rs34776628	ENSG00000271335.4	RP11-324I22.4	3.92	0.000107	0.0342	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs17499247	ENSG00000271335.4	RP11-324I22.4	3.92	0.000107	0.0342	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.966	rs10827491	ENSG00000271335.4	RP11-324I22.4	3.92	0.000107	0.0342	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35314552~35336401:-
STAD	cis	rs5758659	0.652	rs133322	ENSG00000182057.4	OGFRP1	3.92	0.000107	0.0342	0.22	0.21	Cognitive function;	chr22:42009655	chr22:42269753~42275196:+
STAD	cis	rs5758659	0.623	rs133328	ENSG00000182057.4	OGFRP1	3.92	0.000107	0.0342	0.22	0.21	Cognitive function;	chr22:42012075	chr22:42269753~42275196:+
STAD	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	3.92	0.000107	0.0342	0.23	0.21	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
STAD	cis	rs11098499	0.913	rs12186259	ENSG00000260091.1	RP11-33B1.4	3.92	0.000107	0.0342	0.21	0.21	Corneal astigmatism;	chr4:119230884	chr4:119409333~119410233:+
STAD	cis	rs2273156	1	rs17102967	ENSG00000258704.4	SRP54-AS1	-3.92	0.000107	0.0342	-0.24	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011182	chr14:34920858~34982532:-
STAD	cis	rs4648045	0.565	rs11733293	ENSG00000230069.3	LRRC37A15P	3.92	0.000107	0.0342	0.23	0.21	Lymphocyte percentage of white cells;	chr4:102624096	chr4:102727274~102730721:-
STAD	cis	rs55863869	0.748	rs10171049	ENSG00000270956.1	RP11-65L3.4	-3.92	0.000107	0.0342	-0.43	-0.21	QT interval;	chr2:178757137	chr2:178541125~178541799:+
STAD	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-3.92	0.000107	0.0342	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
STAD	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	3.92	0.000107	0.0342	0.26	0.21	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	3.92	0.000107	0.0342	0.26	0.21	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
STAD	cis	rs4713118	0.911	rs9295746	ENSG00000220721.1	OR1F12	3.92	0.000107	0.0342	0.24	0.21	Parkinson's disease;	chr6:27762285	chr6:28073316~28074233:+
STAD	cis	rs7474896	1	rs7086833	ENSG00000099251.13	HSD17B7P2	-3.92	0.000107	0.0342	-0.34	-0.21	Obesity (extreme);	chr10:37988097	chr10:38356380~38378505:+
STAD	cis	rs7989332	0.529	rs9579874	ENSG00000238286.1	SLC35E1P1	3.92	0.000107	0.0342	0.28	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20490039	chr13:20607268~20608131:+
STAD	cis	rs4407350	0.868	rs5765719	ENSG00000279642.1	RP5-1033E15.3	-3.92	0.000107	0.0342	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44521969	chr22:44486295~44486914:-
STAD	cis	rs2562456	0.876	rs7252585	ENSG00000268119.4	CTD-2561J22.5	-3.92	0.000107	0.0342	-0.25	-0.21	Pain;	chr19:21475141	chr19:21444241~21463908:-
STAD	cis	rs6832769	0.961	rs7660808	ENSG00000223305.1	RN7SKP30	-3.92	0.000107	0.0342	-0.23	-0.21	Personality dimensions;	chr4:55590505	chr4:55540502~55540835:-
STAD	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-3.92	0.000107	0.0342	-0.31	-0.21	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-3.92	0.000107	0.0342	-0.31	-0.21	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-3.92	0.000107	0.0342	-0.31	-0.21	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-3.92	0.000107	0.0342	-0.31	-0.21	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-3.92	0.000107	0.0342	-0.31	-0.21	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
STAD	cis	rs17818399	0.645	rs35870739	ENSG00000279254.1	RP11-536C12.1	-3.92	0.000107	0.0342	-0.23	-0.21	Height;	chr2:46557092	chr2:46668870~46670778:+
STAD	cis	rs9304742	0.646	rs10408610	ENSG00000242779.5	ZNF702P	3.92	0.000107	0.0342	0.26	0.21	Psoriasis;	chr19:52960660	chr19:52968251~53037898:-
STAD	cis	rs7926906	1	rs1404532	ENSG00000280367.1	RP11-121L10.2	-3.92	0.000107	0.0342	-0.21	-0.21	Intelligence (multi-trait analysis);	chr11:90805090	chr11:90223153~90226538:+
STAD	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-3.92	0.000107	0.0342	-0.25	-0.21	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
STAD	cis	rs11089937	0.568	rs5756988	ENSG00000211640.3	IGLV6-57	-3.92	0.000108	0.0343	-0.15	-0.21	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22195713~22196460:+
STAD	cis	rs2638953	0.85	rs61920210	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000108	0.0343	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28144951	chr12:28163298~28190738:-
STAD	cis	rs4792901	0.802	rs9898286	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43485174	chr17:43360041~43361361:-
STAD	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	3.92	0.000108	0.0343	0.26	0.21	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
STAD	cis	rs4792901	0.765	rs9894264	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43500629	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs9908678	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43504177	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs55956367	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43504916	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs9907507	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43509677	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.765	rs9908030	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43510523	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs9915326	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43511234	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs9893137	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43513560	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.729	rs9891052	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43515151	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs9895324	ENSG00000279602.1	CTD-3014M21.1	-3.92	0.000108	0.0343	-0.28	-0.21	Dupuytren's disease;	chr17:43516800	chr17:43360041~43361361:-
STAD	cis	rs765787	0.53	rs2554456	ENSG00000259539.1	CTD-2651B20.1	3.92	0.000108	0.0343	0.24	0.21	Uric acid levels;	chr15:45228940	chr15:45152664~45167526:-
STAD	cis	rs6430585	0.528	rs309133	ENSG00000231890.6	DARS-AS1	-3.92	0.000108	0.0343	-0.23	-0.21	Corneal structure;	chr2:135994272	chr2:135985176~136022593:+
STAD	cis	rs7771547	0.605	rs659726	ENSG00000240733.3	RN7SL502P	3.92	0.000108	0.0343	0.18	0.21	Platelet distribution width;	chr6:36500014	chr6:36450912~36451201:-
STAD	cis	rs72802342	0.541	rs185052	ENSG00000261783.1	RP11-252K23.2	3.92	0.000108	0.0343	0.34	0.21	Advanced age-related macular degeneration;	chr16:75433165	chr16:75379818~75381260:-
STAD	cis	rs8062405	0.728	rs9931989	ENSG00000278665.1	RP11-666O2.4	-3.92	0.000108	0.0343	-0.24	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28599241~28601881:-
STAD	cis	rs9291683	0.588	rs3733586	ENSG00000250613.1	RP11-136I13.1	-3.92	0.000108	0.0343	-0.19	-0.21	Bone mineral density;	chr4:9995910	chr4:10410996~10411644:+
STAD	cis	rs9788721	0.836	rs17483686	ENSG00000259419.2	HNRNPCP3	3.92	0.000108	0.0343	0.22	0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78441048	chr15:79236332~79237206:+
STAD	cis	rs2098713	0.561	rs57015453	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000108	0.0343	0.21	0.21	Telomere length;	chr5:37596878	chr5:36666214~36725195:-
STAD	cis	rs6012564	1	rs911411	ENSG00000227431.4	CSE1L-AS1	3.92	0.000108	0.0343	0.19	0.21	Anger;	chr20:49101894	chr20:49040463~49046044:-
STAD	cis	rs1823874	0.71	rs8042933	ENSG00000182397.13	DNM1P46	3.92	0.000108	0.0343	0.22	0.21	IgG glycosylation;	chr15:99824641	chr15:99790156~99806927:-
STAD	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	3.92	0.000108	0.0343	0.26	0.21	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
STAD	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	3.92	0.000108	0.0343	0.29	0.21	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
STAD	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	3.92	0.000108	0.0343	0.29	0.21	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
STAD	cis	rs6095298	0.574	rs67021138	ENSG00000227431.4	CSE1L-AS1	-3.92	0.000108	0.0343	-0.23	-0.21	Intelligence (multi-trait analysis);	chr20:48865189	chr20:49040463~49046044:-
STAD	cis	rs7142881	0.844	rs8018042	ENSG00000258648.1	UBE2CP1	-3.92	0.000108	0.0343	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31589391	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.844	rs2378897	ENSG00000258648.1	UBE2CP1	-3.92	0.000108	0.0343	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31593898	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.844	rs67468105	ENSG00000258648.1	UBE2CP1	-3.92	0.000108	0.0343	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31597130	chr14:30683045~30683598:-
STAD	cis	rs67311347	1	rs7628796	ENSG00000280739.1	EIF1B-AS1	-3.92	0.000108	0.0344	-0.21	-0.21	Renal cell carcinoma;	chr3:40465841	chr3:40173145~40309698:-
STAD	cis	rs757081	0.533	rs56030184	ENSG00000184669.7	OR7E14P	-3.92	0.000108	0.0344	-0.25	-0.21	Systolic blood pressure;	chr11:17046302	chr11:17013998~17053024:+
STAD	cis	rs6432852	0.527	rs6713602	ENSG00000229195.1	AC009495.4	-3.92	0.000108	0.0344	-0.24	-0.21	Diabetic kidney disease;	chr2:165922913	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.527	rs6745016	ENSG00000229195.1	AC009495.4	-3.92	0.000108	0.0344	-0.24	-0.21	Diabetic kidney disease;	chr2:165923236	chr2:165794857~165846091:-
STAD	cis	rs6479891	1	rs4747045	ENSG00000235816.3	PRELID1P3	3.92	0.000108	0.0344	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs4466712	ENSG00000235816.3	PRELID1P3	3.92	0.000108	0.0344	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs72829170	ENSG00000235816.3	PRELID1P3	3.92	0.000108	0.0344	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63427297~63427939:+
STAD	cis	rs2638953	0.853	rs11049636	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000108	0.0344	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28465728	chr12:28163298~28190738:-
STAD	cis	rs2098713	0.561	rs62359058	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000108	0.0344	0.21	0.21	Telomere length;	chr5:37592593	chr5:36666214~36725195:-
STAD	cis	rs2098713	0.561	rs12655908	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000108	0.0344	0.21	0.21	Telomere length;	chr5:37595793	chr5:36666214~36725195:-
STAD	cis	rs2098713	0.561	rs4869530	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000108	0.0344	0.21	0.21	Telomere length;	chr5:37598468	chr5:36666214~36725195:-
STAD	cis	rs2098713	0.561	rs55960353	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000108	0.0344	0.21	0.21	Telomere length;	chr5:37599484	chr5:36666214~36725195:-
STAD	cis	rs9921338	0.961	rs4780358	ENSG00000263080.1	RP11-485G7.5	3.92	0.000108	0.0344	0.31	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11280355	chr16:11341809~11345211:-
STAD	cis	rs10129255	0.536	rs17113249	ENSG00000211959.2	IGHV4-39	3.92	0.000108	0.0344	0.18	0.21	Kawasaki disease;	chr14:106678273	chr14:106421711~106422218:-
STAD	cis	rs950169	0.724	rs11632668	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84393989	chr15:84398316~84411701:-
STAD	cis	rs950169	0.881	rs34591918	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84396135	chr15:84398316~84411701:-
STAD	cis	rs950169	0.887	rs12903946	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84399732	chr15:84398316~84411701:-
STAD	cis	rs950169	0.887	rs62029593	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84400482	chr15:84398316~84411701:-
STAD	cis	rs950169	0.81	rs62029594	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84400554	chr15:84398316~84411701:-
STAD	cis	rs950169	0.881	rs62029596	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84400736	chr15:84398316~84411701:-
STAD	cis	rs950169	0.881	rs4081123	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84401537	chr15:84398316~84411701:-
STAD	cis	rs950169	0.881	rs62029599	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84401867	chr15:84398316~84411701:-
STAD	cis	rs950169	0.8	rs4099846	ENSG00000235370.6	DNM1P51	3.92	0.000108	0.0344	0.26	0.21	Schizophrenia;	chr15:84402196	chr15:84398316~84411701:-
STAD	cis	rs6432852	0.527	rs6704620	ENSG00000229195.1	AC009495.4	-3.92	0.000108	0.0344	-0.23	-0.21	Diabetic kidney disease;	chr2:165920334	chr2:165794857~165846091:-
STAD	cis	rs73198271	0.74	rs3827807	ENSG00000254340.1	RP11-10A14.3	-3.92	0.000108	0.0344	-0.3	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:9141424~9145435:+
STAD	cis	rs528301	0.613	rs4143310	ENSG00000259439.2	RP11-89K21.1	3.92	0.000108	0.0344	0.28	0.21	Alcohol and nicotine co-dependence;	chr2:44897424	chr2:44921077~44939199:-
STAD	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	3.92	0.000108	0.0344	0.26	0.21	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
STAD	cis	rs4713118	0.868	rs760587	ENSG00000243307.2	POM121L6P	-3.92	0.000108	0.0344	-0.25	-0.21	Parkinson's disease;	chr6:27772521	chr6:26896952~26898777:+
STAD	cis	rs6903823	0.508	rs1150718	ENSG00000220721.1	OR1F12	3.92	0.000108	0.0344	0.2	0.21	Pulmonary function;	chr6:28289170	chr6:28073316~28074233:+
STAD	cis	rs6479891	1	rs72837025	ENSG00000235816.3	PRELID1P3	3.92	0.000108	0.0344	0.27	0.21	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63427297~63427939:+
STAD	cis	rs7119038	0.774	rs73005423	ENSG00000255422.1	AP002954.4	3.92	0.000108	0.0344	0.28	0.21	Sjögren's syndrome;	chr11:118810370	chr11:118704607~118750263:+
STAD	cis	rs6180	1	rs2973018	ENSG00000250860.1	CTD-2265D6.2	3.92	0.000108	0.0344	0.17	0.21	Height;	chr5:42723688	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs719756	ENSG00000250860.1	CTD-2265D6.2	3.92	0.000108	0.0344	0.17	0.21	Height;	chr5:42725527	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2972770	ENSG00000250860.1	CTD-2265D6.2	3.92	0.000108	0.0344	0.17	0.21	Height;	chr5:42731670	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs2973023	ENSG00000250860.1	CTD-2265D6.2	3.92	0.000108	0.0344	0.17	0.21	Height;	chr5:42732781	chr5:42466893~42468300:-
STAD	cis	rs8177876	0.731	rs10514512	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000108	0.0344	-0.38	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81030770~81031485:+
STAD	cis	rs11587682	0.714	rs35699789	ENSG00000274963.1	Metazoa_SRP	-3.92	0.000108	0.0344	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150469624	chr1:150568971~150569269:-
STAD	cis	rs7178572	0.743	rs62009090	ENSG00000259792.1	RP11-114H24.6	-3.92	0.000108	0.0344	-0.26	-0.21	Type 2 diabetes;	chr15:77544713	chr15:77993405~77995289:+
STAD	cis	rs919433	0.963	rs12469546	ENSG00000231621.1	AC013264.2	3.92	0.000108	0.0344	0.18	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197314102	chr2:197197991~197199273:+
STAD	cis	rs919433	0.963	rs4850430	ENSG00000231621.1	AC013264.2	3.92	0.000108	0.0344	0.18	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318072	chr2:197197991~197199273:+
STAD	cis	rs919433	0.963	rs10166569	ENSG00000231621.1	AC013264.2	3.92	0.000108	0.0344	0.18	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318715	chr2:197197991~197199273:+
STAD	cis	rs34779708	0.966	rs4934538	ENSG00000271335.4	RP11-324I22.4	3.92	0.000108	0.0344	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35314552~35336401:-
STAD	cis	rs7824557	0.527	rs2572369	ENSG00000205879.4	FAM90A2P	-3.92	0.000108	0.0344	-0.23	-0.21	Retinal vascular caliber;	chr8:11381088	chr8:12172202~12178575:-
STAD	cis	rs718433	0.584	rs1569292	ENSG00000211790.2	TRAV8-4	3.92	0.000108	0.0344	0.17	0.21	Intraocular pressure;	chr14:21748709	chr14:21894433~21895030:+
STAD	cis	rs6430585	0.528	rs309113	ENSG00000231890.6	DARS-AS1	-3.92	0.000108	0.0344	-0.22	-0.21	Corneal structure;	chr2:135979890	chr2:135985176~136022593:+
STAD	cis	rs4400599	0.618	rs1194599	ENSG00000272030.1	RP1-178F15.4	-3.92	0.000108	0.0344	-0.29	-0.21	Platelet distribution width;	chr1:154263976	chr1:153631438~153634397:-
STAD	cis	rs2273156	0.57	rs2010648	ENSG00000258704.4	SRP54-AS1	-3.92	0.000108	0.0345	-0.25	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:35135686	chr14:34920858~34982532:-
STAD	cis	rs860295	0.702	rs10796946	ENSG00000225855.5	RUSC1-AS1	3.92	0.000108	0.0345	0.17	0.21	Body mass index;	chr1:155459699	chr1:155316863~155324176:-
STAD	cis	rs860295	0.676	rs10908466	ENSG00000225855.5	RUSC1-AS1	3.92	0.000108	0.0345	0.17	0.21	Body mass index;	chr1:155459934	chr1:155316863~155324176:-
STAD	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-3.92	0.000108	0.0345	-0.23	-0.21	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
STAD	cis	rs10129255	0.913	rs28861466	ENSG00000224373.3	IGHV4-59	3.92	0.000108	0.0345	0.17	0.21	Kawasaki disease;	chr14:106718572	chr14:106627249~106627825:-
STAD	cis	rs2992257	0.871	rs1001882	ENSG00000251839.1	RNU7-12P	-3.92	0.000108	0.0345	-0.21	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:26408653	chr10:27232255~27232316:-
STAD	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-3.92	0.000108	0.0345	-0.27	-0.21	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-3.92	0.000108	0.0345	-0.27	-0.21	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-3.92	0.000108	0.0345	-0.27	-0.21	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
STAD	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	3.92	0.000109	0.0345	0.26	0.21	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
STAD	cis	rs7589561	0.602	rs10196773	ENSG00000233639.4	LINC01158	3.92	0.000109	0.0345	0.28	0.21	Addiction;	chr2:105781039	chr2:104807572~104853183:-
STAD	cis	rs870825	0.616	rs10013562	ENSG00000249173.4	LINC01093	-3.92	0.000109	0.0345	-0.34	-0.21	Blood protein levels;	chr4:184689332	chr4:184893871~184899454:-
STAD	cis	rs2840044	0.711	rs225301	ENSG00000267369.1	RP11-1094M14.8	-3.92	0.000109	0.0346	-0.19	-0.21	Response to radiotherapy in cancer (late toxicity);	chr17:35595392	chr17:35498218~35499175:+
STAD	cis	rs6499129	0.558	rs16957489	ENSG00000263126.1	CTC-479C5.10	3.92	0.000109	0.0346	0.28	0.21	Waist-to-hip ratio adjusted for body mass index;	chr16:67617976	chr16:67882461~67886367:+
STAD	cis	rs7487075	0.688	rs12227156	ENSG00000272963.1	OR7A19P	3.92	0.000109	0.0346	0.19	0.21	Itch intensity from mosquito bite;	chr12:46615645	chr12:46592573~46593305:+
STAD	cis	rs9287719	0.649	rs10929683	ENSG00000243819.4	RN7SL832P	-3.92	0.000109	0.0346	-0.2	-0.21	Prostate cancer;	chr2:10592082	chr2:10690344~10692099:+
STAD	cis	rs9733	0.596	rs72702556	ENSG00000276103.1	U4	3.92	0.000109	0.0346	0.19	0.21	Tonsillectomy;	chr1:150707639	chr1:150608507~150608623:-
STAD	cis	rs7771547	0.573	rs619011	ENSG00000240733.3	RN7SL502P	3.92	0.000109	0.0346	0.18	0.21	Platelet distribution width;	chr6:36508815	chr6:36450912~36451201:-
STAD	cis	rs7615952	0.558	rs17334039	ENSG00000239804.1	RP11-379B18.1	3.92	0.000109	0.0346	0.26	0.21	Blood pressure (smoking interaction);	chr3:125821465	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.688	rs12638240	ENSG00000239804.1	RP11-379B18.1	3.92	0.000109	0.0346	0.26	0.21	Blood pressure (smoking interaction);	chr3:125822395	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.688	rs12638224	ENSG00000239804.1	RP11-379B18.1	3.92	0.000109	0.0346	0.26	0.21	Blood pressure (smoking interaction);	chr3:125822477	chr3:125787888~125788146:-
STAD	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-3.92	0.000109	0.0346	-0.3	-0.21	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
STAD	cis	rs1348850	0.539	rs1453371	ENSG00000271825.1	RP11-337N6.2	3.92	0.000109	0.0346	0.17	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177363134	chr2:177300600~177302006:+
STAD	cis	rs9902453	0.845	rs7218113	ENSG00000240074.1	RPL9P30	-3.92	0.000109	0.0346	-0.18	-0.21	Coffee consumption (cups per day);	chr17:30045112	chr17:29855759~29856332:+
STAD	cis	rs3764400	0.567	rs8071199	ENSG00000278765.1	RP5-890E16.5	-3.91	0.000109	0.0346	-0.27	-0.21	Body mass index;	chr17:48117973	chr17:48066704~48067293:-
STAD	cis	rs10971721	0.584	rs72731217	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34119555	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.584	rs72731218	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34119678	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.584	rs72731221	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34122376	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.584	rs72731222	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34122864	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.584	rs10971939	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34123437	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.584	rs10971940	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34127213	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.584	rs72731226	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34128832	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.584	rs10971944	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34129008	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.631	rs74450404	ENSG00000281128.1	PTENP1-AS	3.91	0.000109	0.0346	0.31	0.21	Body mass index;	chr9:34134666	chr9:33677268~33688011:+
STAD	cis	rs7520050	0.966	rs785481	ENSG00000280836.1	AL355480.1	3.91	0.000109	0.0346	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs6675726	ENSG00000280836.1	AL355480.1	3.91	0.000109	0.0346	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45581219~45581321:-
STAD	cis	rs1858037	0.836	rs17475335	ENSG00000223739.1	AC007389.2	-3.91	0.000109	0.0346	-0.19	-0.21	Rheumatoid arthritis;	chr2:65378646	chr2:65511771~65512076:-
STAD	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-3.91	0.000109	0.0346	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
STAD	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	3.91	0.000109	0.0346	0.24	0.21	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
STAD	cis	rs1816752	0.719	rs11841989	ENSG00000232858.1	RPL34P27	3.91	0.000109	0.0346	0.13	0.21	Obesity-related traits;	chr13:24423560	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.905	rs9581026	ENSG00000232858.1	RPL34P27	3.91	0.000109	0.0346	0.13	0.21	Obesity-related traits;	chr13:24423788	chr13:24988577~24988925:-
STAD	cis	rs13178541	0.745	rs4513690	ENSG00000248211.1	TRPC7-AS1	-3.91	0.000109	0.0346	-0.27	-0.21	IgG glycosylation;	chr5:135776703	chr5:136214048~136222159:+
STAD	cis	rs2262909	0.962	rs7255049	ENSG00000279377.1	AC003973.3	3.91	0.000109	0.0346	0.21	0.21	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22030309	chr19:21965708~21968529:-
STAD	cis	rs7951911	0.915	rs7131423	ENSG00000254427.1	RP11-430H10.1	3.91	0.000109	0.0346	0.42	0.21	IgG glycosylation;	chr11:45077084	chr11:45355371~45366121:+
STAD	cis	rs7520050	0.966	rs2486447	ENSG00000280836.1	AL355480.1	3.91	0.000109	0.0346	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs1768803	ENSG00000280836.1	AL355480.1	3.91	0.000109	0.0346	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs4660910	ENSG00000280836.1	AL355480.1	3.91	0.000109	0.0346	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45581219~45581321:-
STAD	cis	rs950169	0.8	rs4842847	ENSG00000235370.6	DNM1P51	3.91	0.000109	0.0347	0.26	0.21	Schizophrenia;	chr15:84262447	chr15:84398316~84411701:-
STAD	cis	rs10946940	0.965	rs62401383	ENSG00000280107.1	AL022393.9	3.91	0.000109	0.0347	0.24	0.21	Systemic lupus erythematosus;	chr6:27596768	chr6:28170845~28172521:+
STAD	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	3.91	0.000109	0.0347	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
STAD	cis	rs4713118	0.869	rs9461405	ENSG00000220721.1	OR1F12	3.91	0.000109	0.0347	0.22	0.21	Parkinson's disease;	chr6:27751596	chr6:28073316~28074233:+
STAD	cis	rs4835473	0.9	rs10025455	ENSG00000249741.2	RP11-673E1.3	3.91	0.000109	0.0347	0.24	0.21	Immature fraction of reticulocytes;	chr4:143998417	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.868	rs7683365	ENSG00000249741.2	RP11-673E1.3	3.91	0.000109	0.0347	0.24	0.21	Immature fraction of reticulocytes;	chr4:143999443	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.722	rs7662277	ENSG00000249741.2	RP11-673E1.3	3.91	0.000109	0.0347	0.24	0.21	Immature fraction of reticulocytes;	chr4:143999485	chr4:143911514~143912053:-
STAD	cis	rs28588043	0.55	rs61816051	ENSG00000201126.1	RNU6-773P	-3.91	0.000109	0.0347	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170984135	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.593	rs61816052	ENSG00000201126.1	RNU6-773P	-3.91	0.000109	0.0347	-0.39	-0.21	Number of children (6+ vs. 0 or 1);	chr1:170984168	chr1:171519816~171519913:-
STAD	cis	rs1707322	1	rs10890381	ENSG00000225447.1	RPS15AP10	3.91	0.000109	0.0347	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45645816~45646197:-
STAD	cis	rs1913185	0.891	rs67325724	ENSG00000240032.1	RP11-274H2.3	-3.91	0.000109	0.0347	-0.32	-0.21	Obesity-related traits;	chr3:146156940	chr3:146066344~146069185:-
STAD	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-3.91	0.000109	0.0347	-0.32	-0.21	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
STAD	cis	rs17798991	0.721	rs12954469	ENSG00000267322.2	SNHG22	-3.91	0.000109	0.0347	-0.23	-0.21	Obesity-related traits;	chr18:49603858	chr18:49814023~49851059:+
STAD	cis	rs950169	0.84	rs72748702	ENSG00000235370.6	DNM1P51	3.91	0.000109	0.0347	0.26	0.21	Schizophrenia;	chr15:84246494	chr15:84398316~84411701:-
STAD	cis	rs8141529	0.748	rs7287918	ENSG00000272858.1	CTA-292E10.8	-3.91	0.000109	0.0347	-0.22	-0.21	Lymphocyte counts;	chr22:28885722	chr22:28814914~28815662:+
STAD	cis	rs8141529	0.748	rs1318025	ENSG00000272858.1	CTA-292E10.8	-3.91	0.000109	0.0347	-0.22	-0.21	Lymphocyte counts;	chr22:28887769	chr22:28814914~28815662:+
STAD	cis	rs1075265	0.933	rs918357	ENSG00000235937.1	AC008280.1	3.91	0.000109	0.0347	0.18	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54029552~54030682:-
STAD	cis	rs494453	0.922	rs486982	ENSG00000234020.1	CHIAP3	-3.91	0.000109	0.0347	-0.2	-0.21	Osteoporosis-related phenotypes;	chr1:111710492	chr1:111353275~111367409:-
STAD	cis	rs2446066	0.659	rs11170569	ENSG00000257379.1	RP11-793H13.8	3.91	0.000109	0.0347	0.42	0.21	Red blood cell count;	chr12:53519642	chr12:53441741~53467528:+
STAD	cis	rs858239	0.633	rs858300	ENSG00000230042.1	AK3P3	-3.91	0.000109	0.0347	-0.23	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23129178~23129841:+
STAD	cis	rs2446066	0.872	rs57676448	ENSG00000257379.1	RP11-793H13.8	3.91	0.000109	0.0347	0.34	0.21	Red blood cell count;	chr12:53401003	chr12:53441741~53467528:+
STAD	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	3.91	0.000109	0.0347	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
STAD	cis	rs6693567	0.545	rs2012751	ENSG00000203819.6	HIST2H2BC	3.91	0.000109	0.0347	0.24	0.21	Migraine;	chr1:150465790	chr1:149850193~149850772:-
STAD	cis	rs8141529	0.748	rs5762881	ENSG00000272858.1	CTA-292E10.8	-3.91	0.000109	0.0347	-0.22	-0.21	Lymphocyte counts;	chr22:28893358	chr22:28814914~28815662:+
STAD	cis	rs8141529	0.748	rs9620841	ENSG00000272858.1	CTA-292E10.8	-3.91	0.000109	0.0347	-0.22	-0.21	Lymphocyte counts;	chr22:28894993	chr22:28814914~28815662:+
STAD	cis	rs765787	0.53	rs11636440	ENSG00000259539.1	CTD-2651B20.1	3.91	0.000109	0.0347	0.24	0.21	Uric acid levels;	chr15:45243784	chr15:45152664~45167526:-
STAD	cis	rs7474896	1	rs11598044	ENSG00000099251.13	HSD17B7P2	3.91	0.000109	0.0347	0.34	0.21	Obesity (extreme);	chr10:38053765	chr10:38356380~38378505:+
STAD	cis	rs10986311	0.654	rs2416927	ENSG00000227200.1	RP11-121A14.3	-3.91	0.000109	0.0347	-0.22	-0.21	Vitiligo;	chr9:124316242	chr9:124262876~124265809:+
STAD	cis	rs6095298	0.595	rs7267607	ENSG00000227431.4	CSE1L-AS1	-3.91	0.000109	0.0347	-0.22	-0.21	Intelligence (multi-trait analysis);	chr20:48831333	chr20:49040463~49046044:-
STAD	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-3.91	0.000109	0.0347	-0.2	-0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
STAD	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-3.91	0.000109	0.0348	-0.26	-0.21	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
STAD	cis	rs9463078	0.683	rs1342640	ENSG00000219384.1	RP11-491H9.3	-3.91	0.000109	0.0348	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44775779	chr6:45158870~45159511:+
STAD	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-3.91	0.00011	0.0348	-0.22	-0.21	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
STAD	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-3.91	0.00011	0.0348	-0.22	-0.21	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
STAD	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	3.91	0.00011	0.0348	0.22	0.21	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
STAD	cis	rs1059312	0.522	rs3825181	ENSG00000279500.1	RP11-21K12.2	3.91	0.00011	0.0348	0.2	0.21	Systemic lupus erythematosus;	chr12:128794719	chr12:128813186~128814750:-
STAD	cis	rs2337406	0.929	rs11847182	ENSG00000280411.1	IGHV1-69-2	-3.91	0.00011	0.0348	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106697724	chr14:106762092~106762588:-
STAD	cis	rs6832769	0.961	rs1873092	ENSG00000223305.1	RN7SKP30	-3.91	0.00011	0.0348	-0.23	-0.21	Personality dimensions;	chr4:55578133	chr4:55540502~55540835:-
STAD	cis	rs4835473	0.932	rs34917094	ENSG00000249741.2	RP11-673E1.3	3.91	0.00011	0.0348	0.24	0.21	Immature fraction of reticulocytes;	chr4:143832003	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs11736609	ENSG00000249741.2	RP11-673E1.3	3.91	0.00011	0.0348	0.24	0.21	Immature fraction of reticulocytes;	chr4:143832876	chr4:143911514~143912053:-
STAD	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-3.91	0.00011	0.0348	-0.22	-0.21	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
STAD	cis	rs11089937	0.651	rs928894	ENSG00000211639.2	IGLV4-60	3.91	0.00011	0.0348	0.22	0.21	Periodontitis (PAL4Q3);	chr22:22185882	chr22:22162199~22162681:+
STAD	cis	rs1858037	0.867	rs9789444	ENSG00000223739.1	AC007389.2	-3.91	0.00011	0.0348	-0.19	-0.21	Rheumatoid arthritis;	chr2:65342093	chr2:65511771~65512076:-
STAD	cis	rs2665103	0.61	rs1972460	ENSG00000259429.4	UBE2Q2P2	-3.91	0.00011	0.0348	-0.22	-0.21	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82355142~82420075:+
STAD	cis	rs1790761	0.587	rs4930430	ENSG00000231793.4	DOC2GP	3.91	0.00011	0.0348	0.24	0.21	Mean corpuscular volume;	chr11:67526727	chr11:67612653~67616257:-
STAD	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	3.91	0.00011	0.0348	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
STAD	cis	rs2836974	0.666	rs2836975	ENSG00000238141.2	BRWD1-AS1	-3.91	0.00011	0.0348	-0.21	-0.21	Cognitive function;	chr21:39291694	chr21:39315707~39323218:+
STAD	cis	rs983332	0.668	rs1813398	ENSG00000230721.1	RP4-612B15.2	-3.91	0.00011	0.0348	-0.25	-0.21	Response to TNF antagonist treatment;	chr1:87663477	chr1:86784913~86785467:+
STAD	cis	rs11089937	0.609	rs2213158	ENSG00000211640.3	IGLV6-57	3.91	0.00011	0.0348	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.637	rs2213159	ENSG00000211640.3	IGLV6-57	3.91	0.00011	0.0348	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22195713~22196460:+
STAD	cis	rs4293777	0.967	rs7654347	ENSG00000250896.1	RNPS1P1	3.91	0.00011	0.0348	0.15	0.21	Primary sclerosing cholangitis;	chr4:10724199	chr4:11371975~11372892:+
STAD	cis	rs17708984	0.606	rs3786573	ENSG00000264250.2	RN7SL835P	3.91	0.00011	0.0348	0.18	0.21	Platelet distribution width;Platelet count;	chr19:16082975	chr19:16907462~16907723:+
STAD	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	3.91	0.00011	0.0348	0.21	0.21	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
STAD	cis	rs13412757	0.84	rs59808848	ENSG00000236790.4	LINC00299	-3.91	0.00011	0.0348	-0.23	-0.21	Asthma;Itch intensity from mosquito bite adjusted by bite size;	chr2:8333908	chr2:8007771~8383621:-
STAD	cis	rs7142881	0.815	rs4981869	ENSG00000258648.1	UBE2CP1	-3.91	0.00011	0.0348	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31627218	chr14:30683045~30683598:-
STAD	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	3.91	0.00011	0.0348	0.26	0.21	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
STAD	cis	rs10776614	0.799	rs1838569	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48555632	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs1838568	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48555645	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs1445148	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48555664	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7071095	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48555773	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7085183	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48555984	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7071480	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48556016	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7085335	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48556086	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs1965170	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48556372	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs10857596	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48556629	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs1473323	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48556775	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs1345110	ENSG00000189014.7	FAM35DP	3.91	0.00011	0.0348	0.31	0.21	Self-employment;	chr10:48557123	chr10:47689707~47730436:+
STAD	cis	rs10508774	1	rs35574674	ENSG00000273038.2	RP11-479G22.8	3.91	0.00011	0.0349	0.4	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32527454	chr10:32887255~32889311:-
STAD	cis	rs806321	0.587	rs2765756	ENSG00000237152.3	DLEU7-AS1	-3.91	0.00011	0.0349	-0.24	-0.21	Multiple sclerosis;	chr13:50199350	chr13:50807856~50849905:+
STAD	cis	rs1322639	0.614	rs9294967	ENSG00000261039.2	RP11-417E7.2	3.91	0.00011	0.0349	0.32	0.21	Pulse pressure;	chr6:169165311	chr6:169175304~169182740:-
STAD	cis	rs6657613	0.68	rs7545518	ENSG00000224621.1	RP11-276H7.3	3.91	0.00011	0.0349	0.19	0.21	Hip circumference adjusted for BMI;	chr1:17048247	chr1:16159266~16161883:+
STAD	cis	rs765787	0.53	rs28396110	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45244711	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775834	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45245313	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775835	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45245355	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775836	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45245466	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4775837	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45245486	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs12917187	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45246099	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs11639403	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45246152	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs2413782	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45246292	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs2413780	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45246668	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs11636018	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45246939	chr15:45152664~45167526:-
STAD	cis	rs765787	0.556	rs2413778	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45247199	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs28756676	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45248162	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs55771002	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45249368	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs55920042	ENSG00000259539.1	CTD-2651B20.1	3.91	0.00011	0.0349	0.24	0.21	Uric acid levels;	chr15:45249379	chr15:45152664~45167526:-
STAD	cis	rs6019512	0.846	rs2024595	ENSG00000227431.4	CSE1L-AS1	-3.91	0.00011	0.0349	-0.2	-0.21	Intelligence (multi-trait analysis);	chr20:48901359	chr20:49040463~49046044:-
STAD	cis	rs9921338	0.961	rs7198849	ENSG00000263080.1	RP11-485G7.5	3.91	0.00011	0.0349	0.3	0.21	Vein graft stenosis in coronary artery bypass grafting;	chr16:11279444	chr16:11341809~11345211:-
STAD	cis	rs4713118	0.869	rs6914924	ENSG00000220721.1	OR1F12	3.91	0.00011	0.0349	0.22	0.21	Parkinson's disease;	chr6:27743751	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs6930992	ENSG00000220721.1	OR1F12	3.91	0.00011	0.0349	0.22	0.21	Parkinson's disease;	chr6:27744341	chr6:28073316~28074233:+
STAD	cis	rs7812879	0.673	rs10903338	ENSG00000227888.4	FAM66A	-3.91	0.00011	0.0349	-0.25	-0.21	Systemic lupus erythematosus;	chr8:11452781	chr8:12362019~12388296:+
STAD	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	3.91	0.00011	0.0349	0.24	0.21	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
STAD	cis	rs6499129	0.558	rs7191281	ENSG00000263126.1	CTC-479C5.10	3.91	0.00011	0.0349	0.31	0.21	Waist-to-hip ratio adjusted for body mass index;	chr16:67621230	chr16:67882461~67886367:+
STAD	cis	rs5760842	0.967	rs5760830	ENSG00000203280.4	CTA-221G9.12	-3.91	0.00011	0.0349	-0.26	-0.21	Recurrent major depressive disorder;	chr22:25081637	chr22:25102433~25112692:-
STAD	cis	rs679711	0.597	rs652972	ENSG00000214380.4	RP11-457K10.2	3.91	0.00011	0.0349	0.24	0.21	Sleep depth;	chr3:109900072	chr3:109915976~109916940:-
STAD	cis	rs679711	0.634	rs1164215	ENSG00000214380.4	RP11-457K10.2	-3.91	0.00011	0.0349	-0.24	-0.21	Sleep depth;	chr3:109897195	chr3:109915976~109916940:-
STAD	cis	rs10986311	0.747	rs2282085	ENSG00000227200.1	RP11-121A14.3	-3.91	0.00011	0.0349	-0.23	-0.21	Vitiligo;	chr9:124262761	chr9:124262876~124265809:+
STAD	cis	rs4792901	0.765	rs9913605	ENSG00000279602.1	CTD-3014M21.1	-3.91	0.00011	0.0349	-0.28	-0.21	Dupuytren's disease;	chr17:43515142	chr17:43360041~43361361:-
STAD	cis	rs60180747	0.909	rs17200970	ENSG00000252712.1	SCARNA14	3.91	0.00011	0.0349	0.25	0.21	Testicular germ cell tumor;	chr15:66438707	chr15:66347207~66347342:-
STAD	cis	rs8177876	0.822	rs56166222	ENSG00000261061.1	RP11-303E16.2	-3.91	0.00011	0.0349	-0.39	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81030770~81031485:+
STAD	cis	rs9902453	0.845	rs2617875	ENSG00000263477.1	RP11-338L22.2	3.91	0.00011	0.0349	0.17	0.21	Coffee consumption (cups per day);	chr17:29763006	chr17:29863402~29866092:+
STAD	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	3.91	0.00011	0.0349	0.22	0.21	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
STAD	cis	rs10229583	0.527	rs6943385	ENSG00000279078.1	SND1-IT1	-3.91	0.00011	0.0349	-0.19	-0.21	Type 2 diabetes;	chr7:127668374	chr7:127997597~128000077:+
STAD	cis	rs34779708	0.966	rs1148245	ENSG00000271335.4	RP11-324I22.4	3.91	0.00011	0.035	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35314552~35336401:-
STAD	cis	rs7924176	0.601	rs10824091	ENSG00000213731.2	RAB5CP1	-3.91	0.00011	0.035	-0.21	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74169750	chr10:74423435~74424014:-
STAD	cis	rs5760842	0.967	rs5760834	ENSG00000203280.4	CTA-221G9.12	-3.91	0.00011	0.035	-0.26	-0.21	Recurrent major depressive disorder;	chr22:25083512	chr22:25102433~25112692:-
STAD	cis	rs7208859	0.673	rs999798	ENSG00000263603.1	CTD-2349P21.5	-3.91	0.00011	0.035	-0.24	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30729469~30731202:+
STAD	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	3.91	0.00011	0.035	0.24	0.21	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
STAD	cis	rs2369304	0.736	rs11160289	ENSG00000258412.1	RP11-404P21.5	-3.91	0.00011	0.035	-0.24	-0.21	Neutrophil count;	chr14:95754429	chr14:96210860~96214818:+
STAD	cis	rs1348850	0.914	rs7573763	ENSG00000271825.1	RP11-337N6.2	3.91	0.00011	0.035	0.17	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177385080	chr2:177300600~177302006:+
STAD	cis	rs1015213	1	rs1015213	ENSG00000272024.1	RP11-546K22.3	3.91	0.00011	0.035	0.47	0.21	Glaucoma (primary angle closure);	chr8:51974981	chr8:51950284~51950690:+
STAD	cis	rs5753618	0.504	rs5753661	ENSG00000236132.1	CTA-440B3.1	-3.91	0.00011	0.035	-0.23	-0.21	Colorectal cancer;	chr22:31503811	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.504	rs9606847	ENSG00000236132.1	CTA-440B3.1	-3.91	0.00011	0.035	-0.23	-0.21	Colorectal cancer;	chr22:31505803	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.504	rs9606848	ENSG00000236132.1	CTA-440B3.1	-3.91	0.00011	0.035	-0.23	-0.21	Colorectal cancer;	chr22:31505881	chr22:31816379~31817491:-
STAD	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-3.91	0.00011	0.035	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-3.91	0.00011	0.035	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
STAD	cis	rs9287719	0.593	rs13009015	ENSG00000243819.4	RN7SL832P	3.91	0.000111	0.035	0.2	0.21	Prostate cancer;	chr2:10622992	chr2:10690344~10692099:+
STAD	cis	rs7119038	0.818	rs11217032	ENSG00000255422.1	AP002954.4	3.91	0.000111	0.035	0.28	0.21	Sjögren's syndrome;	chr11:118798896	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.818	rs11217033	ENSG00000255422.1	AP002954.4	3.91	0.000111	0.035	0.28	0.21	Sjögren's syndrome;	chr11:118802997	chr11:118704607~118750263:+
STAD	cis	rs11217036	1	rs11217036	ENSG00000255422.1	AP002954.4	3.91	0.000111	0.035	0.28	0.21	Allergy;	chr11:118805063	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.774	rs11217037	ENSG00000255422.1	AP002954.4	3.91	0.000111	0.035	0.28	0.21	Sjögren's syndrome;	chr11:118806377	chr11:118704607~118750263:+
STAD	cis	rs7119038	0.774	rs11217038	ENSG00000255422.1	AP002954.4	3.91	0.000111	0.035	0.28	0.21	Sjögren's syndrome;	chr11:118806646	chr11:118704607~118750263:+
STAD	cis	rs34779708	0.966	rs11010095	ENSG00000271335.4	RP11-324I22.4	3.91	0.000111	0.035	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35314552~35336401:-
STAD	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-3.91	0.000111	0.035	-0.21	-0.21	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
STAD	cis	rs867371	1	rs11855089	ENSG00000278603.1	RP13-608F4.5	3.91	0.000111	0.035	0.24	0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472203~82472426:+
STAD	cis	rs2115630	0.645	rs2292463	ENSG00000259728.4	LINC00933	-3.91	0.000111	0.035	-0.23	-0.21	P wave terminal force;	chr15:84632519	chr15:84570649~84580175:+
STAD	cis	rs2836950	0.805	rs62223042	ENSG00000255568.3	BRWD1-AS2	-3.91	0.000111	0.035	-0.24	-0.21	Menarche (age at onset);	chr21:39311814	chr21:39313935~39314962:+
STAD	cis	rs7119038	0.509	rs10892258	ENSG00000255239.1	AP002954.6	3.91	0.000111	0.035	0.23	0.21	Sjögren's syndrome;	chr11:118709156	chr11:118688039~118690600:-
STAD	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	3.91	0.000111	0.035	0.3	0.21	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-3.91	0.000111	0.035	-0.31	-0.21	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
STAD	cis	rs4845552	0.767	rs4845551	ENSG00000226855.1	RP11-350G8.3	-3.91	0.000111	0.035	-0.25	-0.21	Hippocampal atrophy;	chr1:153500118	chr1:154378207~154379089:-
STAD	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-3.91	0.000111	0.035	-0.31	-0.21	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
STAD	cis	rs9297145	0.565	rs56132062	ENSG00000272950.1	RP11-307C18.1	-3.91	0.000111	0.035	-0.23	-0.21	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99180575	chr7:98322853~98323430:+
STAD	cis	rs11587682	0.76	rs12126130	ENSG00000274963.1	Metazoa_SRP	-3.91	0.000111	0.035	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150451241	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.628	rs12120775	ENSG00000274963.1	Metazoa_SRP	-3.91	0.000111	0.035	-0.22	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150451397	chr1:150568971~150569269:-
STAD	cis	rs9733	0.566	rs112967224	ENSG00000276103.1	U4	3.91	0.000111	0.0351	0.19	0.21	Tonsillectomy;	chr1:150704787	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72702552	ENSG00000276103.1	U4	3.91	0.000111	0.0351	0.19	0.21	Tonsillectomy;	chr1:150704986	chr1:150608507~150608623:-
STAD	cis	rs2638953	0.962	rs11049518	ENSG00000247934.4	RP11-967K21.1	-3.91	0.000111	0.0351	-0.24	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28303728	chr12:28163298~28190738:-
STAD	cis	rs9902453	0.845	rs2259855	ENSG00000263477.1	RP11-338L22.2	-3.91	0.000111	0.0351	-0.18	-0.21	Coffee consumption (cups per day);	chr17:29770842	chr17:29863402~29866092:+
STAD	cis	rs4792901	0.802	rs72833136	ENSG00000279602.1	CTD-3014M21.1	-3.91	0.000111	0.0351	-0.28	-0.21	Dupuytren's disease;	chr17:43522322	chr17:43360041~43361361:-
STAD	cis	rs870825	0.616	rs72705689	ENSG00000249173.4	LINC01093	-3.91	0.000111	0.0351	-0.33	-0.21	Blood protein levels;	chr4:184718740	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6834156	ENSG00000249173.4	LINC01093	-3.91	0.000111	0.0351	-0.33	-0.21	Blood protein levels;	chr4:184718749	chr4:184893871~184899454:-
STAD	cis	rs6832769	1	rs6812042	ENSG00000223305.1	RN7SKP30	3.91	0.000111	0.0351	0.23	0.21	Personality dimensions;	chr4:55529912	chr4:55540502~55540835:-
STAD	cis	rs2380205	0.546	rs635532	ENSG00000232807.2	RP11-536K7.3	-3.91	0.000111	0.0351	-0.21	-0.21	Breast cancer;	chr10:5928365	chr10:5934270~5945900:-
STAD	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-3.91	0.000111	0.0351	-0.22	-0.21	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
STAD	cis	rs867371	0.762	rs1846910	ENSG00000276710.3	CSPG4P8	-3.91	0.000111	0.0351	-0.24	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82459472~82477258:+
STAD	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-3.91	0.000111	0.0351	-0.24	-0.21	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
STAD	cis	rs7927771	0.8	rs55876153	ENSG00000271350.1	CTD-2384B9.1	-3.91	0.000111	0.0351	-0.22	-0.21	Subjective well-being;	chr11:47395085	chr11:47041027~47041945:-
STAD	cis	rs11098499	0.604	rs17051352	ENSG00000260091.1	RP11-33B1.4	3.91	0.000111	0.0351	0.21	0.21	Corneal astigmatism;	chr4:119660272	chr4:119409333~119410233:+
STAD	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-3.91	0.000111	0.0351	-0.25	-0.21	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
STAD	cis	rs1707322	0.964	rs785508	ENSG00000225447.1	RPS15AP10	-3.91	0.000111	0.0351	-0.16	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45645816~45646197:-
STAD	cis	rs1707322	0.964	rs785509	ENSG00000225447.1	RPS15AP10	-3.91	0.000111	0.0351	-0.16	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45645816~45646197:-
STAD	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	3.91	0.000111	0.0351	0.25	0.21	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
STAD	cis	rs2337406	0.539	rs2583290	ENSG00000274576.2	IGHV2-70	3.91	0.000111	0.0351	0.24	0.21	Alzheimer's disease (late onset);	chr14:106650277	chr14:106770577~106771020:-
STAD	cis	rs10043228	0.609	rs79769112	ENSG00000248445.4	SEMA6A-AS1	-3.91	0.000111	0.0352	-0.29	-0.21	Asthma or chronic obstructive pulmonary disease;	chr5:116381519	chr5:116447547~116508276:+
STAD	cis	rs13224082	0.736	rs10487355	ENSG00000227199.1	ST7-AS1	-3.91	0.000111	0.0352	-0.28	-0.21	Platelet distribution width;	chr7:116906961	chr7:116952446~116954334:-
STAD	cis	rs10911902	0.643	rs78468398	ENSG00000229739.2	RP11-295K2.3	-3.91	0.000111	0.0352	-0.29	-0.21	Schizophrenia;	chr1:186315149	chr1:186435161~186470291:+
STAD	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-3.91	0.000111	0.0352	-0.24	-0.21	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
STAD	cis	rs1876905	0.569	rs354523	ENSG00000272356.1	RP5-1112D6.8	-3.91	0.000111	0.0352	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111309203~111313517:+
STAD	cis	rs1876905	0.68	rs187130	ENSG00000272356.1	RP5-1112D6.8	-3.91	0.000111	0.0352	-0.21	-0.21	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111309203~111313517:+
STAD	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	3.91	0.000111	0.0352	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	3.91	0.000111	0.0352	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	3.91	0.000111	0.0352	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
STAD	cis	rs2638953	0.853	rs11049668	ENSG00000247934.4	RP11-967K21.1	-3.91	0.000111	0.0352	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497680	chr12:28163298~28190738:-
STAD	cis	rs2803122	0.84	rs10757036	ENSG00000272842.1	RP11-513M16.7	-3.91	0.000111	0.0352	-0.19	-0.21	Pulse pressure;	chr9:19236127	chr9:19371386~19371945:-
STAD	cis	rs7829975	0.577	rs940032	ENSG00000254340.1	RP11-10A14.3	-3.91	0.000111	0.0352	-0.28	-0.21	Mood instability;	chr8:8688833	chr8:9141424~9145435:+
STAD	cis	rs10782582	0.569	rs74090722	ENSG00000181227.3	RP4-682C21.2	3.91	0.000111	0.0352	0.21	0.21	Daytime sleep phenotypes;	chr1:75731577	chr1:75743423~75744776:-
STAD	cis	rs4141404	0.818	rs5997897	ENSG00000236132.1	CTA-440B3.1	3.91	0.000111	0.0352	0.22	0.21	Paclitaxel-induced neuropathy;	chr22:31174450	chr22:31816379~31817491:-
STAD	cis	rs7523273	0.565	rs1359147	ENSG00000227887.1	RPS26P13	3.91	0.000111	0.0352	0.21	0.21	Schizophrenia;	chr1:207712805	chr1:208697369~208697698:-
STAD	cis	rs7523273	0.565	rs1998539	ENSG00000227887.1	RPS26P13	3.91	0.000111	0.0352	0.21	0.21	Schizophrenia;	chr1:207713251	chr1:208697369~208697698:-
STAD	cis	rs9326248	0.581	rs6589590	ENSG00000280143.1	AP000892.6	3.91	0.000111	0.0352	0.16	0.21	Blood protein levels;	chr11:117065365	chr11:117204967~117210292:+
STAD	cis	rs11971779	0.68	rs11764236	ENSG00000214815.2	AC008265.2	3.91	0.000111	0.0352	0.23	0.21	Diisocyanate-induced asthma;	chr7:139433768	chr7:138440690~138442238:+
STAD	cis	rs11971779	0.648	rs66463279	ENSG00000214815.2	AC008265.2	3.91	0.000111	0.0352	0.23	0.21	Diisocyanate-induced asthma;	chr7:139433915	chr7:138440690~138442238:+
STAD	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	3.91	0.000111	0.0352	0.28	0.21	Depression;	chr6:28110525	chr6:28115628~28116551:+
STAD	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-3.91	0.000111	0.0352	-0.22	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
STAD	cis	rs9467773	1	rs1321481	ENSG00000243307.2	POM121L6P	3.91	0.000111	0.0352	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs4713008	ENSG00000243307.2	POM121L6P	3.91	0.000111	0.0352	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.967	rs6932865	ENSG00000243307.2	POM121L6P	3.91	0.000111	0.0352	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26896952~26898777:+
STAD	cis	rs9467773	1	rs6933176	ENSG00000243307.2	POM121L6P	3.91	0.000111	0.0352	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26896952~26898777:+
STAD	cis	rs860295	0.776	rs11264362	ENSG00000225855.5	RUSC1-AS1	-3.91	0.000111	0.0352	-0.16	-0.21	Body mass index;	chr1:155345824	chr1:155316863~155324176:-
STAD	cis	rs860295	0.812	rs12131079	ENSG00000225855.5	RUSC1-AS1	-3.91	0.000111	0.0352	-0.16	-0.21	Body mass index;	chr1:155349877	chr1:155316863~155324176:-
STAD	cis	rs11157436	0.918	rs11157426	ENSG00000211813.2	TRAV34	3.91	0.000111	0.0352	0.23	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153691	chr14:22207522~22208129:+
STAD	cis	rs11157436	0.918	rs11157427	ENSG00000211813.2	TRAV34	3.91	0.000111	0.0352	0.23	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154291	chr14:22207522~22208129:+
STAD	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	3.91	0.000111	0.0352	0.2	0.21	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
STAD	cis	rs42490	0.664	rs43227	ENSG00000251136.7	RP11-37B2.1	-3.91	0.000111	0.0352	-0.2	-0.21	Leprosy;	chr8:89809351	chr8:89609409~89757727:-
STAD	cis	rs10946940	1	rs10946940	ENSG00000280107.1	AL022393.9	3.91	0.000111	0.0352	0.24	0.21	Systemic lupus erythematosus;	chr6:27592808	chr6:28170845~28172521:+
STAD	cis	rs6832769	0.925	rs3817444	ENSG00000223305.1	RN7SKP30	3.91	0.000112	0.0353	0.23	0.21	Personality dimensions;	chr4:55509814	chr4:55540502~55540835:-
STAD	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	3.91	0.000112	0.0353	0.33	0.21	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
STAD	cis	rs7937127	0.696	rs72898993	ENSG00000254907.1	RP11-484D2.2	3.91	0.000112	0.0353	0.35	0.21	Fibrinogen levels;	chr11:43352649	chr11:43328748~43359296:-
STAD	cis	rs9902453	0.874	rs3936006	ENSG00000263477.1	RP11-338L22.2	3.91	0.000112	0.0353	0.18	0.21	Coffee consumption (cups per day);	chr17:29930642	chr17:29863402~29866092:+
STAD	cis	rs9788721	0.836	rs17483548	ENSG00000259419.2	HNRNPCP3	3.91	0.000112	0.0353	0.24	0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78437971	chr15:79236332~79237206:+
STAD	cis	rs9788721	0.836	rs17405217	ENSG00000259419.2	HNRNPCP3	3.91	0.000112	0.0353	0.24	0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78438807	chr15:79236332~79237206:+
STAD	cis	rs34779708	0.733	rs12254018	ENSG00000271335.4	RP11-324I22.4	3.91	0.000112	0.0353	0.26	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35314552~35336401:-
STAD	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-3.91	0.000112	0.0353	-0.17	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
STAD	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-3.91	0.000112	0.0353	-0.32	-0.21	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
STAD	cis	rs9463078	0.683	rs911524	ENSG00000219384.1	RP11-491H9.3	-3.91	0.000112	0.0353	-0.2	-0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44779467	chr6:45158870~45159511:+
STAD	cis	rs4792901	0.759	rs75491854	ENSG00000279602.1	CTD-3014M21.1	-3.91	0.000112	0.0353	-0.28	-0.21	Dupuytren's disease;	chr17:43497282	chr17:43360041~43361361:-
STAD	cis	rs227932	0.681	rs7776862	ENSG00000234286.1	AC006026.13	3.91	0.000112	0.0353	0.36	0.21	Schizophrenia;	chr7:23736607	chr7:23680195~23680786:-
STAD	cis	rs7683537	0.501	rs2171838	ENSG00000249173.4	LINC01093	3.91	0.000112	0.0353	0.34	0.21	Systemic lupus erythematosus;	chr4:184746250	chr4:184893871~184899454:-
STAD	cis	rs6479891	1	rs9414800	ENSG00000235816.3	PRELID1P3	3.91	0.000112	0.0353	0.26	0.21	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63427297~63427939:+
STAD	cis	rs11702966	0.61	rs17654182	ENSG00000230634.1	RP5-996D20.3	3.91	0.000112	0.0353	0.37	0.21	Tonsillectomy;	chr22:45846479	chr22:46481329~46481760:-
STAD	cis	rs765787	0.53	rs4442750	ENSG00000259539.1	CTD-2651B20.1	3.91	0.000112	0.0353	0.24	0.21	Uric acid levels;	chr15:45243130	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4444275	ENSG00000259539.1	CTD-2651B20.1	3.91	0.000112	0.0353	0.24	0.21	Uric acid levels;	chr15:45243149	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4270107	ENSG00000259539.1	CTD-2651B20.1	3.91	0.000112	0.0353	0.24	0.21	Uric acid levels;	chr15:45243152	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4544188	ENSG00000259539.1	CTD-2651B20.1	3.91	0.000112	0.0353	0.24	0.21	Uric acid levels;	chr15:45243195	chr15:45152664~45167526:-
STAD	cis	rs7208859	0.725	rs9910051	ENSG00000263603.1	CTD-2349P21.5	-3.91	0.000112	0.0353	-0.25	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30729469~30731202:+
STAD	cis	rs6940638	0.662	rs6915678	ENSG00000216901.1	AL022393.7	3.91	0.000112	0.0353	0.2	0.21	Intelligence (multi-trait analysis);	chr6:27268087	chr6:28176188~28176674:+
STAD	cis	rs11098499	0.874	rs28452522	ENSG00000260091.1	RP11-33B1.4	3.91	0.000112	0.0353	0.21	0.21	Corneal astigmatism;	chr4:119189629	chr4:119409333~119410233:+
STAD	cis	rs4835473	0.932	rs1450235	ENSG00000249741.2	RP11-673E1.3	-3.91	0.000112	0.0353	-0.24	-0.21	Immature fraction of reticulocytes;	chr4:143782927	chr4:143911514~143912053:-
STAD	cis	rs6813195	0.554	rs1023962	ENSG00000243417.1	RP11-555K12.1	-3.91	0.000112	0.0353	-0.21	-0.21	Type 2 diabetes;	chr4:152530204	chr4:152551277~152552364:-
STAD	cis	rs6813195	0.514	rs1484879	ENSG00000243417.1	RP11-555K12.1	-3.91	0.000112	0.0353	-0.21	-0.21	Type 2 diabetes;	chr4:152534476	chr4:152551277~152552364:-
STAD	cis	rs61542988	0.57	rs7781074	ENSG00000228649.7	AC005682.5	-3.91	0.000112	0.0353	-0.27	-0.21	Fibrinogen levels;	chr7:22786741	chr7:22854178~22861579:+
STAD	cis	rs875971	0.83	rs427973	ENSG00000224316.1	RP11-479O9.2	3.91	0.000112	0.0354	0.21	0.21	Aortic root size;	chr7:66061661	chr7:65773620~65802067:+
STAD	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	3.91	0.000112	0.0354	0.17	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
STAD	cis	rs10500715	0.517	rs4576815	ENSG00000254554.1	RP11-351I24.1	3.91	0.000112	0.0354	0.31	0.21	Pancreatic cancer;	chr11:9965681	chr11:10302657~10303704:-
STAD	cis	rs10500715	0.517	rs2403229	ENSG00000254554.1	RP11-351I24.1	3.91	0.000112	0.0354	0.31	0.21	Pancreatic cancer;	chr11:9965704	chr11:10302657~10303704:-
STAD	cis	rs2880765	0.506	rs719138	ENSG00000229212.6	RP11-561C5.4	3.91	0.000112	0.0354	0.3	0.21	Coronary artery disease;	chr15:85511831	chr15:85205440~85234795:-
STAD	cis	rs3770081	1	rs17026729	ENSG00000273080.1	RP11-301O19.1	-3.91	0.000112	0.0354	-0.48	-0.21	Facial emotion recognition (sad faces);	chr2:85875055	chr2:86195590~86196049:+
STAD	cis	rs7829975	0.871	rs777709	ENSG00000233609.3	RP11-62H7.2	-3.91	0.000112	0.0354	-0.23	-0.21	Mood instability;	chr8:8726362	chr8:8961200~8979025:+
STAD	cis	rs883565	0.528	rs11716902	ENSG00000230683.1	DDTP1	3.91	0.000112	0.0354	0.2	0.21	Handedness;	chr3:38916519	chr3:38515448~38515830:-
STAD	cis	rs10129255	0.957	rs67625077	ENSG00000224373.3	IGHV4-59	3.91	0.000112	0.0354	0.17	0.21	Kawasaki disease;	chr14:106715436	chr14:106627249~106627825:-
STAD	cis	rs860295	0.812	rs7556519	ENSG00000225855.5	RUSC1-AS1	3.91	0.000112	0.0354	0.17	0.21	Body mass index;	chr1:155857755	chr1:155316863~155324176:-
STAD	cis	rs6693567	0.526	rs3818978	ENSG00000203819.6	HIST2H2BC	-3.91	0.000112	0.0354	-0.24	-0.21	Migraine;	chr1:150293918	chr1:149850193~149850772:-
STAD	cis	rs10073892	1	rs10213798	ENSG00000250682.4	LINC00491	-3.91	0.000112	0.0354	-0.23	-0.21	Cognitive decline (age-related);	chr5:102323978	chr5:102609156~102671559:-
STAD	cis	rs10073892	1	rs10066445	ENSG00000250682.4	LINC00491	-3.91	0.000112	0.0354	-0.23	-0.21	Cognitive decline (age-related);	chr5:102341625	chr5:102609156~102671559:-
STAD	cis	rs9307551	0.584	rs6819333	ENSG00000250334.4	LINC00989	-3.91	0.000112	0.0354	-0.25	-0.21	Refractive error;	chr4:79540995	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.584	rs2867671	ENSG00000250334.4	LINC00989	-3.91	0.000112	0.0354	-0.25	-0.21	Refractive error;	chr4:79542000	chr4:79492416~79576460:+
STAD	cis	rs9307551	0.584	rs6534429	ENSG00000250334.4	LINC00989	-3.91	0.000112	0.0354	-0.25	-0.21	Refractive error;	chr4:79543006	chr4:79492416~79576460:+
STAD	cis	rs7915414	0.951	rs12772169	ENSG00000230338.1	MTND4P19	3.91	0.000112	0.0354	0.23	0.21	Clopidogrel active metabolite levels;	chr10:94645572	chr10:94774156~94774633:-
STAD	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	3.91	0.000112	0.0354	0.16	0.21	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
STAD	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	3.91	0.000112	0.0354	0.31	0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
STAD	cis	rs4869931	0.929	rs6908127	ENSG00000218358.2	RAET1K	-3.91	0.000112	0.0354	-0.32	-0.21	Systolic blood pressure in sickle cell anemia;	chr6:150682621	chr6:149998019~150005157:-
STAD	cis	rs11157436	0.602	rs11157435	ENSG00000211813.2	TRAV34	3.91	0.000112	0.0354	0.23	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22207522~22208129:+
STAD	cis	rs6430585	0.591	rs75223002	ENSG00000231890.6	DARS-AS1	-3.91	0.000112	0.0354	-0.24	-0.21	Corneal structure;	chr2:135767739	chr2:135985176~136022593:+
STAD	cis	rs6180	1	rs1593071	ENSG00000250860.1	CTD-2265D6.2	3.91	0.000112	0.0354	0.17	0.21	Height;	chr5:42786207	chr5:42466893~42468300:-
STAD	cis	rs1876905	0.597	rs354551	ENSG00000271789.1	RP5-1112D6.7	-3.91	0.000112	0.0354	-0.25	-0.21	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111297126~111298510:+
STAD	cis	rs9463078	0.669	rs7750380	ENSG00000219384.1	RP11-491H9.3	3.91	0.000112	0.0354	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45102297	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.617	rs1359336	ENSG00000219384.1	RP11-491H9.3	3.91	0.000112	0.0354	0.2	0.21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45104137	chr6:45158870~45159511:+
STAD	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000112	0.0354	-0.25	-0.21	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000112	0.0354	-0.25	-0.21	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
STAD	cis	rs8141529	0.748	rs5762881	ENSG00000226471.5	CTA-292E10.6	-3.91	0.000112	0.0354	-0.24	-0.21	Lymphocyte counts;	chr22:28893358	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.748	rs9620841	ENSG00000226471.5	CTA-292E10.6	-3.91	0.000112	0.0354	-0.24	-0.21	Lymphocyte counts;	chr22:28894993	chr22:28800683~28848559:+
STAD	cis	rs4407350	1	rs5765725	ENSG00000279642.1	RP5-1033E15.3	-3.91	0.000112	0.0354	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44525826	chr22:44486295~44486914:-
STAD	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	3.91	0.000112	0.0354	0.31	0.21	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
STAD	cis	rs4792901	0.802	rs56357945	ENSG00000279602.1	CTD-3014M21.1	-3.91	0.000112	0.0354	-0.28	-0.21	Dupuytren's disease;	chr17:43536323	chr17:43360041~43361361:-
STAD	cis	rs7142881	0.815	rs4981868	ENSG00000258648.1	UBE2CP1	-3.91	0.000112	0.0354	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31627177	chr14:30683045~30683598:-
STAD	cis	rs6479891	0.908	rs61853639	ENSG00000235816.3	PRELID1P3	3.91	0.000112	0.0354	0.28	0.21	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63427297~63427939:+
STAD	cis	rs786425	0.835	rs7966867	ENSG00000247373.3	RP11-486O12.2	3.91	0.000112	0.0354	0.15	0.21	Pubertal anthropometrics;	chr12:123694870	chr12:123575891~123585115:-
STAD	cis	rs6095298	0.595	rs34280360	ENSG00000227431.4	CSE1L-AS1	-3.91	0.000112	0.0355	-0.22	-0.21	Intelligence (multi-trait analysis);	chr20:48837634	chr20:49040463~49046044:-
STAD	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-3.91	0.000112	0.0355	-0.22	-0.21	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
STAD	cis	rs1876905	0.68	rs1150082	ENSG00000272356.1	RP5-1112D6.8	-3.91	0.000112	0.0355	-0.2	-0.21	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111309203~111313517:+
STAD	cis	rs2337406	0.714	rs7152055	ENSG00000211972.2	IGHV3-66	3.91	0.000112	0.0355	0.22	0.21	Alzheimer's disease (late onset);	chr14:106818996	chr14:106675017~106675544:-
STAD	cis	rs34421088	0.624	rs6986736	ENSG00000227888.4	FAM66A	-3.91	0.000112	0.0355	-0.22	-0.21	Neuroticism;	chr8:11726994	chr8:12362019~12388296:+
STAD	cis	rs1858037	0.867	rs2118305	ENSG00000223739.1	AC007389.2	-3.91	0.000112	0.0355	-0.19	-0.21	Rheumatoid arthritis;	chr2:65378086	chr2:65511771~65512076:-
STAD	cis	rs9419788	0.708	rs4477375	ENSG00000227995.1	RAB11AP1	-3.91	0.000112	0.0355	-0.24	-0.21	Personality traits in bipolar disorder;	chr10:94223553	chr10:93881293~93881938:-
STAD	cis	rs14027	0.883	rs28486074	ENSG00000279347.1	RP11-85I17.2	-3.91	0.000112	0.0355	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119838736~119840385:-
STAD	cis	rs14027	0.842	rs28634937	ENSG00000279347.1	RP11-85I17.2	-3.91	0.000112	0.0355	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119838736~119840385:-
STAD	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-3.91	0.000112	0.0355	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
STAD	cis	rs2880765	0.835	rs4514633	ENSG00000259295.5	CSPG4P12	3.91	0.000112	0.0355	0.25	0.21	Coronary artery disease;	chr15:85497786	chr15:85191438~85213905:+
STAD	cis	rs7142881	0.779	rs10135539	ENSG00000258648.1	UBE2CP1	3.91	0.000112	0.0355	0.22	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31585305	chr14:30683045~30683598:-
STAD	cis	rs4691139	0.903	rs10434177	ENSG00000248632.1	RP11-366M4.11	3.91	0.000112	0.0355	0.25	0.21	Ovarian cancer in BRCA1 mutation carriers;	chr4:164994379	chr4:164968587~164970002:-
STAD	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-3.91	0.000112	0.0355	-0.21	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
STAD	cis	rs62090893	0.656	rs2581655	ENSG00000264247.1	LINC00909	-3.91	0.000112	0.0355	-0.36	-0.21	Anorexia nervosa;	chr18:75311188	chr18:74591774~74598508:-
STAD	cis	rs9291683	0.61	rs993172	ENSG00000250613.1	RP11-136I13.1	-3.91	0.000112	0.0355	-0.2	-0.21	Bone mineral density;	chr4:10322737	chr4:10410996~10411644:+
STAD	cis	rs8141529	0.748	rs1318026	ENSG00000272858.1	CTA-292E10.8	-3.91	0.000112	0.0355	-0.22	-0.21	Lymphocyte counts;	chr22:28887530	chr22:28814914~28815662:+
STAD	cis	rs73108077	1	rs73108077	ENSG00000277692.1	RP11-358N2.2	-3.91	0.000112	0.0355	-0.32	-0.21	Red blood cell density in sickle cell anemia;	chr20:31419056	chr20:32355053~32355734:+
STAD	cis	rs77988765	0.908	rs7127673	ENSG00000248844.5	RP11-626H12.3	-3.91	0.000112	0.0355	-0.38	-0.21	Post bronchodilator FEV1/FVC ratio;	chr11:70168372	chr11:70056230~70065371:-
STAD	cis	rs2404602	0.735	rs2436996	ENSG00000196274.5	Metazoa_SRP	-3.91	0.000113	0.0355	-0.18	-0.21	Blood metabolite levels;	chr15:76525079	chr15:76230048~76230390:-
STAD	cis	rs1023500	1	rs1023497	ENSG00000205702.9	CYP2D7	-3.91	0.000113	0.0355	-0.24	-0.21	Schizophrenia;	chr22:41944504	chr22:42140203~42144577:-
STAD	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-3.91	0.000113	0.0355	-0.26	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
STAD	cis	rs77861329	1	rs893056	ENSG00000270941.1	RP5-966M1.5	3.91	0.000113	0.0355	0.41	0.21	Macrophage inflammatory protein 1b levels;	chr3:52075548	chr3:52734735~52735013:+
STAD	cis	rs7142881	0.844	rs6571433	ENSG00000258648.1	UBE2CP1	3.91	0.000113	0.0355	0.23	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31567138	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.844	rs6571434	ENSG00000258648.1	UBE2CP1	3.91	0.000113	0.0355	0.23	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31567139	chr14:30683045~30683598:-
STAD	cis	rs7927771	0.864	rs3781626	ENSG00000271350.1	CTD-2384B9.1	-3.91	0.000113	0.0355	-0.23	-0.21	Subjective well-being;	chr11:47421342	chr11:47041027~47041945:-
STAD	cis	rs4792901	0.802	rs9901586	ENSG00000279602.1	CTD-3014M21.1	-3.91	0.000113	0.0355	-0.28	-0.21	Dupuytren's disease;	chr17:43503523	chr17:43360041~43361361:-
STAD	cis	rs1075265	0.756	rs3821081	ENSG00000235937.1	AC008280.1	-3.91	0.000113	0.0355	-0.19	-0.21	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54029552~54030682:-
STAD	cis	rs6686842	0.536	rs17358157	ENSG00000235358.1	RP11-399E6.1	-3.91	0.000113	0.0355	-0.23	-0.21	Height;	chr1:41233850	chr1:41242373~41284861:+
STAD	cis	rs7428	0.527	rs6547612	ENSG00000246575.2	AC093162.5	3.91	0.000113	0.0355	0.22	0.21	Ear protrusion;	chr2:85324061	chr2:85315041~85316529:+
STAD	cis	rs4835473	0.932	rs1849115	ENSG00000249741.2	RP11-673E1.3	-3.91	0.000113	0.0356	-0.23	-0.21	Immature fraction of reticulocytes;	chr4:143989687	chr4:143911514~143912053:-
STAD	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-3.91	0.000113	0.0356	-0.33	-0.21	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
STAD	cis	rs7926906	0.715	rs7127256	ENSG00000280367.1	RP11-121L10.2	-3.91	0.000113	0.0356	-0.21	-0.21	Intelligence (multi-trait analysis);	chr11:90792322	chr11:90223153~90226538:+
STAD	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	3.91	0.000113	0.0356	0.21	0.21	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
STAD	cis	rs7829975	0.777	rs560544	ENSG00000173295.6	FAM86B3P	-3.91	0.000113	0.0356	-0.24	-0.21	Mood instability;	chr8:8779919	chr8:8228595~8244865:+
STAD	cis	rs9902453	0.765	rs3102555	ENSG00000263477.1	RP11-338L22.2	3.91	0.000113	0.0356	0.17	0.21	Coffee consumption (cups per day);	chr17:29717083	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.791	rs3115100	ENSG00000263477.1	RP11-338L22.2	3.91	0.000113	0.0356	0.17	0.21	Coffee consumption (cups per day);	chr17:29718726	chr17:29863402~29866092:+
STAD	cis	rs60180747	0.909	rs78136741	ENSG00000252712.1	SCARNA14	3.91	0.000113	0.0356	0.25	0.21	Testicular germ cell tumor;	chr15:66435972	chr15:66347207~66347342:-
STAD	cis	rs10129255	0.5	rs7157975	ENSG00000232216.1	IGHV3-43	3.91	0.000113	0.0356	0.18	0.21	Kawasaki disease;	chr14:106804049	chr14:106470264~106470800:-
STAD	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-3.91	0.000113	0.0356	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-3.91	0.000113	0.0356	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-3.91	0.000113	0.0356	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
STAD	cis	rs17301013	0.531	rs1653634	ENSG00000227373.4	RP11-160H22.5	-3.91	0.000113	0.0356	-0.29	-0.21	Systemic lupus erythematosus;	chr1:174783348	chr1:174115300~174160004:-
STAD	cis	rs679711	0.565	rs619279	ENSG00000214380.4	RP11-457K10.2	3.91	0.000113	0.0356	0.24	0.21	Sleep depth;	chr3:109917568	chr3:109915976~109916940:-
STAD	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	3.91	0.000113	0.0356	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
STAD	cis	rs1858037	0.867	rs876933	ENSG00000223739.1	AC007389.2	-3.91	0.000113	0.0356	-0.19	-0.21	Rheumatoid arthritis;	chr2:65382303	chr2:65511771~65512076:-
STAD	cis	rs1707322	0.896	rs809774	ENSG00000225447.1	RPS15AP10	-3.91	0.000113	0.0357	-0.16	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45645816~45646197:-
STAD	cis	rs11012350	0.85	rs60946168	ENSG00000240291.1	RP11-499P20.2	-3.91	0.000113	0.0357	-0.3	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18016315	chr10:18513115~18545651:-
STAD	cis	rs4834770	1	rs878374	ENSG00000250412.1	KLHL2P1	3.91	0.000113	0.0357	0.26	0.21	Blood protein levels;	chr4:119316409	chr4:119334329~119378233:+
STAD	cis	rs997295	0.513	rs11635495	ENSG00000270964.1	RP11-502I4.3	-3.91	0.000113	0.0357	-0.25	-0.21	Motion sickness;	chr15:67512344	chr15:67541072~67542604:-
STAD	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-3.91	0.000113	0.0357	-0.26	-0.21	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
STAD	cis	rs2278796	0.639	rs4951153	ENSG00000231691.1	RP11-203F10.5	-3.91	0.000113	0.0357	-0.27	-0.21	Mean platelet volume;	chr1:205001716	chr1:204277005~204277948:+
STAD	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	3.91	0.000113	0.0357	0.23	0.21	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
STAD	cis	rs4845875	0.557	rs4846054	ENSG00000242349.4	NPPA-AS1	3.91	0.000113	0.0357	0.21	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11809173	chr1:11841017~11848079:+
STAD	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-3.91	0.000113	0.0357	-0.22	-0.21	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
STAD	cis	rs7520050	0.966	rs1085243	ENSG00000280836.1	AL355480.1	3.91	0.000113	0.0357	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45581219~45581321:-
STAD	cis	rs73198271	0.813	rs56007835	ENSG00000254340.1	RP11-10A14.3	-3.9	0.000113	0.0357	-0.3	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:9141424~9145435:+
STAD	cis	rs7474896	0.507	rs2474555	ENSG00000228882.1	CICP9	3.9	0.000113	0.0357	0.26	0.21	Obesity (extreme);	chr10:38176292	chr10:38452987~38455365:-
STAD	cis	rs73198271	0.765	rs534103	ENSG00000254340.1	RP11-10A14.3	-3.9	0.000113	0.0357	-0.27	-0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:9141424~9145435:+
STAD	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-3.9	0.000113	0.0357	-0.27	-0.21	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
STAD	cis	rs7916697	0.52	rs10762201	ENSG00000234102.1	KRT19P4	3.9	0.000113	0.0358	0.22	0.21	Optic disc area;	chr10:68280354	chr10:68260557~68261499:+
STAD	cis	rs12682352	0.602	rs1473029	ENSG00000173295.6	FAM86B3P	3.9	0.000113	0.0358	0.24	0.21	Neuroticism;	chr8:8811407	chr8:8228595~8244865:+
STAD	cis	rs10911902	0.643	rs16825335	ENSG00000229739.2	RP11-295K2.3	-3.9	0.000113	0.0358	-0.3	-0.21	Schizophrenia;	chr1:186418612	chr1:186435161~186470291:+
STAD	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-3.9	0.000113	0.0358	-0.2	-0.21	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
STAD	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-3.9	0.000113	0.0358	-0.2	-0.21	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
STAD	cis	rs7924176	0.601	rs7896660	ENSG00000213731.2	RAB5CP1	-3.9	0.000113	0.0358	-0.21	-0.21	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74423435~74424014:-
STAD	cis	rs875971	0.862	rs10276077	ENSG00000224316.1	RP11-479O9.2	-3.9	0.000113	0.0358	-0.2	-0.21	Aortic root size;	chr7:66263424	chr7:65773620~65802067:+
STAD	cis	rs8014252	0.803	rs60120955	ENSG00000259158.2	ADAM20P1	-3.9	0.000114	0.0358	-0.28	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595016	chr14:70468881~70483756:-
STAD	cis	rs8014252	0.803	rs17113651	ENSG00000259158.2	ADAM20P1	-3.9	0.000114	0.0358	-0.28	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595119	chr14:70468881~70483756:-
STAD	cis	rs4784934	0.879	rs9931547	ENSG00000260186.4	RP11-481J2.2	3.9	0.000114	0.0358	0.24	0.21	QT interval;	chr16:58432203	chr16:58421326~58462470:+
STAD	cis	rs7786877	0.508	rs11765509	ENSG00000236305.1	RP11-126L15.4	3.9	0.000114	0.0358	0.26	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100713367	chr7:100837314~100852616:-
STAD	cis	rs6539247	0.509	rs2374584	ENSG00000257890.1	RP11-114F10.2	-3.9	0.000114	0.0358	-0.2	-0.21	Attention function in attention deficit hyperactive disorder;	chr12:106052210	chr12:106050961~106058254:-
STAD	cis	rs1816752	1	rs9511265	ENSG00000232858.1	RPL34P27	3.9	0.000114	0.0358	0.13	0.21	Obesity-related traits;	chr13:24438221	chr13:24988577~24988925:-
STAD	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-3.9	0.000114	0.0358	-0.25	-0.21	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
STAD	cis	rs875971	0.502	rs2465121	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000114	0.0358	-0.19	-0.21	Aortic root size;	chr7:66156017	chr7:66902857~66906297:+
STAD	cis	rs11846409	0.86	rs59055020	ENSG00000274576.2	IGHV2-70	-3.9	0.000114	0.0358	-0.24	-0.21	Rheumatic heart disease;	chr14:106631573	chr14:106770577~106771020:-
STAD	cis	rs304029	0.553	rs304093	ENSG00000229241.1	PNPT1P1	-3.9	0.000114	0.0358	-0.25	-0.21	Diabetic kidney disease;	chr3:4476219	chr3:3981981~3984295:-
STAD	cis	rs6832769	1	rs1522111	ENSG00000223305.1	RN7SKP30	3.9	0.000114	0.0358	0.23	0.21	Personality dimensions;	chr4:55463396	chr4:55540502~55540835:-
STAD	cis	rs9326248	0.581	rs4938331	ENSG00000280143.1	AP000892.6	3.9	0.000114	0.0358	0.16	0.21	Blood protein levels;	chr11:117059966	chr11:117204967~117210292:+
STAD	cis	rs9326248	0.51	rs4938332	ENSG00000280143.1	AP000892.6	3.9	0.000114	0.0358	0.16	0.21	Blood protein levels;	chr11:117060082	chr11:117204967~117210292:+
STAD	cis	rs9326248	0.559	rs4938334	ENSG00000280143.1	AP000892.6	3.9	0.000114	0.0358	0.16	0.21	Blood protein levels;	chr11:117060326	chr11:117204967~117210292:+
STAD	cis	rs7615952	0.546	rs2922194	ENSG00000171084.14	FAM86JP	3.9	0.000114	0.0358	0.34	0.21	Blood pressure (smoking interaction);	chr3:125613419	chr3:125916620~125930024:+
STAD	cis	rs12745968	0.653	rs11164791	ENSG00000229052.2	RP11-386I23.1	-3.9	0.000114	0.0358	-0.2	-0.21	Bipolar disorder and schizophrenia;	chr1:92654077	chr1:92930696~92934098:+
STAD	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-3.9	0.000114	0.0358	-0.21	-0.21	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
STAD	cis	rs494453	0.922	rs2473843	ENSG00000234020.1	CHIAP3	-3.9	0.000114	0.0359	-0.2	-0.21	Osteoporosis-related phenotypes;	chr1:111698035	chr1:111353275~111367409:-
STAD	cis	rs494453	0.845	rs2477427	ENSG00000234020.1	CHIAP3	-3.9	0.000114	0.0359	-0.2	-0.21	Osteoporosis-related phenotypes;	chr1:111698072	chr1:111353275~111367409:-
STAD	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	3.9	0.000114	0.0359	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
STAD	cis	rs11089937	0.597	rs5750579	ENSG00000211640.3	IGLV6-57	3.9	0.000114	0.0359	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.597	rs11089925	ENSG00000211640.3	IGLV6-57	3.9	0.000114	0.0359	0.15	0.21	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22195713~22196460:+
STAD	cis	rs4561483	0.831	rs2018199	ENSG00000260224.1	UBL5P4	3.9	0.000114	0.0359	0.21	0.21	Testicular germ cell tumor;	chr16:11847111	chr16:11968508~11968743:-
STAD	cis	rs2579500	0.538	rs17634791	ENSG00000230606.9	AC159540.1	3.9	0.000114	0.0359	0.23	0.21	Eosinophil percentage of white cells;Eosinophil counts;	chr2:96663115	chr2:97416165~97433527:-
STAD	cis	rs2638953	0.853	rs11049657	ENSG00000247934.4	RP11-967K21.1	-3.9	0.000114	0.0359	-0.23	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481746	chr12:28163298~28190738:-
STAD	cis	rs6432860	0.897	rs12993279	ENSG00000229195.1	AC009495.4	3.9	0.000114	0.0359	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:165981328	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.527	rs62177814	ENSG00000229195.1	AC009495.4	-3.9	0.000114	0.0359	-0.24	-0.21	Diabetic kidney disease;	chr2:165922482	chr2:165794857~165846091:-
STAD	cis	rs7209700	0.547	rs11657517	ENSG00000228782.6	CTD-2026D20.3	-3.9	0.000114	0.0359	-0.23	-0.21	IgG glycosylation;	chr17:47266347	chr17:47450568~47492492:-
STAD	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-3.9	0.000114	0.0359	-0.23	-0.21	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
STAD	cis	rs4407350	0.967	rs5765741	ENSG00000279642.1	RP5-1033E15.3	-3.9	0.000114	0.0359	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44528412	chr22:44486295~44486914:-
STAD	cis	rs953387	1	rs4954392	ENSG00000231890.6	DARS-AS1	-3.9	0.000114	0.0359	-0.21	-0.21	Arthritis (juvenile idiopathic);	chr2:136144037	chr2:135985176~136022593:+
STAD	cis	rs6693567	0.565	rs7513182	ENSG00000203819.6	HIST2H2BC	-3.9	0.000114	0.0359	-0.24	-0.21	Migraine;	chr1:150470136	chr1:149850193~149850772:-
STAD	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-3.9	0.000114	0.0359	-0.24	-0.21	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
STAD	cis	rs748404	0.56	rs1869258	ENSG00000275601.1	AC011330.13	-3.9	0.000114	0.0359	-0.22	-0.21	Lung cancer;	chr15:43511423	chr15:43642389~43643023:-
STAD	cis	rs7202877	0.611	rs56092808	ENSG00000261783.1	RP11-252K23.2	-3.9	0.000114	0.0359	-0.35	-0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75278818	chr16:75379818~75381260:-
STAD	cis	rs1007190	0.881	rs9900293	ENSG00000267405.1	CTC-296K1.4	3.9	0.000114	0.0359	0.24	0.21	DNA methylation (variation);	chr17:44858635	chr17:44794747~44797783:-
STAD	cis	rs8062405	0.755	rs62034325	ENSG00000278665.1	RP11-666O2.4	3.9	0.000114	0.0359	0.24	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28599241~28601881:-
STAD	cis	rs172166	0.637	rs1225592	ENSG00000280107.1	AL022393.9	-3.9	0.000114	0.0359	-0.26	-0.21	Cardiac Troponin-T levels;	chr6:28182464	chr6:28170845~28172521:+
STAD	cis	rs172166	0.637	rs1225595	ENSG00000280107.1	AL022393.9	-3.9	0.000114	0.0359	-0.26	-0.21	Cardiac Troponin-T levels;	chr6:28183562	chr6:28170845~28172521:+
STAD	cis	rs4747011	0.57	rs10999284	ENSG00000273530.1	AC016821.2	3.9	0.000114	0.0359	0.44	0.21	Brain connectivity;	chr10:70348179	chr10:69458672~69458738:+
STAD	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-3.9	0.000114	0.036	-0.25	-0.21	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
STAD	cis	rs10129255	0.912	rs35468694	ENSG00000224373.3	IGHV4-59	3.9	0.000114	0.036	0.17	0.21	Kawasaki disease;	chr14:106784199	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.957	rs8019272	ENSG00000224373.3	IGHV4-59	3.9	0.000114	0.036	0.17	0.21	Kawasaki disease;	chr14:106784709	chr14:106627249~106627825:-
STAD	cis	rs4273100	0.526	rs2074280	ENSG00000262319.1	CTC-457L16.2	-3.9	0.000114	0.036	-0.24	-0.21	Schizophrenia;	chr17:19014602	chr17:19141017~19143689:-
STAD	cis	rs12682352	0.602	rs13260419	ENSG00000253981.4	ALG1L13P	3.9	0.000114	0.036	0.26	0.21	Neuroticism;	chr8:8817666	chr8:8236003~8244667:-
STAD	cis	rs8020095	0.571	rs8003929	ENSG00000196553.12	LINC00238	-3.9	0.000114	0.036	-0.27	-0.21	Depression (quantitative trait);	chr14:67066556	chr14:66486354~66498553:+
STAD	cis	rs6095298	0.574	rs6012544	ENSG00000227431.4	CSE1L-AS1	-3.9	0.000114	0.036	-0.23	-0.21	Intelligence (multi-trait analysis);	chr20:48872270	chr20:49040463~49046044:-
STAD	cis	rs416603	0.967	rs11644184	ENSG00000262703.1	RP11-485G7.6	-3.9	0.000114	0.036	-0.19	-0.21	Type 1 diabetes;	chr16:11271247	chr16:11348143~11349321:-
STAD	cis	rs2310173	0.575	rs757918	ENSG00000281162.1	LINC01127	-3.9	0.000114	0.036	-0.27	-0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101996837	chr2:101962056~101987167:+
STAD	cis	rs17818399	0.815	rs62136873	ENSG00000279254.1	RP11-536C12.1	-3.9	0.000114	0.036	-0.21	-0.21	Height;	chr2:46634098	chr2:46668870~46670778:+
STAD	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	3.9	0.000114	0.036	0.31	0.21	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	3.9	0.000114	0.036	0.31	0.21	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	3.9	0.000114	0.036	0.31	0.21	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	3.9	0.000114	0.036	0.31	0.21	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	3.9	0.000114	0.036	0.31	0.21	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	3.9	0.000114	0.036	0.31	0.21	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
STAD	cis	rs4965006	0.915	rs7969545	ENSG00000255933.1	RP11-495K9.5	-3.9	0.000115	0.036	-0.21	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934612	chr12:131756966~131758047:-
STAD	cis	rs11662586	1	rs11662586	ENSG00000274828.1	RP11-567M16.6	3.9	0.000115	0.036	0.3	0.21	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79956171	chr18:79677287~79679358:-
STAD	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	3.9	0.000115	0.0361	0.28	0.21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
STAD	cis	rs9733	0.596	rs7412396	ENSG00000276103.1	U4	3.9	0.000115	0.0361	0.2	0.21	Tonsillectomy;	chr1:150694321	chr1:150608507~150608623:-
STAD	cis	rs13421350	0.579	rs16860513	ENSG00000232788.1	AC078883.3	3.9	0.000115	0.0361	0.36	0.21	Diabetic kidney disease;	chr2:172477639	chr2:172464262~172466022:-
STAD	cis	rs4631830	0.54	rs2843562	ENSG00000264204.2	AGAP7P	-3.9	0.000115	0.0361	-0.26	-0.21	Prostate-specific antigen levels;	chr10:46099026	chr10:46109621~46131358:+
STAD	cis	rs1322639	0.614	rs6908401	ENSG00000261039.2	RP11-417E7.2	3.9	0.000115	0.0361	0.31	0.21	Pulse pressure;	chr6:169164621	chr6:169175304~169182740:-
STAD	cis	rs10129255	1	rs11621409	ENSG00000224373.3	IGHV4-59	3.9	0.000115	0.0361	0.17	0.21	Kawasaki disease;	chr14:106695603	chr14:106627249~106627825:-
STAD	cis	rs1790761	0.587	rs4930431	ENSG00000231793.4	DOC2GP	-3.9	0.000115	0.0361	-0.24	-0.21	Mean corpuscular volume;	chr11:67526837	chr11:67612653~67616257:-
STAD	cis	rs9902453	0.765	rs1531553	ENSG00000263477.1	RP11-338L22.2	-3.9	0.000115	0.0361	-0.17	-0.21	Coffee consumption (cups per day);	chr17:29739734	chr17:29863402~29866092:+
STAD	cis	rs1322639	0.614	rs6925188	ENSG00000261039.2	RP11-417E7.2	-3.9	0.000115	0.0361	-0.32	-0.21	Pulse pressure;	chr6:169163242	chr6:169175304~169182740:-
STAD	cis	rs8014252	0.803	rs12587714	ENSG00000259158.2	ADAM20P1	-3.9	0.000115	0.0361	-0.27	-0.21	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70537659	chr14:70468881~70483756:-
STAD	cis	rs9420	0.809	rs11600169	ENSG00000265566.2	RN7SL605P	-3.9	0.000115	0.0361	-0.29	-0.21	Schizophrenia;	chr11:57697473	chr11:57528085~57528365:-
STAD	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-3.9	0.000115	0.0361	-0.28	-0.21	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
STAD	cis	rs1318937	1	rs3773471	ENSG00000224660.1	SH3BP5-AS1	-3.9	0.000115	0.0361	-0.19	-0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15261540	chr3:15254184~15264493:+
STAD	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	3.9	0.000115	0.0361	0.27	0.21	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
STAD	cis	rs17507216	0.628	rs28737193	ENSG00000255769.6	GOLGA2P10	-3.9	0.000115	0.0361	-0.32	-0.21	Excessive daytime sleepiness;	chr15:82701318	chr15:82472993~82513950:-
STAD	cis	rs4237845	0.537	rs2002275	ENSG00000273805.1	RP11-620J15.4	-3.9	0.000115	0.0361	-0.23	-0.21	Intelligence (multi-trait analysis);	chr12:57889602	chr12:57894232~57896846:+
STAD	cis	rs794185	0.625	rs2046709	ENSG00000231249.1	ITPR1-AS1	3.9	0.000115	0.0361	0.24	0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4474687	chr3:4490891~4493163:-
STAD	cis	rs10510181	0.637	rs73011300	ENSG00000224318.4	CHL1-AS2	3.9	0.000115	0.0361	0.22	0.21	Adolescent idiopathic scoliosis;	chr3:69300	chr3:195758~197341:-
STAD	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	3.9	0.000115	0.0361	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
STAD	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	3.9	0.000115	0.0361	0.29	0.21	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
STAD	cis	rs870825	0.616	rs4444873	ENSG00000249173.4	LINC01093	-3.9	0.000115	0.0361	-0.33	-0.21	Blood protein levels;	chr4:184707252	chr4:184893871~184899454:-
STAD	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	3.9	0.000115	0.0361	0.26	0.21	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	3.9	0.000115	0.0361	0.26	0.21	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	3.9	0.000115	0.0361	0.26	0.21	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
STAD	cis	rs11089937	0.568	rs12159174	ENSG00000211638.2	IGLV8-61	-3.9	0.000115	0.0362	-0.22	-0.21	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22098700~22099212:+
STAD	cis	rs11089937	0.568	rs11089919	ENSG00000211638.2	IGLV8-61	-3.9	0.000115	0.0362	-0.22	-0.21	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22098700~22099212:+
STAD	cis	rs7829975	0.577	rs17684466	ENSG00000253981.4	ALG1L13P	-3.9	0.000115	0.0362	-0.28	-0.21	Mood instability;	chr8:8687723	chr8:8236003~8244667:-
STAD	cis	rs11846409	0.521	rs10143547	ENSG00000274576.2	IGHV2-70	-3.9	0.000115	0.0362	-0.25	-0.21	Rheumatic heart disease;	chr14:106644638	chr14:106770577~106771020:-
STAD	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	3.9	0.000115	0.0362	0.2	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
STAD	cis	rs2273156	0.929	rs34678475	ENSG00000258704.4	SRP54-AS1	-3.9	0.000115	0.0362	-0.23	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34981897	chr14:34920858~34982532:-
STAD	cis	rs2273156	1	rs12890307	ENSG00000258704.4	SRP54-AS1	-3.9	0.000115	0.0362	-0.23	-0.21	Immunoglobulin light chain (AL) amyloidosis;	chr14:34982926	chr14:34920858~34982532:-
STAD	cis	rs11098499	0.874	rs17839089	ENSG00000260091.1	RP11-33B1.4	3.9	0.000115	0.0362	0.2	0.21	Corneal astigmatism;	chr4:119189914	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.874	rs6826823	ENSG00000260091.1	RP11-33B1.4	3.9	0.000115	0.0362	0.2	0.21	Corneal astigmatism;	chr4:119190943	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.874	rs12509054	ENSG00000260091.1	RP11-33B1.4	3.9	0.000115	0.0362	0.2	0.21	Corneal astigmatism;	chr4:119193920	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.874	rs10022508	ENSG00000260091.1	RP11-33B1.4	3.9	0.000115	0.0362	0.2	0.21	Corneal astigmatism;	chr4:119194073	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.874	rs12502503	ENSG00000260091.1	RP11-33B1.4	3.9	0.000115	0.0362	0.2	0.21	Corneal astigmatism;	chr4:119195100	chr4:119409333~119410233:+
STAD	cis	rs7142881	0.815	rs12881020	ENSG00000258648.1	UBE2CP1	-3.9	0.000115	0.0362	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31645753	chr14:30683045~30683598:-
STAD	cis	rs794185	0.653	rs2819586	ENSG00000231249.1	ITPR1-AS1	-3.9	0.000115	0.0362	-0.23	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470108	chr3:4490891~4493163:-
STAD	cis	rs679711	0.634	rs1164211	ENSG00000214380.4	RP11-457K10.2	3.9	0.000115	0.0362	0.24	0.21	Sleep depth;	chr3:109898404	chr3:109915976~109916940:-
STAD	cis	rs679711	0.634	rs1164210	ENSG00000214380.4	RP11-457K10.2	3.9	0.000115	0.0362	0.24	0.21	Sleep depth;	chr3:109898443	chr3:109915976~109916940:-
STAD	cis	rs42490	0.638	rs40637	ENSG00000251136.7	RP11-37B2.1	-3.9	0.000115	0.0362	-0.2	-0.21	Leprosy;	chr8:89811082	chr8:89609409~89757727:-
STAD	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-3.9	0.000115	0.0362	-0.22	-0.21	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
STAD	cis	rs11233413	0.508	rs7947780	ENSG00000246067.6	RAB30-AS1	-3.9	0.000115	0.0362	-0.2	-0.21	Economic and political preferences (feminism/equality);	chr11:82932718	chr11:83072066~83106719:+
STAD	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-3.9	0.000115	0.0362	-0.26	-0.21	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
STAD	cis	rs13253998	0.56	rs1399610	ENSG00000253952.1	HIGD1AP18	-3.9	0.000115	0.0362	-0.21	-0.21	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr8:77409706	chr8:77013751~77014028:-
STAD	cis	rs7142881	0.844	rs12432746	ENSG00000258648.1	UBE2CP1	-3.9	0.000115	0.0362	-0.22	-0.21	Response to iloperidone treatment (QT prolongation);	chr14:31619998	chr14:30683045~30683598:-
STAD	cis	rs5753618	0.504	rs9606846	ENSG00000236132.1	CTA-440B3.1	-3.9	0.000115	0.0362	-0.23	-0.21	Colorectal cancer;	chr22:31501585	chr22:31816379~31817491:-
STAD	cis	rs5753618	0.555	rs9609304	ENSG00000236132.1	CTA-440B3.1	-3.9	0.000115	0.0362	-0.23	-0.21	Colorectal cancer;	chr22:31501809	chr22:31816379~31817491:-
STAD	cis	rs2466029	0.732	rs2466032	ENSG00000254166.1	CASC19	3.9	0.000115	0.0362	0.29	0.21	Chronic lymphocytic leukemia;	chr8:127197575	chr8:127185635~127203222:-
STAD	cis	rs6693567	0.586	rs875514	ENSG00000203819.6	HIST2H2BC	3.9	0.000115	0.0362	0.24	0.21	Migraine;	chr1:150512079	chr1:149850193~149850772:-
STAD	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-3.9	0.000115	0.0362	-0.17	-0.21	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
STAD	cis	rs2337406	0.538	rs2015470	ENSG00000274576.2	IGHV2-70	-3.9	0.000115	0.0362	-0.25	-0.21	Alzheimer's disease (late onset);	chr14:106631885	chr14:106770577~106771020:-
STAD	cis	rs1850744	1	rs1519095	ENSG00000250268.3	ALG1L14P	-3.9	0.000115	0.0363	-0.43	-0.21	Economic and political preferences;	chr4:9809307	chr4:9166297~9170270:-
STAD	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	3.9	0.000115	0.0363	0.3	0.21	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
STAD	cis	rs149313	0.901	rs697976	ENSG00000272109.1	CTD-2260A17.3	-3.9	0.000115	0.0363	-0.22	-0.21	Blood protein levels;	chr5:96733063	chr5:96804353~96806105:+
STAD	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-3.9	0.000115	0.0363	-0.27	-0.21	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
STAD	cis	rs10129255	0.5	rs4774008	ENSG00000211959.2	IGHV4-39	3.9	0.000115	0.0363	0.18	0.21	Kawasaki disease;	chr14:106681273	chr14:106421711~106422218:-
STAD	cis	rs34779708	0.931	rs4934709	ENSG00000271335.4	RP11-324I22.4	-3.9	0.000116	0.0363	-0.24	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35314552~35336401:-
STAD	cis	rs6929812	0.546	rs2393962	ENSG00000280107.1	AL022393.9	3.9	0.000116	0.0363	0.22	0.21	Neuroticism (multi-trait analysis);	chr6:27495045	chr6:28170845~28172521:+
STAD	cis	rs4970988	0.501	rs11204713	ENSG00000276103.1	U4	3.9	0.000116	0.0363	0.19	0.21	Urate levels;	chr1:150722147	chr1:150608507~150608623:-
STAD	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.27	0.21	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
STAD	cis	rs6012564	0.963	rs6125551	ENSG00000227431.4	CSE1L-AS1	-3.9	0.000116	0.0363	-0.19	-0.21	Anger;	chr20:49103849	chr20:49040463~49046044:-
STAD	cis	rs8181477	1	rs11014504	ENSG00000240291.1	RP11-499P20.2	-3.9	0.000116	0.0363	-0.17	-0.21	Obesity-related traits;	chr10:18495059	chr10:18513115~18545651:-
STAD	cis	rs7789940	0.857	rs12532935	ENSG00000230305.2	AC004980.9	3.9	0.000116	0.0363	0.3	0.21	Multiple sclerosis;	chr7:76310381	chr7:76524515~76532692:+
STAD	cis	rs9902453	0.691	rs140701	ENSG00000263477.1	RP11-338L22.2	3.9	0.000116	0.0363	0.17	0.21	Coffee consumption (cups per day);	chr17:30211514	chr17:29863402~29866092:+
STAD	cis	rs6432860	0.897	rs13001295	ENSG00000229195.1	AC009495.4	3.9	0.000116	0.0363	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:165982791	chr2:165794857~165846091:-
STAD	cis	rs12762955	0.561	rs2620942	ENSG00000229869.1	RP11-363N22.2	-3.9	0.000116	0.0363	-0.26	-0.21	Response to angiotensin II receptor blocker therapy;	chr10:1002458	chr10:933026~942743:+
STAD	cis	rs6693567	0.565	rs696615	ENSG00000203819.6	HIST2H2BC	3.9	0.000116	0.0363	0.24	0.21	Migraine;	chr1:150366512	chr1:149850193~149850772:-
STAD	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	3.9	0.000116	0.0363	0.16	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
STAD	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-3.9	0.000116	0.0363	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
STAD	cis	rs11159086	0.938	rs11623040	ENSG00000259005.1	RP3-449M8.6	3.9	0.000116	0.0363	0.4	0.21	Advanced glycation end-product levels;	chr14:74496743	chr14:74474007~74474864:-
STAD	cis	rs4835473	0.932	rs6852502	ENSG00000249741.2	RP11-673E1.3	-3.9	0.000116	0.0363	-0.23	-0.21	Immature fraction of reticulocytes;	chr4:143987174	chr4:143911514~143912053:-
STAD	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0363	0.26	0.21	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
STAD	cis	rs34779708	0.931	rs12771399	ENSG00000271335.4	RP11-324I22.4	3.9	0.000116	0.0363	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35314552~35336401:-
STAD	cis	rs7429990	0.864	rs13085978	ENSG00000224895.1	VPS26BP1	-3.9	0.000116	0.0363	-0.2	-0.21	Educational attainment (years of education);	chr3:47608585	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.727	rs61675361	ENSG00000224895.1	VPS26BP1	-3.9	0.000116	0.0363	-0.2	-0.21	Educational attainment (years of education);	chr3:47610630	chr3:47960327~47961081:-
STAD	cis	rs66887589	0.616	rs1052633	ENSG00000250412.1	KLHL2P1	3.9	0.000116	0.0363	0.26	0.21	Diastolic blood pressure;	chr4:119294159	chr4:119334329~119378233:+
STAD	cis	rs66887589	0.592	rs2175383	ENSG00000250412.1	KLHL2P1	3.9	0.000116	0.0363	0.26	0.21	Diastolic blood pressure;	chr4:119294681	chr4:119334329~119378233:+
STAD	cis	rs10851478	0.845	rs1484553	ENSG00000259545.2	RP11-325E5.4	-3.9	0.000116	0.0363	-0.23	-0.21	Oral cavity cancer;	chr15:49710264	chr15:49177610~49178741:-
STAD	cis	rs4805566	0.651	rs10406549	ENSG00000267006.1	CTC-448F2.4	3.9	0.000116	0.0363	0.23	0.21	Body mass index;	chr19:30418597	chr19:30028741~30029916:-
STAD	cis	rs8141529	0.719	rs5762880	ENSG00000226471.5	CTA-292E10.6	-3.9	0.000116	0.0363	-0.24	-0.21	Lymphocyte counts;	chr22:28891828	chr22:28800683~28848559:+
STAD	cis	rs8141529	0.748	rs5762882	ENSG00000226471.5	CTA-292E10.6	-3.9	0.000116	0.0363	-0.24	-0.21	Lymphocyte counts;	chr22:28894692	chr22:28800683~28848559:+
STAD	cis	rs858239	0.508	rs10242104	ENSG00000230042.1	AK3P3	-3.9	0.000116	0.0363	-0.23	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23129178~23129841:+
STAD	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	3.9	0.000116	0.0364	0.25	0.21	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	3.9	0.000116	0.0364	0.25	0.21	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	3.9	0.000116	0.0364	0.25	0.21	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
STAD	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	3.9	0.000116	0.0364	0.25	0.21	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
STAD	cis	rs6693567	0.565	rs543179	ENSG00000203819.6	HIST2H2BC	-3.9	0.000116	0.0364	-0.24	-0.21	Migraine;	chr1:150302182	chr1:149850193~149850772:-
STAD	cis	rs11098499	1	rs3749591	ENSG00000260091.1	RP11-33B1.4	3.9	0.000116	0.0364	0.2	0.21	Corneal astigmatism;	chr4:119292875	chr4:119409333~119410233:+
STAD	cis	rs9608946	1	rs7287003	ENSG00000279159.1	RP3-394A18.1	-3.9	0.000116	0.0364	-0.18	-0.21	Red cell distribution width;	chr22:30529505	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs7286807	ENSG00000279159.1	RP3-394A18.1	-3.9	0.000116	0.0364	-0.18	-0.21	Red cell distribution width;	chr22:30529629	chr22:29978950~30028236:-
STAD	cis	rs1040	1	rs10945405	ENSG00000261039.2	RP11-417E7.2	3.9	0.000116	0.0364	0.23	0.21	Joint mobility (Beighton score);	chr6:169221041	chr6:169175304~169182740:-
STAD	cis	rs10129255	0.912	rs67410411	ENSG00000224373.3	IGHV4-59	3.9	0.000116	0.0364	0.17	0.21	Kawasaki disease;	chr14:106680324	chr14:106627249~106627825:-
STAD	cis	rs4713118	0.866	rs9468217	ENSG00000220721.1	OR1F12	3.9	0.000116	0.0364	0.24	0.21	Parkinson's disease;	chr6:27758688	chr6:28073316~28074233:+
STAD	cis	rs10129255	0.785	rs10150044	ENSG00000232216.1	IGHV3-43	3.9	0.000116	0.0364	0.21	0.21	Kawasaki disease;	chr14:106775695	chr14:106470264~106470800:-
STAD	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-3.9	0.000116	0.0364	-0.24	-0.21	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
STAD	cis	rs728616	0.51	rs12768957	ENSG00000225484.5	NUTM2B-AS1	-3.9	0.000116	0.0364	-0.38	-0.21	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80427537	chr10:79663088~79826594:-
STAD	cis	rs4835473	0.932	rs1988206	ENSG00000249741.2	RP11-673E1.3	-3.9	0.000116	0.0364	-0.23	-0.21	Immature fraction of reticulocytes;	chr4:143991344	chr4:143911514~143912053:-
STAD	cis	rs9287719	0.624	rs6740245	ENSG00000243819.4	RN7SL832P	3.9	0.000116	0.0364	0.2	0.21	Prostate cancer;	chr2:10620776	chr2:10690344~10692099:+
STAD	cis	rs4648045	0.796	rs9790601	ENSG00000230069.3	LRRC37A15P	-3.9	0.000116	0.0364	-0.23	-0.21	Lymphocyte percentage of white cells;	chr4:102608806	chr4:102727274~102730721:-
STAD	cis	rs7429990	1	rs7429990	ENSG00000224895.1	VPS26BP1	-3.9	0.000116	0.0364	-0.22	-0.21	Educational attainment (years of education);	chr3:47860313	chr3:47960327~47961081:-
STAD	cis	rs7824557	0.806	rs34171564	ENSG00000254866.2	DEFB109P3	3.9	0.000116	0.0364	0.26	0.21	Retinal vascular caliber;	chr8:11237837	chr8:12150895~12151134:-
STAD	cis	rs7176527	0.706	rs35641144	ENSG00000225151.9	GOLGA2P7	3.9	0.000116	0.0364	0.31	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:84199311~84230136:-
STAD	cis	rs28830936	0.966	rs11635067	ENSG00000250379.1	RP11-23P13.4	3.9	0.000116	0.0364	0.26	0.21	Diastolic blood pressure;	chr15:41832475	chr15:41825099~41827936:-
STAD	cis	rs28830936	0.966	rs1531140	ENSG00000250379.1	RP11-23P13.4	3.9	0.000116	0.0364	0.26	0.21	Diastolic blood pressure;	chr15:41833036	chr15:41825099~41827936:-
STAD	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
STAD	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
STAD	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	3.9	0.000116	0.0364	0.26	0.21	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
STAD	cis	rs9747201	1	rs62078307	ENSG00000281517.1	Metazoa_SRP	3.9	0.000116	0.0364	0.24	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82132177	chr17:81718849~81719095:-
STAD	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	3.9	0.000116	0.0364	0.22	0.21	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
STAD	cis	rs9467773	1	rs9467783	ENSG00000243307.2	POM121L6P	3.9	0.000116	0.0364	0.2	0.21	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26896952~26898777:+
STAD	cis	rs4784934	0.921	rs4784938	ENSG00000260186.4	RP11-481J2.2	3.9	0.000116	0.0364	0.24	0.21	QT interval;	chr16:58433949	chr16:58421326~58462470:+
STAD	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-3.9	0.000116	0.0364	-0.22	-0.21	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
STAD	cis	rs2404602	0.583	rs12592501	ENSG00000196274.5	Metazoa_SRP	3.9	0.000116	0.0364	0.18	0.21	Blood metabolite levels;	chr15:76262449	chr15:76230048~76230390:-
STAD	cis	rs2404602	0.583	rs2139190	ENSG00000196274.5	Metazoa_SRP	3.9	0.000116	0.0364	0.18	0.21	Blood metabolite levels;	chr15:76263198	chr15:76230048~76230390:-
STAD	cis	rs7937890	0.9	rs7118682	ENSG00000254418.1	RP11-21L19.1	-3.9	0.000116	0.0364	-0.22	-0.21	Mitochondrial DNA levels;	chr11:14253004	chr11:14262846~14273691:-
STAD	cis	rs17818399	0.547	rs4952833	ENSG00000279254.1	RP11-536C12.1	-3.9	0.000116	0.0365	-0.23	-0.21	Height;	chr2:46534895	chr2:46668870~46670778:+
STAD	cis	rs9291683	0.546	rs13139055	ENSG00000250613.1	RP11-136I13.1	-3.9	0.000116	0.0365	-0.21	-0.21	Bone mineral density;	chr4:10037300	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.566	rs13115776	ENSG00000250613.1	RP11-136I13.1	-3.9	0.000116	0.0365	-0.21	-0.21	Bone mineral density;	chr4:10038565	chr4:10410996~10411644:+
STAD	cis	rs7674212	0.531	rs4698876	ENSG00000248971.2	KRT8P46	-3.9	0.000116	0.0365	-0.23	-0.21	Type 2 diabetes;	chr4:103012410	chr4:102728746~102730171:-
STAD	cis	rs7674212	0.531	rs7665026	ENSG00000248971.2	KRT8P46	-3.9	0.000116	0.0365	-0.23	-0.21	Type 2 diabetes;	chr4:103015491	chr4:102728746~102730171:-
STAD	cis	rs6480314	0.522	rs4746756	ENSG00000234102.1	KRT19P4	3.9	0.000116	0.0365	0.26	0.21	Optic nerve measurement (disc area);	chr10:68301188	chr10:68260557~68261499:+
STAD	cis	rs11971779	0.648	rs59791374	ENSG00000214815.2	AC008265.2	3.9	0.000116	0.0365	0.23	0.21	Diisocyanate-induced asthma;	chr7:139432216	chr7:138440690~138442238:+
STAD	cis	rs11971779	0.59	rs59602547	ENSG00000214815.2	AC008265.2	3.9	0.000116	0.0365	0.23	0.21	Diisocyanate-induced asthma;	chr7:139432277	chr7:138440690~138442238:+
STAD	cis	rs7615952	0.932	rs13325495	ENSG00000239804.1	RP11-379B18.1	3.9	0.000116	0.0365	0.34	0.21	Blood pressure (smoking interaction);	chr3:125918573	chr3:125787888~125788146:-
STAD	cis	rs9393777	0.623	rs9366658	ENSG00000241549.7	GUSBP2	3.9	0.000116	0.0365	0.29	0.21	Intelligence (multi-trait analysis);	chr6:26469638	chr6:26871484~26956554:-
STAD	cis	rs6604026	0.74	rs6604031	ENSG00000229052.2	RP11-386I23.1	-3.9	0.000116	0.0365	-0.2	-0.21	Multiple sclerosis;	chr1:92935209	chr1:92930696~92934098:+
STAD	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-3.9	0.000116	0.0365	-0.26	-0.21	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
STAD	cis	rs9402743	0.673	rs9483860	ENSG00000217482.2	HMGB1P17	-3.9	0.000116	0.0365	-0.23	-0.21	Systemic lupus erythematosus;	chr6:135646872	chr6:135636086~135636713:-
STAD	cis	rs10782582	0.593	rs74090712	ENSG00000181227.3	RP4-682C21.2	3.9	0.000116	0.0365	0.22	0.21	Daytime sleep phenotypes;	chr1:75723413	chr1:75743423~75744776:-
STAD	cis	rs7523875	0.744	rs61850982	ENSG00000236809.2	SNX25P1	3.9	0.000117	0.0365	0.35	0.21	Mean corpuscular volume;	chr1:211241590	chr1:211417025~211417934:+
STAD	cis	rs7523875	0.744	rs57331968	ENSG00000236809.2	SNX25P1	3.9	0.000117	0.0365	0.35	0.21	Mean corpuscular volume;	chr1:211242403	chr1:211417025~211417934:+
STAD	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-3.9	0.000117	0.0365	-0.31	-0.21	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
STAD	cis	rs14403	0.866	rs3006926	ENSG00000240963.1	RP11-518L10.5	3.9	0.000117	0.0365	0.21	0.21	Schizophrenia;	chr1:243492150	chr1:244375100~244409592:-
STAD	cis	rs10776614	1	rs7904456	ENSG00000226964.1	RHEBP2	3.9	0.000117	0.0365	0.3	0.21	Self-employment;	chr10:48554667	chr10:47706203~47706802:+
STAD	cis	rs12468226	0.938	rs12463937	ENSG00000272966.1	RP11-686O6.1	3.9	0.000117	0.0365	0.31	0.21	Urate levels;	chr2:202246543	chr2:202336739~202337200:+
STAD	cis	rs7202877	0.706	rs247436	ENSG00000261783.1	RP11-252K23.2	3.9	0.000117	0.0365	0.34	0.21	Type 1 diabetes;Type 2 diabetes;	chr16:75412073	chr16:75379818~75381260:-
STAD	cis	rs9902453	1	rs7207021	ENSG00000240074.1	RPL9P30	-3.9	0.000117	0.0365	-0.17	-0.21	Coffee consumption (cups per day);	chr17:30073498	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs9897206	ENSG00000240074.1	RPL9P30	-3.9	0.000117	0.0365	-0.17	-0.21	Coffee consumption (cups per day);	chr17:30079090	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.74	rs2628189	ENSG00000263477.1	RP11-338L22.2	-3.9	0.000117	0.0365	-0.17	-0.21	Coffee consumption (cups per day);	chr17:29761795	chr17:29863402~29866092:+
STAD	cis	rs9907295	0.688	rs9890583	ENSG00000271013.1	AC015849.15	-3.9	0.000117	0.0365	-0.29	-0.21	Fibroblast growth factor basic levels;	chr17:35919389	chr17:35912635~35918010:-
STAD	cis	rs4218	0.724	rs35168204	ENSG00000259732.1	RP11-59H7.3	-3.9	0.000117	0.0366	-0.24	-0.21	Social communication problems;	chr15:59121354	chr15:59121034~59133250:+
STAD	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-3.9	0.000117	0.0366	-0.25	-0.21	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
STAD	cis	rs6834538	0.597	rs4834291	ENSG00000234841.4	RP11-119H12.4	-3.9	0.000117	0.0366	-0.22	-0.21	Free thyroxine concentration;	chr4:112561562	chr4:112826307~112827607:+
STAD	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-3.9	0.000117	0.0366	-0.27	-0.21	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
STAD	cis	rs997295	0.535	rs11630854	ENSG00000270964.1	RP11-502I4.3	-3.9	0.000117	0.0366	-0.25	-0.21	Motion sickness;	chr15:67565778	chr15:67541072~67542604:-
STAD	cis	rs1707322	1	rs946527	ENSG00000225447.1	RPS15AP10	3.9	0.000117	0.0366	0.16	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45645816~45646197:-
STAD	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	3.9	0.000117	0.0366	0.25	0.21	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
STAD	cis	rs716804	0.654	rs2923098	ENSG00000254554.1	RP11-351I24.1	3.9	0.000117	0.0366	0.3	0.21	Neuroticism;	chr11:10347067	chr11:10302657~10303704:-
STAD	cis	rs2070488	0.804	rs7372452	ENSG00000229589.1	ACVR2B-AS1	3.9	0.000117	0.0366	0.25	0.21	Electrocardiographic conduction measures;	chr3:38402807	chr3:38451027~38454820:-
STAD	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	3.9	0.000117	0.0366	0.26	0.21	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	3.9	0.000117	0.0366	0.26	0.21	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	3.9	0.000117	0.0366	0.26	0.21	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	3.9	0.000117	0.0366	0.26	0.21	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	3.9	0.000117	0.0366	0.26	0.21	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
STAD	cis	rs9297145	0.585	rs62473049	ENSG00000272950.1	RP11-307C18.1	-3.9	0.000117	0.0366	-0.23	-0.21	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99180062	chr7:98322853~98323430:+
STAD	cis	rs17818399	0.781	rs34449783	ENSG00000279254.1	RP11-536C12.1	-3.9	0.000117	0.0366	-0.21	-0.21	Height;	chr2:46636416	chr2:46668870~46670778:+
STAD	cis	rs17818399	0.815	rs17768138	ENSG00000279254.1	RP11-536C12.1	-3.9	0.000117	0.0366	-0.21	-0.21	Height;	chr2:46641078	chr2:46668870~46670778:+
STAD	cis	rs7429990	0.864	rs883662	ENSG00000224895.1	VPS26BP1	-3.9	0.000117	0.0366	-0.2	-0.21	Educational attainment (years of education);	chr3:47619342	chr3:47960327~47961081:-
STAD	cis	rs11150038	0.826	rs12448742	ENSG00000261837.1	RP11-264L1.3	-3.9	0.000117	0.0366	-0.31	-0.21	Colorectal or endometrial cancer;	chr16:78032787	chr16:78534374~78535648:+
STAD	cis	rs172166	0.637	rs1071893	ENSG00000280107.1	AL022393.9	-3.9	0.000117	0.0366	-0.26	-0.21	Cardiac Troponin-T levels;	chr6:28199857	chr6:28170845~28172521:+
STAD	cis	rs4407350	0.837	rs4823326	ENSG00000279642.1	RP5-1033E15.3	-3.9	0.000117	0.0366	-0.2	-0.21	Intelligence (multi-trait analysis);	chr22:44512798	chr22:44486295~44486914:-
STAD	cis	rs6432860	0.868	rs545331	ENSG00000229195.1	AC009495.4	3.9	0.000117	0.0366	0.26	0.21	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166057452	chr2:165794857~165846091:-
STAD	cis	rs749052	0.831	rs896991	ENSG00000251485.1	AC068134.10	-3.9	0.000117	0.0367	-0.5	-0.21	Height;	chr2:232062750	chr2:232343116~232343903:+
STAD	cis	rs2836974	0.563	rs997147	ENSG00000238141.2	BRWD1-AS1	-3.9	0.000117	0.0367	-0.21	-0.21	Cognitive function;	chr21:39323399	chr21:39315707~39323218:+
STAD	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-3.9	0.000117	0.0367	-0.36	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
STAD	cis	rs749052	0.831	rs3116226	ENSG00000251485.1	AC068134.10	-3.9	0.000117	0.0367	-0.5	-0.21	Height;	chr2:232020615	chr2:232343116~232343903:+
STAD	cis	rs7142881	0.815	rs11627332	ENSG00000258648.1	UBE2CP1	3.9	0.000117	0.0367	0.22	0.21	Response to iloperidone treatment (QT prolongation);	chr14:31606544	chr14:30683045~30683598:-
STAD	cis	rs716804	0.905	rs7116590	ENSG00000254554.1	RP11-351I24.1	3.9	0.000117	0.0367	0.29	0.21	Neuroticism;	chr11:10238285	chr11:10302657~10303704:-
STAD	cis	rs716804	0.87	rs7117478	ENSG00000254554.1	RP11-351I24.1	3.9	0.000117	0.0367	0.29	0.21	Neuroticism;	chr11:10238287	chr11:10302657~10303704:-
STAD	cis	rs1348850	0.632	rs1405718	ENSG00000271825.1	RP11-337N6.2	3.9	0.000117	0.0367	0.18	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177635081	chr2:177300600~177302006:+
STAD	cis	rs9990333	1	rs9990333	ENSG00000207650.1	MIR570	-3.9	0.000117	0.0367	-0.21	-0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195699401~195699497:+
STAD	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-3.9	0.000117	0.0367	-0.26	-0.21	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
STAD	cis	rs1050288	0.525	rs10743608	ENSG00000230519.2	RP11-1060J15.5	-3.9	0.000117	0.0367	-0.28	-0.21	Pulse pressure;Resting heart rate;	chr12:27786422	chr12:27702338~27702906:+
STAD	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-3.9	0.000117	0.0367	-0.25	-0.2	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
STAD	cis	rs7580658	0.545	rs13001179	ENSG00000236682.1	AC068282.3	-3.9	0.000117	0.0367	-0.25	-0.2	Protein C levels;	chr2:127194617	chr2:127389130~127400580:+
STAD	cis	rs7580658	0.545	rs13001184	ENSG00000236682.1	AC068282.3	-3.9	0.000117	0.0367	-0.25	-0.2	Protein C levels;	chr2:127194630	chr2:127389130~127400580:+
STAD	cis	rs1850744	0.702	rs55916508	ENSG00000250942.1	ENPP7P11	-3.9	0.000117	0.0367	-0.36	-0.2	Economic and political preferences;	chr4:9587710	chr4:9677308~9677934:+
STAD	cis	rs7829975	0.539	rs940031	ENSG00000253981.4	ALG1L13P	-3.9	0.000118	0.0368	-0.27	-0.2	Mood instability;	chr8:8689338	chr8:8236003~8244667:-
STAD	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-3.9	0.000118	0.0368	-0.26	-0.2	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
STAD	cis	rs1707322	1	rs785498	ENSG00000225447.1	RPS15AP10	-3.9	0.000118	0.0368	-0.16	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45645816~45646197:-
STAD	cis	rs7233060	1	rs7233060	ENSG00000274828.1	RP11-567M16.6	-3.9	0.000118	0.0368	-0.31	-0.2	Schizophrenia;	chr18:79632379	chr18:79677287~79679358:-
STAD	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	3.9	0.000118	0.0368	0.26	0.2	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
STAD	cis	rs2348418	0.932	rs10843190	ENSG00000247934.4	RP11-967K21.1	3.9	0.000118	0.0368	0.2	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28507412	chr12:28163298~28190738:-
STAD	cis	rs679711	0.57	rs607043	ENSG00000214380.4	RP11-457K10.2	3.9	0.000118	0.0368	0.24	0.2	Sleep depth;	chr3:109925478	chr3:109915976~109916940:-
STAD	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-3.9	0.000118	0.0368	-0.26	-0.2	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
STAD	cis	rs8054556	0.74	rs11649612	ENSG00000273724.1	RP11-347C12.12	-3.9	0.000118	0.0368	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30336400~30343336:+
STAD	cis	rs8054556	0.716	rs11642933	ENSG00000273724.1	RP11-347C12.12	-3.9	0.000118	0.0368	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30336400~30343336:+
STAD	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-3.9	0.000118	0.0368	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
STAD	cis	rs938554	0.513	rs3775947	ENSG00000250613.1	RP11-136I13.1	-3.9	0.000118	0.0368	-0.2	-0.2	Blood metabolite levels;	chr4:9993616	chr4:10410996~10411644:+
STAD	cis	rs1075265	0.836	rs1421622	ENSG00000235937.1	AC008280.1	-3.9	0.000118	0.0368	-0.18	-0.2	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54029552~54030682:-
STAD	cis	rs6471393	0.798	rs55680024	ENSG00000253848.1	RP11-10N23.5	3.9	0.000118	0.0368	0.25	0.2	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93836533	chr8:93741193~93744534:+
STAD	cis	rs2904967	0.562	rs239255	ENSG00000254614.2	AP003068.23	-3.9	0.000118	0.0368	-0.3	-0.2	Mean corpuscular volume;	chr11:65219657	chr11:65177606~65181834:-
STAD	cis	rs2904967	0.636	rs239256	ENSG00000254614.2	AP003068.23	-3.9	0.000118	0.0368	-0.3	-0.2	Mean corpuscular volume;	chr11:65219920	chr11:65177606~65181834:-
STAD	cis	rs7937890	1	rs2970334	ENSG00000254418.1	RP11-21L19.1	-3.9	0.000118	0.0368	-0.22	-0.2	Mitochondrial DNA levels;	chr11:14307809	chr11:14262846~14273691:-
STAD	cis	rs10911902	0.561	rs1919199	ENSG00000229739.2	RP11-295K2.3	-3.9	0.000118	0.0368	-0.3	-0.2	Schizophrenia;	chr1:186300752	chr1:186435161~186470291:+
STAD	cis	rs66887589	0.616	rs6843509	ENSG00000250412.1	KLHL2P1	3.9	0.000118	0.0368	0.26	0.2	Diastolic blood pressure;	chr4:119299041	chr4:119334329~119378233:+
STAD	cis	rs3758141	0.858	rs6984859	ENSG00000278886.1	RP11-108A14.1	-3.9	0.000118	0.0368	-0.27	-0.2	Body mass index (change over time) in gastrointestinal cancer;	chr8:18873436	chr8:18864681~18865247:-
STAD	cis	rs9368481	0.729	rs10946881	ENSG00000224843.5	LINC00240	-3.9	0.000118	0.0368	-0.23	-0.2	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26956992~27023924:+
STAD	cis	rs62402013	1	rs62402013	ENSG00000224843.5	LINC00240	-3.9	0.000118	0.0368	-0.23	-0.2	Schizophrenia;	chr6:26947221	chr6:26956992~27023924:+
STAD	cis	rs2072510	0.569	rs7970524	ENSG00000257150.2	PGAM1P5	-3.9	0.000118	0.0368	-0.26	-0.2	Metabolite levels (small molecules and protein measures);	chr12:95996374	chr12:95551582~95673999:+
STAD	cis	rs516805	0.528	rs2684245	ENSG00000279453.1	RP3-425C14.4	-3.9	0.000118	0.0368	-0.3	-0.2	Lymphocyte counts;	chr6:122092990	chr6:122436789~122439223:-
STAD	cis	rs6479901	0.512	rs7100372	ENSG00000235816.3	PRELID1P3	-3.9	0.000118	0.0368	-0.26	-0.2	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63427297~63427939:+
STAD	cis	rs6479891	0.818	rs9299455	ENSG00000235816.3	PRELID1P3	-3.9	0.000118	0.0368	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs7899715	ENSG00000235816.3	PRELID1P3	-3.9	0.000118	0.0368	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs4525102	ENSG00000235816.3	PRELID1P3	-3.9	0.000118	0.0368	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63427297~63427939:+
STAD	cis	rs4835473	0.618	rs12499907	ENSG00000249741.2	RP11-673E1.3	3.89	0.000118	0.0368	0.24	0.2	Immature fraction of reticulocytes;	chr4:143999748	chr4:143911514~143912053:-
STAD	cis	rs7927771	0.832	rs1317164	ENSG00000271350.1	CTD-2384B9.1	-3.89	0.000118	0.0368	-0.22	-0.2	Subjective well-being;	chr11:47398206	chr11:47041027~47041945:-
STAD	cis	rs6604026	0.74	rs2893225	ENSG00000229052.2	RP11-386I23.1	-3.89	0.000118	0.0369	-0.2	-0.2	Multiple sclerosis;	chr1:92902939	chr1:92930696~92934098:+
STAD	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-3.89	0.000118	0.0369	-0.25	-0.2	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
STAD	cis	rs9362426	0.503	rs34977536	ENSG00000217776.1	RP11-156F23.2	3.89	0.000118	0.0369	0.21	0.2	Depressive episodes in bipolar disorder;	chr6:87402650	chr6:87070156~87070461:-
STAD	cis	rs34779708	0.931	rs11010132	ENSG00000271335.4	RP11-324I22.4	3.89	0.000118	0.0369	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35314552~35336401:-
STAD	cis	rs11089937	0.597	rs6001076	ENSG00000211640.3	IGLV6-57	3.89	0.000118	0.0369	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.597	rs5995560	ENSG00000211640.3	IGLV6-57	3.89	0.000118	0.0369	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.568	rs6001078	ENSG00000211640.3	IGLV6-57	3.89	0.000118	0.0369	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22195713~22196460:+
STAD	cis	rs950169	0.512	rs4374136	ENSG00000254414.1	RP11-182J1.1	3.89	0.000118	0.0369	0.22	0.2	Schizophrenia;	chr15:83976255	chr15:84631898~84633987:-
STAD	cis	rs6693567	0.565	rs10888584	ENSG00000203819.6	HIST2H2BC	3.89	0.000118	0.0369	0.24	0.2	Migraine;	chr1:150503930	chr1:149850193~149850772:-
STAD	cis	rs6940638	0.688	rs6921388	ENSG00000216915.2	RP1-97D16.1	-3.89	0.000118	0.0369	-0.23	-0.2	Intelligence (multi-trait analysis);	chr6:27112426	chr6:27737000~27738494:-
STAD	cis	rs2836950	0.565	rs8131132	ENSG00000238141.2	BRWD1-AS1	-3.89	0.000118	0.0369	-0.21	-0.2	Menarche (age at onset);	chr21:39166330	chr21:39315707~39323218:+
STAD	cis	rs950169	0.84	rs62019457	ENSG00000259683.1	RP11-182J1.14	3.89	0.000118	0.0369	0.21	0.2	Schizophrenia;	chr15:84558911	chr15:84389729~84395903:+
STAD	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-3.89	0.000118	0.0369	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
STAD	cis	rs12468226	1	rs7597469	ENSG00000272966.1	RP11-686O6.1	3.89	0.000118	0.0369	0.3	0.2	Urate levels;	chr2:202329547	chr2:202336739~202337200:+
STAD	cis	rs12468226	1	rs113877751	ENSG00000272966.1	RP11-686O6.1	3.89	0.000118	0.0369	0.3	0.2	Urate levels;	chr2:202329998	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.935	rs113021930	ENSG00000272966.1	RP11-686O6.1	3.89	0.000118	0.0369	0.3	0.2	Urate levels;	chr2:202330448	chr2:202336739~202337200:+
STAD	cis	rs12468226	1	rs113491584	ENSG00000272966.1	RP11-686O6.1	3.89	0.000118	0.0369	0.3	0.2	Urate levels;	chr2:202331724	chr2:202336739~202337200:+
STAD	cis	rs7868228	1	rs12685591	ENSG00000226393.1	IFNA20P	3.89	0.000118	0.0369	0.34	0.2	Gut microbiome composition (winter);	chr9:21669887	chr9:21321300~21321827:+
STAD	cis	rs1816752	0.905	rs9511242	ENSG00000232858.1	RPL34P27	3.89	0.000118	0.037	0.13	0.2	Obesity-related traits;	chr13:24419261	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.905	rs7317850	ENSG00000232858.1	RPL34P27	3.89	0.000118	0.037	0.13	0.2	Obesity-related traits;	chr13:24419899	chr13:24988577~24988925:-
STAD	cis	rs12468226	0.817	rs6722588	ENSG00000226261.1	AC064836.3	-3.89	0.000118	0.037	-0.34	-0.2	Urate levels;	chr2:202187163	chr2:202336024~202336727:-
STAD	cis	rs6693567	0.565	rs698914	ENSG00000203819.6	HIST2H2BC	3.89	0.000118	0.037	0.24	0.2	Migraine;	chr1:150326292	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.545	rs1260403	ENSG00000203819.6	HIST2H2BC	3.89	0.000118	0.037	0.24	0.2	Migraine;	chr1:150331196	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.545	rs1260385	ENSG00000203819.6	HIST2H2BC	3.89	0.000118	0.037	0.24	0.2	Migraine;	chr1:150343909	chr1:149850193~149850772:-
STAD	cis	rs4589258	0.788	rs10830571	ENSG00000280367.1	RP11-121L10.2	3.89	0.000118	0.037	0.2	0.2	Intelligence (multi-trait analysis);	chr11:90765354	chr11:90223153~90226538:+
STAD	cis	rs4589258	0.788	rs10765388	ENSG00000280367.1	RP11-121L10.2	3.89	0.000118	0.037	0.2	0.2	Intelligence (multi-trait analysis);	chr11:90765672	chr11:90223153~90226538:+
STAD	cis	rs4730250	0.707	rs1981696	ENSG00000273320.1	RP11-22N19.2	3.89	0.000118	0.037	0.32	0.2	Osteoarthritis;	chr7:107153655	chr7:106285480~106286326:+
STAD	cis	rs716804	0.87	rs4910109	ENSG00000254554.1	RP11-351I24.1	3.89	0.000118	0.037	0.29	0.2	Neuroticism;	chr11:10237831	chr11:10302657~10303704:-
STAD	cis	rs1322639	0.614	rs6903921	ENSG00000261039.2	RP11-417E7.2	-3.89	0.000118	0.037	-0.32	-0.2	Pulse pressure;	chr6:169163862	chr6:169175304~169182740:-
STAD	cis	rs1322639	0.614	rs6925950	ENSG00000261039.2	RP11-417E7.2	-3.89	0.000118	0.037	-0.32	-0.2	Pulse pressure;	chr6:169163863	chr6:169175304~169182740:-
STAD	cis	rs4713118	0.869	rs9348775	ENSG00000220721.1	OR1F12	3.89	0.000118	0.037	0.23	0.2	Parkinson's disease;	chr6:27727550	chr6:28073316~28074233:+
STAD	cis	rs10782582	0.593	rs17848068	ENSG00000181227.3	RP4-682C21.2	3.89	0.000118	0.037	0.22	0.2	Daytime sleep phenotypes;	chr1:75724531	chr1:75743423~75744776:-
STAD	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	3.89	0.000118	0.037	0.27	0.2	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
STAD	cis	rs6772849	0.93	rs9868579	ENSG00000242551.2	POU5F1P6	3.89	0.000119	0.037	0.2	0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128674735~128677005:-
STAD	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-3.89	0.000119	0.037	-0.27	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
STAD	cis	rs6813195	0.563	rs4696321	ENSG00000243417.1	RP11-555K12.1	-3.89	0.000119	0.037	-0.21	-0.2	Type 2 diabetes;	chr4:152421493	chr4:152551277~152552364:-
STAD	cis	rs8012947	0.916	rs11851552	ENSG00000279636.2	LINC00216	3.89	0.000119	0.037	0.21	0.2	Alcohol consumption in current drinkers;	chr14:58240032	chr14:58288033~58289158:+
STAD	cis	rs11673344	0.504	rs1667378	ENSG00000267672.1	CTD-2293H3.1	3.89	0.000119	0.037	0.19	0.2	Obesity-related traits;	chr19:37001171	chr19:37091341~37092564:+
STAD	cis	rs74181299	1	rs74181299	ENSG00000232613.5	AC007386.4	-3.89	0.000119	0.037	-0.17	-0.2	Pulse pressure;	chr2:65056838	chr2:65030727~65053017:+
STAD	cis	rs7204230	1	rs16952168	ENSG00000261291.1	RP11-295M3.2	3.89	0.000119	0.037	0.24	0.2	Fibrinogen;	chr16:53318417	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs16952170	ENSG00000261291.1	RP11-295M3.2	3.89	0.000119	0.037	0.24	0.2	Fibrinogen;	chr16:53319577	chr16:53168522~53169450:+
STAD	cis	rs7829975	0.667	rs1877119	ENSG00000253981.4	ALG1L13P	3.89	0.000119	0.037	0.23	0.2	Mood instability;	chr8:8849687	chr8:8236003~8244667:-
STAD	cis	rs12908161	0.959	rs61074241	ENSG00000259295.5	CSPG4P12	3.89	0.000119	0.037	0.31	0.2	Schizophrenia;	chr15:84790165	chr15:85191438~85213905:+
STAD	cis	rs4835473	0.932	rs1849113	ENSG00000249741.2	RP11-673E1.3	3.89	0.000119	0.037	0.24	0.2	Immature fraction of reticulocytes;	chr4:143962512	chr4:143911514~143912053:-
STAD	cis	rs11089937	0.568	rs5756989	ENSG00000211640.3	IGLV6-57	3.89	0.000119	0.037	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22195713~22196460:+
STAD	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-3.89	0.000119	0.0371	-0.23	-0.2	Height;	chr2:231553603	chr2:231508426~231514339:-
STAD	cis	rs9646944	1	rs11677452	ENSG00000234389.1	AC007278.3	3.89	0.000119	0.0371	0.25	0.2	Blood protein levels;	chr2:102248776	chr2:102438713~102440475:+
STAD	cis	rs1850744	0.826	rs114657516	ENSG00000163612.10	FAM86KP	3.89	0.000119	0.0371	0.43	0.2	Economic and political preferences;	chr4:9592233	chr4:9153296~9165451:+
STAD	cis	rs4835473	0.897	rs7676614	ENSG00000249741.2	RP11-673E1.3	3.89	0.000119	0.0371	0.24	0.2	Immature fraction of reticulocytes;	chr4:143695213	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.864	rs7681559	ENSG00000249741.2	RP11-673E1.3	3.89	0.000119	0.0371	0.24	0.2	Immature fraction of reticulocytes;	chr4:143695248	chr4:143911514~143912053:-
STAD	cis	rs1971762	0.73	rs7963016	ENSG00000257379.1	RP11-793H13.8	3.89	0.000119	0.0371	0.26	0.2	Height;	chr12:53679035	chr12:53441741~53467528:+
STAD	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-3.89	0.000119	0.0371	-0.23	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
STAD	cis	rs2957692	0.506	rs111656900	ENSG00000254554.1	RP11-351I24.1	3.89	0.000119	0.0371	0.34	0.2	Circulating vasoactive peptide levels;	chr11:9925300	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.506	rs11042547	ENSG00000254554.1	RP11-351I24.1	3.89	0.000119	0.0371	0.34	0.2	Circulating vasoactive peptide levels;	chr11:9926327	chr11:10302657~10303704:-
STAD	cis	rs9646944	0.636	rs11674302	ENSG00000234389.1	AC007278.3	3.89	0.000119	0.0371	0.28	0.2	Blood protein levels;	chr2:102270668	chr2:102438713~102440475:+
STAD	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-3.89	0.000119	0.0371	-0.21	-0.2	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
STAD	cis	rs2638953	0.776	rs11513467	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000119	0.0371	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210252	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.776	rs11519332	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000119	0.0371	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210254	chr12:28163298~28190738:-
STAD	cis	rs9921338	0.924	rs7204628	ENSG00000263080.1	RP11-485G7.5	3.89	0.000119	0.0371	0.31	0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11341809~11345211:-
STAD	cis	rs4763879	0.778	rs11052497	ENSG00000256673.1	RP11-599J14.2	3.89	0.000119	0.0371	0.22	0.2	Type 1 diabetes;	chr12:9696679	chr12:9398355~9414851:-
STAD	cis	rs1850744	0.702	rs78422890	ENSG00000250942.1	ENPP7P11	-3.89	0.000119	0.0371	-0.35	-0.2	Economic and political preferences;	chr4:9599141	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs11735905	ENSG00000250942.1	ENPP7P11	-3.89	0.000119	0.0371	-0.35	-0.2	Economic and political preferences;	chr4:9600133	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs73802912	ENSG00000250942.1	ENPP7P11	-3.89	0.000119	0.0371	-0.35	-0.2	Economic and political preferences;	chr4:9600873	chr4:9677308~9677934:+
STAD	cis	rs1850744	0.702	rs73802915	ENSG00000250942.1	ENPP7P11	-3.89	0.000119	0.0371	-0.35	-0.2	Economic and political preferences;	chr4:9601576	chr4:9677308~9677934:+
STAD	cis	rs11673344	0.523	rs10406110	ENSG00000267672.1	CTD-2293H3.1	3.89	0.000119	0.0371	0.19	0.2	Obesity-related traits;	chr19:37160027	chr19:37091341~37092564:+
STAD	cis	rs4293777	0.967	rs13137278	ENSG00000250896.1	RNPS1P1	-3.89	0.000119	0.0371	-0.15	-0.2	Primary sclerosing cholangitis;	chr4:10722250	chr4:11371975~11372892:+
STAD	cis	rs5758659	0.652	rs133300	ENSG00000182057.4	OGFRP1	3.89	0.000119	0.0371	0.22	0.2	Cognitive function;	chr22:41993835	chr22:42269753~42275196:+
STAD	cis	rs10129255	0.536	rs8004835	ENSG00000211959.2	IGHV4-39	3.89	0.000119	0.0371	0.18	0.2	Kawasaki disease;	chr14:106686361	chr14:106421711~106422218:-
STAD	cis	rs10129255	0.957	rs10142918	ENSG00000211973.2	IGHV1-69	3.89	0.000119	0.0371	0.2	0.2	Kawasaki disease;	chr14:106782206	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.957	rs10142859	ENSG00000211973.2	IGHV1-69	3.89	0.000119	0.0371	0.2	0.2	Kawasaki disease;	chr14:106782238	chr14:106714684~106715181:-
STAD	cis	rs11673344	0.504	rs4805204	ENSG00000267672.1	CTD-2293H3.1	3.89	0.000119	0.0371	0.19	0.2	Obesity-related traits;	chr19:37136666	chr19:37091341~37092564:+
STAD	cis	rs9847710	0.696	rs62253605	ENSG00000242142.1	SERBP1P3	3.89	0.000119	0.0371	0.21	0.2	Ulcerative colitis;	chr3:52944402	chr3:53064283~53065091:-
STAD	cis	rs34779708	0.966	rs12257770	ENSG00000271335.4	RP11-324I22.4	3.89	0.000119	0.0371	0.23	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35314552~35336401:-
STAD	cis	rs9419788	0.74	rs11187825	ENSG00000227995.1	RAB11AP1	-3.89	0.000119	0.0371	-0.23	-0.2	Personality traits in bipolar disorder;	chr10:94227556	chr10:93881293~93881938:-
STAD	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-3.89	0.000119	0.0371	-0.31	-0.2	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
STAD	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	3.89	0.000119	0.0371	0.28	0.2	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
STAD	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	3.89	0.000119	0.0371	0.28	0.2	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
STAD	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-3.89	0.000119	0.0371	-0.24	-0.2	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
STAD	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-3.89	0.000119	0.0372	-0.24	-0.2	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
STAD	cis	rs7829975	0.539	rs940031	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000119	0.0372	-0.26	-0.2	Mood instability;	chr8:8689338	chr8:8961200~8979025:+
STAD	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-3.89	0.000119	0.0372	-0.23	-0.2	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
STAD	cis	rs449789	0.524	rs4709306	ENSG00000235086.1	FNDC1-IT1	-3.89	0.000119	0.0372	-0.27	-0.2	Pulse pressure;	chr6:159354898	chr6:159240786~159243329:+
STAD	cis	rs1790761	0.868	rs872375	ENSG00000231793.4	DOC2GP	-3.89	0.000119	0.0372	-0.24	-0.2	Mean corpuscular volume;	chr11:67438507	chr11:67612653~67616257:-
STAD	cis	rs2957692	0.548	rs11042615	ENSG00000254554.1	RP11-351I24.1	3.89	0.000119	0.0372	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10086462	chr11:10302657~10303704:-
STAD	cis	rs4561483	0.801	rs33643	ENSG00000260224.1	UBL5P4	3.89	0.000119	0.0372	0.2	0.2	Testicular germ cell tumor;	chr16:11892292	chr16:11968508~11968743:-
STAD	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	3.89	0.000119	0.0372	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
STAD	cis	rs919433	0.783	rs788014	ENSG00000231621.1	AC013264.2	-3.89	0.000119	0.0372	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197364273	chr2:197197991~197199273:+
STAD	cis	rs853679	0.76	rs9393909	ENSG00000220721.1	OR1F12	-3.89	0.000119	0.0372	-0.25	-0.2	Depression;	chr6:28239422	chr6:28073316~28074233:+
STAD	cis	rs4388249	1	rs2300999	ENSG00000271849.1	CTC-332L22.1	3.89	0.000119	0.0372	0.32	0.2	Schizophrenia;	chr5:109749106	chr5:109687802~109688329:-
STAD	cis	rs732716	0.785	rs34080966	ENSG00000269318.1	AC007292.3	3.89	0.000119	0.0372	0.27	0.2	Mean corpuscular volume;	chr19:4417848	chr19:4356637~4358448:-
STAD	cis	rs858239	0.899	rs1881203	ENSG00000230042.1	AK3P3	-3.89	0.000119	0.0372	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23129178~23129841:+
STAD	cis	rs6432852	0.527	rs76591774	ENSG00000229195.1	AC009495.4	-3.89	0.000119	0.0372	-0.24	-0.2	Diabetic kidney disease;	chr2:165914657	chr2:165794857~165846091:-
STAD	cis	rs10073892	0.789	rs10044449	ENSG00000250682.4	LINC00491	-3.89	0.000119	0.0372	-0.23	-0.2	Cognitive decline (age-related);	chr5:102516737	chr5:102609156~102671559:-
STAD	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	3.89	0.000119	0.0372	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
STAD	cis	rs4218	0.505	rs6494064	ENSG00000259732.1	RP11-59H7.3	3.89	0.000119	0.0372	0.22	0.2	Social communication problems;	chr15:59053192	chr15:59121034~59133250:+
STAD	cis	rs2638953	0.853	rs1355475	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000119	0.0372	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482398	chr12:28163298~28190738:-
STAD	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	3.89	0.000119	0.0372	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
STAD	cis	rs1900504	0.537	rs4751997	ENSG00000266200.5	PNLIPRP2	3.89	0.000119	0.0372	0.31	0.2	Tonsillectomy;	chr10:116641715	chr10:116620953~116645143:+
STAD	cis	rs10911902	0.602	rs1919200	ENSG00000229739.2	RP11-295K2.3	-3.89	0.000119	0.0372	-0.3	-0.2	Schizophrenia;	chr1:186300848	chr1:186435161~186470291:+
STAD	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	3.89	0.000119	0.0372	0.23	0.2	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
STAD	cis	rs427941	0.669	rs417013	ENSG00000232445.1	RP11-132A1.4	-3.89	0.000119	0.0372	-0.25	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102176875	chr7:101308346~101310985:+
STAD	cis	rs11169552	0.51	rs7307419	ENSG00000200428.1	Y_RNA	3.89	0.00012	0.0373	0.23	0.2	Colorectal cancer;	chr12:50613230	chr12:50743568~50743684:+
STAD	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	3.89	0.00012	0.0373	0.26	0.2	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
STAD	cis	rs2638953	0.962	rs11049533	ENSG00000247934.4	RP11-967K21.1	-3.89	0.00012	0.0373	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28327471	chr12:28163298~28190738:-
STAD	cis	rs9402743	0.962	rs6935033	ENSG00000236703.1	MYB-AS1	3.89	0.00012	0.0373	0.21	0.2	Systemic lupus erythematosus;	chr6:135659499	chr6:135195083~135195995:-
STAD	cis	rs6480314	0.522	rs2120900	ENSG00000233590.1	RP11-153K11.3	3.89	0.00012	0.0373	0.28	0.2	Optic nerve measurement (disc area);	chr10:68296052	chr10:68233251~68242379:-
STAD	cis	rs7412746	0.611	rs111842513	ENSG00000276103.1	U4	3.89	0.00012	0.0373	0.19	0.2	Melanoma;	chr1:150740450	chr1:150608507~150608623:-
STAD	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-3.89	0.00012	0.0373	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-3.89	0.00012	0.0373	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-3.89	0.00012	0.0373	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
STAD	cis	rs4835473	0.932	rs1473055	ENSG00000249741.2	RP11-673E1.3	-3.89	0.00012	0.0373	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143997714	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs4835126	ENSG00000249741.2	RP11-673E1.3	-3.89	0.00012	0.0373	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143997740	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.639	rs5029916	ENSG00000249741.2	RP11-673E1.3	-3.89	0.00012	0.0373	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143990684	chr4:143911514~143912053:-
STAD	cis	rs2562456	0.837	rs11085462	ENSG00000268119.4	CTD-2561J22.5	3.89	0.00012	0.0373	0.26	0.2	Pain;	chr19:21567449	chr19:21444241~21463908:-
STAD	cis	rs9581094	0.505	rs6490945	ENSG00000273628.1	RP11-756A22.7	3.89	0.00012	0.0374	0.26	0.2	Sudden cardiac arrest;	chr13:24514056	chr13:24933006~24936796:+
STAD	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-3.89	0.00012	0.0374	-0.32	-0.2	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
STAD	cis	rs9435732	0.832	rs7531163	ENSG00000224621.1	RP11-276H7.3	3.89	0.00012	0.0374	0.23	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16986959	chr1:16159266~16161883:+
STAD	cis	rs9435732	0.524	rs9435660	ENSG00000224621.1	RP11-276H7.3	3.89	0.00012	0.0374	0.23	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16987578	chr1:16159266~16161883:+
STAD	cis	rs4713118	0.869	rs2056925	ENSG00000220721.1	OR1F12	3.89	0.00012	0.0374	0.22	0.2	Parkinson's disease;	chr6:27723126	chr6:28073316~28074233:+
STAD	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	3.89	0.00012	0.0374	0.28	0.2	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
STAD	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	3.89	0.00012	0.0374	0.24	0.2	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
STAD	cis	rs4845552	0.767	rs4845549	ENSG00000226855.1	RP11-350G8.3	-3.89	0.00012	0.0374	-0.25	-0.2	Hippocampal atrophy;	chr1:153499809	chr1:154378207~154379089:-
STAD	cis	rs1876905	0.68	rs434034	ENSG00000272356.1	RP5-1112D6.8	-3.89	0.00012	0.0374	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111309203~111313517:+
STAD	cis	rs950169	0.58	rs17532346	ENSG00000259683.1	RP11-182J1.14	3.89	0.00012	0.0374	0.2	0.2	Schizophrenia;	chr15:84628264	chr15:84389729~84395903:+
STAD	cis	rs679711	0.571	rs688898	ENSG00000214380.4	RP11-457K10.2	3.89	0.00012	0.0374	0.24	0.2	Sleep depth;	chr3:109923758	chr3:109915976~109916940:-
STAD	cis	rs1348850	0.567	rs3770011	ENSG00000271825.1	RP11-337N6.2	3.89	0.00012	0.0374	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177673162	chr2:177300600~177302006:+
STAD	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	3.89	0.00012	0.0374	0.22	0.2	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
STAD	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	3.89	0.00012	0.0374	0.22	0.2	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
STAD	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	3.89	0.00012	0.0374	0.23	0.2	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
STAD	cis	rs4474742	1	rs4474742	ENSG00000263477.1	RP11-338L22.2	-3.89	0.00012	0.0374	-0.17	-0.2	Monocyte count;	chr17:29738560	chr17:29863402~29866092:+
STAD	cis	rs4950322	0.58	rs7514970	ENSG00000278811.3	LINC00624	3.89	0.00012	0.0374	0.22	0.2	Protein quantitative trait loci;	chr1:147120516	chr1:147258885~147517875:-
STAD	cis	rs2836950	0.545	rs2836922	ENSG00000238141.2	BRWD1-AS1	-3.89	0.00012	0.0374	-0.21	-0.2	Menarche (age at onset);	chr21:39144382	chr21:39315707~39323218:+
STAD	cis	rs1154275	0.563	rs9859168	ENSG00000240057.4	RP11-572M11.4	-3.89	0.00012	0.0374	-0.19	-0.2	Takotsubo syndrome;	chr3:112797059	chr3:113019532~113183301:+
STAD	cis	rs11012350	0.85	rs61603426	ENSG00000240291.1	RP11-499P20.2	-3.89	0.00012	0.0374	-0.32	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18014232	chr10:18513115~18545651:-
STAD	cis	rs7829975	0.777	rs6989926	ENSG00000254340.1	RP11-10A14.3	-3.89	0.00012	0.0374	-0.26	-0.2	Mood instability;	chr8:8689803	chr8:9141424~9145435:+
STAD	cis	rs4869313	0.655	rs1230358	ENSG00000248734.2	CTD-2260A17.1	3.89	0.00012	0.0375	0.21	0.2	Pediatric autoimmune diseases;	chr5:96876037	chr5:96784777~96785999:+
STAD	cis	rs304029	0.553	rs381617	ENSG00000229241.1	PNPT1P1	3.89	0.00012	0.0375	0.25	0.2	Diabetic kidney disease;	chr3:4481722	chr3:3981981~3984295:-
STAD	cis	rs304029	0.574	rs381618	ENSG00000229241.1	PNPT1P1	3.89	0.00012	0.0375	0.25	0.2	Diabetic kidney disease;	chr3:4481724	chr3:3981981~3984295:-
STAD	cis	rs3764021	0.87	rs11052710	ENSG00000256673.1	RP11-599J14.2	-3.89	0.00012	0.0375	-0.22	-0.2	Type 1 diabetes;	chr12:9723754	chr12:9398355~9414851:-
STAD	cis	rs13178541	0.81	rs11242275	ENSG00000248211.1	TRPC7-AS1	-3.89	0.00012	0.0375	-0.27	-0.2	IgG glycosylation;	chr5:135777234	chr5:136214048~136222159:+
STAD	cis	rs181553	0.664	rs1893529	ENSG00000266696.1	RP11-30L3.2	-3.89	0.00012	0.0375	-0.18	-0.2	Hip circumference adjusted for BMI;	chr18:49169906	chr18:49205912~49208781:+
STAD	cis	rs9902453	0.808	rs56088359	ENSG00000263477.1	RP11-338L22.2	3.89	0.00012	0.0375	0.17	0.2	Coffee consumption (cups per day);	chr17:29846641	chr17:29863402~29866092:+
STAD	cis	rs2243480	0.706	rs6460257	ENSG00000222364.1	RNU6-96P	-3.89	0.00012	0.0375	-0.3	-0.2	Diabetic kidney disease;	chr7:65731813	chr7:66395191~66395286:+
STAD	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-3.89	0.00012	0.0375	-0.26	-0.2	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
STAD	cis	rs11239930	0.517	rs3011809	ENSG00000278811.3	LINC00624	3.89	0.00012	0.0375	0.22	0.2	AIDS progression;	chr1:147077593	chr1:147258885~147517875:-
STAD	cis	rs4142995	0.695	rs2691556	ENSG00000279048.1	RP11-511H23.2	-3.89	0.00012	0.0375	-0.19	-0.2	HDL cholesterol;HDL cholesterol levels;	chr7:17776436	chr7:17940503~17942922:+
STAD	cis	rs12745968	0.589	rs12025792	ENSG00000229052.2	RP11-386I23.1	-3.89	0.00012	0.0375	-0.19	-0.2	Bipolar disorder and schizophrenia;	chr1:92641851	chr1:92930696~92934098:+
STAD	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	3.89	0.000121	0.0375	0.28	0.2	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
STAD	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-3.89	0.000121	0.0375	-0.28	-0.2	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
STAD	cis	rs10508774	0.759	rs56104402	ENSG00000273038.2	RP11-479G22.8	3.89	0.000121	0.0375	0.38	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32697467	chr10:32887255~32889311:-
STAD	cis	rs7204230	1	rs8050349	ENSG00000261291.1	RP11-295M3.2	3.89	0.000121	0.0375	0.24	0.2	Fibrinogen;	chr16:53305964	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs12599349	ENSG00000261291.1	RP11-295M3.2	3.89	0.000121	0.0375	0.24	0.2	Fibrinogen;	chr16:53309159	chr16:53168522~53169450:+
STAD	cis	rs7204230	0.96	rs8053198	ENSG00000261291.1	RP11-295M3.2	3.89	0.000121	0.0375	0.24	0.2	Fibrinogen;	chr16:53309688	chr16:53168522~53169450:+
STAD	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-3.89	0.000121	0.0375	-0.22	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
STAD	cis	rs10508774	0.866	rs10827057	ENSG00000273038.2	RP11-479G22.8	3.89	0.000121	0.0375	0.4	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32442447	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72793595	ENSG00000273038.2	RP11-479G22.8	3.89	0.000121	0.0375	0.4	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32448287	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12251052	ENSG00000273038.2	RP11-479G22.8	3.89	0.000121	0.0375	0.4	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32457697	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12243271	ENSG00000273038.2	RP11-479G22.8	3.89	0.000121	0.0375	0.4	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32457711	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs9971245	ENSG00000273038.2	RP11-479G22.8	3.89	0.000121	0.0375	0.4	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32465485	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs12415588	ENSG00000273038.2	RP11-479G22.8	3.89	0.000121	0.0375	0.4	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32472664	chr10:32887255~32889311:-
STAD	cis	rs17592366	0.762	rs4982227	ENSG00000251726.1	RNU7-41P	-3.89	0.000121	0.0375	-0.23	-0.2	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34877401	chr14:34845300~34845360:-
STAD	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	3.89	0.000121	0.0375	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
STAD	cis	rs11235843	0.853	rs66610247	ENSG00000255928.1	RP11-456I15.2	3.89	0.000121	0.0375	0.36	0.2	Hand grip strength;	chr11:73786315	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.853	rs11235905	ENSG00000255928.1	RP11-456I15.2	3.89	0.000121	0.0375	0.36	0.2	Hand grip strength;	chr11:73786901	chr11:73722349~73722694:+
STAD	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-3.89	0.000121	0.0375	-0.27	-0.2	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
STAD	cis	rs6669008	1	rs1891969	ENSG00000232450.1	RP4-730K3.3	-3.89	0.000121	0.0375	-0.22	-0.2	Bacteremia;	chr1:113643233	chr1:113698884~113699631:-
STAD	cis	rs10986311	0.722	rs944339	ENSG00000227200.1	RP11-121A14.3	-3.89	0.000121	0.0375	-0.22	-0.2	Vitiligo;	chr9:124278699	chr9:124262876~124265809:+
STAD	cis	rs8098244	0.737	rs1154243	ENSG00000267301.1	RPL23AP77	3.89	0.000121	0.0376	0.28	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23963824	chr18:23709825~23710287:-
STAD	cis	rs8098244	0.708	rs1154245	ENSG00000267301.1	RPL23AP77	3.89	0.000121	0.0376	0.28	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964250	chr18:23709825~23710287:-
STAD	cis	rs7829975	0.557	rs7816427	ENSG00000254340.1	RP11-10A14.3	-3.89	0.000121	0.0376	-0.28	-0.2	Mood instability;	chr8:8688374	chr8:9141424~9145435:+
STAD	cis	rs921665	0.831	rs2167962	ENSG00000236760.1	AC019118.3	-3.89	0.000121	0.0376	-0.32	-0.2	World class endurance athleticism;	chr2:3188656	chr2:3131581~3145780:-
STAD	cis	rs9467773	0.967	rs6456732	ENSG00000261353.1	CTA-14H9.5	-3.89	0.000121	0.0376	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26527063~26527404:+
STAD	cis	rs11051970	0.559	rs10431283	ENSG00000274964.1	RP11-817I4.1	-3.89	0.000121	0.0376	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32315070	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs10431225	ENSG00000274964.1	RP11-817I4.1	-3.89	0.000121	0.0376	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32315177	chr12:32339368~32340724:+
STAD	cis	rs953387	1	rs6715785	ENSG00000231890.6	DARS-AS1	-3.89	0.000121	0.0376	-0.21	-0.2	Arthritis (juvenile idiopathic);	chr2:136152703	chr2:135985176~136022593:+
STAD	cis	rs8141529	0.507	rs5762936	ENSG00000226471.5	CTA-292E10.6	-3.89	0.000121	0.0376	-0.36	-0.2	Lymphocyte counts;	chr22:28985389	chr22:28800683~28848559:+
STAD	cis	rs12468226	0.872	rs1061157	ENSG00000272966.1	RP11-686O6.1	3.89	0.000121	0.0376	0.31	0.2	Urate levels;	chr2:202556476	chr2:202336739~202337200:+
STAD	cis	rs12468226	1	rs112753638	ENSG00000272966.1	RP11-686O6.1	3.89	0.000121	0.0376	0.3	0.2	Urate levels;	chr2:202334496	chr2:202336739~202337200:+
STAD	cis	rs875971	0.862	rs4149461	ENSG00000224316.1	RP11-479O9.2	-3.89	0.000121	0.0376	-0.2	-0.2	Aortic root size;	chr7:66279745	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs10261398	ENSG00000224316.1	RP11-479O9.2	-3.89	0.000121	0.0376	-0.2	-0.2	Aortic root size;	chr7:66285177	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs10224872	ENSG00000224316.1	RP11-479O9.2	-3.89	0.000121	0.0376	-0.2	-0.2	Aortic root size;	chr7:66294786	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs949930	ENSG00000224316.1	RP11-479O9.2	-3.89	0.000121	0.0376	-0.2	-0.2	Aortic root size;	chr7:66301835	chr7:65773620~65802067:+
STAD	cis	rs7589728	1	rs7589728	ENSG00000240671.2	IGKV1-8	3.89	0.000121	0.0376	0.25	0.2	Plasma clusterin levels;	chr2:88218921	chr2:88857361~88992931:-
STAD	cis	rs9921338	0.961	rs4780357	ENSG00000263080.1	RP11-485G7.5	3.89	0.000121	0.0376	0.31	0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11277114	chr16:11341809~11345211:-
STAD	cis	rs9601248	0.756	rs2146592	ENSG00000227676.3	LINC01068	-3.89	0.000121	0.0376	-0.25	-0.2	Major depressive disorder;	chr13:79606146	chr13:79566727~79571436:+
STAD	cis	rs7474896	0.559	rs1735629	ENSG00000120555.12	SEPT7P9	-3.89	0.000121	0.0376	-0.25	-0.2	Obesity (extreme);	chr10:37889381	chr10:38383069~38402916:-
STAD	cis	rs1850744	0.609	rs2037315	ENSG00000163612.10	FAM86KP	-3.89	0.000121	0.0376	-0.48	-0.2	Economic and political preferences;	chr4:9720784	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.536	rs2037313	ENSG00000163612.10	FAM86KP	-3.89	0.000121	0.0376	-0.48	-0.2	Economic and political preferences;	chr4:9723087	chr4:9153296~9165451:+
STAD	cis	rs1816752	0.624	rs2096093	ENSG00000273628.1	RP11-756A22.7	-3.89	0.000121	0.0376	-0.25	-0.2	Obesity-related traits;	chr13:24472753	chr13:24933006~24936796:+
STAD	cis	rs6480314	0.522	rs10733842	ENSG00000234102.1	KRT19P4	3.89	0.000121	0.0376	0.25	0.2	Optic nerve measurement (disc area);	chr10:68299286	chr10:68260557~68261499:+
STAD	cis	rs4792901	0.759	rs60442473	ENSG00000279602.1	CTD-3014M21.1	-3.89	0.000121	0.0376	-0.28	-0.2	Dupuytren's disease;	chr17:43501919	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs76971300	ENSG00000279602.1	CTD-3014M21.1	-3.89	0.000121	0.0376	-0.28	-0.2	Dupuytren's disease;	chr17:43503220	chr17:43360041~43361361:-
STAD	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-3.89	0.000121	0.0376	-0.23	-0.2	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
STAD	cis	rs765787	0.53	rs2433228	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000121	0.0377	0.23	0.2	Uric acid levels;	chr15:45223173	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs11854690	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000121	0.0377	0.23	0.2	Uric acid levels;	chr15:45223818	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs28733848	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000121	0.0377	0.23	0.2	Uric acid levels;	chr15:45223849	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs11854689	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000121	0.0377	0.23	0.2	Uric acid levels;	chr15:45223854	chr15:45152664~45167526:-
STAD	cis	rs9902453	0.868	rs7212162	ENSG00000263477.1	RP11-338L22.2	3.89	0.000121	0.0377	0.17	0.2	Coffee consumption (cups per day);	chr17:29994310	chr17:29863402~29866092:+
STAD	cis	rs4713118	0.868	rs10484401	ENSG00000243307.2	POM121L6P	3.89	0.000121	0.0377	0.25	0.2	Parkinson's disease;	chr6:27778811	chr6:26896952~26898777:+
STAD	cis	rs6005807	0.588	rs16986177	ENSG00000226471.5	CTA-292E10.6	-3.89	0.000121	0.0377	-0.33	-0.2	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28233725	chr22:28800683~28848559:+
STAD	cis	rs9307551	0.522	rs13111877	ENSG00000250334.4	LINC00989	-3.89	0.000121	0.0377	-0.25	-0.2	Refractive error;	chr4:79506745	chr4:79492416~79576460:+
STAD	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	3.89	0.000121	0.0377	0.27	0.2	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
STAD	cis	rs427941	0.609	rs4729776	ENSG00000232445.1	RP11-132A1.4	-3.89	0.000121	0.0377	-0.25	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102186784	chr7:101308346~101310985:+
STAD	cis	rs58873874	0.579	rs35536103	ENSG00000251405.2	CTB-109A12.1	3.89	0.000121	0.0377	0.33	0.2	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.579	rs75099611	ENSG00000251405.2	CTB-109A12.1	3.89	0.000121	0.0377	0.33	0.2	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157362615~157460078:-
STAD	cis	rs870825	0.616	rs6552809	ENSG00000249173.4	LINC01093	-3.89	0.000121	0.0377	-0.33	-0.2	Blood protein levels;	chr4:184722830	chr4:184893871~184899454:-
STAD	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-3.89	0.000121	0.0377	-0.25	-0.2	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
STAD	cis	rs6693567	0.565	rs1260374	ENSG00000203819.6	HIST2H2BC	3.89	0.000121	0.0377	0.24	0.2	Migraine;	chr1:150359117	chr1:149850193~149850772:-
STAD	cis	rs6432852	0.55	rs10930191	ENSG00000229195.1	AC009495.4	-3.89	0.000121	0.0377	-0.24	-0.2	Diabetic kidney disease;	chr2:165950096	chr2:165794857~165846091:-
STAD	cis	rs10911902	0.643	rs34585917	ENSG00000229739.2	RP11-295K2.3	-3.89	0.000121	0.0377	-0.29	-0.2	Schizophrenia;	chr1:186317650	chr1:186435161~186470291:+
STAD	cis	rs230529	0.51	rs1120986	ENSG00000248971.2	KRT8P46	-3.89	0.000121	0.0377	-0.22	-0.2	Schizophrenia (treatment resistant);	chr4:102515484	chr4:102728746~102730171:-
STAD	cis	rs8081395	0.627	rs12952730	ENSG00000266701.1	AC005702.4	3.89	0.000121	0.0377	0.26	0.2	White blood cell count;	chr17:59901475	chr17:60042546~60042627:-
STAD	cis	rs9393777	0.513	rs9393737	ENSG00000241549.7	GUSBP2	-3.89	0.000121	0.0377	-0.28	-0.2	Intelligence (multi-trait analysis);	chr6:26617078	chr6:26871484~26956554:-
STAD	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-3.89	0.000121	0.0377	-0.27	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
STAD	cis	rs6430585	0.64	rs3816155	ENSG00000231890.6	DARS-AS1	3.89	0.000121	0.0377	0.25	0.2	Corneal structure;	chr2:135794956	chr2:135985176~136022593:+
STAD	cis	rs11235843	0.929	rs68128239	ENSG00000255928.1	RP11-456I15.2	3.89	0.000121	0.0377	0.35	0.2	Hand grip strength;	chr11:73709547	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs67167213	ENSG00000255928.1	RP11-456I15.2	3.89	0.000121	0.0377	0.35	0.2	Hand grip strength;	chr11:73711163	chr11:73722349~73722694:+
STAD	cis	rs6676180	0.555	rs947430	ENSG00000231365.4	RP11-418J17.1	-3.89	0.000122	0.0378	-0.25	-0.2	Monobrow;	chr1:119236111	chr1:119140396~119275973:+
STAD	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-3.89	0.000122	0.0378	-0.24	-0.2	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
STAD	cis	rs7680126	0.536	rs7661701	ENSG00000250613.1	RP11-136I13.1	-3.89	0.000122	0.0378	-0.25	-0.2	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10062474	chr4:10410996~10411644:+
STAD	cis	rs1499614	1	rs1882655	ENSG00000273448.1	RP11-166O4.6	-3.89	0.000122	0.0378	-0.25	-0.2	Gout;	chr7:66682070	chr7:67333047~67334383:+
STAD	cis	rs1499614	0.831	rs3800822	ENSG00000273448.1	RP11-166O4.6	-3.89	0.000122	0.0378	-0.25	-0.2	Gout;	chr7:66682162	chr7:67333047~67334383:+
STAD	cis	rs919433	0.963	rs12618612	ENSG00000231621.1	AC013264.2	3.89	0.000122	0.0378	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306334	chr2:197197991~197199273:+
STAD	cis	rs919433	0.963	rs13033821	ENSG00000231621.1	AC013264.2	3.89	0.000122	0.0378	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197308812	chr2:197197991~197199273:+
STAD	cis	rs11089937	0.616	rs5757247	ENSG00000211639.2	IGLV4-60	3.89	0.000122	0.0378	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22177186	chr22:22162199~22162681:+
STAD	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	3.89	0.000122	0.0378	0.26	0.2	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
STAD	cis	rs6832769	0.925	rs2899037	ENSG00000223305.1	RN7SKP30	-3.89	0.000122	0.0378	-0.23	-0.2	Personality dimensions;	chr4:55591180	chr4:55540502~55540835:-
STAD	cis	rs794185	0.652	rs2819584	ENSG00000231249.1	ITPR1-AS1	-3.89	0.000122	0.0378	-0.23	-0.2	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470566	chr3:4490891~4493163:-
STAD	cis	rs58521262	0.614	rs10413357	ENSG00000233836.6	RP11-255H23.2	3.89	0.000122	0.0378	0.31	0.2	Testicular germ cell tumor;	chr19:23180813	chr19:23762944~23833314:+
STAD	cis	rs6430585	0.64	rs58301703	ENSG00000231890.6	DARS-AS1	-3.89	0.000122	0.0378	-0.24	-0.2	Corneal structure;	chr2:135774655	chr2:135985176~136022593:+
STAD	cis	rs8141529	0.748	rs132533	ENSG00000226471.5	CTA-292E10.6	3.89	0.000122	0.0378	0.24	0.2	Lymphocyte counts;	chr22:28903583	chr22:28800683~28848559:+
STAD	cis	rs4141404	0.74	rs4820946	ENSG00000236132.1	CTA-440B3.1	-3.89	0.000122	0.0378	-0.23	-0.2	Paclitaxel-induced neuropathy;	chr22:31155174	chr22:31816379~31817491:-
STAD	cis	rs9426935	0.865	rs6427300	ENSG00000272030.1	RP1-178F15.4	3.89	0.000122	0.0378	0.27	0.2	Lentiform nucleus volume;	chr1:153833201	chr1:153631438~153634397:-
STAD	cis	rs9426935	0.932	rs6427306	ENSG00000272030.1	RP1-178F15.4	3.89	0.000122	0.0378	0.27	0.2	Lentiform nucleus volume;	chr1:153839643	chr1:153631438~153634397:-
STAD	cis	rs9426935	0.872	rs4370789	ENSG00000272030.1	RP1-178F15.4	3.89	0.000122	0.0378	0.27	0.2	Lentiform nucleus volume;	chr1:153840689	chr1:153631438~153634397:-
STAD	cis	rs9426935	0.934	rs4581307	ENSG00000272030.1	RP1-178F15.4	3.89	0.000122	0.0378	0.27	0.2	Lentiform nucleus volume;	chr1:153842067	chr1:153631438~153634397:-
STAD	cis	rs9426935	0.966	rs72694233	ENSG00000272030.1	RP1-178F15.4	3.89	0.000122	0.0378	0.27	0.2	Lentiform nucleus volume;	chr1:153845279	chr1:153631438~153634397:-
STAD	cis	rs6686842	0.56	rs61781830	ENSG00000235358.1	RP11-399E6.1	-3.89	0.000122	0.0378	-0.23	-0.2	Height;	chr1:41167695	chr1:41242373~41284861:+
STAD	cis	rs6686842	0.56	rs12127030	ENSG00000235358.1	RP11-399E6.1	-3.89	0.000122	0.0378	-0.23	-0.2	Height;	chr1:41172726	chr1:41242373~41284861:+
STAD	cis	rs2154319	0.559	rs213746	ENSG00000235358.1	RP11-399E6.1	3.89	0.000122	0.0378	0.23	0.2	Height;	chr1:41163143	chr1:41242373~41284861:+
STAD	cis	rs765787	0.53	rs2433229	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000122	0.0378	0.23	0.2	Uric acid levels;	chr15:45223037	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs4331289	ENSG00000259539.1	CTD-2651B20.1	3.89	0.000122	0.0378	0.23	0.2	Uric acid levels;	chr15:45223140	chr15:45152664~45167526:-
STAD	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-3.89	0.000122	0.0378	-0.22	-0.2	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
STAD	cis	rs6813195	0.642	rs2406375	ENSG00000243417.1	RP11-555K12.1	-3.89	0.000122	0.0378	-0.21	-0.2	Type 2 diabetes;	chr4:152446105	chr4:152551277~152552364:-
STAD	cis	rs13224082	0.736	rs12706120	ENSG00000227199.1	ST7-AS1	-3.89	0.000122	0.0378	-0.28	-0.2	Platelet distribution width;	chr7:116916352	chr7:116952446~116954334:-
STAD	cis	rs14027	0.921	rs13262434	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000122	0.0378	-0.19	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733423	chr8:119838736~119840385:-
STAD	cis	rs853679	0.585	rs201001	ENSG00000220721.1	OR1F12	3.89	0.000122	0.0378	0.24	0.2	Depression;	chr6:27841121	chr6:28073316~28074233:+
STAD	cis	rs853679	0.585	rs201000	ENSG00000220721.1	OR1F12	3.89	0.000122	0.0378	0.24	0.2	Depression;	chr6:27841381	chr6:28073316~28074233:+
STAD	cis	rs2115630	1	rs11073730	ENSG00000275120.1	RP11-182J1.17	-3.89	0.000122	0.0378	-0.23	-0.2	P wave terminal force;	chr15:84811365	chr15:84599434~84606463:-
STAD	cis	rs449789	0.524	rs3904936	ENSG00000235086.1	FNDC1-IT1	-3.89	0.000122	0.0378	-0.27	-0.2	Pulse pressure;	chr6:159356910	chr6:159240786~159243329:+
STAD	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	3.89	0.000122	0.0378	0.17	0.2	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
STAD	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-3.89	0.000122	0.0378	-0.2	-0.2	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
STAD	cis	rs2836950	0.545	rs11700449	ENSG00000238141.2	BRWD1-AS1	-3.89	0.000122	0.0378	-0.21	-0.2	Menarche (age at onset);	chr21:39150493	chr21:39315707~39323218:+
STAD	cis	rs7567389	0.505	rs1518760	ENSG00000200250.1	RNU6-1147P	-3.89	0.000122	0.0378	-0.23	-0.2	Self-rated health;	chr2:127382924	chr2:127316873~127316979:+
STAD	cis	rs11089937	0.597	rs4821773	ENSG00000211640.3	IGLV6-57	3.89	0.000122	0.0378	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22195713~22196460:+
STAD	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-3.89	0.000122	0.0378	-0.28	-0.2	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
STAD	cis	rs9463078	0.764	rs494982	ENSG00000219384.1	RP11-491H9.3	3.89	0.000122	0.0378	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44969518	chr6:45158870~45159511:+
STAD	cis	rs73198271	0.595	rs11780672	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000122	0.0378	-0.31	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8726643	chr8:8961200~8979025:+
STAD	cis	rs6933660	0.72	rs6913515	ENSG00000221469.1	AL133260.1	3.89	0.000122	0.0379	0.22	0.2	Menarche (age at onset);	chr6:151432335	chr6:151039916~151039971:-
STAD	cis	rs9287719	0.614	rs12329184	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10582638	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.614	rs10929679	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10582982	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.614	rs10929680	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10583000	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.614	rs10929681	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10583157	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.614	rs6711473	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10583248	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.624	rs10211190	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10585302	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10166765	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10585547	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs6720112	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10585593	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs6730247	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10585762	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs6717431	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10585920	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10184776	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10586320	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.6	rs10197187	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10586513	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.624	rs10199635	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10586514	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.624	rs10199831	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10586737	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.624	rs10187659	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10586834	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10202370	ENSG00000243819.4	RN7SL832P	3.89	0.000122	0.0379	0.2	0.2	Prostate cancer;	chr2:10586917	chr2:10690344~10692099:+
STAD	cis	rs9291683	0.935	rs1860911	ENSG00000250613.1	RP11-136I13.1	-3.89	0.000122	0.0379	-0.19	-0.2	Bone mineral density;	chr4:10273433	chr4:10410996~10411644:+
STAD	cis	rs6832769	0.961	rs28713343	ENSG00000223305.1	RN7SKP30	-3.89	0.000122	0.0379	-0.23	-0.2	Personality dimensions;	chr4:55590924	chr4:55540502~55540835:-
STAD	cis	rs7567389	0.626	rs11683344	ENSG00000200250.1	RNU6-1147P	-3.89	0.000122	0.0379	-0.23	-0.2	Self-rated health;	chr2:127198676	chr2:127316873~127316979:+
STAD	cis	rs79349575	0.783	rs58591767	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48948714	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.783	rs59270107	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48948823	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.783	rs62078370	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48949474	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.783	rs11079844	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48950972	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.783	rs62078372	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48951627	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.783	rs12602933	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48951918	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.783	rs4794003	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48952542	chr17:48874860~48908983:-
STAD	cis	rs79349575	0.783	rs12602746	ENSG00000248278.1	SUMO2P17	3.89	0.000122	0.0379	0.22	0.2	Type 2 diabetes;	chr17:48954379	chr17:48874860~48908983:-
STAD	cis	rs583583	0.928	rs17361839	ENSG00000231196.3	RP11-495P10.8	3.89	0.000122	0.0379	0.27	0.2	Schizophrenia (negative symptoms);	chr1:147627887	chr1:148290890~148295859:-
STAD	cis	rs7204230	1	rs12599823	ENSG00000261291.1	RP11-295M3.2	3.89	0.000122	0.0379	0.24	0.2	Fibrinogen;	chr16:53315316	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs1109646	ENSG00000261291.1	RP11-295M3.2	3.89	0.000122	0.0379	0.24	0.2	Fibrinogen;	chr16:53316927	chr16:53168522~53169450:+
STAD	cis	rs2273156	0.706	rs7144617	ENSG00000258704.4	SRP54-AS1	-3.89	0.000122	0.0379	-0.25	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35028853	chr14:34920858~34982532:-
STAD	cis	rs2404602	0.618	rs12442266	ENSG00000196274.5	Metazoa_SRP	3.89	0.000122	0.0379	0.18	0.2	Blood metabolite levels;	chr15:76274801	chr15:76230048~76230390:-
STAD	cis	rs73198271	0.813	rs17697237	ENSG00000233609.3	RP11-62H7.2	3.89	0.000122	0.0379	0.27	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8961200~8979025:+
STAD	cis	rs4713118	0.786	rs200503	ENSG00000220721.1	OR1F12	3.89	0.000122	0.0379	0.23	0.2	Parkinson's disease;	chr6:27818104	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.786	rs200502	ENSG00000220721.1	OR1F12	3.89	0.000122	0.0379	0.23	0.2	Parkinson's disease;	chr6:27820284	chr6:28073316~28074233:+
STAD	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-3.89	0.000122	0.0379	-0.32	-0.2	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
STAD	cis	rs4388249	1	rs2300997	ENSG00000271849.1	CTC-332L22.1	-3.89	0.000122	0.0379	-0.31	-0.2	Schizophrenia;	chr5:109746893	chr5:109687802~109688329:-
STAD	cis	rs4388249	1	rs11960226	ENSG00000271849.1	CTC-332L22.1	-3.89	0.000122	0.0379	-0.31	-0.2	Schizophrenia;	chr5:109747980	chr5:109687802~109688329:-
STAD	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	3.89	0.000122	0.0379	0.26	0.2	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
STAD	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-3.89	0.000122	0.0379	-0.25	-0.2	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
STAD	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	3.89	0.000122	0.0379	0.31	0.2	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
STAD	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	3.89	0.000122	0.0379	0.21	0.2	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
STAD	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-3.89	0.000122	0.0379	-0.32	-0.2	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
STAD	cis	rs7142881	0.76	rs4143987	ENSG00000258648.1	UBE2CP1	-3.89	0.000122	0.038	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31554353	chr14:30683045~30683598:-
STAD	cis	rs6095298	0.574	rs4428070	ENSG00000227431.4	CSE1L-AS1	-3.89	0.000122	0.038	-0.23	-0.2	Intelligence (multi-trait analysis);	chr20:48841198	chr20:49040463~49046044:-
STAD	cis	rs2919917	0.628	rs2717544	ENSG00000254266.4	RP11-594N15.2	-3.89	0.000122	0.038	-0.28	-0.2	Lymphocyte counts;	chr8:78724307	chr8:78426103~78558503:-
STAD	cis	rs11674184	0.564	rs746579	ENSG00000224177.5	LINC00570	-3.89	0.000122	0.038	-0.27	-0.2	Endometriosis;	chr2:11604568	chr2:11393981~11403077:+
STAD	cis	rs875971	0.964	rs160635	ENSG00000224316.1	RP11-479O9.2	3.89	0.000122	0.038	0.21	0.2	Aortic root size;	chr7:66063931	chr7:65773620~65802067:+
STAD	cis	rs10040610	0.524	rs271419	ENSG00000250490.1	FLJ33360	3.89	0.000122	0.038	0.24	0.2	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6353897	chr5:6310441~6339884:-
STAD	cis	rs11157436	0.602	rs17255447	ENSG00000211813.2	TRAV34	-3.89	0.000123	0.038	-0.23	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22207522~22208129:+
STAD	cis	rs7926906	1	rs1524939	ENSG00000280367.1	RP11-121L10.2	3.89	0.000123	0.038	0.21	0.2	Intelligence (multi-trait analysis);	chr11:90802452	chr11:90223153~90226538:+
STAD	cis	rs9902453	0.817	rs2617880	ENSG00000263477.1	RP11-338L22.2	-3.89	0.000123	0.038	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29779100	chr17:29863402~29866092:+
STAD	cis	rs2790457	0.833	rs1265846	ENSG00000254635.4	WAC-AS1	-3.89	0.000123	0.038	-0.25	-0.2	Multiple myeloma;	chr10:28640168	chr10:28522652~28532743:-
STAD	cis	rs7395581	0.918	rs10501321	ENSG00000271350.1	CTD-2384B9.1	3.89	0.000123	0.038	0.24	0.2	HDL cholesterol;	chr11:47273075	chr11:47041027~47041945:-
STAD	cis	rs6840360	0.642	rs6535803	ENSG00000270265.1	RP11-731D1.4	-3.89	0.000123	0.038	-0.25	-0.2	Intelligence (multi-trait analysis);	chr4:151520762	chr4:151333775~151353224:-
STAD	cis	rs4713118	0.868	rs742047	ENSG00000243307.2	POM121L6P	-3.89	0.000123	0.038	-0.25	-0.2	Parkinson's disease;	chr6:27771601	chr6:26896952~26898777:+
STAD	cis	rs4345303	0.745	rs4458556	ENSG00000206592.1	SNORA18	-3.89	0.000123	0.038	-0.22	-0.2	Interleukin-10 levels;	chr5:79415881	chr5:79220942~79221073:+
STAD	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	3.89	0.000123	0.038	0.22	0.2	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
STAD	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	3.89	0.000123	0.038	0.18	0.2	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
STAD	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	3.89	0.000123	0.038	0.2	0.2	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
STAD	cis	rs9463078	0.817	rs2145826	ENSG00000219384.1	RP11-491H9.3	-3.89	0.000123	0.038	-0.2	-0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44796044	chr6:45158870~45159511:+
STAD	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-3.89	0.000123	0.038	-0.26	-0.2	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
STAD	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	3.89	0.000123	0.038	0.21	0.2	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
STAD	cis	rs172166	0.637	rs1225597	ENSG00000280107.1	AL022393.9	-3.88	0.000123	0.038	-0.26	-0.2	Cardiac Troponin-T levels;	chr6:28194309	chr6:28170845~28172521:+
STAD	cis	rs12745968	0.532	rs10874724	ENSG00000229052.2	RP11-386I23.1	-3.88	0.000123	0.038	-0.2	-0.2	Bipolar disorder and schizophrenia;	chr1:92622626	chr1:92930696~92934098:+
STAD	cis	rs7520050	0.966	rs7556436	ENSG00000280836.1	AL355480.1	-3.88	0.000123	0.038	-0.25	-0.2	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45581219~45581321:-
STAD	cis	rs858239	0.539	rs2390757	ENSG00000230042.1	AK3P3	-3.88	0.000123	0.038	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23129178~23129841:+
STAD	cis	rs9860428	0.564	rs9821278	ENSG00000240057.4	RP11-572M11.4	-3.88	0.000123	0.038	-0.18	-0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112797037	chr3:113019532~113183301:+
STAD	cis	rs2243480	1	rs1499614	ENSG00000222364.1	RNU6-96P	-3.88	0.000123	0.038	-0.32	-0.2	Diabetic kidney disease;	chr7:66265811	chr7:66395191~66395286:+
STAD	cis	rs75920871	0.702	rs59511712	ENSG00000254851.1	RP11-109L13.1	3.88	0.000123	0.038	0.25	0.2	Subjective well-being;	chr11:117075046	chr11:117135528~117138582:+
STAD	cis	rs11098499	0.575	rs9996586	ENSG00000249244.1	RP11-548H18.2	3.88	0.000123	0.038	0.25	0.2	Corneal astigmatism;	chr4:119405787	chr4:119391831~119395335:-
STAD	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-3.88	0.000123	0.0381	-0.32	-0.2	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
STAD	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-3.88	0.000123	0.0381	-0.32	-0.2	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
STAD	cis	rs1850744	0.702	rs73802906	ENSG00000250942.1	ENPP7P11	-3.88	0.000123	0.0381	-0.36	-0.2	Economic and political preferences;	chr4:9596824	chr4:9677308~9677934:+
STAD	cis	rs6432852	0.932	rs4667851	ENSG00000229195.1	AC009495.4	3.88	0.000123	0.0381	0.23	0.2	Diabetic kidney disease;	chr2:165881155	chr2:165794857~165846091:-
STAD	cis	rs138544659	1	rs138544659	ENSG00000259419.2	HNRNPCP3	3.88	0.000123	0.0381	0.22	0.2	Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78608359	chr15:79236332~79237206:+
STAD	cis	rs1964356	0.524	rs7839585	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000123	0.0381	-0.24	-0.2	Mean corpuscular volume;	chr8:8996725	chr8:9141424~9145435:+
STAD	cis	rs9902453	0.904	rs12939344	ENSG00000263477.1	RP11-338L22.2	-3.88	0.000123	0.0381	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30001801	chr17:29863402~29866092:+
STAD	cis	rs2638953	0.779	rs61920241	ENSG00000247934.4	RP11-967K21.1	-3.88	0.000123	0.0381	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28163298~28190738:-
STAD	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	3.88	0.000123	0.0381	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	3.88	0.000123	0.0381	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	3.88	0.000123	0.0381	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
STAD	cis	rs2638953	0.893	rs1464011	ENSG00000247934.4	RP11-967K21.1	-3.88	0.000123	0.0381	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28516871	chr12:28163298~28190738:-
STAD	cis	rs34779708	0.771	rs12098283	ENSG00000271335.4	RP11-324I22.4	3.88	0.000123	0.0381	0.25	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35314552~35336401:-
STAD	cis	rs765787	0.53	rs1706830	ENSG00000259539.1	CTD-2651B20.1	3.88	0.000123	0.0381	0.23	0.2	Uric acid levels;	chr15:45224031	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs1706831	ENSG00000259539.1	CTD-2651B20.1	3.88	0.000123	0.0381	0.23	0.2	Uric acid levels;	chr15:45224032	chr15:45152664~45167526:-
STAD	cis	rs765787	0.53	rs2433227	ENSG00000259539.1	CTD-2651B20.1	3.88	0.000123	0.0381	0.23	0.2	Uric acid levels;	chr15:45224921	chr15:45152664~45167526:-
STAD	cis	rs7512552	0.809	rs696618	ENSG00000203819.6	HIST2H2BC	3.88	0.000123	0.0381	0.24	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150403663	chr1:149850193~149850772:-
STAD	cis	rs2836950	0.565	rs4816617	ENSG00000238141.2	BRWD1-AS1	-3.88	0.000123	0.0381	-0.21	-0.2	Menarche (age at onset);	chr21:39168764	chr21:39315707~39323218:+
STAD	cis	rs73198271	0.74	rs10105690	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000123	0.0381	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.74	rs67766414	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000123	0.0381	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:9141424~9145435:+
STAD	cis	rs9393777	0.557	rs9358949	ENSG00000241549.7	GUSBP2	3.88	0.000123	0.0381	0.31	0.2	Intelligence (multi-trait analysis);	chr6:26485489	chr6:26871484~26956554:-
STAD	cis	rs4589258	0.788	rs11019172	ENSG00000280367.1	RP11-121L10.2	3.88	0.000123	0.0381	0.21	0.2	Intelligence (multi-trait analysis);	chr11:90758906	chr11:90223153~90226538:+
STAD	cis	rs919433	0.963	rs7582736	ENSG00000231621.1	AC013264.2	3.88	0.000123	0.0381	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305618	chr2:197197991~197199273:+
STAD	cis	rs9419788	0.708	rs9325467	ENSG00000227995.1	RAB11AP1	3.88	0.000123	0.0382	0.24	0.2	Personality traits in bipolar disorder;	chr10:94231579	chr10:93881293~93881938:-
STAD	cis	rs7176527	0.848	rs1374463	ENSG00000188388.10	GOLGA6L3	3.88	0.000123	0.0382	0.32	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:85240472~85247170:+
STAD	cis	rs7824557	0.569	rs35418978	ENSG00000205879.4	FAM90A2P	3.88	0.000123	0.0382	0.23	0.2	Retinal vascular caliber;	chr8:11328944	chr8:12172202~12178575:-
STAD	cis	rs2337406	1	rs10459466	ENSG00000254174.1	IGHV1-12	3.88	0.000123	0.0382	0.25	0.2	Alzheimer's disease (late onset);	chr14:106689255	chr14:106122420~106122709:-
STAD	cis	rs6718520	1	rs6718520	ENSG00000229695.1	AC011242.5	3.88	0.000123	0.0382	0.2	0.2	Multiple sclerosis;	chr2:43098432	chr2:43680465~43681622:-
STAD	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	3.88	0.000123	0.0382	0.23	0.2	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
STAD	cis	rs2904967	0.636	rs184734	ENSG00000254614.2	AP003068.23	-3.88	0.000123	0.0382	-0.3	-0.2	Mean corpuscular volume;	chr11:65214732	chr11:65177606~65181834:-
STAD	cis	rs4835473	0.868	rs4350958	ENSG00000249741.2	RP11-673E1.3	-3.88	0.000123	0.0382	-0.24	-0.2	Immature fraction of reticulocytes;	chr4:143744656	chr4:143911514~143912053:-
STAD	cis	rs4639966	0.684	rs487177	ENSG00000255239.1	AP002954.6	-3.88	0.000123	0.0382	-0.26	-0.2	Systemic lupus erythematosus;	chr11:118786588	chr11:118688039~118690600:-
STAD	cis	rs3764400	0.508	rs55696440	ENSG00000278765.1	RP5-890E16.5	3.88	0.000123	0.0382	0.27	0.2	Body mass index;	chr17:48193784	chr17:48066704~48067293:-
STAD	cis	rs10129255	1	rs11621409	ENSG00000232216.1	IGHV3-43	3.88	0.000123	0.0382	0.21	0.2	Kawasaki disease;	chr14:106695603	chr14:106470264~106470800:-
STAD	cis	rs13413635	0.862	rs2695115	ENSG00000225808.1	DNAJC19P5	3.88	0.000123	0.0382	0.26	0.2	Heart rate;	chr2:177918328	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.817	rs2695730	ENSG00000225808.1	DNAJC19P5	3.88	0.000123	0.0382	0.26	0.2	Heart rate;	chr2:177919552	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.817	rs2695731	ENSG00000225808.1	DNAJC19P5	3.88	0.000123	0.0382	0.26	0.2	Heart rate;	chr2:177919580	chr2:177229191~177229506:-
STAD	cis	rs9297145	0.585	rs13235218	ENSG00000272950.1	RP11-307C18.1	-3.88	0.000123	0.0382	-0.23	-0.2	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99187457	chr7:98322853~98323430:+
STAD	cis	rs832187	0.679	rs9879045	ENSG00000280620.1	SCAANT1	3.88	0.000124	0.0383	0.27	0.2	Schizophrenia;	chr3:64016249	chr3:63911518~63911772:-
STAD	cis	rs1816752	0.583	rs6490918	ENSG00000232858.1	RPL34P27	-3.88	0.000124	0.0383	-0.12	-0.2	Obesity-related traits;	chr13:24427977	chr13:24988577~24988925:-
STAD	cis	rs9549328	0.879	rs12428058	ENSG00000267868.1	RP11-120K24.3	3.88	0.000124	0.0383	0.29	0.2	Systolic blood pressure;	chr13:112982190	chr13:112964835~112966131:-
STAD	cis	rs478304	0.903	rs495961	ENSG00000213409.4	RP11-658F2.3	-3.88	0.000124	0.0383	-0.16	-0.2	Acne (severe);	chr11:65773415	chr11:66761575~66762399:-
STAD	cis	rs7829975	0.846	rs7005216	ENSG00000173295.6	FAM86B3P	-3.88	0.000124	0.0383	-0.24	-0.2	Mood instability;	chr8:8689600	chr8:8228595~8244865:+
STAD	cis	rs7015630	0.657	rs12155807	ENSG00000251136.7	RP11-37B2.1	-3.88	0.000124	0.0383	-0.27	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89835484	chr8:89609409~89757727:-
STAD	cis	rs2957692	0.548	rs1822292	ENSG00000254554.1	RP11-351I24.1	3.88	0.000124	0.0383	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10223131	chr11:10302657~10303704:-
STAD	cis	rs62400317	0.762	rs1329711	ENSG00000219384.1	RP11-491H9.3	-3.88	0.000124	0.0383	-0.23	-0.2	Total body bone mineral density;	chr6:44995664	chr6:45158870~45159511:+
STAD	cis	rs12439619	0.739	rs4778988	ENSG00000276710.3	CSPG4P8	-3.88	0.000124	0.0383	-0.28	-0.2	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82459472~82477258:+
STAD	cis	rs7429990	0.828	rs11712152	ENSG00000224895.1	VPS26BP1	-3.88	0.000124	0.0383	-0.2	-0.2	Educational attainment (years of education);	chr3:47655314	chr3:47960327~47961081:-
STAD	cis	rs2337406	1	rs78857163	ENSG00000280411.1	IGHV1-69-2	-3.88	0.000124	0.0383	-0.27	-0.2	Alzheimer's disease (late onset);	chr14:106707435	chr14:106762092~106762588:-
STAD	cis	rs30380	0.632	rs27045	ENSG00000272109.1	CTD-2260A17.3	-3.88	0.000124	0.0383	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr5:96803158	chr5:96804353~96806105:+
STAD	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	3.88	0.000124	0.0383	0.27	0.2	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
STAD	cis	rs1850744	0.609	rs76304666	ENSG00000250942.1	ENPP7P11	-3.88	0.000124	0.0383	-0.35	-0.2	Economic and political preferences;	chr4:9588855	chr4:9677308~9677934:+
STAD	cis	rs9297145	0.585	rs4729521	ENSG00000272950.1	RP11-307C18.1	-3.88	0.000124	0.0383	-0.23	-0.2	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99182897	chr7:98322853~98323430:+
STAD	cis	rs7680126	0.586	rs7689060	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000124	0.0383	-0.22	-0.2	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10303839	chr4:10410996~10411644:+
STAD	cis	rs1876905	0.68	rs354527	ENSG00000272356.1	RP5-1112D6.8	-3.88	0.000124	0.0383	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111309203~111313517:+
STAD	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-3.88	0.000124	0.0383	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
STAD	cis	rs6142102	0.961	rs6059587	ENSG00000264616.1	MIR4755	3.88	0.000124	0.0383	0.22	0.2	Skin pigmentation;	chr20:33955120	chr20:34049119~34049190:+
STAD	cis	rs7520050	0.931	rs6686134	ENSG00000280836.1	AL355480.1	3.88	0.000124	0.0383	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45581219~45581321:-
STAD	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-3.88	0.000124	0.0383	-0.24	-0.2	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
STAD	cis	rs7915414	0.951	rs749744	ENSG00000230338.1	MTND4P19	3.88	0.000124	0.0383	0.23	0.2	Clopidogrel active metabolite levels;	chr10:94646838	chr10:94774156~94774633:-
STAD	cis	rs4927850	0.752	rs7624460	ENSG00000278820.1	AC024937.1	3.88	0.000124	0.0383	0.23	0.2	Pancreatic cancer;	chr3:196021659	chr3:195960500~195960612:-
STAD	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	3.88	0.000124	0.0383	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
STAD	cis	rs16858210	0.618	rs12638094	ENSG00000202502.1	RNA5SP151	3.88	0.000124	0.0383	0.27	0.2	Menopause (age at onset);	chr3:183847771	chr3:183258300~183258416:-
STAD	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-3.88	0.000124	0.0383	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
STAD	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	3.88	0.000124	0.0383	0.26	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
STAD	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	3.88	0.000124	0.0383	0.25	0.2	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
STAD	cis	rs708547	1	rs10003229	ENSG00000269949.1	RP11-738E22.3	-3.88	0.000124	0.0384	-0.29	-0.2	Response to bleomycin (chromatid breaks);	chr4:56943432	chr4:56960927~56961373:-
STAD	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-3.88	0.000124	0.0384	-0.27	-0.2	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
STAD	cis	rs1007190	0.881	rs3744470	ENSG00000267405.1	CTC-296K1.4	3.88	0.000124	0.0384	0.23	0.2	DNA methylation (variation);	chr17:44906533	chr17:44794747~44797783:-
STAD	cis	rs10819861	0.55	rs4743558	ENSG00000175611.10	LINC00476	3.88	0.000124	0.0384	0.23	0.2	Electrocardiographic traits;	chr9:96122862	chr9:95759231~95875977:-
STAD	cis	rs10129255	0.957	rs8022165	ENSG00000224373.3	IGHV4-59	3.88	0.000124	0.0384	0.16	0.2	Kawasaki disease;	chr14:106781682	chr14:106627249~106627825:-
STAD	cis	rs61160187	0.75	rs1807017	ENSG00000215032.2	GNL3LP1	3.88	0.000124	0.0384	0.26	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60891935~60893577:-
STAD	cis	rs7520050	0.966	rs6675946	ENSG00000280836.1	AL355480.1	3.88	0.000124	0.0384	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.931	rs7526678	ENSG00000280836.1	AL355480.1	3.88	0.000124	0.0384	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45581219~45581321:-
STAD	cis	rs11239930	0.517	rs492243	ENSG00000278811.3	LINC00624	3.88	0.000124	0.0384	0.22	0.2	AIDS progression;	chr1:147077930	chr1:147258885~147517875:-
STAD	cis	rs11239930	0.517	rs493000	ENSG00000278811.3	LINC00624	3.88	0.000124	0.0384	0.22	0.2	AIDS progression;	chr1:147077979	chr1:147258885~147517875:-
STAD	cis	rs1816752	0.875	rs3783076	ENSG00000232858.1	RPL34P27	3.88	0.000124	0.0384	0.13	0.2	Obesity-related traits;	chr13:24490319	chr13:24988577~24988925:-
STAD	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-3.88	0.000124	0.0384	-0.31	-0.2	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
STAD	cis	rs4713118	0.513	rs149897	ENSG00000220721.1	OR1F12	3.88	0.000124	0.0384	0.22	0.2	Parkinson's disease;	chr6:28038872	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.513	rs156734	ENSG00000220721.1	OR1F12	3.88	0.000124	0.0384	0.22	0.2	Parkinson's disease;	chr6:28039579	chr6:28073316~28074233:+
STAD	cis	rs11051970	0.559	rs11051925	ENSG00000274964.1	RP11-817I4.1	-3.88	0.000124	0.0384	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32314860	chr12:32339368~32340724:+
STAD	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	3.88	0.000124	0.0384	0.3	0.2	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
STAD	cis	rs2957692	0.548	rs12362060	ENSG00000254554.1	RP11-351I24.1	3.88	0.000124	0.0384	0.32	0.2	Circulating vasoactive peptide levels;	chr11:10235769	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs11042683	ENSG00000254554.1	RP11-351I24.1	3.88	0.000124	0.0384	0.32	0.2	Circulating vasoactive peptide levels;	chr11:10236323	chr11:10302657~10303704:-
STAD	cis	rs28830936	0.966	rs28451764	ENSG00000250379.1	RP11-23P13.4	3.88	0.000124	0.0384	0.26	0.2	Diastolic blood pressure;	chr15:41834385	chr15:41825099~41827936:-
STAD	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	3.88	0.000124	0.0384	0.22	0.2	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
STAD	cis	rs1816752	0.905	rs8002215	ENSG00000232858.1	RPL34P27	3.88	0.000124	0.0384	0.13	0.2	Obesity-related traits;	chr13:24416229	chr13:24988577~24988925:-
STAD	cis	rs10782582	0.593	rs11578480	ENSG00000181227.3	RP4-682C21.2	3.88	0.000124	0.0384	0.21	0.2	Daytime sleep phenotypes;	chr1:75743304	chr1:75743423~75744776:-
STAD	cis	rs10782582	0.593	rs4646960	ENSG00000181227.3	RP4-682C21.2	3.88	0.000124	0.0384	0.21	0.2	Daytime sleep phenotypes;	chr1:75745418	chr1:75743423~75744776:-
STAD	cis	rs10782582	0.593	rs79552201	ENSG00000181227.3	RP4-682C21.2	3.88	0.000124	0.0384	0.21	0.2	Daytime sleep phenotypes;	chr1:75749812	chr1:75743423~75744776:-
STAD	cis	rs7520050	0.931	rs6698247	ENSG00000280836.1	AL355480.1	3.88	0.000124	0.0384	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45581219~45581321:-
STAD	cis	rs10815468	0.563	rs7851954	ENSG00000223621.1	AK4P4	3.88	0.000124	0.0384	0.22	0.2	Bipolar disorder and schizophrenia;	chr9:6796167	chr9:5855781~5856426:-
STAD	cis	rs10776614	0.799	rs7098068	ENSG00000189014.7	FAM35DP	3.88	0.000124	0.0384	0.31	0.2	Self-employment;	chr10:48555672	chr10:47689707~47730436:+
STAD	cis	rs919433	0.963	rs4850429	ENSG00000231621.1	AC013264.2	-3.88	0.000124	0.0384	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313685	chr2:197197991~197199273:+
STAD	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	3.88	0.000124	0.0384	0.31	0.2	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
STAD	cis	rs6432860	1	rs504059	ENSG00000229195.1	AC009495.4	3.88	0.000124	0.0384	0.26	0.2	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166005215	chr2:165794857~165846091:-
STAD	cis	rs259282	0.605	rs35728696	ENSG00000201388.1	SNORA68	3.88	0.000124	0.0384	0.21	0.2	Schizophrenia;	chr19:32617190	chr19:32608337~32608469:-
STAD	cis	rs8099594	0.541	rs4939574	ENSG00000266696.1	RP11-30L3.2	3.88	0.000124	0.0384	0.19	0.2	Height;	chr18:49238453	chr18:49205912~49208781:+
STAD	cis	rs9902453	0.808	rs62068617	ENSG00000263477.1	RP11-338L22.2	3.88	0.000124	0.0384	0.17	0.2	Coffee consumption (cups per day);	chr17:29817710	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.791	rs2729451	ENSG00000263477.1	RP11-338L22.2	-3.88	0.000124	0.0384	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29804316	chr17:29863402~29866092:+
STAD	cis	rs11169552	0.51	rs10783376	ENSG00000200183.1	RNU6-238P	-3.88	0.000124	0.0384	-0.19	-0.2	Colorectal cancer;	chr12:50587466	chr12:50656973~50657078:+
STAD	cis	rs1154275	0.537	rs6789210	ENSG00000240057.4	RP11-572M11.4	-3.88	0.000124	0.0385	-0.19	-0.2	Takotsubo syndrome;	chr3:112797481	chr3:113019532~113183301:+
STAD	cis	rs2253762	0.507	rs4752630	ENSG00000226864.1	ATE1-AS1	3.88	0.000124	0.0385	0.32	0.2	Breast cancer;	chr10:121991440	chr10:121928312~121951965:+
STAD	cis	rs12745968	0.589	rs3903212	ENSG00000229052.2	RP11-386I23.1	-3.88	0.000124	0.0385	-0.19	-0.2	Bipolar disorder and schizophrenia;	chr1:92518498	chr1:92930696~92934098:+
STAD	cis	rs4218	1	rs4218	ENSG00000259732.1	RP11-59H7.3	-3.88	0.000124	0.0385	-0.24	-0.2	Social communication problems;	chr15:59136459	chr15:59121034~59133250:+
STAD	cis	rs7631605	0.905	rs748766	ENSG00000236411.1	NDUFAF4P3	-3.88	0.000124	0.0385	-0.22	-0.2	Cerebrospinal P-tau181p levels;	chr3:37041383	chr3:37789921~37790445:-
STAD	cis	rs9287719	0.649	rs12618726	ENSG00000243819.4	RN7SL832P	3.88	0.000124	0.0385	0.2	0.2	Prostate cancer;	chr2:10588249	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs6714787	ENSG00000243819.4	RN7SL832P	3.88	0.000124	0.0385	0.2	0.2	Prostate cancer;	chr2:10588906	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs2024432	ENSG00000243819.4	RN7SL832P	3.88	0.000124	0.0385	0.2	0.2	Prostate cancer;	chr2:10591348	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs2024433	ENSG00000243819.4	RN7SL832P	3.88	0.000124	0.0385	0.2	0.2	Prostate cancer;	chr2:10591378	chr2:10690344~10692099:+
STAD	cis	rs6693567	0.565	rs497128	ENSG00000203819.6	HIST2H2BC	-3.88	0.000124	0.0385	-0.24	-0.2	Migraine;	chr1:150297528	chr1:149850193~149850772:-
STAD	cis	rs3754214	0.823	rs496203	ENSG00000203819.6	HIST2H2BC	-3.88	0.000124	0.0385	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr1:150297601	chr1:149850193~149850772:-
STAD	cis	rs3754214	0.823	rs494041	ENSG00000203819.6	HIST2H2BC	-3.88	0.000124	0.0385	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr1:150297602	chr1:149850193~149850772:-
STAD	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	3.88	0.000124	0.0385	0.22	0.2	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
STAD	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-3.88	0.000125	0.0385	-0.31	-0.2	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
STAD	cis	rs9902453	0.933	rs4470197	ENSG00000263477.1	RP11-338L22.2	3.88	0.000125	0.0385	0.17	0.2	Coffee consumption (cups per day);	chr17:30137456	chr17:29863402~29866092:+
STAD	cis	rs4713118	0.955	rs9468203	ENSG00000243307.2	POM121L6P	-3.88	0.000125	0.0385	-0.23	-0.2	Parkinson's disease;	chr6:27720888	chr6:26896952~26898777:+
STAD	cis	rs4713118	0.868	rs9468220	ENSG00000220721.1	OR1F12	-3.88	0.000125	0.0385	-0.24	-0.2	Parkinson's disease;	chr6:27765197	chr6:28073316~28074233:+
STAD	cis	rs9733	0.527	rs11204694	ENSG00000276103.1	U4	3.88	0.000125	0.0385	0.19	0.2	Tonsillectomy;	chr1:150680915	chr1:150608507~150608623:-
STAD	cis	rs679711	0.634	rs1164217	ENSG00000214380.4	RP11-457K10.2	-3.88	0.000125	0.0385	-0.24	-0.2	Sleep depth;	chr3:109894645	chr3:109915976~109916940:-
STAD	cis	rs73198271	0.7	rs10090152	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000125	0.0385	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:9141424~9145435:+
STAD	cis	rs7849270	1	rs2254230	ENSG00000234055.1	RP11-247A12.1	-3.88	0.000125	0.0385	-0.24	-0.2	Blood metabolite ratios;	chr9:129142898	chr9:129097854~129100266:+
STAD	cis	rs3808502	0.605	rs11784572	ENSG00000205879.4	FAM90A2P	-3.88	0.000125	0.0385	-0.23	-0.2	Neuroticism;	chr8:11316975	chr8:12172202~12178575:-
STAD	cis	rs7520050	0.966	rs12139630	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0385	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45581219~45581321:-
STAD	cis	rs1858037	0.836	rs1396209	ENSG00000223739.1	AC007389.2	-3.88	0.000125	0.0386	-0.19	-0.2	Rheumatoid arthritis;	chr2:65374100	chr2:65511771~65512076:-
STAD	cis	rs7202877	0.61	rs7202284	ENSG00000261783.1	RP11-252K23.2	-3.88	0.000125	0.0386	-0.33	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75340448	chr16:75379818~75381260:-
STAD	cis	rs28830936	0.966	rs2303518	ENSG00000250379.1	RP11-23P13.4	3.88	0.000125	0.0386	0.25	0.2	Diastolic blood pressure;	chr15:41817777	chr15:41825099~41827936:-
STAD	cis	rs7520050	0.966	rs12144263	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45581219~45581321:-
STAD	cis	rs765787	0.53	rs2413776	ENSG00000259539.1	CTD-2651B20.1	3.88	0.000125	0.0386	0.23	0.2	Uric acid levels;	chr15:45251972	chr15:45152664~45167526:-
STAD	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	3.88	0.000125	0.0386	0.25	0.2	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
STAD	cis	rs7429990	0.965	rs7642590	ENSG00000224895.1	VPS26BP1	3.88	0.000125	0.0386	0.21	0.2	Educational attainment (years of education);	chr3:48058260	chr3:47960327~47961081:-
STAD	cis	rs593531	0.513	rs3867268	ENSG00000280269.1	AP000577.2	3.88	0.000125	0.0386	0.21	0.2	Neuroticism;	chr11:74322332	chr11:74204869~74205746:+
STAD	cis	rs11089937	0.597	rs5757027	ENSG00000211640.3	IGLV6-57	3.88	0.000125	0.0386	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22195713~22196460:+
STAD	cis	rs7429990	0.864	rs12635438	ENSG00000224895.1	VPS26BP1	-3.88	0.000125	0.0386	-0.2	-0.2	Educational attainment (years of education);	chr3:47693210	chr3:47960327~47961081:-
STAD	cis	rs7520050	0.931	rs1707333	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs1085244	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs785520	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs6662641	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs1707335	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs785485	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs785488	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs785489	ENSG00000280836.1	AL355480.1	3.88	0.000125	0.0386	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45581219~45581321:-
STAD	cis	rs12935418	0.616	rs77336552	ENSG00000261061.1	RP11-303E16.2	-3.88	0.000125	0.0386	-0.33	-0.2	Mean corpuscular volume;	chr16:80942989	chr16:81030770~81031485:+
STAD	cis	rs9813712	0.855	rs6806152	ENSG00000253540.4	FAM86HP	-3.88	0.000125	0.0386	-0.3	-0.2	Response to amphetamines;	chr3:130245358	chr3:130099092~130111472:-
STAD	cis	rs2562456	0.561	rs12610883	ENSG00000268119.4	CTD-2561J22.5	3.88	0.000125	0.0386	0.26	0.2	Pain;	chr19:21567257	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.793	rs7259708	ENSG00000268119.4	CTD-2561J22.5	3.88	0.000125	0.0386	0.26	0.2	Pain;	chr19:21567846	chr19:21444241~21463908:-
STAD	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-3.88	0.000125	0.0386	-0.25	-0.2	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
STAD	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	3.88	0.000125	0.0386	0.26	0.2	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	3.88	0.000125	0.0386	0.26	0.2	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	3.88	0.000125	0.0386	0.26	0.2	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
STAD	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	3.88	0.000125	0.0386	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
STAD	cis	rs7631605	0.905	rs11720064	ENSG00000236411.1	NDUFAF4P3	-3.88	0.000125	0.0386	-0.23	-0.2	Cerebrospinal P-tau181p levels;	chr3:37060028	chr3:37789921~37790445:-
STAD	cis	rs11657217	0.677	rs8071194	ENSG00000267719.1	HP09025	-3.88	0.000125	0.0386	-0.21	-0.2	Diastolic blood pressure response to hydrochlorothiazide in hypertension;	chr17:79724688	chr17:79707266~79712317:+
STAD	cis	rs7142881	0.508	rs4981871	ENSG00000258648.1	UBE2CP1	3.88	0.000125	0.0387	0.21	0.2	Response to iloperidone treatment (QT prolongation);	chr14:31649430	chr14:30683045~30683598:-
STAD	cis	rs13413635	0.862	rs2695728	ENSG00000225808.1	DNAJC19P5	-3.88	0.000125	0.0387	-0.26	-0.2	Heart rate;	chr2:177961516	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.862	rs2695107	ENSG00000225808.1	DNAJC19P5	3.88	0.000125	0.0387	0.26	0.2	Heart rate;	chr2:177943174	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.862	rs2695739	ENSG00000225808.1	DNAJC19P5	3.88	0.000125	0.0387	0.26	0.2	Heart rate;	chr2:177943467	chr2:177229191~177229506:-
STAD	cis	rs2695743	0.507	rs1527290	ENSG00000225808.1	DNAJC19P5	3.88	0.000125	0.0387	0.26	0.2	Cough in response to angiotensin-converting enzyme inhibitor drugs;	chr2:177951135	chr2:177229191~177229506:-
STAD	cis	rs13413635	0.73	rs1852503	ENSG00000225808.1	DNAJC19P5	3.88	0.000125	0.0387	0.26	0.2	Heart rate;	chr2:177951246	chr2:177229191~177229506:-
STAD	cis	rs7119	0.717	rs11632729	ENSG00000230459.3	RP11-741G21.1	-3.88	0.000125	0.0387	-0.2	-0.2	Type 2 diabetes;	chr15:77429664	chr15:77278465~77278774:+
STAD	cis	rs9733	0.596	rs56058687	ENSG00000276103.1	U4	3.88	0.000125	0.0387	0.19	0.2	Tonsillectomy;	chr1:150662590	chr1:150608507~150608623:-
STAD	cis	rs4835473	0.932	rs13117421	ENSG00000249741.2	RP11-673E1.3	3.88	0.000125	0.0387	0.24	0.2	Immature fraction of reticulocytes;	chr4:143769405	chr4:143911514~143912053:-
STAD	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	3.88	0.000125	0.0387	0.25	0.2	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
STAD	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	3.88	0.000125	0.0387	0.25	0.2	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	3.88	0.000125	0.0387	0.25	0.2	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	3.88	0.000125	0.0387	0.25	0.2	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	3.88	0.000125	0.0387	0.25	0.2	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
STAD	cis	rs9608946	1	rs737942	ENSG00000279159.1	RP3-394A18.1	-3.88	0.000125	0.0387	-0.16	-0.2	Red cell distribution width;	chr22:30480848	chr22:29978950~30028236:-
STAD	cis	rs9926296	0.744	rs460879	ENSG00000260259.1	RP11-368I7.4	3.88	0.000125	0.0387	0.22	0.2	Vitiligo;	chr16:89646481	chr16:89682620~89686569:-
STAD	cis	rs11235843	0.929	rs11235864	ENSG00000255928.1	RP11-456I15.2	-3.88	0.000125	0.0387	-0.34	-0.2	Hand grip strength;	chr11:73697227	chr11:73722349~73722694:+
STAD	cis	rs9393777	0.528	rs9467989	ENSG00000224843.5	LINC00240	3.88	0.000125	0.0387	0.25	0.2	Intelligence (multi-trait analysis);	chr6:27096496	chr6:26956992~27023924:+
STAD	cis	rs41369048	0.669	rs6660867	ENSG00000238078.1	LINC01352	-3.88	0.000125	0.0387	-0.33	-0.2	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220829255~220832429:+
STAD	cis	rs10073892	0.66	rs10477820	ENSG00000250682.4	LINC00491	3.88	0.000126	0.0387	0.22	0.2	Cognitive decline (age-related);	chr5:102610844	chr5:102609156~102671559:-
STAD	cis	rs765787	0.53	rs11636367	ENSG00000259539.1	CTD-2651B20.1	3.88	0.000126	0.0387	0.24	0.2	Uric acid levels;	chr15:45243664	chr15:45152664~45167526:-
STAD	cis	rs13077017	0.681	rs13073525	ENSG00000272182.1	RP11-802O23.3	3.88	0.000126	0.0387	0.23	0.2	Eating disorders (purging via substances);	chr3:58084803	chr3:58428255~58428815:+
STAD	cis	rs1913185	0.787	rs1449442	ENSG00000240032.1	RP11-274H2.3	-3.88	0.000126	0.0388	-0.31	-0.2	Obesity-related traits;	chr3:146082133	chr3:146066344~146069185:-
STAD	cis	rs6499129	0.558	rs28711261	ENSG00000263126.1	CTC-479C5.10	3.88	0.000126	0.0388	0.31	0.2	Waist-to-hip ratio adjusted for body mass index;	chr16:67583283	chr16:67882461~67886367:+
STAD	cis	rs2115630	0.967	rs11073702	ENSG00000256278.1	RP11-182J1.5	-3.88	0.000126	0.0388	-0.19	-0.2	P wave terminal force;	chr15:84766840	chr15:84611689~84614969:-
STAD	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-3.88	0.000126	0.0388	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
STAD	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-3.88	0.000126	0.0388	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
STAD	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-3.88	0.000126	0.0388	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
STAD	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-3.88	0.000126	0.0388	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
STAD	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-3.88	0.000126	0.0388	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
STAD	cis	rs9902453	0.765	rs3102562	ENSG00000263477.1	RP11-338L22.2	3.88	0.000126	0.0388	0.17	0.2	Coffee consumption (cups per day);	chr17:29713385	chr17:29863402~29866092:+
STAD	cis	rs55675132	0.515	rs67548007	ENSG00000236480.1	PKMP1	3.88	0.000126	0.0388	0.19	0.2	Schizophrenia;	chr1:114744207	chr1:114535995~114537840:+
STAD	cis	rs875971	0.545	rs73142265	ENSG00000273142.1	RP11-458F8.4	3.88	0.000126	0.0388	0.19	0.2	Aortic root size;	chr7:66234510	chr7:66902857~66906297:+
STAD	cis	rs593531	0.592	rs598869	ENSG00000280269.1	AP000577.2	-3.88	0.000126	0.0388	-0.21	-0.2	Neuroticism;	chr11:74335930	chr11:74204869~74205746:+
STAD	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	3.88	0.000126	0.0388	0.31	0.2	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
STAD	cis	rs2191566	0.691	rs8104605	ENSG00000267114.1	CTB-129P6.11	3.88	0.000126	0.0388	0.2	0.2	Acute lymphoblastic leukemia (childhood);	chr19:44084863	chr19:44950044~44954007:-
STAD	cis	rs860295	0.702	rs12067371	ENSG00000225855.5	RUSC1-AS1	3.88	0.000126	0.0388	0.17	0.2	Body mass index;	chr1:155467878	chr1:155316863~155324176:-
STAD	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-3.88	0.000126	0.0388	-0.22	-0.2	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
STAD	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-3.88	0.000126	0.0388	-0.22	-0.2	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
STAD	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-3.88	0.000126	0.0388	-0.25	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
STAD	cis	rs6834538	0.597	rs4833414	ENSG00000234841.4	RP11-119H12.4	-3.88	0.000126	0.0388	-0.22	-0.2	Free thyroxine concentration;	chr4:112548757	chr4:112826307~112827607:+
STAD	cis	rs10782582	0.593	rs6704444	ENSG00000181227.3	RP4-682C21.2	3.88	0.000126	0.0388	0.21	0.2	Daytime sleep phenotypes;	chr1:75739423	chr1:75743423~75744776:-
STAD	cis	rs34779708	0.966	rs7077242	ENSG00000271335.4	RP11-324I22.4	-3.88	0.000126	0.0388	-0.24	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35314552~35336401:-
STAD	cis	rs259282	0.605	rs60968670	ENSG00000201388.1	SNORA68	3.88	0.000126	0.0388	0.21	0.2	Schizophrenia;	chr19:32618076	chr19:32608337~32608469:-
STAD	cis	rs6058526	1	rs67028492	ENSG00000265736.1	AL049539.1	-3.88	0.000126	0.0388	-0.27	-0.2	Chronic obstructive pulmonary disease;	chr20:32104134	chr20:32118654~32118751:-
STAD	cis	rs7208859	0.623	rs9898084	ENSG00000280069.1	CTD-2349P21.3	-3.88	0.000126	0.0388	-0.21	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30738182~30740275:+
STAD	cis	rs6822892	1	rs6536207	ENSG00000248629.1	RP11-154F14.2	3.88	0.000126	0.0388	0.21	0.2	HDL cholesterol levels;	chr4:156803494	chr4:156841359~156842236:+
STAD	cis	rs6822892	1	rs6536208	ENSG00000248629.1	RP11-154F14.2	3.88	0.000126	0.0388	0.21	0.2	HDL cholesterol levels;	chr4:156803816	chr4:156841359~156842236:+
STAD	cis	rs6832769	0.621	rs10033028	ENSG00000223305.1	RN7SKP30	-3.88	0.000126	0.0389	-0.25	-0.2	Personality dimensions;	chr4:55653709	chr4:55540502~55540835:-
STAD	cis	rs2880765	0.835	rs4280192	ENSG00000259295.5	CSPG4P12	3.88	0.000126	0.0389	0.25	0.2	Coronary artery disease;	chr15:85499789	chr15:85191438~85213905:+
STAD	cis	rs867371	0.929	rs7176075	ENSG00000278603.1	RP13-608F4.5	3.88	0.000126	0.0389	0.24	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs8041868	ENSG00000278603.1	RP13-608F4.5	3.88	0.000126	0.0389	0.24	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472203~82472426:+
STAD	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-3.88	0.000126	0.0389	-0.26	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
STAD	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-3.88	0.000126	0.0389	-0.26	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
STAD	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-3.88	0.000126	0.0389	-0.26	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
STAD	cis	rs2880765	0.805	rs34598679	ENSG00000259295.5	CSPG4P12	3.88	0.000126	0.0389	0.25	0.2	Coronary artery disease;	chr15:85498974	chr15:85191438~85213905:+
STAD	cis	rs2880765	0.835	rs4344688	ENSG00000259295.5	CSPG4P12	3.88	0.000126	0.0389	0.25	0.2	Coronary artery disease;	chr15:85499776	chr15:85191438~85213905:+
STAD	cis	rs12682352	0.602	rs6993494	ENSG00000173295.6	FAM86B3P	3.88	0.000126	0.0389	0.24	0.2	Neuroticism;	chr8:8809934	chr8:8228595~8244865:+
STAD	cis	rs7395581	0.918	rs326214	ENSG00000271350.1	CTD-2384B9.1	-3.88	0.000126	0.0389	-0.25	-0.2	HDL cholesterol;	chr11:47276809	chr11:47041027~47041945:-
STAD	cis	rs2880765	0.835	rs4360874	ENSG00000259295.5	CSPG4P12	3.88	0.000126	0.0389	0.25	0.2	Coronary artery disease;	chr15:85497589	chr15:85191438~85213905:+
STAD	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	3.88	0.000126	0.0389	0.2	0.2	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
STAD	cis	rs2739330	0.753	rs4822452	ENSG00000272787.1	KB-226F1.2	-3.88	0.000126	0.0389	-0.21	-0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23969211~23969873:+
STAD	cis	rs870825	0.616	rs7681824	ENSG00000249173.4	LINC01093	-3.88	0.000126	0.0389	-0.33	-0.2	Blood protein levels;	chr4:184696371	chr4:184893871~184899454:-
STAD	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	3.88	0.000126	0.0389	0.2	0.2	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	3.88	0.000126	0.0389	0.2	0.2	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
STAD	cis	rs6012564	1	rs6063352	ENSG00000227431.4	CSE1L-AS1	3.88	0.000126	0.0389	0.19	0.2	Anger;	chr20:49102057	chr20:49040463~49046044:-
STAD	cis	rs6012564	1	rs6063353	ENSG00000227431.4	CSE1L-AS1	3.88	0.000126	0.0389	0.19	0.2	Anger;	chr20:49103273	chr20:49040463~49046044:-
STAD	cis	rs6012564	1	rs6063354	ENSG00000227431.4	CSE1L-AS1	3.88	0.000126	0.0389	0.19	0.2	Anger;	chr20:49103412	chr20:49040463~49046044:-
STAD	cis	rs1876905	0.68	rs373526	ENSG00000272356.1	RP5-1112D6.8	3.88	0.000126	0.039	0.2	0.2	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111309203~111313517:+
STAD	cis	rs66887589	0.774	rs9307477	ENSG00000249244.1	RP11-548H18.2	3.88	0.000126	0.039	0.25	0.2	Diastolic blood pressure;	chr4:119500654	chr4:119391831~119395335:-
STAD	cis	rs6813195	0.642	rs2406600	ENSG00000243417.1	RP11-555K12.1	-3.88	0.000126	0.039	-0.21	-0.2	Type 2 diabetes;	chr4:152389254	chr4:152551277~152552364:-
STAD	cis	rs11098499	0.662	rs13108589	ENSG00000260091.1	RP11-33B1.4	3.88	0.000126	0.039	0.19	0.2	Corneal astigmatism;	chr4:119346947	chr4:119409333~119410233:+
STAD	cis	rs2658084	0.835	rs2662415	ENSG00000271715.1	CTD-2256P15.5	3.88	0.000127	0.039	0.22	0.2	Iris color (L* coordinate);	chr5:10125444	chr5:10269489~10269918:-
STAD	cis	rs3947	0.855	rs1293327	ENSG00000227888.4	FAM66A	-3.88	0.000127	0.039	-0.28	-0.2	Blood protein levels;	chr8:11837477	chr8:12362019~12388296:+
STAD	cis	rs4753788	0.511	rs12224337	ENSG00000261098.1	RP11-819C21.1	-3.88	0.000127	0.039	-0.17	-0.2	Coronary artery disease;	chr11:107269351	chr11:107312132~107316271:-
STAD	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	3.88	0.000127	0.039	0.27	0.2	Pain;	chr19:21567449	chr19:21554640~21569237:-
STAD	cis	rs1876905	0.68	rs1150082	ENSG00000271789.1	RP5-1112D6.7	-3.88	0.000127	0.039	-0.24	-0.2	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111297126~111298510:+
STAD	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	3.88	0.000127	0.039	0.31	0.2	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
STAD	cis	rs34779708	0.931	rs2505631	ENSG00000271335.4	RP11-324I22.4	-3.88	0.000127	0.039	-0.24	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35314552~35336401:-
STAD	cis	rs2390582	0.713	rs10922855	ENSG00000228175.3	GEMIN8P4	3.88	0.000127	0.039	0.32	0.2	Coronary artery calcification;	chr1:90402616	chr1:89993593~89994321:-
STAD	cis	rs2390582	0.713	rs10922857	ENSG00000228175.3	GEMIN8P4	3.88	0.000127	0.039	0.32	0.2	Coronary artery calcification;	chr1:90416543	chr1:89993593~89994321:-
STAD	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	3.88	0.000127	0.039	0.29	0.2	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
STAD	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	3.88	0.000127	0.039	0.45	0.2	QT interval;	chr4:75139193	chr4:75081702~75084717:-
STAD	cis	rs4950322	0.58	rs17355419	ENSG00000278811.3	LINC00624	3.88	0.000127	0.039	0.21	0.2	Protein quantitative trait loci;	chr1:147110094	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.58	rs72706428	ENSG00000278811.3	LINC00624	3.88	0.000127	0.039	0.21	0.2	Protein quantitative trait loci;	chr1:147110219	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.563	rs61838944	ENSG00000278811.3	LINC00624	3.88	0.000127	0.039	0.21	0.2	Protein quantitative trait loci;	chr1:147110275	chr1:147258885~147517875:-
STAD	cis	rs73198271	0.737	rs535094	ENSG00000254340.1	RP11-10A14.3	-3.88	0.000127	0.0391	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:9141424~9145435:+
STAD	cis	rs4950322	0.58	rs2014106	ENSG00000278811.3	LINC00624	3.88	0.000127	0.0391	0.22	0.2	Protein quantitative trait loci;	chr1:147118499	chr1:147258885~147517875:-
STAD	cis	rs4950322	0.58	rs17355474	ENSG00000278811.3	LINC00624	3.88	0.000127	0.0391	0.22	0.2	Protein quantitative trait loci;	chr1:147120541	chr1:147258885~147517875:-
STAD	cis	rs4345958	1	rs4345958	ENSG00000254554.1	RP11-351I24.1	3.88	0.000127	0.0391	0.35	0.2	Breast cancer;	chr11:10299114	chr11:10302657~10303704:-
STAD	cis	rs870825	0.616	rs7683799	ENSG00000249173.4	LINC01093	-3.88	0.000127	0.0391	-0.33	-0.2	Blood protein levels;	chr4:184711010	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28608669	ENSG00000249173.4	LINC01093	-3.88	0.000127	0.0391	-0.33	-0.2	Blood protein levels;	chr4:184711736	chr4:184893871~184899454:-
STAD	cis	rs13421350	0.579	rs4405725	ENSG00000232788.1	AC078883.3	3.88	0.000127	0.0391	0.37	0.2	Diabetic kidney disease;	chr2:172440654	chr2:172464262~172466022:-
STAD	cis	rs875971	0.502	rs11769702	ENSG00000273142.1	RP11-458F8.4	3.88	0.000127	0.0391	0.19	0.2	Aortic root size;	chr7:66255529	chr7:66902857~66906297:+
STAD	cis	rs2859998	0.929	rs13281822	ENSG00000250031.1	RP11-114M5.1	-3.88	0.000127	0.0391	-0.18	-0.2	Narcolepsy with cataplexy;	chr8:58420748	chr8:58424588~58426685:-
STAD	cis	rs2859998	0.929	rs12543440	ENSG00000250031.1	RP11-114M5.1	-3.88	0.000127	0.0391	-0.18	-0.2	Narcolepsy with cataplexy;	chr8:58420837	chr8:58424588~58426685:-
STAD	cis	rs6479891	0.908	rs12412946	ENSG00000235816.3	PRELID1P3	3.88	0.000127	0.0391	0.27	0.2	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs7087279	ENSG00000235816.3	PRELID1P3	-3.88	0.000127	0.0391	-0.27	-0.2	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs59035163	ENSG00000235816.3	PRELID1P3	3.88	0.000127	0.0391	0.27	0.2	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63427297~63427939:+
STAD	cis	rs7829975	0.56	rs17154599	ENSG00000173295.6	FAM86B3P	-3.88	0.000127	0.0391	-0.26	-0.2	Mood instability;	chr8:8693908	chr8:8228595~8244865:+
STAD	cis	rs10028773	0.515	rs9994488	ENSG00000260091.1	RP11-33B1.4	3.88	0.000127	0.0391	0.19	0.2	Educational attainment;	chr4:119666626	chr4:119409333~119410233:+
STAD	cis	rs10911902	0.643	rs1406294	ENSG00000229739.2	RP11-295K2.3	-3.88	0.000127	0.0391	-0.29	-0.2	Schizophrenia;	chr1:186314293	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs76559138	ENSG00000229739.2	RP11-295K2.3	-3.88	0.000127	0.0391	-0.29	-0.2	Schizophrenia;	chr1:186314891	chr1:186435161~186470291:+
STAD	cis	rs2243480	0.522	rs1638736	ENSG00000273448.1	RP11-166O4.6	3.88	0.000127	0.0391	0.26	0.2	Diabetic kidney disease;	chr7:66627321	chr7:67333047~67334383:+
STAD	cis	rs9287719	0.649	rs10929684	ENSG00000243819.4	RN7SL832P	-3.88	0.000127	0.0391	-0.2	-0.2	Prostate cancer;	chr2:10592098	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs12104950	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0391	0.2	0.2	Prostate cancer;	chr2:10591979	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10803724	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0391	0.2	0.2	Prostate cancer;	chr2:10592197	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10803725	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0391	0.2	0.2	Prostate cancer;	chr2:10592220	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10929685	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0391	0.2	0.2	Prostate cancer;	chr2:10592673	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10183359	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0391	0.2	0.2	Prostate cancer;	chr2:10592918	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.624	rs10172926	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0391	0.2	0.2	Prostate cancer;	chr2:10593128	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.601	rs10178751	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0391	0.2	0.2	Prostate cancer;	chr2:10594077	chr2:10690344~10692099:+
STAD	cis	rs6432852	0.527	rs62177810	ENSG00000229195.1	AC009495.4	-3.88	0.000127	0.0391	-0.23	-0.2	Diabetic kidney disease;	chr2:165908919	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.527	rs10176588	ENSG00000229195.1	AC009495.4	-3.88	0.000127	0.0391	-0.23	-0.2	Diabetic kidney disease;	chr2:165913610	chr2:165794857~165846091:-
STAD	cis	rs5753618	0.583	rs738657	ENSG00000236132.1	CTA-440B3.1	-3.88	0.000127	0.0391	-0.22	-0.2	Colorectal cancer;	chr22:31445763	chr22:31816379~31817491:-
STAD	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	3.88	0.000127	0.0392	0.3	0.2	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	3.88	0.000127	0.0392	0.3	0.2	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	3.88	0.000127	0.0392	0.3	0.2	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	3.88	0.000127	0.0392	0.3	0.2	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
STAD	cis	rs11846409	0.932	rs73378158	ENSG00000274576.2	IGHV2-70	-3.88	0.000127	0.0392	-0.24	-0.2	Rheumatic heart disease;	chr14:106638433	chr14:106770577~106771020:-
STAD	cis	rs17818399	1	rs62136864	ENSG00000279254.1	RP11-536C12.1	-3.88	0.000127	0.0392	-0.22	-0.2	Height;	chr2:46601985	chr2:46668870~46670778:+
STAD	cis	rs14027	0.883	rs1469755	ENSG00000279347.1	RP11-85I17.2	-3.88	0.000127	0.0392	-0.18	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119838736~119840385:-
STAD	cis	rs950169	0.96	rs12905475	ENSG00000235370.6	DNM1P51	3.88	0.000127	0.0392	0.28	0.2	Schizophrenia;	chr15:84131743	chr15:84398316~84411701:-
STAD	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-3.88	0.000127	0.0392	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
STAD	cis	rs559928	0.557	rs7122408	ENSG00000236935.1	AP003774.1	3.88	0.000127	0.0392	0.34	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64131354	chr11:64325050~64329504:-
STAD	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0392	0.2	0.2	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	3.88	0.000127	0.0392	0.2	0.2	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
STAD	cis	rs6704644	0.932	rs72982316	ENSG00000234143.1	UGT1A13P	3.88	0.000127	0.0392	0.42	0.2	Bilirubin levels;	chr2:233508073	chr2:233647926~233649026:+
STAD	cis	rs42490	0.614	rs445172	ENSG00000251136.7	RP11-37B2.1	-3.88	0.000127	0.0392	-0.2	-0.2	Leprosy;	chr8:89808322	chr8:89609409~89757727:-
STAD	cis	rs3733585	0.775	rs13124007	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10042307	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.566	rs13144709	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Bone mineral density;	chr4:10042558	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.546	rs13110307	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Bone mineral density;	chr4:10042740	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.566	rs13122689	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Bone mineral density;	chr4:10043024	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.546	rs13129453	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Bone mineral density;	chr4:10043160	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.546	rs12504565	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Bone mineral density;	chr4:10043521	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.546	rs4529049	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Bone mineral density;	chr4:10043765	chr4:10410996~10411644:+
STAD	cis	rs9291683	0.546	rs7442336	ENSG00000250613.1	RP11-136I13.1	-3.88	0.000127	0.0392	-0.21	-0.2	Bone mineral density;	chr4:10044159	chr4:10410996~10411644:+
STAD	cis	rs7246657	0.525	rs10401417	ENSG00000267672.1	CTD-2293H3.1	3.88	0.000127	0.0392	0.26	0.2	Coronary artery calcification;	chr19:36976638	chr19:37091341~37092564:+
STAD	cis	rs6479901	0.557	rs12773283	ENSG00000235816.3	PRELID1P3	-3.88	0.000127	0.0392	-0.25	-0.2	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63427297~63427939:+
STAD	cis	rs2562456	0.917	rs2650804	ENSG00000268117.1	VN1R84P	3.87	0.000128	0.0393	0.27	0.2	Pain;	chr19:21497382	chr19:21719801~21720035:-
STAD	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	3.87	0.000128	0.0393	0.25	0.2	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
STAD	cis	rs10129255	0.5	rs10143242	ENSG00000211959.2	IGHV4-39	3.87	0.000128	0.0393	0.18	0.2	Kawasaki disease;	chr14:106681814	chr14:106421711~106422218:-
STAD	cis	rs7771547	0.642	rs12214285	ENSG00000240733.3	RN7SL502P	-3.87	0.000128	0.0393	-0.18	-0.2	Platelet distribution width;	chr6:36466902	chr6:36450912~36451201:-
STAD	cis	rs5753618	0.504	rs8142121	ENSG00000236132.1	CTA-440B3.1	-3.87	0.000128	0.0393	-0.23	-0.2	Colorectal cancer;	chr22:31486799	chr22:31816379~31817491:-
STAD	cis	rs11235843	0.853	rs60020777	ENSG00000255928.1	RP11-456I15.2	3.87	0.000128	0.0393	0.36	0.2	Hand grip strength;	chr11:73771451	chr11:73722349~73722694:+
STAD	cis	rs2957692	0.527	rs7123453	ENSG00000254554.1	RP11-351I24.1	3.87	0.000128	0.0393	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10141461	chr11:10302657~10303704:-
STAD	cis	rs73198271	0.71	rs3827808	ENSG00000233609.3	RP11-62H7.2	-3.87	0.000128	0.0393	-0.26	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8961200~8979025:+
STAD	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-3.87	0.000128	0.0393	-0.25	-0.2	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
STAD	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000128	0.0393	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
STAD	cis	rs7142881	0.844	rs1947004	ENSG00000258648.1	UBE2CP1	3.87	0.000128	0.0393	0.23	0.2	Response to iloperidone treatment (QT prolongation);	chr14:31565616	chr14:30683045~30683598:-
STAD	cis	rs478304	0.934	rs1193496	ENSG00000213409.4	RP11-658F2.3	3.87	0.000128	0.0393	0.16	0.2	Acne (severe);	chr11:65770085	chr11:66761575~66762399:-
STAD	cis	rs7202877	0.561	rs2865532	ENSG00000261783.1	RP11-252K23.2	-3.87	0.000128	0.0393	-0.33	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75317077	chr16:75379818~75381260:-
STAD	cis	rs7202877	0.61	rs4888381	ENSG00000261783.1	RP11-252K23.2	-3.87	0.000128	0.0393	-0.33	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75322949	chr16:75379818~75381260:-
STAD	cis	rs11089937	0.597	rs5756991	ENSG00000211638.2	IGLV8-61	-3.87	0.000128	0.0393	-0.22	-0.2	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22098700~22099212:+
STAD	cis	rs10129255	0.957	rs4387509	ENSG00000232216.1	IGHV3-43	3.87	0.000128	0.0393	0.21	0.2	Kawasaki disease;	chr14:106704386	chr14:106470264~106470800:-
STAD	cis	rs6822892	0.77	rs11931057	ENSG00000248629.1	RP11-154F14.2	3.87	0.000128	0.0393	0.21	0.2	HDL cholesterol levels;	chr4:156718116	chr4:156841359~156842236:+
STAD	cis	rs11169552	0.51	rs10876072	ENSG00000200428.1	Y_RNA	3.87	0.000128	0.0393	0.23	0.2	Colorectal cancer;	chr12:50619776	chr12:50743568~50743684:+
STAD	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	3.87	0.000128	0.0394	0.18	0.2	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
STAD	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	3.87	0.000128	0.0394	0.26	0.2	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
STAD	cis	rs2957692	0.548	rs11042601	ENSG00000254554.1	RP11-351I24.1	3.87	0.000128	0.0394	0.37	0.2	Circulating vasoactive peptide levels;	chr11:10056056	chr11:10302657~10303704:-
STAD	cis	rs2430307	0.518	rs67763033	ENSG00000185040.12	AC004980.11	3.87	0.000128	0.0394	0.24	0.2	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76888360	chr7:76533703~76540390:-
STAD	cis	rs12682352	0.65	rs13265731	ENSG00000173295.6	FAM86B3P	3.87	0.000128	0.0394	0.24	0.2	Neuroticism;	chr8:8815810	chr8:8228595~8244865:+
STAD	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	3.87	0.000128	0.0394	0.3	0.2	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
STAD	cis	rs6832769	1	rs10016506	ENSG00000223305.1	RN7SKP30	-3.87	0.000128	0.0394	-0.23	-0.2	Personality dimensions;	chr4:55530507	chr4:55540502~55540835:-
STAD	cis	rs6832769	0.961	rs28790098	ENSG00000223305.1	RN7SKP30	-3.87	0.000128	0.0394	-0.23	-0.2	Personality dimensions;	chr4:55531942	chr4:55540502~55540835:-
STAD	cis	rs950169	0.887	rs35986397	ENSG00000235370.6	DNM1P51	3.87	0.000128	0.0394	0.26	0.2	Schizophrenia;	chr15:84400409	chr15:84398316~84411701:-
STAD	cis	rs950169	0.922	rs11631096	ENSG00000259683.1	RP11-182J1.14	3.87	0.000128	0.0394	0.21	0.2	Schizophrenia;	chr15:84557698	chr15:84389729~84395903:+
STAD	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-3.87	0.000128	0.0394	-0.27	-0.2	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
STAD	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-3.87	0.000128	0.0394	-0.27	-0.2	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
STAD	cis	rs1922291	0.546	rs3771185	ENSG00000234389.1	AC007278.3	3.87	0.000128	0.0394	0.2	0.2	Blood protein levels;	chr2:102224047	chr2:102438713~102440475:+
STAD	cis	rs7951911	0.915	rs34290919	ENSG00000254427.1	RP11-430H10.1	3.87	0.000128	0.0394	0.39	0.2	IgG glycosylation;	chr11:45069204	chr11:45355371~45366121:+
STAD	cis	rs7520050	0.966	rs4660321	ENSG00000280836.1	AL355480.1	3.87	0.000128	0.0394	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45581219~45581321:-
STAD	cis	rs6479891	0.841	rs7085869	ENSG00000235816.3	PRELID1P3	-3.87	0.000128	0.0394	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63427297~63427939:+
STAD	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-3.87	0.000128	0.0394	-0.25	-0.2	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
STAD	cis	rs9659323	0.623	rs12091291	ENSG00000231365.4	RP11-418J17.1	3.87	0.000128	0.0395	0.27	0.2	Body mass index;	chr1:118936205	chr1:119140396~119275973:+
STAD	cis	rs6957923	0.609	rs2390791	ENSG00000234286.1	AC006026.13	-3.87	0.000128	0.0395	-0.25	-0.2	Height;	chr7:23539883	chr7:23680195~23680786:-
STAD	cis	rs6180	1	rs2973015	ENSG00000250860.1	CTD-2265D6.2	3.87	0.000128	0.0395	0.17	0.2	Height;	chr5:42717890	chr5:42466893~42468300:-
STAD	cis	rs6180	1	rs6180	ENSG00000250860.1	CTD-2265D6.2	3.87	0.000128	0.0395	0.17	0.2	Height;	chr5:42719137	chr5:42466893~42468300:-
STAD	cis	rs1488193	0.59	rs12695277	ENSG00000240057.4	RP11-572M11.4	-3.87	0.000128	0.0395	-0.35	-0.2	Economic and political preferences;	chr3:112881565	chr3:113019532~113183301:+
STAD	cis	rs9535307	0.929	rs9535310	ENSG00000223676.1	RPL34P26	3.87	0.000129	0.0395	0.25	0.2	Obesity-related traits;	chr13:49721890	chr13:50361410~50361763:-
STAD	cis	rs9535307	0.858	rs2025263	ENSG00000223676.1	RPL34P26	3.87	0.000129	0.0395	0.25	0.2	Obesity-related traits;	chr13:49734711	chr13:50361410~50361763:-
STAD	cis	rs9535307	0.745	rs2181185	ENSG00000223676.1	RPL34P26	3.87	0.000129	0.0395	0.25	0.2	Obesity-related traits;	chr13:49737789	chr13:50361410~50361763:-
STAD	cis	rs9535307	0.929	rs9316474	ENSG00000223676.1	RPL34P26	3.87	0.000129	0.0395	0.25	0.2	Obesity-related traits;	chr13:49739209	chr13:50361410~50361763:-
STAD	cis	rs9535307	0.929	rs4942863	ENSG00000223676.1	RPL34P26	3.87	0.000129	0.0395	0.25	0.2	Obesity-related traits;	chr13:49740272	chr13:50361410~50361763:-
STAD	cis	rs2992257	0.914	rs3006817	ENSG00000251839.1	RNU7-12P	-3.87	0.000129	0.0395	-0.2	-0.2	Response to angiotensin II receptor blocker therapy;	chr10:26434013	chr10:27232255~27232316:-
STAD	cis	rs6693567	0.565	rs834242	ENSG00000203819.6	HIST2H2BC	3.87	0.000129	0.0395	0.24	0.2	Migraine;	chr1:150407382	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.565	rs11205373	ENSG00000203819.6	HIST2H2BC	3.87	0.000129	0.0395	0.24	0.2	Migraine;	chr1:150432232	chr1:149850193~149850772:-
STAD	cis	rs6570726	1	rs6570699	ENSG00000235652.6	RP11-545I5.3	3.87	0.000129	0.0395	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145799409~145886585:+
STAD	cis	rs6570726	1	rs1935615	ENSG00000235652.6	RP11-545I5.3	3.87	0.000129	0.0395	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145799409~145886585:+
STAD	cis	rs7429990	0.828	rs55823596	ENSG00000224895.1	VPS26BP1	-3.87	0.000129	0.0395	-0.2	-0.2	Educational attainment (years of education);	chr3:47758541	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs4858853	ENSG00000224895.1	VPS26BP1	-3.87	0.000129	0.0395	-0.2	-0.2	Educational attainment (years of education);	chr3:47760605	chr3:47960327~47961081:-
STAD	cis	rs4713118	0.715	rs200480	ENSG00000243307.2	POM121L6P	-3.87	0.000129	0.0395	-0.21	-0.2	Parkinson's disease;	chr6:27805886	chr6:26896952~26898777:+
STAD	cis	rs1823874	0.71	rs4246297	ENSG00000182397.13	DNM1P46	-3.87	0.000129	0.0395	-0.22	-0.2	IgG glycosylation;	chr15:99826723	chr15:99790156~99806927:-
STAD	cis	rs9907295	0.818	rs11658222	ENSG00000270894.1	AC015849.13	-3.87	0.000129	0.0395	-0.22	-0.2	Fibroblast growth factor basic levels;	chr17:35825092	chr17:35818399~35823713:+
STAD	cis	rs4835473	0.897	rs12508285	ENSG00000249741.2	RP11-673E1.3	3.87	0.000129	0.0395	0.23	0.2	Immature fraction of reticulocytes;	chr4:143792642	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.9	rs7667544	ENSG00000249741.2	RP11-673E1.3	3.87	0.000129	0.0395	0.23	0.2	Immature fraction of reticulocytes;	chr4:143793802	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs6849896	ENSG00000249741.2	RP11-673E1.3	3.87	0.000129	0.0395	0.23	0.2	Immature fraction of reticulocytes;	chr4:143794927	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs6826665	ENSG00000249741.2	RP11-673E1.3	3.87	0.000129	0.0395	0.23	0.2	Immature fraction of reticulocytes;	chr4:143795140	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.838	rs35998817	ENSG00000249741.2	RP11-673E1.3	3.87	0.000129	0.0395	0.23	0.2	Immature fraction of reticulocytes;	chr4:143795355	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs13134808	ENSG00000249741.2	RP11-673E1.3	3.87	0.000129	0.0395	0.23	0.2	Immature fraction of reticulocytes;	chr4:143798339	chr4:143911514~143912053:-
STAD	cis	rs4293777	0.967	rs4269168	ENSG00000250896.1	RNPS1P1	3.87	0.000129	0.0395	0.15	0.2	Primary sclerosing cholangitis;	chr4:10720980	chr4:11371975~11372892:+
STAD	cis	rs12362063	0.9	rs4375464	ENSG00000255450.1	CTD-2063L20.1	-3.87	0.000129	0.0395	-0.19	-0.2	Hepatitis B;	chr11:29241442	chr11:29275655~29276565:+
STAD	cis	rs4792901	0.592	rs57462570	ENSG00000279602.1	CTD-3014M21.1	-3.87	0.000129	0.0395	-0.28	-0.2	Dupuytren's disease;	chr17:43530611	chr17:43360041~43361361:-
STAD	cis	rs10073892	0.664	rs10051203	ENSG00000250682.4	LINC00491	-3.87	0.000129	0.0395	-0.22	-0.2	Cognitive decline (age-related);	chr5:102550068	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.543	rs12653030	ENSG00000250682.4	LINC00491	-3.87	0.000129	0.0395	-0.22	-0.2	Cognitive decline (age-related);	chr5:102551454	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs1910288	ENSG00000250682.4	LINC00491	-3.87	0.000129	0.0395	-0.22	-0.2	Cognitive decline (age-related);	chr5:102556067	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs10067911	ENSG00000250682.4	LINC00491	-3.87	0.000129	0.0395	-0.22	-0.2	Cognitive decline (age-related);	chr5:102557551	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs2400806	ENSG00000250682.4	LINC00491	-3.87	0.000129	0.0395	-0.22	-0.2	Cognitive decline (age-related);	chr5:102557732	chr5:102609156~102671559:-
STAD	cis	rs718433	0.616	rs2222916	ENSG00000211790.2	TRAV8-4	3.87	0.000129	0.0395	0.17	0.2	Intraocular pressure;	chr14:21744319	chr14:21894433~21895030:+
STAD	cis	rs2638953	0.962	rs11049515	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000129	0.0395	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299564	chr12:28163298~28190738:-
STAD	cis	rs2638953	1	rs11049516	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000129	0.0395	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299649	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs61922979	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000129	0.0395	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301218	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.962	rs11049517	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000129	0.0395	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301627	chr12:28163298~28190738:-
STAD	cis	rs1008953	0.948	rs2038038	ENSG00000232880.1	RP3-453C12.8	3.87	0.000129	0.0395	0.22	0.2	Psoriasis;	chr20:45413368	chr20:45388347~45388705:-
STAD	cis	rs7615952	0.688	rs9754526	ENSG00000239804.1	RP11-379B18.1	3.87	0.000129	0.0396	0.27	0.2	Blood pressure (smoking interaction);	chr3:125824023	chr3:125787888~125788146:-
STAD	cis	rs10073892	0.789	rs10054879	ENSG00000250682.4	LINC00491	-3.87	0.000129	0.0396	-0.24	-0.2	Cognitive decline (age-related);	chr5:102405716	chr5:102609156~102671559:-
STAD	cis	rs9902453	0.753	rs7226121	ENSG00000263477.1	RP11-338L22.2	3.87	0.000129	0.0396	0.17	0.2	Coffee consumption (cups per day);	chr17:29881107	chr17:29863402~29866092:+
STAD	cis	rs7635832	0.66	rs7614147	ENSG00000200355.1	SNORA72	-3.87	0.000129	0.0396	-0.29	-0.2	Intraocular pressure;	chr3:172193059	chr3:172771277~172771405:-
STAD	cis	rs3770081	0.826	rs17026666	ENSG00000273080.1	RP11-301O19.1	-3.87	0.000129	0.0396	-0.46	-0.2	Facial emotion recognition (sad faces);	chr2:85847265	chr2:86195590~86196049:+
STAD	cis	rs7142881	0.815	rs34984098	ENSG00000258648.1	UBE2CP1	-3.87	0.000129	0.0396	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31571834	chr14:30683045~30683598:-
STAD	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-3.87	0.000129	0.0396	-0.24	-0.2	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
STAD	cis	rs6693567	0.565	rs834225	ENSG00000203819.6	HIST2H2BC	3.87	0.000129	0.0396	0.24	0.2	Migraine;	chr1:150328268	chr1:149850193~149850772:-
STAD	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-3.87	0.000129	0.0396	-0.21	-0.2	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
STAD	cis	rs3764400	0.507	rs16954324	ENSG00000278765.1	RP5-890E16.5	3.87	0.000129	0.0396	0.27	0.2	Body mass index;	chr17:48247222	chr17:48066704~48067293:-
STAD	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	3.87	0.000129	0.0396	0.23	0.2	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
STAD	cis	rs2016266	0.502	rs7137242	ENSG00000278108.1	MIR6757	3.87	0.000129	0.0396	0.21	0.2	Bone mineral density;Bone mineral density (spine);	chr12:53245098	chr12:53056944~53057012:+
STAD	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000129	0.0396	-0.27	-0.2	Depression;	chr6:28079011	chr6:28115628~28116551:+
STAD	cis	rs10129255	0.957	rs28887506	ENSG00000224373.3	IGHV4-59	3.87	0.000129	0.0396	0.17	0.2	Kawasaki disease;	chr14:106785589	chr14:106627249~106627825:-
STAD	cis	rs7674212	0.531	rs4699048	ENSG00000248971.2	KRT8P46	-3.87	0.000129	0.0396	-0.22	-0.2	Type 2 diabetes;	chr4:103005570	chr4:102728746~102730171:-
STAD	cis	rs8141529	0.719	rs132561	ENSG00000226471.5	CTA-292E10.6	3.87	0.000129	0.0396	0.24	0.2	Lymphocyte counts;	chr22:28955191	chr22:28800683~28848559:+
STAD	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-3.87	0.000129	0.0397	-0.22	-0.2	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
STAD	cis	rs6480314	0.522	rs80326649	ENSG00000233590.1	RP11-153K11.3	-3.87	0.000129	0.0397	-0.3	-0.2	Optic nerve measurement (disc area);	chr10:68285667	chr10:68233251~68242379:-
STAD	cis	rs56080343	0.515	rs73222056	ENSG00000275759.1	RP11-131L12.3	-3.87	0.000129	0.0397	-0.29	-0.2	Neuroticism;	chr12:118215875	chr12:118428281~118428870:+
STAD	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	3.87	0.000129	0.0397	0.28	0.2	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
STAD	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	3.87	0.000129	0.0397	0.28	0.2	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
STAD	cis	rs2016266	0.502	rs7954558	ENSG00000278108.1	MIR6757	3.87	0.000129	0.0397	0.21	0.2	Bone mineral density;Bone mineral density (spine);	chr12:53244353	chr12:53056944~53057012:+
STAD	cis	rs7655841	0.704	rs1757936	ENSG00000248187.1	RP11-184M15.1	-3.87	0.000129	0.0397	-0.31	-0.2	Chronic obstructive pulmonary disease (moderate to severe);	chr4:129090736	chr4:128567972~128570531:-
STAD	cis	rs9517906	0.523	rs7992643	ENSG00000218502.3	H2AFZP3	-3.87	0.000129	0.0397	-0.18	-0.2	Survival in pancreatic cancer;	chr13:99902784	chr13:99215372~99215758:-
STAD	cis	rs9733	0.565	rs7524620	ENSG00000276103.1	U4	-3.87	0.000129	0.0397	-0.19	-0.2	Tonsillectomy;	chr1:150644223	chr1:150608507~150608623:-
STAD	cis	rs7474896	0.895	rs2749559	ENSG00000099251.13	HSD17B7P2	-3.87	0.000129	0.0397	-0.32	-0.2	Obesity (extreme);	chr10:37922494	chr10:38356380~38378505:+
STAD	cis	rs4869931	0.929	rs9480528	ENSG00000218358.2	RAET1K	3.87	0.000129	0.0397	0.32	0.2	Systolic blood pressure in sickle cell anemia;	chr6:150680424	chr6:149998019~150005157:-
STAD	cis	rs4869931	0.929	rs6899782	ENSG00000218358.2	RAET1K	3.87	0.000129	0.0397	0.32	0.2	Systolic blood pressure in sickle cell anemia;	chr6:150682748	chr6:149998019~150005157:-
STAD	cis	rs748404	0.588	rs2255410	ENSG00000275601.1	AC011330.13	-3.87	0.000129	0.0397	-0.22	-0.2	Lung cancer;	chr15:43538899	chr15:43642389~43643023:-
STAD	cis	rs2098713	0.535	rs11748123	ENSG00000250155.1	CTD-2353F22.1	3.87	0.000129	0.0397	0.21	0.2	Telomere length;	chr5:37575317	chr5:36666214~36725195:-
STAD	cis	rs11089937	0.559	rs2330014	ENSG00000211638.2	IGLV8-61	-3.87	0.000129	0.0397	-0.21	-0.2	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22098700~22099212:+
STAD	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	3.87	0.000129	0.0397	0.37	0.2	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
STAD	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-3.87	0.000129	0.0397	-0.26	-0.2	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
STAD	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	3.87	0.000129	0.0397	0.3	0.2	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
STAD	cis	rs1790761	0.667	rs598811	ENSG00000231793.4	DOC2GP	3.87	0.000129	0.0397	0.24	0.2	Mean corpuscular volume;	chr11:67544205	chr11:67612653~67616257:-
STAD	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-3.87	0.00013	0.0397	-0.26	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
STAD	cis	rs494453	0.6	rs575208	ENSG00000234020.1	CHIAP3	-3.87	0.00013	0.0397	-0.19	-0.2	Osteoporosis-related phenotypes;	chr1:111663769	chr1:111353275~111367409:-
STAD	cis	rs11051970	0.559	rs11051928	ENSG00000274964.1	RP11-817I4.1	-3.87	0.00013	0.0397	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32319580	chr12:32339368~32340724:+
STAD	cis	rs11051970	0.559	rs11051929	ENSG00000274964.1	RP11-817I4.1	-3.87	0.00013	0.0397	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32319617	chr12:32339368~32340724:+
STAD	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	3.87	0.00013	0.0397	0.25	0.2	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
STAD	cis	rs9910055	0.762	rs2240226	ENSG00000260793.2	RP5-882C2.2	-3.87	0.00013	0.0397	-0.23	-0.2	Total body bone mineral density;	chr17:44188850	chr17:44221401~44223710:+
STAD	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-3.87	0.00013	0.0397	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
STAD	cis	rs62246343	0.516	rs2251166	ENSG00000214041.4	PGAM1P4	-3.87	0.00013	0.0397	-0.27	-0.2	Fibrinogen levels;	chr3:9400053	chr3:9348443~9349192:+
STAD	cis	rs2880765	0.546	rs11639291	ENSG00000259295.5	CSPG4P12	3.87	0.00013	0.0397	0.28	0.2	Coronary artery disease;	chr15:85520899	chr15:85191438~85213905:+
STAD	cis	rs7015630	0.738	rs11785163	ENSG00000251136.7	RP11-37B2.1	-3.87	0.00013	0.0397	-0.25	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89857181	chr8:89609409~89757727:-
STAD	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	3.87	0.00013	0.0397	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
STAD	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	3.87	0.00013	0.0398	0.29	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
STAD	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	3.87	0.00013	0.0398	0.29	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
STAD	cis	rs60180747	0.909	rs11629783	ENSG00000252712.1	SCARNA14	-3.87	0.00013	0.0398	-0.24	-0.2	Testicular germ cell tumor;	chr15:66449049	chr15:66347207~66347342:-
STAD	cis	rs2262909	1	rs431328	ENSG00000279377.1	AC003973.3	3.87	0.00013	0.0398	0.2	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22039434	chr19:21965708~21968529:-
STAD	cis	rs4792901	0.759	rs12948043	ENSG00000279602.1	CTD-3014M21.1	-3.87	0.00013	0.0398	-0.28	-0.2	Dupuytren's disease;	chr17:43538462	chr17:43360041~43361361:-
STAD	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-3.87	0.00013	0.0398	-0.27	-0.2	Depression;	chr6:28091242	chr6:28115628~28116551:+
STAD	cis	rs7523875	0.505	rs1947058	ENSG00000236809.2	SNX25P1	3.87	0.00013	0.0398	0.37	0.2	Mean corpuscular volume;	chr1:211478668	chr1:211417025~211417934:+
STAD	cis	rs2492286	0.673	rs17255991	ENSG00000242551.2	POU5F1P6	3.87	0.00013	0.0398	0.32	0.2	Eosinophil counts;	chr3:128637371	chr3:128674735~128677005:-
STAD	cis	rs34779708	0.931	rs6481935	ENSG00000271335.4	RP11-324I22.4	3.87	0.00013	0.0398	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs12242882	ENSG00000271335.4	RP11-324I22.4	3.87	0.00013	0.0398	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs12240347	ENSG00000271335.4	RP11-324I22.4	3.87	0.00013	0.0398	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs4934533	ENSG00000271335.4	RP11-324I22.4	3.87	0.00013	0.0398	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs12248333	ENSG00000271335.4	RP11-324I22.4	3.87	0.00013	0.0398	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.931	rs11010067	ENSG00000271335.4	RP11-324I22.4	-3.87	0.00013	0.0398	-0.24	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35314552~35336401:-
STAD	cis	rs12468226	0.872	rs1061157	ENSG00000226261.1	AC064836.3	3.87	0.00013	0.0398	0.34	0.2	Urate levels;	chr2:202556476	chr2:202336024~202336727:-
STAD	cis	rs6095298	0.553	rs112601802	ENSG00000227431.4	CSE1L-AS1	-3.87	0.00013	0.0398	-0.22	-0.2	Intelligence (multi-trait analysis);	chr20:48837347	chr20:49040463~49046044:-
STAD	cis	rs2638953	0.924	rs11049405	ENSG00000247934.4	RP11-967K21.1	-3.87	0.00013	0.0398	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28163298~28190738:-
STAD	cis	rs61270009	0.955	rs390856	ENSG00000247828.6	TMEM161B-AS1	3.87	0.00013	0.0398	0.26	0.2	Depressive symptoms;	chr5:88251742	chr5:88268895~88436685:+
STAD	cis	rs870825	0.616	rs61539306	ENSG00000249173.4	LINC01093	-3.87	0.00013	0.0398	-0.33	-0.2	Blood protein levels;	chr4:184729122	chr4:184893871~184899454:-
STAD	cis	rs2638953	0.889	rs2045887	ENSG00000247934.4	RP11-967K21.1	-3.87	0.00013	0.0398	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28163298~28190738:-
STAD	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-3.87	0.00013	0.0398	-0.24	-0.2	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
STAD	cis	rs2278796	0.639	rs6661266	ENSG00000231691.1	RP11-203F10.5	3.87	0.00013	0.0398	0.26	0.2	Mean platelet volume;	chr1:205002324	chr1:204277005~204277948:+
STAD	cis	rs72772090	0.634	rs17402639	ENSG00000248734.2	CTD-2260A17.1	-3.87	0.00013	0.0398	-0.35	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96771301	chr5:96784777~96785999:+
STAD	cis	rs72772090	0.634	rs72773912	ENSG00000248734.2	CTD-2260A17.1	-3.87	0.00013	0.0398	-0.35	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96772097	chr5:96784777~96785999:+
STAD	cis	rs4561483	0.832	rs33645	ENSG00000260224.1	UBL5P4	3.87	0.00013	0.0398	0.2	0.2	Testicular germ cell tumor;	chr16:11891344	chr16:11968508~11968743:-
STAD	cis	rs1922291	0.528	rs12472862	ENSG00000234389.1	AC007278.3	-3.87	0.00013	0.0398	-0.2	-0.2	Blood protein levels;	chr2:102224534	chr2:102438713~102440475:+
STAD	cis	rs9907295	0.818	rs4796112	ENSG00000271013.1	AC015849.15	3.87	0.00013	0.0398	0.31	0.2	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35912635~35918010:-
STAD	cis	rs4835473	0.932	rs11730929	ENSG00000249741.2	RP11-673E1.3	3.87	0.00013	0.0398	0.24	0.2	Immature fraction of reticulocytes;	chr4:143834795	chr4:143911514~143912053:-
STAD	cis	rs9535307	0.929	rs1547623	ENSG00000223676.1	RPL34P26	3.87	0.00013	0.0398	0.24	0.2	Obesity-related traits;	chr13:49774051	chr13:50361410~50361763:-
STAD	cis	rs7520050	0.966	rs4660317	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs10749860	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.931	rs6688365	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs61783220	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs7540325	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45581219~45581321:-
STAD	cis	rs7520050	1	rs7540699	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs4660319	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.931	rs11211213	ENSG00000280836.1	AL355480.1	3.87	0.00013	0.0398	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45581219~45581321:-
STAD	cis	rs9733	0.544	rs72700902	ENSG00000276103.1	U4	3.87	0.00013	0.0398	0.19	0.2	Tonsillectomy;	chr1:150660871	chr1:150608507~150608623:-
STAD	cis	rs9733	0.519	rs10788792	ENSG00000276103.1	U4	3.87	0.00013	0.0398	0.19	0.2	Tonsillectomy;	chr1:150666096	chr1:150608507~150608623:-
STAD	cis	rs10073892	0.701	rs28786103	ENSG00000250682.4	LINC00491	-3.87	0.00013	0.0398	-0.24	-0.2	Cognitive decline (age-related);	chr5:102386447	chr5:102609156~102671559:-
STAD	cis	rs9463078	0.809	rs57020561	ENSG00000219384.1	RP11-491H9.3	3.87	0.00013	0.0399	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44894997	chr6:45158870~45159511:+
STAD	cis	rs240993	0.516	rs369594	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.00013	0.0399	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111277932~111278742:+
STAD	cis	rs11846409	0.932	rs28617526	ENSG00000274576.2	IGHV2-70	-3.87	0.00013	0.0399	-0.24	-0.2	Rheumatic heart disease;	chr14:106637322	chr14:106770577~106771020:-
STAD	cis	rs62103177	0.535	rs34299914	ENSG00000261126.6	RP11-795F19.1	3.87	0.00013	0.0399	0.32	0.2	Opioid sensitivity;	chr18:80191353	chr18:80046900~80095482:+
STAD	cis	rs1005277	0.522	rs289648	ENSG00000099251.13	HSD17B7P2	3.87	0.00013	0.0399	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38356380~38378505:+
STAD	cis	rs4237845	0.837	rs7963992	ENSG00000273805.1	RP11-620J15.4	-3.87	0.00013	0.0399	-0.23	-0.2	Intelligence (multi-trait analysis);	chr12:57902166	chr12:57894232~57896846:+
STAD	cis	rs6832769	1	rs11726609	ENSG00000272969.1	RP11-528I4.2	3.87	0.00013	0.0399	0.26	0.2	Personality dimensions;	chr4:55534702	chr4:55547112~55547889:+
STAD	cis	rs1075265	0.875	rs12616212	ENSG00000235937.1	AC008280.1	3.87	0.00013	0.0399	0.2	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54029552~54030682:-
STAD	cis	rs9463078	0.715	rs9296455	ENSG00000219384.1	RP11-491H9.3	3.87	0.00013	0.0399	0.2	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45269044	chr6:45158870~45159511:+
STAD	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	3.87	0.00013	0.0399	0.26	0.2	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
STAD	cis	rs7523273	0.565	rs2761420	ENSG00000227887.1	RPS26P13	-3.87	0.00013	0.0399	-0.2	-0.2	Schizophrenia;	chr1:207716023	chr1:208697369~208697698:-
STAD	cis	rs7204230	1	rs8057688	ENSG00000261291.1	RP11-295M3.2	-3.87	0.00013	0.0399	-0.23	-0.2	Fibrinogen;	chr16:53294067	chr16:53168522~53169450:+
STAD	cis	rs7103648	0.966	rs10838702	ENSG00000280615.1	Y_RNA	3.87	0.00013	0.0399	0.2	0.2	Systolic blood pressure;Diastolic blood pressure;	chr11:47389337	chr11:47614898~47614994:-
STAD	cis	rs1816752	0.819	rs7985478	ENSG00000232858.1	RPL34P27	3.87	0.00013	0.0399	0.13	0.2	Obesity-related traits;	chr13:24417135	chr13:24988577~24988925:-
STAD	cis	rs7078219	0.897	rs10883360	ENSG00000257582.4	LINC01475	-3.87	0.00013	0.0399	-0.25	-0.2	Dental caries;	chr10:99521401	chr10:99526350~99531177:-
STAD	cis	rs9467773	0.595	rs12525810	ENSG00000241549.7	GUSBP2	3.87	0.00013	0.0399	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26871484~26956554:-
STAD	cis	rs360071	0.528	rs360100	ENSG00000242861.1	RP11-285F7.2	-3.87	0.00013	0.0399	-0.19	-0.2	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225879682	chr1:225840883~225846522:-
STAD	cis	rs12477438	0.52	rs1453563	ENSG00000231822.1	AC019097.7	3.87	0.00013	0.0399	0.21	0.2	Chronic sinus infection;	chr2:99103804	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs11683188	ENSG00000231822.1	AC019097.7	3.87	0.00013	0.0399	0.21	0.2	Chronic sinus infection;	chr2:99108049	chr2:99102018~99102752:+
STAD	cis	rs6432860	1	rs507193	ENSG00000229195.1	AC009495.4	3.87	0.00013	0.0399	0.25	0.2	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166020327	chr2:165794857~165846091:-
STAD	cis	rs10986311	0.626	rs4836972	ENSG00000227200.1	RP11-121A14.3	-3.87	0.00013	0.0399	-0.22	-0.2	Vitiligo;	chr9:124319309	chr9:124262876~124265809:+
STAD	cis	rs73198271	0.681	rs35457364	ENSG00000254340.1	RP11-10A14.3	-3.87	0.00013	0.04	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.641	rs34473848	ENSG00000254340.1	RP11-10A14.3	-3.87	0.00013	0.04	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.601	rs11997731	ENSG00000254340.1	RP11-10A14.3	-3.87	0.00013	0.04	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.681	rs11987924	ENSG00000254340.1	RP11-10A14.3	-3.87	0.00013	0.04	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:9141424~9145435:+
STAD	cis	rs9902453	1	rs62070270	ENSG00000240074.1	RPL9P30	3.87	0.000131	0.04	0.17	0.2	Coffee consumption (cups per day);	chr17:29936962	chr17:29855759~29856332:+
STAD	cis	rs2098713	0.535	rs2176478	ENSG00000250155.1	CTD-2353F22.1	3.87	0.000131	0.04	0.21	0.2	Telomere length;	chr5:37626939	chr5:36666214~36725195:-
STAD	cis	rs2098713	0.535	rs1589116	ENSG00000250155.1	CTD-2353F22.1	3.87	0.000131	0.04	0.21	0.2	Telomere length;	chr5:37629567	chr5:36666214~36725195:-
STAD	cis	rs72802342	0.51	rs12932952	ENSG00000261783.1	RP11-252K23.2	-3.87	0.000131	0.04	-0.32	-0.2	Advanced age-related macular degeneration;	chr16:75331588	chr16:75379818~75381260:-
STAD	cis	rs9393813	0.516	rs4711152	ENSG00000280107.1	AL022393.9	-3.87	0.000131	0.04	-0.22	-0.2	Bipolar disorder;	chr6:27412423	chr6:28170845~28172521:+
STAD	cis	rs75920871	0.528	rs7935913	ENSG00000254851.1	RP11-109L13.1	-3.87	0.000131	0.04	-0.22	-0.2	Subjective well-being;	chr11:117073632	chr11:117135528~117138582:+
STAD	cis	rs9902453	0.691	rs140701	ENSG00000240074.1	RPL9P30	3.87	0.000131	0.04	0.18	0.2	Coffee consumption (cups per day);	chr17:30211514	chr17:29855759~29856332:+
STAD	cis	rs4950322	0.518	rs55697094	ENSG00000278811.3	LINC00624	3.87	0.000131	0.04	0.22	0.2	Protein quantitative trait loci;	chr1:147121205	chr1:147258885~147517875:-
STAD	cis	rs11051970	0.592	rs58926489	ENSG00000274964.1	RP11-817I4.1	-3.87	0.000131	0.04	-0.27	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32319949	chr12:32339368~32340724:+
STAD	cis	rs4927850	0.501	rs9881504	ENSG00000252174.1	RNU7-18P	-3.87	0.000131	0.04	-0.2	-0.2	Pancreatic cancer;	chr3:195929743	chr3:196072819~196072880:+
STAD	cis	rs2273156	0.587	rs76767804	ENSG00000258704.4	SRP54-AS1	-3.87	0.000131	0.04	-0.26	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35050161	chr14:34920858~34982532:-
STAD	cis	rs2957692	0.507	rs12362938	ENSG00000254554.1	RP11-351I24.1	3.87	0.000131	0.04	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10134915	chr11:10302657~10303704:-
STAD	cis	rs34779708	0.966	rs35079558	ENSG00000271335.4	RP11-324I22.4	3.87	0.000131	0.04	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35314552~35336401:-
STAD	cis	rs12745968	0.589	rs722356	ENSG00000229052.2	RP11-386I23.1	-3.87	0.000131	0.04	-0.19	-0.2	Bipolar disorder and schizophrenia;	chr1:92516848	chr1:92930696~92934098:+
STAD	cis	rs7617773	1	rs6442108	ENSG00000224895.1	VPS26BP1	3.87	0.000131	0.04	0.21	0.2	Coronary artery disease;	chr3:48151469	chr3:47960327~47961081:-
STAD	cis	rs451417	0.818	rs236103	ENSG00000275632.1	RP5-967N21.11	3.87	0.000131	0.04	0.3	0.2	Menopause (age at onset);	chr20:5977341	chr20:6000418~6000941:+
STAD	cis	rs10782582	0.593	rs11576534	ENSG00000181227.3	RP4-682C21.2	3.87	0.000131	0.04	0.21	0.2	Daytime sleep phenotypes;	chr1:75647066	chr1:75743423~75744776:-
STAD	cis	rs7142881	0.76	rs12881178	ENSG00000258648.1	UBE2CP1	-3.87	0.000131	0.04	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31678901	chr14:30683045~30683598:-
STAD	cis	rs4388249	1	rs3756597	ENSG00000271849.1	CTC-332L22.1	-3.87	0.000131	0.04	-0.31	-0.2	Schizophrenia;	chr5:109739808	chr5:109687802~109688329:-
STAD	cis	rs2562456	0.755	rs2562421	ENSG00000268117.1	VN1R84P	-3.87	0.000131	0.04	-0.27	-0.2	Pain;	chr19:21448502	chr19:21719801~21720035:-
STAD	cis	rs2562456	0.793	rs2562420	ENSG00000268117.1	VN1R84P	-3.87	0.000131	0.04	-0.27	-0.2	Pain;	chr19:21448503	chr19:21719801~21720035:-
STAD	cis	rs11673344	0.504	rs7252940	ENSG00000267672.1	CTD-2293H3.1	3.87	0.000131	0.04	0.18	0.2	Obesity-related traits;	chr19:37138589	chr19:37091341~37092564:+
STAD	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	3.87	0.000131	0.04	0.23	0.2	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
STAD	cis	rs7474896	1	rs2738219	ENSG00000099251.13	HSD17B7P2	-3.87	0.000131	0.04	-0.33	-0.2	Obesity (extreme);	chr10:37869332	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs1322319	ENSG00000099251.13	HSD17B7P2	3.87	0.000131	0.04	0.33	0.2	Obesity (extreme);	chr10:37856581	chr10:38356380~38378505:+
STAD	cis	rs7474896	1	rs2295872	ENSG00000099251.13	HSD17B7P2	3.87	0.000131	0.04	0.33	0.2	Obesity (extreme);	chr10:37857290	chr10:38356380~38378505:+
STAD	cis	rs7829975	0.711	rs4481596	ENSG00000233609.3	RP11-62H7.2	3.87	0.000131	0.04	0.23	0.2	Mood instability;	chr8:8846820	chr8:8961200~8979025:+
STAD	cis	rs1816752	0.819	rs4770664	ENSG00000232858.1	RPL34P27	3.87	0.000131	0.04	0.13	0.2	Obesity-related traits;	chr13:24414695	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.905	rs7571	ENSG00000232858.1	RPL34P27	3.87	0.000131	0.04	0.13	0.2	Obesity-related traits;	chr13:24426479	chr13:24988577~24988925:-
STAD	cis	rs10515750	0.643	rs10054755	ENSG00000248544.2	CTB-47B11.3	3.87	0.000131	0.04	0.24	0.2	Lung function (FEV1/FVC);	chr5:157384037	chr5:157375741~157384950:-
STAD	cis	rs858239	0.862	rs1728292	ENSG00000230042.1	AK3P3	-3.87	0.000131	0.04	-0.22	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23129178~23129841:+
STAD	cis	rs262150	0.659	rs2730275	ENSG00000231419.5	LINC00689	3.87	0.000131	0.0401	0.22	0.2	Facial morphology (factor 20);	chr7:159000706	chr7:159006522~159030195:+
STAD	cis	rs14403	0.913	rs884328	ENSG00000240963.1	RP11-518L10.5	3.87	0.000131	0.0401	0.21	0.2	Schizophrenia;	chr1:243490976	chr1:244375100~244409592:-
STAD	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000131	0.0401	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000131	0.0401	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
STAD	cis	rs7915414	0.951	rs2094296	ENSG00000230338.1	MTND4P19	3.87	0.000131	0.0401	0.22	0.2	Clopidogrel active metabolite levels;	chr10:94663648	chr10:94774156~94774633:-
STAD	cis	rs11846409	0.86	rs73378154	ENSG00000274576.2	IGHV2-70	-3.87	0.000131	0.0401	-0.24	-0.2	Rheumatic heart disease;	chr14:106637687	chr14:106770577~106771020:-
STAD	cis	rs2562456	0.834	rs2173727	ENSG00000268119.4	CTD-2561J22.5	-3.87	0.000131	0.0401	-0.26	-0.2	Pain;	chr19:21491155	chr19:21444241~21463908:-
STAD	cis	rs6430585	0.759	rs4954623	ENSG00000231890.6	DARS-AS1	3.87	0.000131	0.0401	0.24	0.2	Corneal structure;	chr2:135778306	chr2:135985176~136022593:+
STAD	cis	rs7202877	0.561	rs8050662	ENSG00000261783.1	RP11-252K23.2	3.87	0.000131	0.0401	0.33	0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75326836	chr16:75379818~75381260:-
STAD	cis	rs4753788	1	rs4753788	ENSG00000261098.1	RP11-819C21.1	-3.87	0.000131	0.0401	-0.17	-0.2	Coronary artery disease;	chr11:107221129	chr11:107312132~107316271:-
STAD	cis	rs72627123	1	rs17093141	ENSG00000259065.1	RP5-1021I20.1	-3.87	0.000131	0.0401	-0.31	-0.2	Morning vs. evening chronotype;	chr14:73860200	chr14:73787360~73803270:+
STAD	cis	rs9907295	0.71	rs28912068	ENSG00000270894.1	AC015849.13	-3.87	0.000131	0.0401	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35881967	chr17:35818399~35823713:+
STAD	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	3.87	0.000131	0.0401	0.24	0.2	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
STAD	cis	rs1499614	1	rs1638731	ENSG00000273448.1	RP11-166O4.6	3.87	0.000131	0.0401	0.25	0.2	Gout;	chr7:66679692	chr7:67333047~67334383:+
STAD	cis	rs4792901	0.765	rs9892162	ENSG00000279602.1	CTD-3014M21.1	-3.87	0.000131	0.0401	-0.27	-0.2	Dupuytren's disease;	chr17:43523432	chr17:43360041~43361361:-
STAD	cis	rs875971	0.929	rs4122249	ENSG00000224316.1	RP11-479O9.2	3.87	0.000131	0.0401	0.2	0.2	Aortic root size;	chr7:66455949	chr7:65773620~65802067:+
STAD	cis	rs6604026	0.74	rs7536563	ENSG00000229052.2	RP11-386I23.1	-3.87	0.000131	0.0401	-0.19	-0.2	Multiple sclerosis;	chr1:92883489	chr1:92930696~92934098:+
STAD	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-3.87	0.000131	0.0401	-0.23	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
STAD	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-3.87	0.000131	0.0401	-0.27	-0.2	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
STAD	cis	rs953387	0.824	rs6716987	ENSG00000231890.6	DARS-AS1	-3.87	0.000131	0.0401	-0.21	-0.2	Arthritis (juvenile idiopathic);	chr2:136205924	chr2:135985176~136022593:+
STAD	cis	rs7142881	0.508	rs12589170	ENSG00000258648.1	UBE2CP1	3.87	0.000131	0.0402	0.22	0.2	Response to iloperidone treatment (QT prolongation);	chr14:31651087	chr14:30683045~30683598:-
STAD	cis	rs806321	0.755	rs2765762	ENSG00000237152.3	DLEU7-AS1	-3.87	0.000131	0.0402	-0.23	-0.2	Multiple sclerosis;	chr13:50207120	chr13:50807856~50849905:+
STAD	cis	rs17592366	0.818	rs4982211	ENSG00000251726.1	RNU7-41P	3.87	0.000131	0.0402	0.29	0.2	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34789945	chr14:34845300~34845360:-
STAD	cis	rs2638953	0.924	rs11049471	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000131	0.0402	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28228259	chr12:28163298~28190738:-
STAD	cis	rs1816752	0.905	rs4770666	ENSG00000232858.1	RPL34P27	3.87	0.000131	0.0402	0.13	0.2	Obesity-related traits;	chr13:24414891	chr13:24988577~24988925:-
STAD	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	3.87	0.000131	0.0402	0.19	0.2	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
STAD	cis	rs1015213	1	rs7816406	ENSG00000272024.1	RP11-546K22.3	-3.87	0.000132	0.0402	-0.47	-0.2	Glaucoma (primary angle closure);	chr8:51978116	chr8:51950284~51950690:+
STAD	cis	rs1015213	0.737	rs7817432	ENSG00000272024.1	RP11-546K22.3	-3.87	0.000132	0.0402	-0.47	-0.2	Glaucoma (primary angle closure);	chr8:51978123	chr8:51950284~51950690:+
STAD	cis	rs10851478	0.842	rs1395903	ENSG00000259545.2	RP11-325E5.4	-3.87	0.000132	0.0402	-0.24	-0.2	Oral cavity cancer;	chr15:49521300	chr15:49177610~49178741:-
STAD	cis	rs4730250	0.707	rs257373	ENSG00000273320.1	RP11-22N19.2	-3.87	0.000132	0.0402	-0.32	-0.2	Osteoarthritis;	chr7:107157845	chr7:106285480~106286326:+
STAD	cis	rs11157436	0.602	rs2032441	ENSG00000211812.1	TRAV26-2	-3.87	0.000132	0.0402	-0.2	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157682	chr14:22202583~22203368:+
STAD	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	3.87	0.000132	0.0402	0.26	0.2	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
STAD	cis	rs12477438	0.559	rs6733285	ENSG00000231822.1	AC019097.7	3.87	0.000132	0.0403	0.21	0.2	Chronic sinus infection;	chr2:99109112	chr2:99102018~99102752:+
STAD	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	3.87	0.000132	0.0403	0.26	0.2	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
STAD	cis	rs35955747	0.749	rs2027982	ENSG00000236132.1	CTA-440B3.1	3.87	0.000132	0.0403	0.2	0.2	Neutrophil count;Sum basophil neutrophil counts;	chr22:31197449	chr22:31816379~31817491:-
STAD	cis	rs7142881	0.815	rs17098028	ENSG00000258648.1	UBE2CP1	-3.87	0.000132	0.0403	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31630224	chr14:30683045~30683598:-
STAD	cis	rs17826219	0.568	rs11658027	ENSG00000280069.1	CTD-2349P21.3	3.87	0.000132	0.0403	0.21	0.2	Body mass index;	chr17:30767864	chr17:30738182~30740275:+
STAD	cis	rs7208859	0.673	rs9907197	ENSG00000263603.1	CTD-2349P21.5	-3.87	0.000132	0.0403	-0.25	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30729469~30731202:+
STAD	cis	rs7208859	0.673	rs9915963	ENSG00000263603.1	CTD-2349P21.5	-3.87	0.000132	0.0403	-0.25	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30729469~30731202:+
STAD	cis	rs12468226	0.938	rs4675274	ENSG00000272966.1	RP11-686O6.1	-3.87	0.000132	0.0403	-0.3	-0.2	Urate levels;	chr2:202243145	chr2:202336739~202337200:+
STAD	cis	rs6180	0.967	rs1423656	ENSG00000250860.1	CTD-2265D6.2	3.87	0.000132	0.0403	0.17	0.2	Height;	chr5:42779634	chr5:42466893~42468300:-
STAD	cis	rs9926296	0.744	rs164749	ENSG00000260259.1	RP11-368I7.4	3.87	0.000132	0.0403	0.21	0.2	Vitiligo;	chr16:89641816	chr16:89682620~89686569:-
STAD	cis	rs1876905	0.597	rs191631	ENSG00000271789.1	RP5-1112D6.7	-3.87	0.000132	0.0403	-0.25	-0.2	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111297126~111298510:+
STAD	cis	rs1707322	1	rs10890350	ENSG00000225447.1	RPS15AP10	3.87	0.000132	0.0403	0.16	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45645816~45646197:-
STAD	cis	rs9463078	0.677	rs7739928	ENSG00000219384.1	RP11-491H9.3	3.87	0.000132	0.0403	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45100316	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.617	rs9381365	ENSG00000219384.1	RP11-491H9.3	3.87	0.000132	0.0403	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45110238	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.653	rs6899378	ENSG00000219384.1	RP11-491H9.3	3.87	0.000132	0.0403	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45112631	chr6:45158870~45159511:+
STAD	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	3.87	0.000132	0.0403	0.32	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
STAD	cis	rs6964833	1	rs17515241	ENSG00000277072.3	STAG3L2	-3.87	0.000132	0.0403	-0.24	-0.2	Menarche (age at onset);	chr7:74717695	chr7:74882163~74890610:-
STAD	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	3.87	0.000132	0.0403	0.26	0.2	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
STAD	cis	rs6813195	0.781	rs10011174	ENSG00000243417.1	RP11-555K12.1	3.87	0.000132	0.0403	0.2	0.2	Type 2 diabetes;	chr4:152574363	chr4:152551277~152552364:-
STAD	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	3.87	0.000132	0.0403	0.27	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
STAD	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
STAD	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
STAD	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
STAD	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
STAD	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
STAD	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
STAD	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000132	0.0403	-0.32	-0.2	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
STAD	cis	rs4869931	0.929	rs9480529	ENSG00000218358.2	RAET1K	3.87	0.000132	0.0403	0.32	0.2	Systolic blood pressure in sickle cell anemia;	chr6:150681151	chr6:149998019~150005157:-
STAD	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	3.87	0.000132	0.0403	0.26	0.2	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	3.87	0.000132	0.0403	0.26	0.2	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
STAD	cis	rs7520050	0.933	rs12045165	ENSG00000280836.1	AL355480.1	3.87	0.000132	0.0403	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45581219~45581321:-
STAD	cis	rs860295	0.541	rs11264359	ENSG00000225855.5	RUSC1-AS1	3.87	0.000132	0.0403	0.17	0.2	Body mass index;	chr1:155313038	chr1:155316863~155324176:-
STAD	cis	rs9426935	0.966	rs1139620	ENSG00000272030.1	RP1-178F15.4	3.87	0.000132	0.0403	0.27	0.2	Lentiform nucleus volume;	chr1:153805372	chr1:153631438~153634397:-
STAD	cis	rs17592366	1	rs4982208	ENSG00000251726.1	RNU7-41P	-3.87	0.000132	0.0403	-0.27	-0.2	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34752654	chr14:34845300~34845360:-
STAD	cis	rs6832769	1	rs28448438	ENSG00000223305.1	RN7SKP30	-3.87	0.000132	0.0404	-0.23	-0.2	Personality dimensions;	chr4:55550498	chr4:55540502~55540835:-
STAD	cis	rs2832270	0.596	rs73195611	ENSG00000232687.1	RPL12P9	3.87	0.000132	0.0404	0.38	0.2	Response to mTOR inhibitor (everolimus);	chr21:29343464	chr21:29127701~29128188:-
STAD	cis	rs867371	1	rs8037224	ENSG00000278603.1	RP13-608F4.5	3.87	0.000132	0.0404	0.24	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs7166570	ENSG00000278603.1	RP13-608F4.5	3.87	0.000132	0.0404	0.24	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472203~82472426:+
STAD	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-3.87	0.000132	0.0404	-0.3	-0.2	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
STAD	cis	rs10073892	1	rs10062073	ENSG00000250682.4	LINC00491	-3.87	0.000132	0.0404	-0.23	-0.2	Cognitive decline (age-related);	chr5:102374385	chr5:102609156~102671559:-
STAD	cis	rs6693567	0.565	rs832621	ENSG00000203819.6	HIST2H2BC	3.87	0.000132	0.0404	0.24	0.2	Migraine;	chr1:150420433	chr1:149850193~149850772:-
STAD	cis	rs6479891	1	rs61853589	ENSG00000235816.3	PRELID1P3	3.87	0.000132	0.0404	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs9414803	ENSG00000235816.3	PRELID1P3	3.87	0.000132	0.0404	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs9415707	ENSG00000235816.3	PRELID1P3	3.87	0.000132	0.0404	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs12413029	ENSG00000235816.3	PRELID1P3	3.87	0.000132	0.0404	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs9415708	ENSG00000235816.3	PRELID1P3	3.87	0.000132	0.0404	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs12784772	ENSG00000235816.3	PRELID1P3	3.87	0.000132	0.0404	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63427297~63427939:+
STAD	cis	rs1154275	0.537	rs6793183	ENSG00000240057.4	RP11-572M11.4	-3.87	0.000132	0.0404	-0.19	-0.2	Takotsubo syndrome;	chr3:112798908	chr3:113019532~113183301:+
STAD	cis	rs6693567	0.507	rs828784	ENSG00000203819.6	HIST2H2BC	3.87	0.000132	0.0404	0.24	0.2	Migraine;	chr1:150362764	chr1:149850193~149850772:-
STAD	cis	rs6840258	0.943	rs10029915	ENSG00000248180.1	GAPDHP60	3.87	0.000132	0.0404	0.16	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87138465	chr4:87207092~87208086:+
STAD	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-3.87	0.000132	0.0404	-0.26	-0.2	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
STAD	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	3.87	0.000132	0.0404	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
STAD	cis	rs6957923	0.659	rs10280508	ENSG00000234286.1	AC006026.13	-3.87	0.000132	0.0404	-0.25	-0.2	Height;	chr7:23544439	chr7:23680195~23680786:-
STAD	cis	rs10508774	1	rs12415699	ENSG00000273038.2	RP11-479G22.8	3.87	0.000132	0.0404	0.4	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32460476	chr10:32887255~32889311:-
STAD	cis	rs62025270	0.848	rs2554	ENSG00000259295.5	CSPG4P12	-3.87	0.000133	0.0404	-0.36	-0.2	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85191438~85213905:+
STAD	cis	rs7589728	1	rs75181745	ENSG00000240671.2	IGKV1-8	3.87	0.000133	0.0404	0.25	0.2	Plasma clusterin levels;	chr2:88220889	chr2:88857361~88992931:-
STAD	cis	rs7589728	1	rs2363731	ENSG00000240671.2	IGKV1-8	3.87	0.000133	0.0404	0.25	0.2	Plasma clusterin levels;	chr2:88222274	chr2:88857361~88992931:-
STAD	cis	rs875971	0.862	rs4236208	ENSG00000224316.1	RP11-479O9.2	-3.87	0.000133	0.0404	-0.2	-0.2	Aortic root size;	chr7:66284091	chr7:65773620~65802067:+
STAD	cis	rs919433	0.963	rs12617117	ENSG00000231621.1	AC013264.2	3.87	0.000133	0.0405	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197290446	chr2:197197991~197199273:+
STAD	cis	rs10129255	1	rs11627342	ENSG00000224373.3	IGHV4-59	3.87	0.000133	0.0405	0.17	0.2	Kawasaki disease;	chr14:106675823	chr14:106627249~106627825:-
STAD	cis	rs867371	1	rs1174543	ENSG00000278603.1	RP13-608F4.5	-3.87	0.000133	0.0405	-0.24	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs9944197	ENSG00000278603.1	RP13-608F4.5	3.87	0.000133	0.0405	0.24	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472203~82472426:+
STAD	cis	rs7493	0.901	rs13226149	ENSG00000233942.1	AC004012.1	3.87	0.000133	0.0405	0.24	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396288	chr7:95471835~95473998:+
STAD	cis	rs151997	0.925	rs27287	ENSG00000250360.1	CTD-2089N3.1	-3.86	0.000133	0.0405	-0.19	-0.2	Callous-unemotional behaviour;	chr5:50899733	chr5:50965687~50967008:-
STAD	cis	rs2957692	0.548	rs11600251	ENSG00000254554.1	RP11-351I24.1	3.86	0.000133	0.0405	0.33	0.2	Circulating vasoactive peptide levels;	chr11:10139647	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs11606561	ENSG00000254554.1	RP11-351I24.1	3.86	0.000133	0.0405	0.33	0.2	Circulating vasoactive peptide levels;	chr11:10140257	chr11:10302657~10303704:-
STAD	cis	rs4639966	0.756	rs61219050	ENSG00000255239.1	AP002954.6	-3.86	0.000133	0.0405	-0.25	-0.2	Systemic lupus erythematosus;	chr11:118777915	chr11:118688039~118690600:-
STAD	cis	rs9287719	0.649	rs12621977	ENSG00000243819.4	RN7SL832P	3.86	0.000133	0.0405	0.2	0.2	Prostate cancer;	chr2:10581805	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	3.86	0.000133	0.0405	0.2	0.2	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.614	rs12622053	ENSG00000243819.4	RN7SL832P	3.86	0.000133	0.0405	0.2	0.2	Prostate cancer;	chr2:10582014	chr2:10690344~10692099:+
STAD	cis	rs875971	1	rs778706	ENSG00000224316.1	RP11-479O9.2	3.86	0.000133	0.0405	0.2	0.2	Aortic root size;	chr7:66395437	chr7:65773620~65802067:+
STAD	cis	rs494453	0.845	rs523650	ENSG00000234020.1	CHIAP3	-3.86	0.000133	0.0405	-0.2	-0.2	Osteoporosis-related phenotypes;	chr1:111699642	chr1:111353275~111367409:-
STAD	cis	rs4835473	0.832	rs55935372	ENSG00000249741.2	RP11-673E1.3	3.86	0.000133	0.0405	0.24	0.2	Immature fraction of reticulocytes;	chr4:143700626	chr4:143911514~143912053:-
STAD	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	3.86	0.000133	0.0405	0.29	0.2	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
STAD	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	3.86	0.000133	0.0405	0.29	0.2	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
STAD	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	3.86	0.000133	0.0405	0.29	0.2	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
STAD	cis	rs10073892	0.664	rs1910290	ENSG00000250682.4	LINC00491	-3.86	0.000133	0.0405	-0.22	-0.2	Cognitive decline (age-related);	chr5:102556247	chr5:102609156~102671559:-
STAD	cis	rs7283707	0.681	rs17241444	ENSG00000228798.1	AP000473.5	-3.86	0.000133	0.0405	-0.32	-0.2	QRS complex (12-leadsum);	chr21:15772072	chr21:16630827~16640683:+
STAD	cis	rs2273156	1	rs7145608	ENSG00000258704.4	SRP54-AS1	-3.86	0.000133	0.0405	-0.23	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:34994291	chr14:34920858~34982532:-
STAD	cis	rs73198271	0.96	rs17154702	ENSG00000233609.3	RP11-62H7.2	-3.86	0.000133	0.0405	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752370	chr8:8961200~8979025:+
STAD	cis	rs11846409	0.932	rs60917084	ENSG00000274576.2	IGHV2-70	-3.86	0.000133	0.0405	-0.24	-0.2	Rheumatic heart disease;	chr14:106634621	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.932	rs28378201	ENSG00000274576.2	IGHV2-70	-3.86	0.000133	0.0405	-0.24	-0.2	Rheumatic heart disease;	chr14:106637262	chr14:106770577~106771020:-
STAD	cis	rs11089937	0.54	rs5756992	ENSG00000211638.2	IGLV8-61	-3.86	0.000133	0.0405	-0.22	-0.2	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22098700~22099212:+
STAD	cis	rs11089937	0.597	rs9622919	ENSG00000211638.2	IGLV8-61	-3.86	0.000133	0.0405	-0.22	-0.2	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22098700~22099212:+
STAD	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-3.86	0.000133	0.0405	-0.22	-0.2	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
STAD	cis	rs1876905	0.597	rs1150076	ENSG00000271789.1	RP5-1112D6.7	-3.86	0.000133	0.0405	-0.25	-0.2	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111297126~111298510:+
STAD	cis	rs9902453	0.808	rs56088359	ENSG00000240074.1	RPL9P30	3.86	0.000133	0.0405	0.17	0.2	Coffee consumption (cups per day);	chr17:29846641	chr17:29855759~29856332:+
STAD	cis	rs792448	0.603	rs4951588	ENSG00000212044.2	AL360091.1	3.86	0.000133	0.0405	0.21	0.2	White blood cell count (basophil);	chr1:212327091	chr1:212349978~212350069:+
STAD	cis	rs10129255	1	rs10137758	ENSG00000211973.2	IGHV1-69	3.86	0.000133	0.0406	0.2	0.2	Kawasaki disease;	chr14:106697673	chr14:106714684~106715181:-
STAD	cis	rs9788721	0.836	rs11858836	ENSG00000259419.2	HNRNPCP3	3.86	0.000133	0.0406	0.23	0.2	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78490935	chr15:79236332~79237206:+
STAD	cis	rs2732480	0.538	rs1387259	ENSG00000257735.1	RP11-370I10.6	-3.86	0.000133	0.0406	-0.24	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48350945~48442411:+
STAD	cis	rs7078219	1	rs7081330	ENSG00000257582.4	LINC01475	-3.86	0.000133	0.0406	-0.23	-0.2	Dental caries;	chr10:99514708	chr10:99526350~99531177:-
STAD	cis	rs2834188	1	rs13050445	ENSG00000272659.1	AP000295.10	3.86	0.000133	0.0406	0.29	0.2	Narcolepsy;	chr21:33331291	chr21:33309491~33310181:+
STAD	cis	rs2834188	1	rs2252930	ENSG00000272659.1	AP000295.10	3.86	0.000133	0.0406	0.29	0.2	Narcolepsy;	chr21:33331895	chr21:33309491~33310181:+
STAD	cis	rs2834188	1	rs2843994	ENSG00000272659.1	AP000295.10	-3.86	0.000133	0.0406	-0.29	-0.2	Narcolepsy;	chr21:33334564	chr21:33309491~33310181:+
STAD	cis	rs295490	0.748	rs77327267	ENSG00000272656.1	RP11-219D15.3	3.86	0.000133	0.0406	0.52	0.2	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341667	chr3:139349024~139349371:-
STAD	cis	rs3794924	0.925	rs16961977	ENSG00000266521.1	RP11-650P15.1	3.86	0.000133	0.0406	0.36	0.2	Survival in colon cancer;	chr18:31468251	chr18:31496645~31497195:-
STAD	cis	rs1015362	0.503	rs4911371	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000133	0.0406	-0.24	-0.2	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33985617~33988989:-
STAD	cis	rs6693567	0.545	rs5011187	ENSG00000203819.6	HIST2H2BC	3.86	0.000133	0.0406	0.23	0.2	Migraine;	chr1:150450285	chr1:149850193~149850772:-
STAD	cis	rs2351088	0.572	rs11704781	ENSG00000230634.1	RP5-996D20.3	-3.86	0.000133	0.0406	-0.3	-0.2	Tonsillectomy;	chr22:45815661	chr22:46481329~46481760:-
STAD	cis	rs1348850	0.567	rs1527401	ENSG00000271825.1	RP11-337N6.2	3.86	0.000133	0.0406	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177657376	chr2:177300600~177302006:+
STAD	cis	rs10040610	0.822	rs10035149	ENSG00000250490.1	FLJ33360	-3.86	0.000133	0.0406	-0.29	-0.2	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6363613	chr5:6310441~6339884:-
STAD	cis	rs451417	0.818	rs236113	ENSG00000275632.1	RP5-967N21.11	3.86	0.000133	0.0406	0.28	0.2	Menopause (age at onset);	chr20:5953920	chr20:6000418~6000941:+
STAD	cis	rs1858037	0.867	rs964505	ENSG00000223739.1	AC007389.2	-3.86	0.000133	0.0406	-0.19	-0.2	Rheumatoid arthritis;	chr2:65396055	chr2:65511771~65512076:-
STAD	cis	rs741668	0.641	rs1022951	ENSG00000235903.6	CPB2-AS1	3.86	0.000133	0.0406	0.21	0.2	Cerebrospinal fluid clusterin levels;	chr13:46075319	chr13:46052806~46113332:+
STAD	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	3.86	0.000133	0.0406	0.25	0.2	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
STAD	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-3.86	0.000133	0.0406	-0.27	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
STAD	cis	rs9467773	0.62	rs2451732	ENSG00000241549.7	GUSBP2	-3.86	0.000133	0.0406	-0.2	-0.2	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26871484~26956554:-
STAD	cis	rs12571093	0.571	rs4517412	ENSG00000234102.1	KRT19P4	3.86	0.000133	0.0406	0.26	0.2	Optic nerve measurement (disc area);	chr10:68303779	chr10:68260557~68261499:+
STAD	cis	rs12571093	0.571	rs7097498	ENSG00000234102.1	KRT19P4	3.86	0.000133	0.0406	0.26	0.2	Optic nerve measurement (disc area);	chr10:68303780	chr10:68260557~68261499:+
STAD	cis	rs11235843	0.929	rs12366033	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73667929	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs66481935	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73669278	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs72974840	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73669317	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs3825003	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73678067	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs112650783	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73678883	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.853	rs66556722	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73691994	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs4944856	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73694351	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs4944028	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73696525	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs4944029	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73696558	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.866	rs72974869	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73703801	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.778	rs4944861	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73719460	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs67488767	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73721644	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.79	rs11235881	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73727192	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs11235882	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73731956	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs7939193	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73735324	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs4944033	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73737601	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.853	rs12365044	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73741466	chr11:73722349~73722694:+
STAD	cis	rs11235843	0.929	rs10898943	ENSG00000255928.1	RP11-456I15.2	3.86	0.000133	0.0406	0.34	0.2	Hand grip strength;	chr11:73752710	chr11:73722349~73722694:+
STAD	cis	rs2446066	0.872	rs7300593	ENSG00000257379.1	RP11-793H13.8	3.86	0.000133	0.0406	0.34	0.2	Red blood cell count;	chr12:53396666	chr12:53441741~53467528:+
STAD	cis	rs11089937	0.597	rs5757005	ENSG00000211640.3	IGLV6-57	3.86	0.000133	0.0406	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22195713~22196460:+
STAD	cis	rs7989332	0.663	rs9550654	ENSG00000238286.1	SLC35E1P1	3.86	0.000133	0.0406	0.26	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486200	chr13:20607268~20608131:+
STAD	cis	rs718433	0.584	rs4982496	ENSG00000211790.2	TRAV8-4	3.86	0.000133	0.0407	0.17	0.2	Intraocular pressure;	chr14:21752353	chr14:21894433~21895030:+
STAD	cis	rs240993	0.516	rs181294	ENSG00000230177.1	RP5-1112D6.4	-3.86	0.000133	0.0407	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111277932~111278742:+
STAD	cis	rs62025270	0.806	rs62025262	ENSG00000259295.5	CSPG4P12	-3.86	0.000134	0.0407	-0.36	-0.2	Idiopathic pulmonary fibrosis;	chr15:85750002	chr15:85191438~85213905:+
STAD	cis	rs919433	1	rs7422899	ENSG00000231621.1	AC013264.2	3.86	0.000134	0.0407	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298803	chr2:197197991~197199273:+
STAD	cis	rs9907295	0.901	rs11652536	ENSG00000270894.1	AC015849.13	-3.86	0.000134	0.0407	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35891043	chr17:35818399~35823713:+
STAD	cis	rs1005277	0.565	rs2474565	ENSG00000276805.1	RP11-291L22.6	3.86	0.000134	0.0407	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38451030~38451785:+
STAD	cis	rs11037575	0.966	rs2863002	ENSG00000246250.2	RP11-613D13.5	3.86	0.000134	0.0407	0.19	0.2	Neuroblastoma;	chr11:43693218	chr11:43829709~43880726:-
STAD	cis	rs1816752	0.935	rs3816219	ENSG00000232858.1	RPL34P27	3.86	0.000134	0.0407	0.13	0.2	Obesity-related traits;	chr13:24442995	chr13:24988577~24988925:-
STAD	cis	rs1816752	1	rs7988810	ENSG00000232858.1	RPL34P27	3.86	0.000134	0.0407	0.13	0.2	Obesity-related traits;	chr13:24444958	chr13:24988577~24988925:-
STAD	cis	rs2243480	1	rs1796228	ENSG00000273448.1	RP11-166O4.6	3.86	0.000134	0.0407	0.25	0.2	Diabetic kidney disease;	chr7:66568097	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs1267820	ENSG00000273448.1	RP11-166O4.6	3.86	0.000134	0.0407	0.25	0.2	Diabetic kidney disease;	chr7:66585308	chr7:67333047~67334383:+
STAD	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	3.86	0.000134	0.0407	0.23	0.2	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
STAD	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	3.86	0.000134	0.0407	0.2	0.2	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
STAD	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	3.86	0.000134	0.0407	0.28	0.2	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	3.86	0.000134	0.0407	0.28	0.2	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	3.86	0.000134	0.0407	0.28	0.2	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
STAD	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	3.86	0.000134	0.0407	0.28	0.2	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
STAD	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	3.86	0.000134	0.0407	0.28	0.2	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
STAD	cis	rs2901460	0.759	rs1868582	ENSG00000229503.1	AC092155.1	-3.86	0.000134	0.0407	-0.16	-0.2	Mean corpuscular volume;	chr2:62177946	chr2:62532583~62533059:-
STAD	cis	rs6750795	0.542	rs1797388	ENSG00000223198.1	RNU2-22P	-3.86	0.000134	0.0407	-0.24	-0.2	Height;	chr2:231551270	chr2:231501990~231502201:-
STAD	cis	rs494453	0.6	rs474077	ENSG00000234020.1	CHIAP3	-3.86	0.000134	0.0407	-0.19	-0.2	Osteoporosis-related phenotypes;	chr1:111652592	chr1:111353275~111367409:-
STAD	cis	rs494453	0.6	rs530173	ENSG00000234020.1	CHIAP3	-3.86	0.000134	0.0407	-0.19	-0.2	Osteoporosis-related phenotypes;	chr1:111654908	chr1:111353275~111367409:-
STAD	cis	rs494453	0.6	rs561309	ENSG00000234020.1	CHIAP3	-3.86	0.000134	0.0407	-0.19	-0.2	Osteoporosis-related phenotypes;	chr1:111655994	chr1:111353275~111367409:-
STAD	cis	rs4834770	0.668	rs11737086	ENSG00000248280.1	RP11-33B1.2	-3.86	0.000134	0.0407	-0.25	-0.2	Blood protein levels;	chr4:119205962	chr4:119440561~119450157:-
STAD	cis	rs1528149	0.521	rs6959719	ENSG00000224683.1	RPL36AP29	3.86	0.000134	0.0407	0.21	0.2	Sitting height ratio;	chr7:16064461	chr7:16208945~16209265:+
STAD	cis	rs6570726	0.934	rs9484995	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000134	0.0407	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145799409~145886585:+
STAD	cis	rs238295	0.846	rs6053528	ENSG00000230563.2	RP5-828H9.1	3.86	0.000134	0.0407	0.23	0.2	Occipital cortical area (total cortical area interaction);	chr20:5601952	chr20:5471207~5475182:+
STAD	cis	rs9733	0.596	rs12086630	ENSG00000276103.1	U4	3.86	0.000134	0.0408	0.19	0.2	Tonsillectomy;	chr1:150678479	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs2065900	ENSG00000276103.1	U4	3.86	0.000134	0.0408	0.19	0.2	Tonsillectomy;	chr1:150679726	chr1:150608507~150608623:-
STAD	cis	rs806321	0.755	rs2740520	ENSG00000237152.3	DLEU7-AS1	3.86	0.000134	0.0408	0.23	0.2	Multiple sclerosis;	chr13:50212227	chr13:50807856~50849905:+
STAD	cis	rs1154275	0.511	rs10934187	ENSG00000240057.4	RP11-572M11.4	3.86	0.000134	0.0408	0.19	0.2	Takotsubo syndrome;	chr3:112794635	chr3:113019532~113183301:+
STAD	cis	rs7523273	0.565	rs2985104	ENSG00000227887.1	RPS26P13	-3.86	0.000134	0.0408	-0.2	-0.2	Schizophrenia;	chr1:207718667	chr1:208697369~208697698:-
STAD	cis	rs28830936	0.934	rs2412641	ENSG00000250379.1	RP11-23P13.4	3.86	0.000134	0.0408	0.25	0.2	Diastolic blood pressure;	chr15:41832201	chr15:41825099~41827936:-
STAD	cis	rs34779708	0.733	rs3853672	ENSG00000271335.4	RP11-324I22.4	3.86	0.000134	0.0408	0.25	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35314552~35336401:-
STAD	cis	rs1348850	0.914	rs4893957	ENSG00000271825.1	RP11-337N6.2	3.86	0.000134	0.0408	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177515681	chr2:177300600~177302006:+
STAD	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	3.86	0.000134	0.0408	0.26	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
STAD	cis	rs7567389	0.505	rs56273408	ENSG00000200250.1	RNU6-1147P	-3.86	0.000134	0.0408	-0.23	-0.2	Self-rated health;	chr2:127338012	chr2:127316873~127316979:+
STAD	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	3.86	0.000134	0.0408	0.26	0.2	Height;	chr6:109403287	chr6:109382795~109383666:+
STAD	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-3.86	0.000134	0.0408	-0.3	-0.2	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-3.86	0.000134	0.0408	-0.3	-0.2	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
STAD	cis	rs10129255	0.957	rs12589190	ENSG00000211974.3	IGHV2-70	3.86	0.000134	0.0408	0.22	0.2	Kawasaki disease;	chr14:106783079	chr14:106723574~106724093:-
STAD	cis	rs10129255	0.957	rs7493713	ENSG00000211974.3	IGHV2-70	3.86	0.000134	0.0408	0.22	0.2	Kawasaki disease;	chr14:106783685	chr14:106723574~106724093:-
STAD	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	3.86	0.000134	0.0408	0.24	0.2	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
STAD	cis	rs4218	0.543	rs11852461	ENSG00000259732.1	RP11-59H7.3	-3.86	0.000134	0.0408	-0.23	-0.2	Social communication problems;	chr15:59021728	chr15:59121034~59133250:+
STAD	cis	rs2836950	0.959	rs4818008	ENSG00000238141.2	BRWD1-AS1	-3.86	0.000134	0.0408	-0.23	-0.2	Menarche (age at onset);	chr21:39239516	chr21:39315707~39323218:+
STAD	cis	rs2564921	0.704	rs62253649	ENSG00000280417.1	RP11-5O17.1	3.86	0.000134	0.0408	0.23	0.2	Height;	chr3:52967831	chr3:53046166~53048122:+
STAD	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	3.86	0.000134	0.0408	0.22	0.2	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
STAD	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	3.86	0.000134	0.0408	0.22	0.2	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
STAD	cis	rs10073892	0.83	rs10479214	ENSG00000250682.4	LINC00491	-3.86	0.000134	0.0409	-0.24	-0.2	Cognitive decline (age-related);	chr5:102402165	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.744	rs10052881	ENSG00000250682.4	LINC00491	-3.86	0.000134	0.0409	-0.24	-0.2	Cognitive decline (age-related);	chr5:102404795	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.789	rs11745781	ENSG00000250682.4	LINC00491	-3.86	0.000134	0.0409	-0.24	-0.2	Cognitive decline (age-related);	chr5:102407559	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.789	rs1376899	ENSG00000250682.4	LINC00491	-3.86	0.000134	0.0409	-0.24	-0.2	Cognitive decline (age-related);	chr5:102407999	chr5:102609156~102671559:-
STAD	cis	rs9316337	0.582	rs3847996	ENSG00000236953.1	ZDHHC20-IT1	-3.86	0.000134	0.0409	-0.2	-0.2	Schizophrenia;	chr13:21433927	chr13:21376977~21377874:-
STAD	cis	rs6479891	1	rs9414799	ENSG00000235816.3	PRELID1P3	3.86	0.000134	0.0409	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63427297~63427939:+
STAD	cis	rs6479891	1	rs4746119	ENSG00000235816.3	PRELID1P3	3.86	0.000134	0.0409	0.26	0.2	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63427297~63427939:+
STAD	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-3.86	0.000134	0.0409	-0.32	-0.2	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
STAD	cis	rs5753618	0.583	rs7287267	ENSG00000236132.1	CTA-440B3.1	-3.86	0.000134	0.0409	-0.23	-0.2	Colorectal cancer;	chr22:31352429	chr22:31816379~31817491:-
STAD	cis	rs7951911	0.915	rs12289360	ENSG00000254427.1	RP11-430H10.1	3.86	0.000134	0.0409	0.41	0.2	IgG glycosylation;	chr11:45074259	chr11:45355371~45366121:+
STAD	cis	rs10911902	0.561	rs78701198	ENSG00000229739.2	RP11-295K2.3	-3.86	0.000134	0.0409	-0.29	-0.2	Schizophrenia;	chr1:186380240	chr1:186435161~186470291:+
STAD	cis	rs2657294	0.62	rs4746261	ENSG00000226051.5	ZNF503-AS1	3.86	0.000134	0.0409	0.26	0.2	Pneumonia;	chr10:75085874	chr10:75269819~75373500:+
STAD	cis	rs11587682	0.578	rs12121421	ENSG00000274963.1	Metazoa_SRP	-3.86	0.000135	0.0409	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150432190	chr1:150568971~150569269:-
STAD	cis	rs2115630	0.905	rs1975277	ENSG00000275120.1	RP11-182J1.17	-3.86	0.000135	0.0409	-0.23	-0.2	P wave terminal force;	chr15:84786327	chr15:84599434~84606463:-
STAD	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-3.86	0.000135	0.0409	-0.38	-0.2	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
STAD	cis	rs4713118	0.866	rs2179094	ENSG00000243307.2	POM121L6P	-3.86	0.000135	0.0409	-0.24	-0.2	Parkinson's disease;	chr6:27774046	chr6:26896952~26898777:+
STAD	cis	rs7824557	0.815	rs2736372	ENSG00000254866.2	DEFB109P3	3.86	0.000135	0.0409	0.25	0.2	Retinal vascular caliber;	chr8:11248532	chr8:12150895~12151134:-
STAD	cis	rs17818399	0.547	rs7607633	ENSG00000279254.1	RP11-536C12.1	-3.86	0.000135	0.0409	-0.23	-0.2	Height;	chr2:46532288	chr2:46668870~46670778:+
STAD	cis	rs2446066	0.872	rs7133236	ENSG00000257379.1	RP11-793H13.8	3.86	0.000135	0.0409	0.34	0.2	Red blood cell count;	chr12:53397201	chr12:53441741~53467528:+
STAD	cis	rs875971	0.862	rs709596	ENSG00000224316.1	RP11-479O9.2	3.86	0.000135	0.041	0.2	0.2	Aortic root size;	chr7:66360926	chr7:65773620~65802067:+
STAD	cis	rs8177876	0.749	rs2602407	ENSG00000261838.4	RP11-303E16.6	-3.86	0.000135	0.041	-0.37	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059141	chr16:81069854~81076598:+
STAD	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	3.86	0.000135	0.041	0.29	0.2	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
STAD	cis	rs7927771	0.832	rs896816	ENSG00000271350.1	CTD-2384B9.1	3.86	0.000135	0.041	0.22	0.2	Subjective well-being;	chr11:47372787	chr11:47041027~47041945:-
STAD	cis	rs7927771	0.832	rs7940536	ENSG00000271350.1	CTD-2384B9.1	3.86	0.000135	0.041	0.22	0.2	Subjective well-being;	chr11:47373689	chr11:47041027~47041945:-
STAD	cis	rs9608946	0.956	rs35841307	ENSG00000279159.1	RP3-394A18.1	-3.86	0.000135	0.041	-0.17	-0.2	Red cell distribution width;	chr22:30519771	chr22:29978950~30028236:-
STAD	cis	rs7264396	0.635	rs6060681	ENSG00000199676.1	Y_RNA	3.86	0.000135	0.041	0.24	0.2	Total cholesterol levels;	chr20:35918225	chr20:35853252~35853364:-
STAD	cis	rs4835473	0.708	rs7655939	ENSG00000249741.2	RP11-673E1.3	-3.86	0.000135	0.041	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143956889	chr4:143911514~143912053:-
STAD	cis	rs1876905	0.68	rs354540	ENSG00000272356.1	RP5-1112D6.8	-3.86	0.000135	0.041	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111309203~111313517:+
STAD	cis	rs7204230	0.961	rs7197925	ENSG00000261291.1	RP11-295M3.2	3.86	0.000135	0.041	0.24	0.2	Fibrinogen;	chr16:53330567	chr16:53168522~53169450:+
STAD	cis	rs950169	0.922	rs62029585	ENSG00000259683.1	RP11-182J1.14	3.86	0.000135	0.041	0.22	0.2	Schizophrenia;	chr15:84397176	chr15:84389729~84395903:+
STAD	cis	rs2262909	0.853	rs56207853	ENSG00000279377.1	AC003973.3	-3.86	0.000135	0.041	-0.2	-0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22109555	chr19:21965708~21968529:-
STAD	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-3.86	0.000135	0.041	-0.25	-0.2	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
STAD	cis	rs4141404	0.512	rs2070274	ENSG00000236132.1	CTA-440B3.1	3.86	0.000135	0.041	0.21	0.2	Paclitaxel-induced neuropathy;	chr22:31603237	chr22:31816379~31817491:-
STAD	cis	rs449789	0.524	rs6912475	ENSG00000235086.1	FNDC1-IT1	3.86	0.000135	0.041	0.26	0.2	Pulse pressure;	chr6:159326441	chr6:159240786~159243329:+
STAD	cis	rs17507216	0.718	rs4779034	ENSG00000259429.4	UBE2Q2P2	-3.86	0.000135	0.041	-0.31	-0.2	Excessive daytime sleepiness;	chr15:82576799	chr15:82355142~82420075:+
STAD	cis	rs9733	0.526	rs11204696	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150686245	chr1:150608507~150608623:-
STAD	cis	rs9733	0.526	rs11204698	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150687069	chr1:150608507~150608623:-
STAD	cis	rs17685	0.753	rs2286830	ENSG00000280388.1	RP11-229D13.3	3.86	0.000135	0.041	0.17	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76064645	chr7:76043977~76045963:-
STAD	cis	rs9733	0.596	rs6587516	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150650745	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs6678013	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150650809	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs2175615	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150651625	chr1:150608507~150608623:-
STAD	cis	rs9733	0.628	rs72700895	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150653553	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72700897	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150653562	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs6661872	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150655881	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs11204687	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150657404	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs2867304	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150658519	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs6690725	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150659846	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs72702504	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150662898	chr1:150608507~150608623:-
STAD	cis	rs9733	0.536	rs6661415	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150663393	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs11807058	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150667999	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs34140753	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150670107	chr1:150608507~150608623:-
STAD	cis	rs9733	0.569	rs11204691	ENSG00000276103.1	U4	3.86	0.000135	0.041	0.19	0.2	Tonsillectomy;	chr1:150671863	chr1:150608507~150608623:-
STAD	cis	rs8062405	0.755	rs7186573	ENSG00000278665.1	RP11-666O2.4	3.86	0.000135	0.041	0.24	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28599241~28601881:-
STAD	cis	rs12468226	1	rs112306637	ENSG00000272966.1	RP11-686O6.1	3.86	0.000135	0.041	0.3	0.2	Urate levels;	chr2:202334195	chr2:202336739~202337200:+
STAD	cis	rs12468226	1	rs111252524	ENSG00000272966.1	RP11-686O6.1	3.86	0.000135	0.041	0.3	0.2	Urate levels;	chr2:202334465	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.935	rs113188021	ENSG00000272966.1	RP11-686O6.1	3.86	0.000135	0.041	0.3	0.2	Urate levels;	chr2:202336237	chr2:202336739~202337200:+
STAD	cis	rs12468226	1	rs6731027	ENSG00000272966.1	RP11-686O6.1	3.86	0.000135	0.041	0.3	0.2	Urate levels;	chr2:202337443	chr2:202336739~202337200:+
STAD	cis	rs6813195	0.554	rs2292743	ENSG00000243417.1	RP11-555K12.1	-3.86	0.000135	0.041	-0.2	-0.2	Type 2 diabetes;	chr4:152411948	chr4:152551277~152552364:-
STAD	cis	rs10043228	0.609	rs12515880	ENSG00000248445.4	SEMA6A-AS1	-3.86	0.000135	0.041	-0.29	-0.2	Asthma or chronic obstructive pulmonary disease;	chr5:116379403	chr5:116447547~116508276:+
STAD	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	3.86	0.000135	0.0411	0.27	0.2	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
STAD	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	3.86	0.000135	0.0411	0.18	0.2	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
STAD	cis	rs7487075	0.554	rs12229299	ENSG00000272369.1	RP11-446N19.1	3.86	0.000135	0.0411	0.24	0.2	Itch intensity from mosquito bite;	chr12:46691110	chr12:46537502~46652550:+
STAD	cis	rs7204230	0.96	rs12149749	ENSG00000261291.1	RP11-295M3.2	3.86	0.000135	0.0411	0.23	0.2	Fibrinogen;	chr16:53302840	chr16:53168522~53169450:+
STAD	cis	rs9634489	0.567	rs1328055	ENSG00000226977.1	HMGN1P24	-3.86	0.000135	0.0411	-0.21	-0.2	Body mass index;	chr13:96407596	chr13:95809310~95809607:-
STAD	cis	rs2562456	0.876	rs62110163	ENSG00000268119.4	CTD-2561J22.5	3.86	0.000135	0.0411	0.26	0.2	Pain;	chr19:21546020	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.761	rs35008138	ENSG00000268119.4	CTD-2561J22.5	3.86	0.000135	0.0411	0.26	0.2	Pain;	chr19:21548822	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.833	rs2681388	ENSG00000268119.4	CTD-2561J22.5	3.86	0.000135	0.0411	0.26	0.2	Pain;	chr19:21549451	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.876	rs2681370	ENSG00000268119.4	CTD-2561J22.5	3.86	0.000135	0.0411	0.26	0.2	Pain;	chr19:21554036	chr19:21444241~21463908:-
STAD	cis	rs210138	0.637	rs9366825	ENSG00000197251.3	LINC00336	3.86	0.000135	0.0411	0.28	0.2	Testicular germ cell tumor;	chr6:33650408	chr6:33586106~33593338:-
STAD	cis	rs113131010	1	rs113131010	ENSG00000251726.1	RNU7-41P	-3.86	0.000135	0.0411	-0.28	-0.2	High light scatter reticulocyte count;Mean corpuscular volume;Reticulocyte count;	chr14:34772048	chr14:34845300~34845360:-
STAD	cis	rs782590	0.643	rs13032503	ENSG00000162997.14	PRORSD1P	3.86	0.000135	0.0411	0.2	0.2	Metabolic syndrome;	chr2:55511957	chr2:55282319~55284522:+
STAD	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	3.86	0.000135	0.0411	0.3	0.2	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
STAD	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	3.86	0.000135	0.0411	0.26	0.2	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	3.86	0.000135	0.0411	0.26	0.2	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	3.86	0.000135	0.0411	0.26	0.2	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
STAD	cis	rs7771547	0.642	rs629560	ENSG00000240733.3	RN7SL502P	3.86	0.000135	0.0411	0.18	0.2	Platelet distribution width;	chr6:36543614	chr6:36450912~36451201:-
STAD	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	3.86	0.000135	0.0411	0.29	0.2	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
STAD	cis	rs4713118	0.868	rs760587	ENSG00000220721.1	OR1F12	3.86	0.000135	0.0411	0.24	0.2	Parkinson's disease;	chr6:27772521	chr6:28073316~28074233:+
STAD	cis	rs7283707	0.681	rs2242676	ENSG00000228798.1	AP000473.5	-3.86	0.000136	0.0411	-0.33	-0.2	QRS complex (12-leadsum);	chr21:15746932	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs17241409	ENSG00000228798.1	AP000473.5	-3.86	0.000136	0.0411	-0.33	-0.2	QRS complex (12-leadsum);	chr21:15747062	chr21:16630827~16640683:+
STAD	cis	rs4568518	0.903	rs12699937	ENSG00000279048.1	RP11-511H23.2	3.86	0.000136	0.0411	0.18	0.2	Measles;	chr7:17994811	chr7:17940503~17942922:+
STAD	cis	rs58873874	0.737	rs12654973	ENSG00000251405.2	CTB-109A12.1	3.86	0.000136	0.0411	0.34	0.2	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157362615~157460078:-
STAD	cis	rs58873874	0.579	rs74804793	ENSG00000251405.2	CTB-109A12.1	3.86	0.000136	0.0411	0.34	0.2	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157362615~157460078:-
STAD	cis	rs7771547	0.642	rs595954	ENSG00000240733.3	RN7SL502P	3.86	0.000136	0.0412	0.18	0.2	Platelet distribution width;	chr6:36497057	chr6:36450912~36451201:-
STAD	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	3.86	0.000136	0.0412	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	3.86	0.000136	0.0412	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	3.86	0.000136	0.0412	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
STAD	cis	rs7771547	0.642	rs628213	ENSG00000240733.3	RN7SL502P	3.86	0.000136	0.0412	0.18	0.2	Platelet distribution width;	chr6:36540869	chr6:36450912~36451201:-
STAD	cis	rs11673344	0.504	rs2118208	ENSG00000267672.1	CTD-2293H3.1	3.86	0.000136	0.0412	0.18	0.2	Obesity-related traits;	chr19:37135573	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.504	rs2118209	ENSG00000267672.1	CTD-2293H3.1	3.86	0.000136	0.0412	0.18	0.2	Obesity-related traits;	chr19:37135618	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.504	rs4805205	ENSG00000267672.1	CTD-2293H3.1	3.86	0.000136	0.0412	0.18	0.2	Obesity-related traits;	chr19:37136693	chr19:37091341~37092564:+
STAD	cis	rs1823913	0.927	rs34765012	ENSG00000233654.1	AC093388.3	3.86	0.000136	0.0412	0.25	0.2	Obesity-related traits;	chr2:191247926	chr2:190534855~190568102:+
STAD	cis	rs73198271	0.632	rs477018	ENSG00000253981.4	ALG1L13P	-3.86	0.000136	0.0412	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8743307	chr8:8236003~8244667:-
STAD	cis	rs883565	0.502	rs11129810	ENSG00000230683.1	DDTP1	-3.86	0.000136	0.0412	-0.2	-0.2	Handedness;	chr3:38904573	chr3:38515448~38515830:-
STAD	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-3.86	0.000136	0.0412	-0.21	-0.2	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
STAD	cis	rs7512552	0.839	rs1260367	ENSG00000203819.6	HIST2H2BC	3.86	0.000136	0.0412	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150372038	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs1260459	ENSG00000203819.6	HIST2H2BC	3.86	0.000136	0.0412	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150375777	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs834232	ENSG00000203819.6	HIST2H2BC	3.86	0.000136	0.0412	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150382206	chr1:149850193~149850772:-
STAD	cis	rs56114371	0.53	rs9348774	ENSG00000243307.2	POM121L6P	-3.86	0.000136	0.0412	-0.25	-0.2	Breast cancer;	chr6:27721151	chr6:26896952~26898777:+
STAD	cis	rs6180	0.967	rs2972992	ENSG00000250860.1	CTD-2265D6.2	3.86	0.000136	0.0412	0.17	0.2	Height;	chr5:42755570	chr5:42466893~42468300:-
STAD	cis	rs4805566	0.651	rs11084550	ENSG00000267006.1	CTC-448F2.4	3.86	0.000136	0.0412	0.22	0.2	Body mass index;	chr19:30416072	chr19:30028741~30029916:-
STAD	cis	rs4141404	0.923	rs2413035	ENSG00000202019.1	Y_RNA	3.86	0.000136	0.0412	0.28	0.2	Paclitaxel-induced neuropathy;	chr22:31204474	chr22:31230071~31230172:-
STAD	cis	rs11169552	0.51	rs10783372	ENSG00000200428.1	Y_RNA	3.86	0.000136	0.0412	0.22	0.2	Colorectal cancer;	chr12:50558741	chr12:50743568~50743684:+
STAD	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	3.86	0.000136	0.0412	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
STAD	cis	rs7688540	0.8	rs61792060	ENSG00000198155.5	ZNF876P	-3.86	0.000136	0.0412	-0.29	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:212610~255985:+
STAD	cis	rs9467773	1	rs9357010	ENSG00000243307.2	POM121L6P	3.86	0.000136	0.0412	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26896952~26898777:+
STAD	cis	rs10129255	0.957	rs61997760	ENSG00000224373.3	IGHV4-59	3.86	0.000136	0.0412	0.16	0.2	Kawasaki disease;	chr14:106716993	chr14:106627249~106627825:-
STAD	cis	rs9549328	0.731	rs2873371	ENSG00000267868.1	RP11-120K24.3	3.86	0.000136	0.0412	0.29	0.2	Systolic blood pressure;	chr13:112961928	chr13:112964835~112966131:-
STAD	cis	rs9549328	0.7	rs2185001	ENSG00000267868.1	RP11-120K24.3	3.86	0.000136	0.0412	0.29	0.2	Systolic blood pressure;	chr13:112962055	chr13:112964835~112966131:-
STAD	cis	rs10508774	0.852	rs3780873	ENSG00000273038.2	RP11-479G22.8	3.86	0.000136	0.0412	0.42	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32924752	chr10:32887255~32889311:-
STAD	cis	rs9420	0.528	rs34052104	ENSG00000265566.2	RN7SL605P	-3.86	0.000136	0.0412	-0.3	-0.2	Schizophrenia;	chr11:57617046	chr11:57528085~57528365:-
STAD	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	3.86	0.000136	0.0412	0.29	0.2	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
STAD	cis	rs9907295	0.818	rs4796109	ENSG00000270894.1	AC015849.13	-3.86	0.000136	0.0412	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35811904	chr17:35818399~35823713:+
STAD	cis	rs1823913	0.927	rs35530564	ENSG00000233654.1	AC093388.3	3.86	0.000136	0.0412	0.25	0.2	Obesity-related traits;	chr2:191247324	chr2:190534855~190568102:+
STAD	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	3.86	0.000136	0.0412	0.22	0.2	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
STAD	cis	rs2273156	1	rs17102923	ENSG00000258704.4	SRP54-AS1	-3.86	0.000136	0.0412	-0.23	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:34980633	chr14:34920858~34982532:-
STAD	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	3.86	0.000136	0.0412	0.24	0.2	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
STAD	cis	rs2836974	0.583	rs2410124	ENSG00000238141.2	BRWD1-AS1	-3.86	0.000136	0.0412	-0.21	-0.2	Cognitive function;	chr21:39332834	chr21:39315707~39323218:+
STAD	cis	rs7809950	0.911	rs7778250	ENSG00000238832.1	snoU109	3.86	0.000136	0.0412	0.27	0.2	Coronary artery disease;	chr7:107584120	chr7:107603363~107603507:+
STAD	cis	rs6693567	0.545	rs12049177	ENSG00000203819.6	HIST2H2BC	3.86	0.000136	0.0412	0.23	0.2	Migraine;	chr1:150501861	chr1:149850193~149850772:-
STAD	cis	rs2638953	0.962	rs10506029	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000136	0.0412	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28320302	chr12:28163298~28190738:-
STAD	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	3.86	0.000136	0.0413	0.17	0.2	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
STAD	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	3.86	0.000136	0.0413	0.17	0.2	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
STAD	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	3.86	0.000136	0.0413	0.17	0.2	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
STAD	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	3.86	0.000136	0.0413	0.17	0.2	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
STAD	cis	rs34779708	0.706	rs36027395	ENSG00000271335.4	RP11-324I22.4	3.86	0.000136	0.0413	0.26	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35314552~35336401:-
STAD	cis	rs12477438	0.501	rs34272114	ENSG00000231822.1	AC019097.7	3.86	0.000136	0.0413	0.21	0.2	Chronic sinus infection;	chr2:99120980	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs11692336	ENSG00000231822.1	AC019097.7	3.86	0.000136	0.0413	0.21	0.2	Chronic sinus infection;	chr2:99124143	chr2:99102018~99102752:+
STAD	cis	rs2836950	0.545	rs11700813	ENSG00000238141.2	BRWD1-AS1	-3.86	0.000136	0.0413	-0.21	-0.2	Menarche (age at onset);	chr21:39145543	chr21:39315707~39323218:+
STAD	cis	rs1538970	0.781	rs34768551	ENSG00000225447.1	RPS15AP10	3.86	0.000136	0.0413	0.18	0.2	Platelet count;	chr1:45554736	chr1:45645816~45646197:-
STAD	cis	rs870825	0.549	rs10015956	ENSG00000249173.4	LINC01093	-3.86	0.000136	0.0413	-0.34	-0.2	Blood protein levels;	chr4:184693551	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs6825561	ENSG00000249173.4	LINC01093	-3.86	0.000136	0.0413	-0.34	-0.2	Blood protein levels;	chr4:184694378	chr4:184893871~184899454:-
STAD	cis	rs7680126	0.633	rs4697745	ENSG00000250613.1	RP11-136I13.1	3.86	0.000136	0.0413	0.23	0.2	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10303457	chr4:10410996~10411644:+
STAD	cis	rs1816752	0.905	rs7995492	ENSG00000232858.1	RPL34P27	3.86	0.000136	0.0413	0.12	0.2	Obesity-related traits;	chr13:24438885	chr13:24988577~24988925:-
STAD	cis	rs4811196	0.748	rs2344914	ENSG00000199683.1	RN7SKP185	3.86	0.000136	0.0413	0.21	0.2	Bone mineral density;	chr20:37868003	chr20:37975156~37975481:-
STAD	cis	rs62103177	0.564	rs2115996	ENSG00000261126.6	RP11-795F19.1	3.86	0.000136	0.0413	0.32	0.2	Opioid sensitivity;	chr18:79941007	chr18:80046900~80095482:+
STAD	cis	rs1030877	0.515	rs1866038	ENSG00000235319.1	AC012360.4	-3.86	0.000136	0.0413	-0.28	-0.2	Obesity-related traits;	chr2:105262065	chr2:105324210~105330529:+
STAD	cis	rs780096	0.967	rs1260334	ENSG00000234072.1	AC074117.10	-3.86	0.000136	0.0413	-0.15	-0.2	Total body bone mineral density;	chr2:27525730	chr2:27356246~27367622:+
STAD	cis	rs780096	0.967	rs1260333	ENSG00000234072.1	AC074117.10	-3.86	0.000136	0.0413	-0.15	-0.2	Total body bone mineral density;	chr2:27525757	chr2:27356246~27367622:+
STAD	cis	rs950169	0.887	rs220333	ENSG00000259683.1	RP11-182J1.14	3.86	0.000136	0.0413	0.21	0.2	Schizophrenia;	chr15:84547902	chr15:84389729~84395903:+
STAD	cis	rs2253762	0.54	rs79547192	ENSG00000226864.1	ATE1-AS1	3.86	0.000136	0.0413	0.33	0.2	Breast cancer;	chr10:121998664	chr10:121928312~121951965:+
STAD	cis	rs14403	0.874	rs2994327	ENSG00000240963.1	RP11-518L10.5	3.86	0.000136	0.0413	0.2	0.2	Schizophrenia;	chr1:243487556	chr1:244375100~244409592:-
STAD	cis	rs11098499	0.865	rs10213221	ENSG00000260091.1	RP11-33B1.4	3.86	0.000136	0.0413	0.19	0.2	Corneal astigmatism;	chr4:119334771	chr4:119409333~119410233:+
STAD	cis	rs2273156	0.501	rs5014384	ENSG00000258704.4	SRP54-AS1	-3.86	0.000136	0.0413	-0.26	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35038468	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.57	rs4594164	ENSG00000258704.4	SRP54-AS1	-3.86	0.000136	0.0413	-0.26	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35040365	chr14:34920858~34982532:-
STAD	cis	rs2273156	0.57	rs79888893	ENSG00000258704.4	SRP54-AS1	-3.86	0.000136	0.0413	-0.26	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35041470	chr14:34920858~34982532:-
STAD	cis	rs4400599	0.618	rs1194600	ENSG00000272030.1	RP1-178F15.4	-3.86	0.000136	0.0413	-0.29	-0.2	Platelet distribution width;	chr1:154263533	chr1:153631438~153634397:-
STAD	cis	rs6832769	0.922	rs6825994	ENSG00000223305.1	RN7SKP30	-3.86	0.000136	0.0414	-0.23	-0.2	Personality dimensions;	chr4:55524244	chr4:55540502~55540835:-
STAD	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	3.86	0.000136	0.0414	0.25	0.2	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
STAD	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	3.86	0.000137	0.0414	0.26	0.2	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
STAD	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	3.86	0.000137	0.0414	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
STAD	cis	rs1075265	0.749	rs2692518	ENSG00000235937.1	AC008280.1	3.86	0.000137	0.0414	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54029552~54030682:-
STAD	cis	rs6459788	0.502	rs9692347	ENSG00000225224.1	RP4-814D15.2	3.86	0.000137	0.0414	0.13	0.2	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr7:157439965	chr7:157192368~157192832:+
STAD	cis	rs2957692	0.548	rs11042561	ENSG00000254554.1	RP11-351I24.1	-3.86	0.000137	0.0414	-0.33	-0.2	Circulating vasoactive peptide levels;	chr11:9941510	chr11:10302657~10303704:-
STAD	cis	rs1816752	0.783	rs7317439	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0414	0.12	0.2	Obesity-related traits;	chr13:24410939	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.783	rs7139527	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0414	0.12	0.2	Obesity-related traits;	chr13:24411374	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.819	rs9511240	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0414	0.12	0.2	Obesity-related traits;	chr13:24411768	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.819	rs7988388	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0414	0.12	0.2	Obesity-related traits;	chr13:24412675	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.875	rs7993132	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0414	0.12	0.2	Obesity-related traits;	chr13:24412903	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.792	rs7330956	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0414	0.12	0.2	Obesity-related traits;	chr13:24413174	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.777	rs6490915	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0414	0.12	0.2	Obesity-related traits;	chr13:24413724	chr13:24988577~24988925:-
STAD	cis	rs4713118	0.955	rs9393847	ENSG00000243307.2	POM121L6P	-3.86	0.000137	0.0414	-0.24	-0.2	Parkinson's disease;	chr6:27720194	chr6:26896952~26898777:+
STAD	cis	rs716804	0.536	rs10840364	ENSG00000254554.1	RP11-351I24.1	3.86	0.000137	0.0414	0.27	0.2	Neuroticism;	chr11:10093396	chr11:10302657~10303704:-
STAD	cis	rs6471393	0.964	rs2914952	ENSG00000253848.1	RP11-10N23.5	3.86	0.000137	0.0414	0.24	0.2	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93729524	chr8:93741193~93744534:+
STAD	cis	rs12939005	1	rs12939005	ENSG00000275710.1	RP11-257O5.4	-3.86	0.000137	0.0414	-0.3	-0.2	Large artery stroke;	chr17:54909123	chr17:54964474~54964679:+
STAD	cis	rs10229583	0.527	rs7783478	ENSG00000279078.1	SND1-IT1	3.86	0.000137	0.0414	0.2	0.2	Type 2 diabetes;	chr7:127688483	chr7:127997597~128000077:+
STAD	cis	rs11650066	0.962	rs9894918	ENSG00000265356.1	RP11-17M24.1	3.86	0.000137	0.0414	0.26	0.2	Coronary heart disease;	chr17:33957106	chr17:33931132~33936206:-
STAD	cis	rs718433	0.584	rs8015812	ENSG00000211790.2	TRAV8-4	3.86	0.000137	0.0414	0.17	0.2	Intraocular pressure;	chr14:21746791	chr14:21894433~21895030:+
STAD	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-3.86	0.000137	0.0414	-0.22	-0.2	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
STAD	cis	rs870825	0.929	rs55746424	ENSG00000249173.4	LINC01093	-3.86	0.000137	0.0414	-0.37	-0.2	Blood protein levels;	chr4:184668449	chr4:184893871~184899454:-
STAD	cis	rs4845552	0.767	rs28707433	ENSG00000226855.1	RP11-350G8.3	-3.86	0.000137	0.0414	-0.24	-0.2	Hippocampal atrophy;	chr1:153497289	chr1:154378207~154379089:-
STAD	cis	rs4845552	0.767	rs4845548	ENSG00000226855.1	RP11-350G8.3	-3.86	0.000137	0.0414	-0.24	-0.2	Hippocampal atrophy;	chr1:153497691	chr1:154378207~154379089:-
STAD	cis	rs870825	0.616	rs7668009	ENSG00000249173.4	LINC01093	-3.86	0.000137	0.0414	-0.33	-0.2	Blood protein levels;	chr4:184720844	chr4:184893871~184899454:-
STAD	cis	rs938554	0.779	rs13106991	ENSG00000250613.1	RP11-136I13.1	3.86	0.000137	0.0414	0.23	0.2	Blood metabolite levels;	chr4:9957387	chr4:10410996~10411644:+
STAD	cis	rs2436845	0.81	rs2513910	ENSG00000253263.1	KB-1507C5.3	-3.86	0.000137	0.0414	-0.19	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102804878	chr8:102891876~102893608:+
STAD	cis	rs2227564	0.62	rs10740418	ENSG00000271816.1	BMS1P4	3.86	0.000137	0.0414	0.24	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73759564	chr10:73699151~73730487:-
STAD	cis	rs12935418	0.733	rs11150329	ENSG00000261061.1	RP11-303E16.2	-3.86	0.000137	0.0415	-0.32	-0.2	Mean corpuscular volume;	chr16:80945189	chr16:81030770~81031485:+
STAD	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-3.86	0.000137	0.0415	-0.32	-0.2	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
STAD	cis	rs7617773	1	rs9832957	ENSG00000224895.1	VPS26BP1	3.86	0.000137	0.0415	0.21	0.2	Coronary artery disease;	chr3:48143776	chr3:47960327~47961081:-
STAD	cis	rs2723064	0.543	rs2080385	ENSG00000232613.5	AC007386.4	-3.86	0.000137	0.0415	-0.18	-0.2	Atrial fibrillation;	chr2:65065628	chr2:65030727~65053017:+
STAD	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-3.86	0.000137	0.0415	-0.25	-0.2	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
STAD	cis	rs9907295	0.591	rs4796128	ENSG00000270977.1	AC015849.16	-3.86	0.000137	0.0415	-0.29	-0.2	Fibroblast growth factor basic levels;	chr17:35899268	chr17:35893707~35911023:-
STAD	cis	rs7927771	0.832	rs4992357	ENSG00000271350.1	CTD-2384B9.1	-3.86	0.000137	0.0415	-0.22	-0.2	Subjective well-being;	chr11:47372087	chr11:47041027~47041945:-
STAD	cis	rs1075232	0.677	rs72714666	ENSG00000270055.1	CTD-3092A11.2	-3.86	0.000137	0.0415	-0.35	-0.2	Survival in colorectal cancer (non-distant metastatic);	chr15:31200023	chr15:30487963~30490313:+
STAD	cis	rs11673344	0.542	rs1667380	ENSG00000267672.1	CTD-2293H3.1	3.86	0.000137	0.0415	0.19	0.2	Obesity-related traits;	chr19:37001848	chr19:37091341~37092564:+
STAD	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	3.86	0.000137	0.0415	0.27	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
STAD	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	3.86	0.000137	0.0415	0.21	0.2	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
STAD	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	3.86	0.000137	0.0415	0.21	0.2	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
STAD	cis	rs17826219	0.561	rs11655876	ENSG00000263603.1	CTD-2349P21.5	-3.86	0.000137	0.0415	-0.25	-0.2	Body mass index;	chr17:30690132	chr17:30729469~30731202:+
STAD	cis	rs10986311	0.851	rs1045774	ENSG00000227200.1	RP11-121A14.3	-3.86	0.000137	0.0415	-0.22	-0.2	Vitiligo;	chr9:124270328	chr9:124262876~124265809:+
STAD	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	3.86	0.000137	0.0415	0.22	0.2	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
STAD	cis	rs658191	0.661	rs710915	ENSG00000237624.1	OXCT2P1	-3.86	0.000137	0.0415	-0.39	-0.2	Colorectal cancer;	chr1:39487073	chr1:39514956~39516490:+
STAD	cis	rs13413635	0.862	rs11687117	ENSG00000225808.1	DNAJC19P5	-3.86	0.000137	0.0415	-0.26	-0.2	Heart rate;	chr2:177961440	chr2:177229191~177229506:-
STAD	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	3.86	0.000137	0.0415	0.27	0.2	Pain;	chr19:21569041	chr19:21554640~21569237:-
STAD	cis	rs3198697	1	rs3198697	ENSG00000263335.1	AF001548.5	-3.86	0.000137	0.0415	-0.23	-0.2	Triglycerides;	chr16:15036083	chr16:15726674~15732993:+
STAD	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	3.86	0.000137	0.0415	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
STAD	cis	rs2199351	0.876	rs4854853	ENSG00000242899.1	RPL7P16	-3.86	0.000137	0.0415	-0.25	-0.2	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr3:131881023	chr3:132243528~132244265:-
STAD	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	3.86	0.000137	0.0415	0.23	0.2	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
STAD	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	3.86	0.000137	0.0415	0.35	0.2	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
STAD	cis	rs11638815	0.871	rs8033106	ENSG00000259429.4	UBE2Q2P2	-3.86	0.000137	0.0415	-0.26	-0.2	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82630710	chr15:82355142~82420075:+
STAD	cis	rs1850744	0.702	rs13136217	ENSG00000250942.1	ENPP7P11	3.86	0.000137	0.0415	0.39	0.2	Economic and political preferences;	chr4:9720668	chr4:9677308~9677934:+
STAD	cis	rs8012947	0.565	rs4901852	ENSG00000279636.2	LINC00216	3.86	0.000137	0.0416	0.19	0.2	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58288033~58289158:+
STAD	cis	rs6686842	0.536	rs61774688	ENSG00000235358.1	RP11-399E6.1	-3.86	0.000137	0.0416	-0.23	-0.2	Height;	chr1:41212213	chr1:41242373~41284861:+
STAD	cis	rs2638953	0.815	rs1534340	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000137	0.0416	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28515550	chr12:28163298~28190738:-
STAD	cis	rs2286503	0.78	rs2240727	ENSG00000221740.1	SNORD93	3.86	0.000137	0.0416	0.24	0.2	Fibrinogen;	chr7:22812893	chr7:22856613~22856686:+
STAD	cis	rs7176527	0.848	rs17600128	ENSG00000188388.10	GOLGA6L3	3.86	0.000137	0.0416	0.32	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:85240472~85247170:+
STAD	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000137	0.0416	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
STAD	cis	rs593531	0.592	rs3168173	ENSG00000280269.1	AP000577.2	-3.86	0.000137	0.0416	-0.21	-0.2	Neuroticism;	chr11:74331742	chr11:74204869~74205746:+
STAD	cis	rs875971	0.825	rs1000464	ENSG00000224316.1	RP11-479O9.2	-3.86	0.000137	0.0416	-0.2	-0.2	Aortic root size;	chr7:66312922	chr7:65773620~65802067:+
STAD	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	3.86	0.000137	0.0416	0.2	0.2	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
STAD	cis	rs7617773	1	rs7617773	ENSG00000224895.1	VPS26BP1	3.86	0.000137	0.0416	0.2	0.2	Coronary artery disease;	chr3:48152025	chr3:47960327~47961081:-
STAD	cis	rs9309473	0.528	rs2091022	ENSG00000163016.8	ALMS1P	3.86	0.000137	0.0416	0.22	0.2	Metabolite levels;	chr2:73337442	chr2:73644919~73685576:+
STAD	cis	rs7520050	0.778	rs3014216	ENSG00000280836.1	AL355480.1	-3.86	0.000137	0.0416	-0.26	-0.2	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45581219~45581321:-
STAD	cis	rs1816752	0.905	rs7400631	ENSG00000232858.1	RPL34P27	3.86	0.000137	0.0416	0.12	0.2	Obesity-related traits;	chr13:24415927	chr13:24988577~24988925:-
STAD	cis	rs4835473	0.742	rs6537238	ENSG00000249741.2	RP11-673E1.3	-3.86	0.000137	0.0416	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143996463	chr4:143911514~143912053:-
STAD	cis	rs6432852	0.966	rs6710878	ENSG00000229195.1	AC009495.4	3.86	0.000137	0.0416	0.23	0.2	Diabetic kidney disease;	chr2:165882121	chr2:165794857~165846091:-
STAD	cis	rs938554	0.513	rs3775948	ENSG00000250613.1	RP11-136I13.1	-3.86	0.000137	0.0416	-0.2	-0.2	Blood metabolite levels;	chr4:9993558	chr4:10410996~10411644:+
STAD	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-3.86	0.000137	0.0416	-0.25	-0.2	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
STAD	cis	rs1790761	0.559	rs10896190	ENSG00000231793.4	DOC2GP	3.86	0.000137	0.0416	0.24	0.2	Mean corpuscular volume;	chr11:67638652	chr11:67612653~67616257:-
STAD	cis	rs7692387	0.568	rs13143871	ENSG00000260244.1	RP11-588K22.2	3.86	0.000137	0.0416	0.17	0.2	Coronary artery disease;	chr4:155698052	chr4:155734448~155737062:+
STAD	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	3.86	0.000137	0.0416	0.23	0.2	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
STAD	cis	rs7220401	0.789	rs3760456	ENSG00000263477.1	RP11-338L22.2	-3.86	0.000137	0.0416	-0.18	-0.2	Coronary artery disease;	chr17:29621826	chr17:29863402~29866092:+
STAD	cis	rs4474258	0.563	rs3885983	ENSG00000244433.2	PGBD4P7	3.86	0.000137	0.0416	0.22	0.2	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);	chr1:94644891	chr1:94672918~94674161:-
STAD	cis	rs2273156	0.866	rs12891343	ENSG00000241052.1	RP11-173D9.1	-3.86	0.000137	0.0416	-0.22	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:34914344	chr14:35144021~35144480:-
STAD	cis	rs7980687	0.527	rs28533432	ENSG00000257097.1	CLIP1-AS1	3.86	0.000138	0.0416	0.17	0.2	Head circumference (infant);Educational attainment;Height;	chr12:123388695	chr12:122395542~122400857:+
STAD	cis	rs6693567	0.565	rs1313569	ENSG00000203819.6	HIST2H2BC	3.86	0.000138	0.0416	0.23	0.2	Migraine;	chr1:150371695	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.545	rs1313568	ENSG00000203819.6	HIST2H2BC	3.86	0.000138	0.0416	0.23	0.2	Migraine;	chr1:150371704	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.565	rs1260457	ENSG00000203819.6	HIST2H2BC	3.86	0.000138	0.0416	0.23	0.2	Migraine;	chr1:150374898	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.507	rs863862	ENSG00000203819.6	HIST2H2BC	3.86	0.000138	0.0416	0.23	0.2	Migraine;	chr1:150379885	chr1:149850193~149850772:-
STAD	cis	rs1059312	0.545	rs12303387	ENSG00000279500.1	RP11-21K12.2	3.86	0.000138	0.0416	0.19	0.2	Systemic lupus erythematosus;	chr12:128792188	chr12:128813186~128814750:-
STAD	cis	rs7204230	0.557	rs34136065	ENSG00000261291.1	RP11-295M3.2	3.86	0.000138	0.0416	0.22	0.2	Fibrinogen;	chr16:53309267	chr16:53168522~53169450:+
STAD	cis	rs67311347	0.956	rs6771527	ENSG00000280739.1	EIF1B-AS1	-3.86	0.000138	0.0416	-0.21	-0.2	Renal cell carcinoma;	chr3:40465057	chr3:40173145~40309698:-
STAD	cis	rs67311347	0.955	rs6782746	ENSG00000280739.1	EIF1B-AS1	-3.86	0.000138	0.0416	-0.21	-0.2	Renal cell carcinoma;	chr3:40469101	chr3:40173145~40309698:-
STAD	cis	rs624896	0.661	rs337701	ENSG00000249026.2	CTNNAP1	3.86	0.000138	0.0416	0.51	0.2	JT interval (sulfonylurea treatment interaction);	chr5:114395726	chr5:115389643~115392370:-
STAD	cis	rs7131987	0.903	rs6487796	ENSG00000275476.1	RP11-996F15.4	-3.86	0.000138	0.0416	-0.22	-0.2	QT interval;	chr12:29269831	chr12:29277397~29277882:-
STAD	cis	rs2638953	0.962	rs61920565	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000138	0.0417	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28377192	chr12:28163298~28190738:-
STAD	cis	rs7680126	0.596	rs10489070	ENSG00000250613.1	RP11-136I13.1	3.86	0.000138	0.0417	0.22	0.2	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10274728	chr4:10410996~10411644:+
STAD	cis	rs11587682	0.76	rs11582170	ENSG00000274963.1	Metazoa_SRP	-3.86	0.000138	0.0417	-0.21	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150456106	chr1:150568971~150569269:-
STAD	cis	rs4388249	1	rs3797695	ENSG00000271849.1	CTC-332L22.1	-3.86	0.000138	0.0417	-0.3	-0.2	Schizophrenia;	chr5:109741816	chr5:109687802~109688329:-
STAD	cis	rs4388249	1	rs12656571	ENSG00000271849.1	CTC-332L22.1	-3.86	0.000138	0.0417	-0.3	-0.2	Schizophrenia;	chr5:109742339	chr5:109687802~109688329:-
STAD	cis	rs6686842	0.536	rs10493093	ENSG00000235358.1	RP11-399E6.1	-3.86	0.000138	0.0417	-0.23	-0.2	Height;	chr1:41236514	chr1:41242373~41284861:+
STAD	cis	rs7918405	0.696	rs7068695	ENSG00000230018.1	RP11-481H12.1	-3.86	0.000138	0.0417	-0.23	-0.2	QRS duration;	chr10:112756614	chr10:113482616~113483113:+
STAD	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-3.86	0.000138	0.0417	-0.21	-0.2	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
STAD	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-3.86	0.000138	0.0417	-0.21	-0.2	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
STAD	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-3.86	0.000138	0.0417	-0.21	-0.2	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
STAD	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-3.86	0.000138	0.0417	-0.21	-0.2	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
STAD	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-3.86	0.000138	0.0417	-0.21	-0.2	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
STAD	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-3.86	0.000138	0.0417	-0.21	-0.2	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
STAD	cis	rs1850744	0.826	rs6858644	ENSG00000163612.10	FAM86KP	-3.86	0.000138	0.0417	-0.46	-0.2	Economic and political preferences;	chr4:9740057	chr4:9153296~9165451:+
STAD	cis	rs56077333	1	rs56077333	ENSG00000259419.2	HNRNPCP3	3.86	0.000138	0.0417	0.22	0.2	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78606661	chr15:79236332~79237206:+
STAD	cis	rs1348850	0.874	rs4893822	ENSG00000271825.1	RP11-337N6.2	3.85	0.000138	0.0417	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177420999	chr2:177300600~177302006:+
STAD	cis	rs7015630	0.697	rs34699769	ENSG00000251136.7	RP11-37B2.1	-3.85	0.000138	0.0417	-0.27	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89841119	chr8:89609409~89757727:-
STAD	cis	rs6432852	0.527	rs1036146	ENSG00000229195.1	AC009495.4	-3.85	0.000138	0.0417	-0.23	-0.2	Diabetic kidney disease;	chr2:165939222	chr2:165794857~165846091:-
STAD	cis	rs7631605	0.875	rs7372657	ENSG00000236411.1	NDUFAF4P3	-3.85	0.000138	0.0417	-0.23	-0.2	Cerebrospinal P-tau181p levels;	chr3:37059658	chr3:37789921~37790445:-
STAD	cis	rs6832769	1	rs9998146	ENSG00000223305.1	RN7SKP30	-3.85	0.000138	0.0417	-0.23	-0.2	Personality dimensions;	chr4:55531810	chr4:55540502~55540835:-
STAD	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-3.85	0.000138	0.0417	-0.26	-0.2	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
STAD	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000138	0.0418	-0.33	-0.2	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
STAD	cis	rs10508774	0.81	rs11008941	ENSG00000273038.2	RP11-479G22.8	3.85	0.000138	0.0418	0.37	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32444379	chr10:32887255~32889311:-
STAD	cis	rs66887589	0.616	rs11732621	ENSG00000250412.1	KLHL2P1	3.85	0.000138	0.0418	0.26	0.2	Diastolic blood pressure;	chr4:119291728	chr4:119334329~119378233:+
STAD	cis	rs2115630	0.905	rs6496401	ENSG00000256278.1	RP11-182J1.5	-3.85	0.000138	0.0418	-0.19	-0.2	P wave terminal force;	chr15:84754562	chr15:84611689~84614969:-
STAD	cis	rs2115630	1	rs11854313	ENSG00000256278.1	RP11-182J1.5	-3.85	0.000138	0.0418	-0.19	-0.2	P wave terminal force;	chr15:84760817	chr15:84611689~84614969:-
STAD	cis	rs6832769	1	rs4865008	ENSG00000223305.1	RN7SKP30	-3.85	0.000138	0.0418	-0.23	-0.2	Personality dimensions;	chr4:55544688	chr4:55540502~55540835:-
STAD	cis	rs9652601	0.959	rs12927355	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000138	0.0418	-0.23	-0.2	Systemic lupus erythematosus;	chr16:11100914	chr16:11056556~11057034:+
STAD	cis	rs9902453	0.933	rs7224199	ENSG00000263477.1	RP11-338L22.2	3.85	0.000138	0.0418	0.17	0.2	Coffee consumption (cups per day);	chr17:30196708	chr17:29863402~29866092:+
STAD	cis	rs4561483	0.767	rs33633	ENSG00000260224.1	UBL5P4	3.85	0.000138	0.0418	0.2	0.2	Testicular germ cell tumor;	chr16:11901000	chr16:11968508~11968743:-
STAD	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-3.85	0.000138	0.0418	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
STAD	cis	rs11169552	0.51	rs7956591	ENSG00000200428.1	Y_RNA	3.85	0.000138	0.0418	0.22	0.2	Colorectal cancer;	chr12:50555103	chr12:50743568~50743684:+
STAD	cis	rs1876905	0.597	rs1215964	ENSG00000272356.1	RP5-1112D6.8	-3.85	0.000138	0.0418	-0.21	-0.2	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111309203~111313517:+
STAD	cis	rs9907295	0.636	rs4251703	ENSG00000270977.1	AC015849.16	-3.85	0.000138	0.0418	-0.28	-0.2	Fibroblast growth factor basic levels;	chr17:35807954	chr17:35893707~35911023:-
STAD	cis	rs6012564	0.806	rs4810903	ENSG00000227431.4	CSE1L-AS1	-3.85	0.000138	0.0418	-0.19	-0.2	Anger;	chr20:48982668	chr20:49040463~49046044:-
STAD	cis	rs4604732	0.504	rs4634945	ENSG00000227135.1	GCSAML-AS1	3.85	0.000138	0.0418	0.25	0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247472713	chr1:247524679~247526752:-
STAD	cis	rs12468226	0.938	rs114177656	ENSG00000272966.1	RP11-686O6.1	3.85	0.000139	0.0419	0.31	0.2	Urate levels;	chr2:202291596	chr2:202336739~202337200:+
STAD	cis	rs1348850	0.874	rs12996447	ENSG00000271825.1	RP11-337N6.2	3.85	0.000139	0.0419	0.17	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177418864	chr2:177300600~177302006:+
STAD	cis	rs8141529	0.702	rs132536	ENSG00000226471.5	CTA-292E10.6	3.85	0.000139	0.0419	0.23	0.2	Lymphocyte counts;	chr22:28906918	chr22:28800683~28848559:+
STAD	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-3.85	0.000139	0.0419	-0.34	-0.2	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
STAD	cis	rs11098499	0.874	rs13123591	ENSG00000260091.1	RP11-33B1.4	3.85	0.000139	0.0419	0.2	0.2	Corneal astigmatism;	chr4:119184835	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.874	rs7661020	ENSG00000260091.1	RP11-33B1.4	3.85	0.000139	0.0419	0.2	0.2	Corneal astigmatism;	chr4:119185827	chr4:119409333~119410233:+
STAD	cis	rs7520050	0.898	rs785502	ENSG00000280836.1	AL355480.1	3.85	0.000139	0.0419	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45581219~45581321:-
STAD	cis	rs875971	0.545	rs73142245	ENSG00000273142.1	RP11-458F8.4	3.85	0.000139	0.0419	0.19	0.2	Aortic root size;	chr7:66226662	chr7:66902857~66906297:+
STAD	cis	rs2732480	1	rs2732480	ENSG00000258017.1	RP11-386G11.10	-3.85	0.000139	0.0419	-0.23	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:49127782~49147869:+
STAD	cis	rs2957692	0.548	rs61889838	ENSG00000254554.1	RP11-351I24.1	3.85	0.000139	0.0419	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10281374	chr11:10302657~10303704:-
STAD	cis	rs1850744	1	rs1878275	ENSG00000250268.3	ALG1L14P	-3.85	0.000139	0.0419	-0.43	-0.2	Economic and political preferences;	chr4:9775777	chr4:9166297~9170270:-
STAD	cis	rs1850744	1	rs9685502	ENSG00000250268.3	ALG1L14P	-3.85	0.000139	0.0419	-0.43	-0.2	Economic and political preferences;	chr4:9778012	chr4:9166297~9170270:-
STAD	cis	rs451417	0.818	rs236117	ENSG00000275632.1	RP5-967N21.11	3.85	0.000139	0.0419	0.3	0.2	Menopause (age at onset);	chr20:5956529	chr20:6000418~6000941:+
STAD	cis	rs11089937	0.616	rs6001227	ENSG00000211639.2	IGLV4-60	3.85	0.000139	0.0419	0.22	0.2	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22162199~22162681:+
STAD	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	3.85	0.000139	0.0419	0.16	0.2	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
STAD	cis	rs953387	1	rs4954566	ENSG00000231890.6	DARS-AS1	3.85	0.000139	0.0419	0.21	0.2	Arthritis (juvenile idiopathic);	chr2:136143943	chr2:135985176~136022593:+
STAD	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-3.85	0.000139	0.0419	-0.32	-0.2	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
STAD	cis	rs9902453	0.619	rs2244585	ENSG00000263477.1	RP11-338L22.2	-3.85	0.000139	0.0419	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29745158	chr17:29863402~29866092:+
STAD	cis	rs679711	0.601	rs638718	ENSG00000214380.4	RP11-457K10.2	3.85	0.000139	0.0419	0.24	0.2	Sleep depth;	chr3:109914610	chr3:109915976~109916940:-
STAD	cis	rs870825	0.929	rs1405940	ENSG00000249173.4	LINC01093	-3.85	0.000139	0.0419	-0.35	-0.2	Blood protein levels;	chr4:184670327	chr4:184893871~184899454:-
STAD	cis	rs7208859	0.623	rs8067035	ENSG00000280069.1	CTD-2349P21.3	-3.85	0.000139	0.042	-0.21	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30738182~30740275:+
STAD	cis	rs9595908	0.865	rs2761365	ENSG00000281026.1	N4BP2L2-IT2	3.85	0.000139	0.042	0.17	0.2	Body mass index;	chr13:32437687	chr13:32504506~32509395:-
STAD	cis	rs9595908	0.827	rs2761366	ENSG00000281026.1	N4BP2L2-IT2	3.85	0.000139	0.042	0.17	0.2	Body mass index;	chr13:32437735	chr13:32504506~32509395:-
STAD	cis	rs3758785	0.623	rs13447720	ENSG00000255893.1	RP11-685N10.1	-3.85	0.000139	0.042	-0.26	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94432160	chr11:94472908~94473570:-
STAD	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-3.85	0.000139	0.042	-0.2	-0.2	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
STAD	cis	rs11012350	0.649	rs7074271	ENSG00000240291.1	RP11-499P20.2	-3.85	0.000139	0.042	-0.27	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:18022918	chr10:18513115~18545651:-
STAD	cis	rs7915414	0.531	rs9332113	ENSG00000230338.1	MTND4P19	3.85	0.000139	0.042	0.25	0.2	Clopidogrel active metabolite levels;	chr10:94940645	chr10:94774156~94774633:-
STAD	cis	rs10851478	0.872	rs4480740	ENSG00000259545.2	RP11-325E5.4	3.85	0.000139	0.042	0.25	0.2	Oral cavity cancer;	chr15:49463645	chr15:49177610~49178741:-
STAD	cis	rs8177876	0.822	rs12444137	ENSG00000261061.1	RP11-303E16.2	-3.85	0.000139	0.042	-0.37	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81030770~81031485:+
STAD	cis	rs8054556	1	rs4788204	ENSG00000261588.1	AC002310.17	3.85	0.000139	0.042	0.23	0.2	Autism spectrum disorder or schizophrenia;	chr16:29983897	chr16:30587662~30587920:-
STAD	cis	rs2262909	1	rs2262909	ENSG00000279377.1	AC003973.3	3.85	0.000139	0.042	0.21	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21952468	chr19:21965708~21968529:-
STAD	cis	rs8141529	0.673	rs132548	ENSG00000272858.1	CTA-292E10.8	3.85	0.000139	0.042	0.21	0.2	Lymphocyte counts;	chr22:28921571	chr22:28814914~28815662:+
STAD	cis	rs62158211	1	rs4618068	ENSG00000234997.1	AC016745.3	-3.85	0.000139	0.042	-0.26	-0.2	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113351778	chr2:113424495~113425324:+
STAD	cis	rs7103648	0.897	rs11606287	ENSG00000280615.1	Y_RNA	3.85	0.000139	0.042	0.21	0.2	Systolic blood pressure;Diastolic blood pressure;	chr11:47385888	chr11:47614898~47614994:-
STAD	cis	rs7103648	0.897	rs35032070	ENSG00000280615.1	Y_RNA	3.85	0.000139	0.042	0.21	0.2	Systolic blood pressure;Diastolic blood pressure;	chr11:47387041	chr11:47614898~47614994:-
STAD	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	3.85	0.000139	0.042	0.3	0.2	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
STAD	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-3.85	0.000139	0.042	-0.21	-0.2	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
STAD	cis	rs10129255	0.517	rs11625572	ENSG00000232216.1	IGHV3-43	3.85	0.000139	0.042	0.21	0.2	Kawasaki disease;	chr14:106656426	chr14:106470264~106470800:-
STAD	cis	rs10508774	0.81	rs12259710	ENSG00000273038.2	RP11-479G22.8	3.85	0.000139	0.042	0.37	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32536942	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.81	rs1987197	ENSG00000273038.2	RP11-479G22.8	3.85	0.000139	0.042	0.37	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32541667	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.659	rs1413979	ENSG00000273038.2	RP11-479G22.8	3.85	0.000139	0.042	0.37	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32693084	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.659	rs1413978	ENSG00000273038.2	RP11-479G22.8	3.85	0.000139	0.042	0.37	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32693085	chr10:32887255~32889311:-
STAD	cis	rs11150038	0.793	rs2204891	ENSG00000261837.1	RP11-264L1.3	-3.85	0.000139	0.042	-0.31	-0.2	Colorectal or endometrial cancer;	chr16:78028322	chr16:78534374~78535648:+
STAD	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	3.85	0.000139	0.042	0.26	0.2	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
STAD	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-3.85	0.000139	0.042	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
STAD	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-3.85	0.000139	0.042	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
STAD	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-3.85	0.000139	0.042	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
STAD	cis	rs7824557	0.933	rs6601576	ENSG00000254866.2	DEFB109P3	3.85	0.000139	0.042	0.25	0.2	Retinal vascular caliber;	chr8:11242766	chr8:12150895~12151134:-
STAD	cis	rs1075265	0.756	rs2160931	ENSG00000235937.1	AC008280.1	3.85	0.000139	0.042	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54029552~54030682:-
STAD	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-3.85	0.000139	0.042	-0.28	-0.2	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
STAD	cis	rs10782582	0.593	rs6675076	ENSG00000181227.3	RP4-682C21.2	3.85	0.000139	0.0421	0.21	0.2	Daytime sleep phenotypes;	chr1:75652818	chr1:75743423~75744776:-
STAD	cis	rs6832769	1	rs1522106	ENSG00000223305.1	RN7SKP30	-3.85	0.000139	0.0421	-0.22	-0.2	Personality dimensions;	chr4:55441047	chr4:55540502~55540835:-
STAD	cis	rs8081395	0.603	rs1292047	ENSG00000266701.1	AC005702.4	3.85	0.000139	0.0421	0.26	0.2	White blood cell count;	chr17:59877805	chr17:60042546~60042627:-
STAD	cis	rs10129255	1	rs4612959	ENSG00000232216.1	IGHV3-43	3.85	0.000139	0.0421	0.2	0.2	Kawasaki disease;	chr14:106767055	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.957	rs8014696	ENSG00000232216.1	IGHV3-43	-3.85	0.000139	0.0421	-0.2	-0.2	Kawasaki disease;	chr14:106769752	chr14:106470264~106470800:-
STAD	cis	rs9902453	1	rs11080114	ENSG00000240074.1	RPL9P30	-3.85	0.000139	0.0421	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30080269	chr17:29855759~29856332:+
STAD	cis	rs9902453	1	rs7221743	ENSG00000240074.1	RPL9P30	-3.85	0.000139	0.0421	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30080858	chr17:29855759~29856332:+
STAD	cis	rs7829975	0.577	rs79495969	ENSG00000253981.4	ALG1L13P	-3.85	0.00014	0.0421	-0.28	-0.2	Mood instability;	chr8:8687740	chr8:8236003~8244667:-
STAD	cis	rs3764021	0.868	rs7306304	ENSG00000256673.1	RP11-599J14.2	-3.85	0.00014	0.0421	-0.22	-0.2	Type 1 diabetes;	chr12:9724600	chr12:9398355~9414851:-
STAD	cis	rs3764021	0.837	rs7306557	ENSG00000256673.1	RP11-599J14.2	-3.85	0.00014	0.0421	-0.22	-0.2	Type 1 diabetes;	chr12:9724760	chr12:9398355~9414851:-
STAD	cis	rs3764021	0.87	rs7307111	ENSG00000256673.1	RP11-599J14.2	-3.85	0.00014	0.0421	-0.22	-0.2	Type 1 diabetes;	chr12:9725227	chr12:9398355~9414851:-
STAD	cis	rs1850744	0.702	rs60403942	ENSG00000250942.1	ENPP7P11	-3.85	0.00014	0.0421	-0.35	-0.2	Economic and political preferences;	chr4:9601828	chr4:9677308~9677934:+
STAD	cis	rs8062405	0.656	rs7189927	ENSG00000278665.1	RP11-666O2.4	-3.85	0.00014	0.0421	-0.24	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28599241~28601881:-
STAD	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-3.85	0.00014	0.0421	-0.26	-0.2	Pain;	chr19:21475141	chr19:21554640~21569237:-
STAD	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	3.85	0.00014	0.0421	0.32	0.2	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
STAD	cis	rs4407350	0.87	rs135627	ENSG00000279642.1	RP5-1033E15.3	-3.85	0.00014	0.0421	-0.2	-0.2	Intelligence (multi-trait analysis);	chr22:44510522	chr22:44486295~44486914:-
STAD	cis	rs10776614	0.799	rs10857598	ENSG00000189014.7	FAM35DP	3.85	0.00014	0.0421	0.31	0.2	Self-employment;	chr10:48567158	chr10:47689707~47730436:+
STAD	cis	rs12362063	0.9	rs4511302	ENSG00000255450.1	CTD-2063L20.1	3.85	0.00014	0.0421	0.18	0.2	Hepatitis B;	chr11:29243832	chr11:29275655~29276565:+
STAD	cis	rs1348850	0.668	rs13010396	ENSG00000271825.1	RP11-337N6.2	3.85	0.00014	0.0421	0.2	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177628206	chr2:177300600~177302006:+
STAD	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	3.85	0.00014	0.0421	0.26	0.2	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
STAD	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	3.85	0.00014	0.0421	0.27	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
STAD	cis	rs34779708	0.966	rs12761675	ENSG00000271335.4	RP11-324I22.4	-3.85	0.00014	0.0422	-0.24	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35314552~35336401:-
STAD	cis	rs11169552	0.51	rs11169493	ENSG00000200428.1	Y_RNA	-3.85	0.00014	0.0422	-0.23	-0.2	Colorectal cancer;	chr12:50565643	chr12:50743568~50743684:+
STAD	cis	rs2273156	0.587	rs61125355	ENSG00000258704.4	SRP54-AS1	-3.85	0.00014	0.0422	-0.25	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35065995	chr14:34920858~34982532:-
STAD	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-3.85	0.00014	0.0422	-0.27	-0.2	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
STAD	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-3.85	0.00014	0.0422	-0.21	-0.2	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
STAD	cis	rs11157436	0.792	rs12433875	ENSG00000211813.2	TRAV34	3.85	0.00014	0.0422	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154490	chr14:22207522~22208129:+
STAD	cis	rs11089937	0.554	rs5995628	ENSG00000211639.2	IGLV4-60	3.85	0.00014	0.0422	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22194768	chr22:22162199~22162681:+
STAD	cis	rs4568518	0.869	rs12699939	ENSG00000279048.1	RP11-511H23.2	3.85	0.00014	0.0422	0.18	0.2	Measles;	chr7:17997161	chr7:17940503~17942922:+
STAD	cis	rs860295	0.702	rs1556488	ENSG00000225855.5	RUSC1-AS1	3.85	0.00014	0.0422	0.17	0.2	Body mass index;	chr1:155570869	chr1:155316863~155324176:-
STAD	cis	rs7829975	0.902	rs777707	ENSG00000233609.3	RP11-62H7.2	3.85	0.00014	0.0422	0.22	0.2	Mood instability;	chr8:8726834	chr8:8961200~8979025:+
STAD	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	3.85	0.00014	0.0422	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	3.85	0.00014	0.0422	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	3.85	0.00014	0.0422	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	3.85	0.00014	0.0422	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	3.85	0.00014	0.0422	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	3.85	0.00014	0.0422	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
STAD	cis	rs938554	0.513	rs3775946	ENSG00000250613.1	RP11-136I13.1	-3.85	0.00014	0.0422	-0.2	-0.2	Blood metabolite levels;	chr4:9993632	chr4:10410996~10411644:+
STAD	cis	rs6504108	0.874	rs4794447	ENSG00000207306.1	RNU6-1152P	3.85	0.00014	0.0422	0.2	0.2	Body mass index;	chr17:48103362	chr17:48196680~48196786:-
STAD	cis	rs6946494	0.617	rs4728367	ENSG00000231244.1	PSMC1P3	3.85	0.00014	0.0422	0.25	0.2	Visceral adipose tissue adjusted for BMI;	chr7:135809333	chr7:136713871~136715188:+
STAD	cis	rs794185	0.652	rs2633844	ENSG00000231249.1	ITPR1-AS1	-3.85	0.00014	0.0422	-0.23	-0.2	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470207	chr3:4490891~4493163:-
STAD	cis	rs28588043	0.537	rs17620916	ENSG00000201126.1	RNU6-773P	-3.85	0.00014	0.0422	-0.38	-0.2	Number of children (6+ vs. 0 or 1);	chr1:170948318	chr1:171519816~171519913:-
STAD	cis	rs7829975	0.846	rs11779061	ENSG00000173295.6	FAM86B3P	-3.85	0.00014	0.0422	-0.24	-0.2	Mood instability;	chr8:8691922	chr8:8228595~8244865:+
STAD	cis	rs9902453	0.817	rs2628170	ENSG00000263477.1	RP11-338L22.2	-3.85	0.00014	0.0422	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29729594	chr17:29863402~29866092:+
STAD	cis	rs9914988	0.613	rs4794842	ENSG00000264647.1	RP11-68I3.7	3.85	0.00014	0.0422	0.31	0.2	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28963733	chr17:29591703~29592241:-
STAD	cis	rs7586085	1	rs35969972	ENSG00000229195.1	AC009495.4	3.85	0.00014	0.0422	0.22	0.2	Total body bone mineral density;	chr2:165717266	chr2:165794857~165846091:-
STAD	cis	rs7586085	0.966	rs10930177	ENSG00000229195.1	AC009495.4	3.85	0.00014	0.0422	0.22	0.2	Total body bone mineral density;	chr2:165717690	chr2:165794857~165846091:-
STAD	cis	rs7586085	1	rs10204976	ENSG00000229195.1	AC009495.4	3.85	0.00014	0.0422	0.22	0.2	Total body bone mineral density;	chr2:165719876	chr2:165794857~165846091:-
STAD	cis	rs2836974	0.568	rs419469	ENSG00000238141.2	BRWD1-AS1	3.85	0.00014	0.0422	0.21	0.2	Cognitive function;	chr21:39165308	chr21:39315707~39323218:+
STAD	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-3.85	0.00014	0.0422	-0.17	-0.2	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
STAD	cis	rs61542988	0.535	rs10807813	ENSG00000228649.7	AC005682.5	3.85	0.00014	0.0422	0.26	0.2	Fibrinogen levels;	chr7:22790342	chr7:22854178~22861579:+
STAD	cis	rs6432852	1	rs10199236	ENSG00000229195.1	AC009495.4	3.85	0.00014	0.0422	0.23	0.2	Diabetic kidney disease;	chr2:165937901	chr2:165794857~165846091:-
STAD	cis	rs9467773	0.62	rs1027203	ENSG00000241549.7	GUSBP2	3.85	0.00014	0.0423	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26871484~26956554:-
STAD	cis	rs9467773	0.595	rs2172007	ENSG00000241549.7	GUSBP2	3.85	0.00014	0.0423	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26871484~26956554:-
STAD	cis	rs11089937	0.597	rs5757024	ENSG00000211640.3	IGLV6-57	3.85	0.00014	0.0423	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.597	rs5757026	ENSG00000211640.3	IGLV6-57	3.85	0.00014	0.0423	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.597	rs5750582	ENSG00000211640.3	IGLV6-57	3.85	0.00014	0.0423	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs5757028	ENSG00000211640.3	IGLV6-57	3.85	0.00014	0.0423	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.597	rs2213156	ENSG00000211640.3	IGLV6-57	3.85	0.00014	0.0423	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs2213157	ENSG00000211640.3	IGLV6-57	3.85	0.00014	0.0423	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22195713~22196460:+
STAD	cis	rs9733	0.596	rs12089731	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150675322	chr1:150608507~150608623:-
STAD	cis	rs9733	0.519	rs12095002	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150676773	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs12085275	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150677789	chr1:150608507~150608623:-
STAD	cis	rs9733	0.544	rs2867302	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150681174	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs2867301	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150681319	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs7538493	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150682945	chr1:150608507~150608623:-
STAD	cis	rs4970988	0.64	rs7524734	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Urate levels;	chr1:150683210	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs6685702	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150683831	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs7549795	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150684397	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs11204697	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150686495	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs7529998	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150690055	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs11803569	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150691601	chr1:150608507~150608623:-
STAD	cis	rs9733	0.596	rs1336898	ENSG00000276103.1	U4	3.85	0.00014	0.0423	0.19	0.2	Tonsillectomy;	chr1:150692574	chr1:150608507~150608623:-
STAD	cis	rs8054556	0.74	rs12716975	ENSG00000273724.1	RP11-347C12.12	-3.85	0.00014	0.0423	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30336400~30343336:+
STAD	cis	rs870825	0.616	rs7682505	ENSG00000249173.4	LINC01093	-3.85	0.00014	0.0423	-0.33	-0.2	Blood protein levels;	chr4:184719494	chr4:184893871~184899454:-
STAD	cis	rs870825	0.587	rs7682995	ENSG00000249173.4	LINC01093	-3.85	0.00014	0.0423	-0.33	-0.2	Blood protein levels;	chr4:184719530	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7682557	ENSG00000249173.4	LINC01093	-3.85	0.00014	0.0423	-0.33	-0.2	Blood protein levels;	chr4:184719619	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7660939	ENSG00000249173.4	LINC01093	-3.85	0.00014	0.0423	-0.33	-0.2	Blood protein levels;	chr4:184719638	chr4:184893871~184899454:-
STAD	cis	rs7683537	0.725	rs28837443	ENSG00000249173.4	LINC01093	-3.85	0.00014	0.0423	-0.33	-0.2	Systemic lupus erythematosus;	chr4:184720343	chr4:184893871~184899454:-
STAD	cis	rs950037	0.71	rs430600	ENSG00000279778.1	RP11-60A14.1	-3.85	0.00014	0.0423	-0.24	-0.2	Coronary artery disease;	chr1:88760293	chr1:87805286~87808372:-
STAD	cis	rs2115630	0.818	rs7176522	ENSG00000275120.1	RP11-182J1.17	-3.85	0.00014	0.0423	-0.22	-0.2	P wave terminal force;	chr15:84672152	chr15:84599434~84606463:-
STAD	cis	rs10519937	0.935	rs17164903	ENSG00000251032.1	CUL1P1	-3.85	0.00014	0.0423	-0.29	-0.2	IgG glycosylation;	chr5:127473886	chr5:127784618~127787042:-
STAD	cis	rs73193808	1	rs2832230	ENSG00000273017.1	AP000240.9	-3.85	0.00014	0.0423	-0.21	-0.2	Coronary artery disease;	chr21:29164391	chr21:29359002~29359453:+
STAD	cis	rs10129255	0.826	rs7150693	ENSG00000224373.3	IGHV4-59	3.85	0.00014	0.0423	0.16	0.2	Kawasaki disease;	chr14:106705382	chr14:106627249~106627825:-
STAD	cis	rs1154275	0.537	rs6763014	ENSG00000240057.4	RP11-572M11.4	-3.85	0.00014	0.0423	-0.19	-0.2	Takotsubo syndrome;	chr3:112793800	chr3:113019532~113183301:+
STAD	cis	rs4728302	0.869	rs6955240	ENSG00000237821.1	AC083873.4	-3.85	0.00014	0.0423	-0.21	-0.2	Intelligence (multi-trait analysis);Intelligence;	chr7:133897120	chr7:133169416~133170514:-
STAD	cis	rs1348850	0.651	rs4893936	ENSG00000271825.1	RP11-337N6.2	3.85	0.00014	0.0423	0.16	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177375948	chr2:177300600~177302006:+
STAD	cis	rs10412972	0.667	rs12983624	ENSG00000273837.1	LLNLR-470E3.1	3.85	0.00014	0.0423	0.3	0.2	Plasma plasminogen levels;	chr19:51678028	chr19:51639478~51639931:-
STAD	cis	rs73108077	0.605	rs2143192	ENSG00000277692.1	RP11-358N2.2	-3.85	0.000141	0.0423	-0.27	-0.2	Red blood cell density in sickle cell anemia;	chr20:31364639	chr20:32355053~32355734:+
STAD	cis	rs9463078	0.691	rs9381361	ENSG00000219384.1	RP11-491H9.3	3.85	0.000141	0.0423	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45043680	chr6:45158870~45159511:+
STAD	cis	rs4568518	0.803	rs4721679	ENSG00000279048.1	RP11-511H23.2	3.85	0.000141	0.0423	0.18	0.2	Measles;	chr7:17999629	chr7:17940503~17942922:+
STAD	cis	rs240993	0.516	rs1002481	ENSG00000230177.1	RP5-1112D6.4	-3.85	0.000141	0.0423	-0.23	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111390819	chr6:111277932~111278742:+
STAD	cis	rs35955747	0.902	rs7287402	ENSG00000236132.1	CTA-440B3.1	-3.85	0.000141	0.0423	-0.22	-0.2	Neutrophil count;Sum basophil neutrophil counts;	chr22:31258837	chr22:31816379~31817491:-
STAD	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	3.85	0.000141	0.0423	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
STAD	cis	rs4925386	0.84	rs6143034	ENSG00000273619.1	RP5-908M14.9	-3.85	0.000141	0.0423	-0.2	-0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62386303~62386970:-
STAD	cis	rs10129255	1	rs10134517	ENSG00000224373.3	IGHV4-59	3.85	0.000141	0.0423	0.16	0.2	Kawasaki disease;	chr14:106718498	chr14:106627249~106627825:-
STAD	cis	rs6430585	0.702	rs2304601	ENSG00000231890.6	DARS-AS1	-3.85	0.000141	0.0423	-0.24	-0.2	Corneal structure;	chr2:135770464	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.759	rs12467770	ENSG00000231890.6	DARS-AS1	-3.85	0.000141	0.0423	-0.24	-0.2	Corneal structure;	chr2:135778525	chr2:135985176~136022593:+
STAD	cis	rs7103648	0.669	rs7131262	ENSG00000280615.1	Y_RNA	3.85	0.000141	0.0424	0.21	0.2	Systolic blood pressure;Diastolic blood pressure;	chr11:47814750	chr11:47614898~47614994:-
STAD	cis	rs1009077	0.627	rs4834788	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000141	0.0424	-0.28	-0.2	Endometriosis;	chr4:119615235	chr4:119409333~119410233:+
STAD	cis	rs1009077	0.716	rs4834789	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000141	0.0424	-0.28	-0.2	Endometriosis;	chr4:119616839	chr4:119409333~119410233:+
STAD	cis	rs1009077	0.669	rs4834790	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000141	0.0424	-0.28	-0.2	Endometriosis;	chr4:119616866	chr4:119409333~119410233:+
STAD	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	3.85	0.000141	0.0424	0.24	0.2	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
STAD	cis	rs921665	0.831	rs6836	ENSG00000236760.1	AC019118.3	-3.85	0.000141	0.0424	-0.31	-0.2	World class endurance athleticism;	chr2:3189027	chr2:3131581~3145780:-
STAD	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	3.85	0.000141	0.0424	0.25	0.2	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
STAD	cis	rs2832077	0.527	rs2776210	ENSG00000232855.5	AF131217.1	-3.85	0.000141	0.0424	-0.22	-0.2	Cognitive test performance;	chr21:28896236	chr21:28439346~28674848:-
STAD	cis	rs4835473	0.897	rs7662736	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143958036	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.8	rs1849134	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143958260	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.8	rs1849133	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143958262	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.864	rs1849132	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143958309	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.9	rs13123407	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143958713	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.897	rs61611095	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143958802	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.9	rs4835449	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143958830	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.897	rs4835095	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143960431	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.831	rs2667353	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143960462	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.77	rs4835096	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143960685	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1838516	ENSG00000249741.2	RP11-673E1.3	-3.85	0.000141	0.0424	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143962082	chr4:143911514~143912053:-
STAD	cis	rs6832769	1	rs6554286	ENSG00000223305.1	RN7SKP30	-3.85	0.000141	0.0424	-0.23	-0.2	Personality dimensions;	chr4:55534137	chr4:55540502~55540835:-
STAD	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-3.85	0.000141	0.0424	-0.31	-0.2	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
STAD	cis	rs1030877	0.515	rs2576742	ENSG00000235319.1	AC012360.4	-3.85	0.000141	0.0424	-0.28	-0.2	Obesity-related traits;	chr2:105282365	chr2:105324210~105330529:+
STAD	cis	rs9784649	0.76	rs72755820	ENSG00000245662.2	RP11-184E9.1	3.85	0.000141	0.0424	0.26	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25066072	chr5:25190682~25306172:+
STAD	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	3.85	0.000141	0.0424	0.2	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
STAD	cis	rs77861329	0.925	rs72964042	ENSG00000270941.1	RP5-966M1.5	3.85	0.000141	0.0424	0.4	0.2	Macrophage inflammatory protein 1b levels;	chr3:52054469	chr3:52734735~52735013:+
STAD	cis	rs2562456	0.874	rs9304986	ENSG00000268119.4	CTD-2561J22.5	-3.85	0.000141	0.0424	-0.26	-0.2	Pain;	chr19:21499260	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.917	rs2650805	ENSG00000268119.4	CTD-2561J22.5	-3.85	0.000141	0.0424	-0.26	-0.2	Pain;	chr19:21505137	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.917	rs10420016	ENSG00000268119.4	CTD-2561J22.5	-3.85	0.000141	0.0424	-0.26	-0.2	Pain;	chr19:21505800	chr19:21444241~21463908:-
STAD	cis	rs13315649	0.724	rs7624610	ENSG00000242551.2	POU5F1P6	-3.85	0.000141	0.0424	-0.22	-0.2	Sum eosinophil basophil counts;	chr3:128698450	chr3:128674735~128677005:-
STAD	cis	rs2901460	0.759	rs11695470	ENSG00000229503.1	AC092155.1	-3.85	0.000141	0.0424	-0.16	-0.2	Mean corpuscular volume;	chr2:62178317	chr2:62532583~62533059:-
STAD	cis	rs4950322	0.547	rs56864370	ENSG00000278811.3	LINC00624	3.85	0.000141	0.0424	0.21	0.2	Protein quantitative trait loci;	chr1:147111847	chr1:147258885~147517875:-
STAD	cis	rs7937890	0.904	rs11023169	ENSG00000254418.1	RP11-21L19.1	-3.85	0.000141	0.0424	-0.21	-0.2	Mitochondrial DNA levels;	chr11:14269439	chr11:14262846~14273691:-
STAD	cis	rs12468226	1	rs16824599	ENSG00000272966.1	RP11-686O6.1	3.85	0.000141	0.0424	0.3	0.2	Urate levels;	chr2:202358243	chr2:202336739~202337200:+
STAD	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-3.85	0.000141	0.0425	-0.23	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
STAD	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-3.85	0.000141	0.0425	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
STAD	cis	rs2404602	0.583	rs12913096	ENSG00000196274.5	Metazoa_SRP	3.85	0.000141	0.0425	0.18	0.2	Blood metabolite levels;	chr15:76259511	chr15:76230048~76230390:-
STAD	cis	rs330048	0.545	rs11774353	ENSG00000254340.1	RP11-10A14.3	3.85	0.000141	0.0425	0.24	0.2	Systemic lupus erythematosus;	chr8:9295617	chr8:9141424~9145435:+
STAD	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	3.85	0.000141	0.0425	0.2	0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
STAD	cis	rs7119038	0.607	rs12365699	ENSG00000255239.1	AP002954.6	-3.85	0.000141	0.0425	-0.28	-0.2	Sjögren's syndrome;	chr11:118872577	chr11:118688039~118690600:-
STAD	cis	rs10129255	0.912	rs8009135	ENSG00000224373.3	IGHV4-59	3.85	0.000141	0.0425	0.17	0.2	Kawasaki disease;	chr14:106777528	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.5	rs8022547	ENSG00000232216.1	IGHV3-43	3.85	0.000141	0.0425	0.18	0.2	Kawasaki disease;	chr14:106781985	chr14:106470264~106470800:-
STAD	cis	rs4747011	0.57	rs6480454	ENSG00000273530.1	AC016821.2	3.85	0.000141	0.0425	0.43	0.2	Brain connectivity;	chr10:70348419	chr10:69458672~69458738:+
STAD	cis	rs9910055	1	rs9910055	ENSG00000260793.2	RP5-882C2.2	-3.85	0.000141	0.0425	-0.23	-0.2	Total body bone mineral density;	chr17:44205669	chr17:44221401~44223710:+
STAD	cis	rs1930961	0.85	rs5996945	ENSG00000272942.1	CTA-246H3.12	3.85	0.000141	0.0425	0.34	0.2	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25434324~25435070:-
STAD	cis	rs11098499	0.754	rs1980025	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000141	0.0425	-0.19	-0.2	Corneal astigmatism;	chr4:119331651	chr4:119409333~119410233:+
STAD	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	3.85	0.000141	0.0425	0.23	0.2	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
STAD	cis	rs10911902	0.643	rs3766704	ENSG00000229739.2	RP11-295K2.3	-3.85	0.000141	0.0425	-0.29	-0.2	Schizophrenia;	chr1:186342710	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.567	rs76557279	ENSG00000229739.2	RP11-295K2.3	-3.85	0.000141	0.0425	-0.29	-0.2	Schizophrenia;	chr1:186344161	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs2272412	ENSG00000229739.2	RP11-295K2.3	-3.85	0.000141	0.0425	-0.29	-0.2	Schizophrenia;	chr1:186345817	chr1:186435161~186470291:+
STAD	cis	rs7202877	0.61	rs1010631	ENSG00000261783.1	RP11-252K23.2	-3.85	0.000141	0.0425	-0.32	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75294692	chr16:75379818~75381260:-
STAD	cis	rs6750795	0.569	rs1667313	ENSG00000223198.1	RNU2-22P	-3.85	0.000141	0.0425	-0.24	-0.2	Height;	chr2:231543307	chr2:231501990~231502201:-
STAD	cis	rs8072100	0.935	rs8070759	ENSG00000264243.1	RP11-6N17.1	-3.85	0.000141	0.0425	-0.19	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47863342~47865190:+
STAD	cis	rs1007190	0.881	rs34854300	ENSG00000267405.1	CTC-296K1.4	3.85	0.000141	0.0425	0.23	0.2	DNA methylation (variation);	chr17:44891645	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.881	rs8073674	ENSG00000267405.1	CTC-296K1.4	3.85	0.000141	0.0425	0.23	0.2	DNA methylation (variation);	chr17:44891969	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.881	rs9909048	ENSG00000267405.1	CTC-296K1.4	3.85	0.000141	0.0425	0.23	0.2	DNA methylation (variation);	chr17:44896149	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.881	rs16939676	ENSG00000267405.1	CTC-296K1.4	3.85	0.000141	0.0425	0.23	0.2	DNA methylation (variation);	chr17:44898979	chr17:44794747~44797783:-
STAD	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-3.85	0.000141	0.0426	-0.22	-0.2	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
STAD	cis	rs919433	0.927	rs1429412	ENSG00000231621.1	AC013264.2	3.85	0.000142	0.0426	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197197991~197199273:+
STAD	cis	rs6479901	0.512	rs7082090	ENSG00000235816.3	PRELID1P3	3.85	0.000142	0.0426	0.25	0.2	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63427297~63427939:+
STAD	cis	rs17818399	0.502	rs1451152	ENSG00000279254.1	RP11-536C12.1	-3.85	0.000142	0.0426	-0.21	-0.2	Height;	chr2:46573011	chr2:46668870~46670778:+
STAD	cis	rs62246343	0.605	rs7650141	ENSG00000214041.4	PGAM1P4	3.85	0.000142	0.0426	0.28	0.2	Fibrinogen levels;	chr3:9407726	chr3:9348443~9349192:+
STAD	cis	rs950169	0.922	rs11638445	ENSG00000259683.1	RP11-182J1.14	3.85	0.000142	0.0426	0.21	0.2	Schizophrenia;	chr15:84594463	chr15:84389729~84395903:+
STAD	cis	rs7809950	0.817	rs58052742	ENSG00000238832.1	snoU109	3.85	0.000142	0.0426	0.28	0.2	Coronary artery disease;	chr7:107569558	chr7:107603363~107603507:+
STAD	cis	rs2576037	0.583	rs8096263	ENSG00000267724.1	RP11-49K24.8	-3.85	0.000142	0.0426	-0.19	-0.2	Personality dimensions;	chr18:46935253	chr18:47105946~47108062:+
STAD	cis	rs151997	0.925	rs27260	ENSG00000250360.1	CTD-2089N3.1	-3.85	0.000142	0.0426	-0.19	-0.2	Callous-unemotional behaviour;	chr5:50870862	chr5:50965687~50967008:-
STAD	cis	rs4293777	0.933	rs4293779	ENSG00000250896.1	RNPS1P1	3.85	0.000142	0.0426	0.15	0.2	Primary sclerosing cholangitis;	chr4:10722087	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.967	rs4348087	ENSG00000250896.1	RNPS1P1	3.85	0.000142	0.0426	0.15	0.2	Primary sclerosing cholangitis;	chr4:10722771	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.967	rs6448200	ENSG00000250896.1	RNPS1P1	3.85	0.000142	0.0426	0.15	0.2	Primary sclerosing cholangitis;	chr4:10723185	chr4:11371975~11372892:+
STAD	cis	rs16973225	0.749	rs62035557	ENSG00000275695.1	UBE2Q2P6	-3.85	0.000142	0.0426	-0.44	-0.2	Colorectal cancer (aspirin and/or NSAID use interaction);	chr15:81913288	chr15:82445719~82454837:+
STAD	cis	rs17507216	0.671	rs28582623	ENSG00000255769.6	GOLGA2P10	-3.85	0.000142	0.0426	-0.32	-0.2	Excessive daytime sleepiness;	chr15:82577381	chr15:82472993~82513950:-
STAD	cis	rs561341	0.739	rs4795663	ENSG00000265798.5	RP11-271K11.5	-3.85	0.000142	0.0426	-0.24	-0.2	Hip circumference adjusted for BMI;	chr17:31887523	chr17:31038575~31059121:-
STAD	cis	rs11169552	0.51	rs11169479	ENSG00000200183.1	RNU6-238P	-3.85	0.000142	0.0426	-0.19	-0.2	Colorectal cancer;	chr12:50528553	chr12:50656973~50657078:+
STAD	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	3.85	0.000142	0.0426	0.27	0.2	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
STAD	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	3.85	0.000142	0.0426	0.27	0.2	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
STAD	cis	rs10073892	0.664	rs56256048	ENSG00000250682.4	LINC00491	-3.85	0.000142	0.0426	-0.22	-0.2	Cognitive decline (age-related);	chr5:102558927	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs10042544	ENSG00000250682.4	LINC00491	-3.85	0.000142	0.0426	-0.22	-0.2	Cognitive decline (age-related);	chr5:102560049	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs1502840	ENSG00000250682.4	LINC00491	-3.85	0.000142	0.0426	-0.22	-0.2	Cognitive decline (age-related);	chr5:102561216	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs10071721	ENSG00000250682.4	LINC00491	-3.85	0.000142	0.0426	-0.22	-0.2	Cognitive decline (age-related);	chr5:102564887	chr5:102609156~102671559:-
STAD	cis	rs4388249	0.861	rs11956236	ENSG00000271849.1	CTC-332L22.1	-3.85	0.000142	0.0426	-0.3	-0.2	Schizophrenia;	chr5:109871780	chr5:109687802~109688329:-
STAD	cis	rs7927771	0.832	rs10838698	ENSG00000271350.1	CTD-2384B9.1	3.85	0.000142	0.0426	0.22	0.2	Subjective well-being;	chr11:47364372	chr11:47041027~47041945:-
STAD	cis	rs11696739	0.513	rs34600126	ENSG00000242324.1	RP4-576H24.2	3.85	0.000142	0.0427	0.27	0.2	Mean platelet volume;	chr20:1616787	chr20:1516759~1557653:-
STAD	cis	rs2404602	0.735	rs283789	ENSG00000196274.5	Metazoa_SRP	3.85	0.000142	0.0427	0.18	0.2	Blood metabolite levels;	chr15:76485236	chr15:76230048~76230390:-
STAD	cis	rs10073892	0.744	rs10062241	ENSG00000250682.4	LINC00491	-3.85	0.000142	0.0427	-0.23	-0.2	Cognitive decline (age-related);	chr5:102502345	chr5:102609156~102671559:-
STAD	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-3.85	0.000142	0.0427	-0.23	-0.2	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
STAD	cis	rs7927771	0.864	rs755554	ENSG00000271350.1	CTD-2384B9.1	3.85	0.000142	0.0427	0.22	0.2	Subjective well-being;	chr11:47410483	chr11:47041027~47041945:-
STAD	cis	rs2404602	0.583	rs12907668	ENSG00000196274.5	Metazoa_SRP	3.85	0.000142	0.0427	0.18	0.2	Blood metabolite levels;	chr15:76297426	chr15:76230048~76230390:-
STAD	cis	rs875971	0.862	rs12537823	ENSG00000224316.1	RP11-479O9.2	3.85	0.000142	0.0427	0.2	0.2	Aortic root size;	chr7:66255897	chr7:65773620~65802067:+
STAD	cis	rs3754214	0.769	rs509345	ENSG00000203819.6	HIST2H2BC	-3.85	0.000142	0.0427	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr1:150303594	chr1:149850193~149850772:-
STAD	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-3.85	0.000142	0.0427	-0.27	-0.2	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
STAD	cis	rs794185	0.625	rs1844123	ENSG00000231249.1	ITPR1-AS1	-3.85	0.000142	0.0427	-0.23	-0.2	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471177	chr3:4490891~4493163:-
STAD	cis	rs6957923	0.668	rs6956784	ENSG00000234286.1	AC006026.13	-3.85	0.000142	0.0427	-0.25	-0.2	Height;	chr7:23534379	chr7:23680195~23680786:-
STAD	cis	rs10844154	0.561	rs326634	ENSG00000177340.5	FLJ13224	3.85	0.000142	0.0427	0.21	0.2	Emphysema-related traits;Weight;	chr12:32242174	chr12:31324316~31325829:+
STAD	cis	rs2273156	0.587	rs8014377	ENSG00000258704.4	SRP54-AS1	-3.85	0.000142	0.0427	-0.25	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35061851	chr14:34920858~34982532:-
STAD	cis	rs1876905	0.569	rs354542	ENSG00000271789.1	RP5-1112D6.7	-3.85	0.000142	0.0427	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111297126~111298510:+
STAD	cis	rs1876905	0.68	rs1216020	ENSG00000271789.1	RP5-1112D6.7	-3.85	0.000142	0.0427	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111297126~111298510:+
STAD	cis	rs1876905	0.569	rs354541	ENSG00000271789.1	RP5-1112D6.7	-3.85	0.000142	0.0427	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111297126~111298510:+
STAD	cis	rs10129255	0.556	rs6576222	ENSG00000232216.1	IGHV3-43	3.85	0.000142	0.0427	0.18	0.2	Kawasaki disease;	chr14:106776442	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.536	rs6576223	ENSG00000232216.1	IGHV3-43	3.85	0.000142	0.0427	0.18	0.2	Kawasaki disease;	chr14:106776448	chr14:106470264~106470800:-
STAD	cis	rs4713118	0.739	rs2893931	ENSG00000220721.1	OR1F12	3.85	0.000142	0.0427	0.23	0.2	Parkinson's disease;	chr6:27780231	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.824	rs2092075	ENSG00000220721.1	OR1F12	3.85	0.000142	0.0427	0.23	0.2	Parkinson's disease;	chr6:27781551	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.824	rs13211701	ENSG00000220721.1	OR1F12	3.85	0.000142	0.0427	0.23	0.2	Parkinson's disease;	chr6:27782300	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.824	rs9468229	ENSG00000220721.1	OR1F12	3.85	0.000142	0.0427	0.23	0.2	Parkinson's disease;	chr6:27782307	chr6:28073316~28074233:+
STAD	cis	rs7849270	1	rs4713	ENSG00000234055.1	RP11-247A12.1	-3.85	0.000142	0.0427	-0.23	-0.2	Blood metabolite ratios;	chr9:129148526	chr9:129097854~129100266:+
STAD	cis	rs4407350	0.748	rs131170	ENSG00000279642.1	RP5-1033E15.3	-3.85	0.000142	0.0427	-0.2	-0.2	Intelligence (multi-trait analysis);	chr22:44505721	chr22:44486295~44486914:-
STAD	cis	rs73198271	0.74	rs10109886	ENSG00000253893.2	FAM85B	3.85	0.000142	0.0427	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8167819~8226614:-
STAD	cis	rs2638953	0.962	rs11049537	ENSG00000247934.4	RP11-967K21.1	-3.85	0.000142	0.0427	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28331239	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.889	rs10843155	ENSG00000247934.4	RP11-967K21.1	-3.85	0.000142	0.0427	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28334920	chr12:28163298~28190738:-
STAD	cis	rs240993	0.502	rs240966	ENSG00000230177.1	RP5-1112D6.4	-3.85	0.000142	0.0428	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:111277932~111278742:+
STAD	cis	rs11089937	0.568	rs5756989	ENSG00000211638.2	IGLV8-61	-3.85	0.000142	0.0428	-0.21	-0.2	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22098700~22099212:+
STAD	cis	rs896322	0.843	rs1572995	ENSG00000219133.2	RP11-203F10.6	-3.85	0.000142	0.0428	-0.22	-0.2	Mean platelet volume;	chr1:205054884	chr1:204346776~204347258:-
STAD	cis	rs7901056	0.811	rs868093	ENSG00000251839.1	RNU7-12P	-3.85	0.000142	0.0428	-0.19	-0.2	Lymphocyte counts;	chr10:26416903	chr10:27232255~27232316:-
STAD	cis	rs4950322	0.542	rs115179956	ENSG00000278811.3	LINC00624	3.85	0.000142	0.0428	0.21	0.2	Protein quantitative trait loci;	chr1:147172620	chr1:147258885~147517875:-
STAD	cis	rs4792901	0.765	rs12600416	ENSG00000279602.1	CTD-3014M21.1	-3.85	0.000142	0.0428	-0.27	-0.2	Dupuytren's disease;	chr17:43469190	chr17:43360041~43361361:-
STAD	cis	rs867371	1	rs1846911	ENSG00000278603.1	RP13-608F4.5	3.85	0.000143	0.0428	0.23	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472203~82472426:+
STAD	cis	rs9287719	0.686	rs10174605	ENSG00000243819.4	RN7SL832P	3.85	0.000143	0.0428	0.2	0.2	Prostate cancer;	chr2:10585106	chr2:10690344~10692099:+
STAD	cis	rs2992257	0.914	rs3006814	ENSG00000251839.1	RNU7-12P	-3.85	0.000143	0.0428	-0.2	-0.2	Response to angiotensin II receptor blocker therapy;	chr10:26434870	chr10:27232255~27232316:-
STAD	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	3.85	0.000143	0.0428	0.2	0.2	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.625	rs12473787	ENSG00000243819.4	RN7SL832P	3.85	0.000143	0.0428	0.2	0.2	Prostate cancer;	chr2:10577068	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs2160258	ENSG00000243819.4	RN7SL832P	3.85	0.000143	0.0428	0.2	0.2	Prostate cancer;	chr2:10577095	chr2:10690344~10692099:+
STAD	cis	rs162990	0.775	rs335390	ENSG00000277810.1	AL357075.1	-3.85	0.000143	0.0428	-0.22	-0.2	Electroencephalogram traits;	chr6:155369642	chr6:154503980~154504072:+
STAD	cis	rs1850744	0.702	rs2077679	ENSG00000250268.3	ALG1L14P	3.85	0.000143	0.0428	0.42	0.2	Economic and political preferences;	chr4:9606465	chr4:9166297~9170270:-
STAD	cis	rs1850744	0.702	rs1961552	ENSG00000250268.3	ALG1L14P	3.85	0.000143	0.0428	0.42	0.2	Economic and political preferences;	chr4:9606682	chr4:9166297~9170270:-
STAD	cis	rs1850744	0.702	rs11724183	ENSG00000250268.3	ALG1L14P	3.85	0.000143	0.0428	0.42	0.2	Economic and political preferences;	chr4:9608270	chr4:9166297~9170270:-
STAD	cis	rs1850744	0.702	rs4974816	ENSG00000250268.3	ALG1L14P	3.85	0.000143	0.0428	0.42	0.2	Economic and political preferences;	chr4:9611443	chr4:9166297~9170270:-
STAD	cis	rs1850744	0.702	rs4974812	ENSG00000250268.3	ALG1L14P	3.85	0.000143	0.0428	0.42	0.2	Economic and political preferences;	chr4:9612974	chr4:9166297~9170270:-
STAD	cis	rs1850744	0.826	rs11735475	ENSG00000250268.3	ALG1L14P	3.85	0.000143	0.0428	0.42	0.2	Economic and political preferences;	chr4:9613302	chr4:9166297~9170270:-
STAD	cis	rs9902453	0.904	rs4077465	ENSG00000263477.1	RP11-338L22.2	3.85	0.000143	0.0428	0.17	0.2	Coffee consumption (cups per day);	chr17:29973126	chr17:29863402~29866092:+
STAD	cis	rs5763662	1	rs5753002	ENSG00000233010.1	RPEP4	-3.85	0.000143	0.0428	-0.41	-0.2	LDL cholesterol levels;LDL cholesterol;	chr22:30039413	chr22:29608900~29609501:+
STAD	cis	rs34779708	0.931	rs11010130	ENSG00000271335.4	RP11-324I22.4	3.85	0.000143	0.0428	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.897	rs11010131	ENSG00000271335.4	RP11-324I22.4	3.85	0.000143	0.0428	0.24	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35314552~35336401:-
STAD	cis	rs9420	0.528	rs11229077	ENSG00000265566.2	RN7SL605P	3.85	0.000143	0.0428	0.29	0.2	Schizophrenia;	chr11:57631599	chr11:57528085~57528365:-
STAD	cis	rs12900463	0.752	rs12904777	ENSG00000235370.6	DNM1P51	3.85	0.000143	0.0428	0.22	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:84398316~84411701:-
STAD	cis	rs2786865	0.881	rs2744780	ENSG00000270733.1	RP11-231P20.5	3.85	0.000143	0.0428	0.32	0.2	Facial morphology (factor 11, projection of the nose);	chr1:25694293	chr1:26263041~26263398:-
STAD	cis	rs953387	1	rs4954569	ENSG00000231890.6	DARS-AS1	-3.85	0.000143	0.0428	-0.21	-0.2	Arthritis (juvenile idiopathic);	chr2:136155805	chr2:135985176~136022593:+
STAD	cis	rs295490	0.748	rs116416768	ENSG00000272656.1	RP11-219D15.3	3.85	0.000143	0.0428	0.5	0.2	PR interval in Tripanosoma cruzi seropositivity;	chr3:139382294	chr3:139349024~139349371:-
STAD	cis	rs9595908	0.931	rs9591001	ENSG00000281026.1	N4BP2L2-IT2	3.85	0.000143	0.0428	0.16	0.2	Body mass index;	chr13:32468733	chr13:32504506~32509395:-
STAD	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	3.85	0.000143	0.0428	0.28	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
STAD	cis	rs34779708	0.766	rs35308730	ENSG00000271335.4	RP11-324I22.4	3.85	0.000143	0.0428	0.25	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35314552~35336401:-
STAD	cis	rs34779708	0.736	rs34195979	ENSG00000271335.4	RP11-324I22.4	3.85	0.000143	0.0428	0.25	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35314552~35336401:-
STAD	cis	rs1667255	0.83	rs1667254	ENSG00000264859.4	DSG2-AS1	-3.85	0.000143	0.0429	-0.22	-0.2	Retinol levels;	chr18:31606165	chr18:31542146~31556911:-
STAD	cis	rs1120787	0.546	rs61265422	ENSG00000278703.1	RP11-706P11.2	-3.85	0.000143	0.0429	-0.43	-0.2	HIV-1 control;	chr18:57299701	chr18:57588611~57589091:-
STAD	cis	rs11089937	0.597	rs4821768	ENSG00000211640.3	IGLV6-57	3.85	0.000143	0.0429	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.597	rs4821770	ENSG00000211640.3	IGLV6-57	3.85	0.000143	0.0429	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.568	rs4821771	ENSG00000211640.3	IGLV6-57	3.85	0.000143	0.0429	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22195713~22196460:+
STAD	cis	rs6822892	0.966	rs10857297	ENSG00000248629.1	RP11-154F14.2	3.85	0.000143	0.0429	0.21	0.2	HDL cholesterol levels;	chr4:156794799	chr4:156841359~156842236:+
STAD	cis	rs7283707	0.681	rs17307190	ENSG00000228798.1	AP000473.5	-3.85	0.000143	0.0429	-0.33	-0.2	QRS complex (12-leadsum);	chr21:15816525	chr21:16630827~16640683:+
STAD	cis	rs6012564	0.927	rs6019553	ENSG00000227431.4	CSE1L-AS1	-3.85	0.000143	0.0429	-0.2	-0.2	Anger;	chr20:48955014	chr20:49040463~49046044:-
STAD	cis	rs9463078	0.691	rs9381373	ENSG00000219384.1	RP11-491H9.3	3.85	0.000143	0.0429	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45208171	chr6:45158870~45159511:+
STAD	cis	rs4345220	0.546	rs12511338	ENSG00000250906.1	RP11-632F7.3	-3.85	0.000143	0.0429	-0.23	-0.2	Migraine with aura;	chr4:41642568	chr4:40812779~40826151:+
STAD	cis	rs34972666	0.722	rs6036398	ENSG00000226644.4	RP11-128M1.1	-3.85	0.000143	0.0429	-0.38	-0.2	Alzheimer's disease (cognitive decline);	chr20:2410410	chr20:2207217~2213151:+
STAD	cis	rs34779708	0.931	rs13377158	ENSG00000271335.4	RP11-324I22.4	-3.85	0.000143	0.0429	-0.24	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35314552~35336401:-
STAD	cis	rs10129255	0.957	rs12589190	ENSG00000232216.1	IGHV3-43	3.85	0.000143	0.0429	0.2	0.2	Kawasaki disease;	chr14:106783079	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.957	rs7493713	ENSG00000232216.1	IGHV3-43	3.85	0.000143	0.0429	0.2	0.2	Kawasaki disease;	chr14:106783685	chr14:106470264~106470800:-
STAD	cis	rs2404602	0.735	rs4886805	ENSG00000196274.5	Metazoa_SRP	3.85	0.000143	0.0429	0.18	0.2	Blood metabolite levels;	chr15:76447043	chr15:76230048~76230390:-
STAD	cis	rs17301013	0.507	rs10798324	ENSG00000227373.4	RP11-160H22.5	-3.85	0.000143	0.0429	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174787485	chr1:174115300~174160004:-
STAD	cis	rs583583	0.963	rs2236570	ENSG00000231196.3	RP11-495P10.8	3.85	0.000143	0.0429	0.27	0.2	Schizophrenia (negative symptoms);	chr1:147622086	chr1:148290890~148295859:-
STAD	cis	rs9362426	0.672	rs12663865	ENSG00000217776.1	RP11-156F23.2	-3.85	0.000143	0.0429	-0.22	-0.2	Depressive episodes in bipolar disorder;	chr6:87393431	chr6:87070156~87070461:-
STAD	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	3.85	0.000143	0.0429	0.31	0.2	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
STAD	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-3.85	0.000143	0.0429	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
STAD	cis	rs9907295	0.636	rs4251724	ENSG00000270977.1	AC015849.16	-3.85	0.000143	0.0429	-0.27	-0.2	Fibroblast growth factor basic levels;	chr17:35816641	chr17:35893707~35911023:-
STAD	cis	rs1823913	0.927	rs35092718	ENSG00000233654.1	AC093388.3	3.85	0.000143	0.0429	0.25	0.2	Obesity-related traits;	chr2:191243882	chr2:190534855~190568102:+
STAD	cis	rs9307551	0.636	rs1440861	ENSG00000250334.4	LINC00989	3.85	0.000143	0.0429	0.24	0.2	Refractive error;	chr4:79505470	chr4:79492416~79576460:+
STAD	cis	rs10508774	0.81	rs11008965	ENSG00000273038.2	RP11-479G22.8	3.85	0.000143	0.0429	0.37	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32535523	chr10:32887255~32889311:-
STAD	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	3.85	0.000143	0.0429	0.14	0.2	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
STAD	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	3.85	0.000143	0.0429	0.14	0.2	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
STAD	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	3.85	0.000143	0.0429	0.41	0.2	QT interval;	chr4:75108836	chr4:75081702~75084717:-
STAD	cis	rs6693567	0.565	rs4926395	ENSG00000203819.6	HIST2H2BC	3.85	0.000143	0.0429	0.24	0.2	Migraine;	chr1:150432822	chr1:149850193~149850772:-
STAD	cis	rs10129255	0.917	rs8022493	ENSG00000224373.3	IGHV4-59	3.85	0.000143	0.043	0.16	0.2	Kawasaki disease;	chr14:106781820	chr14:106627249~106627825:-
STAD	cis	rs950169	0.922	rs12906983	ENSG00000259683.1	RP11-182J1.14	3.85	0.000143	0.043	0.22	0.2	Schizophrenia;	chr15:84262270	chr15:84389729~84395903:+
STAD	cis	rs9926296	0.744	rs352939	ENSG00000261373.1	VPS9D1-AS1	3.85	0.000143	0.043	0.21	0.2	Vitiligo;	chr16:89643970	chr16:89711856~89718165:+
STAD	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	3.85	0.000143	0.043	0.25	0.2	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	3.85	0.000143	0.043	0.26	0.2	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	3.85	0.000143	0.043	0.26	0.2	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
STAD	cis	rs60180747	1	rs11631448	ENSG00000252712.1	SCARNA14	3.85	0.000143	0.043	0.24	0.2	Testicular germ cell tumor;	chr15:66465623	chr15:66347207~66347342:-
STAD	cis	rs5743030	1	rs7560327	ENSG00000223249.1	Y_RNA	-3.85	0.000143	0.043	-0.34	-0.2	Subcutaneous adipose tissue;	chr2:189907796	chr2:189753464~189753559:+
STAD	cis	rs13113518	0.812	rs12500686	ENSG00000223305.1	RN7SKP30	3.85	0.000143	0.043	0.24	0.2	Height;	chr4:55457922	chr4:55540502~55540835:-
STAD	cis	rs7512552	0.809	rs1694377	ENSG00000203819.6	HIST2H2BC	3.84	0.000144	0.043	0.24	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150320705	chr1:149850193~149850772:-
STAD	cis	rs451417	0.73	rs236128	ENSG00000275632.1	RP5-967N21.11	-3.84	0.000144	0.043	-0.3	-0.2	Menopause (age at onset);	chr20:5999007	chr20:6000418~6000941:+
STAD	cis	rs712022	1	rs712022	ENSG00000246225.5	RP11-17A1.3	-3.84	0.000144	0.043	-0.26	-0.2	Dialysis-related mortality;	chr11:22821609	chr11:22829380~22945393:+
STAD	cis	rs6951245	0.832	rs10266519	ENSG00000229043.2	AC091729.9	-3.84	0.000144	0.043	-0.31	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1160374~1165267:+
STAD	cis	rs11603020	0.95	rs3824988	ENSG00000265566.2	RN7SL605P	3.84	0.000144	0.043	0.29	0.2	Blood protein levels;	chr11:57610495	chr11:57528085~57528365:-
STAD	cis	rs6604026	0.643	rs1360366	ENSG00000229052.2	RP11-386I23.1	-3.84	0.000144	0.043	-0.19	-0.2	Multiple sclerosis;	chr1:92865430	chr1:92930696~92934098:+
STAD	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	3.84	0.000144	0.043	0.28	0.2	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
STAD	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	3.84	0.000144	0.043	0.28	0.2	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
STAD	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	3.84	0.000144	0.043	0.28	0.2	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
STAD	cis	rs6539247	0.509	rs4275717	ENSG00000257890.1	RP11-114F10.2	-3.84	0.000144	0.043	-0.2	-0.2	Attention function in attention deficit hyperactive disorder;	chr12:106052074	chr12:106050961~106058254:-
STAD	cis	rs2245368	0.523	rs67814714	ENSG00000185040.12	AC004980.11	3.84	0.000144	0.0431	0.24	0.2	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;	chr7:76888105	chr7:76533703~76540390:-
STAD	cis	rs9435732	0.778	rs3738815	ENSG00000224621.1	RP11-276H7.3	3.84	0.000144	0.0431	0.23	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16988207	chr1:16159266~16161883:+
STAD	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	3.84	0.000144	0.0431	0.3	0.2	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
STAD	cis	rs10789491	1	rs1890473	ENSG00000225506.2	CYP4A22-AS1	3.84	0.000144	0.0431	0.28	0.2	Response to hepatitis C treatment;	chr1:46684122	chr1:47096653~47179271:-
STAD	cis	rs2803122	0.775	rs10118150	ENSG00000272842.1	RP11-513M16.7	-3.84	0.000144	0.0431	-0.18	-0.2	Pulse pressure;	chr9:19235482	chr9:19371386~19371945:-
STAD	cis	rs58873874	0.522	rs6875379	ENSG00000248544.2	CTB-47B11.3	3.84	0.000144	0.0431	0.25	0.2	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157375741~157384950:-
STAD	cis	rs9467773	0.595	rs13207371	ENSG00000241549.7	GUSBP2	3.84	0.000144	0.0431	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26871484~26956554:-
STAD	cis	rs7204230	1	rs2287077	ENSG00000261291.1	RP11-295M3.2	3.84	0.000144	0.0431	0.24	0.2	Fibrinogen;	chr16:53288208	chr16:53168522~53169450:+
STAD	cis	rs2836974	0.627	rs8127986	ENSG00000238141.2	BRWD1-AS1	-3.84	0.000144	0.0431	-0.21	-0.2	Cognitive function;	chr21:39315285	chr21:39315707~39323218:+
STAD	cis	rs6432852	0.527	rs1897425	ENSG00000229195.1	AC009495.4	-3.84	0.000144	0.0431	-0.23	-0.2	Diabetic kidney disease;	chr2:165930697	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.527	rs61075200	ENSG00000229195.1	AC009495.4	-3.84	0.000144	0.0431	-0.23	-0.2	Diabetic kidney disease;	chr2:165932660	chr2:165794857~165846091:-
STAD	cis	rs1348850	0.598	rs12616259	ENSG00000271825.1	RP11-337N6.2	3.84	0.000144	0.0431	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177639075	chr2:177300600~177302006:+
STAD	cis	rs733592	0.507	rs3825403	ENSG00000226413.2	OR8T1P	-3.84	0.000144	0.0431	-0.22	-0.2	Plateletcrit;	chr12:48063376	chr12:48442030~48442947:-
STAD	cis	rs11168351	0.591	rs4258439	ENSG00000226413.2	OR8T1P	-3.84	0.000144	0.0431	-0.22	-0.2	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48442030~48442947:-
STAD	cis	rs733592	0.507	rs10747529	ENSG00000226413.2	OR8T1P	-3.84	0.000144	0.0431	-0.22	-0.2	Plateletcrit;	chr12:48079586	chr12:48442030~48442947:-
STAD	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	3.84	0.000144	0.0431	0.25	0.2	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
STAD	cis	rs606458	0.92	rs2284301	ENSG00000269038.1	AP001462.6	-3.84	0.000144	0.0431	-0.27	-0.2	Urate levels;	chr11:64734519	chr11:64778954~64779405:+
STAD	cis	rs6539288	0.933	rs7961366	ENSG00000260329.1	RP11-412D9.4	-3.84	0.000144	0.0431	-0.22	-0.2	Total body bone mineral density;	chr12:106902263	chr12:106954029~106955497:-
STAD	cis	rs1348850	0.914	rs12612857	ENSG00000278418.1	MIR6512	3.84	0.000144	0.0431	0.23	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177602416	chr2:177313806~177313882:-
STAD	cis	rs6686842	0.56	rs10889885	ENSG00000235358.1	RP11-399E6.1	-3.84	0.000144	0.0431	-0.23	-0.2	Height;	chr1:41199081	chr1:41242373~41284861:+
STAD	cis	rs6933660	0.745	rs9371517	ENSG00000221469.1	AL133260.1	3.84	0.000144	0.0431	0.22	0.2	Menarche (age at onset);	chr6:151418675	chr6:151039916~151039971:-
STAD	cis	rs765787	0.53	rs28414644	ENSG00000259539.1	CTD-2651B20.1	3.84	0.000144	0.0431	0.23	0.2	Uric acid levels;	chr15:45244523	chr15:45152664~45167526:-
STAD	cis	rs2803122	0.967	rs10757040	ENSG00000273226.1	RP11-513M16.8	-3.84	0.000144	0.0432	-0.2	-0.2	Pulse pressure;	chr9:19241849	chr9:19375451~19375996:+
STAD	cis	rs2803122	0.934	rs2175378	ENSG00000273226.1	RP11-513M16.8	-3.84	0.000144	0.0432	-0.2	-0.2	Pulse pressure;	chr9:19241965	chr9:19375451~19375996:+
STAD	cis	rs9463078	0.691	rs4398713	ENSG00000219384.1	RP11-491H9.3	-3.84	0.000144	0.0432	-0.19	-0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45036191	chr6:45158870~45159511:+
STAD	cis	rs2957692	0.548	rs7948215	ENSG00000254554.1	RP11-351I24.1	-3.84	0.000144	0.0432	-0.33	-0.2	Circulating vasoactive peptide levels;	chr11:10218952	chr11:10302657~10303704:-
STAD	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	3.84	0.000144	0.0432	0.24	0.2	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-3.84	0.000144	0.0432	-0.24	-0.2	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-3.84	0.000144	0.0432	-0.24	-0.2	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-3.84	0.000144	0.0432	-0.24	-0.2	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
STAD	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-3.84	0.000144	0.0432	-0.24	-0.2	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
STAD	cis	rs733592	0.507	rs56129148	ENSG00000226413.2	OR8T1P	-3.84	0.000144	0.0432	-0.22	-0.2	Plateletcrit;	chr12:48091747	chr12:48442030~48442947:-
STAD	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	3.84	0.000144	0.0432	0.22	0.2	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
STAD	cis	rs875971	0.928	rs2036263	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000144	0.0432	-0.2	-0.2	Aortic root size;	chr7:66335210	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs10240949	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000144	0.0432	-0.2	-0.2	Aortic root size;	chr7:66339430	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs7782704	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000144	0.0432	-0.2	-0.2	Aortic root size;	chr7:66340379	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs6460290	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000144	0.0432	-0.2	-0.2	Aortic root size;	chr7:66344119	chr7:65773620~65802067:+
STAD	cis	rs1009077	0.68	rs11724055	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000144	0.0432	-0.25	-0.2	Endometriosis;	chr4:119548880	chr4:119409333~119410233:+
STAD	cis	rs9436116	1	rs9436116	ENSG00000203819.6	HIST2H2BC	3.84	0.000144	0.0432	0.23	0.2	Morning vs. evening chronotype;	chr1:150482248	chr1:149850193~149850772:-
STAD	cis	rs449789	0.524	rs1875819	ENSG00000235086.1	FNDC1-IT1	-3.84	0.000144	0.0432	-0.26	-0.2	Pulse pressure;	chr6:159326711	chr6:159240786~159243329:+
STAD	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	3.84	0.000145	0.0433	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
STAD	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	3.84	0.000145	0.0433	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
STAD	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	3.84	0.000145	0.0433	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
STAD	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	3.84	0.000145	0.0433	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
STAD	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	3.84	0.000145	0.0433	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
STAD	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-3.84	0.000145	0.0433	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
STAD	cis	rs6693567	0.545	rs2133129	ENSG00000203819.6	HIST2H2BC	3.84	0.000145	0.0433	0.23	0.2	Migraine;	chr1:150383061	chr1:149850193~149850772:-
STAD	cis	rs7560272	0.549	rs2421554	ENSG00000163016.8	ALMS1P	3.84	0.000145	0.0433	0.22	0.2	Schizophrenia;	chr2:73579075	chr2:73644919~73685576:+
STAD	cis	rs17401966	0.54	rs1536262	ENSG00000199562.1	RNU6-37P	3.84	0.000145	0.0433	0.15	0.2	Hepatocellular carcinoma;	chr1:10378629	chr1:10298966~10299072:+
STAD	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000145	0.0433	-0.32	-0.2	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000145	0.0433	-0.32	-0.2	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
STAD	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000145	0.0433	-0.32	-0.2	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000145	0.0433	-0.32	-0.2	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000145	0.0433	-0.32	-0.2	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000145	0.0433	-0.32	-0.2	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000145	0.0433	-0.32	-0.2	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
STAD	cis	rs6840360	0.557	rs1143036	ENSG00000270265.1	RP11-731D1.4	-3.84	0.000145	0.0433	-0.24	-0.2	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151333775~151353224:-
STAD	cis	rs6539288	0.933	rs1444583	ENSG00000260329.1	RP11-412D9.4	3.84	0.000145	0.0433	0.22	0.2	Total body bone mineral density;	chr12:106919068	chr12:106954029~106955497:-
STAD	cis	rs3764400	0.508	rs757353	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0433	0.27	0.2	Body mass index;	chr17:48044908	chr17:48066704~48067293:-
STAD	cis	rs7142881	0.815	rs4981857	ENSG00000258648.1	UBE2CP1	-3.84	0.000145	0.0433	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31578794	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs8010049	ENSG00000258648.1	UBE2CP1	-3.84	0.000145	0.0433	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31579282	chr14:30683045~30683598:-
STAD	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-3.84	0.000145	0.0433	-0.23	-0.2	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
STAD	cis	rs13178541	0.745	rs6596262	ENSG00000271824.1	AC009014.3	-3.84	0.000145	0.0433	-0.28	-0.2	IgG glycosylation;	chr5:135723983	chr5:136191468~136193134:-
STAD	cis	rs8072100	0.87	rs10432035	ENSG00000264243.1	RP11-6N17.1	-3.84	0.000145	0.0433	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47863342~47865190:+
STAD	cis	rs10073892	0.626	rs17334032	ENSG00000250682.4	LINC00491	-3.84	0.000145	0.0433	-0.22	-0.2	Cognitive decline (age-related);	chr5:102545927	chr5:102609156~102671559:-
STAD	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	3.84	0.000145	0.0433	0.22	0.2	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
STAD	cis	rs2562456	0.792	rs2562398	ENSG00000268119.4	CTD-2561J22.5	-3.84	0.000145	0.0433	-0.26	-0.2	Pain;	chr19:21540147	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	3.84	0.000145	0.0433	0.27	0.2	Pain;	chr19:21567257	chr19:21554640~21569237:-
STAD	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	3.84	0.000145	0.0433	0.27	0.2	Pain;	chr19:21567846	chr19:21554640~21569237:-
STAD	cis	rs1008953	0.948	rs2247619	ENSG00000232880.1	RP3-453C12.8	3.84	0.000145	0.0433	0.23	0.2	Psoriasis;	chr20:45407809	chr20:45388347~45388705:-
STAD	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-3.84	0.000145	0.0433	-0.22	-0.2	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
STAD	cis	rs1850744	0.702	rs60403942	ENSG00000163612.10	FAM86KP	3.84	0.000145	0.0433	0.42	0.2	Economic and political preferences;	chr4:9601828	chr4:9153296~9165451:+
STAD	cis	rs10073892	0.957	rs10479209	ENSG00000250682.4	LINC00491	-3.84	0.000145	0.0433	-0.23	-0.2	Cognitive decline (age-related);	chr5:102365936	chr5:102609156~102671559:-
STAD	cis	rs3126085	0.825	rs7535078	ENSG00000237975.5	FLG-AS1	-3.84	0.000145	0.0434	-0.28	-0.2	Atopic dermatitis;	chr1:152250439	chr1:152168125~152445456:+
STAD	cis	rs858239	1	rs199357	ENSG00000230042.1	AK3P3	3.84	0.000145	0.0434	0.22	0.2	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23129178~23129841:+
STAD	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-3.84	0.000145	0.0434	-0.27	-0.2	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
STAD	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-3.84	0.000145	0.0434	-0.27	-0.2	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
STAD	cis	rs10073892	0.664	rs12657044	ENSG00000250682.4	LINC00491	-3.84	0.000145	0.0434	-0.22	-0.2	Cognitive decline (age-related);	chr5:102555075	chr5:102609156~102671559:-
STAD	cis	rs7824557	0.606	rs1047950	ENSG00000205879.4	FAM90A2P	3.84	0.000145	0.0434	0.23	0.2	Retinal vascular caliber;	chr8:11327587	chr8:12172202~12178575:-
STAD	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	3.84	0.000145	0.0434	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
STAD	cis	rs6479891	0.841	rs7092504	ENSG00000235816.3	PRELID1P3	-3.84	0.000145	0.0434	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63427297~63427939:+
STAD	cis	rs2859998	0.929	rs12681594	ENSG00000250031.1	RP11-114M5.1	-3.84	0.000145	0.0434	-0.18	-0.2	Narcolepsy with cataplexy;	chr8:58418657	chr8:58424588~58426685:-
STAD	cis	rs2390582	0.771	rs34894890	ENSG00000228175.3	GEMIN8P4	3.84	0.000145	0.0434	0.31	0.2	Coronary artery calcification;	chr1:90413681	chr1:89993593~89994321:-
STAD	cis	rs2834188	1	rs2026254	ENSG00000272659.1	AP000295.10	-3.84	0.000145	0.0434	-0.28	-0.2	Narcolepsy;	chr21:33315727	chr21:33309491~33310181:+
STAD	cis	rs72791417	1	rs1786918	ENSG00000228065.9	LINC01515	3.84	0.000145	0.0434	0.35	0.2	Bronchopulmonary dysplasia;	chr10:65952808	chr10:65570338~65768835:+
STAD	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	3.84	0.000145	0.0434	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
STAD	cis	rs9847710	0.791	rs6808387	ENSG00000242142.1	SERBP1P3	-3.84	0.000145	0.0434	-0.2	-0.2	Ulcerative colitis;	chr3:53045716	chr3:53064283~53065091:-
STAD	cis	rs6683071	0.688	rs3008637	ENSG00000225265.1	TAF1A-AS1	-3.84	0.000145	0.0434	-0.27	-0.2	Cognitive performance;	chr1:222684427	chr1:222589825~222593032:+
STAD	cis	rs3764400	0.567	rs1452662	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0434	0.27	0.2	Body mass index;	chr17:48215948	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.564	rs1452663	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0434	0.27	0.2	Body mass index;	chr17:48216024	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs16953941	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0434	0.27	0.2	Body mass index;	chr17:48218842	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs12939334	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0434	0.27	0.2	Body mass index;	chr17:48225307	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs1979897	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0434	0.27	0.2	Body mass index;	chr17:48232184	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs12946208	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0434	0.27	0.2	Body mass index;	chr17:48234767	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs3897789	ENSG00000278765.1	RP5-890E16.5	3.84	0.000145	0.0434	0.27	0.2	Body mass index;	chr17:48235415	chr17:48066704~48067293:-
STAD	cis	rs338389	0.542	rs7494835	ENSG00000260657.2	RP11-315D16.4	-3.84	0.000145	0.0434	-0.24	-0.2	Survival in rectal cancer;	chr15:68001993	chr15:68267792~68277994:-
STAD	cis	rs2273156	0.517	rs7159324	ENSG00000258704.4	SRP54-AS1	3.84	0.000145	0.0434	0.24	0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35157791	chr14:34920858~34982532:-
STAD	cis	rs9902453	0.904	rs6505148	ENSG00000263477.1	RP11-338L22.2	3.84	0.000145	0.0434	0.17	0.2	Coffee consumption (cups per day);	chr17:29962800	chr17:29863402~29866092:+
STAD	cis	rs860295	0.702	rs10796945	ENSG00000225855.5	RUSC1-AS1	3.84	0.000145	0.0434	0.17	0.2	Body mass index;	chr1:155457897	chr1:155316863~155324176:-
STAD	cis	rs62400317	0.762	rs12202704	ENSG00000219384.1	RP11-491H9.3	-3.84	0.000145	0.0434	-0.23	-0.2	Total body bone mineral density;	chr6:44851877	chr6:45158870~45159511:+
STAD	cis	rs12362063	0.9	rs12793985	ENSG00000255450.1	CTD-2063L20.1	-3.84	0.000145	0.0434	-0.18	-0.2	Hepatitis B;	chr11:29242119	chr11:29275655~29276565:+
STAD	cis	rs11587682	0.76	rs12123103	ENSG00000274963.1	Metazoa_SRP	-3.84	0.000145	0.0434	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150448810	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs11205378	ENSG00000274963.1	Metazoa_SRP	-3.84	0.000145	0.0434	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150448981	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs34933405	ENSG00000274963.1	Metazoa_SRP	-3.84	0.000145	0.0434	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150450126	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.76	rs10888581	ENSG00000274963.1	Metazoa_SRP	-3.84	0.000145	0.0434	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150451696	chr1:150568971~150569269:-
STAD	cis	rs6480314	0.522	rs7895740	ENSG00000233590.1	RP11-153K11.3	-3.84	0.000145	0.0434	-0.28	-0.2	Optic nerve measurement (disc area);	chr10:68313912	chr10:68233251~68242379:-
STAD	cis	rs7474896	1	rs61858625	ENSG00000120555.12	SEPT7P9	3.84	0.000145	0.0434	0.31	0.2	Obesity (extreme);	chr10:37713114	chr10:38383069~38402916:-
STAD	cis	rs7260538	0.808	rs1552219	ENSG00000270164.1	LINC01480	-3.84	0.000145	0.0434	-0.19	-0.2	DDT metabolite (p,p'-DDE levels);	chr19:41019469	chr19:41535183~41536904:+
STAD	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	3.84	0.000145	0.0434	0.29	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
STAD	cis	rs6840360	0.582	rs6813735	ENSG00000270265.1	RP11-731D1.4	-3.84	0.000145	0.0434	-0.25	-0.2	Intelligence (multi-trait analysis);	chr4:151405838	chr4:151333775~151353224:-
STAD	cis	rs6840360	0.582	rs57585665	ENSG00000270265.1	RP11-731D1.4	-3.84	0.000145	0.0434	-0.25	-0.2	Intelligence (multi-trait analysis);	chr4:151405865	chr4:151333775~151353224:-
STAD	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	3.84	0.000145	0.0434	0.3	0.2	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
STAD	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-3.84	0.000145	0.0434	-0.17	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
STAD	cis	rs6832769	0.961	rs7684810	ENSG00000223305.1	RN7SKP30	3.84	0.000145	0.0434	0.23	0.2	Personality dimensions;	chr4:55486627	chr4:55540502~55540835:-
STAD	cis	rs71636778	0.543	rs17162333	ENSG00000260063.1	RP5-968P14.2	-3.84	0.000145	0.0434	-0.39	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26910266	chr1:26692132~26694131:-
STAD	cis	rs853356	0.739	rs1556388	ENSG00000272379.1	RP1-257A7.5	-3.84	0.000145	0.0435	-0.26	-0.2	Height;	chr6:14201403	chr6:13290018~13290490:-
STAD	cis	rs4879656	0.705	rs10813910	ENSG00000225693.1	LAGE3P1	-3.84	0.000145	0.0435	-0.27	-0.2	Menopause (age at onset);	chr9:32965209	chr9:33019682~33020165:-
STAD	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	3.84	0.000145	0.0435	0.27	0.2	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
STAD	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	3.84	0.000145	0.0435	0.27	0.2	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
STAD	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000145	0.0435	0.25	0.2	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
STAD	cis	rs9463078	0.691	rs3920903	ENSG00000219384.1	RP11-491H9.3	3.84	0.000145	0.0435	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45073191	chr6:45158870~45159511:+
STAD	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	3.84	0.000146	0.0435	0.2	0.2	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	3.84	0.000146	0.0435	0.2	0.2	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
STAD	cis	rs10776614	0.799	rs12358311	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48557292	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs12358315	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48557347	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7350439	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48557529	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7350424	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48557685	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.733	rs11101381	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48558022	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs11101382	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48558332	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs56058334	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48558732	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7094216	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48558904	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7087729	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48559058	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7088010	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48559201	chr10:47689707~47730436:+
STAD	cis	rs10776614	0.799	rs7074631	ENSG00000189014.7	FAM35DP	3.84	0.000146	0.0435	0.3	0.2	Self-employment;	chr10:48559324	chr10:47689707~47730436:+
STAD	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	3.84	0.000146	0.0435	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	3.84	0.000146	0.0435	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
STAD	cis	rs57786342	0.806	rs56082161	ENSG00000240210.3	RP11-204K16.1	3.84	0.000146	0.0435	0.26	0.2	Macrophage inflammatory protein 1a levels;	chr14:68749707	chr14:68338728~68339528:-
STAD	cis	rs7512552	0.809	rs2794679	ENSG00000203819.6	HIST2H2BC	3.84	0.000146	0.0435	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150352381	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.646	rs1694367	ENSG00000203819.6	HIST2H2BC	3.84	0.000146	0.0435	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150356993	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs1103115	ENSG00000203819.6	HIST2H2BC	3.84	0.000146	0.0435	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150359828	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs1097070	ENSG00000203819.6	HIST2H2BC	3.84	0.000146	0.0435	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150360479	chr1:149850193~149850772:-
STAD	cis	rs7264396	0.635	rs6058355	ENSG00000199676.1	Y_RNA	3.84	0.000146	0.0435	0.23	0.2	Total cholesterol levels;	chr20:35903421	chr20:35853252~35853364:-
STAD	cis	rs6432852	0.55	rs6432857	ENSG00000229195.1	AC009495.4	3.84	0.000146	0.0435	0.23	0.2	Diabetic kidney disease;	chr2:165983445	chr2:165794857~165846091:-
STAD	cis	rs2820315	0.541	rs10753906	ENSG00000229191.1	RP11-168O16.1	3.84	0.000146	0.0435	0.22	0.2	Coronary artery disease;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr1:201918254	chr1:201023949~201028792:+
STAD	cis	rs6840360	0.642	rs2724577	ENSG00000251611.1	RP11-610P16.1	-3.84	0.000146	0.0435	-0.24	-0.2	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151407551~151408835:-
STAD	cis	rs4388249	1	rs2284989	ENSG00000271849.1	CTC-332L22.1	-3.84	0.000146	0.0435	-0.3	-0.2	Schizophrenia;	chr5:109740787	chr5:109687802~109688329:-
STAD	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-3.84	0.000146	0.0436	-0.3	-0.2	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
STAD	cis	rs2901460	0.686	rs6739306	ENSG00000229503.1	AC092155.1	-3.84	0.000146	0.0436	-0.16	-0.2	Mean corpuscular volume;	chr2:62124974	chr2:62532583~62533059:-
STAD	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	3.84	0.000146	0.0436	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	3.84	0.000146	0.0436	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
STAD	cis	rs875971	0.862	rs778734	ENSG00000224316.1	RP11-479O9.2	3.84	0.000146	0.0436	0.2	0.2	Aortic root size;	chr7:66349862	chr7:65773620~65802067:+
STAD	cis	rs17818399	0.547	rs4952831	ENSG00000279254.1	RP11-536C12.1	-3.84	0.000146	0.0436	-0.23	-0.2	Height;	chr2:46534042	chr2:46668870~46670778:+
STAD	cis	rs11089937	0.597	rs11704434	ENSG00000211638.2	IGLV8-61	-3.84	0.000146	0.0436	-0.23	-0.2	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22098700~22099212:+
STAD	cis	rs2115630	1	rs2115630	ENSG00000275120.1	RP11-182J1.17	-3.84	0.000146	0.0436	-0.22	-0.2	P wave terminal force;	chr15:84821285	chr15:84599434~84606463:-
STAD	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-3.84	0.000146	0.0436	-0.2	-0.2	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
STAD	cis	rs7204230	0.96	rs3803658	ENSG00000261291.1	RP11-295M3.2	-3.84	0.000146	0.0436	-0.24	-0.2	Fibrinogen;	chr16:53314671	chr16:53168522~53169450:+
STAD	cis	rs17507216	0.718	rs4779033	ENSG00000255769.6	GOLGA2P10	3.84	0.000146	0.0436	0.34	0.2	Excessive daytime sleepiness;	chr15:82576634	chr15:82472993~82513950:-
STAD	cis	rs870825	0.616	rs28579226	ENSG00000249173.4	LINC01093	-3.84	0.000146	0.0436	-0.33	-0.2	Blood protein levels;	chr4:184729304	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7692104	ENSG00000249173.4	LINC01093	-3.84	0.000146	0.0436	-0.33	-0.2	Blood protein levels;	chr4:184729741	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs7692367	ENSG00000249173.4	LINC01093	-3.84	0.000146	0.0436	-0.33	-0.2	Blood protein levels;	chr4:184729902	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs10006828	ENSG00000249173.4	LINC01093	-3.84	0.000146	0.0436	-0.33	-0.2	Blood protein levels;	chr4:184730262	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28607131	ENSG00000249173.4	LINC01093	-3.84	0.000146	0.0436	-0.33	-0.2	Blood protein levels;	chr4:184730463	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs28490461	ENSG00000249173.4	LINC01093	-3.84	0.000146	0.0436	-0.33	-0.2	Blood protein levels;	chr4:184730484	chr4:184893871~184899454:-
STAD	cis	rs17818399	1	rs17818399	ENSG00000279254.1	RP11-536C12.1	-3.84	0.000146	0.0436	-0.22	-0.2	Height;	chr2:46598887	chr2:46668870~46670778:+
STAD	cis	rs6432852	0.527	rs6709397	ENSG00000229195.1	AC009495.4	3.84	0.000146	0.0436	0.23	0.2	Diabetic kidney disease;	chr2:165922023	chr2:165794857~165846091:-
STAD	cis	rs9902453	0.791	rs2628166	ENSG00000263477.1	RP11-338L22.2	-3.84	0.000146	0.0436	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29786105	chr17:29863402~29866092:+
STAD	cis	rs62400317	0.762	rs12198308	ENSG00000219384.1	RP11-491H9.3	-3.84	0.000146	0.0436	-0.23	-0.2	Total body bone mineral density;	chr6:44944149	chr6:45158870~45159511:+
STAD	cis	rs6840258	0.891	rs3775209	ENSG00000248180.1	GAPDHP60	3.84	0.000146	0.0436	0.16	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87125794	chr4:87207092~87208086:+
STAD	cis	rs1005277	0.579	rs2474567	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2472175	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2472176	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2983343	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2474569	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2504143	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.602	rs2504142	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2474571	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2472181	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2474574	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2504140	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2474575	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2472182	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.541	rs2263163	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2021649	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2505197	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2505196	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.541	rs2505193	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2474580	ENSG00000276805.1	RP11-291L22.6	3.84	0.000146	0.0436	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38451030~38451785:+
STAD	cis	rs4835473	0.932	rs4260486	ENSG00000249741.2	RP11-673E1.3	-3.84	0.000146	0.0436	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143987556	chr4:143911514~143912053:-
STAD	cis	rs12210905	1	rs9393796	ENSG00000241549.7	GUSBP2	-3.84	0.000146	0.0436	-0.33	-0.2	Hip circumference adjusted for BMI;	chr6:27259186	chr6:26871484~26956554:-
STAD	cis	rs12210905	1	rs9379965	ENSG00000241549.7	GUSBP2	-3.84	0.000146	0.0436	-0.33	-0.2	Hip circumference adjusted for BMI;	chr6:27259282	chr6:26871484~26956554:-
STAD	cis	rs11846409	0.86	rs74091720	ENSG00000274576.2	IGHV2-70	-3.84	0.000146	0.0436	-0.24	-0.2	Rheumatic heart disease;	chr14:106638192	chr14:106770577~106771020:-
STAD	cis	rs867371	1	rs1392976	ENSG00000278603.1	RP13-608F4.5	-3.84	0.000146	0.0436	-0.23	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472203~82472426:+
STAD	cis	rs718433	0.584	rs2874142	ENSG00000211790.2	TRAV8-4	3.84	0.000146	0.0436	0.17	0.2	Intraocular pressure;	chr14:21750036	chr14:21894433~21895030:+
STAD	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-3.84	0.000146	0.0437	-0.22	-0.2	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
STAD	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-3.84	0.000146	0.0437	-0.22	-0.2	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
STAD	cis	rs749052	0.731	rs17199740	ENSG00000251485.1	AC068134.10	3.84	0.000146	0.0437	0.49	0.2	Height;	chr2:231964257	chr2:232343116~232343903:+
STAD	cis	rs2638953	0.962	rs11049531	ENSG00000247934.4	RP11-967K21.1	-3.84	0.000146	0.0437	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322797	chr12:28163298~28190738:-
STAD	cis	rs2638953	1	rs11049532	ENSG00000247934.4	RP11-967K21.1	-3.84	0.000146	0.0437	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28323979	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.925	rs10843154	ENSG00000247934.4	RP11-967K21.1	-3.84	0.000146	0.0437	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28326824	chr12:28163298~28190738:-
STAD	cis	rs2098713	0.535	rs56288111	ENSG00000250155.1	CTD-2353F22.1	3.84	0.000146	0.0437	0.21	0.2	Telomere length;	chr5:37619340	chr5:36666214~36725195:-
STAD	cis	rs2562456	0.755	rs1879234	ENSG00000268117.1	VN1R84P	-3.84	0.000146	0.0437	-0.27	-0.2	Pain;	chr19:21521677	chr19:21719801~21720035:-
STAD	cis	rs58873874	0.579	rs11551374	ENSG00000251405.2	CTB-109A12.1	3.84	0.000146	0.0437	0.32	0.2	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157362615~157460078:-
STAD	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	3.84	0.000147	0.0437	0.3	0.2	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
STAD	cis	rs11603020	0.95	rs11229067	ENSG00000265566.2	RN7SL605P	3.84	0.000147	0.0437	0.29	0.2	Blood protein levels;	chr11:57607473	chr11:57528085~57528365:-
STAD	cis	rs4835473	0.932	rs4287958	ENSG00000249741.2	RP11-673E1.3	-3.84	0.000147	0.0437	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143987719	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs4125545	ENSG00000249741.2	RP11-673E1.3	-3.84	0.000147	0.0437	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143988650	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.897	rs12649594	ENSG00000249741.2	RP11-673E1.3	-3.84	0.000147	0.0437	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143989307	chr4:143911514~143912053:-
STAD	cis	rs8072100	0.935	rs12943464	ENSG00000264243.1	RP11-6N17.1	-3.84	0.000147	0.0437	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47863342~47865190:+
STAD	cis	rs8072100	0.935	rs4793978	ENSG00000264243.1	RP11-6N17.1	-3.84	0.000147	0.0437	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47863342~47865190:+
STAD	cis	rs9392556	0.626	rs626080	ENSG00000230648.1	RP3-406P24.3	-3.84	0.000147	0.0437	-0.23	-0.2	Blood metabolite levels;	chr6:4101333	chr6:4018843~4021215:-
STAD	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	3.84	0.000147	0.0437	0.3	0.2	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	3.84	0.000147	0.0437	0.3	0.2	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
STAD	cis	rs7615952	0.512	rs34085484	ENSG00000239804.1	RP11-379B18.1	3.84	0.000147	0.0437	0.27	0.2	Blood pressure (smoking interaction);	chr3:125825343	chr3:125787888~125788146:-
STAD	cis	rs7615952	0.608	rs35668111	ENSG00000239804.1	RP11-379B18.1	3.84	0.000147	0.0437	0.27	0.2	Blood pressure (smoking interaction);	chr3:125825792	chr3:125787888~125788146:-
STAD	cis	rs11089937	0.589	rs4239891	ENSG00000211638.2	IGLV8-61	-3.84	0.000147	0.0437	-0.21	-0.2	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22098700~22099212:+
STAD	cis	rs10129255	0.917	rs7155356	ENSG00000211973.2	IGHV1-69	3.84	0.000147	0.0437	0.19	0.2	Kawasaki disease;	chr14:106697376	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.917	rs10137601	ENSG00000211973.2	IGHV1-69	3.84	0.000147	0.0437	0.19	0.2	Kawasaki disease;	chr14:106697476	chr14:106714684~106715181:-
STAD	cis	rs4713118	0.869	rs9348775	ENSG00000243307.2	POM121L6P	-3.84	0.000147	0.0437	-0.23	-0.2	Parkinson's disease;	chr6:27727550	chr6:26896952~26898777:+
STAD	cis	rs7474896	0.616	rs2505239	ENSG00000228882.1	CICP9	3.84	0.000147	0.0437	0.26	0.2	Obesity (extreme);	chr10:38151837	chr10:38452987~38455365:-
STAD	cis	rs7474896	0.561	rs2474603	ENSG00000228882.1	CICP9	3.84	0.000147	0.0437	0.26	0.2	Obesity (extreme);	chr10:38156754	chr10:38452987~38455365:-
STAD	cis	rs238295	0.805	rs6053527	ENSG00000230563.2	RP5-828H9.1	3.84	0.000147	0.0437	0.23	0.2	Occipital cortical area (total cortical area interaction);	chr20:5601811	chr20:5471207~5475182:+
STAD	cis	rs718433	0.556	rs1569287	ENSG00000211790.2	TRAV8-4	3.84	0.000147	0.0437	0.17	0.2	Intraocular pressure;	chr14:21747309	chr14:21894433~21895030:+
STAD	cis	rs718433	0.584	rs2075478	ENSG00000211790.2	TRAV8-4	3.84	0.000147	0.0437	0.17	0.2	Intraocular pressure;	chr14:21749767	chr14:21894433~21895030:+
STAD	cis	rs7615952	0.688	rs7624806	ENSG00000241346.1	SNRPCP11	3.84	0.000147	0.0438	0.31	0.2	Blood pressure (smoking interaction);	chr3:125880231	chr3:125816082~125816286:-
STAD	cis	rs73198271	0.737	rs506960	ENSG00000254340.1	RP11-10A14.3	-3.84	0.000147	0.0438	-0.26	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:9141424~9145435:+
STAD	cis	rs6063399	0.502	rs3091737	ENSG00000234698.1	RP11-112L6.2	-3.84	0.000147	0.0438	-0.19	-0.2	Obesity-related traits;	chr20:49376770	chr20:50166362~50171742:+
STAD	cis	rs3764400	0.567	rs67345313	ENSG00000278765.1	RP5-890E16.5	3.84	0.000147	0.0438	0.27	0.2	Body mass index;	chr17:48224839	chr17:48066704~48067293:-
STAD	cis	rs60180747	0.909	rs17200912	ENSG00000252712.1	SCARNA14	3.84	0.000147	0.0438	0.24	0.2	Testicular germ cell tumor;	chr15:66437969	chr15:66347207~66347342:-
STAD	cis	rs10508774	0.789	rs56124718	ENSG00000273038.2	RP11-479G22.8	3.84	0.000147	0.0438	0.42	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32931991	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.852	rs12412565	ENSG00000273038.2	RP11-479G22.8	3.84	0.000147	0.0438	0.42	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32932794	chr10:32887255~32889311:-
STAD	cis	rs10508774	0.852	rs12412570	ENSG00000273038.2	RP11-479G22.8	3.84	0.000147	0.0438	0.42	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32933027	chr10:32887255~32889311:-
STAD	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	3.84	0.000147	0.0438	0.2	0.2	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
STAD	cis	rs10911902	0.643	rs6689129	ENSG00000229739.2	RP11-295K2.3	-3.84	0.000147	0.0438	-0.29	-0.2	Schizophrenia;	chr1:186357078	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs16825243	ENSG00000229739.2	RP11-295K2.3	-3.84	0.000147	0.0438	-0.29	-0.2	Schizophrenia;	chr1:186357769	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs76469621	ENSG00000229739.2	RP11-295K2.3	-3.84	0.000147	0.0438	-0.29	-0.2	Schizophrenia;	chr1:186363848	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs79081972	ENSG00000229739.2	RP11-295K2.3	-3.84	0.000147	0.0438	-0.29	-0.2	Schizophrenia;	chr1:186364669	chr1:186435161~186470291:+
STAD	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-3.84	0.000147	0.0438	-0.2	-0.2	Height;	chr2:46627569	chr2:46668870~46670778:+
STAD	cis	rs189798	0.807	rs9949	ENSG00000253981.4	ALG1L13P	3.84	0.000147	0.0438	0.25	0.2	Myopia (pathological);	chr8:9137002	chr8:8236003~8244667:-
STAD	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-3.84	0.000147	0.0438	-0.26	-0.2	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
STAD	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
STAD	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
STAD	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000147	0.0438	-0.32	-0.2	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
STAD	cis	rs875971	0.929	rs778712	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66384991	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs778710	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66389847	chr7:65773620~65802067:+
STAD	cis	rs875971	0.964	rs778708	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66391332	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs778696	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66405826	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs778694	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66406571	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs4718344	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66409394	chr7:65773620~65802067:+
STAD	cis	rs875971	0.737	rs7803424	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66415618	chr7:65773620~65802067:+
STAD	cis	rs875971	0.83	rs7799834	ENSG00000224316.1	RP11-479O9.2	3.84	0.000147	0.0438	0.2	0.2	Aortic root size;	chr7:66415707	chr7:65773620~65802067:+
STAD	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	3.84	0.000147	0.0438	0.25	0.2	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
STAD	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	3.84	0.000147	0.0438	0.19	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
STAD	cis	rs11089937	0.616	rs5995616	ENSG00000211639.2	IGLV4-60	-3.84	0.000147	0.0438	-0.21	-0.2	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22162199~22162681:+
STAD	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	3.84	0.000147	0.0438	0.23	0.2	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
STAD	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	3.84	0.000147	0.0438	0.23	0.2	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
STAD	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	3.84	0.000147	0.0438	0.23	0.2	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
STAD	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-3.84	0.000147	0.0438	-0.25	-0.2	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
STAD	cis	rs2562456	0.917	rs9304987	ENSG00000268119.4	CTD-2561J22.5	-3.84	0.000147	0.0438	-0.26	-0.2	Pain;	chr19:21499472	chr19:21444241~21463908:-
STAD	cis	rs870825	0.616	rs7682677	ENSG00000249173.4	LINC01093	-3.84	0.000147	0.0438	-0.33	-0.2	Blood protein levels;	chr4:184719563	chr4:184893871~184899454:-
STAD	cis	rs2115630	0.967	rs28595395	ENSG00000256278.1	RP11-182J1.5	-3.84	0.000147	0.0439	-0.2	-0.2	P wave terminal force;	chr15:84791721	chr15:84611689~84614969:-
STAD	cis	rs11846409	0.872	rs2516914	ENSG00000274576.2	IGHV2-70	3.84	0.000147	0.0439	0.24	0.2	Rheumatic heart disease;	chr14:106629835	chr14:106770577~106771020:-
STAD	cis	rs61270009	0.955	rs12163987	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000147	0.0439	0.28	0.2	Depressive symptoms;	chr5:88276209	chr5:88268895~88436685:+
STAD	cis	rs1874124	0.577	rs2807880	ENSG00000238078.1	LINC01352	3.84	0.000147	0.0439	0.26	0.2	Cholesterol, total;	chr1:220869661	chr1:220829255~220832429:+
STAD	cis	rs6012564	0.928	rs6095396	ENSG00000227431.4	CSE1L-AS1	-3.84	0.000147	0.0439	-0.2	-0.2	Anger;	chr20:49010633	chr20:49040463~49046044:-
STAD	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	3.84	0.000147	0.0439	0.45	0.2	QT interval;	chr4:75107557	chr4:75081702~75084717:-
STAD	cis	rs1122401	0.515	rs2564983	ENSG00000241230.3	RN7SL801P	-3.84	0.000147	0.0439	-0.23	-0.2	Smoking initiation;	chr5:54568610	chr5:54048007~54048308:-
STAD	cis	rs6142102	0.812	rs6059574	ENSG00000264616.1	MIR4755	-3.84	0.000147	0.0439	-0.21	-0.2	Skin pigmentation;	chr20:33935366	chr20:34049119~34049190:+
STAD	cis	rs1913185	0.837	rs67154251	ENSG00000240032.1	RP11-274H2.3	-3.84	0.000147	0.0439	-0.31	-0.2	Obesity-related traits;	chr3:146157193	chr3:146066344~146069185:-
STAD	cis	rs1348850	0.789	rs2197611	ENSG00000271825.1	RP11-337N6.2	3.84	0.000147	0.0439	0.17	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177504308	chr2:177300600~177302006:+
STAD	cis	rs6674176	0.551	rs72683973	ENSG00000271329.1	RP5-891H21.5	-3.84	0.000148	0.0439	-0.33	-0.2	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43987353	chr1:44187943~44189049:-
STAD	cis	rs73198271	0.74	rs10092600	ENSG00000254340.1	RP11-10A14.3	-3.84	0.000148	0.0439	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:9141424~9145435:+
STAD	cis	rs10129255	0.912	rs35468694	ENSG00000211974.3	IGHV2-70	3.84	0.000148	0.0439	0.22	0.2	Kawasaki disease;	chr14:106784199	chr14:106723574~106724093:-
STAD	cis	rs10129255	0.957	rs8019272	ENSG00000211974.3	IGHV2-70	3.84	0.000148	0.0439	0.22	0.2	Kawasaki disease;	chr14:106784709	chr14:106723574~106724093:-
STAD	cis	rs2177312	0.53	rs7675353	ENSG00000251129.1	RP11-734I18.1	-3.84	0.000148	0.0439	-0.26	-0.2	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31999465	chr4:31997397~32155406:+
STAD	cis	rs1075265	0.568	rs10865278	ENSG00000235937.1	AC008280.1	3.84	0.000148	0.0439	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54029552~54030682:-
STAD	cis	rs9291683	0.567	rs12499857	ENSG00000250613.1	RP11-136I13.1	-3.84	0.000148	0.0439	-0.19	-0.2	Bone mineral density;	chr4:9993752	chr4:10410996~10411644:+
STAD	cis	rs9601248	0.756	rs9601252	ENSG00000227676.3	LINC01068	-3.84	0.000148	0.0439	-0.25	-0.2	Major depressive disorder;	chr13:79615607	chr13:79566727~79571436:+
STAD	cis	rs2412819	0.599	rs2470120	ENSG00000275601.1	AC011330.13	-3.84	0.000148	0.0439	-0.23	-0.2	Lung cancer;	chr15:43636872	chr15:43642389~43643023:-
STAD	cis	rs13217239	0.646	rs9379956	ENSG00000272312.1	RP11-239L20.6	3.84	0.000148	0.0439	0.2	0.2	Schizophrenia;	chr6:27065956	chr6:27001208~27001648:-
STAD	cis	rs13217239	0.646	rs7747454	ENSG00000272312.1	RP11-239L20.6	3.84	0.000148	0.0439	0.2	0.2	Schizophrenia;	chr6:27066474	chr6:27001208~27001648:-
STAD	cis	rs8062405	0.698	rs7188071	ENSG00000278665.1	RP11-666O2.4	-3.84	0.000148	0.044	-0.24	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28599241~28601881:-
STAD	cis	rs2803122	0.967	rs4977519	ENSG00000273226.1	RP11-513M16.8	-3.84	0.000148	0.044	-0.2	-0.2	Pulse pressure;	chr9:19241204	chr9:19375451~19375996:+
STAD	cis	rs9902453	0.765	rs2264302	ENSG00000263477.1	RP11-338L22.2	-3.84	0.000148	0.044	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29730077	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.765	rs2447935	ENSG00000263477.1	RP11-338L22.2	-3.84	0.000148	0.044	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29730506	chr17:29863402~29866092:+
STAD	cis	rs77861329	1	rs57335685	ENSG00000270941.1	RP5-966M1.5	3.84	0.000148	0.044	0.41	0.2	Macrophage inflammatory protein 1b levels;	chr3:52064442	chr3:52734735~52735013:+
STAD	cis	rs6756513	0.505	rs17037076	ENSG00000244236.3	RN7SL604P	-3.84	0.000148	0.044	-0.24	-0.2	Breast cancer;Platelet count;	chr2:69806517	chr2:69516751~69517046:+
STAD	cis	rs295490	1	rs397940	ENSG00000272656.1	RP11-219D15.3	-3.84	0.000148	0.044	-0.41	-0.2	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520429	chr3:139349024~139349371:-
STAD	cis	rs151997	0.925	rs27286	ENSG00000250360.1	CTD-2089N3.1	-3.84	0.000148	0.044	-0.19	-0.2	Callous-unemotional behaviour;	chr5:50900490	chr5:50965687~50967008:-
STAD	cis	rs2273156	0.673	rs12878219	ENSG00000241052.1	RP11-173D9.1	-3.84	0.000148	0.044	-0.23	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:34911931	chr14:35144021~35144480:-
STAD	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	3.84	0.000148	0.044	0.3	0.2	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
STAD	cis	rs11673344	0.542	rs826325	ENSG00000267672.1	CTD-2293H3.1	3.84	0.000148	0.044	0.19	0.2	Obesity-related traits;	chr19:37003580	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.543	rs12980849	ENSG00000267672.1	CTD-2293H3.1	3.84	0.000148	0.044	0.19	0.2	Obesity-related traits;	chr19:37160812	chr19:37091341~37092564:+
STAD	cis	rs9902453	1	rs9902453	ENSG00000263477.1	RP11-338L22.2	-3.84	0.000148	0.044	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30022077	chr17:29863402~29866092:+
STAD	cis	rs513349	0.964	rs210139	ENSG00000197251.3	LINC00336	3.84	0.000148	0.044	0.22	0.2	Platelet count;	chr6:33575632	chr6:33586106~33593338:-
STAD	cis	rs6772849	0.805	rs61159406	ENSG00000242551.2	POU5F1P6	-3.84	0.000148	0.044	-0.2	-0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128674735~128677005:-
STAD	cis	rs6772849	0.805	rs13325747	ENSG00000242551.2	POU5F1P6	-3.84	0.000148	0.044	-0.2	-0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128674735~128677005:-
STAD	cis	rs2562456	0.72	rs6511250	ENSG00000268119.4	CTD-2561J22.5	-3.84	0.000148	0.044	-0.26	-0.2	Pain;	chr19:21473244	chr19:21444241~21463908:-
STAD	cis	rs5753618	0.583	rs5753612	ENSG00000236132.1	CTA-440B3.1	-3.84	0.000148	0.044	-0.22	-0.2	Colorectal cancer;	chr22:31425493	chr22:31816379~31817491:-
STAD	cis	rs2404602	0.583	rs35707798	ENSG00000196274.5	Metazoa_SRP	3.84	0.000148	0.044	0.17	0.2	Blood metabolite levels;	chr15:76272685	chr15:76230048~76230390:-
STAD	cis	rs7260538	0.773	rs1552223	ENSG00000270164.1	LINC01480	3.84	0.000148	0.044	0.19	0.2	DDT metabolite (p,p'-DDE levels);	chr19:41020047	chr19:41535183~41536904:+
STAD	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	3.84	0.000148	0.044	0.32	0.2	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
STAD	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-3.84	0.000148	0.044	-0.32	-0.2	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
STAD	cis	rs10040610	0.822	rs11743526	ENSG00000250490.1	FLJ33360	3.84	0.000148	0.044	0.29	0.2	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6367799	chr5:6310441~6339884:-
STAD	cis	rs259282	0.605	rs8100423	ENSG00000201388.1	SNORA68	3.84	0.000148	0.044	0.2	0.2	Schizophrenia;	chr19:32618097	chr19:32608337~32608469:-
STAD	cis	rs3947	1	rs4839	ENSG00000238460.1	AC068587.2	-3.84	0.000148	0.044	-0.26	-0.2	Blood protein levels;	chr8:11844424	chr8:12578005~12578152:+
STAD	cis	rs4835473	0.868	rs1828503	ENSG00000249741.2	RP11-673E1.3	3.84	0.000148	0.044	0.23	0.2	Immature fraction of reticulocytes;	chr4:143993354	chr4:143911514~143912053:-
STAD	cis	rs1488193	0.59	rs7640561	ENSG00000240057.4	RP11-572M11.4	-3.84	0.000148	0.044	-0.35	-0.2	Economic and political preferences;	chr3:112808621	chr3:113019532~113183301:+
STAD	cis	rs6012564	1	rs3092411	ENSG00000227431.4	CSE1L-AS1	-3.84	0.000148	0.044	-0.19	-0.2	Anger;	chr20:49074054	chr20:49040463~49046044:-
STAD	cis	rs6012564	0.929	rs2426114	ENSG00000227431.4	CSE1L-AS1	-3.84	0.000148	0.044	-0.19	-0.2	Anger;	chr20:49075855	chr20:49040463~49046044:-
STAD	cis	rs6012564	1	rs2426116	ENSG00000227431.4	CSE1L-AS1	-3.84	0.000148	0.044	-0.19	-0.2	Anger;	chr20:49076510	chr20:49040463~49046044:-
STAD	cis	rs8141529	0.748	rs5997412	ENSG00000272858.1	CTA-292E10.8	-3.84	0.000148	0.044	-0.22	-0.2	Lymphocyte counts;	chr22:28880759	chr22:28814914~28815662:+
STAD	cis	rs860295	1	rs6427286	ENSG00000203761.5	MSTO2P	-3.84	0.000148	0.044	-0.17	-0.2	Body mass index;	chr1:155753506	chr1:155745829~155750137:+
STAD	cis	rs860295	1	rs7541060	ENSG00000203761.5	MSTO2P	-3.84	0.000148	0.044	-0.17	-0.2	Body mass index;	chr1:155758297	chr1:155745829~155750137:+
STAD	cis	rs9990333	0.562	rs12632706	ENSG00000231464.1	AC024937.4	3.84	0.000148	0.044	0.23	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195996738~195998233:+
STAD	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	3.84	0.000148	0.044	0.28	0.2	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
STAD	cis	rs6832769	1	rs726967	ENSG00000223305.1	RN7SKP30	-3.84	0.000148	0.0441	-0.23	-0.2	Personality dimensions;	chr4:55555546	chr4:55540502~55540835:-
STAD	cis	rs9733	0.596	rs6686525	ENSG00000276103.1	U4	3.84	0.000148	0.0441	0.19	0.2	Tonsillectomy;	chr1:150663335	chr1:150608507~150608623:-
STAD	cis	rs6539288	0.933	rs6539289	ENSG00000260329.1	RP11-412D9.4	3.84	0.000148	0.0441	0.22	0.2	Total body bone mineral density;	chr12:106915538	chr12:106954029~106955497:-
STAD	cis	rs11603020	0.851	rs10896631	ENSG00000265566.2	RN7SL605P	-3.84	0.000148	0.0441	-0.3	-0.2	Blood protein levels;	chr11:57613790	chr11:57528085~57528365:-
STAD	cis	rs11603020	0.904	rs4926	ENSG00000265566.2	RN7SL605P	-3.84	0.000148	0.0441	-0.3	-0.2	Blood protein levels;	chr11:57614516	chr11:57528085~57528365:-
STAD	cis	rs11603020	0.904	rs11606677	ENSG00000265566.2	RN7SL605P	-3.84	0.000148	0.0441	-0.3	-0.2	Blood protein levels;	chr11:57615904	chr11:57528085~57528365:-
STAD	cis	rs615632	0.57	rs17734541	ENSG00000254340.1	RP11-10A14.3	3.84	0.000148	0.0441	0.26	0.2	Neuroticism;	chr8:9850923	chr8:9141424~9145435:+
STAD	cis	rs6471393	0.798	rs62525169	ENSG00000253848.1	RP11-10N23.5	3.84	0.000148	0.0441	0.24	0.2	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93804169	chr8:93741193~93744534:+
STAD	cis	rs9926664	0.908	rs8052064	ENSG00000274134.1	MIR6774	3.84	0.000148	0.0441	0.34	0.2	Neutrophil count;Sum basophil neutrophil counts;	chr16:85911625	chr16:85918347~85918416:+
STAD	cis	rs7589728	1	rs6720809	ENSG00000240671.2	IGKV1-8	3.84	0.000148	0.0441	0.25	0.2	Plasma clusterin levels;	chr2:88229424	chr2:88857361~88992931:-
STAD	cis	rs2404602	0.735	rs11635463	ENSG00000196274.5	Metazoa_SRP	-3.84	0.000148	0.0441	-0.18	-0.2	Blood metabolite levels;	chr15:76470645	chr15:76230048~76230390:-
STAD	cis	rs2404602	0.709	rs11072597	ENSG00000196274.5	Metazoa_SRP	-3.84	0.000148	0.0441	-0.18	-0.2	Blood metabolite levels;	chr15:76471173	chr15:76230048~76230390:-
STAD	cis	rs2404602	0.735	rs11857327	ENSG00000196274.5	Metazoa_SRP	-3.84	0.000148	0.0441	-0.18	-0.2	Blood metabolite levels;	chr15:76471922	chr15:76230048~76230390:-
STAD	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	3.84	0.000148	0.0441	0.24	0.2	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
STAD	cis	rs872863	1	rs4838057	ENSG00000236901.4	MIR600HG	3.84	0.000148	0.0441	0.29	0.2	Myopia (pathological);	chr9:123395081	chr9:123109494~123115477:-
STAD	cis	rs2273156	0.57	rs77477310	ENSG00000258704.4	SRP54-AS1	-3.84	0.000148	0.0441	-0.25	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35146587	chr14:34920858~34982532:-
STAD	cis	rs2562456	0.876	rs7252585	ENSG00000268117.1	VN1R84P	-3.84	0.000148	0.0441	-0.26	-0.2	Pain;	chr19:21475141	chr19:21719801~21720035:-
STAD	cis	rs921665	0.831	rs921666	ENSG00000236760.1	AC019118.3	-3.84	0.000148	0.0441	-0.31	-0.2	World class endurance athleticism;	chr2:3188370	chr2:3131581~3145780:-
STAD	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	3.84	0.000148	0.0441	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
STAD	cis	rs3947	1	rs4839	ENSG00000227888.4	FAM66A	-3.84	0.000148	0.0441	-0.26	-0.2	Blood protein levels;	chr8:11844424	chr8:12362019~12388296:+
STAD	cis	rs10779751	0.734	rs2486920	ENSG00000230337.1	RP4-635E18.6	3.84	0.000148	0.0441	0.26	0.2	Body mass index;	chr1:11064993	chr1:11099675~11102100:+
STAD	cis	rs2243480	1	rs2533288	ENSG00000273448.1	RP11-166O4.6	3.84	0.000148	0.0441	0.25	0.2	Diabetic kidney disease;	chr7:66591724	chr7:67333047~67334383:+
STAD	cis	rs10073892	0.664	rs2895833	ENSG00000250682.4	LINC00491	-3.84	0.000148	0.0441	-0.22	-0.2	Cognitive decline (age-related);	chr5:102544785	chr5:102609156~102671559:-
STAD	cis	rs9907295	1	rs11650409	ENSG00000271013.1	AC015849.15	3.84	0.000148	0.0441	0.31	0.2	Fibroblast growth factor basic levels;	chr17:35907949	chr17:35912635~35918010:-
STAD	cis	rs9463078	0.715	rs7768521	ENSG00000219384.1	RP11-491H9.3	3.84	0.000148	0.0442	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45093201	chr6:45158870~45159511:+
STAD	cis	rs4730250	0.634	rs257371	ENSG00000273320.1	RP11-22N19.2	-3.84	0.000149	0.0442	-0.31	-0.2	Osteoarthritis;	chr7:107154598	chr7:106285480~106286326:+
STAD	cis	rs4730250	0.707	rs257372	ENSG00000273320.1	RP11-22N19.2	-3.84	0.000149	0.0442	-0.31	-0.2	Osteoarthritis;	chr7:107156532	chr7:106285480~106286326:+
STAD	cis	rs7771547	0.642	rs605684	ENSG00000240733.3	RN7SL502P	3.84	0.000149	0.0442	0.18	0.2	Platelet distribution width;	chr6:36525488	chr6:36450912~36451201:-
STAD	cis	rs77861329	1	rs13319566	ENSG00000270941.1	RP5-966M1.5	3.84	0.000149	0.0442	0.4	0.2	Macrophage inflammatory protein 1b levels;	chr3:52061539	chr3:52734735~52735013:+
STAD	cis	rs17818399	0.815	rs17768132	ENSG00000279254.1	RP11-536C12.1	3.84	0.000149	0.0442	0.21	0.2	Height;	chr2:46636110	chr2:46668870~46670778:+
STAD	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-3.84	0.000149	0.0442	-0.26	-0.2	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
STAD	cis	rs755249	0.727	rs16826349	ENSG00000182109.6	RP11-69E11.4	3.84	0.000149	0.0442	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39522280~39546187:-
STAD	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	3.84	0.000149	0.0442	0.24	0.2	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
STAD	cis	rs3764400	0.567	rs12936369	ENSG00000278765.1	RP5-890E16.5	3.84	0.000149	0.0442	0.27	0.2	Body mass index;	chr17:48193334	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs36071506	ENSG00000278765.1	RP5-890E16.5	3.84	0.000149	0.0442	0.27	0.2	Body mass index;	chr17:48202410	chr17:48066704~48067293:-
STAD	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	3.84	0.000149	0.0442	0.2	0.2	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	3.84	0.000149	0.0442	0.2	0.2	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	3.84	0.000149	0.0442	0.2	0.2	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	3.84	0.000149	0.0442	0.2	0.2	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
STAD	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	3.84	0.000149	0.0442	0.2	0.2	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
STAD	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	3.84	0.000149	0.0442	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	3.84	0.000149	0.0442	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	3.84	0.000149	0.0442	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	3.84	0.000149	0.0442	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	3.84	0.000149	0.0442	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
STAD	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	3.84	0.000149	0.0442	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
STAD	cis	rs9876781	1	rs4858793	ENSG00000244380.1	RP11-24C3.2	-3.84	0.000149	0.0442	-0.21	-0.2	Longevity;	chr3:48373517	chr3:48440352~48446656:-
STAD	cis	rs12497850	0.864	rs4955410	ENSG00000225399.4	RP11-3B7.1	3.84	0.000149	0.0442	0.23	0.2	Parkinson's disease;	chr3:49143785	chr3:49260085~49261316:+
STAD	cis	rs7829975	0.681	rs2271342	ENSG00000233609.3	RP11-62H7.2	3.84	0.000149	0.0442	0.22	0.2	Mood instability;	chr8:8786428	chr8:8961200~8979025:+
STAD	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-3.84	0.000149	0.0442	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
STAD	cis	rs12702271	0.78	rs10258523	ENSG00000136275.9	C7orf69	3.84	0.000149	0.0442	0.25	0.2	Male-pattern baldness;	chr7:46915436	chr7:47795291~47819847:+
STAD	cis	rs2518049	0.539	rs10795250	ENSG00000205488.7	CALML3-AS1	3.84	0.000149	0.0442	0.24	0.2	Metabolic traits;	chr10:5122644	chr10:5514244~5526246:-
STAD	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-3.84	0.000149	0.0442	-0.26	-0.2	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
STAD	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-3.84	0.000149	0.0443	-0.25	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
STAD	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-3.84	0.000149	0.0443	-0.25	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
STAD	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-3.84	0.000149	0.0443	-0.25	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
STAD	cis	rs7283707	0.681	rs17241416	ENSG00000228798.1	AP000473.5	-3.84	0.000149	0.0443	-0.32	-0.2	QRS complex (12-leadsum);	chr21:15748072	chr21:16630827~16640683:+
STAD	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-3.84	0.000149	0.0443	-0.25	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
STAD	cis	rs10128251	0.746	rs9424194	ENSG00000232807.2	RP11-536K7.3	-3.84	0.000149	0.0443	-0.24	-0.2	Childhood ear infection;	chr10:5682110	chr10:5934270~5945900:-
STAD	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-3.84	0.000149	0.0443	-0.17	-0.2	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
STAD	cis	rs9316337	1	rs9316337	ENSG00000236953.1	ZDHHC20-IT1	-3.84	0.000149	0.0443	-0.2	-0.2	Schizophrenia;	chr13:21388068	chr13:21376977~21377874:-
STAD	cis	rs6471393	0.964	rs1051914	ENSG00000253848.1	RP11-10N23.5	3.84	0.000149	0.0443	0.24	0.2	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93728838	chr8:93741193~93744534:+
STAD	cis	rs12534093	0.595	rs11767313	ENSG00000234286.1	AC006026.13	-3.84	0.000149	0.0443	-0.35	-0.2	Infant length;Height;	chr7:23544903	chr7:23680195~23680786:-
STAD	cis	rs9928842	1	rs7202566	ENSG00000280152.1	RP11-331F4.5	3.84	0.000149	0.0443	0.29	0.2	Alcoholic chronic pancreatitis;	chr16:75213746	chr16:75245994~75250077:-
STAD	cis	rs75422866	0.51	rs73105845	ENSG00000257433.4	RP1-197B17.3	3.84	0.000149	0.0443	0.61	0.2	Pneumonia;	chr12:47741824	chr12:47706085~47742294:+
STAD	cis	rs883565	0.502	rs4374473	ENSG00000230683.1	DDTP1	3.84	0.000149	0.0443	0.2	0.2	Handedness;	chr3:38901127	chr3:38515448~38515830:-
STAD	cis	rs883565	0.502	rs9839582	ENSG00000230683.1	DDTP1	3.84	0.000149	0.0443	0.2	0.2	Handedness;	chr3:38901629	chr3:38515448~38515830:-
STAD	cis	rs12468226	1	rs16839077	ENSG00000272966.1	RP11-686O6.1	3.84	0.000149	0.0443	0.3	0.2	Urate levels;	chr2:202343970	chr2:202336739~202337200:+
STAD	cis	rs4837502	0.955	rs1927902	ENSG00000228512.2	RP11-281A20.2	-3.83	0.000149	0.0443	-0.29	-0.2	Depressive symptoms (multi-trait analysis);	chr9:117756713	chr9:117783448~117868071:+
STAD	cis	rs7204230	0.538	rs1549041	ENSG00000261291.1	RP11-295M3.2	-3.83	0.000149	0.0443	-0.22	-0.2	Fibrinogen;	chr16:53215720	chr16:53168522~53169450:+
STAD	cis	rs6142102	1	rs6142102	ENSG00000264616.1	MIR4755	3.83	0.000149	0.0443	0.21	0.2	Skin pigmentation;	chr20:34116821	chr20:34049119~34049190:+
STAD	cis	rs7429990	0.895	rs35790549	ENSG00000229759.1	MRPS18AP1	3.83	0.000149	0.0443	0.27	0.2	Educational attainment (years of education);	chr3:48029998	chr3:48256350~48256938:-
STAD	cis	rs9813712	0.78	rs7625942	ENSG00000249846.5	RP11-77P16.4	3.83	0.000149	0.0443	0.28	0.2	Response to amphetamines;	chr3:130232611	chr3:130112550~130120579:+
STAD	cis	rs4218	0.813	rs8036907	ENSG00000259732.1	RP11-59H7.3	-3.83	0.000149	0.0443	-0.24	-0.2	Social communication problems;	chr15:59121144	chr15:59121034~59133250:+
STAD	cis	rs938554	0.779	rs11735831	ENSG00000250613.1	RP11-136I13.1	3.83	0.000149	0.0443	0.22	0.2	Blood metabolite levels;	chr4:9949967	chr4:10410996~10411644:+
STAD	cis	rs938554	0.784	rs11726102	ENSG00000250613.1	RP11-136I13.1	3.83	0.000149	0.0443	0.22	0.2	Blood metabolite levels;	chr4:9950040	chr4:10410996~10411644:+
STAD	cis	rs10129255	1	rs9324091	ENSG00000224373.3	IGHV4-59	3.83	0.000149	0.0443	0.17	0.2	Kawasaki disease;	chr14:106676625	chr14:106627249~106627825:-
STAD	cis	rs10129255	1	rs61997605	ENSG00000224373.3	IGHV4-59	3.83	0.000149	0.0443	0.17	0.2	Kawasaki disease;	chr14:106678368	chr14:106627249~106627825:-
STAD	cis	rs10129255	1	rs8012033	ENSG00000224373.3	IGHV4-59	3.83	0.000149	0.0443	0.17	0.2	Kawasaki disease;	chr14:106678854	chr14:106627249~106627825:-
STAD	cis	rs10129255	0.912	rs8011090	ENSG00000224373.3	IGHV4-59	3.83	0.000149	0.0443	0.17	0.2	Kawasaki disease;	chr14:106678896	chr14:106627249~106627825:-
STAD	cis	rs2898290	0.694	rs2248909	ENSG00000270154.1	RP11-419I17.1	-3.83	0.000149	0.0443	-0.22	-0.2	Systolic blood pressure;	chr8:11534584	chr8:12476462~12477122:+
STAD	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	3.83	0.000149	0.0443	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
STAD	cis	rs27434	0.605	rs152468	ENSG00000248734.2	CTD-2260A17.1	3.83	0.000149	0.0443	0.26	0.2	Ankylosing spondylitis;	chr5:96831833	chr5:96784777~96785999:+
STAD	cis	rs1799810	0.64	rs55998444	ENSG00000200250.1	RNU6-1147P	-3.83	0.000149	0.0444	-0.23	-0.2	Self-rated health;	chr2:127362270	chr2:127316873~127316979:+
STAD	cis	rs9902453	0.817	rs2729435	ENSG00000263477.1	RP11-338L22.2	-3.83	0.000149	0.0444	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29794514	chr17:29863402~29866092:+
STAD	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	3.83	0.00015	0.0444	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	3.83	0.00015	0.0444	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	3.83	0.00015	0.0444	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	3.83	0.00015	0.0444	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
STAD	cis	rs4763879	0.865	rs4763840	ENSG00000256673.1	RP11-599J14.2	3.83	0.00015	0.0444	0.22	0.2	Type 1 diabetes;	chr12:9731814	chr12:9398355~9414851:-
STAD	cis	rs8072100	0.701	rs10163469	ENSG00000264243.1	RP11-6N17.1	-3.83	0.00015	0.0444	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47863342~47865190:+
STAD	cis	rs8072100	0.967	rs3760370	ENSG00000264243.1	RP11-6N17.1	-3.83	0.00015	0.0444	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47863342~47865190:+
STAD	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-3.83	0.00015	0.0444	-0.22	-0.2	Height;	chr2:231549981	chr2:231508426~231514339:-
STAD	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	3.83	0.00015	0.0444	0.3	0.2	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
STAD	cis	rs2638953	0.925	rs11049412	ENSG00000247934.4	RP11-967K21.1	-3.83	0.00015	0.0444	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186199	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs2061758	ENSG00000247934.4	RP11-967K21.1	-3.83	0.00015	0.0444	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186575	chr12:28163298~28190738:-
STAD	cis	rs68170813	0.559	rs7794965	ENSG00000273320.1	RP11-22N19.2	3.83	0.00015	0.0444	0.31	0.2	Coronary artery disease;	chr7:107185994	chr7:106285480~106286326:+
STAD	cis	rs6834538	0.597	rs6822451	ENSG00000234841.4	RP11-119H12.4	-3.83	0.00015	0.0444	-0.22	-0.2	Free thyroxine concentration;	chr4:112542109	chr4:112826307~112827607:+
STAD	cis	rs6834538	0.597	rs1486865	ENSG00000234841.4	RP11-119H12.4	-3.83	0.00015	0.0444	-0.22	-0.2	Free thyroxine concentration;	chr4:112544495	chr4:112826307~112827607:+
STAD	cis	rs2346160	0.867	rs2076005	ENSG00000228648.1	RP11-568A7.2	3.83	0.00015	0.0444	0.22	0.2	Parental extreme longevity (95 years and older);	chr6:167291456	chr6:167241891~167245916:+
STAD	cis	rs2704588	0.505	rs28718401	ENSG00000270720.1	RP11-84C13.2	-3.83	0.00015	0.0444	-0.39	-0.2	Longevity;	chr4:89051438	chr4:89119284~89119871:+
STAD	cis	rs11169552	0.51	rs10876060	ENSG00000200428.1	Y_RNA	3.83	0.00015	0.0445	0.22	0.2	Colorectal cancer;	chr12:50571847	chr12:50743568~50743684:+
STAD	cis	rs73193808	0.95	rs12627426	ENSG00000273017.1	AP000240.9	3.83	0.00015	0.0445	0.21	0.2	Coronary artery disease;	chr21:29147136	chr21:29359002~29359453:+
STAD	cis	rs8012947	0.877	rs12879675	ENSG00000279636.2	LINC00216	-3.83	0.00015	0.0445	-0.2	-0.2	Alcohol consumption in current drinkers;	chr14:58240535	chr14:58288033~58289158:+
STAD	cis	rs8177876	0.658	rs11150337	ENSG00000261838.4	RP11-303E16.6	3.83	0.00015	0.0445	0.39	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81069854~81076598:+
STAD	cis	rs1790761	0.692	rs614080	ENSG00000231793.4	DOC2GP	3.83	0.00015	0.0445	0.23	0.2	Mean corpuscular volume;	chr11:67579816	chr11:67612653~67616257:-
STAD	cis	rs4561483	0.801	rs33637	ENSG00000260224.1	UBL5P4	3.83	0.00015	0.0445	0.2	0.2	Testicular germ cell tumor;	chr16:11896018	chr16:11968508~11968743:-
STAD	cis	rs1876905	0.597	rs354546	ENSG00000271789.1	RP5-1112D6.7	-3.83	0.00015	0.0445	-0.24	-0.2	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111297126~111298510:+
STAD	cis	rs60180747	1	rs16953563	ENSG00000252712.1	SCARNA14	-3.83	0.00015	0.0445	-0.24	-0.2	Testicular germ cell tumor;	chr15:66394432	chr15:66347207~66347342:-
STAD	cis	rs6813195	0.602	rs4146039	ENSG00000243417.1	RP11-555K12.1	-3.83	0.00015	0.0445	-0.21	-0.2	Type 2 diabetes;	chr4:152449955	chr4:152551277~152552364:-
STAD	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	3.83	0.00015	0.0445	0.25	0.2	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
STAD	cis	rs11976180	1	rs1540894	ENSG00000204959.4	ARHGEF34P	3.83	0.00015	0.0445	0.27	0.2	Obesity-related traits;	chr7:144070583	chr7:144272445~144286966:-
STAD	cis	rs9907295	0.748	rs11868785	ENSG00000270977.1	AC015849.16	-3.83	0.00015	0.0445	-0.28	-0.2	Fibroblast growth factor basic levels;	chr17:35812214	chr17:35893707~35911023:-
STAD	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-3.83	0.00015	0.0445	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
STAD	cis	rs4293777	0.774	rs13116570	ENSG00000250896.1	RNPS1P1	3.83	0.00015	0.0445	0.15	0.2	Primary sclerosing cholangitis;	chr4:10726214	chr4:11371975~11372892:+
STAD	cis	rs11098499	0.566	rs7664440	ENSG00000260091.1	RP11-33B1.4	3.83	0.00015	0.0445	0.2	0.2	Corneal astigmatism;	chr4:119657385	chr4:119409333~119410233:+
STAD	cis	rs17818399	0.926	rs35682608	ENSG00000279254.1	RP11-536C12.1	-3.83	0.00015	0.0445	-0.22	-0.2	Height;	chr2:46609403	chr2:46668870~46670778:+
STAD	cis	rs17818399	0.926	rs1824050	ENSG00000279254.1	RP11-536C12.1	-3.83	0.00015	0.0445	-0.22	-0.2	Height;	chr2:46612338	chr2:46668870~46670778:+
STAD	cis	rs17818399	0.926	rs1378764	ENSG00000279254.1	RP11-536C12.1	-3.83	0.00015	0.0445	-0.22	-0.2	Height;	chr2:46612542	chr2:46668870~46670778:+
STAD	cis	rs2243480	1	rs2707844	ENSG00000273448.1	RP11-166O4.6	3.83	0.00015	0.0445	0.25	0.2	Diabetic kidney disease;	chr7:66594522	chr7:67333047~67334383:+
STAD	cis	rs6674176	0.611	rs12737898	ENSG00000271329.1	RP5-891H21.5	3.83	0.00015	0.0445	0.31	0.2	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43941729	chr1:44187943~44189049:-
STAD	cis	rs11638815	0.954	rs11635476	ENSG00000259429.4	UBE2Q2P2	3.83	0.00015	0.0445	0.26	0.2	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82670748	chr15:82355142~82420075:+
STAD	cis	rs12477438	0.52	rs2516830	ENSG00000231822.1	AC019097.7	3.83	0.00015	0.0445	0.21	0.2	Chronic sinus infection;	chr2:99157239	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.52	rs2632283	ENSG00000231822.1	AC019097.7	3.83	0.00015	0.0445	0.21	0.2	Chronic sinus infection;	chr2:99159537	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs2516833	ENSG00000231822.1	AC019097.7	3.83	0.00015	0.0445	0.21	0.2	Chronic sinus infection;	chr2:99160942	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.52	rs2516835	ENSG00000231822.1	AC019097.7	3.83	0.00015	0.0445	0.21	0.2	Chronic sinus infection;	chr2:99162668	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs7608938	ENSG00000231822.1	AC019097.7	3.83	0.00015	0.0445	0.21	0.2	Chronic sinus infection;	chr2:99165763	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs6542868	ENSG00000231822.1	AC019097.7	3.83	0.00015	0.0445	0.21	0.2	Chronic sinus infection;	chr2:99166385	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs6727749	ENSG00000231822.1	AC019097.7	3.83	0.00015	0.0445	0.21	0.2	Chronic sinus infection;	chr2:99177127	chr2:99102018~99102752:+
STAD	cis	rs929354	1	rs8101	ENSG00000224629.1	RP5-1142J19.2	3.83	0.00015	0.0445	0.2	0.2	Body mass index;	chr7:157268780	chr7:157263022~157263229:-
STAD	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	3.83	0.00015	0.0445	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	3.83	0.00015	0.0445	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	3.83	0.00015	0.0445	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
STAD	cis	rs11976180	1	rs2961120	ENSG00000204959.4	ARHGEF34P	3.83	0.00015	0.0445	0.27	0.2	Obesity-related traits;	chr7:144059492	chr7:144272445~144286966:-
STAD	cis	rs11976180	1	rs2951360	ENSG00000204959.4	ARHGEF34P	3.83	0.00015	0.0445	0.27	0.2	Obesity-related traits;	chr7:144060256	chr7:144272445~144286966:-
STAD	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-3.83	0.00015	0.0445	-0.21	-0.2	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
STAD	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-3.83	0.00015	0.0445	-0.21	-0.2	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
STAD	cis	rs4660214	0.724	rs2484751	ENSG00000182109.6	RP11-69E11.4	-3.83	0.00015	0.0445	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39522280~39546187:-
STAD	cis	rs494453	0.922	rs480578	ENSG00000234020.1	CHIAP3	-3.83	0.00015	0.0445	-0.2	-0.2	Osteoporosis-related phenotypes;	chr1:111709839	chr1:111353275~111367409:-
STAD	cis	rs9733	0.596	rs2867300	ENSG00000276103.1	U4	3.83	0.00015	0.0445	0.19	0.2	Tonsillectomy;	chr1:150694514	chr1:150608507~150608623:-
STAD	cis	rs938554	0.779	rs4639073	ENSG00000250613.1	RP11-136I13.1	3.83	0.00015	0.0445	0.23	0.2	Blood metabolite levels;	chr4:9972157	chr4:10410996~10411644:+
STAD	cis	rs238295	0.805	rs6076852	ENSG00000230563.2	RP5-828H9.1	-3.83	0.00015	0.0445	-0.24	-0.2	Occipital cortical area (total cortical area interaction);	chr20:5563856	chr20:5471207~5475182:+
STAD	cis	rs238295	0.766	rs6139762	ENSG00000230563.2	RP5-828H9.1	-3.83	0.00015	0.0445	-0.24	-0.2	Occipital cortical area (total cortical area interaction);	chr20:5566048	chr20:5471207~5475182:+
STAD	cis	rs1005277	0.579	rs2504148	ENSG00000276805.1	RP11-291L22.6	3.83	0.00015	0.0445	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs176886	ENSG00000276805.1	RP11-291L22.6	3.83	0.00015	0.0445	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.557	rs176887	ENSG00000276805.1	RP11-291L22.6	3.83	0.00015	0.0445	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38451030~38451785:+
STAD	cis	rs2823455	0.702	rs75507156	ENSG00000228798.1	AP000473.5	-3.83	0.00015	0.0445	-0.32	-0.2	Panic disorder;	chr21:15760281	chr21:16630827~16640683:+
STAD	cis	rs921665	0.831	rs2242084	ENSG00000236760.1	AC019118.3	-3.83	0.00015	0.0445	-0.32	-0.2	World class endurance athleticism;	chr2:3192269	chr2:3131581~3145780:-
STAD	cis	rs9902453	0.838	rs9646436	ENSG00000263477.1	RP11-338L22.2	3.83	0.00015	0.0445	0.17	0.2	Coffee consumption (cups per day);	chr17:29882041	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.838	rs9646437	ENSG00000263477.1	RP11-338L22.2	3.83	0.00015	0.0445	0.17	0.2	Coffee consumption (cups per day);	chr17:29882047	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.838	rs9646438	ENSG00000263477.1	RP11-338L22.2	3.83	0.00015	0.0445	0.17	0.2	Coffee consumption (cups per day);	chr17:29882073	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.808	rs56216220	ENSG00000263477.1	RP11-338L22.2	3.83	0.00015	0.0445	0.17	0.2	Coffee consumption (cups per day);	chr17:29882164	chr17:29863402~29866092:+
STAD	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-3.83	0.00015	0.0445	-0.27	-0.2	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
STAD	cis	rs7567389	0.74	rs1604817	ENSG00000200250.1	RNU6-1147P	3.83	0.00015	0.0446	0.21	0.2	Self-rated health;	chr2:127242345	chr2:127316873~127316979:+
STAD	cis	rs10511652	0.544	rs10963577	ENSG00000236857.3	RAP1BP1	3.83	0.00015	0.0446	0.21	0.2	Myopia;	chr9:18326281	chr9:18717974~18718526:-
STAD	cis	rs7615952	0.546	rs11711150	ENSG00000171084.14	FAM86JP	3.83	0.00015	0.0446	0.34	0.2	Blood pressure (smoking interaction);	chr3:125596819	chr3:125916620~125930024:+
STAD	cis	rs718433	0.584	rs1002180	ENSG00000211790.2	TRAV8-4	3.83	0.00015	0.0446	0.17	0.2	Intraocular pressure;	chr14:21748768	chr14:21894433~21895030:+
STAD	cis	rs9747201	0.963	rs11077982	ENSG00000281517.1	Metazoa_SRP	-3.83	0.000151	0.0446	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82189501	chr17:81718849~81719095:-
STAD	cis	rs9747201	0.862	rs57596657	ENSG00000281517.1	Metazoa_SRP	-3.83	0.000151	0.0446	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82190102	chr17:81718849~81719095:-
STAD	cis	rs9747201	1	rs58119191	ENSG00000281517.1	Metazoa_SRP	-3.83	0.000151	0.0446	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82197453	chr17:81718849~81719095:-
STAD	cis	rs8141529	0.702	rs469992	ENSG00000226471.5	CTA-292E10.6	3.83	0.000151	0.0446	0.24	0.2	Lymphocyte counts;	chr22:28918911	chr22:28800683~28848559:+
STAD	cis	rs9813712	0.717	rs9835466	ENSG00000249846.5	RP11-77P16.4	3.83	0.000151	0.0446	0.3	0.2	Response to amphetamines;	chr3:130258530	chr3:130112550~130120579:+
STAD	cis	rs867371	0.964	rs7169961	ENSG00000278603.1	RP13-608F4.5	3.83	0.000151	0.0446	0.24	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472203~82472426:+
STAD	cis	rs867371	1	rs6495643	ENSG00000278603.1	RP13-608F4.5	3.83	0.000151	0.0446	0.24	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472203~82472426:+
STAD	cis	rs2351088	0.764	rs76991698	ENSG00000230634.1	RP5-996D20.3	-3.83	0.000151	0.0446	-0.35	-0.2	Tonsillectomy;	chr22:45786978	chr22:46481329~46481760:-
STAD	cis	rs782590	0.643	rs13009906	ENSG00000162997.14	PRORSD1P	3.83	0.000151	0.0446	0.2	0.2	Metabolic syndrome;	chr2:55512298	chr2:55282319~55284522:+
STAD	cis	rs11169552	0.51	rs10876058	ENSG00000200428.1	Y_RNA	3.83	0.000151	0.0447	0.22	0.2	Colorectal cancer;	chr12:50562483	chr12:50743568~50743684:+
STAD	cis	rs11169552	0.51	rs4768852	ENSG00000200428.1	Y_RNA	3.83	0.000151	0.0447	0.22	0.2	Colorectal cancer;	chr12:50566506	chr12:50743568~50743684:+
STAD	cis	rs1949733	0.701	rs2631735	ENSG00000251615.3	RP11-774O3.3	-3.83	0.000151	0.0447	-0.19	-0.2	Response to antineoplastic agents;	chr4:8474391	chr4:8355090~8358338:-
STAD	cis	rs2836974	0.59	rs11911822	ENSG00000238141.2	BRWD1-AS1	-3.83	0.000151	0.0447	-0.21	-0.2	Cognitive function;	chr21:39235917	chr21:39315707~39323218:+
STAD	cis	rs149313	1	rs149313	ENSG00000272109.1	CTD-2260A17.3	3.83	0.000151	0.0447	0.22	0.2	Blood protein levels;	chr5:96734501	chr5:96804353~96806105:+
STAD	cis	rs238295	0.805	rs6116855	ENSG00000230563.2	RP5-828H9.1	3.83	0.000151	0.0447	0.23	0.2	Occipital cortical area (total cortical area interaction);	chr20:5574671	chr20:5471207~5475182:+
STAD	cis	rs7512552	0.809	rs828783	ENSG00000203819.6	HIST2H2BC	3.83	0.000151	0.0447	0.24	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150404501	chr1:149850193~149850772:-
STAD	cis	rs7771547	0.607	rs9348997	ENSG00000240733.3	RN7SL502P	-3.83	0.000151	0.0447	-0.18	-0.2	Platelet distribution width;	chr6:36462783	chr6:36450912~36451201:-
STAD	cis	rs6432852	0.527	rs62177812	ENSG00000229195.1	AC009495.4	-3.83	0.000151	0.0447	-0.23	-0.2	Diabetic kidney disease;	chr2:165918627	chr2:165794857~165846091:-
STAD	cis	rs6693567	0.545	rs6664703	ENSG00000203819.6	HIST2H2BC	3.83	0.000151	0.0447	0.23	0.2	Migraine;	chr1:150486611	chr1:149850193~149850772:-
STAD	cis	rs9902453	0.934	rs7211246	ENSG00000263477.1	RP11-338L22.2	3.83	0.000151	0.0447	0.17	0.2	Coffee consumption (cups per day);	chr17:30158744	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.9	rs12451122	ENSG00000263477.1	RP11-338L22.2	3.83	0.000151	0.0447	0.17	0.2	Coffee consumption (cups per day);	chr17:30159358	chr17:29863402~29866092:+
STAD	cis	rs17507216	0.671	rs28582623	ENSG00000259429.4	UBE2Q2P2	-3.83	0.000151	0.0447	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82577381	chr15:82355142~82420075:+
STAD	cis	rs7429990	0.864	rs11712464	ENSG00000224895.1	VPS26BP1	-3.83	0.000151	0.0447	-0.2	-0.2	Educational attainment (years of education);	chr3:47724057	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs56376646	ENSG00000224895.1	VPS26BP1	-3.83	0.000151	0.0447	-0.2	-0.2	Educational attainment (years of education);	chr3:47732588	chr3:47960327~47961081:-
STAD	cis	rs7429990	0.864	rs11927129	ENSG00000224895.1	VPS26BP1	-3.83	0.000151	0.0447	-0.2	-0.2	Educational attainment (years of education);	chr3:47745413	chr3:47960327~47961081:-
STAD	cis	rs2638953	0.886	rs11049594	ENSG00000247934.4	RP11-967K21.1	3.83	0.000151	0.0447	0.23	0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430368	chr12:28163298~28190738:-
STAD	cis	rs2351088	0.706	rs79630679	ENSG00000230634.1	RP5-996D20.3	-3.83	0.000151	0.0447	-0.33	-0.2	Tonsillectomy;	chr22:45818304	chr22:46481329~46481760:-
STAD	cis	rs9463078	0.683	rs6458412	ENSG00000219384.1	RP11-491H9.3	-3.83	0.000151	0.0447	-0.2	-0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44768097	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.683	rs12215252	ENSG00000219384.1	RP11-491H9.3	-3.83	0.000151	0.0447	-0.2	-0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44768528	chr6:45158870~45159511:+
STAD	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-3.83	0.000151	0.0447	-0.25	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
STAD	cis	rs733592	0.524	rs10875726	ENSG00000226413.2	OR8T1P	-3.83	0.000151	0.0447	-0.22	-0.2	Plateletcrit;	chr12:48032209	chr12:48442030~48442947:-
STAD	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-3.83	0.000151	0.0447	-0.34	-0.2	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
STAD	cis	rs60180747	1	rs79065844	ENSG00000252712.1	SCARNA14	3.83	0.000151	0.0447	0.24	0.2	Testicular germ cell tumor;	chr15:66397773	chr15:66347207~66347342:-
STAD	cis	rs11239930	0.517	rs2477569	ENSG00000278811.3	LINC00624	-3.83	0.000151	0.0447	-0.21	-0.2	AIDS progression;	chr1:147076261	chr1:147258885~147517875:-
STAD	cis	rs1345301	0.518	rs1035131	ENSG00000234389.1	AC007278.3	-3.83	0.000151	0.0447	-0.2	-0.2	Waist circumference;	chr2:102246181	chr2:102438713~102440475:+
STAD	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000151	0.0447	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000151	0.0447	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000151	0.0447	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000151	0.0447	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000151	0.0447	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000151	0.0447	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000151	0.0447	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
STAD	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	3.83	0.000151	0.0447	0.21	0.2	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
STAD	cis	rs755249	0.727	rs2242500	ENSG00000182109.6	RP11-69E11.4	3.83	0.000151	0.0447	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39522280~39546187:-
STAD	cis	rs583583	0.963	rs2236570	ENSG00000238107.1	RP11-495P10.5	3.83	0.000151	0.0447	0.25	0.2	Schizophrenia (negative symptoms);	chr1:147622086	chr1:148295180~148297556:+
STAD	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000151	0.0447	-0.24	-0.2	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000151	0.0447	-0.24	-0.2	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000151	0.0447	-0.24	-0.2	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
STAD	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000151	0.0447	-0.24	-0.2	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
STAD	cis	rs2803122	0.745	rs10123714	ENSG00000232978.2	RP11-146N23.4	-3.83	0.000151	0.0448	-0.17	-0.2	Pulse pressure;	chr9:19231645	chr9:19291337~19292576:-
STAD	cis	rs11098499	0.697	rs35280960	ENSG00000260091.1	RP11-33B1.4	3.83	0.000151	0.0448	0.19	0.2	Corneal astigmatism;	chr4:119335904	chr4:119409333~119410233:+
STAD	cis	rs67311347	0.544	rs7644181	ENSG00000280739.1	EIF1B-AS1	-3.83	0.000151	0.0448	-0.21	-0.2	Renal cell carcinoma;	chr3:40314174	chr3:40173145~40309698:-
STAD	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	3.83	0.000151	0.0448	0.25	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
STAD	cis	rs7283707	0.681	rs78477606	ENSG00000228798.1	AP000473.5	-3.83	0.000151	0.0448	-0.33	-0.2	QRS complex (12-leadsum);	chr21:15757487	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs74712252	ENSG00000228798.1	AP000473.5	-3.83	0.000151	0.0448	-0.33	-0.2	QRS complex (12-leadsum);	chr21:15757921	chr21:16630827~16640683:+
STAD	cis	rs2877649	1	rs9323503	ENSG00000258744.1	RP11-80A15.1	-3.83	0.000151	0.0448	-0.52	-0.2	Smooth-surface caries;	chr14:24466389	chr14:24501594~24508688:+
STAD	cis	rs2877649	1	rs57120899	ENSG00000258744.1	RP11-80A15.1	-3.83	0.000151	0.0448	-0.52	-0.2	Smooth-surface caries;	chr14:24467052	chr14:24501594~24508688:+
STAD	cis	rs2877649	1	rs60777821	ENSG00000258744.1	RP11-80A15.1	-3.83	0.000151	0.0448	-0.52	-0.2	Smooth-surface caries;	chr14:24467107	chr14:24501594~24508688:+
STAD	cis	rs2877649	1	rs10220332	ENSG00000258744.1	RP11-80A15.1	-3.83	0.000151	0.0448	-0.52	-0.2	Smooth-surface caries;	chr14:24468273	chr14:24501594~24508688:+
STAD	cis	rs2877649	1	rs112410718	ENSG00000258744.1	RP11-80A15.1	-3.83	0.000151	0.0448	-0.52	-0.2	Smooth-surface caries;	chr14:24473350	chr14:24501594~24508688:+
STAD	cis	rs3794924	0.925	rs35427815	ENSG00000266521.1	RP11-650P15.1	3.83	0.000151	0.0448	0.37	0.2	Survival in colon cancer;	chr18:31466438	chr18:31496645~31497195:-
STAD	cis	rs3794924	0.925	rs35293326	ENSG00000266521.1	RP11-650P15.1	3.83	0.000151	0.0448	0.37	0.2	Survival in colon cancer;	chr18:31466467	chr18:31496645~31497195:-
STAD	cis	rs1876905	0.569	rs354542	ENSG00000230177.1	RP5-1112D6.4	-3.83	0.000151	0.0448	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111277932~111278742:+
STAD	cis	rs1876905	0.68	rs1216020	ENSG00000230177.1	RP5-1112D6.4	-3.83	0.000151	0.0448	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111277932~111278742:+
STAD	cis	rs1876905	0.569	rs354541	ENSG00000230177.1	RP5-1112D6.4	-3.83	0.000151	0.0448	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111277932~111278742:+
STAD	cis	rs151997	0.925	rs27570	ENSG00000250360.1	CTD-2089N3.1	-3.83	0.000151	0.0448	-0.19	-0.2	Callous-unemotional behaviour;	chr5:50896140	chr5:50965687~50967008:-
STAD	cis	rs8072100	0.967	rs11656855	ENSG00000264243.1	RP11-6N17.1	-3.83	0.000151	0.0448	-0.19	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47863342~47865190:+
STAD	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-3.83	0.000151	0.0448	-0.21	-0.2	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
STAD	cis	rs11976180	1	rs11976180	ENSG00000204959.4	ARHGEF34P	3.83	0.000151	0.0448	0.27	0.2	Obesity-related traits;	chr7:144044487	chr7:144272445~144286966:-
STAD	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	3.83	0.000151	0.0448	0.3	0.2	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
STAD	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-3.83	0.000152	0.0448	-0.31	-0.2	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
STAD	cis	rs2243480	0.901	rs13237344	ENSG00000273448.1	RP11-166O4.6	3.83	0.000152	0.0448	0.25	0.2	Diabetic kidney disease;	chr7:66557269	chr7:67333047~67334383:+
STAD	cis	rs2262909	0.962	rs1526884	ENSG00000213976.4	CTD-2561J22.2	3.83	0.000152	0.0448	0.25	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22120849	chr19:21382865~21387177:+
STAD	cis	rs2957692	0.548	rs1442737	ENSG00000254554.1	RP11-351I24.1	3.83	0.000152	0.0449	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10165828	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs4281477	ENSG00000254554.1	RP11-351I24.1	3.83	0.000152	0.0449	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10185855	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs34683105	ENSG00000254554.1	RP11-351I24.1	3.83	0.000152	0.0449	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10186753	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs4910095	ENSG00000254554.1	RP11-351I24.1	3.83	0.000152	0.0449	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10187621	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs2403292	ENSG00000254554.1	RP11-351I24.1	3.83	0.000152	0.0449	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10191519	chr11:10302657~10303704:-
STAD	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-3.83	0.000152	0.0449	-0.31	-0.2	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
STAD	cis	rs2901460	0.6	rs11691452	ENSG00000229503.1	AC092155.1	-3.83	0.000152	0.0449	-0.17	-0.2	Mean corpuscular volume;	chr2:62187979	chr2:62532583~62533059:-
STAD	cis	rs2901460	0.731	rs11680440	ENSG00000229503.1	AC092155.1	-3.83	0.000152	0.0449	-0.17	-0.2	Mean corpuscular volume;	chr2:62187991	chr2:62532583~62533059:-
STAD	cis	rs7119	0.717	rs16968835	ENSG00000230459.3	RP11-741G21.1	-3.83	0.000152	0.0449	-0.2	-0.2	Type 2 diabetes;	chr15:77441919	chr15:77278465~77278774:+
STAD	cis	rs4243830	1	rs12027598	ENSG00000229519.2	RP11-58A11.2	-3.83	0.000152	0.0449	-0.24	-0.2	Body mass index;	chr1:6540744	chr1:6547905~6548619:+
STAD	cis	rs875971	1	rs10215948	ENSG00000224316.1	RP11-479O9.2	-3.83	0.000152	0.0449	-0.2	-0.2	Aortic root size;	chr7:66282799	chr7:65773620~65802067:+
STAD	cis	rs860295	0.702	rs10908471	ENSG00000225855.5	RUSC1-AS1	3.83	0.000152	0.0449	0.17	0.2	Body mass index;	chr1:155573151	chr1:155316863~155324176:-
STAD	cis	rs860295	0.702	rs10908472	ENSG00000225855.5	RUSC1-AS1	3.83	0.000152	0.0449	0.17	0.2	Body mass index;	chr1:155574465	chr1:155316863~155324176:-
STAD	cis	rs860295	0.702	rs11264383	ENSG00000225855.5	RUSC1-AS1	3.83	0.000152	0.0449	0.17	0.2	Body mass index;	chr1:155575555	chr1:155316863~155324176:-
STAD	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	3.83	0.000152	0.0449	0.29	0.2	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
STAD	cis	rs595244	1	rs363820	ENSG00000259705.1	RP11-227D13.1	-3.83	0.000152	0.0449	-0.33	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48436833	chr15:48645951~48652016:+
STAD	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-3.83	0.000152	0.0449	-0.33	-0.2	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
STAD	cis	rs1395	0.677	rs113353646	ENSG00000234072.1	AC074117.10	-3.83	0.000152	0.0449	-0.18	-0.2	Blood metabolite levels;	chr2:27269806	chr2:27356246~27367622:+
STAD	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-3.83	0.000152	0.0449	-0.21	-0.2	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
STAD	cis	rs9287719	0.649	rs10929677	ENSG00000243819.4	RN7SL832P	3.83	0.000152	0.0449	0.2	0.2	Prostate cancer;	chr2:10577422	chr2:10690344~10692099:+
STAD	cis	rs8177876	0.584	rs2549899	ENSG00000261061.1	RP11-303E16.2	3.83	0.000152	0.0449	0.27	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81030770~81031485:+
STAD	cis	rs10782582	0.546	rs79652169	ENSG00000181227.3	RP4-682C21.2	3.83	0.000152	0.0449	0.21	0.2	Daytime sleep phenotypes;	chr1:75768197	chr1:75743423~75744776:-
STAD	cis	rs7771547	0.642	rs668499	ENSG00000240733.3	RN7SL502P	3.83	0.000152	0.0449	0.18	0.2	Platelet distribution width;	chr6:36528602	chr6:36450912~36451201:-
STAD	cis	rs11673344	0.504	rs6510593	ENSG00000267672.1	CTD-2293H3.1	3.83	0.000152	0.0449	0.19	0.2	Obesity-related traits;	chr19:37143153	chr19:37091341~37092564:+
STAD	cis	rs919433	0.927	rs3843857	ENSG00000231621.1	AC013264.2	3.83	0.000152	0.0449	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197331241	chr2:197197991~197199273:+
STAD	cis	rs4835473	0.932	rs6813011	ENSG00000249741.2	RP11-673E1.3	-3.83	0.000152	0.0449	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143914496	chr4:143911514~143912053:-
STAD	cis	rs13178541	0.81	rs4566785	ENSG00000248211.1	TRPC7-AS1	-3.83	0.000152	0.0449	-0.26	-0.2	IgG glycosylation;	chr5:135774028	chr5:136214048~136222159:+
STAD	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	3.83	0.000152	0.0449	0.23	0.2	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
STAD	cis	rs10789491	0.953	rs1866770	ENSG00000225506.2	CYP4A22-AS1	3.83	0.000152	0.0449	0.29	0.2	Response to hepatitis C treatment;	chr1:46716796	chr1:47096653~47179271:-
STAD	cis	rs9608946	0.957	rs35102600	ENSG00000279159.1	RP3-394A18.1	-3.83	0.000152	0.045	-0.17	-0.2	Red cell distribution width;	chr22:30530334	chr22:29978950~30028236:-
STAD	cis	rs10129255	0.5	rs7159033	ENSG00000211959.2	IGHV4-39	3.83	0.000152	0.045	0.18	0.2	Kawasaki disease;	chr14:106701709	chr14:106421711~106422218:-
STAD	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	3.83	0.000152	0.045	0.32	0.2	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
STAD	cis	rs9291683	0.538	rs11727199	ENSG00000250613.1	RP11-136I13.1	-3.83	0.000152	0.045	-0.19	-0.2	Bone mineral density;	chr4:10034566	chr4:10410996~10411644:+
STAD	cis	rs62400317	0.762	rs12193264	ENSG00000219384.1	RP11-491H9.3	-3.83	0.000152	0.045	-0.23	-0.2	Total body bone mineral density;	chr6:44963056	chr6:45158870~45159511:+
STAD	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	3.83	0.000152	0.045	0.18	0.2	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
STAD	cis	rs6019512	0.525	rs6125554	ENSG00000227431.4	CSE1L-AS1	3.83	0.000152	0.045	0.18	0.2	Intelligence (multi-trait analysis);	chr20:49111570	chr20:49040463~49046044:-
STAD	cis	rs10510102	0.516	rs79528809	ENSG00000226864.1	ATE1-AS1	3.83	0.000152	0.045	0.34	0.2	Breast cancer;	chr10:121980309	chr10:121928312~121951965:+
STAD	cis	rs867371	0.82	rs12443224	ENSG00000278603.1	RP13-608F4.5	3.83	0.000152	0.045	0.23	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82472203~82472426:+
STAD	cis	rs7204230	1	rs62049781	ENSG00000261291.1	RP11-295M3.2	3.83	0.000152	0.045	0.24	0.2	Fibrinogen;	chr16:53249097	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs8052956	ENSG00000261291.1	RP11-295M3.2	3.83	0.000152	0.045	0.24	0.2	Fibrinogen;	chr16:53257632	chr16:53168522~53169450:+
STAD	cis	rs7204230	0.921	rs62049782	ENSG00000261291.1	RP11-295M3.2	3.83	0.000152	0.045	0.24	0.2	Fibrinogen;	chr16:53264471	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62049783	ENSG00000261291.1	RP11-295M3.2	3.83	0.000152	0.045	0.24	0.2	Fibrinogen;	chr16:53264655	chr16:53168522~53169450:+
STAD	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000152	0.045	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
STAD	cis	rs6832769	1	rs11726609	ENSG00000223305.1	RN7SKP30	3.83	0.000152	0.045	0.23	0.2	Personality dimensions;	chr4:55534702	chr4:55540502~55540835:-
STAD	cis	rs12908161	0.853	rs12912342	ENSG00000259295.5	CSPG4P12	3.83	0.000152	0.045	0.28	0.2	Schizophrenia;	chr15:84704985	chr15:85191438~85213905:+
STAD	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	3.83	0.000152	0.045	0.29	0.2	Height;	chr6:109773423	chr6:109382795~109383666:+
STAD	cis	rs9747201	0.962	rs35051180	ENSG00000281517.1	Metazoa_SRP	3.83	0.000152	0.045	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82177170	chr17:81718849~81719095:-
STAD	cis	rs9747201	1	rs56283054	ENSG00000281517.1	Metazoa_SRP	3.83	0.000152	0.045	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82177450	chr17:81718849~81719095:-
STAD	cis	rs6840360	0.642	rs2709838	ENSG00000270265.1	RP11-731D1.4	-3.83	0.000152	0.045	-0.24	-0.2	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151333775~151353224:-
STAD	cis	rs494453	0.736	rs548129	ENSG00000234020.1	CHIAP3	-3.83	0.000152	0.045	-0.2	-0.2	Osteoporosis-related phenotypes;	chr1:111658548	chr1:111353275~111367409:-
STAD	cis	rs2562456	0.516	rs56072098	ENSG00000268119.4	CTD-2561J22.5	-3.83	0.000152	0.045	-0.25	-0.2	Pain;	chr19:21469158	chr19:21444241~21463908:-
STAD	cis	rs9291683	0.609	rs7678012	ENSG00000250613.1	RP11-136I13.1	-3.83	0.000152	0.045	-0.18	-0.2	Bone mineral density;	chr4:9992148	chr4:10410996~10411644:+
STAD	cis	rs7829975	0.501	rs4840353	ENSG00000233609.3	RP11-62H7.2	-3.83	0.000152	0.045	-0.25	-0.2	Mood instability;	chr8:8723060	chr8:8961200~8979025:+
STAD	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-3.83	0.000152	0.045	-0.3	-0.2	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
STAD	cis	rs9291683	0.704	rs11726271	ENSG00000250613.1	RP11-136I13.1	3.83	0.000152	0.045	0.19	0.2	Bone mineral density;	chr4:10096568	chr4:10410996~10411644:+
STAD	cis	rs3811273	1	rs10151596	ENSG00000211816.2	TRAV38-1	-3.83	0.000152	0.045	-0.28	-0.2	Periodontal disease-related phenotypes;	chr14:22255314	chr14:22271968~22272563:+
STAD	cis	rs786425	0.707	rs1969272	ENSG00000247373.3	RP11-486O12.2	-3.83	0.000152	0.045	-0.15	-0.2	Pubertal anthropometrics;	chr12:123685746	chr12:123575891~123585115:-
STAD	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-3.83	0.000152	0.045	-0.31	-0.2	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
STAD	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-3.83	0.000152	0.045	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
STAD	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	3.83	0.000152	0.045	0.25	0.2	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
STAD	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	3.83	0.000152	0.045	0.2	0.2	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
STAD	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	3.83	0.000152	0.045	0.2	0.2	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
STAD	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	3.83	0.000153	0.0451	0.3	0.2	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	3.83	0.000153	0.0451	0.3	0.2	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	3.83	0.000153	0.0451	0.3	0.2	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	3.83	0.000153	0.0451	0.3	0.2	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	3.83	0.000153	0.0451	0.3	0.2	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	3.83	0.000153	0.0451	0.3	0.2	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
STAD	cis	rs7220401	0.521	rs2278217	ENSG00000240074.1	RPL9P30	3.83	0.000153	0.0451	0.17	0.2	Coronary artery disease;	chr17:29577599	chr17:29855759~29856332:+
STAD	cis	rs7220401	0.521	rs11080105	ENSG00000240074.1	RPL9P30	3.83	0.000153	0.0451	0.17	0.2	Coronary artery disease;	chr17:29577693	chr17:29855759~29856332:+
STAD	cis	rs17401966	0.597	rs11121526	ENSG00000199562.1	RNU6-37P	3.83	0.000153	0.0451	0.16	0.2	Hepatocellular carcinoma;	chr1:10191024	chr1:10298966~10299072:+
STAD	cis	rs4792901	0.722	rs12601849	ENSG00000279602.1	CTD-3014M21.1	-3.83	0.000153	0.0451	-0.26	-0.2	Dupuytren's disease;	chr17:43468920	chr17:43360041~43361361:-
STAD	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000153	0.0451	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
STAD	cis	rs997295	0.57	rs60066681	ENSG00000270964.1	RP11-502I4.3	-3.83	0.000153	0.0451	-0.25	-0.2	Motion sickness;	chr15:67515738	chr15:67541072~67542604:-
STAD	cis	rs12549025	0.536	rs9644075	ENSG00000253390.1	CTC-756D1.2	-3.83	0.000153	0.0451	-0.29	-0.2	Reticulocyte fraction of red cells;	chr8:23502448	chr8:23458601~23484971:+
STAD	cis	rs7829975	0.557	rs7816427	ENSG00000253981.4	ALG1L13P	-3.83	0.000153	0.0452	-0.27	-0.2	Mood instability;	chr8:8688374	chr8:8236003~8244667:-
STAD	cis	rs61542988	0.606	rs4722185	ENSG00000228649.7	AC005682.5	3.83	0.000153	0.0452	0.26	0.2	Fibrinogen levels;	chr7:22793092	chr7:22854178~22861579:+
STAD	cis	rs875971	0.545	rs73142233	ENSG00000273142.1	RP11-458F8.4	3.83	0.000153	0.0452	0.19	0.2	Aortic root size;	chr7:66221293	chr7:66902857~66906297:+
STAD	cis	rs9341808	0.754	rs6916405	ENSG00000272129.1	RP11-250B2.6	3.83	0.000153	0.0452	0.22	0.2	Sitting height ratio;	chr6:80314471	chr6:80355424~80356859:+
STAD	cis	rs11723530	0.538	rs12502965	ENSG00000201818.1	RNY4P17	3.83	0.000153	0.0452	0.21	0.2	Myopia (pathological);	chr4:169880873	chr4:169005249~169005344:+
STAD	cis	rs11723530	0.538	rs10010441	ENSG00000201818.1	RNY4P17	3.83	0.000153	0.0452	0.21	0.2	Myopia (pathological);	chr4:169881973	chr4:169005249~169005344:+
STAD	cis	rs8099594	0.666	rs17725481	ENSG00000266696.1	RP11-30L3.2	-3.83	0.000153	0.0452	-0.2	-0.2	Height;	chr18:49460787	chr18:49205912~49208781:+
STAD	cis	rs4972539	0.501	rs2358088	ENSG00000234415.1	RPL5P7	-3.83	0.000153	0.0452	-0.22	-0.2	Parental longevity (mother's age at death);	chr2:173193616	chr2:173871653~173872465:-
STAD	cis	rs2562456	0.917	rs2681389	ENSG00000268119.4	CTD-2561J22.5	-3.83	0.000153	0.0452	-0.26	-0.2	Pain;	chr19:21509773	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.917	rs6511256	ENSG00000268119.4	CTD-2561J22.5	-3.83	0.000153	0.0452	-0.26	-0.2	Pain;	chr19:21510513	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.917	rs2681392	ENSG00000268119.4	CTD-2561J22.5	-3.83	0.000153	0.0452	-0.26	-0.2	Pain;	chr19:21513185	chr19:21444241~21463908:-
STAD	cis	rs11587682	0.806	rs16836143	ENSG00000274963.1	Metazoa_SRP	-3.83	0.000153	0.0452	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150346605	chr1:150568971~150569269:-
STAD	cis	rs10782582	0.593	rs11163967	ENSG00000181227.3	RP4-682C21.2	3.83	0.000153	0.0452	0.21	0.2	Daytime sleep phenotypes;	chr1:75688500	chr1:75743423~75744776:-
STAD	cis	rs7142881	0.76	rs35316258	ENSG00000258648.1	UBE2CP1	-3.83	0.000153	0.0452	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31584215	chr14:30683045~30683598:-
STAD	cis	rs7204230	0.96	rs62048016	ENSG00000261291.1	RP11-295M3.2	3.83	0.000153	0.0452	0.24	0.2	Fibrinogen;	chr16:53154481	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62048018	ENSG00000261291.1	RP11-295M3.2	3.83	0.000153	0.0452	0.24	0.2	Fibrinogen;	chr16:53158519	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62048020	ENSG00000261291.1	RP11-295M3.2	3.83	0.000153	0.0452	0.24	0.2	Fibrinogen;	chr16:53161035	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs12599521	ENSG00000261291.1	RP11-295M3.2	3.83	0.000153	0.0452	0.24	0.2	Fibrinogen;	chr16:53161352	chr16:53168522~53169450:+
STAD	cis	rs10905065	0.735	rs10795347	ENSG00000215267.7	AKR1C7P	-3.83	0.000153	0.0452	-0.27	-0.2	Menopause (age at onset);	chr10:5700114	chr10:5275173~5288470:-
STAD	cis	rs12554020	0.581	rs4255201	ENSG00000227603.1	RP11-165J3.6	3.83	0.000154	0.0453	0.38	0.2	Schizophrenia;	chr9:93401055	chr9:93435332~93437121:-
STAD	cis	rs930421	1	rs930421	ENSG00000226491.1	FTOP1	-3.83	0.000154	0.0453	-0.2	-0.2	Attention deficit hyperactivity disorder;	chr2:42754099	chr2:42797225~42798712:-
STAD	cis	rs10129255	0.879	rs7160512	ENSG00000232216.1	IGHV3-43	3.83	0.000154	0.0453	0.2	0.2	Kawasaki disease;	chr14:106694574	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.879	rs7159157	ENSG00000232216.1	IGHV3-43	3.83	0.000154	0.0453	0.2	0.2	Kawasaki disease;	chr14:106694578	chr14:106470264~106470800:-
STAD	cis	rs3126085	0.935	rs11204951	ENSG00000237975.5	FLG-AS1	-3.83	0.000154	0.0453	-0.28	-0.2	Atopic dermatitis;	chr1:152251928	chr1:152168125~152445456:+
STAD	cis	rs2638953	0.777	rs10843181	ENSG00000247934.4	RP11-967K21.1	-3.83	0.000154	0.0453	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28163298~28190738:-
STAD	cis	rs5753618	0.583	rs5753639	ENSG00000236132.1	CTA-440B3.1	3.83	0.000154	0.0453	0.21	0.2	Colorectal cancer;	chr22:31474414	chr22:31816379~31817491:-
STAD	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	3.83	0.000154	0.0453	0.45	0.2	QT interval;	chr4:75124631	chr4:75081702~75084717:-
STAD	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	3.83	0.000154	0.0453	0.45	0.2	QT interval;	chr4:75125224	chr4:75081702~75084717:-
STAD	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	3.83	0.000154	0.0453	0.45	0.2	QT interval;	chr4:75125677	chr4:75081702~75084717:-
STAD	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	3.83	0.000154	0.0453	0.45	0.2	QT interval;	chr4:75125682	chr4:75081702~75084717:-
STAD	cis	rs6674176	0.551	rs2486006	ENSG00000271329.1	RP5-891H21.5	3.83	0.000154	0.0454	0.3	0.2	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43980962	chr1:44187943~44189049:-
STAD	cis	rs7829975	0.577	rs7816329	ENSG00000254340.1	RP11-10A14.3	-3.83	0.000154	0.0454	-0.27	-0.2	Mood instability;	chr8:8686333	chr8:9141424~9145435:+
STAD	cis	rs6012564	1	rs2024959	ENSG00000227431.4	CSE1L-AS1	3.83	0.000154	0.0454	0.19	0.2	Anger;	chr20:49078854	chr20:49040463~49046044:-
STAD	cis	rs11673344	0.504	rs11666786	ENSG00000267672.1	CTD-2293H3.1	3.83	0.000154	0.0454	0.19	0.2	Obesity-related traits;	chr19:37133947	chr19:37091341~37092564:+
STAD	cis	rs9467773	1	rs9467782	ENSG00000243307.2	POM121L6P	3.83	0.000154	0.0454	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26896952~26898777:+
STAD	cis	rs9467773	0.935	rs9461270	ENSG00000243307.2	POM121L6P	3.83	0.000154	0.0454	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26896952~26898777:+
STAD	cis	rs2638953	0.962	rs11049530	ENSG00000247934.4	RP11-967K21.1	-3.83	0.000154	0.0454	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322220	chr12:28163298~28190738:-
STAD	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	3.83	0.000154	0.0454	0.18	0.2	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
STAD	cis	rs12681366	0.636	rs2921388	ENSG00000253704.1	RP11-267M23.4	3.83	0.000154	0.0454	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94440531	chr8:94553722~94569745:+
STAD	cis	rs679711	0.634	rs612145	ENSG00000214380.4	RP11-457K10.2	3.83	0.000154	0.0454	0.23	0.2	Sleep depth;	chr3:109908877	chr3:109915976~109916940:-
STAD	cis	rs679711	0.601	rs655376	ENSG00000214380.4	RP11-457K10.2	3.83	0.000154	0.0454	0.23	0.2	Sleep depth;	chr3:109910300	chr3:109915976~109916940:-
STAD	cis	rs679711	0.634	rs582946	ENSG00000214380.4	RP11-457K10.2	3.83	0.000154	0.0454	0.23	0.2	Sleep depth;	chr3:109910779	chr3:109915976~109916940:-
STAD	cis	rs679711	0.634	rs581999	ENSG00000214380.4	RP11-457K10.2	3.83	0.000154	0.0454	0.23	0.2	Sleep depth;	chr3:109910975	chr3:109915976~109916940:-
STAD	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	3.83	0.000154	0.0454	0.24	0.2	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
STAD	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	3.83	0.000154	0.0454	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
STAD	cis	rs4950322	0.518	rs4950306	ENSG00000278811.3	LINC00624	3.83	0.000154	0.0454	0.21	0.2	Protein quantitative trait loci;	chr1:147117838	chr1:147258885~147517875:-
STAD	cis	rs7512552	0.803	rs9435997	ENSG00000261716.1	RP11-196G18.22	-3.83	0.000154	0.0454	-0.22	-0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150317053	chr1:149844498~149849024:-
STAD	cis	rs11587682	0.806	rs12726415	ENSG00000274963.1	Metazoa_SRP	-3.83	0.000154	0.0454	-0.21	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150430137	chr1:150568971~150569269:-
STAD	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	3.83	0.000154	0.0454	0.19	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
STAD	cis	rs7617773	0.963	rs6771787	ENSG00000224895.1	VPS26BP1	3.83	0.000154	0.0454	0.21	0.2	Coronary artery disease;	chr3:48152752	chr3:47960327~47961081:-
STAD	cis	rs7617773	1	rs6771889	ENSG00000224895.1	VPS26BP1	3.83	0.000154	0.0454	0.21	0.2	Coronary artery disease;	chr3:48152836	chr3:47960327~47961081:-
STAD	cis	rs7617773	0.823	rs9839446	ENSG00000224895.1	VPS26BP1	3.83	0.000154	0.0454	0.21	0.2	Coronary artery disease;	chr3:48153176	chr3:47960327~47961081:-
STAD	cis	rs7617773	0.823	rs9839447	ENSG00000224895.1	VPS26BP1	3.83	0.000154	0.0454	0.21	0.2	Coronary artery disease;	chr3:48153177	chr3:47960327~47961081:-
STAD	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-3.83	0.000154	0.0454	-0.24	-0.2	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
STAD	cis	rs240993	0.516	rs173286	ENSG00000230177.1	RP5-1112D6.4	-3.83	0.000154	0.0454	-0.21	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111292391	chr6:111277932~111278742:+
STAD	cis	rs7015630	0.657	rs34970073	ENSG00000251136.7	RP11-37B2.1	-3.83	0.000154	0.0455	-0.29	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89825134	chr8:89609409~89757727:-
STAD	cis	rs10129255	0.957	rs10136560	ENSG00000232216.1	IGHV3-43	3.83	0.000154	0.0455	0.21	0.2	Kawasaki disease;	chr14:106787630	chr14:106470264~106470800:-
STAD	cis	rs9902453	0.765	rs2729448	ENSG00000263477.1	RP11-338L22.2	-3.83	0.000154	0.0455	-0.17	-0.2	Coffee consumption (cups per day);	chr17:29764935	chr17:29863402~29866092:+
STAD	cis	rs7680126	0.633	rs2024280	ENSG00000250613.1	RP11-136I13.1	3.83	0.000154	0.0455	0.23	0.2	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10290189	chr4:10410996~10411644:+
STAD	cis	rs1005277	0.579	rs1985707	ENSG00000276805.1	RP11-291L22.6	3.83	0.000154	0.0455	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.557	rs1854563	ENSG00000276805.1	RP11-291L22.6	3.83	0.000154	0.0455	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2505240	ENSG00000276805.1	RP11-291L22.6	3.83	0.000154	0.0455	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.579	rs2505241	ENSG00000276805.1	RP11-291L22.6	3.83	0.000154	0.0455	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38451030~38451785:+
STAD	cis	rs1005277	0.54	rs2224248	ENSG00000276805.1	RP11-291L22.6	3.83	0.000154	0.0455	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38451030~38451785:+
STAD	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	3.83	0.000154	0.0455	0.22	0.2	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	3.83	0.000154	0.0455	0.22	0.2	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
STAD	cis	rs1336472	0.509	rs4916032	ENSG00000234496.2	MRPS21P1	3.83	0.000154	0.0455	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr1:65215939	chr1:65092392~65092614:-
STAD	cis	rs2638953	0.64	rs1511549	ENSG00000247934.4	RP11-967K21.1	-3.83	0.000154	0.0455	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28578968	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.64	rs1511548	ENSG00000247934.4	RP11-967K21.1	-3.83	0.000154	0.0455	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28579057	chr12:28163298~28190738:-
STAD	cis	rs733592	1	rs733592	ENSG00000258273.1	RP11-370I10.4	3.83	0.000155	0.0455	0.24	0.2	Plateletcrit;	chr12:48035993	chr12:48333755~48333901:-
STAD	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-3.83	0.000155	0.0455	-0.27	-0.2	Pain;	chr19:21491155	chr19:21554640~21569237:-
STAD	cis	rs1850744	0.702	rs2077679	ENSG00000163612.10	FAM86KP	3.83	0.000155	0.0455	0.43	0.2	Economic and political preferences;	chr4:9606465	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs1961552	ENSG00000163612.10	FAM86KP	3.83	0.000155	0.0455	0.43	0.2	Economic and political preferences;	chr4:9606682	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs11724183	ENSG00000163612.10	FAM86KP	3.83	0.000155	0.0455	0.43	0.2	Economic and political preferences;	chr4:9608270	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs4974816	ENSG00000163612.10	FAM86KP	3.83	0.000155	0.0455	0.43	0.2	Economic and political preferences;	chr4:9611443	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs4974812	ENSG00000163612.10	FAM86KP	3.83	0.000155	0.0455	0.43	0.2	Economic and political preferences;	chr4:9612974	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.826	rs11735475	ENSG00000163612.10	FAM86KP	3.83	0.000155	0.0455	0.43	0.2	Economic and political preferences;	chr4:9613302	chr4:9153296~9165451:+
STAD	cis	rs17592366	0.941	rs80306194	ENSG00000251726.1	RNU7-41P	-3.83	0.000155	0.0455	-0.28	-0.2	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34873533	chr14:34845300~34845360:-
STAD	cis	rs6772849	0.896	rs4857859	ENSG00000242551.2	POU5F1P6	-3.83	0.000155	0.0455	-0.2	-0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128674735~128677005:-
STAD	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	3.83	0.000155	0.0455	0.24	0.2	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
STAD	cis	rs75920871	0.528	rs12274388	ENSG00000254851.1	RP11-109L13.1	3.83	0.000155	0.0455	0.22	0.2	Subjective well-being;	chr11:117075522	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.528	rs7484045	ENSG00000254851.1	RP11-109L13.1	3.83	0.000155	0.0455	0.22	0.2	Subjective well-being;	chr11:117076174	chr11:117135528~117138582:+
STAD	cis	rs75920871	0.528	rs10082609	ENSG00000254851.1	RP11-109L13.1	3.83	0.000155	0.0455	0.22	0.2	Subjective well-being;	chr11:117078358	chr11:117135528~117138582:+
STAD	cis	rs55704346	0.811	rs11726777	ENSG00000271172.1	RP11-660M5.1	3.83	0.000155	0.0455	0.22	0.2	Tonsillectomy;	chr4:25178165	chr4:25220403~25220913:+
STAD	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	3.83	0.000155	0.0455	0.25	0.2	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
STAD	cis	rs7512552	0.839	rs696616	ENSG00000203819.6	HIST2H2BC	3.83	0.000155	0.0456	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150363697	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs1694369	ENSG00000203819.6	HIST2H2BC	3.83	0.000155	0.0456	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150378625	chr1:149850193~149850772:-
STAD	cis	rs4218	0.543	rs4775110	ENSG00000259732.1	RP11-59H7.3	-3.83	0.000155	0.0456	-0.22	-0.2	Social communication problems;	chr15:59023685	chr15:59121034~59133250:+
STAD	cis	rs559928	0.548	rs11231713	ENSG00000236935.1	AP003774.1	3.83	0.000155	0.0456	0.33	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164377	chr11:64325050~64329504:-
STAD	cis	rs559928	0.593	rs112275221	ENSG00000236935.1	AP003774.1	3.83	0.000155	0.0456	0.33	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64169522	chr11:64325050~64329504:-
STAD	cis	rs8012947	0.916	rs11851552	ENSG00000180189.10	HMGB1P14	3.83	0.000155	0.0456	0.2	0.2	Alcohol consumption in current drinkers;	chr14:58240032	chr14:58284773~58285363:+
STAD	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	3.83	0.000155	0.0456	0.3	0.2	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
STAD	cis	rs4792901	0.759	rs3179927	ENSG00000279602.1	CTD-3014M21.1	-3.83	0.000155	0.0456	-0.27	-0.2	Dupuytren's disease;	chr17:43524543	chr17:43360041~43361361:-
STAD	cis	rs79349575	0.783	rs2112617	ENSG00000248278.1	SUMO2P17	3.83	0.000155	0.0456	0.22	0.2	Type 2 diabetes;	chr17:48899763	chr17:48874860~48908983:-
STAD	cis	rs7915414	0.951	rs1998591	ENSG00000230338.1	MTND4P19	3.83	0.000155	0.0456	0.22	0.2	Clopidogrel active metabolite levels;	chr10:94648221	chr10:94774156~94774633:-
STAD	cis	rs7915414	0.901	rs1998590	ENSG00000230338.1	MTND4P19	3.83	0.000155	0.0456	0.22	0.2	Clopidogrel active metabolite levels;	chr10:94648248	chr10:94774156~94774633:-
STAD	cis	rs6479891	1	rs11814792	ENSG00000235816.3	PRELID1P3	3.83	0.000155	0.0456	0.25	0.2	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63427297~63427939:+
STAD	cis	rs10466239	0.57	rs4627023	ENSG00000230555.2	RP11-517P14.2	3.83	0.000155	0.0456	0.31	0.2	Telomere length;	chr10:43370437	chr10:43420738~43422100:+
STAD	cis	rs210138	0.591	rs6935686	ENSG00000197251.3	LINC00336	3.83	0.000155	0.0456	0.28	0.2	Testicular germ cell tumor;	chr6:33646350	chr6:33586106~33593338:-
STAD	cis	rs875971	0.862	rs778724	ENSG00000224316.1	RP11-479O9.2	3.83	0.000155	0.0456	0.2	0.2	Aortic root size;	chr7:66364304	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs778686	ENSG00000224316.1	RP11-479O9.2	3.83	0.000155	0.0456	0.2	0.2	Aortic root size;	chr7:66370923	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs778684	ENSG00000224316.1	RP11-479O9.2	3.83	0.000155	0.0456	0.2	0.2	Aortic root size;	chr7:66371416	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs778680	ENSG00000224316.1	RP11-479O9.2	3.83	0.000155	0.0456	0.2	0.2	Aortic root size;	chr7:66375427	chr7:65773620~65802067:+
STAD	cis	rs875971	0.862	rs11769079	ENSG00000224316.1	RP11-479O9.2	3.83	0.000155	0.0456	0.2	0.2	Aortic root size;	chr7:66377141	chr7:65773620~65802067:+
STAD	cis	rs4407350	0.682	rs135624	ENSG00000279642.1	RP5-1033E15.3	3.83	0.000155	0.0456	0.2	0.2	Intelligence (multi-trait analysis);	chr22:44494805	chr22:44486295~44486914:-
STAD	cis	rs539514	0.664	rs479824	ENSG00000261105.4	LMO7-AS1	3.83	0.000155	0.0456	0.25	0.2	Type 1 diabetes;	chr13:75734224	chr13:75604700~75635994:-
STAD	cis	rs35851103	0.6	rs4841662	ENSG00000254527.1	ENPP7P12	-3.83	0.000155	0.0456	-0.22	-0.2	Neuroticism;	chr8:11986249	chr8:12205759~12206389:-
STAD	cis	rs7142881	0.787	rs1348352	ENSG00000258648.1	UBE2CP1	-3.83	0.000155	0.0456	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31652786	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs1816815	ENSG00000258648.1	UBE2CP1	-3.83	0.000155	0.0456	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31652885	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs66753375	ENSG00000258648.1	UBE2CP1	-3.83	0.000155	0.0456	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31654815	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs1443144	ENSG00000258648.1	UBE2CP1	-3.83	0.000155	0.0456	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31658244	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs1443143	ENSG00000258648.1	UBE2CP1	-3.83	0.000155	0.0456	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31658331	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs4981876	ENSG00000258648.1	UBE2CP1	-3.83	0.000155	0.0456	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31662067	chr14:30683045~30683598:-
STAD	cis	rs12586317	0.576	rs10143690	ENSG00000241052.1	RP11-173D9.1	-3.82	0.000155	0.0456	-0.19	-0.2	Psoriasis;	chr14:35182739	chr14:35144021~35144480:-
STAD	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-3.82	0.000155	0.0456	-0.21	-0.2	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
STAD	cis	rs875971	0.545	rs10261710	ENSG00000273142.1	RP11-458F8.4	3.82	0.000155	0.0456	0.19	0.2	Aortic root size;	chr7:66249202	chr7:66902857~66906297:+
STAD	cis	rs10129255	0.646	rs55995061	ENSG00000211973.2	IGHV1-69	3.82	0.000155	0.0456	0.19	0.2	Kawasaki disease;	chr14:106799309	chr14:106714684~106715181:-
STAD	cis	rs60180747	1	rs79809053	ENSG00000252712.1	SCARNA14	3.82	0.000155	0.0457	0.24	0.2	Testicular germ cell tumor;	chr15:66460830	chr15:66347207~66347342:-
STAD	cis	rs12477438	0.501	rs13033012	ENSG00000231822.1	AC019097.7	3.82	0.000155	0.0457	0.2	0.2	Chronic sinus infection;	chr2:99178686	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs13000731	ENSG00000231822.1	AC019097.7	3.82	0.000155	0.0457	0.2	0.2	Chronic sinus infection;	chr2:99178768	chr2:99102018~99102752:+
STAD	cis	rs2262909	0.925	rs56073035	ENSG00000279377.1	AC003973.3	-3.82	0.000155	0.0457	-0.2	-0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22093496	chr19:21965708~21968529:-
STAD	cis	rs2262909	0.962	rs73019889	ENSG00000279377.1	AC003973.3	-3.82	0.000155	0.0457	-0.2	-0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22095024	chr19:21965708~21968529:-
STAD	cis	rs9362426	0.551	rs6912282	ENSG00000217776.1	RP11-156F23.2	-3.82	0.000155	0.0457	-0.22	-0.2	Depressive episodes in bipolar disorder;	chr6:87393282	chr6:87070156~87070461:-
STAD	cis	rs7204230	1	rs62049763	ENSG00000261291.1	RP11-295M3.2	3.82	0.000155	0.0457	0.24	0.2	Fibrinogen;	chr16:53219807	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs12596346	ENSG00000261291.1	RP11-295M3.2	3.82	0.000155	0.0457	0.24	0.2	Fibrinogen;	chr16:53220264	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62049766	ENSG00000261291.1	RP11-295M3.2	3.82	0.000155	0.0457	0.24	0.2	Fibrinogen;	chr16:53229442	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62049768	ENSG00000261291.1	RP11-295M3.2	3.82	0.000155	0.0457	0.24	0.2	Fibrinogen;	chr16:53234511	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs62049769	ENSG00000261291.1	RP11-295M3.2	3.82	0.000155	0.0457	0.24	0.2	Fibrinogen;	chr16:53236840	chr16:53168522~53169450:+
STAD	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000156	0.0457	-0.31	-0.2	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
STAD	cis	rs7680126	0.5	rs11735668	ENSG00000250613.1	RP11-136I13.1	3.82	0.000156	0.0457	0.24	0.2	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10147031	chr4:10410996~10411644:+
STAD	cis	rs875971	1	rs6460296	ENSG00000224316.1	RP11-479O9.2	3.82	0.000156	0.0457	0.2	0.2	Aortic root size;	chr7:66430152	chr7:65773620~65802067:+
STAD	cis	rs10028773	0.515	rs9994651	ENSG00000260091.1	RP11-33B1.4	3.82	0.000156	0.0457	0.19	0.2	Educational attainment;	chr4:119666648	chr4:119409333~119410233:+
STAD	cis	rs2574985	0.739	rs3011789	ENSG00000231345.3	BEND3P1	-3.82	0.000156	0.0457	-0.32	-0.2	Subjective well-being;	chr10:50549644	chr10:50655967~50660472:+
STAD	cis	rs950169	0.922	rs67804993	ENSG00000259683.1	RP11-182J1.14	3.82	0.000156	0.0457	0.21	0.2	Schizophrenia;	chr15:84560799	chr15:84389729~84395903:+
STAD	cis	rs6832769	0.925	rs4371676	ENSG00000223305.1	RN7SKP30	3.82	0.000156	0.0457	0.23	0.2	Personality dimensions;	chr4:55462841	chr4:55540502~55540835:-
STAD	cis	rs6832769	1	rs4864998	ENSG00000223305.1	RN7SKP30	3.82	0.000156	0.0457	0.23	0.2	Personality dimensions;	chr4:55466439	chr4:55540502~55540835:-
STAD	cis	rs6832769	0.961	rs2140077	ENSG00000223305.1	RN7SKP30	3.82	0.000156	0.0457	0.23	0.2	Personality dimensions;	chr4:55472786	chr4:55540502~55540835:-
STAD	cis	rs1913185	0.787	rs59850864	ENSG00000240032.1	RP11-274H2.3	-3.82	0.000156	0.0458	-0.29	-0.2	Obesity-related traits;	chr3:146111375	chr3:146066344~146069185:-
STAD	cis	rs61542988	0.797	rs4329182	ENSG00000228649.7	AC005682.5	3.82	0.000156	0.0458	0.25	0.2	Fibrinogen levels;	chr7:22843002	chr7:22854178~22861579:+
STAD	cis	rs61542988	0.756	rs5013587	ENSG00000228649.7	AC005682.5	3.82	0.000156	0.0458	0.25	0.2	Fibrinogen levels;	chr7:22843041	chr7:22854178~22861579:+
STAD	cis	rs2638953	0.924	rs7961407	ENSG00000247934.4	RP11-967K21.1	-3.82	0.000156	0.0458	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7974904	ENSG00000247934.4	RP11-967K21.1	-3.82	0.000156	0.0458	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7974979	ENSG00000247934.4	RP11-967K21.1	-3.82	0.000156	0.0458	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28163298~28190738:-
STAD	cis	rs14027	0.855	rs6983932	ENSG00000279347.1	RP11-85I17.2	3.82	0.000156	0.0458	0.18	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119849840	chr8:119838736~119840385:-
STAD	cis	rs1167827	0.71	rs1167836	ENSG00000278416.1	PMS2L2	3.82	0.000156	0.0458	0.26	0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75344015~75359550:-
STAD	cis	rs7671266	0.616	rs4320137	ENSG00000250613.1	RP11-136I13.1	-3.82	0.000156	0.0458	-0.25	-0.2	Cardiovascular disease risk factors;	chr4:10071345	chr4:10410996~10411644:+
STAD	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	3.82	0.000156	0.0458	0.23	0.2	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
STAD	cis	rs8073060	0.671	rs9894813	ENSG00000267369.1	RP11-1094M14.8	3.82	0.000156	0.0458	0.2	0.2	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35546829	chr17:35498218~35499175:+
STAD	cis	rs6832769	1	rs28670674	ENSG00000223305.1	RN7SKP30	-3.82	0.000156	0.0458	-0.23	-0.2	Personality dimensions;	chr4:55540936	chr4:55540502~55540835:-
STAD	cis	rs10911902	0.643	rs28715477	ENSG00000229739.2	RP11-295K2.3	-3.82	0.000156	0.0458	-0.29	-0.2	Schizophrenia;	chr1:186326392	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs3766707	ENSG00000229739.2	RP11-295K2.3	-3.82	0.000156	0.0458	-0.29	-0.2	Schizophrenia;	chr1:186335955	chr1:186435161~186470291:+
STAD	cis	rs4561483	0.801	rs154148	ENSG00000260224.1	UBL5P4	3.82	0.000156	0.0458	0.2	0.2	Testicular germ cell tumor;	chr16:11862621	chr16:11968508~11968743:-
STAD	cis	rs1876905	0.569	rs354542	ENSG00000272356.1	RP5-1112D6.8	-3.82	0.000156	0.0458	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111309203~111313517:+
STAD	cis	rs1876905	0.68	rs1216020	ENSG00000272356.1	RP5-1112D6.8	-3.82	0.000156	0.0458	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111309203~111313517:+
STAD	cis	rs1876905	0.569	rs354541	ENSG00000272356.1	RP5-1112D6.8	-3.82	0.000156	0.0458	-0.2	-0.2	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111309203~111313517:+
STAD	cis	rs11098499	0.874	rs9995277	ENSG00000250412.1	KLHL2P1	3.82	0.000156	0.0458	0.27	0.2	Corneal astigmatism;	chr4:119187448	chr4:119334329~119378233:+
STAD	cis	rs755249	0.501	rs1889830	ENSG00000182109.6	RP11-69E11.4	-3.82	0.000156	0.0458	-0.24	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39522280~39546187:-
STAD	cis	rs10508774	0.925	rs11008947	ENSG00000273038.2	RP11-479G22.8	3.82	0.000156	0.0458	0.39	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32476487	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs58255751	ENSG00000273038.2	RP11-479G22.8	3.82	0.000156	0.0458	0.39	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32477241	chr10:32887255~32889311:-
STAD	cis	rs860295	0.812	rs11264363	ENSG00000225855.5	RUSC1-AS1	3.82	0.000156	0.0458	0.16	0.2	Body mass index;	chr1:155348517	chr1:155316863~155324176:-
STAD	cis	rs6072091	0.855	rs6016400	ENSG00000273951.1	RP4-620E11.8	3.82	0.000156	0.0458	0.23	0.2	Nose morphology;	chr20:40651414	chr20:41485571~41486225:-
STAD	cis	rs7283707	0.681	rs79071989	ENSG00000228798.1	AP000473.5	-3.82	0.000156	0.0458	-0.33	-0.2	QRS complex (12-leadsum);	chr21:15807837	chr21:16630827~16640683:+
STAD	cis	rs9291683	0.595	rs10939665	ENSG00000250613.1	RP11-136I13.1	-3.82	0.000156	0.0458	-0.19	-0.2	Bone mineral density;	chr4:10036004	chr4:10410996~10411644:+
STAD	cis	rs8014252	0.803	rs7158201	ENSG00000259158.2	ADAM20P1	3.82	0.000156	0.0458	0.27	0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543829	chr14:70468881~70483756:-
STAD	cis	rs17772222	0.606	rs1955598	ENSG00000258789.1	RP11-507K2.3	-3.82	0.000156	0.0458	-0.23	-0.2	Coronary artery calcification;	chr14:88357311	chr14:88551597~88552493:+
STAD	cis	rs7560272	0.564	rs10496190	ENSG00000163016.8	ALMS1P	-3.82	0.000156	0.0458	-0.21	-0.2	Schizophrenia;	chr2:73411695	chr2:73644919~73685576:+
STAD	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	3.82	0.000156	0.0458	0.27	0.2	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
STAD	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	3.82	0.000156	0.0458	0.28	0.2	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
STAD	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	3.82	0.000156	0.0458	0.29	0.2	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
STAD	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	3.82	0.000156	0.0458	0.29	0.2	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
STAD	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-3.82	0.000156	0.0458	-0.29	-0.2	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
STAD	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-3.82	0.000156	0.0458	-0.26	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
STAD	cis	rs2877649	1	rs12323581	ENSG00000258744.1	RP11-80A15.1	-3.82	0.000156	0.0458	-0.52	-0.2	Smooth-surface caries;	chr14:24475358	chr14:24501594~24508688:+
STAD	cis	rs11079159	0.637	rs7218159	ENSG00000263096.1	RP11-515O17.2	-3.82	0.000156	0.0459	-0.33	-0.2	QRS duration;	chr17:55277434	chr17:55271504~55273653:-
STAD	cis	rs4713118	0.866	rs2179094	ENSG00000220721.1	OR1F12	3.82	0.000156	0.0459	0.23	0.2	Parkinson's disease;	chr6:27774046	chr6:28073316~28074233:+
STAD	cis	rs4792901	0.802	rs28636996	ENSG00000279602.1	CTD-3014M21.1	-3.82	0.000156	0.0459	-0.27	-0.2	Dupuytren's disease;	chr17:43495418	chr17:43360041~43361361:-
STAD	cis	rs6068583	0.86	rs56733934	ENSG00000197670.6	RP4-724E16.2	-3.82	0.000156	0.0459	-0.31	-0.2	Colorectal adenoma (advanced);	chr20:53560015	chr20:53552770~53575863:+
STAD	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-3.82	0.000156	0.0459	-0.21	-0.2	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
STAD	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-3.82	0.000156	0.0459	-0.21	-0.2	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
STAD	cis	rs1790761	0.967	rs7110021	ENSG00000231793.4	DOC2GP	-3.82	0.000156	0.0459	-0.24	-0.2	Mean corpuscular volume;	chr11:67486093	chr11:67612653~67616257:-
STAD	cis	rs6946494	0.617	rs2920487	ENSG00000231244.1	PSMC1P3	-3.82	0.000156	0.0459	-0.25	-0.2	Visceral adipose tissue adjusted for BMI;	chr7:135810838	chr7:136713871~136715188:+
STAD	cis	rs8141529	0.748	rs6519766	ENSG00000226471.5	CTA-292E10.6	3.82	0.000156	0.0459	0.23	0.2	Lymphocyte counts;	chr22:28874003	chr22:28800683~28848559:+
STAD	cis	rs7915414	0.585	rs1409657	ENSG00000230338.1	MTND4P19	3.82	0.000156	0.0459	0.25	0.2	Clopidogrel active metabolite levels;	chr10:94654871	chr10:94774156~94774633:-
STAD	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-3.82	0.000156	0.0459	-0.2	-0.2	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
STAD	cis	rs2834188	0.883	rs16997869	ENSG00000272659.1	AP000295.10	3.82	0.000156	0.0459	0.28	0.2	Narcolepsy;	chr21:33324562	chr21:33309491~33310181:+
STAD	cis	rs1144713	0.531	rs1716941	ENSG00000276115.1	RP11-817I4.2	-3.82	0.000156	0.0459	-0.23	-0.2	Obesity-related traits;	chr12:32102160	chr12:32352349~32354144:+
STAD	cis	rs860295	0.812	rs12081192	ENSG00000225855.5	RUSC1-AS1	3.82	0.000156	0.0459	0.16	0.2	Body mass index;	chr1:155768253	chr1:155316863~155324176:-
STAD	cis	rs919433	0.927	rs13032495	ENSG00000231621.1	AC013264.2	3.82	0.000157	0.0459	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197197991~197199273:+
STAD	cis	rs1167827	0.71	rs1167836	ENSG00000232729.6	AC083884.8	-3.82	0.000157	0.0459	-0.14	-0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:74688939~74729001:-
STAD	cis	rs2262909	0.962	rs401424	ENSG00000279377.1	AC003973.3	3.82	0.000157	0.0459	0.2	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22049221	chr19:21965708~21968529:-
STAD	cis	rs8141529	0.748	rs5752826	ENSG00000272858.1	CTA-292E10.8	-3.82	0.000157	0.046	-0.21	-0.2	Lymphocyte counts;	chr22:28873820	chr22:28814914~28815662:+
STAD	cis	rs2957692	0.548	rs11042609	ENSG00000254554.1	RP11-351I24.1	3.82	0.000157	0.046	0.33	0.2	Circulating vasoactive peptide levels;	chr11:10075469	chr11:10302657~10303704:-
STAD	cis	rs7142881	0.815	rs7154174	ENSG00000258648.1	UBE2CP1	-3.82	0.000157	0.046	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31581916	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs17098014	ENSG00000258648.1	UBE2CP1	-3.82	0.000157	0.046	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31583497	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs58110472	ENSG00000258648.1	UBE2CP1	-3.82	0.000157	0.046	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31583772	chr14:30683045~30683598:-
STAD	cis	rs732716	0.785	rs11667543	ENSG00000269318.1	AC007292.3	-3.82	0.000157	0.046	-0.28	-0.2	Mean corpuscular volume;	chr19:4374853	chr19:4356637~4358448:-
STAD	cis	rs6813195	0.554	rs718089	ENSG00000243417.1	RP11-555K12.1	-3.82	0.000157	0.046	-0.2	-0.2	Type 2 diabetes;	chr4:152491242	chr4:152551277~152552364:-
STAD	cis	rs7204230	0.557	rs2216069	ENSG00000261291.1	RP11-295M3.2	3.82	0.000157	0.046	0.22	0.2	Fibrinogen;	chr16:53256677	chr16:53168522~53169450:+
STAD	cis	rs9287719	0.649	rs10207885	ENSG00000243819.4	RN7SL832P	3.82	0.000157	0.046	0.2	0.2	Prostate cancer;	chr2:10593062	chr2:10690344~10692099:+
STAD	cis	rs2739330	0.76	rs1007888	ENSG00000272787.1	KB-226F1.2	-3.82	0.000157	0.046	-0.22	-0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23969211~23969873:+
STAD	cis	rs6946494	0.51	rs58168272	ENSG00000231244.1	PSMC1P3	3.82	0.000157	0.046	0.25	0.2	Visceral adipose tissue adjusted for BMI;	chr7:135820982	chr7:136713871~136715188:+
STAD	cis	rs7615952	0.575	rs35949599	ENSG00000239804.1	RP11-379B18.1	3.82	0.000157	0.046	0.26	0.2	Blood pressure (smoking interaction);	chr3:125825359	chr3:125787888~125788146:-
STAD	cis	rs7142881	0.815	rs12890288	ENSG00000258648.1	UBE2CP1	-3.82	0.000157	0.046	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31631300	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs12890184	ENSG00000258648.1	UBE2CP1	-3.82	0.000157	0.046	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31631394	chr14:30683045~30683598:-
STAD	cis	rs73198271	0.74	rs10094270	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.773	rs66618176	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.694	rs73201840	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.694	rs113694763	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.694	rs115037021	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.694	rs114184516	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.74	rs28521727	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.74	rs28402110	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.74	rs10098636	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.74	rs10112989	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8167819~8226614:-
STAD	cis	rs73198271	0.74	rs10113326	ENSG00000253893.2	FAM85B	3.82	0.000157	0.046	0.3	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8167819~8226614:-
STAD	cis	rs1133146	0.532	rs12460704	ENSG00000238150.1	AC008753.3	3.82	0.000157	0.046	0.21	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr19:53172468	chr19:53775599~53775882:+
STAD	cis	rs9287719	0.649	rs6722126	ENSG00000243819.4	RN7SL832P	3.82	0.000157	0.046	0.2	0.2	Prostate cancer;	chr2:10581516	chr2:10690344~10692099:+
STAD	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-3.82	0.000157	0.046	-0.3	-0.2	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
STAD	cis	rs2574985	0.738	rs3011770	ENSG00000231345.3	BEND3P1	-3.82	0.000157	0.046	-0.3	-0.2	Subjective well-being;	chr10:50511625	chr10:50655967~50660472:+
STAD	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	3.82	0.000157	0.046	0.26	0.2	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
STAD	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	3.82	0.000157	0.046	0.26	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
STAD	cis	rs1707322	1	rs4073847	ENSG00000281133.1	AL355480.3	3.82	0.000157	0.046	0.24	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45580892~45580996:-
STAD	cis	rs7170668	0.93	rs4984581	ENSG00000259348.1	RP11-4G2.1	3.82	0.000157	0.046	0.2	0.2	Motion sickness;	chr15:95472992	chr15:96028089~96046930:-
STAD	cis	rs7520050	0.966	rs12409773	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.046	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45581219~45581321:-
STAD	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-3.82	0.000157	0.046	-0.2	-0.2	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
STAD	cis	rs7119038	0.818	rs6589684	ENSG00000255422.1	AP002954.4	-3.82	0.000157	0.046	-0.26	-0.2	Sjögren's syndrome;	chr11:118740248	chr11:118704607~118750263:+
STAD	cis	rs9399186	1	rs9402819	ENSG00000272189.1	RP3-325F22.5	-3.82	0.000157	0.046	-0.39	-0.2	Pursuit maintenance gain;	chr6:136527032	chr6:136550661~136552554:+
STAD	cis	rs7809950	0.953	rs1468336	ENSG00000238832.1	snoU109	3.82	0.000157	0.046	0.27	0.2	Coronary artery disease;	chr7:107567805	chr7:107603363~107603507:+
STAD	cis	rs7520050	1	rs12410070	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.046	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs12410071	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.046	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45581219~45581321:-
STAD	cis	rs172166	0.637	rs1225592	ENSG00000220721.1	OR1F12	3.82	0.000157	0.0461	0.21	0.2	Cardiac Troponin-T levels;	chr6:28182464	chr6:28073316~28074233:+
STAD	cis	rs172166	0.637	rs1225595	ENSG00000220721.1	OR1F12	3.82	0.000157	0.0461	0.21	0.2	Cardiac Troponin-T levels;	chr6:28183562	chr6:28073316~28074233:+
STAD	cis	rs9733	0.596	rs2275236	ENSG00000276103.1	U4	-3.82	0.000157	0.0461	-0.19	-0.2	Tonsillectomy;	chr1:150697476	chr1:150608507~150608623:-
STAD	cis	rs4792901	0.802	rs55989313	ENSG00000279602.1	CTD-3014M21.1	-3.82	0.000157	0.0461	-0.27	-0.2	Dupuytren's disease;	chr17:43528880	chr17:43360041~43361361:-
STAD	cis	rs4345303	0.772	rs9293778	ENSG00000206592.1	SNORA18	-3.82	0.000157	0.0461	-0.21	-0.2	Interleukin-10 levels;	chr5:79398092	chr5:79220942~79221073:+
STAD	cis	rs4792901	0.802	rs8079750	ENSG00000279602.1	CTD-3014M21.1	-3.82	0.000157	0.0461	-0.27	-0.2	Dupuytren's disease;	chr17:43501129	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.759	rs12601484	ENSG00000279602.1	CTD-3014M21.1	-3.82	0.000157	0.0461	-0.27	-0.2	Dupuytren's disease;	chr17:43501506	chr17:43360041~43361361:-
STAD	cis	rs60180747	1	rs74397736	ENSG00000252712.1	SCARNA14	3.82	0.000157	0.0461	0.23	0.2	Testicular germ cell tumor;	chr15:66409162	chr15:66347207~66347342:-
STAD	cis	rs4664293	0.625	rs4665102	ENSG00000224152.1	AC009506.1	3.82	0.000157	0.0461	0.23	0.2	Monocyte percentage of white cells;	chr2:159666076	chr2:159615296~159617082:+
STAD	cis	rs4763879	0.778	rs9332411	ENSG00000256673.1	RP11-599J14.2	3.82	0.000157	0.0461	0.21	0.2	Type 1 diabetes;	chr12:9681749	chr12:9398355~9414851:-
STAD	cis	rs870825	0.86	rs11132253	ENSG00000249173.4	LINC01093	-3.82	0.000157	0.0461	-0.35	-0.2	Blood protein levels;	chr4:184674318	chr4:184893871~184899454:-
STAD	cis	rs6432852	0.527	rs2217579	ENSG00000229195.1	AC009495.4	-3.82	0.000157	0.0461	-0.23	-0.2	Diabetic kidney disease;	chr2:165937878	chr2:165794857~165846091:-
STAD	cis	rs6686842	0.536	rs11209720	ENSG00000235358.1	RP11-399E6.1	-3.82	0.000157	0.0461	-0.22	-0.2	Height;	chr1:41224745	chr1:41242373~41284861:+
STAD	cis	rs6686842	0.536	rs11209721	ENSG00000235358.1	RP11-399E6.1	-3.82	0.000157	0.0461	-0.22	-0.2	Height;	chr1:41224972	chr1:41242373~41284861:+
STAD	cis	rs36051895	0.622	rs10974952	ENSG00000254017.1	IGHEP2	-3.82	0.000157	0.0461	-0.21	-0.2	Pediatric autoimmune diseases;	chr9:5079828	chr9:5113549~5114804:+
STAD	cis	rs7937127	0.696	rs1001459	ENSG00000254907.1	RP11-484D2.2	3.82	0.000157	0.0461	0.35	0.2	Fibrinogen levels;	chr11:43516986	chr11:43328748~43359296:-
STAD	cis	rs6940638	0.606	rs6456771	ENSG00000243307.2	POM121L6P	-3.82	0.000157	0.0461	-0.24	-0.2	Intelligence (multi-trait analysis);	chr6:27264616	chr6:26896952~26898777:+
STAD	cis	rs9304742	0.854	rs11084211	ENSG00000242779.5	ZNF702P	3.82	0.000157	0.0461	0.27	0.2	Psoriasis;	chr19:52957608	chr19:52968251~53037898:-
STAD	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-3.82	0.000157	0.0461	-0.24	-0.2	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
STAD	cis	rs10911902	0.643	rs16825150	ENSG00000229739.2	RP11-295K2.3	-3.82	0.000157	0.0461	-0.29	-0.2	Schizophrenia;	chr1:186306628	chr1:186435161~186470291:+
STAD	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-3.82	0.000157	0.0461	-0.38	-0.2	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
STAD	cis	rs7520050	0.966	rs6695809	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs11211199	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs4376778	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45581219~45581321:-
STAD	cis	rs1135642	0.57	rs17262010	ENSG00000270244.1	RP11-123J14.4	3.82	0.000157	0.0461	0.42	0.2	Food addiction;	chr4:76938606	chr4:76886029~76886370:-
STAD	cis	rs1135642	0.57	rs77963984	ENSG00000270244.1	RP11-123J14.4	3.82	0.000157	0.0461	0.42	0.2	Food addiction;	chr4:76941347	chr4:76886029~76886370:-
STAD	cis	rs2273156	0.929	rs12894820	ENSG00000258704.4	SRP54-AS1	3.82	0.000157	0.0461	0.23	0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966319	chr14:34920858~34982532:-
STAD	cis	rs6142102	0.923	rs4911379	ENSG00000264616.1	MIR4755	3.82	0.000157	0.0461	0.21	0.2	Skin pigmentation;	chr20:33947499	chr20:34049119~34049190:+
STAD	cis	rs10129255	0.957	rs10140904	ENSG00000224373.3	IGHV4-59	3.82	0.000157	0.0461	0.16	0.2	Kawasaki disease;	chr14:106776558	chr14:106627249~106627825:-
STAD	cis	rs7520050	0.966	rs7539932	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs61783200	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs6680380	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs10890354	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.931	rs6697557	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs6701614	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.933	rs11211203	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45581219~45581321:-
STAD	cis	rs7520050	0.966	rs6672898	ENSG00000280836.1	AL355480.1	3.82	0.000157	0.0461	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45581219~45581321:-
STAD	cis	rs2834188	1	rs2834188	ENSG00000272659.1	AP000295.10	-3.82	0.000158	0.0462	-0.28	-0.2	Narcolepsy;	chr21:33316948	chr21:33309491~33310181:+
STAD	cis	rs2834188	0.961	rs8130807	ENSG00000272659.1	AP000295.10	-3.82	0.000158	0.0462	-0.28	-0.2	Narcolepsy;	chr21:33317708	chr21:33309491~33310181:+
STAD	cis	rs10129255	0.957	rs10136781	ENSG00000224373.3	IGHV4-59	3.82	0.000158	0.0462	0.16	0.2	Kawasaki disease;	chr14:106780451	chr14:106627249~106627825:-
STAD	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	3.82	0.000158	0.0462	0.24	0.2	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
STAD	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-3.82	0.000158	0.0462	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
STAD	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	3.82	0.000158	0.0462	0.37	0.2	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
STAD	cis	rs1790761	0.802	rs2276118	ENSG00000231793.4	DOC2GP	-3.82	0.000158	0.0462	-0.24	-0.2	Mean corpuscular volume;	chr11:67521123	chr11:67612653~67616257:-
STAD	cis	rs1075265	0.933	rs7573491	ENSG00000235937.1	AC008280.1	3.82	0.000158	0.0462	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54029552~54030682:-
STAD	cis	rs1075265	0.933	rs2042143	ENSG00000235937.1	AC008280.1	3.82	0.000158	0.0462	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54029552~54030682:-
STAD	cis	rs66887589	0.807	rs13134517	ENSG00000249244.1	RP11-548H18.2	3.82	0.000158	0.0462	0.25	0.2	Diastolic blood pressure;	chr4:119484107	chr4:119391831~119395335:-
STAD	cis	rs66887589	0.837	rs6534135	ENSG00000249244.1	RP11-548H18.2	3.82	0.000158	0.0462	0.25	0.2	Diastolic blood pressure;	chr4:119485147	chr4:119391831~119395335:-
STAD	cis	rs66887589	0.837	rs7661498	ENSG00000249244.1	RP11-548H18.2	3.82	0.000158	0.0462	0.25	0.2	Diastolic blood pressure;	chr4:119486953	chr4:119391831~119395335:-
STAD	cis	rs9297145	0.585	rs17147666	ENSG00000272950.1	RP11-307C18.1	-3.82	0.000158	0.0462	-0.23	-0.2	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99183834	chr7:98322853~98323430:+
STAD	cis	rs9907295	0.579	rs9899866	ENSG00000270894.1	AC015849.13	3.82	0.000158	0.0462	0.24	0.2	Fibroblast growth factor basic levels;	chr17:35908466	chr17:35818399~35823713:+
STAD	cis	rs11089937	0.626	rs737840	ENSG00000211640.3	IGLV6-57	3.82	0.000158	0.0462	0.16	0.2	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs737841	ENSG00000211640.3	IGLV6-57	3.82	0.000158	0.0462	0.16	0.2	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22195713~22196460:+
STAD	cis	rs9902453	0.935	rs9898424	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000158	0.0462	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30065928	chr17:29863402~29866092:+
STAD	cis	rs792448	0.743	rs351378	ENSG00000212044.2	AL360091.1	3.82	0.000158	0.0462	0.21	0.2	White blood cell count (basophil);	chr1:212251854	chr1:212349978~212350069:+
STAD	cis	rs8012947	0.607	rs1051858	ENSG00000279636.2	LINC00216	3.82	0.000158	0.0462	0.19	0.2	Alcohol consumption in current drinkers;	chr14:58364424	chr14:58288033~58289158:+
STAD	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-3.82	0.000158	0.0462	-0.24	-0.2	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
STAD	cis	rs7015630	0.648	rs16901016	ENSG00000251136.7	RP11-37B2.1	-3.82	0.000158	0.0462	-0.25	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89839916	chr8:89609409~89757727:-
STAD	cis	rs9813712	0.953	rs6782280	ENSG00000253540.4	FAM86HP	3.82	0.000158	0.0462	0.27	0.2	Response to amphetamines;	chr3:130245370	chr3:130099092~130111472:-
STAD	cis	rs8141529	0.748	rs5762874	ENSG00000272858.1	CTA-292E10.8	-3.82	0.000158	0.0462	-0.21	-0.2	Lymphocyte counts;	chr22:28873670	chr22:28814914~28815662:+
STAD	cis	rs2070488	0.775	rs6599204	ENSG00000229589.1	ACVR2B-AS1	3.82	0.000158	0.0462	0.24	0.2	Electrocardiographic conduction measures;	chr3:38484243	chr3:38451027~38454820:-
STAD	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	3.82	0.000158	0.0462	0.21	0.2	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
STAD	cis	rs6693567	0.545	rs6699093	ENSG00000203819.6	HIST2H2BC	-3.82	0.000158	0.0462	-0.23	-0.2	Migraine;	chr1:150467975	chr1:149850193~149850772:-
STAD	cis	rs6693567	0.565	rs6684939	ENSG00000203819.6	HIST2H2BC	-3.82	0.000158	0.0462	-0.23	-0.2	Migraine;	chr1:150468087	chr1:149850193~149850772:-
STAD	cis	rs1005277	0.505	rs200931	ENSG00000099251.13	HSD17B7P2	3.82	0.000158	0.0462	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38356380~38378505:+
STAD	cis	rs2638953	0.924	rs1841962	ENSG00000247934.4	RP11-967K21.1	3.82	0.000158	0.0462	0.22	0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28220919	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.888	rs1871152	ENSG00000247934.4	RP11-967K21.1	3.82	0.000158	0.0462	0.22	0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28226893	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.924	rs7969582	ENSG00000247934.4	RP11-967K21.1	3.82	0.000158	0.0462	0.22	0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28236725	chr12:28163298~28190738:-
STAD	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000158	0.0462	-0.21	-0.2	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
STAD	cis	rs2154319	0.666	rs3845571	ENSG00000235358.1	RP11-399E6.1	-3.82	0.000158	0.0462	-0.22	-0.2	Height;	chr1:41250367	chr1:41242373~41284861:+
STAD	cis	rs9659323	0.65	rs61528304	ENSG00000231365.4	RP11-418J17.1	-3.82	0.000158	0.0462	-0.27	-0.2	Body mass index;	chr1:118920976	chr1:119140396~119275973:+
STAD	cis	rs11089937	0.523	rs4820352	ENSG00000211639.2	IGLV4-60	3.82	0.000158	0.0462	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22189203	chr22:22162199~22162681:+
STAD	cis	rs679711	0.634	rs1520740	ENSG00000214380.4	RP11-457K10.2	3.82	0.000158	0.0462	0.23	0.2	Sleep depth;	chr3:109887924	chr3:109915976~109916940:-
STAD	cis	rs679711	0.634	rs1178859	ENSG00000214380.4	RP11-457K10.2	3.82	0.000158	0.0462	0.23	0.2	Sleep depth;	chr3:109887983	chr3:109915976~109916940:-
STAD	cis	rs679711	0.576	rs1164223	ENSG00000214380.4	RP11-457K10.2	3.82	0.000158	0.0462	0.23	0.2	Sleep depth;	chr3:109889703	chr3:109915976~109916940:-
STAD	cis	rs11089937	0.512	rs13054756	ENSG00000211640.3	IGLV6-57	3.82	0.000158	0.0462	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22195713~22196460:+
STAD	cis	rs2638953	0.924	rs11049475	ENSG00000247934.4	RP11-967K21.1	-3.82	0.000158	0.0462	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28163298~28190738:-
STAD	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-3.82	0.000158	0.0462	-0.26	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
STAD	cis	rs2262909	0.962	rs2017521	ENSG00000279377.1	AC003973.3	3.82	0.000158	0.0462	0.2	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21943336	chr19:21965708~21968529:-
STAD	cis	rs2262909	1	rs2175366	ENSG00000279377.1	AC003973.3	3.82	0.000158	0.0462	0.2	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21945477	chr19:21965708~21968529:-
STAD	cis	rs8012947	0.651	rs74055634	ENSG00000279636.2	LINC00216	3.82	0.000158	0.0463	0.19	0.2	Alcohol consumption in current drinkers;	chr14:58361359	chr14:58288033~58289158:+
STAD	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	3.82	0.000158	0.0463	0.29	0.2	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
STAD	cis	rs6432860	1	rs565348	ENSG00000229195.1	AC009495.4	3.82	0.000158	0.0463	0.24	0.2	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166016789	chr2:165794857~165846091:-
STAD	cis	rs593531	0.513	rs7944333	ENSG00000280269.1	AP000577.2	3.82	0.000158	0.0463	0.21	0.2	Neuroticism;	chr11:74311384	chr11:74204869~74205746:+
STAD	cis	rs7824557	0.606	rs2736270	ENSG00000205879.4	FAM90A2P	3.82	0.000158	0.0463	0.22	0.2	Retinal vascular caliber;	chr8:11335084	chr8:12172202~12178575:-
STAD	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	3.82	0.000158	0.0463	0.25	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
STAD	cis	rs2880765	0.835	rs4281668	ENSG00000259295.5	CSPG4P12	3.82	0.000158	0.0463	0.26	0.2	Coronary artery disease;	chr15:85504055	chr15:85191438~85213905:+
STAD	cis	rs6813195	0.801	rs2054759	ENSG00000243417.1	RP11-555K12.1	-3.82	0.000158	0.0463	-0.2	-0.2	Type 2 diabetes;	chr4:152578838	chr4:152551277~152552364:-
STAD	cis	rs6180	1	rs1345824	ENSG00000250860.1	CTD-2265D6.2	3.82	0.000158	0.0463	0.17	0.2	Height;	chr5:42723960	chr5:42466893~42468300:-
STAD	cis	rs4237845	0.537	rs12312955	ENSG00000273805.1	RP11-620J15.4	-3.82	0.000158	0.0463	-0.23	-0.2	Intelligence (multi-trait analysis);	chr12:57871440	chr12:57894232~57896846:+
STAD	cis	rs73108077	0.736	rs73105954	ENSG00000277692.1	RP11-358N2.2	-3.82	0.000158	0.0463	-0.32	-0.2	Red blood cell density in sickle cell anemia;	chr20:31355903	chr20:32355053~32355734:+
STAD	cis	rs7202877	0.61	rs8053632	ENSG00000261783.1	RP11-252K23.2	-3.82	0.000158	0.0463	-0.32	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75331042	chr16:75379818~75381260:-
STAD	cis	rs1816752	0.837	rs7324645	ENSG00000232858.1	RPL34P27	3.82	0.000158	0.0463	0.12	0.2	Obesity-related traits;	chr13:24426717	chr13:24988577~24988925:-
STAD	cis	rs9907295	0.901	rs4796120	ENSG00000270894.1	AC015849.13	3.82	0.000158	0.0463	0.23	0.2	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35818399~35823713:+
STAD	cis	rs62400317	0.731	rs12214435	ENSG00000219384.1	RP11-491H9.3	-3.82	0.000158	0.0463	-0.23	-0.2	Total body bone mineral density;	chr6:44938980	chr6:45158870~45159511:+
STAD	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000158	0.0464	-0.18	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
STAD	cis	rs12468226	1	rs16839090	ENSG00000272966.1	RP11-686O6.1	3.82	0.000158	0.0464	0.29	0.2	Urate levels;	chr2:202348338	chr2:202336739~202337200:+
STAD	cis	rs7202877	0.656	rs8048677	ENSG00000261783.1	RP11-252K23.2	-3.82	0.000158	0.0464	-0.33	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75358130	chr16:75379818~75381260:-
STAD	cis	rs3805389	0.504	rs62308708	ENSG00000249700.7	SRD5A3-AS1	-3.82	0.000158	0.0464	-0.3	-0.2	Waist-to-hip ratio adjusted for body mass index;	chr4:55626177	chr4:55363971~55395847:-
STAD	cis	rs748404	0.56	rs2255663	ENSG00000275601.1	AC011330.13	3.82	0.000158	0.0464	0.21	0.2	Lung cancer;	chr15:43536810	chr15:43642389~43643023:-
STAD	cis	rs10782582	0.609	rs80059220	ENSG00000181227.3	RP4-682C21.2	3.82	0.000159	0.0464	0.21	0.2	Daytime sleep phenotypes;	chr1:75813427	chr1:75743423~75744776:-
STAD	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-3.82	0.000159	0.0464	-0.25	-0.2	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
STAD	cis	rs9948	0.881	rs7594727	ENSG00000235833.1	AC159540.14	-3.82	0.000159	0.0464	-0.26	-0.2	Erectile dysfunction and prostate cancer treatment;	chr2:96824133	chr2:97523949~97524976:-
STAD	cis	rs4784934	0.569	rs56139189	ENSG00000260186.4	RP11-481J2.2	3.82	0.000159	0.0464	0.23	0.2	QT interval;	chr16:58434186	chr16:58421326~58462470:+
STAD	cis	rs287982	0.611	rs79276033	ENSG00000269973.1	RP11-95D17.1	-3.82	0.000159	0.0464	-0.37	-0.2	Nonsyndromic cleft lip with cleft palate;	chr2:9835868	chr2:9936360~9939590:+
STAD	cis	rs10073892	0.664	rs62369689	ENSG00000250682.4	LINC00491	-3.82	0.000159	0.0464	-0.22	-0.2	Cognitive decline (age-related);	chr5:102531867	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs9327861	ENSG00000250682.4	LINC00491	-3.82	0.000159	0.0464	-0.22	-0.2	Cognitive decline (age-related);	chr5:102532173	chr5:102609156~102671559:-
STAD	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000159	0.0464	-0.34	-0.2	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
STAD	cis	rs219780	0.768	rs219784	ENSG00000233818.1	AP000695.4	3.82	0.000159	0.0464	0.26	0.2	Kidney stones;	chr21:36459569	chr21:36445731~36532408:+
STAD	cis	rs7512552	0.78	rs1260411	ENSG00000203819.6	HIST2H2BC	3.82	0.000159	0.0464	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150409612	chr1:149850193~149850772:-
STAD	cis	rs7937127	0.744	rs11602173	ENSG00000254907.1	RP11-484D2.2	-3.82	0.000159	0.0464	-0.34	-0.2	Fibrinogen levels;	chr11:43460399	chr11:43328748~43359296:-
STAD	cis	rs7589728	0.858	rs79992736	ENSG00000240671.2	IGKV1-8	3.82	0.000159	0.0464	0.23	0.2	Plasma clusterin levels;	chr2:88231056	chr2:88857361~88992931:-
STAD	cis	rs9902453	0.904	rs11080115	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000159	0.0464	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30081052	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.935	rs7220151	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000159	0.0464	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30007692	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.838	rs7217638	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000159	0.0464	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30009754	chr17:29863402~29866092:+
STAD	cis	rs9902453	1	rs9912741	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000159	0.0464	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30032493	chr17:29863402~29866092:+
STAD	cis	rs9902453	1	rs9891871	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000159	0.0464	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30043173	chr17:29863402~29866092:+
STAD	cis	rs9902453	0.967	rs6505155	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000159	0.0464	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30045765	chr17:29863402~29866092:+
STAD	cis	rs9902453	1	rs9890205	ENSG00000263477.1	RP11-338L22.2	-3.82	0.000159	0.0464	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30055686	chr17:29863402~29866092:+
STAD	cis	rs11867934	0.531	rs3803761	ENSG00000226478.3	UPF3AP1	-3.82	0.000159	0.0464	-0.22	-0.2	Diabetic retinopathy;	chr17:17213098	chr17:16745636~16746761:-
STAD	cis	rs61542988	0.532	rs12673996	ENSG00000228649.7	AC005682.5	3.82	0.000159	0.0465	0.26	0.2	Fibrinogen levels;	chr7:22793781	chr7:22854178~22861579:+
STAD	cis	rs7487075	0.93	rs6582656	ENSG00000272963.1	OR7A19P	3.82	0.000159	0.0465	0.19	0.2	Itch intensity from mosquito bite;	chr12:46449633	chr12:46592573~46593305:+
STAD	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	3.82	0.000159	0.0465	0.29	0.2	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
STAD	cis	rs870825	0.616	rs2130393	ENSG00000249173.4	LINC01093	-3.82	0.000159	0.0465	-0.32	-0.2	Blood protein levels;	chr4:184721181	chr4:184893871~184899454:-
STAD	cis	rs870825	0.616	rs4623060	ENSG00000249173.4	LINC01093	-3.82	0.000159	0.0465	-0.32	-0.2	Blood protein levels;	chr4:184721789	chr4:184893871~184899454:-
STAD	cis	rs7683537	0.673	rs1401363	ENSG00000249173.4	LINC01093	-3.82	0.000159	0.0465	-0.32	-0.2	Systemic lupus erythematosus;	chr4:184722708	chr4:184893871~184899454:-
STAD	cis	rs4835473	0.897	rs13135627	ENSG00000249741.2	RP11-673E1.3	3.82	0.000159	0.0465	0.23	0.2	Immature fraction of reticulocytes;	chr4:143691099	chr4:143911514~143912053:-
STAD	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	3.82	0.000159	0.0465	0.26	0.2	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
STAD	cis	rs11098499	0.874	rs17839089	ENSG00000250412.1	KLHL2P1	3.82	0.000159	0.0465	0.27	0.2	Corneal astigmatism;	chr4:119189914	chr4:119334329~119378233:+
STAD	cis	rs11098499	0.874	rs6826823	ENSG00000250412.1	KLHL2P1	3.82	0.000159	0.0465	0.27	0.2	Corneal astigmatism;	chr4:119190943	chr4:119334329~119378233:+
STAD	cis	rs11098499	0.874	rs12509054	ENSG00000250412.1	KLHL2P1	3.82	0.000159	0.0465	0.27	0.2	Corneal astigmatism;	chr4:119193920	chr4:119334329~119378233:+
STAD	cis	rs11098499	0.874	rs10022508	ENSG00000250412.1	KLHL2P1	3.82	0.000159	0.0465	0.27	0.2	Corneal astigmatism;	chr4:119194073	chr4:119334329~119378233:+
STAD	cis	rs11098499	0.874	rs12502503	ENSG00000250412.1	KLHL2P1	3.82	0.000159	0.0465	0.27	0.2	Corneal astigmatism;	chr4:119195100	chr4:119334329~119378233:+
STAD	cis	rs10129255	0.957	rs10140904	ENSG00000232216.1	IGHV3-43	3.82	0.000159	0.0465	0.2	0.2	Kawasaki disease;	chr14:106776558	chr14:106470264~106470800:-
STAD	cis	rs4561483	0.734	rs33655	ENSG00000260224.1	UBL5P4	3.82	0.000159	0.0465	0.2	0.2	Testicular germ cell tumor;	chr16:11876524	chr16:11968508~11968743:-
STAD	cis	rs8141529	0.719	rs9625619	ENSG00000272858.1	CTA-292E10.8	-3.82	0.000159	0.0465	-0.22	-0.2	Lymphocyte counts;	chr22:28876340	chr22:28814914~28815662:+
STAD	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-3.82	0.000159	0.0465	-0.24	-0.2	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
STAD	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-3.82	0.000159	0.0465	-0.24	-0.2	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
STAD	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-3.82	0.000159	0.0465	-0.24	-0.2	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
STAD	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-3.82	0.000159	0.0465	-0.2	-0.2	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
STAD	cis	rs9608946	1	rs13750	ENSG00000279159.1	RP3-394A18.1	-3.82	0.000159	0.0465	-0.17	-0.2	Red cell distribution width;	chr22:30489113	chr22:29978950~30028236:-
STAD	cis	rs9420	0.528	rs11229075	ENSG00000265566.2	RN7SL605P	-3.82	0.000159	0.0465	-0.29	-0.2	Schizophrenia;	chr11:57623550	chr11:57528085~57528365:-
STAD	cis	rs7975161	0.58	rs10735393	ENSG00000257999.1	RP11-61E11.2	3.82	0.000159	0.0465	0.35	0.2	Toenail selenium levels;	chr12:104286883	chr12:105102472~105107179:-
STAD	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-3.82	0.000159	0.0465	-0.28	-0.2	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
STAD	cis	rs9907295	0.901	rs9907121	ENSG00000271013.1	AC015849.15	-3.82	0.000159	0.0465	-0.31	-0.2	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.901	rs4796118	ENSG00000271013.1	AC015849.15	-3.82	0.000159	0.0465	-0.31	-0.2	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35912635~35918010:-
STAD	cis	rs9907295	0.901	rs9914401	ENSG00000271013.1	AC015849.15	-3.82	0.000159	0.0465	-0.31	-0.2	Fibroblast growth factor basic levels;	chr17:35861810	chr17:35912635~35918010:-
STAD	cis	rs6479891	0.778	rs7896676	ENSG00000235816.3	PRELID1P3	-3.82	0.000159	0.0465	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63427297~63427939:+
STAD	cis	rs6479891	0.915	rs7896677	ENSG00000235816.3	PRELID1P3	-3.82	0.000159	0.0465	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63427297~63427939:+
STAD	cis	rs7617773	1	rs6442109	ENSG00000224895.1	VPS26BP1	3.82	0.000159	0.0466	0.21	0.2	Coronary artery disease;	chr3:48151491	chr3:47960327~47961081:-
STAD	cis	rs7617773	1	rs11711766	ENSG00000224895.1	VPS26BP1	3.82	0.000159	0.0466	0.21	0.2	Coronary artery disease;	chr3:48151680	chr3:47960327~47961081:-
STAD	cis	rs11089937	0.616	rs4991801	ENSG00000211639.2	IGLV4-60	3.82	0.000159	0.0466	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22178958	chr22:22162199~22162681:+
STAD	cis	rs1577917	0.687	rs34618171	ENSG00000234155.1	RP11-30P6.6	3.82	0.000159	0.0466	0.28	0.2	Response to antipsychotic treatment;	chr6:86101447	chr6:85387219~85390186:-
STAD	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	3.82	0.000159	0.0466	0.24	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
STAD	cis	rs7142881	0.697	rs1545276	ENSG00000258648.1	UBE2CP1	-3.82	0.000159	0.0466	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31652711	chr14:30683045~30683598:-
STAD	cis	rs7915414	0.901	rs34870400	ENSG00000230338.1	MTND4P19	3.82	0.000159	0.0466	0.23	0.2	Clopidogrel active metabolite levels;	chr10:94675066	chr10:94774156~94774633:-
STAD	cis	rs7142881	0.815	rs2378895	ENSG00000258648.1	UBE2CP1	-3.82	0.000159	0.0466	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31588613	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.844	rs8013916	ENSG00000258648.1	UBE2CP1	-3.82	0.000159	0.0466	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31597701	chr14:30683045~30683598:-
STAD	cis	rs860295	1	rs10908482	ENSG00000203761.5	MSTO2P	-3.82	0.000159	0.0466	-0.17	-0.2	Body mass index;	chr1:155744082	chr1:155745829~155750137:+
STAD	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000159	0.0466	-0.31	-0.2	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
STAD	cis	rs4821940	0.84	rs138036	ENSG00000272834.1	RP5-1042K10.13	3.82	0.000159	0.0466	0.2	0.2	Chronotype;Morning vs. evening chronotype;	chr22:40223775	chr22:40415003~40415445:+
STAD	cis	rs9928842	0.882	rs6564241	ENSG00000280152.1	RP11-331F4.5	3.82	0.000159	0.0466	0.31	0.2	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75245994~75250077:-
STAD	cis	rs3126085	0.935	rs4845429	ENSG00000237975.5	FLG-AS1	-3.82	0.000159	0.0466	-0.28	-0.2	Atopic dermatitis;	chr1:152252900	chr1:152168125~152445456:+
STAD	cis	rs9535307	0.929	rs1581745	ENSG00000223676.1	RPL34P26	3.82	0.000159	0.0466	0.24	0.2	Obesity-related traits;	chr13:49756821	chr13:50361410~50361763:-
STAD	cis	rs4792901	0.722	rs35714338	ENSG00000279602.1	CTD-3014M21.1	-3.82	0.000159	0.0466	-0.27	-0.2	Dupuytren's disease;	chr17:43536845	chr17:43360041~43361361:-
STAD	cis	rs8177876	0.749	rs2549896	ENSG00000261838.4	RP11-303E16.6	-3.82	0.000159	0.0466	-0.35	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054334	chr16:81069854~81076598:+
STAD	cis	rs7208859	0.725	rs9891656	ENSG00000263603.1	CTD-2349P21.5	-3.82	0.000159	0.0466	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30729469~30731202:+
STAD	cis	rs10129255	0.5	rs10142931	ENSG00000232216.1	IGHV3-43	3.82	0.000159	0.0466	0.18	0.2	Kawasaki disease;	chr14:106782288	chr14:106470264~106470800:-
STAD	cis	rs9467773	1	rs1321480	ENSG00000243307.2	POM121L6P	3.82	0.000159	0.0466	0.2	0.2	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26896952~26898777:+
STAD	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	3.82	0.000159	0.0466	0.25	0.2	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
STAD	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	3.82	0.000159	0.0466	0.25	0.2	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
STAD	cis	rs4474258	0.53	rs1341644	ENSG00000244433.2	PGBD4P7	3.82	0.000159	0.0466	0.21	0.2	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);	chr1:94642776	chr1:94672918~94674161:-
STAD	cis	rs1816752	0.905	rs7991450	ENSG00000232858.1	RPL34P27	3.82	0.00016	0.0466	0.12	0.2	Obesity-related traits;	chr13:24425898	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.774	rs7986162	ENSG00000232858.1	RPL34P27	3.82	0.00016	0.0466	0.12	0.2	Obesity-related traits;	chr13:24425941	chr13:24988577~24988925:-
STAD	cis	rs1850744	1	rs2280208	ENSG00000250268.3	ALG1L14P	-3.82	0.00016	0.0466	-0.42	-0.2	Economic and political preferences;	chr4:9798419	chr4:9166297~9170270:-
STAD	cis	rs1850744	1	rs938556	ENSG00000250268.3	ALG1L14P	-3.82	0.00016	0.0466	-0.42	-0.2	Economic and political preferences;	chr4:9800742	chr4:9166297~9170270:-
STAD	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-3.82	0.00016	0.0466	-0.24	-0.2	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
STAD	cis	rs1790761	0.501	rs4930210	ENSG00000231793.4	DOC2GP	-3.82	0.00016	0.0466	-0.24	-0.2	Mean corpuscular volume;	chr11:67637255	chr11:67612653~67616257:-
STAD	cis	rs1876905	0.68	rs1215848	ENSG00000271789.1	RP5-1112D6.7	-3.82	0.00016	0.0466	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111297126~111298510:+
STAD	cis	rs1876905	0.68	rs402940	ENSG00000271789.1	RP5-1112D6.7	-3.82	0.00016	0.0466	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111297126~111298510:+
STAD	cis	rs9652601	0.959	rs741172	ENSG00000274038.1	RP11-66H6.4	-3.82	0.00016	0.0466	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11106941	chr16:11056556~11057034:+
STAD	cis	rs11676348	0.791	rs4133195	ENSG00000237281.1	CATIP-AS2	-3.82	0.00016	0.0467	-0.2	-0.2	Ulcerative colitis;	chr2:218086522	chr2:218326889~218357966:-
STAD	cis	rs2957692	0.548	rs12360783	ENSG00000254554.1	RP11-351I24.1	3.82	0.00016	0.0467	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10163818	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.548	rs7945980	ENSG00000254554.1	RP11-351I24.1	3.82	0.00016	0.0467	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10179698	chr11:10302657~10303704:-
STAD	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	3.82	0.00016	0.0467	0.32	0.2	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
STAD	cis	rs4948102	0.642	rs766333	ENSG00000226278.1	PSPHP1	-3.82	0.00016	0.0467	-0.23	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55764797~55773288:+
STAD	cis	rs7651446	0.85	rs62277159	ENSG00000240875.4	LINC00886	-3.82	0.00016	0.0467	-0.48	-0.2	Ovarian cancer;Epithelial ovarian cancer;	chr3:156808293	chr3:156747346~156817062:-
STAD	cis	rs2562456	0.917	rs6511253	ENSG00000268117.1	VN1R84P	-3.82	0.00016	0.0467	-0.27	-0.2	Pain;	chr19:21495996	chr19:21719801~21720035:-
STAD	cis	rs5758659	0.652	rs133336	ENSG00000182057.4	OGFRP1	3.82	0.00016	0.0467	0.21	0.2	Cognitive function;	chr22:42020299	chr22:42269753~42275196:+
STAD	cis	rs6813195	0.622	rs10023327	ENSG00000243417.1	RP11-555K12.1	-3.82	0.00016	0.0467	-0.2	-0.2	Type 2 diabetes;	chr4:152570890	chr4:152551277~152552364:-
STAD	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-3.82	0.00016	0.0467	-0.2	-0.2	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
STAD	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-3.82	0.00016	0.0467	-0.2	-0.2	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
STAD	cis	rs7829975	0.517	rs12542733	ENSG00000233609.3	RP11-62H7.2	-3.82	0.00016	0.0467	-0.23	-0.2	Mood instability;	chr8:8967348	chr8:8961200~8979025:+
STAD	cis	rs2446066	0.591	rs11170517	ENSG00000257379.1	RP11-793H13.8	3.82	0.00016	0.0467	0.41	0.2	Red blood cell count;	chr12:53360125	chr12:53441741~53467528:+
STAD	cis	rs1577917	0.559	rs2223788	ENSG00000234155.1	RP11-30P6.6	3.82	0.00016	0.0467	0.27	0.2	Response to antipsychotic treatment;	chr6:86102202	chr6:85387219~85390186:-
STAD	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-3.82	0.00016	0.0467	-0.25	-0.2	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
STAD	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-3.82	0.00016	0.0467	-0.25	-0.2	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
STAD	cis	rs583583	0.78	rs2275552	ENSG00000231196.3	RP11-495P10.8	3.82	0.00016	0.0467	0.26	0.2	Schizophrenia (negative symptoms);	chr1:147659830	chr1:148290890~148295859:-
STAD	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	3.82	0.00016	0.0467	0.27	0.2	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
STAD	cis	rs1043099	0.549	rs9608904	ENSG00000222915.1	RNU6-564P	3.82	0.00016	0.0467	0.28	0.2	Rheumatoid arthritis;	chr22:30412772	chr22:30421045~30421148:+
STAD	cis	rs875971	1	rs6979382	ENSG00000224316.1	RP11-479O9.2	3.82	0.00016	0.0467	0.2	0.2	Aortic root size;	chr7:66421388	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs6961990	ENSG00000224316.1	RP11-479O9.2	3.82	0.00016	0.0467	0.2	0.2	Aortic root size;	chr7:66423583	chr7:65773620~65802067:+
STAD	cis	rs763121	0.813	rs2179143	ENSG00000280859.1	AL022326.1	-3.82	0.00016	0.0467	-0.23	-0.2	Menopause (age at onset);	chr22:38641979	chr22:39319019~39319147:-
STAD	cis	rs1850744	0.702	rs78422890	ENSG00000163612.10	FAM86KP	3.82	0.00016	0.0467	0.42	0.2	Economic and political preferences;	chr4:9599141	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs11735905	ENSG00000163612.10	FAM86KP	3.82	0.00016	0.0467	0.42	0.2	Economic and political preferences;	chr4:9600133	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs73802912	ENSG00000163612.10	FAM86KP	3.82	0.00016	0.0467	0.42	0.2	Economic and political preferences;	chr4:9600873	chr4:9153296~9165451:+
STAD	cis	rs1850744	0.702	rs73802915	ENSG00000163612.10	FAM86KP	3.82	0.00016	0.0467	0.42	0.2	Economic and political preferences;	chr4:9601576	chr4:9153296~9165451:+
STAD	cis	rs6467136	0.765	rs4731370	ENSG00000273184.1	RP11-212P7.3	3.82	0.00016	0.0467	0.25	0.2	Type 2 diabetes;	chr7:127570153	chr7:128455840~128493859:+
STAD	cis	rs10197862	0.518	rs35181686	ENSG00000234389.1	AC007278.3	3.82	0.00016	0.0467	0.23	0.2	Asthma and hay fever;Asthma;	chr2:102476125	chr2:102438713~102440475:+
STAD	cis	rs8141529	0.748	rs715531	ENSG00000272858.1	CTA-292E10.8	-3.82	0.00016	0.0467	-0.22	-0.2	Lymphocyte counts;	chr22:28886691	chr22:28814914~28815662:+
STAD	cis	rs2436845	0.934	rs2679758	ENSG00000253263.1	KB-1507C5.3	-3.82	0.00016	0.0467	-0.2	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102858978	chr8:102891876~102893608:+
STAD	cis	rs2436845	0.934	rs892485	ENSG00000253263.1	KB-1507C5.3	-3.82	0.00016	0.0467	-0.2	-0.2	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102862394	chr8:102891876~102893608:+
STAD	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	3.82	0.00016	0.0468	0.24	0.2	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
STAD	cis	rs11673344	0.504	rs12984458	ENSG00000267672.1	CTD-2293H3.1	-3.82	0.00016	0.0468	-0.18	-0.2	Obesity-related traits;	chr19:37138189	chr19:37091341~37092564:+
STAD	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	3.82	0.00016	0.0468	0.3	0.2	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
STAD	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	3.82	0.00016	0.0468	0.3	0.2	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
STAD	cis	rs6496044	0.548	rs7163032	ENSG00000259295.5	CSPG4P12	3.82	0.00016	0.0468	0.25	0.2	Interstitial lung disease;	chr15:85529188	chr15:85191438~85213905:+
STAD	cis	rs6496044	0.527	rs7163068	ENSG00000259295.5	CSPG4P12	3.82	0.00016	0.0468	0.25	0.2	Interstitial lung disease;	chr15:85529235	chr15:85191438~85213905:+
STAD	cis	rs12468226	0.938	rs116601501	ENSG00000272966.1	RP11-686O6.1	3.82	0.00016	0.0468	0.3	0.2	Urate levels;	chr2:202274567	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs80282360	ENSG00000272966.1	RP11-686O6.1	3.82	0.00016	0.0468	0.3	0.2	Urate levels;	chr2:202275121	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs76658848	ENSG00000272966.1	RP11-686O6.1	3.82	0.00016	0.0468	0.3	0.2	Urate levels;	chr2:202275548	chr2:202336739~202337200:+
STAD	cis	rs6832769	0.961	rs13138697	ENSG00000223305.1	RN7SKP30	3.82	0.00016	0.0468	0.23	0.2	Personality dimensions;	chr4:55497142	chr4:55540502~55540835:-
STAD	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-3.82	0.00016	0.0468	-0.21	-0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
STAD	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	3.82	0.00016	0.0468	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
STAD	cis	rs2574985	0.739	rs2983359	ENSG00000231345.3	BEND3P1	-3.82	0.00016	0.0468	-0.32	-0.2	Subjective well-being;	chr10:50541899	chr10:50655967~50660472:+
STAD	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	3.82	0.00016	0.0468	0.26	0.2	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
STAD	cis	rs9472414	0.66	rs13209827	ENSG00000183239.5	RP5-1120P11.4	-3.82	0.00016	0.0468	-0.23	-0.2	Height;	chr6:45030895	chr6:44089242~44089696:-
STAD	cis	rs238295	0.805	rs1056244	ENSG00000230563.2	RP5-828H9.1	3.82	0.00016	0.0468	0.23	0.2	Occipital cortical area (total cortical area interaction);	chr20:5570388	chr20:5471207~5475182:+
STAD	cis	rs867371	0.502	rs2047679	ENSG00000259429.4	UBE2Q2P2	-3.82	0.00016	0.0468	-0.22	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82355142~82420075:+
STAD	cis	rs11976180	1	rs11975942	ENSG00000204959.4	ARHGEF34P	3.82	0.00016	0.0468	0.27	0.2	Obesity-related traits;	chr7:144043487	chr7:144272445~144286966:-
STAD	cis	rs10911902	0.643	rs74537283	ENSG00000229739.2	RP11-295K2.3	-3.82	0.00016	0.0468	-0.29	-0.2	Schizophrenia;	chr1:186328038	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.643	rs3736597	ENSG00000229739.2	RP11-295K2.3	-3.82	0.00016	0.0468	-0.29	-0.2	Schizophrenia;	chr1:186331918	chr1:186435161~186470291:+
STAD	cis	rs4237845	0.514	rs4760339	ENSG00000273805.1	RP11-620J15.4	-3.82	0.00016	0.0468	-0.23	-0.2	Intelligence (multi-trait analysis);	chr12:57874366	chr12:57894232~57896846:+
STAD	cis	rs2880765	0.546	rs35316253	ENSG00000259295.5	CSPG4P12	3.82	0.00016	0.0468	0.28	0.2	Coronary artery disease;	chr15:85522329	chr15:85191438~85213905:+
STAD	cis	rs858239	0.899	rs10262243	ENSG00000230042.1	AK3P3	-3.82	0.000161	0.0468	-0.22	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23129178~23129841:+
STAD	cis	rs2351088	0.536	rs17574591	ENSG00000230634.1	RP5-996D20.3	-3.82	0.000161	0.0468	-0.3	-0.2	Tonsillectomy;	chr22:45780034	chr22:46481329~46481760:-
STAD	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	3.82	0.000161	0.0469	0.27	0.2	Pain;	chr19:21568976	chr19:21554640~21569237:-
STAD	cis	rs7615952	0.673	rs16834637	ENSG00000242229.1	RPS3AP14	3.82	0.000161	0.0469	0.35	0.2	Blood pressure (smoking interaction);	chr3:125886628	chr3:125795106~125795885:+
STAD	cis	rs1144713	0.743	rs2668273	ENSG00000223722.3	RP11-467L13.5	-3.82	0.000161	0.0469	-0.2	-0.2	Obesity-related traits;	chr12:32093560	chr12:31754720~31755121:+
STAD	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	3.82	0.000161	0.0469	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
STAD	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	3.82	0.000161	0.0469	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
STAD	cis	rs12887734	0.546	rs4906376	ENSG00000269958.1	RP11-73M18.8	3.82	0.000161	0.0469	0.19	0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805828	chr14:103696353~103697163:+
STAD	cis	rs7209700	0.821	rs2292863	ENSG00000228782.6	CTD-2026D20.3	-3.82	0.000161	0.0469	-0.21	-0.2	IgG glycosylation;	chr17:47291764	chr17:47450568~47492492:-
STAD	cis	rs7209700	0.821	rs4642	ENSG00000228782.6	CTD-2026D20.3	-3.82	0.000161	0.0469	-0.21	-0.2	IgG glycosylation;	chr17:47292411	chr17:47450568~47492492:-
STAD	cis	rs7209700	0.821	rs4634	ENSG00000228782.6	CTD-2026D20.3	-3.82	0.000161	0.0469	-0.21	-0.2	IgG glycosylation;	chr17:47292423	chr17:47450568~47492492:-
STAD	cis	rs11235843	0.929	rs4944032	ENSG00000255928.1	RP11-456I15.2	-3.82	0.000161	0.0469	-0.34	-0.2	Hand grip strength;	chr11:73702076	chr11:73722349~73722694:+
STAD	cis	rs30380	0.632	rs26497	ENSG00000272109.1	CTD-2260A17.3	-3.82	0.000161	0.0469	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr5:96803064	chr5:96804353~96806105:+
STAD	cis	rs8012947	1	rs12878264	ENSG00000180189.10	HMGB1P14	-3.82	0.000161	0.0469	-0.2	-0.2	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58284773~58285363:+
STAD	cis	rs644418	0.545	rs62297302	ENSG00000249685.1	RP11-360F5.3	3.82	0.000161	0.0469	0.23	0.2	Facial morphology (factor 21, depth of nasal alae);	chr4:38140187	chr4:39133913~39135608:+
STAD	cis	rs4728302	0.869	rs10253633	ENSG00000237821.1	AC083873.4	-3.82	0.000161	0.0469	-0.2	-0.2	Intelligence (multi-trait analysis);Intelligence;	chr7:133906116	chr7:133169416~133170514:-
STAD	cis	rs4728302	0.869	rs10224575	ENSG00000237821.1	AC083873.4	-3.82	0.000161	0.0469	-0.2	-0.2	Intelligence (multi-trait analysis);Intelligence;	chr7:133906122	chr7:133169416~133170514:-
STAD	cis	rs4728302	0.838	rs10224828	ENSG00000237821.1	AC083873.4	-3.82	0.000161	0.0469	-0.2	-0.2	Intelligence (multi-trait analysis);Intelligence;	chr7:133906318	chr7:133169416~133170514:-
STAD	cis	rs4728302	0.838	rs10225115	ENSG00000237821.1	AC083873.4	-3.82	0.000161	0.0469	-0.2	-0.2	Intelligence (multi-trait analysis);Intelligence;	chr7:133906682	chr7:133169416~133170514:-
STAD	cis	rs8072100	0.764	rs2644349	ENSG00000264243.1	RP11-6N17.1	-3.82	0.000161	0.0469	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47863342~47865190:+
STAD	cis	rs9297145	0.565	rs6952161	ENSG00000272950.1	RP11-307C18.1	3.82	0.000161	0.0469	0.22	0.2	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:99135714	chr7:98322853~98323430:+
STAD	cis	rs6430585	0.702	rs3213890	ENSG00000231890.6	DARS-AS1	-3.82	0.000161	0.0469	-0.24	-0.2	Corneal structure;	chr2:135794618	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.536	rs3213892	ENSG00000231890.6	DARS-AS1	-3.82	0.000161	0.0469	-0.24	-0.2	Corneal structure;	chr2:135794947	chr2:135985176~136022593:+
STAD	cis	rs10851478	0.872	rs1818308	ENSG00000259545.2	RP11-325E5.4	-3.82	0.000161	0.0469	-0.24	-0.2	Oral cavity cancer;	chr15:49523453	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs12907918	ENSG00000259545.2	RP11-325E5.4	-3.82	0.000161	0.0469	-0.24	-0.2	Oral cavity cancer;	chr15:49524485	chr15:49177610~49178741:-
STAD	cis	rs10851478	0.872	rs17402115	ENSG00000259545.2	RP11-325E5.4	-3.82	0.000161	0.0469	-0.24	-0.2	Oral cavity cancer;	chr15:49532564	chr15:49177610~49178741:-
STAD	cis	rs6430585	0.583	rs73957037	ENSG00000231890.6	DARS-AS1	-3.82	0.000161	0.0469	-0.23	-0.2	Corneal structure;	chr2:135830461	chr2:135985176~136022593:+
STAD	cis	rs9907295	0.591	rs78655848	ENSG00000270977.1	AC015849.16	-3.82	0.000161	0.0469	-0.27	-0.2	Fibroblast growth factor basic levels;	chr17:35856952	chr17:35893707~35911023:-
STAD	cis	rs9907295	0.591	rs9908928	ENSG00000270977.1	AC015849.16	-3.82	0.000161	0.0469	-0.27	-0.2	Fibroblast growth factor basic levels;	chr17:35862013	chr17:35893707~35911023:-
STAD	cis	rs870825	0.616	rs1401358	ENSG00000249173.4	LINC01093	-3.82	0.000161	0.0469	-0.33	-0.2	Blood protein levels;	chr4:184718903	chr4:184893871~184899454:-
STAD	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000161	0.047	-0.22	-0.2	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
STAD	cis	rs9463078	0.683	rs227851	ENSG00000219384.1	RP11-491H9.3	-3.82	0.000161	0.047	-0.19	-0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44731472	chr6:45158870~45159511:+
STAD	cis	rs6432860	0.932	rs552878	ENSG00000229195.1	AC009495.4	3.82	0.000161	0.047	0.26	0.2	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:165996544	chr2:165794857~165846091:-
STAD	cis	rs4407350	0.933	rs5765732	ENSG00000279642.1	RP5-1033E15.3	-3.82	0.000161	0.047	-0.2	-0.2	Intelligence (multi-trait analysis);	chr22:44526881	chr22:44486295~44486914:-
STAD	cis	rs10782582	0.593	rs12131344	ENSG00000181227.3	RP4-682C21.2	3.82	0.000161	0.047	0.22	0.2	Daytime sleep phenotypes;	chr1:75670752	chr1:75743423~75744776:-
STAD	cis	rs17685	0.753	rs4732595	ENSG00000280388.1	RP11-229D13.3	-3.82	0.000161	0.047	-0.17	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76125821	chr7:76043977~76045963:-
STAD	cis	rs10782582	0.569	rs1770892	ENSG00000181227.3	RP4-682C21.2	3.82	0.000161	0.047	0.22	0.2	Daytime sleep phenotypes;	chr1:75923674	chr1:75743423~75744776:-
STAD	cis	rs10129255	0.957	rs12589190	ENSG00000211973.2	IGHV1-69	3.82	0.000161	0.047	0.19	0.2	Kawasaki disease;	chr14:106783079	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.957	rs7493713	ENSG00000211973.2	IGHV1-69	3.82	0.000161	0.047	0.19	0.2	Kawasaki disease;	chr14:106783685	chr14:106714684~106715181:-
STAD	cis	rs721917	0.506	rs2758538	ENSG00000244733.5	RP11-506M13.3	-3.82	0.000161	0.047	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79893047	chr10:79660891~79677996:+
STAD	cis	rs11089937	0.626	rs9622955	ENSG00000211640.3	IGLV6-57	3.82	0.000161	0.047	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs4821781	ENSG00000211640.3	IGLV6-57	3.82	0.000161	0.047	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs5750589	ENSG00000211640.3	IGLV6-57	3.82	0.000161	0.047	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.626	rs5757038	ENSG00000211640.3	IGLV6-57	3.82	0.000161	0.047	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22195713~22196460:+
STAD	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	3.82	0.000161	0.047	0.25	0.2	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
STAD	cis	rs2834188	1	rs2409488	ENSG00000272659.1	AP000295.10	-3.82	0.000161	0.047	-0.28	-0.2	Narcolepsy;	chr21:33316609	chr21:33309491~33310181:+
STAD	cis	rs9747201	0.963	rs4789729	ENSG00000281517.1	Metazoa_SRP	-3.82	0.000161	0.047	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82188213	chr17:81718849~81719095:-
STAD	cis	rs9903692	0.505	rs208005	ENSG00000278765.1	RP5-890E16.5	-3.82	0.000161	0.047	-0.27	-0.2	Pulse pressure;	chr17:48162623	chr17:48066704~48067293:-
STAD	cis	rs11650066	0.962	rs9902981	ENSG00000265356.1	RP11-17M24.1	3.82	0.000161	0.047	0.26	0.2	Coronary heart disease;	chr17:33957031	chr17:33931132~33936206:-
STAD	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	3.82	0.000161	0.047	0.24	0.2	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
STAD	cis	rs7204230	0.538	rs3760010	ENSG00000261291.1	RP11-295M3.2	3.81	0.000161	0.047	0.21	0.2	Fibrinogen;	chr16:53306168	chr16:53168522~53169450:+
STAD	cis	rs8012947	0.607	rs8004532	ENSG00000279636.2	LINC00216	3.81	0.000161	0.047	0.19	0.2	Alcohol consumption in current drinkers;	chr14:58363791	chr14:58288033~58289158:+
STAD	cis	rs7204230	0.883	rs7186520	ENSG00000261291.1	RP11-295M3.2	3.81	0.000161	0.047	0.23	0.2	Fibrinogen;	chr16:53144338	chr16:53168522~53169450:+
STAD	cis	rs262150	0.659	rs2527237	ENSG00000231419.5	LINC00689	-3.81	0.000161	0.047	-0.22	-0.2	Facial morphology (factor 20);	chr7:159005803	chr7:159006522~159030195:+
STAD	cis	rs7829975	0.508	rs4841006	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000161	0.047	-0.24	-0.2	Mood instability;	chr8:8643964	chr8:9141424~9145435:+
STAD	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-3.81	0.000161	0.047	-0.24	-0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
STAD	cis	rs9907295	0.688	rs4572457	ENSG00000270894.1	AC015849.13	-3.81	0.000161	0.047	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35813645	chr17:35818399~35823713:+
STAD	cis	rs7849270	0.879	rs3124495	ENSG00000234055.1	RP11-247A12.1	-3.81	0.000161	0.047	-0.25	-0.2	Blood metabolite ratios;	chr9:129093731	chr9:129097854~129100266:+
STAD	cis	rs603446	0.967	rs180346	ENSG00000254851.1	RP11-109L13.1	-3.81	0.000161	0.047	-0.22	-0.2	Triglycerides;	chr11:116741943	chr11:117135528~117138582:+
STAD	cis	rs6500550	0.636	rs2158443	ENSG00000263011.1	RP11-473M20.11	-3.81	0.000161	0.0471	-0.24	-0.2	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3635781	chr16:3106764~3109576:+
STAD	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	3.81	0.000161	0.0471	0.25	0.2	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
STAD	cis	rs7313075	1	rs7313075	ENSG00000258308.4	RP11-554E23.2	3.81	0.000161	0.0471	0.28	0.2	Height;	chr12:102236901	chr12:101954998~101962390:-
STAD	cis	rs6012564	1	rs2426112	ENSG00000227431.4	CSE1L-AS1	-3.81	0.000162	0.0471	-0.19	-0.2	Anger;	chr20:49073602	chr20:49040463~49046044:-
STAD	cis	rs6012564	1	rs2426113	ENSG00000227431.4	CSE1L-AS1	-3.81	0.000162	0.0471	-0.19	-0.2	Anger;	chr20:49073652	chr20:49040463~49046044:-
STAD	cis	rs2638953	0.924	rs1478334	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000162	0.0471	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189425	chr12:28163298~28190738:-
STAD	cis	rs14027	0.855	rs6469854	ENSG00000279347.1	RP11-85I17.2	3.81	0.000162	0.0471	0.18	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119849726	chr8:119838736~119840385:-
STAD	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	3.81	0.000162	0.0471	0.21	0.2	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
STAD	cis	rs1005277	0.522	rs289649	ENSG00000099251.13	HSD17B7P2	3.81	0.000162	0.0471	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38356380~38378505:+
STAD	cis	rs9902453	0.866	rs4795529	ENSG00000263477.1	RP11-338L22.2	3.81	0.000162	0.0471	0.17	0.2	Coffee consumption (cups per day);	chr17:30116531	chr17:29863402~29866092:+
STAD	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-3.81	0.000162	0.0471	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-3.81	0.000162	0.0471	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
STAD	cis	rs875971	0.964	rs1643388	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66379575	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs778722	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66379841	chr7:65773620~65802067:+
STAD	cis	rs875971	0.964	rs778721	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66380410	chr7:65773620~65802067:+
STAD	cis	rs875971	0.895	rs778700	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66401463	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs778699	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66403303	chr7:65773620~65802067:+
STAD	cis	rs875971	0.929	rs778692	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66407462	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs4718343	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66409301	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs1968225	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66409786	chr7:65773620~65802067:+
STAD	cis	rs875971	1	rs6460295	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66417741	chr7:65773620~65802067:+
STAD	cis	rs875971	0.964	rs6978721	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0471	0.2	0.2	Aortic root size;	chr7:66418217	chr7:65773620~65802067:+
STAD	cis	rs12913547	0.67	rs11637816	ENSG00000270964.1	RP11-502I4.3	3.81	0.000162	0.0471	0.25	0.2	Corneal structure;	chr15:67150217	chr15:67541072~67542604:-
STAD	cis	rs1395	0.71	rs1992291	ENSG00000234072.1	AC074117.10	-3.81	0.000162	0.0472	-0.19	-0.2	Blood metabolite levels;	chr2:27281444	chr2:27356246~27367622:+
STAD	cis	rs7520050	0.933	rs6661163	ENSG00000280836.1	AL355480.1	3.81	0.000162	0.0472	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45581219~45581321:-
STAD	cis	rs73198271	0.96	rs73198288	ENSG00000233609.3	RP11-62H7.2	-3.81	0.000162	0.0472	-0.3	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756430	chr8:8961200~8979025:+
STAD	cis	rs73198271	1	rs55971558	ENSG00000233609.3	RP11-62H7.2	-3.81	0.000162	0.0472	-0.3	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756893	chr8:8961200~8979025:+
STAD	cis	rs1836229	0.874	rs1434254	ENSG00000212829.8	RPS26P3	3.81	0.000162	0.0472	0.17	0.2	Restless legs syndrome;	chr9:8826278	chr9:9090898~9091245:+
STAD	cis	rs860295	1	rs6427287	ENSG00000203761.5	MSTO2P	-3.81	0.000162	0.0472	-0.17	-0.2	Body mass index;	chr1:155753629	chr1:155745829~155750137:+
STAD	cis	rs7615952	0.611	rs35321002	ENSG00000242229.1	RPS3AP14	3.81	0.000162	0.0472	0.35	0.2	Blood pressure (smoking interaction);	chr3:125893222	chr3:125795106~125795885:+
STAD	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-3.81	0.000162	0.0472	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
STAD	cis	rs1009077	0.68	rs13103899	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000162	0.0472	-0.25	-0.2	Endometriosis;	chr4:119517147	chr4:119409333~119410233:+
STAD	cis	rs6430585	0.528	rs309120	ENSG00000231890.6	DARS-AS1	-3.81	0.000162	0.0472	-0.22	-0.2	Corneal structure;	chr2:135951217	chr2:135985176~136022593:+
STAD	cis	rs6430585	0.528	rs3112496	ENSG00000231890.6	DARS-AS1	-3.81	0.000162	0.0472	-0.22	-0.2	Corneal structure;	chr2:135953494	chr2:135985176~136022593:+
STAD	cis	rs7849270	1	rs2541161	ENSG00000234055.1	RP11-247A12.1	-3.81	0.000162	0.0472	-0.23	-0.2	Blood metabolite ratios;	chr9:129122523	chr9:129097854~129100266:+
STAD	cis	rs412050	0.793	rs74576380	ENSG00000228050.1	TOP3BP1	-3.81	0.000162	0.0472	-0.34	-0.2	Attention deficit hyperactivity disorder;	chr22:21928908	chr22:22223187~22224566:-
STAD	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-3.81	0.000162	0.0472	-0.24	-0.2	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
STAD	cis	rs6772849	0.83	rs4857917	ENSG00000242551.2	POU5F1P6	-3.81	0.000162	0.0472	-0.2	-0.2	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128674735~128677005:-
STAD	cis	rs2638953	0.924	rs12369144	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000162	0.0472	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341109	chr12:28163298~28190738:-
STAD	cis	rs262150	0.659	rs2527236	ENSG00000231419.5	LINC00689	3.81	0.000162	0.0472	0.22	0.2	Facial morphology (factor 20);	chr7:159003953	chr7:159006522~159030195:+
STAD	cis	rs6432852	0.55	rs1813502	ENSG00000229195.1	AC009495.4	3.81	0.000162	0.0472	0.23	0.2	Diabetic kidney disease;	chr2:165989506	chr2:165794857~165846091:-
STAD	cis	rs6686842	0.56	rs213738	ENSG00000235358.1	RP11-399E6.1	3.81	0.000162	0.0472	0.22	0.2	Height;	chr1:41156676	chr1:41242373~41284861:+
STAD	cis	rs2839186	0.632	rs17176110	ENSG00000215447.6	BX322557.10	-3.81	0.000162	0.0472	-0.22	-0.2	Testicular germ cell tumor;	chr21:46286621	chr21:45288052~45291738:+
STAD	cis	rs2562456	0.917	rs6511253	ENSG00000268119.4	CTD-2561J22.5	-3.81	0.000162	0.0472	-0.26	-0.2	Pain;	chr19:21495996	chr19:21444241~21463908:-
STAD	cis	rs1816752	1	rs7999554	ENSG00000232858.1	RPL34P27	3.81	0.000162	0.0472	0.13	0.2	Obesity-related traits;	chr13:24435631	chr13:24988577~24988925:-
STAD	cis	rs7204230	1	rs8052283	ENSG00000261291.1	RP11-295M3.2	3.81	0.000162	0.0472	0.23	0.2	Fibrinogen;	chr16:53250054	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs7191436	ENSG00000261291.1	RP11-295M3.2	3.81	0.000162	0.0472	0.23	0.2	Fibrinogen;	chr16:53253631	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs6499510	ENSG00000261291.1	RP11-295M3.2	3.81	0.000162	0.0472	0.23	0.2	Fibrinogen;	chr16:53254353	chr16:53168522~53169450:+
STAD	cis	rs875971	0.964	rs60193905	ENSG00000224316.1	RP11-479O9.2	3.81	0.000162	0.0472	0.2	0.2	Aortic root size;	chr7:66506273	chr7:65773620~65802067:+
STAD	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	3.81	0.000162	0.0472	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
STAD	cis	rs7142881	0.815	rs11156690	ENSG00000258648.1	UBE2CP1	-3.81	0.000162	0.0472	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31570721	chr14:30683045~30683598:-
STAD	cis	rs2243480	0.522	rs1638736	ENSG00000230358.3	RP11-166O4.1	3.81	0.000162	0.0472	0.25	0.2	Diabetic kidney disease;	chr7:66627321	chr7:67279778~67286230:+
STAD	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-3.81	0.000162	0.0472	-0.22	-0.2	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
STAD	cis	rs360071	0.528	rs360097	ENSG00000242861.1	RP11-285F7.2	-3.81	0.000162	0.0472	-0.19	-0.2	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);	chr1:225878055	chr1:225840883~225846522:-
STAD	cis	rs151997	0.962	rs26088	ENSG00000250360.1	CTD-2089N3.1	-3.81	0.000162	0.0472	-0.19	-0.2	Callous-unemotional behaviour;	chr5:50876836	chr5:50965687~50967008:-
STAD	cis	rs151997	0.925	rs26087	ENSG00000250360.1	CTD-2089N3.1	-3.81	0.000162	0.0472	-0.19	-0.2	Callous-unemotional behaviour;	chr5:50877077	chr5:50965687~50967008:-
STAD	cis	rs151997	0.925	rs27847	ENSG00000250360.1	CTD-2089N3.1	-3.81	0.000162	0.0472	-0.19	-0.2	Callous-unemotional behaviour;	chr5:50880363	chr5:50965687~50967008:-
STAD	cis	rs9393777	0.513	rs7754159	ENSG00000224843.5	LINC00240	3.81	0.000162	0.0473	0.3	0.2	Intelligence (multi-trait analysis);	chr6:26620084	chr6:26956992~27023924:+
STAD	cis	rs9379850	0.73	rs9393738	ENSG00000224843.5	LINC00240	3.81	0.000162	0.0473	0.3	0.2	Intelligence (multi-trait analysis);	chr6:26620430	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs9379905	ENSG00000224843.5	LINC00240	3.81	0.000162	0.0473	0.3	0.2	Intelligence (multi-trait analysis);	chr6:26630762	chr6:26956992~27023924:+
STAD	cis	rs7520050	0.833	rs1085242	ENSG00000280836.1	AL355480.1	3.81	0.000162	0.0473	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45581219~45581321:-
STAD	cis	rs2262909	0.889	rs61268244	ENSG00000213976.4	CTD-2561J22.2	3.81	0.000162	0.0473	0.25	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22127328	chr19:21382865~21387177:+
STAD	cis	rs2262909	0.962	rs11673195	ENSG00000213976.4	CTD-2561J22.2	3.81	0.000162	0.0473	0.25	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22131012	chr19:21382865~21387177:+
STAD	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-3.81	0.000162	0.0473	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
STAD	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-3.81	0.000162	0.0473	-0.23	-0.2	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
STAD	cis	rs10911902	0.643	rs6664763	ENSG00000229739.2	RP11-295K2.3	-3.81	0.000163	0.0473	-0.28	-0.2	Schizophrenia;	chr1:186357043	chr1:186435161~186470291:+
STAD	cis	rs2562456	0.958	rs2562508	ENSG00000268119.4	CTD-2561J22.5	-3.81	0.000163	0.0473	-0.25	-0.2	Pain;	chr19:21543479	chr19:21444241~21463908:-
STAD	cis	rs11628318	0.614	rs7155489	ENSG00000259230.1	CTD-2555C10.3	3.81	0.000163	0.0473	0.31	0.2	Platelet count;	chr14:102656782	chr14:102545254~102555826:+
STAD	cis	rs6813195	0.881	rs6828651	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000163	0.0473	-0.2	-0.2	Type 2 diabetes;	chr4:152593101	chr4:152551277~152552364:-
STAD	cis	rs2734839	0.964	rs2734831	ENSG00000270179.1	RP11-159N11.4	3.81	0.000163	0.0473	0.23	0.2	Information processing speed;	chr11:113422874	chr11:113368478~113369117:+
STAD	cis	rs17401966	0.931	rs17410217	ENSG00000199562.1	RNU6-37P	3.81	0.000163	0.0473	0.16	0.2	Hepatocellular carcinoma;	chr1:10311796	chr1:10298966~10299072:+
STAD	cis	rs716804	0.715	rs2957693	ENSG00000254554.1	RP11-351I24.1	3.81	0.000163	0.0473	0.29	0.2	Neuroticism;	chr11:10347147	chr11:10302657~10303704:-
STAD	cis	rs748404	0.666	rs12906481	ENSG00000205771.5	CATSPER2P1	-3.81	0.000163	0.0473	-0.32	-0.2	Lung cancer;	chr15:43467356	chr15:43726918~43747094:-
STAD	cis	rs748404	0.666	rs35958032	ENSG00000205771.5	CATSPER2P1	-3.81	0.000163	0.0473	-0.32	-0.2	Lung cancer;	chr15:43494397	chr15:43726918~43747094:-
STAD	cis	rs6432852	0.527	rs12329293	ENSG00000229195.1	AC009495.4	-3.81	0.000163	0.0473	-0.23	-0.2	Diabetic kidney disease;	chr2:165945372	chr2:165794857~165846091:-
STAD	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-3.81	0.000163	0.0473	-0.31	-0.2	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-3.81	0.000163	0.0473	-0.31	-0.2	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
STAD	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-3.81	0.000163	0.0473	-0.31	-0.2	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
STAD	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	3.81	0.000163	0.0473	0.21	0.2	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
STAD	cis	rs7199343	0.564	rs12325558	ENSG00000280092.1	AC002044.3	3.81	0.000163	0.0473	0.2	0.2	Kawasaki disease;	chr16:72974349	chr16:73005601~73006141:-
STAD	cis	rs9747201	0.926	rs34153075	ENSG00000281517.1	Metazoa_SRP	3.81	0.000163	0.0473	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82177852	chr17:81718849~81719095:-
STAD	cis	rs79149102	0.579	rs6495138	ENSG00000260288.3	RP11-24M17.4	-3.81	0.000163	0.0473	-0.31	-0.2	Lung cancer;	chr15:75012351	chr15:75737820~75763321:+
STAD	cis	rs9362426	0.708	rs7744793	ENSG00000217776.1	RP11-156F23.2	-3.81	0.000163	0.0474	-0.22	-0.2	Depressive episodes in bipolar disorder;	chr6:87392322	chr6:87070156~87070461:-
STAD	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	3.81	0.000163	0.0474	0.3	0.2	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-3.81	0.000163	0.0474	-0.3	-0.2	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-3.81	0.000163	0.0474	-0.3	-0.2	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
STAD	cis	rs2957692	0.506	rs11042550	ENSG00000254554.1	RP11-351I24.1	3.81	0.000163	0.0474	0.33	0.2	Circulating vasoactive peptide levels;	chr11:9927965	chr11:10302657~10303704:-
STAD	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-3.81	0.000163	0.0474	-0.22	-0.2	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
STAD	cis	rs2115630	1	rs11073730	ENSG00000256278.1	RP11-182J1.5	-3.81	0.000163	0.0474	-0.19	-0.2	P wave terminal force;	chr15:84811365	chr15:84611689~84614969:-
STAD	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	3.81	0.000163	0.0474	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
STAD	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	3.81	0.000163	0.0474	0.2	0.2	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
STAD	cis	rs7192392	0.713	rs11641087	ENSG00000279991.1	RP11-190D6.1	3.81	0.000163	0.0474	0.19	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr16:78889315	chr16:78166717~78168514:-
STAD	cis	rs3758785	0.565	rs598645	ENSG00000255893.1	RP11-685N10.1	3.81	0.000163	0.0474	0.22	0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94338579	chr11:94472908~94473570:-
STAD	cis	rs992157	1	rs6736362	ENSG00000224928.2	KRT8P30	-3.81	0.000163	0.0474	-0.21	-0.2	Colorectal cancer;	chr2:218250385	chr2:218953401~218954050:-
STAD	cis	rs17592366	0.838	rs12434654	ENSG00000251726.1	RNU7-41P	-3.81	0.000163	0.0474	-0.22	-0.2	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34869840	chr14:34845300~34845360:-
STAD	cis	rs4792901	0.694	rs9907819	ENSG00000279602.1	CTD-3014M21.1	-3.81	0.000163	0.0474	-0.27	-0.2	Dupuytren's disease;	chr17:43525497	chr17:43360041~43361361:-
STAD	cis	rs4792901	0.802	rs9908559	ENSG00000279602.1	CTD-3014M21.1	-3.81	0.000163	0.0474	-0.27	-0.2	Dupuytren's disease;	chr17:43525793	chr17:43360041~43361361:-
STAD	cis	rs2243480	0.708	rs35825036	ENSG00000273448.1	RP11-166O4.6	3.81	0.000163	0.0474	0.25	0.2	Diabetic kidney disease;	chr7:66521515	chr7:67333047~67334383:+
STAD	cis	rs2243480	1	rs13237037	ENSG00000273448.1	RP11-166O4.6	3.81	0.000163	0.0474	0.25	0.2	Diabetic kidney disease;	chr7:66532895	chr7:67333047~67334383:+
STAD	cis	rs2836974	0.533	rs418298	ENSG00000238141.2	BRWD1-AS1	3.81	0.000163	0.0474	0.2	0.2	Cognitive function;	chr21:39164728	chr21:39315707~39323218:+
STAD	cis	rs1348850	0.567	rs880899	ENSG00000271825.1	RP11-337N6.2	3.81	0.000163	0.0474	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177667688	chr2:177300600~177302006:+
STAD	cis	rs1348850	0.567	rs880898	ENSG00000271825.1	RP11-337N6.2	3.81	0.000163	0.0474	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177667742	chr2:177300600~177302006:+
STAD	cis	rs172166	0.637	rs1233691	ENSG00000280107.1	AL022393.9	-3.81	0.000163	0.0475	-0.25	-0.2	Cardiac Troponin-T levels;	chr6:28186119	chr6:28170845~28172521:+
STAD	cis	rs9902453	1	rs11080114	ENSG00000263477.1	RP11-338L22.2	-3.81	0.000163	0.0475	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30080269	chr17:29863402~29866092:+
STAD	cis	rs9902453	1	rs7221743	ENSG00000263477.1	RP11-338L22.2	-3.81	0.000163	0.0475	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30080858	chr17:29863402~29866092:+
STAD	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	3.81	0.000163	0.0475	0.3	0.2	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
STAD	cis	rs9921338	0.961	rs72773833	ENSG00000263080.1	RP11-485G7.5	3.81	0.000163	0.0475	0.3	0.2	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319417	chr16:11341809~11345211:-
STAD	cis	rs10776614	0.799	rs10491040	ENSG00000189014.7	FAM35DP	3.81	0.000163	0.0475	0.31	0.2	Self-employment;	chr10:48574372	chr10:47689707~47730436:+
STAD	cis	rs35146811	0.66	rs6465760	ENSG00000214142.2	RPL7P60	3.81	0.000163	0.0475	0.25	0.2	Coronary artery disease;	chr7:99993795	chr7:100139629~100140682:-
STAD	cis	rs7208859	0.623	rs9895785	ENSG00000280069.1	CTD-2349P21.3	3.81	0.000163	0.0475	0.21	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30738182~30740275:+
STAD	cis	rs794185	0.562	rs304095	ENSG00000231249.1	ITPR1-AS1	-3.81	0.000163	0.0475	-0.23	-0.2	Multiple sclerosis--Brain Glutamate Levels;	chr3:4474856	chr3:4490891~4493163:-
STAD	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-3.81	0.000163	0.0475	-0.25	-0.2	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
STAD	cis	rs7560272	0.723	rs1052161	ENSG00000163016.8	ALMS1P	3.81	0.000163	0.0475	0.21	0.2	Schizophrenia;	chr2:73601411	chr2:73644919~73685576:+
STAD	cis	rs782590	0.643	rs5012561	ENSG00000162997.14	PRORSD1P	3.81	0.000163	0.0475	0.2	0.2	Metabolic syndrome;	chr2:55514896	chr2:55282319~55284522:+
STAD	cis	rs2562456	0.876	rs11085467	ENSG00000268119.4	CTD-2561J22.5	3.81	0.000163	0.0475	0.25	0.2	Pain;	chr19:21569041	chr19:21444241~21463908:-
STAD	cis	rs2638953	0.853	rs11049646	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000163	0.0475	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28476139	chr12:28163298~28190738:-
STAD	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-3.81	0.000163	0.0475	-0.24	-0.2	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
STAD	cis	rs453301	0.506	rs476845	ENSG00000173295.6	FAM86B3P	-3.81	0.000163	0.0475	-0.23	-0.2	Joint mobility (Beighton score);	chr8:8765367	chr8:8228595~8244865:+
STAD	cis	rs9393777	0.557	rs6933999	ENSG00000224843.5	LINC00240	3.81	0.000163	0.0475	0.25	0.2	Intelligence (multi-trait analysis);	chr6:27107150	chr6:26956992~27023924:+
STAD	cis	rs7512552	0.839	rs1260421	ENSG00000203819.6	HIST2H2BC	3.81	0.000163	0.0475	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150385304	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs1627235	ENSG00000203819.6	HIST2H2BC	3.81	0.000163	0.0475	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150386382	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs1694362	ENSG00000203819.6	HIST2H2BC	3.81	0.000163	0.0475	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150394487	chr1:149850193~149850772:-
STAD	cis	rs6432852	0.527	rs62177817	ENSG00000229195.1	AC009495.4	-3.81	0.000164	0.0475	-0.23	-0.2	Diabetic kidney disease;	chr2:165932333	chr2:165794857~165846091:-
STAD	cis	rs6432852	0.527	rs10203040	ENSG00000229195.1	AC009495.4	-3.81	0.000164	0.0475	-0.23	-0.2	Diabetic kidney disease;	chr2:165935436	chr2:165794857~165846091:-
STAD	cis	rs1598856	1	rs11934404	ENSG00000248971.2	KRT8P46	-3.81	0.000164	0.0475	-0.22	-0.2	Primary biliary cholangitis;	chr4:102516444	chr4:102728746~102730171:-
STAD	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-3.81	0.000164	0.0475	-0.25	-0.2	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
STAD	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-3.81	0.000164	0.0475	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
STAD	cis	rs1009077	0.716	rs9992502	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000164	0.0475	-0.28	-0.2	Endometriosis;	chr4:119621659	chr4:119409333~119410233:+
STAD	cis	rs1009077	0.716	rs10025536	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000164	0.0475	-0.28	-0.2	Endometriosis;	chr4:119621715	chr4:119409333~119410233:+
STAD	cis	rs763121	1	rs1946990	ENSG00000280859.1	AL022326.1	3.81	0.000164	0.0475	0.23	0.2	Menopause (age at onset);	chr22:38516766	chr22:39319019~39319147:-
STAD	cis	rs1075265	0.836	rs1363063	ENSG00000235937.1	AC008280.1	3.81	0.000164	0.0476	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54029552~54030682:-
STAD	cis	rs7204230	1	rs1477027	ENSG00000261291.1	RP11-295M3.2	3.81	0.000164	0.0476	0.23	0.2	Fibrinogen;	chr16:53251010	chr16:53168522~53169450:+
STAD	cis	rs10129255	0.912	rs35468694	ENSG00000211973.2	IGHV1-69	3.81	0.000164	0.0476	0.19	0.2	Kawasaki disease;	chr14:106784199	chr14:106714684~106715181:-
STAD	cis	rs10129255	0.957	rs8019272	ENSG00000211973.2	IGHV1-69	3.81	0.000164	0.0476	0.19	0.2	Kawasaki disease;	chr14:106784709	chr14:106714684~106715181:-
STAD	cis	rs12468226	0.938	rs78928733	ENSG00000272966.1	RP11-686O6.1	3.81	0.000164	0.0476	0.3	0.2	Urate levels;	chr2:202283787	chr2:202336739~202337200:+
STAD	cis	rs12468226	0.938	rs77062060	ENSG00000272966.1	RP11-686O6.1	3.81	0.000164	0.0476	0.3	0.2	Urate levels;	chr2:202285639	chr2:202336739~202337200:+
STAD	cis	rs61270009	0.955	rs13189889	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000164	0.0476	0.27	0.2	Depressive symptoms;	chr5:88365589	chr5:88268895~88436685:+
STAD	cis	rs4713118	0.955	rs9380011	ENSG00000243307.2	POM121L6P	-3.81	0.000164	0.0476	-0.23	-0.2	Parkinson's disease;	chr6:27716145	chr6:26896952~26898777:+
STAD	cis	rs412050	0.895	rs2329886	ENSG00000228050.1	TOP3BP1	-3.81	0.000164	0.0476	-0.34	-0.2	Attention deficit hyperactivity disorder;	chr22:21944102	chr22:22223187~22224566:-
STAD	cis	rs9902453	0.933	rs8080343	ENSG00000263477.1	RP11-338L22.2	3.81	0.000164	0.0476	0.17	0.2	Coffee consumption (cups per day);	chr17:30129740	chr17:29863402~29866092:+
STAD	cis	rs13401620	0.587	rs12989995	ENSG00000224789.1	AC012363.4	-3.81	0.000164	0.0476	-0.25	-0.2	Breast size;	chr2:120103506	chr2:120174885~120216544:-
STAD	cis	rs2957692	0.507	rs10770077	ENSG00000254554.1	RP11-351I24.1	3.81	0.000164	0.0476	0.3	0.2	Circulating vasoactive peptide levels;	chr11:9946807	chr11:10302657~10303704:-
STAD	cis	rs716804	0.905	rs11042685	ENSG00000254554.1	RP11-351I24.1	3.81	0.000164	0.0476	0.29	0.2	Neuroticism;	chr11:10241004	chr11:10302657~10303704:-
STAD	cis	rs716804	0.846	rs11827024	ENSG00000254554.1	RP11-351I24.1	3.81	0.000164	0.0476	0.29	0.2	Neuroticism;	chr11:10243526	chr11:10302657~10303704:-
STAD	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	3.81	0.000164	0.0476	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
STAD	cis	rs4763879	0.739	rs7310460	ENSG00000256673.1	RP11-599J14.2	3.81	0.000164	0.0476	0.21	0.2	Type 1 diabetes;	chr12:9688177	chr12:9398355~9414851:-
STAD	cis	rs9608946	0.784	rs9608959	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000164	0.0476	-0.17	-0.2	Red cell distribution width;	chr22:30505990	chr22:29978950~30028236:-
STAD	cis	rs7580658	0.545	rs885276	ENSG00000236682.1	AC068282.3	-3.81	0.000164	0.0476	-0.25	-0.2	Protein C levels;	chr2:127193328	chr2:127389130~127400580:+
STAD	cis	rs6813195	0.881	rs4696327	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000164	0.0476	-0.2	-0.2	Type 2 diabetes;	chr4:152594428	chr4:152551277~152552364:-
STAD	cis	rs7100689	0.646	rs10749581	ENSG00000225484.5	NUTM2B-AS1	3.81	0.000164	0.0476	0.28	0.2	Post bronchodilator FEV1;	chr10:80381895	chr10:79663088~79826594:-
STAD	cis	rs870825	0.616	rs35533356	ENSG00000249173.4	LINC01093	-3.81	0.000164	0.0476	-0.33	-0.2	Blood protein levels;	chr4:184717980	chr4:184893871~184899454:-
STAD	cis	rs2337406	0.714	rs7150993	ENSG00000211972.2	IGHV3-66	3.81	0.000164	0.0476	0.2	0.2	Alzheimer's disease (late onset);	chr14:106818515	chr14:106675017~106675544:-
STAD	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	3.81	0.000164	0.0476	0.33	0.2	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
STAD	cis	rs13217239	0.608	rs6930508	ENSG00000272312.1	RP11-239L20.6	3.81	0.000164	0.0476	0.2	0.2	Schizophrenia;	chr6:27085363	chr6:27001208~27001648:-
STAD	cis	rs13217239	0.646	rs2142685	ENSG00000272312.1	RP11-239L20.6	3.81	0.000164	0.0476	0.2	0.2	Schizophrenia;	chr6:27086718	chr6:27001208~27001648:-
STAD	cis	rs6813195	0.554	rs2628570	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000164	0.0476	-0.2	-0.2	Type 2 diabetes;	chr4:152452528	chr4:152551277~152552364:-
STAD	cis	rs10129255	0.5	rs988134	ENSG00000232216.1	IGHV3-43	3.81	0.000164	0.0477	0.18	0.2	Kawasaki disease;	chr14:106776698	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.5	rs988133	ENSG00000232216.1	IGHV3-43	3.81	0.000164	0.0477	0.18	0.2	Kawasaki disease;	chr14:106776724	chr14:106470264~106470800:-
STAD	cis	rs66887589	0.807	rs9799664	ENSG00000249244.1	RP11-548H18.2	3.81	0.000164	0.0477	0.25	0.2	Diastolic blood pressure;	chr4:119405523	chr4:119391831~119395335:-
STAD	cis	rs66887589	0.627	rs3872807	ENSG00000249244.1	RP11-548H18.2	3.81	0.000164	0.0477	0.25	0.2	Diastolic blood pressure;	chr4:119439096	chr4:119391831~119395335:-
STAD	cis	rs66887589	0.56	rs9684327	ENSG00000249244.1	RP11-548H18.2	3.81	0.000164	0.0477	0.25	0.2	Diastolic blood pressure;	chr4:119444286	chr4:119391831~119395335:-
STAD	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-3.81	0.000164	0.0477	-0.25	-0.2	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
STAD	cis	rs17401966	0.597	rs3903151	ENSG00000199562.1	RNU6-37P	3.81	0.000164	0.0477	0.16	0.2	Hepatocellular carcinoma;	chr1:10200534	chr1:10298966~10299072:+
STAD	cis	rs1790761	0.967	rs7131041	ENSG00000231793.4	DOC2GP	-3.81	0.000164	0.0477	-0.24	-0.2	Mean corpuscular volume;	chr11:67462713	chr11:67612653~67616257:-
STAD	cis	rs2273156	0.57	rs941653	ENSG00000258704.4	SRP54-AS1	-3.81	0.000164	0.0477	-0.25	-0.2	Immunoglobulin light chain (AL) amyloidosis;	chr14:35123332	chr14:34920858~34982532:-
STAD	cis	rs10466239	0.73	rs2460535	ENSG00000230555.2	RP11-517P14.2	3.81	0.000164	0.0477	0.26	0.2	Telomere length;	chr10:43325932	chr10:43420738~43422100:+
STAD	cis	rs1075265	0.87	rs10207537	ENSG00000235937.1	AC008280.1	3.81	0.000164	0.0477	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54029552~54030682:-
STAD	cis	rs8067354	0.789	rs4622571	ENSG00000266701.1	AC005702.4	3.81	0.000164	0.0477	0.26	0.2	Hemoglobin concentration;	chr17:59807036	chr17:60042546~60042627:-
STAD	cis	rs3764021	0.933	rs2268146	ENSG00000278635.1	CTD-2318O12.1	-3.81	0.000164	0.0477	-0.2	-0.2	Type 1 diabetes;	chr12:9716675	chr12:9415641~9416718:+
STAD	cis	rs733592	0.894	rs886589	ENSG00000258273.1	RP11-370I10.4	3.81	0.000164	0.0477	0.24	0.2	Plateletcrit;	chr12:48083414	chr12:48333755~48333901:-
STAD	cis	rs733592	0.524	rs10875727	ENSG00000226413.2	OR8T1P	-3.81	0.000164	0.0477	-0.22	-0.2	Plateletcrit;	chr12:48032360	chr12:48442030~48442947:-
STAD	cis	rs2803122	0.745	rs10123714	ENSG00000272842.1	RP11-513M16.7	-3.81	0.000164	0.0477	-0.18	-0.2	Pulse pressure;	chr9:19231645	chr9:19371386~19371945:-
STAD	cis	rs10129255	0.518	rs8009594	ENSG00000232216.1	IGHV3-43	3.81	0.000164	0.0477	0.18	0.2	Kawasaki disease;	chr14:106777494	chr14:106470264~106470800:-
STAD	cis	rs10129255	0.518	rs8009612	ENSG00000232216.1	IGHV3-43	3.81	0.000164	0.0477	0.18	0.2	Kawasaki disease;	chr14:106777510	chr14:106470264~106470800:-
STAD	cis	rs2638953	0.924	rs7307078	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000164	0.0477	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184645	chr12:28163298~28190738:-
STAD	cis	rs1023500	1	rs7293091	ENSG00000205702.9	CYP2D7	-3.81	0.000164	0.0477	-0.24	-0.2	Schizophrenia;	chr22:41945304	chr22:42140203~42144577:-
STAD	cis	rs6479891	1	rs10733790	ENSG00000235816.3	PRELID1P3	-3.81	0.000164	0.0477	-0.26	-0.2	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63427297~63427939:+
STAD	cis	rs6539288	0.739	rs4964511	ENSG00000260329.1	RP11-412D9.4	-3.81	0.000164	0.0477	-0.22	-0.2	Total body bone mineral density;	chr12:106966468	chr12:106954029~106955497:-
STAD	cis	rs11587682	0.806	rs12121966	ENSG00000274963.1	Metazoa_SRP	-3.81	0.000164	0.0477	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150367040	chr1:150568971~150569269:-
STAD	cis	rs11587682	0.714	rs72696844	ENSG00000274963.1	Metazoa_SRP	-3.81	0.000164	0.0477	-0.22	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150372485	chr1:150568971~150569269:-
STAD	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-3.81	0.000164	0.0477	-0.24	-0.2	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
STAD	cis	rs870825	0.616	rs35818632	ENSG00000249173.4	LINC01093	-3.81	0.000165	0.0477	-0.34	-0.2	Blood protein levels;	chr4:184728507	chr4:184893871~184899454:-
STAD	cis	rs1639906	0.895	rs78469080	ENSG00000201794.1	RN7SKP130	-3.81	0.000165	0.0478	-0.2	-0.2	Colonoscopy-negative controls vs population controls;	chr7:2161094	chr7:2999094~2999394:+
STAD	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	3.81	0.000165	0.0478	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
STAD	cis	rs6539288	0.901	rs2041894	ENSG00000260329.1	RP11-412D9.4	-3.81	0.000165	0.0478	-0.22	-0.2	Total body bone mineral density;	chr12:106956389	chr12:106954029~106955497:-
STAD	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-3.81	0.000165	0.0478	-0.25	-0.2	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
STAD	cis	rs6693567	0.565	rs6685252	ENSG00000203819.6	HIST2H2BC	-3.81	0.000165	0.0478	-0.24	-0.2	Migraine;	chr1:150287533	chr1:149850193~149850772:-
STAD	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	3.81	0.000165	0.0478	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
STAD	cis	rs2512987	1	rs2512985	ENSG00000254731.1	CTD-2005H7.1	-3.81	0.000165	0.0478	-0.23	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703401	chr11:86703099~86714092:+
STAD	cis	rs7255045	0.752	rs2418568	ENSG00000266721.1	MIR5695	3.81	0.000165	0.0478	0.21	0.2	Mean corpuscular volume;	chr19:12877067	chr19:12920320~12920404:+
STAD	cis	rs11098499	0.82	rs28535956	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000165	0.0478	-0.2	-0.2	Corneal astigmatism;	chr4:119615703	chr4:119409333~119410233:+
STAD	cis	rs867371	0.929	rs1045508	ENSG00000278603.1	RP13-608F4.5	-3.81	0.000165	0.0478	-0.23	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472203~82472426:+
STAD	cis	rs73198271	0.71	rs11779565	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000165	0.0478	-0.27	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:9141424~9145435:+
STAD	cis	rs10500715	0.905	rs7933475	ENSG00000254554.1	RP11-351I24.1	3.81	0.000165	0.0478	0.27	0.2	Pancreatic cancer;	chr11:9963486	chr11:10302657~10303704:-
STAD	cis	rs12745968	0.587	rs1034218	ENSG00000229052.2	RP11-386I23.1	-3.81	0.000165	0.0478	-0.19	-0.2	Bipolar disorder and schizophrenia;	chr1:92583574	chr1:92930696~92934098:+
STAD	cis	rs10986311	0.802	rs7045589	ENSG00000227200.1	RP11-121A14.3	3.81	0.000165	0.0479	0.21	0.2	Vitiligo;	chr9:124348075	chr9:124262876~124265809:+
STAD	cis	rs7615952	0.673	rs34209763	ENSG00000242229.1	RPS3AP14	3.81	0.000165	0.0479	0.35	0.2	Blood pressure (smoking interaction);	chr3:125880752	chr3:125795106~125795885:+
STAD	cis	rs7615952	0.8	rs35390120	ENSG00000242229.1	RPS3AP14	3.81	0.000165	0.0479	0.35	0.2	Blood pressure (smoking interaction);	chr3:125880966	chr3:125795106~125795885:+
STAD	cis	rs73198271	0.583	rs11781985	ENSG00000253893.2	FAM85B	-3.81	0.000165	0.0479	-0.3	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8167819~8226614:-
STAD	cis	rs7523273	0.565	rs2104303	ENSG00000227887.1	RPS26P13	-3.81	0.000165	0.0479	-0.2	-0.2	Schizophrenia;	chr1:207713339	chr1:208697369~208697698:-
STAD	cis	rs2836974	0.666	rs4818015	ENSG00000238141.2	BRWD1-AS1	3.81	0.000165	0.0479	0.21	0.2	Cognitive function;	chr21:39303567	chr21:39315707~39323218:+
STAD	cis	rs9291683	0.588	rs17247314	ENSG00000250613.1	RP11-136I13.1	-3.81	0.000165	0.0479	-0.19	-0.2	Bone mineral density;	chr4:10003119	chr4:10410996~10411644:+
STAD	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-3.81	0.000165	0.0479	-0.19	-0.2	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
STAD	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-3.81	0.000165	0.0479	-0.23	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
STAD	cis	rs5758659	1	rs134900	ENSG00000205702.9	CYP2D7	3.81	0.000165	0.048	0.2	0.2	Cognitive function;	chr22:42287337	chr22:42140203~42144577:-
STAD	cis	rs10508774	1	rs11812263	ENSG00000273038.2	RP11-479G22.8	3.81	0.000165	0.048	0.39	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32669384	chr10:32887255~32889311:-
STAD	cis	rs10508774	1	rs72782254	ENSG00000273038.2	RP11-479G22.8	3.81	0.000165	0.048	0.39	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32674404	chr10:32887255~32889311:-
STAD	cis	rs1799949	0.965	rs8067269	ENSG00000279602.1	CTD-3014M21.1	3.81	0.000165	0.048	0.25	0.2	Menopause (age at onset);	chr17:43083782	chr17:43360041~43361361:-
STAD	cis	rs28588043	0.537	rs17562792	ENSG00000201126.1	RNU6-773P	-3.81	0.000165	0.048	-0.38	-0.2	Number of children (6+ vs. 0 or 1);	chr1:170948373	chr1:171519816~171519913:-
STAD	cis	rs2283792	0.765	rs9607241	ENSG00000224086.5	LL22NC03-86G7.1	-3.81	0.000166	0.048	-0.18	-0.2	Multiple sclerosis;	chr22:21750584	chr22:21938293~21977632:+
STAD	cis	rs11098499	0.874	rs13123591	ENSG00000250412.1	KLHL2P1	3.81	0.000166	0.048	0.27	0.2	Corneal astigmatism;	chr4:119184835	chr4:119334329~119378233:+
STAD	cis	rs11098499	0.874	rs7661020	ENSG00000250412.1	KLHL2P1	3.81	0.000166	0.048	0.27	0.2	Corneal astigmatism;	chr4:119185827	chr4:119334329~119378233:+
STAD	cis	rs7221109	0.961	rs757411	ENSG00000278834.1	RP11-458J1.1	3.81	0.000166	0.048	0.21	0.2	Type 1 diabetes;	chr17:40618898	chr17:40648300~40649718:+
STAD	cis	rs7221109	0.961	rs9911533	ENSG00000278834.1	RP11-458J1.1	3.81	0.000166	0.048	0.21	0.2	Type 1 diabetes;	chr17:40619224	chr17:40648300~40649718:+
STAD	cis	rs875971	0.964	rs6945019	ENSG00000224316.1	RP11-479O9.2	3.81	0.000166	0.048	0.2	0.2	Aortic root size;	chr7:66457471	chr7:65773620~65802067:+
STAD	cis	rs11667325	0.7	rs11084120	ENSG00000268316.1	AC006272.2	3.81	0.000166	0.048	0.28	0.2	Neutrophil percentage of granulocytes;	chr19:51795237	chr19:51839771~51840945:-
STAD	cis	rs11667325	0.7	rs11084121	ENSG00000268316.1	AC006272.2	3.81	0.000166	0.048	0.28	0.2	Neutrophil percentage of granulocytes;	chr19:51795259	chr19:51839771~51840945:-
STAD	cis	rs76878669	0.538	rs4930360	ENSG00000254855.1	RP11-867G23.1	-3.81	0.000166	0.048	-0.23	-0.2	Educational attainment (years of education);	chr11:66375776	chr11:66264777~66265666:-
STAD	cis	rs55702914	1	rs56234206	ENSG00000231621.1	AC013264.2	-3.81	0.000166	0.048	-0.17	-0.2	Major depression and alcohol dependence;	chr2:197351271	chr2:197197991~197199273:+
STAD	cis	rs4691139	0.534	rs12502815	ENSG00000248632.1	RP11-366M4.11	3.81	0.000166	0.048	0.19	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:165020935	chr4:164968587~164970002:-
STAD	cis	rs728616	0.558	rs35547640	ENSG00000272447.1	RP11-182L21.6	-3.81	0.000166	0.048	-0.31	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80379394	chr10:79825902~79827602:+
STAD	cis	rs2739330	0.732	rs5760175	ENSG00000272787.1	KB-226F1.2	-3.81	0.000166	0.048	-0.22	-0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23969211~23969873:+
STAD	cis	rs17818399	0.749	rs4142759	ENSG00000279254.1	RP11-536C12.1	-3.81	0.000166	0.048	-0.22	-0.2	Height;	chr2:46556751	chr2:46668870~46670778:+
STAD	cis	rs13421350	0.579	rs74483274	ENSG00000232788.1	AC078883.3	3.81	0.000166	0.048	0.37	0.2	Diabetic kidney disease;	chr2:172438523	chr2:172464262~172466022:-
STAD	cis	rs13421350	0.579	rs80010354	ENSG00000232788.1	AC078883.3	3.81	0.000166	0.048	0.37	0.2	Diabetic kidney disease;	chr2:172438582	chr2:172464262~172466022:-
STAD	cis	rs9907295	0.636	rs4251703	ENSG00000270894.1	AC015849.13	-3.81	0.000166	0.048	-0.19	-0.2	Fibroblast growth factor basic levels;	chr17:35807954	chr17:35818399~35823713:+
STAD	cis	rs595244	1	rs636178	ENSG00000259705.1	RP11-227D13.1	3.81	0.000166	0.048	0.36	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48605085	chr15:48645951~48652016:+
STAD	cis	rs595244	0.901	rs2466790	ENSG00000259705.1	RP11-227D13.1	3.81	0.000166	0.048	0.36	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607202	chr15:48645951~48652016:+
STAD	cis	rs595244	1	rs1678981	ENSG00000259705.1	RP11-227D13.1	3.81	0.000166	0.048	0.36	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607900	chr15:48645951~48652016:+
STAD	cis	rs595244	1	rs1018148	ENSG00000259705.1	RP11-227D13.1	-3.81	0.000166	0.048	-0.36	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48610929	chr15:48645951~48652016:+
STAD	cis	rs3213758	0.541	rs8056869	ENSG00000275191.1	RP11-36I17.2	-3.81	0.000166	0.048	-0.31	-0.2	Vitiligo (non-segmental);	chr16:53653467	chr16:53628256~53628816:-
STAD	cis	rs76917914	0.78	rs2417727	ENSG00000236896.1	RP11-535C21.3	3.81	0.000166	0.048	0.27	0.2	Immature fraction of reticulocytes;	chr9:98084193	chr9:97986551~97987656:-
STAD	cis	rs9463078	0.653	rs1080415	ENSG00000219384.1	RP11-491H9.3	3.81	0.000166	0.048	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45231697	chr6:45158870~45159511:+
STAD	cis	rs9608946	1	rs8138759	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000166	0.048	-0.17	-0.2	Red cell distribution width;	chr22:30488440	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs9606735	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000166	0.048	-0.17	-0.2	Red cell distribution width;	chr22:30488844	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs9606736	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000166	0.048	-0.17	-0.2	Red cell distribution width;	chr22:30490590	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs17738527	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000166	0.048	-0.17	-0.2	Red cell distribution width;	chr22:30492507	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs17738540	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000166	0.048	-0.17	-0.2	Red cell distribution width;	chr22:30492540	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs8137718	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000166	0.048	-0.17	-0.2	Red cell distribution width;	chr22:30492972	chr22:29978950~30028236:-
STAD	cis	rs9608946	1	rs9606739	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000166	0.048	-0.17	-0.2	Red cell distribution width;	chr22:30495307	chr22:29978950~30028236:-
STAD	cis	rs11169552	0.51	rs12231317	ENSG00000200428.1	Y_RNA	3.81	0.000166	0.048	0.23	0.2	Colorectal cancer;	chr12:50647222	chr12:50743568~50743684:+
STAD	cis	rs8054556	0.74	rs12444978	ENSG00000261588.1	AC002310.17	3.81	0.000166	0.048	0.22	0.2	Autism spectrum disorder or schizophrenia;	chr16:29913101	chr16:30587662~30587920:-
STAD	cis	rs7824557	0.527	rs2572376	ENSG00000205879.4	FAM90A2P	-3.81	0.000166	0.0481	-0.22	-0.2	Retinal vascular caliber;	chr8:11380247	chr8:12172202~12178575:-
STAD	cis	rs7824557	0.527	rs2736305	ENSG00000205879.4	FAM90A2P	-3.81	0.000166	0.0481	-0.22	-0.2	Retinal vascular caliber;	chr8:11380264	chr8:12172202~12178575:-
STAD	cis	rs595244	1	rs1036476	ENSG00000259705.1	RP11-227D13.1	3.81	0.000166	0.0481	0.36	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48622578	chr15:48645951~48652016:+
STAD	cis	rs7512552	0.839	rs4581308	ENSG00000203819.6	HIST2H2BC	-3.81	0.000166	0.0481	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150304444	chr1:149850193~149850772:-
STAD	cis	rs7204230	1	rs17302113	ENSG00000261291.1	RP11-295M3.2	3.81	0.000166	0.0481	0.24	0.2	Fibrinogen;	chr16:53138241	chr16:53168522~53169450:+
STAD	cis	rs7204230	1	rs8057285	ENSG00000261291.1	RP11-295M3.2	3.81	0.000166	0.0481	0.24	0.2	Fibrinogen;	chr16:53149968	chr16:53168522~53169450:+
STAD	cis	rs860295	0.702	rs10908470	ENSG00000225855.5	RUSC1-AS1	3.81	0.000166	0.0481	0.17	0.2	Body mass index;	chr1:155557222	chr1:155316863~155324176:-
STAD	cis	rs1577917	0.523	rs1413724	ENSG00000234155.1	RP11-30P6.6	3.81	0.000166	0.0481	0.27	0.2	Response to antipsychotic treatment;	chr6:86104831	chr6:85387219~85390186:-
STAD	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	3.81	0.000166	0.0481	0.22	0.2	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
STAD	cis	rs950169	0.922	rs12910334	ENSG00000259683.1	RP11-182J1.14	3.81	0.000166	0.0481	0.22	0.2	Schizophrenia;	chr15:84403620	chr15:84389729~84395903:+
STAD	cis	rs7142881	0.76	rs1545275	ENSG00000258648.1	UBE2CP1	-3.81	0.000166	0.0481	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31651018	chr14:30683045~30683598:-
STAD	cis	rs6813195	0.514	rs964475	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000166	0.0481	-0.2	-0.2	Type 2 diabetes;	chr4:152431643	chr4:152551277~152552364:-
STAD	cis	rs6813195	0.554	rs57199846	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000166	0.0481	-0.2	-0.2	Type 2 diabetes;	chr4:152432804	chr4:152551277~152552364:-
STAD	cis	rs6813195	0.554	rs2676337	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000166	0.0481	-0.2	-0.2	Type 2 diabetes;	chr4:152437154	chr4:152551277~152552364:-
STAD	cis	rs6813195	0.554	rs6852336	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000166	0.0481	-0.2	-0.2	Type 2 diabetes;	chr4:152439603	chr4:152551277~152552364:-
STAD	cis	rs227932	0.867	rs116981	ENSG00000232627.1	AC021876.4	3.81	0.000166	0.0481	0.29	0.2	Schizophrenia;	chr7:23590849	chr7:23365618~23365976:+
STAD	cis	rs3764400	0.567	rs208012	ENSG00000278765.1	RP5-890E16.5	-3.81	0.000166	0.0481	-0.26	-0.2	Body mass index;	chr17:48180655	chr17:48066704~48067293:-
STAD	cis	rs3764400	0.567	rs208011	ENSG00000278765.1	RP5-890E16.5	-3.81	0.000166	0.0481	-0.26	-0.2	Body mass index;	chr17:48180983	chr17:48066704~48067293:-
STAD	cis	rs55675132	0.515	rs6676639	ENSG00000236480.1	PKMP1	3.81	0.000166	0.0481	0.19	0.2	Schizophrenia;	chr1:114739429	chr1:114535995~114537840:+
STAD	cis	rs12517545	1	rs2029517	ENSG00000255883.1	RP11-79P5.10	-3.81	0.000166	0.0481	-0.25	-0.2	Systemic juvenile idiopathic arthritis;	chr5:74385939	chr5:73508685~73509254:+
STAD	cis	rs7142881	0.78	rs6571437	ENSG00000258648.1	UBE2CP1	-3.81	0.000166	0.0481	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31610780	chr14:30683045~30683598:-
STAD	cis	rs7142881	0.815	rs8022163	ENSG00000258648.1	UBE2CP1	-3.81	0.000166	0.0481	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31611267	chr14:30683045~30683598:-
STAD	cis	rs447735	0.587	rs11647958	ENSG00000260259.1	RP11-368I7.4	3.81	0.000166	0.0481	0.22	0.2	Hemoglobin concentration;	chr16:89654501	chr16:89682620~89686569:-
STAD	cis	rs7777677	0.925	rs4726540	ENSG00000211721.2	TRBV6-5	3.81	0.000166	0.0481	0.21	0.2	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142450947~142451448:+
STAD	cis	rs2143950	0.765	rs75359261	ENSG00000258704.4	SRP54-AS1	-3.81	0.000166	0.0481	-0.27	-0.2	Atopic dermatitis;	chr14:35235851	chr14:34920858~34982532:-
STAD	cis	rs1348850	0.874	rs2166558	ENSG00000271825.1	RP11-337N6.2	3.81	0.000166	0.0481	0.17	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177508924	chr2:177300600~177302006:+
STAD	cis	rs6832769	0.857	rs28377791	ENSG00000223305.1	RN7SKP30	-3.81	0.000166	0.0481	-0.23	-0.2	Personality dimensions;	chr4:55607014	chr4:55540502~55540835:-
STAD	cis	rs10515750	0.643	rs10063413	ENSG00000248544.2	CTB-47B11.3	-3.81	0.000166	0.0481	-0.23	-0.2	Lung function (FEV1/FVC);	chr5:157384435	chr5:157375741~157384950:-
STAD	cis	rs875971	0.862	rs6959268	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000166	0.0481	-0.2	-0.2	Aortic root size;	chr7:66347979	chr7:65773620~65802067:+
STAD	cis	rs55702914	1	rs55702914	ENSG00000231621.1	AC013264.2	-3.81	0.000166	0.0481	-0.17	-0.2	Major depression and alcohol dependence;	chr2:197349672	chr2:197197991~197199273:+
STAD	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	3.81	0.000166	0.0481	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
STAD	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	3.81	0.000166	0.0481	0.45	0.2	QT interval;	chr4:75144808	chr4:75081702~75084717:-
STAD	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	3.81	0.000166	0.0481	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	3.81	0.000166	0.0481	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
STAD	cis	rs721917	0.506	rs4320898	ENSG00000278616.1	BEND3P3	-3.81	0.000166	0.0481	-0.21	-0.2	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79682997~79685436:+
STAD	cis	rs721917	0.506	rs4322333	ENSG00000278616.1	BEND3P3	-3.81	0.000166	0.0481	-0.21	-0.2	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79682997~79685436:+
STAD	cis	rs1075265	0.756	rs2542576	ENSG00000235937.1	AC008280.1	3.81	0.000166	0.0481	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54029552~54030682:-
STAD	cis	rs7989332	0.631	rs9506498	ENSG00000238286.1	SLC35E1P1	3.81	0.000166	0.0481	0.24	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20486694	chr13:20607268~20608131:+
STAD	cis	rs9291683	0.645	rs11557743	ENSG00000250613.1	RP11-136I13.1	3.81	0.000166	0.0482	0.19	0.2	Bone mineral density;	chr4:10116753	chr4:10410996~10411644:+
STAD	cis	rs7927771	0.832	rs10838699	ENSG00000271350.1	CTD-2384B9.1	3.81	0.000166	0.0482	0.22	0.2	Subjective well-being;	chr11:47364522	chr11:47041027~47041945:-
STAD	cis	rs9902453	0.716	rs3098949	ENSG00000240074.1	RPL9P30	3.81	0.000166	0.0482	0.17	0.2	Coffee consumption (cups per day);	chr17:29651676	chr17:29855759~29856332:+
STAD	cis	rs7709377	0.595	rs153594	ENSG00000248445.4	SEMA6A-AS1	-3.81	0.000166	0.0482	-0.18	-0.2	Metabolite levels  (X-11787);	chr5:116300091	chr5:116447547~116508276:+
STAD	cis	rs238295	0.805	rs1983694	ENSG00000230563.2	RP5-828H9.1	3.81	0.000166	0.0482	0.23	0.2	Occipital cortical area (total cortical area interaction);	chr20:5593488	chr20:5471207~5475182:+
STAD	cis	rs2638953	0.741	rs10843194	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000167	0.0482	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510237	chr12:28163298~28190738:-
STAD	cis	rs9902453	0.808	rs10445400	ENSG00000240074.1	RPL9P30	3.81	0.000167	0.0482	0.18	0.2	Coffee consumption (cups per day);	chr17:29856041	chr17:29855759~29856332:+
STAD	cis	rs9902453	0.817	rs4794861	ENSG00000240074.1	RPL9P30	3.81	0.000167	0.0482	0.18	0.2	Coffee consumption (cups per day);	chr17:29856156	chr17:29855759~29856332:+
STAD	cis	rs6479901	0.557	rs4746125	ENSG00000235816.3	PRELID1P3	3.81	0.000167	0.0482	0.25	0.2	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63427297~63427939:+
STAD	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-3.81	0.000167	0.0482	-0.25	-0.2	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
STAD	cis	rs10483554	0.706	rs35566823	ENSG00000258401.1	RP11-326E7.1	3.81	0.000167	0.0482	0.34	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49364561	chr14:49373966~49374383:+
STAD	cis	rs10964378	0.961	rs10117648	ENSG00000231909.7	MAP1LC3BP1	3.81	0.000167	0.0482	0.22	0.2	Asthma;	chr9:19981499	chr9:19460926~19464524:-
STAD	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	3.81	0.000167	0.0482	0.24	0.2	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
STAD	cis	rs2919009	0.766	rs56259440	ENSG00000227165.6	WDR11-AS1	-3.81	0.000167	0.0482	-0.3	-0.2	Obesity-related traits;	chr10:120809566	chr10:120761812~120851345:-
STAD	cis	rs7283707	0.681	rs57733106	ENSG00000228798.1	AP000473.5	-3.81	0.000167	0.0482	-0.31	-0.2	QRS complex (12-leadsum);	chr21:15749161	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.579	rs17241423	ENSG00000228798.1	AP000473.5	-3.81	0.000167	0.0482	-0.31	-0.2	QRS complex (12-leadsum);	chr21:15749176	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs10482876	ENSG00000228798.1	AP000473.5	-3.81	0.000167	0.0482	-0.31	-0.2	QRS complex (12-leadsum);	chr21:15749320	chr21:16630827~16640683:+
STAD	cis	rs7283707	0.681	rs74917734	ENSG00000228798.1	AP000473.5	-3.81	0.000167	0.0482	-0.31	-0.2	QRS complex (12-leadsum);	chr21:15753935	chr21:16630827~16640683:+
STAD	cis	rs7142881	0.815	rs12882018	ENSG00000258648.1	UBE2CP1	-3.81	0.000167	0.0482	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31605125	chr14:30683045~30683598:-
STAD	cis	rs9907295	0.685	rs4796131	ENSG00000270894.1	AC015849.13	-3.81	0.000167	0.0482	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35904812	chr17:35818399~35823713:+
STAD	cis	rs1345301	0.552	rs1558626	ENSG00000234389.1	AC007278.3	-3.81	0.000167	0.0482	-0.2	-0.2	Waist circumference;	chr2:102245610	chr2:102438713~102440475:+
STAD	cis	rs1345301	0.518	rs1558624	ENSG00000234389.1	AC007278.3	-3.81	0.000167	0.0482	-0.2	-0.2	Waist circumference;	chr2:102245773	chr2:102438713~102440475:+
STAD	cis	rs7283707	0.681	rs74774121	ENSG00000229425.1	AJ006998.2	-3.81	0.000167	0.0482	-0.35	-0.2	QRS complex (12-leadsum);	chr21:15802579	chr21:15370522~15402305:-
STAD	cis	rs66887589	0.616	rs11731675	ENSG00000250412.1	KLHL2P1	3.81	0.000167	0.0482	0.25	0.2	Diastolic blood pressure;	chr4:119291359	chr4:119334329~119378233:+
STAD	cis	rs11051970	0.559	rs10844179	ENSG00000274964.1	RP11-817I4.1	3.81	0.000167	0.0482	0.27	0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32316667	chr12:32339368~32340724:+
STAD	cis	rs638893	1	rs649338	ENSG00000255422.1	AP002954.4	-3.81	0.000167	0.0483	-0.34	-0.2	Vitiligo;	chr11:118834945	chr11:118704607~118750263:+
STAD	cis	rs6496044	0.963	rs7165300	ENSG00000259407.1	RP11-158M2.3	-3.81	0.000167	0.0483	-0.21	-0.2	Interstitial lung disease;	chr15:85526838	chr15:85744109~85750281:-
STAD	cis	rs10129255	0.872	rs8015406	ENSG00000224373.3	IGHV4-59	3.81	0.000167	0.0483	0.16	0.2	Kawasaki disease;	chr14:106670611	chr14:106627249~106627825:-
STAD	cis	rs5758659	0.652	rs133358	ENSG00000182057.4	OGFRP1	3.81	0.000167	0.0483	0.21	0.2	Cognitive function;	chr22:42046535	chr22:42269753~42275196:+
STAD	cis	rs7512552	0.809	rs2794685	ENSG00000203819.6	HIST2H2BC	3.81	0.000167	0.0483	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150339792	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.839	rs1625468	ENSG00000203819.6	HIST2H2BC	3.81	0.000167	0.0483	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150349010	chr1:149850193~149850772:-
STAD	cis	rs7512552	0.78	rs2794681	ENSG00000203819.6	HIST2H2BC	3.81	0.000167	0.0483	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150349475	chr1:149850193~149850772:-
STAD	cis	rs57960857	1	rs57960857	ENSG00000251022.5	THAP9-AS1	3.81	0.000167	0.0483	0.2	0.2	Neutrophil percentage of white cells;	chr4:82886057	chr4:82893009~82900960:-
STAD	cis	rs10789491	1	rs601060	ENSG00000225506.2	CYP4A22-AS1	-3.81	0.000167	0.0483	-0.28	-0.2	Response to hepatitis C treatment;	chr1:46673908	chr1:47096653~47179271:-
STAD	cis	rs7502499	0.781	rs8080108	ENSG00000240995.2	RP11-708H21.1	-3.81	0.000167	0.0483	-0.22	-0.2	Cancer;Coronary artery disease;	chr17:49436349	chr17:49148339~49149111:-
STAD	cis	rs17401966	0.54	rs3748581	ENSG00000199562.1	RNU6-37P	3.81	0.000167	0.0483	0.14	0.2	Hepatocellular carcinoma;	chr1:10381606	chr1:10298966~10299072:+
STAD	cis	rs6813195	0.642	rs10033601	ENSG00000243417.1	RP11-555K12.1	-3.81	0.000167	0.0483	-0.2	-0.2	Type 2 diabetes;	chr4:152330909	chr4:152551277~152552364:-
STAD	cis	rs4243830	0.826	rs3908553	ENSG00000229519.2	RP11-58A11.2	-3.81	0.000167	0.0483	-0.25	-0.2	Body mass index;	chr1:6561861	chr1:6547905~6548619:+
STAD	cis	rs6588634	0.573	rs2184104	ENSG00000236776.1	RPL21P23	-3.81	0.000167	0.0483	-0.28	-0.2	Pulse pressure;	chr1:56446550	chr1:56538452~56538911:+
STAD	cis	rs75920871	0.528	rs1531707	ENSG00000254851.1	RP11-109L13.1	3.81	0.000167	0.0483	0.22	0.2	Subjective well-being;	chr11:117073996	chr11:117135528~117138582:+
STAD	cis	rs1922291	0.546	rs3771187	ENSG00000234389.1	AC007278.3	-3.81	0.000167	0.0483	-0.2	-0.2	Blood protein levels;	chr2:102223898	chr2:102438713~102440475:+
STAD	cis	rs1922291	0.546	rs12472872	ENSG00000234389.1	AC007278.3	-3.81	0.000167	0.0483	-0.2	-0.2	Blood protein levels;	chr2:102224384	chr2:102438713~102440475:+
STAD	cis	rs2412488	0.566	rs6837934	ENSG00000269506.2	RP11-571I18.5	3.81	0.000167	0.0483	0.2	0.2	DNA methylation (variation);	chr4:53510988	chr4:54059597~54061210:+
STAD	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-3.81	0.000167	0.0483	-0.28	-0.2	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
STAD	cis	rs4869931	0.929	rs59466561	ENSG00000218358.2	RAET1K	3.81	0.000167	0.0483	0.31	0.2	Systolic blood pressure in sickle cell anemia;	chr6:150683983	chr6:149998019~150005157:-
STAD	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	3.81	0.000167	0.0483	0.22	0.2	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
STAD	cis	rs8054556	0.74	rs8059619	ENSG00000261588.1	AC002310.17	3.81	0.000167	0.0483	0.22	0.2	Autism spectrum disorder or schizophrenia;	chr16:29914124	chr16:30587662~30587920:-
STAD	cis	rs8054556	0.74	rs10083738	ENSG00000261588.1	AC002310.17	3.81	0.000167	0.0483	0.22	0.2	Autism spectrum disorder or schizophrenia;	chr16:29916381	chr16:30587662~30587920:-
STAD	cis	rs10782582	0.609	rs1796810	ENSG00000181227.3	RP4-682C21.2	3.81	0.000167	0.0483	0.21	0.2	Daytime sleep phenotypes;	chr1:75937620	chr1:75743423~75744776:-
STAD	cis	rs10782582	0.609	rs1770882	ENSG00000181227.3	RP4-682C21.2	3.81	0.000167	0.0483	0.21	0.2	Daytime sleep phenotypes;	chr1:75945864	chr1:75743423~75744776:-
STAD	cis	rs10782582	0.609	rs1630302	ENSG00000181227.3	RP4-682C21.2	3.81	0.000167	0.0483	0.21	0.2	Daytime sleep phenotypes;	chr1:75946405	chr1:75743423~75744776:-
STAD	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	3.81	0.000167	0.0483	0.2	0.2	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
STAD	cis	rs2638953	0.777	rs11049681	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000167	0.0483	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508722	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs11049683	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000167	0.0483	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs10843193	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000167	0.0483	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.853	rs7485676	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000167	0.0483	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28163298~28190738:-
STAD	cis	rs72843166	0.545	rs1107041	ENSG00000272164.1	RP11-180P8.5	-3.81	0.000167	0.0483	-0.23	-0.2	Intelligence (multi-trait analysis);	chr17:62928589	chr17:63004672~63005152:-
STAD	cis	rs72843166	0.545	rs72839486	ENSG00000272164.1	RP11-180P8.5	-3.81	0.000167	0.0483	-0.23	-0.2	Intelligence (multi-trait analysis);	chr17:62937300	chr17:63004672~63005152:-
STAD	cis	rs9733	0.596	rs7418501	ENSG00000276103.1	U4	3.81	0.000167	0.0483	0.19	0.2	Tonsillectomy;	chr1:150739420	chr1:150608507~150608623:-
STAD	cis	rs73198271	0.71	rs11779561	ENSG00000254340.1	RP11-10A14.3	-3.81	0.000167	0.0483	-0.28	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:9141424~9145435:+
STAD	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	3.81	0.000167	0.0484	0.21	0.2	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
STAD	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	3.81	0.000167	0.0484	0.21	0.2	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
STAD	cis	rs6964587	0.967	rs7801058	ENSG00000243107.1	AC000120.7	3.81	0.000167	0.0484	0.19	0.2	Breast cancer;	chr7:92155067	chr7:92200014~92206857:-
STAD	cis	rs1007190	0.881	rs9914884	ENSG00000267405.1	CTC-296K1.4	3.81	0.000167	0.0484	0.23	0.2	DNA methylation (variation);	chr17:44878221	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.881	rs3816275	ENSG00000267405.1	CTC-296K1.4	3.81	0.000167	0.0484	0.23	0.2	DNA methylation (variation);	chr17:44879959	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.881	rs11079378	ENSG00000267405.1	CTC-296K1.4	3.81	0.000167	0.0484	0.23	0.2	DNA methylation (variation);	chr17:44880094	chr17:44794747~44797783:-
STAD	cis	rs1007190	0.881	rs9915066	ENSG00000267405.1	CTC-296K1.4	3.81	0.000167	0.0484	0.23	0.2	DNA methylation (variation);	chr17:44884798	chr17:44794747~44797783:-
STAD	cis	rs7176527	0.706	rs35641144	ENSG00000188388.10	GOLGA6L3	3.81	0.000167	0.0484	0.32	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:85240472~85247170:+
STAD	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	3.81	0.000167	0.0484	0.29	0.2	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
STAD	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	3.81	0.000167	0.0484	0.21	0.2	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
STAD	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	3.81	0.000167	0.0484	0.21	0.2	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
STAD	cis	rs11587682	0.714	rs12121133	ENSG00000274963.1	Metazoa_SRP	-3.81	0.000167	0.0484	-0.21	-0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150446621	chr1:150568971~150569269:-
STAD	cis	rs11098499	0.754	rs4107728	ENSG00000260091.1	RP11-33B1.4	3.81	0.000167	0.0484	0.19	0.2	Corneal astigmatism;	chr4:119332755	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs17049949	ENSG00000260091.1	RP11-33B1.4	3.81	0.000167	0.0484	0.19	0.2	Corneal astigmatism;	chr4:119334135	chr4:119409333~119410233:+
STAD	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-3.81	0.000167	0.0484	-0.21	-0.2	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
STAD	cis	rs6012564	1	rs755587	ENSG00000227431.4	CSE1L-AS1	3.81	0.000167	0.0484	0.19	0.2	Anger;	chr20:49104420	chr20:49040463~49046044:-
STAD	cis	rs12477438	0.52	rs720229	ENSG00000231822.1	AC019097.7	3.81	0.000168	0.0484	0.2	0.2	Chronic sinus infection;	chr2:99087810	chr2:99102018~99102752:+
STAD	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-3.81	0.000168	0.0484	-0.24	-0.2	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
STAD	cis	rs2115630	0.967	rs8028490	ENSG00000256278.1	RP11-182J1.5	-3.81	0.000168	0.0484	-0.19	-0.2	P wave terminal force;	chr15:84734657	chr15:84611689~84614969:-
STAD	cis	rs8072100	0.967	rs8078880	ENSG00000264243.1	RP11-6N17.1	-3.81	0.000168	0.0484	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47863342~47865190:+
STAD	cis	rs263063	0.92	rs4807681	ENSG00000280239.1	CTB-50L17.8	-3.81	0.000168	0.0484	-0.28	-0.2	Periodontitis (CDC/AAP);	chr19:5037753	chr19:4448810~4450836:+
STAD	cis	rs733592	0.929	rs4760678	ENSG00000258273.1	RP11-370I10.4	3.81	0.000168	0.0484	0.24	0.2	Plateletcrit;	chr12:48067798	chr12:48333755~48333901:-
STAD	cis	rs733592	0.965	rs1978161	ENSG00000258273.1	RP11-370I10.4	3.81	0.000168	0.0484	0.24	0.2	Plateletcrit;	chr12:48073938	chr12:48333755~48333901:-
STAD	cis	rs7937127	0.744	rs55931860	ENSG00000254907.1	RP11-484D2.2	3.81	0.000168	0.0484	0.34	0.2	Fibrinogen levels;	chr11:43478592	chr11:43328748~43359296:-
STAD	cis	rs7937127	0.744	rs7104153	ENSG00000254907.1	RP11-484D2.2	3.81	0.000168	0.0484	0.34	0.2	Fibrinogen levels;	chr11:43478744	chr11:43328748~43359296:-
STAD	cis	rs10129255	0.912	rs61996059	ENSG00000224373.3	IGHV4-59	3.81	0.000168	0.0484	0.16	0.2	Kawasaki disease;	chr14:106716897	chr14:106627249~106627825:-
STAD	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	3.81	0.000168	0.0484	0.3	0.2	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
STAD	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	3.81	0.000168	0.0484	0.3	0.2	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
STAD	cis	rs11169552	0.51	rs4238106	ENSG00000200428.1	Y_RNA	3.81	0.000168	0.0484	0.22	0.2	Colorectal cancer;	chr12:50603808	chr12:50743568~50743684:+
STAD	cis	rs11169552	0.51	rs10876070	ENSG00000200428.1	Y_RNA	3.81	0.000168	0.0484	0.22	0.2	Colorectal cancer;	chr12:50608305	chr12:50743568~50743684:+
STAD	cis	rs12482963	0.83	rs2155615	ENSG00000237569.1	TUBAP	-3.81	0.000168	0.0484	-0.21	-0.2	Colonoscopy-negative controls vs population controls;	chr21:22604724	chr21:23407658~23409128:-
STAD	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-3.81	0.000168	0.0484	-0.2	-0.2	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
STAD	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	3.81	0.000168	0.0484	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
STAD	cis	rs6657613	0.68	rs6701200	ENSG00000224621.1	RP11-276H7.3	-3.8	0.000168	0.0484	-0.19	-0.2	Hip circumference adjusted for BMI;	chr1:17049085	chr1:16159266~16161883:+
STAD	cis	rs6756513	0.505	rs2228203	ENSG00000244236.3	RN7SL604P	-3.8	0.000168	0.0484	-0.24	-0.2	Breast cancer;Platelet count;	chr2:69806452	chr2:69516751~69517046:+
STAD	cis	rs4927850	0.723	rs7630825	ENSG00000278820.1	AC024937.1	3.8	0.000168	0.0484	0.23	0.2	Pancreatic cancer;	chr3:196026869	chr3:195960500~195960612:-
STAD	cis	rs76917914	0.82	rs58427887	ENSG00000236896.1	RP11-535C21.3	3.8	0.000168	0.0485	0.27	0.2	Immature fraction of reticulocytes;	chr9:98058389	chr9:97986551~97987656:-
STAD	cis	rs10911902	0.643	rs16825183	ENSG00000229739.2	RP11-295K2.3	-3.8	0.000168	0.0485	-0.29	-0.2	Schizophrenia;	chr1:186336861	chr1:186435161~186470291:+
STAD	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-3.8	0.000168	0.0485	-0.23	-0.2	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
STAD	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-3.8	0.000168	0.0485	-0.23	-0.2	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
STAD	cis	rs7015630	0.657	rs6984540	ENSG00000251136.7	RP11-37B2.1	-3.8	0.000168	0.0485	-0.26	-0.2	Inflammatory bowel disease;Crohn's disease;	chr8:89835724	chr8:89609409~89757727:-
STAD	cis	rs10911902	0.643	rs16825224	ENSG00000229739.2	RP11-295K2.3	-3.8	0.000168	0.0485	-0.29	-0.2	Schizophrenia;	chr1:186349723	chr1:186435161~186470291:+
STAD	cis	rs9902453	1	rs6505158	ENSG00000240074.1	RPL9P30	-3.8	0.000168	0.0485	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30076330	chr17:29855759~29856332:+
STAD	cis	rs9595908	0.929	rs7328939	ENSG00000281026.1	N4BP2L2-IT2	-3.8	0.000168	0.0485	-0.16	-0.2	Body mass index;	chr13:32552711	chr13:32504506~32509395:-
STAD	cis	rs786425	0.866	rs7302449	ENSG00000247373.3	RP11-486O12.2	-3.8	0.000168	0.0485	-0.15	-0.2	Pubertal anthropometrics;	chr12:123688199	chr12:123575891~123585115:-
STAD	cis	rs4792901	0.759	rs2271957	ENSG00000279602.1	CTD-3014M21.1	-3.8	0.000168	0.0485	-0.26	-0.2	Dupuytren's disease;	chr17:43521572	chr17:43360041~43361361:-
STAD	cis	rs4474258	0.563	rs1341643	ENSG00000244433.2	PGBD4P7	-3.8	0.000168	0.0485	-0.21	-0.2	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);	chr1:94642818	chr1:94672918~94674161:-
STAD	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	3.8	0.000168	0.0485	0.21	0.2	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
STAD	cis	rs2348418	0.864	rs1949978	ENSG00000247934.4	RP11-967K21.1	3.8	0.000168	0.0485	0.19	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28443951	chr12:28163298~28190738:-
STAD	cis	rs748404	0.578	rs512628	ENSG00000275601.1	AC011330.13	-3.8	0.000168	0.0485	-0.21	-0.2	Lung cancer;	chr15:43326536	chr15:43642389~43643023:-
STAD	cis	rs12586317	0.576	rs6571702	ENSG00000241052.1	RP11-173D9.1	-3.8	0.000168	0.0485	-0.19	-0.2	Psoriasis;	chr14:35181352	chr14:35144021~35144480:-
STAD	cis	rs858239	0.511	rs10256996	ENSG00000230042.1	AK3P3	3.8	0.000168	0.0485	0.22	0.2	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23129178~23129841:+
STAD	cis	rs7607316	0.95	rs6431477	ENSG00000234949.2	AC104667.3	-3.8	0.000168	0.0485	-0.27	-0.2	Airflow obstruction;	chr2:236618184	chr2:237591020~237595981:+
STAD	cis	rs7607316	0.95	rs6431478	ENSG00000234949.2	AC104667.3	-3.8	0.000168	0.0485	-0.27	-0.2	Airflow obstruction;	chr2:236618273	chr2:237591020~237595981:+
STAD	cis	rs12633726	0.515	rs7640298	ENSG00000230497.2	EEF1B2P8	-3.8	0.000168	0.0485	-0.32	-0.2	Influenza A (H1N1) severity;	chr3:175032049	chr3:175059361~175060031:-
STAD	cis	rs1348850	0.914	rs4893823	ENSG00000271825.1	RP11-337N6.2	-3.8	0.000168	0.0485	-0.17	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177421083	chr2:177300600~177302006:+
STAD	cis	rs9902453	0.765	rs2169810	ENSG00000263477.1	RP11-338L22.2	3.8	0.000168	0.0486	0.17	0.2	Coffee consumption (cups per day);	chr17:29840923	chr17:29863402~29866092:+
STAD	cis	rs1499614	0.803	rs1796229	ENSG00000273448.1	RP11-166O4.6	3.8	0.000168	0.0486	0.25	0.2	Gout;	chr7:66654674	chr7:67333047~67334383:+
STAD	cis	rs1499614	0.901	rs3936	ENSG00000273448.1	RP11-166O4.6	3.8	0.000168	0.0486	0.25	0.2	Gout;	chr7:66661502	chr7:67333047~67334383:+
STAD	cis	rs240993	0.909	rs11153279	ENSG00000271789.1	RP5-1112D6.7	3.8	0.000168	0.0486	0.19	0.2	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111297126~111298510:+
STAD	cis	rs12935418	0.733	rs35115578	ENSG00000261061.1	RP11-303E16.2	-3.8	0.000168	0.0486	-0.27	-0.2	Mean corpuscular volume;	chr16:80946392	chr16:81030770~81031485:+
STAD	cis	rs1816752	0.905	rs4769352	ENSG00000232858.1	RPL34P27	3.8	0.000168	0.0486	0.12	0.2	Obesity-related traits;	chr13:24426237	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.805	rs4769353	ENSG00000232858.1	RPL34P27	3.8	0.000168	0.0486	0.12	0.2	Obesity-related traits;	chr13:24426318	chr13:24988577~24988925:-
STAD	cis	rs10986311	0.733	rs2274780	ENSG00000227200.1	RP11-121A14.3	-3.8	0.000168	0.0486	-0.21	-0.2	Vitiligo;	chr9:124312742	chr9:124262876~124265809:+
STAD	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	-3.8	0.000168	0.0486	-0.2	-0.2	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
STAD	cis	rs1707322	0.789	rs10789473	ENSG00000225447.1	RPS15AP10	3.8	0.000168	0.0486	0.16	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45645816~45646197:-
STAD	cis	rs7915414	0.531	rs10509679	ENSG00000230338.1	MTND4P19	-3.8	0.000168	0.0486	-0.24	-0.2	Clopidogrel active metabolite levels;	chr10:94948469	chr10:94774156~94774633:-
STAD	cis	rs950169	0.922	rs2033284	ENSG00000235370.6	DNM1P51	3.8	0.000168	0.0486	0.25	0.2	Schizophrenia;	chr15:84391575	chr15:84398316~84411701:-
STAD	cis	rs1816752	0.712	rs2862898	ENSG00000232858.1	RPL34P27	3.8	0.000168	0.0486	0.12	0.2	Obesity-related traits;	chr13:24414323	chr13:24988577~24988925:-
STAD	cis	rs1816752	0.652	rs2902356	ENSG00000232858.1	RPL34P27	3.8	0.000168	0.0486	0.12	0.2	Obesity-related traits;	chr13:24414333	chr13:24988577~24988925:-
STAD	cis	rs7103648	0.966	rs1534576	ENSG00000280615.1	Y_RNA	-3.8	0.000168	0.0486	-0.2	-0.2	Systolic blood pressure;Diastolic blood pressure;	chr11:47398112	chr11:47614898~47614994:-
STAD	cis	rs62103177	0.564	rs11874805	ENSG00000261126.6	RP11-795F19.1	3.8	0.000169	0.0486	0.31	0.2	Opioid sensitivity;	chr18:79937110	chr18:80046900~80095482:+
STAD	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-3.8	0.000169	0.0486	-0.23	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
STAD	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-3.8	0.000169	0.0486	-0.23	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
STAD	cis	rs4835473	0.932	rs4835118	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000169	0.0486	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143981994	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs4835471	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000169	0.0486	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143982153	chr4:143911514~143912053:-
STAD	cis	rs6604026	0.698	rs4847384	ENSG00000229052.2	RP11-386I23.1	-3.8	0.000169	0.0486	-0.19	-0.2	Multiple sclerosis;	chr1:92916722	chr1:92930696~92934098:+
STAD	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-3.8	0.000169	0.0486	-0.31	-0.2	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
STAD	cis	rs1876905	0.68	rs354540	ENSG00000271789.1	RP5-1112D6.7	-3.8	0.000169	0.0486	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111297126~111298510:+
STAD	cis	rs7170668	0.93	rs12910890	ENSG00000259348.1	RP11-4G2.1	3.8	0.000169	0.0487	0.2	0.2	Motion sickness;	chr15:95473444	chr15:96028089~96046930:-
STAD	cis	rs7943953	0.661	rs4360718	ENSG00000254952.1	AP001257.1	-3.8	0.000169	0.0487	-0.21	-0.2	Odorant perception (&beta-ionone);	chr11:59307364	chr11:60159687~60160822:-
STAD	cis	rs28588043	0.594	rs17562854	ENSG00000201126.1	RNU6-773P	-3.8	0.000169	0.0487	-0.38	-0.2	Number of children (6+ vs. 0 or 1);	chr1:170949392	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs17562882	ENSG00000201126.1	RNU6-773P	-3.8	0.000169	0.0487	-0.38	-0.2	Number of children (6+ vs. 0 or 1);	chr1:170949494	chr1:171519816~171519913:-
STAD	cis	rs28588043	0.594	rs17562888	ENSG00000201126.1	RNU6-773P	-3.8	0.000169	0.0487	-0.38	-0.2	Number of children (6+ vs. 0 or 1);	chr1:170949950	chr1:171519816~171519913:-
STAD	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	3.8	0.000169	0.0487	0.22	0.2	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
STAD	cis	rs12468226	1	rs7597156	ENSG00000272966.1	RP11-686O6.1	3.8	0.000169	0.0487	0.28	0.2	Urate levels;	chr2:202329339	chr2:202336739~202337200:+
STAD	cis	rs10129255	0.785	rs10150044	ENSG00000224373.3	IGHV4-59	3.8	0.000169	0.0487	0.16	0.2	Kawasaki disease;	chr14:106775695	chr14:106627249~106627825:-
STAD	cis	rs11098499	0.754	rs66900435	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0487	0.19	0.2	Corneal astigmatism;	chr4:119328270	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs1980027	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0487	0.19	0.2	Corneal astigmatism;	chr4:119330422	chr4:119409333~119410233:+
STAD	cis	rs11239930	0.517	rs584107	ENSG00000278811.3	LINC00624	-3.8	0.000169	0.0487	-0.21	-0.2	AIDS progression;	chr1:147075862	chr1:147258885~147517875:-
STAD	cis	rs765787	0.53	rs1648285	ENSG00000259539.1	CTD-2651B20.1	3.8	0.000169	0.0487	0.23	0.2	Uric acid levels;	chr15:45225307	chr15:45152664~45167526:-
STAD	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	3.8	0.000169	0.0487	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
STAD	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-3.8	0.000169	0.0487	-0.25	-0.2	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
STAD	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-3.8	0.000169	0.0487	-0.25	-0.2	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
STAD	cis	rs30380	0.632	rs149189	ENSG00000272109.1	CTD-2260A17.3	-3.8	0.000169	0.0487	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr5:96802101	chr5:96804353~96806105:+
STAD	cis	rs30380	0.632	rs26495	ENSG00000272109.1	CTD-2260A17.3	-3.8	0.000169	0.0487	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr5:96802137	chr5:96804353~96806105:+
STAD	cis	rs30380	0.632	rs26496	ENSG00000272109.1	CTD-2260A17.3	-3.8	0.000169	0.0487	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr5:96802179	chr5:96804353~96806105:+
STAD	cis	rs867371	0.502	rs1846908	ENSG00000259429.4	UBE2Q2P2	-3.8	0.000169	0.0487	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82355142~82420075:+
STAD	cis	rs2665103	0.655	rs1501367	ENSG00000259429.4	UBE2Q2P2	-3.8	0.000169	0.0487	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82355142~82420075:+
STAD	cis	rs11696739	0.513	rs2209313	ENSG00000242324.1	RP4-576H24.2	-3.8	0.000169	0.0487	-0.26	-0.2	Mean platelet volume;	chr20:1618496	chr20:1516759~1557653:-
STAD	cis	rs10508774	0.81	rs12256909	ENSG00000273038.2	RP11-479G22.8	3.8	0.000169	0.0487	0.36	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32665919	chr10:32887255~32889311:-
STAD	cis	rs595244	1	rs595244	ENSG00000259705.1	RP11-227D13.1	3.8	0.000169	0.0488	0.37	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48548638	chr15:48645951~48652016:+
STAD	cis	rs595244	1	rs1561207	ENSG00000259705.1	RP11-227D13.1	3.8	0.000169	0.0488	0.37	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48566774	chr15:48645951~48652016:+
STAD	cis	rs9326248	0.559	rs484646	ENSG00000280143.1	AP000892.6	3.8	0.000169	0.0488	0.16	0.2	Blood protein levels;	chr11:116862140	chr11:117204967~117210292:+
STAD	cis	rs916888	0.61	rs199453	ENSG00000260075.1	NSFP1	3.8	0.000169	0.0488	0.27	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46372855~46487141:+
STAD	cis	rs6095360	0.727	rs13044144	ENSG00000227431.4	CSE1L-AS1	-3.8	0.000169	0.0488	-0.24	-0.2	Intelligence (multi-trait analysis);	chr20:48912271	chr20:49040463~49046044:-
STAD	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-3.8	0.000169	0.0488	-0.21	-0.2	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
STAD	cis	rs11671005	0.779	rs3794970	ENSG00000269600.1	AC016629.3	3.8	0.000169	0.0488	0.3	0.2	Mean platelet volume;	chr19:58474893	chr19:58593896~58599355:-
STAD	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	3.8	0.000169	0.0488	0.21	0.2	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
STAD	cis	rs11098499	0.754	rs28643450	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119324087	chr4:119409333~119410233:+
STAD	cis	rs10028773	0.7	rs7671797	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Educational attainment;	chr4:119327002	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs7672372	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119327251	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs7672594	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119327388	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs7672778	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119327430	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs2036860	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119327779	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs12513083	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119328457	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs12509621	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119328505	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs1511017	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119329650	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.789	rs12498994	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119329663	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs12507565	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119329966	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.826	rs12511640	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119330093	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs1980026	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119330488	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.722	rs28713555	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119330840	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.743	rs11098501	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119330862	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs11098502	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119330908	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.708	rs11732686	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119331175	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs11724409	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119331206	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.789	rs1980024	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119331892	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs34425882	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119332022	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.754	rs7689729	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119335037	chr4:119409333~119410233:+
STAD	cis	rs10028773	0.7	rs7690338	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Educational attainment;	chr4:119335313	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.865	rs3956464	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119335609	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.619	rs28502463	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119335868	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.648	rs2002047	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119336073	chr4:119409333~119410233:+
STAD	cis	rs11098499	0.775	rs2002049	ENSG00000260091.1	RP11-33B1.4	3.8	0.000169	0.0488	0.19	0.2	Corneal astigmatism;	chr4:119336262	chr4:119409333~119410233:+
STAD	cis	rs10514928	1	rs10514928	ENSG00000228782.6	CTD-2026D20.3	-3.8	0.000169	0.0488	-0.37	-0.2	Left atrial antero-posterior diameter;	chr17:47426173	chr17:47450568~47492492:-
STAD	cis	rs606458	0.92	rs10897524	ENSG00000269038.1	AP001462.6	-3.8	0.000169	0.0488	-0.27	-0.2	Urate levels;	chr11:64735891	chr11:64778954~64779405:+
STAD	cis	rs10073892	0.673	rs924680	ENSG00000250682.4	LINC00491	-3.8	0.000169	0.0488	-0.22	-0.2	Cognitive decline (age-related);	chr5:102545009	chr5:102609156~102671559:-
STAD	cis	rs10073892	0.664	rs924679	ENSG00000250682.4	LINC00491	-3.8	0.000169	0.0488	-0.22	-0.2	Cognitive decline (age-related);	chr5:102545011	chr5:102609156~102671559:-
STAD	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	3.8	0.000169	0.0488	0.17	0.2	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
STAD	cis	rs749052	0.561	rs3103261	ENSG00000251485.1	AC068134.10	-3.8	0.000169	0.0488	-0.49	-0.2	Height;	chr2:232128864	chr2:232343116~232343903:+
STAD	cis	rs7142881	0.815	rs7142098	ENSG00000258648.1	UBE2CP1	-3.8	0.000169	0.0488	-0.21	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31578011	chr14:30683045~30683598:-
STAD	cis	rs6832769	1	rs3805152	ENSG00000223305.1	RN7SKP30	3.8	0.000169	0.0488	0.22	0.2	Personality dimensions;	chr4:55493491	chr4:55540502~55540835:-
STAD	cis	rs6832769	1	rs6824057	ENSG00000223305.1	RN7SKP30	3.8	0.000169	0.0488	0.22	0.2	Personality dimensions;	chr4:55501111	chr4:55540502~55540835:-
STAD	cis	rs6832769	1	rs12646078	ENSG00000223305.1	RN7SKP30	3.8	0.000169	0.0488	0.22	0.2	Personality dimensions;	chr4:55502037	chr4:55540502~55540835:-
STAD	cis	rs6832769	1	rs6837710	ENSG00000223305.1	RN7SKP30	3.8	0.000169	0.0488	0.22	0.2	Personality dimensions;	chr4:55508288	chr4:55540502~55540835:-
STAD	cis	rs79349575	0.756	rs2291726	ENSG00000248278.1	SUMO2P17	-3.8	0.000169	0.0488	-0.22	-0.2	Type 2 diabetes;	chr17:48961892	chr17:48874860~48908983:-
STAD	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	3.8	0.000169	0.0488	0.23	0.2	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
STAD	cis	rs1075265	0.692	rs805358	ENSG00000235937.1	AC008280.1	3.8	0.000169	0.0488	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54029552~54030682:-
STAD	cis	rs1850744	0.826	rs7685513	ENSG00000250942.1	ENPP7P11	-3.8	0.000169	0.0488	-0.37	-0.2	Economic and political preferences;	chr4:9726975	chr4:9677308~9677934:+
STAD	cis	rs2904967	0.636	rs239253	ENSG00000254614.2	AP003068.23	-3.8	0.000169	0.0488	-0.3	-0.2	Mean corpuscular volume;	chr11:65217272	chr11:65177606~65181834:-
STAD	cis	rs561341	0.739	rs9906455	ENSG00000265798.5	RP11-271K11.5	-3.8	0.00017	0.0488	-0.24	-0.2	Hip circumference adjusted for BMI;	chr17:31888650	chr17:31038575~31059121:-
STAD	cis	rs561341	0.739	rs8070554	ENSG00000265798.5	RP11-271K11.5	-3.8	0.00017	0.0488	-0.24	-0.2	Hip circumference adjusted for BMI;	chr17:31889849	chr17:31038575~31059121:-
STAD	cis	rs875971	1	rs2077593	ENSG00000224316.1	RP11-479O9.2	3.8	0.00017	0.0488	0.2	0.2	Aortic root size;	chr7:66427543	chr7:65773620~65802067:+
STAD	cis	rs2998286	0.723	rs332168	ENSG00000254635.4	WAC-AS1	-3.8	0.00017	0.0488	-0.29	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28607488	chr10:28522652~28532743:-
STAD	cis	rs4639966	0.836	rs10892282	ENSG00000255239.1	AP002954.6	3.8	0.00017	0.0488	0.25	0.2	Systemic lupus erythematosus;	chr11:118757069	chr11:118688039~118690600:-
STAD	cis	rs7688540	0.68	rs77762064	ENSG00000275426.1	CH17-262A2.1	3.8	0.00017	0.0488	0.3	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:281154	chr4:149738~150317:+
STAD	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-3.8	0.00017	0.0488	-0.21	-0.2	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
STAD	cis	rs4950322	0.58	rs4950308	ENSG00000278811.3	LINC00624	3.8	0.00017	0.0488	0.21	0.2	Protein quantitative trait loci;	chr1:147120092	chr1:147258885~147517875:-
STAD	cis	rs748404	0.601	rs502157	ENSG00000275601.1	AC011330.13	3.8	0.00017	0.0489	0.2	0.2	Lung cancer;	chr15:43236375	chr15:43642389~43643023:-
STAD	cis	rs14027	0.883	rs10087723	ENSG00000279347.1	RP11-85I17.2	-3.8	0.00017	0.0489	-0.18	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119838736~119840385:-
STAD	cis	rs9902453	0.967	rs4994355	ENSG00000263477.1	RP11-338L22.2	-3.8	0.00017	0.0489	-0.17	-0.2	Coffee consumption (cups per day);	chr17:30059266	chr17:29863402~29866092:+
STAD	cis	rs9393777	0.513	rs6904071	ENSG00000224843.5	LINC00240	3.8	0.00017	0.0489	0.33	0.2	Intelligence (multi-trait analysis);	chr6:27079477	chr6:26956992~27023924:+
STAD	cis	rs9393777	0.513	rs34388707	ENSG00000224843.5	LINC00240	3.8	0.00017	0.0489	0.33	0.2	Intelligence (multi-trait analysis);	chr6:27082617	chr6:26956992~27023924:+
STAD	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	3.8	0.00017	0.0489	0.29	0.2	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
STAD	cis	rs1075265	0.744	rs10203576	ENSG00000235937.1	AC008280.1	3.8	0.00017	0.0489	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54029552~54030682:-
STAD	cis	rs7688540	0.8	rs73793597	ENSG00000198155.5	ZNF876P	-3.8	0.00017	0.0489	-0.28	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:212610~255985:+
STAD	cis	rs11089937	0.651	rs1543779	ENSG00000211639.2	IGLV4-60	-3.8	0.00017	0.0489	-0.21	-0.2	Periodontitis (PAL4Q3);	chr22:22194092	chr22:22162199~22162681:+
STAD	cis	rs6813195	0.781	rs4696326	ENSG00000243417.1	RP11-555K12.1	-3.8	0.00017	0.0489	-0.19	-0.2	Type 2 diabetes;	chr4:152590488	chr4:152551277~152552364:-
STAD	cis	rs786425	0.804	rs11057320	ENSG00000247373.3	RP11-486O12.2	-3.8	0.00017	0.0489	-0.15	-0.2	Pubertal anthropometrics;	chr12:123656815	chr12:123575891~123585115:-
STAD	cis	rs4925386	0.84	rs6143035	ENSG00000273619.1	RP5-908M14.9	3.8	0.00017	0.0489	0.19	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62386303~62386970:-
STAD	cis	rs7512552	0.839	rs12045304	ENSG00000203819.6	HIST2H2BC	3.8	0.00017	0.0489	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150427342	chr1:149850193~149850772:-
STAD	cis	rs1707322	0.827	rs12125508	ENSG00000225447.1	RPS15AP10	3.8	0.00017	0.0489	0.16	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45645816~45646197:-
STAD	cis	rs9368481	0.594	rs2636425	ENSG00000241549.7	GUSBP2	3.8	0.00017	0.0489	0.21	0.2	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26871484~26956554:-
STAD	cis	rs11098499	0.913	rs10006304	ENSG00000250412.1	KLHL2P1	3.8	0.00017	0.049	0.27	0.2	Corneal astigmatism;	chr4:119203150	chr4:119334329~119378233:+
STAD	cis	rs6832769	0.925	rs6554292	ENSG00000223305.1	RN7SKP30	-3.8	0.00017	0.049	-0.23	-0.2	Personality dimensions;	chr4:55584943	chr4:55540502~55540835:-
STAD	cis	rs6832769	0.961	rs10026692	ENSG00000223305.1	RN7SKP30	-3.8	0.00017	0.049	-0.23	-0.2	Personality dimensions;	chr4:55586539	chr4:55540502~55540835:-
STAD	cis	rs12210905	1	rs9368492	ENSG00000241549.7	GUSBP2	-3.8	0.00017	0.049	-0.32	-0.2	Hip circumference adjusted for BMI;	chr6:27253739	chr6:26871484~26956554:-
STAD	cis	rs7915414	0.671	rs12775423	ENSG00000230338.1	MTND4P19	3.8	0.00017	0.049	0.24	0.2	Clopidogrel active metabolite levels;	chr10:94649638	chr10:94774156~94774633:-
STAD	cis	rs7915414	0.671	rs12782132	ENSG00000230338.1	MTND4P19	3.8	0.00017	0.049	0.24	0.2	Clopidogrel active metabolite levels;	chr10:94649746	chr10:94774156~94774633:-
STAD	cis	rs7915414	0.671	rs7085420	ENSG00000230338.1	MTND4P19	3.8	0.00017	0.049	0.24	0.2	Clopidogrel active metabolite levels;	chr10:94650453	chr10:94774156~94774633:-
STAD	cis	rs997295	0.57	rs17241808	ENSG00000270964.1	RP11-502I4.3	-3.8	0.00017	0.049	-0.24	-0.2	Motion sickness;	chr15:67600454	chr15:67541072~67542604:-
STAD	cis	rs17507216	0.718	rs72753931	ENSG00000259429.4	UBE2Q2P2	-3.8	0.00017	0.049	-0.31	-0.2	Excessive daytime sleepiness;	chr15:82721485	chr15:82355142~82420075:+
STAD	cis	rs10782582	0.609	rs10873797	ENSG00000181227.3	RP4-682C21.2	3.8	0.00017	0.049	0.21	0.2	Daytime sleep phenotypes;	chr1:75911506	chr1:75743423~75744776:-
STAD	cis	rs7731390	0.618	rs12153431	ENSG00000248245.1	CTB-49A3.2	-3.8	0.00017	0.049	-0.28	-0.2	IgG glycosylation;	chr5:132482965	chr5:133160438~133224413:+
STAD	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	3.8	0.00017	0.049	0.24	0.2	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
STAD	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	3.8	0.00017	0.049	0.23	0.2	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
STAD	cis	rs11612508	0.567	rs11054918	ENSG00000255670.1	RP11-253I19.3	3.8	0.00017	0.049	0.21	0.2	Inflammatory bowel disease;	chr12:12455116	chr12:12485353~12491581:+
STAD	cis	rs1075265	0.716	rs7573991	ENSG00000235937.1	AC008280.1	3.8	0.00017	0.049	0.18	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54029552~54030682:-
STAD	cis	rs2957692	0.506	rs55784591	ENSG00000254554.1	RP11-351I24.1	3.8	0.00017	0.049	0.33	0.2	Circulating vasoactive peptide levels;	chr11:9928378	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.506	rs10840327	ENSG00000254554.1	RP11-351I24.1	3.8	0.00017	0.049	0.33	0.2	Circulating vasoactive peptide levels;	chr11:9930421	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.506	rs61876943	ENSG00000254554.1	RP11-351I24.1	3.8	0.00017	0.049	0.33	0.2	Circulating vasoactive peptide levels;	chr11:9930791	chr11:10302657~10303704:-
STAD	cis	rs2957692	0.506	rs61876944	ENSG00000254554.1	RP11-351I24.1	3.8	0.00017	0.049	0.33	0.2	Circulating vasoactive peptide levels;	chr11:9930810	chr11:10302657~10303704:-
STAD	cis	rs1020064	0.895	rs2250659	ENSG00000235319.1	AC012360.4	-3.8	0.00017	0.049	-0.28	-0.2	AIDS;	chr2:105273227	chr2:105324210~105330529:+
STAD	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	3.8	0.00017	0.049	0.23	0.2	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
STAD	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	3.8	0.00017	0.049	0.31	0.2	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
STAD	cis	rs5997397	1	rs5997397	ENSG00000226471.5	CTA-292E10.6	-3.8	0.00017	0.049	-0.23	-0.2	Red cell distribution width;	chr22:28758467	chr22:28800683~28848559:+
STAD	cis	rs2483058	0.515	rs3849275	ENSG00000261000.1	RP11-534L20.5	-3.8	0.00017	0.049	-0.24	-0.2	Cholesterol and Triglycerides;	chr1:206432315	chr1:206503948~206504456:+
STAD	cis	rs1348850	0.632	rs11682717	ENSG00000271825.1	RP11-337N6.2	3.8	0.00017	0.049	0.18	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177634512	chr2:177300600~177302006:+
STAD	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	3.8	0.000171	0.0491	0.29	0.2	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
STAD	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-3.8	0.000171	0.0491	-0.2	-0.2	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
STAD	cis	rs56114371	0.53	rs9357045	ENSG00000243307.2	POM121L6P	-3.8	0.000171	0.0491	-0.25	-0.2	Breast cancer;	chr6:27721148	chr6:26896952~26898777:+
STAD	cis	rs1823913	0.892	rs35596292	ENSG00000233654.1	AC093388.3	3.8	0.000171	0.0491	0.24	0.2	Obesity-related traits;	chr2:191246890	chr2:190534855~190568102:+
STAD	cis	rs11159086	1	rs72730186	ENSG00000259005.1	RP3-449M8.6	3.8	0.000171	0.0491	0.4	0.2	Advanced glycation end-product levels;	chr14:74475610	chr14:74474007~74474864:-
STAD	cis	rs2562456	0.876	rs11668606	ENSG00000268119.4	CTD-2561J22.5	3.8	0.000171	0.0491	0.25	0.2	Pain;	chr19:21554618	chr19:21444241~21463908:-
STAD	cis	rs2562456	0.876	rs2681395	ENSG00000268119.4	CTD-2561J22.5	3.8	0.000171	0.0491	0.25	0.2	Pain;	chr19:21555338	chr19:21444241~21463908:-
STAD	cis	rs2880765	0.835	rs7168860	ENSG00000259295.5	CSPG4P12	3.8	0.000171	0.0491	0.25	0.2	Coronary artery disease;	chr15:85493799	chr15:85191438~85213905:+
STAD	cis	rs11089937	0.963	rs5757098	ENSG00000211638.2	IGLV8-61	3.8	0.000171	0.0491	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22098700~22099212:+
STAD	cis	rs9307551	0.584	rs4975053	ENSG00000250334.4	LINC00989	3.8	0.000171	0.0491	0.24	0.2	Refractive error;	chr4:79546733	chr4:79492416~79576460:+
STAD	cis	rs997154	0.655	rs2008345	ENSG00000257285.4	RP11-298I3.1	3.8	0.000171	0.0491	0.31	0.2	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:22929609~22955562:+
STAD	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	3.8	0.000171	0.0491	0.25	0.2	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
STAD	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	3.8	0.000171	0.0491	0.25	0.2	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
STAD	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	3.8	0.000171	0.0491	0.25	0.2	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
STAD	cis	rs6840360	0.642	rs2724577	ENSG00000251603.1	RP11-164P12.4	-3.8	0.000171	0.0491	-0.24	-0.2	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151667224~151670502:+
STAD	cis	rs10971721	0.822	rs10971791	ENSG00000281128.1	PTENP1-AS	3.8	0.000171	0.0491	0.3	0.2	Body mass index;	chr9:33920912	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971792	ENSG00000281128.1	PTENP1-AS	3.8	0.000171	0.0491	0.3	0.2	Body mass index;	chr9:33920955	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72727329	ENSG00000281128.1	PTENP1-AS	3.8	0.000171	0.0491	0.3	0.2	Body mass index;	chr9:33921666	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs11848	ENSG00000281128.1	PTENP1-AS	3.8	0.000171	0.0491	0.3	0.2	Body mass index;	chr9:33921921	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971793	ENSG00000281128.1	PTENP1-AS	3.8	0.000171	0.0491	0.3	0.2	Body mass index;	chr9:33922628	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs10971794	ENSG00000281128.1	PTENP1-AS	3.8	0.000171	0.0491	0.3	0.2	Body mass index;	chr9:33924314	chr9:33677268~33688011:+
STAD	cis	rs10971721	0.822	rs72727353	ENSG00000281128.1	PTENP1-AS	3.8	0.000171	0.0491	0.3	0.2	Body mass index;	chr9:33950824	chr9:33677268~33688011:+
STAD	cis	rs10911902	0.602	rs6425024	ENSG00000229739.2	RP11-295K2.3	-3.8	0.000171	0.0491	-0.29	-0.2	Schizophrenia;	chr1:186305001	chr1:186435161~186470291:+
STAD	cis	rs10911902	0.602	rs2273777	ENSG00000229739.2	RP11-295K2.3	-3.8	0.000171	0.0491	-0.29	-0.2	Schizophrenia;	chr1:186305043	chr1:186435161~186470291:+
STAD	cis	rs12931792	0.712	rs56399904	ENSG00000273724.1	RP11-347C12.12	3.8	0.000171	0.0492	0.2	0.2	Tonsillectomy;	chr16:30154862	chr16:30336400~30343336:+
STAD	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	3.8	0.000171	0.0492	0.22	0.2	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
STAD	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-3.8	0.000171	0.0492	-0.24	-0.2	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
STAD	cis	rs2638953	0.889	rs11049538	ENSG00000247934.4	RP11-967K21.1	-3.8	0.000171	0.0492	-0.23	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335801	chr12:28163298~28190738:-
STAD	cis	rs12468226	1	rs75040639	ENSG00000272966.1	RP11-686O6.1	3.8	0.000171	0.0492	0.29	0.2	Urate levels;	chr2:202486973	chr2:202336739~202337200:+
STAD	cis	rs4713118	0.696	rs2394002	ENSG00000220721.1	OR1F12	3.8	0.000171	0.0492	0.23	0.2	Parkinson's disease;	chr6:27780236	chr6:28073316~28074233:+
STAD	cis	rs4730250	0.707	rs257381	ENSG00000273320.1	RP11-22N19.2	-3.8	0.000171	0.0492	-0.31	-0.2	Osteoarthritis;	chr7:107163518	chr7:106285480~106286326:+
STAD	cis	rs9813712	0.78	rs55929137	ENSG00000249846.5	RP11-77P16.4	3.8	0.000171	0.0492	0.28	0.2	Response to amphetamines;	chr3:130236002	chr3:130112550~130120579:+
STAD	cis	rs8072100	0.875	rs9635762	ENSG00000264243.1	RP11-6N17.1	-3.8	0.000171	0.0492	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47863342~47865190:+
STAD	cis	rs8072100	0.967	rs4793842	ENSG00000264243.1	RP11-6N17.1	-3.8	0.000171	0.0492	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47863342~47865190:+
STAD	cis	rs8072100	0.967	rs8075411	ENSG00000264243.1	RP11-6N17.1	-3.8	0.000171	0.0492	-0.18	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47863342~47865190:+
STAD	cis	rs427941	0.595	rs6465851	ENSG00000232445.1	RP11-132A1.4	-3.8	0.000171	0.0492	-0.24	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102184183	chr7:101308346~101310985:+
STAD	cis	rs4805566	0.763	rs10421254	ENSG00000267006.1	CTC-448F2.4	3.8	0.000171	0.0492	0.22	0.2	Body mass index;	chr19:30419879	chr19:30028741~30029916:-
STAD	cis	rs10132760	0.734	rs10142589	ENSG00000211778.2	TRAV4	-3.8	0.000171	0.0492	-0.18	-0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21717865	chr14:21736152~21736982:+
STAD	cis	rs67311347	0.577	rs2371129	ENSG00000265327.2	RN7SL411P	-3.8	0.000171	0.0492	-0.21	-0.2	Renal cell carcinoma;	chr3:40206902	chr3:40209005~40209304:+
STAD	cis	rs10129255	0.957	rs17113284	ENSG00000232216.1	IGHV3-43	-3.8	0.000171	0.0492	-0.2	-0.2	Kawasaki disease;	chr14:106684476	chr14:106470264~106470800:-
STAD	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-3.8	0.000171	0.0492	-0.24	-0.2	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
STAD	cis	rs4835473	0.897	rs4423826	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000171	0.0492	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143992165	chr4:143911514~143912053:-
STAD	cis	rs919433	0.889	rs787998	ENSG00000231621.1	AC013264.2	-3.8	0.000171	0.0492	-0.17	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351368	chr2:197197991~197199273:+
STAD	cis	rs7523273	0.565	rs11118451	ENSG00000227887.1	RPS26P13	3.8	0.000171	0.0492	0.2	0.2	Schizophrenia;	chr1:207714148	chr1:208697369~208697698:-
STAD	cis	rs7523273	0.565	rs11118453	ENSG00000227887.1	RPS26P13	3.8	0.000171	0.0492	0.2	0.2	Schizophrenia;	chr1:207714651	chr1:208697369~208697698:-
STAD	cis	rs7523273	0.546	rs2796261	ENSG00000227887.1	RPS26P13	-3.8	0.000171	0.0492	-0.2	-0.2	Schizophrenia;	chr1:207715415	chr1:208697369~208697698:-
STAD	cis	rs7523273	0.565	rs2796280	ENSG00000227887.1	RPS26P13	-3.8	0.000171	0.0492	-0.2	-0.2	Schizophrenia;	chr1:207716000	chr1:208697369~208697698:-
STAD	cis	rs6832769	1	rs28514423	ENSG00000223305.1	RN7SKP30	-3.8	0.000171	0.0492	-0.23	-0.2	Personality dimensions;	chr4:55563072	chr4:55540502~55540835:-
STAD	cis	rs7937890	0.967	rs963212	ENSG00000254418.1	RP11-21L19.1	-3.8	0.000171	0.0492	-0.22	-0.2	Mitochondrial DNA levels;	chr11:14303186	chr11:14262846~14273691:-
STAD	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	3.8	0.000171	0.0492	0.22	0.2	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
STAD	cis	rs11702966	0.668	rs111496845	ENSG00000230634.1	RP5-996D20.3	-3.8	0.000171	0.0492	-0.31	-0.2	Tonsillectomy;	chr22:45782369	chr22:46481329~46481760:-
STAD	cis	rs12477438	0.52	rs1133978	ENSG00000231822.1	AC019097.7	3.8	0.000171	0.0492	0.2	0.2	Chronic sinus infection;	chr2:99125501	chr2:99102018~99102752:+
STAD	cis	rs12477438	0.501	rs13008171	ENSG00000231822.1	AC019097.7	3.8	0.000171	0.0492	0.2	0.2	Chronic sinus infection;	chr2:99126956	chr2:99102018~99102752:+
STAD	cis	rs1395	0.744	rs1122227	ENSG00000234072.1	AC074117.10	-3.8	0.000171	0.0493	-0.19	-0.2	Blood metabolite levels;	chr2:27321418	chr2:27356246~27367622:+
STAD	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-3.8	0.000171	0.0493	-0.17	-0.2	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
STAD	cis	rs9463078	0.702	rs9369530	ENSG00000219384.1	RP11-491H9.3	3.8	0.000171	0.0493	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45057174	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.754	rs9349309	ENSG00000219384.1	RP11-491H9.3	3.8	0.000171	0.0493	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45058077	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.665	rs9367214	ENSG00000219384.1	RP11-491H9.3	3.8	0.000171	0.0493	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45058175	chr6:45158870~45159511:+
STAD	cis	rs9463078	0.653	rs1411148	ENSG00000219384.1	RP11-491H9.3	3.8	0.000171	0.0493	0.19	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:45075881	chr6:45158870~45159511:+
STAD	cis	rs2253762	0.54	rs7358186	ENSG00000226864.1	ATE1-AS1	3.8	0.000171	0.0493	0.33	0.2	Breast cancer;	chr10:122000816	chr10:121928312~121951965:+
STAD	cis	rs1147246	0.668	rs325096	ENSG00000280354.1	RP11-83B20.4	3.8	0.000172	0.0493	0.21	0.2	Amyotrophic lateral sclerosis (sporadic);	chr12:125398689	chr12:124542503~124542873:+
STAD	cis	rs595244	1	rs1678982	ENSG00000259705.1	RP11-227D13.1	-3.8	0.000172	0.0493	-0.36	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48609223	chr15:48645951~48652016:+
STAD	cis	rs11929092	0.74	rs12488110	ENSG00000226345.1	AC083822.2	-3.8	0.000172	0.0493	-0.23	-0.2	Mean corpuscular volume;	chr3:196190295	chr3:196423322~196423522:+
STAD	cis	rs919433	0.927	rs7592748	ENSG00000231621.1	AC013264.2	3.8	0.000172	0.0493	0.17	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305964	chr2:197197991~197199273:+
STAD	cis	rs1816752	0.87	rs9581029	ENSG00000232858.1	RPL34P27	3.8	0.000172	0.0493	0.12	0.2	Obesity-related traits;	chr13:24425147	chr13:24988577~24988925:-
STAD	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	3.8	0.000172	0.0493	0.2	0.2	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
STAD	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	3.8	0.000172	0.0493	0.22	0.2	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
STAD	cis	rs116095464	0.542	rs28650039	ENSG00000250848.1	CTD-2083E4.5	-3.8	0.000172	0.0493	-0.31	-0.2	Breast cancer;	chr5:273839	chr5:288833~290321:-
STAD	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	3.8	0.000172	0.0493	0.21	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
STAD	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-3.8	0.000172	0.0493	-0.26	-0.2	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
STAD	cis	rs1930961	1	rs6004668	ENSG00000272942.1	CTA-246H3.12	3.8	0.000172	0.0493	0.33	0.2	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25434324~25435070:-
STAD	cis	rs2286503	0.839	rs4722189	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22820855	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.809	rs4719716	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22821750	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.78	rs981792	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22822020	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.839	rs2270108	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22822512	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.839	rs2270107	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22822564	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.839	rs2270105	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22822848	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.839	rs2270103	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22823103	chr7:22856613~22856686:+
STAD	cis	rs2286503	0.839	rs10276099	ENSG00000221740.1	SNORD93	3.8	0.000172	0.0493	0.23	0.2	Fibrinogen;	chr7:22823331	chr7:22856613~22856686:+
STAD	cis	rs1639906	0.895	rs62443039	ENSG00000201794.1	RN7SKP130	-3.8	0.000172	0.0493	-0.2	-0.2	Colonoscopy-negative controls vs population controls;	chr7:2169719	chr7:2999094~2999394:+
STAD	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-3.8	0.000172	0.0493	-0.25	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
STAD	cis	rs7142881	0.815	rs11626320	ENSG00000258648.1	UBE2CP1	-3.8	0.000172	0.0493	-0.22	-0.2	Response to iloperidone treatment (QT prolongation);	chr14:31570255	chr14:30683045~30683598:-
STAD	cis	rs853679	0.599	rs188015	ENSG00000219392.1	RP1-265C24.5	-3.8	0.000172	0.0493	-0.35	-0.2	Depression;	chr6:27909668	chr6:28115628~28116551:+
STAD	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	3.8	0.000172	0.0493	0.18	0.2	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
STAD	cis	rs7554547	0.739	rs2050269	ENSG00000199347.1	RNU5E-1	3.8	0.000172	0.0494	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr1:11886432	chr1:11908152~11908271:+
STAD	cis	rs7554547	0.765	rs2050268	ENSG00000199347.1	RNU5E-1	3.8	0.000172	0.0494	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr1:11886487	chr1:11908152~11908271:+
STAD	cis	rs7554547	0.765	rs2050267	ENSG00000199347.1	RNU5E-1	3.8	0.000172	0.0494	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr1:11886516	chr1:11908152~11908271:+
STAD	cis	rs4293777	0.774	rs13143205	ENSG00000250896.1	RNPS1P1	3.8	0.000172	0.0494	0.15	0.2	Primary sclerosing cholangitis;	chr4:10726260	chr4:11371975~11372892:+
STAD	cis	rs8177876	0.731	rs77145371	ENSG00000261838.4	RP11-303E16.6	3.8	0.000172	0.0494	0.45	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.908	rs80187824	ENSG00000261838.4	RP11-303E16.6	3.8	0.000172	0.0494	0.45	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.731	rs74882687	ENSG00000261838.4	RP11-303E16.6	3.8	0.000172	0.0494	0.45	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.642	rs76909932	ENSG00000261838.4	RP11-303E16.6	3.8	0.000172	0.0494	0.45	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81069854~81076598:+
STAD	cis	rs8177876	0.822	rs8177939	ENSG00000261838.4	RP11-303E16.6	3.8	0.000172	0.0494	0.45	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81069854~81076598:+
STAD	cis	rs17592366	0.775	rs4981254	ENSG00000251726.1	RNU7-41P	-3.8	0.000172	0.0494	-0.22	-0.2	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34868629	chr14:34845300~34845360:-
STAD	cis	rs7926906	1	rs1540170	ENSG00000280367.1	RP11-121L10.2	3.8	0.000172	0.0494	0.21	0.2	Intelligence (multi-trait analysis);	chr11:90796288	chr11:90223153~90226538:+
STAD	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	3.8	0.000172	0.0494	0.25	0.2	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
STAD	cis	rs6432860	1	rs1834840	ENSG00000229195.1	AC009495.4	-3.8	0.000172	0.0494	-0.25	-0.2	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166029210	chr2:165794857~165846091:-
STAD	cis	rs6432860	1	rs1834839	ENSG00000229195.1	AC009495.4	-3.8	0.000172	0.0494	-0.25	-0.2	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166029378	chr2:165794857~165846091:-
STAD	cis	rs6432860	1	rs7595154	ENSG00000229195.1	AC009495.4	-3.8	0.000172	0.0494	-0.25	-0.2	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166029602	chr2:165794857~165846091:-
STAD	cis	rs10129255	0.833	rs61997797	ENSG00000211972.2	IGHV3-66	3.8	0.000172	0.0494	0.17	0.2	Kawasaki disease;	chr14:106815190	chr14:106675017~106675544:-
STAD	cis	rs11673344	0.504	rs10402907	ENSG00000267672.1	CTD-2293H3.1	3.8	0.000172	0.0494	0.18	0.2	Obesity-related traits;	chr19:37112874	chr19:37091341~37092564:+
STAD	cis	rs11673344	0.563	rs4805199	ENSG00000267672.1	CTD-2293H3.1	3.8	0.000172	0.0494	0.18	0.2	Obesity-related traits;	chr19:37115527	chr19:37091341~37092564:+
STAD	cis	rs27434	0.605	rs2351012	ENSG00000248734.2	CTD-2260A17.1	3.8	0.000172	0.0494	0.25	0.2	Ankylosing spondylitis;	chr5:96856044	chr5:96784777~96785999:+
STAD	cis	rs9907295	0.901	rs9789051	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35892000	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.901	rs3809769	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35892484	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.901	rs76016589	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35892923	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.901	rs4796124	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35893280	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.901	rs11656556	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35894090	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.818	rs11653204	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35894538	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.792	rs4796125	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35894847	chr17:35818399~35823713:+
STAD	cis	rs9907295	0.901	rs79730543	ENSG00000270894.1	AC015849.13	-3.8	0.000172	0.0494	-0.23	-0.2	Fibroblast growth factor basic levels;	chr17:35896537	chr17:35818399~35823713:+
STAD	cis	rs11089937	0.568	rs12159174	ENSG00000211640.3	IGLV6-57	3.8	0.000172	0.0494	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22195713~22196460:+
STAD	cis	rs11089937	0.568	rs11089919	ENSG00000211640.3	IGLV6-57	3.8	0.000172	0.0494	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22195713~22196460:+
STAD	cis	rs9463078	0.764	rs6910294	ENSG00000219384.1	RP11-491H9.3	3.8	0.000172	0.0494	0.2	0.2	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr6:44844828	chr6:45158870~45159511:+
STAD	cis	rs7512552	0.839	rs834231	ENSG00000261716.1	RP11-196G18.22	-3.8	0.000172	0.0494	-0.21	-0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150416916	chr1:149844498~149849024:-
STAD	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	3.8	0.000172	0.0494	0.18	0.2	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
STAD	cis	rs4407350	0.901	rs5765717	ENSG00000279642.1	RP5-1033E15.3	-3.8	0.000172	0.0494	-0.2	-0.2	Intelligence (multi-trait analysis);	chr22:44521766	chr22:44486295~44486914:-
STAD	cis	rs11169552	0.51	rs12231309	ENSG00000200428.1	Y_RNA	3.8	0.000172	0.0494	0.23	0.2	Colorectal cancer;	chr12:50647279	chr12:50743568~50743684:+
STAD	cis	rs10129255	0.912	rs61997792	ENSG00000211973.2	IGHV1-69	3.8	0.000172	0.0494	0.2	0.2	Kawasaki disease;	chr14:106799304	chr14:106714684~106715181:-
STAD	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-3.8	0.000172	0.0494	-0.23	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
STAD	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-3.8	0.000172	0.0494	-0.23	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
STAD	cis	rs12971120	0.947	rs3764509	ENSG00000273669.1	RP11-405M12.4	3.8	0.000172	0.0494	0.22	0.2	Refractive error;	chr18:74499889	chr18:75073543~75074205:+
STAD	cis	rs12971120	0.947	rs8084109	ENSG00000273669.1	RP11-405M12.4	3.8	0.000172	0.0494	0.22	0.2	Refractive error;	chr18:74501077	chr18:75073543~75074205:+
STAD	cis	rs12971120	0.947	rs8084410	ENSG00000273669.1	RP11-405M12.4	3.8	0.000172	0.0494	0.22	0.2	Refractive error;	chr18:74501251	chr18:75073543~75074205:+
STAD	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-3.8	0.000172	0.0494	-0.22	-0.2	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
STAD	cis	rs11089937	0.585	rs6001229	ENSG00000211639.2	IGLV4-60	-3.8	0.000172	0.0495	-0.21	-0.2	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22162199~22162681:+
STAD	cis	rs17401966	1	rs4845934	ENSG00000199562.1	RNU6-37P	3.8	0.000172	0.0495	0.17	0.2	Hepatocellular carcinoma;	chr1:10408889	chr1:10298966~10299072:+
STAD	cis	rs4835473	0.897	rs4835119	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143982210	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs4835120	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143982370	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs4835472	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143982398	chr4:143911514~143912053:-
STAD	cis	rs4835473	1	rs4835473	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143982419	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.897	rs4835474	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143982444	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs6847869	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143982881	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.897	rs6846984	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143983098	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.736	rs11724009	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143984291	chr4:143911514~143912053:-
STAD	cis	rs4323050	0.514	rs28647406	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.604	rs11938387	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000172	0.0495	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143984476	chr4:143911514~143912053:-
STAD	cis	rs3917265	0.591	rs6743219	ENSG00000234389.1	AC007278.3	-3.8	0.000173	0.0495	-0.2	-0.2	Atopic dermatitis;	chr2:102215251	chr2:102438713~102440475:+
STAD	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-3.8	0.000173	0.0495	-0.18	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
STAD	cis	rs7204230	1	rs8053033	ENSG00000261291.1	RP11-295M3.2	3.8	0.000173	0.0495	0.23	0.2	Fibrinogen;	chr16:53289001	chr16:53168522~53169450:+
STAD	cis	rs6840360	0.642	rs2709825	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000173	0.0495	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151333775~151353224:-
STAD	cis	rs6840360	0.607	rs2724547	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000173	0.0495	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151333775~151353224:-
STAD	cis	rs6840360	0.642	rs2724578	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000173	0.0495	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151333775~151353224:-
STAD	cis	rs6840360	0.574	rs2709844	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000173	0.0495	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151333775~151353224:-
STAD	cis	rs7607316	0.95	rs60496880	ENSG00000234949.2	AC104667.3	-3.8	0.000173	0.0495	-0.27	-0.2	Airflow obstruction;	chr2:236619320	chr2:237591020~237595981:+
STAD	cis	rs755249	0.501	rs2484749	ENSG00000182109.6	RP11-69E11.4	-3.8	0.000173	0.0495	-0.24	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39522280~39546187:-
STAD	cis	rs2239557	0.508	rs61245231	ENSG00000259065.1	RP5-1021I20.1	-3.8	0.000173	0.0495	-0.29	-0.2	Common traits (Other);	chr14:73845492	chr14:73787360~73803270:+
STAD	cis	rs7520050	0.966	rs6668284	ENSG00000280836.1	AL355480.1	3.8	0.000173	0.0495	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45581219~45581321:-
STAD	cis	rs925550	0.592	rs1026157	ENSG00000224786.1	CETN4P	3.8	0.000173	0.0495	0.26	0.2	Primary biliary cholangitis;	chr4:122702738	chr4:122730548~122732193:-
STAD	cis	rs2243480	1	rs958550	ENSG00000230295.1	RP11-458F8.2	3.8	0.000173	0.0495	0.24	0.2	Diabetic kidney disease;	chr7:66170692	chr7:66880708~66882981:+
STAD	cis	rs1420956	0.562	rs16943820	ENSG00000265369.3	PCAT18	3.8	0.000173	0.0495	0.23	0.2	Obesity-related traits;	chr18:27599849	chr18:26687621~26703638:-
STAD	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-3.8	0.000173	0.0495	-0.21	-0.2	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
STAD	cis	rs7520050	0.966	rs10890383	ENSG00000280836.1	AL355480.1	3.8	0.000173	0.0495	0.25	0.2	Reticulocyte count;Red blood cell count;	chr1:46122831	chr1:45581219~45581321:-
STAD	cis	rs2957692	0.548	rs17359113	ENSG00000254554.1	RP11-351I24.1	3.8	0.000173	0.0495	0.34	0.2	Circulating vasoactive peptide levels;	chr11:10162312	chr11:10302657~10303704:-
STAD	cis	rs1348850	0.837	rs12619074	ENSG00000271825.1	RP11-337N6.2	3.8	0.000173	0.0496	0.17	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177607608	chr2:177300600~177302006:+
STAD	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	3.8	0.000173	0.0496	0.21	0.2	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
STAD	cis	rs12893668	0.572	rs7148857	ENSG00000269958.1	RP11-73M18.8	3.8	0.000173	0.0496	0.18	0.2	Reticulocyte count;	chr14:103676900	chr14:103696353~103697163:+
STAD	cis	rs4835473	0.932	rs1511425	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000173	0.0496	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143985122	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1849120	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000173	0.0496	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143985337	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs4835476	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000173	0.0496	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143985517	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1828502	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000173	0.0496	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143985797	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs7668698	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000173	0.0496	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143986333	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs6537231	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000173	0.0496	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143986489	chr4:143911514~143912053:-
STAD	cis	rs4835473	0.932	rs1877234	ENSG00000249741.2	RP11-673E1.3	-3.8	0.000173	0.0496	-0.23	-0.2	Immature fraction of reticulocytes;	chr4:143986774	chr4:143911514~143912053:-
STAD	cis	rs35955747	0.869	rs131213	ENSG00000236132.1	CTA-440B3.1	-3.8	0.000173	0.0496	-0.21	-0.2	Neutrophil count;Sum basophil neutrophil counts;	chr22:31357863	chr22:31816379~31817491:-
STAD	cis	rs9733	0.596	rs72702523	ENSG00000276103.1	U4	3.8	0.000173	0.0496	0.19	0.2	Tonsillectomy;	chr1:150677949	chr1:150608507~150608623:-
STAD	cis	rs12807809	1	rs36053597	ENSG00000245498.5	RP11-677M14.7	3.8	0.000173	0.0496	0.29	0.2	Schizophrenia;	chr11:124736588	chr11:124800450~124834487:+
STAD	cis	rs4345303	0.745	rs6892318	ENSG00000206592.1	SNORA18	-3.8	0.000173	0.0496	-0.21	-0.2	Interleukin-10 levels;	chr5:79395210	chr5:79220942~79221073:+
STAD	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	3.8	0.000173	0.0496	0.27	0.2	Depression;	chr6:28167882	chr6:28115628~28116551:+
STAD	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	3.8	0.000173	0.0496	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
STAD	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	3.8	0.000173	0.0496	0.16	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
STAD	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-3.8	0.000173	0.0496	-0.19	-0.2	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
STAD	cis	rs12745968	0.589	rs3936944	ENSG00000229052.2	RP11-386I23.1	-3.8	0.000173	0.0496	-0.19	-0.2	Bipolar disorder and schizophrenia;	chr1:92641401	chr1:92930696~92934098:+
STAD	cis	rs1971762	0.762	rs7976793	ENSG00000257379.1	RP11-793H13.8	3.8	0.000173	0.0496	0.25	0.2	Height;	chr12:53679285	chr12:53441741~53467528:+
STAD	cis	rs10782582	0.609	rs11161848	ENSG00000181227.3	RP4-682C21.2	3.8	0.000173	0.0496	0.21	0.2	Daytime sleep phenotypes;	chr1:75902037	chr1:75743423~75744776:-
STAD	cis	rs867371	0.502	rs28610286	ENSG00000259429.4	UBE2Q2P2	-3.8	0.000173	0.0496	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82355142~82420075:+
STAD	cis	rs4835473	0.932	rs7669198	ENSG00000249741.2	RP11-673E1.3	3.8	0.000173	0.0496	0.22	0.2	Immature fraction of reticulocytes;	chr4:143821229	chr4:143911514~143912053:-
STAD	cis	rs2278796	0.639	rs12145998	ENSG00000231691.1	RP11-203F10.5	-3.8	0.000173	0.0496	-0.26	-0.2	Mean platelet volume;	chr1:205000291	chr1:204277005~204277948:+
STAD	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	3.8	0.000173	0.0496	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
STAD	cis	rs6832769	1	rs11133399	ENSG00000223305.1	RN7SKP30	-3.8	0.000173	0.0497	-0.22	-0.2	Personality dimensions;	chr4:55547664	chr4:55540502~55540835:-
STAD	cis	rs9902453	0.904	rs8078638	ENSG00000263477.1	RP11-338L22.2	3.8	0.000173	0.0497	0.17	0.2	Coffee consumption (cups per day);	chr17:29963340	chr17:29863402~29866092:+
STAD	cis	rs2115630	0.967	rs11073731	ENSG00000275120.1	RP11-182J1.17	-3.8	0.000173	0.0497	-0.22	-0.2	P wave terminal force;	chr15:84811882	chr15:84599434~84606463:-
STAD	cis	rs9733	0.596	rs12077833	ENSG00000276103.1	U4	3.8	0.000173	0.0497	0.19	0.2	Tonsillectomy;	chr1:150701857	chr1:150608507~150608623:-
STAD	cis	rs13358864	0.92	rs72824988	ENSG00000254187.1	CTB-78F1.1	3.8	0.000173	0.0497	0.26	0.2	Uric acid levels;	chr5:168062088	chr5:167653228~167660481:-
STAD	cis	rs2390582	0.563	rs12735216	ENSG00000228175.3	GEMIN8P4	3.8	0.000174	0.0497	0.32	0.2	Coronary artery calcification;	chr1:90296151	chr1:89993593~89994321:-
STAD	cis	rs11098499	0.863	rs13136462	ENSG00000260091.1	RP11-33B1.4	3.8	0.000174	0.0497	0.2	0.2	Corneal astigmatism;	chr4:119622018	chr4:119409333~119410233:+
STAD	cis	rs1816752	0.646	rs3783073	ENSG00000273628.1	RP11-756A22.7	-3.8	0.000174	0.0497	-0.24	-0.2	Obesity-related traits;	chr13:24493222	chr13:24933006~24936796:+
STAD	cis	rs8098244	0.737	rs1258137	ENSG00000267301.1	RPL23AP77	3.8	0.000174	0.0497	0.28	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23980147	chr18:23709825~23710287:-
STAD	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	3.8	0.000174	0.0497	0.24	0.2	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
STAD	cis	rs11673344	0.504	rs7259332	ENSG00000267672.1	CTD-2293H3.1	3.8	0.000174	0.0498	0.18	0.2	Obesity-related traits;	chr19:37143389	chr19:37091341~37092564:+
STAD	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-3.8	0.000174	0.0498	-0.16	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
STAD	cis	rs11673344	0.523	rs7255724	ENSG00000267672.1	CTD-2293H3.1	3.8	0.000174	0.0498	0.19	0.2	Obesity-related traits;	chr19:37158675	chr19:37091341~37092564:+
STAD	cis	rs7512552	0.839	rs1498308	ENSG00000203819.6	HIST2H2BC	3.8	0.000174	0.0498	0.23	0.2	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150322682	chr1:149850193~149850772:-
STAD	cis	rs1790761	0.52	rs4930461	ENSG00000184224.3	C11orf72	3.8	0.000174	0.0498	0.23	0.2	Mean corpuscular volume;	chr11:67627424	chr11:67602880~67606706:-
STAD	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	3.8	0.000174	0.0498	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	3.8	0.000174	0.0498	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	3.8	0.000174	0.0498	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	3.8	0.000174	0.0498	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	3.8	0.000174	0.0498	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
STAD	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	3.8	0.000174	0.0498	0.17	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
STAD	cis	rs7615952	0.8	rs11915699	ENSG00000241346.1	SNRPCP11	3.8	0.000174	0.0498	0.31	0.2	Blood pressure (smoking interaction);	chr3:125913841	chr3:125816082~125816286:-
STAD	cis	rs1030877	0.515	rs2576736	ENSG00000235319.1	AC012360.4	-3.8	0.000174	0.0498	-0.28	-0.2	Obesity-related traits;	chr2:105274514	chr2:105324210~105330529:+
STAD	cis	rs658191	0.661	rs11206163	ENSG00000237624.1	OXCT2P1	-3.8	0.000174	0.0498	-0.42	-0.2	Colorectal cancer;	chr1:39478816	chr1:39514956~39516490:+
STAD	cis	rs73198271	0.74	rs10094270	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.773	rs66618176	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.694	rs73201840	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.694	rs113694763	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.694	rs115037021	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.694	rs114184516	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.74	rs28521727	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.74	rs28402110	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.74	rs10098636	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.74	rs10112989	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:9141424~9145435:+
STAD	cis	rs73198271	0.74	rs10113326	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000174	0.0498	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:9141424~9145435:+
STAD	cis	rs10129255	1	rs10129255	ENSG00000232216.1	IGHV3-43	-3.8	0.000174	0.0498	-0.2	-0.2	Kawasaki disease;	chr14:106767970	chr14:106470264~106470800:-
STAD	cis	rs10776614	0.799	rs10857598	ENSG00000226964.1	RHEBP2	3.8	0.000174	0.0498	0.29	0.2	Self-employment;	chr10:48567158	chr10:47706203~47706802:+
STAD	cis	rs2957692	0.548	rs7938491	ENSG00000254554.1	RP11-351I24.1	3.8	0.000174	0.0498	0.31	0.2	Circulating vasoactive peptide levels;	chr11:10149845	chr11:10302657~10303704:-
STAD	cis	rs2638953	0.815	rs10843186	ENSG00000247934.4	RP11-967K21.1	-3.8	0.000174	0.0498	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482921	chr12:28163298~28190738:-
STAD	cis	rs2638953	0.815	rs1511551	ENSG00000247934.4	RP11-967K21.1	-3.8	0.000174	0.0498	-0.22	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483897	chr12:28163298~28190738:-
STAD	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-3.8	0.000174	0.0498	-0.21	-0.2	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
STAD	cis	rs2562456	0.754	rs55771551	ENSG00000268081.1	RP11-678G14.2	3.8	0.000174	0.0498	0.27	0.2	Pain;	chr19:21563578	chr19:21554640~21569237:-
STAD	cis	rs1816752	0.875	rs1050110	ENSG00000232858.1	RPL34P27	3.8	0.000174	0.0498	0.12	0.2	Obesity-related traits;	chr13:24435347	chr13:24988577~24988925:-
STAD	cis	rs4132699	0.503	rs9410319	ENSG00000225460.1	RP13-93L13.1	-3.8	0.000174	0.0498	-0.27	-0.2	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89401607	chr9:89472237~89472692:+
STAD	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	3.8	0.000174	0.0498	0.26	0.2	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
STAD	cis	rs3749237	0.576	rs4241406	ENSG00000225399.4	RP11-3B7.1	3.8	0.000174	0.0498	0.21	0.2	Resting heart rate;	chr3:49562993	chr3:49260085~49261316:+
STAD	cis	rs2836974	0.568	rs429955	ENSG00000238141.2	BRWD1-AS1	3.8	0.000174	0.0498	0.2	0.2	Cognitive function;	chr21:39167834	chr21:39315707~39323218:+
STAD	cis	rs11118620	0.853	rs12037861	ENSG00000257551.1	HLX-AS1	3.8	0.000174	0.0499	0.23	0.2	Heart failure;	chr1:220864835	chr1:220832763~220880140:-
STAD	cis	rs4713118	0.869	rs9366700	ENSG00000220721.1	OR1F12	3.8	0.000174	0.0499	0.22	0.2	Parkinson's disease;	chr6:27729172	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs6456802	ENSG00000220721.1	OR1F12	3.8	0.000174	0.0499	0.22	0.2	Parkinson's disease;	chr6:27730576	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs9393851	ENSG00000220721.1	OR1F12	3.8	0.000174	0.0499	0.22	0.2	Parkinson's disease;	chr6:27731802	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs9461400	ENSG00000220721.1	OR1F12	3.8	0.000174	0.0499	0.22	0.2	Parkinson's disease;	chr6:27732780	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs9295742	ENSG00000220721.1	OR1F12	3.8	0.000174	0.0499	0.22	0.2	Parkinson's disease;	chr6:27735053	chr6:28073316~28074233:+
STAD	cis	rs4713118	0.869	rs9461401	ENSG00000220721.1	OR1F12	3.8	0.000174	0.0499	0.22	0.2	Parkinson's disease;	chr6:27735512	chr6:28073316~28074233:+
STAD	cis	rs12468226	1	rs58288071	ENSG00000272966.1	RP11-686O6.1	3.8	0.000174	0.0499	0.29	0.2	Urate levels;	chr2:202350016	chr2:202336739~202337200:+
STAD	cis	rs654950	0.934	rs654220	ENSG00000229901.1	RP11-399E6.4	-3.8	0.000174	0.0499	-0.22	-0.2	Airway imaging phenotypes;	chr1:41536885	chr1:41375004~41375669:-
STAD	cis	rs4713118	0.869	rs9283883	ENSG00000220721.1	OR1F12	3.8	0.000174	0.0499	0.22	0.2	Parkinson's disease;	chr6:27747691	chr6:28073316~28074233:+
STAD	cis	rs591584	0.73	rs7342170	ENSG00000255893.1	RP11-685N10.1	-3.8	0.000174	0.0499	-0.24	-0.2	Macrophage Migration Inhibitory Factor levels;	chr11:94581311	chr11:94472908~94473570:-
STAD	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-3.8	0.000174	0.0499	-0.22	-0.2	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
STAD	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-3.8	0.000174	0.0499	-0.22	-0.2	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
STAD	cis	rs1383484	1	rs28612730	ENSG00000254414.1	RP11-182J1.1	-3.8	0.000174	0.0499	-0.17	-0.2	Height;	chr15:83842454	chr15:84631898~84633987:-
STAD	cis	rs4218	0.531	rs10431791	ENSG00000259732.1	RP11-59H7.3	-3.8	0.000174	0.0499	-0.22	-0.2	Social communication problems;	chr15:59055159	chr15:59121034~59133250:+
STAD	cis	rs6940638	0.615	rs9393801	ENSG00000243307.2	POM121L6P	-3.8	0.000174	0.0499	-0.21	-0.2	Intelligence (multi-trait analysis);	chr6:27274902	chr6:26896952~26898777:+
STAD	cis	rs73198271	0.843	rs11775888	ENSG00000233609.3	RP11-62H7.2	-3.8	0.000174	0.0499	-0.29	-0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8748188	chr8:8961200~8979025:+
STAD	cis	rs4835473	0.778	rs6853798	ENSG00000249741.2	RP11-673E1.3	3.79	0.000174	0.0499	0.23	0.2	Immature fraction of reticulocytes;	chr4:143801153	chr4:143911514~143912053:-
STAD	cis	rs9467773	1	rs1884946	ENSG00000243307.2	POM121L6P	3.79	0.000174	0.0499	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26896952~26898777:+
STAD	cis	rs4293777	0.967	rs10003123	ENSG00000250896.1	RNPS1P1	3.79	0.000174	0.0499	0.15	0.2	Primary sclerosing cholangitis;	chr4:10721634	chr4:11371975~11372892:+
STAD	cis	rs4293777	0.967	rs4293778	ENSG00000250896.1	RNPS1P1	3.79	0.000174	0.0499	0.15	0.2	Primary sclerosing cholangitis;	chr4:10721880	chr4:11371975~11372892:+
STAD	cis	rs2199351	1	rs79760409	ENSG00000242899.1	RPL7P16	-3.79	0.000174	0.0499	-0.24	-0.2	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr3:131872365	chr3:132243528~132244265:-
STAD	cis	rs116095464	0.558	rs7703803	ENSG00000250848.1	CTD-2083E4.5	-3.79	0.000174	0.0499	-0.31	-0.2	Breast cancer;	chr5:292196	chr5:288833~290321:-
STAD	cis	rs116095464	0.558	rs9654452	ENSG00000250848.1	CTD-2083E4.5	-3.79	0.000174	0.0499	-0.31	-0.2	Breast cancer;	chr5:299446	chr5:288833~290321:-
STAD	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-3.79	0.000174	0.0499	-0.24	-0.2	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
STAD	cis	rs5769707	0.605	rs9616702	ENSG00000213279.2	RP1-29C18.9	-3.79	0.000174	0.0499	-0.27	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49572264~49575426:-
STAD	cis	rs76878669	0.561	rs10750784	ENSG00000254855.1	RP11-867G23.1	3.79	0.000174	0.0499	0.23	0.2	Educational attainment (years of education);	chr11:66343195	chr11:66264777~66265666:-
STAD	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	3.79	0.000174	0.0499	0.28	0.2	Height;	chr6:109769861	chr6:109382795~109383666:+
STAD	cis	rs9420	0.528	rs11229080	ENSG00000265566.2	RN7SL605P	-3.79	0.000174	0.0499	-0.29	-0.2	Schizophrenia;	chr11:57632038	chr11:57528085~57528365:-
STAD	cis	rs11172055	0.775	rs10876940	ENSG00000269903.1	RP11-571M6.18	-3.79	0.000174	0.0499	-0.25	-0.2	Migraine;	chr12:56871233	chr12:57814494~57814926:+
STAD	cis	rs2446066	0.872	rs2608302	ENSG00000257379.1	RP11-793H13.8	3.79	0.000174	0.0499	0.31	0.2	Red blood cell count;	chr12:53396512	chr12:53441741~53467528:+
STAD	cis	rs6832769	1	rs1522108	ENSG00000223305.1	RN7SKP30	3.79	0.000175	0.0499	0.22	0.2	Personality dimensions;	chr4:55514566	chr4:55540502~55540835:-
STAD	cis	rs3847687	0.901	rs12370258	ENSG00000226356.2	RPS6P20	3.79	0.000175	0.0499	0.2	0.2	Longevity;	chr12:131042756	chr12:131292068~131293176:-
STAD	cis	rs6059101	0.576	rs755171	ENSG00000230753.4	ZNF341-AS1	3.79	0.000175	0.0499	0.24	0.2	Ulcerative colitis;	chr20:33124784	chr20:33787373~33811097:-
STAD	cis	rs2262909	1	rs765527	ENSG00000213976.4	CTD-2561J22.2	3.79	0.000175	0.0499	0.25	0.2	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21946753	chr19:21382865~21387177:+
STAD	cis	rs1900504	0.614	rs2915761	ENSG00000266200.5	PNLIPRP2	-3.79	0.000175	0.0499	-0.29	-0.2	Tonsillectomy;	chr10:116601682	chr10:116620953~116645143:+
STAD	cis	rs2512987	1	rs2512986	ENSG00000254731.1	CTD-2005H7.1	-3.79	0.000175	0.0499	-0.23	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703286	chr11:86703099~86714092:+
STAD	cis	rs2512987	1	rs2433420	ENSG00000254731.1	CTD-2005H7.1	-3.79	0.000175	0.0499	-0.23	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703319	chr11:86703099~86714092:+
STAD	cis	rs4784934	1	rs9928581	ENSG00000260186.4	RP11-481J2.2	3.79	0.000175	0.05	0.24	0.2	QT interval;	chr16:58427461	chr16:58421326~58462470:+
STAD	cis	rs6674176	0.551	rs2242637	ENSG00000271329.1	RP5-891H21.5	3.79	0.000175	0.05	0.3	0.2	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43935712	chr1:44187943~44189049:-
STAD	cis	rs7204230	0.557	rs2892458	ENSG00000261291.1	RP11-295M3.2	3.79	0.000175	0.05	0.21	0.2	Fibrinogen;	chr16:53315759	chr16:53168522~53169450:+
STAD	cis	rs4713118	0.869	rs7773070	ENSG00000220721.1	OR1F12	3.79	0.000175	0.05	0.22	0.2	Parkinson's disease;	chr6:27761048	chr6:28073316~28074233:+
STAD	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	28.9	2.79e-94	2.29e-83	1.22	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-27.24	4.31e-88	1.23e-77	-1.19	-0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	27.18	7.49e-88	1.23e-77	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	27.18	7.49e-88	1.23e-77	1.21	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	26.79	2.14e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	26.78	2.38e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	26.78	2.38e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	26.78	2.38e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	26.78	2.38e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	26.78	2.38e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	26.78	2.38e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	26.77	2.57e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	26.77	2.57e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	26.77	2.66e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	26.77	2.66e-86	9.51e-77	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	26.75	3.07e-86	1.05e-76	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	26.63	8.56e-86	2.51e-76	1.19	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	26.63	8.56e-86	2.51e-76	1.19	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	26.63	8.56e-86	2.51e-76	1.19	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	26.57	1.48e-85	2.89e-76	1.19	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	26.53	2.07e-85	3.95e-76	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	26.52	2.36e-85	4.22e-76	1.19	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	26.51	2.48e-85	4.34e-76	1.18	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
STAD	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	25.98	2.73e-83	2.2e-74	1.05	0.81	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	25.97	2.97e-83	2.35e-74	1.06	0.81	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	25.96	3.1e-83	2.4e-74	1.05	0.81	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	25.93	4.28e-83	3.22e-74	1.05	0.81	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	25.93	4.28e-83	3.22e-74	1.05	0.81	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	25.93	4.28e-83	3.22e-74	1.05	0.81	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	25.88	6.16e-83	3.88e-74	1.05	0.81	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	25.88	6.16e-83	3.88e-74	1.05	0.81	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	25.75	2.02e-82	9.16e-74	1.04	0.81	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	25.72	2.58e-82	1.14e-73	1.15	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	25.72	2.74e-82	1.19e-73	1.14	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
STAD	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-25.48	2.15e-81	8.89e-73	-1.03	-0.81	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	25.45	2.77e-81	1.11e-72	1.05	0.81	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	25.45	2.77e-81	1.11e-72	1.05	0.81	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	25.45	2.77e-81	1.11e-72	1.05	0.81	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	25.45	2.77e-81	1.11e-72	1.05	0.81	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	25.45	2.77e-81	1.11e-72	1.05	0.81	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	25.35	7.02e-81	2.79e-72	1.05	0.81	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	25.34	7.49e-81	2.84e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	25.34	7.49e-81	2.84e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	25.34	7.49e-81	2.84e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	25.34	7.49e-81	2.84e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	25.34	7.49e-81	2.84e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	25.34	7.49e-81	2.84e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-25.34	7.76e-81	2.92e-72	-1.16	-0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	25.3	1.05e-80	3.93e-72	1.05	0.81	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	25.28	1.28e-80	4.78e-72	1.03	0.81	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	25.28	1.32e-80	4.88e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	25.25	1.67e-80	6.15e-72	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	25.24	1.91e-80	7.01e-72	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	25.23	2.04e-80	7.4e-72	1.18	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	25.23	2.04e-80	7.4e-72	1.18	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	25.21	2.42e-80	8.75e-72	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	25.09	7.19e-80	2.57e-71	1.17	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	25.09	7.19e-80	2.57e-71	1.17	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	25.09	7.19e-80	2.57e-71	1.17	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	25.08	7.48e-80	2.65e-71	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	25.08	7.48e-80	2.65e-71	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	25.01	1.5e-79	5.1e-71	1.04	0.8	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	24.89	4.13e-79	1.36e-70	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	24.89	4.13e-79	1.36e-70	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	24.82	7.93e-79	2.59e-70	1.16	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	24.75	1.49e-78	4.77e-70	1.16	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	24.68	2.69e-78	8.51e-70	1.16	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
STAD	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	24.64	3.93e-78	1.24e-69	1.04	0.8	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	24.58	6.55e-78	2.05e-69	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	24.55	8.48e-78	2.62e-69	1.03	0.8	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	24.55	8.48e-78	2.62e-69	1.03	0.8	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	24.47	1.8e-77	5.49e-69	1.03	0.8	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	24.47	1.8e-77	5.49e-69	1.03	0.8	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	24.47	1.81e-77	5.52e-69	1.03	0.8	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	24.41	3e-77	9.08e-69	1.03	0.8	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
STAD	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	24.28	1.04e-76	3.13e-68	1.04	0.79	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	24.25	1.3e-76	3.89e-68	1.02	0.79	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	24.24	1.46e-76	4.35e-68	1.02	0.79	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
STAD	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	24.2	2.05e-76	6.04e-68	1.04	0.79	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	23.96	1.82e-75	5.24e-67	1.02	0.79	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	23.84	5.32e-75	1.52e-66	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	23.77	9.59e-75	2.74e-66	1.02	0.79	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	23.74	1.25e-74	3.55e-66	1.11	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	23.74	1.34e-74	3.76e-66	1.03	0.79	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
STAD	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	23.74	1.34e-74	3.76e-66	1.03	0.79	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	23.71	1.65e-74	4.58e-66	1.14	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	23.71	1.65e-74	4.58e-66	1.14	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	23.69	2.08e-74	5.69e-66	1.11	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	23.68	2.26e-74	6.18e-66	1.14	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	23.66	2.68e-74	7.29e-66	1.14	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	23.62	3.84e-74	1.04e-65	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	23.55	7.49e-74	2.01e-65	1.14	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	23.51	1.02e-73	2.72e-65	1.01	0.78	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	23.51	1.03e-73	2.73e-65	1.01	0.78	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	23.51	1.03e-73	2.73e-65	1.01	0.78	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	23.48	1.38e-73	3.62e-65	1.01	0.78	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	23.48	1.38e-73	3.62e-65	1.01	0.78	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	23.47	1.45e-73	3.79e-65	1.13	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	23.47	1.45e-73	3.79e-65	1.13	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
STAD	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	23.46	1.6e-73	4.13e-65	1.04	0.78	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
STAD	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	23.46	1.6e-73	4.13e-65	1.04	0.78	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	23.44	1.9e-73	4.88e-65	1.01	0.78	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	23.44	1.9e-73	4.88e-65	1.01	0.78	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	23.38	3.28e-73	8.32e-65	1.01	0.78	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	23.38	3.28e-73	8.32e-65	1.01	0.78	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	23.27	9.27e-73	2.34e-64	1.02	0.78	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	23.25	1.13e-72	2.85e-64	1.02	0.78	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
STAD	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-23.21	1.54e-72	3.85e-64	-1.02	-0.78	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	23	1.11e-71	2.74e-63	1.01	0.78	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	22.99	1.22e-71	3.01e-63	0.95	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
STAD	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	22.97	1.43e-71	3.49e-63	1.01	0.78	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	22.92	2.32e-71	5.52e-63	1.02	0.78	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
STAD	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	22.85	4.41e-71	1.04e-62	1.01	0.78	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	22.8	6.86e-71	1.61e-62	1.01	0.77	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	22.74	1.13e-70	2.65e-62	1	0.77	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	22.73	1.28e-70	2.97e-62	1.01	0.77	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	22.72	1.38e-70	3.19e-62	1	0.77	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	22.67	2.24e-70	5.18e-62	1.01	0.77	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
STAD	trans	rs1816752	1	rs9511272	ENSG00000237917.1	PARP4P1	22.61	3.63e-70	8.36e-62	1.03	0.77	Obesity-related traits;	chr13:24446495	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	22.44	1.82e-69	4.15e-61	0.99	0.77	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	22.44	1.85e-69	4.15e-61	0.99	0.77	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	22.34	4.7e-69	1.05e-60	0.99	0.77	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	22.32	5.45e-69	1.18e-60	0.99	0.77	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	22.32	5.45e-69	1.18e-60	0.99	0.77	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	22.32	5.45e-69	1.18e-60	0.99	0.77	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	22.32	5.45e-69	1.18e-60	0.99	0.77	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	22.32	5.45e-69	1.18e-60	0.99	0.77	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	22.32	5.45e-69	1.18e-60	0.99	0.77	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	22.32	5.45e-69	1.18e-60	0.99	0.77	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	22.25	9.98e-69	2.14e-60	1.11	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-22.23	1.2e-68	2.57e-60	-0.93	-0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
STAD	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	22.15	2.56e-68	5.44e-60	0.99	0.77	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	22.15	2.56e-68	5.44e-60	0.99	0.77	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	22.14	2.86e-68	6.06e-60	0.98	0.77	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	22.13	3.09e-68	6.5e-60	1.11	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
STAD	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	22.13	3.23e-68	6.78e-60	1.24	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	22.08	5.04e-68	1.05e-59	0.94	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	22.08	5.04e-68	1.05e-59	0.94	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	22.06	5.79e-68	1.2e-59	1.11	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	22.06	5.79e-68	1.2e-59	1.11	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	21.98	1.19e-67	2.45e-59	1.1	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	21.98	1.19e-67	2.45e-59	1.1	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	21.92	2.05e-67	4.16e-59	0.98	0.76	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	21.74	1.1e-66	2.22e-58	0.98	0.76	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	21.72	1.39e-66	2.81e-58	0.98	0.76	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	21.68	1.9e-66	3.81e-58	0.99	0.76	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	21.68	1.9e-66	3.81e-58	0.99	0.76	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	21.66	2.24e-66	4.46e-58	0.93	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	21.66	2.24e-66	4.46e-58	0.93	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	21.66	2.24e-66	4.46e-58	0.93	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	21.63	3.06e-66	5.95e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	21.63	3.06e-66	5.95e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	21.63	3.06e-66	5.95e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	21.63	3.06e-66	5.95e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	21.63	3.06e-66	5.95e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	21.63	3.06e-66	5.95e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	21.63	3.17e-66	6.1e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	21.63	3.17e-66	6.1e-58	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	21.57	5.42e-66	1.04e-57	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	21.56	5.63e-66	1.08e-57	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	21.56	5.68e-66	1.09e-57	0.93	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
STAD	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	21.52	8.59e-66	1.64e-57	1.22	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	21.42	2.06e-65	3.9e-57	0.92	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	21.31	5.68e-65	1.05e-56	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	21.31	5.68e-65	1.05e-56	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	21.28	7.44e-65	1.36e-56	1.08	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	21.28	7.44e-65	1.36e-56	1.08	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
STAD	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	21.22	1.4e-64	2.52e-56	0.98	0.75	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	21.22	1.4e-64	2.52e-56	0.98	0.75	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	21.22	1.4e-64	2.52e-56	0.98	0.75	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	21.06	5.86e-64	1.03e-55	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
STAD	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-21.02	8.63e-64	1.5e-55	-0.93	-0.75	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	20.77	8.98e-63	1.54e-54	0.89	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	20.71	1.56e-62	2.65e-54	0.89	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
STAD	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	20.71	1.58e-62	2.67e-54	0.97	0.74	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	20.68	2.04e-62	3.37e-54	0.97	0.74	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	20.68	2.04e-62	3.37e-54	0.97	0.74	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	20.68	2.04e-62	3.37e-54	0.97	0.74	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	20.51	9.47e-62	1.53e-53	0.93	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	20.48	1.33e-61	2.13e-53	0.93	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	20.39	2.9e-61	4.6e-53	1.04	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	20.36	3.86e-61	6.08e-53	0.91	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
STAD	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	20.2	1.66e-60	2.59e-52	1.19	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	20.16	2.44e-60	3.78e-52	0.95	0.73	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	20.09	4.87e-60	7.49e-52	1.05	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	20.09	4.87e-60	7.49e-52	1.05	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	20.06	6.05e-60	9.28e-52	0.95	0.73	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	19.69	1.99e-58	2.91e-50	0.89	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	19.68	2.24e-58	3.27e-50	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
STAD	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	19.67	2.38e-58	3.46e-50	1.17	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
STAD	trans	rs916888	0.773	rs199445	ENSG00000263503.1	RP11-707O23.5	19.53	8.64e-58	1.24e-49	1.25	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45600869~45602340:-
STAD	trans	rs916888	0.773	rs199443	ENSG00000263503.1	RP11-707O23.5	19.53	8.64e-58	1.24e-49	1.25	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45600869~45602340:-
STAD	trans	rs916888	0.773	rs199535	ENSG00000263503.1	RP11-707O23.5	19.53	9.17e-58	1.3e-49	1.27	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	19.52	9.24e-58	1.31e-49	0.88	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	19.52	9.24e-58	1.31e-49	0.88	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
STAD	trans	rs916888	0.773	rs199534	ENSG00000263503.1	RP11-707O23.5	19.46	1.75e-57	2.44e-49	1.26	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45600869~45602340:-
STAD	trans	rs916888	0.773	rs199533	ENSG00000263503.1	RP11-707O23.5	19.44	1.94e-57	2.69e-49	1.26	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	19.44	1.99e-57	2.75e-49	0.88	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	19.33	5.57e-57	7.68e-49	0.88	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	19.33	5.57e-57	7.68e-49	0.88	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
STAD	trans	rs916888	0.773	rs199447	ENSG00000263503.1	RP11-707O23.5	19.17	2.53e-56	3.45e-48	1.26	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.581	rs2245384	ENSG00000224114.1	RP11-343H5.4	19.02	9.92e-56	1.34e-47	1.01	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:206695837~206696269:-
STAD	trans	rs916888	0.773	rs199448	ENSG00000263503.1	RP11-707O23.5	18.94	2.15e-55	2.87e-47	1.22	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45600869~45602340:-
STAD	trans	rs916888	0.779	rs199528	ENSG00000263503.1	RP11-707O23.5	18.62	4.43e-54	5.51e-46	1.23	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45600869~45602340:-
STAD	trans	rs916888	0.821	rs199525	ENSG00000263503.1	RP11-707O23.5	18.62	4.43e-54	5.51e-46	1.23	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45600869~45602340:-
STAD	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	18.59	5.77e-54	7.13e-46	0.85	0.71	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
STAD	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-18.52	1.08e-53	1.32e-45	-0.89	-0.71	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
STAD	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	18.45	2.1e-53	2.51e-45	0.89	0.7	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	18.4	3.18e-53	3.78e-45	0.89	0.7	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	18.3	8.41e-53	9.89e-45	0.89	0.7	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	18.29	9.51e-53	1.11e-44	0.89	0.7	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
STAD	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	18.29	9.51e-53	1.11e-44	0.89	0.7	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	18.29	9.51e-53	1.11e-44	0.89	0.7	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
STAD	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-18.27	1.11e-52	1.29e-44	-0.89	-0.7	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
STAD	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	18.26	1.17e-52	1.35e-44	0.89	0.7	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	18.24	1.43e-52	1.64e-44	0.88	0.7	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	18.22	1.74e-52	1.98e-44	0.89	0.7	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	18.22	1.74e-52	1.98e-44	0.89	0.7	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
STAD	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	18.17	2.75e-52	3.1e-44	0.85	0.7	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
STAD	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	18.17	2.75e-52	3.1e-44	0.85	0.7	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
STAD	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	18.17	2.75e-52	3.1e-44	0.85	0.7	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
STAD	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	18.15	3.4e-52	3.82e-44	0.88	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
STAD	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	18.15	3.51e-52	3.93e-44	0.92	0.7	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
STAD	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	18.14	3.77e-52	4.22e-44	0.87	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
STAD	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-18.13	3.91e-52	4.37e-44	-0.87	-0.7	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
STAD	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	18.12	4.44e-52	4.94e-44	0.88	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	18.12	4.44e-52	4.94e-44	0.88	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	18.12	4.44e-52	4.94e-44	0.88	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
STAD	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	18.09	6.15e-52	6.73e-44	0.88	0.7	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	18.09	6.15e-52	6.73e-44	0.88	0.7	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	18.09	6.15e-52	6.73e-44	0.88	0.7	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	18.09	6.15e-52	6.73e-44	0.88	0.7	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	18.09	6.15e-52	6.73e-44	0.88	0.7	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	18.09	6.15e-52	6.73e-44	0.88	0.7	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	18.09	6.15e-52	6.73e-44	0.88	0.7	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	18.07	7.28e-52	7.95e-44	0.89	0.7	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	18.06	8.05e-52	8.7e-44	0.88	0.7	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	18.06	8.05e-52	8.7e-44	0.88	0.7	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	18.06	8.05e-52	8.7e-44	0.88	0.7	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	18.06	8.19e-52	8.82e-44	0.88	0.7	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	18.06	8.19e-52	8.82e-44	0.88	0.7	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	18.06	8.19e-52	8.82e-44	0.88	0.7	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
STAD	trans	rs916888	0.687	rs199456	ENSG00000263503.1	RP11-707O23.5	17.98	1.61e-51	1.71e-43	1.2	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45600869~45602340:-
STAD	trans	rs916888	0.773	rs199451	ENSG00000263503.1	RP11-707O23.5	17.98	1.61e-51	1.71e-43	1.2	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45600869~45602340:-
STAD	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	17.98	1.62e-51	1.72e-43	0.88	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	17.98	1.62e-51	1.72e-43	0.88	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
STAD	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	17.98	1.65e-51	1.74e-43	0.85	0.7	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
STAD	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	17.92	2.83e-51	2.97e-43	0.89	0.69	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	17.89	3.76e-51	3.93e-43	0.88	0.69	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
STAD	trans	rs916888	0.773	rs199439	ENSG00000263503.1	RP11-707O23.5	17.88	4.06e-51	4.22e-43	1.18	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	17.87	4.43e-51	4.6e-43	0.83	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	17.87	4.43e-51	4.6e-43	0.83	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
STAD	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-17.86	5.22e-51	5.41e-43	-0.88	-0.69	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	17.85	5.73e-51	5.92e-43	0.85	0.69	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	17.84	6.11e-51	6.23e-43	0.88	0.69	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	17.84	6.11e-51	6.23e-43	0.88	0.69	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	17.84	6.11e-51	6.23e-43	0.88	0.69	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	17.84	6.11e-51	6.23e-43	0.88	0.69	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	17.84	6.11e-51	6.23e-43	0.88	0.69	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	17.84	6.17e-51	6.28e-43	0.88	0.69	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	17.83	6.68e-51	6.78e-43	0.88	0.69	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
STAD	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	17.82	7.29e-51	7.38e-43	0.94	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
STAD	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	17.82	7.55e-51	7.63e-43	0.87	0.69	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	17.81	7.97e-51	8.03e-43	0.88	0.69	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	17.81	7.97e-51	8.03e-43	0.88	0.69	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
STAD	trans	rs916888	0.773	rs199457	ENSG00000263503.1	RP11-707O23.5	17.81	8.43e-51	8.48e-43	1.2	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45600869~45602340:-
STAD	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	17.79	9.81e-51	9.83e-43	0.87	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
STAD	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	17.77	1.16e-50	1.16e-42	0.85	0.69	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
STAD	trans	rs13177918	0.581	rs2245384	ENSG00000213058.3	RP4-765C7.2	17.76	1.24e-50	1.23e-42	0.97	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:178411616~178411972:+
STAD	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	17.75	1.48e-50	1.46e-42	0.85	0.69	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
STAD	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	17.74	1.52e-50	1.5e-42	0.86	0.69	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
STAD	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	17.74	1.52e-50	1.5e-42	0.86	0.69	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
STAD	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	17.72	1.86e-50	1.83e-42	0.87	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
STAD	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	17.71	2.01e-50	1.97e-42	0.87	0.69	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	17.64	3.83e-50	3.74e-42	0.88	0.69	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
STAD	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	17.63	4.31e-50	4.19e-42	1.08	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
STAD	trans	rs916888	0.773	rs199535	ENSG00000280022.1	RP11-707O23.1	17.62	4.63e-50	4.49e-42	1.16	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45592621~45593369:+
STAD	trans	rs916888	0.773	rs538628	ENSG00000263503.1	RP11-707O23.5	17.61	5.1e-50	4.94e-42	1.17	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45600869~45602340:-
STAD	trans	rs916888	0.821	rs70600	ENSG00000263503.1	RP11-707O23.5	17.56	8.27e-50	7.97e-42	1.19	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45600869~45602340:-
STAD	trans	rs7949030	0.622	rs34894392	ENSG00000186676.3	EEF1GP1	17.55	9.01e-50	8.68e-42	0.88	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62607349	chr7:125033453~125035301:+
STAD	trans	rs916888	0.773	rs169201	ENSG00000263503.1	RP11-707O23.5	17.54	1.01e-49	9.66e-42	1.19	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45600869~45602340:-
STAD	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	17.53	1.13e-49	1.07e-41	0.89	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
STAD	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	17.5	1.48e-49	1.39e-41	0.88	0.69	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
STAD	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	17.42	3.03e-49	2.8e-41	0.93	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
STAD	trans	rs916888	0.773	rs1378358	ENSG00000263503.1	RP11-707O23.5	17.4	3.81e-49	3.52e-41	1.18	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45600869~45602340:-
STAD	trans	rs916888	0.773	rs199534	ENSG00000280022.1	RP11-707O23.1	17.37	4.75e-49	4.37e-41	1.15	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45592621~45593369:+
STAD	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	17.35	5.82e-49	5.34e-41	0.87	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
STAD	trans	rs916888	0.773	rs9896243	ENSG00000263503.1	RP11-707O23.5	17.32	7.5e-49	6.86e-41	1.17	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	17.31	8.75e-49	7.99e-41	0.81	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-17.3	9.22e-49	8.4e-41	-1.06	-0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
STAD	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	17.27	1.22e-48	1.11e-40	0.85	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
STAD	trans	rs916888	0.773	rs199533	ENSG00000280022.1	RP11-707O23.1	17.25	1.44e-48	1.3e-40	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45592621~45593369:+
STAD	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-17.22	1.97e-48	1.77e-40	-0.86	-0.68	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	17.21	2.11e-48	1.9e-40	0.92	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
STAD	trans	rs916888	0.773	rs199445	ENSG00000280022.1	RP11-707O23.1	17.18	2.74e-48	2.45e-40	1.13	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45592621~45593369:+
STAD	trans	rs916888	0.773	rs199443	ENSG00000280022.1	RP11-707O23.1	17.18	2.74e-48	2.45e-40	1.13	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45592621~45593369:+
STAD	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	17.17	3.04e-48	2.71e-40	0.87	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	17.11	5.53e-48	4.92e-40	0.88	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	17.1	6.15e-48	5.47e-40	0.89	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
STAD	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-17.08	7.01e-48	6.2e-40	-0.86	-0.68	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
STAD	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-17.08	7.1e-48	6.27e-40	-0.84	-0.68	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
STAD	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	17.05	9.62e-48	8.42e-40	0.88	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
STAD	trans	rs916888	0.773	rs199447	ENSG00000280022.1	RP11-707O23.1	17.05	9.9e-48	8.66e-40	1.14	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45592621~45593369:+
STAD	trans	rs916888	0.773	rs199448	ENSG00000280022.1	RP11-707O23.1	17.04	1.03e-47	9.02e-40	1.12	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45592621~45593369:+
STAD	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-17.02	1.3e-47	1.13e-39	-0.79	-0.67	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
STAD	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	16.97	2.07e-47	1.8e-39	0.88	0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	16.97	2.07e-47	1.8e-39	0.88	0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-16.88	4.44e-47	3.82e-39	-0.86	-0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	16.85	6.38e-47	5.43e-39	0.88	0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
STAD	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	16.82	7.89e-47	6.69e-39	0.83	0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
STAD	trans	rs916888	0.687	rs199456	ENSG00000280022.1	RP11-707O23.1	16.8	1.01e-46	8.52e-39	1.12	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45592621~45593369:+
STAD	trans	rs916888	0.773	rs199451	ENSG00000280022.1	RP11-707O23.1	16.8	1.01e-46	8.52e-39	1.12	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45592621~45593369:+
STAD	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-16.71	2.34e-46	1.96e-38	-0.86	-0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	16.69	2.81e-46	2.3e-38	0.64	0.67	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
STAD	trans	rs916888	0.773	rs199457	ENSG00000280022.1	RP11-707O23.1	16.69	2.83e-46	2.31e-38	1.11	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45592621~45593369:+
STAD	trans	rs916888	0.779	rs199528	ENSG00000280022.1	RP11-707O23.1	16.66	3.56e-46	2.89e-38	1.12	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45592621~45593369:+
STAD	trans	rs916888	0.821	rs199525	ENSG00000280022.1	RP11-707O23.1	16.66	3.56e-46	2.89e-38	1.12	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45592621~45593369:+
STAD	trans	rs916888	0.773	rs199439	ENSG00000280022.1	RP11-707O23.1	16.64	4.15e-46	3.37e-38	1.1	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45592621~45593369:+
STAD	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-16.61	5.66e-46	4.49e-38	-0.86	-0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
STAD	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	16.53	1.19e-45	9.33e-38	0.91	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
STAD	trans	rs916888	0.773	rs169201	ENSG00000280022.1	RP11-707O23.1	16.48	1.97e-45	1.52e-37	1.11	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45592621~45593369:+
STAD	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	16.45	2.52e-45	1.94e-37	0.86	0.66	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
STAD	trans	rs916888	0.773	rs538628	ENSG00000280022.1	RP11-707O23.1	16.36	5.72e-45	4.36e-37	1.08	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45592621~45593369:+
STAD	trans	rs916888	0.773	rs1378358	ENSG00000280022.1	RP11-707O23.1	16.32	8.44e-45	6.39e-37	1.1	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45592621~45593369:+
STAD	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	16.29	1.06e-44	7.98e-37	1.03	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
STAD	trans	rs916888	0.821	rs199506	ENSG00000263503.1	RP11-707O23.5	-16.28	1.25e-44	9.33e-37	-1.13	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	16.26	1.46e-44	1.09e-36	0.9	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.581	rs2245384	ENSG00000239528.1	RPS14P8	16.26	1.49e-44	1.11e-36	0.78	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr5:116562562~116562930:+
STAD	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-16.1	6.37e-44	4.59e-36	-1.02	-0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
STAD	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	16.01	1.41e-43	9.99e-36	0.87	0.65	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	15.99	1.73e-43	1.21e-35	0.86	0.65	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.679	rs7999480	ENSG00000237917.1	PARP4P1	-15.93	3.17e-43	2.15e-35	-0.82	-0.65	Obesity-related traits;	chr13:24397865	chrY:26594851~26634652:-
STAD	trans	rs916888	0.821	rs70600	ENSG00000280022.1	RP11-707O23.1	15.92	3.43e-43	2.32e-35	1.09	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45592621~45593369:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-15.88	4.85e-43	3.23e-35	-0.63	-0.65	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-15.88	4.85e-43	3.23e-35	-0.63	-0.65	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
STAD	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	15.87	5.27e-43	3.51e-35	0.86	0.65	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
STAD	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	15.86	5.75e-43	3.81e-35	0.87	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-15.83	8.05e-43	5.29e-35	-0.63	-0.65	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000235459.5	RPS26P31	-15.8	1.01e-42	6.58e-35	-0.65	-0.65	Cognitive function;	chr12:56042145	chr7:122681315~122681662:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-15.69	2.68e-42	1.71e-34	-0.62	-0.64	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000235459.5	RPS26P31	-15.66	3.81e-42	2.39e-34	-0.65	-0.64	Cognitive function;	chr12:56007301	chr7:122681315~122681662:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	15.64	4.58e-42	2.87e-34	0.58	0.64	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
STAD	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	15.42	3.25e-41	1.94e-33	0.86	0.64	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
STAD	trans	rs916888	0.697	rs199516	ENSG00000263503.1	RP11-707O23.5	-15.38	5.05e-41	2.95e-33	-1.08	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	15.24	1.75e-40	9.81e-33	0.87	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
STAD	trans	rs916888	0.821	rs199506	ENSG00000280022.1	RP11-707O23.1	-15.16	3.58e-40	1.98e-32	-1.04	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45592621~45593369:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	15.13	4.86e-40	2.67e-32	0.6	0.63	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
STAD	trans	rs13177918	0.559	rs3901731	ENSG00000224114.1	RP11-343H5.4	15.11	5.59e-40	3.06e-32	0.86	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr1:206695837~206696269:-
STAD	trans	rs916888	0.821	rs199513	ENSG00000263503.1	RP11-707O23.5	-15.1	6.23e-40	3.4e-32	-1.03	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	15.08	7.72e-40	4.2e-32	0.85	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
STAD	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	15.06	9.16e-40	4.96e-32	0.83	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
STAD	trans	rs916888	0.821	rs199512	ENSG00000263503.1	RP11-707O23.5	-15.02	1.29e-39	6.93e-32	-1.06	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45600869~45602340:-
STAD	trans	rs916888	0.821	rs199509	ENSG00000263503.1	RP11-707O23.5	-15.02	1.29e-39	6.93e-32	-1.06	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45600869~45602340:-
STAD	trans	rs916888	0.821	rs199507	ENSG00000263503.1	RP11-707O23.5	-15.02	1.29e-39	6.93e-32	-1.06	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45600869~45602340:-
STAD	trans	rs916888	0.821	rs199505	ENSG00000263503.1	RP11-707O23.5	-15.02	1.29e-39	6.93e-32	-1.06	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45600869~45602340:-
STAD	trans	rs916888	0.821	rs70602	ENSG00000263503.1	RP11-707O23.5	-15.02	1.29e-39	6.93e-32	-1.06	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45600869~45602340:-
STAD	trans	rs916888	0.821	rs415430	ENSG00000263503.1	RP11-707O23.5	-14.94	2.73e-39	1.45e-31	-1.06	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45600869~45602340:-
STAD	trans	rs916888	0.779	rs430685	ENSG00000263503.1	RP11-707O23.5	-14.94	2.73e-39	1.45e-31	-1.06	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45600869~45602340:-
STAD	trans	rs13177918	0.581	rs2748244	ENSG00000224114.1	RP11-343H5.4	14.91	3.5e-39	1.85e-31	0.85	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr1:206695837~206696269:-
STAD	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-14.85	5.89e-39	3.09e-31	-0.82	-0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000204652.6	RPS26P8	-14.82	7.96e-39	4.15e-31	-0.59	-0.62	Cognitive function;	chr12:56042145	chr17:45608571~45608918:+
STAD	trans	rs916888	0.738	rs199515	ENSG00000263503.1	RP11-707O23.5	-14.79	1.06e-38	5.48e-31	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45600869~45602340:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	14.77	1.24e-38	6.41e-31	0.58	0.62	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
STAD	trans	rs916888	0.697	rs199516	ENSG00000280022.1	RP11-707O23.1	-14.73	1.85e-38	9.45e-31	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45592621~45593369:+
STAD	trans	rs916888	0.821	rs199504	ENSG00000263503.1	RP11-707O23.5	-14.68	2.78e-38	1.41e-30	-1.05	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45600869~45602340:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000204652.6	RPS26P8	-14.66	3.47e-38	1.76e-30	-0.58	-0.62	Cognitive function;	chr12:56007301	chr17:45608571~45608918:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	14.64	4.02e-38	2.03e-30	0.54	0.62	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	14.64	4.13e-38	2.08e-30	0.54	0.62	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-14.6	5.74e-38	2.88e-30	-0.56	-0.62	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
STAD	trans	rs916888	0.821	rs199513	ENSG00000280022.1	RP11-707O23.1	-14.6	6.25e-38	3.13e-30	-0.97	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45592621~45593369:+
STAD	trans	rs1816752	0.624	rs2862901	ENSG00000237917.1	PARP4P1	-14.58	7.13e-38	3.56e-30	-0.81	-0.62	Obesity-related traits;	chr13:24461101	chrY:26594851~26634652:-
STAD	trans	rs916888	0.821	rs415430	ENSG00000280022.1	RP11-707O23.1	-14.53	1.14e-37	5.67e-30	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45592621~45593369:+
STAD	trans	rs916888	0.779	rs430685	ENSG00000280022.1	RP11-707O23.1	-14.53	1.14e-37	5.67e-30	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45592621~45593369:+
STAD	trans	rs916888	0.821	rs199512	ENSG00000280022.1	RP11-707O23.1	-14.52	1.2e-37	5.96e-30	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45592621~45593369:+
STAD	trans	rs916888	0.821	rs199509	ENSG00000280022.1	RP11-707O23.1	-14.52	1.2e-37	5.96e-30	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45592621~45593369:+
STAD	trans	rs916888	0.821	rs199507	ENSG00000280022.1	RP11-707O23.1	-14.52	1.2e-37	5.96e-30	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45592621~45593369:+
STAD	trans	rs916888	0.821	rs199505	ENSG00000280022.1	RP11-707O23.1	-14.52	1.2e-37	5.96e-30	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45592621~45593369:+
STAD	trans	rs916888	0.821	rs70602	ENSG00000280022.1	RP11-707O23.1	-14.52	1.2e-37	5.96e-30	-1.01	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45592621~45593369:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-14.5	1.52e-37	7.47e-30	-0.56	-0.61	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
STAD	trans	rs13177918	0.559	rs3901731	ENSG00000213058.3	RP4-765C7.2	14.49	1.58e-37	7.76e-30	0.84	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr1:178411616~178411972:+
STAD	trans	rs916888	0.821	rs199504	ENSG00000280022.1	RP11-707O23.1	-14.49	1.61e-37	7.89e-30	-1.01	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45592621~45593369:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-14.43	2.83e-37	1.38e-29	-0.55	-0.61	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-14.43	2.83e-37	1.38e-29	-0.55	-0.61	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-14.38	4.2e-37	2.03e-29	-0.59	-0.61	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000243403.1	RP11-330L19.1	-14.37	4.67e-37	2.26e-29	-0.59	-0.61	Cognitive function;	chr12:56042145	chr15:64592979~64593326:+
STAD	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	14.35	5.63e-37	2.72e-29	0.68	0.61	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
STAD	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	14.35	5.63e-37	2.72e-29	0.68	0.61	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
STAD	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	14.35	5.9e-37	2.84e-29	0.7	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
STAD	trans	rs916888	0.821	rs199514	ENSG00000263503.1	RP11-707O23.5	-14.32	7.62e-37	3.65e-29	-1.03	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45600869~45602340:-
STAD	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-14.28	1.08e-36	5.09e-29	-0.78	-0.61	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-14.28	1.12e-36	5.25e-29	-0.76	-0.61	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-14.28	1.12e-36	5.25e-29	-0.78	-0.61	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-14.28	1.12e-36	5.25e-29	-0.78	-0.61	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-14.28	1.12e-36	5.25e-29	-0.78	-0.61	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-14.28	1.12e-36	5.25e-29	-0.78	-0.61	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-14.28	1.13e-36	5.28e-29	-0.78	-0.61	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
STAD	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	14.24	1.55e-36	7.22e-29	0.68	0.61	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
STAD	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	14.24	1.55e-36	7.22e-29	0.68	0.61	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	14.24	1.55e-36	7.22e-29	0.59	0.61	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
STAD	trans	rs13177918	0.581	rs2748244	ENSG00000213058.3	RP4-765C7.2	14.22	1.85e-36	8.57e-29	0.83	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr1:178411616~178411972:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-14.21	1.98e-36	9.16e-29	-0.53	-0.61	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-14.21	1.98e-36	9.16e-29	-0.53	-0.61	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-14.19	2.35e-36	1.08e-28	-0.53	-0.61	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000243403.1	RP11-330L19.1	-14.19	2.46e-36	1.13e-28	-0.59	-0.61	Cognitive function;	chr12:56007301	chr15:64592979~64593326:+
STAD	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-14.19	2.48e-36	1.14e-28	-0.77	-0.61	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-14.16	3.2e-36	1.47e-28	-0.77	-0.61	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-14.14	3.94e-36	1.81e-28	-0.77	-0.61	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-14.13	4.11e-36	1.85e-28	-0.77	-0.6	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-14.13	4.28e-36	1.92e-28	-0.77	-0.6	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
STAD	trans	rs7930295	0.505	rs34303332	ENSG00000236257.1	EI24P2	14.13	4.3e-36	1.93e-28	0.88	0.6	Schizophrenia;	chr11:125544288	chr1:158454198~158455273:+
STAD	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-14.12	4.38e-36	1.97e-28	-0.77	-0.6	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-14.12	4.46e-36	2e-28	-0.77	-0.6	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-14.12	4.46e-36	2e-28	-0.77	-0.6	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-14.12	4.46e-36	2e-28	-0.77	-0.6	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-14.12	4.46e-36	2e-28	-0.77	-0.6	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-14.12	4.46e-36	2e-28	-0.77	-0.6	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
STAD	trans	rs916888	0.821	rs199514	ENSG00000280022.1	RP11-707O23.1	-14.12	4.49e-36	2.01e-28	-0.99	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45592621~45593369:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-14.12	4.76e-36	2.13e-28	-0.58	-0.6	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
STAD	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-14.11	5.03e-36	2.25e-28	-0.77	-0.6	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-14.1	5.5e-36	2.45e-28	-0.57	-0.6	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-14.1	5.5e-36	2.45e-28	-0.57	-0.6	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
STAD	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-14.1	5.51e-36	2.45e-28	-0.77	-0.6	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
STAD	trans	rs916888	0.773	rs9896243	ENSG00000280022.1	RP11-707O23.1	14.08	6.3e-36	2.8e-28	1	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45592621~45593369:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000223416.3	RPS26P15	-14.08	6.36e-36	2.83e-28	-0.6	-0.6	Cognitive function;	chr12:56007301	chr1:58056133~58056480:-
STAD	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-14.06	7.64e-36	3.38e-28	-0.78	-0.6	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-14.06	7.67e-36	3.39e-28	-0.78	-0.6	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-14.06	7.67e-36	3.39e-28	-0.78	-0.6	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-14.06	7.91e-36	3.49e-28	-0.57	-0.6	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000223416.3	RPS26P15	-14.05	8.65e-36	3.82e-28	-0.6	-0.6	Cognitive function;	chr12:56042145	chr1:58056133~58056480:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	14.03	9.94e-36	4.38e-28	0.54	0.6	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
STAD	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-14.03	1.02e-35	4.48e-28	-0.77	-0.6	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-14.03	1.02e-35	4.48e-28	-0.77	-0.6	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-14.03	1.02e-35	4.48e-28	-0.77	-0.6	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-14.03	1.02e-35	4.49e-28	-0.77	-0.6	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-14.03	1.02e-35	4.49e-28	-0.77	-0.6	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-14.03	1.04e-35	4.56e-28	-0.77	-0.6	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-14	1.32e-35	5.77e-28	-0.77	-0.6	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
STAD	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	14	1.36e-35	5.94e-28	0.75	0.6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
STAD	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-13.99	1.45e-35	6.34e-28	-0.77	-0.6	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
STAD	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-13.98	1.68e-35	7.28e-28	-0.67	-0.6	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
STAD	trans	rs7930295	0.556	rs9704355	ENSG00000236257.1	EI24P2	13.98	1.68e-35	7.29e-28	0.87	0.6	Schizophrenia;	chr11:125478435	chr1:158454198~158455273:+
STAD	trans	rs7930295	0.556	rs6590146	ENSG00000236257.1	EI24P2	13.97	1.73e-35	7.51e-28	0.86	0.6	Schizophrenia;	chr11:125479933	chr1:158454198~158455273:+
STAD	trans	rs7949030	0.929	rs11231173	ENSG00000186676.3	EEF1GP1	13.95	2.13e-35	9.21e-28	0.77	0.6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62651449	chr7:125033453~125035301:+
STAD	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	13.93	2.42e-35	1.05e-27	0.67	0.6	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
STAD	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-13.93	2.49e-35	1.07e-27	-0.77	-0.6	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-13.92	2.73e-35	1.18e-27	-0.76	-0.6	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-13.92	2.73e-35	1.18e-27	-0.76	-0.6	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-13.92	2.73e-35	1.18e-27	-0.76	-0.6	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-13.92	2.73e-35	1.18e-27	-0.76	-0.6	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
STAD	trans	rs7949030	0.964	rs2957122	ENSG00000186676.3	EEF1GP1	-13.92	2.74e-35	1.18e-27	-0.73	-0.6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62624628	chr7:125033453~125035301:+
STAD	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-13.91	3.06e-35	1.32e-27	-0.76	-0.6	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-13.89	3.67e-35	1.58e-27	-0.78	-0.6	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-13.88	3.79e-35	1.63e-27	-0.76	-0.6	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	13.88	3.85e-35	1.65e-27	0.76	0.6	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
STAD	trans	rs7949030	1	rs3018561	ENSG00000186676.3	EEF1GP1	-13.88	3.99e-35	1.71e-27	-0.73	-0.6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62624757	chr7:125033453~125035301:+
STAD	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-13.86	4.52e-35	1.94e-27	-0.77	-0.6	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-13.86	4.84e-35	2.07e-27	-0.54	-0.6	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
STAD	trans	rs1816752	0.669	rs4770699	ENSG00000237917.1	PARP4P1	-13.85	5.05e-35	2.16e-27	-0.77	-0.6	Obesity-related traits;	chr13:24488234	chrY:26594851~26634652:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-13.83	5.94e-35	2.54e-27	-0.56	-0.6	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-13.82	6.86e-35	2.92e-27	-0.52	-0.6	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
STAD	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	13.82	6.86e-35	2.92e-27	0.75	0.6	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
STAD	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-13.8	7.92e-35	3.36e-27	-0.78	-0.6	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-13.8	8.1e-35	3.43e-27	-0.57	-0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
STAD	trans	rs916888	0.738	rs199515	ENSG00000280022.1	RP11-707O23.1	-13.79	8.83e-35	3.74e-27	-0.93	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45592621~45593369:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-13.78	9.77e-35	4.13e-27	-0.56	-0.6	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-13.78	9.77e-35	4.13e-27	-0.56	-0.6	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-13.77	1.02e-34	4.32e-27	-0.53	-0.6	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
STAD	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-13.76	1.18e-34	4.96e-27	-0.76	-0.59	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
STAD	trans	rs11098499	0.908	rs28499576	ENSG00000276997.3	RP11-378J18.9	13.75	1.31e-34	5.49e-27	0.67	0.59	Corneal astigmatism;	chr4:119465522	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	13.73	1.49e-34	6.25e-27	0.54	0.59	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
STAD	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	13.73	1.5e-34	6.29e-27	0.66	0.59	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
STAD	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-13.73	1.54e-34	6.44e-27	-0.76	-0.59	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
STAD	trans	rs11098499	0.738	rs28408407	ENSG00000276997.3	RP11-378J18.9	13.71	1.88e-34	7.79e-27	0.66	0.59	Corneal astigmatism;	chr4:119454875	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs1809406	ENSG00000276997.3	RP11-378J18.9	13.71	1.88e-34	7.79e-27	0.66	0.59	Corneal astigmatism;	chr4:119455967	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs2389809	ENSG00000276997.3	RP11-378J18.9	13.71	1.88e-34	7.79e-27	0.66	0.59	Corneal astigmatism;	chr4:119456244	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs10020027	ENSG00000276997.3	RP11-378J18.9	13.71	1.88e-34	7.79e-27	0.66	0.59	Corneal astigmatism;	chr4:119460724	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.779	rs7356491	ENSG00000276997.3	RP11-378J18.9	13.71	1.88e-34	7.79e-27	0.66	0.59	Corneal astigmatism;	chr4:119460819	chr1:222477252~222504622:-
STAD	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-13.7	2e-34	8.28e-27	-0.76	-0.59	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
STAD	trans	rs11098499	0.909	rs9994810	ENSG00000276997.3	RP11-378J18.9	13.7	2.02e-34	8.37e-27	0.66	0.59	Corneal astigmatism;	chr4:119460435	chr1:222477252~222504622:-
STAD	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-13.7	2.02e-34	8.37e-27	-0.76	-0.59	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-13.68	2.27e-34	9.41e-27	-0.52	-0.59	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
STAD	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-13.68	2.45e-34	1.01e-26	-0.76	-0.59	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
STAD	trans	rs11098499	0.866	rs72676074	ENSG00000276997.3	RP11-378J18.9	13.67	2.53e-34	1.05e-26	0.67	0.59	Corneal astigmatism;	chr4:119438686	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	13.67	2.63e-34	1.08e-26	0.66	0.59	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
STAD	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-13.67	2.7e-34	1.11e-26	-0.76	-0.59	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-13.66	2.76e-34	1.14e-26	-0.76	-0.59	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-13.66	2.88e-34	1.19e-26	-0.77	-0.59	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-13.65	3.09e-34	1.27e-26	-0.76	-0.59	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
STAD	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-13.62	3.86e-34	1.58e-26	-0.76	-0.59	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000225071.1	GS1-184P14.2	-13.62	4.09e-34	1.67e-26	-0.54	-0.59	Cognitive function;	chr12:56042145	chrX:24429573~24429920:-
STAD	trans	rs11098499	0.738	rs72918577	ENSG00000276997.3	RP11-378J18.9	13.61	4.32e-34	1.76e-26	0.66	0.59	Corneal astigmatism;	chr4:119405546	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	13.6	4.8e-34	1.95e-26	0.54	0.59	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
STAD	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-13.6	4.82e-34	1.96e-26	-0.75	-0.59	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
STAD	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-13.6	4.84e-34	1.97e-26	-0.71	-0.59	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-13.59	5.27e-34	2.14e-26	-0.58	-0.59	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
STAD	trans	rs11098499	0.865	rs4001305	ENSG00000276997.3	RP11-378J18.9	13.59	5.35e-34	2.17e-26	0.67	0.59	Corneal astigmatism;	chr4:119438081	chr1:222477252~222504622:-
STAD	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-13.59	5.44e-34	2.2e-26	-0.72	-0.59	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-13.57	6.57e-34	2.65e-26	-0.54	-0.59	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000225071.1	GS1-184P14.2	-13.55	7.31e-34	2.94e-26	-0.54	-0.59	Cognitive function;	chr12:56007301	chrX:24429573~24429920:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-13.52	1e-33	3.98e-26	-0.51	-0.59	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-13.52	1e-33	3.98e-26	-0.51	-0.59	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
STAD	trans	rs7930295	0.556	rs35904963	ENSG00000236257.1	EI24P2	13.52	1.01e-33	4e-26	0.86	0.59	Schizophrenia;	chr11:125476956	chr1:158454198~158455273:+
STAD	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	13.49	1.25e-33	4.96e-26	0.68	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
STAD	trans	rs11098499	0.954	rs13107475	ENSG00000276997.3	RP11-378J18.9	13.48	1.41e-33	5.57e-26	0.66	0.59	Corneal astigmatism;	chr4:119471856	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	13.47	1.49e-33	5.85e-26	0.65	0.59	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
STAD	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-13.45	1.81e-33	7.13e-26	-0.74	-0.59	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
STAD	trans	rs11098499	0.954	rs10034623	ENSG00000276997.3	RP11-378J18.9	13.44	2.02e-33	7.94e-26	0.66	0.59	Corneal astigmatism;	chr4:119476674	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6849171	ENSG00000276997.3	RP11-378J18.9	13.43	2.25e-33	8.8e-26	0.65	0.59	Corneal astigmatism;	chr4:119488394	chr1:222477252~222504622:-
STAD	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-13.42	2.31e-33	9.02e-26	-0.76	-0.59	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
STAD	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	13.41	2.58e-33	1.01e-25	0.69	0.58	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
STAD	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-13.39	3.05e-33	1.19e-25	-0.66	-0.58	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-13.38	3.3e-33	1.28e-25	-0.57	-0.58	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-13.38	3.3e-33	1.28e-25	-0.57	-0.58	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
STAD	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	13.37	3.7e-33	1.42e-25	0.66	0.58	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000196656.7	AC004057.1	-13.37	3.72e-33	1.43e-25	-0.53	-0.58	Cognitive function;	chr12:56042145	chr4:113214046~113217170:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-13.37	3.81e-33	1.46e-25	-0.57	-0.58	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
STAD	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	13.36	4.04e-33	1.55e-25	0.8	0.58	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
STAD	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	13.36	4.04e-33	1.55e-25	0.8	0.58	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
STAD	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	13.33	5.09e-33	1.95e-25	0.66	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	13.3	7.04e-33	2.67e-25	0.58	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.954	rs11098525	ENSG00000276997.3	RP11-378J18.9	13.29	7.88e-33	2.9e-25	0.65	0.58	Corneal astigmatism;	chr4:119468997	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	13.28	8.38e-33	3.08e-25	0.86	0.58	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000234513.1	AC073072.7	-13.28	8.57e-33	3.15e-25	-0.55	-0.58	Cognitive function;	chr12:56042145	chr7:22773646~22773993:-
STAD	trans	rs11098499	0.909	rs7681978	ENSG00000276997.3	RP11-378J18.9	13.27	8.88e-33	3.25e-25	0.65	0.58	Corneal astigmatism;	chr4:119462620	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs11941899	ENSG00000276997.3	RP11-378J18.9	13.26	9.45e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119461603	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.821	rs28665282	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119463031	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.738	rs10026493	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119463039	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs7681214	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119464165	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs28559989	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119465472	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs28632018	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119465575	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs71614449	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119465900	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs35063680	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119465947	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs34858317	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119465955	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs17046116	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119466104	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs17046118	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119466341	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs7654587	ENSG00000276997.3	RP11-378J18.9	13.26	9.52e-33	3.43e-25	0.65	0.58	Corneal astigmatism;	chr4:119467251	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs71614422	ENSG00000276997.3	RP11-378J18.9	13.26	1.01e-32	3.61e-25	0.65	0.58	Corneal astigmatism;	chr4:119438185	chr1:222477252~222504622:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000227887.1	RPS26P13	-13.25	1.03e-32	3.7e-25	-0.58	-0.58	Cognitive function;	chr12:56042145	chr1:208697369~208697698:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000204652.6	RPS26P8	-13.25	1.09e-32	3.87e-25	-0.52	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:45608571~45608918:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-13.24	1.22e-32	4.32e-25	-0.55	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
STAD	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	13.23	1.24e-32	4.42e-25	0.64	0.58	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
STAD	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	13.23	1.25e-32	4.46e-25	0.78	0.58	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
STAD	trans	rs11098499	0.954	rs10518331	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119402440	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs13133522	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119403269	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs35091806	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119404374	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs35165976	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119404475	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs2389802	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119404577	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6846442	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119405168	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.738	rs34566984	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119440115	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.738	rs34965784	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119440431	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs17009122	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119441248	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs9685777	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119444810	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs71614438	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119450097	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs66506550	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119450290	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs7659501	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119450397	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs28655325	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119451844	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.657	rs71614442	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119458191	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs2892848	ENSG00000276997.3	RP11-378J18.9	13.23	1.33e-32	4.54e-25	0.65	0.58	Corneal astigmatism;	chr4:119460186	chr1:222477252~222504622:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000227887.1	RPS26P13	-13.22	1.44e-32	4.92e-25	-0.59	-0.58	Cognitive function;	chr12:56007301	chr1:208697369~208697698:-
STAD	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	13.21	1.52e-32	5.15e-25	0.64	0.58	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-13.2	1.74e-32	5.9e-25	-0.52	-0.58	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-13.2	1.74e-32	5.9e-25	-0.52	-0.58	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000196656.7	AC004057.1	-13.19	1.76e-32	5.95e-25	-0.53	-0.58	Cognitive function;	chr12:56007301	chr4:113214046~113217170:-
STAD	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	13.18	2.07e-32	6.93e-25	0.81	0.58	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
STAD	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	13.18	2.07e-32	6.93e-25	0.81	0.58	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
STAD	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	13.18	2.07e-32	6.93e-25	0.81	0.58	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
STAD	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	13.18	2.07e-32	6.93e-25	0.81	0.58	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
STAD	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	13.18	2.07e-32	6.93e-25	0.81	0.58	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
STAD	trans	rs7949030	0.78	rs3017666	ENSG00000186676.3	EEF1GP1	-13.15	2.55e-32	8.46e-25	-0.71	-0.58	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62636945	chr7:125033453~125035301:+
STAD	trans	rs11098499	0.821	rs10032151	ENSG00000276997.3	RP11-378J18.9	13.14	2.73e-32	9.03e-25	0.65	0.58	Corneal astigmatism;	chr4:119470473	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs10032158	ENSG00000276997.3	RP11-378J18.9	13.14	2.73e-32	9.03e-25	0.65	0.58	Corneal astigmatism;	chr4:119470477	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6838814	ENSG00000276997.3	RP11-378J18.9	13.14	2.73e-32	9.03e-25	0.65	0.58	Corneal astigmatism;	chr4:119471288	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10006525	ENSG00000276997.3	RP11-378J18.9	13.14	2.77e-32	9.16e-25	0.65	0.58	Corneal astigmatism;	chr4:119487776	chr1:222477252~222504622:-
STAD	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-13.12	3.35e-32	1.09e-24	-0.74	-0.58	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
STAD	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-13.12	3.43e-32	1.11e-24	-0.78	-0.58	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	13.12	3.52e-32	1.14e-24	0.56	0.58	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
STAD	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	13.09	4.27e-32	1.38e-24	0.8	0.58	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-13.08	4.73e-32	1.53e-24	-0.53	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
STAD	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	13.08	4.83e-32	1.55e-24	0.78	0.58	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000234513.1	AC073072.7	-13.08	5e-32	1.61e-24	-0.54	-0.58	Cognitive function;	chr12:56007301	chr7:22773646~22773993:-
STAD	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-13.05	6.12e-32	1.96e-24	-0.85	-0.57	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
STAD	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-13.05	6.29e-32	2.01e-24	-0.73	-0.57	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
STAD	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	13.04	7.01e-32	2.24e-24	0.64	0.57	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.505	rs75122014	ENSG00000276997.3	RP11-378J18.9	13.04	7.1e-32	2.26e-24	0.65	0.57	Corneal astigmatism;	chr4:119441271	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs1480931	ENSG00000276997.3	RP11-378J18.9	13.02	7.99e-32	2.53e-24	0.64	0.57	Corneal astigmatism;	chr4:119474654	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-13.01	8.97e-32	2.83e-24	-0.84	-0.57	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-13.01	8.97e-32	2.83e-24	-0.84	-0.57	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs7436506	ENSG00000276997.3	RP11-378J18.9	13.01	9.24e-32	2.91e-24	0.65	0.57	Corneal astigmatism;	chr4:119472614	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10008459	ENSG00000276997.3	RP11-378J18.9	13.01	9.24e-32	2.91e-24	0.65	0.57	Corneal astigmatism;	chr4:119473076	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs2127821	ENSG00000276997.3	RP11-378J18.9	13.01	9.24e-32	2.91e-24	0.65	0.57	Corneal astigmatism;	chr4:119473380	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10006706	ENSG00000276997.3	RP11-378J18.9	13	9.85e-32	3.1e-24	0.64	0.57	Corneal astigmatism;	chr4:119487997	chr1:222477252~222504622:-
STAD	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-13	9.89e-32	3.11e-24	-0.72	-0.57	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
STAD	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-13	9.95e-32	3.13e-24	-0.79	-0.57	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
STAD	trans	rs11098499	0.618	rs35265692	ENSG00000276997.3	RP11-378J18.9	12.99	1.06e-31	3.32e-24	0.65	0.57	Corneal astigmatism;	chr4:119403980	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs3733520	ENSG00000276997.3	RP11-378J18.9	12.99	1.07e-31	3.35e-24	0.64	0.57	Corneal astigmatism;	chr4:119502325	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	12.97	1.24e-31	3.87e-24	0.64	0.57	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.779	rs28495013	ENSG00000276997.3	RP11-378J18.9	12.97	1.24e-31	3.88e-24	0.65	0.57	Corneal astigmatism;	chr4:119454676	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-12.97	1.28e-31	3.98e-24	-0.85	-0.57	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
STAD	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	12.96	1.34e-31	4.18e-24	0.78	0.57	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
STAD	trans	rs11098499	0.909	rs10026736	ENSG00000276997.3	RP11-378J18.9	12.95	1.46e-31	4.54e-24	0.65	0.57	Corneal astigmatism;	chr4:119463167	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs28572238	ENSG00000276997.3	RP11-378J18.9	12.95	1.48e-31	4.59e-24	0.64	0.57	Corneal astigmatism;	chr4:119395531	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs28714195	ENSG00000276997.3	RP11-378J18.9	12.95	1.48e-31	4.59e-24	0.64	0.57	Corneal astigmatism;	chr4:119395795	chr1:222477252~222504622:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-12.94	1.64e-31	5.07e-24	-0.53	-0.57	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	12.94	1.67e-31	5.19e-24	0.56	0.57	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
STAD	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	12.93	1.85e-31	5.74e-24	0.87	0.57	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs3890049	ENSG00000276997.3	RP11-378J18.9	12.92	2.02e-31	6.22e-24	0.65	0.57	Corneal astigmatism;	chr4:119405128	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs71629403	ENSG00000276997.3	RP11-378J18.9	12.92	2.02e-31	6.22e-24	0.65	0.57	Corneal astigmatism;	chr4:119451412	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs28571712	ENSG00000276997.3	RP11-378J18.9	12.92	2.02e-31	6.22e-24	0.65	0.57	Corneal astigmatism;	chr4:119454825	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs9994730	ENSG00000276997.3	RP11-378J18.9	12.92	2.02e-31	6.22e-24	0.65	0.57	Corneal astigmatism;	chr4:119460409	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs2389803	ENSG00000276997.3	RP11-378J18.9	-12.92	2.03e-31	6.25e-24	-0.64	-0.57	Corneal astigmatism;	chr4:119472356	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	12.91	2.11e-31	6.51e-24	0.52	0.57	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.954	rs67265404	ENSG00000276997.3	RP11-378J18.9	12.91	2.15e-31	6.6e-24	0.65	0.57	Corneal astigmatism;	chr4:119438115	chr1:222477252~222504622:-
STAD	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-12.9	2.33e-31	7.15e-24	-0.75	-0.57	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
STAD	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-12.89	2.52e-31	7.73e-24	-0.83	-0.57	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-12.89	2.67e-31	8.18e-24	-0.52	-0.57	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
STAD	trans	rs11098499	0.909	rs9759478	ENSG00000276997.3	RP11-378J18.9	12.88	2.83e-31	8.65e-24	0.65	0.57	Corneal astigmatism;	chr4:119446843	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs10017335	ENSG00000276997.3	RP11-378J18.9	-12.87	2.94e-31	8.97e-24	-0.64	-0.57	Corneal astigmatism;	chr4:119460368	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6849561	ENSG00000276997.3	RP11-378J18.9	-12.87	3.17e-31	9.67e-24	-0.65	-0.57	Corneal astigmatism;	chr4:119488539	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6848389	ENSG00000276997.3	RP11-378J18.9	12.86	3.24e-31	9.88e-24	0.63	0.57	Corneal astigmatism;	chr4:119481467	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs17005535	ENSG00000276997.3	RP11-378J18.9	12.86	3.29e-31	1e-23	0.64	0.57	Corneal astigmatism;	chr4:119490407	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-12.85	3.78e-31	1.15e-23	-0.83	-0.57	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
STAD	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	12.84	3.97e-31	1.21e-23	0.78	0.57	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
STAD	trans	rs11098499	0.954	rs11098526	ENSG00000276997.3	RP11-378J18.9	12.84	4.06e-31	1.23e-23	0.64	0.57	Corneal astigmatism;	chr4:119469204	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	12.83	4.37e-31	1.32e-23	0.5	0.57	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
STAD	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	12.82	4.68e-31	1.41e-23	0.8	0.57	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
STAD	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	12.81	5.13e-31	1.55e-23	0.85	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
STAD	trans	rs11098499	0.909	rs28884220	ENSG00000276997.3	RP11-378J18.9	12.81	5.21e-31	1.57e-23	0.64	0.57	Corneal astigmatism;	chr4:119386056	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs28793658	ENSG00000276997.3	RP11-378J18.9	12.81	5.21e-31	1.57e-23	0.64	0.57	Corneal astigmatism;	chr4:119386059	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-12.8	5.68e-31	1.71e-23	-0.84	-0.57	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs17050695	ENSG00000276997.3	RP11-378J18.9	12.8	5.81e-31	1.75e-23	0.64	0.57	Corneal astigmatism;	chr4:119568372	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-12.79	6.11e-31	1.84e-23	-0.83	-0.57	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.779	rs80242894	ENSG00000276997.3	RP11-378J18.9	12.79	6.29e-31	1.89e-23	0.65	0.57	Corneal astigmatism;	chr4:119454597	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-12.79	6.41e-31	1.92e-23	-0.52	-0.57	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
STAD	trans	rs11098499	0.908	rs7696649	ENSG00000276997.3	RP11-378J18.9	12.78	6.66e-31	2e-23	0.64	0.57	Corneal astigmatism;	chr4:119401022	chr1:222477252~222504622:-
STAD	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	12.78	6.71e-31	2.01e-23	0.77	0.57	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
STAD	trans	rs11098499	0.954	rs4309825	ENSG00000276997.3	RP11-378J18.9	-12.77	7.19e-31	2.15e-23	-0.63	-0.57	Corneal astigmatism;	chr4:119393726	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs7695996	ENSG00000276997.3	RP11-378J18.9	12.77	7.27e-31	2.18e-23	0.64	0.57	Corneal astigmatism;	chr4:119400878	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs9993199	ENSG00000276997.3	RP11-378J18.9	-12.77	7.5e-31	2.24e-23	-0.62	-0.57	Corneal astigmatism;	chr4:119471718	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	12.76	7.71e-31	2.29e-23	0.62	0.57	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
STAD	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	12.76	7.71e-31	2.29e-23	0.62	0.57	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000212829.8	RPS26P3	-12.76	7.79e-31	2.32e-23	-0.51	-0.57	Cognitive function;	chr12:56084218	chr9:9090898~9091245:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000212829.8	RPS26P3	-12.76	7.79e-31	2.32e-23	-0.51	-0.57	Cognitive function;	chr12:56084874	chr9:9090898~9091245:+
STAD	trans	rs11098499	0.954	rs59866101	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119375436	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.618	rs6858383	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119375617	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs6832410	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119375645	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs1112817	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119376645	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.779	rs10016060	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119377257	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10005644	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119377322	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs10016448	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119377690	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.657	rs9996569	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119377849	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs11723757	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119378514	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs11729050	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119378911	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs28429722	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119378938	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10014845	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119379922	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.779	rs7674500	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119382438	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs4373140	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119386543	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs13113483	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119387884	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.542	rs10440343	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119388632	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs28668716	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119388720	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.779	rs10011097	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119389204	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.542	rs7677836	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119389483	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs10002083	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119389997	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10024844	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119390373	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs4345162	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119391804	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.657	rs4463052	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119392103	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs13151285	ENSG00000276997.3	RP11-378J18.9	12.76	8.07e-31	2.35e-23	0.64	0.57	Corneal astigmatism;	chr4:119393586	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs11098513	ENSG00000276997.3	RP11-378J18.9	12.75	8.74e-31	2.54e-23	0.64	0.57	Corneal astigmatism;	chr4:119394920	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs12508173	ENSG00000276997.3	RP11-378J18.9	12.74	9.42e-31	2.73e-23	0.64	0.57	Corneal astigmatism;	chr4:119397371	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs12504149	ENSG00000276997.3	RP11-378J18.9	12.74	9.42e-31	2.73e-23	0.64	0.57	Corneal astigmatism;	chr4:119397422	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10008392	ENSG00000276997.3	RP11-378J18.9	12.74	9.42e-31	2.73e-23	0.64	0.57	Corneal astigmatism;	chr4:119397684	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10518328	ENSG00000276997.3	RP11-378J18.9	12.74	9.52e-31	2.75e-23	0.64	0.57	Corneal astigmatism;	chr4:119480624	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6822679	ENSG00000276997.3	RP11-378J18.9	12.74	9.52e-31	2.75e-23	0.64	0.57	Corneal astigmatism;	chr4:119481547	chr1:222477252~222504622:-
STAD	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-12.73	1.02e-30	2.94e-23	-0.73	-0.56	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
STAD	trans	rs11098499	0.954	rs7437420	ENSG00000276997.3	RP11-378J18.9	12.73	1.06e-30	3.05e-23	0.63	0.56	Corneal astigmatism;	chr4:119391748	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-12.73	1.07e-30	3.08e-23	-0.52	-0.56	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
STAD	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	12.72	1.16e-30	3.33e-23	0.87	0.56	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	12.72	1.16e-30	3.33e-23	0.87	0.56	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	12.72	1.16e-30	3.33e-23	0.87	0.56	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	12.72	1.16e-30	3.33e-23	0.87	0.56	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	12.72	1.16e-30	3.33e-23	0.87	0.56	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	12.72	1.16e-30	3.33e-23	0.87	0.56	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
STAD	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	12.72	1.17e-30	3.34e-23	0.84	0.56	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
STAD	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-12.71	1.21e-30	3.47e-23	-0.82	-0.56	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-12.7	1.3e-30	3.71e-23	-0.5	-0.56	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
STAD	trans	rs11098499	0.618	rs28491261	ENSG00000276997.3	RP11-378J18.9	12.7	1.31e-30	3.74e-23	0.63	0.56	Corneal astigmatism;	chr4:119373745	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs59394118	ENSG00000276997.3	RP11-378J18.9	12.7	1.31e-30	3.74e-23	0.63	0.56	Corneal astigmatism;	chr4:119374396	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs9996417	ENSG00000276997.3	RP11-378J18.9	12.7	1.31e-30	3.74e-23	0.63	0.56	Corneal astigmatism;	chr4:119374707	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs12499324	ENSG00000276997.3	RP11-378J18.9	12.7	1.34e-30	3.81e-23	0.64	0.56	Corneal astigmatism;	chr4:119472631	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs9998585	ENSG00000276997.3	RP11-378J18.9	12.7	1.34e-30	3.81e-23	0.64	0.56	Corneal astigmatism;	chr4:119475647	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs6842762	ENSG00000276997.3	RP11-378J18.9	12.7	1.34e-30	3.81e-23	0.64	0.56	Corneal astigmatism;	chr4:119477081	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs28634456	ENSG00000276997.3	RP11-378J18.9	12.69	1.43e-30	4.04e-23	0.65	0.56	Corneal astigmatism;	chr4:119454623	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs78332141	ENSG00000276997.3	RP11-378J18.9	12.69	1.43e-30	4.04e-23	0.65	0.56	Corneal astigmatism;	chr4:119454627	chr1:222477252~222504622:-
STAD	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	12.69	1.51e-30	4.27e-23	0.77	0.56	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
STAD	trans	rs11098499	0.954	rs12508504	ENSG00000276997.3	RP11-378J18.9	12.68	1.55e-30	4.38e-23	0.63	0.56	Corneal astigmatism;	chr4:119489452	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.58	rs12509234	ENSG00000276997.3	RP11-378J18.9	12.68	1.57e-30	4.43e-23	0.64	0.56	Corneal astigmatism;	chr4:119398279	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs10014719	ENSG00000276997.3	RP11-378J18.9	12.68	1.57e-30	4.43e-23	0.64	0.56	Corneal astigmatism;	chr4:119399560	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-12.68	1.58e-30	4.46e-23	-0.84	-0.56	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
STAD	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	12.68	1.61e-30	4.54e-23	0.87	0.56	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	12.68	1.61e-30	4.54e-23	0.87	0.56	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	12.68	1.61e-30	4.54e-23	0.87	0.56	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs10017543	ENSG00000276997.3	RP11-378J18.9	12.67	1.76e-30	4.94e-23	0.64	0.56	Corneal astigmatism;	chr4:119400265	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs4577559	ENSG00000276997.3	RP11-378J18.9	12.67	1.78e-30	4.99e-23	0.64	0.56	Corneal astigmatism;	chr4:119482888	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs7656252	ENSG00000276997.3	RP11-378J18.9	12.67	1.78e-30	4.99e-23	0.64	0.56	Corneal astigmatism;	chr4:119483113	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs28845498	ENSG00000276997.3	RP11-378J18.9	12.67	1.78e-30	4.99e-23	0.64	0.56	Corneal astigmatism;	chr4:119484031	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs28753180	ENSG00000276997.3	RP11-378J18.9	12.67	1.78e-30	4.99e-23	0.64	0.56	Corneal astigmatism;	chr4:119484212	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs56270433	ENSG00000276997.3	RP11-378J18.9	12.67	1.78e-30	4.99e-23	0.64	0.56	Corneal astigmatism;	chr4:119484875	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs11098527	ENSG00000276997.3	RP11-378J18.9	12.65	2.02e-30	5.65e-23	0.64	0.56	Corneal astigmatism;	chr4:119478751	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs4507344	ENSG00000276997.3	RP11-378J18.9	12.65	2.1e-30	5.87e-23	0.63	0.56	Corneal astigmatism;	chr4:119386330	chr1:222477252~222504622:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000196933.5	RPS26P11	-12.64	2.2e-30	6.15e-23	-0.54	-0.56	Cognitive function;	chr12:56042145	chrX:72044545~72044892:+
STAD	trans	rs11098499	0.697	rs4560394	ENSG00000276997.3	RP11-378J18.9	12.64	2.25e-30	6.28e-23	0.64	0.56	Corneal astigmatism;	chr4:119392280	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-12.63	2.49e-30	6.94e-23	-0.84	-0.56	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-12.63	2.49e-30	6.94e-23	-0.84	-0.56	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000212829.8	RPS26P3	-12.63	2.56e-30	7.14e-23	-0.53	-0.56	Cognitive function;	chr12:56042145	chr9:9090898~9091245:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	12.61	2.87e-30	7.99e-23	0.56	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
STAD	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-12.61	2.87e-30	7.99e-23	-0.82	-0.56	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	12.61	3.02e-30	8.38e-23	0.84	0.56	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-12.61	3.05e-30	8.46e-23	-0.83	-0.56	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-12.61	3.05e-30	8.46e-23	-0.83	-0.56	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs12502423	ENSG00000276997.3	RP11-378J18.9	12.6	3.14e-30	8.7e-23	0.63	0.56	Corneal astigmatism;	chr4:119503017	chr1:222477252~222504622:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000212829.8	RPS26P3	-12.6	3.34e-30	9.25e-23	-0.53	-0.56	Cognitive function;	chr12:56007301	chr9:9090898~9091245:+
STAD	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	12.59	3.48e-30	9.63e-23	0.77	0.56	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
STAD	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-12.59	3.55e-30	9.81e-23	-0.84	-0.56	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000196933.5	RPS26P11	-12.59	3.63e-30	1e-22	-0.54	-0.56	Cognitive function;	chr12:56007301	chrX:72044545~72044892:+
STAD	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-12.58	3.77e-30	1.04e-22	-0.88	-0.56	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-12.58	3.96e-30	1.09e-22	-0.49	-0.56	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-12.57	4.05e-30	1.11e-22	-0.51	-0.56	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-12.57	4.05e-30	1.11e-22	-0.51	-0.56	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
STAD	trans	rs1552244	0.872	rs115331527	ENSG00000230342.2	FANCD2P2	12.56	4.36e-30	1.2e-22	0.71	0.56	Alzheimer's disease;	chr3:10112820	chr3:11859674~11891172:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000233778.3	RP11-777J24.1	-12.56	4.58e-30	1.25e-22	-0.53	-0.56	Cognitive function;	chr12:56042145	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.954	rs7681544	ENSG00000276997.3	RP11-378J18.9	12.56	4.64e-30	1.27e-22	0.63	0.56	Corneal astigmatism;	chr4:119490100	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs11940028	ENSG00000276997.3	RP11-378J18.9	12.56	4.64e-30	1.27e-22	0.63	0.56	Corneal astigmatism;	chr4:119490752	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs11935596	ENSG00000276997.3	RP11-378J18.9	12.56	4.64e-30	1.27e-22	0.63	0.56	Corneal astigmatism;	chr4:119491302	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs12507964	ENSG00000276997.3	RP11-378J18.9	12.56	4.64e-30	1.27e-22	0.63	0.56	Corneal astigmatism;	chr4:119491906	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs11098530	ENSG00000276997.3	RP11-378J18.9	12.56	4.64e-30	1.27e-22	0.63	0.56	Corneal astigmatism;	chr4:119491999	chr1:222477252~222504622:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	12.55	5.01e-30	1.37e-22	0.55	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.909	rs10020034	ENSG00000276997.3	RP11-378J18.9	12.55	5.09e-30	1.39e-22	0.63	0.56	Corneal astigmatism;	chr4:119373176	chr1:222477252~222504622:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-12.54	5.23e-30	1.43e-22	-0.5	-0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
STAD	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-12.54	5.3e-30	1.44e-22	-0.83	-0.56	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-12.54	5.3e-30	1.44e-22	-0.83	-0.56	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
STAD	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	12.54	5.31e-30	1.44e-22	0.77	0.56	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
STAD	trans	rs11098499	0.954	rs11729521	ENSG00000276997.3	RP11-378J18.9	12.54	5.46e-30	1.49e-22	0.63	0.56	Corneal astigmatism;	chr4:119495633	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs11734241	ENSG00000276997.3	RP11-378J18.9	12.54	5.46e-30	1.49e-22	0.63	0.56	Corneal astigmatism;	chr4:119495717	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	12.53	5.68e-30	1.54e-22	0.57	0.56	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
STAD	trans	rs13177918	0.559	rs3901731	ENSG00000239528.1	RPS14P8	12.53	6.16e-30	1.67e-22	0.64	0.56	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr5:116562562~116562930:+
STAD	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	12.51	6.73e-30	1.83e-22	0.82	0.56	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs67852463	ENSG00000230342.2	FANCD2P2	12.51	7.09e-30	1.92e-22	0.72	0.56	Alzheimer's disease;	chr3:10115521	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.954	rs12510138	ENSG00000276997.3	RP11-378J18.9	12.51	7.11e-30	1.93e-22	0.63	0.56	Corneal astigmatism;	chr4:119502780	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs17006190	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119497683	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs28685688	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119499179	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs7687843	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119500056	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs2306455	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119500814	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10031483	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119501481	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10031665	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119501697	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs3733519	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119502293	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs3733523	ENSG00000276997.3	RP11-378J18.9	12.51	7.25e-30	1.96e-22	0.63	0.56	Corneal astigmatism;	chr4:119502564	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-12.51	7.26e-30	1.96e-22	-0.82	-0.56	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-12.51	7.26e-30	1.96e-22	-0.82	-0.56	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs6834796	ENSG00000276997.3	RP11-378J18.9	12.5	7.95e-30	2.14e-22	0.63	0.56	Corneal astigmatism;	chr4:119493538	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs6835635	ENSG00000276997.3	RP11-378J18.9	12.47	9.52e-30	2.55e-22	0.63	0.56	Corneal astigmatism;	chr4:119537712	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-12.47	9.57e-30	2.57e-22	-0.58	-0.56	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
STAD	trans	rs7930295	0.687	rs7117500	ENSG00000236257.1	EI24P2	12.47	9.7e-30	2.6e-22	0.84	0.56	Schizophrenia;	chr11:125504232	chr1:158454198~158455273:+
STAD	trans	rs11098499	0.865	rs11722183	ENSG00000276997.3	RP11-378J18.9	12.47	1.01e-29	2.7e-22	0.61	0.56	Corneal astigmatism;	chr4:119359442	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	12.46	1.08e-29	2.89e-22	0.82	0.56	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs6858592	ENSG00000276997.3	RP11-378J18.9	12.46	1.1e-29	2.93e-22	0.63	0.56	Corneal astigmatism;	chr4:119537537	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	12.46	1.13e-29	3e-22	0.82	0.56	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	12.45	1.21e-29	3.22e-22	0.86	0.56	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000233778.3	RP11-777J24.1	-12.44	1.3e-29	3.46e-22	-0.52	-0.56	Cognitive function;	chr12:56007301	chr8:92144088~92144435:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	12.44	1.31e-29	3.49e-22	0.52	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
STAD	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-12.43	1.4e-29	3.7e-22	-0.84	-0.56	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-12.43	1.42e-29	3.76e-22	-0.78	-0.56	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	12.43	1.45e-29	3.85e-22	0.54	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	12.42	1.47e-29	3.9e-22	0.53	0.56	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
STAD	trans	rs11098499	0.863	rs13134665	ENSG00000276997.3	RP11-378J18.9	12.42	1.56e-29	4.13e-22	0.63	0.56	Corneal astigmatism;	chr4:119505275	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	12.42	1.58e-29	4.15e-22	0.86	0.56	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	12.42	1.58e-29	4.15e-22	0.86	0.56	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-12.4	1.79e-29	4.7e-22	-0.48	-0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
STAD	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	12.39	1.9e-29	4.98e-22	0.82	0.55	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs10004484	ENSG00000276997.3	RP11-378J18.9	12.39	1.93e-29	5.06e-22	0.63	0.55	Corneal astigmatism;	chr4:119521273	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs1155576	ENSG00000276997.3	RP11-378J18.9	12.39	1.93e-29	5.06e-22	0.63	0.55	Corneal astigmatism;	chr4:119529004	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs73842633	ENSG00000276997.3	RP11-378J18.9	12.38	2.21e-29	5.8e-22	0.64	0.55	Corneal astigmatism;	chr4:119454309	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.779	rs7699346	ENSG00000276997.3	RP11-378J18.9	12.37	2.26e-29	5.91e-22	0.63	0.55	Corneal astigmatism;	chr4:119389387	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000244604.1	RP11-713H12.1	12.37	2.32e-29	6.05e-22	0.54	0.55	Cognitive function;	chr12:56076841	chr17:8561230~8561576:+
STAD	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	12.37	2.34e-29	6.11e-22	0.84	0.55	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	12.37	2.34e-29	6.11e-22	0.84	0.55	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	12.37	2.34e-29	6.11e-22	0.84	0.55	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-12.36	2.54e-29	6.63e-22	-0.84	-0.55	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-12.35	2.92e-29	7.58e-22	-0.48	-0.55	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-12.35	2.92e-29	7.58e-22	-0.48	-0.55	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
STAD	trans	rs1552244	0.748	rs113890152	ENSG00000230342.2	FANCD2P2	12.34	2.94e-29	7.64e-22	0.7	0.55	Alzheimer's disease;	chr3:10044302	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs10018280	ENSG00000276997.3	RP11-378J18.9	12.33	3.26e-29	8.43e-22	0.63	0.55	Corneal astigmatism;	chr4:119556984	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs6534141	ENSG00000276997.3	RP11-378J18.9	12.33	3.26e-29	8.43e-22	0.63	0.55	Corneal astigmatism;	chr4:119564068	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs2127823	ENSG00000276997.3	RP11-378J18.9	12.33	3.26e-29	8.43e-22	0.63	0.55	Corneal astigmatism;	chr4:119564515	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3775858	ENSG00000276997.3	RP11-378J18.9	12.33	3.26e-29	8.43e-22	0.63	0.55	Corneal astigmatism;	chr4:119564873	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-12.33	3.33e-29	8.6e-22	-0.6	-0.55	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-12.32	3.59e-29	9.25e-22	-0.54	-0.55	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
STAD	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-12.32	3.66e-29	9.42e-22	-0.81	-0.55	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-12.32	3.66e-29	9.42e-22	-0.81	-0.55	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-12.32	3.66e-29	9.42e-22	-0.81	-0.55	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
STAD	trans	rs13177918	0.581	rs2748244	ENSG00000239528.1	RPS14P8	12.32	3.66e-29	9.43e-22	0.63	0.55	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr5:116562562~116562930:+
STAD	trans	rs11098499	0.909	rs11723839	ENSG00000276997.3	RP11-378J18.9	12.32	3.74e-29	9.62e-22	0.62	0.55	Corneal astigmatism;	chr4:119378518	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs12506546	ENSG00000276997.3	RP11-378J18.9	12.32	3.74e-29	9.62e-22	0.62	0.55	Corneal astigmatism;	chr4:119380463	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	12.32	3.76e-29	9.67e-22	0.82	0.55	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	12.32	3.76e-29	9.67e-22	0.82	0.55	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	12.32	3.76e-29	9.67e-22	0.82	0.55	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
STAD	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	12.31	3.95e-29	1.01e-21	0.7	0.55	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
STAD	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-12.3	4.15e-29	1.07e-21	-0.81	-0.55	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs58275763	ENSG00000230342.2	FANCD2P2	12.3	4.49e-29	1.15e-21	0.7	0.55	Alzheimer's disease;	chr3:10101590	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000227586.5	RP11-162A23.5	-12.29	4.65e-29	1.19e-21	-0.54	-0.55	Cognitive function;	chr12:56083910	chr10:123171535~123171875:-
STAD	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	12.29	4.82e-29	1.23e-21	0.61	0.55	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
STAD	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-12.28	5.06e-29	1.29e-21	-0.81	-0.55	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-12.28	5.25e-29	1.34e-21	-0.87	-0.55	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	12.27	5.67e-29	1.44e-21	0.85	0.55	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	12.27	5.67e-29	1.44e-21	0.85	0.55	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs61077902	ENSG00000230342.2	FANCD2P2	12.26	6.22e-29	1.58e-21	0.69	0.55	Alzheimer's disease;	chr3:10084469	chr3:11859674~11891172:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000233778.3	RP11-777J24.1	-12.26	6.27e-29	1.59e-21	-0.49	-0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:92144088~92144435:-
STAD	trans	rs1552244	1	rs6786638	ENSG00000230342.2	FANCD2P2	12.25	6.58e-29	1.66e-21	0.68	0.55	Alzheimer's disease;	chr3:10076391	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6442150	ENSG00000230342.2	FANCD2P2	12.25	6.58e-29	1.66e-21	0.68	0.55	Alzheimer's disease;	chr3:10080891	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6764168	ENSG00000230342.2	FANCD2P2	12.25	6.58e-29	1.66e-21	0.68	0.55	Alzheimer's disease;	chr3:10082121	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-12.25	6.82e-29	1.72e-21	-0.81	-0.55	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.909	rs79026312	ENSG00000276997.3	RP11-378J18.9	12.25	6.86e-29	1.73e-21	0.63	0.55	Corneal astigmatism;	chr4:119519522	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs35111518	ENSG00000276997.3	RP11-378J18.9	12.25	6.86e-29	1.73e-21	0.63	0.55	Corneal astigmatism;	chr4:119519527	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs55822690	ENSG00000230342.2	FANCD2P2	12.24	7.27e-29	1.83e-21	0.69	0.55	Alzheimer's disease;	chr3:10086319	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs9997631	ENSG00000276997.3	RP11-378J18.9	12.23	7.68e-29	1.93e-21	0.62	0.55	Corneal astigmatism;	chr4:119548840	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	12.23	7.68e-29	1.93e-21	0.83	0.55	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs2272123	ENSG00000230342.2	FANCD2P2	12.23	7.94e-29	2e-21	0.69	0.55	Alzheimer's disease;	chr3:10098431	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs1383532	ENSG00000276997.3	RP11-378J18.9	-12.22	8.4e-29	2.11e-21	-0.62	-0.55	Corneal astigmatism;	chr4:119513249	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs9995234	ENSG00000276997.3	RP11-378J18.9	12.22	8.42e-29	2.11e-21	0.63	0.55	Corneal astigmatism;	chr4:119400672	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs877636	ENSG00000234513.1	AC073072.7	-12.22	8.53e-29	2.14e-21	-0.53	-0.55	Cognitive function;	chr12:56086799	chr7:22773646~22773993:-
STAD	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-12.22	8.78e-29	2.2e-21	-0.6	-0.55	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
STAD	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-12.22	8.78e-29	2.2e-21	-0.6	-0.55	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.69	rs34818745	ENSG00000276997.3	RP11-378J18.9	12.22	8.92e-29	2.23e-21	0.63	0.55	Corneal astigmatism;	chr4:119335900	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs17032295	ENSG00000230342.2	FANCD2P2	12.21	9.01e-29	2.25e-21	0.68	0.55	Alzheimer's disease;	chr3:10044996	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-12.21	9.22e-29	2.3e-21	-0.5	-0.55	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.863	rs1552095	ENSG00000276997.3	RP11-378J18.9	12.21	9.41e-29	2.35e-21	0.63	0.55	Corneal astigmatism;	chr4:119539151	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs35741213	ENSG00000230342.2	FANCD2P2	12.21	9.49e-29	2.37e-21	0.69	0.55	Alzheimer's disease;	chr3:10045977	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs10019674	ENSG00000276997.3	RP11-378J18.9	-12.21	9.67e-29	2.41e-21	-0.62	-0.55	Corneal astigmatism;	chr4:119522334	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs17032299	ENSG00000230342.2	FANCD2P2	12.2	9.84e-29	2.45e-21	0.71	0.55	Alzheimer's disease;	chr3:10045954	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-12.2	1.06e-28	2.63e-21	-0.54	-0.55	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000227586.5	RP11-162A23.5	-12.19	1.08e-28	2.68e-21	-0.54	-0.55	Cognitive function;	chr12:56080024	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.954	rs10017371	ENSG00000276997.3	RP11-378J18.9	12.19	1.12e-28	2.79e-21	0.62	0.55	Corneal astigmatism;	chr4:119372621	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-12.19	1.14e-28	2.84e-21	-0.6	-0.55	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
STAD	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	12.18	1.16e-28	2.87e-21	0.81	0.55	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-12.18	1.16e-28	2.88e-21	-0.86	-0.55	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	12.18	1.25e-28	3.09e-21	0.86	0.55	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs1383533	ENSG00000276997.3	RP11-378J18.9	12.17	1.29e-28	3.17e-21	0.62	0.55	Corneal astigmatism;	chr4:119513421	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs2291185	ENSG00000276997.3	RP11-378J18.9	12.17	1.29e-28	3.17e-21	0.62	0.55	Corneal astigmatism;	chr4:119513678	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs7664986	ENSG00000276997.3	RP11-378J18.9	12.17	1.37e-28	3.37e-21	0.62	0.55	Corneal astigmatism;	chr4:119508797	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.818	rs10008791	ENSG00000276997.3	RP11-378J18.9	12.17	1.37e-28	3.37e-21	0.62	0.55	Corneal astigmatism;	chr4:119510314	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs11736416	ENSG00000276997.3	RP11-378J18.9	12.17	1.37e-28	3.37e-21	0.62	0.55	Corneal astigmatism;	chr4:119510506	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3775845	ENSG00000276997.3	RP11-378J18.9	12.17	1.37e-28	3.37e-21	0.62	0.55	Corneal astigmatism;	chr4:119511292	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3775843	ENSG00000276997.3	RP11-378J18.9	12.16	1.38e-28	3.4e-21	0.62	0.55	Corneal astigmatism;	chr4:119506689	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3775844	ENSG00000276997.3	RP11-378J18.9	12.16	1.38e-28	3.4e-21	0.62	0.55	Corneal astigmatism;	chr4:119506878	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3822190	ENSG00000276997.3	RP11-378J18.9	12.16	1.38e-28	3.4e-21	0.62	0.55	Corneal astigmatism;	chr4:119506943	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3822191	ENSG00000276997.3	RP11-378J18.9	12.16	1.38e-28	3.4e-21	0.62	0.55	Corneal astigmatism;	chr4:119506946	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	12.16	1.47e-28	3.6e-21	0.61	0.55	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
STAD	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-12.16	1.47e-28	3.6e-21	-0.81	-0.55	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	12.16	1.47e-28	3.61e-21	0.49	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
STAD	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-12.15	1.54e-28	3.75e-21	-0.8	-0.55	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-12.15	1.54e-28	3.75e-21	-0.8	-0.55	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-12.15	1.54e-28	3.75e-21	-0.8	-0.55	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-12.15	1.54e-28	3.75e-21	-0.8	-0.55	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
STAD	trans	rs1552244	0.81	rs7612908	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10047464	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.935	rs7649243	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10047786	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs7615646	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10048089	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.81	rs6809572	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10058461	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs112847840	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10059968	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs722509	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10060693	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6793396	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10069243	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6772315	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10071960	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.935	rs7621551	ENSG00000230342.2	FANCD2P2	12.15	1.54e-28	3.75e-21	0.69	0.55	Alzheimer's disease;	chr3:10072521	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-12.15	1.58e-28	3.84e-21	-0.53	-0.55	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-12.15	1.58e-28	3.84e-21	-0.53	-0.55	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	12.14	1.77e-28	4.28e-21	0.54	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
STAD	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-12.13	1.8e-28	4.35e-21	-0.85	-0.55	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-12.13	1.89e-28	4.56e-21	-0.57	-0.55	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-12.12	1.94e-28	4.69e-21	-0.5	-0.55	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-12.12	1.95e-28	4.7e-21	-0.49	-0.55	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-12.12	1.95e-28	4.7e-21	-0.49	-0.55	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
STAD	trans	rs1552244	0.935	rs7652190	ENSG00000230342.2	FANCD2P2	12.12	2.01e-28	4.85e-21	0.7	0.55	Alzheimer's disease;	chr3:10063466	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs34868248	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119521275	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3733525	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119525893	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3775847	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119526487	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3775848	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119526569	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs10013305	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119529269	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs3775849	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119529753	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.818	rs7688802	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119530513	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs7695620	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119531621	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs12502389	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119533036	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.821	rs3775852	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119533401	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.82	rs6534140	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119534156	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs7657849	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119534339	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs10034450	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119534494	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs1480939	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119535772	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs1480940	ENSG00000276997.3	RP11-378J18.9	12.1	2.31e-28	5.51e-21	0.62	0.55	Corneal astigmatism;	chr4:119536527	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs12374115	ENSG00000230342.2	FANCD2P2	-12.1	2.33e-28	5.56e-21	-0.68	-0.55	Alzheimer's disease;	chr3:10093082	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-12.1	2.35e-28	5.61e-21	-0.85	-0.55	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	12.1	2.39e-28	5.71e-21	0.78	0.55	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs76041173	ENSG00000230342.2	FANCD2P2	12.1	2.4e-28	5.73e-21	0.69	0.55	Alzheimer's disease;	chr3:10037011	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000227586.5	RP11-162A23.5	-12.1	2.49e-28	5.93e-21	-0.53	-0.55	Cognitive function;	chr12:56084218	chr10:123171535~123171875:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000227586.5	RP11-162A23.5	-12.1	2.49e-28	5.93e-21	-0.53	-0.55	Cognitive function;	chr12:56084874	chr10:123171535~123171875:-
STAD	trans	rs1552244	0.935	rs35148833	ENSG00000230342.2	FANCD2P2	12.09	2.59e-28	6.15e-21	0.69	0.55	Alzheimer's disease;	chr3:10075253	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.81	rs35711405	ENSG00000230342.2	FANCD2P2	12.09	2.59e-28	6.15e-21	0.69	0.55	Alzheimer's disease;	chr3:10075255	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	12.07	3e-28	7.12e-21	0.85	0.54	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
STAD	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	12.07	3e-28	7.12e-21	0.65	0.54	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
STAD	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	12.07	3.02e-28	7.17e-21	0.82	0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000212829.8	RPS26P3	-12.07	3.17e-28	7.52e-21	-0.49	-0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:9090898~9091245:+
STAD	trans	rs11098499	0.863	rs7678400	ENSG00000276997.3	RP11-378J18.9	12.07	3.23e-28	7.64e-21	0.62	0.54	Corneal astigmatism;	chr4:119540802	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs1480936	ENSG00000276997.3	RP11-378J18.9	12.07	3.23e-28	7.64e-21	0.62	0.54	Corneal astigmatism;	chr4:119541706	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-12.06	3.31e-28	7.82e-21	-0.8	-0.54	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs3822195	ENSG00000276997.3	RP11-378J18.9	12.06	3.37e-28	7.97e-21	0.62	0.54	Corneal astigmatism;	chr4:119550505	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-12.05	3.66e-28	8.64e-21	-0.86	-0.54	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs13140391	ENSG00000276997.3	RP11-378J18.9	12.05	3.81e-28	8.99e-21	0.62	0.54	Corneal astigmatism;	chr4:119582282	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs13140409	ENSG00000276997.3	RP11-378J18.9	12.05	3.81e-28	8.99e-21	0.62	0.54	Corneal astigmatism;	chr4:119582305	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs6833334	ENSG00000276997.3	RP11-378J18.9	12.05	3.81e-28	8.99e-21	0.62	0.54	Corneal astigmatism;	chr4:119583072	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs7648104	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10031627	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs113771705	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10034299	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs111392584	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10034307	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs17032276	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10035291	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs17032277	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10035339	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs17032278	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10036271	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs66797209	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10036842	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs7631678	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10037132	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs7637888	ENSG00000230342.2	FANCD2P2	12.04	3.95e-28	9.24e-21	0.69	0.54	Alzheimer's disease;	chr3:10039038	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs58452170	ENSG00000276997.3	RP11-378J18.9	12.04	3.99e-28	9.34e-21	0.62	0.54	Corneal astigmatism;	chr4:119538519	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	12.04	4.01e-28	9.39e-21	0.83	0.54	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs7669520	ENSG00000276997.3	RP11-378J18.9	12.04	4.05e-28	9.47e-21	0.62	0.54	Corneal astigmatism;	chr4:119594123	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs59732491	ENSG00000276997.3	RP11-378J18.9	12.03	4.26e-28	9.89e-21	0.62	0.54	Corneal astigmatism;	chr4:119568433	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs9884402	ENSG00000276997.3	RP11-378J18.9	12.03	4.26e-28	9.89e-21	0.62	0.54	Corneal astigmatism;	chr4:119568827	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.731	rs9995026	ENSG00000276997.3	RP11-378J18.9	12.03	4.26e-28	9.89e-21	0.62	0.54	Corneal astigmatism;	chr4:119569344	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs11723090	ENSG00000276997.3	RP11-378J18.9	12.03	4.26e-28	9.89e-21	0.62	0.54	Corneal astigmatism;	chr4:119569437	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs11098532	ENSG00000276997.3	RP11-378J18.9	12.03	4.26e-28	9.89e-21	0.62	0.54	Corneal astigmatism;	chr4:119569571	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-12.03	4.33e-28	1e-20	-0.57	-0.54	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
STAD	trans	rs1552244	1	rs35198334	ENSG00000230342.2	FANCD2P2	12.02	4.59e-28	1.06e-20	0.69	0.54	Alzheimer's disease;	chr3:10062869	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs7619340	ENSG00000230342.2	FANCD2P2	12.02	4.59e-28	1.06e-20	0.69	0.54	Alzheimer's disease;	chr3:10066494	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6781811	ENSG00000230342.2	FANCD2P2	-12.02	4.91e-28	1.13e-20	-0.67	-0.54	Alzheimer's disease;	chr3:10080238	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs10030660	ENSG00000276997.3	RP11-378J18.9	12.02	4.95e-28	1.14e-20	0.62	0.54	Corneal astigmatism;	chr4:119515549	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs13149407	ENSG00000276997.3	RP11-378J18.9	12.02	4.95e-28	1.14e-20	0.62	0.54	Corneal astigmatism;	chr4:119516670	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs7615764	ENSG00000230342.2	FANCD2P2	12.01	5.03e-28	1.15e-20	0.68	0.54	Alzheimer's disease;	chr3:10040908	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs35220123	ENSG00000230342.2	FANCD2P2	12.01	5.03e-28	1.15e-20	0.68	0.54	Alzheimer's disease;	chr3:10041485	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.935	rs4441636	ENSG00000230342.2	FANCD2P2	12.01	5.03e-28	1.15e-20	0.68	0.54	Alzheimer's disease;	chr3:10042192	chr3:11859674~11891172:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	12.01	5.21e-28	1.19e-20	0.52	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
STAD	trans	rs11098499	0.954	rs878373	ENSG00000276997.3	RP11-378J18.9	12.01	5.32e-28	1.21e-20	0.61	0.54	Corneal astigmatism;	chr4:119316329	chr1:222477252~222504622:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000242970.2	AC068522.4	-11.99	5.96e-28	1.35e-20	-0.55	-0.54	Cognitive function;	chr12:56007301	chr8:58588420~58588764:-
STAD	trans	rs11098499	0.863	rs3775854	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119550816	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs2306456	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119551267	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs2306457	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119551684	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs11947234	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119553704	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs6853998	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119554705	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs6858777	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119554811	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs11933966	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119555560	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs36040693	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119556461	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs11731756	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119557541	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs34308924	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119560276	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs2170276	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119564669	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs1552092	ENSG00000276997.3	RP11-378J18.9	11.98	6.9e-28	1.55e-20	0.62	0.54	Corneal astigmatism;	chr4:119567341	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	11.97	7.57e-28	1.7e-20	0.6	0.54	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
STAD	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	11.97	7.58e-28	1.7e-20	0.61	0.54	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
STAD	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	11.97	7.58e-28	1.7e-20	0.61	0.54	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	11.96	7.71e-28	1.73e-20	0.51	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
STAD	trans	rs11098499	0.863	rs3822192	ENSG00000276997.3	RP11-378J18.9	11.96	7.84e-28	1.76e-20	0.62	0.54	Corneal astigmatism;	chr4:119524565	chr1:222477252~222504622:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000242970.2	AC068522.4	-11.95	8.45e-28	1.89e-20	-0.55	-0.54	Cognitive function;	chr12:56042145	chr8:58588420~58588764:-
STAD	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	11.95	8.76e-28	1.96e-20	0.6	0.54	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	11.95	8.76e-28	1.96e-20	0.6	0.54	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	11.95	8.76e-28	1.96e-20	0.6	0.54	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-11.95	8.84e-28	1.98e-20	-0.6	-0.54	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.863	rs1010740	ENSG00000276997.3	RP11-378J18.9	-11.95	8.95e-28	2e-20	-0.62	-0.54	Corneal astigmatism;	chr4:119542254	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	11.95	8.95e-28	2e-20	0.61	0.54	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	11.95	8.99e-28	2.01e-20	0.6	0.54	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10006877	ENSG00000276997.3	RP11-378J18.9	11.94	9.07e-28	2.02e-20	0.61	0.54	Corneal astigmatism;	chr4:119321638	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	11.94	9.11e-28	2.03e-20	0.61	0.54	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	11.94	9.11e-28	2.03e-20	0.61	0.54	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	11.94	9.11e-28	2.03e-20	0.61	0.54	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	11.94	9.26e-28	2.06e-20	0.6	0.54	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	11.94	9.26e-28	2.06e-20	0.6	0.54	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	11.94	9.26e-28	2.06e-20	0.6	0.54	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs7699064	ENSG00000276997.3	RP11-378J18.9	-11.94	9.46e-28	2.1e-20	-0.62	-0.54	Corneal astigmatism;	chr4:119507154	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	11.94	9.61e-28	2.13e-20	0.61	0.54	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs1546505	ENSG00000276997.3	RP11-378J18.9	11.94	9.72e-28	2.16e-20	0.61	0.54	Corneal astigmatism;	chr4:119320069	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-11.94	9.73e-28	2.16e-20	-0.84	-0.54	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-11.94	9.73e-28	2.16e-20	-0.84	-0.54	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-11.93	1e-27	2.22e-20	-0.77	-0.54	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000227586.5	RP11-162A23.5	-11.92	1.09e-27	2.42e-20	-0.55	-0.54	Cognitive function;	chr12:56042145	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	11.92	1.14e-27	2.52e-20	0.6	0.54	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	11.92	1.15e-27	2.53e-20	0.79	0.54	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-11.92	1.15e-27	2.54e-20	-0.86	-0.54	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs3822194	ENSG00000276997.3	RP11-378J18.9	11.91	1.19e-27	2.62e-20	0.61	0.54	Corneal astigmatism;	chr4:119550493	chr1:222477252~222504622:-
STAD	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	11.91	1.19e-27	2.63e-20	0.81	0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
STAD	trans	rs11098499	0.909	rs1546502	ENSG00000276997.3	RP11-378J18.9	11.91	1.2e-27	2.66e-20	0.61	0.54	Corneal astigmatism;	chr4:119314743	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs12505469	ENSG00000276997.3	RP11-378J18.9	11.91	1.23e-27	2.71e-20	0.61	0.54	Corneal astigmatism;	chr4:119328430	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs2017057	ENSG00000276997.3	RP11-378J18.9	11.91	1.23e-27	2.71e-20	0.61	0.54	Corneal astigmatism;	chr4:119336556	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.82	rs6829903	ENSG00000276997.3	RP11-378J18.9	11.91	1.23e-27	2.71e-20	0.62	0.54	Corneal astigmatism;	chr4:119585729	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs6534139	ENSG00000276997.3	RP11-378J18.9	-11.9	1.35e-27	2.96e-20	-0.62	-0.54	Corneal astigmatism;	chr4:119528301	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	11.9	1.36e-27	2.97e-20	0.78	0.54	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	11.9	1.37e-27	2.98e-20	0.6	0.54	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-11.89	1.4e-27	3.04e-20	-0.8	-0.54	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	11.89	1.4e-27	3.05e-20	0.6	0.54	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	11.89	1.4e-27	3.05e-20	0.6	0.54	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	11.89	1.4e-27	3.05e-20	0.6	0.54	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	11.89	1.4e-27	3.05e-20	0.6	0.54	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	11.89	1.4e-27	3.05e-20	0.6	0.54	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
STAD	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	11.89	1.4e-27	3.05e-20	0.61	0.54	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	11.89	1.45e-27	3.14e-20	0.6	0.54	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	11.89	1.45e-27	3.14e-20	0.6	0.54	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	11.89	1.45e-27	3.14e-20	0.6	0.54	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	11.89	1.45e-27	3.14e-20	0.6	0.54	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	11.89	1.45e-27	3.14e-20	0.6	0.54	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000204652.6	RPS26P8	11.88	1.53e-27	3.32e-20	0.5	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:45608571~45608918:+
STAD	trans	rs11098499	0.863	rs11098531	ENSG00000276997.3	RP11-378J18.9	11.88	1.54e-27	3.34e-20	0.61	0.54	Corneal astigmatism;	chr4:119543846	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs28718422	ENSG00000276997.3	RP11-378J18.9	11.88	1.54e-27	3.34e-20	0.61	0.54	Corneal astigmatism;	chr4:119545149	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs12498539	ENSG00000276997.3	RP11-378J18.9	11.88	1.54e-27	3.34e-20	0.61	0.54	Corneal astigmatism;	chr4:119547215	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.818	rs12498599	ENSG00000276997.3	RP11-378J18.9	11.88	1.54e-27	3.34e-20	0.61	0.54	Corneal astigmatism;	chr4:119547348	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs10009626	ENSG00000276997.3	RP11-378J18.9	11.88	1.54e-27	3.34e-20	0.61	0.54	Corneal astigmatism;	chr4:119548850	chr1:222477252~222504622:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000212994.5	RPS26P6	-11.87	1.64e-27	3.53e-20	-0.49	-0.54	Cognitive function;	chr12:56042145	chr8:100895771~100896118:+
STAD	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-11.87	1.66e-27	3.57e-20	-0.53	-0.54	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	11.87	1.66e-27	3.58e-20	0.54	0.54	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
STAD	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	11.87	1.66e-27	3.59e-20	0.6	0.54	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	11.87	1.68e-27	3.62e-20	0.6	0.54	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	11.87	1.71e-27	3.69e-20	0.6	0.54	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	11.87	1.71e-27	3.69e-20	0.6	0.54	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-11.87	1.78e-27	3.83e-20	-0.8	-0.54	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs6820115	ENSG00000276997.3	RP11-378J18.9	11.86	1.82e-27	3.91e-20	0.59	0.54	Corneal astigmatism;	chr4:119477027	chr1:222477252~222504622:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	11.86	1.85e-27	3.99e-20	0.49	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
STAD	trans	rs1552244	1	rs68045038	ENSG00000230342.2	FANCD2P2	11.86	1.87e-27	4.01e-20	0.68	0.54	Alzheimer's disease;	chr3:10110144	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.938	rs34750074	ENSG00000230342.2	FANCD2P2	11.86	1.88e-27	4.03e-20	0.68	0.54	Alzheimer's disease;	chr3:10050056	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	11.86	1.89e-27	4.05e-20	0.6	0.54	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-11.86	1.9e-27	4.08e-20	-0.59	-0.54	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	11.86	1.91e-27	4.09e-20	0.6	0.54	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	11.86	1.91e-27	4.1e-20	0.81	0.54	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.82	rs13128602	ENSG00000276997.3	RP11-378J18.9	-11.86	1.91e-27	4.1e-20	-0.61	-0.54	Corneal astigmatism;	chr4:119538211	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	11.85	1.95e-27	4.18e-20	0.6	0.54	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	11.85	2.07e-27	4.43e-20	0.6	0.54	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	11.85	2.07e-27	4.43e-20	0.6	0.54	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs3756156	ENSG00000276997.3	RP11-378J18.9	11.84	2.16e-27	4.6e-20	0.61	0.54	Corneal astigmatism;	chr4:119603686	chr1:222477252~222504622:-
STAD	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	11.83	2.39e-27	5.06e-20	0.52	0.54	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.908	rs1002152	ENSG00000276997.3	RP11-378J18.9	11.83	2.48e-27	5.26e-20	0.6	0.54	Corneal astigmatism;	chr4:119352232	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	11.82	2.68e-27	5.65e-20	0.6	0.54	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	11.81	2.72e-27	5.74e-20	0.58	0.54	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
STAD	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	11.81	2.73e-27	5.75e-20	0.53	0.54	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-11.81	2.76e-27	5.81e-20	-0.59	-0.54	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-11.81	2.8e-27	5.89e-20	-0.83	-0.54	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs13319597	ENSG00000230342.2	FANCD2P2	-11.81	2.82e-27	5.94e-20	-0.65	-0.54	Alzheimer's disease;	chr3:10084628	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.935	rs41520445	ENSG00000230342.2	FANCD2P2	-11.8	3e-27	6.31e-20	-0.67	-0.54	Alzheimer's disease;	chr3:10111457	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	11.8	3.02e-27	6.35e-20	0.6	0.54	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-11.8	3.06e-27	6.44e-20	-0.82	-0.54	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-11.8	3.06e-27	6.44e-20	-0.82	-0.54	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
STAD	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-11.8	3.13e-27	6.57e-20	-0.8	-0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
STAD	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	11.8	3.19e-27	6.7e-20	0.8	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	11.8	3.21e-27	6.73e-20	0.5	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000242970.2	AC068522.4	-11.8	3.22e-27	6.75e-20	-0.51	-0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:58588420~58588764:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	11.78	3.56e-27	7.43e-20	0.51	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+
STAD	trans	rs1552244	1	rs67006488	ENSG00000230342.2	FANCD2P2	11.78	3.79e-27	7.9e-20	0.67	0.53	Alzheimer's disease;	chr3:10111309	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6764068	ENSG00000230342.2	FANCD2P2	11.77	4.04e-27	8.4e-20	0.67	0.53	Alzheimer's disease;	chr3:10112158	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs113522867	ENSG00000230342.2	FANCD2P2	11.77	4.04e-27	8.4e-20	0.67	0.53	Alzheimer's disease;	chr3:10112819	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs113153120	ENSG00000230342.2	FANCD2P2	11.77	4.04e-27	8.4e-20	0.67	0.53	Alzheimer's disease;	chr3:10114714	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs112509186	ENSG00000230342.2	FANCD2P2	11.77	4.04e-27	8.4e-20	0.67	0.53	Alzheimer's disease;	chr3:10114849	chr3:11859674~11891172:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000227586.5	RP11-162A23.5	-11.77	4.1e-27	8.52e-20	-0.55	-0.53	Cognitive function;	chr12:56007301	chr10:123171535~123171875:-
STAD	trans	rs1552244	1	rs56394721	ENSG00000230342.2	FANCD2P2	11.77	4.14e-27	8.6e-20	0.68	0.53	Alzheimer's disease;	chr3:10109111	chr3:11859674~11891172:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-11.76	4.16e-27	8.64e-20	-0.52	-0.53	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
STAD	trans	rs11098499	0.82	rs28394116	ENSG00000276997.3	RP11-378J18.9	11.76	4.29e-27	8.9e-20	0.61	0.53	Corneal astigmatism;	chr4:119603128	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.818	rs55825515	ENSG00000276997.3	RP11-378J18.9	11.76	4.44e-27	9.18e-20	0.62	0.53	Corneal astigmatism;	chr4:119565247	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	11.75	4.65e-27	9.61e-20	0.59	0.53	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000212994.5	RPS26P6	-11.75	4.82e-27	9.94e-20	-0.49	-0.53	Cognitive function;	chr12:56007301	chr8:100895771~100896118:+
STAD	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	11.75	4.86e-27	1e-19	0.59	0.53	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	11.74	4.99e-27	1.03e-19	0.57	0.53	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.82	rs11737395	ENSG00000276997.3	RP11-378J18.9	11.74	5.08e-27	1.04e-19	0.62	0.53	Corneal astigmatism;	chr4:119599549	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-11.74	5.11e-27	1.05e-19	-0.85	-0.53	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
STAD	trans	rs11098499	1	rs13435802	ENSG00000276997.3	RP11-378J18.9	-11.74	5.13e-27	1.05e-19	-0.59	-0.53	Corneal astigmatism;	chr4:119256805	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	11.74	5.33e-27	1.1e-19	0.59	0.53	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-11.73	5.7e-27	1.17e-19	-0.59	-0.53	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
STAD	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-11.73	5.74e-27	1.17e-19	-0.81	-0.53	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.909	rs1546504	ENSG00000276997.3	RP11-378J18.9	11.73	5.75e-27	1.18e-19	0.6	0.53	Corneal astigmatism;	chr4:119320024	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	11.72	5.99e-27	1.22e-19	0.82	0.53	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
STAD	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	11.72	6.02e-27	1.23e-19	0.53	0.53	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	11.72	6.12e-27	1.24e-19	0.59	0.53	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775841	ENSG00000276997.3	RP11-378J18.9	11.72	6.17e-27	1.25e-19	0.6	0.53	Corneal astigmatism;	chr4:119504622	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-11.72	6.27e-27	1.27e-19	-0.85	-0.53	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-11.72	6.33e-27	1.28e-19	-0.83	-0.53	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	11.71	6.37e-27	1.29e-19	0.6	0.53	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-11.71	6.73e-27	1.36e-19	-0.59	-0.53	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	11.71	6.85e-27	1.38e-19	0.59	0.53	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	11.7	7e-27	1.41e-19	0.59	0.53	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-11.7	7.11e-27	1.43e-19	-0.58	-0.53	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.932	rs2777885	ENSG00000187870.7	RNFT1P3	-11.7	7.49e-27	1.51e-19	-0.59	-0.53	White blood cell count;	chr17:59753112	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	11.68	8.25e-27	1.65e-19	0.59	0.53	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-11.68	8.79e-27	1.76e-19	-0.76	-0.53	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	11.67	9.25e-27	1.85e-19	0.59	0.53	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-11.67	9.62e-27	1.92e-19	-0.81	-0.53	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-11.67	9.62e-27	1.92e-19	-0.81	-0.53	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	11.66	9.81e-27	1.96e-19	0.59	0.53	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.899	rs2777898	ENSG00000187870.7	RNFT1P3	-11.66	1.04e-26	2.07e-19	-0.59	-0.53	White blood cell count;	chr17:59738247	chr17:20743333~20754501:-
STAD	trans	rs8081395	0.899	rs8070345	ENSG00000187870.7	RNFT1P3	-11.66	1.04e-26	2.07e-19	-0.59	-0.53	White blood cell count;	chr17:59739396	chr17:20743333~20754501:-
STAD	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-11.65	1.06e-26	2.12e-19	-0.79	-0.53	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs17032396	ENSG00000230342.2	FANCD2P2	-11.65	1.08e-26	2.15e-19	-0.68	-0.53	Alzheimer's disease;	chr3:10111875	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	11.65	1.11e-26	2.2e-19	0.76	0.53	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	11.65	1.11e-26	2.2e-19	0.76	0.53	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
STAD	trans	rs8081395	0.899	rs2645477	ENSG00000187870.7	RNFT1P3	-11.65	1.12e-26	2.23e-19	-0.58	-0.53	White blood cell count;	chr17:59768263	chr17:20743333~20754501:-
STAD	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-11.65	1.13e-26	2.23e-19	-0.76	-0.53	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	11.64	1.15e-26	2.29e-19	0.6	0.53	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-11.64	1.16e-26	2.3e-19	-0.58	-0.53	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
STAD	trans	rs1552244	1	rs66838678	ENSG00000230342.2	FANCD2P2	11.64	1.22e-26	2.41e-19	0.67	0.53	Alzheimer's disease;	chr3:10108666	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs68067759	ENSG00000230342.2	FANCD2P2	11.64	1.22e-26	2.41e-19	0.67	0.53	Alzheimer's disease;	chr3:10108851	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.935	rs7618815	ENSG00000230342.2	FANCD2P2	11.64	1.22e-26	2.41e-19	0.67	0.53	Alzheimer's disease;	chr3:10109361	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs7652935	ENSG00000230342.2	FANCD2P2	11.64	1.22e-26	2.41e-19	0.67	0.53	Alzheimer's disease;	chr3:10109454	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs67134728	ENSG00000230342.2	FANCD2P2	11.64	1.22e-26	2.41e-19	0.67	0.53	Alzheimer's disease;	chr3:10109747	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.82	rs28535956	ENSG00000276997.3	RP11-378J18.9	-11.64	1.23e-26	2.43e-19	-0.6	-0.53	Corneal astigmatism;	chr4:119615703	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.834	rs2665397	ENSG00000187870.7	RNFT1P3	-11.63	1.25e-26	2.48e-19	-0.59	-0.53	White blood cell count;	chr17:59749370	chr17:20743333~20754501:-
STAD	trans	rs8081395	0.804	rs2777884	ENSG00000187870.7	RNFT1P3	-11.63	1.27e-26	2.5e-19	-0.59	-0.53	White blood cell count;	chr17:59753065	chr17:20743333~20754501:-
STAD	trans	rs8081395	0.866	rs2777899	ENSG00000187870.7	RNFT1P3	-11.63	1.27e-26	2.5e-19	-0.59	-0.53	White blood cell count;	chr17:59755030	chr17:20743333~20754501:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000244604.1	RP11-713H12.1	-11.63	1.27e-26	2.51e-19	-0.52	-0.53	Cognitive function;	chr12:56083910	chr17:8561230~8561576:+
STAD	trans	rs11098499	0.82	rs28578366	ENSG00000276997.3	RP11-378J18.9	-11.63	1.3e-26	2.57e-19	-0.59	-0.53	Corneal astigmatism;	chr4:119615750	chr1:222477252~222504622:-
STAD	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	11.62	1.38e-26	2.71e-19	0.8	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	11.62	1.38e-26	2.71e-19	0.8	0.53	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-11.62	1.38e-26	2.72e-19	-0.8	-0.53	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	11.62	1.4e-26	2.75e-19	0.59	0.53	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-11.62	1.44e-26	2.83e-19	-0.6	-0.53	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-11.61	1.49e-26	2.92e-19	-0.87	-0.53	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs3736115	ENSG00000276997.3	RP11-378J18.9	-11.61	1.51e-26	2.96e-19	-0.59	-0.53	Corneal astigmatism;	chr4:119567548	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-11.61	1.54e-26	3.03e-19	-0.59	-0.53	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	11.61	1.55e-26	3.04e-19	0.59	0.53	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
STAD	trans	rs1552244	1	rs9820598	ENSG00000230342.2	FANCD2P2	11.61	1.55e-26	3.04e-19	0.65	0.53	Alzheimer's disease;	chr3:10076228	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs57631744	ENSG00000230342.2	FANCD2P2	11.61	1.55e-26	3.04e-19	0.65	0.53	Alzheimer's disease;	chr3:10077278	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.872	rs6792951	ENSG00000230342.2	FANCD2P2	11.61	1.55e-26	3.04e-19	0.65	0.53	Alzheimer's disease;	chr3:10077919	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.935	rs6805869	ENSG00000230342.2	FANCD2P2	11.61	1.55e-26	3.04e-19	0.65	0.53	Alzheimer's disease;	chr3:10078233	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs9827740	ENSG00000230342.2	FANCD2P2	11.61	1.55e-26	3.04e-19	0.65	0.53	Alzheimer's disease;	chr3:10078847	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	11.6	1.62e-26	3.16e-19	0.6	0.53	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.82	rs13122709	ENSG00000276997.3	RP11-378J18.9	11.6	1.64e-26	3.21e-19	0.6	0.53	Corneal astigmatism;	chr4:119634201	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	11.6	1.67e-26	3.25e-19	0.59	0.53	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	11.6	1.67e-26	3.25e-19	0.59	0.53	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	11.6	1.67e-26	3.25e-19	0.59	0.53	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	11.6	1.67e-26	3.25e-19	0.59	0.53	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	11.6	1.67e-26	3.25e-19	0.59	0.53	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.938	rs7652951	ENSG00000230342.2	FANCD2P2	11.6	1.71e-26	3.33e-19	0.66	0.53	Alzheimer's disease;	chr3:10022079	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs7611218	ENSG00000230342.2	FANCD2P2	11.6	1.71e-26	3.33e-19	0.66	0.53	Alzheimer's disease;	chr3:10022276	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.872	rs6803517	ENSG00000230342.2	FANCD2P2	11.6	1.71e-26	3.33e-19	0.66	0.53	Alzheimer's disease;	chr3:10023742	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs9834980	ENSG00000230342.2	FANCD2P2	11.6	1.71e-26	3.33e-19	0.66	0.53	Alzheimer's disease;	chr3:10023844	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs17032268	ENSG00000230342.2	FANCD2P2	11.6	1.71e-26	3.33e-19	0.66	0.53	Alzheimer's disease;	chr3:10026288	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs3846177	ENSG00000230342.2	FANCD2P2	11.6	1.71e-26	3.33e-19	0.66	0.53	Alzheimer's disease;	chr3:10026888	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000239210.2	RPS26P55	11.6	1.74e-26	3.38e-19	0.53	0.53	Cognitive function;	chr12:56076841	chr19:34533427~34534084:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	11.59	1.75e-26	3.4e-19	0.53	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000244604.1	RP11-713H12.1	-11.59	1.77e-26	3.44e-19	-0.54	-0.53	Cognitive function;	chr12:56042145	chr17:8561230~8561576:+
STAD	trans	rs11098499	0.954	rs11722872	ENSG00000276997.3	RP11-378J18.9	11.59	1.77e-26	3.44e-19	0.59	0.53	Corneal astigmatism;	chr4:119311875	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	11.59	1.79e-26	3.47e-19	0.59	0.53	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000227887.1	RPS26P13	-11.58	1.9e-26	3.68e-19	-0.51	-0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:208697369~208697698:-
STAD	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-11.58	1.9e-26	3.69e-19	-0.83	-0.53	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	11.58	1.95e-26	3.71e-19	0.59	0.53	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-11.58	1.98e-26	3.78e-19	-0.5	-0.53	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
STAD	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	11.58	2.04e-26	3.87e-19	0.8	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	11.58	2.06e-26	3.9e-19	0.59	0.53	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	11.58	2.06e-26	3.9e-19	0.59	0.53	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	11.58	2.06e-26	3.9e-19	0.59	0.53	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	11.58	2.06e-26	3.9e-19	0.59	0.53	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
STAD	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-11.57	2.09e-26	3.97e-19	-0.59	-0.53	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
STAD	trans	rs1552244	1	rs56270432	ENSG00000230342.2	FANCD2P2	11.57	2.14e-26	4.04e-19	0.66	0.53	Alzheimer's disease;	chr3:10045833	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000234192.1	RP11-57C13.5	11.57	2.15e-26	4.07e-19	0.52	0.53	Cognitive function;	chr12:56076841	chr10:87642607~87642954:+
STAD	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	11.57	2.2e-26	4.15e-19	0.53	0.53	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	11.57	2.23e-26	4.22e-19	0.59	0.53	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000224553.1	AC008065.1	-11.57	2.24e-26	4.23e-19	-0.53	-0.53	Cognitive function;	chr12:56080024	chr2:171374931~171375278:-
STAD	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
STAD	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
STAD	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	11.56	2.29e-26	4.32e-19	0.8	0.53	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs61052895	ENSG00000230342.2	FANCD2P2	11.56	2.31e-26	4.34e-19	0.67	0.53	Alzheimer's disease;	chr3:10105832	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs4260416	ENSG00000230342.2	FANCD2P2	11.56	2.4e-26	4.5e-19	0.66	0.53	Alzheimer's disease;	chr3:10083599	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs4269070	ENSG00000230342.2	FANCD2P2	11.56	2.4e-26	4.5e-19	0.66	0.53	Alzheimer's disease;	chr3:10084399	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	11.55	2.47e-26	4.63e-19	0.59	0.53	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	11.55	2.47e-26	4.63e-19	0.59	0.53	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	11.55	2.47e-26	4.63e-19	0.59	0.53	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	11.55	2.47e-26	4.63e-19	0.59	0.53	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	11.55	2.48e-26	4.66e-19	0.59	0.53	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	11.55	2.5e-26	4.69e-19	0.59	0.53	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	11.55	2.5e-26	4.69e-19	0.59	0.53	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs2292239	ENSG00000234513.1	AC073072.7	11.55	2.52e-26	4.71e-19	0.51	0.53	Cognitive function;	chr12:56088396	chr7:22773646~22773993:-
STAD	trans	rs1552244	1	rs113134644	ENSG00000230342.2	FANCD2P2	11.55	2.59e-26	4.84e-19	0.65	0.53	Alzheimer's disease;	chr3:10044602	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.866	rs7665125	ENSG00000276997.3	RP11-378J18.9	11.55	2.61e-26	4.87e-19	0.58	0.53	Corneal astigmatism;	chr4:119480924	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-11.54	2.67e-26	4.97e-19	-0.81	-0.53	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	11.54	2.72e-26	5.06e-19	0.59	0.53	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	11.54	2.72e-26	5.06e-19	0.59	0.53	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	11.54	2.72e-26	5.06e-19	0.59	0.53	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000244604.1	RP11-713H12.1	-11.54	2.75e-26	5.12e-19	-0.54	-0.53	Cognitive function;	chr12:56007301	chr17:8561230~8561576:+
STAD	trans	rs11098499	0.863	rs13136462	ENSG00000276997.3	RP11-378J18.9	11.54	2.8e-26	5.21e-19	0.6	0.53	Corneal astigmatism;	chr4:119622018	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-11.54	2.84e-26	5.28e-19	-0.8	-0.53	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-11.54	2.85e-26	5.29e-19	-0.53	-0.53	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
STAD	trans	rs1552244	0.938	rs67667957	ENSG00000230342.2	FANCD2P2	11.53	2.9e-26	5.39e-19	0.67	0.53	Alzheimer's disease;	chr3:10125580	chr3:11859674~11891172:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000224553.1	AC008065.1	-11.53	2.96e-26	5.5e-19	-0.55	-0.53	Cognitive function;	chr12:56042145	chr2:171374931~171375278:-
STAD	trans	rs1552244	0.882	rs113268531	ENSG00000230342.2	FANCD2P2	11.53	3.01e-26	5.59e-19	0.66	0.53	Alzheimer's disease;	chr3:10125385	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.938	rs56274701	ENSG00000230342.2	FANCD2P2	11.53	3.01e-26	5.59e-19	0.66	0.53	Alzheimer's disease;	chr3:10126106	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs9879080	ENSG00000230342.2	FANCD2P2	11.52	3.2e-26	5.93e-19	0.66	0.53	Alzheimer's disease;	chr3:10042540	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs9809061	ENSG00000230342.2	FANCD2P2	11.52	3.2e-26	5.93e-19	0.66	0.53	Alzheimer's disease;	chr3:10043446	chr3:11859674~11891172:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000243538.1	CTB-55B8.1	-11.52	3.22e-26	5.97e-19	-0.52	-0.53	Cognitive function;	chr12:56007301	chr5:16902294~16902641:-
STAD	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	11.52	3.4e-26	6.29e-19	0.59	0.53	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
STAD	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-11.51	3.44e-26	6.35e-19	-0.49	-0.53	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-11.51	3.47e-26	6.4e-19	-0.5	-0.53	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-11.51	3.47e-26	6.4e-19	-0.5	-0.53	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
STAD	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-11.51	3.48e-26	6.41e-19	-0.59	-0.53	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	11.51	3.53e-26	6.51e-19	0.52	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
STAD	trans	rs877636	1	rs705696	ENSG00000234513.1	AC073072.7	11.5	3.82e-26	7.02e-19	0.53	0.53	Cognitive function;	chr12:56086864	chr7:22773646~22773993:-
STAD	trans	rs1552244	0.808	rs17032306	ENSG00000230342.2	FANCD2P2	11.5	3.95e-26	7.2e-19	0.66	0.53	Alzheimer's disease;	chr3:10049715	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.872	rs7646073	ENSG00000230342.2	FANCD2P2	11.5	3.95e-26	7.2e-19	0.66	0.53	Alzheimer's disease;	chr3:10055721	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.81	rs4019706	ENSG00000230342.2	FANCD2P2	11.5	3.95e-26	7.2e-19	0.66	0.53	Alzheimer's disease;	chr3:10071178	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.872	rs6771931	ENSG00000230342.2	FANCD2P2	11.5	3.95e-26	7.2e-19	0.66	0.53	Alzheimer's disease;	chr3:10071724	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs9824585	ENSG00000230342.2	FANCD2P2	11.5	3.95e-26	7.2e-19	0.66	0.53	Alzheimer's disease;	chr3:10073118	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.938	rs7625049	ENSG00000230342.2	FANCD2P2	11.5	3.95e-26	7.2e-19	0.66	0.53	Alzheimer's disease;	chr3:10073935	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6782602	ENSG00000230342.2	FANCD2P2	11.5	3.95e-26	7.2e-19	0.66	0.53	Alzheimer's disease;	chr3:10074857	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	11.5	3.98e-26	7.26e-19	0.59	0.53	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	11.5	3.98e-26	7.26e-19	0.59	0.53	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	11.5	3.98e-26	7.26e-19	0.59	0.53	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	11.49	4.2e-26	7.64e-19	0.47	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
STAD	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	11.49	4.29e-26	7.8e-19	0.59	0.53	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	11.49	4.29e-26	7.8e-19	0.59	0.53	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	11.48	4.51e-26	8.18e-19	0.49	0.53	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
STAD	trans	rs1552244	1	rs12152515	ENSG00000230342.2	FANCD2P2	11.48	4.57e-26	8.28e-19	0.64	0.53	Alzheimer's disease;	chr3:10102292	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	11.48	4.68e-26	8.46e-19	0.59	0.53	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	11.48	4.68e-26	8.46e-19	0.59	0.53	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	11.48	4.68e-26	8.46e-19	0.59	0.53	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	11.48	4.68e-26	8.46e-19	0.59	0.53	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	11.48	4.68e-26	8.46e-19	0.59	0.53	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	11.48	4.7e-26	8.5e-19	0.59	0.53	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	11.48	4.75e-26	8.54e-19	0.59	0.53	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	11.48	4.75e-26	8.54e-19	0.59	0.53	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	11.47	4.82e-26	8.62e-19	0.59	0.52	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	11.47	4.9e-26	8.76e-19	0.59	0.52	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	11.47	5.02e-26	8.97e-19	0.59	0.52	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs7659194	ENSG00000276997.3	RP11-378J18.9	11.47	5.16e-26	9.22e-19	0.58	0.52	Corneal astigmatism;	chr4:119285992	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	11.46	5.23e-26	9.34e-19	0.82	0.52	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000243538.1	CTB-55B8.1	-11.46	5.27e-26	9.41e-19	-0.52	-0.52	Cognitive function;	chr12:56042145	chr5:16902294~16902641:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000244604.1	RP11-713H12.1	-11.46	5.53e-26	9.84e-19	-0.51	-0.52	Cognitive function;	chr12:56084218	chr17:8561230~8561576:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000244604.1	RP11-713H12.1	-11.46	5.53e-26	9.84e-19	-0.51	-0.52	Cognitive function;	chr12:56084874	chr17:8561230~8561576:+
STAD	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	11.46	5.58e-26	9.94e-19	0.59	0.52	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
STAD	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	11.46	5.58e-26	9.94e-19	0.59	0.52	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
STAD	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	11.46	5.58e-26	9.94e-19	0.59	0.52	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
STAD	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	11.46	5.58e-26	9.94e-19	0.59	0.52	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
STAD	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-11.46	5.63e-26	1e-18	-0.82	-0.52	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-11.46	5.63e-26	1e-18	-0.82	-0.52	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-11.45	5.7e-26	1.01e-18	-0.5	-0.52	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
STAD	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	11.45	5.79e-26	1.03e-18	0.89	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
STAD	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-11.45	5.82e-26	1.03e-18	-0.74	-0.52	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	11.45	5.9e-26	1.05e-18	0.59	0.52	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	11.45	6.13e-26	1.09e-18	0.57	0.52	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	11.44	6.26e-26	1.11e-18	0.6	0.52	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.935	rs35586456	ENSG00000230342.2	FANCD2P2	11.44	6.35e-26	1.12e-18	0.66	0.52	Alzheimer's disease;	chr3:10075254	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	11.44	6.42e-26	1.13e-18	0.59	0.52	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
STAD	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	11.44	6.57e-26	1.16e-18	0.59	0.52	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
STAD	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	11.44	6.65e-26	1.16e-18	0.58	0.52	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	11.43	6.77e-26	1.18e-18	0.59	0.52	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	11.43	6.85e-26	1.19e-18	0.77	0.52	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	11.43	6.94e-26	1.2e-18	0.58	0.52	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	11.43	6.94e-26	1.2e-18	0.58	0.52	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	11.43	6.94e-26	1.2e-18	0.58	0.52	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	11.43	6.94e-26	1.2e-18	0.58	0.52	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	11.43	7.11e-26	1.23e-18	0.59	0.52	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	11.43	7.11e-26	1.23e-18	0.59	0.52	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	11.43	7.18e-26	1.24e-18	0.59	0.52	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	11.43	7.18e-26	1.24e-18	0.59	0.52	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	11.42	7.27e-26	1.26e-18	0.58	0.52	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs28374891	ENSG00000276997.3	RP11-378J18.9	11.42	7.46e-26	1.29e-18	0.58	0.52	Corneal astigmatism;	chr4:119262395	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs877636	ENSG00000227887.1	RPS26P13	-11.42	7.55e-26	1.3e-18	-0.54	-0.52	Cognitive function;	chr12:56086799	chr1:208697369~208697698:-
STAD	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-11.42	7.79e-26	1.34e-18	-0.53	-0.52	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
STAD	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	11.41	7.94e-26	1.37e-18	0.79	0.52	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	11.41	7.94e-26	1.37e-18	0.79	0.52	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	11.41	7.94e-26	1.37e-18	0.79	0.52	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	11.41	7.94e-26	1.37e-18	0.79	0.52	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	11.41	8e-26	1.38e-18	0.59	0.52	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	11.41	8.02e-26	1.38e-18	0.59	0.52	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	11.41	8.02e-26	1.38e-18	0.59	0.52	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	11.41	8.02e-26	1.38e-18	0.59	0.52	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	11.41	8.26e-26	1.42e-18	0.49	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
STAD	trans	rs11098499	0.954	rs1022145	ENSG00000276997.3	RP11-378J18.9	11.41	8.38e-26	1.44e-18	0.58	0.52	Corneal astigmatism;	chr4:119309824	chr1:222477252~222504622:-
STAD	trans	rs4822044	0.568	rs1883370	ENSG00000268568.1	AC007228.9	11.41	8.39e-26	1.44e-18	0.8	0.52	Cannabis dependence symptom count;	chr22:41747736	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	11.41	8.39e-26	1.44e-18	0.58	0.52	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000224553.1	AC008065.1	-11.41	8.43e-26	1.45e-18	-0.53	-0.52	Cognitive function;	chr12:56083910	chr2:171374931~171375278:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000196656.7	AC004057.1	-11.41	8.54e-26	1.46e-18	-0.45	-0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr4:113214046~113217170:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-11.4	9.06e-26	1.55e-18	-0.53	-0.52	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
STAD	trans	rs11098499	0.955	rs35197422	ENSG00000276997.3	RP11-378J18.9	11.39	9.54e-26	1.63e-18	0.58	0.52	Corneal astigmatism;	chr4:119248159	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs1511015	ENSG00000276997.3	RP11-378J18.9	11.39	9.54e-26	1.63e-18	0.58	0.52	Corneal astigmatism;	chr4:119249318	chr1:222477252~222504622:-
STAD	trans	rs11098499	1	rs10029750	ENSG00000276997.3	RP11-378J18.9	11.39	9.54e-26	1.63e-18	0.58	0.52	Corneal astigmatism;	chr4:119251388	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs6804473	ENSG00000230342.2	FANCD2P2	11.39	9.58e-26	1.63e-18	0.65	0.52	Alzheimer's disease;	chr3:10018741	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs9845756	ENSG00000230342.2	FANCD2P2	11.39	9.58e-26	1.63e-18	0.65	0.52	Alzheimer's disease;	chr3:10025864	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs33917318	ENSG00000230342.2	FANCD2P2	11.39	9.58e-26	1.63e-18	0.65	0.52	Alzheimer's disease;	chr3:10026113	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.935	rs35515831	ENSG00000230342.2	FANCD2P2	11.39	9.58e-26	1.63e-18	0.65	0.52	Alzheimer's disease;	chr3:10029678	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6442148	ENSG00000230342.2	FANCD2P2	11.39	9.58e-26	1.63e-18	0.65	0.52	Alzheimer's disease;	chr3:10036605	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs2160869	ENSG00000230342.2	FANCD2P2	11.39	9.58e-26	1.63e-18	0.65	0.52	Alzheimer's disease;	chr3:10037571	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.955	rs11944880	ENSG00000276997.3	RP11-378J18.9	-11.39	9.6e-26	1.63e-18	-0.58	-0.52	Corneal astigmatism;	chr4:119238179	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs6815725	ENSG00000276997.3	RP11-378J18.9	11.39	9.6e-26	1.63e-18	0.58	0.52	Corneal astigmatism;	chr4:119237255	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs1551	ENSG00000276997.3	RP11-378J18.9	11.39	9.6e-26	1.63e-18	0.58	0.52	Corneal astigmatism;	chr4:119237345	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs11931312	ENSG00000276997.3	RP11-378J18.9	11.39	9.6e-26	1.63e-18	0.58	0.52	Corneal astigmatism;	chr4:119237868	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-11.39	9.7e-26	1.64e-18	-0.59	-0.52	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	11.39	9.74e-26	1.65e-18	0.59	0.52	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-11.39	9.89e-26	1.68e-18	-0.77	-0.52	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs12152512	ENSG00000230342.2	FANCD2P2	11.39	1e-25	1.7e-18	0.64	0.52	Alzheimer's disease;	chr3:10102086	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
STAD	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
STAD	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	11.38	1.03e-25	1.74e-18	0.8	0.52	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
STAD	trans	rs11098499	1	rs13116504	ENSG00000276997.3	RP11-378J18.9	11.38	1.05e-25	1.78e-18	0.58	0.52	Corneal astigmatism;	chr4:119288257	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs28555550	ENSG00000276997.3	RP11-378J18.9	11.38	1.05e-25	1.78e-18	0.58	0.52	Corneal astigmatism;	chr4:119289885	chr1:222477252~222504622:-
STAD	trans	rs11098499	1	rs28419773	ENSG00000276997.3	RP11-378J18.9	11.38	1.05e-25	1.78e-18	0.58	0.52	Corneal astigmatism;	chr4:119289906	chr1:222477252~222504622:-
STAD	trans	rs11098499	1	rs11726229	ENSG00000276997.3	RP11-378J18.9	11.38	1.05e-25	1.78e-18	0.58	0.52	Corneal astigmatism;	chr4:119290425	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-11.38	1.05e-25	1.78e-18	-0.6	-0.52	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
STAD	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-11.38	1.06e-25	1.79e-18	-0.51	-0.52	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	11.38	1.07e-25	1.8e-18	0.58	0.52	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	11.38	1.07e-25	1.8e-18	0.6	0.52	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-11.38	1.08e-25	1.82e-18	-0.76	-0.52	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	11.38	1.09e-25	1.83e-18	0.59	0.52	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.78	rs12504773	ENSG00000276997.3	RP11-378J18.9	11.38	1.1e-25	1.85e-18	0.6	0.52	Corneal astigmatism;	chr4:119640994	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs3895942	ENSG00000230342.2	FANCD2P2	11.37	1.11e-25	1.86e-18	0.65	0.52	Alzheimer's disease;	chr3:10067061	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-11.37	1.16e-25	1.95e-18	-0.83	-0.52	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000196933.5	RPS26P11	-11.36	1.21e-25	2.02e-18	-0.47	-0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:72044545~72044892:+
STAD	trans	rs1552244	1	rs9875081	ENSG00000230342.2	FANCD2P2	11.36	1.23e-25	2.06e-18	0.65	0.52	Alzheimer's disease;	chr3:10042251	chr3:11859674~11891172:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000234513.1	AC073072.7	11.36	1.24e-25	2.07e-18	0.48	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:22773646~22773993:-
STAD	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	11.36	1.25e-25	2.08e-18	0.79	0.52	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	11.36	1.25e-25	2.08e-18	0.79	0.52	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	11.36	1.27e-25	2.12e-18	0.59	0.52	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	11.36	1.27e-25	2.12e-18	0.59	0.52	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	11.36	1.27e-25	2.12e-18	0.59	0.52	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	11.36	1.27e-25	2.12e-18	0.59	0.52	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs1397608	ENSG00000276997.3	RP11-378J18.9	11.36	1.28e-25	2.13e-18	0.57	0.52	Corneal astigmatism;	chr4:119240589	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs7685268	ENSG00000276997.3	RP11-378J18.9	11.36	1.28e-25	2.13e-18	0.57	0.52	Corneal astigmatism;	chr4:119241033	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs7684942	ENSG00000276997.3	RP11-378J18.9	11.36	1.28e-25	2.13e-18	0.57	0.52	Corneal astigmatism;	chr4:119241046	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	11.36	1.29e-25	2.14e-18	0.79	0.52	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	11.36	1.29e-25	2.14e-18	0.79	0.52	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	11.36	1.29e-25	2.14e-18	0.79	0.52	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-11.36	1.29e-25	2.14e-18	-0.59	-0.52	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.935	rs11926481	ENSG00000230342.2	FANCD2P2	11.35	1.35e-25	2.24e-18	0.64	0.52	Alzheimer's disease;	chr3:10100418	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.78	rs7680914	ENSG00000276997.3	RP11-378J18.9	11.35	1.37e-25	2.27e-18	0.59	0.52	Corneal astigmatism;	chr4:119641898	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	11.35	1.38e-25	2.29e-18	0.59	0.52	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs35643470	ENSG00000276997.3	RP11-378J18.9	11.35	1.38e-25	2.3e-18	0.58	0.52	Corneal astigmatism;	chr4:119263793	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs13145352	ENSG00000276997.3	RP11-378J18.9	-11.35	1.41e-25	2.34e-18	-0.6	-0.52	Corneal astigmatism;	chr4:119488808	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs7651058	ENSG00000230342.2	FANCD2P2	11.34	1.43e-25	2.36e-18	0.66	0.52	Alzheimer's disease;	chr3:10025280	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-11.34	1.43e-25	2.37e-18	-0.59	-0.52	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	11.34	1.46e-25	2.42e-18	0.59	0.52	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
STAD	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-11.34	1.47e-25	2.42e-18	-0.83	-0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
STAD	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-11.34	1.47e-25	2.42e-18	-0.83	-0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	11.34	1.47e-25	2.43e-18	0.58	0.52	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.73	rs12505735	ENSG00000276997.3	RP11-378J18.9	11.34	1.47e-25	2.43e-18	0.59	0.52	Corneal astigmatism;	chr4:119611801	chr1:222477252~222504622:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000235459.5	RPS26P31	11.34	1.5e-25	2.47e-18	0.58	0.52	Cognitive function;	chr12:56050848	chr7:122681315~122681662:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000227586.5	RP11-162A23.5	-11.34	1.53e-25	2.52e-18	-0.5	-0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	11.33	1.54e-25	2.53e-18	0.58	0.52	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs10518329	ENSG00000276997.3	RP11-378J18.9	11.33	1.56e-25	2.57e-18	0.57	0.52	Corneal astigmatism;	chr4:119480680	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs2272125	ENSG00000230342.2	FANCD2P2	11.33	1.59e-25	2.61e-18	0.62	0.52	Alzheimer's disease;	chr3:10096385	chr3:11859674~11891172:+
STAD	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-11.33	1.63e-25	2.68e-18	-0.81	-0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
STAD	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-11.33	1.63e-25	2.68e-18	-0.81	-0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-11.33	1.63e-25	2.68e-18	-0.81	-0.52	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-11.33	1.63e-25	2.68e-18	-0.81	-0.52	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-11.33	1.63e-25	2.68e-18	-0.81	-0.52	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-11.33	1.63e-25	2.68e-18	-0.81	-0.52	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
STAD	trans	rs1552244	1	rs6442146	ENSG00000230342.2	FANCD2P2	11.33	1.65e-25	2.71e-18	0.65	0.52	Alzheimer's disease;	chr3:10031860	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs35993975	ENSG00000230342.2	FANCD2P2	11.32	1.68e-25	2.75e-18	0.68	0.52	Alzheimer's disease;	chr3:10026110	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	11.32	1.71e-25	2.79e-18	0.58	0.52	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	11.32	1.76e-25	2.88e-18	0.59	0.52	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	11.32	1.76e-25	2.88e-18	0.59	0.52	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	11.31	1.82e-25	2.96e-18	0.8	0.52	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	11.31	1.82e-25	2.96e-18	0.8	0.52	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	11.31	1.82e-25	2.97e-18	0.58	0.52	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	11.31	1.82e-25	2.97e-18	0.58	0.52	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs877636	ENSG00000223416.3	RPS26P15	-11.31	1.84e-25	2.99e-18	-0.53	-0.52	Cognitive function;	chr12:56086799	chr1:58056133~58056480:-
STAD	trans	rs11098499	0.955	rs4145951	ENSG00000276997.3	RP11-378J18.9	11.31	1.87e-25	3.04e-18	0.58	0.52	Corneal astigmatism;	chr4:119234662	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs35916640	ENSG00000276997.3	RP11-378J18.9	11.31	1.87e-25	3.04e-18	0.58	0.52	Corneal astigmatism;	chr4:119234697	chr1:222477252~222504622:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000244604.1	RP11-713H12.1	-11.31	1.89e-25	3.07e-18	-0.51	-0.52	Cognitive function;	chr12:56080024	chr17:8561230~8561576:+
STAD	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-11.3	1.99e-25	3.23e-18	-0.76	-0.52	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-11.3	1.99e-25	3.23e-18	-0.76	-0.52	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-11.3	1.99e-25	3.23e-18	-0.76	-0.52	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-11.3	1.99e-25	3.23e-18	-0.76	-0.52	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	11.3	2.01e-25	3.26e-18	0.59	0.52	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	11.3	2.03e-25	3.29e-18	0.52	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
STAD	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	11.3	2.05e-25	3.32e-18	0.58	0.52	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	11.3	2.08e-25	3.36e-18	0.79	0.52	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	11.3	2.08e-25	3.36e-18	0.79	0.52	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	11.3	2.08e-25	3.36e-18	0.79	0.52	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	11.3	2.13e-25	3.44e-18	0.59	0.52	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000224553.1	AC008065.1	-11.29	2.17e-25	3.5e-18	-0.54	-0.52	Cognitive function;	chr12:56007301	chr2:171374931~171375278:-
STAD	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	11.29	2.18e-25	3.52e-18	0.79	0.52	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.913	rs10010696	ENSG00000276997.3	RP11-378J18.9	11.29	2.2e-25	3.55e-18	0.58	0.52	Corneal astigmatism;	chr4:119243148	chr1:222477252~222504622:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	11.29	2.22e-25	3.59e-18	0.46	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
STAD	trans	rs11098499	0.954	rs3733524	ENSG00000276997.3	RP11-378J18.9	11.29	2.23e-25	3.59e-18	0.6	0.52	Corneal astigmatism;	chr4:119502574	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	11.29	2.23e-25	3.6e-18	0.82	0.52	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	11.29	2.25e-25	3.63e-18	0.59	0.52	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	11.29	2.25e-25	3.63e-18	0.59	0.52	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs11098500	ENSG00000276997.3	RP11-378J18.9	11.29	2.3e-25	3.7e-18	0.57	0.52	Corneal astigmatism;	chr4:119298084	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-11.28	2.41e-25	3.87e-18	-0.81	-0.52	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.731	rs6846966	ENSG00000276997.3	RP11-378J18.9	11.28	2.45e-25	3.93e-18	0.57	0.52	Corneal astigmatism;	chr4:119372053	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs6847778	ENSG00000276997.3	RP11-378J18.9	11.28	2.45e-25	3.93e-18	0.57	0.52	Corneal astigmatism;	chr4:119372427	chr1:222477252~222504622:-
STAD	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-11.28	2.52e-25	4.05e-18	-0.58	-0.52	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
STAD	trans	rs11098499	1	rs6837898	ENSG00000276997.3	RP11-378J18.9	11.27	2.6e-25	4.17e-18	0.58	0.52	Corneal astigmatism;	chr4:119257999	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	11.27	2.71e-25	4.33e-18	0.58	0.52	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	11.27	2.71e-25	4.33e-18	0.58	0.52	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	11.26	2.79e-25	4.45e-18	0.58	0.52	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	11.26	2.79e-25	4.45e-18	0.58	0.52	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	11.26	2.79e-25	4.45e-18	0.58	0.52	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	11.26	2.79e-25	4.45e-18	0.58	0.52	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	11.26	2.79e-25	4.45e-18	0.58	0.52	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	11.26	2.81e-25	4.49e-18	0.59	0.52	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs56386062	ENSG00000276997.3	RP11-378J18.9	11.26	2.88e-25	4.59e-18	0.58	0.52	Corneal astigmatism;	chr4:119233980	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs13114751	ENSG00000276997.3	RP11-378J18.9	11.26	2.88e-25	4.59e-18	0.58	0.52	Corneal astigmatism;	chr4:119235462	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.913	rs35271032	ENSG00000276997.3	RP11-378J18.9	11.26	2.88e-25	4.59e-18	0.58	0.52	Corneal astigmatism;	chr4:119235504	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	11.26	2.93e-25	4.67e-18	0.59	0.52	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	11.26	2.93e-25	4.67e-18	0.59	0.52	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	11.26	2.98e-25	4.74e-18	0.58	0.52	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-11.25	3e-25	4.77e-18	-0.83	-0.52	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
STAD	trans	rs13177918	0.677	rs3797622	ENSG00000226396.1	RP5-1056L3.3	11.25	3.13e-25	4.98e-18	0.53	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:19608114~19608568:+
STAD	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-11.25	3.14e-25	4.99e-18	-0.83	-0.52	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	11.25	3.15e-25	5e-18	0.58	0.52	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	11.25	3.18e-25	5.05e-18	0.58	0.52	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000224553.1	AC008065.1	-11.25	3.19e-25	5.07e-18	-0.52	-0.52	Cognitive function;	chr12:56084218	chr2:171374931~171375278:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000224553.1	AC008065.1	-11.25	3.19e-25	5.07e-18	-0.52	-0.52	Cognitive function;	chr12:56084874	chr2:171374931~171375278:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000235459.5	RPS26P31	11.24	3.25e-25	5.16e-18	0.58	0.52	Cognitive function;	chr12:56009793	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-11.24	3.25e-25	5.16e-18	-0.58	-0.52	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-11.24	3.31e-25	5.24e-18	-0.58	-0.52	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
STAD	trans	rs1552244	1	rs9881859	ENSG00000230342.2	FANCD2P2	11.24	3.47e-25	5.49e-18	0.65	0.52	Alzheimer's disease;	chr3:10031130	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	11.23	3.65e-25	5.78e-18	0.57	0.52	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	11.23	3.76e-25	5.95e-18	0.58	0.52	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
STAD	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	11.23	3.79e-25	5.99e-18	0.75	0.52	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	11.22	3.84e-25	6.07e-18	0.59	0.52	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000223416.3	RPS26P15	11.21	4.18e-25	6.59e-18	0.5	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:58056133~58056480:-
STAD	trans	rs11098499	0.955	rs1511018	ENSG00000276997.3	RP11-378J18.9	11.21	4.31e-25	6.8e-18	0.57	0.52	Corneal astigmatism;	chr4:119240425	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs2292239	ENSG00000204652.6	RPS26P8	11.2	4.53e-25	7.13e-18	0.5	0.52	Cognitive function;	chr12:56088396	chr17:45608571~45608918:+
STAD	trans	rs11098499	1	rs58601355	ENSG00000276997.3	RP11-378J18.9	11.19	4.97e-25	7.81e-18	0.59	0.52	Corneal astigmatism;	chr4:119265212	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs1511019	ENSG00000276997.3	RP11-378J18.9	11.19	5.01e-25	7.87e-18	0.58	0.52	Corneal astigmatism;	chr4:119244852	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	11.19	5.06e-25	7.94e-18	0.57	0.52	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.572	rs6797536	ENSG00000230342.2	FANCD2P2	-11.19	5.09e-25	7.98e-18	-0.74	-0.52	Alzheimer's disease;	chr3:10127118	chr3:11859674~11891172:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000235459.5	RPS26P31	11.19	5.12e-25	8.02e-18	0.58	0.52	Cognitive function;	chr12:56002984	chr7:122681315~122681662:+
STAD	trans	rs11098499	1	rs6849889	ENSG00000276997.3	RP11-378J18.9	11.19	5.13e-25	8.04e-18	0.58	0.52	Corneal astigmatism;	chr4:119265193	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	11.19	5.22e-25	8.18e-18	0.59	0.52	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	11.18	5.36e-25	8.39e-18	0.6	0.52	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
STAD	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	11.18	5.39e-25	8.44e-18	0.58	0.52	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.935	rs2272124	ENSG00000230342.2	FANCD2P2	11.18	5.46e-25	8.54e-18	0.63	0.52	Alzheimer's disease;	chr3:10096505	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs55882090	ENSG00000230342.2	FANCD2P2	11.18	5.46e-25	8.54e-18	0.63	0.52	Alzheimer's disease;	chr3:10097398	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	11.18	5.62e-25	8.77e-18	0.78	0.52	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
STAD	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	11.18	5.62e-25	8.77e-18	0.78	0.52	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
STAD	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	11.18	5.62e-25	8.77e-18	0.78	0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
STAD	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	11.18	5.62e-25	8.77e-18	0.78	0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
STAD	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-11.18	5.63e-25	8.79e-18	-0.88	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
STAD	trans	rs11098499	0.866	rs12501602	ENSG00000276997.3	RP11-378J18.9	11.18	5.71e-25	8.9e-18	0.57	0.52	Corneal astigmatism;	chr4:119366780	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	11.18	5.8e-25	9.04e-18	0.58	0.51	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
STAD	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-11.17	5.85e-25	9.12e-18	-0.89	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
STAD	trans	rs11098499	0.913	rs67073020	ENSG00000276997.3	RP11-378J18.9	11.17	6.02e-25	9.38e-18	0.59	0.51	Corneal astigmatism;	chr4:119231402	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	11.17	6.15e-25	9.58e-18	0.58	0.51	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	11.16	6.32e-25	9.83e-18	0.46	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
STAD	trans	rs877636	1	rs4759229	ENSG00000227887.1	RPS26P13	-11.16	6.49e-25	1.01e-17	-0.54	-0.51	Cognitive function;	chr12:56080696	chr1:208697369~208697698:-
STAD	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	11.16	6.61e-25	1.03e-17	0.76	0.51	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	11.16	6.61e-25	1.03e-17	0.76	0.51	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.754	rs10213554	ENSG00000276997.3	RP11-378J18.9	-11.16	6.61e-25	1.03e-17	-0.56	-0.51	Corneal astigmatism;	chr4:119339630	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	11.16	6.62e-25	1.03e-17	0.58	0.51	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-11.16	6.68e-25	1.04e-17	-0.57	-0.51	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000235459.5	RPS26P31	11.16	6.81e-25	1.06e-17	0.57	0.51	Cognitive function;	chr12:56023144	chr7:122681315~122681662:+
STAD	trans	rs11098499	1	rs11098499	ENSG00000276997.3	RP11-378J18.9	11.16	6.81e-25	1.06e-17	0.57	0.51	Corneal astigmatism;	chr4:119266456	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs35434465	ENSG00000276997.3	RP11-378J18.9	11.15	6.96e-25	1.08e-17	0.57	0.51	Corneal astigmatism;	chr4:119248223	chr1:222477252~222504622:-
STAD	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	11.15	7.21e-25	1.12e-17	0.87	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.913	rs11098496	ENSG00000276997.3	RP11-378J18.9	11.15	7.25e-25	1.12e-17	0.57	0.51	Corneal astigmatism;	chr4:119246311	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000235459.5	RPS26P31	11.15	7.37e-25	1.14e-17	0.57	0.51	Cognitive function;	chr12:56041628	chr7:122681315~122681662:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000234513.1	AC073072.7	11.14	7.58e-25	1.17e-17	0.54	0.51	Cognitive function;	chr12:56002984	chr7:22773646~22773993:-
STAD	trans	rs11098499	1	rs12506395	ENSG00000276997.3	RP11-378J18.9	11.14	7.67e-25	1.19e-17	0.58	0.51	Corneal astigmatism;	chr4:119263939	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	11.14	7.8e-25	1.2e-17	0.57	0.51	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-11.14	7.9e-25	1.22e-17	-0.75	-0.51	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-11.14	7.9e-25	1.22e-17	-0.75	-0.51	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000235459.5	RPS26P31	11.13	8.1e-25	1.25e-17	0.57	0.51	Cognitive function;	chr12:56013288	chr7:122681315~122681662:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000235459.5	RPS26P31	11.13	8.1e-25	1.25e-17	0.57	0.51	Cognitive function;	chr12:56018703	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	11.13	8.16e-25	1.26e-17	0.59	0.51	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
STAD	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	11.13	8.23e-25	1.27e-17	0.86	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
STAD	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	11.13	8.23e-25	1.27e-17	0.86	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
STAD	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	11.12	8.77e-25	1.35e-17	0.51	0.51	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
STAD	trans	rs1552244	1	rs7622963	ENSG00000230342.2	FANCD2P2	11.12	8.79e-25	1.35e-17	0.63	0.51	Alzheimer's disease;	chr3:10098141	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs7622966	ENSG00000230342.2	FANCD2P2	11.12	8.79e-25	1.35e-17	0.63	0.51	Alzheimer's disease;	chr3:10098149	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs34179822	ENSG00000230342.2	FANCD2P2	11.12	8.79e-25	1.35e-17	0.63	0.51	Alzheimer's disease;	chr3:10098333	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.938	rs7647987	ENSG00000230342.2	FANCD2P2	11.12	8.79e-25	1.35e-17	0.63	0.51	Alzheimer's disease;	chr3:10099012	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs3826	ENSG00000230342.2	FANCD2P2	11.12	8.79e-25	1.35e-17	0.63	0.51	Alzheimer's disease;	chr3:10099381	chr3:11859674~11891172:+
STAD	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	11.12	8.87e-25	1.36e-17	0.51	0.51	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-11.12	9.07e-25	1.39e-17	-0.58	-0.51	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	11.11	9.61e-25	1.48e-17	0.57	0.51	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
STAD	trans	rs13177918	0.677	rs13177951	ENSG00000226396.1	RP5-1056L3.3	11.11	9.62e-25	1.48e-17	0.53	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs13177970	ENSG00000226396.1	RP5-1056L3.3	11.11	9.62e-25	1.48e-17	0.53	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs13164105	ENSG00000226396.1	RP5-1056L3.3	11.11	9.62e-25	1.48e-17	0.53	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:19608114~19608568:+
STAD	trans	rs11098499	0.955	rs13113112	ENSG00000276997.3	RP11-378J18.9	11.11	9.77e-25	1.5e-17	0.57	0.51	Corneal astigmatism;	chr4:119234885	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs2292239	ENSG00000227887.1	RPS26P13	11.11	1e-24	1.54e-17	0.53	0.51	Cognitive function;	chr12:56088396	chr1:208697369~208697698:-
STAD	trans	rs11098499	0.662	rs13108589	ENSG00000276997.3	RP11-378J18.9	11.1	1.1e-24	1.69e-17	0.55	0.51	Corneal astigmatism;	chr4:119346947	chr1:222477252~222504622:-
STAD	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-11.1	1.12e-24	1.71e-17	-0.75	-0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
STAD	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	11.09	1.18e-24	1.81e-17	0.75	0.51	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	11.09	1.18e-24	1.81e-17	0.75	0.51	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	11.09	1.18e-24	1.81e-17	0.5	0.51	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
STAD	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-11.09	1.2e-24	1.83e-17	-0.76	-0.51	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000234513.1	AC073072.7	11.09	1.2e-24	1.83e-17	0.54	0.51	Cognitive function;	chr12:56009793	chr7:22773646~22773993:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000235459.5	RPS26P31	11.08	1.23e-24	1.87e-17	0.57	0.51	Cognitive function;	chr12:56041720	chr7:122681315~122681662:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000243403.1	RP11-330L19.1	11.08	1.23e-24	1.87e-17	0.55	0.51	Cognitive function;	chr12:56009793	chr15:64592979~64593326:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-11.08	1.27e-24	1.93e-17	-0.48	-0.51	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
STAD	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	11.08	1.27e-24	1.94e-17	0.57	0.51	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	11.08	1.27e-24	1.94e-17	0.57	0.51	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000227887.1	RPS26P13	-11.08	1.28e-24	1.95e-17	-0.54	-0.51	Cognitive function;	chr12:56080595	chr1:208697369~208697698:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000196656.7	AC004057.1	11.08	1.29e-24	1.97e-17	0.46	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr4:113214046~113217170:-
STAD	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	11.08	1.29e-24	1.97e-17	0.76	0.51	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	11.08	1.32e-24	2.01e-17	0.58	0.51	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	11.07	1.35e-24	2.05e-17	0.76	0.51	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	11.07	1.35e-24	2.05e-17	0.76	0.51	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs6857105	ENSG00000276997.3	RP11-378J18.9	11.07	1.37e-24	2.08e-17	0.57	0.51	Corneal astigmatism;	chr4:119301143	chr1:222477252~222504622:-
STAD	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-11.07	1.43e-24	2.16e-17	-0.88	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
STAD	trans	rs11098499	0.754	rs1980025	ENSG00000276997.3	RP11-378J18.9	-11.06	1.56e-24	2.37e-17	-0.56	-0.51	Corneal astigmatism;	chr4:119331651	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-11.05	1.6e-24	2.42e-17	-0.48	-0.51	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
STAD	trans	rs13177918	0.677	rs4841	ENSG00000226396.1	RP5-1056L3.3	11.05	1.64e-24	2.47e-17	0.53	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs13183077	ENSG00000226396.1	RP5-1056L3.3	11.05	1.64e-24	2.47e-17	0.53	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:19608114~19608568:+
STAD	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	11.05	1.65e-24	2.49e-17	0.7	0.51	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	11.05	1.67e-24	2.53e-17	0.75	0.51	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	11.04	1.79e-24	2.7e-17	0.76	0.51	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-11.03	1.87e-24	2.81e-17	-0.8	-0.51	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
STAD	trans	rs13177918	0.626	rs12186649	ENSG00000226396.1	RP5-1056L3.3	11.03	1.91e-24	2.88e-17	0.54	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs2070841	ENSG00000226396.1	RP5-1056L3.3	11.03	1.97e-24	2.97e-17	0.53	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:19608114~19608568:+
STAD	trans	rs11098499	0.738	rs28687057	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119359657	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.775	rs67281037	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119360002	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.506	rs12374346	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Educational attainment;	chr4:119360550	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs12374244	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119360817	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs12374352	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119360822	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs6857892	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119361541	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.909	rs28581362	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119362393	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.82	rs12503082	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119363162	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs12499602	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119363232	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.774	rs11098505	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119363472	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs13105020	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119364533	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs6824111	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119364813	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.779	rs10857066	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119365441	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.775	rs10029303	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119365600	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs9995136	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119365690	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs13125526	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119366864	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs12513310	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119366884	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.564	rs11098507	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119367131	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs12510451	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119367988	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.774	rs73842616	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119369528	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.645	rs72676059	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119369673	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.569	rs55845118	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119369758	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs7677068	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119370549	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.866	rs9991221	ENSG00000276997.3	RP11-378J18.9	11.02	2.05e-24	3.06e-17	0.56	0.51	Corneal astigmatism;	chr4:119370952	chr1:222477252~222504622:-
STAD	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	11.02	2.12e-24	3.17e-17	0.62	0.51	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
STAD	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	11.02	2.13e-24	3.18e-17	0.57	0.51	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.687	rs71610270	ENSG00000276997.3	RP11-378J18.9	11.02	2.17e-24	3.23e-17	0.56	0.51	Corneal astigmatism;	chr4:119366281	chr1:222477252~222504622:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000227887.1	RPS26P13	11.01	2.25e-24	3.35e-17	0.51	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:208697369~208697698:-
STAD	trans	rs1816752	0.603	rs9551099	ENSG00000237917.1	PARP4P1	-11.01	2.29e-24	3.41e-17	-0.67	-0.51	Obesity-related traits;	chr13:24410978	chrY:26594851~26634652:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-11.01	2.31e-24	3.45e-17	-0.44	-0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
STAD	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-11	2.52e-24	3.75e-17	-0.78	-0.51	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000243403.1	RP11-330L19.1	11	2.53e-24	3.76e-17	0.55	0.51	Cognitive function;	chr12:56013288	chr15:64592979~64593326:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000243403.1	RP11-330L19.1	11	2.53e-24	3.76e-17	0.55	0.51	Cognitive function;	chr12:56018703	chr15:64592979~64593326:+
STAD	trans	rs13177918	0.686	rs12654827	ENSG00000226396.1	RP5-1056L3.3	11	2.56e-24	3.8e-17	0.52	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs13160685	ENSG00000226396.1	RP5-1056L3.3	11	2.56e-24	3.8e-17	0.52	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:19608114~19608568:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000239210.2	RPS26P55	-10.99	2.61e-24	3.88e-17	-0.53	-0.51	Cognitive function;	chr12:56042145	chr19:34533427~34534084:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000243403.1	RP11-330L19.1	10.99	2.62e-24	3.89e-17	0.56	0.51	Cognitive function;	chr12:56002984	chr15:64592979~64593326:+
STAD	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	10.99	2.64e-24	3.93e-17	0.56	0.51	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
STAD	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	10.99	2.66e-24	3.95e-17	0.85	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
STAD	trans	rs1552244	1	rs6807846	ENSG00000230342.2	FANCD2P2	10.99	2.66e-24	3.95e-17	0.63	0.51	Alzheimer's disease;	chr3:10092807	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	10.99	2.75e-24	4.08e-17	0.57	0.51	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
STAD	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	10.98	2.82e-24	4.19e-17	0.86	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
STAD	trans	rs13177918	0.651	rs13184111	ENSG00000226396.1	RP5-1056L3.3	10.98	2.93e-24	4.35e-17	0.54	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:19608114~19608568:+
STAD	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-10.98	2.94e-24	4.37e-17	-0.88	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000234513.1	AC073072.7	10.98	2.96e-24	4.39e-17	0.53	0.51	Cognitive function;	chr12:56023144	chr7:22773646~22773993:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000234192.1	RP11-57C13.5	-10.98	2.98e-24	4.41e-17	-0.5	-0.51	Cognitive function;	chr12:56083910	chr10:87642607~87642954:+
STAD	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	10.98	3.01e-24	4.46e-17	0.77	0.51	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000234513.1	AC073072.7	10.97	3.09e-24	4.58e-17	0.53	0.51	Cognitive function;	chr12:56013288	chr7:22773646~22773993:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000234513.1	AC073072.7	10.97	3.09e-24	4.58e-17	0.53	0.51	Cognitive function;	chr12:56018703	chr7:22773646~22773993:-
STAD	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-10.97	3.18e-24	4.7e-17	-0.49	-0.51	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
STAD	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	10.96	3.3e-24	4.88e-17	0.77	0.51	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
STAD	trans	rs13177918	0.677	rs57890152	ENSG00000226396.1	RP5-1056L3.3	10.96	3.33e-24	4.92e-17	0.52	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:19608114~19608568:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000204652.6	RPS26P8	-10.96	3.33e-24	4.93e-17	-0.5	-0.51	Cognitive function;	chr12:56080595	chr17:45608571~45608918:+
STAD	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-10.96	3.37e-24	4.97e-17	-0.7	-0.51	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	10.96	3.43e-24	5.07e-17	0.56	0.51	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000234513.1	AC073072.7	10.96	3.48e-24	5.13e-17	0.53	0.51	Cognitive function;	chr12:56041628	chr7:22773646~22773993:-
STAD	trans	rs13177918	0.677	rs13171800	ENSG00000226396.1	RP5-1056L3.3	10.96	3.55e-24	5.24e-17	0.52	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:19608114~19608568:+
STAD	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	10.95	3.59e-24	5.29e-17	0.57	0.51	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000243403.1	RP11-330L19.1	10.95	3.83e-24	5.63e-17	0.55	0.51	Cognitive function;	chr12:56050848	chr15:64592979~64593326:+
STAD	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-10.95	3.85e-24	5.67e-17	-0.87	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
STAD	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-10.95	3.85e-24	5.67e-17	-0.87	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000212829.8	RPS26P3	10.94	3.95e-24	5.81e-17	0.48	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:9090898~9091245:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000224553.1	AC008065.1	-10.94	4.04e-24	5.93e-17	-0.5	-0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr2:171374931~171375278:-
STAD	trans	rs1552244	1	rs17032414	ENSG00000230342.2	FANCD2P2	10.94	4.07e-24	5.99e-17	0.63	0.51	Alzheimer's disease;	chr3:10116618	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	10.94	4.08e-24	6e-17	0.75	0.51	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
STAD	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-10.94	4.16e-24	6.11e-17	-0.55	-0.51	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000239210.2	RPS26P55	-10.93	4.21e-24	6.18e-17	-0.53	-0.51	Cognitive function;	chr12:56007301	chr19:34533427~34534084:-
STAD	trans	rs11098499	0.754	rs9991959	ENSG00000276997.3	RP11-378J18.9	-10.93	4.25e-24	6.23e-17	-0.54	-0.51	Corneal astigmatism;	chr4:119332618	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	10.93	4.3e-24	6.31e-17	0.53	0.51	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000239210.2	RPS26P55	-10.93	4.31e-24	6.32e-17	-0.51	-0.51	Cognitive function;	chr12:56083910	chr19:34533427~34534084:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000243403.1	RP11-330L19.1	10.93	4.37e-24	6.41e-17	0.55	0.51	Cognitive function;	chr12:56023144	chr15:64592979~64593326:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-10.93	4.52e-24	6.62e-17	-0.6	-0.51	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
STAD	trans	rs11098499	0.775	rs10021601	ENSG00000276997.3	RP11-378J18.9	10.93	4.52e-24	6.62e-17	0.55	0.51	Corneal astigmatism;	chr4:119361408	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.78	rs7692994	ENSG00000276997.3	RP11-378J18.9	10.92	4.88e-24	7.13e-17	0.56	0.51	Corneal astigmatism;	chr4:119506334	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.913	rs12186259	ENSG00000276997.3	RP11-378J18.9	10.92	4.89e-24	7.15e-17	0.59	0.51	Corneal astigmatism;	chr4:119230884	chr1:222477252~222504622:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000243403.1	RP11-330L19.1	10.91	5.17e-24	7.54e-17	0.54	0.51	Cognitive function;	chr12:56041720	chr15:64592979~64593326:+
STAD	trans	rs13177918	0.677	rs13161417	ENSG00000226396.1	RP5-1056L3.3	10.91	5.18e-24	7.56e-17	0.52	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs13161156	ENSG00000226396.1	RP5-1056L3.3	10.91	5.18e-24	7.56e-17	0.52	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:19608114~19608568:+
STAD	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	10.91	5.19e-24	7.57e-17	0.86	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
STAD	trans	rs877636	1	rs877636	ENSG00000227586.5	RP11-162A23.5	-10.91	5.2e-24	7.58e-17	-0.53	-0.51	Cognitive function;	chr12:56086799	chr10:123171535~123171875:-
STAD	trans	rs877636	1	rs4759229	ENSG00000204652.6	RPS26P8	-10.9	5.54e-24	8.07e-17	-0.5	-0.51	Cognitive function;	chr12:56080696	chr17:45608571~45608918:+
STAD	trans	rs13177918	0.677	rs3857421	ENSG00000226396.1	RP5-1056L3.3	-10.9	5.62e-24	8.18e-17	-0.52	-0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:19608114~19608568:+
STAD	trans	rs1552244	1	rs7610821	ENSG00000230342.2	FANCD2P2	10.9	5.63e-24	8.19e-17	0.63	0.51	Alzheimer's disease;	chr3:10094466	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-10.9	5.75e-24	8.37e-17	-0.56	-0.51	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	10.89	5.89e-24	8.57e-17	0.56	0.51	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-10.89	6.01e-24	8.73e-17	-0.83	-0.51	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000243403.1	RP11-330L19.1	10.89	6.03e-24	8.76e-17	0.55	0.51	Cognitive function;	chr12:56041628	chr15:64592979~64593326:+
STAD	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-10.89	6.15e-24	8.93e-17	-0.52	-0.51	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
STAD	trans	rs877636	1	rs2292239	ENSG00000212829.8	RPS26P3	10.88	6.31e-24	9.15e-17	0.49	0.51	Cognitive function;	chr12:56088396	chr9:9090898~9091245:+
STAD	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	10.88	6.36e-24	9.21e-17	0.75	0.51	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.644	rs10050092	ENSG00000276997.3	RP11-378J18.9	10.88	6.38e-24	9.24e-17	0.56	0.51	Corneal astigmatism;	chr4:119610930	chr1:222477252~222504622:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-10.88	6.39e-24	9.26e-17	-0.52	-0.51	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
STAD	trans	rs13177918	0.677	rs13161099	ENSG00000226396.1	RP5-1056L3.3	10.88	6.57e-24	9.51e-17	0.52	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:19608114~19608568:+
STAD	trans	rs11098499	0.955	rs13129661	ENSG00000276997.3	RP11-378J18.9	10.88	6.76e-24	9.78e-17	0.57	0.5	Corneal astigmatism;	chr4:119231754	chr1:222477252~222504622:-
STAD	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-10.87	7.1e-24	1.03e-16	-0.87	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
STAD	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-10.87	7.1e-24	1.03e-16	-0.87	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
STAD	trans	rs11098499	0.754	rs11732087	ENSG00000276997.3	RP11-378J18.9	10.86	7.55e-24	1.09e-16	0.55	0.5	Corneal astigmatism;	chr4:119318676	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.789	rs9991166	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119316696	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.708	rs10005237	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119316742	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs878372	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119317625	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs10213267	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119317919	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs10212775	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119318089	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs2964	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119318976	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs1511025	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119319083	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs1546503	ENSG00000276997.3	RP11-378J18.9	10.86	7.68e-24	1.11e-16	0.55	0.5	Corneal astigmatism;	chr4:119320012	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs6789156	ENSG00000230342.2	FANCD2P2	10.86	7.95e-24	1.14e-16	0.61	0.5	Alzheimer's disease;	chr3:10082436	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6791810	ENSG00000230342.2	FANCD2P2	-10.85	8.08e-24	1.16e-16	-0.64	-0.5	Alzheimer's disease;	chr3:10082760	chr3:11859674~11891172:+
STAD	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-10.85	8.15e-24	1.17e-16	-0.86	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
STAD	trans	rs13177918	0.629	rs13161261	ENSG00000226396.1	RP5-1056L3.3	10.85	8.73e-24	1.25e-16	0.52	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:19608114~19608568:+
STAD	trans	rs1552244	1	rs9811771	ENSG00000230342.2	FANCD2P2	10.84	8.74e-24	1.25e-16	0.62	0.5	Alzheimer's disease;	chr3:10092265	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs1552244	ENSG00000230342.2	FANCD2P2	10.84	8.74e-24	1.25e-16	0.62	0.5	Alzheimer's disease;	chr3:10093893	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-10.84	8.88e-24	1.27e-16	-0.72	-0.5	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
STAD	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-10.84	9.09e-24	1.3e-16	-0.52	-0.5	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
STAD	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	10.83	9.53e-24	1.36e-16	0.75	0.5	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.78	rs10013652	ENSG00000276997.3	RP11-378J18.9	10.83	9.55e-24	1.36e-16	0.55	0.5	Corneal astigmatism;	chr4:119371101	chr1:222477252~222504622:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000234513.1	AC073072.7	10.83	9.87e-24	1.41e-16	0.53	0.5	Cognitive function;	chr12:56050848	chr7:22773646~22773993:-
STAD	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-10.83	1e-23	1.43e-16	-0.49	-0.5	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.575	rs907204	ENSG00000276997.3	RP11-378J18.9	10.83	1.01e-23	1.43e-16	0.55	0.5	Corneal astigmatism;	chr4:119317499	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.575	rs907205	ENSG00000276997.3	RP11-378J18.9	10.83	1.01e-23	1.43e-16	0.55	0.5	Corneal astigmatism;	chr4:119317509	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	10.83	1.02e-23	1.45e-16	0.55	0.5	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.882	rs6443279	ENSG00000230342.2	FANCD2P2	10.83	1.02e-23	1.45e-16	0.63	0.5	Alzheimer's disease;	chr3:10011915	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs36006511	ENSG00000230342.2	FANCD2P2	10.83	1.02e-23	1.45e-16	0.63	0.5	Alzheimer's disease;	chr3:10012507	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs67569278	ENSG00000230342.2	FANCD2P2	10.82	1.04e-23	1.49e-16	0.65	0.5	Alzheimer's disease;	chr3:10108209	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.708	rs1546506	ENSG00000276997.3	RP11-378J18.9	10.82	1.09e-23	1.55e-16	0.55	0.5	Corneal astigmatism;	chr4:119320085	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs12506610	ENSG00000276997.3	RP11-378J18.9	10.82	1.09e-23	1.55e-16	0.55	0.5	Corneal astigmatism;	chr4:119320504	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.743	rs10003567	ENSG00000276997.3	RP11-378J18.9	10.82	1.09e-23	1.55e-16	0.55	0.5	Corneal astigmatism;	chr4:119320519	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs10006259	ENSG00000276997.3	RP11-378J18.9	10.82	1.09e-23	1.55e-16	0.55	0.5	Corneal astigmatism;	chr4:119320990	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs28652763	ENSG00000276997.3	RP11-378J18.9	10.82	1.09e-23	1.55e-16	0.55	0.5	Corneal astigmatism;	chr4:119321157	chr1:222477252~222504622:-
STAD	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-10.81	1.13e-23	1.6e-16	-0.52	-0.5	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
STAD	trans	rs877636	1	rs2292239	ENSG00000223416.3	RPS26P15	10.81	1.15e-23	1.63e-16	0.51	0.5	Cognitive function;	chr12:56088396	chr1:58056133~58056480:-
STAD	trans	rs13177918	0.677	rs13181401	ENSG00000226396.1	RP5-1056L3.3	10.81	1.15e-23	1.63e-16	0.51	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs4541646	ENSG00000226396.1	RP5-1056L3.3	10.81	1.15e-23	1.63e-16	0.51	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs3900644	ENSG00000226396.1	RP5-1056L3.3	10.81	1.15e-23	1.63e-16	0.51	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs2070844	ENSG00000226396.1	RP5-1056L3.3	10.81	1.15e-23	1.63e-16	0.51	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.677	rs2073472	ENSG00000226396.1	RP5-1056L3.3	10.81	1.15e-23	1.63e-16	0.51	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.629	rs2070842	ENSG00000226396.1	RP5-1056L3.3	10.81	1.15e-23	1.63e-16	0.51	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:19608114~19608568:+
STAD	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-10.81	1.15e-23	1.63e-16	-0.7	-0.5	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
STAD	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-10.81	1.16e-23	1.64e-16	-0.86	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
STAD	trans	rs877636	1	rs877636	ENSG00000212829.8	RPS26P3	-10.81	1.21e-23	1.71e-16	-0.49	-0.5	Cognitive function;	chr12:56086799	chr9:9090898~9091245:+
STAD	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	10.81	1.21e-23	1.71e-16	0.84	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.754	rs12510269	ENSG00000276997.3	RP11-378J18.9	10.8	1.22e-23	1.72e-16	0.55	0.5	Corneal astigmatism;	chr4:119320491	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs705696	ENSG00000227887.1	RPS26P13	10.8	1.23e-23	1.74e-16	0.54	0.5	Cognitive function;	chr12:56086864	chr1:208697369~208697698:-
STAD	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-10.8	1.25e-23	1.76e-16	-0.86	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
STAD	trans	rs1552244	0.572	rs58862481	ENSG00000230342.2	FANCD2P2	10.8	1.3e-23	1.84e-16	0.8	0.5	Alzheimer's disease;	chr3:10122624	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs9849434	ENSG00000230342.2	FANCD2P2	-10.79	1.41e-23	1.99e-16	-0.63	-0.5	Alzheimer's disease;	chr3:10092026	chr3:11859674~11891172:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000227586.5	RP11-162A23.5	10.79	1.41e-23	1.99e-16	0.51	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:123171535~123171875:-
STAD	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	10.78	1.43e-23	2e-16	0.84	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
STAD	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	10.78	1.43e-23	2e-16	0.84	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.754	rs9999724	ENSG00000276997.3	RP11-378J18.9	10.78	1.47e-23	2.06e-16	0.54	0.5	Corneal astigmatism;	chr4:119318789	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs7628448	ENSG00000230342.2	FANCD2P2	10.78	1.48e-23	2.08e-16	0.66	0.5	Alzheimer's disease;	chr3:10105144	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs17032283	ENSG00000230342.2	FANCD2P2	10.78	1.51e-23	2.11e-16	0.6	0.5	Alzheimer's disease;	chr3:10039861	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.754	rs12711071	ENSG00000276997.3	RP11-378J18.9	10.78	1.53e-23	2.15e-16	0.55	0.5	Corneal astigmatism;	chr4:119319779	chr1:222477252~222504622:-
STAD	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	10.77	1.58e-23	2.21e-16	0.77	0.5	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
STAD	trans	rs13177918	0.557	rs12520101	ENSG00000226396.1	RP5-1056L3.3	10.77	1.59e-23	2.23e-16	0.52	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:19608114~19608568:+
STAD	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	10.77	1.64e-23	2.3e-16	0.76	0.5	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
STAD	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	10.77	1.64e-23	2.3e-16	0.76	0.5	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.73	rs78971550	ENSG00000276997.3	RP11-378J18.9	10.76	1.73e-23	2.42e-16	0.56	0.5	Corneal astigmatism;	chr4:119359886	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.645	rs78422072	ENSG00000276997.3	RP11-378J18.9	10.76	1.73e-23	2.42e-16	0.56	0.5	Corneal astigmatism;	chr4:119359887	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-10.76	1.75e-23	2.44e-16	-0.7	-0.5	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.754	rs28643450	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119324087	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.7	rs7671797	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Educational attainment;	chr4:119327002	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs7672372	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119327251	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs7672594	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119327388	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs7672778	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119327430	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs2036860	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119327779	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs12513083	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119328457	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs12509621	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119328505	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs1511017	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119329650	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.789	rs12498994	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119329663	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs12507565	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119329966	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.826	rs12511640	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119330093	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs1980026	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119330488	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.722	rs28713555	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119330840	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.743	rs11098501	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119330862	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs11098502	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119330908	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.708	rs11732686	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119331175	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs11724409	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119331206	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.789	rs1980024	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119331892	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs34425882	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119332022	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs7689729	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119335037	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.7	rs7690338	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Educational attainment;	chr4:119335313	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.865	rs3956464	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119335609	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.619	rs28502463	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119335868	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.648	rs2002047	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119336073	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.775	rs2002049	ENSG00000276997.3	RP11-378J18.9	10.76	1.77e-23	2.46e-16	0.54	0.5	Corneal astigmatism;	chr4:119336262	chr1:222477252~222504622:-
STAD	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	10.76	1.81e-23	2.52e-16	0.61	0.5	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
STAD	trans	rs1552244	0.882	rs3846168	ENSG00000230342.2	FANCD2P2	10.75	1.82e-23	2.53e-16	0.63	0.5	Alzheimer's disease;	chr3:9955241	chr3:11859674~11891172:+
STAD	trans	rs7930295	0.841	rs58929810	ENSG00000236257.1	EI24P2	10.75	1.88e-23	2.62e-16	0.79	0.5	Schizophrenia;	chr11:125460892	chr1:158454198~158455273:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000234192.1	RP11-57C13.5	-10.75	1.91e-23	2.65e-16	-0.51	-0.5	Cognitive function;	chr12:56042145	chr10:87642607~87642954:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-10.75	1.93e-23	2.68e-16	-0.59	-0.5	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-10.75	1.93e-23	2.68e-16	-0.59	-0.5	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
STAD	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	10.75	1.95e-23	2.7e-16	0.57	0.5	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000234513.1	AC073072.7	10.74	2.01e-23	2.79e-16	0.52	0.5	Cognitive function;	chr12:56041720	chr7:22773646~22773993:-
STAD	trans	rs11098499	0.754	rs4107728	ENSG00000276997.3	RP11-378J18.9	10.74	2.02e-23	2.81e-16	0.54	0.5	Corneal astigmatism;	chr4:119332755	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs17049949	ENSG00000276997.3	RP11-378J18.9	10.74	2.02e-23	2.81e-16	0.54	0.5	Corneal astigmatism;	chr4:119334135	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	10.74	2.04e-23	2.83e-16	0.57	0.5	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
STAD	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	10.74	2.05e-23	2.84e-16	0.85	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
STAD	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	10.74	2.05e-23	2.84e-16	0.85	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.754	rs714899	ENSG00000276997.3	RP11-378J18.9	10.74	2.08e-23	2.88e-16	0.54	0.5	Corneal astigmatism;	chr4:119321880	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-10.74	2.1e-23	2.9e-16	-0.73	-0.5	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-10.73	2.18e-23	3.02e-16	-0.72	-0.5	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
STAD	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	10.73	2.2e-23	3.04e-16	0.84	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	10.73	2.25e-23	3.1e-16	0.56	0.5	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-10.73	2.28e-23	3.15e-16	-0.71	-0.5	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.826	rs4472123	ENSG00000276997.3	RP11-378J18.9	10.72	2.36e-23	3.25e-16	0.55	0.5	Corneal astigmatism;	chr4:119315475	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.882	rs17050660	ENSG00000230342.2	FANCD2P2	-10.72	2.38e-23	3.28e-16	-0.63	-0.5	Alzheimer's disease;	chr3:9960088	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-10.72	2.42e-23	3.33e-16	-0.73	-0.5	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
STAD	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-10.72	2.45e-23	3.37e-16	-0.85	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
STAD	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-10.72	2.45e-23	3.37e-16	-0.85	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
STAD	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	10.72	2.47e-23	3.4e-16	0.64	0.5	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
STAD	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	10.72	2.51e-23	3.45e-16	0.73	0.5	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.754	rs2036857	ENSG00000276997.3	RP11-378J18.9	10.71	2.55e-23	3.51e-16	0.54	0.5	Corneal astigmatism;	chr4:119328085	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs2036856	ENSG00000276997.3	RP11-378J18.9	10.71	2.55e-23	3.51e-16	0.54	0.5	Corneal astigmatism;	chr4:119328133	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs4443261	ENSG00000276997.3	RP11-378J18.9	10.71	2.55e-23	3.51e-16	0.54	0.5	Corneal astigmatism;	chr4:119328146	chr1:222477252~222504622:-
STAD	trans	rs1552244	1	rs6414438	ENSG00000230342.2	FANCD2P2	10.71	2.6e-23	3.57e-16	0.61	0.5	Alzheimer's disease;	chr3:10032140	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	10.71	2.7e-23	3.7e-16	0.56	0.5	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000239210.2	RPS26P55	-10.7	2.79e-23	3.83e-16	-0.5	-0.5	Cognitive function;	chr12:56080024	chr19:34533427~34534084:-
STAD	trans	rs11098499	0.865	rs10213221	ENSG00000276997.3	RP11-378J18.9	10.7	2.81e-23	3.85e-16	0.54	0.5	Corneal astigmatism;	chr4:119334771	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.935	rs28815328	ENSG00000230342.2	FANCD2P2	10.7	2.88e-23	3.95e-16	0.61	0.5	Alzheimer's disease;	chr3:10020543	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs28684871	ENSG00000230342.2	FANCD2P2	10.7	2.88e-23	3.95e-16	0.61	0.5	Alzheimer's disease;	chr3:10030951	chr3:11859674~11891172:+
STAD	trans	rs1552244	1	rs6442147	ENSG00000230342.2	FANCD2P2	10.7	2.88e-23	3.95e-16	0.61	0.5	Alzheimer's disease;	chr3:10036563	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-10.7	2.89e-23	3.96e-16	-0.71	-0.5	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	10.69	3e-23	4.1e-16	0.56	0.5	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	10.69	3e-23	4.1e-16	0.56	0.5	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	10.69	3.07e-23	4.2e-16	0.77	0.5	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	10.69	3.15e-23	4.29e-16	0.55	0.5	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	10.69	3.15e-23	4.29e-16	0.55	0.5	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	10.69	3.15e-23	4.29e-16	0.55	0.5	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.675	rs11098534	ENSG00000276997.3	RP11-378J18.9	10.68	3.23e-23	4.4e-16	0.55	0.5	Corneal astigmatism;	chr4:119635617	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs66900435	ENSG00000276997.3	RP11-378J18.9	10.68	3.25e-23	4.42e-16	0.54	0.5	Corneal astigmatism;	chr4:119328270	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs1980027	ENSG00000276997.3	RP11-378J18.9	10.68	3.25e-23	4.42e-16	0.54	0.5	Corneal astigmatism;	chr4:119330422	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	10.68	3.3e-23	4.49e-16	0.55	0.5	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	10.68	3.3e-23	4.49e-16	0.55	0.5	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-10.68	3.41e-23	4.64e-16	-0.71	-0.5	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	10.67	3.5e-23	4.76e-16	0.56	0.5	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.789	rs10212719	ENSG00000276997.3	RP11-378J18.9	10.67	3.74e-23	5.08e-16	0.54	0.5	Corneal astigmatism;	chr4:119333282	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs17595608	ENSG00000276997.3	RP11-378J18.9	10.66	4.09e-23	5.54e-16	0.54	0.5	Corneal astigmatism;	chr4:119329351	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	10.66	4.09e-23	5.54e-16	0.54	0.5	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs705696	ENSG00000223416.3	RPS26P15	10.65	4.24e-23	5.74e-16	0.53	0.5	Cognitive function;	chr12:56086864	chr1:58056133~58056480:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000234192.1	RP11-57C13.5	-10.65	4.25e-23	5.76e-16	-0.49	-0.5	Cognitive function;	chr12:56084218	chr10:87642607~87642954:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000234192.1	RP11-57C13.5	-10.65	4.25e-23	5.76e-16	-0.49	-0.5	Cognitive function;	chr12:56084874	chr10:87642607~87642954:+
STAD	trans	rs9611565	0.592	rs4481089	ENSG00000268568.1	AC007228.9	-10.65	4.27e-23	5.78e-16	-0.74	-0.5	Vitiligo;	chr22:41584888	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs5996039	ENSG00000268568.1	AC007228.9	-10.65	4.27e-23	5.78e-16	-0.74	-0.5	Vitiligo;	chr22:41585953	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs57102627	ENSG00000268568.1	AC007228.9	-10.65	4.27e-23	5.78e-16	-0.74	-0.5	Vitiligo;	chr22:41591623	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs28750375	ENSG00000268568.1	AC007228.9	-10.65	4.27e-23	5.78e-16	-0.74	-0.5	Vitiligo;	chr22:41594640	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-10.65	4.43e-23	5.98e-16	-0.57	-0.5	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.572	rs7645667	ENSG00000230342.2	FANCD2P2	10.64	4.55e-23	6.15e-16	0.79	0.5	Alzheimer's disease;	chr3:10115653	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	10.64	4.68e-23	6.32e-16	0.77	0.5	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.722	rs1814814	ENSG00000276997.3	RP11-378J18.9	10.64	4.71e-23	6.35e-16	0.53	0.5	Corneal astigmatism;	chr4:119336969	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.644	rs7693919	ENSG00000276997.3	RP11-378J18.9	10.64	4.77e-23	6.44e-16	0.55	0.5	Corneal astigmatism;	chr4:119619416	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.57	rs6832740	ENSG00000276997.3	RP11-378J18.9	10.63	4.82e-23	6.5e-16	0.55	0.5	Corneal astigmatism;	chr4:119624981	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.644	rs6855918	ENSG00000276997.3	RP11-378J18.9	10.63	4.82e-23	6.5e-16	0.55	0.5	Corneal astigmatism;	chr4:119625144	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	10.63	4.86e-23	6.54e-16	0.76	0.5	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
STAD	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	10.63	4.86e-23	6.54e-16	0.76	0.5	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	10.63	4.86e-23	6.54e-16	0.76	0.5	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	10.63	4.86e-23	6.54e-16	0.76	0.5	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	10.63	4.86e-23	6.54e-16	0.76	0.5	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	10.63	4.86e-23	6.55e-16	0.56	0.5	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
STAD	trans	rs7930295	1	rs11220081	ENSG00000236257.1	EI24P2	10.63	4.87e-23	6.56e-16	0.78	0.5	Schizophrenia;	chr11:125453646	chr1:158454198~158455273:+
STAD	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	10.63	5.01e-23	6.74e-16	0.56	0.5	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
STAD	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-10.63	5.01e-23	6.74e-16	-0.5	-0.5	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
STAD	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-10.63	5.01e-23	6.74e-16	-0.5	-0.5	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
STAD	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-10.63	5.01e-23	6.74e-16	-0.5	-0.5	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
STAD	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-10.63	5.01e-23	6.74e-16	-0.5	-0.5	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
STAD	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	10.63	5.04e-23	6.78e-16	0.63	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
STAD	trans	rs1552244	0.882	rs2130813	ENSG00000230342.2	FANCD2P2	10.63	5.13e-23	6.89e-16	0.62	0.5	Alzheimer's disease;	chr3:9997022	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs17081288	ENSG00000230342.2	FANCD2P2	10.63	5.13e-23	6.89e-16	0.62	0.5	Alzheimer's disease;	chr3:10000429	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.816	rs56271597	ENSG00000230342.2	FANCD2P2	10.63	5.13e-23	6.89e-16	0.62	0.5	Alzheimer's disease;	chr3:10001106	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs13066757	ENSG00000230342.2	FANCD2P2	10.63	5.13e-23	6.89e-16	0.62	0.5	Alzheimer's disease;	chr3:10003346	chr3:11859674~11891172:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000239210.2	RPS26P55	-10.62	5.24e-23	7.03e-16	-0.5	-0.5	Cognitive function;	chr12:56084218	chr19:34533427~34534084:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000239210.2	RPS26P55	-10.62	5.24e-23	7.03e-16	-0.5	-0.5	Cognitive function;	chr12:56084874	chr19:34533427~34534084:-
STAD	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	10.62	5.49e-23	7.37e-16	0.58	0.5	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
STAD	trans	rs877636	1	rs4759229	ENSG00000227586.5	RP11-162A23.5	-10.62	5.53e-23	7.42e-16	-0.52	-0.5	Cognitive function;	chr12:56080696	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	10.61	5.69e-23	7.62e-16	0.54	0.5	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	10.61	5.69e-23	7.62e-16	0.54	0.5	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	10.61	5.69e-23	7.62e-16	0.54	0.5	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
STAD	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	10.61	5.88e-23	7.87e-16	0.6	0.5	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
STAD	trans	rs1552244	0.882	rs67631672	ENSG00000230342.2	FANCD2P2	10.61	5.97e-23	7.99e-16	0.61	0.5	Alzheimer's disease;	chr3:9963084	chr3:11859674~11891172:+
STAD	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	10.6	6.25e-23	8.36e-16	0.83	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.722	rs7673476	ENSG00000276997.3	RP11-378J18.9	10.6	6.38e-23	8.52e-16	0.53	0.5	Corneal astigmatism;	chr4:119327528	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-10.6	6.4e-23	8.56e-16	-0.73	-0.5	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	10.6	6.42e-23	8.58e-16	0.55	0.5	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000225071.1	GS1-184P14.2	10.59	6.76e-23	9.01e-16	0.5	0.49	Cognitive function;	chr12:56050848	chrX:24429573~24429920:-
STAD	trans	rs11098499	0.697	rs35280960	ENSG00000276997.3	RP11-378J18.9	10.59	6.87e-23	9.15e-16	0.55	0.49	Corneal astigmatism;	chr4:119335904	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs2292239	ENSG00000227586.5	RP11-162A23.5	10.59	6.88e-23	9.17e-16	0.51	0.49	Cognitive function;	chr12:56088396	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	10.59	7.02e-23	9.34e-16	0.54	0.49	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	10.59	7.02e-23	9.34e-16	0.54	0.49	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	10.59	7.02e-23	9.34e-16	0.54	0.49	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-10.59	7.02e-23	9.34e-16	-0.54	-0.49	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	10.59	7.14e-23	9.51e-16	0.54	0.49	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	10.59	7.14e-23	9.51e-16	0.54	0.49	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
STAD	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-10.58	7.46e-23	9.93e-16	-0.68	-0.49	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
STAD	trans	rs7930295	1	rs34504992	ENSG00000236257.1	EI24P2	10.58	7.72e-23	1.03e-15	0.77	0.49	Schizophrenia;	chr11:125446177	chr1:158454198~158455273:+
STAD	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	10.57	7.9e-23	1.05e-15	0.56	0.49	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000234192.1	RP11-57C13.5	-10.57	7.92e-23	1.05e-15	-0.51	-0.49	Cognitive function;	chr12:56007301	chr10:87642607~87642954:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000234192.1	RP11-57C13.5	-10.57	7.95e-23	1.06e-15	-0.49	-0.49	Cognitive function;	chr12:56080024	chr10:87642607~87642954:+
STAD	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	10.56	8.93e-23	1.18e-15	0.62	0.49	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
STAD	trans	rs11098499	0.535	rs7671759	ENSG00000276997.3	RP11-378J18.9	10.55	9.26e-23	1.23e-15	0.55	0.49	Corneal astigmatism;	chr4:119326939	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs878376	ENSG00000276997.3	RP11-378J18.9	10.55	9.53e-23	1.26e-15	0.54	0.49	Corneal astigmatism;	chr4:119316547	chr1:222477252~222504622:-
STAD	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-10.55	9.69e-23	1.28e-15	-0.5	-0.49	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
STAD	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-10.55	9.72e-23	1.28e-15	-0.5	-0.49	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
STAD	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-10.55	9.72e-23	1.28e-15	-0.5	-0.49	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
STAD	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-10.55	9.72e-23	1.28e-15	-0.5	-0.49	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
STAD	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-10.55	9.86e-23	1.3e-15	-0.84	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
STAD	trans	rs877636	1	rs4759229	ENSG00000212829.8	RPS26P3	-10.54	1.02e-22	1.34e-15	-0.48	-0.49	Cognitive function;	chr12:56080696	chr9:9090898~9091245:+
STAD	trans	rs11098499	0.754	rs10212714	ENSG00000276997.3	RP11-378J18.9	10.54	1.03e-22	1.36e-15	0.54	0.49	Corneal astigmatism;	chr4:119333147	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000225071.1	GS1-184P14.2	10.54	1.05e-22	1.38e-15	0.5	0.49	Cognitive function;	chr12:56009793	chrX:24429573~24429920:-
STAD	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	10.54	1.06e-22	1.4e-15	0.5	0.49	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-10.53	1.12e-22	1.47e-15	-0.54	-0.49	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	10.53	1.14e-22	1.5e-15	0.54	0.49	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-10.52	1.2e-22	1.58e-15	-0.52	-0.49	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000196933.5	RPS26P11	-10.52	1.21e-22	1.59e-15	-0.49	-0.49	Cognitive function;	chr12:56080595	chrX:72044545~72044892:+
STAD	trans	rs11098499	0.644	rs28787668	ENSG00000276997.3	RP11-378J18.9	10.52	1.22e-22	1.6e-15	0.54	0.49	Corneal astigmatism;	chr4:119633532	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.644	rs7676296	ENSG00000276997.3	RP11-378J18.9	10.52	1.22e-22	1.6e-15	0.54	0.49	Corneal astigmatism;	chr4:119634532	chr1:222477252~222504622:-
STAD	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	10.52	1.23e-22	1.62e-15	0.54	0.49	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
STAD	trans	rs13177918	0.75	rs59354956	ENSG00000226396.1	RP5-1056L3.3	10.52	1.23e-22	1.62e-15	0.5	0.49	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:19608114~19608568:+
STAD	trans	rs7930295	1	rs34238592	ENSG00000236257.1	EI24P2	10.52	1.24e-22	1.63e-15	0.77	0.49	Schizophrenia;	chr11:125445059	chr1:158454198~158455273:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000227586.5	RP11-162A23.5	-10.52	1.26e-22	1.66e-15	-0.52	-0.49	Cognitive function;	chr12:56080595	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-10.51	1.28e-22	1.68e-15	-0.53	-0.49	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs4759229	ENSG00000196933.5	RPS26P11	-10.51	1.29e-22	1.69e-15	-0.49	-0.49	Cognitive function;	chr12:56080696	chrX:72044545~72044892:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-10.51	1.32e-22	1.73e-15	-0.58	-0.49	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
STAD	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	10.51	1.33e-22	1.74e-15	0.55	0.49	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-10.51	1.35e-22	1.77e-15	-0.73	-0.49	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.954	rs6857105	ENSG00000275858.1	RP11-291L22.8	10.51	1.37e-22	1.79e-15	0.54	0.49	Corneal astigmatism;	chr4:119301143	chr10:38450738~38451069:-
STAD	trans	rs7930295	1	rs28593289	ENSG00000236257.1	EI24P2	10.5	1.4e-22	1.83e-15	0.77	0.49	Schizophrenia;	chr11:125446628	chr1:158454198~158455273:+
STAD	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	10.5	1.41e-22	1.84e-15	0.55	0.49	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs34835603	ENSG00000276997.3	RP11-378J18.9	10.5	1.42e-22	1.85e-15	0.54	0.49	Corneal astigmatism;	chr4:119632273	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.615	rs28850368	ENSG00000276997.3	RP11-378J18.9	10.5	1.42e-22	1.85e-15	0.54	0.49	Corneal astigmatism;	chr4:119633158	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs938056	ENSG00000276997.3	RP11-378J18.9	10.5	1.44e-22	1.88e-15	0.54	0.49	Corneal astigmatism;	chr4:119316298	chr1:222477252~222504622:-
STAD	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	10.5	1.44e-22	1.88e-15	0.75	0.49	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
STAD	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-10.5	1.45e-22	1.9e-15	-0.5	-0.49	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
STAD	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	10.5	1.46e-22	1.91e-15	0.83	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
STAD	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	10.49	1.52e-22	1.98e-15	0.54	0.49	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	10.49	1.52e-22	1.98e-15	0.54	0.49	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	10.49	1.52e-22	1.98e-15	0.54	0.49	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	10.49	1.52e-22	1.98e-15	0.54	0.49	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs10012252	ENSG00000276997.3	RP11-378J18.9	10.49	1.56e-22	2.03e-15	0.54	0.49	Corneal astigmatism;	chr4:119637984	chr1:222477252~222504622:-
STAD	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	10.49	1.57e-22	2.04e-15	0.81	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
STAD	trans	rs7930295	1	rs6590145	ENSG00000236257.1	EI24P2	10.49	1.57e-22	2.04e-15	0.77	0.49	Schizophrenia;	chr11:125448020	chr1:158454198~158455273:+
STAD	trans	rs1552244	0.816	rs9847657	ENSG00000230342.2	FANCD2P2	10.49	1.6e-22	2.08e-15	0.57	0.49	Alzheimer's disease;	chr3:10131808	chr3:11859674~11891172:+
STAD	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	10.48	1.62e-22	2.11e-15	0.62	0.49	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000212829.8	RPS26P3	-10.48	1.64e-22	2.13e-15	-0.48	-0.49	Cognitive function;	chr12:56080595	chr9:9090898~9091245:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	10.48	1.64e-22	2.14e-15	0.47	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000225071.1	GS1-184P14.2	10.48	1.69e-22	2.19e-15	0.5	0.49	Cognitive function;	chr12:56002984	chrX:24429573~24429920:-
STAD	trans	rs877636	1	rs705696	ENSG00000227586.5	RP11-162A23.5	10.48	1.71e-22	2.22e-15	0.53	0.49	Cognitive function;	chr12:56086864	chr10:123171535~123171875:-
STAD	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-10.47	1.75e-22	2.28e-15	-0.83	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
STAD	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	10.47	1.78e-22	2.31e-15	0.53	0.49	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.604	rs2389882	ENSG00000276997.3	RP11-378J18.9	10.47	1.85e-22	2.4e-15	0.54	0.49	Corneal astigmatism;	chr4:119645578	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.882	rs13063098	ENSG00000230342.2	FANCD2P2	10.46	1.89e-22	2.45e-15	0.62	0.49	Alzheimer's disease;	chr3:9968235	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.832	rs3732968	ENSG00000230342.2	FANCD2P2	10.46	1.89e-22	2.45e-15	0.62	0.49	Alzheimer's disease;	chr3:9971589	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs67762674	ENSG00000230342.2	FANCD2P2	10.46	1.89e-22	2.45e-15	0.62	0.49	Alzheimer's disease;	chr3:9972801	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.82	rs2389885	ENSG00000276997.3	RP11-378J18.9	10.46	2e-22	2.59e-15	0.56	0.49	Corneal astigmatism;	chr4:119612776	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs1849457	ENSG00000276997.3	RP11-378J18.9	10.46	2.02e-22	2.61e-15	0.54	0.49	Corneal astigmatism;	chr4:119333200	chr1:222477252~222504622:-
STAD	trans	rs13177918	0.75	rs58256223	ENSG00000226396.1	RP5-1056L3.3	10.46	2.04e-22	2.63e-15	0.49	0.49	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:19608114~19608568:+
STAD	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	10.45	2.07e-22	2.67e-15	0.54	0.49	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	10.45	2.07e-22	2.67e-15	0.54	0.49	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	10.45	2.07e-22	2.67e-15	0.54	0.49	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	10.45	2.17e-22	2.79e-15	0.53	0.49	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	10.45	2.21e-22	2.84e-15	0.53	0.49	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000225071.1	GS1-184P14.2	10.44	2.24e-22	2.88e-15	0.49	0.49	Cognitive function;	chr12:56013288	chrX:24429573~24429920:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000225071.1	GS1-184P14.2	10.44	2.24e-22	2.88e-15	0.49	0.49	Cognitive function;	chr12:56018703	chrX:24429573~24429920:-
STAD	trans	rs11098499	0.644	rs10009566	ENSG00000276997.3	RP11-378J18.9	10.44	2.24e-22	2.89e-15	0.54	0.49	Corneal astigmatism;	chr4:119637453	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-10.44	2.25e-22	2.9e-15	-0.63	-0.49	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
STAD	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	10.44	2.27e-22	2.93e-15	0.75	0.49	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
STAD	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	10.44	2.28e-22	2.94e-15	0.54	0.49	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	10.44	2.34e-22	3.02e-15	0.53	0.49	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.882	rs56332224	ENSG00000230342.2	FANCD2P2	10.44	2.35e-22	3.02e-15	0.61	0.49	Alzheimer's disease;	chr3:9995637	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	10.44	2.37e-22	3.05e-15	0.54	0.49	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000225071.1	GS1-184P14.2	10.44	2.39e-22	3.07e-15	0.49	0.49	Cognitive function;	chr12:56023144	chrX:24429573~24429920:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000225071.1	GS1-184P14.2	10.43	2.41e-22	3.1e-15	0.49	0.49	Cognitive function;	chr12:56041628	chrX:24429573~24429920:-
STAD	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	10.43	2.51e-22	3.22e-15	0.53	0.49	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	10.43	2.52e-22	3.23e-15	0.54	0.49	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	10.42	2.64e-22	3.38e-15	0.54	0.49	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
STAD	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	10.42	2.64e-22	3.39e-15	0.83	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	10.42	2.75e-22	3.52e-15	0.54	0.49	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-10.42	2.76e-22	3.53e-15	-0.54	-0.49	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000227586.5	RP11-162A23.5	10.42	2.76e-22	3.54e-15	0.49	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:123171535~123171875:-
STAD	trans	rs1816752	0.524	rs1965154	ENSG00000237917.1	PARP4P1	-10.42	2.77e-22	3.54e-15	-0.62	-0.49	Obesity-related traits;	chr13:24498062	chrY:26594851~26634652:-
STAD	trans	rs9611565	0.559	rs8139993	ENSG00000268568.1	AC007228.9	-10.42	2.77e-22	3.54e-15	-0.73	-0.49	Vitiligo;	chr22:41599331	chr19:56672574~56673901:-
STAD	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	10.41	2.82e-22	3.61e-15	0.54	0.49	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	10.41	2.91e-22	3.72e-15	0.54	0.49	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-10.41	2.95e-22	3.77e-15	-0.75	-0.49	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
STAD	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-10.41	2.96e-22	3.78e-15	-0.84	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
STAD	trans	rs11098499	0.644	rs3806808	ENSG00000276997.3	RP11-378J18.9	10.41	2.99e-22	3.81e-15	0.54	0.49	Corneal astigmatism;	chr4:119629930	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	10.41	2.99e-22	3.81e-15	0.53	0.49	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	10.41	2.99e-22	3.81e-15	0.53	0.49	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	10.41	3.01e-22	3.85e-15	0.53	0.49	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	10.41	3.03e-22	3.86e-15	0.53	0.49	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs2389880	ENSG00000276997.3	RP11-378J18.9	10.4	3.09e-22	3.94e-15	0.54	0.49	Corneal astigmatism;	chr4:119638715	chr1:222477252~222504622:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000204652.6	RPS26P8	10.4	3.09e-22	3.94e-15	0.51	0.49	Cognitive function;	chr12:56050848	chr17:45608571~45608918:+
STAD	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	10.4	3.16e-22	4.02e-15	0.79	0.49	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	10.39	3.33e-22	4.24e-15	0.53	0.49	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs9996644	ENSG00000276997.3	RP11-378J18.9	10.39	3.41e-22	4.33e-15	0.54	0.49	Corneal astigmatism;	chr4:119317722	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.691	rs9996494	ENSG00000276997.3	RP11-378J18.9	10.39	3.41e-22	4.33e-15	0.54	0.49	Corneal astigmatism;	chr4:119317725	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.572	rs12107622	ENSG00000230342.2	FANCD2P2	10.39	3.53e-22	4.48e-15	0.78	0.49	Alzheimer's disease;	chr3:10130214	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs2054478	ENSG00000230342.2	FANCD2P2	10.39	3.53e-22	4.48e-15	0.78	0.49	Alzheimer's disease;	chr3:10130527	chr3:11859674~11891172:+
STAD	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	10.39	3.56e-22	4.52e-15	0.64	0.49	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000204652.6	RPS26P8	10.39	3.56e-22	4.52e-15	0.52	0.49	Cognitive function;	chr12:56002984	chr17:45608571~45608918:+
STAD	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	10.38	3.61e-22	4.58e-15	0.51	0.49	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.592	rs80477	ENSG00000268568.1	AC007228.9	10.38	3.63e-22	4.6e-15	0.72	0.49	Vitiligo;	chr22:41605179	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	10.38	3.63e-22	4.6e-15	0.53	0.49	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	10.38	3.65e-22	4.63e-15	0.53	0.49	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000212829.8	RPS26P3	10.38	3.8e-22	4.82e-15	0.45	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:9090898~9091245:+
STAD	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	10.38	3.84e-22	4.85e-15	0.52	0.49	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	10.38	3.84e-22	4.85e-15	0.52	0.49	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	10.38	3.84e-22	4.85e-15	0.52	0.49	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	10.38	3.84e-22	4.85e-15	0.52	0.49	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	10.38	3.84e-22	4.85e-15	0.52	0.49	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.604	rs2389886	ENSG00000276997.3	RP11-378J18.9	10.37	3.95e-22	5e-15	0.55	0.49	Corneal astigmatism;	chr4:119649267	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-10.36	4.32e-22	5.45e-15	-0.74	-0.49	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-10.36	4.32e-22	5.45e-15	-0.74	-0.49	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-10.36	4.32e-22	5.45e-15	-0.74	-0.49	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-10.36	4.32e-22	5.45e-15	-0.74	-0.49	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-10.36	4.32e-22	5.45e-15	-0.74	-0.49	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-10.36	4.32e-22	5.45e-15	-0.74	-0.49	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-10.36	4.32e-22	5.45e-15	-0.74	-0.49	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
STAD	trans	rs916888	0.61	rs199452	ENSG00000263503.1	RP11-707O23.5	10.36	4.34e-22	5.48e-15	0.63	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45600869~45602340:-
STAD	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	10.36	4.43e-22	5.59e-15	0.54	0.49	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000204652.6	RPS26P8	10.36	4.44e-22	5.59e-15	0.51	0.49	Cognitive function;	chr12:56009793	chr17:45608571~45608918:+
STAD	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	10.36	4.47e-22	5.63e-15	0.54	0.49	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs705696	ENSG00000204652.6	RPS26P8	10.35	4.63e-22	5.82e-15	0.49	0.49	Cognitive function;	chr12:56086864	chr17:45608571~45608918:+
STAD	trans	rs11098499	0.866	rs11098506	ENSG00000276997.3	RP11-378J18.9	10.35	4.78e-22	6.01e-15	0.53	0.49	Corneal astigmatism;	chr4:119363816	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	10.35	4.84e-22	6.08e-15	0.52	0.49	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	10.35	4.84e-22	6.08e-15	0.52	0.49	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	10.35	4.92e-22	6.17e-15	0.54	0.49	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000225071.1	GS1-184P14.2	10.34	4.98e-22	6.24e-15	0.49	0.49	Cognitive function;	chr12:56041720	chrX:24429573~24429920:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000227586.5	RP11-162A23.5	10.34	5.26e-22	6.59e-15	0.49	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	10.34	5.28e-22	6.61e-15	0.53	0.49	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000242970.2	AC068522.4	10.34	5.35e-22	6.7e-15	0.49	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:58588420~58588764:-
STAD	trans	rs7930295	0.822	rs7112666	ENSG00000236257.1	EI24P2	10.33	5.4e-22	6.76e-15	0.76	0.49	Schizophrenia;	chr11:125437980	chr1:158454198~158455273:+
STAD	trans	rs7930295	1	rs7930295	ENSG00000236257.1	EI24P2	10.33	5.55e-22	6.95e-15	0.74	0.49	Schizophrenia;	chr11:125443703	chr1:158454198~158455273:+
STAD	trans	rs877636	0.701	rs34415530	ENSG00000227887.1	RPS26P13	10.33	5.63e-22	7.04e-15	0.54	0.49	Cognitive function;	chr12:56050848	chr1:208697369~208697698:-
STAD	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	10.33	5.65e-22	7.06e-15	0.54	0.49	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	10.33	5.65e-22	7.06e-15	0.52	0.49	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs877636	ENSG00000233778.3	RP11-777J24.1	-10.33	5.71e-22	7.14e-15	-0.47	-0.49	Cognitive function;	chr12:56086799	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.739	rs10031033	ENSG00000275858.1	RP11-291L22.8	10.32	5.93e-22	7.4e-15	0.53	0.49	Corneal astigmatism;	chr4:119230297	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-10.32	5.96e-22	7.45e-15	-0.7	-0.49	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
STAD	trans	rs7930295	0.822	rs7128228	ENSG00000236257.1	EI24P2	10.32	6.03e-22	7.53e-15	0.76	0.49	Schizophrenia;	chr11:125437512	chr1:158454198~158455273:+
STAD	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	10.32	6.13e-22	7.65e-15	0.55	0.49	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	10.32	6.14e-22	7.65e-15	0.53	0.49	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	10.32	6.14e-22	7.65e-15	0.53	0.49	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	10.32	6.2e-22	7.7e-15	0.52	0.49	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	10.32	6.24e-22	7.74e-15	0.53	0.48	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	10.31	6.35e-22	7.87e-15	0.45	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.663	rs9996501	ENSG00000276997.3	RP11-378J18.9	10.31	6.38e-22	7.9e-15	0.53	0.48	Corneal astigmatism;	chr4:119317763	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.697	rs28458294	ENSG00000276997.3	RP11-378J18.9	10.31	6.38e-22	7.9e-15	0.53	0.48	Corneal astigmatism;	chr4:119317769	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.663	rs28369503	ENSG00000276997.3	RP11-378J18.9	10.31	6.38e-22	7.9e-15	0.53	0.48	Corneal astigmatism;	chr4:119317770	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.604	rs2389887	ENSG00000276997.3	RP11-378J18.9	10.31	6.47e-22	8.01e-15	0.55	0.48	Corneal astigmatism;	chr4:119649489	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs6847248	ENSG00000276997.3	RP11-378J18.9	10.31	6.49e-22	8.04e-15	0.56	0.48	Corneal astigmatism;	chr4:119304800	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.954	rs11098524	ENSG00000276997.3	RP11-378J18.9	10.31	6.53e-22	8.08e-15	0.54	0.48	Corneal astigmatism;	chr4:119468877	chr1:222477252~222504622:-
STAD	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	10.31	6.55e-22	8.1e-15	0.58	0.48	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
STAD	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-10.31	6.72e-22	8.32e-15	-0.84	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
STAD	trans	rs1552244	1	rs7626117	ENSG00000230342.2	FANCD2P2	10.3	7.06e-22	8.72e-15	0.55	0.48	Alzheimer's disease;	chr3:10098987	chr3:11859674~11891172:+
STAD	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	10.3	7.13e-22	8.8e-15	0.55	0.48	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
STAD	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	10.3	7.31e-22	9.02e-15	0.58	0.48	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
STAD	trans	rs11098499	1	rs3749591	ENSG00000276997.3	RP11-378J18.9	10.3	7.34e-22	9.05e-15	0.54	0.48	Corneal astigmatism;	chr4:119292875	chr1:222477252~222504622:-
STAD	trans	rs916888	0.647	rs199449	ENSG00000263503.1	RP11-707O23.5	10.29	7.53e-22	9.29e-15	0.63	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45600869~45602340:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000227887.1	RPS26P13	10.29	7.72e-22	9.52e-15	0.55	0.48	Cognitive function;	chr12:56002984	chr1:208697369~208697698:-
STAD	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-10.29	7.74e-22	9.54e-15	-0.74	-0.48	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-10.29	7.87e-22	9.69e-15	-0.46	-0.48	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
STAD	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-10.29	7.89e-22	9.72e-15	-0.57	-0.48	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
STAD	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-10.28	7.97e-22	9.82e-15	-0.46	-0.48	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
STAD	trans	rs7930295	1	rs34880099	ENSG00000236257.1	EI24P2	10.28	8.05e-22	9.91e-15	0.76	0.48	Schizophrenia;	chr11:125442413	chr1:158454198~158455273:+
STAD	trans	rs11098499	1	rs1011054	ENSG00000276997.3	RP11-378J18.9	-10.28	8.33e-22	1.02e-14	-0.55	-0.48	Corneal astigmatism;	chr4:119281232	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.882	rs13063929	ENSG00000230342.2	FANCD2P2	10.27	8.91e-22	1.1e-14	0.6	0.48	Alzheimer's disease;	chr3:9968624	chr3:11859674~11891172:+
STAD	trans	rs877636	1	rs4759229	ENSG00000196656.7	AC004057.1	-10.27	9.13e-22	1.12e-14	-0.46	-0.48	Cognitive function;	chr12:56080696	chr4:113214046~113217170:-
STAD	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	10.26	9.39e-22	1.15e-14	0.57	0.48	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
STAD	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	10.26	9.39e-22	1.15e-14	0.57	0.48	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
STAD	trans	rs9611565	0.525	rs9611549	ENSG00000268568.1	AC007228.9	-10.26	9.77e-22	1.2e-14	-0.65	-0.48	Vitiligo;	chr22:41309905	chr19:56672574~56673901:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	10.26	9.78e-22	1.2e-14	0.45	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000233278.1	RPS26P2	10.26	1e-21	1.23e-14	0.48	0.48	Cognitive function;	chr12:56076841	chr9:30831878~30832225:-
STAD	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	10.25	1.02e-21	1.25e-14	0.52	0.48	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	10.25	1.02e-21	1.25e-14	0.52	0.48	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	10.25	1.02e-21	1.25e-14	0.52	0.48	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
STAD	trans	rs916888	0.61	rs199444	ENSG00000263503.1	RP11-707O23.5	10.25	1.02e-21	1.25e-14	0.63	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45600869~45602340:-
STAD	trans	rs916888	0.61	rs199442	ENSG00000263503.1	RP11-707O23.5	10.25	1.02e-21	1.25e-14	0.63	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45600869~45602340:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000223416.3	RPS26P15	10.25	1.04e-21	1.27e-14	0.54	0.48	Cognitive function;	chr12:56002984	chr1:58056133~58056480:-
STAD	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	10.25	1.06e-21	1.3e-14	0.52	0.48	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.863	rs1010739	ENSG00000276997.3	RP11-378J18.9	10.25	1.07e-21	1.31e-14	0.54	0.48	Corneal astigmatism;	chr4:119542316	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.566	rs7664440	ENSG00000276997.3	RP11-378J18.9	10.25	1.08e-21	1.32e-14	0.55	0.48	Corneal astigmatism;	chr4:119657385	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	10.25	1.08e-21	1.32e-14	0.52	0.48	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	10.25	1.08e-21	1.32e-14	0.52	0.48	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000227887.1	RPS26P13	10.24	1.14e-21	1.39e-14	0.54	0.48	Cognitive function;	chr12:56009793	chr1:208697369~208697698:-
STAD	trans	rs877636	1	rs2292239	ENSG00000243538.1	CTB-55B8.1	10.24	1.15e-21	1.41e-14	0.49	0.48	Cognitive function;	chr12:56088396	chr5:16902294~16902641:-
STAD	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	10.24	1.16e-21	1.41e-14	0.7	0.48	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.874	rs13139045	ENSG00000276997.3	RP11-378J18.9	10.24	1.16e-21	1.41e-14	0.53	0.48	Corneal astigmatism;	chr4:119247433	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	10.24	1.17e-21	1.42e-14	0.53	0.48	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.882	rs55808392	ENSG00000230342.2	FANCD2P2	10.23	1.22e-21	1.48e-14	0.59	0.48	Alzheimer's disease;	chr3:10012997	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs13075842	ENSG00000230342.2	FANCD2P2	10.23	1.22e-21	1.48e-14	0.59	0.48	Alzheimer's disease;	chr3:10014129	chr3:11859674~11891172:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000204652.6	RPS26P8	10.23	1.22e-21	1.49e-14	0.5	0.48	Cognitive function;	chr12:56023144	chr17:45608571~45608918:+
STAD	trans	rs9611565	0.506	rs4822020	ENSG00000268568.1	AC007228.9	-10.23	1.27e-21	1.55e-14	-0.64	-0.48	Vitiligo;	chr22:41304199	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-10.22	1.31e-21	1.59e-14	-0.76	-0.48	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
STAD	trans	rs9611519	0.732	rs1883826	ENSG00000268568.1	AC007228.9	-10.22	1.31e-21	1.6e-14	-0.64	-0.48	Neuroticism;	chr22:41307424	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.604	rs34278750	ENSG00000276997.3	RP11-378J18.9	10.22	1.33e-21	1.61e-14	0.54	0.48	Corneal astigmatism;	chr4:119649981	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.604	rs10022185	ENSG00000276997.3	RP11-378J18.9	10.22	1.33e-21	1.61e-14	0.54	0.48	Corneal astigmatism;	chr4:119650610	chr1:222477252~222504622:-
STAD	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	10.22	1.34e-21	1.63e-14	0.57	0.48	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
STAD	trans	rs9611565	0.506	rs2024567	ENSG00000268568.1	AC007228.9	-10.22	1.34e-21	1.63e-14	-0.64	-0.48	Vitiligo;	chr22:41303202	chr19:56672574~56673901:-
STAD	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-10.22	1.37e-21	1.66e-14	-0.44	-0.48	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	10.22	1.37e-21	1.67e-14	0.51	0.48	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000204652.6	RPS26P8	10.2	1.52e-21	1.84e-14	0.5	0.48	Cognitive function;	chr12:56041628	chr17:45608571~45608918:+
STAD	trans	rs877636	1	rs2292239	ENSG00000224553.1	AC008065.1	10.2	1.57e-21	1.9e-14	0.51	0.48	Cognitive function;	chr12:56088396	chr2:171374931~171375278:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000204652.6	RPS26P8	10.2	1.61e-21	1.95e-14	0.5	0.48	Cognitive function;	chr12:56013288	chr17:45608571~45608918:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000204652.6	RPS26P8	10.2	1.61e-21	1.95e-14	0.5	0.48	Cognitive function;	chr12:56018703	chr17:45608571~45608918:+
STAD	trans	rs9611565	0.506	rs2024566	ENSG00000268568.1	AC007228.9	-10.2	1.62e-21	1.96e-14	-0.64	-0.48	Vitiligo;	chr22:41301334	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs877636	ENSG00000196933.5	RPS26P11	-10.19	1.63e-21	1.97e-14	-0.47	-0.48	Cognitive function;	chr12:56086799	chrX:72044545~72044892:+
STAD	trans	rs9611565	0.506	rs1984839	ENSG00000268568.1	AC007228.9	-10.19	1.64e-21	1.98e-14	-0.63	-0.48	Vitiligo;	chr22:41289933	chr19:56672574~56673901:-
STAD	trans	rs13177918	0.626	rs13175436	ENSG00000226396.1	RP5-1056L3.3	10.19	1.68e-21	2.03e-14	0.5	0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:19608114~19608568:+
STAD	trans	rs1552244	0.688	rs7645137	ENSG00000230342.2	FANCD2P2	10.19	1.68e-21	2.03e-14	0.61	0.48	Alzheimer's disease;	chr3:9978865	chr3:11859674~11891172:+
STAD	trans	rs916888	0.61	rs199436	ENSG00000263503.1	RP11-707O23.5	-10.19	1.75e-21	2.11e-14	-0.62	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45600869~45602340:-
STAD	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-10.18	1.84e-21	2.22e-14	-0.67	-0.48	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs2292239	ENSG00000233778.3	RP11-777J24.1	10.18	1.87e-21	2.25e-14	0.46	0.48	Cognitive function;	chr12:56088396	chr8:92144088~92144435:-
STAD	trans	rs877636	1	rs705696	ENSG00000212829.8	RPS26P3	10.17	1.92e-21	2.32e-14	0.48	0.48	Cognitive function;	chr12:56086864	chr9:9090898~9091245:+
STAD	trans	rs13177918	0.603	rs13175992	ENSG00000226396.1	RP5-1056L3.3	10.17	1.93e-21	2.33e-14	0.49	0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:19608114~19608568:+
STAD	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	10.16	2.06e-21	2.49e-14	0.56	0.48	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
STAD	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	10.16	2.16e-21	2.6e-14	0.51	0.48	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
STAD	trans	rs916888	0.61	rs199452	ENSG00000280022.1	RP11-707O23.1	10.16	2.18e-21	2.62e-14	0.6	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45592621~45593369:+
STAD	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	10.16	2.2e-21	2.65e-14	0.58	0.48	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000196656.7	AC004057.1	-10.15	2.32e-21	2.78e-14	-0.45	-0.48	Cognitive function;	chr12:56080595	chr4:113214046~113217170:-
STAD	trans	rs877636	1	rs2292239	ENSG00000196656.7	AC004057.1	10.15	2.39e-21	2.87e-14	0.44	0.48	Cognitive function;	chr12:56088396	chr4:113214046~113217170:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000227887.1	RPS26P13	10.14	2.44e-21	2.93e-14	0.54	0.48	Cognitive function;	chr12:56013288	chr1:208697369~208697698:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000227887.1	RPS26P13	10.14	2.44e-21	2.93e-14	0.54	0.48	Cognitive function;	chr12:56018703	chr1:208697369~208697698:-
STAD	trans	rs11098499	0.913	rs12186259	ENSG00000275858.1	RP11-291L22.8	10.14	2.45e-21	2.95e-14	0.55	0.48	Corneal astigmatism;	chr4:119230884	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	10.14	2.47e-21	2.96e-14	0.51	0.48	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
STAD	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	10.14	2.48e-21	2.98e-14	0.53	0.48	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
STAD	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-10.14	2.5e-21	2.99e-14	-0.65	-0.48	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000244604.1	RP11-713H12.1	-10.14	2.51e-21	3.01e-14	-0.46	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:8561230~8561576:+
STAD	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	10.14	2.53e-21	3.03e-14	0.65	0.48	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
STAD	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	10.14	2.55e-21	3.05e-14	0.75	0.48	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	10.14	2.55e-21	3.05e-14	0.75	0.48	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000227887.1	RPS26P13	10.14	2.56e-21	3.06e-14	0.54	0.48	Cognitive function;	chr12:56023144	chr1:208697369~208697698:-
STAD	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	10.13	2.68e-21	3.21e-14	0.7	0.48	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	10.13	2.69e-21	3.22e-14	0.52	0.48	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000204652.6	RPS26P8	10.13	2.71e-21	3.24e-14	0.5	0.48	Cognitive function;	chr12:56041720	chr17:45608571~45608918:+
STAD	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	10.13	2.8e-21	3.35e-14	0.68	0.48	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs877636	ENSG00000243538.1	CTB-55B8.1	-10.12	2.89e-21	3.45e-14	-0.49	-0.48	Cognitive function;	chr12:56086799	chr5:16902294~16902641:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000227586.5	RP11-162A23.5	10.11	3.09e-21	3.68e-14	0.54	0.48	Cognitive function;	chr12:56041720	chr10:123171535~123171875:-
STAD	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	10.11	3.17e-21	3.78e-14	0.57	0.48	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
STAD	trans	rs11098499	0.754	rs1814813	ENSG00000276997.3	RP11-378J18.9	-10.11	3.2e-21	3.82e-14	-0.54	-0.48	Corneal astigmatism;	chr4:119337052	chr1:222477252~222504622:-
STAD	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-10.1	3.37e-21	4.01e-14	-0.59	-0.48	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000227586.5	RP11-162A23.5	10.1	3.42e-21	4.07e-14	0.54	0.48	Cognitive function;	chr12:56009793	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	10.1	3.43e-21	4.08e-14	0.52	0.48	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.821	rs56155624	ENSG00000276997.3	RP11-378J18.9	10.1	3.46e-21	4.11e-14	0.55	0.48	Corneal astigmatism;	chr4:119369871	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs2292239	ENSG00000196933.5	RPS26P11	10.09	3.61e-21	4.28e-14	0.47	0.48	Cognitive function;	chr12:56088396	chrX:72044545~72044892:+
STAD	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-10.09	3.63e-21	4.32e-14	-0.81	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
STAD	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	10.09	3.68e-21	4.37e-14	0.52	0.48	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	10.09	3.83e-21	4.54e-14	0.51	0.48	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	10.09	3.83e-21	4.54e-14	0.51	0.48	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.532	rs4504231	ENSG00000276997.3	RP11-378J18.9	10.09	3.84e-21	4.55e-14	0.52	0.48	Corneal astigmatism;	chr4:119665736	chr1:222477252~222504622:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000227586.5	RP11-162A23.5	10.08	3.98e-21	4.72e-14	0.54	0.48	Cognitive function;	chr12:56002984	chr10:123171535~123171875:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	10.08	4.01e-21	4.75e-14	0.45	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000227586.5	RP11-162A23.5	10.08	4.04e-21	4.78e-14	0.54	0.48	Cognitive function;	chr12:56023144	chr10:123171535~123171875:-
STAD	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-10.08	4.08e-21	4.83e-14	-0.59	-0.48	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
STAD	trans	rs13177918	0.626	rs67026795	ENSG00000226396.1	RP5-1056L3.3	10.07	4.24e-21	5.02e-14	0.49	0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.603	rs10447222	ENSG00000226396.1	RP5-1056L3.3	10.07	4.24e-21	5.02e-14	0.49	0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:19608114~19608568:+
STAD	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-10.07	4.26e-21	5.04e-14	-0.59	-0.48	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
STAD	trans	rs877636	1	rs877636	ENSG00000224553.1	AC008065.1	-10.07	4.43e-21	5.23e-14	-0.51	-0.48	Cognitive function;	chr12:56086799	chr2:171374931~171375278:-
STAD	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	10.07	4.45e-21	5.25e-14	0.52	0.48	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
STAD	trans	rs13177918	0.626	rs3819332	ENSG00000226396.1	RP5-1056L3.3	10.07	4.53e-21	5.34e-14	0.49	0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.626	rs13170300	ENSG00000226396.1	RP5-1056L3.3	10.07	4.53e-21	5.34e-14	0.49	0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:19608114~19608568:+
STAD	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	10.06	4.54e-21	5.35e-14	0.52	0.48	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	10.06	4.54e-21	5.35e-14	0.52	0.48	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000243538.1	CTB-55B8.1	-10.06	4.64e-21	5.46e-14	-0.45	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr5:16902294~16902641:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000227887.1	RPS26P13	10.06	4.71e-21	5.55e-14	0.53	0.48	Cognitive function;	chr12:56041628	chr1:208697369~208697698:-
STAD	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	10.06	4.79e-21	5.63e-14	0.51	0.48	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-10.06	4.85e-21	5.7e-14	-0.45	-0.48	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
STAD	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	10.06	4.86e-21	5.72e-14	0.52	0.48	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000227586.5	RP11-162A23.5	10.05	4.92e-21	5.78e-14	0.54	0.48	Cognitive function;	chr12:56013288	chr10:123171535~123171875:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000227586.5	RP11-162A23.5	10.05	4.92e-21	5.78e-14	0.54	0.48	Cognitive function;	chr12:56018703	chr10:123171535~123171875:-
STAD	trans	rs1552244	0.882	rs13099136	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9989747	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.744	rs6763366	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9991860	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.51	rs13075308	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9993241	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.808	rs7615088	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9994212	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs17050699	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9995483	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs61429272	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9995636	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs2030564	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9997360	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs9757159	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9997482	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.816	rs17050701	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:9999870	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs55840655	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:10001006	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.816	rs56387520	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:10001098	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs56224841	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:10002330	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs13088350	ENSG00000230342.2	FANCD2P2	10.05	5e-21	5.85e-14	0.58	0.48	Alzheimer's disease;	chr3:10002942	chr3:11859674~11891172:+
STAD	trans	rs877636	1	rs877636	ENSG00000239210.2	RPS26P55	-10.05	5.05e-21	5.91e-14	-0.51	-0.48	Cognitive function;	chr12:56086799	chr19:34533427~34534084:-
STAD	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	10.05	5.07e-21	5.93e-14	0.53	0.48	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
STAD	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-10.05	5.16e-21	6.04e-14	-0.59	-0.48	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
STAD	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	10.05	5.21e-21	6.1e-14	0.56	0.48	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
STAD	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-10.04	5.43e-21	6.35e-14	-0.45	-0.48	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
STAD	trans	rs877636	0.701	rs34415530	ENSG00000227586.5	RP11-162A23.5	10.04	5.62e-21	6.56e-14	0.54	0.47	Cognitive function;	chr12:56050848	chr10:123171535~123171875:-
STAD	trans	rs877636	1	rs705696	ENSG00000196656.7	AC004057.1	10.04	5.66e-21	6.61e-14	0.46	0.47	Cognitive function;	chr12:56086864	chr4:113214046~113217170:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000223416.3	RPS26P15	10.04	5.68e-21	6.63e-14	0.52	0.47	Cognitive function;	chr12:56050848	chr1:58056133~58056480:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000233778.3	RP11-777J24.1	-10.03	5.76e-21	6.72e-14	-0.46	-0.47	Cognitive function;	chr12:56080595	chr8:92144088~92144435:-
STAD	trans	rs9611565	0.506	rs1883825	ENSG00000268568.1	AC007228.9	-10.03	5.8e-21	6.76e-14	-0.64	-0.47	Vitiligo;	chr22:41307404	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.525	rs1883827	ENSG00000268568.1	AC007228.9	-10.03	5.8e-21	6.76e-14	-0.64	-0.47	Vitiligo;	chr22:41307575	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-10.03	5.8e-21	6.76e-14	-0.68	-0.47	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
STAD	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	10.03	5.82e-21	6.79e-14	0.54	0.47	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
STAD	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	10.03	6.04e-21	7.04e-14	0.52	0.47	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	10.03	6.04e-21	7.04e-14	0.52	0.47	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs10028773	ENSG00000276997.3	RP11-378J18.9	-10.03	6.14e-21	7.15e-14	-0.5	-0.47	Corneal astigmatism;	chr4:119344104	chr1:222477252~222504622:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000233778.3	RP11-777J24.1	10.02	6.21e-21	7.23e-14	0.5	0.47	Cognitive function;	chr12:56050848	chr8:92144088~92144435:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000223416.3	RPS26P15	10.02	6.41e-21	7.45e-14	0.52	0.47	Cognitive function;	chr12:56009793	chr1:58056133~58056480:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000227887.1	RPS26P13	10.02	6.46e-21	7.5e-14	0.53	0.47	Cognitive function;	chr12:56041720	chr1:208697369~208697698:-
STAD	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-10.02	6.55e-21	7.61e-14	-0.75	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
STAD	trans	rs877636	0.847	rs705704	ENSG00000227586.5	RP11-162A23.5	10.02	6.66e-21	7.73e-14	0.54	0.47	Cognitive function;	chr12:56041628	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	10.01	6.86e-21	7.95e-14	0.52	0.47	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	10.01	6.86e-21	7.95e-14	0.52	0.47	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	10.01	6.86e-21	7.95e-14	0.52	0.47	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
STAD	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	10	7.38e-21	8.55e-14	0.56	0.47	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
STAD	trans	rs1552244	0.626	rs2886396	ENSG00000230342.2	FANCD2P2	10	7.41e-21	8.58e-14	0.57	0.47	Alzheimer's disease;	chr3:9995986	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.569	rs6002328	ENSG00000268568.1	AC007228.9	-10	7.5e-21	8.68e-14	-0.62	-0.47	Vitiligo;	chr22:41314030	chr19:56672574~56673901:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000244604.1	RP11-713H12.1	10	7.6e-21	8.8e-14	0.48	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:8561230~8561576:+
STAD	trans	rs877636	1	rs4759229	ENSG00000233778.3	RP11-777J24.1	-10	7.77e-21	8.98e-14	-0.46	-0.47	Cognitive function;	chr12:56080696	chr8:92144088~92144435:-
STAD	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	9.99	7.87e-21	9.1e-14	0.64	0.47	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs4759229	ENSG00000243538.1	CTB-55B8.1	-9.99	7.87e-21	9.1e-14	-0.49	-0.47	Cognitive function;	chr12:56080696	chr5:16902294~16902641:-
STAD	trans	rs916888	0.531	rs183211	ENSG00000263503.1	RP11-707O23.5	9.99	8.11e-21	9.37e-14	0.61	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45600869~45602340:-
STAD	trans	rs916888	0.61	rs199453	ENSG00000263503.1	RP11-707O23.5	9.99	8.14e-21	9.4e-14	0.61	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45600869~45602340:-
STAD	trans	rs916888	0.61	rs199438	ENSG00000263503.1	RP11-707O23.5	9.99	8.42e-21	9.72e-14	0.62	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45600869~45602340:-
STAD	trans	rs11098499	0.644	rs17517414	ENSG00000276997.3	RP11-378J18.9	9.98	8.8e-21	1.01e-13	0.51	0.47	Corneal astigmatism;	chr4:119340946	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	9.98	8.83e-21	1.02e-13	0.52	0.47	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	9.98	8.85e-21	1.02e-13	0.66	0.47	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000243538.1	CTB-55B8.1	-9.98	8.87e-21	1.02e-13	-0.49	-0.47	Cognitive function;	chr12:56080595	chr5:16902294~16902641:-
STAD	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	9.98	9.09e-21	1.05e-13	0.44	0.47	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000224553.1	AC008065.1	-9.98	9.17e-21	1.06e-13	-0.51	-0.47	Cognitive function;	chr12:56080595	chr2:171374931~171375278:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	9.97	9.38e-21	1.08e-13	0.44	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	9.97	9.66e-21	1.11e-13	0.51	0.47	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
STAD	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	9.96	9.96e-21	1.14e-13	0.56	0.47	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
STAD	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	9.96	9.96e-21	1.14e-13	0.56	0.47	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
STAD	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	9.96	1.04e-20	1.2e-13	0.52	0.47	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	9.96	1.05e-20	1.21e-13	0.7	0.47	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	9.96	1.06e-20	1.21e-13	0.51	0.47	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	9.95	1.11e-20	1.28e-13	0.64	0.47	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
STAD	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	9.95	1.13e-20	1.3e-13	0.44	0.47	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000233278.1	RPS26P2	-9.95	1.16e-20	1.33e-13	-0.48	-0.47	Cognitive function;	chr12:56042145	chr9:30831878~30832225:-
STAD	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	9.94	1.16e-20	1.33e-13	0.57	0.47	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
STAD	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-9.94	1.17e-20	1.34e-13	-0.66	-0.47	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
STAD	trans	rs8081395	0.627	rs180536	ENSG00000187870.7	RNFT1P3	9.94	1.18e-20	1.35e-13	0.53	0.47	White blood cell count;	chr17:59919445	chr17:20743333~20754501:-
STAD	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-9.94	1.2e-20	1.37e-13	-0.78	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
STAD	trans	rs7930295	0.558	rs34743519	ENSG00000236257.1	EI24P2	9.93	1.31e-20	1.49e-13	0.78	0.47	Schizophrenia;	chr11:125483367	chr1:158454198~158455273:+
STAD	trans	rs11098499	0.779	rs6815934	ENSG00000276997.3	RP11-378J18.9	9.93	1.31e-20	1.5e-13	0.5	0.47	Corneal astigmatism;	chr4:119346155	chr1:222477252~222504622:-
STAD	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	9.93	1.34e-20	1.52e-13	0.56	0.47	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
STAD	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-9.93	1.35e-20	1.53e-13	-0.59	-0.47	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
STAD	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	9.92	1.36e-20	1.55e-13	0.7	0.47	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	9.92	1.36e-20	1.55e-13	0.7	0.47	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
STAD	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-9.92	1.39e-20	1.58e-13	-0.52	-0.47	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
STAD	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	9.92	1.44e-20	1.64e-13	0.52	0.47	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	9.92	1.44e-20	1.64e-13	0.52	0.47	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.572	rs59132826	ENSG00000230342.2	FANCD2P2	9.92	1.46e-20	1.66e-13	0.72	0.47	Alzheimer's disease;	chr3:10128041	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs58223482	ENSG00000230342.2	FANCD2P2	9.92	1.46e-20	1.66e-13	0.72	0.47	Alzheimer's disease;	chr3:10128062	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs113406084	ENSG00000230342.2	FANCD2P2	9.92	1.46e-20	1.66e-13	0.72	0.47	Alzheimer's disease;	chr3:10128506	chr3:11859674~11891172:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000223416.3	RPS26P15	9.92	1.46e-20	1.66e-13	0.52	0.47	Cognitive function;	chr12:56013288	chr1:58056133~58056480:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000223416.3	RPS26P15	9.92	1.46e-20	1.66e-13	0.52	0.47	Cognitive function;	chr12:56018703	chr1:58056133~58056480:-
STAD	trans	rs11098499	0.661	rs10015965	ENSG00000276997.3	RP11-378J18.9	9.91	1.47e-20	1.67e-13	0.5	0.47	Corneal astigmatism;	chr4:119347082	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.6	rs4001390	ENSG00000276997.3	RP11-378J18.9	9.91	1.49e-20	1.7e-13	0.5	0.47	Educational attainment;	chr4:119344628	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.691	rs2136911	ENSG00000276997.3	RP11-378J18.9	9.91	1.49e-20	1.7e-13	0.5	0.47	Corneal astigmatism;	chr4:119344704	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.554	rs2175381	ENSG00000276997.3	RP11-378J18.9	9.91	1.49e-20	1.7e-13	0.5	0.47	Corneal astigmatism;	chr4:119344812	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.599	rs3864142	ENSG00000276997.3	RP11-378J18.9	9.91	1.49e-20	1.7e-13	0.5	0.47	Corneal astigmatism;	chr4:119345036	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.605	rs6833140	ENSG00000276997.3	RP11-378J18.9	9.91	1.49e-20	1.7e-13	0.5	0.47	Corneal astigmatism;	chr4:119345667	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.568	rs6838457	ENSG00000276997.3	RP11-378J18.9	9.91	1.49e-20	1.7e-13	0.5	0.47	Educational attainment;	chr4:119346212	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.535	rs10005542	ENSG00000276997.3	RP11-378J18.9	9.91	1.49e-20	1.7e-13	0.5	0.47	Corneal astigmatism;	chr4:119347147	chr1:222477252~222504622:-
STAD	trans	rs12709013	0.591	rs149479	ENSG00000230849.2	GOT2P2	-9.91	1.52e-20	1.73e-13	-0.54	-0.47	Blood metabolite ratios;	chr16:58703171	chr1:173141100~173142350:-
STAD	trans	rs10028773	0.666	rs12498657	ENSG00000276997.3	RP11-378J18.9	9.91	1.54e-20	1.74e-13	0.51	0.47	Educational attainment;	chr4:119341711	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000233778.3	RP11-777J24.1	9.91	1.55e-20	1.76e-13	0.49	0.47	Cognitive function;	chr12:56009793	chr8:92144088~92144435:-
STAD	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	9.91	1.57e-20	1.77e-13	0.56	0.47	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
STAD	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	9.9	1.6e-20	1.81e-13	0.74	0.47	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
STAD	trans	rs10028773	0.632	rs34481394	ENSG00000275858.1	RP11-291L22.8	9.9	1.64e-20	1.85e-13	0.52	0.47	Educational attainment;	chr4:119327219	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.666	rs35231872	ENSG00000275858.1	RP11-291L22.8	9.9	1.64e-20	1.85e-13	0.52	0.47	Educational attainment;	chr4:119327221	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.7	rs35653026	ENSG00000275858.1	RP11-291L22.8	9.9	1.64e-20	1.85e-13	0.52	0.47	Educational attainment;	chr4:119327223	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	9.9	1.64e-20	1.86e-13	0.63	0.47	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
STAD	trans	rs8081395	0.627	rs12952730	ENSG00000187870.7	RNFT1P3	9.9	1.66e-20	1.88e-13	0.53	0.47	White blood cell count;	chr17:59901475	chr17:20743333~20754501:-
STAD	trans	rs916888	0.61	rs199436	ENSG00000280022.1	RP11-707O23.1	-9.9	1.68e-20	1.9e-13	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45592621~45593369:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000223416.3	RPS26P15	9.9	1.69e-20	1.91e-13	0.52	0.47	Cognitive function;	chr12:56023144	chr1:58056133~58056480:-
STAD	trans	rs877636	1	rs4759229	ENSG00000224553.1	AC008065.1	-9.89	1.75e-20	1.97e-13	-0.51	-0.47	Cognitive function;	chr12:56080696	chr2:171374931~171375278:-
STAD	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-9.89	1.76e-20	1.98e-13	-0.58	-0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
STAD	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-9.89	1.79e-20	2.02e-13	-0.43	-0.47	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-9.89	1.79e-20	2.02e-13	-0.43	-0.47	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
STAD	trans	rs916888	0.647	rs199449	ENSG00000280022.1	RP11-707O23.1	9.89	1.8e-20	2.03e-13	0.59	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45592621~45593369:+
STAD	trans	rs1552244	0.572	rs6785976	ENSG00000230342.2	FANCD2P2	9.89	1.82e-20	2.05e-13	0.73	0.47	Alzheimer's disease;	chr3:10126963	chr3:11859674~11891172:+
STAD	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-9.89	1.84e-20	2.07e-13	-0.44	-0.47	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	9.89	1.85e-20	2.08e-13	0.51	0.47	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
STAD	trans	rs8081395	0.603	rs1292047	ENSG00000187870.7	RNFT1P3	9.88	1.87e-20	2.1e-13	0.53	0.47	White blood cell count;	chr17:59877805	chr17:20743333~20754501:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	9.88	1.93e-20	2.17e-13	0.51	0.47	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.722	rs10006192	ENSG00000276997.3	RP11-378J18.9	9.88	2e-20	2.25e-13	0.5	0.47	Corneal astigmatism;	chr4:119341867	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.615	rs28551750	ENSG00000276997.3	RP11-378J18.9	9.88	2e-20	2.25e-13	0.5	0.47	Corneal astigmatism;	chr4:119343746	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.691	rs9995716	ENSG00000276997.3	RP11-378J18.9	9.88	2e-20	2.25e-13	0.5	0.47	Corneal astigmatism;	chr4:119343841	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs705696	ENSG00000233778.3	RP11-777J24.1	9.87	2.03e-20	2.28e-13	0.47	0.47	Cognitive function;	chr12:56086864	chr8:92144088~92144435:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000233778.3	RP11-777J24.1	9.87	2.05e-20	2.3e-13	0.49	0.47	Cognitive function;	chr12:56041720	chr8:92144088~92144435:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000233778.3	RP11-777J24.1	9.86	2.18e-20	2.44e-13	0.49	0.47	Cognitive function;	chr12:56013288	chr8:92144088~92144435:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000233778.3	RP11-777J24.1	9.86	2.18e-20	2.44e-13	0.49	0.47	Cognitive function;	chr12:56018703	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.604	rs17051352	ENSG00000276997.3	RP11-378J18.9	9.86	2.22e-20	2.48e-13	0.54	0.47	Corneal astigmatism;	chr4:119660272	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	9.86	2.23e-20	2.49e-13	0.51	0.47	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs12510133	ENSG00000276997.3	RP11-378J18.9	9.86	2.24e-20	2.49e-13	0.5	0.47	Corneal astigmatism;	chr4:119350189	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.754	rs12506487	ENSG00000276997.3	RP11-378J18.9	9.86	2.24e-20	2.49e-13	0.5	0.47	Corneal astigmatism;	chr4:119350206	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.691	rs12502524	ENSG00000276997.3	RP11-378J18.9	9.86	2.24e-20	2.49e-13	0.5	0.47	Corneal astigmatism;	chr4:119350259	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.691	rs28396837	ENSG00000276997.3	RP11-378J18.9	9.86	2.24e-20	2.49e-13	0.5	0.47	Corneal astigmatism;	chr4:119350386	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.629	rs28369518	ENSG00000276997.3	RP11-378J18.9	9.86	2.24e-20	2.49e-13	0.5	0.47	Corneal astigmatism;	chr4:119350475	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000223416.3	RPS26P15	9.85	2.39e-20	2.65e-13	0.52	0.47	Cognitive function;	chr12:56041628	chr1:58056133~58056480:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000233778.3	RP11-777J24.1	9.85	2.39e-20	2.66e-13	0.49	0.47	Cognitive function;	chr12:56023144	chr8:92144088~92144435:-
STAD	trans	rs916888	0.61	rs142167	ENSG00000263503.1	RP11-707O23.5	-9.85	2.43e-20	2.7e-13	-0.61	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45600869~45602340:-
STAD	trans	rs1552244	0.882	rs13084194	ENSG00000230342.2	FANCD2P2	9.85	2.44e-20	2.71e-13	0.59	0.47	Alzheimer's disease;	chr3:9989808	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs13099507	ENSG00000230342.2	FANCD2P2	9.85	2.44e-20	2.71e-13	0.59	0.47	Alzheimer's disease;	chr3:9989919	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs55962400	ENSG00000230342.2	FANCD2P2	9.85	2.44e-20	2.71e-13	0.59	0.47	Alzheimer's disease;	chr3:10002773	chr3:11859674~11891172:+
STAD	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-9.85	2.46e-20	2.72e-13	-0.78	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000242970.2	AC068522.4	9.85	2.46e-20	2.73e-13	0.47	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:58588420~58588764:-
STAD	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-9.84	2.54e-20	2.82e-13	-0.68	-0.47	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
STAD	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	9.84	2.59e-20	2.88e-13	0.53	0.47	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
STAD	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	9.84	2.65e-20	2.93e-13	0.68	0.47	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
STAD	trans	rs10028773	0.632	rs34481394	ENSG00000276997.3	RP11-378J18.9	9.84	2.66e-20	2.95e-13	0.53	0.47	Educational attainment;	chr4:119327219	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.666	rs35231872	ENSG00000276997.3	RP11-378J18.9	9.84	2.66e-20	2.95e-13	0.53	0.47	Educational attainment;	chr4:119327221	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.7	rs35653026	ENSG00000276997.3	RP11-378J18.9	9.84	2.66e-20	2.95e-13	0.53	0.47	Educational attainment;	chr4:119327223	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.572	rs6442154	ENSG00000230342.2	FANCD2P2	9.84	2.68e-20	2.97e-13	0.69	0.47	Alzheimer's disease;	chr3:10127101	chr3:11859674~11891172:+
STAD	trans	rs877636	0.847	rs705704	ENSG00000233778.3	RP11-777J24.1	9.84	2.68e-20	2.97e-13	0.49	0.47	Cognitive function;	chr12:56041628	chr8:92144088~92144435:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000233778.3	RP11-777J24.1	9.83	2.78e-20	3.08e-13	0.49	0.47	Cognitive function;	chr12:56002984	chr8:92144088~92144435:-
STAD	trans	rs1552244	0.882	rs13064570	ENSG00000230342.2	FANCD2P2	9.83	2.8e-20	3.1e-13	0.61	0.47	Alzheimer's disease;	chr3:9955861	chr3:11859674~11891172:+
STAD	trans	rs13190036	1	rs6889220	ENSG00000228305.2	AC016734.2	9.83	2.92e-20	3.22e-13	0.52	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr2:63622178~63622831:-
STAD	trans	rs916888	0.61	rs199444	ENSG00000280022.1	RP11-707O23.1	9.83	2.95e-20	3.26e-13	0.58	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45592621~45593369:+
STAD	trans	rs916888	0.61	rs199442	ENSG00000280022.1	RP11-707O23.1	9.83	2.95e-20	3.26e-13	0.58	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45592621~45593369:+
STAD	trans	rs1552244	0.515	rs111560858	ENSG00000230342.2	FANCD2P2	9.82	3.02e-20	3.34e-13	0.72	0.47	Alzheimer's disease;	chr3:10125161	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.748	rs9862221	ENSG00000230342.2	FANCD2P2	9.82	3.03e-20	3.34e-13	0.58	0.47	Alzheimer's disease;	chr3:10017974	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.691	rs17009144	ENSG00000276997.3	RP11-378J18.9	-9.82	3.04e-20	3.35e-13	-0.5	-0.47	Corneal astigmatism;	chr4:119349640	chr1:222477252~222504622:-
STAD	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-9.81	3.3e-20	3.64e-13	-0.43	-0.47	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
STAD	trans	rs1552244	0.572	rs57268864	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10122549	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs59074548	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10122663	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs3774208	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10123038	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs6783705	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10123099	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs68013239	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10124027	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs68121641	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10124161	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.515	rs67342818	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10124722	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs66514627	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10124948	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs3894322	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10127281	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs3894323	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10127283	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.572	rs67439440	ENSG00000230342.2	FANCD2P2	9.81	3.31e-20	3.64e-13	0.72	0.47	Alzheimer's disease;	chr3:10127819	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000234513.1	AC073072.7	9.81	3.33e-20	3.67e-13	0.47	0.47	Cognitive function;	chr12:55981956	chr7:22773646~22773993:-
STAD	trans	rs9611565	0.572	rs139569	ENSG00000268568.1	AC007228.9	-9.81	3.41e-20	3.75e-13	-0.65	-0.47	Vitiligo;	chr22:41815137	chr19:56672574~56673901:-
STAD	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-9.8	3.59e-20	3.94e-13	-0.43	-0.47	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
STAD	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	9.8	3.59e-20	3.95e-13	0.63	0.47	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
STAD	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	9.8	3.6e-20	3.96e-13	0.55	0.47	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
STAD	trans	rs8067354	0.789	rs1292068	ENSG00000187870.7	RNFT1P3	9.8	3.62e-20	3.98e-13	0.53	0.47	Hemoglobin concentration;	chr17:59851958	chr17:20743333~20754501:-
STAD	trans	rs1552244	0.816	rs13059144	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9968513	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs66559400	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9970867	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs68153882	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9971426	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs3732967	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9973753	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs3732966	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9974056	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs13062917	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9975348	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.816	rs13076197	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9978089	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs34779351	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9980117	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs13077641	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9981251	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs13074282	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9983015	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs67895180	ENSG00000230342.2	FANCD2P2	9.79	3.73e-20	4.09e-13	0.57	0.47	Alzheimer's disease;	chr3:9984395	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	9.78	4.03e-20	4.41e-13	0.5	0.47	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000223416.3	RPS26P15	9.78	4.16e-20	4.55e-13	0.51	0.47	Cognitive function;	chr12:56041720	chr1:58056133~58056480:-
STAD	trans	rs11098499	0.691	rs10010355	ENSG00000276997.3	RP11-378J18.9	9.78	4.24e-20	4.63e-13	0.5	0.47	Corneal astigmatism;	chr4:119339888	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.691	rs9307471	ENSG00000276997.3	RP11-378J18.9	9.78	4.24e-20	4.63e-13	0.5	0.47	Corneal astigmatism;	chr4:119340107	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000234513.1	AC073072.7	9.78	4.26e-20	4.65e-13	0.47	0.47	Cognitive function;	chr12:55982097	chr7:22773646~22773993:-
STAD	trans	rs1552244	0.882	rs13089863	ENSG00000230342.2	FANCD2P2	-9.78	4.26e-20	4.65e-13	-0.56	-0.47	Alzheimer's disease;	chr3:9990575	chr3:11859674~11891172:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000196933.5	RPS26P11	9.78	4.27e-20	4.66e-13	0.44	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:72044545~72044892:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000234192.1	RP11-57C13.5	9.77	4.36e-20	4.76e-13	0.47	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:87642607~87642954:+
STAD	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-9.77	4.43e-20	4.83e-13	-0.43	-0.47	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-9.77	4.43e-20	4.83e-13	-0.43	-0.47	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
STAD	trans	rs1552244	0.882	rs6443276	ENSG00000230342.2	FANCD2P2	9.77	4.52e-20	4.93e-13	0.56	0.47	Alzheimer's disease;	chr3:9967221	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs34706481	ENSG00000230342.2	FANCD2P2	9.77	4.54e-20	4.95e-13	0.58	0.46	Alzheimer's disease;	chr3:9962439	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs3755782	ENSG00000230342.2	FANCD2P2	9.77	4.55e-20	4.96e-13	0.57	0.46	Alzheimer's disease;	chr3:9987621	chr3:11859674~11891172:+
STAD	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-9.77	4.58e-20	4.99e-13	-0.43	-0.46	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-9.77	4.58e-20	4.99e-13	-0.43	-0.46	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-9.77	4.58e-20	4.99e-13	-0.43	-0.46	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
STAD	trans	rs1552244	0.882	rs68080705	ENSG00000230342.2	FANCD2P2	9.77	4.65e-20	5.06e-13	0.57	0.46	Alzheimer's disease;	chr3:9984059	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000235459.5	RPS26P31	9.77	4.67e-20	5.08e-13	0.51	0.46	Cognitive function;	chr12:55976127	chr7:122681315~122681662:+
STAD	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-9.76	4.81e-20	5.24e-13	-0.74	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000235459.5	RPS26P31	9.76	5.01e-20	5.44e-13	0.55	0.46	Cognitive function;	chr12:56055651	chr7:122681315~122681662:+
STAD	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	9.76	5.05e-20	5.48e-13	0.69	0.46	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000234513.1	AC073072.7	9.76	5.08e-20	5.51e-13	0.47	0.46	Cognitive function;	chr12:55981353	chr7:22773646~22773993:-
STAD	trans	rs11098499	0.722	rs10025925	ENSG00000276997.3	RP11-378J18.9	9.75	5.09e-20	5.52e-13	0.5	0.46	Corneal astigmatism;	chr4:119350589	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.731	rs10015579	ENSG00000276997.3	RP11-378J18.9	9.75	5.09e-20	5.52e-13	0.5	0.46	Corneal astigmatism;	chr4:119350647	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	9.75	5.23e-20	5.67e-13	0.66	0.46	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	9.75	5.23e-20	5.67e-13	0.66	0.46	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
STAD	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-9.75	5.36e-20	5.8e-13	-0.77	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
STAD	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-9.75	5.36e-20	5.8e-13	-0.77	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
STAD	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-9.75	5.36e-20	5.8e-13	-0.77	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
STAD	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-9.75	5.36e-20	5.8e-13	-0.77	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
STAD	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-9.75	5.36e-20	5.8e-13	-0.77	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	9.75	5.38e-20	5.82e-13	0.5	0.46	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000233278.1	RPS26P2	-9.75	5.42e-20	5.87e-13	-0.48	-0.46	Cognitive function;	chr12:56007301	chr9:30831878~30832225:-
STAD	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-9.74	5.65e-20	6.11e-13	-0.43	-0.46	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
STAD	trans	rs1552244	0.882	rs56125067	ENSG00000230342.2	FANCD2P2	9.74	5.74e-20	6.2e-13	0.59	0.46	Alzheimer's disease;	chr3:9942446	chr3:11859674~11891172:+
STAD	trans	rs916888	0.531	rs183211	ENSG00000280022.1	RP11-707O23.1	9.73	6.05e-20	6.54e-13	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45592621~45593369:+
STAD	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	9.73	6.24e-20	6.73e-13	0.66	0.46	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	9.73	6.24e-20	6.73e-13	0.66	0.46	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000234354.3	RPS26P47	-9.73	6.26e-20	6.76e-13	-0.57	-0.46	Cognitive function;	chr12:56007301	chr13:100539901~100540248:-
STAD	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-9.73	6.32e-20	6.82e-13	-0.77	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
STAD	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-9.73	6.32e-20	6.82e-13	-0.77	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
STAD	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	9.73	6.38e-20	6.88e-13	0.66	0.46	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	9.72	6.44e-20	6.94e-13	0.5	0.46	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	9.72	6.45e-20	6.94e-13	0.51	0.46	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
STAD	trans	rs1552244	0.882	rs13100734	ENSG00000230342.2	FANCD2P2	9.72	6.54e-20	7.05e-13	0.56	0.46	Alzheimer's disease;	chr3:9981194	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs35056669	ENSG00000230342.2	FANCD2P2	9.72	6.58e-20	7.08e-13	0.57	0.46	Alzheimer's disease;	chr3:9972487	chr3:11859674~11891172:+
STAD	trans	rs916888	0.61	rs199453	ENSG00000280022.1	RP11-707O23.1	9.72	6.66e-20	7.16e-13	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45592621~45593369:+
STAD	trans	rs1552244	0.572	rs3843008	ENSG00000230342.2	FANCD2P2	9.72	6.66e-20	7.17e-13	0.71	0.46	Alzheimer's disease;	chr3:10132058	chr3:11859674~11891172:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000242970.2	AC068522.4	9.72	6.77e-20	7.28e-13	0.46	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:58588420~58588764:-
STAD	trans	rs877636	1	rs705696	ENSG00000212994.5	RPS26P6	9.72	6.8e-20	7.3e-13	0.45	0.46	Cognitive function;	chr12:56086864	chr8:100895771~100896118:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	9.72	6.87e-20	7.38e-13	0.5	0.46	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.722	rs17595727	ENSG00000276997.3	RP11-378J18.9	-9.72	6.87e-20	7.38e-13	-0.5	-0.46	Corneal astigmatism;	chr4:119340919	chr1:222477252~222504622:-
STAD	trans	rs916888	0.61	rs199438	ENSG00000280022.1	RP11-707O23.1	9.72	6.88e-20	7.39e-13	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45592621~45593369:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000234354.3	RPS26P47	-9.72	6.91e-20	7.42e-13	-0.56	-0.46	Cognitive function;	chr12:56042145	chr13:100539901~100540248:-
STAD	trans	rs11098499	0.913	rs56122576	ENSG00000276997.3	RP11-378J18.9	9.71	7e-20	7.51e-13	0.52	0.46	Corneal astigmatism;	chr4:119208181	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.913	rs68128210	ENSG00000276997.3	RP11-378J18.9	9.71	7e-20	7.51e-13	0.52	0.46	Corneal astigmatism;	chr4:119216664	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.913	rs13126596	ENSG00000276997.3	RP11-378J18.9	9.71	7e-20	7.51e-13	0.52	0.46	Corneal astigmatism;	chr4:119219574	chr1:222477252~222504622:-
STAD	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	9.71	7.03e-20	7.53e-13	0.52	0.46	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000233278.1	RPS26P2	-9.71	7.07e-20	7.57e-13	-0.46	-0.46	Cognitive function;	chr12:56080024	chr9:30831878~30832225:-
STAD	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	9.7	7.5e-20	8.04e-13	0.51	0.46	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
STAD	trans	rs13177918	0.559	rs12109637	ENSG00000226396.1	RP5-1056L3.3	9.7	7.75e-20	8.3e-13	0.47	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:19608114~19608568:+
STAD	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	9.7	7.81e-20	8.36e-13	0.66	0.46	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	9.7	7.81e-20	8.36e-13	0.66	0.46	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
STAD	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-9.7	8e-20	8.56e-13	-0.62	-0.46	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000234513.1	AC073072.7	9.69	8.28e-20	8.86e-13	0.47	0.46	Cognitive function;	chr12:55988132	chr7:22773646~22773993:-
STAD	trans	rs11098499	0.532	rs4504231	ENSG00000275858.1	RP11-291L22.8	9.69	8.35e-20	8.93e-13	0.5	0.46	Corneal astigmatism;	chr4:119665736	chr10:38450738~38451069:-
STAD	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	9.69	8.38e-20	8.97e-13	0.56	0.46	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
STAD	trans	rs877636	1	rs4759229	ENSG00000239210.2	RPS26P55	-9.69	8.42e-20	9e-13	-0.5	-0.46	Cognitive function;	chr12:56080696	chr19:34533427~34534084:-
STAD	trans	rs1552244	0.572	rs7645759	ENSG00000230342.2	FANCD2P2	9.69	8.48e-20	9.07e-13	0.71	0.46	Alzheimer's disease;	chr3:10115684	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.644	rs3986377	ENSG00000276997.3	RP11-378J18.9	9.68	8.76e-20	9.35e-13	0.5	0.46	Corneal astigmatism;	chr4:119339115	chr1:222477252~222504622:-
STAD	trans	rs10028773	0.556	rs4473640	ENSG00000276997.3	RP11-378J18.9	9.68	8.76e-20	9.35e-13	0.5	0.46	Educational attainment;	chr4:119339282	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.572	rs73117481	ENSG00000230342.2	FANCD2P2	9.68	8.77e-20	9.36e-13	0.71	0.46	Alzheimer's disease;	chr3:10118448	chr3:11859674~11891172:+
STAD	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-9.68	9.07e-20	9.67e-13	-0.43	-0.46	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
STAD	trans	rs1552244	0.882	rs17050672	ENSG00000230342.2	FANCD2P2	9.68	9.13e-20	9.74e-13	0.59	0.46	Alzheimer's disease;	chr3:9983779	chr3:11859674~11891172:+
STAD	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	9.68	9.26e-20	9.86e-13	0.51	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
STAD	trans	rs9611565	0.571	rs7364123	ENSG00000268568.1	AC007228.9	-9.67	1e-19	1.07e-12	-0.64	-0.46	Vitiligo;	chr22:41820322	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs877636	ENSG00000242970.2	AC068522.4	-9.66	1.03e-19	1.09e-12	-0.48	-0.46	Cognitive function;	chr12:56086799	chr8:58588420~58588764:-
STAD	trans	rs1552244	0.572	rs17032426	ENSG00000230342.2	FANCD2P2	9.66	1.03e-19	1.1e-12	0.7	0.46	Alzheimer's disease;	chr3:10125428	chr3:11859674~11891172:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	9.66	1.04e-19	1.1e-12	0.42	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
STAD	trans	rs13190036	1	rs4976682	ENSG00000228305.2	AC016734.2	9.65	1.1e-19	1.17e-12	0.52	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr2:63622178~63622831:-
STAD	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	9.65	1.11e-19	1.17e-12	0.67	0.46	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
STAD	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-9.65	1.14e-19	1.21e-12	-0.76	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
STAD	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	9.65	1.16e-19	1.23e-12	0.52	0.46	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	9.65	1.16e-19	1.23e-12	0.52	0.46	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	9.65	1.16e-19	1.23e-12	0.52	0.46	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
STAD	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	9.65	1.17e-19	1.24e-12	0.77	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
STAD	trans	rs13177918	1	rs35007082	ENSG00000226396.1	RP5-1056L3.3	9.65	1.18e-19	1.25e-12	0.53	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:19608114~19608568:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000244604.1	RP11-713H12.1	9.65	1.18e-19	1.25e-12	0.46	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:8561230~8561576:+
STAD	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	9.64	1.19e-19	1.26e-12	0.52	0.46	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
STAD	trans	rs9611565	0.607	rs132792	ENSG00000268568.1	AC007228.9	9.64	1.19e-19	1.26e-12	0.65	0.46	Vitiligo;	chr22:41666818	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.604	rs12642411	ENSG00000276997.3	RP11-378J18.9	9.64	1.21e-19	1.28e-12	0.53	0.46	Corneal astigmatism;	chr4:119659370	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	9.64	1.21e-19	1.28e-12	0.5	0.46	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
STAD	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	9.64	1.22e-19	1.29e-12	0.5	0.46	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
STAD	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
STAD	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
STAD	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
STAD	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-9.64	1.24e-19	1.31e-12	-0.43	-0.46	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.874	rs13123591	ENSG00000275858.1	RP11-291L22.8	9.64	1.24e-19	1.31e-12	0.52	0.46	Corneal astigmatism;	chr4:119184835	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs7661020	ENSG00000275858.1	RP11-291L22.8	9.64	1.24e-19	1.31e-12	0.52	0.46	Corneal astigmatism;	chr4:119185827	chr10:38450738~38451069:-
STAD	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	9.63	1.28e-19	1.35e-12	0.52	0.46	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
STAD	trans	rs7930295	1	rs10893380	ENSG00000236257.1	EI24P2	-9.63	1.32e-19	1.39e-12	-0.73	-0.46	Schizophrenia;	chr11:125441778	chr1:158454198~158455273:+
STAD	trans	rs877636	0.701	rs34415530	ENSG00000224553.1	AC008065.1	9.63	1.33e-19	1.4e-12	0.53	0.46	Cognitive function;	chr12:56050848	chr2:171374931~171375278:-
STAD	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	9.63	1.37e-19	1.44e-12	0.65	0.46	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	9.63	1.37e-19	1.44e-12	0.65	0.46	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
STAD	trans	rs1552244	0.882	rs7636817	ENSG00000230342.2	FANCD2P2	9.62	1.46e-19	1.53e-12	0.56	0.46	Alzheimer's disease;	chr3:9973192	chr3:11859674~11891172:+
STAD	trans	rs916888	0.779	rs199498	ENSG00000263503.1	RP11-707O23.5	9.62	1.47e-19	1.55e-12	0.6	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45600869~45602340:-
STAD	trans	rs877636	1	rs2292239	ENSG00000242970.2	AC068522.4	9.62	1.48e-19	1.56e-12	0.47	0.46	Cognitive function;	chr12:56088396	chr8:58588420~58588764:-
STAD	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-9.61	1.54e-19	1.63e-12	-0.64	-0.46	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
STAD	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-9.61	1.57e-19	1.65e-12	-0.7	-0.46	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	9.61	1.58e-19	1.66e-12	0.48	0.46	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
STAD	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	9.6	1.62e-19	1.71e-12	0.63	0.46	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
STAD	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-9.6	1.68e-19	1.77e-12	-0.43	-0.46	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
STAD	trans	rs11098499	0.821	rs56155624	ENSG00000275858.1	RP11-291L22.8	9.6	1.72e-19	1.81e-12	0.52	0.46	Corneal astigmatism;	chr4:119369871	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.739	rs10031033	ENSG00000276997.3	RP11-378J18.9	9.59	1.75e-19	1.84e-12	0.51	0.46	Corneal astigmatism;	chr4:119230297	chr1:222477252~222504622:-
STAD	trans	rs13177918	0.559	rs10447224	ENSG00000226396.1	RP5-1056L3.3	9.59	1.75e-19	1.84e-12	0.47	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:19608114~19608568:+
STAD	trans	rs13177918	0.559	rs10447225	ENSG00000226396.1	RP5-1056L3.3	9.59	1.75e-19	1.84e-12	0.47	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:19608114~19608568:+
STAD	trans	rs13190036	1	rs351862	ENSG00000228305.2	AC016734.2	-9.59	1.77e-19	1.86e-12	-0.51	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr2:63622178~63622831:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000224553.1	AC008065.1	9.59	1.78e-19	1.87e-12	0.48	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr2:171374931~171375278:-
STAD	trans	rs1552244	0.515	rs67626468	ENSG00000230342.2	FANCD2P2	9.59	1.86e-19	1.95e-12	0.7	0.46	Alzheimer's disease;	chr3:10119834	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	9.58	1.91e-19	2.01e-12	0.62	0.46	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
STAD	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-9.58	1.95e-19	2.04e-12	-0.43	-0.46	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
STAD	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	9.58	2e-19	2.09e-12	0.55	0.46	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
STAD	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	9.58	2.01e-19	2.1e-12	0.65	0.46	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	9.58	2.01e-19	2.1e-12	0.65	0.46	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	9.58	2.01e-19	2.1e-12	0.65	0.46	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
STAD	trans	rs13190036	1	rs17078781	ENSG00000228305.2	AC016734.2	-9.58	2.02e-19	2.11e-12	-0.51	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr2:63622178~63622831:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000224553.1	AC008065.1	9.57	2.07e-19	2.17e-12	0.53	0.46	Cognitive function;	chr12:56009793	chr2:171374931~171375278:-
STAD	trans	rs11098499	0.874	rs13123591	ENSG00000276997.3	RP11-378J18.9	9.57	2.11e-19	2.2e-12	0.52	0.46	Corneal astigmatism;	chr4:119184835	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.874	rs7661020	ENSG00000276997.3	RP11-378J18.9	9.57	2.11e-19	2.2e-12	0.52	0.46	Corneal astigmatism;	chr4:119185827	chr1:222477252~222504622:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	9.56	2.25e-19	2.35e-12	0.41	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000239210.2	RPS26P55	-9.56	2.25e-19	2.35e-12	-0.49	-0.46	Cognitive function;	chr12:56080595	chr19:34533427~34534084:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	9.56	2.27e-19	2.37e-12	0.49	0.46	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000234513.1	AC073072.7	9.56	2.35e-19	2.45e-12	0.47	0.46	Cognitive function;	chr12:55976127	chr7:22773646~22773993:-
STAD	trans	rs13190036	1	rs13167431	ENSG00000228305.2	AC016734.2	-9.55	2.38e-19	2.48e-12	-0.51	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr2:63622178~63622831:-
STAD	trans	rs1552244	0.882	rs9312044	ENSG00000230342.2	FANCD2P2	9.55	2.46e-19	2.57e-12	0.55	0.46	Alzheimer's disease;	chr3:9995797	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs6796419	ENSG00000230342.2	FANCD2P2	9.55	2.46e-19	2.57e-12	0.55	0.46	Alzheimer's disease;	chr3:9999128	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.752	rs9867091	ENSG00000230342.2	FANCD2P2	9.55	2.46e-19	2.57e-12	0.55	0.46	Alzheimer's disease;	chr3:10001745	chr3:11859674~11891172:+
STAD	trans	rs877636	1	rs4759229	ENSG00000242970.2	AC068522.4	-9.55	2.48e-19	2.58e-12	-0.48	-0.46	Cognitive function;	chr12:56080696	chr8:58588420~58588764:-
STAD	trans	rs877636	1	rs877636	ENSG00000234192.1	RP11-57C13.5	-9.55	2.5e-19	2.6e-12	-0.48	-0.46	Cognitive function;	chr12:56086799	chr10:87642607~87642954:+
STAD	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-9.55	2.53e-19	2.64e-12	-0.51	-0.46	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000196656.7	AC004057.1	9.54	2.63e-19	2.74e-12	0.46	0.46	Cognitive function;	chr12:56009793	chr4:113214046~113217170:-
STAD	trans	rs13190036	0.901	rs28563911	ENSG00000228305.2	AC016734.2	9.54	2.64e-19	2.75e-12	0.51	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr2:63622178~63622831:-
STAD	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-9.54	2.64e-19	2.75e-12	-0.43	-0.46	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
STAD	trans	rs13177918	1	rs13161334	ENSG00000226396.1	RP5-1056L3.3	9.54	2.75e-19	2.86e-12	0.52	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:19608114~19608568:+
STAD	trans	rs11098499	0.913	rs10006304	ENSG00000276997.3	RP11-378J18.9	9.53	2.76e-19	2.88e-12	0.52	0.46	Corneal astigmatism;	chr4:119203150	chr1:222477252~222504622:-
STAD	trans	rs916888	0.61	rs142167	ENSG00000280022.1	RP11-707O23.1	-9.53	2.79e-19	2.9e-12	-0.57	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45592621~45593369:+
STAD	trans	rs11098499	0.569	rs10023641	ENSG00000276997.3	RP11-378J18.9	9.53	2.8e-19	2.92e-12	0.49	0.46	Corneal astigmatism;	chr4:119337255	chr1:222477252~222504622:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000234513.1	AC073072.7	9.53	2.81e-19	2.92e-12	0.46	0.46	Cognitive function;	chr12:55996580	chr7:22773646~22773993:-
STAD	trans	rs877636	1	rs877636	ENSG00000234354.3	RPS26P47	-9.53	2.85e-19	2.97e-12	-0.58	-0.46	Cognitive function;	chr12:56086799	chr13:100539901~100540248:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000233778.3	RP11-777J24.1	9.53	2.89e-19	3e-12	0.42	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.874	rs6851169	ENSG00000276997.3	RP11-378J18.9	9.53	2.9e-19	3.01e-12	0.52	0.46	Corneal astigmatism;	chr4:119196355	chr1:222477252~222504622:-
STAD	trans	rs13190036	0.892	rs71601339	ENSG00000228305.2	AC016734.2	-9.52	2.97e-19	3.09e-12	-0.51	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr2:63622178~63622831:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	9.52	3.05e-19	3.17e-12	0.48	0.46	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
STAD	trans	rs13190036	0.901	rs28684504	ENSG00000228305.2	AC016734.2	9.52	3.08e-19	3.2e-12	0.52	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr2:63622178~63622831:-
STAD	trans	rs11098499	0.562	rs58583086	ENSG00000276997.3	RP11-378J18.9	-9.52	3.12e-19	3.24e-12	-0.49	-0.46	Corneal astigmatism;	chr4:119635207	chr1:222477252~222504622:-
STAD	trans	rs1552244	0.572	rs3894321	ENSG00000230342.2	FANCD2P2	9.52	3.17e-19	3.29e-12	0.63	0.46	Alzheimer's disease;	chr3:10127208	chr3:11859674~11891172:+
STAD	trans	rs877636	1	rs705696	ENSG00000224553.1	AC008065.1	9.51	3.24e-19	3.36e-12	0.51	0.46	Cognitive function;	chr12:56086864	chr2:171374931~171375278:-
STAD	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	9.51	3.26e-19	3.38e-12	0.6	0.46	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000234513.1	AC073072.7	9.51	3.26e-19	3.38e-12	0.46	0.46	Cognitive function;	chr12:55980911	chr7:22773646~22773993:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000242970.2	AC068522.4	-9.51	3.28e-19	3.4e-12	-0.48	-0.46	Cognitive function;	chr12:56080595	chr8:58588420~58588764:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000212829.8	RPS26P3	9.51	3.33e-19	3.45e-12	0.48	0.46	Cognitive function;	chr12:56009793	chr9:9090898~9091245:+
STAD	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-9.51	3.33e-19	3.45e-12	-0.71	-0.46	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
STAD	trans	rs13190036	1	rs35535623	ENSG00000228305.2	AC016734.2	-9.51	3.39e-19	3.51e-12	-0.51	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr2:63622178~63622831:-
STAD	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	9.5	3.51e-19	3.63e-12	0.77	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
STAD	trans	rs13190036	1	rs34832871	ENSG00000228305.2	AC016734.2	-9.5	3.51e-19	3.63e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr2:63622178~63622831:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000212829.8	RPS26P3	9.5	3.58e-19	3.7e-12	0.48	0.45	Cognitive function;	chr12:56002984	chr9:9090898~9091245:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	9.5	3.68e-19	3.8e-12	0.48	0.45	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
STAD	trans	rs13190036	1	rs34446750	ENSG00000228305.2	AC016734.2	-9.49	3.88e-19	4e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr2:63622178~63622831:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000233278.1	RPS26P2	-9.49	3.91e-19	4.04e-12	-0.45	-0.45	Cognitive function;	chr12:56083910	chr9:30831878~30832225:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000212829.8	RPS26P3	9.49	3.92e-19	4.04e-12	0.48	0.45	Cognitive function;	chr12:56050848	chr9:9090898~9091245:+
STAD	trans	rs13190036	0.901	rs6556309	ENSG00000228305.2	AC016734.2	9.48	4.05e-19	4.17e-12	0.49	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr2:63622178~63622831:-
STAD	trans	rs11098499	0.874	rs17839089	ENSG00000276997.3	RP11-378J18.9	9.48	4.09e-19	4.21e-12	0.51	0.45	Corneal astigmatism;	chr4:119189914	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.874	rs6826823	ENSG00000276997.3	RP11-378J18.9	9.48	4.09e-19	4.21e-12	0.51	0.45	Corneal astigmatism;	chr4:119190943	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.874	rs12509054	ENSG00000276997.3	RP11-378J18.9	9.48	4.09e-19	4.21e-12	0.51	0.45	Corneal astigmatism;	chr4:119193920	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.874	rs10022508	ENSG00000276997.3	RP11-378J18.9	9.48	4.09e-19	4.21e-12	0.51	0.45	Corneal astigmatism;	chr4:119194073	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.874	rs12502503	ENSG00000276997.3	RP11-378J18.9	9.48	4.09e-19	4.21e-12	0.51	0.45	Corneal astigmatism;	chr4:119195100	chr1:222477252~222504622:-
STAD	trans	rs8081395	0.58	rs180515	ENSG00000187870.7	RNFT1P3	9.48	4.13e-19	4.24e-12	0.51	0.45	White blood cell count;	chr17:59946914	chr17:20743333~20754501:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000239210.2	RPS26P55	9.48	4.17e-19	4.29e-12	0.53	0.45	Cognitive function;	chr12:56002984	chr19:34533427~34534084:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000224553.1	AC008065.1	9.48	4.3e-19	4.42e-12	0.53	0.45	Cognitive function;	chr12:56023144	chr2:171374931~171375278:-
STAD	trans	rs11098499	0.874	rs9995277	ENSG00000276997.3	RP11-378J18.9	9.48	4.32e-19	4.44e-12	0.51	0.45	Corneal astigmatism;	chr4:119187448	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.874	rs6832670	ENSG00000276997.3	RP11-378J18.9	9.47	4.52e-19	4.64e-12	0.52	0.45	Corneal astigmatism;	chr4:119197637	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.874	rs6822498	ENSG00000276997.3	RP11-378J18.9	9.47	4.52e-19	4.64e-12	0.52	0.45	Corneal astigmatism;	chr4:119199028	chr1:222477252~222504622:-
STAD	trans	rs13190036	1	rs13157667	ENSG00000228305.2	AC016734.2	-9.47	4.59e-19	4.71e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr2:63622178~63622831:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000243403.1	RP11-330L19.1	9.47	4.63e-19	4.75e-12	0.48	0.45	Cognitive function;	chr12:55976127	chr15:64592979~64593326:+
STAD	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	9.47	4.66e-19	4.77e-12	0.65	0.45	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	9.47	4.66e-19	4.77e-12	0.65	0.45	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
STAD	trans	rs877636	1	rs705696	ENSG00000243538.1	CTB-55B8.1	9.46	4.79e-19	4.9e-12	0.48	0.45	Cognitive function;	chr12:56086864	chr5:16902294~16902641:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000196656.7	AC004057.1	9.46	4.85e-19	4.96e-12	0.46	0.45	Cognitive function;	chr12:56002984	chr4:113214046~113217170:-
STAD	trans	rs877636	1	rs705696	ENSG00000239210.2	RPS26P55	9.46	4.89e-19	5.01e-12	0.5	0.45	Cognitive function;	chr12:56086864	chr19:34533427~34534084:-
STAD	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	9.46	4.91e-19	5.02e-12	0.51	0.45	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000224553.1	AC008065.1	9.46	4.95e-19	5.06e-12	0.53	0.45	Cognitive function;	chr12:56002984	chr2:171374931~171375278:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000224553.1	AC008065.1	9.46	5.01e-19	5.13e-12	0.53	0.45	Cognitive function;	chr12:56013288	chr2:171374931~171375278:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000224553.1	AC008065.1	9.46	5.01e-19	5.13e-12	0.53	0.45	Cognitive function;	chr12:56018703	chr2:171374931~171375278:-
STAD	trans	rs11098499	0.874	rs6851169	ENSG00000275858.1	RP11-291L22.8	9.45	5.11e-19	5.22e-12	0.51	0.45	Corneal astigmatism;	chr4:119196355	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000212829.8	RPS26P3	9.45	5.19e-19	5.3e-12	0.48	0.45	Cognitive function;	chr12:56023144	chr9:9090898~9091245:+
STAD	trans	rs11098499	0.739	rs9996382	ENSG00000275858.1	RP11-291L22.8	9.45	5.32e-19	5.43e-12	0.49	0.45	Corneal astigmatism;	chr4:119229857	chr10:38450738~38451069:-
STAD	trans	rs916888	0.61	rs199446	ENSG00000263503.1	RP11-707O23.5	-9.45	5.35e-19	5.46e-12	-0.59	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45600869~45602340:-
STAD	trans	rs916888	0.61	rs199536	ENSG00000263503.1	RP11-707O23.5	-9.45	5.35e-19	5.46e-12	-0.59	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45600869~45602340:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000212829.8	RPS26P3	9.45	5.37e-19	5.47e-12	0.48	0.45	Cognitive function;	chr12:56013288	chr9:9090898~9091245:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000212829.8	RPS26P3	9.45	5.37e-19	5.47e-12	0.48	0.45	Cognitive function;	chr12:56018703	chr9:9090898~9091245:+
STAD	trans	rs13190036	0.901	rs55741473	ENSG00000228305.2	AC016734.2	-9.45	5.4e-19	5.5e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr2:63622178~63622831:-
STAD	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-9.44	5.49e-19	5.6e-12	-0.75	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
STAD	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	9.44	5.67e-19	5.78e-12	0.59	0.45	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
STAD	trans	rs941207	0.542	rs11171986	ENSG00000121089.4	NACA3P	-9.43	6.03e-19	6.14e-12	-0.43	-0.45	Platelet count;	chr12:56819043	chr4:164943290~164943937:+
STAD	trans	rs877636	0.847	rs705704	ENSG00000224553.1	AC008065.1	9.43	6.1e-19	6.21e-12	0.53	0.45	Cognitive function;	chr12:56041628	chr2:171374931~171375278:-
STAD	trans	rs1552244	0.572	rs17032440	ENSG00000230342.2	FANCD2P2	-9.43	6.16e-19	6.27e-12	-0.7	-0.45	Alzheimer's disease;	chr3:10128135	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.874	rs13139045	ENSG00000275858.1	RP11-291L22.8	9.43	6.34e-19	6.45e-12	0.49	0.45	Corneal astigmatism;	chr4:119247433	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs17839089	ENSG00000275858.1	RP11-291L22.8	9.42	6.37e-19	6.48e-12	0.5	0.45	Corneal astigmatism;	chr4:119189914	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs6826823	ENSG00000275858.1	RP11-291L22.8	9.42	6.37e-19	6.48e-12	0.5	0.45	Corneal astigmatism;	chr4:119190943	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs12509054	ENSG00000275858.1	RP11-291L22.8	9.42	6.37e-19	6.48e-12	0.5	0.45	Corneal astigmatism;	chr4:119193920	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs10022508	ENSG00000275858.1	RP11-291L22.8	9.42	6.37e-19	6.48e-12	0.5	0.45	Corneal astigmatism;	chr4:119194073	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs12502503	ENSG00000275858.1	RP11-291L22.8	9.42	6.37e-19	6.48e-12	0.5	0.45	Corneal astigmatism;	chr4:119195100	chr10:38450738~38451069:-
STAD	trans	rs13190036	1	rs71601343	ENSG00000228305.2	AC016734.2	-9.42	6.48e-19	6.59e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr2:63622178~63622831:-
STAD	trans	rs13190036	1	rs71601344	ENSG00000228305.2	AC016734.2	-9.42	6.48e-19	6.59e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr2:63622178~63622831:-
STAD	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	9.42	6.66e-19	6.76e-12	0.48	0.45	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
STAD	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-9.42	6.74e-19	6.85e-12	-0.48	-0.45	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
STAD	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-9.41	6.93e-19	7.03e-12	-0.63	-0.45	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
STAD	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	9.41	6.93e-19	7.04e-12	0.59	0.45	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000224553.1	AC008065.1	9.41	7e-19	7.1e-12	0.47	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr2:171374931~171375278:-
STAD	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	9.41	7.05e-19	7.15e-12	0.59	0.45	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000239210.2	RPS26P55	9.41	7.06e-19	7.15e-12	0.52	0.45	Cognitive function;	chr12:56050848	chr19:34533427~34534084:-
STAD	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	9.4	7.43e-19	7.52e-12	0.64	0.45	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
STAD	trans	rs13190036	1	rs7714695	ENSG00000228305.2	AC016734.2	-9.4	7.44e-19	7.53e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr2:63622178~63622831:-
STAD	trans	rs13190036	1	rs59737888	ENSG00000228305.2	AC016734.2	-9.4	7.44e-19	7.53e-12	-0.51	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr2:63622178~63622831:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000243403.1	RP11-330L19.1	9.4	7.44e-19	7.53e-12	0.52	0.45	Cognitive function;	chr12:56055651	chr15:64592979~64593326:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000233278.1	RPS26P2	-9.4	7.45e-19	7.53e-12	-0.45	-0.45	Cognitive function;	chr12:56084218	chr9:30831878~30832225:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000233278.1	RPS26P2	-9.4	7.45e-19	7.53e-12	-0.45	-0.45	Cognitive function;	chr12:56084874	chr9:30831878~30832225:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000212829.8	RPS26P3	9.4	7.82e-19	7.91e-12	0.47	0.45	Cognitive function;	chr12:56041628	chr9:9090898~9091245:+
STAD	trans	rs877636	0.701	rs34415530	ENSG00000196656.7	AC004057.1	9.39	8.03e-19	8.11e-12	0.46	0.45	Cognitive function;	chr12:56050848	chr4:113214046~113217170:-
STAD	trans	rs877636	1	rs2292239	ENSG00000239210.2	RPS26P55	9.39	8.22e-19	8.3e-12	0.48	0.45	Cognitive function;	chr12:56088396	chr19:34533427~34534084:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000239210.2	RPS26P55	-9.39	8.25e-19	8.33e-12	-0.45	-0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr19:34533427~34534084:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000234513.1	AC073072.7	-9.39	8.26e-19	8.34e-12	-0.44	-0.45	Cognitive function;	chr12:55996852	chr7:22773646~22773993:-
STAD	trans	rs13177918	0.581	rs2245384	ENSG00000226396.1	RP5-1056L3.3	9.39	8.32e-19	8.4e-12	0.45	0.45	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:19608114~19608568:+
STAD	trans	rs8067354	0.872	rs2645488	ENSG00000187870.7	RNFT1P3	9.39	8.34e-19	8.41e-12	0.51	0.45	Hemoglobin concentration;	chr17:59812044	chr17:20743333~20754501:-
STAD	trans	rs877636	1	rs2292239	ENSG00000244604.1	RP11-713H12.1	9.39	8.45e-19	8.52e-12	0.47	0.45	Cognitive function;	chr12:56088396	chr17:8561230~8561576:+
STAD	trans	rs11098499	0.874	rs6832670	ENSG00000275858.1	RP11-291L22.8	9.39	8.59e-19	8.66e-12	0.51	0.45	Corneal astigmatism;	chr4:119197637	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs6822498	ENSG00000275858.1	RP11-291L22.8	9.39	8.59e-19	8.66e-12	0.51	0.45	Corneal astigmatism;	chr4:119199028	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs9995277	ENSG00000275858.1	RP11-291L22.8	9.38	9.01e-19	9.07e-12	0.5	0.45	Corneal astigmatism;	chr4:119187448	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs877636	ENSG00000244604.1	RP11-713H12.1	-9.37	9.92e-19	9.97e-12	-0.47	-0.45	Cognitive function;	chr12:56086799	chr17:8561230~8561576:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000196656.7	AC004057.1	9.36	1.03e-18	1.03e-11	0.45	0.45	Cognitive function;	chr12:56013288	chr4:113214046~113217170:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000196656.7	AC004057.1	9.36	1.03e-18	1.03e-11	0.45	0.45	Cognitive function;	chr12:56018703	chr4:113214046~113217170:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000239210.2	RPS26P55	9.36	1.07e-18	1.08e-11	0.52	0.45	Cognitive function;	chr12:56009793	chr19:34533427~34534084:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	9.35	1.1e-18	1.11e-11	0.48	0.45	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000212829.8	RPS26P3	9.35	1.11e-18	1.11e-11	0.47	0.45	Cognitive function;	chr12:56041720	chr9:9090898~9091245:+
STAD	trans	rs1552244	0.572	rs67227131	ENSG00000230342.2	FANCD2P2	9.35	1.16e-18	1.16e-11	0.73	0.45	Alzheimer's disease;	chr3:10131060	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	9.34	1.23e-18	1.23e-11	0.44	0.45	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000234192.1	RP11-57C13.5	9.34	1.25e-18	1.25e-11	0.45	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:87642607~87642954:+
STAD	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	9.33	1.27e-18	1.27e-11	0.59	0.45	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-9.33	1.34e-18	1.33e-11	-0.47	-0.45	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
STAD	trans	rs916888	0.61	rs199446	ENSG00000280022.1	RP11-707O23.1	-9.32	1.36e-18	1.36e-11	-0.56	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45592621~45593369:+
STAD	trans	rs916888	0.61	rs199536	ENSG00000280022.1	RP11-707O23.1	-9.32	1.36e-18	1.36e-11	-0.56	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45592621~45593369:+
STAD	trans	rs13190036	1	rs13177748	ENSG00000228305.2	AC016734.2	-9.32	1.41e-18	1.4e-11	-0.5	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr2:63622178~63622831:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000234354.3	RPS26P47	-9.32	1.44e-18	1.43e-11	-0.52	-0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr13:100539901~100540248:-
STAD	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	9.32	1.46e-18	1.45e-11	0.64	0.45	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	9.31	1.56e-18	1.55e-11	0.65	0.45	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.739	rs4833612	ENSG00000275858.1	RP11-291L22.8	-9.3	1.58e-18	1.57e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119226441	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.739	rs10013032	ENSG00000275858.1	RP11-291L22.8	-9.3	1.58e-18	1.57e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119228264	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.739	rs951570	ENSG00000275858.1	RP11-291L22.8	-9.3	1.58e-18	1.57e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119229312	chr10:38450738~38451069:-
STAD	trans	rs916888	0.647	rs199524	ENSG00000263503.1	RP11-707O23.5	-9.3	1.59e-18	1.58e-11	-0.6	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45600869~45602340:-
STAD	trans	rs916888	0.647	rs199523	ENSG00000263503.1	RP11-707O23.5	-9.3	1.59e-18	1.58e-11	-0.6	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45600869~45602340:-
STAD	trans	rs8081395	0.651	rs1292067	ENSG00000187870.7	RNFT1P3	-9.3	1.68e-18	1.66e-11	-0.5	-0.45	White blood cell count;	chr17:59853285	chr17:20743333~20754501:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000243538.1	CTB-55B8.1	9.3	1.69e-18	1.67e-11	0.49	0.45	Cognitive function;	chr12:56050848	chr5:16902294~16902641:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	9.29	1.7e-18	1.68e-11	0.44	0.45	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000196656.7	AC004057.1	9.29	1.7e-18	1.68e-11	0.45	0.45	Cognitive function;	chr12:56041720	chr4:113214046~113217170:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000224553.1	AC008065.1	9.29	1.72e-18	1.7e-11	0.52	0.45	Cognitive function;	chr12:56041720	chr2:171374931~171375278:-
STAD	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	9.29	1.76e-18	1.74e-11	0.59	0.45	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
STAD	trans	rs1552244	0.882	rs7633769	ENSG00000230342.2	FANCD2P2	9.29	1.77e-18	1.75e-11	0.54	0.45	Alzheimer's disease;	chr3:9978938	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.751	rs12715665	ENSG00000230342.2	FANCD2P2	9.29	1.77e-18	1.75e-11	0.54	0.45	Alzheimer's disease;	chr3:9979917	chr3:11859674~11891172:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	9.29	1.8e-18	1.78e-11	0.46	0.45	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000239210.2	RPS26P55	9.29	1.82e-18	1.79e-11	0.52	0.45	Cognitive function;	chr12:56023144	chr19:34533427~34534084:-
STAD	trans	rs11098499	0.739	rs9884728	ENSG00000275858.1	RP11-291L22.8	-9.28	1.84e-18	1.81e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119205924	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.739	rs6534130	ENSG00000275858.1	RP11-291L22.8	-9.28	1.84e-18	1.81e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119210184	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.739	rs7441137	ENSG00000275858.1	RP11-291L22.8	-9.28	1.84e-18	1.81e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119212066	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.526	rs10026625	ENSG00000275858.1	RP11-291L22.8	9.28	1.86e-18	1.83e-11	0.47	0.45	Corneal astigmatism;	chr4:119358981	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000243538.1	CTB-55B8.1	9.28	1.89e-18	1.87e-11	0.44	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr5:16902294~16902641:-
STAD	trans	rs13190036	1	rs13175695	ENSG00000228305.2	AC016734.2	9.28	1.91e-18	1.88e-11	0.48	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr2:63622178~63622831:-
STAD	trans	rs13190036	1	rs3733875	ENSG00000228305.2	AC016734.2	-9.28	1.94e-18	1.91e-11	-0.5	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr2:63622178~63622831:-
STAD	trans	rs916888	0.61	rs199454	ENSG00000280022.1	RP11-707O23.1	-9.27	1.97e-18	1.94e-11	-0.56	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45592621~45593369:+
STAD	trans	rs877636	0.702	rs773112	ENSG00000227887.1	RPS26P13	9.27	1.98e-18	1.95e-11	0.48	0.45	Cognitive function;	chr12:55982097	chr1:208697369~208697698:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	9.27	2.02e-18	1.98e-11	0.43	0.45	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000239210.2	RPS26P55	9.27	2.07e-18	2.04e-11	0.51	0.45	Cognitive function;	chr12:56041720	chr19:34533427~34534084:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000239210.2	RPS26P55	9.26	2.15e-18	2.11e-11	0.52	0.45	Cognitive function;	chr12:56013288	chr19:34533427~34534084:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000239210.2	RPS26P55	9.26	2.15e-18	2.11e-11	0.52	0.45	Cognitive function;	chr12:56018703	chr19:34533427~34534084:-
STAD	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-9.26	2.15e-18	2.11e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000239210.2	RPS26P55	9.26	2.15e-18	2.11e-11	0.52	0.45	Cognitive function;	chr12:56041628	chr19:34533427~34534084:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	9.26	2.16e-18	2.12e-11	0.47	0.45	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
STAD	trans	rs11098499	0.739	rs2203039	ENSG00000275858.1	RP11-291L22.8	-9.26	2.27e-18	2.23e-11	-0.48	-0.45	Corneal astigmatism;	chr4:119211192	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000239210.2	RPS26P55	9.26	2.28e-18	2.24e-11	0.46	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr19:34533427~34534084:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000196656.7	AC004057.1	9.25	2.3e-18	2.26e-11	0.45	0.45	Cognitive function;	chr12:56023144	chr4:113214046~113217170:-
STAD	trans	rs7930295	0.558	rs34141026	ENSG00000236257.1	EI24P2	9.25	2.33e-18	2.29e-11	0.71	0.45	Schizophrenia;	chr11:125433911	chr1:158454198~158455273:+
STAD	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	9.25	2.34e-18	2.29e-11	0.49	0.45	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
STAD	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-9.25	2.42e-18	2.37e-11	-0.57	-0.45	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
STAD	trans	rs1552244	0.572	rs41464050	ENSG00000230342.2	FANCD2P2	9.24	2.48e-18	2.43e-11	0.65	0.45	Alzheimer's disease;	chr3:10116709	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.882	rs3755783	ENSG00000230342.2	FANCD2P2	9.24	2.48e-18	2.43e-11	0.56	0.45	Alzheimer's disease;	chr3:9987605	chr3:11859674~11891172:+
STAD	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-9.24	2.55e-18	2.5e-11	-0.47	-0.44	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
STAD	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-9.24	2.59e-18	2.53e-11	-0.64	-0.44	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
STAD	trans	rs877636	0.847	rs705704	ENSG00000196656.7	AC004057.1	9.24	2.6e-18	2.55e-11	0.45	0.44	Cognitive function;	chr12:56041628	chr4:113214046~113217170:-
STAD	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	9.24	2.61e-18	2.55e-11	0.47	0.44	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.71	rs4145952	ENSG00000276997.3	RP11-378J18.9	9.24	2.64e-18	2.58e-11	0.49	0.44	Corneal astigmatism;	chr4:119234651	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	9.24	2.65e-18	2.59e-11	0.43	0.44	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
STAD	trans	rs877636	1	rs2292239	ENSG00000234354.3	RPS26P47	9.23	2.74e-18	2.68e-11	0.55	0.44	Cognitive function;	chr12:56088396	chr13:100539901~100540248:-
STAD	trans	rs1552244	0.688	rs113940455	ENSG00000230342.2	FANCD2P2	9.23	2.77e-18	2.7e-11	0.57	0.44	Alzheimer's disease;	chr3:9972481	chr3:11859674~11891172:+
STAD	trans	rs13190036	1	rs28580074	ENSG00000228305.2	AC016734.2	9.23	2.79e-18	2.73e-11	0.5	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr2:63622178~63622831:-
STAD	trans	rs916888	0.61	rs199454	ENSG00000263503.1	RP11-707O23.5	-9.22	2.88e-18	2.81e-11	-0.58	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45600869~45602340:-
STAD	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	9.22	2.92e-18	2.84e-11	0.57	0.44	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
STAD	trans	rs66887589	0.592	rs28580295	ENSG00000275858.1	RP11-291L22.8	9.22	2.94e-18	2.86e-11	0.46	0.44	Diastolic blood pressure;	chr4:119357718	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.592	rs62320740	ENSG00000275858.1	RP11-291L22.8	9.22	2.94e-18	2.86e-11	0.46	0.44	Diastolic blood pressure;	chr4:119358331	chr10:38450738~38451069:-
STAD	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	9.21	3.17e-18	3.08e-11	0.53	0.44	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
STAD	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	9.21	3.17e-18	3.08e-11	0.53	0.44	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
STAD	trans	rs916888	0.647	rs199524	ENSG00000280022.1	RP11-707O23.1	-9.21	3.23e-18	3.14e-11	-0.57	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45592621~45593369:+
STAD	trans	rs916888	0.647	rs199523	ENSG00000280022.1	RP11-707O23.1	-9.21	3.23e-18	3.14e-11	-0.57	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45592621~45593369:+
STAD	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	9.21	3.26e-18	3.16e-11	0.47	0.44	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	9.21	3.26e-18	3.16e-11	0.47	0.44	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	9.21	3.26e-18	3.16e-11	0.47	0.44	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
STAD	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	9.2	3.36e-18	3.26e-11	0.53	0.44	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
STAD	trans	rs11098499	0.874	rs28452522	ENSG00000276997.3	RP11-378J18.9	9.2	3.38e-18	3.28e-11	0.51	0.44	Corneal astigmatism;	chr4:119189629	chr1:222477252~222504622:-
STAD	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	9.2	3.46e-18	3.36e-11	0.58	0.44	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
STAD	trans	rs1552244	0.554	rs6768339	ENSG00000230342.2	FANCD2P2	-9.19	3.66e-18	3.54e-11	-0.48	-0.44	Alzheimer's disease;	chr3:9964395	chr3:11859674~11891172:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-9.19	3.74e-18	3.62e-11	-0.45	-0.44	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
STAD	trans	rs11098499	0.779	rs6815934	ENSG00000275858.1	RP11-291L22.8	9.19	3.78e-18	3.66e-11	0.46	0.44	Corneal astigmatism;	chr4:119346155	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.6	rs4001390	ENSG00000275858.1	RP11-291L22.8	9.18	4.09e-18	3.94e-11	0.46	0.44	Educational attainment;	chr4:119344628	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs2136911	ENSG00000275858.1	RP11-291L22.8	9.18	4.09e-18	3.94e-11	0.46	0.44	Corneal astigmatism;	chr4:119344704	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.554	rs2175381	ENSG00000275858.1	RP11-291L22.8	9.18	4.09e-18	3.94e-11	0.46	0.44	Corneal astigmatism;	chr4:119344812	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.599	rs3864142	ENSG00000275858.1	RP11-291L22.8	9.18	4.09e-18	3.94e-11	0.46	0.44	Corneal astigmatism;	chr4:119345036	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	9.18	4.09e-18	3.94e-11	0.46	0.44	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.568	rs6838457	ENSG00000275858.1	RP11-291L22.8	9.18	4.09e-18	3.94e-11	0.46	0.44	Educational attainment;	chr4:119346212	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.535	rs10005542	ENSG00000275858.1	RP11-291L22.8	9.18	4.09e-18	3.94e-11	0.46	0.44	Corneal astigmatism;	chr4:119347147	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.592	rs11731571	ENSG00000276997.3	RP11-378J18.9	9.18	4.14e-18	4e-11	0.48	0.44	Diastolic blood pressure;	chr4:119300030	chr1:222477252~222504622:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000242206.2	RPS26P35	9.17	4.23e-18	4.08e-11	0.45	0.44	Cognitive function;	chr12:56076841	chr8:118761856~118762201:-
STAD	trans	rs8067354	0.831	rs2333617	ENSG00000187870.7	RNFT1P3	-9.17	4.3e-18	4.14e-11	-0.5	-0.44	Hemoglobin concentration;	chr17:59818859	chr17:20743333~20754501:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000243538.1	CTB-55B8.1	9.17	4.35e-18	4.2e-11	0.49	0.44	Cognitive function;	chr12:56002984	chr5:16902294~16902641:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000234192.1	RP11-57C13.5	9.17	4.46e-18	4.29e-11	0.45	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:87642607~87642954:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	9.16	4.52e-18	4.35e-11	0.4	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
STAD	trans	rs8067354	0.83	rs2453913	ENSG00000187870.7	RNFT1P3	9.16	4.53e-18	4.36e-11	0.49	0.44	Hemoglobin concentration;	chr17:59782789	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	9.16	4.58e-18	4.4e-11	0.47	0.44	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	9.16	4.58e-18	4.4e-11	0.47	0.44	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	9.16	4.58e-18	4.4e-11	0.47	0.44	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	9.16	4.58e-18	4.4e-11	0.47	0.44	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	9.16	4.58e-18	4.4e-11	0.47	0.44	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.608	rs2003816	ENSG00000268568.1	AC007228.9	9.16	4.69e-18	4.51e-11	0.63	0.44	Vitiligo;	chr22:41699136	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.694	rs11090056	ENSG00000268568.1	AC007228.9	9.16	4.69e-18	4.51e-11	0.63	0.44	Vitiligo;	chr22:41699900	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.661	rs10015965	ENSG00000275858.1	RP11-291L22.8	9.16	4.7e-18	4.52e-11	0.46	0.44	Corneal astigmatism;	chr4:119347082	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs705696	ENSG00000196933.5	RPS26P11	9.16	4.73e-18	4.55e-11	0.45	0.44	Cognitive function;	chr12:56086864	chrX:72044545~72044892:+
STAD	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	9.15	4.89e-18	4.7e-11	0.53	0.44	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
STAD	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	9.15	4.89e-18	4.7e-11	0.53	0.44	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000239210.2	RPS26P55	9.15	5.04e-18	4.84e-11	0.45	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr19:34533427~34534084:-
STAD	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-9.15	5.05e-18	4.85e-11	-0.57	-0.44	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
STAD	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	9.15	5.06e-18	4.85e-11	0.53	0.44	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
STAD	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	9.14	5.29e-18	5.07e-11	0.71	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
STAD	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-9.14	5.32e-18	5.1e-11	-0.62	-0.44	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-9.14	5.37e-18	5.15e-11	-0.62	-0.44	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	9.14	5.4e-18	5.18e-11	0.44	0.44	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000212994.5	RPS26P6	9.14	5.41e-18	5.18e-11	0.45	0.44	Cognitive function;	chr12:56050848	chr8:100895771~100896118:+
STAD	trans	rs13190036	0.901	rs10056655	ENSG00000228305.2	AC016734.2	9.14	5.53e-18	5.3e-11	0.48	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr2:63622178~63622831:-
STAD	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-9.14	5.57e-18	5.33e-11	-0.56	-0.44	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
STAD	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	9.13	5.63e-18	5.39e-11	0.47	0.44	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	9.13	5.63e-18	5.39e-11	0.47	0.44	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
STAD	trans	rs13190036	1	rs351864	ENSG00000228305.2	AC016734.2	-9.13	6.03e-18	5.76e-11	-0.49	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr2:63622178~63622831:-
STAD	trans	rs9611565	0.694	rs5758411	ENSG00000268568.1	AC007228.9	9.12	6.13e-18	5.85e-11	0.63	0.44	Vitiligo;	chr22:41683730	chr19:56672574~56673901:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000242206.2	RPS26P35	-9.12	6.37e-18	6.08e-11	-0.44	-0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:118761856~118762201:-
STAD	trans	rs1552244	0.882	rs28366039	ENSG00000230342.2	FANCD2P2	9.12	6.42e-18	6.13e-11	0.55	0.44	Alzheimer's disease;	chr3:9987304	chr3:11859674~11891172:+
STAD	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	9.12	6.44e-18	6.14e-11	0.41	0.44	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
STAD	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	9.12	6.45e-18	6.16e-11	0.58	0.44	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
STAD	trans	rs1552244	0.832	rs61056817	ENSG00000230342.2	FANCD2P2	9.12	6.45e-18	6.16e-11	0.56	0.44	Alzheimer's disease;	chr3:9985957	chr3:11859674~11891172:+
STAD	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	9.11	6.55e-18	6.24e-11	0.54	0.44	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
STAD	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-9.11	6.68e-18	6.37e-11	-0.57	-0.44	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000234513.1	AC073072.7	9.11	6.88e-18	6.56e-11	0.49	0.44	Cognitive function;	chr12:56055651	chr7:22773646~22773993:-
STAD	trans	rs13190036	0.901	rs6898107	ENSG00000228305.2	AC016734.2	9.11	6.96e-18	6.62e-11	0.48	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr2:63622178~63622831:-
STAD	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	9.1	7.18e-18	6.82e-11	0.54	0.44	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000243538.1	CTB-55B8.1	9.1	7.2e-18	6.84e-11	0.48	0.44	Cognitive function;	chr12:56009793	chr5:16902294~16902641:-
STAD	trans	rs1552244	0.7	rs9833566	ENSG00000230342.2	FANCD2P2	9.1	7.21e-18	6.85e-11	0.57	0.44	Alzheimer's disease;	chr3:9939987	chr3:11859674~11891172:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000223416.3	RPS26P15	9.1	7.45e-18	7.08e-11	0.51	0.44	Cognitive function;	chr12:56055651	chr1:58056133~58056480:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000234192.1	RP11-57C13.5	-9.1	7.5e-18	7.12e-11	-0.43	-0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:87642607~87642954:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000225071.1	GS1-184P14.2	9.1	7.56e-18	7.17e-11	0.47	0.44	Cognitive function;	chr12:56055651	chrX:24429573~24429920:-
STAD	trans	rs13190036	0.901	rs10072499	ENSG00000228305.2	AC016734.2	-9.09	7.84e-18	7.43e-11	-0.48	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr2:63622178~63622831:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000227586.5	RP11-162A23.5	9.09	7.86e-18	7.45e-11	0.48	0.44	Cognitive function;	chr12:55982097	chr10:123171535~123171875:-
STAD	trans	rs8067354	0.872	rs2645466	ENSG00000187870.7	RNFT1P3	9.09	7.88e-18	7.46e-11	0.49	0.44	Hemoglobin concentration;	chr17:59775853	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.71	rs6851130	ENSG00000275858.1	RP11-291L22.8	-9.09	7.95e-18	7.53e-11	-0.48	-0.44	Corneal astigmatism;	chr4:119212557	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	9.09	7.96e-18	7.54e-11	0.47	0.44	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
STAD	trans	rs8067354	0.872	rs1292060	ENSG00000187870.7	RNFT1P3	9.09	7.99e-18	7.57e-11	0.5	0.44	Hemoglobin concentration;	chr17:59836488	chr17:20743333~20754501:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000244604.1	RP11-713H12.1	9.08	8.34e-18	7.89e-11	0.44	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:8561230~8561576:+
STAD	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	9.08	8.45e-18	7.99e-11	0.43	0.44	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
STAD	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	9.08	8.63e-18	8.16e-11	0.37	0.44	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
STAD	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-9.08	8.64e-18	8.17e-11	-0.56	-0.44	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-9.08	8.64e-18	8.17e-11	-0.56	-0.44	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
STAD	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-9.07	8.89e-18	8.39e-11	-0.49	-0.44	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
STAD	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-9.07	8.9e-18	8.4e-11	-0.37	-0.44	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000243538.1	CTB-55B8.1	9.07	9.06e-18	8.55e-11	0.48	0.44	Cognitive function;	chr12:56013288	chr5:16902294~16902641:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000243538.1	CTB-55B8.1	9.07	9.06e-18	8.55e-11	0.48	0.44	Cognitive function;	chr12:56018703	chr5:16902294~16902641:-
STAD	trans	rs13190036	0.901	rs4631	ENSG00000228305.2	AC016734.2	9.07	9.18e-18	8.62e-11	0.49	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr2:63622178~63622831:-
STAD	trans	rs11098499	0.588	rs2389874	ENSG00000276997.3	RP11-378J18.9	-9.07	9.29e-18	8.71e-11	-0.48	-0.44	Corneal astigmatism;	chr4:119633836	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000243538.1	CTB-55B8.1	9.06	9.46e-18	8.88e-11	0.48	0.44	Cognitive function;	chr12:56041628	chr5:16902294~16902641:-
STAD	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	9.06	9.87e-18	9.24e-11	0.47	0.44	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
STAD	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	9.06	9.87e-18	9.24e-11	0.47	0.44	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
STAD	trans	rs13190036	0.792	rs6874206	ENSG00000228305.2	AC016734.2	-9.06	9.9e-18	9.27e-11	-0.47	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr2:63622178~63622831:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000227586.5	RP11-162A23.5	9.06	9.96e-18	9.32e-11	0.49	0.44	Cognitive function;	chr12:55988132	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	9.05	1.04e-17	9.68e-11	0.46	0.44	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	9.05	1.04e-17	9.68e-11	0.46	0.44	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
STAD	trans	rs6708331	0.504	rs2169837	ENSG00000232654.1	FAM136BP	9.05	1.04e-17	9.7e-11	0.53	0.44	Obesity-related traits;	chr2:70324775	chr6:3045384~3045800:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000227887.1	RPS26P13	9.05	1.09e-17	1.02e-10	0.47	0.44	Cognitive function;	chr12:55981956	chr1:208697369~208697698:-
STAD	trans	rs66887589	0.592	rs28580295	ENSG00000276997.3	RP11-378J18.9	9.04	1.12e-17	1.04e-10	0.46	0.44	Diastolic blood pressure;	chr4:119357718	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.592	rs62320740	ENSG00000276997.3	RP11-378J18.9	9.04	1.12e-17	1.04e-10	0.46	0.44	Diastolic blood pressure;	chr4:119358331	chr1:222477252~222504622:-
STAD	trans	rs112721625	1	rs112721625	ENSG00000187870.7	RNFT1P3	9.04	1.15e-17	1.07e-10	0.48	0.44	Monocyte count;	chr17:59850066	chr17:20743333~20754501:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000243538.1	CTB-55B8.1	9.04	1.18e-17	1.09e-10	0.48	0.44	Cognitive function;	chr12:56023144	chr5:16902294~16902641:-
STAD	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	9.03	1.19e-17	1.1e-10	0.74	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000243538.1	CTB-55B8.1	9.03	1.23e-17	1.14e-10	0.48	0.44	Cognitive function;	chr12:56041720	chr5:16902294~16902641:-
STAD	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	9.03	1.24e-17	1.15e-10	0.53	0.44	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000196933.5	RPS26P11	9.03	1.25e-17	1.16e-10	0.46	0.44	Cognitive function;	chr12:56041720	chrX:72044545~72044892:+
STAD	trans	rs8067354	0.789	rs4622571	ENSG00000187870.7	RNFT1P3	9.03	1.27e-17	1.17e-10	0.49	0.44	Hemoglobin concentration;	chr17:59807036	chr17:20743333~20754501:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000244604.1	RP11-713H12.1	-9.03	1.27e-17	1.18e-10	-0.46	-0.44	Cognitive function;	chr12:56080595	chr17:8561230~8561576:+
STAD	trans	rs66887589	0.616	rs7659403	ENSG00000276997.3	RP11-378J18.9	9.02	1.32e-17	1.22e-10	0.47	0.44	Diastolic blood pressure;	chr4:119286099	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.616	rs11098497	ENSG00000276997.3	RP11-378J18.9	9.02	1.35e-17	1.25e-10	0.47	0.44	Diastolic blood pressure;	chr4:119265913	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.588	rs6534149	ENSG00000276997.3	RP11-378J18.9	-9.02	1.36e-17	1.26e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119638137	chr1:222477252~222504622:-
STAD	trans	rs7930295	0.558	rs11220069	ENSG00000236257.1	EI24P2	9.01	1.37e-17	1.27e-10	0.71	0.44	Schizophrenia;	chr11:125428235	chr1:158454198~158455273:+
STAD	trans	rs66887589	0.616	rs11732621	ENSG00000276997.3	RP11-378J18.9	9.01	1.39e-17	1.28e-10	0.47	0.44	Diastolic blood pressure;	chr4:119291728	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.616	rs11731675	ENSG00000276997.3	RP11-378J18.9	9.01	1.39e-17	1.29e-10	0.47	0.44	Diastolic blood pressure;	chr4:119291359	chr1:222477252~222504622:-
STAD	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	9.01	1.4e-17	1.29e-10	0.57	0.44	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	9.01	1.4e-17	1.29e-10	0.57	0.44	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
STAD	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	9	1.51e-17	1.4e-10	0.54	0.44	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
STAD	trans	rs877636	1	rs4759229	ENSG00000244604.1	RP11-713H12.1	-9	1.53e-17	1.41e-10	-0.46	-0.44	Cognitive function;	chr12:56080696	chr17:8561230~8561576:+
STAD	trans	rs66887589	0.616	rs11098498	ENSG00000276997.3	RP11-378J18.9	9	1.54e-17	1.42e-10	0.47	0.44	Diastolic blood pressure;	chr4:119265964	chr1:222477252~222504622:-
STAD	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-9	1.54e-17	1.42e-10	-0.58	-0.44	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000243538.1	CTB-55B8.1	9	1.58e-17	1.45e-10	0.42	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr5:16902294~16902641:-
STAD	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	9	1.58e-17	1.45e-10	0.49	0.44	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000212994.5	RPS26P6	8.99	1.62e-17	1.49e-10	0.44	0.44	Cognitive function;	chr12:56009793	chr8:100895771~100896118:+
STAD	trans	rs7554511	1	rs7522462	ENSG00000244144.1	RP11-757F18.3	8.98	1.72e-17	1.58e-10	0.52	0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200912467	chr3:112185480~112185998:-
STAD	trans	rs11098499	0.698	rs4422403	ENSG00000276997.3	RP11-378J18.9	8.98	1.72e-17	1.58e-10	0.47	0.43	Corneal astigmatism;	chr4:119337039	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.526	rs10026625	ENSG00000276997.3	RP11-378J18.9	8.98	1.74e-17	1.59e-10	0.47	0.43	Corneal astigmatism;	chr4:119358981	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000227586.5	RP11-162A23.5	8.98	1.75e-17	1.61e-10	0.48	0.43	Cognitive function;	chr12:55981956	chr10:123171535~123171875:-
STAD	trans	rs10028773	0.515	rs9994488	ENSG00000276997.3	RP11-378J18.9	8.98	1.8e-17	1.65e-10	0.47	0.43	Educational attainment;	chr4:119666626	chr1:222477252~222504622:-
STAD	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-8.98	1.8e-17	1.66e-10	-0.56	-0.43	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
STAD	trans	rs10028773	0.515	rs9994651	ENSG00000276997.3	RP11-378J18.9	8.97	1.88e-17	1.72e-10	0.46	0.43	Educational attainment;	chr4:119666648	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000223416.3	RPS26P15	8.97	1.89e-17	1.73e-10	0.46	0.43	Cognitive function;	chr12:55982097	chr1:58056133~58056480:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000227887.1	RPS26P13	8.97	1.91e-17	1.75e-10	0.52	0.43	Cognitive function;	chr12:56055651	chr1:208697369~208697698:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000227887.1	RPS26P13	8.97	1.93e-17	1.77e-10	0.47	0.43	Cognitive function;	chr12:55981353	chr1:208697369~208697698:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000196933.5	RPS26P11	8.97	1.93e-17	1.77e-10	0.46	0.43	Cognitive function;	chr12:56050848	chrX:72044545~72044892:+
STAD	trans	rs11098499	0.615	rs59867181	ENSG00000276997.3	RP11-378J18.9	-8.97	1.94e-17	1.77e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119635312	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.562	rs2389879	ENSG00000276997.3	RP11-378J18.9	-8.97	1.94e-17	1.77e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119636529	chr1:222477252~222504622:-
STAD	trans	rs877636	1	rs705696	ENSG00000242970.2	AC068522.4	8.97	1.97e-17	1.8e-10	0.47	0.43	Cognitive function;	chr12:56086864	chr8:58588420~58588764:-
STAD	trans	rs11098499	0.691	rs10028773	ENSG00000275858.1	RP11-291L22.8	-8.96	2e-17	1.83e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119344104	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.874	rs28452522	ENSG00000275858.1	RP11-291L22.8	8.95	2.15e-17	1.96e-10	0.49	0.43	Corneal astigmatism;	chr4:119189629	chr10:38450738~38451069:-
STAD	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	8.95	2.17e-17	1.98e-10	0.57	0.43	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-8.95	2.18e-17	1.99e-10	-0.49	-0.43	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
STAD	trans	rs8067354	0.872	rs7224006	ENSG00000187870.7	RNFT1P3	-8.95	2.23e-17	2.03e-10	-0.49	-0.43	Hemoglobin concentration;	chr17:59818977	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.872	rs1295925	ENSG00000187870.7	RNFT1P3	-8.95	2.23e-17	2.03e-10	-0.49	-0.43	Hemoglobin concentration;	chr17:59832902	chr17:20743333~20754501:-
STAD	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	8.95	2.26e-17	2.06e-10	0.46	0.43	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
STAD	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	8.95	2.26e-17	2.06e-10	0.57	0.43	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	8.95	2.26e-17	2.06e-10	0.57	0.43	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000212994.5	RPS26P6	8.94	2.32e-17	2.1e-10	0.44	0.43	Cognitive function;	chr12:56041628	chr8:100895771~100896118:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000234354.3	RPS26P47	-8.94	2.39e-17	2.18e-10	-0.55	-0.43	Cognitive function;	chr12:56080595	chr13:100539901~100540248:-
STAD	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	8.93	2.48e-17	2.25e-10	0.73	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
STAD	trans	rs13190036	0.748	rs28395268	ENSG00000228305.2	AC016734.2	8.93	2.49e-17	2.26e-10	0.46	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr2:63622178~63622831:-
STAD	trans	rs877636	1	rs4759229	ENSG00000234354.3	RPS26P47	-8.93	2.51e-17	2.27e-10	-0.55	-0.43	Cognitive function;	chr12:56080696	chr13:100539901~100540248:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000212994.5	RPS26P6	8.93	2.54e-17	2.31e-10	0.44	0.43	Cognitive function;	chr12:56002984	chr8:100895771~100896118:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000196933.5	RPS26P11	8.93	2.59e-17	2.35e-10	0.46	0.43	Cognitive function;	chr12:56009793	chrX:72044545~72044892:+
STAD	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-8.93	2.59e-17	2.35e-10	-0.56	-0.43	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
STAD	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-8.93	2.6e-17	2.36e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs4759229	ENSG00000234192.1	RP11-57C13.5	-8.93	2.62e-17	2.37e-10	-0.46	-0.43	Cognitive function;	chr12:56080696	chr10:87642607~87642954:+
STAD	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	8.92	2.77e-17	2.51e-10	0.37	0.43	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000196933.5	RPS26P11	8.92	2.83e-17	2.56e-10	0.46	0.43	Cognitive function;	chr12:56002984	chrX:72044545~72044892:+
STAD	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-8.91	3.06e-17	2.77e-10	-0.56	-0.43	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000227586.5	RP11-162A23.5	8.9	3.08e-17	2.78e-10	0.47	0.43	Cognitive function;	chr12:55981353	chr10:123171535~123171875:-
STAD	trans	rs11098499	0.562	rs13101722	ENSG00000276997.3	RP11-378J18.9	-8.9	3.09e-17	2.8e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119634820	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000212994.5	RPS26P6	8.9	3.12e-17	2.82e-10	0.44	0.43	Cognitive function;	chr12:56023144	chr8:100895771~100896118:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000212994.5	RPS26P6	8.9	3.17e-17	2.86e-10	0.44	0.43	Cognitive function;	chr12:56013288	chr8:100895771~100896118:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000212994.5	RPS26P6	8.9	3.17e-17	2.86e-10	0.44	0.43	Cognitive function;	chr12:56018703	chr8:100895771~100896118:+
STAD	trans	rs66887589	0.616	rs10032299	ENSG00000276997.3	RP11-378J18.9	8.9	3.18e-17	2.87e-10	0.46	0.43	Diastolic blood pressure;	chr4:119285264	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000223416.3	RPS26P15	8.9	3.18e-17	2.87e-10	0.47	0.43	Cognitive function;	chr12:55976127	chr1:58056133~58056480:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000223416.3	RPS26P15	8.9	3.24e-17	2.93e-10	0.46	0.43	Cognitive function;	chr12:55981956	chr1:58056133~58056480:-
STAD	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	8.9	3.25e-17	2.93e-10	0.57	0.43	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	8.9	3.25e-17	2.93e-10	0.57	0.43	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	8.9	3.25e-17	2.93e-10	0.57	0.43	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.616	rs1052633	ENSG00000276997.3	RP11-378J18.9	8.9	3.25e-17	2.93e-10	0.46	0.43	Diastolic blood pressure;	chr4:119294159	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.592	rs2175383	ENSG00000276997.3	RP11-378J18.9	8.9	3.25e-17	2.93e-10	0.46	0.43	Diastolic blood pressure;	chr4:119294681	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.71	rs4145952	ENSG00000275858.1	RP11-291L22.8	8.89	3.37e-17	3.04e-10	0.47	0.43	Corneal astigmatism;	chr4:119234651	chr10:38450738~38451069:-
STAD	trans	rs877636	1	rs2292239	ENSG00000234192.1	RP11-57C13.5	8.88	3.7e-17	3.33e-10	0.45	0.43	Cognitive function;	chr12:56088396	chr10:87642607~87642954:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000212994.5	RPS26P6	8.87	3.83e-17	3.45e-10	0.43	0.43	Cognitive function;	chr12:56041720	chr8:100895771~100896118:+
STAD	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	8.87	3.9e-17	3.51e-10	0.56	0.43	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	8.87	4e-17	3.6e-10	0.56	0.43	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000227887.1	RPS26P13	8.87	4.06e-17	3.65e-10	0.47	0.43	Cognitive function;	chr12:55980911	chr1:208697369~208697698:-
STAD	trans	rs877636	1	rs705696	ENSG00000234354.3	RPS26P47	8.86	4.25e-17	3.82e-10	0.56	0.43	Cognitive function;	chr12:56086864	chr13:100539901~100540248:-
STAD	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-8.86	4.41e-17	3.96e-10	-0.55	-0.43	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-8.86	4.41e-17	3.96e-10	-0.55	-0.43	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000196933.5	RPS26P11	8.86	4.42e-17	3.97e-10	0.46	0.43	Cognitive function;	chr12:56013288	chrX:72044545~72044892:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000196933.5	RPS26P11	8.86	4.42e-17	3.97e-10	0.46	0.43	Cognitive function;	chr12:56018703	chrX:72044545~72044892:+
STAD	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	8.85	4.54e-17	4.07e-10	0.55	0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
STAD	trans	rs877636	1	rs705696	ENSG00000244604.1	RP11-713H12.1	8.85	4.71e-17	4.23e-10	0.46	0.43	Cognitive function;	chr12:56086864	chr17:8561230~8561576:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000227887.1	RPS26P13	8.85	4.76e-17	4.27e-10	0.46	0.43	Cognitive function;	chr12:55996580	chr1:208697369~208697698:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000239210.2	RPS26P55	8.84	4.89e-17	4.38e-10	0.44	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr19:34533427~34534084:-
STAD	trans	rs13190036	1	rs13185316	ENSG00000228305.2	AC016734.2	-8.83	5.14e-17	4.6e-10	-0.48	-0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr2:63622178~63622831:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000242206.2	RPS26P35	-8.83	5.17e-17	4.63e-10	-0.43	-0.43	Cognitive function;	chr12:56080024	chr8:118761856~118762201:-
STAD	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	8.83	5.31e-17	4.75e-10	0.72	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000223416.3	RPS26P15	8.83	5.32e-17	4.76e-10	0.46	0.43	Cognitive function;	chr12:55981353	chr1:58056133~58056480:-
STAD	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-8.83	5.49e-17	4.91e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	8.83	5.5e-17	4.92e-10	0.45	0.43	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
STAD	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	8.82	5.53e-17	4.94e-10	0.56	0.43	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
STAD	trans	rs916888	0.61	rs199530	ENSG00000263503.1	RP11-707O23.5	-8.82	5.61e-17	5.01e-10	-0.55	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45600869~45602340:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000227887.1	RPS26P13	8.82	5.75e-17	5.14e-10	0.47	0.43	Cognitive function;	chr12:55976127	chr1:208697369~208697698:-
STAD	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-8.82	5.77e-17	5.15e-10	-0.55	-0.43	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
STAD	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-8.82	5.92e-17	5.28e-10	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-8.82	5.92e-17	5.28e-10	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9827021	ENSG00000197582.5	GPX1P1	-8.82	5.92e-17	5.28e-10	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49477331	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9818590	ENSG00000197582.5	GPX1P1	-8.82	5.92e-17	5.28e-10	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49487663	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs35261698	ENSG00000197582.5	GPX1P1	-8.82	5.92e-17	5.28e-10	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500406	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs6766131	ENSG00000197582.5	GPX1P1	-8.82	5.92e-17	5.28e-10	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501499	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9821311	ENSG00000197582.5	GPX1P1	-8.82	5.92e-17	5.28e-10	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49506223	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000227887.1	RPS26P13	8.81	5.94e-17	5.29e-10	0.47	0.43	Cognitive function;	chr12:55988132	chr1:208697369~208697698:-
STAD	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-8.81	6.02e-17	5.37e-10	-0.56	-0.43	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000196933.5	RPS26P11	8.81	6.27e-17	5.58e-10	0.45	0.43	Cognitive function;	chr12:56023144	chrX:72044545~72044892:+
STAD	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-8.8	6.41e-17	5.7e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
STAD	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	8.8	6.57e-17	5.85e-10	0.36	0.43	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
STAD	trans	rs1552244	0.608	rs7615408	ENSG00000230342.2	FANCD2P2	8.8	6.62e-17	5.89e-10	0.48	0.43	Alzheimer's disease;	chr3:9958502	chr3:11859674~11891172:+
STAD	trans	rs66887589	0.616	rs11731675	ENSG00000275858.1	RP11-291L22.8	8.8	6.65e-17	5.91e-10	0.45	0.43	Diastolic blood pressure;	chr4:119291359	chr10:38450738~38451069:-
STAD	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	8.8	6.79e-17	6.04e-10	0.73	0.43	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	8.8	6.8e-17	6.05e-10	0.41	0.43	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
STAD	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	8.79	7.2e-17	6.39e-10	0.49	0.43	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000196933.5	RPS26P11	8.78	7.52e-17	6.67e-10	0.45	0.43	Cognitive function;	chr12:56041628	chrX:72044545~72044892:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000239210.2	RPS26P55	8.78	7.68e-17	6.8e-10	0.52	0.43	Cognitive function;	chr12:56055651	chr19:34533427~34534084:-
STAD	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	8.78	7.8e-17	6.91e-10	0.56	0.43	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	8.77	8.23e-17	7.27e-10	0.49	0.43	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	8.77	8.23e-17	7.27e-10	0.49	0.43	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000227586.5	RP11-162A23.5	8.77	8.38e-17	7.4e-10	0.47	0.43	Cognitive function;	chr12:55980911	chr10:123171535~123171875:-
STAD	trans	rs13190036	0.551	rs4976639	ENSG00000228305.2	AC016734.2	8.76	8.89e-17	7.85e-10	0.45	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr2:63622178~63622831:-
STAD	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	8.76	8.9e-17	7.85e-10	0.46	0.43	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
STAD	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	8.75	9.19e-17	8.1e-10	0.5	0.43	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
STAD	trans	rs877636	1	rs705696	ENSG00000234192.1	RP11-57C13.5	8.75	9.27e-17	8.17e-10	0.46	0.43	Cognitive function;	chr12:56086864	chr10:87642607~87642954:+
STAD	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-8.75	9.42e-17	8.3e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
STAD	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-8.75	9.42e-17	8.3e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
STAD	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	8.75	9.5e-17	8.36e-10	0.72	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
STAD	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	8.75	9.5e-17	8.36e-10	0.72	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
STAD	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	8.75	9.5e-17	8.36e-10	0.72	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
STAD	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	8.75	9.5e-17	8.36e-10	0.72	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
STAD	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	8.75	9.5e-17	8.36e-10	0.72	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000242206.2	RPS26P35	-8.75	9.68e-17	8.51e-10	-0.43	-0.43	Cognitive function;	chr12:56084218	chr8:118761856~118762201:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000242206.2	RPS26P35	-8.75	9.68e-17	8.51e-10	-0.43	-0.43	Cognitive function;	chr12:56084874	chr8:118761856~118762201:-
STAD	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-8.74	1.01e-16	8.89e-10	-0.55	-0.43	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-8.74	1.01e-16	8.89e-10	-0.55	-0.43	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
STAD	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-8.74	1.01e-16	8.89e-10	-0.55	-0.43	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
STAD	trans	rs66887589	0.616	rs6843509	ENSG00000276997.3	RP11-378J18.9	8.74	1.03e-16	9.03e-10	0.46	0.43	Diastolic blood pressure;	chr4:119299041	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-8.74	1.04e-16	9.13e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000243538.1	CTB-55B8.1	8.74	1.06e-16	9.29e-10	0.42	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr5:16902294~16902641:-
STAD	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	8.73	1.08e-16	9.46e-10	0.35	0.42	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
STAD	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	8.73	1.11e-16	9.71e-10	0.72	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
STAD	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	8.73	1.11e-16	9.71e-10	0.72	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
STAD	trans	rs11220082	0.602	rs10893383	ENSG00000236257.1	EI24P2	-8.73	1.12e-16	9.81e-10	-0.56	-0.42	Schizophrenia;	chr11:125466237	chr1:158454198~158455273:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000227586.5	RP11-162A23.5	8.73	1.14e-16	9.97e-10	0.47	0.42	Cognitive function;	chr12:55976127	chr10:123171535~123171875:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000234192.1	RP11-57C13.5	-8.72	1.16e-16	1.01e-09	-0.45	-0.42	Cognitive function;	chr12:56080595	chr10:87642607~87642954:+
STAD	trans	rs66887589	0.616	rs11732621	ENSG00000275858.1	RP11-291L22.8	8.72	1.18e-16	1.03e-09	0.45	0.42	Diastolic blood pressure;	chr4:119291728	chr10:38450738~38451069:-
STAD	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-8.72	1.21e-16	1.06e-09	-0.35	-0.42	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
STAD	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	8.72	1.22e-16	1.06e-09	0.49	0.42	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000223416.3	RPS26P15	8.71	1.3e-16	1.13e-09	0.46	0.42	Cognitive function;	chr12:55988132	chr1:58056133~58056480:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000234513.1	AC073072.7	8.7	1.32e-16	1.15e-09	0.43	0.42	Cognitive function;	chr12:55990903	chr7:22773646~22773993:-
STAD	trans	rs1552244	0.554	rs4488814	ENSG00000230342.2	FANCD2P2	-8.7	1.37e-16	1.19e-09	-0.45	-0.42	Alzheimer's disease;	chr3:9960716	chr3:11859674~11891172:+
STAD	trans	rs66887589	0.616	rs6822808	ENSG00000276997.3	RP11-378J18.9	8.7	1.41e-16	1.23e-09	0.46	0.42	Diastolic blood pressure;	chr4:119296210	chr1:222477252~222504622:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-8.69	1.43e-16	1.24e-09	-0.4	-0.42	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
STAD	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	8.69	1.44e-16	1.25e-09	0.48	0.42	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
STAD	trans	rs1552244	0.554	rs7638846	ENSG00000230342.2	FANCD2P2	8.68	1.55e-16	1.35e-09	0.47	0.42	Alzheimer's disease;	chr3:10006917	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.515	rs28853661	ENSG00000230342.2	FANCD2P2	8.68	1.56e-16	1.35e-09	0.58	0.42	Alzheimer's disease;	chr3:10135975	chr3:11859674~11891172:+
STAD	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	8.68	1.57e-16	1.36e-09	0.62	0.42	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
STAD	trans	rs916888	0.61	rs199530	ENSG00000280022.1	RP11-707O23.1	-8.68	1.61e-16	1.39e-09	-0.53	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45592621~45593369:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000204652.6	RPS26P8	8.68	1.61e-16	1.39e-09	0.44	0.42	Cognitive function;	chr12:55988132	chr17:45608571~45608918:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000224553.1	AC008065.1	8.68	1.63e-16	1.42e-09	0.44	0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr2:171374931~171375278:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000204652.6	RPS26P8	8.66	1.83e-16	1.58e-09	0.43	0.42	Cognitive function;	chr12:55982097	chr17:45608571~45608918:+
STAD	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-8.66	1.84e-16	1.59e-09	-0.52	-0.42	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
STAD	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	8.66	1.85e-16	1.59e-09	0.36	0.42	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
STAD	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	8.66	1.88e-16	1.63e-09	0.36	0.42	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000204652.6	RPS26P8	8.66	1.89e-16	1.63e-09	0.43	0.42	Cognitive function;	chr12:55981956	chr17:45608571~45608918:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000227887.1	RPS26P13	-8.65	1.96e-16	1.69e-09	-0.45	-0.42	Cognitive function;	chr12:55996852	chr1:208697369~208697698:-
STAD	trans	rs9611565	1	rs1109151	ENSG00000268568.1	AC007228.9	-8.64	2.06e-16	1.77e-09	-0.55	-0.42	Vitiligo;	chr22:41356940	chr19:56672574~56673901:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000235459.5	RPS26P31	8.64	2.08e-16	1.79e-09	0.46	0.42	Cognitive function;	chr12:55990903	chr7:122681315~122681662:+
STAD	trans	rs8067354	0.958	rs8081468	ENSG00000187870.7	RNFT1P3	8.64	2.1e-16	1.81e-09	0.47	0.42	Hemoglobin concentration;	chr17:59759563	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.958	rs2333563	ENSG00000187870.7	RNFT1P3	8.64	2.1e-16	1.81e-09	0.47	0.42	Hemoglobin concentration;	chr17:59762207	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.958	rs2777889	ENSG00000187870.7	RNFT1P3	8.64	2.1e-16	1.81e-09	0.47	0.42	Hemoglobin concentration;	chr17:59770645	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.872	rs2645483	ENSG00000187870.7	RNFT1P3	8.64	2.1e-16	1.81e-09	0.47	0.42	Hemoglobin concentration;	chr17:59770823	chr17:20743333~20754501:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000242206.2	RPS26P35	-8.64	2.13e-16	1.83e-09	-0.43	-0.42	Cognitive function;	chr12:56083910	chr8:118761856~118762201:-
STAD	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	8.64	2.14e-16	1.84e-09	0.48	0.42	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	8.64	2.14e-16	1.84e-09	0.48	0.42	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	8.64	2.14e-16	1.84e-09	0.48	0.42	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	8.64	2.14e-16	1.84e-09	0.48	0.42	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000223416.3	RPS26P15	8.64	2.15e-16	1.84e-09	0.45	0.42	Cognitive function;	chr12:55980911	chr1:58056133~58056480:-
STAD	trans	rs877636	0.736	rs773107	ENSG00000235459.5	RPS26P31	8.64	2.16e-16	1.86e-09	0.48	0.42	Cognitive function;	chr12:55975722	chr7:122681315~122681662:+
STAD	trans	rs11039798	0.512	rs3974936	ENSG00000134612.10	FOLH1B	8.63	2.25e-16	1.93e-09	0.67	0.42	Axial length;	chr11:48983460	chr11:89639227~89698718:+
STAD	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-8.63	2.35e-16	2.01e-09	-0.36	-0.42	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
STAD	trans	rs11039798	0.588	rs1814768	ENSG00000134612.10	FOLH1B	8.62	2.36e-16	2.02e-09	0.67	0.42	Axial length;	chr11:48965903	chr11:89639227~89698718:+
STAD	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-8.62	2.43e-16	2.08e-09	-0.54	-0.42	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000242970.2	AC068522.4	8.62	2.43e-16	2.08e-09	0.48	0.42	Cognitive function;	chr12:56002984	chr8:58588420~58588764:-
STAD	trans	rs13190036	1	rs625882	ENSG00000228305.2	AC016734.2	-8.62	2.44e-16	2.09e-09	-0.44	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr2:63622178~63622831:-
STAD	trans	rs66887589	0.616	rs1052633	ENSG00000275858.1	RP11-291L22.8	8.62	2.49e-16	2.13e-09	0.44	0.42	Diastolic blood pressure;	chr4:119294159	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.592	rs2175383	ENSG00000275858.1	RP11-291L22.8	8.62	2.49e-16	2.13e-09	0.44	0.42	Diastolic blood pressure;	chr4:119294681	chr10:38450738~38451069:-
STAD	trans	rs11039798	0.512	rs28453037	ENSG00000134612.10	FOLH1B	8.61	2.61e-16	2.23e-09	0.68	0.42	Axial length;	chr11:48985377	chr11:89639227~89698718:+
STAD	trans	rs11098499	0.739	rs9996382	ENSG00000276997.3	RP11-378J18.9	8.61	2.62e-16	2.23e-09	0.46	0.42	Corneal astigmatism;	chr4:119229857	chr1:222477252~222504622:-
STAD	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	8.61	2.65e-16	2.26e-09	0.51	0.42	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
STAD	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	8.61	2.68e-16	2.29e-09	0.48	0.42	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
STAD	trans	rs11220082	0.644	rs34435097	ENSG00000236257.1	EI24P2	-8.6	2.74e-16	2.34e-09	-0.55	-0.42	Schizophrenia;	chr11:125469075	chr1:158454198~158455273:+
STAD	trans	rs11220082	0.666	rs7103665	ENSG00000236257.1	EI24P2	-8.6	2.74e-16	2.34e-09	-0.55	-0.42	Schizophrenia;	chr11:125472998	chr1:158454198~158455273:+
STAD	trans	rs11220082	0.644	rs61917855	ENSG00000236257.1	EI24P2	-8.6	2.74e-16	2.34e-09	-0.55	-0.42	Schizophrenia;	chr11:125473652	chr1:158454198~158455273:+
STAD	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	8.6	2.74e-16	2.34e-09	0.35	0.42	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
STAD	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	8.6	2.76e-16	2.35e-09	0.48	0.42	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000242206.2	RPS26P35	-8.6	2.8e-16	2.39e-09	-0.44	-0.42	Cognitive function;	chr12:56042145	chr8:118761856~118762201:-
STAD	trans	rs11098499	0.754	rs10518300	ENSG00000276997.3	RP11-378J18.9	-8.6	2.84e-16	2.42e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119328344	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000204652.6	RPS26P8	8.6	2.87e-16	2.44e-09	0.43	0.42	Cognitive function;	chr12:55980911	chr17:45608571~45608918:+
STAD	trans	rs1552244	0.554	rs6800204	ENSG00000230342.2	FANCD2P2	8.59	2.93e-16	2.49e-09	0.45	0.42	Alzheimer's disease;	chr3:9953720	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs6762594	ENSG00000230342.2	FANCD2P2	8.59	2.93e-16	2.49e-09	0.45	0.42	Alzheimer's disease;	chr3:9953832	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000204652.6	RPS26P8	8.59	3e-16	2.55e-09	0.43	0.42	Cognitive function;	chr12:55981353	chr17:45608571~45608918:+
STAD	trans	rs9611565	1	rs5758314	ENSG00000268568.1	AC007228.9	-8.59	3.02e-16	2.56e-09	-0.54	-0.42	Vitiligo;	chr22:41366519	chr19:56672574~56673901:-
STAD	trans	rs11220082	0.666	rs12789687	ENSG00000236257.1	EI24P2	-8.59	3.05e-16	2.59e-09	-0.55	-0.42	Schizophrenia;	chr11:125461254	chr1:158454198~158455273:+
STAD	trans	rs11220082	0.666	rs12223186	ENSG00000236257.1	EI24P2	-8.59	3.05e-16	2.59e-09	-0.55	-0.42	Schizophrenia;	chr11:125461743	chr1:158454198~158455273:+
STAD	trans	rs10028773	0.515	rs9994651	ENSG00000275858.1	RP11-291L22.8	8.59	3.11e-16	2.64e-09	0.44	0.42	Educational attainment;	chr4:119666648	chr10:38450738~38451069:-
STAD	trans	rs916888	0.779	rs199498	ENSG00000280022.1	RP11-707O23.1	8.58	3.14e-16	2.67e-09	0.53	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45592621~45593369:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000227586.5	RP11-162A23.5	-8.58	3.29e-16	2.79e-09	-0.45	-0.42	Cognitive function;	chr12:55996852	chr10:123171535~123171875:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000227586.5	RP11-162A23.5	8.58	3.33e-16	2.82e-09	0.45	0.42	Cognitive function;	chr12:55996580	chr10:123171535~123171875:-
STAD	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	8.58	3.34e-16	2.83e-09	0.5	0.42	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
STAD	trans	rs8067354	1	rs8067354	ENSG00000187870.7	RNFT1P3	8.57	3.39e-16	2.87e-09	0.47	0.42	Hemoglobin concentration;	chr17:59744069	chr17:20743333~20754501:-
STAD	trans	rs66887589	0.592	rs11731571	ENSG00000275858.1	RP11-291L22.8	8.57	3.4e-16	2.88e-09	0.45	0.42	Diastolic blood pressure;	chr4:119300030	chr10:38450738~38451069:-
STAD	trans	rs1552244	0.554	rs3846167	ENSG00000230342.2	FANCD2P2	8.57	3.55e-16	3e-09	0.45	0.42	Alzheimer's disease;	chr3:9954742	chr3:11859674~11891172:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000233778.3	RP11-777J24.1	8.56	3.72e-16	3.14e-09	0.46	0.42	Cognitive function;	chr12:56055651	chr8:92144088~92144435:-
STAD	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	8.56	3.74e-16	3.16e-09	0.48	0.42	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
STAD	trans	rs11220082	0.627	rs34912904	ENSG00000236257.1	EI24P2	-8.55	3.94e-16	3.33e-09	-0.55	-0.42	Schizophrenia;	chr11:125475460	chr1:158454198~158455273:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000242970.2	AC068522.4	8.55	3.99e-16	3.37e-09	0.47	0.42	Cognitive function;	chr12:56009793	chr8:58588420~58588764:-
STAD	trans	rs11220082	0.666	rs12224788	ENSG00000236257.1	EI24P2	-8.54	4.23e-16	3.57e-09	-0.55	-0.42	Schizophrenia;	chr11:125459165	chr1:158454198~158455273:+
STAD	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	8.54	4.26e-16	3.6e-09	0.51	0.42	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	8.54	4.34e-16	3.65e-09	0.51	0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
STAD	trans	rs8067354	0.957	rs9896742	ENSG00000187870.7	RNFT1P3	8.54	4.4e-16	3.71e-09	0.47	0.42	Hemoglobin concentration;	chr17:59749169	chr17:20743333~20754501:-
STAD	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	8.54	4.47e-16	3.76e-09	0.48	0.42	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	8.54	4.47e-16	3.76e-09	0.48	0.42	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	8.54	4.47e-16	3.76e-09	0.48	0.42	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000242970.2	AC068522.4	8.53	4.54e-16	3.81e-09	0.47	0.42	Cognitive function;	chr12:56050848	chr8:58588420~58588764:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000204652.6	RPS26P8	8.52	4.98e-16	4.17e-09	0.43	0.42	Cognitive function;	chr12:55976127	chr17:45608571~45608918:+
STAD	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	8.52	5.02e-16	4.21e-09	0.35	0.42	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
STAD	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	8.51	5.17e-16	4.34e-09	0.36	0.42	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000242206.2	RPS26P35	-8.51	5.24e-16	4.39e-09	-0.44	-0.42	Cognitive function;	chr12:56007301	chr8:118761856~118762201:-
STAD	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-8.51	5.33e-16	4.45e-09	-0.58	-0.42	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-8.51	5.33e-16	4.45e-09	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-8.51	5.33e-16	4.45e-09	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-8.51	5.33e-16	4.45e-09	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-8.51	5.33e-16	4.45e-09	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-8.51	5.33e-16	4.45e-09	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs4625	ENSG00000197582.5	GPX1P1	-8.51	5.39e-16	4.51e-09	-0.59	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49534707	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs3811697	ENSG00000197582.5	GPX1P1	-8.51	5.39e-16	4.51e-09	-0.59	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49553337	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9837027	ENSG00000197582.5	GPX1P1	-8.51	5.46e-16	4.56e-09	-0.6	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559580	chrX:13378735~13379340:-
STAD	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	8.51	5.53e-16	4.62e-09	0.36	0.42	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
STAD	trans	rs877636	0.701	rs34415530	ENSG00000244604.1	RP11-713H12.1	8.5	5.59e-16	4.66e-09	0.47	0.42	Cognitive function;	chr12:56050848	chr17:8561230~8561576:+
STAD	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	8.5	5.61e-16	4.67e-09	0.48	0.42	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
STAD	trans	rs66887589	0.72	rs11724758	ENSG00000275858.1	RP11-291L22.8	8.5	5.65e-16	4.71e-09	0.43	0.42	Diastolic blood pressure;	chr4:119318723	chr10:38450738~38451069:-
STAD	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	8.5	5.78e-16	4.81e-09	0.35	0.42	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000233278.1	RPS26P2	8.49	5.98e-16	4.97e-09	0.42	0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:30831878~30832225:-
STAD	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	8.49	6.04e-16	5.02e-09	0.48	0.42	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	8.49	6.04e-16	5.02e-09	0.48	0.42	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000233278.1	RPS26P2	-8.49	6.13e-16	5.09e-09	-0.41	-0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:30831878~30832225:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000242970.2	AC068522.4	8.49	6.2e-16	5.15e-09	0.47	0.42	Cognitive function;	chr12:56013288	chr8:58588420~58588764:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000242970.2	AC068522.4	8.49	6.2e-16	5.15e-09	0.47	0.42	Cognitive function;	chr12:56018703	chr8:58588420~58588764:-
STAD	trans	rs9858542	0.903	rs17080528	ENSG00000197582.5	GPX1P1	-8.49	6.38e-16	5.29e-09	-0.59	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49352409	chrX:13378735~13379340:-
STAD	trans	rs11039798	0.507	rs56994343	ENSG00000134612.10	FOLH1B	8.48	6.46e-16	5.35e-09	0.64	0.41	Axial length;	chr11:48875418	chr11:89639227~89698718:+
STAD	trans	rs9858542	0.953	rs6997	ENSG00000197582.5	GPX1P1	-8.48	6.79e-16	5.62e-09	-0.58	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9858280	ENSG00000197582.5	GPX1P1	-8.48	6.86e-16	5.68e-09	-0.59	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49560304	chrX:13378735~13379340:-
STAD	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	8.47	7.07e-16	5.85e-09	0.56	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000242970.2	AC068522.4	8.47	7.27e-16	6.02e-09	0.47	0.41	Cognitive function;	chr12:56041628	chr8:58588420~58588764:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000242970.2	AC068522.4	8.47	7.33e-16	6.06e-09	0.46	0.41	Cognitive function;	chr12:56041720	chr8:58588420~58588764:-
STAD	trans	rs13090388	1	rs13090388	ENSG00000197582.5	GPX1P1	-8.47	7.36e-16	6.08e-09	-0.59	-0.41	Educational attainment (years of education);Intelligence (multi-trait analysis);	chr3:49353649	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000242970.2	AC068522.4	8.46	7.45e-16	6.15e-09	0.46	0.41	Cognitive function;	chr12:56023144	chr8:58588420~58588764:-
STAD	trans	rs66887589	0.616	rs6843509	ENSG00000275858.1	RP11-291L22.8	8.46	7.78e-16	6.42e-09	0.44	0.41	Diastolic blood pressure;	chr4:119299041	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.616	rs11098497	ENSG00000275858.1	RP11-291L22.8	8.45	8.07e-16	6.65e-09	0.44	0.41	Diastolic blood pressure;	chr4:119265913	chr10:38450738~38451069:-
STAD	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	8.45	8.2e-16	6.75e-09	0.36	0.41	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000227586.5	RP11-162A23.5	8.45	8.21e-16	6.76e-09	0.5	0.41	Cognitive function;	chr12:56055651	chr10:123171535~123171875:-
STAD	trans	rs11039798	0.588	rs1847640	ENSG00000134612.10	FOLH1B	8.45	8.42e-16	6.93e-09	0.66	0.41	Axial length;	chr11:48982473	chr11:89639227~89698718:+
STAD	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	8.45	8.42e-16	6.93e-09	0.35	0.41	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
STAD	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	8.44	8.55e-16	7.03e-09	0.48	0.41	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
STAD	trans	rs9858542	0.953	rs1801143	ENSG00000197582.5	GPX1P1	-8.43	9.22e-16	7.56e-09	-0.59	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49532767	chrX:13378735~13379340:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000243538.1	CTB-55B8.1	8.43	9.34e-16	7.65e-09	0.48	0.41	Cognitive function;	chr12:56055651	chr5:16902294~16902641:-
STAD	trans	rs11039798	0.512	rs11040205	ENSG00000134612.10	FOLH1B	8.43	9.47e-16	7.75e-09	0.66	0.41	Axial length;	chr11:48985808	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.512	rs1988465	ENSG00000134612.10	FOLH1B	8.43	9.47e-16	7.75e-09	0.66	0.41	Axial length;	chr11:48989751	chr11:89639227~89698718:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000204652.6	RPS26P8	8.43	9.66e-16	7.9e-09	0.41	0.41	Cognitive function;	chr12:55996580	chr17:45608571~45608918:+
STAD	trans	rs11039798	0.528	rs10839208	ENSG00000134612.10	FOLH1B	8.43	9.74e-16	7.97e-09	0.65	0.41	Axial length;	chr11:49008904	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000212829.8	RPS26P3	8.43	9.75e-16	7.98e-09	0.42	0.41	Cognitive function;	chr12:55981956	chr9:9090898~9091245:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	8.42	9.93e-16	8.11e-09	0.5	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
STAD	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	8.41	1.05e-15	8.58e-09	0.38	0.41	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
STAD	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	8.41	1.06e-15	8.6e-09	0.47	0.41	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
STAD	trans	rs66887589	0.616	rs7659403	ENSG00000275858.1	RP11-291L22.8	8.41	1.07e-15	8.71e-09	0.44	0.41	Diastolic blood pressure;	chr4:119286099	chr10:38450738~38451069:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000227586.5	RP11-162A23.5	8.41	1.08e-15	8.76e-09	0.46	0.41	Cognitive function;	chr12:55990903	chr10:123171535~123171875:-
STAD	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	8.4	1.16e-15	9.44e-09	0.36	0.41	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
STAD	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	8.4	1.16e-15	9.44e-09	0.36	0.41	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
STAD	trans	rs10028773	0.515	rs9994488	ENSG00000275858.1	RP11-291L22.8	8.39	1.25e-15	1.02e-08	0.44	0.41	Educational attainment;	chr4:119666626	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000234192.1	RP11-57C13.5	8.39	1.28e-15	1.03e-08	0.47	0.41	Cognitive function;	chr12:56041628	chr10:87642607~87642954:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000234192.1	RP11-57C13.5	8.39	1.28e-15	1.04e-08	0.47	0.41	Cognitive function;	chr12:56002984	chr10:87642607~87642954:+
STAD	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	8.38	1.3e-15	1.06e-08	0.36	0.41	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000244604.1	RP11-713H12.1	8.38	1.33e-15	1.08e-08	0.47	0.41	Cognitive function;	chr12:56002984	chr17:8561230~8561576:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000204652.6	RPS26P8	-8.38	1.33e-15	1.08e-08	-0.41	-0.41	Cognitive function;	chr12:55996852	chr17:45608571~45608918:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000212829.8	RPS26P3	8.38	1.34e-15	1.08e-08	0.42	0.41	Cognitive function;	chr12:55976127	chr9:9090898~9091245:+
STAD	trans	rs66887589	0.616	rs11098498	ENSG00000275858.1	RP11-291L22.8	8.38	1.34e-15	1.08e-08	0.44	0.41	Diastolic blood pressure;	chr4:119265964	chr10:38450738~38451069:-
STAD	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	8.38	1.35e-15	1.09e-08	0.55	0.41	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
STAD	trans	rs1552244	0.554	rs3732964	ENSG00000230342.2	FANCD2P2	8.38	1.35e-15	1.09e-08	0.45	0.41	Alzheimer's disease;	chr3:10007155	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs3732963	ENSG00000230342.2	FANCD2P2	8.38	1.35e-15	1.09e-08	0.45	0.41	Alzheimer's disease;	chr3:10007201	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.608	rs3732962	ENSG00000230342.2	FANCD2P2	8.38	1.35e-15	1.09e-08	0.45	0.41	Alzheimer's disease;	chr3:10007267	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs2272118	ENSG00000230342.2	FANCD2P2	8.38	1.35e-15	1.09e-08	0.45	0.41	Alzheimer's disease;	chr3:10007603	chr3:11859674~11891172:+
STAD	trans	rs7554511	1	rs7554511	ENSG00000244144.1	RP11-757F18.3	8.38	1.36e-15	1.1e-08	0.48	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr3:112185480~112185998:-
STAD	trans	rs11098499	0.739	rs9884728	ENSG00000276997.3	RP11-378J18.9	-8.38	1.37e-15	1.1e-08	-0.45	-0.41	Corneal astigmatism;	chr4:119205924	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.739	rs6534130	ENSG00000276997.3	RP11-378J18.9	-8.38	1.37e-15	1.1e-08	-0.45	-0.41	Corneal astigmatism;	chr4:119210184	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.739	rs7441137	ENSG00000276997.3	RP11-378J18.9	-8.38	1.37e-15	1.1e-08	-0.45	-0.41	Corneal astigmatism;	chr4:119212066	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000233778.3	RP11-777J24.1	8.38	1.37e-15	1.11e-08	0.42	0.41	Cognitive function;	chr12:55982097	chr8:92144088~92144435:-
STAD	trans	rs11098499	0.739	rs2203039	ENSG00000276997.3	RP11-378J18.9	-8.38	1.38e-15	1.11e-08	-0.45	-0.41	Corneal astigmatism;	chr4:119211192	chr1:222477252~222504622:-
STAD	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	8.38	1.38e-15	1.12e-08	0.51	0.41	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
STAD	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	8.38	1.38e-15	1.12e-08	0.35	0.41	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
STAD	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	8.38	1.38e-15	1.12e-08	0.35	0.41	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
STAD	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	8.38	1.38e-15	1.12e-08	0.35	0.41	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
STAD	trans	rs10816533	1	rs10124033	ENSG00000232063.1	RP11-307E17.8	-8.38	1.39e-15	1.12e-08	-0.7	-0.41	Height;	chr9:96851822	chr9:94332476~94360948:+
STAD	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-8.37	1.48e-15	1.19e-08	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000234192.1	RP11-57C13.5	8.36	1.5e-15	1.21e-08	0.46	0.41	Cognitive function;	chr12:56023144	chr10:87642607~87642954:+
STAD	trans	rs66887589	0.616	rs10032299	ENSG00000275858.1	RP11-291L22.8	8.36	1.53e-15	1.23e-08	0.44	0.41	Diastolic blood pressure;	chr4:119285264	chr10:38450738~38451069:-
STAD	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	8.36	1.54e-15	1.24e-08	0.47	0.41	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
STAD	trans	rs11098499	0.739	rs4833612	ENSG00000276997.3	RP11-378J18.9	-8.36	1.54e-15	1.24e-08	-0.45	-0.41	Corneal astigmatism;	chr4:119226441	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.739	rs10013032	ENSG00000276997.3	RP11-378J18.9	-8.36	1.54e-15	1.24e-08	-0.45	-0.41	Corneal astigmatism;	chr4:119228264	chr1:222477252~222504622:-
STAD	trans	rs11098499	0.739	rs951570	ENSG00000276997.3	RP11-378J18.9	-8.36	1.54e-15	1.24e-08	-0.45	-0.41	Corneal astigmatism;	chr4:119229312	chr1:222477252~222504622:-
STAD	trans	rs11220082	0.666	rs35203305	ENSG00000236257.1	EI24P2	-8.36	1.57e-15	1.26e-08	-0.54	-0.41	Schizophrenia;	chr11:125468987	chr1:158454198~158455273:+
STAD	trans	rs877636	0.701	rs34415530	ENSG00000234192.1	RP11-57C13.5	8.36	1.59e-15	1.28e-08	0.46	0.41	Cognitive function;	chr12:56050848	chr10:87642607~87642954:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000233778.3	RP11-777J24.1	8.36	1.6e-15	1.29e-08	0.42	0.41	Cognitive function;	chr12:55981956	chr8:92144088~92144435:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000234192.1	RP11-57C13.5	8.35	1.61e-15	1.29e-08	0.46	0.41	Cognitive function;	chr12:56009793	chr10:87642607~87642954:+
STAD	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	8.35	1.61e-15	1.3e-08	0.66	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
STAD	trans	rs1552244	0.608	rs6764807	ENSG00000230342.2	FANCD2P2	8.35	1.65e-15	1.33e-08	0.45	0.41	Alzheimer's disease;	chr3:9957119	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs34391585	ENSG00000230342.2	FANCD2P2	8.35	1.65e-15	1.33e-08	0.45	0.41	Alzheimer's disease;	chr3:9957524	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.515	rs7613004	ENSG00000230342.2	FANCD2P2	8.35	1.65e-15	1.33e-08	0.45	0.41	Alzheimer's disease;	chr3:9958229	chr3:11859674~11891172:+
STAD	trans	rs13177918	0.626	rs2748240	ENSG00000226396.1	RP5-1056L3.3	8.35	1.66e-15	1.33e-08	0.4	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:19608114~19608568:+
STAD	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-8.35	1.66e-15	1.34e-08	-0.36	-0.41	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
STAD	trans	rs13190036	0.591	rs78523677	ENSG00000228305.2	AC016734.2	-8.35	1.67e-15	1.34e-08	-0.43	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr2:63622178~63622831:-
STAD	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-8.35	1.69e-15	1.36e-08	-0.52	-0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
STAD	trans	rs13177918	0.798	rs12514700	ENSG00000226396.1	RP5-1056L3.3	8.34	1.81e-15	1.45e-08	0.46	0.41	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:19608114~19608568:+
STAD	trans	rs11039798	0.528	rs10769559	ENSG00000134612.10	FOLH1B	8.34	1.81e-15	1.45e-08	0.65	0.41	Axial length;	chr11:49010894	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000212829.8	RPS26P3	8.34	1.84e-15	1.47e-08	0.42	0.41	Cognitive function;	chr12:55981353	chr9:9090898~9091245:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000234192.1	RP11-57C13.5	8.33	1.91e-15	1.52e-08	0.46	0.41	Cognitive function;	chr12:56041720	chr10:87642607~87642954:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000234192.1	RP11-57C13.5	8.33	1.92e-15	1.53e-08	0.46	0.41	Cognitive function;	chr12:56013288	chr10:87642607~87642954:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000234192.1	RP11-57C13.5	8.33	1.92e-15	1.53e-08	0.46	0.41	Cognitive function;	chr12:56018703	chr10:87642607~87642954:+
STAD	trans	rs941207	0.547	rs56183434	ENSG00000121089.4	NACA3P	8.32	1.99e-15	1.59e-08	0.38	0.41	Platelet count;	chr12:56676145	chr4:164943290~164943937:+
STAD	trans	rs1552244	0.554	rs58020561	ENSG00000230342.2	FANCD2P2	8.32	2.01e-15	1.6e-08	0.45	0.41	Alzheimer's disease;	chr3:10012998	chr3:11859674~11891172:+
STAD	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	8.32	2.03e-15	1.62e-08	0.5	0.41	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000212829.8	RPS26P3	8.32	2.04e-15	1.63e-08	0.42	0.41	Cognitive function;	chr12:55982097	chr9:9090898~9091245:+
STAD	trans	rs13086611	1	rs13086611	ENSG00000197582.5	GPX1P1	-8.32	2.07e-15	1.65e-08	-0.58	-0.41	Educational attainment;	chr3:49347984	chrX:13378735~13379340:-
STAD	trans	rs1552244	0.554	rs13081079	ENSG00000230342.2	FANCD2P2	8.31	2.15e-15	1.72e-08	0.45	0.41	Alzheimer's disease;	chr3:10014664	chr3:11859674~11891172:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000244604.1	RP11-713H12.1	8.31	2.18e-15	1.74e-08	0.46	0.41	Cognitive function;	chr12:56009793	chr17:8561230~8561576:+
STAD	trans	rs11039798	0.588	rs61932767	ENSG00000134612.10	FOLH1B	8.31	2.28e-15	1.81e-08	0.62	0.41	Axial length;	chr11:48683254	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000233778.3	RP11-777J24.1	8.3	2.38e-15	1.89e-08	0.41	0.41	Cognitive function;	chr12:55981353	chr8:92144088~92144435:-
STAD	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	8.3	2.4e-15	1.91e-08	0.47	0.41	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	8.3	2.4e-15	1.91e-08	0.47	0.41	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	8.3	2.4e-15	1.91e-08	0.47	0.41	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	8.3	2.4e-15	1.91e-08	0.47	0.41	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
STAD	trans	rs1552244	0.554	rs17050704	ENSG00000230342.2	FANCD2P2	8.29	2.5e-15	1.98e-08	0.44	0.41	Alzheimer's disease;	chr3:10004050	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs34883592	ENSG00000230342.2	FANCD2P2	8.29	2.5e-15	1.98e-08	0.44	0.41	Alzheimer's disease;	chr3:10004481	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs17050705	ENSG00000230342.2	FANCD2P2	8.29	2.5e-15	1.98e-08	0.44	0.41	Alzheimer's disease;	chr3:10004714	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs2272120	ENSG00000230342.2	FANCD2P2	8.29	2.5e-15	1.98e-08	0.44	0.41	Alzheimer's disease;	chr3:10005019	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs13079240	ENSG00000230342.2	FANCD2P2	8.29	2.5e-15	1.98e-08	0.44	0.41	Alzheimer's disease;	chr3:10005562	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs2272121	ENSG00000230342.2	FANCD2P2	8.29	2.5e-15	1.98e-08	0.44	0.41	Alzheimer's disease;	chr3:10005996	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs3732965	ENSG00000230342.2	FANCD2P2	8.29	2.5e-15	1.98e-08	0.44	0.41	Alzheimer's disease;	chr3:10007076	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000212829.8	RPS26P3	8.29	2.5e-15	1.98e-08	0.42	0.41	Cognitive function;	chr12:55988132	chr9:9090898~9091245:+
STAD	trans	rs1552244	0.554	rs6443275	ENSG00000230342.2	FANCD2P2	8.28	2.67e-15	2.11e-08	0.44	0.41	Alzheimer's disease;	chr3:9967135	chr3:11859674~11891172:+
STAD	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	8.28	2.68e-15	2.12e-08	0.47	0.41	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
STAD	trans	rs877636	1	rs877636	ENSG00000233278.1	RPS26P2	-8.28	2.71e-15	2.14e-08	-0.43	-0.41	Cognitive function;	chr12:56086799	chr9:30831878~30832225:-
STAD	trans	rs66887589	0.616	rs6822808	ENSG00000275858.1	RP11-291L22.8	8.28	2.72e-15	2.15e-08	0.43	0.41	Diastolic blood pressure;	chr4:119296210	chr10:38450738~38451069:-
STAD	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	8.28	2.77e-15	2.18e-08	0.36	0.41	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
STAD	trans	rs13190036	1	rs6889220	ENSG00000226986.4	RP11-543B16.2	8.27	2.84e-15	2.25e-08	0.45	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr1:211207239~211207897:+
STAD	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	8.27	2.97e-15	2.34e-08	0.5	0.41	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
STAD	trans	rs11039798	0.588	rs59777067	ENSG00000134612.10	FOLH1B	8.27	2.99e-15	2.36e-08	0.66	0.41	Axial length;	chr11:48993798	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.591	rs74992349	ENSG00000134612.10	FOLH1B	8.25	3.31e-15	2.6e-08	0.66	0.41	Axial length;	chr11:48997700	chr11:89639227~89698718:+
STAD	trans	rs13190036	0.551	rs28932178	ENSG00000228305.2	AC016734.2	-8.25	3.33e-15	2.62e-08	-0.43	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr2:63622178~63622831:-
STAD	trans	rs7554511	1	rs35730213	ENSG00000244144.1	RP11-757F18.3	-8.25	3.38e-15	2.66e-08	-0.48	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905101	chr3:112185480~112185998:-
STAD	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	8.25	3.39e-15	2.67e-08	0.37	0.41	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
STAD	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	8.25	3.39e-15	2.67e-08	0.37	0.41	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
STAD	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	8.25	3.39e-15	2.67e-08	0.37	0.41	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
STAD	trans	rs66887589	0.72	rs2036858	ENSG00000275858.1	RP11-291L22.8	8.25	3.42e-15	2.68e-08	0.42	0.41	Diastolic blood pressure;	chr4:119328082	chr10:38450738~38451069:-
STAD	trans	rs877636	0.736	rs773107	ENSG00000243403.1	RP11-330L19.1	8.25	3.43e-15	2.7e-08	0.45	0.41	Cognitive function;	chr12:55975722	chr15:64592979~64593326:+
STAD	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	8.25	3.44e-15	2.7e-08	0.46	0.41	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	8.25	3.44e-15	2.7e-08	0.46	0.41	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	8.25	3.44e-15	2.7e-08	0.46	0.41	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
STAD	trans	rs10816533	1	rs11562317	ENSG00000232063.1	RP11-307E17.8	-8.24	3.49e-15	2.74e-08	-0.69	-0.41	Height;	chr9:96806453	chr9:94332476~94360948:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000244604.1	RP11-713H12.1	8.24	3.61e-15	2.83e-08	0.46	0.41	Cognitive function;	chr12:56013288	chr17:8561230~8561576:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000244604.1	RP11-713H12.1	8.24	3.61e-15	2.83e-08	0.46	0.41	Cognitive function;	chr12:56018703	chr17:8561230~8561576:+
STAD	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	8.24	3.64e-15	2.86e-08	0.4	0.4	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
STAD	trans	rs7554511	0.894	rs11589638	ENSG00000244144.1	RP11-757F18.3	-8.23	3.73e-15	2.92e-08	-0.44	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200925807	chr3:112185480~112185998:-
STAD	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	8.23	3.82e-15	2.99e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
STAD	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	8.23	3.83e-15	3e-08	0.51	0.4	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
STAD	trans	rs7617480	0.61	rs4955420	ENSG00000197582.5	GPX1P1	8.23	3.92e-15	3.06e-08	0.55	0.4	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chrX:13378735~13379340:-
STAD	trans	rs3770081	1	rs78032828	ENSG00000229880.1	IMMTP1	8.23	3.95e-15	3.09e-08	0.78	0.4	Facial emotion recognition (sad faces);	chr2:86081909	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs56104203	ENSG00000229880.1	IMMTP1	8.23	3.95e-15	3.09e-08	0.78	0.4	Facial emotion recognition (sad faces);	chr2:86109133	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs12620810	ENSG00000229880.1	IMMTP1	8.23	3.95e-15	3.09e-08	0.78	0.4	Facial emotion recognition (sad faces);	chr2:86164358	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs17584578	ENSG00000229880.1	IMMTP1	-8.23	3.95e-15	3.09e-08	-0.78	-0.4	Facial emotion recognition (sad faces);	chr2:86080501	chr21:44675868~44678086:-
STAD	trans	rs13177918	0.798	rs13182116	ENSG00000226396.1	RP5-1056L3.3	-8.22	4.02e-15	3.14e-08	-0.45	-0.4	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:19608114~19608568:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000223416.3	RPS26P15	8.22	4.02e-15	3.14e-08	0.43	0.4	Cognitive function;	chr12:55996580	chr1:58056133~58056480:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000244604.1	RP11-713H12.1	8.22	4.05e-15	3.17e-08	0.46	0.4	Cognitive function;	chr12:56041628	chr17:8561230~8561576:+
STAD	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9841110	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9853683	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs12330269	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs34363169	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs6766581	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs7622302	ENSG00000197582.5	GPX1P1	-8.22	4.21e-15	3.28e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chrX:13378735~13379340:-
STAD	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	8.22	4.21e-15	3.28e-08	0.49	0.4	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
STAD	trans	rs877636	0.736	rs773107	ENSG00000225071.1	GS1-184P14.2	8.22	4.28e-15	3.33e-08	0.42	0.4	Cognitive function;	chr12:55975722	chrX:24429573~24429920:-
STAD	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	8.22	4.28e-15	3.34e-08	0.54	0.4	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	8.21	4.42e-15	3.44e-08	0.55	0.4	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	8.21	4.42e-15	3.44e-08	0.55	0.4	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	8.21	4.42e-15	3.44e-08	0.55	0.4	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-8.2	4.6e-15	3.57e-08	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs11719996	ENSG00000197582.5	GPX1P1	-8.2	4.63e-15	3.59e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000244604.1	RP11-713H12.1	8.2	4.65e-15	3.61e-08	0.45	0.4	Cognitive function;	chr12:56023144	chr17:8561230~8561576:+
STAD	trans	rs10037055	0.636	rs13166688	ENSG00000228305.2	AC016734.2	-8.2	4.68e-15	3.63e-08	-0.41	-0.4	Migraine without aura;	chr5:177156965	chr2:63622178~63622831:-
STAD	trans	rs11039798	0.557	rs4441015	ENSG00000134612.10	FOLH1B	8.2	4.7e-15	3.64e-08	0.64	0.4	Axial length;	chr11:49005518	chr11:89639227~89698718:+
STAD	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-8.2	4.73e-15	3.67e-08	-0.54	-0.4	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
STAD	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	8.2	4.73e-15	3.67e-08	0.35	0.4	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000204652.6	RPS26P8	8.2	4.77e-15	3.7e-08	0.45	0.4	Cognitive function;	chr12:56055651	chr17:45608571~45608918:+
STAD	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	8.2	4.79e-15	3.71e-08	0.36	0.4	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
STAD	trans	rs13190036	0.551	rs7732930	ENSG00000228305.2	AC016734.2	-8.19	4.94e-15	3.82e-08	-0.41	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr2:63622178~63622831:-
STAD	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-8.19	5.19e-15	4.02e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
STAD	trans	rs1552244	0.706	rs279545	ENSG00000230342.2	FANCD2P2	8.18	5.42e-15	4.19e-08	0.44	0.4	Alzheimer's disease;	chr3:9930809	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000233778.3	RP11-777J24.1	8.18	5.47e-15	4.23e-08	0.41	0.4	Cognitive function;	chr12:55988132	chr8:92144088~92144435:-
STAD	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	8.18	5.5e-15	4.24e-08	0.44	0.4	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
STAD	trans	rs11098499	0.71	rs6851130	ENSG00000276997.3	RP11-378J18.9	-8.18	5.56e-15	4.29e-08	-0.44	-0.4	Corneal astigmatism;	chr4:119212557	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000212829.8	RPS26P3	8.18	5.6e-15	4.32e-08	0.41	0.4	Cognitive function;	chr12:55980911	chr9:9090898~9091245:+
STAD	trans	rs7554511	0.858	rs12140420	ENSG00000244144.1	RP11-757F18.3	-8.18	5.61e-15	4.33e-08	-0.47	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993159	chr3:112185480~112185998:-
STAD	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-8.18	5.62e-15	4.34e-08	-0.37	-0.4	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
STAD	trans	rs66887589	0.72	rs11724758	ENSG00000276997.3	RP11-378J18.9	8.17	5.69e-15	4.38e-08	0.42	0.4	Diastolic blood pressure;	chr4:119318723	chr1:222477252~222504622:-
STAD	trans	rs7554511	0.894	rs296546	ENSG00000244144.1	RP11-757F18.3	8.17	5.81e-15	4.47e-08	0.43	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921963	chr3:112185480~112185998:-
STAD	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	8.17	6.01e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	8.17	6.02e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	8.17	6.02e-15	4.63e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	8.17	6.04e-15	4.65e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000233778.3	RP11-777J24.1	8.16	6.17e-15	4.74e-08	0.41	0.4	Cognitive function;	chr12:55976127	chr8:92144088~92144435:-
STAD	trans	rs7554511	0.894	rs296545	ENSG00000244144.1	RP11-757F18.3	8.16	6.23e-15	4.78e-08	0.43	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921564	chr3:112185480~112185998:-
STAD	trans	rs13190036	0.551	rs7710269	ENSG00000228305.2	AC016734.2	-8.16	6.26e-15	4.81e-08	-0.41	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr2:63622178~63622831:-
STAD	trans	rs13190036	1	rs6880798	ENSG00000228305.2	AC016734.2	8.16	6.29e-15	4.83e-08	0.43	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr2:63622178~63622831:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000223416.3	RPS26P15	-8.16	6.38e-15	4.9e-08	-0.42	-0.4	Cognitive function;	chr12:55996852	chr1:58056133~58056480:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000233278.1	RPS26P2	8.15	6.57e-15	5.04e-08	0.41	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:30831878~30832225:-
STAD	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	8.15	6.71e-15	5.14e-08	0.49	0.4	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
STAD	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-8.15	6.72e-15	5.15e-08	-0.37	-0.4	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
STAD	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-8.15	6.72e-15	5.15e-08	-0.37	-0.4	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
STAD	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	8.15	6.92e-15	5.3e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
STAD	trans	rs11220082	0.666	rs2241514	ENSG00000236257.1	EI24P2	-8.14	7.02e-15	5.37e-08	-0.52	-0.4	Schizophrenia;	chr11:125456130	chr1:158454198~158455273:+
STAD	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	8.14	7.02e-15	5.37e-08	0.46	0.4	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
STAD	trans	rs13190036	0.551	rs1052432	ENSG00000228305.2	AC016734.2	-8.14	7.11e-15	5.44e-08	-0.43	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr2:63622178~63622831:-
STAD	trans	rs11039798	0.512	rs1588069	ENSG00000134612.10	FOLH1B	8.14	7.18e-15	5.49e-08	0.6	0.4	Axial length;	chr11:48673319	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.623	rs7294273	ENSG00000134612.10	FOLH1B	8.14	7.18e-15	5.49e-08	0.6	0.4	Axial length;	chr11:48683822	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.582	rs60764175	ENSG00000134612.10	FOLH1B	8.14	7.18e-15	5.49e-08	0.6	0.4	Axial length;	chr11:48754304	chr11:89639227~89698718:+
STAD	trans	rs3770081	1	rs2303340	ENSG00000229880.1	IMMTP1	8.14	7.45e-15	5.68e-08	0.75	0.4	Facial emotion recognition (sad faces);	chr2:86106070	chr21:44675868~44678086:-
STAD	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-8.13	7.61e-15	5.8e-08	-0.37	-0.4	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
STAD	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	8.13	7.64e-15	5.82e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	8.13	7.64e-15	5.82e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	8.13	7.64e-15	5.82e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	8.13	7.64e-15	5.82e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
STAD	trans	rs7554511	1	rs55838263	ENSG00000244144.1	RP11-757F18.3	-8.13	7.74e-15	5.9e-08	-0.48	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905600	chr3:112185480~112185998:-
STAD	trans	rs7554511	1	rs12132298	ENSG00000244144.1	RP11-757F18.3	-8.13	7.74e-15	5.9e-08	-0.48	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905967	chr3:112185480~112185998:-
STAD	trans	rs7554511	1	rs12132349	ENSG00000244144.1	RP11-757F18.3	-8.13	7.74e-15	5.9e-08	-0.48	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906114	chr3:112185480~112185998:-
STAD	trans	rs7554511	0.964	rs59655222	ENSG00000244144.1	RP11-757F18.3	-8.13	7.74e-15	5.9e-08	-0.48	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906769	chr3:112185480~112185998:-
STAD	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	8.13	7.84e-15	5.97e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	8.13	7.84e-15	5.97e-08	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000196656.7	AC004057.1	8.13	7.86e-15	5.99e-08	0.43	0.4	Cognitive function;	chr12:56055651	chr4:113214046~113217170:-
STAD	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	8.12	8.14e-15	6.19e-08	0.35	0.4	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
STAD	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	8.12	8.37e-15	6.36e-08	0.41	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
STAD	trans	rs11039798	0.588	rs11039818	ENSG00000134612.10	FOLH1B	8.11	8.66e-15	6.58e-08	0.62	0.4	Axial length;	chr11:48540568	chr11:89639227~89698718:+
STAD	trans	rs6708331	0.517	rs11692018	ENSG00000232654.1	FAM136BP	8.11	8.79e-15	6.67e-08	0.49	0.4	Obesity-related traits;	chr2:70142022	chr6:3045384~3045800:+
STAD	trans	rs1552244	0.554	rs3846169	ENSG00000230342.2	FANCD2P2	-8.11	8.79e-15	6.67e-08	-0.44	-0.4	Alzheimer's disease;	chr3:9955370	chr3:11859674~11891172:+
STAD	trans	rs9858542	0.953	rs11711485	ENSG00000197582.5	GPX1P1	-8.11	8.8e-15	6.67e-08	-0.58	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chrX:13378735~13379340:-
STAD	trans	rs10917477	0.594	rs2792043	ENSG00000224237.1	MINOS1P3	8.11	8.87e-15	6.73e-08	0.51	0.4	Thyroid function;	chr1:19598168	chr3:27214816~27215018:-
STAD	trans	rs9858542	0.953	rs11713474	ENSG00000197582.5	GPX1P1	-8.1	9.34e-15	7.06e-08	-0.57	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49574024	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9811982	ENSG00000197582.5	GPX1P1	-8.1	9.34e-15	7.06e-08	-0.57	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49586944	chrX:13378735~13379340:-
STAD	trans	rs1552244	0.554	rs6786636	ENSG00000230342.2	FANCD2P2	8.1	9.48e-15	7.16e-08	0.43	0.4	Alzheimer's disease;	chr3:10004019	chr3:11859674~11891172:+
STAD	trans	rs877636	0.702	rs773112	ENSG00000224553.1	AC008065.1	8.1	9.48e-15	7.17e-08	0.45	0.4	Cognitive function;	chr12:55982097	chr2:171374931~171375278:-
STAD	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-8.09	9.96e-15	7.51e-08	-0.51	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000233278.1	RPS26P2	-8.09	1e-14	7.55e-08	-0.43	-0.4	Cognitive function;	chr12:56080595	chr9:30831878~30832225:-
STAD	trans	rs11039798	0.588	rs6485869	ENSG00000134612.10	FOLH1B	8.09	1.01e-14	7.6e-08	0.62	0.4	Axial length;	chr11:48555351	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.588	rs11039781	ENSG00000134612.10	FOLH1B	8.09	1.03e-14	7.73e-08	0.63	0.4	Axial length;	chr11:48501533	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.588	rs11039782	ENSG00000134612.10	FOLH1B	8.09	1.03e-14	7.73e-08	0.63	0.4	Axial length;	chr11:48503233	chr11:89639227~89698718:+
STAD	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	8.09	1.03e-14	7.73e-08	0.5	0.4	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
STAD	trans	rs11039798	0.544	rs114343057	ENSG00000134612.10	FOLH1B	8.09	1.03e-14	7.76e-08	0.63	0.4	Axial length;	chr11:48536620	chr11:89639227~89698718:+
STAD	trans	rs7554511	1	rs12131796	ENSG00000244144.1	RP11-757F18.3	-8.08	1.07e-14	8.04e-08	-0.48	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200909599	chr3:112185480~112185998:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000224553.1	AC008065.1	8.08	1.07e-14	8.08e-08	0.46	0.4	Cognitive function;	chr12:55976127	chr2:171374931~171375278:-
STAD	trans	rs6708331	0.517	rs6743372	ENSG00000232654.1	FAM136BP	8.08	1.09e-14	8.18e-08	0.49	0.4	Obesity-related traits;	chr2:70125508	chr6:3045384~3045800:+
STAD	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-8.08	1.09e-14	8.23e-08	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000233778.3	RP11-777J24.1	8.08	1.1e-14	8.26e-08	0.41	0.4	Cognitive function;	chr12:55980911	chr8:92144088~92144435:-
STAD	trans	rs3770081	1	rs17027011	ENSG00000229880.1	IMMTP1	8.08	1.12e-14	8.38e-08	0.75	0.4	Facial emotion recognition (sad faces);	chr2:86179433	chr21:44675868~44678086:-
STAD	trans	rs7554511	0.893	rs11580823	ENSG00000244144.1	RP11-757F18.3	-8.08	1.12e-14	8.41e-08	-0.48	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201014361	chr3:112185480~112185998:-
STAD	trans	rs3770081	1	rs3770066	ENSG00000229880.1	IMMTP1	8.07	1.14e-14	8.56e-08	0.72	0.4	Facial emotion recognition (sad faces);	chr2:86165227	chr21:44675868~44678086:-
STAD	trans	rs877636	1	rs2292239	ENSG00000233278.1	RPS26P2	8.07	1.16e-14	8.7e-08	0.42	0.4	Cognitive function;	chr12:56088396	chr9:30831878~30832225:-
STAD	trans	rs11039798	0.588	rs7479642	ENSG00000134612.10	FOLH1B	8.07	1.17e-14	8.76e-08	0.62	0.4	Axial length;	chr11:48532256	chr11:89639227~89698718:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000234513.1	AC073072.7	8.07	1.17e-14	8.78e-08	0.43	0.4	Cognitive function;	chr12:55975722	chr7:22773646~22773993:-
STAD	trans	rs11039798	0.588	rs12284168	ENSG00000134612.10	FOLH1B	8.07	1.17e-14	8.8e-08	0.62	0.4	Axial length;	chr11:48534075	chr11:89639227~89698718:+
STAD	trans	rs10037055	0.685	rs10039241	ENSG00000228305.2	AC016734.2	-8.06	1.22e-14	9.11e-08	-0.4	-0.4	Migraine without aura;	chr5:177151071	chr2:63622178~63622831:-
STAD	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-8.06	1.22e-14	9.14e-08	-0.46	-0.4	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
STAD	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-8.06	1.22e-14	9.15e-08	-0.5	-0.4	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000196656.7	AC004057.1	8.06	1.22e-14	9.17e-08	0.39	0.4	Cognitive function;	chr12:55982097	chr4:113214046~113217170:-
STAD	trans	rs1552244	0.554	rs2272119	ENSG00000230342.2	FANCD2P2	8.06	1.23e-14	9.17e-08	0.43	0.4	Alzheimer's disease;	chr3:10007668	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.608	rs9837460	ENSG00000230342.2	FANCD2P2	8.06	1.23e-14	9.17e-08	0.43	0.4	Alzheimer's disease;	chr3:10008238	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs28667821	ENSG00000230342.2	FANCD2P2	8.06	1.23e-14	9.17e-08	0.43	0.4	Alzheimer's disease;	chr3:10009083	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.543	rs28719585	ENSG00000230342.2	FANCD2P2	8.06	1.23e-14	9.17e-08	0.43	0.4	Alzheimer's disease;	chr3:10009129	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs7349576	ENSG00000230342.2	FANCD2P2	8.06	1.23e-14	9.17e-08	0.43	0.4	Alzheimer's disease;	chr3:10009209	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.515	rs6768768	ENSG00000230342.2	FANCD2P2	8.06	1.23e-14	9.24e-08	0.52	0.4	Alzheimer's disease;	chr3:10135969	chr3:11859674~11891172:+
STAD	trans	rs1552244	0.554	rs2272122	ENSG00000230342.2	FANCD2P2	8.06	1.26e-14	9.41e-08	0.44	0.4	Alzheimer's disease;	chr3:10006291	chr3:11859674~11891172:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000223416.3	RPS26P15	8.05	1.33e-14	9.95e-08	0.45	0.4	Cognitive function;	chr12:55975722	chr1:58056133~58056480:-
STAD	trans	rs7554511	1	rs41299637	ENSG00000244144.1	RP11-757F18.3	-8.05	1.34e-14	1e-07	-0.48	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908722	chr3:112185480~112185998:-
STAD	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	8.05	1.35e-14	1.01e-07	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
STAD	trans	rs9858542	0.953	rs7633271	ENSG00000197582.5	GPX1P1	-8.05	1.39e-14	1.03e-07	-0.57	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49518530	chrX:13378735~13379340:-
STAD	trans	rs13190036	0.551	rs11955537	ENSG00000228305.2	AC016734.2	-8.04	1.41e-14	1.05e-07	-0.4	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr2:63622178~63622831:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000234354.3	RPS26P47	8.04	1.45e-14	1.08e-07	0.54	0.4	Cognitive function;	chr12:56002984	chr13:100539901~100540248:-
STAD	trans	rs13190036	1	rs28580074	ENSG00000226986.4	RP11-543B16.2	8.04	1.45e-14	1.08e-07	0.45	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr1:211207239~211207897:+
STAD	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	8.04	1.45e-14	1.08e-07	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
STAD	trans	rs11039798	0.588	rs11039807	ENSG00000134612.10	FOLH1B	8.04	1.46e-14	1.09e-07	0.61	0.4	Axial length;	chr11:48527839	chr11:89639227~89698718:+
STAD	trans	rs13190036	0.901	rs28684504	ENSG00000226986.4	RP11-543B16.2	8.04	1.47e-14	1.09e-07	0.45	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr1:211207239~211207897:+
STAD	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	8.03	1.49e-14	1.11e-07	0.36	0.4	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
STAD	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-8.03	1.52e-14	1.13e-07	-0.53	-0.4	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
STAD	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	8.03	1.54e-14	1.14e-07	0.44	0.4	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000244604.1	RP11-713H12.1	8.03	1.54e-14	1.14e-07	0.44	0.4	Cognitive function;	chr12:56041720	chr17:8561230~8561576:+
STAD	trans	rs6708331	0.54	rs6546576	ENSG00000232654.1	FAM136BP	8.03	1.56e-14	1.16e-07	0.48	0.4	Obesity-related traits;	chr2:70174356	chr6:3045384~3045800:+
STAD	trans	rs877636	1	rs4759229	ENSG00000233278.1	RPS26P2	-8.03	1.59e-14	1.17e-07	-0.42	-0.4	Cognitive function;	chr12:56080696	chr9:30831878~30832225:-
STAD	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	8.03	1.59e-14	1.18e-07	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000235459.5	RPS26P31	-8.02	1.65e-14	1.23e-07	-0.42	-0.4	Asthma;	chr12:55970537	chr7:122681315~122681662:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000224553.1	AC008065.1	8.02	1.69e-14	1.25e-07	0.45	0.4	Cognitive function;	chr12:55981956	chr2:171374931~171375278:-
STAD	trans	rs13190036	1	rs628506	ENSG00000228305.2	AC016734.2	-8.02	1.7e-14	1.26e-07	-0.41	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr2:63622178~63622831:-
STAD	trans	rs10917477	0.653	rs1770480	ENSG00000224237.1	MINOS1P3	8.02	1.7e-14	1.26e-07	0.51	0.4	Thyroid function;	chr1:19590290	chr3:27214816~27215018:-
STAD	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	8.02	1.71e-14	1.26e-07	0.46	0.4	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000196656.7	AC004057.1	8.02	1.71e-14	1.26e-07	0.39	0.4	Cognitive function;	chr12:55988132	chr4:113214046~113217170:-
STAD	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	8.01	1.75e-14	1.29e-07	0.46	0.4	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
STAD	trans	rs11039798	0.588	rs7116858	ENSG00000134612.10	FOLH1B	8.01	1.75e-14	1.29e-07	0.61	0.4	Axial length;	chr11:48522368	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.588	rs7946443	ENSG00000134612.10	FOLH1B	8.01	1.75e-14	1.29e-07	0.61	0.4	Axial length;	chr11:48523952	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.588	rs6485857	ENSG00000134612.10	FOLH1B	8.01	1.75e-14	1.29e-07	0.61	0.4	Axial length;	chr11:48534959	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.565	rs7118675	ENSG00000134612.10	FOLH1B	8.01	1.77e-14	1.3e-07	0.61	0.4	Axial length;	chr11:48510511	chr11:89639227~89698718:+
STAD	trans	rs13190036	0.901	rs6556309	ENSG00000226986.4	RP11-543B16.2	8.01	1.79e-14	1.32e-07	0.42	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr1:211207239~211207897:+
STAD	trans	rs7554511	0.894	rs296543	ENSG00000244144.1	RP11-757F18.3	8.01	1.83e-14	1.35e-07	0.43	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200920705	chr3:112185480~112185998:-
STAD	trans	rs10037055	0.741	rs4976640	ENSG00000228305.2	AC016734.2	-8	1.84e-14	1.36e-07	-0.38	-0.4	Migraine without aura;	chr5:177125006	chr2:63622178~63622831:-
STAD	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	8	1.84e-14	1.36e-07	0.5	0.4	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
STAD	trans	rs13190036	1	rs4976682	ENSG00000226986.4	RP11-543B16.2	8	1.84e-14	1.36e-07	0.44	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr1:211207239~211207897:+
STAD	trans	rs11039798	0.545	rs7118670	ENSG00000134612.10	FOLH1B	8	1.85e-14	1.36e-07	0.61	0.4	Axial length;	chr11:48510504	chr11:89639227~89698718:+
STAD	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	8	1.85e-14	1.36e-07	0.46	0.4	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
STAD	trans	rs66887589	0.616	rs13113885	ENSG00000276997.3	RP11-378J18.9	8	1.88e-14	1.38e-07	0.43	0.4	Diastolic blood pressure;	chr4:119300021	chr1:222477252~222504622:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000224553.1	AC008065.1	8	1.88e-14	1.39e-07	0.49	0.4	Cognitive function;	chr12:56055651	chr2:171374931~171375278:-
STAD	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	8	1.88e-14	1.39e-07	0.34	0.4	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
STAD	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	8	1.91e-14	1.41e-07	0.43	0.4	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
STAD	trans	rs11039798	0.588	rs10838923	ENSG00000134612.10	FOLH1B	7.99	1.97e-14	1.45e-07	0.62	0.39	Axial length;	chr11:48513312	chr11:89639227~89698718:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000212829.8	RPS26P3	7.99	2.07e-14	1.52e-07	0.4	0.39	Cognitive function;	chr12:55996580	chr9:9090898~9091245:+
STAD	trans	rs7113874	0.592	rs34009921	ENSG00000266891.1	RP11-692N5.2	7.99	2.07e-14	1.52e-07	0.54	0.39	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8597314	chr18:9734882~9735602:-
STAD	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-7.98	2.12e-14	1.55e-07	-0.51	-0.39	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
STAD	trans	rs6708331	0.54	rs11890701	ENSG00000232654.1	FAM136BP	7.98	2.15e-14	1.58e-07	0.49	0.39	Obesity-related traits;	chr2:70133325	chr6:3045384~3045800:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000196656.7	AC004057.1	7.98	2.17e-14	1.59e-07	0.39	0.39	Cognitive function;	chr12:55981956	chr4:113214046~113217170:-
STAD	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	7.98	2.21e-14	1.62e-07	0.48	0.39	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
STAD	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	7.98	2.25e-14	1.65e-07	0.49	0.39	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
STAD	trans	rs6708331	0.517	rs9989836	ENSG00000232654.1	FAM136BP	7.97	2.26e-14	1.66e-07	0.49	0.39	Obesity-related traits;	chr2:70115595	chr6:3045384~3045800:+
STAD	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	7.97	2.35e-14	1.72e-07	0.49	0.39	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
STAD	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	7.97	2.35e-14	1.72e-07	0.49	0.39	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000234354.3	RPS26P47	7.97	2.39e-14	1.74e-07	0.47	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr13:100539901~100540248:-
STAD	trans	rs877636	1	rs2292239	ENSG00000242206.2	RPS26P35	7.97	2.4e-14	1.76e-07	0.42	0.39	Cognitive function;	chr12:56088396	chr8:118761856~118762201:-
STAD	trans	rs7554511	0.858	rs11584383	ENSG00000244144.1	RP11-757F18.3	7.96	2.41e-14	1.76e-07	0.46	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200966738	chr3:112185480~112185998:-
STAD	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	7.96	2.42e-14	1.77e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	7.96	2.42e-14	1.77e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	7.96	2.42e-14	1.77e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	7.96	2.42e-14	1.77e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
STAD	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	7.96	2.43e-14	1.77e-07	0.48	0.39	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
STAD	trans	rs3770081	0.59	rs11891333	ENSG00000229880.1	IMMTP1	7.96	2.49e-14	1.82e-07	0.69	0.39	Facial emotion recognition (sad faces);	chr2:85951271	chr21:44675868~44678086:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000224553.1	AC008065.1	7.96	2.55e-14	1.86e-07	0.44	0.39	Cognitive function;	chr12:55981353	chr2:171374931~171375278:-
STAD	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	7.95	2.58e-14	1.88e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	7.95	2.58e-14	1.88e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	7.95	2.58e-14	1.88e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	7.95	2.58e-14	1.88e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	7.95	2.58e-14	1.88e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
STAD	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	7.95	2.65e-14	1.93e-07	0.5	0.39	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
STAD	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	7.95	2.71e-14	1.98e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
STAD	trans	rs3770081	1	rs60981340	ENSG00000229880.1	IMMTP1	7.94	2.82e-14	2.05e-07	0.69	0.39	Facial emotion recognition (sad faces);	chr2:85949923	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs735737	ENSG00000229880.1	IMMTP1	7.94	2.82e-14	2.05e-07	0.69	0.39	Facial emotion recognition (sad faces);	chr2:85949978	chr21:44675868~44678086:-
STAD	trans	rs6708331	0.517	rs12617812	ENSG00000232654.1	FAM136BP	7.94	2.86e-14	2.08e-07	0.48	0.39	Obesity-related traits;	chr2:70132339	chr6:3045384~3045800:+
STAD	trans	rs6708331	0.517	rs7599072	ENSG00000232654.1	FAM136BP	7.94	2.86e-14	2.08e-07	0.48	0.39	Obesity-related traits;	chr2:70132874	chr6:3045384~3045800:+
STAD	trans	rs6708331	0.517	rs12992553	ENSG00000232654.1	FAM136BP	7.94	2.86e-14	2.08e-07	0.48	0.39	Obesity-related traits;	chr2:70133130	chr6:3045384~3045800:+
STAD	trans	rs6708331	0.517	rs11890741	ENSG00000232654.1	FAM136BP	7.94	2.86e-14	2.08e-07	0.48	0.39	Obesity-related traits;	chr2:70133374	chr6:3045384~3045800:+
STAD	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	7.94	2.86e-14	2.08e-07	0.48	0.39	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
STAD	trans	rs13190036	0.515	rs2878686	ENSG00000228305.2	AC016734.2	-7.94	2.87e-14	2.09e-07	-0.41	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr2:63622178~63622831:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000196656.7	AC004057.1	7.94	2.88e-14	2.09e-07	0.39	0.39	Cognitive function;	chr12:55976127	chr4:113214046~113217170:-
STAD	trans	rs9858542	0.951	rs1800668	ENSG00000197582.5	GPX1P1	-7.94	2.95e-14	2.14e-07	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358324	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs1987628	ENSG00000197582.5	GPX1P1	-7.94	2.95e-14	2.14e-07	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49361826	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs7648841	ENSG00000197582.5	GPX1P1	-7.94	2.95e-14	2.14e-07	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs6446264	ENSG00000197582.5	GPX1P1	-7.94	2.95e-14	2.14e-07	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs11706370	ENSG00000197582.5	GPX1P1	-7.94	2.95e-14	2.14e-07	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chrX:13378735~13379340:-
STAD	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	7.93	3.04e-14	2.2e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
STAD	trans	rs66887589	0.616	rs13113885	ENSG00000275858.1	RP11-291L22.8	7.93	3.05e-14	2.21e-07	0.42	0.39	Diastolic blood pressure;	chr4:119300021	chr10:38450738~38451069:-
STAD	trans	rs11220082	0.666	rs56398391	ENSG00000236257.1	EI24P2	-7.93	3.11e-14	2.25e-07	-0.53	-0.39	Schizophrenia;	chr11:125444220	chr1:158454198~158455273:+
STAD	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	7.93	3.13e-14	2.27e-07	0.43	0.39	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000196656.7	AC004057.1	7.92	3.17e-14	2.29e-07	0.39	0.39	Cognitive function;	chr12:55980911	chr4:113214046~113217170:-
STAD	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	7.92	3.21e-14	2.32e-07	0.53	0.39	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	7.92	3.21e-14	2.32e-07	0.53	0.39	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
STAD	trans	rs9611519	0.78	rs3171692	ENSG00000268568.1	AC007228.9	-7.92	3.22e-14	2.32e-07	-0.53	-0.39	Neuroticism;	chr22:41246208	chr19:56672574~56673901:-
STAD	trans	rs9611519	0.78	rs1983631	ENSG00000268568.1	AC007228.9	-7.92	3.22e-14	2.33e-07	-0.52	-0.39	Neuroticism;	chr22:41248070	chr19:56672574~56673901:-
STAD	trans	rs9858542	0.903	rs35999162	ENSG00000197582.5	GPX1P1	-7.92	3.32e-14	2.4e-07	-0.57	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559797	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000196656.7	AC004057.1	7.91	3.39e-14	2.44e-07	0.38	0.39	Cognitive function;	chr12:55981353	chr4:113214046~113217170:-
STAD	trans	rs6708331	0.54	rs28623550	ENSG00000232654.1	FAM136BP	7.91	3.53e-14	2.55e-07	0.48	0.39	Obesity-related traits;	chr2:70139260	chr6:3045384~3045800:+
STAD	trans	rs6708331	0.517	rs12999042	ENSG00000232654.1	FAM136BP	7.91	3.53e-14	2.55e-07	0.48	0.39	Obesity-related traits;	chr2:70139679	chr6:3045384~3045800:+
STAD	trans	rs11039798	0.66	rs717897	ENSG00000134612.10	FOLH1B	-7.9	3.64e-14	2.62e-07	-0.59	-0.39	Axial length;	chr11:48354052	chr11:89639227~89698718:+
STAD	trans	rs1552244	0.507	rs6443274	ENSG00000230342.2	FANCD2P2	7.9	3.77e-14	2.72e-07	0.41	0.39	Alzheimer's disease;	chr3:9953604	chr3:11859674~11891172:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000212994.5	RPS26P6	7.9	3.86e-14	2.77e-07	0.42	0.39	Cognitive function;	chr12:56055651	chr8:100895771~100896118:+
STAD	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	7.89	3.89e-14	2.8e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
STAD	trans	rs7617480	0.61	rs10865954	ENSG00000197582.5	GPX1P1	7.89	3.92e-14	2.82e-07	0.53	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chrX:13378735~13379340:-
STAD	trans	rs11039798	0.588	rs12294395	ENSG00000134612.10	FOLH1B	7.89	3.94e-14	2.83e-07	0.62	0.39	Axial length;	chr11:48455308	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773112	ENSG00000196933.5	RPS26P11	7.89	4.01e-14	2.88e-07	0.4	0.39	Cognitive function;	chr12:55982097	chrX:72044545~72044892:+
STAD	trans	rs8067354	0.574	rs2526354	ENSG00000187870.7	RNFT1P3	7.89	4.01e-14	2.88e-07	0.49	0.39	Hemoglobin concentration;	chr17:59899297	chr17:20743333~20754501:-
STAD	trans	rs6708331	0.564	rs4632370	ENSG00000232654.1	FAM136BP	7.89	4.03e-14	2.89e-07	0.47	0.39	Obesity-related traits;	chr2:70149693	chr6:3045384~3045800:+
STAD	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	7.89	4.05e-14	2.91e-07	0.45	0.39	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000212829.8	RPS26P3	-7.89	4.08e-14	2.93e-07	-0.39	-0.39	Cognitive function;	chr12:55996852	chr9:9090898~9091245:+
STAD	trans	rs11039798	0.511	rs717896	ENSG00000134612.10	FOLH1B	-7.89	4.09e-14	2.93e-07	-0.6	-0.39	Axial length;	chr11:48353783	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.582	rs1483119	ENSG00000134612.10	FOLH1B	-7.89	4.09e-14	2.93e-07	-0.6	-0.39	Axial length;	chr11:48360782	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.557	rs4436575	ENSG00000134612.10	FOLH1B	-7.89	4.09e-14	2.93e-07	-0.6	-0.39	Axial length;	chr11:48377342	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.623	rs635632	ENSG00000134612.10	FOLH1B	-7.89	4.09e-14	2.93e-07	-0.6	-0.39	Axial length;	chr11:48377980	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.623	rs594615	ENSG00000134612.10	FOLH1B	-7.89	4.09e-14	2.93e-07	-0.6	-0.39	Axial length;	chr11:48381252	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.511	rs7948129	ENSG00000134612.10	FOLH1B	-7.88	4.17e-14	2.98e-07	-0.62	-0.39	Axial length;	chr11:48146276	chr11:89639227~89698718:+
STAD	trans	rs10037055	0.812	rs11949435	ENSG00000228305.2	AC016734.2	7.88	4.26e-14	3.05e-07	0.38	0.39	Migraine without aura;	chr5:177287931	chr2:63622178~63622831:-
STAD	trans	rs12145833	0.538	rs4658547	ENSG00000154608.12	CEP170P1	7.88	4.27e-14	3.05e-07	0.64	0.39	Obesity (early onset extreme);	chr1:243227829	chr4:118467590~118554204:+
STAD	trans	rs12145833	0.538	rs9803701	ENSG00000154608.12	CEP170P1	7.88	4.27e-14	3.05e-07	0.64	0.39	Obesity (early onset extreme);	chr1:243228332	chr4:118467590~118554204:+
STAD	trans	rs877636	1	rs705696	ENSG00000233278.1	RPS26P2	7.88	4.34e-14	3.1e-07	0.43	0.39	Cognitive function;	chr12:56086864	chr9:30831878~30832225:-
STAD	trans	rs13190036	0.892	rs71601339	ENSG00000226986.4	RP11-543B16.2	-7.88	4.42e-14	3.16e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr1:211207239~211207897:+
STAD	trans	rs10037055	0.853	rs12660023	ENSG00000228305.2	AC016734.2	7.87	4.5e-14	3.21e-07	0.38	0.39	Migraine without aura;	chr5:177273884	chr2:63622178~63622831:-
STAD	trans	rs11039571	0.544	rs7947811	ENSG00000134612.10	FOLH1B	-7.87	4.57e-14	3.26e-07	-0.62	-0.39	D-dimer levels;	chr11:48146186	chr11:89639227~89698718:+
STAD	trans	rs13190036	0.551	rs11957608	ENSG00000228305.2	AC016734.2	-7.87	4.61e-14	3.28e-07	-0.4	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr2:63622178~63622831:-
STAD	trans	rs10037055	0.853	rs4976680	ENSG00000228305.2	AC016734.2	7.87	4.62e-14	3.29e-07	0.38	0.39	Migraine without aura;	chr5:177275745	chr2:63622178~63622831:-
STAD	trans	rs10037055	0.853	rs4976681	ENSG00000228305.2	AC016734.2	7.87	4.62e-14	3.29e-07	0.38	0.39	Migraine without aura;	chr5:177277662	chr2:63622178~63622831:-
STAD	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	7.87	4.62e-14	3.29e-07	0.43	0.39	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000196933.5	RPS26P11	7.87	4.62e-14	3.29e-07	0.41	0.39	Cognitive function;	chr12:55988132	chrX:72044545~72044892:+
STAD	trans	rs11220082	0.627	rs35102191	ENSG00000236257.1	EI24P2	-7.87	4.62e-14	3.29e-07	-0.52	-0.39	Schizophrenia;	chr11:125455250	chr1:158454198~158455273:+
STAD	trans	rs10037055	0.853	rs10036193	ENSG00000228305.2	AC016734.2	-7.87	4.66e-14	3.32e-07	-0.38	-0.39	Migraine without aura;	chr5:177141519	chr2:63622178~63622831:-
STAD	trans	rs10037055	0.853	rs9885210	ENSG00000228305.2	AC016734.2	-7.87	4.66e-14	3.32e-07	-0.38	-0.39	Migraine without aura;	chr5:177142187	chr2:63622178~63622831:-
STAD	trans	rs13190036	1	rs17078781	ENSG00000226986.4	RP11-543B16.2	-7.87	4.71e-14	3.35e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr1:211207239~211207897:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000224553.1	AC008065.1	7.87	4.73e-14	3.36e-07	0.44	0.39	Cognitive function;	chr12:55988132	chr2:171374931~171375278:-
STAD	trans	rs7554511	0.893	rs11589573	ENSG00000244144.1	RP11-757F18.3	-7.86	4.8e-14	3.41e-07	-0.47	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005987	chr3:112185480~112185998:-
STAD	trans	rs7554511	0.858	rs12142704	ENSG00000244144.1	RP11-757F18.3	-7.86	4.82e-14	3.42e-07	-0.46	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200988569	chr3:112185480~112185998:-
STAD	trans	rs10816533	1	rs7859307	ENSG00000232063.1	RP11-307E17.8	7.86	4.82e-14	3.42e-07	0.68	0.39	Height;	chr9:96842489	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10979329	ENSG00000232063.1	RP11-307E17.8	7.86	4.82e-14	3.42e-07	0.68	0.39	Height;	chr9:96854542	chr9:94332476~94360948:+
STAD	trans	rs11039798	0.66	rs28435129	ENSG00000134612.10	FOLH1B	7.86	4.84e-14	3.44e-07	0.61	0.39	Axial length;	chr11:48608243	chr11:89639227~89698718:+
STAD	trans	rs7554511	0.893	rs6427868	ENSG00000244144.1	RP11-757F18.3	-7.86	4.91e-14	3.49e-07	-0.46	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200960354	chr3:112185480~112185998:-
STAD	trans	rs10816533	1	rs7032889	ENSG00000232063.1	RP11-307E17.8	7.86	4.91e-14	3.49e-07	0.68	0.39	Height;	chr9:96859520	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs12236179	ENSG00000232063.1	RP11-307E17.8	7.86	4.91e-14	3.49e-07	0.68	0.39	Height;	chr9:96863448	chr9:94332476~94360948:+
STAD	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	7.86	4.93e-14	3.5e-07	0.35	0.39	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
STAD	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	7.86	4.96e-14	3.52e-07	0.44	0.39	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
STAD	trans	rs11220082	0.644	rs36143594	ENSG00000236257.1	EI24P2	-7.86	4.97e-14	3.53e-07	-0.52	-0.39	Schizophrenia;	chr11:125457076	chr1:158454198~158455273:+
STAD	trans	rs13190036	1	rs7714695	ENSG00000226986.4	RP11-543B16.2	-7.86	5.02e-14	3.56e-07	-0.44	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr1:211207239~211207897:+
STAD	trans	rs13190036	1	rs59737888	ENSG00000226986.4	RP11-543B16.2	-7.86	5.02e-14	3.56e-07	-0.44	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr1:211207239~211207897:+
STAD	trans	rs11039798	0.588	rs3924476	ENSG00000134612.10	FOLH1B	7.85	5.14e-14	3.64e-07	0.6	0.39	Axial length;	chr11:48560181	chr11:89639227~89698718:+
STAD	trans	rs13190036	0.901	rs4631	ENSG00000226986.4	RP11-543B16.2	7.85	5.17e-14	3.66e-07	0.44	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr1:211207239~211207897:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000212829.8	RPS26P3	7.85	5.18e-14	3.67e-07	0.43	0.39	Cognitive function;	chr12:56055651	chr9:9090898~9091245:+
STAD	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	7.84	5.56e-14	3.94e-07	0.44	0.39	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
STAD	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	7.84	5.62e-14	3.97e-07	0.55	0.39	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
STAD	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	7.84	5.62e-14	3.97e-07	0.55	0.39	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
STAD	trans	rs11039798	0.588	rs7483361	ENSG00000134612.10	FOLH1B	7.84	5.66e-14	3.99e-07	0.6	0.39	Axial length;	chr11:48572234	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.588	rs10160381	ENSG00000134612.10	FOLH1B	7.84	5.66e-14	3.99e-07	0.6	0.39	Axial length;	chr11:48577939	chr11:89639227~89698718:+
STAD	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	7.84	5.67e-14	4.01e-07	0.47	0.39	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
STAD	trans	rs13190036	0.901	rs55741473	ENSG00000226986.4	RP11-543B16.2	-7.84	5.76e-14	4.07e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr1:211207239~211207897:+
STAD	trans	rs13190036	1	rs13157667	ENSG00000226986.4	RP11-543B16.2	-7.83	5.89e-14	4.16e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr1:211207239~211207897:+
STAD	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	7.83	5.97e-14	4.21e-07	0.47	0.39	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
STAD	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-7.83	5.98e-14	4.22e-07	-0.47	-0.39	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
STAD	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-7.83	5.98e-14	4.22e-07	-0.5	-0.39	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000226339.1	RPS26P56	7.83	6.06e-14	4.27e-07	0.38	0.39	Cognitive function;	chr12:56076841	chrX:129408382~129408621:+
STAD	trans	rs13190036	1	rs13167431	ENSG00000226986.4	RP11-543B16.2	-7.83	6.21e-14	4.38e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr1:211207239~211207897:+
STAD	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	7.82	6.37e-14	4.48e-07	0.43	0.39	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000196933.5	RPS26P11	7.82	6.38e-14	4.49e-07	0.4	0.39	Cognitive function;	chr12:55976127	chrX:72044545~72044892:+
STAD	trans	rs1552244	0.554	rs6762397	ENSG00000230342.2	FANCD2P2	7.82	6.65e-14	4.67e-07	0.44	0.39	Alzheimer's disease;	chr3:9966156	chr3:11859674~11891172:+
STAD	trans	rs9581094	0.505	rs6490945	ENSG00000237917.1	PARP4P1	7.81	6.68e-14	4.69e-07	0.52	0.39	Sudden cardiac arrest;	chr13:24514056	chrY:26594851~26634652:-
STAD	trans	rs11039798	0.623	rs6485879	ENSG00000134612.10	FOLH1B	7.81	6.72e-14	4.73e-07	0.6	0.39	Axial length;	chr11:48566432	chr11:89639227~89698718:+
STAD	trans	rs13190036	1	rs71601343	ENSG00000226986.4	RP11-543B16.2	-7.81	6.75e-14	4.74e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr1:211207239~211207897:+
STAD	trans	rs13190036	1	rs71601344	ENSG00000226986.4	RP11-543B16.2	-7.81	6.75e-14	4.74e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr1:211207239~211207897:+
STAD	trans	rs10917477	0.624	rs1320978	ENSG00000224237.1	MINOS1P3	7.81	6.83e-14	4.8e-07	0.5	0.39	Thyroid function;	chr1:19621479	chr3:27214816~27215018:-
STAD	trans	rs11039798	0.623	rs588700	ENSG00000134612.10	FOLH1B	-7.81	6.84e-14	4.8e-07	-0.6	-0.39	Axial length;	chr11:48428337	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773109	ENSG00000224553.1	AC008065.1	7.81	7.01e-14	4.92e-07	0.44	0.39	Cognitive function;	chr12:55980911	chr2:171374931~171375278:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000233278.1	RPS26P2	7.81	7.02e-14	4.93e-07	0.44	0.39	Cognitive function;	chr12:56009793	chr9:30831878~30832225:-
STAD	trans	rs13190036	1	rs35535623	ENSG00000226986.4	RP11-543B16.2	-7.81	7.12e-14	4.99e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr1:211207239~211207897:+
STAD	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	7.8	7.28e-14	5.1e-07	0.44	0.39	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000227887.1	RPS26P13	7.8	7.3e-14	5.12e-07	0.42	0.39	Cognitive function;	chr12:55990903	chr1:208697369~208697698:-
STAD	trans	rs11039798	0.588	rs10437592	ENSG00000134612.10	FOLH1B	7.8	7.36e-14	5.15e-07	0.6	0.39	Axial length;	chr11:48577307	chr11:89639227~89698718:+
STAD	trans	rs6708331	0.517	rs13017427	ENSG00000232654.1	FAM136BP	7.8	7.4e-14	5.18e-07	0.47	0.39	Obesity-related traits;	chr2:70154399	chr6:3045384~3045800:+
STAD	trans	rs7399018	0.739	rs7953955	ENSG00000223825.5	DAZAP2P1	7.8	7.43e-14	5.2e-07	0.45	0.39	Cisplatin-induced ototoxicity;	chr12:51214683	chr2:202201384~202201886:-
STAD	trans	rs7554511	0.858	rs12118735	ENSG00000244144.1	RP11-757F18.3	-7.8	7.47e-14	5.23e-07	-0.46	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200981832	chr3:112185480~112185998:-
STAD	trans	rs7554511	0.858	rs7539693	ENSG00000244144.1	RP11-757F18.3	-7.8	7.47e-14	5.23e-07	-0.46	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200986438	chr3:112185480~112185998:-
STAD	trans	rs3770081	1	rs1036554	ENSG00000229880.1	IMMTP1	7.8	7.49e-14	5.25e-07	0.75	0.39	Facial emotion recognition (sad faces);	chr2:86008976	chr21:44675868~44678086:-
STAD	trans	rs10037055	1	rs6886255	ENSG00000228305.2	AC016734.2	7.79	7.63e-14	5.34e-07	0.37	0.39	Migraine without aura;	chr5:177291360	chr2:63622178~63622831:-
STAD	trans	rs13190036	0.551	rs9313751	ENSG00000228305.2	AC016734.2	-7.79	7.83e-14	5.47e-07	-0.4	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr2:63622178~63622831:-
STAD	trans	rs8067354	0.574	rs2531899	ENSG00000187870.7	RNFT1P3	-7.79	8.13e-14	5.68e-07	-0.48	-0.39	Hemoglobin concentration;	chr17:59929832	chr17:20743333~20754501:-
STAD	trans	rs13190036	0.901	rs28715668	ENSG00000226986.4	RP11-543B16.2	7.79	8.14e-14	5.69e-07	0.43	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr1:211207239~211207897:+
STAD	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	7.78	8.17e-14	5.7e-07	0.34	0.39	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000196933.5	RPS26P11	7.78	8.28e-14	5.78e-07	0.4	0.39	Cognitive function;	chr12:55981956	chrX:72044545~72044892:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000227887.1	RPS26P13	7.78	8.5e-14	5.93e-07	0.45	0.39	Cognitive function;	chr12:55975722	chr1:208697369~208697698:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000223416.3	RPS26P15	7.78	8.51e-14	5.93e-07	0.41	0.39	Cognitive function;	chr12:55990903	chr1:58056133~58056480:-
STAD	trans	rs13190036	0.901	rs28563911	ENSG00000226986.4	RP11-543B16.2	7.78	8.53e-14	5.95e-07	0.43	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr1:211207239~211207897:+
STAD	trans	rs10037055	1	rs10037055	ENSG00000228305.2	AC016734.2	-7.78	8.59e-14	5.99e-07	-0.36	-0.39	Migraine without aura;	chr5:177264278	chr2:63622178~63622831:-
STAD	trans	rs6708331	0.517	rs2028879	ENSG00000232654.1	FAM136BP	7.77	8.78e-14	6.12e-07	0.46	0.39	Obesity-related traits;	chr2:70127505	chr6:3045384~3045800:+
STAD	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	7.77	9e-14	6.26e-07	0.44	0.39	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
STAD	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	7.77	9.08e-14	6.31e-07	0.42	0.39	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	7.77	9.08e-14	6.31e-07	0.42	0.39	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	7.77	9.08e-14	6.31e-07	0.42	0.39	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	7.77	9.08e-14	6.31e-07	0.42	0.39	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000231366.1	RP11-399N22.3	7.77	9.17e-14	6.37e-07	0.4	0.39	Cognitive function;	chr12:56076841	chr10:70794230~70794523:-
STAD	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	7.77	9.27e-14	6.44e-07	0.34	0.39	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
STAD	trans	rs10037055	0.853	rs9313749	ENSG00000228305.2	AC016734.2	-7.77	9.28e-14	6.45e-07	-0.37	-0.39	Migraine without aura;	chr5:177170693	chr2:63622178~63622831:-
STAD	trans	rs8067354	0.574	rs2526353	ENSG00000187870.7	RNFT1P3	7.76	9.36e-14	6.5e-07	0.5	0.39	Hemoglobin concentration;	chr17:59911246	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.574	rs1292035	ENSG00000187870.7	RNFT1P3	7.76	9.36e-14	6.5e-07	0.5	0.39	Hemoglobin concentration;	chr17:59912196	chr17:20743333~20754501:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000239210.2	RPS26P55	-7.76	9.52e-14	6.6e-07	-0.42	-0.39	Cognitive function;	chr12:55996852	chr19:34533427~34534084:-
STAD	trans	rs7554511	0.929	rs55757739	ENSG00000244144.1	RP11-757F18.3	-7.76	9.55e-14	6.63e-07	-0.46	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200997848	chr3:112185480~112185998:-
STAD	trans	rs8067354	0.574	rs1295923	ENSG00000187870.7	RNFT1P3	7.76	9.65e-14	6.69e-07	0.49	0.39	Hemoglobin concentration;	chr17:59883075	chr17:20743333~20754501:-
STAD	trans	rs13190036	1	rs34446750	ENSG00000226986.4	RP11-543B16.2	-7.76	9.65e-14	6.69e-07	-0.43	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr1:211207239~211207897:+
STAD	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	7.76	9.69e-14	6.71e-07	0.42	0.38	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000233278.1	RPS26P2	7.76	9.92e-14	6.86e-07	0.44	0.38	Cognitive function;	chr12:56013288	chr9:30831878~30832225:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000233278.1	RPS26P2	7.76	9.92e-14	6.86e-07	0.44	0.38	Cognitive function;	chr12:56018703	chr9:30831878~30832225:-
STAD	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	7.75	1e-13	6.93e-07	0.55	0.38	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000233278.1	RPS26P2	7.75	1e-13	6.94e-07	0.39	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:30831878~30832225:-
STAD	trans	rs13190036	1	rs351862	ENSG00000226986.4	RP11-543B16.2	-7.75	1.01e-13	6.97e-07	-0.43	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr1:211207239~211207897:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000234354.3	RPS26P47	7.74	1.08e-13	7.43e-07	0.52	0.38	Cognitive function;	chr12:56009793	chr13:100539901~100540248:-
STAD	trans	rs7554511	0.893	rs17419032	ENSG00000244144.1	RP11-757F18.3	7.74	1.09e-13	7.54e-07	0.46	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201029403	chr3:112185480~112185998:-
STAD	trans	rs7554511	0.893	rs11586763	ENSG00000244144.1	RP11-757F18.3	-7.74	1.11e-13	7.67e-07	-0.47	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020316	chr3:112185480~112185998:-
STAD	trans	rs7554511	0.893	rs55862304	ENSG00000244144.1	RP11-757F18.3	-7.74	1.11e-13	7.67e-07	-0.47	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020647	chr3:112185480~112185998:-
STAD	trans	rs6708331	0.54	rs9677885	ENSG00000232654.1	FAM136BP	7.74	1.13e-13	7.76e-07	0.47	0.38	Obesity-related traits;	chr2:70154687	chr6:3045384~3045800:+
STAD	trans	rs6708331	0.54	rs9679269	ENSG00000232654.1	FAM136BP	7.74	1.13e-13	7.76e-07	0.47	0.38	Obesity-related traits;	chr2:70154696	chr6:3045384~3045800:+
STAD	trans	rs13177918	0.559	rs3901731	ENSG00000226396.1	RP5-1056L3.3	7.74	1.13e-13	7.81e-07	0.37	0.38	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr1:19608114~19608568:+
STAD	trans	rs66887589	0.777	rs4643791	ENSG00000275858.1	RP11-291L22.8	-7.73	1.14e-13	7.87e-07	-0.4	-0.38	Diastolic blood pressure;	chr4:119344464	chr10:38450738~38451069:-
STAD	trans	rs11220237	1	rs12288151	ENSG00000236257.1	EI24P2	7.73	1.14e-13	7.88e-07	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125873344	chr1:158454198~158455273:+
STAD	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	7.73	1.19e-13	8.22e-07	0.43	0.38	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
STAD	trans	rs13190036	1	rs34832871	ENSG00000226986.4	RP11-543B16.2	-7.73	1.21e-13	8.31e-07	-0.43	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr1:211207239~211207897:+
STAD	trans	rs11039798	0.588	rs12278284	ENSG00000134612.10	FOLH1B	7.72	1.26e-13	8.64e-07	0.59	0.38	Axial length;	chr11:48590511	chr11:89639227~89698718:+
STAD	trans	rs7554511	0.894	rs2297909	ENSG00000244144.1	RP11-757F18.3	-7.72	1.3e-13	8.93e-07	-0.4	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200991179	chr3:112185480~112185998:-
STAD	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	7.71	1.32e-13	9.09e-07	0.43	0.38	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	7.71	1.32e-13	9.09e-07	0.43	0.38	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
STAD	trans	rs6708331	0.517	rs6546570	ENSG00000232654.1	FAM136BP	7.71	1.33e-13	9.12e-07	0.47	0.38	Obesity-related traits;	chr2:70122901	chr6:3045384~3045800:+
STAD	trans	rs13177918	0.603	rs2748241	ENSG00000226396.1	RP5-1056L3.3	7.71	1.35e-13	9.27e-07	0.37	0.38	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:19608114~19608568:+
STAD	trans	rs877636	0.702	rs773112	ENSG00000239210.2	RPS26P55	7.71	1.38e-13	9.42e-07	0.43	0.38	Cognitive function;	chr12:55982097	chr19:34533427~34534084:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000243538.1	CTB-55B8.1	7.71	1.38e-13	9.45e-07	0.41	0.38	Cognitive function;	chr12:55982097	chr5:16902294~16902641:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000233278.1	RPS26P2	7.71	1.38e-13	9.47e-07	0.44	0.38	Cognitive function;	chr12:56023144	chr9:30831878~30832225:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000219993.1	RP11-288G3.3	-7.71	1.38e-13	9.48e-07	-0.39	-0.38	Cognitive function;	chr12:56042145	chr6:7506203~7506549:+
STAD	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	7.7	1.43e-13	9.77e-07	0.34	0.38	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
STAD	trans	rs9611519	0.78	rs5751072	ENSG00000268568.1	AC007228.9	-7.7	1.48e-13	1.01e-06	-0.46	-0.38	Neuroticism;	chr22:41260505	chr19:56672574~56673901:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000233278.1	RPS26P2	7.7	1.48e-13	1.01e-06	0.44	0.38	Cognitive function;	chr12:56002984	chr9:30831878~30832225:-
STAD	trans	rs11220237	0.841	rs7118459	ENSG00000236257.1	EI24P2	7.69	1.5e-13	1.02e-06	0.56	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125867837	chr1:158454198~158455273:+
STAD	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	7.69	1.5e-13	1.02e-06	0.46	0.38	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.777	rs4643791	ENSG00000276997.3	RP11-378J18.9	-7.69	1.52e-13	1.04e-06	-0.4	-0.38	Diastolic blood pressure;	chr4:119344464	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000239210.2	RPS26P55	7.69	1.52e-13	1.04e-06	0.43	0.38	Cognitive function;	chr12:55981956	chr19:34533427~34534084:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000196933.5	RPS26P11	7.69	1.53e-13	1.04e-06	0.39	0.38	Cognitive function;	chr12:55981353	chrX:72044545~72044892:+
STAD	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	7.69	1.53e-13	1.04e-06	0.53	0.38	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
STAD	trans	rs7554511	0.893	rs10494828	ENSG00000244144.1	RP11-757F18.3	-7.69	1.53e-13	1.05e-06	-0.45	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200987904	chr3:112185480~112185998:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000196656.7	AC004057.1	7.69	1.54e-13	1.05e-06	0.37	0.38	Cognitive function;	chr12:55996580	chr4:113214046~113217170:-
STAD	trans	rs8067354	0.527	rs1292039	ENSG00000187870.7	RNFT1P3	7.69	1.54e-13	1.05e-06	0.49	0.38	Hemoglobin concentration;	chr17:59897552	chr17:20743333~20754501:-
STAD	trans	rs11039798	0.588	rs666165	ENSG00000134612.10	FOLH1B	-7.69	1.55e-13	1.06e-06	-0.59	-0.38	Axial length;	chr11:48435887	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	7.69	1.55e-13	1.06e-06	0.42	0.38	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
STAD	trans	rs13177918	0.603	rs2343806	ENSG00000226396.1	RP5-1056L3.3	7.69	1.56e-13	1.06e-06	0.37	0.38	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:19608114~19608568:+
STAD	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	7.69	1.58e-13	1.08e-06	0.47	0.38	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
STAD	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-7.69	1.59e-13	1.08e-06	-0.5	-0.38	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
STAD	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	7.69	1.59e-13	1.08e-06	0.46	0.38	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000233278.1	RPS26P2	7.69	1.59e-13	1.08e-06	0.44	0.38	Cognitive function;	chr12:56041628	chr9:30831878~30832225:-
STAD	trans	rs10037055	0.853	rs1546363	ENSG00000228305.2	AC016734.2	-7.68	1.6e-13	1.09e-06	-0.37	-0.38	Migraine without aura;	chr5:177174030	chr2:63622178~63622831:-
STAD	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	7.68	1.61e-13	1.09e-06	0.53	0.38	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
STAD	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	7.68	1.61e-13	1.09e-06	0.42	0.38	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
STAD	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	7.68	1.63e-13	1.1e-06	0.34	0.38	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000234192.1	RP11-57C13.5	7.68	1.63e-13	1.11e-06	0.42	0.38	Cognitive function;	chr12:55980911	chr10:87642607~87642954:+
STAD	trans	rs7554511	0.858	rs3208703	ENSG00000244144.1	RP11-757F18.3	-7.68	1.65e-13	1.12e-06	-0.46	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200970514	chr3:112185480~112185998:-
STAD	trans	rs6708331	0.517	rs6546572	ENSG00000232654.1	FAM136BP	7.68	1.65e-13	1.12e-06	0.47	0.38	Obesity-related traits;	chr2:70146510	chr6:3045384~3045800:+
STAD	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	7.68	1.66e-13	1.12e-06	0.42	0.38	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	7.68	1.66e-13	1.12e-06	0.42	0.38	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
STAD	trans	rs9858542	0.953	rs9814873	ENSG00000197582.5	GPX1P1	-7.68	1.67e-13	1.13e-06	-0.53	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.574	rs1296279	ENSG00000187870.7	RNFT1P3	7.68	1.67e-13	1.13e-06	0.49	0.38	Hemoglobin concentration;	chr17:59888370	chr17:20743333~20754501:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000233278.1	RPS26P2	7.68	1.68e-13	1.13e-06	0.44	0.38	Cognitive function;	chr12:56050848	chr9:30831878~30832225:-
STAD	trans	rs13190036	1	rs3733875	ENSG00000226986.4	RP11-543B16.2	-7.68	1.68e-13	1.14e-06	-0.42	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr1:211207239~211207897:+
STAD	trans	rs6708331	0.517	rs7579922	ENSG00000232654.1	FAM136BP	7.68	1.69e-13	1.14e-06	0.46	0.38	Obesity-related traits;	chr2:70134781	chr6:3045384~3045800:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000196933.5	RPS26P11	7.68	1.69e-13	1.14e-06	0.43	0.38	Cognitive function;	chr12:56055651	chrX:72044545~72044892:+
STAD	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-7.67	1.71e-13	1.15e-06	-0.42	-0.38	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000234354.3	RPS26P47	7.67	1.73e-13	1.17e-06	0.52	0.38	Cognitive function;	chr12:56013288	chr13:100539901~100540248:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000234354.3	RPS26P47	7.67	1.73e-13	1.17e-06	0.52	0.38	Cognitive function;	chr12:56018703	chr13:100539901~100540248:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000234354.3	RPS26P47	7.67	1.75e-13	1.18e-06	0.52	0.38	Cognitive function;	chr12:56050848	chr13:100539901~100540248:-
STAD	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-7.67	1.77e-13	1.2e-06	-0.54	-0.38	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-7.67	1.77e-13	1.2e-06	-0.54	-0.38	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-7.67	1.78e-13	1.2e-06	-0.55	-0.38	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-7.67	1.78e-13	1.2e-06	-0.55	-0.38	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-7.67	1.78e-13	1.2e-06	-0.55	-0.38	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.961	rs10154992	ENSG00000197582.5	GPX1P1	7.67	1.8e-13	1.21e-06	0.54	0.38	Menarche (age at onset);	chr3:49238644	chrX:13378735~13379340:-
STAD	trans	rs12138950	0.681	rs10917472	ENSG00000224237.1	MINOS1P3	7.67	1.8e-13	1.22e-06	0.54	0.38	Hypothyroidism;Thyroid volume;	chr1:19524218	chr3:27214816~27215018:-
STAD	trans	rs11220237	1	rs10893434	ENSG00000236257.1	EI24P2	7.67	1.81e-13	1.22e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125836029	chr1:158454198~158455273:+
STAD	trans	rs11220237	1	rs10893435	ENSG00000236257.1	EI24P2	7.67	1.81e-13	1.22e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125838890	chr1:158454198~158455273:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000239210.2	RPS26P55	7.67	1.81e-13	1.22e-06	0.42	0.38	Cognitive function;	chr12:55996580	chr19:34533427~34534084:-
STAD	trans	rs66887589	0.807	rs9799664	ENSG00000276997.3	RP11-378J18.9	7.67	1.82e-13	1.22e-06	0.4	0.38	Diastolic blood pressure;	chr4:119405523	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.627	rs3872807	ENSG00000276997.3	RP11-378J18.9	7.67	1.82e-13	1.22e-06	0.4	0.38	Diastolic blood pressure;	chr4:119439096	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.56	rs9684327	ENSG00000276997.3	RP11-378J18.9	7.67	1.82e-13	1.22e-06	0.4	0.38	Diastolic blood pressure;	chr4:119444286	chr1:222477252~222504622:-
STAD	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	7.66	1.86e-13	1.25e-06	0.46	0.38	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-7.66	1.87e-13	1.26e-06	-0.55	-0.38	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000234192.1	RP11-57C13.5	7.66	1.88e-13	1.27e-06	0.42	0.38	Cognitive function;	chr12:55981956	chr10:87642607~87642954:+
STAD	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	7.66	1.88e-13	1.27e-06	0.53	0.38	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
STAD	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	7.66	1.89e-13	1.27e-06	0.52	0.38	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	7.66	1.9e-13	1.28e-06	0.54	0.38	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
STAD	trans	rs11039798	0.511	rs2047812	ENSG00000134612.10	FOLH1B	-7.66	1.93e-13	1.29e-06	-0.61	-0.38	Axial length;	chr11:48140490	chr11:89639227~89698718:+
STAD	trans	rs2069408	1	rs2069408	ENSG00000243403.1	RP11-330L19.1	-7.65	1.96e-13	1.32e-06	-0.39	-0.38	Asthma;	chr12:55970537	chr15:64592979~64593326:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000233778.3	RP11-777J24.1	7.65	1.98e-13	1.33e-06	0.38	0.38	Cognitive function;	chr12:55996580	chr8:92144088~92144435:-
STAD	trans	rs11220237	1	rs7121477	ENSG00000236257.1	EI24P2	7.65	1.98e-13	1.33e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125853528	chr1:158454198~158455273:+
STAD	trans	rs11220237	0.925	rs6590178	ENSG00000236257.1	EI24P2	7.65	1.98e-13	1.33e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125853735	chr1:158454198~158455273:+
STAD	trans	rs916888	0.773	rs199445	ENSG00000264057.1	RP11-583F2.1	7.65	2.01e-13	1.35e-06	0.48	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:64927634~64934203:+
STAD	trans	rs916888	0.773	rs199443	ENSG00000264057.1	RP11-583F2.1	7.65	2.01e-13	1.35e-06	0.48	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:64927634~64934203:+
STAD	trans	rs11220237	1	rs3862623	ENSG00000236257.1	EI24P2	7.65	2.02e-13	1.36e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850351	chr1:158454198~158455273:+
STAD	trans	rs11220237	1	rs7124578	ENSG00000236257.1	EI24P2	7.65	2.02e-13	1.36e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850600	chr1:158454198~158455273:+
STAD	trans	rs11039798	0.588	rs11039855	ENSG00000134612.10	FOLH1B	7.65	2.04e-13	1.37e-06	0.59	0.38	Axial length;	chr11:48588539	chr11:89639227~89698718:+
STAD	trans	rs7647973	0.961	rs11130186	ENSG00000197582.5	GPX1P1	7.65	2.05e-13	1.37e-06	0.53	0.38	Menarche (age at onset);	chr3:49238395	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	7.65	2.06e-13	1.38e-06	0.42	0.38	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	7.65	2.06e-13	1.38e-06	0.42	0.38	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
STAD	trans	rs13190036	1	rs13177748	ENSG00000226986.4	RP11-543B16.2	-7.65	2.08e-13	1.39e-06	-0.42	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr1:211207239~211207897:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000239210.2	RPS26P55	7.64	2.11e-13	1.41e-06	0.43	0.38	Cognitive function;	chr12:55988132	chr19:34533427~34534084:-
STAD	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	7.64	2.11e-13	1.41e-06	0.42	0.38	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
STAD	trans	rs13190036	0.748	rs28395268	ENSG00000226986.4	RP11-543B16.2	7.64	2.12e-13	1.42e-06	0.4	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr1:211207239~211207897:+
STAD	trans	rs66887589	0.87	rs10518336	ENSG00000275858.1	RP11-291L22.8	7.64	2.15e-13	1.44e-06	0.4	0.38	Diastolic blood pressure;	chr4:119601779	chr10:38450738~38451069:-
STAD	trans	rs11039798	0.588	rs10838970	ENSG00000134612.10	FOLH1B	7.64	2.17e-13	1.45e-06	0.59	0.38	Axial length;	chr11:48584715	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.588	rs7108164	ENSG00000134612.10	FOLH1B	7.64	2.17e-13	1.45e-06	0.59	0.38	Axial length;	chr11:48604811	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.588	rs10838979	ENSG00000134612.10	FOLH1B	7.64	2.17e-13	1.45e-06	0.59	0.38	Axial length;	chr11:48605258	chr11:89639227~89698718:+
STAD	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	7.64	2.17e-13	1.45e-06	0.45	0.38	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000196656.7	AC004057.1	-7.64	2.19e-13	1.46e-06	-0.36	-0.38	Cognitive function;	chr12:55996852	chr4:113214046~113217170:-
STAD	trans	rs66887589	0.72	rs2036858	ENSG00000276997.3	RP11-378J18.9	7.64	2.2e-13	1.47e-06	0.4	0.38	Diastolic blood pressure;	chr4:119328082	chr1:222477252~222504622:-
STAD	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-7.64	2.22e-13	1.48e-06	-0.34	-0.38	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
STAD	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	7.63	2.23e-13	1.49e-06	0.46	0.38	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
STAD	trans	rs7554511	0.861	rs296563	ENSG00000244144.1	RP11-757F18.3	7.63	2.24e-13	1.5e-06	0.4	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200975712	chr3:112185480~112185998:-
STAD	trans	rs66887589	0.775	rs6843229	ENSG00000276997.3	RP11-378J18.9	7.63	2.29e-13	1.53e-06	0.4	0.38	Diastolic blood pressure;	chr4:119502932	chr1:222477252~222504622:-
STAD	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	7.63	2.34e-13	1.56e-06	0.42	0.38	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000204652.6	RPS26P8	7.63	2.35e-13	1.57e-06	0.39	0.38	Cognitive function;	chr12:55990903	chr17:45608571~45608918:+
STAD	trans	rs3770081	1	rs3770087	ENSG00000229880.1	IMMTP1	7.63	2.36e-13	1.57e-06	0.72	0.38	Facial emotion recognition (sad faces);	chr2:86039945	chr21:44675868~44678086:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000239210.2	RPS26P55	7.62	2.4e-13	1.59e-06	0.43	0.38	Cognitive function;	chr12:55981353	chr19:34533427~34534084:-
STAD	trans	rs11039798	0.588	rs6485891	ENSG00000134612.10	FOLH1B	7.62	2.4e-13	1.6e-06	0.59	0.38	Axial length;	chr11:48590472	chr11:89639227~89698718:+
STAD	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	7.62	2.44e-13	1.62e-06	0.33	0.38	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
STAD	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	7.62	2.44e-13	1.62e-06	0.33	0.38	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
STAD	trans	rs11220237	1	rs11220238	ENSG00000236257.1	EI24P2	7.62	2.44e-13	1.62e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125839807	chr1:158454198~158455273:+
STAD	trans	rs11220237	1	rs11220239	ENSG00000236257.1	EI24P2	7.62	2.44e-13	1.62e-06	0.57	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125840630	chr1:158454198~158455273:+
STAD	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	7.62	2.44e-13	1.62e-06	0.42	0.38	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	7.62	2.44e-13	1.62e-06	0.42	0.38	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000234192.1	RP11-57C13.5	7.62	2.49e-13	1.65e-06	0.42	0.38	Cognitive function;	chr12:55981353	chr10:87642607~87642954:+
STAD	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	7.62	2.5e-13	1.66e-06	0.46	0.38	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.961	rs11130187	ENSG00000197582.5	GPX1P1	7.61	2.55e-13	1.69e-06	0.53	0.38	Menarche (age at onset);	chr3:49270439	chrX:13378735~13379340:-
STAD	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-7.61	2.56e-13	1.7e-06	-0.5	-0.38	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-7.61	2.56e-13	1.7e-06	-0.5	-0.38	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
STAD	trans	rs9611519	0.78	rs5751071	ENSG00000268568.1	AC007228.9	-7.61	2.57e-13	1.7e-06	-0.46	-0.38	Neuroticism;	chr22:41260328	chr19:56672574~56673901:-
STAD	trans	rs66887589	0.807	rs13134517	ENSG00000276997.3	RP11-378J18.9	7.61	2.59e-13	1.72e-06	0.4	0.38	Diastolic blood pressure;	chr4:119484107	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.837	rs6534135	ENSG00000276997.3	RP11-378J18.9	7.61	2.59e-13	1.72e-06	0.4	0.38	Diastolic blood pressure;	chr4:119485147	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.837	rs7661498	ENSG00000276997.3	RP11-378J18.9	7.61	2.59e-13	1.72e-06	0.4	0.38	Diastolic blood pressure;	chr4:119486953	chr1:222477252~222504622:-
STAD	trans	rs11220237	1	rs10893444	ENSG00000236257.1	EI24P2	7.61	2.6e-13	1.73e-06	0.56	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125875652	chr1:158454198~158455273:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000234354.3	RPS26P47	7.61	2.6e-13	1.73e-06	0.51	0.38	Cognitive function;	chr12:56023144	chr13:100539901~100540248:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000239210.2	RPS26P55	7.61	2.65e-13	1.76e-06	0.43	0.38	Cognitive function;	chr12:55980911	chr19:34533427~34534084:-
STAD	trans	rs7647973	0.925	rs9834003	ENSG00000197582.5	GPX1P1	7.61	2.69e-13	1.78e-06	0.53	0.38	Menarche (age at onset);	chr3:49179039	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.925	rs4955421	ENSG00000197582.5	GPX1P1	7.61	2.69e-13	1.78e-06	0.53	0.38	Menarche (age at onset);	chr3:49181455	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.925	rs4955423	ENSG00000197582.5	GPX1P1	7.61	2.69e-13	1.78e-06	0.53	0.38	Menarche (age at onset);	chr3:49183015	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.925	rs6446256	ENSG00000197582.5	GPX1P1	7.61	2.69e-13	1.78e-06	0.53	0.38	Menarche (age at onset);	chr3:49186777	chrX:13378735~13379340:-
STAD	trans	rs11220237	1	rs59868022	ENSG00000236257.1	EI24P2	7.6	2.72e-13	1.8e-06	0.56	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850985	chr1:158454198~158455273:+
STAD	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	7.6	2.72e-13	1.8e-06	0.46	0.38	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
STAD	trans	rs11220082	0.644	rs12577961	ENSG00000236257.1	EI24P2	-7.6	2.73e-13	1.8e-06	-0.51	-0.38	Schizophrenia;	chr11:125438943	chr1:158454198~158455273:+
STAD	trans	rs11220082	0.542	rs11220079	ENSG00000236257.1	EI24P2	-7.6	2.75e-13	1.82e-06	-0.51	-0.38	Schizophrenia;	chr11:125450033	chr1:158454198~158455273:+
STAD	trans	rs11220237	1	rs56338707	ENSG00000236257.1	EI24P2	7.6	2.81e-13	1.86e-06	0.56	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125883330	chr1:158454198~158455273:+
STAD	trans	rs11220237	0.92	rs11220263	ENSG00000236257.1	EI24P2	7.6	2.81e-13	1.86e-06	0.56	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr11:125885375	chr1:158454198~158455273:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000219993.1	RP11-288G3.3	7.6	2.82e-13	1.86e-06	0.37	0.38	Cognitive function;	chr12:56076841	chr6:7506203~7506549:+
STAD	trans	rs616147	0.671	rs674192	ENSG00000214263.2	RPSAP53	-7.6	2.86e-13	1.89e-06	-0.48	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr13:67266845~67267706:-
STAD	trans	rs11039798	0.557	rs683180	ENSG00000134612.10	FOLH1B	-7.6	2.89e-13	1.91e-06	-0.59	-0.38	Axial length;	chr11:48442397	chr11:89639227~89698718:+
STAD	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	7.6	2.9e-13	1.91e-06	0.45	0.38	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
STAD	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	7.59	2.96e-13	1.95e-06	0.43	0.38	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000234192.1	RP11-57C13.5	7.59	3.02e-13	1.99e-06	0.41	0.38	Cognitive function;	chr12:55982097	chr10:87642607~87642954:+
STAD	trans	rs7113874	0.578	rs1026021	ENSG00000266891.1	RP11-692N5.2	-7.59	3.05e-13	2.01e-06	-0.53	-0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8543231	chr18:9734882~9735602:-
STAD	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	7.59	3.06e-13	2.02e-06	0.54	0.38	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
STAD	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-7.59	3.1e-13	2.04e-06	-0.43	-0.38	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
STAD	trans	rs7647973	0.961	rs4955417	ENSG00000197582.5	GPX1P1	7.58	3.18e-13	2.09e-06	0.53	0.38	Menarche (age at onset);	chr3:49260772	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.748	rs28439855	ENSG00000275858.1	RP11-291L22.8	7.58	3.2e-13	2.11e-06	0.39	0.38	Diastolic blood pressure;	chr4:119341101	chr10:38450738~38451069:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000242206.2	RPS26P35	-7.58	3.2e-13	2.11e-06	-0.41	-0.38	Cognitive function;	chr12:56080595	chr8:118761856~118762201:-
STAD	trans	rs3749237	1	rs1317140	ENSG00000197582.5	GPX1P1	7.58	3.23e-13	2.12e-06	0.48	0.38	Resting heart rate;	chr3:49841219	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.574	rs1292033	ENSG00000187870.7	RNFT1P3	7.58	3.28e-13	2.15e-06	0.48	0.38	Hemoglobin concentration;	chr17:59913236	chr17:20743333~20754501:-
STAD	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	7.58	3.3e-13	2.17e-06	0.33	0.38	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
STAD	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	7.57	3.34e-13	2.19e-06	0.42	0.38	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	7.57	3.34e-13	2.19e-06	0.42	0.38	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	7.57	3.34e-13	2.19e-06	0.42	0.38	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
STAD	trans	rs7554511	0.893	rs72749166	ENSG00000244144.1	RP11-757F18.3	-7.57	3.38e-13	2.22e-06	-0.46	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031177	chr3:112185480~112185998:-
STAD	trans	rs66887589	0.87	rs10518336	ENSG00000276997.3	RP11-378J18.9	7.57	3.39e-13	2.23e-06	0.4	0.38	Diastolic blood pressure;	chr4:119601779	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000244604.1	RP11-713H12.1	7.57	3.4e-13	2.23e-06	0.41	0.38	Cognitive function;	chr12:55982097	chr17:8561230~8561576:+
STAD	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	7.57	3.42e-13	2.25e-06	0.44	0.38	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
STAD	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	7.57	3.47e-13	2.28e-06	0.51	0.38	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
STAD	trans	rs7113874	0.559	rs34378489	ENSG00000266891.1	RP11-692N5.2	7.57	3.49e-13	2.29e-06	0.53	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8407803	chr18:9734882~9735602:-
STAD	trans	rs9611519	0.78	rs2235849	ENSG00000268568.1	AC007228.9	-7.57	3.51e-13	2.3e-06	-0.45	-0.38	Neuroticism;	chr22:41257536	chr19:56672574~56673901:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000234354.3	RPS26P47	7.57	3.53e-13	2.31e-06	0.51	0.38	Cognitive function;	chr12:56041628	chr13:100539901~100540248:-
STAD	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-7.56	3.55e-13	2.33e-06	-0.43	-0.38	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
STAD	trans	rs10816533	1	rs6477733	ENSG00000232063.1	RP11-307E17.8	7.56	3.61e-13	2.36e-06	0.58	0.38	Height;	chr9:96862781	chr9:94332476~94360948:+
STAD	trans	rs66887589	0.777	rs10015883	ENSG00000275858.1	RP11-291L22.8	7.56	3.62e-13	2.37e-06	0.39	0.38	Diastolic blood pressure;	chr4:119346991	chr10:38450738~38451069:-
STAD	trans	rs10037055	0.853	rs2336237	ENSG00000228305.2	AC016734.2	7.56	3.64e-13	2.39e-06	0.37	0.38	Migraine without aura;	chr5:177238878	chr2:63622178~63622831:-
STAD	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-7.56	3.73e-13	2.44e-06	-0.33	-0.38	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
STAD	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	7.55	3.78e-13	2.47e-06	0.43	0.38	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
STAD	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	7.55	3.85e-13	2.52e-06	0.33	0.38	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
STAD	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	7.55	3.87e-13	2.52e-06	0.42	0.38	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	7.55	3.87e-13	2.52e-06	0.42	0.38	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
STAD	trans	rs66887589	0.774	rs9307477	ENSG00000276997.3	RP11-378J18.9	7.55	3.87e-13	2.53e-06	0.4	0.38	Diastolic blood pressure;	chr4:119500654	chr1:222477252~222504622:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000233278.1	RPS26P2	7.55	3.87e-13	2.53e-06	0.43	0.38	Cognitive function;	chr12:56041720	chr9:30831878~30832225:-
STAD	trans	rs10816533	1	rs7037169	ENSG00000232063.1	RP11-307E17.8	7.55	3.97e-13	2.59e-06	0.65	0.38	Height;	chr9:96838313	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs7037100	ENSG00000232063.1	RP11-307E17.8	7.55	3.97e-13	2.59e-06	0.65	0.38	Height;	chr9:96844247	chr9:94332476~94360948:+
STAD	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-7.55	3.98e-13	2.59e-06	-0.54	-0.38	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	7.55	3.98e-13	2.6e-06	0.41	0.38	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	7.55	4e-13	2.6e-06	0.42	0.38	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
STAD	trans	rs616147	0.671	rs675595	ENSG00000214263.2	RPSAP53	-7.55	4.03e-13	2.63e-06	-0.47	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr13:67266845~67267706:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000196933.5	RPS26P11	7.54	4.03e-13	2.63e-06	0.39	0.38	Cognitive function;	chr12:55980911	chrX:72044545~72044892:+
STAD	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	7.54	4.05e-13	2.64e-06	0.46	0.38	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs11715915	ENSG00000197582.5	GPX1P1	7.54	4.15e-13	2.7e-06	0.55	0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	7.54	4.19e-13	2.73e-06	0.42	0.38	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000243538.1	CTB-55B8.1	7.54	4.22e-13	2.74e-06	0.4	0.38	Cognitive function;	chr12:55981956	chr5:16902294~16902641:-
STAD	trans	rs11039798	0.588	rs584899	ENSG00000134612.10	FOLH1B	-7.54	4.23e-13	2.75e-06	-0.57	-0.38	Axial length;	chr11:48409856	chr11:89639227~89698718:+
STAD	trans	rs916888	0.773	rs199535	ENSG00000264057.1	RP11-583F2.1	7.53	4.41e-13	2.87e-06	0.48	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:64927634~64934203:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000243538.1	CTB-55B8.1	7.53	4.47e-13	2.9e-06	0.4	0.38	Cognitive function;	chr12:55981353	chr5:16902294~16902641:-
STAD	trans	rs66887589	0.967	rs3775842	ENSG00000276997.3	RP11-378J18.9	7.53	4.5e-13	2.92e-06	0.4	0.38	Diastolic blood pressure;	chr4:119506577	chr1:222477252~222504622:-
STAD	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	7.53	4.56e-13	2.96e-06	0.41	0.38	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
STAD	trans	rs9858542	0.953	rs71324979	ENSG00000197582.5	GPX1P1	-7.53	4.59e-13	2.98e-06	-0.54	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49582218	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.903	rs9875617	ENSG00000197582.5	GPX1P1	-7.53	4.59e-13	2.98e-06	-0.54	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49597263	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.574	rs1291947	ENSG00000187870.7	RNFT1P3	7.52	4.62e-13	3e-06	0.47	0.37	Hemoglobin concentration;	chr17:59918975	chr17:20743333~20754501:-
STAD	trans	rs7647973	0.961	rs4955443	ENSG00000197582.5	GPX1P1	7.52	4.63e-13	3e-06	0.53	0.37	Menarche (age at onset);	chr3:49249185	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	7.52	4.63e-13	3e-06	0.45	0.37	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
STAD	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	7.52	4.63e-13	3e-06	0.45	0.37	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
STAD	trans	rs3770081	1	rs58515922	ENSG00000229880.1	IMMTP1	7.52	4.69e-13	3.04e-06	0.72	0.37	Facial emotion recognition (sad faces);	chr2:85945914	chr21:44675868~44678086:-
STAD	trans	rs4834770	1	rs10034579	ENSG00000276997.3	RP11-378J18.9	7.52	4.7e-13	3.05e-06	0.41	0.37	Blood protein levels;	chr4:119322874	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000244604.1	RP11-713H12.1	7.52	4.72e-13	3.06e-06	0.41	0.37	Cognitive function;	chr12:55981956	chr17:8561230~8561576:+
STAD	trans	rs2069408	1	rs2069408	ENSG00000234513.1	AC073072.7	-7.52	4.87e-13	3.15e-06	-0.37	-0.37	Asthma;	chr12:55970537	chr7:22773646~22773993:-
STAD	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-7.51	5.03e-13	3.25e-06	-0.49	-0.37	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000233778.3	RP11-777J24.1	-7.51	5.07e-13	3.28e-06	-0.37	-0.37	Cognitive function;	chr12:55996852	chr8:92144088~92144435:-
STAD	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-7.51	5.07e-13	3.28e-06	-0.33	-0.37	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
STAD	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	7.51	5.15e-13	3.33e-06	0.38	0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
STAD	trans	rs11098499	0.575	rs9996586	ENSG00000276997.3	RP11-378J18.9	7.5	5.28e-13	3.41e-06	0.39	0.37	Corneal astigmatism;	chr4:119405787	chr1:222477252~222504622:-
STAD	trans	rs10037055	0.853	rs10056008	ENSG00000228305.2	AC016734.2	-7.5	5.29e-13	3.41e-06	-0.36	-0.37	Migraine without aura;	chr5:177194147	chr2:63622178~63622831:-
STAD	trans	rs7399018	0.739	rs7399073	ENSG00000223825.5	DAZAP2P1	7.5	5.35e-13	3.45e-06	0.44	0.37	Cisplatin-induced ototoxicity;	chr12:51220266	chr2:202201384~202201886:-
STAD	trans	rs11039798	0.588	rs589834	ENSG00000134612.10	FOLH1B	-7.5	5.46e-13	3.51e-06	-0.57	-0.37	Axial length;	chr11:48397830	chr11:89639227~89698718:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000219993.1	RP11-288G3.3	-7.5	5.47e-13	3.52e-06	-0.38	-0.37	Cognitive function;	chr12:56007301	chr6:7506203~7506549:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000234354.3	RPS26P47	7.5	5.51e-13	3.55e-06	0.5	0.37	Cognitive function;	chr12:56041720	chr13:100539901~100540248:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000242206.2	RPS26P35	7.5	5.53e-13	3.56e-06	0.39	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:118761856~118762201:-
STAD	trans	rs13190036	1	rs13175695	ENSG00000226986.4	RP11-543B16.2	7.49	5.64e-13	3.63e-06	0.4	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr1:211207239~211207897:+
STAD	trans	rs8067354	0.574	rs1292050	ENSG00000187870.7	RNFT1P3	7.49	5.71e-13	3.67e-06	0.47	0.37	Hemoglobin concentration;	chr17:59887808	chr17:20743333~20754501:-
STAD	trans	rs7113874	0.545	rs72855149	ENSG00000266891.1	RP11-692N5.2	7.49	5.74e-13	3.69e-06	0.51	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8586160	chr18:9734882~9735602:-
STAD	trans	rs8067354	0.574	rs2250526	ENSG00000187870.7	RNFT1P3	7.49	5.77e-13	3.71e-06	0.47	0.37	Hemoglobin concentration;	chr17:59874612	chr17:20743333~20754501:-
STAD	trans	rs13190036	0.901	rs6898107	ENSG00000226986.4	RP11-543B16.2	7.49	5.8e-13	3.72e-06	0.41	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr1:211207239~211207897:+
STAD	trans	rs11039571	0.588	rs10734564	ENSG00000134612.10	FOLH1B	-7.49	5.81e-13	3.73e-06	-0.61	-0.37	D-dimer levels;	chr11:48138877	chr11:89639227~89698718:+
STAD	trans	rs7647973	0.925	rs11130183	ENSG00000197582.5	GPX1P1	7.49	5.82e-13	3.73e-06	0.52	0.37	Menarche (age at onset);	chr3:49191513	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.925	rs6808036	ENSG00000197582.5	GPX1P1	7.49	5.82e-13	3.73e-06	0.52	0.37	Menarche (age at onset);	chr3:49199006	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-7.49	5.87e-13	3.77e-06	-0.53	-0.37	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
STAD	trans	rs1190596	0.83	rs3736807	ENSG00000181359.5	HSP90AA6P	7.49	5.88e-13	3.77e-06	0.43	0.37	Behavioural disinhibition (generation interaction);	chr14:102086438	chr4:170581470~170605450:-
STAD	trans	rs11220237	1	rs11518432	ENSG00000236257.1	EI24P2	7.49	5.93e-13	3.8e-06	0.56	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125814838	chr1:158454198~158455273:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000234192.1	RP11-57C13.5	7.48	6.09e-13	3.9e-06	0.42	0.37	Cognitive function;	chr12:55988132	chr10:87642607~87642954:+
STAD	trans	rs877636	1	rs4759229	ENSG00000242206.2	RPS26P35	-7.48	6.12e-13	3.92e-06	-0.41	-0.37	Cognitive function;	chr12:56080696	chr8:118761856~118762201:-
STAD	trans	rs7647973	0.925	rs4384984	ENSG00000197582.5	GPX1P1	7.48	6.16e-13	3.94e-06	0.53	0.37	Menarche (age at onset);	chr3:49252445	chrX:13378735~13379340:-
STAD	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-7.48	6.19e-13	3.96e-06	-0.33	-0.37	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
STAD	trans	rs66887589	0.807	rs13134517	ENSG00000275858.1	RP11-291L22.8	7.48	6.2e-13	3.96e-06	0.39	0.37	Diastolic blood pressure;	chr4:119484107	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.837	rs6534135	ENSG00000275858.1	RP11-291L22.8	7.48	6.2e-13	3.96e-06	0.39	0.37	Diastolic blood pressure;	chr4:119485147	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.837	rs7661498	ENSG00000275858.1	RP11-291L22.8	7.48	6.2e-13	3.96e-06	0.39	0.37	Diastolic blood pressure;	chr4:119486953	chr10:38450738~38451069:-
STAD	trans	rs7113874	0.592	rs12808779	ENSG00000266891.1	RP11-692N5.2	7.48	6.23e-13	3.98e-06	0.53	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8416280	chr18:9734882~9735602:-
STAD	trans	rs9858542	0.953	rs11926781	ENSG00000197582.5	GPX1P1	-7.48	6.24e-13	3.99e-06	-0.54	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49565856	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	7.48	6.26e-13	4e-06	0.41	0.37	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
STAD	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	7.48	6.29e-13	4.02e-06	0.41	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
STAD	trans	rs7554511	0.861	rs11583546	ENSG00000244144.1	RP11-757F18.3	-7.48	6.3e-13	4.03e-06	-0.46	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200933479	chr3:112185480~112185998:-
STAD	trans	rs66887589	0.774	rs9307477	ENSG00000275858.1	RP11-291L22.8	7.48	6.34e-13	4.05e-06	0.39	0.37	Diastolic blood pressure;	chr4:119500654	chr10:38450738~38451069:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000243328.1	RP11-520P18.1	7.47	6.45e-13	4.12e-06	0.35	0.37	Cognitive function;	chr12:56076841	chr8:143065915~143066587:-
STAD	trans	rs3770081	1	rs1561328	ENSG00000229880.1	IMMTP1	7.47	6.47e-13	4.13e-06	0.7	0.37	Facial emotion recognition (sad faces);	chr2:86045635	chr21:44675868~44678086:-
STAD	trans	rs66887589	0.775	rs6843229	ENSG00000275858.1	RP11-291L22.8	7.47	6.52e-13	4.16e-06	0.39	0.37	Diastolic blood pressure;	chr4:119502932	chr10:38450738~38451069:-
STAD	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-7.47	6.56e-13	4.19e-06	-0.48	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
STAD	trans	rs10037055	0.853	rs10476219	ENSG00000228305.2	AC016734.2	-7.47	6.6e-13	4.21e-06	-0.36	-0.37	Migraine without aura;	chr5:177201547	chr2:63622178~63622831:-
STAD	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	7.47	6.64e-13	4.23e-06	0.49	0.37	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
STAD	trans	rs11220237	0.92	rs1365081	ENSG00000236257.1	EI24P2	-7.47	6.75e-13	4.3e-06	-0.56	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125778087	chr1:158454198~158455273:+
STAD	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	7.46	6.89e-13	4.39e-06	0.42	0.37	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
STAD	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-7.46	7.03e-13	4.47e-06	-0.49	-0.37	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-7.46	7.03e-13	4.47e-06	-0.49	-0.37	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-7.46	7.03e-13	4.47e-06	-0.49	-0.37	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-7.46	7.03e-13	4.47e-06	-0.49	-0.37	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
STAD	trans	rs9611519	0.808	rs5751074	ENSG00000268568.1	AC007228.9	-7.45	7.28e-13	4.62e-06	-0.45	-0.37	Neuroticism;	chr22:41269718	chr19:56672574~56673901:-
STAD	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-7.45	7.33e-13	4.65e-06	-0.49	-0.37	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.728	rs12655271	ENSG00000231752.4	EMBP1	-7.45	7.42e-13	4.71e-06	-0.51	-0.37	Schizophrenia;	chr5:50212921	chr1:121519112~121571892:+
STAD	trans	rs7554511	0.858	rs6701496	ENSG00000244144.1	RP11-757F18.3	-7.45	7.42e-13	4.71e-06	-0.46	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201038700	chr3:112185480~112185998:-
STAD	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	7.45	7.45e-13	4.72e-06	0.51	0.37	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	7.45	7.46e-13	4.73e-06	0.36	0.37	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
STAD	trans	rs11220237	1	rs3824921	ENSG00000236257.1	EI24P2	7.45	7.48e-13	4.74e-06	0.57	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125891563	chr1:158454198~158455273:+
STAD	trans	rs12497850	1	rs4858831	ENSG00000197582.5	GPX1P1	7.45	7.49e-13	4.75e-06	0.48	0.37	Parkinson's disease;	chr3:48698125	chrX:13378735~13379340:-
STAD	trans	rs13177918	0.581	rs2748244	ENSG00000226396.1	RP5-1056L3.3	7.45	7.52e-13	4.77e-06	0.36	0.37	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr1:19608114~19608568:+
STAD	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	7.45	7.66e-13	4.85e-06	0.48	0.37	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
STAD	trans	rs11039798	0.588	rs643668	ENSG00000134612.10	FOLH1B	-7.45	7.69e-13	4.86e-06	-0.57	-0.37	Axial length;	chr11:48391847	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000242970.2	AC068522.4	7.45	7.71e-13	4.88e-06	0.41	0.37	Cognitive function;	chr12:55976127	chr8:58588420~58588764:-
STAD	trans	rs13190036	0.901	rs10056655	ENSG00000226986.4	RP11-543B16.2	7.44	7.78e-13	4.92e-06	0.4	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr1:211207239~211207897:+
STAD	trans	rs13190036	1	rs13185316	ENSG00000226986.4	RP11-543B16.2	-7.44	7.82e-13	4.94e-06	-0.42	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr1:211207239~211207897:+
STAD	trans	rs916888	0.773	rs199534	ENSG00000264057.1	RP11-583F2.1	7.44	7.84e-13	4.95e-06	0.47	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:64927634~64934203:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	7.44	7.94e-13	5.02e-06	0.36	0.37	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
STAD	trans	rs11220237	1	rs34506449	ENSG00000236257.1	EI24P2	7.44	7.97e-13	5.03e-06	0.56	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125833712	chr1:158454198~158455273:+
STAD	trans	rs11220237	1	rs7937508	ENSG00000236257.1	EI24P2	7.44	7.97e-13	5.03e-06	0.56	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125834587	chr1:158454198~158455273:+
STAD	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-7.44	8.02e-13	5.06e-06	-0.48	-0.37	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
STAD	trans	rs877636	0.702	rs773109	ENSG00000244604.1	RP11-713H12.1	7.44	8.05e-13	5.08e-06	0.41	0.37	Cognitive function;	chr12:55980911	chr17:8561230~8561576:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000239210.2	RPS26P55	7.44	8.1e-13	5.11e-06	0.42	0.37	Cognitive function;	chr12:55976127	chr19:34533427~34534084:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000244604.1	RP11-713H12.1	7.44	8.13e-13	5.13e-06	0.41	0.37	Cognitive function;	chr12:55988132	chr17:8561230~8561576:+
STAD	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	7.44	8.29e-13	5.22e-06	0.51	0.37	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	7.44	8.29e-13	5.22e-06	0.51	0.37	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
STAD	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-7.44	8.29e-13	5.22e-06	-0.48	-0.37	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-7.43	8.37e-13	5.27e-06	-0.49	-0.37	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-7.43	8.37e-13	5.27e-06	-0.49	-0.37	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-7.43	8.37e-13	5.27e-06	-0.49	-0.37	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-7.43	8.37e-13	5.27e-06	-0.49	-0.37	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
STAD	trans	rs6708331	0.517	rs9989876	ENSG00000232654.1	FAM136BP	7.43	8.41e-13	5.29e-06	0.45	0.37	Obesity-related traits;	chr2:70115578	chr6:3045384~3045800:+
STAD	trans	rs6708331	0.517	rs10496178	ENSG00000232654.1	FAM136BP	7.43	8.41e-13	5.29e-06	0.45	0.37	Obesity-related traits;	chr2:70115683	chr6:3045384~3045800:+
STAD	trans	rs13190036	0.551	rs4976639	ENSG00000226986.4	RP11-543B16.2	7.43	8.44e-13	5.31e-06	0.39	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr1:211207239~211207897:+
STAD	trans	rs11220237	1	rs11220261	ENSG00000236257.1	EI24P2	7.43	8.44e-13	5.31e-06	0.54	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125877574	chr1:158454198~158455273:+
STAD	trans	rs7554511	0.825	rs12122809	ENSG00000244144.1	RP11-757F18.3	-7.43	8.46e-13	5.32e-06	-0.46	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201045838	chr3:112185480~112185998:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000234192.1	RP11-57C13.5	7.43	8.48e-13	5.34e-06	0.41	0.37	Cognitive function;	chr12:55976127	chr10:87642607~87642954:+
STAD	trans	rs916888	0.773	rs199447	ENSG00000264057.1	RP11-583F2.1	7.43	8.52e-13	5.36e-06	0.47	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:64927634~64934203:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000244604.1	RP11-713H12.1	7.43	8.76e-13	5.51e-06	0.41	0.37	Cognitive function;	chr12:55981353	chr17:8561230~8561576:+
STAD	trans	rs3770081	1	rs2164879	ENSG00000229880.1	IMMTP1	7.42	8.87e-13	5.55e-06	0.71	0.37	Facial emotion recognition (sad faces);	chr2:86034456	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs12328085	ENSG00000229880.1	IMMTP1	7.42	8.87e-13	5.55e-06	0.71	0.37	Facial emotion recognition (sad faces);	chr2:86034886	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs3770090	ENSG00000229880.1	IMMTP1	7.42	8.87e-13	5.55e-06	0.71	0.37	Facial emotion recognition (sad faces);	chr2:86036165	chr21:44675868~44678086:-
STAD	trans	rs7554511	0.707	rs3767501	ENSG00000244144.1	RP11-757F18.3	7.42	8.9e-13	5.57e-06	0.43	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053951	chr3:112185480~112185998:-
STAD	trans	rs66887589	0.807	rs7694483	ENSG00000275858.1	RP11-291L22.8	7.42	9.1e-13	5.7e-06	0.39	0.37	Diastolic blood pressure;	chr4:119484774	chr10:38450738~38451069:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000226339.1	RPS26P56	-7.42	9.11e-13	5.7e-06	-0.36	-0.37	Cognitive function;	chr12:56080024	chrX:129408382~129408621:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000242206.2	RPS26P35	7.42	9.16e-13	5.73e-06	0.39	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:118761856~118762201:-
STAD	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	7.42	9.43e-13	5.9e-06	0.53	0.37	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
STAD	trans	rs7554511	0.823	rs67602696	ENSG00000244144.1	RP11-757F18.3	-7.41	9.57e-13	5.98e-06	-0.46	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201043809	chr3:112185480~112185998:-
STAD	trans	rs7554511	0.655	rs3767502	ENSG00000244144.1	RP11-757F18.3	7.41	9.6e-13	6e-06	0.44	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053970	chr3:112185480~112185998:-
STAD	trans	rs11295209	1	rs11295209	ENSG00000276997.3	RP11-378J18.9	-7.41	9.63e-13	6.01e-06	-0.4	-0.37	Plateletcrit;	chr4:119559079	chr1:222477252~222504622:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	7.41	9.75e-13	6.08e-06	0.37	0.37	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
STAD	trans	rs7554511	0.691	rs10920091	ENSG00000244144.1	RP11-757F18.3	-7.41	9.98e-13	6.22e-06	-0.38	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005936	chr3:112185480~112185998:-
STAD	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	7.4	1.02e-12	6.36e-06	0.45	0.37	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.967	rs1480933	ENSG00000276997.3	RP11-378J18.9	7.4	1.03e-12	6.44e-06	0.39	0.37	Diastolic blood pressure;	chr4:119512093	chr1:222477252~222504622:-
STAD	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-7.4	1.04e-12	6.47e-06	-0.49	-0.37	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
STAD	trans	rs7647973	0.922	rs6809851	ENSG00000197582.5	GPX1P1	7.4	1.04e-12	6.48e-06	0.52	0.37	Menarche (age at onset);	chr3:49272354	chrX:13378735~13379340:-
STAD	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-7.4	1.05e-12	6.51e-06	-0.48	-0.37	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-7.4	1.05e-12	6.51e-06	-0.48	-0.37	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
STAD	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	7.4	1.05e-12	6.54e-06	0.5	0.37	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-7.4	1.06e-12	6.58e-06	-0.53	-0.37	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
STAD	trans	rs7554511	0.858	rs11583328	ENSG00000244144.1	RP11-757F18.3	7.4	1.06e-12	6.59e-06	0.45	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201033045	chr3:112185480~112185998:-
STAD	trans	rs11220237	0.92	rs12272767	ENSG00000236257.1	EI24P2	7.4	1.07e-12	6.67e-06	0.56	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125824748	chr1:158454198~158455273:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000224553.1	AC008065.1	7.39	1.08e-12	6.71e-06	0.41	0.37	Cognitive function;	chr12:55996580	chr2:171374931~171375278:-
STAD	trans	rs877636	0.736	rs773107	ENSG00000227586.5	RP11-162A23.5	7.39	1.08e-12	6.72e-06	0.43	0.37	Cognitive function;	chr12:55975722	chr10:123171535~123171875:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000226339.1	RPS26P56	-7.39	1.09e-12	6.8e-06	-0.36	-0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:129408382~129408621:+
STAD	trans	rs7113874	0.578	rs34059271	ENSG00000266891.1	RP11-692N5.2	7.39	1.1e-12	6.86e-06	0.51	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8546311	chr18:9734882~9735602:-
STAD	trans	rs7554511	0.763	rs3913893	ENSG00000244144.1	RP11-757F18.3	-7.39	1.12e-12	6.93e-06	-0.44	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201046655	chr3:112185480~112185998:-
STAD	trans	rs7647973	1	rs3905330	ENSG00000197582.5	GPX1P1	7.39	1.14e-12	7.05e-06	0.52	0.37	Menarche (age at onset);	chr3:49513341	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	7.39	1.14e-12	7.09e-06	0.45	0.37	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	7.39	1.14e-12	7.09e-06	0.45	0.37	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
STAD	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	7.38	1.15e-12	7.15e-06	0.52	0.37	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
STAD	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-7.38	1.16e-12	7.19e-06	-0.32	-0.37	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000242307.1	RPS26P52	-7.38	1.16e-12	7.21e-06	-0.39	-0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr16:13922332~13922679:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000244604.1	RP11-713H12.1	7.38	1.16e-12	7.21e-06	0.41	0.37	Cognitive function;	chr12:55976127	chr17:8561230~8561576:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000212994.5	RPS26P6	7.38	1.17e-12	7.23e-06	0.37	0.37	Cognitive function;	chr12:55976127	chr8:100895771~100896118:+
STAD	trans	rs7647973	1	rs1009051	ENSG00000197582.5	GPX1P1	7.38	1.17e-12	7.24e-06	0.53	0.37	Menarche (age at onset);	chr3:49484116	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs3870339	ENSG00000197582.5	GPX1P1	7.38	1.17e-12	7.24e-06	0.53	0.37	Menarche (age at onset);	chr3:49499430	chrX:13378735~13379340:-
STAD	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-7.38	1.18e-12	7.27e-06	-0.48	-0.37	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-7.38	1.18e-12	7.27e-06	-0.48	-0.37	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-7.38	1.18e-12	7.27e-06	-0.48	-0.37	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-7.38	1.18e-12	7.27e-06	-0.48	-0.37	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-7.38	1.18e-12	7.27e-06	-0.48	-0.37	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-7.38	1.18e-12	7.27e-06	-0.48	-0.37	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
STAD	trans	rs7647973	0.826	rs9834535	ENSG00000197582.5	GPX1P1	7.38	1.2e-12	7.42e-06	0.54	0.37	Menarche (age at onset);	chr3:49341364	chrX:13378735~13379340:-
STAD	trans	rs7554511	0.861	rs10920074	ENSG00000244144.1	RP11-757F18.3	-7.38	1.21e-12	7.44e-06	-0.4	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200943599	chr3:112185480~112185998:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000226339.1	RPS26P56	-7.38	1.21e-12	7.47e-06	-0.38	-0.37	Cognitive function;	chr12:56042145	chrX:129408382~129408621:+
STAD	trans	rs12138950	0.681	rs9783019	ENSG00000224237.1	MINOS1P3	7.38	1.22e-12	7.52e-06	0.5	0.37	Hypothyroidism;Thyroid volume;	chr1:19523162	chr3:27214816~27215018:-
STAD	trans	rs66887589	0.967	rs6844263	ENSG00000276997.3	RP11-378J18.9	7.38	1.22e-12	7.55e-06	0.39	0.37	Diastolic blood pressure;	chr4:119512652	chr1:222477252~222504622:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000196933.5	RPS26P11	7.37	1.23e-12	7.57e-06	0.38	0.37	Cognitive function;	chr12:55996580	chrX:72044545~72044892:+
STAD	trans	rs13190036	0.792	rs6874206	ENSG00000226986.4	RP11-543B16.2	-7.37	1.24e-12	7.66e-06	-0.4	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr1:211207239~211207897:+
STAD	trans	rs877636	1	rs877636	ENSG00000242206.2	RPS26P35	-7.37	1.25e-12	7.71e-06	-0.4	-0.37	Cognitive function;	chr12:56086799	chr8:118761856~118762201:-
STAD	trans	rs11220237	1	rs7934485	ENSG00000236257.1	EI24P2	7.37	1.26e-12	7.75e-06	0.56	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125804339	chr1:158454198~158455273:+
STAD	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-7.37	1.29e-12	7.92e-06	-0.41	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
STAD	trans	rs7554511	0.624	rs5010839	ENSG00000244144.1	RP11-757F18.3	-7.37	1.29e-12	7.97e-06	-0.41	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201042916	chr3:112185480~112185998:-
STAD	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	7.37	1.3e-12	8e-06	0.32	0.37	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
STAD	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-7.36	1.31e-12	8.05e-06	-0.48	-0.37	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
STAD	trans	rs7554511	0.763	rs55734382	ENSG00000244144.1	RP11-757F18.3	-7.36	1.31e-12	8.07e-06	-0.43	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201049931	chr3:112185480~112185998:-
STAD	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-7.36	1.33e-12	8.19e-06	-0.49	-0.37	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-7.36	1.33e-12	8.19e-06	-0.48	-0.37	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-7.36	1.33e-12	8.19e-06	-0.48	-0.37	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-7.36	1.33e-12	8.19e-06	-0.48	-0.37	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-7.36	1.33e-12	8.19e-06	-0.48	-0.37	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-7.36	1.33e-12	8.19e-06	-0.48	-0.37	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-7.36	1.33e-12	8.19e-06	-0.48	-0.37	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
STAD	trans	rs12497850	0.931	rs4974082	ENSG00000197582.5	GPX1P1	7.36	1.34e-12	8.25e-06	0.49	0.37	Parkinson's disease;	chr3:48961890	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.574	rs2531898	ENSG00000187870.7	RNFT1P3	7.36	1.35e-12	8.31e-06	0.47	0.37	Hemoglobin concentration;	chr17:59934990	chr17:20743333~20754501:-
STAD	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-7.36	1.38e-12	8.45e-06	-0.48	-0.37	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
STAD	trans	rs1190596	0.83	rs2298877	ENSG00000181359.5	HSP90AA6P	7.36	1.38e-12	8.48e-06	0.43	0.37	Behavioural disinhibition (generation interaction);	chr14:102081887	chr4:170581470~170605450:-
STAD	trans	rs1190596	0.83	rs4947	ENSG00000181359.5	HSP90AA6P	7.36	1.4e-12	8.57e-06	0.43	0.37	Behavioural disinhibition (generation interaction);	chr14:102084466	chr4:170581470~170605450:-
STAD	trans	rs1190596	0.83	rs61992489	ENSG00000181359.5	HSP90AA6P	7.36	1.4e-12	8.57e-06	0.43	0.37	Behavioural disinhibition (generation interaction);	chr14:102086830	chr4:170581470~170605450:-
STAD	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	7.35	1.4e-12	8.57e-06	0.53	0.37	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000226339.1	RPS26P56	-7.35	1.42e-12	8.71e-06	-0.38	-0.37	Cognitive function;	chr12:56007301	chrX:129408382~129408621:+
STAD	trans	rs7554511	0.825	rs11576681	ENSG00000244144.1	RP11-757F18.3	-7.35	1.43e-12	8.77e-06	-0.45	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201034923	chr3:112185480~112185998:-
STAD	trans	rs8067354	0.574	rs2526358	ENSG00000187870.7	RNFT1P3	7.35	1.48e-12	9.03e-06	0.47	0.37	Hemoglobin concentration;	chr17:59865224	chr17:20743333~20754501:-
STAD	trans	rs13190036	1	rs351864	ENSG00000226986.4	RP11-543B16.2	-7.34	1.49e-12	9.14e-06	-0.4	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr1:211207239~211207897:+
STAD	trans	rs3096299	0.503	rs4785677	ENSG00000215030.5	RPL13P12	-7.34	1.5e-12	9.15e-06	-0.31	-0.37	Multiple myeloma (IgH translocation);	chr16:89488693	chr17:17383377~17384012:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	7.34	1.51e-12	9.22e-06	0.36	0.37	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
STAD	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-7.34	1.51e-12	9.25e-06	-0.41	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
STAD	trans	rs12497850	1	rs1352420	ENSG00000197582.5	GPX1P1	7.34	1.52e-12	9.27e-06	0.49	0.37	Parkinson's disease;	chr3:48719858	chrX:13378735~13379340:-
STAD	trans	rs7554511	0.666	rs2221581	ENSG00000244144.1	RP11-757F18.3	-7.34	1.53e-12	9.37e-06	-0.38	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201012797	chr3:112185480~112185998:-
STAD	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	7.34	1.58e-12	9.67e-06	0.32	0.37	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
STAD	trans	rs12145833	0.538	rs10754798	ENSG00000154608.12	CEP170P1	7.34	1.58e-12	9.68e-06	0.57	0.37	Obesity (early onset extreme);	chr1:243146656	chr4:118467590~118554204:+
STAD	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	7.33	1.59e-12	9.7e-06	0.53	0.37	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000204652.6	RPS26P8	-7.33	1.6e-12	9.78e-06	-0.37	-0.37	Asthma;	chr12:55970537	chr17:45608571~45608918:+
STAD	trans	rs877636	0.74	rs705698	ENSG00000233778.3	RP11-777J24.1	7.33	1.61e-12	9.84e-06	0.37	0.37	Cognitive function;	chr12:55990903	chr8:92144088~92144435:-
STAD	trans	rs7554511	0.707	rs6702590	ENSG00000244144.1	RP11-757F18.3	7.33	1.61e-12	9.86e-06	0.43	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201050977	chr3:112185480~112185998:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000243538.1	CTB-55B8.1	7.33	1.62e-12	9.89e-06	0.4	0.37	Cognitive function;	chr12:55988132	chr5:16902294~16902641:-
STAD	trans	rs1190596	0.732	rs7156564	ENSG00000181359.5	HSP90AA6P	7.33	1.63e-12	9.97e-06	0.42	0.37	Behavioural disinhibition (generation interaction);	chr14:102092251	chr4:170581470~170605450:-
STAD	trans	rs3749237	0.964	rs10865959	ENSG00000197582.5	GPX1P1	7.33	1.65e-12	1.01e-05	0.46	0.37	Resting heart rate;	chr3:49853569	chrX:13378735~13379340:-
STAD	trans	rs4834770	1	rs4834770	ENSG00000276997.3	RP11-378J18.9	7.33	1.66e-12	1.01e-05	0.4	0.37	Blood protein levels;	chr4:119320694	chr1:222477252~222504622:-
STAD	trans	rs4834770	1	rs6823963	ENSG00000276997.3	RP11-378J18.9	7.33	1.66e-12	1.01e-05	0.4	0.37	Blood protein levels;	chr4:119321009	chr1:222477252~222504622:-
STAD	trans	rs4834770	1	rs4834771	ENSG00000276997.3	RP11-378J18.9	7.33	1.66e-12	1.01e-05	0.4	0.37	Blood protein levels;	chr4:119321617	chr1:222477252~222504622:-
STAD	trans	rs4834770	1	rs1397613	ENSG00000276997.3	RP11-378J18.9	7.33	1.66e-12	1.01e-05	0.4	0.37	Blood protein levels;	chr4:119321774	chr1:222477252~222504622:-
STAD	trans	rs4834770	1	rs6857641	ENSG00000276997.3	RP11-378J18.9	7.33	1.66e-12	1.01e-05	0.4	0.37	Blood protein levels;	chr4:119322356	chr1:222477252~222504622:-
STAD	trans	rs4834770	1	rs2282688	ENSG00000276997.3	RP11-378J18.9	7.33	1.66e-12	1.01e-05	0.4	0.37	Blood protein levels;	chr4:119322567	chr1:222477252~222504622:-
STAD	trans	rs3770081	1	rs12622009	ENSG00000229880.1	IMMTP1	7.33	1.69e-12	1.03e-05	0.7	0.37	Facial emotion recognition (sad faces);	chr2:86021202	chr21:44675868~44678086:-
STAD	trans	rs11220237	1	rs7938074	ENSG00000236257.1	EI24P2	7.33	1.69e-12	1.03e-05	0.56	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr11:125804743	chr1:158454198~158455273:+
STAD	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	7.32	1.71e-12	1.04e-05	0.36	0.37	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
STAD	trans	rs8067354	0.574	rs9789060	ENSG00000187870.7	RNFT1P3	7.32	1.73e-12	1.06e-05	0.48	0.37	Hemoglobin concentration;	chr17:59941209	chr17:20743333~20754501:-
STAD	trans	rs916888	0.773	rs199533	ENSG00000264057.1	RP11-583F2.1	7.32	1.75e-12	1.06e-05	0.46	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:64927634~64934203:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000243328.1	RP11-520P18.1	-7.32	1.75e-12	1.07e-05	-0.35	-0.37	Cognitive function;	chr12:56080024	chr8:143065915~143066587:-
STAD	trans	rs10816533	1	rs12349869	ENSG00000232063.1	RP11-307E17.8	7.32	1.76e-12	1.07e-05	0.66	0.37	Height;	chr9:96751070	chr9:94332476~94360948:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000243538.1	CTB-55B8.1	-7.32	1.77e-12	1.08e-05	-0.38	-0.37	Cognitive function;	chr12:55996852	chr5:16902294~16902641:-
STAD	trans	rs8067354	0.54	rs1051424	ENSG00000187870.7	RNFT1P3	7.32	1.79e-12	1.09e-05	0.48	0.37	Hemoglobin concentration;	chr17:59946963	chr17:20743333~20754501:-
STAD	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-7.31	1.82e-12	1.1e-05	-0.48	-0.37	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-7.31	1.83e-12	1.11e-05	-0.48	-0.37	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	7.31	1.83e-12	1.11e-05	0.48	0.37	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	7.31	1.83e-12	1.11e-05	0.48	0.37	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	7.31	1.83e-12	1.11e-05	0.48	0.37	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	7.31	1.83e-12	1.11e-05	0.48	0.37	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-7.31	1.83e-12	1.11e-05	-0.48	-0.37	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-7.31	1.83e-12	1.11e-05	-0.48	-0.37	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000243538.1	CTB-55B8.1	7.31	1.84e-12	1.12e-05	0.39	0.37	Cognitive function;	chr12:55976127	chr5:16902294~16902641:-
STAD	trans	rs9611519	0.761	rs35445172	ENSG00000268568.1	AC007228.9	-7.31	1.85e-12	1.12e-05	-0.44	-0.37	Neuroticism;	chr22:41264297	chr19:56672574~56673901:-
STAD	trans	rs7113874	0.592	rs10500703	ENSG00000266891.1	RP11-692N5.2	7.31	1.86e-12	1.12e-05	0.52	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8412317	chr18:9734882~9735602:-
STAD	trans	rs66887589	0.777	rs2017058	ENSG00000275858.1	RP11-291L22.8	7.31	1.86e-12	1.13e-05	0.38	0.37	Diastolic blood pressure;	chr4:119336584	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.777	rs1814815	ENSG00000275858.1	RP11-291L22.8	7.31	1.86e-12	1.13e-05	0.38	0.37	Diastolic blood pressure;	chr4:119336936	chr10:38450738~38451069:-
STAD	trans	rs9611519	0.78	rs9611528	ENSG00000268568.1	AC007228.9	-7.31	1.9e-12	1.15e-05	-0.44	-0.37	Neuroticism;	chr22:41252498	chr19:56672574~56673901:-
STAD	trans	rs10037055	0.741	rs2336405	ENSG00000228305.2	AC016734.2	-7.31	1.9e-12	1.15e-05	-0.36	-0.37	Migraine without aura;	chr5:177230288	chr2:63622178~63622831:-
STAD	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-7.31	1.92e-12	1.16e-05	-0.48	-0.37	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
STAD	trans	rs10908521	0.685	rs11264568	ENSG00000227183.3	HDGFP1	-7.3	2e-12	1.21e-05	-0.43	-0.37	Uric acid clearance;	chr1:156836077	chrX:131646639~131646890:+
STAD	trans	rs10908521	0.685	rs11264569	ENSG00000227183.3	HDGFP1	-7.3	2e-12	1.21e-05	-0.43	-0.37	Uric acid clearance;	chr1:156836098	chrX:131646639~131646890:+
STAD	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	7.3	2.01e-12	1.22e-05	0.41	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
STAD	trans	rs13190036	0.901	rs10072499	ENSG00000226986.4	RP11-543B16.2	-7.3	2.02e-12	1.22e-05	-0.39	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr1:211207239~211207897:+
STAD	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	7.3	2.03e-12	1.23e-05	0.52	0.37	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	7.3	2.03e-12	1.23e-05	0.52	0.37	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.966	rs6792510	ENSG00000197582.5	GPX1P1	7.3	2.04e-12	1.23e-05	0.49	0.37	Parkinson's disease;	chr3:48685869	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.609	rs1292066	ENSG00000187870.7	RNFT1P3	7.29	2.09e-12	1.26e-05	0.44	0.36	Hemoglobin concentration;	chr17:59854953	chr17:20743333~20754501:-
STAD	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	7.28	2.19e-12	1.32e-05	0.48	0.36	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
STAD	trans	rs4834770	0.718	rs4833618	ENSG00000276997.3	RP11-378J18.9	-7.28	2.21e-12	1.33e-05	-0.4	-0.36	Blood protein levels;	chr4:119388345	chr1:222477252~222504622:-
STAD	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	7.28	2.23e-12	1.34e-05	0.47	0.36	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	7.28	2.23e-12	1.34e-05	0.47	0.36	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
STAD	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	7.28	2.23e-12	1.34e-05	0.46	0.36	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
STAD	trans	rs11220237	1	rs11220221	ENSG00000236257.1	EI24P2	7.28	2.24e-12	1.35e-05	0.55	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr11:125796232	chr1:158454198~158455273:+
STAD	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-7.28	2.24e-12	1.35e-05	-0.48	-0.36	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-7.28	2.24e-12	1.35e-05	-0.48	-0.36	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
STAD	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	7.28	2.27e-12	1.37e-05	0.52	0.36	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
STAD	trans	rs13253073	0.525	rs35509895	ENSG00000260318.1	COX6CP1	7.28	2.29e-12	1.37e-05	0.49	0.36	Glucose homeostasis traits;	chr8:99872093	chr16:11903923~11904137:-
STAD	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-7.28	2.29e-12	1.38e-05	-0.48	-0.36	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
STAD	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-7.28	2.3e-12	1.38e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
STAD	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	7.28	2.3e-12	1.38e-05	0.48	0.36	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000242970.2	AC068522.4	7.28	2.31e-12	1.39e-05	0.4	0.36	Cognitive function;	chr12:55981956	chr8:58588420~58588764:-
STAD	trans	rs10037055	0.853	rs6890580	ENSG00000228305.2	AC016734.2	-7.27	2.37e-12	1.42e-05	-0.36	-0.36	Migraine without aura;	chr5:177226519	chr2:63622178~63622831:-
STAD	trans	rs916888	0.773	rs199448	ENSG00000264057.1	RP11-583F2.1	7.27	2.37e-12	1.42e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:64927634~64934203:+
STAD	trans	rs7554511	0.707	rs10800755	ENSG00000244144.1	RP11-757F18.3	7.27	2.39e-12	1.43e-05	0.43	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054852	chr3:112185480~112185998:-
STAD	trans	rs7554511	0.707	rs10800756	ENSG00000244144.1	RP11-757F18.3	7.27	2.39e-12	1.43e-05	0.43	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054931	chr3:112185480~112185998:-
STAD	trans	rs10908521	0.685	rs1998977	ENSG00000227183.3	HDGFP1	-7.27	2.42e-12	1.45e-05	-0.43	-0.36	Uric acid clearance;	chr1:156834329	chrX:131646639~131646890:+
STAD	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-7.27	2.44e-12	1.46e-05	-0.49	-0.36	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
STAD	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	7.27	2.45e-12	1.47e-05	0.52	0.36	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	7.27	2.45e-12	1.47e-05	0.52	0.36	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	7.27	2.49e-12	1.49e-05	0.52	0.36	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	7.27	2.49e-12	1.49e-05	0.52	0.36	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
STAD	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	7.27	2.49e-12	1.49e-05	0.44	0.36	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
STAD	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	7.27	2.49e-12	1.49e-05	0.44	0.36	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
STAD	trans	rs3770081	1	rs17026854	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86053373	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs3770082	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86053799	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs2278087	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86054823	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs60649958	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86055877	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs17618001	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86062180	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs75109362	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86062766	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs75713195	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86063536	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs79152960	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86063538	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs57398459	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86064203	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs77309268	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86066171	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs76052260	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86101604	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs77621359	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86103230	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs3810827	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86107263	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs3731819	ENSG00000229880.1	IMMTP1	7.26	2.51e-12	1.5e-05	0.74	0.36	Facial emotion recognition (sad faces);	chr2:86141518	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs2289237	ENSG00000229880.1	IMMTP1	-7.26	2.51e-12	1.5e-05	-0.74	-0.36	Facial emotion recognition (sad faces);	chr2:86039151	chr21:44675868~44678086:-
STAD	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	7.26	2.52e-12	1.51e-05	0.47	0.36	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
STAD	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-7.26	2.53e-12	1.51e-05	-0.46	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
STAD	trans	rs7113874	0.659	rs7935453	ENSG00000266891.1	RP11-692N5.2	7.26	2.55e-12	1.53e-05	0.45	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625216	chr18:9734882~9735602:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000242970.2	AC068522.4	7.26	2.61e-12	1.56e-05	0.39	0.36	Cognitive function;	chr12:55982097	chr8:58588420~58588764:-
STAD	trans	rs12138950	0.625	rs12041608	ENSG00000224237.1	MINOS1P3	-7.26	2.62e-12	1.57e-05	-0.48	-0.36	Hypothyroidism;Thyroid volume;	chr1:19515431	chr3:27214816~27215018:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000226339.1	RPS26P56	-7.26	2.62e-12	1.57e-05	-0.36	-0.36	Cognitive function;	chr12:56083910	chrX:129408382~129408621:+
STAD	trans	rs10037055	0.687	rs6556308	ENSG00000228305.2	AC016734.2	-7.26	2.63e-12	1.57e-05	-0.35	-0.36	Migraine without aura;	chr5:177219700	chr2:63622178~63622831:-
STAD	trans	rs66887589	0.748	rs28439855	ENSG00000276997.3	RP11-378J18.9	7.26	2.65e-12	1.58e-05	0.38	0.36	Diastolic blood pressure;	chr4:119341101	chr1:222477252~222504622:-
STAD	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	7.25	2.68e-12	1.6e-05	0.53	0.36	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	7.25	2.68e-12	1.6e-05	0.53	0.36	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-7.25	2.68e-12	1.6e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-7.25	2.68e-12	1.6e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-7.25	2.68e-12	1.6e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-7.25	2.68e-12	1.6e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-7.25	2.68e-12	1.6e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-7.25	2.68e-12	1.6e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
STAD	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-7.25	2.69e-12	1.6e-05	-0.48	-0.36	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
STAD	trans	rs877636	0.702	rs773109	ENSG00000243538.1	CTB-55B8.1	7.25	2.7e-12	1.61e-05	0.39	0.36	Cognitive function;	chr12:55980911	chr5:16902294~16902641:-
STAD	trans	rs7647973	0.961	rs7626076	ENSG00000197582.5	GPX1P1	7.25	2.7e-12	1.61e-05	0.52	0.36	Menarche (age at onset);	chr3:49260706	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.925	rs6446257	ENSG00000197582.5	GPX1P1	-7.25	2.73e-12	1.63e-05	-0.52	-0.36	Menarche (age at onset);	chr3:49216059	chrX:13378735~13379340:-
STAD	trans	rs7554511	0.707	rs3767498	ENSG00000244144.1	RP11-757F18.3	-7.25	2.76e-12	1.64e-05	-0.42	-0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051599	chr3:112185480~112185998:-
STAD	trans	rs8067354	0.574	rs7219089	ENSG00000187870.7	RNFT1P3	7.25	2.78e-12	1.65e-05	0.47	0.36	Hemoglobin concentration;	chr17:59955504	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.54	rs7221472	ENSG00000187870.7	RNFT1P3	7.25	2.78e-12	1.65e-05	0.47	0.36	Hemoglobin concentration;	chr17:59959376	chr17:20743333~20754501:-
STAD	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	7.25	2.82e-12	1.68e-05	0.4	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
STAD	trans	rs7113874	0.512	rs7952429	ENSG00000266891.1	RP11-692N5.2	7.25	2.82e-12	1.68e-05	0.51	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516370	chr18:9734882~9735602:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000243538.1	CTB-55B8.1	7.25	2.82e-12	1.68e-05	0.38	0.36	Cognitive function;	chr12:55996580	chr5:16902294~16902641:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000196933.5	RPS26P11	7.25	2.83e-12	1.68e-05	0.38	0.36	Cognitive function;	chr12:55990903	chrX:72044545~72044892:+
STAD	trans	rs10037055	0.947	rs10063803	ENSG00000228305.2	AC016734.2	7.24	2.84e-12	1.69e-05	0.35	0.36	Migraine without aura;	chr5:177240326	chr2:63622178~63622831:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000223416.3	RPS26P15	-7.24	2.84e-12	1.69e-05	-0.38	-0.36	Asthma;	chr12:55970537	chr1:58056133~58056480:-
STAD	trans	rs66887589	0.777	rs10015883	ENSG00000276997.3	RP11-378J18.9	7.24	2.85e-12	1.69e-05	0.38	0.36	Diastolic blood pressure;	chr4:119346991	chr1:222477252~222504622:-
STAD	trans	rs3770081	1	rs73947314	ENSG00000229880.1	IMMTP1	7.24	2.85e-12	1.7e-05	0.73	0.36	Facial emotion recognition (sad faces);	chr2:86045993	chr21:44675868~44678086:-
STAD	trans	rs10037055	0.853	rs10035180	ENSG00000228305.2	AC016734.2	-7.24	2.87e-12	1.7e-05	-0.35	-0.36	Migraine without aura;	chr5:177171501	chr2:63622178~63622831:-
STAD	trans	rs7113874	0.578	rs12787407	ENSG00000266891.1	RP11-692N5.2	7.24	2.89e-12	1.72e-05	0.51	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8532605	chr18:9734882~9735602:-
STAD	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	7.24	2.9e-12	1.72e-05	0.47	0.36	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000242970.2	AC068522.4	7.24	2.91e-12	1.73e-05	0.4	0.36	Cognitive function;	chr12:55988132	chr8:58588420~58588764:-
STAD	trans	rs66887589	0.967	rs13104219	ENSG00000276997.3	RP11-378J18.9	7.24	2.95e-12	1.75e-05	0.39	0.36	Diastolic blood pressure;	chr4:119517019	chr1:222477252~222504622:-
STAD	trans	rs12497850	1	rs4858828	ENSG00000197582.5	GPX1P1	7.24	2.98e-12	1.77e-05	0.48	0.36	Parkinson's disease;	chr3:48687378	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.807	rs7694483	ENSG00000276997.3	RP11-378J18.9	7.24	3e-12	1.78e-05	0.38	0.36	Diastolic blood pressure;	chr4:119484774	chr1:222477252~222504622:-
STAD	trans	rs12497850	1	rs6788650	ENSG00000197582.5	GPX1P1	7.24	3e-12	1.78e-05	0.47	0.36	Parkinson's disease;	chr3:48712110	chrX:13378735~13379340:-
STAD	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	7.24	3.01e-12	1.79e-05	0.48	0.36	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
STAD	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	7.23	3.06e-12	1.82e-05	0.47	0.36	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
STAD	trans	rs12497850	1	rs4858798	ENSG00000197582.5	GPX1P1	7.23	3.08e-12	1.82e-05	0.48	0.36	Parkinson's disease;	chr3:48689679	chrX:13378735~13379340:-
STAD	trans	rs9611519	0.78	rs2284079	ENSG00000268568.1	AC007228.9	-7.23	3.08e-12	1.83e-05	-0.44	-0.36	Neuroticism;	chr22:41262628	chr19:56672574~56673901:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000219993.1	RP11-288G3.3	-7.23	3.13e-12	1.85e-05	-0.35	-0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr6:7506203~7506549:+
STAD	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	7.23	3.13e-12	1.86e-05	0.46	0.36	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-7.23	3.14e-12	1.86e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000243328.1	RP11-520P18.1	-7.23	3.15e-12	1.87e-05	-0.35	-0.36	Cognitive function;	chr12:56083910	chr8:143065915~143066587:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000224161.3	RPS26P54	-7.23	3.2e-12	1.89e-05	-0.34	-0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr18:59761558~59761905:+
STAD	trans	rs12497850	0.931	rs7628719	ENSG00000197582.5	GPX1P1	7.23	3.2e-12	1.9e-05	0.48	0.36	Parkinson's disease;	chr3:48958054	chrX:13378735~13379340:-
STAD	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-7.22	3.23e-12	1.91e-05	-0.47	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
STAD	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	7.22	3.25e-12	1.92e-05	0.4	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
STAD	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-7.22	3.28e-12	1.94e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
STAD	trans	rs12497850	0.644	rs11928552	ENSG00000197582.5	GPX1P1	7.22	3.3e-12	1.95e-05	0.48	0.36	Parkinson's disease;	chr3:48702450	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000242970.2	AC068522.4	7.22	3.31e-12	1.96e-05	0.39	0.36	Cognitive function;	chr12:55981353	chr8:58588420~58588764:-
STAD	trans	rs12497850	0.931	rs4974085	ENSG00000197582.5	GPX1P1	7.22	3.31e-12	1.96e-05	0.47	0.36	Parkinson's disease;	chr3:48887467	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.967	rs1155577	ENSG00000276997.3	RP11-378J18.9	-7.22	3.4e-12	2.01e-05	-0.38	-0.36	Diastolic blood pressure;	chr4:119528655	chr1:222477252~222504622:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000196933.5	RPS26P11	-7.22	3.43e-12	2.03e-05	-0.36	-0.36	Cognitive function;	chr12:55996852	chrX:72044545~72044892:+
STAD	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-7.21	3.44e-12	2.03e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
STAD	trans	rs7113874	0.545	rs12791925	ENSG00000266891.1	RP11-692N5.2	7.21	3.46e-12	2.04e-05	0.51	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8530038	chr18:9734882~9735602:-
STAD	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-7.21	3.46e-12	2.04e-05	-0.47	-0.36	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
STAD	trans	rs13190036	0.551	rs1052432	ENSG00000226986.4	RP11-543B16.2	-7.21	3.49e-12	2.06e-05	-0.38	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr1:211207239~211207897:+
STAD	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-7.21	3.53e-12	2.08e-05	-0.48	-0.36	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
STAD	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-7.21	3.53e-12	2.09e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
STAD	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-7.21	3.53e-12	2.09e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
STAD	trans	rs8067354	0.54	rs12600680	ENSG00000187870.7	RNFT1P3	7.21	3.55e-12	2.1e-05	0.47	0.36	Hemoglobin concentration;	chr17:59960013	chr17:20743333~20754501:-
STAD	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-7.21	3.57e-12	2.1e-05	-0.41	-0.36	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
STAD	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	7.21	3.62e-12	2.13e-05	0.47	0.36	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
STAD	trans	rs9611519	0.78	rs2235850	ENSG00000268568.1	AC007228.9	-7.21	3.62e-12	2.13e-05	-0.44	-0.36	Neuroticism;	chr22:41261622	chr19:56672574~56673901:-
STAD	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	7.21	3.62e-12	2.13e-05	0.48	0.36	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
STAD	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	7.2	3.68e-12	2.17e-05	0.51	0.36	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
STAD	trans	rs10028773	0.546	rs13117947	ENSG00000275858.1	RP11-291L22.8	7.2	3.7e-12	2.18e-05	0.38	0.36	Educational attainment;	chr4:119335905	chr10:38450738~38451069:-
STAD	trans	rs12497850	0.931	rs7431710	ENSG00000197582.5	GPX1P1	7.2	3.7e-12	2.18e-05	0.48	0.36	Parkinson's disease;	chr3:48898150	chrX:13378735~13379340:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000244641.2	RPS26P43	-7.2	3.71e-12	2.19e-05	-0.36	-0.36	Cognitive function;	chr12:56007301	chr11:123049787~123050353:-
STAD	trans	rs11220237	0.925	rs9651705	ENSG00000236257.1	EI24P2	7.2	3.83e-12	2.25e-05	0.54	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr11:125798921	chr1:158454198~158455273:+
STAD	trans	rs916888	0.61	rs142167	ENSG00000264070.1	DND1P1	-7.2	3.86e-12	2.27e-05	-0.46	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45585871~45586929:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000244641.2	RPS26P43	-7.2	3.86e-12	2.27e-05	-0.36	-0.36	Cognitive function;	chr12:56042145	chr11:123049787~123050353:-
STAD	trans	rs7554511	0.894	rs404339	ENSG00000244144.1	RP11-757F18.3	-7.2	3.86e-12	2.27e-05	-0.39	-0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917763	chr3:112185480~112185998:-
STAD	trans	rs12497850	0.863	rs4858799	ENSG00000197582.5	GPX1P1	7.19	3.91e-12	2.3e-05	0.47	0.36	Parkinson's disease;	chr3:48690771	chrX:13378735~13379340:-
STAD	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	7.19	3.91e-12	2.3e-05	0.53	0.36	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
STAD	trans	rs12709013	0.591	rs4784986	ENSG00000233719.3	GOT2P3	7.19	3.94e-12	2.31e-05	0.42	0.36	Blood metabolite ratios;	chr16:58803007	chr12:9641802~9643007:+
STAD	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-7.19	3.94e-12	2.32e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
STAD	trans	rs12497850	0.931	rs4974087	ENSG00000197582.5	GPX1P1	7.19	3.98e-12	2.34e-05	0.48	0.36	Parkinson's disease;	chr3:48881799	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs28642807	ENSG00000197582.5	GPX1P1	7.19	3.98e-12	2.34e-05	0.48	0.36	Parkinson's disease;	chr3:48889383	chrX:13378735~13379340:-
STAD	trans	rs12138950	0.681	rs10799822	ENSG00000224237.1	MINOS1P3	7.19	4e-12	2.35e-05	0.48	0.36	Hypothyroidism;Thyroid volume;	chr1:19513327	chr3:27214816~27215018:-
STAD	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	7.19	4.01e-12	2.35e-05	0.41	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
STAD	trans	rs4834770	1	rs4336213	ENSG00000276997.3	RP11-378J18.9	7.19	4.04e-12	2.37e-05	0.39	0.36	Blood protein levels;	chr4:119315314	chr1:222477252~222504622:-
STAD	trans	rs3770081	1	rs12612513	ENSG00000229880.1	IMMTP1	7.19	4.06e-12	2.38e-05	0.73	0.36	Facial emotion recognition (sad faces);	chr2:86074102	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs12614260	ENSG00000229880.1	IMMTP1	7.19	4.06e-12	2.38e-05	0.73	0.36	Facial emotion recognition (sad faces);	chr2:86075956	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs74733602	ENSG00000229880.1	IMMTP1	7.19	4.06e-12	2.38e-05	0.73	0.36	Facial emotion recognition (sad faces);	chr2:86076319	chr21:44675868~44678086:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000242970.2	AC068522.4	7.19	4.09e-12	2.4e-05	0.43	0.36	Cognitive function;	chr12:56055651	chr8:58588420~58588764:-
STAD	trans	rs3096299	0.503	rs9925045	ENSG00000215030.5	RPL13P12	-7.19	4.11e-12	2.41e-05	-0.31	-0.36	Multiple myeloma (IgH translocation);	chr16:89490068	chr17:17383377~17384012:-
STAD	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-7.18	4.18e-12	2.45e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-7.18	4.18e-12	2.45e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-7.18	4.18e-12	2.45e-05	-0.53	-0.36	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
STAD	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	7.18	4.2e-12	2.46e-05	0.4	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
STAD	trans	rs12709013	0.755	rs1424245	ENSG00000233719.3	GOT2P3	7.18	4.23e-12	2.48e-05	0.39	0.36	Blood metabolite ratios;	chr16:58729926	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-7.18	4.23e-12	2.48e-05	-0.48	-0.36	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-7.18	4.23e-12	2.48e-05	-0.48	-0.36	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	7.18	4.24e-12	2.48e-05	0.47	0.36	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
STAD	trans	rs12497850	0.931	rs9311434	ENSG00000197582.5	GPX1P1	7.18	4.35e-12	2.54e-05	0.47	0.36	Parkinson's disease;	chr3:48846714	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs7623023	ENSG00000197582.5	GPX1P1	7.18	4.35e-12	2.54e-05	0.47	0.36	Parkinson's disease;	chr3:48876805	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.574	rs1292043	ENSG00000187870.7	RNFT1P3	7.18	4.35e-12	2.55e-05	0.46	0.36	Hemoglobin concentration;	chr17:59856808	chr17:20743333~20754501:-
STAD	trans	rs12138950	0.681	rs60066365	ENSG00000224237.1	MINOS1P3	7.18	4.4e-12	2.57e-05	0.47	0.36	Hypothyroidism;Thyroid volume;	chr1:19512191	chr3:27214816~27215018:-
STAD	trans	rs8067354	0.54	rs72840315	ENSG00000187870.7	RNFT1P3	7.18	4.4e-12	2.58e-05	0.46	0.36	Hemoglobin concentration;	chr17:59940781	chr17:20743333~20754501:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000240427.1	RPS26P34	7.18	4.41e-12	2.58e-05	0.37	0.36	Cognitive function;	chr12:56076841	chr8:81627269~81627617:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	7.18	4.41e-12	2.58e-05	0.35	0.36	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000229032.1	RP11-91A18.1	7.18	4.42e-12	2.58e-05	0.37	0.36	Cognitive function;	chr12:56076841	chr1:51980473~51980814:+
STAD	trans	rs7113874	0.613	rs35225809	ENSG00000266891.1	RP11-692N5.2	7.18	4.42e-12	2.58e-05	0.51	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8512038	chr18:9734882~9735602:-
STAD	trans	rs10908521	0.685	rs12746582	ENSG00000227183.3	HDGFP1	-7.17	4.44e-12	2.6e-05	-0.43	-0.36	Uric acid clearance;	chr1:156836231	chrX:131646639~131646890:+
STAD	trans	rs12497850	1	rs12497850	ENSG00000197582.5	GPX1P1	7.17	4.45e-12	2.6e-05	0.47	0.36	Parkinson's disease;	chr3:48711556	chrX:13378735~13379340:-
STAD	trans	rs7113874	0.527	rs12790154	ENSG00000266891.1	RP11-692N5.2	7.17	4.51e-12	2.64e-05	0.52	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8383601	chr18:9734882~9735602:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000226339.1	RPS26P56	-7.17	4.52e-12	2.64e-05	-0.35	-0.36	Cognitive function;	chr12:56084218	chrX:129408382~129408621:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000226339.1	RPS26P56	-7.17	4.52e-12	2.64e-05	-0.35	-0.36	Cognitive function;	chr12:56084874	chrX:129408382~129408621:+
STAD	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	7.17	4.71e-12	2.75e-05	0.52	0.36	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-7.17	4.71e-12	2.75e-05	-0.52	-0.36	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9682444	ENSG00000197582.5	GPX1P1	7.16	4.73e-12	2.76e-05	0.48	0.36	Parkinson's disease;	chr3:48815206	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9755490	ENSG00000197582.5	GPX1P1	7.16	4.73e-12	2.76e-05	0.48	0.36	Parkinson's disease;	chr3:48834231	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.897	rs9681717	ENSG00000197582.5	GPX1P1	7.16	4.73e-12	2.76e-05	0.48	0.36	Parkinson's disease;	chr3:48835565	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9840684	ENSG00000197582.5	GPX1P1	7.16	4.73e-12	2.76e-05	0.48	0.36	Parkinson's disease;	chr3:48856347	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs4974079	ENSG00000197582.5	GPX1P1	7.16	4.73e-12	2.76e-05	0.48	0.36	Parkinson's disease;	chr3:48869036	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.897	rs6446252	ENSG00000197582.5	GPX1P1	7.16	4.73e-12	2.76e-05	0.48	0.36	Parkinson's disease;	chr3:48873692	chrX:13378735~13379340:-
STAD	trans	rs12138950	0.681	rs4362008	ENSG00000224237.1	MINOS1P3	7.16	4.75e-12	2.77e-05	0.47	0.36	Hypothyroidism;Thyroid volume;	chr1:19511064	chr3:27214816~27215018:-
STAD	trans	rs12138950	0.711	rs10799821	ENSG00000224237.1	MINOS1P3	7.16	4.75e-12	2.77e-05	0.47	0.36	Hypothyroidism;Thyroid volume;	chr1:19511475	chr3:27214816~27215018:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000231366.1	RP11-399N22.3	-7.16	4.78e-12	2.78e-05	-0.37	-0.36	Cognitive function;	chr12:56080024	chr10:70794230~70794523:-
STAD	trans	rs1190596	0.549	rs11621083	ENSG00000181359.5	HSP90AA6P	7.16	4.78e-12	2.79e-05	0.42	0.36	Behavioural disinhibition (generation interaction);	chr14:102093201	chr4:170581470~170605450:-
STAD	trans	rs3770081	0.59	rs34522092	ENSG00000229880.1	IMMTP1	7.16	4.79e-12	2.79e-05	0.73	0.36	Facial emotion recognition (sad faces);	chr2:85981182	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs56326127	ENSG00000229880.1	IMMTP1	7.16	4.79e-12	2.79e-05	0.73	0.36	Facial emotion recognition (sad faces);	chr2:85985078	chr21:44675868~44678086:-
STAD	trans	rs12709013	0.574	rs839418	ENSG00000233719.3	GOT2P3	7.16	4.81e-12	2.8e-05	0.41	0.36	Blood metabolite ratios;	chr16:58705426	chr12:9641802~9643007:+
STAD	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	7.16	4.82e-12	2.81e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
STAD	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	7.16	4.94e-12	2.88e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
STAD	trans	rs10908521	0.717	rs11264572	ENSG00000227183.3	HDGFP1	-7.16	4.95e-12	2.88e-05	-0.43	-0.36	Uric acid clearance;	chr1:156836245	chrX:131646639~131646890:+
STAD	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	7.16	4.97e-12	2.89e-05	0.47	0.36	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000242206.2	RPS26P35	7.16	4.98e-12	2.9e-05	0.42	0.36	Cognitive function;	chr12:56009793	chr8:118761856~118762201:-
STAD	trans	rs66887589	0.807	rs9799664	ENSG00000275858.1	RP11-291L22.8	7.16	5e-12	2.91e-05	0.38	0.36	Diastolic blood pressure;	chr4:119405523	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.627	rs3872807	ENSG00000275858.1	RP11-291L22.8	7.16	5e-12	2.91e-05	0.38	0.36	Diastolic blood pressure;	chr4:119439096	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.56	rs9684327	ENSG00000275858.1	RP11-291L22.8	7.16	5e-12	2.91e-05	0.38	0.36	Diastolic blood pressure;	chr4:119444286	chr10:38450738~38451069:-
STAD	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-7.15	5.05e-12	2.94e-05	-0.47	-0.36	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
STAD	trans	rs66887589	1	rs66887589	ENSG00000276997.3	RP11-378J18.9	-7.15	5.09e-12	2.96e-05	-0.38	-0.36	Diastolic blood pressure;	chr4:119588124	chr1:222477252~222504622:-
STAD	trans	rs9899728	0.764	rs7219493	ENSG00000213954.3	ATP5HP3	7.15	5.09e-12	2.96e-05	0.5	0.36	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr9:14068932~14069417:+
STAD	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-7.15	5.12e-12	2.98e-05	-0.47	-0.36	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-7.15	5.12e-12	2.98e-05	-0.47	-0.36	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
STAD	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-7.15	5.12e-12	2.98e-05	-0.47	-0.36	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
STAD	trans	rs877636	0.74	rs705698	ENSG00000212829.8	RPS26P3	7.15	5.16e-12	2.99e-05	0.37	0.36	Cognitive function;	chr12:55990903	chr9:9090898~9091245:+
STAD	trans	rs3770081	1	rs2241437	ENSG00000229880.1	IMMTP1	7.15	5.17e-12	3e-05	0.71	0.36	Facial emotion recognition (sad faces);	chr2:86133450	chr21:44675868~44678086:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000234192.1	RP11-57C13.5	7.15	5.17e-12	3e-05	0.39	0.36	Cognitive function;	chr12:55996580	chr10:87642607~87642954:+
STAD	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-7.15	5.25e-12	3.05e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
STAD	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-7.15	5.25e-12	3.05e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
STAD	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	7.15	5.32e-12	3.09e-05	0.46	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
STAD	trans	rs11220237	1	rs12273204	ENSG00000236257.1	EI24P2	7.15	5.35e-12	3.1e-05	0.54	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr11:125784704	chr1:158454198~158455273:+
STAD	trans	rs11220237	1	rs11220218	ENSG00000236257.1	EI24P2	7.15	5.35e-12	3.1e-05	0.54	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr11:125793961	chr1:158454198~158455273:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000224553.1	AC008065.1	-7.15	5.35e-12	3.11e-05	-0.39	-0.36	Cognitive function;	chr12:55996852	chr2:171374931~171375278:-
STAD	trans	rs12497850	0.931	rs7430198	ENSG00000197582.5	GPX1P1	7.14	5.36e-12	3.11e-05	0.48	0.36	Parkinson's disease;	chr3:48951327	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.866	rs6791234	ENSG00000197582.5	GPX1P1	7.14	5.36e-12	3.11e-05	0.48	0.36	Parkinson's disease;	chr3:48958704	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs6446196	ENSG00000197582.5	GPX1P1	7.14	5.36e-12	3.11e-05	0.48	0.36	Parkinson's disease;	chr3:48967290	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.805	rs6446198	ENSG00000197582.5	GPX1P1	7.14	5.36e-12	3.11e-05	0.48	0.36	Parkinson's disease;	chr3:48970205	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-7.14	5.46e-12	3.16e-05	-0.47	-0.36	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	7.14	5.51e-12	3.19e-05	0.47	0.36	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.507	rs2645478	ENSG00000187870.7	RNFT1P3	7.14	5.51e-12	3.19e-05	0.46	0.36	Hemoglobin concentration;	chr17:59937351	chr17:20743333~20754501:-
STAD	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-7.14	5.52e-12	3.2e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
STAD	trans	rs12497850	0.931	rs6446205	ENSG00000197582.5	GPX1P1	7.14	5.53e-12	3.2e-05	0.48	0.36	Parkinson's disease;	chr3:48997778	chrX:13378735~13379340:-
STAD	trans	rs7113874	0.578	rs35807094	ENSG00000266891.1	RP11-692N5.2	7.14	5.54e-12	3.21e-05	0.5	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8528798	chr18:9734882~9735602:-
STAD	trans	rs4929947	0.515	rs67191473	ENSG00000266891.1	RP11-692N5.2	7.14	5.54e-12	3.21e-05	0.5	0.36	Menarche (age at onset);	chr11:8530643	chr18:9734882~9735602:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000242206.2	RPS26P35	7.14	5.55e-12	3.21e-05	0.42	0.36	Cognitive function;	chr12:56050848	chr8:118761856~118762201:-
STAD	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-7.14	5.67e-12	3.28e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
STAD	trans	rs13190036	0.591	rs78523677	ENSG00000226986.4	RP11-543B16.2	-7.13	5.83e-12	3.37e-05	-0.37	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr1:211207239~211207897:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000243328.1	RP11-520P18.1	-7.13	5.9e-12	3.41e-05	-0.34	-0.36	Cognitive function;	chr12:56084218	chr8:143065915~143066587:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000243328.1	RP11-520P18.1	-7.13	5.9e-12	3.41e-05	-0.34	-0.36	Cognitive function;	chr12:56084874	chr8:143065915~143066587:-
STAD	trans	rs66887589	0.967	rs59516282	ENSG00000276997.3	RP11-378J18.9	-7.13	5.94e-12	3.43e-05	-0.38	-0.36	Diastolic blood pressure;	chr4:119580861	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.934	rs12648182	ENSG00000276997.3	RP11-378J18.9	-7.13	5.94e-12	3.43e-05	-0.38	-0.36	Diastolic blood pressure;	chr4:119582736	chr1:222477252~222504622:-
STAD	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-7.13	5.97e-12	3.45e-05	-0.31	-0.36	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
STAD	trans	rs7554511	0.707	rs3861928	ENSG00000244144.1	RP11-757F18.3	-7.12	6.12e-12	3.53e-05	-0.41	-0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051446	chr3:112185480~112185998:-
STAD	trans	rs3096299	0.503	rs9940093	ENSG00000215030.5	RPL13P12	-7.12	6.13e-12	3.54e-05	-0.3	-0.36	Multiple myeloma (IgH translocation);	chr16:89492297	chr17:17383377~17384012:-
STAD	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-7.12	6.14e-12	3.55e-05	-0.4	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000212829.8	RPS26P3	7.12	6.15e-12	3.55e-05	0.39	0.36	Cognitive function;	chr12:55975722	chr9:9090898~9091245:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000219993.1	RP11-288G3.3	-7.12	6.23e-12	3.6e-05	-0.36	-0.36	Cognitive function;	chr12:56083910	chr6:7506203~7506549:+
STAD	trans	rs7647973	0.961	rs7619016	ENSG00000197582.5	GPX1P1	7.12	6.39e-12	3.68e-05	0.51	0.36	Menarche (age at onset);	chr3:49235156	chrX:13378735~13379340:-
STAD	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	7.12	6.45e-12	3.72e-05	0.47	0.36	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
STAD	trans	rs7647973	0.925	rs7429661	ENSG00000197582.5	GPX1P1	7.11	6.58e-12	3.79e-05	0.51	0.36	Menarche (age at onset);	chr3:49191367	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9876848	ENSG00000197582.5	GPX1P1	7.11	6.61e-12	3.81e-05	0.47	0.36	Parkinson's disease;	chr3:48806626	chrX:13378735~13379340:-
STAD	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	7.11	6.67e-12	3.84e-05	0.31	0.36	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
STAD	trans	rs1336472	0.509	rs4916032	ENSG00000263535.1	AK4P1	-7.11	6.67e-12	3.84e-05	-0.49	-0.36	Venous thromboembolism (SNP x SNP interaction);	chr1:65215939	chr17:31345521~31346187:+
STAD	trans	rs12497850	0.897	rs7373778	ENSG00000197582.5	GPX1P1	7.11	6.72e-12	3.87e-05	0.47	0.36	Parkinson's disease;	chr3:48798959	chrX:13378735~13379340:-
STAD	trans	rs11220237	0.92	rs10893426	ENSG00000236257.1	EI24P2	7.11	6.72e-12	3.87e-05	0.54	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr11:125778426	chr1:158454198~158455273:+
STAD	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-7.11	6.73e-12	3.88e-05	-0.47	-0.36	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-7.11	6.73e-12	3.88e-05	-0.47	-0.36	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
STAD	trans	rs916888	0.687	rs199456	ENSG00000264057.1	RP11-583F2.1	7.11	6.85e-12	3.94e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:64927634~64934203:+
STAD	trans	rs916888	0.773	rs199451	ENSG00000264057.1	RP11-583F2.1	7.11	6.85e-12	3.94e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:64927634~64934203:+
STAD	trans	rs7647973	1	rs6774724	ENSG00000197582.5	GPX1P1	7.11	6.87e-12	3.95e-05	0.51	0.36	Menarche (age at onset);	chr3:49344478	chrX:13378735~13379340:-
STAD	trans	rs10908521	0.685	rs7534418	ENSG00000227183.3	HDGFP1	-7.1	6.91e-12	3.97e-05	-0.42	-0.36	Uric acid clearance;	chr1:156836011	chrX:131646639~131646890:+
STAD	trans	rs7113874	0.511	rs35091649	ENSG00000266891.1	RP11-692N5.2	7.1	6.99e-12	4.02e-05	0.5	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8526636	chr18:9734882~9735602:-
STAD	trans	rs877636	0.736	rs773107	ENSG00000224553.1	AC008065.1	7.1	7.04e-12	4.04e-05	0.43	0.36	Cognitive function;	chr12:55975722	chr2:171374931~171375278:-
STAD	trans	rs9899728	0.665	rs2307008	ENSG00000213954.3	ATP5HP3	7.1	7.04e-12	4.05e-05	0.49	0.36	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr9:14068932~14069417:+
STAD	trans	rs10037055	0.636	rs13166688	ENSG00000226986.4	RP11-543B16.2	-7.1	7.24e-12	4.16e-05	-0.36	-0.36	Migraine without aura;	chr5:177156965	chr1:211207239~211207897:+
STAD	trans	rs7113874	0.659	rs67320655	ENSG00000266891.1	RP11-692N5.2	7.09	7.39e-12	4.24e-05	0.5	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8497662	chr18:9734882~9735602:-
STAD	trans	rs7113874	0.625	rs35760680	ENSG00000266891.1	RP11-692N5.2	7.09	7.39e-12	4.24e-05	0.5	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500525	chr18:9734882~9735602:-
STAD	trans	rs7113874	0.659	rs2121313	ENSG00000266891.1	RP11-692N5.2	7.09	7.39e-12	4.24e-05	0.5	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501495	chr18:9734882~9735602:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000219993.1	RP11-288G3.3	-7.09	7.43e-12	4.26e-05	-0.35	-0.36	Cognitive function;	chr12:56080024	chr6:7506203~7506549:+
STAD	trans	rs2069408	1	rs2069408	ENSG00000227586.5	RP11-162A23.5	-7.09	7.48e-12	4.29e-05	-0.39	-0.36	Asthma;	chr12:55970537	chr10:123171535~123171875:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000239210.2	RPS26P55	7.09	7.54e-12	4.32e-05	0.4	0.36	Cognitive function;	chr12:55990903	chr19:34533427~34534084:-
STAD	trans	rs941207	0.526	rs2242497	ENSG00000121089.4	NACA3P	-7.09	7.57e-12	4.34e-05	-0.31	-0.36	Platelet count;	chr12:56598846	chr4:164943290~164943937:+
STAD	trans	rs877636	0.692	rs11171739	ENSG00000244641.2	RPS26P43	7.09	7.66e-12	4.39e-05	0.34	0.36	Cognitive function;	chr12:56076841	chr11:123049787~123050353:-
STAD	trans	rs916888	0.773	rs199439	ENSG00000264057.1	RP11-583F2.1	7.09	7.69e-12	4.41e-05	0.44	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:64927634~64934203:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-7.09	7.71e-12	4.42e-05	-0.34	-0.36	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
STAD	trans	rs10908521	0.626	rs11264570	ENSG00000227183.3	HDGFP1	-7.09	7.78e-12	4.46e-05	-0.43	-0.36	Uric acid clearance;	chr1:156836167	chrX:131646639~131646890:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000242206.2	RPS26P35	7.08	7.84e-12	4.48e-05	0.42	0.36	Cognitive function;	chr12:56013288	chr8:118761856~118762201:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000242206.2	RPS26P35	7.08	7.84e-12	4.48e-05	0.42	0.36	Cognitive function;	chr12:56018703	chr8:118761856~118762201:-
STAD	trans	rs941207	0.526	rs9634277	ENSG00000121089.4	NACA3P	-7.08	7.86e-12	4.5e-05	-0.32	-0.36	Platelet count;	chr12:56640910	chr4:164943290~164943937:+
STAD	trans	rs2950393	0.926	rs9634247	ENSG00000121089.4	NACA3P	-7.08	7.86e-12	4.5e-05	-0.32	-0.36	Platelet distribution width;	chr12:56641056	chr4:164943290~164943937:+
STAD	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	7.08	7.86e-12	4.5e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
STAD	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	7.08	7.86e-12	4.5e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
STAD	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-7.08	7.88e-12	4.51e-05	-0.39	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
STAD	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-7.08	7.95e-12	4.55e-05	-0.46	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
STAD	trans	rs12497850	0.931	rs11920534	ENSG00000197582.5	GPX1P1	7.08	8.01e-12	4.58e-05	0.47	0.36	Parkinson's disease;	chr3:48900328	chrX:13378735~13379340:-
STAD	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	7.08	8.02e-12	4.58e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
STAD	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-7.08	8.1e-12	4.63e-05	-0.47	-0.36	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-7.08	8.23e-12	4.7e-05	-0.47	-0.36	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-7.08	8.23e-12	4.7e-05	-0.47	-0.36	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	7.08	8.26e-12	4.71e-05	0.47	0.36	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
STAD	trans	rs11098499	0.575	rs9996586	ENSG00000275858.1	RP11-291L22.8	7.07	8.56e-12	4.89e-05	0.37	0.36	Corneal astigmatism;	chr4:119405787	chr10:38450738~38451069:-
STAD	trans	rs10037055	0.853	rs1363405	ENSG00000228305.2	AC016734.2	7.07	8.57e-12	4.89e-05	0.34	0.36	Migraine without aura;	chr5:177209881	chr2:63622178~63622831:-
STAD	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	7.07	8.62e-12	4.92e-05	0.38	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
STAD	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-7.07	8.65e-12	4.93e-05	-0.47	-0.36	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
STAD	trans	rs7647973	0.731	rs7617480	ENSG00000197582.5	GPX1P1	-7.07	8.7e-12	4.96e-05	-0.52	-0.36	Menarche (age at onset);	chr3:49173299	chrX:13378735~13379340:-
STAD	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-7.07	8.8e-12	5.01e-05	-0.46	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
STAD	trans	rs7647973	0.925	rs9881860	ENSG00000197582.5	GPX1P1	7.07	8.82e-12	5.03e-05	0.51	0.36	Menarche (age at onset);	chr3:49315089	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs13064911	ENSG00000197582.5	GPX1P1	7.07	8.83e-12	5.03e-05	0.47	0.36	Parkinson's disease;	chr3:48914952	chrX:13378735~13379340:-
STAD	trans	rs916888	0.773	rs1378358	ENSG00000264057.1	RP11-583F2.1	7.07	8.87e-12	5.05e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:64927634~64934203:+
STAD	trans	rs66887589	0.967	rs56173225	ENSG00000276997.3	RP11-378J18.9	-7.06	8.89e-12	5.06e-05	-0.38	-0.36	Diastolic blood pressure;	chr4:119588817	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.967	rs7678973	ENSG00000276997.3	RP11-378J18.9	-7.06	8.89e-12	5.06e-05	-0.38	-0.36	Diastolic blood pressure;	chr4:119590662	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000242206.2	RPS26P35	7.06	8.91e-12	5.07e-05	0.41	0.36	Cognitive function;	chr12:56023144	chr8:118761856~118762201:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000224161.3	RPS26P54	-7.06	8.92e-12	5.08e-05	-0.34	-0.36	Cognitive function;	chr12:56080024	chr18:59761558~59761905:+
STAD	trans	rs66887589	0.934	rs56843000	ENSG00000276997.3	RP11-378J18.9	-7.06	8.92e-12	5.08e-05	-0.38	-0.36	Diastolic blood pressure;	chr4:119595442	chr1:222477252~222504622:-
STAD	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-7.06	8.92e-12	5.08e-05	-0.47	-0.36	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
STAD	trans	rs916888	0.773	rs199457	ENSG00000264057.1	RP11-583F2.1	7.06	8.93e-12	5.08e-05	0.45	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:64927634~64934203:+
STAD	trans	rs3770081	1	rs57083584	ENSG00000229880.1	IMMTP1	7.06	9e-12	5.12e-05	0.73	0.35	Facial emotion recognition (sad faces);	chr2:86056525	chr21:44675868~44678086:-
STAD	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-7.06	9.11e-12	5.18e-05	-0.38	-0.35	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-7.06	9.14e-12	5.2e-05	-0.38	-0.35	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
STAD	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-7.06	9.18e-12	5.21e-05	-0.47	-0.35	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-7.06	9.18e-12	5.21e-05	-0.47	-0.35	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-7.06	9.18e-12	5.21e-05	-0.47	-0.35	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-7.06	9.18e-12	5.21e-05	-0.47	-0.35	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
STAD	trans	rs7930295	0.632	rs11220215	ENSG00000236257.1	EI24P2	7.06	9.19e-12	5.22e-05	0.55	0.35	Schizophrenia;	chr11:125771766	chr1:158454198~158455273:+
STAD	trans	rs13190036	0.551	rs28932178	ENSG00000226986.4	RP11-543B16.2	-7.06	9.2e-12	5.22e-05	-0.37	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr1:211207239~211207897:+
STAD	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-7.06	9.21e-12	5.23e-05	-0.47	-0.35	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	7.06	9.21e-12	5.23e-05	0.47	0.35	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
STAD	trans	rs66887589	0.934	rs41464847	ENSG00000276997.3	RP11-378J18.9	-7.06	9.3e-12	5.28e-05	-0.38	-0.35	Diastolic blood pressure;	chr4:119611246	chr1:222477252~222504622:-
STAD	trans	rs7930295	0.632	rs35245130	ENSG00000236257.1	EI24P2	7.06	9.31e-12	5.28e-05	0.55	0.35	Schizophrenia;	chr11:125771018	chr1:158454198~158455273:+
STAD	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-7.06	9.33e-12	5.29e-05	-0.46	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
STAD	trans	rs916888	0.779	rs199528	ENSG00000264057.1	RP11-583F2.1	7.06	9.38e-12	5.32e-05	0.45	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:64927634~64934203:+
STAD	trans	rs916888	0.821	rs199525	ENSG00000264057.1	RP11-583F2.1	7.06	9.38e-12	5.32e-05	0.45	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:64927634~64934203:+
STAD	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-7.06	9.42e-12	5.34e-05	-0.39	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
STAD	trans	rs877636	1	rs705696	ENSG00000242206.2	RPS26P35	7.06	9.44e-12	5.35e-05	0.4	0.35	Cognitive function;	chr12:56086864	chr8:118761856~118762201:-
STAD	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	7.05	9.51e-12	5.39e-05	0.54	0.35	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
STAD	trans	rs12497850	0.931	rs4072859	ENSG00000197582.5	GPX1P1	7.05	9.55e-12	5.41e-05	0.48	0.35	Parkinson's disease;	chr3:48994772	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000242206.2	RPS26P35	7.05	9.61e-12	5.45e-05	0.41	0.35	Cognitive function;	chr12:56041628	chr8:118761856~118762201:-
STAD	trans	rs3770081	1	rs58365138	ENSG00000229880.1	IMMTP1	7.05	9.61e-12	5.45e-05	0.72	0.35	Facial emotion recognition (sad faces);	chr2:85985982	chr21:44675868~44678086:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000224161.3	RPS26P54	-7.05	9.63e-12	5.46e-05	-0.35	-0.35	Cognitive function;	chr12:56007301	chr18:59761558~59761905:+
STAD	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	7.05	9.63e-12	5.46e-05	0.38	0.35	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
STAD	trans	rs12497850	0.931	rs7647813	ENSG00000197582.5	GPX1P1	7.05	9.79e-12	5.54e-05	0.47	0.35	Parkinson's disease;	chr3:48795915	chrX:13378735~13379340:-
STAD	trans	rs877636	0.701	rs7302200	ENSG00000244604.1	RP11-713H12.1	7.05	9.79e-12	5.55e-05	0.42	0.35	Cognitive function;	chr12:56055651	chr17:8561230~8561576:+
STAD	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-7.05	9.92e-12	5.61e-05	-0.47	-0.35	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
STAD	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-7.05	9.93e-12	5.62e-05	-0.46	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000242970.2	AC068522.4	7.05	9.93e-12	5.62e-05	0.39	0.35	Cognitive function;	chr12:55980911	chr8:58588420~58588764:-
STAD	trans	rs9899728	0.764	rs9660	ENSG00000213954.3	ATP5HP3	7.05	1e-11	5.68e-05	0.48	0.35	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr9:14068932~14069417:+
STAD	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-7.05	1e-11	5.68e-05	-0.52	-0.35	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs7627404	ENSG00000197582.5	GPX1P1	7.04	1.01e-11	5.71e-05	0.47	0.35	Parkinson's disease;	chr3:48782235	chrX:13378735~13379340:-
STAD	trans	rs4834770	1	rs878374	ENSG00000276997.3	RP11-378J18.9	7.04	1.03e-11	5.83e-05	0.39	0.35	Blood protein levels;	chr4:119316409	chr1:222477252~222504622:-
STAD	trans	rs8067354	0.574	rs1292042	ENSG00000187870.7	RNFT1P3	7.04	1.04e-11	5.85e-05	0.45	0.35	Hemoglobin concentration;	chr17:59857634	chr17:20743333~20754501:-
STAD	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	7.04	1.05e-11	5.9e-05	0.45	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
STAD	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	7.04	1.06e-11	5.96e-05	0.45	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
STAD	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-7.04	1.06e-11	5.97e-05	-0.46	-0.35	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000242206.2	RPS26P35	7.04	1.06e-11	5.98e-05	0.41	0.35	Cognitive function;	chr12:56041720	chr8:118761856~118762201:-
STAD	trans	rs3770081	1	rs58898686	ENSG00000229880.1	IMMTP1	7.04	1.07e-11	6e-05	0.71	0.35	Facial emotion recognition (sad faces);	chr2:85989786	chr21:44675868~44678086:-
STAD	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	7.03	1.08e-11	6.1e-05	0.55	0.35	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
STAD	trans	rs12138950	0.681	rs28630511	ENSG00000224237.1	MINOS1P3	7.03	1.09e-11	6.12e-05	0.47	0.35	Hypothyroidism;Thyroid volume;	chr1:19516538	chr3:27214816~27215018:-
STAD	trans	rs12709013	0.636	rs1646256	ENSG00000233719.3	GOT2P3	7.03	1.1e-11	6.17e-05	0.4	0.35	Blood metabolite ratios;	chr16:58712114	chr12:9641802~9643007:+
STAD	trans	rs13190036	1	rs351864	ENSG00000217325.2	PRELID1P1	-7.03	1.1e-11	6.18e-05	-0.39	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr6:126643488~126644390:+
STAD	trans	rs3770081	1	rs3770081	ENSG00000229880.1	IMMTP1	7.03	1.1e-11	6.21e-05	0.73	0.35	Facial emotion recognition (sad faces);	chr2:86053802	chr21:44675868~44678086:-
STAD	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	7.03	1.13e-11	6.33e-05	0.44	0.35	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
STAD	trans	rs3770081	1	rs11899576	ENSG00000229880.1	IMMTP1	7.03	1.13e-11	6.37e-05	0.67	0.35	Facial emotion recognition (sad faces);	chr2:86029070	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs3770089	ENSG00000229880.1	IMMTP1	7.02	1.16e-11	6.53e-05	0.71	0.35	Facial emotion recognition (sad faces);	chr2:86036692	chr21:44675868~44678086:-
STAD	trans	rs12497850	0.865	rs7649458	ENSG00000197582.5	GPX1P1	7.02	1.16e-11	6.54e-05	0.47	0.35	Parkinson's disease;	chr3:48882694	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000234354.3	RPS26P47	7.02	1.17e-11	6.56e-05	0.46	0.35	Cognitive function;	chr12:55981956	chr13:100539901~100540248:-
STAD	trans	rs7930295	0.632	rs12287044	ENSG00000236257.1	EI24P2	7.02	1.17e-11	6.57e-05	0.55	0.35	Schizophrenia;	chr11:125772649	chr1:158454198~158455273:+
STAD	trans	rs7930295	0.632	rs2081502	ENSG00000236257.1	EI24P2	7.02	1.17e-11	6.57e-05	0.55	0.35	Schizophrenia;	chr11:125773374	chr1:158454198~158455273:+
STAD	trans	rs13358908	1	rs13358908	ENSG00000231752.4	EMBP1	-7.02	1.17e-11	6.59e-05	-0.47	-0.35	Schizophrenia;	chr5:46349602	chr1:121519112~121571892:+
STAD	trans	rs916888	0.821	rs70600	ENSG00000264057.1	RP11-583F2.1	7.02	1.18e-11	6.62e-05	0.45	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:64927634~64934203:+
STAD	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-7.02	1.19e-11	6.66e-05	-0.45	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
STAD	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-7.02	1.19e-11	6.66e-05	-0.45	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
STAD	trans	rs12497850	0.931	rs7616815	ENSG00000197582.5	GPX1P1	7.02	1.19e-11	6.67e-05	0.46	0.35	Parkinson's disease;	chr3:48742282	chrX:13378735~13379340:-
STAD	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	7.02	1.19e-11	6.67e-05	0.46	0.35	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
STAD	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-7.02	1.19e-11	6.68e-05	-0.3	-0.35	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
STAD	trans	rs7647973	1	rs9862534	ENSG00000197582.5	GPX1P1	7.02	1.21e-11	6.81e-05	0.49	0.35	Menarche (age at onset);	chr3:49560631	chrX:13378735~13379340:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000196656.7	AC004057.1	7.01	1.22e-11	6.85e-05	0.35	0.35	Cognitive function;	chr12:55990903	chr4:113214046~113217170:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000240427.1	RPS26P34	-7.01	1.24e-11	6.94e-05	-0.38	-0.35	Cognitive function;	chr12:56042145	chr8:81627269~81627617:+
STAD	trans	rs12138950	0.596	rs10917471	ENSG00000224237.1	MINOS1P3	7.01	1.25e-11	6.98e-05	0.47	0.35	Hypothyroidism;Thyroid volume;	chr1:19521118	chr3:27214816~27215018:-
STAD	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	7.01	1.25e-11	7e-05	0.46	0.35	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	7.01	1.25e-11	7e-05	0.46	0.35	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	7.01	1.25e-11	7e-05	0.46	0.35	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	7.01	1.25e-11	7e-05	0.46	0.35	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	7.01	1.25e-11	7e-05	0.46	0.35	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	7.01	1.25e-11	7e-05	0.46	0.35	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	7.01	1.25e-11	7e-05	0.46	0.35	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
STAD	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-7.01	1.25e-11	7e-05	-0.46	-0.35	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-7.01	1.25e-11	7e-05	-0.46	-0.35	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000239210.2	RPS26P55	7.01	1.26e-11	7.04e-05	0.42	0.35	Cognitive function;	chr12:55975722	chr19:34533427~34534084:-
STAD	trans	rs12497850	0.931	rs4974080	ENSG00000197582.5	GPX1P1	7.01	1.27e-11	7.11e-05	0.47	0.35	Parkinson's disease;	chr3:48993395	chrX:13378735~13379340:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000219993.1	RP11-288G3.3	-7.01	1.28e-11	7.17e-05	-0.35	-0.35	Cognitive function;	chr12:56084218	chr6:7506203~7506549:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000219993.1	RP11-288G3.3	-7.01	1.28e-11	7.17e-05	-0.35	-0.35	Cognitive function;	chr12:56084874	chr6:7506203~7506549:+
STAD	trans	rs877636	1	rs877636	ENSG00000226339.1	RPS26P56	-7	1.3e-11	7.24e-05	-0.37	-0.35	Cognitive function;	chr12:56086799	chrX:129408382~129408621:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000234192.1	RP11-57C13.5	7	1.3e-11	7.26e-05	0.42	0.35	Cognitive function;	chr12:56055651	chr10:87642607~87642954:+
STAD	trans	rs7364180	0.582	rs139568	ENSG00000268568.1	AC007228.9	7	1.3e-11	7.28e-05	0.42	0.35	Alzheimer's disease biomarkers;	chr22:41814981	chr19:56672574~56673901:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000242206.2	RPS26P35	7	1.36e-11	7.58e-05	0.42	0.35	Cognitive function;	chr12:56002984	chr8:118761856~118762201:-
STAD	trans	rs12497850	0.931	rs13316620	ENSG00000197582.5	GPX1P1	7	1.37e-11	7.65e-05	0.47	0.35	Parkinson's disease;	chr3:49007922	chrX:13378735~13379340:-
STAD	trans	rs877636	0.74	rs705702	ENSG00000234192.1	RP11-57C13.5	-7	1.37e-11	7.65e-05	-0.38	-0.35	Cognitive function;	chr12:55996852	chr10:87642607~87642954:+
STAD	trans	rs12497850	0.931	rs9311432	ENSG00000197582.5	GPX1P1	7	1.37e-11	7.65e-05	0.47	0.35	Parkinson's disease;	chr3:48813010	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9311433	ENSG00000197582.5	GPX1P1	7	1.37e-11	7.65e-05	0.47	0.35	Parkinson's disease;	chr3:48826402	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs7430501	ENSG00000197582.5	GPX1P1	7	1.37e-11	7.65e-05	0.47	0.35	Parkinson's disease;	chr3:48852686	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs10780033	ENSG00000197582.5	GPX1P1	7	1.37e-11	7.65e-05	0.47	0.35	Parkinson's disease;	chr3:48853842	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.864	rs7431857	ENSG00000197582.5	GPX1P1	7	1.37e-11	7.65e-05	0.47	0.35	Parkinson's disease;	chr3:48862914	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs12493289	ENSG00000197582.5	GPX1P1	7	1.37e-11	7.65e-05	0.47	0.35	Parkinson's disease;	chr3:48867728	chrX:13378735~13379340:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000234354.3	RPS26P47	6.99	1.38e-11	7.7e-05	0.46	0.35	Cognitive function;	chr12:55982097	chr13:100539901~100540248:-
STAD	trans	rs66887589	0.967	rs2892869	ENSG00000276997.3	RP11-378J18.9	-6.99	1.39e-11	7.73e-05	-0.38	-0.35	Diastolic blood pressure;	chr4:119600142	chr1:222477252~222504622:-
STAD	trans	rs7647973	0.731	rs9831648	ENSG00000197582.5	GPX1P1	6.99	1.4e-11	7.8e-05	0.52	0.35	Menarche (age at onset);	chr3:49176870	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9835307	ENSG00000197582.5	GPX1P1	6.99	1.41e-11	7.85e-05	0.47	0.35	Parkinson's disease;	chr3:48820372	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.934	rs7681980	ENSG00000276997.3	RP11-378J18.9	-6.99	1.42e-11	7.93e-05	-0.37	-0.35	Diastolic blood pressure;	chr4:119612068	chr1:222477252~222504622:-
STAD	trans	rs7647973	1	rs1464569	ENSG00000197582.5	GPX1P1	6.99	1.43e-11	7.94e-05	0.51	0.35	Menarche (age at onset);	chr3:49422917	chrX:13378735~13379340:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000244641.2	RPS26P43	6.99	1.43e-11	7.99e-05	0.39	0.35	Cognitive function;	chr12:56050848	chr11:123049787~123050353:-
STAD	trans	rs12497850	0.931	rs62262517	ENSG00000197582.5	GPX1P1	6.99	1.43e-11	7.99e-05	0.47	0.35	Parkinson's disease;	chr3:49097481	chrX:13378735~13379340:-
STAD	trans	rs3096299	0.632	rs4399533	ENSG00000215030.5	RPL13P12	-6.99	1.45e-11	8.08e-05	-0.3	-0.35	Multiple myeloma (IgH translocation);	chr16:89472974	chr17:17383377~17384012:-
STAD	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	6.99	1.46e-11	8.11e-05	0.46	0.35	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	6.99	1.46e-11	8.11e-05	0.46	0.35	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
STAD	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	6.99	1.46e-11	8.11e-05	0.46	0.35	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000242206.2	RPS26P35	6.98	1.48e-11	8.25e-05	0.36	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:118761856~118762201:-
STAD	trans	rs877636	1	rs4759229	ENSG00000226339.1	RPS26P56	-6.98	1.48e-11	8.25e-05	-0.37	-0.35	Cognitive function;	chr12:56080696	chrX:129408382~129408621:+
STAD	trans	rs4834770	1	rs878375	ENSG00000276997.3	RP11-378J18.9	6.98	1.5e-11	8.33e-05	0.38	0.35	Blood protein levels;	chr4:119316419	chr1:222477252~222504622:-
STAD	trans	rs3096299	0.685	rs4785675	ENSG00000215030.5	RPL13P12	-6.98	1.52e-11	8.46e-05	-0.3	-0.35	Multiple myeloma (IgH translocation);	chr16:89473566	chr17:17383377~17384012:-
STAD	trans	rs3096299	0.685	rs4238830	ENSG00000215030.5	RPL13P12	-6.98	1.52e-11	8.46e-05	-0.3	-0.35	Multiple myeloma (IgH translocation);	chr16:89473833	chr17:17383377~17384012:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000231366.1	RP11-399N22.3	-6.98	1.56e-11	8.65e-05	-0.36	-0.35	Cognitive function;	chr12:56084218	chr10:70794230~70794523:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000231366.1	RP11-399N22.3	-6.98	1.56e-11	8.65e-05	-0.36	-0.35	Cognitive function;	chr12:56084874	chr10:70794230~70794523:-
STAD	trans	rs12497850	0.931	rs13315711	ENSG00000197582.5	GPX1P1	6.97	1.57e-11	8.69e-05	0.47	0.35	Parkinson's disease;	chr3:48948966	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs7636057	ENSG00000197582.5	GPX1P1	6.97	1.57e-11	8.69e-05	0.47	0.35	Parkinson's disease;	chr3:48955149	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs7643368	ENSG00000197582.5	GPX1P1	6.97	1.57e-11	8.69e-05	0.47	0.35	Parkinson's disease;	chr3:48955422	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs7621015	ENSG00000197582.5	GPX1P1	6.97	1.57e-11	8.69e-05	0.47	0.35	Parkinson's disease;	chr3:48978623	chrX:13378735~13379340:-
STAD	trans	rs877636	0.736	rs773107	ENSG00000233778.3	RP11-777J24.1	6.97	1.57e-11	8.7e-05	0.38	0.35	Cognitive function;	chr12:55975722	chr8:92144088~92144435:-
STAD	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	6.97	1.57e-11	8.72e-05	0.45	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
STAD	trans	rs10815468	0.624	rs7037259	ENSG00000215210.3	RBMXP2	-6.97	1.58e-11	8.75e-05	-0.38	-0.35	Bipolar disorder and schizophrenia;	chr9:6784144	chr9:30689105~30690272:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000204652.6	RPS26P8	6.97	1.59e-11	8.8e-05	0.38	0.35	Cognitive function;	chr12:55975722	chr17:45608571~45608918:+
STAD	trans	rs7113874	0.578	rs67067089	ENSG00000266891.1	RP11-692N5.2	6.97	1.61e-11	8.94e-05	0.49	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508480	chr18:9734882~9735602:-
STAD	trans	rs2727020	0.729	rs6485965	ENSG00000134612.10	FOLH1B	6.97	1.66e-11	9.18e-05	0.41	0.35	Coronary artery disease;	chr11:49145178	chr11:89639227~89698718:+
STAD	trans	rs7647973	1	rs974495	ENSG00000197582.5	GPX1P1	6.96	1.67e-11	9.22e-05	0.51	0.35	Menarche (age at onset);	chr3:49363049	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs11719762	ENSG00000197582.5	GPX1P1	6.96	1.67e-11	9.22e-05	0.51	0.35	Menarche (age at onset);	chr3:49371569	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs10155014	ENSG00000197582.5	GPX1P1	6.96	1.67e-11	9.22e-05	0.51	0.35	Menarche (age at onset);	chr3:49394888	chrX:13378735~13379340:-
STAD	trans	rs216303	0.642	rs216314	ENSG00000241717.1	VWFP1	6.96	1.67e-11	9.24e-05	0.48	0.35	Low vWF levels;	chr12:6027414	chr22:16690103~16704477:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000224161.3	RPS26P54	6.96	1.69e-11	9.33e-05	0.33	0.35	Cognitive function;	chr12:56076841	chr18:59761558~59761905:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000234354.3	RPS26P47	6.96	1.69e-11	9.36e-05	0.5	0.35	Cognitive function;	chr12:56055651	chr13:100539901~100540248:-
STAD	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	6.96	1.69e-11	9.37e-05	0.46	0.35	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.897	rs7432989	ENSG00000197582.5	GPX1P1	6.96	1.69e-11	9.37e-05	0.46	0.35	Parkinson's disease;	chr3:49067703	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	6.95	1.79e-11	9.89e-05	0.46	0.35	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	6.95	1.79e-11	9.89e-05	0.46	0.35	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000231366.1	RP11-399N22.3	-6.95	1.82e-11	1e-04	-0.37	-0.35	Cognitive function;	chr12:56083910	chr10:70794230~70794523:-
STAD	trans	rs10037055	0.685	rs10039241	ENSG00000226986.4	RP11-543B16.2	-6.95	1.82e-11	1e-04	-0.35	-0.35	Migraine without aura;	chr5:177151071	chr1:211207239~211207897:+
STAD	trans	rs3770081	1	rs6750765	ENSG00000229880.1	IMMTP1	6.95	1.82e-11	0.000101	0.67	0.35	Facial emotion recognition (sad faces);	chr2:86073185	chr21:44675868~44678086:-
STAD	trans	rs13190036	0.551	rs7710269	ENSG00000226986.4	RP11-543B16.2	-6.95	1.83e-11	0.000101	-0.36	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr1:211207239~211207897:+
STAD	trans	rs1190596	0.689	rs2224460	ENSG00000181359.5	HSP90AA6P	6.95	1.84e-11	0.000102	0.39	0.35	Behavioural disinhibition (generation interaction);	chr14:102097460	chr4:170581470~170605450:-
STAD	trans	rs877636	0.692	rs11171739	ENSG00000242307.1	RPS26P52	6.95	1.86e-11	0.000102	0.37	0.35	Cognitive function;	chr12:56076841	chr16:13922332~13922679:-
STAD	trans	rs12497850	0.931	rs3774628	ENSG00000197582.5	GPX1P1	6.95	1.86e-11	0.000103	0.46	0.35	Parkinson's disease;	chr3:48764407	chrX:13378735~13379340:-
STAD	trans	rs11220082	0.761	rs1044314	ENSG00000236257.1	EI24P2	-6.95	1.87e-11	0.000103	-0.46	-0.35	Schizophrenia;	chr11:125431909	chr1:158454198~158455273:+
STAD	trans	rs7113874	0.534	rs2311392	ENSG00000266891.1	RP11-692N5.2	6.94	1.89e-11	0.000104	0.5	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8468889	chr18:9734882~9735602:-
STAD	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	6.94	1.89e-11	0.000104	0.47	0.35	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	6.94	1.89e-11	0.000104	0.47	0.35	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	6.94	1.89e-11	0.000104	0.47	0.35	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
STAD	trans	rs11220237	1	rs12795730	ENSG00000236257.1	EI24P2	6.94	1.89e-11	0.000104	0.56	0.35	Itch intensity from mosquito bite adjusted by bite size;	chr11:125846182	chr1:158454198~158455273:+
STAD	trans	rs12497850	0.805	rs11130176	ENSG00000197582.5	GPX1P1	6.94	1.9e-11	0.000105	0.46	0.35	Parkinson's disease;	chr3:48806644	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9311430	ENSG00000197582.5	GPX1P1	6.94	1.9e-11	0.000105	0.46	0.35	Parkinson's disease;	chr3:48807818	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.961	rs6778080	ENSG00000197582.5	GPX1P1	-6.94	1.9e-11	0.000105	-0.49	-0.35	Menarche (age at onset);	chr3:49279905	chrX:13378735~13379340:-
STAD	trans	rs3770081	0.826	rs1019591	ENSG00000229880.1	IMMTP1	6.94	1.9e-11	0.000105	0.66	0.35	Facial emotion recognition (sad faces);	chr2:86071476	chr21:44675868~44678086:-
STAD	trans	rs13190036	0.901	rs6898107	ENSG00000217325.2	PRELID1P1	6.94	1.91e-11	0.000105	0.38	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr6:126643488~126644390:+
STAD	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	6.94	1.93e-11	0.000106	0.47	0.35	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000242970.2	AC068522.4	6.94	1.95e-11	0.000107	0.38	0.35	Cognitive function;	chr12:55996580	chr8:58588420~58588764:-
STAD	trans	rs916888	0.773	rs169201	ENSG00000264057.1	RP11-583F2.1	6.94	1.97e-11	0.000108	0.44	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:64927634~64934203:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000196656.7	AC004057.1	6.93	2.02e-11	0.000111	0.36	0.35	Cognitive function;	chr12:55975722	chr4:113214046~113217170:-
STAD	trans	rs12709013	0.514	rs8062639	ENSG00000233719.3	GOT2P3	6.93	2.08e-11	0.000114	0.41	0.35	Blood metabolite ratios;	chr16:58800264	chr12:9641802~9643007:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000234354.3	RPS26P47	6.93	2.08e-11	0.000114	0.46	0.35	Cognitive function;	chr12:55981353	chr13:100539901~100540248:-
STAD	trans	rs12709013	0.591	rs149479	ENSG00000233719.3	GOT2P3	-6.93	2.08e-11	0.000114	-0.41	-0.35	Blood metabolite ratios;	chr16:58703171	chr12:9641802~9643007:+
STAD	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-6.93	2.08e-11	0.000114	-0.39	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000229032.1	RP11-91A18.1	-6.93	2.09e-11	0.000115	-0.37	-0.35	Cognitive function;	chr12:56042145	chr1:51980473~51980814:+
STAD	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-6.93	2.12e-11	0.000116	-0.44	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
STAD	trans	rs12709013	0.59	rs982848	ENSG00000230849.2	GOT2P2	6.92	2.15e-11	0.000118	0.37	0.35	Blood metabolite ratios;	chr16:58704294	chr1:173141100~173142350:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000226339.1	RPS26P56	-6.92	2.16e-11	0.000118	-0.37	-0.35	Cognitive function;	chr12:56080595	chrX:129408382~129408621:+
STAD	trans	rs6790105	1	rs6790105	ENSG00000197582.5	GPX1P1	6.92	2.16e-11	0.000119	0.51	0.35	Childhood ear infection;	chr3:49355976	chrX:13378735~13379340:-
STAD	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	6.92	2.19e-11	0.00012	0.39	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
STAD	trans	rs13190036	0.551	rs11955537	ENSG00000226986.4	RP11-543B16.2	-6.92	2.21e-11	0.000121	-0.35	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr1:211207239~211207897:+
STAD	trans	rs2727020	0.729	rs10742932	ENSG00000134612.10	FOLH1B	-6.91	2.28e-11	0.000124	-0.41	-0.35	Coronary artery disease;	chr11:49151682	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	6.91	2.28e-11	0.000125	0.37	0.35	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	6.91	2.28e-11	0.000125	0.37	0.35	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	6.91	2.28e-11	0.000125	0.37	0.35	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000242307.1	RPS26P52	-6.91	2.31e-11	0.000126	-0.37	-0.35	Cognitive function;	chr12:56084218	chr16:13922332~13922679:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000242307.1	RPS26P52	-6.91	2.31e-11	0.000126	-0.37	-0.35	Cognitive function;	chr12:56084874	chr16:13922332~13922679:-
STAD	trans	rs12709013	0.591	rs30834	ENSG00000233719.3	GOT2P3	6.91	2.34e-11	0.000128	0.4	0.35	Blood metabolite ratios;	chr16:58715394	chr12:9641802~9643007:+
STAD	trans	rs7647973	1	rs62259944	ENSG00000197582.5	GPX1P1	-6.9	2.42e-11	0.000132	-0.52	-0.35	Menarche (age at onset);	chr3:49393450	chrX:13378735~13379340:-
STAD	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	6.9	2.43e-11	0.000133	0.5	0.35	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.645	rs2102507	ENSG00000187870.7	RNFT1P3	6.9	2.44e-11	0.000133	0.42	0.35	Hemoglobin concentration;	chr17:59798546	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs2645491	ENSG00000187870.7	RNFT1P3	6.9	2.44e-11	0.000133	0.42	0.35	Hemoglobin concentration;	chr17:59799688	chr17:20743333~20754501:-
STAD	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-6.9	2.46e-11	0.000134	-0.46	-0.35	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
STAD	trans	rs11220237	1	rs11220237	ENSG00000236257.1	EI24P2	6.9	2.47e-11	0.000135	0.56	0.35	Itch intensity from mosquito bite adjusted by bite size;	chr11:125838942	chr1:158454198~158455273:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000243328.1	RP11-520P18.1	-6.9	2.49e-11	0.000136	-0.35	-0.35	Cognitive function;	chr12:56007301	chr8:143065915~143066587:-
STAD	trans	rs13190036	1	rs6880798	ENSG00000226986.4	RP11-543B16.2	6.9	2.49e-11	0.000136	0.37	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr1:211207239~211207897:+
STAD	trans	rs8067354	0.645	rs2665400	ENSG00000187870.7	RNFT1P3	6.9	2.5e-11	0.000136	0.42	0.35	Hemoglobin concentration;	chr17:59802840	chr17:20743333~20754501:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000231366.1	RP11-399N22.3	-6.9	2.53e-11	0.000137	-0.36	-0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:70794230~70794523:-
STAD	trans	rs12497850	0.931	rs11924597	ENSG00000197582.5	GPX1P1	6.9	2.54e-11	0.000138	0.46	0.35	Parkinson's disease;	chr3:48900357	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.897	rs9850134	ENSG00000197582.5	GPX1P1	6.9	2.54e-11	0.000138	0.46	0.35	Parkinson's disease;	chr3:48919714	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.931	rs9867373	ENSG00000197582.5	GPX1P1	6.9	2.54e-11	0.000138	0.46	0.35	Parkinson's disease;	chr3:48923505	chrX:13378735~13379340:-
STAD	trans	rs12497850	0.865	rs13072911	ENSG00000197582.5	GPX1P1	6.9	2.54e-11	0.000138	0.46	0.35	Parkinson's disease;	chr3:48924695	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	6.9	2.55e-11	0.000139	0.46	0.35	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000244604.1	RP11-713H12.1	6.89	2.61e-11	0.000142	0.38	0.35	Cognitive function;	chr12:55996580	chr17:8561230~8561576:+
STAD	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-6.89	2.63e-11	0.000143	-0.44	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
STAD	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-6.89	2.63e-11	0.000143	-0.44	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
STAD	trans	rs3770081	1	rs2118521	ENSG00000229880.1	IMMTP1	6.89	2.63e-11	0.000143	0.66	0.35	Facial emotion recognition (sad faces);	chr2:85977256	chr21:44675868~44678086:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000243538.1	CTB-55B8.1	6.89	2.64e-11	0.000143	0.37	0.35	Cognitive function;	chr12:55990903	chr5:16902294~16902641:-
STAD	trans	rs877636	1	rs2292239	ENSG00000226339.1	RPS26P56	6.89	2.64e-11	0.000143	0.36	0.35	Cognitive function;	chr12:56088396	chrX:129408382~129408621:+
STAD	trans	rs66887589	0.777	rs2017058	ENSG00000276997.3	RP11-378J18.9	6.88	2.75e-11	0.000149	0.36	0.35	Diastolic blood pressure;	chr4:119336584	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.777	rs1814815	ENSG00000276997.3	RP11-378J18.9	6.88	2.75e-11	0.000149	0.36	0.35	Diastolic blood pressure;	chr4:119336936	chr1:222477252~222504622:-
STAD	trans	rs10037055	1	rs10037055	ENSG00000226986.4	RP11-543B16.2	-6.88	2.75e-11	0.000149	-0.33	-0.35	Migraine without aura;	chr5:177264278	chr1:211207239~211207897:+
STAD	trans	rs3096299	0.685	rs8050512	ENSG00000215030.5	RPL13P12	-6.88	2.76e-11	0.00015	-0.3	-0.35	Multiple myeloma (IgH translocation);	chr16:89485912	chr17:17383377~17384012:-
STAD	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	6.88	2.77e-11	0.00015	0.39	0.35	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
STAD	trans	rs12709013	0.646	rs8046154	ENSG00000233719.3	GOT2P3	-6.88	2.86e-11	0.000155	-0.4	-0.35	Blood metabolite ratios;	chr16:58773978	chr12:9641802~9643007:+
STAD	trans	rs916888	0.773	rs538628	ENSG00000264057.1	RP11-583F2.1	6.88	2.87e-11	0.000155	0.43	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:64927634~64934203:+
STAD	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	6.88	2.87e-11	0.000155	0.46	0.35	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
STAD	trans	rs16937956	0.597	rs12793878	ENSG00000266891.1	RP11-692N5.2	6.88	2.9e-11	0.000157	0.44	0.35	Body mass index;	chr11:8380662	chr18:9734882~9735602:-
STAD	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	6.87	2.93e-11	0.000158	0.46	0.35	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
STAD	trans	rs11220237	0.62	rs11220184	ENSG00000236257.1	EI24P2	6.87	2.93e-11	0.000159	0.52	0.35	Itch intensity from mosquito bite adjusted by bite size;	chr11:125681713	chr1:158454198~158455273:+
STAD	trans	rs12497850	0.931	rs6414613	ENSG00000197582.5	GPX1P1	6.87	2.96e-11	0.00016	0.47	0.35	Parkinson's disease;	chr3:48998452	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.925	rs4955439	ENSG00000197582.5	GPX1P1	-6.87	2.97e-11	0.00016	-0.49	-0.35	Menarche (age at onset);	chr3:49208212	chrX:13378735~13379340:-
STAD	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	6.87	2.97e-11	0.00016	0.39	0.35	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
STAD	trans	rs12497850	0.897	rs9884022	ENSG00000197582.5	GPX1P1	6.87	2.99e-11	0.000162	0.46	0.35	Parkinson's disease;	chr3:48919429	chrX:13378735~13379340:-
STAD	trans	rs13253073	0.545	rs35769167	ENSG00000260318.1	COX6CP1	6.87	3.05e-11	0.000164	0.49	0.35	Glucose homeostasis traits;	chr8:99872095	chr16:11903923~11904137:-
STAD	trans	rs7647973	1	rs11928090	ENSG00000197582.5	GPX1P1	6.87	3.07e-11	0.000166	0.49	0.35	Menarche (age at onset);	chr3:49567471	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	6.86	3.11e-11	0.000168	0.45	0.35	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.536	rs1646260	ENSG00000233719.3	GOT2P3	6.86	3.13e-11	0.000169	0.4	0.35	Blood metabolite ratios;	chr16:58734951	chr12:9641802~9643007:+
STAD	trans	rs13190036	0.515	rs2878686	ENSG00000226986.4	RP11-543B16.2	-6.86	3.13e-11	0.000169	-0.36	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr1:211207239~211207897:+
STAD	trans	rs12709013	0.591	rs30841	ENSG00000233719.3	GOT2P3	6.86	3.13e-11	0.000169	0.4	0.35	Blood metabolite ratios;	chr16:58709819	chr12:9641802~9643007:+
STAD	trans	rs11220237	0.544	rs11220178	ENSG00000236257.1	EI24P2	6.86	3.19e-11	0.000172	0.51	0.35	Itch intensity from mosquito bite adjusted by bite size;	chr11:125666232	chr1:158454198~158455273:+
STAD	trans	rs66887589	0.967	rs3775842	ENSG00000275858.1	RP11-291L22.8	6.86	3.21e-11	0.000173	0.36	0.35	Diastolic blood pressure;	chr4:119506577	chr10:38450738~38451069:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000224161.3	RPS26P54	-6.86	3.24e-11	0.000175	-0.34	-0.35	Cognitive function;	chr12:56042145	chr18:59761558~59761905:+
STAD	trans	rs16937956	0.626	rs34922792	ENSG00000266891.1	RP11-692N5.2	6.85	3.31e-11	0.000179	0.44	0.35	Body mass index;	chr11:8394952	chr18:9734882~9735602:-
STAD	trans	rs4834770	0.746	rs2389747	ENSG00000276997.3	RP11-378J18.9	6.85	3.43e-11	0.000185	0.37	0.35	Blood protein levels;	chr4:119314947	chr1:222477252~222504622:-
STAD	trans	rs4834770	0.717	rs1022146	ENSG00000276997.3	RP11-378J18.9	6.85	3.43e-11	0.000185	0.37	0.35	Blood protein levels;	chr4:119314948	chr1:222477252~222504622:-
STAD	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	6.85	3.47e-11	0.000187	0.5	0.35	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	6.85	3.48e-11	0.000187	0.45	0.35	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
STAD	trans	rs916888	0.821	rs199506	ENSG00000204650.12	CRHR1-IT1	-6.84	3.52e-11	0.000189	-0.53	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45620328~45648216:+
STAD	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	6.84	3.53e-11	0.00019	0.46	0.35	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
STAD	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-6.84	3.53e-11	0.00019	-0.35	-0.35	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
STAD	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	6.84	3.61e-11	0.000194	0.46	0.35	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	6.84	3.61e-11	0.000194	0.46	0.35	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	6.84	3.61e-11	0.000194	0.46	0.35	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	6.84	3.61e-11	0.000194	0.46	0.35	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
STAD	trans	rs16937956	0.597	rs4584570	ENSG00000266891.1	RP11-692N5.2	6.84	3.62e-11	0.000194	0.44	0.35	Body mass index;	chr11:8384489	chr18:9734882~9735602:-
STAD	trans	rs16937956	0.597	rs2311434	ENSG00000266891.1	RP11-692N5.2	6.84	3.62e-11	0.000194	0.44	0.35	Body mass index;	chr11:8384502	chr18:9734882~9735602:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000234354.3	RPS26P47	6.84	3.65e-11	0.000196	0.46	0.35	Cognitive function;	chr12:55988132	chr13:100539901~100540248:-
STAD	trans	rs12709013	0.591	rs4410065	ENSG00000233719.3	GOT2P3	6.84	3.65e-11	0.000196	0.4	0.35	Blood metabolite ratios;	chr16:58800968	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.591	rs2406234	ENSG00000233719.3	GOT2P3	6.84	3.65e-11	0.000196	0.4	0.35	Blood metabolite ratios;	chr16:58801840	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.591	rs2086206	ENSG00000233719.3	GOT2P3	6.84	3.65e-11	0.000196	0.4	0.35	Blood metabolite ratios;	chr16:58802094	chr12:9641802~9643007:+
STAD	trans	rs13190036	0.901	rs10056655	ENSG00000217325.2	PRELID1P1	6.84	3.7e-11	0.000198	0.37	0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr6:126643488~126644390:+
STAD	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-6.84	3.7e-11	0.000199	-0.51	-0.34	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.934	rs2715016	ENSG00000276997.3	RP11-378J18.9	-6.83	3.72e-11	2e-04	-0.38	-0.34	Diastolic blood pressure;	chr4:119531201	chr1:222477252~222504622:-
STAD	trans	rs877636	0.847	rs772921	ENSG00000244641.2	RPS26P43	6.83	3.73e-11	2e-04	0.38	0.34	Cognitive function;	chr12:56009793	chr11:123049787~123050353:-
STAD	trans	rs12709013	0.569	rs30837	ENSG00000233719.3	GOT2P3	6.83	3.77e-11	0.000202	0.4	0.34	Blood metabolite ratios;	chr16:58711942	chr12:9641802~9643007:+
STAD	trans	rs9611519	0.78	rs2235852	ENSG00000268568.1	AC007228.9	-6.83	3.78e-11	0.000203	-0.42	-0.34	Neuroticism;	chr22:41265150	chr19:56672574~56673901:-
STAD	trans	rs16937956	0.657	rs35976355	ENSG00000266891.1	RP11-692N5.2	6.83	3.79e-11	0.000203	0.43	0.34	Body mass index;	chr11:8407110	chr18:9734882~9735602:-
STAD	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	6.83	3.8e-11	0.000204	0.49	0.34	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
STAD	trans	rs16937956	0.597	rs35022013	ENSG00000266891.1	RP11-692N5.2	6.83	3.83e-11	0.000205	0.44	0.34	Body mass index;	chr11:8395956	chr18:9734882~9735602:-
STAD	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	6.83	3.85e-11	0.000207	0.46	0.34	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
STAD	trans	rs11295209	1	rs11295209	ENSG00000275858.1	RP11-291L22.8	-6.83	3.89e-11	0.000208	-0.37	-0.34	Plateletcrit;	chr4:119559079	chr10:38450738~38451069:-
STAD	trans	rs3096299	0.658	rs12443705	ENSG00000215030.5	RPL13P12	-6.83	3.9e-11	0.000209	-0.3	-0.34	Multiple myeloma (IgH translocation);	chr16:89480646	chr17:17383377~17384012:-
STAD	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	6.83	3.92e-11	0.00021	0.45	0.34	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	6.83	3.92e-11	0.00021	0.47	0.34	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
STAD	trans	rs3096299	0.504	rs4785574	ENSG00000215030.5	RPL13P12	-6.83	3.95e-11	0.000211	-0.3	-0.34	Multiple myeloma (IgH translocation);	chr16:89502467	chr17:17383377~17384012:-
STAD	trans	rs12709013	0.591	rs30838	ENSG00000233719.3	GOT2P3	6.82	3.99e-11	0.000214	0.4	0.34	Blood metabolite ratios;	chr16:58711513	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.574	rs35321124	ENSG00000233719.3	GOT2P3	6.82	4e-11	0.000214	0.4	0.34	Blood metabolite ratios;	chr16:58786561	chr12:9641802~9643007:+
STAD	trans	rs8010715	0.816	rs1134340	ENSG00000238000.1	RP11-274E7.2	6.82	4.01e-11	0.000214	0.29	0.34	IgG glycosylation;	chr14:24125004	chr5:98213402~98214121:+
STAD	trans	rs8010715	0.816	rs6573573	ENSG00000238000.1	RP11-274E7.2	6.82	4.01e-11	0.000214	0.29	0.34	IgG glycosylation;	chr14:24130048	chr5:98213402~98214121:+
STAD	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	6.82	4.05e-11	0.000216	0.45	0.34	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
STAD	trans	rs11039571	0.588	rs61917001	ENSG00000134612.10	FOLH1B	6.82	4.06e-11	0.000217	0.55	0.34	D-dimer levels;	chr11:48212115	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	6.82	4.1e-11	0.000219	0.45	0.34	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
STAD	trans	rs877636	0.692	rs2271194	ENSG00000242307.1	RPS26P52	-6.82	4.11e-11	0.000219	-0.37	-0.34	Cognitive function;	chr12:56083910	chr16:13922332~13922679:-
STAD	trans	rs13190036	0.551	rs7732930	ENSG00000226986.4	RP11-543B16.2	-6.82	4.11e-11	0.000219	-0.35	-0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr1:211207239~211207897:+
STAD	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	6.82	4.14e-11	0.000221	0.45	0.34	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
STAD	trans	rs11220237	0.544	rs10893405	ENSG00000236257.1	EI24P2	6.81	4.22e-11	0.000225	0.5	0.34	Itch intensity from mosquito bite adjusted by bite size;	chr11:125641211	chr1:158454198~158455273:+
STAD	trans	rs7647973	0.961	rs7638750	ENSG00000197582.5	GPX1P1	-6.81	4.25e-11	0.000226	-0.51	-0.34	Menarche (age at onset);	chr3:49415524	chrX:13378735~13379340:-
STAD	trans	rs8067354	0.645	rs2645489	ENSG00000187870.7	RNFT1P3	6.81	4.36e-11	0.000232	0.41	0.34	Hemoglobin concentration;	chr17:59806010	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs2645486	ENSG00000187870.7	RNFT1P3	6.81	4.36e-11	0.000232	0.41	0.34	Hemoglobin concentration;	chr17:59808540	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs2645487	ENSG00000187870.7	RNFT1P3	6.81	4.36e-11	0.000232	0.41	0.34	Hemoglobin concentration;	chr17:59808764	chr17:20743333~20754501:-
STAD	trans	rs1051424	0.642	rs115869798	ENSG00000187870.7	RNFT1P3	6.81	4.36e-11	0.000232	0.41	0.34	Obesity-related traits;	chr17:59815468	chr17:20743333~20754501:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000224553.1	AC008065.1	-6.81	4.39e-11	0.000234	-0.38	-0.34	Asthma;	chr12:55970537	chr2:171374931~171375278:-
STAD	trans	rs9858542	1	rs11718165	ENSG00000197582.5	GPX1P1	-6.81	4.4e-11	0.000234	-0.5	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49659364	chrX:13378735~13379340:-
STAD	trans	rs9858542	1	rs11709525	ENSG00000197582.5	GPX1P1	-6.81	4.42e-11	0.000235	-0.51	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49653063	chrX:13378735~13379340:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000224161.3	RPS26P54	-6.81	4.44e-11	0.000236	-0.33	-0.34	Cognitive function;	chr12:56083910	chr18:59761558~59761905:+
STAD	trans	rs12497850	0.931	rs11705888	ENSG00000197582.5	GPX1P1	6.81	4.44e-11	0.000236	0.46	0.34	Parkinson's disease;	chr3:48779856	chrX:13378735~13379340:-
STAD	trans	rs877636	0.562	rs1131017	ENSG00000242307.1	RPS26P52	-6.8	4.47e-11	0.000238	-0.38	-0.34	Cognitive function;	chr12:56042145	chr16:13922332~13922679:-
STAD	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	6.8	4.48e-11	0.000238	0.45	0.34	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	6.8	4.48e-11	0.000238	0.45	0.34	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	6.8	4.48e-11	0.000238	0.45	0.34	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	6.8	4.48e-11	0.000238	0.45	0.34	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
STAD	trans	rs3770081	1	rs2012798	ENSG00000229880.1	IMMTP1	6.8	4.51e-11	0.000239	0.69	0.34	Facial emotion recognition (sad faces);	chr2:85955633	chr21:44675868~44678086:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000240427.1	RPS26P34	-6.8	4.51e-11	0.000239	-0.37	-0.34	Cognitive function;	chr12:56007301	chr8:81627269~81627617:+
STAD	trans	rs66887589	0.66	rs4833613	ENSG00000275858.1	RP11-291L22.8	-6.8	4.54e-11	0.000241	-0.36	-0.34	Diastolic blood pressure;	chr4:119229001	chr10:38450738~38451069:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000244641.2	RPS26P43	6.8	4.54e-11	0.000241	0.38	0.34	Cognitive function;	chr12:56041628	chr11:123049787~123050353:-
STAD	trans	rs11220237	0.544	rs7949943	ENSG00000236257.1	EI24P2	6.8	4.57e-11	0.000243	0.51	0.34	Itch intensity from mosquito bite adjusted by bite size;	chr11:125677765	chr1:158454198~158455273:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000244604.1	RP11-713H12.1	-6.8	4.6e-11	0.000244	-0.37	-0.34	Cognitive function;	chr12:55996852	chr17:8561230~8561576:+
STAD	trans	rs12709013	0.613	rs4238801	ENSG00000233719.3	GOT2P3	6.8	4.6e-11	0.000244	0.4	0.34	Blood metabolite ratios;	chr16:58738275	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs4575523	ENSG00000233719.3	GOT2P3	6.8	4.6e-11	0.000244	0.4	0.34	Blood metabolite ratios;	chr16:58738559	chr12:9641802~9643007:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000196933.5	RPS26P11	6.8	4.63e-11	0.000246	0.38	0.34	Cognitive function;	chr12:55975722	chrX:72044545~72044892:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000226339.1	RPS26P56	6.8	4.65e-11	0.000247	0.39	0.34	Cognitive function;	chr12:56002984	chrX:129408382~129408621:+
STAD	trans	rs12709013	0.636	rs967852	ENSG00000233719.3	GOT2P3	6.8	4.66e-11	0.000247	0.4	0.34	Blood metabolite ratios;	chr16:58807313	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.591	rs7184377	ENSG00000233719.3	GOT2P3	6.8	4.66e-11	0.000247	0.4	0.34	Blood metabolite ratios;	chr16:58808765	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.613	rs6499984	ENSG00000233719.3	GOT2P3	6.8	4.66e-11	0.000247	0.4	0.34	Blood metabolite ratios;	chr16:58810209	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.574	rs9302706	ENSG00000233719.3	GOT2P3	6.8	4.66e-11	0.000247	0.4	0.34	Blood metabolite ratios;	chr16:58812060	chr12:9641802~9643007:+
STAD	trans	rs1051424	0.651	rs1292063	ENSG00000187870.7	RNFT1P3	-6.8	4.7e-11	0.000249	-0.41	-0.34	Obesity-related traits;	chr17:59830407	chr17:20743333~20754501:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000225071.1	GS1-184P14.2	-6.8	4.71e-11	0.000249	-0.33	-0.34	Asthma;	chr12:55970537	chrX:24429573~24429920:-
STAD	trans	rs7647973	1	rs6805609	ENSG00000197582.5	GPX1P1	-6.8	4.73e-11	0.000251	-0.53	-0.34	Menarche (age at onset);	chr3:49434089	chrX:13378735~13379340:-
STAD	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-6.8	4.74e-11	0.000251	-0.37	-0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
STAD	trans	rs7647973	0.925	rs6769821	ENSG00000197582.5	GPX1P1	6.79	4.77e-11	0.000253	0.5	0.34	Menarche (age at onset);	chr3:49207224	chrX:13378735~13379340:-
STAD	trans	rs877636	0.809	rs1689510	ENSG00000244641.2	RPS26P43	6.79	4.79e-11	0.000254	0.38	0.34	Cognitive function;	chr12:56002984	chr11:123049787~123050353:-
STAD	trans	rs10037055	0.741	rs4976640	ENSG00000226986.4	RP11-543B16.2	-6.79	4.88e-11	0.000258	-0.33	-0.34	Migraine without aura;	chr5:177125006	chr1:211207239~211207897:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000244641.2	RPS26P43	6.79	4.93e-11	0.000261	0.37	0.34	Cognitive function;	chr12:56041720	chr11:123049787~123050353:-
STAD	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-6.79	4.93e-11	0.000261	-0.45	-0.34	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
STAD	trans	rs66887589	0.934	rs6817317	ENSG00000276997.3	RP11-378J18.9	-6.79	4.95e-11	0.000262	-0.36	-0.34	Diastolic blood pressure;	chr4:119621672	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.934	rs7672519	ENSG00000276997.3	RP11-378J18.9	-6.79	4.95e-11	0.000262	-0.36	-0.34	Diastolic blood pressure;	chr4:119622957	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.87	rs59590064	ENSG00000276997.3	RP11-378J18.9	-6.79	4.96e-11	0.000262	-0.36	-0.34	Diastolic blood pressure;	chr4:119618598	chr1:222477252~222504622:-
STAD	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	6.79	4.98e-11	0.000264	0.37	0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
STAD	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	6.79	4.99e-11	0.000264	0.45	0.34	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	6.79	4.99e-11	0.000264	0.45	0.34	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	6.79	4.99e-11	0.000264	0.45	0.34	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
STAD	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-6.79	5e-11	0.000264	-0.37	-0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
STAD	trans	rs7312770	1	rs7312770	ENSG00000244641.2	RPS26P43	-6.79	5.04e-11	0.000266	-0.32	-0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr11:123049787~123050353:-
STAD	trans	rs10816533	1	rs10117162	ENSG00000232063.1	RP11-307E17.8	6.78	5.06e-11	0.000267	0.61	0.34	Height;	chr9:96841714	chr9:94332476~94360948:+
STAD	trans	rs12709013	0.536	rs9930758	ENSG00000233719.3	GOT2P3	6.78	5.09e-11	0.000269	0.4	0.34	Blood metabolite ratios;	chr16:58803167	chr12:9641802~9643007:+
STAD	trans	rs10037055	0.853	rs10036193	ENSG00000226986.4	RP11-543B16.2	-6.78	5.1e-11	0.000269	-0.33	-0.34	Migraine without aura;	chr5:177141519	chr1:211207239~211207897:+
STAD	trans	rs10037055	0.853	rs9885210	ENSG00000226986.4	RP11-543B16.2	-6.78	5.1e-11	0.000269	-0.33	-0.34	Migraine without aura;	chr5:177142187	chr1:211207239~211207897:+
STAD	trans	rs877636	1	rs877636	ENSG00000219993.1	RP11-288G3.3	-6.78	5.1e-11	0.000269	-0.36	-0.34	Cognitive function;	chr12:56086799	chr6:7506203~7506549:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000244641.2	RPS26P43	6.78	5.22e-11	0.000275	0.38	0.34	Cognitive function;	chr12:56023144	chr11:123049787~123050353:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000234192.1	RP11-57C13.5	6.78	5.25e-11	0.000277	0.38	0.34	Cognitive function;	chr12:55990903	chr10:87642607~87642954:+
STAD	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-6.78	5.27e-11	0.000278	-0.46	-0.34	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.591	rs30840	ENSG00000233719.3	GOT2P3	6.78	5.27e-11	0.000278	0.39	0.34	Blood metabolite ratios;	chr16:58710165	chr12:9641802~9643007:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000242970.2	AC068522.4	-6.78	5.27e-11	0.000278	-0.36	-0.34	Cognitive function;	chr12:55996852	chr8:58588420~58588764:-
STAD	trans	rs12497850	0.931	rs13064784	ENSG00000197582.5	GPX1P1	6.78	5.28e-11	0.000278	0.45	0.34	Parkinson's disease;	chr3:49098528	chrX:13378735~13379340:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000244641.2	RPS26P43	6.78	5.32e-11	0.000281	0.38	0.34	Cognitive function;	chr12:56013288	chr11:123049787~123050353:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000244641.2	RPS26P43	6.78	5.32e-11	0.000281	0.38	0.34	Cognitive function;	chr12:56018703	chr11:123049787~123050353:-
STAD	trans	rs66887589	0.967	rs6844263	ENSG00000275858.1	RP11-291L22.8	6.78	5.33e-11	0.000281	0.36	0.34	Diastolic blood pressure;	chr4:119512652	chr10:38450738~38451069:-
STAD	trans	rs12709013	0.576	rs2432622	ENSG00000233719.3	GOT2P3	6.77	5.41e-11	0.000285	0.4	0.34	Blood metabolite ratios;	chr16:58749681	chr12:9641802~9643007:+
STAD	trans	rs10037055	0.812	rs11949435	ENSG00000226986.4	RP11-543B16.2	6.77	5.66e-11	0.000298	0.33	0.34	Migraine without aura;	chr5:177287931	chr1:211207239~211207897:+
STAD	trans	rs66887589	0.776	rs10518337	ENSG00000276997.3	RP11-378J18.9	-6.76	5.7e-11	3e-04	-0.36	-0.34	Diastolic blood pressure;	chr4:119653719	chr1:222477252~222504622:-
STAD	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-6.76	5.71e-11	3e-04	-0.49	-0.34	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
STAD	trans	rs12709013	0.591	rs9932967	ENSG00000233719.3	GOT2P3	6.76	5.71e-11	3e-04	0.4	0.34	Blood metabolite ratios;	chr16:58805583	chr12:9641802~9643007:+
STAD	trans	rs916888	0.821	rs70600	ENSG00000204650.12	CRHR1-IT1	6.76	5.79e-11	0.000304	0.53	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45620328~45648216:+
STAD	trans	rs66887589	1	rs66887589	ENSG00000275858.1	RP11-291L22.8	-6.76	5.92e-11	0.000311	-0.36	-0.34	Diastolic blood pressure;	chr4:119588124	chr10:38450738~38451069:-
STAD	trans	rs877636	0.702	rs773108	ENSG00000234354.3	RPS26P47	6.76	5.94e-11	0.000312	0.46	0.34	Cognitive function;	chr12:55976127	chr13:100539901~100540248:-
STAD	trans	rs702485	0.84	rs836478	ENSG00000249936.3	RAC1P2	-6.76	6.02e-11	0.000316	-0.3	-0.34	HDL cholesterol levels;HDL cholesterol;	chr7:6392059	chr4:46723830~46724408:-
STAD	trans	rs10815468	0.624	rs7045291	ENSG00000215210.3	RBMXP2	6.76	6.03e-11	0.000316	0.38	0.34	Bipolar disorder and schizophrenia;	chr9:6786418	chr9:30689105~30690272:+
STAD	trans	rs12709013	0.535	rs9924136	ENSG00000233719.3	GOT2P3	6.76	6.06e-11	0.000318	0.4	0.34	Blood metabolite ratios;	chr16:58779573	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	6.75	6.14e-11	0.000322	0.45	0.34	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
STAD	trans	rs16937956	0.657	rs3751095	ENSG00000266891.1	RP11-692N5.2	6.75	6.19e-11	0.000324	0.43	0.34	Body mass index;	chr11:8413530	chr18:9734882~9735602:-
STAD	trans	rs16937956	0.657	rs3751096	ENSG00000266891.1	RP11-692N5.2	6.75	6.19e-11	0.000324	0.43	0.34	Body mass index;	chr11:8413531	chr18:9734882~9735602:-
STAD	trans	rs11220082	0.787	rs11220064	ENSG00000236257.1	EI24P2	-6.75	6.2e-11	0.000325	-0.44	-0.34	Schizophrenia;	chr11:125424186	chr1:158454198~158455273:+
STAD	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	6.75	6.23e-11	0.000326	0.45	0.34	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	6.75	6.23e-11	0.000326	0.45	0.34	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
STAD	trans	rs16937956	0.597	rs72852616	ENSG00000266891.1	RP11-692N5.2	6.75	6.25e-11	0.000328	0.43	0.34	Body mass index;	chr11:8385339	chr18:9734882~9735602:-
STAD	trans	rs16937956	0.597	rs12788149	ENSG00000266891.1	RP11-692N5.2	6.75	6.25e-11	0.000328	0.43	0.34	Body mass index;	chr11:8385383	chr18:9734882~9735602:-
STAD	trans	rs12497850	0.931	rs7626445	ENSG00000197582.5	GPX1P1	6.75	6.33e-11	0.000332	0.45	0.34	Parkinson's disease;	chr3:49077111	chrX:13378735~13379340:-
STAD	trans	rs11220237	0.764	rs7940086	ENSG00000236257.1	EI24P2	6.75	6.37e-11	0.000334	0.53	0.34	Itch intensity from mosquito bite adjusted by bite size;	chr11:125722518	chr1:158454198~158455273:+
STAD	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	6.74	6.57e-11	0.000344	0.46	0.34	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	6.74	6.63e-11	0.000347	0.45	0.34	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
STAD	trans	rs10816533	1	rs10119556	ENSG00000232063.1	RP11-307E17.8	6.74	6.68e-11	0.000349	0.6	0.34	Height;	chr9:96789704	chr9:94332476~94360948:+
STAD	trans	rs877636	0.74	rs705698	ENSG00000224553.1	AC008065.1	6.74	6.69e-11	0.00035	0.39	0.34	Cognitive function;	chr12:55990903	chr2:171374931~171375278:-
STAD	trans	rs16937956	0.597	rs12788830	ENSG00000266891.1	RP11-692N5.2	6.74	6.71e-11	0.00035	0.44	0.34	Body mass index;	chr11:8380429	chr18:9734882~9735602:-
STAD	trans	rs16937956	0.597	rs12793685	ENSG00000266891.1	RP11-692N5.2	6.74	6.71e-11	0.00035	0.44	0.34	Body mass index;	chr11:8380583	chr18:9734882~9735602:-
STAD	trans	rs2727020	0.688	rs2734002	ENSG00000134612.10	FOLH1B	6.74	6.75e-11	0.000352	0.4	0.34	Coronary artery disease;	chr11:49212610	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.612	rs603672	ENSG00000134612.10	FOLH1B	6.74	6.75e-11	0.000352	0.4	0.34	Coronary artery disease;	chr11:49213014	chr11:89639227~89698718:+
STAD	trans	rs877636	1	rs705696	ENSG00000226339.1	RPS26P56	6.74	6.77e-11	0.000354	0.37	0.34	Cognitive function;	chr12:56086864	chrX:129408382~129408621:+
STAD	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	6.73	6.85e-11	0.000357	0.45	0.34	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
STAD	trans	rs1336472	0.615	rs11208611	ENSG00000263535.1	AK4P1	6.73	6.89e-11	0.000359	0.46	0.34	Venous thromboembolism (SNP x SNP interaction);	chr1:65218742	chr17:31345521~31346187:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000243328.1	RP11-520P18.1	-6.73	6.9e-11	0.00036	-0.34	-0.34	Cognitive function;	chr12:56042145	chr8:143065915~143066587:-
STAD	trans	rs9858542	1	rs4283605	ENSG00000197582.5	GPX1P1	-6.73	6.92e-11	0.000361	-0.51	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49641218	chrX:13378735~13379340:-
STAD	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-6.73	7.02e-11	0.000366	-0.43	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
STAD	trans	rs10037055	0.853	rs9313749	ENSG00000226986.4	RP11-543B16.2	-6.73	7.07e-11	0.000369	-0.33	-0.34	Migraine without aura;	chr5:177170693	chr1:211207239~211207897:+
STAD	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-6.73	7.08e-11	0.000369	-0.35	-0.34	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
STAD	trans	rs877636	1	rs4759229	ENSG00000219993.1	RP11-288G3.3	-6.73	7.09e-11	0.00037	-0.36	-0.34	Cognitive function;	chr12:56080696	chr6:7506203~7506549:+
STAD	trans	rs877636	0.702	rs773109	ENSG00000234354.3	RPS26P47	6.73	7.11e-11	0.00037	0.45	0.34	Cognitive function;	chr12:55980911	chr13:100539901~100540248:-
STAD	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	6.73	7.11e-11	0.000371	0.45	0.34	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
STAD	trans	rs13190036	1	rs625882	ENSG00000226986.4	RP11-543B16.2	-6.73	7.12e-11	0.000371	-0.36	-0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr1:211207239~211207897:+
STAD	trans	rs216303	0.642	rs216315	ENSG00000241717.1	VWFP1	6.73	7.18e-11	0.000374	0.46	0.34	Low vWF levels;	chr12:6027748	chr22:16690103~16704477:-
STAD	trans	rs10816533	1	rs12237908	ENSG00000232063.1	RP11-307E17.8	6.73	7.18e-11	0.000374	0.6	0.34	Height;	chr9:96821112	chr9:94332476~94360948:+
STAD	trans	rs10037055	0.853	rs12660023	ENSG00000226986.4	RP11-543B16.2	6.73	7.2e-11	0.000375	0.33	0.34	Migraine without aura;	chr5:177273884	chr1:211207239~211207897:+
STAD	trans	rs10037055	0.853	rs4976680	ENSG00000226986.4	RP11-543B16.2	6.72	7.29e-11	0.000379	0.33	0.34	Migraine without aura;	chr5:177275745	chr1:211207239~211207897:+
STAD	trans	rs10037055	0.853	rs4976681	ENSG00000226986.4	RP11-543B16.2	6.72	7.29e-11	0.000379	0.33	0.34	Migraine without aura;	chr5:177277662	chr1:211207239~211207897:+
STAD	trans	rs10028773	0.546	rs13117947	ENSG00000276997.3	RP11-378J18.9	6.72	7.29e-11	0.000379	0.36	0.34	Educational attainment;	chr4:119335905	chr1:222477252~222504622:-
STAD	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	6.72	7.35e-11	0.000382	0.45	0.34	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.645	rs28516945	ENSG00000187870.7	RNFT1P3	6.72	7.4e-11	0.000385	0.41	0.34	Hemoglobin concentration;	chr17:59739217	chr17:20743333~20754501:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000212994.5	RPS26P6	6.72	7.42e-11	0.000386	0.34	0.34	Cognitive function;	chr12:55990903	chr8:100895771~100896118:+
STAD	trans	rs702485	0.933	rs836559	ENSG00000249936.3	RAC1P2	6.72	7.43e-11	0.000386	0.31	0.34	HDL cholesterol levels;HDL cholesterol;	chr7:6409132	chr4:46723830~46724408:-
STAD	trans	rs2727020	0.664	rs4929893	ENSG00000134612.10	FOLH1B	-6.72	7.45e-11	0.000387	-0.4	-0.34	Coronary artery disease;	chr11:49174780	chr11:89639227~89698718:+
STAD	trans	rs12497850	0.931	rs9840050	ENSG00000197582.5	GPX1P1	6.72	7.52e-11	0.000391	0.45	0.34	Parkinson's disease;	chr3:49095877	chrX:13378735~13379340:-
STAD	trans	rs877636	0.74	rs772920	ENSG00000234354.3	RPS26P47	6.72	7.58e-11	0.000394	0.44	0.34	Cognitive function;	chr12:55996580	chr13:100539901~100540248:-
STAD	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	6.72	7.59e-11	0.000394	0.49	0.34	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
STAD	trans	rs12497850	0.897	rs6781790	ENSG00000197582.5	GPX1P1	6.72	7.63e-11	0.000396	0.45	0.34	Parkinson's disease;	chr3:49007334	chrX:13378735~13379340:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000240427.1	RPS26P34	-6.72	7.65e-11	0.000397	-0.35	-0.34	Cognitive function;	chr12:56083910	chr8:81627269~81627617:+
STAD	trans	rs9329221	0.905	rs10283145	ENSG00000253981.4	ALG1L13P	-6.71	7.75e-11	0.000402	-0.45	-0.34	Neuroticism;	chr8:10383901	chr8:8236003~8244667:-
STAD	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	6.71	7.81e-11	0.000405	0.43	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
STAD	trans	rs12709013	0.636	rs1646281	ENSG00000233719.3	GOT2P3	6.71	7.86e-11	0.000408	0.4	0.34	Blood metabolite ratios;	chr16:58750512	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.613	rs1618602	ENSG00000233719.3	GOT2P3	6.71	7.86e-11	0.000408	0.4	0.34	Blood metabolite ratios;	chr16:58756080	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.613	rs8049462	ENSG00000233719.3	GOT2P3	6.71	7.86e-11	0.000408	0.4	0.34	Blood metabolite ratios;	chr16:58757654	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.66	rs257629	ENSG00000233719.3	GOT2P3	6.71	7.86e-11	0.000408	0.4	0.34	Blood metabolite ratios;	chr16:58758044	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	6.71	7.87e-11	0.000408	0.45	0.34	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	6.71	7.87e-11	0.000408	0.45	0.34	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.636	rs8045466	ENSG00000233719.3	GOT2P3	6.71	8.03e-11	0.000417	0.39	0.34	Blood metabolite ratios;	chr16:58765113	chr12:9641802~9643007:+
STAD	trans	rs8067354	0.645	rs9910518	ENSG00000187870.7	RNFT1P3	6.71	8.07e-11	0.000418	0.41	0.34	Hemoglobin concentration;	chr17:59734706	chr17:20743333~20754501:-
STAD	trans	rs7554511	0.858	rs10920084	ENSG00000244144.1	RP11-757F18.3	-6.71	8.11e-11	0.00042	-0.33	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993667	chr3:112185480~112185998:-
STAD	trans	rs3096299	0.719	rs12934708	ENSG00000215030.5	RPL13P12	-6.71	8.13e-11	0.000421	-0.3	-0.34	Multiple myeloma (IgH translocation);	chr16:89457382	chr17:17383377~17384012:-
STAD	trans	rs916888	0.821	rs199514	ENSG00000204650.12	CRHR1-IT1	-6.71	8.13e-11	0.000422	-0.52	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45620328~45648216:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000224161.3	RPS26P54	-6.71	8.18e-11	0.000424	-0.32	-0.34	Cognitive function;	chr12:56084218	chr18:59761558~59761905:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000224161.3	RPS26P54	-6.71	8.18e-11	0.000424	-0.32	-0.34	Cognitive function;	chr12:56084874	chr18:59761558~59761905:+
STAD	trans	rs9858542	1	rs9812791	ENSG00000197582.5	GPX1P1	-6.71	8.21e-11	0.000425	-0.5	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49644878	chrX:13378735~13379340:-
STAD	trans	rs9858542	1	rs13316695	ENSG00000197582.5	GPX1P1	-6.71	8.21e-11	0.000425	-0.5	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49647484	chrX:13378735~13379340:-
STAD	trans	rs9858542	1	rs6770670	ENSG00000197582.5	GPX1P1	-6.71	8.21e-11	0.000425	-0.5	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49649249	chrX:13378735~13379340:-
STAD	trans	rs9858542	1	rs34762726	ENSG00000197582.5	GPX1P1	-6.71	8.21e-11	0.000425	-0.5	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49651777	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.904	rs7293482	ENSG00000231752.4	EMBP1	6.7	8.47e-11	0.000438	0.46	0.34	P wave duration;	chr5:46003984	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.967	rs35648163	ENSG00000231752.4	EMBP1	6.7	8.51e-11	0.00044	0.46	0.34	P wave duration;	chr5:45945778	chr1:121519112~121571892:+
STAD	trans	rs66887589	0.967	rs1480933	ENSG00000275858.1	RP11-291L22.8	6.7	8.56e-11	0.000443	0.36	0.34	Diastolic blood pressure;	chr4:119512093	chr10:38450738~38451069:-
STAD	trans	rs8067354	0.645	rs56236317	ENSG00000187870.7	RNFT1P3	6.7	8.58e-11	0.000444	0.41	0.34	Hemoglobin concentration;	chr17:59744764	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs7215180	ENSG00000187870.7	RNFT1P3	6.7	8.58e-11	0.000444	0.41	0.34	Hemoglobin concentration;	chr17:59744993	chr17:20743333~20754501:-
STAD	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	6.7	8.6e-11	0.000445	0.45	0.34	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
STAD	trans	rs7930295	0.632	rs12099165	ENSG00000236257.1	EI24P2	6.7	8.61e-11	0.000445	0.54	0.34	Schizophrenia;	chr11:125770546	chr1:158454198~158455273:+
STAD	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-6.7	8.63e-11	0.000446	-0.45	-0.34	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	6.7	8.64e-11	0.000447	0.45	0.34	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000219993.1	RP11-288G3.3	-6.7	8.68e-11	0.000448	-0.36	-0.34	Cognitive function;	chr12:56080595	chr6:7506203~7506549:+
STAD	trans	rs8010715	0.816	rs762093	ENSG00000238000.1	RP11-274E7.2	6.69	8.9e-11	0.000459	0.29	0.34	IgG glycosylation;	chr14:24122709	chr5:98213402~98214121:+
STAD	trans	rs916888	0.821	rs199512	ENSG00000204650.12	CRHR1-IT1	-6.69	9.04e-11	0.000466	-0.51	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45620328~45648216:+
STAD	trans	rs916888	0.821	rs199509	ENSG00000204650.12	CRHR1-IT1	-6.69	9.04e-11	0.000466	-0.51	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45620328~45648216:+
STAD	trans	rs916888	0.821	rs199507	ENSG00000204650.12	CRHR1-IT1	-6.69	9.04e-11	0.000466	-0.51	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45620328~45648216:+
STAD	trans	rs916888	0.821	rs199505	ENSG00000204650.12	CRHR1-IT1	-6.69	9.04e-11	0.000466	-0.51	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45620328~45648216:+
STAD	trans	rs916888	0.821	rs70602	ENSG00000204650.12	CRHR1-IT1	-6.69	9.04e-11	0.000466	-0.51	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45620328~45648216:+
STAD	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-6.69	9.22e-11	0.000475	-0.44	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
STAD	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-6.69	9.22e-11	0.000475	-0.44	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000226339.1	RPS26P56	6.68	9.29e-11	0.000478	0.38	0.34	Cognitive function;	chr12:56009793	chrX:129408382~129408621:+
STAD	trans	rs1814175	0.538	rs1684260	ENSG00000134612.10	FOLH1B	6.68	9.32e-11	0.00048	0.4	0.34	Height;	chr11:49202679	chr11:89639227~89698718:+
STAD	trans	rs2069408	1	rs2069408	ENSG00000212829.8	RPS26P3	-6.68	9.53e-11	0.00049	-0.34	-0.34	Asthma;	chr12:55970537	chr9:9090898~9091245:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000229032.1	RP11-91A18.1	-6.68	9.54e-11	0.000491	-0.36	-0.34	Cognitive function;	chr12:56007301	chr1:51980473~51980814:+
STAD	trans	rs9858542	1	rs9858542	ENSG00000197582.5	GPX1P1	6.68	9.57e-11	0.000492	0.5	0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49664550	chrX:13378735~13379340:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000229032.1	RP11-91A18.1	-6.68	9.59e-11	0.000493	-0.35	-0.34	Cognitive function;	chr12:56083910	chr1:51980473~51980814:+
STAD	trans	rs2727020	0.729	rs2299650	ENSG00000134612.10	FOLH1B	-6.68	9.67e-11	0.000497	-0.4	-0.34	Coronary artery disease;	chr11:49152455	chr11:89639227~89698718:+
STAD	trans	rs7113874	0.592	rs10840057	ENSG00000266891.1	RP11-692N5.2	6.68	9.73e-11	5e-04	0.48	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8476681	chr18:9734882~9735602:-
STAD	trans	rs9858542	1	rs2172252	ENSG00000197582.5	GPX1P1	-6.67	9.91e-11	0.000509	-0.51	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49640874	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	6.67	9.98e-11	0.000513	0.44	0.34	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	6.67	9.98e-11	0.000513	0.44	0.34	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
STAD	trans	rs66887589	0.934	rs2715016	ENSG00000275858.1	RP11-291L22.8	-6.67	1.01e-10	0.000516	-0.37	-0.34	Diastolic blood pressure;	chr4:119531201	chr10:38450738~38451069:-
STAD	trans	rs877636	0.692	rs2271194	ENSG00000244641.2	RPS26P43	-6.67	1.01e-10	0.000517	-0.32	-0.34	Cognitive function;	chr12:56083910	chr11:123049787~123050353:-
STAD	trans	rs4276421	0.935	rs4502836	ENSG00000231752.4	EMBP1	6.67	1.01e-10	0.000518	0.46	0.34	P wave duration;	chr5:45956617	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs1615326	ENSG00000230849.2	GOT2P2	6.67	1.02e-10	0.000522	0.36	0.34	Blood metabolite ratios;	chr16:58747148	chr1:173141100~173142350:-
STAD	trans	rs916888	0.821	rs199504	ENSG00000204650.12	CRHR1-IT1	-6.67	1.02e-10	0.000525	-0.51	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45620328~45648216:+
STAD	trans	rs66887589	0.967	rs13104219	ENSG00000275858.1	RP11-291L22.8	6.67	1.03e-10	0.000526	0.36	0.34	Diastolic blood pressure;	chr4:119517019	chr10:38450738~38451069:-
STAD	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	6.67	1.03e-10	0.000529	0.4	0.34	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
STAD	trans	rs3096299	0.685	rs4785676	ENSG00000215030.5	RPL13P12	-6.67	1.03e-10	0.00053	-0.29	-0.34	Multiple myeloma (IgH translocation);	chr16:89487216	chr17:17383377~17384012:-
STAD	trans	rs4276421	0.839	rs28885449	ENSG00000231752.4	EMBP1	6.67	1.03e-10	0.00053	0.46	0.34	P wave duration;	chr5:45994103	chr1:121519112~121571892:+
STAD	trans	rs2727020	0.566	rs10839234	ENSG00000134612.10	FOLH1B	-6.67	1.04e-10	0.000535	-0.4	-0.34	Coronary artery disease;	chr11:49163972	chr11:89639227~89698718:+
STAD	trans	rs66887589	0.967	rs56173225	ENSG00000275858.1	RP11-291L22.8	-6.67	1.04e-10	0.000535	-0.35	-0.34	Diastolic blood pressure;	chr4:119588817	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.967	rs7678973	ENSG00000275858.1	RP11-291L22.8	-6.67	1.04e-10	0.000535	-0.35	-0.34	Diastolic blood pressure;	chr4:119590662	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.934	rs56843000	ENSG00000275858.1	RP11-291L22.8	-6.67	1.04e-10	0.000535	-0.35	-0.34	Diastolic blood pressure;	chr4:119595442	chr10:38450738~38451069:-
STAD	trans	rs12138950	0.681	rs10917468	ENSG00000224237.1	MINOS1P3	-6.66	1.06e-10	0.000542	-0.45	-0.34	Hypothyroidism;Thyroid volume;	chr1:19516860	chr3:27214816~27215018:-
STAD	trans	rs10037055	1	rs6886255	ENSG00000226986.4	RP11-543B16.2	6.66	1.06e-10	0.000544	0.32	0.34	Migraine without aura;	chr5:177291360	chr1:211207239~211207897:+
STAD	trans	rs12497850	0.931	rs6791542	ENSG00000197582.5	GPX1P1	6.66	1.07e-10	0.000548	0.44	0.34	Parkinson's disease;	chr3:48749786	chrX:13378735~13379340:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000244641.2	RPS26P43	6.66	1.08e-10	0.000551	0.33	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr11:123049787~123050353:-
STAD	trans	rs702485	0.712	rs836551	ENSG00000249936.3	RAC1P2	6.66	1.09e-10	0.000557	0.31	0.34	HDL cholesterol levels;HDL cholesterol;	chr7:6402168	chr4:46723830~46724408:-
STAD	trans	rs11220082	0.698	rs35285862	ENSG00000236257.1	EI24P2	-6.65	1.11e-10	0.000569	-0.44	-0.34	Schizophrenia;	chr11:125435199	chr1:158454198~158455273:+
STAD	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-6.65	1.12e-10	0.000574	-0.46	-0.34	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	6.65	1.12e-10	0.000574	0.46	0.34	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.645	rs9901606	ENSG00000187870.7	RNFT1P3	6.65	1.12e-10	0.000575	0.41	0.34	Hemoglobin concentration;	chr17:59734046	chr17:20743333~20754501:-
STAD	trans	rs12497850	1	rs12493578	ENSG00000197582.5	GPX1P1	-6.65	1.15e-10	0.000587	-0.47	-0.34	Parkinson's disease;	chr3:48692683	chrX:13378735~13379340:-
STAD	trans	rs7113874	0.625	rs16938253	ENSG00000266891.1	RP11-692N5.2	6.65	1.16e-10	0.000593	0.48	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478833	chr18:9734882~9735602:-
STAD	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	6.64	1.19e-10	0.000605	0.45	0.34	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	6.64	1.19e-10	0.000605	0.45	0.34	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.681	rs9907923	ENSG00000187870.7	RNFT1P3	6.64	1.2e-10	0.000609	0.41	0.34	Hemoglobin concentration;	chr17:59747566	chr17:20743333~20754501:-
STAD	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	6.64	1.2e-10	0.00061	0.36	0.34	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
STAD	trans	rs702485	0.933	rs836558	ENSG00000249936.3	RAC1P2	6.64	1.2e-10	0.000612	0.31	0.34	HDL cholesterol levels;HDL cholesterol;	chr7:6408360	chr4:46723830~46724408:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000226339.1	RPS26P56	6.64	1.2e-10	0.000613	0.38	0.34	Cognitive function;	chr12:56041720	chrX:129408382~129408621:+
STAD	trans	rs8067354	0.645	rs11079389	ENSG00000187870.7	RNFT1P3	6.64	1.21e-10	0.000616	0.41	0.34	Hemoglobin concentration;	chr17:59810591	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs2665403	ENSG00000187870.7	RNFT1P3	6.64	1.21e-10	0.000616	0.41	0.34	Hemoglobin concentration;	chr17:59812624	chr17:20743333~20754501:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000226339.1	RPS26P56	6.64	1.22e-10	0.00062	0.38	0.34	Cognitive function;	chr12:56023144	chrX:129408382~129408621:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000234354.3	RPS26P47	-6.64	1.24e-10	0.000631	-0.43	-0.34	Cognitive function;	chr12:55996852	chr13:100539901~100540248:-
STAD	trans	rs3770081	1	rs12617717	ENSG00000229880.1	IMMTP1	6.63	1.26e-10	0.000639	0.7	0.34	Facial emotion recognition (sad faces);	chr2:86115180	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs2303339	ENSG00000229880.1	IMMTP1	-6.63	1.26e-10	0.000639	-0.7	-0.34	Facial emotion recognition (sad faces);	chr2:86119057	chr21:44675868~44678086:-
STAD	trans	rs66887589	0.967	rs2892869	ENSG00000275858.1	RP11-291L22.8	-6.63	1.27e-10	0.000643	-0.35	-0.34	Diastolic blood pressure;	chr4:119600142	chr10:38450738~38451069:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000226339.1	RPS26P56	6.63	1.29e-10	0.000653	0.38	0.34	Cognitive function;	chr12:56050848	chrX:129408382~129408621:+
STAD	trans	rs11220237	0.764	rs34125226	ENSG00000236257.1	EI24P2	6.63	1.31e-10	0.000665	0.55	0.34	Itch intensity from mosquito bite adjusted by bite size;	chr11:125738705	chr1:158454198~158455273:+
STAD	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	6.63	1.32e-10	0.000669	0.39	0.34	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
STAD	trans	rs13190036	0.551	rs9313751	ENSG00000226986.4	RP11-543B16.2	-6.63	1.32e-10	0.000669	-0.35	-0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr1:211207239~211207897:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000226339.1	RPS26P56	6.63	1.32e-10	0.000669	0.38	0.34	Cognitive function;	chr12:56013288	chrX:129408382~129408621:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000226339.1	RPS26P56	6.63	1.32e-10	0.000669	0.38	0.34	Cognitive function;	chr12:56018703	chrX:129408382~129408621:+
STAD	trans	rs877636	0.562	rs1131017	ENSG00000231366.1	RP11-399N22.3	-6.62	1.34e-10	0.000676	-0.36	-0.34	Cognitive function;	chr12:56042145	chr10:70794230~70794523:-
STAD	trans	rs877636	1	rs877636	ENSG00000244641.2	RPS26P43	-6.62	1.36e-10	0.000687	-0.34	-0.34	Cognitive function;	chr12:56086799	chr11:123049787~123050353:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000226339.1	RPS26P56	6.62	1.37e-10	0.000695	0.34	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:129408382~129408621:+
STAD	trans	rs9858542	0.953	rs9824092	ENSG00000197582.5	GPX1P1	-6.62	1.38e-10	0.000698	-0.5	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49636714	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs9862080	ENSG00000197582.5	GPX1P1	-6.62	1.38e-10	0.000698	-0.5	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637025	chrX:13378735~13379340:-
STAD	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	6.62	1.4e-10	0.000705	0.35	0.34	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000243538.1	CTB-55B8.1	6.62	1.41e-10	0.000712	0.38	0.34	Cognitive function;	chr12:55975722	chr5:16902294~16902641:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000233278.1	RPS26P2	6.61	1.42e-10	0.000717	0.37	0.34	Cognitive function;	chr12:55981956	chr9:30831878~30832225:-
STAD	trans	rs12709013	0.591	rs30842	ENSG00000233719.3	GOT2P3	-6.61	1.44e-10	0.000726	-0.38	-0.33	Blood metabolite ratios;	chr16:58709550	chr12:9641802~9643007:+
STAD	trans	rs216303	0.642	rs216318	ENSG00000241717.1	VWFP1	6.61	1.45e-10	0.00073	0.46	0.33	Low vWF levels;	chr12:6030095	chr22:16690103~16704477:-
STAD	trans	rs9858542	1	rs9836291	ENSG00000197582.5	GPX1P1	-6.61	1.46e-10	0.000735	-0.5	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49660026	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.934	rs2389873	ENSG00000276997.3	RP11-378J18.9	-6.61	1.47e-10	0.000741	-0.35	-0.33	Diastolic blood pressure;	chr4:119633559	chr1:222477252~222504622:-
STAD	trans	rs66887589	0.934	rs4834792	ENSG00000276997.3	RP11-378J18.9	-6.61	1.47e-10	0.000741	-0.35	-0.33	Diastolic blood pressure;	chr4:119634541	chr1:222477252~222504622:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000219993.1	RP11-288G3.3	6.61	1.5e-10	0.000754	0.38	0.33	Cognitive function;	chr12:56050848	chr6:7506203~7506549:+
STAD	trans	rs11220082	0.661	rs2321158	ENSG00000236257.1	EI24P2	6.6	1.5e-10	0.000758	0.42	0.33	Schizophrenia;	chr11:125414990	chr1:158454198~158455273:+
STAD	trans	rs11220082	0.787	rs34632138	ENSG00000236257.1	EI24P2	-6.6	1.51e-10	0.00076	-0.44	-0.33	Schizophrenia;	chr11:125428402	chr1:158454198~158455273:+
STAD	trans	rs877636	0.669	rs7297175	ENSG00000242307.1	RPS26P52	-6.6	1.52e-10	0.000765	-0.36	-0.33	Cognitive function;	chr12:56080024	chr16:13922332~13922679:-
STAD	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	6.6	1.53e-10	0.000768	0.45	0.33	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-6.6	1.53e-10	0.000769	-0.45	-0.33	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.645	rs72840522	ENSG00000187870.7	RNFT1P3	6.6	1.56e-10	0.000784	0.4	0.33	Hemoglobin concentration;	chr17:59752631	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs9899611	ENSG00000187870.7	RNFT1P3	6.6	1.56e-10	0.000784	0.4	0.33	Hemoglobin concentration;	chr17:59754829	chr17:20743333~20754501:-
STAD	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	6.6	1.56e-10	0.000785	0.45	0.33	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.645	rs2173120	ENSG00000187870.7	RNFT1P3	6.6	1.57e-10	0.00079	0.41	0.33	Hemoglobin concentration;	chr17:59815279	chr17:20743333~20754501:-
STAD	trans	rs2727020	0.729	rs685789	ENSG00000134612.10	FOLH1B	6.59	1.6e-10	0.000803	0.39	0.33	Coronary artery disease;	chr11:49219676	chr11:89639227~89698718:+
STAD	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-6.59	1.61e-10	0.000809	-0.37	-0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
STAD	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-6.59	1.62e-10	0.000814	-0.45	-0.33	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
STAD	trans	rs916888	0.821	rs415430	ENSG00000204650.12	CRHR1-IT1	-6.59	1.63e-10	0.000816	-0.51	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45620328~45648216:+
STAD	trans	rs916888	0.779	rs430685	ENSG00000204650.12	CRHR1-IT1	-6.59	1.63e-10	0.000816	-0.51	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45620328~45648216:+
STAD	trans	rs10037055	0.853	rs1546363	ENSG00000226986.4	RP11-543B16.2	-6.59	1.64e-10	0.000824	-0.32	-0.33	Migraine without aura;	chr5:177174030	chr1:211207239~211207897:+
STAD	trans	rs12497850	0.931	rs9846123	ENSG00000197582.5	GPX1P1	-6.59	1.65e-10	0.000826	-0.44	-0.33	Parkinson's disease;	chr3:49050679	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.904	rs57299032	ENSG00000231752.4	EMBP1	6.59	1.65e-10	0.000826	0.45	0.33	P wave duration;	chr5:45998162	chr1:121519112~121571892:+
STAD	trans	rs877636	0.847	rs705704	ENSG00000226339.1	RPS26P56	6.59	1.65e-10	0.000827	0.38	0.33	Cognitive function;	chr12:56041628	chrX:129408382~129408621:+
STAD	trans	rs4276421	0.744	rs4541667	ENSG00000231752.4	EMBP1	6.59	1.66e-10	0.000832	0.45	0.33	P wave duration;	chr5:46060767	chr1:121519112~121571892:+
STAD	trans	rs1292059	1	rs1292059	ENSG00000187870.7	RNFT1P3	6.59	1.67e-10	0.000838	0.41	0.33	Eosinophil percentage of granulocytes;	chr17:59880527	chr17:20743333~20754501:-
STAD	trans	rs4276421	0.874	rs71618219	ENSG00000231752.4	EMBP1	6.58	1.69e-10	0.000847	0.45	0.33	P wave duration;	chr5:45950598	chr1:121519112~121571892:+
STAD	trans	rs66887589	0.87	rs2389875	ENSG00000276997.3	RP11-378J18.9	-6.58	1.7e-10	0.000849	-0.36	-0.33	Diastolic blood pressure;	chr4:119635859	chr1:222477252~222504622:-
STAD	trans	rs4276421	0.904	rs6451843	ENSG00000231752.4	EMBP1	6.58	1.72e-10	0.00086	0.45	0.33	P wave duration;	chr5:45946683	chr1:121519112~121571892:+
STAD	trans	rs9611519	0.894	rs9611488	ENSG00000268568.1	AC007228.9	-6.58	1.76e-10	0.000879	-0.46	-0.33	Neuroticism;	chr22:41066588	chr19:56672574~56673901:-
STAD	trans	rs9611519	0.894	rs4821998	ENSG00000268568.1	AC007228.9	-6.58	1.76e-10	0.000879	-0.46	-0.33	Neuroticism;	chr22:41072269	chr19:56672574~56673901:-
STAD	trans	rs877636	0.562	rs10876864	ENSG00000242307.1	RPS26P52	-6.58	1.77e-10	0.000886	-0.37	-0.33	Cognitive function;	chr12:56007301	chr16:13922332~13922679:-
STAD	trans	rs12367822	0.597	rs2371559	ENSG00000121089.4	NACA3P	-6.58	1.78e-10	0.000889	-0.28	-0.33	Platelet aggregation;	chr12:56805073	chr4:164943290~164943937:+
STAD	trans	rs12497850	0.931	rs1134591	ENSG00000197582.5	GPX1P1	6.57	1.8e-10	0.000902	0.42	0.33	Parkinson's disease;	chr3:48935459	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-6.57	1.81e-10	0.000903	-0.45	-0.33	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
STAD	trans	rs7554511	0.894	rs11579874	ENSG00000244144.1	RP11-757F18.3	6.57	1.82e-10	0.00091	0.37	0.33	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200951234	chr3:112185480~112185998:-
STAD	trans	rs11220237	0.544	rs10893412	ENSG00000236257.1	EI24P2	-6.57	1.83e-10	0.000914	-0.49	-0.33	Itch intensity from mosquito bite adjusted by bite size;	chr11:125669307	chr1:158454198~158455273:+
STAD	trans	rs10037055	0.853	rs10056008	ENSG00000226986.4	RP11-543B16.2	-6.57	1.84e-10	0.00092	-0.32	-0.33	Migraine without aura;	chr5:177194147	chr1:211207239~211207897:+
STAD	trans	rs7647973	0.559	rs9586	ENSG00000197582.5	GPX1P1	6.57	1.89e-10	0.000942	0.5	0.33	Menarche (age at onset);	chr3:49176204	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.731	rs13084037	ENSG00000197582.5	GPX1P1	6.57	1.9e-10	0.000946	0.5	0.33	Menarche (age at onset);	chr3:49176633	chrX:13378735~13379340:-
STAD	trans	rs16937956	0.688	rs10500704	ENSG00000266891.1	RP11-692N5.2	6.56	1.91e-10	0.000953	0.42	0.33	Body mass index;	chr11:8429677	chr18:9734882~9735602:-
STAD	trans	rs7312770	0.612	rs773114	ENSG00000229032.1	RP11-91A18.1	6.56	1.93e-10	0.000964	0.35	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:51980473~51980814:+
STAD	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	6.56	1.95e-10	0.000971	0.39	0.33	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
STAD	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	6.56	1.95e-10	0.000973	0.49	0.33	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
STAD	trans	rs10037055	0.853	rs10476219	ENSG00000226986.4	RP11-543B16.2	-6.56	1.96e-10	0.000974	-0.32	-0.33	Migraine without aura;	chr5:177201547	chr1:211207239~211207897:+
STAD	trans	rs13190036	0.551	rs11957608	ENSG00000226986.4	RP11-543B16.2	-6.56	1.97e-10	0.000982	-0.34	-0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr1:211207239~211207897:+
STAD	trans	rs9858542	0.953	rs6803222	ENSG00000197582.5	GPX1P1	-6.56	1.98e-10	0.000984	-0.5	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49628543	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs1873625	ENSG00000197582.5	GPX1P1	-6.56	1.98e-10	0.000984	-0.5	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49629531	chrX:13378735~13379340:-
STAD	trans	rs9858542	0.953	rs11710037	ENSG00000197582.5	GPX1P1	-6.56	1.98e-10	0.000984	-0.5	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637901	chrX:13378735~13379340:-
STAD	trans	rs941207	0.756	rs7313074	ENSG00000257210.1	NACAP3	-6.56	1.98e-10	0.000985	-0.39	-0.33	Platelet count;	chr12:56760705	chr12:93124063~93124543:-
STAD	trans	rs9858542	0.953	rs9827708	ENSG00000197582.5	GPX1P1	-6.56	1.99e-10	0.000989	-0.48	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49612556	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	6.56	2.01e-10	0.000998	0.45	0.33	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000219993.1	RP11-288G3.3	6.56	2.02e-10	0.00101	0.38	0.33	Cognitive function;	chr12:56009793	chr6:7506203~7506549:+
STAD	trans	rs10815468	0.585	rs4742264	ENSG00000215210.3	RBMXP2	6.55	2.03e-10	0.00101	0.36	0.33	Bipolar disorder and schizophrenia;	chr9:6783414	chr9:30689105~30690272:+
STAD	trans	rs11220237	0.764	rs9943542	ENSG00000236257.1	EI24P2	6.55	2.07e-10	0.00103	0.51	0.33	Itch intensity from mosquito bite adjusted by bite size;	chr11:125707970	chr1:158454198~158455273:+
STAD	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	6.55	2.09e-10	0.00104	0.39	0.33	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
STAD	trans	rs66887589	0.776	rs10518337	ENSG00000275858.1	RP11-291L22.8	-6.55	2.11e-10	0.00105	-0.35	-0.33	Diastolic blood pressure;	chr4:119653719	chr10:38450738~38451069:-
STAD	trans	rs916888	0.773	rs199534	ENSG00000204650.12	CRHR1-IT1	6.55	2.12e-10	0.00105	0.52	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45620328~45648216:+
STAD	trans	rs3096299	0.658	rs3934737	ENSG00000215030.5	RPL13P12	-6.55	2.12e-10	0.00105	-0.28	-0.33	Multiple myeloma (IgH translocation);	chr16:89493801	chr17:17383377~17384012:-
STAD	trans	rs11220082	0.761	rs11220065	ENSG00000236257.1	EI24P2	-6.55	2.13e-10	0.00106	-0.43	-0.33	Schizophrenia;	chr11:125425343	chr1:158454198~158455273:+
STAD	trans	rs2950393	0.804	rs1466382	ENSG00000257210.1	NACAP3	-6.55	2.13e-10	0.00106	-0.33	-0.33	Platelet distribution width;	chr12:56723050	chr12:93124063~93124543:-
STAD	trans	rs702485	0.811	rs836549	ENSG00000249936.3	RAC1P2	6.55	2.14e-10	0.00106	0.31	0.33	HDL cholesterol levels;HDL cholesterol;	chr7:6400314	chr4:46723830~46724408:-
STAD	trans	rs7647973	0.848	rs4955411	ENSG00000197582.5	GPX1P1	6.54	2.17e-10	0.00107	0.51	0.33	Menarche (age at onset);	chr3:49107871	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.848	rs4292260	ENSG00000197582.5	GPX1P1	6.54	2.17e-10	0.00107	0.51	0.33	Menarche (age at onset);	chr3:49111457	chrX:13378735~13379340:-
STAD	trans	rs66887589	0.967	rs1155577	ENSG00000275858.1	RP11-291L22.8	-6.54	2.19e-10	0.00109	-0.35	-0.33	Diastolic blood pressure;	chr4:119528655	chr10:38450738~38451069:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000242970.2	AC068522.4	6.54	2.2e-10	0.00109	0.36	0.33	Cognitive function;	chr12:55990903	chr8:58588420~58588764:-
STAD	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	6.54	2.21e-10	0.00109	0.44	0.33	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
STAD	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	6.54	2.21e-10	0.0011	0.37	0.33	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
STAD	trans	rs11220237	0.764	rs11220207	ENSG00000236257.1	EI24P2	6.54	2.24e-10	0.00111	0.54	0.33	Itch intensity from mosquito bite adjusted by bite size;	chr11:125747298	chr1:158454198~158455273:+
STAD	trans	rs10037055	0.853	rs2336237	ENSG00000226986.4	RP11-543B16.2	6.54	2.24e-10	0.00111	0.32	0.33	Migraine without aura;	chr5:177238878	chr1:211207239~211207897:+
STAD	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	6.54	2.25e-10	0.00111	0.49	0.33	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
STAD	trans	rs4276421	0.967	rs7443384	ENSG00000231752.4	EMBP1	6.54	2.27e-10	0.00112	0.45	0.33	P wave duration;	chr5:45960791	chr1:121519112~121571892:+
STAD	trans	rs9858542	0.953	rs9837341	ENSG00000197582.5	GPX1P1	-6.53	2.3e-10	0.00114	-0.5	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49627334	chrX:13378735~13379340:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000244604.1	RP11-713H12.1	6.53	2.32e-10	0.00115	0.36	0.33	Cognitive function;	chr12:55990903	chr17:8561230~8561576:+
STAD	trans	rs12709013	0.591	rs6499980	ENSG00000233719.3	GOT2P3	6.53	2.32e-10	0.00115	0.39	0.33	Blood metabolite ratios;	chr16:58787972	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.591	rs899375	ENSG00000233719.3	GOT2P3	6.53	2.32e-10	0.00115	0.39	0.33	Blood metabolite ratios;	chr16:58792325	chr12:9641802~9643007:+
STAD	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-6.53	2.32e-10	0.00115	-0.39	-0.33	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
STAD	trans	rs2727020	0.729	rs34647977	ENSG00000134612.10	FOLH1B	-6.53	2.33e-10	0.00115	-0.39	-0.33	Coronary artery disease;	chr11:49173991	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000233278.1	RPS26P2	6.53	2.33e-10	0.00115	0.37	0.33	Cognitive function;	chr12:55988132	chr9:30831878~30832225:-
STAD	trans	rs11220237	0.544	rs12361784	ENSG00000236257.1	EI24P2	-6.53	2.35e-10	0.00116	-0.49	-0.33	Itch intensity from mosquito bite adjusted by bite size;	chr11:125685531	chr1:158454198~158455273:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000229032.1	RP11-91A18.1	6.53	2.38e-10	0.00118	0.35	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:51980473~51980814:+
STAD	trans	rs877636	0.692	rs10876870	ENSG00000240427.1	RPS26P34	-6.53	2.39e-10	0.00118	-0.34	-0.33	Cognitive function;	chr12:56084218	chr8:81627269~81627617:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000240427.1	RPS26P34	-6.53	2.39e-10	0.00118	-0.34	-0.33	Cognitive function;	chr12:56084874	chr8:81627269~81627617:+
STAD	trans	rs4276421	0.934	rs7443410	ENSG00000231752.4	EMBP1	6.53	2.39e-10	0.00118	0.45	0.33	P wave duration;	chr5:45960831	chr1:121519112~121571892:+
STAD	trans	rs16937956	0.597	rs16937958	ENSG00000266891.1	RP11-692N5.2	6.53	2.39e-10	0.00118	0.43	0.33	Body mass index;	chr11:8382988	chr18:9734882~9735602:-
STAD	trans	rs66887589	0.66	rs4833613	ENSG00000276997.3	RP11-378J18.9	-6.53	2.4e-10	0.00118	-0.35	-0.33	Diastolic blood pressure;	chr4:119229001	chr1:222477252~222504622:-
STAD	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	6.53	2.4e-10	0.00118	0.44	0.33	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.904	rs7444405	ENSG00000231752.4	EMBP1	6.53	2.4e-10	0.00119	0.45	0.33	P wave duration;	chr5:45915373	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.904	rs4274988	ENSG00000231752.4	EMBP1	6.53	2.4e-10	0.00119	0.45	0.33	P wave duration;	chr5:45926339	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.935	rs7725537	ENSG00000231752.4	EMBP1	6.53	2.4e-10	0.00119	0.45	0.33	P wave duration;	chr5:45927191	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.935	rs35730142	ENSG00000231752.4	EMBP1	6.53	2.4e-10	0.00119	0.45	0.33	P wave duration;	chr5:45927453	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.816	rs6451835	ENSG00000231752.4	EMBP1	6.53	2.4e-10	0.00119	0.45	0.33	P wave duration;	chr5:45928735	chr1:121519112~121571892:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000219993.1	RP11-288G3.3	6.52	2.43e-10	0.0012	0.38	0.33	Cognitive function;	chr12:56002984	chr6:7506203~7506549:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000233278.1	RPS26P2	6.52	2.44e-10	0.0012	0.37	0.33	Cognitive function;	chr12:55981353	chr9:30831878~30832225:-
STAD	trans	rs10816533	1	rs7850707	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96782463	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs7847673	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96782539	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs7848081	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96782838	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10978963	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96783799	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10978968	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96784167	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10978970	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96784176	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10978971	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96784203	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10978973	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96784304	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10120515	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96784883	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs28678226	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96785864	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10117923	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96788165	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10115492	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96788455	chr9:94332476~94360948:+
STAD	trans	rs10816533	0.661	rs10121639	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96789167	chr9:94332476~94360948:+
STAD	trans	rs10816533	1	rs10116439	ENSG00000232063.1	RP11-307E17.8	6.52	2.44e-10	0.0012	0.58	0.33	Height;	chr9:96789823	chr9:94332476~94360948:+
STAD	trans	rs10940346	1	rs7704686	ENSG00000231752.4	EMBP1	-6.52	2.45e-10	0.00121	-0.45	-0.33	Schizophrenia;	chr5:50548995	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs62064901	ENSG00000230849.2	GOT2P2	6.52	2.47e-10	0.00122	0.36	0.33	Blood metabolite ratios;	chr16:58776758	chr1:173141100~173142350:-
STAD	trans	rs3096299	0.642	rs12934829	ENSG00000215030.5	RPL13P12	-6.52	2.48e-10	0.00122	-0.29	-0.33	Multiple myeloma (IgH translocation);	chr16:89456941	chr17:17383377~17384012:-
STAD	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	6.52	2.49e-10	0.00123	0.43	0.33	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
STAD	trans	rs11220237	0.62	rs60531419	ENSG00000236257.1	EI24P2	6.52	2.52e-10	0.00124	0.5	0.33	Itch intensity from mosquito bite adjusted by bite size;	chr11:125692958	chr1:158454198~158455273:+
STAD	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	6.52	2.54e-10	0.00125	0.44	0.33	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
STAD	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	6.52	2.55e-10	0.00125	0.39	0.33	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
STAD	trans	rs12145833	0.596	rs61833913	ENSG00000154608.12	CEP170P1	-6.52	2.55e-10	0.00125	-0.59	-0.33	Obesity (early onset extreme);	chr1:243276726	chr4:118467590~118554204:+
STAD	trans	rs12145833	0.596	rs12026068	ENSG00000154608.12	CEP170P1	-6.52	2.55e-10	0.00125	-0.59	-0.33	Obesity (early onset extreme);	chr1:243277050	chr4:118467590~118554204:+
STAD	trans	rs12145833	0.596	rs12134228	ENSG00000154608.12	CEP170P1	-6.52	2.55e-10	0.00125	-0.59	-0.33	Obesity (early onset extreme);	chr1:243284316	chr4:118467590~118554204:+
STAD	trans	rs7113874	0.592	rs75600349	ENSG00000266891.1	RP11-692N5.2	6.52	2.56e-10	0.00126	0.5	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8426545	chr18:9734882~9735602:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000243538.1	CTB-55B8.1	-6.51	2.57e-10	0.00126	-0.35	-0.33	Asthma;	chr12:55970537	chr5:16902294~16902641:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000243328.1	RP11-520P18.1	-6.51	2.57e-10	0.00126	-0.34	-0.33	Cognitive function;	chr12:56080595	chr8:143065915~143066587:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000219993.1	RP11-288G3.3	6.51	2.59e-10	0.00127	0.38	0.33	Cognitive function;	chr12:56013288	chr6:7506203~7506549:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000219993.1	RP11-288G3.3	6.51	2.59e-10	0.00127	0.38	0.33	Cognitive function;	chr12:56018703	chr6:7506203~7506549:+
STAD	trans	rs80033912	0.713	rs7629936	ENSG00000197582.5	GPX1P1	6.51	2.6e-10	0.00128	0.42	0.33	Intelligence (multi-trait analysis);	chr3:49799274	chrX:13378735~13379340:-
STAD	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-6.51	2.6e-10	0.00128	-0.35	-0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
STAD	trans	rs7364180	0.515	rs6002503	ENSG00000268568.1	AC007228.9	-6.51	2.61e-10	0.00128	-0.39	-0.33	Alzheimer's disease biomarkers;	chr22:41812668	chr19:56672574~56673901:-
STAD	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	6.51	2.62e-10	0.00128	0.32	0.33	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
STAD	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	6.51	2.64e-10	0.00129	0.44	0.33	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
STAD	trans	rs9329221	0.905	rs6601451	ENSG00000253981.4	ALG1L13P	-6.51	2.68e-10	0.00131	-0.43	-0.33	Neuroticism;	chr8:10386171	chr8:8236003~8244667:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000244641.2	RPS26P43	-6.51	2.7e-10	0.00132	-0.31	-0.33	Cognitive function;	chr12:56084218	chr11:123049787~123050353:-
STAD	trans	rs877636	0.692	rs7971751	ENSG00000244641.2	RPS26P43	-6.51	2.7e-10	0.00132	-0.31	-0.33	Cognitive function;	chr12:56084874	chr11:123049787~123050353:-
STAD	trans	rs916888	0.821	rs199513	ENSG00000264057.1	RP11-583F2.1	-6.51	2.71e-10	0.00133	-0.39	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:64927634~64934203:+
STAD	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	6.5	2.73e-10	0.00134	0.44	0.33	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	6.5	2.73e-10	0.00134	0.44	0.33	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
STAD	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	6.5	2.75e-10	0.00135	0.42	0.33	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	6.5	2.75e-10	0.00135	0.42	0.33	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	6.5	2.75e-10	0.00135	0.42	0.33	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	6.5	2.75e-10	0.00135	0.42	0.33	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	6.5	2.75e-10	0.00135	0.42	0.33	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	6.5	2.75e-10	0.00135	0.42	0.33	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
STAD	trans	rs916888	0.773	rs199447	ENSG00000204650.12	CRHR1-IT1	6.5	2.76e-10	0.00135	0.52	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45620328~45648216:+
STAD	trans	rs12497850	0.829	rs8926	ENSG00000197582.5	GPX1P1	6.5	2.78e-10	0.00136	0.44	0.33	Parkinson's disease;	chr3:49015352	chrX:13378735~13379340:-
STAD	trans	rs916888	0.687	rs199456	ENSG00000204650.12	CRHR1-IT1	6.5	2.8e-10	0.00137	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45620328~45648216:+
STAD	trans	rs916888	0.773	rs199451	ENSG00000204650.12	CRHR1-IT1	6.5	2.8e-10	0.00137	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45620328~45648216:+
STAD	trans	rs16937956	0.597	rs34617462	ENSG00000266891.1	RP11-692N5.2	6.5	2.83e-10	0.00138	0.42	0.33	Body mass index;	chr11:8403484	chr18:9734882~9735602:-
STAD	trans	rs8010715	0.771	rs2277481	ENSG00000238000.1	RP11-274E7.2	6.5	2.83e-10	0.00138	0.28	0.33	IgG glycosylation;	chr14:24118336	chr5:98213402~98214121:+
STAD	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	6.5	2.85e-10	0.00139	0.43	0.33	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
STAD	trans	rs941207	0.756	rs2926743	ENSG00000257210.1	NACAP3	6.5	2.86e-10	0.0014	0.39	0.33	Platelet count;	chr12:56720316	chr12:93124063~93124543:-
STAD	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	6.5	2.86e-10	0.0014	0.44	0.33	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	6.5	2.86e-10	0.0014	0.44	0.33	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
STAD	trans	rs2727020	0.729	rs2866328	ENSG00000134612.10	FOLH1B	6.5	2.87e-10	0.00141	0.39	0.33	Coronary artery disease;	chr11:49260869	chr11:89639227~89698718:+
STAD	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	6.5	2.88e-10	0.00141	0.37	0.33	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
STAD	trans	rs4276421	0.845	rs4426926	ENSG00000231752.4	EMBP1	6.5	2.89e-10	0.00141	0.45	0.33	P wave duration;	chr5:45994241	chr1:121519112~121571892:+
STAD	trans	rs3096299	0.692	rs4785565	ENSG00000215030.5	RPL13P12	-6.49	2.94e-10	0.00144	-0.28	-0.33	Multiple myeloma (IgH translocation);	chr16:89449351	chr17:17383377~17384012:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000244641.2	RPS26P43	-6.49	3.02e-10	0.00147	-0.31	-0.33	Cognitive function;	chr12:56080024	chr11:123049787~123050353:-
STAD	trans	rs3096299	0.685	rs12446145	ENSG00000215030.5	RPL13P12	-6.49	3.05e-10	0.00149	-0.28	-0.33	Multiple myeloma (IgH translocation);	chr16:89476287	chr17:17383377~17384012:-
STAD	trans	rs877636	0.847	rs705704	ENSG00000219993.1	RP11-288G3.3	6.48	3.07e-10	0.0015	0.38	0.33	Cognitive function;	chr12:56041628	chr6:7506203~7506549:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000212994.5	RPS26P6	6.48	3.07e-10	0.0015	0.34	0.33	Cognitive function;	chr12:55975722	chr8:100895771~100896118:+
STAD	trans	rs2727020	0.729	rs588458	ENSG00000134612.10	FOLH1B	6.48	3.09e-10	0.00151	0.39	0.33	Coronary artery disease;	chr11:49192496	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.729	rs4315497	ENSG00000134612.10	FOLH1B	6.48	3.09e-10	0.00151	0.39	0.33	Coronary artery disease;	chr11:49192947	chr11:89639227~89698718:+
STAD	trans	rs916888	0.697	rs199516	ENSG00000204650.12	CRHR1-IT1	-6.48	3.13e-10	0.00152	-0.5	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45620328~45648216:+
STAD	trans	rs8067354	0.645	rs2271304	ENSG00000187870.7	RNFT1P3	6.48	3.15e-10	0.00153	0.4	0.33	Hemoglobin concentration;	chr17:59737280	chr17:20743333~20754501:-
STAD	trans	rs8010715	0.785	rs2877611	ENSG00000238000.1	RP11-274E7.2	6.48	3.15e-10	0.00154	0.28	0.33	IgG glycosylation;	chr14:24126221	chr5:98213402~98214121:+
STAD	trans	rs8010715	0.816	rs7153156	ENSG00000238000.1	RP11-274E7.2	6.48	3.15e-10	0.00154	0.28	0.33	IgG glycosylation;	chr14:24129637	chr5:98213402~98214121:+
STAD	trans	rs8010715	0.816	rs6573572	ENSG00000238000.1	RP11-274E7.2	6.48	3.15e-10	0.00154	0.28	0.33	IgG glycosylation;	chr14:24130021	chr5:98213402~98214121:+
STAD	trans	rs8010715	0.816	rs8015168	ENSG00000238000.1	RP11-274E7.2	6.48	3.15e-10	0.00154	0.28	0.33	IgG glycosylation;	chr14:24130663	chr5:98213402~98214121:+
STAD	trans	rs2727020	0.702	rs609054	ENSG00000134612.10	FOLH1B	6.48	3.18e-10	0.00155	0.38	0.33	Coronary artery disease;	chr11:49198173	chr11:89639227~89698718:+
STAD	trans	rs3096299	0.719	rs2353581	ENSG00000215030.5	RPL13P12	-6.48	3.21e-10	0.00156	-0.29	-0.33	Multiple myeloma (IgH translocation);	chr16:89452500	chr17:17383377~17384012:-
STAD	trans	rs4276421	0.904	rs4569880	ENSG00000231752.4	EMBP1	6.47	3.26e-10	0.00158	0.44	0.33	P wave duration;	chr5:46011373	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.874	rs4569881	ENSG00000231752.4	EMBP1	6.47	3.26e-10	0.00158	0.44	0.33	P wave duration;	chr5:46011667	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.816	rs13362078	ENSG00000231752.4	EMBP1	6.47	3.26e-10	0.00158	0.44	0.33	P wave duration;	chr5:46013351	chr1:121519112~121571892:+
STAD	trans	rs8010715	0.816	rs6573565	ENSG00000238000.1	RP11-274E7.2	-6.47	3.27e-10	0.00159	-0.28	-0.33	IgG glycosylation;	chr14:24125524	chr5:98213402~98214121:+
STAD	trans	rs877636	0.809	rs1689510	ENSG00000224161.3	RPS26P54	6.47	3.28e-10	0.00159	0.36	0.33	Cognitive function;	chr12:56002984	chr18:59761558~59761905:+
STAD	trans	rs8067354	0.645	rs2132715	ENSG00000187870.7	RNFT1P3	6.47	3.28e-10	0.00159	0.39	0.33	Hemoglobin concentration;	chr17:59781013	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs2173119	ENSG00000187870.7	RNFT1P3	6.47	3.28e-10	0.00159	0.39	0.33	Hemoglobin concentration;	chr17:59782344	chr17:20743333~20754501:-
STAD	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	6.47	3.32e-10	0.00161	0.31	0.33	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
STAD	trans	rs9329221	0.772	rs7824675	ENSG00000253981.4	ALG1L13P	-6.47	3.32e-10	0.00161	-0.42	-0.33	Neuroticism;	chr8:10385908	chr8:8236003~8244667:-
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000226339.1	RPS26P56	6.47	3.33e-10	0.00162	0.33	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:129408382~129408621:+
STAD	trans	rs1563304	1	rs1563304	ENSG00000263503.1	RP11-707O23.5	6.47	3.34e-10	0.00162	0.61	0.33	Neuroticism;	chr17:46797087	chr17:45600869~45602340:-
STAD	trans	rs7930295	0.632	rs12271647	ENSG00000236257.1	EI24P2	6.47	3.4e-10	0.00165	0.54	0.33	Schizophrenia;	chr11:125754161	chr1:158454198~158455273:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000219993.1	RP11-288G3.3	6.47	3.4e-10	0.00165	0.37	0.33	Cognitive function;	chr12:56023144	chr6:7506203~7506549:+
STAD	trans	rs4276421	0.901	rs10056175	ENSG00000231752.4	EMBP1	6.47	3.42e-10	0.00166	0.45	0.33	P wave duration;	chr5:45934503	chr1:121519112~121571892:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000233278.1	RPS26P2	6.47	3.43e-10	0.00167	0.4	0.33	Cognitive function;	chr12:56055651	chr9:30831878~30832225:-
STAD	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	6.47	3.45e-10	0.00167	0.42	0.33	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
STAD	trans	rs2727020	0.755	rs652655	ENSG00000134612.10	FOLH1B	6.46	3.47e-10	0.00169	0.38	0.33	Coronary artery disease;	chr11:49229741	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	6.46	3.49e-10	0.00169	0.44	0.33	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	6.46	3.49e-10	0.00169	0.44	0.33	P wave duration;	chr5:45904860	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.967	rs7725171	ENSG00000231752.4	EMBP1	6.46	3.54e-10	0.00172	0.44	0.33	P wave duration;	chr5:45923684	chr1:121519112~121571892:+
STAD	trans	rs877636	1	rs4759229	ENSG00000243328.1	RP11-520P18.1	-6.46	3.55e-10	0.00172	-0.34	-0.33	Cognitive function;	chr12:56080696	chr8:143065915~143066587:-
STAD	trans	rs10037055	0.853	rs1363405	ENSG00000226986.4	RP11-543B16.2	6.46	3.55e-10	0.00172	0.31	0.33	Migraine without aura;	chr5:177209881	chr1:211207239~211207897:+
STAD	trans	rs12709013	0.792	rs11646756	ENSG00000230849.2	GOT2P2	6.46	3.55e-10	0.00172	0.35	0.33	Blood metabolite ratios;	chr16:58773598	chr1:173141100~173142350:-
STAD	trans	rs4925166	1	rs4925166	ENSG00000188933.13	USP32P1	6.46	3.58e-10	0.00174	0.39	0.33	Multiple sclerosis;	chr17:18307496	chr17:16786489~16804455:+
STAD	trans	rs2980439	0.846	rs2980437	ENSG00000270154.1	RP11-419I17.1	-6.46	3.6e-10	0.00174	-0.32	-0.33	Neuroticism;	chr8:8237241	chr8:12476462~12477122:+
STAD	trans	rs12709013	0.729	rs1657179	ENSG00000233719.3	GOT2P3	6.46	3.66e-10	0.00177	0.35	0.33	Blood metabolite ratios;	chr16:58735115	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs1473206	ENSG00000233719.3	GOT2P3	6.46	3.66e-10	0.00177	0.35	0.33	Blood metabolite ratios;	chr16:58737529	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs1473205	ENSG00000233719.3	GOT2P3	6.46	3.66e-10	0.00177	0.35	0.33	Blood metabolite ratios;	chr16:58737547	chr12:9641802~9643007:+
STAD	trans	rs10983614	1	rs7867776	ENSG00000244196.1	PPIAP15	-6.45	3.68e-10	0.00178	-0.31	-0.33	Survival in pancreatic cancer;	chr9:117310348	chr3:109471329~109471812:-
STAD	trans	rs13177918	0.734	rs6579791	ENSG00000226396.1	RP5-1056L3.3	6.45	3.69e-10	0.00179	0.35	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:19608114~19608568:+
STAD	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-6.45	3.7e-10	0.00179	-0.44	-0.33	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
STAD	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	6.45	3.7e-10	0.00179	0.39	0.33	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
STAD	trans	rs2727020	0.638	rs1164668	ENSG00000134612.10	FOLH1B	6.45	3.7e-10	0.00179	0.39	0.33	Coronary artery disease;	chr11:49309075	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	6.45	3.72e-10	0.0018	0.45	0.33	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
STAD	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-6.45	3.72e-10	0.0018	-0.33	-0.33	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
STAD	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	6.45	3.73e-10	0.0018	0.38	0.33	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
STAD	trans	rs916888	0.773	rs169201	ENSG00000204650.12	CRHR1-IT1	6.45	3.76e-10	0.00182	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45620328~45648216:+
STAD	trans	rs916888	0.773	rs199457	ENSG00000204650.12	CRHR1-IT1	6.45	3.8e-10	0.00184	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45620328~45648216:+
STAD	trans	rs4276421	0.845	rs4492122	ENSG00000231752.4	EMBP1	6.45	3.82e-10	0.00185	0.45	0.33	P wave duration;	chr5:45982952	chr1:121519112~121571892:+
STAD	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-6.45	3.83e-10	0.00185	-0.42	-0.33	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
STAD	trans	rs12709013	0.636	rs1646284	ENSG00000233719.3	GOT2P3	6.45	3.86e-10	0.00186	0.38	0.33	Blood metabolite ratios;	chr16:58752093	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	6.44	3.89e-10	0.00188	0.44	0.33	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	6.44	3.89e-10	0.00188	0.44	0.33	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
STAD	trans	rs66887589	0.967	rs59516282	ENSG00000275858.1	RP11-291L22.8	-6.44	3.91e-10	0.00188	-0.34	-0.33	Diastolic blood pressure;	chr4:119580861	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.934	rs12648182	ENSG00000275858.1	RP11-291L22.8	-6.44	3.91e-10	0.00188	-0.34	-0.33	Diastolic blood pressure;	chr4:119582736	chr10:38450738~38451069:-
STAD	trans	rs4276421	0.736	rs7445572	ENSG00000231752.4	EMBP1	6.44	3.95e-10	0.0019	0.44	0.33	P wave duration;	chr5:45920315	chr1:121519112~121571892:+
STAD	trans	rs9858542	0.903	rs11921590	ENSG00000197582.5	GPX1P1	-6.44	3.95e-10	0.00191	-0.49	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606760	chrX:13378735~13379340:-
STAD	trans	rs877636	0.692	rs10876870	ENSG00000229032.1	RP11-91A18.1	-6.44	4e-10	0.00193	-0.34	-0.33	Cognitive function;	chr12:56084218	chr1:51980473~51980814:+
STAD	trans	rs877636	0.692	rs7971751	ENSG00000229032.1	RP11-91A18.1	-6.44	4e-10	0.00193	-0.34	-0.33	Cognitive function;	chr12:56084874	chr1:51980473~51980814:+
STAD	trans	rs877636	0.702	rs773112	ENSG00000233278.1	RPS26P2	6.44	4.01e-10	0.00193	0.36	0.33	Cognitive function;	chr12:55982097	chr9:30831878~30832225:-
STAD	trans	rs4276421	0.774	rs6884716	ENSG00000231752.4	EMBP1	6.44	4.01e-10	0.00193	0.44	0.33	P wave duration;	chr5:46115267	chr1:121519112~121571892:+
STAD	trans	rs877636	1	rs4759229	ENSG00000244641.2	RPS26P43	-6.44	4.04e-10	0.00195	-0.34	-0.33	Cognitive function;	chr12:56080696	chr11:123049787~123050353:-
STAD	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	6.44	4.09e-10	0.00197	0.42	0.33	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
STAD	trans	rs7113874	0.613	rs4326784	ENSG00000266891.1	RP11-692N5.2	6.44	4.1e-10	0.00197	0.43	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8511602	chr18:9734882~9735602:-
STAD	trans	rs3096299	0.685	rs4329923	ENSG00000215030.5	RPL13P12	-6.44	4.1e-10	0.00198	-0.28	-0.33	Multiple myeloma (IgH translocation);	chr16:89493770	chr17:17383377~17384012:-
STAD	trans	rs7113874	0.545	rs2084187	ENSG00000266891.1	RP11-692N5.2	6.44	4.11e-10	0.00198	0.43	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515394	chr18:9734882~9735602:-
STAD	trans	rs7113874	0.613	rs2100067	ENSG00000266891.1	RP11-692N5.2	6.44	4.11e-10	0.00198	0.43	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515503	chr18:9734882~9735602:-
STAD	trans	rs7113874	0.578	rs7924477	ENSG00000266891.1	RP11-692N5.2	6.44	4.11e-10	0.00198	0.43	0.33	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516700	chr18:9734882~9735602:-
STAD	trans	rs9858213	1	rs9858213	ENSG00000197582.5	GPX1P1	-6.43	4.12e-10	0.00198	-0.49	-0.33	Educational attainment;	chr3:49694428	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.967	rs10062508	ENSG00000231752.4	EMBP1	6.43	4.15e-10	0.002	0.44	0.33	P wave duration;	chr5:45961764	chr1:121519112~121571892:+
STAD	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	6.43	4.23e-10	0.00203	0.39	0.33	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
STAD	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-6.43	4.28e-10	0.00206	-0.43	-0.33	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
STAD	trans	rs877636	0.562	rs10876864	ENSG00000231366.1	RP11-399N22.3	-6.43	4.33e-10	0.00208	-0.35	-0.33	Cognitive function;	chr12:56007301	chr10:70794230~70794523:-
STAD	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	6.43	4.34e-10	0.00208	0.44	0.33	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.638	rs4551075	ENSG00000231752.4	EMBP1	6.43	4.36e-10	0.00209	0.43	0.33	P wave duration;	chr5:46011710	chr1:121519112~121571892:+
STAD	trans	rs916888	0.773	rs199535	ENSG00000204650.12	CRHR1-IT1	6.43	4.36e-10	0.00209	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45620328~45648216:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000234354.3	RPS26P47	6.42	4.39e-10	0.00211	0.46	0.33	Cognitive function;	chr12:55975722	chr13:100539901~100540248:-
STAD	trans	rs66887589	0.934	rs2389873	ENSG00000275858.1	RP11-291L22.8	-6.42	4.41e-10	0.00211	-0.34	-0.33	Diastolic blood pressure;	chr4:119633559	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.934	rs4834792	ENSG00000275858.1	RP11-291L22.8	-6.42	4.41e-10	0.00211	-0.34	-0.33	Diastolic blood pressure;	chr4:119634541	chr10:38450738~38451069:-
STAD	trans	rs9858542	1	rs9822268	ENSG00000197582.5	GPX1P1	-6.42	4.41e-10	0.00212	-0.48	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49682296	chrX:13378735~13379340:-
STAD	trans	rs9858542	1	rs13085791	ENSG00000197582.5	GPX1P1	-6.42	4.41e-10	0.00212	-0.48	-0.33	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684365	chrX:13378735~13379340:-
STAD	trans	rs3770081	1	rs61477982	ENSG00000229880.1	IMMTP1	6.42	4.43e-10	0.00213	0.63	0.33	Facial emotion recognition (sad faces);	chr2:85933409	chr21:44675868~44678086:-
STAD	trans	rs916888	0.779	rs199528	ENSG00000204650.12	CRHR1-IT1	6.42	4.54e-10	0.00218	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45620328~45648216:+
STAD	trans	rs916888	0.821	rs199525	ENSG00000204650.12	CRHR1-IT1	6.42	4.54e-10	0.00218	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45620328~45648216:+
STAD	trans	rs12709013	0.792	rs12325510	ENSG00000230849.2	GOT2P2	6.42	4.55e-10	0.00218	0.35	0.33	Blood metabolite ratios;	chr16:58749707	chr1:173141100~173142350:-
STAD	trans	rs2727020	0.731	rs10450572	ENSG00000134612.10	FOLH1B	6.42	4.56e-10	0.00218	0.38	0.33	Coronary artery disease;	chr11:49259521	chr11:89639227~89698718:+
STAD	trans	rs3096299	0.719	rs2911262	ENSG00000215030.5	RPL13P12	-6.42	4.58e-10	0.00219	-0.28	-0.33	Multiple myeloma (IgH translocation);	chr16:89448633	chr17:17383377~17384012:-
STAD	trans	rs4276421	0.774	rs7720482	ENSG00000231752.4	EMBP1	-6.42	4.59e-10	0.0022	-0.44	-0.33	P wave duration;	chr5:46106061	chr1:121519112~121571892:+
STAD	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	6.41	4.69e-10	0.00224	0.37	0.33	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000233278.1	RPS26P2	6.41	4.71e-10	0.00225	0.36	0.33	Cognitive function;	chr12:55980911	chr9:30831878~30832225:-
STAD	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	6.41	4.79e-10	0.00229	0.38	0.33	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
STAD	trans	rs8067354	0.645	rs2645492	ENSG00000187870.7	RNFT1P3	-6.41	4.83e-10	0.00231	-0.39	-0.33	Hemoglobin concentration;	chr17:59798193	chr17:20743333~20754501:-
STAD	trans	rs877636	1	rs705696	ENSG00000244641.2	RPS26P43	6.41	4.86e-10	0.00232	0.34	0.33	Cognitive function;	chr12:56086864	chr11:123049787~123050353:-
STAD	trans	rs13190036	0.748	rs28395268	ENSG00000217325.2	PRELID1P1	6.41	4.86e-10	0.00232	0.34	0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr6:126643488~126644390:+
STAD	trans	rs916888	0.773	rs199445	ENSG00000204650.12	CRHR1-IT1	6.41	4.88e-10	0.00233	0.5	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45620328~45648216:+
STAD	trans	rs916888	0.773	rs199443	ENSG00000204650.12	CRHR1-IT1	6.41	4.88e-10	0.00233	0.5	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45620328~45648216:+
STAD	trans	rs7647973	0.626	rs1463728	ENSG00000197582.5	GPX1P1	6.41	4.89e-10	0.00234	0.52	0.33	Menarche (age at onset);	chr3:49609971	chrX:13378735~13379340:-
STAD	trans	rs2727020	0.587	rs1164658	ENSG00000134612.10	FOLH1B	6.41	4.91e-10	0.00235	0.38	0.33	Coronary artery disease;	chr11:49276999	chr11:89639227~89698718:+
STAD	trans	rs916888	0.773	rs199533	ENSG00000204650.12	CRHR1-IT1	6.4	4.93e-10	0.00236	0.51	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45620328~45648216:+
STAD	trans	rs10816533	1	rs10118617	ENSG00000232063.1	RP11-307E17.8	6.4	4.93e-10	0.00236	0.57	0.33	Height;	chr9:96788187	chr9:94332476~94360948:+
STAD	trans	rs4276421	0.845	rs4371763	ENSG00000231752.4	EMBP1	6.4	4.94e-10	0.00236	0.44	0.33	P wave duration;	chr5:45983120	chr1:121519112~121571892:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000219993.1	RP11-288G3.3	6.4	4.97e-10	0.00238	0.37	0.33	Cognitive function;	chr12:56041720	chr6:7506203~7506549:+
STAD	trans	rs4276421	0.904	rs34462057	ENSG00000231752.4	EMBP1	6.4	5.05e-10	0.00241	0.43	0.33	P wave duration;	chr5:45900215	chr1:121519112~121571892:+
STAD	trans	rs10037055	0.687	rs6556308	ENSG00000226986.4	RP11-543B16.2	-6.4	5.05e-10	0.00241	-0.32	-0.33	Migraine without aura;	chr5:177219700	chr1:211207239~211207897:+
STAD	trans	rs10037055	0.853	rs6890580	ENSG00000226986.4	RP11-543B16.2	-6.4	5.07e-10	0.00242	-0.32	-0.33	Migraine without aura;	chr5:177226519	chr1:211207239~211207897:+
STAD	trans	rs9594759	0.818	rs12430303	ENSG00000246640.1	RP11-1094H24.4	6.4	5.09e-10	0.00243	0.39	0.33	Bone mineral density (spine);	chr13:42457891	chr17:50050349~50055739:-
STAD	trans	rs877636	1	rs877636	ENSG00000243328.1	RP11-520P18.1	-6.4	5.09e-10	0.00243	-0.33	-0.33	Cognitive function;	chr12:56086799	chr8:143065915~143066587:-
STAD	trans	rs916888	0.773	rs538628	ENSG00000204650.12	CRHR1-IT1	6.4	5.14e-10	0.00245	0.5	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45620328~45648216:+
STAD	trans	rs3096299	0.728	rs1011749	ENSG00000215030.5	RPL13P12	-6.4	5.14e-10	0.00245	-0.28	-0.33	Multiple myeloma (IgH translocation);	chr16:89444461	chr17:17383377~17384012:-
STAD	trans	rs4276421	0.845	rs34040576	ENSG00000231752.4	EMBP1	6.4	5.15e-10	0.00246	0.44	0.33	P wave duration;	chr5:46005596	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.904	rs13360955	ENSG00000231752.4	EMBP1	6.4	5.15e-10	0.00246	0.44	0.33	P wave duration;	chr5:46005842	chr1:121519112~121571892:+
STAD	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	6.4	5.16e-10	0.00246	0.54	0.33	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
STAD	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	6.4	5.16e-10	0.00246	0.54	0.33	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
STAD	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	6.4	5.16e-10	0.00246	0.54	0.33	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
STAD	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	6.4	5.16e-10	0.00246	0.54	0.33	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
STAD	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	6.4	5.16e-10	0.00246	0.54	0.33	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
STAD	trans	rs2176862	1	rs4312690	ENSG00000203620.2	RP11-84A19.2	-6.4	5.17e-10	0.00247	-0.68	-0.33	Plasma amyloid beta peptide concentrations (ABx-42);	chr3:46571732	chr1:31842019~31855568:-
STAD	trans	rs11220237	0.688	rs3913027	ENSG00000236257.1	EI24P2	6.4	5.18e-10	0.00247	0.53	0.33	Itch intensity from mosquito bite adjusted by bite size;	chr11:125735038	chr1:158454198~158455273:+
STAD	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	6.39	5.23e-10	0.00249	0.54	0.33	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
STAD	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	6.39	5.25e-10	0.0025	0.43	0.33	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.645	rs72838857	ENSG00000187870.7	RNFT1P3	6.39	5.27e-10	0.00251	0.39	0.33	Hemoglobin concentration;	chr17:59759406	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs16943838	ENSG00000187870.7	RNFT1P3	6.39	5.27e-10	0.00251	0.39	0.33	Hemoglobin concentration;	chr17:59762243	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.645	rs1874548	ENSG00000187870.7	RNFT1P3	6.39	5.27e-10	0.00251	0.39	0.33	Hemoglobin concentration;	chr17:59763996	chr17:20743333~20754501:-
STAD	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	6.39	5.28e-10	0.00251	0.54	0.33	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
STAD	trans	rs11220082	0.556	rs10790735	ENSG00000236257.1	EI24P2	-6.39	5.29e-10	0.00252	-0.4	-0.32	Schizophrenia;	chr11:125423135	chr1:158454198~158455273:+
STAD	trans	rs13190036	1	rs655623	ENSG00000226986.4	RP11-543B16.2	6.39	5.29e-10	0.00252	0.34	0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr1:211207239~211207897:+
STAD	trans	rs4276421	0.934	rs6451840	ENSG00000231752.4	EMBP1	6.39	5.36e-10	0.00255	0.44	0.32	P wave duration;	chr5:45935584	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.87	rs6451842	ENSG00000231752.4	EMBP1	6.39	5.36e-10	0.00255	0.44	0.32	P wave duration;	chr5:45936431	chr1:121519112~121571892:+
STAD	trans	rs7819412	0.74	rs7844536	ENSG00000254340.1	RP11-10A14.3	-6.39	5.37e-10	0.00255	-0.42	-0.32	Triglycerides;	chr8:11176519	chr8:9141424~9145435:+
STAD	trans	rs8067354	0.645	rs2645467	ENSG00000187870.7	RNFT1P3	6.39	5.42e-10	0.00258	0.39	0.32	Hemoglobin concentration;	chr17:59777422	chr17:20743333~20754501:-
STAD	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	6.39	5.48e-10	0.0026	0.39	0.32	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
STAD	trans	rs4276421	0.839	rs7719401	ENSG00000231752.4	EMBP1	6.39	5.49e-10	0.00261	0.44	0.32	P wave duration;	chr5:45938713	chr1:121519112~121571892:+
STAD	trans	rs8067354	0.681	rs76856339	ENSG00000187870.7	RNFT1P3	6.39	5.51e-10	0.00262	0.4	0.32	Hemoglobin concentration;	chr17:59723605	chr17:20743333~20754501:-
STAD	trans	rs8067354	0.507	rs72840511	ENSG00000187870.7	RNFT1P3	6.39	5.51e-10	0.00262	0.4	0.32	Hemoglobin concentration;	chr17:59728650	chr17:20743333~20754501:-
STAD	trans	rs9858542	0.903	rs11917431	ENSG00000197582.5	GPX1P1	-6.39	5.52e-10	0.00262	-0.48	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606579	chrX:13378735~13379340:-
STAD	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	6.38	5.52e-10	0.00262	0.42	0.32	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	6.38	5.52e-10	0.00262	0.42	0.32	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
STAD	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-6.38	5.64e-10	0.00268	-0.43	-0.32	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-6.38	5.64e-10	0.00268	-0.43	-0.32	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
STAD	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	6.38	5.64e-10	0.00268	0.38	0.32	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
STAD	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	6.38	5.64e-10	0.00268	0.38	0.32	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
STAD	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	6.38	5.67e-10	0.00269	0.48	0.32	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
STAD	trans	rs216303	0.642	rs216335	ENSG00000241717.1	VWFP1	6.38	5.75e-10	0.00273	0.46	0.32	Low vWF levels;	chr12:6038839	chr22:16690103~16704477:-
STAD	trans	rs66887589	0.934	rs7681980	ENSG00000275858.1	RP11-291L22.8	-6.38	5.81e-10	0.00276	-0.34	-0.32	Diastolic blood pressure;	chr4:119612068	chr10:38450738~38451069:-
STAD	trans	rs10037055	0.741	rs2336405	ENSG00000226986.4	RP11-543B16.2	-6.38	5.85e-10	0.00277	-0.31	-0.32	Migraine without aura;	chr5:177230288	chr1:211207239~211207897:+
STAD	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-6.37	5.86e-10	0.00278	-0.34	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
STAD	trans	rs1563304	1	rs1563304	ENSG00000280022.1	RP11-707O23.1	6.37	5.9e-10	0.0028	0.58	0.32	Neuroticism;	chr17:46797087	chr17:45592621~45593369:+
STAD	trans	rs916888	0.773	rs199439	ENSG00000204650.12	CRHR1-IT1	6.37	5.9e-10	0.0028	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45620328~45648216:+
STAD	trans	rs4276421	0.935	rs6451834	ENSG00000231752.4	EMBP1	6.37	5.92e-10	0.00281	0.44	0.32	P wave duration;	chr5:45927208	chr1:121519112~121571892:+
STAD	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	6.37	5.97e-10	0.00283	0.38	0.32	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
STAD	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	6.37	5.97e-10	0.00283	0.38	0.32	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
STAD	trans	rs11039798	0.778	rs7944523	ENSG00000134612.10	FOLH1B	6.37	5.99e-10	0.00284	0.57	0.32	Axial length;	chr11:48889467	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.925	rs12277669	ENSG00000134612.10	FOLH1B	6.37	5.99e-10	0.00284	0.57	0.32	Axial length;	chr11:48903764	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.764	rs76882342	ENSG00000134612.10	FOLH1B	6.37	5.99e-10	0.00284	0.57	0.32	Axial length;	chr11:48917539	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.844	rs11040177	ENSG00000134612.10	FOLH1B	6.37	5.99e-10	0.00284	0.57	0.32	Axial length;	chr11:48954659	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs7125559	ENSG00000134612.10	FOLH1B	6.37	5.99e-10	0.00284	0.57	0.32	Axial length;	chr11:48962655	chr11:89639227~89698718:+
STAD	trans	rs9858542	1	rs9882740	ENSG00000197582.5	GPX1P1	-6.37	6e-10	0.00284	-0.48	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49665051	chrX:13378735~13379340:-
STAD	trans	rs9858542	1	rs1131095	ENSG00000197582.5	GPX1P1	-6.37	6e-10	0.00284	-0.48	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49676792	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.792	rs12598527	ENSG00000230849.2	GOT2P2	6.37	6e-10	0.00284	0.34	0.32	Blood metabolite ratios;	chr16:58772987	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs12600201	ENSG00000230849.2	GOT2P2	6.37	6e-10	0.00284	0.34	0.32	Blood metabolite ratios;	chr16:58773132	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs12600206	ENSG00000230849.2	GOT2P2	6.37	6e-10	0.00284	0.34	0.32	Blood metabolite ratios;	chr16:58773169	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs11076263	ENSG00000230849.2	GOT2P2	6.37	6e-10	0.00284	0.34	0.32	Blood metabolite ratios;	chr16:58773295	chr1:173141100~173142350:-
STAD	trans	rs9364687	0.664	rs9364688	ENSG00000207378.1	RNU6-748P	6.37	6.04e-10	0.00286	0.36	0.32	Body mass index;	chr6:163480359	chr8:98462944~98463050:-
STAD	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-6.37	6.07e-10	0.00287	-0.41	-0.32	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
STAD	trans	rs6708331	0.941	rs6749886	ENSG00000232654.1	FAM136BP	6.37	6.08e-10	0.00288	0.5	0.32	Obesity-related traits;	chr2:70062968	chr6:3045384~3045800:+
STAD	trans	rs4276421	0.55	rs34812524	ENSG00000231752.4	EMBP1	6.37	6.09e-10	0.00288	0.43	0.32	P wave duration;	chr5:46054030	chr1:121519112~121571892:+
STAD	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	6.37	6.1e-10	0.00288	0.54	0.32	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
STAD	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	6.37	6.15e-10	0.00291	0.42	0.32	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	6.37	6.15e-10	0.00291	0.42	0.32	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
STAD	trans	rs7647973	0.71	rs1491983	ENSG00000197582.5	GPX1P1	6.36	6.24e-10	0.00295	0.52	0.32	Menarche (age at onset);	chr3:49602370	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.677	rs11130211	ENSG00000197582.5	GPX1P1	6.36	6.24e-10	0.00295	0.52	0.32	Menarche (age at onset);	chr3:49607776	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.667	rs11721148	ENSG00000197582.5	GPX1P1	6.36	6.24e-10	0.00295	0.52	0.32	Menarche (age at onset);	chr3:49609236	chrX:13378735~13379340:-
STAD	trans	rs10815468	0.542	rs10975834	ENSG00000215210.3	RBMXP2	6.36	6.27e-10	0.00297	0.35	0.32	Bipolar disorder and schizophrenia;	chr9:6795668	chr9:30689105~30690272:+
STAD	trans	rs2727020	0.688	rs4929894	ENSG00000134612.10	FOLH1B	-6.36	6.33e-10	0.00299	-0.38	-0.32	Coronary artery disease;	chr11:49174781	chr11:89639227~89698718:+
STAD	trans	rs877636	1	rs2292239	ENSG00000224161.3	RPS26P54	6.36	6.35e-10	0.003	0.32	0.32	Cognitive function;	chr12:56088396	chr18:59761558~59761905:+
STAD	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	6.36	6.46e-10	0.00305	0.54	0.32	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
STAD	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	6.36	6.46e-10	0.00305	0.54	0.32	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
STAD	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	6.36	6.46e-10	0.00305	0.54	0.32	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
STAD	trans	rs7113874	0.659	rs2166470	ENSG00000266891.1	RP11-692N5.2	-6.36	6.46e-10	0.00305	-0.42	-0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501625	chr18:9734882~9735602:-
STAD	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	6.36	6.5e-10	0.00307	0.38	0.32	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
STAD	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	6.36	6.51e-10	0.00307	0.38	0.32	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
STAD	trans	rs66887589	0.87	rs2389875	ENSG00000275858.1	RP11-291L22.8	-6.36	6.54e-10	0.00308	-0.34	-0.32	Diastolic blood pressure;	chr4:119635859	chr10:38450738~38451069:-
STAD	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-6.36	6.56e-10	0.00309	-0.43	-0.32	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-6.36	6.56e-10	0.00309	-0.43	-0.32	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-6.36	6.56e-10	0.00309	-0.43	-0.32	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-6.35	6.58e-10	0.0031	-0.43	-0.32	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-6.35	6.58e-10	0.0031	-0.43	-0.32	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
STAD	trans	rs2727020	0.729	rs4980439	ENSG00000134612.10	FOLH1B	-6.35	6.61e-10	0.00312	-0.38	-0.32	Coronary artery disease;	chr11:49320694	chr11:89639227~89698718:+
STAD	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	6.35	6.66e-10	0.00314	0.43	0.32	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
STAD	trans	rs877636	1	rs2292239	ENSG00000219993.1	RP11-288G3.3	6.35	6.67e-10	0.00314	0.34	0.32	Cognitive function;	chr12:56088396	chr6:7506203~7506549:+
STAD	trans	rs9858542	1	rs9823546	ENSG00000197582.5	GPX1P1	-6.35	6.68e-10	0.00315	-0.48	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49668079	chrX:13378735~13379340:-
STAD	trans	rs9858542	1	rs11130213	ENSG00000197582.5	GPX1P1	-6.35	6.68e-10	0.00315	-0.48	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49674864	chrX:13378735~13379340:-
STAD	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	6.35	6.71e-10	0.00316	0.36	0.32	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
STAD	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-6.35	6.72e-10	0.00316	-0.37	-0.32	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
STAD	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-6.35	6.74e-10	0.00317	-0.43	-0.32	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
STAD	trans	rs7113874	0.659	rs12577287	ENSG00000266891.1	RP11-692N5.2	6.35	6.78e-10	0.00319	0.42	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498370	chr18:9734882~9735602:-
STAD	trans	rs7113874	0.659	rs12274454	ENSG00000266891.1	RP11-692N5.2	6.35	6.78e-10	0.00319	0.42	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500419	chr18:9734882~9735602:-
STAD	trans	rs7113874	0.659	rs57757082	ENSG00000266891.1	RP11-692N5.2	6.35	6.78e-10	0.00319	0.42	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8507106	chr18:9734882~9735602:-
STAD	trans	rs877636	1	rs877636	ENSG00000242307.1	RPS26P52	-6.35	6.86e-10	0.00323	-0.37	-0.32	Cognitive function;	chr12:56086799	chr16:13922332~13922679:-
STAD	trans	rs916888	0.773	rs1378358	ENSG00000204650.12	CRHR1-IT1	6.35	6.94e-10	0.00326	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45620328~45648216:+
STAD	trans	rs9364687	0.664	rs4709717	ENSG00000207378.1	RNU6-748P	6.34	7.05e-10	0.00331	0.35	0.32	Body mass index;	chr6:163473632	chr8:98462944~98463050:-
STAD	trans	rs9364687	0.664	rs4709718	ENSG00000207378.1	RNU6-748P	6.34	7.05e-10	0.00331	0.35	0.32	Body mass index;	chr6:163474756	chr8:98462944~98463050:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000196656.7	AC004057.1	-6.34	7.07e-10	0.00332	-0.31	-0.32	Asthma;	chr12:55970537	chr4:113214046~113217170:-
STAD	trans	rs12709013	0.729	rs34324769	ENSG00000230849.2	GOT2P2	6.34	7.08e-10	0.00333	0.35	0.32	Blood metabolite ratios;	chr16:58778131	chr1:173141100~173142350:-
STAD	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	6.34	7.27e-10	0.00341	0.43	0.32	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
STAD	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	6.34	7.29e-10	0.00342	0.46	0.32	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
STAD	trans	rs11039798	0.92	rs61448762	ENSG00000134612.10	FOLH1B	6.34	7.31e-10	0.00343	0.6	0.32	Axial length;	chr11:48902204	chr11:89639227~89698718:+
STAD	trans	rs7113874	0.659	rs7931834	ENSG00000266891.1	RP11-692N5.2	6.34	7.38e-10	0.00346	0.42	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8503746	chr18:9734882~9735602:-
STAD	trans	rs9364687	0.664	rs2294709	ENSG00000207378.1	RNU6-748P	6.33	7.45e-10	0.00349	0.35	0.32	Body mass index;	chr6:163486209	chr8:98462944~98463050:-
STAD	trans	rs12709013	0.792	rs62066815	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58751577	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.766	rs1657175	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58755527	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1646290	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58755807	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1364346	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58756420	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs257626	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58759574	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs257625	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58759978	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1646262	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58760593	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs257623	ENSG00000230849.2	GOT2P2	6.33	7.5e-10	0.00352	0.35	0.32	Blood metabolite ratios;	chr16:58761247	chr1:173141100~173142350:-
STAD	trans	rs4276421	1	rs4331911	ENSG00000231752.4	EMBP1	6.33	7.69e-10	0.0036	0.43	0.32	P wave duration;	chr5:45859273	chr1:121519112~121571892:+
STAD	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	6.33	7.69e-10	0.0036	0.43	0.32	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
STAD	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	6.33	7.69e-10	0.0036	0.43	0.32	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	6.33	7.69e-10	0.0036	0.43	0.32	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
STAD	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	6.33	7.69e-10	0.0036	0.43	0.32	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	6.33	7.69e-10	0.0036	0.43	0.32	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
STAD	trans	rs877636	1	rs2292239	ENSG00000244641.2	RPS26P43	6.33	7.71e-10	0.00361	0.32	0.32	Cognitive function;	chr12:56088396	chr11:123049787~123050353:-
STAD	trans	rs7113874	0.612	rs11517715	ENSG00000266891.1	RP11-692N5.2	6.33	7.75e-10	0.00363	0.42	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8490341	chr18:9734882~9735602:-
STAD	trans	rs4276421	0.967	rs4541666	ENSG00000231752.4	EMBP1	6.33	7.77e-10	0.00364	0.43	0.32	P wave duration;	chr5:45857027	chr1:121519112~121571892:+
STAD	trans	rs10815468	0.542	rs6477109	ENSG00000215210.3	RBMXP2	6.33	7.81e-10	0.00366	0.35	0.32	Bipolar disorder and schizophrenia;	chr9:6794938	chr9:30689105~30690272:+
STAD	trans	rs4276421	0.967	rs4866979	ENSG00000231752.4	EMBP1	-6.32	7.85e-10	0.00367	-0.43	-0.32	P wave duration;	chr5:45804745	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs7185513	ENSG00000230849.2	GOT2P2	6.32	7.86e-10	0.00368	0.35	0.32	Blood metabolite ratios;	chr16:58794889	chr1:173141100~173142350:-
STAD	trans	rs8010715	0.816	rs11574503	ENSG00000238000.1	RP11-274E7.2	-6.32	7.86e-10	0.00368	-0.27	-0.32	IgG glycosylation;	chr14:24132109	chr5:98213402~98214121:+
STAD	trans	rs12709013	0.636	rs9937713	ENSG00000233719.3	GOT2P3	6.32	7.9e-10	0.0037	0.36	0.32	Blood metabolite ratios;	chr16:58771921	chr12:9641802~9643007:+
STAD	trans	rs10815468	0.585	rs4742263	ENSG00000215210.3	RBMXP2	6.32	7.92e-10	0.0037	0.35	0.32	Bipolar disorder and schizophrenia;	chr9:6782225	chr9:30689105~30690272:+
STAD	trans	rs7395662	0.553	rs11040122	ENSG00000134612.10	FOLH1B	6.32	7.93e-10	0.00371	0.38	0.32	HDL cholesterol;	chr11:48879486	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.935	rs4473777	ENSG00000231752.4	EMBP1	6.32	7.97e-10	0.00372	0.44	0.32	P wave duration;	chr5:45968760	chr1:121519112~121571892:+
STAD	trans	rs66887589	0.934	rs6817317	ENSG00000275858.1	RP11-291L22.8	-6.32	7.97e-10	0.00372	-0.34	-0.32	Diastolic blood pressure;	chr4:119621672	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.934	rs7672519	ENSG00000275858.1	RP11-291L22.8	-6.32	7.97e-10	0.00372	-0.34	-0.32	Diastolic blood pressure;	chr4:119622957	chr10:38450738~38451069:-
STAD	trans	rs66887589	0.87	rs59590064	ENSG00000275858.1	RP11-291L22.8	-6.32	7.99e-10	0.00373	-0.34	-0.32	Diastolic blood pressure;	chr4:119618598	chr10:38450738~38451069:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000224161.3	RPS26P54	-6.32	7.99e-10	0.00373	-0.33	-0.32	Cognitive function;	chr12:56080595	chr18:59761558~59761905:+
STAD	trans	rs490234	0.841	rs829311	ENSG00000229567.1	RP4-717I23.2	6.32	7.99e-10	0.00373	0.27	0.32	Mean arterial pressure;	chr9:125632344	chr1:93278961~93279129:-
STAD	trans	rs9364687	0.664	rs9364691	ENSG00000207378.1	RNU6-748P	6.32	8.05e-10	0.00376	0.35	0.32	Body mass index;	chr6:163526392	chr8:98462944~98463050:-
STAD	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	6.32	8.06e-10	0.00376	0.38	0.32	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000244641.2	RPS26P43	6.32	8.12e-10	0.00379	0.31	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr11:123049787~123050353:-
STAD	trans	rs916888	0.738	rs199515	ENSG00000264057.1	RP11-583F2.1	-6.32	8.12e-10	0.00379	-0.38	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:64927634~64934203:+
STAD	trans	rs11039798	0.764	rs2089208	ENSG00000134612.10	FOLH1B	6.32	8.26e-10	0.00385	0.57	0.32	Axial length;	chr11:48878308	chr11:89639227~89698718:+
STAD	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	6.32	8.29e-10	0.00387	0.52	0.32	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
STAD	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	6.32	8.29e-10	0.00387	0.52	0.32	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
STAD	trans	rs216303	0.57	rs216321	ENSG00000241717.1	VWFP1	6.32	8.29e-10	0.00387	0.45	0.32	Low vWF levels;	chr12:6034818	chr22:16690103~16704477:-
STAD	trans	rs4276421	0.967	rs6865429	ENSG00000231752.4	EMBP1	-6.31	8.32e-10	0.00388	-0.43	-0.32	P wave duration;	chr5:45830406	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.904	rs4489075	ENSG00000231752.4	EMBP1	6.31	8.41e-10	0.00392	0.43	0.32	P wave duration;	chr5:46018903	chr1:121519112~121571892:+
STAD	trans	rs3096299	0.754	rs2965816	ENSG00000215030.5	RPL13P12	6.31	8.46e-10	0.00394	0.28	0.32	Multiple myeloma (IgH translocation);	chr16:89447775	chr17:17383377~17384012:-
STAD	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-6.31	8.55e-10	0.00398	-0.43	-0.32	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-6.31	8.55e-10	0.00398	-0.43	-0.32	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs11644344	ENSG00000233719.3	GOT2P3	6.31	8.59e-10	0.004	0.35	0.32	Blood metabolite ratios;	chr16:58803080	chr12:9641802~9643007:+
STAD	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-6.31	8.61e-10	0.00401	-0.41	-0.32	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-6.31	8.61e-10	0.00401	-0.43	-0.32	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-6.31	8.64e-10	0.00402	-0.43	-0.32	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs1646276	ENSG00000230849.2	GOT2P2	6.31	8.65e-10	0.00403	0.34	0.32	Blood metabolite ratios;	chr16:58749654	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1646277	ENSG00000230849.2	GOT2P2	6.31	8.65e-10	0.00403	0.34	0.32	Blood metabolite ratios;	chr16:58750037	chr1:173141100~173142350:-
STAD	trans	rs9364687	0.664	rs2294706	ENSG00000207378.1	RNU6-748P	-6.31	8.69e-10	0.00404	-0.35	-0.32	Body mass index;	chr6:163521130	chr8:98462944~98463050:-
STAD	trans	rs877636	1	rs2292239	ENSG00000243328.1	RP11-520P18.1	6.31	8.69e-10	0.00404	0.32	0.32	Cognitive function;	chr12:56088396	chr8:143065915~143066587:-
STAD	trans	rs3096299	0.658	rs4785679	ENSG00000215030.5	RPL13P12	-6.31	8.71e-10	0.00405	-0.28	-0.32	Multiple myeloma (IgH translocation);	chr16:89499705	chr17:17383377~17384012:-
STAD	trans	rs702485	0.967	rs836513	ENSG00000249936.3	RAC1P2	6.31	8.75e-10	0.00407	0.29	0.32	HDL cholesterol levels;HDL cholesterol;	chr7:6420638	chr4:46723830~46724408:-
STAD	trans	rs916888	0.821	rs199504	ENSG00000264057.1	RP11-583F2.1	-6.3	8.85e-10	0.00411	-0.4	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:64927634~64934203:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000233278.1	RPS26P2	6.3	8.95e-10	0.00416	0.36	0.32	Cognitive function;	chr12:55976127	chr9:30831878~30832225:-
STAD	trans	rs9364687	0.664	rs724826	ENSG00000207378.1	RNU6-748P	6.3	9.03e-10	0.00419	0.35	0.32	Body mass index;	chr6:163517562	chr8:98462944~98463050:-
STAD	trans	rs9364687	0.628	rs4709720	ENSG00000207378.1	RNU6-748P	6.3	9.04e-10	0.0042	0.35	0.32	Body mass index;	chr6:163503273	chr8:98462944~98463050:-
STAD	trans	rs9364687	0.689	rs9364689	ENSG00000207378.1	RNU6-748P	6.3	9.04e-10	0.0042	0.35	0.32	Body mass index;	chr6:163508308	chr8:98462944~98463050:-
STAD	trans	rs12709013	0.792	rs12325054	ENSG00000230849.2	GOT2P2	6.3	9.1e-10	0.00422	0.34	0.32	Blood metabolite ratios;	chr16:58749804	chr1:173141100~173142350:-
STAD	trans	rs702485	0.903	rs836526	ENSG00000249936.3	RAC1P2	6.3	9.18e-10	0.00426	0.29	0.32	HDL cholesterol levels;HDL cholesterol;	chr7:6426458	chr4:46723830~46724408:-
STAD	trans	rs702485	0.84	rs836477	ENSG00000249936.3	RAC1P2	6.3	9.21e-10	0.00427	0.29	0.32	HDL cholesterol levels;HDL cholesterol;	chr7:6392586	chr4:46723830~46724408:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000240427.1	RPS26P34	-6.3	9.25e-10	0.00429	-0.33	-0.32	Cognitive function;	chr12:56080024	chr8:81627269~81627617:+
STAD	trans	rs916888	0.697	rs199516	ENSG00000264057.1	RP11-583F2.1	-6.29	9.33e-10	0.00432	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:64927634~64934203:+
STAD	trans	rs11039798	0.841	rs10839174	ENSG00000134612.10	FOLH1B	6.29	9.37e-10	0.00434	0.56	0.32	Axial length;	chr11:48909633	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.925	rs7929225	ENSG00000134612.10	FOLH1B	6.29	9.37e-10	0.00434	0.56	0.32	Axial length;	chr11:48910187	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.844	rs7126949	ENSG00000134612.10	FOLH1B	6.29	9.37e-10	0.00434	0.56	0.32	Axial length;	chr11:48950614	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.92	rs116109043	ENSG00000134612.10	FOLH1B	6.29	9.37e-10	0.00434	0.56	0.32	Axial length;	chr11:48955388	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs7125913	ENSG00000134612.10	FOLH1B	6.29	9.37e-10	0.00434	0.56	0.32	Axial length;	chr11:48962766	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.658	rs4980431	ENSG00000134612.10	FOLH1B	-6.29	9.49e-10	0.0044	-0.38	-0.32	Coronary artery disease;	chr11:49328519	chr11:89639227~89698718:+
STAD	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-6.29	9.56e-10	0.00442	-0.38	-0.32	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
STAD	trans	rs12145833	1	rs2802727	ENSG00000154608.12	CEP170P1	6.29	9.59e-10	0.00444	0.49	0.32	Obesity (early onset extreme);	chr1:243320024	chr4:118467590~118554204:+
STAD	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-6.29	9.64e-10	0.00446	-0.27	-0.32	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
STAD	trans	rs7395662	0.791	rs4347396	ENSG00000134612.10	FOLH1B	6.29	9.69e-10	0.00448	0.38	0.32	HDL cholesterol;	chr11:48874377	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.759	rs4347397	ENSG00000134612.10	FOLH1B	6.29	9.69e-10	0.00448	0.38	0.32	HDL cholesterol;	chr11:48874394	chr11:89639227~89698718:+
STAD	trans	rs3096299	0.685	rs2911244	ENSG00000215030.5	RPL13P12	-6.28	9.93e-10	0.00459	-0.28	-0.32	Multiple myeloma (IgH translocation);	chr16:89455452	chr17:17383377~17384012:-
STAD	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	6.28	9.96e-10	0.0046	0.41	0.32	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
STAD	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-6.28	9.98e-10	0.00461	-0.32	-0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
STAD	trans	rs12709013	0.621	rs6499974	ENSG00000233719.3	GOT2P3	6.28	1.01e-09	0.00466	0.36	0.32	Blood metabolite ratios;	chr16:58769642	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.81	rs13190242	ENSG00000231752.4	EMBP1	6.28	1.02e-09	0.0047	0.43	0.32	P wave duration;	chr5:46054443	chr1:121519112~121571892:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000244641.2	RPS26P43	6.28	1.03e-09	0.00475	0.37	0.32	Cognitive function;	chr12:56055651	chr11:123049787~123050353:-
STAD	trans	rs12709013	0.792	rs1615326	ENSG00000233719.3	GOT2P3	6.28	1.04e-09	0.00478	0.35	0.32	Blood metabolite ratios;	chr16:58747148	chr12:9641802~9643007:+
STAD	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-6.28	1.04e-09	0.0048	-0.34	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
STAD	trans	rs7113874	0.613	rs10840066	ENSG00000266891.1	RP11-692N5.2	6.28	1.04e-09	0.00482	0.42	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8510456	chr18:9734882~9735602:-
STAD	trans	rs7395662	0.784	rs79037165	ENSG00000134612.10	FOLH1B	6.27	1.05e-09	0.00485	0.38	0.32	HDL cholesterol;	chr11:48843912	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773112	ENSG00000242206.2	RPS26P35	6.27	1.05e-09	0.00485	0.36	0.32	Cognitive function;	chr12:55982097	chr8:118761856~118762201:-
STAD	trans	rs66887589	0.934	rs41464847	ENSG00000275858.1	RP11-291L22.8	-6.27	1.06e-09	0.00488	-0.34	-0.32	Diastolic blood pressure;	chr4:119611246	chr10:38450738~38451069:-
STAD	trans	rs9329221	0.905	rs10283145	ENSG00000173295.6	FAM86B3P	-6.27	1.06e-09	0.00489	-0.4	-0.32	Neuroticism;	chr8:10383901	chr8:8228595~8244865:+
STAD	trans	rs7554511	0.577	rs3861929	ENSG00000244144.1	RP11-757F18.3	6.27	1.06e-09	0.00489	0.36	0.32	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201056722	chr3:112185480~112185998:-
STAD	trans	rs2727020	0.729	rs7924782	ENSG00000134612.10	FOLH1B	-6.27	1.06e-09	0.0049	-0.37	-0.32	Coronary artery disease;	chr11:49245697	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	6.27	1.07e-09	0.00492	0.43	0.32	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
STAD	trans	rs2727020	0.729	rs1164666	ENSG00000134612.10	FOLH1B	-6.27	1.07e-09	0.00495	-0.37	-0.32	Coronary artery disease;	chr11:49274315	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.729	rs1164685	ENSG00000134612.10	FOLH1B	6.27	1.08e-09	0.00496	0.37	0.32	Coronary artery disease;	chr11:49272108	chr11:89639227~89698718:+
STAD	trans	rs877636	0.859	rs3741499	ENSG00000244641.2	RPS26P43	-6.27	1.08e-09	0.00499	-0.33	-0.32	Cognitive function;	chr12:56080595	chr11:123049787~123050353:-
STAD	trans	rs3096299	0.719	rs2965817	ENSG00000215030.5	RPL13P12	-6.27	1.09e-09	0.00501	-0.27	-0.32	Multiple myeloma (IgH translocation);	chr16:89446826	chr17:17383377~17384012:-
STAD	trans	rs80033912	0.64	rs6785832	ENSG00000197582.5	GPX1P1	6.27	1.09e-09	0.00502	0.4	0.32	Intelligence (multi-trait analysis);	chr3:49186883	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.588	rs9883000	ENSG00000197582.5	GPX1P1	6.26	1.12e-09	0.00513	0.51	0.32	Menarche (age at onset);	chr3:49630258	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.636	rs1646268	ENSG00000233719.3	GOT2P3	6.26	1.12e-09	0.00516	0.36	0.32	Blood metabolite ratios;	chr16:58743292	chr12:9641802~9643007:+
STAD	trans	rs12200782	0.53	rs9379892	ENSG00000242375.1	RP11-498P14.3	6.26	1.13e-09	0.00519	0.44	0.32	Small cell lung carcinoma;	chr6:26582186	chr9:97195351~97197687:-
STAD	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	6.26	1.13e-09	0.0052	0.38	0.32	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
STAD	trans	rs9594759	1	rs4512994	ENSG00000246640.1	RP11-1094H24.4	6.26	1.14e-09	0.00525	0.38	0.32	Bone mineral density (spine);	chr13:42465537	chr17:50050349~50055739:-
STAD	trans	rs9594759	0.967	rs9594766	ENSG00000246640.1	RP11-1094H24.4	6.26	1.14e-09	0.00525	0.38	0.32	Bone mineral density (spine);	chr13:42465907	chr17:50050349~50055739:-
STAD	trans	rs9594759	0.967	rs12428853	ENSG00000246640.1	RP11-1094H24.4	6.26	1.14e-09	0.00525	0.38	0.32	Bone mineral density (spine);	chr13:42469110	chr17:50050349~50055739:-
STAD	trans	rs9594759	0.84	rs12428878	ENSG00000246640.1	RP11-1094H24.4	6.26	1.14e-09	0.00525	0.38	0.32	Bone mineral density (spine);	chr13:42469459	chr17:50050349~50055739:-
STAD	trans	rs9594759	0.936	rs34335227	ENSG00000246640.1	RP11-1094H24.4	6.26	1.14e-09	0.00525	0.38	0.32	Bone mineral density (spine);	chr13:42476144	chr17:50050349~50055739:-
STAD	trans	rs9594759	0.934	rs2062305	ENSG00000246640.1	RP11-1094H24.4	6.26	1.14e-09	0.00525	0.38	0.32	Bone mineral density (spine);	chr13:42478744	chr17:50050349~50055739:-
STAD	trans	rs11039798	0.687	rs11499938	ENSG00000134612.10	FOLH1B	6.26	1.15e-09	0.00528	0.57	0.32	Axial length;	chr11:48935745	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.784	rs75694945	ENSG00000134612.10	FOLH1B	6.26	1.15e-09	0.0053	0.38	0.32	HDL cholesterol;	chr11:48843911	chr11:89639227~89698718:+
STAD	trans	rs9364687	0.639	rs13202282	ENSG00000207378.1	RNU6-748P	6.26	1.16e-09	0.00533	0.35	0.32	Body mass index;	chr6:163509211	chr8:98462944~98463050:-
STAD	trans	rs538867	0.661	rs114772633	ENSG00000214263.2	RPSAP53	6.26	1.17e-09	0.00535	0.83	0.32	Alzheimer's disease (cognitive decline);	chr3:39403407	chr13:67266845~67267706:-
STAD	trans	rs13177918	0.734	rs6579790	ENSG00000226396.1	RP5-1056L3.3	6.25	1.17e-09	0.00538	0.34	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:19608114~19608568:+
STAD	trans	rs12709013	0.636	rs1865836	ENSG00000233719.3	GOT2P3	6.25	1.18e-09	0.0054	0.36	0.32	Blood metabolite ratios;	chr16:58768143	chr12:9641802~9643007:+
STAD	trans	rs9329221	0.935	rs3750311	ENSG00000253981.4	ALG1L13P	-6.25	1.19e-09	0.00543	-0.42	-0.32	Neuroticism;	chr8:10426092	chr8:8236003~8244667:-
STAD	trans	rs877636	0.736	rs773107	ENSG00000244604.1	RP11-713H12.1	6.25	1.19e-09	0.00544	0.37	0.32	Cognitive function;	chr12:55975722	chr17:8561230~8561576:+
STAD	trans	rs216303	0.642	rs216324	ENSG00000241717.1	VWFP1	6.25	1.19e-09	0.00544	0.45	0.32	Low vWF levels;	chr12:6036059	chr22:16690103~16704477:-
STAD	trans	rs9611519	1	rs5758267	ENSG00000268568.1	AC007228.9	6.25	1.19e-09	0.00545	0.41	0.32	Neuroticism;	chr22:41223346	chr19:56672574~56673901:-
STAD	trans	rs12709013	0.792	rs8049572	ENSG00000233719.3	GOT2P3	6.25	1.19e-09	0.00545	0.35	0.32	Blood metabolite ratios;	chr16:58809672	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	6.25	1.19e-09	0.00545	0.43	0.32	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
STAD	trans	rs11039798	0.777	rs2202454	ENSG00000134612.10	FOLH1B	6.25	1.22e-09	0.00558	0.57	0.32	Axial length;	chr11:48989457	chr11:89639227~89698718:+
STAD	trans	rs12145833	0.596	rs3926866	ENSG00000154608.12	CEP170P1	-6.25	1.23e-09	0.00561	-0.6	-0.32	Obesity (early onset extreme);	chr1:243274330	chr4:118467590~118554204:+
STAD	trans	rs877636	1	rs4759229	ENSG00000242307.1	RPS26P52	-6.25	1.23e-09	0.00561	-0.37	-0.32	Cognitive function;	chr12:56080696	chr16:13922332~13922679:-
STAD	trans	rs9594759	1	rs2093816	ENSG00000246640.1	RP11-1094H24.4	6.25	1.23e-09	0.00564	0.38	0.32	Bone mineral density (spine);	chr13:42471900	chr17:50050349~50055739:-
STAD	trans	rs12709013	0.792	rs1657165	ENSG00000230849.2	GOT2P2	6.25	1.24e-09	0.00566	0.34	0.32	Blood metabolite ratios;	chr16:58747980	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.818	rs1646273	ENSG00000230849.2	GOT2P2	6.25	1.24e-09	0.00566	0.34	0.32	Blood metabolite ratios;	chr16:58748318	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.597	rs8051078	ENSG00000233719.3	GOT2P3	6.25	1.24e-09	0.00567	0.35	0.32	Blood metabolite ratios;	chr16:58774200	chr12:9641802~9643007:+
STAD	trans	rs1063857	0.656	rs216293	ENSG00000241717.1	VWFP1	6.25	1.24e-09	0.00567	0.32	0.32	vWF levels;Coagulation factor levels;	chr12:6044493	chr22:16690103~16704477:-
STAD	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	6.24	1.24e-09	0.00568	0.34	0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
STAD	trans	rs12709013	0.766	rs34438483	ENSG00000233719.3	GOT2P3	6.24	1.24e-09	0.00568	0.35	0.32	Blood metabolite ratios;	chr16:58810530	chr12:9641802~9643007:+
STAD	trans	rs2980439	0.818	rs2945249	ENSG00000270154.1	RP11-419I17.1	6.24	1.26e-09	0.00575	0.31	0.32	Neuroticism;	chr8:8237204	chr8:12476462~12477122:+
STAD	trans	rs9329221	0.905	rs13252982	ENSG00000253981.4	ALG1L13P	-6.24	1.26e-09	0.00576	-0.43	-0.32	Neuroticism;	chr8:10397595	chr8:8236003~8244667:-
STAD	trans	rs9329221	0.905	rs13254263	ENSG00000253981.4	ALG1L13P	-6.24	1.26e-09	0.00576	-0.43	-0.32	Neuroticism;	chr8:10397671	chr8:8236003~8244667:-
STAD	trans	rs11039798	0.688	rs12277029	ENSG00000134612.10	FOLH1B	6.24	1.26e-09	0.00577	0.55	0.32	Axial length;	chr11:48831281	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.654	rs1164676	ENSG00000134612.10	FOLH1B	6.24	1.27e-09	0.00579	0.39	0.32	Height;	chr11:49303316	chr11:89639227~89698718:+
STAD	trans	rs877636	0.701	rs34415530	ENSG00000224161.3	RPS26P54	6.24	1.27e-09	0.00579	0.35	0.32	Cognitive function;	chr12:56050848	chr18:59761558~59761905:+
STAD	trans	rs4276421	0.845	rs10434580	ENSG00000231752.4	EMBP1	6.24	1.28e-09	0.00583	0.43	0.32	P wave duration;	chr5:46010910	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs1646289	ENSG00000230849.2	GOT2P2	6.24	1.28e-09	0.00585	0.34	0.32	Blood metabolite ratios;	chr16:58755689	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs11649133	ENSG00000233719.3	GOT2P3	6.24	1.3e-09	0.00595	0.34	0.32	Blood metabolite ratios;	chr16:58803275	chr12:9641802~9643007:+
STAD	trans	rs7395662	1	rs10839171	ENSG00000134612.10	FOLH1B	6.24	1.31e-09	0.00596	0.38	0.32	HDL cholesterol;	chr11:48901482	chr11:89639227~89698718:+
STAD	trans	rs10037055	0.853	rs10035180	ENSG00000226986.4	RP11-543B16.2	-6.24	1.31e-09	0.00598	-0.31	-0.32	Migraine without aura;	chr5:177171501	chr1:211207239~211207897:+
STAD	trans	rs7395662	1	rs12419576	ENSG00000134612.10	FOLH1B	-6.24	1.31e-09	0.00598	-0.38	-0.32	HDL cholesterol;	chr11:48560092	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs61930968	ENSG00000134612.10	FOLH1B	-6.24	1.31e-09	0.00598	-0.38	-0.32	HDL cholesterol;	chr11:48560097	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.792	rs62064940	ENSG00000230849.2	GOT2P2	6.24	1.31e-09	0.00598	0.34	0.32	Blood metabolite ratios;	chr16:58796560	chr1:173141100~173142350:-
STAD	trans	rs9329221	0.87	rs11777976	ENSG00000253981.4	ALG1L13P	-6.23	1.32e-09	0.00602	-0.43	-0.32	Neuroticism;	chr8:10397892	chr8:8236003~8244667:-
STAD	trans	rs12709013	0.792	rs11649387	ENSG00000233719.3	GOT2P3	6.23	1.32e-09	0.00603	0.34	0.32	Blood metabolite ratios;	chr16:58803176	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-6.23	1.32e-09	0.00603	-0.42	-0.32	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs1646270	ENSG00000230849.2	GOT2P2	6.23	1.33e-09	0.00608	0.34	0.32	Blood metabolite ratios;	chr16:58745823	chr1:173141100~173142350:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000242307.1	RPS26P52	-6.23	1.33e-09	0.00608	-0.37	-0.32	Cognitive function;	chr12:56080595	chr16:13922332~13922679:-
STAD	trans	rs12709013	0.766	rs12599331	ENSG00000233719.3	GOT2P3	6.23	1.34e-09	0.0061	0.34	0.32	Blood metabolite ratios;	chr16:58805307	chr12:9641802~9643007:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000224161.3	RPS26P54	6.23	1.35e-09	0.00613	0.35	0.32	Cognitive function;	chr12:56009793	chr18:59761558~59761905:+
STAD	trans	rs3096299	0.685	rs4785568	ENSG00000215030.5	RPL13P12	-6.23	1.36e-09	0.00619	-0.27	-0.32	Multiple myeloma (IgH translocation);	chr16:89487299	chr17:17383377~17384012:-
STAD	trans	rs3770081	1	rs59968392	ENSG00000229880.1	IMMTP1	6.23	1.38e-09	0.00627	0.62	0.32	Facial emotion recognition (sad faces);	chr2:85907490	chr21:44675868~44678086:-
STAD	trans	rs74781061	0.932	rs11629749	ENSG00000227288.3	RP5-837I24.1	6.23	1.38e-09	0.00627	0.4	0.32	Endometriosis;	chr15:74627252	chr1:81501794~81503468:+
STAD	trans	rs12709013	0.792	rs62064940	ENSG00000233719.3	GOT2P3	6.23	1.39e-09	0.00633	0.35	0.32	Blood metabolite ratios;	chr16:58796560	chr12:9641802~9643007:+
STAD	trans	rs11220237	0.62	rs4325320	ENSG00000236257.1	EI24P2	6.22	1.4e-09	0.00635	0.47	0.32	Itch intensity from mosquito bite adjusted by bite size;	chr11:125700860	chr1:158454198~158455273:+
STAD	trans	rs7395662	0.819	rs12269855	ENSG00000134612.10	FOLH1B	-6.22	1.4e-09	0.00635	-0.37	-0.32	HDL cholesterol;	chr11:48757100	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.792	rs12595974	ENSG00000230849.2	GOT2P2	6.22	1.4e-09	0.00635	0.34	0.32	Blood metabolite ratios;	chr16:58769132	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1836877	ENSG00000230849.2	GOT2P2	6.22	1.4e-09	0.00635	0.34	0.32	Blood metabolite ratios;	chr16:58769821	chr1:173141100~173142350:-
STAD	trans	rs877636	1	rs877636	ENSG00000224161.3	RPS26P54	-6.22	1.4e-09	0.00636	-0.32	-0.32	Cognitive function;	chr12:56086799	chr18:59761558~59761905:+
STAD	trans	rs11039798	0.61	rs11530356	ENSG00000134612.10	FOLH1B	6.22	1.41e-09	0.00639	0.55	0.32	Axial length;	chr11:48814738	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-6.22	1.41e-09	0.0064	-0.42	-0.32	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	6.22	1.41e-09	0.00642	0.42	0.32	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-6.22	1.41e-09	0.00642	-0.42	-0.32	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-6.22	1.41e-09	0.00642	-0.42	-0.32	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
STAD	trans	rs4845552	0.767	rs4845551	ENSG00000216867.2	AC114776.1	6.22	1.41e-09	0.00642	0.53	0.32	Hippocampal atrophy;	chr1:153500118	chr2:110633947~110634333:+
STAD	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	6.22	1.42e-09	0.00644	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	6.22	1.44e-09	0.00651	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	6.22	1.44e-09	0.00651	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	6.22	1.44e-09	0.00651	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
STAD	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	6.22	1.44e-09	0.00651	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
STAD	trans	rs12709013	0.693	rs1627257	ENSG00000230849.2	GOT2P2	6.22	1.44e-09	0.00653	0.34	0.32	Blood metabolite ratios;	chr16:58763764	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.755	rs1628029	ENSG00000230849.2	GOT2P2	6.22	1.44e-09	0.00653	0.34	0.32	Blood metabolite ratios;	chr16:58763846	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs12926512	ENSG00000230849.2	GOT2P2	6.22	1.44e-09	0.00653	0.34	0.32	Blood metabolite ratios;	chr16:58768317	chr1:173141100~173142350:-
STAD	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	6.22	1.45e-09	0.00656	0.38	0.32	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000234192.1	RP11-57C13.5	6.22	1.46e-09	0.0066	0.37	0.32	Cognitive function;	chr12:55975722	chr10:87642607~87642954:+
STAD	trans	rs7395662	0.697	rs11530291	ENSG00000134612.10	FOLH1B	6.22	1.47e-09	0.00666	0.37	0.32	HDL cholesterol;	chr11:48742651	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.764	rs1121450	ENSG00000134612.10	FOLH1B	6.22	1.48e-09	0.00667	0.55	0.32	Axial length;	chr11:48875924	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.729	rs2204366	ENSG00000134612.10	FOLH1B	6.21	1.48e-09	0.00668	0.37	0.32	Coronary artery disease;	chr11:49327815	chr11:89639227~89698718:+
STAD	trans	rs9581094	0.591	rs9553318	ENSG00000237917.1	PARP4P1	-6.21	1.49e-09	0.00674	-0.46	-0.32	Sudden cardiac arrest;	chr13:24477107	chrY:26594851~26634652:-
STAD	trans	rs10815468	0.563	rs7851954	ENSG00000215210.3	RBMXP2	6.21	1.49e-09	0.00674	0.34	0.32	Bipolar disorder and schizophrenia;	chr9:6796167	chr9:30689105~30690272:+
STAD	trans	rs877636	1	rs877636	ENSG00000229032.1	RP11-91A18.1	-6.21	1.5e-09	0.00675	-0.35	-0.32	Cognitive function;	chr12:56086799	chr1:51980473~51980814:+
STAD	trans	rs877636	0.884	rs705705	ENSG00000224161.3	RPS26P54	6.21	1.5e-09	0.00675	0.34	0.32	Cognitive function;	chr12:56041720	chr18:59761558~59761905:+
STAD	trans	rs2950393	0.611	rs7138821	ENSG00000121089.4	NACA3P	-6.21	1.5e-09	0.00675	-0.26	-0.32	Platelet distribution width;	chr12:56796206	chr4:164943290~164943937:+
STAD	trans	rs616147	0.671	rs675595	ENSG00000183298.5	RP11-556K13.1	-6.21	1.5e-09	0.00677	-0.32	-0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr1:101786340~101787219:-
STAD	trans	rs538867	1	rs78956920	ENSG00000214263.2	RPSAP53	6.21	1.5e-09	0.00678	0.8	0.32	Alzheimer's disease (cognitive decline);	chr3:39437633	chr13:67266845~67267706:-
STAD	trans	rs7395662	0.624	rs11040162	ENSG00000134612.10	FOLH1B	6.21	1.53e-09	0.00689	0.38	0.32	HDL cholesterol;	chr11:48938439	chr11:89639227~89698718:+
STAD	trans	rs11220237	0.62	rs28602740	ENSG00000236257.1	EI24P2	6.21	1.54e-09	0.00695	0.47	0.32	Itch intensity from mosquito bite adjusted by bite size;	chr11:125691815	chr1:158454198~158455273:+
STAD	trans	rs4276421	0.736	rs8188290	ENSG00000231752.4	EMBP1	6.21	1.55e-09	0.00698	0.42	0.32	P wave duration;	chr5:46047215	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.636	rs1595180	ENSG00000233719.3	GOT2P3	6.21	1.56e-09	0.00703	0.35	0.32	Blood metabolite ratios;	chr16:58770545	chr12:9641802~9643007:+
STAD	trans	rs7395662	1	rs7948486	ENSG00000134612.10	FOLH1B	6.2	1.57e-09	0.00706	0.37	0.32	HDL cholesterol;	chr11:48890588	chr11:89639227~89698718:+
STAD	trans	rs16937956	0.657	rs16938063	ENSG00000266891.1	RP11-692N5.2	-6.2	1.57e-09	0.00708	-0.39	-0.32	Body mass index;	chr11:8410110	chr18:9734882~9735602:-
STAD	trans	rs916888	0.821	rs199512	ENSG00000264057.1	RP11-583F2.1	-6.2	1.57e-09	0.00708	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:64927634~64934203:+
STAD	trans	rs916888	0.821	rs199509	ENSG00000264057.1	RP11-583F2.1	-6.2	1.57e-09	0.00708	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:64927634~64934203:+
STAD	trans	rs916888	0.821	rs199507	ENSG00000264057.1	RP11-583F2.1	-6.2	1.57e-09	0.00708	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:64927634~64934203:+
STAD	trans	rs916888	0.821	rs199505	ENSG00000264057.1	RP11-583F2.1	-6.2	1.57e-09	0.00708	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:64927634~64934203:+
STAD	trans	rs916888	0.821	rs70602	ENSG00000264057.1	RP11-583F2.1	-6.2	1.57e-09	0.00708	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:64927634~64934203:+
STAD	trans	rs877636	0.736	rs773107	ENSG00000242970.2	AC068522.4	6.2	1.6e-09	0.00718	0.37	0.32	Cognitive function;	chr12:55975722	chr8:58588420~58588764:-
STAD	trans	rs12709013	0.686	rs151817	ENSG00000233719.3	GOT2P3	-6.2	1.61e-09	0.00724	-0.34	-0.32	Blood metabolite ratios;	chr16:58704014	chr12:9641802~9643007:+
STAD	trans	rs11039798	0.614	rs2174703	ENSG00000134612.10	FOLH1B	6.2	1.63e-09	0.00732	0.55	0.32	Axial length;	chr11:48766690	chr11:89639227~89698718:+
STAD	trans	rs877636	1	rs705696	ENSG00000224161.3	RPS26P54	6.2	1.63e-09	0.00732	0.33	0.32	Cognitive function;	chr12:56086864	chr18:59761558~59761905:+
STAD	trans	rs4845552	0.767	rs28707433	ENSG00000216867.2	AC114776.1	6.2	1.63e-09	0.00732	0.52	0.32	Hippocampal atrophy;	chr1:153497289	chr2:110633947~110634333:+
STAD	trans	rs4845552	0.767	rs4845548	ENSG00000216867.2	AC114776.1	6.2	1.63e-09	0.00732	0.52	0.32	Hippocampal atrophy;	chr1:153497691	chr2:110633947~110634333:+
STAD	trans	rs12709013	0.766	rs11648511	ENSG00000230849.2	GOT2P2	6.2	1.64e-09	0.00737	0.34	0.32	Blood metabolite ratios;	chr16:58798171	chr1:173141100~173142350:-
STAD	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-6.2	1.65e-09	0.00739	-0.42	-0.32	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-6.2	1.65e-09	0.0074	-0.42	-0.32	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
STAD	trans	rs9858542	1	rs3197999	ENSG00000197582.5	GPX1P1	-6.19	1.66e-09	0.00743	-0.49	-0.32	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684099	chrX:13378735~13379340:-
STAD	trans	rs9594759	0.967	rs1853573	ENSG00000246640.1	RP11-1094H24.4	6.19	1.66e-09	0.00746	0.38	0.32	Bone mineral density (spine);	chr13:42460832	chr17:50050349~50055739:-
STAD	trans	rs916888	0.738	rs199515	ENSG00000204650.12	CRHR1-IT1	-6.19	1.67e-09	0.00748	-0.46	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45620328~45648216:+
STAD	trans	rs11039798	1	rs11039904	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48661045	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs8188963	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48664141	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.92	rs9667596	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48669641	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.841	rs11500573	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48692348	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.92	rs11039940	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48694764	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.614	rs11039954	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48720266	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs11039978	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48738685	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs115429994	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48739631	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.764	rs7294013	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48740864	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.92	rs8186465	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48775219	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.764	rs11040030	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48779433	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.614	rs8188910	ENSG00000134612.10	FOLH1B	6.19	1.68e-09	0.00751	0.55	0.32	Axial length;	chr11:48804188	chr11:89639227~89698718:+
STAD	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	6.19	1.69e-09	0.00755	0.52	0.32	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
STAD	trans	rs12145833	1	rs10926984	ENSG00000154608.12	CEP170P1	-6.19	1.7e-09	0.00758	-0.51	-0.32	Obesity (early onset extreme);	chr1:243298851	chr4:118467590~118554204:+
STAD	trans	rs4276421	0.762	rs10043270	ENSG00000231752.4	EMBP1	6.19	1.7e-09	0.0076	0.43	0.32	P wave duration;	chr5:45967846	chr1:121519112~121571892:+
STAD	trans	rs7113874	0.659	rs12574009	ENSG00000266891.1	RP11-692N5.2	6.19	1.7e-09	0.0076	0.41	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498406	chr18:9734882~9735602:-
STAD	trans	rs877636	0.859	rs3741499	ENSG00000231366.1	RP11-399N22.3	-6.19	1.71e-09	0.00762	-0.35	-0.32	Cognitive function;	chr12:56080595	chr10:70794230~70794523:-
STAD	trans	rs12709013	0.686	rs244919	ENSG00000233719.3	GOT2P3	-6.19	1.74e-09	0.00776	-0.34	-0.32	Blood metabolite ratios;	chr16:58704146	chr12:9641802~9643007:+
STAD	trans	rs877636	1	rs4759229	ENSG00000231366.1	RP11-399N22.3	-6.19	1.74e-09	0.00777	-0.35	-0.32	Cognitive function;	chr12:56080696	chr10:70794230~70794523:-
STAD	trans	rs4845552	0.767	rs9436094	ENSG00000216867.2	AC114776.1	6.18	1.75e-09	0.00781	0.52	0.32	Hippocampal atrophy;	chr1:153498316	chr2:110633947~110634333:+
STAD	trans	rs4845552	0.767	rs6679509	ENSG00000216867.2	AC114776.1	6.18	1.75e-09	0.00781	0.52	0.32	Hippocampal atrophy;	chr1:153498821	chr2:110633947~110634333:+
STAD	trans	rs4845552	0.767	rs1964151	ENSG00000216867.2	AC114776.1	6.18	1.76e-09	0.00781	0.53	0.32	Hippocampal atrophy;	chr1:153502839	chr2:110633947~110634333:+
STAD	trans	rs7395662	0.892	rs11040010	ENSG00000134612.10	FOLH1B	6.18	1.76e-09	0.00783	0.37	0.32	HDL cholesterol;	chr11:48755377	chr11:89639227~89698718:+
STAD	trans	rs877636	0.847	rs2017445	ENSG00000224161.3	RPS26P54	6.18	1.77e-09	0.00786	0.34	0.32	Cognitive function;	chr12:56013288	chr18:59761558~59761905:+
STAD	trans	rs877636	0.847	rs1701704	ENSG00000224161.3	RPS26P54	6.18	1.77e-09	0.00786	0.34	0.32	Cognitive function;	chr12:56018703	chr18:59761558~59761905:+
STAD	trans	rs10940346	0.807	rs6898102	ENSG00000231752.4	EMBP1	-6.18	1.77e-09	0.00788	-0.4	-0.32	Schizophrenia;	chr5:50578496	chr1:121519112~121571892:+
STAD	trans	rs916888	0.821	rs415430	ENSG00000264057.1	RP11-583F2.1	-6.18	1.77e-09	0.00788	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:64927634~64934203:+
STAD	trans	rs916888	0.779	rs430685	ENSG00000264057.1	RP11-583F2.1	-6.18	1.77e-09	0.00788	-0.39	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:64927634~64934203:+
STAD	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-6.18	1.79e-09	0.00795	-0.42	-0.32	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
STAD	trans	rs877636	1	rs4759229	ENSG00000224161.3	RPS26P54	-6.18	1.79e-09	0.00797	-0.32	-0.32	Cognitive function;	chr12:56080696	chr18:59761558~59761905:+
STAD	trans	rs4276421	0.845	rs62372987	ENSG00000231752.4	EMBP1	6.18	1.79e-09	0.00797	0.43	0.32	P wave duration;	chr5:45979889	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.792	rs12596434	ENSG00000230849.2	GOT2P2	6.18	1.8e-09	0.00798	0.34	0.32	Blood metabolite ratios;	chr16:58792309	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs12928733	ENSG00000233719.3	GOT2P3	6.18	1.8e-09	0.00801	0.34	0.32	Blood metabolite ratios;	chr16:58807216	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs62066381	ENSG00000233719.3	GOT2P3	6.18	1.8e-09	0.00801	0.34	0.32	Blood metabolite ratios;	chr16:58807981	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs36098613	ENSG00000233719.3	GOT2P3	6.18	1.8e-09	0.00801	0.34	0.32	Blood metabolite ratios;	chr16:58810562	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-6.18	1.81e-09	0.00805	-0.42	-0.32	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
STAD	trans	rs2645694	0.626	rs2645705	ENSG00000229217.1	CYCSP11	6.18	1.84e-09	0.00817	0.36	0.32	Emphysema distribution in smoking;	chr4:76909281	chr3:10057973~10058287:-
STAD	trans	rs2645694	0.626	rs2703143	ENSG00000229217.1	CYCSP11	6.18	1.84e-09	0.00817	0.36	0.32	Emphysema distribution in smoking;	chr4:76909288	chr3:10057973~10058287:-
STAD	trans	rs2645694	0.651	rs2703144	ENSG00000229217.1	CYCSP11	6.18	1.84e-09	0.00817	0.36	0.32	Emphysema distribution in smoking;	chr4:76909352	chr3:10057973~10058287:-
STAD	trans	rs7113874	0.659	rs12295855	ENSG00000266891.1	RP11-692N5.2	6.18	1.85e-09	0.00822	0.41	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8505871	chr18:9734882~9735602:-
STAD	trans	rs3770081	1	rs2241435	ENSG00000229880.1	IMMTP1	6.17	1.86e-09	0.00824	0.62	0.32	Facial emotion recognition (sad faces);	chr2:86133793	chr21:44675868~44678086:-
STAD	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	6.17	1.86e-09	0.00824	0.36	0.32	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
STAD	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	6.17	1.86e-09	0.00827	0.43	0.32	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000219993.1	RP11-288G3.3	6.17	1.87e-09	0.00831	0.32	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr6:7506203~7506549:+
STAD	trans	rs4276421	0.774	rs4428422	ENSG00000231752.4	EMBP1	6.17	1.88e-09	0.00835	0.42	0.31	P wave duration;	chr5:46017216	chr1:121519112~121571892:+
STAD	trans	rs9329221	0.772	rs7824675	ENSG00000173295.6	FAM86B3P	-6.17	1.89e-09	0.00839	-0.38	-0.31	Neuroticism;	chr8:10385908	chr8:8228595~8244865:+
STAD	trans	rs2288884	0.634	rs17835649	ENSG00000271032.1	CTD-2527I21.14	6.17	1.89e-09	0.0084	0.37	0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997362	chr19:35014961~35025335:-
STAD	trans	rs916888	0.773	rs9896243	ENSG00000204650.12	CRHR1-IT1	6.17	1.91e-09	0.00846	0.49	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45620328~45648216:+
STAD	trans	rs9594759	0.967	rs1830790	ENSG00000246640.1	RP11-1094H24.4	6.17	1.93e-09	0.00854	0.37	0.31	Bone mineral density (spine);	chr13:42452525	chr17:50050349~50055739:-
STAD	trans	rs877636	0.847	rs2456973	ENSG00000224161.3	RPS26P54	6.17	1.94e-09	0.00859	0.34	0.31	Cognitive function;	chr12:56023144	chr18:59761558~59761905:+
STAD	trans	rs11039798	0.764	rs12277213	ENSG00000134612.10	FOLH1B	6.17	1.96e-09	0.00866	0.55	0.31	Axial length;	chr11:48760624	chr11:89639227~89698718:+
STAD	trans	rs2069408	1	rs2069408	ENSG00000227887.1	RPS26P13	-6.16	1.97e-09	0.0087	-0.34	-0.31	Asthma;	chr12:55970537	chr1:208697369~208697698:-
STAD	trans	rs7395662	0.611	rs11040073	ENSG00000134612.10	FOLH1B	6.16	1.97e-09	0.0087	0.37	0.31	HDL cholesterol;	chr11:48834072	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.655	rs2202458	ENSG00000134612.10	FOLH1B	6.16	1.97e-09	0.0087	0.37	0.31	HDL cholesterol;	chr11:48834995	chr11:89639227~89698718:+
STAD	trans	rs9611519	0.929	rs4820425	ENSG00000268568.1	AC007228.9	-6.16	1.97e-09	0.00872	-0.45	-0.31	Neuroticism;	chr22:41035338	chr19:56672574~56673901:-
STAD	trans	rs9329221	0.905	rs13252982	ENSG00000173295.6	FAM86B3P	-6.16	1.98e-09	0.00874	-0.4	-0.31	Neuroticism;	chr8:10397595	chr8:8228595~8244865:+
STAD	trans	rs9329221	0.905	rs13254263	ENSG00000173295.6	FAM86B3P	-6.16	1.98e-09	0.00874	-0.4	-0.31	Neuroticism;	chr8:10397671	chr8:8228595~8244865:+
STAD	trans	rs7395662	0.963	rs9666932	ENSG00000134612.10	FOLH1B	6.16	1.98e-09	0.00874	0.37	0.31	HDL cholesterol;	chr11:48704688	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.926	rs7122869	ENSG00000134612.10	FOLH1B	6.16	1.98e-09	0.00874	0.37	0.31	HDL cholesterol;	chr11:48706447	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.892	rs9667579	ENSG00000134612.10	FOLH1B	6.16	1.98e-09	0.00874	0.37	0.31	HDL cholesterol;	chr11:48708596	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs8189076	ENSG00000134612.10	FOLH1B	6.16	1.98e-09	0.00874	0.37	0.31	HDL cholesterol;	chr11:48711423	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.857	rs3902433	ENSG00000134612.10	FOLH1B	6.16	1.98e-09	0.00874	0.37	0.31	HDL cholesterol;	chr11:48711772	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.889	rs11039972	ENSG00000134612.10	FOLH1B	6.16	1.98e-09	0.00874	0.37	0.31	HDL cholesterol;	chr11:48737700	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.667	rs2865612	ENSG00000134612.10	FOLH1B	6.16	1.98e-09	0.00874	0.37	0.31	HDL cholesterol;	chr11:48758670	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.766	rs11648511	ENSG00000233719.3	GOT2P3	6.16	1.99e-09	0.00877	0.34	0.31	Blood metabolite ratios;	chr16:58798171	chr12:9641802~9643007:+
STAD	trans	rs216303	0.554	rs216320	ENSG00000241717.1	VWFP1	6.16	1.99e-09	0.0088	0.44	0.31	Low vWF levels;	chr12:6034190	chr22:16690103~16704477:-
STAD	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	6.16	1.99e-09	0.0088	0.36	0.31	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
STAD	trans	rs11039798	0.92	rs11500574	ENSG00000134612.10	FOLH1B	6.16	2.01e-09	0.00885	0.56	0.31	Axial length;	chr11:48692434	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.688	rs8188953	ENSG00000134612.10	FOLH1B	6.16	2.01e-09	0.00885	0.56	0.31	Axial length;	chr11:48727649	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs12225599	ENSG00000134612.10	FOLH1B	6.16	2.01e-09	0.00885	0.56	0.31	Axial length;	chr11:48734316	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.541	rs12283728	ENSG00000134612.10	FOLH1B	6.16	2.01e-09	0.00885	0.56	0.31	Axial length;	chr11:48774855	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.636	rs8060717	ENSG00000233719.3	GOT2P3	6.16	2.02e-09	0.00892	0.35	0.31	Blood metabolite ratios;	chr16:58765574	chr12:9641802~9643007:+
STAD	trans	rs77954165	0.614	rs4742249	ENSG00000215210.3	RBMXP2	6.16	2.03e-09	0.00893	0.41	0.31	Stem cell growth factor beta levels;	chr9:6728508	chr9:30689105~30690272:+
STAD	trans	rs702485	0.868	rs836471	ENSG00000249936.3	RAC1P2	6.16	2.03e-09	0.00895	0.27	0.31	HDL cholesterol levels;HDL cholesterol;	chr7:6395481	chr4:46723830~46724408:-
STAD	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	6.16	2.05e-09	0.00903	0.42	0.31	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.636	rs4499224	ENSG00000233719.3	GOT2P3	6.16	2.06e-09	0.00908	0.35	0.31	Blood metabolite ratios;	chr16:58770364	chr12:9641802~9643007:+
STAD	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	6.15	2.12e-09	0.0093	0.41	0.31	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
STAD	trans	rs9329221	0.87	rs11777976	ENSG00000173295.6	FAM86B3P	-6.15	2.12e-09	0.00931	-0.4	-0.31	Neuroticism;	chr8:10397892	chr8:8228595~8244865:+
STAD	trans	rs877636	0.847	rs772921	ENSG00000242307.1	RPS26P52	6.15	2.13e-09	0.00936	0.39	0.31	Cognitive function;	chr12:56009793	chr16:13922332~13922679:-
STAD	trans	rs1063857	0.656	rs216292	ENSG00000241717.1	VWFP1	6.15	2.13e-09	0.00938	0.32	0.31	vWF levels;Coagulation factor levels;	chr12:6043810	chr22:16690103~16704477:-
STAD	trans	rs877636	0.669	rs7297175	ENSG00000229032.1	RP11-91A18.1	-6.15	2.14e-09	0.00939	-0.33	-0.31	Cognitive function;	chr12:56080024	chr1:51980473~51980814:+
STAD	trans	rs7395662	0.791	rs7945791	ENSG00000134612.10	FOLH1B	6.15	2.14e-09	0.0094	0.37	0.31	HDL cholesterol;	chr11:48914788	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.791	rs11040136	ENSG00000134612.10	FOLH1B	6.15	2.14e-09	0.0094	0.37	0.31	HDL cholesterol;	chr11:48918239	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.617	rs1976509	ENSG00000134612.10	FOLH1B	6.15	2.14e-09	0.0094	0.37	0.31	HDL cholesterol;	chr11:48943051	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.688	rs11040338	ENSG00000134612.10	FOLH1B	6.15	2.15e-09	0.00945	0.37	0.31	Coronary artery disease;	chr11:49339049	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs2221559	ENSG00000134612.10	FOLH1B	6.15	2.16e-09	0.0095	0.37	0.31	HDL cholesterol;	chr11:48686421	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs11499897	ENSG00000134612.10	FOLH1B	6.15	2.16e-09	0.0095	0.37	0.31	HDL cholesterol;	chr11:48696314	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.895	rs3903506	ENSG00000134612.10	FOLH1B	6.15	2.16e-09	0.0095	0.37	0.31	HDL cholesterol;	chr11:48696961	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.716	rs11647582	ENSG00000233719.3	GOT2P3	6.15	2.17e-09	0.00951	0.34	0.31	Blood metabolite ratios;	chr16:58801474	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs35684307	ENSG00000233719.3	GOT2P3	6.15	2.17e-09	0.00951	0.34	0.31	Blood metabolite ratios;	chr16:58801651	chr12:9641802~9643007:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000240427.1	RPS26P34	6.15	2.18e-09	0.00956	0.34	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:81627269~81627617:+
STAD	trans	rs4276421	0.904	rs10070596	ENSG00000231752.4	EMBP1	6.15	2.18e-09	0.00958	0.42	0.31	P wave duration;	chr5:46004129	chr1:121519112~121571892:+
STAD	trans	rs877636	0.847	rs705704	ENSG00000224161.3	RPS26P54	6.15	2.19e-09	0.00958	0.34	0.31	Cognitive function;	chr12:56041628	chr18:59761558~59761905:+
STAD	trans	rs9611519	0.894	rs8136923	ENSG00000268568.1	AC007228.9	-6.15	2.19e-09	0.00961	-0.44	-0.31	Neuroticism;	chr22:41074518	chr19:56672574~56673901:-
STAD	trans	rs7395662	0.791	rs12273724	ENSG00000134612.10	FOLH1B	6.15	2.2e-09	0.00962	0.37	0.31	HDL cholesterol;	chr11:48824158	chr11:89639227~89698718:+
STAD	trans	rs11809230	0.541	rs59103514	ENSG00000260209.1	RP11-680F20.10	6.14	2.21e-09	0.00966	0.54	0.31	Cannabis use (initiation);	chr1:69674288	chr11:125873031~125874528:-
STAD	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-6.14	2.22e-09	0.00972	-0.35	-0.31	Mumps;	chr20:2665687	chr6:28783633~28784004:-
STAD	trans	rs9611519	0.894	rs9623320	ENSG00000268568.1	AC007228.9	-6.14	2.23e-09	0.00975	-0.44	-0.31	Neuroticism;	chr22:41082478	chr19:56672574~56673901:-
STAD	trans	rs877636	0.701	rs34415530	ENSG00000242307.1	RPS26P52	6.14	2.26e-09	0.0099	0.39	0.31	Cognitive function;	chr12:56050848	chr16:13922332~13922679:-
STAD	trans	rs12709013	0.792	rs12325510	ENSG00000233719.3	GOT2P3	6.14	2.28e-09	0.00999	0.34	0.31	Blood metabolite ratios;	chr16:58749707	chr12:9641802~9643007:+
STAD	trans	rs7395662	0.747	rs11040106	ENSG00000134612.10	FOLH1B	6.14	2.29e-09	0.00999	0.37	0.31	HDL cholesterol;	chr11:48867574	chr11:89639227~89698718:+
STAD	trans	rs7617480	0.648	rs6801211	ENSG00000197582.5	GPX1P1	6.14	2.31e-09	0.0101	0.46	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chrX:13378735~13379340:-
STAD	trans	rs12145833	1	rs76473275	ENSG00000154608.12	CEP170P1	-6.14	2.31e-09	0.0101	-0.51	-0.31	Obesity (early onset extreme);	chr1:243297253	chr4:118467590~118554204:+
STAD	trans	rs12200782	0.53	rs6929908	ENSG00000242375.1	RP11-498P14.3	6.14	2.32e-09	0.0101	0.44	0.31	Small cell lung carcinoma;	chr6:26555061	chr9:97195351~97197687:-
STAD	trans	rs7312770	0.637	rs705700	ENSG00000226339.1	RPS26P56	6.14	2.33e-09	0.0102	0.31	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:129408382~129408621:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000244641.2	RPS26P43	6.13	2.33e-09	0.0102	0.31	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr11:123049787~123050353:-
STAD	trans	rs877636	0.702	rs773112	ENSG00000244641.2	RPS26P43	6.13	2.34e-09	0.0102	0.33	0.31	Cognitive function;	chr12:55982097	chr11:123049787~123050353:-
STAD	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	6.13	2.34e-09	0.0102	0.35	0.31	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
STAD	trans	rs7647973	0.667	rs4241405	ENSG00000197582.5	GPX1P1	6.13	2.36e-09	0.0103	0.51	0.31	Menarche (age at onset);	chr3:49604594	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.71	rs12637313	ENSG00000197582.5	GPX1P1	6.13	2.36e-09	0.0103	0.51	0.31	Menarche (age at onset);	chr3:49608025	chrX:13378735~13379340:-
STAD	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	6.13	2.36e-09	0.0103	0.43	0.31	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
STAD	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-6.13	2.37e-09	0.0103	-0.44	-0.31	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
STAD	trans	rs916888	0.773	rs199448	ENSG00000204650.12	CRHR1-IT1	6.13	2.39e-09	0.0104	0.48	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45620328~45648216:+
STAD	trans	rs13190036	1	rs628506	ENSG00000226986.4	RP11-543B16.2	-6.13	2.41e-09	0.0105	-0.33	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr1:211207239~211207897:+
STAD	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	6.13	2.41e-09	0.0105	0.37	0.31	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
STAD	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	6.13	2.42e-09	0.0105	0.41	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
STAD	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	6.13	2.42e-09	0.0105	0.41	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
STAD	trans	rs12709013	0.636	rs4538000	ENSG00000233719.3	GOT2P3	6.13	2.45e-09	0.0107	0.35	0.31	Blood metabolite ratios;	chr16:58744506	chr12:9641802~9643007:+
STAD	trans	rs11220082	0.661	rs11220054	ENSG00000236257.1	EI24P2	-6.13	2.45e-09	0.0107	-0.4	-0.31	Schizophrenia;	chr11:125415184	chr1:158454198~158455273:+
STAD	trans	rs877636	0.74	rs772920	ENSG00000233278.1	RPS26P2	6.13	2.45e-09	0.0107	0.34	0.31	Cognitive function;	chr12:55996580	chr9:30831878~30832225:-
STAD	trans	rs11039798	1	rs12281162	ENSG00000134612.10	FOLH1B	6.13	2.46e-09	0.0107	0.55	0.31	Axial length;	chr11:48628939	chr11:89639227~89698718:+
STAD	trans	rs877636	1	rs2292239	ENSG00000231366.1	RP11-399N22.3	6.13	2.46e-09	0.0107	0.34	0.31	Cognitive function;	chr12:56088396	chr10:70794230~70794523:-
STAD	trans	rs12709013	0.792	rs7185513	ENSG00000233719.3	GOT2P3	6.12	2.49e-09	0.0108	0.34	0.31	Blood metabolite ratios;	chr16:58794889	chr12:9641802~9643007:+
STAD	trans	rs11039798	0.764	rs11039929	ENSG00000134612.10	FOLH1B	6.12	2.5e-09	0.0109	0.55	0.31	Axial length;	chr11:48681737	chr11:89639227~89698718:+
STAD	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	6.12	2.51e-09	0.0109	0.38	0.31	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
STAD	trans	rs12709013	0.804	rs8051459	ENSG00000230849.2	GOT2P2	6.12	2.52e-09	0.0109	0.35	0.31	Blood metabolite ratios;	chr16:58783436	chr1:173141100~173142350:-
STAD	trans	rs7395662	0.963	rs11040016	ENSG00000134612.10	FOLH1B	6.12	2.53e-09	0.011	0.37	0.31	HDL cholesterol;	chr11:48761945	chr11:89639227~89698718:+
STAD	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	6.12	2.57e-09	0.0111	0.4	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
STAD	trans	rs7113874	0.659	rs1867810	ENSG00000266891.1	RP11-692N5.2	6.12	2.57e-09	0.0112	0.41	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483981	chr18:9734882~9735602:-
STAD	trans	rs12709013	0.792	rs12596434	ENSG00000233719.3	GOT2P3	6.12	2.58e-09	0.0112	0.34	0.31	Blood metabolite ratios;	chr16:58792309	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1646272	ENSG00000233719.3	GOT2P3	6.12	2.58e-09	0.0112	0.35	0.31	Blood metabolite ratios;	chr16:58746508	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.66	rs1657163	ENSG00000233719.3	GOT2P3	6.12	2.58e-09	0.0112	0.35	0.31	Blood metabolite ratios;	chr16:58746688	chr12:9641802~9643007:+
STAD	trans	rs7617480	0.585	rs7373072	ENSG00000197582.5	GPX1P1	6.12	2.59e-09	0.0112	0.46	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48922584	chrX:13378735~13379340:-
STAD	trans	rs7395662	0.746	rs8186207	ENSG00000134612.10	FOLH1B	-6.12	2.6e-09	0.0113	-0.37	-0.31	HDL cholesterol;	chr11:48743813	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1794162	ENSG00000134612.10	FOLH1B	-6.11	2.63e-09	0.0114	-0.35	-0.31	Height;	chr11:49877954	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.791	rs10839468	ENSG00000134612.10	FOLH1B	-6.11	2.65e-09	0.0115	-0.34	-0.31	Height;	chr11:49964738	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs6486046	ENSG00000134612.10	FOLH1B	-6.11	2.65e-09	0.0115	-0.34	-0.31	Height;	chr11:49975471	chr11:89639227~89698718:+
STAD	trans	rs877636	0.847	rs2456973	ENSG00000242307.1	RPS26P52	6.11	2.65e-09	0.0115	0.39	0.31	Cognitive function;	chr12:56023144	chr16:13922332~13922679:-
STAD	trans	rs10037055	0.947	rs10063803	ENSG00000226986.4	RP11-543B16.2	6.11	2.67e-09	0.0116	0.3	0.31	Migraine without aura;	chr5:177240326	chr1:211207239~211207897:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000226339.1	RPS26P56	6.11	2.69e-09	0.0116	0.34	0.31	Cognitive function;	chr12:55981956	chrX:129408382~129408621:+
STAD	trans	rs12709013	0.636	rs72792430	ENSG00000233719.3	GOT2P3	-6.11	2.7e-09	0.0117	-0.35	-0.31	Blood metabolite ratios;	chr16:58746990	chr12:9641802~9643007:+
STAD	trans	rs7554511	0.893	rs12122721	ENSG00000244144.1	RP11-757F18.3	6.11	2.71e-09	0.0117	0.33	0.31	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201015352	chr3:112185480~112185998:-
STAD	trans	rs2727020	0.729	rs1917325	ENSG00000134612.10	FOLH1B	-6.11	2.72e-09	0.0118	-0.36	-0.31	Coronary artery disease;	chr11:49348452	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.704	rs4144700	ENSG00000134612.10	FOLH1B	-6.11	2.72e-09	0.0118	-0.36	-0.31	Coronary artery disease;	chr11:49349282	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	6.1	2.78e-09	0.012	0.42	0.31	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
STAD	trans	rs7303433	1	rs16926279	ENSG00000279434.1	RP11-85K15.3	-6.1	2.78e-09	0.012	-0.45	-0.31	Schizophrenia;	chr12:23486913	chr14:35086035~35088059:+
STAD	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	6.1	2.79e-09	0.0121	0.42	0.31	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
STAD	trans	rs7647973	0.71	rs2029591	ENSG00000197582.5	GPX1P1	-6.1	2.8e-09	0.0121	-0.51	-0.31	Menarche (age at onset);	chr3:49609548	chrX:13378735~13379340:-
STAD	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	6.1	2.82e-09	0.0122	0.53	0.31	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
STAD	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	6.1	2.82e-09	0.0122	0.53	0.31	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
STAD	trans	rs12709013	0.792	rs1657165	ENSG00000233719.3	GOT2P3	6.1	2.83e-09	0.0122	0.34	0.31	Blood metabolite ratios;	chr16:58747980	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.818	rs1646273	ENSG00000233719.3	GOT2P3	6.1	2.83e-09	0.0122	0.34	0.31	Blood metabolite ratios;	chr16:58748318	chr12:9641802~9643007:+
STAD	trans	rs7395662	0.963	rs11039950	ENSG00000134612.10	FOLH1B	6.1	2.84e-09	0.0122	0.37	0.31	HDL cholesterol;	chr11:48715919	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.597	rs1616072	ENSG00000233719.3	GOT2P3	6.1	2.84e-09	0.0123	0.35	0.31	Blood metabolite ratios;	chr16:58747194	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs2575374	ENSG00000233719.3	GOT2P3	6.1	2.84e-09	0.0123	0.35	0.31	Blood metabolite ratios;	chr16:58747494	chr12:9641802~9643007:+
STAD	trans	rs8010715	1	rs3742500	ENSG00000238000.1	RP11-274E7.2	6.1	2.85e-09	0.0123	0.28	0.31	IgG glycosylation;	chr14:24142769	chr5:98213402~98214121:+
STAD	trans	rs9594759	0.967	rs9594768	ENSG00000246640.1	RP11-1094H24.4	6.1	2.85e-09	0.0123	0.37	0.31	Bone mineral density (spine);	chr13:42475346	chr17:50050349~50055739:-
STAD	trans	rs877636	0.847	rs2017445	ENSG00000242307.1	RPS26P52	6.1	2.85e-09	0.0123	0.39	0.31	Cognitive function;	chr12:56013288	chr16:13922332~13922679:-
STAD	trans	rs877636	0.847	rs1701704	ENSG00000242307.1	RPS26P52	6.1	2.85e-09	0.0123	0.39	0.31	Cognitive function;	chr12:56018703	chr16:13922332~13922679:-
STAD	trans	rs3096299	0.667	rs2965947	ENSG00000215030.5	RPL13P12	-6.1	2.86e-09	0.0123	-0.27	-0.31	Multiple myeloma (IgH translocation);	chr16:89452262	chr17:17383377~17384012:-
STAD	trans	rs7395662	0.687	rs11602892	ENSG00000134612.10	FOLH1B	-6.1	2.86e-09	0.0123	-0.37	-0.31	HDL cholesterol;	chr11:48937600	chr11:89639227~89698718:+
STAD	trans	rs2980439	0.818	rs2948294	ENSG00000270154.1	RP11-419I17.1	6.1	2.86e-09	0.0123	0.3	0.31	Neuroticism;	chr8:8237439	chr8:12476462~12477122:+
STAD	trans	rs11039798	1	rs6485908	ENSG00000134612.10	FOLH1B	-6.1	2.88e-09	0.0124	-0.53	-0.31	Axial length;	chr11:48630646	chr11:89639227~89698718:+
STAD	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	6.1	2.88e-09	0.0124	0.37	0.31	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	6.1	2.88e-09	0.0124	0.37	0.31	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
STAD	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	6.1	2.88e-09	0.0124	0.37	0.31	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
STAD	trans	rs12709013	0.636	rs1646282	ENSG00000233719.3	GOT2P3	6.1	2.91e-09	0.0125	0.35	0.31	Blood metabolite ratios;	chr16:58741296	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs4784977	ENSG00000233719.3	GOT2P3	6.1	2.91e-09	0.0125	0.35	0.31	Blood metabolite ratios;	chr16:58742120	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1657161	ENSG00000233719.3	GOT2P3	6.1	2.91e-09	0.0125	0.35	0.31	Blood metabolite ratios;	chr16:58743234	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1646269	ENSG00000233719.3	GOT2P3	6.1	2.91e-09	0.0125	0.35	0.31	Blood metabolite ratios;	chr16:58743412	chr12:9641802~9643007:+
STAD	trans	rs11039798	0.925	rs10769373	ENSG00000134612.10	FOLH1B	6.09	2.94e-09	0.0126	0.56	0.31	Axial length;	chr11:48510428	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs6485848	ENSG00000134612.10	FOLH1B	6.09	2.95e-09	0.0127	0.56	0.31	Axial length;	chr11:48519965	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs10838942	ENSG00000134612.10	FOLH1B	6.09	2.95e-09	0.0127	0.56	0.31	Axial length;	chr11:48535611	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs7479655	ENSG00000134612.10	FOLH1B	6.09	2.95e-09	0.0127	0.56	0.31	Axial length;	chr11:48555162	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.841	rs11039783	ENSG00000134612.10	FOLH1B	6.09	2.97e-09	0.0127	0.57	0.31	Axial length;	chr11:48505276	chr11:89639227~89698718:+
STAD	trans	rs4845552	0.723	rs4845550	ENSG00000216867.2	AC114776.1	6.09	2.99e-09	0.0128	0.51	0.31	Hippocampal atrophy;	chr1:153500080	chr2:110633947~110634333:+
STAD	trans	rs12709013	0.59	rs982848	ENSG00000233719.3	GOT2P3	6.09	3e-09	0.0129	0.33	0.31	Blood metabolite ratios;	chr16:58704294	chr12:9641802~9643007:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000224161.3	RPS26P54	6.09	3.03e-09	0.013	0.3	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr18:59761558~59761905:+
STAD	trans	rs11039798	1	rs34044596	ENSG00000134612.10	FOLH1B	6.09	3.04e-09	0.013	0.57	0.31	Axial length;	chr11:48506384	chr11:89639227~89698718:+
STAD	trans	rs9594759	0.967	rs9533108	ENSG00000246640.1	RP11-1094H24.4	6.09	3.04e-09	0.013	0.37	0.31	Bone mineral density (spine);	chr13:42450574	chr17:50050349~50055739:-
STAD	trans	rs12709013	0.792	rs11644344	ENSG00000230849.2	GOT2P2	6.09	3.05e-09	0.0131	0.34	0.31	Blood metabolite ratios;	chr16:58803080	chr1:173141100~173142350:-
STAD	trans	rs12542166	1	rs12542166	ENSG00000224490.4	TTC21B-AS1	6.09	3.06e-09	0.0131	0.54	0.31	White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy;	chr8:121970599	chr2:165933857~165949891:+
STAD	trans	rs9650657	0.572	rs11250098	ENSG00000254340.1	RP11-10A14.3	-6.09	3.09e-09	0.0132	-0.38	-0.31	Neuroticism;	chr8:10961097	chr8:9141424~9145435:+
STAD	trans	rs7395662	1	rs10838954	ENSG00000134612.10	FOLH1B	-6.09	3.09e-09	0.0132	-0.37	-0.31	HDL cholesterol;	chr11:48557771	chr11:89639227~89698718:+
STAD	trans	rs916888	0.773	rs9896243	ENSG00000264057.1	RP11-583F2.1	6.08	3.1e-09	0.0133	0.39	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:64927634~64934203:+
STAD	trans	rs2280018	0.581	rs7404524	ENSG00000279135.1	RP11-261P13.5	6.08	3.11e-09	0.0133	0.36	0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr13:20712431~20714146:+
STAD	trans	rs7395662	0.927	rs8188938	ENSG00000134612.10	FOLH1B	6.08	3.13e-09	0.0134	0.36	0.31	HDL cholesterol;	chr11:48669314	chr11:89639227~89698718:+
STAD	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	6.08	3.15e-09	0.0135	0.4	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
STAD	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	6.08	3.15e-09	0.0135	0.4	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
STAD	trans	rs2727020	0.558	rs1164675	ENSG00000134612.10	FOLH1B	6.08	3.16e-09	0.0135	0.38	0.31	Coronary artery disease;	chr11:49304420	chr11:89639227~89698718:+
STAD	trans	rs7617480	0.648	rs9284885	ENSG00000197582.5	GPX1P1	6.08	3.16e-09	0.0135	0.46	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48845667	chrX:13378735~13379340:-
STAD	trans	rs7395662	0.724	rs10400308	ENSG00000134612.10	FOLH1B	-6.08	3.18e-09	0.0136	-0.37	-0.31	HDL cholesterol;	chr11:48869694	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.709	rs11040113	ENSG00000134612.10	FOLH1B	-6.08	3.18e-09	0.0136	-0.37	-0.31	HDL cholesterol;	chr11:48874101	chr11:89639227~89698718:+
STAD	trans	rs877636	0.847	rs705704	ENSG00000242307.1	RPS26P52	6.08	3.18e-09	0.0136	0.39	0.31	Cognitive function;	chr12:56041628	chr16:13922332~13922679:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000234354.3	RPS26P47	6.08	3.2e-09	0.0136	0.41	0.31	Cognitive function;	chr12:55990903	chr13:100539901~100540248:-
STAD	trans	rs12709013	0.792	rs8049572	ENSG00000230849.2	GOT2P2	6.08	3.2e-09	0.0137	0.33	0.31	Blood metabolite ratios;	chr16:58809672	chr1:173141100~173142350:-
STAD	trans	rs4276421	0.967	rs4541665	ENSG00000231752.4	EMBP1	-6.08	3.2e-09	0.0137	-0.42	-0.31	P wave duration;	chr5:45796444	chr1:121519112~121571892:+
STAD	trans	rs7395662	0.927	rs2135690	ENSG00000134612.10	FOLH1B	6.08	3.2e-09	0.0137	0.36	0.31	HDL cholesterol;	chr11:48712049	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.658	rs8189235	ENSG00000134612.10	FOLH1B	6.08	3.2e-09	0.0137	0.36	0.31	HDL cholesterol;	chr11:48718512	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.581	rs10769445	ENSG00000134612.10	FOLH1B	6.08	3.2e-09	0.0137	0.36	0.31	HDL cholesterol;	chr11:48744042	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.625	rs11040006	ENSG00000134612.10	FOLH1B	6.08	3.2e-09	0.0137	0.36	0.31	HDL cholesterol;	chr11:48752750	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.892	rs11040014	ENSG00000134612.10	FOLH1B	6.08	3.2e-09	0.0137	0.36	0.31	HDL cholesterol;	chr11:48761505	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.792	rs1646276	ENSG00000233719.3	GOT2P3	6.08	3.23e-09	0.0138	0.34	0.31	Blood metabolite ratios;	chr16:58749654	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs1646277	ENSG00000233719.3	GOT2P3	6.08	3.23e-09	0.0138	0.34	0.31	Blood metabolite ratios;	chr16:58750037	chr12:9641802~9643007:+
STAD	trans	rs702485	0.84	rs836480	ENSG00000249936.3	RAC1P2	6.08	3.25e-09	0.0138	0.28	0.31	HDL cholesterol levels;HDL cholesterol;	chr7:6391773	chr4:46723830~46724408:-
STAD	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	6.08	3.26e-09	0.0139	0.35	0.31	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
STAD	trans	rs7395662	1	rs8189391	ENSG00000134612.10	FOLH1B	6.08	3.26e-09	0.0139	0.37	0.31	HDL cholesterol;	chr11:48838237	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs7479498	ENSG00000134612.10	FOLH1B	-6.07	3.27e-09	0.0139	-0.36	-0.31	HDL cholesterol;	chr11:48638947	chr11:89639227~89698718:+
STAD	trans	rs9594759	0.967	rs9525625	ENSG00000246640.1	RP11-1094H24.4	-6.07	3.29e-09	0.014	-0.37	-0.31	Bone mineral density (spine);	chr13:42443894	chr17:50050349~50055739:-
STAD	trans	rs9402743	1	rs7739635	ENSG00000243302.3	RP11-274B21.2	6.07	3.3e-09	0.014	0.22	0.31	Systemic lupus erythematosus;	chr6:135676640	chr7:128651185~128652334:+
STAD	trans	rs7395662	0.963	rs11039772	ENSG00000134612.10	FOLH1B	-6.07	3.32e-09	0.0141	-0.37	-0.31	HDL cholesterol;	chr11:48492340	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs11039773	ENSG00000134612.10	FOLH1B	-6.07	3.32e-09	0.0141	-0.37	-0.31	HDL cholesterol;	chr11:48492379	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.698	rs78553793	ENSG00000134612.10	FOLH1B	6.07	3.32e-09	0.0141	0.57	0.31	Axial length;	chr11:48925784	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs7929173	ENSG00000134612.10	FOLH1B	-6.07	3.32e-09	0.0141	-0.34	-0.31	Height;	chr11:49922455	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000226339.1	RPS26P56	6.07	3.33e-09	0.0141	0.35	0.31	Cognitive function;	chr12:55988132	chrX:129408382~129408621:+
STAD	trans	rs702485	0.967	rs836539	ENSG00000249936.3	RAC1P2	6.07	3.35e-09	0.0142	0.28	0.31	HDL cholesterol levels;HDL cholesterol;	chr7:6436873	chr4:46723830~46724408:-
STAD	trans	rs77954165	0.568	rs12352193	ENSG00000215210.3	RBMXP2	6.07	3.36e-09	0.0142	0.4	0.31	Stem cell growth factor beta levels;	chr9:6725319	chr9:30689105~30690272:+
STAD	trans	rs12709013	0.766	rs34438483	ENSG00000230849.2	GOT2P2	6.07	3.36e-09	0.0143	0.33	0.31	Blood metabolite ratios;	chr16:58810530	chr1:173141100~173142350:-
STAD	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	6.07	3.38e-09	0.0143	0.32	0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
STAD	trans	rs7395662	0.857	rs11040074	ENSG00000134612.10	FOLH1B	-6.07	3.4e-09	0.0144	-0.37	-0.31	HDL cholesterol;	chr11:48835174	chr11:89639227~89698718:+
STAD	trans	rs702485	0.836	rs836483	ENSG00000249936.3	RAC1P2	6.07	3.41e-09	0.0145	0.28	0.31	HDL cholesterol levels;HDL cholesterol;	chr7:6388110	chr4:46723830~46724408:-
STAD	trans	rs12709013	0.792	rs1657170	ENSG00000230849.2	GOT2P2	6.07	3.41e-09	0.0145	0.33	0.31	Blood metabolite ratios;	chr16:58752082	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs1646270	ENSG00000233719.3	GOT2P3	6.07	3.44e-09	0.0146	0.34	0.31	Blood metabolite ratios;	chr16:58745823	chr12:9641802~9643007:+
STAD	trans	rs9611519	0.929	rs12484477	ENSG00000268568.1	AC007228.9	-6.07	3.44e-09	0.0146	-0.44	-0.31	Neuroticism;	chr22:41033080	chr19:56672574~56673901:-
STAD	trans	rs9611519	0.929	rs4820423	ENSG00000268568.1	AC007228.9	-6.07	3.44e-09	0.0146	-0.44	-0.31	Neuroticism;	chr22:41034334	chr19:56672574~56673901:-
STAD	trans	rs7395662	0.5	rs7947055	ENSG00000134612.10	FOLH1B	6.07	3.45e-09	0.0146	0.37	0.31	HDL cholesterol;	chr11:48955534	chr11:89639227~89698718:+
STAD	trans	rs9329221	0.935	rs3750310	ENSG00000253981.4	ALG1L13P	-6.06	3.48e-09	0.0147	-0.41	-0.31	Neuroticism;	chr8:10425916	chr8:8236003~8244667:-
STAD	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-6.06	3.5e-09	0.0148	-0.41	-0.31	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
STAD	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	6.06	3.5e-09	0.0148	0.41	0.31	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
STAD	trans	rs7395662	0.609	rs10839190	ENSG00000134612.10	FOLH1B	6.06	3.5e-09	0.0148	0.37	0.31	HDL cholesterol;	chr11:48935456	chr11:89639227~89698718:+
STAD	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	6.06	3.52e-09	0.0149	0.53	0.31	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
STAD	trans	rs6708331	0.941	rs11903933	ENSG00000232654.1	FAM136BP	6.06	3.54e-09	0.015	0.45	0.31	Obesity-related traits;	chr2:70149812	chr6:3045384~3045800:+
STAD	trans	rs877636	0.702	rs61937249	ENSG00000244641.2	RPS26P43	6.06	3.56e-09	0.015	0.33	0.31	Cognitive function;	chr12:55988132	chr11:123049787~123050353:-
STAD	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	6.06	3.59e-09	0.0151	0.37	0.31	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
STAD	trans	rs2727020	0.681	rs1976901	ENSG00000134612.10	FOLH1B	-6.06	3.6e-09	0.0152	-0.36	-0.31	Coronary artery disease;	chr11:49357145	chr11:89639227~89698718:+
STAD	trans	rs216303	0.722	rs216296	ENSG00000241717.1	VWFP1	6.06	3.62e-09	0.0152	0.4	0.31	Low vWF levels;	chr12:6045504	chr22:16690103~16704477:-
STAD	trans	rs877636	0.702	rs773111	ENSG00000244641.2	RPS26P43	6.06	3.63e-09	0.0153	0.33	0.31	Cognitive function;	chr12:55981956	chr11:123049787~123050353:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000219993.1	RP11-288G3.3	6.06	3.64e-09	0.0153	0.35	0.31	Cognitive function;	chr12:55988132	chr6:7506203~7506549:+
STAD	trans	rs11039798	0.92	rs12279378	ENSG00000134612.10	FOLH1B	6.06	3.64e-09	0.0153	0.56	0.31	Axial length;	chr11:48549478	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.92	rs12292685	ENSG00000134612.10	FOLH1B	6.06	3.64e-09	0.0153	0.56	0.31	Axial length;	chr11:48549480	chr11:89639227~89698718:+
STAD	trans	rs7577262	0.834	rs7602303	ENSG00000266269.1	AC002395.1	6.06	3.65e-09	0.0153	0.5	0.31	Blood pressure measurement (cold pressor test);	chr2:233923588	chr12:111487478~111487578:-
STAD	trans	rs7395662	0.963	rs7952491	ENSG00000134612.10	FOLH1B	-6.05	3.66e-09	0.0154	-0.36	-0.31	HDL cholesterol;	chr11:48641743	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs1588068	ENSG00000134612.10	FOLH1B	-6.05	3.66e-09	0.0154	-0.36	-0.31	HDL cholesterol;	chr11:48650193	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs1605364	ENSG00000134612.10	FOLH1B	-6.05	3.66e-09	0.0154	-0.36	-0.31	HDL cholesterol;	chr11:48663291	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.926	rs12288788	ENSG00000134612.10	FOLH1B	-6.05	3.66e-09	0.0154	-0.36	-0.31	HDL cholesterol;	chr11:48665311	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000226339.1	RPS26P56	6.05	3.74e-09	0.0157	0.34	0.31	Cognitive function;	chr12:55981353	chrX:129408382~129408621:+
STAD	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-6.05	3.74e-09	0.0157	-0.41	-0.31	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
STAD	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-6.05	3.74e-09	0.0157	-0.41	-0.31	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.613	rs1657178	ENSG00000233719.3	GOT2P3	6.05	3.77e-09	0.0158	0.35	0.31	Blood metabolite ratios;	chr16:58735300	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.585	rs7188608	ENSG00000233719.3	GOT2P3	6.05	3.77e-09	0.0158	0.35	0.31	Blood metabolite ratios;	chr16:58736236	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1657176	ENSG00000233719.3	GOT2P3	6.05	3.77e-09	0.0158	0.35	0.31	Blood metabolite ratios;	chr16:58736833	chr12:9641802~9643007:+
STAD	trans	rs877636	0.702	rs773111	ENSG00000242206.2	RPS26P35	6.05	3.77e-09	0.0158	0.35	0.31	Cognitive function;	chr12:55981956	chr8:118761856~118762201:-
STAD	trans	rs74781061	0.932	rs6495121	ENSG00000227288.3	RP5-837I24.1	6.05	3.77e-09	0.0158	0.39	0.31	Endometriosis;	chr15:74711167	chr1:81501794~81503468:+
STAD	trans	rs9611519	0.929	rs9611469	ENSG00000268568.1	AC007228.9	-6.05	3.78e-09	0.0159	-0.44	-0.31	Neuroticism;	chr22:41037315	chr19:56672574~56673901:-
STAD	trans	rs9611519	0.929	rs73174657	ENSG00000268568.1	AC007228.9	-6.05	3.78e-09	0.0159	-0.44	-0.31	Neuroticism;	chr22:41038154	chr19:56672574~56673901:-
STAD	trans	rs7395662	0.864	rs7483617	ENSG00000134612.10	FOLH1B	-6.05	3.8e-09	0.0159	-0.36	-0.31	HDL cholesterol;	chr11:48530107	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000226339.1	RPS26P56	6.05	3.81e-09	0.016	0.34	0.31	Cognitive function;	chr12:55976127	chrX:129408382~129408621:+
STAD	trans	rs877636	0.701	rs7302200	ENSG00000242206.2	RPS26P35	6.05	3.82e-09	0.016	0.38	0.31	Cognitive function;	chr12:56055651	chr8:118761856~118762201:-
STAD	trans	rs7617480	0.648	rs9864243	ENSG00000197582.5	GPX1P1	6.05	3.84e-09	0.0161	0.46	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48945299	chrX:13378735~13379340:-
STAD	trans	rs9611519	0.894	rs9611486	ENSG00000268568.1	AC007228.9	-6.05	3.86e-09	0.0162	-0.44	-0.31	Neuroticism;	chr22:41062780	chr19:56672574~56673901:-
STAD	trans	rs9611519	0.929	rs9611474	ENSG00000268568.1	AC007228.9	-6.04	3.87e-09	0.0162	-0.44	-0.31	Neuroticism;	chr22:41038854	chr19:56672574~56673901:-
STAD	trans	rs877636	0.702	rs773109	ENSG00000244641.2	RPS26P43	6.04	3.88e-09	0.0163	0.33	0.31	Cognitive function;	chr12:55980911	chr11:123049787~123050353:-
STAD	trans	rs11039798	1	rs7942042	ENSG00000134612.10	FOLH1B	6.04	3.89e-09	0.0163	0.56	0.31	Axial length;	chr11:48498718	chr11:89639227~89698718:+
STAD	trans	rs941207	0.756	rs7978685	ENSG00000257210.1	NACAP3	6.04	3.9e-09	0.0164	0.37	0.31	Platelet count;	chr12:56709370	chr12:93124063~93124543:-
STAD	trans	rs11039798	0.541	rs11040166	ENSG00000134612.10	FOLH1B	6.04	3.92e-09	0.0164	0.56	0.31	Axial length;	chr11:48943897	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.764	rs12418936	ENSG00000134612.10	FOLH1B	6.04	3.92e-09	0.0164	0.56	0.31	Axial length;	chr11:48964866	chr11:89639227~89698718:+
STAD	trans	rs941207	1	rs941207	ENSG00000257210.1	NACAP3	-6.04	3.93e-09	0.0164	-0.38	-0.31	Platelet count;	chr12:56629500	chr12:93124063~93124543:-
STAD	trans	rs11039798	0.92	rs11040015	ENSG00000134612.10	FOLH1B	6.04	3.94e-09	0.0165	0.54	0.31	Axial length;	chr11:48761578	chr11:89639227~89698718:+
STAD	trans	rs7617480	0.648	rs14018	ENSG00000197582.5	GPX1P1	6.04	3.94e-09	0.0165	0.49	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48746837	chrX:13378735~13379340:-
STAD	trans	rs9611519	0.929	rs926914	ENSG00000268568.1	AC007228.9	-6.04	3.95e-09	0.0165	-0.44	-0.31	Neuroticism;	chr22:41022150	chr19:56672574~56673901:-
STAD	trans	rs12709013	0.792	rs12935488	ENSG00000230849.2	GOT2P2	6.04	3.99e-09	0.0167	0.33	0.31	Blood metabolite ratios;	chr16:58766320	chr1:173141100~173142350:-
STAD	trans	rs1336472	1	rs1855982	ENSG00000263535.1	AK4P1	6.04	4e-09	0.0167	0.4	0.31	Venous thromboembolism (SNP x SNP interaction);	chr1:65230170	chr17:31345521~31346187:+
STAD	trans	rs10037055	0.636	rs13166688	ENSG00000217325.2	PRELID1P1	-6.04	4e-09	0.0168	-0.31	-0.31	Migraine without aura;	chr5:177156965	chr6:126643488~126644390:+
STAD	trans	rs17012589	0.695	rs1605398	ENSG00000237223.5	SULT1C2P1	6.04	4.01e-09	0.0168	0.36	0.31	Bone mineral density (Ward's triangle area);	chr12:85200698	chr2:108322238~108353799:+
STAD	trans	rs17012589	0.695	rs2660463	ENSG00000237223.5	SULT1C2P1	6.04	4.01e-09	0.0168	0.36	0.31	Bone mineral density (Ward's triangle area);	chr12:85202084	chr2:108322238~108353799:+
STAD	trans	rs10908521	0.611	rs7516736	ENSG00000227183.3	HDGFP1	-6.04	4.03e-09	0.0169	-0.36	-0.31	Uric acid clearance;	chr1:156825994	chrX:131646639~131646890:+
STAD	trans	rs9364687	0.664	rs9346960	ENSG00000207378.1	RNU6-748P	6.04	4.05e-09	0.0169	0.34	0.31	Body mass index;	chr6:163464258	chr8:98462944~98463050:-
STAD	trans	rs3792615	1	rs3792614	ENSG00000261649.4	GOLGA6L7P	6.04	4.06e-09	0.017	0.67	0.31	Type 2 diabetes;	chr4:163611821	chr15:28842235~28848675:-
STAD	trans	rs8010715	0.816	rs2332224	ENSG00000238000.1	RP11-274E7.2	6.04	4.06e-09	0.017	0.27	0.31	IgG glycosylation;	chr14:24129335	chr5:98213402~98214121:+
STAD	trans	rs9611519	1	rs6002271	ENSG00000268568.1	AC007228.9	-6.03	4.12e-09	0.0172	-0.44	-0.31	Neuroticism;	chr22:41170591	chr19:56672574~56673901:-
STAD	trans	rs916888	0.821	rs199514	ENSG00000264057.1	RP11-583F2.1	-6.03	4.16e-09	0.0174	-0.38	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:64927634~64934203:+
STAD	trans	rs11039798	0.844	rs41431447	ENSG00000134612.10	FOLH1B	6.03	4.18e-09	0.0174	0.57	0.31	Axial length;	chr11:48961647	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs11039779	ENSG00000134612.10	FOLH1B	-6.03	4.22e-09	0.0176	-0.37	-0.31	HDL cholesterol;	chr11:48496343	chr11:89639227~89698718:+
STAD	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-6.03	4.23e-09	0.0176	-0.32	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
STAD	trans	rs2110483	1	rs2192502	ENSG00000218803.1	GSTM2P1	-6.03	4.24e-09	0.0177	-0.51	-0.31	PR interval in Tripanosoma cruzi seropositivity;	chr7:94269957	chr6:111046868~111047521:-
STAD	trans	rs2110483	1	rs10248279	ENSG00000218803.1	GSTM2P1	-6.03	4.24e-09	0.0177	-0.51	-0.31	PR interval in Tripanosoma cruzi seropositivity;	chr7:94270682	chr6:111046868~111047521:-
STAD	trans	rs7395662	0.963	rs7120743	ENSG00000134612.10	FOLH1B	-6.03	4.26e-09	0.0177	-0.37	-0.31	HDL cholesterol;	chr11:48901093	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs7119550	ENSG00000134612.10	FOLH1B	-6.03	4.26e-09	0.0177	-0.37	-0.31	HDL cholesterol;	chr11:48906102	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.929	rs10839173	ENSG00000134612.10	FOLH1B	-6.03	4.26e-09	0.0177	-0.37	-0.31	HDL cholesterol;	chr11:48909206	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs1857786	ENSG00000134612.10	FOLH1B	-6.03	4.26e-09	0.0177	-0.37	-0.31	HDL cholesterol;	chr11:48945872	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs11040172	ENSG00000134612.10	FOLH1B	-6.03	4.26e-09	0.0177	-0.37	-0.31	HDL cholesterol;	chr11:48946945	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.824	rs12787989	ENSG00000134612.10	FOLH1B	-6.03	4.26e-09	0.0177	-0.37	-0.31	HDL cholesterol;	chr11:48949335	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773110	ENSG00000244641.2	RPS26P43	6.03	4.3e-09	0.0179	0.33	0.31	Cognitive function;	chr12:55981353	chr11:123049787~123050353:-
STAD	trans	rs7395662	1	rs55834832	ENSG00000134612.10	FOLH1B	-6.03	4.3e-09	0.0179	-0.37	-0.31	HDL cholesterol;	chr11:48541031	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs11039821	ENSG00000134612.10	FOLH1B	-6.03	4.3e-09	0.0179	-0.37	-0.31	HDL cholesterol;	chr11:48541323	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs12361812	ENSG00000134612.10	FOLH1B	-6.03	4.3e-09	0.0179	-0.37	-0.31	HDL cholesterol;	chr11:48541552	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882016	ENSG00000134612.10	FOLH1B	-6.03	4.3e-09	0.0179	-0.37	-0.31	HDL cholesterol;	chr11:48548573	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882120	ENSG00000134612.10	FOLH1B	-6.03	4.3e-09	0.0179	-0.37	-0.31	HDL cholesterol;	chr11:48551977	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882123	ENSG00000134612.10	FOLH1B	-6.03	4.3e-09	0.0179	-0.37	-0.31	HDL cholesterol;	chr11:48554187	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.636	rs12325516	ENSG00000233719.3	GOT2P3	6.03	4.33e-09	0.018	0.35	0.31	Blood metabolite ratios;	chr16:58749899	chr12:9641802~9643007:+
STAD	trans	rs9611519	0.894	rs13053242	ENSG00000268568.1	AC007228.9	-6.02	4.35e-09	0.0181	-0.44	-0.31	Neuroticism;	chr22:41063482	chr19:56672574~56673901:-
STAD	trans	rs7395662	1	rs11039777	ENSG00000134612.10	FOLH1B	-6.02	4.37e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48495497	chr11:89639227~89698718:+
STAD	trans	rs74781061	0.86	rs1456432	ENSG00000227288.3	RP5-837I24.1	6.02	4.38e-09	0.0182	0.39	0.31	Endometriosis;	chr15:74710710	chr1:81501794~81503468:+
STAD	trans	rs7395662	1	rs10838943	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48535890	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs4882109	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48536133	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882111	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48536895	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882010	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48537621	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs10838944	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48538019	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs4882112	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48539531	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs11039817	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.37	-0.31	HDL cholesterol;	chr11:48539928	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs4881658	ENSG00000134612.10	FOLH1B	-6.02	4.38e-09	0.0182	-0.34	-0.31	Height;	chr11:49919571	chr11:89639227~89698718:+
STAD	trans	rs74233809	1	rs11191502	ENSG00000254698.1	RP11-659G9.3	-6.02	4.39e-09	0.0182	-0.38	-0.31	Birth weight;	chr10:103005737	chr11:82963681~83039115:-
STAD	trans	rs7395662	1	rs10769371	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48509632	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs4882094	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48510908	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882096	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48512550	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs7478900	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48522451	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs7125110	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48523955	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs4882002	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48525179	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.89	rs11039806	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48526164	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs12365220	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48534405	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.929	rs12363679	ENSG00000134612.10	FOLH1B	-6.02	4.39e-09	0.0182	-0.36	-0.31	HDL cholesterol;	chr11:48534471	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.716	rs11647582	ENSG00000230849.2	GOT2P2	6.02	4.4e-09	0.0182	0.33	0.31	Blood metabolite ratios;	chr16:58801474	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs35684307	ENSG00000230849.2	GOT2P2	6.02	4.4e-09	0.0182	0.33	0.31	Blood metabolite ratios;	chr16:58801651	chr1:173141100~173142350:-
STAD	trans	rs7395662	0.816	rs12420341	ENSG00000134612.10	FOLH1B	-6.02	4.44e-09	0.0183	-0.36	-0.31	HDL cholesterol;	chr11:48871832	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.658	rs11493304	ENSG00000134612.10	FOLH1B	-6.02	4.44e-09	0.0183	-0.36	-0.31	HDL cholesterol;	chr11:48874039	chr11:89639227~89698718:+
STAD	trans	rs2980436	1	rs2980436	ENSG00000270154.1	RP11-419I17.1	-6.02	4.46e-09	0.0184	-0.29	-0.31	Schizophrenia;	chr8:8234503	chr8:12476462~12477122:+
STAD	trans	rs7395662	0.929	rs11039903	ENSG00000134612.10	FOLH1B	-6.02	4.46e-09	0.0184	-0.36	-0.31	HDL cholesterol;	chr11:48658153	chr11:89639227~89698718:+
STAD	trans	rs7647973	0.769	rs6772452	ENSG00000197582.5	GPX1P1	6.02	4.51e-09	0.0186	0.44	0.31	Menarche (age at onset);	chr3:49003029	chrX:13378735~13379340:-
STAD	trans	rs1814175	0.754	rs10839453	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49934263	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1996982	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49951067	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs7950856	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49954842	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10839465	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49960004	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs7932683	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49962090	chr11:89639227~89698718:+
STAD	trans	rs7554511	0.792	rs12126806	ENSG00000244144.1	RP11-757F18.3	-6.02	4.55e-09	0.0188	-0.32	-0.31	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200994697	chr3:112185480~112185998:-
STAD	trans	rs12709013	0.792	rs1646289	ENSG00000233719.3	GOT2P3	6.02	4.55e-09	0.0188	0.33	0.31	Blood metabolite ratios;	chr16:58755689	chr12:9641802~9643007:+
STAD	trans	rs12145833	0.92	rs12354170	ENSG00000154608.12	CEP170P1	-6.02	4.55e-09	0.0188	-0.49	-0.31	Obesity (early onset extreme);	chr1:243294474	chr4:118467590~118554204:+
STAD	trans	rs1814175	0.791	rs1722011	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49877788	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.791	rs1722023	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49886584	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.765	rs1794141	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49892583	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1988416	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49910772	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.791	rs9787917	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49915729	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs12277258	ENSG00000134612.10	FOLH1B	-6.02	4.55e-09	0.0188	-0.34	-0.31	Height;	chr11:49918664	chr11:89639227~89698718:+
STAD	trans	rs877636	1	rs705696	ENSG00000219993.1	RP11-288G3.3	6.02	4.57e-09	0.0188	0.34	0.31	Cognitive function;	chr12:56086864	chr6:7506203~7506549:+
STAD	trans	rs7395662	0.864	rs10838951	ENSG00000134612.10	FOLH1B	-6.01	4.62e-09	0.019	-0.36	-0.31	HDL cholesterol;	chr11:48549536	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.765	rs1721990	ENSG00000134612.10	FOLH1B	-6.01	4.62e-09	0.019	-0.34	-0.31	Height;	chr11:49890602	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.694	rs1616798	ENSG00000233719.3	GOT2P3	6.01	4.62e-09	0.019	0.33	0.31	Blood metabolite ratios;	chr16:58739433	chr12:9641802~9643007:+
STAD	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-6.01	4.63e-09	0.0191	-0.32	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
STAD	trans	rs9611519	0.929	rs9611465	ENSG00000268568.1	AC007228.9	-6.01	4.63e-09	0.0191	-0.44	-0.31	Neuroticism;	chr22:41030135	chr19:56672574~56673901:-
STAD	trans	rs9611519	0.929	rs9611466	ENSG00000268568.1	AC007228.9	-6.01	4.63e-09	0.0191	-0.44	-0.31	Neuroticism;	chr22:41030295	chr19:56672574~56673901:-
STAD	trans	rs2645694	0.626	rs2703140	ENSG00000229217.1	CYCSP11	6.01	4.63e-09	0.0191	0.35	0.31	Emphysema distribution in smoking;	chr4:76908904	chr3:10057973~10058287:-
STAD	trans	rs2645694	0.626	rs2645704	ENSG00000229217.1	CYCSP11	6.01	4.63e-09	0.0191	0.35	0.31	Emphysema distribution in smoking;	chr4:76909652	chr3:10057973~10058287:-
STAD	trans	rs7554511	0.861	rs965321	ENSG00000244144.1	RP11-757F18.3	6.01	4.64e-09	0.0191	0.32	0.31	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036374	chr3:112185480~112185998:-
STAD	trans	rs753955	0.593	rs12430111	ENSG00000260114.2	CTD-2574D22.4	-6.01	4.65e-09	0.0191	-0.27	-0.31	Lung cancer;	chr13:23834651	chr16:29919634~29921905:-
STAD	trans	rs7395662	0.597	rs2135684	ENSG00000134612.10	FOLH1B	-6.01	4.66e-09	0.0192	-0.36	-0.31	HDL cholesterol;	chr11:48726917	chr11:89639227~89698718:+
STAD	trans	rs916888	0.821	rs199506	ENSG00000264057.1	RP11-583F2.1	-6.01	4.69e-09	0.0193	-0.38	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:64927634~64934203:+
STAD	trans	rs3792615	1	rs6813882	ENSG00000261649.4	GOLGA6L7P	6.01	4.69e-09	0.0193	0.67	0.31	Type 2 diabetes;	chr4:163615769	chr15:28842235~28848675:-
STAD	trans	rs1814175	0.935	rs11040465	ENSG00000134612.10	FOLH1B	-6.01	4.7e-09	0.0193	-0.35	-0.31	Height;	chr11:49667771	chr11:89639227~89698718:+
STAD	trans	rs7944735	0.832	rs7130876	ENSG00000134612.10	FOLH1B	6.01	4.7e-09	0.0193	0.53	0.31	Intraocular pressure;	chr11:48029443	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.601	rs2432621	ENSG00000233719.3	GOT2P3	6.01	4.74e-09	0.0195	0.35	0.31	Blood metabolite ratios;	chr16:58749676	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs62064901	ENSG00000233719.3	GOT2P3	6.01	4.76e-09	0.0195	0.34	0.31	Blood metabolite ratios;	chr16:58776758	chr12:9641802~9643007:+
STAD	trans	rs1814175	0.817	rs1615305	ENSG00000134612.10	FOLH1B	-6.01	4.79e-09	0.0196	-0.34	-0.31	Height;	chr11:49873670	chr11:89639227~89698718:+
STAD	trans	rs877636	1	rs705696	ENSG00000243328.1	RP11-520P18.1	6.01	4.82e-09	0.0198	0.32	0.31	Cognitive function;	chr12:56086864	chr8:143065915~143066587:-
STAD	trans	rs9329221	0.905	rs6601451	ENSG00000173295.6	FAM86B3P	-6.01	4.84e-09	0.0198	-0.38	-0.31	Neuroticism;	chr8:10386171	chr8:8228595~8244865:+
STAD	trans	rs1814175	0.791	rs10769625	ENSG00000134612.10	FOLH1B	-6	4.88e-09	0.02	-0.34	-0.31	Height;	chr11:49848335	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.791	rs7395713	ENSG00000134612.10	FOLH1B	-6	4.88e-09	0.02	-0.34	-0.31	Height;	chr11:49856335	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.781	rs2866734	ENSG00000134612.10	FOLH1B	-6	4.88e-09	0.02	-0.34	-0.31	Height;	chr11:49864786	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1621090	ENSG00000134612.10	FOLH1B	-6	4.88e-09	0.02	-0.34	-0.31	Height;	chr11:49874316	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.765	rs1722003	ENSG00000134612.10	FOLH1B	-6	4.88e-09	0.02	-0.34	-0.31	Height;	chr11:49874344	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.654	rs12289625	ENSG00000134612.10	FOLH1B	6	4.88e-09	0.02	0.36	0.31	HDL cholesterol;	chr11:48795690	chr11:89639227~89698718:+
STAD	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-6	4.88e-09	0.02	-0.41	-0.31	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
STAD	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-6	4.88e-09	0.02	-0.41	-0.31	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
STAD	trans	rs2980003	0.784	rs2980004	ENSG00000261330.1	RP11-281J9.1	-6	4.94e-09	0.0202	-0.29	-0.31	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:65084363	chr16:77892422~77892915:+
STAD	trans	rs12709013	0.729	rs34324769	ENSG00000233719.3	GOT2P3	6	4.94e-09	0.0202	0.34	0.31	Blood metabolite ratios;	chr16:58778131	chr12:9641802~9643007:+
STAD	trans	rs216303	1	rs216295	ENSG00000241717.1	VWFP1	-6	4.95e-09	0.0202	-0.39	-0.31	Low vWF levels;	chr12:6045040	chr22:16690103~16704477:-
STAD	trans	rs1814175	0.817	rs7947286	ENSG00000134612.10	FOLH1B	-6	4.96e-09	0.0203	-0.34	-0.31	Height;	chr11:49853105	chr11:89639227~89698718:+
STAD	trans	rs721352	0.613	rs7045097	ENSG00000234415.1	RPL5P7	-6	4.97e-09	0.0203	-0.31	-0.31	Chronic sinus infection;	chr9:6402856	chr2:173871653~173872465:-
STAD	trans	rs801193	0.613	rs2016325	ENSG00000236529.1	RP13-254B10.1	-6	4.98e-09	0.0203	-0.34	-0.31	Aortic root size;	chr7:66858513	chr7:65840212~65840596:+
STAD	trans	rs11039798	1	rs7131020	ENSG00000134612.10	FOLH1B	6	5e-09	0.0204	0.54	0.31	Axial length;	chr11:48620580	chr11:89639227~89698718:+
STAD	trans	rs9329221	1	rs9329221	ENSG00000253981.4	ALG1L13P	6	5e-09	0.0204	0.36	0.31	Neuroticism;	chr8:10382692	chr8:8236003~8244667:-
STAD	trans	rs7374058	0.767	rs7619257	ENSG00000254759.1	NAP1L1P1	-6	5.02e-09	0.0205	-0.31	-0.31	Alzheimer disease and age of onset;	chr3:26187879	chr11:126067539~126068601:+
STAD	trans	rs877636	0.702	rs773112	ENSG00000226339.1	RPS26P56	6	5.04e-09	0.0205	0.34	0.31	Cognitive function;	chr12:55982097	chrX:129408382~129408621:+
STAD	trans	rs1336472	1	rs1336472	ENSG00000263535.1	AK4P1	-6	5.05e-09	0.0206	-0.4	-0.31	Venous thromboembolism (SNP x SNP interaction);	chr1:65230247	chr17:31345521~31346187:+
STAD	trans	rs3857747	0.578	rs10281352	ENSG00000278969.1	RP11-662I13.3	6	5.05e-09	0.0206	0.35	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40344337	chr12:24902309~24904681:+
STAD	trans	rs2645694	0.626	rs2703136	ENSG00000229217.1	CYCSP11	6	5.08e-09	0.0207	0.35	0.31	Emphysema distribution in smoking;	chr4:76907804	chr3:10057973~10058287:-
STAD	trans	rs4450131	0.9	rs11245333	ENSG00000249487.5	LINC01586	-6	5.09e-09	0.0207	-0.31	-0.31	White blood cell count (basophil);	chr10:124694519	chr15:88585566~88605110:-
STAD	trans	rs7395662	0.963	rs12365014	ENSG00000134612.10	FOLH1B	-6	5.09e-09	0.0207	-0.36	-0.31	HDL cholesterol;	chr11:48607882	chr11:89639227~89698718:+
STAD	trans	rs8010715	1	rs8010715	ENSG00000238000.1	RP11-274E7.2	5.99	5.14e-09	0.0209	0.28	0.31	IgG glycosylation;	chr14:24139938	chr5:98213402~98214121:+
STAD	trans	rs12709013	0.636	rs1657164	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58747949	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.537	rs1657167	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58748955	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.597	rs11076259	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58749860	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs11076260	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58749942	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1646278	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58750084	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1646280	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58750420	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.597	rs1646286	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58752651	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1624301	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58753491	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1626006	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58753691	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.684	rs1646287	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58753774	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.671	rs1369933	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58753927	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs1369934	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58754124	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.561	rs1657174	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58755139	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.613	rs1646288	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58755576	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.561	rs727484	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58756568	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs257628	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58758924	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs257627	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58758956	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs191783	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58759994	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs257624	ENSG00000233719.3	GOT2P3	5.99	5.15e-09	0.0209	0.34	0.31	Blood metabolite ratios;	chr16:58760994	chr12:9641802~9643007:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000231366.1	RP11-399N22.3	5.99	5.17e-09	0.021	0.33	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:70794230~70794523:-
STAD	trans	rs2862774	1	rs2862774	ENSG00000265257.4	RP11-21J18.1	-5.99	5.18e-09	0.021	-0.44	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr2:113040100	chr18:9102736~9254346:+
STAD	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	5.99	5.22e-09	0.0212	0.37	0.31	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
STAD	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	5.99	5.22e-09	0.0212	0.37	0.31	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
STAD	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	5.99	5.22e-09	0.0212	0.37	0.31	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
STAD	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	5.99	5.22e-09	0.0212	0.37	0.31	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
STAD	trans	rs10037055	0.685	rs10039241	ENSG00000217325.2	PRELID1P1	-5.99	5.23e-09	0.0212	-0.31	-0.31	Migraine without aura;	chr5:177151071	chr6:126643488~126644390:+
STAD	trans	rs1814175	0.817	rs11518158	ENSG00000134612.10	FOLH1B	-5.99	5.23e-09	0.0212	-0.34	-0.31	Height;	chr11:49964083	chr11:89639227~89698718:+
STAD	trans	rs7647973	0.961	rs56324858	ENSG00000197582.5	GPX1P1	-5.99	5.25e-09	0.0213	-0.51	-0.31	Menarche (age at onset);	chr3:49506796	chrX:13378735~13379340:-
STAD	trans	rs9329221	0.935	rs6601450	ENSG00000253981.4	ALG1L13P	5.99	5.25e-09	0.0213	0.36	0.31	Neuroticism;	chr8:10385591	chr8:8236003~8244667:-
STAD	trans	rs3792615	1	rs78088780	ENSG00000261649.4	GOLGA6L7P	5.99	5.27e-09	0.0214	0.68	0.31	Type 2 diabetes;	chr4:163618499	chr15:28842235~28848675:-
STAD	trans	rs3096299	0.719	rs2911265	ENSG00000215030.5	RPL13P12	-5.99	5.28e-09	0.0214	-0.27	-0.31	Multiple myeloma (IgH translocation);	chr16:89444920	chr17:17383377~17384012:-
STAD	trans	rs7647973	0.592	rs6774202	ENSG00000197582.5	GPX1P1	5.99	5.34e-09	0.0216	0.48	0.31	Menarche (age at onset);	chr3:49650346	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.792	rs11649387	ENSG00000230849.2	GOT2P2	5.99	5.38e-09	0.0218	0.33	0.31	Blood metabolite ratios;	chr16:58803176	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs11646756	ENSG00000233719.3	GOT2P3	5.99	5.39e-09	0.0218	0.33	0.31	Blood metabolite ratios;	chr16:58773598	chr12:9641802~9643007:+
STAD	trans	rs1814175	0.647	rs61306292	ENSG00000134612.10	FOLH1B	-5.99	5.4e-09	0.0218	-0.34	-0.31	Height;	chr11:49834488	chr11:89639227~89698718:+
STAD	trans	rs7121616	0.92	rs7109445	ENSG00000234176.1	HSPA8P1	5.98	5.41e-09	0.0219	0.26	0.31	Breast cancer;	chr11:123094779	chrX:121203182~121205014:-
STAD	trans	rs12709013	0.792	rs11649133	ENSG00000230849.2	GOT2P2	5.98	5.42e-09	0.0219	0.33	0.31	Blood metabolite ratios;	chr16:58803275	chr1:173141100~173142350:-
STAD	trans	rs3857747	0.578	rs7807217	ENSG00000278969.1	RP11-662I13.3	5.98	5.43e-09	0.022	0.35	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40339995	chr12:24902309~24904681:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000219993.1	RP11-288G3.3	5.98	5.46e-09	0.0221	0.31	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr6:7506203~7506549:+
STAD	trans	rs3096299	0.658	rs4291902	ENSG00000215030.5	RPL13P12	-5.98	5.47e-09	0.0221	-0.26	-0.31	Multiple myeloma (IgH translocation);	chr16:89493907	chr17:17383377~17384012:-
STAD	trans	rs11098499	0.863	rs17050695	ENSG00000120555.12	SEPT7P9	5.98	5.48e-09	0.0221	0.33	0.31	Corneal astigmatism;	chr4:119568372	chr10:38383069~38402916:-
STAD	trans	rs12709013	0.792	rs12928733	ENSG00000230849.2	GOT2P2	5.98	5.57e-09	0.0225	0.32	0.31	Blood metabolite ratios;	chr16:58807216	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs62066381	ENSG00000230849.2	GOT2P2	5.98	5.57e-09	0.0225	0.32	0.31	Blood metabolite ratios;	chr16:58807981	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.792	rs36098613	ENSG00000230849.2	GOT2P2	5.98	5.57e-09	0.0225	0.32	0.31	Blood metabolite ratios;	chr16:58810562	chr1:173141100~173142350:-
STAD	trans	rs4845552	0.716	rs3915524	ENSG00000216867.2	AC114776.1	5.98	5.58e-09	0.0225	0.51	0.31	Hippocampal atrophy;	chr1:153504425	chr2:110633947~110634333:+
STAD	trans	rs9611519	0.828	rs9611460	ENSG00000268568.1	AC007228.9	-5.98	5.59e-09	0.0226	-0.45	-0.31	Neuroticism;	chr22:41022293	chr19:56672574~56673901:-
STAD	trans	rs2209875	0.588	rs7469084	ENSG00000234819.1	RP11-336N8.4	5.98	5.62e-09	0.0227	0.36	0.31	Pelvic organ prolapse (moderate/severe);	chr9:89366248	chr9:78219120~78219357:+
STAD	trans	rs2156107	0.826	rs2187113	ENSG00000227252.1	AC105760.2	-5.98	5.63e-09	0.0227	-0.62	-0.31	Fractional exhaled nitric oxide (childhood);	chr18:72897259	chr2:237059434~237085817:-
STAD	trans	rs877636	0.884	rs705705	ENSG00000242307.1	RPS26P52	5.98	5.63e-09	0.0227	0.38	0.31	Cognitive function;	chr12:56041720	chr16:13922332~13922679:-
STAD	trans	rs3857747	0.519	rs12701819	ENSG00000278969.1	RP11-662I13.3	5.98	5.63e-09	0.0227	0.35	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40330806	chr12:24902309~24904681:+
STAD	trans	rs3857747	0.578	rs59337346	ENSG00000278969.1	RP11-662I13.3	5.98	5.63e-09	0.0227	0.35	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40331605	chr12:24902309~24904681:+
STAD	trans	rs3857747	0.578	rs4452702	ENSG00000278969.1	RP11-662I13.3	5.98	5.63e-09	0.0227	0.35	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40332272	chr12:24902309~24904681:+
STAD	trans	rs12145833	0.748	rs11807162	ENSG00000154608.12	CEP170P1	-5.98	5.64e-09	0.0228	-0.52	-0.31	Obesity (early onset extreme);	chr1:243291378	chr4:118467590~118554204:+
STAD	trans	rs7312770	0.637	rs705700	ENSG00000240427.1	RPS26P34	5.97	5.72e-09	0.0231	0.32	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:81627269~81627617:+
STAD	trans	rs10940346	0.777	rs11744698	ENSG00000231752.4	EMBP1	-5.97	5.73e-09	0.0231	-0.39	-0.31	Schizophrenia;	chr5:50586024	chr1:121519112~121571892:+
STAD	trans	rs12709013	0.766	rs12599331	ENSG00000230849.2	GOT2P2	5.97	5.76e-09	0.0232	0.32	0.31	Blood metabolite ratios;	chr16:58805307	chr1:173141100~173142350:-
STAD	trans	rs12709013	0.636	rs1646279	ENSG00000233719.3	GOT2P3	5.97	5.76e-09	0.0232	0.34	0.31	Blood metabolite ratios;	chr16:58750235	chr12:9641802~9643007:+
STAD	trans	rs3857747	0.538	rs11764504	ENSG00000278969.1	RP11-662I13.3	5.97	5.8e-09	0.0234	0.35	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40333359	chr12:24902309~24904681:+
STAD	trans	rs7395662	1	rs4929903	ENSG00000134612.10	FOLH1B	-5.97	5.92e-09	0.0238	-0.36	-0.31	HDL cholesterol;	chr11:48891780	chr11:89639227~89698718:+
STAD	trans	rs4276421	1	rs4276421	ENSG00000231752.4	EMBP1	-5.97	5.93e-09	0.0238	-0.41	-0.31	P wave duration;	chr5:45801977	chr1:121519112~121571892:+
STAD	trans	rs702485	1	rs702485	ENSG00000249936.3	RAC1P2	5.97	5.93e-09	0.0238	0.28	0.31	HDL cholesterol levels;HDL cholesterol;	chr7:6409641	chr4:46723830~46724408:-
STAD	trans	rs3770081	0.536	rs7562837	ENSG00000229880.1	IMMTP1	5.97	5.94e-09	0.0239	0.46	0.31	Facial emotion recognition (sad faces);	chr2:86079128	chr21:44675868~44678086:-
STAD	trans	rs7395662	0.713	rs11512404	ENSG00000134612.10	FOLH1B	-5.97	5.94e-09	0.0239	-0.36	-0.31	HDL cholesterol;	chr11:48914619	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.711	rs11512405	ENSG00000134612.10	FOLH1B	-5.97	5.94e-09	0.0239	-0.36	-0.31	HDL cholesterol;	chr11:48914805	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.889	rs11517696	ENSG00000134612.10	FOLH1B	-5.97	5.94e-09	0.0239	-0.36	-0.31	HDL cholesterol;	chr11:48918521	chr11:89639227~89698718:+
STAD	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-5.97	5.98e-09	0.024	-0.41	-0.31	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
STAD	trans	rs1814175	0.817	rs7946556	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49923322	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs2866863	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49931690	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs4881627	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49932403	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.781	rs12286395	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49932510	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs7927373	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49936088	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10769641	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49938589	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.781	rs11040681	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49960104	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs6486044	ENSG00000134612.10	FOLH1B	-5.97	6e-09	0.0241	-0.34	-0.31	Height;	chr11:49961168	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1794164	ENSG00000134612.10	FOLH1B	-5.97	6.01e-09	0.0241	-0.34	-0.31	Height;	chr11:49878058	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.546	rs1614397	ENSG00000134612.10	FOLH1B	-5.97	6.01e-09	0.0241	-0.34	-0.31	Height;	chr11:49891832	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1319547	ENSG00000134612.10	FOLH1B	-5.97	6.01e-09	0.0241	-0.34	-0.31	Height;	chr11:49895153	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.74	rs10839439	ENSG00000134612.10	FOLH1B	-5.97	6.01e-09	0.0241	-0.34	-0.31	Height;	chr11:49896688	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs11040651	ENSG00000134612.10	FOLH1B	-5.97	6.01e-09	0.0241	-0.34	-0.31	Height;	chr11:49916843	chr11:89639227~89698718:+
STAD	trans	rs941207	0.756	rs2958149	ENSG00000257210.1	NACAP3	5.97	6.01e-09	0.0241	0.36	0.31	Platelet count;	chr12:56716008	chr12:93124063~93124543:-
STAD	trans	rs7395662	0.927	rs4882141	ENSG00000134612.10	FOLH1B	-5.97	6.02e-09	0.0241	-0.36	-0.31	HDL cholesterol;	chr11:48605973	chr11:89639227~89698718:+
STAD	trans	rs12200782	0.505	rs9295696	ENSG00000242375.1	RP11-498P14.3	5.97	6.04e-09	0.0242	0.42	0.31	Small cell lung carcinoma;	chr6:26550060	chr9:97195351~97197687:-
STAD	trans	rs3857747	0.578	rs4598149	ENSG00000278969.1	RP11-662I13.3	5.97	6.04e-09	0.0242	0.35	0.31	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40339474	chr12:24902309~24904681:+
STAD	trans	rs3096299	0.563	rs4600467	ENSG00000215030.5	RPL13P12	-5.96	6.06e-09	0.0243	-0.26	-0.31	Multiple myeloma (IgH translocation);	chr16:89496108	chr17:17383377~17384012:-
STAD	trans	rs216303	1	rs216299	ENSG00000241717.1	VWFP1	5.96	6.07e-09	0.0243	0.39	0.31	Low vWF levels;	chr12:6047469	chr22:16690103~16704477:-
STAD	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-5.96	6.07e-09	0.0243	-0.31	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
STAD	trans	rs7395662	0.804	rs8186428	ENSG00000134612.10	FOLH1B	-5.96	6.09e-09	0.0244	-0.35	-0.31	HDL cholesterol;	chr11:48713125	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.782	rs66468703	ENSG00000134612.10	FOLH1B	-5.96	6.09e-09	0.0244	-0.35	-0.31	HDL cholesterol;	chr11:48717221	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.736	rs4882036	ENSG00000134612.10	FOLH1B	-5.96	6.09e-09	0.0244	-0.35	-0.31	HDL cholesterol;	chr11:48727832	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10769598	ENSG00000134612.10	FOLH1B	-5.96	6.1e-09	0.0244	-0.34	-0.31	Height;	chr11:49647774	chr11:89639227~89698718:+
STAD	trans	rs916888	0.821	rs199513	ENSG00000204650.12	CRHR1-IT1	-5.96	6.13e-09	0.0245	-0.45	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45620328~45648216:+
STAD	trans	rs12709013	0.636	rs8054414	ENSG00000233719.3	GOT2P3	5.96	6.13e-09	0.0245	0.35	0.31	Blood metabolite ratios;	chr16:58749772	chr12:9641802~9643007:+
STAD	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	5.96	6.14e-09	0.0245	0.34	0.31	Mumps;	chr20:2666724	chr6:28783633~28784004:-
STAD	trans	rs7617480	0.558	rs12715430	ENSG00000197582.5	GPX1P1	5.96	6.22e-09	0.0248	0.45	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48905422	chrX:13378735~13379340:-
STAD	trans	rs12145833	0.85	rs2490392	ENSG00000154608.12	CEP170P1	5.96	6.22e-09	0.0248	0.47	0.31	Obesity (early onset extreme);	chr1:243299221	chr4:118467590~118554204:+
STAD	trans	rs7829975	0.536	rs2980439	ENSG00000270154.1	RP11-419I17.1	5.96	6.22e-09	0.0248	0.3	0.31	Mood instability;	chr8:8237348	chr8:12476462~12477122:+
STAD	trans	rs7395662	0.759	rs11529442	ENSG00000134612.10	FOLH1B	5.96	6.25e-09	0.025	0.36	0.31	HDL cholesterol;	chr11:48798434	chr11:89639227~89698718:+
STAD	trans	rs12129573	0.608	rs604654	ENSG00000272945.1	CTD-3216D2.5	-5.96	6.27e-09	0.025	-0.29	-0.31	Schizophrenia;	chr1:73448006	chr20:34281632~34286466:-
STAD	trans	rs7395662	0.889	rs1848158	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48675742	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs9645642	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48683903	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.895	rs1121000	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48690238	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs8189397	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48690318	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs11039937	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48691030	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.895	rs1827971	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48696950	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs4882170	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48702662	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs2865923	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48703403	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.7	rs11493668	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48706030	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs2135681	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48706836	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs2135680	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48706873	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.895	rs8186350	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48717709	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.781	rs11499902	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48721179	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs10454482	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48733425	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.895	rs4882238	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48733988	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.547	rs10769442	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48743475	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.658	rs2865610	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48751065	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.818	rs34486360	ENSG00000134612.10	FOLH1B	-5.96	6.27e-09	0.025	-0.36	-0.31	HDL cholesterol;	chr11:48760920	chr11:89639227~89698718:+
STAD	trans	rs941207	0.756	rs9634246	ENSG00000257210.1	NACAP3	-5.96	6.31e-09	0.0251	-0.37	-0.31	Platelet count;	chr12:56640604	chr12:93124063~93124543:-
STAD	trans	rs941207	0.756	rs2950394	ENSG00000257210.1	NACAP3	-5.96	6.31e-09	0.0251	-0.37	-0.31	Platelet count;	chr12:56644548	chr12:93124063~93124543:-
STAD	trans	rs941207	0.756	rs1465081	ENSG00000257210.1	NACAP3	-5.96	6.31e-09	0.0251	-0.37	-0.31	Platelet count;	chr12:56656390	chr12:93124063~93124543:-
STAD	trans	rs7395662	0.571	rs1605358	ENSG00000134612.10	FOLH1B	-5.96	6.32e-09	0.0251	-0.35	-0.3	HDL cholesterol;	chr11:48667766	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs28525029	ENSG00000134612.10	FOLH1B	-5.96	6.34e-09	0.0252	-0.33	-0.3	Height;	chr11:50086656	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs28544182	ENSG00000134612.10	FOLH1B	-5.96	6.34e-09	0.0252	-0.33	-0.3	Height;	chr11:50090417	chr11:89639227~89698718:+
STAD	trans	rs12709013	0.559	rs8060721	ENSG00000233719.3	GOT2P3	5.96	6.38e-09	0.0253	0.34	0.3	Blood metabolite ratios;	chr16:58765581	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.636	rs8044542	ENSG00000233719.3	GOT2P3	5.96	6.38e-09	0.0253	0.34	0.3	Blood metabolite ratios;	chr16:58765620	chr12:9641802~9643007:+
STAD	trans	rs3096299	0.685	rs3803682	ENSG00000215030.5	RPL13P12	-5.96	6.38e-09	0.0254	-0.26	-0.3	Multiple myeloma (IgH translocation);	chr16:89478228	chr17:17383377~17384012:-
STAD	trans	rs1814175	0.727	rs2140597	ENSG00000134612.10	FOLH1B	-5.95	6.42e-09	0.0255	-0.34	-0.3	Height;	chr11:49852394	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10839401	ENSG00000134612.10	FOLH1B	-5.95	6.42e-09	0.0255	-0.34	-0.3	Height;	chr11:49854592	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.715	rs1722007	ENSG00000134612.10	FOLH1B	-5.95	6.42e-09	0.0255	-0.34	-0.3	Height;	chr11:49875767	chr11:89639227~89698718:+
STAD	trans	rs877636	0.74	rs705702	ENSG00000233278.1	RPS26P2	-5.95	6.42e-09	0.0255	-0.33	-0.3	Cognitive function;	chr12:55996852	chr9:30831878~30832225:-
STAD	trans	rs216303	1	rs216301	ENSG00000241717.1	VWFP1	5.95	6.46e-09	0.0256	0.39	0.3	Low vWF levels;	chr12:6048822	chr22:16690103~16704477:-
STAD	trans	rs216303	1	rs216302	ENSG00000241717.1	VWFP1	5.95	6.46e-09	0.0256	0.39	0.3	Low vWF levels;	chr12:6048856	chr22:16690103~16704477:-
STAD	trans	rs2069408	1	rs2069408	ENSG00000244604.1	RP11-713H12.1	-5.95	6.47e-09	0.0256	-0.33	-0.3	Asthma;	chr12:55970537	chr17:8561230~8561576:+
STAD	trans	rs12709013	0.792	rs62066815	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58751577	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.766	rs1657175	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58755527	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs1646290	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58755807	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs1364346	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58756420	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs257626	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58759574	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs257625	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58759978	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs1646262	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58760593	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs257623	ENSG00000233719.3	GOT2P3	5.95	6.47e-09	0.0256	0.33	0.3	Blood metabolite ratios;	chr16:58761247	chr12:9641802~9643007:+
STAD	trans	rs7395662	0.622	rs2865620	ENSG00000134612.10	FOLH1B	-5.95	6.47e-09	0.0256	-0.36	-0.3	HDL cholesterol;	chr11:48786359	chr11:89639227~89698718:+
STAD	trans	rs9594759	0.936	rs9533104	ENSG00000246640.1	RP11-1094H24.4	5.95	6.47e-09	0.0256	0.37	0.3	Bone mineral density (spine);	chr13:42443759	chr17:50050349~50055739:-
STAD	trans	rs2288884	0.634	rs80309583	ENSG00000271032.1	CTD-2527I21.14	5.95	6.5e-09	0.0257	0.36	0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51996949	chr19:35014961~35025335:-
STAD	trans	rs2727020	0.729	rs10839268	ENSG00000134612.10	FOLH1B	-5.95	6.51e-09	0.0258	-0.36	-0.3	Coronary artery disease;	chr11:49358776	chr11:89639227~89698718:+
STAD	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	5.95	6.52e-09	0.0258	0.35	0.3	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
STAD	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	5.95	6.52e-09	0.0258	0.35	0.3	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
STAD	trans	rs877636	0.702	rs773110	ENSG00000242206.2	RPS26P35	5.95	6.53e-09	0.0258	0.35	0.3	Cognitive function;	chr12:55981353	chr8:118761856~118762201:-
STAD	trans	rs77954165	0.568	rs1052489	ENSG00000215210.3	RBMXP2	5.95	6.54e-09	0.0259	0.39	0.3	Stem cell growth factor beta levels;	chr9:6723861	chr9:30689105~30690272:+
STAD	trans	rs1814175	0.754	rs28593359	ENSG00000134612.10	FOLH1B	-5.95	6.56e-09	0.0259	-0.33	-0.3	Height;	chr11:50083198	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs28594987	ENSG00000134612.10	FOLH1B	-5.95	6.56e-09	0.0259	-0.33	-0.3	Height;	chr11:50086022	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs28502006	ENSG00000134612.10	FOLH1B	-5.95	6.56e-09	0.0259	-0.33	-0.3	Height;	chr11:50090770	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.781	rs28681334	ENSG00000134612.10	FOLH1B	-5.95	6.56e-09	0.0259	-0.33	-0.3	Height;	chr11:50092006	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs28679516	ENSG00000134612.10	FOLH1B	-5.95	6.56e-09	0.0259	-0.33	-0.3	Height;	chr11:50096826	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1390676	ENSG00000134612.10	FOLH1B	-5.95	6.56e-09	0.0259	-0.33	-0.3	Height;	chr11:50097606	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.895	rs2221553	ENSG00000134612.10	FOLH1B	-5.95	6.59e-09	0.026	-0.36	-0.3	HDL cholesterol;	chr11:48667232	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.817	rs1848151	ENSG00000134612.10	FOLH1B	-5.95	6.59e-09	0.026	-0.36	-0.3	HDL cholesterol;	chr11:48671106	chr11:89639227~89698718:+
STAD	trans	rs216303	1	rs216303	ENSG00000241717.1	VWFP1	5.95	6.6e-09	0.0261	0.4	0.3	Low vWF levels;	chr12:6049879	chr22:16690103~16704477:-
STAD	trans	rs216303	1	rs216304	ENSG00000241717.1	VWFP1	5.95	6.6e-09	0.0261	0.4	0.3	Low vWF levels;	chr12:6050371	chr22:16690103~16704477:-
STAD	trans	rs2950393	0.804	rs1026565	ENSG00000257210.1	NACAP3	5.95	6.62e-09	0.0261	0.3	0.3	Platelet distribution width;	chr12:56744044	chr12:93124063~93124543:-
STAD	trans	rs7395662	1	rs4882132	ENSG00000134612.10	FOLH1B	-5.95	6.63e-09	0.0262	-0.36	-0.3	HDL cholesterol;	chr11:48571573	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.553	rs7479975	ENSG00000134612.10	FOLH1B	-5.95	6.64e-09	0.0262	-0.35	-0.3	Coronary artery disease;	chr11:49560412	chr11:89639227~89698718:+
STAD	trans	rs334353	0.568	rs10733708	ENSG00000259535.1	RPL21P12	-5.95	6.65e-09	0.0262	-0.29	-0.3	Age-related macular degeneration;	chr9:99106460	chr14:103148597~103149408:+
STAD	trans	rs9594759	1	rs7990020	ENSG00000246640.1	RP11-1094H24.4	5.95	6.67e-09	0.0263	0.36	0.3	Bone mineral density (spine);	chr13:42470810	chr17:50050349~50055739:-
STAD	trans	rs7577262	0.834	rs10803665	ENSG00000266269.1	AC002395.1	5.95	6.67e-09	0.0263	0.49	0.3	Blood pressure measurement (cold pressor test);	chr2:233925989	chr12:111487478~111487578:-
STAD	trans	rs7573615	0.561	rs17043797	ENSG00000209482.1	SNORD83A	5.95	6.67e-09	0.0263	0.66	0.3	Post bronchodilator FEV1/FVC ratio;	chr2:52914962	chr22:39315213~39315307:-
STAD	trans	rs7573615	0.561	rs17043801	ENSG00000209482.1	SNORD83A	5.95	6.67e-09	0.0263	0.66	0.3	Post bronchodilator FEV1/FVC ratio;	chr2:52915148	chr22:39315213~39315307:-
STAD	trans	rs7573615	0.561	rs17043805	ENSG00000209482.1	SNORD83A	5.95	6.67e-09	0.0263	0.66	0.3	Post bronchodilator FEV1/FVC ratio;	chr2:52915330	chr22:39315213~39315307:-
STAD	trans	rs7573615	0.561	rs17043807	ENSG00000209482.1	SNORD83A	5.95	6.67e-09	0.0263	0.66	0.3	Post bronchodilator FEV1/FVC ratio;	chr2:52915415	chr22:39315213~39315307:-
STAD	trans	rs1063857	0.656	rs216291	ENSG00000241717.1	VWFP1	5.95	6.71e-09	0.0265	0.3	0.3	vWF levels;Coagulation factor levels;	chr12:6042707	chr22:16690103~16704477:-
STAD	trans	rs8130944	0.859	rs8128442	ENSG00000271113.1	RP11-159H10.4	5.95	6.74e-09	0.0266	0.34	0.3	Perceived unattractiveness to mosquitoes;	chr21:42690345	chr8:69794062~69794734:+
STAD	trans	rs74233809	1	rs11191543	ENSG00000254698.1	RP11-659G9.3	-5.94	6.78e-09	0.0267	-0.38	-0.3	Birth weight;	chr10:103064630	chr11:82963681~83039115:-
STAD	trans	rs12129573	0.514	rs10789372	ENSG00000272945.1	CTD-3216D2.5	-5.94	6.78e-09	0.0267	-0.29	-0.3	Schizophrenia;	chr1:73444693	chr20:34281632~34286466:-
STAD	trans	rs7647973	0.89	rs73073004	ENSG00000197582.5	GPX1P1	-5.94	6.83e-09	0.0269	-0.5	-0.3	Menarche (age at onset);	chr3:49452587	chrX:13378735~13379340:-
STAD	trans	rs7395662	1	rs11039819	ENSG00000134612.10	FOLH1B	-5.94	6.84e-09	0.0269	-0.36	-0.3	HDL cholesterol;	chr11:48540629	chr11:89639227~89698718:+
STAD	trans	rs7577262	0.834	rs7558436	ENSG00000266269.1	AC002395.1	5.94	6.87e-09	0.027	0.49	0.3	Blood pressure measurement (cold pressor test);	chr2:233927034	chr12:111487478~111487578:-
STAD	trans	rs206936	0.528	rs116144226	ENSG00000270883.1	RP11-461L13.5	5.94	6.88e-09	0.027	0.66	0.3	Body mass index;	chr6:34312140	chr4:152317902~152318364:-
STAD	trans	rs7617480	0.648	rs6796790	ENSG00000197582.5	GPX1P1	5.94	6.89e-09	0.027	0.45	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chrX:13378735~13379340:-
STAD	trans	rs12709013	0.792	rs12325054	ENSG00000233719.3	GOT2P3	5.94	6.93e-09	0.0272	0.33	0.3	Blood metabolite ratios;	chr16:58749804	chr12:9641802~9643007:+
STAD	trans	rs941207	0.756	rs2958153	ENSG00000257210.1	NACAP3	5.94	6.98e-09	0.0274	0.37	0.3	Platelet count;	chr12:56687733	chr12:93124063~93124543:-
STAD	trans	rs941207	0.724	rs1979325	ENSG00000257210.1	NACAP3	5.94	6.99e-09	0.0274	0.35	0.3	Platelet count;	chr12:56728152	chr12:93124063~93124543:-
STAD	trans	rs7395662	1	rs7395662	ENSG00000134612.10	FOLH1B	5.94	7.04e-09	0.0276	0.36	0.3	HDL cholesterol;	chr11:48497341	chr11:89639227~89698718:+
STAD	trans	rs77954165	0.614	rs7028933	ENSG00000215210.3	RBMXP2	5.94	7.05e-09	0.0276	0.39	0.3	Stem cell growth factor beta levels;	chr9:6722942	chr9:30689105~30690272:+
STAD	trans	rs74233809	1	rs11191505	ENSG00000254698.1	RP11-659G9.3	-5.94	7.06e-09	0.0276	-0.37	-0.3	Birth weight;	chr10:103007134	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs74444347	ENSG00000254698.1	RP11-659G9.3	-5.94	7.06e-09	0.0276	-0.37	-0.3	Birth weight;	chr10:103009518	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs12221335	ENSG00000254698.1	RP11-659G9.3	-5.94	7.06e-09	0.0276	-0.37	-0.3	Birth weight;	chr10:103009635	chr11:82963681~83039115:-
STAD	trans	rs7395662	1	rs11039871	ENSG00000134612.10	FOLH1B	5.94	7.08e-09	0.0277	0.36	0.3	HDL cholesterol;	chr11:48605068	chr11:89639227~89698718:+
STAD	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-5.94	7.09e-09	0.0278	-0.43	-0.3	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
STAD	trans	rs13190036	0.551	rs7732930	ENSG00000217325.2	PRELID1P1	-5.94	7.13e-09	0.0279	-0.31	-0.3	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr6:126643488~126644390:+
STAD	trans	rs2645694	0.532	rs2645706	ENSG00000229217.1	CYCSP11	5.94	7.13e-09	0.0279	0.35	0.3	Emphysema distribution in smoking;	chr4:76908453	chr3:10057973~10058287:-
STAD	trans	rs2645694	0.626	rs904050	ENSG00000229217.1	CYCSP11	5.93	7.16e-09	0.028	0.34	0.3	Emphysema distribution in smoking;	chr4:76904936	chr3:10057973~10058287:-
STAD	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-5.93	7.19e-09	0.0281	-0.43	-0.3	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
STAD	trans	rs216303	1	rs216298	ENSG00000241717.1	VWFP1	5.93	7.19e-09	0.0281	0.39	0.3	Low vWF levels;	chr12:6047311	chr22:16690103~16704477:-
STAD	trans	rs7395662	0.745	rs10838830	ENSG00000134612.10	FOLH1B	5.93	7.23e-09	0.0282	0.37	0.3	HDL cholesterol;	chr11:48212380	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.553	rs61904166	ENSG00000134612.10	FOLH1B	-5.93	7.26e-09	0.0283	-0.35	-0.3	Coronary artery disease;	chr11:49559909	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773109	ENSG00000226339.1	RPS26P56	5.93	7.32e-09	0.0286	0.34	0.3	Cognitive function;	chr12:55980911	chrX:129408382~129408621:+
STAD	trans	rs4862307	0.72	rs12650935	ENSG00000261848.4	CTD-2309O5.3	5.93	7.33e-09	0.0286	0.35	0.3	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184068412	chr17:3134969~3177031:-
STAD	trans	rs3942852	0.774	rs10838812	ENSG00000134612.10	FOLH1B	-5.93	7.36e-09	0.0287	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165372	chr11:89639227~89698718:+
STAD	trans	rs3942852	0.774	rs10838813	ENSG00000134612.10	FOLH1B	-5.93	7.36e-09	0.0287	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165417	chr11:89639227~89698718:+
STAD	trans	rs3942852	0.774	rs10838814	ENSG00000134612.10	FOLH1B	-5.93	7.36e-09	0.0287	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165626	chr11:89639227~89698718:+
STAD	trans	rs702485	0.933	rs836556	ENSG00000249936.3	RAC1P2	-5.93	7.37e-09	0.0287	-0.28	-0.3	HDL cholesterol levels;HDL cholesterol;	chr7:6407410	chr4:46723830~46724408:-
STAD	trans	rs877636	0.702	rs61937249	ENSG00000242206.2	RPS26P35	5.93	7.37e-09	0.0287	0.35	0.3	Cognitive function;	chr12:55988132	chr8:118761856~118762201:-
STAD	trans	rs7395662	0.681	rs2865641	ENSG00000134612.10	FOLH1B	-5.93	7.41e-09	0.0289	-0.35	-0.3	HDL cholesterol;	chr11:48919547	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs10742862	ENSG00000134612.10	FOLH1B	-5.93	7.43e-09	0.029	-0.36	-0.3	HDL cholesterol;	chr11:48627764	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs6485911	ENSG00000134612.10	FOLH1B	-5.93	7.43e-09	0.029	-0.36	-0.3	HDL cholesterol;	chr11:48633232	chr11:89639227~89698718:+
STAD	trans	rs13177918	0.717	rs6874318	ENSG00000226396.1	RP5-1056L3.3	-5.93	7.5e-09	0.0292	-0.32	-0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:19608114~19608568:+
STAD	trans	rs941207	0.855	rs2256341	ENSG00000257210.1	NACAP3	-5.93	7.53e-09	0.0293	-0.37	-0.3	Platelet count;	chr12:56599930	chr12:93124063~93124543:-
STAD	trans	rs74233809	1	rs35125602	ENSG00000254698.1	RP11-659G9.3	-5.92	7.55e-09	0.0294	-0.37	-0.3	Birth weight;	chr10:102896282	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs11191453	ENSG00000254698.1	RP11-659G9.3	-5.92	7.55e-09	0.0294	-0.37	-0.3	Birth weight;	chr10:102900095	chr11:82963681~83039115:-
STAD	trans	rs7395662	0.833	rs1963073	ENSG00000134612.10	FOLH1B	-5.92	7.59e-09	0.0295	-0.35	-0.3	HDL cholesterol;	chr11:48953542	chr11:89639227~89698718:+
STAD	trans	rs7617480	0.648	rs7653408	ENSG00000197582.5	GPX1P1	5.92	7.63e-09	0.0297	0.45	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48934918	chrX:13378735~13379340:-
STAD	trans	rs2727020	0.553	rs3862350	ENSG00000134612.10	FOLH1B	-5.92	7.65e-09	0.0298	-0.35	-0.3	Coronary artery disease;	chr11:49574360	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.746	rs10839429	ENSG00000134612.10	FOLH1B	-5.92	7.67e-09	0.0299	-0.33	-0.3	Height;	chr11:49885293	chr11:89639227~89698718:+
STAD	trans	rs6708331	1	rs7597199	ENSG00000232654.1	FAM136BP	5.92	7.71e-09	0.03	0.45	0.3	Obesity-related traits;	chr2:70114443	chr6:3045384~3045800:+
STAD	trans	rs7647973	0.771	rs9865051	ENSG00000197582.5	GPX1P1	5.92	7.72e-09	0.03	0.47	0.3	Menarche (age at onset);	chr3:49128636	chrX:13378735~13379340:-
STAD	trans	rs7395662	1	rs7931984	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48559283	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs6485875	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48559482	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.929	rs10838956	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48560213	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs7949554	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48560440	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.895	rs7924481	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48560905	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.929	rs10838959	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48563180	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882129	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48567222	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs4882130	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48567402	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs10838966	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48568171	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs34636547	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48568551	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs10769382	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48568863	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs7951432	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48569728	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs7121992	ENSG00000134612.10	FOLH1B	-5.92	7.72e-09	0.03	-0.36	-0.3	HDL cholesterol;	chr11:48571030	chr11:89639227~89698718:+
STAD	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-5.92	7.72e-09	0.03	-0.35	-0.3	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
STAD	trans	rs4834770	0.765	rs1511016	ENSG00000276997.3	RP11-378J18.9	5.92	7.76e-09	0.0301	0.33	0.3	Blood protein levels;	chr4:119249200	chr1:222477252~222504622:-
STAD	trans	rs74233809	1	rs77787671	ENSG00000254698.1	RP11-659G9.3	-5.92	7.76e-09	0.0301	-0.37	-0.3	Birth weight;	chr10:103016448	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs11191515	ENSG00000254698.1	RP11-659G9.3	-5.92	7.76e-09	0.0301	-0.37	-0.3	Birth weight;	chr10:103016770	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs11191519	ENSG00000254698.1	RP11-659G9.3	-5.92	7.76e-09	0.0301	-0.37	-0.3	Birth weight;	chr10:103025161	chr11:82963681~83039115:-
STAD	trans	rs9594759	0.967	rs9533100	ENSG00000246640.1	RP11-1094H24.4	5.92	7.84e-09	0.0304	0.36	0.3	Bone mineral density (spine);	chr13:42422412	chr17:50050349~50055739:-
STAD	trans	rs34734847	0.703	rs7978125	ENSG00000225573.4	RPL35P5	-5.92	7.84e-09	0.0304	-0.19	-0.3	Mean corpuscular volume;	chr12:120729236	chr7:66606738~66607107:-
STAD	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-5.92	7.85e-09	0.0304	-0.36	-0.3	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
STAD	trans	rs12709013	0.792	rs12595974	ENSG00000233719.3	GOT2P3	5.92	7.91e-09	0.0306	0.33	0.3	Blood metabolite ratios;	chr16:58769132	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs1836877	ENSG00000233719.3	GOT2P3	5.92	7.91e-09	0.0306	0.33	0.3	Blood metabolite ratios;	chr16:58769821	chr12:9641802~9643007:+
STAD	trans	rs12718244	0.816	rs1379182	ENSG00000249626.1	RP11-496H1.1	-5.92	7.94e-09	0.0307	-0.32	-0.3	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:50147821	chr3:197634315~197635811:+
STAD	trans	rs3792615	1	rs3792615	ENSG00000261649.4	GOLGA6L7P	-5.92	7.94e-09	0.0307	-0.68	-0.3	Type 2 diabetes;	chr4:163611649	chr15:28842235~28848675:-
STAD	trans	rs9594759	1	rs9533118	ENSG00000246640.1	RP11-1094H24.4	5.92	7.95e-09	0.0308	0.36	0.3	Bone mineral density (spine);	chr13:42473124	chr17:50050349~50055739:-
STAD	trans	rs3857747	0.537	rs11766930	ENSG00000278969.1	RP11-662I13.3	5.91	7.97e-09	0.0309	0.35	0.3	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40382015	chr12:24902309~24904681:+
STAD	trans	rs1814175	0.817	rs12295885	ENSG00000134612.10	FOLH1B	-5.91	7.98e-09	0.0309	-0.33	-0.3	Height;	chr11:50015241	chr11:89639227~89698718:+
STAD	trans	rs6708331	1	rs35734267	ENSG00000232654.1	FAM136BP	5.91	7.98e-09	0.0309	0.45	0.3	Obesity-related traits;	chr2:70054058	chr6:3045384~3045800:+
STAD	trans	rs12709013	0.693	rs1627257	ENSG00000233719.3	GOT2P3	5.91	7.98e-09	0.0309	0.33	0.3	Blood metabolite ratios;	chr16:58763764	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.755	rs1628029	ENSG00000233719.3	GOT2P3	5.91	7.98e-09	0.0309	0.33	0.3	Blood metabolite ratios;	chr16:58763846	chr12:9641802~9643007:+
STAD	trans	rs12709013	0.792	rs12926512	ENSG00000233719.3	GOT2P3	5.91	7.98e-09	0.0309	0.33	0.3	Blood metabolite ratios;	chr16:58768317	chr12:9641802~9643007:+
STAD	trans	rs3096299	0.719	rs2965945	ENSG00000215030.5	RPL13P12	-5.91	7.98e-09	0.0309	-0.26	-0.3	Multiple myeloma (IgH translocation);	chr16:89447609	chr17:17383377~17384012:-
STAD	trans	rs877636	1	rs2292239	ENSG00000242307.1	RPS26P52	5.91	8e-09	0.0309	0.34	0.3	Cognitive function;	chr12:56088396	chr16:13922332~13922679:-
STAD	trans	rs9364687	0.639	rs9347760	ENSG00000207378.1	RNU6-748P	5.91	8.06e-09	0.0311	0.33	0.3	Body mass index;	chr6:163533540	chr8:98462944~98463050:-
STAD	trans	rs9364687	0.639	rs9364692	ENSG00000207378.1	RNU6-748P	5.91	8.06e-09	0.0311	0.33	0.3	Body mass index;	chr6:163535297	chr8:98462944~98463050:-
STAD	trans	rs9364687	0.639	rs2321703	ENSG00000207378.1	RNU6-748P	5.91	8.06e-09	0.0311	0.33	0.3	Body mass index;	chr6:163536704	chr8:98462944~98463050:-
STAD	trans	rs9364687	0.639	rs9347762	ENSG00000207378.1	RNU6-748P	5.91	8.06e-09	0.0311	0.33	0.3	Body mass index;	chr6:163540049	chr8:98462944~98463050:-
STAD	trans	rs9364687	0.639	rs13199835	ENSG00000207378.1	RNU6-748P	5.91	8.06e-09	0.0311	0.33	0.3	Body mass index;	chr6:163544118	chr8:98462944~98463050:-
STAD	trans	rs9611519	0.964	rs4820428	ENSG00000268568.1	AC007228.9	5.91	8.11e-09	0.0313	0.42	0.3	Neuroticism;	chr22:41141585	chr19:56672574~56673901:-
STAD	trans	rs74233809	1	rs11191514	ENSG00000254698.1	RP11-659G9.3	-5.91	8.11e-09	0.0313	-0.37	-0.3	Birth weight;	chr10:103013607	chr11:82963681~83039115:-
STAD	trans	rs1814175	0.715	rs10839409	ENSG00000134612.10	FOLH1B	-5.91	8.12e-09	0.0313	-0.33	-0.3	Height;	chr11:49863095	chr11:89639227~89698718:+
STAD	trans	rs7647973	0.807	rs4955416	ENSG00000197582.5	GPX1P1	5.91	8.18e-09	0.0316	0.45	0.3	Menarche (age at onset);	chr3:49070995	chrX:13378735~13379340:-
STAD	trans	rs3942852	0.774	rs924715	ENSG00000134612.10	FOLH1B	-5.91	8.2e-09	0.0317	-0.42	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48159508	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.764	rs11040208	ENSG00000134612.10	FOLH1B	5.91	8.24e-09	0.0318	0.57	0.3	Axial length;	chr11:48990957	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.935	rs28586931	ENSG00000134612.10	FOLH1B	-5.91	8.25e-09	0.0318	-0.35	-0.3	Height;	chr11:49672320	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.935	rs10839329	ENSG00000134612.10	FOLH1B	-5.91	8.25e-09	0.0318	-0.35	-0.3	Height;	chr11:49672654	chr11:89639227~89698718:+
STAD	trans	rs2980439	0.783	rs2955587	ENSG00000270154.1	RP11-419I17.1	5.91	8.31e-09	0.032	0.3	0.3	Neuroticism;	chr8:8240557	chr8:12476462~12477122:+
STAD	trans	rs7395662	0.963	rs60772766	ENSG00000134612.10	FOLH1B	-5.91	8.39e-09	0.0323	-0.36	-0.3	HDL cholesterol;	chr11:48699459	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.929	rs11493665	ENSG00000134612.10	FOLH1B	-5.91	8.39e-09	0.0323	-0.36	-0.3	HDL cholesterol;	chr11:48699483	chr11:89639227~89698718:+
STAD	trans	rs7617480	0.549	rs9879978	ENSG00000197582.5	GPX1P1	5.91	8.4e-09	0.0324	0.45	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48809167	chrX:13378735~13379340:-
STAD	trans	rs7395662	0.89	rs4882133	ENSG00000134612.10	FOLH1B	-5.91	8.41e-09	0.0324	-0.36	-0.3	HDL cholesterol;	chr11:48571898	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs10838967	ENSG00000134612.10	FOLH1B	-5.91	8.41e-09	0.0324	-0.36	-0.3	HDL cholesterol;	chr11:48573455	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs7481308	ENSG00000134612.10	FOLH1B	-5.91	8.41e-09	0.0324	-0.36	-0.3	HDL cholesterol;	chr11:48578515	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs11039851	ENSG00000134612.10	FOLH1B	-5.91	8.41e-09	0.0324	-0.36	-0.3	HDL cholesterol;	chr11:48579287	chr11:89639227~89698718:+
STAD	trans	rs4845552	0.716	rs16835382	ENSG00000216867.2	AC114776.1	5.91	8.41e-09	0.0324	0.51	0.3	Hippocampal atrophy;	chr1:153503184	chr2:110633947~110634333:+
STAD	trans	rs12709013	0.636	rs10852565	ENSG00000233719.3	GOT2P3	5.91	8.41e-09	0.0324	0.34	0.3	Blood metabolite ratios;	chr16:58771277	chr12:9641802~9643007:+
STAD	trans	rs7113874	0.625	rs10743073	ENSG00000266891.1	RP11-692N5.2	-5.9	8.48e-09	0.0326	-0.39	-0.3	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483072	chr18:9734882~9735602:-
STAD	trans	rs13190036	0.551	rs11955537	ENSG00000217325.2	PRELID1P1	-5.9	8.5e-09	0.0327	-0.31	-0.3	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr6:126643488~126644390:+
STAD	trans	rs7395662	0.819	rs1473579	ENSG00000134612.10	FOLH1B	-5.9	8.53e-09	0.0328	-0.35	-0.3	HDL cholesterol;	chr11:48880001	chr11:89639227~89698718:+
STAD	trans	rs9788927	1	rs7192963	ENSG00000219682.4	RP3-425P12.4	-5.9	8.59e-09	0.033	-0.41	-0.3	Pit-and-Fissure caries;	chr16:7881573	chr6:25140003~25141403:+
STAD	trans	rs74781061	0.932	rs2198843	ENSG00000227288.3	RP5-837I24.1	5.9	8.59e-09	0.033	0.38	0.3	Endometriosis;	chr15:74708889	chr1:81501794~81503468:+
STAD	trans	rs941207	0.724	rs4788	ENSG00000257210.1	NACAP3	5.9	8.63e-09	0.0331	0.35	0.3	Platelet count;	chr12:56712876	chr12:93124063~93124543:-
STAD	trans	rs12709013	0.792	rs12935488	ENSG00000233719.3	GOT2P3	5.9	8.64e-09	0.0332	0.33	0.3	Blood metabolite ratios;	chr16:58766320	chr12:9641802~9643007:+
STAD	trans	rs1814175	0.817	rs7109440	ENSG00000134612.10	FOLH1B	-5.9	8.67e-09	0.0333	-0.33	-0.3	Height;	chr11:49944744	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.864	rs11039917	ENSG00000134612.10	FOLH1B	-5.9	8.73e-09	0.0335	-0.35	-0.3	HDL cholesterol;	chr11:48673876	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.929	rs8186263	ENSG00000134612.10	FOLH1B	-5.9	8.73e-09	0.0335	-0.35	-0.3	HDL cholesterol;	chr11:48716383	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.824	rs4882180	ENSG00000134612.10	FOLH1B	-5.9	8.73e-09	0.0335	-0.35	-0.3	HDL cholesterol;	chr11:48727805	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.824	rs12785858	ENSG00000134612.10	FOLH1B	-5.9	8.73e-09	0.0335	-0.35	-0.3	HDL cholesterol;	chr11:48757254	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs10769370	ENSG00000134612.10	FOLH1B	5.9	8.77e-09	0.0336	0.54	0.3	Axial length;	chr11:48493878	chr11:89639227~89698718:+
STAD	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	5.9	8.77e-09	0.0336	0.41	0.3	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
STAD	trans	rs4845552	0.767	rs4845549	ENSG00000216867.2	AC114776.1	5.9	8.79e-09	0.0337	0.5	0.3	Hippocampal atrophy;	chr1:153499809	chr2:110633947~110634333:+
STAD	trans	rs2950393	0.804	rs2926752	ENSG00000257210.1	NACAP3	5.9	8.85e-09	0.0339	0.31	0.3	Platelet distribution width;	chr12:56710144	chr12:93124063~93124543:-
STAD	trans	rs2950393	0.777	rs2958148	ENSG00000257210.1	NACAP3	5.9	8.85e-09	0.0339	0.31	0.3	Platelet distribution width;	chr12:56710153	chr12:93124063~93124543:-
STAD	trans	rs3942852	0.726	rs1503171	ENSG00000134612.10	FOLH1B	-5.9	8.87e-09	0.034	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48153600	chr11:89639227~89698718:+
STAD	trans	rs3942852	0.726	rs10742836	ENSG00000134612.10	FOLH1B	-5.9	8.87e-09	0.034	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48154279	chr11:89639227~89698718:+
STAD	trans	rs3942852	0.696	rs4597030	ENSG00000134612.10	FOLH1B	-5.9	8.87e-09	0.034	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48155021	chr11:89639227~89698718:+
STAD	trans	rs3942852	0.774	rs1039481	ENSG00000134612.10	FOLH1B	-5.9	8.87e-09	0.034	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48160685	chr11:89639227~89698718:+
STAD	trans	rs3942852	0.774	rs2270990	ENSG00000134612.10	FOLH1B	-5.9	8.87e-09	0.034	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48163431	chr11:89639227~89698718:+
STAD	trans	rs12129573	0.608	rs628933	ENSG00000272945.1	CTD-3216D2.5	-5.89	8.91e-09	0.0341	-0.28	-0.3	Schizophrenia;	chr1:73451564	chr20:34281632~34286466:-
STAD	trans	rs7395662	1	rs11039800	ENSG00000134612.10	FOLH1B	5.89	9e-09	0.0344	0.36	0.3	HDL cholesterol;	chr11:48521027	chr11:89639227~89698718:+
STAD	trans	rs7944735	0.517	rs7952205	ENSG00000134612.10	FOLH1B	5.89	9e-09	0.0344	0.52	0.3	Intraocular pressure;	chr11:48177675	chr11:89639227~89698718:+
STAD	trans	rs747782	0.582	rs11039571	ENSG00000134612.10	FOLH1B	5.89	9e-09	0.0344	0.52	0.3	Intraocular pressure;	chr11:48185707	chr11:89639227~89698718:+
STAD	trans	rs7647973	0.71	rs9869120	ENSG00000197582.5	GPX1P1	5.89	9.04e-09	0.0345	0.49	0.3	Menarche (age at onset);	chr3:49586632	chrX:13378735~13379340:-
STAD	trans	rs877636	1	rs877636	ENSG00000231366.1	RP11-399N22.3	-5.89	9.05e-09	0.0346	-0.34	-0.3	Cognitive function;	chr12:56086799	chr10:70794230~70794523:-
STAD	trans	rs73108077	0.605	rs2143192	ENSG00000279352.1	RP11-411B10.7	5.89	9.08e-09	0.0347	0.56	0.3	Red blood cell density in sickle cell anemia;	chr20:31364639	chr18:14010054~14010917:+
STAD	trans	rs2980003	0.784	rs7817683	ENSG00000261330.1	RP11-281J9.1	-5.89	9.15e-09	0.0349	-0.28	-0.3	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:65080461	chr16:77892422~77892915:+
STAD	trans	rs2980003	0.784	rs7817859	ENSG00000261330.1	RP11-281J9.1	-5.89	9.15e-09	0.0349	-0.28	-0.3	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:65080569	chr16:77892422~77892915:+
STAD	trans	rs7395662	0.819	rs11039913	ENSG00000134612.10	FOLH1B	-5.89	9.16e-09	0.0349	-0.35	-0.3	HDL cholesterol;	chr11:48670529	chr11:89639227~89698718:+
STAD	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-5.89	9.17e-09	0.035	-0.43	-0.3	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
STAD	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	5.89	9.19e-09	0.035	0.34	0.3	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
STAD	trans	rs6763848	0.646	rs4508757	ENSG00000186831.10	KRT17P2	-5.89	9.2e-09	0.0351	-0.34	-0.3	Prostate cancer (SNP x SNP interaction);	chr3:1463952	chr17:18426861~18431848:+
STAD	trans	rs2950393	0.804	rs2958132	ENSG00000257210.1	NACAP3	5.89	9.22e-09	0.0351	0.3	0.3	Platelet distribution width;	chr12:56750749	chr12:93124063~93124543:-
STAD	trans	rs1814175	0.817	rs7947526	ENSG00000134612.10	FOLH1B	-5.89	9.24e-09	0.0352	-0.33	-0.3	Height;	chr11:49962104	chr11:89639227~89698718:+
STAD	trans	rs216303	1	rs216294	ENSG00000241717.1	VWFP1	5.89	9.26e-09	0.0353	0.39	0.3	Low vWF levels;	chr12:6044584	chr22:16690103~16704477:-
STAD	trans	rs11039798	0.841	rs7950737	ENSG00000134612.10	FOLH1B	5.89	9.26e-09	0.0353	0.53	0.3	Axial length;	chr11:48569126	chr11:89639227~89698718:+
STAD	trans	rs12129573	0.637	rs1500429	ENSG00000272945.1	CTD-3216D2.5	-5.89	9.33e-09	0.0355	-0.28	-0.3	Schizophrenia;	chr1:73451428	chr20:34281632~34286466:-
STAD	trans	rs941207	0.789	rs2958145	ENSG00000257210.1	NACAP3	-5.89	9.37e-09	0.0357	-0.36	-0.3	Platelet count;	chr12:56662290	chr12:93124063~93124543:-
STAD	trans	rs17253792	0.822	rs12323476	ENSG00000258957.1	RP11-363J20.1	5.89	9.37e-09	0.0357	0.53	0.3	Putamen volume;	chr14:55706004	chr14:69183020~69214092:-
STAD	trans	rs1814175	0.817	rs1851860	ENSG00000134612.10	FOLH1B	-5.89	9.37e-09	0.0357	-0.33	-0.3	Height;	chr11:49839758	chr11:89639227~89698718:+
STAD	trans	rs74233809	1	rs10883815	ENSG00000254698.1	RP11-659G9.3	-5.89	9.38e-09	0.0357	-0.37	-0.3	Birth weight;	chr10:102979422	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs112390216	ENSG00000254698.1	RP11-659G9.3	-5.89	9.38e-09	0.0357	-0.37	-0.3	Birth weight;	chr10:102981274	chr11:82963681~83039115:-
STAD	trans	rs7032940	0.784	rs10980253	ENSG00000232823.2	TXNP1	5.88	9.45e-09	0.0359	0.35	0.3	Height;	chr9:110205555	chr10:119683127~119683823:-
STAD	trans	rs769111	0.812	rs2908734	ENSG00000230383.1	AC009245.3	5.88	9.49e-09	0.0361	0.21	0.3	Tourette syndrome;	chr7:12030911	chr7:137721985~137722846:+
STAD	trans	rs2727020	0.681	rs2866362	ENSG00000134612.10	FOLH1B	-5.88	9.57e-09	0.0364	-0.35	-0.3	Coronary artery disease;	chr11:49357764	chr11:89639227~89698718:+
STAD	trans	rs2727020	1	rs2727020	ENSG00000134612.10	FOLH1B	5.88	9.61e-09	0.0365	0.39	0.3	Coronary artery disease;	chr11:49089855	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs4882146	ENSG00000134612.10	FOLH1B	-5.88	9.62e-09	0.0365	-0.36	-0.3	HDL cholesterol;	chr11:48638617	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.926	rs11039893	ENSG00000134612.10	FOLH1B	-5.88	9.7e-09	0.0368	-0.35	-0.3	HDL cholesterol;	chr11:48636202	chr11:89639227~89698718:+
STAD	trans	rs7312770	0.612	rs773114	ENSG00000243328.1	RP11-520P18.1	5.88	9.72e-09	0.0369	0.3	0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:143065915~143066587:-
STAD	trans	rs74233809	1	rs11191531	ENSG00000254698.1	RP11-659G9.3	-5.88	9.72e-09	0.0369	-0.37	-0.3	Birth weight;	chr10:103047141	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs12219027	ENSG00000254698.1	RP11-659G9.3	-5.88	9.72e-09	0.0369	-0.37	-0.3	Birth weight;	chr10:103051446	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs3781285	ENSG00000254698.1	RP11-659G9.3	-5.88	9.72e-09	0.0369	-0.37	-0.3	Birth weight;	chr10:103065908	chr11:82963681~83039115:-
STAD	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-5.88	9.76e-09	0.037	-0.43	-0.3	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
STAD	trans	rs2950393	0.804	rs7980317	ENSG00000257210.1	NACAP3	5.88	9.76e-09	0.037	0.3	0.3	Platelet distribution width;	chr12:56764399	chr12:93124063~93124543:-
STAD	trans	rs12282928	0.625	rs924714	ENSG00000279086.1	RP11-667F14.1	5.88	9.81e-09	0.0372	0.42	0.3	Migraine - clinic-based;	chr11:48194301	chr7:116209234~116211511:-
STAD	trans	rs1814175	0.626	rs1722008	ENSG00000134612.10	FOLH1B	-5.88	9.84e-09	0.0373	-0.33	-0.3	Height;	chr11:49876124	chr11:89639227~89698718:+
STAD	trans	rs7944735	0.767	rs1017875	ENSG00000134612.10	FOLH1B	5.87	1.01e-08	0.0383	0.49	0.3	Intraocular pressure;	chr11:47977666	chr11:89639227~89698718:+
STAD	trans	rs2110483	1	rs10250360	ENSG00000218803.1	GSTM2P1	-5.87	1.02e-08	0.0385	-0.5	-0.3	PR interval in Tripanosoma cruzi seropositivity;	chr7:94266453	chr6:111046868~111047521:-
STAD	trans	rs2950393	0.804	rs2290894	ENSG00000257210.1	NACAP3	5.87	1.02e-08	0.0386	0.31	0.3	Platelet distribution width;	chr12:56714911	chr12:93124063~93124543:-
STAD	trans	rs941207	0.805	rs2958139	ENSG00000257210.1	NACAP3	-5.87	1.02e-08	0.0386	-0.37	-0.3	Platelet count;	chr12:56610884	chr12:93124063~93124543:-
STAD	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	5.87	1.03e-08	0.0388	0.35	0.3	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
STAD	trans	rs9611519	0.929	rs71327107	ENSG00000268568.1	AC007228.9	-5.87	1.03e-08	0.0389	-0.44	-0.3	Neuroticism;	chr22:41022225	chr19:56672574~56673901:-
STAD	trans	rs2110483	1	rs7783183	ENSG00000218803.1	GSTM2P1	-5.87	1.03e-08	0.0389	-0.51	-0.3	PR interval in Tripanosoma cruzi seropositivity;	chr7:94264079	chr6:111046868~111047521:-
STAD	trans	rs1190596	0.65	rs1190600	ENSG00000181359.5	HSP90AA6P	5.87	1.03e-08	0.0389	0.36	0.3	Behavioural disinhibition (generation interaction);	chr14:102125121	chr4:170581470~170605450:-
STAD	trans	rs12145833	1	rs61833916	ENSG00000154608.12	CEP170P1	-5.87	1.03e-08	0.039	-0.47	-0.3	Obesity (early onset extreme);	chr1:243306644	chr4:118467590~118554204:+
STAD	trans	rs2789047	0.881	rs9320773	ENSG00000216863.8	LY86-AS1	-5.87	1.03e-08	0.039	-0.3	-0.3	Peak creatinine levels in vancomycin therapy;	chr6:120855351	chr6:6346465~6622771:-
STAD	trans	rs1814175	0.817	rs1851858	ENSG00000134612.10	FOLH1B	-5.87	1.04e-08	0.0391	-0.33	-0.3	Height;	chr11:49834086	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.754	rs28663627	ENSG00000134612.10	FOLH1B	-5.86	1.06e-08	0.0398	-0.33	-0.3	Height;	chr11:50089669	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs1809986	ENSG00000134612.10	FOLH1B	-5.86	1.06e-08	0.0398	-0.36	-0.3	HDL cholesterol;	chr11:48965987	chr11:89639227~89698718:+
STAD	trans	rs7623687	0.579	rs73082331	ENSG00000197582.5	GPX1P1	-5.86	1.06e-08	0.0399	-0.6	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr3:48957510	chrX:13378735~13379340:-
STAD	trans	rs3770081	1	rs7570836	ENSG00000229880.1	IMMTP1	5.86	1.06e-08	0.0401	0.59	0.3	Facial emotion recognition (sad faces);	chr2:85914310	chr21:44675868~44678086:-
STAD	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	5.86	1.07e-08	0.0401	0.34	0.3	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
STAD	trans	rs10019912	0.92	rs28600753	ENSG00000229619.3	MBNL1-AS1	-5.86	1.07e-08	0.0403	-0.32	-0.3	Pursuit maintenance gain;	chr4:167909379	chr3:152262616~152269555:-
STAD	trans	rs7395662	1	rs11039820	ENSG00000134612.10	FOLH1B	-5.86	1.07e-08	0.0403	-0.36	-0.3	HDL cholesterol;	chr11:48540700	chr11:89639227~89698718:+
STAD	trans	rs2209875	0.573	rs74703137	ENSG00000234819.1	RP11-336N8.4	5.86	1.07e-08	0.0404	0.35	0.3	Pelvic organ prolapse (moderate/severe);	chr9:89336429	chr9:78219120~78219357:+
STAD	trans	rs9650657	0.547	rs11250099	ENSG00000254340.1	RP11-10A14.3	5.86	1.07e-08	0.0404	0.36	0.3	Neuroticism;	chr8:10961147	chr8:9141424~9145435:+
STAD	trans	rs74233809	0.901	rs17878846	ENSG00000254698.1	RP11-659G9.3	-5.86	1.08e-08	0.0405	-0.37	-0.3	Birth weight;	chr10:102870655	chr11:82963681~83039115:-
STAD	trans	rs3942852	0.774	rs10838811	ENSG00000134612.10	FOLH1B	-5.86	1.08e-08	0.0406	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165243	chr11:89639227~89698718:+
STAD	trans	rs816535	1	rs816535	ENSG00000279352.1	RP11-411B10.7	5.86	1.08e-08	0.0406	0.46	0.3	Parkinson disease and lewy body pathology;	chr20:26275360	chr18:14010054~14010917:+
STAD	trans	rs3770081	1	rs73945535	ENSG00000229880.1	IMMTP1	5.86	1.08e-08	0.0407	0.59	0.3	Facial emotion recognition (sad faces);	chr2:85897750	chr21:44675868~44678086:-
STAD	trans	rs3770081	1	rs73943909	ENSG00000229880.1	IMMTP1	5.86	1.08e-08	0.0407	0.59	0.3	Facial emotion recognition (sad faces);	chr2:85916255	chr21:44675868~44678086:-
STAD	trans	rs8130944	0.859	rs756577	ENSG00000271113.1	RP11-159H10.4	5.86	1.08e-08	0.0407	0.33	0.3	Perceived unattractiveness to mosquitoes;	chr21:42698213	chr8:69794062~69794734:+
STAD	trans	rs7395662	1	rs6485872	ENSG00000134612.10	FOLH1B	-5.86	1.09e-08	0.0408	-0.35	-0.3	HDL cholesterol;	chr11:48558158	chr11:89639227~89698718:+
STAD	trans	rs12310956	0.531	rs10772110	ENSG00000230305.2	AC004980.9	-5.86	1.09e-08	0.0411	-0.4	-0.3	Morning vs. evening chronotype;	chr12:33688820	chr7:76524515~76532692:+
STAD	trans	rs4276421	0.688	rs7293424	ENSG00000231752.4	EMBP1	5.86	1.1e-08	0.0411	0.4	0.3	P wave duration;	chr5:46184874	chr1:121519112~121571892:+
STAD	trans	rs2077654	1	rs2077654	ENSG00000253497.1	IGKV1-13	-5.86	1.1e-08	0.0411	-0.38	-0.3	Gout;	chr11:17406354	chr2:89045995~89046466:-
STAD	trans	rs3770081	1	rs58672934	ENSG00000229880.1	IMMTP1	5.86	1.1e-08	0.0411	0.59	0.3	Facial emotion recognition (sad faces);	chr2:85936113	chr21:44675868~44678086:-
STAD	trans	rs9402633	0.877	rs9376061	ENSG00000236296.6	GUSBP5	5.86	1.1e-08	0.0412	0.43	0.3	Platelet count;	chr6:134733843	chr4:143559472~143649305:+
STAD	trans	rs2980003	0.784	rs2956312	ENSG00000261330.1	RP11-281J9.1	-5.85	1.11e-08	0.0416	-0.28	-0.3	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:65081836	chr16:77892422~77892915:+
STAD	trans	rs74233809	1	rs12221193	ENSG00000254698.1	RP11-659G9.3	-5.85	1.11e-08	0.0416	-0.38	-0.3	Birth weight;	chr10:102905510	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs77180047	ENSG00000254698.1	RP11-659G9.3	-5.85	1.11e-08	0.0416	-0.38	-0.3	Birth weight;	chr10:102907000	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs12221064	ENSG00000254698.1	RP11-659G9.3	-5.85	1.11e-08	0.0416	-0.38	-0.3	Birth weight;	chr10:102917369	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs17115213	ENSG00000254698.1	RP11-659G9.3	-5.85	1.11e-08	0.0416	-0.38	-0.3	Birth weight;	chr10:102921386	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs77602510	ENSG00000254698.1	RP11-659G9.3	-5.85	1.11e-08	0.0416	-0.38	-0.3	Birth weight;	chr10:102922845	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs78821730	ENSG00000254698.1	RP11-659G9.3	-5.85	1.11e-08	0.0416	-0.38	-0.3	Birth weight;	chr10:102924787	chr11:82963681~83039115:-
STAD	trans	rs74233809	1	rs12411886	ENSG00000254698.1	RP11-659G9.3	-5.85	1.11e-08	0.0416	-0.38	-0.3	Birth weight;	chr10:102925542	chr11:82963681~83039115:-
STAD	trans	rs10488029	1	rs6964418	ENSG00000235363.1	SNRPGP10	5.85	1.11e-08	0.0416	0.48	0.3	IgG glycosylation;	chr7:37026425	chr1:205351247~205351471:+
STAD	trans	rs9594759	0.967	rs7331068	ENSG00000246640.1	RP11-1094H24.4	5.85	1.11e-08	0.0417	0.36	0.3	Bone mineral density (spine);	chr13:42468140	chr17:50050349~50055739:-
STAD	trans	rs3857747	0.537	rs4421260	ENSG00000278969.1	RP11-662I13.3	5.85	1.11e-08	0.0417	0.34	0.3	3-hydroxypropylmercapturic acid levels in smokers;	chr7:40385309	chr12:24902309~24904681:+
STAD	trans	rs74233809	1	rs77860422	ENSG00000254698.1	RP11-659G9.3	-5.85	1.12e-08	0.0418	-0.37	-0.3	Birth weight;	chr10:102988252	chr11:82963681~83039115:-
STAD	trans	rs11039798	1	rs9667626	ENSG00000134612.10	FOLH1B	5.85	1.12e-08	0.0419	0.54	0.3	Axial length;	chr11:48464325	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs10838918	ENSG00000134612.10	FOLH1B	5.85	1.12e-08	0.0419	0.54	0.3	Axial length;	chr11:48485897	chr11:89639227~89698718:+
STAD	trans	rs1190596	1	rs1190596	ENSG00000181359.5	HSP90AA6P	5.85	1.12e-08	0.0419	0.4	0.3	Behavioural disinhibition (generation interaction);	chr14:102129288	chr4:170581470~170605450:-
STAD	trans	rs4276421	1	rs13340341	ENSG00000231752.4	EMBP1	5.85	1.12e-08	0.042	0.39	0.3	P wave duration;	chr5:45860834	chr1:121519112~121571892:+
STAD	trans	rs9329221	0.967	rs7005363	ENSG00000173295.6	FAM86B3P	-5.85	1.13e-08	0.0421	-0.32	-0.3	Neuroticism;	chr8:10426238	chr8:8228595~8244865:+
STAD	trans	rs11716531	0.51	rs513546	ENSG00000228110.4	ST13P19	-5.85	1.13e-08	0.0422	-0.36	-0.3	Diastolic blood pressure;	chr3:27307429	chr1:210265636~210267241:-
STAD	trans	rs11039798	0.764	rs11039771	ENSG00000134612.10	FOLH1B	5.85	1.13e-08	0.0423	0.54	0.3	Axial length;	chr11:48491721	chr11:89639227~89698718:+
STAD	trans	rs17092148	1	rs6088579	ENSG00000259248.4	USP3-AS1	-5.85	1.13e-08	0.0423	-0.33	-0.3	Neuroticism;	chr20:34696820	chr15:63544247~63601589:-
STAD	trans	rs7395662	0.963	rs2089209	ENSG00000134612.10	FOLH1B	-5.85	1.14e-08	0.0424	-0.36	-0.3	HDL cholesterol;	chr11:48965568	chr11:89639227~89698718:+
STAD	trans	rs7312770	0.612	rs1873914	ENSG00000229032.1	RP11-91A18.1	5.85	1.14e-08	0.0426	0.32	0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:51980473~51980814:+
STAD	trans	rs4746818	1	rs1506770	ENSG00000236849.4	LINC01474	-5.85	1.14e-08	0.0427	-0.45	-0.3	Left atrial antero-posterior diameter;	chr10:69204601	chr9:72871728~72874109:-
STAD	trans	rs2950393	0.777	rs2926747	ENSG00000257210.1	NACAP3	5.85	1.15e-08	0.0429	0.31	0.3	Platelet distribution width;	chr12:56716147	chr12:93124063~93124543:-
STAD	trans	rs7554511	0.861	rs10753888	ENSG00000244144.1	RP11-757F18.3	-5.85	1.15e-08	0.0431	-0.31	-0.3	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201037057	chr3:112185480~112185998:-
STAD	trans	rs77954165	0.667	rs7036678	ENSG00000215210.3	RBMXP2	5.85	1.16e-08	0.0432	0.38	0.3	Stem cell growth factor beta levels;	chr9:6720682	chr9:30689105~30690272:+
STAD	trans	rs11220082	0.591	rs11220061	ENSG00000236257.1	EI24P2	-5.85	1.16e-08	0.0432	-0.39	-0.3	Schizophrenia;	chr11:125422172	chr1:158454198~158455273:+
STAD	trans	rs721352	0.536	rs7860427	ENSG00000234415.1	RPL5P7	5.85	1.16e-08	0.0433	0.3	0.3	Chronic sinus infection;	chr9:6385637	chr2:173871653~173872465:-
STAD	trans	rs74781061	0.929	rs12439505	ENSG00000227288.3	RP5-837I24.1	5.85	1.17e-08	0.0435	0.43	0.3	Endometriosis;	chr15:74494021	chr1:81501794~81503468:+
STAD	trans	rs74781061	0.858	rs35752918	ENSG00000227288.3	RP5-837I24.1	5.85	1.17e-08	0.0435	0.43	0.3	Endometriosis;	chr15:74494240	chr1:81501794~81503468:+
STAD	trans	rs74781061	0.929	rs79534854	ENSG00000227288.3	RP5-837I24.1	5.85	1.17e-08	0.0435	0.43	0.3	Endometriosis;	chr15:74494257	chr1:81501794~81503468:+
STAD	trans	rs11235843	0.565	rs1723840	ENSG00000224856.2	RP4-796I17.5	-5.84	1.17e-08	0.0436	-0.38	-0.3	Hand grip strength;	chr11:73762840	chr22:43957027~43957348:+
STAD	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	5.84	1.17e-08	0.0437	0.31	0.3	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
STAD	trans	rs73108077	0.736	rs6119276	ENSG00000279352.1	RP11-411B10.7	5.84	1.18e-08	0.0438	0.57	0.3	Red blood cell density in sickle cell anemia;	chr20:31363733	chr18:14010054~14010917:+
STAD	trans	rs11039798	1	rs7123704	ENSG00000134612.10	FOLH1B	5.84	1.18e-08	0.0439	0.53	0.3	Axial length;	chr11:48558983	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs3902927	ENSG00000134612.10	FOLH1B	5.84	1.18e-08	0.0439	0.53	0.3	Axial length;	chr11:48559905	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs3902928	ENSG00000134612.10	FOLH1B	5.84	1.18e-08	0.0439	0.53	0.3	Axial length;	chr11:48559906	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs7104642	ENSG00000134612.10	FOLH1B	5.84	1.18e-08	0.0439	0.53	0.3	Axial length;	chr11:48566982	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs7928243	ENSG00000134612.10	FOLH1B	5.84	1.18e-08	0.0439	0.53	0.3	Axial length;	chr11:48567640	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.791	rs11040472	ENSG00000134612.10	FOLH1B	-5.84	1.18e-08	0.0439	-0.33	-0.3	Height;	chr11:49681564	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs7483795	ENSG00000134612.10	FOLH1B	-5.84	1.18e-08	0.0439	-0.33	-0.3	Height;	chr11:49683378	chr11:89639227~89698718:+
STAD	trans	rs3942852	0.688	rs10742834	ENSG00000134612.10	FOLH1B	-5.84	1.18e-08	0.0439	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48148165	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs12418254	ENSG00000134612.10	FOLH1B	-5.84	1.18e-08	0.044	-0.36	-0.3	HDL cholesterol;	chr11:48966710	chr11:89639227~89698718:+
STAD	trans	rs2950393	0.804	rs3214051	ENSG00000257210.1	NACAP3	5.84	1.19e-08	0.0442	0.3	0.3	Platelet distribution width;	chr12:56725452	chr12:93124063~93124543:-
STAD	trans	rs6708331	1	rs13000817	ENSG00000232654.1	FAM136BP	5.84	1.19e-08	0.0443	0.45	0.3	Obesity-related traits;	chr2:70046575	chr6:3045384~3045800:+
STAD	trans	rs7647973	0.769	rs11130181	ENSG00000197582.5	GPX1P1	5.84	1.19e-08	0.0443	0.44	0.3	Menarche (age at onset);	chr3:49072486	chrX:13378735~13379340:-
STAD	trans	rs2950393	0.804	rs7967600	ENSG00000257210.1	NACAP3	5.84	1.19e-08	0.0443	0.3	0.3	Platelet distribution width;	chr12:56768208	chr12:93124063~93124543:-
STAD	trans	rs11039798	1	rs10160423	ENSG00000134612.10	FOLH1B	5.84	1.2e-08	0.0444	0.54	0.3	Axial length;	chr11:48435675	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs7102865	ENSG00000134612.10	FOLH1B	5.84	1.2e-08	0.0444	0.54	0.3	Axial length;	chr11:48436809	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.576	rs10839305	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0444	-0.34	-0.3	Coronary artery disease;	chr11:49577181	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.781	rs1851872	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0445	-0.33	-0.3	Height;	chr11:49988233	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs4405313	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0445	-0.33	-0.3	Height;	chr11:49992098	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10769648	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0445	-0.33	-0.3	Height;	chr11:49992454	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs3974439	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0445	-0.33	-0.3	Height;	chr11:50001069	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10128730	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0445	-0.33	-0.3	Height;	chr11:50001830	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs11040700	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0445	-0.33	-0.3	Height;	chr11:50002293	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.712	rs9665784	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0445	-0.33	-0.3	Height;	chr11:50009095	chr11:89639227~89698718:+
STAD	trans	rs6763848	0.646	rs4295155	ENSG00000186831.10	KRT17P2	-5.84	1.2e-08	0.0446	-0.34	-0.3	Prostate cancer (SNP x SNP interaction);	chr3:1464068	chr17:18426861~18431848:+
STAD	trans	rs1814175	0.817	rs4084376	ENSG00000134612.10	FOLH1B	-5.84	1.2e-08	0.0446	-0.33	-0.3	Height;	chr11:49809608	chr11:89639227~89698718:+
STAD	trans	rs6708331	1	rs12999430	ENSG00000232654.1	FAM136BP	5.84	1.21e-08	0.0447	0.44	0.3	Obesity-related traits;	chr2:70079653	chr6:3045384~3045800:+
STAD	trans	rs9882792	0.784	rs9868231	ENSG00000229701.1	MTND2P20	-5.84	1.21e-08	0.0447	-0.32	-0.3	Breast cancer;	chr3:190071566	chr2:155264163~155264823:-
STAD	trans	rs867743	0.779	rs2326501	ENSG00000214132.4	RP11-420O16.2	5.84	1.21e-08	0.0447	0.55	0.3	Schizophrenia;	chr8:59838316	chr5:20304045~20305448:-
STAD	trans	rs206936	0.528	rs79954907	ENSG00000270883.1	RP11-461L13.5	5.84	1.21e-08	0.0447	0.67	0.3	Body mass index;	chr6:34433482	chr4:152317902~152318364:-
STAD	trans	rs1814175	0.817	rs11040474	ENSG00000134612.10	FOLH1B	-5.84	1.21e-08	0.0449	-0.33	-0.3	Height;	chr11:49686889	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs11039774	ENSG00000134612.10	FOLH1B	-5.84	1.22e-08	0.045	-0.36	-0.3	HDL cholesterol;	chr11:48492407	chr11:89639227~89698718:+
STAD	trans	rs9329221	0.905	rs4841329	ENSG00000253981.4	ALG1L13P	-5.84	1.23e-08	0.0454	-0.4	-0.3	Neuroticism;	chr8:10395588	chr8:8236003~8244667:-
STAD	trans	rs9611519	0.894	rs4821990	ENSG00000268568.1	AC007228.9	-5.84	1.23e-08	0.0455	-0.42	-0.3	Neuroticism;	chr22:41042706	chr19:56672574~56673901:-
STAD	trans	rs7312770	1	rs7312770	ENSG00000243328.1	RP11-520P18.1	-5.84	1.23e-08	0.0456	-0.28	-0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:143065915~143066587:-
STAD	trans	rs7647973	0.667	rs9869256	ENSG00000197582.5	GPX1P1	5.84	1.23e-08	0.0456	0.49	0.3	Menarche (age at onset);	chr3:49586662	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.71	rs6446285	ENSG00000197582.5	GPX1P1	5.84	1.23e-08	0.0456	0.49	0.3	Menarche (age at onset);	chr3:49588873	chrX:13378735~13379340:-
STAD	trans	rs1814175	0.817	rs11493756	ENSG00000134612.10	FOLH1B	-5.83	1.24e-08	0.0458	-0.33	-0.3	Height;	chr11:49996346	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.653	rs10839480	ENSG00000134612.10	FOLH1B	-5.83	1.24e-08	0.0458	-0.33	-0.3	Height;	chr11:50013036	chr11:89639227~89698718:+
STAD	trans	rs56176327	0.583	rs7613603	ENSG00000197582.5	GPX1P1	-5.83	1.25e-08	0.046	-0.48	-0.3	Intelligence (multi-trait analysis);	chr3:49775433	chrX:13378735~13379340:-
STAD	trans	rs7647973	0.593	rs7620848	ENSG00000197582.5	GPX1P1	-5.83	1.25e-08	0.046	-0.48	-0.3	Menarche (age at onset);	chr3:49790588	chrX:13378735~13379340:-
STAD	trans	rs11039798	0.92	rs11040013	ENSG00000134612.10	FOLH1B	5.83	1.25e-08	0.0461	0.53	0.3	Axial length;	chr11:48761310	chr11:89639227~89698718:+
STAD	trans	rs10019912	0.92	rs28436763	ENSG00000229619.3	MBNL1-AS1	-5.83	1.25e-08	0.0462	-0.32	-0.3	Pursuit maintenance gain;	chr4:167909364	chr3:152262616~152269555:-
STAD	trans	rs7944735	0.517	rs11039538	ENSG00000134612.10	FOLH1B	5.83	1.26e-08	0.0463	0.53	0.3	Intraocular pressure;	chr11:48133438	chr11:89639227~89698718:+
STAD	trans	rs2069408	1	rs2069408	ENSG00000233778.3	RP11-777J24.1	-5.83	1.26e-08	0.0464	-0.3	-0.3	Asthma;	chr12:55970537	chr8:92144088~92144435:-
STAD	trans	rs2727020	0.553	rs10839295	ENSG00000134612.10	FOLH1B	-5.83	1.27e-08	0.0466	-0.34	-0.3	Coronary artery disease;	chr11:49505793	chr11:89639227~89698718:+
STAD	trans	rs7395662	0.963	rs7483713	ENSG00000134612.10	FOLH1B	-5.83	1.27e-08	0.0468	-0.36	-0.3	HDL cholesterol;	chr11:48607662	chr11:89639227~89698718:+
STAD	trans	rs747782	0.528	rs10838881	ENSG00000134612.10	FOLH1B	5.83	1.27e-08	0.0468	0.51	0.3	Intraocular pressure;	chr11:48365723	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.764	rs10838882	ENSG00000134612.10	FOLH1B	5.83	1.27e-08	0.0468	0.51	0.3	Axial length;	chr11:48371483	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs12223271	ENSG00000134612.10	FOLH1B	5.83	1.27e-08	0.0468	0.51	0.3	Axial length;	chr11:48395868	chr11:89639227~89698718:+
STAD	trans	rs747782	0.528	rs4370963	ENSG00000134612.10	FOLH1B	5.83	1.27e-08	0.0468	0.51	0.3	Intraocular pressure;	chr11:48412391	chr11:89639227~89698718:+
STAD	trans	rs1351696	1	rs1351696	ENSG00000134612.10	FOLH1B	-5.83	1.27e-08	0.0468	-0.51	-0.3	D-dimer levels;	chr11:48360919	chr11:89639227~89698718:+
STAD	trans	rs747782	0.528	rs624348	ENSG00000134612.10	FOLH1B	-5.83	1.27e-08	0.0468	-0.51	-0.3	Intraocular pressure;	chr11:48379243	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.623	rs584851	ENSG00000134612.10	FOLH1B	-5.83	1.27e-08	0.0468	-0.51	-0.3	Axial length;	chr11:48394769	chr11:89639227~89698718:+
STAD	trans	rs9611519	0.929	rs2064560	ENSG00000268568.1	AC007228.9	-5.83	1.28e-08	0.0469	-0.42	-0.3	Neuroticism;	chr22:41134036	chr19:56672574~56673901:-
STAD	trans	rs6540556	0.954	rs7548219	ENSG00000223745.6	RP4-717I23.3	5.83	1.28e-08	0.0469	0.26	0.3	Red blood cell count;	chr1:209763121	chr1:93262186~93346025:-
STAD	trans	rs9650657	0.589	rs10107145	ENSG00000254340.1	RP11-10A14.3	-5.83	1.29e-08	0.0472	-0.39	-0.3	Neuroticism;	chr8:10900703	chr8:9141424~9145435:+
STAD	trans	rs7395662	1	rs12806328	ENSG00000134612.10	FOLH1B	-5.83	1.29e-08	0.0474	-0.35	-0.3	HDL cholesterol;	chr11:48626419	chr11:89639227~89698718:+
STAD	trans	rs11809230	0.541	rs72938999	ENSG00000260209.1	RP11-680F20.10	5.83	1.29e-08	0.0475	0.53	0.3	Cannabis use (initiation);	chr1:69721006	chr11:125873031~125874528:-
STAD	trans	rs74233809	1	rs76752100	ENSG00000254698.1	RP11-659G9.3	-5.83	1.3e-08	0.0476	-0.37	-0.3	Birth weight;	chr10:103034329	chr11:82963681~83039115:-
STAD	trans	rs12129573	0.575	rs10749824	ENSG00000272945.1	CTD-3216D2.5	-5.83	1.3e-08	0.0477	-0.28	-0.3	Schizophrenia;	chr1:73435264	chr20:34281632~34286466:-
STAD	trans	rs877636	0.74	rs705698	ENSG00000244641.2	RPS26P43	5.83	1.3e-08	0.0478	0.32	0.3	Cognitive function;	chr12:55990903	chr11:123049787~123050353:-
STAD	trans	rs9841829	0.61	rs11127893	ENSG00000260219.2	RP11-347C12.10	5.83	1.3e-08	0.0478	0.35	0.3	Alcohol consumption;	chr3:85475020	chr16:30355441~30357104:+
STAD	trans	rs2727020	0.576	rs1814175	ENSG00000134612.10	FOLH1B	-5.83	1.3e-08	0.0478	-0.34	-0.3	Coronary artery disease;	chr11:49537620	chr11:89639227~89698718:+
STAD	trans	rs11039798	0.925	rs7482967	ENSG00000134612.10	FOLH1B	5.83	1.3e-08	0.0478	0.53	0.3	Axial length;	chr11:48591975	chr11:89639227~89698718:+
STAD	trans	rs11039798	1	rs12280020	ENSG00000134612.10	FOLH1B	5.83	1.3e-08	0.0478	0.53	0.3	Axial length;	chr11:48597292	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.869	rs10769600	ENSG00000134612.10	FOLH1B	-5.82	1.31e-08	0.0479	-0.34	-0.3	Height;	chr11:49660280	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.935	rs11040462	ENSG00000134612.10	FOLH1B	-5.82	1.31e-08	0.0479	-0.34	-0.3	Height;	chr11:49661606	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.935	rs11040463	ENSG00000134612.10	FOLH1B	-5.82	1.31e-08	0.0479	-0.34	-0.3	Height;	chr11:49664022	chr11:89639227~89698718:+
STAD	trans	rs7647973	0.848	rs4955426	ENSG00000197582.5	GPX1P1	5.82	1.31e-08	0.0479	0.49	0.3	Menarche (age at onset);	chr3:49106005	chrX:13378735~13379340:-
STAD	trans	rs6540556	0.954	rs643118	ENSG00000223745.6	RP4-717I23.3	5.82	1.31e-08	0.048	0.25	0.3	Red blood cell count;	chr1:209761496	chr1:93262186~93346025:-
STAD	trans	rs7395662	0.963	rs6485906	ENSG00000134612.10	FOLH1B	-5.82	1.31e-08	0.048	-0.35	-0.3	HDL cholesterol;	chr11:48630109	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs6485907	ENSG00000134612.10	FOLH1B	-5.82	1.31e-08	0.048	-0.35	-0.3	HDL cholesterol;	chr11:48630143	chr11:89639227~89698718:+
STAD	trans	rs7395662	1	rs11039890	ENSG00000134612.10	FOLH1B	-5.82	1.31e-08	0.048	-0.35	-0.3	HDL cholesterol;	chr11:48631916	chr11:89639227~89698718:+
STAD	trans	rs6708331	1	rs13429940	ENSG00000232654.1	FAM136BP	5.82	1.31e-08	0.048	0.44	0.3	Obesity-related traits;	chr2:70152736	chr6:3045384~3045800:+
STAD	trans	rs6708331	0.938	rs13000514	ENSG00000232654.1	FAM136BP	5.82	1.31e-08	0.048	0.44	0.3	Obesity-related traits;	chr2:70167884	chr6:3045384~3045800:+
STAD	trans	rs6708331	1	rs7578027	ENSG00000232654.1	FAM136BP	5.82	1.31e-08	0.048	0.44	0.3	Obesity-related traits;	chr2:70173976	chr6:3045384~3045800:+
STAD	trans	rs1814175	0.817	rs7481230	ENSG00000134612.10	FOLH1B	-5.82	1.32e-08	0.0483	-0.33	-0.3	Height;	chr11:49750683	chr11:89639227~89698718:+
STAD	trans	rs877636	0.702	rs773108	ENSG00000242206.2	RPS26P35	5.82	1.32e-08	0.0483	0.34	0.3	Cognitive function;	chr12:55976127	chr8:118761856~118762201:-
STAD	trans	rs77954165	0.568	rs6477104	ENSG00000215210.3	RBMXP2	5.82	1.33e-08	0.0485	0.38	0.3	Stem cell growth factor beta levels;	chr9:6722393	chr9:30689105~30690272:+
STAD	trans	rs1814175	0.817	rs10839351	ENSG00000134612.10	FOLH1B	-5.82	1.33e-08	0.0486	-0.33	-0.3	Height;	chr11:49736601	chr11:89639227~89698718:+
STAD	trans	rs77954165	0.73	rs72697555	ENSG00000215210.3	RBMXP2	5.82	1.33e-08	0.0487	0.38	0.3	Stem cell growth factor beta levels;	chr9:6720077	chr9:30689105~30690272:+
STAD	trans	rs7395662	1	rs7925955	ENSG00000134612.10	FOLH1B	-5.82	1.33e-08	0.0487	-0.35	-0.3	HDL cholesterol;	chr11:48625981	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.553	rs3907576	ENSG00000134612.10	FOLH1B	-5.82	1.34e-08	0.0488	-0.34	-0.3	Coronary artery disease;	chr11:49515087	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.575	rs10769587	ENSG00000134612.10	FOLH1B	-5.82	1.34e-08	0.0488	-0.34	-0.3	Coronary artery disease;	chr11:49528297	chr11:89639227~89698718:+
STAD	trans	rs2727020	0.514	rs4980444	ENSG00000134612.10	FOLH1B	-5.82	1.34e-08	0.0488	-0.34	-0.3	Coronary artery disease;	chr11:49529212	chr11:89639227~89698718:+
STAD	trans	rs538867	0.661	rs2016412	ENSG00000214263.2	RPSAP53	5.82	1.35e-08	0.0491	0.78	0.3	Alzheimer's disease (cognitive decline);	chr3:39393561	chr13:67266845~67267706:-
STAD	trans	rs1814175	0.817	rs10769613	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49748140	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10839358	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49749420	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.791	rs11040513	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49756601	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.654	rs7482446	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49757468	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs4881645	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49769616	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.791	rs10219223	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49769916	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs4881623	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49783439	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs1818890	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49835330	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.817	rs10839397	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49835522	chr11:89639227~89698718:+
STAD	trans	rs1814175	0.715	rs11040586	ENSG00000134612.10	FOLH1B	-5.82	1.36e-08	0.0496	-0.33	-0.3	Height;	chr11:49836880	chr11:89639227~89698718:+
STAD	trans	rs12129573	0.608	rs6676874	ENSG00000272945.1	CTD-3216D2.5	-5.82	1.36e-08	0.0496	-0.28	-0.3	Schizophrenia;	chr1:73442676	chr20:34281632~34286466:-
STAD	trans	rs7944735	0.517	rs12274550	ENSG00000134612.10	FOLH1B	5.82	1.36e-08	0.0496	0.52	0.3	Intraocular pressure;	chr11:48175200	chr11:89639227~89698718:+
STAD	trans	rs17548007	1	rs61941129	ENSG00000183444.10	OR7E38P	-5.82	1.36e-08	0.0496	-0.65	-0.3	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr12:102994971	chr7:97966090~97967074:-
STAD	trans	rs7617480	0.648	rs6766238	ENSG00000197582.5	GPX1P1	5.82	1.37e-08	0.0499	0.45	0.3	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chrX:13378735~13379340:-